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EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Alternative Small-Molecule Therapies
#1 Galectins in glioblastoma: opportunities for combined therapy. David
Cachia,1 Arindam Rano Chatterjee,1 William Alexander Vandergrift,1 Sunil J.
Patel,1 Gabriel A. Rabinovich,2 Arabinda Das1. 1Medical University of South
Carolina, Charleston, SC; 2Institute of Biology and Experimental Medicine,
CONICET, Vuelta de Obligado, Argentina.
Background: Despite aggressive treatment, including surgical resection, radi-
ation and chemotherapy, over 90% of glioblastoma (GB) patients experience
tumor recurrence. This may be due to high migratory potential, angiogenesis,
molecular heterogeneity and a strong immunosuppressive environment. GB
expresses high levels of carbohydrate-binding galectin proteins and histone
deacetylase (HDAC) activity. The aim of this study was: 1) identify the differen-
tial expressions of galectin 1-15 protein levels in human GB patient samples as
compared to normal tissue (obtained from Institutional Tissue Bank) and (2)
modulate the galectin functions with and without a HDAC inhibitor (DATS:
Dially Triisulfıde and SAHA: Suberoylanilide Hydroxamic Acid ) or bevaci-
zumab in in vitro GB models. Methods: The effects of TMZ, ionizing radiation,
or combined chemoradiation on galectin protein secretion and expression were
assessed in human GB cells and human umbilical vein endothelial cells
(HUVECs). Results: We found increased galectin-1 protein expression in hu-
man GB tissue. We also observed that HUVEC co-culture with GB cells in-
creased galectin-1 protein expression by 14 - 20% following bevacizumab, and
conferred a bevacizumab protective benefıt to GB cells. Our in vitro models
promisingly demonstrated that 72 hr treatments with 25Mof galectin 1 inhib-
itorHDAC inhibitor induce antitumor activity in GB cells. Western blot and
activities assay results also demonstrated that combination blockade of HDAC
activity and galectin-1 augmented apoptosis in GB cells, which mechanistically
involves activation of caspase-3 and inhibition of anti-apoptotic protein (sur-
vivin, p-Akt, and Mcl-1 expression). Conclusion: Our in vitro culture results
suggest possible benefıt in combining a galectin inhibitor with an HDAC inhib-
itor in GB. Further studies in different animal models are warranted.
#2 Functional and mechanistic interrogation of BET bromodomain de-
graders for the treatment of metastatic castration resistant prostate cancer.
Steven Kregel, Rohit Malik, Irfan A. Asangani, Kari Wilder-Romans, Xia Jiang,
Ingrid J. Apel, Gautham Ravi, Jean Tien, Xuhong Cao, Felix Y. Feng, Corey
Speers, Shaomeng Wang, Arul M. Chinnaiyan. University of Michigan, Ann
Arbor, MI.
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease
with about 30,000 estimated annual deaths in U.S, with a vast majority of CRPC
driven by androgen receptor (AR) signaling. AR-signaling is critical for the
development and progression of prostate cancer, and AR also the main thera-
peutic clinical target. AR-targeted therapies, such as AR-antagonists, provide
substantial benefıts in the treatment of mCRPC; however, majority of patients
fail these therapies and succumb to the disease. Therefore, there is a clear and
pressing need to develop new therapeutics against the AR axis in CRPC. One
such novel strategy for targeting the AR-pathway and inhibiting the growth of
CRPC has been the use of bromodomain and extraterminal (BET) protein in-
hibitors such a JQ1. However, a new class of molecules that target BET bro-
modomain proteins through their proteasomal degradation can improve effı-
cacy and specifıcity of these inhibitors. Based on our fındings, we hypothesized
that pharmacologic BET degradation represents an important advance in the
treatment of CRPC, and may provide a novel therapeutic strategy for advanced
prostate cancer. These inhibitors affect AR-positive prostate cancer cells prefer-
entially over AR-negative and benign prostate epithelial cells, and proteomic
and genomicmechanistic studies confırmdisruption of oncogenicAR andMYC
signaling, both in vivo and in vitro. The overall goal is to develop very potent
small molecule that leads to the proteasomal-degradation of BET proteins, with
optimized in vivo properties, and to provide a compelling scientifıc rationale,
including detailedmechanistic insight, to facilitate advancement of BETdegrad-
ers as a novel potential therapeutic strategy for patients with mCRPC.
#3 Targeting epigeneticmodifıers in diffuse largeB-cell lymphoma.Aarthi
Goverdhan, Heng-Huan Lee, Mien-Chie Hung. UTMD Anderson Cancer Cen-
ter, Houston, TX.
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-
Hodgkin lymphoma, accounting for approximately 40% of all cases worldwide.
In the last fıve years, researchers uncovered that DLBCL is characterized by
widespread epigenetic deregulation. Lymphoma cells harbor loss-of-function
mutations in transcriptional activators (KMT2D, EP300, CREBBP) and gain-of-
function mutations in transcriptional repressors (EZH2). In our study, we aim
to identify epigenetic vulnerabilities in lymphoma cells that can be targeted to
deliver cytotoxic responses. We screened the therapeutic effıcacy of a panel of
lysine and arginine methyltransferase inhibitors in multiple lymphoma cell
lines. Through these screens, we identifıed the Type I Protein Arginine Methyl-
transferase (PRMT) family as an attractive therapeutic target that induced cyto-
toxicity. Mechanistic dissection revealed that Type I PRMT inhibition caused
apoptosis through deregulation of transcription factors and pro-survival genes.
In addition, we uncovered novel crosstalk between PRMTs and other epigenetic
modifıers that influenced cell fate in lymphoma. Our study demonstrates a crit-
ical role for Type I PRMTs in DLBCL, and adds a lucrative target to the growing
list of promising epigenetics-based therapies.
#4 Inhibitory effects of aprotinin on survival and local invasion of human
breast cancer cell lines. Saeed Soleyman-Jahi, Kazem Zendehdel, Fatemeh Sa-
deghi, Ziba Afshari, Tahereh Barati, SamadMohammadnezhad, Sevil Ghasemi,
Saeed Amanpour. Cancer Research Center, Tehran University of Medical Sci-
ences, Tehran, Islamic Republic of Iran.
Background: Aprotinin is a nonspecifıc serine protease inhibitor, which can
inhibit kallikrein and many downstream extracellular matrix degrading en-
zymes. In this study, we assessed inhibitory effects of aprotinin on local invasion
of human breast cancer cell lines. Methods: We assessed effects of aprotinin on
local invasion and survival of human breast cancer cell lines MDA-MB231 and
SK-BR-3 in vitro. CHEMICON Cell Invasion Assay Kit was used to assess local
invasion of tumoral cells. MTT assay was used to determine the anti-prolifera-
tive activity of aprotinin on different cancer cell lines. Mean optical densities of
duplicate experiments were calculated for both assays. HDF-1 human fıbroblast
cell line was used as control normal cell. In addition, local invasion and survival
of tumor cell lines treated with aprotinin were compared with untreated exper-
iments. Results: Cancer cell lines showed more invasion compared to HDF-1.
Aprotinin signifıcantly decreased the invasiveness of MDA-MB231 in concen-
tration of 1 TIU/ml, 1.3 TIU/ml, and 1.7 TIU/ml in comparison with untreated
group (ANOVA P 0.001). Treatment of SK-BR-3 with 1.3 TIU/ml aprotinin
trended towards reduction of invasion optical density (P  0.06). Treatment
with different concentrations of aprotinin signifıcantly decreased the surviving
fraction and signifıcantly inhibited the growth of all cell lines tested in this study
(ANOVA P 0.001). Conclusion: Aprotinin inhibited the survival and local
invasion of human breast cancer cell lines MDA-MB231 and SK-BR-3. Al-
though the growth inhibitory effect was signifıcant in both cell lines, inhibition
of local invasion was more pronounced in case of MDA-MB231. Future molec-
ular studies could shed further lights onmechanisms underlying anti-neoplastic
effects of aprotinin and its potential therapeutic effects.
#5 The effects of SIRT1 inhibitors nicotinamide and Ex-527 on lymphoma
cells.Manuela Guardi, Mariaelena Pistoni, Raffaele Frazzi. Arcispedale S.Maria
Nuova - IRCCS, Reggio Emilia, Italy.
SIRT1 is a well-known lysine-deacetylase, having both histone and non-his-
tone proteins as molecular targets. SIRT1 may function as a tumor promoter as
well as a tumor suppressor in a context-dependentmanner.We previously dem-
onstrated that the treatment with resveratrol at concentrations able to induce
apoptosis leads to SIRT1 down-regulation in lymphoma cells. Here we look for
SIRT1 inhibition in order to investigate the effects on proliferation potential,
apoptosis induction and targets modulation at a molecular level. The aim is to
study whether SIRT1 inhibition affects cell cycle and proliferation capability of
lymphoma cells. Experimental procedures. Diffuse large-B cell lymphoma de-
rived cell line Toledo; human lymphoblastoid cell line GGB #7; SIRT1 inhibi-
tors: nicotinamide (NAM) and Ex-527; cell cycle analysis; caspase-3 activity
fluorimetric assay; genotoxicity assay gamma-H2AX; fluorescence-activated cell
sorting intracellular staining for acetylated-H4K16histone.Newdata.We found
that the calculated IC50s for SIRT1 inhibition is 50mM forNAMand 343Mfor
Ex-527. The treatment with either NAM or Ex-527 leads to cell cycle arrest in
both Toledo and GGB#7 cells, although in a different fashion. Namely, NAM
causes an S-phase accumulation of Toledowhile it leadsGGB #7 toG0/G1 phase
arrest with a concomitant decrease in S-phase already after 10mM. In both cell
lines NAM 50mM induces apoptosis as demonstrated by caspase-3 activation
and sub-G1 peak appearance in the cell cycle profıles. Ex-527 causes an accumu-
lation in the S phase of Toledo cells and a decrease of G2/M in GGB#7 cells. No
induction of apoptosis at the IC50 concentration was observed in both cell lines.
Genotoxicity of the above mentioned treatments was investigated through the
quantitation of gamma-H2AX histone released by treated cells. No genotoxic
effects have been observed upon the treatments with these two inhibitors even at
the concentration where NAM induces apoptosis. In order to correlate the ob-
served changes with SIRT1 inhibition, we studied the acetylatedH4K16 histone,
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a direct target of SIRT1 deacetylation. Our preliminary data indicate that NAM
treatment increases the percentage of acetylated H4K16. Conclusions. Lym-
phoma and lymphoblastoid cells are affected by SIRT1 inhibition. NAM and
Ex-527 cause cell cycle arrest and growth inhibition. Only NAM 50mM induces
apoptosis without genotoxic effects. Overall, our data suggest the direct involve-
ment of SIRT1 during the observed cell cycle arrest and growth inhibition me-
diated by these inhibitors.
#6 New chk1 inhibitor development & the feasibility of use of chk1 inhib-
itor with antimetabolite for NSCLC. Injae Chung. Duksung Women’s Univer-
sity, Seoul, Republic of Korea.
DNA damaging anticancer agents activate checkpoints that stop the cell cycle
to prevent additional DNA replication &mitosis until damaged region has been
repaired. One of the important regulatory proteins activated in DNA damage
response pathway is Checkpoint kinase 1 (Chk1). Therefore, Chk1 inhibitors
have emerged as promising new therapeutics for cancer. In order to fınd novel
Chk1 inhibitor, we have conducted a structure based virtual screening. Several
smallmolecules have shown 75 - 100% inhibition of Chk1 in the binding affınity
assay. Combined with the results of kinase assay with ATP &mechanism based
cell assay, hit candidates has been led. Lung cancer is the leading cause of cancer
related deaths in Korea. About 85 % of lung cancer is non-small cell lung carci-
noma (NSCLC) worldwide. Chemotherapy for NSCLC is often regarded inef-
fective. To test the feasibility of Chk1 inhibitor to sensitize antimetabolite in
NSCLC, growth inhibition induced by gemcitabine plus MK8776 was assessed
inA549&H1129 cells. These cells are insensitive to theMK8776when treated as
a single agent (IC5010 M). In contrast, MK8776 reduced the concentration
of gemcitabine required to inhibit H1299 or A540 cell growth by almost 3-30
fold or 6-15 fold, respectively, depending on the concentration used. These
results would imply the potential clinical utility of Chk1 inhibitor as an adjuvant
for antimetabolite such as gemcitabine for NSCLC. Further studies to evaluate
the effectiveness of Chk1 inhibitor including newmolecules would bewarranted
in additional preclinical and clinical settings. [The chemical library used in this
study was kindly provided by Korea Chemical Bank & KIST. This study was
supported by a grant (2015R1D1A1A01057014) from the National Research
Foundation of Korea.]
#7 Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses
lung cancer growth by targeting Aurora B. Xiang Li,1 Haitao Li,1 Shengqing
Li,1 Feng Zhu,1 Dong Joon Kim,1 Hua Xie,1 Yan Li,1 Janos Nadas,1 Naomi Oi,1
Tatyana Zykova,1 Dong Hoon Yu,1 Mee-Hyun Lee,1 Myoung Ok Kim,1 Lei
Wang,1 Wei Ya Ma,1 Ronald A. Lubet,2 Ann M. Bode,1 Ziming Dong,3 Zigang
Dong1. 1University of Minnesota, Austin, MN; 2National Cancer Institute,
Bethesda, MD; 3Zhengzhou University, Zhengzhou, China.
Ceftriaxone, an FDA-approved third-generation cephalosporin antibiotic,
has antimicrobial activity against both gram-positive and gram-negative organ-
isms. Generally, ceftriaxone is used for a variety of infections such as communi-
ty-acquired pneumonia, meningitis and gonorrhea. Its primary molecular tar-
gets are the penicillin-binding proteins. However, other activities of ceftriaxone
remain unknown. Herein, we report for the fırst time that ceftriaxone has anti-
tumor activity in vitro and in vivo. Kinase profıling results predicted that Aurora
Bmight be a potential ’off’ target of ceftriaxone. Pull-down assay data confırmed
that ceftriaxone could bind with Aurora B in vitro and in A549 cells. Further-
more, ceftriaxone (500 M) suppressed anchorage-independent cell growth by
targeting Aurora B in A549, H520 and H1650 lung cancer cells. Importantly, in
vivo xenograft animal model results showed that ceftriaxone effectively sup-
pressed A549 and H520 lung tumor growth by inhibiting Aurora B. These data
suggest the anticancer effıcacy of ceftriaxone for the treatment of lung cancers
through its inhibition of Aurora B.
#8 Anandamide reduces cellmigration, invasion, and induces apoptosis in
an in vitro model of prostate cancer. Domenica Roberto,1 Laurence Klotz,2
Vasundara Venkateswaran1. 1Sunnybrook Research Institute, Toronto, Ontario,
Canada; 2Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Introduction and Objective: Prostate cancer (PCa) is the most commonly
diagnosed cancer inmen and the second leading cause of cancer related death in
Canada. A large body of evidence supports a possible role for cannabinoids in
certain aspects of human health and disease, acting as palliative agents as well as
inhibitors of cancer cell proliferation, migration, invasion, and the angiogenesis
of tumours. Anandamide (AEA) is a highly potent endogenously produced
compound that acts as an agonist of the cannabinoid receptors (CB1 andCB2) as
well as the transient receptor potential vanilloid receptor 1. AEA is mainly me-
tabolized by fatty acid amide hydrolase (FAAH) and overexpression of the en-
zyme in PCa tissues is correlated with greater invasivity, malignancy and in-
creasing Gleason score. Majority of studies have focused on the effect of AEA
treatment on cell proliferation, without much focus on prostate cancer biology.
This study aims to determine the anti-cancer effect of AEA on PCa cells. We
hypothesize that anandamide will reduce migration, invasion, and induce apo-
ptosis in PCa cells. Methodology: Human PCa cells (DU145, LNCaP, and PC3)
were treated with AEA at concentrations ranging from 1M to 40M and
growth of cells (using the MTS assay) was assessed at various times. Wound-
healing assays were conducted to investigate the migratory potential of cells
following 24hr exposure to treatment, and trans-well invasion assays were per-
formed to explore the influence of AEA on cell invasion. Flow cytometry, using
the FITCAnnexinV dead cell apoptosis kit, was used to detect the proportion of
apoptotic versus proliferating cells following anandamide treatment. Results:
There was a signifıcant reduction in the proliferation of DU145 cells at concen-
trations of 20Mand40MAEAcompared to controls (p0.02, 0.005). LNCaP
cells on the other hand required a higher concentration of AEA to achieve this
effect (p0.05). Cell migration and invasion studies on DU145 cells revealed a
signifıcant reduction in cellmotility at 20Mand 40MAEA (p0.006, 0.0005)
aswell as a signifıcant reduction in cell invasion at 20Mand40M((p0.0002,
0.0001). Flow cytometry results indicate a signifıcant increase in the proportion
of apoptotic cells compared to control (3 fold change) when treated with 20M
and 40M in DU145 and LNCaP cells. Conclusion: We have shown that AEA
has greatest signifıcant influence on cell migration, invasion, and apoptosis.
Further analysis on the role of AEA in these pathways is underway exploring
alterations in expression levels of key proteins implicated in cell migration and
apoptosis. Funding/ Conflicts of Interest: None
#9 Suppression of the invasion and growth of human head and neck squa-
mous cell carcinomas via regulating STAT3 signaling andmiR-21/-catenin
axis with HJC0152. YuWang,1 SinanWang,2 YanshengWu,1 Jia Zhou,3 Qiang
Shen,4 Xuan Zhou1. 1Tianjin Medical University Cancer Hospital, Tianjin, Chi-
na; 2Tianjin Medical University General Hospital, Tianjin, China; 3University of
Texas Medical Branch, Galveston, TX; 4The University of Texas MD Anderson
Cancer Center, Houston, TX.
Signal transducer and activator of transcription 3 (STAT3) is involved in the
tumor growth andmetastasis of human head and neck squamous cell carcinoma
(HNSCC) and is therefore a target with therapeutic potential. In this study, we
show that HJC0152, a recently developed anticancer agent and a STAT3 signal-
ing inhibitor, exhibits promising antitumor effects against HNSCC both in vitro
and in vivo via inactivating STAT3 and downstream microRNA-21/-catenin
axis. HJC0152 treatment effıciently suppressed HNSCC cell proliferation, ar-
rested the cell cycle at the G0/G1 phase, induced apoptosis, and reduced cell
invasion in both SCC25 and CAL27 cell lines. Moreover, HJC0152 inhibited
nuclear translocation of phosphorylated STAT3 at Tyr705 and decreased VHL/
-catenin signaling activity via regulation ofmicroRNA-21. Loss-of-function of
VHL remarkably compromised the antitumor effect of HJC0152 in both cell
lines. In our SCC25-derived orthotopic mouse models, HJC0152 treatment sig-
nifıcantly abrogated STAT3/-catenin expression in vivo, which leading to a
global decrease of tumor growth and invasion. With its favorable aqueous solu-
bility and oral bioavailability, HJC0152 holds the potential to be translated into
the clinic as a promising therapeutic strategy for patients with HNSCC.
#10 A small molecule derivative effectively inhibits proliferation of pan-
creatic cancer cells by targeting Sp1 and survivin. Myrna Hurtado,1 Umesh
Sankpal,1 Aboubacar Kaba,2 Shahela Mahammad,1 Alvin Holder,3 Jamboor
Vishwanatha,1 Riyaz Basha1. 1University of North Texas Health Science Center,
Fort Worth, TX; 2Alabama State University, Montgomery, AL; 3Old Dominion
University, Norfolk, VA.
Pancreatic cancer is one of the most fatal malignancies due to its poor prog-
nosis.With current standard treatment options, the overall 5 year survival rate is
about 16% and these treatment plans often cause high toxicity. Therefore, there
is an urgent need for identifying more effective and less toxic agents for the
treatment of this malignancy. Tolfenamic acid (TA) is a generic drug used to
treatmigraine headaches but has been demonstrated to have anti-cancer activity
in pre-clinical studies. It is known to downregulate the transcription factor Spec-
ifıcity protein 1 (Sp1). Sp1 regulates several genes involved in cell proliferation
and apoptosis, including survivin, an inhibitor of apoptosis protein. Interest-
ingly, a recent discovery proposed that copper(II) complex of TA can result in
higher therapeutic response; however its effıcacy was not tested in gastro-intes-
tinal cancers. In this study, we assessed the therapeutic effıcacy of a Cu(II)-
containing complex of TA (Cu-TA) using human pancreatic cancer cell lines.
MIA PaCa-2 and Panc-1 cells were treated with increasing concentrations of
vehicle (DMSO), equimolar CuCl2 (negative control), TA or Cu-TA and the cell
viability was measured at 24 and 48 h post-treatment using CellTiter-Glo kit.
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CuTA was further tested for its effect on Sp1 and survivin expression in MIA
PACa-2 cells by Western blot (protein) and quantitative PCR (mRNA). The
activation of apoptosis was determined by measuring the activity of effector
caspases using the Caspase3/7-Glo kit and the apoptotic cell population through
flow cytometric analysis usingAnnexin-V staining. Cell cycle arrest was assessed
by flow cytometry with propidium iodide staining. While both TA and Cu-TA
caused dose/time-dependent response to inhibit pancreatic cancer cell growth,
Cu-TA showed higher effıcacy when compared to TA. Cu-TA was highly effec-
tive in inhibiting Sp1 and survivin protein expression and showed similar trend
for inducing apoptotic markers and causing cell cycle arrest in early phase (G0/
G1). The results of qPCR demonstrated that the expression of survivin mRNA
was signifıcantly lower following both Cu-TA and TA treatment; however, the
mRNA expression of Sp1 remained unchanged. This indicates that TA and
Cu-TA could be working in similar mechanism by effecting Sp1 post-transla-
tionally, perhaps through proteasome-dependent degradation. These results
demonstrate that Cu-TA is more effective than TA and potentially useful for
pancreatic cancer treatment after clinical testing. Studies to precisely under-
stand the underlying mechanisms of Cu-TA are currently under investigation
through molecular profıling analysis.
#11 The oncolytic peptide LTX-315 enhances T cell clonality and induces
synergy with chemotherapy. Ketil André Camilio,1 Meng Yu Wang,2 Janne
Nestvold,1 Gunhild Mælandsmo,2 Baldur Sveinbjørnsson,1 Øystein Rekdal1.
1Lytix Biopharma AS, Oslo, Norway; 2Oslo University Hospital, Oslo, Norway.
LTX-315, a novel oncolytic peptide is effective against both drug-resistant and
drug-sensitive cancer cells with lower toxicity towards normal cells. Intratu-
moral treatmentwith LTX-315 results in growth inhibition, complete regression
and long lasting tumor-specifıc immune responses. The oncolytic effect of LTX-
315 involves perturbation of the plasmamembrane and distortion of intracellu-
lar organelles including the mitochondria with subsequent release of Damage-
Associated Molecular Pattern molecules (DAMPs) such as ATP, cytochrome c
and HMGB1. LTX-315 effectively induces necrosis within the tumor followed
by the release of tumor antigens as demonstrated by a greater increase in tumor
infıltrating CD8 T cells, expansion of T cell clonality, and number of clones
within the tumor microenvironment. LTX-315‘s ability to modify the tumor
microenvironment makes it ideal as a combination partner for other cancer
therapies, including chemotherapy and immune checkpoint inhibitors. In pre-
clinical tumor models, combination of LTX-315 and chemotherapeutic agents
such as cyclophosphamide and doxorubicin demonstrates signifıcant synergy.
#12 Evaluation of metformin and clotam combination for medulloblas-
toma.Umesh T. Sankpal,1 W Paul Bowman,1 Jeffrey C. Murray,2 Riyaz Basha1.
1Univ. of North Texas Health Science Ctr., Fort Worth, TX; 2Cook Children’s
Medical Center, Fort Worth, TX.
Medulloblastoma (MB) is the most common malignant brain tumor in chil-
dren. Standard treatment, which includes surgery, chemotherapy, and radia-
tion, is successful for most patients, but survivors often suffer from signifıcant
long-term side effects affecting their neurocognitive and growth potential.
Therefore, there is a critical need to understand the molecular processes that
regulate MB growth and fınd less toxic therapies. Survivin (BIRC5) was identi-
fıed as a protein belonging to the Inhibitor of Apoptosis Protein family that
inhibits apoptosis by inhibiting caspase activation. Survivin expression is also
associated with increased resistance of tumor cells to radiation and chemother-
apy. InMB, several studies suggest that increased expression of survivin serves as
amarker of tumormorphology and is associatedwith poor prognosis. Specifıcity
protein 1 (Sp1) is one of the transcription factors that regulates the expression of
survivin gene. Sp1 is also shown to be overexpressed in some cancer cells and is
associated with poor prognosis. In this study, we are testing a strategy of target-
ing survivin in MB using anti-diabetic drug Metformin, which targets Sp1, and
theNSAIDClotam (Tolfenamic acid, TA), which targets Sp1 and survivin. Dose
response curves were established by treatingMB cell linesDAOY andD283with
increasing concentrations of metformin or TA andmeasuring cell viability at 24
and 48h post-treatment using the CellTiter-Glo Cell Viability Assay. A time and
dose dependent inhibition of cell proliferation was observed for both the drugs.
Metformin dose response was then repeated in the presence of 25 or 50MTA.
Our results indicate that TA signifıcantly increased the growth inhibitory re-
sponse of metformin. To further characterize this response, we determined the
combination index (CI) using the Chou-Talalay method. We found that the CI
valueswere between 0.85 to 0.61 for various combinations ofmetformin andTA,
strongly suggesting a synergistic effect of the two drugs on cell proliferation.
Combination ofmetformin and TAwas also accompanied by a 3-4 fold increase
in apoptotic cells at 48h post-treatment, as determined by AnnexinV staining of
DAOYcells.Western blot analysis ofDAOYcells treatedwith the two drugs also
revealed a decrease in survivin and Bcl-2 protein levels, and an increase in
cleaved-PARP. In conclusion, the anticancer activity ofmetformin inMB cells is
enhanced in the presence of TA. Both drugs synergistically combine to inhibit
MB cell proliferation and increase apoptosis, which in part may be the result of
a decrease in survivin levels. This combination strategy may therefore represent
a novel targeted therapy forMB. Studies are underway to determinewhether this
drug combination can enhance the response of chemotherapy inMB cells, since
both TA and metformin are known to sensitize cancer cells to chemotherapy.
#13 Chromatin unfolding small molecules as a novel type of anticancer
agents. Katerina V. Gurova. Roswell Park Cancer Institute, Buffalo, NY.
Although targeted therapy was the major focus of anti-cancer drug develop-
ment, recently revealed enormous heterogeneity of tumors planted a seed of
doubt in it as a potential cure for cancer. Very few universal cancer targets are
known and they lack cancer specifıcity. DNA is one of this sort, but activity of
drugs targeting DNA was traditionally attributed to their ability to block DNA
replication and cause DNA damage with a plethora of harmful long lasting
effects in normal cells. We have found that reversible binding of DNA by non-
DNAdamaging small molecules, curaxins, has strong anticancer effect in differ-
ent preclinical models without deleterious consequences associated with DNA
damage (REF). In this study we explained the mechanism of activity of curaxin
clinical lead, CBL0137, through alteration of chromatin organization in tumor
cells. Intercalation of the curaxin carbazolemoiety between base pairs andDNA
major and minor groove binding with curaxin side chains cause an increase in
inter base pair distance and untwisting of the double helix (18o). Such altera-
tion of DNA helical shape leads to decreased nucleosome stability and chroma-
tin opening, creating sites for the high affınity binding of histone chaperone
complex FACT.We named this phenomenon “chromatin trapping of FACT” or
c-trapping. Consequences of C-trapping are much more deleterious for tumor,
than for normal cells. First, c-trapping is an equivalent of functional inactivation
of FACT. FACT is critical for oncogenic transformation and tumor, but not
normal cell, viability and growth (REF). FACT is essential for the activity of
several transcription factors, such as NF-kappaB, HSF1, MYC etc., with impor-
tant roles in tumor cell proliferation and survival (REF). Further, deregulation of
transcription caused by curaxin-dependent chromatin decondensation leads to
upregulation of transcription from heterochromatin. This leads to the forma-
tion of double stranded RNAs from centromeric and pericentromeric repetitive
elements, which mimics a viral infection and induces an IFN response, a pow-
erful inhibitor of tumor cell growth. Additionally, c-trapping of FACT leads to
casein kinase 2 mediated phosphorylation and activation of wild type p53 lead-
ing to p53-dependent death of cells. Thus non-DNA damaging DNA binding
small molecules compromise cancer cell viability via alteration of nucleosome
stability and chromatin organization. This is a novel mechanism of anti-cancer
activity of small molecules with broad applicability to different types of cancer
while lacking the harmful effects of DNA damaging chemotherapy.
#14 Anticancer activities of terpenoid compounds isolated from the plant
centipeda minma against nasopharyngeal carcinoma cells. Bei-bei Liu,1 Kui-
yuan Zhu,1 Chi-on Chan,1 Ling-Hua Zhang,2 Daniel Kam-Wah Mok,1 Si-bao
Chen1. 1State Key Laboratory of ChineseMedicine andMolecular Pharmacology,
The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen,
China; 2NANOBIOTEC LLC, Whippany, NJ.
Nasopharyngeal carcinoma (NPC) is one of common cancers throughout
south-east Asia, southern China and other regions. Radiotherapy and chemo-
therapy are the standard treatments for NPC with severe adverse effects, multi-
drug resistance, and insensitivity to advanced NPC. Complementary and novel
treatments for NPC gain considerable interest around the world. The medicinal
plant Centipeda minma is traditionally used in China for the treatment of vari-
ous nasal diseases such as allergy, rhinitis, sinusitis and nasopharyngeal carci-
noma. In the current study, we studied the anticancer potential of an ethanol
extract (CME) and 3 pure sesquiterpenoids (A1, A2, A3) extracts from Centi-
peda minma against NPC cells in vitro and some underlying mechanisms of
actions. The NPC cell lines CNE-1 and CNE-2 cells were treated with either
CME or 3 pure compounds (A1, A2, A3). Proliferation of NPC cells was inhib-
ited in a concentration- and time-dependent manner. For 48 h treatment, the
IC50 values were 41.57 to 24.98g/mL for CME, and 2.3 to 7.5MforA1 toA3.
While these extracts showed no appreciable effect on normal human LO2 hepa-
tocytes, signifıcant numbers of NPC cells underwent apoptotic morphological
changes following treatments. Cytometric analysis demonstrated that treat-
ments with CME and compounds results in NPC cell cycle arrest at the G2/M
phase and eventually apoptosis in a concentration and time-dependentmanner.
Western blot analysis showed that these extracts could down-regulate Bcl-2
expression, up-regulate Bax expression and caspase-8, 9, 3 activities. In addition,
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the potential anti-NPC actions might be also associated with the marked inhi-
bition of multiple signal transduction pathways including EGFR, VEGFR,
HER2, FGFR, IGF-1R, PI3K/AKT/mTOR, MAP/ERK and Jan/Stat3 pathways.
In summary, the Centipedaminma extract and terpenoids are potential apopto-
sis inducing agents to kill NPC cells and may be promising anti-cancer drug
leads against nasopharyngeal carcinoma. The exact mechanism of actions re-
mains further study.
#15 Suppression of adaptive responses to targeted therapies by transcrip-
tional inhibition. Maria Rusan,1 Kapsok Li,1 Yvonne Li,1 Camilla L. Chris-
tensen,1 Brian J. Abraham,2 Nicholas Kwiatkowski,1 Kevin Buczkowski,1 Bruno
Bockorny,1 Ting Chen,1 Shuai Li,1 Haikuo Zhang,1 Hideko Terai,1 Tiffany Ta-
vares,1 Tinghu Zhang,1 Tae Jung Kim,1 Michael Silkes,1 Tenny Mudianto,1 Li
Tan,1 Takeshi Shimamura,3 MatthewMeyerson,1 HideoWatanabe,4 Nathanael
S. Gray,1 Richard A. Young,2 Kwok-KinWong,1 Peter S. Hammerman1. 1Dana-
Farber Cancer Institute, Boston, MA; 2MIT Whitehead Inst. for Biomed. Resea,
Cambridge, MA; 3Loyola University Chicago, Maywood, IL; 4Icahn School of
Medicine at Mount Sinai, New York, NY.
Tumor cells become dependent on the expression of key genes that drive
hallmark tumor traits, but these “addictions” also represent potential vulnera-
bilities for therapeutic intervention. Treating tumor cells with a small molecule
inhibitor of the transcriptional kinaseCDK7 selectively suppresses expression of
key dependency genes inmultiple cancers.Our previouswork showed responses
to the CDK7 inhibitor THZ1 were especially noteworthy in T cell leukemias,
small cell lung cancers, and triple-negative breast cancers—tumor types where
the prognoses are especially unfavorable. The genes whose expression is most
sensitive to CDK7 inhibition and whose expression is essential for tumor cell
survival are often associated with super-enhancers—clusters of constituent en-
hancers that are bound by unusually large amounts of transcription apparatus
including CDK7 itself. This “Achilles’ cluster” of super-enhancer-associated
genes thus represents the set of addictions of tumor cells whose expression is
important for tumor cell survival. Transcriptional inhibition synergizes with
targeted therapies in models of multiple tumor types. Treating tumors with
therapies that target kinase proteins such as EGFR, FGFR, and KRAS leads to
resistance, which is concurrent with changes in the activities of enhancers and
super-enhancers and gene expression programs of resistant cells. Treating cells
with a transcriptional inhibitor in addition to targeted therapies prevents “re-
wiring” of the gene expression program and increases cell death in tumor mod-
els. Thus transcriptional inhibition represents a promising avenue in both
monotherapy and combination settings where drug resistance is acquired.
#16 Evaluation of the effıcacy of clotrimazole treatment in human mela-
noma cell lines that overexpress the multidrug resistance-associated protein
(MRP) and the lung resistance-related protein (LRP). Steven D. Blake, Shelby
G.McKamey, ChristopherM. Tweed, DavidW. Koh.Ohio Northern University,
Ada, OH.
Drug resistance to chemotherapy, mediated in part by overexpression of P-
glycoprotein (MDR-1), multidrug resistance-associated protein (MRP), or lung
resistance-realted protein (LRP), continues to be a major problem in the treat-
ment of melanoma. Because we previously demonstrated the ability of clotrim-
azole to enhance cytotoxicity in human metastatic melanoma cells, here we
evaluated the ability of clotrimazole to treat drug-resistant human melanoma
cells that overexpressMRP and/or LRP.We utilized humanmelanoma cell lines
that overexpress eitherMDR or LRP, and humanmelanoma cell lines that over-
express both. Cell growth and cell death were analyzed by flow cytometry, pro-
liferation assays, and immunoblotting after drug treatments and RNA interfer-
ence. Clotrimazole caused signifıcant decreases in proliferation and increases in
cell death in both drug-sensitivemelanoma lines and those overexpressingMRP
and LRP. No extensive cell death was induced by clotrimazole treatment in
noncancerous human skin cell lines. These results indicate that clotrimazole
selectively induces cytotoxicity in both drug-sensitive and drug-resistant mela-
noma lines. As clotrimazole is known to inhibit various transient receptor po-
tential (TRP) ion channels, we pretreated thesemelanoma lines with TRP inhib-
itors or RNAi. Inhibitors of the TRP melastatin-8 channel (TRPM8) or TRP
vanilloid-1 (TRPV1) failed to produce comparable levels of cell death caused by
clotrimazole. However, RNAi silencing of the TRPM2 cation channel caused
signifıcant levels of cell death in both drug-sensitive and drug-resistant mela-
noma lines. These results indicated that inhibition of TRPM2channelsmay have
a primary role in the ability of clotrimazole to treat drug-sensitive and drug-
resistant melanoma lines. In conclusion, this study demonstrated that clotrim-
azole selectively increases cell death in drug-resistantmelanoma lines, withmin-
imal deleterious effects in normal skin cells. Taken together, we conclude that
clotrimazole has in vitro effıcacy toward the treatment of drug-resistant human
melanoma cells. Thus, these preliminary studies indicate that clotrimazole has
the potential to successfully treat drug resistant melanoma in the future.
#17 Anti-metastatic platinum through glycan targeting in breast cancer.
Samantha J. Katner,1 Erica Peterson J. Peterson,1 Eriko Katsuta,2 Stephanie C.
DeMasi,1 Jennifer Koblinski,1 Kazuaki Takabe,2 Nicholas P. Farrell1. 1Virginia
Commonwealth University, Richmond, VA; 2Roswell Park Cancer Institute, Buf-
falo, NY.
The high affınity of polynuclear platinum compounds (PPCs) for heparan
sulfate (HS) is mediated through a “sulfate clamp” and PPC interactions can be
conceptualized as “polyarginine” mimics. Strong HS-PPC binding protects the
oligosaccharide against sulfate loss throughmetalloshielding.1Metalloshielding
will in principle affect HS interactions with relevant enzymes and proteins such
as heparanase and growth factors, similar in concept to inhibition of DNA-
protein binding through modifıcation of DNA structure and conformation.2
PPCs inhibit cleavage of a model pentasaccharide by heparanase and further
modulate bFGF binding to HS, and bFGF-induced migration and signaling in
colon cancer cells.3 The end-point of functionalmodulation ofHS interactions is
inhibition of angiogenesis and metastasis.3 Following proof-of-principle of
strong in vivo anti-metastatic activity of PPCs in clinically relevant breast cancer
models,4 this contribution examines the underlying mechanism of platinums as
anti-metastatic agents. We report on the cellular effects of PPC-HS metal-
loshielding on multiple growth factor signaling pathways (bFGF, HB-EGF) and
specifıc syndecan (Sdc)-dependent signaling in breast cancer. Coupledwith pre-
viously demonstratedDNAbinding, PPCs represent intrinsically dual- function
agents combining platinum cytotoxicity with anti-angiogenic effects derived
from fırst principles through glycan targeting. [1] Mangrum, J.B., Engelmann,
B.J., Peterson, E.J., Ryan, J.J., Berners-Price, S.J., Farrell, N.P. Chemical Com-
munications 2014, 50, 4056-4058. [2] Chiodelli, P., Bugatti, A., Urbinati, C.,
Rusnati, M. Molecules 2015, 20, 6342-6388. [3] Peterson, E.J., Daniel, A.G.,
Katner, S.J., Bohlmann, L., Chang,C., Bezos, A., Parish, C.R., von Itzstein, M.,
Berners-Price, S.J., Farrell, N.P. Chem. Sci. 2016, DOI: 10.1039/C6SC02515C.
[4] E. Katsuta, S. Demasi, S. Katner, H. Aoki, E. Peterson, E., N.P. Farrell and K.
Takabe. (2016). Proc. AACR New Orleans, LA. Abstract #3064. DC 1-5 April
2017
#18 Vorinostat reexpressed estrogen receptor (ER) in triple negative
breast cancer cell line subtypes and sensitized cells to tamoxifen and indole-
3-carbinol in vitro. Beverly D. Lyn-Cook,1 Julie Getz,1 Beverly Word,1 Rhonda
Moore,2 Gustav Miranda-Carboni3. 1FDA-NCTR, Jefferson, AR; 2FDA/Center
for Tobacco Product, FDA, MD; 3University of Tennessee Health Science Center,
Memphis, TN.
Triple negative breast cancer (TNBC) is one of themost aggressive subtypes of
breast cancer. Although about 85% of breast cancers are estrogen positive, about
15% falls into this category. This subtype of cancer lacks targeted therapies
receptors, such as the estrogen receptor (ER), progesterone receptor (PR), and
the human epidermal growth factor receptor-2 (HER2). These patients are lim-
ited to cytotoxic chemotherapieswith harsh side effects. In addition to occurring
in younger women, other risk factors for TNBC include: being of African de-
scent, BRCA1 mutation, a strong family history of breast cancer, lifestyle and
environmental factors. Although mutations are involved in the initiation of
TNBC, research has revealed that individuals are controlled by factors other
than DNA sequences such as epigenetic mechanisms. Environmental and life-
style related factors, such as the lack of population-based screening, and lack of
access to care-factors, the urban environment, food deserts, social stress, racism,
diet, lack of exercise, alcohol intake, and tobacco use (i.e. cigarette smoking)
have all been described as factors associated with breast cancer related dispari-
ties. This study investigated the role of epigenetic mechanisms in the re-expres-
sion of ER receptors in triple negative breast cancer (TNBC) cells by examining
the effects of a FDA-approved epigenetic drug (vorinostat) and the dietary agent
(indole-3-carbinol) on three subtypes of triple negative breast cancer. Basal-like
2 (HCC1806), mesenchymal stem cell-like (MSL) MDA-MB-231 and mesen-
chymal (BT-549) cell lines were treated with vorinostat for 6, 12, 24 and 48 hrs
alone. TheERwas expressed inHCC1806 (3-fold) andMDA-MB-231 (5-fold) at
6 hr. The ER was not expressed in BT-549 cells at any time point. MTS assay
demonstrated a signifıcant decreased in proliferation (60%) in MDA-MB-231
when treated with vorinostat (10, 20 or 30 M) and 10 M of tamoxifen. Fur-
thermore, a signifıcant decrease (40%) in proliferation was also detected in
MDA-MB-231 cells treatmentedwith I3C (200M) and vorinostat (10, 20 or 30
M). Our preliminary results show that three triple-negative cell lines repre-
senting three subtypes responded different to treatment with vorinostat in re-
expressing the estrogen receptor. However, these results showed promising re-
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sult for the use of this drug in sensitizing triple negative breast cancer cells to
tamoxifen and a dietary agent, indole-3-carbinol. Further functional studies are
currently underway.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Antibodies, Bispecifıcs, and Antibody-Drug Conjugates
#20 Xentuzumab, a humanized IGF-1 and IGF-2 ligand neutralizing anti-
body, improves the antitumor effıcacy of enzalutamide in preclinical models
of prostate cancer. Ulrike Weyer-Czernilofsky,1 Marco H. Hofmann,1 Paul J.
Adam,1 Flavio Solca,1 Katrin Friedbichler,1 Norbert Kraut,1 Eva Corey,2
Thomas Bogenrieder1. 1Boehringer Ingelheim RCVGmbH&CoKG,Wien, Aus-
tria; 2University of Washington, Seattle, WA.
Background: The proliferative and pro-survival signals driven by the insulin-
like growth factor (IGF) ligands, IGF-1 and IGF-2, are transmitted through their
binding to the IGF-1 receptor (IGF-1R). In addition, IGF-2 activates the insulin
receptor variant A (IR-A) that is expressed during embryonic development as
well as in many cancers. A large body of preclinical evidence suggests that IGF
signaling plays a key role in cancer by driving therapy resistance, due to cross-
talk with other signaling networks such as androgen receptor signaling. The aim
of this study was to explore the potential of the IGF-1/-2 ligand blocking anti-
body, xentuzumab (BI 836845[1]), to enhance the anti-tumor activity of enzalu-
tamide in prostate cancer cell lines and in a patient-derived prostate cancer
xenograft model. Methods: Effects of enzalutamide, xentuzumab and combina-
tions thereof on in vitro proliferation, survival, cell cycle and signaling were
evaluated using the prostate cancer cell lines VCaP, DuCaP, MDA PCa 2b, and
LNCaP. The in vivo effıcacy of enzalutamide, alone and in combination with
xentuzumab was investigated using LuCaP 96CR, a patient-derived xenograft
model of castration-resistant prostate cancer. Tumors were implanted s.c. into
castrate SCIDmice.When tumors exceeded 150mm3 animals were randomized
into groups: 1) Control; 2) enzalutamide (50 mg/kg QD po), 3) xentuzumab (BI
836845[1], 200 mg/kg QW ip) in combination with enzalutamide. Results: Cell
viability was more effectively reduced by the combination of enzalutamide and
xentuzumab than either drug alone in three of four cell lines expressing the
IGF-1R and the androgen receptor (AR). In VCaP cells, prolonged inhibition of
IGF pathway signaling and enhanced blockade of proliferation as well as induc-
tion of apoptosis was observed after combination treatment. In vivo, enzalut-
amide monotherapy did not show signifıcant antitumor effıcacy in the LuCaP
96CR model, however, combined treatment with xentuzumab signifıcantly in-
hibited progression of LuCaP 96CR tumor growth (p0.001 vs. enzalutamide
alone). Reduced serum PSA levels were observed after enzalutamide and com-
bination treatment. Enzalutamide plus xentuzumab inhibited tumor growth at
tolerated doses and resulted in signifıcant improvements in survival. Conclu-
sions: These studies demonstrated that addition of the IGF-1/-2 neutralizing
antibody xentuzumab to enzalutamide results in improved anti-neoplastic ac-
tivity in a subset of prostate cancer cell lines in vitro, and to re-sensitization to
enzalutamide in a patient-derived xenograft model of CRPC. Reference: [1]
Friedbichler K et al. (2014). Mol Cancer Ther 13(2):399-409.
#21 Regulation of proliferation and invasion through the inhibition of
IGF signaling pathway on Epstein-Barr virus associated gastric cancer. Inhye
Jeong,1 Hoi Young Lee,2 Jae Kyung Roh,3 Tae Soo Kim,3 Suk Kyeong Lee,4
Woo-Ick Jang,5 Hyun Cheol Chung,1 Sun Young Rha6. 1Song-dang Institute for
Cancer Research, Brain Korea 21 PLUS Project for Medical Science, Yonsei Uni-
versity College of Medicine, Seoul, Republic of Korea; 2Department of Pharmacol-
ogy, College of Medicine, Konyang University, Seoul, Republic of Korea; 3Song-
dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul,
Republic of Korea; 4Research Institute of Immunobiology, Department ofMedical
Lifescience, College of Medicine, Catholic University of Korea, Seoul, Republic of
Korea; 5Handok, Inc., Seoul, Republic of Korea; 6Song-dang Institute for Cancer
Research, Brain Korea 21 PLUS Project for Medical Science, Division of Medical
Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei Uni-
versity Health System, Seoul, Republic of Korea.
Epstein-Barr virus associated gastric cancer (EBVaGC) is one subtype of four
molecular classifıcations by TCGA group. Specifıcally, EBV related viral RNAs,
microRNAs and proteins regulate cancer progression phenomena like aggres-
siveness, motility, invasion and metastasis. Nonetheless, understanding the
mechanisms of viral growth dependency beyond malignant EBV transforma-
tion are still defıcient. Finding the EBV dependent pathway with signifıcant
biological role and the clinically appropriated drug is needed for EBVaGC in this
regard. We investigated new therapeutic target and its role of regulating in pro-
liferation and invasion using EBVaGC cell line model. First, we determined
proliferation both of AGS and EBV infected AGS (AGS-EBV) cell lines during 7
days by proliferation assay. For the test of BI836845 (IGF ligand neutralizing
antibody, Boehringer Ingelheim, German) effıcacy, CCK-8 assay was per-
formed. mRNA expression levels of IGF-1R, IGF-1, IGFBP-3 and IGFBP-6
which is the key regulator of IGF-signaling were measured by RT-PCR. Also,
protein expression levels of IGF associated and downstream factors were con-
fırmed byWestern blotting. Lastly, invasiveness of cells was detected by invasion
assay. As a result, AGS-EBV showed the slower proliferation rate compared to
AGS, but the sensitivity to BI836845 was signifıcantly increased in a dose-de-
pendent manner (p0.001). Interestingly, baseline IGFBP-3 mRNA expression
of was enhanced in AGS-EBV compared with AGS. In addition, BI836845
treated group showed up-regulated IGFBP-3 mRNA level in AGS and down-
regulated IGFBP-3 mRNA level in AGS-EBV. When BI836845 treated to
AGS-EBV, phospho-Akt level was highly inhibited. Moreover, invasiveness
of AGS-EBV was elevated about 2 fold more than AGS. Treatment of BI836845
inAGS-EBV represented signifıcant decrease the invasiveness (p0.08). In con-
clusion, AGS-EBV seems to modulate their proliferation and invasion through
the IGF signaling pathway. Inhibition of IGF signaling pathway would be the
potential therapeutic strategy for EBV associated gastric cancer.
#22 MM-161, a fırst-in-class pan-FGFRantibody.TamaraDake,Greg Finn,
Melissa Geddie, Neeraj Kohli, Maja Razlog, Lihui Xu, Violette Paragas, Haluk
Yuzugullu, Sara Ghassemifar, Yasmin Hashambhoy-Ramsay, Charlotte Mc-
Donagh,MarcoMuda, Birgit Schoeberl.Merrimack Pharmaceuticals, Inc, Cam-
bridge, MA.
Aberrant signaling of the FGFR pathway has long been known to promote
tumorigenesis and angiogenesis across multiple cancer indications. However,
the development of an effective and well-tolerated FGFR targeted inhibitor has
been hindered by the need to block the activation of multiple mitogenic recep-
torswhile avoiding signifıcant toxicities associatedwith blocking endocrine FGF
ligands. Here we disclose for the fırst time a novel FGFR targeted antibody,
MM-161, designed to block ligand-dependent signaling driven by all four FGF
receptors, specifıcally the IIIc-isoforms. MM-161 is well tolerated in mice and
cynomolgus monkeys with no signifıcant weight loss observed in either species.
Effıcacy studies demonstrated that MM-161 monotherapy leads to signifıcant
tumor growth inhibition or tumor regression of xenografts of human lung, renal
and endometrial cancer amongst others. Importantly,MM-161has a dualmech-
anism of action by inhibiting both proliferation and angiogenesis. We will pres-
ent data illustrating that inhibition of multiple FGFRs is desirable to achieve
tumor regression. Furthermore, we will show combination studies with relevant
standard of care therapies in models of lung and renal cancer. Taken together,
our preclinical data strongly supports the clinical evaluation of MM-161 in can-
cer patients.
#23 Antibody targeting of ADAM8 for treatment of triple-negative breast
cancer. Sonia G. Das, Stefania Pianetti, Gail E. Sonenshein, Nora D. Mineva.
Tufts Univ. School of Medicine, Boston, MA.
Triple-Negative Breast Cancer (TNBC) accounts for 25% of breast cancer
deaths. Current therapeutic options are restricted to chemotherapy (CT) and
radiation, which fail to block disease progression. Recently, we identifıed the cell
surface protein ADAM8 as a critical driver of TNBC tumor growth and of me-
tastasis in half of all breast cancers (EMBO Mol. Med. 6:278, 2014). Elevated
ADAM8 levels correlate with poor breast cancer patient outcome. One third of
TNBC patient samples have high ADAM8 levels, while it is undetectable in
normal breast tissue. ADAM8 Metalloproteinase (MP) and Disintegrin (DI)
domains promote angiogenesis needed for tumor growth, and cancer cell adhe-
sion to and invasion through the endotheliumneeded for dissemination, respec-
tively. Using a prototype reagent in mice, we validated a unique antibody-based
strategy that simultaneously targets ADAM8 MP/DI activities as an effective
therapeutic intervention in TNBC. Our group has now prepared a panel of
pre-clinical, highly specifıc anti-human ADAM8mouse monoclonal antibodies
(ADPs) of either IgG1or IgG2 subclasswith dualMP/DI antagonist activity. The
top 6 ADPs bind ADAM8 with low dissociation constants of 1.3 x 10-9 M to
7.23 x 10-8 M. The 4 most effective inhibitory ADPs in cell-based assays were
screened in a single-dose effıcacy study (10 mg/kg 3x/wk) against pre-existing
MDA-MB-231 cell-derived tumors (50-75 mm3). ADP2 and ADP13 treatment
resulted in signifıcant tumor volume reduction, of 47% and 52%, respectively.
Dose-response curves are in progress. ADP13 was also tested in a neo-adjuvant
model for its ability to reduce metastases. Antibody treatment was initiated as
above and continued for 6weeks after tumors were resected at a volume of200
mm3.Metastases in dissected organswere examinedusing biophotonic imaging.
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ADP13 substantially decreased metastasis to multiple organs. Lastly, a neo-ad-
juvant survival experiment was performed, as above, except that following sur-
gical resection of tumors mice were treated for 12 weeks. Recurrence at the
primary site was assessed using palpation. Mice were sacrifıced when recurrent
tumors reached 900 mm3. ADP13 treatment resulted in signifıcantly improved
disease-free survival (P0.05) and overall survival (P0.03). More recently, we
noted that ADAM8 regulates miRNAs associated with resistance to CT and
showed that ADAM8 inhibition sensitizes TNBC cells to Cisplatin, Paclitaxel,
and Doxorubicin. In vivo testing of a combinatorial anti-ADAM8  CT ap-
proach is in progress and may present a promising strategy for early entry into
the clinic. Conclusions: A new anti-ADAM8 antibody therapeutic shows effı-
cacy against TNBC tumor growth and dissemination, and improves survival in
pre-clinical testing. We hypothesize that addition of an anti-ADAM8 antibody
to current CT standards of care will enhance tumor killing, reduce metastasis,
and increase survival of patients with ADAM8-expressing TNBC.
#24 HMBD001, a novel anti-ErbB3 antibody with a unique mechanism of
action, effectively inhibits tumor growth in pre-clinical models of ErbB3
solid tumors. Jerome D. Boyd-Kirkup, Dipti Thakkar, Piers J. Ingram. Hum-
mingbird Bioscience, Singapore.
Gastric cancer is the second highest cause of cancer mortality in Asia. Over-
expression of ErbB3, a cell surface RTK, occurs in60% ofmGCpatients where
it is signifıcantly associated with poorer survival. Ligand binding to ErbB3 trig-
gers heterodimerization and downstream signaling through Akt. Neutralizing
antibodies that inhibit ligand binding show poor effıcacy in clinical trials, likely
due to high levels of ligand independent activation in many tumor types. Di-
rectly inhibiting heterodimerization could be more effective, however, current
methods of antibody isolation offer limited control over the site of antibody
binding and, therefore, mechanism of action, requiring extensive screening of
antibodies and posing signifıcant challenges to identifying suitable candidates
for therapeutic development. Hummingbird Bioscience has used its proprietary
Rational Antibody Development Platform for the design and development of
novel therapeutic antibodies against ErbB3. Computational sequence and struc-
tural analyses predicted highly specifıc surface epitopes, with strong antigenicity
and good safety profıles, where antibody binding would inhibit dimerization.
Subsequently, Hummingbird’s directed evolution mouse immunization strat-
egy effıciently isolated monoclonal antibodies that bound with low nM (Kd 
5nM) affınity to these epitopes on native folded ErbB3. Furthermore, these
mAbs showed ELISA cross-reactivity to ErbB3 in model organisms (mouse, rat,
monkey) but no binding to other EGFR family proteins. Antibody HMBD001
was found to strongly inhibit the phosphorylation of ErbB3 and decrease down-
stream signaling through the Akt pathway (90% decrease in p-ErbB3 and 60%
decrease in p-AKT observed at 24 hrs) resulting in the inhibition of tumor cell
proliferation in models of ErbB3 gastric cancer (over 90% inhibition of NCI-
N87 proliferation after 5 days) and breast cancer (up to 85% inhibition of BT474
proliferation after 5 days). In mouse NCI-N87 gastric cancer CDX models,
weekly doses of HMBD001 achieved greater than 90% inhibition of tumor
growth (at 25 days) with no observable adverse toxicity. The fırst in-human trial
of HMBD001 is planned for 2018.
#25 Efect of nimotuzumab on malignant pleural mesothelioma cell lines.
Saé Muñiz-Hernández,1 Vanessa Izquierdo-Sánchez,1 Jorge A. Mendoza-
Desión,1 Carolina González-Torres,2 Oscar Arrieta1. 1Instituto Nacional de
Cancerología de México, Ciudad de México, Mexico; 2Instituto Nacional de Me-
dicina Genómica, Ciudad de México, Mexico.
Malignant Pleural Mesothelioma (MPM) is one of the most clinically aggres-
sive malignancies, with a median survival time of less than 12 months. The
monotherapy or combination of therapy with platinum-antifolate chemother-
apy agents,may provide survival and life quality improvement inMPMpatients.
EGFR has been a target for new development drugs that could be used as on-
cologyc treatment. Nimotuzumab is a humanized antibody, design byCentro de
Inmunología Molecular (Habana, Cuba), for treatment EGFR overexpress neo-
plasms. This antibody was approved for treatment of head and neck cancer and
metastasic colorectal cancer.MPM exhibit an important expression of EGFR. In
this study, we analyzed the efect of nimotuzumab on two cell lines derived of
MPM and a xenograph model of one of them, in atimic nude mouse model.
MSTO-211 and H2452 mesothelioma cell lines; MRC-5 normal lung cell line
and A431 as EGFR positive cell line were used for all assays. We analyzed the
viability of cell lines using violet cristal assays. Apoptosis were analyzed with
Anexin-V-Fluos Staining kit accordin to manufacturer instructions. We ana-
lyzed the EGFR expression by WB assays. Finally, we generated a xenograft
model with MSTO cells in nu/nu mice, and we treated a group with nimotu-
zumab or cisplatin-gemcitabine one doses/week. Nimotuzumab at any concen-
tration (50, 100, 400 g/mL) no modifıed the cellular viability, in both tumor
andnormal cells, the assayswas followed from24h to 96 h after exposition.With
respect at apoptosis, we no found signifıcant diferences between control and
exposured samples at 48 and 72 h after nimotuzumab treatment. In order to
analyzed the EGFR expression in mesothelioma cell lines, we obtained protein
total extract and then a WB was realized. The total protein from MSTO-211,
H2452, A431 and MRC-5 cultures in normal conditions and exposed at nimo-
tuzumab 100g/mLby 24h,were obtained; then a PAGE-SDSwere realized.We
observed that both mesotelioma derived cell lines showed similar EGFR expre-
sion when it compared with A431 in normal culture conditions; while MRC-5
no showed EGFR expresion. When cellular cultures were exposed to nimotu-
zumab 100 g/mL by 24h, H2452 and A431 cells showed similar EGFR expres-
sion while MSTO-211 showed high expression. Mice nu/nu (n3) were subcu-
taneously inoculated in the dorsal right flank with MSTO-211 cells. Treatment
was applied to animals when tumors were 50 mm3. First mice group received
nimotuzumab, second group received cisplatin-gemcitabine; and third groupno
received treatmed. Nimotuzumab induced a reduction in tumor volumen and
mice survival by 4 weeksmore that those in the other groups. In vitro exposition
of nimotuzumab in mesotelioma cell lines no affect their viability or induce
apoptosis. According with the treatment scheme used in this work, nimotu-
zumab treatment induce a major survival and low toxicity in mice with meso-
thelioma pleural malignant xenograph.
#26 Panitumumab interacts with TAS-102 leading to combinational anti-
cancer effects by blocking EGFR-mediated tumor response to trifluridine.
Kazuhide Nakamura,1 Yuji Baba,1 Toshiya Tamura,1 Yoshihiko Satoh,1
Masamitsu Gotou,1 Hiroshi Sawada,1 Shunsuke Ebara,1 Kazunori Shibuya,2
Jumpei Soeda2. 1Takeda Pharmaceutical Company Limited, Fujisawa, Japan;
2Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Panitumumab is a monoclonal antibody raised against the human epidermal
growth factor receptor (EGFR). TAS-102 is a novel chemotherapeutic agent
containing trifluridine (FTD) as the active cytotoxic component. Both panitu-
mumab and TAS-102 have been approved for the treatment of metastatic colo-
rectal cancer (mCRC). In this study, we show the mechanism underlying the
anti-cancer effects of the panitumumab/TAS-102 combination in preclinical
models. Co-treatment with panitumumab and FTD exerted additive and syner-
gistic anti-proliferative effects in LIM1215 and SW48 colon cancer cells, respec-
tively. Consistent with the in vitro effects, panitumumab/TAS-102 combination
led to tumor regression in LIM1215 and COL-01-JCK colon cancer patient-
derived xenograft models. In LIM1215 cells, FTD induced ERK/Akt/STAT3
phosphorylation and subsequent serine/threonine phosphorylation of EGFR,
while it had no effects on EGFR tyrosine phosphorylation. Panitumumab and
the tyrosine kinase inhibitor erlotinib reduced the basal level of EGFR tyrosine
phosphorylation and reversed the FTD-induced ERK/Akt/STAT3 and EGFR
serine/threonine phosphorylation. These results suggested that FTD together
with the basal activity of the EGFR tyrosine kinase induced downstream pro-
survival signaling through ERK/Akt/STAT3. Collectively, we propose that pa-
nitumumab interacts with FTD by targeting EGFR-mediated adaptive re-
sponses, thereby exerting anti-cancer effects in combination with TAS-102.
These preclinical fındings provide a compelling rationale to evaluate anti-EGFR
antibodies combined with TAS-102 against mCRC.
#27 Combination of paclitaxel and Sym015, a mixture of twomonoclonal
antibodies directed atMET receptor, to increase anti-tumor effects in gastric
cancer. Hyun Jeong Kim,1 Sun Kyoung Kang,2 Ivan Horak,3 Michael Kragh,3
Woo Sun Kwon,2 Tae Soo Kim,2 Inhye Jeong,1 Sun Young Rha,4 Hyun Cheol
Chung4. 1Song-Dang Institute for Cancer Research, Brain Korea 21 PLUS Project
for Medical Science, Yonsei University College of Medicine, Seoul, Republic of
Korea; 2Song-Dang Institute for Cancer Research, Yonsei University College of
Medicine, Seoul, Republic of Korea; 3Symphogen A/S, Ballerup, Denmark; 4Song-
Dang Institute for Cancer Research, Brain Korea 21 PLUS Project for Medical
Science, Division of Medical Oncology, Department of Internal Medicine, Yonsei
Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
MET is a proto-oncogene that encodes a protein known as hepatocyte growth
factor receptor (HGFR), involved in proliferative, survival and invasive/meta-
static abilities of cancer cells. MET has received considerable attention as a
potential target for cancer therapy, including gastric cancer (GC). MET ampli-
fıcation is present in 4-5% of GC patients, and associated with poor outcomes
and signifıcantly shorter median survival. Although intensive efforts have been
directed toward the development of HGF-MET axis inhibitors, there are some
issues for clinical translation; 1) proper biomarker to select patients, 2) proper
chemotherapy combination partner and 3) proper line of treatment. Therefore,
exploring drug to inhibit HGF-MET axis is essential. Among them, Sym015
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(Copenhagen, Demark), a mixture of two monoclonal antibodies directed at
MET receptor, is one of the leading agents in the pipeline. In this study, we had
49 GC cell lines including 27 Korean cancer patients. Those cells were analyzed
by whole exome sequencing (WES) and RNA sequencing to understand biolog-
ical and molecular characteristics. Also, expression levels of MET and MET-
associated molecules were determined by western blot and HGF expression was
evaluated by ELISA. Sensitivity of Sym015 was screened in 49 GC cell lines and
combination with paclitaxel was performed in 6MET amplifıcation cell lines by
CCK-8 assay. Combination index (CI) and dose reduction index (DRI) were
evaluated by CalcuSyn software. Among 49 GC cell lines, we confırmed 6 cell
lines with MET amplifıcation including 2 novel Korean cancer patient cell lines
(YCC-31 and YCC-34) and 17 (34.7 %) cell lines were sensitive to Sym015 with
2068 % inhibition rate at 100 nM. And our data showed that Sym015 was
related to MET amplifıcation, c-Met/p-Met overexpression and exon 14 dele-
tion, as we expected. Also, the 6 MET amplifıed cell lines (SNU5, SNU520,
MKN45, YCC-31, YCC-34 andHs746T)were all sensitive to Sym015 and down-
regulate expression of c-Met/p-Met. Using MET amplifıed GC cell lines, we
evaluated the effıcacy and potential mechanism of Sym015 in combination with
paclitaxel, which is the standard agent for second line treatment of metastatic
GC. CI values determined at the ED50 indicated that 3 of 6 cell lines (MKN45,
SNU520 and YCC-31) had synergistic effects (CI values  0.7). When used in
combination to treat 4 cell lines (MKN45, SNU520, YCC-31 and Hs-746T), the
dose at ED50 of Sym015 could be reduced by 2.2-13.6 fold, based on DRI anal-
ysis. Also, theDRI for paclitaxel indicated that dose reductions up to 4.7-7.1 fold
(MKN45 and SNU520) could be obtained. Our results indicate that Sym015 was
sensitive to MET amplifıed cell lines and the Sym015 combined with paclitaxel
therapy had synergistic effects in MET amplifıed GC.
#28 Cell penetrating proteins targeting Mcl-1 induce in vitro and in vivo
on-target cancer cell killing of Mcl-1 dependent cell lines. Sabrina Deroo,1
Sophie Thiolloy,2 Johan Desmet,3 Franky Baatz,1 Karen Vandenbroucke,3 Eric
Lorent,3 Paula Henderikx,2 Philippe Alard,3 Stefan Loverix,3 Ignace Lasters,3
Yvonne McGrath3. 1Complix Luxembourg S.A., Esch-sur-Alzette, Luxembourg;
2Complix N.V. Headquarters, Diepenbeek, Belgium; 3Complix N.V., Zwijnaarde
(Ghent), Belgium.
The pro-survival proteinMyeloidCell Leukaemia-1 (Mcl-1) plays an essential
role in survival of numerous cancers. MCL-1 gene amplifıcations occur in a
variety of human cancers and overexpression of theMcl-1 protein is often asso-
ciated with chemotherapeutic resistance and disease relapse. Complix has de-
veloped Cell Penetrating Alphabodies (CPAB), a novel and unique therapeutic
class of proteins engineered to effıciently enter cells and inhibit proteins includ-
ing Mcl-1. High affınity Alphabodies (ABs) targeting Mcl-1 were engineered by
a combination of rational design and phage library screening. In affınity assays,
these ABs were shown to bind to Mcl-1 with picomolar affınities whilst binding
to Bcl-XL and Bcl-2 was below the detection limit of the assay. In vitro, CPAB
uptake was shown to occur rapidly with cytosolic levels reaching up to 1 M
within 2 hours of CPAB exposure. Uptake was associated with cell death of the
Mcl-1 dependent multiple myeloma (MM) cell line NCI-H929 (IC500.5 M)
and killing was correlated with caspase-3/7 activation. Anti-Mcl-1 CPAB were
also shown to disrupt Mcl-1-Bak and Mcl-1-Bim complexes in H929 cells and
induced dose-dependent Bak activation. In a panel of MM cell lines, anti-Mcl-1
CPAB induced cell death with amedian IC50 of 0.96Mand cell killing was not
restricted to a specifıc subset of MM cell lines (CCDN1, MAF, MMSET). Gene
expression analysis revealed that the anti-Mcl-1 CPAB cell killing potency cor-
relates with MCL-1 gene expression but correlates best with the MCL-1:BCL-2
gene expression ratio. The same gene expression correlation analysis of the Bcl-2
targeting agent Venetoclax revealed an inverse pattern to that achieved with the
Mcl-1 specifıc CPAB. In vivo, CPAB conferredwith an albumin binding domain
for extension of half-life, showed a serum half-life in mice of more than 1 hour
and associated tumor concentrations of more than 1 M. Immunohistochem-
istry and direct detection of fractionated tumor tissue confırmed the intracellu-
lar presence of the CPAB in the tumor cells. When given daily IV at 20 mg/kg,
anti-Mcl-1CPAB induced tumor growth inhibition of 50%versus control in two
MM xenograft models (H929 and MOLP-8). Tumor growth remained signifı-
cantly inhibited even two days after the last treatment in theMOLP-8model and
tumor growth inhibition was associated with increased staining of cleaved
caspase-3 as compared to vehicle treated tumors. In summary, anti-Mcl-1CPAB
effıciently kill Mcl-1 dependent cancer cell lines by on-target effects as demon-
strated by (1) disruption of Mcl-1-Bak and Mcl-1-Bim complexes, (2) Bak acti-
vation and (3) correlation of potency with MCL-1:BCL-2 gene expression ratio.
These CPAB induced a robust reduction in tumor growth in mouse models and
represent a best-in-class cell penetrating protein therapeutics for tackling intra-
cellular PPI critical to diseases with unmet medical need.
#29 Addition of Galunisertib to DC101 increased angiogenesis inhibition
and tumor growth control in hepatocellular carcinoma (HCC). Annemilai
Tijeras-Raballand,1 Christian Hobeika,2 Elise Payen,3 Matthieu Martinet,1
Philippe Bonnin,3 KarimA. Benhadji,4 Clarisse Eveno,2Marc Pocard,2 Sandrine
Faivre,5 Eric Raymond,6 Armand de Gramont1. 1AFR Oncology, Paris, France;
2Inserm U965-Lariboisiere University Hospital, Paris, France; 3Inserm U965-
Lariboisiere University Hospital, Paris, France; 4Eli Lilly Company, New Jersey,
NJ; 5Beaujon University Hospital, Clichy, France; 6Saint-Joseph Hospital, Paris,
France.
Introduction: Galunisertib is a selective ATP-mimetic TGF- receptor
(TGFR)-I inhibitor andDC101 is a rat antagonist antibody tomouseVEGFR-2
and is used to model VEGFR-2 blockade in murine tumor models. Ramuci-
rumab and galunisertib being independently under clinical investigation in
HCC patients, our study aimed at exploring the anti-tumoral potency of a com-
bination of galunisertib and DC101 in an in vivo transgenic model of HCC.
Methods: Transgenic mice developing stage-defıned HCC were treated for 8
weeks (W) fromW8 toW16with either vehicle, DC101 (40mg/kg, twice weekly,
IP), galunisertib (100mg/kg, daily, oral gavage) or DC101 plus galunisertib. Tu-
mor growth was evaluated by ultrasound (liver size) and by the number of
macronodules at sacrifıce. Angiogenesis was evaluated by doppler (blood flow in
the coeliac trunk) and by CD31 staining. Results: Liver size and the number of
liver tumor macronodules were signifıcantly lower in all treatment arms com-
pared to placebo control at both the W12 intermediary sacrifıce and W16 fınal
sacrifıce; the combination of galunisertib and DC101 showing increased tumor
control atW16 (4,430,55mean liver volume (inmm3) in the combination arm
vs 5,220,86, 5,680,78, 7,091,54 in the DC101, galunisertib and placebo
arms respectively). Angiogenesis assessed by measuring the mean blood flow in
the coeliac trunk (TCm), decreased in all treatment arms compared to placebo.
AtW16, galunisetib potentiated the effect ofDC101with aTCmdecrease of 66%
compared to 59% and 10% in the DC101 and galunisertib, respectively. These
results will be confırmed by the assessment of micronodules number on HPS
section for tumor growth and CD31 staining for angiogenesis analysis (number
of vessels and the vessel lumen area). The effects of the combination versus
monotherapies will be evaluated on the immune landscape. Conclusion: The
combination of galunisertib andDC101 showed promising anti-tumor activities
that were associated with decreased angiogenesis.
#30 S100A11 is a prominent therapeutic target in malignant pleural me-
sothelioma. Hiroki Sato, Hiromasa Yamamoto, Kei Namba, Hidejiro Torigoe,
Takahiro Yoshioka, Kazuhiko Shien, Junichi Soh, Shinichi Toyooka. Okayama
Univ. Hospital, Okayama City, Japan.
[Background & Purpose] Malignant pleural mesothelioma (MPM) is an ag-
gressive tumor arising from themesothelial cells that show a seriousmalignancy
in thoracic cavity with a median survival time of 9-12 months. The therapeutic
approaches in clinical standard are limited to surgery and chemotherapy for
early and advanced stages, respectively. The strategies unfortunately provide
only palliation, thus further advanced approach is required. S100A11, a Ca2-
binding small protein with two EF-hands, is frequently upregulated in various
human cancer tissues. It has been reported that S100A11 plays an important role
in progression of many cancers derived from thyroid, ovarian and lung tissues,
but its roles and signature in MPM are poorly understood. In this study, we
investigated the impact of S100A11 in MPM cell lines and resected tumors.
[Material & Methods] We explored the expression of S100A11 in 7 MPM cell
lines (HP-1, H28, MSTO-211H, H2052, H290, H2452, and YUMC44) and 2
normal mesothelial cell lines (Met-5A and LP-9). We analyzed the effect of
S100A11 on cell proliferation, colony formation,migration, invasion and down-
stream signaling. The effıcacy of anti-S100A11 antibody on cell proliferation and
downstream signaling was also determined. [Results] We found that S100A11
protein was consistently upregulated in 7 MPM cell lines at a signifıcant level in
comparison to 2 normal mesothelial cells. The same phenomenon was also con-
fırmed in MPM tissue sections by immunohistochemistry, i.e., S100A11 was
strongly stained atMPMcells, but not at surrounding normal lung cells. Specifıc
knockdown of S100A11 by small interfering RNA turned the aggressive cells
into the attenuated phenotypes for proliferation, invasion andmigration. Those
were notably observed in both 2 MPM cell lines (H2052 and H2452). Interest-
ingly, we found that MPM cell lines but not normal cells actively secreted the
S100A11 protein. To pursue this, we next tried to inhibit the function of the
secreted S100A11. Administration of S100A11 neutralizing antibody signifı-
cantly inhibited the proliferation of 4 MPM cell lines (H2052, H2452, H28, and
H290). The antibody had no effect on the proliferation of only one MPM cell
line, MSTO-211H, which showed no secretion of S100A11. Taken together,
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these results suggest that S100A11 secreted fromMPM cells can be a prominent
target for effective MPM therapy. [Conclusion] Our results suggest that
S100A11 is a possible therapeutic target in MPM.
#31 Preclinical development of a novel biparatopic HER2 antibody with
activity in low to high HER2 expressing cancers. Nina Weisser, Grant Wick-
man, Rupert Davies, Gerry Rowse. Zymeworks, Vancouver, British Columbia,
Canada.
HER2-directed therapies have improved clinical outcomes for many patients
with HER2 overexpressing breast and gastric cancer. Despite these successes,
there remains a need to develop effective HER2-targeted therapies for these and
other HER2-expressing tumors, particularly in the setting of recurrent or met-
astatic disease.One approach is to develop a singlemultifunctional antibody that
has improved capacity and effıciency for bindingHER2 comparedwith available
HER2 inhibitors, can elicit ADCC, block ligand induced heterodimerization of
HER2 with other HER family receptors, and down-regulate HER2 protein on
the cell surface. ZW25 is a novel humanized, IgG1-like bispecifıc antibody di-
rected against two distinct epitopes on the HER2 receptor. ZW25 has low nM
binding affınity (0.9-16 nM) to recombinant HER2 and to cultured cancer cells
with a range of HER2 expression, and shows higher maximal binding (1.4-1.9x)
than monospecifıc HER2 antibodies on all tumor cell lines tested. The unique
structure of ZW25 favors crosslinking of multiple HER2 receptors which is
thought to promote clustering, and improvesHER2 internalization compared to
monospecifıc HER2 antibodies. In vitro studies demonstrated that ZW25 alone
caused signifıcant inhibition in growth of human cancer cell lines with a wide
range of HER2 expression (5-54% inhibition depending on the cell line), and
inhibited ligand-mediated tumor cell proliferation. ZW25 elicited concentra-
tion-dependent ADCC at nM potency (0.05-64 nM) with maximal lysis up to
52% on TNBC cell lines expressing HER2 at a 0/1 level. ZW25 also exhibited
synergy and additivity withmultiple chemotherapeutic agents including platins,
taxanes, microtubule inhibitors, and DNA synthesis inhibitors in various HER2
expressing tumor cell lines. In vivo studies demonstrated antitumor activity
and/or improved survival against xenografts from a range of tumor types. In a
HER2 3 gastric cancer PDX model ZW25 induced signifıcant tumor regres-
sions, exhibiting 307% tumor growth inhibition relative to hIgG control and a
70% complete regression rate (trastuzumab exhibited 111% tumor growth con-
trol with no complete regressions). In a HER2 1 breast cancer PDX model
ZW25 signifıcantly improved median survival (58 vs 28 days) and exhibited
141% tumor growth inhibition relative to hIgG control (trastuzumab exhibited
63% tumor growth inhibition, with median survival 39 days). In a low HER2-
expressing NSCLC CDX model ZW25 improved median survival compared to
hIgG control or cisplatin ( 66 vs 25 or 26 d respectively) and exhibited 159%
tumor growth inhibition relative to hIgG control. In a GLP repeat dose toxicol-
ogy study, ZW25 was well tolerated with no adverse effects at doses up to 150
mg/kg weekly IV for up to 8 weeks. Based on these fındings, a fırst in human
clinical trial of ZW25 has been initiated in patients with recurrent and/or met-
astatic HER2-expressing cancers.
#32 Preclinical evaluation of MCLA-158: A bispecifıc antibody targeting
LGR5 and EGFR using patient-derived colon carcinoma organoids. Rob
Roovers,1 BramHerpers,2Mark James,3 Berina Eppink,4 CarmeCortina,3David
Maussang-Detaille,4 Ingrid Kolfschoten,4 Sylvia Boy,5 Marc van de Wetering,5
Wim De Lau,6 Robert Doornbos,4 Kuan Yan,2 Lucia Salinaro,2 Lex Bakker,4
john de Kruif,4 Hans Clevers,6 Robert Vries,5 Eduard Batlle,3 Leo Price,2 Mark
Throsby1. 1Merus, Utrecht, Netherlands; 2OcellO BV, Leiden, Netherlands; 3IRB
Barcelona, Barcelona, Spain; 4Merus NV, Utrecht, Netherlands; 5HUB, Utrecht,
Netherlands; 6The Hubrecht Institute, Utrecht, Netherlands.
Background. Colorectal cancer (CRC) is the third most common cancer and
remains a large unmet need. Dysregulation ofWnt and receptor tyrosine kinase
(RTK) signalling pathways are important oncogenic driving events in CRC.Due
to this dysregulation, Wnt target genes are expressed at higher levels in CRC
particularly in tumor initiating cells. We previously performed an unbiased
screen of bispecifıc antibodies (bAbs) targeting Wnt and RTK targets that re-
sulted in the selection of MCLA-158. Methods. A cohort of 32 genetically and
transcriptionally annotated patient-derived colorectal cancer and normal colon
organoids were used to functionally characterize responses to antibodies based
on morphological changes with high content 3D imaging. Binding affınity was
measured by surface plasma resonance and cell based assays. The antibody bind-
ing epitopes were mapped by shotgun mutagenesis and FACS based screening.
Ligand (R-spondin or EGF) blocking activity was measured in vitro by compe-
tition for ligand binding or functional inhibition of ligand dependent growth. In
vivo activity was evaluated in xenograft models generated from organoids sub-
cutaneously implanted into immunocompromised mice. Safety was evaluated
via once weekly intravenous administration ofMCLA-158 to cynomolgusmon-
keys for 4 weeks and monitoring for pathological changes. Results. MCLA-158,
an ADCC enhanced common light chain IgG1 bispecifıc antibody, binds in
domain III of EGFR and in the N-Cap/1st LRR of LGR5, both ligand binding
regions, however, only EGF binding was blocked by MCLA-158. MCLA-158
demonstrated inhibitory activity in 74% of tumor organoids independent of
KRASmutational status but was not active on organoids of the cohort harboring
both KRAS and PIK3CA mutations. MCLA-158 was signifıcantly more active
on organoids derived from tumors than fromnormal tissue in contrast to cetux-
imab, which demonstrated equivalent activity on both (range 20-100 fold, n4).
In vivo activity was evaluated against tumor organoids with different KRAS
mutation status shown to be sensitive toMCLA-158 in vitro. In all cases,MCLA-
158 signifıcantly inhibited the growth of the tumor compared to both control
and cetuximab treatment. Inhibitors of both theWnt and EGFR pathways have
shown signifıcant toxicity in humans. An initial evaluation of MCLA-158 tox-
icity in cynomolgusmonkeys did not demonstrate any pathological fınding after
repeated dosing at 25mg/kg. Conclusions. MCLA-158 demonstrates superior
activity compared to reference antibodies in both in vitro and in vivo tumor
organoid based assays regardless of KRAS status and was well tolerated in non-
human primates. These preclinical data suggest MCLA-158 could benefıt pa-
tients with metastatic CRC and warrant clinical evaluation.
#33 The binding mode of the bispecifıc anti-HER2xHER3 antibody
MCLA-128 is responsible for its potent inhibition of HRG-driven tumori-
genesis. David Maussang-Detaille,1 Camilla de Nardis,2 Linda Hendriks,1
Carina Bartelink-Clements,1 Eric Rovers,1 Tristan Gallenne,1 Robert Doorn-
bos,1 Lex Bakker,1 John de Kruif,1 Ton Logtenberg,1 Piet Gros,2 Cecile Geuijen,1
Mark Throsby1. 1Merus, Utrecht, Netherlands; 2Utrecht University, Utrecht,
Netherlands.
Introduction: MCLA-128 is as an ADCC-enhanced IgG1 bispecifıc antibody
that targets the HER2:HER3 dimer and is currently being tested in Phase I/II
clinical trials. MCLA-128 demonstrates an in vitro potency superior to other
anti-HER2 and anti-HER3 antibodies in cells stimulated with high concentra-
tions of heregulin (HRG) thereby overcoming one of the resistancemechanisms
of current HER2 therapies. This study investigates the binding mode of MCLA-
128 and proof of concept studies in HRG-driven tumor models. Methods: Ala-
nine scanning shotgunmutagenesis was used tomap the epitopes ofMCLA-128
to HER2 and HER3. Fab fragments of MCLA-128 were crystallized with the
soluble extracellular domains of HER2 and HER3. SAXS analysis on the HER2-
HER3-MCLA-128 complex was performed to investigate the binding mode
of the bispecifıc antibody in solution. Ligand-induced dimer specifıcity was
investigated with PathHunter® heterodimerization assays. Bispecifıc anti-
HER2xHER3 antibody and its parental anti-HER3 monoclonal antibody were
labelled with 64Cu to compare their biodistribution profıles. The effıcacy of
MCLA-128 in HRG-driven systems was shown in vitro in MDA-MB-175 cells
and in vivo in an orthotopic intracranial patient-derived xenograft (PDX)model
originating fromabreast cancer brainmetastasis Results: The shotgunmutagen-
esis study identifıed that the bispecifıc antibody MCLA-128 binds amino acids
T144, R166, R181 in HER2 domain I and R426 in HER3 domain III. Crystallo-
graphic studies confırmed the involvement of these critical residues and sug-
gested that MCLA-128 locks the HER3 receptor in its ligand-unbound inactive
confırmation. SAXS analysis suggests that the bispecifıc antibody MCLA-128
forms inter-dimer rather than intra-dimer interactions. In vitro, MCLA-128
specifıcally blocked HRG-induced signaling of HER2:HER3 but not HER2:
HER4 heterodimers. Biodistribution of MCLA-128 in a xenograft model of
breast cancer showed that the penetration of MCLA-128 in JIMT-1 HER2-am-
plifıed tumors is HER2-dependent despite the high affınity of theHER3 Fab arm
for its receptor.MCLA-128 effıciently blocked tumor growth of theHRG-driven
HER2 (1) breast cancer cell line MDA-MB-175 in 3D in vitro. Treatment of
orthotopically transplantedHER2-amplifıed breast cancer brain tumors inmice
led to 100% survival with MCLA-128, in contrast to 38% and 0% survival in
T-DM1 and vehicle treated mice respectively. Conclusion: MCLA-128 targets
HER2-positive tumors via its HER2 arm and locks HER3 in an inactive confır-
mation. The potent anti-proliferative activity of MCLA-128 in vitro and in vivo
supports the clinical development of this bispecifıc HER2xHER3 antibody in
HRG-driven tumors.
#34 A MET x MET bispecifıc antibody that induces receptor degradation
potently inhibits the growth of MET-addicted tumor xenografts. John
DaSilva. Regeneron Pharmaceuticals, Tarrytown, NY.
Aberrant regulation of MET receptor tyrosine kinase signaling is associ-
ated with development and progression of various human tumors. Elevated
MET signaling during tumorigenesis results from MET amplifıcation, mu-
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tation or up-regulation of the ligand, HGF. MET amplifıcation is thought to
be a key driver of oncogenesis in non-small cell lung cancers (NSCLC) and
oesophagogastric malignancies. In addition, mutations resulting in exon 14
deletion of MET have been described as oncogenic drivers in a subset of
NSCLC. Both preclinical and recent clinical results indicate that tumors
harboring these genetic alterations respond to MET inhibitors, validating
MET as a cancer driver. We have developed a novel bispecifıc antibody that
binds to two distinct epitopes on MET. The METxMET bispecifıc antibody
blocks HGF binding and exhibits very low agonist activity (much weaker
than either of its parental antibodies). Furthermore, the METxMET bispe-
cifıc antibody effectively promotes MET degradation, thereby inhibiting li-
gand-independent signaling in MET-amplifıed tumor cells. The METxMET
bispecifıc antibody exhibits strong anti-tumor effıcacy in xenograft models
harboring MET genetic alterations, either completely inhibiting tumor
growth (EBC1 MET-amplifıed NSCLC) or promoting substantial tumor re-
gression (SNU5 MET-amplifıed gastric cancer, Hs746T MET-amplifıed/
MET exon 14 skip gastric cancer). Analysis of lysates from SNU5 tumors
treated with the METxMET bispecifıc antibody confırms its ability to effec-
tively promote MET degradation in vivo. Finally, the METxMET bispecifıc
antibody strongly inhibits the growth of a glioblastoma xenograft model
(U118) driven by autocrine HGF signaling. In summary, we have generated
a novel METxMET bispecifıc antibody that potently inhibits the growth of
MET-dependent tumor xenografts. Our data suggest that antibody-medi-
ated MET degradation may be an effective clinical strategy in tumors har-
boring MET genetic alterations.
#35 The dual inhibition of Met and EGFR by ME22S, a novel MET/EGFR
bispecifıcmonoclonal antibody, suppresses the proliferation and invasion of
laryngeal cancer. Bok-Soon Lee,1 Dae Ho Kim,1 Yeon Soo Kim,2 Jae Won
Chang,3 Bon Seok Koo,3 Ho RyunWon,1 Haeng-Jun Kim,1 Hyun-Young Cha,1
JiMin Lee,4 Kyung-AhKim,4 Chul-HoKim1. 1AjouUniversity, Suwon, Republic
of Korea; 2KonyangUniversity Hospital, Daejeon, Republic of Korea; 3Chungnam
National University,, Daejeon, Republic of Korea; 4Samsung Advanced Institute
of Technology (SAIT), Suwon, Republic of Korea.
Background and purpose: It has been reported that the abnormal activa-
tion of receptor tyrosine kinases is associated with the development of many
human carcinomas and the high activation of EGFR and Met mediates the
tumorigenicity of laryngeal carcinoma. In this study, we have done the ther-
apeutic effıcacy of ME22S, a novel EGFR/Met bispecifıc antibody, in laryn-
geal carcinoma in vitro and in vivo was thoroughly evaluated. Methods: The
effects of ME22S on cell viability was assessed through MTT assays, then
Western blotting and immunocytochemistry were used to determine the
expression of EGFR and Met. Also, wound healing and invasion assays were
performed to observe the inhibitory effects of ME22S. Results: We found the
ability of ME22S reducing the expression of both EGFR and Met and signif-
icantly inhibiting the cell migration, invasion, and proliferation of SNU899
and HN3 in vitro. Also the notably reduced levels of p-Met, p-ERK, and
p-AKT were found when the cells were treated with only ME22S alone or
with HGF together. Meanwhile, ME22S, interestingly enough, caused
caspase-3-dependent apoptotic cell death when HN3 cells were treated with
ME22S for 72h, decreased the HGF-induced Slug expression, and also inhib-
ited the tumor growth of HN3 cells in a xenograft model in vivo. Conclusion:
Taken together, our fındings suggest that the dual inhibition of EGFR and
Met through ME22S largely suppresses the invasion and growth of laryngeal
carcinoma both in vitro and in vivo, hence, can be a practical approach as a
novel therapeutic strategy for the treatment of laryngeal carcinoma.
#36 Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug con-
jugates (ADCs) demonstrate tumor specifıcity in vitro and in vivo antitumor
effıcacy. JillianM. Prendergast,1 David A. Eavarone,1 Patricia E. Rao,1 AdamD.
Curtis,2 Lindsay S. Shopland,2 Todd A. Hoffert,2 Jenna Stein,1 Jeff Behrens,1
Daniel T. Dransfıeld1. 1Siamab Therapeutics, Inc., Newton, MA; 2Eastern Maine
Medical Center, Brewer, ME.
Tumor-associated carbohydrate antigens (TACAs) historically have been
challenging targets for antibody therapeutics. Sialyl-Tn (STn) is a cancer specifıc
antigen that is expressed on the cell surface of carcinomas including ovarian,
colon, prostate, and pancreatic tumors but is rarely present in normal tissue. STn
expression has been linked to innate immune suppression, a chemoresistant
phenotype, metastasis, and poor prognosis. Previous attempts to target this an-
tigen in the clinic with synthetic glycan vaccines proved safe but lacked effıcacy.
We have developed highly selective humanized monoclonal antibodies and an-
tibody drug conjugates (ADCs) targeting TACAs, such as STn. Remarkable
sequence homology across all anti-STn mAbs was observed in both heavy and
light chains, and hot spots for hypermutation were identifıed. These antibodies
were selected using our glycan microarray that enriches for candidates whose
binding is protein-independent, highly selective and demonstrates exceptional
target affınity. Lead humanized candidates demonstrated single digit nanomolar
EC50s in ELISA/flow cytometric assays, STn selective cell internalization, and
STn specifıc glycan binding on Siamab’s proprietary glycan array. STn binding
sites in common tumor lines (ovarian, gastric and breast) were determined per
cell and subsequent cytotoxicity assays in these lines demonstrated in vitro effı-
cacy. Tumor microarray experiments revealed membranous staining in cancer-
ous tissues of various indications. Binding studies of anti-STn antibodies to
primary human cancer samples by flow cytometry demonstrated that both tu-
mor and Myeloid-Derived Suppressor Cells (MDSC, both myeloid and granu-
locytic) express STn. In an OVCAR3 xenograft model, 30 days after the last
anti-STn ADC dose was given, groups treated (Q7Dx4) exhibited mean tumor
volumes below the Day 1 pre-treatment mean tumor volumes (155mm3). Flow
cytometric analysis of tumors from thesemice demonstrated that anti-STnADC
treatment reduces STn expression on the primary tumor in a dose-dependent
manner (Q7Dx4 vs. single dose) compared to the isotype-ADC control. Our
data demonstrates that high-affınity, STn-selective mAbs show promise as ther-
apies for solid tumors and could also target MDSCs to promote antitumor im-
mune responses.
#37 Novel antibody-drug conjugates targeting ADAM9-expressing solid
tumors demonstrate potent preclinical activity. StuartW. Hicks,1 Nicholas C.
Yoder,1 Deryk Loo,2 Asli Muvaffak,1 Yinghui Zhou,1Megan E. Fuller,1Molly A.
McShea,1 Marian Themeles,1 Katherine H. Mucciarone,1 Juniper A. Scribner,2
Bhaswati Barat,2 Thomas Sun,2 James Tamura,2 Francine Z. Chen,3 Kerry A.
Donahue,1 Tom Chittenden1. 1Immunogen, Inc., Waltham, MA; 2MacroGenics,
Inc., South San Francisco, CA; 3MacroGenics, Inc., Waltham, MA.
ADAM9, also known as MDC9 or meltrin-, is a member of the ADAM (a
disintegrin and metalloproteinase) family of proteases, which have been im-
plicated in cytokine and growth factor shedding, and cell migration. Dys-
regulation of ADAM9 has been implicated in tumor progression and metas-
tasis, as well as pathological neovascularization. ADAM9 overexpression has
been shown to correlate with poor prognosis in prostate, renal, and pancre-
atic cancers. Using an immunization approach in which antibodies were
raised to fetal progenitor and stem-like cancer cell lines followed by screen-
ing on tumor and normal tissues, we identifıed ADAM9 as a promising cell
surface tumor target. FFPE-IHC expression analysis revealed that ADAM9 is
overexpressed in multiple solid tumor indications relative to corresponding
normal tissues. The overexpression of ADAM9 in tumors coupled with its
restricted expression in normal tissues make ADAM9 an attractive target for
antibody-drug conjugate (ADC) therapy. Here, we describe two ADCs both
of which are based on a high affınity anti-ADAM9 antibody to selectively
target ADAM9-expressing tumors. The fırst ADC utilizes the maytansine-
derived microtubule disruptor, DM4, linked via a hindered disulfıde hydro-
philic linker (sulfo-SPDB). The second ADC exploits an ultra-potent DNA
alkylating payload, DGN549, which is conjugated to two engineered cys-
teines via a peptide linker. Both conjugates bound with similar subnanomo-
lar affınity to ADAM9-expressing cells. In vitro cytotoxicity studies showed
that anti-ADAM9ADCs can kill a broad panel of ADAM9-positve tumor cell
lines, including lung, pancreatic, renal, prostate, and colon tumor cell lines.
In particular, the anti-ADAM9-DGN549 conjugate was extremely potent
with IC50 values ranging from 0.1 to 65 pM and was at least 2 logs more
active than a non-targeting conjugate. Surprisingly, effıcient in vitro cyto-
toxicity was observed at ADAM9 expression levels as low as a few thousand
cell surface receptors per cell. Consistent with their in vitro activity, both
anti-ADAM9 ADCs displayed compelling anti-tumor activity in xenograft
models. In a CaLu3 non-small cell lung cancer xenograft model, anti-AD-
AM9-DM4 induced tumor growth delay at a single 1.25 mg Ab/kg dose. In
the same model, a single intravenous dose of 0.25 mg Ab/kg of the anti-
ADAM9-DGN549 produced durable complete remissions in 8/8 mice. A
non-targeting DGN549 ADC was inactive even when dosed at 10 times that
of the anti-ADAM9 ADC, demonstrating that targeted delivery of DGN549
through ADAM9 binding is required for activity. These data demonstrate
that anti-ADAM9 ADCs exhibit antitumor activity against a broad panel of
ADAM9-positive malignancies and cause durable remissions in preclinical
models at doses expected to be clinically achievable. Anti-ADAM9 ADCs
represent a promising therapeutic strategy to target a wide range of ADAM9-
expressing tumors.
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#38 Target validation, antibody discovery and preclinical data supporting
ADAM9 as an antibody-drug conjugate therapeutic target for solid tumors.
Juniper A. Scribner,1 Bhaswati Barat,2 Stuart W. Hicks,3 Nicholas C. Yoder,3
Thomas Son,1 Lusiana Widjaja,2 Gundo Diedrich,2 Sergey Gorlatov,2 Jeff
Hooley,1 Ann Easton,1 Peter Lung,1 Anushka De Costa,1 Francine Chen,1 Mi-
chael Chiechi,1 PamLi,1Monica Licea,1 Timothy E.Hotaling,1Michael Spliedt,2
Valentina Ciccarone,2 Nadia Gantt,2 James Tamura,2 Megan E. Fuller,3 Molly
McShea,3 Scott Koenig,2 Syd Johnson,2 Paul A. Moore,2 Ezio Bonvini,2 Deryk
Loo1. 1MacroGenics, Inc, South San Francisco, CA; 2MacroGenics, Inc, Rockville,
MD; 3ImmunoGen, Inc., Waltham, MA.
Introduction: A target-unbiased approach based on intact cell immunizations
with fetal progenitor cells and cancer stem cells, followed by an immunohisto-
chemistry (IHC) screen for cancer-specifıc candidates, led to the identifıcation
of anti-ADAM9 (a disintegrin and metalloproteinase) mAbs with highly differ-
ential tumor-versus-normal tissue binding. ADAM9 is a cell surface protein
over-expressed in multiple tumors, with a possible role in promotion and pro-
gression of cancer through multiple mechanisms, including modulation of ad-
hesion and migration as well as processing of tumorigenic and pro-angiogenic
factors. In this preclinical study, we performed target/mAb validation and eval-
uated the therapeutic potential of anti-ADAM9 antibody-drug conjugates
(ADCs) toward ADAM9-expressing solid cancers. Methods: IHC was per-
formedwith anti-ADAM9mAbs to confırm and extend available data of human
normal and tumor tissue expression. Epitope mapping studies were conducted
to defıne epitope-specifıcity. mAbs were also screened to identify those that
effıciently internalized into tumor cells. In vitro cellular processing studies were
performed to further evaluate themAbs asADCcandidates. SelectedmAbswere
converted to ADCs via chemical conjugation to potent anti-microtubule (DM4)
or DNA alkylating (DGN549) agents; in vitro cytotoxicity studies were con-
ducted with tumor cell lines representing human cancer types that overexpress
ADAM9. A lead mAb was then selected for humanization and affınity matura-
tion to yield a development candidate. Results: Anti-ADAM9 mAbs exhibited
strong reactivity toward the tumor epithelium of solid cancers, including pan-
creatic, kidney, prostate, bladder, breast, colon, lung, and ovarian cancer, but
limited reactivity toward normal tissues. Anti-ADAM9 mAbs were effıciently
internalized and processed by tumor cell lines, including lines with only modest
ADAM9 expression. Anti-ADAM9 ADCs exhibited specifıc, dose-dependent
cytotoxicity toward ADAM9-positive cancer cell lines in vitro, with IC50 values
in the sub-nanomolar range. Humanization and affınity maturation of the lead
mAb yielded a development candidate that retains potent antitumor activity
toward ADAM9-positive tumor cell lines and equivalent, high affınity binding
to both human and cynomolgusmonkeyADAM9. Conclusion: ADAM9 is a cell
surface antigen that is over-expressed on a wide range of solid cancers. Anti-
ADAM9mAbs that were strongly reactive with representative tumors exhibited
high affınity for the antigen and were effıciently internalized and processed by
ADAM9-bearing tumor cells. Anti-ADAM9 ADCs demonstrated dose-depen-
dent cytotoxicity in vitro toward a panel of ADAM9-positive tumor cell lines.
Our fındings demonstrate that an ADC targeting ADAM9may serve as a poten-
tial therapeutic for ADAM9-expressing solid tumors.
#39 Discovery of PEN-221, an SSTR2-targeting maytansinoid conjugate
with potent activity in vitro and in vivo.BrianH.White, Patrick Bazinet, Kerry
Whalen,MichelleDuPont, JamesM.Quinn, RossitzaAlargova, TsunAuYeung,
Adam Brockman, James Gifford, Haley Oller, Kristina Kriksciukaite, Charles-
Andre Lemelin, Patrick Lim Soo, Benoit Moreau, Samantha Perino, Gitanjali
Sharma, Rajesh Shinde, Beata Sweryda-Krawiec, Mary Simcox, Richard
Wooster, Mark T. Bilodeau. Tarveda Therapeutics, Watertown, MA.
Here we describe the discovery and the structure of PEN-221, a somatostatin
receptor 2 (SSTR2) targeting peptide conjugated to DM1. PEN-221 is the fırst
clinical compound from Tarveda’s Pentarin platform, which utilizes miniatur-
ized drug conjugates that diffuse rapidly and deeply into solid tumors. Antibody
drug conjugates (ADCs) have garnered a signifıcant amount of attention in their
ability to direct cytotoxic drugs to cancer cells; however, the effıcacy of ADCs in
solid tumors is limited by the slow diffusion of such large molecules through
solid tumor tissue. Pentarins are designed to improve the effıcacy of targeted
therapies through effective tumor cell targeting and enhanced tumor penetra-
tion. SSTR2, a GPCR overexpressed in multiple types of neuroendocrine tu-
mors, including small cell lung cancers, internalizes rapidly upon agonist stim-
ulation,making it an ideal vector for delivering cytotoxic payloads. Examination
of a variety of SSTR2 targeting ligands, as well as several potential conjugation
sites, led to the identifıcation of the C-terminal side chain of [Tyr3]-octreotate
amide as the best conjugation site for a lipophilic payload. The use of DM1 as a
payload afforded superior receptor affınity and receptor internalization when
compared to other similarly potent microtubule-targeting agents. In vitro stud-
ies show that PEN-221 has receptor-dependent cytotoxic effects, and preclinical
studies demonstrate PEN-221 induces tumor regression in several SSTR2 ex-
pressing xenograft models.
#40 Development of a novel antibody-drug conjugate targeting endosia-
lin/TEM-1: potent antitumor activity in sarcoma. Gianluca Sala,1 Stefano
Iacobelli,2 Emily Capone,2 Enza PIccolo,2 Jean-Fred Sauniere,2 Vanessa Van-
nucci Douet3. 1University of Chieti, Chieti, Italy; 2Mediapharma srl, Chieti, Italy;
3Mediapharma srl, Paris, France.
The TEM-1/Endosialin/CD248 receptor is expressed in the cell surface of
tumor-associated stroma cells, as well as in sarcoma and neuroblastoma cells.
This receptor is emerging as an attractive molecule in diagnostics and therapeu-
tics because of its expression across the stroma of many human tumors, the low
to absent expression in normal tissues and accessibility from the vascular circu-
lation. In this study, we present evidence of the preclinical effıcacy of a novel
Antibody-Drug Conjugate (ADC). It consists of a humanized TEM-1monoclo-
nal antibody (E.8-3) conjugated to a highly potent payload (TEM-1-ADC). In
TEM-1 expressing cancer cell lines, this TEM-1-ADC demonstrated a powerful,
specifıc and target-dependent killing activity. High expression levels of TEM-1
in cells correlated with effıcient internalization, effıcacy, and cytotoxic effects in
vitro. Effıcacy studies demonstrated that TEM-1-ADC treatment leads to a long
lasting tumor growth inhibition of cell line-based models of human sarcoma.
Taken together, our results demonstrated that TEM-1 is an attractive target in
sarcoma and suggest that TEM-1-ADC has the potential to be developed into a
biotherapeutic agent in these malignancies.
#41 An Antibody Drug Conjugate targeting HER-3 demonstrates prom-
ising antitumor effıcacy in a wide range of human cancer. Gianluca Sala,1
Manuela Iezzi,1 Alessia Lamolinara,1 Emily Capone,2 Stefano Iacobelli,2 Jean-
Fred Sauniere,2 Sara Ponziani,3 Francesco Giansanti,3 Rodolfo Ippoliti3. 1Uni-
versity of Chieti, Chieti, Italy; 2Mediapharma srl, University of L’Aquila, Italy;
3University of L’Aquila, L’Aquila, Italy.
The HER-3 receptor is emerging as an attractive molecule in therapeutics
because of its overexpression acrossmany human cancers and because of its role
in in several compensatory processes that underlay emergence of resistance to
certain cancer drugs. In this study, we present evidence of the preclinical effıcacy
of a novel Antibody-Drug Conjugate (ADC) targeting HER-3. It consists of a
humanized HER-3 monoclonal antibody (mAb EV20), which recognizes the
HER-3 extracellular domain, conjugated to different payloads (HER-3-ADC)s.
InHER-3 expressing cancer cell lines, these HER-3-ADCs demonstrated a pow-
erful, specifıc and target-dependent killing activity. High expression levels of
HER-3 in tumor cells correlated with effıcient internalization, effıcacy, and cy-
totoxic effects in vitro. Effıcacy studies demonstrated that HER-3-ADCs treat-
ment leads to a long lasting tumor growth inhibition of cell line-basedmodels of
human head and neck, breast, pancreatic, prostatic, lung, stomach cancers and
melanoma. Overall, these fındings validate HER-3 as an attractive therapeutic
target in multiple solid tumors and support further clinical development and
application of HER-3 targeting ADCs.
#42 Preclinical development of a duocarmycin-based antibody-drug con-
jugate targeting B7-H3 for solid cancer. Thomas Son,1 Juniper A. Scribner,1
Jeff Hooley,1 Michael Chiechi,1 Pam Li,1 Timothy E. Hotaling,1 Anushka De
Costa,1 Yan Chen,1 Francine Chen,1 Bhaswati Barat,2 Valentina Ciccarone,2
Timur Gaynutdinov,2 James Tamura,2 Scott Koenig,2 Syd Johnson,2 Paul A.
Moore,2 Ezio Bonvini,2 Deryk Loo1. 1MacroGenics, Inc., South San Francisco,
CA; 2MacroGenics, Inc., Rockville, MD.
Introduction: B7-H3, amember of the B7 family of immunomodulatorymol-
ecules, is overexpressed in a wide range of solid cancers. B7-H3 overexpression
has been correlated with disease severity and poor outcome in several cancer
types. Proof-of-concept studies targeting B7-H3 demonstrated that auristatin-
based B7-H3 antibody-drug conjugates (ADCs) exhibited potent cytotoxicity in
vitro and antitumor activity in vivo toward a range of B7-H3-expressing tumor
cell lines. Based on these preliminary results, we undertook preclinical develop-
ment of a B7-H3 ADC comprised of a humanized B7-H3 mAb conjugated to a
potent DNA alkylating payload. Methods: Chimeric B7-H3 mAbs were conju-
gated to vc-seco-DUocarmycin-hydroxyBenzamide Azaindole (DUBA) (ADC
conjugated and provided by Synthon Biopharmecuticals B.V). In vitro and in
vivo activity studies were conducted with tumor cell lines that overexpress B7-
H3. Based on the potency analysis, together with the biophysical properties and
immunohistochemistry (IHC) profıles of the candidates, a lead mAb was se-
lected for preclinical development. The mAb was humanized via CDR grafting
and conjugated to DUBA to yield the development candidateMGC018. In vitro
and in vivo studies were then conducted with MGC018 to confırm and extend
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the results with the chimeric ADCs. Results: Confırming our previous data and
consistent with a growing body of literature, B7-H3 mAbs exhibited strong
reactivity toward carcinoma cells and the vasculature of solid cancers. Chimeric
B7-H3-DUBA ADCs demonstrated specifıc, dose-dependent cytotoxicity to-
ward B7-H3-positive tumor cell lines in vitro and potent antitumor activity in
vivo. The humanized ADC development candidate, MGC018, retained the fa-
vorable biophysical properties and the normal tissue-versus-tumor IHC profıle
of the parental mAb. MGC018 displayed cytotoxicity toward B7-H3-positive
tumor cell lines in vitro, with IC50 values in the sub-nM range, and potent
antitumor activity in vivo, resulting in tumor stasis and tumor regression inmice
bearing B7-H3-positive human tumor xenografts, representing breast, lung and
ovarian cancers. Conclusion: MGC018, a preclinical candidate comprised of a
humanizedmAb targeting B7-H3 conjugated to the potent DNA alkylating pay-
load DUBA via a cleavable peptide linker, exhibited a favorable preclinical pro-
fıle, with strong reactivity toward tumor cells and tumor-associated vasculature,
limited normal tissue reactivity, potent cytotoxicity in vitro and antitumor ac-
tivity in vivo toward a range of B7-H3-expressing tumor cell lines representing
several cancer types. Our fındings support further preclinical development of
MGC018 to evaluate its potential as an ADC therapeutic for B7-H3-expressing
solid cancers.
#43 ASN004, a novel 5T4-targeted Dolaflexin ADC, achieves complete
regressions and tumor-free survivors in a broad variety of solid tumor mod-
els. Roger A. Smith, David J. Zammit, Sanjeeva P. Reddy. Asana BioSciences,
Lawrenceville, NJ.
ASN004 is anAntibodyDrugConjugate (ADC) that targets the 5T4 oncofetal
antigen (trophoblast glycoprotein). High expression of 5T4 is observed in awide
range of malignant tumors, while very limited expression is found in normal
tissues. ASN004 incorporates a novel single-chain homo-dimer antibody, Flexi-
mer® linker technology (MersanaTherapeutics), and several cytotoxic dolastatin
(auristatin) analog warheads per ADC molecule with a drug/antibody ratio of
15:1. ASN004 shows high affınity for the 5T4 antigen (Kd  30 pM) and
5T4-expressing tumor cells; rapid cellular internalization; and potent, selective
cytotoxicity. ASN004 provides complete tumor regressions and tumor-free sur-
vivors inmultiple tumor xenograftmodels, derived fromhuman tumor cell lines
having both high and low 5T4 expression levels. Tumor-free survivors were
achieved at doses that are well-tolerated, based on xenograft body weight mea-
sures and exploratory toxicology studies in pharmacologically-relevant non-
human primates. As well, tumor-free survivors were achieved in xenograft tu-
mor models following administration of a single dose of ASN004, as low as 1
mg/kg iv. The broad activity of ASN004 has been demonstrated by its superior
effıcacy in a head-to-head study against trastuzumab-DM1, in a low-5T4, high-
HER2 expressing tumor xenograftmodel. Finally, tumor xenografts that initially
responded to ASN004 and later showed tumor regrowth, had not developed
resistance and responded well to subsequent treatment with ASN004. Overall,
ASN004 is demonstrated to be an ADC with high therapeutic potential in mul-
tiple tumor types, encompassing a wide range of 5T4-expression levels. IND-
enabling toxicology studies are ongoing, in preparation for advancement to
clinical studies in patients with solid tumors.
#44 U3-1402, a novel HER3-targeting ADC, and a novel DNA topoisom-
erase I inhibitor inhibit the growth of non-small cell lung cancer with EGFR
mutation. Kimio Yonesaka,1 Koji Haratani,1 Kenji Hirotani,2 Kazuhiko Naka-
gawa1. 1Kindai University Faculty of Medicine, Japan; 2Daiichi Sankyo Co., Ltd.,
Japan.
Background HER3, a member of the HER family, is overexpressed in non-
small cell lung cancer (NSCLC), especially in those with EGFR mutation. Anti-
HER3 antibody therapies, including patritumab, are effective, but limited in
their effıcacy, for patients withNSCLC.U3-1402 is a novel ADC composed of an
anti-HER3 antibody (patritumab) and a novel potent topoisomerase I inhibitor
DX-8951. U3-1402 achieved a high drug-to-antibody ratio (DAR: 7-8), because
it is homogeneously conjugated with the payload. Here, we aimed to preclini-
cally evaluate U3-1402’s effıcacy in NSCLC, especially in those with EGFR mu-
tation. Materials and methods An in vitro growth inhibition assay was used to
evaluate the sensitivity of 14 NSCLC cell lines to U3-1402. Cells were treated
with U3-1402 at different concentrations (0-10g/ml) over 7 days; 50% growth
inhibitory concentration relative to control (IC50) was calculated. PC9,
HCC827, HCC827GR5, Ma70, Ma70GR, 11-18, H1650, HCC4006, and H1975
cells had the EGFR mutation. HCC827GR and Ma70GR were EGFR-TKI resis-
tant clones, withMET genomic amplifıcation and an unknown resistancemech-
anism, established from HCC827 and Ma70 cells, respectively. HER3 mRNA
expression levels were measured by quantitative reverse transcription-PCR
(qRT-PCR) and the ratiowas calculated against house-keeping genes in each cell
line. Results The in vitro growth inhibition assay indicated that HCC827GR5,
Ma70GR, and 11-18 cells were sensitive to U3-1402 (IC50 values 1.0, 5.2, 3.2
g/ml, respectively). However, other cells were relatively resistant to U3-1402,
having IC50 values greater than 10 g/ml. Notably, HCC827GR5 cells were
more sensitive to U3-1402 than parental HCC827 cells were. Specifıcally, 1.0
g/ml U3-1402 reduced the viable cell proportion to 50% of control in
HCC827GR5 cells, but the effect was limited to 95% of control in HCC827
parental cells. Furthermore, EGFR-TKI erlotinib increased sensitivity to U3-
1402 in HCC827GR5 cells. Specifıcally, 1.0 M erlotinib reduced the viable cell
proportion to 69% of control, and 1.0 g/ml U3-1402 reduced it to 50% of
control in HCC827GR5 cells, but both agents combined reduced it to 3% of
control. In an effort to clarify the underlying mechanism by which EGFR-TKI
resistant HCC827GR5 cells were more sensitive to U3-1402 than parental
HCC827 cells were, we evaluated the HER3mRNA expression in both cell lines.
HCC827GR5 cells had signifıcantly higher levels of HER3mRNA than parental
HCC827 cells did (1.85 vs 0.65, t-test; p 0.003). ConclusionsU3-1402 preclini-
cally exhibited its effıcacy in NSCLC with EGFR mutation. Its effıcacy was en-
hanced by EGFR-TKI combination. Sensitivity to U3-1402 might depend on
HER3 expression levels. These results provide a rationale for U3-1402 alone or
in combination with EGFR-TKI to be investigated in patients with NSCLCwith
EGFR mutation and aberrant HER3 expression.
#45 In vitro and in vivo activity of a novel c-Met-targeting antibody-drug
conjugate using a DNA-alkylating, indolinobenzodiazepine payload. Katha-
rine C. Lai, Asli Muvaffak, Min Li, Marian Themeles, Surina Sikka, Kerry Do-
nahue, Stuart W. Hicks, Angela Romanelli, Thomas Chittenden. ImmunoGen,
Inc., Waltham, MA.
Purpose: c-Met dysregulation and/or overexpression are associated with tu-
mor progression, metastasis and poor prognosis in numerous cancers. Despite
strong pre-clinical evidence that blocking c-Met activity inhibits tumor cell
growth andmetastasis, targeted therapies have thus far failed to deliver an effec-
tive treatment option to the majority of patients. To address patients with both
c-Met over-expressing and MET amplifıed tumors, we designed an antibody-
drug conjugate (ADC) comprised of a humanized anti-c-Met monoclonal anti-
body linked to a highly potent indolinobenzodiazepineDNA-alkylating payload
(DGN549) to enable activity against not only MET amplifıed but also c-Met
over-expressing tumors. Experimental Design: Panels ofmonoclonal antibodies
(Abs) against c-Met were generated and screened for antagonistic and agonistic
activity in the presence or absence of the c-Met ligand, HGF. Lead Abs were
humanized and conjugated to DGN549 either through lysine (Drug-to-Ab ratio
(DAR) 2.5) or engineered cysteine residues (DAR 2.0). Abs were also conju-
gated via lysine residues to the potent anti-microtubule maytansine derivative,
DM4, using a sulfo-SPDB linker (DAR 3.5). Binding and cytotoxicity of ADCs
were tested in vitro on normal and cancer cell lines with varying c-Met levels.
Expression of c-Met was evaluated in patient tumors and xenografts along with
normal human tissues using the CONFIRM immunohistochemistry assay. In
vivo effıcacy of anti-c-Met-DGN549 and anti-c-Met-DM4 ADCs was tested in
both MET amplifıed and c-Met over-expressed (but non-amplifıed) xenograft
tumormodels. Results: A humanized anti-c-Met antibody, hucMet27, was iden-
tifıed which exhibits low c-Met agonist activity. Conjugates of hucMet27 were
prepared with two different payloads, DGN549 and DM4, and in vitro and in
vivo activity were determined. BothDGN549 andDM4 conjugates of hucMet27
bound with similar sub-nanomolar affınity to c-Met-expressing cells. huc-
Met27-DGN549 conjugates exhibited potent cytotoxicity against a large panel of
c-Met expressing cell lines. By contrast, the potency of the hucMet27-DM4
conjugate was restricted mainly to cell lines harboring MET amplifıcation, de-
spite all cell lines demonstrating sensitivity to the unconjugated payload. When
tested in mice bearing human xenograft tumors, both hucMet27-DGN549 and
hucMet-DM4 conjugates were highly active in aMET amplifıedmodel, whereas
hucMet27-DGN549 was more potent in inducing regressions in a model with
c-Met over-expression without MET amplifıcation. Conclusion: hucMet27-
DGN549 exhibits compelling c-Met targeted anti-cancer activity in vitro and in
vivo, and represents a promising therapeutic strategy to deliver a potent cyto-
toxic agent to tumor cells bearing a wide range of c-Met expression.
#46 Preclinical activity of novel antibody-drug conjugates with pyrrole-
based kinesin spindle protein inhibitors targeting different tumor antigens.
Anette Sommer,1 Sandra Berndt,1 Hans-Georg Lerchen,2 Beatrix Stelte-Lud-
wig,2 SvenWittrock,2 Anne-Sophie Rebstock,2 Lisa Dietz,2 ChristophMahlert,2
Simone Greven,2 Nils Griebenow,2 Yolanda Cancho-Grande,2 Rolf Jautelat,2
Heiner Apeler,2 Bertolt Kreft1. 1Bayer AG, Berlin, Germany; 2Bayer AG, Wup-
pertal, Germany.
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Antibody-drug conjugates (ADCs) are promising agents that are developed
for targeted delivery of cytotoxic payloads to tumor cells. ADCs share a common
design of antibody, linker, and cytotoxic payload. Despite signifıcant efforts, the
number of available payload classes with a differentiated mode-of-action that
can successfully be employed to generate antibody-drug conjugates (ADCs) is
still rather limited. So far, only ADCswithmicrotubule depolymerizing orDNA
binding payloads have been approved. The identifıcation of ADC payload
classes with a novelmode-of-actionwill increase therapeutic options and poten-
tially help to overcome resistance. Inhibitors of the kinesin spindle protein
(KSP/Eg5/KIF11) have generated interest due to their high anti-tumor activity.
However, the transfer of the potency of smallmoleculeKSP inhibitors (KSPis) to
highly effıcient clinical regimens with a suffıcient therapeutic window remains
challenging. Through the conjugation of a novel pyrrole subclass of KSPis to
antibodies targeting different cancer antigens, we generated a panel of ADCs
and characterized themboth in vitro and in vivo.ADCs targeting either EGFRor
TWEAKR/Fn14 showed strong and specifıc internalization and displayed spe-
cifıc and potent anti-proliferative effıcacy in vitro. In cytotoxicity assays, these
ADCs exhibited sub-nanomolar potency in antigen-positive cancer cell lines
(EGFR/TWEAKR-pos. NCI-H292; TWEAKR-pos. BxPC3, LoVo) and more
than 100-fold selectivity versus non-targeted control-ADC containing the same
linker and the same payload. Furthermore, selective anti-tumor effıcacy of
EGFR- and TWEAKR-KSPi-ADCs was demonstrated in vivo using both cancer
cell line-derived models of NSCLC (NCI-H292), urothelial cell carcinoma
(UCC) (KU-19-19), and renal cell carcinoma (A498), as well as in the
TWEAKR-positive patient-derived xenograft UCC model BFX469. At doses of
5-10 mg/kg qw or bw potent anti-tumor effıcacy with treated-to-control ratios
(T/C) between 0.16 to 0.28 as well as complete regressions were observed. In
summary, KSP inhibitors have been established as a promising new payload
class allowing the generation of highly potent and selective ADCs for the treat-
ment of solid tumors.
#47 SYD985, a novel duocarmycin-based HER2-targeting antibody-drug
conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma
with HER2/neu expression. Gulden Menderes, Elena Bonazzoli, Stefania Bel-
lone, Jonathan Black, Gary Altwerger, Alice Masserdotti, Francesca Pettinella,
Luca Zammataro, Natalia Buza, Pei Hui, Elena Ratner, Babak Litkouhi, Dan-
Arin Silasi, Masoud Azodi, Peter Schwartz, Alessandro D. Santin. Yale Univ.
School of Medicine, New Haven, CT.
Introduction: Carcinosarcoma (CS) is a rare and highly aggressive gyneco-
logic malignancy. The amplifıcation of HER2/neu has been reported to occur in
25%-56% of uterine and ovarian CSs with signifıcant heterogeneity of the ex-
pression within epithelial and in-between epithelial and mesenchymal compo-
nents. The reported high incidencemakesHER2/neu an attractive target for new
molecularly targeted therapies. We investigated the effıcacy of SYD985, (Syn-
thon-Biopharmaceuticals), a novel HER2-targeting antibody-drug conjugate
(ADC) composed of a monoclonal antibody (mAb) similar to trastuzumab
linked to a highly potent DNA-alkylating agent (i.e., duocarmycin) in uterine
and ovarian carcinosarcoma. We also compared the anti-tumor activity of
SYD985 to trastuzumab emtansine (T-DM1), a FDA-approved ADC, against
multiple primary CS cell lines expressing different levels ofHER2/neu in in vitro
and in vivo experiments.Methods: Eight primaryCS cell lineswere evaluated for
HER2/neu surface expression by IHC and gene amplifıcation using FISH assays.
The cytotoxicity of SYD985 and T-DM1 was evaluated using these eight CS
primary cell lines with differential HER2/neu expression (i.e., 0, 1, and 3).
Antibody-dependent cellular cytotoxicity (ADCC), proliferation, viability and
bystander killing experiments were performed using Cr51-release assays, pro-
pidium iodide-based and flow cytometry assays, respectively. SYD985 and
T-DM1 in vivo activity was also studied in mouse xenograft models. Results:
Similar ADCC were induced by SYD985 and T-DM1 when effector cells were
present against CS cell lines with different HER2/neu expression. In contrast,
SYD985 was signifıcantly more cytotoxic compared to T-DM1 in the absence of
the effector cells. SYD985 is 7 to 54 fold more potent than T-DM1 in compara-
tive experiments and unlike T-DM1, it is active against CS demonstrating mod-
erate/low or heterogeneous HER2/neu expression. Specifıcally, in HER2/neu
0/1 cell lines the mean IC50’s were 0.060g/mL and 3.221g/mL for SYD985
vs T-DM1 (p0.0001) and in HER2/neu 3 cell lines 0.013 g/mL and 0.096
g/mL, (p0.0001), respectively, (p0.0001). Unlike T-DM1, SYD985 induced
effıcient bystander killing of HER2/neu 0/1 EOC cells admixed with HER2/
neu 3 cells. In vivo studies confırmed that SYD985 is more active than T-DM1
in CS and effective against HER2/neu 3 xenografts. Conclusions: We demon-
strate for the fırst time that SYD985 is a novel ADC with remarkable activity
against CS not only with strong (3) but also with low (0/1) HER2/neu ex-
pression . Clinical studies with SYD985 in patients harboring chemotherapy-
resistant uterine and ovarian CS with low, moderate and high HER2 expression
are warranted.
#48 Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting au-
ristatin-based antibody drug conjugate.Alex Yurkovetskiy, Dmitry Gumerov,
Elena Ter-Ovanesyan, Patrick Conlon, Michael Devit, Charlie Bu, Natalya
Bodyak, Timothy Lowinger, Donald Bergstrom. Mersana Therapeutics, Inc.,
Cambridge, MA.
The ADCXMT-1522 consists of a novel human IgG1 anti-HER2monoclonal
antibody and a novel, auristatin-based cytotoxic payload (Auristatin F-hydroxy-
propylamide, AF-HPA). An average DAR of 12 AF-HPAmolecules is achieved
via a biodegradable polymer conjugation platform. The non-clinical DMPK
properties of XMT-1522 have been characterized in vitro in plasma and micro-
somal stability studies, and in vivo in plasma and tissue disposition and excre-
tion studies. Sample analysis for total AF-HPA drug payload and released (free)
AF-HPA and itsmetabolites was performed by ESI LC/MS/MS; total antibody
was determined byELISA. The half-life forAF-HPA release in plasmawas found
to be greater than 120 hours in all species tested. Microsomal stability studies
showed that AF-HPA was further converted to other metabolites including the
carboxylic acid auristatin F (AF), as well as monomethyl auristatin F-HPA
(MMAF-HPA) and MMAF. The pharmacokinetic profıles of XMT-1522 were
evaluated inmouse, rat and cynomolgusmonkey. The antibody of XMT-1522 is
cross-reactive with monkey, but not rodent, HER2. In mouse and rat, XMT-
1522 exposure was dose-proportional; exposure was slightly greater than dose-
proportional in monkey consistent with saturation of target-mediated clear-
ance. All species showed extended exposure to total AF-HPAdrug payload, with
measured clearance and volume of distribution similar for total AF-HPA and
the antibody component of XMT-1522. Exposure to free AF-HPA and AF was
less than 1/1000th the exposure of total AF-HPA. These data indicate the vast
majority of AF-HPA in plasma is antibody-conjugated, indicating high stability
of the ADC in systemic circulation. XMT-1522 tissue disposition was studied in
NCI-N87 HER2-positive gastric cancer xenograft tumor bearing mice. After a
single 3 mg/kg dose of XMT-1522, free AF-HPA and its metabolite AF were
measurable in tumor tissue until the last time point measured (2 weeks). Total
AF-HPA and free AF-HPA achieved peak tumor concentrations 48 hours after
dosing. In contrast, AF achieved peak tumor concentration 7 days after dosing
and showed only a slight decline in tumor concentration at 14 days, consistent
with intracellular trapping of this poorly cell-permeablemetabolite. Exposure to
freeAF-HPAorAF in other tissueswas at least an order ofmagnitude lower than
in tumor; in tissues withmeasurable free drug, AF was the predominant species.
XMT-1522 excretion studies, conducted in rat, indicated that the AF-HPA pay-
load was mainly excreted by the gastrointestinal route. In the fırst 96 hours after
administration 33% of the AF-HPA dose was excreted in feces, compared to 3%
excreted in urine. The major contributing metabolites both in feces and urine
were conjugated AF-HPA, AF, and free AF-HPA. In conclusion, the plasma
kinetics, tissue distribution and excretion profıle of XMT-1522 are acceptable
for clinical evaluation in cancer patients.
#49 Modulating insulin receptor splicing as a potential therapeutic ap-
proach for rhabdomyosarcoma. Brianne Sanford,1 Chelsea Brown,1 Hemant
Bid,1 Thomas Beebe,1 Daniel Comiskey,1 Frank Rigo,2 Peter Houghton,3 Dawn
Chandler1. 1Nationwide Children’s Hospital, Columbus, OH; 2Ionis Pharmaceu-
ticals, CA; 3University of Texas Health Science Center, TX.
The insulin receptor (IN-R) is subject to alternative splicing to produce two iso-
forms: the full-length IN-R B isoform and an isoform lacking exon 11 known as
IN-R A which is the predominant isoform expressed in sarcoma cells. This short
exon encodes for 12 amino acids but the resulting receptor has high affınity for a
growth hormone called insulin-like growth factor 2 (IGF2), which exquisitely re-
sponds to autocrine and paracrine signaling. Increased IN-R A levels observed in
rhabdomyosarcoma (RMS) coupled with increased expression of IGF2, programs
the tumor cell for enhanced growth and angiogenesis, two important factors in
tumorigenesis. Furthermore, IGF2 can maintain angiogenesis through IN-R A
when the cognate receptor for IGF2, the IGF-1 receptor, is blocked. Interestinglywe
have shown that hypoxia increases alternative splicing to produce more IN-R A.
This is an interesting fınding since adaptation to the hypoxic environment is a hall-
mark of the neoplastic phenotype. Therefore, we hypothesize that expression of
splicing factors is altered under hypoxic conditions which leads to increased alter-
native splicing and generation of IN-RA, allowing the cancer cells a growth advan-
tage which contributes tometastasis beyond themicrometastatic phase. To charac-
terize sequence elements and splicing factors involved in the regulation of IN-R
alternative splicing, we have developed a hypoxia-inducible splicing system, which
recapitulates the splicing patterns observed in tumors. We have shown that se-
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quence elements preceding exon 11 are critical to the increased alternative splicing
we see under hypoxic conditions. As such, we have targeted these regions for anti-
sense oligonucleotide (ASO) development to increase full-length splicing of IN-R,
with the goal of restricting proliferative signaling by IGF2 activation of IN-RA.We
performed anASOwalk to target regions important for exon inclusion or exclusion
and have successfully targeted a region known to be a binding site for the splicing
factorCUGBP1.RMS-derivedcell lines almost exclusively express IN-RAbutwhen
treated with our lead ASO compound we see a dramatic decrease in alternative
splicing resulting in increased levels of the full-length insulin receptor.Wehave also
shown that RMS-derived cells treated with our splice modulating ASO exhibit re-
duced cell proliferation and migratory properties. With these promising data we
postulate thatmodulation of IN-R splicing can be used in conjunction with already
established anti-IGF-1 receptor therapies in the treatment of RMS.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Antibody Technology
#50 HTI-1511, a novel anti-EGFR-ADC, overcomes mutation resistance
and demonstrates signifıcant activity against multiple tumor types in pre-
clinical studies. Jesse D. Bahn,1 Feng Gao,1 Lei Huang,1 Barbara Blouw,1 Chun-
mei Zhao,1 Kelly Chen,1 Susan Zimmerman,1 Erin K.Wise,2Maria L.Mancini,2
Matthew Bird,3 William McDowell,3 Curtis B. Thompson,1 Sanna Rosengren,1
Christopher D. Thanos1. 1Halozyme Therapeutics, San Diego, CA; 2Champions
Oncology, Inc, Baltimore,MD; 3Abzena,Antitope Limited&PolyTherics Limited,
Cambridge, United Kingdom.
Multiple solid tumor types over-express epidermal growth factor receptor
(EGFR). Antibodies that target the receptor are often accompanied by adverse skin
reactions due to interactionwith receptors expressed innormal tissue.Additionally,
downstreammutations (KRAS,BRAF)within tumors can result inEGFR-indepen-
dent activation and resistance to treatment. We have previously described HTI-
1511, an antibody-drug conjugate in pre-clinical development that targets EGFR.
HTI-1511 carries the potent cytotoxin MMAE and a novel bis-alkylating linker,
connected to a monoclonal antibody engineered to have improved specifıcity for
EGFR in the tumor microenvironment (Huang et. al. AACR National Meeting,
2016,NewOrleans,LA).Herewescreenedapanelofover70 tumorcell linesderived
fromvarious solid tumormalignancies forbothEGFRexpressionby flowcytometry
andsensitivity to cell growth inhibitionbyHTI-1511 invitro.Cell linesderived from
head and neck squamous cell carcinoma (SCC15, CAL27, FaDu, CAL33, SCC25
[IC50 0.52 nM - 3.1 nM]), non-small cell lung cancer (HCC827, NCI-H1666, PC-9,
NCI-H1650[IC500.04nM-6.2nM]), andpancreatic carcinoma(BxPC-3,PANC-1,
AsPC-1 [IC50 0.99 nM - 4.44 nM]) showed particular sensitivity to HTI-1511. In
conjunction, HTI-1511 effıcacy was assessed in vivo for tumor growth inhibition
(TGI) in several human tumor xenograft models. Evaluations in the human xeno-
grafts A431 (epidermoid, 93% TGI at 3.0 mg/kg, p0.05), BxPC3 (pancreatic,
100%TGI at 3.0mg/kg, p0.05), AsPC-1 (pancreatic,100%TGI at 3.0mg/kg,
p0.05), and FaDu (HNSCC, 100% TGI at 3.0 mg/kg, p0.05) indicated dose
dependent tumor regressions in all cases, and no observed toxicity when adminis-
teredweekly atdose levelsup to3mg/kg forup toeightweeks.HTI-1511anti-tumor
activity was also investigated in a group of patient derived xenograft (PDX)models.
An initial study evaluated weekly administration of a single dose level of 2.5 mg/kg
HTI-1511 in three different PDXmodels. TGI of 83% (p0.05) was observed in a
BRAFmut colorectal cancermodel and 57% (p0.05) in awildtype colorectal cancer
model, as well as 46% (not signifıcant) TGI seen in a wild type renal cell carcinoma
model. A separate study in a NSCLC (KRASmut) PDXmodel demonstrated a dose
dependent responsewith greater than100%TGIat 1.0 and3.0mg/kg (bothp0.05,
and also p0.05 to a non-cognate antibody ADC control). The non-cognate anti-
body control yielded 67.4% (not signifıcant) TGI by itself compared to the vehicle
control group. These results support further development ofHTI-1511 as a possible
treatment for EGFRoverexpressing tumors, including thosewith downstream acti-
vatingmutations in the KRAS/BRAF pathway.
#51 Characterization of themechanismof action, pharmacodynamics and
preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-con-
taining antibody-drug conjugate (ADC) targetingCD19-expressing hemato-
logical malignancies. Francesca Zammarchi,1 Simon Corbett,2 Karin Have-
nith,1 Narinder Janghra,2 Konstantinos Kiakos,2 Teresa Marafıoti,2 David G.
Williams,3 Simon Chivers,1 Phil W. Howard,3 John A. Hartley,2 Patrick H. van
Berkel1. 1ADC Therapeutics, London, United Kingdom; 2University College Lon-
don, London, United Kingdom; 3Spirogen/MedImmune, London, United King-
dom.
ADCT-402, currently in Phase I clinical trials for B-cell hematological malig-
nancies, is anADC composed of a recombinant humanized IgG1 against human
CD19, stochastically conjugated via a cleavable linker to a PBD dimer cytotoxin
(DAR of 2.3). PBD dimers, DNAminor groove interstrand cross-linking agents,
are gaining increasing attention and are currently being tested as the ADC war-
heads in several clinical trials. ADCT-402 has potent and targeted cytotoxicity
against a panel of human lymphoma and leukemia cell lines in vitro. In vivo,
ADCT-402 demonstrates dose-dependent antitumor activity against Burkitt’s
lymphoma xenograft models. Moreover, ADCT-402 is markedly superior to
maytansinoid- and auristatin-based CD19-targeting ADCs in the Ramos xeno-
graft model. In a rat toxicology study, a single dose of ADCT-402 at 2 mg/kg is
well tolerated with a favorable PK profıle and excellent stability in vivo. The
current study aimed to further defıne the mechanism of action (MOA) of
ADCT-402 and validate its pharmacology and preclinical safety for clinical de-
velopment. CD19 is a clinically validated target with restricted normal tissue
expression and a widespread expression in the majority of B-cell malignancies.
Importantly, we show here the consistent expression of CD19 in matched sam-
ples (initial diagnosis and relapsed/refractory) from panels of lymphoma pa-
tients, indicating that relapsed/refractory patients are appropriate for treatment
with ADCT-402. ADCT-402was shown to be effıciently internalized by CD19
cells in vitro. Moreover, in line with the PBD dimer MOA, following a 2 hour
exposure to ADCT-402, DNA interstrand cross-links reached a peak between 8
- 12 hours and persisted for up to 36 hours post-treatment. In contrast, the peak
of cross-link formation for the PBD dimer warhead alone was observed imme-
diately after 2 hour incubation, while a non-targeted PBD-ADC did not yield
any appreciableDNA cross-links. In SCIDmice s.c. implantedwith Ramos cells,
a single dose of ADCT-402 was administered at 0.33 or 1 mg/kg. Twenty-four
hours after treatment, excised tumors showed a dose proportional increase in
intensity of staining by an anti-PBD payload antibody, as well as in DNA cross-
linking and in -H2AX formation. In contrast, no DNA cross-linking was ob-
served in matched lymphocyte samples. The toxicity of ADCT-402 was further
evaluated in a repeat dose cynomolgus monkey study. ADCT-402 was clinically
well toleratedwith an acceptable off-target safety profıle. The PKof theADCwas
consistent with normal antibody clearance with a half-life of about 12 to 17 days.
These data confırm the MOA of ADCT-402 and provide relevant pharmacody-
namic assays and preclinical safety assessment to guide the clinical development
of this promising ADC in B-cell malignancies.
#52 Mechanistic and benchmarking studies of ADCT-502, a pyrroloben-
zodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) tar-
getingHER2-expressing solid tumors. Francesca Zammarchi,1 HallaW. Rein-
ert,2 Narinder Janghra,2 Simon Corbett,2 Maria Mellinas-Gomez,3 Sajidah
Chowdhury,3 NehaArora,3 Peter Tyrer,3 Francois Bertelli,3 DavidG.Williams,3
Philip W. Howard,3 John A. Hartley,2 Patrick H. van Berkel1. 1ADC Therapeu-
tics, London, United Kingdom; 2University College London, London, United
Kingdom; 3Spirogen/MedImmune, London, United Kingdom.
ADCT-502 is anADCcomposed of an engineered version of humanized IgG1
trastuzumab, directed against human HER2, site-specifıcally conjugated to the
highly cytotoxic PBD-based linker-drug tesirine (drug-antibody ratio of 1.7). In
vitro, ADCT-502 has highly potent and targeted cytotoxicity against various
solid cancer cell lines. In vivo, ADCT-502 demonstrates strong and durable
antitumor activity in mouse xenografts with various levels of HER2, but is inac-
tive in a HER2-negative xenograft. ADCT-502 is stable, well tolerated and has a
favorable PK profıle both in rat and cynomolgus monkey. The current study
aimed to defıne further the mechanism of action of ADCT-502 and to bench-
mark its activity in xenograft models against ado-trastuzumab emtansine (T-
DM1), the ADC currently approved for the treatment of HER2 metastatic
breast cancers. ADCT-502 bound and internalized effıciently in JIMT-1 cells
(HER2) and co-localized with lysosomes within 2 hours. PBD dimers bind in
the DNA minor groove and exert cytotoxicity via the formation of DNA inter-
strand cross-links. Following a 2-hour exposure to ADCT-502, DNA inter-
strand cross-linking peaked between 12 and 24 hours, after which cross-links
persisted at least 36 hours. In contrast, cross-link formation by an equimolar
concentration of warhead alone, peaked immediately following drug exposure
and a non-targeted ADC did not produce DNA crosslinks in these cells. More-
over, ADCT-502 showed indirect bystander killing activity in HER2-negative
MDA-MB-468 cells incubated with conditioned medium from ADCT-502-
treated HER2 SK-BR-3 cells. In vivo, antitumor activity of ADCT-502 was
compared to T-DM1 in both cell line- and patient-derived-xenograft (PDX)
models. For example, in a HER2 1, FISH- breast cancer PDX, ADCT-502
showed dose-dependent antitumor activity resulting in 1/8 and 8/8 TFS after a
single dose at 0.1 and 0.2 mg/kg, respectively. Conversely, a single dose of
T-DM1 at 30 mg/kg showed only marginal activity compared to the control.
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Similarly, in a HER2 1, FISH- esophageal cancer PDX, while a single dose of
ADCT-502 at 0.44 mg/kg resulted in strong and durable antitumor activity,
single doses of T-DM1 at either 10 or 30 mg/kg showed no activity compared to
the control. These data confırm that the mechanism of cell killing of ADCT-502
is via target-specifıc internalization and subsequent cross-linking of DNA. They
also show superior in vivo antitumor activity ofADCT-502 compared toT-DM1
in various tumor xenografts, including those with low HER2 levels. Taken to-
gether, these results support the development of ADCT-502 not only in patients
that have become resistant/refractory to T-DM1, but also in patients whose
tumors express low levels of HER2, and are not eligible for treatment with
T-DM1.
#53 Antibody-drug conjugates (ADCs) of peptide-linked Indolino-Benzo-
diazepine (IGN) DNA-alkylator provides improved anti-tumor activity over
that of a crosslinker.Michael L. Miller, Manami Shizuka, Jose F. Ponte, Leanne
Lanieri, Dilrukshi Vitharana, Qifeng Qiu, Emily E. Reid, Katie E. Archer, Rui
Wu, Erin K. Maloney, Olga Ab, Jan Pinkas, Ravi V. Chari. ImmunoGen, Inc.,
Waltham, MA.
We recently disclosed highly active antibody-drug conjugates (ADCs) that
incorporated the novel DNA alkylating indolino-benzodiazepine (termed IGN)
dimer, DGN549 (IGN-P1). The stereochemistry of the alanyl moiety of the
protease-cleavable alanine-alanine linker usedwas shown to impact ADC catab-
olism, bystander killing activity, and in vivo effıcacy (Shizuka, et al., AACR 2016
#2959). Building upon these results, here we describe preclinical results from a
head-to-head comparison of ADCs of the mono-imine containing DGN549
with its corresponding DNA cross-linking diimine version, IGN-P1 diimine.
IGN-P1 diimine and DGN549 were conjugated to a folate receptor- (FR)-
binding antibody and an EpCAM-binding antibody. The resulting ADCs dem-
onstrated similar high in vitro potency (IC50 3-100 pM) and specifıcity to-
wards several cancer cell lines. Further in vitro studies revealed that the DNA
alkylating anti-FR-DGN549 ADC demonstrated superior bystander cell-kill-
ing activity compared to its DNA crosslinking counterpart, anti-FR-IGN-P1
diimine. In vivo, this improved bystander killing ability translated into better in
vivo activity for the DNA alkylating ADC. In an endometrial tumor xenograft
model establishedwith Ishikawa cells, the anti-FR-DGN549 induced complete
regressions at a single dose of 140 g/kg Ab dose (equivalent to 5 g/kg linked
IGN). The cross-linking anti-FR-IGN-P1 diimine had to be used at twice the
dose to achieve the same level of anti-tumor activity. The in vivo tolerability in
CD-1 mice also displayed differences in the two ADCs.We found that the ADC
of the DNA crosslinker was at least two-fold less tolerated than the correspond-
ing ADC of the DNA alkylator. These results indicate that a 4 fold greater
therapeutic index can be achieved when using a DNA alkylating mono-imine
DGN549 ADC as compared to the DNA crosslinking IGN-P1 diimine ADC.
#54 Themany faces of antibody inGprotein-coupled receptor biology. Lei
Chen, Wing-Tai Cheung. School of Biomedical Sciences, Faculty of Medicine,
Chinese University of Hong Kong, Hong Kong.
G protein-coupled receptors (GPCRs), the largest family of cell-surface recep-
tor proteins mediating signal transmission, play a pivotal role in many physio-
logical functions and are involved inmultiple diseases. Although receptor activ-
ities of GPCRs are successfully modulated by many small molecules which
represent 30%of allmarketed drugs today, in fact only a fewGPCRmembers are
targeted and many more GPCRs of interest are intractable targets of small mol-
ecules, like orphan GPCRs and GPCRs with large binding sites. Besides, small
molecule drugs rarely trigger GPCR-mediated apoptosis or induce direct cell
killing, which is crucial for cancer therapies. Therefore, for these GPCRs, anti-
body-based drug would be a good alternative. Despite being eagerly sought for,
the production of monoclonal antibody (mAb) targeting GPCR is hindered by
the low expression of recombinant GPCR on cell surface, and relatively small
exposed regions with glycosylation and conformational heterogeneity. There-
fore those conventional methods that were well established for generation of
mAbs targeting soluble proteins usually showed frustrating results in the case of
GPCRs. To bypass the production and purifıcation of recombinant GPCR pro-
teins, we developed a novel approach of transplanting immunogenic conforma-
tional epitopes of GPCR into an antibody scaffold to make a water soluble sur-
rogate antigen of GPCR, named as GPCR-antigenized antibody which can be
easily and abundantly produced in bacteria for animal immunization. In cou-
pled with phage display technology and cell panning strategy, which allow the
retrieval of specifıc binders from a huge number of candidates, we have success-
fully isolated scFv antibodies for two humanGPCRs, theMAS1 receptor and the
chemokine receptor CXCR4. These antibodies showed good specifıcity in im-
munofluorescent staining, flow cytometry analysis, western protein immuno-
blot and immunoprecipitation assay. The results demonstrated this novel ap-
proachmay offer a generic and effectivemethod to generate specifıcmonoclonal
antibody targetingGPCR for diagnostic and therapeutic applications. [The proj-
ect is partly funded by a CUHK direct grant (4054300)]
#55 Generationof half-life extended anti-CD33BiTE® antibody constructs
compatible with once-weekly dosing. Tara L. Arvedson,1 Mercedesz Balazs,2
Pamela Bogner,3 Kurt Black,1 KevinGraham,1AnjaHenn,3Matthias Friedrich,3
Patrick Hoffmann,3 Roman Kischel,3 Peter Kufer,3 Ralf Lutterbuese,3 Markus
Muenz,3 Tobias Raum,3 BennoRattel,3 KarenRex,1DanRock,2Oliver Thomas,3
Joachim Wahl,3 Andreas Wolf,3 Angela Coxon1. 1Amgen, Thousand Oaks, CA;
2Amgen, San Francisco, CA; 3Amgen, Munich, Germany.
T cell engaging bispecifıc antibody constructs (BiTE®), such as blinatumomab
which targets CD19-positive cells, have shown great promise for treating certain
CD19-positive hematological malignancies. Blinatumomab comprises a single
chain Fv (scFv) that binds CD19 and a scFv that targets the T cell CD3 protein.
The molecular weight of this “canonical” BiTE® is 55 kDa, making it suscep-
tible to kidney-mediated clearance and resulting in a short serum half-life ( 4
hours). To maintain effective serum concentrations, canonical BiTE® antibody
constructs must be administered by continuous IV (cIV) infusion. While there
are many advantages associated with cIV administration (e.g., safety and uni-
form PK profıle), patient convenience could be enhanced if the BiTE® antibody
construct were compatible with once-weekly administration. To achieve this,
the serumhalf-life of the BiTE® antibody construct would need to be extended. A
canonical BiTE® targeting CD33 (AMG 330) is currently being evaluated in a
phase I clinical trial. Like blinatumomab, AMG 330 is dosed cIV. To extend the
serum half-life of AMG 330 and enable once-weekly dosing, several approaches
were evaluated including fusion of AMG 330 to human albumin and Fc-con-
taining moieties. Each of these half-life extended (HLE) constructs was evalu-
ated in vitro, in mouse xenograft models and in non-human primates. In vitro
assays evaluated 1) binding to both human and cynomolgus CD33 and CD3
proteins, and 2) cytotoxicity using human and cynomolgus target and effector
cells. In each of these assays the canonical and HLE BiTE® antibody constructs
demonstrated similar activity: single-digit nM binding and single digit pM cy-
totoxicity. Canonical and HLE BiTE® antibody constructs were subsequently
evaluated in an orthotopic mouse model in which MOLM13 cells were admin-
istered IV and activated human T cells were administered IP two days later. The
Fc-based HLE BiTE® antibody constructs provided a similar survival advantage
when administeredQ4DorQ5Das the canonical BiTE®when administeredQD.
However, the albumin fusion–based HLE BiTE® was less effıcacious when ad-
ministered Q4D than the QD- administered canonical BiTE®. Lastly, the PK/PD
relationship was evaluated for each of the constructs in non-human primates.
The serumhalf-lives varied from6hours for the canonical BiTE® to 44-167hours
for the HLE BiTE® antibody constructs. Each of the HLE BiTE® antibody con-
structs showed on-target depletion of CD33-positive monocytes and neutro-
phils in the blood and depletion of CD33-positive cells in the bone marrow.
These data demonstrate that half-life extendedBiTE® antibody constructs can be
generated that retain comparable in vitro and in vivo activity as a canonical
BiTE® and achieve a serum half-life compatible with once weekly dosing.
#56 Antibody-drug conjugates containing glucuronide-tubulysin pay-
loads display activity in MDR and heterogeneous tumor models. Patrick
J. Burke, Joseph Z. Hamilton, Joshua H. Hunter, Julia H. Cochran, Thomas A.
Pires, Christopher I. Leiske, KimK. Emmerton, Peter D. Senter, Robert P. Lyon,
Scott C. Jeffrey. Seattle Genetics, Inc., Bothell, WA.
While antibody-drug conjugates (ADCs) fınd increasing application in can-
cer treatment regimens, de novo or treatment-emergent resistance mechanisms
could impair clinical benefıt. Two resistance mechanisms that emerge under
continuous ADC exposure in vitro include upregulation of transporters that
confer multidrug resistance (MDR) and loss of cognate antigen expression.
New technologies that circumvent these resistance mechanisms may serve to
extend the utility of next generation ADCs. Recently, we developed the quater-
nary ammonium linker system to expand the scope of conjugatable payloads to
include tertiary amine-containing compounds and applied the linker to tubu-
lysins, a highly potent class of microtubule disrupting agents that maintain ac-
tivity in MDR cell lines. Quaternary ammonium-linked glucuronide-tubuly-
sin drug-linkers were synthesized and evaluated as ADCs. The resulting
conjugates were potent and immunologically specifıc across a panel of cancer
cell lines, including those displaying the MDR phenotype. The ADCs also dem-
onstrate potent bystander activity in a co-culture model containing amixture of
antigen-positive and -negative cell lines. Incorporation of a PEG12 side chain in
the linker enabled loading at 8-drugs/Ab for increased in vivo potency while
maintaining suitable ADC pharmacokinetic properties. In vivo, the glucuro-
nide-tubulysin conjugates displayed activity in MDR xenograft models and
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bystander activity in an admixed Ag/Ag- heterogeneous tumor model. Thus,
the glucuronide-tubulysin drug-linkers represent a promising new payload for
ADCs, combining conjugate potency in the presence of the MDR phenotype
with robust activity in models of tumor antigen heterogeneity.
#57 Generation and characterization of novel anti-glycanmonoclonal an-
tibody against acute myeloid leukemia. Chong Kok Teo,1 Wee Joo Chng,2
Andre Boon Hwa Choo1. 1Bioprocessing Technology Institute, Singapore, Singa-
pore; 2National University Cancer Institute, Singapore, Singapore, Singapore.
Hematological malignancies encompass a wide spectrum of cancers from
hematopoietic and lymphoid tissues. Under this grouping, the various forms of
leukemia, lymphoma and myeloma have been classifıed into more than 60 dis-
tinct disease types, each having particular clinical features and disease outcomes.
Among these diseases, curative treatments with high long-term survival rate
have been developed for some, e.g. Chronic Myeloid Leukemia, while such ef-
fective regimens are still unavailable formany others, e.g.MultipleMyeloma and
Acute Myeloid Leukemia. In this study, a panel of antibodies was raised against
SLAMF7, a cell surface marker that was associated to Multiple Myeloma.
Among the antibodies, TAG-HC2 was surprisingly found to have preferential
binding to SLAMF7 expressed on Acute Myeloid Leukemia (AML) cell lines
instead. Characterization of TAG-HC2 revealed that the binding of TAG-HC2
to SLAMF7 requires the N-glycosylation of the antigen. Functionally, TAG-
HC2does not have non-specifıc binding to normal cell lineswhen tested via flow
cytometry and immunohistochemistry. TAG-HC2, when complexed with sa-
porin-conjugated secondary mAb, was able to internalize into and kill AML cell
lines. These results suggest that TAG-HC2 has the potential to be developed into
an Antibody Drug Conjugate against AML.
#58 Local intratumoral treatment with anti-mesothelin Immunotoxins
overcomes resistance to anti-CTLA-4 therapy.Yasmin Leshem,1 Xiu-fen Liu,1
Tapan Bera,1 Masaki Terabe,1 Jay A. Berzofsky,1 Birgit Bossenmaier,2 Gerhard
Niederfellner,2 James O’Brien,1 Yoram Reiter,3 Ira Pastan1. 1NIH, Bethesda,
MD; 2Roche Pharmaceutical Research&EarlyDevelopment, Penzberg, Germany;
3Technion israel institute of technology, Haifa, Israel.
Background: SS1P and RG7787 are immunotoxins composed of anti-meso-
thelin antibody fused to a fragment from pseudomonas exotoxin A. We previ-
ously observed delayed tumor responses in patients treated with SS1P leading us
to hypothesis that immunotoxins can provoke anti-tumor immunity. We hy-
pothesize that intra-tumoral injection of SS1P or RG7787 will produce immu-
nologic death and convert living tumors to a source of antigens and boost the
therapeutic effect of immune check point blockade. Method: A BALB/c breast
cancer cell line was transfected with human mesothelin (66C14-M) and grown
in BALB/cmice transgenic for humanmesothelin. SS1P or RG7787was injected
directly into established tumors (80-100 mm3) and anti-CTLA-4 administered
IP. Results: We observed total tumor regressions in 23 out of 38 mice (60%)
treated with anti-CTLA-4 and either RG7787 or SS1P. No cure was achieved
when the drugs were given as a monotherapy supporting the case for synergic
anti-tumor activity. Pathologic evaluation of regressing tumors showed a mas-
sive inflammation of admixed eosinophils and mononuclear cells located in a
collar surrounding the tumors. Tumor regression was associated with increased
number of CD8 cells and was blocked when CD8 cells were depleted by an
antibody. In addition, cured mice were resistant to re-implantation of 66C14
cells not expressing mesothelin indicating that a long-term anti-tumor immu-
nity was formed. To determine if pathogen associated molecular patterns con-
tributed to the response, we combined anti-CTLA-4 with an inactive RG7787
and observed a major reduction in anti-tumor activity (P0.01) indicating that
the effect is not mediated by recognition of a foreign bacterial protein. Conclu-
sions:We suggest that injecting immunotoxins into tumors is a useful approach
to boost the activity of anti-CTLA-4. Based on the synergistic anti-tumor effect
demonstrated in this study we believe that there is a strong rational to explore
such combination therapies in patients.
#59 Engineering glypican-3 targeting immunotoxins for the treatment of
liver cancer. Bryan D. Fleming, Brittany Nixon, Ira Pastan, Mitchell Ho. Na-
tional Cancer Institute, Bethesda, MD.
The expression of glypican-3 (GPC3) in hepatocellular carcinoma offers a
target with high tissue specifıcity and cell signaling implications. A human single
domain antibody discovered by phage display technology, HN3, was fused to
domain II and domain III of Pseudomonas exotoxin A. This protein (HN3-
PE38) showed a high level of cytotoxic activity with a IC50 of 0.4 nM on Hep3B
cells, but a relatively lowmaximum tolerated dose of 0.8mg/kg inmice. In order
to produce an immunotoxin with reduced toxicity, a new version was con-
structed that removed domain II and seven B cell epitopes from the Pseudomo-
nas toxin. This deimmunized immunotoxin (HN3-mPE24) was shown to have a
similar IC50 of 0.2 nM on Hep3B cells. To determine if further deimmunization
was possible, three new versions have been generated with T cell epitopes or a
series of both B and T cell epitopes removed. These include the HN3-T20 im-
munotoxin which had six T cell epitopes removed, HN3-T19 with 4 B cell, 4 T
cell and 2 shared epitopes, and HN3-M11 with 5 B cell, 4 T cell and 2 shared
epitopes. A comparative analysis of these immunotoxinswasmade using in vitro
cell proliferation assays using Hep3B. Both the HN3-T20 (IC50 0.6 nM) and
HN3-T19 (IC50 0.8 nM) immunotoxins had similar activity to HN3-mPE24
(IC50 0.7 nM) in a side by side comparison. The HN3-M11 variant had poor
cytotoxicity and was excluded from in vivo examination. A Hep3B subcutane-
ous xenograft model was generated in athymic nude mice and was followed by
nine rounds of intravenous immunotoxin treatments. ThemPE24, T20 and T19
immunotoxins all showed an increase in average survival rate 70 days (mPE24),
76 days (T20) and 72 days (T19) when compared to the 55 days for PE38 and the
41 days for PBS alone. Additionally, the T20 and the T19 showed a maximum
tolerated dose that was similar to that of the mPE24 with dosages as high as 10
mg/kg being well tolerated. This data would suggest that the HN3-T19 immu-
notoxins has potential clinical applications because it represents themost deim-
munized immunotoxin to date.
#60 Reducing toxicity of antibody-drug conjugates through modulation
of pharmacokinetics. Jessica Simmons, Francisco Zapata, Haley Neff-Laford,
Joshua Hunter, Julia Cochran, Patrick Burke, Robert P. Lyon. Seattle Genetics,
Bothell, WA.
Antibody-drug conjugates (ADCs) continue to emerge as effective therapeu-
tics in a variety of oncology indications. Research onADCs has revealed that the
physicochemical properties of the drug-linker component can exert a signifıcant
impact on the disposition of the ADCs, particularly at higher levels of drug
loading. We have recently reported (Nature Biotechnology 33, 733-735 (2015);
Molecular Cancer Therapeutics, manuscript accepted) that these properties can
bemodulated through the judicious incorporation of small, discrete PEG chains
of varying lengths into a monomethyl auristatin E (MMAE) drug-linker. Ho-
mogeneousDAR8ADCs preparedwith these drug-linkers using native cysteine
conjugation display a continuum of pharmacokinetic behaviors that mirror the
length of the incorporated PEG chain. We selected four of these drug-linkers
that span the range of observed pharmacokinetics and used them as model
compounds to evaluate the impact of ADC clearance on the concentration pro-
fıle of released MMAE in normal tissues and consequent toxicology in the
Sprague-Dawley rat. Faster clearingADCs (preparedwith drug-linkers contain-
ing very short or no PEG modifıer) produced higher tissue MMAE Cmax values
at early post-dose time points relative to slower clearing ADCs that incorporate
longer PEG chains. This fınding indicates that MMAE concentrations in tissues
are proportional to the rate at which the ADC is catabolized, a process which
converts the conjugated payload into free drug. Faster clearing ADCs also ex-
hibited diminished tolerability, with greater histologic depletion of bone mar-
row and more dramatic decreases and/or delayed recovery in select peripheral
hematology parameters. These results provide a strategy for reducing the non-
antigen-mediated toxicity of ADCs through modulation of pharmacokinetics.
#61 Zymelink drug conjugate platform: redefıning the therapeutic win-
dow for ADCs. Stuart Barnscher, John Babcook, Jamie Rich, Geoff Winters,
Graham Garnett, Andrea Hernandez, Vincent Fung, Kevin Yin, Kevin Ham-
blett, Rupert Davies. Zymeworks, Vancouver, British Columbia, Canada.
Antibody drug conjugates (ADCs) combine the specifıcity of monoclonal
antibodies with potent antineoplastic small molecules, and promise effıcacy
without the systemic toxicity of chemotherapy. Despite this tremendous poten-
tial, most clinical ADCs have failed to provide suffıcient therapeutic benefıt
before the onset of off-target dose-limiting platform toxicities. Here we report
the development of proprietary protease cleavable N-acyl sulfonamide linked
hemiasterlin and auristatin payloads, Zymelink, that allow the generation of an
effıcacious ADCplatformwith improved tolerability. Both Zymelink drug-link-
erswere conjugated viamaleimides to endogenous cysteines. As Zymelink drug-
linkers aremore polar thanmaleimide valine citrullinemonomethyl auristatin E
drug-linker, the resulting ADCs can be produced with potential advantages in
PK, effıcacy and safety. The resulting ADCs exhibit potent in vitro cytotoxicity.
A trastuzumab-based ADC prepared with Zymelink drug-linker and demon-
strated at least equivalent effıcacy compared to a trastuzumab-based ADC pre-
pared with MMAE, promoting durable complete regressions in a patient-de-
rived xenograft model. Zymelink hemiasterlin and auristatin ADCs were
tolerated at 5-6 fold higher doses compared to a MMAE ADC in cynomolgus
monkeys. The maximum tolerated dose of the MMAE ADC was just 3 mg/kg
based on severe neutropenia. Zymelink hemiasterlin ADC was tolerated at 15
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mg/kg with no evidence of neutropenia or elevations in transaminases.
Zymelink auristatin ADCwas tolerated at 18mg/kg based on increased levels of
transaminases at 24 mg/kg. Moreover, Zymelink ADCs exhibited greater serum
exposure at equivalent doses. These results suggest Zymelink ADCs have a
greatly expanded therapeutic window compared to MMAE conjugates.
#62 CD19 - a potential target for Amanitin-based ADCs. Torsten Hechler,
Aniko Palfı, Christoph Müller, Christian Lutz, Andreas Pahl, Michael Kulke.
Heidelberg Pharma, Ladenburg, Germany.
Background ATACs (antibody-targeted Amanitin conjugates) comprise a
new class of antibody-drug conjugates using amanitin as toxic payload. Amani-
tin binds to the eukaryotic RNApol II and thereby inhibits the cellular transcrip-
tion process at very low concentrations. In the current study, in vitro and in vivo
data of new ATACs targeting CD19 (also known as B4, CVID3) are presented.
CD19, a class I transmembrane glycoprotein with no signifıcant homology to
any known protein, is expressed in B cells and B-cell malignancies like in B-cell
acute lymphocytic leukemia (B-ALL) and B cell chronic lymphocytic leukemia
(B-CLL). Therefore it is an ideal target for Amanitin based ADCs. Material and
methods Cell lines: Raji (Burkitt Lymphoma), Nalm-6 (B-ALL) and HL-60
(CD19-negative cell line). Antibody: anti-CD19 Thiomab (licensed from the
German Cancer Research Center; Heidelberg, Germany). Synthesis of CD19-
Thiomab-ATACs:Maleimide amanitin compoundswere conjugated site specif-
ically to engineered cysteine residues of the anti-CD19 Thiomab. Cell prolifer-
ation assay: Quantitative determination of cytotoxicity was performed by
CellTiter Glo 2.0 assay (Promega) or WST-1 assay (Roche). Animal models:
Mouse xenograft tumor models were performed. Tolerability was assessed in
mice and non-human primates (NHP). Results CD19-Thiomab-ATACs
showed in vitro cytotoxicity onCD19 cell lines in picomolar range, whereas no
cytotoxic activity on CD19- cells was observed. In mouse xenograft models,
CD19 showed dose-dependent tumor regression and complete remission after
single dose i.v. of 2mg/kg and 4mg/kg. In a disseminating Raji xenograft model,
median survival was increased from 6 days (vehicle control) to 105 days (CD19-
Thiomab-30.2115 treated group at 6mg/kg, single dose). On day 154, 4 animals
were still alive and in good overall condition. Safety profıling in Cynomolgus
monkey revealed a good tolerability after sequentially applied doses of 0.3, 1.0,
3.0 and 5.0 mg/kg. Hematology and clinical chemistry data show minor altera-
tions: transient increase in liver enzymes (ALT and AST) in combination with a
transient increase in LDH. The half-life of the ADC in serum is 7-11 days; the
free toxin is detectable at serum levels close to the lower limit of quantifıcation
only (LLOQ 1.2 nM). Conclusions In the current study, in vitro and in vivo
data of Amanitin-ADCs targeting CD19 are presented. CD19 is expressed on
cells of the B cell lineage, ranging from the pre-B cells until the terminal differ-
entiation to plasma cells. It is expressed in most acute lymphoblastic leukemias
(ALL), chronic lymphocytic leukemias (CLL) and B cell lymphomas (Kemeng et
al. (2012); ExpHematolOncol 1: 36). The preclinical data showhigh cytotoxicity
in picomolar range, very good effıcacy in tumor xenograft models and tolerabil-
ity in an exploratory tolerability study in NHP. The positive fındings of these
initial experiments encourage Heidelberg Pharma to further proceed with anti-
CD19-Amanitin-based ADCs towards clinics.
#63 Targeting osteosarcoma with graphene oxide-associated anti-HER2
antibodies. Xinjian Chen. University of Utah, Salt Lake City, UT.
Osteosarcoma (OS) is themost common primary cancer of the bone affecting
children and adolescents. While over the last two decades the neoadjuvant che-
motherapy has improved survival of the patients with resectable OS, the prog-
nosis for unresectable or recurrent tumors remains poor due to the lack of
effective treatment. Given that a majority osteosarcomas overexpress HER2, a
phase II clinical trial of anti-HER2 antibody trastuzumab in conjunction with
chemotherapy has been carried out to treat metastatic OS. However, no signif-
icant therapeutic benefıt was observed. We recently reported that association of
anti-CD20 antibody rituximab with a nanomaterial graphene oxide (GO) sub-
stantially enhances the anti-lymphoma activity of the antibody. Here we have
studied antitumor activity of GO-associated trastuzumab (TRA). Similar to
RTX, TRA could be stably associated with functionalized GO through non-
covalent interactions, and GO-associated TRA (TRA/GO) showed markedly
enhanced HER2 binding activity with capacity to aggregate (cap) HER2 on the
target cells. Treating HER2OS as well as Ewing’s sarcoma cell lines in culture
with TRA/GO resulted in rapid sarcoma cell death within 12 hr, while free TRA
or the cytotoxin-conjugated TRA (ado-trastuzumab emtansine) showed no sig-
nifıcant cytotoxic effects. TRA/GO manifested no cytotoxicity to human lym-
phocytes, in contrast to chemotherapeutic drugs such as doxorubicin and ox-
aliplatin.We fınd that the ability to kill the sarcoma cells results from the unique
capacity of TRA/GO to simultaneously induce oxidative stress as well as intense
detrimentalHER2 signaling, which leads to a complete disappearance of amajor
tyrosine-phosphorylated protein and caspase 8, and a partial loss of RIPK1 along
with an increase in RIPK3 levels within 5 min, followed by necroptosis of the
target cells. Intravenous administration of TRA/GO rapidly eradicated estab-
lished xenograft human OS in the lung as well as at subcutaneous locations in
NOD/ragko/gko immunodefıcient mice in the absence of chemotherapy, result-
ing in indefınite survival of the animals. In contrast, free TRA treatment failed to
do so. No appreciable side effects were observed of TRA/GO in vivo. These
results therefore demonstrate a novel strategy to substantially enhance the ther-
apeutic capacity of anti-cancer antibodies. Given the increasing variety of hu-
manmalignancies that are found to overexpress Her2, including sarcomas, car-
cinomas and neurological malignancies, our fındings should have broad
therapeutic implications. As TRA/GO does not harm lymphocytes, TRA/GO-
based therapymay constitute a unique opportunity to implement immunother-
apy that is now known to play an important role in control tumor progression.
#64 Meditope SnAP-body technology facilitates enhanced internalization
and in vivo effıcacy of antibody therapeutics. Karin Forster, Elisabeth Gar-
diner, Stephanie Hsieh.Meditope Biosciences, San Diego, CA.
Meditope Biosciences has developed a way to use SnAP technology to pro-
mote internalization of antibody receptor complexes through a novel construct
called a SnAP-body. Meditope’s SnAP platform functionalizes monoclonal an-
tibodies to bind to specifıc meditope peptides; this property can be used to
directly facilitate receptor crosslinking when meditope-enabled antibodies are
bound to cell surface receptors. SnAP-bodies are self-crosslinking meditope-
enabled antibodies which permit ameditope peptide to specifıcally interact with
a meditope-enabled antibody at the cell surface upon antigen engagement. An-
tigen-antibody complex formation through the specifıc contact of the SnAP-
bodies and their cognate epitopes on the target antigen can increase clustering or
co-localization of a cell surface antigen on a cell, which can promote enhanced
internalization of the SnAP-body. The increased internalization can be used to
clear or reduce the concentration of a cell surface antigen from the surface of a
target cell or tumor. Enhancing internalization can increase the effıcacy of anti-
body-based therapeutics, and in the case of antibody-drug conjugates, which
require receptor internalization to deliver cytotoxic payloads, can reduce the
amount of drug necessary to achieve a therapeutic effect. In vitro studies of
SnAP-body binding to cell surface antigens demonstrate accelerated internal-
ization of the antibody. In vivo, this translates into enhanced effıcacy. The ability
to see equivalent effıcacy in the absence of toxin suggests a unique role for
SnAP-body constructs in cancer therapeutics, especially in cases where lack of
effıcacy for a specifıc target is correlated with poor receptor internalization.
#65 RESPECT (REsidue-SPEcifıc Conjugation Technology): A platform
technology utilizing native cysteine and lysine residues for the generation of
homogeneous antibody-drug conjugates. Earl Albone, Jared Spidel, Xin
Cheng, Young Chul Park, Sara Jacob, Arielle Verdi, Andrew Milinichik, Ben
Vaessen, J. Bradford Kline, Luigi Grasso.Morphotek, Inc, Exton, PA.
The randomconjugationof toxins, dyes, peptides, or other payloads tomonoclo-
nal antibodies often targets free thiol groups generatedbypartial reductionmethods
or lysine residues using succinimide- or isothiocyanate-based chemistry. There re-
mains a need for conjugation technologies targeting specifıc amino acid residues as
a way to produce a homogeneous antibody-drug conjugate (ADC) product with a
defıned drug-to-antibody ratio (DAR). Our REsidue-SPEcifıc Conjugation Tech-
nology (RESPECT) utilizes two methods by which payloads can be conjugated to
specifıc residues in an antibody. Our cysteine-specifıc conjugationmethod exploits
a unique intrachain disulfıde bond in the light chain of rabbit antibodies between
residues 80 and171of the variable and constant domains, respectively.Ourhuman-
ization strategy allows retention of the cysteine at position 80with a free thiol group
that is both amenable for residue-specifıc conjugation and compatible with optimal
antibody biophysical properties including antigen binding and structural stability.
This platform has been optimized via antibody engineering strategy stems from in
silico modeling, extensive mutagenesis, and crystallographic studies, which have
alloweddefıning the contribution of neighboring residues to the retention of a reac-
tive thiol group as well as the desired humanized antibody’s properties. Our C-ter-
minal lysine-specifıc linkage method employs the transglutaminase enzyme that
catalyzes the formation of a stable isopeptide bond between the -carboxyamide
group (acyl donor) of a glutamine and the-amino group (acyl acceptor) of a lysine.
While we found no acyl acceptor sites in recombinant wild-type IgG, all antibodies
investigated lacked theC-terminal Lys447 due to cleavage by carboxypeptidase B in
the antibody production cell line. Blocking the cleavage of Lys447 by addition of a
C-terminal amino acid resulted in transamidation of Lys447 by a variety of acyl
donor substrates in the presence of any non-acidic, non-proline amino acid residue
at position 448. Antibody-drug conjugates (ADCs) prepared using our RESPECT
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Antibody Technology
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 201716
technology targeting the tumor associated-mesothelin protein produced uniform
drug-to-antibody ratios (DAR) and were shown to be highly potent and specifıc in
vitro and effective in vivo in reduction of tumor growth in a highly aggressive me-
sothelin-expressing xenograft tumormodel.
#66 Highly potent, anthracycline-based antibody drug conjugates gener-
ated by enzymatic, site-specifıc conjugation. Roger R. Beerli. NBE-Therapeu-
tics AG, Basel, Switzerland.
Antibody drug conjugates (ADCs) are highly potent and selective anti-tumor
drugs, combining the specifıc targeting of monoclonal antibodies with the po-
tency of small molecule toxic payloads. Here, we employed enzymatic, site-
specifıc conjugation to generate homogenous ADCs based on a derivative of the
highly potent anthracycline toxin PNU-159682 and a non-cleavable peptide
linker, using the anti-HER-2 antibody trastuzumab (part of trastuzumab
emtansine) and the anti-CD30 antibody cAC10 (part of brentuximab vedotin).
Characterization of the resulting ADCs in vitro and in vivo showed that they
were highly stable and exhibited potencies exceeding that of ADCs based on
conventional tubulin-targeting payloads, such as trastuzumab emtansine and
brentuximab vedotin. Antitumor activity in an immune-competent host in-
volved activation of the immune system, as shown by evaluation of a trastu-
zumab-PNU ADC in a Kadcyla-resistant HER2-positive orthotopic breast can-
cer model. Depletion of CD8 T cells severely reduced the antitumor activity of
the ADC, demonstrating an important role for T cells in driving tumor regres-
sion. Furthermore, when tumor-free animals were rechallenged with the same
tumor, tumor growth was entirely inhibited in the absence of any further ADC
administration, indicating the development of an immunologic memory. In
summary, we present a novel ADC format endowed not only with highly potent
cytotoxicity, but also with effective immune-stimulatory functions.
#67 Characterization and preclinical development of STRO-001, a novel
CD74-targeting antibody-drug conjugate (ADC) for the treatment ofB-cellma-
lignancies. Cristina Abrahams, Xiaofan Li, Venita DeAlmeida, Millicent Embry,
Abigail Yu, Stellanie Krim, Heidi Hoffmann, James Zawada, Maureen Bruhns,
Shannon Matheny, Stuart Bussell, Toni Kline, Alice Yam, Ryan Stafford, Trevor
Hallam,Mark Lupher, ArturoMolina. Sutro Biopharma, South San Francisco, CA.
CD74 is a type II transmembrane glycoprotein involved in the formation and
transport of MHC class II protein. CD74 is highly expressed in many B-cell
malignancies with limited expression in normal tissues (Stein R. et al., CCR
2007). STRO-001 is a novel CD74-targetingADCcontaining an anti-CD74 agly-
cosylated human IgG1 antibody (SP7219) conjugated to a non-cleavable diben-
zocyclooctyne (DBCO)-maytansinoid linker-warhead. SP7219 was discovered
from a Fab ribosome display library based on Sutro’s Xpress CFTM technology.
Highly effıcient site-specifıc conjugation enabled by our cell-free antibody pro-
duction and click chemistry results in a well-defıned homogeneous ADC drug
product with a drug-antibody ratio (DAR) of 2. Conjugation sites were selected
based on highest stability both in vitro and in vivo, thereby limiting loss of drug
moiety from STRO-001 in circulation. Due to its limited cell permeability, the
major catabolite released by STRO-001 has 1000X lower cell killing activity on
CD74 positive and negative cells compared to the reference cytotoxic may-
tansine. In vitro cytotoxicity assays show potent activity of STRO-001 in a di-
verse panel of B-cell tumor lines including 4 multiple myeloma (MM), 9 germi-
nal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL), 3 activated
B-cell (ABC) DLBCL, and 3 mantle cell lymphoma (MCL) cell lines with IC50
ranging from 0.17-20 nM. CD74 cell surface expression is required for STRO-
001 cytotoxic activity but expression level, as measured by antibody-binding
capacity, does not correlate with in vitro potency (R20.4640). STRO-001 in-
hibits the formation of visceral tumors (p0.004) and prevents growth of
CD138 plasma cells in bone marrow (BM) after 4 weekly doses of 3 mg/kg in
the ARP-1 disseminated MM xenograft model. STRO-001 dosed at 3 mg/kg
weekly x 3 also eradicates malignant BM plasma cells (p0.0001) and prolongs
survival in the MM.1S disseminated model (100% animals alive at 90 days).
STRO-001 exhibits dose-dependent tumor growth inhibition in SU-DHL-6
xenografts starting at 2.5 mg/kg weekly x 3 doses. The combination of benda-
mustine/rituximab (BR)  STRO-001 further improves tumor suppression in
SU-DHL-6 xenografts compared to vehicle (p 0.002) or BR alone (p 0.02).
Preliminary studies with a MCL xenograft model, Jeko-1, demonstrate potent
anti-tumor activity compared to vehicle (p0.0001) starting at a single STRO-
001 dose of 3 mg/kg, with ongoing tumor stasis up to 21 days after treatment.
STRO-001 reduces normal B-cells in cynomologous monkeys, providing phar-
macodynamic evidence of B-cell targeting. Based on these encouraging obser-
vations, STRO-001 is advancing to IND-enabling studies for the treatment of
CD74-expressing B-cell malignancies.
#68 Methotrexate prevents primary immune responses against recombi-
nant immunotoxin inmurinemodels.EmilyM.King, RonitMazor, Ira Pastan.
National Cancer Institute, NIH, Bethesda, MD.
Recombinant immunotoxins (rITs) are composed of a tumor antigen-target-
ing antibody fragment fused to a portion of Pseudomonas exotoxin A. rITs have
been effective in clinical trials for patients with hematologic malignancies. The
CD22 targeting rIT Moxetumomab Pasudotox has achieved overall response
rates of 86% and complete remission rates of 46% in patients with relapsed-
refractory Hairy Cell Leukemia. However, the therapeutic effıcacy of rITs
against solid tumors is limited by their immunogenicity in immune-competent
patients. In clinical trials to treat mesothelioma patients with SS1P, a rIT target-
ing mesothelin, 90% of patients developed neutralizing antibodies against SS1P
after one cycle of treatment.When immunosuppressive chemotherapy and SS1P
were combined, more cycles of rIT could be given and several patients with
advanced chemo-refractory mesothelioma had striking tumor regressions. This
implicates high therapeutic potential for rITs against solid tumors once immu-
nogenicity is surmounted. Methotrexate (MTX) is a folate antagonist which
interferes with purine biosynthesis, and is used to treat osteosarcomas and other
cancers. MTX also interferes with T cell responses and is used to treat autoim-
mune diseases. Based on its immunosuppressive properties, Joly et al. demon-
strated that low-dose MTX prevented the formation of ADAs against recombi-
nant human alglucosidase alfa in mice in an antigen-specifıc manner. We
hypothesized that MTXwould similarly prevent the formation of ADAs against
rITs in an antigen-specifıc manner. To test our hypotheses, mice were treated
with themesothelin-targeting rITRG7787with orwithoutMTXgiven 0, 24, and
48 hours after RG7787 treatment. Serum was collected and anti-RG7787 ADAs
were measured by direct ELISA. We found that six doses of RG7787 combined
with lowdoseMTX (1mg/kg) inhibited the formation ofADAs against RG7787.
This inhibition was sustained through six challenges with RG7787 without ad-
ditional MTX. Further, we found that immunization with RG7787 plus MTX
induced RG7787-specifıc tolerance, and had no effect on the ADA response
against a second protein, ovalbumin. We conclude that combination of MTX
and RG7787 is effective at preventing primary immune responses in a durable,
antigen-specifıc manner. We propose to combine this agent in immune-com-
petent cancer patients receiving rIT therapy to prevent rIT immunogenicity.
#69 Anti-podocalyxin cancer-specifıc monoclonal antibody: preclinical
study. Shinji Yamada. Tohoku University, Sendai, Japan.
Background: Podocalyxin, a CD34-related sialomucin, is expressed in many tu-
mors including colorectal cancers, breast cancers, mesothelial tumors, and brain
tumors. Overexpression of podocalyxin has been reported to be an independent
predictor of progression, metastasis, and poor outcome. However, PODXL is
known to be highly expressed in normal cells including many epithelial cells and
endothelial cells; therefore, podocalyxin could not be a target of antibody therapy.
Although many monoclonal antibodies (mAbs) against podocalyxin have been es-
tablished, theybind toboth cancer andnormal cells.We recently established anovel
technology for developing cancer-specifıc mAbs (CasMabs), which could target
only cancer cells although those membrane proteins are highly expressed in both
cancer and normal cells.Methods:We fırst produced a podocalyxin-expressing gli-
oblastoma cell line.We purifıed human podocalyxin using PA-tag, and immunized
mice with those proteins. CasMabs were screened using flow cytometry against
podocalyxin-expressing cancer cells and podocalyxin-expressing normal cells. The
cancer specifıcitywasconfırmedusing immunohistochemistryagainstbreast cancer
tissues. Furthermore, a human-mouse chimeric anti-podocalyxin mAb was pro-
duced. Antibody-dependent cellular cytotoxicity (ADCC) was investigated in vitro
using glioblastoma cells as target cells and human NK cells as effector cells. The in
vivo effıcacy was evaluated using xenograft models of podocalyxin-expressing cell
lines. Furthermore, we investigated the toxicity of chPcMab-6 using cynomolgus
monkey. Results: A cancer-specifıc anti-podocalyxinmAb (clone: PcMab-6;mouse
IgG1, kappa) was established. PcMab-6 reacted with podocalyxin-expressingmany
cancer cell lines including brain tumors, malignant mesotheliomas, colon cancers,
and pancreatic cancers whereas it did not bind to vascular endothelial cells in flow
cytometry. Furthermore, PcMab-6 reacted only with podocalyxin-expressing can-
cer cells, not with VECs in breast cancer tissues using immunohistochemistry. Fur-
thermore, we produced chPcMab-6, a human-mouse chimeric mAb of PcMab-6,
which also reacts with only podocalyxin-expressing cancer cells. ChPcMab-6 pos-
sesses ADCC activity in vitro and antitumor effect in vivo. Single injection of chPc-
Mab-6 induced no clinical abnormality inmale cynomolgusmonkey (2mg/kg and
20 mg/kg) . In addition, abnormal values were not observed in hematologic test,
urineanalysis, andmeasurementof seruminflammatorycytokines.Tissuedisorders
were not found in histology and relative organweight on postmortemexamination.
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Conclusion: ChPcMab-6, a cancer-specifıc human-mouse chimeric anti-podoca-
lyxin mAb could be useful for targeting podocalyxin in cancer, although podoca-
lyxin is highly expressed inmany normal cells.
#70 Elucidating the roles of antibody pharmacokinetics and maleimide
stability in the toxicology of antibody-drug conjugates. Haley Neff-LaFord,
Franciso Zapata, Wendi Schultz, Cindy Balasubramanian, Paul Pittmen,
Shawna Hengel, Russell Sanderson, Nagendra Chemuturi, Jocelyn Setter, Rob-
ert P. Lyon. Seattle Genetics, Bothell, WA.
Antibody-drug conjugates (ADCs) continue to emerge as effective therapeu-
tics in a variety of oncology indications, with two agents currently approved and
many more in late-stage clinical trials. These ADCs employ drug-linkers that
were developedmany years ago, and are now recognized to have properties that
may adversely impact the activity and toxicology of the ADCs prepared with
them. Two such properties that are now well appreciated are the reversibility of
maleimide-based drug conjugation, and the impact of drug conjugation on the
pharmacokinetics of the ADC. We recently reported advances in drug-linker
design that independently address both of these properties, resulting in the ir-
reversible conjugation of drugs which have minimal impact on antibody phar-
macokinetics, even at high levels of drug loading (Nature Biotechnology 32,
1059-1062 (2014), Nature Biotechnology 33, 733-735 (2015)). We have now
prepared drug-linkers of monomethylauristatin E (MMAE) that orthogonally
employ these features to enable a systematic evaluation of the relative contribu-
tions of maleimide instability and accelerated plasma clearance on the in vivo
behavior of MMAE ADCs. Biodistribution studies with these molecules have
revealed that the concentration of released MMAE in normal tissues is greatly
impacted by the rate of ADC clearance (fast clearance results in greater Cmax of
free drug), while stabilization of themaleimide has a relatively small effect. These
differences in observed free drug concentrations were paralleled in tolerability
studies, with ADC clearance rates exerting a greater impact on hematology pa-
rameters than maleimide stability. Collectively, these results suggest that ADC
pharmacokinetics dominate the biodistribution and toxicology profıles for a
given drug payload, with conjugate stability playing a relatively minor role.
#71 Bystander activity and in vivo effıcacy of a folate receptor  (FR)-
targeting antibody-drug conjugate with a novel peptide linker. Qifeng Qiu,
Rui Wu, Leanne Lanieri, Erin Maloney, Anna Skaletskaya, Shan Jin, Lintao
Wang, Olga Ab, Joe Ponte, Yulius Setiady, Wayne Widdison, Thomas Keating,
Ravi Chari, Richard Gregory, Erica Hong. ImmunoGen, Inc, Waltham, MA.
Folate receptor  (FR) is an antigen that is overexpressed on the cell surface
of solid tumors including ovarian cancer. The differential expression on cancer
cells makes FR an attractive target for antibody-drug conjugates (ADCs), and
an ADC targeting FR, Mirvetuximab soravtansine, has demonstrated promis-
ing activity and safety profıles in the clinic. Here, we employed a new linker (NL)
to enhance the bystander activity of ADCs, which is the ability of ADCs to
generate cell-permeable catabolites that can diffuse into and kill proximal cancer
cells with little or no target expression. With the goal of improving the potency
of anti-FR ADC in solid tumors with heterogeneous FR expression, we con-
structed the M9346A-NL-DM. M9346A-NL-DM is a conjugate of the tubulin-
disrupting maytansinoid (DM), linked via a novel linker to M9346A, a human-
ized antibody that binds FR with high affınity. After cellular uptake and
catabolism of the ADC, the new linker undergoes lysosomal cleavage followed
by self-immolation to generate free DM that can readily penetrate neighboring
cancer cells. Correspondingly, M9346A-NL-DM showed enhanced bystander
cytotoxic activity against proximal antigen-negative cells in vitro. In the xeno-
graft tumor models in vivo, M9346A-NL-DM demonstrated enhanced effıcacy
against tumors with heterogeneous expression of FR. Interestingly, M9346A-
NL-DM also showed improved antitumor activity against a tumor model with
homogeneous expression of FR, possibly due to better tumor penetration of
the cell-permeable catabolite. In summary, M9346A-NL-DM is a novel ADC
with enhanced bystander activity and antitumor activity that can target tumors
with heterogeneous expression of FR.
#72 Induction of immune tolerance to recombinant immunotoxin LMB-
100 using synthetic vaccine particles encapsulating rapamycin.RonitMazor,1
Emily King,1 Takashi Kei Kishimoto,2 Ira Pastan1. 1National Cancer Institute,
Bethesda, MD; 2Selacta Bioscince Inc., Boston, MA.
Recombinant Immunotoxins (RITs) are genetically engineered proteins de-
signed for cancer therapy. LMB-100 is a second generationRIT that is composed
of a humanized Fab targeting mesothelin and a de-immunized fragment of
Pseudomonas Exotoxin A. Due to the bacterial origin of the toxin, LMB-100 is
immunogenic, although less immunogenic than fırst generation immunotoxins.
Almost all patients treated with LMB-100 made anti-drug antibodies (ADAs)
after two or more cycles of treatment that neutralized the RIT and greatly low-
ered effıcacy. Kishimoto et al. demonstrated that Synthetic Vaccine Particles
containing Rapamycin (SVP-R) inhibited the formation of ADAs, when admin-
istered with a foreign protein such as KLH or Pegsiticase. The SVP-R are taken
up by macrophages and dendritic cells and increase the number of regulatory T
cells in treated mice. Here we evaluated the effıcacy of combination therapy of
LMB-100 and SVP-R to eradicate mesothelin expressing tumors while prevent-
ing ADA formation. To evaluate if SVP-R can prevent ADAs against LMB-100,
we immunized immune-competentmice with a combination of SVP-R and RIT
and measured ADAs titers by ELISA and by a functional neutralization assay.
We found that the treatment reduced ADA titers by more than 99%. To deter-
mine if the mice were tolerized to LMB-100, we treated the mice with two doses
of SVP-R and six doses of LMB-100 to induce tolerance; and followed by nine
challenges of LMB-100 given over 6 weeks. We found that the ADAs were re-
duced by 98%, indicating development of immunological tolerance to LMB-100.
To show that the tolerance is transferable, we tolerized themice with six doses of
SVP-R and LMB-100 and adoptively transferred their splenocytes to naïve re-
cipientmice. The recipientmice were challengedwith six doses of LMB-100 and
ADA titers were measured. We found that splenocytes from tolerized mice in-
duced a 66%decrease inADA formation in the recipientmice indicating that the
tolerance was mediated by cells of the immune system. To demonstrate that
immune suppression is useful in treating tumors, we implanted mouse breast
cancer cells expressing human mesothelin into Balb/c mice with a normal im-
mune system and treated them with LMB-100. LMB-100 produced tumor re-
gressions when given before ADAs developed, but was inactive in mice with
pre-existing ADAs. However, when mice with preexisting ADAs were treated
with LMB-100 and SVP-R, anti-tumor activity was restored and ADAs sup-
pressed (P0.0001). SVP-R are being evaluated in humans to prevent ADA to
Pegsiticase, an enzyme for refractory gout treatment. Our data indicates that
combining SVP-Rwith LMB-100 should be useful in treating cancer by allowing
more treatment cycles and better effıcacy. This approach can be used to increase
the effıcacy of other immunogenic agents such as CAR-T cells, antibody drug
conjugates and viral gene therapy vectors.
#73 Role of macrophages in the antitumor activity of an anti-transferrin
receptor 1 antibody ch128.1 in a xenograft model of multiple myeloma. Lai
Sum Leoh, Yoon Kyung Kim, Pierre V. Candelaria, Otoniel Martínez-Maza,
Tracy R. Daniels-Wells, Manuel L. Penichet. UCLA, Los Angeles, CA.
The transferrin receptor 1 (TfR1), also known as CD71, is a membrane gly-
coprotein involved in cellular iron uptake and regulation of cell growth. The
high level of TfR1 expression on malignant cells and its key role in cancer cell
pathology make this receptor an attractive target for antibody cancer therapy.
We previously developed a mouse/human chimeric IgG3 specifıc for human
TfR1 (ch128.1). This antibody exhibits direct cytotoxicity against certain human
malignant B cells in vitro through TfR1 degradation and iron deprivation. Im-
portantly, ch128.1 shows remarkable anti-tumor activity in xenograft models of
disseminated multiple myeloma (MM) in immunosuppressed mice (SCID-
Beige). Interestingly, this anti-tumor protection was observed even against MM
cells (KMS-11 cells) that show no sensitivity to this antibody in vitro, suggesting
the in vivo contributions of antibody effector functions. This possibility was
supported by the lack of anti-tumor protection observed using a ch128.1 Fc
mutant with impaired binding to FcRs and to the complement component
C1q. To examine host effector functions involved in ch128.1-mediated protec-
tion in our mouse model bearing KMS-11 tumors, depletion studies of comple-
ment and macrophages were performed. Complement depletion using cobra
venom factor (CVF) did not affect protection, suggesting that complement-
mediated cytotoxicity (CDC) is not a relevantmechanism of action. Notably, we
now report that macrophage depletion using clodronate liposomes (clodrolip)
signifıcantly reduced protection, suggesting that these effector cells play a rele-
vant role in the anti-tumor activity. Consistent with this result, we also report
that ch128.1 is capable of eliciting antibody-dependent cell-mediated cytotoxic-
ity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP)
against KMS-11 cells in the presence of the murine macrophage cell line J774.2
or murine bone marrow-derived macrophages. To examine the role of iron
deprivation in ch128.1-mediated tumor death in vivo, animals treated with
ch128.1 were systemically supplemented with iron in a preliminary study. How-
ever, no difference in survival was observed, suggesting that iron deprivation is
not a contributor to the effects of ch128.1 in our in vivo model or the iron dose
tested was not optimal. Our results suggest that macrophages play a key role in
ch128.1-mediated anti-tumor protection in our model and that ch128.1 can be
an effective therapy of incurable human B-cell malignancies such as MM.
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#74 Discovery of new therapeutic monoclonal antibodies to challenging
GPCRs, ion channels and transporters. Lewis J. Stafford, Ross Chambers, Sha-
ron H. Willis, Moniquetta Hall, Brad Screnci, Manu Mabila, David Tucker,
Trevor Barnes, Rachel Fong, Andrew Ettenger, Jennifer Pfaff, Chidananda Sulli,
Nicholas Molino, Andrew Hudacek, Benjamin J. Doranz, Joseph Rucker. Inte-
gral Molecular, Philadelphia, PA.
The objective of this work was to evaluate the ability to generate panels of
monoclonal antibodies against a set of highly challenging targets including GP-
CRs (CB1, C5AR, CXCR5 and CGRPR), transporters (GLUT4), and ion chan-
nels (P2X3). Integral membrane proteins are important drug targets andmono-
clonal antibodies (MAbs) directed against them are highly sought for
therapeutic purposes. However, the complex structure of multispan membrane
protein targets makes the discovery of these MAbs especially challenging. To
address this need, Integral Molecular has developed theMPSDiscovery Engine®
to enable the isolation, characterization, and engineering of monoclonal anti-
bodies for GPCRs, ion channels, and transporters. MPS utilizes a collection of
technologies to address each of the barriers to monoclonal antibody develop-
ment against the native extracellular epitopes of multispan membrane proteins.
These include, antigen engineering to attain high levels of surface expression,
DNA and Lipoparticle immunization to present native epitopes to the immune
system, diverse immunization host species to deal with highly conserved pro-
teins, Lipoparticles (high concentration native membrane proteins) to enable
phage display and microfludic B-cell isolation, and shotgun mutagenesis (com-
prehensive Alanine scanning) for epitope mapping. Using the MPS Discovery
Engine® we were able to successfully generate large panels of antibodies to the
targets that were able to bind to the native extracellular epitopes on cells by flow
cytometry. A subset of the antibodies had antagonist activity.With this technol-
ogy we have the ability to target intact, conformation specifıc, and functional
antibodies to complex membrane proteins.
#75 Comparison of site-specifıc and lysine-linked indolino-benzodiaz-
epine antibody-drug conjugates (ADCs).Chen Bai,1 Nicholas C. Yoder,1 Alan
Wilhelm,1 Sharlene Adams,1 Kathleen Whiteman,2 Jenny Lee,1 Katie
O’Callaghan,2 Erin Maloney,1 Manami Shizuka,1 Yelena Kovtun,1 Thomas A.
Keating1. 1ImmunoGen, Inc., Waltham, MA; 2Current Address: Unum Thera-
peutics Inc., Cambridge, MA.
ADCs are a promising modality for cancer therapy enabled by chemical con-
jugation of potent cytotoxic compounds tomonoclonal antibodies.Whilemany
ADCs in clinical evaluation employ heterogeneous conjugation chemistries
where the payload is linked through lysine or endogenous cysteine residues,
there has recently been considerable interest in site-specifıc conjugation. ADCs
prepared using site-specifıc methods are believed to have a wider therapeutic
index compared to heterogeneous ADCs. We have previously shown that site-
specifıc ADCs incorporating the maytansinoid-based tubulin inhibitor DM1
were less effıcacious in vivo when compared to analogous lysine-linked conju-
gates (Yoder et al AACR 2015 Abstract #545). More recently, we presented
results from the evaluation of 2.5-3.0 drug-to-antibody ratio (DAR) heteroge-
neous lysine-linked and 2 DAR site-specifıc ADCs using antibodies with engi-
neered cysteines at position 442 in the heavy chains (known as CYSMABTM).
These ADCs used the peptide-linked indolino-benzodiazepine DNA alkylator
DGN549 (also known as IGN-P1) as the effector. Unlike the DM1 case, site-
specifıc DGN549 ADCs were at least as active in vivo when compared to lysine-
linked ADCs (Yoder et al AACR 2016 Abstract #2960). We have made further
pharmacological comparisons between CYSMAB and lysine-linked DGN549
ADCs atmatched payload doses using twodifferent antibodies targeting distinct
cell surface receptors. In the case of mAb1, CYSMAB and lysine-linked ADCs
were comparably active. FormAb2, theCYSMABADCwasmore active than the
lysine-linked ADC in some models and similarly active in others. The mAb1
CYSMAB ADC exhibited a signifıcantly higher maximum tolerated dose
(MTD) compared to the lysine-linked ADC. In contrast, theMTDs of themAb2
ADCs were similar. However, the mAb2 CYSMAB conjugate was better toler-
ated in terms of median lethal dose. The mechanism for the improved tolerabil-
ity of the mAb1 CYSMAB conjugate is not apparent. In an effort to understand
whether it is a consequence of conjugation chemistry or DAR, we compared the
tolerability of the mAb1 CYSMAB conjugate to that of a 4 DAR site-specifıc
analog and found that both factors contribute. To determine if our observations
can be rationalized in terms of in vivo disposition, we compared the pharmaco-
kinetics of mAb1 CYSMAB and lysine-linked ADCs atmatched antibody doses.
Intriguingly, the CYSMAB ADC showed slightly greater exposure. These re-
sults, along with our previous work on site-specifıc DM1 ADCs, indicate that in
some cases site-specifıc conjugation can lead to improved effıcacy and tolerabil-
ity. However, generalizations cannot be made across different combinations of
antibody, linker, and payload. We conclude that the advantages and disadvan-
tages of site-specifıc conjugation should be carefully considered for every can-
didate ADC.
#76 Synthetic lethal targeting of BRCA mutant tumors with antibody
linked pyrrolobenzodiazepine dimers. Haihong Zhong, Ravinder Tammali,
Cui Chen, Christine Fazenbaker, Kennedy Maureen, Noel Monks, Jay Harper,
Ronald Herbst, Dave Tice.Medimmune, Gaithersburg, MD.
Pyrrolbenzodiazepine dimers (PBDs) are amongst the most potent DNA al-
kylating agents, with activity against a broad spectrum of tumors. PBDs form
cross-links within the minor groove of DNA causing double strand breaks
(DSB). DNA repair genes such as BRCA1 and BRCA2 play important roles in
homologous recombination repair (HRR) of DSB. Cells defective in BRCA1 or
BRCA2 are known to be sensitive toDNA interstrand crosslinks. Accordingly, it
is possible that PBD-based ADCs will have enhanced killing of cells (synthetic
lethality) in which HR processes are defective by inactivation of BRCA1 or
BRCA2 genes in breast, ovarian and other cancers. To determine anti-tumor
activity of PBD dimers, we have used MEDI0641, PBD-dimer conjugated to
anti-5T4 antibody, against BRCA wild type and mutant xenograft tumor mod-
els. MEDI0641 was3-fold more potent in BRCA1 or BRCA2 mutant models
than in wild-type xenografts. Similar observations were seen in 25 patient-de-
rived xenograft (PDX) models (19 breast and 6 ovarian) bearing mutations in
BRCA1 or BRCA2 (blinded to 5T4 expression) treated with MEDI0641. Out of
a total of 25 PDXmodels, 17 models had tumor regression with a single admin-
istration of MEDI0641 at 0.3 mg/kg (response rate  68%), and 14 models
showed response to 0.1 mg/kg of MEDI0641 (response rate  56%). In BRCA
wild-type PDX models, a higher dose of 1 mg/kg was required to achieve full
anti-tumor effıcacy. Retrospective analysis of 5T4 expression in PDX tumors
demonstrated no correlation between effıcacy and target expression in BRCA
mutant PDX models. To further delineate the role of BRCA1/2 mutations in
determining sensitivity to PBD, we used siRNA knock-down of both BRCA1
and BRCA2 in theDNA repair wild typeHeLa cells. Knockdown of BRCA genes
sensitized Hela cells to PBD payload andMEDI0641 in vitro. Anti-tumor activ-
ity of MEDI0641 was further examined in isogenic BRCA2 knockout xenograft
models. Genetic deletion of BRCA2 markedly increased anti-tumor activity of
MEDI0641. In conclusion, PBD based ADCs may have improved therapeutic
window in cancer patients with somatic BRCA mutations.
#77 Preclinical evaluation of HDP-101, an anti-BCMA antibody-drug
conjugate.TorstenHechler, Aniko Palfı, ChristophMüller, Christian Lutz, An-
dreas Pahl, Michael Kulke. Heidelberg Pharma GmbH, Ladenburg, Germany.
Background: ATACs (antibody-targeted Amanitin conjugates) comprise a
new class of antibody-drug conjugates using amanitin as toxic payload. Amani-
tin binds to the eukaryotic RNApol II and thereby inhibits the cellular transcrip-
tion process at very low concentrations. In the current study, in vitro and in vivo
data of newATACs targeting BCMA (BCellMaturationAntigen, also known as
CD269) are presented. BCMA is selectively expressed onmalignant plasma cells
like inmultiplemyeloma (MM) andhence considered an ideal target forAmani-
tin based ADCs. Material and methods: MM cell lines: NCI-H929, MM.1S Luc
(stable luciferase transfected) and CCRF-CEM (BCMA negative). Antibody:
anti-BCMA Thiomab (Max Delbrück Centrum, Berlin; derivatization and pro-
duction at Heidelberg Pharma). Synthesis of HDP-101: Maleimide amanitin
compounds were conjugated to substituted cysteine residues of the anti-BCMA
Thiomab. Cell proliferation assay: Quantitative determination of cytotoxicity
was performed by CellTiter Glo 2.0 assay (Promega) or WST.1 assay (Roche).
Animal models: Subcutaneous and metastatic mouse xenograft tumor models
with MM cell lines NCI-H929 and MM.1S Luc were performed in single-dose
andmultiple-dosing experiments. Tolerability was assessed inmice and nonhu-
man primates (NHP). Results: HDP-101 showed in vitro cytotoxicity on
BCMA cell lines in picomolar range, whereas no cytotoxic activity on BCMA-
cells was observed. In mouse xenograft models, HDP-101 caused dose-depen-
dent tumor regression and complete remission after a single i.v. dose of 2.0
mg/kg and 4.0mg/kg in s.c. xenografts and after single i.v. doses from 0.1mg/kg
to 2.0 mg/kg in disseminating xenografts. Safety profıling in Cynomolgus mon-
keys revealed a good tolerability and therapeutic index after sequentially applied
doses of 0.3, 1.0, andmultiple dose application of 4 x 3.0mg/kg.Hematology and
clinical chemistry parameters were unaffected except liver enzymes and LDH: A
mild to moderate and transient increase was observed. The half-life of the ADC
in serum was 7-9 days; the free toxin was detectable at levels close to the lower
limit of quantifıcation only (LLOQ 1.2nM). Conclusions: Targeted cytotoxic
drug delivery to BCMA positive MM cell lines was achieved by using HDP-101,
an anti-BCMA-ATAC. The mode of action of the payload Amanitin led to an
effıcient anti-tumor potential in vitro and in vivo with good tolerability in NHP
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studies. Using ADCs in the therapy of multiple myeloma is a promising ap-
proach, especially by using a cytotoxic agent whose mode of action differs from
other commonly used toxins, like ATACs. First-in-human trial is expected to
start in 2018.
#78 Highly effıcient antibody drug conjugation with a novel photoactiva-
tion strategy. Elisabeth Gardiner, Karin Forster, Robert McKenzie. Meditope
Biosciences, San Diego, CA.
Meditope SnAP (site-specifıc novel antibody platform) technology is a novel
way to target molecules to antibodies in a site specifıc, non-destructive fashion.
A “meditope” is a proprietary peptide that can bind a meditope-enabled anti-
body in a unique site and in such away that antigen binding is not compromised.
This specifıc peptide antibody interaction can be readily employed for site-spe-
cifıc covalent conjugation of cytotoxic payloads to any meditope-enabled anti-
body. To facilitate covalent conjugation, the meditope peptide has been ratio-
nally designed with a photoactivatable side chain and the generation of the
antibody-drug conjugate (ADC) occurs in a highly effıcient manner following
the specifıc binding of themeditope to the enabled antibody. To test the hypoth-
esis that photoactivation would be an effıcacious and homogenous way to make
anADC,meditope-enabled ADCswere designed and tested in vitro and in vivo.
Toxin conjugation was tested, as was effıciency of covalent interaction following
short-term exposure of the antibody peptide conjugates to a nondestructive
wavelength of 340 nM. Photoactivation proved to be a highly effıcient and scal-
able way tomake anADC. Payload stability was confırmed in vivo withmultiple
toxins and in vivo potency of two unique ADCs were tested in an EGFR positive
gastric cancer xenograft aswell as aHER2positive ovarian cancer xenograft. The
meditope-enabled photogenerated anti-HER2 ADC was benchmarked against
conventionally conjugated T-DM1 and showed equivalent effıcacy, but with the
site-directed conjugated meditope ADC using less toxin. Meditope-directed
photoactivated-controlled conjugation can be readily extended to any medi-
tope-enabled antibody, resulting in a novel way to develop ADCs. This method-
ology, with its high effıciency, speed and homogeneity has evident advantages
for the development of antibody-drug conjugates.
#79 Trastuzumab and C6.5 diabody armed with deBouganin overcome
drug resistance to ADCs comprised of anti-microtubule agents. Shilpa
Chooniedass,1 Rachelle L. Dillon,1 Arjune Premsukh,1 Gregory P. Adams,2 Glen
C.MacDonald,3 JeannickCizeau1. 1Viventia Bio Inc.,Winnipeg,Manitoba, Can-
ada; 2Eleven Biotherapeutics Inc., Philadelphia, PA; 3Eleven Biotherapeutics Inc,
Winnipeg, Manitoba, Canada.
DeBouganin (deB) is a de-immunized form of bouganin, a Ribosome Inacti-
vating Protein (RIP) that when internalized blocks protein synthesis thereby
leading to cell death. When conjugated to trastuzumab (T-deB) or genetically
attached to the C6.5 diabody, deBouganin was more potent than DM1 and
unaffected bymechanisms of resistance to whichDM1 is susceptible. To further
highlight the differentiatingmechanism of action of deBouganin, HCC1419 and
BT-474 tumor cells that survived T-DM1 or trastuzumab-MMAE (T-MMAE)
treatment in vitro were re-exposed to T-DM1, T-MMAE, or treated with T-deB
or an anti-HER2 C6.5 diabody-deBouganin fusion protein. C6.5 diabody-de-
Bouganin and T-deB were potent against HCC1419 and BT-474 cells surviving
T-DM1 or T-MMAE treatment. However, the surviving cell populations were
resistant to T-DM1, T-MMAE, DM1, MMAE and taxol treatment. In addition,
cross-resistance was seen against trastuzumab-duocarmycin which contains a
payload with a cell cycle independent mechanism of action. The contribution of
multi-drug resistance, Bcl-2 family members and other survival pathways ac-
counting for the resistant phenotype will be discussed. Overall, the data suggest
that treatment with chemotherapeutics or ADCs comprised of small molecule
compounds such as anti-microtubule agents, can lead to the outgrowth of tumor
cells resistant to similar agents. In contrast, antibodies and antibody fragments
armed with deBouganin can overcome these mechanisms of resistance andmay
therefore represent a more effective treatment option.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Gene
Expression of Drug Resistance
#80 Pooled shRNA screening using mouse xenografts of human hepato-
cellular carcinoma cells identifıes CDK5 as a potentialmechanismmediating
sorafenib resistance. Tzu-Hsuan Lin,1 Wen-Chi Feng,1 Yu-Yun Shao,1 Li-
Chun Lu,1 Ya-Jhen Chen,2 Ann-Lii Cheng,1 Chih-Hung Hsu1. 1National Tai-
wan University College of Medicine, Taipei, Taiwan; 2National Taiwan Univer-
sity Hospital, Taipei, Taiwan.
Background: Sorafenib is the only approved systemic agent for hepatocellular
carcinoma (HCC). However, the effıcacy of sorafenib is modest for HCC with
low objective response rate and short time to tumor progression, indicating that
the inherent and acquired resistance underlies the limited success of sorafenib in
HCC.We conducted a pooled shRNA screening in mouse xenografts of human
HCC cells treated with sorafenib, and intended to identify genes that are in-
volved in the therapeutic effıcacy of sorafenib. Materials and Methods: We in-
troduced a pool of 3920 shRNAs targeting 1960 genes, including various kinases,
transcriptional factors, phosphatase and cytokine, into Huh7 HCC cells by ret-
rovirus infection. The Huh7 cells after infection with pooled shRNAs were im-
planted subcutaneously in immunocompromised mice, and were treated with
vehicle or sorafenib at the dose of 30mg/kg/day for 4 weeks. Genomic DNAs
were extracted fromHCCxenografts, PCR-amplifıed of the shRNA regions, and
deep-sequenced of the PCR products to quantify the abundance of each shRNA.
Candidate genes were identifıed from those shRNAs with statistically different
frequencies between vehicle-treated and sorafenib-treated xenografts, and were
further validated by their impacts on sorafenib-sensitivity in HCC cells. Results:
By calculating the abundance frequencies of each shRNA of sorafenib- treated
xenografts versus that of vehicle-treated xenografts, we found that 3 candidate
sorafenib- resistance genes because their shRNA abundance was signifıcantly
decreased in sorafenib-treated xenografts. Among them, only the cyclin depen-
dent kinase 5 (CDK5) was further investigated because its expression was con-
fırmed to be increased in sorafenib- treated xenografts. In PLC5 and a sorafenib-
resistant subline of Huh7 cells (Huh7-SR), downregulation of CDK5 by RNA
interference or roscovitine, a CDK5 inhibitor, enhanced the sensitivity to
sorafenib- induced growth-suppression. On the other hand, overexpression of
CDK5 increased the resistance to sorafenib in Huh7 cells. Mechanistically,
sorafenib combined with shRNA-mediated CDK5 downregulation augmented
the induction of apoptosis, and resulted in an increased downregulation of mul-
tiple anti-apoptosis molecules such as XIAP and survivin in PLC5 andHuh7-SR
cells. In 8 paired human HCC tissues, we found 3 of them have unequivocally
increased expression of CDK5 inHCC cells of post-sorafenib HCC tissues com-
pared with those of pre-treatment tissues. Conclusions: Our results suggest that
increasedCDK5 expressionmaymediate resistance to sorafenib inHCC in vivo,
and targeting CDK5 is warranted further studies in the treatment of HCC. (This
study was supported by grants MOST 103-2314-B-002 -181 -MY2, MOST 105-
2314-B-002-194-, MOST 103-2314-B-002 -090 - & MOST 104-2314-B-002
-073).
#81 E2F4/p107 complex regulates chemotherapy resistance in human
colorectal cancer stem cells. Junichi Matsubara,1 Yong F. Li,2 Piero Dalerba,3
Debashis Sahoo,4 Taichi Isobe,2 Russ B. Altman,2 Michael F. Clarke2. 1Kyoto
University, Kyoto, Japan; 2Stanford University, Stanford, CA; 3Columbia Univer-
sity, New York, NY; 4University of California San Diego, San Diego, CA.
Most cancer patients experience disease progression despite one or multiple
lines of treatment with cytotoxic chemotherapy. Evidence from human trials
and in vivo experiments on patient-derived xenograft (PDX) tumor lines indi-
cates that cancer stem cells (CSCs) can survive chemotherapy treatment. How-
ever, the mechanism of chemotherapy resistance in CSCs is not fully elucidated.
To identify newmechanisms of the drug-resistance in colorectal cancer, we used
gene-expression microarrays to examine the gene expression profıle of CSCs
and non-CSCs in four human PDX models of colorectal cancer, both before-
and-after treatment with cytotoxic chemotherapy. The gene-expression data
were analyzed using IndependentComponentAnalysis (ICA) followed byTran-
scription Factor Target Genes (TFTG) enrichment analysis, which identifıed the
transcription factor E2F4 as a candidate regulator of chemotherapy resistance in
colorectal CSCs. E2F4 was predominantly expressed in the CSC-enriched cell
population (CD44/CD166human colorectal cancer cells). E2F4 knock-down
sensitizes cancer cells to chemotherapy in three different PDX tumors as well as
HT29 cells. Co-immunoprecipitation experiments showed that E2F4 forms a
complex with p107 and DP-1, which also contributed to the chemotherapy re-
sistance. Simultaneous knock-down of both E2F4 and p107 enhanced chemo-
therapy sensitivity more than E2F4 knock-down alone. In normal intestinal
crypt cells E2F4 was dispensable for chemotherapy resistance. ChIP-seq and
RNA-seq experiments revealed that LDHA is a key downstream target of E2F4.
LDHA knock-down sensitizes cancer cells to chemotherapy. High LDHA ex-
pression in tumor tissues was an independent poor prognostic factor in colorec-
tal cancer patients (n466), as well as in non-small cell lung cancer (n1,926)
and breast cancer (n3,554). Thus, the E2F4/p107-LDHApathway represents a
novel therapeutic target to overcome chemotherapy resistance in CSCs.
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#82 MiR-206-mediated c-MET suppressionmodulates BCRP/ABCG2 lev-
els in NRF2-silenced cancer cells. Bo-hyun Choi, In-geun Ryoo, Donghyeok
Kim, Sujin Lee, Mi-Kyoung Kwak. The Catholic University of Korea, Bucheon,
Gyeonggi-do, Republic of Korea.
Breast cancer resistance protein (BCRP/ABCG2), a xenobiotic efflux trans-
porter, is responsible for anticancer resistance in tumors. NF-E2-related factor 2
(NRF2) is a critical transcription factor in cellular defense system by regulating
the expression of antioxidant and detoxifying enzymes; however, its overexpres-
sion is often associated with tumor resistance to chemotherapy. In the present
study, we demonstrate that NRF2 modulation affects the expression of hepato-
cyte growth factor receptor (HGFR/c-MET) and consequently suppresses
BCRP/ABCG2 activity in cancer cells. Interfering RNA-mediated stable inhibi-
tion of NRF2 in both ovarian carcinoma SKOV3 and renal carcinoma A498 cell
lines reduced the expression of c-MET and this was accompanied by BCRP/
ABCG2 down-regulation. The treatment of cells with pharmacological or ge-
netic inhibitor of c-MET decreased BCRP/ABCG2 level and subsequently in-
creased intracellular accumulation of doxorubicin and Hoechst 33342,
indicating a link between c-MET and BCRP/ABCG2 activity. As a potential
molecular mechanism of altered c-MET expression, miR-206 was identifıed as a
predictive regulator of c-MET. As experimental evidence, transient and stable
expressions of miR-206 in SKOV3 and A498 cells repressed c-MET and BCRP/
ABCG2 levels. In addition, NRF2-knockdown cancer cells expressed higher lev-
els of miR-206 compared to the control cells, and the treatment of NRF2 knock-
down cells with the miR-206 inhibitor could restore c-MET and BCRP/ABCG
levels. Collectively, our results showed that the NRF2 silencing-mediated miR-
206 regulation could suppress BCRP/ABCG2 levels through c-MET modula-
tion, which is providing an additional evidence of chemosensitization of tumor
cells by NRF2 inhibition.
#83 Irinotecan resistance in type 2 interleukin-1 receptor overexpressed
colorectal cancer cells is overcome by inhibitor of MEK. Ai-Chung Mar,1
Chun-Ho Chu,2 Te-Chang Lee1. 1Academia Sinica - Inst. of Biomedical Sci.,
Taipei, Taiwan; 2Department of Surgery, Taipei, Taiwan.
We have previously demonstrated that the expression of interleukin-1 recep-
tor type II (IL1R2) is closely associated with the advanced staging and distant
metastasis in patients with CRC. We also found that enhanced expression of
IL1R2 played certain roles to resist the targeted therapeutics, regorafenib, in
CRC cells. Whether IL1R2 expression is associated with the resistance to che-
motherapeutics is unclear. Irinotecan, a water-soluble and semisynthetic deriv-
ative of camptothecin, is one of widely used fırst- and second-line chemothera-
peutics for treatment of patients with metastatic colorectal cancer (CRC).
Herein, we fırst demonstrated that enhanced expression of IL1R2 resulted in
increased resistance ofCRCcells to irinotecan using IL1R2 ectopically expressed
HCT116 and DLD-1 cells, which were IL1R2 low expressing CRC cells, and
IL1R2 silenced HT29 cells, which were IL1R2 high expressing CRC cells. Since
we have shown that IL1R2 may activate MEK/ERK signaling by inhibition of
PP2A, we further revealed that a specifıc inhibitor of MEK, CI-1040, could
overcome the irinotecan resistance in IL1R2-overexpressing DLD-1 and HT29
cells. Our result showed that the combination of irinotecan and CI-1040 syner-
gistically suppressed the cell growth in high IL1R2 expressing CRC cells but less
signifıcant in low IL1R2 expressing cells. We also confırmed that treatment of
IL1R2-overexpressing CRC cells with CI-1040 signifıcantly suppressed the
pERK, a downstream target of MEK. These results support that IL1R2 mediates
through activation of MEK/ERK signaling to cause irinotecan resistance in hu-
man CRC cells. The investigation how IL1R2 induces irinotecan resistance is
ongoing. Accordingly, we may suggest that combined treatment of irinotecan
and MEK-ERK inhibitor is a potential therapeutic strategy against IL1R2 over-
expression related irinotecan resistant CRC.
#84 CCN1/Cyr61 regulation of gemcitabine-resistant phenotype in pan-
creatic cancer: involvement of CTGF and dCK. Vijayalaxmi G. Gupta, Gargi
Maity, Inamul Haque, Sushanta K. Banerjee, Snigdha Banerjee. Kansas City VA
Medical Center and University of Kansas Medical Center, Kansas City, KS.
With an estimated half a million new cases and similar mortality rates for
2016, pancreatic ductal adenocarcinoma (PDAC) remains a life-threatening and
challenging disease to diagnose and treat. As per American Cancer Society
(ACS), varying effıcacy in different patients has led to an increase in the mortal-
ity rate of PDAC.Gemcitabine (GEM) remains the drug of choice either alone or
in combination, but is unsuccessful in reducing or curing PDAC in most pa-
tients. The limited effıcacies of these drugs are due to the acquisition of chemo-
resistant characteristics of PDAC.Although severalmolecular and physiological
factors have been shown to correlate with the GEM-resistance, defıned molec-
ular mechanism(s) of GEM-resistance remains amystery. Previous studies have
shown thatCCN1,which is overexpressed inPDACandknown to associatewith
PDAC progression, is critical for drug resistance. Here, we found that while the
pancreatic cancer cell lines (i.e., Panc-1 and AsPC-1) in which CCN1 is overex-
pressed are typically GEM-resistant, the knocking down of CCN1 makes them
sensitive to GEM.Mechanistic studies revealed that CCN1 regulates two impor-
tant genes that are directly involved in regulation GEM-sensitivity in PDAC.
These include cancer cell-secreted connective tissue growth factor (CTGF), a
regulator of desmoplasia, and Deoxycytidine kinase (dCK), an enzyme that en-
hances gemcitabine sensitivity and effıcacy in cancer cells. The deletion ofCCN1
in PDAC cells blocks CTGF expression and under co-cultured conditions pre-
vent the growth of alpha-smooth muscle actin (-SMA)-positive stellate cells,
which are required for desmoplastic growth in pancreatic cancers. CCN1 abla-
tion upregulates dCK expression in PDAC cell lines as compared to CCN1
expressed PDAC cells. These two events enhance the anti-proliferative effect of
GEM and can be rescued by CTGF-treatment or blocking dCK. In conclusion,
CCN1 promotes GEM-resistance in PDAC cell through the regulation of CTGF
and dCK and the mechanistic insights provided by these studies may help in
designing future therapeutic strategies to combat PDAC.
#85 Establishment of cabazitaxel-resistant prostate cancer cell lines.Atsu-
shiMizokami,1 KazuakiMachioka,1 Kouji Izumi,1Maolake Aerken,1 Ariunbold
Natsagdorji,1 Yoshifumi Kadono,1 Yuta Takezawa,1 Hiroaki Iwamoto,1 Evan T.
Keller2. 1Kanazawa University, Kanazawa, Japan; 2University of Michigan, Ann
Arbor, MI.
Background: The fınal treatment for castration-resistant prostate cancer
(CRPC) is generally cabazitaxel treatment. However, once CRPC becomes resis-
tant to cabazitaxel, the patients are obliged to best supportive care. Therefore,
the elucidation of the mechanism of the cabazitaxel-resistance and the conquest
are important themes to improve the prognosis of the patients. We already
established paclitaxel/docetaxel-resistant prostate cancer, PC-3-TxR and
DU145-TxR cells, and characterized those cell lines previously. Then we further
tried to establish cabazitaxel-resistant prostate cancer cell lines, and character-
ized those cell lines. Materials and Methods: We established two cabazitaxel-
resistant cell lines, PC-3-TxR/CxR and DU145-TxR/CxR by increasing concen-
tration of cabazitaxel from 1 nM to 30 nM gradually when PC-3-TxR and
DU145-TxR cells were passaged.We confırmed the IC50 of docetaxel and caba-
zitaxel of these cells. Next we purifıed total RNA and performed cDNAmicroar-
ray (Agilent and compared gene expression profıles among these cells. Results
and Conclusion: IC50 of PC-3-TxR and PC-3-TxR/CxR for cabazitaxel was 1.3
nM and 15.4 nM, respectively. IC50 of DU145-TxR and DU145-TxR/CxR was
7.0 nM and 30. 8 nM, respectively. Comparison of cDNA microarray between
PC-3-TxR and PC-3-TxR/CxR cells or between DU145-TxR and DU145-TxR/
CxR cells revealed that 4,470 genes in PC-3-TxR/CxR, and 1,345 genes in
DU145-TxR/CxR cells were upregulated more than 3-fold and 4,683 genes PC-
3-TxR/CxR and 1,537 genes were downregulated less than 0.3-fold, respectively.
Especially, although expression of ABCB1 (MDR) gene was upregulated in
DU145-TxR by 500-fold compared with DU145 cells, it was not upregulated in
not upregulated in DU145-TxR/CxR cells any more. In contrast, expression of
ABCB1 gene was upregulated in PC-3-TxR by 20-fold comparedwith PC-3 cells
and it was further upregulated in PC-3-TxR/CxR by 40-fold compared with
PC-3-TxR. In conclusion, various genes were regulated in cabazitaxel-resistant
PCa cells and different mechanisms might be involved in this resistance in dif-
ferent cell lines.
#86 Time course analysis of gene expression and epigenetic interactions in
acquired cetuximab resistance in head and neck squamous cell carcinoma.
Luciane T. Kagohara,1 Genevieve Stein-O’Brien,1 Sijia Li,1 Manjusha Thakar,1
Ruchira Ranaweera,2 Michael Considine,1 Joseph A. Califano,3 Christine H.
Chung,2 Daria Gaykalova,1 Elana J. Fertig1. 1Johns Hopkins University, Balti-
more, MD; 2Moffıtt Cancer Center, Tampa, FL; 3University of California San
Diego, San Diego, CA.
The current study performs time course genomics and epigenomics profıling
to determine the complex dynamics of interactions between gene expression
and epigenetic changes that alter cellular signaling and drive acquired therapeu-
tic resistance. Targeted therapeutic agents block the activity of specifıcmolecules
critical for tumor progression. Cetuximab is a monoclonal antibody against
EGFR currently used in the treatment of head and neck squamous cell carci-
noma (HNSCC) and metastatic colorectal cancers. Similar to many targeted
therapeutics, cetuximab improves survival for a brief period of two years, after
which most patients acquire resistance resulting in tumor progression or recur-
rence. The mechanisms that alter cellular signaling pathways and cause resis-
tance are poorly understood.We hypothesize that themolecular alterations that
precede the resistance phenotype are more likely to be responsible for the resis-
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tance than thewidespread alterations observed once the resistance is established.
To test this hypothesis, we develop a novel time course experimental and bioin-
formaticsmodel of acquired resistance. Specifıcally, this protocol enablesweekly
profıling of RNA, DNA, and proliferation as cetuximab resistance developed in
vitro. We apply the CoGAPS bioinformatics algorithm to perform integrated
analysis of gene expression and DNA methylation. This analysis distinguishes
signatures of sustained activation of cellular pathways in response to treatment
from signatures of clonal expansion associated with acquired cetuximab resis-
tance. Despite identifying massive changes in gene expression driven by thera-
peutic response, only the expression changes associated with the acquired resis-
tance, and not response to treatment, have corresponding epigenetic signatures.
The genomic signature associated with acquired resistance is enriched for gene
targets of the AP-2 family of transcription factors. In a previous study, we found
that these gene targets were overexpressed after short-term treatment in cetux-
imab sensitive cell lines andHNSCC tumors. Our data suggest that this family of
transcription factors serves as a feedbackmechanism tomaintain homeostasis to
growth factors receptor signaling. As a result, AP-2 transcription factors serve as
a natural mechanism to cause subsequent therapeutic resistance without addi-
tion of genetic alterations. Further investigation is needed to determine the role
of AP-2 transcription factors in acquired cetuximab resistance.
#87 Treatment schedules influence acquisition of Doxorubicin resistance
through epigenetic mechanism in breast cancer cells. Logeswari Ponnusamy,
Prathap Kumar S. Mahalingaiah, Kamaleshwar P. Singh. The Institute of Envi-
ronmental & Human Health, Texas Tech University, Lubbock, TX.
Breast cancer is the leading cause of cancer related mortality in women. Che-
motherapy resistance is a major limitation in clinical treatment of breast cancer.
Mounting evidence implicates the epigenetic aberrations in acquired chemore-
sistance. However, the influence of treatment schedules and associated epige-
netic changes on acquisition of doxorubicin resistance in breast cancer is not
clear. Therefore, objective of this study was to evaluate the impact of treatment
schedules on acquisition of doxorubicin resistance and themolecularmechanis-
tic basis of this process in breast cancer cells. To address this question, two
different treatment strategies viz, continuous exposure and intermittent expo-
sure were used to generate doxorubicin resistant cells lines from ER-positive
MCF-7 and triple negative MDA-MB-231 breast cancer cell lines. The level of
resistance against doxorubicin and the temporal sequence of molecular changes
associated with the resistance phenotype were evaluated at 4 months and 18
months’ following exposure to doxorubicin. Results revealed that intermittent
exposure to doxorubicin resulted in signifıcantly higher level of resistance as
compared to continuous exposure. ER-positiveMCF-7 cells developed relatively
earlier and high level of resistance when compared to MDA-MB-231 cells. Ad-
ditionally, the resistance to doxorubicin-induced cytotoxicity was associated
with transient acquisition of EMT andCSC-like phenotype in breast cancer cells
around 4 months following doxorubicin. Gene and protein expression analysis
further revealed temporal changes in the expression of epigenetic regulatory
genes and histone modifıcations respectively. The temporal changes in expres-
sion of genes were positively correlated with doxorubicin exposure time during
resistance development. In summary, the result of this study for the fırst time
suggests that the treatment schedules influence the acquisition of doxorubicin
resistance potentially through epigeneticmechanisms. The fındings of this study
will be helpful in chemotherapy of breast cancer to achieve the best clinical
result.
#88 The role of RBPMS in cisplatin resistant ovarian cancer. Perla M.
Báez-Vega,1 Fatma Valiyeva,1 Ginette Santiago,2 Pablo Vivas-Mejia1. 1Univer-
sity of Puerto Rico Comprehensive Cancer Center, San Juan, PR; 2University of
Puerto Rico Medical Sciences Campus, San Juan, PR.
Epithelial ovarian cancer is the fıfth leading cause of cancer-associated deaths
among women in the United States. High-grade serous ovarian cancer (HG-
SOC) is the most common type of epithelial ovarian cancer and accounts for
70-80% of ovarian cancer patient deaths. RNA-Binding Protein With Multiple
Splicing (RBPMS) is a member of a family of proteins that bind to the nascent
RNA transcripts and regulate their processing, including the pre-mRNA splic-
ing and the transport, localization, and stability of theRNAmolecules.However,
little is known about the biological function of RBPMS family in ovarian cancer.
We hypothesized that decreasing the expression of RBPMS in high-grade serous
ovarian cancer increases ovarian cancer progression and platinum-based drug
resistance. Quantitative real-time PCR (qPCR) andWestern blot (WB) analysis
were conducted to determine the basal mRNA and protein expression of RB-
PMS in ovarian cancer cells. The invasion ability of the ovarian cancer cells after
targeting RBPMS with silencing RNA (siRNA) was determined by invasion as-
says. The proliferation rate of the ovarian cancer cells overexpressing RBPMS
was determine by colony formation assay. RBPMS is highly expressed in A2780
cells when compared to the cisplatin resistance ovarian cancer cells andHGSOC
cancer cells. Targeting RBPMS increased the invasion ability of the A2780 cells.
Cisplatin resistant, A2780CP20 cells overexpressing RBPMS showed a de-
creased in cell proliferation when compared to the A2780CP20 empty vector
clones. We described here for the fırst time the mRNA and protein expression
profıle of RBPMS in HGSOC and epithelial ovarian cancer cells. These studies
will help to better understand the role of RBPMS in ovarian cancer and may
support the use of RBPMS as an adjuvant treatment to overcome the platinum-
based chemotherapy resistance characteristic of the high-grade serous ovarian
cancer.
#89 Targeting Rho/MRTF regulated gene transcription in drug-resistant
melanoma. Sean A. Misek,1 Scott D. Larsen,2 Kathleen A. Gallo,1 Richard R.
Neubig1. 1Michigan State Univ., East Lansing, MI; 2University of Michigan, Ann
Arbor, MI.
Much of the recent focus of melanoma targeted therapy has been on the ERK
pathway, which is aberrantly activated in approximately 90% of melanoma tu-
mors (over half of which express BRAFV600E). Current targeted therapies such as
vemurafenib (BRAFV600E inhibitor), or a combination therapy using dabrafenib
(BRAFV600E inhibitor) and low dose trametinib (MEK inhibitor) shows pro-
found initial effects in a majority of BRAFV600E expressing tumors. However,
these responses are often short-lived and resistances typically develops within
months. Resistance to these targeted therapies can arise from multiple mecha-
nisms, including activation of pro-survival signaling pathways parallel to the
ERK pathway. The goal of this work is to identify pharmacologically targetable
resistance mechanisms so that effective combination therapies can be devel-
oped. Despite the clear role of the RhoA subfamily of Rho GTPases (RhoA/B/C)
asmelanoma oncogenes, their role in drug resistance is not well understood. It is
challenging to develop small molecule inhibitors which directly target the activ-
ity of small Rho GTPases, so an alternative approach is to inhibit downstream
pathways. Through modulation of the actin cytoskeleton Rho can induce gene
transcription through multiple transcriptional co-activators including Myocar-
din-Related Transcription Factor (MRTF) and Yes-Associated Protein 1 (YAP).
My bioinformatics analysis demonstrates that MRTF-A gene expression is cor-
related with poor overall survival in a large cohort of cutaneous melanoma
patients. Furthermore, expression of a set of 216 MRTF target genes is enriched
in dabrafenib/trametinib resistant cutaneous melanoma tumors compared to
matched pre-treatment tumors, suggesting that MRTF activation may be in-
volved in drug resistance. Based upon these results I hypothesized that small Rho
GTPases may promote resistance toMAPK pathway targeted therapies through
activation of MRTF/YAP. To test this hypothesis, I generated vemurafenib re-
sistant melanoma cells through chronic exposure to vemurafenib. This vemu-
rafenib-resistant cell population is enriched for actin stress fıber positive cells,
and these cells have increased Myosin Light Chain 2 (MLC2) phosphorylation,
suggesting that there is increased Rho activation. Furthermore, these drug resis-
tant cells are more sensitive to pharmacological inhibition of MRTF activity.
These preliminary data suggest that vemurafenib resistant melanoma cells may
be re-wired to depend on the Rho-induced gene transcription for their survival,
and that a combination therapy simultaneously targeting these two pathways
may be an effective treatment strategy for BRAF inhibitor-resistant melanomas.
#90 STING colocalizes with gamma-H2AX upon treatment of breast can-
cer cells with genotoxics: A new role in DNA repair. Laura Cheredame,1 Julie
Gaston,1VanessaYvonnet,1OlivierDeas,1Marie-Françe Poupon,1 Jean-Gabriel
Judde,1 Vincent Goffın,2 Stefano Cairo1. 1XenTech, Evry, France; 2Inserm
U1151, Institut Necker Enfants Malades (INEM), University of Paris Descartes,
Faculty of Medicine, Paris, France.
One of the current tumor immunotherapy strategies involves the use of
STING agonist, a well-known inducer of interferon (IFN) signaling in the im-
mune system, to promote tumor-rejection. However, recent evidence also indi-
cates that constitutive activation of IFN signaling in the tumormay lead to a bad
outcome. For instance, increased expression of IFN- stimulated genes (ISGs) at
time of surgery was associated with early breast cancer recurrence, and an IFN-
related DNA damage resistance signature (IRDS) was identifıed as a predictive
marker of recurrence after radiotherapy. Thus, IFNs secreted into the tumor
microenvironment may have complex opposite effects on tumor behavior and
response to treatment. Using patient-derived xenograft (PDX) models, we pre-
viously showed that the IFN/STAT1 pathway was activated within breast cancer
cells in response to chemotherapy and that this pathway may be involved in
treatment resistance and recurrence. The aim of this study was to elucidate the
mechanisms by which IFN-signaling is triggered in breast cancer cells following
chemotherapy and how its activation leads to tumor survival and recurrence. To
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this aim, the breast cancer cell lineMCF7 was treated in vitro with mafosfamide
and the activity of different IFN pathway effectors wasmonitored using western
blot, immunofluorescence and cell fractionation techniques. We found that in
breast cancer cells, similarly to what is observed in immune cells, type I IFN
expression is triggered in a STING-dependent manner. STING silencing abro-
gated chemotherapy-induced type I IFN production and signaling, while poten-
tiating genotoxic treatment effıcacy by promoting cell death and delaying cell
colony regrowth. Surprisingly, while STING is described as an endoplasmic
reticulum resident protein that relocalizes to perinuclear vesicles upon activa-
tion in immune cells, we showed that STING is constitutively present in the
nucleus of breast cancer cells and, under activation, forms nuclear clusters that
co-localize with gH2AX at DNA breaks. This study provides the fırst demon-
stration of STING activation in breast cancer cells and describes a potential new
role for the nuclear form of STING in DNA damage response. Our data suggest
that genotoxic stress-induced STING activation is a cell-intrinsic mechanism of
breast cancer cell survival and regrowth. Whether STING pro-survival role is
IFN-dependent (through the activation of given ISGs), IFN-independent
(through its involvement in the DNA damage response) or both is currently
under investigation.
#91 Molecular insight into drug resistance in acute myeloid leukemia: An
in-silico and in-vitro approach.Urja Desai, SheefaMirza, Sonia Parikh, Rakesh
Rawal. The Gujarat Cancer & Research Institute, Ahmedabad,Gujarat,India, In-
dia.
INTRODUCTION: Drug resistance of leukemic stem cells is a surmountable
obstacle to effective chemotherapy in acute myeloid leukemia (AML). P-glyco-
protein (Pgp) and FLT3 undoubtedly contribute to worse prognosis and mech-
anisms of these proteins lead to shorter survival and chemotherapy resistance.
Due to heterogeneity of stem cells in AML, outcome of patients with a normal
karyotype is highly challenging and changes in drug resistance genes likely to be
identifıed which will contribute to a better understanding of the disease biology,
eventually leading to the development of alternative therapeutic approaches
regarding drug resistance in AML. METHODOLOGY: Blood and Bone-mar-
row samples were collected from newly diagnosed adult AML patients with
normal karyotype. Gene expression analysis of MDR genes like Pgp, MRP1,
BCRP and LRP was done by qRT-PCR in FLT3-ITD/- and CD34/- sub-
groups. Higher expression of Pgp amongst all MDR genes instigated to under-
take in-silico analysis of Pgp with natural compound library using YASARA.
MTT assay was used to fınd out IC50 value of natural compounds shortlisted
from in-silico analysis and used alone or with cytarabine on THP-1 cell line and
in primary AML stem cells. Pgp inhibitory activity of natural compounds was
assessed by fluorimetric MDR assay. RESULTS: A signifıcant upregulation of
Pgp expression was observed in FLT3-ITD, CD34 group after cytarabine
exposure during their induction (73) therapy. Docking analysis revealed cur-
cumin, hesperidin and silymarin having better binding affınity with Pgp as com-
pared to its known inhibitor Verapamil. Furthermore, these selected com-
pounds were used in-vitro, and results of MTT assay suggested 6.1M,
40.73M, 63.09M and 54.95M IC50 values of cytarabine, curcumin, hesper-
idin and silymarin respectively in THP-1 cell line. Combination index (CI) anal-
ysis revealed that curcumin (25M), hesperidin (30M) and silymarin (35M)
having synergistic effect with cytarabine and decreased IC50 value of cytarabine
(1M). In addition to this, Silymarin at 250nM and 500nM concentration
showed equivalent inhibition of Pgp as compared to control Verapamil. CON-
CLUSION: A combination of in-silico and in-vitro screening revealed Cur-
cumin, Hesperidin and Silibinin can be used as MDR modulators as well as
chemosensitizer to reduce the cytotoxicity profıle and drug resistance in AML.
#92 Acquisition of temozolomide resistance: Identifıcation of a new drug
tolerant stage in glioblastoma cells. Marion Rabé,1 Hicham Janati,2 Solenne
Dumont,1 Christelle Thibault-Carpentier,3 Jean Clairambault,2 François M.
Vallette,1 Catherine Gratas1. 1Université de Nantes, UMR INSERM892/
CNRS6299, Nantes, France; 2Inria-Paris-Rocquencourt, Le Chesnay, France; 3IG-
BMC, Illkirch-Graffenstaden, France.
Glioblastomamultiforme (GBM) are the most aggressive and common brain
tumors in adults. Despite surgery and combined radio-chemotherapy with te-
mozolomide (TMZ), tumor reccurence always occurs. Themedian survival time
for patients diagnosed with GBM is about 14 months with less than 5% survival
at 5 years. Today themainmarker of TMZ resistance is themethylation status of
MGMT promoter. Patients with a methylated promoter usually have a better
response to treatment than patients with an unmethylated promoter. Indeed
MGMT is an enzyme involved in DNA repair mechanisms that abrogates TMZ
effects. However, in clinical trials targeting theMGMT enzyme,median survival
of patients was not improved. It is thus essential to decipher the mechanisms
involved in the acquisition ofTMZresistance to identify new therapeutic targets.
To achieve this goal TMZ resistant cells were generated by continuous treatment
of the U251 human glioblastoma cell line. These cells are sensitive to TMZ and
do not express MGMT. We performed transcriptomic analysis by RNA-Seq on
U251 treated with TMZ (50M) for different time and selected differentially
expressed genes. We also evaluated target genes expression in single cells by
RT-qPCR using C1-HD-Biomark technology (Fluidigm). Transcriptome pro-
fıling allowed to identify a transient phase with TMZ tolerant cells before acqui-
sition of complete resistance. These cells are characterized by a modifıed mor-
phology and a no proliferative state. In this population we identifıed a subset of
genes with the same transient overexpression. Similar results were observed in
other glioblastoma cell lines and under other stress conditions. In contrast, sta-
ble expression of MGMT appeared later with the emergence of the TMZ resis-
tant population. Interestingly single cell qPCR showed that MGMT expression
in the resistant cells could not be explained by clonal selection of MGMT posi-
tive cells. Drug screening on the TMZ tolerant cells revealed a potent killing
activity of histone deacetylating agents (HDAC inhibitors). In conclusion, we
have shown that glioblastoma cells become resistant after a transient state of
TMZ tolerance. Identifıcation of this singular population highlights newmolec-
ular targets and a new therapeutic window. Targeting these tolerant cells could
avoid emergence of resistance and tumor recurrence, thereby patients survival
could be improved.
#93 Transcriptional control of glucocorticoid responses in leukemia. Lai
N. Chan, Zhengshan Chen, Gang Xiao, Jae Woong Lee, Kadriye Nehir Cosgun,
Huimin Geng, Valeria Cazzaniga, Hilde Schjerven, Ross A. Dickins, Markus
Muschen. UCSF, San Francisco, CA.
Glucocorticoids (GCs) are central to all major therapy regimens for pre-B
cell-derived acute lymphoblastic leukemia (ALL), but have no activity in my-
eloid leukemia. Such divergent responses represent an empirically established
clinical standard; however, neither the mechanism by which GCs induce cell
death nor the biological basis for the distinct responses in B-cell and myeloid
leukemias is clear. Studying patient-derived samples revealed that NR3C1 (glu-
cocorticoid receptor) levels were 6- to 20-fold higher in pre-B ALL compared to
chronicmyeloid leukemia (CML).High levels ofNr3c1were reduced uponB- to
myeloid-lineage conversion, suggesting that regulation of NR3C1 expression
and GC responsiveness depend on a B-cell transcriptional program. B-cell tran-
scription factors (e.g. PAX5, IKZF1) are critical for B-cell development, yet they
are genetically lesioned inmore than 80% of pre-B ALL cases. Despite such high
frequency, the signifıcance of these inactivating lesions remains elusive. Com-
bining ChIP-seq and RNA-seq analyses, we identifıed a novel B-cell transcrip-
tional program for activation of NR3C1 and its transcriptional target TXNIP (a
negative regulator of glucose uptake). Reconstitution of PAX5 or IKZF1 expres-
sion in haploinsuffıcient patient-derived pre-B ALL cells increased NR3C1 and
TXNIP levels. Conversely, expression of dominant negative mutant of PAX5 or
IKZF1 abolished NR3C1 expression. Loss of Nr3c1 or Txnip in murine BCR-
ABL1-driven pre-B ALL cells resulted in survival advantage in competitive
growth assays. Importantly, loss ofNr3c1 or Txnip signifıcantly elevated glucose
uptake, lactate production and cellular ATP levels. These fındings suggest that
GCs induce cell death by exacerbating glucose and energy depletion. Notably,
reconstitution of PAX5 or IKZF1 rendered haploinsuffıcient patient-derived
pre-B ALL cells more sensitive to dexamethasone (dex) treatment. In contrast,
dominant-negative PAX5 or IKZF1 largely de-sensitized pre-B ALL cells ex-
pressing wildtype PAX5 or IKZF1. These fındings suggest that B-cell transcrip-
tion factors set the threshold forGC responsiveness in pre-BALL. Since relapsed
ALL cells often acquire GC resistance, drug-combinations may be useful to
prevent GC-resistance. As expected, loss of Nr3c1 abrogated responses to GCs.
Interestingly, loss of Txnip also largely rescued GC-induced cell death in pre-B
ALL cells. On this basis, we tested drug interactions between GCs and TXNIP
agonists, 3-O-methylglucose (3-OMG) and D-allose. Treating patient-derived
GC-refractory pre-BALL cellswith 3-OMGorD-allose strongly synergizedwith
GC-treatment. Collectively, our fındings provide a mechanistic explanation for
the empiric fınding that GCs are effective in the treatment of B-cell but not
myeloidmalignancies, and identify TXNIP as a novel therapeutic target in pre-B
ALL.
#94 Association of xCT overexpression with RTKI resistance and metas-
tases in clear cell renal cell carcinoma. Sreenivasulu Chintala, Remi Adelaiye-
Ogala, Ashley Orillion, Sreevani Arisa, May Elbanna, Nur P. Damayanti, Ro-
berto Pili. Indiana University-Purdue University, Indianapolis, IN.
Background: Cystine/glutamate exchanger xCT is a catalytic component of
system xc- involved in transport of ’conditionally indispensable’ amino acid
cystine. Cystine transport is a rate limiting step for the synthesis of glutathione,
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a major intracellular redox regulator. Recently, we and other groups reported
the overexpression of xCT and its association with drug resistance in several
human cancers including bladder, glioma, breast, and colon. There are no stud-
ies to show the xCT expression in clear cell renal cell carcinoma (ccRCC) and its
association with tyrosine kinase inhibitors resistance andmetastasis. In the cur-
rent studywe have evaluated xCT expression in human ccRCC tumors arranged
in tissue microarray (TMA) and determined its role in receptor tyrosine kinase
inhibitor (RTKI) resistance and metastases using the patient derived tumor
xenografts (PDX) models and TKI resistance ccRCC cells. Methods: Human
Renal cell carcinoma tumornephrectomy specimens arranged in tissuemicroar-
ray (TMA) were used to determine xCT expression by immunohistochemistry.
Patient derived tumor xenografts (PDX) of primary, metastasis, and sunitinib
resistance were used to determine the role of xCT in RCC. To understand the
molecular alterations associated with RTKI resistance, we have generated
sunitinib resistance 786 OR ccRCC cells and performed RNAseq analysis. To
determine the xCT inhibition effect on ccRCC tumor metastases, sulfasalazine,
an inhibitor of xCT was used to treat metastatic ccRCC tumor xenografts trans-
planted in SCIDmice. Results: Immunohistochemical evaluation of xCT inRCC
TMA revealed that 70 % (19 out of 27) of the tumors express different levels of
xCT. Association with tumor response to RTKI will be presented. RTKI less
responsive PDX RP-R-02 was developed using the dose escalation treatment
strategy andwas found to have an upregulation of xCTwhen the tumors become
less responsive to sunitinib. RNAseq analysis revealed differential gene expres-
sion of various pathway genes including lysosome biogenesis and function such
as SLC7A11, HPS4, HPS5, CTSB, IFI30, PPT1, SCPEP1, TPP1, ATP6AP1L,
MCOLN1, PRKAG2, andVPS18 in sunitinib resistant 786OR cells compared to
parental cells supports the role of lysosomes function in RTKI drug resistance.
Furthermore, xCT inhibitor sulfasalazine treatment signifıcantly decreased the
metastasis lung nodules of RP-R-02LM in SCID mice demonstrated the xCT
role in RCC tumor metastasis. Conclusions: We found preliminary evidence
that overexpression of xCT may be associated with RTKI resistance in ccRCC.
These results suggest that targeting the xCT in ccRCCmay reverse the resistance
and enhance the effıcacy of RTKI. Additional studies using larger numbers of
ccRCC tumors are required to identify xCT as a potential predictive biomarker
for response/resistance to RTKI in ccRCC patients.
#95 Targeting BRD4 overcomes cetuximab resistance in HNSCC. Toni
Brand, Yan Zeng, Brandon Leonard, Rachel O’ Keefe, Hua Li, Daniel Johnson,
JenniferGrandis,Neil E. Bhola.University of California San Francisco, San Fran-
cisco, CA.
Background: Nearly 600,000 people are diagnosed with head and neck cancer
worldwide and 60% succumb to the disease within 5 years. The epidermal
growth factor receptor (EGFR) is a major driver of HNSCC and in 2006 the
EGFR monoclonal antibody cetuximab was FDA-approved for HNSCC treat-
ment.However, cetuximab has not conferred signifıcant long-termbenefıt com-
pared to chemoradiation in patients with poorly differentiated recurrent-meta-
static HNSCC. We and others have demonstrated that cetuximab treatment
activates alternative receptor tyrosine kinases (RTKs) including Fibroblast
Growth Factor (FGF) receptors,Met andAxl inHNSCC. To circumvent admin-
istration of multiple RTK inhibitors in combination with cetuximab, we sought
to identify a common molecular target that regulates the expression of these
RTKs. Bromodomain-containing protein-4 (BRD4) has been shown to regulate
the transcription of RTKs in breast cancer models. Hypothesis: We hypothe-
sized that targeting BRD4 will overcome cetuximab resistance by depleting the
expression of alternative RTKs in HNSCC.We further hypothesize that genetic
and pharmacological targeting of BRD4 will synergize with cetuximab. Results:
Using a phospho-RTK array, 72-hour cetuximab treatment increased or sus-
tained phosphorylated levels of EGFR, HER2, HER3, MET, and AXL in several
HNSCCcell lines. Treatmentwith the BRD4 inhibitor JQ1 abrogated both phos-
phorylated and total RTK abundance in the presence of cetuximab. Cetuximab
and JQ1 robustly decreased phosphorylated Src and induced the senescence
marker p21. Phenotypically, cetuximab and JQ1 signifıcantly decreased survival
and increased apoptosis in 6 HNSCC cell line models, while the normal oral
keratinocyte cell line NOKsi had approximately 10-fold higher IC50s for the
BRD4 inhibitors, JQ1 and I-BET762, relative to HNSCC cell lines. Importantly,
twoHNSCCmodels of acquired cetuximab resistance exhibited robust sensitiv-
ity to pharmacological (JQ1, IBET-762) and genetic (RNAi) BRD4 targeting
strategies.Moreover, exogneous overexpression of different RTKs (HER3, ALK,
and ROR1) resulted in cetuximab resistance that was reversed upon BRD4 tar-
geting (RNAi and JQ1). Combination of cetuximab and JQ1 in co-culture ex-
periments with T cells decreased the CD4/CD25 Treg population and
PD-L1 expression on HNSCC cell lines. Further, preliminary fındings indicate
that JQ1 treatment prevents outgrowth of cetuximab-treated HNSCC patient-
derived xenograft models. Conclusion: Our fındings indicate that targeting
BRD4 decreases the activation and expression of multiple RTKs that mediate
resistance to the FDA-approved EGFR inhibitor cetuximab. Furthermore,
BRD4 abrogates expression of immunosuppressive markers, making it a prom-
ising tumor intrinsic and extrinsic therapeutic strategy for HNSCC.
#96 Didhydropyrimdine dehydrogenase (DPYD) provides resistance to
5-flurouracil in mutant p53 (mtp53) expressing colorectal cancer cells.
Prashanth Ravishankar Gokare,1 Niklas Finnberg,1 David Dicker,1 Maureen
Murphy2. 1Fox Chase Cancer Ctr., Philadelphia, PA; 2Wistar Institute, Philadel-
phia, PA.
5-Flurouracil (5-FU) is a mainstay of colorectal cancer therapy. Even though
much is known about the 5-FUmechanism of action, very little is known about
the genetic determinants which provide sensitivity and resistance to 5-FU. Here
we provide fırst insights into p53, a major predictor of 5-FU response, modulat-
ing nucleotide catabolism specifıcally through the control of the rate limiting
enzyme dihydropyrimidine dehydrogenase (DPYD). Colorectal cancer cells ex-
pressingmtp53 specifıcally showhigher expression ofDPYD as compared to the
wildtype p53 (wtp53) carrying cells. Higher expression of DPYD in mtp53 cells
specifıcally provides increased resistance to 5-FU as indicated by cellular prolif-
eration and long term clonogenic assays. Furthermore, knockdown of DPYD in
mtp53 cells preferentially resensitizes them to 5-FU as opposed to cells express-
ingWtp53 by decreasing the viability and increasing apoptosis observed in these
cells. Pharmacological inhibition of DPYD with gimeracil, clinical inhibitor of
5-FU phenocopies the effects seen by siRNA/shRNA mediated knockdown of
DPYD. Finally, invivo studies with tumor xenograft from mtp53 carrying cells
shown increase resistance to 5-FU therapy which is abrogated by stable knock-
down of DPYD expression or in combination gimeracil. Preliminary analysis of
TCGA patients treated with 5-FU indicate differential expression of DPYD
based on specifıc Tp53 mutation status. Taken together our study provides fırst
insights into crosstalk between nucleotide catabolism and mtp53 under condi-
tions of DNA damage and metabolic stress having major implications on the
therapeutic response to 5-FU the in the clinic.
#97 RNA sequencing of bladder cancer patient-derived xenograft mod-
els identifıes genes associated with chemoresistance. Kelly A. Martin,1
Nicholas R. Hum,1 Aimy Sebastian,1 Deepa K. Murugesh,1 Chong-Xian
Pan,2 Ai-Hong Ma,2 Ralph de Vere White,2 Gaby Loots1. 1Lawrence Liver-
more National Laboratory, Livermore, CA; 2UC Davis Comprehensive Cancer
Center, Sacramento, CA.
Background: Bladder cancer is among the top ten most common cancers,
with about 380,000 new cases and 150,000 deaths per year worldwide.
Platinum-based combination chemotherapy is commonly used to treat ad-
vanced bladder cancer. It has been shown that only 50% of the patients
with advanced bladder cancer respond to platinum-based therapy. Methods:
We have utilized a patient-derived bladder cancer xenograft (PDX) platform
to characterize the molecular mechanisms that contribute to resistance of
gemcitabine-cisplatin combination therapy in advanced bladder cancer. We
have also identifıed key regulatory pathways in our PDX models that can be
targeted to treat chemotherapy resistant bladder cancer using RNAseq anal-
ysis. Transcriptome profıling of P0 (passage 0) bladder cancer xenograft
tumors from 4 PDX lines (2 gemcitabine-cisplatin resistant lines and 2 drug
sensitive lines) was performed by RNA-Seq analysis, before and after a 21-
day cisplatin/gemcitabine drug treatment regimen. Results: The RNA-seq
data has indicated signifıcant differences between the transcriptional profıles
of drug-sensitive and drug-resistant tumors. PDXs retainedmorphology and
shared 92-97% of genetic alterations of parental cancer cells. We identifıed
333 genes 2 fold up or down regulated in the drug resistant tumors com-
pared to the drug sensitive tumors. Signifıcantly up-regulated genes in drug
resistant tumors analyzed include metabolic enzymes ALDH2, ALDH3A1,
ALDH4A1 and ALDH7A1, transporter proteins ABCA1, SLC1A4, SLC2A5,
SLC30A1, SLC39A6, SLC7A5 and SLC9A3, Notch ligand JAG2, Growth hor-
mone receptor GHR and transmembrane protein GPNMB. Consistent with
the change of cell surface proteins such as GHR and GPNMB, the MAPK and
the PI3K-AKT pathways were upregulated when PDXs became resistant to
cisplatin treatment. Additional changes in gene expression based on RNA-
seq data before and after drug treatment were also found. Conclusion:
Chemoresistance to gemcitabine and cisplatin is associated with altered ex-
pression of several cell surface proteins and upregulation of the downstream
signaling pathways. Targeting these cell surface proteins can possibly be
harnessed to overcome chemoresistance. GPNMB is a type I transmembrane
protein that has previously been shown to be up-regulated in many meta-
static cancers including breast cancer. Potentially targeting GPNMB with
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glembatumumab vedotin, an antibody-drug-conjugate has shown promis-
ing results in treating several cancers including breast cancer and osteosar-
coma. Further studies will elucidate whether targeting GPNMB is an effec-
tive strategy for the treatment of chemotherapy resistant bladder cancer.
This study received funding by a developmental grant from the UCDCC.
This work was conducted under the auspices of the USDOE by LLNL (DE-
AC52-07NA27344). IM number: LLNL-688318.
#98 TET suppresses protein translation, differentially effects polysome
loading of cell cycle regulatory proteins and inhibits cell growth and prolif-
eration of prostate cancer cells. Praveen K. Jaiswal, Sweaty Koul, Qin Dong,
Hari Koul. LSU Health Sciences Center - Shreveport, Shreveport, LA.
Introduction: Translational control is a critical component in development
and progression of cancer and could be explored to develop antineoplastic ther-
apies. Results from our laboratory have shown that TET (a derivative of Tetran-
drine) inhibits cell growth and promotes apoptosis of prostate cancer (PCa)
cells. However, the underlying molecular mechanisms are not clearly under-
stood.Weobserved that TET inhibited 4EBPphosphorylation, suggesting that it
might inhibit translational initiation. In the present study we evaluated the ef-
fects of TET on Translation in general and cell cycle related proteins in partic-
ular. Methods: Androgen dependent PCa cells LNCaP and Enz resistant CRPCa
cells 22Rv1 were maintained in supplemented RPMI as recommended. Where
indicated cells were treated with TET (0 or 20M) for various time points (2h,
8h, 18h and 24h). At the end of the experimental periods cells were pulsed with
cycloheximide for 10 minutes in RPMI media. Cytoplasmic RNA was collected
by lysing cells in polysome lysis buffer. Cell lysates were centrifuged and the
resulting cytosolic supernatant was separated by density (a 10% to 50% sucrose)
gradient and centrifugation. Fractions were collected using a TELEDYNE ISCO
DensityGradient Fractionation Systemwith continuousmonitoring of untrans-
lated mRNAs. Polysome (P)/Monosome (M) ratio were measured. The total
RNA in each fraction was extracted using TRIzol LS (Invitrogen) and qRT PCR
was done for p21, p27, CyclinD1 and c-Myc gene for each fraction. Cell viability
was measured by MTT assay at various time points. Results: TET treatment
resulted in decreased protein synthesis. TET treatment resulted in decrease of
RNAassociatedwith Polysomes. Therewere a signifıcant shift in P/M ratio from
0.82 (control) to 0.48 (24 h. TET) [TET 2hrs (0.75), 8h (0.69) and 18hrs (0.52)] in
LNCaP and P/M ratio form 0.91 (control) to 0.32 (8 h TET) [TET 2h (0.78) and
4h (0.53)] in 22Rv1 cells. The decrease of the P/M ratio suggests that TET inhib-
its translation initiation in prostate cancer cells independent of the androgen
dependence. While there was generalized decrease in translation and specifıc
decrease in mRNA for Cyclin D1, c-Myc associated with polysomes following
TET treatment. In quite contrast to these fındings, we observed an increase in
mRNA for p21 and p27 in polysomal fractions of TET treated cells as compare to
control at 24 h in LNCaP cells. These data suggest differential effects of TET
treatment on polysome loading of cell cycle regulatory proteins. Moreover, TET
inhibited growth andproliferation of LNCaP and 22Rv1 cells in dose aswell as in
time dependent fashion. Conclusions: TET targets translational machinery and
differentially effects translation of cell cycle regulatory genes by effecting their
polysome loading and effects cell growth and proliferation of androgen depen-
dent and castrate resistant PCa cells.
#99 Identify potential kinetochore protein inhibitors to overcome cispla-
tin resistance. Chen Yin-Ju, Jeng-Fong Chiou. Taipei Medical University, Tai-
pei, Taiwan.
Cisplain is themost commonly used chemotherapeutic drug for cancer, while
the resistance causes treatment failure. Cisplatin resistancemay involve inmany
molecular changes so identify aberrations in cisplatin-resistant (CR) genes and
fınd new therapeutic strategies could provide valuable information to reduce
therapeutic resistance. The aim of this study is to search CR genes and identify
potential novel drugs to overcome cisplatin resistance. To identify aberrations in
CR genes, three CR genetic signatures were collected and analyzed differential
expression genes from lung, ovarian and oral cancer cells. After integration of
CR signatures, the kinetochore associated proteins, including NUF2, SPC25,
PC24, DSN1, SKA2, KNTC1, MIS18A and SKA1 were up-regulated in various
CR cells. Silencing of kinetochore associated proteins increased cisplatin sensi-
tivity. For identifıcation of kinetochore associated protein inhibitors to over-
come cisplatin resistance, CR signatures were queried to the Connectivity map
(Cmap) database to search for potential drugs which may reverse cisplatin re-
sistance. 3 compounds exhibited cytotoxicity effect on the cisplatin-resistant
cells and reduced kinetochore associated proteins expression level. Taking to-
gether, this study demonstrates kinetochore associated proteins participate in
cisplatin resistance and identify potential inhibitors to overcome cisplatin resis-
tance.
#100 Pancreatic cancer cells rely on the NADPH producing enzyme,
IDH1, for adaptive survival against acute metabolic stress. Ali Vaziri-Gohar,
Mahsa Zarei, Jonathan R. Brody, Jordan M. Winter. Thomas Jefferson Univer-
sity, Philadelphia, PA.
We recently demonstrated that pancreatic cancer cells adapt to low nutrient
conditions and chemotherapeutic stress through an adaptive response where
HuR (ELAVL1) protects cells from oxidative damage induced by metabolic
stress. RNA sequencing data and a series of protein-RNA interaction assays
proved that HuR stabilizes transcript levels of the NADPH producing enzyme,
isocitrate dehydrogenase 1 (IDH1). HuR-knockout cells had near-complete loss
of IDH1 expression (manuscript under review). In light of the fact that IDH1-
null mice are particularly sensitive to oxidative damage, we hypothesize that this
enzyme plays a critical role in PDA survival of acute stress. We examined the
expression levels of all eight well-characterized NADPH-generating enzymes in
pancreatic cancer cells in vitro, and demonstrate that only IDH1 and phospho-
gluconate dehydrogenase (PGD) are upregulated by2-fold after incubation in
low glucose (5 mM) for 48 hours. IDH1-knockout MiaPaCa2 cells were gener-
ated through CRISPR gene editing, such that mRNA expression was detected at
5% of control levels. ROS levels detected by DCFDA measurements were
increased by 55% in IDH1-knockout cells compared to isogenic controls under
normal culture conditions, with even higher levels under low glucose and che-
motherapy stress for 48 hours. Additionally, IDH1-knockout cells were more
sensitive to chemotherapy under both high and low glucose conditions, com-
pared to IDH1-profıcient control cells. Taken together these results suggest that
IDH1 expression is important for acute antioxidant defense in pancreatic cancer
cells in the face of metabolic stress, and represents a potential therapeutic target.
#101 Adaptive feedback reactivates MAPK signaling in KRAS-mutant
cancers with inhibition of MEK, but not ERK. Leanne G. Ahronian, Sandra
Misale, Jason T. Godfrey, Koki Nishimura, Lifeng Chen, Jeffrey A. Engel-
man, Ryan B. Corcoran. Massachusetts General Hospital Cancer Center,
Charlestown, MA.
Activatingmutations in the KRAS oncogene occur in about 40% of colorectal
cancers (CRCs) and over 90% of pancreatic ductal adenocarcinomas (PDACs).
Since development of small molecules capable of inhibiting KRAS directly has
proven diffıcult, alternative strategies have instead focused on inhibiting down-
stream effector pathways, such as the MAPK pathway. However, inhibition of
the MAPK pathway alone with MEK inhibitors, such as selumetinib and tra-
metinib, produces only cytostatic effects and is insuffıcient to kill KRAS-mutant
cancer cells. We hypothesized that inhibition of an additional kinase during
MEK inhibitor treatment could improve response. We performed a kinase-
targeting shRNA screen to fınd kinaseswhose knockdownwould cooperatewith
trametinib inKRAS-mutant CRC andPDACcell lines. The kinases found in this
screen represent potential therapeutic targets to inhibit in combination with
MEK. Interestingly, despite using a very high concentration of trametinib in the
screen to enrich for hits outside of the MAPK pathway, the most highly ranked
kinases in the screen were members of the MAPK pathway, including ARAF,
BRAF, CRAF, and MEK1. This suggests that even at high concentration, tra-
metinib produces suboptimal MAPK inhibition. Indeed, we found that while
MEK inhibitors produce robust inhibition ofMAPK signaling initially, pathway
reactivationwas observed by 48-96 hours despite regular replenishment of drug.
This feedback reactivation was accompanied by marked increases in active
CRAF and phosphorylated MEK. In fact, experimental approaches that artifı-
cially increased upstream signaling flux through the MAPK pathway led to a
10-fold reduction in the ability of MEK inhibitors to inhibit the MAPK path-
way. Remarkably, despite triggering the same degree of adaptive upstream
MAPK signaling as seenwithMEK inhibitor, we found that ERK inhibitors were
able to maintain MAPK pathway suppression. Importantly, these differences in
MAPK pathway suppression amount to differences in cell viability. Over four
weeks, ERK inhibitor treatment reduces the outgrowth of KRAS-mutant cell
lines compared to those treated with MEK inhibitors. Additionally, as these
inhibitors are not used as monotherapies, replacement of trametinib with an
ERK inhibitor in therapeutically relevant combination treatments improved cell
responses over four weeks. Despite the feedback reactivation of theMAPKpath-
way, we fınd that ERK inhibitors are less sensitive to this signaling than MEK
inhibitors, and can effectively maintain suppression of MAPK signaling. The
fındings of our screen demonstrate that MAPK pathway targeting is key to
successful treatment ofKRAS-mutant cancers, and that ERK inhibition provides
greater opportunity for inactivatingMAPK. Further exploration into the mech-
anisms of pathway feedback will be necessary to developing valuable clinical
combinations for KRAS-mutant cancers.
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#102 Overcoming MET inhibitor resistance in GBM therapy. Nichola A.
Cruickshanks,1 Ying Zhang,1 Sarah Hatef,1 Julia Wulfkuhle,2 Isela Gallagher,2
Alexander Koeppel,1 David Schiff,1 See Phan,3 Stephen Turner,1 Emanuel Petri-
coin,2 Roger Abounader1. 1University of Virginia, Charlottesville, VA; 2George
Mason University, Manassas, VA; 3Genentech, Menlo Park, CA.
Glioblastoma (GBM) is themost common andmost lethal primarymalignant
brain tumor. The receptor tyrosine kinase MET is frequently upregulated or
over activated in GBM. Clinically applicable MET inhibitors have been devel-
oped and tested in the lab and in clinical trials. However, resistance to single
modality anti-MET drugs frequently occurs, rendering these agents ineffective.
This study aimed to determine the mechanisms of MET inhibitor resistance in
GBM and to use the acquired information to develop novel therapeutic ap-
proaches to overcome resistance.We investigated two clinically applicableMET
inhibitors: PF-02341066, an ATP-competitive small molecule inhibitor ofMET,
andMetMab, amonovalent monoclonal antibody that binds to the extracellular
domain of theMET receptor.We generated PF-02341066 andMetMab resistant
GBM cell lines and primary cells by subjecting them to increasing concentra-
tions of drug over a period of time.We utilized RNA sequencing (RNA-seq) and
reverse phase protein arrays (RPPA) in addition to death and proliferation as-
says to identify the pathways altered in the resistant GBMcells compared to wild
type GBM cells. We discovered many critical proteins that were altered in the
resistant cells lines compared to wild type cells. These included FAK, COX-2,
p-FGFR1, Vimentin, mTOR and p-STAT3. There was substantial but not com-
plete overlap between the molecules that were altered in cells resistant to the
small molecule as compared to molecules that were changed in cells resistant to
the antibody. The protein changes in resistant GBM cells were verifıed by west-
ern blotting. Notably, we discovered that both COX-2 and p-FGFR1 were up-
regulated in GBM resistant cells and thus investigated whether inhibition of
these targets could restore MET inhibitor sensitivity. Celecoxib, an FDA-ap-
proved drug, acts to inhibit COX-2 and Debio-1347 acts to inhibit the FGFR
family, with a higher affınity for FGFR1. Combining Celecoxib or Debio-1347
with PF-02341066 or MetMab led to increased cell death in resistant cells com-
pared to either agent alone. In addition, the drug combination decreased resis-
tance to cell proliferation inhibition compared to either agent alone, indicating
restored sensitivity to both MET inhibitors. We are currently undertaking in
vivo experiments to establish whether the combination of celecoxib and MET
inhibitors can restore sensitivity toMET inhibition in resistant cells as effectively
in vivo as seenwith in vitro experiments. These data indicate thatMET inhibitor
resistance can be overcome by targeting the resulting upregulated pathways
using FDA-approved drugs and that multi-drug combinations may revert resis-
tance during treatment.
#103 Blockage of Cdc7/CDK9 signaling sensitizes triple negative breast
cancer toEGFR-targeted therapy.RonanP.McLaughlin,1 JichaoHe,1Vera van
der Noord,1 Jevin Redel,1 Marcel Smid,2 Lambert Dorssers,2 John Martens,2
John Foekens,2 Yinghui Zhang,1 Bob van deWater1. 1Leiden University, Leiden,
Netherlands; 2Erasmus University Medical Center, Rotterdam, Netherlands.
The treatment of Triple-Negative Breast Cancer (TNBC) still represents a
profound clinical challenge, the disease being disproportionately responsi-
ble for breast cancer-associated deaths. As a consequence, the identifıcation
of targeted agents, which synergize with current therapeutic options, is par-
amount. Resistance to EGFR-tyrosine kinase inhibitors (TKIs), despite fre-
quent EGFR overexpression and reliance on downstream signalling path-
ways in TNBC, remains endemic. Recent data has also suggested that kinase-
inhibition of EGFR in itself is insuffıcient, given the kinase-independent
functions of the protein in transcriptional regulation and DNA-repair may
permit prolonged EGFR-mediated signalling in the presence of inhibitors.
We performed a kinase inhibitor drug screen (378 kinase inhibitors targeting
40 different cancer-related kinases) to identify synergistic activity with
EGFR inhibition in TNBC. We demonstrate that the dual cdc7/CDK9 inhib-
itor PHA-767491 synergizes with multiple EGFR-TKIs (Erlotinib, Gefıtinib
and Lapatinib) in vitro to overcome resistance to EGFR-targeted therapy in
various TNBC cell lines. Combined inhibition of EGFR and cdc7/CDK9
resulted in reduced cell proliferation, accompanied by induction of apopto-
sis and G2-M cell cycle-arrest. Combination therapy inhibited crucial com-
ponents of the DNA-replicative machinery and also proteins involved in
CDK9-mediated transcriptional elongation. Moreover, higher expression of
cdc7 and POLR2A was found to be signifıcantly correlated with poorer sur-
vival rates in breast cancer patients. Additionally, this synergistic combina-
tion effectively inhibited the growth of cells isolated from patient-derived
TNBC xenografts under ex vivo culture conditions, highlighting the utility of
targeting common transcriptional nodes in cancers addicted to growth fac-
tor-mediated signalling pathways.
#104 miRNAs in the 14q32 cluster are involved in lapatinib resistance.
Juliette Chupin,1 Ai Nagano,1 Victoria Haley,2 Catherine Lenihan,1 Franc-
esca Cavicchioli,1 Karen O’Leary,1 Natasha Sahgal,1 Cristiana Lo Nigro,3
Alice Shia,1 Claude Chelala,1 Peter Schmid1. 1Barts Cancer Institute, London,
United Kingdom; 2Open University, London, United Kingdom; 3Ospedale Cu-
neo, Italy.
HER2 is over-expressed in around 20-25% of breast cancers. Due to increased
cell growth and differentiation signaling resulting from HER2 over-expression,
this sub-type of the disease is associated with aggressive tumor progression and
poor prognosis. HER2 targeted therapy has improved patient prognosis, how-
ever, only a subgroup of patients derives the optimal benefıt, while other patients
have refractory disease or develop resistance. miRNAs are small non coding
RNAs involved in the RNAi machinery. They are often aberrantly expressed in
tumors and miRNA profıles have been seen to evolve over the course of treat-
ment implicating them in therapeutic resistance. Methods: miRNA array com-
pleted on the Human TaqMan miRNA card. Gene expression profıling per-
formed by Illumina Human HT12 v4.0 array. Differential gene expression used
LIMMA1 empirical Bayes statistics module. Adjusted p-values calculated by
Benjamini and Hochberg procedure. In silico target prediction used miRWalk.
Lapatinib resistant cells generated by culturing cells in increasing doses of lapa-
tinib up to 2M. IC50 obtained from drug cytotoxicity measured by MTT ana-
lyzed by nonlinear regression. Results: A panel of miRNAs differentially ex-
pressed in paired lapatinib sensitive/resistant BT-474 HER2 positive breast
cancer cells were identifıed by miRNA array. Three miRNAs, located in the
14q32 region, were selected for further investigation of their role in resistance to
HER2-targeted therapy: miR-127-3p, miR-409-3p, and miR-495-3p. RT-qPCR
also confırmed upregulation of these miRNAs in HCC1954 and SKBR-3 HER2
positive cells with acquired resistance to lapatinib, linking increased miRNA
expression with acquired resistance. To understand the mechanism behind the
miRNA expression in resistant cells we explored epigenetic changes between the
sensitive and resistant lines. Global methylation reversal revealed upregulation
of all miRNAs in the sensitive cells with a further increase upon addition of an
HDAC inhibitor. De-methylation had less effect in resistant cells, indicating loss
of methylation as a key component in miRNA upregulation in the process of
lapatinib resistance. Using differential gene expression analysis in paired lapa-
tinib-sensitive/resistant BT-474 cells combined with in silico analysis we iden-
tifıed putative targets of these miRNAs. BASP1, a c-MYC transcriptional inhib-
itor, was down-regulated in the BT-474/L resistant cells. Knock-down altered
sensitivity to lapatinib, with an 8 fold shift in IC50 towards resistance, indicating
reduced expression of the protein could be involved in the resistancemachinery.
Conclusions:miR-127,miR-409, andmiR-495, clustered to the 14q32 region are
subject to epigenetic control, which is altered in lapatinib resistant cells. Result-
ing upregulation of the miRNAs appears to post-transcriptionally regulate
genes, such as BASP1, involved in an acquired resistancemechanism to lapatinib
in HER2 positive breast cancer cell lines.
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#105 Depletion of extracellular cystine and cysteine by a mutagenized
human enzyme causes ROSmediated cytotoxicity in pancreatic cancer cells .
Sabin Kshattry, Achinto Saha, Shira Cramer, John DiGiovanni, Stefano Tiziani,
NathalieMunoz, George Georgiou, Everett Stone.University of Texas at Austin,
Austin, TX.
Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate
at 7%. The oncogeneKRAS that ismutationally activated in over 90%of PDACs,
has been shown to be involved in regulating redox homeostasis. Hence, pertur-
bation of oxidative balance might provide a therapeutic window to effectively
treat pancreatic cancer. One strategy to achieve this is to target the tripeptide
glutathione (GSH) – amajor intracellular antioxidant. Cysteine (Cys), which has
the functional moiety of GSH, can either be synthesized de novo or imported,
predominantly as cystine (CSSC) that is then reduced intracellularly to Cys. In
cancer, intracellular Cys synthesis has to be supplemented with extracellular
import in order to fulfıl the excessive metabolic demand of proliferation, which
includes maintenance of oxidative balance through GSH synthesis. We hypoth-
esize that this increased requirement for Cys/CSSC import in tumor cells will
make them selectively sensitive to prolonged depletion of these amino acids in
the serum by a genetically engineered human enzyme called Cyst(e)inase. In
addition, we believe that combining Cyst(e)inase with other redox balance per-
turbing agents will produce a synergistic therapeutic effect. In our study, Cys-
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t(e)inase treatment of cultured pancreatic cancer cell lines (Panc1, MIA-PaCa2,
BxPC3) decreased intracellular Cys and GSH, and inhibited cell growth. Sensi-
tivity to Cyst(e)inase was correlated with ROS accumulation (Panc1MIA-
PaCa2BxPC3). Panc1 cells exhibited G2-arrest and apoptotic cell death fol-
lowing 24 hours of treatment whereas BxPC3 cells underwent only a G1-arrest
and no cell death even after 72 hours of treatment. Further mechanistic investi-
gation showed activation of AMP kinase and other stress related kinases (p38,
ERK and JNK), and DNA damage signaling (ATM) only in the more sensitive
cell lines. Inhibition of the mTORC1-p70S6K-S6 ribosomal protein signaling
pathway was observed in all 3 cell lines. Cyst(e)inase displayed synergistic cyto-
toxicitywhen combinedwith buthionine sulfoximine (GSHsynthesis inhibitor),
auranofın (thioredoxin reductase inhibitor), sulfasalazine (inhibitor of cystine
import) and the natural compound curcumin known to increase intracellular
ROS, indicating that concurrently inhibiting alternative cellular antioxidant
pathways or directly increasing intracellular ROSmight improve the anti-tumor
effıcacy of Cyst(e)inase. The effect of biweekly intraperitoneal Cyst(e)inase
treatment on growth of pancreatic cancer cell xenografts in nude mice will also
be reported. Collectively, the current data suggest that depletion of extracellular
Cys/CSSC using Cyst(e)inase may have utility either as a monotherapy or a
combination therapy for pancreatic cancer.
#106 Traditional medicinal plants effect on fıve cancer cell lines. Elbert L.
Myles. Tennessee State Univ., Nashville, TN.
Cancer refers to as a group of numerous diseases that can originate in various
parts of the body. From the beginning of human history natural compounds
have been used for medical purposes. Many of the most frequently used natural
compounds have their origin from plants. Plants are very diverse and responsi-
ble for the synthesis of a number different secondary compounds. Scientist and
non-scientist have taken advantage of these secondary compounds treatment of
a variety of diseases. In the current study, we are investigating the viability of
specifıc cancer cell lines after exposure to methanolic extracts from each of the
following plants. The plants are Costus, Fenugreek, and Rhamnus. The cell lines
used in this investigation are lung cancer (A549), colon cancer, (SW620 and
Colo320), breast cancer (BT549), and cervical cancer (HeLa). The determina-
tion of cell viability found inhibition. The three test compounds were methano-
lic extracts from the plants Costus, Fenugreek, and Rhamnus. All showed differ-
ent levels of viability and was dependent on the specifıc cell line.
#107 Mechanism of anticancer activity of BPS-001 (lyophilized leech sa-
liva extract). Amr Ammar,1 Emma Guns,1 Omer Kucuk,2 Abdualrahman Ab-
dualkader,3 Mohamed Alaama,3 A.B.M. Helal Uddin,3 Abbas Ghawi,3 Mo-
hamed Hassona1. 1Univ. of British Columbia, Vancouver, British Columbia,
Canada; 2Emory University, Atlanta, GA; 3International Islamic University Ma-
laysia, Kuantan, Malaysia.
Recent studies, investigating the composition and therapeutic potential of
leech saliva have identifıed many peptides and proteins with multiple therapeu-
tic properties including anti-thrombotic, antimicrobial and anti-metastatic. In
vitro anti-cancer effects were shown in breast, prostate and lung cells lines. In
vivo anticancer activity of the extract was shown in multiple breast and prostate
cancer xenografts studied by our lab. In our previous studies, BPS-001 was
non-toxic and demonstrated various activities including pro-apoptotic proper-
ties, inhibition of cellular adhesion, angiogenesis and downregulation of AR
expression. To investigate the affected pathways, mechanistic studies were car-
ried out using in vivo and in vitro treated samples. Protein expression in samples
was determined byWestern blotting of in vitro and in vivo samples. AR expres-
sion was measured using an eGFP reporter assay in LNCaP cells, with PSA also
measured in themedia using cobas e 411 analyzer. BPS-001 inhibited Proteinase
Activated Receptor 1 (PAR-1) which is responsible for hormone like cellular
signals in different cancer cells including those of the breast and prostate. More-
over, in LNCaP cells AR activation and PSA expression were signifıcantly inhib-
ited after treatment with BPS-001. Inhibition of PI3K and PLCG2 were also
observed. It has been found that BPS-001 modulates a plethora of pathways
which makes it a very promising candidate for treatment of cancer with an
important advantage of low toxicity and potential resistance.
#108 In vitro and in vivo characterization of novel scorpion venom-based
peptides for the treatment of colon cancer.BinLi,HangFaiKWOK.University
of Macau, Macau, China.
In the last decade,many of the venom-based bioactive peptides demonstrated
with a broad and diverse spectrum of pharmacological activities, which help to
enlarging the current drug-screening library for searching of new specifıc bio-
markers and novel prototype drugs for diagnosis of diseases such as cancer.
Moreover, it paved a new insight to overcome the current drug discovery prob-
lems, which including drug resistance problem, side effect and so on. Here we
report the discovery of a panel of novel venom-based peptides, which can sig-
nifıcantly inhibit the growth of human colon cancer cells. Through our in-house
developed high throughput screening techniques and bioinformatics analysis,
we successfully isolated eight novel peptides from scorpion venoms with anti-
cancer activities. We performed a series of anti-proliferative assays to demon-
strate that these peptides could inhibit the growth of a broad spectrum of tumor
cells, especially in human colon cancer cell line; while almost have no effect on
normal human epithelial cells.Haemolysis assaywas also performed to showour
peptides do not cause any harm on normal human red blood cells, which point
to the direction of bringing those peptides into the preclinic trial studies. Before
the in vivo studies, we are currently investigating the anticancer mechanisms
and involved signal pathways of these peptides. LDHassay and real-time live cell
analysiswere performed, and from those data it indicates that the peptidesmight
actually work by inhibiting the cancer cell growth instead of disrupt their cell
membrane directly. Flow cytometry and western bolt results also showed that
the peptides have a signifıcantG1 phase cell cycle arrest effect through inhibiting
cyclin dependent kinases CDK4 and up-regulating the expression of cell cycle
protein regulator Cyclin D3, p27, p21.Moreover, from our current data, it dem-
onstrated that our peptides wouldn’t induce any apoptosis during the cell cycle
process. With the solid anticancer mechanism/pathway data, the potential anti-
cancer peptides to target in vivo malignant tumor will be evaluated in cancer
xenograft animal model to demonstrate the growth inhibitor activity of our lead
peptides. In summary, our study demonstrate that our peptides can inhibit tu-
mor cell growth via cell-cycle arrest, and almost have no cytotoxicity on human
epithelial cells, which could lead our lead peptides to further clinical investiga-
tion for the new strategy of peptide mono-/combination therapy.
#109 Effects of trifluoperazine analogue onA549 human lung cancer cells.
Joo Yeon Jeong, Jinhyun Ryu, Nal Ae Yoon, Seokmin Kang, Hyemin Seong,
Ahmad Fudhaili, Juyeong Park, Jimin Sim, Jiyeon Lee, Soohyun Hwang, Sang
Soo Kang. Gyeongsang National University, Jinju, Republic of Korea.
Although there have been great advancement in technology, molecular diag-
nosis, therapeutics, lung cancer is still the leading cause of cancer related mor-
tality all over the world. Recently, some antipsychotic drugs have been shown to
possess the anticancer activity. Thus the present study was designed to evaluate
the anticancer effects of trifluoperazine (TFP), a commonly used antipsychotic
drug, and its synthetic analogs on human lung cancer cell lines. To this end,
effects of TFP and its selected analog on A549 cells were investigated in vitro as
well as in vivo experiments. Synthetic TFP analogs were evaluated by the viabil-
ity of A549 cells following drug treatment and compared to TFP. KCFC51, a
selected TFP analog, signifıcantly inhibited the proliferation of A549 cells. Fur-
ther experiment showed that TFP and KCFC51 had activities to inhibit the
migration, and anchorage dependent/independent colony formation of A549
cells. Western blot analysis revealed that TFP and KCFC51 affect the protein
expression levels related to cell apoptosis and cell cycle. KCFC51 showed stron-
ger anticancer effects in all the experiment than TFP. Flow cytometric analysis
showed that KCFC51 induced sub-G1 population and reduced cell population
in S andG2/Mphase. In addition, the two in vivo experimentalmodels, KCFC51
also showed powerful anticancer effect in skin xenograft tumor growth and
orthotropic lung cancer development than TFP. Thus present study demon-
strates that a synthetic TFP analog has anti-lung cancer activity and provides a
potential therapeutic candidate for lung cancer.
#110 Quantitative high throughput screening as a tool to identify novel
therapies in bladder cancer. Reema Railkar, Thomas Sanford, L. Spencer
Krane, Piyush K. Agarwal. NCI-NIH, Bethesda, MD.
Introduction: Bladder cancer (CaB) is the 4th most common cancer among
men in the US. It is the most expensive malignancies to treat from diagnosis to
death. No new pharmacological agents have been approved for treatment of
bladder cancer since the approval of BCG in 1990. Thus, there is an urgent need
for development of new treatment therapies. Quantitative high throughput
screening (qHTS) of representative cancer lines with oncology drugs may iden-
tify new treatments or re-purpose already existing therapies for different disease.
We utilized this technique to identify new therapies in two primary bladder lines
(T24 and UMUC3) and their metastatic lines (T24T, SLT3 and FL3 of T24 and
LUL-2 for UMUC3). Methods: We screened 7 bladder cancer cell lines against
1,912 oncology drugs using a 48 hour cell proliferation assay with an ATP-
based readout (CellTiterGlo) to determine activity and potency of compounds
in a dose responsemanner. One of the candidate drugs inhibitory in all cell lines
tested is flavopiridol, a pan CDK inhibitor. We further characterized the mech-
anism of action and in vivo effects of flavopiridol using various cell based assays
and mouse xenograft studies. Results: The initial screen identifıed 95 com-
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pounds active in 7 cell lines. The top 50 compounds were further analyzed for
molecular size of200 g/mol and TPSA90. This identifıed mitomycin C and
8 novel compounds. Further testing revealed Flavopiridol to be most consistent
with qHTS data having IC50 of 100-300nM in all the cell lines tested. Flavopiri-
dol induces G2/M arrest; however, very little apoptosis was seen suggesting
cytostatic rather than cytotoxic mechanism of flavopiridol action. Flavopiridol
showed dose dependent inhibition ofmigration, invasion and colony formation
in CaB cell lines tested. Xenograft studies in rapidly growing UMUC-3 cells
showed slowing of tumor growth but not complete reduction indicating cyto-
static mechanism of flavopiridol. However, in slow growing cells, 5637, 5/8
treated mice showed complete tumor reduction. Conclusions: qHTS can iden-
tify novel compounds. Flavopiridol seems to be a very effective inhibitor both in
vitro and in vivo. Physical properties of Flavopiridol are most suited for intra-
vesical use whichmay lead to it being an effective inhibitor of CaB in the bladder
at higher doses without any/few systemic toxicities. Studies are underway to
elucidate the use of flavopiridol as a single intravesical agent.
#111 Targeting STAT3 and telomerase for the treatment of colorectal can-
cer. Seyung Chung,1 Quincy Okobi,2 Debbie Adekoya,3 Jaydutt Vadgama1.
1Charles Drew University, Los Angeles, CA; 2UC Santa Cruz, Los Angeles, CA;
3University of Dublin, Ireland.
There is an increasing evidence of pro-inflammatory cytokines involvement
in cancer development. Here, we found that two cytokines, IL-6 and TNF-,
induced colorectal cancer cells more active and invasive. Combined treatments
of IL-6 and TNF- phosphorylated transcription factors STAT3 in a synergistic
manner. STAT3 and NF-B physically interacted upon cytokine stimulation.
Similarly, STAT1 hetero-dimerized with STAT3 and the binding affınity was
enhanced with cytokine treatments. STAT3 bound the promoter region of hu-
man telomerase reverse transcriptase (hTERT), and IL-6 and TNF- stimula-
tion further enhanced this STAT3 binding affınity. Withaferin A, an anti-in-
flammatory steroidal lactone, inhibited the IL-6 and TNF- induced cancer cell
invasiveness and decreased colonosphere formation. Notably, withaferin A in-
hibited STAT3 phosphorylation and abolished the STAT3 and NF-B interac-
tions. STAT3 binding to hTERT promoter was inhibited and telomerase activity
was decreased with the withaferin A treatments. Taken together, pro-inflamma-
tory cytokines induced-cancer cell invasiveness ismediated by STAT3 regulated
mechanism in colorectal cancer cells. Our study suggests the novel natural com-
pound therapy for the metastatic colorectal cancer in clinical settings.
#112 Identifying drugs that target ovarian cancer tumor initiating cells.
Michelle K. Ozaki, Carrie D. House, Christina M. Annunziata.National Cancer
Institute, Bethesda, MD.
Ovarian cancer is the most lethal gynecological cancer, with overall fıve-year
survival for women with advanced disease being at only 25%. The current stan-
dard of care is treatment with a platinum-based chemotherapy drug. Unfortu-
nately, a subpopulation of tumor cells often persists, contributing to platinum-
based chemotherapy resistance and disease recurrence. In this study we
investigated drugs to target these putative tumor-initiating cells (TICs), and
explored the pathways of these drugs in both adherent proliferative cell culture
conditions and non-adherent TIC-enriched cultures. We conducted a drug
screen under both growth conditions, in order to identify compounds that are
able to inhibit growth of TICs. Of the drugs identifıed, we focused further efforts
on those involved with inhibiting the NF-kappaB pathway because prior studies
have linked NF-kappaB activity with drug resistance and poor survival. Cell
viability assays done with the four drugs, bardoxolone methyl, salinomycin,
disulfıram, and elesclomol, show these drugs inhibit the growth of ovarian can-
cer cell lines both as TICs and in corresponding adherent cultures. Disulfıram
showed preferential killing of TICs in some of the cell lines tested. All drugs
showed some evidence for inhibitingNF-kappaB onWestern blot, and ability to
decrease CD133/ALDHdouble-positive TICs on flow cytometry. Carboplatin is
known to kill proliferative ovarian cancer cells, and increase the relative percent-
age of CD133/ALDH positive TICs. Our ongoing studies will address combina-
tion of each drug with carboplatin, with the hypothesis that these drugs will
increase in vivo effıcacy by suppressingTICs, and thereby decrease recurrence of
platinum-resistant ovarian cancer.
#113 Evaluating the anticancer activity of two flexible heteroarotinoid
analogs on breast cancer. Emily Ginn,1 Hongye Zou,1 Maryam M. Fallatah,1
Shengquan Liu,2 Maggie C. Louie1. 1Dominican University, San Rafael, CA;
2Touro University, Vallejo, CA.
Flexible heteroarotiniods (flex-hets) are compounds derived from retinoic
acid and recent studies have indicated that these compounds exhibit anti-
cancer activity. Amongst the flexible heteroarotinoids, SHetA2 has been to
shown block the growth of cervical, head and neck, kidney, lung, and ovarian
cancers, and most recently, prostate and breast cancers. However, due to
SHetA2’s limitations— a high degree of hydrophobicity, non-selectivity, and
potential liver toxicity— a second generation of analogs was developed. Re-
sults from our recent study suggest that one of the second-generation ana-
logs, 1-(1-(naphthalen-1-yl)ethyl)-3-(4-nitrophenyl)thiourea (SL-1-09) ex-
hibits anti-cancer activities against both ER and ER- breast cancer cells at
micromolar concentrations. Since SL-1-09 is a racemic mixture, the R (SL-
1-29) and S (SL-1-30) enantiomers were purifıed and investigated for their
anti-cancer properties. Our results suggest that SL-1-30 has greater growth
inhibitory effects on T47D, MCF7, MDA-MB-453, MDA-MB-468 cells in
comparison to SL1-29, suggesting that the activity observed in SL-1-09 is
likely associated with the S enantiomer. Consistent with this data, breast
cancer cells treated with SL-1-09 and SL-1-30 express lower levels of proteins
that regulate the cell cycle (i.e, cyclin A, cyclin B, cyclin D1, cyclin E and
cdk2). These results demonstrate that SL-1-30 and SL-1-09 inhibit breast
cancer cell growth, potentially by blocking cell cycle progression, however
further studies are necessary for determining the mechanisms of action.
#114 TG02 induces cell cycle arrest in glioblastoma. Yu-Ting Su, Robert
Chen, Hallie Lappin, HeruiWang, DraganMaric, Orieta Celiku, Aiguo Li,Mark
R. Gilbert, Jing Wu. NIH, Bethesda, MD.
Dysregulated cell cycle contributes to the limitless replicative potential of
cancer cells. The cyclin-dependent kinases (CDKs) and cyclins, the CDK-
regulatory proteins are the key cell cycle machinery and can be targets for
cancer therapy. TG02, a pyrimidine-based multi-kinase inhibitor has an
anti-glioma effect which was demonstrated by our previous studies. An in
vitro kinase spectrum assay of TG02 demonstrated inhibitory effects in sev-
eral CDKs at the nanomolar level. To further investigate the molecular
mechanisms of TG02-induced cell cycle regulation in glioma, a cell cycle
analysis was performed by flow cytometry using the Click-It Edu Flow Cy-
tometric Assay Kit in GSC923 andU251 cell lines, a human stem-like cell and
patient derived cell line, respectively. Protein expression of CDKs and cy-
clins was tested by Western blotting. RNAseq analysis using Next Genera-
tion Sequencing was performed (only GSC923) and followed by a supervised
hierarchical clustering analysis of cell cycle pathways that were derived from
Qiangen’s Ingenuity Pathway Analysis (IPA). Our results showed that TG02
treatment results in G2/M-phase arrest in glioma cell lines. The protein
expression of CDK1, CDK2, cyclin A2 and cyclinB1 are downregulated in
both TG02 treated cell lines. Additionally, RNAseq analysis revealed down-
regulation of cyclins A2, B1 and B2 and signifıcant irregulation in mRNA
expression of G2/M checkpoint and spindle formation proteins, indicating
G2 checkpoint and mitosis progression are also affected by TG02. Taken
together, we demonstrated that TG02 induced cell cycle G2/M arrest
through downregulating CDK and cyclin expression signaling in the preclin-
ical models of glioblastoma. These fındings strongly support the further
investigation of TG02 as a potential therapy for malignant gliomas.
#115 Flubendazole targets cancer stem-like properties and the HER2/Akt
signaling pathway in HER2-positive breast cancer with trastuzumab resis-
tance.Daeil Sung, Youngkwan Cho, Eunhye Oh, Tae-Min Cho, Yoon-Jae Kim,
Ji Young Kim, Jae hong Seo. Korea University, Seoul, Republic of Korea.
Background and Propose: HER2-positive breast cancers are associated with
an aggressive phenotype and trastuzumab resistance leading to poor clinical
outcomes. Flubendazole (FLU) is a potent anthelmintic agent that inhibits mi-
crotubule polymerization, and also exhibits anticancer activity in several cancer
types. The objective of the present study was to investigate the effect of FLU on
apoptosis, HER2/Akt signaling pathway, cancer stem cell (CSC)-like properties
and trastuzumab-resistance in HER2-positive breast cancer cells. Methods:
FLU-induced antitumor effects were characterized by MTS assay, Sub-G1 and
G2/M-phase arrest population, Annexin-V analysis, ALDH1 activity assay,
Western blotting and immunofluorescence. For in vivo study, trastuzumab-
resistant JIMT1 cells were injected into the mammary fat pads of BALB/c nude
mice. We then determined the tumor growth and CSC-like properties. Results
and conclusion: FLU signifıcantly reduced cell viability and induced apoptosis
with accompanied by activation of caspase-3, -7, and -8, as well as PARP cleav-
age in HER2-positive cell lines (MDA-MB-453, SKBR3 and BT474). FLU-in-
duced apoptosis is associated with signifıcant decreases in expression levels of
HER2, p-HER2 (Tyr1221/1222), HER3, and p-HER3 (Tyr1289). FLU treatment
also resulted in G2/M-phase arrest of the cell cycle, as evidenced by a marked
downregulation of phospho-Histone H3 expression. These results were closely
related to the decline of CSC-like properties, coinciding with the suppression of
ALDH1 activity. These effects were also observed in trastuzumab-resistant
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JIMT-1 cells, and signifıcant reductions in tumor growth and ALDH1A1 down-
regulation were observed in xenograft models together with downregulation of
HER2 expression in vivo. Our fındings suggest that FLU may be potentially
effective for the treatment of HER2-positive breast cancer with trastuzumab
resistance.
#116 Erufosine, a third-generation alkylphosphocholine with cytotoxic
and cytostatic effects in breast and colorectal cancer cells. Asim Pervaiz,1
Saqib Mahmood,1 Martin R. Berger2. 1Univ. of Health Sciences, Lahore, Paki-
stan; 2German Cancer Research Center (DKFZ), Heidelberg, Germany.
Introduction: Breast and colorectal cancers are highlymalignant diseaseswith
low 5-year survival rate (21%) in advanced stages, which highlights the need of
fınding new therapeutic options. Considering this, we are interested in exploring
the anticancer potential of erufosine, a membrane targeting synthetic lipid ana-
logue belonging to a class of antineoplastic agents known as alkylphosphocho-
lines (APCs). Properties such as intravenous administration and signifıcantly
reduced hemolytic activity as compared to previous APC generations, and effı-
cient cytotoxic effects against malignant cells make it an attractive anticancer
compound. Materials and Methods: In the present experiments, we studied the
effects of erufosine against breast (MDA-MB-231 and MCF-7) and colorectal
(SW480 and SW620) cancer cell lines. Following exposure to erufosine (0.78-
100M) for 24, 48 and 72h, cytotoxic effects were measured byMTT dye reduc-
tion assay and inhibitory concentrations (IC) were identifıed by GraphPad
Prism software 6. Erufosine mediated cytostatic effects were highlighted by
means of propidium iodide (PI) based labeling of the DNA followed by flow
cytometry analysis. Furthermore, the cells were exposed to increasing concen-
trations of erufosine (IC25, 50, 75) and alterations in cell cycle relevant genes
(CCNA1, CCND1, CCNE1, CCNE2, CDK1, CDK4) were investigated by
qRT-PCRmethodology. Results Erufosine was highly active against the selected
cell lines (IC50 10M, 24h) and induced signifıcant arrest in the G2/M phase
of the cell cycle. The cytostatic effects were more pronounced in the two meta-
static cell lines of breast (MDA-MB-231) and colorectal (SW620) cancers. At
molecular levels, erufosine induced expression of CCNA1 (	 2fold) in SW480,
SW620, and MCF-7 cells, while the expression was inhibited in MDA-MB-231
cells at high concentrations (IC50, IC75). Therewere no signifıcant alterations (
2fold) in the expression levels of CCND1, CCNE1 and CDK4 in the four cell
lines. CCNE2 was signifıcantly downregulated in breast cancer cell lines only.
Noteworthy, alterations in CDK1 were associated with cell lines from primary
cancers, where the expression was upregulated in SW480 cells and downregu-
lated in MCF-7 cells. Conclusion: Antineoplastic effects of erufosine contribute
to decreased proliferation of breast and colorectal cancer cell lines. This syn-
thetic lipid induces arrest in G2/M phase and alterations in cell cycle relevant
genes in the selected panel of breast and colorectal cancer cells. Characteristics
like in vivo stability,minimal hemolytic activity, no toxicity to bonemarrow and
antineoplastic effects (cytotoxic/cytostatic) against cancer cells make it an at-
tractive therapeutic compound. Further understanding at molecular levels sup-
ported by in vivo experimentation will pave the way to validate its therapeutic
potential against cancers.
#117 Anti-proliferative and cytotoxic effects of verteporfın in endometrial
cancer cells.Radhika P. Gogoi,1 JessicaM. Castañeda-Gill,2 Raghu P.Metpally,1
Sarath B. Krishnamurthy,1 Jamboor K. Vishwanatha,2 David J. Carey,1 John D.
Nash,1 Venkata Ramesh Dasari1. 1Geisinger Health System, Danville, PA; 2Uni-
versity of North Texas Health Science Center, Fort Worth, TX.
Endometrial cancer (EMCA) is the most prevalent gynecologic cancer in
women in the United States. The relatively poor prognosis and limited thera-
peutic options in advanced endometrial cancer underscores the urgency in de-
veloping new and more effective treatment modalities. On the basis of clinical
and histopathological features, EMCA is classifıed into type I and type II disease
groups. Type 1 is estrogen potentiated, estrogen receptor (ER) and progesterone
receptor (PR) positive, and generally carries a favorable prognosis. Type 2 is
ER/PR negative and carries a much poorer prognosis. We investigated the ther-
apeutic effıcacy and mechanism of action of Verteporfın (VP), a benzoporphy-
rin derivative in EMCA. Treatment with VP resulted in a decrease in cell viabil-
ity, invasion and an increase in cytotoxicity of EMCA cells. Similarly, VP
treatment increased apoptosis in organoids, developed from patient-derived
xenografts. Since the half-life of verteporfın is very short, we evaluated the longer
duration effıcacy of VP, encapsulated in mPEG-PLGA polymers. Our results
demonstrated that VP nanoparticles (NP) decreased cell viability in both Type 1
(HEC-1-B) and Type 2 (ARK-1) EMCA cell lines over a period of 4 days.We did
not observe any lethal effects of blank NP to the EMCA cells. In order to deter-
mine the effıcacy of VP in changing cellular transcriptome, we performed
RNASeq of EMCA cells after treatment with VP. RNASeq data analysis was
carried out using latest version of Kallisto and Sleuth software. Based on the
global gene expression whole transcriptome analysis, we observed that HEC-
1-A VP treated cells show 225 differentially expressed transcripts (out of 204
genes); whereas HEC-1-B VP treated cells show 12315 differentially expressed
transcripts (out of 7870 genes). There were 114 differentially expressed tran-
scripts (out of 105 genes) common to both the cell lines.We observed that ATM,
ATR, BRCA2, CDK4, ERBB2, JAK2, NF1, NOTCH and TET2 are some of the
differentially expressed genes after VP treatment. To test the effıcacy of VP
under in vivo conditions, we developed a subcutaneous mouse model of EMCA
using HEC-1-B-GFP cells. IP administration of VP in this model achieved 21%
tumor regression. To more accurately simulate the results in vivo in a clinically
relevantmodel, we have developed an orthotopic tumormodel with IV injection
of VP. Taken together, our results suggest that VP is a promising chemothera-
peutic agent for the treatment of endometrial cancer.
#118 Targeting cancer with a novel BET bromodomain inhibitor ODM-
207. Anu-Maarit Moilanen,1 Mari Björkman,1 Reetta Riikonen,1 Chan-
drasekhar Abbineni,2 Mahaboobi Jaleel,2 Sivapriya Marappan,2 Tarja Ikonen,3
GirishDaginakatte,2 AravindAB,2 ElinaMattila,1 Juha Rantala,4 Susanta Sama-
jdar,2 Murali Ramachandra,2 Pekka Kallio1. 1Orion Corporation Orion Pharma,
Turku, Finland; 2Aurigene Discovery Technologies Limited, Bangalore, India;
3Orion Corporation Orion Pharma, Finland; 4Misvik Biology, Turku, Finland.
Background: Bromodomain and extra-terminal (BET) family proteins are
dual bromodomain-containing epigenetic readers that bind to acetylated-lysine
residues at gene promoter and enhancer elements in histones and recruit protein
complexes to promote transcriptional elongation. Recent evidence demon-
strates that BET bromodomain inhibition leads to anti-proliferative activity in
pre-clinical models of many hematological malignancies and solid tumors. Se-
lective inhibition of BET bromodomains by small molecule inhibitors has
emerged as a promising therapeutic strategy for the treatment of cancer. In this
study, we evaluated the antitumor activity of ODM-207, a novel, potent and
highly selective BET bromodomain inhibitor. Methods and Results: ODM-207
is a potent and selective BET inhibitor that is structurally unrelated to the ben-
zodiazepine like inhibitors such as JQ1, I-BET762, and OTX015. We tested the
preclinical activity of ODM-207 across multiple tumor types in a 4-day growth
inhibition in vitro assay.ODM-207 potently inhibits cell viability of awide range
of hematological and solid tumor cell lines. ODM-207 also shows potent anti-
proliferative effects in patient-derived cancer cells representing various tumor
types. In VCaP prostate cancer cell lines, ODM-207 induced apoptosis consis-
tent with increased expression of pro-apoptotic regulators, whereas potent an-
tiproliferative effects associated with cell cycle arrest and cellular senescence
were seen in e.g. LNCaP prostate cancer cell line. To gain insight onmechanisms
of acquired BET inhibitor resistance, we generated a cell line with resistance to
BET-inhibition by culturing LNCaP prostate cancer cells with increasing con-
centrations of OTX015, a potent and selective BET-inhibitor. Interestingly,
ODM-207 is also able to inhibit proliferation and downregulate Myc levels in
cells that have acquired resistance to BET-inhibitors OTX015 and I-BET762. In
xenograft models, oral treatment with ODM-207 signifıcantly inhibits tumor
growth at a dose which is well tolerated. Conclusions: In summary, these studies
demonstrate that ODM-207 is a potent inhibitor of BET proteins in models of
hematologic malignancies and solid tumors in vitro and in vivo and support its
clinical development for the treatment of cancer.
#119 Vitamin K2 targets castration-resistant prostate cancer VCaP cells
by reactive oxygen species mediated apoptotic cell death. Subramanyam
Dasari,1 Maarten C. Bosland,2 Andre Kajdacsy- Balla,2 Gnanasekar Munirathi-
nam1. 1University of Illinois, College of Medicine at Rockford, Rockford, IL; 2Uni-
versity of Illinois at Chicago, Chicago, IL.
Prostate Cancer (PCa) is the second most common cancer in western countries
especially inUSpopulation, inwhich castration-resistant prostate cancer (CRPC) is
themajor cause forpatientmortality.Current treatmentoptions available forCRPC
are not effıcient and have undesirable side effects. Hence there is an urgent need to
developnon-toxic andeffective treatment strategies forCRPC.VitaminK2(VK2), a
natural menaquinone has several medicinal values including anti-cancer activity
and anti-osteoporosis effect. The aim of this study is to evaluate the therapeutic
effects of Vitamin K2 (VK2) and its anti-cancer mechanism against CRPC. In this
study, we have usedVCaP cell line (ATCC)which is established fromapatientwith
hormone refractory prostate cancer. VCaP cells were treated with various concen-
trations of VK2 to evaluate its effects on cell viability by MTT assay, anchorage
independent growth by soft agar assay, cellular senescence by beta-galactosidase
staining assay and cancer cell migration by wound healing assay. We have also
assessed theVK2-inducedproductionof intracellular reactiveoxygen species (ROS)
usingDCF(2=,7=-dichlorofluorescein)probebased fluorescenceassay.VK2induced
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apoptosis was detected byAnnexin-V FITC andTUNEL assays.Western blot anal-
ysiswasutilized touncover theanti-proliferative andanti-metastaticmechanismsof
VK2 against CRPC.Our results showed that VK2 signifıcantly inhibits the prolifer-
ation of VCaP cells in a dose dependent manner at 48 hrs treatment in vitro. MTT
data also showed that anti-proliferative effects of VK2 were signifıcantly abrogated
in the presence of anti-oxidant N-acetyl cysteine (NAC) and caspase inhibitor Z-
VAD-FMK suggesting that ROS and caspase activation as the underlying anti-can-
cer mechanisms of VK2 in CRPC cells. In addition, VK2 reduced the migration
potential of VCaP cells in wound healing assay and inhibited anchorage indepen-
dent growth of these cells when compared to untreated cells. Annexin-V and
TUNELassaysconfırmedthatVK2 inducesapoptosis inVCaPcells.Our results also
suggested that the VK2 has the ability to enforce growth arrest in CRPC cells by
activating cellular senescence. Western blot analysis revealed that VK2 downregu-
lated the expression of BiP, survivin,MMP-2, and PCNAwhile activating PARP-1,
p21 and DNA damage response marker, phospho-H2AX in VCaP cells. Further-
more, VCaP cells treated with VK2 resulted in the activation of Caspase-3 and-7
apoptotic mediators. These results correlated with translocation of Bax and Cyto-
chrome C to cytoplasm following VK2 treatment in VCaP cells as determined by
confocal immunofluorescence analysis. In conclusion our study suggests that VK2
might be an effective anti-proliferative and anti-metastatic agent for CRPC by spe-
cifıcally targeting key anti-apoptotic, cell cycle progression andmetastasis promot-
ing signalingmolecules.
#120 A study of in vitro and in vivo effects of a novel peptide and rhenium
compounds on prostate cancer.HirendraN. Banerjee,1 SashaHodge,1William
Kahan,1 Santosh Mandal,2 DavidWeber,3 Rena Lapidus,4 Fazlul Sarkar,5 Somi-
ranjan Ghosh6. 1Elizabeth City State University, Elizabeth City, NC; 2Morgan
State University, Baltimore, MD; 3University of Maryland Medical School, Balti-
more, MD; 4Greenbaum Cancer Center, University of Maryland, Baltimore, MD;
5Wayne State University Koromanos Cancer Center, Detroit, MI; 6Howard Uni-
versity, Washington, DC.
Emerging evidence suggests that acquisition of the epithelial-to-mesenchy-
mal transition (EMT), a process that resembles the genesis of cancer stem-like
cells, contributes to tumor aggressiveness and is mediated by deregulated ex-
pression of microRNAs (miRNAs), such as miR-200 and let-7 family. Loss of
miR-200 expression results in the over-expression of Lin28B, which is prevalent
in human Prostate Cancer( PCa) . Lin28B is also known to block the processing
of another miRNA (pre-let-7 and pri-let-7), resulting in decreased mature let-7,
thereby leads to increased Suz12 and EZH2 expression, which are important
components of the polycomb repressive complex 2 (PRC2). Thus, over- expres-
sion of Lin28B and loss of miR-200 and let-7 appear to be responsible for PCa
aggressiveness. A group of novel rhenium compounds have shown promising
anti-cancer properties in various cancer cell lines tested in our laboratories. Our
current investigations show that re-expression ofmiR-200b,miR-200c, and let-7
could be achieved by treating cells with our newly developed rhenium com-
pounds by down-regulating the expression of Lin28B and EZH2. Based on our
preliminary results, we hypothesize that over-expression of Lin28B leads to the
acquisition of invasive and metastatic characteristics in PCa cells (EMT-pheno-
type cells) via down-regulation of miR-200b and miR-200c, resulting in in-
creased expression of Suz12, ZEB1, and ZEB2. We also hypothesize that over-
expression of Lin28B represses the maturation of let-7 family, leading to
increased expression of EZH2, and these processes can be attenuated by treat-
ment of cells with novel rhenium compounds in vitro. Our experiments were
done on prostate cancer cell lines derived frombothCaucasian(CA) andAfrican
American (AA)patients and also biopsy samples obtained frombothCAandAA
patients at Henry Ford Hospital and Karmanos Cancer Center of Wayne State
University, Detroit, MI. We confırmed using gene expression studies by micro
array and Real-Time PCR and then data analysis by Ingenuity software system-
the validity of our hypothesis and continued our research by testing one of these
rhenium compounds-RPR1 on prostate cancer model of nude mice at Green-
baum Cancer Center(GCC) of University of Maryland at Baltimore. In vitro
studies by Real -Time PCR, Flow Cytometry, Western Blotting ,Smart-Flare
technology, cell death and proliferation assays along with inhibition of spheroid
forming assays showed effıcacy of these rhenium compounds as anti cancer
agents. In vivo studies also showed decrease of tumor volume and mass ,no
toxicity, thus effıcacy of these novel drugs. ACKNOWLEDGEMENT: Sup-
ported by NIH- 3R01CA164318-03S1 and NIH-T-34-GM100831, a NSF-VES-
TEM award and NSF-LSAMP award .
#121 Identifıcation and characterization of calcium channel blockers as
inhibitors of YAP/TAZ and glioblastoma cells. Wei Li, Zhijun Liu, Jennifer
Xavier, Hong-Gang Wang. Penn State Univ. College of Medicine, Hershey, PA.
Glioblastomas (GBM) are the most aggressive primary brain tumors. De-
spite major advances in neuroimaging and neurosurgical techniques over
the past decades, the neurosurgical management of GBM patients remains
challenging. Median survival of the patients is about 14.6 months. In order to
radically alter the clinical course of these tumors, it is important to develop
targeted therapies based on identifıed oncogenic mutations and signaling
pathways that drive their development and sustain their maintenance. In a
screen for small molecules, which can inhibit the growth of human glioblas-
toma cells, we identifıed a set of calcium channel blockers (CCB). We found
that these CCB induce cell death through an apoptosis-independent process.
To understand the mechanisms of the non-apoptotic cell death induced by
these CCB, we dissected cellular signaling which is responsible for the cell
death induction. We found that these CCB are able to inhibit YAP and TAZ,
two oncogenic effectors of the Hippo tumor suppressor pathway. Impor-
tantly, GBM cells expressing the YAP active mutant or overexpressing YAP
are less sensitive to these CCB. These results suggested that inhibition of
YAP/TAZ is a mechanism by which CCB suppress tumor cell growth. The
Hippo pathway is an essential signaling network in regulating tissue homeo-
stasis. In this pathway, the transcription co-activators YAP and TAZ pro-
mote a gene expression program favoring cell proliferation, survival and
self-renewal. In normal brain, the nuclear accumulation of YAP is largely
limited to regions harboring neural progenitor cells. However, increased
nuclear accumulation of YAP is found in various brain tumors, especially
those more aggressive subsets of gliomas. In addition, high expression of
YAP is associated with reduced mean survival in astrocytoma patients. Our
results identifıed a novel approach to target the Hippo pathway for GBM
treatment. We will present our work in further characterizing these regula-
tions and therapeutic potentials of these calcium channel blockers in the
conference.
#122 Preclinical update on targeting KRAS wild-type colorectal cancer
with an EGFR-targeted monoclonal tri-body mixture, MM-151. Shawn P.
Carey, HongfangWang, Erika Handly, Brittany Ahlstedt, Daniel Gaddy, Jeffrey
D. Kearns, Greg Finn, Birgit Schoeberl, Rachel Nering.Merrimack Pharmaceu-
ticals, Cambridge, MA.
Within KRAS wild-type colorectal cancer (KRAS-wt CRC), standard of
care treatment includes EGFR-directed monoclonal antibodies (mAb) in
combination with an irinotecan-based chemotherapy regimen. While such
combinations have clinically established synergy, the underlying mecha-
nisms of synergy remain elusive, and resistance invariably develops against
either the EGFR-targeted therapy or irinotecan, leaving patients with limited
treatment options. MM-151 consists of three anti-EGFR IgG1 mAbs that
bind simultaneously to non-overlapping epitopes on the EGFR extracellular
domain (ECD). Preclinical and clinical studies have demonstrated that oli-
goclonal targeting of EGFR with MM-151 results in blockade of the EGFR
pathway via potent inhibition of ligand-driven signal amplifıcation and re-
ceptor downregulation. Critically, these activities are uniquely maintained
in the presence of high-affınity EGFR ligands as well as mutations in the ECD
of EGFR, both of which drive resistance to cetuximab and panitumumab.
Here, we tested the preclinical hypothesis that comprehensive inhibition of
the EGFR pathway by MM-151 leads to enhanced antitumor activity when
combined with chemotherapy inmodels of KRAS-wt CRC. In vitro studies to
investigate the activity of MM-151 in combination with SN-38, the active
metabolite of irinotecan, showed that MM-151 potentiates SN-38-induced
cell death in KRAS-wt CRC models. Treatment with MM-151 potently sup-
presses EGFR pathway activation caused by SN-38, and the combination
enhances stress and pro-apoptotic signaling, leading to increased apoptosis.
Notably, these synergistic activities are maintained in the presence of two
key mechanisms of resistance to cetuximab: high-affınity ligands and EGFR
ECD mutations. Dose scheduling studies demonstrated that sustained treat-
ment withMM-151 following transient SN-38 exposure - a hallmark of small
molecule therapy - partially overcomes the sub-optimal activity of chemo-
therapy alone. Finally, data from in vivo xenograft and PDX studies strongly
supports the addition of MM-151 to irinotecan-based chemotherapy regi-
mens for KRAS-wt CRC. In summary, we present data supporting the hy-
pothesis that comprehensive antagonism of the EGFR pathway via oligoclo-
nal targeting of EGFR with MM-151 leads to antitumor activity when
combined with chemotherapy in preclinical KRAS-wt CRC models. The
ability of MM-151 and SN-38 to overcome both de novo and acquired mech-
anisms of resistance within CRC models supports further clinical evaluation
of this combination in metastatic CRC patients.
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#123 A novel J-series prostamide mediates D-series prostamide-induced
apoptosis in skin cancer: receptor-independent signaling. Eman Soliman,1
Daniel Ladin,2 Hussam Albassam,2 Ahmed E. Elhassanny,2 Andrew Morris,3
Allison Danell,3 Rukiyah VanDross4. 1Faculty of Pharmacy, Zagazig University,
Zagazig, Egypt; 2Brody School of Medicine, East Carolina University, Greenville,
NC; 3Department of Chemistry, East Carolina University, Greenville, NC; 4Brody
School of Medicine and Center for Health Disparities East Carolina University,
Greenville, NC.
Non-melanoma skin cancer (NMSC) is the most common cancer in the
United States. The absence of selective toxicity is amajor problem that limits the
utility of chemotherapeutic and radiation therapy for NMSCs. Our previous
data showed that the endocannabinoid, anandamide, selectively induced apo-
ptosis in non-melanoma skin cancer (NMSC) cells which overexpress cycloox-
ygenase-2. The cytotoxic effect of anandamide was mediated by the production
of ethanolamide-conjugated D- and J-series prostaglandins (PGs), also known
as prostamideD2 (PMD2) and prostamide J2 (PMJ2), respectively. The aimof the
current study was to determine if tumorigenic keratinocytes are more sensitive
to PMD2 than non-tumorigenic cells and to examinewhether the cytotoxicity of
PMD2 is mediated by its downstream metabolite PMJ2. To determine if PMD2
demonstrates preferential toxicity, tumorigenic (JWF2) and non-tumorigenic
(HaCaT) keratinocytes were utilized. A signifıcant reduction in cell viability was
observed in JWF2 but not in HaCaT cells treated with PMD2. In tumorigenic
keratinocytes, PMD2 induced apoptotic cell death, oxidative stress and in-
creased the expression of apoptotic ER stress protein, C/EBP homologous pro-
tein-10 (CHOP10). In addition, use of the antioxidant, trolox, and ER stress
inhibitor, salubrinal, inhibited the cytotoxic effect of PMD2. Furthermore, the
use of prostaglandin D receptor (DP1 and DP2) antagonists did not inhibit
PMD2-induced apoptosis indicating that the activity was mediated by a recep-
tor-independent pathway. Similar effects were observed in keratinocytes treated
with the structurally-related arachidonic acid metabolite, prostaglandin D2
(PGD2). Interestingly, PMD2 increased the production of J-series prostaglan-
dins in both tumorigenic and non-tumorigenic keratinocytes. LC-ESI-MS/MS
analysis detected ethanolamide- conjugated J series PG (15-deoxy, 	12,14 pros-
tamide J2, 15d-PMJ2) in PMD2-treated cell culture media. Since selective inhib-
itors of the J-series prostaglandins are not available, 15d-PMJ2 was synthesized
to examine its direct activity. Exogenous 15d-PMJ2 mimicked the activity of
PMD2 demonstrating preferential cytotoxicity towards tumorigenic compared
to non-tumorigenic keratinocytes. In addition, 15d-PMJ2 induced oxidative
stress, ER stress and apoptosis in tumorigenic keratinocytes. These fındings
suggest that the cytotoxicity of PMD2 is mediated by 15dPMJ2. Since PMD2 and
its metabolite 15d-PMJ2 are preferentially toxic towards tumorigenic cells,
PMD2 or 15d-PMJ2 may be an ideal topical treatment for NMSC that will elicit
minimal toxicity in healthy surrounding skin cells.
#124 Imipridone ONC201 promotes intra-tumoral accumulation of
CD3/NK cells that contribute to its anti-tumor effıcacy. JessicaWagner,1
C. Leah Kline,1 Lanlan Zhou,1 Andrew Zloza,2 Charles Chesson,2 Jenna New-
man,2 Howard Kaufman,2 Joseph Bertino,2 Mark Stein,2 Wafık El-Deiry1. 1Fox
Chase Cancer Center, Philadelphia, PA; 2Rutgers Cancer Institute of New Jersey,
New Brunswick, NJ.
ONC201, a fırst-in-class oral anti-tumor agent, upregulates the pro-apoptotic
immune cytokine TRAIL and activates the integrated stress response leading to
upregulationof death receptor 5 inbulk tumor and cancer stemcells.Wepreviously
demonstrated thatONC201 exerts a dose- and schedule-dependent effect on tumor
progression in vivo while suppressing Akt/ERK signaling in tumors in a dose/fre-
quency-dependent manner (Wagner et al., AACR, 2016). We also provided evi-
dence that ONC201 exhibits a potent anti-metastatic effect (Wagner et al., AACR,
2016). We observe accumulation and activation of TRAIL-secreting NK cells
withinONC201-treated tumors inC57/BL6,Balb/c, andathymicnude tumor-bear-
ing mice. Importantly, ONC201 exerts in vivo anti-tumor effıcacy on tumor cell
lines that areONC201-resistant in vitro, including acquired stable resistance. Using
the NK-depleting antibody GM1, we demonstrate that the activation and TRAIL
secretion of NK cells by ONC201 signifıcantly contributes to in vivo anti-tumor
effıcacy, including TRAIL/ONC201-resistant tumors. We are currently investigat-
ing how ONC201 recruits NK cells to the tumor by examining NK-recruiting
chemokine factors within the tumor site. We have also demonstrated upregulation
of CD3T cells byONC201 in syngeneicmice. Finally, we observed an increase in
activated TRAIL-secreting NK cells in the peripheral blood of patients upon
ONC201administration in the clinic.Our results demonstratenovel andpotentially
signifıcant increases in cytotoxic NK cell recruitment to tumors. The results offer a
unique pathway of immune stimulation for cancer therapy that may be combined
with immune checkpoint or targeted cancer therapy strategies. We are currently
investigating the role of NK cells and CD3 cells in ONC201’s ability to inhibit
metastasisbyusingametastaticmodel that involves surgically removing theprimary
tumor and allowing metastases to grow in vivo before treatment. These fındings
indicate that ONC201 possess immunomodulatory activity and provide a rationale
for combining ONC201 with PD-1/PDL-1 inhibitors, a combination we are cur-
rently testing in syngeneic immunocompetent mousemodels.
#125 Differential effects of inhibitors of epigeneticmodifıers on IDHmu-
tant cell lines. Alişan Kayabolen, Tugba Bagci Onder. Koç University, I˙stanbul,
Turkey.
Our aim is to fınd effective drug treatments for IDHmutant glioma cells and
investigate their mechanism of actions by analysing genetic and epigenetic al-
terations upon drug treatments. Drug screen was performed on IDH mutant
and wild type cell lines by using a library of epigenetic modifıer inhibitors. Hits
for IDH mutant cells were validated with individual treatments. Combination
treatments of these inhibitors were also performed to see synergistic effects.
Then, IDH wild type glioma cells and BJ fıbroblasts were transduced with mu-
tant IDH1 overexpression plasmid, and checked if they were sensitized to these
drugs or not. Based on drug screen performed on IDH mutant and wild type
glioma cell lines, we found that IDH mutant cell lines, MGG119 and MGG152,
were highly sensitive to 5-azacytidine, Chaetocin andGSK-J4. For IDH1mutant
MGG152 cell line, IC50 value for GSK-J4 is 5.2  1.3 M, for 5-azacytidine is
2.2  0.3 M, and for Chaetocin is 10.2  1.0 nM at 48h. On the other hand,
these drugs did not affect viability of IDH wild type glioma cell lines and fıbro-
blasts around these concentrations. Moreover, combination of drugs, especially
combination of Chaetocin and 5-azacytidine had a highly synergistic effect on
IDH mutant cells while it was still ineffective on IDH wild type cells. After
transduced with mutant IDH overexpression plasmid, fıbroblasts became more
sensitive to these drugs. On the other hand, although their growth rate was
reduced, IDH wild type glioma cells were not signifıcantly sensitized to these
drugs upon mutant IDH overexpression. IDH mutation mainly inhibits DNA
and histone demethylation, and leads to hypermethylation phenotype. There-
fore, it is an expected result that IDH mutant cell lines are sensitive to 5-azacy-
tidine which is an inhibitor of DNAmethyltransferases, and Chaetocin which is
an inhibitor of H3K9methyltransferases. However, it was interesting to observe
that GSK-J4 which is an inhibitor of H3K27 demethylases is also effective on
IDH mutant cells. This may be a result of dependency on low number of active
genes since IDH mutation causes downregulation of many genes by methyl-
ation. GSK-J4may downregulate these genes by increasingH3K27methylation.
On the other hand, these effects might also be results of induced cell stress upon
drug treatment. To answer this question, now we are trying to knock-down
target genes of these drugs by shRNA, and obtaining compatible results. We are
also planning to performRNA-seq analysis to see genes with altered expressions
upondrug treatments. To conclude, unlike IDHwild type glioma cells or healthy
fıbroblasts, IDHmutant glioma cells were found to be sensitive to few epigenetic
drugs in low concentrations. This was confırmed by sensitization of fıbroblasts
to these drugs upon mutant IDH1 overexpression. In addition, combination of
these drugs had a highly synergistic effect on mutant cells which may give op-
portunity to use drugs in very low concentrations effıciently.
#126 A chemogenomic approach reveals the action of splicingmodulators
at the branch point adenosine binding pocket defıned by the PHF5A/SF3b
complex. Teng Teng, Jennifer Tsai, Xiaoling Puyang, Michael Seiler, Shouyong
Peng, Daniel Aird, Silvia Buonamici, Benjamin Caleb, Betty Chan, Laura Cor-
son, Jacob Feala, Peter Fekkes, Craig Karr, Manav Korpal, Yoshiharu Mizui,
Eunice Park, James Palacino, Peter Smith, Vanitha Subramanian, Jeremy Wu,
Lihua Yu, Agustin Chicas, Markus Warmuth, Nicholas Larsen, Ping Zhu. H3
Biomedicine Inc., Cambridge, MA.
DysregulationofRNAsplicing can cause various formsof cancer andneuromus-
cular disorders. Thus, developing compounds with splicing-modulating activity
represents a promising therapeutic approach for these diseases. Natural products
such as pladienolide, herboxidiene, and spliceostatin have been identifıed as potent
splicingmodulators thatbindSF3B1, amemberof theSF3b subcomplex that assem-
bles into the U2 snRNP. Using integrated chemogenomic, structural and biochem-
ical approaches, we show that PHF5A, another core component of the SF3b com-
plex, is also targeted by these modulators. Whole exome sequencing of E7107
(pladienolide analogue) and herboxidiene resistant clones identifıed commonmu-
tations in eitherPHF5A-Y36, SF3B1-K1071, SF3B1-R1074, or SF3B1-V1078,which
confers resistance to these modulators as assessed by splicing modulation and cell
growth inhibition, suggesting a common site of interaction for these splicing mod-
ulators. We determine the crystal structure of human PHF5A and fınd that Y36 is
located on the surface in a region of high sequence conservation. Analysis of the
cryo-EMspliceosomeBact complex fromyeast shows that thesemutations cluster in
awell-defınedpocket surrounding thebranchpoint adenosine suggesting apossible
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competitive mode of action for these modulators. Whole-transcriptome RNA-seq
analysis reveals that PHF5A Y36C alters the profıle of splicing modulators from
inducing intron-retention events to exon-skipping events. Furthermore, the differ-
ential inGCcontent between adjacent introns and exons correlateswith the relative
intron strength,making some splicing eventsmore susceptible tomodulation. Col-
lectively,wepropose thatPHF5A-SF3B1 is a central node forbinding to these small-
molecule splicingmodulators offering novel approaches tomodulate specifıc splic-
ing events.
#127 Effıcacy of novel IRAK4 inhibitor CA4948 inAML andMDS.Gaurav
S. Choudhary,1 Tushar D. Bhagat,1 Maria Elena S. Samson,2 Shanisha Gordon,1
Dagny Von Ahrens,1 Kith Pradhan,1 Aditi Shastri,1 Andrea Pellagatti,3 Jacque-
line Boutlwood,3 Robert N. Booher,2 Ulrich Steidl,1 Amit Verma1. 1Albert Ein-
stein College of Medicine, Bronx, NY; 2Curis, Inc., MA; 3University of Oxford,
United Kingdom.
Myelodysplastic syndrome (MDS) & Acute Myeloid Leukemia (AML) are
hematologic malignancies that arise from a population of aberrant hematopoi-
etic stem cells (HSCs). Overactivated innate immune signaling pathways such as
IRAK1, TRAF6, IL1RAP, S100A9 and IL8 have been demonstrated in MDS/
AML and play important roles in propagation of disease. IRAK4 (interleukin-1
receptor-associated kinase 4), is a protein kinase involved in signaling innate
immune responses and forms a critical signaling complex with IRAK1. To de-
termine its role in disease pathobiology, we analyzed transcriptomic data from
CD34 stem and progenitor cells from 183 MDS patients and found signifı-
cantly increased expression of IRAK4 inMDS samples belonging to the high risk
RAEB category (Refractory anemia with excess of blasts, N80, P Value0.05
when compared to healthy controls). Furthermore, increased IRAK4 expression
was predictive of signifıcantly adverse prognosis (P value  0.05, median sur-
vival of 2.6 years compared to 5.2 years for group with lower IRAK4). Clinical
correlations revealed that MDS patients with higher IRAK4 expression in stem/
progenitor cells had signifıcantly higher transfusion dependence and had higher
leukemic blast counts (Mean Blast Count 9.3% vs 3.9%, P0.05), further dem-
onstrating IRAK4 to be an adverse prognostic marker in MDS. IRAK4 was also
overexpressed in highly purifıed FACS sorted disease initiating stem cell popu-
lations (Long Term-HSC, CD34/CD38-/CD90/Lin –ve) fromAMLpatients
with complex cytogenetics when compared to healthy controls. To functionally
determine the role of IRAK4 in MDS/AML pathogenesis, we utilized CA-4948,
a potent, oral, small-molecule inhibitor of IRAK4, to assess the effect of inhib-
iting IRAK4 catalytic activity. In vitro, CA-4948 blocked downstream NF-B
pathway signaling, including secretion of proinflammatory cytokines, in Toll-
like receptor stimulated THP1 leukemic cells. CA-4948 was tested in clonogenic
assays fromprimaryMDSandAML samples.MDS andAMLare associatedwith
block in differentiation that leads to cytopenias that are the cause ofmorbidity in
these patients. Treatment with CA-4948 led to increased erythroid and myeloid
differentiation in a majority of samples. Furthermore, drug treatment led to
decreased viability of MDS/AML stem cells (CD34/CD38-/Lin-ve) In vivo
studies using a THP1 leukemia xenograftmodel inNSGmice demonstrated that
CA-4948 was well tolerated and led to signifıcantly decreased disease burden
after 6weeks of treatment. In conclusion, we demonstrate that IRAK4 is upregu-
lated in stem and progenitor cells inMDS andAML and is an adverse prognostic
marker. Importantly, a novel, specifıc, inhibitor of IRAK4 shows preclinical in
vitro and in vivo effıcacy in MDS and AML models.
#128 The next-generation CDK2/9 inhibitor CYC065 elicits marked anti-
neoplastic effects in lung cancer by engaging antimetastatic pathways.Masa-
nori Kawakami, Jason Roszik, Lin Zheng, Jonathan Kurie, Lisa Maria Musta-
chio, Xi Liu, Ethan Dmitrovsky. The University of Texas MD Anderson Cancer
Center, Houston, TX.
We previously reported CDK2 antagonism with the fırst generation CDK2/
9/7 inhibitor seliciclib (CYC202; Cyclacel) triggered anaphase catastrophe. This
occurred when genomically unstable cancer cells with supernumerary centro-
somes (a hallmark of cancer) fail to cluster excessive centrosomes at mitosis.
This causes multipolar cell division and apoptotic death. Anaphase catastrophe
is conferred after CDK2 antagonism of aneuploid cancer cells, sparing bipolar
normal cells with two centrosomes. CYC065 (Cyclacel) is a next-generation
CDK2/9 inhibitor that is undergoing clinical trial. Here, we explored CYC065
activity against lung cancer cells, some with known high metastatic potential.
CYC065 substantially inhibited growth, triggered apoptosis, and induced ana-
phase catastrophe in murine (ED1, LKR13, and 393P) and human (Hop62,
A549, and H1299) lung cancer cells. In marked contrast, these effects were
largely unseen in bipolar immortalized pulmonary epithelial (murine C10 and
human BEAS-2B) cells. We sought to explore whether CYC065 antineoplastic
effects engaged antimetastatic pathways. In vitro migration and invasion assays
were performed. CYC065 markedly inhibited migration and invasion of lung
cancer cells (murine: 344SQ andKC2; human: A549 andH1299). Reverse Phase
Protein Arrays (RPPAs) interrogated nearly 300 growth-regulatory proteins in
murine (344SQ and KC2) and human (A549 and H1299) lung cancer cells over
time (6, 12, 24, and 48 hours) after CYC065 or vehicle treatments. These lung
cancer cells have high metastatic as well migration or invasive potentials. When
highlighted proteins were clustered after CYC065 treatment, some species were
clustered as signifıcantly up-regulated or down-regulated in all cells over studied
time points. Not surprisingly, up-regulated proteins included those involved in
DNA damage or apoptosis. In addition to known CDK targets like phosphory-
lated retinoblastoma protein, novel proteins were markedly down-regulated,
including mTOR pathway and integrin pathway proteins such as FAK phos-
phorylation and Src phosphorylation. Affected pathways were identifıed using
Ingenuity Pathway Analysis (IPA). IPA revealed up-regulation of pathways that
engaged ATM signaling, G2/MDNAdamage checkpoint regulation, or apopto-
sis signaling. Down-regulated pathways affected mTOR signaling, cyclins, cell
cycle regulation, or integrin pathways. Mouse studies will be presented that
examine in vivo effects of CYC065 in reducing metastases. Taken together, the
next-generation CDK2/9 inhibitor, CYC065, elicits marked antineoplastic ef-
fects by antagonizing migration and invasion of lung cancer cells. Comprehen-
sive RPPA and IPA studies found that distinct pathways trigger these effects.
#129 Assessing themechanismand therapeutic potential ofmodulators of
the humanmediator complex-associated protein kinases CDK8 andCDK19.
Paul A. Clarke,1Maria-JesusOrtiz-Ruiz,2 Robert Te Poele,1 OlajumokeAdeniji-
Popoola,1 Gary Box,1 Christina Esdar,2 Kenneth Ewan,3 Sharon Gowan,1 Alexis
De Haven Brandon,1 Phllip Hewitt,2 Wolfgang Kaufmann,2 Aurelie Mallinger,1
Florence Raynaud,1 Felix Rohdich,2 Kai Schiemann,2 Stephanie Simon,2 Rich-
ard Schneider,2 Melanie Valenti,1 Julian Blagg,1 Trevor Dale,3 Suzanne Eccles,1
Paul Workman,1 Dirk Wienke Dirk Wienke2. 1Institute of Cancer Research,
London, United Kingdom; 2Merck KGaA,Darmstadt, Germany; 3Cardiff Univer-
sity, Cardiff, United Kingdom.
Mediator-associated protein kinases CDK8 and CDK19 are context-depen-
dent drivers or suppressors of tumorigenesis. Their inhibition is predicted to
have pleiotropic effects, but it is unclear whether this will impact on the clinical
utility of CDK8/19 inhibitors. We identifıed two structurally differentiated
chemical series, suitable for exploring their function. In addition to tools that
fulfıl the criteria set out for chemical probes, the lead compounds from each
series, CCT251921 and MSC2530818, had optimal pharmacological and phar-
maceutical properties making them suitable for preclinical studies. Having po-
tent, highly selective, orally bioavailable exemplar compounds from these series
in hand, we were well positioned to investigate the therapeutic potential of dual
CDK8/19 inhibition. The compounds exhibited modest anti-tumor activity in
colorectal cancer cell line xenograft models with modulation of p-STAT1SER727,
a target engagement biomarker, and altered gene expression profıles, including
super-enhancer regulated gene expression, consistent with the inhibition of
CDK8/19. In PDX-derived cell cultures we observed inhibition of soft-agar
growth in cells derived from different tumor types. However, we only detected
signifıcant antitumour activity in 1 of 6 colorectal PDX models tested in vivo,
and one example of sensitization to standard of care chemotherapy, despite
showing inhibition of p-STAT1SER727. Acute myeloid leukemia cells were the
most sensitive cancer type in the PDX panel with therapeutic potency seen in
systemic and sub-cutaneous models. Signifıcantly, the compounds impacted on
stem cell biology. In a bone progenitormodel we saw dose-responsive activation
and inhibition of markers of bone matrix and bone deposition that was distinct
fromWNTblockade. Treatment of a diverse collection of normal cell co-culture
models detected a unique response profıle consistent with stimulation of an
immune/inflammatory response. In vivo treatment of a genetically engineered
mouse model expressing oncogenic beta-catenin shifted cells within hyperplas-
tic intestinal crypts from a stem cell to a transit amplifying phenotype. Finally, in
pre-clinical tolerability studies we observed a similar, widespread adverse safety
profıle at therapeutically relevant exposures for both CCT251921 and
MSC2530818. At the concentrations tested we detected 80% inhibition of
p-STAT1SER727 and increased IL-12 plasma levels. Since the observed patholog-
ical effects were generated with two potent, highly selective, but structurally
distinct compounds, we conclude that the adverse consequences of treatment
are the direct result of inhibition of CDK8 and/or CDK19. The serious and
complex nature of the toxicity observed indicates that the clinical development
of either series of CDK8/19 modulators, or other chemotypes with similar pro-
fıles, will be extremely challenging.
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#130 Discovery and characterization of small molecules targeting the
DNA-bindingETSdomainofERG inprostate cancer.MiriamS. Butler,1Mani
Roshan-Moniri,1 Michael Hsing,1 Desmond Lau,2 Ari Kim,1 Paul Yen,1 Marta
Mroczek,1 Mannan Nouri,1 Scott Lien,1 Peter Axerio-Cilies,1 Kush Dalal,1
Clement Yau,1 Fariba Ghaidi,1 Yubin Guo,1 Takeshi Yamazaki,1 Sam Lawn,1
MartinGleave,1 Cheryl Y.Gregory-Evans,1 Lawrence P.McIntosh,1 Paul S. Ren-
nie,1 Artem Cherkasov,1 Michael E. Cox1. 1Vancouver Prostate Centre, Vancou-
ver, British Columbia, Canada; 2University of British Columbia, Vancouver, Brit-
ish Columbia, Canada.
Genomic alterations involving translocations of the ETS-related gene ERGoccur
in approximately half of prostate cancer cases. These alterations result in aberrant,
androgen-regulated production of ERG protein variants that directly contribute to
disease development and progression. This study describes the discovery and char-
acterization of a new class of small molecule ERG antagonists identifıed through
rational in silico methods. These antagonists are designed to sterically block DNA
binding by the ETSdomain of ERGand thereby disrupt transcriptional activity.We
confırmed the direct binding of a lead compound, VPC-18005, with the ERG-ETS
domain using biophysical approaches.We then demonstratedVPC-18005 reduced
migration and invasion rates of ERG expressing prostate cancer cells, and reduced
metastasis in a zebrafısh xenograftmodel. These results demonstrate proof-of-prin-
cipal that small molecule targeting of the ERGETS domain can suppress transcrip-
tional activity and reverse transformed characteristics of prostate cancers aberrantly
expressing ERG. Clinical advancement of the developed small molecule inhibitors
may provide new therapeutic agents for use as alternatives to, or in combination
with, current therapies formenwithERG-expressingmetastatic castration-resistant
prostate cancer.
#131 Chemotherapeutic effects of naturally occurring colossolactones
against solid tumor cells in-vitro. Mohammed A. Baghdadi,1 Fahad A. Al-
Abbasi,2 Ali M. El-Halawany,3 AhmedM. Al-Abd4. 1King Faisal Specialist Hos-
pital & Research Centre, Jeddah, Saudi Arabia; 2King Abdulaziz University, Jed-
dah, Saudi Arabia; 3Faculty of Pharmacy, Cairo University, Cairo, Egypt;
4National Research Centre of Egypt, Giza, Egypt.
Colossolactones were isolated previously from the Vietnamese mushroom
ganoderma colossum, such triterpenoids. The different colossolactone com-
pounds (schisanalactonoe a, colossolactone I, ergosterol, colossolactone III, co-
lossolactone II, colossolactone IV, colossolactone E) characterized by the pres-
ence of a six-membered lactone ring (ringD)with orwithout a seven-membered
lactone rings (ring A) were isolated. In the current study, using DPPH free
radical scavenging assay, all colossolactone compounds showed weak antioxi-
dant activity with EC50’s of 99.46, 220.32, 219.65, 100.81, 238.54, 116.57 and
131.94M, respectively. Isolated compounds were examined for their potential
anticancer activity against breast (MCF-7), cervix (HeLa), colorectal (HCT-116)
and liver (HepG2) cancer cells. Cytotoxicity of the isolated compounds was
assessed in the aforementioned cell lines using SRB assay after 72 h of exposure
and fıtted using Emax model. Amongst colossolactones, schisanalactonoe-A and
colossolactone-IV showed the best cytotoxic profıle in all cell lines under inves-
tigation with IC50’s ranged from 4.9 to 64.2M; and R-fraction less than 47.5%.
Further mechanistic studies for the detailed mechanism of cytotoxicity of
schisanalactonoe-A and colossolactone-IV are currently carried out.
#132 African polyherbal formulation alleviates benzene-induced leuke-
mia inWistar rats.Olufemi E. Akanni,1 Ayodeji Faremi,2 Aminat O. Agboola,1
Adekemi R. Akanni,3 Oluseyi E. Bamisaye4. 1Ladoke Akintola University of
Technology, Department of Medical Laboratory Science, College of Health Sci-
ences, Osogbo, Nigeria; 2Ladoke Akintola University of Technology, Department
of Chemical Pathology; College of Health Sciences, Osogbo, Nigeria; 3Ladoke Ak-
intola University of Technology, Department of Medical Microbiology and Para-
sitology, College of Health Sciences, Osogbo, Nigeria; 4Afe Babalola University,
Department of Medical Laboratory Science, College of Medicine and Health Sci-
ences, Ado Ekiti, Nigeria.
Background: Chemotherapy and radiotherapy are effective cancer treatment
options but they are accompanied by serious side effects. Therefore, more effec-
tive therapies are sorely needed. This study investigated the chemotherapeutic
effects of a polyherbal formulation on benzene induced leukemia inWistar rats.
The polyherbal formulation is composed of fruits such asOrange, Lime, Lemon,
Pineapple, Grape and Vegetables like; Pumpkin leave, Garden egg in honey
medium.Method: Leukemiawas induced by injecting 0.2ml of benzene solution
intravenously through the tail at 48 h intervals for four weeks. Leukemia devel-
oped in 92% of rats within 2 to 4 weeks after the last benzene injection and
further observed for leukemia development in appropriate rat groups. Leukemia
burden was assessed using indicator parameters such as total leukocyte, red
blood cell count, hematocrit, and hemoglobin concentration. Immunopheno-
typing enumeration of CD 19 expression also corroborated the leukemia assess-
ment by providing specifıc cellular marker for differentiation of the developed
leukemia type. Exactly 0.48 ml of the polyherbal formulation was administered
orally by gavage using oral cannular once daily post leukemia induction for four
weeks. Results: Leukemia induction reflected in signifıcant reduction in hemat-
ocrit, hemoglobin concentration, red cell count and a marked and a signifıcant
increase in leukocyte count and CD 19 expression over the control (p 0.05).
There is signifıcant difference between the leukemia group treated with poly-
herbal formulation and the leukemia positive control group untreated. Conclu-
sion: This study reveals profound chemotherapeutic activity of the polyherbal
formulation against experimentally developed leukemia by reversing the in-
duced leukemia in the positive control rat group, hence the ability of the poly-
herbal formulation in alleviating the cancer symptoms.
Table 1. Hematological parameters in polyherbal formulation treated leukemia
bearingWistar rats
Estimated parameters
Negative
control rats
(MeanSD)
Leukemia
Positive rats.
(MeanSD)
Polyherbal
formulation
treated
leukemic rats
(MeanSD)
CD 19 (X 109/L) 47.59 1.39 89.41 1.72 62.32 1.42*
Total Leukocyte count (X 109/L) 6.84 0.30 11.08 0.31 7.45 0.65*
Red blood cells(X 1012/L) 6.30 0.38 3.5 0.38 5.10 0.03*
Hematocrit (L/L) 0.43 0.17 0.26. 0.20 0.37 0.08*
Hemoglobin (g/dl) 13.62 0.69 6.63 0.96 11.80 2.96*
Platelets (X 109/L) 554.80 92.23 389.50 146.10 425.10 60.8*
*Signifıcance at p0.05
#133 Aloe-emodin as a potential lead targets lung cancer stem cells. Pei-
Jung Lee,1Wan-JiunChen,2 Chao-ChiHo,3 Pan-ChyrYang,3Huei-WenChen4.
1Graduate Institute of Oncology, National Taiwan University Medical College,
Taipei, Taiwan; 2Institute of Statistical Science, Academia Sinica, Taipei, Taiwan,
Taipei, Taiwan; 3Department of Internal Medicine, National Taiwan University
Hospital and National Taiwan University Medical College, Taipei, Taiwan;
4Graduate Institute of Toxicology, National Taiwan University Medical College,
Taipei, Taiwan.
Cancer stem cells (CSCs) have been proposed to be responsible for tumor
initiating, drug resistance, metastasis, and recurrence. Many novel therapeutic
strategies have been designed to target and eliminate CSCs. According to our
previous study, we have established a model of CSCs and cancer associated
fıbroblasts (CAFs) co-culture system for anti-CSCs drug screening. Here, we
report one of the potential hits screened via this platform and the anti-CSCs
activitywas further investigated both in vitro and in vivo.Human lungCSCs and
CAFs were primary cultured from patient with lung adenocarcinoma according
to our previous study. Image-based high content screening system was used to
analyze different parameters after drug treatment. Tumorogenicity and self-
renew ability are examined by sphere forming ability. Aldehyde dehydrogenase
(ALDH) activity was used to analyze stem cell population by flow cytometry.
The expression level of stemness-related genes, Nanog, Oct3/4 and Sox2 were
validated by real-time reverse transcriptase Q-PCR. The effıcacy of the lead on
tumor growth was examined by the xenograft model. Lung cancer stemness
markers of the xenograft tumor tissues were also evaluated by immunohisto-
chemistry. Using the image-based high content screening system to screen over
one thousands of compounds, we have identifıed aloe-emodin (AE) shows
higher potency targeting on lung cancer stem cells (under the concentration of 1
M) and high specifıcity targeting on the cancer cell lines (IC50  20 M);
compared to normal human bronchial epithelium cells and human normal fı-
broblast represented by IC50 (26.77 M v.s. 39.13 M). The level of stemness
markers, Nanog, Sox2 and Oct3/4 were signifıcantly down regulated after AE
treatment compared to cisplatin treatment. AE could suppress tumor initiating
abilities and self-renew capacities represented by the ability to grow as tumors
spheres in CL152 ALDH cells. Besides, AE could inhibit ALDH population in
CL152 cells (40% reduced). Also, the AE can inhibit the cisplatin-induced
ALDHpopulation as well. Furthermore, we found that AE combine with cispla-
tin could inhibit tumor growth as comparing to cisplatin treatment in subcuta-
neousmodels inNOD/SCIDmice, whereas, AE can inhibit the level of Nanog in
mice tumor tissues. According to these results, AE is a potential lead targeting on
lung cancer stem cells. To discover the pharmacological mechanism of AE on
cancer stem cells will be helpful to develop new strategy for lung cancer therapy.
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#134 A dual mTOR-PI3K inhibitor DCB-HDG2-57 with Hedgehog sig-
naling pathway antagonist activity. Ying-Shuan Lee, Mann-Yan Kuo, Chia
Wei Liu, Yu-Wen Tseng, Win Yin Wei, Shian-Yi Chiou, Her Sheng Lin, Y.-Y.
Lu, Chu-Bin Liao, Shao-Zheng Pen.Development Center for Biotechnology, New
Taipei City, Taiwan.
The Hedgehog (Hh) signaling pathway is a critical regulator of embryonic
patterning, and aberrant Hh pathway activation has been implicated in a di-
verse spectrum of cancers. Therefore, components of the Shh pathway (such as
Shh, SMO, and GLI1/2) are viable therapeutic targets for anti-tumor strategy.
Smo antagonists such as GDC-0449 and NVP-LDE225 have received FDA ap-
proval for treating basal cell carcinoma. However, acquired resistance has
emerged as a challenge to targeted therapeutics and may limit their anti-cancer
effıcacy. Studies have linked the hyperactive phosphatidylinositol-3-kinase
(PI3K)/AKT/mTOR signaling pathway in a variety of human cancers and drug
resistance condition. The synergistic role of PI3K/AKT/mTOR in Hh signaling
in embryonic development and Hh-dependent tumors has been reported. Both
the PI3K/Akt/mTOR and Hh pathway also play important role in maintaining
the stem cell-like properties of cancer stem cell (CSCs). We report here the
development of a potent dualmTOR-PI3K inhibitor designatedDCB-HDG2-57
with Hh signaling pathway antagonist activity. In vitro biochemical assays
showed that DCB-HDG2-57 inhibited recombinant pI3K and mTOR kinase
with IC50 of 27.2 and 133 nM, respectively. DCB-HDG2-57 is also highly active
in cellular assays, as evidenced by inhibition of phosphorylation of cellular
downstream targets of PI3K-mTOR kinases ribosomal protein S6 kinase (S6K1,
Ser240/24) in the colon (LS-180) andpancreatic cancer (MiaPaCa2 andPANC1)
cell lines. Interestingly, DCB-HDG2-57 demonstrated Hh signaling pathway
antagonist activity in a 293 cell-based Gli-luciferase inhibition assay upon ago-
nist treatment, and retains inhibition activity against the Smo wild-type and
D473Hmutant co-transfectionwith IC50 of 261.8 and 327.7 nM, respectively. In
addition, DCB-HDG2-57 can signifıcantly decrease the cancer stem cell liked
side population of PANC1 pancreatic cell, and inhibited the migration of
E3LZ10.7 pancreatic cancer cell. DCB-HDG2-57 demonstrated in vivo tumor
growth inhibition activity in LS-180 colon cancer xenograft model and reduced
the Gli-1 RNA abundance in the tumor. Taken together, our data demonstrate
that combined pharmacological blockade of mTOR-PI3K and Hh pathway of
DCB-HDG2-57 can provide a therapeutic strategy for targeting ligand-depen-
dent Hh cancer.
#135 Targeted therapy of hormone receptor-positive breast cancer har-
boring PIK3CA and AKT1 genetic aberrations. Maryam Shariati, Kurt W.
Evans, Stephen M. Scott, Huiqin Chen, Funda Meric-Bernstam. The University
of Texas MD Anderson Cancer Center, Houston, TX.
Introduction: Molecular alterations in the PI3K/Akt/mTOR pathway is im-
plicated in the pathogenesis of ERpositive breast cancerwith high frequency and
therefore is the major focus of drug development. Activating mutations of this
signaling pathway occur in more than 70% of breast tumors. The genetic alter-
ations affectingmajor components of PI3K/Akt/mTOR include genes encoding
the PI3K catalytic subunits p110 (PIK3CA) and the PI3K effector AKT1. De-
spite the effıcacy of the available smallmolecule inhibitors for targeting different
components of PI3K pathway, the contribution of PIK3CA and AKT1 genetic
alterations to targeted therapy is not well understood. We speculated that ER
positive breast tumors with PIK3CA and AKT1 alterations are more sensitive to
PI3K and Akt inhibitors due to differential downstream pathway effectors.
Methods:We used a panel of isogenicMCF7 cell lines with oncogenicmutations
of PIK3CA and AKT1 established through somatic cell gene targeting. A series
of pharmacological compounds currently approved for breast cancer therapy or
in clinical trials in targeting PI3K/Akt/mTOR pathway were evaluated using
viability, clonogenic and cell cycle analysis assays. We performed functional
proteomic profıling using reverse phase proteomic analysis (RPPA) to investi-
gate differential protein expression in response to PI3K pathway inhibition in
PIK3CA and AKT1 mutants MCF7 cell lines. In vivo experiment was done to
evaluate the effıcacy of the inhibitors in suppressing tumor growth. Results: We
demonstrated that PIK3CA (E545K) and AKT1 (E17K) sensitized cells to the
inhibitory effects of BYL719 (p110 catalytic subunit inhibitor) and AZD5363
(pan-AKT kinase inhibitor) on survival, cell cycle progression and colony for-
mation ability. The presence of PIK3CA andAKT1mutations conferred growth
advantage and exhibited increased proliferation in vitro and in vivo. These al-
terations dramatically increased Akt phosphorylation and induced activation of
PI3K downstream effectors. RPPA analysis revealed several proteins differen-
tially expressed in PIK3CA and AKT1 mutant cells compared with wild type
(p-value  0.05). Conclusion: PIK3CA and AKT1 mutations showed distinct
effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast
cancer model. The presence of these genetic alterations in estrogen receptor
(ER) positive breast cancer provided proliferative advantage and enhanced their
sensitivity to targeted PI3K inhibition. These results will contribute to identify
single agent and combination therapies targeting PI3K pathway with maximal
activity at tolerated dose and selection for individuals most likely to be respon-
sive based on their genomic alterations.
#136 Phospho-S6 levels correlate with response to Copanlisib (BAY 80-
6946) in multiple myeloma. Sarah Larson, Mao Yu Peng, Monica Mead, An-
drae Vandross, Dylan Conklin, Erika Von Euw, Dennis J. Slamon.UCLA, Santa
Monia, CA.
Background: Copanlisib (BAY 80-6946) is a reversible, pan-class I PI3K in-
hibitor with preferential activity for the alpha isoform, which may be of partic-
ular importance in multiple myeloma. Here we demonstrated the in vitro effı-
cacy of copanlisib in a panel of 20 multiple myeloma cell lines. Baseline levels of
phospho-S6 (P-S6) correlatedwith sensitivity to copanlisib, resulting in a poten-
tial biomarker of response. In addition, the change of P-S6 post-treatment could
be used as a pharmacodynamic biomarker for copanlisib treatment. Methods:
We screened a panel of 20 multiple myeloma cell lines and selected 3 sensitive:
NCI-H929,MM.1S, L-363, and 3 resistant: AMO-1, JJN3, COLO-677 for further
analysis. We performed apoptosis and cell senescence assays following 72 hours
of 50nM and 100nM copanlisib exposure. Cell cycle analysis and induction of
apoptosis were performed by FACS after propidium iodide or PI/ANX-V FITC
staining, respectively. Cellular senescence was determined by measuring -ga-
lactosidase activity in cells treated for 96 hours. Reverse phase protein array
(RPPA) was performed at baseline and post treatment for proteomic analysis
with confırmatorywestern blots. Flow cytometrywas also performed tomonitor
the post-treatment P-S6 level changes. Results: Copanlisib treatment induced
apoptosis in the sensitive cell lines (50-80% AN-V cells) but not in resistant
cell lines (1-5% AN-V cells). An increased cell cycle arrest in G1 was also
observed in the sensitive cell lines but not in the resistant lines. The cell senes-
cence assays confırmed apoptosis rather than cell senescence as the mechanism
of inhibition of proliferation. RPPA analysis demonstrated lower baseline p-S6
(S235/236, S240/244) protein levels in sensitive compared to resistant cell lines
and this was confırmed with western blot analysis. Treatment with copanlisib
resulted in a greater decrease in p-S6 in the sensitive cell lines NCI-H929 and
L363 (53-83%, 73-93% respectively) than in the resistant cell lines COLO-677
and JJN3 (5-27%, and 38-67%, respectively), whichwas validated bywestern blot
and phospho-flow. We also showed by RPPA and WB that copanlisib down-
regulates pro-survival and proliferation molecules including p-S6K1, p-S6 and
p-4EBP1, and upregulates pro-apoptotic PDCD4 in all cell lines, but to a greater
extent in sensitive cell lines. Finally, pharmacodynamic p-S6 response remained
at different post-treatment time points. Discussion: A differential response to
copanlisib is seen in the myeloma cell line panel. A subgroup of multiple my-
eloma cell lines demonstrated median IC50 values in the low nanomolar range
(5-100nM), and responses correlatedwith low baseline P-S6. This p-S6 stratifıed
response was only observed with PI3K-alpha inhibitors, but not with inhibitors
targeting other PI3K isoforms or pan-PI3K inhibitors. Further studiesmay allow
development of a new patient screening method or companion diagnostic.
#137 FT-1518, a new generation selective and potent mTORC1 and
mTORC2 inhibitor: an in vitro and in vivo profıle.Alain C. Mita,1 MonicaM.
Mita,1 Anthony D. William,2 Khalid Pasha,3 Chandra Siddamadappa,2 Kevin
Zikaras,2 Felix T. Garzon2. 1Samuel Oschin Comprehensive Cancer Institute, Ce-
dars-Sinai Medical Center, Los Angeles, CA; 2FTG BIO, Hackensack, NJ; 3Vipra-
gen Biosciences Pvt. Ltd., Mysore, India.
Mammalian target of rapamycin (mTOR) is a clinically validated target in the
treatment of cancer. mTOR forms two distinct multiprotein complexes,
mTORC1 and mTORC2 which regulate cell growth, metabolism, proliferation,
and survival. Rapamycin analogues target only the mTORC1 complex but do
not affect the mTORC2 complex, which is an important driver for cancer cell
growth and survival. The new generation of “Selective”mTOR inhibitors, block-
ing both mTORC1 and mTORC2 signaling might increase the effıcacy and
safety while expanding the therapeutic potential of these anticancer agents.
Herein we describe FT-1518, a low nanomolar potent, kinase and PI3K sub
family selective mTOR inhibitor. FT-1518 not only exhibited high oral bioavail-
ability in preclinical species but has demonstrated excellentmicrosomal stability
with no inhibitory activity towards undesired CYPs. FT-1518 showed high sus-
tained tumor exposure and target Inhibition in a single oral dose xenograft
model. FT-1518 depicted very good growth inhibitory activity across a large
panel of hematologic and solid tumor cell lines with most activities falling into
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low nanomolar range. mTOR kinase inhibition in cells, by FT-1518, resulted in
more potent inhibition of the mTOR pathway biomarkers (mTORC 1 & 2 bio-
markers [pAkt(S473) and pS6(S240/244) or p70 S6K), no inhibition of PI3K
biomarker [pAkt(T308)], and improved anti-proliferative activity as compared
with rapamycin. FT-1518 exhibited dose-dependent and higher tumor growth
inhibition (TGI) inmultiple solid tumor xenografts comparedwith rapalogs and
is poised to enter the clinic with a favorable toxicology profıle.
#138 FOXO proteins mediate adaptive resistance to PI3K inhibition in
mucinous colorectal cancers.Murali R. Kuracha, Peter Thomas, BrianW. Log-
gie, Venkatesh Govindarajan. Creighton University, Omaha, NE.
Purpose: Mucinous colon adenocarcinomas (MCAs) comprise a substantial
fraction (10-15%) of sporadic colorectal cancers (CRCs). MCAs show a distinct
range of genetic modifıcations compared to nonmucinous CRCs and are more
prone to peritoneal dissemination and distant metastasis. These aggressive can-
cers show a poorer response to chemotherapy and are often diffıcult to treat. A
higher mutation rate in effectors of the KRAS-RAF-MEK (80% vs 42%) and
PI3K-AKT-mTOR (60% vs 22%) pathways in MCAs over nonmucinous CRCs
suggested potential targets for therapy. Our previous results showed that,
MCAs, though initially sensitive to PI3K inhibition (PI3Ki), later develop adap-
tive resistance. The purpose of this study was to test whether FOXO transcrip-
tion factors mediate this adaptive resistance to PI3Ki single agent treatment.
Methods: PI3K was inactivated in MCA cell lines, LS174T (KRAS G12D, PI3K
H1047R) and RW7213 (KRAS G12C, PI3K WT), by treatment with GDC0941
(Pictilisib), a small molecule inhibitor of class I PI3K. Alterations in phosphor-
ylation of effectors in the PI3K-AKT or MEK-ERK pathways were determined
using western blots. FOXO nuclear localization was assessed by immunocyto-
chemistry, confocalmicroscopy andnuclear fractionation studies. Expression of
FOXOproteins (FOXO1, FOXO3 and FOXO4) was reduced by short inhibitory
RNAs (siRNAs). FOXO1 was also inhibited in MCA cells using AS1842856, a
small molecule inhibitor. Results: Immunohistochemical analysis and nuclear
fractionation studies showed signifıcant nuclear enrichment of FOXO1 and
FOXO3 in MCA cell lines in response to PI3K inhibitor treatment. Upon
siRNA-mediated knockdown of FOXOs, rebound ERK phosphorylation seen in
response to PI3Ki treatment was substantially reduced. Concomitant with this
decrease was a reduction in expression of receptor tyrosine kinases (RTKs) IR,
IGFR, HER2 and HER3. Combinatorial treatment of PI3K and FOXO1 inhibi-
tors resulted in amore pronounced loss of cell viability compared to single agent
treatment. Conclusions: Our results suggest that resistance to PI3K single agent
inhibition seen in MCA cells is mediated, at least in part, by nuclear transloca-
tion of FOXO proteins, particularly FOXO1. Our results support amodel where
PI3K inhibition results in increased FOXO nuclear localization which in turn,
leads to transcriptional upregulation and activation of RTKs which then lead to
rebound activation of the MEK-ERK pathway and increased survival and resis-
tance. A role for FOXOproteins inmediating PI3Ki resistance in KRAS-mutant
MCA cells has not been described before. Our results suggest that PI3Ki single
agent therapy is unlikely to be successful in KRAS-mutantMCAs due to FOXO-
mediated resistance thus providing a rationale for combination treatment strat-
egies.
#139 M2698, a novel dual inhibitor of p70S6KandAkt: preclinical effıcacy
in gastric cancer. Shota Fukuoka,1 Takashi Kojima,1 Yoshikatsu Koga,2
Mayumi Yamauchi,1 Masahiro Yasunaga,2 Yasuhiro Matsumura,2 Toshihiko
Doi,1 Takayuki Yoshino,1 Toshio Kuronita,3 Anderson Clark,4 Brian Elenbaas,4
Atsuhi Ohtsu1. 1Division of Gastrointestinal Oncology, National Cancer Center
Hospital East, Kashiwa, Japan; 2Division of Developmental Therapeutics, Re-
search Center for Innovative Oncology, National Cancer Center Hospital East,
Kashiwa, Japan; 3Merck Serono Co Limited, Tokyo, Japan; 4EMD Serono Re-
search & Development Institute, Inc, Billerica, MA.
M2698 is a selective, ATP-competitive dual inhibitor of p70S6K and Akt1/3
that is being evaluated in a phase I clinical trial in cancer patients. The dual
nature of M2698 may result in improved clinical effıcacy by blocking the in-
creased AKT activity in a compensatory feedback loop induced by PI3K/AKT/
mTOR (PAM) pathway inhibition. In previous preclinical studies, M2698 was
shown to have potent anti-proliferative activity in vitro, and inhibit tumor
growth in some xenograft models in vivo. The current study examined the ef-
fects of M2698 on cell proliferation in a panel of 13 gastric cancer cell lines, as
gastric cancers often harbor mutations in PAM pathway genes that deregulate
this signalling pathway. Cells were treated with M2698 at a range of concentra-
tions and proliferation was evaluated at least twice using the WST-8 cell prolif-
eration assay kit (Dojindo Molecular Technologies, Inc. Japan). Two cell lines,
HGC-27 and IM95m, were particularly sensitive to M2698 (50% growth inhibi-
tion concentration [GI50] 84 and 160 nM, respectively). The GI50 values for all
other cell lines were10-fold higher. AlthoughHGC-27 and IM95m each carry
a PIK3CA hotspot point mutation, the presence of an activating PI3K pathway
mutation was not the sole determinant of sensitivity, as a third PIK3CAmutant
cell line, MKN1, was far less sensitive to M2698 (GI50 9.0 uM). Western blot
analysis of pharmacodynamic biomarkers showed that M2698 (1 uM) blocked
the PAM pathway in both sensitive and resistant cell lines, inhibiting
phospho[p]
S6 and p
PRAS40, despite increased p
Akt. Some biomarkers from
the PAM pathway and other signaling pathways appeared to be associated with
sensitivity to M2698, but these candidate biomarkers need to be validated in a
larger panel of cell lines. Treatment of HGC-27-tumor-bearing mice with
M2698 (10, 20, 30 mg/kg/day) for 14 days resulted in signifıcant tumor growth
inhibition (80.2-98.6%) at Day 29 compared to treatment with vehicle (p0.01).
In conclusion, we have shown that gastric cancer cell lines have a range of
sensitivities to M2698 and the sensitivity cannot be explained solely by genetic
mutations in the PAM pathway. M2698 provides potent PAM pathway inhibi-
tion in both sensitive and resistant gastric cancer cell lines by blocking both
p70S6K and Akt. M2698 signifıcantly inhibits tumor growth in the HGC-27
xenograft model in vivo.
#140 Discovery and biological evaluation of PQR530, a highly potent dual
pan-PI3K/mTORC1/2 inhibitor.Denise Rageot,1 Florent Beaufıls,2 AnnaMe-
lone,1 Alexander M. Sele,1 Thomas Bohnacker,1 Marc Lang,2 Jürgen Mestan,2
Petra Hillmann,2 Paul Hebeisen,2 Doriano Fabbro,2 Matthias P. Wymann1.
1University of Basel, Basel, Switzerland; 2PIQUR Therapeutics AG, Basel, Swit-
zerland.
The PI3K/AKT/mTOR signaling pathway plays a fundamental role in cell
proliferation, growth and survival and aberrant activation of this signaling path-
way has been shown to drive the progression of malignant tumors.[1] Drugs
targeting the pathway at multiple points, such as dual PI3K/mTOR inhibitors
appear to have the broadest activity profıle to address cancer therapeutic strat-
egies and are currently being explored in numerous clinical studies. Recently, we
presented PQR309, a novel, brain-penetrant pan-PI3K/mTOR inhibitor, which
entered phase II clinical trials in 2016.[2]Here, we report the lead optimization of
PQR530, a potent and brain-penetrant follow-up compound as pan-PI3K/
mTORC1/2 inhibitor. The development of a follow-up compound concentrated
on the improvement of both, the potency and the selectivity for all targeted
kinases, namely the class IA PI3K isoforms as well as mTOR. We present a
detailed ligand-based structure-activity relationship study which was obtained
by systematic modifıcations of the hinge region as well as the affınity binding
substituents. This study led to the identifıcation of PQR530, a dual pan-PI3K/
mTORC1/2 inhibitor showing excellent activities in cellular assays as well as in
PI3K andmTOR enzymatic binding assays. In A2058melanoma cells PQR530
inhibited protein kinase B (PKB, pSer473) and ribosomal protein S6 (pS6,
pSer235/236) phosphorylation with IC50 values of 0.07 M. PQR530 showed
excellent selectivity over a wide panel of kinases, as well as excellent selectivity
versus unrelated receptor enzymes and ion channels. Moreover, PQR530 dis-
played potency in a panel of 44 cancer cell lines (NTRCOncolinesTM) to prevent
cancer cell growth (mean value for GI50 of 426 nM). Oral application of PQR530
to mice resulted in a dose-proportional PK and demonstrated good oral bio-
availability and excellent brain penetration.[3] An optimized, robust synthetic
route allowed rapid access to multi-gram quantities of PQR530 for pre-clinical
development in only 4 steps. In conclusion, PQR530 inhibits all PI3K isoforms
and the mammalian target of rapamycin (mTOR) complexes C1/2 potently and
selectively, and shows anti-tumor effects in vitro and in vivo. [1]M. P.Wymann,
M. Zvelebil, M. Laffargue (2003). Phosphoinositide 3-kinase signalling – which
way to target? Trends Pharmacol Sci.; 24, 366-376. [2] V. Cmiljanovic et. al.
“PQR309: Structure-Based Design, Synthesis and Biological Evaluation of a
Novel, Selective, Dual Pan-PI3K/mTOR Inhibitor” presented at AACR Annual
Meeting 2015, April 18-22, Philadelphia, Pennsylvania, USA. [3] P. Hillmann et
al. “Pharmacological Characterization of the Selective, Orally Bioavailable, Po-
tent Dual PI3K/mTORC1/2 Inhibitor PQR530” abstract submitted for AACR
Annual Meeting 2017, April 1-5, Washington, D. C., USA.
#141 CD44 positive and sorafenib resistant hepatocellular carcinomas re-
spond to the ATP-competitive mTOR inhibitor INK128.Mohamed Badawi,1
Jihye Kim,1 Dhruvitkumar Sutaria,1 Tasneem Motiwala,2 Ryan Reyes,2 Nissar
Wani,2 Samson Jacob,2 Mitch Phelps,1 Thomas Schmittgen3. 1College of Phar-
macy, The Ohio State University, Columbus, OH; 2College of Medicine, The Ohio
State University, Columbus, OH; 3College of Pharmacy, University of Florida,
Gainesville, FL.
The PI3K/AKT/mTOR pathway is activated in about 50% of patients with
hepatocellular carcinoma (HCC). Allosteric mTOR inhibitors, also known as
rapalogs, fail to show any signifıcant clinical utility. In an effort to identify new
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pathways and compounds to treat advanced HCC, we considered the ATP-
competitive mTOR inhibitor INK128. ATP-competitive mTOR inhibitors at-
tenuate both mTORC1 and mTORC2. We evaluated INK128 in sorafenib sen-
sitive and insensitive HCC cell lines, CD44low and CD44high HCC and those cell
lines with acquired sorafenib resistance. CD44 was signifıcantly increased in
Huh7 cells made resistant to sorafenib. Forced expression of CD44 enhanced
cellular proliferation andmigration, and rendered the cells more sensitive to the
anti-proliferative effects of INK128. INK128 suppressed CD44 expression by
blocking phosphorylation of eukaryotic translation initiation factor 4EBP1 in
HCC cells while allosteric mTOR inhibitors do not. Moreover, INK128 exhib-
ited potent anti-proliferative and anti-migration effects on the mesenchymal-
like HCC cells, CD44high and sorafenib resistant HCC cells compared to the
allosteric mTOR inhibitor everolimus. Combination studies of INK128 and
sorafenib showed an additive to synergistic anti-proliferative effect in CD44high
HCC cells. Our fındings suggest that ATP-competitive mTOR inhibitors are
effective in treating advanced HCC patients who express CD44, and are insen-
sitive or resistant to sorafenib. It also highlights the potential use of CD44 as a
biomarker of response in these patients.
#142 Exploiting replicative vulnerabilities to counter incomplete re-
sponses to PI3K/Akt/mTOR inhibition. Sameer Chopra,1 Mario Niepel,2
Anne Jenney,2MarcHafner,2 Peter Sorger2. 1Dana-Farber Cancer Institute, Bos-
ton, MA; 2Harvard Medical School, Boston, MA.
While a broad range of cancers harbor mutations that dysregulate PI3K-Akt-
mTOR signaling, most small molecule drugs targeting this pathway have failed
to demonstrate effıcacy for the treatment of solid tumors. In this study, we
investigated the mechanisms that account for drug effıcacy and failure in PI3K-
pathway dysregulated triple negative breast cancer (TNBC) cell lines using a
diverse collection of 25 PI3K-Akt-mTOR inhibitors. Drug response phenotypes
and changes in signaling were quantifıed using time-lapse imaging and quanti-
tative single cell immunofluorescence microscopy, respectively. We identifıed
GSK2126458 and Torin2 as having superior potency and effıcacy in PI3K-path-
way dysregulated TNBC. Unlike other PI3K pathway inhibitors, whose ineffec-
tiveness arises from insuffıcient induction of apoptosis and variable inhibition of
cell cycle progression at G1/S, GSK2126458 and Torin2 each rapidly induce
caspase 3/7 activity anddurably inhibit the proliferation of surviving cells.While
the effectiveness of GSK2126458 in vitro appears to arise from near-complete
suppression of PI3K-Akt-mTOR signaling, this approach has already proved
unachievable in clinical trials. An alternative therapeutic strategy was identifıed
by characterizing the mechanism of action of Torin2, a tool compound that
inhibits both mTOR kinase and the DNA damage response kinases ATR, ATM,
and DNA-PK. Unlike all other PI3K-Akt-mTOR inhibitors studied, Torin2
counters incomplete drug block atG1/S by concomitant induction of intolerable
replication stress in S phase cells. The unique cell cycle pharmacology of Torin2
is recreated by combining inhibitors ofmTOR andATR/Chk1 kinases presently
undergoing evaluation in clinical trials. In the context of combination therapy,
where cytotoxicity arises from targeting S phase vulnerabilities rather than from
PI3K-Akt-mTOR inhibition in G1, submaximal doses of mTOR kinase inhibi-
tors are suffıcient and confer benefıt by preventing the outgrowth of cells that
survive fractional killing from ATR/Chk1 inhibition. These fındings suggest a
novel strategy for mitigating the failure of precision monotherapy and have
implications for the treatment of tumors where genetic lesions in the PI3K path-
way co-occur with replicative vulnerabilities.
#143 Preclinical studies on potential therapeutic combination partners
for the potent and selective PI3K inhibitor INCB050465 in DLBCL. Mat-
thew C. Stubbs, Robert Collins, Leslie Hall, Alla Volgina, Holly Koblish, Sang
Hyun Lee, Timothy Burn, Phillip C. Liu, Jin Lu, Eddy Yue, Yun-Long Li, An-
drew P. Combs, Wenqing Yao, Gregory Hollis, Reid Huber, Bruce Ruggeri,
Peggy Scherle. Incyte Corp., Wilmington, DE.
The delta isoform of PI3K (PI3K) plays an essential role in B-cell develop-
ment and function by mediating the signaling of key receptors on B cells. In-
creasedmalignant B cell proliferation and survival has also been associated with
aberrant activation of PI3K, making selective inhibition of this isoform an
attractive therapeutic approach for the treatment of B cell malignancies.
INCB050465 is a potent inhibitor of PI3K, with a20,000 fold selectivity over
other PI3K isoforms. Emerging clinical data indicate that INCB050465 mono-
therapy is well tolerated and results in promising clinical responses in patients
with various lymphoma histologies, including those with DLBCL.We therefore
sought to explore rational combination strategies for INCB050465 using mouse
xenograft models of ABC-subtype (HBL-1), GCB-subtype (Pfeiffer), and GCB/
double-hit (WILL-2) humanDLBCL, evaluating standard of care agents such as
bendamustine and rituximab, as well as with targeted agents. PIM inhibition is a
logical addition to PI3K inhibition as a therapeutic approach as both kinases
play a critical role in the AKT signaling pathway, having overlapping substrates.
Likewise BET inhibition is a rational addition to PI3K inhibition in “double-
hit”DLBCLdue to de-regulation ofMYC transcriptional activity. In vivo studies
performed in the Pfeiffer xenograft model demonstrate that INCB050465 com-
bined with the pan-PIM inhibitor INCB053914 yielded complete tumor regres-
sions. This profound decrease in tumor cell survival was due in part to the
signifıcant reduction in pBAD levels resulting from dual PIM and PI3K inhi-
bition. Despite modest single agent activity in vivo, the combination of
INCB050465 with BET inhibitors, INCB054329 or INCB057643, resulted in
signifıcant anti-tumor effıcacy in all of the DLBCLmodels studied, and caused a
marked repression in tumor MYC expression. To study the transcriptional ef-
fects of combining PI3K and BET inhibitors in this lymphomamodel, WILL-2
xenograft tumors from mice treated with single dose INCB050465,
INCB054329, the combination, or vehicle control were analyzed by RNAseq.
INCB050465 enhanced the ability of INCB054329 to repress a MYC-driven
transcriptional program, and the combination also regulated multiple develop-
mental and inflammatory pathways. Together, these data support the clinical
evaluation of the PI3K inhibitor INCB050465 as part of a combination regimen
with PIM or BET inhibitors for the treatment of DLBCL.
#144 Src leads to a novel mechanism of resistance to PI3K inhibitors
through regulation of PI3K/p85 activation. Gui Chul Kim, Hae Yun Nam,
Hyang Ju Lee, Min Kyung Kim, Geun Hee Lee, Myung Woul Han, Seong Who
KIM. Univ. of Ulsan, Seoul, Republic of Korea.
Activation of the PI3K pathway is commonly observed and is correlated with
tumor development, progression, poor prognosis, and resistance to cancer ther-
apies, such as radiotherapy, in most cancers. As a central node of this pathway,
PI3K is an attractive target for PI3K-addicted cancer therapy and PI3K inhibi-
tors may thus restore sensitivity to other treatments when administered as part
of combination regimens.Here, we found that PI3K/p85was expressed predom-
inantly in the radioresistant head and neck cancer cell line (HN31 cell line). And
then, we investigatedwhether PI3Kmodulationwas crucial for the development
of novel treatment strategies for radioresistant cancer cell line. Interestingly, we
found that head and neck cancer cell lines with PI3K/p85 activation showed the
resistance to PI3K inhibitors and the resistance mechanism was associated with
Src activation which is a member of a superfamily of membrane-associated
nonreceptor protein tyrosine kinases. Src inhibitor improves the effıcacy of PI3K
inhibitor treatment through suppression of Src and PI3K/p85 activation in
HN31 cell line. Collectively, our study highlights the role of p85 and Src activa-
tion in the resistance for PI3K inhibition and the potential clinical application of
combination regimens of Src andPI3K inhibitors in head and neck cancers. This
is the fırst investigation to analyze the role of Src in resistance to the PI3K
inhibitors of head and neck cancer. As a consequence, a greater understanding
of resistance mechanisms through our results will enable the rational design of
combination regimens and sequential treatment algorithms to improve clinical
outcomes.
#145 PIK3CB inhibitors selectively block the survival of glioblastoma
cells. Lamvy Le,1 Zhi Sheng2. 1Virginia Tech Carilion Research Institute, Roa-
noke, VA; 2Virginia Polytechnic Inst. & State Univ., Roanoke, VA.
Objective: To explore the divergent role of PI3K isoforms in glioblastoma
Background: Glioblastoma multiforme is the most malignant brain tumor in
adults. Despite aggressive treatments, the median survival and fıve-year overall
survival of glioblastoma patients remains low (14.6 months and 4.7%, respec-
tively). Nearly 90% of patients experience recurrence within two years, leaving
patients with few treatment options. Recently, PI3K pan inhibitors have been
used to treat recurrent glioblastoma and achieved modest effect in the clinic.
PI3K has four catalytic isoforms (PIK3CA, B, D, andG); hence, it is possible that
these isoforms may have different roles in glioblastoma and need to be selec-
tively targeted. This idea is further supported by our recent results, in which we
have shown that elevated expression of PIK3CB, but not other PI3K isoforms,
signifıcantly correlated with higher rate, risk, and poor prognosis of recurrent
glioblastomas. Hence, we hypothesize that PIK3CB-selective inhibitors are
more effective for glioblastoma. Design/Methods: We used a panel of glioblas-
toma cells with different levels of PIK3CB, treated them with PI3K-isoform-
selective inhibitors, and compared them to pan PI3K inhibitors. We measured
cell viability using the MTS cell viability assay. Normal human astrocytes were
used as controls to determine toxicity. Results:We found that PIK3CB inhibitors
TGX-221 and GSK2636771 signifıcantly blocked the proliferation of PIK3CB-
high U87MG and SF295 cells, while it had no effect on the viability of PIK3CB-
lowA172 and LN229 cells. In contrast, other PI3K inhibitors and pan inhibitors
either non-selectively blocked or had no effect on these cells. Importantly, these
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compounds, but not PIK3CB inhibitors, blocked the growth of astrocytes. Con-
clusions: Selective blockade of PIK3CB, but not other PI3K isoforms, is an ef-
fective therapy for glioblastoma with a low toxicity to normal tissues.
#146 The PI3K inhibitor, taselisib, has a uniquemechanism of action that
leads to enhanced potency in PIK3CA mutant models. Kyung W. Song, Kyle
A. Edgar, Donald S. Kirkpatrick, Lilian Phu, Stephen Schmidt, Michelle Nan-
nini, Rebecca Hong, Eric Cheng, Lisa Crocker, Amy Young, Deepak Sampath,
Lori Friedman. Genentech, South Sanfrancisco, CA.
Activating mutations in PIK3CA are commonly found in a wide variety of
human cancers, and the dysregulation of the phosphoinositide-3 kinase (PI3K)
signaling pathway has been implicated in tumor cell growth and survival. Ta-
selisib (GDC-0032), a novel, oral, selective inhibitor of p110alpha, sparing inhi-
bition of p110beta, is more potent in cancer cells bearing PIK3CAmutants than
those with wildtype PIK3CA. Preclinical studies demonstrate that taselisib in-
ducesmore apoptotic cell death in PIK3CAmutant cancer cells than other PI3K
inhibitors. We have discovered that taselisib has a dual mechanism of action,
both blocking PI3K signaling, and inducing a decrease in p110a protein levels.
Mass spec analysis reveals that taselisib treatment leads to the specifıc depletion
of mutant p110alpha without signifıcant change in wildtype p110alpha protein
levels. This drug-induced p110a protein depletion is rescued by E1 inhibitors
and by proteasome inhibitors. Other clinical PI3K inhibitors, including
p110alpha selective and pan-PI3K inhibitors, are unable to induce the depletion
of mutant p110 alpha protein. Furthermore, we have discovered that taselisib
more effectively maintains pathway suppression in PIK3CA mutant cells at 24
hrs in response to feedback. In comparison to other clinical-stage PI3K inhibi-
tors administered at a maximum tolerated dose, taselisib has superior effıcacy
with increased tumor regressions in PIK3CAmutant xenograft models. In sum-
mary, these preclinical studies indicate that PI3K inhibitors, which have the
ability to trigger degradation of mutant p110a protein, can more effectively
suppress the signaling pathway, which may result in greater anti-tumor activity
and improved therapeutic index in PIK3CA mutant tumors.
#147 Metformin suppresses triple-negative breast cancer stem cells by tar-
geting KLF5 for degradation. Peiguo Shi, Zhongmei Zhou, Rong Liu, Ceshi
Chen. Kunming Inst. of Zoology, Kunming, China.
Out of the breast cancer subtypes, triple-negative breast cancer (TNBC) has the
poorest prognosis without effective targeted therapies. A stem cell transcription
factor KLF5 is over-expressed in basal type TNBC and promoting cell proliferation,
survival and stemness. Previously, we demonstrated that Mifepristone suppresses
basal TNBC stem cells by down-regulating KLF5 expression through inducing the
expression ofmiR-153. In this study,Metformin, a fırst-line drug for type 2 diabetes
mellitus, was demonstrated to target breast cancer stem cells selectively. However,
the effıciency and themechanism of action ofmetformin in TNBC are unclear.We
demonstrated thatmetformindecreased thepercentageofTNBCstemcellspartially
through the downregulation of the expression of KLF5 and its downstream target
genes, such as Nanog and FGF-BP1, in TNBC cell lines. Metformin induced
GSK3-mediated KLF5 protein phosphorylation and degradation through the in-
hibition of PKA activity in TNBC cells. Consistently, PKA activators increased the
expression levels of KLF5.We observed a positive correlation between p-CREB and
KLF5 protein levels in human TNBC samples. These fındings suggest that met-
formin suppresses TNBC stem cells partially through the PKA-GSK3-KLF5 sig-
naling pathway.
#148 Adual and selective smallmolecule inhibitor of EGFRandPI3kinase
shows promising preclinical activity against KRAS and BRAF mutant colo-
rectal tumors. Joel D. Maust, Elizabeth K. Ziemke, Christy L. Frankowski-
McGregor, Jun Beom Ku, Rachel Mumby, Karin M. Hardiman, Christopher E.
Whitehead, Judith S. Sebolt-Leopold. Univ. of Michigan, Ann Arbor, MI.
Agents targeting epidermal growth factor receptor (EGFR) have met with
limited success in the clinical management of colorectal cancer (CRC). Muta-
tions inKRAS, BRAF, and PIK3CA are important drivers of resistance to EGFR-
targeted therapy. Conversely, EGFR-mediated feedback mechanisms serve to
mediate resistance to MEK inhibitor-based treatment of CRC by reactivating
MAP kinase signaling. Our central hypothesis is that a dual small molecule
inhibitor that potently and selectively targets only EGFR andPI3KA,when com-
bined with aMEK inhibitor, will be highly effıcacious against subpopulations of
BRAFmutant orKRASmutant colorectal cancers that are dependent upon these
kinasemolecules to drive tumor progression. Employing a computational mod-
eling approach, we exploited the known binding modes of structurally related
ATP binding site inhibitors of EGFR and PI3K to design small molecules that
simultaneously inhibit both kinases in a selective manner. To the best of our
knowledge, the lead compound MTX-211, whose binding mode is flipped in
PI3K compared to EGFR, represents a fırst in class selective inhibitor of these
two critical oncogenic kinases. MTX-211 exhibits a favorable pharmaceutical
and selectivity profıle, possessing sub- to low nanomolar potency against both
targets, 70% oral bioavailability, strong pharmacodynamic modulation of
both EGFR and PI3K signaling, and strong in vivo single agent effıcacy against
multiple BRAFmt and KRASmt colorectal cancer models, as evidenced by T/C
values of 29 to 36% after 10-14 days of oral dosing of 50 mg/kg. A signifıcantly
higher degree of in vivo activity is seen whenMTX-211 is co-administered with
the MEK inhibitor trametinib (400% increase in survival compared to single
agent arms), lending support for this polypharmacology approach over triple
drug combination strategies. Based on its promising therapeutic profıle, MTX-
211 is the focus of an ongoing mouse trial of a large panel of patient-derived
xenograft BRAFmt and KRASmt CRC models to inform the design of future
human clinical trials.
#149 Co-targetingmTORC and EGFR signaling as a potential therapeutic
strategy in HNSCC. Adam D. Swick, Prashanth J. Prabakaran, Amal Javaid,
Margot Miller, Michael Fisher, Emmanuel Sampene, Irene M. Ong, Kwangok
Nickel, Randall J. Kimple. Univ. of Wisconsin-Madison, Madison, WI.
Background -Head and neck squamous cell carcinomas (HNSCCs) have high
rates of mutation and other alterations along the PI3K/AKT/mTORC signaling
axis. This has led to interest in the use of therapeutics targeting this pathway,
however identifying reliable predictive biomarkers to guide patient selection
remains challenging. Despite excellent preclinical data, the use of these com-
pounds as monotherapy has been underwhelming in initial clinical trials. The
EGFR monoclonal antibody cetuximab remains the only approved targeted
agent for HNSCC and with reasonable toxicity profıles, has potential use in
combination therapy. Methods - Both catalytic mTORC (AZD8055) and PI3K/
mTORC(NVP-BEZ-235) inhibitors were tested /- cetuximab in several in
vitro and in vivo pre-clinical models. A panel of HNSCC cell lines and patient
derived xenografts (PDX) were evaluated for PI3K/AKT/mTORC pathwaymu-
tation by sequencing and potential protein biomarker by immunoblot and IHC.
Cell lines were assayed for sensitivity to all three agents by growth inhibition and
clonogenic survival assay. DNA replication(BrdU uptake) and apoptosis (Ca-
pase 3/7 activity) were investigated to assess the mechanism of inhibition. The
specifıcity of the molecular targeted effects was confırmed by siRNA knock-
down. Five unique PDX models that presented PIK3CA mutation or intrinsic
cetuximab resistancewere treatedwith a combination of cetuximab and the dual
mTORC inhibitorAZD8055 in a nudemousemodel. Results -Assessment of the
panel of HNSCC cell lines by mutational hotspot sequencing did not reveal any
obvious sensitizing mutations, whereas putative protein biomarkers (e.g.
PIK3CA, pAKT) were elevated in some cell lines. All cell lines showed modest
response to both PI3K/mTORC and dual mTORC inhibition. The addition of
cetuximab to either agent produced modest additive effect. Mechanistic studies
revealed that growth inhibition rather than death induction was the major anti-
cancer effect. SiRNA knockdown showed similar molecular signaling and func-
tional effects to drug inhibition. Using the PDX models, in vivo single agent
mTORC inhibition inhibited growth of a PIK3CA mutant cancer, but had no
effect on any PIK3CAWT or a second PIK3CA mutant model. In all models the
combination therapy showed greater growth delay than monotherapy. Conclu-
sions - The uniformability of PI3K/mTORCandmTORC inhibition to suppress
the growth of HNSCC cells highlights the role of this signaling pathway to drive
the proliferation. In vivo, despite some PDX models meeting likely selection
criteria, the single agent therapy was largely ineffective. Conversely the combi-
nation treatment produced growth delay and suggests the potential for adding a
catalytic mTORC inhibitor to cetuximab therapy for HNSCC patients. Overall,
these results add to a growing body of evidence suggesting that attempts to
match genetic alternation or other biomarker to the optimal therapy in HNSCC
remains complex and challenging.
#150 Identifıcation of determinants of sensitivity toAKT inhibition using
breast cancer (BC) patient-derived tumor xenografts (PDX). Albert Gris-Ol-
iver,1MafaldaOliveira,1MartaGuzman,1Olga Rodríguez,1 Judit Grueso,1Mau-
rizio Scaltriti,2 William J. Howat,3 J Carl Barrett,4 Javier Cortés,5 José Baselga,2
Gaia Schiavon,3 Barry R.Davies,3 Cristina Saura,1 Violeta Serra1. 1Vall d’Hebron
Institute of Oncology, Barcelona, Spain; 2Memorial Sloan Kettering Cancer Cen-
ter, New York, NY; 3AstraZeneca, Cambridge, United Kingdom; 4AstraZeneca,
Waltham, MA; 5Ramón y Cajal University Hospital, Madrid, Spain.
The antitumor activity of AKT inhibitors is being investigated for the treat-
ment of BC with activation of the PI3K/AKT pathway. Putative predictive bio-
markers that are being tested in ongoing trials are PTEN loss/mutation (mut)
(around 40% of triple negative BC) and AKT1 mutation (4-5% ER/HER2-
BC). The BEECH trial is evaluating the activity of the pan-AKT1/2/3 inhibitor
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(AKTi) AZD5363 in combination with the antimicrotubule agent paclitaxel in
HER2-negative (HER2-) metastatic BC. We aimed to identify response bio-
markers to the single agent AKTi and its degree of synergy in combination with
paclitaxel, using HER2- patient-derived tumor xenografts (PDX). Fifteen PDX
have been established from BC patients receiving standard treatment at our
Hospital, as well as from those participating in the BEECH trial, when sample
was available, by implanting their tumor biopsies at baseline, on-treatment and
at progression. The antitumor activity of AZD5363 as single agent and in com-
bination with paclitaxel has been measured in these PDX. Genotyping and pro-
tein levels have been analyzed by exome sequencing, capture-based sequencing,
Western blot and immunohistochemistry (IHC). AZD5363 monotherapy re-
sults in disease stabilization or tumor regression in 3 out of 15 PDX (2/9 ER-/
HER2- and 1/6 ER/HER2-). We found a positive association between high
levels of pAKT S473 byWestern blot and antitumor response. Interestingly, the
two ER-/HER2- responding PDX harbor a PTEN frameshift mutation or gene
loss concomitant with an activating mutation within the PI3K pathway
(PIK3CA or PIK3R1). The ER/HER2- PDX responder harbors an AKT1-
p.E17K mutation. AZD5363 plus paclitaxel, at a clinically relevant dose, results
in disease stabilization in 2/11 PDX that progress to either single agent (1/7
ER-/HER2- and 1/4 ER/HER2-); the latter PDX being derived from the base-
line tumor biopsy of a BEECH trial patient who benefıted from this combination
for one year. Altogether these results suggest that double-altering events in the
PI3K pathway, including PTEN loss/mut and a second PI3K-pathway alteration
in ER-/HER2- tumors, or AKT1-p.E17K in ER/HER2- tumors, and conse-
quent high pAkt S473 levels could be associatedwith intrinsic sensitivity to AKT
inhibition. The predictive value of these alterations as determinants of response
to AKTi deserves further investigation.
#151 Inhibition of AKT-1 for the treatment of human non-small cell lung
cancer (NSCLC) in-vitro.PaigeM.Chorner, RogerA.Moorehead.University of
Guelph, Guelph, Ontario, Canada.
AKT is a serine-threonine kinase implicated in tumorigenesis as a central
regulator of cellular growth, proliferation, survival, metabolism, and migra-
tion. Activated AKT is overexpressed in 50-70% of NSCLC tumors and has
exhibited an association with poor prognosis as well as chemotherapeutic
resistance to platinum-based therapy. Accordingly, AKT inhibitors such as
MK-2206 are currently undergoing clinical investigation for the treatment of
human NSCLC however, these agents broadly target all three (1-3) AKT
isoforms. Recent evidence suggests opposing roles of the AKT isoforms in
tumorigenesis where loss of AKT-1 inhibits while the loss of AKT-2 en-
hances lung tumor development in transgenic mouse models. Based on these
fındings, we hypothesized that preferential inhibition of AKT-1 would war-
rant a more effective therapeutic strategy for NSCLC compared to the cur-
rent clinical approach of broad AKT inhibition. WST-1 cell viability assays
have revealed that a selective AKT-1 inhibitor A-674563 is a more potent
regulator of survival in 6 NSCLC cell lines compared to a pan-AKT inhibitor
MK-2206. Furthermore, off-target CDK2 inhibition likely contributes to the
observed benefıts of the AKT-1 inhibitor as the reduction in cell viability
largely parallels the effects of a CDK2 inhibitor PHA-848125. In addition,
the cell lines with higher endogenous CDK2 and p-CDK2 expression are
more sensitive to the AKT-1 inhibitor relative to the pan-AKT inhibitor
MK-2206. Basal protein and RNA levels in each of the cell lines have also
shown that high AKT-3 expression may confer resistance to the pan-AKT
inhibitor MK-2206. Thus, AKT-3 expression has the potential to serve as a
predictive marker for patient response to AKT-1 versus broad AKT-inhibi-
tion. Cell cycle analysis demonstrated that the AKT-1 inhibitor decreases the
proportion of cells in the Go/G1 phase and increases the proportion of cells
in the S-phase, indicating a possible S-phase cell cycle arrest. These differ-
ences are also more signifıcant in the cell lines with augmented sensitivity to
the AKT-1 inhibitor. Therefore, altered cell cycle progression could be the
major driver of the therapeutic benefıts of the AKT-1 inhibitor. Overall, our
fındings suggest that AKT-1 inhibition is signifıcantly more effective at re-
ducing NSCLC cell viability in-vitro compared to pan-AKT inhibition. Fur-
thermore, cell lines with higher CDK2 and AKT-3 expression have margin-
ally increased sensitivity to the AKT-1 inhibitor A-674563 compared to the
pan-AKT inhibitor MK-2206. Future research will focus on understanding
the mechanism of action of the AKT-1 inhibitor through combined western
blot, AKT antibody array, flow cytometry, and confocal microscopy data.
Additionally, we will investigate the toxicity of these inhibitors on normal
human small airway epithelial cells (HSAECs) to ensure preferential activity
against malignant over somatic cells.
#152 Dual mTORC1/2 inhibition sensitizes testicular cancer cell lines to-
ward cisplatin treatment. Fernanda Ximena Rosas Plaza, Gerda de Vries, Al-
bert J. Suurmeijer, Jourik A. Gietema, Marcel A.T.M. van Vugt, Steven de Jong.
UMCG, University of Groningen, Groningen, Netherlands.
Testicular cancer (TC) patients with metastatic disease and poor prognosis
have a 50% 5-year survival. It has been reported that resistant TC cell lines show
hyperactivation of the PI3K/Akt/mTOR pathway. In this study we investigated
the potential benefıt from PI3K, Akt andmTOR inhibition in combination with
cisplatin in TC. Our panel of embryonal carcinoma cell lines include the cispla-
tin-sensitive cells: Tera and 833KE and the cisplatin-resistant cells: Scha, TeraCP
and NCCIT. Western blotting showed that the resistant TC cell line TeraCP
expresses higher levels of p-Akt compared to the sensitive cell line Tera. To
evaluate sensitization towards cisplatin, TC cell lines were treated with cisplatin
and/or PI3K inhibitor GDC0941, Akt inhibitor MK2206, mTORC1 inhibitor
everolimus and mTORC1/2 inhibitors AZD8055 and AZD2014 for 24 hours
andDilC5/PI stainingwas performed to estimate apoptosis with flow cytometry.
All TC cell lines were strongly sensitized bymTORC1/2 inhibition by increasing
cisplatin induced apoptosis to 60-80% when cisplatin alone induced only 15-
30%. TC cells were also sensitized by mTORC1 and PI3K inhibition but to a
lesser extent. Akt inhibition did not sensitize Scha or Tera cells to cisplatin, while
TeraCP was marginally sensitized. We then evaluated clonogenic capacity in
cells pretreated with AZD8055 for 24 hours and seeded in the presence of dif-
ferent concentrations of cisplatin for 6 days. Clonogenic capacity was reduced in
Tera and TeraCP after mTORC1/2 inhibition with AZD8055 compared with
control cells treated with cisplatin only. Western blot done with Scha, Tera and
TeraCP lysates treated for 24 hours with AZD8055, everolimus, GDC0941 and
MK2206 showed that only mTOR inhibition was able to block S6 phosphoryla-
tion. In addition, we performed immunohistochemistry of p-S6 and Ki-67 in
paraffın embedded tissue from TC patients. IHC showed that patient derived
xenografts showed high expression of these markers compared to non-cancer-
ous tissue, meaning that the mTOR pathway is very active in this tumor type.
These data indicate that TC relies on the PI3K/Akt/mTOR pathway for survival
and mTORC1/2 inhibition showed the stronger sensitizing effect towards cis-
platin treatment.We consider addingmTORC1C/2 inhibition to cisplatin based
treatment a potential therapeutic option for chemoresistant TC patients that
warrants further in vivo investigations. Supported by CONACYT grant 381543
and Dutch Cancer Society grant RUG 2014-6691.
#153 Tricyclic fused pyrimidinopyrrolo-oxazines reveal conformational
preferences of morpholine for PI3K hinge region binding. Alexander M.
Sele,1 Denise Rageot,1 Florent Beaufıls,1 Anna Melone,1 Thomas Bohnacker,1
Eileen Jackson,1 Jean-Baptiste Langlois,1 Paul Hebeisen,2 Doriano Fabbro,2
Matthias P. Wymann1. 1University of Basel, Basel, Switzerland; 2PIQUR Thera-
peutics AG, Basel, Switzerland.
Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases, produce
PtdIns(3,4,5)P3 and trigger intracellular signaling pathways that are vital to cell
growth, proliferation, survival andmigration. Constitutive activation of PI3K is
frequently observed inmany tumor types, which defınes PI3K as a valuable drug
target in oncology.1 Numerous PI3K inhibitors in clinical development contain
a morpholine moiety that mediates hinge region binding in the ATP pocket of
PI3K by a hydrogen bond with the active site valine backbone nitrogen (Val851
in PI3K)2. We present here novel pyrimidinopyrrolo-oxazines related to the
clinically advanced, pyridinylmorpholine and triazinylmorpholine derived pan-
PI3K/mTOR inhibitors BKM120 and PQR309. The novel fused tricyclic core of
these compounds contains twomorpholine moieties of which one is conforma-
tionally restricted by the introduction of a methylene bridge that links the py-
rimidine core with one of the twomorpholine moieties. This modifıcation leads
to the generation of two regioisomers, each existing as a set of enantiomers. We
investigated the influence of this conformational restriction on PI3K inhibitory
activity and analyzed the distinct selectivity profıles and potencies of the respec-
tive stereo- and regio-isomers. The design and preparation of specifıc com-
pounds in combination with biological assays (phosphorylation of PKB and S6,
binding affınity to p110), structure-activity relationship (SAR) and molecular
modelling studies allowed us to understand the binding mode of these com-
pounds and acquire valuable information that potentially lead to the develop-
ment of derivatives with a distinct selectivity profıle (e.g. PI3K versusmTOR). A
selection of compounds demonstrated inhibition of protein kinase B (pSer473)
and ribosomal protein S6 (pSer235/236) phosphorylation with IC50 values in
the nanomolar range and high inhibitory potency of all PI3K isoforms
(Ki(p110)  40 nM). Single p.o. administration of our lead compound to SD
rats resulted in good oral bioavailability as well as excellent brain penetration.
Furthermore, mechanism of action-based increases in glucose levels and insulin
levels have been observed. In conclusion, we present here the development,
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optimization, preparation and biological evaluation of a novel class of potent,
orally available and brain-penetrant pan-PI3K inhibitors that represent an in-
novative extension to known pyrimidinomorpholine derived PI3K inhibitors.
Moreover, our results add to the understanding of how introducing specifıc
structural and conformational modifıcations can lead to the development of
optimized, selective PI3K and mTOR inhibitors. [1] Thorpe, L. M.; Yuzugullu,
H.; Zhao, J. J. Nat. Rev. Cancer 2015, 15, 7-24. [2] Andrs, M.; Korabecny, J.; Jun,
D.; Hodny, Z.; Bartek, J.; Kuca, K. J. Med. Chem. 2015, 58, 41-71.
#154 The phosphatidylinositol-3-kinase (PI3K) inhibitor (i) copanlisib is
active in preclinical models of B-cell lymphomas as single agent and in com-
bination with conventional and targeted agents including venetoclax and
palbociclib. Eugenio Gaudio,1 Ivo Kwee,1 Filippo Spriano,1 Chiara Tarantelli,1
Andrea Rinaldi,1 Thibaud Jourdan,2 Melanie Berthold,2 Alberto Arriibas,1 An-
astasion Stathis,1 Davide Rossi,1 Ningshu Liu,2 Martin Lange,2 Oliver Politz,2
Emanuele Zucca,1 Francesco Bertoni1. 1Institute of Oncology Research - IOR,
Bellinzona, Switzerland; 2Bayer AG, Berlin, Germany.
Introduction: Copanlisib (BAY80 6946) is a highly selective pan class I PI3K-i
with predominant inhibitory activity against PI3K and PI3K, in clinical de-
velopment as single agent and in combination for lymphoma patients. To ad-
dress single agent antitumor activity in different lymphomas and to understand
the molecular basis of resistance mechanisms for rational combination, we per-
formed a screening of copanlisib as single agent and in combination with 15
other anticancer agents in 17 cell lines derived from mantle cell lymphoma
(MCL), marginal zone lymphoma (MZL) and chronic lymphocytic leukemia
(CLL). Methods: MCL (Jeko1, Rec1, JVM2, Granta519, Maver1, Mino1, SP-49,
SP-53, UPN1, Z138), MZL (Karpas1718, VL51, SSK41, ESKOL, HAIR-M,
HC-1) andCLL (MEC1) cell lineswere exposed to increasing doses of copanlisib
alone and in combination with other compounds using the fıxed ratio set-up.
Tested compounds included approved and experimental inhibitors of key reg-
ulatory pathways. Synergy was assessed via Chou-Talalay combination index
(CI). Gene expression profıling (GEP) was done using Illumina Human
HT12Expression BeadChips and GSEA (FDR0.25). Results Copanlisib
showed antitumor activity in most cell lines (median IC5022nM; 95%C.I.:
15-98). The other most active drugs were bortezomib (5nM; 5-7), romidepsin
(34nM; 2-94), roniciclib (23nM; 18-29), panobinostat (161nM; 11-1263), MI2
(490nM; 224-1000). The remaining had median IC50s 500nM. Copanlisib-
containing combinations often gave synergy/additive effects: copanlisib with
venetoclax was benefıcial in 16/17; with MI2 in 15; with palbociclib or ibrutinib
in 14; with BAY 1125976 or panobinostat in 13; with lenalidomide or BAY
1238097 in 12; with rituximab in 11; with romidepsin in 10; with roniciclib in 9;
with bortezomib in 8; with BAY 1143572 in 7; with bendamustine in 6; with
ruxolitinib in 2. Combinations with venetoclax and with palbociclib were the
most promising, achieving CI values0.5 in 7 and 6 cell lines, respectively. GEP
before treatment identifıed genesets associated with different sensitivity to these
2 combinations. High expression of genes involved in IFN signaling, oxidative
phosphorylation, fatty acid metabolism, apoptosis, PI3K/AKT/mTOR and IL6/
JAK/STAT signaling and low expression of cell cycle genes were associated with
synergism to copanlisib/venetoclax. Largely the opposite was observed for the
palbociclib combination, more active with high expression of E2F/MYC targets
and cell cycle genes and low expression of genes involved in IFN PI3K/AKT/
mTOR and IL6/JAK/STAT signaling. Conclusion: Copanlisib was active in
MCL,MZL andCLLmodels. Combinations with BCL2-i venetoclax andCDK4/
CDK6-i palbociclib were the most synergistic. Specifıc GEP features might pre-
dict lymphomas that could benefıt from these regimens.
#155 Addition of RP6530, a dual PI3K/ inhibitor, accentuates Ro-
midepsin activity in NHL cells in vitro. Srikant Viswanadha,1 Satyanarayana
Eleswarapu,1 Seeta Nyayapathy,1 Swaroop Vakkalanka2. 1Incozen Therapeutics
Pvt. Ltd., ShameerpetHyderabad, India; 2Rhizen Pharmaceuticals SA, LaChaux-
de-Fonds, Switzerland.
Background: Relapsed or refractory Non-Hodgkin’s Lymphoma (NHL) rep-
resents a signifıcant unmet medical need. Novel treatment options currently
being explored include Romidepsin, a histone deacetylase inhibitor, which has
demonstrated signifıcant preclinical and clinical activity. Because the PI3Kpath-
way is often activated inNHL, combining Romidepsinwith a PI3K / inhibitor
may be a viable alternative to chemotherapy. RP6530 is a novel, potent, and
selective PI3K / inhibitor that demonstrated high potency against PI3K
(IC5025 nM) and  (IC5033 nM) enzymes with selectivity over  (300-
fold) and  (100-fold) isoforms. Dose-escalation trials to evaluate the safety
and effıcacy of RP6530 in patients with hematological malignancies are cur-
rently underway at several sites inUS andEurope. The objective of this studywas
to evaluate the effect of a combination of Romidepsin and RP6530 in NHL cells.
Methods: Combination of Romidepsin and RPRP6530 was evaluated in the fol-
lowing NHL cell lines: OCI-LY-1, OCI-LY-10, RAJI, DAUDI, TOLEDO, JEKO,
MAVER, and SU-DHL-1. Synergism or additivity between Romidepsin and
RP6530 was determined using different concentrations of the compounds in a
5 x 5 grid and calculated based on the BLISS score. Effect on apoptosis and cell
cycle were estimated by flow cytometry. Phosphorylated AKT and PARP were
determined by Western Blotting. Results: Synergism or additivity between Ro-
midepsin and RP6530 for anti-proliferative activity was noticed in all the cell
lines testedwith effect beingmost pronounced inOCI-LY-1, OCI-LY-10, JEKO,
and SU-DHL-1. Incubating cells with 3-5 nM Romidepsin and 3 or 5 M
RP6530 resulted in a 2 to 5-fold increase in the total apoptotic population. Cell
cycle analysis indicated that the combination of Romidepsin (1-5 nM) and
RP6530 (1-5 M) caused a G0/G1 arrest (2 to 3-fold) with a corresponding
increase in percent of apoptotic cells. While Romidepsin had minimal effect of
pAKT, treatment with RP6530 reduced expression by 40-90% across cell lines.
Further, Romidepsin RP6530 enhanced expression of cleaved PARP (8 to
60-fold) compared to either agent alone Conclusions: Addition of RP6530, a
potent and selective dual PI3K/ inhibitor, potentiated Romidepsin activity in
NHL cells. Findings provide a rationale for use of the combination in future
clinical trials involving naïve or relapsedNHL patients thereby providing a safer
alternative to currently available therapy.
#156 Preclinical characterization of GDC-0077, a specifıc PI3K alpha in-
hibitor in early clinical development.Kyle Edgar, EmilyHanan, Steven Staben,
Stephen Schmidt, Rebecca Hong, Kyung Song, Amy Young, Patricia Hamilton,
Alfonso Arrazate, Cecile de la Cruz, Marcia Belvin, Michelle Nannini, Lori S.
Friedman, Deepak Sampath. Genentech, South San Francisco, CA.
The phosphatidylinositol 3kinase (PI3K)/protein kinase B (Akt)/mammalian
target of rapamycin (mTOR) signaling pathway is a major regulator of tumor
cell growth, proliferation and survival. Dysregulation of the PI3K/Akt/mTOR
signaling pathway through multiple mechanisms has been described in solid
tumor malignancies, including activating and transforming “hotspot” muta-
tions as well as amplifıcation of PIK3CA that encodes the p110 alpha subunit of
PI3K.Hotspotmutations of PIK3CAmutation are frequently observed in breast
cancer with a prevalence of approximately 30%. GDC0077 is a potent inhibitor
of PI3K alpha (IC50 0.038 0.003 nM) and exerts its activity by binding to the
ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to
PIP3. Biochemically, GDC-0077 is more than 300fold selective over other Class
I PI3K isoforms such as beta, delta, and gamma and more than 2000 fold more
selective over PI3K class II and III family members. Importantly, GDC-0077 is
more selective for mutant versus wild-type PI3K alpha in cell based assays.
Compared to the PI3K inhibitor, taselisib, the improved biochemical selectivity
of GDC-0077 against PI3K delta is demonstrated in human CD69 B-cells,
which are primarily dependent on PI3K delta for proliferation and survival and
were more sensitive to taselisib than GDC-0077. Mechanism of action studies
indicate that GDC-0077 induces depletion of mutant PI3K alpha protein result-
ing in reduction of PI3K pathway biomarkers such as pAkt and pPRAS40, inhi-
bition of cell proliferation and increased apoptosis in human PIK3CA mutant
breast cancer cell lines to a greater extent when compared to PIK3CA wild-type
cells. In vivo, daily oral treatment with GDC-0077 in cell-culture-derived and
patient derived PIK3CA mutant breast cancer xenograft models, resulted in
tumor regressions, induction of apoptosis and a reduction of pAkt, pPRAS40,
and pS6RP in a dose-dependent fashion. In vivo effıcacy in a PIK3CAmutant
human breast cancer xenograft model was also improved when GDC0077 was
combined with standardofcare therapies for hormone-receptor positive (HR)
breast cancer such as anti-estrogens (fulvestrant) or CDK4/6 inhibitor (palbo-
ciclib). Collectively, the preclinical data provide rationale for evaluating
GDC0077, a PI3K alpha mutant selective inhibitor, as a single agent and in
combination with standardofcare endocrine and targeted therapies that may
provide additional benefıt to patients that harbor PIK3CA mutations.
#157 Targeting distinct nodes of the PI3K/AKT/mTOR cascade in pros-
tate cancer cells: impact on cell proliferation, apoptosis and pathway signal-
ing. Rute B. Marques, Ashraf Aghai, Wendy Stam, Wytske M. van Weerden.
Erasmus MC, Rotterdam, Netherlands.
Inactivation of the PTEN gene is a common event in PCa, leading to activa-
tion of the PI3K/AKT/mTOR pathway and promoting PCa progression. Inhib-
itors targeting this pathway are currently being developed as anticancer agents.
While recent clinical trials with mTORC1 inhibitors have shown limited single-
agent effıcacy in castration-resistant prostate cancer (CRPC), it is still not known
whether targeting alternative nodes of the PI3K/AKT/mTOR cascade may im-
prove response. The current study aimed to characterize the response of PCa cell
lines to multiple inhibitors targeting the PI3K, AKT and mTOR nodes of the
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cascade and identify possible mechanisms of resistance. The impact of the dif-
ferent PI3K/AKT/mTOR inhibitors on cell proliferation and apoptosis was
measured by WST-1 and ApoTox-Glo assays, respectively, in a broad panel of
established PCa cell lines and primary cell cultures generated from patient-
derived xenografts. PTEN-negative PCa cell lines showed strong response to
PI3K/, AKT and mTOR inhibition, whereas PTEN-positive cells were resis-
tant to PI3K/ and showed variable sensitivity to mTOR inhibitors. MTORC1
inhibitor showed low IC50 but reached plateau at about 70-80% growth inhibi-
tion. In contrast, mTORC1/2 inhibitor could reach complete growth inhibition
at 1M concentration, in sensitive cell lines. Furthermore, treatment with
PI3K or AKT inhibitor in combination with androgen depletion induced apo-
ptosis in various PTEN-negative models, which is consistent with previously
reported synergistic effect of PI3K/AKT and androgen receptor co-targeting.
The effect of the inhibitors on phosphorylation of PI3K downstream targets
(AKT, PRAS40, GSK3, S6K1 and 4EBP1) was analyzed by phospho-specifıc
western blotting. Perturbation of different nodes of the PI3K/AKT/mTOR cas-
cade resulted in differential phosphorylation of downstream targets, but there
was no evident correlation with in vitro growth inhibition. In conclusion, the
current study validates PI3K and AKT as alternative targets in PTEN-negative
PCa, whereas PTEN-positive models showed preferential yet variable responses
towards mTOR inhibitors.
#158 ASN003, a highly selective inhibitor of B-Raf and PI3 kinases, shows
strong antitumor activity in B-Raf inhibitor resistant patient-derived xeno-
graft models. Scott K. Thompson,1 Roger A. Smith,1 Niranjan Rao,1 Michael J.
Wick,2 Sanjeeva P. Reddy1. 1Asana BioSciences, Lawrenceville, NJ; 2South texas
Accelerated Research Therapeutics, San Antonio, TX.
The RAS-RAF-MEK and PI3K-AKT-mTOR pathways are two major signal-
ing pathways involved in human cancer. Components of these two pathways are
frequently mutated in a wide variety of solid tumors. Concurrent double muta-
tions in the two pathways are also observed quite often in a broad range of tumor
types. Additionally, inhibition of one of these pathways often leads to the up-
regulation of the other pathway and development of resistance. In preclinical
models, combined inhibition of both pathways has been shown to impart greater
effıcacy as compared to inhibition of either pathway alone. ASN003 is a novel,
highly selective, small-molecule inhibitor of both RAS-RAF and PI3K pathways,
discovered using a rational design approach. ASN003 shows potent inhibitory
activity against B-RAF and PI3K kinases (low nM IC50).Within the PI3K family,
ASN003 has high selectivity for inhibition of PI3K and PI3K over PI3K. In a
panel of 292 kinases, ASN003 showed high selectivity for inhibiting B-RAF and
PI3 kinases, and associated mutant kinases. In cell-based mechanistic studies,
ASN003 inhibited phosphorylation of ERK, AKT and S6, and showed strong
antiproliferative activity (IC50 60-300 nM) in cell lines with B-RAF and PI3K
pathway mutations as well as in vemurafenib-resistant cell lines. In pharmaco-
dynamic studies inmultiple tumormodels, ASN003 showed strong inhibition of
the phosphorylation of downstream targets of B-RAF and PI3K, confırming
appropriate target engagement. In in vivo effıcacy studies, ASN003 showed
strong tumor growth inhibition or regression inmultiple tumor xenograft mod-
els, including A375 (B-Raf V600E mutation), RKO (B-Raf V600E and PIK3CA
mutations), andA2058 (B-Raf V600Emutation and PTEN loss).We now report
that ASN003 also showed strong tumor growth inhibition (80%) in a patient-
derived xenograft (PDX) model established from a relapsed patient with pro-
gressive B-Raf mutant melanoma who showed initial response to vemurafenib.
Sequencing analysis showed that the vemurafenib resistant tumor acquired a
concurrent PIK3CAmutation. Dual targeting of the B-RAF and PI3K pathways
with ASN003 has the potential to treat and/or prevent the acquired resistance to
selective B-RAF inhibitors, and may also treat a broader patient population and
provide greater effıcacy and survival benefıt than selective B-RAF inhibitors or
selective PI3K pathway inhibitors alone. ASN003 is currently in Phase I clinical
development in patients with advanced solid tumors, including tumors with
B-Raf V600 mutation, PI3 kinase pathway alterations or PTEN loss.
#159 Pharmacological characterization of the selective, orally bioavail-
able, potent dual PI3K/mTORC1/2 inhibitor PQR530. Petra Hillmann,1 De-
nise Rageot,2 Florent Beaufıls,1 Anna Melone,2 Alexander Sele,2 Robert A. Et-
tlin,1 Jürgen Mestan,1 Vladimir Cmiljanovic,1 Marc Lang,1 Elisabeth Singer,3
Carolin Walter,3 Hoa HP Nguyen,3 Paul Hebeisen,1 Matthias P. Wymann,2
Doriano Fabbro1. 1PIQURTherapeutics, Basel, Switzerland; 2University of Basel,
Basel, Switzerland; 3University of Tübingen, Tübingen, Germany.
Introduction: The phosphatidylinositol 3-kinase (PI3K) signaling path-
way plays a fundamental role in many cellular processes like growth, sur-
vival, proliferation, differentiation and motility. In cancers several muta-
tions have been identifıed that lead to constitutive activation of PI3K.
PQR530 is a novel, ATP site directed inhibitor of all PI3K isoforms and the
mammalian target of rapamycin (mTOR) complexes C1/2 that is currently in
pre-clinical development. PQR530 potently binds to its targets, inhibits cell
proliferation and shows excellent selectivity versus related and unrelated
kinases [1]. Results: PQR530 inhibits PI3K signaling in stimulated MCF7
cells as detected by PathScan analysis. Excellent tolerability has been found
for PQR530 during GLP toxicological testing in rats and dogs. Increase in
insulin and blood glucose, a treatable class effect of PI3K inhibitors, has been
observed after PQR530 administration to mice. Investigation of mutagenic-
ity and hERG binding resulted in a clean profıle. PQR530 exhibited dose-
proportional pharmacokinetics (PK) in male C57BL/6J mice. A maximum
concentration (Cmax) in plasma and brain was reached after 30 minutes (7.8
g/ml and 112.6 g/ml, respectively) indicating that effıcacious concentra-
tions were reached in both tissues. The calculated half-life (t1/2) for plasma
and brain was approximately 5 hours. PQR530 potently inhibited PI3K sig-
naling in vivo for several hours after administration of a single oral dose of 50
mg/kg. Tumor growth was signifıcantly decreased in SUDHL-6 lymphoma,
RIVA lymphoma and OVCAR-3 ovarian cancer mouse xenografts using
daily, oral administration. Conclusion: PQR530 is a potent, ATP competitive
pan-PI3K and mTORC1/2 inhibitor. The physico-chemical properties of
PQR530 result in good oral bioavailability and excellent brain penetration.
PQR530 is well tolerated and effıciently inhibits tumor growth in xenograft
models. Preclinical data allow for further development of the compound. [1]
Rageot D, et al., Discovery and biological evaluation of PQR530, a highly
potent dual pan-PI3K/mTORC1/2 inhibitor, abstract submitted for AACR
Annual Meeting 2017, April 1-5, Washington, D. C., USA.
#160 High target binding affınity with long lasting cellular target engage-
ment and high dose intermittent schedule of PI3K inhibitor copanlisib con-
tribute to the potent anti-tumor activity and good safety profıle. Amaury E.
Fernández-Montalván,1 Victoria Georgi,1 James Vasta,1 Sarah Glaeske,1 Vera
Puetter,1 Matthew B. Robers,2 Ursula Moenning,1 Andrea Sturz,1 Julien Le-
franc,1 Karl Ziegelbauer,1 Michael Brands,1 Christian Stegmann,1 William J.
Scott,1 Ningshu Liu1. 1Bayer AG, Berlin, Germany; 2Promega Inc, Berlin, Ger-
many.
Introduction: Several generations of PI3K inhibitors have been tested in
clinic. However, thus far, clinical activity has been moderate. Different from
other oral PI3K inhibitors dosed continuously, copanlisib (BAY 80-6946) is
an intravenous PI3K inhibitor given intermittently to patients. Copanlisib
dosed once weekly demonstrated clinical benefıt with an improved safety
profıle, and therefore challenges the concept of default continuous dosing of
PI3K inhibitors. However, it is still unclear if this concept can be generalized
and whether ’micropharmacokinetic parameters’ also contributed to the po-
tent anti-tumor profıle of copanlisib. Here, we report the characterization of
binding kinetics for copanlisib, as well as the functional consequence in vivo.
Methods: A set of PI3K inhibitors were characterized in 1) a kinetic probe
competition assay (kPCA); 2) a cellular nanoBRET target engagement assay;
3) a cellular washout study with the assessment on pathway engagement; and
4) in vivo pharmacokinetics analysis. Results: Copanlisib showed nearly dif-
fusion-controlled on- and relatively slow off-rates with kon  3.45E7 [M-
1*s-1] and koff  1.67E-3 [s-1] to PI3K. Consequently, it exhibited very
high affınity to PI3K ( Ki ePCA  9.31E-11[M] and KD kPCA  4.77E-11
[M]). In a cellular nanoBRET target engagement assay, the apparent half-life
(t1/2) of ca. 2 hours greatly surpassed the 6.9 min measured using kPCA. The
high affınity to PI3K also translated into potent cellular pathway engage-
ment demonstrated by inhibition of p-AKT and p-PRAS40 in the
PIK3CAmut KPL4 cell line. In a cellular washout study, p-AKT and
p-PRAS40 were assessed till 168 h after incubation with copanlisib for 1 h
followed by a washout step. A dose- and time-dependent pathway engage-
ment was observed even at 72 h post washout. This result indicated that in
cells, copanlisib engages PI3K for an extremely long time, likely due to
rebinding effects facilitated by the fast equilibration kinetics of the com-
pound and its micropharmacokinetic properties. Interestingly, in vivo, BAY
80-6946 levels were approximately 100-fold higher in the tumor than in
plasma at 48 hours and drug clearance from the tumor occurred more slowly
than from plasma. This high and prolonged tumor exposure might be ex-
plained, at least in part, by the high expression of PI3K and long lasting
target occupancy of copanlisib in tumors. Conclusion: Copanlisib demon-
strated high affınity to PI3K with protracted target engagement at cellular
and in vivo levels. This ’micropharmacokinetic feature’ not only supports
intermittent dosing but likely also explains the high exposure in tumors vs
plasma, potent anti-tumor activity and good safety profıles.
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#161 Medulloblastoma therapy targetingHedgehog andPI3K-mTOR sig-
naling pathways in combination with chemotherapy. Nagendra K. Chatur-
vedi, Don W. Coulter, Timothy R. McGuire, Matthew J. Kling, Sutapa Ray,
Shantaram S. Joshi, John G. Sharp. University of Nebraska Medical Center,
Omaha, NE.
Medulloblastoma (MB) is the most frequent malignant brain tumor in chil-
dren. MB patients with high-risk disease have poorly understood biology and
few targeted therapies available. Preclinical studies and molecular profıling of
MB have revealed that the aberrant activation and interaction of the SHH and
PI3K/AKT/mTOR signaling networks are frequently associatedwith poor prog-
nosis MB cases. Emerging evidence also demonstrate the key role of activated
PI3K/AKT/mTOR pathway components in SHH-driven MB therapy-resis-
tance, thus combined targeting of the SHH and PI3K/AKT/mTOR pathways
may be a viable therapeutic strategy to treat high-risk patients. Therefore, we
investigated the combined effıcacy of SHH inhibitor vismodegib and PI3K-
mTOR dual inhibitor BEZ235 or their combination, individually with the che-
motherapeutic drug cisplatin against high-risk MB. Using four MB cell lines,
including non-MYC and MYC amplifıed cell lines, and a xenograft mouse
model, the in vitro and in vivo effıcacies of the proposed therapies on cell
growth/survival along with associated molecular mechanism(s) were investi-
gated. Our results showed that both inhibitors as single agents signifıcantly
decreasedMB cell growth and induced apoptosis by targeting the keymolecules
of the associated pathways in vitro. BEZ235 as single agent showed a greater
anti-MB effıcacy compared to vismodegib. Combined treatment of vismodegib
and BEZ235 together or with cisplatin signifıcantly decreased MB cell growth/
survival and anchorage-independent growth in a dose-dependent fashion com-
pared to single agent activity. Corresponding changes in the expression of the
targetedmolecules following therapywere observed. Results from the combined
approach suggested that the inhibitors not only suppressed MB cell growth/
survival when combined, but also signifıcantly enhanced the cytotoxic effects of
cisplatin. Of these combinations, BEZ235 exhibited a signifıcantly greater effı-
cacy in enhancing the cisplatin-mediated MB cytotoxicity. In vitro studies also
demonstrated that the MYC amplifıed MB cell lines showed a higher sensitivity
to these combined therapies compared to relatively non-MYC amplifıed cell
lines. Therefore, as a next logical step, we tested the effıcacy of above combined
approaches against MYC-amplifıed MB in vivo using NSG mice. Our in vivo
results showed that the combination of vismodegib and BEZ235 or their com-
binations individually with cisplatin signifıcantly delayed tumor growth and
increased survival of xenograft mice compared to single agent activity. These
combination not only signifıcantly reduced tumor growth and increased sur-
vival of the mice but also signifıcantly enhanced anti-MB effıcacy by targeting
SHH andmTOR pathways inMB in vivo. Thus, our studies lay a foundation for
translating these combined therapeutic strategies to the clinical setting to deter-
mine their effıcacies in high-risk MB patients.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
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#162 A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate
served as a potentially novel angiogenesis inhibitor in endometrioid endo-
metrial cancer. Jianzhang Wang,1 Chi Wai Man,1 Xueying Yang,1 Joseph
Kwong,1 Q. Ping Dou,2 Tak Hang Chan,3 Chi Chiu Wang1. 1The Chinese Uni-
versity of Hong Kong, Hong Kong, Hong Kong; 2Wayne State University, Detroit,
MI; 3The Hong Kong Polytechnic University, Hong Kong, Hong Kong.
Background and aim: Anti-angiogenesis is a promising treatment in endo-
metrioid endometrial cancer (EEC) while the present anti-angiogenic drugs still
have limitations such as drug tolerance, toxicity profıle and substantial costs.
(-)-Epigallocatechin-3-gallate (EGCG), the major polyphenol of green tea, is
associated with anti-cancer benefıts, but it is unstable and has poor bioavailabil-
ity. These limitations can be solved through peracetate ester of EGCG as a pro-
drug (ProEGCG), while little is known about its anti-angiogenesis effect in can-
cer. The objective is to study the effect and underling mechanism of ProEGCG
on EEC angiogenesis. Methods and Results: Tumor xenografts were established
by subcutaneous injection of a human EEC cell line (RL95-2) into nude mice,
and ProEGCG or control was orally administered every day. 35 days later, mice
treated with ProEGCG showed signifıcant reduction in lesion size and MVD
without major toxic effects compared to control. To fınd out how ProEGCG
inhibits tumor progress and angiogenesis, microarray analysis of excised lesions
was conducted and indicated thatHIF-1, VEGFAandCXCR4were downregu-
lated by ProEGCG. Compared to control, immunohistochemistry showed that
ProEGCG reduced expression of HIF-1 and VEGFA in RL95-2 cells and de-
creased CXCR4 expression in tumor-associated macrophages (TAMs) and en-
dothelial cells (ECs). To further study the role of ProEGCG on EEC cells, qRT-
PCR andWestern blotting proved that hypoxia (1%O2) upregulated the level of
HIF-1 andVEGFA in EEC cell lines, whichwas reversed by ProEGCG through
inhibiting hypoxia-induced ROS formation. It is known that TAMs play an
important role in tumor angiogenesis, anddouble immunofluorescence of F4/80
and CD206 antibodies in xenografts was applied and found that TAMs infıltra-
tion was reduced in ProEGCG group with decreased VEGFA in TAMs. More-
over, proliferation and migration of ECs are critical for tumor angiogenesis. To
study the effect of ProEGCG on ECs, tube formation and invasion assays were
conducted. The addition of ProEGCG on ECs showed less capillary tube-like
structure formation and less invaded ECs by inhibition of CXCR4 expression on
ECs. However, it was still unclear if CXCL12, the ligand of CXCR4, was affected.
Immunostaining for CXCL12 in tumor lesions indicated that ProEGCG de-
creased CXCL12 expression in cancer and stromal cells, which was further con-
fırmed in primary human endometrial stromal cells by addition of ProEGCG.
Conclusion: Our study was the fırst to reveal the mechanism of anti-angiogen-
esis of ProEGCG, which decreased HIF1/VEGFA expression in tumor cells,
inhibited recruitment and differentiation of TAMs and tube formation of endo-
thelial cells via CXCL12/CXCR4 reduction. These fındings provided that
ProEGCG would be an effective, safe and economic anti-angiogenic drug for
EEC.
#163 Evaluation of ETS2101 and its combination with anti-mCTLA4
monoclonal antibody on CD4 and CD8 TILs in a subcutaneous colorectal
cancermodel of CT-26. Lorcan Sherry,1 Mark Anderson,1 JohnWaller,1 Adam
Sardar,2 Victoria Flores,2 Daniel Hynes2. 1OracleBio, Biocity Scotland, United
Kingdom; 2e-Therapeutics, Long Hanborough, United Kingdom.
ETS2101, (HU-211, Dexanabinol) is a synthetic cannabinoid with limited
affınity to cannabinoid receptors 1 and 2 (CB1 and CB2), reducing its psy-
chotropic potential in comparison to other molecules in the cannabinoid
class. ETS2101 has been found to have effects on immune cell function in
vitro. The presence of Tumor Infıltrating Lymphocytes (TILs) has been pre-
viously shown to correlate with better patient outcomes during various an-
titumor therapies in a multitude of cancers. This study utilized immunohis-
tochemistry (IHC) combined with digital image analysis to quantify CD4
and CD8 TILs within CT-26 tumors treated with ETS2101 in combination
with a checkpoint inhibitor, anti-mCTLA4. A CT-26 colon carcinoma tumor
line was implanted s.c. into immune-competent mice. Ten days post implan-
tation groups were treated with ETS2101 administered at 200 mg/kg QD in
combination with anti-mCTLA-4 administered as 10 mg/kg i.p. BiW. Thirty
seven days post treatment, tumors were collected and IHCwas performed for
CD4 and CD8 TILs on FFPE tumor sections (n12-15 per group).
Whole slide images were generated per IHC section and customized algo-
rithms developed within the Indica Labs HALO platform to classify viable
tumor present across each section and to quantify CD4 or CD8 stain area
within the viable tumor region of interest (ROI). Anti-mCTLA4 mono-
therapy resulted in regression of 44% tumors (7% CR) and anti-mCTLA4 
ETS2101 combination therapy resulted in regression of 74% tumors (36%
CR). There was a signifıcant increase in CD8 % staining of viable tumor
observed following anti-mCTLA4 monotherapy treatment versus control
(2.16% v. 1.16%, P0.0027) and anti-mCTLA4  ETS2101 combination
therapy (2.18% v. 1.10%, P0.0019) compared to control. A similar trend
was observed for CD4% staining of viable tumor with a signifıcant increase
observed following anti-mCTLA4 monotherapy treatment versus control
(1.82% v. 0.49%, P0.0083) and anti-mCTLA4  ETS2101 combination
therapy (1.93% v. 0.41%, P0.0028) compared to control. Although, there
was no signifıcant difference between anti-mCTLA4 monotherapy treat-
ment and anti-mCTLA4  ETS2101 combination therapy for either marker
alone, following treatment with the combination a statistically signifıcant
relationship between best overall response and the ratio of CD8:CD8
TILs was observed (P0.0186). In summary, there was an observed differ-
ence in the number of mice exhibiting a partial/complete regression in tumor
volume for the combination arm 74% (36% CR) versus the antibody mono-
therapy arm 44% (7% CR). A statistically signifıcant relationship (p0.0186)
was observed between the best overall tumor response and the ratio of
CD8:CD4 TILs. IHC combined with image analysis can be utilized to
evaluate therapeutic response on TILs within the context of their tumor
microenvironment.
#164 Enhanced antitumor effıcacy by recruiting macrophages as effector
cells via bispecifıc antibodiesmediatedbyCD89.BingyuLi, LijunXu,KunXie,
Fei Tao, Renhao Li, Hua Gu, Jianmin Fang. Tongji University, Shanghai, China.
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Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of key mech-
anisms through which antibody therapeutics can lyse tumor target cells. ADCC
is usually mediated by IgG through recruiting effector cells, mostly NK cells, via
IgG Fc receptor. In order to enhance specifıc tumor lysis by ADCC, a common
strategy is to design a bispecifıc antibody that binds a tumor cell surface antigen
and T cell marker CD3, thus to recruit T cells as effector cells. An example of this
type of design is the FDA-approved bispecifıc antibody blinatumomab. We are
interested in designing novel bispecifıc strategies to achieve improved ADCC
effect. Since tumors are often infıltrated by macrophages and neutrophils, it
would be advantageous to turn these types of cells into effector cells for ADCC.
We have designed several bispecifıc strategies that can target a tumor associated
antigen (TAA) andCD89 (FcRI). The aim is to lyse tumors through connecting
tumor cells toCD89-expressing immune effector cells, such asmacrophages and
neutrophils. The CD89 bispecifıc antibodies were produced by HEK293 cells
and showed binding activities to both CD89 and TAA. The CD89 bispecifıc
antibodies can recruit CD89-expressing immune cells and induced enhanced
tumor cells-killing in human whole blood ADCC assays. Since mouse does not
express human CD89 homologue, we generated a transgenic mouse strain with
specifıc expression of CD89 on macrophages and monocytes. In this transgenic
mouse model, the CD89 bispecifıc antibodies showed signifıcant anti-tumor
activities, demonstrating that the bispecifıc antibodies can redirect macro-
phages, including M2 macrophages, to mediate additional effector function in
tumor microenvironment.
#165 A novel in vitro microenvironment modeling platform for HCC
therapeutics and biomarker development. Mohd Feroz Mohd Omar, Benny
Tang, Sheng Chun Chang, Sarah Hong Hui Low, Gim Hwa Tan, Richie Soong,
Bhaskar Bhattacharya. National University of Singapore, Singapore, Singapore.
Background: Hepatocellular carcinoma (HCC) is characterized by hypoxia,
hypoglycemia and lactic acidosis within the microenvironment due a highly
glycolytic phenotype. However, routine culture conditions of HCC cells employ
supra-physiological glucose, pH-buffered media, and normoxia. The aim of the
study was to simulate themicroenvironment features of HCC in vitro by cultur-
ing HCC cells in their native (NAT) conditions (hypoglycemia, hypoxia and
lactic acidosis) and examine phenotypic, transcriptomic and pharmacological
differences compared to cells cultured in standard (ST) culture conditions.
Methods: Six HCC cell lines were cultured in NAT or ST conditions. Pharma-
cological response to cytotoxic drugs and targeted agents were evaluated using
the MTS assay. Phenotypic differences were examined using standard tech-
niques. Transcriptomic analysis was carried out using the Illumina Hu-
manHT-12 expression kit. Results: HCC cells cultured in NAT conditions have
higher doubling time than cells cultured in ST conditions. However, no remark-
able differences in the cell cycle profıles were observed when cultured in either
NAT or ST conditions. Protein analysis revealed an increase in phosphorylation
of AKT and decrease in the levels of AMPK in all cells cultured in NAT but not
in ST conditions. Increase in the protein levels of GLUT1, HK2, LDHA, and a
decrease in PDHA was observed only in cells cultured in NAT conditions. Fur-
thermore, the HCC cells in NAT conditions exhibited lower levels of reactive
oxygen species and ATP consistent with the elevated glycolysis and ineffıcient
oxidative phosphorylation phenotype of HCC. Thirty-one genes were found to
be aberrantly expressed by gene expression analysis, most notably NDRG1, a
hypoxia-associated gene was upregulated in NAT cells, validated by qPCR. Up-
regulated NDRG1 was maintained even up reversal of the NAT condition. The
panel of thirty-one genes were found to be associated with poor prognosis ex-
clusively in HCC based on data available via TCGA supporting the validity of
NAT culture condition. Differences in the IC50 of doxorubicin, sorafenib, PI3K,
c-MET and HDAC inhibitors but not AKT, MEK, mTOR, Wnt inhibitors were
observed in cells cultured in NAT compared with ST conditions suggesting
microenvironment modelling can influence pharmacological response of cer-
tain class of compounds. Additional genomic and metabolomics analysis are
currently being undertaken to characterize the HCC cells in NAT conditions.
Conclusion: In conclusion, HCC cells when cultured in NAT condition exhibit
more of the tumor characteristics than cells in ST condition and this can be
utilized as an informative platform for better understanding of disease biology
and pharmacology.
#166 Recombinant protein MBP-NAP restricts tumor progression by
triggering T-cell immunity in mouse metastatic melanoma model. Ting
Wang,1 Cong Ding,1 Zhenyu Ji,2 Xin Liu,1 Mingxuan Du,1 Qiaozhen Kang1.
1Zhengzhou University, Zhengzhou, China; 2Henan Academy of Medical and
Pharmaceutical Sciences, Zhengzhou, China.
The pro-inflammatory and immunomodulatory properties of Helicobacter
pylori neutrophil activating protein (Hp-NAP) not only make it play an impor-
tant role in disease pathogenesis, but also make it a potential candidate for
applications, including vaccine and drug development.Our previouswork dem-
onstrated that the recombinant Hp-NAP fused with the maltose-binding pro-
tein of Escherichia coli (rMBP-NAP) exert an important role in regulating the
differentiation of Th1 cells. As a potential TLR2 ligand, it was reported to possess
the ability to induce systemic antitumor immunity inmurine hepatomaH22 and
sarcoma S180 tumor models. To further understand the antitumor and immu-
nomodulatory effect of rMBP-NAP, we elucidate the effect and mechanism of
rMBP-NAP at the local immune response modulation in established mouse
B16-F10 melanoma pulmonary metastasis model. Our results demonstrated
that metastatic lung tumor growth was signifıcantly arrested after rMBP-NAP
treatment, along with marked reduction in the number of lung nodules and
signifıcant increase in survival. Flow cytometry immunophenotyping and
Quantitative RT-PCR analyses demonstrated that rMBP-NAP could induce
both local and systemic immune responses, which associated with higher influx
of CD3CD4T cells, CD3CD8T cells and higher secretion of interferon
(IFN)- and interleukin (IL)-27 cytokines. The intraperitoneal administration
of rMBP-NAP in mice promoted infıltration of lymphocyte in the lungs and
reduced the production of several proinflammatory cytokines, such as IL-6 and
transforming growth factor beta (TGF) -, indicating an anti-inflammatory ef-
fect in local area. By comparing with control mice, mRNA expression of chemo-
kines also revealed that rMBP-NAP treatment substantially decreased the ex-
pression of CCL2 and CCL20 in tumor tissues, which are central to recruit
myeloid-derived suppressor cell (MDSC) and regulatory T cells (Treg) to tumor
microenviroment and form immunosuppression. Moreover, we assess the ex-
pression of vascular marker CD34 in pulmonary section using immunohisto-
chemical method, the results showed the vascularization was apparently inhib-
ited in rMBP-NAP treated tumor bearing mouse. In conclusion, rMBP-NAP
could induce the activation of effective Th1/Tc1 cells and the production of
relevant inflammatory cytokines and chemokines, which are responsible for
enhencing T cell immunity and reversing immunosuppression against meta-
static cancer progression. Our fındings strongly indicate that rMBP-NAP treat-
ment might be a novel therapeutic approach against metastatic melanoma, and
rMBP-NAP might be a potential template for the development of agents that
could be used as immunomodulatory adjuvant in the therapy againstmelanoma.
#167 Ibrutinib regulates tumor microenvironment and enhances re-
sponse to everolimus in renal cell carcinoma mouse models. Jun Chen,
Chun-Te Chen, Jing Liu, Jeff Hsu, Taisei Kinoshita, Betty Y. Chang. Pharmacy-
clics, LLC, an AbbVie Company, Sunnyvale, CA.
Introduction: Ibrutinib (ibr), a fırst-in-class, once-daily, oral inhibitor of Bru-
ton’s tyrosine kinase (BTK), is indicated for the treatment of patients with CLL/
SLL, MCL and WM. Ibr also inhibits EGFR/HER2 and has demonstrated effı-
cacy against EGFRNSCLC andHER2 breast cancer in vitro and in xenograft
models (Gao 2014; Chen 2016). Further, ibr modulated host immunity and
enhanced anti-PD-L1 activity in solid tumor models otherwise insensitive to
BTK or HER kinase inhibition (Sagiv-Barfı 2015), suggesting that ibr may be
active in renal cell carcinoma (RCC) via multiple mechanisms. Here we deter-
mined the impact of ibr alone and in combination with everolimus (eve) on
tumor growth and the tumor microenvironment in syngeneic and xenograft
RCCmousemodels.Methods: Cell proliferationwas determinedwithCellTiter-
Glo using a 3-day treatment regimen. Subcutaneous implantation of 786-0 and
Renca cells established xenograft and syngeneic models in nude and immune-
competent mice. Treatment started when tumor volume reached 150 mm3
(786-0) or 55 mm3 (Renca) and was measured twice weekly. Immunophenoty-
ing of tumor infıltrates was determined by flow cytometry. For Treg differenti-
ation, magnetically-sorted CD4CD25- mouse splenic T cells were stimulated
with anti-CD3/CD28 antibodies and TGF-1 for 5 days. Results: Ibr signifı-
cantly inhibited the growth of syngeneic Renca tumors (TGI%32.4 at Day 19,
p0.05) in Balb/c mice and enhanced the effıcacy of eve, although Renca cells
were not sensitive to ibr in vitro. The combination signifıcantly reduced the
numbers of splenic and tumor Tregs in addition to reducing PD-1 expression on
tumor CD8 T cells. Consistently, in vitro Treg differentiation assays revealed
that, while the combination of ibr and eve signifıcantly reduced Treg differenti-
ation, either drug alone showed little effect. In 786-0 xenograft model, ibr alone
slowed tumor growth in a subgroupofmice and signifıcantly enhanced the effect
of eve (p0.05 or 0.01). To identify whether BTK or EGFR/HER2 is the target,
CGI-1746, a BTK inhibitor, and lapatinib, an EGFR/HER2 inhibitor, were
tested. Surprisingly, both CGI-1746 and lapatinib were active in inhibiting tu-
mor growth (TGI%26.7 or 37.6 respectively, p0.05 or 0.01), and slightly
potentiated the effıcacy of eve. However, consistent with ibr results, neither
CGI-1746 nor lapatinib showed any effect on the cell growth of 786-0 cells.
Conclusion: This study suggests that ibr has antitumor activity against RCC
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alone and when combined with eve in animal models. This effect may be medi-
ated by modulation of the tumor microenvironment, such as inhibiting Treg
differentiation and suppressingPD-1 expression onCD8Tcells, and bothBTK
and EGFR/HER2 are involved. Further investigation is needed to clarify the
mechanism of action, but the results here provide a rationale for ibr as a novel
agent for RCC in combination with mTOR inhibitors.
#168 Loss of function mutation in TIMP2 gene accelerates tumorigenesis
and mortality in murine model of lung cancer through EGFR signaling.
Sarvesh Kumar, Sandra Jensen, David Peeney, Ananda Chowdhury, Beiyang
Wei, William G. Stetler-Stevenson. NCI/NIH, Bethesda, MD.
The aim of this study is to determine the effect of the tissue inhibitor of
metalloproteinase-2 (TIMP-2) on lung tumorigenesis and investigate the under-
lying molecular mechanisms using an orthotopic mouse model with a loss of
function mutation in the Timp2 gene (T2M). T2M and wildtype (WT) control
mice were given 1x106 Lewis lung carcinoma cells transfected with luciferase
(LL/2-Luc-M38, Caliper) in 50L PBS via intratracheal installation. IVIS imag-
ing revealed a higher tumor burden in T2Mmice compared to WT littermates,
suggesting that loss of function of the Timp2 gene enhances tumor growth
(p0.05).We also conducted a Kaplan-Meier analysis to determine the effect of
this mutation on mortality following cancer development. We found that LL/2
tumor-induced mortality was signifıcantly higher in T2M mice compared to
WT controls (p  0.01). Histologic analysis and H&E staining of lung tissue
sections revealed a signifıcant increase in the number of tumor nodules of T2M
mice compared to WT controls (p0.01). CD31 staining showed a signifıcant
increase in microvessel density (MVD) in T2Mmice compared to WT controls
(p0.01). Given that VEGF is a primary driver of tumor neovascularization, we
determined mRNA levels of VEGF expression in healthy and tumor bearing
mice by qRTPCR analysis. Interestingly, basal VEGF expression levels were
increased in lungs of both non-tumor bearing and tumor bearing T2M mice
compared to WT controls (p0.01). VEGF is the direct downstream target of
HIF-2, a transcription factor implicated in tumor hypoxia and expression cor-
relates with decreased overall survival in non-small cell lung cancer (NSCLC)
patients. Similarly, an examination of TIMP-2 andHIF-2mRNAexpression in
a small cohort of patient samples revealed decreased TIMP-2 and increased
HIF2 in NSCLC tumors compared to surrounding non-tumor lung tissue.
Hypoxia induces EGFR signaling through HIF-2. Thus, we determined the
effect of mutated T2M on the EGFR signaling pathway. We found increased
levels of EGFR phosphorylation as well as downstream ERK and Akt activation
in tumor bearing and non-tumor bearing T2M lungs compared toWT controls.
In conclusion, these fındings offer new avenues for TIMP-2 research in regulat-
ing hypoxic mediators within the tumor microenvironment through EGFR sig-
naling, suggesting TIMP-2 as a novel bio-therapeutic for lung cancer therapy. *
Corresponding author This work is supported by center for cancer research,
intramural research program, NCI/NIH research grants ZIA BC011204 & ZIA
SC 009179 to WGSS.
#169 Preclinical effıcacy and sensitivity determinants of evofosfamide in
molecularly defınedmodels of head andneck squamous cell carcinoma.Fran-
cis W. Hunter,1 Avik Shome,1 Dan Li,1 Way W. Wong,1 Peter Tsai,1 Nooriyah
Poonawala,1 Purvi M. Kakadiya,1 Troy M. Ketelä,2 Maria K. Kondratyev,2
Courtney R. Lynch,1 Tet-Woo Lee,1 Khanh B. Tran,1 Jules B. Devaux,1 Rachel
Zussman,1 Cho R. Hong,1 Dennis Kee,3 Andrew M. Macann,4 Anthony J.
Hickey,1 Stefan K. Bohlander,1 Cristin G. Print,1 William R. Wilson,1 Bradly G.
Wouters,2 Stephen M. Jamieson1. 1University of Auckland, Auckland, New Zea-
land; 2Princess Margaret Cancer Centre, Toronto, Ontario, Canada; 3LabPLUS,
Auckland, New Zealand; 4Auckland City Hospital, Auckland, New Zealand.
Tumor hypoxia is prevalent in head and neck squamous cell carcinoma (HN-
SCC), where it limits radiotherapy outcomes. Hypoxia-activated prodrugs
(HAPs) have been developed to target hypoxic regions of tumors. These agents
undergo oxygen-sensitive reductive activation, thereby delivering cytotoxic spe-
cies within hypoxic cells. This study investigated the effıcacy and sensitivity
determinants of the clinical-stage HAP evofosfamide (TH-302) using molecu-
larly-characterized models of HNSCC. We deployed a collection of 27 HPV-
negative HNSCC cell lines derived from lesions of varying TNM stages and
primary, nodal or recurrent sites. The collection was characterized for gene
expression by RNA-seq, from which somatic variants were also called. Their
transcriptomic features were investigated in the context of pan-cancer TCGA
data by hierarchical clustering. The potency and hypoxic selectivity of 3 HAPs -
evofosfamide, PR-104A and SN30000 - were assessed by antiproliferative assay
in 22 lines and compared to bromo-isophosphoramide mustard (Br-IPM), cis-
platin and 5-FU. The antitumor activity of evofosfamide (50mg/kg qdx5 for 2-3
cycles with or without a single 10 Gy dose of radiation on day 5 of cycle 1) was
evaluated in HNSCC xenografts in addition to a PDX isolated from an SCC of
the glottic larynx. The hypoxic fraction at baseline and after 5 days of treatment
was quantifıed by pimonidazole staining. Genetic modifıers of sensitivity to
evofosfamide and its cytotoxic metabolite Br-IPM were explored through
whole-genome CRISPR-Cas9 screens using the GeCKO v2 library. High-
throughput screens with a custom shRNA pool were performed in one HNSCC
and two pancreatic ductal adenocarcinoma cell lines to identify reductases re-
sponsible for the activation of evofosfamide in hypoxic cells. Evofosfamide was
more potent andmore selective for hypoxic HNSCC cells in vitro than PR-104A
or SN30000. Cell line sensitivity to evofosfamide was correlated with Br-IPM
and cisplatin but not with PR-104A, SN30000 or 5-FU, indicating distinct sen-
sitivity determinants. Evidence of antitumor activity with evofosfamide was ob-
served in vivo. CRISPR screens identifıed potential evofosfamide sensitivity
genes that were reproducibly enriched following drug exposure. Reductase-fo-
cused RNA interference screens defıned a cluster of sensitivity genes that
mapped to mitochondrial electron transport, whereas shRNA’s targeted against
presumed activating enzymes such as POR were not enriched. Concentration-
dependent oxidation of cytochrome a and decreased respirationwas observed in
cells exposed to evofosfamide, suggesting reduction by mitochondrial com-
plexes. This study provides a rationale for the clinical evaluation of evofosfamide
with radiotherapy in genetically defıned subsets of HNSCC patients.
#170 An innovative immunotherapeutic strategy for ovarian cancer: Gly-
comimetic peptides.Katherine F. Roby,1 Laura L. Eggink,2 J. KennethHoober2.
1Univ. of Kansas Medical Ctr., Kansas City, KS; 2Susavion Biosciences, Inc.,
Tempe, AZ.
Successful treatment strategies for women with ovarian cancer remain elu-
sive.Wehypothesize that novelmeans of activating anti-cancer immune activity
will be an important component of a multifaceted approach to successful treat-
ment. The present set of studies tests the hypothesis that novel peptidemimetics
of C-type lectin receptor ligands, sv4L and sv6D, enhance anti-cancer immune
activity and limit the progression of ovarian cancer in a mouse model. We
further test the hypothesis that sv6D will function in synergy with additional
immune modulators and conventional cytotoxic therapy. C-Type lectin recep-
tors were targeted that are specifıc for N-acetylgalactosamine (GalNAc). Both
svL4 and sv6D bind GalNAc-specifıc C-type lectin receptors including
CLEC10A/CD301 with a KD in the low nanomolar range. CLEC10A is a trans-
membrane, endocytic receptor expressed on dermal dendritic cells, macro-
phages and immature dendritic cells. Further, studies with the B16 mouse mel-
anoma model and spontaneous tumors (histiocytic sarcoma and mammary
gland tumor) in dogs showed that treatment with svL4 correlated with reduced
tumor-associated Treg cells. In the present studies subcutaneous injection of
svL4 or sv6D every other day over 5 days stimulated a several-fold proliferation
of immune cells in the peritoneal cavity of healthy mice. These results indicated
that svL4 and/or sv6D might exhibit signifıcant activity on peritoneal tumors.
Effıcacy of svL4 and sv6D each as a single agent and as a combination therapy
with paclitaxel or anti-PD-1 was tested in C57BL6 female mice bearing ovarian
ID8 intraperitoneal tumors. As a single agent, 0.1 nmole/g doses of svL4 or sv6D
had a signifıcant effect on suppressing ascites formation, a measure of tumor
progression, and overall survival. Drug combination studies revealed a positive
therapeutic interaction with sv6D and the cytotoxic paclitaxel. As single agents,
sv6D and paclitaxel each had a signifıcant effect on extending survival (median
survival 140.5 and 150 days, respectively, vs. 122 days with no treatment). Sur-
vival was extended further with combination treatment when sv6D was admin-
istered to mice previously treated with paclitaxel (median survival 169 days).
Also, a positive interaction was observed with sv6D and the check-point inhib-
itor anti-PD-1. Administration of sv6D following anti-PD-1 treatment resulted
in a signifıcant survival advantage compared to treatment with either agent
alone. These data demonstrate 1) sv4L and sv6D mobilize immune cells in the
peritoneal cavity, 2) svL4 or sv6D as single agents slow progression of ovarian
cancer and enhance survival in a mouse model of ovarian cancer, 3) sv6D in
combination with paclitaxel or anti-PD-1 extends survival past that of either
agent alone. Taken together these date demonstrate the potential for this novel
approach of harnessing lectin receptors as ameans toward effective cancer treat-
ment.
#171 Targeting the tumor microenvironment: inhibition of carbonic an-
hydrase 9 impedes brain tumor initiating cell chemoresistance and delays
glioblastoma growth in vivo. Nathaniel H. Boyd,1 Kiera Walker,1 Paul C. Mc-
Donald,2 Mark O. Bevensee,1 Yancey G. Gillespie,1 Burt Nabors,1 Shoukat Ded-
har,2 Anita B. Hjelmeland1. 1University of Alabama at Birmingham, Birming-
ham, AL; 2BC Cancer Research Centre, Vancouver, British Columbia, Canada.
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Brain tumor initiating cells (BTICs) are resistant to chemo- and radiotherapy,
providing a reservoir for tumor recurrence and a desirable target for glioma
treatments. Standard of care for glioblastoma (GBM; grade IV astrocytoma)
includes the chemotherapeutic agent temozolomide, which prolongs life expec-
tancy by months and is not curative. Prior studies suggested the effıcacy of
chemotherapies including temozolomide was increased by reducing expression
of carbonic anhydrase 9 (CA9). CA9 is a hypoxia responsive gene elevated in
tumors that is important for regulating intracellular pH and contributing to the
acidic extracellular microenvironment. After confırming basal and hypoxia-
induced expression of CA9 in GBM BTICs, we targeted CA9 activity with the
smallmolecule inhibitor SLC-0111 alone or in combinationwith temozolomide.
Inmultiple GBMBTIC lines, SLC-0111 reduced cell growth in vitro and showed
additional benefıt when used concurrently with temozolomide. Importantly,
SLC-0111 inhibited the enrichment of BTICs after temozolomide treatment as
determined via BTIC marker expression and neurosphere formation capacity.
These data suggested the potential of SLC-0111 as a chemosensitizer, which we
next evaluated in preclinical studies using a subcutaneous recurrent GBM
model. GBMs treatedwith SLC-0111 in combinationwith temozolomide signif-
icantly regressed and the resulting in vivo growth delay was greater than that of
temozolomide or SLC-0111 alone. Together, our data suggest that SLC-0111 can
sensitize GBM BTICs to the chemotherapy temozolomide and signifıcantly de-
lay disease progression.
CANCER CHEMISTRY: Basic and Applied Nanotechnologies and
Therapeutic Approaches
#172 Oxidative stress and hepatotoxicity induced by graphene oxide in
Sprague-Dawley Rats. Anita K. Patlolla, Paul B. Tchounwou. Jackson State
Univ., Jackson, MS.
Graphene oxide (GO) has been extensively explored as a promising nanoma-
terial for applications in biology because of its unique properties. Therefore,
systematic investigation of GO toxicity is essential to determine its fate in the
environment and potential adverse health effect. The aim of this study was to
investigate the effect of graphene oxide on the induction of reactive oxygen
species (ROS), the activity of certain liver enzymes (Alanine ALT, Aspartate
AST, alkaline phosphatases ALP), and concentration of lipid hydroperoxide
(LHP) in serum and histopathological evaluation of liver tissue in Sprague-
Dawley rats. Four groups of fıve male rats were orally administered GOs, once a
day for fıve days, with doses of 0, 10, 20 and 40 mg/Kg GO. A control group was
alsomade of fıve rats. Blood and liver were collected 24 h after the last treatment
following standard protocols. GO’s exposure increased the induction of ROS,
the activities of the liver enzymes (ALT, AST, ALP), concentration of lipid hy-
droperoxide (LHP) and morphological alterations of the liver tissue in exposed
groups compared to control. The highest two doses, 20 and 40 mg/kg, showed
statistically signifıcant (p 0.05) increases in the induction of ROS, activities of
ALT, ALP , LHP concentration, and morphological alterations of liver tissue
compared to control. However, AST activity showed no effect. Taken together,
the results of this study demonstrate that GO is hepatotoxic, and its toxicitymay
be mediated through oxidative stress.
#173 Synthesis of substituted tetrahydroisoquinoline derivatives as anti-
cancer agents.KinfeKenRedda,MadhaviGangapuram, Suresh Eyunni.Florida
A&M University, Tallahassee, FL.
Breast cancer is the second leading cause of cancer-related deaths in women
today and is the most common cancer among women, excluding non-mela-
noma skin cancers. Over 246,000 women will be diagnosed with breast cancer
and 40,450 are expected to die of it in 2016. Estrogen receptors ER, ER and
their associated steroid hormones play vital role in breast cancer development
and progression. Estrogen binds and activates the estrogen receptors in certain
breast cancer cells. Endocrine therapy which aims to block ER action (antago-
nism) on breast tumor cells and thereby stopping the proliferation of cancer cells
is a very useful strategy in treating breast cancer. Tamoxifen is the fırst selective
estrogen receptor modulator (SERM) and is the leading drug used in treating
breast cancer. Although Tamoxifen has shown great benefıt in treating breast
cancer, its agonistic effect on the uterus is said to be associated with an increased
risk of developing endometrial cancer. We are interested in designing a single
chemical entity which acts at specifıc multiple biomolecular targets. This strat-
egy may exert favorable advantages in improving effıcacy at desired multiple
targets and lower incidence of side effects. Thus, alternative chemical entities,
preferably non-steroidal molecules which act as estrogen receptor modulators
and microtubule disruptors are sought. The tetrahydroisoquinoline (THIQ)
core structure is an important pharmacophore in natural products and small
molecules which act as drug molecules. The steroidomimetic tetrahydroiso-
quinoline moieties were reported to be selective SERMs and microtubule dis-
ruptors. Based on these considerations and in continuation with our previous
research, herein we report in vitro cytotoxic and in silico docking studies of
substituted THIQs. Novel substituted THIQ derivatives were designed and syn-
thesized. N-amination of substituted isoquinolines by the aminating agent, O-
mesytelene sulfnylhydroxylamine led to the formation of ylides. The ylides were
reduced using sodium borohydride to yield the desired substituted tetrahy-
droisoquinolines in moderate to good yields. These compounds were evaluated
for their cytotoxic effects usingMCF-7, MDA-MB-231 and Ishikawa cells using
the CellTiter-Glo luminescent cell viability assay. Among all the compounds
screened, 4-ethyl-N-(8-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)benzamide
showed IC50 values of 0.61, 1.36 and 0.09 g/ml onMCF-7, MDA-MB-231 and
Ishikawa cells respectively. This research was supported by the National Center
for Research Resources and the National Institute of Minority Health and
Health Disparities of the National Institutes of Health through Grant Number 8
G12MD007582-28.
#174 Preclinical activity of new liposomal formulation of doxorubicin
(TLD-1). Massimo Broggini,1 Federica Guffanti,1 Roberta Affatato,1 Lavinia
Morosi,1 Patrick Buschor,2 Christoph Matthieu,2 Florian Weiss,2 Andreas
Konig,2 Peter Halbherr,2 Stefan Halbherr2. 1Mario Negri Inst. for Pharmacol.
Research, Milan, Italy; 2InnoMedica, Bern, Switzerland.
Background: InnoMedica is a young company with focus on clinical transla-
tion of nanomedicine. The company employs its ownmanufacturing technology
that gives rise to a novel liposome platform. The platform allows for specifıc
shaping of nanosurfaces. This leads to amyriad of different particle designs with
highly distinct biological functions. In a fırst approach, the lead-formulation
TLD-1 (targeted liposomal doxorubicin) was developed in order to ameliorate
chemotherapeutic outcome for patients, taking into account the patterns of
biodistribution in the entire organism as well as nanoparticle-cell interactions
and subcellular localisation. Methods: Pharmacologic properties of TLD-1 were
investigated in vitro and in vivo. Human ovarian cancer cells A2780 were cul-
tured in both 2D and 3D settings and antineoplastic activity of different formu-
lations of doxorubicinwasmeasured by quantifıcation of cell viability. The same
formulations were also compared in three animal models of cancer including
murine breast cancer 4T1, human breast cancer MDA-MB231, and A2780.
MDA-MB231 and A2780 cells were grown in vitro and injected subcutaneously
(sc) in immunodefıcientmice (Athymic Nude-Foxn1nu). 4T1 cells were injected
either sc or in the mammary fat pad of immunocompetent mice (BALB/c). The
different drug products were injected intravenously twice weekly for a total of
three weeks. Activity was determined with caliper measurements of tumor di-
ameters every three days. Animal body weight was recorded as index of toxicity.
Doxorubicinwas determined in plasma and tissues byHPLC-MS. Results: In 2D
and 3D cell culture assays, TLD-1 showed a marked increase in cytotoxicity
compared to Caelyx and was close to free drug. In all three animal models,
TLD-1 showed activity superior to that of free doxorubicin given at the same
dose and compared well to Caelyx both in terms of activity and toxicity. Con-
clusions: A couple of nanoparticulate features of TLD-1 liposomes are believed
to attribute to the difference in antitumor activity. Cytotoxicity data from cell
culture experiments indicate that TLD-1 liposomes are readily taken up by can-
cer cells and release their drug load into the cytoplasm. Commercial liposomes
as in Caelyx seem to largely remain outside of cancer cells. In sum, TLD-1 is a
novel and highly active antineoplastic nanodrug that has the potential to out-
perform free drug as well as commercial liposomal formulations of doxorubicin.
#175 Combination of plasmonic photothermal therapy with surgery ap-
plied to naturally occurringmammary tumors in canines and felines: clinical
outcomes andmolecular studies.Moustafa R. Ali,1 HaithemA. Farghali,2 Hala
R.Ali,2 AhmedH.Osman,2 YousefA. Soliman,2 YueWu,1 IbrahimM. Ibrahim,2
Salah A. Selim,2 DongM. Shin,3Mostafa A. El-Sayed1. 1Georgia Inst. of Technol-
ogy, Atlanta, GA; 2Veterinary Medicine, Cairo University, Cairo, Egypt; 3Emory
University, Atlanta, GA.
Plasmonic Photothermal Therapy (PPTT) is a cancer therapy where gold
nanorods (AuNRs) are injected at the tumor site and near-infrared light (safe to
bio-system) is applied to generate localized heat causing cancer cell death. PPTT
is a potentially good alternative to replace traditional surgery for localized tu-
mors. However, for large tumors (volume	10 cm3), PPTT could be ineffective
due to an uneven distribution of injected AuNRs causing possible inhomogene-
ity of heat. Surgery is frequently recommended in those cases. However, it car-
ries a high risk of cancer recurrence. For effective treatment of large tumors, we
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combined both PPTT and surgical resection and applied it to naturally occur-
ring tumors in mammary glands of dogs and cats, which could realistically
represent their human equivalents at the molecular level. For the experimental
design, we divided the animals into three different groups. 20 cases (7 cats and 13
dogs) were all diagnosed with adenocarcinoma; the animals were monitored for
1-2 years after treatments. Group (I): three cases were solely treated by mastec-
tomy (control group); all of them died within a few weeks. Group (II): fıve cases
were treated with mastectomy fırst. Then, each tumor wound was divided into
two halves, and only one half was exposed to PPTT.After treatment, two cases in
this group rendered complete remission. In the other three cases, the half wound
that was not exposed to PPTT had tumor recurrence causing animal death
within one year. Group (III): 12 cases were treated with surgery followed by
PPTT treatment. This regime showed complete remission without any recur-
rence for eight cases. However, four cases died 4-12 months after therapy for
reasons such as pneumonia (no tumor found, based on X ray). Histopathology
results showed a decrease of cancer grades before (variant grades from 1-4) and
after two weeks of treatment via PPTT and surgery (grade 0). Blood tests (con-
ducted 1 year after therapy) showed no obvious change in liver and kidney
functions in groups II and III. In addition, X-ray diffraction showed no metas-
tasis 1- 2 years after treatment. We have performed quantitative, real time-PCR
analysis two weeks before and after treatment to study the expression levels of
several important genes. The genes that are responsible for repairing cancer cells
such as BRCA1, BRCA2, and CD163-IL-10 were signifıcantly diminished two
weeks after treatment (group III). Furthermore, tumor microenvironment cells
such as tumor-associated macrophages (TAMs) were greatly altered after treat-
ment. TAM 1, which retards tumor growth, augmented, and TAM 2, which
promotes tumorigenesis, was diminished, which explains the animals’ increased
survival rate. In conclusion, our study demonstrates the feasibility of applying
PPTT after surgery for large tumors in dogs and cats.
#176 Early development of GMC1, a novelmolecule targeting FKBP52 for
the treatment of hormone-refractory prostate cancer.Huan Xie, Oscar Ekpe-
nyong. Texas Southern University, Houston, TX.
Purpose: GMC1 directly inhibits FKBP52, effectively blocking androgen re-
ceptor dependent gene expression and androgen-stimulated proliferation. This
make it an attractive option for the treatment of hormone-dependent and hor-
mone-independent prostate cancer. This study investigated an analytical
method for GMC1 quantifıcation, pre-formulation characteristics of GMC1,
and developed intravenous formulations for the evaluation of GMC1 in animal
models. Method: An LC/MS/MS method for the quantifıcation of GMC1 in
solution, plasma and urine was developed, validated and applied to the determi-
nation of the stability, log P, plasma protein binding and solubility of GMC1 in
various solvents. Liposomal formulations and co-solvent systems with various
ratios of high capacity vehicles were formulated and the optimal formulation
applied, at 2mg/kg single IV bolus dose, to the pharmacokinetic study of GMC1
in a rat model. Result: The intra- and inter-day accuracy (%RE) and precision
(%CV) of the LC/MS/MS method ranged from 1.6 – 11.7 % and 1.4 – 8.8 %,
respectively. GMC1 is stable in solid and solution state, moderately lipophilic
(log P  1.38  0.05), poorly water soluble (0.4  0.01 mg/mL), and highly
plasma protein bound (71%). The optimal formulation consisting of PEG 300
and Labrasol ® (1:1, v/v) allowed us to achieve a GMC1 concentration of 10 mg/
mL, and tolerated an aqueous environment. GMC1 has a tri-exponential dispo-
sitionwith a Cmax of 7.6 1.97mg/L, clearance of 0.53 L/kg/hr,-distribution,
-phase and terminal elimination half-lives of 0.1 0.04 hr, 1.2 0.34 hr, and
19.7 5.09 hr respectively. Conclusion: The LC/MS/MS method, formulations
and pharmacokinetic study can be applied to the pre-clinical and clinical devel-
opment of GMC1. Grant Support: This work was performed under funding
from NIH/NIGMS grant (5SC3GM102018) and NIH/NIMHD/RCMI grant
(5G12MD007605).
#177 Thymidine quinoxaline conjugates as a novel selective and effective
photosensitizer for anticancer photodynamic therapy. Qibing Zhou, Zhiwei
Wang, Rong Yang, TingQian, Dejun Zhang.HuazhongUniv. of Science&Tech-
nology, Wuhan, China.
Thymidine quinoxaline conjugates are a new class anticancer agent that ex-
hibits selective anticancer activity by targeting the abnormally high level of thy-
midine kinase of the thymidine salvage pathway in cancer cells. In addition, the
conjugated quinoxaline moiety could also act as a photosensitizer to generate
reactive oxygen species that would signifıcantly enhance the anticancer activity.
Therefore, a variety of structural derivatives were synthesized and investigated
for the potential of combined anticancer activity. We found that the thymidine
moiety was critical for the accumulation of compounds in cancer cells and thus
their activity. On the other hand, the substitutions and additional conjugation of
quinoxaline moiety had signifıcant impact on the effectiveness to generate reac-
tive oxygen species for enhanced potency. Among all the compounds studied,
dT-QP exhibited a potent activity against liver cancer cells with IC50 at 20 nM
under photo-irradiation at 400nmwavelength for 20min. This potent activity of
dT-QP was 12 times more effective than that of the clinically used photosensi-
tizer protoporphyrin IX (IC50 at 250 nM) under the same condition and 5 times
more potent than anticancer drug doxorubicin (IC50 at 100 nM). In addition,
thymidine quinoxaline conjugates were found to form aggregates with an aver-
age size of 200 nm. Further optimization of the aggregating condition led to a
highly stable suspension of 90 nm size nanoparticles containing a tumor-specifıc
peptide that could be used for in vivo study. Therefore, thymidine quinoxaline
analogs could be a selective anticancer agent and effective photosensitizer for
potential photodynamic therapy.
#178 Peptide nanofıbers: targeted therapies for glioblastomamultiforme.
Diana M. Leite,1 Rong Zhu,2 Eugen Barbu,1 Peter Hinterdorfer,2 Geoffrey J.
Pilkington,1 Aikaterini Lalatsa1. 1University of Portsmouth, Portsmouth, United
Kingdom; 2Johannes Kepler University, University of Linz, Linz, Austria.
Glioblastomamultiforme (GBM) is a malignant brain tumor with poor prog-
nosis due to tumor heterogeneity, poor drug blood-brain barrier (BBB) perme-
ability and targeting. GBM biopsies indicated the overexpression of G-protein
coupled receptors (GPCRs) that when activated by neuropeptide agonists result
in an antiproliferative effect. However, translation of these neuropeptides into
novel therapies for GBM is frustrated by their short half-life (5 minutes) and
inability to cross the BBB. Here, we present a novel strategy based on the lip-
idization of peptide agonists which results in peptide amphiphiles able to self-
assemble into nanofıbers that can entrap brain impermeable drugs, possess an
enhanced stability to enzymatic degradation, permeate across an all human in
vitro BBB model and are able to target GBM cells resulting in a signifıcant
antiproliferative effect. Peptide amphiphiles were synthesized using solid-phase
peptide synthesis and characterised using pyrene, thioflavin T, circular dichro-
ismand transmission electronmicroscopy experiments.Nanofıberswere loaded
with brain impermeable cytotoxic drugs (e.g. paclitaxel) and their stability was
studied in biological media (plasma, brain, liver and GBM cell lysates). BBB
permeation was studied in an all human in vitro Transwell model. The antipro-
liferative effect of the nanofıbers was evaluated on U-87 MG cells. Targeting of
the nanofıbers to the GPCRwas evaluated using single-molecule force spectros-
copy (SMFS). Peptide amphiphiles self-assemble into stable nanofıbers at con-
centrations above 189 M and are able to solubilize high amounts of paclitaxel
(1.8 mg) ensuring that the resulting nanomedicine can be clinically translat-
able. Both unloaded- and paclitaxel loaded-nanofıbers showed superior stability
compared to the parent neuropeptide in the presence of plasma, brain, liver and
cell homogenates (6-fold). Nanofıbers elicited a strong antiproliferative effect
(IC50: 5.06M) resulting in a cell cycle arrest at G2/M in a GPCR positive GBM
cell line (U-87MG). Loading paclitaxel (1nM) within the nanofıbers resulted in
a synergistic effect evidenced by a decrease in cell survival by 32%. Nanofıbers
counteracted the forskolin-induced increase of intracellular cAMP levels indi-
cating that the GPCR is linked to the GI protein known tomediate the antipro-
liferative effect on GBM. Confocal studies confırmed the internalization of the
peptide while SMFS studies supported specifıc binding of the nanofıbers to
GPCR on U-87MG cell surface with equivalent binding probability to peptide
agonists and increased residence time. Texas Red labelled nanofıbers permeate
across an in vitro BBB model enabling the permeation of paclitaxel (Papp: 8.45
x10-6 cm/s). Thus, described peptide nanofıbers are a novel targeted nanomedi-
cine for GBM therapy able to be clinically translated. In vivo proof of concept
studies and pharmacokinetics are under way.
#179 Plasma membrane lipid therapy: disruption of oncogenic Ras
spatiotemporal organization by membrane-targeted dietary bioactives
(MTDB).Natividad R. Fuentes,1 Rola Barhoumi,1 MohamedMlih,2 Jason Kar-
pac,2 PaulHardin,1 Trevor Steele,1 Spencer Behmer,1 IanPrior,3 Robert S. Chap-
kin1. 1Texas A&MUniversity, College Station, TX; 2Texas A&MHealth Sciences
Center, College Station, TX; 3University of Liverpool, Liverpool, United Kingdom.
Approximately 30 to 50% of colorectal cancers contain KRas mutations,
which confer resistance to standard therapy and have therefore been termed
“undruggable.” Since no curative treatments for KRas driven colon cancer are
available, there is a critical need to develop toxicologically innocuous KRas ther-
apeutic approaches that are free of safety problems intrinsic to drugs adminis-
tered over long periods of time. High fıdelity signaling of Ras is dependent on its
spatial organization into defıned nanoclusters on the plasmamembrane. This is
noteworthy, because select nonsteroidal anti-inflammatory drugs, through di-
rect modulation of the biophysical properties of the plasma membrane, alter
oncogenic Ras nanoclustering and attenuate signal transduction. These fındings
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suggest that Ras nanoclusters represent a novel target for future interventions.
Consistent with this rationale, we hypothesize that select amphiphilic mem-
brane targeted dietary bioactives (MTDB’s), e.g., polyunsaturated fatty acids
(n-3 PUFA) docosahexaenoic acid (DHA, 22:6	4,7,10,13,16,19) and eicosapenta-
enoic acid (EPA, 20:5	5,8,11,14,17), [1] modulate the rigidity of the plasma mem-
brane, [2] modify Ras nanocluster formation, [3] disrupt oncogenic Ras driven
signaling (pERK), and [4] suppress phenotype (hyper-proliferation) in vitro and
in vivo.Our studies utilized a variety of complementarymodels includingmouse
colonic crypts, Drosophilamidguts, and isogenic human andmouse colonic cell
lines. Using a membrane order sensitive dye, Di-4-ANEPPDHQ, we initially
characterized the rigidity of the plasma membrane in mouse colonic crypts
and young adult mouse colonocytes (YAMC) cells. Quantifıcation of Ras
nanocluster formation was determined by fluorescence lifetime imaging mi-
croscopy (FLIM) combined with fluorescence resonance energy transfer
(FRET) of fluorescently tagged Ras membrane targeting domains. In addi-
tion, oncogenic Ras driven signaling (pERK) and phenotype (hyper-prolif-
eration) was determined by targeting expression of RasV12 or KRasG12D to
Drosophila midgut stem cells and mouse colon, respectively. In vitro and in
vivo incorporation of n-3 PUFA consistently reduced plasma membrane
rigidity and tH-Ras clustering, while increasing tK-Ras clustering and the
mixing of tH and tK proteins. These changes in membrane spatiotemporal
organization were associated with a reduction in oncogenic RasV12 driven
ERK phosphorylation and intestinal stem cell proliferation.These novel
fındings demonstrate a unique role for MTDBs in the modulation of Ras
nanoscale spatial organization and signaling. Establishing a role for MTDBs
in Ras-dependent oncogenesis would have a major translational impact be-
cause these bioactives are safe, well tolerated, relatively inexpensive, and
provide additional health benefıts, such as reduction in mortality. This work
was support by NIH grant R35CA197707.
#180 PhAc-ALGP-Dox is a new tumor selective peptide prodrug of doxo-
rubicin that shows improved effıcacy and systemic tolerance in triple nega-
tive breast cancer models. Andrea Casazza,1 Massimiliano Mazzone,2 Peter
Pokreisz1. 1CoBioRes NV, Leuven, Belgium; 2VIB Vesalius Research Center, Leu-
ven, Belgium.
Use of traditional chemotherapeutic drugs is restricted by severe side
effects and lack of tumor specifıcity of these cytotoxic agents. Less toxic
prodrug that can be selectively activated in tumor tissue have been explored
in attempts to improve the therapeutic index. Some approaches to the devel-
opment of tumor activating prodrugs take advantage of inherent properties
of the tumor, for example, selective enzyme expression, hypoxia, or low
extracellular pH in the vicinity of the tumor. CoBioRes makes use of capped,
tetrapeptidic prodrug of existing chemotherapeutics. Doxorubicin (Dox)
was the fırst chemotherapeutic that was linked to the tetrapeptide sequence
and tested experimentally (PhAc-ALGP-Dox). This approach makes the
prodrug impermeable to cell membranes of both normal and tumor cells.
Furthermore, it remains stable in blood by the use of the capping group on
the amino-terminal group of the peptide that prevents aspecifıc activation by
circulating esopeptidases. The prodrug as such is thus not active. The peptide
sequences have been developed to be sensitive to the hydrolytic action of a
selected group of peptidases that are released within the tumor microenvi-
ronment. These peptidases, which accumulate in the tumors, also play an
important role in cancer cell invasion and metastasis. What makes this ap-
proach unique is that it is not targeting a single enzyme, but requires, for its
selectivity, a two-step activation based on enzymes with an increasing selec-
tivity. In vivo activation starts when the tetrapeptide prodrug is exposed to
endonucleases (CD10 and THOP1) leading to the formation of intermedi-
ates that are still inactive and poorly permeable through cell membranes.
This leads to a tissue distribution that is determined by the expression of the
endonucleases. Since these are known to be overexpressed in several tumors,
and only present at lower level in some normal tissues, the prodrug will be
preferentially located and activated in the vicinity of tumors. The second step
of the activation is the cleavage at the prolyl by dipeptidases FAP and DPPIV,
releasing the free doxorubicin. The simultaneous expression of all the en-
zymes involved in the prodrug activation was confırmed both in human
triple negative breast cancer biopsies and in experimental triple negative
breast cancer models. In vitro analysis of PhAc-ALGP-Dox reveals higher
tumor cells tropism and higher cytotoxicity in cancer cells than in normal
cells. In vivo PhAc-ALGP-Dox gives promising preliminary results in terms
of systemic tolerance even at high concentration, and in vivo effıcacy in
xenograft mouse models compared to free doxorubicin. Taken together,
these results provide a strong rationale for further investigation aimed at
unleashing the potential clinical value of this compound.
#181 Discovery of novel targeted therapeutics for metastatic breast can-
cer.Cristina Del Valle,1 Eliud Hernández,1 Cornelis P. Vlaar,1 Luis A. Cubano,2
Suranganie Dharmawardhane,1 Linette Castillo-Pichardo2. 1University of
Puerto Rico, Medical Sciences Campus, San Juan, PR; 2Universidad Central del
Caribe, Guaynabo, PR.
Metastatic disease is the primary cause of breast cancer mortality, due to
the lack of effective therapy. The Rho GTPase Rac is integral for the promo-
tion of cancer cell migration/invasion, proliferation, and survival. Sincemet-
astatic breast cancers often overexpress or exhibit high Rac activity, inhibi-
tion of Rac is a viable strategy against metastatic cancer. Recently, we
characterized EHop-016, a small molecule that inhibits Rac activity of met-
astatic breast cancer cells with an IC50 of 1 M. EHop-016 is 10-100 times
more active than previously available Rac inhibitors, and is the fırst com-
pound shown to inhibit the activation of Rac by the oncogenic GEF Vav.
EHop-016 inhibits the activity of the Rac downstream effector p21 activated
kinase (PAK), lamellipodia extension, and cell migration of metastatic breast
cancer cells. We also reported that EHop-016 at 	 25 mg/kg Body Weight
(BW) signifıcantly reduced tumor growth, metastasis, and angiogenesis in a
mouse model. However, our recent pharmacokinetic study of EHop-016 in a
mouse model demonstrated that the bioavailability of Ehop-016 needs to be
improved for further pharmacological development. Therefore our hypoth-
esis is that improvement of the EHop-016 structure will provide probes with
increased potency against Rac and, therefore, increased bioavailability.
Herein we have tested several Ehop-016 derivatives for their effects on breast
cancer cell viability and Rac activation. Using MTT assays we found that the
Ehop-016 derivatives, HV-107 andHV-118, signifıcantly inhibit the viability
of metastatic breast cancer cell lines MDA-MB-231 and MDA-MB-435. The
effects of HV-107 andHV-118 on the inhibition of Rac activation were tested
by ELISA-based Rac activity assays and pulldown assays. Results show that at
250nM, HV-107 inhibits Rac activation by 55%, whereas HV-118 has a sim-
ilar effect at 100nM in MDA-MB-231 and MDA-MB-435 cells. Taken to-
gether, our fındings suggest HV-107 and HV-118 as promising Ehop-016
derivatives with potential as anti-metastatic agents, which should be further
characterized. This study was supported by awards from the Susan Komen
for the Cure, NIH/NIMHHD U54MD008149, and the Puerto Rico Science
and Technology Trust to SD; NIH/NCRRR25GM061838 to UPRMSC; NIH/
NIMHHD RCMI 8G12MD007583RCMI, Title V PPOHA 031M10505 and
Title V Cooperative P031S130068 from U.S. Department of Education to
UCC; and PRINBRE (NIH/NIGMS P20GM103475-13) Pilot Project to LCP.
#182 Anew anticancer agent derived fromdecenoic acid for the treatment
of colon cancer. Masumi Suzui,1 Saeko Ando,1 Harutoshi Matsumoto,1 Kat-
sumi Fukamachi,1 Mitsuru Futakuchi,1 Naoki Yoshimi2. 1Department of Molec-
ular Toxicology, Nagoya City University Graduate School ofMedical Sciences and
Medical School, Nagoya, Japan; 2Department of Pathology and Oncology, Grad-
uate School of Medicine and Faculty of Medicine, University of the Ryukyus,
Okinawa, Japan.
The fınal goal of the current study is to create a promising lead compound that
targets human colon carcinoma. After discovering in vitro antiproliferative activity
of a naturally occurring compound, 10-hydroxy-2-decenoic acid, we designed and
synthesized over 150 derivatives. The initial screening resulted in the discovery of
three primary lead compounds,we thenproceededwithmodifıcations in side chain
and eventually obtained a second-generation lead compound, namedPPI (patented
in2014),whose IC50was0.3M.Wefocusedonthe transcription factorSTAT3that
is able to drive carcinogenesis, apoptosis, and angiogenesis-related genes. In silico
docking simulation exhibited that PPI can bind to SH2 domain of STAT3, suggest-
ing that this drug blocks dimerization of STAT3, therebyPPI inactivates function of
STAT3. PPI inhibited transcriptional activity of STAT3 when SW480, SW837, and
HT29 human colon carcinoma cells were treated with 3.7 to 5 M PPI for 24h.
Flowcytometry analysis indicated thatwhenHT29cellswere treatedwith1MPPI,
thepercentageof cells inG1 increasedby5%and thiswas associatedwith a concom-
itant decrease of cells in the S andG2-Mphases of the cell cycle. The results indicate
that PPI causes carcinoma cells to arrest in the G1 phase. When HT29 cells were
treated with 10 M PPI, subG1 fraction and DNA fragmentation were seen, indi-
cating induction of apoptosis. We then performed western blot analysis to deter-
mine whether treatment of carcinoma cells with PPI alters cellular levels of the G1
cell cycle control protein cyclin D1 and apoptosis/angiogenesis-related molecules.
WhenHT29 cells were treated with PPI for 24 to 48h, there was amarked decrease
in the levels of expression of the Bcl-2, Bcl-xL, and VEGF proteins and a marked
increase in the levels of expression of the cleaved caspase 3, 7, 8, 9, and PARP pro-
teins. PPI also inhibited expression levels and nuclear tanslocation of pSTAT3. To
see if PPI exerts preventive effect on tumor promotion, F344 rats received sc injec-
tions of a carcinogen azoxymethane and then treatedwith soybean oil or PPI. There
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was a dose dependent decrease in multiplicity of aberrant crypt foci (ACF) in the
colon.PPI inhibited theoccurrenceof largerACFconsistingofmore than4aberrant
crypts, indicating inhibitoryeffectofPPIontumorpromotion. Inamousexenograft
model, PPI decreased the size and number of blood vessels in the tumor. All mice
survivedwithout causing signifıcant bodyweight loss during experiment. No histo-
pathological abnormality was found in any of organ site. To confırm the effects of
PPI on angiogenesis, we performed chorioallantoic membrane assays and found a
dose-dependent decrease in average number of blood vessels. Inhibition of STAT3
by PPImay affect the function ofmolecules that are related to apoptosis, angiogen-
esis, and cell cycle progression and eventually contributes to PPI-induced growth
inhibition.
#183 Brassinolide, a plant steroid hormone, reverses drug resistance in
human small-cell lung carcinoma cells. David Sadava, Susan E. Kane. City of
Hope, Duarte, CA.
Small-cell lung carcinoma (SCLC)has a dismal prognosis in part because ofmul-
tidrug resistance (MDR). Epibrassinolide (EB) is a steroid hormone present in
higher plants, where it has numerous physiological effects and acts via a LRR-RLK
membrane receptor and GSK3/SHAGGY pathway, resulting in stabilization of a
transcription factor. The parallels to theWnt signaling pathway, which is activated
inSCLCand results in increased-catenin, prompted investigationsof the effects of
EB on SCLC cells, particularly showing MDR. SCLC cells were NCI-H69 and a
derived line, VPA17, showing resistance to etoposide (9-fold), doxorubicin (20-
fold) and vincristine (10-fold). EB was cytotoxic to both cell lines (IC50  2 uM),
indicating a lack of cross-resistance. EBwas pro-apoptotic after 24 h asmeasured by
ELISA of BUdR-labeled DNA fragments. Apoptosis was also indicated by an in-
crease in caspase-3 specifıc activity (to 2.5 enzyme units/mg protein vs. 0.01 for
untreated controls).Matrigel assays showed that EB reduced the SCLCcell invasion
phenotype by 80% in a time-dependent fashion. Pre-incubation ofVPA17 cells in 1
MEB for 96 h reduced the IC50 for etoposide (6.0 uM to 1.8M)anddoxorubicin
(0.37M to 0.09M). Synergism between EB and chemotherapy drugs was deter-
mined by exposure of VPA17 cells to 1:1 ratios at the appropriate IC50 values of EB:
etoposide or EB: doxorubicin. After 4 days, the combination index (CI) was deter-
minedusingCalcuSyn software. EBand etoposide showedmodest synergism (CI
0.80 at ED50 and CI 0.90 at ED95); EB and doxorubicin also showed synergism
(CI0.65 at ED50andCI0.90 at ED95). TheWnt --catenin signalingpathway
was investigated as a possible explanation for the pharmacological effects of EB. In
the presence of EB, SCLC cells showed a time- and dose dependent reduction of
-catenin (maximum 80% reduction). Cell fractionation studies showed that the
reduction was primarily in nuclear -catenin. Transcription analyses of SCLC cells
showed EB led to signifıcant reduction in expression of-catenin-dependent genes
that are anti-apoptotic (e.g., c-Jun, survivin), cell division-related (e.g., CCND1 cy-
clin, sox9), and metastasis-related (e.g., MMP7, uPAR). Down-regulation of the
-catenin promoter was confırmed by transfection of SCLC cells with a construct
containing the promoter coupled to a luciferase reporter (reduced by 85%).WIKI4,
a known inhibitor ofWnt signaling, was cytotoxic to SCLC cells (IC50 0.02 uM).
Synergism between EB andWIKI4 was determined by exposure of VPA17 cells to
1:1 ratios at the appropriate IC50 values of EB: WIKI4, as above. EB and WIKI4
showed antagonism (CI 1.09 at ED50 andCI 1.35 at ED95), suggesting that EB
andWIKI4 act on the same pathway. Taken together, these data indicate that EB, a
naturalproductwithwidespreadoccurrence inplants, ispharmacologically active in
both drug-sensitive and drug-resistant SCLC cells and acts through theWnt signal-
ing pathway.
#184 Effects of the magnetic-organic compound Fe(salen) on anaplastic
thyroid cancer cells. Shuzo Tamura,1 Takashi Oshima,1 Mariko Kamiya,1
Shinya Amano,1 Toru Aoyama,1 Hirotaka Nakayama,1 Nobuyasu Suganuma,2
Tsutomu Sato,1 Hiroshi Harada,1 Manabu Shiozawa,2 Takaki Yoshikawa,2 Yo-
hei Miyagi,2 Yasushi Rino,1 MunetakaMasuda1. 1Yokohama city university, Yo-
kohama city, Japan; 2Kanagawa cancer center, Yokohama city, Japan.
Introduction: Although anaplastic thyroid cancer (ATC) is a rare disease, it is
a cancer with one of the worst prognoses. Even in patients who receive multi-
disciplinary treatment, the 1-year survival rate is less than 30%. Because about
50% of patients with ATC die of airway obstruction, control of local progression
is very important in the management of ATC. Novel treatments for ATC, espe-
cially those that can control local disease, are expected to emerge. Recently,
several studies have reported that the magnetic organic compound -oxo N,N-
bis(salicylidene)ethylenediamine iron (Fe(salen)) is effective against malignant
melanoma and lingual cancer. Fe(Salen) itself is magnetic andmight be effective
as a local treatment by externally applying a magnetic fıeld. Fe(salen) thus has
the potential to become a novel treatment for ATCs. In this study, we evaluated
uselessness of Fe(salen) as an anticancer drug for ATC. Methods: The in vivo
anticancer effect of Fe(salen) againstATCcell lines (KTA1,KTA2,TTA2,TTA3,
8305c, 8505c) was evaluated by XTT assay. In addition, the effectiveness of
combined therapy with paclitaxel, which is currently a standard chemotherapy
for ATCs, was evaluated by the Chou and Talalay method. Colony formation
assay was performed to evaluate differences in effects depending on the order of
drug administration. In addition, to clarify the mechanism of Fe(salen) on can-
cer cells, changes in the cell cycle after Fe(salen) treatment were examined by
flow cytometry. Results: Fe(salen) showed anticancer activity with an IC50 value
of less than 100M against KTA1, KTA2, TTA2, TTA3, 8305c, and 8505c cells.
In particular, the IC50 values were less than 10 M against TTA3 (8.824.58
M) and 8305c (7.064.11M) cells. Combination therapy with paclitaxel had
a synergistic effect, with a combination index of less than 1. No signifıcant
difference was detected in anticancer effect depending on the order of drug
administration. G2/M cell cycle arrest was observed in 8305c cells on flow cy-
tometry after Fe(salen) treatment. Conclusion: Our results showed that Fe-
(salen) has an anticancer effect on ATC cells and that Fe(salen) and paclitaxel
have synergistic activity. We will evaluate the in vivo effectiveness of Fe(salen)
treatment in an orthotopic mouse model, focusing on local control achieved by
applying a magnetic fıeld.
#185 Development of a novel non-diuretic brain-penetrating ethacrynic
acid analog and demonstration of its potent effıcacy in orthotopic glioblas-
toma (GBM) models. Surendra R. Punganuru, Hanumantha Rao Madala,
Kalkunte S. Srivenugopal. Texas Tech Univ. Health Sciences Ctr., Amarillo, TX.
The incidence of pediatric and adult brain tumors has continued to rise and
temozolomide (TMZ) has remained the sole choice for chemotherapy of these
cancers. A number of factors including the ineffıcient drug entry through the
BBB, intratumoral heterogeneity, overexpression of MGMT repair protein and
bone marrow toxicity due to alkylating regimens have impeded successful ther-
apy of these cancers. There is, therefore, an urgent need to design new, more
effective brain-penetrating drugs that can effectively eliminate brain tumors.We
are highly interested in exploiting the elevated oxidative stress present in glio-
mas and have synthesized a hydrophobic, non-diuretic analog of ethacrynic acid
(EA) called KSS72 [1-(2,3-dichloro-4-methoxyphenyl)-2-methylenebutan-1-
one] by removing the carboxylate side chain. KSS72 was selectively cytotoxic to
cancer cells including gliomas. Compared to EA which does not cross the BBB,
Pharmacokinetics following intravenous or oral administrations in mice
showed its excellent penetrance through the blood brain-barrier, KSS72 accu-
mulating at levels equivalent to TMZ (25% of plasma levels) in the brain In vitro
assays measuring protein carbonyl content, GSH content, ROS generation,
GSTpi enzyme activity and others showed thatKSS72 triggers a redox imbalance
by inhibitingGSTpi and by lowering the antioxidant (GSH) and reducing equiv-
alent (NADPH) levels, leading to a signifıcant elevation of ROS levels. We also
showed the upregulation of endoplasmic reticulum (ER) stress-responsive pro-
teins, activation of MAPK, autophagy and apoptotic pathways by KSS72 in sev-
eral cell lines. KSS72-induced autophagy was a post event of redox perturbation
that displayed a wide array of characteristic features including double membra-
nous vacuoles with entrapped organelles, acidic vesicular organelles, and in-
creased expression of LC3-II and beclin-1. In view of its excellent brain pen-
etrance and multiple cytocidal events mediated by ROS and autophagy, we
tested the antitumor effıcacy of KSS72 in humanGBM cell lines and intracranial
GBM xenografts. SF-188 human GBM cells expressing fırefly luciferase were
injected into the brain just left of bregma for the development of orthotopic
GBM in nude mice. These mice were given 25 mg/kg/day of KSS72 intraperito-
neally for 2 weeks. The animals when imaged by IVIS after luciferin injections
showed a complete lack of intracranial tumors in all KSS72 administered ani-
mals. H&E staining of mouse brain sections confırmed the total elimination of
GBMbyKSS72. KSS72 did not exert any toxicity on host tissues and serumALT
and AST levels were not altered. In summary, we conclude that KSS72 acting
through multiple pathways of oxidative stress is a hugely promising non-toxic
anti-glioma drug with potential to enter clinical trials (supported by CPRIT
grants RP130266 and RP170207 to KSS).
#186 FDA approved drug Bazedoxifene as a novel inhibitor of IL 6 and IL
11/GP130 signaling for osteosarcoma therapy. Xiaojuan Wu,1 Hui Xiao,2
Chenglong Li,3 Jiayuh Lin4. 1Tongji Hospital, Huazhong University of Science
and Technology, Wuhan, China; 2Center for Childhood Cancer and Blood Dis-
eases, the Research Institute at Nationwide Children’s Hospital, College of Medi-
cine, The Ohio State University, Department of Pediatrics, OH; 3College of Phar-
macy, University of Florida, Gainesville, FL; 4University of Maryland School of
Medicine, Baltimore, MD.
IL-6 and L-11 signaling pathways play an important role in cancer cell sur-
vival and progression, including osteosarcoma. IL-6/IL-11 binds to IL-6/IL-11
R to form a binary complex, then recruits GP130 to form the IL-6/IL-6 R/
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GP130 or IL-11/IL-11 R/GP130 heterotrimer and triggers a signaling cascade
downstream.One of themajor downstream effectors of IL-6 is STAT3. STAT3 is
persistently activated in many human osteosarcoma specimens and cell lines
and STAT3 is required for osteosarcoma cells survival. So IL-6 and IL-11 present
a viable novel target for osteosarcoma therapy. To date, however, no small mol-
ecules that target both IL-6/GP130 and IL-11/GP130 signaling pathways are
available for cancer therapy. To overcome this critical problem, we have utilized
a novel drug discovery approach combining Multiple Ligand Simultaneous
Docking and drug repositioning to target GP130. Drug repositioning refers to
reuse fragments from the existing FDA-approved drugs for new applications
and could potentially reposition the existing drugs as novel, off-target inhibitors
of the GP130 as their new target. Using this novel method, we have identifıed a
FDA-approved drug Bazedoxifene with a novel function to inhibit IL-6 and
GP130 proteinprotein interactions. Furthmore, because IL-11 binds to the same
domain of GP130 as IL-6, Bazedoxifene should also inhibit IL-11/GP130 signal-
ing. Accordingly, Bazedoxifene can indeed inhibit the induction of P-STAT3 by
both IL-6 and IL-11. Bazedoxifene appeared specifıc to IL-6 and IL-11 as phos-
phorylation of STAT1 and STAT3 by IFN- and LIF respectively were not af-
fected by the compound. Bazedoxifene inhibited P-STAT3 and induced apopto-
sis in human osteosarcoma cell lines expressing IL-6 and IL-11. In addition,
Bazedoxifene can inhibit colony formation after the drug treatments in cancer
cells.IL-6 but not IFN- could rescue the Bazedoxifene-mediated inhibition of
cell viability in osteosarcoma cells. These results further support that IL-6/
GP130 signaling pathway is one of the main targets of Bazedoxifene-mediated
inhibition in osteosarcoma cells. To determine the in vivo activity of Bazedox-
ifene, we further tested the effıcacy of Bazedoxifene in tumor xenografts gener-
ated from the SJSA osteosarcoma cells that show persistent IL-6/STAT3 activa-
tion. Bazedoxifene via oral gavage inhibited P-STAT3 and the growth of SJSA
tumor xenografts. These data demonstrated that Bazedoxifene is potent in sup-
pressing tumor growth and is orally bioavailable in inhibiting P-STAT3. It fur-
ther indicates that Bazedoxifene is a promising IL-6/GP130-targeting drug,
which likely to have in vivo anti-tumor activity in osteosarcoma. In summary,
Bazedoxifene already approved for safety by the FDA as a novel inhibitor of
IL-6/GP130 and IL-11/GP130 signaling should provide an easier path to clinical
trials and have a potential to improve the outcome of osteosarcoma.
#187 Effıcient delivery of Bcl2 siRNA by DNA nanoparticles to inhibit
cellular growth and cancer progression.MohammadAminur Rahman,1 Peng-
fei Wang,2 Dongsheng Wang,1 Selwyn J. Hurwitz,2 Zhengjia Chen,2 Zhuo G.
Chen,1 Yonggang Ke,2 Dong M. Shin1. 1Emory Univ. Winship Cancer Inst., At-
lanta, GA; 2Emory University, Atlanta, GA.
Background: Short interfering RNA (siRNA) has emerged as a promising
molecular therapeutic tool for targeted cancer treatment. However, systemically
administered siRNA has demonstrated only limited success, due to limited de-
livery to cancer cells. Therefore, the lack of a robust and versatile siRNAdelivery
system is a critical issue in translating this therapeutic tool for cancer treatment.
Recent developments in DNA nanotechnology have made programmable DNA
nanoparticles (DNPs) a potent drug delivery platform. This study focuses on the
development of a novel DNP-based siRNA delivery system to knockdown Bcl2
gene, as a targeted cancer therapeutic.Methods: Structural DNA technologywas
applied to design a library of DNPs with different sizes and shapes. Flow cytom-
etry, confocal imaging, and electron microscopy were utilized to study the cel-
lular internalization of DNPs. The effıcacy of Bcl2 knockdown by DNP-siBcl2
and the resulting influence on cell growth and progression were assessed in
cancer cells (in vitro) and in mice bearing corresponding tumor xenografts (in
vivo). Results:DNPs of varying sizes (10-120nm) and shapes (polyhedral or rod)
were constructed using DNA origami techniques and successfully verifıed by
agarose gel electrophoresis, atomic forcemicroscopy, and transmission electron
microscopy. The cell internalization capabilities of three DNPs including a tet-
rahedron (TET, diameter: 10 nm), a small rod (SR, 5x5x30 nm), and a large rod
(BR, 10x10x120 nm) were examined. BR internalized with relatively higher ef-
fıciency and rate compared to TET and SR, and also demonstrated the most
effıcient knockdown of Bcl2. BR-siBcl2 demonstrated signifıcant cell growth
inhibition of DMS53 and H146 small cell lung cancer (SCLC) cell lines after
48hrs of treatment. A pilot studywith BR-siBcl2 (1.25mg/kg, iv) inmice bearing
DMS53 tumor xenograft (n3) slowed tumor growth compared with buffer
control andnaked siBcl2. Signifıcant differenceswere observed in tumor volume
by pairwise comparison between the two groups: Buffer vs DNP-BR-siBcl2
(p0.007), and siBcl2 vs DNP-BR-siBcl2 (0.028), respectively. No toxicity was
observed in lung, liver, kidney, heart, brain, or spleen. Conclusions: Our novel
DNP formulations demonstrated substantial cellular internalization of siBcl2.
Targeting Bcl2 and its downstream signaling intermediaries reduced cellular
growth. We validated the strategy of silencing of Bcl2 using DNPs in order to
inhibit cancer progression in vivo.We believe that theDNPs andmethodologies
developed in this project will be applicable to knockdown of Bcl2 and other gene
targets and may be applicable to future anti-cancer therapy. (This work is sup-
ported by NIH grant R21EB022828-01).
#188 Preventive effect of aerosolized bexarotene in three major subtypes
of lung cancer: adenocarcinoma, squamous cell carcinoma and small cell
lung cancer inmice.Qi Zhang,1 Jing Pan,1Marker S.Miller,2 Ronald A. Lubet,2
Yian Wang,1 Ming You1. 1Medical College of Wisconsin, Milwaukee, WI; 2Na-
tional Cancer Institute, Rockville, MD.
Lung cancer is the leading cause of cancer-related deaths in the United States.
The 5 year survival rate for lung cancer patients has remained a dismal 15% for
3 decades. Thus, the development of chemopreventive agents that could prevent
lung cancer could potentially reduce the incidence and mortality of pulmonary
neoplasms. Bexarotene has exhibited inhibitory effects in preclinical in vivo
models of mammary and lung tumorigenesis, has been approved for clinical use
in the treatment of cutaneous T-cell lymphoma, and has shown effıcacy in phase
I/II trials of non-small cell lung cancer (NSCLC). Preclinical studies have dem-
onstrated that it is highly effective in the prevention of all three major subtypes
of lung cancer in mouse models: adenocarcinoma (AD), squamous cell carci-
noma (SCC), and small cell lung cancer (SCLC). The major side effects of bex-
arotene when administered orally to rodents or human patients have been hy-
pertriglyceridemia and hypercholesterolemia. Previous studies in a mouse
model of lung AD have demonstrated that aerosol delivery of bexarotene
through nasal inhalation exhibited potent chemopreventive activity similar to
that observed following oral administration (59 to74% reductions in lung tumor
multiplicity). The signifıcant decreases in tumor multiplicity and tumor load
were achieved without hypertriglycerides that accompany oral bexarotene ad-
ministration. In this study, aerosolized delivery of 10-30 mg/ml bexarotene
showed a signifıcant chemopreventive effect in all three major subtypes. In the
N-nitroso-tris-chloroethylurea (NTCU) induced mouse SCCmodel, 1 week af-
ter the fırst dose of NTCU a dose dependent decrease in tumor formation was
observed, with the highest dose causing 75% (p0.001) and 42% (p0.01) de-
creases in SCC tumor burden and the percentage of SCC tumors, respectively.
Tumor load was decreased by 73% in A/Jp53 mouse AD model and by 41% in
A/Jp53Rb mouse SCLC model. Aerosol delivery of bexarotene had no effect on
animal body weight and other signs of toxicity, and no effect on triglyceride and
cholesterol level. Aerosolized bexarotene formulation was effective against all 3
major lung cancer cell types and would be amajor advance achieving signifıcant
reductions in preventing lung cancer incidence in persons at high risk of lung
cancer e.g. former or present smokers.
#189 Development of peptidomimetic inhibitors of the ERG gene fusion
product in prostate cancer. Xiaoju Wang. The University of Michigan, Ann
Arbor, MI.
Transcription factors play a key role in the development of diverse cancers,
and therapeutically targeting them has remained a challenge. In prostate cancer,
the gene encoding the transcription factor ERG is recurrently rearranged and
plays a critical role in prostate oncogenesis. Here, we identifıed a series of pep-
tides that interact specifıcally with the DNA binding domain of ERG. ERG in-
hibitory peptides and derived peptidomimetics (EIPs) bound with high affınity
and specifıcity leading to proteolytic degradation of ERG protein. The EIPs
attenuated ERG-mediated transcription, chromatin recruitment, protein-pro-
tein interactions, cell invasion, and tumor growth. Thus, peptidomimetic target-
ing of transcription factor fusion products may provide a promising therapeutic
strategy for prostate cancer as well as other cancers.
#190 Identifıcation of compound isolated from Beilschmiedia tsangii as a
liver cancer specifıc NRF2 inhibitor. Yi Siao Chen, Chih Chung Lai, Yi Ping
Kuo, Hsun Shuo Chang, Ih Sheng Chen, Chia-Hung Yen. Kaohsiung Medical
Univ., Kaohsiung City, Taiwan.
Drug resistance is themain cause of cancer recurrence and amajor obstacle to
the success of anticancer therapy. NRF2, a pivotal transcription factor regulates
antioxidant response and detoxifıcation, has been shown to participate in the
development of cancer drug resistance. Functional suppression of NRF2 ren-
dered cancer cell more susceptible to anticancer treatments. Beilschmiedia tsan-
giiMerr. (Lauraceae) is amedium-sized evergreen tree. It has been reported that
Beilschmiedia extract showed a strong antioxidant activity. In continuation of
our bioactivity studies on this species, we tested the effects of 23 compounds
isolated from the B. tsangii onNRF2 activity.We identifıed rel-(7R,8R,7=R,8=R)-
3,4,3=,4=-dimethylene-dioxy-5,5=-dimethoxy-7,7=-epoxylignan (BT04) signifı-
cantly inhibitedNRF2 activity in liver cancer cell (Huh7)with an IC50 value of 17
M, but not in keratinocyte (HacaT cell). By contrast, luteolin, a known NRF2
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inhibitor, suppressedNRF2 activity in bothHuh7 cell andHacaT cell.Moreover,
the mRNA level of NRF2 target genes, NQO1 and HO1, were signifıcantly de-
creased inHuh7 upon BT04 treatment, while thoseNRF2 target genes remained
unchanged in BT04-treated HacaT cell. A moderate cytotoxic effect of BT04 on
Huh7 cell was also observed. Accordingly, our result suggested that BT04 can
specifıcally inhibit NRF2 activity in liver cancer, which in turn indicated that
BT04 could be a potential adjuvant to improve chemoresistance.
#191 Double blockade of interacting CK2 and EGFR pathways by tumor-
targeting nanobioconjugates increases therapeutic effıcacy against glioblas-
toma multiforme. Julia Y. Ljubimova. Cedars-Sinai Medical Center, Los Ange-
les, CA.
Introduction: Glioblastoma multiforme (GBM) remains the deadliest brain
tumor in adults, and is notorious for drug and radiation resistance. To inhibit
GBMs more effectively, polymalic acid-based blood-brain barrier crossing
nanobioconjugates were synthesized that are delivered to the cytoplasm of can-
cer cells and specifıcally inhibit the master regulator serine/threonine protein
kinase CK2 and the wild-type/mutated epidermal growth factor receptor
(EGFR/EGFRvIII), which are overexpressed in gliomas according toTheCancer
Genome Atlas (TCGA) GBM database. Methods and Results: The used nano-
bioconjugates are novel nanotherapeutics where all moieties are covalently con-
nected to poly(-L-malic acid) (PMLA). Our biodegradable and non-toxic
nanodrugs bind to the receptors enriched on tumor vasculature and cross the
BBB by transcytosis. They specifıcally bind to cancer cells and after internaliza-
tion exit to the tumor cell cytoplasm using pH-sensitive endosomal disruption
unit. Two xenogeneic mouse models bearing intracranial human GBMs from
cell lines LN229 andU87MG that expressed bothCK2 andEGFRwere used. The
knockdown of CK2 and EGFR/EGFRvIII suppressed their downstream pro-
survival signaling. Treatment also markedly reduced the expression of pro-
grammed death-ligand 1 (PD-L1), a negative regulator of cytotoxic lympho-
cytes. Downregulation of CK2 and EGFR also caused suppression of heat shock
protein 90 (Hsp90) co-chaperone Cdc37, which may inhibit the activity of key
cellular kinases. Inhibition of either target was associated with downregulation
of the other target as well, which may underlie effıcacy of the dual nanobiocon-
jugate that is directed against both CK2 and EGFR. Importantly, the single
nanodrugs, and especially the dual nanodrug, markedly suppressed the expres-
sion of cancer stem cell markers c-Myc, CD133, and nestin, which could con-
tribute to the effıcacy of these nanodrugs. In both tumor models, the dually
targeting nanobioconjugate signifıcantly increased (up to 2-fold) animal sur-
vival compared with the control group. Conclusion: The versatile nanobiocon-
jugates developed in this study, with the ability of anti-cancer drug delivery
across biobarriers and inhibition of key tumor regulators, offer a promising
nanotherapeutic approach to treat GBMs and to potentially prevent drug resis-
tance and retard the brain tumor recurrence. Support: NIH grants U01
CA151815, R01 CA136841, R01 CA188743, R01 CA209921, R01 EY013431
#192 Targeting stearoyl CoA desaturase 1 (SCD1) in hepatobilliary carci-
noma. John Alton Copland,1 Laura A. Marlow,1 Ilah Bok,1 James L. Miller,1
Matsuda Akiko,1 Yan W. Asmann,1 Vivekananda Sarangi,2 Steven R. Alberts,2
Kabir Mody,1 Lewis R. Roberts,2 Mark J. Truty,2 Tushar C. Patel1. 1Mayo Clinic
Florida, Jacksonville, FL; 2Mayo Clinic, Rochester, MN.
Background: The paucity of effective therapeutic agents for hepatocellular
cancer (HCC) underscores the critical need for more effective therapeutic strat-
egies. Recent studies indicate lipid biosynthesis and desaturation is required for
HCC survival. Targeting these may prove benefıcial because such changes con-
tribute to therapeutic resistance. Stearoyl CoA desaturase (SCD1), a key medi-
ator of fatty acid (FA) biosynthesis and rate-limiting in conversion of saturated
fatty acids (SFAs) to mono-unsaturated fatty acids (MUFAs), is upregulated in
HCC and many other cancers. As such, we therapeutically targeted a novel
lipogenic tumor survival mechanism mediated by SCD1 as a means to combat
the chemoresistance associatedwithHCC. In so doing, we evaluated a novel lead
SCD1 inhibitor in HCC.Methods: Paraffın embedded patient HCC tissues were
examined for SCD1 expression. Using combined computational and synthetic
chemistry approaches, we synthesized four novel specifıc SCD1 inhibitors with
SSI-4 being the lead SCD1 inhibitor. HCC cell lines were examined using pro-
liferation assays for response to SSI-4. IC50 concentrations for blocking SCD1
enzyme activity was determined. Blood half-life and bioavailability of single
dose SSI-4 was determined. Mechanisms of action of SCD1 were examined that
included Endoplasmic reticulum (ER) stress. In vivo, antitumor activity was
determined usingHCCpatient derived xenograft (PDX)mousemodels. Results:
We identifıed elevated SCD1 mRNA and protein in HCCs tissues. SSI-4 dose-
dependently inhibits cell proliferation in HCC cell lines with specifıcity demon-
strated by oleic acid (MUFA) co-culture. Single dose oral gavage SSI-4 demon-
strated a half-life of 4 hours and excellent oral bioavailability. SSI-4 was well
tolerated with long-term daily dosing. SSI-4 treatment of HCC cells and tumors
led to endoplasmic reticulum (ER) stress followed by apoptotic cell death. Single
agent SSI-4 demonstrated antitumor activity in HCC PDX mouse models with
suppression of ER stress regulated proteins. Conclusions: Targeting a novel lipid
metabolic pathway in HCC may provide effective therapy for aggressive HCC.
#193 Inhibitors ofMPS1: Discovery of CCT289346, a highly potent, selec-
tive and orally available preclinical candidate. Hannah L. Woodward, Paolo
Innocenti, Kwai-Ming J. Cheung, Sébastien Naud, Angela Hayes, Alan T. Hen-
ley, Amir Faisal, Grace Mak, Gary Box, Isaac M. Westwood, Michael Carter,
MelanieValenti, Alexis DeHaven Brandon, LisaO’Fee, Harry Saville, Rosemary
Burke, Rob van Montfort, Florence Raynaud, Suzanne A. Eccles, Spiros Linar-
dopoulos, Julian Blagg, Swen Hoelder. Institute of Cancer Research, Sutton,
United Kingdom.
MPS1 (also known as TTK), is a dual-specifıcity protein kinase and one of the
main components of the spindle assembly checkpoint. Cancer cells heavily rely
onMPS1 to cope with aneuploidy resulting from aberrant numbers of chromo-
somes and MPS1 has been found to be upregulated in a large number of tumor
types. Extensive work by us and other groups has shown that MPS1 inhibitors
are effective against a variety of cancers, particularly when used in combination
with other drugs, for example, tubulin-targeting agents. We recently reported
the structure-based design and discovery of a series of pyrido[3,4-d]pyrimidines
inhibitors of MPS1 (1). Advanced compounds showed very potent inhibition of
MPS1 in biochemical and cellular assays. However, these compounds suffered
fromhigh lipophilicity andpronouncedmetabolism inhuman livermicrosomes
preventing progression into preclinical development. Here we report the op-
timisation of this series ultimately yielding CCT289346, our preclinical candi-
date. CCT289346 shows excellent potency, kinase selectivity, and ADME prop-
erties including stability in human liver microsomes. The compound has been
produced on a kilogram scale and is currently undergoing preclinical develop-
ment. We will discuss our design approach and hypotheses leading to the dis-
covery of CCT289346 and disclose in vivo effıcacy data. References 1. Innocenti
P et al. Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar
Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.
Journal of Medicinal Chemistry. 2016; 59(8):3671-88.
#194 Effective targeting ofMYCexpressionwith a novel nucleic acid bind-
ing (G4-quadruplex) small molecule coupled with HDAC inhibition syner-
gizes to limit myeloma growth. Snehal M. Gaikwad,1 David R. Calabrese,2
Elena C. Leon,1 John K. Simmons,1 Shuling Zhang,1 Aleksandra Michalowski,1
SayehGorjifard,1 ZawPhyo,1Daniel Connors,1 John S. Schneekloth,2 Beverly A.
Mock1. 1CCR, NCI, NIH, Bethesda, MD; 2CCR, NCI, NIH, Frederick, MD.
MYC is deregulated in many malignancies and its aberrant expression is as-
sociated with tumorigenesis and tumormaintenance.We employed a therapeu-
tic strategy to target both MYC transcription, and protein stability. Previously,
we developed a small moleculemicroarray and screened it forMYCG4-binding
compounds. The stabilization of G-quadraplex (G4) structures by nucleic acid
binding smallmolecules in theNHE III region of theMYCpromoter slowsMYC
transcription. We identifıed a benzofuran containing small molecule that could
selectively and reversibly stabilize MYC-G4 DNA and reduce MYC expression.
This compound demonstrated a G4-dependent mechanism of action showing
toxicity in multiple myeloma cell lines containing a G4 in their MYC promoter
whereas minimal effects were seen in a Burkitt’s lymphoma line lacking the
MYC G4 sequence. Gene expression analysis validated that this compound se-
lectively inhibited MYC and other MYC effectors, but did little to limit the
expression of other G4 containing genes. The synthesis of more than 15 analogs
identifıed a new benzofuran-containing analog with enhanced inhibitory activ-
ity in a diverse panel of human cancer cell lines (NCI-60), including a number of
myeloma cell lines. EDGE-seq data confırmed that the new analog is similar to
the original compound in having higher affınity for the G4 inMYC compared to
the G4 in BCL2, KRAS, VEGFA and HIF1A. In addition, the analog was syner-
gistic with entinostat, an HDAC inhibitor that can affect MYC protein stability,
in limiting myeloma cells, but not PBMCs. The more potent growth inhibitory
activity of the new analog allowed us to generate suffıcient quantities to evaluate
its pharmacokinetics and toxicity in mice. The compound was well tolerated in
a dose-escalation toxicity study; no adverse effects were observed and prelimi-
nary pharmacokinetic studies showed promising serum bioavailability and ex-
posure properties when administered either intravenously, intraperitoneally or
orally. In an assessment of short term in vivo activity, MYC protein expression
was inhibited in multiple myeloma xenografts. Longer term studies to evaluate
the anti-tumor activity of the compound are currently in progress. Thus, our
data provide evidence that smallmolecule stabilization of theMYCG4 can drive
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transcriptional silencing of oncogenic MYC both in vitro and in vivo. Further-
more, synergistic tumor cell killing was achieved when the MYC G4 inhibitor
was coupled with HDAC inhibition.
#195 Evaluation of the cell surface binding of phycocyanin and associated
mechanisms causing cell death in prostate cancer cells. Paramjot Kaur,1
SivanesanDhandayuthapani,1 Shona Joseph,2 SyedHussain,2MiroslavGantar,3
Appu Rathinavelu1. 1Rumbaugh Goodwin Institute for Cancer Research, Nova
Southeastern University, FL; 2Halmos College of Natural Sciences and Oceanog-
raphy,Nova SoutheasternUniversity, Fort Lauderdale, FL; 3Florida International
University, Miami, FL.
Plant and microbial metabolites are constantly explored to identify novel
therapeutics with promising potential for treating diseases such as cancer. Ma-
rine-derived compounds are also tapped frequently for their effıcacy in treating
cancers and are used both in mono and combination therapies. The potential of
cyanobacteria (blue-green algae) as the source of anticancer agents has been
explored for many decades and, as a result of continuing efforts, several com-
pounds have emerged as templates for the development of new anticancer drugs
from these microorganisms. The C-phycocyanin (C-PC) tested in our experi-
ments was derived from the cyanobacteria Limnothrix sp., strain 37-2-1, which
is found abundantly in Florida’s Everglades. In our previous studies, this fluo-
rescent compound was found to potentiate the cytotoxic effects of Taxol and
Topotecan. In LNCaP prostate cancer cells, C-PC was able to induce apoptosis
by itself through activation of the apoptotic pathway and completing DNA frag-
mentation. Itwas originally anticipated thatC-PCmight penetrate the cellmem-
brane to induce mitochondrial damage and trigger the apoptotic process
through activations of caspases. In order to verify this possibility, experiments
were conducted to determine the uptake of C-PC using LNCaP cells. When we
incubated the cells with C-PC at the concentrations of 250 and 500g/mL for 12
hrs and assessed the cellular uptake by capturing the fluorescence signals at the
wavelength of 605 nm, using a fluorescence microscope, the signals were ob-
served only with the periphery of the cells. Furthermore, with subsequent
washes using PBS, the fluorescence signal that was seen to be associated with the
plasmamembrane was reduced gradually and was removed completely after the
3rd wash without any signs of penetration into the cytoplasm. The binding of
C-PC to the plasma membrane was very transient and quickly dissociated at
room temperature. However, after incubating the cells with the same concen-
trations of C-PC, there was up-regulation of proapoptotic markers such as p53
and p21 and as a result, the cells showed a signifıcant reduction (65%) in
viability. So far, our results suggest that the cytotoxicity towards LNCaP cells
might have been triggered by the binding of C-PC to the cell membrane recep-
tors such as FasR, TRAIL-R, TNF-R, which may be linked to the mediators of
extrinsic and intrinsic apoptotic signals. Hence, our fındings are signifıcant for
explaining some of the apoptotic events triggered by C-PC.However, additional
studies are required to identify the actual receptors involved in triggering the
pathway. (The support from the Royal Dames of Cancer Research Inc., Ft. Lau-
derdale, Florida is gratefully acknowledged).
#196 Identifıcation of small molecule inhibitors of the notch transcrip-
tional activation complex. Luisana Astudillo, Anthony Capobianco. Univ. of
Miami Miller School of Medicine, Miami, FL.
Deregulation of the Notch pathway underlies many aspects of cancer physi-
ology depending on cell type and context. In many human cancers, aberrant
Notch activity has been demonstrated to play a role in the initiation and main-
tenance of the neoplastic phenotype. Notch also plays a central role in cancer
stem cells, whichmay underlie a role inmetastasis and resistance to therapy. The
important and diverse role played by Notch in cancer makes it an exceedingly
attractive target for anti-neoplastic therapeutics. However, the full range of po-
tential targets in the pathway have been under-explored. Through computer-
aided drug design we explored potential ligand binding sites and screened for
compounds that could disrupt the assembly of the Notch transcriptional activa-
tion complex. An in vitro assay that quantitatively measures the assembly of the
Notch transcriptional complex on DNA was used for screening. We have re-
cently reported the identifıcation and characterization of a small molecule in-
hibitor of the Notch transcriptional activation complex, termed Inhibitor of
Mastermind Recruitment-1 (IMR-1). Herein we report the characterization of
small molecule inhibitors of Notch derived from IMR-1 that were identifıed
through a combination of structure-activity relationship studies and molecular
docking simulations.We demonstrate that these compounds inhibit the growth
of Notch dependent cell lines and decrease Notch target gene transcription.
#197 Anti-cancer activity of extract from the Jamaican round-leaf yellow
yam (RLY2) (Dioscorea cayenensis). Sasha-Gay A. Wright,1 Wesley G. Gray,2
Helen Asemota1. 1University of the West Indies, Mona Campus, Kingston, Ja-
maica; 2Southern University and A&M College, Baton Rouge, LA.
The Jamaican Round-Leaf yellow yams (RLY2), Dioscorea cayenensis, are
edible tubers, bulbils or rhizomes that are of considerable economic value
and possess several health benefıts. These RLY2 are a rich source of anti-
oxidants, vitamins and phytochemicals. In addition to its nutritional value,
the Jamaican populace regards RLY2 as an herbal medicine useful in treat-
ment of diabetes mellitus, hypertension and certain kind of cancers. Chem-
ical analysis of RLY2 revealed the presence of a myriad of bioactive ingredi-
ents that are likely to be lost due to the method of preparation for
consumption. Thus, we hypothesized that mild extraction of RLY2 will pre-
served the bioactive analytes that give RLY2 its anti-cancer property. To test
this hypothesis, different ethanolic extracts of RLY2 were prepared, and their
bioactivity demonstrated in two models of prostate cancer. The present
study demonstrates dosage and time-dependence inhibition in both the an-
drogen sensitive LNCaP and androgen insensitive DU-145 prostate cancer
cell lines. We observed that DU-145 was three-times more sensitive to RLY2
ethanol extract than LNCaP. Growth of LNCaP for 3-days with varying con-
centration of RLY2 ethanol extract resulted in an IC50 of 750 ppm (95% C.I.
726-791ppm), whereas DU-145 resulted in an IC 50 of 250 ppm (95% C.I.
236-281ppm). The maximum growth inhibition by RLY2 extract occurs
within twenty-four hours for both LNCaP and DU-145 with no signifıcant
changes after 5-days. To determine the mechanism of toxicity by RLY2, we
induced both LNCaP andDU-145 with RLY2 for 0-24h and prepared cells for
flow cytometer analysis. The effect of RLY2 on cell cycle and degree of apo-
ptosis will be discussed. Our data indicated that the ethanol extract of RLY2
was more sensitive toward androgen-insensitive prostate cancer. Thus, this
study suggests that RLY2 contain bioactive chemical that may be used in
grade II prostate adenocarcinoma represented by the DU-145 phenotype.
#198 Low molecular weight pyrrolobenzodiazepine (PBD) monomers
have potent cytotoxicity in haematological tumor cells. David B. Corcoran,1
Thomas Lewis,2 Amrit Varsha,1 Chris Pepper,2 David E. Thurston,1 Khondaker
Miraz Rahman1. 1King’s College London, London, United Kingdom; 2University
of Cardiff, Cardiff, United Kingdom.
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) have long been of interest
as potential chemotherapeutic agents due to their ability to form covalent
adducts within the minor groove of the DNA helix. The most effective syn-
thetic modifıcations to PBD cores have involved the conjugation of two
DNA-interactive moieties via their C8/C8’-positions to create PBD dimers
capable of cross-linking duplex DNA which improves cytotoxicity. Research
to date has focussed on adding substituents to the C8-position of the PBD
core to improve DNA-interaction and cytotoxicity. All of these approaches
tend to increase the molecular weight of the compounds, although this has
not prevented their successful development to the clinic, either as stand-
alone agents (e.g., SJG-136) or as a component of Antibody-Drug Conju-
gates (ADCs) (e.g., SGN-CD33A). During a structure-activity relationship
(SAR) study, we embarked on a “molecular pruning” exercise to sequentially
reduce the length and bulk of the C8-substituent of a PBD monomer expect-
ing the cytotoxicity to reduce with a decrease in length/bulk, and to establish
the minimal pharmacophore. Surprisingly, we found that reducing the
length of the C8-substituent maintained cytotoxicity and in some cases en-
hanced it. A 20-member library of short C8-substituted PBD monomers has
been synthesized featuring C8-substituents of various chemical composition
and length, with some containing aniline substituents. Cytotoxicity evalua-
tion in several tumour cell types (e.g., primary CLL, JJN-3 and MDA-MB-
231) was carried out, and low nanomolar to high picomolar IC50 values were
obtained for several library members including DC-1-194 (IC50 4.2nM in
CLL, and 0.79nM in MDA MB 231), DC-1-255 (IC50  9.5nM in CLL, and
1.1nM in MDA MB 231), DC-1-253 (IC50  8.4nM in CLL, and 10nM in
JJN-3) and DC-1-275 (IC50 7.6nM in CLL, and 9.6nM in JJN-3). Remark-
ably, many of these more-active compounds had very short C8-substituents.
HPLC and FRET based DNA binding studies were also carried out, in order
to confırm the capacity of these molecules to form adducts with DNA. The
observations reported here are signifıcant, as they add to an evolving under-
standing of the SAR of PBDmonomer structures. The results presented here
may also have signifıcance for the future development of PBD-based thera-
peutic agents where there may be advantages to working with lower molec-
ular weight molecules.
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#199 Silibinin suppresses bladder cancer through down-regulation of ac-
tin cytoskeleton and PI3K/Akt signaling pathways. Mitsuho Imai-Sumida,1
Takeshi Chiyomaru,2 Shahana Majid,1 Priyanka Kulkarni,1 Pritha Dasgupta,1
Sharanjot Saini,1 Taku Kato,1 Shigekatsu Maekawa,1 Yutaka Hashimoto,1
Marisa Shiina,1 Guoren Deng,1 Varahram Shahryari,1 Hannah Nip,1 Rajvir Da-
hiya,1 Yuichiro Tanaka,1 Soichiro Yamamura1. 1UCSF VA Medical Ctr., San
Francisco, CA; 2National Hospital Organization KagoshimaMedical Center, Ka-
goshima, Japan.
Silibinin is the major active constituent of silymarin, an extract of milk thistle
seeds. Silibinin has been shown to have signifıcant anti-cancer effects in a variety
ofmalignancies.However, themolecularmechanisms of silibinin action in blad-
der cancer have not been studied extensively. In the present study, we found that
silibinin (10M) signifıcantly suppressed proliferation and invasion of T24 and
UM-UC-3 human bladder cancer cells. In this study, we investigated themolec-
ular mechanisms underlying these effects of silibinin. Our results showed that
silibinin down-regulates actin cytoskeleton-related Ras-Rac-PAK1 pathways
and the phosphatidylinositide 3-kinase (PI3K)/Akt signaling pathway in these
bladder cancer cell lines. These pathways were found to promote cellular trans-
formation and cancer development and have crosstalk through Ras cascades.
We investigated the role of silibinin on Ras, and found that silibinin suppresses
levels of trimethylated histone H3 lysine 4 and acethylated H3 at the K-RAS
promoter. We also found that silibinin downregulates long non-coding RNAs:
HOTAIR and ZFAS1, which are known to play roles as oncogenic lncRNAs in
various cancers. This study shows that silibinin exerts anti-cancer effects
through down-regulation of the actin cytoskeleton and PI3K/Akt pathways and
thus suppresses the development and progression of bladder cancer.
#200 Long lasting inhibition of TGF- receptor Type 1 inhibitor (TGF-
R1) for treatment of pancreatic cancer. Cristian Rodriguez-Aguayo,1 Emine
Bayraktar,1 Haifa Shen,2 Gabriel Lopez-Berestein1. 1UT MD Anderson Cancer
Ctr., Houston, TX; 2The Methodist Hospital Research Institue, Houston, TX.
Pancreatic cancer stroma is a high component of total tumor volume and
activators of fıbro-genesis such as Transforming growth factor- (TGF-) are
abundantly secreted by pancreatic stellate cells (PSCs) to the tumor microenvi-
ronment. Aberrant TGF- signaling pathways are associated withmany human
diseases, including bone diseases, immune-suppression, fıbrosis, cancer pro-
gression and metastasis. However, the precise mechanism of this phenomenon
in pancreatic cancer remains unclear. In this study we hypothesized that inhibi-
tion of TGF- Type I receptor kinase (TGF- R1) in pancreatic cancer and
stellate cells regulates proliferation and fıbrosis through the regulation of TGF-
R1 signaling pathway in PC cells, resulting in decreased migration, and de-
creased proliferation. We analyzed a TGF- R1 data set of PC patients from the
Cancer Genome Atlas. Furthermore, the analysis of a panel of pancreatic cancer
cell lines showed that TGFR-
1 at mRNA and protein levels were higher in PC
cells when compared with human pancreatic duct epithelial (HPDE) normal
cells. In vitro cell viability, growth, cell-cycle progression, migration, invasion
and apoptosis, as well as in vivo therapeutic effectiveness in murine xenograft
models, were also assessed following the inhibition of TGF- R1 in pancreatic
cancer and stellate cells. The experimental validation identifıes TGFR-1 asso-
ciated with PC survival. Signifıcant inhibition of cell growth, invasion, migra-
tion, angiogenesis and fıbro-genesis. Furthermore, treatment with LY-DMPC:
DMPG-MSV inhibited growth of CAPAN-II tumors. These fındings identify
TGFR-1 as a potential therapeutic target in pancreatic cancers expressing high
levels of this oncogenic protein.
#201 Targeting colorectal cancer lungmetastasis microenvironment with
PI3K inhibitors and chemotherapy. Piotr Rychahou, Younsoo Bae, Derek A.
Reichel, Yekaterina Zaytseva, Eun Y. Lee, Heidi L. Weiss, B. Mark Evers. Uni-
versity of Kentucky, Lexington, KY.
Introduction: Colorectal cancer (CRC) is the second leading cause of cancer
deaths in the US; systemic metastasis to the lungs occurs in approximately 10-
20% of patients with CRC. The toxicity of currently available anticancer drugs
and the ineffıciency of chemotherapeutic treatments, especially for advanced
stages of the CRCmetastatic disease, have severely limited the treatment options
in patients with CRC lungmetastasis. Here, we evaluated nanocarrier that accu-
mulates selectively in normal lung stroma and lung metastasis tumor microen-
vironment. The purpose of our study was to: (i) demonstrate lung-selective
delivery of nanoparticles into the tumor microenvironment and surrounding
normal parenchyma as a targeted therapy for CRC lung metastasis, and (ii)
evaluate effect of lung selective delivery of PX-866 and SN-38 loaded nanopar-
ticles on CRC lungmetastasis growth. Methods: (1) HT29 LungM3 cell line was
derived from the human CRC line HT29 following multiple rounds of in vivo
selection for lung metastasis in immunodefıcient mice. (2) Polymeric nanopar-
ticles were constructed and loaded with fluorescent dye (Alexa 547), pan-PI3K
inhibitor PX-866 or SN-38. Fluorescent nanoparticles were administered intra-
venously into mice at 1, 4, 8, 24h timepoints. (3) Nanoparticle drug delivery was
quantifıed in lung, liver and kidney tissue samples byHPLC. (4) CT26 andHT29
LungM3 cell lines were injected intravenously to establish lungmetastasis. Mice
were then treated with PX-866 and SN-38 loaded nanoparticles every 3 days
intravenously for 31 days. Results: Lung selective accumulation of Alexa-546
fluorescently-labeled nanoparticles was confırmed by confocal imaging of fro-
zen tissue sections from lung, liver, kidney and spleen. Selective PI3K inhibition
in lung tissue was confırmed by western blot analysis of protein extracts from
lung, liver, kidney and spleen for pAkt (S473) expression.HPLCanalysis showed
predominant PX-866 drug delivery to lungs and minimal drug delivery to kid-
ney and liver tissues. Treatment with PX-866 loaded nanoparticles demon-
strated a marked suppression of lung metastasis growth; CRC lung metastases
were not detected after treatment with SN-38 loaded nanoparticles. Notably,
administration of PX-866 and SN-38 nanoparticles had no deleterious effect on
normal lung, kidney or liver parenchyma. Conclusions: We demonstrate selec-
tive and effıcient delivery of drug-loaded nanoparticles to lungs with minimal
accumulation in kidneys, liver and immune system, suggesting that lung selec-
tive drug delivery is a viable treatment strategy for CRC lung metastasis. More-
over, treatment of mice with CRC lung metastases with either PX-866 or SN-38
loaded nanoparticles resulted in a marked suppression of metastatic growth.
Polymeric nanocarriers have a potential to revolutionize drug delivery and to
signifıcantly improve current approaches to the treatment of patients with CRC
lung metastasis.
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#202 Comprehensive spatialmappingbyMALDI imagingmass spectrom-
etry of the N-glycan tissue glycome and database generation for eighteen
tumor types. Richard R. Drake, Kacey Talbot, Kim Norris-Caneda, Evelyn
Bruner, Peggi M. Angel.Medical Univ. of South Carolina, Charleston, SC.
Glycoproteins account for approximately 80% of the proteins located at the
cell surface and in the extracellular environment, and serve as binding ligands
for cell adhesion, extracellular matrix molecules, signaling receptors, immune
cells, lectins and pathogens. Alterations and changes in cell surface glycosylation
during tumorigenesis are well documented, including the major N-linked gly-
can class of glycosylated proteins. We have recently developed a MALDI imag-
ing mass spectrometry (MALDI-IMS) method to spatially profıle N-linked gly-
cans in frozen and formalin-fıxed paraffın-embedded (FFPE) tissue sections and
tissuemicroarrays (TMAs). In order to facilitatemethod development andmax-
imize glycome determinations for many cancer types, we have generated two
custom TMAs comprised of multiple tissue core pairs of non-tumor and tumor
regions representing eighteen different tumor types (pancreatic, colon, prostate,
breast, lung,melanoma, sarcoma, head/neck, kidney, liver, glioma, ovarian, thy-
roid, uterine, cervical, testicular, gastric, bladder). Tissues are incubated with a
molecular coating of peptideN-glycosidase, and releasedN-glycans are detected
directly using MALDI-FTICR imaging, linked directly with tissue histopathol-
ogy. The method is able to simultaneously identify and distinguish 50 or more
components of the N-glycome on a single slide. The approach allows compari-
son of the similarities and differences in N-glycome compositions across each
tumor tissue type, as well determine the relative abundance of each individual
glycan across all tumor types. For example, an increase in highmannose glycans
is common to many tumor types. From the TMA data, this glycan class is con-
sistently elevated for colon, prostate, lung, breast and bladder cancers, while the
other tumor types are variable. Differences in branching complexity, bisecting
N-acetylglucs0amine, and the degree of fucosylation and sialylation are also
readily evaluable. Additionally, data from each of the TMA core pairs is being
compared systematically to the N-glycans detected in the source FFPE blocks.
The goal is to generate an extensible reference database of expected N-glycans
for each tumor tissue type. This will also provide a framework to expand to other
classes of glycans, and complementary glycan data generated by other methods
on the same TMA cores.
#203 Automated, high throughput mass spectrometry imaging of serial
sections for investigation of tumor heterogeneity in three dimensions.Emrys
A. Jones,1 Fiona Henderson,2 David Coope,2 Joanna Denbigh,2 Steven Pringle,1
AdamMcMahon,2 KayeWilliams2. 1Waters, Wilmslow, United Kingdom; 2Uni-
versity of Manchester, Manchester, United Kingdom.
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For the purpose of investigating the potential of automation and high
throughput mass spectrometry imaging, we have combined a desorption elec-
trospray ionisation (DESI)MS systemwith a robotic slide loader. The analysis of
tissue sections on multiple slides could allow, for example, large patient cohorts
to be analysed with almost no input from the operator. Here we present another
use of such a system, the mapping and visualisation of tissues in 3D from serial
sections. All experiments were carried out on a Waters Xevo G2-XS Q-ToF
equipped with a Prosolia (Indianapolis) 2D DESI stage. The automated slide
loader andmodifıed plate holder were provided by Prior Scientifıc (Cambridge).
As an ambient ionisation technique, the DESI sampling procedure occurs out-
side of the vacuum of the instrument and is therefore suited to accommodate
slide handling devices. A modifıed top plate was created that, once in place,
allows the Prior PL200 microscope slide loader to load slides from the holding
cassettes to the stage and back. A snapshot of the slide being taken and object
defınition algorithms is used to identify the location of the tissue(s) on the slide.
These co-ordinates are then written to the experiment fıle and the acquisition
commences. This process will continue until all slides are analysed. Recent tech-
nological advances have led to the time taken for a single MS tissue image being
reduced from the region of hours to minutes. This then opens up the possibility
of automatic sample loading and high throughput usage. Fifteen sections taken
at 120m steps through a human glioma were analysed automatically by the
DESI system.Datawas collected in both positive andnegative ionmode from the
same tissue to increase the molecular coverage. Sections taken from between
those use for the imaging were used for H&E staining and CA-9, Ki67 and SCD
immunohistochemistry staining. Once all sections were analysed, recently de-
veloped software allowed for the reconstruction of the sections into a three
dimensional representation of the chemically distinct regions within the whole
tissue volume. This process which involves peak picking, object alignment
and rotation as well as a non negative matrix factorisation step is all done
automatically.When these regions identifıed from the 3Dmass spectrometry
mapping are compared to the CA-9 and Ki67 IHC stains the regions of
hypoxia and proliferation clearly correlate indicating that mass spectrome-
try imaging could be a useful tool for the determination of hypoxia within
excised tissue. Further to these identifıed regions was the discovery of mo-
lecular signals that were only present on the boundary between the hypoxic
and normoxic regions; the identities and roles of which are currently under
investigation. Faster and automated mass spectrometry imaging allows
whole tissues to be chemically mapped in three dimensions in a few hours
providing insights into tumour heterogeneity.
#204 In vitro metabolomics of mesothelioma: Challenges and outcomes.
Sabrina Lagniau,1 Kevin Lamote,1 Lore Vandermeersch,1 HermanVan Langen-
hove,1 Jan P. van Meerbeeck,2 Karim Y. Vermaelen1. 1Ghent University, Ghent,
Belgium; 2Antwerp University Hospital, Edegem, Belgium.
Introduction: Early detection of malignant pleural mesothelioma (MPM) is
likely to improve outcome in affected patients. From our previous studies (Me-
soBreath 1 & 2) we developed a screening tool in which volatile organic com-
pounds (VOCs) in breath allowed discrimination of MPM patients from at risk
controls. However it is not yet clear which VOCs arise from the neoplastic cells
themselves or from the host response. Identifying the cancer cell-specifıc com-
pounds should increase the specifıcity of our breathomic signature model.
Therefore, we set up an in vitro experimental setup model for VOC analysis
from the headspace of mesothelioma cell lines. Methods Standard polystyrene
culture flasks (NunclonTMDelta Surface, Thermo Scientifıc) weremountedwith
an adapted cap accommodating teflon inlet and outlet tubes. The inlet tube
provides environmental air while an external pump (Gilian GilAir Plus, Sensi-
dyne) draws headspace air from the outlet tube over an adsorption column
(Tenax GR, Markes International, UK). The adsorption columns were further
processed on aGC-MSplatform (GC: FocusGC, ThermoFinnigan,Milan, Italy;
DSQII Single Quadrupole MS, Thermo Finnigan, Austin, TX, USA). VOC pro-
fıles were processed using supervised clustering algorithms and principal com-
ponent analysis. Results: Using this setup, we have investigated the impact of
flow and total sampled volume on the concentration and range of VOCs de-
tected. For a constant flow, VOCs were detected in higher concentrations
with increasing sample volume. For a constant volume, a lower sampling
flow yielded a higher concentration of detected VOCs. Most of the VOCs
obtained were alkanes and ketones. We will show data illustrating the differ-
ential VOC profıles of container plastic, cell culture medium and growing
mesothelioma cancer cells, as well as the differential VOC output of epithe-
lioid vs sarcomatoid mesothelioma cell lines. Conclusions: We have succes-
fully developed an in vitro experimental setup allowing collection and anal-
ysis of VOCs emanating from mesothelioma cancer cell line cultures. This
platform will allow us to investigate how VOC profıles are impacted in dif-
ferent experimental conditions (e.g. hypoxia, nutrient deprivation, cytostat-
ics, co-culture with leukocytes). The data collected will help us to pinpoint
the cancer cell-derived VOCs from patient exhaled breath, and increase the
robustness of our mesothelioma breathomic signature.
#205 Underlying mechanisms of genome-proteome discordance in squa-
mous cell lung cancer. Paul A. Stewart, Robbert J. Slebos, Eric A. Welsh, Ling
Cen, Yonghong Zhang, Zhihua Chen, Chia-Ho Cheng, Fredrik Pettersson, An-
ders Berglund, Guolin Zhang, Bin Fang, Victoria Izumi, Sean Yoder, Katherine
Fellows, Ann Chen, Jamie K. Teer, Steven A. Eschrich, JohnM. Koomen, Eric B.
Haura.Moffıtt Cancer Center, Tampa, FL.
Introduction: Genomic analyses have yielded a tremendous amount of data
on the genetic changes in lung cancers, but translating these experiments into
actionable information benefıtting lung squamous cell carcinoma (SQLC) pa-
tients has proven more diffıcult. Studies by the NCI Clinical Proteomic Tumor
Analysis Consortium (CPTAC), our group, and others have demonstrated that
gene and protein expression show only moderate correlation, demonstrating
limitations in explaining phenotypic changes from genomics alone. These fınd-
ings indicate a clear need for integrative proteogenomics to better understand
tumor biology, especially in a complex disease like SQLC. Experimental: We
have assembled a comprehensive proteogenomic dataset including DNA copy
number (Affymetrix CytoScan HDAssay), targeted exome sequencing (Agilent
Comprehensive Cancer Panel), RNA-sequencing (IlluminaNextSeq), and shot-
gun proteomics (Q Exactive LC-MS/MS) on 116 surgically resected SQLC tu-
mor samples with extensive clinical and follow up data. Results: We have iden-
tifıed 6584 high confıdence proteins from preliminary proteomic analysis. After
quality control fıltering, we utilized 5562 gene-protein pairs for further analysis.
Clustering of patient RNA expression in this patient cohort has been unable to
fully reproduce themolecular classifıcation previously published for SQLC. Fur-
thermore, proteomic results indicate yet another potential classifıcation strategy
selecting patient subgroups that differ at protein level. We observed a 0.29 me-
dian Spearman’s correlation of 5562 gene-protein pairs. There were 2781 highly
correlated gene-protein pairs (greater than median) and 2781 poorly correlated
gene-protein pairs (less than median) including 773 anti-correlated gene-pro-
tein pairs (less than 0). We hypothesized that poorly correlated gene-protein
pairs could be functionally related in a pathway-dependentmanner. Enrichment
analysis of poorly correlated proteins identifıed pathways related tomRNApro-
cessing, growth factor signaling (EGFR, FGFR), and nonsense-mediated decay
(NMD). Interestingly, there were 9 frequently mutated SQLC genes in the low
correlation gene-protein pairs but only 3 in the highly correlated pairs. We
found three distinct patient subgroups by clustering poorly correlated proteins.
Analysis of these subgroups showed differentially expressed pathways related to
mRNA processing, ubiquitination, and NMD. Conclusion: Differential modu-
lation of the proteome outside of genomic regulation may suggest important
regulatory mechanisms in cancer and give new insights into treating SQLC.
Analysis of poorly correlated gene-protein pairs suggests certain pathways are
dysregulated in cancer, and ongoingDNAanalysis and future analyses involving
miRNAs, RNA-binding proteins, and the ubiquitin proteome system will help
elucidate our preliminary fındings.
#206 Proteogenomic classifıcations and outcome in squamous cell carci-
noma of the lung.Robbert J.C. Slebos, Paul A. Stewart, Eric A.Welsh, Ling Cen,
Yonghong Zhang, Zhihua Chen, Chia-Ho Cheng, Fredrik Pettersson, Anders E.
Berglund, Guolin Zhang, Bin Fang, Victoria Izumi, Sean J. Yoder, KatherineM.
Fellows, Y Ann Chen, Jamie Teer, Steven Eschrich, John Koomen, Eric Haura.
Moffıtt Cancer Center, Tampa, FL.
Introduction: Genomic analyses have yielded a tremendous amount of
knowledge on the genetic changes in lung cancers, but translating this informa-
tion into actionable data benefıtting patients has proven diffıcult. The integra-
tion of proteomic analyses with genomics and gene expression profıling allows a
more detailed description of the biological processes, thus improving our un-
derstanding of cancer phenotypes. These insights can potentially be used for
better classifıcation and help to guide patient selection for targeted therapies.
Experimental: We analyzed 116 surgically resected squamous cell lung carci-
noma samples for copy-number alterations, gene expression profıling, targeted
exome-sequencing and global proteomic profıling. The cohort consisted of
mostly early stage tumors (83% Stage I or II) with complete follow-up (median
58 months). Copy number status was analyzed using the Affymetrix CytoScan
array, DNA mutation status was assessed using a customized version of the
Agilent Comprehensive Cancer Panel for targeted sequencing, and gene expres-
sion profıling was carried out by RNA-sequencing. Proteomic analysis was per-
formed using TMT labeling, 12- fraction bRPLC separation and LC-MS/MS
analysis with a Thermo Q-Exactive mass spectrometer. Database searches were
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performed using multiple search engines against RefSeq version 78, and sum-
marized using IDPicker 3. Results: The non-redundant protein inventory con-
sisted ofmore than 6,000 protein groupswith a protein FDR5%. Tumorswere
classifıed according to well established gene expression criteria into 4 classes:
Classical, Basal, Primitive and Secretory. At the protein level, the Classical sub-
type was associated with xenobiotic and energy metabolism; the Basal subtype
with defense responses and extracellular matrix changes; the Primitive subtype
with nucleic acid metabolism; and the Secretory subtype with p38 signaling.
These fındings confırm and expand on previous mRNA expression studies of
squamous cell lung carcinoma. Proteomics-based classifıcation identifıed two
sub-categorieswithin theClassical subtype, whichwere characterized by inflam-
matory and stress response signaling. Within this group, patients with high
expression of inflammation-associated proteins had better cancer-specifıc sur-
vival than those with low expression (p0.04, Log-rank test). Targeted exome
sequencing of 154 cancer-associated genes revealed frequentmutations in TP53,
CDKN2A, NFE2L2, and other genes. Proteomic expression of genes located in
amplifıed chromosomal regions was used to identify driver genes in squamous
cell lung carcinoma. Conclusion: Our results provide new biological insights
from the addition of protein measurements to genomic datasets that have the
potential to improve classifıcation. The data suggest that proteins involved in
immune responses are important for the biological behavior and outcome of the
Classical subtype in squamous cell lung carcinoma.
#207 Reliable identifıcation of mutations in bottom-up proteomics. Mi-
roslav Hruska, Lakshman Varanasi, Jiri Voller, Petr Dzubak, Marian Hajduch.
Institute ofMolecular and TranslationalMedicine, Faculty ofMedicine andDen-
tistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Knowledge of missense mutations is of signifıcant biological importance as it
provides valuable insights into alterations of phenotype. While identifıcation of
reference proteins is routinely performed in proteomics, identifıcation of muta-
tions remains still fairly uncommon. Well-established methods for reference
peptides are generally insuffıcient for altered ones; e.g., utilizing mutant-aug-
mented database search usually results in inadmissible proportion of false pos-
itives. This undesirable situation is, however, rather natural consequence of
peptide fragmentation, its computational modelling and evaluation of their cor-
respondence. Often, there are many peptides having the same or similar agree-
ment with acquired spectrum, thereby preventing agreement-based decision.
These situations happen frequently in identifıcation of mutant peptides (e.g.,
homologous peptides with PTMs, semi-specifıc peptides), therefore their reli-
able identifıcation requires additional treatment. To deeper understand proper-
ties of identifıcation, we have formally studied generalized version of the iden-
tifıcation problem and derived its optimal solution under particular
assumptions. In proteomics, the selection of optimal solution can be always
found in fınite time; moreover, the strategy is straightforward to implement,
enables parallelization and provides guarantees over claimed interpretations.
The solution utilizes almost exclusively spectral data of product ions without
additional LC/MS information. In practice, however, it is benefıcial to employ
precursor isotopic distribution analysis for correction of non-monoisotopic se-
lection of precursor as that would otherwise systematically result in artefacts.
The behaviour of proposed method was validated in a variety of scenarios that
could be broadly categorized as direct (known spectral content) and indirect
(partial knowledge of sample content). For direct validation, synthetic combi-
natorial peptide library of 400 peptides (all coded amino acids in 12. and 13.
codon of KRAS peptide) wasmeasured and interpreted; the sensitivity and spec-
ifıcity obtained was 0.81 and 0.99 respectively. Indirect validation was, at fırst,
performed on in-house samples with RNA-Seq data available (HCT116), giving
97 missense RNA-Seq supported mutations. Similarly, the analysis was done on
proteome data of NCI60 cell lines, resulting on average in 23 SNVs with maxi-
mum of 56 SNVs (HCC-2998). Identifıed alterations correspond, in general, to
highly expressed genes. In summary, the approachwas shown to reliably identify
missensemutations in a range of cancer cell lines; its wide applicability enhances
interpretation of standard bottom-up proteomics data.
#208 Proteomic measurements of protein abundance and phosphoryla-
tion identify novel kinase-substrate relationships in ovarian cancer. Jason E.
McDermott,1 Tao Liu,1 Samuel Payne,1 Vladislav Petyuk,1 Hui Zhang,2 Zhen
Zhang,2 Daniel Chan,2 Richard Smith,1 Karin Rodland,1 Clinical Proteomic Tu-
mor Analysis Consortium. 1Pacifıc Northwest National Laboratory, Richland,
WA; 2Johns Hopkins Medical Insitutions, Baltimore, MD.
As part of the Clinical Proteomic Tumor Analysis Consortium (CPTAC), we
have recently published the fırst large-scale proteomic and phosphoproteomic
analysis of high-grade serous ovarian tumors. We observed that phosphoryla-
tion status was an excellent indicator of pathway activity and could discriminate
between patient survival times. This dataset covers tumor samples from 69 pa-
tients with deep phosphoproteomic depth (20,000 phosphopeptides confı-
dently identifıed). Our continuing analysis of this dataset, reported here, has
revealed that the correlation between kinase protein abundance and abundance
of phosphorylated target peptides is very low, indicating that kinase abundance
is not a good proxy for phosphorylation status overall. However, highly corre-
lated kinase-substrate pairs are signifıcantly more likely to be true relationships
(from existing knowledge), demonstrating that this method could be used to
predict novel kinase targets in some cases. Using this approach we predicted
novel kinase-target relationships and constructed a kinase activity network of
ovarian cancer. To better analyze cancer-relevant pathway activity we developed
a novel approach that characterizes correlation, differential abundance, and sta-
tistical interactions between components to analyze multiple omics types in the
context of signaling and functional pathways. We used this approach, called the
Layered Enrichment Analysis of Pathways (LEAP), to identify active pathways
in molecular subtypes of ovarian cancer, contrasting observations in patients
stratifıed for short versus long overall survival. This analysis resulted in a pre-
treatment protein-based signature that is signifıcantly predictive of overall sur-
vival. Our results show that integration of multiple omics types has the ability to
inform our understanding of novel kinase-substrate interactions, and poten-
tially identify novel interactions associated with patient survival.
#209 Proteomic analysis of therapeutic biomarkers in decalcifıed bone
metastases. Fabiola Cecchi,1 Shankar Sellappan,1 Sarit Schwartz,1 Chao Gong,2
Marlene Darfler,1 Kerry Scott,1 StevenW.Mamus,3 Mike Emmert-Buck,4 Todd
Hembrough1. 1NantOmics, Ellicott City,MD; 2NantOmics, Rockville,MD; 3Can-
cer Center of Sarasota-Manatee, Sarasota, FL; 4NIH, Bethesda, MD.
Introduction: Targeted therapies successful in treating primary tumors are
often ineffective against corresponding metastatic lesions. Tumors and their
bone metastases are biologically distinct, as reflected by discordant biomarker
status. Decalcifıcation of bone destroys protein and can preclude molecular
analysis. A profıling method that does not depend on tissue antigenicity or
nucleic acid preservation could increase the diagnostic value of decalcifıed bone
samples. We assessed the effects of decalcifıcation on proteomic analysis of tu-
mor tissue.We also quantifıed 27 therapeutically-relevant proteins in decalcifıed
bone metastases of cancer patients using mass spectrometry-based proteomic
analysis. Methods: To examine the effects of decalcifıcation on protein quanti-
fıcation, we used 3 non-bone tissue specimens from lung adenocarcinoma, lung
squamous cell carcinoma, and colon medullary carcinoma. Non-bone tumor
tissue was expected to perform similarly in proteomic analyses to bone tissue,
which was not available. Tissue specimens were processed without decalcifıca-
tion andwith hydrochloric acid-basedDecal-Stat™ decalcifıcation solution for 1,
3, 12, and 24 hours prior to paraffın embedding, tissue sectioning, and mass
spectrometric analysis. Proteomic analysis was also performed on 26 previously
decalcifıed biopsies of metastatic bone lesions from patients with cancers of the
lung (n7), breast (n7), stomach (n3) and 8 other indications. Archived
tumor tissue was microdissected and solubilized to tryptic peptides. Target pro-
teins in each liquefıed tumor sample were quantitated in triplicate with a multi-
plexed, selected reaction monitoring mass spectrometry assay. Results: In the
non-bone tumors, non-decalcifıed & decalcifıed samples yielded similar quan-
tities of total protein (range: 19.2 - 24.1 g) and of all 20 protein biomarkers
detected. The 26 bonemetastases expressed 20 of the 27 protein targets tested.Of
the 7 bone samples from lung cancer patients, 5 expressed EGFR protein and 5
expressed hENT1 protein (a marker of response to gemcitabine). A metastatic
bone tumor from a breast cancer patient expressed hENT1 (129 amol/g) and
overexpressed HER2 (5750 amol/g; this exceeds a level previously correlated
with increased survival in trastuzumab-treated patients). Bone lesions from
prostate & gynecologic cancers overexpressed AR, hENT1, EGFR and TOPO1
proteins. Conclusions: A commonly used decalcifying solution had no discern-
able effects on proteomic quantifıcation of biomarker proteins in archived tu-
mor samples. Targeted proteomics can quantify an entire panel of therapeuti-
cally-relevant proteins from a single decalcifıed bone biopsy specimen.
Proteomic analysis of bonemetastases upon diagnosis ofmetastasis or at relapse
could inform treatment decisions, particularly in patients who have disease pro-
gression only in bone lesions or whose bone biomarkers are discordant from
those of the primary tumor.
#210 Development of scores reflective of biological processes underlying
human disease states frommass spectrometry of serum.Carlos Oliveira, Julia
Grigorieva, KristaD.Meyer, JoannaRoder,HeinrichRoder.Biodesix, Inc., Boul-
der, CO.
A method was developed that allows the evaluation of complex biological
processes from mass spectrometry of human serum samples. Applying gene
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set enrichment analysis ideas to matched protein expression data from a
panel of 1129 proteins and deep MALDI® mass spectral data from a set of 49
human serum samples with lung cancer (n45) or non-cancer (n4), sub-
sets of mass spectral features associated with selected biological functions
were identifıed. Biological functions included acute response, complement
system, and wound healing and the protein members of each function were
assigned using the intersection of gene ontologies and the protein panel.
Using mass spectral data collected from an independent NSCLC sample
cohort (n85) from patients treated with targeted therapy, principal com-
ponent analysis was used to derive scoring functions (combinations of the
feature subsets) for each biological class. These scoring functions were vali-
dated in an additional NSCLC sample set (n123) treated with chemother-
apy. The scoring functions can be applied to mass spectra obtained from any
human serum sample to generate scores associated with individual biological
processes. We have developed scoring functions for several biological pro-
cesses. Acute response score was associated with outcome in Cox propor-
tional hazard analysis in several independent patient cohorts across multiple
therapies and indications, including lung cancer, as mentioned, and ovarian
cancer (n165) treated with platinum doublets following surgery. Choice of
a single cutoff allowed stratifıcation of patients into groups with signifıcantly
better or worse outcome. In a cohort of nivolumab treated NSCLC patients
(n67) with available longitudinal samples, outcome was also found to de-
pend on changes in scores during therapy. Interestingly, while the distribu-
tions of acute phase scores were quite similar across multiple tumor types,
scores for other biological functions, such as wound healing, varied consid-
erably. This may reflect differences in relative importance of individual bio-
logical functions between tumor types. A scoring system based on biological
functional categories has a wide range of uses that could be tested and ap-
plied in a clinical setting. Currently, tests that measure a single biomarker for
monitoring a particular disease have questionable utility and limit the use-
fulness to the clinician and patient treatment decision making. A tool that
measures the activity of a complex biological process could be useful in
deciding when an intervention is needed (screening), or for monitoring the
effects during therapy.
#211 Protein painting identifıes PD-1: PDL-1 therapeutic targets at pro-
tein-protein interfaces. Alessandra Luchini, Luisa Paris, Virginia Espina,
Kelsey Mitchell, Angela Dailing, Lance A. Liotta. George Mason Univ., Manas-
sas, VA.
The next generation of molecular cancer therapeutics will target pivotal
protein-protein interaction interfaces participating in immune cell receptor
signaling, oncogenes, and suppressor genes. We have created a wholly novel,
technology “protein painting” for the rapid direct sequencing of hidden
native protein-protein interaction hot spots. Our technology, employs pre-
viously unexplored small molecule (12 Å) aryl hydrocarbon dyes or “paints”
to cut out, and MS sequence, only the hidden unmodifıed contact interfaces
between two or more interacting native proteins. Novel Technology: Paint
chemistries have extremely high affınities (rapid on-rates, and very slow
off-rates that are ten to 100 times higher than most protein-protein interac-
tions). When mixed with a native pre-formed protein complex for only 5
minutes at physiologic pH and salinity, the paints non-covalently coat all
external sites on the protein without altering the 3D conformation of the
complex, but cannot gain access to the solvent inaccessible hidden protein-
protein interaction domains. Each paint molecule spans less than 3 amino
acids, and has high affınity for protease cleavage consensus sites. Following
painting, the proteins are dissociated. This leaves the paint molecules coat-
ing surfaces not participating in the interface. Following dissociation, the
proteins are linearized, digested with trypsin, and sequenced by standard
MS. The paint molecules remain non-covalently bound after the proteins are
denatured. Trypsin will not cleave the regions of the protein that are
“painted”. Following proteolysis peptides emerging from MS will be gener-
ated exclusively from the unmodifıed opposing points where the proteins
were in intimate contact. Results: Protein Painting identifıed hot spot do-
mains between PD-L1:PD-1, including two surface interface regions that are
separated in the linear sequence but adjacent in the 3D structure. We created
novel cyclized multivalent inhibitors that block both sides of the PD-L1:
PD-1 interface and markedly suppress cell-cell coupling and abolished
downstream signaling through this complex in cultured tumor cell immune
cell interactions. A very high correlation (p&lt0.0003) was found for known
contact points predicted by crystal structure, with a 97% specifıcity for true
positive hot spots: 95% agreement with Robetta prediction software for
known complexes. Protein painting outperforms (425%) hydrogen deute-
rium exchange and cross linking for number of positive hits and % true pos-
itive hits. Conclusions: Protein painting is a new tool to identify highly
specifıc drug targets located within protein interaction interfaces, yielding
inhibitors that abolish protein signaling relevant to cancer immunotherapy.
#212 Identifıcationbymass spectrometry of uniquephosphoproteins sub-
sequent to signaling through c-ErbB2. C Sidhanth, Manoj Garg, P Manasa, S
Krishna Priya, S Bindhya, S Sneha, R.P. Nagare, S Shirley,MKanchan, Trivadi S.
Ganesan. Cancer Institute (WIA), Chennai, India.
The receptor tyrosine kinase c-ErbB2 is amplifıed in breast and ovarian
cancer. The linear pathways through which signals by c-ErbB2 are trans-
duced is well known. However, second generation questions that address
spatial aspects of signaling remain. To address this, we have undertaken a
mass spectrometry approach to identify phosphoproteins. We have used two
tyrosine kinase inhibitors, Lapatinib and CP724714, that inhibit phosphor-
ylation of c-ErbB2 to identify phosphoproteins. SKOV-3, an ovarian cancer
cell line that endogenously overexpresses c-ErbB2 was grown in culture
without serum for 72 hrs. Cells were then stimulated in the presence or
absence of inhibitor with EGF (100ng/ml) as a ligand for 60 mins. Subse-
quently, cells were lysed and evaluated by western blotting with anti-phos-
photyrosine antibody (4G10). Following stimulation of cells with EGF, max-
imal phosphorylation of c-ErbB2 was observed at 60 minutes. Lapatinib
(10M) and CP724714 (15M) completely inhibited phosphorylation of
c-ErbB2, which was confırmed by immunoprecipitation. This was further
confırmed by the inhibition of downstream effectors (Erk1/2, Akt). Lapa-
tinib (10 M) also completely inhibited phosphorylation of EGFR while
CP724714 (15M) only inhibited partially. Cellular lysates were prepared
from quiescent cells (grown without serum), after stimulation with EGF in
the presence or absence of inhibitors. Purifıed phosphoproteins from all
three samples following digestion with trypsin were subjected to mass spec-
trometry (Nano LC ESI MS/MS). We identifıed totally 62 phosphoproteins.
Twenty seven phosphoproteins were observed in all the 3 samples while 17
phosphoproteins were identifıed both in the EGF stimulated and lapatinib
treated samples. Eighteen unique phosphoproteins were observed only in the
EGF stimulated sample suggesting that they are specifıc to signaling by c-
ErbB2. The novel phosphoproteins included the proteins that partcipate in
carbohydrate metabolism,cytoskeleton, cell migration and proliferation. We
have evaluated two phosphoproteins, LASP-1 and Aldose reductase that has
not been previously described following phosphorylation of c-ErbB2.
LASP-1 is an oncogene and is located as the same arm 17q21 as c-ErbB2. It
was not expressed in the normal ovary or fallopian tube. However, it was
over-expressed in 17% of tumours (n85) from patients with ovarian can-
cer. c-ErbB2 was not expressed in tumours that expressed LASP1. Aldose
reductase is a cytosolic NADPH dependent oxidoreductase that catalyzes the
reduction of glucose to sorbitol, the fırst step in polyol pathway of glucose
metabolism. The activity of aldose reductase in reducing NADPH as a sub-
strate was signifıcantly higher in lysates from EGF stimulated as compared to
the starved cells. Identifıcation of phosphoproteins by using mass spectrom-
etry is promising in identifying novel substrates and pathways following
phosphorylation of c-ErbB2.
#213 Integrated proteogenomic analysis of laser capture microdissected
breast tumors. Viswanadham Sridhara,1 Tao Liu,2 Marina A. Gritsenko,2 Lori
A. Sturtz,1 Albert J. Kovatich,3 VladislavA. Petyuk,2 BrendaDeyarmin,1 JasonE.
McDermott,2 Anil K. Shukla,2 Ronald J. Moore,2 Matthew E. Monroe,2 Bob-
bie-Jo M. Webb-Robertson,2 Jeffrey A. Hooke,3 Leigh Fantacone-Campbell,3
Praveen Kumar Raj Kumar,1 Leonid Kvecher,1 Jianfang Liu,1 Jennifer Kane,1
Jennifer Melley,1 Stella Somiari,1 Joji Iida,1 Stephen C. Benz,4 Justin Golovato,4
Shahrooz Rabizadeh,5 Patrick Soon-Shiong,5 Richard D. Smith,2 Richard J. Mu-
ral,1 CraigD. Shriver,6HaiHu,1 KarinD. Rodland2. 1Chan Soon-Shiong Institute
of Molecular Medicine at Windber, Windber, PA; 2Pacifıc Northwest National
Laboratory, Richland, WA; 3CBCP, Henry Jackson Foundation, Rockville, MD;
4NantOmics, LLC, Culver City, CA; 5NantWorks, LLC, Culver City, CA; 6Murtha
Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD.
Introduction: Molecular characteristics of breast tumors play an important
role in determining patients’ survival outcome. Here, we report preliminary
fındings of proteogenomic profıling of 50 breast tumors using RNA-Seq and
mass-spectrometry (MS) based proteomic technologies. An additional 60 tu-
mors are being analyzed, including WGS for all samples. We are also collecting
patient survival outcome data. Methods: Cases used in this study were drawn
from the Clinical Breast Care Project, where patients were consented using an
IRB-approved protocol. A total of 50 breast tumors were selected and processed
by laser capture microdissection (LCM). This cohort includes 36 Caucasian
Americans (CA) and 8 African Americans (AA), and the age of the patients is
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57 13 years. Protein and RNA were extracted using the Illustra triplePrep kit,
which isolates DNA from the same cells as well. Quantitative global proteomics
and phosphoproteomics analyses were performed using isobaric TMT 6-plex
labeling with the “universal reference” strategy and IMAC enrichment of phos-
phopeptides. Mass spectrometry data were acquired using a Q-Exactive instru-
ment and analyzed using Proteome Discoverer with Byonic node. Phosphopep-
tide abundance was normalized to abundance measurements of the parent
protein for all of the phosphorylation analyses. Phosphoproteomic data was also
searched for the presence of O-GlcNAc modifıcations. RNA-Seq analyses were
done on Illumina HiSeq and the data were analyzed using GSNAP. Results:
There were 19 Luminal A, 7 Luminal B, 8 HER2-enriched, and 16 basal-like
subtypes based on the PAM50 algorithm. In the global proteomics data, we were
able to quantitate8600 proteins. Unsupervised clustering on the highly vary-
ing proteins across the samples resulted in two primary clusters, with one being
luminal-enriched. The other cluster contains a basal-like tumor sub-cluster and
a sub-cluster of mixed subtypes. Differential protein expression analyses be-
tween the two primary clusters confırmed knownmarkers (e.g., overexpression
of KRT8/KRT18 in luminal-enriched cluster). The luminal-enriched cluster is
primarily CAwith post-menopausal status. A similar search of the phosphopro-
teomic data yielded quantitation of 12500 phosphopeptides. Unsupervised
clustering of the phosphoproteins resulted in four primary groups, with one
being basal-enriched and another being luminal-enriched. We also observed
50 overexpressed phosphopeptides. While some of these phosphosites have
been previously reported (e.g., on RANBP2), other phosphosites appeared to be
novel (e.g., on IRF2BP2). Conclusion: Analysis of LCM breast tumors using
proteogenomic technologies resulted in basal- and luminal-enriched clusters,
thus enabling us to study protein and phosphopeptide markers across multiple
platforms. The views expressed in this article are those of the author and do not
reflect the offıcial policy of the Department of Defense, or U.S. Government.
#214 ARID1AandARID1Bdependent proteomics.Yutaka Shoji,1 Kumiko
Kato-Shoji,1 Kelly A. Conrads,2 Rusheeswar Challa,1 Brian L. Hood,2 Nicholas
W. Bateman,2 Thomas P. Conrads,2 John I. Risinger1. 1Michigan State Univ.,
Grand Rapids, MI; 2Women’s Health Integrated Research Center at Inova Health
System, Annandale, VA.
Protein sub-units of the SWI/SNF nucleosome and chromatin remodeling
complexes are frequently mutated in cancer. The ARID1A and ARID1B DNA
interacting component are among these mutated proteins. Alterations in
ARID1A have been reported in breast, colon, lung, kidney, pancreatic, bladder,
cervical, ovarian and uterine cancers whereas ARID1B mutation is less com-
mon. Additional data suggests ARID1Amutant cancers are dependent on func-
tional ARID1B and that targeting ARID1Bmay be a therapeutic strategy. How-
ever, ARID1A and 1B are often co-inactivated in aggressive un/dedifferentiated
carcinomas of the ovary and endometrium suggesting tumor suppressive func-
tions might exist not only in ARID1A but also in 1B. In this study, we examined
the effects of restoring ARID1A or 1B in an undifferentiated endometrial ade-
nocarcinoma cell line harboring inactivating mutations in both genes. ACI-98
cells derived from a stage IV undifferentiated endometrial cancer were found to
lack expression of ARID1A and 1B protein. We subsequently identifıed two
individual truncating mutations in ARID1A and 1B by genomic DNA and
cDNA sequencing indicating no wild-type message was expressed. Restoration
of ARID1A in ACI-98 cells using a Tet-on system revealed remarkable growth
inhibition, however, ARID1B restoration showed only a moderate cell growth
inhibition with cells taking on a flattened phenotype. Clones of ARID1A/1B
restored cells were treated w/wo doxycycline (Dox) for 48h a time point prior to
cell death or morphologic changes and protein changes catalogued using LC
MS/MS. We identifıed 771 and 1168 differentially expressed proteins (z-score
0.05) from ARID1A or 1B restored clones compared to dox free control and
138 proteins were common in these two groups (up-regulated: 57, down-regu-
lated: 37, reverse regulation between ARID1A and 1B: 44). We performed path-
way analysis of the ARID1A and 1B proteome by Advaita Pathway Guide soft-
ware and this analysis identifıed 10 signifıcantly impacted pathways in ARID1A
and 17 pathways in ARID1B. However, there was no common pathway between
the two. Wnt signaling pathway (KEGG: 04310) was among ARID1A distin-
guished pathways with 9 of 46 proteins being differentially expressed. Among
these NKD1 a negative regulator of the Wnt--catenin-Tcf signaling pathway
was increased in ARID1A restored cells more than 10 fold. We confırmed the
differential expression of NKD1 using qRT-PCR followingARID1A expression.
The p53 signaling pathway (KEGG: 04916) was signifıcantly (11 of 34 proteins)
affected following ARID1B complementation. We confırmed the differential
expression of FAS was up-regulated 6 fold in proteomics and 3.4 fold in qPCR.
These results suggest that restoration of ARID1A or 1B both effect cell prolifer-
ation to varying degree. The lack of overlap between the proteomes of
ARID1A/1B restored cells indicates distinct pathways underlying these induced
phenotypes and different function of SWI/SNFARID1A or SWI/SNFARID1B.
#215 Characterization by mass spectrometry of protein kinase C sub-
strates differentially phosphorylated in LNCaP cells in response to phorbol
ester and bryostatin 1 treatment. Noemi Kedei,1 Sudipto Das,2 Thorkell An-
dresson,2 PeterM. Blumberg1. 1National Cancer Institute, Bethesda, MD; 2Fred-
erick National Laboratory for Cancer Research, Frederick, MD.
Bryostatin 1 (bryo 1) is a natural product of therapeutic interest for cancer and
Alzheimer disease. Its unique behavior as a protein kinase C activator that par-
adoxically antagonizes many but not all phorbol ester responses has led to in-
tense interest in its mechanism of action. Recently, using microarray analysis in
two different cellular systems (LNCaP prostate cancer and U937 leukemia cell
lines) where the typical phorbol ester PMA and bryo 1 have different biology, we
have shown that a core mechanism contributing to the unique biology of bryo 1
is transiency of action resulting in a variable extent of decreased or missing late
responses. We have excluded that there is a class of genes whose transcription is
uniquely regulated at early times by bryo 1. In continuing to explore the mech-
anisms underlying the variable transiency of the responses by bryo 1 we have
evaluated the substrates phosphorylated after treatment with PMA and bryo 1.
Since PMA and bryo 1 induce differential subcellular localization of PKCs, they
should result in differential access to substrates and consequent differences in
the pattern of substrate phosphorylation. Whole cell lysates of LNCaP cells
treated for 30 min with fully effective doses (100 nM) of PMA and bryo 1 and
with DMSO as vehicle control were subjected to mass spectroscopic analysis.
The comprehensive analysis identifıed several thousand phosphopeptides after
drug treatment including the expected phosphopeptides for ERK2 (S185, Y187)
and PKCdelta (S299, S302, S304). Many of peptides were similarly phosphory-
lated in response to both drugs (e.g. S641/S646 of Fam129B, S310 of actin-
related protein 2/3 complex subunit 1B, S876 of RhoGEF and pleckstrin do-
main-containing protein 2, or multiple previously unknown sites for PKD1
(S239, S247), while a limited number were differentially phosphorylated. PMA
specifıc phosphorylations included PKCdelta at Y313, mTOR at T2471, MAP4
at S624 and/or T627, E3 ubiquitin-protein ligases ZNRF2 at S82 andHUWE1 at
S3818. Bryo 1 specifıc phosphorylations included BCL2-like 13 at S303,
TOM1L2 at S424, and MAP2K2 in the T17, T25, S26 region. Selected specifıc
phosphorylations are being validated using phostag gels, a method that enables
the separation of phosphorylated proteins from their non-phosphorylated
counterparts on SDS-gels. The identifıcation of PKC substrates that are differ-
entially phosphorylated by bryo 1 should both facilitate screening of other li-
gands capturing the biological behavior of bryo 1 aswell as further illuminate the
specifıcs of the pathways downstream of PKC activation by these differently
acting ligands.
#216 Tracking expression, post-translational modifıcations and interac-
tions of EGF signalling proteins in A431 cells with antibody microarrays.
Lambert Yue, Steven Pelech. University of British Columbia, Vancouver, British
Columbia, Canada.
Elucidation of epidermal growth factor (EGF) signalling pathways in cancer
cells has helped to defıne the mechanisms for their neoplastic transformation
and potential drug targets for therapeutic intervention. Antibody microarrays
are promising tools to evaluate alterations in the levels and phosphorylation
status of hundreds of proteins of interest with onlymicrogram amounts of crude
cell and tissue lysate protein. However, interpretations of the results from tradi-
tional antibody microarray approaches have been hampered by the problems
associated with sample preparation and protein detection, even when reliable
antibodies are deployed in these arrays. The Kinex™ KAM-900P antibody mi-
croarray permitted semi-quantitative measurements of the expressions, post-
translational modifıcations and interactions of proteins with 100 g or less of
lysate proteins. These microarrays utilize approximately 878 different pan- and
phosphosite-specifıc antibodies for tracking protein kinases, phosphatases and
other low abundance regulatory proteins. Multiple detection protocols were
developed with the KAM-900P slides to enable high depth profıling of protein
levels, phosphorylation and protein-protein interactions in A431 cells in re-
sponse to EGF treatment. One method (KAM) involved the capture of in vitro
biotin-labeled proteins, followed by their detectionwith a secondary dye-labeled
anti-biotin antibody. False positive signals from associated proteins in com-
plexes with the targets were reduced by chemical cleavage with NTCB prior to
their capture on the array, and this also produced more uniformity of the dye
signals for protein targets despite vast differences in their sizes. Transient
changes in protein phosphorylation in EGF treated cells that were typically lost
when processed by conventional methods were better preserved by chemical
CANCER CHEMISTRY: Proteomics and Mass Spectrometry 1
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 55
cleavage right at time of sample homogenization. Biotin-labeling and subse-
quent detection of the protein on the array with a dye-labeled secondary anti-
body further reduced non-specifıc background signals, allowed for a greater
dynamic range of detection, and enhanced discrimination of subtle changes. In
conjunction with other detection protocols, such as the usage of dye-labeled
reporter antibodies for generic protein-tyrosine phosphorylation in sandwich
antibody microarrays (SAM format) or generic protein phosphorylation with
nanoparticles such as pAMIGO (PAM format), it is also feasible to monitor
changes in general post-translational modifıcations of target proteins or their
specifıc association with other adapter, scaffolding and chaperone proteins of
interest for which antibody probes are available.
#217 Quantitative analysis of two cancer signaling pathways using multi-
plex immunoprecipitation and targeted mass spectrometry. Bhavin Patel,
Leigh Foster, Gregory Potts, Abid Haseeb, Alex Behling, John Rogers. Thermo
Fisher Scientifıc, Rockford, IL.
Background: The AKT/mTOR and RAS/ERK pathways represent key mech-
anisms for cells to regulate cell survival, proliferation, and motility. In addition
to their independent signaling cascades, which provide offsetting mechanisms,
these two pathways extensively engage in cross-talk in order to both positively
and negatively regulate each other. The quantitation of protein expression and
modifıcations of pathway targets are critical for characterization of disease,
monitoring cancer progression and determining treatment response. Somema-
jor bottlenecks in the accurate quantitation of these proteins are the lack of
rigorously validated reagents and a reliance on semi-quantitative results from
available immunoassays. Mass spectrometry (MS) is increasingly becoming the
detection method of choice for proteins and their post-translational modifıca-
tions (PTMs). Immunoprecipitation coupled with MS (IP-MS) enables assess-
ment of antibody specifıcity and identifıcation of low-abundant targets. Multi-
plexed IP coupled with targetedMS (mIP-tMS) can quantitatemultiple proteins
of interest, PTMs and interacting partners in a single MS run. The objective of
this study was to determine the effıcacy of mIP-tMS for quantitation of the
AKT/mTOR and RAS/ERK pathway proteins and to compare these results ver-
sus Western blotting (WB). Methods: Serum starved and LY294002 treated
HCT116 andA549 cells were stimulated with IGF-1. Antibodies to targets in the
AKT/mTOR and RAS/ERK pathways were selected for verifıcation of antibody
specifıcity by IP-MS. mIP-tMS assays were developed and validated for absolute
quantitation of targets in these pathways and benchmarked withWB across two
unstimulated, IGF-1 stimulated and LY294002 treated cell lysates as well as
several tissue lysates. Results: Previously, we showed that an optimized IP-MS
workflow for Protein A/G and Streptavidinmagnetic beads increases target pro-
tein yieldwith lownon-specifıc background. In this study, we validated antibod-
ies to several AKT/mTOR and RAS/ERK pathway targets using the optimized
IP-MS workflow. mIP-tMS assays allowed absolute quantitation for multiple
total and phosphorylated targets from both pathways in low to sub-nanogram
concentrations across two unstimulated, IGF-1 stimulated and LY294002
treated cell lysates. The benchmarking of mIP-tMS assays showed low correla-
tion for quantitation of total and phosphorylated targets relative to WB. This
lower correlation may be due to differences in the specifıcity of antibodies used
for each assay technique. Conclusion: Overall, the mIP-tMS assays can be used
for effective identifıcation and quantitation of AKT/mTOR and RAS/ERK path-
way proteins in multiple cancer cell lines and tissue samples. Major advantages
of this assay are high confıdence in target identity coupled with simultaneous
absolute quantitation of multiple targets and their PTMs from cancer signaling
pathways.
#218 Functional proteomic analysis of TRI immunocomplex in TGF-
signaling. Liuya Tang,1 Zhaojing Meng,2 Mary Heller,1 Ming Zhou,2 Ying
Zhang1. 1NCI-CCR, Bethesda, MD; 2Frederick National Laboratory for Cancer
Research, Frederick, MD.
Transforming growth factor-beta (TGF-) regulates awide array of biological
responses ranging from proliferation to apoptosis, and alterations in its signal-
ing pathway are associated with a variety of human diseases, including cancer.
During the activation of TGF- signaling, TGF- receptor I (TRI) plays an
important role in transducing signals to downstream effectors. To identify TRI
interacting proteinswhich are responsible for Smad-dependent pathways aswell
as Smad-independent pathways, we employed a large-scale quantitative pro-
teomic analysis of TRI immunocomplex. AML12 cells were labeled with L-
Lysine and L-Arginine (K0R0, light) or L-Lysine-13C6-15N2 and L-Arginine-U-
13C6-15N4 (K8R10, heavy). The cells cultured in K8R10 medium (H: Heavy)
were transfected with Flag-TRI, while the cells cultured in K0R0 medium (L:
Light) were transfected with Flag vector. The cell lysates were combined at equal
protein amount, and TRI immunocomplex were purifıed using FLAG M2
agarose. The resulting peptides from eluted TRI immunocomplex were sub-
jected tomass spectrometry quantitation. If a proteinwhose ratio ofH/Lwas not
smaller than 1.3, it was categorized as a constitutively interacting protein of
TRI. A total of 687 proteins were quantitated and 325 proteins were defıned as
constitutively interacting proteins. Pathway enrichment analysis found these
proteins are involved in a number of signaling pathways, which indicates the
cross-talks between TGF- signaling and other signaling. Future work will in-
clude validation of interaction between TRI and candidate proteins, and un-
derstand functional signifıcance of candidate proteins in TGF- signaling or
signaling cross-talks by a series of molecular biological approaches.
#219 Identifıcation of the mechanistic target of rapamycin complex 2-as-
sociated interactome involved in brain cancer cell motility by affınity purifı-
cation-mass spectrometry.NaphatChantaravisoot,1 PiriyaWongkongkathep,1
Fuyuhiko Tamanoi,2 Trairak Pisitkun1. 1Chulalongkorn University, Bangkok,
Thailand; 2UCLA, Los Angeles, CA.
TheMechanistic Target of RapamycinComplex 2 (mTORC2), amultiprotein
complex with serine-threonine kinase activity, drives several cellular processes
of normal cells to promote proper metabolic activity, survival, proliferation,
differentiation and movement. On the other hand, mTORC2 has been impli-
cated as a critical player in tumorigenesis, stimulation of cell growth, cancer
metabolic reprogramming, and development of highly migratory and invasive
capabilities of cancers. Therefore, characterization of mTORC2 is necessary not
only for better understandings of knownmTORC2-mediated functions, but also
for the discovery of new roles and more interacting partners of mTORC2 sig-
naling network in cancers, particularly ones with hyperactivatedmTORC2 such
as glioblastoma. However, until now mTORC2 is still partially characterized.
Previously, mTORC2 was reported to be associated with Filamin A and Myo-
sin-9 which have been known to play important roles in cellular activities re-
quiring locomotion, including cancer migration and invasion. The complex
participates in regulating glioblastoma migration and invasion, and Filamin A
acts as a physiological downstream target of mTORC2. Currently, proteomics
has emerged as a powerful tool to identify, quantify, and examine a large number
of proteins. Therefore, in order to extensively unravel mTORC2 signaling path-
way, the use of proteomics is necessary. We characterized mTORC2 by pro-
teomic analysis based on affınity purifıcation coupled to mass spectrometry
(AP-MS) using antibodies against RICTOR, a specifıc component of mTORC2.
The protein-protein interactions between RICTOR and other associated pro-
teins were assessed. In addition to canonical components ofmTORC2, the study
has revealed more insights into a number of mTORC2 interacting partners
which can be categorized and related to themain functions previously identifıed
such as actin cytoskeleton reorganization, fatty acid metabolism, protein trans-
lation. Interestingly, we also found other types of cytoskeletal proteins, nucleo-
tidemetabolism, less-characterized and low abundance proteins associated with
mTORC2 such as Hornerin and Desmoplakin. In addition, we have carried out
the identifıcation of condition-specifıc interactions for a dynamic view of
mTORC2 interactome and found changes in the mTORC2-associated proteins
from different conditions. Furthermore, proteomic approaches can also be rel-
evant to investigation and prediction of mTORC2 upstream regulators, down-
stream targets, and complex localization. Ultimately, this project will uncover
some unknownmolecularmechanisms, and result in a signifıcant impact on the
fıeld of signal transduction machinery in cancers.
#220 Proteomic identifıcation of therapeutics targets for Enzalutamide
resistance in Castration Resistant Prostate Cancer. Lauriane VELOT,1 Domi-
nique Levesque,2 François-Michel Boisvert,2 Nicolas Bisson,1 Frédéric Pouliot1.
1Centre de recherche sur le cancer, Centre de recherche du CHU de Quebec -
Université Laval, Québec, Quebec, Canada; 2Faculté de Médecine et des sciences
de la santé - Université Sherbrooke, Sherbrooke, Quebec, Canada.
Prostate cancer (PC) is the most frequently diagnosed cancer in Canadian
men and is the 3rd cause of cancer mortality. The Androgen Receptor (AR) is
activated by androgens (e.g. testosterone), which leads to prostatic cell prolifer-
ation. The primary treatment for advanced PC is androgen-deprivation therapy,
which is achieved via surgical or chemical castration. Nevertheless, most PCwill
become castration-resistant (CRPC). Although new anti-androgens (e.g. En-
zalutamide) were developed to improve patients’ survival, their effıcacy is still
very limited andmostCRPCpatientswill die from the diseasewithin a few years.
We postulate that by gaining insights into AR signalling networks in the context
of CRPC, we could better direct patients towards the best-suited therapy and
propose new therapeutic targets. To this aim,we took advantage of an innovative
proteomics approach, namely proximity-labeling (BioID), to characterize global
AR signalling networks in hormone-dependant LAPC4 cells. We identifıed 45
AR-associated proteins in non-stimulated cells, 35 of which were not previously
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reported. Upon androgenic stimulation, the AR signalling network increased to
320 proteins, including 278 (253 were novel) that were restricted to androgen-
stimulated cells. Enzalutamide treatment resulted in a loss of 259 proteins from
the network when compared to stimulated cells. As expected, this reproduced
quite faithfully the status of non-stimulated LAPC4 cells. Interestingly, we iden-
tifıed 4 proteins in the AR network specifıcally after Enzalutamide treatment.
These are interesting targets that may be relevant for the acquisition or the
prediction of Enzalutamide resistance. Hence, they could become in time alter-
native therapeutic targets for CRPC treatment, to be used when Enzalutamide
fails.
#221 Integrated functional proteomics ofMET/VEGFR inhibitors reveals
complex mechanism of action of foretinib in NSCLC. Natalia J. Sumi, Bin
Fang, Lily L. Rix, Muhammad Ayaz, Fumi Kinose, Eric A. Welsh, Steven A.
Eschrich, Harshani R. Lawrence, John M. Koomen, Eric B. Haura, Uwe Rix.
Moffıtt Cancer Center, Tampa, FL.
BACKGROUND: Foretinib (FORE) and cabozantinib (CABO) are twoMET/
VEGFR inhibitors with similar chemical structures. CABO is FDA-approved for
medullary thyroid and renal cancer; in addition, it is in clinical trials for treat-
ment of non-small cell lung cancer (NSCLC). Through an unbiased viability
screen we have observed potent cellular activity of FORE, but not CABO, in
several NSCLC cell lines.We have previously shown that most NSCLC cell lines
are insensitive to MET or VEGFR inhibition, suggesting off-target activity of
FORE in these cells. The aimof this project is to identify themechanismof action
of FORE inNSCLC and design an optimized combination therapy.METHODS:
Cellular viability assayswere done usingCellTiter-Glo, cell cycle analysis by flow
cytometry. Western blotting was performed to evaluate the induction of apo-
ptosis through PARP1 and caspase cleavage, as well changes in signaling. We
synthesized FOREandCABOanalogues andperformeddifferential quantitative
chemical and phosphoproteomics to determine the target kinase profıle and
pathway effects in NSCLC cells. Changes in gene expression upon drug treat-
ment were measured by RNA-seq. RNAi in combination with pharmacological
inhibitors was performed to interrogate targets and pathways. RESULTS: FORE
showed greater potency in NSCLC cell lines than CABO with regard to inhibi-
tion of viability and induction of apoptosis. FORE decreased phosphorylation of
AKT and ERK. Chemical and phosphoproteomics revealed several kinases, such
as MEK and MAP4K5, to bind preferentially by FORE over CABO that differ-
entially affect the adherens junction andMAPK signaling pathways. Target val-
idation showed differential inhibition of MEK1/2 and MAP4K5. Cellular vali-
dation with RNAi in combination with pharmacological inhibitors suggested
that MEK1/2, MAP4K5 and IGF1R are involved in the mechanism of action of
foretinib in NSCLC cells. RNA-seq pathway analysis furthermore suggested
regulation of chromatin organization and Wnt pathway signaling by foretinib.
CONCLUSION: Our results suggest that the difference in the effıcacy between
FORE and CABO is related to polypharmacology of FORE, which simultane-
ously targets IGF1R, MEK1/2 and MAP4K5. This difference results in diver-
gence in signaling pathway inhibition and induces distinct effects in NSCLC.
The establishment of FORE targets and signaling pathways can lead to opti-
mized combination therapy for NSCLC and identifıcation of new actionable
kinases in lung cancer cells.
#222 Protein network mapping of bladder cancer: tumor compartment
and microenvironment analysis. Kimberley A. Hodge,1 Andrew Hau,2 Mari-
aelena Pierobon,1 Donna Hansel,2 Emanuel Petricoin1. 1George Mason Univer-
sity, Manassas, VA; 2University of California: San Diego, San Diego, CA.
Background: Interactions between tumor and stroma are of intense inter-
est in the fıeld of oncology and provide new opportunities to understand the
driving mechanisms behind tumor progression, metastases and responsiveness
to therapy. Laser capture microdissection (LCM) coupled with reverse phase
proteinmicroarrays (RPPA) are ideal technologies for isolating different cellular
compartments from heterogeneous tissues and for exploring protein signaling
networks. Material and Methods: We explored protein signaling networks of
epithelium andmatched surrounding stroma of 16 bladder cancers (BC) includ-
ing papillary (n8) and invasive (n8) tumors. Tumor epithelium and
matched surrounding stroma were isolated with LCM for each case. Signaling
network analysis of dissected material was performed using RPPA, allowing for
the measurement of 111 proteins and phosphoproteins. Wilcoxon Rank Sum
Testwas used to compare the signaling network of papillary and invasive lesions.
Spearman Rho correlation analysis (correlation coeffıcient 0.90) was used to
explore signaling networks of each cellular compartment across histotypes. Re-
sults: Mean comparison of tumor epithelium revealed increased PD-L1 and
PDGFR expression in invasive tumors compared to papillary lesions (p 0.015
and p0.028 respectively). Correlation analysis of the epithelium compart-
ments collected frompapillary and invasive cancers revealed different signatures
with invasive cases showing a phenotype of proliferation and survival in contrast
to papillary tumors which were characterized by wound healing and metabolic
network activation. Analysis of stroma showed increased expression of MMP9
in invasive compared to papillary stroma (p 0.05). While stroma surround-
ing both invasive and papillary tumors showed high correlation between mem-
bers of the PI3K/AKT pathway, only invasive BC presented with interconnec-
tions between immune response proteins. Finally, receptor tyrosine kinases
(RTKs) in the invasive epithelium appeared to be highly correlatedwith RTKs in
the stroma as well as their downstream targets suggesting cross-talk between the
two compartments. Conclusions: LCM-RPPA workflow is a unique tool for
exploring tumor and surrounding microenvironment interactions in BC. Sig-
naling networks of epithelial cells and surrounding stroma of invasive BC has
unique characteristics compared to papillary tumors including increased ex-
pression of immune checkpoint PD-L1 and PDGFR in the epithelium, two
potential therapeutic targets for this group of patients, along with increased
interaction between PI3K/AKT pathway and proteins involved in immune
modulation. If validated in a larger cohort of patients, these fındingsmay lead to
better understanding of the molecular mechanisms driving invasive tumors of
the bladder especially in the context of tumor-stroma interactions.
#223 Targeting critical signaling nodes usingmultiplexed antibody based
phosphopeptide enrichment with iMRM validation. Charles L. Farnsworth,
Yiying Zhu, Matthew Stokes. Cell Signaling Technology, Danvers, MA.
Introduction: A challenge for biomedical researchers is to develop assays to
analyze complex systems that interrogate whole cellular signaling networks.
Here we show the results of employing antibody based immunoaffınity enrich-
ment of phosphopeptides derived from critical signaling nodes to quantitate
changes in phosphorylationuponkinase inhibitor treatment.Human cancer cell
lines, including gastric and breast adenocarcinomas were treated with kinase
inhibitors and cellular extracts were digested with trypsin and peptides were
purifıed. A pool of phosphorylation dependent site-specifıc antibodies was em-
ployed to enrich for known sites of phosphorylation. Following antibody based
enrichment these peptides were identifıed and quantifıed using liquid chroma-
tography/tandem mass spectrometry (LC-MS/MS). Phosphopeptides were
identifıed using SEQUEST, and differences in abundance were determined by
employing label-freeMS1 based quantifıcation using Progenesis fromNon-Lin-
ear Dynamics. We also show validation data for a number of the antibodies
employed using immuno-multiple reactionmonitoring, or iMRM. Employing a
QExactive mass Spectrometer (Thermo Scientifıc) we developed calibration
curves for a number of the targeted tryptic phosphopeptides using combinations
of heavy and light peptides with endogenous cancer cell line peptides as a back-
ground matrix. Experimental Results: Cell lines were treated with DMSO or
inhibitors to which the cell lines should be sensitive/insensitive. Following pep-
tide purifıcation, a pool of antibodies were multiplexed and used to enrich for
phosphopeptides derived from signaling proteins across a number of signaling
pathways. The results show signifıcant changes in abundance formany proteins/
sites, including activation loop tyrosine residues of tyrosine kinases, changes in
sites on proteins in the AKT/PI3K pathway, sites in the MAPK pathway, and
other critical regulators of cellular signaling such as sites on PKC family mem-
bers. Targeted LC-MS/MS methods using iMRM were used to confırm these
results and show the promise of using such targeted strategies for quantifying
changes in phosphorylation consistently across many samples. Conclusion:The
strategy of multiplexing antibodies for immuno-enrichment allows for simulta-
neous detection and quantifıcation of hundreds to thousands of known phos-
phorylation sites that have been shown to be important nodes of regulation.
Targeted LC-MS/MS methods such as iMRM will allow researchers to confı-
dently profıle changes in both total levels as well as phosphorylation site occu-
pancy for critical signaling proteins.
#224 Critical variables for automated protein immunodetection using
western blot. Alexander Margulis,1 David P. Chimento,2 Russ Yukhananov1.
1Precision Biosystems, Mansfıeld, MA; 2Rockland Immunochemicals, Inc., Lim-
erick, PA.
Reliable immunodetection of proteins is a critical step in the discovery of
novel biomarkers. It is often performed manually. The immunodetection pro-
tocol consists of multiple steps including blocking of nonspecifıc binding sites,
incubation using primary and secondary antibodies and extensive washing be-
tween steps that easily introduce bias and errors. The quality of results depends
on multiple subjective and objective factors such as the qualifıcation and tech-
nical skills of the personnel performing the assay and the accuracy of temporal
and temperature control, especially during the immunodetection step. BlotCy-
cler™, automatedwestern blot processor, use fluidic control system that allows to
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eliminate the variability associatedwith immunodetection and to achieve higher
sensitivity by optimized washing procedure.We used BlotCycler to analyze crit-
ical variables for immunodetection including temperature, incubation time and
reagent mixing. Relatively small changes in duration and temperature of incu-
bation signifıcantly affect not only the intensity of signal but also the specifıcity
of antibody interaction with antigen. Automated immunodetection at 4ºC sig-
nifıcantly improve the specifıcity of detection and sensitivity that allows repro-
ducible detection of low expressing proteins. Automated processing using Blot-
Cycler allows optimization and control of critical variables leading to improved
reproducibility and specifıcity of immunodetection and should be routinely
used for biomarker candidate discovery and confırmation, reliable protein
quantifıcation, primary antibody specifıcity testing, and optimization of pri-
mary and secondary antibodies concentrations.
#225 Chemoproteomic evaluation of target engagement in clinical sam-
ples. Tyzoon K. Nomanbhoy. ActivX Biosciences, Inc., La Jolla, CA.
One of the challenges during the clinical development of kinase inhibitors is
understanding whether or not a compound is actually binding the kinase of
interest, in the appropriate tissue, during the course of compound treatment.
While compound concentration in blood can be determined from pharmaco-
dynamics, there are very few approaches that directly measure whether or not
the compound is binding the target kinase.Herein, we apply a chemoproteomics
platform (KiNativ®) using a desthiobiotin ATP acyl phosphate probe (ATP
probe), to monitor target engagement in clinical samples. As a proof of concept,
we demonstrate that compound can be added to whole blood, after which pe-
ripheral blood mononuclear cells (PBMCs) are isolated, lysed, labeled with the
ATP probe, and analyzed by mass spectrometry to determine whether or not
compound treatment blocks the probe-labeling of the target. We successfully
applied this approach in the analysis of both the reversible JNK inhibitor CC-
930, as well as the covalent BTK inhibitor Ibrutinib (Imbruvica®). We then ex-
tended the study to monitor the inhibition of BTK by Ibrutinib in PBMCs iso-
lated from patients undergoing drug treatment. Finally, we demonstrate that in
addition to profıling kinases in PBMCs isolated from whole blood, this method
can also be used to profıle kinases in solid tumors. Thus, the chemoproteomics
approach described here could be applied as a general method tomonitor target
engagement for inhibitors developed against a variety of different kinases in
clinical samples.
#226 Verifıcation of prostate cancer genomics biomarker candidates at
protein level using PRISM-SRM. Hui Wang,1 Yuqian Gao,1 Athena Schep-
moes,1 Gyorgy Petrovics,2 Jennifer Cullen,2 Thomas Fillmore,1 Tujin Shi,1Wei-
Jun Qian,1 Richard Smith,1 Brandi Weaver,3 Robin Leach,3 Ian Thompson,3
Sudhir Srivastava,4 Jacob Kagan,4 Albert Dobi,2 Karin Rodland,1 Shiv Srivas-
tava,2 Tao Liu1. 1Pacifıc Northwest National Laboratory, Richland, WA; 2Uni-
formed Services University of the Health Sciences, Bethesda, MD; 3University of
Texas Health Science Center at San Antonio, San Antonio, TX; 4National Cancer
Institute, Bethesda, MD.
Mass spectrometry (MS) based targeted proteomics such as selected reaction
monitoring (SRM) provides an antibody-independent strategy for sensitive,
specifıc and multiplexed verifıcation of genomics biomarker candidates at the
protein level. In order to identify a panel of proteins with the potential to dis-
criminate between aggressive and indolent forms of prostate cancer and predict
prostate cancer progression, we have selected 52 protein candidates from exist-
ing prostate cancer genomics data sets and validated cancer drivers, and per-
formed quantitative proteomics analysis in tumor and control tissue samples
using the highly sensitive PRISM (high-pressure, high-resolution separations
coupled with intelligent selection and multiplexing)-SRM approach. PRISM-
SRM assays have been developed for the 52 prostate cancer biomarker candi-
dates including: prostate cancer prognosis associated genes, prostate cancer as-
sociated genes that were up-regulated in transcriptomics studies, and other
cancer-related genes (including the ERG or ETV1 isoforms). Two sets of tissue
samples were analyzed using PRISM-SRMwith heavy isotope-labeled synthetic
peptides as internal standards: 1) 10 high Gleason-score (7-9) primary prostate
tumors and 10 benign prostatic hyperplasia (BPH) tissues (OCT-embedded
specimens); and 2) 10 primary tumors from patients showing metastatic pro-
gression, 10 primary tumors from patients who showed biochemical recurrence
(BCR), and 10 primary tumors from patients with no BCR or metastatic pro-
gression after more than ten years of follow-up after radical prostatectomy
(FFPE whole mount prostate specimens). Overall, PRISM-SRM analyses of all
the patient tissue samples enabled the detection of 48 out of 52 biomarker can-
didates, suggesting extremely low level of expression of the remaining 6 genes
(HXC6, OSTP, TWST1, and ERG8); in comparison regular LC-SRM can only
detect 21 of these candidates at the protein level. In the 10 high Gleason-score
tumors and 10 BPH controls, 13 proteins were found differentially abundant
with P0.05. In the 10X10X10 FFPE sample analysis, there were three proteins
discriminating between “metastatic progression” and “no progression” tumors,
one protein discriminated between BCR and “no progression” tumors, and four
proteins discriminated between metastatic progression and BCR tumors
(P0.05). These promising biomarker candidates will be further evaluated, in-
dividually and in panels, in independent, larger cohort for their potential prog-
nostic applications. In summary, PRISM-SRM provides a highly sensitive
method for quantifıcation and rapid screening of multiple potential biomarker
candidates at the protein level. This approach holds great potential for rapidly
translating genomics-based discovery candidates into protein-based biomark-
ers.
#227 Mass spectrometry-based proteomics analysis of the non-small cell
lung cancer secretome. Emmanuel K. Cudjoe, Tareq Saleh, David A. Gewirtz,
AdamM. Hawkridge. Virginia Commonwealth University, Richmond, VA.
Non-small cell lung cancer (NSCLC) is themore common subtype (80%) of
lung cancer, a leading cause of cancer death worldwide. NSCLC has one of the
lowest 5-year relative survival rates due to a combination of late stage diagnosis
and treatment relapse. Autophagy, a stress responsemechanism inwhich cancer
cells recycle organelles, and proteins to generate the necessary nutrients and
metabolic intermediates for survival, is thought to be one of the principal mech-
anisms of treatment resistance and relapse in cancer. Due to its relatively refrac-
tory nature to chemo/radiotherapy, our long-term goal is to identify molecular
signatures and pathways of autophagy that can be targeted to improve the sen-
sitivity of NSCLC to radiotherapy. H1299 /-p53 cells were cultured to85%
confluency, themedia exchanged to serum-freeDMEM, and treatedwith 6Gy of
ionizing radiation. After 12 hours, secreted proteomes were collected, processed
and analyzed by reverse-phase nanoLC-MS/MS (Q-Exactive, ThermoFisher). A
total of 364 secreted proteins were identifıed, of which 163 were quantifıed in at
least 2 replicates of one condition. 29 unique proteins were identifıed to be
present in all samples except H1299 p53 cells which were not treated with
ionizing radiation. These proteins included HMGA1, LSM8, CAST, CAPZB,
CHGB, GSS, and HSPA9 and were associated principally with protein secretion
and chaperone activities. Functional enrichment analysis using FunRich re-
vealed that the secretome was enriched for exosomal, lysosomal, cytoplasmic,
and cytoskeletal proteins (2 fold, p-value 0.0001). Using ANOVA, 24 pro-
teinswere found to be signifıcantly differentially secreted between IR treated and
untreated /-p53 cells. Amongst these proteins are GPI, TXNRD1, FAM3C,
DSTN, CLEC11A, HSPA9, and ALDOA. Of the signifıcant genes, only GPI and
TXNRD1 showed an interaction effect i.e. the effect of p53 status on the expres-
sion of GPI and TXNRD1 in the secretome depends on IR treatment status. In
the pairwise comparison between –p53 and p53 cells treatedwith IR, proteins
over-secreted in –p53 cells by	 2 fold include LSM8, CANX, CHGB and SCG2
whereas GNB2L1 was over-expressed by2 fold in p53 cell secretomes. Cal-
nexin, an ER chaperone protein that is associated with senescence, has been
identifıed in previous studies as a sero-marker of lung cancer but not as amarker
for distinguishing between the autophagic responses of NSCLC to IR. The novel
functional and potential diagnostic value of these differentially secreted proteins
as a function of p53 expression, irradiation and functional autophagy status in
the context of NSCLC will be discussed.
#228 Identifıcation of a novel biomarker to predict castration-resistant
prostate cancer (CRPC) by the proteome analysis. Hiroji Uemura,1 Noriaki
Arakawa,2 Yusuke Itoh,3 Takashi Kawahara,1 Yasuhide Miyoshi,1 Masahiro
Yao,3 Shouhei Akiba,4 Norihisa Ohtake5. 1Yokohama City University Medical
Center, Yokohama, Japan; 2Yokohama City University, Yokohama, Japan; 3Yo-
kohamaCity University Graduate School ofMedicine, Yokohama, Japan; 4Tosoh,
Tokyo, Japan; 5Tosoh, Yokohama, Japan.
Prostate specifıc antigen (PSA) is useful for screening prostate cancer, while it
has no reliable correlation with pathological malignancy of prostate cancer and
is not a predictor for castration resistant prostate cancer (CRPC). In order to
explore novel biomarkers to predict the development of CRPC, we performed
proteomics from secreted proteins from human prostate cancer cells and iden-
tifıed the candidates of biomarker for CRPC. Materials and Methods: The pro-
teins secreted from 6 prostate cancers in culture medium were analyzed and
compared with 8 other cancer cells including renal and urothelial cancers using
LTQ Orbitrap mass spectrometer. With the focus on high tissue specifıcity, the
candidate biomarker proteins were then identifıed through analysis of gene ex-
pressions in proteins common to human prostate cancers by real time qPCR.
Next, a system to measure the identifıed mouse monoclonal antibodies against
the focused proteins was established. Finally, serum levels of these proteins from
33 patients with benign prostate hyperplasia (BPH), 31 with untreated prostate
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cancer (PCa) and 35withCRPC,weremeasured. Results: The proteome analysis
identifıed 12 candidates of secreted cell membrane proteins as new biomarkers.
The proteome analysis indicated that not onlymaturedGDF15, but pro-peptide
as well as fragments (GDPP) are released from prostate cancer cells. Patients’
serum was analyzed for matured and pro-peptide GDF15 using ELISA and im-
munoprecipitation-MRM mass spectrometry. The results showed that the se-
rum level of GDDP-1, one of the processing forms of GDPP, was signifıcantly
higher in CRPC than those in BPH and untreated PCa (P0.01). ROC analysis
also showed that the AUC of GDPP-1(0.86) was higher than that of matured
GDF15 (0.76).When the cutoff value of GDPP-1 was set at 4.0 ng/mL, there was
a signifıcant difference of overall survival (OS) in CRPC patients between those
withmore than 4.0 ng/mL compared to less than 4.0 ng/mL ofGDPP-1, whereas
there was no signifıcant difference of OS measurable by PSA in CRPC patients.
These data suggest that GDPP-1 may be a novel biomarker for CRPC. Conclu-
sion: GDPP-1 shows potential as a novel biomarker for CRPC.
#229 Establishing reference intervals of human urine proteome for mon-
itoring physiological and pathological changes. Wenchuan Leng,1 Xiaotian
Ni,2 Changqing Sun,3 AnnaMalovannaya,4 YiWang,4 JunQin1. 1National Cen-
ter for Protein Sciences (The PHOENIX Center, Beijing), Beijing, China; 2East
China Normal University, Shanghai, China; 3Tianjin Baodi Hospital, Tianjin,
China; 4Baylor College of Medicine, Houston, TX.
Urine as a true non-invasive sampling source holds great potential for bio-
marker discovery. But the lack of method for profıling urine proteome in high
throughput and systematic evaluation of variations in urine proteomes based on
large number of population have been being themajor obstacles for successfully
fınding new biomarkers from urine. Due to low throughput, only limited num-
ber of urine samples can be measured in discovery phase of biomarker studies,
which make it hard to determine whether proteins differentially expressed be-
tween groups represent actual differences between control and disease states or
just physiological variations among individuals. So, candidate biomarkers often
fail in validation phase. Here, we report a streamlined workflow with capacity of
measuring 8 urine proteomes per day per MS at the coverage of more than 1500
proteins. With this workflow, we systematically evaluated variations in 497 hu-
man urine proteomes from 167 apparently healthy donors, allowing us to eval-
uate day to day and inter-personal variation in human urine proteome. Then
personal and pan-human reference intervals (RIs) of urine proteome were es-
tablished based on this large-scale dataset. We demonstrated that RIs can be
used to monitor physiological changes by detecting transient outlier proteins,
such as trans-continental travel and common flu. And it was also found that if
the underlying cause is physiological variation, outlier proteins will fall back to
the normal range in the follow upmeasurement, as exemplifıed in the intercon-
tinental travel case. Persistent outlier proteins may be indicative of non-physi-
ological conditions. These results indicate that periodical measurements of a
person’s urine proteome could establish a personal health archive that would be
valuable for detecting future health issues. Furthermore, we proposed a com-
plete novel strategy dependent on RIs-based algorithm for biomarker discovery
and validation to screen for diseases, which were exemplifıed by analyzing 154
urine proteomes from patients with 7 types of cancers. The algorithm can dis-
tinguish normal people from cancer patients with specifıcity of 0.95 and sensi-
tivity of 0.85. This study paves a way to use urine proteome for health monitor-
ing and disease screening.
#230 Proteomic approaches in the discovery of novel drug targets or po-
tential biomarkers in breast cancer. Ioanna-Maria Orfanou, Theodoros
Karampelas, George Mermelekas, Konstantinos Vougas, Constantin Tamvako-
poulos. Biomedical Research Foundation Academy of Athens, Athens, Greece.
The aim of this study is the detection, identifıcation and quantifıcation of
known and new candidate cell membrane receptors that are overexpressed in
Breast Cancer (BC) cells. In order to achieve this goal we have developed State-
of-the-Art Proteomic approaches. These novel membrane target receptors can
be used either as biomarkers or for the design of targeted drugs against aggres-
sive disease subtypes with poor prognosis and therapeutic outcomes, such as
Triple Negative BC (TNBC) and HER2 overexpressing BC. For our study, four
well characterized BC epithelial cell lines were selected: HCC-1954 and SKBR3
(HER2 overexpressing), MDA-MB-231 (TNBC) and MCF-10A (benign con-
trol). We employed a combination of subcellular fractionation and membrane
enrichment protocols and combined those with quantitative, tandem Mass-
Spectrometry (MS) based Proteomics. The discovery phase of our approach
included: the GeLC-MS/MS technique, where protein fractions were fırst sepa-
rated by 1D-gel electrophoresis followed by In-Gel enzymatic digestion prior to
identifıcation by a high resolution Orbitrap mass analyser. A complementary
approach for known proteins associated with BC that cannot be readily detected
in the discovery phase, such as GPCR receptors, was based on nano LC-MRM
analysis. Proof of Concept experiments, with the use of a Triple Quadrupole
(QqQ) instrument, were based on the detection of standard peptides derived
from the protein of interest after following an in solution tryptic digestion pro-
tocol. Using GeLC-MS/MS approach we identifıed the well-known BC involved
receptors, EGFR and HER2, as well as other potential protein targets in concor-
dance with the literature (e.g. TFR1, EPHA2, GPCR5A). We further confırmed
these results byWestern blot analysis. Certain GPCRs expected to be present in
the cell lines tested were not detected in the studies used on the GeLC-MS/MS
analysis, thus we proceeded to the more sensitive and quantitative nanoLC-
MRM approach. As a paradigm target we chose the GnRH receptor, an estab-
lished target for personalized therapy known to be expressed in BC. The quan-
titative nanoLC-MRM approach revealed GnRHR signifıcant expression in the
MDA-MB-231BC line and in theWPE-NB26-3 Prostate cancer cell line (used as
an overexpressing GNRHR positive control). Our results indicate that the strat-
egy of combining and applying various Proteomic approaches into selected cell
lines for the identifıcation of new protein targets will add more information to
the genetic and histological classifıcation of the tumor in order to achieve our
goal, which is a holistic view of a patient’smolecular profıling that can ultimately
lead to treatment in the most effective way.
PREVENTION RESEARCH: Diet and Cancer
#231 The polyphenolic plant lignan secoisolariciresinol diglycoside re-
ducesmammary tumor growth, possibly via inhibition of local inflammatory
signaling. Claire G. Lineberger,1 Laura W. Bowers,1 Nikki A. Ford,2 Emily L.
Rossi,1 BruceK.Kimler,3 Carol J. Fabian,3 StephenD.Hursting1. 1TheUniversity
of North Carolina at Chapel Hill, Chapel Hill, NC; 2The University of North
Carolina at Chapel Hill, Austin, TX; 3The University of Kansas Medical Center,
Kansas City, KS.
Background: Secoisolariciresinol diglycoside (SDG) is a polyphenolic plant
lignan found in flax and sesame seeds as well as legumes, whole grains, fruits and
vegetables. It is metabolized by the gut bacteria into two major enterolignans:
enterolactone (ENL) and enterodiol (END). These enterolignans have been as-
sociated with reduced breast cancer risk and progression in population studies
as well as decreased tumor growth in preclinical models of breast cancer.
Methods: The impact of SDG supplementation on tumor growth in a mouse
model of basal-like breast cancer was examined. C57BL/6 mice were fed a con-
trol diet (10% kcal from fat) or control diet with SDG supplementation (100
mg/kg food) for eight weeks, then both groups were orthotopically injected with
E0771 mammary tumor cells. An inflammatory signaling qPCR array (Qiagen)
was performed on mammary tissue distal to tumor. Tumors were stained by
immunohistochemistry (IHC) for Ki67 to measure proliferation levels and
phospho-p65 to determine inflammatory signaling pathway activation. Tumors
and mammary tissue were also stained for F4/80 to quantify macrophage infıl-
tration. Serum level of hormones, adipokines, and cytokines were measured via
luminex assay (Bio-Rad). Results: SDG supplementation signifıcantly decreased
tumor weight (p0.05). SDG did not affect body weight or body fat percentage
but did signifıcantly decrease expression of F4/80, CRP, and other pro-inflam-
matory markers in the mammary tissue. IHC staining revealed no difference in
tumor proliferation; however, SDG supplementation did reduce inflammatory
signaling in the tumors, indicated by a signifıcant decrease in phospho-p65
staining. However, serum cytokine levels were not signifıcantly different be-
tween the groups. Tumors are currently being stained by IHC for cleaved
caspase 3 to measure levels of apoptosis. In addition, cell culture experiments
will be conducted to defıne the impact of ENL treatment on protumorigenic
cross-talk between tumor cells, adipocytes, and macrophages. Specifıcally, the
effects of conditionedmedia fromadipocyte/macrophage co-cultures (with /-
ENL treatment) on mouse E0771 and human MDA-MB-231 tumor cell prolif-
eration, migration and invasion will be examined. Conclusions: SDG supple-
mentation reduced mammary tumor growth in association with SDG’s effects
on local, but not systemic, inflammatory signaling.
#232 Modifıcation of dietary sugar on the chemotherapeutic potential in
breast cancer.Yan Jiang, Patrea R. Rhea, LorenzoCohen, Peiying Yang.UTMD
Anderson Cancer Ctr., Houston, TX.
Background: The estimated cost of breast cancer (BCa) care in theU.S. is over
16 billion dollars yearly, more than any other cancer. Thus, identifying contrib-
utors to BCa development and barriers in BCa treatment is a continuing focus of
BCa research. The per capita consumption of sugar in Americans has surged to
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70 lb per year, and an increase in the consumption of added sugars is identifıed
as a pivotal contributor to worldwide epidemics of non-communicable diseases
including cancer. However, whether dietary sugar affects the effıcacy of the
chemotherapy in BCa is questionable. In current study, we investigated the
impact of glucose or sucrose on the chemotherapeutic effect of chemo-agents,
especially doxorubicin, in the growth of BCa cells or tumors. Methods: BCa cell
(human MDA-MB-231, SUM159, T47D, BT474, MDA-MB-468 and MCF-7)
proliferationwas assessed in 3-D culture system. BALB/C nu/numice were used
to investigate tumor growth with/without doxorubicin treatment upon feeding
sucrose enriched diet. Apoptotic gene array and microarray analysis were used
to determine gene expression profıle. Results: Among six human BCa cells
tested, glucose treatment (30 mM) promoted the growth of MDA-MB-231 and
SUM159 cells after 10 days by 2.5 to 3 fold, respectively. In contrast, T47D,
BT474, MDA-MB-468 andMCF-7 cells did not respond to glucose stimulation.
Glucose treatment abrogated doxorubicin-induced cell apoptosis in triple neg-
ative BCa cells including MDA-MB-231 and SUM159 cells, and 4T1 (mouse)
cells. Additionally, the apoptotic effect of chemotherapeutic agents, such as epi-
rubicin, 5-FU and cyclophosphamide in MDA-MB-231 cells were also blocked
by glucose treatment. Furthermore, gene expression analysis demonstrated that
glucose signifıcantly altered apoptotic genes in doxorubicin treated MDA-MB-
231 cells. Compared to doxorubicin alone, glucose/doxorubicin co-treatment
decreased a number of pro-apoptotic gene expression of including PEA15, BAX,
and BcL2L11; while increased anti-apoptotic geneNFB family. Finally, inmice
bearing MDA-MB-231 cell derived tumors, doxorubicin (4 mg/kg body weight
weekly for 4 weeks) inhibited the growth primary tumors by 50% compared to
that in control mice. In the same study, for the mice fed with sucrose diet,
treatment of doxorubicin only reduced the tumor growth by less than 20%
compared to control diet fed mice without doxorubicin treatment, suggesting
that dietary sugar might negatively impact the chemotherapeutic agent in BCa.
Conclusion: The results of our study indicated that glucose (sucrose) altered
BCa responses to doxorubicin in vitro and in vivo. Therefore, dietary sugar may
potentially interfere with the effıcacy of chemotherapeutic agents in BCa pa-
tients which warrants further investigation. This study was support by a gener-
ous donation of Leighton and Lynda Steward, The William A. and Madeline
Welder Smith Foundation and the University of Texas Startup Fund.
#233 The impact of omega-3 fatty acid supplementation on obesity-in-
duced inflammatory signaling within the breast tumor microenvironment.
Duan K. Quach,1 Brittany Harlow,1 Laura Winikka,1 Andrew Brenner,2 Murali
Beeram,3 Stefano Tiziani,1 Lucy Lengfelder,1 Gloria Galvan,1 Christopher Jolly,1
Linda deGraffenried1. 1The University of Texas at Austin, Austin, TX; 2UT
Health San Antonio MD Anderson, San Antonio, TX; 3The START Center for
Cancer Care, San Antonio, TX.
The Impact of Omega-3 Fatty Acid Supplementation on Obesity-induced
Inflammatory Signaling within in the Breast Tumor Microenvironnment. Obe-
sity is associated with a worsened prognosis in breast cancer. This is in part due
to the role of prostaglandin E2 (PGE2) in the obesity-inflammation-aromatase
axis. Omega-3 polyunsaturated fatty acids (PUFAs) have demonstrated anti-
cancer effects through multiple pathways, including suppression of the pro-
inflammatory COX2-PGE2 pathway. In order to determine if supplementation
with omega-3 fatty acids can effectively suppress PGE2 production in obese
postmenopausal women, we conducted a 30 day non-interventional study with
correlative biomarker endpoints. Forty (40) postmenopausal women were pro-
vided oral daily supplements of 1500mg of docosahexaoic acid (DHA) and
2500mg eicosapentanoic acid (EPA). Serum samples were collected prior to and
on day 29 of taking the supplement and analyzed for PGE2 levels. Fifty-fıve
percent (55%) of the subjects demonstrated a signifıcant suppression of PGE2
levels. To test if response could be based upon the ratio of omega-6 to omega-3
fatty acids on inflammatory signaling within the breast, pre-clinical studies were
performed on different cell types found in the tumor microenvironment. Mac-
rophages, breast cancer epithelial cells and pre-adipocytes were exposed to ome-
ga-6 and omega-3 fatty acids at ratios of 46:1, 20:1, 10:1 and 1.3:1 for 24 hours.
While breast cancer epithelial cells demonstrated limited response to PUFA
concentrations, the macrophage and adipocyte cells produced high levels of
PGE2 when exposed to higher ratios of omega-6 fatty acids, which was effec-
tively suppressed in a dose-dependentmannerwith increasing levels of omega-3
fatty acids. These data suggest that obese breast cancer patients may have a
particular benefıt to omega-3 fatty acid supplementation. Ongoing studies will
assess how PUFA-modulated changes in inflammatory signaling from different
cells within the microenvironment impact breast cancer cell proliferation, ther-
apeutic resistance, and migration as measures of breast cancer progression.
These mechanistic studies, in combination with our on-going NCI-funded pro-
spective clinical study in newly diagnosed breast cancer patients, will signifı-
cantly contribute to understanding how ratios of omega-6 to omega-3 fatty acids
canmodulate inflammatory signaling within the tumormicroenvironment, and
if this can be used to improve therapeutic response in the obese breast cancer
population.
#234 Association between fecal microbiome, diet, and colon adenomas
and hyperplastic polyps. Yang Yu,1 Joshua Millstein,1 Amie E. Hwang,2 Bing
Ma,3 Guoqin Yu,4 Laura H. Buchanan,5 Michael Humphreys,3 Ann S. Hamil-
ton,5 John Zadnick,6 Myles G. Cockburn,7 James Buxbaum,2 Heinz-Josef Lenz,5
Thomas M. Mack,5 Jacques Ravel,3 Wendy Cozen5. 1Keck School of Medicine of
USC, University of Southern California, Los Angeles, CA; 2University of Southern
California Keck School of Medicine, Los Angeles, CA; 3University of Maryland,
Baltimore, MD; 4National Cancer Institute, National Institutes of Health,
Bethesda, MD; 5USC/Norris Comprehensive Cancer Ctr., Los Angeles, CA; 6Uni-
versity of Southern California, Los Angeles, CA; 7University of Colorado Cancer
Center, Denver, CO.
Background: Colorectal cancer arises from adenomatous and serrated colon
polyps that are identifıable with colonoscopy. Generally, a healthy gut is char-
acterized by higher fecal microbiota. We conducted a study to determine
whether fecal microbiota composition and structure are associated with colon
adenomas andhyperplastic polyps in a set of identical (MZ,monozygotic) twins.
Methods: We enrolled 83 individual twins from the California Twin Program.
Of these, 56 (representing 38 twin pairs) had documented past colonoscopy and
no gastrointestinal diseases, cancer or recent antibiotic use. Body mass index
(BMI) and food frequency information was collected 15 years before stool col-
lection and again at the time of stool collection. The V4 region of the 16S rRNA
gene was sequenced using the HiSeq 2500 system. Alpha diversity measures
including number of OTU (operational taxonomic units) and Shannon index
were calculated for each sample. Mixed ANOVA models with a random effect
accounting for twin pair status, were used to examine the association of alpha
diversity with polyp status. Results: Alpha diversitymeasured by Shannon index
and number of uniqueOTUswas inversely associatedwith obesity and high beef
consumption and positively associated with yogurt consumption. Surprisingly,
we found that fecal microbiota alpha diversity was higher in subjects with ade-
nomas and hyperplastic polyps compared to subjects with no polyps. When
restricted to subjects with colonoscopy in the 3 years prior to stool collection,
differences were stronger and statistically signifıcant (mean OTUs for subjects
with adenoma, hyperplastic polyps and no polyps 908, 850, and 801, respec-
tively; Padenoma vs. no  0.017, Phyperplastic vs no  0.007; Plinear trend 0.018). In
order to determine whether diet changes may have played a role, we examined
dietary change from food frequency questionnaires collected 15 years apart. We
found that subjects with no polyps increased yogurt consumption by 50% over
the 15 year period, whereas subjects diagnosed with adenomas and hyperplastic
polyps increased their yogurt consumption more (140% and 130%, respec-
tively). Conclusion: Participants diagnosed with adenomas and hyperplastic
polyps had higher fecal microbiota alpha diversity compared to those without
polyps. The timing of measurement of fecal microbiota years after colonoscopy
obscures the causal relationship between adenoma and fecal microbiome. One
possibility is that subjects may have increased their yogurt consumption after a
polyp diagnosis, resulting in increased fecal alpha diversity, compared to sub-
jects who were not diagnosed with polyps. Alternatively, polyp removal may
alter microbial diversity. A third possibility is that polyp susceptibility is associ-
ated with an outgrowth of deleterious bacteria, still present after polyp removal,
reflected as increased alpha diversity. Twin comparisons will be presented.
#235 Probiotics ameliorate Porphyromonas gingivalis-promoted pancre-
atic cancer progression in oncogenic Kras transgenic mice.Ming-Shiou Jan,1
Wan-Ting Chen,1 Yu-Jen Chen,1 Chia-Wei Lin,1 Wen-Wei Chang,1 Chung-
Hung Tsai,1 Jia-Shiou Peng,2 Li-Jin Hsu3. 1Chung ShanMedical University, Tai-
chung, Taiwan; 2Chung-Jen Junior Collerge of Nursing, Health Science andMan-
agement, Chiayi, Taiwan; 3National Cheng Kung University, Tainan, Taiwan.
Periodontal disease has been shown to play important roles in the pathogen-
esis of many chronic diseases. Recent epidemiological studies and microbiome
analysis have suggested that periodontal disease may be associated with the
progression of pancreatic cancer. Our recent study has demonstrated that oral-
smear of a periodontitis pathogen Porphyromonas gingivalis (P. gingivalis) sig-
nifıcantly induced pancreatic cancer deterioration in the KrasG12D/-Pdx-1-Cre
transgenic mouse model. Higher expression levels of epithelial-mesenchymal
transition (EMT)markers, such asN-Cadherin,SMA, SNAIL-1,Vimentin and
ZEB1, were observed in P. gingivalis-treated KrasG12D/-Pdx-1-Cremice than the
untreated controls. In an attempt to develop a prophylactic treatment for pan-
creatic cancer, the mice were fed with a combination of two probiotics, Lacto-
bacillus reuteri and Lactobacillus paracasei, for four consecutive weeks after
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oral-smear of P. gingivalis. These probiotic strains have been demonstrated to
have the effıcacy of either anti-inflammation or enhancement of cell-mediated
immunity, respectively. Our results demonstrated that oral administration of
the probiotics signifıcantly suppressed oncogenic Kras-induced pancreatic can-
cer development and reversed P. gingivalis-stimulated cancer deterioration in
mice. Signifıcantly reduced expression of the aforementioned EMT markers in
pancreatic cancer tissues was observed in KrasG12D/-Pdx-1-Cre transgenic mice
treatedwith the probiotics. Our results suggest that themicrobiota profıle is very
important for pancreatic cancer development. The manipulation of microbiota
for enhancing antitumor immunity may be an emerging strategy for cancer
prevention.
#236 Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for
reducing breast cancer risk in obese postmenopausal women.AndreaManni,
John P. Richie, Susann E. Schetter, AnaCalcagnotto, Neil Trushin, Cesar Aliaga,
Karam El-Bayoumy. Penn State Univ. Hershey Medical Ctr., Hershey, PA.
Preclinical and epidemiologic data suggest that a unique feature of lipogenesis
in cancer cells which has received limited attention is the accumulation of
monounsaturated fatty acids (MUFA) which are largely derived from saturated
fatty acids (SFA) by the action of stearoyl-Co-A desaturase (SCD-1). Activation
of SCD-1, a delta-9 fatty acid desaturase, is considered to be an important factor
in the development of obesity and several types of cancer including breast can-
cer.However, no data are available on how changes in SCD-1 activity induced by
potential chemopreventive agents relate to established biomarkers of breast can-
cer risk. To address this issue, we measured the activity of SCD-1, expressed as
the ratios of palmitoleic acid (C16:ln7) to palmitic acid (C16:0) (SCD-16) and
oleic acid (C18:ln9) to steric acid (C18:0) (SCD-18) in plasma samples of post-
menopausal women enrolled in our recently published clinical trial (Sandhu N,
et al Cancer Prev Res 9:275, 2016) designed to test the individual and combined
effect of the antiestrogen Raloxifene and the omega-3 preparation Lovaza on
breast density, a validated biomarker of breast cancer risk. We observed that
daily administration of Lovaza (1,860 mg eicosapentaenoic [EPA] 1,500 mg
docosahexaenoic [DHA]) signifıcantly reduced SCD-1 activity, an effect which
was sustained for the two-year duration of the trial. Raloxifene, on the other
hand, did not signifıcantly alter SCD-1 activity in our subjects. SCD-1 activity
was positively correlated with BMI (for SCD-16, r0.45, p01; for SCD-18,
r0.23, p0.01) and paralleled changes in BMI in the same direction over the
two years of the study. These fındings support the role of this enzyme in the
development of obesity. Importantly, decreasing levels of SCD-1 were found to
be associated with a progressive reduction in breast density in obese women
(BMI	30) (for SCD-16; r0.47, p0.01; for SCD-18; r0.36, p0.05). No
correlation between breast density and SCD-1 was observed in non-obese sub-
jects (r0.02 for SCD-16 and 0.04 for SCD-18). Our results suggest that BMI-
related factors play an important role in the reduction of breast density by ome-
ga-3 fatty acids. They also indicate that SCD-1 may be a useful biomarker in
future clinical trials testing the benefıt of nutritional interventions in reducing
obesity associated breast cancer risk.
#237 Increased NSCLC tumorigenesis in mice fed a high fat diet is associ-
ated with increased plasma IGF-1 levels and PD-1 expression in CD4 tu-
mor-infıltrating lymphocytes. Regan M. Memmott,1 Krista Pearman,2 Joell
Gills,3 Tony Tullot,2 Valerie Wong,2 Benjamin Singer,4 Kristin Lastwika,5
Franco D’Alessio,6 Phillip Dennis,7 Jeffrey William Norris2. 1University of Ari-
zona Phoenix, Phoenix, AZ; 2Midwestern Univ. - Glendale Campus, Glendale,
AZ; 3Johns HopkinsMedical Institute, Baltimore,MD; 4Northwestern University,
Evanston, IL; 5Fred Hutchinson Cancer Research Institute, Seattle, WA; 6Johns
Hopkins University - School of Medicine, Baltimore, MD; 7Astra-Zeneca, MD.
Lung cancer is the leading cause of cancer-related mortality worldwide, and
85% of lung cancer cases are associated with tobacco use. Activating mutations
in K-ras have been identifıed in 25% of tobacco-associated lung adenocarci-
nomas. Usingmouse models of K-ras-driven lung tumorigenesis, we previously
demonstrated that deletion of the IGF-1 gene or reduction of systemic IGF-1
levels using the antidiabetic drug metformin markedly reduced tumor burden.
Preclinical and clinical studies suggest that diet composition is the best predictor
of IGF-1 levels. Therefore, we hypothesized that diets high in fat or carbohydrate
would promote lung tumorigenesis by increasing systemic IGF-1 levels. To as-
sess the effect of diet on systemic IGF-1 levels, 9 week old C57Bl/6J andA/Jmice
were fed standard cereal, high-carbohydrate, or high-fat (HFD) diets for 12
weeks. Compared to cereal-fed control mice, plasma IGF-1 and insulin levels
were increased in both strains of mice fed a HFD, but not in mice fed a diet high
in carbohydrate. This was not due to obesity, as only the C57Bl/6J mice fed a
HFD had an increase in body weight.We then investigated the effect of HFD on
lung tumorigenesis using two mouse models. In the fırst, C57Bl/6LA2 mice,
which harbor a mutation in K-ras, were fed either cereal diet or HFD for 10
weeks following weaning. Lung tumor burden in the mice fed HFD was in-
creased 2.7-fold compared to littermates fed cereal diet. In the secondmodel, the
tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1 butanone (NNK)
was given by intraperitoneal injection to A/J mice beginning at 6 weeks of age.
This carcinogen causes lung tumor development by inducing K-ras mutations.
After 3 weekly injections of NNK, the mice were randomized to cereal diet or
HFD for ten weeks. Mice fed HFD had a 60% increase in lung tumor burden. In
both models, there was no relationship between the weight of the mice and lung
tumor burden. Immunohistochemical analysis of the proliferationmarkerKi-67
showed no signifıcant difference in expression between tumors frommice fed a
HFD or a cereal diet. Therefore, we evaluated tumor-infıltrating lymphocytes
(TIL) from mice on both diets. Interestingly, both immunohistochemical anal-
ysis and flow cytometry demonstrated a 50% reduction in the number of TIL in
mice fed HFD compared to mice fed a cereal diet. Additionally, HFD was asso-
ciated with a 2-fold increase in PD-1CD4 TIL, and the PD-1 staining inten-
sity in these lymphocytes was signifıcantly greater than in mice fed a cereal diet.
These results may suggest that a high fat diet increases lung tumorigenesis by
increasing systemic IGF-1 levels and by creating an immune-permissive tumor
microenvironment.
#238 Evidence of early colorectal cancer risk and prevention pathways in
the fecal microbiome of colonoscopy patients: associations with diet and cir-
culating adipocytokines. Carrie R. Daniel,1 Kristi L. Hoffman,1 G S. Raju,1
SamirM.Hanash,1 Diane S. Hutchinson,2 Nadim J. Ajami,2 RichardG. Fowler,1
Gladys J. Browman,1 Akhil Sood,1 Paul Scheet,1 Xifeng Wu,1 Joseph F.
Petrosino2. 1The University of TexasMDAnderson Cancer Center, Houston, TX;
2Baylor College of Medicine, Houston, TX.
Accumulating evidence suggests that the gut microbiome’s role in early colo-
rectal cancer etiology extends beyond the pro-carcinogenic activities of specifıc
pathogens and is largely influenced by the wider microbial community of com-
mensal bacteria. To identify early microbiome-related pathways and potential
dietary intervention targets, we conducted an epidemiologic study among can-
cer-free colonoscopy patients at known and varied risk of colorectal neoplasia.
Sporadic patients undergoing colonoscopy screening provided consent and fast-
ing blood. Polyps, if found, were removed at colonoscopy and 1 month later
(prior studies show the effect of the colonoscopy prep dissipates within this time
period), eligible patients provided a stool sample via mail kit (n47). Patients
completed comprehensive dietary assessments and clinicopathologic factors,
including screening history, were abstracted from electronic medical records.
We characterized the fecal microbiome via whole genome shotgun sequencing
(Illumina HiSeq) and circulating blood adipocytokines via Luminex multiplex
assays (Millipore). Majority of the patients were female and recently diagnosed
with precancerous polyps, primarily tubular and sessile serrated adenomas.
Polyp patients were more likely to be obese and to not consume alcohol, but
otherwise similar by age, diet composition, and other risk factors to patientswith
normal colonoscopy fındings. We observed no effects of time interval between
colonoscopy and fecal sample collection, or of recent polyp diagnosis/removal,
on microbial alpha or beta diversity. Correlation networks between species re-
vealed that Faecalibacterium prausnitzii inversely correlated with E. coli, the
most abundant species in our sample, and co-occurred with other short chain
fatty acid-metabolizing bacteria, including Anaerostipes hadrus and Roseburia
hominis, known butyrate-producers. Among recurrent patients (n14), Bacte-
roides fragilis co-occurred with Bilophila wadsworthia (r0.6; P0.02). Higher
intake of fıber and/or overall diet quality, as defıned by theHealthy Eating Index,
was associated with several bacteria largely linked to butyrate production (e.g.,
Bifıdobacterium animalis, F. prausnitzii, Roseburia intestinalis, Coprococcus
eutactus, Eubacterium eligens). These same dietary factors were inversely cor-
related with Blautia hydrogenotrophica, an acetogen, and other bacteria impli-
cated in inflammation and colorectal cancer (e.g., B. fragilis). Biologically plau-
sible associations between microbial (functional gene content) pathways
important to cancer risk (e.g., one-carbon, lysine, carbohydrate and fatty acid
metabolism) with dietary factors and circulating adipocytokines involved in
immunity, inflammation, and glucose metabolism support the functionality of
these diet-microbe relationships.
#239 Associations of polyunsaturated fat, bile acids, and gut microbiota
on colorectal adenoma risk. Tengteng Wang, Nicole M. Brown, Amber N.
McCoy, Robert S. Sandler, Temitope O. Keku. University of North Carolina at
Chapel Hill, ChapeL Hill, NC.
Background: Intestinal microbiota, and their metabolites are increasingly recog-
nized as important players in the genesis of colorectal adenomas and cancer. Epide-
miological studieshave also shown that polyunsaturated fat intake is associatedwith
PREVENTION RESEARCH: Diet and Cancer
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 61
decreased riskof colorectal adenomas.This studyexamined theassociationbetween
adherent gutmicrobiota andmucosal bile acids, and total polyunsaturated fat intake
in relation to colorectal adenomas in a case-control study. Methods: Participants
were 217 adenoma cases and 218 adenoma-free controls who underwent screening
colonoscopies and completed food frequency questionnaires. The mucosal adher-
ent microbiota was characterized by bacterial 16S rRNA sequencing. Global
metabolomics of colonicmucosal tissuewas conductedby gas chromatography and
mass spectrometry on a subset of samples. Genus level microbiota and bile acids
were compared between cases and controls using t-test with correction formultiple
comparison. Logistic regression and Pearson correlations were used to estimate
adjusted odds ratios (ORs) and 95% confıdence intervals (CIs), and correlation co-
effıcients for theassociationamongmicrobiotaabundance,bile acids concentration,
and total polyunsaturated fat intake. Results: Adenoma subjects had a signifıcantly
higher bacterial abundance of Sphingomonas, Marinomonas and Ralstonia, but
lower abundance of Adlercreutzia compared to controls. The concentration of
eleven bile acids (Chenodeoxycholate, Cholate, Deoxycholate, Glycochenodeoxy-
cholate,Glycocholenate sulfate, 7-ketodeoxycholate; 12-dehydrocholate,Tauroche-
nodeoxycholate, Taurocholate, Taurodeoxycholate, Taurolithocholate 3-sulfate,
and Tauroursodeoxycholate) were signifıcantly elevated in cases compared to con-
trols. Subjects with increased abundance of Sphingomonas and Ralstonia were sig-
nifıcantly more likely to have adenomas (OR 2.17, 95% CI 1.31-3.57; OR 1.19, 95%
CI 1.02-1.38) respectively. Subjectswith increased abundance ofAdlercreutziawere
less likely tohaveadenomas(OR0.44,95%CI0.21-0.93).Themultivariableadjusted
OR for those in the high relative to the low level of total polyunsaturated fat intake
was 0.46 (95%CI0.27-0.80). The correlations betweenbacterial diversity and eleven
bile acids also signifıcantly differed by case control status. Conclusion: The interac-
tions of the gut microbiota, bile acids and consumption of polyunsaturated fat are
associated with colorectal adenoma risk.
#240 Dietary patterns and risk of colorectal neoplasia in Puerto Rican
Hispanics: A case control study. Julyann Perez-Mayoral,1 Sachelly Julian,2
Marievelisse Soto-Salgado,2 Michael J. Gonzalez,2 Marcia Cruz-Correa1. 1Uni-
versity of Puerto Rico Comprehensive Cancer Center, San Juan, PR; 2University of
Puerto Rico Medical Sciences Campus, San Juan, PR.
Colorectal cancer (CRC) is the leading cause of cancer death in Puerto Rico and
second cause of death in the US. It is well accepted that modifıable lifestyle habits
such as diet, contribute to CRC development. Diet could reduce up to 70% of CRC
cases. Dietary patterns vary according to race/ethnicity. Puerto Rican Hispanics
(PRH) have been shown to have a distinct diet compared to US non-Hispanic
Whites (NHW). According to the BRFSS, only 17.7% of PRH and 23.4% of NHW
consume fruit and vegetables fıve times per day. The objective of this study was to
describe the association of specifıc food groups consumption with the risk of colo-
rectal neoplasia (CRN: polyps and/or CRC) in PRH. The validated Colon Cancer
Family Registry food frequency questionnaire was administered to healthy individ-
uals (controls) and individuals with CRN (cases) recruited through the Puerto Rico
Colorectal Cancer Registry (PURIFICAR). Models adjusted by age, gender, educa-
tional attainment and family history of CRC were fıtted to estimate the odds ratios
(OR) with 95% confıdence intervals (CI) through a polytomous logistic regression
models comparing cases and controls. A total of 577 subjects were included in the
study (controls254; polyps50; and CRC273). The frequency of consumption
of fruits, lowfatdairyproducts, eggs,pasta/rice,non-friedchicken, andseafoodwere
signifıcantly different between controls and CRN cases (p0.05). Adjustedmodels
showed that a higher consumptionof fruits (OR	once per day0.29) and full-fat dairy
products (OR	once per day0.22) were associated with decreased risk of polyps
(p0.05). A frequency of consumption of 2-4 times per week, when com-
pared to  1 per week, of full-fat dairy products (OR2-4 times per week0.51),
seafood (OR2-4 times per week0.49), and red meats (OR2-4 times per week0.56)
was associated with a decreased risk of CRC (p0.05). Our results showed
that a higher consumption of fruits and full-fat dairy products signifıcantly
reduce the risk of polyps in PRH. In addition, consumption of seafood,
full-fat dairy, and red meats up to 4 times per week may reduce the risk of
CRC in PRH. Educational interventions for cancer prevention in PRH
should incorporate nutritional information tailor to our community.
#241 Vimentin offers a potential target for the prevention of ovarian tu-
mor progression and recurrence. Aparna Yellapa,1 Janice M. Bahr,2 Sameer
Sharma,1 Pincas Bitterman,1 Sanjib Basu,1 Animesh Barua1. 1Rush University
Medical Center, Chicago, IL; 2University of Illinois at Urbana-Champaign, Urba-
na-Champaign, IL.
Background: Aggressive rates of progression and frequent recurrence are the
main causes of high rates of death due to ovarian cancer (OVCA). Vimentin, an
intermediate fılament protein, expressed by ovarian mesenchymal cells may be
involved in OVCA metastasis and recurrence. Ashwagandha (Withania som-
nifera, ASH, a natural product) has shown to improve tumor-associated stress
against severalmalignancies. Objectives: The goals of this studywere to examine
whether (1) OVCA progression is associated with vimentin expression; and
whether (2) OVCA progression and vimentin expression can be prevented by
dietary supplementation of Ashwagandha (ASH) in laying hen model of spon-
taneous OVCA. Methods: Exploratory study: Clinical specimen from normal
ovaries (n10), benign tumors (n5) and malignant ovarian epithelial cancers
at early (n7) and late stages (n16)were collected frompatients and examined
for vimentin expression. Prospective study: 4-year old laying hens with normal
ovaries or ovaries with early stage OVCA were supplemented with 2% dietary
ASH root powder or basal diet (24 hens in each group containing 18 healthy, 6
with early stage OVCA). Hens were provided with feed and water ad libitum for
120 days and euthanized thereafter. Tumor stageswere recorded; serum, normal
or cancer ovaries were collected. Expression of vimentin both in clinical and
preclinical treated or untreated specimens was examined. Statistical differences
in the intensity of vimentin expression among different pathological and ASH
supplemented groups were determined using ANOVA and t-tests. Results: Vi-
mentin was localized in the nucleus and cytoplasm of normal ovarian, benign
andmalignant cells. Compared with normal and benign tumors, the intensity of
vimentin expression was signifıcantly (P0.0001) lower in early stage OVCA
and increased remarkably in late stage OVCA. Similar to OVCA patients, inten-
sity of vimentin expression was lower in hens with early OVCA than normal
hens, and increased signifıcantly (P0.0001) in hens with late stage OVCA. As
compared with untreated hens, tumor incidence and progression as well as
vimentin expression decreased signifıcantly in hens treated with 2% dietary
ASH.Conclusions: Results of the present study suggest that vimentin expression
increased during tumor metastasis. ASH treatment reduced OVCA metastasis
by inhibiting vimentin expression. Therefore, vimentin may represent a poten-
tial target for ASH to prevent OVCA progression and metastasis. Support: Sup-
port: R21CA187309-02.
#242 The anti-tumor effect and the impact on gut microbiota of gypeno-
sides Rd and Rb3 in ApcMin/ mice. W.L. Wendy Hsiao,1 Guoxin Huang,1
Imran Khan,1 Lei Chen,2 Xiaoang Li1. 1State Key Lab of Quality Research in
Chinese Medicine, Macau Univ of Sci. & Tech, Macau, China; 2Rutgers Univer-
sity, Piscataway, NJ.
Gut commensal microbiota (GM) is closely associated with health and dis-
eases, including cancer. In our previous studies, we have demonstrated that
Gynostemma pentaphyllum saponins (GpS) exert anticancer effects in both
athymic and ApcMin/ mice. Our recent study also showed that GpS exhibited
prebiotic effect by up regulating the benefıcial bacteria and improving the epi-
thelial microenvironment of the gut. Gypenoside IV (Rb3) and gypenoside VII
(Rd) are the two constituents of GpS. The Rd exhibits stronger anticancer effect
than Rb3 in an in vitro cell model system established in our lab. Our aim is to
confırm the antitumor effect of these two compounds, as well as their impact on
GM in the ApcMin/mousemodel. In the study, single daily dose of Rb3 or Rd at
20mg/kg, and solvent control were orally fed to themice for 8 weeks, started at 6
weeks of age before the appearance of spontaneous intestinal polyps. The fecal
microbiome was analyzed by enterobacterial repetitive intergenic consensus
(ERIC)-PCR and 16S rRNA gene pyrosequencing technique. We found that Rd
was more effective than Rb3 in reducing polyp formation, and improving the
intestinal lining by up-regulating anti-inflammatory cytokines IL-4 and IL-10.
Rd, not Rb3, might facilitate intestinal tissue repair by enhancing M2 marker
while suppressing M1 markers expression. Moreover, Rd treatment greatly en-
hanced the ratio of Bacteroidetes vs Firmicutes, while profoundly reduced the
abundance of cancer-cachexia-associated bacteria, such as Parabacteroides
goldsteinii (22.25%), Dysgonomonas wimpennyi (48.54%) and Blautia coc-
coides (36.77%). These fındings suggested that the level of antitumor effect of the
gypenoside might be correlated with its ability to modulate the gut microbiota
from dysbiosis state to symbiosis. This study was supported by Macau Science
and Technology Development Fund 015/2014/A1.
#243 Diet and exercise-induced weight maintenance, alone and in combi-
nation with a whole tumor cell vaccine, delays mammary tumor growth and
reduces MDSC accumulation. Yitong Xu, William J. Turbitt, Andrea M. Mas-
tro, Connie J. Rogers. Pennsylvania State University, University Park, PA.
Obesity andphysical inactivity increasebreast cancer risk,while thepreventionof
weight gain by diet and exercise can be protective. Numerous biological mecha-
nism(s) have been proposed to explain the benefıcial effects of weightmaintenance;
however few studies have examined the immune response to energy balance. We
have previously shown that diet and exercise-induced weight maintenance (WM)
achieved via a 10% restriction in calories and access to voluntary running wheels in
combination with a whole tumor cell vaccine (VAX) signifıcantly reduced mam-
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mary tumor growth andmetastases in the 4T1mammary tumormodel. ThisWM-
induced reduction in tumor growth occurred concurrently with an elevation in
tumor specifıc IFN-productionanda reduction in thenumberofmyeloid-derived
suppressor cells (MDSCs).However, because tumor size ispositively correlatedwith
immune suppression, the goal of the current study was to investigate if mice in the
WMVAX intervention had enhanced anti-tumor immune responses and/or
fewer MDSCs controlling for tumor size. Female BALB/c mice were randomized
into weight gain (WG) andWM groups (n8/group) and had access to voluntary
running wheels or standard cages, respectively.WGmice were fed ad libitumwhile
WMmice were energy-restricted by 10% to maintain a stable body weight. After 8
weeks on the intervention, all mice were orthotopically injected with 5x104 4T1.2
cells into the fourth mammary fat pad and continued on their intervention. Once
injected, bothWGandWMmicewere further randomized into vaccination (VAX)
and vehicle control (VEH) groups (n4/gr) and administered 1x106 irradiated
4T1.2 cells (VAX) or HBSS (VEH) at day 7 post-tumor implantation. Primary tu-
mor growth was quantifıed, andmice were sacrifıced when tumor volume reached
0.1-0.2 cm3. WMmice weighed signifıcantly less thanWGmice over the course of
the study (p0.001). Mice in bothWMVEH andWMVAX groups took a sig-
nifıcantly longer number of days post tumor implantation to reach a tumor size of
0.1-0.2 cm3 (26.3 3.3 d, p0.003; 23.8 0.5 d, p0.039, respectively) compared
to the WGVEH group (18.3 2.5 d). Despite the fact that mice were sacrifıced
when the tumor volumes were standardized at 0.1-0.2 cm3, the combination of
WMVAX resulted in a signifıcant reduction of splenic MDSC accumulation
(p0.049) and enhanced CD4 T cell proliferation ex vivo. These results suggest
that diet and exercise-inducedWMwas highly effective in delaying primary mam-
mary tumor growth. The combination of WM and an allogenic whole tumor cell
vaccinereducedpro-tumorigenicMDSCaccumulationandenhancedeffectorTcell
function.Furthermore, thesedata suggest thatdiet andexercisemaybechanging the
tumor microenvironment at an early stage of tumor growth favoring tumor clear-
ance. This work is supported by R21 CA209144; T32AI074551.
#244 Eicosapentaenoic acid reduces effects of some adipocyte derived fac-
tors on breast cancer cell inflammation and glucose metabolism. Arwa Al-
jawadi,1 Sara Alhaj,1 Suranganie Dharamawardhane,2 Shane Scoggin,1 Lauren
Gollahon,1 Preethi Gunaratne,3 Naima Moustaid-Moussa1. 1Texas Tech Univ.,
Lubbock, TX; 2University of Puerto RicoMedical Sciences Campus, San Juan, PR,
Puerto Rico; 3University of Houston, Houston, TX.
Breast cancer is still the leading cause of death in women among all cancer types.
Obesity, a chronic low grade inflammatory disease, is a key contributor to the pro-
gression of breast cancer especially in women, post-menopause. Given the current
understanding of cancer-related inflammation and associated microvesicles in re-
structuring the microenvironment, we hypothesized that adipocyte-derived cyto-
kines and exosomes negatively impact breast cancer progression. By contrast, eico-
sapentaenoic acid (EPA), a dietary omega 3 polyunsaturated fatty acid and a well-
established anti-inflammatory compound will reduce adipocyte-secreted pro-
inflammatory factors, thereby reducing breast cancer progression. To test these
hypotheses, we investigated the effects of conditioned media or exosomes from
3T3-L1adipocytesorhumanmesenchymal stemcells (HMSC), treated /- 100uM
EPA onMCF7 andMDA-MB231 breast cancer cells for 24 – 72 h. Following treat-
ment, changes in breast cancer cell gene expressionweremeasured usingRT-qPCR
and glycolytic rate was measured using XFe24 Seahorse extracellular flux analyze.
We observed that conditioned medium from HMSC signifıcantly increased the
mRNAexpression levels of oncogenic genes such as signal transducer and activator
of transcription 3 (STAT3), baculoviral IAP repeat-containing protein3 (BIRC3)
known as cIAP2, and the lipogenic fatty acids synthase (FASN). In contrast, condi-
tionedmedia fromEPA-treated human adipocytes reduced the expression levels of
these genes. Similarly, exosomes isolated from EPA-treated adipocytes showed a
signifıcant reduction inmRNA expression levels of STAT3 and cIAP2 in both can-
cer cell lines. Furthermore, glycolysis was signifıcantly reduced in MCF7 but not
MDA-MB231 cells incubated with 3T3-L1 adipocyte-conditioned medium pre-
treated with EPA for 24 hrs. Taken together, our data suggest that adipocytes play a
signifıcant role in promoting breast cancer progression by providing a microenvi-
ronment that increases survival and inflammation. EPA is a promising anti-inflam-
matory nutrient thatmay help reduce breast cancer cell inflammation and survival,
possibly by modulating adipocyte-derived cytokines and exosomes in obesity and
thus warrants further investigations.
#245 Dietary long-chain omega-3 fatty acids reduce adipose inflammation
in mammary tissue of mice fed moderate fat-isocaloric diets. Saraswoti
Khadge,1 Geoffrey M. Thiele,1 John Graham Sharp,1 Lynell W. Klassen,1 Timo-
thy R. McGuire,1 Michael J. Duryee,1 Holly C. Britton,1 Alicia J. Dafferner,1
Jordan Beck,2 Paul Black,2 Concetta C. DiRusso,2 James E. Talmadge1. 1Univ. of
Nebraska Medical Ctr., Omaha, NE; 2Univ. of Nebraska,-Lincoln, Lincoln, NE.
Increased adipose tissue Inflammation and breast density; including ductal epi-
thelial hyperplasia have been associated with increased risks for breast cancer.
Omega 6 (6) and omega 3 (3) fatty acids (FAs); serve as substrates for pro-
inflammatory and inflammation resolvingmediators respectively, emphasizing the
potential regulatory role for dietary intake of these FAs in inflammation. Western
diets have a 6:3 FA ratio of 15:1 with low levels of long-chain (LC)-3FA.
White adipose tissue inflammatory foci, characterized by crown-like structures
(CLS) consisting of dead adipocytes and adjacentmacrophages in breast tissue have
beenrelated tobreast cancer risk inoverweight andobesewomenpresumablyby the
obesity-inflammation-aromatase axis. However, a role of dietary 6:3 FA in adi-
pose inflammation, independent of obesity is not clear.Herein,we examined effects
of dietary 6:3 ratio on the mammary tissue microenvironment and adipose in-
flammation using amoderate fat, iso-caloric diets, and pair-fedmodel. The Lieber-
DeCarli diet containing 21:1 ratio of 6:3 FA was used as a 6 diet, whereas
encapsulated fısh oil containing a 3:1 ratio of eicosapentaenoic (EPA) and docosa-
hexaenoic (DHA) acidwas used to decrease6:3 ratio to 0.7:1 in the3 diet. Both
iso-caloric diets contained 35.5% of calories derived from fat and were pair-fed to
maintain iso-intake. Female BALB/c mice were established on the6 and3 diets
for 10 weeks and weight gain and diet consumption monitored. There were no
differences in the volumeofdiet consumedandweight gainbetweendietary groups.
At autopsy, mammary fat pads (MFP) were collected and analyzed for fatty acid
composition, histopathology, epithelial proliferation and macrophage infıltration.
Arachidonic acid (AA) levels in theMFPswerenotdifferent between the groupsbut
EPA and DHA were absent in the MFPs from the 6 diet fed mice. Whereas,
(2.41/- 0.5) mole% of EPA and (1.52/-0.29) mole% of DHA were detected in
MFP of 3 diet fed mice. The MFP of 6 diet fed mice had signifıcantly increased
areas of unilocular adipocytes relative to adipocytes of the 3 group. Similarly, 6
diet fed mice had increased connective tissue in the ductal stroma, signifıcantly
higher numbers of proliferating cells in the ductal epithelium, as well as in adipose
tissue area of MFP. In addition, 6 diet fed mice had a signifıcant increase in the
numbersofCLS inmammaryadipose tissue. Insummary,ourstudiesdemonstrated
that despite the comparable levels of AA inMFP in both of groups, the presence of
LC-3 FA (EPA andDHA)was able to reduce inflammation in theMFP of3 diet
fed mice, thus regulating the MFP microenvironments by reducing macrophage
infıltration and ductal epithelial proliferation in an obesity-independent manner.
#246 Assessing microbial dysbiosis of electronic cigarettes and cigarette
smokers using oral and lungmicrobiome.Kevin Ying,1 Min-Ae Song,1 Daniel
Y.Weng,1QuentinNickerson,1David Frankhouser,1 Pearlly S. Yan,1 Ralf Bund-
schuh,1 Mark D. Wewers,1 Ewy Mathé,1 Jo L. Freudenheim,2 Peter G. Shields1.
1The Ohio State University, Columbus, OH; 2University at Buffalo, Buffalo, NY.
The link between smoking tobacco and changes in the oral microbiome in
response to tobacco smoking are well established. It is not known if there are
changes in response to electronic cigarettes (e-cig). These changes in the micro-
biome are associated with increased numbers of disease causing pathogens. Cur-
rently there arenopublished studies thathave investigated the relationshipof smok-
ing tobacco on both the oral and lung microbiome. There is insuffıcient evidence
showing whether changes in oral cavity and lungmicrobiome are also seen in e-cig
users. We will study the oral cavity and lung of non-smokers, smokers and e-cig
users to examine concordance between oral cavity and the lungs as well as compar-
ing the three groups, examining the microbiomes and expression of inflammatory
markers. We hypothesize that microbial dysbiosis and expression of inflammatory
cytokines will differ for smokers and non-smokers; and that e-cig users will have
microbial dysbiosis similar to cigarette smokers. A cross-sectional study is being
conducted on three groups, 1) never-smokers, 2) cigarette smokers, and 3) e-cig
users. For each studyparticipant, saliva andbronchoalveolar lavage (BAL) are being
collected tomeasuremicrobiome.RNAisextracted fromsalivaandBALsamples for
total transcriptome analysis using RNA-seq. This analysis will detect human and
bacterial reads thereby allowing observations of bacterial communities as well as
human inflammatory cytokine response to bacterial presence. 85% to 98% of BAL
sample reads aligned to the human genome compared to less than 50% from saliva
samples. The alignment results allow us to deduce that the majority of reads from
BAL samples are human and that the majority of the reads in saliva samples are
bacterial. Preliminary results showdetection of humanRNAexpression and of bac-
terial reads are present in both saliva and BAL samples. More samples are being
processed and the comparison of BAL and saliva samples between the three groups
will be discussed.
#247 Nutrient stress via folic acidmodulation causes systemic and cancer-
specifıc metabolic reprogramming and differential effects on primary and
metastatic mammary tumor growth in lean and obese mice. Ciara H.
O’Flanagan,1 XuewenChen,1 ZahraAshkavand,2 SergeyA. Krupenko,2 Stephen
D. Hursting1. 1Univ. of North Carolina at Chapel Hill, Chapel Hill, NC; 2Nutri-
tion Research Institute, Kannapolis, NC.
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Many foods are currently fortifıedwith folic acid (FA), a synthetic folate (Vitamin
B9). Folate defıciency causesmany human health defects,most notably anemia and
neural tube defects. The effects of excess supplementation on human health have to
date been understudied. The rise in obesity in the last three decades further compli-
cates this issue, with the combined effects of excess or insuffıcient folic acid intake
and an obese phenotype being unknown. Obesity is associated with a number of
cancers, including triplenegativebreast cancer (TNBC).TNBCcomprises16%ofall
breast cancers, is highly aggressive and more likely to recur and metastasize than
other breast cancers. Unlike other subtypes, TNBC does not respond to hormone-
targeted therapies and treatment options are limited to cytotoxic chemotherapy.
Here, we examined the effects of FA supplementation and defıciency on tumor
growth, metastasis and metabolism in obesity-responsive models of primary (M-
Wnt) and metastatic (metM-Wnt; MDA-MB-231) TNBC. FA supplementation
and defıciency signifıcantly enhanced primary tumor growth and invasiveness in
lean mice, while no difference in tumor size was detected in obese groups. FA sup-
plementation reduced while defıciency increased survival and reduced lung tumor
metastasis incidence in lean, but not obese mice. Liver and tumor metabolomic
profıling revealed thatmodulationofdietaryFAcausedsystemicand tumor-specifıc
metabolic reprogramming, altering pathways involved in fatty acid, purine, amino
acid, glutathione and energy metabolism. Short term in vitro FA withdrawal re-
sulted in reducedproliferation,migration and invasionandenergyproduction in all
cell lines, as well as signifıcant changes in gene expression profıle, particularly of
many metabolic pathways. In contrast, chronic in vitro FA depletion resulted in
heightenedoxidative stress, autophagyandapoptosis inmetastaticTNBCcells,with
nonmetastatic TNBC cells being able to adapt to and withstand the nutrient stress
via thepentosephosphatepathwayandglutathione redoxsignaling.Taken together,
these results suggest that modulation of dietary folic acid in lean (but not obese)
individuals causes systemic and tumor-specifıc metabolic reprogramming, which
may confer a growth advantage in nonmetastatic cells and from which metastatic
TNBC cells cannot recover. Moreover, obesity and FA excess cause similar meta-
bolic and procancer effects and in combination, are not synergistic.
#248 Eicosapentaenoic acid attenuates obesity-related hepatocellular car-
cinogenesis. Akane Inoue-Yamauchi, Hiroko Itagaki, Hideaki Oda. Tokyo
Women’s Medical University, Tokyo, Japan.
The population of obesity caused by excess energy intake and insuffıcient
physical activity is increasing worldwide. Excess accumulation of body fat is a
risk of health, indeed obesity is associated with the pathogenesis of various
disease including type II diabetes, cardiovascular disease and cancer. Among
various kinds of cancer, the risk of hepatocellular carcinoma (HCC) is strongly
influenced by obesity. Studies using diet-induced obesity mouse models show
that obesity enhances tumor development inducing chronic inflammation in
liver. In fact, obesity failed to promote HCC formation in the absence of inflam-
matory cytokines IL-6 and TNF-. Eicosapentaenoic acid (EPA), an omega-3
polysaturated fatty acid, has been shown its anti-inflammatory properties and
could be therapeutically useful to ameliorate inflammatory diseases. However,
little is known about the effects of EPAon liver cancer which is linked to obesity-
related inflammation. Therefore, we tested the effects of EPA on obesity-in-
duced inflammatory response and following tumor development. We used the
hepatic procarcinogen dietylnitrosamine (DEN) to induce HCC formation in
mice. Since high-fat diet (HFD) can induce obesity and signifıcantly enhance
HCC formation in DEN-injected mice, this model is useful to assess tumor
promotion on obesity. Using this model, we examined therapeutic potential of
EPA in obesity-related cancer. As a result, we found that tumor growth in mice
fed HFD supplemented with EPA was reduced compared to HFD-fed mice,
indicating that EPA attenuates obesity-related hepatocarcinogenesis. Interest-
ingly, EPA had no obvious effects on obesity-induced inflammation, instead,
inhibited tumor growth by suppression of the protumorigenic transcription
factor Stat3 signaling. These data suggest translational implications for the treat-
ment of obesity-related HCC.
#249 Dietary supplementation with methylseleninic acid reduces male
mammary tumorigenesis in MMTV-PyMT mice. Sneha Sundaram. Grand
Forks Human Nutrition Research Center, ARS, USDA, Grand Forks, ND.
Male breast cancer makes up approximately 1% of all breast cancers and less
than 1% of all cancers in men in the United States. However, it is an aggressive
disease with poor prognosis and the incidence of male breast cancer is on the
rise. The present study investigated the effects of dietary supplementation of
selenium on male breast carcinogenesis in MMTV-PyMT mice (FVB/N back-
ground). Three-week-oldmalemice were weaned onto the AIN93G diet with or
without supplementation of selenium in the form of methylseleninic acid (2.5
mg Se/kg). Mice were euthanized 10 weeks after the fırst palpable mammary
tumor was detected. There were no differences in food intake and body weight
between the groups. The median latency (the age at which the fırst palpable
tumor was detected) was 14.1 and 13.9 weeks and the incidence of palpable
mammary tumor was 71% and 70% for the control and the selenium group,
respectively. Selenium supplementation compared to the control diet reduced
mammary tumor progression by 258% and tumor weight by 84%, respectively.
Tumor progression was defıned as the change in tumor volume from detection
of the fırst palpablemammary tumor to termination 10weeks later. Incidence of
lungmetastasiswas 74%and 50% in control and seleniumgroup, respectively. In
mice bearing lung metastases, selenium supplementation signifıcantly reduced
the number ofmetastases by 83% compared to the control group. In conclusion,
dietary supplementation with selenium in the form of methylseleninic acid re-
duces male breast carcinogenesis and its metastasis in mice. It indicates that
selenium may be useful in male breast cancer prevention.
#250 Methionine restriction increases macrophage tumoricidal activity
and signifıcantly inhibits prostate cancer growth. Ashley R. Orillion,1
Sreenivasulu Chintala,1 Remi Adelaiye-Ogala,1 Li Shen,2 Nur Damayanti,1 May
Elbanna,1 Sreevani Arisa,1 Bennett Elzey,3 Chinghai Kao,1 Luigi Fontana,4 Ro-
berto Pili1. 1IndianaUniv.-PurdueUniv. Indianapolis, Indianapolis, IN; 2Roswell
Park Cancer Institute, Buffalo, NY; 3Purdue University, Lafayette, IN; 4Washing-
ton University, St. Louis, MO.
Background:Ourpreviouswork showeda signifıcant reductionof tumorgrowth,
macrophage infıltration, circulating IGF-1, andmTOR activation with low protein
diet in a patient derived xenograft model of prostate cancer. The evolutionarily
conserved, nutrient sensing, mTOR pathway plays a central role in both develop-
ment of advanced stage prostate cancer and immune responsiveness. This study
presents novel data on the impact of dietary proteinmodifıcation on the function of
the host immune system in response to prostate cancer and immunotherapy.
Methods:Our In vitro studies utilized bonemarrowor tumor derived (RP-B6Myc)
macrophages. In vivo studies utilized the recently characterized RP-B6Mycmodel.
Micewere fed ad libitum control ormethionine restricted diets for fourweeks prior
to S.C. implantation with 1mm2 tumor pieces. Treatment of survivin peptide
vaccine (1mg/ml S.C. 1 X week) and anti-PD-1 (20mg/kg I.P. 2 X week) began at
50mm2 tumor size. Tumor volumes were blindly recorded 2 X week. End point
analyses include: tumor weight, flow cytometric analysis, proteomic profıler analy-
ses, andmicrobiomeanalyses fromeachdiet and treatmentgroup.Results:Weshow
here that while methionine restriction (MR) has little impact on our RP-B6 Myc
prostate cancer cell line, it does yield a signifıcant alteration in both the polarization
and function of M1 and M2 macrophages. In the in vitro MR conditions, we ob-
served signifıcantly enhanced polarization of M1macrophages and reduced polar-
ization ofM2macrophages. Functional analysis revealed increased tumoricidal ac-
tivity of bothM1, ‘antitumor’, andM2, ‘pro-tumor,’ macrophages suggesting a flip
in M2 function from tumor-promoting to tumoricidal. Further analysis of the re-
leased cytokines in MRmedia conditions yielded signifıcant increase of antitumor
cytokines & chemokines, such as IL-12, IL-27, CXCL9, CXCL10, CXCL11, CCL2,
CCL4, and TNF-alpha, a double-edged sword which in our system correlates with
decreased cancer cell viability upon co-culture with amino acid restricted M1 and
M2 macrophages. Our preliminary results show dietary MR yielding a signifıcant
inhibition of prostate cancer growth in the RP-B6-Myc model and our ongoing
study with survivin peptide vaccine and anti-PD-1 immunotherapies will be avail-
able to present in the conference. Conclusions: Our data suggest that restricting
methionine is suffıcient to alter both the polarization and tumoricidal function of
macrophages. Our preliminarily results show that restricted dietary methionine is
able to inhibit prostate cancer growth,modify the host immune response and better
inhibitprostate cancergrowthaloneor incombinationwith immunotherapy.These
results provide a strong basis to consider diet restriction as a means to limit cancer
growth targeting tumor immune system and potentially to enhance cancer patient
responses to immunotherapy.
#252 Resveratrol and pterostibene selectively chemosensitize Burkitt’s
lymphoma cells to 5-Fluorouracil. Connor J. Peck, Michelle H. Townsend,
Kim L. O’Neill. Brigham Young University, Provo, UT.
In the current study, we assess the chemosensitization activity of the naturally
occurring polyphenols resveratrol (RES) and pterostilbene (PTER) to 5-Fluo-
rouracil (5-FU) in Burkitt’s B-cell lymphoma. RES is a stilbenoid compound
found in a variety of fruits, plants, and nuts. In addition to antioxidant and
anti-aging properties, RES has been shown to exhibit signifıcant anti-tumor
activity against a variety of malignancies. Since the compound is typically pro-
tective of normal cells, its anti-cancer activity makes it a promising candidate as
both a chemopreventative nutritional supplement and a chemotherapeutic
agent. PTER, an analog of RES, has likewise shown anti-cancer activity. Its ther-
apeutic potential, however, is much less understood. Recent studies have inves-
tigated the use of these and other natural compounds in adjuvant chemotherapy
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strategies, many of which continue to produce underwhelming rates of re-
sponse. Here, we investigate the chemosensitization capacity of both RES and
PTER to 5-FU, a commonly used drug in chemotherapy, in healthy lymphocytes
and in Burkitt’s B-cell lymphoma (Raji) cells. MTS assays are used to measure
the viability of malignant and normal lymphocytes after 5-FU treatment with or
without co-incubation of RES, PTER, or RES/PTER combinations.We fınd that
Raji co-incubation with physiologically relevant concentrations (10uM) of
either RES or PTER signifıcantly increases 5-FU toxicity in Raji cells, with data
suggesting PTER to be slightly more effective than RES. Interestingly, RES/
PTER combinatorial treatments further increase chemosensitization, an impor-
tant fınding considering the typically low bioavailability of each individual com-
pound in vivo. Together, these data support the potential use of RES as a
chemosensitizing adjuvant and provide new evidence that its analog, PTER, also
possesses signifıcant chemosensitization capacity. Furthermore, our studies
suggest that low physiological concentrations of PTER and RES may be still be
suffıcient to induce signifıcant anti-cancer effects.
#253 Mammary tumorigenesis causes bone loss and dietary selenium sup-
plementation does not affect such bone loss inmaleMMTV-PyMTmice. Lin
Yan. USDA-ARS, Grand Forks, ND.
Cancer progression is accompanied by wasting that eventually results in ca-
chexia characterized by signifıcant weight loss and multi-organ functional fail-
ures. Limited clinical trials indicate that bone is adversely affected by cancer-
associated wasting. To determine the effects of breast cancer on skeletal health,
we performed micro-computed tomographic analysis of femurs and vertebrae
collected froma recently completed study showing that dietary supplementation
with selenium (methylseleninic acid, 2.5 mg Se/kg) reduced male mammary
tumorigenesis in MMTV-PyMT mice. Compared to age-matched non-tumor-
bearing mice (MMTV-PyMT negative), the presence of mammary tumors sig-
nifıcantly reduced bone volume fraction, trabecular thickness and bonemineral
density and increased the structure model index (an indicator of the plate- and
rod-like geometry of trabecular structure) in femoral trabecular bone. Mam-
mary tumor development did not affect vertebral trabeculae nor femoral and
vertebral cortical bone, except it signifıcantly reduced cortical bone thickness of
vertebrae. There were no differences in aforementionedmeasurements between
groups with or without selenium supplementation. In conclusion, mammary
tumorigenesis causes bone loss and dietary selenium supplementation at 2.5 mg
Se/kg, which is antitumorigenic, does not affect mammary tumor-associated
bone loss in this male MMTV-PyMT breast cancer model.
#254 The potential ofLactobacillusprobiotic treatments in colorectal can-
cer (CRC). Imen Kahouli,1 Meenakshi Malhotra,2 Susan Westfall,1 Moulay
Alaoui-Jamali,1 Satya Prakash1. 1McGill University, Montreal, Quebec, Canada;
2Standford University, Palo Alto, CA.
Colorectal cancer (CRC) is the third leading cause of death worldwide. It
is known to be a type of cancer that is preventable by changes in diet and
lifestyle. Mounting evidence are supporting the role of gut microbiome in
the etiology of CRC and emphasize on the potential of probiotics as biothera-
peutics in the prevention and management of CRC. Lactobacillus probiotic
bacteria were suggested to balance pathogenic and oncogenic microbial
community in the colon and produce anti-tumorigenic and anti-inflamma-
tory effects in healthy individuals at risk and CRC patients. There is a need,
however, for studies that focus on identifying potent probiotic strains with
activity against CRC and inhibit cancer growth. This report discusses and
present fındings about the formulation of novel probiotic Lactobacillus bio-
therapeutic for CRC based on anti-CRC proliferative effect, immune mod-
ulation and metabolic activity, in vitro and in vivo, using a genetically-
induced animal CRC model. Results and metabolomic analysis
demonstrated the potential acrion of probiotic treatment to change host and
gut microbiome co-metabolic profıles, produce local and systemic anti-in-
flammatory effects, inhibit cancer-causing events, and improve overall gut
health.
#255 Dietary amphiphilic polyphenols modulate the biophysical proper-
ties of plasma membrane organization and membrane-dependent macropi-
nocytosis. Michael L. Salinas, Natividad R. Fuentes, Rola Barhoumi, Robert S.
Chapkin. Texas A&M University, College Station, TX.
Ras-driven cancers exhibit a distinct high metabolic demand necessary for
biosynthetic growth/proliferation, in some cases resulting in over stimula-
tion of macropinocytosis, a process intended for nutrient acquisition. A
hallmark of Ras-driven macropinocytosis is plasma membrane ruffling re-
sulting in invaginations and the formation of macropinosomes, extracellular
nutrient-packed vesicles distinct from other endocytic processes due to their
size, independence of vesicle-coating proteins, and are the result of rapid
polymerization and branching of cytoskeletal actin fılaments. These cyto-
skeletal manipulations are driven by spatial/temporal regulators down-
stream of Ras along with lipid rafts and their components. Drugs and other
extrinsic factors, e.g., polyunsaturated fatty acids, have been shown to bio-
physically modulate these lipid domains.We hypothesize that unique dietary
polyphenolic amphiphilic molecules [1] modulate plasma membrane fluid-
ity, [2] disrupt macropinocytosis, and [3] suppress macropinocytosis-de-
pendent proliferation. Young adult mouse colonocyte (YAMC) cells, ex-
pressing an HRas mutation, were treated with 1, 10, and 100 M ()-
catechin or procyanidin B2 for 30 min. For macropinocytosis assessment,
cells were stimulated with 25 ng/mL epidermal growth factor (EGF) for 5
min following a 30-minute pretreatment. Membrane order was measured in
whole cells and giant plasma membrane vesicles (GPMV) utilizing a lipid-
packing detection dye, Di-4-ANEPPDHQ, and assayed using a combination
of fluorescence image-based flow cytometry (Amnis FlowSight) and confocal
microscopy. In addition, macropinocytosis was determined by uptake of
fluorescently labeled 70 kDa dextran (FITC-dextran). The uptake was visu-
alized by fluorescence image-based flow cytometry. In the GPMV model,
()-catechin increased membrane fluidity, and procyanidin B2 decreased
membrane fluidity in a dose-dependent manner. In contrast, in the whole
cell model, interaction of ()-catechin and procyanidin B2 with the plasma
membrane resulted in an increase in membrane fluidity in a dose-dependent
manner. Interestingly, plasma membrane fluidifıcation in the whole cell
model was associated with a signifıcant 27-67% inhibition of macropinocy-
tosis. These observations indicate that dietary amphiphilic molecules
(DAMs) modulate plasma membrane organization, which is linked to mac-
ropinocytosis, an essential fuel-obtaining process. Establishing a role for
DAMs in membrane-dependent oncogenesis is noteworthy because these
molecules are innocuous and found in high abundance in a variety of fruits,
vegetables, and walnuts. This work was support by NIH grant R35CA197707.
#256 Delta tocopherol inhibits urothelial tumorigenesis in the UPII mu-
tant Ha-ras transgenic mouse model and induces apoptosis via activation of
the ATF4/CHOP-DR5 pathway. Christopher A. Blair,1 Maggie Wu,1 Tim
Huynh,1 Hanze Hu,1 Arman Walia,1 Chung S. Yang,2 Xiaolin Zi1. 1UC Irvine,
Irvine, CA; 2Rutgers University, Piscataway, NJ.
Epidemiological studies have reported that Vitamin E intake was inversely
related to the risk of multiple cancers including human urinary bladder
cancer. Tocopherols (T) are the major forms of vitamin E in the U.S. diet,
exist as -T, -T, -T and -T. Compared to -T, the anti-cancer effect of
other Ts and their mechanisms of action remain largely unknown. We have
shown that -T is the most effective one among the Ts in reducing the
viabilities of bladder cancer cell lines with IC50s of under 10 M, whereas
there is no or minimal effect of -T at a concentration of up to 50 M on the
viability of bladder cancer cell lines. -T treatment of bladder cancer cell
lines, RT4 andUMUC-3, resulted in apoptosis via marked induction of death
receptor-5 (DR5) expression and then activation of caspase 3, 8, and 9 lead-
ing to PARP cleavage and apoptotic morphology. siRNA knockdown of DR5
expression signifıcantly attenuated the apoptotic effects of -T in bladder
cancer cells. Consistent with the above results, -T treatment signifıcantly
upregulated the expression of ER stress sensors PERK and IRE1, as well as
downstream components GRP78, ATF4, and CHOP. These results suggested
that -T can induce endoplasmic reticulum stress and the Unfolded Protein
Response, triggering its apoptotic effect. Furthermore, homozygous male
UPII mutant Ha-ras transgenic mice that mimic the development and pro-
gression of human urothelial cell carcinoma (UCC) with H-ras activation
were fed with vehicle control diet (n20) or diet supplemented with -T
(0.2% in diet) for 150 days (n18). The -T diet signifıcantly decreased the
mean bladder weights (serves as a surrogate of tumor weight) of survived
Ha-ras mutant mice by 56% (control vs -T, 0.259 0.015 gram vs. 0.114
0.012 gram, P0.0001) with no signifıcant difference in overall body mass
and no detectable indication of toxicity. Our results suggest that -T is a
potent anti-cancer agent and deserves further investigation in preventing the
recurrence and progression of non-muscle-invasive UCC.
#256A Validation of methyl donors between two foodmeasurements in a
colorectal cancer study. Lufei Young, S. Pamela K. Shiao. Augusta University,
Augusta, GA.
Purpose: The purpose of this study was to validate methyl donor intakes
between 30-day food frequency questionnaire (FFQ) and 24-hour food record
(FR) in a colorectal cancer study. Background: Dietary methyl donors play piv-
otal roles in cancer prevention by promoting adequate metabolism and DNA
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methylation. The FFQ and 24-hour FR are themost commonly usedmethods to
assess adequate nutrient intake, including methyl donors and other vital micro-
nutrients that are essential to promotemetabolism andmethylation.While FFQ
provides best estimates in dietary intakes, a 24-hour food record is less time
consuming for subject burden.Methods: A total of 134 participants’ dietary data
were collected using FFQ and 24-hour FR by using US Department of Agricul-
ture computerized programs. Bland and Altman methodology was used to val-
idate the bias and agreement between these twomeasurements. Results: Overall,
the 24-hourmeasurements presented underestimated values across all nutrients
in comparison to FFQ measurements. Using a 10% criterion on the differences
between the twomeasurements, the percentage bias for 24-hour FR compared to
30-day FFQ was acceptable for most B vitamins, including B1 (-6.90.15), B2
(-8.66 0.12), B3 (-9.25 0.12), B6 (-5.02, 0.14), and B9 (folate: -7.900.24).
However, the bias was greater for protein based methyl donors, including B12
(-17.23 0.14), choline (-13.38 0.11), Glycine (-17.53 0.10), andMethionine
(-18.88 0.09). The correlations between the two measurements on all methyl
donors ranged from 0.92 to 0.99. The precisions for all measurements based on
the standard error (SE) were less than and within 0.03% (0.007 -0.021%). And,
the agreements between the two measurements were less than and within 10%
for Glycine and methionine (8.96 - 9.58%), based on the standard deviation
(SD); however, greater than 10% for other protein based methyl donors includ-
ing choline and other B vitamins (10.5-24.11%). Conclusion: Proper dietary
intakes of methyl donors are vital for cancer prevention. These fındings point
out the importance of further validation and use ofmore accurate foodmeasure-
ment to monitor dietary intake, and the interpretation of nutrient reports with
caution.
EPIDEMIOLOGY: Descriptive Epidemiology Including Trends in
Incidence and Prognosis
#257 Estrogen receptor positive and negative breast cancer secular trends in
Ireland (2004-2013). Maeve Mullooly,1 Jeanne Murphy,1 Gretchen L. Gierach,1
BrittnyDavis,1 PaulWalsh,2 SandraDeady,2Thomas I. Barron,3MarkE. Sherman,4
Philip S. Rosenberg,1 William F. Anderson1. 1National Cancer Institute, Bethesda,
MD; 2NationalCancerRegistry Ireland, Ireland; 3JohnsHopkinsBloomberg School of
Public Health, Baltimore, MD; 4Mayo Clinic, Jacksonville, FL.
Background: Estrogen receptor (ER) status in breast cancer is strongly asso-
ciated with etiologic factors, prognosis and treatment response. Data suggest
that population-based incidence rates of ER-positive (ER) tumors are increas-
ing and ER-negative (ER-) cancers have fallen over time in the United States
(US), Denmark and Scotland.Whether these trends are consistent in other pop-
ulations with different etiologic exposures and across ER/HER2 subtypes is
unknown.We, therefore, analyzed breast cancer secular trends in Ireland by ER
expression; and for the fırst time, by joint expression of ER/HER2, a well-
established clinical marker of uncertain etiological signifıcance. Methods: This
study included invasive breast cancers (n24,845; 2004-2013) among women
aged 20-84 years within the population-based National Cancer Registry of Ire-
land (97% coverage). The general population at risk (n10,401,986) was ob-
tained from the Irish Central Statistics Offıce. Using a validated approach to
account for missing ER/HER2-status, we assessed ER and ER/HER2 sec-
ular trends with age-standardized incidence rates (ASR) and estimated annual
percentage change (EAPC) with 95% confıdence intervals (95%CI). Results:
Over the 10-year follow-up period, 19,264 ER and 4,161 ER- breast cancers
were diagnosed (1,420 were ER-unknown). ASRs increased signifıcantly for
ER (EAPC: 2.20%/year (95%CI: 0.97, 3.45%/year)) and decreased signifıcantly
for ER- cancers (EAPC: -3.43%/year (95%CI: -5.05, -1.78%/year)). The ER-spe-
cifıc trends were qualitatively similar among three age groups (50, 50-64 and
	65 years).With further stratifıcation byHER2 expression, ER/HER2- can-
cers rose (EAPC: 2.87%/year (95%CI: 1.33, 4.44%/year)), ER/HER2 cancers
were statistically flat, while ER-/HER cancers signifıcantly declined. Conclu-
sion: Secular trends for ER cancers in Ireland were similar to those previously
observed in the US and Denmark. Further, trends for ER/HER2 followed those
for ER, although rates were constant for ER/HER tumors. The divergence of
cancer incidence patterns by ER among independent populations over time
could reflect comparable changes in risk factor exposures with dual or opposite
effects for risk of ER and ER- cancers (e.g., obesity, age at fırst birth/parity).
Additionally, although HER2 is a well-established clinical predictive and prog-
nostic marker for breast cancer outcome, it did not appear to substantively
impact breast cancer incidence trends.
#258 The changes of esophagealmalignant tumors by histopathology over
40 years (1975-2014) at a single institute in northern China. Xue Ke Zhao,1
Hai Jun Yang,2 Zong Min Fan,1 Ji Lin Li,3 Li Min He,4 Yun Zhou,5 Liu Qin
Yang,6 Ying Fa Zhou,7 Sa Tang,6 Yang Yang,1 Lei Ma,4 Wei Li Han,8 Li Dong
Wang1. 1The First Affıliated Hospital of Zhengzhou University, Zhengzhou, Chi-
na; 2Anyang TumorHospital, China; 3Linzhou Esophageal Cancer Hospital, Chi-
na; 4The First People’s Hospital of Nanyang, China; 5Henan Provincial People’s
Hospital, Zhengzhou, China; 6Central Hospital of Xinxiang, China; 7The Second
Affıliated Hospital of Zhengzhou University, Zhengzhou, China; 8Xijing Hospital
of the Fourth Military Medical University, China.
It has been well recognized that esophageal squamous cell carcinoma (ESCC)
is themajor histopathological type of esophageal cancer in China. However, it is
not even clear howmany histopathological types of esophagealmalignant tumor
(EMT) exist and if the histopathological patterns have changed over the past
decades in China. The present study was thus undertaken to characterize the
histopathological patterns over 40 years at a single institute in northern China,
the high incidence area for esophageal cancer. All the patient information was
from esophageal cancer database inHenan Key Laboratory for Esophageal Can-
cer Research of the First Affıliated Hospital, Zhengzhou University in Henan,
China (1973-2015). A total of 66,216 patients with MET and detailed histo-
pathological records were enrolled in this study, including 39,873 males with a
mean age of 606 and 26,343 females with amean age of 606 from 1975-2014.
All the patients were classifıed into four period groups based on the diagnosed
time, group I (1975-1984, 4,331/6.5 %), group II (1985-1994, 14,577/22%),
group III (1995-2004, 20,781/31.4%) and group IV (2005-2014, 26,527/40.1%).
The results demonstrated 12 different histopathological types of EMT. Themost
common type was ESCC (64,800, 97.4%), followed by esophageal adenocarci-
noma (EAC, 1268, 1.9%), esophageal small cell carcinoma (201, 0.3%), esopha-
geal adenosquamous carcinomas (EASC, 119, 0.18 %), esophageal spindle cell
carcinoma (76, 0.11%), esophageal undifferentiated carcinoma (37, 0.06%),
esophageal malignant melanoma (5, 0.008%), esophageal stromal tumor (3,
0.005%), esophageal clear cell carcinoma (2, 0.003%), esophageal malignant
schwannoma (1, 0.002%), esophageal lymphatic tumor (1, 0.002%) and esoph-
ageal smooth muscle cell sarcoma (1, 0.002%). Time trending analysis showed
that, over the past 40 years, ESCC was relatively stable (98.9%, 98.0%, 97.0%,
97.1%, respectively). However, EAC (0.97%, 1.66%, 2.30%, 1.87%, respectively),
small cell carcinoma (0.02%, 0.17%, 0.28%, 0.43%, respectively) and spindle cell
carcinoma (0.02%, 0.01%, 0.10%, 0.22%, respectively) increased apparently. The
present study indicates that ESCC remains the major histopathological type for
Chinese esophageal cancer. Interestingly, esophageal adenocarcinoma, small
cell carcinoma and spindle cell carcinoma seem to increasing over the past de-
cades. The improved molecular diagnostic biomarkers and the changes of life-
style including the diet patterns resulted from recent economic development in
China, may contribute to the changes of esophageal histopathological types.
[Supported by Joint Funds of the National Nature Science Foundation of Chian
(U1301227), National Nature Science Foundation of China (81472323), and
Correspondence to: Li Dong Wang, Email: ldwang2007@126.com]
#259 A case series of vitreoretinal lymphoma inNewYork City with expo-
sure to Chernobyl nuclear disaster decades earlier. Sanford Kempin,1 Paul
Finger,2 Robert Gale,3 John Rescigno,1 Jeffrey Rubin,2 Walter Choi,1 Rebecca
Fisher,4 Alexander Aizman,2 Ilona Genis,5 Roxana Moslehi* (Corresponding
Author)6. 1Mount Sinai / Beth Israel Comprehensive Cancer Center, New York
City, NY; 2New York Eye and Ear Infırmary of Mount Sinai, New York City, NY;
3Imperial College London, London, NY; 4Mount Sinai / St. Luke’s Roosevelt Hos-
pital, New York City, NY; 5Maimonides Medical Center, Brooklyn, NY; 6Univer-
sity at Albany, State University of New York, Albany, NY.
Background: Vitreoretinal lymphoma (VRL) is an unusual presentation of
primary central nervous system lymphoma and a subcategory of intraocular
lymphoma (IOL). The etiology and epidemiology of this rare malignancy is
unknown.Methods:Wediagnosed 10 subjectswithVRL in our clinical practices
in New York City (NYC) during 2010-2013. Upon systematic collection of de-
mographic and exposure history, 6 patients reported residence in regions prox-
imal to the Chernobyl nuclear disaster (4 Ukraine, 1 Poland, 1 Moldova). We
studied clinical variables including presentation, diagnostic parameters, thera-
pies and survival of this case series. To provide context, we examined popula-
tion-based incidence data from the Surveillance, Epidemiology and End Results
(SEER) program to determine age-adjusted incidence rates of IOL (there is no
unique code for VRL) per 100,000 person-years in theUnited States (US) during
1992-2013. New York State (NYS) rates are not reported to SEER and were
examined separately using NYS Cancer Registry (NYSCR). Incidence trends
using 10-year intervals (1992-2002 and 2003-2013) were also analyzed. Results:
All six subjects (5 females) were diagnosed with diffuse large B-cell lymphoma
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with bilateral presentation. Diagnosis in all cases was made by immunohisto-
chemical analysis on tumor specimen obtained by vitreous fıne needle aspira-
tion, vitreous biopsy or stereotactic brain biopsy.Median age at diagnosis was 76
years (range, 62-84 years). Median interval from Chernobyl accident (1986) to
diagnosis was 26 years (range, 24-27 years). We identifıed no other common
exposure or environmental risk factor. There were 68 cases of primary IOL
during 1992-2013 in the 13 SEER areas. IOL rates per 100,000 person-years for
both sexes were highest among Asian/Pacifıc Islanders (0.010 for males and
0.014 for females) followed bywhites (0.009 formales and 0.008 for females) and
(based on small numbers) by blacks. Analysis of incidence trends showed an
increase in rates among Asian/Pacifıc Islander females from 0.005 in 1992-2002
to 0.018 in 2003-2013 and amongmales from0.006 to 0.013. Rates amongwhites
increased for both genders. Analysis ofNYSCRdata revealed 44 cases of primary
IOL. IOL rates per 100,000 person-years for both genders were highest among
whites (0.010 for males and 0.012 for females) followed by Asian/Pacifıc Island-
ers (0.007 formales and females). Analysis of trends revealed increase in rates for
both genders and racial groups. Conclusions:Our analyses highlight the rarity of
VRL and reveal an increase in incidence, particularly among Asian/Pacifıc Is-
landers where IOL rates tripled within two decades. Based on incidence rates, 8
cases of IOL (with a subset being VRL) are expected in 4 years in NYS. Our
observation of 10 cases of VRL in 4 years in our practices in NYC is unantici-
pated. The sole common environmental factor we identifıed was residence in
regions proximal to the Chernobyl nuclear disaster.
#260 Incidence rates and outcomes of fallopian tube carcinomas: Data
from the North American Association of Central Cancer Registries.Mark E.
Sherman,1 Sally B. Coburn,2 Hannah Yang,2 William Anderson,2 Philip Rosen-
berg,2 Gretchen Gierach,2 Nicolas Wentzensen,2 Kathy Cronin,2 Britton Trab-
ert2. 1Mayo Clinic, Jacksonville, FL; 2National Cancer Institute, Bethesda, MD.
Background: Serous tubal intraepithelial carcinoma (STIC) is hypothesized to
give rise to many cancers that have been historically classifıed as ovarian prima-
ries. Although STIC is gaining status as a diagnostic entity, similar appearing
lesions would likely have been reported as fallopian tubal carcinoma in-situ
(FT-CIS) in the past. Accordingly to characterize patterns of reporting and be-
havior for tubal cancers, we analyzed population-based data for incidence rate
trends, co-occurrence with cancer at other sites and survival of FT-CIS and
invasive fallopian tube carcinoma (FT-Inv). Methods: We analyzed data for
FT-CIS and FT-Inv included within 33 registries using the Cancer Incidence in
North America Deluxe Analytical Files provided by the North American Asso-
ciation of Central Cancer Registries (1995-2012). Primary site of invasive carci-
nomas were defıned according to the International Classifıcation of Diseases for
Oncology (3rd edition) topography codes (ovarian (C56.9), fallopian tube
(C57.0), and primary peritoneal cancers (C48.1-.2, 48.8)). We excluded cancers
with non-epithelial histology. Total counts, incidence rates per 1 million ad-
justed to the 2000 standard US population and age-standardized stage-specifıc
survival were computed. Temporal incidence rate patterns were analyzed by
joinpoint regressionwith estimates of annual percentage change (APC). Results:
Cases in which the fırst cancer diagnosis was FT-CIS, included 98 FT-CIS alone;
27 FT-CIS followed by another cancer diagnosis within 1 year and 172 cases in
which FT-CIS was diagnosed concurrently with another cancer as compared
with 5513 invasive tubal carcinomas over the same period. The incidence rate of
FT-CIS was stable from 1995-2002, then signifıcantly increased from 2002-2012
[APC (95% CI)  16.2% (10.9-21.7)]. Rates of early stage high-grade serous
FT-Inv increased signifıcantly from 2002-2012 [10.4% (6.1-14.9)] and rates of
late stage high-grade serous FT-Inv rose sharply from 2002-2012 [20.0% (17.5-
22.6)]. Five-year age-standardized survival for women with FT-CIS only was
75.6% overall, reflecting 89.1% survival for women less than 50 years and 70.9%
for women 50 years or older; survival for high-grade early stage serous FT-Inv
was 77.8%. Conclusions: Diagnoses of FT-CIS and FT-Inv have increased dra-
matically, likely reflecting changes in diagnostic pathology practice. Developing
standardized reporting for FT-CIS (and in the future, STIC) when present with
concurrent invasive cancer are needed, given that this occurs often. Based on
limited data, 5-year survival for FT-CIS and early stage FT-Inv are similar, but
future studies to evaluate data for STIC will be required, which will likely be
achievable only through national registries that are large enough to capture
suffıcient cases.
#261 Pancreatic cancer incidence trends and recentpatterns overall andby
histologic type among US men and women by racial/ethnic group: evidence
fromtheSurveillance, Epidemiology, andEndResults (SEER)program.Van-
essa L. Gordon-Dseagu,1 Susan Devesa,1 Mike Goggins,2 Rachael Stolzenberg-
Solomon1. 1NCI, Rockville, MD; 2Johns Hopkins University, MD.
Introduction: Pancreatic cancer incidence has been rising. We examined in-
cidence patterns by sex, race, age, and histologic subtype. Methods: We used
data from the Surveillance, Epidemiology and End Results (SEER) registries (9,
13 and 18) to calculate counts, age-adjusted rates (2000 US Standard Popula-
tion), annual percent changes (APCs) and incidence rate ratios (IRRs) for all
pancreatic cancers and main histologic subgroups. Results: Pancreatic cancer
incidence rates declined among males between 1974 and 1991, and increased in
the 1992-2013 period among white Hispanics and non-Hispanics (APC 0.73
and 0.84, respectively). Among females, incidence rates also rose signifıcantly
during 1992-2013 among white non-Hispanics, white Hispanics, and Asians
(APC 0.81, 0.56, and 1.23, respectively). In contrast, rates among black males
and females changed little. Within age groups, rates signifıcantly increased
amongmales who were white non-Hispanic age	55 years and white Hispanics
in the 55-74 age group.Amongblackmales, rates declined in the 45-54 age group
at a statistically signifıcant pace. Pancreatic cancer incidence rates for females
rose among white non-Hispanics in all age groups85 years (range: 0.47-4.01),
among Asians of ages 55-84, and white Hispanics in the 55-64 age-group. Most
pancreatic cancers were specifıed as adenocarcinoma, not otherwise specifıed
(NOS) or ductal adenocarcinoma. Rates increased among all racial/ethnic
groups for adenocarcinoma, NOS and ductal adenocarcinoma while those for
cystic mucinous ductal adenocarcinoma and poorly specifıed type decreased.
The incidence rates of non-secretory pancreatic endocrine cancer rose6% per
year amongwhite non-Hispanics andAsian/Pacifıc Islanders. Overall incidence
rates were signifıcantly higher amongmales than females (M/F IRR1.28). The
IRRwas1.00 at all ages35, but rates among femaleswere signifıcantly higher
at younger ages (IRR0.81). TheM/F IRRs were elevated for acinar cell adeno-
carcinoma (2.85), non-secretory endocrine cancers (1.47) and ductal cystic or
mucinous adenocarcinomas (1.11), while for solid pseudopapillary adenocarci-
noma therewas a signifıcant female excess (0.22). Conclusion: Pancreatic cancer
incidence rates vary within demographic groups and histologic subtypes.
#262 Analysis of demographics, survival and patterns of care of pediatric
glioblastoma using National Cancer Database. Jigisha Thakkar, Meng Liu,
Emily Van Meter Dressler, John L. Villano. University of Kentucky, Lexington,
KY.
Background: We analyzed the largest clinical database in the United States,
theNational CancerDatabase (NCDB), comprising over 70%of cases diagnosed
and/or treated at commission on Cancer approved institutions. We analyzed
current hospital-based epidemiologic frequency, survival and patterns of care of
pediatric glioblastoma (GBM). Methods: Cases included patients 0-19 years be-
tween 1998-2011. Inclusion criteria for histology codes included for GBM 9440,
9441 and 9442 (9440 (GBM), 9441(Giant Cell) and 9442 (Sarcomatas compo-
nent) and tumor sites (C70.0-C72.9, C75.1-C75.3) related to the brain: brain
stem, cerebellum, cerebrum, ventricle and brain not otherwise specifıed (NOS).
Kaplan-Meier survival estimates were calculated for each demographic criteria
and treatment plan and Cox proportional hazards models were employed to
assess the risk of mortality. Demographic variables analyzed were age, gender,
race, Hispanic origin, income, education, region and insurance status. Compar-
isons were made among histologic subtypes and primary site. Results: 1173
patients with GBM from age 0 to 19 years were identifıed from 1998 to 2011 in
the United States, of which 21.5%, 24.5% and 54.0% were in age group 0-5, 6-10
and 11-19 years old. The largest group (48%) received advanced care including a
combination of radiation (XRT), chemotherapy and surgery. On the other
hand, the no treatment group was the smallest comprising of 4% cases. 14%
received surgery only, 8% received a combination of XRT and surgery and
9% received a combination of XRT and chemotherapy. Patients that received
combination of XRT, chemotherapy and surgery had signifıcantly improved
survival when compared to those without any treatment (p  0.0048). Pa-
tients that received surgery or chemotherapy had signifıcantly improved
survival as compared to patients that did not receive the above treatments
(p 0.0027). Conclusion: We report an extensive demographic and survival
analysis of pediatric GBM. Observed difference likely reflect biology across
age, gender, race and origin groups. Our analysis demonstrates concern in
the delivery of optimal care to a large percentage of pediatric patients. These
treatments include surgery and chemotherapy that have demonstrated sur-
vival benefıts. Adverse effects of chemotherapy and XRT can limit the ap-
propriate administration of treatment.
#263 Epidemiology of primary lung cancer and its trend northeast of Iran
during 1985-2012. Maryam Salehi,1 Pardis Shojaee,1 Soodabeh Shahidsales,1
Seyed Amir Aledavood,1 Mehdi Seilaniantoosi,1 Golboo Goshayeshi,1 Fahimeh
Khoshroo2. 1MashhadUniversity ofMedical Sciences,Mashhad, IslamicRepublic
of Iran; 2Razavi Hospital, Mashhad, Islamic Republic of Iran.
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Introduction: In this study we investigated epidemiology and trends of pri-
mary lung cancers in northeast of Iran during 1985-2012. Methods: In this
cross-sectional study records of primary lung cancers from 1985 to 2012 in
Mashhad, northeast of Iran, were investigated. Data were obtained from the
referral oncologic hospital and private radiation oncology clinic. To study
trends, the duration of study was categorized into three periods: 1985-1995,
1995-2005 and 2005-2012. Statistically signifıcant level was considered 0.05.
Results: Of 939 cases with mean age of 60.57 (12.31) years, 660(70.3%) were
male. Male to female ratio was 2.36. Mean age was 61.4712.01 years for males
and 58.4512.75 for females (p0.001). Mean age at diagnosis and rate of
smokers was unchanged in three intervals (table 1).
Time period 1985-1995 1995-2005 2005-20012 P value
Age(years) 60.6711.74 60.5712.24 60.4912.94 0.98
Gender:
Male
female
167 (78.4)
46 (21.6)
330 (68.6)
151 (31.4)
163 (66.5)
82 (33.5
0.01
Male to female ratio 3.63 2.18 1.99
Smoking history:
Yes
no
69 (76.7)
21(23.3)
211 (67.8)
100 (32.2)
100 (65)
54 (35)
0.15
Smokers:
Male
Female
59 (85.5)
10 (14.5)
159 (75.4)
52 (24.6)
74 (74)
26 (26)
0.16
Male-to-female
ratio of smokers
5.9 3.06 2.84
Squamous cell carcinoma with relative frequency of 44.2% was the most fre-
quent pathologic subtype in total population followed by adenocarcinoma
(18.2%), Small Cell Lung cancer (16.8%), large Cell carcinoma (1.3%) and other
subtypes (19.5%). Relative frequency of pathologic subtypes had signifıcant
changes in three intervals (p 0.001). Relative frequency of adenocarcinoma
and large cell carcinoma were increasing while it was decreasing for SCC and
SCLCs during three recent decades. There was statistically signifıcant difference
in mean age at diagnosis (p0.001), rate of smokers (p0.001) and male to
female ratio (p0.01) between four leading pathologic subtypes. Mean age at
diagnosis (55.9212.90 years), male to female ratio (1.69), and rate of smokers
(46.8%) were lowest in adenocarcinomas. Conclusion: Similar to universal pic-
ture, adenocarcinoma showed increasing rates during recent three decades with
higher prevalence among younger aged patients, women and nonsmokers.
These trends are indicative of changes in exposures and smoking habits and
reveal the need for regional studies in this context.
#264 Time trending for the ratio of rural and urban patients with esoph-
ageal squamous cell carcinoma in a single institute in northern China over
the past 30 years. Shou Jia Hu,1 Hai Jun Yang,2 Neng ChaoWang,2 XiuMin Li,3
Shuang Lv,4QiDeBao,5WenBinYue,6HuiMeng,1Dan FengDu,1 XueMin Li,7
Fu You Zhou,2 Jian Li,8 Li DongWang1. 1Henan Key Laboratory for Esophageal
Cancer Research, the First Affıliated Hospital of Zhengzhou University, Zheng-
zhou City, China; 2Anyang Tumor Hospital, Anyang, China; 3Cancer Research
Center, Xinxiang Medical University, Xinxiang City, China; 4School of Basic
Medical Sciences, Xinxiang Medical University, Xinxiang City, China; 5Anyang
District Hospital, Anyang, China; 6Puyang City Oil Field General Hospital, Puy-
ang, China; 7Cixian Hospital, Cixian, Handan, China; 8Henan Provincial Peo-
ple’s Hospital, Zhengzhou City, China.
Esophageal squamous cell carcinoma (ESCC) has been well characterized as a
major histological type in China and occurred predominantly in the mountain
rural regionwith poor economics.Nutritional defıciencies have been recognized
as major risk for esophageal carcinogenesis in these rural regions. In the past
decades, the rural economic status in China has improved apparently. However,
the time trending for ESCC in rural regions has not been characterized. The
present study was thus undertaken to determine the time trending for the ratio
of rural and urban patients with ESCC in a single institute in northern China
over the past 30 years (1985-2014). All the 66,515 ESCC patients in this study
were derived from the esophageal and gastric cardia carcinoma databases of 500
thousands patients (1973-2015) established by Henan Key Laboratory for
Esophageal Cancer Research of the First Affıliated Hospital of Zhengzhou Uni-
versity in Henan, China. Of the ESCC patients, 50,313 patients had been re-
corded with detailed address. Based on the diagnosed time, these patients were
divided into three groups with periods of 1985-1994, 1995-2004 and 2005-2014.
The rural and urban regions were recognized based on the government admin-
istrative division of China. The rural region in China refers to the farmer village
with hundreds to thousands population. Chi-Square test was used to analyze the
different distributions of ESCC patients with a p-value of less than 0.05 as sig-
nifıcant. The results demonstrated that more than 84% of the ESCC patients
occurred in rural regions with an overall ratio of 5:1 for rural and urban regions
(p 0.0001). Moreover, over the past 30 years with three periods, the ratios for
rural and urban regions were 5.4:1, 5.5:1 and 5.4:1, respectively. The present
results also demonstrated that over the past 30 years with three periods, ESCC
occurred predominantly in males with ratios for male and female as 1.5:1, 1.4:1
and 1.5:1, respectively in rural regions and 1.6:1, 1.6:1 and 1.8:1, respectively in
urban regions. Interestingly, the mean age both in male and female in urban
regions was slightly older than that in rural regions (urban vs. rural: 60.79.86
vs. 59.89.38 inmale and 62.29.57 vs. 60.69.47 in female, respectively). The
present study demonstrated that ESCC remains the major healthy burden in
rural regions in China. Considering the relative low socioeconomic status in
China, the prevention and control of ESCC should be enhanced in rural regions
in terms of more control programs, medical and education resources. [Sup-
ported by National High-Tech Research and Development Program of China
(SQ2015AA0202183), Project for Characteristic and Advantage Discipline of
Henan Province (20151208)
#265 Global transition in cardia and non-cardia gastric cancer incidence,
1998-2007. Aesun Shin,1 Dalis Seungeun Kim,2 Hyungtaek Woo1. 1Seoul Na-
tional Univ. College of Medicine, Seoul, Republic of Korea; 2USFMorsani College
of Medicine, Seoul, FL.
Gastric cardia and non-cardia cancer differs in their descriptive patterns and
risk factors. The objective of this study was to determine the global trends in
incidence of cardiac and non-cardiac gastric cancer. Ninety two high quality
registries with the proportion of Not Otherwise Specifıed (NOS) gastric cancer
(ICD-10 code C16.8-9) below 50% and the total number of gastric cancer cases
above 300 were selected from 225 registries in Cancer Incidence of Five Conti-
nent (CI5) volume 9 and 262 registries fromCI5 volume 10. TheNOS cases were
re-distributed to cardia and non-cardia according to the registry-specifıc pro-
portion. Age-standardized incidence rates (ASRs) per 100,000 population and
incidence rate ratios (IRR) from 1998-2002 to 2003-2007 were calculated. Non-
cardia cancer incidence was signifıcantly decreased in 5 out of 10 Asian regis-
tries, 17 out of 18 European registries, 27 out of 56 North American registries,
and all 5 Oceanian registries in men. Only two registries in Asia showed a sig-
nifıcant increase in non-cardia cancer incidence. In contrast, cardia cancer sig-
nifıcantly increased in one Asian registry, two European registries, and two
NorthAmerican registries. Signifıcant decrease in cardia cancer was observed in
3 Asian registries, 6 European registries, 11 North American registries, and 3
Oceanian registries inmen. In women, six registries (1 Asian, 2 European, and 3
North American) showed signifıcant increase in non-cardia cancer, whereas
registries 25 (3 Asian, 13 European, 8NorthAmerican, and 1Oceanian) showed
signifıcant decrease in non-cardia cancer incidence. Cardia cancer in women
increased in 16 registries (2 Asian and 14 North American) and decreased in 9
registries (1 Asian, 5 European, and 3 North American). In conclusion, non-
cardia cancer incidence decreased in most registries, whereas decrease in cardia
cancer is more prominent in men but not in women.
#266 Trends in age distribution of breast cancer, in north east of Iran:
Report of six thousand patients over 30 years. Maryam Salehi, Soodabeh
Shahidsales, Mehdi Seilaniantousi, Gholamhosein Noferesti, Mahta Salehi,
Amirhossein mohammadian bajgiran.Mashhad University of Medical Sciences,
Mashhad, Islamic Republic of Iran.
Aim:This studywas aimed to evaluate the age at the timeof diagnosis of breast
cancer and it’s probably changes in distribution among patients during 30 years.
Methods: This cross- sectional studywas conducted inMashhad, Iran from1981
until 2011. The data of patientswere obtained fromcase records. The duration of
study was categorized into three periods: 1981-1990, 1991-2000 and 2001-2011.
SPSS software was used for analyses. The difference was considered signifıcant if
P0.05. Result: From 6274 breast cancer cases, 174 patients were male (2.5%)
and the others 6100 were female (97.5%).Mean age at the time of diagnosis was
49.07  12.07 years (male: 56.48  14.14, female: 48.8 12.01). There was
signifıcant difference in age by sex (p0.001). Table 1 presents the mean age of
studied patients in each 10 years of study. ANOVA test showed that there was
not statistical signifıcant difference (P value 0.1).
Decades Frequency Mean age SD Youngest Oldest
1981-1990 467 47.97 12.043 18 88
2000-1991 1771 49.03 12.338 20 99
2001-2011 3949 49.22 11.954 20 98
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The most histologic type of breast cancer was ductal carcinoma 65.6% others
percent in order were: NOS 19.6%, lobular 3.7%, medullary 2.8%, adenocarci-
noma 2.8%, tubular and papillary 0.2% and 5.1% of other types. Relative fre-
quency of histologic types had signifıcant differences among 3 intervals (p
0.001), the frequency of adenocarcinomawas decreasing but ductal carcinoma
was increasing during 3 decades. Mean age of ductal carcinoma, lobular, med-
ullary and adenocarcinoma was 48.911.8, 50.612.4, 46.411.4, 50.211.9,
respectively. Mean age had signifıcant differences among these main histologic
types (p 0.002).98% of patients were urban and 2% were rural. Mean age of
these 2 groups has statistical signifıcant difference (P  0.001) and is 10 years
older in rural patients. Frequency of people who live in urban area was increased
signifıcantly (p00.1) during these 30 years compare with rural area. Conclu-
sion: breast cancer occurs in Iranian women at least one decade younger than
women in developed countries we found no change in mean age of diagnosis of
breast cancer during these 30 years from 1981 to 2011.
#267 GeoSurveillance of invasive cervical cancer incidence by counties in
the state of Maryland. Sally Peprah, Frank Curriero, Amber D’Souza. Johns
Hopkins University, Baltimore, MD.
Background: Invasive cervical cancer (ICC) is a highly preventable cancer
whose rates have dramatically declined over the past few decades. In spite of the
progress made, new ICC cases are recorded annually in Maryland and in other
parts of theUnited Sates.We assessed if ICC incidence varied signifıcantly 2005-
2012 and across countieswithin the state ofMaryland.Methods:Using a discrete
Poissonmodel we evaluated signifıcant space-time clusters of both high and low
ICC incidence rates over a retrospective 10-year period. All analyses were con-
ducted at the county level, using 2-year aggregates of time. We adjusted for age,
percentminority, cervical cancer screening rates,median income, obesity aswell
as smoking rates within each county in our fınal cluster detection analysis. Re-
sults: ICC was 13.1 per 100,000 female population and did vary by county and
over the 10-year period assessed. We identifıed fıve signifıcant space-time clus-
ters of ICC incidence, three of which were clusters of higher than expected rates.
Themost likely cluster identifıed was a cluster of low ICC incidence [aRR0.08,
p-value0.01] observed for the period 2009-2012 and comprised six high-in-
come suburban counties. The other cluster of low rate [aRR0.41,
p-value0.01], which was a secondary cluster, was observed for the same time
period, 2009-2012 in three high to moderate-income suburban counties. There
were two clusters of high ICC incidence, observed for recent time periods. One
cluster [aRR1.74, p-value0.01], which was made up of a single moderate to
low-income urban county was identifıed for the period 2009-2012. The other
cluster of elevated rates [aRR2.47, p-value0.01] was identifıed in a suburban
moderate-income county for the period 2011-2012. Additionally, for the period
2005-2008 we identifıed a historical cluster of elevated incidence [aRR2.53,
p-value0.01]. Conclusion: Overtime some counties in Maryland have experi-
enced signifıcantly lower rates of disease than expected. However there aremore
recent clusters of higher than expected rates of disease, which are not explained
by the county level variables adjusted for. These clusters of high rates need to be
further examined and addressed.
#268 Tracking HPV vaccination of young boys: is parental recall as de-
pendable as physician records. Nosayaba Osazuwa-Peters,1 Betelihem B.
Tobo,2MeeraMuthukrishnan,2 Daphne Lew,2 Betty Chen,3 Eric Adjei Boakye2.
1St. Louis Univ. Cancer Center, Saint Louis, MO; 2St. Louis Univ., Saint Louis,
MO; 3St. Louis Univ. School of Medicine, Saint Louis, MO.
Introduction: HPV vaccine is administered to young boys and girls aged
11-12 years inmultiple doses rather than single dose. The interval between doses
is critical as well as completion of the dose series. Moreover, the administration
of the HPV vaccine in 2 doses is a recent change from the 3 doses previously
recommended for children aged 11-12 years. Therefore, it is critical that HPV
vaccination uptake records are accurately kept as interventions are developed to
increase HPV vaccine uptake. Previous studies on the validity of parental re-
ported HPV vaccine uptake have focused only on adolescent girls. This is be-
cause the HPV vaccine recommendation for boys came 5 years after that for
girls. Currently, vaccination rates among boys lag behind those for girls across
the United States. This study compared the validity of parent- vs. provider-
reported HPV vaccine initiation and completion rates among a national sample
of adolescent boys in theUnited States.Methods:We analyzed the 2014National
Immunization Survey-Teen data for adolescent boys only (n 9,493), and ob-
tained information on the records of HPV vaccine uptake [initiation (	1 dose)
and completion (	 3 doses)] for both parents (parental recall) and provider
reports (electronicmedical records).We compared the validity of parent- versus
provider-reported HPV vaccination by computing validity measures [sensitiv-
ity, specifıcity, positive predictive value (PPV), negative predictive value (NPV),
and kappa]. Results: Rates reported by provider and parental recall were similar
for HPV vaccine initiation (41.8% vs. 42.7%, respectively), and completion
(19.6% vs. 21.9%, respectively). Compared to provider report, parent-reported
HPV vaccine initiation had a sensitivity of 83.0%, a specifıcity of 88.8%, a PPVof
84.1%, a NPV of 87.9%, and a kappa coeffıcient of 0.72. Compared to provider
report, parent-reported HPV vaccine completion had a sensitivity of 68.6%, a
specifıcity of 92.9%, a PPV of 72.9%, a NPV of 91.4%, and a kappa coeffıcient of
0.63. Conclusions: Both parent- and provider-reported HPV vaccine initiation
and completion rates were comparable; however, parental recall of HPV vaccine
completion among boys was less sensitive. Ongoing surveillance of HPV vacci-
nation rates among boys is important as more studies are designed to improve
HPV vaccine uptake and understand parental HPV vaccine barriers. In this
regard, parental recall may be used as an effective alternative in assessing HPV
vaccine uptake in the United States.
#269 The descriptive epidemiology of gynecologic cancers: an interna-
tional comparison of incidence, survival and mortality. Zoubida Zaidi,
Mokhtar Hamdi Cherif. University Hospital of Setif, Setif, Algeria.
Introduction: Gynecologic Cancers are the most common cancers in women,
in 2012, Cervical Cancer (CC) is ranking as the fourthwith an estimated 528.000
new cases and Ovarian Cancer (OC) is the seventh most common for females
with nearly 239.000 new cases worldwide. Aim: this communication presents
the latest international descriptive epidemiological data for invasive GC, includ-
ing incidence, survival andmortality in theworldwide.Methods: -The incidence
and mortality statistics presented for GC worldwide were taken from the Inter-
national Agency for Research on Cancer IARC: * the Cancer Incidence in fıve
Continents Vol X and * GLOBOCAN database, 2012. -The data of cancer sur-
vival are taken from: * Cancer survival in fıve continents, a worldwide popula-
tion-based study (CONCORD) version 2, 1995-2009. Estimated fıve-year net
survival, adjusted for background mortality by single year of age, sex, calendar
year in each country. Results: CC is the most common cancer among women in
45 countries mainly in sub-Saharan Africa, part of Asia and some countries in
Central and SouthAmerica, the lowest incidence rates inwestern Europe, North
America, Australia and the easternMediterranean. Almost 55% of all new cases
of OC occurred in countries very high level of human development mainly
northern Europe and America and Oceanic, Africa presents the lowest inci-
dence. -Data for CC are available for 602 225 women, CC survival was 50% or
higher in most countries, except for Libya (Benghazi, 39%) and India (Karuna-
gappally, 46%). During 2005-09, age-standardised 5-year net survival was 70%
or higher in Iceland, Mauritius, Norway, South Korea, and Taiwan, for Qatar is
also above 70% (based on only 16 cases and is not age-standardised). -Data for
ovarian cancer are available for 779 302 women, during 2005-09, age-standard-
ised 5-year net survival was 40% or higher in Ecuador, the USA, nine countries
in Asia, and eight countries in Europe. Survival in other countries was mostly in
the range 30-40%, except for Libya (22%). Conclusions: The evolution of cancers
in women shows a consistent and very striking pattern during the epidemiolog-
ical transition with rapid declines in the incidence of cervical cancer. Compari-
son of population-based cancer survival CONCORD study 2 showed very wide
variations in survival from gynecologic cancer worldwide.
#270 Trends in colorectal cancer survival in ArabWorld, 1990-2009. Zou-
bida Zaidi, Mokhtar Hamdi Cherif. University Hospital of Setif, Setif, Algeria.
Introduction: Cancer survival is a key measure of the effectiveness of
health-care systems. Globally, colon and rectum cancer ranked third for
cancer incidence and fourth for cancer death in 2013. For developed coun-
tries it ranked second for incidence and mortality, and in developing coun-
tries it ranked fourth for both incidence and mortality. An increasing trend
in incidence is reported from various registries of Arab world, Kuwait and
Saudi Arabia present the highest incidences worldwide. Objective: To de-
scribe the trends of the survival of colorectal cancer patients diagnosed in
Arab countries. Material and Methods: This report is a summary of the two
survival fıgures of CONCORD study 1 (1990-1994) and CONCORD study 2
(1995-2009). Individual colon and rectum tumour records were submitted
by 06 population-based cancer registries in Arab countries (Jordan, Saoudi
Arabia, Qatar, Algeria, Lybia and Tunisia) for 9050 patients (15-99 years)
diagnosed during 1990-2009 and followed up to 31 December 2009 . Esti-
mated fıve-year net survival, adjusted for background mortality by single
year of age, sex, calendar year in each country. Results : For patients diag-
nosed during the period 2005-2009, the age-standardized fıve-years net sur-
vivals were respectively higher 68,2% for colon cancer and 77,8% for rectum
cancer in Qatar and the lowest rate for rectal cancer 21% in Jordan, between
1995-1999 and 2005-2009, Survival increased in Algeria, but this trend is less
reliable Conclusions: Comparison of population-based cancer survival
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CONCORD study showed very wide variations in survival from colorectal
cancer in Arab world. Cancer survival research is being used to formulate
cancer control and the need to implement effective strategies of primary
prevention.
#271 Clinicopathological andmolecular study of breast cancer inAlgerian
women from the Aures region: Data from the anti-cancer center of Batna.
Farid Cherbal,1 Chiraz Mehemmai,2 Khadidja Gassi,1 Abdelmoumene Gue-
dioura,3 Yosr Hamdi,2 Wassila Benbrahim,4 Rabah Bakour1. 1Unit of Genetics,
LMCB, Faculty of Biological Sciences, USTHB, Algiers, Algeria; 2Laboratoire de
Génomique Biomédicale et Oncogénétique (LR11 IPT 05) Institut Pasteur de Tu-
nis, Tunis, Tunisia; 3LOBEM, Faculty of Biological Sciences, USTHB, Algiers,
Algeria; 4Anti-cancer center of Batna, Batna, Algeria.
Background: Breast cancer is currently the leading cause of cancer morbidity
and mortality among Algerian women. The aim of this study was to analyze the
different proportions and distribution of breast cancer molecular subtypes and
to determine their associations with some clinical and pathological characteris-
tics in women from the Aures region. We also screened for the prevalence of
BRCA1 germlinemutations inHBOC patients. Materials andMethods: Clinical
and tumor characteristics data of 1144 breast cancer patients were collected
from cancer registry of anticancer center of Batna. Breast cancers were
diagnosed between 2011 and 2015. Breast cancer subtypes defınitions were as
follow:Luminal A (ER and/or PR,HER2-), Luminal B (ER and/or
PR,HER2),TNBC (ER-, PR-,HER2-) and HER2 (ER-, PR-, HER2). We
also compared patients with TNBC and those with other breast cancer subtypes.
Differences between the two groups with regard to clinicopathologic parame-
ters: age at diagnosis, menopausal status, histological type, histological grade,
breast feeding and oral contraception were examined using Chi square test.
BRCA1 was screened by PCR direct sequencing in 22 HBOC patients including
all exons where a mutation was previously found in Algerian population (exons
3, 5, 11). Results: The mean age at diagnosis cancer was 48.5 years. Proportions
of luminal A, luminal B, TNBC and HER2 breast cancer subtypes were
47.29%, 21.94%, 21.24% and 9.52%, respectively. We noted a signifıcant differ-
ence in the distribution of age at diagnosis among the four cancer subtypes (P
0.04). Invasive Ductal Carcinoma was the most common histological type in all
breast cancer subtypes. Tumors with histological grade 2 and 3 were more com-
mon in patients for the four breast cancer subtypes. Our data showed signifıcant
differences between premenopausal and postmenopausal status (P0.00) and
tumor histological grade (P0.03) between TNBC and non TNBCpatients. The
proportion of premenopausal status was higher in TNBC and non TNBC.
Among tumor with histological grade III, TNBC accounted for 33.33% for all
TNBCpatients and nonTNBC accounted for 30.23% for all non TNBCpatients.
The three BRCA1 recurrent mutations c.83_84delTG, c.181TG and
c.798_799delTT have not been detected in our present study. Conclusion: We
report here for the fırst time, the distribution of molecular subtypes of breast
cancer and some clinical and pathological characteristics in a cohort of female
breast cancer patients from the Aures region. Interestingly, the proportion of
TNBC subtype in women found in our study is similar to African-American
breast cancer patients and higher than reported in white women in Europe and
America. Further studies are needed to determine the outcome of the different
breast cancer subtypes in the Aures region. Large studies of the screening of
BRCA1 and BRCA2 genes are on going for the implementation of the genetic
testing.
#272 Circadian disruption and cancer risk in the United States. Neil E.
Caporaso,1 FangyiGu,1 ShangdaXu,1 Susan S.Devesa,1 Fanni Zhang,2 Elizabeth
B. Klerman,3 Barry Graubard1. 1NCI-DCEG, Rockville, MD; 2IMS Corporation,
Rockville, MD; 3Harvard Medical School, Boston, MA.
Circadian disruption is a probable human carcinogen. Dawn and dusk times
occur latter in western compared to eastern regions of each time zone, produc-
ing discrepancies between individuals’ biological clock and social time which
may lead to circadian disruption and increased risk of cancer. We examined
associations between longitude distance from the time zone meridian and age-
standardized county-specifıc cancer incidence rates for total and 23 specifıc
cancers by gender. Fourmillionwhiteswere diagnosedwith cancer during 2000-
2012 in the Surveillance, Epidemiology and End Results Program in residents of
607 counties in 11 continental US states. The models were adjusted for latitude,
poverty, smoking, and state as well as rural/urban location, obesity, and His-
panic composition. The total cancer incidence rates for counties located in the
western regions of time zones were signifıcantly elevated for both men and
women after Bonferroni correction. The rate ratio (RR) per fıve degrees of lon-
gitude toward the west (corresponding to 20 minutes delay of sunrise) was 1.03
(95% confıdence intervals, CI, 1.02-1.04, p2.710-6) for men and 1.04 (95%
CI, 1.03-1.05, p3.8 10-10) for women. Chronic lymphocytic leukemia rates
for counties in the western portions of time zones were signifıcantly elevated for
both men (RR1.13, 95% CI1.08-1.20, p3.1 x10-6) and women (RR1.12,
95%CI1.05-1.19, p3.7 x10-4). Among men, western location within a time
zone was associated with elevated risk of prostate cancer (RR1.04, 95%
CI1.02-1.07, p4.8 x 10-4). Among women, western location within a time
zone was associated with an increase in breast cancer (RR1.04, 95% CI1.02-
1.06, p6.5 x 10-5) and corpus uteri cancer (RR1.10, 95% CI1.07-1.14,
p2.4 x 10-9 among others. The increased cancer risk with western residency
within a time zone is in accord with the circadian disruption hypothesis. Our
fındings suggest that circadian disruption is not a rare phenomenon affecting
only shift workers or international travelers but may be widespread in the gen-
eral population which has broader implications for public health than generally
appreciated.
#273 Risk of primary central nervous system lymphomas in solid organ
transplant recipients. Parag Mahale, Meredith S. Shiels, Eric A. Engels. Na-
tional Cancer Institute, Rockville, MD.
Background: The risk of primary central nervous system lymphoma (PCNSL)
is greatly increased inHIV-infected people. Case series have describedPCNSL in
immunosuppressed solid organ transplant (SOT) recipients (SOTRs). Herein,
we examine the incidence and risk factors for PCNSL in SOTRs. Methods: We
used data from the Transplant Cancer Match Study, which links the US trans-
plant registry with 17 cancer registries (1987 - 2014). PCNSL risk relative to the
general population was estimated as a standardized incidence ratio (SIR ob-
served/expected cases). Poisson regression was used to estimate adjusted inci-
dence rate ratios (aIRR) of PCNSL across subgroups of SOTRs. Logistic regres-
sion was used for case-case comparisons of PCNSL with other non-Hodgkin
lymphomas (NHL). Results:We included 288,637 SOTs. Therewere 173 PCNSL
cases (SIR 57.7; 95%CI 49.4-66.9) and 2,583 other NHLs (SIR 7.3; 95%CI 7.0-
7.6). Most PCNSL were diffuse large B-cell lymphomas (n118; 68.2%). Com-
pared to kidney SOTRs, PCNSL risk was lower in liver SOTRs (aIRR 0.5; 95%CI
0.3-0.9), not different in heart and/or lung SOTRs (aIRR 0.9; 95%CI 0.6-1.5) and
higher in other/multiple SOTRs (aIRR 2.4; 95%CI 1.5-3.8). Asians/Pacifıc Is-
landers had higher PCNSL risk than non-Hispanic whites (aIRR 2.0; 95%CI
1.2-3.3). People who received induction therapy with alemtuzumab (aIRR 2.8;
95%CI 1.5-5.5) or polyclonal antibodies (aIRR 1.9; 95%CI 1.3-2.8) had higher
PCNSL risk. SOTRs who were seronegative for Epstein-Barr virus (EBV) at
transplant had higher risk (aIRR 2.0; 95%CI 1.1-3.5) than seropositive SOTRs.
PCNSL risk was high in the fırst 1.5 years after SOT (0.5-1 year, aIRR 2.6; 1-1.5
years, aIRR 2.3; vs. 0-0.5 year) and progressively decreased over time
(ptrend0.0001). Risk did not differ according to the age at SOT, sex, or main-
tenance immunosuppressive regimen. Compared to other NHL, PCNSL cases
were more likely to be middle aged (18-64 years) at transplant (p0.009),
Asians/Pacifıc Islanders (p0.02), or have received induction therapy with
polyclonal antibodies (p0.002), and less likely to be liver or heart and/or lung
SOTRs (p0.02). EBV serostatus did not differ between PCNSL and other NHL
(p0.11). Conclusions: PCNSL risk is very elevated among SOTRs. Because
EBV-seronegative SOTRs are at risk of primary infection after SOT, these results
highlight the important contribution of EBV to PCNSL. Risk is highest within
1.5 years after transplant, in people who receive multiple non-thoracic organs,
and is associated with induction therapy with alemtuzumab or polyclonal anti-
bodies. Case-case differences with other NHLs suggest unique etiologic factors
leading to PCNSL.
#274 Early-onset colorectal cancer is distinct from traditional colorectal
cancer. Doron Betel, Heather Yeo, Rhonda Yantiss, Xi E. Zheng, Jonathan S.
Abelson, Manish A. Shah.Weill Cornell Medicine, New York, NY.
Background&Objective: Colorectal cancer (CRC) is the fourthmost commonly
diagnosed cancer worldwide, responsible for over 700,000 deaths annually. Al-
though CRC rates have declined 3.1%/year annually over the past decade, annual
incidence rates of CRC among patients between 20-49 years old have increased by
more than 1.4% per year over the same time period and these early-onset CRCs
(E-CRC) now comprise 10-18% of newly diagnosed cases. Our hypothesis is that
E-CRC represents a distinct subtype of CRC with unique drivers. To examine this,
we analyzed national data sources such as the SEER database, the Behavioral Risk
FactorSurveillanceSurvey (BRFSS), and theCancerGenomeAtlas (TCGA) tochar-
acterize the epidemiology and genetics differences between early onset CRC (E-
CRC) and typical CRC (T-CRC). Methods: The SEER database was analyzed to
characterize the clinical and pathological differences between E-CRC patients
(20-49 years) and T-CRC group ( 50 years). We compared rates of age-adjusted
CRCwith known lifestyle risk factors using population data from the BRFSS. Based
ondifferences in clinical presentation andanatomical locationwehypothesized that
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there are underlying molecular differences between E-CRCs and T-CRC that may
explain thesedifferences.To investigate thiswe analyzed theTCGACRCdataset for
genomicmarkers that can distinguish betweenE-CRCandT-CRC tumors. Results:
E-CRC incidence has risen at an annual rate of 1.4% per year from 2000-2011,
whereas T-CRC incidence has declined by 3.1%per year amongpatients 50 years or
olderduring the sameperiod.Relative toT-CRC,E-CRCratesare signifıcantlymore
prevalent in theBlackpopulation than theWhiteorHispanicpopulations.Anatom-
ical location of E-CRC is signifıcantly increased towards the distal colonwhen com-
pared to T-CRC locations suggesting a distinct etiology. Analysis of risk factors
confırmed that U.S counties with high rates of diabetes, obesity and smoking were
signifıcantly correlated with higher T-CRC rates. However, no such correlations
were observed for E-CRC rates. Analysis of the limited number of E-CRC in the
TCGA cohort identifıed a number of known oncogenes that are suggestive of dis-
tinctE-CRCtumorigenesis.Conclusions:Our results suggest thatE-CRCappears to
bedistinct fromT-CRC.YoungpatientswithCRCrepresentadistinctpatientgroup
withuniqueepidemiologyandmechanismsofdiseasedevelopment.The increase in
left sided colon and rectal cancers is consistentwith earlier reports and although the
underlying reasons areunknown, they are suggestiveofdifferences in tumorgenesis
and mutational characteristics. To follow up on this hypothesis we are performing
additional genetic and epigenetic characterization of E-CRC andmatching T-CRC
samples collected atWeill Cornell.
#275 The prevalence of endometrial cancer in women with postmenopausal
bleeding: a systematic review and meta-analysis. Megan A. Clarke,1 Beverly J.
Long,2 Arena Del MarMorillo,1 Jamie N. Bakkum-Gamez,2 NicolasWentzensen1.
1National Cancer Institute, Rockville, MD; 2Mayo Clinic, Rochester, MN.
Background: Endometrial cancer is highly curable when detected early, but clin-
ical symptoms are oftenmissed.Most cancers arise in womenwith abnormal post-
menopausalbleeding (PMB).However,PMBisnot specifıc for endometrial cancers.
In previous reports, the prevalence of endometrial cancer in womenwith PMBwas
reported to range from 3-25%. Because of the importance for guiding clinical man-
agement and endometrial cancer risk prediction, we conducted a systematic review
and meta-analysis to obtain precise prevalence estimates of endometrial cancer in
womenwithPMB.Methods:A systematic reviewandmeta-analysis summarizedall
peer-reviewed studies reporting endometrial cancer prevalence in women with
PMB, published before Sept. 1, 2016. We calculated a pooled prevalence estimate
and 95% confıdence interval (CI) using a random-effects model, and quantifıed
heterogeneity across studies using the I2 statistic. Subgroupmeta-analyseswere per-
formed to investigate sources of variability according to selection criteria for endo-
metrial thickness (ET) andhormone replacement therapy (HRT).We also stratifıed
by study location to determine whether prevalence estimates varied by country or
region if5 studies included per country. Results: 105 studies were included, con-
tributingdata for37,000womenwithPMBand3,028withcancer from34countries.
Overall, the pooled prevalence of endometrial cancer inwomenwith PMBwas 11%
(95%CI 10-12%), with I294.3%.Among studies that selectedwomenwith amin-
imum ET (	 4mm; n14), the pooled prevalence of endometrial cancer was 17%
(95% CI 14-20%) compared with studies that did not select for ET (10%, 95% CI
9-11%). In studies that excludedwomen usingHRT (n34), the pooled prevalence
of endometrial cancerwas15%(95%CI12-17%)comparedwith studies thatdidnot
exclude women using HRT (9%, 95% CI 8-10%). Stratifıcation by study location
revealed variation in prevalence estimates. For example, in the United States (n9)
and theUnitedKingdom(n16),prevalenceof endometrial cancerwas4%(95%CI
2-7%) and 5% (95%CI 4-6%), respectively, whereas in Italy (n14), the prevalence
was 11% (95% 8-14%). Regional differences were also observed, ranging from 8%
(95%CI 3-14%) in South Central Asia (n5) to 18% (95%CI 12-23%) in Southern
Europe (n11). Conclusions: The overall prevalence of endometrial cancer among
unselected women with PMB is approximately 10% with substantial heterogeneity
across studies.Marked geographic differences in the prevalence endometrial cancer
were observed. Factors related to selection for ET and/or HRT use may partially
contribute to this variability. Risk prediction models depend on precise prevalence
estimates for accurate prediction and utility in clinicalmanagement.More research
is needed to test the applicability of endometrial cancer risk prediction models in
high-risk subgroups and in study populations from diverse geographic regions.
#276 Retrospective analysis of epidemiological variants ofmalignancies in
Sokoto, NorthwesternNigeria. SaddikuM. Sahabi, Kabiru Abdullahi.Usmanu
Danfodiyo University Teaching Hospital, Sokoto, Nigeria.
Background: The burden of cancer in Nigeria is increasing. Information
on incidence, prevalence, pattern, and high risk factors are essential for
evaluation and cancer control. This report is a follow up from earlier previ-
ous report published in 2005 on cancers seen in Usmanu Danfodiyo Univer-
sity Teaching Hospital (UDUTH) Sokoto. Objectives: The aim of this study
is to determine epidemiological variants of all malignancies seen from 1
January 2006 to 31 December 2015. Materials and Methods: This is a retro-
spective review of all malignancies seen at the UsmanuDanfodiyo University
Teaching Hospital in Sokoto during the period 2006 to 2016. There was no
restriction on gender or age groups. Mean, frequencies, percentages, and
independent sample t-test were performed using SPSS version 21.0 for Win-
dows. Signifıcant level set at p 0.05. Results: A total of 3933 cancer patients
were seen during the ten-year period. There were more female malignancies
(n2260, 57.5%) compared to male malignancies (n1673, 42.5%). The
overall mean age (years) was 44.28, median age was 45.0, modal age was 50,
and SD was 18.69; the age range was 1 to 99 years. Males (mean age 45.77,
median age inmale 50.0, modal age 60, and SD 21.03) were signifıcantly older
than females (mean age 43.18, median age 45.0, modal age 50, and SD 16.67).
The adult malignancies account for 90.9% (n3575) and childhood malig-
nancies account for 9.1% (n358). Overall, the ten most commonmalignan-
cies were: breast 763 (19.4%), cervix 312 (7.9%), prostate 267 (6.8%), lymph
node 248 (6.3%), skin 225 (5.7%), bladder 191 (4.9%), rectum 114 (2.9%),
ovary 110 (2.8%), eye 97 (2.5%), soft tissue 95 (2.4%). In males, the ten most
frequent malignancies were: prostate 267 (16.00%), bladder 160 (9.60%),
skin 138 (8.20%), nasophraynx 87 (5.2%), lymph node 85 (5.10%), rectum 61
(3.60%), eye 55 (3.30%), salivary gland 38 (2.3%), larynx 37 (2.20%), and anal
37 (2.20%). In females, the ten most common malignancies were breast 731
(731%), cervix 302 (13.40%), lymph node 163 (7.20%), ovary 110 (4.90%),
skin 87 (3.80%) endometrial 61 (2.70%), rectum 53 (2.30%), nasophraynx 45
(2.0%), soft tissue 43 (1.90%), and eye 42 (1.90%). Conclusion: Our study
concludes that malignancies of the breast, cervix, and prostate are the three
most common in our environment. These malignancies tend to present at
younger age (less than 50 years of age) compared to other developing coun-
tries. Therefore, public education and well developed screening programs
are urgently needed to overcome this burden.
#277 A retrospective analysis of pediatric and adolescent oncology pa-
tients and congenital anomalies. Jeannette R.Wong-Siegel, Kimberly Johnson,
Katie Gettinger, ToddDruley.WashingtonUniversity in St. Louis, St. Louis,MO.
Introduction: Congenital anomalies (CAs) are a leading cause of infant death
and contribute to long-term disability and repeated hospitalizations. Many ep-
idemiology studies have suggested that children with CAs have an increased
cancer risk compared to those without CAs. This retrospective case series fur-
ther investigates associations between CAs and cancer in a large academic cen-
ter’s pediatric and adolescent oncology patient population. Methods: Electronic
medical records of 1,435 oncology patients diagnosed from birth to 23 years of
age at St. Louis Children’s Hospital from January 1, 2004 - December 31, 2014
were reviewed. CA information was extracted and verifıed with ICD-9 codes
when available. Patients followed for 1 year at SLCH (n193), and those
diagnosed with a chromosomal anomaly or known cancer predisposition
syndrome (n113) were excluded from the analysis. Bivariate analyses com-
pared demographic and other characteristics between patients with and
without a CAwith signifıcant differences determined by chi-square tests. We
calculated age-adjusted standardized rate ratios (SRRs) to evaluate whether
the observed number of CAs among specifıc cancer types (benign, bone,
CNS, epithelial, leukemia, lymphoma, germ cell, and soft tissue tumors)
varied from the expected number using the CA rates from the entire cohort
as the reference. Differences in survival time distributions in cancer cases
with CAs versus those without CAs were evaluated with the log-rank test.
Results: Of 1,129 SLCH pediatric cancer patients, 156 (14%) patients were
identifıed with a CA. Overall there was an increased proportion of patients
with a CNS tumor who also had a CA compared to those without a CA
(p0.005). Neurological anomalies were specifıcally found to be in excess in
CNS tumor cases versus the overall population of pediatric cancer patients
(SRR 1.42 95% CI 1.02-1.92 p0.038). There were no signifıcant differ-
ences by age at primary tumor diagnosis, but patients with a CNS tumor and
CA were diagnosed an average of 1.5 years earlier (7.7 vs. 9.2 years, p0.075)
compared to those without a CA. The rate of CAs did not vary signifıcantly
by sex, but a signifıcant excess of males with a neurological anomaly was
observed among all patients diagnosed5 years of age (M/F ratio2.55 95%
CI 1.15-5.56 p0.02). Finally, survival between those with and without a CA
was not signifıcantly different (p0.24). Conclusions: This study provides
additional insight into the association between specifıc types of CAs and
cancer development. Our results suggest children with neurological anom-
alies are more likely to develop CNS cancers and may be more likely to
develop cancer at an earlier age, particularly inmales. Our study supports the
need for additional longitudinal surveillance and research that may improve
outcomes as well as translational research to investigate any associated de-
velopmental mechanisms that may underlie tumor predisposition.
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#278 The Sister Study:Morbid conditions at enrollment in a breast cancer
cohort.M. Elizabeth Hodgson,1 Whitney D. Arroyave,1 Sandra Deming-Halv-
erson,1AimeeA.D’Aloisio,1Dale P. Sandler2. 1Social and Scientifıc Systems, Inc.,
Durham,NC; 2Epidemiology Branch, National Institute of EnvironmentalHealth
Sciences, Research Triangle Park, NC.
The Sister Study is a prospective cohort of 50,884 unaffected sisters of women
diagnosed with breast cancer; given that participants were at increased risk of
developing breast cancer, we wanted to investigate the prevalence of other con-
ditions at enrollment. We compared demographic, lifestyle, and selected self-
reported morbid conditions between Sister Study participants and women in
NHANES, a representative sample of the US population, using age-adjusted
prevalence, overall and by race/ethnicity. Demographically, women in the Sister
Study are more likely than women in NHANES to be non-Hispanic white, well-
educated and to have had higher household incomes. They were also somewhat
more likely to have been post-menopausal at enrollment and have ever used
hormonal birth control or hormone replacement therapy. The Sister Study has a
lower prevalence of current smokers and a higher prevalence of alcohol con-
sumption than among women in NHANES. BMI was lower in the Sister Study.
Sister Study participants generally had a lower age-adjusted prevalence of self-
reported chronic morbid conditions at baseline than did women in NHANES.
For cardio- and cerebrovascular conditions, for example, heart attack and stroke
were lower in the Sister Study (0.9% vs. 2.4%; 0.6% vs. 3.1%, respectively) as were
self-reported hypertension and high cholesterol (22.8% vs. 34.5%; 28.6% vs.
40.7%). This pattern was similar across all race/ethnicity groups with the excep-
tion of angina, which was similar to NHANES overall (2.1% vs. 2.2%). Preva-
lence of diabetes was lower in the Sister Study (4.9% vs. 9.5%) as were cancers
other than breast or non-melanoma skin (4.4% vs. 8.1%) and rheumatoid arthri-
tis (3.3% vs. 6.2%). Again, this was similar across race/ethnicity groups. A few
conditions had a higher prevalence in the Sister Study: uterine fıbroids, endo-
metriosis, osteoporosis, and allergies (22.0% vs. 13.7%; 12.2% vs. 7.7%; 17.0% vs.
8.6%; and 54.1% vs. 44.2%). Thyroid disease (excluding cancer), asthma,
Crohn’s disease, and ulcerative colitis were similar in the Sister Study and
NHANES (19.4% vs. 18.5%; 14.6% vs. 15.0%; 0.5% vs. 0.4%; and 1.4% vs. 1.3%).
Two or more morbid conditions were reported by just over one third of Sister
Study participants. After restriction to college graduates, differences between
the Sister study andNHANESwere no longer apparent. The few exceptionswere
differences that would be expected, given Sister Study participants’ ability to
participate in a long-term study, healthy behaviors and access to care: lower
prevalence of hypertension and high cholesterol; higher prevalence of self-re-
ported fıbroids, osteoporosis, and allergies. Although Sister Study participants
do differ in a few respects from the NHANES population, the cohort is a unique
and well characterized resource, well-suited for research on the incidence of
number of chronic conditions, in addition to breast cancer.
#279 Clinicopathologic features and management of bronchopulmonary
and pleural malignancies in Ile Ife, Nigeria. Olanisun O. Adewole. Obafemi
Awolowo University/Teaching Hospital, Ile Ife, Nigeria.
Introduction. Lung cancer is the most common cause of cancer related death
worldwide with increasing incidence in developing countries, Nigeria inclusive.
The aim of this study is to evaluate the clinical patterns, diagnostic procedures
andmanagement of bronchopulmonary cancer (BPC) and pleural cancer (PLC)
in Ile Ife, Nigeria. Method. All cases of bronchopulmonary and pleural cancer
seen over an eighteen year period (1990-2015) at OAUTHC, Ile Ife, Nigeria, a
tertiary center were reviewed. Cases were identifıed from the admission and
discharge fıles on the wards and were retrieved fro the main medical record
library. All retrieved cases were analyzed and presented, using a descriptive
statistics. Results. Thirty seven cases of BPC and PLC were identifıed of which
twenty two case fıles were fully retrievable, and these are presented. There were
twenty one cases of BPC and two PLC. The male to female ratio of BPC was 2:1
while it is 1:1 for PLC. The mean age of patients was 51 years (range 48-85yrs)
and 45(30-66yrs) for BPC and PLC respectively. Cough andweight loss were the
most common symptoms among al the patients.45% had chest pain while 15%
had hemoptysis. Two patients had progressive dyspnea. Smoking and indoor/
outdoor pollution were identifıed as the risk factors in 20% each of the patients
with BPC .10%of patients with BPChad a past history of TB about 10 years prior
to the presentation.One of the cases of PLChad some exposure to asbestos in his
work as a carpenter. Three patients with BPC presented with features of SVCO.
Pleural effusion was the main chest pathology, it was found in 65% of the BPC
cases and the entire PLC. The right hemithoraxweremainly involved. Diagnosis
weremade by pleural fluid cytology, pleural biopsies, FNAC, LN biopsies, bron-
choscopy in 41%, 10%, 10%,15% and 5% of BPC respectively. Other diagnostic
procedures done in PLC included open thoracotomy. Adenocarcinoma was the
commonest histologic type of BPC, while it was mesothelioma for PLC. Few
of the patients with Adenocarcinoma had history of smoking. 30% 0f the
BPCwere secondaries from breast, cervix, bone and skin. Death rate was 50%
within two weeks of diagnosis, three patients discharge against medical ad-
vice. The remaining were referred to another center. Conclusion. Primary
BPC are the commonest in this review except in females. With increasing
industrialization, atmospheric pollution, cigarette smoking and poverty in
most developing countries, the incidence and problems of BPC and PLC
would be expected to rise. More studies to identify risk factors and training
for physicians in diagnostic procedures and treatment of BPC are urgently
needed in resource limited countries.
#280 The maximum tumor length and lymph node metastasis in esopha-
geal squamous cell carcinomas. Shuang Lv,1 Shuang Lv,2 Fu You Zhou,3 Hai
Jun Yang,3 Bei Li,2 Li Na Liu,2 Yan Jie Xia,2 Yan Ru Qin,2 Rui Tai Fan,2 Fan Kai
Xiao,2 Li Dong Wang2. 1Xinxiang Medical University, Xinxiang, China; 2The
First Affıliated Hospital of Zhengzhou University, China; 3Anyang Tumor Hospi-
tal, China.
The lymph node metastasis (LNM) is one of the crucial risk factors for
esophageal squamous cell carcinomas (ESCC) prognosis. However, it is dif-
fıcult to precisely determine the LNM status before surgery. The maximum
tumor length (MTL) may reflect the ESCC growth speed and could be calcu-
lated accurately either with computed tomography or ultrasound endoscopy
before esophagectomy. Therefore the present study was designed to deter-
mine if the MTL could reflect the LNM status for ESCC. A total of 22,660
ESCC patients was enrolled in this study from the ESCC database (1973-
2015) in Henan Key Laboratory for Esophageal Cancer Research of the First
Affıliated Hospital, Zhengzhou University. Of these patients, there were
13,793 males with an mean age of 608, and 8,867 females with an mean age
of 618. All the cases had been performed radical esophagectomy. The MTL
and LNM records were retrieved from the medical records in hospitals.
Based on the 6th version of UICC criteria, the LNM was classifıed as N0 and
N1. The MTL was classifıed as 5 groups: 2cm, 	2 and 4cm, 	4 and
6cm , 	6 and 8cm , 	8cm. The SPSS21.0 software and Spearman rank
correlation were used to determine the correlation of MTL and LNM. The
results demonstrated that the average and median of MTL were 4.11.8 cm
and 4.0 cm (range: 0.1-18 cm) in these ESCC patients. The positive lymph
node metastasis rates in each MTL groups were 19.1%, 34.1%, 45.8%, 51.5%,
and 54.1%, respectively. Spearman rank correlation analysis indicated that
MTL was strongly correlated with LNM (r0.997, P0.001), suggesting that
MTL could reflect the LNM status in ESCC and that MTL could be used as
one of clinical staging parameters for ESCC. [Supported by Major Science
and Technology Projects of Henan Province (161100311300). National Key
Research and Development Program: Precision Medicine (2016).
#281 Site specifıc risk factors for colorectal cancer. Samir Gupta,1 Ranier
Bustamante,1 Ashley Earles,1 Maria E. Martinez,2 Karen Messer,2 Christina D.
Williams,3 Andrew J. Gawron,4 Tonya Kaltenbach,5 Lin Liu2. 1VA San Diego
Healthcare System, San Diego, CA; 2University of California, San Diego, La Jolla,
CA; 3DurhamVAMedical Center, Durham, NC; 4VA Salt Lake City Health Care
System, Salt Lake City, UT; 5San Francisco VA Health Care System, San Fran-
cisco, CA.
Background: Most studies of colorectal cancer (CRC) risk factors pool cases
across anatomical sites, though tumor characteristics and embryologic origins
differ. Our aim was to conduct a site-stratifıed (proximal, distal, rectal) case
control study of candidate risk factors forCRC.Methods:Our study basewasUS
Veterans with 1 colonoscopy 1999-2011. CRC cases at baseline colonoscopy
were identifıed with the Veterans Affairs Central Cancer Registry. Controls had
normal colonoscopy without biopsy, no history of CRC, and no CRC within 3
years of index colonoscopy. Age, sex, race/ethnicity, body mass index (BMI),
diabetes, and smoking were considered candidate risk factors. Primary outcome
was CRC, stratifıed by site. Site-specifıc odds ratios (OR) and 95% confıdence
intervals (CI) for each risk factor were computed with unadjusted and adjusted
multinomial logistic regressionmodels. Results:We identifıed 21,739CRC cases
and 616,323 normal colonoscopy controls. For cases combined vs. controls,
median age was 68 vs. 61 years, 98% vs. 95%weremale, median BMIwas 27.8 vs.
28.8 kg/m2, 28% vs. 24% had diabetes, and 25% vs. 29% were non-smokers;
race/ethnicity was similar. Presence and strength of associations differed by risk
factor and CRC site (Table). Smoking was more closely associated with rectal
(OR1.84) than proximal (OR1.59) or distal cancer (OR1.50). Diabetes was
more closely associated with proximal than distal or rectal cancer (OR1.28,
1.17 and 1.12, respectively). Blacks had reduced odds for rectal (OR0.89), but
increased odds for distal (OR1.27) and particularly proximal cancer
(OR1.60)when compared to non-Hispanicwhites. Formales vs. females, odds
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of rectal was higher than distal or proximal cancer (OR2.64, 1.95 and 1.32,
respectively). Conclusions: Presence and strength of association of cancer risk
factors may differ by CRC site. Site should be a key consideration in future
studies of CRC risk.
Site specifıc risk factors for 21,739 CRC cases compared to 616,323
normal colonoscopy controls
Anatomic Site
of CRC*
Proximal
(n7,686)
Distal
(n7,036)
Rectal
(n7,017)
Candidate Risk Factor OR (CI) OR (CI) OR (CI)
Age, years† 1.100 (1.096-1.103) 1.065 (1.062-1.069)‡ 1.055 (1.051-1.059)‡§
Gender, male vs.
female
1.318 (1.080-1.608) 1.950 (1.538-2.471)‡ 2.636 (2.006-3.463)‡
Race/ethnicity
Black vs.
non-Hispanic
white
1.596 (1.480-1.720) 1.270 (1.167-1.381)‡ 0.886 (0.808-0.971)‡§
Hispanic vs.
non-Hispanic
white
1.291 (1.123-1.485) 1.531 (1.337-1.753) 1.219 (1.053-1.411)§
Asian vs.
non-Hispanic
white
0.872 (0.634-1.201) 0.917 (0.662-1.272) 0.556 (0.371-0.832)
BMI, kg/m2† 0.994 (0.988-1.000) 1.005 (0.999-1.012)‡ 0.963 (0.957-0.970)‡§
Diabetes, yes vs. no 1.278 (1.196-1.366) 1.170 (1.089-1.257) 1.119 (1.038-1.207)‡
Smoking
Current vs. never 1.594 (1.476-1.722) 1.500 (1.383-1.627) 1.837 (1.695-1.992)‡§
Former vs. never 0.997 (0.926-1.073) 1.082 (1.001-1.171) 1.085 (0.998-1.119)
* Multinomial analyses adjusted for other risk factors, as well as year of colonoscopy,
1999-2011
† by one unit increment
‡ p0.05 when compared to proximal cancer
§ p0.05 when compared to distal cancer
CRC, colorectal cancer; BMI, body mass index.
#283 Establishing the predominant type of leukemia among patients at-
tending the Uganda Cancer Institute. Gerald Nsubuga. Uganda Cancer Insti-
tute, Kampala, Uganda.
Introduction: Leukemia is a cancer of white blood cells. It is characterized by
an abnormal accumulation of WBC in the bone marrow which leads to bone
marrow failure and is manifested in form of anemia and thrombocytopenia.
This arises fromneoplastic transformation usually of a single cell. There are four
common types of leukemia: 1) Acute lymphoblastic leukemia (ALL); 2) Acute
myeloblastic leukemia (AML); 3) Chronic lymphocytic leukemia (CLL); and
Chronic myeloid/myclocytic leukemia (CML). Methods: The study was de-
signed to fınd out the predominant type of leukemia. 80 leukemia cases which
comprised of all bone marrow aspirates and peripheral blood slide results with
specifıc age, sex and ward of the patients was analyzed in the hematology labo-
ratory. Results: The study was revealed that leukemia occurred in following
order of types of predominant that is AML 15 (18.75%), CLL 12(15%) and least
type was CML 11(13.75%). The result also showed that the most affected age
group by all age. Brackets of (01-20) years. From the study amale preponderance
(M: F) of 4:3 was found in cases of ALL. The study emphasizes that special
staining techniques be adopted in diagnosing and typing of leukemia. Conclu-
sions: From the results presented, ALL is the predominant type of leukemia
affecting children and young adults. AML was found to affect children, young
adults, and adults. CLL and CMLwere found to occur at the same incidence, the
elderly (61-70 and 71-80 years). Other types were rare in these age group simi-
larly CLL and CML were rare in children and young adults.
#284 The trending of lymph node dissection for esophageal squamous cell
carcinoma over 40 years in China. Pei Nan Chen,1 Fu You Zhou,2 Hong Mei
Chen,1 Xiao Shan Feng,3 Lei Sun,4 Ling Yuan,5 Ping He,6 Ying Pan,7 Tao Jiang,3
Min Jie Wu,8 Wen Jun Gao,9 Jin Chang Wei,10 Li Dong Wang1. 1The First
Affıliated Hospital of Zhengzhou University, Zhengzhou, China; 2Anyang Tumor
Hospital, China; 3The First AffıliatedHospital of HenanUniversity of Science and
Technology, China; 4People’s Hospital of Qixian, China; 5Cancer Hospital of
Henan Province, Zhengzhou, China; 6The Second People’s Hospital of Xinxiang,
China; 7The Third Affıliated Hospital of Xinxiang Medical University, China;
8The Fifth Affıliated Hospital of Zhengzhou University, Zhengzhou, China; 9Peo-
ple’s Hospital of Linzhou, China; 10The Hospital of Linzhou Esophageal Cancer,
China.
The accumulated evidences have indicated the importance of lymph node
dissection (LND) in improving survival for esophageal squamous cell carcinoma
(ESCC). However, it is largely unclear in terms of standard lymph node dissec-
tion, e.g., how many is suitable and which node station is more important, etc.
The present study was undertaken to summarize the trending of lymph node
dissection for ESCC over 40 years at a single institute in northern China. A total
of 27,260 ESCCpatients were enrolled in this study from1974 to 2016, including
16,565males with amean age of 59.727.82 and 10695 females with amean age
of 60.38.51. All the patients were from the ESCC database in Henan Key
Laboratory for Esophageal Cancer Research of the First Affıliated Hospital,
Zhengzhou University (1973–2016). All the patients had pathological LND re-
cords, including the number dissected. The patients were classifıed into four
period groups based on the diagnosed time, group I (1974 to 1986, 367/1.3%),
group II (1987 to 1996, 3182/11.7%), group III (1997 to 2006, 10, 494/38.5%) and
group IV (2007 to 2016, 13,217/48.5%). The SPSS21.0 software was used to
evaluate the trending changes of LND at different periods. The results showed
that the total number of LND/themean number by each patient from group I to
group IV was 3,000/8.43, 22,001/7.07, 87,740/8.36, and 159,340/12.06, respec-
tively (p0.0001). Further analysis indicated that the total number of LND/the
mean number by each patient from group I to group IV inmales was 1,634/7.93,
13,428/6.99, 53,143/8.53 and 100,073/12.19, respectively and 1,366/8.48, 8,573/
6.80, 34,597/8.11, 59,267/11.83, respectively in females. The present results in-
dicate an apparent increasing in number of LND from 1987 to 2016 for esoph-
ageal cancer surgical treatment in China. Further analysis is needed to correlate
the LND and metastasis and survival. [National High–Tech Research and De-
velopment Program of China (SQ2015AA0202183), Major Science and Tech-
nology Projects of Henan Province (161100311300).
#285 Standardized prediction estimates for cancerous and noncancerous
gynecological lesions: a preliminary study in an oil city ofNigerDelta region.
Felix M. Onyije,1 Anthony A. Ngokere,2 Aloysius E. Ligha,1 Osaro O. Mgbere,3
Godwin O. Avwioro4. 1Niger Delta University, Wilberorce Island, Amassoma,
Nigeria; 2Nnamdi Azikiwe University, Awka, Nigeria; 3Institute of Community
Health, University of Houston, Texas Medical Center, Houston, TX; 4Delta State
University, Abraka, Delta State, Nigeria.
The objective of this pilot study was to determine the epidemiology of gyne-
cologic cancer and non-cancerous lesions and to develop standardized predic-
tion estimates for the diseases in thirty-fıve years time. The impact of cancerous
and non-cancerous lesions on women’s health cannot be underestimated, espe-
cially where there is constant emission of hydrocarbons and contaminatedwater
level through oil spillage. Data used for this retrospective study comprised of 679
records and covering the period 2010-2014 were retrieved from the archive of
BraithwaiteMemorial SpecialistHospital (BMSH)Histopathology laboratory in
Port Harcourt, Nigeria. Total of 32 (4.6%) cancerous and 665 (95.4%) non-
cancerous lesions were diagnosed with the distribution pattern differing signif-
icantly (p0.001) by year of diagnosis, developmental stage and age category.
Leiomyoma recorded the highest 5-year standardized prevalence rate of 0.508,
and without intervention, it is estimated that the number of cases diagnosed will
rise from 235 in 2015 to 1883 by the year 2050. This was followed by ovarian cyst
with a prevalence rate of 0.124 and projected increase from 57 in 2015 to 461 by
the year 2050. Similarly, the product of conception is also predicted to increase
from 34 to 277 by the year 2050. The 700% increase prediction of cancerous and
non-cancerous lesions by 2050 calls for urgent attention for both governmental
and private agencies to fund awareness campaigns and screening for women,
especially for those residing in oil and gas producing areas where oil and gas
pollution are common. This may help reduce morbidity and mortality associ-
ated with these conditions.
#286 Forecast of the incidence and etiology of liver cancer in Taiwan,
Japan, United States, and United Kingdom: toward harmonization of East
andWest. Emily Han-ChungH.Hsiue,1Wei-Cheng Lo,2 Hsien-Ho Lin,2 Chih-
HungHsu,3Ann-Lii Cheng3. 1JohnsHopkins School ofMedicine, Baltimore,MD;
2Institute of Epidemiology and Preventive Medicine, College of Public Health,
National Taiwan University, Taipei, Taiwan; 3National Taiwan University Hos-
pital, Taipei, Taiwan.
Background: The global epidemiology of primary liver cancer (PLC), primar-
ily hepatocellular carcinoma (HCC), has evolved signifıcantly in the past de-
cades because of improved control of viral hepatitis and the growing prevalence
of metabolic factors. We conducted a quantitative forecast of the incidence and
etiology of PLC.Methods: Incidence rates of PLCwere projected in two endemic
Asian countries (Taiwan and Japan) and two Western countries (the United
States and United Kingdom) with rigorous cancer registry. The annual inci-
dence of PLC (ICD-10 C22.0) between 1980 and 2013 were obtained from the
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Taiwan Cancer Registry Database, the Japan National Cancer Center, the US
SEER 9 database, Cancer Research UK, and the European Network of Cancer
Registry. Incidence rates were projected to year 2035 by an age-period-cohort
model with a power link function. The population attributable fractions (PAF)
of chronic hepatitis B (HBV), chronic hepatitis C (HCV), alcohol consumption,
obesity, and diabetes mellitus (DM) for HCC in Taiwan were projected to 2045.
The prevalence of each risk factor was obtained from national surveys and pro-
jected inferentially by using a log-linearmodel or simple linear assumption. The
relative risk of each factorwas derived frompooled literature data. Results: From
2013 to 2035, incidence rates of PLC in Taiwan are estimated to decrease by
more than 50% in both men (49.3 to 24.2/100,000) and women (19.7 to 9.2/
100,000). In Japan, incidence rates have plateaued in the 1990s, and are expected
to continue to decline to 17.0/100,000 for men and 6.3/100,000 for women.
Conversely, rates in the UK are projected to increase by more than 30% in both
men (13.5 to 18.2/100,000) and women (6.0 to 8.1/100,000). A more modest
increase is expected in the US, from 10.2 to 12.5/100,000 for men and 3.3 to
3.5/100,000 forwomen. InTaiwan, the PAFofHBV, the predominant risk factor
of HCC, is predicted to decrease from 54.3% in 2015 to 34.4% in 2045. By 2045,
the PAFs of obesity and DM are estimated to reach 11.9% and 15.4%, respec-
tively, the latter similar to that ofHCV (15.0%). Conclusion: PLC incidence rates
are forecast to follow a trend of convergence in four representative countries.
Metabolic factors are expected to play increasingly important etiologic role in
HCC even in regions currently endemic for viral hepatitis.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Cell
Cycle Checkpoint and Progression
#287 BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor
activity. Gerhard Siemeister,1 Anne Mengel,1 Wilhelm Bone,1 Jens Schröder,1
Sabine Zitzmann-Kolbe,1 Hans Briem,1 Amaury E. Fernández-Montalván,1 Si-
monHolton,1 UrsulaMönning,1 Oliver von Ahsen,1 Sandra Johanssen,1 Arwed
Cleve,1 Marion Hitchcock,1 Kirstin Meyer,1 Franz von Nussbaum,2 Michael
Brands,1 Dominik Mumberg,1 Karl Ziegelbauer1. 1Bayer Pharma AG, Berlin,
Germany; 2Bayer S.A.S, Lyon, France.
The spindle assembly checkpoint represents a highly conserved surveillance
mechanism which safeguards correct chromosome segregation by delaying an-
aphase onset until all chromosomes are properly bi-oriented on the spindle
apparatus. Non-catalytic functions of the mitotic kinase BUB1 (budding unin-
hibited by benzimidazoles 1) were reported to be essential for spindle assembly
checkpoint activation. In contrast, the catalytic function of BUB1 plays a minor
role in spindle assembly checkpoint activation but is required for chromosome
arm resolution and positioning of the chromosomal passenger complex for res-
olution of spindle attachment errors. Here, we disclose for the fırst time the
structure and functional characterization of a novel, fırst-in-class Bub1 kinase
inhibitor. Medicinal chemistry efforts resulted in BAY 1816032 featuring high
potency, long target residence time and good oral bioavailablity. It inhibits
BUB1 enzymatic activity with an IC50 of 7 nanomol/L, shows slow dissociation
kinetics resulting in a long target residence time of 87 min, and an excellent
selectivity on a panel of 395 kinases. Mechanistically BAY 1816032 abrogated
nocodazole-inducedThr-120 phosphorylation of themajor BUB1 target protein
histone H2A in HeLa cells with an IC50 of 29 nanomol/L, induced lagging
chromosomes and mitotic delay. Persistent lagging chromosomes and misseg-
regationwere observedupon combinationwith low concentrations of paclitaxel.
Single agent BAY 1816032 inhibited proliferation of various tumor cell lines
with a median IC50 of 1.4 micromol/L and demonstrated synergy or additivity
with paclitaxel or docetaxel in almost all cell lines evaluated (minimal combina-
tion index 0.3). In tumor xenograft studies BAY 1816032 onlymarginally inhib-
ited tumor growth as single agent upon oral administration, however, upon
combination with paclitaxel or docetaxel a strong and statistically signifıcant
reduction of tumor size as compared to the respective monotherapy was ob-
served. Intratumoral levels of phospho-Thr120 H2A were found to be strongly
reduced, and no hints on drug-drug interactions were found. In line with the
good tolerability in xenograft studies, no relevant fındings from non-GLP 2
weeks toxicological studies in rat and dog were reported. Our fındings validate
the innovative concept of interference withmitotic checkpoints and justify clin-
ical proof of concept studies evaluating BUB1 inhibitor BAY 1816032 in com-
bination with taxanes in order to enhance their effıcacy and potentially over-
come resistance.
#288 Loss of a branched actin checkpoint in cancer cells. Nicolas Molinie,
Svetlana Rubtsova, Alexis Gautreau. CNRS / Ecole Polytechnique, Palaiseau,
France.
Cell proliferation depends on multiple signals, such as growth factors, adhe-
sion to the substratum and to neighboring cells. Cancer cells proliferate inde-
pendently of these signals. The same stimuli also induce actin polymerization.
Here we investigate whether the actin cytoskeleton plays a role in transmitting
the proliferation signal. We found that inactivation of the Arp2/3 complex by
either a chemical inhibitor or by siRNAs blocks S phase entry in untransformed
human breast cell lines and in primary breast epithelial cells. In contrast, breast
cancer cell lines did not respond to Arp2/3 inhibition. Inactivating the tumor
suppressor p21WAF1/CIP1, or Rb, converts sensitive cells into unresponsive
cells further highlighting that this response to Arp2/3 inactivation is at the heart
of the transformation process. The depletion of theWAVE complex, the Arp2/3
activator that generates branched actin in lamellipodia, but not of other Arp2/3
activators, blocks cell cycle progression. Conversely, activation of WAVE by
active Rac, or depletion of Arpin, which antagonizes WAVE, potentiates cell
cycle progression. Together, these results show that branched actin networks
generated in lamellipodia are sensed and convey an essential signal for S Phase
entry. The signal that branched actin delivers integrates stimulation from solu-
ble growth factor withmechanotransduction from cell adhesions to the substra-
tum and to neighboring cells. This signaling pathway qualifıes as a checkpoint,
which is required in normal cells, but lost in transformed cells, thatmonitors the
integrity of branched actin networks and instructs the cell as a response that the
required conditions to proliferate are fulfılled.
#289 The key role of Mitostatin in the maintenance of genome stability.
Angela Lauriola,1 Andrea Caporali,2 Sabine Mai,3 Domenico D’Arca1. 1Univer-
sity of Modena and Reggio Emilia, Modena, Italy; 2University/BHF Centre For
Cardiovascular Science, The Queen’s Medical Research Institute, Edinburgh,
United Kingdom; 3Manitoba Institute of Cell Biology, CancerCare Manitoba,
University of Manitoba, Winnipeg, Manitoba, Canada.
Genomic instability is a characteristic of most cancers and it refers to an
increased tendency of alterations in the genome during the life cycle of cells. The
fıdelity of DNA replication is highly ensured by different checkpoints; the acti-
vation of spindle checkpoints prevents cells from premature entry into mitosis,
avoiding incorrect chromosome segregation and aneuploidy, a typical feature of
many cancers. Mitostatin, a novel protein, endowed with tumor suppressor
activity, has been reported to bind centrosomal proteinsOdf2 andninein, and its
depletion causes an alteration of the anchorage of microtubules to the centro-
some. Since functional defects of centrosomes are associated to mitotic failure,
Mitostatinmay have a key role in guarding the fıdelity ofmitosis in cells.Herewe
show that the depletion of Mitostatin in cancer cells, synchronized by aphidico-
lin (G1/S) block and released into nocodazole-containing medium, leads to mi-
totic slippage and adaptation to the spindle checkpoint in the presence of a
spindle inhibitor. Concomitantly, Mitostatin depletion promotes the early deg-
radation of Mad2 and cyclin B1. Since the activated spindle checkpoint delays
cell exit from mitosis by preventing cyclin B1 proteolysis, the cyclin B1 early
degradation leads to mitotic checkpoint escape and resulting chromosome in-
stability. In particular, we observed a premature sister-chromatid separation,
chromosome bridges and mis-segregation in anaphase that are consistent with
defective activation of the spindle checkpoint.In this study, we report for the fırst
time that the depletion ofMitostatin induces an increase of numerical and struc-
tural chromosomal aberrations compared to control cells. These aberrations
include aneuploidy (P.0005), the formation of triradials (P.0061) and bro-
ken chromosomes (P.0066). Moreover, 3D nuclear telomere analysis using
TeloView shows decreases in telomeric signals (P.0061), in the total number of
aggregates (P.0027), and in total intensity (P.018) and single intensity
(P.019) in cells depleted of Mitostatin. These fındings suggest that telomere
dysfunction is increased in the absence of Mitostatin; the decrease in telomere
intensity is associated with ongoing proliferation (mitotic slippage), and the
maintenance of telomeric aggregates is indicative of ongoing genomic instabil-
ity. Taken together, these observations suggest that Mitostatin plays a critical
role in guarding the fıdelity of mitosis, enabling the optimal activation of the
spindle checkpoint. Thus, low levels of Mitostatin found in certain human tu-
morsmay contribute to cellular transformation by promoting genomic instabil-
ity.
#290 A novel function of HGF in the activation of Chk1 phosphorylation
in colon cancer cells.Na Song, Xiaofang Che, Xiujuan Qu, Lu Xu, Kezuo Hou,
Yunpeng Liu. The First Hospital of China Medical University, Shenyang, China.
ATR/Chk1 pathway plays an essential role in modulation of DNA damage
response (DDR) and homologous recombination (HR). Particularly, Chk1
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phosphorylation is involved in cancer prognosis and therapeutic resistance.
Although some receptor tyrosine kinases (RTKs) participate in the regula-
tion of Chk1 phosphorylation, the effect of hepatocyte growth factor (HGF)
on Chk1 phosphorylation is unknown. In the present study, Western blot-
ting and subcellular fractionation were performed to identify the expression
and the location of Chk1 phosphorylation in the presence of HGF. With
small interfering RNA transfections, co-immunoprecipitations were per-
formed to detect the interaction between TopBP1 and ATR complex. Our
results demonstrated that HGF moderately activated Chk1 phosphorylation
in colon cancer cells via upregulation of TopBP1, RAD51, and complex
formation of TopBP1 and ATR. Furthermore, AKT activation promoted by
HGF served as an important intermediator linking HGF/MET signaling and
Chk1 phosphorylation. Depletion of AKT activity attenuated expression of
basal line p-Chk1 and induced Chk1 activation due to HGF stimulation.
Meantime, activation of AKT directly regulated expression of TopBP1 and
RAD51. Suppression of AKT restored HGF-induced upregulation of
TopBP1, RAD51, and enhancement of TopBP1/ATR complex as well. Our
studies showed that HGF was implicated in regulating Chk1 phosphoryla-
tion and further demonstrated that AKT activity was responsible for HGF-
induced Chk1 phosphorylation, which might potentially result in manage-
ment of prognosis and therapeutic sensitivity in cancer therapy.
#291 Sequential treatment with the Wee1 inhibitor, AZD1775, enhances
the effect of trabectedin in the L-sarcomas. Elgilda Musi, Grazia Ambrosini,
Gary K. Schwartz. Columbia University Medical Center, New York, NY.
Soft tissue sarcomas are heterogeneousmesenchymal neoplasms and account
for 1% of all cancers in adults. Over 50 sarcomas subtypes have been classifıed
and many have very limited treatment options. Chemotherapies such as doxo-
rubicin, dacarbazine and gemcitabine have had very low response rates. Two of
the most common subtypes of sarcomas are liposarcoma and leiomyosarcoma,
also referred to as the L-sarcomas. Trabectedin, a marine derived compound
from the sea sponge, Ecteinascidia turbinate, has recently been approved for the
treatment of L-sarcomas which has shown a modest effect over common thera-
pies. As aDNAdamaging agent, we hypothesized that trabectedinwould induce
a G2 cell cycle arrest and subsequent inhibition ofWee1 would abrogate this cell
cycle checkpoint and induce apoptosis. We therefore examined the effects of
trabectedin followed by AZD1775, aWee1 inhibitor, in a panel of 6 sarcoma cell
lines including liposarcoma (LS141, DDLS) and leiomyosarcoma (SK-LMS, SK-
UT1, SK-UT1b). IC50s concentrations of trabectedin were determined to be
between 0.5 to 2nM, while IC50s for AZD1775 were in the range of 100-200 nM.
In vitro results have shown an enhanced inhibition of cell viability with combi-
nation treatment in all cell lines at concentrations of 1nM trabectedin for 24hrs
followed by 100nM AZD1775 for 48hrs. We also examined biochemical effects
with sequential drug treatment (24hrs trabectedin followed by 24hrs AZD1775)
which presented an increase of cyclinA1 and cyclin B1 indicative of G2 cell cycle
arrest along with increase of phospho-H2AX, indicative of DNA damage by
trabectedin, while subsequent treatment with the Wee1 inhibitor showed de-
crease of phosphorylation of CDC2 (Tyr15). Flow cytometric analysis indicated
G2/M cell cycle arrest with trabectedin and abrogation of G2/Mwith AZD1775.
These observations correlated with enhanced apoptosis as measured by bio-
chemical PARP cleavage and DNA content (sub-G1 population). Taken to-
gether these results provide a foundation for the development of the sequential
treatment of trabectedin followed by theWee1 inhibitor, AZD775, in the L-sar-
comas.
#292 Synthesis and characterization of the novel benzylindazole-based
BUB1kinase inhibitorBAY1816032with potent anti-tumor activity.Marion
Hitchcock,1 Anne Mengel,2 Carl Nising2. 1Bayer AG, Cambridge, MA; 2Bayer
AG, Berlin, Germany.
BUB1 (budding uninhibited by benzimidazoles 1) is a serine/threonine pro-
tein kinase. The protein is bound to kinetochores and plays a key role in the
establishment of the mitotic spindle checkpoint and chromosome congression
prior to anaphase. Inhibition of BUB1 kinase represents a novel approach for
cancer treatment: whereas cell cycle arrest is the predominant mode of action of
a number of antimitotic cancer drugs (e.g. taxanes and vinca alkaloids), BUB1
inhibition results in aneuploidy and cell death by driving cells through mitosis
irrespective ofmisattached chromosomes.Here, we disclose for the fırst time the
structure and functional characterization of a novel, fırst-in-class Bub1 kinase
inhibitor. Medicinal chemistry efforts resulted in BAY 1816032 featuring high
potency, long target residence time and good oral bioavailability. BAY 1816032
is highly selective for BUB1 displaying single digit nanomolar biochemical po-
tency and double-digit nanomolar cellular potency (H2A induced HeLa-cells).
Synergistic effects can be observed when BUB1 inhibitor BAY 1816032 is com-
bined with low doses of paclitaxel affecting chromosome segregation and cell
proliferation. X-ray data of benzylindoles allowed a better understanding of the
binding mode. Further data on structure-activity relationships including phar-
macokinetic characterization, drug metabolism and the synthesis of BAY
1816032 and analogues will be presented. These results validate the innovative
concept of interference with mitotic checkpoints and justify clinical proof of
concept studies evaluating BUB1 inhibitor BAY 1816032 in combination with
taxanes in order to enhance their effıcacy and to potentially overcome resistance.
#293 Screening the druggable genome for synthetic lethal interactions
with the CHK1 inhibitor PNT737. Rebecca Rogers,1 Mike I. Walton,1 Paul
Clarke,1 Ian Collins,1 Michelle D. Garrett,2 Paul Workman1. 1The Institute of
Cancer Research, London, United Kingdom; 2University of Kent, Kent, United
Kingdom.
Check point kinase 1 (CHK1) is a key regulator of the cell cycle, DNAdamage
repair and DNA replication. CHK1 inhibition sensitises cancer cells to geno-
toxic agents and recent studies have indicated that CHK1 inhibitors could be
used as single agents to treat cancers with high levels of replication stress. We
have recently described the discovery of a highly selective and orally bioavailable
CHK1 inhibitor, PNT737, that not only has potent antitumour activity in com-
bination with standard-of-care genotoxic agents but also as a single agent in
defıned tumour types. Here we sought to identify gene products whose loss
would be synthetically lethal with CHK1 inhibition, with the aim of identifying
patient populations likely to be sensitive to single agent CHK1 inhibition or to
novel combinations utilising CHK1 inhibitors. To do this, we performed a large
siRNA screen of the druggable genome (6500 genes) in A549 (NSCLC) and
SW620 (colon cancer) cell lines, with and without PNT737 treatment, and de-
termined effects on cell viability by SRB. POLA1, POLE and POLE2 (B-family
DNA polymerases) were identifıed as signifıcant hits causing synthetic lethality
with PNT737 in both cancer cell lines. Treatment with additional siRNA se-
quences subsequently validated these genes in both the original two cell lines and
extra NSCLC and colon cancer cell lines. Interestingly, a number of biomarkers
for replication stress, pRPA2 and pCHK1, were increased in cells treated with
POLA1, POLE and POLE2 siRNA in combination with PNT737, in comparison
to cells treated with the siRNA or drug alone. Further studies conducted with
PNT737 and the B-family DNA polymerase inhibitor aphidicolin showed that
these agents had a synergistic effect on inhibiting cell viability on 8 out of 9
NSCLC and colon cancer cell lines tested. In addition, immunofluorescence
analysis revealed that there was an increase in the level of H2AX, a marker of
DNA damage, in 4 out of 5 cell lines that exhibited synergy when treated with a
combination of aphidicolin and PNT737, as compared to cells treated with ei-
ther agent alone. Our data indicate that the combination of a reduction in
POLA1, POLE or POLE2 activity (by siRNA transfection or aphidicolin treat-
ment) and CHK1 activity (PNT737 treatment) increases replication stress and
DNAdamage inNSCLCand colon cancer cells. Encouragingly, our data support
the case for the use of the clinically relevant combination of PNT737 and gem-
citabine, as gemcitabine is metabolised it is incorporated into DNA, inhibiting
the B-family DNA polymerases. Furthermore, it will now be important to estab-
lish if subsets of colon and endometrial cancers with mutations in their POLE
proofreading domain are sensitive to CHK1 inhibitors.
#294 Override the doxorubicin-inducedG2/M checkpoint using cell-cycle
checkpoint inhibitors on acute lymphoblastic leukemia. Andrea Ghelli
Luserna di Rorà,1 Ilaria Iacobucci,2 Enrica Imbrogno,1 Anna Ferrari,1 Valentina
Robustelli,1 Cristina Papayannidis,1 Maria Chiara Abbenante,1 Antonella
Padella,3 Giovanni Marconi,1 Sandro Grilli,1 Giovanni Martinelli1. 1University
of Bologna, Bologna, Italy; 2St. Jude Children’s Research Hospital, Memphis, TN;
3University of Bologna, Montecassiano, Italy.
The topoisomerase 2 inhibitor, doxorubicin, has been showed by different
groups to induce cell cycle arrest in various kind of tumor cells. Specifıcally
doxorubicin-treated cells activate the G2/M cell cycle checkpoint as a conse-
quence of the induction of DNA damages. During the last years many studies
have been showed the effıcacy of different cell cycle checkpoint inhibitors in
single agent or in combination with various DNA damaging agents. These stud-
ies showed that the inhibition of key proteins of the cell cycle, like Chk1 and
Wee1, deeply sensitize tumor cells to the treatment with genotoxic agent. On
these bases, the aim of the study was to evaluate the effıcacy of a selective Chk1/
Chk2 inhibitor and a Wee1 inhibitor in combination with doxorubicin for the
treatment of acute lymphoblastic leukemia. Firstly we evaluate the effect of
doxorubicin treatment on a panel of human B and T ALL cell lines in term of
reduction of the cell viability, modifıcation of cell cycle profıle and activation of
the DNA damage response. For this reason the cells were treated with doxoru-
bicin (0.25, 0.5 and 1uM) for 24 and 48 hours and the reduction of the cell
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viability was quantifıed using WST-1 reagents. In all the cell lines treated the
cytotoxic effect of doxorubicin was time and dose dependent. Then the induc-
tion of the apoptosis (Pi/Annexin V) and the effect on cell cycle profıle (Pi
staining) was evaluated in all the cell lines. In line with the literature the treat-
ment with doxorubicin arrested the cells in G2/M phase. Then the effect of the
combinations between doxorubicin and the two checkpoint kinase inhibitorwas
assessed in all the cell lines. Different cell lines were treated with doxorubicin (5,
10, 25 and 50 nM for themore sensitive cell lines; 50, 100, 250 and 500 nM for the
less sensitive cell lines) in combination with the Chk1/Chk2 inhibitor (2, 5 and
10 nM) for 24 and 48 hours. The combination showed a additively effect in term
of reduction of the cell viability and induction of apoptosis. Different cell lines
were pre-treated for 18 hours with doxorubicin and then with Chk1/Chk2 in-
hibitor for different time points. Interestingly the inhibition of both Chk1/Chk2
proteins removed the G2/M arrest induced by the pre-treatment with doxoru-
bicin, progressively reducing the number of cells in G2/M phase, increasing the
percentage of cells in sub-G1 phase. Similar results were seen combining aWee1
inhibitor with doxorubicin on several ALL cell lines. In our opinion the combi-
nation between the cell cycle checkpoint inhibitors and doxorubicin could be a
promising strategy for the treatment of B/T-ALL. Supported by ELN, AIL,
AIRC, progetto Regione-Università 2010-12 (L. Bolondi), FP7 NGS-PTL proj-
ect.
#295 CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid
tumors and displays synergistic anti-tumor activity in combination with
Wee1 inhibition.AlexVo,1 Janelle Taylor,1 Robert Rosler,1 Julia Piasecki,1Dina
Leviten,1 Teresa Sierra,1 Ashley Dozier,1 Kevin Klucher,2 Bob Boyle,3 Rich
Boyce,3 Scott Peterson1. 1CascadianTherapeutics, Seattle,WA; 2none,WA; 3Sen-
tinel Oncology, Cambridge, United Kingdom.
Background: Checkpoint kinase 1 (Chk1) is a serine/threonine protein kinase
that regulates cell division in response to genotoxic stress by arresting cell cycle
progression in the S & G2 phases. Pharmacological inhibition of Chk1 is pro-
posed to target tumor cells with increased DNA replication stress, resulting in
the uncoupling of DNA replication checkpoint function and the induction of
DNA damage and cell death. These properties make Chk1 inhibition a novel
therapeutic approach as a single agent in cancerswith high replication stress that
is driven by oncogenic signaling and loss of parallel DNA damage response
pathway function.Methods andResults: This report highlights the activity of the
orally bioavailable, selective small molecule Chk1 inhibitor, CASC-578, in solid
tumor derived cell lines. CASC-578 is a sub-nanomolar enzymatic inhibitor of
Chk1 with limited off-target activity against a panel of protein kinases. When
evaluated in a large cell line panel in vitro, CASC-578 demonstrated a broad
potency range as a single agent in solid tumor derived cells lines, with IC50s
ranging from 30 nM to greater than 50 M. Several solid tumor types demon-
strated enriched sensitivity to CASC-578 in vitro, including gastric, non-small
cell lung and ovarian cancers. Treatment of sensitive cell lines with CASC-578
resulted in the induction of DNA damage, as measured by phosphorylated his-
tone H2AX, and the induction of cell death. CASC-578 was active as a single
agent in SK-MES-1 andNCI-H727NSCLC tumor xenograftmodels in vivowith
minimal effects on body weight in treated mice. In addition to the potent single
agent activity of CASC-578, combination with the Wee1 inhibitor AZD-1775
was highly synergistic in vitro in multiple solid tumor cell lines and the combi-
nation was more effıcacious than either agent alone in NSCLC tumor xenograft
models. These data support the advancement of CASC-578 into clinical devel-
opment as a potential therapeutic agent for the treatment of solid tumor dis-
eases. Experiments are ongoing to identify biomarkers associated with sensitiv-
ity to CASC-578 as a single agent in solid tumor cell lines to prospectively
identify tumor genotypes that are more responsive to the drug.
#296 Interplay of humanMGMTDNArepair proteinwith PCNA / p21cip1
andMGMT’s novel role as an S-phase checkpoint.AGMMostofa, Kalkunte S.
Srivenugopal. Texas Tech University Health Sciences Center, Amarillo, TX.
O6-Methylguanine-DNA methyltransferase (MGMT) is a critical antimuta-
genic DNA repair protein that protects the genome and an established target for
improving the effıcacy of alkylating agents. In contrast with the stoichiometric
repair reaction performed by a single small MW protein, we show for the fırst
time that MGMT in human glioblastoma cells specifıcally associates with
PCNA, p21cip1, and undergoes selective degradation atmid-S-phase alongwith
replication-licensing components tomaintain genomic integrity. First, we iden-
tifıed a PCNA-Interacting Protein (PIP box) motif between amino acids 61-70,
QCTAWLNAYF in the MGMT protein. PCNA encircles the DNA and func-
tions as a sliding clamp by interacting with DNA metabolic proteins having a
PIP-box tomake the replication processive. In p53-null H1299 lung cancer cells
engineered to express the p21cip1, either by Tet-off conditional or lentiviral
stable transfections, a reciprocal immunoprecipitation/western blot analyses us-
ing antibodies to PCNAorMGMTconfırmed the specifıc association ofMGMT
and PCNA proteins. Expression of the CDK inhibitor p21 disrupted the inter-
action between PCNAandMGMT in cells, indicating its regulatory role inDNA
repair during cell cycle blockade. Confocal immunofluorescence imaging in
glioblastoma cells and isogenic HCT116 cells with and without p21cip1 expres-
sion, showed a co-localization of MGMT and PCNA proteins in glioma cells;
when cellswere subjected to alkylationDNAdamage, the co-localization pattern
was punctate and more prominent, suggesting that PCNA functions to recruit
the repair protein to the damage sites. To probe the cell-cycle dependent regu-
lation ofMGMT,we used synchronized humanGBMcells at theG1/S boundary
using double thymidine-block or single thymidine-mimosine blocks. Cells re-
leased into the S-phase showed that the MGMT disassociates from PCNA dur-
ing the late S-phase and undergoes specifıc degradation before re-accumulating
inG2/M.The replication-licensing proteinCdt1 andp21cip1were also observed
to undergo co-degradation in S-phase, which has been established as a key step
in marking the replication origin sites. MGMT inhibition, either by O6-benzyl-
guanine or specifıc shRNAs greatly impeded the progression of cells into the
S-phase in synchronized cells. DNA synthesis measured by 3H-thymidine or
BrdU incorporation was also curtailed signifıcantly by MGMT inhibition. Fur-
thermore, enforced expression of MGMT in two GBM cell lines led to a moder-
ate endo-reduplication of the genome. Collectively, we show new non-repair
functions forMGMT, its requirement for cell cycle progression and timed elim-
ination to maintain genomic stability. On the clinical front, the observations
provide a clear biochemical rationale for combining MGMT inhibitors (apart
from the alkylators) with antimetabolites [supported by CPRIT grants
RP130266 & RP170207 to KSS].
#297 Thenovel orally available sub-nanomolar potent and selective check-
point kinase 1 inhibitor CASC-578 is highly active in mantle cell lymphoma
as a single agent and in combination with Wee1 inhibition. Robert Rosler,1
Janelle Taylor,1 Dina Leviten,1 Teresa Sierra,1 Ashley Dozier,1 Kevin Klucher,2
Rich Boyce,3 Bob Boyle,3 Alex Vo,1 Scott Peterson1. 1Cascadian Therapeutics,
Seattle, WA; 2none, CA; 3Sentinel Oncology, Cambridge, United Kingdom.
Background: Checkpoint kinase 1 (Chk1) is a serine/threonine protein kinase
that regulates cell division by arresting progression in the S & G2 phases of the
cell cycle in response to genotoxic stress. Pharmacological inhibition of Chk1
uncouples the completion of DNA replication from G2/M phase transition in
tumor cells that have impaired DNA damage response networks, resulting in
DNA damage induction, mitotic catastrophe and cell death. These properties
make Chk1 inhibition an attractive therapeutic approach as a single agent, or to
enhance the effıcacy of other cancer drugs that target DNA damage response
pathways. Methods and Results: This report highlights the activity of the orally
bioavailable, selective, small molecule Chk1 inhibitor, CASC-578, in multiple
mantle cell lymphoma (MCL) models in vitro and in tumor mouse xenograft
studies. MCL have the common genetic biomarker t(11;14)(q13;q32), a chro-
mosomal translocation leading to the constitutive expression of the oncogene
CCND1which encodes cyclinD1, a cell cycle-regulating protein. This genotypic
characteristic has been observed in the clear majority of patients with MCL in
the clinic and may provide a rationale for sensitivity to Chk1 inhibition. Con-
sistent with this idea, CASC-578 demonstrated remarkable potency as a single
agent in blocking the proliferation of MCL cell lines in vitro, with an average
IC50 of 61 nM. Treatment with CASC-575 as a single agent resulted in the
induction of DNA damage, as measured by phosphorylated histone H2AX
and activation of apoptosis, as measured by cleaved caspase. In a JEKO-1
xenograft tumor study, CASC-578 as a single agent completely regressed
subcutaneously implanted tumors in the majority of mice after oral drug
administration using 20 mg/kg daily or when dosed on an intermittent
schedule at 25mg/kg, withminimal effects on body weight. In addition to the
observed single agent activity of CASC-578, the combination of CASC-578,
and the Wee1 inhibitor AZD-1775, was highly synergistic in MCL cell lines
including JEKO-1, REC-1, Z-138 andMAVER-1 in vitro. CASC-578 was also
highly potent as a single agent, and in combination with AZD-1775, in block-
ing the proliferation of a variety of leukemia derived cell lines in vitro. Taken
together, these data support the advancement of CASC-578 into clinical
development as a potential therapeutic agent for the treatment of MCL, as
well as other hematological malignancies.
#298 WEE1 inhibitor activity correlates to AXL/mTOR expression and
exhibits synergy with temozolomide (TMZ) in small cell lung cancer (SCLC).
Triparna Sen, Pan Tong, Lixia Diao, YouHong-Fan, C. Allison Stewart, John V.
Heymach, JingWang, Lauren A. Byers.UTMDAnderson Cancer Center, Hous-
ton, TX.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Cell Cycle Checkpoint and Progression
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 201776
Background: WEE1 inhibitors (WEEi) are a novel class of small molecule
inhibitors that are now under early clinical trials for small cell lung cancer
(SCLC). WEE1 is a protein kinase that plays a key role in regulating the G2
checkpoint in response to DNA damage. Moreover, because WEE1 inhibition
induces a HR defıcient state, dual targeting ofWEE1 and PARP (another prom-
ising target previously identifıed in our group)may induce synthetic lethality. In
the present study we evaluate the effıcacy of AZD1775 alone and with the PARP
inhibitor, olaparib; investigate the mechanisms of primary resistance to
AZD1775 in SCLC models; and assess the combinatorial effıcacy of AZD1775
treatment with the chemotherapy drug, temozolomide (TMZ), that has shown
promise in patients with recurrent SCLC and has been included in the National
Comprehensive Cancer Network guidelines for standard treatment for SCLC.
Results: Combination of AZD1775 with olaparib revealed an additive effect in
vitro in 90% of SCLC cell lines. AZD1775 combined with TMZ synergistically
decreased viability, increased DNA damage and apoptosis in SCLC cell lines
(n10) irrespective of MGMT status or initial response to AZD1775 alone.
However, unlike the sensitive cells, SCLC cell lines showing primary resistance
to AZD1775 had an intact DNA repair mechanism (after DNA damage), which
may contribute to the resistance mechanism. Proteomic analysis revealed AXL
(receptor tyrosine kinase) and phospho-S6K (S240/244) asmarkers of AZD1775
resistance and treatment with AXL inhibitor, TP0903 (40nM), resensitized the
cells to AZD1775. Pre and post-AZD1775 treated samples revealed sustained
activation of mTOR pathway in AZD1775 primary resistant lines. We further
demonstrated that pre-treatment of the cells with the mTOR inhibitor everoli-
mus sensitized SCLC cells to AZD1775 by causing downregulation of AKT/
mTOR pathway. Conclusion:WEE1 inhibitors are currently in clinical trials for
SCLC patients. However, as with any targeted therapy, drug resistance is an
important barrier to clinical benefıt which could be addressed with therapeutic
combinations. We show the effıcacy of single agent AZD1775 and in combina-
tionwith olaparib.WEE1 inhibitor, AZD1775 synergizes with TMZ irrespective
of MGMT status in all tested in vitro models which warrants further clinical
investigation. We also show that the activity of the WEE1 inhibitors might be
limited in cancer cells overexpressing of AXL and activatedmTOR pathway and
that AXL and mTOR inhibition re-sensitized the cells to AZD1775. Our work
supports further exploration of the combination of PARP and WEE1 in SCLC
and also the possibility of AXL/mTOR inhibition as a mechanism to overcome
WEE1 inhibition resistance in SCLC. SCLC is a disease with very limited thera-
peutic options and no targeted agents with proven benefıt; thus the results from
this study have clear translational benefıt.
#299 RNA editing enzyme ADAR1 accelerates normal hematopoiesis cell
cycle by regulation microRNA biogenesis. Qingfei Jiang, Maria Anna Zipeto,
Nathan Delos Santos, SheldonMorris, Catriona Jamieson.University of Califor-
nia, San Diego, La Jolla, CA.
Compelling murine studies demonstrate that adenosine-to-inosine (A-to-I)
RNA editing mediated by adenosine deaminase associated with RNA1
(ADAR1) is vital for both fetal and adult hematopoiesis. While genetic ablation
of ADAR1 leads to murine embryonic lethality due to severe defects in erythro-
poiesis, conditional deletion in the hematopoietic system impairs maintenance
indicative of cell type and context specifıc roles for ADAR1 in cell fate specifı-
cation and self-renewal. By regulating mRNA and microRNA (miRNA) stabil-
ity, ADAR1 exhibit wide-ranging effects on embryonic development and stem
cell regulation. We have previously shown that inflammation-responsive
ADAR1 plays important roles in both stem cell differentiation and self-renewal
in CML (chronic myeloid leukemia) disease progression. Here, we describe a
novel function of ADAR1 in cell cycle regulation of normal hematopoietic stem
cell and progenitors (HSPC) by regulation of miRNA biogenesis. Our results
demonstrated that ADAR1 induces G0 to G1 phase transition in normal cord
blood HSPCs, as demonstrated by elevated expression of Ki67, reduced DiR
signal, and enhanced in vivo cord blood engraftment. Cell cycle qRT-qPCR
microarray of 84 cell cycle transcripts and whole transcriptome RNA-sequenc-
ing analysis of KEGG cell cycle pathway indicate that several cell cycle genes are
differentially expression upon overexpression of ADAR1WT or an A-to-I edit-
ing defıcient ADAR1 mutant (ADAR1E912A). We previously demonstrated that
impaired biogenesis of let-7 miRNAs by ADAR1 WT induces enhanced self-
renewal in cord blood CD34 HSPCs. To determine the miRNA targets of
ADAR1-mediated RNA editing, we performed miRNome miScript PCR array
of 1008 miRNA candidates in cord blood CD34 HSPCs overexpressing
ADAR1WTorADAR1E912A. Total of 263miRNAswere differentially expressed
(142 upregulated and 121 downregulated) by comparing ADAR1 WT to the
backbone control. Interestingly, ADAR1E912Amutant also exhibit A-to-I editing
independent regulation of miRNAs (307 upregulated and 59 downregulated).
We found that the expression of miR-26a-5p, a miRNA frequently downregu-
lated in leukemia, is inhibited by ADAR1-mediated RNA editing. ADAR1 di-
rectly binds and edits the DROSHA cleavage site of primarymiR-26a transcript,
thereby prevent miR26a-5p maturation. Moreover, lentiviral expression of ma-
turemiR26-5p reverses the effect of ADAR1WT, including enhancedCDKN1A
expression, inhibition of cord bloodproliferation in vivo, aswell as reducedHSC
self-renewal as measured by colony-formation assay. Our fınding suggests care-
fully regulated A-to-I editing by ADAR1 is essential for the maintenance of
proper cell proliferation in HSC. For future study, it will be interesting to inves-
tigate if the elevated expression of ADAR1 in CML BC LSC contributes to false
regulation of cell cycle that leads to the expansion of malignant leukemia stem
cells.
#300 Taeumjowi-tang (TJ001) induces G2/M cell cycle arrest but not apo-
ptosis in p53-mutant prostate cancer via up-regulation of p21WAF/CIP1. Soo-
Yeon Kang, Hyo In Kim, Se Hyang Hong, Jin Mo Ku, Kangwook Lee, Myeong-
Sun Kim, Yu-jeong Choi, Chunhoo Cheon, Youme Ko, ChingWenHuang, Yui
Sasaki, Sohyeon Kang, Hye-Sook Seo, Tai Young Kim, Ji Hye Kim, Yong Cheol
Shin, Seong-Gyu Ko. Kyung Hee University, Seoul, Republic of Korea.
Taeumjowi-tang (TJ001) is a traditional Korean medicine that usually pre-
scribed for Tae-um person to regulate stomach-related symptoms including
headache, indigestion, and jaundice. Other studies on anti-obesity effect of
TJ001 have also been researched, but have never been reported as a cure for
cancer. In the present study, we investigated the molecular mechanism that
TJ001 induces G2/M cell cycle arrest in DU145 (p53-mutant) prostate cancer
cells. The missense mutation in human p53 gene (TP53) confers oncological
effect to tumor suppressor p53-mutant protein. In prostate cancer, this gain-of-
function of p53-mutant is associated with androgen-independence, increased
angiogenesis, andmetastasis. Our in vitro studies showed that a water extract of
TJ001 induced G2/M cell cycle arrest via p53-mutant status and p21WAF/CIP1
up-regulation. Conventinally, p21WAF/CIP1 is induced by mediating p53 regula-
tion, but, in experiments, handling the p53-dependent and -independent path-
way. Although serine15-phosphorylated p53 and p53 proteins remained un-
changed, p21WAF/CIP1 expression is induced and cyclin B1/Cdc2 complex is
inactivated by a decrease of cyclin B1. In addition, in p53-independent pathway,
the level of Cdc25C expression decreased and Serine-216 phosphorylated
Cdc25C increased. Generally, concomitant with G2/M cell cycle arrest come the
apoptosis cell death, but in the study, prolongedG2/Mcell cycle arrest developed
not apoptosis but cell senescence. Therefore, our data suggest that TJ001 is
helpful for p53-mutant prostate cancer treatment.
#301 Prognostic value of metastatic tumoral caveolin-1 expression in pa-
tients with resected gastric cancer. JihyungHong,1Der Sheng Sun,2 SoonAuck
Hong,3 Hye SungWon,2 Han Hong Lee,4 Okran Kim,5 Yoon Ho Ko6. 1Incheon
St.Mary’sHospital, TheCatholic University of Korea, Incheon, Republic of Korea;
2Division of Oncology, Department of InternalMedicine, The Catholic University
of Korea, Seoul, Republic of Korea; 3Department of Pathology, Soonchunhyang
University Cheonan Hosptial, Cheonan, Republic of Korea; 4Department of Gen-
eral Surgery, The Catholic University of Korea, Seoul, Republic of Korea; 5Cancer
Research Institute, College of Medicine, The Catholic University of Korea, Seoul,
Republic of Korea; 6Division of Oncology, Department of Internal Medicine, The
Catholic University of Korea, Seoul, Republic of Korea.
Background: Caveolin-1 (Cav-1), as the main component of caveolae, has
complex roles in tumourigenesis and clinical outcomes in a variety of human
malignancies.We investigated Cav-1 in primary andmetastatic tumor of gastric
cancer (GC) and its association with clinical outcomes. Method: All specimens
evaluatedwere obtained from145patientswithGCwhohadundergone curative
gastrectomy. The primary outcomes measured were the expression levels of
Cav-1 by immunohistochemistry and its association with clinicopathological-
parameters and patient survival. Results: Among the 145 patients, the frequency
of high expression of stromal Cav-1 within primary tumor and tumoral Cav-1
protein inmetastatic lymph nodewere 22.5% (18/145) and 16.6% (15/91). In the
multivariate analysis tumoral Cav-1 protein in metastatic lymph node showed
prognostic signifıcance for relapse-free survival (RFS, HR, 3.934; 95%CI, 1.882-
8.224; P0.001) and cancer-specifıc survival outcome (CSS, HR, 3.985; 95% CI,
1.620 - 8.623; P 0.002). In addition, it remained as a strong indicator of poor
prognosis for RFS (HR, 3.137; 95% CI, 1.445 - 6.810; P 0.004) and CSS (HR,
2.509; 95% CI, 1.079 - 5.838; P  0.033). Conclusions: High expression of tu-
moral Cav-1 protein in metastatic lymph node shows a strong negative associ-
ationwith the clinical outcomes in patientswith curatively resectedGC, suggest-
ing that this protein have potential uses as novel prognostic markers.
#302 A novel epigenetic pathway in medulloblastoma. Nagi Ayad, Clara
Penas. Univ. of Miami Miller School of Medicine, Miami, FL.
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Medulloblastoma is the most commonmalignant pediatric brain tumor with
variable prognosis due to its clinical and genomic heterogeneity. Despite recent
treatment advances, approximately 40% of children experience tumour recur-
rence, and 30% will die from this disease. Therefore there is a need to develop
novel therapies for patients. We recently reported that Casein kinase 1 (CK1)
may be an attractive therapeutic target for medulloblastoma. CK1 is a serine/
threonine kinase that controls cell cycle progression, signal transduction and
neurogenesis. We found high levels of CK1 protein in mouse models of me-
dulloblastoma and humanmedulloblastoma samples. Furthermore, CK1 inhi-
bition dramatically reduced medulloblastoma tumor progression. We demon-
strate here that CK1 phosphorylates the epigenetic reader bromodomain-
containing protein 4 (BRD4). BRD4 has been identifıed as a therapeutic target in
several cancers, including medulloblastoma. We demonstrate that CK1 phos-
phorylates BRD4 and that CK1 is required for BRD4 binding to the Gli1 pro-
moter in vitro and in vivo. Furthermore, combined CK1/BRD4 inhibition is a
novel means of reducing medulloblastoma growth downstream of SUFU and
SMO. These studies defıne a novel therapeutic means of inhibiting SMO inhib-
itor resistant medulloblastoma.
#303 Oncogenic activity of amplifıed miniature chromosome mainte-
nance 8 in human malignancies. Jian-Hua Luo, Dong-Mei He, Baoguo Ren,
Yan Yu. Univ. of Pittsburgh Medical Ctr., Pittsburgh, PA.
Miniature chromosome maintenance (MCM) proteins play critical roles in
DNA replication licensing, initiation and elongation. MCM8, one of the MCM
proteins playing critical role inDNA repairing and recombination, was found to
have over-expression and increased DNA copy number in a variety of human
malignancies. The gain of MCM8 is associated with aggressive clinical features
of several human cancers. Increased expression of MCM8 in prostate cancer is
associated with cancer recurrence. Forced expression ofMCM8 in RWPE1 cells,
the immortalized but non-transformedprostate epithelial cell line, exhibited fast
cell growth and transformation, while knocked down of MCM8 in PC3, DU145
and LNCaP cells induced cell growth arrest, and decreased tumor volumes and
mortality of severe combined immunodefıciency mice xenografted with PC3
and DU145 cells. MCM8 bound cyclin D1 and activated Rb protein phosphor-
ylation by cyclin-dependent kinase 4 in vitro and in vivo. The cyclin D1/MCM8
interaction is required for Rb phosphorylation and for S phase entry in cancer
cells. As a result, our study showed that copy number increase and overexpres-
sion of MCM8 may play critical roles in human cancer development.
#304 CLIC1 membrane insertion is a pivotal regulator of glioblastoma
stem cell G1-S transition by promoting an increase of chloride permeability.
Ivan Verduci,1 Valentina Carlini,1 Federica M. Raciti,1 Matteo Conti,1 Federica
Barbieri,2 Tullio Florio,2 Michele Mazzanti1. 1University of Milano, Milano, It-
aly; 2University of Genova, Genova, Italy.
Glioblastoma (GBM) is the most aggressive and lethal brain tumor and, despite
aggressive surgery and adjuvant radiotherapy and/or chemotherapy, the prognosis
remains invariantly poor. As for most of solid and hematological malignancies, it
wasdemonstrated that thebulkof tumor cells inGBMis generatedbya rare fraction
of self-renewing, multipotent cancer stem cells (CSCs) and the persistence of CSCs
within the tumor mass is considered the main determinant of GBM development,
progression, recurrence and radio- or chemoresistance. Thus, one of themain goals
ofcurrent research is to identify specifıcbiologicalmechanismsor intracellularpath-
ways of CSCs whose pharmacological targetingmight affect their survival and pro-
liferation. Inparticular, little isknownabout thepossibility that themolecularmech-
anisms underlying cell-cycle control in GBM CSCs are endowed with specifıc and
unique features as compared with normal cells. Our study is based on the observa-
tion thatGBMcells express higher levels of chloride intracellular channel 1 (CLIC1)
as compared tononmalignantbraincells and that inCSCsCLIC1 ismainly localized
in themembrane forminganactivechannel.Conversely, inphysiological conditions
CLIC1 is mainly a cytoplasmic protein only transiently translocating to the mem-
brane.We recently showed that the different level of activity of CLIC1 in CSCs and
normal mesenchymal stem cells confers CLIC1-targeting drugs (for example the
biguanidemetformin) selective cytotoxicity toward tumorcells.Herewereport, that
in response to stress conditions, CLIC1 increases the probability tomodify its struc-
ture going froma cytoplasmic hydrophilic form to a transmembrane conformation.
Once in the membrane, CLIC1 acts as a chloride permeability, participating, to-
gether with NADPHoxidase, to the generation of a chronic state of oxidative stress
that favor the transitionbetweenG1andSphase.Thepeculiarity ofCLIC1exposure
on the external face of the GMB CSC plasma membrane support the idea that this
protein could represent a main determinant of the cell cycle progression in this
tumor cell subpopulation and thus an accessible and relevant pharmacological tar-
get to eradicate CSCs in GBM.
#305 TET blocks cell cycle progression in pancreatic cancer cells at G1-S
boundary by decreasing cyclin D1 and increasing CDK inhibitors (CKIs),
p21 (WAF1, Cip1) and p27 (Kip1). Karnika Singh, Qin Dong, Sweaty Koul,
Hari K. Koul. LSUHSC, Shreveport, LA.
Introduction: Pancreatic cancer (PaCa) is the fourth leading cause of cancer
related deaths in the United States with an overall fıve-year survival rate of less
than fıve percent. The current standard treatment/s for PaCa are largely ineffec-
tive thus there is an urgent need for development of therapeutic agents for the
treatment of PaCa. Owing to its mutational landscape, which involves mutated
KRAS and p53 genes these cancer cells have a deregulated G1 checkpoint of cell
cycle control and therefore confer high rate of proliferation and therapeutic
resistance. Recently we observed that Tetrandrine derivative (TET), a bis-ben-
zylisoquinoline alkaloid halts cell cycle progression at G0/G1 boundary in vitro
and in vivo. In the present study we evaluated potential mechanism of TET
induced cell cycle arrest in two pancreatic cancer cells with either wild type
KRAS or mutant KRAS, and mutant p53 by evaluating critical cell cycle regula-
tory proteins involved inG0/G1 to S transition.Methods: Pancreatic Cancer cell
lines: BxPC3 (Pancreatic Ductal Adeno-Carcinoma) andMiaPaCa2 (pancreatic
carcinoma) were used in the study. Cells were treated with various concentra-
tions of TET for different time points. Cell proliferation was evaluated using the
MTT survival assay. Cell cycle was analyzed following PI staining via Flow cy-
tometry. Changes in protein expression were analyzed byWestern Blot analysis
in cells. Changes inmRNAwere evaluated by real time PCR. Results: Treatment
of pancreatic cancer cells with TET resulted in decreased levels cyclin D1 and
phospho-Rb, two critical proteins required for G0/G1 to S transition. Pretreat-
ment of the cells with proteasomal inhibitor MG132 was able to increase the
levels of cyclin D1 in control cells but was unable to prevent its loss upon TET
treatment. Our results also show that levels of CKIs, p21WAF1/Cip1 and p27Kip1
were increased at the protein level. Gene expression analysis revealed that cyclin
D1 mRNA was decreased and p21WAF1/Cip1 mRNA was increased while there
was no signifıcant change in p27 mRNA levels. The cycloheximide chase re-
vealed that TET stabilizes p27Kip1 and to some extent p21WAF1/Cip1 as well, sug-
gesting that TET increased p27Kip1 and also p21WAF1/Cip1 levels in part by in-
creasing protein stability. These data suggest a complex mechanism by which
TET regulates expression of critical cell cycle regulatory molecules at both tran-
scriptional, translational and post-translational level. Such a mechanism would
provide for cell cycle arrest in pancreatic cancer cells following TET treatment.
Conclusion: These results show that TET halts cell cycle at G0/G1 boundary in
PaCa cells by modulating the cell cycle regulatory proteins and stabilizing the
CKIs by altering their protein stability, suggesting that TET can not only halt
deregulated cell cycle but also overcome the therapeutic resistance in pancreatic
cancer cells.
#306 Antitumor effect of Wee1 inhibitor in gastric cancer cells.
Seongyeong Kim,1 Ahrum Min,1 So Hyeon Kim,1 Dong Hyeon Ha,1 Hyemin
Jang,1 Yu JIn Kim,1 Hee Jun Kim,2 Kyung-Hun Lee,1 Tae-Yong Kim,1 Do-Youn
Oh,1 Yung-Jue Bang,1 Seock-Ah Im1. 1SNU Cancer research Institute, Seoul,
Republic of Korea; 2Chung-Ang University College ofMedicine, Seoul, Republic of
Korea.
Background: A cell cycle checkpoint is a key step to watch any damages and,
it is needed to maintain genomic stability. Thus, to jeopardize cell cycle check-
point is an attractive strategy for cancer treatment. Wee1 is a G2 cell cycle
regulator that phosphorylate cdc2 on tyrosine 15 for inhibiting its activity. The
activation ofWee1 can delayG2phase progression and cells can have a chance to
repair DNA damages. Therefore, to inhibit wee1 can accelerate DNA damage
accumulation in the cell. AZD1775 is a fırst-in-class wee1 inhibitor. So far, pre-
vious studies showed the antitumor effect of AZD1775 as a mono-therapeutic
agent or combination treatment with other chemo-agents. However, the activity
of wee1 in gastric cancer (GC) cells is not yet fully understood. Thus, we would
like to study whether AZD1775 has an antitumor effect against GC or not.
Materials and methods: We determined the antitumor effects of AZD1775 on
GCcells using a cytotoxicity assay, cell cycle analysis, immunofluorescence assay
and western blotting by AZD1775 treatment. Results: AZD1775 effectively in-
hibit GC cell proliferation. The TP53 gene status or p-Wee1 expression levels
were not associated with AZD1775 sensitivity. AZD1775 effectively down-reg-
ulated p-Wee1 and p-cdc2 expressions in SNU-601, a sensitive cell line. How-
ever, these effectswere not signifıcant inKATO-III cells, which is less sensitive to
AZD1775. Cell cycle analysis revealed that the cells had different responses by
AZD1775 treatment. SNU-601 cells were enriched in S phase when we decide
cell cycle only by its DNA contents. However, KATO-III cells were arrested in
G2/M phase. The sub-G1 population was dramatically increased only in SNU-
601 cells. A population of BrdU-positive and p-HH3 positive cells was signifı-
cantly increased in the SNU-601 cells which indicate that prematuremitosis was
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Cell Cycle Checkpoint and Progression
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 201778
increased. However, no differences were observed in KATO-III cells. Moreover,
due to premature mitotic entry, multi-nucleated cells were observed only in
SNU-601 cells. Conclusion: AZD1775 effectively inhibited the growth ofGC cell
lines. The inhibition of cdc2 by AZD1775 was observed only in a sensitive cell
line. Moreover, early mitotic entry was induced by AZD1775, and it led the
induction of mitotic catastrophe. This result indicates that AZD1775 have an
antitumor effect onGCand the possibility of adoption to the clinical trial design.
#307 TRIB3 regulates cell cycle progression and programmed cell death in
non-small cell lung cancer. Abeer Almiman, Daotai Nie, Jamila Adom. South-
ern Illinois Univ. School of Medicine, Springfıeld, IL.
Introduction: The pseudokinase Tribbles pseudokinase 3 (TRIB3) is known
as a regulator in cellular responses to a variety of stresses such as glucose insuf-
fıciency and (ER) stress. TRIB3 has been described in some studies as a tumor
suppressor due to its effect on inactivating PI3K/Akt pathway, but other studies
suggest TRIB3 as a stimulator of tumor progression. In this study, we aimed to
defıne the functions of TRIB3 in in non-small cell lung cancer. Methods: TRIB3
expression was altered using a lentiviral vector to overexpress TRIB3 in non-
small cell lung cancer. ACRISPR-CAS9 constructwith guiding sequencematch-
ing to TRIB3 gene was used to knock out its expression. Cell proliferation was
evaluated usingMTS and trypan blue assays. Boyden chamber assay was used to
assess the cell migration while cell cycle phases were determined using flow
cytometry. Heatmap analysis was performed to assess the changes in the expres-
sions of genes in cell cycle progression and apoptosis. Results: TRIB3 overex-
pression led to reduced cell proliferation and migration. Moreover, it contrib-
uted to the increased of cell cycle arrest at G0/G1 phase. QPCR analyses of cell
cycle related genes showed an upregulation of CDK inhibitors in (NCI-H358)
TRIB3 overexpression cells, while depletion of TRIB3 led to the down-regula-
tion of CDK inhibitors. TRIB3 overexpression led to downregulation of LC3B
and other autophagy markers while increasing the expression of apoptotic
genes. Conclusion: Increased TRIB3 expression in non-small cell lung cancer
cells inhibited proliferation by blocking cell cycle progression through the up-
regulation of CDK inhibitors, led to activation of cell death through apoptosis.
Our study reveals a signifıcant role of TRIB3 in regulating cell cycle progression,
apoptosis and autophagy.
#308 The PP2A-B56 phosphatase opposes cyclin E autocatalytic degrada-
tion via site-specifıc dephosphorylation. Ryan J. Davis, Jherek Swanger, Bruce
E. Clurman. Fred Hutchinson Cancer Research Ctr., Seattle, WA.
Cyclin E, in conjunction with its catalytic partner cyclin-dependent kinase 2
(CDK2), regulates cell cycle progression as cells exit quiescence and enter S-
phase. Multiple mechanisms control cyclin E-CDK2 activity during the cell cy-
cle, including phosphorylation-dependent cyclin E ubiquitylation by the
SCFFbw7 ubiquitin ligase. Serine 384 (S384) is the critical cyclin E phosphory-
lation site that stimulates Fbw7 binding and subsequent cyclin E degradation.
Because S384 is autophosphorylated by CDK2, cyclin E therefore instigates its
own degradation in an autocatalytic manner. This presents a paradox as to how
cyclin E-CDK2 is able to phosphorylate its numerous substrates prior to cyclin E
autophosphorylation-catalyzed degradation. Here we fınd that the PP2A-B56
phosphatase specifıcally dephosphorylates cyclin E at S384, thereby uncoupling
cyclin E degradation from cyclin E-CDK2 activity. Furthermore, the rate of S384
dephosphorylation is high in interphase and low inmitosis, allowing PP2A-B56
to oppose autocatalytic cyclin E degradation and maintain cyclin E-CDK2 ac-
tivity at the G1/S transition.
#309 Effect of histonedeacetylase (HDAC) inhibitor ongene expression in
MDM2 transfected prostate cancer cells. Thiagarajan Venkatesan,1 Ali Alas-
eem,2 Khalid Alhazzani,2 Thanigaivelan Kanagasabai,1 Appu Rathinavelu1.
1Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern Univer-
sity, Fort Lauderdale, FL; 2College of Pharmacy, Nova Southeastern University,
Fort Lauderdale, FL.
Deacetylation of histone gives a tag for epigenetic repression and plays an
important role in transcriptional regulation, cell cycle progression, and devel-
opmental events. HDACs catalyse the removal of the acetyl moiety from the
lysine residues of proteins including the core nucleosomal histones. Through
removal of critical acetyl groups from histones, HDACs can create a chromatin
conformation that can prevent the transcription of genes that encode for pro-
teins involved in cell cycle regulation. Thus together with histone acetyltrans-
ferases (HATs), HDACs regulate the level of acetylation and alter multitude of
cellular functions and their characteristics. Several alterations of HDAC and
HAT levels and activities have been found to be enacted by translocation, am-
plifıcation, overexpression, or mutation of the relevant genes in a variety of
cancers. In many cancer cell lines, overexpression or activation of the HDAC
enzymes result in histone hypo-acetylation and consequent promotion of pro-
cancerous mechanisms. Therefore, HDAC inhibitors represent a potential new
class of antitumor agents with cytotoxic activity and the ability to regulate gene
expression in tumor cells. In this study we evaluated the effects of Vorinostat
(suberoylanilide hydroxamic acid), which is a potent inhibitor of HDAC activ-
ity, on cell cycle regulation in MDM2 (mouse double minute 2 homolog) over-
expressing cells. MDM2 amplifıcation or overexpression is found in many tu-
mors that eventually lead to the inactivation of the cell cycle control and loss of
pro-apoptotic functions through both p53 dependent and independent mecha-
nisms. The PCR array, qRT-PCR, and western blot analysis of MDM2 overex-
pressing prostate cancer cells (LNCaP-MST), after treating with Nutlin-3 (20
m) and 17-AAG (10 m), was able to trigger p21 expression and down-regu-
lation of BIRC5 (Baculoviral IAP Repeat Containing 5). Similarly, when we
treated theMDM2 transfected LNCaP-MST cells with vorinostat (7.5m for 24
hrs), some of the above mentioned changes, similar to Nutlin-3 treatment, were
observed. As a result of HDAC inhibition the mRNA levels of p21, p53 and
TIMP-1 were signifıcantly elevated, while the levels of BIRC5 was signifıcantly
down-regulated. Thus, treatment of MDM2 overexpressing cell lines with
HDAC inhibitor resulted in activation of p21 and consequent decrease in cell
proliferation due to resumption of cell cycle arrest. Our results with LNCaP-
MST cells offer convincing evidence to suggest that the inhibition of HDAC can
control cell proliferative signals in MDM2 overexpressing prostate cancer cells.
(The generous support from the Royal Dames of Cancer Research Inc., Ft. Lau-
derdale, Florida is gratefully acknowledged).
#310 Enhanced stability of D-type cyclins correlates with glioblastoma
resistance to ionizing radiation. Fadila Guessous, Mouadh Benamar, Hui
Zhong, Tarek Abbas. Univ. of Virginia, Charlottesville, VA.
Transition from G1 to S phase of the cell cycle is promoted by D-type
cyclins (D1, D2 and D3), regulatory subunits critical for the activation of
cyclin dependent kinases 4 and 6 (CDK4/6), which phosphorylate and inac-
tivate the retinoblastoma protein (pRb) and activate the transcription factor
E2F1 to promote the expression of genes essential for DNA synthesis. De-
regulated expression of D-type cyclins is frequently observed in human ma-
lignancies and correlates with increased proliferation. Cyclin Ds overexpres-
sion is also associated with radioresistance, leading to radiotherapy failure
and disease recurrence. Cyclin D1 undergoes ubiquitin-dependent degrada-
tion following the exposure of cancer cells to ionizing radiation (IR), and this
has been shown to be critical for IR-induced G1 growth arrest and sensitivity
of cancer cells to IR. While the role of cyclin D1 overexpression in drug
resistance is already well documented, less is known about the role of cyclins
D2 and D3 in radio-resistance in human cancer cells, particularly in brain
neoplasms. In the present study, we investigated the effect of IR on different
D-type cyclins (D1, D2, D3) in human glioblastoma cell lines as well as in
tumor-derived mouse oligodendrocytes progenitor cells (OPCs). Here, we
show that exposure of human astrocytes to increasing levels of IR led to a
rapid proteasomal degradation of all three D-type cyclins. On the other
hand, IR failed to induce signifıcant cyclin Ds degradation in a number of
human glioblastoma cells (U87, A172, U251, Snb19). Analysis of cell cycle
profıle of all glioblastoma cells tested and exposed to IR showed prominent
cell cycle arrest in G1 starting at 24 hours following exposure. Furthermore,
we show that the steady-state levels of D-type cyclin is higher in OPCs
compared to mouse NIH3T3 cells and fail to undergo proteasomal degrada-
tion following IR exposure. Collectively, these results suggest that the deg-
radation of D-type cyclins is not critical for IR-induced G1 cell cycle arrest in
GMB and may underlie their resistance to IR. Understanding the role of
cyclin Ds in promoting radioresistance may lead to a useful pharmacological
strategy to enhance radiotherapy outcome and help implement a more ef-
fective treatment modality.
#311 Development of AZD2811, an aurora kinase B inhibitor, incorpo-
rated into an AccurinTM nanoparticle for use in haematological and solid
cancers. Susan Ashton,1 Nicholas Floch,2 Paula Taylor,1 Colin Howes,2 Doug
Ferguson,3 Matthew Ling,4 Maureen Hattersley,3 Shenghua Wen,3 Kim Mar-
atea,3 Adina Hughes,4 Sean Redmond,3 Wolfram Brugger,2 Simon Smith,2 Al-
exanderMacDonald,2 Keith Parry,5 Howard Burris,6 Young-Ho Song,7 JimNo-
lan,7 Elizabeth Pease,2 Simon T. Barry2. 1AstraZeneca, Macclesfıeld Cheshire,
United Kingdom; 2AstraZeneca, Cambridge, United Kingdom; 3AstraZeneca,
Gatehouse Park Boston, MA; 4AstraZeneca, Macclesfıeld, United Kingdom;
5Sarah Cannon Research Institute, London, United Kingdom; 6Sarah Cannon
Research Institute, Nashville, TN; 7Pfızer, New York, NY.
A nanoparticle formulation of AZD2811, a selective aurora kinase B inhibitor, is
currently under clinical development for the treatment of both haematological and
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solid tumour disease. AZD2811 is the active derivative of the prodrug Barasertib
(AZD1152)whichgavepromising clinical activity in elderlyAMLpatients delivered
as a 7-day infusion (Kantarjian et al, Cancer, 119, 2611-2619, 2013). To address the
limitations associatedwith the clinical utility ofBarasertib andother cell cycle inhib-
itors in the clinic, AZD2811 has been incorporated into anAccurinTM nanoparticle
using a pamoic acid ion pairing approach to optimise drug release rate (Song et al,
Journal of Controlled Release, 229, 106-119, 2016), improve the drug exposure to
tumourandreduce thedurationof administration.Aproofofprinciple formulation
of AZD2811 as an AccurinTM nanoparticle established the principle that anti-tu-
mour activity and improved therapeutic index could be achieved (Ashton et al,
Science Translational Medicine, 325, 1-10, 2016). The clinical nanoparticle formu-
lation of AZD2811 has been optimised for drug loading and release rate. In pre-
clinical models, the clinical formulation can be used flexibly to optimise drug deliv-
ery for use in both haematological disease such asAML, or in solid tumour settings.
Anti-tumour activity in solid tumours can be achieved at doseswhere bonemarrow
toxicity is reduced compared to Barasertib. In sensitive xenograft and PDX solid
tumourmodels greater than 90% tumour regression is observed after a total dose of
50mg/kgwithno tumourprogression forgreater than40days. In contrast, forAML,
increasing the dose intensity by 2-4 fold leads to neutropenia and to complete tu-
mour regression ina rangeofAMLxenograftmodels for greater than60days.These
data establish the concept that drug delivery using nanoparticles is able to resolve
therapeutic index challenges, and is able to do so across different disease types.
AZD2811 is currently in Phase 1 clinical trial (D6130C0000). The current pre-clin-
ical and clinical data with this novel approach to inhibition of the cell cycle will be
discussed.
#312 Anti-proliferative effects of cinnamon extract in colon cancer. Pat-
rick P. Carriere, Hina Mir, Neeraj Kapur, Clarence E. Clark, Shailesh Singh.
Morehouse School of Medicine, Atlanta, GA.
Colon cancer is the third most lethal cancer worldwide, and is estimated to
cause 49,190 cancer-related deaths in the U.S. in 2016 alone. Current treatments
for colon cancer are limited in their capacity to target tumor cells employing
adaptive mechanisms necessary for survival and proliferation, often resulting in
poor prognosis. Therefore, it is critical to develop novel target-specifıc therapeu-
tic approaches with minimal cytotoxicity to normal cells, in order to mitigate
potential side effects. Proanthocyanidins represent a subclass of flavonoids,
which have been widely investigated for their chemopreventive and therapeutic
potential. Cinnamtannin B-1 (CTB-1) is a proanthocyanidin shown to have
anti-cancer effects in several cancers, but its anti-cancer potential in colon can-
cer has not been tested. Hence, the focus of this study was to determine the
anticancer effects of CTB-1 in colon cancer. Our results show that CTB-1 treat-
ment signifıcantly decreases the cell viability and proliferation of DLD-1 and
COLO 201 human colon cancer cells in a time and dose-dependent manner. In
addition, CTB-1 treatment modulated the cell cycle progression of colon cancer
cells via G2/M arrest, coupled with a reduction of cells in the S phase. The
expression and/or phosphorylation of key molecules involved in apoptosis and
cell cycle progression were also modulated in response to CTB-1 treatment.
Collectively, these fındings, for the fırst time, shed light on the anti-proliferative
effects of CTB-1 in colon cancer, and further demonstrate its potential as a novel
therapeutic/preventive agent.
#313 Tbata induces G2/M cell cycle arrest and sensitizes osteosarcoma
cells to etoposide in ap53-independentmanner.MilosD.Miljkovic, FrancisA.
Flomerfelt, Ronald E. Gress. National Cancer Institute, Bethesda, MD.
Thymus, brain, and testes-associated (Tbata) is a negative control cell-cycle
gene highly expressed in murine thymic epithelial cells (TECs). Tbata protein
binds to Uba3, inhibiting formation of Nedd8 E1 and subsequent target degra-
dation via neddylation of several cell cycle control proteins needed for G2/M
transition, which may be a major mechanism of TEC growth arrest during thy-
mic involution. Etoposide is a cytotoxic drug which targets the enzyme toposi-
merase II — increased 2-3 fold during the G2 phase. To further characterize
effect of Tbata on the cell cycle, we modifıed p53 wild-type U2OS cells derived
from human osteosarcoma to express a Tbata/mCherry fusion protein when
mifepristone is added to culturemedia. Tbata-expressing cells identifıed on flow
cytometry did exhibit growth arrest, with quantitative assessment of DNA con-
tent in U2OS cells by flow cytometry establishing that 32% of Tbata/mCherry-
expressing cells were in theG2phasewhen exposed tomifepristone for 24 hours,
compared to 11% of mCherry-expressing cells. Gene expression studies were
consistent with these results. Cells expressing Tbata/mCherry were also more
sensitive to etoposide at 0.5, 1, and 5 times the IC50 dose. To test whether p53
function was required, we further modifıed the cells to overexpress a dominant
negative p53mutant alongwithTbata/mCherry. SimilarG2 arrest and increased
sensitivity to etoposidewere observed, indicating that the effects of Tbata did not
require normal p53 function. Potential Tbata analogues or mimetics may there-
fore be used as an adjunct to G2-targeted chemotherapy.
#314 Evaluation of effective drug combinations of sonidegib and riboci-
clib for treatment of Sonic hedgehog medulloblastoma using mathematical
models of the cell cycle and Hedgehog pathways. Zack Jones, Jessica Roberts,
HaleyHouke,MartineRoussel, Clinton Stewart, Carl Panetta. St. JudeChildren’s
Research Hospital, Memphis, TN.
Sonic hedgehog (SHH) tumors account for roughly 25% of all pediatric medul-
loblastoma.Aberrant signalingof theSHHpathway, typicallyviaPatched-1(PTCH)
mutation, results in cell proliferation and subsequent tumor formation. Smooth-
ened (SMO) inhibitors such as sonidegib have beenused clinically to combat tumor
progression and have shown initial promise. However, many tumors acquire resis-
tance to therapy. Combination therapy with an additional agent targeting another
node in pathways affecting cell-cycle progression such as ribociclib, a cyclin D-de-
pendent kinase (CDK) 4/6 inhibitor, may improve therapy and reduce tumor bur-
den by delaying or preventing the development of resistance. Identifıcation and
evaluation of effective anti-cancer drug combinations, along with their schedule,
sequence, and dosage are a major challenge due to the large number of possible
combinations in addition to the cost and time involved in experimentally testing
eachpossiblepermutation.Mathematicalmodels canaid in thediscoveryofoptimal
drug combinations. A mathematical model of the SHH and Cyclin D / CDK / Rb
pathways was designed to evaluate effective sequences and schedules of sonidegib
and ribociclib for the treatment of SHHmedulloblastoma. Themodel was parame-
terized using in vitro data from studies treating theNIH3T3 cell linewith sonidegib
and ribociclib singly or in combination. Flow cytometry analysis was used to quan-
tify response to treatmentbyobtainingcell-cyclephasedistributions foreachdrugas
a single agent or in combination. Uncertainty and sensitivity analysis of the model
parameters were evaluated via Latin Hypercube Sampling and Partial Rank Corre-
lation Coeffıcient analysis to interpret the effects of amplifıcation or deletion of
nodes in the pathway, evaluate potential targetable nodes, and identify sensitive
parameters that need robust quantifıcation. Sensitivity analysis indicated that the
formation of Cyclin D/CDK4/6 complexes and the dephosphorylation of Rb were
signifıcant nodes that should be included in the model. Uncertainty analysis indi-
cated that themajority of the variability lies in the distribution of cells inG0/G1 and
S phase. Simulations of single agent treatment predict a similar response between
sonidegib and ribociclib, with co-treatment indicative of an additive effect. Optimal
control theory methods are being applied to this model to help determine effective
sequence, schedule, and dose of sonidegib and ribociclib to improve effıcacy and
reduce drug resistance in the treatment of SHHmedulloblastoma.
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#315 S100B regulates IL-6 signaling via the p90 ribosomal S6 kinase (RSK)
in malignant melanoma. Milad J. Alasady,1 Kaylin A. Adipietro,1 Adam D.
Pierce,1 Paul T. Wilder,1 Kira G. Hartman,1 David J. Weber,1 Nissim Hay2.
1University of Maryland, Baltimore, Baltimore, MD; 2University of Illinois, Chi-
cago, Chicago, IL.
S100B is a tumor marker that is highly elevated during the progression of
malignant melanoma. However, the function of S100B in the progression of
melanoma is notwell understood.Herewepropose a regulatorymechanism that
defınes interplay between S100B, Interleukin-6 (IL-6), STAT3, and CREB. First,
we show that S100B inhibits IL-6 mRNA and protein levels, and that silencing
S100B in melanoma cell lines induces the expression and secretion of IL-6.
Consistent with this result, STAT3 phosphorylation and its activation occur
upon S100B ablation and IL-6 production.Our data suggest that S100B exerts its
effect on the IL-6 pathway via p90 ribosomal S6 kinase (RSK), leading to activa-
tion of transcription factor CREB. Elevated S100B in melanoma cells were
shown to bind directly to RSK, sterically block its phosphorylation (at Thr573)
and sequester RSK in the cytoplasm (Hartman et al., 2014). Silencing of S100B
enables RSK nuclear translocation, which in turn elevates CREB phosphoryla-
tion and its transcriptional activity in the nucleus to induce IL-6 expression,
which is consistent with these newer observations. Because IL-6 can inhibit the
proliferation ofmelanocytes and early stagemelanoma cells, we propose that the
suppression of IL-6 by elevated S100B may be a mechanism for cancer cells to
circumvent the inhibitory effect of IL-6 at early stages of melanoma. Addition-
ally, the suppression of IL-6 by elevated S100B may also curb local immune
response(s), which otherwise would be elevated by the secreted IL-6.
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#316 Identifıcation of SGK1 as a potential therapeutic target in castrate
resistance prostate cancer. Massar I. Alsamraae, Urzsula McClurg, Craig N.
Robson, Stuart McCracken. Northern Institute For Cancer Research, Newcastle
upon Tyne, United Kingdom.
Introduction: Prostate cancer (PC) is the most common male cancer in the
UK, with approximately 1 in 8 men developing the disease within their lifetime
(Prostate Cancer UK). The androgen receptor (AR) has a crucial role in the
proliferation and progression of prostate cancer. Patients respond to anti-an-
drogen therapy in the early stage of the disease, however many will develop
resistance, entering a “castrate-resistant” disease state (CRPC), carrying a very
poor prognosis, posing a major clinical challenge (1). The development of sec-
ond generation anti-androgen therapies, such as Enzalutamide and ARN-509,
have shown promise in the treatment of CRPC patients, but response rates of
just 50% and the development of resistance to these drugs have limited their
success in the clinic (2,3). This study aims to interrogate the global gene expres-
sion consequences of anti-androgen resistance in an LNCaP prostate cancer cell
line model, resistant to Enzalutamide. In our gene microarray, SGK1 demon-
strates high expression in Enzalutamide resistant cells. Our subsequent experi-
ments suggest SGK1 may serve as a biomarker of resistance or perhaps an ex-
ploitable target inCRPC.Methods:A genemicroarraywas used to determine the
gene profıle of parental LNCaP cells, sensitive to anti-androgen drugs, versus
in-house generated LNCaP-Enzalutamide Resistant cells. QPCR to determine
the mRNA level of SGK1 /- Dihydrotestosterone (DHT), /-Dexametha-
sone.Western blot used to detect the protein level of the SGK1. IncuCyte used to
determine the proliferation.WoundHealing Assay to detect the direction of the
cells toward the edges Results: These preliminary data demonstrate an increase
in expression of SGK1 in the LNCaP-Enz-R cell line model, compared with
parental LNCaP cell, at both the protein and mRNA levels. We have demon-
strated that stimulating AR by DHT also increases SGK1 expression at both the
protein and mRNA levels, in both cell lines. In addition, it is shown that activa-
tion of the glucocorticoid receptor (GR) by stimulation with Dexamethasone
increases SGK1 expression at themRNA level only in LNCaP cells, however high
SGK1 expression is observed at the mRNA AND protein level in the LNCaP-
Enz-R cell line. Inhibition of SGK1using smallmolecular inhibitors signifıcantly
decreases proliferation andmigration of the LNCaP-Enz-R cell line, whereas no
signifıcant difference is seen in the parental, androgen sensitive LNCaP cell line.
Conclusion: Increased expression of SGK1 in Enzalutamide, Casodex and
ARN509 resistant cell line models was observed, compared with parental LN-
CaP cells. AR regulates SGK1 in both parental LNCaP and LNCaP-Enz-R cell
linemodels. GR regulates SGK1 in the LNCaP-Enz-R cell line alone. SGK1 has a
vital role in the proliferation andmigration of the LNCaP-Enz-R cell linemodel.
SGK1 could represent either a future biomarker of Enzalutamide-resistance, or
a potential therapeutic target in advanced disease.
#317 Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4
andCDK6 inhibitor (abemaciclib) enhances antitumor effıcacy inKRASmu-
tant non-small cell lung cancer (NSCLC).Wenjuan Wu, Shripad V. Bhagwat,
Constance King, Susan Pratt, Xueqian Gong, Julie Stewart, Bonita Jones, Robert
Flack, Richard Beckman, Beverly Falcon, Jason Manro, William T. McMillen,
Ramon V. Tiu, Sheng-Bin Peng, Christoph Reinhard, Sajan Joseph, Sean Bu-
chanan. Eli Lilly and Company, Indianapolis, IN.
ERK1/2, a key downstream effector of RAS mutations, is involved in the
signaling network which drives cell proliferation, survival, metastasis and
cancer resistance to drug treatment (including MEK and BRAF inhibitors).
Lung cancer is a leading cause of cancer death worldwide. KRAS mutation
present in up to 30% of NSCLC patients is associated with a poor prognosis
and represents an unmet medical need. In KRAS mutant NSCLC, enhanced
ERK activation cooperates with dysregulation of the cell cycle checkpoint
(e.g., cyclin D, CDK4 and CDK6 complex), and contributes to tumor pro-
gression; thus, the simultaneous inhibition of ERK and the CDK4/6 pathway
is hypothesized to augment tumor growth inhibition. LY3214996, a novel
and highly selective small molecule inhibitor of ERK1 and ERK2, is currently
in phase I clinical trial and has been shown to inhibit cell proliferation in RAS
or BRAF mutant tumor cells in vitro and xenograft tumor growth in vivo.
Abemaciclib, a CDK4 and CDK6-selective inhibitor is currently in phase III
studies for ER positive breast cancer and KRASmutant NSCLC. In this study
we explore the potential effıcacy of combined inhibition of ERK1/2 and
CDK4 and CDK6 in KRAS mutant NSCLC. The combination of LY3214996
and abemaciclib synergistically inhibited cell proliferation in 85% of KRAS
mutant cells in an unbiased NSCLC panel. Combination treatment with
LY3214996 and abemaciclib signifıcantly decreased levels of phospho-
p90RSK, phospho-Rb, phospho-S6 and Ki67; and synergistically inhibited
cell proliferation and survival in KRAS mutant NSCLC cell lines including
NCI-H2122 (G-12C), A549 (G-12S) and NCI-H441 (G-12V). Subsequent in
vivo studies showed that the combination treatment with LY3214996 and
abemaciclib was well tolerated and led to more robust tumor growth inhibi-
tion or regression in all KRAS mutant NSCLC xenograft models (H2122,
A549 and H441) compared with either single agent treatment (p0.002).
Furthermore, in xenograft tumors the combination of LY3214996 and abe-
maciclib resulted in more signifıcant reduction of phospho-p90RSK, phos-
pho-Rb, phospho-S6 and Ki67 in H2122 tumors compared with either single
agent. Overall, the combined inhibition of ERK1/2 and CDK4 and CDK6was
tolerated and enhanced antitumor effıcacy in several KRAS mutant NSCLC
preclinical models. These data support the feasibility of combining ERK
inhibitor LY3214996 with CDK4 and CDK6 inhibitor abemaciclib as a
promising strategy for the treatment of KRAS mutant NSCLC patients, and
provides the rationale for the combination study in the on-going phase I
LY3214996 clinic trial (NCT02857270).
#318 Identifıcation of FERM domain-containing protein 5 (FRMD5) as a
novel target of -catenin/TCF7L2 complex. Yoichi Furukawa, Chi Zhu, To-
moyuki Ohsugi, Yumi Terakado, Rei Noguchi, Tsuneo Ikenoue, Kiyoshi Yama-
guchi. Univ. of Tokyo, Tokyo, Japan.
Deregulated Wnt signaling is one of the earliest steps in colorectal tumor-
igenesis. The impairment results most frequently from APC mutations,
which leads to the accumulation of -catenin and subsequent activation of
TCF7L2. Although previous studies have identifıed a number of target genes
of the activated -catenin/TCF7L2 transcriptional complex such as cMYC
and CCND1, the comprehensive effect of the activation on tumorigenesis
remains to be elucidated. To understand the precise molecular mechanisms
underlying colorectal cancer, we searched for novel genes regulated by the
complex in colorectal tumors. We performed expression profıle analysis of
HCT116 and SW480 colon cancer cells treated with -catenin siRNAs, and
combined these data with public microarray data of LS174 cells treated with
a dominant-negative form of TCF7L2. As a result, we identifıed a total of 134
genes that were regulated by both -catenin and TCF7L2. Subsequent ChIP-
sequence with TCF7L2 antibody selected 11 genes from the 134 genes as
candidates of direct target genes. In this study, we focused on FERMdomain-
containing protein 5 (FRMD5) among the 11 candidates. Quantitative PCR
confırmed that its expression was reduced by -catenin siRNA in HCT116
and SW480 cells. ChIP-quantitative PCR analysis with ant-TCF7L2 antibody
also corroborated the interaction of TCF7L2 with a region (hg19; chr15:
44,449,680-44,450,487) within intron 1 of FRMD5. Reporter assay with plas-
mids containing this region revealed that the reporter activity was down-
regulated by the knockdown of -catenin. These data suggested that FRMD5
is a direct target of -catenin/TCF7L2 complex, and that the region is in-
volved in the transcriptional activation through an interaction with the com-
plex. Consistently, its expression was elevated in colorectal tumors com-
pared to normal colonic mucosa in public microarray data. To uncover the
role of FRMD5 in colorectal carcinogenesis, we analyzed expression profıle
of HCT116 cells treated with FRMD5 siRNA, and combined the data with
profıle with -catenin siRNA. Gene set analysis with 53 commonly up-reg-
ulated and 36 commonly down-regulated genes by both FRMD5 and
-catenin disclosed that the gene sets of DNA replication, cell cycle, and
extracellular matrix (ECM) were altered by FRMD5. These data may be
useful for the future studies of colorectal carcinogenesis.
#319 Cholesterol inhibition reduces Hh mediated chondrosarcoma.
Qingxia Wei,1 Eyal Ramu,2 Mushriq AL-Jazrawe,1 Raymond Poon,1 Jay Wun-
der,2 Benjamin Alman3. 1The Hospital for Sick Children, Toronto, Ontario, Can-
ada; 2Mount Sinai Hospital, Toronto, Ontario, Canada; 3Duke University, Dur-
ham, NC.
Constitutive activation of Hh signaling is a common occurrence in chondro-
sarcoma(CSA). Gene profıling analysis showed that Gli transcription regulates
genes that govern cholesterol homeostasis, which alters cholesterol accumula-
tion in chondrocytes; a higher level of Gli-mediated transcription results in
accumulation of intracellular cholesterol. Here we determined if targeting cho-
lesterol-processing genes downstream of Hh signalling could be used as a novel
treatment approach. With institutional review board approval, human CSA
samples were obtained fresh from surgery. For in vitro studies, CSA explants of
2mmx2mmx2mmcubic in size establihed as organ cultures. For in vivo studies,
one million CSA cells were subcutanously injected into NSG mice. Cells from
fıve CSAs were treated both in vitro and in vivo with a hedgehog inhibitor,
Cur61414, a cholesterol inhibitor, Lovastatin, or both. In vitro, CSA explants
were treated for 48 hrs at concentration of 20 M of each drug. In vivo, mice
were treated with 4.5mg/kg/day of Cur61414, Lovastatin, or both by intraperi-
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toneal injection for 4 wks. At the end of treatment, the explants or xenografts
were harvested and processed for further analysis. RT-PCRwas used tomeausre
the expression of Hh and cholesterol target genes. Tumor size was meausred
from the xenografts. Blockade of Hh signaling signifıcantly decreased Gli1 gene
expression by 30%, increased 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGCR) expression for more than 300% indicating decreased intracellular
cholesterol. Treatment with the cholesterol inhibitor Lovastatin increased ex-
pression of HMGCR for more than 500%. The combination of Hh and choles-
terol blockage resulted in increased expression of HMGCR for more than
3400%. Analysis of chondrosarcoma xenografts in vivo showed a signifıcnat
decrease in tumor size with Lovastatin (32% decline), 3 folds reducation of
Brdu() cells, and 2.4 fold increase of Caspase-3 cells, treatment with Cur
61414 reduced the tumor growth by 5% with no signifıcant reduction of
Brdu() cells but 2.6 fold increase of Caspase-3 () cells . The combination
treatment of lovastatin and Cur61414 on xenografts resulted in a signifıcnat
decrease in tumor size (32% decline), 3 fold reduction of Brdu () cells, but no
signifıcant changes of Caspase-3 () cells . These data suggest that cholesterol
functions downstream of Hh signaling pathway in CSA. The more effective
reduction in tumor growth with cholesterol inhibition compared to Hh block-
ade suggests cholesterol blockade is an effective therapeutic approach.
#320 Potential of targeting of MYC-driven cancers via CIP2A without
detrimental physiological effects. Xi Qiao. Turku University, Turku, Finland.
Transcription factorMYC is a driver of many human cancers due to its wide-
spread effects on gene expression. An understanding of the mechanisms deter-
mining MYC’s transcriptional and proliferation-promoting activities in vivo
could facilitate approaches for MYC targeting. However, post-translational
mechanisms that controlMYC function in vivo are poorly understood.Here, we
demonstrate that MYC phosphorylation at serine 62 enhances MYC accumula-
tion on Lamin A/C-associated nuclear structures and that the protein phospha-
tase 2A (PP2A) inhibitor protein CIP2A is required for this process. CIP2A is
also critical for serum-induced MYC phosphorylation and for MYC-elicited
proliferation induction in vitro. Complementary transgenic approaches and an
intestinal regeneration model further demonstrated the in vivo importance of
CIP2A and serine 62 phosphorylation for MYC activity upon DNA damage-
induced proliferation. However, targeting of CIP2A did not influence the nor-
mal function of intestinal crypt cells or general well-being of the mice. Mean-
while, in breast cancer cells, CIP2A depletion was shown to inhibit the MYC
serine 62 phosphorylation, MYC-mediated gene expression, and anchorage-
independent growth. Furthermore, CIP2A supports MDA-MB-231 xenograft
growth in nudemice. Therefore, results of these studies collectively suggest for a
novel opportunity to targetMYC’s function inMYC- driven cancers via CIP2A,
and without detrimental physiological effects.
#321 MUC1 regulates TGF function in pancreatic cancer. Priyanka Gro-
ver,1 Monica D. Nye,1 Mahboubeh Yazdanifar,1 Mohammad Ahmad,1 Ru
Zhou,1 Lopamudra Das Roy,1 Kajal Grover,2 Shu-taWu,1 Sritama Nath,1 Pinku
Mukherjee1. 1Univ. of North Carolina - Charlotte, Charlotte, NC; 2Univ. of North
Carolina - Chapel Hill, NC.
In 2016, Pancreatic Cancer (PC) has moved to 3rd leading cause of cancer-
related deaths in the USAwith 94% dying within 5 years of diagnosis. 90% of PC
is PancreaticDuctal Adenocarcinoma (PDA), of which 80%of PDAoverexpress
tumor associated Mucin-1 (tMUC1), a membrane bound glycoprotein that is
hypoglycosylated. Overexpression of tMUC1 is associated with metastasis and
poor prognosis. However the mechanism remains obscure. Transforming
growth factor- (TGF-) plays a role in poor prognosis. TGF- is a cytokine
with dual functionality. Within normal cells and early carcinogenesis, TGF-
functions as a tumor suppressor and induces apoptosis. This effect is mediated
by activation of the canonical Smad pathway via engagement of TGF-Receptor
1 (TGF-RI). However during later stages of cancer, TGF- becomes a tumor
promoter and stimulates epithelial to mesenchymal transition, migration, and
invasion thus enhancing metastasis. This TGF- effect is mediated by the non-
canonical Erk1/2 pathway.Wehave recently shown correlation between tMUC1
andTGF-within an exogenous tMUC1model of PDA. Therefore, it is hypoth-
esized that the mechanism between the two newly connected pathways exists in
PDA tumors with high endogenous tMUC1 levels.We propose that the tyrosine
kinases present in the cytoplasmic tail of tMUC1 are intermediary between the
two pathways, thus leading to enhanced metastasis. First the secretion levels of
TGF-1 were assessed in a panel of 13 PDA cell lines with variable expression
levels of tMUC1 by ELISA. The effects of TGF-1 to induce apoptosis versus
invasiveness on a variety of tMUC1 high and tMUC1 low PDA cell lines were
determined. The effects of tMUC1 knockdown were evaluated in tMUC1 high
cell lines via siRNA. We studied the role of tyrosine kinases and other protein
complexes in mediating the interactions between tMUC1 and TGF- via pro-
teomics analysis. Finally, we evaluated the anti-tumor effıcacy of neutralizing
TGF-1 in vivo in high and low tMUC1-expressing PDA tumors. In tMUC1
high PDA cells, TGF-1 is secreted less when compared to tMUC1 low PDA
cells, allowing for the more resistant cells to diminish TGF- mediated effects
endogenously. It is shown that with TGF-1 treatment, tMUC1 high cells are
more invasive, resist apoptosis, and activate Erk pathway, while tMUC1 low cells
activate SMAD pathway. However, tMUC1 knockdown via siRNA does not
affect TGF- receptor levels.When studying the tyrosine kinases, c-Src becomes
more phosphorylated in the presence of TGF-1 in tMUC1 high cells, while in
tMUC1 low cells c-Src becomes more deactivated in the presence of TGF-1.
Finally, within the mouse model, tMUC1-high PDA tumors respond to the
neutralization of TGF-1 by decreasing tumor size, while having no statistical
effect on tMUC1-low PDA tumors. tMUC1 expression is influential in TGF-
function in an endogenousmodel. Neutralizing TGF- in tMUC1 high express-
ing tumors can be considered as a possible treatment. This has high clinical
signifıcance for patients with PDA.
#322 Distinct pools of ShcA coupled tyrosine kinase signaling influences
breast tumor heterogeneity and therapeutic responsiveness. Jacqueline R.
Ha,1 Ryuhjin Ahn,1 Young Kyuen Im,1 Valerie Sabourin,1 Harvey W. Smith,2
Ivan Topisirovic,1 Tony Pawson,3 Peter Siegel,2William J.Muller,2 Josie Ursini-
Siegel1. 1Lady Davis Institute for Medical Research, McGill University, Montreal,
Quebec, Canada; 2Goodman Cancer Research Centre, McGill University, Mon-
treal, Quebec, Canada; 3Samuel Lunenfeld Research Institute, Mount Sinai Hos-
pital, Toronto, Ontario, Canada.
Phospho-tyrosine (pTyr) signaling networks are frequently activated in
breast cancers (BrCa) and are considered to bemajor oncogenic drivers of tumor
progression. Therapeutic interventions, such as the tyrosine kinase (TK) inhib-
itor Trastuzumab, focus on targeting TK activity and downstream effectors.
Although successful for early stage tumors, a subset of patients experience re-
lapse due to intrinsic or acquired resistance. This includes activation of alterna-
tive receptor tyrosine kinase (RTK) and/or cytoplasmic TKs, many of which
require recruitment of the adaptor protein, ShcA. ShcA is a key convergence
point downstream of RTKs and serves to integrate multiple signal transduction
pathways dysregulated in BrCa. Specifıcally, ShcA contains two pTyr binding
motifs including an amino-terminal PTB domain and a carboxy-terminal SH2
domain which facilitate its interactions with TKs including ErbB2 and Src Fam-
ily Kinases (SFK), respectively. The CH-1 domain houses three tyrosine phos-
phorylation sites at residues 239/240 and 317 which transduce Ras-dependent
and independent signals. Using a well characterized transgenic mouse model of
BrCa where ShcA can no longer engage the transforming oncogene through its
PTB domain, we demonstrate that loss of PTB-driven ShcA (ShcA-PTBMut)
signaling delaysmammary tumor onset. However, once formed, the growth and
angiogenic potential of these tumors is signifıcantly increased relative to control
mice. Increased growth potential of ShcA-PTBMut tumors is associated with the
hyper-activation of the c-Src tyrosine kinase. Deletion of c-Src in ShcA-PTBMut
breast tumor cells signifıcantly delays tumor onset but is dispensable for the
growth of tumors that retain an intact ShcA PTB domain. These data suggest
that the ShcA PTB domain can recruit negative regulators that limit the activa-
tion of downstream tumorigenic signaling networks. Interestingly, tumors ex-
pressing ShcA-PTBMut debilitated in SH2drivenpTyr interactions (SH2Mut), are
signifıcantly delayed in tumor onset relative to ShcA-PTBMut controls. Paradox-
ically, deletion of c-Src in the context of ShcA-PTBMut-SH2Mut further acceler-
ates tumor growth which is attributed to increased levels of Fyn and Lyn. These
observations support the high dependence of intracellular ShcA pools on other
SFK familymembers to retain tumorigenic potential when adapting to low levels
and/or activity of c-Src. We demonstrate that uncoupling of PTB-driven ShcA
signaling from upstream RTKs can potentiate ShcA signaling from intracellular
pools to hyper-activate SFKs. This data is clinically relevant as c-Src is frequently
hyper-activated in Trastuzumab-resistant BrCa. This is the fırst study to identify
a tumor suppressive role of the ShcA PTB domain and to characterize an intrin-
sic ShcA SH2 domain-SFK dependent resistance mechanism downstream of
activated RTKs in mammary tumorigenesis.
#323 A rapid flow cytometry method for analyzing NF-	B activation and
translocation in whole blood. George C. Brittain, Sergei Gulnik. Beckman
Coulter, Inc., Miami, FL.
Background: The end point of most cell-signaling cascades is the transloca-
tion of protein complexes into the nucleus tomodify transcriptional activity. For
this reason, the analysis of cytoplasmic vs. nuclear localization provides impor-
tant insights into cell activation. However, assessing nuclear translocation in
complex cell mixtures, such as whole blood, is a diffıcult task. Leukocytes are a
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rare event in blood, with many subpopulations, requiring the cells to fırst be
concentrated, sorted, rested and often expanded prior to furthermolecular anal-
yses. This process can take weeks, and questions regarding physiological rele-
vance arise from even the fırst preparatory steps.Here, we present a buffer-based
system to lyse RBCs and differentially stain leukocytes in order to enable the
quantitative analysis of cytoplasmic vs. nuclear localization in endogenous cells
by flow cytometry. We demonstrate the use of this system by analyzing the
activation of NF-B signaling in whole-bloodmonocytes following lipopolysac-
charide (LPS) stimulation.Methods: Themain components of theWhole Blood
Nuclear Localization Kit are two buffers: Buffer 1 permeabilizes the cytoplasmic
membrane, leaving the nuclear membrane intact, while Buffer 2 permeabilizes
both the cytoplasmic and nuclear membranes. Briefly, blood was treated for
different timeswith LPS, fıxed for 10min, split into 2 fractions, and then onewas
lysed for 30 min with Buffer 1 and the other with Buffer 2. Each fraction was
washed, stained and acquired on a CytoFLEX-S flow cytometer (Beckman
Coulter, Brea, CA). The cytoplasmic and nuclear signals were calculated using
the compensated results from the two tubes. Blood was collected onsite daily
from healthy, consenting human adults. Results: Following LPS stimulation,
nuclear p50 and RelA increased maximally in monocytes by 10 min. Phospho-
RelA S536 was maximal by 5 min mostly in the cytoplasm, while phospho-RelA
S529 was maximal by 10 min in the nucleus. IB degraded maximally by 10
min. Additional kinase signaling will be presented, as well as controls to dem-
onstrate the partitioning effıciency. Conclusions: This system is very fast and
user friendly, and can help to improve our understanding of normal and aber-
rant signaling in blood, while also saving researchers time and resources com-
pared to conventional procedures, e.g., purifying leukocytes and performing
Western blots. It provides clear delineation of the nucleus withminimal perinu-
clear staining, and can even be used to improve the quantitation of nuclear
signals from 2D microscopic images. Finally, this system can enable research
where blood volumes are limited, such as with rare and precious samples and
small-animal studies. ***This kit and the CytoFLEX-S are for Research Use
Only. Beckman Coulter and the Beckman Coulter product and service marks
mentioned herein are trademarks or registered trademarks of BeckmanCoulter,
Inc. in the United States and other countries.***
#324 Investigating the dependence of canine bladder transitional cell car-
cinoma on activated mutant BRAF. Kathryn Cronise, Belen Hernandez, Dan-
iel L. Gustafson, Dawn L. Duval. Colorado State Univ., Fort Collins, CO.
Transitional cell carcinoma (TCC) accounts for approximately 2% of diag-
nosedmalignancies in canines. Themajority of canine TCCs are invasive, inter-
mediate to high grade tumors sharing similarities with human muscle invasive
TCCs in risk factors, histology, sites of metastasis, and therapeutic response to
single agents.Whole exome sequencing of canineTCC tumorswas performed to
identify somatic mutations in known cancer driver and repressor genes that
could potentially contribute to canine TCC pathogenesis. A valine to glutamic
acidmutation in BRAFhomologous to the activatingV600Emutation identifıed
in human melanoma, colorectal and thyroid cancers was identifıed in 70% of
sequenced tumors. Sensitivity to the BRAFV600E inhibitor Vemurafenib was
tested in three BRAF mutant canine TCC cell lines (Bliley, Tyler1 and Tyler2)
and two BRAF wild type canine TCC cell lines (Angus1 and Kinsey). All fıve
canine TCC cell lines exhibited IC50s greater than 10M, with BRAF mutant
cell lines being slightly more sensitive. These sensitivity ranges are similar to
those of some mutant human colorectal cancer cell lines, indicating that addi-
tional mechanisms may contribute to Vemurafenib resistance. Western blot
analysis was performed to measure relative abundance of pERK, a downstream
target of BRAF, in canine TCCs in response to serum starvation. All TCC cell
lines showed sustained pERK expression in the absence of serum, indicating
constitutive activation of the MAPK pathway. The fıve canine TCC lines were
treated with 15MVemurafenib for 6 and 24 hours and their lysates were ana-
lyzed for pERK protein expression. pERK abundance was decreased in only the
BRAF mutant cell lines after 6 hours of treatment. However, this decrease was
less pronounced after 24 hours, suggesting that resistance mechanisms are by-
passing BRAF to activate ERK. Sequence analysis of an additional panel of for-
malin-fıxed paraffın embedded canine TCCs also revealed a mutation in
RanBP2 in 31% of samples. Strikingly, the RanBP2 mutation appeared to be
mutually exclusive to BRAFV to Emutant tumors with only two of the analyzed
samples carrying both mutations. Signifıcant tumor heterogeneity was impli-
cated due to low level mutant amplifıcation in these samples. It has been re-
ported that loss of RanBP2 is synthetic lethal in BRAF V600Emutant colorectal
cancer. Since RanBP2 forms complexes with CRM1 at the nuclear pore complex
for nuclear export and at the kinetochore during mitosis, canine TCC cell lines
were treated with KPT-185, a CRM1 inhibitor. BRAFmutant TCC cell lines had
IC50 values ranging from45nM to 65nMandwere approximately ten-foldmore
sensitive than wild type cell lines. Overall, this data indicates that the pathogen-
esis of canine TCC likely depends on driving factors in addition to constitutive
BRAF signaling, but Vemurafenib resistant BRAF mutant tumors can be tar-
geted through inhibition of the nucleopore complex.
#325 Pediatric relapsed acute lymphoblastic leukemia patients display en-
richment of the PI3K/mTOR pathway and respond to the dual PI3K/mTOR
inhibitor PKI-587. Mohiuddin Gazi, Sausan A. Moharram, Alissa Marhäll,
Kinjal Shah, Julhash U. Kazi. Lund University, Lund, Sweden.
Although signifıcant improvements have been observed in the treatment of
acute lymphoblastic leukemia, there is a substantial subset of high-risk T-ALL
patients with relatively poor prognosis. T-cell acute lymphoblastic leukemia
(T-All) is a hematopoietic malignancy affecting lymphoblast of T-cell lineage
which cause lots of hematopoietic cancer related deaths every year all over the
world. The current overall cure rates of newly diagnosed childhood ALL are
more than 80% in Europe, but approximately 20% of patients relapse due to
treatment failure in childhood ALL. Like other leukemia types, alterations of
PI3K/mTOR pathway are predominant in T-ALL which is also responsible for
treatment failure and relapse. In this study, two different gene expression data
sets of relapsed patients also displayed enrichment of the PI3K/mTOR pathway.
Out of 88 different inhibitors targetingmultiple components of this pathway, we
observed that PKI-587was themost selective to the T-ALL cell line CCRF-CEM.
Thus, we characterized the activity of the novel dual PI3K/mTOR pathway in-
hibitor PKI-587 using CCRF-CEM and Molt3 cells. We observed that PKI-587
blocked proliferation, colony formation and induced apoptosis in theT-ALL cell
lines and selectively abrogated PI3K/mTORwithout affecting theMAPK signal-
ing. In vivo PI3K/mTOR inhibition delayed tumor progression, and reduced
tumor load in a NSG/SCID xenograft mouse model. Since no deceptive body
weight decrease was noticed, our conclusion is that this dose is effective andwell
tolerated. The benefıcial effects of PKI-587 on T-ALL cells that has been ob-
served in this study both in vitro and in vivo warrant further investigation.
#326 Baseline IL-17 receptor signaling is essential for controlling aberrant
JNK-dependent cellular proliferation via maintenance of endogenous level
of ubiquitin-editing enzyme A20. Chi Yan, Yang Lei, Anna L. Greenshields,
DavidW.Hoskin, Tong-JunLin, JunWang.DalhousieUniversity,Halifax,Nova
Scotia, Canada.
The molecular mechanisms underlying aberrant activation of NF-B and
JNK in cancer remain incompletely understood. Here, we demonstrate that
baseline IL-17 receptor (IL-17R) signaling is essential for controlling aberrant
NF-B and JNK activation, and restraining JNK-dependent homeostatic cellu-
lar proliferation.Using a shRNAknockdown approach, we demonstrated in B16
melanoma and 4T1 breast carcinoma murine cell lines that IL-17RA silencing
markedly enhanced tumor cell growth in vitro and in vivo. Through mapping
IL-17R signaling pathways, we further demonstrated that baseline IL-17A/IL-
17R signaling actively restrained JNK phosphorylation in vitro and in vivo via
the maintenance of basal expression of the ubiquitin-editing enzyme A20, a
negative regulator of NF-B and JNK. Remarkably, IL-17RA reconstitution ev-
idently restored the A20 level, and suppressed cell proliferation and JNK activity
in tumor cells. The reconstitution of A20 in IL-17RA knockdown subclones was
able to restore the normal rate of cellular proliferation and associated JNK/c-Jun
activity. Finally, meta-analysis of human cancer microarray and RNA-Seq data-
sets confırmed signifıcant co-expression of IL-17RA and A20. Furthermore,
alterations (mutation, upregulation or downregulation) of IL-17RA level inmel-
anoma, ER breast cancer and colorectal cancer patients were associated with
poorer overall survival compared to the respective patients with normal baseline
IL-17RA expression. Together, our data demonstrates a previously unrecog-
nized molecular mechanism underlying aberrant activation of NF-B and JNK
in cancer cells. This work highlights the unique biological role of proinflamma-
tory IL-17R signaling in the maintenance of A20 to regulate the pathogenesis of
human cancer, which draws caution on the utility of IL-17A neutralizing anti-
body in cancer therapy. CY is a PhD student supported by the graduate student
scholarship from the IWKHealth Centre and received a trainee award from the
Beatrice Hunter Cancer Research Institute with funds provided by the Cancer
Research Training Program as part of The Terry Fox Foundation Strategic
Health Research Training Program in Cancer Research in CIHR.
#327 EpCAM/EpEX regulate tumor progression through EGFR signaling
in colon cancer cells.Kang-HaoLiang, Jun-Kai Lai, I-I Kuan,Hsien-ChengTso,
Han-Chung Wu. Academia Sinica - Inst. of Cell. & Organismic Bio., Taipei,
Taiwan.
Epithelial cell adhesion molecule (EpCAM) is highly expressed in advanced
epithelial cancers and tumor-initiated cells (TICs), but its roles in cancer pro-
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gression remain to be elucidated. Here, we showed that the extracellular domain
of EpCAM (EpEX) could bind to EGFR through EGF-like domain I, and subse-
quently activated its downstream molecules, ERK1/2 and Akt. EGFR inhibitor
and knockdown of EGFR by shRNA ablated EpEX-induced ERK1/2 phosphor-
ylation. Regulated intramembrane proteolysis (RIP) of EpCAM was induced
similarly by EpEX and EGF through EGFR-dependent activation of ERK path-
way. MEK inhibitor, U0126, could abolish ADAM17 and PS2 phosphorylation
induced by EpEX. EpAb2-6, an anti-EpEX neutralizing monoclonal antibody,
inhibits EpEX-activated EGFR-PI3K-AKT pathway in detached colon cancer
cells. Moreover, intracellular domain of EpCAM (EpICD), the product of RIP-
induced cleavage of EpCAM, is necessary for nuclear accumulation of
-catenin, and their target gene expressions in vitro and in mouse xenograft
models. We also found that an increase of nuclear EpICD observed in CRCs
predicted metastasis and poor prognosis in CRC patients. Finally, in animal
model studies, EpAb2-6 therapy exhibited an enhanced antitumor effect and
markedly extended the survival time of mice with human colorectal cancer in
metastatic and orthotopic models. These results demonstrate that EpEX works
as a growth factor in activating EGFR-mediated signaling, and as a potential
target for treatment of colon cancer. This researchwas supported by grants from
Academia Sinica andMinistry of Science and Technology [MOST 104-0210-01-
09-02,MOST 105-0210-01-13-01], and the National Science Council (NSC103-
2321-B-001-064), Taiwan (to H-CWu).
#328 PARP inhibitors suppress growth of EGFR-mutant cancers by tar-
geting nuclear PKM2. Nan Li, Steven H. Lin. UT MD Anderson Cancer Ctr.,
Houston, TX.
Poly(ADP-robose) polymerase-1 (PARP1) or ADP-ribosyltransferase diph-
theria toxin-like 1 (ARTD1) is the most abundant and the best understood
member of the 17 PARP family proteins. PARP1 binds to both single strand
breaks (SSBs) and double-strand breaks (DSBs) and participates in the recogni-
tion, excision and repair of DNA damage. The most extensively studied role of
PARP1 is its involvement in base excision repair (BER) and PARP inhibition
induced-trapping of PARP1 during BER. Moreover, suppression of PARP1/2
leads to synthetic lethality in BRCA1/2-defecient tumors, indicating that
PARP1-dependent BER and BRCA-dependent homologous repair pathway
have overlapping and redundant functions in DNA repair. Recent studies have
also pointed to a broader utility of PARP inhibitors beyond hereditary BRCA-
defıcient cancers. Pyruvate kinase isoform M2 (PKM2) is a glycolysis enzyme
that converts phosphoenolpyruvate (PEP) into pyruvate. Up-regulation of
PKM2 has been shown recently to be an important feature of tumorigenesis. In
tumor cells, PKM2 forms a dimmer that is catalytically inactive as a glycolysis
enzyme, but provides advantage for tumor progressiondue toWarburg effect. In
this report, we demonstrated that poly-ADP-ribose (PAR) is required for nu-
clear retention and nuclear function of PKM2. PKM2 translocates into nucleus
and binds to PAR upon EGF stimulation. PARP inhibition, or the PKM2-C/A
mutant, which abolishes the PKM2/PAR interaction, suppresses the nuclear
function of PKM2. In addition, PARP inhibition also diminishes the nuclear
PKM2-dependent glycolysis and tumor growth. Moreover, we showed that nu-
clear localization of PKM2 correlates with PAR expression in EGFR-mutant
human lung cancer tissues. Interestingly, PARP inhibition leads to growth sup-
pression of some EGFR-mutant lung cancer cells, which are resistant to EGFR
inhibitor. These data together support an unexpected function of PARP inhibi-
tion in tumor suppression and indicate that nuclear PKM2may serve as a prom-
ising biomarker for the further development of PARP inhibitor-based therapies.
#329 Selinexor or KPT-8602 mediated XPO1 inhibition synergizes with
dexamethasone to repress convergent pathways in the mTORC1 signaling
network and drive cell death in multiple myeloma. Christian Argueta, Tri-
nayan Kashyap, Boris Klebanov, Hua Chang, Sharon Friedlander, Erkan Balo-
glu, Yosef Landesman, Margaret Lee, Humphrey Gardner, Sharon Shacham,
William Senapedis. Karyopharm Therapeutics Inc., Newton, MA.
Background: Dexamethasone (DEX), a synthetic glucocorticoid (GC), is ad-
ministered to nearly allmultiplemyeloma (MM)patients as a single agent and in
combination with other chemotherapies or targeted agents. DEX and other GCs
bind to glucocorticoid receptors (GR) in the cytoplasm, induce nuclear translo-
cation and regulate GR-dependent gene expression networks in the nucleus.
Selective Inhibitor of Nuclear Export (SINE) compounds (selinexor and KPT-
8602) exhibit potent anti-tumor activity in MM especially when combined with
DEX. SINE compounds enhance nuclear localization of tumor suppressor pro-
teins (TSPs) through inhibition of the nuclear export protein, XPO1. We dis-
covered that inhibition of the mechanistic Target of Rapamycin Complex 1
(mTORC1) pathway is a primary driver of the combination effect. Here we
further elucidate the molecular mechanism of action of the SINE-DEX synergy
in MM. Methods: GRMM.1S and GRnull MM.1R MM cell lines were treated
with SINE compounds and/or DEX for 24 hours. Whole cell lysates were sub-
jected to SDS-PAGE and western blot analysis. Gene expression and GR tran-
scriptional activity was analyzed using qPCR and ELISA, respectively. Cell via-
bility was examined using the Celltiter-Fluor assay. Results: We found that MM
cell lines treated with SINE compounds (selinexor or KPT-8602) have increased
basal GR protein levels. Consistent with these results, the SINE-DEX combina-
tion shows enhanced GR transcriptional activity. Several GR-DEX target genes
are known to inhibit theGTPase, Ras homolog enriched in brain (RHEB), which
is required for mTORC1 activation. We discovered that the SINE-DEX combi-
nation not only reduces RHEB protein but also induces the RHEB inhibitory
pathways containing REDD1 and the KLF15-BCAT2 axis. Although SINE com-
pound-mediated inhibition of mTORC1 (i.e. reduced phosphorylation of S6K1
and 4E-BP1) is GR independent, SINE-DEX inhibition is more robust in GR
MM.1S cell line when compared to the GRnull MM.1R cells. The combination
resulted in the selinexor IC50 inMM.1S cells shifting from40 nM to 11 nM in the
presence of low dose DEX. As expected, DEX did not modulate the SINE com-
pounds IC50s inMM.1R cells. Conclusion:We show that SINE compound inhi-
bition of MM cell viability is enhanced with DEX. Our results indicate that this
combinatorial effect is due to convergent suppression of mTORC1 signaling by
GR targets. The fındings provide mechanism of action data around the SINE-
DEX combination inMMwith suggestive biomarkers (REDD1, KLF15, BCAT2
and GR) that may predict best response to the combination. Therefore, these
data may translate directly to the current clinical development of SINE com-
pounds.
#330 SGK1 activation is essential for PI3K-dependent tumor develop-
ment.Arturo Orlacchio, Antonio Di Cristofano.Albert Einstein College ofMed-
icine, Bronx, NY.
The PI3K signaling cascade is frequently activated in human cancer, with
AKT being commonly considered its major transforming conduit. Conditional
deletion of Pten in themouse thyroid epithelium induces constitutive activation
of the PI3Kpathway,which causes thyroid hyperplasia at birth that progresses to
invasive andmetastatic follicular carcinoma. Concomitant loss of p53 or activa-
tion of KRAS dramatically accelerates the development of aggressive and lethal
tumors. The PDK1 kinase plays a key role in the PI3K signaling cascade, directly
activating, in a PI3K-dependent manner, not only AKT but also a set of addi-
tional AGC kinases, including, S6K, PKC, and SGK. Using in vivo, ex vivo, and
in vitro genetic and pharmacological approaches, we now show that AKT acti-
vation is not suffıcient to transform thyroid epithelial cells. Concomitant acti-
vation of additional PDK1-dependent pathways is absolutely required to de-
velop neoplastic lesions in vivo, and to induce cell proliferation ex vivo, inmouse
models based on Pten loss, alone and in combination with additional genetic
alterations. In particular, we show that onemember of the SGK family, SGK1, is
an essential mediator of the transformation process downstream of PI3K. Ge-
netic andpharmacological SGK1 inhibition strongly reduces cell proliferation in
Pten-/-and PIK3CA-mutant cell lines.Moreover we show that concomitant SGK
inhibition signifıcantly increases the effıcacy of inhibitors targeting AKT or
PI3K. Taken together, our data identify an essential and druggable signaling
cascade that critically cooperates with AKT activation to transform thyroid ep-
ithelial cells.
#331 SIRPB1 promotes prostate cancer cell proliferation & migration.
Qiong Song,1 SiyuanQin,1 Chunlin Zou,1WenchuWang,1 LihuiWang,1 Haibo
Tong,1 William J. Catalona,2 Jian Zhang,1 Yi Lu,1 ZhouWang3. 1Guangxi Med-
ical University, Nanning, China; 2Northwestern University Feinberg School of
Medicine, Chicago, IL; 3University of Pittsburgh School of Medicine, pittsburgh,
PA.
Signal-regulatory-protein beta 1(SIRPB1) is a member of the signal-regulato-
ry-protein (SIRP) family that belongs to the immunoglobulin superfamily and is
capable of modulating receptor tyrosine kinase-coupled signaling. The copy-
number variations (CNV) at the SIRPB1 locus were associated with aggressive-
ness of prostate cancer in patients. To test if SIRPB1 could affect prostate cancer
development and progression, we investigated the potential role and mecha-
nisms of SIRPB1 action in prostate cancer cell lines in vitro and in xenograft
tumors. Knockdown of SIRPRB1 by RNA interference resulted in signifıcant
suppression of cell colony formation, cell mobility, cell migration, and invasion.
The knockdown also induced cell cycle arrest during the G0/G1 phase and a
remarkable enhancement of apoptosis in PC3 prostate cancer cells. In contrast,
overexpression of SIPRB1 signifıcantly induced cell migration, invasion, colony
formation and cell cycle in C4-2 prostate cancer cells. Furthermore, overexpres-
sion of SIRPB1 in C4-2 cell model enhanced its tumor take rate in nude mice.
Also, SIRPB1 mRNA expression was increased in up to 39% of the prostate
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cancer specimens based on in silico analysis of several public databases. These
results suggest that SIRPB1 is a potential oncogene in the prostate and could be
used as a biomarker to identify patients at risk of developing aggressive prostate
cancer.
#332 Loss of primary cilia promotes LPA-driven proliferation in glioblas-
toma. Yuriy Loskutov.West Virginia University, Morgantown, WV.
Glioblastoma is one of the most common brain cancers with a median sur-
vival of 13 months. Therapeutic approaches for this type of cancer are very
limited, creating an urgent need to develop new strategies for the treatment.
Recently several groups reported that glioblastoma have a drastic decrease in
primary cilia, suggesting that loss of cilia might be important for glioblastoma
biology. The primary cilium is a ubiquitous microtubule based organelle pre-
sented on most of human cells. It plays signifıcant role in embryonic develop-
ment and tissue homeostasis, serving as a hub for multiple signaling cascades
including RTK, Sonic Hedgehog, Wnt and Hippo. Here we report that loss of
primary cilia in immortalized astrocytes stimulate cell proliferation and drasti-
cally change ERK1/2 activation in response to serum. These changes depend on
lysophosphotidic acid (LPA), a water-soluble lipid metabolite, implicated in
chemotactic and proliferative signaling. The receptor to LPA type 1 tends to
accumulate in the primary cilia, indicating its potential role in inhibition/restric-
tion of LPA-dependent mitogenic signaling via dynamic changes in primary
cilium. Loss of primary cilia can lead to LPA receptors 1 redistribution to the
plasmamembrane and switch cellular response for the LPA, allowing it to act as
mitogen. Inhibition of LPA receptors with a small molecule inhibitor, Ki16425,
is signifıcantly decreasing the growth of glioblastoma PDXs. Overall, our fınd-
ings clearly indicate that loss of primary cilia is suffıcient to severely change
mitogen-driven signal transduction and point towards the new therapeutic tar-
get for glioblastoma.
#333 Identifıcation of a natural product small molecule inhibitor against
Wnt/-catenin signalling pathway.Mohd Saleem Dar,1 Aehtesham Hussain,2
Paramjeet Singh,1 Qazi Parvaiz Hassan,2 Satdarshan Paul Monga,3 Mohd Jamal
Dar*1. 1Cancer Pharmacology Division, CSIR-Indian Institute of Integrative
Medicine, Jammu, J&K, India; 2Microbial Biotechnology Division, CSIR-Indian
Institute of Integrative Medicine, Srinagar, J&K, India; 3Department of Pathol-
ogy, University of Pittsburgh, School of Medicine S-417 BST, Pittsburgh, PA, PA.
Wnt/-catenin signalling pathway plays an important role inmany processes
like cell proliferation, differentiation, regeneration, carcinogenesis and regulates
stem cell pluripotency. -Catenin, the central component of Wnt/-catenin
signalling pathway has a vast number of binding partners and thus plays differ-
ent roles in the cells.Mutations of-catenin are seen inmany cancers, including
liver cancer, colorectal cancer, lung carcinoma, ovarian cancer and malignant
breast tumours. Till date there is not even a single small molecule in clinical use
that can block the -catenin activity or the activities of this signalling pathway.
In this study, we establishedmany assays for screening smallmolecule inhibitors
of this signalling pathway. Initially, we created a library of -catenin deletion
and point mutants and carried out a comprehensive comparative analysis of
these mutants by luciferase reporter assays, GFP-fluorescence, immunoblotting
and protein-protein interactions.We then screenedmany known and unknown
natural and synthetic molecules against the wnt/-catenin pathway and got 2
hits: C-18 and 055A, bioactive metabolites from actinomycetes. The IC50 (cell
toxicity) of these molecules along with salinomycin, a known ionophore and
inhibitor of-catenin, were determined in different human cancer cells byMTT
assay. The IC50 of 055A, C-18 and salinomycin in HepG2 cells was 7.5M,
9.7M and 25M respectively. Interestingly, C-18 was ineffective against non-
cancerous cell line (HEK-293 cells) even upto 60M. This shows that C-18 is a
very promising hit because it is active against cancer cells and spares non-can-
cerous cells. The sub lethal doses of these molecules were then tested for
-catenin mediated transcription by luciferase reporter assay in HepG2 cells
which harbours a -catenin deletion responsible for enhanced -catenin medi-
ated transcriptional activity. Our results show that C-18 and 055A signifıcantly
block the -catenin activity in a dose dependent manner. The inhibition of
wnt/-catenin pathway by C-18 was observed at lower nanomolar concentra-
tions in comparison to 055A and salinomycin which shows activity in micro-
molar concentrations. The -catenin target gene expression analysis showed
marked decrease in cyclinD1 by immunoblot analysis upon treatment ofHepG2
cells with C-18. Interestingly, C-18 treated HepG2 cells failed to show any apo-
ptosis as confırmed by Parp-1 and caspase-3 immunoblotting indicating that
C-18 can be targeted to block the activity of wnt/-catenin pathway, and could
act as a lead molecule. Therefore, it warrants further experimentation and vali-
dation which are underway to draw the further conclusions.
#334 PTEN-L regulates epithelial growth and macrophage function. An-
drew L. Wolfe,1 Benjamin D. Hopkins,2 Sebastián A. Riquelme,3 Kipyegon Ki-
tur,3 Sait Ozturk,2 Kyeongah Kang,2 Romain Remark,2 Adeeb Rahman,2
Chyuan-ShengLin,3MiriamMerad,2Matthias Szabolcs,3 Shu-HsiaChen,2Alice
Prince,3 RamonParsons2. 1University of California San Francisco, San Francisco,
CA; 2Mount Sinai School ofMedicine, NewYork, NY; 3ColumbiaUniversity, New
York, NY.
PTEN is among the most frequently mutated and deleted tumor suppressor
genes inmanymalignancies, including breast cancer. An alternatively translated
long form of PTEN, termed PTEN-L, has divergent functionality from PTEN,
although its function at the organism level has not been studied. Here, we report
a knockout mouse with specifıc ablation of PTEN-L expression but intact ex-
pression of PTEN. These mice display mammary ductal hyperplasia character-
ized by increased luminal growth and increased numbers of macrophages in the
surrounding stroma. Macrophages are particularly affected by PTEN-L loss,
with signifıcant changes to their secretomes and functional defıciencies in clear-
ing bacterial infections, consistent with a shift toward an M2-like polarization.
Overall, these fındings demonstrate that PTEN-L has unique functions in regu-
lating mammary epithelial growth and macrophage functionality that are inde-
pendent of canonical PTEN.
#335 In situ protein complexes as a measure of AXL signaling and inhibi-
tor response in cell linemodels of lung cancer.AnurimaMajumder,1 YunBai,1
Fumi Kinose,1 Erin D. Lew,2 Yumi Yokoyama,2 Danielle Murphy,2 Gary Li,1
Eric B. Haura1. 1Moffıtt Cancer Center, Tampa, FL; 2Ignyta, Inc, San Diego, CA.
AXL kinase overexpression is associated with metastasis and poor prognosis
in various cancers. Recent studies show that epithelial-mesenchymal transition
(EMT) and associated activation of AXL is one of the mechanisms by which
tumors develop resistance to targeted therapies, such as EGFR tyrosine kinase
inhibitor (TKI) in lung cancer. These studies have made AXL an attractive drug
target. However, the lack of genetic alterations in AXL and recent evidence
suggesting that ligand secretion into the tumor microenvironment plays a key
role in signaling and resistance in cancer cells, underscore the need for assays to
visualize active AXL signaling associated complexes. In this study, we aimed to
develop a Proximity LigationAssay (PLA) to effectivelymeasure AXL activation
in tumor tissues in situ, and to use the assay to evaluate the pharmacodynamic
effect of a novel AXL TKI, RXDX-106, in lung cancer models. To this end,
several lung cancer cell lines were analyzed for total and phosphorylated AXL
(pAXL) expression as well as effects of AXL TKI on downstream signaling.
Co-immunoprecipitation studies were also conducted to identify adaptor pro-
teins that form active signaling complexes with AXL kinase, and PLAs were
developed to detect these complexes in situ. H1299 and Calu1 cells have the
highest pAXL among the cells screened. RXDX-106 potently inhibits pAXL and
downstream pAKT, but does not affect pERK or cell viability, in these cell lines.
We also observe an increase in total AXL in response to the RXDX-106. Co-
immunoprecipitation shows RXDX-106-dependent reduction in AXL-PI3KR1
(Phosphoinositide-3-Kinase, Regulatory Subunit 1) interaction that is consis-
tent with the drug-induced reduction in pAKT by western blot. Based on this
observation, we developed PLA to detect active AXL:PI3KR1 and AXL:pY100
signaling complexes in these cells. H1299 and Calu1 cells have high basal AXL:
PI3KR1 and AXL:pY100 PLA foci that are abrogated by RXDX-106, in both
fresh fıxed and formalin-fıxed paraffın-embedded cells. As expected, the
HCC827 cells, which lack ligand independent pAXL, do not show signifıcant
labeling by either PLA. Overall, we demonstrate that RXDX-106 is a potent
inhibitor of AXL kinase and its downstream PI3K/AKT signaling pathway. We
also show that activated AXL signaling complexes can be annotated specifıcally
by PLA. The data provides justifıcation for the extension of our PLA as a tool to
measure drug-targetable signaling complexes to identify new models of acti-
vated AXL and enrich for activated AXL in patient tissues.
#336 PIK3CB/p110B is a survival factor in glioblastoma.Kevin J. Pridham,
Sujuan Guo, Zhi Sheng. Virginia Polytechnic Institute and State University,
Blacksburg, VA.
Glioblastoma multiforme (GBM) is lethal even after surgical removal of the
tumor, radiation, and chemotherapy. Residual tumor cells form an intractable
tumor in nearly all patients within two years. Recurrent GBM is incurable due to
resistance to current therapies. Inhibitors of PI3K (phosphatidylinositol-4,5-
biphosphate 3-kinase)-a signaling pathway that causally contributes to tumor
formation/recurrence-have been used to treat recurrent GBMs and achieved
modest clinical effect. This is perhaps attributed to non-selective inhibition of
PI3K isoforms, which yields intolerable toxicity. Class IA PI3K isoforms include
three catalytic subunits (PIK3CA, B, or D that encodes p110,, or ) and three
regulatory subunits (PIK3R1-3 that encodes p85 isoforms). Our recent work
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indicates that PIK3CB levels positively correlate with the chances/risk of GBM
recurrence, while being inversely associated with patient prognosis. This sug-
gests that PIK3CB/p110 is important for GBM cell survival. To test this hy-
pothesis, we fırst measured the expression of PI3K isoforms in a panel of 9 GBM
cell lines. We found that U87MG, SF295, and U251 expressed much higher
levels of p110, coinciding with the levels of phosphorylated AKT. We then
knocked down PIK3CA, B, and D in human U87MG cells and found that only
depletion of PIK3CB/p110 resulted in an inactivation of downstream AKT.
Moreover, knockdown of PIK3CB/p110, but not other isoforms, induced sub-
stantial growth inhibition in U87MG, SF295 and U251 cells. This is congruent
with the result that inhibition of PIK3CB/p110 activated apoptosis in U87MG
cells.We also report that treatment of p110high GBMcells with isoform specifıc
inhibitors selectively represses the viability of these cells. Finally, we report that
ectopic expression of p110, but not p110 or , partially rescued U87MG cells
from growth inhibition induced by TGX-221, a p110-selective inhibitor. Col-
lectively, our results demonstrate that PIK3CB/p110 is an important selective
survival factor in GBM, underscoring the divergent roles of PI3K isoforms in
GBM disease progression/recurrence and future therapeutic intervention.
#337 Sonic Hedgehog ligand drives tumor progression and chromosomal
instability in amousemodel of small cell lung cancer.Anette Szczepny,1 Sam-
uel Rogers,2 Samantha Jayasekara,1 Kwon Park,3 RachaelMcCloy,2 Julien Sage,4
Craig Peacock,5 Jason Cain,1 Andrew Burgess,2 David Neil Watkins2. 1Hudson
Institute of Medical Research, Victoria, Australia; 2Garvan Institute of Medical
Research, Darlinghurst, Australia; 3University of Virginia, Charlottesville, VA;
4Stanford Cancer Institute, Stanford, CA; 5Cleveland Clinic, Cleveland, OH.
Activation of the Hedgehog (Hh) signaling pathway is well documented in
many cancers including Small Cell Lung Cancer (SCLC). Whilst it has been
shown that Smoothened, the central Hh pathway mediator, is required for the
initiation and progression of SCLC in a mouse model, it is unclear what drives
activation of this pathway in these tumors. To address this question, we used a
well-characterized conditional genetic mouse model of SCLC in which inhala-
tion of recombinant adenovirus expressing Cre can trigger recombination at
loxP sites in the airway epithelium. When the virus is administered to mice
double homozygous for the conditional p53 and Rb knockout alleles (p53lox/lox;
Rblox/lox), mice develop multiple tumors over 9 months. In order to manipulate
Shh expression in this model, we crossed these animals with either gain-of-
function or loss-of-function Shh alleles to observe the effects on SCLC initiation
and progression in vivo. Aged cohorts of AdenoCre-infected p53lox/lox;Rblox/lox;
ShhTgmice developedmore frequent and signifıcantly larger tumors compared
to p53lox/lox;Rblox/lox littermate controls, with tumors exhibiting a highly malig-
nant and proliferative phenotype. Conversely, deletion of Shh resulted in no
signifıcant change in tumor number but a dramatic reduction in tumor size in
p53
lox/lox
;Rblox/lox;Shhlox/lox mice compared to littermate controls. Interestingly,
Shh ligand overexpression also induced marked chromosomal instability and
the Smoothened-independent nuclear translocation and activity of Cyclin B1. In
turn, overexpression of Cyclin B1 induced chromosomal instability in cells lack-
ing both p53 and Rb. These results suggest that Shh ligand drives progression of
SCLC by activating both the canonical and non-canonical arms of the Hh path-
way and that Shh may be a potentially useful therapeutic target.
#338 Unexpected activity of multiple targeted cancer drugs in regulating
ciliary dynamics. Anna Kiseleva,1 Vladislav Korobeynikov,2 Anna Nikonova,1
Alexander Deneka,1 Margret Einarson,1 Emmanuelle Nicolas,1 Petr Makhov,1
Vladimir Kolenko,1 Jeffrey Peterson,1 Zeng-jie Yang,1 Erica Golemis1. 1Fox
Chase Cancer Center, Philadelphia, PA; 2Columbia University, New York, NY.
The primary cilium is an antenna-like structure protruding from the cell
surface, which provides a platform for receptors for signaling systems including
PDGF-alpha, Hedgehog, Wnt, and others that influence cell differentiation and
proliferation decisions. Under normal physiological growth conditions, the cil-
ium forms after mitosis and in quiescent cells, extending from a basal body
centered at a centriole, with timed resorption in G0 or early G1. Cancer cells
have altered ciliary dynamics, with some (medulloblastomas and basal cell car-
cinomas) often dependent on cilia, and other tumor types downregulating them.
In prior work, we defıned Aurora-A, an oncogenic kinase typically thought of as
a mitotic regulator, as transiently activated at the basal body, and absolutely
required for resorption of cilia at the G0/G1 boundary, and we showed the
targeted Aurora-A inhibitor entirely blocked ciliary resorption. In subsequent
work, we found that a second drug, the EGFR inhibitor erlotinib, also affected
ciliary resorption, positioning erlotinib and alisertib to influence cilia-depen-
dent signaling. In this study, we broadly assessed the activity of a panel of tar-
geted preclinical and clinical agents of known specifıcity for action in controlling
ciliary dynamics. For this, we developed stable hTERT-RPE1 cell line models
with integrated Arl13b-GFP reporters to visualize cilia, and performed a mid-
throughput screen of 180 drugs for activity in 1) independently inducing ciliary
resorption in quiescentG0 cells, or 2) blocking ciliary resorption in cells induced
to cycle by serum treatment. With a5% hit rate overall, we identifıed 9 com-
pounds inducing, and 7 compounds blocking resorption. This included some
agents commonly used in the clinic, such as sunitinib, which had never previ-
ously been linked to control of the ciliary protrusion/resorption cycle. Mecha-
nistic analysis confırmed these compounds controlled activation of Aurora-A at
the basal body; in vivo testing demonstrated sunitinib resulted in loss of cilia not
only in vitro, but also in normal kidney, kidney tumors, and in renal cysts asso-
ciated with polycystic kidney disease (PKD), a disease dependent on defective
signaling from intact cilia. Further, sunitinib was successful in controlling PKD-
dependent cyst development, as predicted by current models for this ciliopathy.
These data for the fırst time suggest newmechanisms for activity of sunitinib and
other drugs, in which they can influence activity of lateral signaling pathways
such as Wnt and PDGFa by regulating the availability of receptors on a ciliary
signaling platform.
#339 Identifıcation of a novel isoform of WNT/planar cell polarity
VANGL2 in breast cancer. Jean-Paul Borg, AlexandraWalton, Eric Bailly, Syl-
vie Marchetto, Stéphane Audebert. CRCM Inserm-Institut Paoli-Calmettes,
Marseille, France.
The WNT/PCP pathway is an evolutionarily conserved developmental pro-
cess which is essential in embryogenesis and development of polarized struc-
tures in metazoans. Its importance in human diseases is best demonstrated in
neural tube closure defects and cancer. WNT/PCP signaling involves a set of
evolutionarily conserved WNT/PCP genes encoding WNT ligands, transmem-
brane (vangl2, frizzled, fat, dachsous) and cytoplasmic (scribble, prickle, dishev-
elled, diego) molecules triggering a genetically well-defıned non-canonical
WNT-JNK pathway. Recent work has linked defects of this pathway to breast
cancer aggressiveness.We have shown that the non-canonicalWNT/PCP trans-
membrane receptor VANGL2 is overexpressed in poor prognosis basal breast
cancers and implicated in tumor growth. We also found that VANGL2 binds
through its C-terminal sequence to Scribble and p62/SQSTM1 which are in-
volved in cancer cellmigration and growth.A recent in silico studyhas suggested
the existence of an N-terminally extended VANGL2 isoform (VANGL2-Long),
owing to the occurrence of an alternative non-AUG translation initiation site,
upstream of the conventional start site. Translation initiation from this alterna-
tive site is expected to add an N-terminal extension of 48 amino acids. Accord-
ingly, by analyzing VANGL2 immunoprecipitates by mass spectrometry, we
identifıed a peptide mapping upstream of the fırst methionine supporting the
existence of a longer isoform of VANGL2. While missing in Drosophila, this
N-terminal extension is found in all vertebrate VANGL2 sequences that have
been examined, suggesting a function for VANGL2-Long. We provide further
experimental evidence in favor of the VANGL2-Long isoform, using polyclonal
antibodies that have been raised against the predicted VANGL2 N-terminal
extension. Using these tools, we characterized VANGL2-Long and showed that
it dimerizeswithVANGL2 andVANGL1, a close homologue, at the endogenous
level in living cells. Our data depict a complex organization of VANGL1/
VANGL2 molecules at the plasma membrane and improve the mechanistic
understanding of VANGL2 in normal and cancer cells.
#340 SRMS regulates normal and oncogenic KIT signaling. Sachin Raj M
Nagaraj, Julhash U. Kazi, Lars Rönnstrand. Lund University, Lund, Sweden.
SRMS (Src-related tyrosine kinase lackingC-terminal regulatory tyrosine and
N-terminal myristoylation sites) belongs to a family of non-receptor tyrosine
kinases, which harbours a Src homology 3 and a Src homology 2, as well as a
protein kinase domain. SRMS was fırst identifıed in a screen for the genes that
regulate the growth and differentiation of neuroepithelial cells. SRMS, however,
is an understudied member of this family. The present study was undertaken in
order to explore the role of SRMS in signaling downstream of KIT. The receptor
tyrosine kinase KIT, also known as the stem cell factor receptor, plays a key role
in several developmental processes and have been implicated in many human
cancers such as gastrointestinal stromal tumors, acute myeloid leukemia and
testicular carcinoma. To understand the role of SRMS in KIT signaling, we
generated Ba/F3 cell lines overexpressing KIT and SRMS. We observed that
SRMS regulates normal and oncogenic KIT signaling differentially with respect
to cell proliferation and apoptosis. SRMS association triggers KIT ubiquitina-
tion which in turn downregulates the receptor. Further, expression of SRMS
downregulates wild-type KIT-mediated phosphorylation of AKT, ERK1/2, p38.
Taken together the data demonstrates that SRMS regulates both normalKIT and
an oncogenic mutant of KIT, and have differential impact on receptor down-
stream signaling.
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#341 Investigating a novel GPCR ITIMmotif in regulating Shp2 binding,
signaling, and migration. Ryan D. Paulukinas, Lili T. Belcastro, Catherine C.
Moore. Philadelphia College of Pharmacy, University of the Sciences, Philadel-
phia, PA.
Aberrant expression of CXCR4, a chemokine G protein-coupled receptor
(GPCR), promotes a migratory and invasive phenotype during breast cancer
metastasis, however the mechanism is unknown. Here we investigate the role of
CXCR4 tyrosine phosphorylation within a novel ITIMmotif. Following activa-
tion, CXCR4 is normally phosphorylated on Ser/Thr residues, which promotes
receptor desensitization and internalization. We found previously that Ser/Thr
phosphorylation of CXCR4 is delayed upon SDF gradient sensing, and corre-
lates with sustained signaling to SHP2, a protein that drives hyperproliferation
and invasion of breast cancer. Since SHP2 is known to be recruited to tyrosine
phosphorylated ITIM motifs (immmunoreceptor tyrosine-based inhibitory
consensus motifs), we investigated if CXCR4 contains an ITIM motif, and if
tyrosine phosphorylation within this motif regulates SHP2 binding, signaling,
and migration. Specifıcally, we assessed 1) if CXCR4 is tyrosine phosphorylated
asmeasured by recombinant phosphatase assay, phospho-Ab development, and
tyrosine mutagenesis (YF); 2) if tyrosine mutagenesis alters CXCR4 membrane
localization, internalization, and SDF gradient sensing, by ELISA; 3) if tyrosine
mutagenesis disrupts CXCR4 interaction with SHP2, by co-IP; 4) if tyrosine
mutagenesis alters CXCR4 sustained signaling to SHP2, by Western; and 5) if
tyrosine mutation (YF) within the novel ITIMmotif in CXCR4 alters migration
of metastatic breast cancer cells, by transwell motility assays. Our results dem-
onstrate that CXCR4 phosphorylation is sensitive to recombinant tyrosine
phosphatase treatment and tyrosine mutagenesis, suggesting that CXCR4 is in-
deed tyrosine phosphorylated within the ITIMmotif.We determined that while
tyrosine phosphorylation within the ITIM motif is not required for CXCR4
membrane localization, internalization, or SDFgradient sensing, it does regulate
CXCR4 binding and signaling to SHP2. Investigating the role in CXCR4 medi-
ated migration is on going. To date, our data support a working model that
tyrosine phosphorylation of CXCR4within an ITIMmotif is critical for binding
to SHP2 and transducing sustained signaling to SHP2. These data have impli-
cations on aggressive breast cancers with dysregulated CXCR4 and SHP2. These
studies were supported by NIH grant GM-097718, PA Department of Health
grant SAP4100057688, and the Milton Lev Memorial Faculty Research Fund.
#342 WHSC1L1-mediated EGFR mono-methylation enhances the cyto-
plasmic and nuclear oncogenic activity of EGFR in head and neck cancer.
Vassiliki Saloura,1 Theodore Vougiouklakis,1 Makda Zewde,1 Xiaolan Deng,1
Kazuma Kiyotani,1 Jae-Hyun Park,1 Yo Matsuo,2 Mark Lingen,1 Naoshi Do-
hmae,3 Takehiro Suzuki,3 Ryuji Hamamoto,1 YusukeNakamura1. 1Univ. of Chi-
cago, Chicago, IL; 2Oncotherapy Science, Japan; 3RIKEN, Japan.
While multiple post-translational modifıcations have been reported to regu-
late the function of epidermal growth factor receptor (EGFR), the effect of pro-
teinmethylation on its functionhas not beenwell characterized. In this study,we
show thatWHSC1L1mono-methylates lysine 721 in the tyrosine kinase domain
of EGFR, and that this methylation leads to enhanced activation of its down-
stream ERK cascade without EGF stimulation. We also show that EGFR K721
mono-methylation not only affects the function of cytoplasmic EGFR, but also
that of nuclear EGFR.WHSC1L1-mediatedmethylation of EGFR in the nucleus
enhanced its interactionwith PCNA in squamous cell carcinomaof the head and
neck (SCCHN) cells and resulted in enhanced DNA synthesis and cell cycle
progression. Overall, our study demonstrates the multifaceted oncogenic func-
tion of the protein lysine methyltransferase WHSC1L1 in SCCHN, which is
mediated through direct non-histone methylation of the EGFR protein with
effects both in its cytoplasmic and nuclear functions.
#343 Proteomic and functional studies identify DCAF7 as major partner
of DYRK1A. Varsha Anathapadmanabhan,1 Selene Swanson,2 Siddharth
Saini,1 Vijay Menon,1 Larisa Litovchick1. 1Virginia Commonwealth University,
Richmond, VA; 2Stowers Institute for Biomedical Research, Kansas City, MO.
Human DYRK1A protein kinase is encoded by dosage-dependent gene since
an extra copy contributes to Down syndrome (DS) pathogenesis while loss of
one allele causes severe developmental defects. Current knowledge of
DYRK1A’s role in phosphorylation of proteins involved in cell cycle control,
transcription and tumor suppression does not fully explain dosage-dependent
function of this important kinase. Using MudPIT proteomic analysis, we iden-
tifıed DYRK1A interacting proteins in human T98G cell line. Four independent
DYRK1A-HA pull-down samples were analyzed to identify 50 proteins that
were specifıcally detected in 3 out of 4 replicates. This analysis identifıed WD-
repeat protein DCAF7 as major partner of DYRK1A that was most highly en-
riched amongDYRK1A-binding proteins. Furthermore, glycerol gradient ultra-
centrifugation showed almost exact co-fractionation of DCAF7 and DYRK1A.
DCAF7 has been shown to bind several protein kinases including DYRK1A,
DYRK1B, HIPK2 andMAP3K1 suggesting that it serves as a scaffold protein in
signal transduction. However, the function of DCAF7 is not established yet. In
order to understand the functional relationship between DCAF7 and DYRK1A,
we undertookMudPIT proteomic analysis of DCAF7 binding proteins in T98G
cells and compared the data with the DYRK1A interactome dataset. Analysis of
three independent DCAF7-HA pull-down samples identifıed 32 proteins spe-
cifıcally detected in all three replicates including DCAF7, DYRK1A and fıve
proteins earlier detected in DYRK1AMudPIT analysis. Given the proposed role
of DCAF7 as a scaffold protein, we tested whether DCAF7 mediates its interac-
tion with some of its interacting proteins. Interestingly, we found that RNF169,
a recently characterized RING-domain ubiquitin ligase involved in the DNA
double-strand break (DSB) repair, binds to N-terminus of DYRK1A indepen-
dently of DCAF7. Furthermore, our data show that DYRK1A is required for
DCAF7-RNF169 interaction because this interaction was abolished in human
U-2 OS cells where DYRK1A gene was disrupted using CRISPR-Cas9 editing
(DYRK1A-KO cells). Interestingly, stable overexpression of DCAF7 in
DYRK1A-KO U-2 OS cells rescued some of the phenotypes observed in these
cells, suggesting that DCAF7 could be an effector downstream of DYRK1A.Our
fındings revealed an unexpected scaffolding role of DYRK1A that is required for
mediating the interaction between DNA repair protein RNF169 and the WD-
repeat proteinDCAF7.While further studies are needed to understand the exact
role of the RNF169-DCAF7 interaction in DNA repair, the novel role of
DYRK1A as a scaffold protein could explain some aspects of the dosage-depen-
dent function of this protein kinase. In addition, we report here an initial func-
tional characterization of the DCAF7-DYRK1A interaction in human cells and
discuss novel functional interactions of DCAF7 that could be independent of
DYRK1A.
#344 Chondroitin sulfatases regulate Wnt signaling through effects on
Shp2, phospho-Erk1,2, c-Myc, and histone methylation of DKK3 in prostate
cancer and prostate stem cells. Joanne Kramer Tobacman, Sumit Bhattacha-
ryya, Leo Feferman. Univ. of Illinois at Chicago, Chicago, IL.
The chondroitin sulfatases N-acetylgalactosamine 4-sulfatase (arylsulfatase
B; ARSB) andN-acetylgalactosamine 6-sulfatase (galactose 6-sulfatase, GALNS)
remove the 4-sulfate and 6-sulfate groups of chondroitin sulfates. ARSB acts to
remove 4-sulfate groups of chondroitin 4-sulfate (C4S) or dermatan sulfate, and
GALNS acts to remove 6-sulfate groups of chondroitin 6-sulfate (C6S) or chon-
droitin 4,6-disulfate, as well as keratan sulfate. In human prostate cancer tissues,
ARSB activity was markedly reduced and GALNS activity increased. By immu-
nohistochemistry ofmalignant prostate tissue captured by lasermicrodissection
and by assay of human prostate stromal and epithelial cell lines, ARSB was
predominant in stromal cells of the extracellular matrix, whereas GALNS pre-
dominated in prostate epithelial cells. When ARSB was reduced by silencing in
human prostate stem cells or GALNS was increased by overexpression in the
stem cells, SHP2 binding to chondroitin 4-sulfate increased, leading to inhibi-
tion of phosphatase action and sustained phosphorylation of Erk1,2. Erk activa-
tion enabled increase in c-Myc binding to nuclear DNA and increased expres-
sion of DNMT 1a, 3a, and 3b. DNMT activation increased following ARSB
silencing or GALNS overexpression, and was blocked by ERK inhibition. In-
creasedDNMTactivity led to the increased promotermethylation ofDKK3, and
the subsequent inhibition of nuclear -catenin nuclear translocation and Wnt
signaling. Decline in Wnt signaling was manifested by reduced TCF-LEF nu-
clear binding, and decline in the mRNA expression of c-Myc and GATA. Since
c-Myc activation can lead to increased expression of cell cycle regulators, the
changes in chondroitin sulfation mediated by sulfatases can lead to profound
effects in cell proliferation. Hence, the modifıcation of sulfatase activity, mani-
fested as increased chondroitin 4-sulfate, provides the platform for an extensive
extracellular-intracellular signaling network that can regulate phosphorylation,
DNApromotermethylation, and proliferation, and affect development andma-
lignant transformation.
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#345 PTEN tumor suppressive effects in glioblastoma are partlymediated
byMETdownregulation via ap53-miR-34a axis.FadillaGuessous,1NicholaA.
Cruickshanks,1 Ying Zhang,1 David Schiff,1 Jann Sarkaria,2 Roger Abounader1.
1University of Virginia, Charlottesville, VA; 2Mayo Clinic, Charlottesville, VA.
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Glioblastoma (GBM) is themost common andmost lethal primarymalignant
brain tumor. Two common alterations in GBM are loss of the tumor suppressor
PTEN and upregulation of the oncogenic receptor tyrosine kinase MET. We
uncovered a new connection between PTEN and MET expressions and func-
tions in GBM. We found that PTEN expression in GBM cell lines (U87, U373,
A172, LNZ-308) and primary cells (GBM8) inhibits MET expression. We un-
covered the molecular basis and functional signifıcance of this connection.
Based on our previous work and published literature, PTEN stabilizes p53, p53
induces miR-34a expression, and miR-34a inhibits MET expression. We there-
fore hypothesized that PTEN inhibits MET by regulating p53 and miR-34a and
that the PTEN tumor suppressive effects are partlymediated byMETdownregu-
lation. To verify the hypothesis, we fırst showed that PTEN restoration leads to
miR-34a upregulation in GBM cells. We then showed that this latter effect is
p53-dependent as p53 knockdown with a specifıc shRNA partly reversed PTEN
induction of miR-34a. We also showed that PTEN-induced downregulation of
MET expression can be rescued by inhibition of miR-34a with an anti-miR3a.
We therefore established a new molecular cascade that links PTEN, p53, miR-
34a andMET inGBM. To determine the functional relevance of this cascade, we
assessed the effects of PTEN onGBM cell death and invasion also in the settings
of shRNA-mediated knockdown of p53 and anti-miR-mediated inhibition of
miR-34a. PTEN strongly induced GBM cell death (measured by Annexin
V/7AAD flow cytometry) and inhibited transwell invasion though a collagen IV
matrix. The PTEN effects on cell death and invasion were partly reduced by p53
knock-down and miR-34a inhibition. This demonstrates that the tumor sup-
pressive effects of PTEN in GBM are partly mediated by the PTEN/p53/miR-
34a/MET cascade. In ongoing experiments, we are investigating the expressions
of PTEN, MET, p53 and miR-34a in human GBM tissues to determine if there
are potential correlations that are consistent with our above fındings. Alto-
gether, this study establishes a newmolecular and functional link betweenPTEN
and MET that involves p53 and miR-34a in GBM.
#346 Fatty acid synthase is a risk factor for bleomycin-induced lung fıbro-
sis in mice.Mi-Yeon Jung.Mayo Clinic, Rochester, MN.
Pulmonary fıbrosis is a signifıcant complication in cancer patients treated
with radiation or various chemotherapeutic agents. One such reagent, bleomy-
cin, is used to treat a variety of cancers including, but not limited to, lymphoma,
ovarian cancer, and melanoma. Its effıcacy, however, is impacted by the inci-
dence of signifıcant pulmonary fıbrosis, which often becomes dose limiting. In
studies investigating the role(s) ofmetabolism in the profıbrotic actions of trans-
forming growth factor beta, we previously determined that increased fatty acid
synthase (FASN) expression was observed in the fıbrotic areas of lungs from
idiopathic pulmonary fıbrosis (IPF) patients compared to healthy controls. In
that FASN levels are signifıcantly increased in numerous human tumors includ-
ing breast, prostate, colorectal, and ovarian, we wished to integrate these fınd-
ings by examining whether inhibiting FASN activity could reduce pulmonary
fıbrosis. To that end, the cerulenin-derived FASN inhibitor C75 was tested in a
murine treatment model of bleomycin-induced lung fıbrosis. Following addi-
tion of C75, there was signifıcant diminution in a number of profıbrotic targets
including collagen 11, fıbronectin, connective tissue growth factor, and total
lung collagen as assessed by hydroxyproline content. Not only was there a C75
dose-dependent decrease in the aforementioned targets, but lung function as
assessed by peripheral blood oxygenation (on room air) was also stabilized/
improved. Thus, FASN inhibition might reflect a possible target to maintain
normal lung physiology in the context of cancer chemotherapy. This work was
supported by Public Health Service grants GM-055816 and GM-054200 from
the National Institutes of General Medical Sciences.
#347 The role of Pin1 in chemosensitivity of BRCA1-defıcient breast can-
cers. Catherine Knowlson, Paul Mullan, Niamh Buckley. Queen’s University
Belfast, Belfast, United Kingdom.
BRCA1-defıcient breast cancers are largely triple negative (ER, PR and
HER2 negative) and express markers representing the basal-like subgroup. Tri-
ple receptor negativity means that there are no targeted therapies available for
this subtype, which consequently has the poorest overall survival rates. Given
that BRCA1 dysfunction or ’BRCAness’ is often observed in triple negative
breast cancers (TNBCs), it is likely that loss of BRCA1 also plays a key role in
their pathogenesis. Therefore to improve TNBC treatment responses, investiga-
tion into the underlying biology is required. It has been reported that levels of the
prolyl isomerase Pin1 are upregulated in the absence of functional BRCA1, and
that levels correlate with tumor grade. Pin1 alters the conformation of target
proteins to affect their regulation and function.Many of these target proteins are
implicated in key oncogenic signalling pathways, including BRCA1-associated
pathways, such as cell cycle and growth regulation, DNA damage response,
transcriptional regulation and NFB signalling. We have observed that Pin1
levels are indeed upregulated in BRCA1-defıcent cell lines compared tomatched
BRCA1 reconstituted cells, and that Pin1 plays a role in their growth rate and
responsiveness to chemotherapy. BRCA1-defıcient cells are sensitive to DNA
damaging agents due to loss of DNA repair functions, notably homologous
recombination (HR) repair of double strand breaks. We have identifıed a corre-
lation between Pin1 levels and sensitivity to PARP inhibitors, which are toxic to
HRdefıcient cells due to synthetic lethality.Ongoingworkwill establishwhether
Pin1 levels may be utilized as a biomarker of BRCAness and PARP inhibitor
sensitivity. In contrast, during treatment of breast cancer cells with microtubule
damaging agents, the presence of BRCA1 is required to promote apoptosis
through MEKK3 and JNK, therefore BRCA1 defıcient cells are less sensitive.
Knockdown of Pin1 in BRCA1-defıcient cells sensitizes them to the taxane Pac-
litaxel, due to repression of the anti-apoptotic proteinMcl-1, while Pin1 knock-
down in BRCA1 profıcient cells has no effect on sensitivity as Mcl-1 levels are
repressed through theMEKK3 pathway.We have also identifıed that several Src
family kinases (SFKs) are upregulated by Pin1 in a BRCA1-defıcient back-
ground, and may play a role in taxane sensitivity. Pre-treatment with the Src/
SFK inhibitor Dasatinib increases cytotoxicity of Paclitaxel, suggesting that
combination treatment of Dasatinib and Paclitaxel may be an effective treat-
ment option for BRCA1-defıcient breast cancers. In conclusion, we have found
that Pin1 may be an important oncogenic mediator downstream of dysfunc-
tional BRCA1 facilitating the viability of TNBCs. We propose that Pin1 could
serve as a predictive marker of PARP and Src inhibitor treatments, allowing
clinicians to make better informed treatment decisions for this heterogeneous
and aggressive subtype of breast cancer.
#348 Comparison of the response of the NCI60 NSCLC panel with the
response of patient-derived NSCLC lines to approved and investigational
agents. Beverly A. Teicher,1 David Evans,2 Thomas Silvers,2 Michael Selby,2
Rene Delosh,2 Julie Laudeman,2 Chad Ogle,2 Russell Reinhart,2 Joel Morris,3
Gurmeet Kaur,1 James Doroshow1. 1National Cancer Inst., Bethesda, MD; 2Lei-
dos Biomedical Research, Inc., Frederick, MD; 3National Cancer Inst., Rockville,
MD.
An 800 compound screen with the NCI60 cell lines and 5 patient-derived
NSCLC lines (PDNSCLC), was conducted at 9 concentrations and included the
FDAapproved oncology agents and an investigational agents library. The screen
was conducted using 384-well monolayer cultures, an exposure time of 72 hrs
and compound concentrations from 1 nM to 10 uM. CellTiter-Glo was used to
measure viability as an endpoint. The NCI60 NSCLC panel consists of 9 cell
lines: A549, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23, NCI-H322M,
NCI-H460 and NCI-H522. The response of these lines was compared with the
response of 5 PD NSCLC lines and 60 SCLC lines. While both sets of NSCLC
lines had similar responses to the majority of compounds, there were some
marked differences. Differences in response of the NCI60 NSCLC lines and the
PDNSCLC lines were notable upon exposure to tubulin fragmenters, KSP/EG5
inhibitors, GAR transformylase inhibitors, Polo-like kinase-1 inhibitors
(PLK1), MEK inhibitors, and IAP inhibitors. The NCI60 NSCLC lines were
more sensitive to the tubulin fragmenters than were the PD NSCLC and the
SCLC lines. Verubulin had a mean GI50 in NCI60 NSCLC of 0.0037 uM and
0.0042 uM in SCLC versus 0.047uM in the PDNSCLC lines. TheNCI60NSCLC
lines were more sensitive to the KSP inhibitor, ARRY-520 (mean GI50 0.0049
uM) than the SCLC lines (0.028 uM) and the PD NSCLC lines (0.26 uM). The
NCI60NSCLC lines (meanGI50 0.019 uM) and the SCLC lines (meanGI50 0.04
uM) were more sensitive to PLK1 inhibitors such as BI-2536 than the PD
NSCLC lines (0.13 uM). However, the NCI60 NSCLC lines (mean GI50 0.8 uM)
and the SCLC lines (mean GI50 0.134 uM) were less sensitive than the PD
NSCLC lines (mean GI50 0.025uM) to GAR transformylase inhibitors such as
pelitrexol. The NCI60 NSCLC lines (mean GI50 6.3 uM) and SCLC lines (mean
GI50 10 uM) were also less responsive to IAP inhibitors, than were PD NSCLC
lines (meanGI50 1.6 uM). A heterogeneous response to theMEK inhibitors such
as cobimetinib (GDC-0973) was observed with the SCLC lines (mean GI50 8.9
uM) versus 1.15 uM in the NCI60 NSCLC lines and 0.56 uM in the PD NSCLC
lines. PD NSCLC lines exhibit some interesting differences in response from
established lung cancer lines upon in vitro exposure to anticancer agents and
thus add to our knowledge and understanding of NSCLC and help inform dis-
covery efforts and/or clinical development of therapeutics in this disease. This
project was funded in part with federal funds from theNCI,NIH, under contract
no. HHSN261200800001E.
#349 Eribulin induces cortical localization of E-cadherin, p120-catenin
and beta-catenin in breast cancer cells. Alison D. Clark, Nicholas F. Dybdal-
Hargreaves, Susan L. Mooberry. UTHSCSA, San Antonio, TX.
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Eribulin provides a survival advantage for breast cancer patients, particularly
those with triple-negative and HER2-negative subtypes.1,2 Mechanistically, er-
ibulin was shown to reverse epithelial-to-mesenchymal transition (EMT) in
breast cancer models.3 E-cadherin is a central regulator responsible for mainte-
nance of the epithelial phenotype and loss of cortical E-cadherin and its down-
stream signaling is an early and signifıcant event in EMT. Short term treatment
of HCC1937 breast cancer cells with eribulin initiated cortical E-cadherin local-
ization in manner different from other microtubule targeting agents. Cortical
E-cadherin plays essential roles in cell adhesion and in regulating theWnt path-
way, whose aberrant activity is implicated in EMT. At the adherens junctions
p120-catenin and -catenin bind to E-cadherin, an interaction facilitated by
microtubules. Cortical sequestration of p120- and -catenin at the adherens
junctions stabilizes these complexes and inhibits their ability to stimulate sig-
naling pathways that contribute to EMT. We tested whether eribulin, which
binds to the plus ends of microtubules, promotes EMT reversal by influencing
p120- and -catenin localization and activity. Our results show that eribulin
induces cortical localization of p120-catenin and -catenin with E-cadherin in
HCC1937 cells, consistent with the formation of normal adherens junctions.
Eribulin also stimulated the phosphorylation of Ser33/37 and Thr41 on
-catenin which promotes proteasomal degradation, which would be expected
to further inhibit oncogenic signaling. Collectively, our results suggest that er-
ibulin contributes to reversal of EMT through modulation of downstream sig-
naling initiated by cortical localization of p120- and -catenin at the adherens
junctions. Funding for this work was provided by Eisai Inc. 1. Cortes J., et al.,
Lancet 377:914-923, 2011 2. Twelves, C., et al., Breast Cancer Res Treat 148:553-
561, 2014 3. Yoshida, T., et al., Br J of Cancer 110: 1497-1505, 2014.
#350 Pregnancy at early age is associatedwith a reductionof progesterone-
responsive cells and epithelial Wnt signaling in human breast tissue. Robert
Mechera,1 SimoneMünst,1 Silvio Däster,1 Salvatore Piscuoglio,1 Charlotte Ng,1
Fabienne Meier-Abt,2 Walter P. Weber,1 Savas D. Soysal1. 1University Hospital
Basel, Basel, Switzerland; 2University Hospital Zuerich, Zuerich, Switzerland.
Background: Pregnancy at early age is the most signifıcant modifıable factor
which consistently decreases lifetime breast cancer risk. However, the underly-
ing mechanisms haven’t been conclusively identifıed. Studies in mice suggest a
reduction in progesterone-receptor (PR) sensitive epithelial cells as well as a
downregulation of the Wnt signaling pathway as being one of the main mecha-
nisms for the protective effect of early pregnancy. The aim of our study was to
validate these fındings in humans.Methods:We collected benign breast tissue of
123 women who had been stratifıed according to age at fırst pregnancy and the
occurrence of subsequent breast cancer, and performed immunohistochemistry
for PR, Wnt4 and the Wnt-target Versican. Results: The number of PR positive
epithelial cells was signifıcantly lower in the group of women with early preg-
nancy and no subsequent breast cancer compared to the group of nulliparous
women with subsequent invasive breast cancer (p0.017). In women with early
pregnancy, expression of Versican andWnt4 was signifıcantly lower compared
to nulliparous women (p0.0064 and p0.0156 respectively), and Versican
expression was also signifıcant lower compared to women with late pregnancy
(p0.0001). Discussion: Our results confırm prior observations in mice and
suggest a role of downregulation of epithelial Wnt signaling in the protective
effect of early pregnancy in humans. This results in a decreased proliferation of
stem/progenitor cells; therefore, the Wnt signaling pathway may represent a
potential target for breast cancer prevention in humans.
#351 mTOR-ERK co-targeting strategies for head and neck cancer ther-
apy. Zhiyong Wang,1 Esteban Delgado,2 Kosuke Yamaguchi,1 Ramiro Iglesias-
Bartolomé,3 Panomwat Amornphimoltham,1 Alfredo Molinolo,1 Qianming
Chen,4 J.Silvio Gutkind1. 1Moores Cancer Center, University of California, San
Diego, La Jolla, CA; 2SanDiego StateUniversity, SanDiego, CA; 3National Cancer
Institute, NIH, Bethesda, MD; 4West China School of Stomatology, Sichuan Uni-
versity, Chengdu, China.
Despite therapeutic advances in the past decade, head and neck squamous cell
carcinoma (HNSCC) continues to be a major public health concern. Although
recent studies of human cancer genomes identifıed remarkable complexity of
genomic alterations in HNSCC, surprisingly, most aberrations have fallen
within key driver signaling pathways. Among them, PI3K/AKT/mTORpathway
ismost frequently activated in over 80%of theHNSCCpatients.We showed that
the majority of HNSCC lesions exhibit high levels of phosphorylated ribosomal
S6 protein (pS6), key downstream target of the AKT-mTOR pathway, and that
inhibition of mTOR by the use of rapamycin causes a rapid decrease in the level
of pS6 and the apoptotic death of HNSCC tumor xenografts, thereby causing
tumor regression. Our initial studies identifıed the AKT-mTOR pathway as a
potential therapeutic target for HNSCC and provided strong rational to initiate
multiple clinical trials. Indeed, inhibitors of PI3K/AKT/mTOR block mTOR
activity and exert a benefıcial response in HNSCC patients. However, therapeu-
tic resistancewas evidenced in several trials, whichmight be due to the activation
of adaptive survival signaling in tumor cells. To explore the therapeutic option
that can overcome the resistance, we performed a synthetic lethality screen in
HNSCC cell lines using shRNA libraries. We found that multiple molecules
involved in ERK pathway were highly represented. Furthermore, treating HN-
SCC cell lines harboring activated mTOR with small molecule inhibitors that
target PI3K/AKT/mTOR pathway can sequentially induce ERK activation,
which is consistent with the fındings observed in numerous clinical trials. We
demonstrated that co-targeting mTOR and ERK using trametinib, a MEK1/2
inhibitor or cetuximab, anEGFRmonoclonal antibody, exhibited the synergistic
effect by sensitizing HNSCC to priming with the mTOR inhibitor. Specifıcally,
mTOR-ERK co-targeting prevented the growth of HNSCC tumor xenografts by
decreasing cell proliferation, reducing lymphangiogenesis and activating apo-
ptosis. In addition, we have recently used a phosphoproteomics approach to
identify themolecular mechanisms of ERK feedback activation caused by PI3K/
AKT/mTOR inhibition. Overall, our promising fındings from these preclinical
studies suggest that the use of mTOR-ERK co-targeting strategies may provide
the novel alternative approach to achieve durable responses (cure) in HNSCC
cancer patients.
#352 The role of p62 (SQTSM1) in the transforming growth factor  sig-
naling pathway. Evelyn Ng, Adrian Gunaratne, John Di Guglielmo. Western
University, London, Ontario, Canada.
Transforming growth factor beta (TGF) is a cytokine that regulates many
cellular processes, including cellular adhesion, proliferation and apoptosis. Its
canonical downstream effectors include Smad2/3 proteins, which are phosphor-
ylated and then translocate to the nucleus to alter gene transcriptional programs
and promote processes such as epithelial-to-mesenchymal transition (EMT).
Previous studies in our lab have shown that atypical Protein Kinase C (aPKC)
isoforms associate with TGF receptors and modulate receptor traffıcking and
signal transduction. An aPKC-associated protein, p62 (SQSTM1) has been im-
plicated in TGF-dependent EMT, however the mechanisms remain unclear-
.Here, we investigate the localization of p62 and its potential roles inmodulating
TGF signaling via knockdown and overexpression studies. Using antibody
feeding and immunofluorescence microscopy, we support previous fındings
showing that p62 localizes to late endosomes. In addition, using a co-immuno-
precipitation approach, we observed that p62 may associate with TGF type II
receptor. To explore the functional role of p62 in TGF signaling, we conducted
protein silencing using siRNA. We observed TGF-independent decreases in
E-cadherin expression. However these changes were independent of the phos-
phorylation status or nuclear translocation of Smad2.P62 also plays an impor-
tant role in autophagy by targeting proteins for degradation. Recently, pro-
longed TGF stimulation has been shown to induce cellular autophagy.
Therefore, it is in our interest to characterize the relationship between TGF-
dependent EMT and autophagy, and to determine whether p62 has a regulatory
role between these two processes.
#353 ROR1 inhibits ASK1-mediated pro-apoptotic signaling in lung ade-
nocarcinoma. Lisa Ida, Tomoya Yamaguchi, Taisuke Kajino, Kiyoshi Yanag-
isawa, Yukako Shimada,Motoshi Suzuki, Takashi Takahashi.Division ofMolec-
ular Carcinogenesis, Center for Neurological Diseases and Cancer; Nagoya
University, Nagoya, Japan.
We previously reported that the receptor tyrosine kinase-like orphan receptor
1 (ROR1) is transcriptionally activated by TTF-1/NKX2-1 lineage-survival on-
cogene in lung adenocarcinoma and maintains a favorable balance between
pro-survival PI3K-AKT and pro-apoptotic ASK1-p38 signaling. Although in-
depth mechanistic insight into how ROR1 sustains EGFR-mediated PI3K-AKT
signaling in both kinase-dependent and -independent manners has been ob-
tained, it remains elusive how ROR1 inhibits pro-apoptotic signaling. In the
present study, we investigated the underlying mechanism of ROR1-mediated
inhibition of the ASK1-p38MAPK signaling pathway. Co-treatment with
siASK1 resulted in partial but signifıcant alleviation of siROR1-mediated growth
inhibition in the lung adenocarcinoma cell lines PC-9 and NCI-H1975, which
readily express both ROR1 and ASK1. Signifıcant decreases in auto-phosphor-
ylation of ASK1 at threonine 845 and p38 phosphorylation at threonine 180 and
tyrosine 182 were observed in ROR1-transfected MSTO-211H cells in both
steady state and oxidative stress-elicited conditions, suggesting ROR1-mediated
negative regulation of the ASK1-p38 axis. ROR1 was shown to interact physi-
callywithASK1 through theC-terminal serine/threonine-rich domain of ROR1.
An in vitro kinase assay using cellular ASK1 prepared from ASK1-transfected
293T cells as well as recombinant MBP-tagged kinase-defıcient MKK6 revealed
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that co-incubation of ASK1with recombinant GST-tagged ROR1 clearly dimin-
ished ASK1 auto-phosphorylation andMKK6 phosphorylation. We further ex-
amined whether the kinase activity of ROR1 is required for inhibition of ASK1
activity using MSTO-211H cells stably transfected with either a wild-type or a
kinase-dead mutant of ROR1. In contrast to wild-type ROR1, kinase-dead
ROR1 failed to signifıcantly repress hydrogen peroxide-induced ASK1 phos-
phorylation as well as consequential p38 phosphorylation and increase in
sub-G1 cells. Since we previously found that ROR1 activates SRC, we also exam-
ined whether SRC is involved in the ROR1-sustained ASK1 inhibition. Intro-
duction of constitutively active SRC signifıcantly reduced siROR1-induced
ASK1activity in PC-9 cells, while co-transfection of SRC and ASK1 resulted in
tyrosine phosphorylation of ASK1, which was accompanied with diminished
ASK1 phosphorylation at threonine 845. Finally, the interaction between SRC
and ASK1 was found to be enhanced by the presence of ROR1 by an in vitro
pull-down assay. Taken together, the present fındings support our notion that
ROR1 sustains lung adenocarcinoma survival, at least in part, through direct
physical interaction with both ASK1 and SRC, which consequently results in
repression of the pro-apoptotic ASK1-p38 axis in a ROR1 kinase activity-depen-
dent manner.
#354 Inhibition of Smad3 signaling with a TAT fusion peptide prevented
TGF--induced fıbronectin expression and cellmigration inmalignant glio-
mas. Jeonghan Kang.Mayo Clinic, Rochester, MN.
Malignant primary brain tumors represent one of themost common causes of
cancer death in theworld.Grade IV gliomas (glioblastomamultiform,GBM) are
routinely resistant to current chemoradiationchemo radiation therapy with a
median progression-free and overall survival for glioblastoma following current
chemoradiation of7 and 15months, respectively.While TGF- functions as a
growth inhibitor for most normal cell types, many tumors (including GBMs)
have lost this inhibitory response and TGF- now functions to promote tumor
progression and/or dissemination. As aberrant TGF- signaling is often consid-
ered a hallmark of high-grade gliomas, we examined whether inhibition of spe-
cifıc components would impact the malignant phenotype of glioblastoma. The
primary mediators of TGF- action are the Smad proteins (R-Smads), Smad2
and Smad3. Following receptor activation and R-Smad phosphorylation, they
translocate to the nucleus to modulate gene expression. Since we previously
determined that a cell penetrating peptide conjugate of the HIV TAT protein
fused to a 30 amino acid sequence from sorting nexin 9 (SNX9) prevented
Smad3, but not Smad2, nuclear import and target gene expression in models of
organ fıbrosis, we further investigated whether it might similarly impact aspects
of GBM proliferation. To that end, twenty-one patient-derived xenografts
(PDXs) were examined for their responsiveness to TGF-. Of those, TGF-
stimulated migration and fıbronectin expression in seven (33%), which was
prevented by inhibiting Smad3 signaling with the TAT-SNX9 peptide but not a
control peptide unable to block Smad3 action. These fındings indicate that the
TGB-b/Smad3 axis is a potentially importantmediator of glioma cell invasion in
a signifıcant minority of GBM models. specifıcally targeting Smad3 might be
effective in a subset of gliomas. This work was supported by Public Health
Service grantsGM-055816 andGM-054200 from theNational Institutes ofGen-
eralMedical Sciences and P50 CA-108961Developmental Pilot Award from the
National Cancer Institute.
#355 TET2-lossmodifıes androgen signaling inprostate cancer.Michael L.
Nickerson,1 Sudipto Das,2 Kate Im,1 Sevilay Turan,1 Sonja Berndt,1 Hongchuan
Li,1Hong Lou,1 Seth Brodie,1 Kalpit Shah,1 Jean-Noel Billaud,3 TongwuZhang,1
Joseph Boland,1 Stephen Anderson,1 Meredith Yeager,1 Michael Dean,1
Thorkell Andresson2. 1National Cancer Institute, Bethesda, MD; 2Leidos Bio-
medical, MD; 3Ingenuity, CA.
Molecular markers for metastatic prostate cancer (PCa) can be identifıed by
sequencing metastatic tumor genomes. We recently identifıed cancer gene mu-
tations in a patient with metastatic disease using next generation sequencing
(NGS) of DNA from 5metastatic tumors and blood.We characterized a somatic
non-conservative substitution in the methylcytosine dioxygenase ten-eleven
translocation 2 (TET2) in all metastatic tumors but not the blood or primary
adenocarcinoma. Analysis of metastatic tumors from additional patients re-
vealed frequent somatic loss and sequence alteration of TET2, which was previ-
ously observed to be altered in 5-15% of myeloid, kidney and colon cancer.
Genome-wide association studies previously identifıed non-coding risk variants
associated with PCa and melanoma, and rare germline missense variants are
observed in African-Americans with PCa. We sought to further investigate the
role of TET2 in PCa. We performed fıne-mapping of PCa risk across the TET2
locus using genotypes from the PEGASUS case-control cohort and identify six
new risk variants in introns 1 and 2. Electrophoretic mobility shift assays show
two risk SNPs are bound by the transcription factor octamer-binding protein 1
(Oct1). Full length TET2 (2002 aa) is expressed in normal prostate and cancer
tissue and is signifıcantly reduced in a subset of the Cancer Genome Atlas
(TCGA) PCa tumors that are associated with metastatic disease and reduced
disease-free survival. TET2-loss drives a cancer phenotype as siRNA-mediated
knockdown (KD) signifıcantly increases LNCaP and DU145 cell proliferation,
and LNCaP transwell migration and wound healing. Affınity chromatography,
mass spectrometry and co-immunoprecipitation confırm that endogenous
TET2 binds the androgen receptor (AR) in LNCaP cell extracts. TET2 KD alters
the expression of a subset of androgen-responsive genes including increased
prostate-specifıc antigen (KLK3/PSA) expression, and published data indicate
TET-catalyzed hydroxymethylcytosine (hmC) and TET2 binding sites proximal
to KLK3. Analysis of TCGA PCa tumor RNA-seq reveals TET2 expression is
co-regulated with the expression of genes encoding functions metabolizing
2-oxoglutarate and succinate including the lysine demethylase KDM6A,
BRCA1-associated BAP1, and citric acid cycle enzymes IDH1-2, SDHA-B and
FH. Co-expression is conserved across all 31 TCGA cancers examined. Exami-
nation of genomic locations associated with TET2-binding and hmC, and gene
expression changes during androgen signaling indicate a putative role for TET2
as an energy sensor that modifıes androgen-AR signaling. Decreased TET2
mRNA expression in TCGA PCa tumors that are associated with reduced pa-
tient survival indicates TET2 expression may be an informative biomarker of
PCa disease progression.
#356 DARPP-32, a bridge between pro-inflammatory NF-kB and STAT3
signaling in gastric cancer. Shoumin Zhu, Mohammed Soutto, Zheng Chen,
Wael El-Rifai. Surgery, Nashville, TN.
Background: Gastric cancer is one of the most frequently diagnosed malig-
nancies with poor prognosis in the world. We have previously shown that Do-
pamine and cAMP-regulated phosphoprotein,Mr 32000 (DARPP-32) is a novel
cancer gene, which is overexpressed in 2/3 of gastric cancers patients; and asso-
ciated with increased cancer cell survival, drug resistance, and invasion. How-
ever, the mechanisms of how DARPP-32 promotes gastric carcinogenesis re-
main unclear. Methods: DARPP-32 promoter activity and stat3 activity were
measured by luciferase. The mRNA and protein levels were evaluated by quan-
titative real-time PCR and Western blot analysis. The association between
DARPP-32 and STAT3 was evaluated by immunofluorescence. SOCS3 degra-
dation was analyzed by Ubiquitination Assay. The interaction between
DARPP-32 and IGF1R was evaluated by co-immunoprecipitation assays. Re-
sults: Promoter analysis of DARPP-32 indicated the presence of NF-B tran-
scription factor putative binding sites in the DARPP-32 promoter region. We
cloned theDARPP-32 promoter into the luciferase reporter (pGL3-Luc). TNF-
treatment induced DARPP-32 reporter activity (P 0.01). Using deletion con-
structs of DARPP-32 promoter and ChIP assay, we demonstrated that the se-
quence (-996 to -1008 bp), containing putative NF-B binding sites, is the most
active region. We confırmed that activation of NF-kB by TNF- and H.pylori
infection leads to induction of DARPP-32 mRNA and protein level. Interest-
ingly, we found that DARPP-32 induction leads to increased phosphorylation of
STAT3 and activation of STAT3 luciferase reporter (P0.01). We detected a
decrease in the protein level of SOC3, a negative regulator of STAT3.DARPP-32
shortened the SOCS3 protein half-life by mediating an increase in phosphory-
lation and ubiquitination of the SOCS3 protein following treatment with
MG132 and IL6. Furthermore, we detected an increase in SRC and IGF1R phos-
phorylation in DARPP-32-overexpressing cells. SRC inhibitor (Dasatinib) and
SRC-siRNA blocked DARPP-32-induced activation of STAT3. We further ex-
amined our hypothesis that DARPP-32 could interact with IGF1R and enhance
IGF1R autophosphorylation. Using co-immunoprecipitation, we found that
DARPP-32 and IGF1R co-exist in the same protein complex. Conclusion: We
demonstrated, for the fırst time, the role of NF-B inDARPP-32 transcriptional
regulation. The in vitro studies indicate thatDARPP-32 plays a role in activation
of STAT3 signaling through inhibition of SOCS3 and activation of IGF1R and
SRC. DARPP-32 interacted with IGF1R, which increasing the phosphorylation
of IGF1R and SRC, and induced SOCS3 phosphorylation and degradation. This
cascade of events leads to STAT3 activation in gastric cancer cells. We propose
DARPP-32 as an important signaling bridge between NF-kB and STAT3 in
response to pro-inflammatory signaling in gastric carcinogenesis.
#357 NKX2-1 regulates SMAD and non-SMAD pathways in thyroid stem
cells. Manabu Iwadate, Yoshinori Takizawa, Shioko Kimura. National Cancer
Institute, MD.
NKX2-1 plays a critical role in thyroid differentiation. Recently, we estab-
lished Side Population cells-derived Thyroid cell line (SPTL) from mouse thy-
roid Side Population cells. In SPTL cells, NKX2-1, PAX8 and E-cadherin were
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not expressed when examined by western blotting. Immunocytochemistry re-
vealed that only 1% of SPTL cells were NKX2-1 positive. When GFP-SPTL cells
were directly injected into mouse thyroid, a few GFP-SPTL cells with weak
expression of NKX2-1 were found in part of thyroid follicle, suggesting that
SPTL cells have potential of thyroid stem cells. Comprehensive gene expression
analysis indicated that TGF-beta signaling pathway is critical for SPTL cells.
TGF-beta signaling and NKX2-1 appear to play an important role in thyroid
stem cells and thyroid differentiation.Herewe show thatNKX2-1 regulates both
SMAD and non-SMADpathways in SPTL cells. To examine the role of NKX2-1
in SPTL cells, we produced SPTL cells having doxycycline-inducible Nkx2-1
expression (named SPTL(Nkx2-1on)). In SPTL(Nkx2-1on) cells, doxycycline
induced NKX2-1 as expected, while PAX8 and E-cadherin expression was not.
Upon overexpression of NKX2-1 in SPTL(Nkx2-1on) cells, TGF-beta-induced
phospho-SMAD3 expression was inhibited. Additionally, NKX2-1 enhanced
the expression of phospho-AKT. In GFP-myrAKT(constitutively active AKT)-
overexpressing SPTL cells, AKT was found localized in their cytoplasm. TGF-
beta did not induce phospho-SMAD3 in these cells. The data indicate that
NKX2-1 inhibits SMAD pathway through AKT activation. Ourwork demon-
strates that TGF-beta signaling is controlled by NKX2-1 in thyroid stem cells.
#358 LTB and LTBR mediates alternative Nf-kB activation through NIk
and RELB/NF-kB2 to promote cell migration of HNSCC. Rita Das, Jamie
Coupar, Anthony saleh, Paul E. Clavijo, Zhong Chen, Carter VanWaes. NIH-
NIDCD, Bethesda, MD.
Nuclear factor-B (NF-B) includes a family of NF-B/REL transcription
factors that regulate key inflammatory and cancer genes, and which are aber-
rantly activated in head and neck squamous cell carcinomas (HNSCC). Lym-
photoxin beta/Lymphotoxin beta receptor (LT/LTR) can mediate activation
of the “alternative”NF-Bpathway that includesNF-B-inducing kinase (NIK),
Inhibitor-B kinase  (IKK), and transcription factors RELB/NF-B2. While
LT is expressed in lymph nodes whereHNSCC spread, the role of this pathway
in pathogenesis of HNSCC is not well studied. Analysis of The Cancer Genome
Atlas (TCGA) data reveals that LTR is amplifıed or overexpressed in larynx or
oral cavity HNSCC, while LT/, NIK, (MAP3K14) and RELB are overex-
pressed in oropharynx and tonsil cancers. Similarly, we observed overexpression
of LTR, NIK, and RELB proteins in subsets of HNSCC cell lines. In UM-
SCC46, LT enhanced nuclear translocation of RELB/NF-B2 (p52) subunit
proteins, while LTR siRNA knockdown decreased the expression of its target
kinase NIK and RELB/NF-B2 (p52). NIK knockdown also decreased RELB/
NF-B2 (p52) protein expression, whereas LT treatment stabilized NIK, and
RELB/NF-B2 (p52). Functional LT-mediated NF-B activation was exam-
ined using a stably transfected NF-B reporter cell line for -lactamase/Fret
activity. Knockdown of LTR andNIKdecreasedNF-B activity, whereas treat-
ment with LT partially restored it. Treatment with a NIK inhibitor (1, 3[2H,
4H]-Iso-Quinoline Dione) reduced the protein expression of NIK, IKK, and
RELB/NF-B2 (p52) in the cytoplasm and/or in the nucleus, and blocked LT
induced translocation of RELB to nucleus.NIK andRELBknockdownby siRNA
or usingNIK inhibitor slowedHNSCCmigration. Knockdown ofNIK inhibited
the LT-induced expression of MET, and SERPINE1 genes involved in migra-
tion, and knockdown of MET by siRNA inhibited the migration of HNSCC cell
lines. Our fındings show that LT/LT receptor promotes activation of the
alternative NIK-IKKa-RELB/NF-B2 pathway, to enhance MET-mediated cell
migration inHNSCC.Thismay help explainwhyHNSCCexhibitmigration and
metastasis to local lymph nodes, where LT is expressed. The constitutive and
LT induced activation of NIK and downstreamNF-B alternate pathway pro-
teins, RELB and NF-B2/p52 could be therapeutic targets in HNSCC. (Sup-
ported by NIDCD intramural projects ZIA-DC-000016, 74).
#359 C1GALT1 activates multiple RTKs and promotes malignant behav-
iors in pancreatic adenocarcinoma cells. Ting-Chun Kuo,1 Hsueh-Fen Juan,2
Yu-Wen Tien,1 Min-Chuan Huang2. 1National Taiwan University Hospital,
Taipei, Taiwan; 2National Taiwan University, Taipei, Taiwan.
Pancreatic adenocarcinoma (PDAC), stands up to the 4th in all cancer
mortalities and remains the most in progress in America. Curative resection
remains the most and only potential strategy but only 1520% of patients
are candidates. Even though, many of them have dismal prognosis. Aberrant
glycosylation illustrates an attribution of cancer, especially fot promoting
malignant behaviors in adenocarcinomas. Altered expression of glycans,
such as GalNAc1-O-S/T (Tn antigen) and Gal1,3-GalNAc-S/T (T anti-
gen), is hallmark of cancers. Core 1 1,3-galactosyltransferase (C1GALT1)
catalyzes the transfer of Gal to Tn antigen to form T antigen. C1GALT1 is
reported to contribute to clinicopathological features and malignant pheno-
types in various cancers. However, the expression and function of C1GALT1
in PDAC remain unrevealed. Our data showed that C1GALT1 was overex-
pressed in PDAC tissues and correlated with poor prognosis. C1GALT1
knockdown inhibited viability, migration, and invasion analyzed by MTT,
transwell migration, and Matrigel invasion assays, respectively, in PDAC
cells, associated with increased Tn antigen but decreased T antigen expres-
sion. Conversely, C1GALT1 overexpression promoted these malignant be-
haviors. C1GALT1 knockdown inhibited AKT and ERK activities in PDAC
cells. Consistently, phospho-receptor tyrosine kinase (p-RTK) array showed
decreased phosphorylation of several RTKs including EGFR, IGF1R, and
FLT3. Additionally, flow cytometry of C1GALT1 knockdown cells showed
enhanced apoptosis, which was associated with decreased catalase, Bcl-x,
and death receptor DR5 revealed by apoptosis array. We also found that
C1GALT1 knockdown arrested G1 progression in PDAC cells. Furthermore,
gene set enrichment analysis of cDNA microarray indicated that C1GALT1
regulated cell cycle, cytoskeleton, and chromatin structure in PDAC cells.
These fındings indicate that higher C1GALT1 expression predicts worse
survival of PDAC and enhances malignant characters in PDAC cells, high-
lighting a fundamental role of C1GALT1 in PDAC development.
#360 Leveraging a novel ITIM motif in GPCRs for targeted antibody de-
sign. Lili T. Belcastro,1 Anastasia Jancina,2 Christina Adams,2 Ryan D. Pauluki-
nas,2 Catherine C. Moore1. 1Cancer Biology Program, The Wistar Institute and
University of the Sciences, Philadelphia, PA; 2Philadelphia College of Pharmacy,
University of the Sciences, Philadelphia, PA.
CXCR4, a chemokine GPCR, is essential for migration of neuronal, hemato-
poietic, and breast cancer cells duringmetastasis wherebyCXCR4 dysregulation
promotes migration and invasion. Following SDF stimulation, CXCR4 is phos-
phorylated on Ser/Thr residues which initiates adaptor recruitment, receptor
desensitization, and traffıcking to endocytic sites.Herewe show that stimulation
with gradient SDF, delays receptor phosphorylation and traffıcking, leading to
sustained signaling to a novel CXCR4-SHP2-ERK pathway. SHP2 is a tyrosine
phosphatase implicated in HER2() and triple-negative breast cancers,
whereby it transduces mitogenic and migratory signals driving hyperprolifera-
tion and invasion. SHP2 is recruited to tyrosine phosphorylated ITIM motifs
(immmunoreceptor tyrosine-based inhibitory consensus motifs), a hallmark
found in inhibitory immune receptors with little evidence in GPCRs. Here we
identify an ITIMmotif in CXCR4 that regulates both SHP2 binding and signal-
ing. Specifıcally, we assessed if gradient SDF stimulation of CXCR4 1) delays
receptor phosphorylation and traffıcking, 2) sustains signaling to SHP2-ERK, 3)
induces SHP2-dependent migration; and if CXCR4 Tyr mutation within the
ITIM motif 4) maintains SDF gradient sensing ability, and 5) disrupts interac-
tionwith and signaling to SHP2. Our data demonstrate that gradient SDF delays
receptor Ser/Thr phosphorylation and internalization thereby sustaining signal-
ing to SHP2-ERK and driving SHP2-dependent migration. Furthermore, the
ITIM mutant maintains SDF gradient sensing ability, but disrupts interaction
with and signaling to SHP2. Our data support a working model that CXCR4
contains a functional ITIMmotif which we are currently leveraging for targeted
antibody design for use inmigration studies of aggressive breast cancer cellswith
dysregulated CXCR4. These studies were supported by NIH grant GM-097718,
PA Department of Health grant SAP4100057688, and theMilton LevMemorial
Faculty Research Fund.
#361 Loss of cholangiocyte primary cilia induces LKB1 downregulation
and defective AMPK signaling. Adrian P. Mansini, Kristen M. Thelen, Sergio
A. Gradilone. University of Minnesota, Austin, MN.
Cholangiocarcinoma (CCA) is a malignancy arising from cholangiocytes, the
epithelial cells lining the biliary tree. CCA is an uncommon, but devastating
cancer that is increasing in incidence. Over the past 3 decades, 5-years survival
rates have remained at 10%. Although surgical resection and liver transplanta-
tion are potentially curative therapies, most patients are diagnosed at late stages
and are not eligible for these options. Therefore, it is imperative to identify novel
targets leading to new therapeutic strategies for this devastating disease. Cholan-
giocytes express primary cilia that function as chemo, mechano, and osmosen-
sors controlling several molecular pathways.We showed cilia are absent in CCA
cells, and experimental deciliation of normal cholangiocytes induced a malig-
nant like phenotype, with signifıcant invasion and proliferation, suggesting the
loss of cilia could be associated with CCA development. LKB1 is a tumor sup-
pressor described to be expressed in primary cilia inMDCKcells, and is involved
in AMPK activation through a ciliary dependent mechanism. AMPK functions
as metabolic and stress check points. Interestingly, patients with intrahepatic
CCA and low expression of LKB1 have poor prognosis. Therefore, we hypoth-
esized that primary cilia function as tumor suppressor organelles through a
LKB1-AMPK-p53 pathway. To test this hypothesis, fırst LKB1 subcellular local-
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ization was evaluated by confocal microscopy. We show for the fırst time that
LKB1 is enriched in cholangiocyte primary cilia in a normal human cholangio-
cyte cell line (NHC).However, in experimental deciliatedNHCand theCCAcell
line KMCH, LKB1 is found dispersed in the cell cytoplasm. Next, we analyzed
cellular expression levels of LKB1, AMPK (T172), p53 (s15), p53 and p21 by
western blot. We found experimentally deciliated cholangiocytes and CCA cells
exhibit defective AMPK signaling characterized by lower levels of LKB1 (-70%
and -85%), AMPK (T172) (-72% and -71%), p53 (-37% and -83%), p53 (S15)
(-38% and -100%) and p21 (-59% and -87%) relative to NHC. These molecular
characteristics correlated with increased cell proliferation in deciliated cells
(28%) and CCA cells (27%). Finally, we attempted to rescue the phenotype by
using the AMPK activator, ampkinone. This treatment induced 20% inhibition
of proliferation on experimental deciliated cholangiocytes and 18% in CCA
cells, while not affecting NHC cells and the inhibition was associated with phos-
phorylation of AMPK and p21 up-regulation. In summary, our data suggest
cholangiocyte primary cilia may normally function as tumor suppressors via a
mechanism involving LKB1 andAMPK. The loss of cilia in CCA impairs LKB1-
AMPK-p53-p21 signaling inducing a proliferative phenotype that may be res-
cued by specifıc activation of AMPK, warranting further studies to assess its use
as a potential therapeutic approach.
#362 Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefıtinib re-
sistance in lung adenocarcinoma.YojiroMakino,1 Jeong-HwanYoon,2 Eunjin
Bae,3Mitsuyasu Kato,4 KeijiMiyazawa,5 TatsuoOhira,1 Norihiko Ikeda,1Masa-
hiko Kuroda,3 Mizuko Mamura3. 1Tokyo Medical University Hospital, Tokyo,
Japan; 2Kyungpook National University Hospital, Daegu, Republic of Korea; 3To-
kyo Medical University, Tokyo, Japan; 4University of Tsukuba, Ibaraki, Japan;
5University of Yamanashi, Yamanashi, Japan.
Cancer-associated inflammation develops resistance to the epidermal
growth-factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small
cell lung cancers (NSCLCs) harboring oncogenic EGFRmutations. Stat3-medi-
ated Interleukin (IL)-6 signaling and Smad-mediated transforming growth fac-
tor- (TGF-) signaling play crucial regulatory roles in cancer-associated in-
flammation. Here we show that Stat3 represses Smad3 in cooperation with c-Ski
and SnoN, whereby renders gefıtinib-sensitive HCC827 cells resistant. IL-6 sig-
naling via phosphorylated Stat3 induced gefıtinib resistance. By contrast, TGF-
upregulated gefıtinib sensitivity. We found that IL-6 signaling via phosphory-
lated Stat3 repressed, whereas TGF- upregulated the expression of Smad3 in
HCC827 cells. Promoter analyses showed that Stat3 synergizedwith c-Ski/SnoN
to repress Smad-induced transcription of the Smad3 gene. Smad3 induced ap-
optosis by upregulating pro-apoptotic genes such as Caspase 3 and downregu-
lating anti-apoptotic genes such as Bcl2. Our results suggest that preventing
IL-6/Stat3-induced loss of Smad3 can be a therapeutic strategy to prevent ge-
fıtinib resistance in NSCLCs with gefıtinib-sensitive EGFR mutation.
#363 STAT5 inhibition induces apoptosis in peripheral T cell lymphoma.
Haley M. Simpson, Aki Furusawa, Kavitha Sadashivaiah, Arnob Banerjee. Uni-
versity of Maryland Baltimore, Baltimore, MD.
Peripheral T cell lymphoma (PTCL) is a heterogeneous malignancy with ex-
tremely poor prognosis. Five-year overall survival is40% and can be as low as
12% for specifıc subtypes. There is, therefore, an urgent need to identify and
develop novel therapeutic targets and approaches. A number of recent sequenc-
ing studies, including a whole exome sequencing analysis of primary PTCL
patients conducted by our laboratory, have revealed recurrent oncogenic driver
mutations in the common gamma chain/JAK/STAT signaling pathway, result-
ing in the aberrant activation of the transcriptional regulator STAT5. STAT5has
additionally been found to be upregulated or contain activating mutations in
30-40%of PTCL cases of specifıc subtypes. These fındings highlight STAT5 as an
oncogenic driver of PTCL and suggest a role for it in novel therapeutic ap-
proaches. Based on these data, we aimed to evaluate STAT5mechanistically as a
therapeutic target in PTCL. The drug, pimozide, which is an FDA approved
neuroleptic agent, was recently identifıed by drug screen to be a STAT5 inhibi-
tor. We assessed the effıcacy of pimozide in PTCL using resazurin dye assay,
Fluorescence Activated Cell Sorting (FACS), and immunoblot analysis. Our
data demonstrate a concentration dependent reduction in STAT5 activity and
the number of viable cells in PTCL cell lines after culture with pimozide. This is
shown to be due to an increase in cell death by apoptosis. To verify that pimoz-
ide’s effıcacy is due to its inhibition of STAT5 activity, we transduced PTCL cell
lines with anti-STAT5 shRNA to knock down STAT5 and assessed PTCL cell
survival and proliferation. We show that STAT5 knockdown results in a three-
fold reduction in PTCL cell viability, which occurs due to an increase in apopto-
sis. Furthermore, our data supports a TRAIL dependent mechanism for induc-
tion of apoptosis shown by an upregulation of TRAIL by PTCL cells after STAT5
knockdown or culture with pimozide. Mitochondrial membrane potential is
also disrupted. These fındings have potential clinical implications, as we further
demonstrate that pimozide inhibits STAT5 phosphorylation, reduces cell viabil-
ity, and induces apoptosis in primary PTCL patient samples ex vivo. This re-
search supports further exploration of STAT5 as a therapeutic target in PTCL
and the development of STAT5 inhibition in the treatment of PTCL.To facilitate
the development of non-chemotherapeutic dependent therapeutic approaches
for PTCL, we are now assessing STAT5 inhibition in combination with small
molecule inducers of apoptosis including TRAIL pathway and PARP inhibitors.
PARP inhibitors have shown effıcacy in malignancies with DNA damage re-
sponse pathway mutations, which have been identifıed in up to half of cases of
certain subtypes of PTCL. We also aim to further investigate the use of JAK
inhibitors, kinases responsible for STAT5 activation, in combination in PTCL,
as several have demonstrated clinical effıcacy in other hematologic malignan-
cies.
#364 Mass cytometry of human glioblastoma characterizes more than 99
percent of cells and reveals intratumoral cell subsets defıned by contrasting
signaling network profıles. Nalin Leelatian,1 Justine Sinnaeve,1 Bret C. Mob-
ley,2 Akshitkumar M. Mistry,2 Daniel Liu,1 Kyle D. Weaver,2 Reid C. Thomp-
son,2 Lola B. Chambless,2 Rebecca A. Ihrie,1 Jonathan M. Irish1. 1Vanderbilt
University, Nashville, TN; 2Vanderbilt University School of Medicine, Nashville,
TN.
Background: Glioblastoma (GBM) remains largely incurable despite intense
study of resected tissue. Prior studies have revealedGBMcell subsets (Patel et al.,
Science 2014) and have implicated subset emergence as a potential mechanism
of poor outcome in other cancer types. Signaling in rare cells or a mix of cell
subsets may enable therapy resistance and recurrence of GBM. For example,
STAT3 RNA expression has been previously shown to correlate with poor out-
come inGBM (Jahani-Asl et al., NatNeurosci 2016 andTCGA). The complexity
ofGBM, combinedwith the interconnectedness between cancer and host cells in
the microenvironment, means that a single cell biology approach is needed to
comprehensively characterize patient biopsy cells and determine how protein
expression, signaling, and functional capabilities impact treatment response.
Methods: We developed a novel mass cytometry approach to characterize hu-
man GBM that identifıed 90-95% of tumor cells (Leelatian & Doxie et al.,
Cytometry B 2016). Here, we applied this approach using a newly created 35-
antibody mass cytometry panel focused on basal phospho-protein signaling.
The published panel of 16 identity proteins included SOX2, CD44, Nestin,
PDGFR, S100B, and NCAM. This panel was augmented to measure 10 addi-
tional proteins and 9 phospho-proteins including p-STAT3, p-EGFR, and
p-NFB. Signalingmeasurements were chosen tomatch prior single cell studies
of signaling networks that stratifıed clinical outcomes in blood cancers (Irish et
al., Cell 2004; PNAS 2010, Levine et al., Cell 2015). Between 10,000 and 250,000
viable cells were characterized for each tumor (N 7). Tumors were collected
with informed consent and in accord with the Declaration of Helsinki. Results:
This new 35-antibodymass cytometry panel positively identifıed99% ofGBM
cells. Subsets ofGBMcells displayed protein expression thatmatched previously
observed transcriptional molecular subclasses (Verhaak et al., Cancer Cell 2010
and TCGA). Strikingly, this panel revealed novel GBM cell subsets defıned by
contrasting basal signaling profıles. An inverse correlation was observed be-
tween baseline STAT3 phosphorylation and the abundance of CD45 leuko-
cytes. Additionally, similar signaling patterns were seen in cells that expressed
proteins associated with distinct functions, such as proliferation and migration.
Conclusions: The correlation between low STAT3 signaling and high immune
cell abundance provides evidence for the idea that an intimate relationship exists
between immune cells and GBM tumor growth and survival. Moreover, single
cell analysis may reveal biomarkers of treatment response and allow prediction
of clinical outcomes. The abnormal signaling mechanisms observed here in
some GBM cell subsets should be studied further as potential targets for novel
cancer-selective combination therapies.
#365 Cross-talk between BRAF and Hippo/YAP1 signaling in melanoma.
Mohan Kumar Durai Raj,1 Jonathan Nguyen,1 Namrata Bora-singhal,1 Jane
Messina,1 Geoffrey Gibney,2 Srikumar Chellappan1. 1H. LeeMoffıtt Cancer Cen-
ter and Research Institute, Tampa, FL; 2MedStar Georgetown University Hospi-
tal, Lombardi Comprehensive Cancer Center, Washington, DC.
Hippo/YAP1 signaling pathway is a tumor suppressive pathway that controls
the organ size by modulating the cell growth, proliferation and apoptosis and is
conserved from Drosophila to mammals. In mammals, the Hippo tumor sup-
pressor pathway consists of cascade of kinases in whichMST1/2 phosphorylates
and activates LATS1/2. The latter phosphorylates the oncogenic transcriptional
coactivators YAP1 and TAZ, leading to their cytoplasmic retention by 14-3-3
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proteins and/or degradation. Inactivation of MST and LATS kinases allows
YAP1 and/ or TAZ nuclear translocation and subsequent activation of their
target genes. Deregulation of Hippo pathway can induce tumors in model or-
ganisms and occurs in wide range of human cancers includingmelanoma.Mer-
lin, a key component of this pathwaywhich inhibits YAP1, ismutated/deleted in
8% of melanoma. Majority of uveal melanomas are driven by Gq/11 mutations
that trigger YAP1 nuclear translocation, promoting tumor growth. High levels
of YAP1 in BRAFV600E mutant tumors confer resistance to RAF- and MEK-
targeted therapy in patients. Our results show that YAP1 level is elevated in
melanoma and the YAP1 inhibitor verteporfın alone or in combination with
B-RAF inhibitor PLX4720 reduces the viability, invasion and anchorage-inde-
pendent growth of B-RAF V600E mutant SK-MEL-28 and SK-MEL-5 cells. In
addition, verteporfın treatment also reduced the viability of PLX4720 resistant
1205 cells. Western blot analysis of verteporfın and PLX4720 treated SK-
MEL-28 and SK-MEL-5 cells displayed reduced levels of YAP1, B-RAF, pERK,
MEK and pMEK.We also report a novel physical interaction betweenYAP1 and
B-RAF; this could be detected using double immunofluorescence and immuno-
precipitation-western blotting techniques in both B-RAF V600E mutant and
N-Ras mutant melanoma cells. Proximity ligation assays on tissue microarray
showed that YAP1-B-RAF interaction is elevated in metastatic melanoma com-
pared to normal skin. These novel fındings highlight the crosstalk between B-
RAF andHippo/YAP1 signaling whichmight have a potential role inmelanoma
development and progression. Further, experiments are in progress to elucidate
the functional signifıcance of YAP1-B-RAF interaction in melanoma.
#366 Disruption of TCF7L1 mediated transcriptional repression pro-
motes pancreatic tumorigenesis. Kathleen M. Kershaw, Bridgette T. Ho, Mis-
sael I. Vasquez, Anna R. Lay, David W. Dawson. UCLA, Los Angeles, CA.
While phenotypic studies demonstrateWnt/-catenin signaling is critical for
the initiation and progression of pancreatic adenocarcinoma (PDA), the down-
stream transcriptional effectors tied to its effects are largely unknown. Previous
work from our group has identifıed differential patterns of LEF/TCF expression
linked to variations in Wnt activation and function in PDA, including reduced
TCF7L1 (aka TCF3) message and protein levels in pancreatic tumors with ele-
vatedWnt pathway activity. Consistent with this observation, we foundTCF7L1
protein levels rapidly diminished in PDA lines after Wnt pathway activation
mediated by either Wnt3A ligand or GSK3 inhibitor. RNAi-mediated knock-
down of TCF7L1 in PDA lines phenocopiedmost of the pro-tumorigenic effects
seen withWnt3A ligand treatment. Because TCF7L1 commonly represses tran-
scription and is rapidly downregulated in PDA upon Wnt activation, we ex-
plored its transcriptional derepression as a potentially important mechanism
through which Wnt signaling promotes pancreatic tumorigenesis. Candidate
genes linked to TCF7L1-mediated transcriptional repression in PDAwere iden-
tifıed by RNA-sequencing of MiaPaCa-2 and PANC1 lines following RNAi-
mediated knockdown of TCF7L1. A total of 196 genes upregulated at least 1.5-
fold in both cell lines were identifıed, representing potential direct targets of
TCF7L1-mediated transcriptional repression. Gene ontology analysis among
these 196 upregulated genes revealed enrichment of categories including small
GTPase-mediated signal transduction, RAS protein signal transduction, regula-
tion of axon extension, and regulation of synaptic plasticity. Among top upregu-
lated genes was prostaglandin E synthase (PTGES), an enzyme catalyzing the
isomerization of prostaglandin H2 to prostaglandin E2 (PGE2) as the fınal step
in PGE2 synthesis from arachidonic acid. Notably, PGE2 stimulates pancreatic
cancer proliferation, invasion, angiogenesis and metastasis. Validation experi-
ments in TCF7L1-expressing PDA lines confırmed PTGESmessage and protein
levels rapidly increased in response to TCF7L1 depletion and were associated
with a corresponding increase inPGE2production asmeasured byELISA. PGE2
increased Wnt reporter activity in PDA cell lines, a potentially important feed-
forward mechanism whereby Wnt signaling may be reinforced upon its activa-
tion. In conclusion, TCF7L1 represses target genes with known roles in PDA,
while reduction in TCF7L1 through Wnt pathway activation or alternative
means is apparently tied to a program of transcriptional derepression linked to
the promotion of pancreatic tumorigenesis.
#367 Trop-2 activates a dormant Na/K-ATPase/PKC/CD9/ezrin sig-
naling axis to override the basal growth program of cancer cells.Marco Tre-
rotola,1 Valeria Relli,1 Romina Tripaldi,1 Andrea Sacchetti,2 Kristina Havas,3
Pasquale Simeone,1 Emanuela Guerra,1 Annalaura Aloisi,4 Rossana La Sorda,1
Rossano Lattanzio,1 Daniele Vergara,5 Isabelle Fournier,6Michel Salzet,6Mauro
Piantelli,1 SaverioAlberti1. 1‘G.D’Annunzio‘University of Chieti-Pescara, Chieti,
Italy; 2JosephineNefkens Institute, ErasmusMC,Rotterdam,Netherlands; 3IFOM
the FIRC Institute of Molecular Oncology, Milan, Italy; 4San Raffaele Scientifıc
Institute, Milan, Italy; 5University of Salento, Lecce, Italy; 6Université de Lille 1,
Cité Scientifıque, Villeneuve D’Ascq Cedex, France.
Trop-2 is overexpressed inmost human cancers, suggesting selective pressure for
a key, conserved function. Here we show that Trop-2 stimulates cancer cell growth
through the activationof a constitutively expressed, yet otherwisedormant, growth-
controlmodule.Wediscovered that crosslinking ofmembraneTrop-2with specifıc
Abs leads toacytoplasmicCa2 raise through interactionwith theNa/K-ATPase
1 subunit andmobilization of the intracellular stores. This triggers a feed-forward
loop through Trop-2-dependent activation and membrane recruitment of PKC;,
which in turn phosphorylates theTrop-2 cytoplasmic tail at two target sites, activat-
ing the molecule to stimulate its downstream signaling targets Akt and ERK. Our
fındings indicate that the Trop-2-triggered cell growth operates through binding
and extensive crosstalk with CD9, CD81, CD82 and CD151 through PKC. De-
tailed analysis of CD9 and CD81 indicates that they bind to the HIKE region of the
Trop-2 intracellular tail.Correspondingly,we found that theHIKEregionofTrop-2
mediates its anchoring to the -actin cytoskeleton through direct interaction with
theERMprotein ezrin.Consistently, theTrop-2-dependentdynamic remodelingof
the cell cytoskeleton is discovered to occur through activation of myosin II and
binding of annexins A1/A11, -actinin and gelsolin. Systematic drug screening,
gene expression silencing and site-directed mutagenesis revealed that cytoskeleton
disassembly, HIKE deletion and CD9 inhibition revert the growth of Trop-2-ex-
pressing cancer cells to that of their Trop-2-null counterparts. On the other hand,
these inhibitors have no effects on basal cell growth. This indicates that Trop-2-
centered protein interactions and activations are an essential step for the Trop-2-
dependent cancer growth.Tight co-expressionof thekey components of theTrop-2
growth-stimulatory complex is found in a large breast cancer case series, thus indi-
cating strong clinical relevance. Hence, Trop-2 triggers a universal, but otherwise
dormant, layer of cancer growth, that overrides basal cell growth regulatory mech-
anisms and sensitizes tumors to targeted anticancer therapies.
#368 Shoc2 scaffold protein role in Ras-MAPK signaling and cell survival
in pancreatic adenocarcinoma cells. Camilla R. Borges, Pamela V. Andrade,
Mirella Baroni, Vanessa S. Silveira. Ribeirao Preto Medical School - University of
Sao Paulo, Ribeirao Preto, Brazil.
Background: The highlymalignant potential and aggressiveness of pancreatic
adenocarcinoma cells ismainly promoted by oncogenic KRAS activation, which
triggers innumerous signaling pathways and controls key processes for tumor
progression such as cell proliferation, cell survival andmetabolic reprograming.
Interestingly, recent studies suggest that the major adjustments in metabolic
reprogramming, mediated by KRAS activity, are regulated by MAP kinase ac-
tivities. As SHOC2 scaffold protein plays an important role linking RAS to
downstream signal transducers in the RAS/ERKMAP kinase signaling cascade,
this study aimed to evaluate the mechanisms underlying RAS/ERK activation
mediated by SHOC2 and the outcome in pancreatic adenocarcinoma cells pro-
liferation and survival. Experimental design: RNAseq data from Pancreatic Ad-
enocarcinoma (data generated by the TCGA Research Network: http://cancer-
genome.nih.gov/) was analyzed by using the cBioPortal (Sci. Signal. 6, pl1
(2013)). Gene expression analysis and protein expression was performed by
quantitative RT-PCR and western blot respectively in pancreatic cell lines and
normal pancreatic tissue. To address the role of SHOC2 in human pancreatic
carcinoma cell lines (AsPC-1, PANC-1 andMIAPaCa-2) shRNA lentiviral con-
structs containing shRNA for SHOC2 or empty vector were used. Puromycin
selection was performed to generate stable transformed lineages. Gene knock-
down was confırmed by qRT-PCR and western blot. Doubling time and cell
proliferation assay was performed in a 4-dayMTT assay. Colony-forming assay
(CFA)was tested in triplicate and t-test was used to analyze the data (alpha value
was set at 5%). Results: Gene expression analysis by RNA-seq revealed that
SHOC2 is highly expressed (a 10-fold log scale upregulation) in pancreatic ad-
enocarcinoma samples. SHOC2 was also upregulated in pancreatic carcinoma
cell lines in comparison to normal pancreatic tissue in both mRNA and protein
analysis. After SHOC2 gene knockdown cell lines showed proliferation rates
reduction and clearly increased their doubling time. In survival analysis both
PANC-1 andMIAPaCa-2 cell lines showed a signifıcant decrease in self-renewal
capability (p 0.003 and p 0.002 respectively) in shRNA#SHOC2 transduced
cells compared to controls (empty vector) suggesting that SHOC2 may play a
role in pancreatic carcinoma cells survival. To further address if this outcome
was ERK-mediated, we investigate ERK activation after SHOC2 knockdown.
Unexpectedly, we did not observe any modulation on ERK phosphorylation,
suggesting that SHOC2 function in pancreatic carcinoma cell survival may oc-
cur through other molecules rather than only ERK-mediated. SHOC2 knock-
down had no major effects in ERK activation and cell growth in AsPC-1 cells.
Conclusion: In pancreatic carcinoma cells we suggest that SHOC2 can play an
important role in oncogenic signaling and lead to tumor cell survival.
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#369 Therapeutic targeting of the Wnt antagonist DKK1 with a human-
ized monoclonal antibody in oncology indications. Michael H. Kagey,1
Yinyuan Wu,2 Xinjun Zhang,2 Cynthia A. Sirad,1 Shane E. Mulligan,1 Xi He,2
Christopher K. Mirabelli1. 1Leap Therapeutics, Cambridge, MA; 2Boston Chil-
dren’s Hospital, Harvard Medical School, Boston, MA.
Wnt signaling is a fundamental pathway that is dysregulated in oncology. The
Wnt antagonist DKK1 is expressed in a variety of tumor types which frequently
correlates with a poor prognosis, including overall survival. DKK1 has known
oncogenic activity by stimulating proliferation, metastasis, and angiogenesis,
and recently been implicated in contributing to an immunosuppressive tumor
microenvironment. The neutralization ofDKK1 is hypothesized to have effıcacy
from both a direct antitumor effect and through an immune stimulated re-
sponse. Here we describe the characterization of DKN-01, a humanized mono-
clonal therapeutic antibody to DKK1. DKN-01 binds DKK1 with high affınity
and selectivity, disrupts the interaction ofDKK1with the LRP6 co-receptor, and
neutralizesDKK1 activity in a cell based assay. In vivo,DKN-01 has effıcacy both
as a monotherapy and in combination with chemotherapies in a non-small cell
lung (NSCLC) cancer A549 xenograft model. Results suggest that DKN-01 has
an antiangiogenic effect and may stimulate a NK cell mediated antitumor re-
sponse. Clinically, DKN-01 is being evaluated in relapsed/refractory esophageal
cancer patients in combination with paclitaxel, and preliminary results demon-
strate promising activity. Archival patient tumor samples are currently being
analyzed genetically and by IHC forDKK1 and-catenin staining for biomarker
identifıcation. Taken together, our results suggest that DKN-01, a novel thera-
peutic, has clinical effıcacy by disruptingWnt signaling, which results in a direct
anti-tumor effect and stimulates a pro-inflammatory tumor response.
#370 T-PLL cells resemble memory-type T-cells with aberrant effector
functions implicating a leukemogenic cooperation of TCL1A and TCR sig-
naling. Alexandra Schrader,1 Kathrin Warner,2 Sebastian Oberbeck,1 Giuliano
Crispatzu,1 Petra Mayer,1 Sabine Pützer,1 Hans Diebner,3 Stephan Stilgen-
bauer,4 Georg Hopfınger,5 Jan Dürig,6 Torsten Haferlach,7 Mark Lanasa,8 Ingo
Roeder,3MichaelHallek,1 DimitriosMougiakakos,9Michael vonBergwelt-Bail-
don,1 Monika Brüggemann,10 Sebastian Newrzela,2 Hinrich Abken,1 Marco
Herling1. 1Department I of Internal Medicine, Center for Integrated Oncology
(CIO) Köln-Bonn, University of Cologne (UoC), Germany; 2Senckenberg Institute
of Pathology, Goethe-University, Frankfurt/M., Germany; 3Faculty of Medicine
Carl Gustav Carus, Technische Universität Dresden, Institute for Medical Infor-
matics and Biometry, Dresden, Germany; 4Department III of Internal Medicine,
University Hospital, Ulm, Germany; 5Department of Internal Medicine I, Bone
Marrow Transplantation Unit, Medical University of Vienna, Vienna, Austria;
6Clinic for Hematology, University Hospital Essen, Essen, Germany; 7MLL Mu-
nich Leukemia Laboratory,Munich, Germany; 8Duke UniversityMedical Center,
Durham, NC; 9Department of Medicine 5, Haematology and Oncology, Univer-
sity Hospital Erlangen, Germany; 10Medical Department II of Hematology and
Oncology, University Hospitals of Schleswig Holstein, Campus Kiel, Germany.
The pathogenesis of the rare and aggressive T-cell prolymphocytic leuke-
mia (T-PLL) is poorly understood, which particularly applies to a mechanis-
tic concept around its hallmark oncogene TCL1A. Existing data implicate
TCL1A as a catalytic enhancer of the oncogenic kinase AKT, a central node
in a T-cell’s antigen receptor (TCR) signaling cascade, which mediates pro-
liferation and differentiation. The levels and role of TCR activation in T-
PLL’s pathogenesis are not known. To fırst clarify which physiological T-cell
subset T-PLL cells most resemble, we performed comprehensive global gene
expression profıling and immunophenotyping of primary T-PLL (n79) in
comparison to healthy-donor derived T-cell populations. Principle compo-
nent analyses and gene signature alignments revealed a high similarity of
T-PLL cells to (central) memory T-lymphocytes over naïve T-cells. Surface
markers revealed a spectrum of memory-type differentiation (n69/79;
87%) with predominant central-memory stages (n35/79; 44%). The usually
TCR and/or CD28-coreceptor positive T-PLL cells revealed no restrictions
to genetic or surface TCR-clonotypes. The abnormally high basal activation
levels (surface CD25, CD38, CD69) correlated in their degree with inferior
clinical outcomes (med. survival 20.8 vs 58.3 mo.; p0.0012). In parallel,
T-PLL cells lost expression of negative-regulatory TCR-co-receptors (e.g.
CTLA-4, LAG3). Fittingly, TCR engagement of primary T-PLL cells revealed
a trend to hyperactive intracellular responses and interleukin(IL)-2 release
alongside a prominent Th1-cytokine program. T-PLL cells also showed a
robust resistance to stimulation-induced cell death and agonistic CD95 liga-
tion. TCR-derived signals (phospho-kinase induction, IL-2 release) were
enhanced in vitro by the modulated presence of TCL1A with kinetics indic-
ative of a sensitizer relationship, mainly in the CD3 axis as opposed to the
CD28 branch. A mouse model with TCL1A-initiated protracted develop-
ment of T-PLL (Lckpr-TCL1Atg) revealed congruent fındings with the aber-
rant T-cell phenotype of human T-PLL. TCL1A expressing T-cells of this
model, that were further equipped with monoclonal epitope-defıned TCRs
against ovalbumine or a chimeric-antigen-receptor (CAR) against carcino-
embryonic antigen, gained a pre-leukemic growth advantage in scenarios of
pulsed or continuous low-level receptor stimulation. Overall, we establish
that T-PLL cells resemble antigen-experienced memory T-cells. Retention of
functional effector responses to TCR stimulation and loss of restricting ac-
tivation regulators underlie a highly activated phenotype and a marked re-
sistance to death-inducing signals. TCL1A proactively enhances TCR re-
sponses and we postulate that this leukemogenic cooperation drives
accumulation of memory-type cells that utilize amplifıed, hence permissive,
low-level cognate antigen input.
#371 Developing small molecule therapeutics to target AKT signaling in
non-small cell lung cancer. Balaji Chandrasekaran,1 Deeksha Pal,1 Venkatesh
Kolluru,1 Srinivasa R. Ramisetti,2 Arun K. Sharma,2 Murali Ankem,1 Chendil
Damodaran1. 1University of Louisville, Louisville, KY; 2Pennsylvania State Uni-
versity, Hershey, PA.
Lung cancer remains a leading public health problem which is evidenced
by its increasing death rate. Platinum-based chemotherapy is the fırst-line of
treatment for patients in advanced stages of non-small cell lung cancer
(NSCLC), however the success rates are not quite impressive. Hence, devel-
oping individualized treatment strategies for metastatic lung cancer gains
momentum, such as Tyrosine kinase inhibitors erlotinib and gefıtinib, or
ALK inhibitors ceritinib and alectinib are commonly used in the clinic. Re-
cent reports suggest that pAKT(ser473) is highly expressed in NSCLC and
higher nuclear expression of pAKT correlated with poor prognosis and an
independent prognostic marker for survival. Our lab is interested to develop
novel small molecules which specifıcally inhibit AKT signaling in NSCLC.
Structure-activity relationship (SAR) studies in our laboratory have recently
ideintifed one such compound, AKS-407, that effectively inhibited cell
growth at nanomolar concentration in NSCLC cell lines (A549 and H460;
250nM). Molecular studies revealed AKS-407 inhibited AKT signaling by
down regulating pAKT(ser473) expression and downstream events includ-
ing NFB activation, BCl-2 expression in both the cell lines. As signaling
through AKT regulates epithelial-mesenchymal transition (EMT) in
NSCLC, we determined the effect of AKS-407 on EMT phenotype on NSCLC
cells. Treatment of AKS-407 inhibited the mesenchymal markers includes
snail, MMP9, N-cadherin, -catenin and vimentin expression that resulted
in blocking invasion and migration of A549 and H-460 cells. These results
suggest AKS-407 to be a promising small molecule targeting AKT signaling
pathway which remains an important target for the development of effective
treatment of metastatic NSCLC. Validating in-vivo effıcacy of this potential
drug candidate would further support our overall goal of the study.
#372 Optimizing verticalMAPKpathway inhibition forRASmutant non-
small cell lung cancer. Jens Köhler,1 Cloud P. Paweletz,2 Yanan Kuang,2 Pra-
fulla Gokhale,2Margaret K.Wilkens,2 Hong Tiv,2 AtsukoOgino,1 JihyunChoi,1
Paul T. Kirschmeier,2 Pasi A. Jänne1. 1Dana-Farber Cancer Institute, Boston,
MA; 2Belfer Center for Applied Cancer Science, Boston, MA.
Introduction: Non-small cell lung tumors (NSCLC) with mutations in genes
encoding for Ras proteins (H-, N-, K-Ras) exhibit activation of the MAPK sig-
naling pathway. Mek inhibitors, however, have limited effıcacy in patients af-
fected by this genotype-defıned tumor subtype and major resistance derives
from insuffıcient suppression or reactivation of the extracellular signal-regu-
lated kinase (Erk) as a result of dynamic kinome reprogramming. Erk inhibitors
may overcome limitations of Mek inhibition due to the bottleneck function of
Erk proteins in submitting mitogenic and anti-apoptotic signals. Combinations
of both drug classes (”vertical pathway inhibition“) may further increase treat-
ment effıcacy but inevitably potentiate toxicity hence requiring alternative dos-
ing schedules. Methods: We investigated the effıcacy of vertical MAPK inhibi-
tion with selumetinib (Mek inhibitor) and SCH772984 (Erk inhibitor) in
commercially available and patient-derived RAS mutant NSCLC models. A
quantitative RT-PCR based 12-gene signature was used as a surrogate to assess
Erk-dependent transcriptional output. Pulsatile drug regimens were investi-
gated in xenograft models. Results: In a genetically simple, patient-derived
NRAS-mutant lung cancer cell line (DFCI168), we observed strongest in vitro
suppression of Erk-dependent transcriptional output and delay of feedback re-
activation by verticalMAPKpathway inhibitionwith a selumetinib/SCH772984
combination compared to either drug alone. Deeper MAPK pathway suppres-
sion in ourmodel cell line was accompanied by higher anti-proliferative activity
in a panel of RAS mutant cell lines in vitro (n5 patient-derived, n19 com-
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mercially available cell lines) and in vivo (n2). The degree of transcriptional
output suppression of cell lines (n8) with different sensitivities towards Mek/
Erk inhibition did not differ signifıcantly at 24 hrs in vitro. Gastrointestinal
toxicities (i.e. peritonitis-like symptoms) occurred when continuously adminis-
tered SCH772984 was intermittently combined with selumetinib (4 days ON, 3
days OFF) but resolved when both drugs were given intermittently (4 days ON,
3 days OFF). None of the drug treatments, however, could cure the mice. Con-
clusion: We have demonstrated that deeper and prolonged transcriptional out-
put suppression by vertical MAPK pathway inhibition translates into superior
effıcacy in RASmutant lung cancer models compared to single agent treatment.
Other factors (e.g. signaling pathways) are likely to influence the overall out-
come of vertical MAPK pathway inhibition. Toxicities observed in PDXmodels
overlap with those reported from genetically engineered mouse models
(GEMM)with loss ofMek1/2 or Erk1/2 and can bemitigated by pulsatile dosing
schedules.
#373 Wnt signaling induces anti-apoptotic effect in colorectal cancer cells
through the suppression of IFITs.Tomoyuki Ohsugi, Kiyoshi Yamaguchi, Chi
Zhu, Tsuneo Ikenoue, Yoichi Furukawa. Division of Clinical Genome Research
The Institute of Medical Science The University of Tokyo, Tokyo, Japan.
ImpairedWnt signaling pathway plays a crucial role in the development of
colorectal cancer through the activation of -catenin/TCF complex. Al-
though genes up-regulated by Wnt/-catenin signaling has been well stud-
ied, the down-regulated genes are poorly understood. To clarify the compre-
hensive changes regulated by the signaling in colorectal cancer cells, we
explored a global gene expression of CRC cells transfected with -catenin
siRNAs or dominant negative form of TCF7L2 (dnTCF7L2). Consequently,
a set of genes that were negatively regulated by -catenin/TCF were identi-
fıed. Among the genes, three members of interferon-induced proteins with
tetratricopeptide repeats (IFIT) family (IFIT1, IFIT2, and IFIT3) expression
were signifıcantly increased by the inhibition of -catenin/TCF. Compari-
son of gene expression data from normal colonic mucosa and the tumor
tissues showed that the expression of IFIT1 and IFIT2 in the tumors was
signifıcantly lower than that in normal tissues. To elucidate the mechanism
of IFITs expression regulated by -catenin/TCF, we performed a reporter
assay using plasmid containing 1.2-kb of 5’-flanking region of the IFIT2
gene. As a result, the reporter activity was signifıcantly enhanced by either
transduction of -catenin or dnTCF7L2, suggesting that blockage of
-catenin/TCF stimulated IFITs through the promoter. In addition, we
found that overexpression of IFIT2 increased apoptosis and decreased cell
proliferation in SW480 and HCT116 cells. These results imply that Wnt
signaling may promote anti-apoptotic effect in cancer cells through the sup-
pression of IFIT2. Our fındings suggest that analysis of down-regulated
genes in response to activated Wnt/-catenin signaling provides a better
understanding of human colorectal carcinogenesis.
#374 KMT2A promotes tumor growth by activating hTERT and CBP sig-
naling and predicts poor prognosis in human melanoma. Changlin Zhang,1
Ranran Tang,2 Kefang Zhang,3 Wenlin Huang,1 Wuguo Deng1. 1Sun Yat-sen
University Cancer Center; State Key Laboratory of Oncology in South China;
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; 2Da-
lian Medical University, Dalain, China; 3Global Life Care Federation, Hong
Kong, China.
Melanoma is an aggressive type of cutaneous malignancy. Although the in-
hibitors targeting BRAF and/orMEK pathways provide a therapeutic option for
non-resectable melanoma driven by BRAF mutation, melanoma, especially
metastatic melanoma, has still become one of the most threatening malignan-
cies. Thus, identifying the exact molecular mechanisms involved in melanoma
growth and discovering the novel targets for melanoma therapy is urgently
needed. In this study, we screened a siRNA library targeting 6024 human genes
in human melanoma cells and identifıed KMT2A as a potential therapeutic
target for melanoma. KMT2A was highly expressed in melanoma cell lines and
tumor tissues of melanoma patients. Knockdown of KMT2A by siRNA or
shRNA signifıcantly inhibited cell viability and colony formation, whereas ex-
ogenous expression of KMT2A effectively promoted cell growth in variousmel-
anoma cell lines. Furthermechanism studies showed that theKMT2A-mediated
regulation of melanoma growth was through targeting the hTERT and CBP
signaling. Knockdown of KMT2A signifıcantly inhibited hTERT promoter ac-
tivity and protein expression and attenuated telomerase activity. Overexpres-
sion of hTERT rescued the KMT2A knockdown-mediated melanoma cell
growth. By contrast, exogenous expression of KMT2A activated hTERT tran-
scription and expression and increased telomerase activity in melanoma cells.
Moreover, we found that KMT2A promoted hTERT expression and melanoma
cell growth by cooperating with the transcriptional co-activator CBP, which
interacted with and acetylated KMT2A. Inhibition of CBP by siRNA or a CBP-
specifıc inhibitor suppressed the acetylation of KMT2A, abrogated the binding
of KMT2A on the hTERT promoter and down-regulated hTERT expression,
thereby inhibiting the growth of melanoma cells. Conversely, overexpression of
CBP increased KMT2A acetylation and the binding to hTERT promoter, result-
ing in the promotion of hTERT expression and cell growth. The in vivo studies
also showed that KMT2Apromotedmelanoma growth by activating the hTERT
signaling in a xenograft tumor mouse model. Furthermore, the analyses for
the clinical samples demonstrated that KMT2A expression was positively
correlated with hTERT in tumor tissues of melanoma patients, and the high
expression of both KMT2A and hTERT was associated with the worse clin-
ical TNM staging and poor prognosis in melanoma patients. Taken together,
our results indicate that KMT2A promotes melanoma growth by activating
hTERT and CBP signaling in human melanoma. Our study therefore pro-
vides new insights into understanding the regulatory mechanism of mela-
noma growth and suggests that the KMT2A/CBP/hTERT signaling may be a
potential therapeutic target for human melanoma. Funding support: This
work was supported by the funds from the National Natural Science Foun-
dation of China (81071687, 81272195), the State “973 Program” of China
(2014CB542005).
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#375 Oncologist use and perception of large panel next generation tumor
sequencing.AlisonM. Schram,Dalicia Reales, JesseGalle, RoyCambria, Robert
Durany, Darren Feldman, Eric Sherman, Jonathan Rosenberg, Gabriella
D’Andrea, Shrujal Baxi, Yelena Janjigian, William Tap, Maura Dickler, José
Baselga, Barry Taylor, Debyani Chakravarty, Jianjiong Gao, Nikolaus D.
Schultz, David B. Solit, Michael F. Berger, David M. Hyman. Memorial Sloan
Kettering Cancer Center, New York, NY.
At Memorial Sloan Kettering, we have used a clinically validated custom
hybridization capture-based NGS assay (MSK-IMPACT) to sequence the
tumors of more than 10,000 patients. We sought to determine physician
perception and use of these results, including whether they changed man-
agement and the reasoning behind this decision-making. All physicians who
ordered MSK-IMPACT testing for patients where it was not considered
routine were asked to complete a questionnaire quarterly (Table). Physician
determination of genomic “actionability” was compared to OncoKB, a cu-
rated knowledge base of somatic variants (OncoKB.org). Responses were
received from 146 of 258 physicians emailed (57%) regarding 1932 of 9147
patients (21%). Physician respondents comprised a diversity of cancer spe-
cialties including medical oncology (67%), pediatric oncology (8%), surgery
(6%), radiation oncology (5%), and neuro-oncology (5%). A total of 49 can-
cer types were represented. Physicians indicated that sequencing altered
management in 331 (20%) of profıled patients in need of a treatment change.
Among those in whom treatment was reportedly not altered, physicians
indicated the presence of at least one actionable alteration in 55% (805/1474)
of cases. However, only 45% of these cases harbored a genomic variant an-
notated as actionable by OncoKB. Among patients in whom physicians
deemed the report non-actionable, 12% had OncoKB annotated actionable
variants. Across the cases annotated as potentially actionable by OncoKB,
physicians identifıed an actionable alteration in 81% of cases. At the time of
data analysis, 297 (15%) patients had been enrolled in at least one clinical
trial of targeted therapy at MSKCC including 224 (12%) patients on genomi-
cally-matched trials, 76% of whom participated after IMPACT profıling. As
the clinical adoption of NGS panels expands, continued education of physi-
cians as well as maintained knowledge bases for annotation will be necessary
to expand the utility of this approach and the opportunity for precision
medicine.
TABLE
Questions
Responses,
N (%)
DID alter treatment, as follows:
1. Patient enrolled to a therapeutic protocol at MSKCC 265 (14)
2. Patient enrolled to a therapeutic protocol at another institution 15 (1)
3. Patient treated with off-label use of an FDA approved therapy 43 (2)
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TABLE
Questions
Responses,
N (%)
DID NOT alter treatment, as follows:
4. Actionable mutation(s) identifıed, but no therapeutic
protocol was available
175 (9)
5. Actionable mutation(s) identifıed, but patient declined
participation in, or was ineligible for, available therapeutic
protocol
115 (6)
6. Actionable mutation(s) identifıed, but patient deteriorated,
progressed, or died before results could be used
176 (9)
7. Actionable mutation(s) identifıed and therapeutic study
available, but patient has not recurred/progressed
since MSK-IMPACT result
339 (18)
8. No actionable mutation identifıed 669 (35)
Other 135 (7)
TOTAL 1932
#376 Biospecimen and data resources for cancer research from NCI’s BPV
program. Ping Guan, HelenM.Moore.National Cancer Institute, Bethesda, MD.
The Biospecimen Preanalytical Variables (BPV) Programwas initiated by the
National Cancer Institute’s Biorepositories and Biospecimen Research Branch
to evaluate the impact of preanalytical factors on the molecular integrity of
biospecimens. Selected preanalytical factors including cold ischemic time (delay
to formalin fıxation (DTF)), time in formalin (TIF), freezingmethods, and stor-
age temperatures and durations were examined for their potential effects on
molecular profıles from surgical resection tissues and matched blood from four
cancer types (kidney, ovary, colon and lung). The BPV program has collected
tumor specimens from 364 cancer patients. Each specimen was annotated with
300 data elements that cover steps in the collection, handling, and processing
procedures, pathology review, and clinical information. NCI conducted multi-
ple studies using these specimens to evaluate the preanalytical impacts on dif-
ferent analytical platforms including gene expression profıling, copy number
variation, proteomics and metabolomics profıling. The program invites inter-
ested organizations to work with NCI through collaboration to further evaluate
preanalytical effects on molecular analyses (https://techtransfer.cancer.gov/
availabletechnologies/e-000-2013). The remaining specimens are available to
support relevant research focusing on biospecimen science and/or clinical bio-
marker assay development (https://specimens.cancer.gov/search/). The IT in-
frastructure that was developed to support BPV biospecimen collection and
management has been further developed into open source products (https://
github.com/NCIP/CDR and https://github.com/NCIP/CDR-Lite). The con-
trolled vocabulary that records the terms and defınitions used in describing the
overall biospecimen collection efforts has been refıned and published at publicly
accessible CDE repositories: NCI’s caDSR (https://cdebrowser.nci.nih.gov/
CDEBrowser/ ) and NIH’s CDE portal (https://cde.nlm.nih.gov/cde/search ).
An ongoing collaboration with an academic ontology consortium will map the
CDEs to existing biobanking ontology frameworks and make them publicly
available. The BPV program has generated a wide range ofomics data.We are
preparing a BPV data compendium to be submitted to dbGaP at NCBI. These
data will be used as the experimental evidence to develop evidence-based best
practices for fıt-for-purpose collection, processing, and storage of biospecimens
for cancer research.
#377 International Cancer Genome Consortium (ICGC). Jennifer L. Jen-
nings,1 Lincoln D. Stein,1 Fabien Calvo2. 1Ontario Institute for Cancer Research,
Toronto, Ontario, Canada; 2Inst. Gustave Roussy, Villejuif, France.
The International Cancer Genome Consortium (ICGC) was established to
bring together researchers from around the globe to comprehensively analyze
the genomic, transcriptomic, and epigenomic changes in 50 different tumor
types or subtypes that are of clinical and societal importance across the globe
(International network of cancer genome projects. Nature 464, 993-998 (15
April 2010)). As of November 2016, the ICGC has received commitments from
researchers and funding organizations in Asia, Australia, Europe, North Amer-
ica and South America for 103 project teams in 17 jurisdictions to study more
than 25,000 tumor genomes. Processed data is available via the Data Coordina-
tion Centre (http://dcc.icgc.org) based at the Ontario Institute for Cancer Re-
search and is updated semi-annually. The August 2016 release (Version 22) in
total comprises data frommore than 16,000 cancer donors spanning 70 projects
and 21 tumor sites. The Pan-Cancer Analysis of Whole Genomes (PCAWG)
project of the ICGC and The Cancer Genome Atlas (TCGA) is coordinating
analysis of more than 2,600 cancer genomes, with the extensive use of cloud
computing. Because of the very large size of the pan-cancer dataset, with 5,000
whole genome sequences, PCAWG is using a distributed compute cloud envi-
ronment (generated by computing centres in the USA, Europe and Asia) that
meets the project’s technical requirements and the bioethical framework of
ICGC and its member projects. Each genome is being characterized through a
suite of standardized algorithms, including alignment to the reference genome,
uniform quality assessment, and the calling of multiple classes of somatic mu-
tations. Scientists participating in the research projects of PCAWG are address-
ing a series of fundamental questions about cancer biology and evolution based
on these data. The fırst phase of ICGC, which is slated for completion in 2018,
has focused on developing extensive catalogs of tumor genomic information.
The proposed second phase, ICGCmed, will link genomics to clinical informa-
tion and health, including lifestyle, patient history, response to therapies, and
underlying causes of disease, for a broad spectrum of cancers, including preneo-
plastic lesions, early cancers and metastases. The goal will be to accelerate the
movement of genomic information into the clinic to guide prevention, early
detection, diagnosis, and prognosis, and provide the information needed to
match a patient’s disease to the most effective combinations of therapy. The
ICGC develops policies and quality control criteria to help harmonize the work
of member projects located in different jurisdictions. Data produced by ICGC
projects aremade rapidly and freely available to qualifıed researchers around the
world via the data cloud and through the ICGC Data Coordination Center at
(http://dcc.icgc.org). More information can be found on www.icgc.org.
#378 The Cancer Genome Collaboratory. Christina K. Yung,1 George L.
Mihaiescu,1 Bob Tiernay,1 Junjun Zhang,1 Francois Gerthoffert,1 Andy Yang,1
Jared Baker,1 Guillaume Bourque,2 Paul C. Boutros,1 Bartha M. Knoppers,2 BF
Francis Ouellette,1 Cenk Sahinalp,3 Sohrab P. Shah,4 Vincent Ferretti,1 Lincoln
D. Stein1. 1Ontario Institute for Cancer Research, Toronto, Ontario, Canada;
2McGill University, Montreal, Quebec, Canada; 3Simon Fraser University, Van-
couver, British Columbia, Canada; 4BC Cancer Agency, Vancouver, British Co-
lumbia, Canada.
The Cancer Genome Collaboratory is an academic compute cloud designed
to enable computational research on the world’s largest and most comprehen-
sive cancer genome dataset, the International Cancer Genome Consortium
(ICGC). The ICGC is on target to categorize the genomes of 25,000 tumors by
2018. A subproject of ICGC, the PanCancer Analysis of Whole Genomes
(PCAWG) alone has generated over 800TBof harmonized sequence alignments,
variants and interpreted data from over 2,800 cancer patients. A dataset of this
size requiresmonths to download and signifıcant resources to store and process.
Bymaking the ICGCdata available in cloud compute form in the Collaboratory,
researchers can bring their analysis methods to the cloud, yielding benefıts from
the high availability, scalability and economy offered by cloud services, avoiding
a large investment in static compute resources and essentially eliminating the
time needed to download the data. To facilitate the computational analysis on
the ICGC data, the Collaboratory has developed software solutions that are
optimized for typical cancer genomics workloads, including well tested and
accurate genome aligners and somatic variant calling pipelines. We have devel-
oped a simple to use, but fast and secure, data transfer tool that imports genomic
data from cloud object storage into the user’s compute instances. Because a
growing number of cancer datasets have restrictions on their storage locations, it
is important to have software solutions that are interoperable across multiple
cloud environments.We have successfully demonstrated interoperability across
The Cancer Genome Atlas (TCGA) dataset hosted at University of Chicago’s
Bionimbus ProtectedData Cloud, the ICGCdataset hosted at the Collaboratory,
and ICGCdatasets stored in theAmazonWebServices (AWS) S3 storage. Lastly,
we have developed a non-intrusive user authorization system that allows the
Collaboratory to authenticate against the ICGCData Access Compliance Offıce
(DACO) when researchers require access to controlled tier data. We anticipate
that our software solutions will be implemented on additional commercial and
academic clouds. The Collaboratory is actively growing, with a target hardware
infrastructure of over 3000 CPU cores and 15 petabytes of raw storage. As of
November 2016, the Collaboratory holds information on 2,000 ICGC PCAWG
donors (500TB total). We anticipate expanding the Collaboratory to host the
entire ICGCdataset of 25,000 donors (approximately 5PB) and to extend its data
management and analysis facilities across multiple clouds. During the current
closed beta phase, the Collaboratory has been successfully utilized by multiple
research groups, most notably PCAWGproject researchers who analyzed thou-
sands of genomes at scale over a fewweeks’ time. The Collaboratory will open to
the public during the second quarter of 2017. We invite cancer researchers to
learn more about our cloud resources at cancercollaboratory.org, and apply for
access to the Collaboratory.
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#379 Genomic profıling of the tumors harboring activating epidermal
growth factor receptor mutations. Jingrui Jiang, Meaghan Russell, Cheryl Eif-
ert, Angeliki Pantazi, Ruobai Sun, Stephen Lyle, Joerg Heyer, Alexei Protopo-
pov. KEW Inc, Cambridge, MA.
Introduction: EGFR is a kinase of the HER/ERBB family and an oncogenic
driver, especially for NSCLC, HNSCC and CRC. EGFR targeted therapies have
been successfully used for treating cancer patients harboring activating EGFR
mutations. However a main challenge is acquired drug resistance due to muta-
tions or alternative signaling.While developing next generation drugs is a prom-
ising strategy, targeting other alternatives is also an attractive therapeutic option.
The purpose of our study is to investigate themutational landscape of the tumors
harbored activating EGFR mutations and to pinpoint potential strategies for
overcoming acquired drug resistance and for combinational therapies.
Methods: CancerPlex, a NGS large panel test, which includes targeted, full-gene
sequencing of over 400 genes, was applied to analyze a cohort of 2294 patient
FFPE samples across majority of solid tumor types. Results: 1, Among 293 (out
of 2294, 12.8%) samples harbored EGFRmutations, 86 (86/293, 29.4%) samples
harbored actionable EGFR mutations (namely AE group), such as exon 19 de-
letion and L858R, which includes 84 lung cancer (79 NSCLC), 1 glioblastoma,
and 1 urothelial carcinoma. 2, The genes/variants in the AE group are then
subjected to further functional analysis and mapped to several pathways/ bio-
logical functions. Our results show that the mutational landscape of activating
mutant EGFRs covers most main signaling pathways and biological processes
with several features: a), Receptors at different classes, including PKHD1, ROS1,
and ERBB2, and genes involving in genome and epigenome stabilities, including
ARID1A,, KMT2D, and XPC, have the highest mutation rate in the context of
activating EGFR mutations. b), PI3K/AKT/mTOR and Ras-Raf-MEK are two
main pathways transducing ligand activated EGFR signals. Our results show
that themutant variants in the PI3K-AKT-mTORpathway are almost 50%more
than those in Ras-Raf-MEK pathway, suggesting that activating mutant EGFRs
might preferentially rely on effectors in the PI3K pathway, such as PIK3CA and
RICTOR, to transduce oncogenic signals. Of note, no KRAS mutation is found
in theAE group. c), As expected,mutations are also found in theTP53/apoptosis
and Rb/cell cycle pathways with higher variant number in the TP53/apoptosis
axis. d) Strikingly, the number ofmutant variants in theWnt/beta-catenin path-
way tops that in the PI3K and TP53 pathways. Several recent publications dem-
onstrated that theWnt/beta-catenin pathway is abnormally activated inNSCLC
andmay be amainmechanism of the drug resistance. Our fınding that the genes
in the Wnt/beta-catenin pathway, including APC, AXIN2, RNF43, and BCL9,
are mutated to a great extent in the context of activating EGFR mutations sup-
ports the notion that targeting the Wnt/beta-catenin pathway, in combination
with EGFR targeted therapies, is a promising therapeutic strategy for the treat-
ment and overcoming drug resistance of EGFR-driven tumors.
#380 Systematic identifıcation of novel functional tumor-specifıc muta-
tions in receptor tyrosine kinases based on their pan-cancer mutational pro-
fıles in Japanese patients with cancer. Masakuni Serizawa,1 Takeshi Na-
gashima,2 Yuji Shimoda,2 Shumpei Ohnami,3 Sumiko Ohnami,3 Keiichi
Ohshima,4 Tohru Mochizuki,4 Takashi Nakajima,5 Kenichi Urakami,3 Masa-
toshi Kusuhara,6 Ken Yamaguchi7. 1Drug Discovery and Development Division,
Shizuoka Cancer Center Research Institute, Shizuoka, Japan; 2SRL, Inc., Tokyo,
Japan; 3Cancer Diagnostics Division, Shizuoka Cancer Center Research Institute,
Shizuoka, Japan; 4Medical Genetics Division, Shizuoka Cancer Center Research
Institute, Shizuoka, Japan; 5Division of Pathology, Shizuoka Cancer Center, Shi-
zuoka, Japan; 6Region Resources Division, Shizuoka Cancer Center Research In-
stitute, Shizuoka, Japan; 7Shizuoka Cancer Center, Shizuoka, Japan.
Background: Recent accumulation of large amounts of cancer genome infor-
mation has revealed the presence of tumor-specifıc mutations with unknown
functions; characterization of thesemutations should facilitate the identifıcation
of novel therapeutic targets. Some tumor-specifıcmutations in receptor tyrosine
kinases (RTKs) act as oncogenic drivers inmultiple cancer types.Here,we aimed
to identify novel, functional, tumor-specifıc, single nucleotide variants (SNVs)
in cancer-related RTKs based on pan-cancer mutational profıles in Japanese
patients with cancer. Methods: Surgically resected tissue and corresponding
peripheral blood samples of 1,685 patients enrolled in Project HOPE (High-tech
Omics-based Patient Evaluation), an ongoing prospective molecular profıling
study at the Shizuoka Cancer Center, collected between January 2014 and De-
cember 2015, were subjected to whole-exome sequencing with an ion torrent
proton platform. Newly detected tumor-specifıc SNVs that could represent
functional mutations between the transmembrane and kinase domains of 35
cancer-related RTKs were subjected to serum response element (SRE)-reporter
assay to assess effects on extracellular signal-regulated kinase (ERK) signaling
relevant to cancer cell survival. Results: We identifıed 201,422 nonsynonymous
tumor-specifıc SNVs in 1,685 patients. Of these SNVs, 1,049 were observed in
our focused 35 cancer-related RTKs. Approximately 45% of patients with lung
squamous cell carcinoma, which was themost frequent cancer type, followed by
lung adenocarcinoma (39%), harbored tumor-specifıc SNVs in RTKs. The rel-
ative frequencies of tumor-specifıc SNVs in RTKs in other tumor types were
32%, 31%, 29%, 28%, and 19% in liver cancer, colorectal cancer, gastric cancer,
head andneck cancer, and breast cancer, respectively. After fıltering out of SNVs
registered in multiple cancer-related databases, such as COSMIC, dbSNP, and
DoCM, to select putative novel tumor-specifıc SNVs, 22 SNVs were selected as
novel tumor-specifıc SNVs with high potential as functional mutations through
an additional selection process based on amino acid substitution patterns and
multiple alignment of amino acid residues coupled with information regarding
functionalmutations. Among these SNVs, 13 had already been assessed using an
SRE reporter assay. We identifıed two SNVs in NTRK1 and IGF1R that were
involved in activation of the ERK pathway, indicating that these SNVs may be
activating mutations. Moreover, inactivating mutations were also identifıed.
Nine SNVs in FLT3, NTRK1, EPHA5, ERBB4, FGFR3, and KDR signifıcantly
reduced ERK activity. Conclusions: A systematic evaluation of functionally un-
known tumor-specifıc SNVs detected in cancer genome sequencing is necessary
to expand the range of molecularly targeted cancer therapeutics.
#381 Genomic alterations in mucins in cancer. Ryan J. King, Fang Yu,
Pankaj K. Singh. University of Nebraska Medical Center, Omaha, NE.
Mucins promote the growth, aggressiveness, and invasiveness of various can-
cer types. Changes in the expression or localization of mucins can signifıcantly
alter patient survival. Due to their predominance in multiple cancers, biomark-
ers and therapeutic agents have been developed to improve patient care. How-
ever, an extensive investigation across multiple cancer subtypes examining the
genomic status of the cohort of mucins has not been performed and could yield
signifıcant leads into new roles of mucins in different cancers. Utilizing The
Cancer Genome Atlas, the cancers of 11 mucin expressing tissues were exam-
ined for the genomic alterations in mutations, mRNA expression levels, copy
numbers, methylation status, and the impact on patient survival due to these
genomic features. It was discovered that different mucins across multiple tissue
origins and cancer subtypes might have a different rate, pattern, and survival
impact. MUC1 was not mutated in the majority of cancers; however, we did
observe a frequent T112Pmutation in pancreatic tumors that was also present in
other cancers. MUC4 was frequently mutated at H4205 and MUC4 mutations
were seen to have survival differences. Multiple signifıcant differences were dis-
covered in mRNA expression, which varied distinctly between cohorts. One
such pattern was observed with de novo expression of MUC21 in colorectal
cancers, in which mRNA expression was suddenly induced in cancer and in-
creased in a stage dependent manner. Copy number alterations were seen for
only a few cancer subtypes and mucins, includingMUC4 in lung squamous cell
carcinomas. Global promoter demethylation was generally observed across the
cancers. MUC15 in renal cancers was seen to be one of the most demethylated
mucins, in which mRNA was seen to be substantially decreased or expunged.
This extensive study investigated the status of multiple mucins in multiple can-
cer settings and highlights a few noticeable mucins that are suggested to be
further studied for roles in biomarkers, survival, and etiology for cancer progres-
sion.
#382 Genome-wide location analysis of DNA adducts in vivo. BrianWoo,
Christopher Fang, Paolo Abada, Stephen B. Howell, Olivier Harismendy. UC
San Diego, La Jolla, CA.
DNA adducts are the biochemical consequences of exposure to UV light,
carcinogens or DNA-reactive drugs. They play a central role inmalignant trans-
formation and the selective killing of cancer cells by chemotherapeutic agents.
The functional consequences of DNA adducts is likely to depend on their exact
location in the genome with respect to histones and sites where histones and
DNAaremodifıed.However, tools that permit precise genome-widemapping of
adduct locations have poor resolution or are too specifıc to the type of DNA-
adduct. Here we present the development of amolecular assay (Ad-Seq) capable
of identifying the genomic location of damagedDNAbases in whole cells. Using
naked DNA treated with cisplatin (cDDP) or ultra-violet (UV) light as the dam-
aging agents, the strategy relies on differential exonuclease digestion to enrich
genome-wide libraries for fragments containing DNA adducts, followed by
high-throughput sequencing. Consistent with the expected adduct chemistry,
the 5’ end of the reads were enriched in TT, TC or CT di-nucleotides in the UV
treated DNA (4x) and in AG or GG in the cDDP treated DNA (1.5x), suggest-
ing a positive predictive value of 76% and 44% and UV (TT) and cDDP (GG)
adduct detection, respectively. Applied in vivo to IMR90 cells, Ad-Seq revealed
that the fraction of AG/GG loci was higher in DNA from the cDDP-treated cells
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at all coverage depths, reaching 1.5x enrichment for the highest depth quartile.
This indicates that the method is selective and that even low covered loci show
enrichment of AG/GG sequences. The enrichment in purines was limited to 3
nucleotides downstream of the read start site, confırming the high resolution of
the exonuclease digestion. A total of 11 x 103 AG/GG loci were identifıed in
replicate in cDDP-treated samples and were absent from untreated controls.
With about 60 x103 expected adducts per genome, the current assay therefore
captured up to 18% of cDDP adducts. The most covered adduct sites were sig-
nifıcantly enriched in the quiescent chromatin domains (depleted of histone
modifıcations, p6.7x10-31), and depleted in the transcription start sites
(p4.9x10-12), as defıned by the ENCODE consortium. This may be reflective
of the differences in DNA accessibility or the mechanisms of repair in these
distinct regions of the genome. The analysis was performed using the PipeDuct
computational package, which was developed to align the sequencing reads and
provide general statistics and quality control information of Ad-Seq data. Ad-
Seq is therefore a novel, unbiased method to map DNA-adducts and study in
vivo the genome-wide specifıcity of their formation and repair.
#383 Surveyof spliceosomegenemutations andassociated splicingdefects
across 33 cancer types.Michael Seiler, ShouyongPeng,AnantAgrawal, Jennifer
Tsai, James Palacino, Silvia Buonamici, Lihua Yu. H3 Biomedicine, Inc, Cam-
bridge, MA.
Hotspot mutations in the core spliceosome genes SF3B1, U2AF1, SRSF2 have
been reported at high frequency in hematological malignancies and with lower
occurrence in solid tumors. The TCGA Exome-seq and RNAseq data from 33
tumor types, the majority solid tumors, provides a unique opportunity to defıne
the landscape of spliceosome mutations and associated splicing alterations in
human malignancies. To this end, we compiled a list of 404 genes known to be
involved in splicing. We performed 2 different mutational analyses; for the fırst
analysis each tumor type was evaluated independently usingMutSig2CV and 68
signifıcantly mutated genes (q  0.1) were identifıed. The second analysis was
performed by systematically looking for genes across all tumor types with loss of
function (LoF) or hotspot in-framemutations, which identifıed an additional 12
genes. Among the 80 genes, EEF1A1, HNRNPCL1, PCBP1, PHF5A and ZC3H4
carry hotspot mutations in addition to the previously reported spliceosome
genes SF1, SF3B1, SRSF2 and U2AF1. Interestingly, we observed that known
leukemia mutation/deletion near P95 in SRSF2 were also present in uveal mel-
anoma. Furthermore, the 2 hotspot mutations in U2AF1 identifıed in leukemia
and lung adenocarcinoma (LUAD) were detected in an additional 9 tumor
types. We identifıed new SF3B1 hotspot mutations p.L833F, p.E862K,
p.E902K/G, and p.R957Q located in the heat domains (HD) 9-12 in AML, blad-
der (BLCA), and endometrial cancers. Unexpectedly, alternative exon usagewas
the most common splicing event observed in p.E902K mutant BLCA samples.
This observation differs from the reported alternative 3’ splice site usage induced
by SF3B1 hotspot mutations located in the HDs 4-8. The majority of mutated
spliceosome genes (52/80) contained LoF mutations across multiple tumor
types. In particular, RBM10 showed the highest mutation frequency in LUAD
(6.5%) and BLCA (3.8%), and FUBP1 in low grade glioma (8.0%). Differential
splicing analysis comparing RBM10 LoFmutant and wild type LUAD identifıed
exon inclusion and intron skipping asmajor splicing alterations, consistent with
data showing RBM10 knock-down induces alternative exon usage within spe-
cifıc genes. Additionally, we identifıed cassette exon usage as the major splicing
alteration in FUBP1 mutant versus wild type glioma samples. FUBP1 has been
reported to bind and repress inclusion of AT rich exons, and confırming this
fındingwe observed higher AT content in exons included in FUBP1 LoFmutant
samples when compared to unaffected following exons. These fındings suggest
that LoF mutations in spliceosome genes impact splicing regulation and may
play a critical role in cancer. In conclusion, the landscape of hotspot and LoF
mutations in multiple spliceosome genes and associated splicing alterations
highlight the increasing importance of the splicing machinery in tumorigenesis
in solid tumors beyond hematological malignancies.
#384 The implications of splicing variant of AIMP2 lacking exon 2 among
various cancer types: An analysis of the ICGC/TCGAdatabase and clinical vali-
dation. Dong Chan Kim,1 Ryul Kim,2 Daeyoon Kim,1 Hyojin Song,1 Dong-Yeop
Shin,2 Inho Kim,2 Kwang-Sung Ahn,3 NamHoon Kwon,4 Sunghoon Kim,4 Sung-
Soo Yoon,2 Youngil Koh2. 1Cancer Research Institute, Seoul National University
College of Medicine, Seoul, Republic of Korea; 2Internal Medicine, Seoul National
University Hospital, Seoul, Republic of Korea; 3Functional Genome Institute, PDXen
Biosystem Inc., Seoul, Republic ofKorea; 4MedicinalBioconvergenceResearchCenter,
Seoul National University, Suwon, Republic of Korea.
Aminoacyl-tRNA synthetase interacting multifunctional proteins (AIMP) is the
multiple tRNAsynthetase complex protein called themulti-tRNAcomplex (MRC).
In cancer, the splicing variant of AIMP2 derives a several signaling cascades, which
are crucial for cancer proliferation. Detecting an exon-2 depleted splicing variant
(AIMP2-DX2) is an issue of growing importance in cancer therapy. This study
suggests the evidence for interrelation between the AIMP2-DX2 and cancer devel-
opment.We analyzed AIMP2 and AIMP2-DX2 gene expression and their ratio on
7 commercial cancer cell lines and Multiple myeloma patient derived 536MM cell
line by RT-PCR and targeted RNA sequencing. Extended this profıle, the distribu-
tion of AIMP2-DX2/AIMP2 ratio andAIMP2-relatedmajor cancer pathways were
analyzed using the samples in the ICGC/TCGAdatabase.Over 23 cancer types, 753
samples were used inWTS analysis. In the DEG set analysis, 10 pre-defıned major
cancer pathways were analyzed among 16 cancer types. Some cancer types, espe-
cially acute myeloid leukemia (AML) showed most signifıcant association with
AIMP2-DX2 in terms of cancer signaling pathways. We focused on clinical impli-
cations of AIMP2-DX2/AIMP2 ratio in the ICGC/TCGA database. 19 AML sam-
ples were used, Overall survival (OS) showed that patients with AIMP2-DX2/
AIMP2 ratio higher than Q1 shows poor OS and Most of the genes including
MEK1/2,ERK,MNK1/2 in thispathwayhadpositiveassociationwithAIMP2-DX2/
AIMP2 ratio. In colon carcinoma and hepatocellular carcinoma, OS curves had a
tendency in a similarway toAML. For the clinical validation of the prognostic value
of AIMP2-DX2, 51 AML patients were included in this analysis. The correlation
betweenAIMP2-DX2 expression and survival outcomeswas investigated in clinical
validation cohort of AML. The AIMP2-DX2-positive group had signifıcantly infe-
rior OS rate and had worse RFS compare to AIMP2-DX2-negative group. Our se-
quential data shows that the AIMP2-DX2/AIMP2 expression and their ratio can
possibly be an indicator to measure malignancy of various cancer types.
#385 Network-driven discovery of cancer drivers and pathways using
2,500 whole cancer genomes. Jüri Reimand. Ontario Institute for Cancer Re-
search, Toronto, Ontario, Canada.
Cancer driver genes exhibit unexpectedly high mutation rates in large cancer
genomic datasets.Wehypothesize that drivermutations specifıcally altermolecular
interaction networks by disrupting “active sites” - interaction interfaces in proteins
and DNA. We present ActiveDriverWGS, a novel computational method to dis-
cover cancer drivers in whole-genome sequencing (WGS) data. ActiveDriverWGS
fınds genome regions that are signifıcantly enriched in somatic single nucleotide
variants (SNVs) and indels and ascertains whether these associate to known active
sites. Analysis of active sites allows us to predict the mechanisms of mutation on
three layers of the central dogma: regulatory DNA with transcription factor (TF)
binding sites (TFBS), mRNAwithmicroRNA binding sites in untranslated regions
(UTRs), and post-translational modifıcation (PTM) sites in proteins. To discover
cancer driver genes and pathways, we analysed theWGSdataset of2,500 samples
from the International Cancer Genome Consortium (ICGC) Pan-Cancer Analysis
Working Group (PCAWG). We found 61 protein-coding candidates with 34
known drivers (P10-40), validating the high accuracy of our method. 40 genes
have signifıcantmutations of PTMsites, suggesting that rewiring of PTMsignalling
networks is a commononcogenicmechanism. For example, the BRAFV600E SNV
flanks two phosphorylation sites and one ubiquitination site (FDR P10-44), a
novel interpretation and potential avenue for precision therapies targeting the ki-
nase and ubiquitin network of BRAF. In the non-coding genome, we detected
known lncRNAs (NEAT1,MALAT1), promoters (TERT,WDR74) and novel can-
didates with mutation enrichment. For example, an enhancer on chr6 has a muta-
tion hotspot in 33 patients (FDR P10-19), with 20 SNVs affecting bindingmotifs
of cancer-associated TFs FOXO3, SOX2, HMGA2 (FDR P10-10). Thus our
method discovers non-coding drivers and their candidate mechanisms in a single
analysis. Our ActiveDriverPWmethod extends coding and non-coding mutations
to biological pathways. We found 600 mutation-enriched pathways in the
PCAWG pan-cancer dataset. Of these 200 are also signifıcant when only non-
codingmutations are analysed, showing that the non-coding genome includes pre-
viously unstudiedmutations in pathways. The DNA double-strand break response
pathway (FDR p10-10) includes non-coding SNVs in20 histones and chroma-
tin modifıers, such as the demethylase KDM4B with 46 SNVs in its promoter and
enhancers. ActiveDriverPW maps mutations of the long tail that affect genes in
hallmark cancer processes yet remain undiscovered in gene-focused analyses. Our
methods accurately capture known drivers in the ICGC-PCAWG dataset and sug-
gest specifıcmechanistic details.Our benchmarks also emphasize the robust perfor-
mance of our methods. ActiveDriverWGS and ActiveDriverPW are valuable addi-
tions to the toolbox for cancer genome analysis.
#386 OnkoInsight: an end-to-end cancer informatics pipeline to generate
insights from large sequencing datasets. Li Tai Fang, MarghoobMohiyuddin,
Yao Fu, Lijing Yao, Narges Bani Asadi, Hugo Y. Lam. Roche Sequencing Solu-
tions, Belmont, CA.
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OnkoInsight is a pipeline designed to detect cancer driver genes from large
sequencing datasets. It includes the somatic mutation detection module Somat-
icSeq, and the novel driver gene detection module GSMuta. SomaticSeq lever-
ages an ensemble approach and machine learning to accurately detect somatic
mutations. In Stage 5 of the ICGC-TCGA DREAM Somatic Mutation Chal-
lenge, SomaticSeq v1 placed #1 and #2 in the INDEL and SNV sub-challenges. In
the current project, we used the improved SomaticSeq v2.2.2, which now ex-
tractsmost features directly from the BAM fıles instead of SAMtools, and has the
added function of handling multiple variant calls at the same position. We in-
corporated MuTect, Indelocator, VarScan2, SomaticSniper, VarDict, MuSE,
and LoFreq. GSMuta detects regions, genes, and pathways that are enriched for
somatic mutations. It identifıes cancer drivers and distinguishes between onco-
genes and tumor-suppressing genes. As a demonstration of the capability and
scalability of OnkoInsight, we deployed the tools as docker images, developed
the pipeline using common workflow language, and analyzed over 1,000 TCGA
lung cancer patients with tumor-normal whole exome sequencing data on Can-
cer Genomics Cloud. The project involved 569 adenocarcinoma (LUAD) and
490 squamous cell carcinoma (LUSC) samples. On average, SomaticSeq de-
tected over 700 somatic mutations per sample. The predicted mutation rate was
consistent with the expected mutation rates of LUAD and LUSC. Once we ob-
tained the high-confıdence somatic mutations from SomaticSeq, we used
GSMuta to detect driver genes in LUAD and LUSC separately. We detected 97
and 50 driver genes for LUAD and LUSC, respectively. To assess the quality of
GSMuta’s driver gene prediction, we compared the results with known lung
cancer driver genes. Indeed, GSMuta reproduced 16 out of the 18 LUAD driver
genes reported by TCGA’s landmark study such as EGFR, KRAS, and BRAF. It
reported 9 out of 10 LUSCdriver genes reported byTCGA such as PTEN. LUAD
and LUSC shared nine predicted driver genes, and the pathway disruption was
homogenous across the two subtypes. It also detected some potential new driver
genes. The project was completed in less than a week for over 1,000 pairs of
exomes on the cloud at a cost of less than ten dollars per pair. This demonstrated
that our OnkoInsight pipeline is highly scalable and can be deployed to reliably
analyze population-sized cancer data sets in a reasonable time frame. (L.T.F.,
M.M., and Y.F. had equal contribution).
#387 Targeted exome sequences of cancer-related genes in human cancers
using amplicon sequencing. Yasushi Sasaki, Takafumi Nakagaki, Miyuki Ta-
mura, Hisayo Fukushima, Hiroshi Ikeda, Ryota Koyama, Masashi Idogawa,
Takashi Tokino. Sapporo Medical University, Sapporo, Japan.
Objectives:Next-generation sequencing technologies have revolutionized cancer
genomics research byproviding a comprehensivemethodof detecting somatic can-
cer genome alterations. Platforms for genomic DNA alterations aremore common
in clinical practice and include whole genome/exome sequencing analysis. These
tests are still very expensive, although the costs are comingdownsubstantially.Here,
we aimed to determine the effıcacy and advantages of targeted exome sequencing of
known cancer-related genes in human cancers using amplicon sequencing.
Methods: DNA was extracted from 61 human cancer specimens and their corre-
spondingnon-cancerous tissues, includingoral squamouscell carcinomas (OSCCs)
andmultiple myelomas (MMs). Forty nanograms of DNAwere used for multiplex
PCR amplifıcation with an Ion Ampliseq Comprehensive Cancer Panel that offers
targeted coverage of all exons in 409 tumor suppressor genes and oncogenes fre-
quently citedand frequentlymutated inhumancancers.Thisplatformwasdesigned
to be amplifıcation based capture with 15,992 regions (1.6 megabases in total size).
Purifıed DNA libraries were sequenced with 6-8 samples on Ion Proton P1 chip.
Sequence reads of tumor andnormal sampleswere aligned to thehg19genome, and
generated BAM fıles were used to detect somaticmutations (pointmutation, inser-
tion and deletion) and copy number variations. Results: Each sample underwent on
mean 8.4 million sequencing reads after quality fıltering. The mean base coverage
depthwas530, and95%of targetedbaseswere representedbyat least20reads.The
number of non-synonymous somatic mutations in 47 patients with OSCC ranged
from 1 to 21 with a mean of 7.5 (6.4/Mb). The most frequent mutations in OSCC
were in TP53 (63.8%), NOTCH1 (25.5%), CDKN2A (19.2%), TAF1L (17.0%),
SYNE1 (14.9%) and PIK3CA (8.5%). We also detected a mean of 6.1 (range 3-11)
non-synonymous mutations per MM patient. Somatic mutations were found in
knownMM-associated genes, including TP53 andNRAS. Pathway assessment has
shown that somatic aberrationswithinMMgenomes aremainly involved in several
important pathways, including cell cycle regulation,RTK-MAPK-PI3KandNF-kB.
We found several genetic alterations that may have been associated with the poor
prognosis and poor response to chemotherapy of MM patients. Conclusions: This
study demonstrates the utility of using a semiconductor-based sequencing to effı-
ciently identify somatic genetic alterations in human cancers. The targeted next-
generation sequencing using low amounts of FFPEDNA is a valuable tool for rapid
(5 days) and high-throughput genetic testing in research and clinical settings.
#388 A benchmark study for identifying cancer drivers in the non-coding
part of the genome. Damien Drubay,1 Daniel Gautheret,2 Stefan Michiels1.
1INSERM, Gustave Roussy, Villejuif, France; 2Université Paris-Sud, CNRS, CEA,
Gif-sur-Yvette, France.
Purpose: Prioritizing potential deleterious variants is an essential task to guide
research and validation of new pathological variants in the immensity of the ge-
nome.Many tools have been introduced to detect new variants in the coding part of
the genome.Detailedknowledgeof coding sequences led to effıcient statisticalmod-
els forcancerdriverdiscovery.Thechallenge isgreater for thenon-codingpartof the
genome due to its large size (98% of the genome) which contains many non-
functional or unknown features. Several deleteriousness scores have been proposed
in the last decade, but no large-scale comparison has been realized to date to assess
their ability to identify cancer drivers.Material andmethod:Wecompared the lead-
ing scoring systems (CADD, FATHMM-MKL, Funseq2 and GWAVA) and some
recent competitors (DANN, SNP and SOM scores) for their ability to discriminate
assumed pathologic variants in the non-coding genome (as identifıed by 928 Clin-
Var variants / 44,158 recurrentCOSMICmutations) fromassumednon-pathologic
variants (100,000 randomly sampled 1000 Genomes project variants with minor
allele frequency 1%). To defıne the pathogenic variants using COSMIC as refer-
ence, we varied the threshold for number of COSMIC recurrences from2 to 10.We
compared the sensibility, specifıcity and precision of the scoring systems using the
area under the curve (AUC) of receiver operating characteristic (ROC) and preci-
sion-recall (PR) curves. Results: Most scores had good sensibility and specifıcity for
the detection of the ClinVar variants (AUCROC0.90). As far as precision for
ClinVar variants was concerned, the top performing methods were CADD
(AUCPR0.84), DANN (AUCPR0.83) and, to a lesser extent, FATHMM-MKL
(AUCPR0.75). When using a threshold of 3 recurrences to defıne true pathoge-
nicity of COSMIC variants, the AUCROC ranged from 0.52 (DANN) to 0.80
(GWAVA) but precision was low with AUCPR ranging from 0.05 (DANN, SOM-
melanoma) to 0.18 (GWAVA). Increasing the pathogenicity threshold to 10 recur-
rences increased AUCROC values (ranging from 0.50 (SOMmelanoma) to 0.89
(GWAVA)) but decreased precision values (AUCPR ranging from 0 to 0.02). Dis-
cussion: This large scale benchmark study distinguished CADD as the best tool to
detect variantswith features similar to those ofClinVar,which aremainly located in
protein coding regions. However, based on the results using COSMIC, GWAVA
outperformed CADD for variants in other regions, including lincRNAs, pseudo-
genes and other parts of the genome “dark matter”, for which there is increased
interest. This should nevertheless be balanced by the potential presence of non-
pathologic variants in the COSMIC database due to sequencing errors and limita-
tion of the recurrence criteria to defıne pathologic status in the instable fragile ge-
nomeregions.Thedevelopmentof agold standardas consistent asClinVar for these
regions will be necessary to confırm our tool ranking.
#389 Integrating diverse transcriptomic alterations to identify cancer-rel-
evant genes. Natalie R. Davidson,1 PanCancer Analysis of Whole Genomes 3
(PCAWG-3) for ICGC, Alvis Brazma,2 Angela N. Brooks,3 Claudia Calabrese,2
Nuno A. Fonseca,2 Jonathan Goke,4 Yao He,5 Xueda Hu,5 Andre Kahles,1
Kjong-Van Lehmann,1 Fenglin Liu,5 Gunnar Rätsch,1 Siliang Li,6 Roland F.
Schwarz,7 Mingyu Yang,5 Zemin Zhang,5 Fan Zhang,5 Liangtao Zheng5. 1ETH
Zurich, Zurich, Switzerland; 2European Molecular Biology Laboratory - Euro-
pean Bioinformatics Institute, Hinxton, United Kingdom; 3University of Califor-
nia, Santa Cruz, Santa Cruz, CA; 4Genome Institute of Singapore, Singapore,
Singapore; 5Peking-Tsinghua Center for Life Sciences, Beijing, China; 6BGI-Shen-
zhen, Shenzhen, China; 7Berlin Institute for Medical Systems Biology,, Berlin,
Germany.
Introduction: We present a novel method to identify cancer driver genes that
jointly examines any number of diverse transcriptomic alterations with the goal to
uncover highly recurrent and heterogeneous patterns in 1190 samples across 26
cancer types as part of thePanCancerAnalysis ofWholeGenomes (PCAWG)of the
InternationalCancerGenomeConsortium (ICGC).Motivation: Previous pan-can-
cer genomic studies have focused on the analysis of somaticmutations as the driver
of phenotypic changes. Here, we propose a method to integrate a wide variety of
RNAandDNAchanges to redefıne the concept of driver events and account for the
transcriptome’s role in tumorigenesis. PTK2provides amotivating example, since it
has many RNA alterations that correlate with patient survival, such as overexpres-
sion, exon-skips, and alternative promoter usage. In our analysis, we integrate an
unprecedented amount of various alterations including gene fusions, RNA editing,
alternative splicing, expressionoutliers, alternative promoters, allele specifıc expres-
sion, and somatic mutations. This enables us to also identify mutually exclusive
(MutE) and co-occurring (CoO) patterns between different types of alterations
within a gene.Methods: Ourmethod has 3main strengths: flexibility to handle any
numberor typeof alteration, sensitivity todifferent frequencies of alterations so rare
events arenot lost in the recurrenceanalysis, anddiversityof ranking such thatgenes
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withmultiple alterations are prioritized.Ourmethod is summarized in two steps: 1)
Identify genes that are both recurrently and heterogeneously altered across many
samples by calculating a rank-based score for each gene. 2) IdentifyMutE andCoO
patterns between alteration types for the genes identifıed in the previous step. To
ensure that alterations were comparable, we applied a thresholding model to bina-
rize all alterations for gene-sample pairs, allowing us to account for the properties of
the different modalities involved. Step 1 of our method calculates a score for each
gene that takes intoaccount: 1) thenumberofalterations toageneacrossall samples,
2) the rarityof eachalteration, and3)howmany typesof alterations areobservedper
gene.The score is thenused to rank thegenes and topgenes are considered forMutE
and CoO analyses. Results: Our top 100 ranked genes were highly enriched for
cancer census genes (adjusted p-value: 2.06e-9), indicating that we identify cancer
relevant genes. Our top fıve ranked cancer census genes were IGF2, ERBB2, RARA,
CREBBP, andARID1A; all of which had at least 4 of 7 possible alterations, showing
our scoring method prioritizes genes with diverse alterations. We also found that
alternative promoter usage and alternative splicing were highly co-occurring alter-
ations,withPTK2having thehighest co-occurrencebetween them. In summary,we
propose a new method to analyze various RNA disruptions and show it can yield
new insights beyond genomic variation.
#390 Identifıcation and characterization of survival-associated genomic
features across tumor types. Joan Smith,1 Ann Lin,2 Chris Giuliano,2 Jason M.
Sheltzer2. 1Google, New York, NY; 2Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY.
The basic biology that differentiates a primary cell from a transformed cell has
been elucidated over the past several decades. Mutations in a limited number of
oncogenes and tumor suppressors free the cell from growth-inhibitory checkpoints
and allow proliferation in the absence of external stimuli, leading to tumor forma-
tion. Yet, primary tumors themselves are rarely deadly: greater than 90% of cancer
mortality results frommetastasis. What drives metastasis, and, more broadly, what
distinguishes a lethal cancer from one with a favorable prognosis, is poorly under-
stood. To address this question, we have performed a comprehensivemeta-analysis
ongenomicdata fromprimary tumors that are linked topatients’ clinical outcomes.
Utiliizing data from 20,000 patients, we have identifıed protein-coding genes,
lncRNAs,miRNAs,methylation sites, andCNVs in primary tumors that are signif-
icantly associated with patient prognosis across cancer types. Multivariate analysis
reveals a hierarchy of survival determinants: the strongest mortality-associated fac-
torsareenriched forcomponentsof themitotic cell cycle,while secondaryclustersof
genes are involved in extracellularmatrix remodeling, cell motility, and angiogene-
sis. Survival-associated genomic features are indicative of immune infıltration into
primary tumorsandoxidativephosphorylationactivity. Invitroand invivoanalyses
reveal that mortality-associated genes rarely promote the direct transformation of
primary cells. Instead, CRISPR mutagenesis reveals that these genes largely repre-
sent tumor dependencies, and in their absence cancer cells fail to proliferate.
Through this analysis,wehave identifıednewgenetic dependencies commonacross
cancer cells, including C16ORF59 and C5ORF46. In total, our results represent the
largest assessmentofgenomic features linked tocancerprognosis completed todate,
and offer several lines of insight into the biological differences between fatal and
benign cancers.
#391 A comparative genomics approach to understanding the control of
cell context dependent P53 binding. Varsha Sundaresan,1 Ying Li,2 Benedetto
DiCiaccio,1 Victor T. Lin,1 Lei Zhou1. 1University of Florida, Gainesville, FL;
2Macau University of Science and Technology, Macau, China.
Cancer is considered to be a genetic disease characterized by sequential accu-
mulation of mutations. Recent studies have provided evidence that epigenetic
changes and regulatory sequence mutations could also dysregulate oncogenes
and tumor suppressors. As a transcription factor, P53 is activated in response to
oncogenic stress and exerts distinct anti-proliferative functions based on the
stressor and cell type. Though a number of ChIP-Seq studies have identifıed
thousands of P53 binding sites in mammalian genomes, the functionality of
these binding sites remains to be established. In addition, we know little about
what controls stress and cell context specifıc binding profıle of P53. Tradition-
ally,mutations in the coding regions of p53 have been extensively studied to gain
insights on its role in cancer and to identify strategies to restore the functions of
p53 in cancer cells. We hypothesize that mutations in or epigenetic silencing of
functionally important P53 binding sites play an important role in tumorigen-
esis as well. Since functional regulatory regions tend to be more evolutionarily
conserved, in this project we propose using a comparative genomics approach to
identify functional P53 binding sites and determine if these regions are involved
in tumorigenesis. In order to study how P53 binding following DNA damage
differs between cell types, we aim to perform comparison betweenP53ChIP-Seq
data generated in our lab from Drosophila embryos at different developmental
stages and a cell line (Kc167) aswell as published datasets frommammalian stem
cells and differentiated cells. Differential expression analysis using RNA-Seq
exhibited that at an early stem cell-like stage there is P53-dependent induction of
pro-apoptotic genes in response to DNA damage but not in the differentiated
stages. We are seeking to establish functionally signifıcant P53 binding sites by
combining ChIP-Seq data and gene expression data obtained using RNA-Seq.
The importance of these binding sites will be verifıed by CRISPR-Cas9 -medi-
ated genome editing.Wewill also perform comparison studies ofDNAdamage-
induced P53 binding in human, mouse and Drosophila to identify analogous
patterns. Knowledge gained from this studywill help us to understand the role of
non-coding regulatory regions in tumorigenesis, and predict patient response to
apoptosis inducing therapeutic agents. It may also lead to novel strategies to
restore cellular sensitivity to chemotherapy or radiation.
#392 Application of somaticmutation-based expression profıles for high-
throughput phenotyping in cancer. Frederick S. Varn, Yue Wang, Chao
Cheng. Geisel School of Medicine at Dartmouth College, Hanover, NH.
Somatic mutations have been heavily implicated in initiating and driving
cancer growth and metastasis. These alterations serve as upstream events that
have broad transcriptional effects by altering protein structure and function and
interfering with signaling pathways. Here, we apply an iterative approach that
utilizes patient gene expression profıles to defınemutation-associated transcrip-
tomic signatures. We use these signatures to quantify the level at which a given
somatic mutation affects its gene’s downstream activities. Using TP53 in breast
cancer as an example, we show that while TP53 mutations are the primary
predictor of altered p53 activity, events such as copy number alterations and
methylation changes may represent alternative routes to high p53 disruption.
Conversely, we identify a class of TP53 mutations that have minimal down-
stream transcriptomic effects. By expanding this approach to other genes and
tumor types, we show that mutation signatures derived from different tissue
types exhibit varying levels of conservation, suggesting a degree of tissue-speci-
fıcity in the downstream effects of somatic mutations. To provide functional
context to our results, we examine the associations between different mutation
signatures and various cancer-related features, including patient survival, im-
mune infıltration, and pathway activity. Together, our results indicate the utility
of using patient gene expression profıles to study mutation function. Going
forward, these results may be useful in functionally annotating variants of un-
known signifıcance and broadening the potential of precision medicine-based
therapeutic approaches.
#393 Predicting DNA accessibility in the pan-cancer tumor genome using
RNA-Seq,WGS, anddeep learning.KamilWnuk,1 Jeremi Sudol,1 ShahroozRabi-
zadeh,1 Patrick Soon-Shiong,2 Christopher Szeto,3 Charles Vaske3. 1NantOmics,
Culver City, CA; 2NantWorks, Culver City, CA; 3NantOmics, Santa Cruz, CA.
DNA accessibility, chromatin regulation, and genomemethylation are key driv-
ers of cancer transcription. However, there is much left to be understood about the
functional implications of sequence-level data to the regulation of gene expression,
especially when it comes to the noncoding genome. Recently [Kelley, D., Snoek, J.,
andRinn, J.,GenomeRes. 2016] trainedneural networks to effectively predictDNA
accessibility in multiple cell types. These models make it possible to explore the
impact of mutations on the predicted accessibility and thus directly link one aspect
of the gene regulation puzzle all the way down to the sequence level. We present a
model with improved performance on the original dataset of 164 ENCODE and
Roadmap Epigenomics Consortium sample types, and then extend the method to
provide predictions on any sample with RNA-Seq data without need of DNase-seq
for the sample. We fırst demonstrate that with several model and algorithmic
changeswe improveperformanceacross164cell types fromameanAUCof0.895 to
a mean AUC of 0.910. Unfortunately current accessibility models require DNase-
seq for each new cell type. Models for detecting transcription factor binding sites,
which rely onChIP-seq for training data, also share this issue. In order to generalize
sequence-based predictive models to apply to unseen cell types without requiring
re-training we investigate using RNA-Seq as a proxy signature of cell type. The
model aims to capture the interdependence of gene expression levels that character-
ize a cell with the regulatory logic in which sequence-level signatures are combined
to determine accessibility without restriction to cell type. We explore the model’s
performance when applied to held-out cell types in the ENCODE and Roadmap
EpigenomicsConsortiumdataaswell asdata fromtheTCGAPan-Cancer initiative.
We look for the impact of non-coding changes inwhole-genome sequencingdata in
TCGA samples, and report on predicted differences in DNA accessibility across
cancer subtypes.
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#394 Saturationmutagenesis of KRAS reveals the functional landscape of
missense variants. Eejung Kim,1 Seav Huong Ly,1 Nicole S. Persky,1 Belinda
Wang,1 Xiaoping Yang,1 Federica Piccioni,1 Katherine Labella,1 Mihir Doshi,1
Robert E. Lintner,1 Cong Zhu,1 Scott Steelman,1 David E. Root,1 CoryM. Johan-
nessen,1 Alex B. Burgin,1 Laura E. MacConaill,2 William C. Hahn,1 Andrew J.
Aguirre1. 1Broad Institute, MA; 2Dana-Farber Cancer Institute, MA.
KRAS is the most commonly mutated oncogenes and is a major driver of
tumor initiation and progression. Understanding the functional consequences
of cancer-associated KRAS variants may have important clinical implications.
For example, KRAS mutation status defınes those that are likely to respond to
EGFR-directed therapy in KRAS-mutant metastatic colorectal cancer. A com-
pendium of all possible oncogenic KRAS alleles would serve as a roadmap for
future therapeutic strategies directed at KRAS itself or downstream signaling
effectors. Comprehensive mutagenesis of KRAS may also elucidate structure-
function relationships that reveal novel biochemical properties that may be ex-
ploited for therapeutic gain. We performed saturation mutagenesis of both a
wild-type (WT) and a G12D mutant form of KRAS cDNA and generated lenti-
viral expression libraries of 3,553 and 3,534 single amino acid substitution mu-
tants of each backbone. We utilized these WT and G12D mutagenesis libraries
for functional genetic screening to identify gain- and loss-of-function missense
variants that alter critical oncogenic properties of KRAS. First, we sought to
comprehensively identify all possible oncogenic missense mutations in KRAS
that mediate oncogenic transformation. We stably transduced the WT library
into immortalized human epithelial cells and evaluated growth in low attach-
ment (GILA), an assay that is highly correlated with in vivo tumor formation.
We identifıed all previously known hotspot oncogenic alleles of KRAS as well as
many functionally relevant alleles that are also discovered at lower frequency in
human tumors. Moreover, we also discovered a group of transforming KRAS
variants that have not been well described in human tumors, thus revealing
potentially novel activating mechanisms for oncogenic KRAS. In parallel, we
utilized the G12D mutagenesis library to perform second-site suppressor
screening to identify loss-of-function single amino acid changes that abrogate
the transforming ability of oncogenic KRAS. We performed positive-selection
screening in primary cell lines for variants that enable bypass of oncogene-
induced senescence. Additionally, we conducted a negative-selection screen
with the G12D library in a KRAS-dependent cancer cell line with inducible
suppression of endogenous KRAS, thus identifying all possible second-site mu-
tations that abolish KRAS-driven signaling necessary for maintenance of cellu-
lar proliferation and viability. Structure-function analysis of these data may
reveal novel patterns of amino-acid changes that result in inactivation of onco-
genic KRAS. In summary, this comprehensive dictionary of gain- and loss-of-
function KRAS mutants will facilitate understanding of clinically important
mutations and also yield novel insights into structure-function relationships
that may improve our understanding of the KRAS oncogene.
#395 Activation mechanisms of cancer associated MEK1 mutants. Yijun
Gao,1 Matthew T. Chang,1 Daniel McKay,2 Rona D. Yaeger,1 Merna Torres,1
KevenMuniz,1 DrostenMatthias,3 Omar I. Abdel-Wahab,1 Mariano Barbacid,3
GiordanoCaponigro,2 Darrin Stuart,2 David Solit,1 Barry S. Taylor,1 ZhanYao,1
Neal Rosen1. 1Memorial SloanKetteringCancerCenter, NewYork,NY; 2Novartis
Institutes for BioMedical Research, Cambridge,MA,USA.,MA; 3CentroNacional
de Investigaciones Oncológicas, Madrid, Spain., Spain.
Activating BRAFmutants drive human tumors by dysregulating ERK signal-
ing despite ERK-dependent feedback suppression of RAS. These RAF mutants
become RAS independent, by either of two mechanisms, and they are thus un-
affected by feedback inhibition of upstream signaling. Recently, it has become
clear thatmutation activation ofMEK1 orMEK2 occur at appreciable frequency
in human tumors, but the mechanism of activation of these mutants and
whether they remain dependent on upstream activation of RAS or RAF signal-
ing remains unknown. Here we characterized themechanism of activation of 18
recurrent MEK1 mutants identifıed in human cancer. Based on these data, they
fall into three classes. The kinase activity of fırst class remains dependent onRAF
mediated phosphorylation of S218 and S222; the second class of MEK mutants
has basal RAF-independent activity, but can be further stimulated by RAF and
the third class no longer requires phosphorylation of S218 and S222 and signals
in a RAF independent manner. These features determined their sensitivity to
ERK-dependent feedback regulation and the ability to drive ERK signaling out-
put in cells. The more RAF-independent activity the mutants acquired, the bet-
ter they could activate downstream ERK pathway, leading to increased trans-
forming activities in MEF cells in the absence of RAF. This is consistent with
their genetic association with RAS, RAF and NF1 mutations in human tumors.
The Class 3 RAF-independent MEK1 mutants tend to be mutually exclusive
with those mutants, while coexistence with RAS/RAF/NF1 mutations is fre-
quently observed in tumors with Class 1 or 2 MEK1 mutants. Moreover, func-
tional class correlated with sensitivities of ERK signaling driven by these mu-
tants to MEK inhibitors that function by different mechanisms. Unlike RAF
dependent or regulatedMEK1mutants, the ERK signaling driven by RAF inde-
pendent MEK1 mutants is insensitive to an allosteric MEK inhibitor that func-
tions by preventing RAF mediated MEK phosphorylation. However, signaling
driven by all classes of MEK1mutants is sensitive to an ATP competitive MEK1
inhibitor which targets MEK1 kinase activity.
#396 Detecting copy number variations using WES datasets in patient
derived xenografts. Jia Xue,1 Wubin Qian,1 Sheng Guo,1 Jie Cai,1 Henry Qix-
iang Li2. 1Crown Bioscience, Inc., Santa Clara, CA; 2Crown Bioscience, Inc., Bei-
jing, China.
Amplifıcation or deletion of oncogenes and tumor suppressors can be onco-
genic, whichmay serve as drug targets and biomarkers for disease prognosis and
drug response. Traditionally, array-based assays, e.g. Affymetrix SNP6.0® and
lately OncoScan®, have been used to detect DNA copy number variations
(CNVs). These assays have limitations including insuffıcient probe availability
for some genes, cross hybridization, imprecise measurement of fluorescent sig-
nal, less suitability of tumor samples, and high cost. Whole exome sequencing
(WES) is now widely used to profıle tumor samples, and provides a fast and
effıcient determination for pointmutations, insertions and deletions at theDNA
level. Recently, WES is being used to profıle CNVs with some success, but also
suffers frommany drawbacks, such as the requirement of paired normal tissues,
the need of a large batch of samples, the inadequacy of detecting chromosomal-
level CNVs, the incapability to detect CNVs in low coverage genomic regions.
We have developed a CNV detection pipeline on both genomic (segment) level
and gene level from WES data using the concept of off-target and on-target
reads1, and evaluated it in a set of 155 patient-derived xenografts (PDXs), with
head-to-head comparison to Affymetrix SNP6.0® and OncoScan® on 5 models
with 2 passages from each. PDX is a well-accepted experimental model mimick-
ing original patient in histo-&molecular pathology2. Reads derived frommouse
contaminants were removed fromWES datasets to avoid mouse signal interfer-
ence, which cannot be done in array-based techniques. RT-PCR was used to
experimentally validate CNVs for selected genes. We found that the average
off-target rate for our PDX models is approximately 15%, and off-target reads
were uniformly distributed across genome. The comparison with array-based
technologies indicates that 1) WES has the highest resolution (20kb) while On-
coScan® is the second (50-100 kb), followed by SNP6.0® (100-200kb), 2) the
OncoScan® CNV calls are very similar to ourWESmethods at the genome level,
yet 3) WES gives a much higher accuracy on CNV inference for genes flanking
the 900 cancer related genes with enhanced probe densities on OncoScan®,
suggesting that ourWESmethod has the highest accuracy. RT-PCR results con-
fırmed the observations. In summary, our WES-based approach gives a better
solution in CNV detection in PDX models. References 1. Kuilman T, Velds A,
Kemper K, Ranzani M, Bombardelli L, Hoogstraat M, Nevedomskaya E, Xu G,
de Ruiter J, Lolkema MP, Ylstra B, Jonkers J, et al. CopywriteR: DNA copy
number detection from off-target sequence data. Genome biology 2015;16:49. 2.
Guo S, QianW, Cai J, Zhang L,Wery JP, Li QX. Molecular Pathology of Patient
Tumors, Patient-Derived Xenografts, and Cancer Cell Lines. Cancer research
2016;76:4619-26.
#397 Whole genome copy number variation analysis using a SNP-focused
targeted sequencing panel for tumor analysis. JiashiWang,1 Kristina Giorda,1
Zhongwu Lai,2 Daniel Stetson,2 Mirna Jarosz1. 1Integrated DNA Technologies,
Redwood City, CA; 2Astrazeneca, Boston, MA.
Accurate genome-wide copy number variation (CNV) analysis is critical for
disease and cancer research. Current approaches for CNV analysis include flu-
orescence in situ hybridization (FISH), array comparative genomic hybridiza-
tion (array CGH), and SNP arrays. Unfortunately, these methods are not sensi-
tive enough for real world cancer samples because of tumor ploidy, purity and
heterogeneity. NGS-based targeted sequencing is increasingly being used for
CNV analysis due to throughput, coverage, cost, and sample input require-
ments. For CNV analysis, detection power is improved by combining both read
depth and SNP allele frequency analysis, particularly for copy-neutral events
such as loss of heterozygosity. A custom xGen Lockdown CNV backbone panel
was developed for broad, uniform genome coverage and to enrich for popula-
tion-based SNPs. We demonstrate use of the panel as an addition to the xGen
ExomeResearchPanel and a customcancer focused panel.Downstreamanalysis
incorporates both read depth and observed minor allele frequencies to deter-
mine CNVs with enhanced sensitivity. To increase the resolution for large-scale
alterations of chromosome 7, a hot-spot for disease-associated CNVs, probe
density was increased 6 fold. A known standard, NA12878, was used to validate
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the panel’s ability to detect heterozygous SNPs with high confıdence. In addi-
tion, mixtures of cancer cell lines from the Cancer Cell Line Encyclopedia
(CCLE) were tested with varying levels of background copy-neutral genomic
DNA. The sensitivity and specifıcity of the panel to detect CNV and LOH events
with was assessed using deep exome and Affymetrix SNP array data. The ability
to detect copy number alterations with high resolution and accuracy would be a
valuable resource for disease and cancer research.
#398 Using off-target data from comprehensive genomic profıling to
characterize the genomic architecture of copy number alterations in tumor
sequencing data. Caitlin F. Connelly, Zachary R. Chalmers, Philip J. Stephens,
Garrett M. Frampton. Foundation Medicine, Inc., Cambridge, MA.
Background: Copy number alterations are common driver mutations in can-
cer. Identifying genes which show altered copy number and knowing the break-
points of copy number alterations gives insight into their functionality as well as
the mechanisms responsible for the alterations. While copy number alterations
have been well-studied in common tumor types, there are still many rare tumor
types which have not been characterized. Targeted genomic profıling using cap-
ture methods results in sequencing a subset of genes to extremely high coverage
(500x) and sequencing off-target regions spanning the rest of the genome to
low (0.5x – 1x) coverage. We used this data to identify the approximate break-
points of alterations that extend beyond targeted regions and to identify novel,
recurrent copy number alterations in clinical tumor samples.Methods:We used
standard methods to identify copy number alterations in the off-target regions.
Briefly, we calculated coverage in 10 kb windows across the genome, excluding
the targeted regions which are sequenced at high coverage, corrected for GC-
bias, calculated the log ratio of coverage for the tumor compared to an unrelated
normal sample, and then used a segmentation algorithm to segment the genome
into copy number regions and identify regions with signifıcantly different copy
number than the surrounding regions.We sequenced cell lineDNAwith known
copy number variants and used this data to assess the accuracy and precision of
these methods. Copy number alterations were fıltered against known common
copy number variant regions, and we identifıed copy number alterations over-
lapping known genes to identify potentially functional alterations. Results: We
applied these methods to tumor samples that underwent comprehensive
genomic profıling as part of clinical care. Our cohort consisted of a large and
diverse set of “real world” unbiased clinical specimens and containedmany rare
and unusual tumors not included in larger sequencing efforts. Using this data,
we characterized the landscape of copy number variants genome-wide in rare
tumor typeswhich have not previously been characterized and identifıed unique
copy number alterations in these tumor types. Further, we characterized the
breakpoints of copy number alterations across the cohort. Conclusions:We will
present novel copy number alterations in rare tumor types and the recurrent
breakpoints for common alterations acrossmultiple tumor types. These fındings
will provide insight into the mechanisms of cancer progression.
#399 CPTAC phase II fınal report.Mathangi Thiagarajan. Leidos Biomedi-
cal Research Inc., Rockville, MD.
National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium
(CPTAC) is a comprehensive and coordinated effort to accelerate the under-
standing of the molecular basis of cancer through the application of robust,
quantitative, proteomic technologies and workflows. The primary goal for this
program is to systematically identify proteins that derive from alterations in
cancer genomes and related biological processes, integrate the genomic and
proteomic data from analysis of common cancer biospecimen and provide this
data with accompanying assays and protocols to the community. The phase II
effortmanaged by the Leidos Biomedical Research Inc. had a goal to procure and
qualify a minimum of 100 cases from 3 cancer types (Breast, Ovarian and Co-
lon). Tissues and analytes from the 100 cases were sent to proteomic and
genomic characterization centers for analysis. The proteomic data were made
available through the Data Coordinating Center (DCC) and the genomic data
were made available through NCI’s Genomic Data Commons (GDC). The suc-
cess from the phase II effort has set precedence for amuch larger phase III effort
that will focus on additional cancer types and cases. Preliminary analysis results
confırm the need for the combination of the genomic and proteomic approaches
to produce a more comprehensive inventory of the detectable proteins in a
tumor and advance our understanding of cancer biology.
#400 NCI’s CPTAC Phase III, proteogenomic analysis of additonal
cancer types. Linda I. Hannick. Frederick National Lab for Cancer Research,
Rockville, MD.
The Clinical Proteomics Tumor Analysis Consortium (CPTAC) is a National
Cancer Institute initiative that seeks to uncover the molecular basis of cancer
using a proteogenomic approach to study prospective cancer specimens. Leidos
Biomed provides an infrastructure for supporting the collection of high quality
biospecimens and data, in addition to project and subcontract management for
the program. CPTAC applies the understanding of themolecular basis of cancer
to identify biomarker candidates. Phase II of CPTAC, completed in 2016, col-
lected over 500 cases from breast, colon and ovarian patients. In early 2016,
CPTACPhase III began to collect and analyze 200 cases of each of ten additional
cancers. The goal is to collect 200 qualifıed cases of fıve to six tumor types over a
fıve-year period, although the program is currently accruing from ten. The study
entails collection and pathology evaluation of biospecimens, high-quality clini-
cal data and images from clinical sites around the world. A biorepository eval-
uates and processes the biospecimens, sending nucleic acids to a sequencing
center and tissues to proteomics groups. Data are combined and analyzed by
translational centers. Genomic data are made available to the research commu-
nity through the NCI Genomic Data Commons. Proteomic data aremade avail-
able through the Data Coordinating Center. We report here on progress in
collection of tissues and clinical data, and use of biorepository, proteomics and
genomics and analysis centers.
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#401 Designing for success: the right CRISPR design strategies for the
right experiment. Leigh Brody, Neil Humphryes-Kirilov, Victor Dillard, Riley
Doyle. Desktop Genetics, London, United Kingdom.
CRISPR design is a complex multivariate problem. The weight of each vari-
able differs depending on the experiment under consideration. Current meth-
ods of designingCRISPR experiments are based on a single-variable, resulting in
poor experimental outcomes. From the numerous experiments enabled by the
DESKGEN platform, we can demonstrate key design improvements to maxi-
mise experimental outcome. Our current scoring methods were tested and val-
idated using an sgRNA library of over 3,500 sgRNAs in essential genes with a
variety of predicted sgRNA activities and specifıcities. The predicted ’good’
sgRNAs achieved signifıcantly higher read depletion for essential genes, with
fewer failing sgRNAs, compared to sgRNAs that didn’tmeet the scoring criteria.
Our scoring algorithm incorporates multiple published observations for choos-
ing effective sgRNAs, which differs from other CRISPR tools that tend to focus
on one factor such as sgRNA sequence or specifıcity. We were unable to fınd
correlations for some currently accepted sgRNA selection criteria, such as posi-
tion within a gene, which demonstrates the need to constantly challenge and
improve sgRNA design rules.
#402 Biomarker-based pooled CRISPR-Cas9 screening: Platform devel-
opment and validation. Tim M. Scales, Benedict C. Cross. Horizon Discovery,
Cambridge, United Kingdom.
Functional genomic screening with CRISPR-Cas9 has provided a powerful
and precise new way to interrogate the phenotypic consequences of gene loss in
high-throughput, unbiased analyses. Rapid development of pooled lentivirus
and deep-sequencing-led approaches have allowed us and others to exploit this
technology in target ID, target validation, drug MOA analysis and patient strat-
ifıcation. Adaptation of the Cas9 nuclease by domain fusion and catalytic inac-
tivation has further provided a novel way to both up and down-regulate gene
expression using targeted, high-throughput CRISPRi and CRISPRa tools. To
date, the vast majority of screens have been conducted using sgRNA abundance
in surviving cell populations as anNGS-based proxy for proliferation, for exam-
ple for in vitro resistance analysis to a cytotoxic treatment regimen. However,
where cellular pathophysiology is uncoupled from cell health, the enormous
promise of pooled CRISPR-Cas9 screening has been largely untapped. We now
report on the development of a FACS-based platform that can be used to mon-
itor biomarker-based cellular response in combination with high-throughput
genetic screening. The endogenous interaction between CD28 and CD80 was
used as a proof-of-concept paradigm and the performance of our platform was
measured in screen-simulation conditions. We fınd that FACS-linked NGS was
able to robustly identify the CD28 deleted cells from a complex population using
a FITC-labelled CD80-Fc. Pseudo-blinding of the data yielded unambiguous
identifıcation of the expected target guides, with robust screening metrics, vali-
dating a new platform for myriad discovery programmes.
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#403 CRISPR/Cas9 genome-wide sgRNA libraries for loss-of-function
and gain-of-function genetic screens. Donato Tedesco, Paul Diehl, Mikhail
Makhanov, Sylvain Baron, Alex Chenchik. Cellecta, Inc., Mountain View, CA.
Genome-wide loss-of-function screening is a fundamentalmethod to identify
genes responsible for driving biological processes. Complex pooled lentiviral-
based libraries expressing large numbers of genetic disruptors, such as shRNAs
(RNAi) or sgRNAs (CRISPR), make large-scale cell screening practical. While
RNAi-based approaches have proven to be an effective strategy for these screens,
recent work has showed CRISPR-based technologies offer not only an effective
alternative, but distinct advantage. We will present unpublished data from ge-
netic screens in human cancer cell lines using CRISPR-Knockout (KO), CRIS-
PRi and CRISPRa technologies, as well as RNAi. Although loss-of-function
shRNAand sgRNApooled library screens are similar in concept, the gene loss of
function is achieved by different mechanisms (mRNA degradation with RNAi,
full gene disruption with CRISPR-KO, transcriptional inhibition with CRIS-
PRi), so some divergences are expected and indeed observed when comparing
results obtained using one method versus the other. Furthermore, contrary to
RNAi, CRISPR technology can be modifıed to activate gene expression
(CRISPRa), thus enabling the use of genome-wide gain-of-function screening in
gene function studies.
#404 A bi-clustering based computational approach to identifymolecular
markers for Neoadjuvant chemotherapy outcome prediction in complement
to cancer subtype classifıcations. Chi Zhang,1 Sen Liang2. 1Indiana University,
School of Medicine, Indianapolis, IN; 2Jilin University, Chang Chun, China.
Molecular stratifıcation models have been well established for most cancer
types to classify tumors into sub-types by using genome level molecular charac-
teristics. Tumors of certain sub-type have distinct response to specifıc therapies.
Hence a reliable molecular classifıcation model can be applied to determine
treatment strategy. Recent neoadjuvant chemotherapy, immunotherapies and
gene targeted drugs and their possible combinations raise a demand for small
subsets of novel molecular markers for outcome prediction in addition to the
complete molecular profıle based classifıcation. However, it is unknown what
genes have predictive power for a certain therapeutic strategy while the highly
crossed clinical features increase the diffıcult to determine sample groups for
marker identifıcation that form a bi-clustering problem. In addition, predictive
maker may be varied among different cancer sub-types. In this work, we devel-
oped a bi-clustering based computational framework to identify transcriptomic
markers for predicting the outcome of neoadjuvant chemotherapy and adjuvant
chemotherapy. Our computational approach identifıes functional related gene
expression modules show signifıcant expression patterns in a subset of samples
that are highly associated with one or several disease sub-types and with high
predictive power for the outcome of certain. By applying the analysis to 8 breast
carcinoma, 10 colorectal carcinoma and 3 acute myeloid leukemia data sets in
public domain, we have identifıed sets of gene markers with high predictive
power for chemotherapy outcome complementary to the existing molecular
classifıcations, suggesting the bi-clustering based approach can improve the
whole genome level molecular classifıcation based outcome prediction.
#405 A novel panel of 325 biomarkers is part of a large interconnected
network representingmultiple cell signaling pathways and allowing develop-
ment of predictive tests for oncology drugs. Edward C. Goodwin, Said Attiya,
Marcia Fournier. BioArray Genetics, Inc., Farmington, CT.
Background: We developed an algorithm based on the gene expression of
tumor biopsies to identify the best combination of biomarkers to reliably predict
a patient’s response to relevant cancer treatments. This algorithm is derived
from 325 genes whose expression showed signifıcant changes during differenti-
ation of non-malignant human mammary epithelial cells cultured in laminin-
rich extracellular matrix. Of these 325 genes, 251 are novel and not present in 9
other cancer based gene expression panels such as FoundationOne or PAM50.
These differentiated cells formed multicellular structures with defıned lumens
and tight junctions and with specifıc localizations of cadherin and integrins. In
contrast, cells from breast cancers displayed a general loss of structure. Previous
work showed that different sets of these 325 biomarkers accurately predicted
overall breast cancer patients’ survival or response to neoadjuvant therapy in
multiple independent studies. Objective: Predict cell-signaling pathways, drug
associations, and disease associations for the 325 biomarkers (BA325) in con-
trast to other cancer gene panels. Methods and Results: The Qiagen Ingenuity
program was used to identify pathways and disease states containing signifıcant
overlap with BA325. Multiple cell signaling pathways including cell prolifera-
tion, migration, invasion, and metabolism were found in BA325, while most
other cancer biomarker panels were highly concentrated in cell proliferation.
Examples of signifıcant pathway associations relevant for oncology drug discov-
ery and targeted treatments include Cell Cycle Control of Chromosomal Repli-
cation (p8.1E-14), Polo-like-kinase and HSP90 complex (p6.3E-07), G2/M
DNADamageCheckpoint (p6.4E-07), Integrin Signaling (p3E-05), Integrin
Linked Kinase Signaling (p4.51E-05), BRCA1 DNA Damage Response
(p1.75E-04), Estrogen Mediated S-phase entry (p4.24E-04), Regulation of
Actin Based Motility by RHO (p4.55E-04), Adherins Junction Remodeling
(p5.6E-04), Actin Cytoskeleton Signaling (p7.25E-04), Mismatch Repair
(p1.6E-03), RAN Signaling (p1.64E-03), Protein Ubiquitination (p1.78E-
03) and Cholesterol Biosynthesis (p4.8E-03). This wide coverage of cellular
signaling pathways provides an advantage in developing predictive tests for
treatments targeting highly complex cell signaling networks. Surprisingly, even
though theBA325 panelwas obtained during non-malignant differentiation, the
most signifıcant disease state associated with these genes was mammary tumor,
demonstrating the validity of this approach to probe breast cancer biology. Con-
clusion: This analysis demonstrates that the BA325 panel is useful both in un-
derstanding non-malignant mammary epithelial differentiation and breast can-
cer tumors.
#406 CRISPR pooled screening of hundreds of cancer cell lines identifıes
differential dependencies on epigenetic pathways and synthetic lethal rela-
tionships. Alexandra R. Grassian, Darren Harvey, Julian Fowler, Allison E.
Drew, Igor Feldman, Richard Chesworth, Robert Copeland, Jesse J. Smith, Scott
Ribich. Epizyme, Inc., Cambridge, MA.
Target identifıcation is a critical step in drug discovery, but the process has
many challenges including non-specifıc reagents, limited ability to test numer-
ous models, and incomplete target inhibition. Pooled screening with CRISPR/
Cas9 permits the quick and accurate examination of proliferation effects across
many genes and many cell lines. To determine the specifıc dependencies of cell
lines on epigenetic pathways, we designed a CRISPR/Cas9 library to target 640
epigenetic genes and screened more than 200 cell lines covering a variety of
oncology indications, including breast, lung, and renal cell carcinoma (RCC).
We fınd that CRISPR pooled screening is a highly effective approach for target
identifıcation and provides robust, highly reproducible data as long as a suffı-
cient number of small guide RNAs are used. We identify known pan-essential
genes, including in the transcription (CDK9), translation (EIF4A1 and EIF4A3)
and splicing (SRSF2) machinery. We additionally identify many novel pan-es-
sential genes across a variety of epigenetic pathways, including histone acety-
lases and deacetylases, chromatin remodeling factors, helicases and others. We
also investigated epigenetic synthetic lethal interactions that have been previ-
ously reported. For example, it has been reported that the SWI/SNF family
displays paralog synthetic lethality for SMARCA2 in the context of SMARCA4
mutations, and for ARID1B in the context of ARID1A mutations. While we do
see that some of the same trends hold, the synthetic lethal relationship appears to
be more complex than previously realized, including the need to examine
mRNA levels in addition to mutation type. Most importantly, we identify more
than 100 epigenetic genes which show selective sensitivity, i.e. where knockout
shows an anti-proliferative effect in only a subset of the cell lines. These are the
most promising targets for further drug discovery programs. We have used
additionally CRISPR/Cas9-domain based screening to identify the functionally
relevant sites formany of these genes. Furthermore, we can overlay gene expres-
sion andmutation data to identify novel synthetic lethal relationships. One gene
that displays selective sensitivity is EGLN1, the prolyl hydroxylase for the hy-
poxia-inducible factor, HIF1.We fınd that EGLN1 is required for proliferation
only in RCC cell lines which retain wild-type VHL, another component of the
hypoxia response pathway,which is frequently lost inRCC.As such, EGLN1 loss
is synthetically lethal in the presence of wild-type VHL in RCC cells. Thus this
approach not only identifıes an enzymatic drug target but also a patient stratifı-
cation method. Other novel synthetic lethal interactions have also been identi-
fıed. Our data demonstrates that CRISPR pooled screening is a powerful tech-
nique for identifıcation of epigenetic synthetic lethal interactions.
#407 Whole-genome pooled CRISPR/Cas library screens to identify new
hepatocellular carcinoma drivers and drug targets in combination with
sorafenib. Takahiro Kodama,1 Justin Y. Newberg,2 Nancy A. Jenkins,2 Tetsuo
Takehara,1 Neal G. Copeland2. 1Osaka University Graduate School of Medicine,
Suita, Japan; 2Houston Methodist Research Institute, Houston, TX.
Backgrounds and Aims: Hepatocellular carcinoma (HCC) is a deadly cancer
and itsmortality rate ranks third among all cancer types worldwide. To compre-
hensively understand its genetic drivers, over 500 HCC genomes have been
sequenced but they reveal the existence of thousands of infrequently mutated
genes. This intra- and inter-tumor heterogeneity, combined with large number
of passenger mutations, has made it diffıcult to identify the true drivers of HCC.
In addition, sorafenib is the currently only FDA-approvedmolecular target drug
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inHCCbut its anti-tumor effect is very limited. To overcome these problems,we
performed two forward genetic screens using recently innovatedwhole-genome
pooled CRISPR/Cas library.Methods: Two human liver cancer cell lines, Huh-7
and SNU-398,were lentivirally transducedwithGeckov2 library and transduced
cells were selected with puromycin. First, transduced cells were orthotopically
injected into the liver of the Nudemice andmonitored for tumor formation. To
identify potential tumor suppressor genes (TSGs) in the liver, gRNAs enriched
in the orthotopic liver tumors were determined by sequencing of gDNA in these
tumors. Next, transduced cells were treated with vehicle or sorafenib in vitro for
14 days. To identify potential targets which inhibition show synergistic anti-
tumor effect with sorafenib, we determined gRNAs depleted in cells with
sorafenib treatment compared to cells with vehicle treatment. Results: In the fırst
in vivo screening, we identifıed 62 genes targeted by 2 or more highly enriched
gRNAs in Huh-7 cells-derived tumors and 47 genes in SNU-398 cells-derived
tumors. Twenty-nine genes were common including 4miRNAs. TCGA analysis
revealed that HCC patients with mutation or copy number alteration in any of
these genes showed worse overall survival and disease free survival compared to
HCC patients without them. In addition, gene expression levels of 3 candidate
TSGs, BPHL, CTSZ and PLCG2 were signifıcantly negatively correlated with
poor survival of HCC patients. In the second in vitro screening, CYP7B1,
HS3ST5,NLRC4, andMir-1237were identifıed as potential drug targets in com-
bination with sorafenib in HCC. Conclusion: Whole-genome pooled CRISPR/
Cas library screens discovered potential new hepatocellular carcinoma drivers
and drug targets in combination with sorafenib.
#408 Investigating the biology of atypical teratoid/rhabdoid tumors by
whole genome CRISPR/Cas9 screening.Matthew P. Selby, Martina A. Finetti,
Matthew Bashton, Ruth E. Cranston, Yura Grabovska, Alicia Del-Carpio-Pons,
Amanda Smith, Simon Bailey, Steven C. Clifford, DanielWilliamson.Newcastle
University, Newcastle upon Tyne, United Kingdom.
Atypical Teratoid/Rhabdoid Tumors are rare, highly aggressive, paediatric
tumours with a dismal prognosis. Rhabdoid Tumours (RT) have one key genetic
defect (biallelic inactivation of SMARCB1 in  90% of patients) which, when
re-expressed in RT cells, causes differentiation and growth arrest. We used
whole genome CRISPR (clustered regularly interspaced short palindromic re-
peats)/Cas9 screening; a technique by which mutations are created systemati-
cally in each gene in the genome - to identify novel SMARCB1-dependent ther-
apeutic targets and synthetic lethal relationships in RT. A panel of RT cell lines
were transduced with a GeCKO (Genome Scale CRISPR Knock-Out) library
which contains 122,441 guide constructs targeting 19,050 genes and 1,864 miR-
NAs; each cell contained a single CRISPR insert. This panel was further trans-
duced with a SMARCB1 expression lentivirus or an empty vector control, cells
were collected at 0, 7 and14 days post infection (300x library coverage, 3.7 x 107
cells per time point). CRISPR inserts were sequenced, counted, normalized and
analyzed to identify those whose abundance was signifıcantly altered, represent-
ing candidate gene targets which promote or inhibit RT cell growth/viability in
a SMARCB1-dependentmanner. CRISPR hits were further cross-validatedwith
primary patient and functional model genomic data (RNA-sequencing/450k
DNA methylation array) to identify several high confıdence deleterious events
with strong SMARCB1 dependency. Hundreds of signifıcantly enriched (both
positively and negatively) genes were identifıed which alter when SMARCB1 is
present or absent includingMYC family targets, cell cycle targets, SHH pathway
and the Aurora kinase family. TGF was identifıed as a top upstream
SMARCB1/methylation dependent regulator and when SMARCB1 re-expres-
sion data was overlaid onto the TGF canonical pathway showed a convincing
enrichment in pathway regulation. Pathwaymembers SMAD2/3 showed a ’syn-
thetic lethal’ phenotype and represent a functional SMARCB1-dependent rela-
tionship which is also observed in SMARCB1 re-expression and methylation
model data and is characteristic of primary RT. This phenotype was validated
functionally by expression of a dominant negative TGFBR2. Combining RNA-
sequencing and 450KDNAmethylationmicroarray data fromprimary tumours
and experimental models, coupled with whole-genome functional screening,
provides a genome-wide view of key RT tumorigenic genes/pathways and their
SMARCB1 dependence. These data suggest synthetic lethal phenotypes and en-
able prioritisation of true SMARCB1-dependent events and therapeutic targets,
in this rare yet lethal paediatric tumour.
#409 Genome engineering to generate models of chromosome arm-level
aneuploidies in lung carcinoma. Alison M. Taylor, Gavin Ha, Juliann Shih,
Xiaoyang Zhang, Joshua M. Francis, Matthew Meyerson. Dana-Farber Cancer
Institute/Broad Institute, Boston, MA.
Almost 90% of tumors are aneuploid and have arm- or whole- chromosome
level copy number changes. Arm-level copy number alterations cluster by tumor
type, suggesting that specifıc arm-level changes are influenced by cell type. Sys-
tematic methods of generating copy number changes on a particular chromo-
some have not been tested, leaving the effects of specifıc aneuploidies in cancer
unclear. The most frequent genomic alteration in lung squamous cell carcino-
mas (SCCs) is loss of chromosome 3p. This alteration occurs in 90% of lung
SCCs, and covers the entire length of the chromosome arm. Over two-thirds of
3p genes show signifıcantly decreased expression. However, the phenotypic ef-
fects of 3p loss in tumorigenesis are not known. We used the CRISPR-Cas9
system to generate double-strand breaks (DSBs) and produce partial aneup-
loidies of arm-level loss. We have targeted guide RNAs adjacent to centromeric
satellite-repeat sequences on chromosome arm 3p. At this location, we induced
homologous recombination with a selection cassette and artifıcial telomere. We
have successfully isolated almost 90 clones of immortalized lung epithelial cells
with deletion of the 3p arm, with 8 validated by whole genome sequencing.
Consistent with patient data, expression of 3p genes is also decreased upon
deletion. Phenotypic characterization revealed that cells with chromosome 3p
deletion proliferate more slowly than their siblings. 3p deleted cells show in-
creased G1 arrest, but do not undergo increased apoptosis or cell death. We are
currently testing 3p loss in combination with other frequent SCC alterations,
such as SOX2 and TP63 gain. We have also identifıed expression changes in
trans, outside of chromosome 3p. These studies provide a robustmodel that will
address a gap in our understanding of aneuploidy in cancer by using targeted
endonuclease technology to create models of partial aneuploidies. Future work
will include investigation of how different chromosomal changes contribute to
cancer formation, which will have implications on our understanding of tumor-
igenesis.
#410 Identifying ovarian cancer specifıc targeted drugs using high-
throughput drug sensitivity profıles of primary cancer cells. Astrid Mu-
rumägi,1 AkiraHirasawa,2 SuleimanKhan,1 Daniela Ungureanu,3Mariliina Ar-
jama,1 Teijo Pellinen,1 Samuli Eldfors,1 Riitta Koivisto-Korander,4 Arto
Leminen,4 Ralf Bützow,4 Tero Aittokallio,1 Olli Kallioniemi1. 1Helsinki Univ.,
Inst. for Molecular Medicine, Helsinki, Finland; 2Keio University School of Med-
icine, Tokyo, Japan; 3TampereUniv., Inst. of Biosciences andMedical Technology,
Tampere, Finland; 4Helsinki University Hospital, Helsinki, Finland.
Ovarian cancer (OvCa) is the sixth most common cancer in women and
leading cause of death from gynecologic diseases. Poor prognosis in OvCa is
due to late diagnosis and acquired resistance to the commonly used plati-
num-based regimens. A signifıcant setback for OvCa treatment is the lack of
reliable biomarkers and effective targeted therapies. In order to discover
novel therapeutic opportunities with approved and emerging drugs for
OvCa, we have established primary cultures using ascites or tumor tissue
samples from chemo-refractory ovarian cancer patients for ex vivo Drug
Sensitivity and Resistance Testing (DSRT) and genomic profıling. In addi-
tion, we have performed DSRT with 31 established OvCa cell lines. Compar-
ison of the drug sensitivity profıles of ten primary cancer cell cultures and 31
OvCa cell lines revealed previously unanticipated cancer selective drug vul-
nerabilities. Several drug groups were identifıed suggesting that the sensitive
samples were addicted to the corresponding signaling networks. For exam-
ple, in a 53-year old chemorefractory low grade serous OvCa patient,
genomic and transcriptomic analyses revealed a fusion gene of NRG-1, a
target that was recently reported to involve the NRG1/ERBB3 activation loop
in OvCa. We found high expression of ERBB2 and ERBB3 by RNA-seq as
well as high levels of phospho-ERBB3, phospho-ERBB2 and phospho-EGFR
by immunohistochemistry. In agreement with the molecular mechanism,
DSRT analysis identifıed signifıcant sensitivity of primary cancer cells to
EGFR inhibitors, such as erlotinib and to dual EGFR and Her2 inhibitor
afatinib. The patient has received combination therapy of gemcitabine and
erlotinib during nine months, followed by afatinib monotheraphy that has
lead to complete remission after six months treatment. We have detected
activated NRG1/ERBB3 activation loop also in several additional ovarian
cancer patient cases, highlighting the importance of this signaling pathway
in ovarian cancer pathogenesis. Our study reveals that a subset of serous
ovarian cancer patients with activating NRG1/ERBB3 signaling loop have
clinical benefıts from repurposing dual EGFR/Her2 inhibitor afatinib, pro-
viding a basis for the clinical use of EGFR and dual EGFR/Her2 tyrosine
kinase inhibitors in clinical treatment. In conclusion, DSRT technology to-
gether with molecular profıling provides a powerful strategy to identify tu-
mor driver signals and select clinically actionable inhibitors. Hence, this type
of systems medicine approach can signifıcantly improve the power of mainly
genomics-oriented personalized medicine approaches.
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#411 In vivo pooled shRNA library identifıes KPNB1 as a new drug target
for epithelial ovarian cancer. Michiko Kodama,1 Takahiro Kodama,1 Kosuke
Yoshihara,2 Kae Hashimoto,1 Seiji Mabuchi,1 Kenjiro Sawada,1 Tadashi
Kimura,1 Neal Copeland,3 Nancy Jenkins3. 1Osaka University Graduate School
of Medicine, Suita, Japan; 2Nigata University Graduate School of Medical and
Dental Sciences, Japan; 3Houston Methodist Research Institute, Houston, TX.
Objective Epithelial ovarian cancer (EOC) is a most lethal cancer in gynecol-
ogy, of which cure rate is 30%. To seek its new therapeutic targets, we performed
in vivo loss of function screen. Method Human EOC cell line, SKOV3, was
transduced with pooled druggable shRNA library containing 42450 shRNAs
targeting 7490 genes. Transduced cells were intraperitoneally injected into 12
female nudemice andmonitored for PC tumor formation. Genomic DNA of 12
biggest PC tumors were sequenced to identify shRNAs depleted in these tumors.
Results Ten potential drug targets were identifıed, including 2 known onco-
genes, ERBB2 and RAF1. Second highest ranked gene, KPNB1, is known as a
nuclear transporter. KPNB1 inhibition signifıcantly decreased and overexpres-
sion increased in vitro cell proliferation in multiple EOC cell lines. KPNB1
inhibition caused multi-phase cell cycle delay at both of G1/S and G2/M transi-
tion via elevation of p21 and p27 and induced apoptosis. KPNB1 inhibition
signifıcantly decreased in vivo tumor formation through the samemechanism as
in vitro, because more cleaved PARP and less Ki67 positive cells were found in
KPNB1 knockdown tumors via immunochemical staining.We found a positive
correlation between KPNB1 mRNA levels and poor survival of EOC patients,
suggesting the oncogenic role of KPNB1 in human EOC. Comprehensive mass
spectrometric study identifıed that KPNB1positively regulated severalmembers
of anaphase promoting complex/cyclosome. Lastly, we found that ivermectin, a
well-known anti-parasitic drug, exerted an anti-proliferative effect on EOC cell
lines via KPNB1 inhibition, and its combination with paclitaxel synergistically
suppressed cell proliferation in vitro and inhibited tumor formation in vivo.
Conclusion In vivo pooled shRNA library screen identifıed KPNB1 as a new
drug target for EOC. Ivermectin can be a new therapeutics for EOC especially
combined with paclitaxel.
#412 Genetic variation in platinum-sensitive and platinum-resistant
high-grade serous epithelial ovarian cancer. Tara Castellano, Leslie H. Clark,
Naim Rashid, Victoria Bae-Jump. University of North Carolina at Chapel Hill,
Chapel Hill, NC.
Background: We examined the association of platinum resistance with ge-
netic mutations in high grade serous ovarian cancer (HSOC) patients undergo-
ing high-throughput genomic tumor sequencing. Methods: Snap-frozen and
fresh frozen paraffın embedded tissue samples were collected from HSOC pa-
tients enrolled on UNCseq (NCT01457196). UNCSeq is an institutional proto-
col which uses next generation sequencing to detect genetic mutations in a wide
array of malignancies. Illumina libraries were prepared separately from tumor
and amatched normal sample from each patient. Relevant targets were enriched
by a custom designed Agilent SureSelect hybrid capture enrichment library us-
ing standard protocols. Samples were sequenced on IlluminaHiSeqmachines in
a variety of formats. Mutations with a quality score100 were fıltered from the
data set, and only mutations rated to have a moderate to high impact were
retained. Medical record review determined platinum sensitivity or platinum
resistance. Tumors were defıned as platinum sensitive or resistant if patients
were noted to have or 6 months of disease free interval following comple-
tion of induction therapy, respectively. Results: Overall 39 HSOC cases met
inclusion criteria; 32 tumors met criteria for platinum sensitive and 7 platinum
resistant. 308 mutations were noted in at least one individual across all patients.
The top observed mutations in platinum sensitive HSOC were TP53 (41%, n
13), GucylA2 (19%, n6), MLL2 (19%, n6) and MTOR (16%, n5). The top
observed mutations in platinum resistant tumors were TP53 (71%, n5), TET1
(43%, n3), NF1 (43%, n3) andMLL3 (43%, n3). There was a trend toward
more p53mutations in resistant tumors (71%versus 41%, p0.21) Therewas no
difference in the total number of mutations per tumor in platinum sensitive and
resistant patients, (3 vs. 4, p0.516). Conclusions:Wedid not detect a difference
in the number of genetic mutations in HSOC according to platinum sensitivity.
Platinum resistant tumors had a trend toward higher frequency of TP53 muta-
tions than platinum sensitive HSOCs. Furthermore, we identifıed 3 frequently
mutated genes in platinum resistantHSOC: TET1, an epigenetic regulator, NF1,
a tumor suppressor gene and MLL3, a histone modifıer gene. Ongoing tumor
sequencing of HSOCs on UNCseq will help to confırm these results.
#413 Neo-epitope detection and immune infıltrate analysis of colorectal
cancer samples. FangYin Lo,1NitinMandloi,2 TimothyYeatman,3 Kiran Paul,2
Ashwini Patil,2 Steven Anderson,4 Ravi Gupta,2 Anup Madan1. 1Covance
Genomics Laboratory, Redmond,WA; 2MedGenome Inc, Foster City, CA; 3Gibbs
Cancer Center, Spartanburg, SC; 4Covance Genomics Laboratory, Durham, SC.
Colorectal cancer (CRC) is the third most common type of cancer in the United
States. Targeted therapies that use monoclonal antibodies (mAbs) to EGFR have
been shown to benefıt some CRC patients. Until recently, KRAS has been the only
predictive biomarker for anti-EGFR therapy for metastatic CRC. However, 40% to
60% of patients with wild-type KRAS do not respond to anti-EGFR therapy. Previ-
ously we have stratifıed 55 CRC samples by applying a RAS gene signature score
which measures MEK pathway functional output independent of tumor genotype.
We showed that samples that have RAS activating mutations such as KRAS and
BRAF have signifıcant higher RAS scores (p0.001). Here, we further investigate
the potential immune reactivity in these CRC samples, and thereby the potential
benefıt of immunotherapy, by evaluating the tumor neo-epitope burden, and the
qualityof immunecell infıltrationbasedonexome-seqandRNA-seqanalysis. In the
53 samples that were sequenced, 779 unique non-synonymousmutations were de-
tected by exome-seq. These 779mutations spanned across 263 genes. Themajority
of these mutations are not shared between samples ( 5% of the mutations were
sharedbymore than2samples). Severaldrivergenemutationswere identifıed in this
study, including KRAS, TP53, PIK3CA, APC andHER2. HLA prediction based on
Exome-Seq and RNA-Seq data shows that 86.7% of the alleles predicted to be
present in 53 samples were concordant between the two RNA-seq datasets. The
predicted alleles based on exome-seq and RNA-seq results have 67-69% concor-
dance. Prediction of neo-epitopes show that HLA-binding neo-epitopes are more
frequent than TCR-binding ones, and that most neo-epitopes are private and not
shared between samples. Amore in-depth analysis of the tumormicroenvironment
was performed using the RNA-seq data. The epithelial, stromal and immune con-
tent of the tumors was comparable to tumors from TCGA CRC data. Next, the
immune cell compartment was further stratifıed into 7 different immune cell types
using signatures specifıc toCD8andCD4T,T-regulatory,NK,B-cells,Macrophages
andMyeloid derived suppressor cells (MDSC). The immunemake up of colorectal
cancer is dominated bymacrophages andMDSCs. Interestingly, both granulocytic
G- andmonocyticM-MDSCsarepresent together, supporting the idea thatMDSCs
confer an immune suppressivemicroenvironment in this cancer. Signifıcantly, high
MDSC infıltrated tumors showed upregulated expression of pro-tumorigenic insu-
lin-like growth factor pathway genes. Additionally, tumors with lower burden of
MDSCshowed signature of complement activation suggesting innate cell-mediated
anti-tumorigenic mechanisms of tumor control in CRC. These analyses provide
potential biomarkers to stratify CRCpatients based on their immune reactivity and
predict response to cancer immunotherapy drugs.
#414 Identifying selective vulnerabilities in colorectal cancer molecular
subtypes using in vivo functional genomic screens.Akira Inoue, Bahar Salim-
ian Rizi, Alessandro Carugo, Sahil Seth, Christopher Bristow, Giannicola Geno-
vese, Andrea Viale, David G. Menter, Scott Kopetz, Giulio F. Draetta. The Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX.
Colorectal cancer (CRC) is a leading cause of cancer-related morbidity
and mortality with signifıcantly heterogeneous features and drug responses.
Recently, the international Colorectal Cancer Subtyping Consortium iden-
tifıed four robust consensus molecular subtypes of CRC (CMS1-4) using
large-scale gene expression data. These fındings may enable us to identify
molecularly homogenous subsets of CRC patients and accelerate effective
drug development strategies. To identify potential therapeutic targets and
novel selective vulnerabilities in CRC molecular subtypes, we developed an
in vivo loss-of-function genomic screen using CRC patient-derived xeno-
grafts (PDXs) for each molecular subtype. Our PDX-derived CRC models
underwent comprehensive integrated molecular characterization of mRNA
profıles, DNA mutations, and histochemical profıles upon confırmed serial
retransplantation to determine whether characteristics of the subtypes are
recapitulated in vivo. Because the original CMS classifıcation algorithm was
trained and validated using Affymetrix data, profıling the PDX-derived cell
lines using this technology provided the most robust analysis of the CMS
subtypes. In vivo pooled short hairpin RNA (shRNA) screens rely on specifıc
elimination of individual shRNAs in a cell population and require that the
infected tumor cell population is adequately endowed with engraftment ca-
pacity when implanted into recipient mice. Therefore, we determined the
transduction effıciency of the PDXmodels, the frequency of tumor-initiating
cells, and the maximum library complexity allowed by each model. To iden-
tify targets that represent selective vulnerabilities in specifıc CRC molecular
subtypes, we screened each model in vivo with an shRNA library targeting
about 200 genes specifıcally belonging to U.S. Food and Drug Administra-
tion-approved targeted therapies (FDAome; 10 shRNAs/gene ). We lever-
aged redundant shRNA activity analysis to evaluate “hits” (or top-scoring
genes) emerging from our screening. We further applied ranking-based ana-
lytics in combination with integromic approaches (use of computational
packages to unravel relationships between -omics) to inform on selective
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CMS specifıc top-scoring genes. One of the benefıts of using an FDAome
library is the direct correspondence of target genes with clinically available
drugs. We therefore tested these drugs for validation in fully annotated
PDXs. These efforts, in association with systematic profıling of the CMS
subtypes at the patient level through adaptation of NanoString technology,
may enable us to stratify CRC patients who will benefıt from selective U.S.
Food and Drug Administration-approved drugs and to rapidly design suc-
cessful preclinical and clinical trials in CRC patients.
#415 In vivo shRNA library screening to identify novel targets for head
andneck squamous cell carcinoma.Curtis R. Pickering,1 TongxinXie,1Manish
Kumar,1 Ramya L. Parimi,1 Liang P. Yang,1 Jiping Wang,1 Sahil Seth,1 Christo-
pher A. Bristow,1 Alessandro Carugo,1 Frederick S. Robinson,1 Giulio F.
Draetta,1 Heath Skinner,1Mitchell J. Frederick,2 Jeffrey N.Myers1. 1The Univer-
sity of TexasMDAnderson Cancer Center, Houston, TX; 2Baylor College of Med-
icine, Houston, TX.
Head and neck squamous cell carcinoma (HNSCC) is a diverse group of
tumors from the upper aerodigestive tract that are treated primarily with
surgery, chemotherapy, and/or radiation. Recent genomic studies have char-
acterized the genomic alterations in HNSCC but they failed to identify novel
oncogenic drivers for therapeutic targeting. In order to identify novel targets
we have utilized an in vivo shRNA library screening platform in a panel of
genomically characterized HNSCC cell lines. The screens were performed
alone or in combination with platinum-based chemotherapy or radiation,
and the screening libraries included known druggable targets, DNA repair
genes, and HNSCC candidate driver genes. Initial results indicate that this in
vivo screening is able to identify targets that may not be found through
traditional in vitro screening approaches and related to tumor-stromal in-
teractions and metabolism. These genes emphasize the importance of in-
cluding the tumor microenvironment in studies to understand driver genes
and identify novel therapeutic interventions.
#416 Identifıcation of therapeutic combinations in glioblastoma using
personalized gene expression networks. Vasileios Stathias, Michele Forlin,
Bryce Allen, Stephan Schürer, Nagi G. Ayad. University of Miami, Miami, FL.
The goal of our study was to identify patient-specifıc gene expression
networks from Glioblastoma Patient-Derived Xenografts (PDXs) and deter-
mine novel therapeutic compound combinations using those networks. Gli-
oblastoma is the most common malignant primary adult brain tumor with a
standard of care consisting of maximal surgical resection followed by radio-
therapy and adjuvant temozolomide (TMZ) chemotherapy. However, de-
spite medical advances in the fıeld, recurrence is almost universal, suggesting
the need for more personalized and targeted therapeutic approaches. For
this, we obtained, transcriptional data from Glioblastoma PDXs and used
them to identify their respective differentially expressed genes. Patient-spe-
cifıc gene expression networks were then created and their biological rele-
vance was supplemented by integrating themwith TCGAGlioblastoma tran-
scriptional data. In order to identify compound combinations specifıc for
those networks, we used the extensive chemical perturbation signatures
from the Library of Network-based Cellular Signatures (LINCS). From the
large number of L1000 transcriptional data we extracted gene expression
signatures that were indicative of specifıc LINCS compounds. We then com-
pared those signatures to the patient-specifıc networks in order to prioritize
compound combinations that were inducing discordant transcriptional
changes in distinct sub-networks of the PDXs transcriptome. The most or-
thogonal compound combinations were then chosen and used in in-vitro cell
viability assays of Glioblastoma PDXs in order to evaluate their effectiveness.
The above process can be used to prioritize compound combinations with
potential therapeutic effect in a patient-specifıc manner.
#417 Defıning molecular mechanisms of resistance to glioblastoma im-
munity using a novel CRISPR/Cas9 in vivo loss-of-function screening plat-
form.Martha R. Neagu,1 Robert T.Manguso,1 Hans Pope,2Maria C. Speranza,2
Gordon J. Freeman,2 JohnDoench,3 ArleneH. Sharpe,1WilliamNicholasHain-
ing2. 1HarvardMedical School, Boston, MA; 2Dana Farber Cancer Institute, Bos-
ton, MA; 3Broad Institute of Harvard and MIT, Cambridge, MA.
OVERVIEW: Despite the impact of cancer immunotherapy, expanding its
clinical utility requires a rational method for identifying combination ther-
apies and resistance mechanisms. This is pertinent to glioblastoma (GBM),
where initial trials show uncertain response rates. Functional genomic
screens used to identify new therapies and escape mechanisms were gener-
ally conducted in vitro, where interaction with the immune system is absent.
Here we present the development of a high-throughput, in vivo, loss-of-
function screening platform for GBM immune-escape mechanisms. METH-
ODS: CT2A- and GL261-astrocytoma cells bearing Cas9-endonuclease were
engineered to express a library of barcoded single guide RNAs (sgRNAs).
These cells form tumors when implanted intracranially in immunocompe-
tent mice. Tumor-bearing mice were treated with vaccination or PD-1
checkpoint blockade. Dropout of sgRNAs targeting putative immune eva-
sion molecules or enrichment of sgRNAs mimicking resistance mechanisms
were detected using next-generation sequencing at the time of tumor im-
plantation and harvest post-immunotherapy. RESULTS: We fırst developed
an in vivo, pooled, loss-of-function genetic screen using Cas9/CRISPR ge-
nome editing in mouse transplantable tumors subjected to titratable, selec-
tive immune-pressure. Screening 2,400 genes expressed by melanoma cells
for those that synergize with or cause resistance to checkpoint blockade
recovered known immune-evasion molecules PD-L1 and CD47. Novel im-
munotherapy targets validated individually, identifying essential pathways
of immune-evasion. We then sought to recapitulate this approach in the
CNS, and showed that 500-1000 genes can be functionally screened under
graded immune-pressure. In optimized immune-competent CT2A and
GL261 GBM models, tumors derived from cancer stem cell CD133hi-rich
neurospheres were sensitive to immunotherapy and more aggressive and
infıltrative than tumors derived from adherent tumor cells. A neurosphere
based immune-competent model can be scaled up to a whole-genome screen
due to a shorter experimental time requirement and improved engraftment
allowing for functional screening of 1000 genes. We curated a GBM-spe-
cifıc library based on differential in vitro and in vivo gene expression profıles
of CT2A and GL261 cells exposed to graded immune pressure. We are now
screening this GBM-specifıc library in our optimized in vivo pooled loss-of-
function genetic screen using immune-pressure titration to identify novel
immunotherapy targets in GBM. CONCLUSIONS: This assay provides the
fırst high-throughput method for systematically identifying resistance
mechanisms and new candidate targets for immunotherapy in CNS tumors.
Our optimized model could be scaled up to whole-genome loss of function
screens, serving as an important tool for identifıcation of next-generation
and combination immunotherapies.
#418 Adaptive resistance to chemotherapy in triple-negative breast cancer
revealed by single cell DNA and RNA sequencing. Charissa Kim,1 Ruli Gao,1
Emi Sei,1 Rachel Brandt,1 Nicola Crosetto,2 Theodoros Foukakis,2 Nicholas
Navin1. 1The University of Texas MD Anderson Cancer Center, Houston, TX;
2Karolinska Institutet, Stockholm, Sweden.
Triple-negative breast cancer (TNBC) is an aggressive subtype that displays
extensive intratumor heterogeneity and frequently (46%) develops resistance to
neoadjuvant chemotherapy (NAC). Currently, the genomic basis of chemore-
sistance remains poorly understood. An important question is whether resis-
tance to chemotherapy is driven by the selection of rare pre-existing subclones
with genomic mutations and transcriptional programs that confer resistance to
chemotherapy (adaptive resistance) or by the spontaneous induction of new
mutations and expression changes that confer a resistant phenotype (acquired
resistance). To investigate this question we applied single cell DNA and RNA
sequencing methods and deep-exome sequencing to longitudinal time-point
samples collected from a cohort of 20 TNBC patients. Deep-exome sequencing
of the cohort at three time points revealed a random death model, wherein
multiple clones were targeted, as opposed to the selection of specifıc somatic
mutations. In contrast, single cell copy number profıling of 800 cells from 8
patients identifıed an adaptive resistance model, wherein minor subclones from
the pre-treatment tumors were selected and expanded in response to NAC.
Similarly, single cell RNA sequencing of8000 cells from 8 patients identifıed
subclones with chemoresistant phenotypes that were selected in response to
NAC, resulting in the expansion of the resistant tumormass. These data suggest
that chemoresistance evolves through the selection of copy number changes and
expression changes in signaling pathways associated with chemoresistance,
rather than point mutations. This adaptive resistance model has important
translational implications in clinical diagnostics, by suggesting that resistant
clones can be detected in TNBC patients prior to the administration of chemo-
therapy.
#419 Integrative analysis of multi-omics tumor profıles identifıes path-
ways associated with resistance to anti-HER2 therapy in early stage breast
cancer. Salendra Singh,1 Hannah Gilmore,1 Maysa Abu-Khalaf,2 George
Somlo,3 William Sikov,4 Lyndsay Harris,5 Vinay Varadan1. 1Case Western Re-
serve Univ., Cleveland, OH; 2Sidney KimmelMedical College at Thomas Jefferson
University, Philadelphia, PA; 3City of Hope National Med Center, Duarte, CA;
4Warren Alpert Medical School of Brown University, Providence, RI; 5National
Cancer Institute, Rockville, MD.
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Background: HER2 positive breast cancers are heterogeneous at both the
clinical and molecular levels, with the HER2-enriched subtype exhibiting
increased levels of immune infıltration signatures and the highest rate of
pathologic complete response (pCR), while the HER2-Basal subtype is resis-
tant to anti-HER2 therapy (Varadan et al, CCR 2016). Here we aim to char-
acterize the molecular underpinnings of response and their interaction with
increased immune infıltration across these HER2-subtypes using integrative
analyses of genomic and transcriptomic data from two multicenter trials
(DFCI 03-311 and BrUOG 211B). Methods: Fresh tumor core biopsies were
taken at baseline and a 2-week time point after a single dose of trastuzumab.
80 HER2 early breast cancer (EBC) patients were enrolled in the 03-311
trial, and 60 patients in the 211B trial. Biopsy samples were profıled for gene
expression (Microrrays:03-311; RNAseq:211B), somatic mutations (Whole-
exome sequencing: 211B; Targeted Sequencing: 03-311) and somatic copy-
number aberrations (SNP-arrays: 03-311; Whole-exome Sequencing: 211B).
Subtyping was performed using gene expression data and tumors were clas-
sifıed into HER2-Enriched, HER2-Luminal and HER2-Basal subtypes. Inte-
grative analysis of gene expression and copy-number data to infer signaling
network activities per sample, was performed using the recently developed
InFlo framework (Dimitrova et al, Oncogene 2016). Results: HER2-Basal
tumors exhibited lower average copy number for HER2 and were less likely
to have high-level amplifıcations of co-amplicons (e.g. 11q13, 20q13). In the
211B and 03-311 trials, respectively, 62% and 63% of somatic mutations
persisted after one dose of therapy, while 21% and 19% of mutations were
undetectable after one dose of therapy. Tumors harboring amplifıcations in
the 8p11 (FGFR1) genomic locus exhibited higher indices immune signa-
tures associated with macrophages (P0.0073) and T-cells (P  0.0493) in
211B, but this association did not achieve signifıcance in the 03-311 trial.
Integrative InFlo-based analysis of tumor gene expression and copy-number
profıles after one dose of trastuzumab in the 211B trial revealed signifıcantly
higher activity of signaling pathways associated with CD4 T-cells in the
responders (P0.008), while higher activity of mTOR pathway was observed
in non-responders (P0.0014). Conclusions: Changes in mutational profıles
over time may either be related to therapy-induced alterations of clonal
architecture or the consequence of intra-tumor heterogeneity, thus warrant-
ing further exploration. Integrative analysis of gene expression and copy-
number profıles reveal signaling pathways associated with response and re-
sistance, enabling the discovery of biomarkers of response to anti-HER2
therapy.
#420 Preclinical evaluation of the SF3B1 inhibitor E7107 in triple negative
breast cancer. Praveen Sridhar, Stefanie Chan, Ying-Jie Lock, Fabio Petrocca.
Boston University, Boston, MA.
Triple-negative breast cancers (TNBC) are the most aggressive subtype of
breast cancer and account for roughly 15%of humanbreast cancers.No effective
targeted therapies are currently available against these tumors, at least in part
due to their genetic and epigenetic heterogeneity. Yet, TNBCs are commonly
enriched for cells arrested in a progenitor-like state. We therefore performed a
genome-wide siRNA lethality screen to identify selective TNBC dependencies
associated with this particular phenotype in vitro. These studies led to the iden-
tifıcation of several spliceosome genes, including the core splicing factor SF3B1,
as selectively and recurrently essential for progenitor-like (or basal-A) TNBC
cell lines. On this basis, we examined the antitumor effect of E7107, a clinically
tested SF3B1 inhibitor, on multiple TNBC cell lines. In vitro, treatment with
E7107 for 24-48 hr selectively killed basal-A cell lines relative to differentiated
luminal cell lines, decreasing viability by40% or more in 5 of 6 basal-A lines
tested. E7107-treated cells appeared to die of apoptosis based on immunoblot-
ting for multiple apoptotic markers. In mice, E7107 (5 mg/kg i.v. for 4 consec-
utive days) suppressed the growth of preformed tumors by80% and50% in
2 different cell-line-derived xenograft models and was remarkably well-toler-
ated at this dose. Of note, tumor response in vivo closelymirrored cell sensitivity
in vitro, suggesting that in vitro analysis provides a fair estimate of TNBC re-
sponse to E7107 inmice. Amongst 2 additional patient-derived xenograft (PDX)
models tested, E7107 inhibited tumor growth by 50% in one model. Thus,
E7107 was therapeutically active against 3 of 4 xenograft models tested. Prelim-
inary mechanistic studies in vitro and in vivo pointed toMCL1 inactivation as a
major mechanism of action of E7107 in top responders. Together, these data
suggest that the spliceosome is a druggable target in TNBC, and that E7107 or
similar SF3B1 inhibitors could be effective in a TNBC subset that needs to be
further defıned.
#421 Comprehensive genomic analysis ofmetastatic breast cancers reveals
ESR1 fusions as a recurrentmechanismof endocrine therapy resistance.Ryan
J. Hartmaier,1 Nolan Priedigkeit,2 Laurie Gay,1 Michael E. Goldberg,1 James
Suh,1 Siraj Ali,1 Jeffery Ross,1 Michaela Tsai,3 Barbara Haley,4 Julio Peguero,5
Rena D. Callahan,6 Irina Sachelarie,7 John Cho,8 Amir Bahreini,2 Shannon L.
Puhalla,2 Steffı Oesterreich,2AjuMathew,2 PeterC. Lucas,2Nancy E.Davidson,2
Adam M. Brufsky,2 Philip J. Stephens,1 Juliann Chmielecki,1 Adrian V. Lee2.
1Foundation Medicine, Cambridge, MA; 2University of Pittsburgh Cancer Insti-
tute, Pittsburgh, PA; 3Minnesota Oncology, Minneapolis, MN; 4UT Southwestern
Medical Center, Dallas, TX; 5Memorial HermannHospital, Houston, TX; 6UCLA
Medical Center, Santa Monica, CA; 7Carlisle Regional Medical Center, Carlisle,
PA; 8New Bern Cancer Care, New Bern, NC.
Metastatic breast cancer is often intractable due to its inherent ability to over-
come current therapies. Genomic alterations are frequently responsible for ther-
apeutic resistance. To better understand genomic mechanisms of acquired re-
sistance in breast cancer we undertook a detailed characterization of single
nucleotide variation (SNV) and structural variation (SV) in paired primary-
metastasis metachronous tumors from 6 breast cancer patients (median time to
recurrence 7.3 years). In ER-positive recurrent tumors treated with endocrine
therapies, we identifıedmultiplemetastatic-acquired variants in ESR1 including
a novel constitutively active, ligand-independent ESR1-DAB2 gene fusion. Im-
portantly, this fusion resulted from a breakpoint in intron 4, retaining theDNA-
binding domain but eliminating the ligand-binding domain (LBD), concordant
to a similar fusion reported previously in a xenograft model. Hybrid capture
based genomic profıling from 7,800 breast cancers identifıed similar exon/
intron 4 fusions in 5 tumors with direct paired-read evidence. Using a novel
copy number shift detection strategy, 58 additional tumors showed indirect
evidence of a rearrangement at exon 4 based on a novel copy number shift
detection strategy. ESR1 fusion and copy number shift positive tumors are
strongly enriched inmetastatic disease (78%; p10-4) supporting their expected
involvement in endocrine therapy resistance. Clinical followupwas available for
7 patients. 6/7 tumors were clinically ER-positive and received extensive endo-
crine therapy with progressive disease. Together, these data indicate that ESR1
fusions involving exon/intron 4 are a recurrent, albeit rare, mechanism of endo-
crine therapy resistance in breast cancer. The absence of the LBD implies these
fusions will not respond to other ER targeted therapies. Additional studies are
needed to identify appropriate treatment options to overcome this mechanism
of resistance.
#422 Lymph node metastasis evolution drives immune evasion and tar-
geted therapy resistance in gastro-esophageal adenocarcinomas (GEAs).
MatthewN. Davies,1 Louise J. Barber,1 Georgia Spain,1 Filipa Lopes,1 Katharina
von Loga,1 Beatrice Griffıths,1 Andrew Woolston,1 Donat Alpar,1 Marta Go-
mez,1 Kamil A. Lipinski,1 Kerry Fenwick,1 Zakaria Eltahir,2 Stefano Lise,1 Emese
I. Agoston,3 Laszlo Harsanyi,3 Richard Marais,4 Andrew Wotherspoon,2 A
Szasz,3 Caroline Springer,1 Marco Gerlinger1. 1The Institute of Cancer Research,
London, United Kingdom; 2The Royal Marsden Hospital, London, United King-
dom; 3Semmelweis University, Budapest, Hungary; 4Cancer Research UK Man-
chester Institute, Manchester, United Kingdom.
GEAs are aggressive tumors in which several targeted therapy trials have
failed. We assessed intratumor heterogeneity (ITH) and its impact on progres-
sion and therapy failure by applying an 81-gene NGS panel and SNP array copy
number aberration (CNA) analysis to multiple primary tumor (T) regions and
lymph node (LN)metastases from 9GEAs. Analysis of 39 samples found ITH in
all cases. 8 chromosomally instable (CIN)GEAspredominantly evolved through
CNAs, with 17-76% of the genome affected by heterogeneous CNAs. A micro-
satellite instable GEA showed parallel evolution and diversifıed exclusively
through point mutations (58% ITH). This demonstrates ongoing genomic in-
stability rather than punctuated evolution and that specifıc instability mecha-
nisms impact evolutionary trajectories. LNmetastases contributedmore to ITH
(p0.01) than any anatomic location within T. Further, subclonal aberrations
that activate the Mitogen Activated Protein Kinase-pathway (MAPK-pw), in-
cluding ERBB3, ERK2, KRAS and NRAS amplifıcations (amp) and NRAS mu-
tations, were detected in LNmetastases from 4/8 CIN GEAs. Subclonal MAPK-
activating amp were enriched in LN (p0.019) compared to T regions that only
exhibited a single subclonal MET amp. Convergent evolution of LN subclones
across several GEAs suggests that selection pressures differ systematically be-
tween LN and T ecosystems. To assess the phenotypes established by MAPK-
activating amp evolution, we analyzed 135 published primary CIN subtype
GEAs. Cytolytic activity (CYT), estimating tumor immune recognition from
RNA expression data, correlated with the mutation load in GEAs with EGFR,
ERBB2 orMET amp (p0.04). In contrast, CYTdid not correlate withmutation
load in GEAs with KRAS or ERBB3 amp (p0.22, NRAS/ERK2: insuffıcient
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data), indicating that these specifıc alterations, that also recurrently evolved in
LN, may enable immune evasion. Downregulation of TAP and Class I MHC
genes (p0.05) in KRAS or ERBB3 ampGEAs suggested impaired antigen pro-
cessing and presentation as the mechanisms driving T cell immune evasion.
Moreover, ITH of MAPK-activating amp is likely to confer resistance to up-
stream tyrosine kinase inhibition. We used GEA cell lines with various MAPK-
activating amp (ERBB2, MET, NRAS) to investigate downstream MAPK-pw
inhibition as a novel strategy to broadly target heterogeneous subclones. Growth
control was incomplete with ERK- and MEK-inhibitors but the panRAF/SRC
inhibitor CCT196969 was effective in all lines, suggesting that it can effectively
intercept subclonal heterogeneity in GEAs. In conclusion, we identifıed ITH
with parallel and convergent evolution in 9/9 metastatic GEAs. Distinct selec-
tion pressures in LN foster the evolution of subclonal MAPK-activating amp
that decrease immunogenicity and drive evolutionary pre-adaptation to future
targeted drugs that can be intercepted by panRAF/SRC inhibitors.
#423 Detection of genetic alterations to predict the chemotherapeutic re-
sponses in unresectable pancreatic ductal adenocarcinomas. Joo Kyung Park,
Kwang Hyuck Lee, Donghyun Park, Woong-Yang Park, Dae-Soon Son, Jong
Kyun Lee, Kyu Taek Lee. Samsung Medical Center, Seoul, Republic of Korea.
Background & Aims: Next-generation sequencing (NGS) that enables the
analyses ofmassively parallel sequences of DNA can advance the understanding
of the underlying molecular pathophysiologies of cancer. Such recent genomic
analyses have revealed a complex mutational landscape for PDACs. The aims of
this study were to investigate the genomic profıle to predict the chemotherapy
response in unresectable PDACs. Methods: The total of 80 pathologically con-
fırmed PDACs were enrolled and genomic DNAwas extracted and quality con-
trol metrics of DNA analytes were measured. The specimens that passed a qual-
ity control test underwent targeted deep sequencing using a customized cancer
panel (CancerSCAN) enriched in the exons of 83 genes. Results: Clinical prog-
nostic factors associated with survival in PDAC were gender, tumor mass size,
stage and chemotherapy response rate. (P0.078, 0.009, 0.052 and0.001, re-
spectively). Multivariate Cox proportional-hazards analysis revealed chemo-
therapy response rate (P 0.001, hazard ratio (HR) 1.908, 95% CI, 1.281 to
2.840) is an independent prognostic factor. There were 56 (71%) and 9 (11%)
study patients who underwent gemcitabine based chemotherapy and FOLFIRI-
NOX respectively. Response rate of study patients were as follows; CRPR 14
(20%), SD (27%) andPD28 (41%). Therewere only 9 (16%) and 4 (50%) patients
whohadCRPR response gemcitabine based chemotherapy andFOLFIRINOX
respectively. Conclusion: Targeted sequencing using EUS-FNA specimens in
PDAC showed excellent compatibilities to analyze genomic profıles of PDACs.
Furthermore, novel genes associated with survival, metastasis and chemother-
apy response in PDAC were identifıed.
#424 Landscape of somaticmutations in drug-resistant acutemyeloid leu-
kemia. Samuli Eldfors,1 Mika Kontro,2 Yevhen Akimov,1 Olli Kallioniemi,1
Kimmo Porkka,2 Caroline Heckman1. 1Inst. for Molec. Medicine Finland
(FIMM), Helsinki, Finland; 2Helsinki University Central Hospital Cancer Center,
Helsinki, Finland.
Introduction: Most patients with acute myeloid leukemia (AML) initially re-
spond to cytarabine-anthracycline induction chemotherapy. However, in many
patients, the disease recurs in a lethal drug-resistant form. Somatic mutations
underlying the pathogenesis of AML have been extensively characterized by
sequencing of newly diagnosed AMLs. However, the mutations driving therapy
resistance and disease progression at relapse have not beenwell characterized. In
this study, we have exome sequenced a cohort of relapsed and refractory AMLs
and compared the landscape of somatic mutations at relapse to diagnosis phase
AMLs to identify mutations that contribute to therapy resistance and disease
progression. Materials andMethods: We performed exome sequencing of diag-
nosis phase AMLs (n70) and relapsed or primary refractory AMLs (n54).
Patients with AMLM3 subtype were excluded from the study. Paired diagnosis
and relapse samples were available from 27 patients. A skin biopsy was used as
the germline control. Nine patients had received an allogeneic hematopoietic
stem cell transplant before relapse. Somatic mutations were called using
varscan2 and copy number aberrations using copyCat. Since the identifıcation
of large insertions from next-generation sequencing data remains challenging
using existing algorithms, FLT3 internal tandem duplications (FLT3-ITDs)
were identifıed using a novel custom algorithm optimized for FLT3-ITD detec-
tion. Population variants were fıltered out to remove donor-derived germline
variants in chimeric post-transplant relapse samples. Results: Comparison of
somatic mutation frequencies in diagnosis and relapse and refractory samples
showed that on average relapsed tumors have a higher number of driver muta-
tions than tumors at diagnosis. WT1, TP53, CBL, IDH1 and PTPN11 were
mutated at a higher frequency in relapsed samples than at diagnosis, with 13 %,
11 %, 11 %, 9 % and 9 % of relapsed or refractory samples and 4 %, 6 %, 3 %, 4 %
and 7 % of diagnosis mutated respectively. Analysis of paired diagnosis-relapse
samples showed that in patients with WT1, CBL or PTPN11 mutation at diag-
nosis the second allele is frequently mutated or lost due to uniparental disomy
occurring at relapse. Conclusions: On average relapsed AMLs have a higher
number of driver mutations than diagnosis phase AMLs indicating that acqui-
sition of additional driver mutations contributes to relapse. AMLs frequently
acquire additional mutations in the same genes and pathways that already har-
bored mutations at diagnosis.
#425 SMRT® Sequencing of full-length androgen receptor isoforms in
prostate cancer reveals previously hidden drug resistant variants. Manish
Kohli,1 Yeung Ho,2 David W. Hillman,1 Jamie L. Van Etten,2 Christine Hen-
zler,2 Rendong Yang,2 Yingming Li,2 Elizabeth Tseng,3 Ting Hon,3 Tyson A.
Clark,3 LiguoWang,1 Kevin Silverstein,2 LieweiWang,1 ScottM. Dehm2. 1Mayo
Clinic, Rochester, MN; 2University of Minnesota, Minneapolis, MN; 3Pacifıc Bio-
sciences, Menlo Park, CA.
Prostate cancer is the most frequently diagnosed male cancer. For prostate
cancer that has progressed to an advanced or metastatic stage, androgen depri-
vation therapy (ADT) is the standard of care. ADT inhibits activity of the an-
drogen receptor (AR), a master regulator transcription factor in normal and
cancerous prostate cells. The major limitation of ADT is the development of
castration-resistant prostate cancer (CRPC), which is almost invariably due to
transcriptional re-activation of the AR. One mechanism of AR transcriptional
re-activation is expression of AR-V7, a truncated, constitutively active AR vari-
ant (AR-V) arising from alternative AR pre-mRNA splicing. Noteworthy,
AR-V7 is being developed as a predictive biomarker of primary resistance to
androgen receptor (AR)-targeted therapies in CRPC.Multiple additional AR-V
species are expressed in clinical CRPC, but the extent to which these may be
co-expressed with AR-V7 or predict resistance is not known. Here we utilized
long read sequencing to identify and quantify AR isoforms expressed in CRPC.
To unambiguously characterize all AR isoforms, we prepared Iso-Seq™ libraries
via 3’ rapid amplifıcation of cDNA ends (RACE) with RNA isolated from pros-
tate cancer cell lines and xenograft tissues using a forward primer anchored in
AR exon 1. 3’RACE reactions were subjected to single molecule, real-time
(SMRT®) long-read sequencing with a Pacifıc Biosciences RSII System. Our
work identifıed AR-V9 as a truncated isoform that is frequently co-expressed
with AR-V7 in CRPC. Mechanistically, our work re-annotated AR-V7 and
AR-V9 mRNAs, showing these two species shared a common 3’ terminal
exon containing separate splice acceptor sites. Taking into account this new
information, novel siRNAs and antibodies which could distinguish between
AR-V7 and AR-V9 were designed, validated and used to measure the relative
expression of these two AR isoforms in CRPC cells with a view to determin-
ing the potential of AR-V9 as a predictive biomarker of primary resistance to
AR-targeted therapies.
#426 Targeted genome profıling in patients with advanced hepatocellular
carcinoma treated with sorafenib. Wonseok Kang, Kyung Kim, Joon Hyeok
Lee, Ho Yeong Lim, Woong-Yang Park, Jeeyun Lee, Yong Han Paik. Samsung
Medical Center, SungkyunkwanUniversity School ofMedicine, Seoul, Republic of
Korea.
Background/Objectives: Sorafenib is the only approved targeted agent as fırst-
line treatment for advanced hepatocellular carcinoma (HCC). Unfortunately,
many HCC patients are initially not responsive to sorafenib. Due to anatomic
limitations and underlying liver dysfunction, genomic studies of HCC patients
have not been actively pursued yet compared to other solid tumors; especially, in
sorafenib-treated subset. In this study, we have retrospectively identifıed ad-
vanced HCC patients who had archival tumor tissues available for targeted
genomic sequencing and who had been treated with sorafenib. Methods: We
performed targeted genomic profıling for 381 cancer-related genes from 42
HCC (32 hepatitis B virus-related, 1 alcohol-related, 7 unknown) patients
treated with sorafenib at SamsungMedical Center, Seoul, Korea from July 2008
to October 2013. We excluded 2 patients who were lost to follow up for evalua-
tion of treatment response to sorafenib. Results: Of the 40 patients, there were 5
confırmed PRs, 7 SDs, and 28 PDs. In 40 patients, there were 6 CDKN2B ampli-
fıcations, 4 NTRK1 amplifıcations, 2 MET amplifıcations, 2 FGF19 amplifıca-
tions, 2 CCND1 amplifıcations, 1 EGFR amplifıcation, 1 FGF23 amplifıcation
and 1 CCNE1 amplifıcation. In cell cycle-related genes, those patients with ab-
errations were less likely to respond to sorafenib. Of note, two patients whose
tumor had CCND1 amplifıcations had de novo resistance to sorafenib. Conclu-
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Genomic Screening for Cancer Dependencies and Drug Response
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017108
sions: Our study demonstrates inter-patient heterogeneity in advanced HCC
patients and the role of cell cycle-associated genes in resistance mechanism to
sorafenib is being investigated.
#427 Apath towardsdetermining tumormutationburdenand identifying
neoantigens using next-generation sequencing (NGS). Alex So, Shannon Ka-
plan, Nai-yu Wang, Shile Zhang, Aaron Wise, Kristina Kruglyak, Karen
Gutekunst. Illumina, San Diego, CA.
Introduction: The recent clinical demonstrations that cancer immunotherapy
is effective for some patients, but not others has led to widespread interest in
identifying cancer genetic factors that can predict positive response. Impor-
tantly, it has been shown by various studies that tumormutation burden (TMB)
and predicted neoantigen load correlate with patient response to checkpoint
inhibitors. This project aims to develop a clinical next-generation sequencing
(NGS) assay that utilizes TMB and neoantigen information to guide cancer
immunotherapy selection. Experimental Procedures: Whole exome sequencing
(WES) and whole transcriptome sequencing (WTS) libraries were generated
using Illumina’s TruSeq® Exome and RNA Access library preparation kits, re-
spectively. The samples were pair-end sequenced (2x75bp) using HiSeq® 2000
and 2500 instruments. Data Summary: Here, we demonstrate a workflow using
tumor/normal WES and tumor-only WTS to determine expressed TMB. Using
theWES data, we were also able to accurately identify human leukocyte antigen
(HLA) major histocompatibility complex (MHC) Class I genes at four-digit
resolution. We then identifıed putative neoantigens, defıned as peptides with
mutated amino acids, that were expressed in the tumor samples and predicted to
bind to the respective HLA sequences. In addition, as a path towards developing
a clinical assay for TMB and neoantigen determination, we tested the ability of
reagents developed for Illumina’s Trusight® Tumor 170 panel to be used for an
exome panel. With workflow modifıcations, we achieved comparable quality of
sequencing metrics as compared to the TruSeq® Exome kit. Conclusion: Our
data demonstrate a path towards developing a clinical assay that can be used to
assess TMB and neoantigen candidates.
#428 Supporting neoantigen identifıcation for personalized cancer vac-
cines throughanalytical validationof anaugmented content enhanced (ACE)
exome.Ravi K.Alla, Jennifer Yen, SeanM. Boyle, RichardChen.Personalis, Inc.,
Menlo Park, CA.
The identifıcation of neoantigens has become a critical step in the devel-
opment of neoantigen-based personalized cancer vaccines and other immu-
notherapy applications. Since neoantigens can be generated from tumor
specifıc mutations in any expressed gene, the fırst step in identifıcation of
neoantigens typically involves deep exome and transcriptome sequencing on
the tumor and exome sequencing of the matched normal. As personalized
vaccines enter clinical trials with the potential for clinical use, there is a
growing need for strong analytical validation of these platforms. To address
this we have developed our ACE Exome (200X) and Transcriptome plat-
forms for neoantigen identifıcation which utilitize an augmented exome
approach designed to increase sensitivity for neoantigens in low complexity,
traditionally hard to sequencing regions. To enable this platform for neoan-
tigen based personalized cancer vaccines, we have performed a validation of
both our ACE Exome (tumor and normal) and ACE transcriptome platforms
for detecting DNA-based SNVs and Indels, as well as for RNA based small
variant and fusion calls. These are variant types are especially important for
neoantigen identifıcation. In this abstract we describe the ACE Exome vali-
dation. We used 11 cancer cell lines and their matched normals to assess
analytical sensitivity and limits of detection (LOD) for small variant (SNV
and Indel) detection using our ACE exome and Tumor Normal bioinformat-
ics pipeline. We identifıed a gold set of variants, 875 SNVs and 19 Indels that
were previously validated in these 11 cell lines (COSMIC, CCLE and Sanger
Sequencing confırmed variants). These gold set variants were used to calcu-
late our analytical sensitivity (percent of gold variants detected across the 11
cell line pairs using our assay). To determine our LOD, we chose 3 of the 11
cancer cell lines and created 6 dilutions (5%, 10%, 20%, 30%, 50% and 80%
tumor purity) with their matched normal. We then determined Positive
Predictive Agreement (PPA, percent of pure cell line variants detected in a
diluted samples) and False Discovery Rate (FDR, percent of erroneously
detected variants in the diluted sample that were not detected in the pure cell
lines) metrics for variants across different minor allelic frequencies (MAF)
in the diluted samples. The ACE “Tumor Normal” Exome assay had a high
sensitivity of 98% for SNVs and 95% for Indels. The assay also showed robust
PPA (sensitivity) of 97% and FDR (specifıcity) of 2% for SNVs withMAF
10% and PPA of 87% and FDR of 3% for Indels with MAF  10%. We
demonstrate that the ACE “Tumor Normal” Exome assay is highly accurate
for identifıcation of SNVs and Indels in cancer exomes. With high analytical
sensitivity, PPA and low FDR we believe this assay provides augmented
ability to detect cancer driver and potential neoantigen generatingmutations
across various tumor types.
#429 Integrated genomic DNA and RNA profıling to predict cancer im-
munotherapy response. Pan Du, Xiaohong Wang, Zhixin Zhao, Huiquang
Wang, Shidong Jia. Predicine Inc, Hayward, CA.
Immunotherapy response varies widely, making it diffıcult for physicians to
knowwhether immunotherapy will be effective for a given patient. Recent stud-
ies have reported that patients with high PD-L1 gene expression are likely to
respond to checkpoint blocking drugs, but there are still many patients whose
tumor test for the PD-L1 protein are negative and can respond to the drugs. In
addition to the potential link between mismatch repair (MMR) gene mutations
and clinical response to anti-PD1 immunotherapy drug, recent fındings show
that tumor mutation burden and microsatellite instable (MSI) are good indica-
tors of the cancer immunotherapy responses. Using Predicine’s proprietary
Gene RADAR (RNA and DNA single molecular digital Readings) technology,
here we report the development of PrediSeq-CI (Cancer Immunotherapy) panel
for comprehensive genomic profıling of DNA and RNA that are associated with
cancer immunotherapy response. The panel has been tested using both tissue
biopsy and plasma samples. The development of PrediSeq-CI test has potential
to enable precision medicine in cancer immunotherapy. Finally, we also devel-
oped a liquid biopsy droplet digital PCR test to measure PD-L1 expression in
blood.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Metabolic Pathways in Cancer
#430 Combination of CB-839 and everolimus is effective in inhibiting
growth of endocrine resistant breast cancer in vivo. Yassi Fallah,1 Diane M.
Demas,1 Susan Demo,2 Ayesha N. Shajahan-Haq1. 1Georgetown Lombardi
Comp. Cancer Ctr., Washington, DC; 2Calithera Biosciences, South San Fran-
cisco, CA.
About 70%of all breast cancers are estrogen receptor alphapositive (ER).Anti-
hormone therapysuchasantiestrogensareoftenused to treatERbreast cancerbut
breast cancer cells can develop resistance to these drugs (endocrine resistance). Un-
fortunately, 50% percent of all antiestrogen treated tumors eventually develop
endocrine resistance, and therefore, there is an urgent need to fındways to treat this
incurable disease.We have shown that endocrine resistant breast cancer cells show
an increased dependence on the amino acid glutamine and this process is regulated
by MYC activation via the unfolded protein response (UPR). Metabolites of glu-
tamine such as glutamate and proline are signifıcantly elevated in endocrine resis-
tant cells. Cellular changes in glutamine are sensed by the mammalian target of
rapamycin (mTOR) complex, mTORC1, which is known to be deregulated in en-
docrine resistant breast cancer. In this study, we used human antiestrogen (Fulves-
trant/Faslodex or Tamoxifen) sensitive and resistant ER breast cancer cells and
xenografts to test the effıcacy of CB-839, an anti-glutaminase, and everolimus
(Afınitor), a mTORC1 inhibitor. Combination of CB-839 and everolimus, but not
each drug alone, inhibited growth of antiestrogen resistant tumors compared to
vehicle alone at 4 weeks post-treatment. The combination treatment did not signif-
icantly inhibit growth of antiestrogen sensitive tumors comparedwith its respective
vehicle alone treatment. Thus, a combination strategy that targets glutaminedepen-
dence and increasedmTORactivationmaybe anovel strategy in treating endocrine
resistant breast cancer.
#431 IDH1-mutated gliomas rely on anaplerosis of glutamate and lactate
whereas IDH1 wild-type gliomas rely on glycolysis and acetate anaplerosis.
MohammedKhurshed,1 Krissie Lenting,2 Remco J.Molenaar,1WilliamP. Leen-
ders,2 Cornelis J. van Noorden1. 1Academic Medical Center, Amsterdam, Neth-
erlands; 2Radboudumc, Amsterdam, Netherlands.
Hotspot mutations in isocitrate dehydrogenase 1 (IDH1MT) initiate low grade
glioma (LGG) and secondary glioblastoma and induce neomorphic activity that
converts -ketoglutarate (-KG) to the oncometabolite D-2-hydroxyglutarate (D-
2-HG). This causes metabolic rewiring that is not fully understood and in vitro
studies have shown that IDH1MT cancer cells rely on glutaminolysis, providing cells
with -KG via activities of glutaminase (GLS) and glutamate dehydrogenase
(GLUD). Here, we fırst show by in silico analysis of 269 IDH1wild-type (IDH1WT)
and 408 IDH1MT gliomas, obtained from the The Cancer Genome Atlas (TCGA)
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database, that IDH1WT gliomas have high expression levels of genes encoding for
enzymes that are involved in glycolysis and acetate anaplerosis. On the other hand,
the tricarboxylic acid (TCA) cycle, rather than glycolytic lactate production, is the
predominant metabolic pathway in IDH1MT gliomas and is driven by lactate and
glutamate anaplerosis to facilitate production of -KG, and ultimately D-2-HG.
IDH1WT- and IDH1MT-related differences in expression were found in both LGG
and glioblastoma. Furthermore, via in situ enzymatic activity mapping, we show in
human gliomas and in xenocraft models that GLUD activity is increased and GLS
activity is decreased in IDH1MTglioma, indicating that IDH1MTgliomasdependon
glutamatolysis, rather than glutaminolysis. We show that transcript levels in our
xenocraft models are in good agreement with our in silico analysis of the TCGA
database. Finally, we confırmed the glutamate dependency of IDH1MT gliomas by
MRS-flux analysis, whereas IDH1WT gliomas show high lactate production. Taken
together,we show that IDH1WTgliomashave a typicalWarburgphenotype and rely
on acetate anaplerosis whereas IDH1MT gliomas are glutamate and lactate depen-
dent. Thismetabolic rewiring in IDH1MT glioma, enables targeting of glutaminoly-
sis rather than direct inhibition of IDH1MT for therapy. It diminishes the supply of
glutamate-derived-KGanddirectly inhibits theproductionofD-2-HGandsimul-
taneously worsen the redox status of the glioma cells by inhibiting NAD(P)H pro-
duction by GLUD. A candidate drug to inhibit GLUD is epigallocatechin-3-gallate
gallate, a component of green tea that is currently receiving high interest as anti-
cancer agent.
#432 xCT inhibition disrupts redox homeostasis in CD44v-expressing tu-
mor cells showing glutaminolytic metabolism in head and neck squamous
cell carcinoma. Shogo Okazaki,1 Kenji Tsuchihashi,2 Oltea Sampetrean,1
Hideyuki Saya,1 Osamu Nagano1. 1Institute for Advanced Medical Research,
School of Medicine, Keio University, Tokyo, Japan; 2Kyushu University Graduate
School of Medical Sciences, Fukuoka City, Japan.
Metabolic changes favoring aerobic glycolysis and glutaminolysis may influ-
ence the sensitivity of tumor cells to anticancer drugs. We previously showed
that sulfasalazine, an inhibitor of xCT-dependent cystine transport, selectively
induces oxidative damage in undifferentiated tumor cells that express CD44
variant (CD44v) at a high level, without affecting CD44v-negative differentiated
tumor cells, in head and neck squamous cell carcinoma (HNSCC). However,
whether metabolic changes contribute to the xCT dependency of CD44v-ex-
pressing HNSCC cells has remained unknown. Here we show that CD44v-ex-
pressing HNSCC cells manifest a highly glutaminolytic phenotype and consti-
tutively generate reactive oxygen species through glutamine metabolism
pathway, and that xCT plays a key role in maintaining redox homeostasis in
these cells. Inhibition of xCT suppressed the consumption of glutamine without
affecting that of glucose in these cells, indicating that CD44v-expressing HN-
SCC cells also rely on xCT for maintenance of glutaminolysis. Furthermore,
administration of sulfasalazine, but not that of the anticancer drug cisplatin,
selectively depleted CD44v-expressing undifferentiated tumor cells positive for
the glutamine transporter ASCT2 in human HNSCC tumors formed in nude
mice. Targeting of xCT is thus a potential therapeutic approach for ASCT2-
expressing HNSCC tumors in which cellular metabolism is shifted toward en-
hanced glutaminolysis.
#433 Glycogen accumulation in aggressive breast cancers during hypoxic
exposure.Megan Altemus, Joel Yates, ZhiFen Wu, LiWei Bao, Sofıa Merajver.
University of Michigan, Ann Arbor, MI.
Isolation of specifıc metabolic alterations in aggressive triple negative and
inflammatory breast cancers represents a compelling avenue for the develop-
ment of treatments for these diseases. The ability of cancer to utilize diverse
metabolic pathways to modulate increased survival and proliferation is well
established. Indeed, we have previously described a series of metabolic adapta-
tions in the triple negative inflammatory breast cancer cell line SUM149 and
demonstrated a role for the small GTPase RhoC in the metabolic phenotype of
the cell line. In this work we seek to describe a survival mechanism for cancer
cells that are subjected to hypoxic environments. Hypoxic survival or growth is
often necessitated at the center of a growing tumor mass or if the tumor is
growing in the lymphatic system, as is often the case for inflammatory breast
cancers. Here we investigate the regulation of glycogen levels in breast cancer
and normal-like cell lines in atmospheric and 1% oxygen environments. Re-
serves of glucose are typically stored in liver and muscle cells as the polysaccha-
ride glycogen. Elevated levels of glycogen have previously been observed in
various cancers, and recent studies have implicated the importance of glycogen
metabolism in promoting cancer cell survival. We hypothesize that aggressive
breast cancers utilize modifıcations of the glycogen synthesis and degradation
pathways to provide nutritional flexibility as they proliferate and invade into
diverse environments. MCF10A, SUM149, and SUM190 cell lines demonstrate
a greater than 10-fold increase in glycogen accumulation when subjected to
hypoxic growth conditions. MDA-MB-231 cells also increase glycogen storage,
though at levels on the order of 2-3 times higher in hypoxia when compared to
normoxic growth. Conditionedmedia for all cell lines in normoxic and hypoxic
conditions were analyzed for glucose and lactate levels to determine changes in
metabolite consumption. The data presented indicate an unexpected accumu-
lation of glycogen in response to hypoxic conditions. Studies to determine the
mechanisms throughwhich these changes occur andwhy they are important for
continued survival and growth of the cancer cells are ongoing and will be pre-
sented.
#434 Characterizing the role of serine metabolism in pediatric sarcomas.
Sameer Issaq,1 Ria Kidner,1 Jason Rohde,2 Matthew Boxer,2 Lee Helman1. 1Na-
tional Cancer Institute, Bethesda, MD; 2National Institutes of Health, Rockville,
MD.
Sarcomas represent a diverse group of malignancies with unique molecular
andpathological characteristics. In order to improve sarcoma treatment, a better
understanding of the alterations associated with specifıc sarcoma subtypes is
critically important. Renewed interest in the altered metabolic properties of
cancer cells has led to an exploration of targeting metabolic dependencies as a
novel therapeutic strategy. Metabolism of the amino acid serine is frequently
altered in cancer, supporting a number of critical biological processes, including
protein, lipid, and nucleotide synthesis, and redox balance. The fırst, rate-limit-
ing step in the serine synthesis pathway is catalyzed by the enzyme 3-phospho-
glycerate dehydrogenase (PHGDH), which is overexpressed in several cancers.
Previous work has shown that PHGDH loss or inhibition is selectively toxic to
cancer cells with high PHGDH expression or increased flux through the serine
synthesis pathway. In this study, we have characterized the dependency of pedi-
atric sarcomas on serine metabolism by examining expression of PHGDH in
Ewing sarcoma and rhabdomyosarcoma cell lines, and evaluating the effects of
PHGDH inhibition and serine deprivation on cellular proliferation and bioen-
ergetic properties. We show that PHGDH is highly expressed in pediatric
sarcoma cell lines, and that PHGDH knockdown resulted in decreased prolifer-
ation, especially under conditions of serine limitation.Moreover, pharmacolog-
ical inhibition of PHGDHresulted in a dose-dependent decrease in proliferation
andmitochondrial bioenergetic function. Furthermore, individual sarcoma cell
lines were differentially sensitive to serine deprivation, indicating that some
sarcoma cells may depend on extracellular serine in addition to de novo serine
synthesis. Our fındings suggest that the dependency of pediatric sarcomas on
serine metabolism should be further investigated in order to identify vulnera-
bilities that could be targeted for potential therapeutic benefıt.
#435 Regulation of macropinocytosis-dependent cell survival in pancre-
atic cancer cells. Sung Eun Kim, Man-Tzu Wang, Frank McCormick. UCSF,
San Francisco, CA.
Cancer cells utilize multiple scavenging mechanisms to support growth in
nutrient-poor, hypoxic environments. Signaling pathways to accommodate
thesemechanismsmay not be required for oncogenesis per se but are crucial for
cancer cell survival. These processes, known as non-oncogene addiction, can be
conferred by specifıc oncogenes that reprogram metabolism or by the tumor
microenvironment. Understanding how these pathways are regulated can pro-
vide novel opportunities for therapeutic intervention. Studies showed that
KRAS-mutant cancer cells, including pancreatic ductal adenocarcinoma
(PDAC), upregulate macropinocytosis, a caveolin- and clathrin-independent
endocytic process, to import extracellular protein to support growth upon nu-
trient depletion. Similarly, high levels of macropinocytic uptake are observed in
PDACmurinemodels and also in human PDAC specimens. This process serves
as a scavengingmechanism for cancer cells to survive andproliferate in nutrient-
deprived tumor microenvironments. Thus, uncovering the key players of this
pathway and the mechanisms underlying their regulation will be important to
fınd potential therapeutic targets. Here, we used the Informer set of small mol-
ecules to screen regulators of survival in culture conditions supplemented with
either glutamine or extracellular protein. The Informer set drug library consists
of small molecules including FDA-approved drugs and clinical candidates that
have high selectivity for their targets and regulate many cellular pathways. We
fınd that survival of cells grown in conditions supplemented with glutamine or
exogenous protein is differentially regulated by distinct drug subsets. This sug-
gests that different pathways of nutrient uptake, processing, and utilization are
used in cells depending on the nutrient source. Further examination to deter-
mine the mechanism of pathway inhibition and applicability may unravel po-
tential uses for therapeutics.
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#436 Folate cycle represents a new metabolic vulnerability for hepatocel-
lular carcinoma treatment. Derek Lee, Iris Ming-Jing Xu, David Kung-Chun
Chiu, RobinKit-HoLai, Chun-MingWong, IreneOi-LinNg, CarmenChak-Lui
Wong. The University of Hong Kong, Hong Kong.
Hepatocellular carcinoma (HCC), primary liver cancer, ranks the third most
lethal cancerworldwide due to late symptompresentation and lack of promising
curative therapy.Metabolic reprogramming has been recognized as amajor and
new hallmark of cancer in recent years. Better understanding of its underpin-
ning molecular mechanisms favoring cancer growth will be crucial for the de-
velopment of effective HCC therapeutics. The folate cycle fuels metabolic pro-
cesses and the production of metabolites essential to cell growth and
tumorigenesis maintenance. Through the shuttling of a single carbon unit by a
folate derivative through the tetrahydrofolate (THF) backbone in the cytoplas-
mic and mitochondrial compartments, metabolites like NADPH - a major cel-
lular antioxidant for redox balance, s-adenosylmethionine (SAM) - precursor of
DNA and histonemethylation, and pyrimidine and purine - the building blocks
of DNA are produced.We found folate to be indispensable forHCC cell growth.
Furthermore, methylene-THF dehydrogenase 1-like (MTHFD1L), a key en-
zyme facilitating the folate cycle from the mitochondria, was found to be signif-
icantly up-regulated in HCC with association to poorer clinical features for
patients. Genetic inhibition of MTHFD1L by knockdown and knockout by
shRNA and CRISPR-Cas9 systems, respectively, blocked NADPH production.
Rapid elevation in oxidative stress induced DNA damage and cell cycle delay;
ultimately inhibiting HCC proliferation. Binding of the transcription factor
NRF2, a potent protector of oxidative stress, and MTHFD1L was confırmed by
ChIP assay. NRF2 over-expression using the CRISPR-activating system inHCC
cells further highlighted the dependent relationship between NRF2 and
MTHFD1L.Metabolomics analysis showed thatMTHFD1L knockdown caused
a disruption to the folate cycle and accumulation of serine. Surprisingly,
MTHFD1L knockdown did not reduce the levels of SAM and nucleotides.
Knockdown of MTHFD1L in HCC cells signifıcantly inhibited primary liver
tumor growth and lungmetastasis in orthotopic liver implantationmodel. Ther-
apeutically, the administration of methotrexate, an anti-folate agent, sensitized
HCC cells towards Sorafenib treatment both in vitro and vivo. The folate cycle
represents a metabolic vulnerability and attractive therapeutic target for HCC.
Inhibition of MTHFD1L disrupts the folate cycle and sensitizes HCC cells to-
wards its convention treatment agent, Sorafenib in various HCCmousemodels.
Our investigationunravels ametabolic vulnerability in cancerwhich contributes
to better understanding and is benefıcial for the development of precise inhibi-
tors specifıcally targeting associated pathways.
#437 Stromal support of pancreatic tumormetabolism.CostasA. Lyssiotis.
University of Michigan, Ann Arbor, MI.
Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive disease charac-
terized by a prominent desmoplastic stromal reaction and deregulated metabo-
lism. The role of stroma in PDACbiology is complex and has been shown to play
critical roles that may differ depending on the biological context. The intense
stromal reaction also impacts the vasculature, leading to a highly hypoxic and
nutrient poor environment. As such, these tumorsmust adapt hownutrients are
captured and utilized to support their metabolic needs. In this talk, I will de-
scribe how stromal-associated pancreatic stellate cells (PSCs) are critical for
PDACmetabolism through the secretion of non-essential amino acids (NEAA).
Specifıcally, we uncovered an undescribed role for alanine, which outcompetes
glucose and glutamine-derived carbon in PDAC to fuel the tricarboxylic acid
(TCA) cycle, and thus NEAA and lipid biosynthesis. This shift in fuel sources
decreases the dependence on glucose and serum-derived nutrients, which are
limiting in the pancreatic tumor microenvironment. Moreover, we demon-
strated that PSC alanine secretion is dependent on PSC autophagy, a process
stimulated by the cancer cells. Thus, our results demonstrate a novel metabolic
crosstalk between PSCs and cancer cells, with PSC-derived alanine as an alter-
native carbon source, and highlight a previously unappreciated metabolic net-
work within pancreatic tumors where diverse fuel sources are utilized to pro-
mote growth in an austere tumor microenvironment.
#438 Cholesterol biosynthesis is a critical metabolic dependency in pan-
creatic cancer. Linara Gabitova, Alena Klochkova, Diana Restifo, Aleksandra
Mazitova, EdnaCukierman, TiffıneyHartman, Igor Astsaturov. Fox Chase Can-
cer Center, Philadelphia, PA.
Pancreatic cancer is rapidly rising to become the 2nd leading cause of
cancer deaths by 2020 in the USA. The rise in pancreatic cancer incidence is
paralleled by the epidemic of obesity, type 2 diabetes, and associated increase
in blood cholesterol, although mechanistic explanations for this are cur-
rently unknown. We and others have demonstrated that cancers with acti-
vated EGFR and KRAS signaling have increased demands for cholesterol and
are vulnerable to interference with cholesterol uptake or endogenous cho-
lesterol biosynthesis. We recently identifıed a metabolic step in the distal
cholesterol pathway, mediated by SC4MOL and NSDHL enzymes, as a crit-
ical regulator of cell growth in the keratinocyte model of KRAS-induced
carcinogenesis via the LXR agonistic effect of accumulating C4-methyl-
sterols. Based on these preliminary data, we set out to test if pancreatic
cancer initiation and progression depend on accelerated cholesterol biosyn-
thesis in a genetic mouse model containing a conditional cholesterol path-
way enzyme defıciency (conditional knockout of Nsdhlf/f) in the context of
pancreatic cancer development in KPC mice (LSL-KrasG12D;Tp53f/f;Pdx1-
Cre). Results: Conditional inactivation of NSDHL alone in pancreatic tissue
during normal development produced no apparent phenotype. As expected,
the NSDHL-suffıcient KPCmice as well as heterozygous Nsdhlf/ littermates
did not survive beyond 8 weeks of age due to rapid development of progres-
sive pancreatic tumors showing complete displacement of pancreatic tissue
with adenocarcinoma and high-grade PanIN lesions. Contrastingly, the sur-
vival of pancreatic conditional NSDHL-null mice was signifıcantly extended
beyond the median survival of 50 days in NSDHL-suffıcient age-matched
controls. Furthermore, the progression of pancreatic lesions from ADM to
PanIN3 was remarkably delayed on NSDHL-null background, with only a
proportion of animals developing adenocarcinoma. Evaluation of pancreatic
tissues revealed a dramatic reduction of tumor-induced desmoplasia at all
stages of pancreatic cancer development. Our ongoing studies will address
the role of cholesterol metabolism in pancreatic cancer progression via reg-
ulation of tumor-specifıc production of stroma-recruiting growth factors.
Conclusions: Our studies demonstrated for the fırst time essential genetic
evidence for metabolic dependency of pancreatic cancer on cholesterol me-
tabolism. We identifıed NSDHL as a critical target in the endogenous path-
way of cholesterol biosynthesis, and determined that blockade of NSDHL
has dramatic consequences on the reciprocal signaling between the KRAS-
transformed pancreatic cancer cells and the stroma.
#439 Metabolic flux analysis reveals targets to sensitize chemoresistance
in acute myeloid leukemia induced by mesenchymal stromal cell-derived
exosomes. Abhinav Achreja,1 Hongyun Zhao,1 Ziwen Zhu,1 Jonathan Gersz-
berg,1 Marina Y. Konopleva,2 Michael Andreeff,2 Deepak Nagrath1. 1University
of Michigan, Ann Arbor, MI; 2The University of Texas MD Anderson Cancer
Center, Houston, TX.
The tumormicroenvironment has a pleiotropic role in supporting cancer cell
growth, metastasis and drug resistance. Exosomes from mesenchymal stromal
cells (MSC) were found to regulate metabolism of acute myeloid leukemia
(AML) cells that led to a chemoresistant phenotype. Exosomes carry a host of
proteins, nucleotides and metabolites that can induce metabolic reprogram-
ming recipient cells via direct supply of metabolite cargo or through signaling.
We utilized 13C tracer techniques and two metabolic flux analysis techniques to
reveal the mechanism of metabolic reprogramming induced by MSC-derived
exosomes. First, 13C metabolic flux analysis was used to quantify intracellular
fluxes of central carbon, amino acids and fatty acid metabolism in AML cells
cultured with and without exosomes in media with 13C substrates. Second, we
employed a novel technique, exosome-mediated metabolic flux analysis (Exo-
MFA), to estimate direct support provided by metabolite supply from exosome
cargo by introducing 13C-labeled exosomes. The combined analysis dissected
the metabolite supply from exosome cargo from the overall reprogramming of
metabolic pathways due to exosomes. Our results revealed key metabolic path-
ways that could be targeted to inhibit exosome-induced reprogramming to re-
verse the chemoresistant phenotype.
#440 The oncogenic activity of a pro-oxidant intracellular milieu is
associated with redox dependent activation of NF-kB. Michelle Y. Yee,
Stephen J. Chong, Shazib Pervaiz. National Univ. of Singapore, Singapore,
Singapore.
Evidence over the years has highlighted that intracellular redox status
plays a critical role in determining cell fate. To date, we have shown that a
pro-oxidant milieu, specifıcally a mild elevation of intracellular superoxide,
promotes cancer cell survival and chemoresistance. To that end, we demon-
strated in vitro that elevated superoxide, upon silencing of superoxide dis-
mutase (SOD1), resulted in sustained phosphorylation of Bcl-2 at serine 70,
thereby stabilizing its anti-apoptotic activity. These fındings were corrobo-
rated by the abundance of Serine 70 Bcl2-phosphorylation and low SOD1
expression in lysates of patients with aggressive lymphomas and/or disease
with poor prognosis. In addition to the anti-apoptotic protein Bcl-2, the
pro-inflammatory transcription factor nuclear factor kappa B (NF-B)- me-
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diated signaling was also shown to be modulated by intracellular redox mi-
lieu. As constitutive activation of NF-B has been reported in various human
tumors, which is often associated with malignant progression and chemo-
therapeutic resistance, here we set out to investigate whether a pro-oxidant
environment, specifıcally the upregulation of intracellular superoxide, was
associated with the induction of NF-B transcriptional activity. Indeed, we
demonstrate that elevated intracellular superoxide via the pharmacological
inhibition and genetic silencing of SOD1 results in enhanced activation of
canonical NF-B signalling. This is accompanied by increased p65 nuclear
localization and transcription of NF-B regulated genes, which potentially
confer survival advantages to tumour cells upon chemotherapeutic treat-
ments. Considering the association between NF-kB activation, chronic in-
flammation and the process of carcinogenesis, these preliminary data pro-
vide a novel mechanism of activation of this master transcriptional factor
with potential therapeutic implications.
#441 GOT1 regulates anaplerotic glutamine metabolism under chronic
acidosis stress in pancreatic cancer. Jaime Abrego, Venugopal Gunda, Enza
Vernucci, Surendra Shukla, Ryan J. King, AneeshaDasgupta, Nina Chaika, Pan-
kaj Kumar Singh. UNMC Eppley Inst. for Cancer Research, Omaha, NE.
Epithelial-cell derived tumors exhibit theWarburg effect that is characterized
by an increased rate of glycolysis and lactate release, as well as, reduced oxidative
metabolism. It is known that these metabolic alterations of cancer cells result in
a tumor microenvironment with a lower pH than that of the plasma. However,
little is known regarding the physiology andmetabolismof cancer cells enduring
chronic acidosis. Here, we cultured pancreatic cancer cells in chronic acidosis,
i.e. pH 6.9 to 7.0, and observed a shift from glycolytic metabolism to oxidative
metabolism that also results in reduced cell growth and increased intracellular
ROS levels. We identifıed that this is due to an increase in glutamine uptake and
increased expression of the transaminase enzyme GOT1 that enhances glu-
tamine metabolism. Survival in low pH is reduced upon depletion of GOT1 due
to further increased intracellular ROS levels. Thus, GOT1 plays an important
role in energy metabolism and ROS balance in chronic acidosis stress. Our
studies suggest the therapeutic potential of targeting anaplerotic glutamine me-
tabolism in pancreatic cancer.
#442 Smallmolecule inhibitors of SHMT1/2 validate serinemetabolismas
a target in the treatment of c-Myc positive solid tumors. Tomasz Rzymski,
Anna Wrobel, Karolina Pyziak, Agnieszka Sroka, Marta Sowinska, Agnieszka
Dreas, Marcin Krol, Pawel Guzik, Agnieszka Adamus, Agnieszka Przybylowicz,
Katarzyna Hamara, Magdalena Sieprawska-Lupa, Artur Biela, Krzysztof Br-
zozka. Selvita S.A., Krakow, Poland.
Manyoncogenesmodulatemetabolic pathways and alteredmetabolism is one
of the hallmarks of cancer. In order to sustain proliferation, cell growth and
adopt to a very specifıc tumor microenvironment, cancer cells have to undergo
metabolic reprogramming. Increased uptake of glucose, consumed in anaerobic
manner, allows to maintain essential bioenergetic and biosynthetic pathways.
Various reports indicated that many cancers cells are crucially dependent on
serine, which could be either imported or synthesized by the serine synthesis
pathway (SSP) branched from glycolysis. Serine can be converted to glycine by
Serine Hydroxymethyltransferases isoforms 1 and 2 (SHMT1/2), which provide
also carbon for the folate cycle. There is a growing interest in targeting SSP and
SHMT1/2 have been proposed as druggable targets for the treatment of various
cancers. One of the major challenges is validation of these concepts by high
quality pharmacological and genetic tools, particularly in the context of high
tumor heterogeneity, artifıcial tissue culture conditions and many branching
points of tumor metabolism, which eventually result in acquired resistance. We
have identifıed and characterized a series of sub micromolar dual SHMT1/2
inhibitors. Affınity of these compounds to protein targets has been confırmed in
biochemical and binding assays and further corroborated by X-ray crystallogra-
phy studies. In order to confırm effıcacy of these compounds in cancer cells, both
sensitive and resistant cells to the inhibition of SSP have been identifıed by using
conditioned serine and glycine depleted media. Moreover functional roles of
both paralogs: SHMT1, which fuels cytoplasmic folate cycle and SHMT2, which
is responsible for the mitochondrial branch, were further confırmed by gene
knockdown studies. Cell lines resistant to depletion of serine in cell culture
media were characterized by elevated levels of proteins involved in the synthesis
of serine, namely PHGDH, PSAT1, SHMT2, c-Myc amplifıcation and increased
13C flux from glucose to serine and glycine. Metabolic flux analysis further
indicated that treatment with presented SHMT1/2 inhibitors effectively blocked
the production of glycine from glucose and serine in cancer cells. Viability stud-
ies confırmed anti-cancer effıcacy of SHMT1/2 inhibitors at concentrations con-
sistent with metabolic flux studies in the same cells. Moreover rescue experi-
ments with media supplemented with glycine and formate, which is a crucial
intermediate between mitochondrial and cytoplasmic branches of folate cycle,
were suffıcient to reduce activity of SHMT1/2 inhibitors. Finally synergistic
studies with antifolates provided an insight how effıcacy of SHMT1/2 could be
exploited therapeutically also in rational combinations with approved drugs.
#443 Lymphatic endothelium protects breast cancer cells from death by
inducingmetabolic adaptations.Mirela Berisa,1 Simona Podgrabinska,1 Bran-
donNicolay,2 RaulMostoslavsky,2 JerryChipuk,1Mihaela Skobe1. 1Icahn School
of Medicine at Mount Sinai, New York, NY; 2Massachusetts General Hospital
Cancer Center, Boston, MA.
The lymphatic vasculature is an important pathway for breast cancer dissem-
ination, yet it is not understood whether and how the lymphatic vessel microen-
vironment influences cancer metastasis. We demonstrate that lymphatic endo-
thelial cells (LECs) promote survival of triple-negative breast cancer cells
(TNBCs) under stress by improving mitochondrial function and inducing met-
abolic shift to promote cellular energy production. LECs protected TNBCs from
death in vitro induced by the loss of attachment and nutrient deprivation. Cell
death was preceded with a sharp increase in reactive oxygen species (ROS),
strong up-regulation of Nrf2-mediated oxidative stress response genes and a
rapid decline of mitochondrial activity. LECs lowered ROS levels, decreased
mitochondrial superoxide formation and enhanced mitochondrial activity in
TNBCs. RNAseq transcriptome analysis identifıed key regulator of mitochon-
drial metabolism and cellular bioenergetics, peroxisome proliferator-activated
receptor gamma coactivator (PPARGC1A/PGC-1, to be specifıcally up-regu-
lated in breast cancer cells by LEC-derived factors. Inhibition studies demon-
strated that the TNBC survival was dependent on pentose phosphate pathway
(PPP) activity. Notably, LECs induced a metabolic shift from glycolysis to fatty-
acid oxidation (FAO) and oxidative phosphorylation to maintain ATP and sus-
tain cell viability. These data demonstrate that lymphatic endotheliumpromotes
survival of breast cancer cells by regulating energy production and maintaining
redox homeostasis. Our fındings suggest that lymphatic endotheliummay facil-
itatemetastasis by promoting survival of breast cancer cells within the lymphatic
vasculature.
#444 Monocarboxylate transporter 1 inhibition with AZD3965 increases
cancer cell dependence onbioenergeticmetabolismpredicating combination
therapy with mitochondrial inhibitors. Mounia Beloueche-Babari,1 Teresa
Casals Galobart,1 Slawomir Wantuch,1 Paul D. Smith,2 Martin O. Leach1. 1In-
stitute of Cancer Research, London, Sutton, United Kingdom; 2AstraZeneca,
Cambridge, United Kingdom.
Monocarboxylate transporters (MCTs) are key mediators of lactate transport
that have emerged as promising targets for anti-cancer therapy. The MCT1
inhibitor AZD3965 (AstraZeneca) has shown promising activity in various pre-
clinical models and is currently in phase I/II clinical testing. Understanding the
impact of this drug on tumour cell metabolism may unravel dependencies that
could be exploited for combination therapy. Here we investigate changes in
glucose metabolism induced by AZD3965 treatment using 13C NMR isoto-
pomer analysis, and examine their signifıcance for cell survival usingmitochon-
drial metabolism inhibitors. Exposure of Raji human lymphoma cells to
AZD3965 in media supplemented with [1-13C]glucose led to a marked reduc-
tion in glucose uptake and lactate production in the cellular growthmedia along-
side a build-up in intracellular [3- 13C]lactate and [1-13C]glucose levels, indica-
tive of blockade of lactate excretion and inhibition of overall glycolytic activity.
These effects were concomitant with increased [4-13C]glutamate levels, consis-
tent with re-routing of pyruvate towards mitochondrial metabolism and en-
hanced flux through oxidative pyruvate dehydrogenase. Further, AZD3965
treatment was paralleledwith a signifıcant increase in levels of steady state Krebs
cycle-related metabolites (including succinate, fumarate, acetate and NAD/
NADH) and cellular ATP, as revealed by bioluminescent and 1HNMR analyses,
indicating improved mitochondrial metabolism and cellular re-energization.
Co-administration of the mitochondrial complex I inhibitor metformin or the
mitochondrial pyruvate carrier inhibitor UK5099 markedly potentiated the an-
ti-proliferative effects of AZD3965 and led to signifıcantly increased cell death,
indicating that the observed upregulation in mitochondrial metabolism was
necessary to maintain cell survival under MCT1 inhibitor-induced metabolic
stress. Similar effects were observed with a second human lymphoma cell line,
Hut78. Our fındings show that MCT1 inhibition leads to a shift in cellular me-
tabolism towards mitochondrial bioenergetic metabolism, creating a metabolic
vulnerability that could be exploited for combinatorial therapy to increase the
effıcacy of AZD3965.
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#445 Effıcient tumorigenesis after genetic dissociation of glycolysis and
the TCA cycle. Laura E. Jackson,1 Sucheta Kulkarni,1 Huabo Wang,1 Jie Lu,1
Sivakama Bharathi,1 Radha Uppala,1 Mulchand S. Patel,2 Eric S. Goetzman,1
Edward V. Prochownik1. 1Children’s Hospital of Pittsburgh of UPMC, Pitts-
burgh, PA; 2State University of New York at Buffalo, Buffalo, NY.
Virtually all tumors undergo some form of metabolic re-programming to
match anabolic needs with energy supply. The best-known form of this is the
Warburg effect by which tumors become more reliant on glycolysis over mito-
chondrial oxidative phosphorylation, even when their oxygen supply is abun-
dant. Nonetheless, mitochondria retain some residual activity in order to pro-
vide both ATP and critical metabolic building blocks and other substrates for
processes such as lipid biosynthesis and protein acetylation. The pyruvate dehy-
drogenase (PDH) complex (PDC) is themain enzymatic link between glycolysis
and the TCA cycle and irreversibly converts the end-stage glycolytic product
pyruvate into the critical TCA substrate, acetyl-coenzyme A (AcCoA). In a
mouse model of the pediatric liver cancer hepatoblastoma (HB), we recently
showed PDH to be highly up-regulated, despite reduced mitochondrial func-
tion. We postulated that this might represent a response to pyruvate depletion
due to upstream shunting of glycolytic intermediates into anabolic pathways. To
test this idea, we examined in vivo tumorigenesis in mice bearing a hepatocyte-
specifıc conditional knockout of the pdha1 subunit (KO mice). The survival of
these mice was marginally longer than the wild-type (WT) controls, although
tumor sizes at time of death were20% smaller. KOmice expressed virtually no
PDH (and hence no PDC activity) and had high blood lactate levels. This sug-
gested that they succumbed with smaller tumors as a result of severe lactic
acidosis that could not be corrected by hyperventilation due to respiratory com-
promise by the large HBs that restricted lung volumes. This was supported by
studies performed in a modifıed form of this model in which only tumors were
PDC defıcient whereas the surrounding liver parenchyma was not. These mice
now survived longer than did their WT counterparts and their tumors reached
comparable sizes. They also had lower lactate levels than the pan-KO mice.
Oxygen consumption rates of WT and KO tumors were similar yet were lower
than those of normal livers. Rates of fatty acid -oxidation by WT and KO
tumors were also lower than those of liver, indicating that both types of tumors
preferentially divert fatty acids into membrane synthesis rather than toward
supplying AcCoA. Taken together, these fındings demonstrate the remarkable
capacity for nearly normal HB pathogenesis despite the severing of glycolysis
from the TCA cycle.
#446 Differential effects of folate depletion onmetabolic reprogramming
and oxidative stress in nonmetastatic andmetastatic claudin-low breast can-
cer cells. Xuewen Chen, Ciara H. O’Flanagan, Stephen D. Hursting. University
of North Carolina, Chapel Hill, NC.
Folate coenzymes play an important role in biosynthesis and methylation
reactions. Aberrant folate metabolism has been implicated in the develop-
ment of several cancer types, though mechanisms underlying folate metab-
olism and cancer development remain unclear. We previously showed that a
folate-restricted diet can exert differential effects on metastatic versus non-
metastatic murine claudin-low breast cancer cells in vivo. Specifıcally, folate
restriction increased growth and invasion of orthotopically transplanted M-
Wnt (nonmetastatic) tumor cells, but decreased growth and lung metastases
of transplanted metM-Wnt cells, a metastatic subclone of M-Wnt cells. The
current study set out to explore the underlying mechanism. To examine the
effect of long-term folate depletion (LFD) on M-Wnt and metM-Wnt cell
metabolism, oxidative stress and autophagic flux in vitro, the two cell lines
were grown in standard and folate-depleted media for 14 days. metM-Wnt
cells showed higher oxidative stress, as measured by ROS staining and Nrf2
expression, and phosphorylation of the key nutrient sensor, AMPK, com-
pared to M-Wnt cells when grown in standard growth medium. LFDM-Wnt
cells showed an increased dependence on glycolysis compared to those cul-
tured in standard medium. Both M-Wnt and metM-Wnt cells displayed a
high autophagy level in LFD, measured by LC3B cleavage, and AMPK phos-
phorylation. However, LFDmetM-Wnt cells showed low viability, increased
apoptosis and loss of redox defense, as measured by cleaved-caspase 3 and
Nrf2 expressions. These results suggest that non-metastatic M-Wnt cells
undergo metabolic reprogramming, including a shift from oxidative phos-
phorylation to glycolysis that may fuel cell growth and proliferation. Further,
an elevated autophagic flux may mitigate nutrient stress induced by folate
depletion, which allows them to withstand LFD and which may contribute to
a more invasive primary tumor in response to folate restriction. In contrast,
metM-Wnt cells are unable to undergo this metabolic adaptation, and dis-
play increased oxidative stress and cell death in response to LFD, preventing
the development of metastatic lesions in vitro. This study highlights different
responses of primary and metastatic breast cancer cells to folate depletion.
The results provide additional rationale for targeting folate metabolism as a
potential strategy for treating metastatic breast cancer.
#447 ZAG promotes cachexia-associated white adipose tissue browning
and energy wastage. Sawsan Elattar, Satyanarayana Ande. Augusta University,
Augusta, GA.
Cancer cachexia is a complex condition of tissuewasting that affects up to 80%
of cancer patients. To date, there is no effective treatment for cachexia due to the
complex nature of this condition. Energy wasting in cachexia is caused by ex-
cessive lipid and protein turnover in the body, browning of white adipose tissue
(WAT), and futile metabolic cycling such as glucose recycling between the liver
and tumor. Therefore, identifying and inhibiting factors that promote WAT
browning, and glucose and lipid recycling can reduce energy wasting and ame-
liorate cachexia in cancer patients. Zinc-2-glycoprotein (ZAG), a lipid mobi-
lizing factor secreted by multiple cancers, has been shown to promote lipolysis
and inhibit lipogenesis in WAT. However, whether ZAG plays any role beyond
lipolysis and participates in other energy wasting mechanisms of cachexia such
as glucose and lipid recycling, and WAT browning has not been explored. Our
initial studies indicate that while ZAG is highly expressed in the heart, kidney,
and liver of wild-type mice, the basal expression of ZAG is very low in WAT at
both the mRNA and protein levels. To investigate the metabolic functions of
ZAG in vivo, ZAG-expressing 293 cells were implanted subcutaneously in athy-
mic nude mice, and analyzed them after 3 and 6 weeks. We detected a 3-fold
increase in the circulating plasma levels of ZAG. Importantly, the increase in
ZAG levels was associated with a decrease in body weight gain without any
differences in food consumption and physical activity. Morphological examina-
tion of eFAT pads of ZAG-cell implantedmice showed smaller size compared to
controls. In addition, histological examination of eFAT showed cell shrinkage
and almost complete depletion of fat stores, suggesting enhanced lipolysis in the
WAT. Notably, ZAG induced the expression of beige, mitochondrial, and ther-
mogenesis genes atmRNA level in the eFAT.Moreover, the expression of brown
adipocyte-specifıc thermogenic genes such as Ebf2, Prdm16, PGC1, UCP1,
SRC1 and IRF4 were strongly induced at the protein level in eWAT of ZAG-cell
implantedmice suggesting that ZAGcausesWATbrowning. Furthermore,met-
abolic analysis revealed increased O2 consumption and heat production in
ZAG-cell implanted mice compared to controls indicating increased total body
energy expenditure. ZAG-cell implanted mice also displayed reduced respira-
tory exchange ratio indicating increased consumption of lipids. Overall, our
fındings suggest that ZAG functions beyond lipolysis and causes signifıcant
energy wasting by causing WAT browning and promoting glucose and lipid
catabolism in the beige cells. These fındings suggest that ZAG plays a predomi-
nant role in the development of cachexia, and thus, may represent a novel ther-
apeutic target to block energy wasting and delay or prevent cachexia in cancer
patients.
#448 Role of fructose in prostate cancer.Daniela Carreño,1 Nestor Corro,1
Marcia Arredondo,1 Carmen Navarro,1 Verónica Torres,1 Viviana Monteci-
nos,1 Paula Sotomayor,2 FranciscoNualart,3 Julio Cesar Cárdenas,4 Alejandro S.
Godoy1. 1Pontifıcia Universidad Católica de Chile, Santiago, Chile; 2Universidad
Andres Bello, Santiago, Chile; 3Universidad de Concepción, Concepción, Chile;
4Universidad de Chile, Santiago, Chile.
The elevated level of glucose uptake andmetabolism in cancers is the basis for
the clinical localization of primary cancers and sites of metastasis by positron
emission tomography (PET scanning), based on the enhanced cellular uptake of
2-deoxy-2-[18F]-fluoro-D-glucose (FDG). In prostate cancer (CaP), however,
FDG-PET imaging has shown limited clinical applicability. This striking differ-
ence suggests that CaP cells utilize hexoses other than glucose, such as fructose,
as the principal energy source. The purpose of this study was to determine
whether or not fructose is a/the principal source of energy for CaP cells. mRNA
and protein expression for the glucose transporter Glut-1 and fructose trans-
porters Glut-2, Glut-5, Glut-7, Glut-9 and Glut-11 was analyzed in benign
(PWR-1E, RWPE-1) andmalignant (LNCaP, vCaP, LNCaP-C4-2, DU-145, and
PC-3) human prostate cell lines using qRT-PCR and western blot, respectively.
In addition, Glut(s) protein expression was analyzed on a tissue microarray
containing 200 formalin-fıxed paraffın-embedded benign and malignant hu-
man prostate tissues using immunohistochemistry. Fructose and glucose uptake
was measured in vitro in benign and malignant human prostate cell lines using
radiolabelled D-[U-14C]-fructose or 2-[1,2-3H]-deoxy-D-[3H]-glucose, respec-
tively. Lastly, the effect of fructose or glucose on the levels ofATP,mitochondrial
metabolism, and expression of the enzymes hexokinase-2 (HK2), type-C fruc-
tokinase (KHK-C), pyruvate kinase M2 (PKM2) and type-A lactate dehydroge-
nase (LDH-A) was analyzed in benign and malignant human prostate cell lines
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using chemiluminescence, seahorse, and qRT-PCR analyses, respectively. Our
results indicated that expression of the fructose transporters, Glut-5 and Glut-9,
was increased in CaP cell lines and in human CaP tissues compared to benign
cell lines and benign prostate tissues, respectively. Glut-1 expression, however,
did not differ between benign and malignant human prostate cells. Transport
assays demonstrated that CaP cell lines have a higher capacity to transport fruc-
tose compared to benign cell lines. However, glucose uptake was not altered
between benign andmalignant human prostate cell lines. ATP levels in CaP cells
were similar in the presence of fructose or glucose. Fructose, but not glucose,
signifıcantly altered mRNA expression of HK2, KHK-C, PKM2, and LDH-A in
malignant human prostate cells. Taken together, our results suggest that fruc-
tose may represent an alternative energy source and may reprogram hexose
metabolism in CaP cells.
#449 Reduced argininosuccinate synthetase expression in refractory sar-
comas: impacts on therapeutic potential and drug resistance. Eisuke Ko-
bayashi,1 Youngji Kim,1 Daisuke Kubota,2 Yoshiyuki Suehara,1 Akira Kawai,1
Shigehisa Kitano1. 1National Cancer Center Hospital, Tokyo, Japan; 2Juntendo
University, Tokyo, Japan.
Introduction: Treating drug-resistant sarcomas remain a major challenge.
The present study aimed to identify a novel therapy for drug-resistant sarcomas
based on a metabolic errors involving argininosuccinate synthetase1 (ASS1).
Methods: We assessed the expression of ASS1 and P-glycoprotein (P-gp) in
osteosarcoma (KHOS), doxorubicin (Dox)-resistant osteosarcoma (KHOSR2),
epithelioid sarcomas (ES-X and VAESBJ), alveolar soft part sarcoma (ASPS-
KY), and each clinical specimen. Each cell was cultured in arginine-containing
and arginine-free media. Cell growth was assessed using an XTT assay and flow
cytometry. We analyzed the induction of autophagy in arginine-free medium.
Moreover, we assessed the expression of P-gp in after suppressing ASS1 in Dox-
sensitive cells (MCF-7, KHOS) and in after transfecting the ASS1 into Dox-
resistant cells (ES-X, VAESBJ, ASPS-KY and KHOSR2). Results: The expression
of ASS1 was reduced in Dox-resistant sarcoma cells. Immunohistochemistry
(IHC) and real-time PCR showed that there was interestingly an inverse rela-
tionship between the expression of ASS1 and the expression of P-gp. The inhi-
bition of cellular proliferation with G1-arrest was shown to lead to autophagy
with arginine deprivation. In addition, the combination of autophagy inhibitor
plus arginine deprivation wasmore effective than arginine deprivation alone. In
cells in which the expression of ASS1was suppressed, the expression of P-gpwas
upregulated in comparison to negative controls. Discussion: These results indi-
cate that the reduced expression of ASS1 expression in Dox-resistant sarcomas
may contribute to drug resistance. ASS1 defıciency is a potential target for novel
drug therapies. The combination of arginine deprivation therapy and an au-
tophagy inhibitor may have anti-tumor effects in refractory sarcomas. Signifı-
cance: As the induction of autophagy by the deprivation arginine may have a
pro-survival role in patients with ASS1-defıcient sarcomas, the combination of
arginine deprivation therapy with autophagymodulators might potentiate anti-
tumor effects in patients with drug-resistant sarcomas.
#450 Aldo-keto reductase family 1memberb1 links glucosemetabolism to
epithelial-to-mesenchymal transition. Annemarie Schwab,1 Aarif Siddiqui,1
Maria Eleni Vazakidou,1 Francesca Napoli,1 Martin Boettcher,2 Bianca
Menchicchi,3 Ida Rapa,4 Maximilian Waldner,3 Dimitrios Mougiakakos,2
MarcoVolante,4 FlorianGreten,5 ThomasBrabletz,6 PaoloCeppi1. 1IZKF Junior
Group 1, University Hospital Erlangen, Erlangen, Germany; 2Department of In-
ternal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Er-
langen, Germany; 3Department of Medicine 1, University Hospital Erlangen, Er-
langen, Germany; 4Pathology Unit, San Luigi Hospital, University of Turin,
Turin, Italy; 5Georg-Speyer-Haus, Institute for Tumor Biology and Experimental
Therapy, Frankfurt am Main, Germany; 6Experimental Medicine I, FAU Erlan-
gen-Nürnberg, Erlangen, Germany.
Introduction: We performed a bioinformatic analysis to identify metabolic
genes connected with the process of epithelial-to-mesenchymal-transition
(EMT) and the results indicated a possible role for aldo-keto reductase family 1
member B1 (AKR1B1). AKR1B1 is a member of the polyol pathway responsible
for catalyzing the reduction of numerous aldehydes, such as glucose. Based on
the importance of EMT during carcinogenesis and metastatic progression and
on the relevance of enhanced glycolytic rate in cancer cells, we investigated a
direct role for AKR1B1 during EMT and tumor progression. Experimental Pro-
cedure: The bioinformatic analysis was performed on datasets from the NCI60
panel of cancer cell lines. Cancer cells from lung, breast and ovarian origin have
been investigated in vitro: changes in EMTmarkers were monitored by western
blotting aswell as immunofluorescence, growth assayswere performedusing the
IncuCyte® ZOOM,migration rate was tested by wound-healing assays. Changes
in stem-like properties were determined by western blotting, FACS and sphere-
formation assays. Immunohistochemistry (IHC) was performed on FFPE spec-
imens from lung cancer patients. Additionally, IHC was performed on samples
from a mouse model of AOM-induced colon tumorigenesis in mice with an
intestinal epithelial cell-specifıc p53 deletion (which were shown to undergo
EMT) and in the wildtype counterparts. Results: AKR1B1 gene and protein
expression was found signifıcantly higher (7-fold) in mesenchymal-like cells.
ShRNA-mediated knockdown of AKR1B1 lead to mesenchymal-to-epithelial
transition in vitro and suppressed EMT induced by TGF- or by high glucose
levels. Besides reduced migration, AKR1B1-defıcient cells displayed decreased
proliferation rate and colony-formation ability.Moreover,AKR1B1knockdown
or its inhibition with specifıc drugs diminished cancer stem cells. The pheno-
types observed with AKR1B1 knockdown could be obtained by targeting sorbi-
tol dehydrogenase (SORD), the second and last enzyme of the polyol pathway.
Suppression of each enzyme resulted in an impaired glycolytic and oxidative
metabolism and adding fructose, the end-product of the polyol pathway, res-
cued the expression of EMT markers. IHC on samples from the AOM-induced
colon cancer model indicated a higher AKR1B1 expression in invasive tumors
from p53	IEC mice as compared to both p53-defıcient non-invasive or wildtype
tumors. Finally, AKR1B1 staining of cancer tissues from a cohort of lung cancer
patients confırmed a signifıcant correlationwith EMT and a negative prognostic
value. Conclusion: In summary, we describe a glucose-related pathway with a
previously unknown role in regulating cancer plasticity and EMT, which links
altered glucose metabolism to growth andmigratory ability, with several poten-
tial implications. Targeting polyol pathway enzymes could be a potentially ef-
fective therapeutic strategy to arrest cancer progression.
#451 Germ freemice accelerate cachexia-associated cancer.RodrigoXavier
das Neves,1 Soumen Roy,1 Amiran Dzutsev,1 April Huang,1 Loretta Smith,1
Simone Difılippantonio,1 Hawes Misty,1 Marília Seelaender,2 Giorgio
Trinchieri1. 1NCI, Bethesda, MD; 2ICB, Sao Paulo, Brazil.
The syndrome of cancer cachexia is currently defıned as a state of ill health,
malnutrition and physical wastingwithmarkedwhite adipose tissue (WAT) and
skeletal musclemass wasting, representing the clinical consequence of a chronic
and systemic inflammatory response. Over the last decade, WAT has been rec-
ognized as an important endocrine organ, and earning a lot of attention during
cancer cachexia development. We investigated the role of microbiota along the
cachexia associated cancer. We performed experiments with conventional and
Germ Free mice (GF) (n6 in each group) of 8-10 weeks old C57B/6, which
were subcutaneously injected with LLC cells [4x106 cells in 0.2 mL; Tumor-
bearing, (TB) or PBS control (C)]. We performed Immunohistochemistry, RT-
qPCR, and Western Blot. We observed that GF Tumor-bearing mice have in-
creased several symptoms of the cachexia compared to conventional TB mice.
TheWATmass was decreased 50% in GF Tumor-bearing mice compared to all
groups, which indicates a pathway related to lipolysis, as we found increased
level of phosphorylated enzymes in GF Tumor-bearing mice. We also observed
that GF Tumor bearing mice decreased skeletal muscle mass and gene expres-
sion that are related with atrophy were increased in GF Tumor bearing mice.
Our data suggested that homeostasis ofmicrobiotamay impair the development
of the cachexia syndrome.
#452 Activation of Akt pathway and autophagy promotes resistance to
FASN inhibition in colorectal cancer patient-derived xenograft models.
Yekaterina Y. Zaytseva,1 Piotr G. Rychahou,1 Anh-Thu Le,1 Robert M. Flight,1
Timothy L. Scott,1 Jennifer W. Harris,1 Sally Hodges,1 Brent J. Hallahan,1 Dana
L. Napier,1 Jinpeng Liu,1 ChiWang,1Manjula Sunkara,1 AndrewMorris,1 Ji Tae
Kim,1 SivakumaranTheruArumugam,1AndrewLane,1 TeresaW. Fan,1Hunter
Moseley,1 Tianyan Gao,1 Eun Y. Lee,1 Heidi L. Weiss,1 Timothy S. Heuer,2
George Kemble,2 B Mark Evers1. 1University of Kentucky, Lexington, KY; 23-V
Biosciences, Menlo Park, CA.
Fatty Acid Synthase (FASN), a key enzyme of de novo lipogenesis, is upregu-
lated in many cancers including colorectal cancer (CRC); increased FASN ex-
pression is associated with poor prognosis. Potent FASN inhibitors developed
by 3-V Biosciences demonstrate anti-tumor activity in vitro and in vivo and a
favorable tolerability profıle in a Phase I clinical trial in solid tumor patients.
However, CRC characteristics associated with responsiveness to FASN inhibi-
tion are not fully understood. The purpose of our study was: (i) to determine the
effect of FASN inhibition on tumor growth in CRC patient-derived xenografts
(PDXs); (ii) to identify potential biomarkers associated with CRC responsive-
ness to FASN inhibition; and (iii) to explore new combination strategies with
FASN inhibitors. METHODS. Tumor growth was assessed in 9 PDXs estab-
lished in NSGmice using freshly resected specimens. Once the xenografts grew
to 100 mm3, mice were randomized into two groups (n5) to receive either
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Metabolic Pathways in Cancer
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017114
vehicle or TVB-3664 or four groups (n10) for TVB-3664 treatment in combi-
nation with either MK2206 or Chloroquine (CQ). Tumor volume and animal
weights were measured weekly. Western blot analysis and immunohistochem-
istry staining were used to identify FASN-mediated changes in signaling path-
ways. Changes in metabolites and lipids were analyzed by nuclear magnetic
resonance andmass spectrometry in plasma and tumor tissues.NextGeneration
Sequencing was used to assess the mutation profıle of 198 oncogenes in patient
tumors and PDXs. RESULTS. PDXs showed a wide range of sensitivity to FASN
inhibition: TVB-3664 treatment attained signifıcant response (reduced tumor
volume) in 3 PDXs, signifıcant response followed by developed resistance in one
PDX, and no response in 5 PDXs. Activation of Akt and AMPK pathways was
associated with resistance to FASN inhibition and combination of TVB-3664
with either MK2206 or CQ led to a signifıcant reduction in tumor volume as
compared to either drug alone. Moreover, TVB-3664 treatment signifıcantly
decreased the total palmitate level in plasma and the levels of triglycerides, dig-
lycerides, phosphatidylserines, phosphatidylethanolamines, and phosphatidyl-
cholines in tumor tissues. Furthermore, a signifıcant decrease in the levels of
AXP-1, AXP-2 andmyo-Inositol-2 was observed in tumors responsive to FASN
inhibition. CONCLUSIONS. Our studies demonstrate that TVB-3664 shows
anti-tumor activity in CRC. Importantly, our results suggest that activation of
Akt and autophagy are major mechanisms of resistance to FASN inhibition and
demonstrate that combine inhibition of these pathways and FASNmay be a new
therapeutic approach in CRC.Ongoing studies of correlation betweenmutation
andmetabolic profıles of tumors and tumor response to FASN inhibition aim to
identify a subset of CRC patients that are likely to respond to FASN-targeted
therapy.
#453 Orlistat as a novel targeted therapy for obesity-driven endometrial
cancer. Stephanie Sullivan,1 Arthur-Quan Tran,2 Weiya Wysham,2 Paola Geh-
rig,2 Chunxiao Zhou,2 Victoria Bae-Jump2. 1University of North Carolina, Cha-
pel Hill, OH; 2University of North Carolina, Chapel Hill, NC.
Introduction: Obesity is associated with increased risk for and worse out-
comes from endometrial cancer (EC). Orlistat is a weight loss medication that
has been shown to be a potent inhibitor of fatty acid synthase (FAS), and FAS is
known to be upregulated in ECs. Thus, we sought to investigate the anti-tumor-
igenic potential of orlistat in EC cell lines and a genetically engineered mouse
model of endometrioid EC (LKB1fl/flp53fl/fl mousemodel).Methods: Two endo-
metrial cell lines, ECC-1 and KLE, were used. Cell proliferation was assessed by
MTT assay after exposure to orlistat. Western immunoblotting was performed
to evaluate the effect of orlistat on downstream targets of fatty acid metabolism.
LKB1fl/flp53fl/fl mice were fed a control low fat diet (LFD; 10% calories from fat,
lean group) versus a high fat diet (HFD; 60% calories derived from fat, obese
group) to mimic diet-induced obesity, starting at 3 wks of age. AdCre was in-
jected at 6 wks of age to induce invasive EC. Mice were treated with placebo or
orlistat (200 mg/kg/day, IM) following tumor onset for 4 weeks (N10 mice/
group). Immunohistochemistry was performed to assess for the effect of orlistat
on expression of Ki-67 (marker of cell proliferation), vascular endothelial
growth factor (VEGF) and phosphorylated (p)-acetyl-CoA carboxylase (ACC).
Results: Orlistat inhibited growth in a dose-dependent manner for both endo-
metrial cell lines with a mean IC50 for ECC-1 of 88.7 uM and 145.4 uM for KLE
(p0.05). In addition, orlistat decreased expression of FAS, ACC and carnitine
palmitolytransferase 1A, consistent with an inhibitory effect on fatty acid me-
tabolism. In both the obese and lean LKB1fl/flp53fl/fl mice, treatment with orlistat
resulted in decreased tumor weight/size as well as Ki-67 expression (p0.05),
but the difference was more pronounced in obese mice. Orlistat decreased tu-
mor weight/size by 66% in the obese mice and 23% in the lean mice (p0.05).
Immunohistochemistry revealed that p-ACC and VEGF expression was higher
in the obese versus leanmice at baseline (p0.05). Orlistat reducedVEGF in the
endometrial tumors of both the obese and lean mice (p0.05) but only de-
creased expression of p-ACC in the tumors of obese mice (55%, p0.05). Con-
clusions: Orlistat inhibited EC cell proliferation and endometrial tumor growth
in an endometrioid EC mouse model, with increased effıcacy in obese versus
lean mice. Therefore, orlistat may be worthy of drug repurposing as an anti-
tumorigenic agent in EC, with the potential added benefıt of weight loss in this
obesity-linked disease.
#455 Phosphoenolpyruvate carboxykinase coordinatesmetabolic flexibil-
ity to control tumor growth. Emily Montal, Ashley Ropell, Geoffrey Girnun.
Stony Brook University, Stony Brook, NY.
Colorectal cancer (CRC) is the third most common cancer (excluding skin
cancer) and the third leading cause of cancer death in the United States. While
rates are declining among individuals over 50 years of age due to increased
screening, the incidence of CRC in the US population under 50 years of age is
increasing. Therefore, better treatment approaches are urgently needed. Studies
are emerging that highlight an important role for the TCA cycle in regulating
cancer cell proliferation. The TCA cycle integrates glucose, amino acid and lipid
metabolism depending on cellular needs. In addition, biosynthetic pathways
crucial to tumor growth require the TCA cycle for the processing of glucose and
glutamine derived carbons. Phosphoenolpyruvate carboxykinase (PEPCK) is
well known for its role in gluconeogenesis. However, PEPCKplays an important
role in mediating TCA cycle flux. We recently showed that PEPCK promotes
colon cancer growth in vitro and in vivo, independent of its role in gluconeo-
genesis. This growth advantage was mediated in part through regulating meta-
bolic flux of glucose and glutamine to biosynthetic precursors, such as lipids and
nucleic acids. These effects of PEPCK on glucose metabolism and cell prolifer-
ation are in part mediated via activation of mTORC1. Currently we are investi-
gating themechanism(s) responsible for how PEPCK regulates cell signaling via
metabolic flux. We are also seeking to identify ways in which we can utilize
PEPCK as a therapeutic target.
#456 Functional analysis of DEC1 and DEC2 in cancer metabolism.
Fuyuki Sato, Yasueru Muragaki. Wakayama Medical University, Wakayama
city, Japan.
Basic helix-loop-helix (bHLH) transcription factor DEC1 (bHLHE40/Stra13/
Sharp2) and DEC2 (bHLHE41/Sharp1) are clock genes that show a circadian
rhythm in various tissues. However, the function of DEC1 and DEC2 in metab-
olism has not been poorly understood. AMP-activated protein kinase (AMPK)
activity plays important roles in the metabolic process and circadian rhythm.
However, how circadian rhythm of phosphorylation of AMPK (pAMPK) is
regulated has been yet understood. The aim of this study is to investigate
whether there is a direct correlation between DEC1 and DEC2 expression and
AMPK activity in normal and cancer cells. There was an inverse relationship
between DEC1 expression and AMPK activity. DEC1 protein and pAMPK
showed a circadian rhythm in themouse liver with different peak levels. Knock-
ing down DEC1 expression increased pAMPK, whereas overexpression of
DEC1 decreased it. DEC1 bound to the E-box of the LKB1 promoter, decreased
LKB1 activity and total protein levels. In addition, pAMPK immunoreactivity
was strongly detected in the liver and lung of DEC2 knockout mice compared
with that of wild-typemice. Interestingly,medium change induced the circadian
rhythm of DEC2, but not DEC1 in cancer cells. We conclude that DEC1 and
DEC2 negatively regulates AMPK activity via LKB1, and play important roles in
cancer cell metabolism.
#457 Satisfying the fatty acid demand of prostate cancer: Outlier overex-
pression of genes involved in de novo synthesis vs fatty acid uptake defıne two
different and potentially synergistic prostate cancer phenotypes. Sandra M.
Gaston,1 James Kearns,1 GeorgeW.Adams,2 Soroush Rais-Bahrami,3 JeffreyW.
Nix,3 Peter N. Kolettis,3 James E. Bryant,3 Mark S. DeGuenther,2 Denise Oel-
schlager,3 Dennis Otali,3 William E. Grizzle3. 1Tufts Medical Center, Boston,
MA; 2Urology Centers of Alabama, Birmingham,AL; 3TheUniversity of Alabama
at Birmingham, Birmingham, AL.
Malignant transformation increases cellular demand for fatty acids (FA).
Many cancers, including prostate cancer (PCa), show increased expression of
fatty acid synthase (FASN), the enzyme that catalyzes the de novo synthesis of
the FA palmitate. De novo FA synthesis is energetically expensive; in most nor-
mal cells FASN expression is low and de novo synthesis suppressed in favor of
utilization of exogenous FA. In contrast, in cancer cells, de novo FA synthesis is
an important source of precursors needed to support tumor growth.Muchof the
research effort on FA in cancer has focused on FASN and the other genes in-
volved in de novo FA synthesis. However a number of observations suggest that
alternate mechanisms for FA acquisition are also important, most notably stud-
ies showing that cancer cells can be rescued from the pro-apoptotic effect of
FASN inhibition by exogenous palmitate. Using a biopsy-based approach de-
signed to identify high risk prostate cancer phenotypes that are common in
African American (AA) men, we identifıed a PCa subtype with outlier ( 10
fold) mRNA overexpression of fatty acid binding protein 5 (FABP5). FABP5
facilitates the utilization of palmitate and other FAs from outside the cell, and a
FABP5 overexpression phenotype may confer a selective advantage when di-
etary FAs are abundant or when FASN is targeted as a therapy. The FABP5
outlier overexpression phenotype was observed in 7% Gleason sum (GS) 7-10
PCas. We also observed a second molecular subtype with outlier FASN overex-
pression in 9% of GS 7-10 PCas. With few exceptions these two PCa subtypes
showed an “either-or” pattern with top quartile overexpression of FABP5 or
FASNbut not both (Spearman r 0.385; P 0.0001). Interestingly, in lowgrade
(GS 6) PCas, median FABP5 mRNA overexpression is higher in AA than in
EuropeanAmerican (EA)men (P 0.01)withGS6PCas fromAAmen showing
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median FABP5 expression levels as high as that observed in GS 7-10 PCas. IHC
confırmed variable expression of both FABP5 and FASN, including “patch-
work” PCaswith highGleason pattern (GP) areas overexpressing FABP5 next to
low GP areas overexpressing FASN. The net result may be a selective advantage
for the high grade cancer if FABP5 allows it to exploit the FA being synthesized
by the adjacent low grade focus. In a subset of PCas, FABP5 IHC showed robust
nuclear staining consistent with its proposed role in regulating fatty acid medi-
ated gene expression; the ratio of FABP5 nuclear/cytoplasmic staining was
higher in PCa fromAA than fromEApatients (P 0.05). Identifıcation of a PCa
subtype with high levels of FABP5 overexpression suggests a previously unrec-
ognized mechanism by which some PCas can increase FA supply without de
novo synthesis. Such a PCa subtype might be particularly sensitive to dietary
interventions and relatively insensitive to FASN inhibitors.
#458 Cholinemetabolism in cancer cellsmodifıes PD-L1 expression.Balaji
Krishnamachary, Marie-France Penet, Yelena Mironchik, Zaver M. Bhujwalla.
Johns Hopkins Univ., Baltimore, MD.
Increased expression of choline kinase- (Chk-), the enzyme that converts
choline to phosphocholine has been observed in most cancer cells including
breast (1). This increase of choline kinase results in increased production of
phosphocholine that is used in the synthesis of membrane phosphatidylcholine.
We investigated the relationship between Chk- and the programmed death
ligand-1 (PD-L1) expression in triple negative MDA-MB-231 human breast
cancer cells. Expression of PD-L1 in response to the secretion of interferon
gamma (IFN) by cytotoxic T cells and its binding to the immune checkpoint
PD-1 on T cells results in cancer cells escaping destruction by the immune
system (2). Quantitative real-time PCR analysis (q-RT-PCR) did not reveal any
change in PD-L1 mRNA expression between MDA-MB-231 expressing an
empty vector control plasmid (231-EV) and MDA-MB-23 stably expressing
shRNA against Chk (231-Chk). However, there was a difference in the mean
intensity fluorescence (MIF) between 231-EV (325 11.5, n2) and 231-Chk
(52718.5, n2) in the FACS analysis. Upon induction with IFN (10ng/ml)
for 24h, there was 1.23 fold increase in PD-L1 mRNA in 231-Chk compared to
231-EV. Interestingly, theMIP for cell surface expression of PD-L1 was 60021
(n2) for 231-EV compared to 87216 (n2) for 231-Chk cells. Values repre-
sent mean SE. These data suggest that the cell surface increase of PD-L1 in
231-Chk cells could be due to translocation. Increased PD-L1 expression creates
an opportunity to deliver PD-L1 targeted nanoparticles carrying therapeutic
cargo. Since most conventional treatments result in a decrease of Chk- and
phosphocholine, our data suggest that these treatmentsmay also result in cancer
cells escaping immune surveillance through expression of PD-L1. Acknowl-
edgements: This work was supported by NIH R01CA136576 and P50
CA103175. Reference: 1)GlundeK et al, CancerRes 65, 11034 (2005)., 2) ZouW,
Chen L, Nat Rev Immunol 8(6), 467-77 (2008).
#459 Targeting MUC1 mediated nucleotide metabolism sensitizes pan-
creatic tumors to radiation therapy.VENUGOPALGUNDA, Joshua Souchek,
Jaime Abrego, Gennifer Goode, Enza Vernucci, Surendra K. Shukla, Aneesha
DasGupta, Nina V. Chaika, Ryan King, Fang Yu, Tadayoshi Bessho, Chi Lin,
Wang Shou, Li Sicong, Pankaj K. Singh. UNMC, Omaha, NE.
Pancreatic cancer has the lowest survival rate of six perecent among all the
cancers in the US and is projected to be the second leading cause of cancer
related deaths in a decade. Radiation therapy provides onlymarginal increases in
the survival rate in pancreatic cancer, due to poor responsiveness of pancreatic
tumors. Clinical trials indicate a signifıcant response to radiation only in twenty
percent of primary pancreatic tumors.Whilemultiple factors cause resistance to
radiation therapy, the biological mechanisms mediating such innate resistance
are currently being explored. Overexpression of MUC1 facilitates chemo and
radiation resistance in pancreatic cancer. MUC1 overepxression also promotes
pancreatic tumor growth through metabolic upregulation. We investigated the
in vivo role of MUC1 mediated metabolic alterations in radiation response of
pancreatic tumors. Our fındings indicate that MUC1 expressing pancreatic tu-
mors survive better upon radiation treatment. Metabolomic analysis through
liquid chromatography coupled tandem mass spectrometry approach revealed
that MUC1 expressing pancreatic tumors exhibit higher glycolytic and nucleo-
tide metabolites upon irradiation. MUC1 expressing tumors also possess rela-
tively higher PPP and nucleotide metabolites. Glycolytic inhibition using bro-
mopyruvate revealed that MUC1 induced radiation resistance could be
abrogated through inhibition of glucose carbon flux into nucleotidemetabolism
by BrPA. Treatment with BrPA effectively reduced glycolysis, pentose phos-
phate pathway and nucleotide levels in irradiated MUC1 expressing cells. Fur-
thermore, a combination of BrPA and radiation reduced tumor growth in
MUC1 expressing tumors. Metabolomic analysis showed a decrease in the gly-
colysis, PPP and nucleotidemetabolites inMUC1 expressing tumors upon com-
bination treatment with radiation and BrPA. Hence, our fındings demonstrate
that glycolytic inhibition could be used to effectively target MUC1 mediated
radiation-resistance in pancreatic tumors.
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#460 A central microRNA checkpoint for the inflammatory stem cell
niche. Xiling Shen. Duke Univ., Durham, NC.
ThemicroRNAmiR-34a is awell-known tumor suppressor in various types of
cancer. Previous studies largely focused on its role in suppressing oncogenic
pathways such as Bcl2 and Myc. This study will demonstrate a previously un-
known function of miR-34a—a central protector of tissue integrity in the in-
flammatory colon stem cell niche by modulating both proinflammatory re-
sponse and stem cell behavior. Epigenetic silencing of miR-34a by a long non-
coding RNA (lncRNA), Lnc34a, subverts this checkpoint to promote cancer
stem cell proliferation. InDSS- and bacteria-induced colitismodels,miR-34a (1)
suppresses differentiation of CD4 T cells into Th17 cells by directly targeting
multiple interleukin receptors, (2) blocks recruitment of Th17 cells to the in-
flammatory site by directly targeting chemokine CCL22 from epithelial cells, (3)
attenuates the effect of IL17 on stem cells by directly targeting IL17 receptors in
stem cells, and (4) switches on asymmetric division to curb stem cell prolifera-
tion. We further show that a novel lncRNA, Lnc34a, is upregulated by Notch
signaling during colorectal cancer (CRC) progression and epigenetically si-
lences miR-34a promoter by recruiting Dnmt3 and HDAC1. This process re-
moves the miR-34a checkpoint of the inflammatory niche and contributes to
proliferation of stem-like cancer cells. Our fınding of miR-34a as an inflamma-
tory checkpoint suggests potential therapeutic strategies to reinforce or restore
such miR-34a functions in colitis patients to prevent CRC and in CRC patients
to prevent proliferation of cancer stem cells. Furthermore, MRX34, a miR-34a
mimic, is the fırst microRNA mimics to reach phase II clinical trial for cancer
therapy, which is ongoing. However, delivery effıciency into the tumor is always
a challenge for microRNA mimics. Our discovery of Lnc34a, which recruits
epigenetic regulator to silencemiR-34a, provides a promising therapeutic target,
because it ismuch easier to develop smallmolecule inhibitors to disrupt lncRNA
structure or block its functional interaction with protein than to restore mi-
croRNA expression.
#461 Dichotomous roles of Dicer1 in rhabdomyosarcoma and angiosar-
coma. Jason A. Hanna, Matthew R. Garcia, Catherine J. Drummond, Jonathon
C. Go, David Finkelstein, Jerold E. Rehg, Mark E. Hatley. St. Jude Children’s
Research Hospital, Memphis, TN.
Pediatric and adult angiosarcomas are rare and highly aggressive soft tis-
sue sarcomas with an extremely poor prognosis. Due to the rarity of this
disease especially in children, the molecular drivers and optimized treatment
strategies for patients are lacking, highlighting the need for genetic and in
vivo animal models. MicroRNAs are a class of small RNAs that regulate gene
expression and are often dysregulated in cancers including sarcomas. DI-
CER1 is required for microRNA biogenesis and germline DICER1mutations
result in a cancer predisposition syndrome associated with increased risk of
benign and malignant tumors including rhabdomyosarcoma (RMS), a pedi-
atric soft tissue sarcoma resembling developmentally arrested skeletal mus-
cle. Here we show Dicer1 expression is required for tumorigenesis in a
mouse model of RMS driven by activation of oncogenic Smoothened by Cre
recombinase expressed from the adipose protein 2 (aP2) promoter (aP2-
Cre). Unexpectedly, in studying the role of Dicer1 in RMS, we found that
Dicer1 deletion with aP2-Cre leads to aggressive angiosarcoma. Angiosar-
coma development was independent of the Smoothened oncogene and other
genetically engineered oncogenes or tumor suppressor loss, providing the
fırst in vivomousemodel of biallelic Dicer1 loss alone driving tumorigenesis.
Angiosarcomas in aP2-Cre;Dicer1Flox/- mice histologically and genetically
resemble human angiosarcoma and were enriched for microRNA-23 target
genes including the oncogene Ccnd1 as well as Adam19, Plau, andWsb1 that
promote invasiveness and metastasis. The aP2-Cre;Dicer1Flox/- model pro-
vides a simple in vivo animal model to study angiosarcoma for novel thera-
peutics and the molecular mechanisms of cancer initiation, progression, and
metastasis. In addition, our results demonstrate DICER1 and microRNAs
play major and opposing roles in sarcomagenesis.
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#462 The role ofmiR-24 as a race-related genetic factor in prostate cancer.
Yutaka Hashimoto,1 Marisa Shiina,1 Taku Kato,1 Soichiro Yamamura,1
Yuichiro Tanaka,1 ShahanaMajid,1 Sharanjot Saini,1 Varahram Shahryari,1 Pri-
yanka Kulkarni,1 Pritha Dasgupta,1 Yozo Mitsui,1 Mitsuho Sumida,1 Guoren
Deng,1 Laura Tabatabai,1 Deepak Kumar,2 Rajvir Dahiya1. 1University of Cali-
fornia at San Francisco & VAMedical Center, San Francisco, CA; 2University of
the District of Columbia, Washington, DC.
The incidence of prostate cancer (PCa) among African-Americans (AfA)
is signifıcantly higher than Caucasian-Americans (CaA) but the genetic basis
for this disparity is not known. To address this problem, we analyzedmiRNA
expression in AfA (n81) and CaA (n51) PCa patients. Here, we found
that miR-24 is differentially expressed in AfA and CaA PCa patients and
attempt to clarify its role in AfA patients. Also, the public sequencing data of
the miR-24 promoter confırmed that it was highly methylated and down-
regulated in PCa patients. Utilizing a VAMCSF and NDRI patient cohorts,
we discovered that miR-24 expression was linked to a racial difference be-
tween AfA/CaA PCa patients. Interestingly, miR-24 was restored after treat-
ment of PCa cells with 5Aza-CdR in an AfA cell line (MDA-PCa-2b), while
restoration of miR-24 was not observed in CaA cells, DU-145. Ectopic ex-
pression of miR-24 showed decreased growth and induced apoptosis, though
the effect was less in the CaA cell line compared to the AfA cell line. Finally,
we found unique changes in biological pathways and processes associated
with miR-24 transfected AfA cells by quantitative PCR-based gene expres-
sion array. Evaluation of the altered pathways showed that AR, PDPK1,
IGF1, and IGFBP5 were markedly decreased in the AfA derived cell line
compared with CaA cells, and there was a reciprocal regulatory relationship
of miR-24/target expression in prostate cancer patients. These results dem-
onstrate that miR-24 may be a central regulator of key events that contribute
to race-related tumorigenesis and has potential to be a therapeutic agent for
PCa treatment.
#463 MicroRNA-7 suppresses RB1 expression leading to chromosomal
instability in leukemia cells harboring c-Kit mutation. Keiji Kurata,1
Shinichiro Kawamoto,1 Ryota Masutani,2 Kimikazu Yakushijin,1 Katsuya
Yamamoto,1HiroshiMatsuoka,1 Takayuki Takubo,3HironobuMinami1. 1Kobe
University Hospital, Kobe City, Japan; 2Osaka Medical College Hospital, Osaka,
Japan; 3Japanese Red Cross Osaka Blood Center, Osaka, Japan.
C-Kit mutation D816V is a well-known indicator of poor prognosis in acute
myeloid leukemia (AML) harboring t(8;21) chromosomal translocations. How-
ever, the mechanism the D816V mutation promotes therapeutic resistance is
still under investigation. C-Kit V814 mutation is a murine counterpart of the
human D816V. We utilized a murine IL-3 dependent cell line Ba/F3 with or
without the c-Kit V814 mutation to investigate its downstream signaling path-
way and the effect on the expression of bcl-2 family members and critical gran-
ulocytic transcription factors. The c-Kit V814 and wild type (WT) c-Kit were
retrovirally transduced into Ba/F3 cells. Unexpectedly, Gata1mRNAwas signif-
icantly downregulated to one-tenth in V814Ba/F3 cells (p 0.01), contrary to
the previous reports that WT c-Kit signaling induces Gata1 expression. When
V814Ba/F3 cells were treated with several c-Kit signaling pathway inhibitors,
mRNA and protein expression levels of Gata1 recovered to normal levels only
withMEK1/2 inhibitor (PD325901) treatment.We thenhypothesized thatmiR-
NAsmight control Gata1 transcription.We used an array to identify differences
in miRNA expression between Ba/F3 cells and V814Ba/F3 cells, and between
V814Ba/F3 cells treatedwith or without PD325901. OnlymiR-7a-5p andmiR-
706 were signifıcantly upregulated in V814Ba/F3 cells compared with Ba/F3
without the V814 mutation, and downregulated ( 2-fold) in cells treated with
PD325901 comparedwith controls.We focused our further analysis onmiR-7 as
it is highly conserved in vertebrates. The differences in miR-7 expression were
confırmed using qRT-PCR (10.5-fold change, p  0.01). In silico analysis im-
plicated Rb1 as a candidate miR-7 target that may regulate Gata1 transcription.
Luciferase reporter constructs containing murine and human Rb1 miR-7 target
sequence exhibited 0.51 and 0.49 times lower luciferase activity than the con-
trols, respectively (p 0.01). To further determine the biological signifıcance of
the c-Kitmutation that would transform the cells tomore aggressive phenotype,
we focused on DNA and chromosomal instability caused by RB1 deterioration.
We exposedWT c-Kit Ba/F3 and V814Ba/F3 cells to 4 Gy irradiation and then
used immunohistochemistry to analyze the frequency ofH2AX foci in the cells.
The percentage of cells with more than 10 H2AX foci was signifıcantly higher
in V814Ba/F3 cells than WT Ba/F3 cells (27% vs. 14%, p  0.05), Here, we
clearly show that a single mutation of c-Kit is suffıcient to regulate miR-7 ex-
pression leading to RB1 translational suppression. Since c-Kitmutation requires
only a single step to inhibit RB1, this mechanism is more likely to facilitate
oncogenesis than bi-allelic RB1 chromosomal and/or gene alterations in leuke-
mia cells. Taken together, we identifıed miR-7 as a suppressor of RB1 in V814
mutation-positive cells, which might reflect the responsibility of D816V to re-
fractory feature in AML.
#464 Novel role of xpo1 in regulating MicroRNAs related to pancreatic
ductal adenocarcinoma invasion and metastasis. Asfar S. Azmi,1 Yiwei Li,1
IrfanaMuqbil,1 AmroAboukameel,1William Senapedis,2 Erkan Baloglu,2 Yosef
Landesman,2 Michael Kauffman,2 Sharon Shacham,2 Philip A. Philip,1 Ramzi
M. Mohammad1. 1Wayne State Univ., Detroit, MI; 2Karyopharm Therapeutics,
Newton, MA.
Objective: There are no known reports on the role of exportin 1 (XPO1; also
known as chromosome maintenance region 1 [CRM1]) in microRNA biology.
In this study, we for the fırst time demonstrate that interfering with XPO1 ma-
chinery can influence miRNA signaling leading to suppression of pancreatic
ductal adenocarcinoma (PDAC) proliferation, invasion and metastasis.
Methods: miRNA arrays (LCSciences, Houston, TX) were performed on total
RNA samples from PDAC cell lines (HPAC, MiaPaCa-2, AsPc-1 and L3.6pl)
and normal human pancreatic ductal epithelial (HPDE) cells. PDAC cells were
treated with XPO1 inhibitor (Selinexor) or transfected with control siRNA,
XPO1 siRNA (Santa Cruz), miR-control or miR-145 mimic (Applied biosys-
tems) all at a fınal concentration of 20 nM using DharmaFact Transfection
Reagent (Dharmacon, Lafayette. CO). The total RNA and total protein from
treated or transfected cells were subjected to real-time PCR or immunoblot
analysis in order to measure expression level of miR-145, let-7d, miR-34c, miR-
320, miR-205, and miR-145 target or downstream genes including EGFR,
MMP1, MT-MMP, c-Myc, Sox-2, and PAK4. The impact of XPO1 inhibitor
Selinexor on PDAC growth, proliferation, invasion and migrations was also
evaluated using MTT and scratch assay. Results: In this study, we show that
PDACcells have signifıcantly reduced expression ofmiR-145when compared to
normal pancreatic duct epithelial cells. Similarly, forced expression of miR-145
in PDAC cells inhibited cell proliferation and migration. Conversely, we dem-
onstrate that RNAi of XPO1 by siRNA knockdown or chemical inhibition of
XPO1 by selective inhibitor of nuclear export compound (Selinexor) restores
miR-145 expression in PDAC cells ultimately leading to inhibition of cell pro-
liferation and migration. In addition, we show that the inhibition of cell prolif-
eration andmigration by Selinexor is mediated through the down-regulation of
knownmiR-145 signals including EGFR, MMP1, MT-MMP, c-Myc, PAK4 and
Sox-2. Selinexor also induced the expression of two important tumor suppres-
sive miRNAs, miR-34c and let-7d, leading to the up-regulation of p21WAF1. We
also observed the down-regulation of oncomir mir-205. Conclusions: These
results are the fırst to show that targeted inhibition of the nuclear exporter
protein XPO1 by RNAi or Selinexor could restore tumor suppressive miRs in
PDAC.
#465 Downregulation of miR-193a and its correlation with clinical and
pathological behavior of colorectal cancer. Afraa M. Mamoori,1 Riajul Wa-
hab,1 Farhadul Islam,1 Katherine Lee,1 Robert A. Smith,2 Vinod Gopalan,1 Al-
fred Ky Lam1. 1Cancer Molecular Pathology, School of Medicine, Menzies Health
Institute Queensland, Gold Coast, Australia; 2Genomics Research Centre, Insti-
tute forHealth andBiomedical Innovation,QueenslandUniversity of Technology,
Brisbane, Australia.
Aim: Deregulation of miR-193a expression was reported to have signifıcant
roles in cancer development and progression. This study aimed to investigate
the expression pattern and clinicopathological implication of miR-193a-3p in
patients with colorectal cancer. Also, the bio-physiological effects of miR-193a
in colon cancer cells were examined.Methodology: Fresh frozen tissues from 70
matched colorectal cancers (adenocarcinomas) and adjacent noncancer tissue
were prospectively collected with no selection bias. Expression level of
miR193a-3p was measured by quantitative real-time polymerase chain reaction
(qRT-PCR). Immunohistochemical staining was used to detect the expression
level of K-ras protein as a predicted downstream target for miR-193a. Restora-
tion of the miR-193a level in the cell lines was achieved by permanent transfec-
tion. Multiple functional and immunological assays were performed to analyze
miR-193’s cellular implications and target affınity in colon cancer cell lines.
Results: Downregulation of miR-193a-3p was noted in the majority of the colo-
rectal cancer tissues when compared to nontumor colorectal tissues (70%, n
49/70). In addition, high prevalence of miR-193a downregulation was noted in
early stage colon cancer tissues and cell lines (SW480) when compared to ad-
vanced staged colorectal carcinomas. Immunohistochemical analysis revealed
inverse correlation betweenmiR-193a andK-ras expression inwhich highK-ras
protein expression was reported in 28/49 cases with miR-193a downregulation.
Analogues fındingswere also observed in cell lines usingWestern blot (P value
0.05). Overexpression of miR-193a in colon cancer cell lines resulted in reduced
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cell proliferation, increased apoptosis and a less accumulation of cells in the
G0-G1 phase cell cycle. Conclusion: The current study confırms the downregu-
lation of miR-193a-3P in colorectal cancer and its tumour suppressor effects in
vitro plays a key role in the modulation of K-ras regulated molecular signalling
pathways in colon cancers.
#466 Role of miR-15b-3p in mitoquinone induced autophagy of breast
cancer cells. Francesca Mascia, Kaytee Pokrzywinski, Ashutosh Rao. FDA/
CDER, Silver Spring, MD.
Mitoquinone, a redox-active mitochondrially targeted ubiquinone, activates
autophagy more potently in breast cancer cells (MDA-MB-231) than in normal
breast cells (MCF-12A).Mitoquinone induces the production of reactive oxygen
species (ROS) and a concomitant activation of the Nrf2-dependent antioxidant
response. MicroRNA are endogenous small double stranded RNA that bind to
the 3’ UTR of several target mRNAs and function through translational repres-
sion or mRNA degradation. The goal of this study was to evaluate microRNA as
a link between oxidative stress and autophagy signaling. We performed RNA
sequencing analysis of themicroRNAsmodulated bymitoquinone treatment of
MDA-MB-231 cells. miRNAs were identifıed using Illumina RNA sequencing.
DEseq analysis revealed 97miRNAs that were differentially expressed at an 
0.05. Within this set, 15 miRNAs were down-regulated by stimulation with
mitoquinone making them attractive as potential autophagy inhibitors. We
characterized the role of amiR-15b-3p by transfecting the cells withmiR-mimic
and anti-miR before inducing an autophagy response. Western blot analysis
showed a reduction in the expression of the autophagy marker LC3, the au-
tophagosome chaperon p62 and the transcription factor Nrf2 in presence of the
miR-15b-3p mimic. Conversely, miR-15b-3p mimic pre-treatment increased
the expression of the cell cycle inhibitor p27 both at the basal level and after
mitoquinone stimulation for 48 hrs. The administration of the anti-miR-15b-3p
did not change the expression level of these proteins suggesting thatmiR-15b-3p
may work with other miRs toward regulating autophagy. Combining the action
of miR-15b-3p mimic with redox active chemotherapeutic drugs could repre-
sent a novel strategy for breast cancer therapy by reducing survival signaling
through autophagy.
#467 Analysis of human hypoxia related miRNAs in MDM2 transfected
prostate cancer cells. Saad Ebrahim Alobid,1 Thiagarajan Venkatesan,2 Ali
Alaseem,1 Khalid Alhazzani,1 Appu Rathinavelu1. 1Nova Southeastern Univ.
College of Pharmacy, Davie, FL; 2Rumbaugh Goodwin Institute for Cancer Re-
search, Nova Southeastern University, Davie, FL.
Recent studies have shown the crucial role of miRNAs in regulating cancer
initiation, progression and metastatic process via influencing gene expression
patterns. However, the distinct mechanism by which miRNA regulates tumori-
genesis remains as an area requiring detailed research investigations. In our
earlier studies, we have demonstrated a positive correlation between MDM2
expression and hypoxia inducible factor -1alpha (HIF-1) levels in both nor-
moxic and hypoxic conditions using prostate cancer cell lines. Subsequently, we
postulated that the upregulation of HIF-1 is most likely regulated byMDM2 in
cancers cells that are positive for this gene expression. Hence, to confırm our
hypothesis, we utilizedmiScriptmiRNAPCRArray analysis (Qiagen, USA) and
compared the gene expression profıle of the hypoxia signaling pathway in LN-
CaP (prostate cancer cells) and LNCaP-MST (MDM2 transfected prostate can-
cer cells) under normoxic conditions. This study was expected to outline how
MDM2 impacts the differential expression of miRNAs and leading to enhance-
ment of tumor angiogenesis via increase inHIF-1 or other genes of the hypoxia
signaling pathway. Our preliminary data indicate that hsamiR99a5p,
hsamiR125b5p, hsamiR1385p, hsamiR199b5p and hsalet7c5p are signifıcantly
upregulated in LNCaP-MST cells compared to LNCaP. In addition, some of the
miRNAs such as hsalet7d5p, hsalet7e5p, hsalet7f5p, hsalet7g5p and hsalet7i5p
are signifıcantly downregulated in the same cells. Among the upregulated miR-
NAs, hsamiR125b5p emerged as an important gene that is known to downregu-
late the protein levels of hypoxia inducible factor 1alpha inhibitor (HIF1AN or
FIH), which can normally inhibit the transcriptional activity of HIF-1 in both
normoxic and hypoxic conditions. Therefore, overexpression of hsamiR125b5p
seems to be associated with the increase in HIF-1 level. From the aforemen-
tioned fındings, it is confırmed that the MDM2 overexpression is impacting
miRNA levels such as hsamiR125b5p that are involved in hypoxia related sig-
naling pathway. Thus, our results offer a convincing evidence that MDM2 can
promote angiogenesis and increase metastatic potential of cancers through al-
tering the miRNA expression levels. (The fınancial support from the Royal
Dames of Cancer Research Inc., Ft. Lauderdale, Florida is gratefully acknowl-
edged).
#468 Evaluation of microRNA inhibition in medulloblastoma. Alexander
Vavra,1 Sydney Stoops,2 JonathanWhite2. 1Kansas City Univeristy, Kansas City,
MO; 2MRIGlobal, Kansas City, MO.
Medulloblastoma is the most common pediatric malignant brain tumor.
The current treatment plan consists of a combination of surgery, radiation,
and chemotherapy which results in an 80% fıve year survival rate. However,
the survival rate does not take into account the developmental delays and
learning disabilities inherited as a result of the aggressive treatment plan on
a developing brain. As such the development of new treatment options is
needed. While many protein targets are currently being explored for thera-
peutic intervention, the role of non-coding RNAs is of increasing interest.
Specifıcally microRNA profıling in medulloblastoma has been performed by
others to highlight expression profıles which can be mapped to the disease
state and also to potentially identify associated protein targets. Moreover, it
is particularly intriguing that microRNAs themselves may be directly tar-
geted as therapeutic points of intervention. With this in mind, our lab is
currently investigating methods for directly targeting microRNAs in medul-
loblastoma and we have recently validated several upregulated miRNAs for
further investigation. Specifıcally, we evaluated the expression profıle eigh-
teen selected miRNAs in DAOY and D341 cell lines. Our results indicate that
four miRNAs (miR-196a, miR-183, miR-96, and miR-182) are statistically
overexpressed in both cell lines. Results of these fındings and our initial
efforts to target these selected miRNAs will be described.
#469 Microrna signature as a potential biomarker for predicting sur-
vival in colon cancer. Havjin Jacob, Luka Stanisavljevic, Kristian Eeg Storli,
Olav Dahl, Mette Pernille Myklebust. Clinical Department of Science, Bergen,
Norway.
Background: Colon cancer is one of the most common cancers with increas-
ing incidence and high mortality worldwide. Prognosis and choice of treatment
is largely based on the tumor stage at presentation. Thus, fınding novel biomark-
ers for predicting survival is highly desirable. Lately, several studies have been
looking at microRNAs (miRNAs) in several cancers, including colon cancer.
MicroRNAs are conserved, non-coding RNAmolecules that play an important
role in the regulation of post-transcriptional gene expression. Material and
Methods: In the present study, we have profıled miRNA in one hundred and
seventy twoTNMstage I-IV colon cancer patients and 10 corresponding normal
colon tissue samples. Total RNA was extracted from freshly frozen tissues, and
the expression of miRNA profıle were assessed using Pick andMix focus panels
from Exiqon containing 84 miRNAs that have been linked to cancer. Results:
The results were visualized in a heatmap (Qlucore omics Software) and more
than 20 miRNAs were found to be differentially expressed in tumors compared
to the normal colon. Further, twelve miRNAs were found to discriminate be-
tween relapse and no-relapse patients in TNM- stage II and III, and four of these
miRNAs (miR-23a, miR-25, miR-30d andmiR-31) were found to be statistically
signifıcant in binary logistic regression with relapse as outcome variable. In
univariate analysis, low expression of the four-miRNA signature was associated
with better 3-year disease-free survival (DFS), 88 % versus 63% in low versus
high signature, respectively (P0.001). Moreover, the signature was a predictor
of poor relapse-free survival in multivariate analyses (P0.001; HR 31; 95% CI:
3.8-248.9). Another regression analyses method (LASSO) identifıed a 16-
miRNA signature, and the four miRNAs found earlier were among them. The
16-miRNA signature was associated with better survival (P0.001). Conclu-
sion: The present study has identifıed a four-miRNA signature predicting re-
lapse in colon cancer stage II and III patients.
#470 Epstein-Barr virus-encodedmiR-BART5modulates PIAS3-pSTAT3
and p21waf1 in gastric carcinoma cells. Dong Ha Kim,1 Chan Jin Yoon,1 Jin-
Seoub Kim,1 Sunyoung Park,2 Euno Choi,2 Jun Hee Woo,3 Mee Soo Chang2.
1Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul,
Republic of Korea; 2Seoul National University College of Medicine Boramae Hos-
pital, Seoul, Republic of Korea; 3AsanMedical Center, University of Ulsan College
of Medicine, Seoul, Republic of Korea.
The ubiquitous Epstein-Barr virus (EBV) is associated with a subset of
gastric carcinomas. MicroRNAs (miRs) are 222 nucleotide non-coding
RNAs, and regulate various functions in cells. EBV-encoded miRs in gastric
carcinoma cells have been identifıed, but the targets and roles of EBV-en-
coded miRs remain elusive. In the present study, we investigated cellular
target of miR-BART5, and its possibility as an oncomiR. In naturally EBV-
infected gastric carcinoma cells and EBV-positive gastric carcinoma tissues,
the comprehensive EBV-miR profıle revealed the expression of 22 EBVmiRs
(each having -3p and -5p) composed of miR-BART cluster 1 and cluster 2,
without miR-BHRFs. Using bioinformatics analysis, we focused on miR-
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BART5 which shared seed sequence homology with hsa-miR-18a and miR-
18b having oncomiR function, and protein inhibitor of activated STAT3
(PIAS3) mRNA. The western blot results confırmed that PIAS3 protein ex-
pression was reduced in miR-BART5-expressing gastric carcinoma cells
(EBV-negative gastric carcinoma cells transfected with miR-BART5), com-
pared with miR-control mock cells. Also PIAS3 expression was signifıcantly
lower in naturally EBV-infected gastric carcinoma cells than in EBV-nega-
tive gastric carcinoma or EBV-infected lymphoma cells. Moreover, there was
a statistically signifıcant inverse correlation between the expression of miR-
BART5 and PIAS3. The luciferase reporter activity in cells diminished after
co-transfection of pEZX-MT06 vector-PIAS3 3=UTR andmiR-BART5, com-
pared with co-transfection of empty vector and miR-control or co-transfec-
tion of empty vector and miR-BART5. When we tested twenty proteins as
downstream candidates of miR-BART5, pSTAT3 increased and p21waf1 de-
creased in miR-BART5-expressing gastric carcinoma cells, compared with
mock cells, and nuclear translocation of pSTAT3 was observed in miR-
BART5-expressing gastric carcinoma cells. In a reverse context that natu-
rally EBV-infected gastric carcinoma cells were transfected with anti-miR-
BART5, protein levels were changed likewise; PIAS3 increased, pSTAT3
decreased and p21waf1 increased. However, there were no statistically signif-
icant differences in cellular biologic properties such as proliferation, apopto-
sis, invasion and migration between miR-BART5-expressing gastric carci-
noma cells and mock cells, or between naturally EBV-infected gastric
carcinoma cells transfected with anti-miR-BART5 and mock cells. Taken
together, miR-BART5 not only targets directly PIAS3 and then modulates
PIAS3-pSTAT3 axis, but also decreases p21waf1 protein, although it fails to
alter cellular proliferation in gastric carcinoma cells. This suggests that a
single viral microRNA is not suffıcient to implement oncogenic function,
despite directly targeting cellular protein involved in oncogenesis. Instead, a
whole cluster like miR-BART cluster 1 or cluster 2 may be advocate to con-
trol cellular biologic property.
#471 HER2 regulates PARP-1 expression by suppressing the let-7a mi-
croRNA in HER2 breast cancer. Eddy Shih-Hsin Yang, Monicka Wielgos,
Rajani Rajbhandari, Shi Wei, Susan Nozell. Univ. of Alabama at Birmingham,
Birmingham, AL.
Background: HER2 breast cancers are sensitive to PARP inhibition and
express elevated levels of the PARP-1 protein. However, the mode of regulation
of PARP-1 expression by HER2 is not well understood. MicroRNAs are small
non-coding RNAs that function in RNA silencing and post-transcriptional reg-
ulation of gene expression. In this study, we investigate whether PARP1 expres-
sion in human breast cancer cells is regulated by HER2 regulation of microR-
NAs.Methods:HumanHER2 breast cancer cell lines BT-474 and SKBR3were
used in this study. MDA-MB-231 (non-HER2 expressing breast cancer cells)
stably transfected with a HER2 wild-type plasmid (231 HER2) or the vector
control (231 NEO) were also utilized. To identify candidate microRNAs regu-
lated by HER2 overexpression, we performed the nCounter miRNA Expression
Assay. MicroRNA and mRNA expression were validated via qRT-PCR analysis
in breast cancer cell lines or patient primary tumors. Cells were also transfected
with a HER2 siRNA, a let-7a mimic, and an inhibitor of let-7a as well as their
respective controls. Western blot analysis and fırefly luciferase assays were used
to determine whether the 3’UTR of PARP1 was being directly targeted by the
let-7amicroRNA.Results:HER2did not regulate PARP-1 at themRNA level but
increased PARP-1 protein in HER2 breast cancer cells. Specifıcally, ectopic
HER2 overexpression correlated with increased PARP-1 protein levels in the
231 HER2 cell line. Conversely, silencing HER2 reduced PARP-1 protein levels
in the BT-474 and SKBR3 cell lines. NanoString nCounter analysis revealed that
the HER2 breast cancer cell lines expressed low levels of the let-7amicroRNA.
Further, let-7a expression was upregulated after HER2 knockdown in the two
native HER2 breast cancer cell lines. The let-7a mimic also reduced both
PARP1 protein expression and luciferase activity in the 231 HER2 and BT-474
cell lines, whereas the let-7a inhibitor reversed these effects in the 231 NEO cell
line. Importantly, human HER2 breast tumors expressed higher levels of
PARP-1 and lower levels of let-7a; whereas, the HER2- breast tumors expressed
lower levels of PARP-1 and higher levels of let-7a. Further, overexpression of the
let-7a mimic reduced cell proliferation in HER2 breast cancer cells. Conclu-
sions: These results suggest that let-7a regulates PARP-1 expression in HER2
breast tumors. Let-7a may also be a potential therapeutic target and predictive
biomarker of PARPi sensitivity in HER2 breast cancer patients.
#472 Role of miRNAome deregulation in the pathogenesis of non-alco-
holic steatohepatitis (NASH)-derived hepatocellular carcinoma. Juliana F.
Ortega,1 Aline DeConti,1 Kostiantyn Dreval,1 Fernando S. Moreno,2 Frederick
A. Beland,1 Igor P. Pogribny1. 1NCTR/FDA, Jefferson, AR; 2University of Sao
Paulo, Sao Paulo, Brazil.
Recent epidemiological studies have attributed the growing incidence of
liver cancer, including hepatocellular carcinoma (HCC), in the United States
to NASH, an advanced form of non-alcoholic fatty liver disease. Elucidating
the molecular pathways that lead to the development of NASH-derived HCC
is critical not only for identifying early diagnostic biomarkers of the disease,
but also for treatment and prevention. We have investigated the role of
microRNAs (miRNAs) in the development of NASH-derived HCC by using
a Stelic Animal Model (STAM) of liver carcinogenesis. Using Liver miFinder
PCR arrays, we examined the miRNA profıles in the livers of STAMmice and
identifıed 25 and 35 miRNAs that were differentially expressed at a NASH-
fıbrotic stage (12 weeks) and in full-fledged HCC (20 weeks), respectively.
Among these differentially expressed miRNAs, 18 miRNAs were in com-
mon. Multi-algorithm target prediction analysis of the common differen-
tially expressed miRNAs revealed the involvement of these miRNAs in the
deregulation of major molecular processes associated with the development
of HCC, including epithelial-mesenchymal transition, HCC stem cell acti-
vation, and the induction of the -catenin/Wnt and Hippo signaling path-
ways. These fındings were confırmed by a marked up-regulation of Yes-
associated protein 1 (YAP1), the main effector of the Hippo-pathway, the
activation of epithelial-mesenchymal transition, and an increased-expres-
sion of hepatic progenitor cell markers. In addition to the common differ-
entially expressed miRNAs, 10 miRNAs, including 5 members of the poly-
cistronic oncomir miR-17-92 cluster, were found to be over-expressed in
only HCC. These results indicate the fundamental role of miRNAs in the
development of NASH-associated HCC. This is evidenced by the early oc-
currence of miRNA alterations at the preneoplastic stage of liver carcinogen-
esis, the persistence of these changes in HCC, and the accumulation of ad-
ditional miRNA alterations in HCC, and by the existence of a mechanistic
link between miRNA alterations and deregulation key cancer-related path-
ways.
#473 PRKRA/PACT expression promotes chemoresistance in mucinous
ovarian cancer. Takeshi Hisamatsu,1 Michael McGuire,1 Sherry Y. Wu,1 Raje-
sha Rupaimoole,1 Sunila Pradeep,1 Kyunghee Noh,1 Justyna Filant,1 Jean M.
Hansen,1 Yasmin Lyons,1 Kshipra M. Gharpure,1 Archana S. Nagaraja,1 Linge-
gowda S. Mangala,1 Takashi Mitamura,1 Cristian Rodriguez-Aguayo,1 Geoffrey
A. Bartholomeusz,1 Cristina Ivan,1 Ju-Seong Lee,1 Koji Matsuo,2 Michael Fru-
movitz,1 Kwong K. Wong,1 Gabriel Lopez-Berestein,1 Anil K. Sood1. 1UT MD
Anderson Cancer Ctr., Houston, TX; 2University of Southern California, Los An-
geles, CA.
Purpose: To investigate the mechanisms of chemotherapy resistance and de-
veloping strategies to enhance therapeutic responses in mucinous ovarian can-
cer (MOC). Experimental design:We carried out a kinome-based siRNA screen
using human MOC to identify novel targets to enhance the effıcacy of chemo-
therapy inMOCcell lines. In vitro and in vivo validation studieswere carried out
using MOC models. We specifıcally interrogated the role of PRKRA in MOC
based on our screen results. Results: Among the 939 genes in the screen, we
focused on PRKRA/PACT because it was one of the top 5 target genes that
exhibited the greatest extent of synthetic lethality in the target gene-siRNA plus
oxaliplatin group relative to the target gene-siRNA group. The combination of
oxaliplatin plus siPRKRA treatment resulted in signifıcantly reduced cell viabil-
ity compared with oxaliplatin plus control siRNA in RMUG-L-ip1 or RMUG-
S-ip1 MOC cells (p0.001), while knockdown of PRKRA did not result in a
signifıcant change in cell viability compared with the control. We also observed
a 2.1-fold increase in cell apoptosis in vitro after treatment with oxaliplatin plus
siPRKRA in both MOC cells (p0.05). Using orthotopic mouse models of
MOC,we observed an 88% reduction (p0.01) in tumorweight and 75% reduc-
tion in the number of tumor nodules (p0.01) in the siPRKRA plus oxaliplatin
group comparedwith the control siRNAplus oxaliplatin group. PRKRA expres-
sion in humanMOCwas signifıcantly higher relative to high-grade serous ovar-
ian tumors as evaluated by immunohistochemistry. Furthermore, we found that
the interaction between PACT andDicer can regulatematuration ofmicroRNA.
In particular, mature-miR-515-3p was found to be inhibited by the interaction
between PACT and Dicer. Expression of miR-515-3p promotes chemosensitiv-
ity inMOCby targeting themRNAof the anti-apoptotic geneAXL. Conclusion:
The PRKRA/PACT axis represents an important therapeutic opportunity in
MOC for enhancing oxaliplatin effıcacy.
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#474 Estrogen-responsive miRNAs as modulators of E2-induced apopto-
sis in AI-resistant breast cancer. Reiner Hoppe,1 Ping Fan,2 Stefan Winter,1
Florian Büttner,3 V. Craig Jordan,2 Hiltrud B. Brauch3. 1Dr. Margarete Fischer-
Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen,
Tuebingen, Germany; 2MD Anderson Cancer Center, University of Texas, Hous-
ton, TX; 3Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stutt-
gart, and University of Tuebingen, Tuebingen, German Cancer Consortium
(DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Long-term estrogen deprivation with tamoxifen or aromatase inhibitors (AI)
is the basic principle of endocrine treatment of ER-positive breast cancer. Ac-
quired resistance is however a major obstacle in treatment success. Based on
clinical observations and in vitro as well as animal in vivo experiments it has
been suggested that tumor cell clones evolve over time and become vulnerable to
E2-induced apoptosis, thereby potentially providing a promising second line
treatment option. In vitro, this vulnerability is mimicked in the AI-resistant
breast cancer models MCF-7:5C and MCF-7:2A, which during long-term E2-
deprivation reconfıgure their survival signaling including endoplasmic reticu-
lum, oxidative and inflammatory stress related pathways. E2-stimulation of
these cells initiates an unfolded protein response which in turn triggers apopto-
sis through the intrinsic and subsequently extrinsic pathway (Jordan VC 2015).
Recently, we identifıed miRNA profıles matching the biology of AI resistance
and vulnerability to E2-induced apoptosis (Hoppe R et al. 2016). Here we inves-
tigate the modulatory role of miRNAs in E2-induced apoptosis through the
identifıcation of their global expression changes in E2-stimulated 5C and 2A
models compared to MCF-7:WS8 reference. Each cell line was treated with 10-9
M E2 or vehicle over a 72h time course (6, 12, 24, 72 h). miRNA profıles were
generated using Affymetrix GeneChip miRNA2.0 arrays. At each time point
relative miRNA expression changes (E2/control) were evaluated resulting in a
total of 72 (5C), 104 (2A) and 94 (WS8) differentially expressed miRNAs (FC
1.5 or 1/1.5, Pt-test 0.05). Differential expression analyses between consec-
utive time points revealed 16 (5C), 43 (2A) and 27 (WS8) miRNAs (maximum
absolute FC difference  1.5, PF-test  0.05). Differential area under the curve
(dAUC) analyses at 6-72, 6-24, and 24-72 h mined the overall, early, and late-
responding miRNAs of the different phenotypes (Ppermutation test  0.05). Rep-
resentative early down-regulatedmiRNA candidates potentiallymodulating E2-
induced apoptosis in 5C cells are miR-543 and miR-432 of the DLK1-DIO3
locus on Chr. 14q32.31. Late responding up-regulated miRNA candidates are
miR-150* andmiR-149* the low expression of which in tumor tissues registered
inTheCancerGenomeAtlas (miRNA-Seq v. 3.1.17.0)was associatedwithworse
outcome in all PAM50 breast cancer subtypes and Lum B, respectively (HR 
2.1, 95%CI: 1.4-3.2; P 0.00017;HR 6.8, 95%CI: 1.5-3.0; P 0.0036).We are
currently in the process to subject respective miRNA sets to functional enrich-
ment analyses (KEGG, GO) and to correlate E2-responsive miRNA candidates
with respective transcriptome signatures. In summary, we will present miRNAs
matching to the biological processes inherent to E2-induced apoptosis. These
may serve as potential targets for the amplifıcation of the apoptotic trigger upon
E2-treatment.
#475 Role ofmicroRNA-34a in regulating oncoprotein STMN1.Balabhad-
rapatruni V.S.K. Chakravarthi,1 Rohit Mehra,2 Rui Wang,2 Darshan Shimoga
Chandrashekar,1 Sai Akshaya Hodigere Balasubramanya,1 Irfan A. Asangani,3
Robert J. Lonigro,2 Arul M. Chinnaiyan,2 Sooryanarayana Varambally1. 1Uni-
versity of Alabama at Birmingham, Birmingham, AL; 2University of Michigan,
Ann Arbor, MI; 3University of Pennsylvania, Philadelphia, PA.
MicroRNAs, as negative regulators of gene expression, play a major role in
cellular homeostasis. Downregulation of miRs is common in cancer which re-
sults in upregulation of multiple oncogenes in cancer. Here we show that stath-
min (STMN1), which is over-expressed and oncogenic in wide variety of can-
cers, is regulated bymicroRNA-34 in prostate cancer. Earlier studies suggest that
stathmin is involved in vital cellular processes such as cell proliferation, motility
andmetastasis. In the present study, we show elevated expression of stathmin in
metastatic prostate cancer. Functionally, knockdown of stathmin in prostate
cancer cells resulted in reduced cell proliferation and invasion in vitro, and
tumor growth and metastasis in vivo. We also show that tumor suppressor
microRNAmiR-34a targets stathmin andmir-34 is regulated by transcriptional
corepressor CtBP1 (C-Terminal Binding Protein 1). Further, Microarray anal-
yses using stathmin modulated prostate cancer cell line RNA revealed multiple
molecular alterations which may play a critical role in STMN1-mediated onco-
genic activity. Thus, our study suggests that CtBP1-regulated miR-34a modu-
lates stathmin expression in prostate cancer. This study therefore demonstrates
functional role of CtBP1-miR-34a-Stathmin axis in prostate cancer progression.
#476 MicroRNAmediated regulation of ATF5 contributes to homeostasis
and benign to malignant transformation in breast cancer cells. Kari Ann
Gaither, Bhanupriya Madarampalli, David X. Liu.Washington State University,
Spokane, WA.
The transcription factor ATF5 modulates survival, proliferation, differentia-
tion, and homeostasis. In unstressed conditions, ATF5 has a short half-life and is
rapidly degraded due to post-translational modifıcations. Conversely, ATF5 is
upregulated in cells under cellular stress. Furthermore, we have found thatATF5
is elevated and is a survival factor in transformed C6 glioma and MCF7 breast
cancer compared to non-transformed cells. Regulation of ATF5 expression is
not fully understood. We hypothesized that microRNA (miRNA) play a role in
regulating the expression ofATF5 at the 3’ UTR and sought to better understand
the role ofATF5 in the transformation to amalignant cell phenotype. Todate, no
studies have examined the regulation of ATF5 by miRNA. MiRNAs are endog-
enous small non-coding RNAs 20-25 nucleotides in length that contribute to
regulation of gene expression at the translational level. We used in silico mod-
eling programs to identifymiRNAs predicted to bind to the 3’ UTRofATF5.We
then aimed to identify the presence of specifıcmiRNA and their ability to down-
regulate ATF5 during cellular stress and other physiological conditions in vitro.
Luciferase reporter assays and immunoprecipitations of ATF5 3’ UTR mRNA
and cell lysate were performed and microRNA quantity analyzed via qPCR
analysis. Subsequently, transfections of precursormicroRNAwere carried out in
human MCF10A breast epithelial, MCF7 mammary epithelial, and breast ade-
nocarcinomaMDA-MB-231 cell lines, and expression levels of ATF5weremea-
sured under varying physiological conditions viaWestern Blot analysis. In vitro
migration and invasion assays were performed and transformation was studied
via MCF10A mammary epithelial cells with inducible SRC. We demonstrate
that miRNA are bound to the 3’ UTR of ATF5 and that miRNAs 433-3p and
520b help to regulate the expression of ATF5 under varying stress conditions
and at steady state in MCF10A, MCF7, and MDA-MB-231 cells. Additionally,
preliminary data indicate that ATF5 is upregulated during transformation of
MCF10A cells with inducible SRC and is overexpressed in MDA-MB-231 cells
as compared to MCF7 and MCF10A cell lines, and suggest that ATF5 may
enhance migration and invasion. Further studies are necessary to elucidate the
role of ATF5 in transformation, migration, and invasion. Better understanding
of the regulation of ATF5 could have implications in a broad range of human
malignancies.
#477 Down-regulated miR-23a contributes to invasion and metastasis of
cutaneous melanoma by promoting autophagy. Weinan Guo, Huina Wang,
Yuqi Yang, Sen Guo, Weigang Zhang, Tao Zhao, Lin Liu, Zhe Jian, Ling Liu,
Gang Wang, Tianwen Gao, Qiong Shi, Chunying Li. Department of Dermatol-
ogy, Xijing Hospital, Fourth Military Medical University, Xi’an, China.
Background: The occurrence of invasion and metastasis is the major cause of
mortality in melanoma. Recent studies suggest that dysregulated miRNAs play
critical roles in this procedure, but the underlying mechanism remains elusive.
Here, we show that down-regulated miR-23a can promote invasion-metastasis
cascade through autophagy in melanoma. Methods: The role of miR-23a in
prognosis was assessed in a cohort ofmelanoma patients (n 192)withKaplan-
Meier analysis. The effects of miR-23a overexpression were investigated using
assays of invasion, migration and in a xenograft model (n 10mice per group).
Autophagy-related target of miR-23a was confırmed by bioinformatics analysis,
luciferase assays and immunoblotting. Molecular studies were performed to
determine the downstream cellular and molecular mechanisms. All statistical
tests were two-sided. Results: Serum miR-23a level was signifıcantly down-reg-
ulated in melanoma patients (P .001) and was highly correlated with poor
clinical outcomes (P  .027, log-rank test). In addition, miR-23a level was re-
markably decreased in metastatic melanoma tissues and cell lines (P.05,
P.01). Moreover, miR-23a overexpression prevented the invasion and migra-
tion in vitro and lung and liver metastasis in vivo (both P .05), by targeting
ATG12 and inhibiting autophagy. Mechanically, miR-23a-ATG12 axis attenu-
ated invasion and migration through autophagy-mediated AMPK-RhoA path-
way. Finally, the down-regulation of miR-23a in metastatic melanoma was
caused by RUNX2 in a transcriptional repression-manner. Conclusion: MiR-
23a can act as a crucial epigenetic repressor of melanoma invasion and metas-
tasis in an autophagy-dependent way, which indicates that miR-23a-mediated
autophagy inhibition can be exploited to restrain invasion-metastasis cascade in
melanoma treatment.
#478 Regulation of cross talk between AR and wnt/beta-catenin pathways
in prostate cancer. Alexis Plaga, Girish C. Shukla. Cleveland State University,
Cleveland, OH.
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Prostate Cancer (PCa) is the secondmost commonly diagnosed cancer in the
United States with 180,890 males diagnosed and is predicted to cause approxi-
mately 26,000 deaths in 2016. The current treatment of androgen deprivation
therapy (ADT) initially depletes circulating androgens; however, intratumoral
androgens rescue androgen receptor (AR) signaling and promotes the develop-
ment of castration resistant prostate cancer (CRPC). The dysregulation of the
Wnt/-catenin signaling pathway has been implicated in the development of
many cancers including PCa. The disruption of this signaling leads to the stabi-
lization of -catenin which upregulates many genes involved in tumorigenesis.
Additionally, -catenin acts as AR cofactor. Our previous studies show that AR
is a direct target of miR-644a. We hypothesized that targeting the expression of
both the -catenin pathway and AR by conventional drugs and/or tumor sup-
pressor miR-644a would have synergistic therapeutic benefıts. In this study, we
are investigating miR-644a mediated posttranscriptional downregulation of
GSK3- and -catenin in the wnt/-catenin signaling pathway. The effect of
miR-644a in combination with inhibitors (-catenin or GSK3-) was also as-
sessed using proliferation assays and a signifıcant downregulationwas observed.
We will further study the posttranscriptional effects of tumor suppressor miR-
644a on the wnt/-catenin pathway and also the processing and regulation of
miR-644a in PCa.
#479 Modeling miRNA induced silencing in breast cancer with PARA-
DIGM.Andrew J. Sedgewick,1 Panayiotis V. Benos,2 Shahrooz Rabizadeh,3 Pat-
rick Soon-Shiong,3 Charles J. Vaske1. 1Nantomics LLC, Santa Cruz, CA; 2Uni-
versity of Pittsburgh, Pittsburgh, PA; 3Nantworks, Culver City, CA.
Introduction: MicroRNAs play an important role in regulation of gene ex-
pression and are known biomarkers for breast cancer as well as other malignan-
cies. PARADIGM is a pathway based algorithm that allows for integration of
multiple genomic data types with a curated pathway database to make pathway
activity predictions. We added a model of gene silencing due to miRNA to the
PARADIGM algorithm in order to study miRNA expression in a pathway con-
text. Results: We curated a set of 7751 miRNA-mRNA interactions from the
intersection of 3 target prediction algorithms. These interactions involved 66
miRNA and 2814 mRNA transcripts. We ran this model on global DNA copy
number, RNAseq and miRNAseq data from 697 patients in the TCGA breast
cancer cohort, and studied changes in the interactions between miRNAs and
their targets between different tumor subtypes. Themedian activity of the RNA-
induced silencing complex (RISC) predicted by ourmodel is signifıcantly higher
in Basal tumors than other subtypes. In addition, RISC activity is signifıcantly
associatedwith overall survival of patientswith LuminalA tumors. ThemiRNA-
target pairs with the largest correlation changes between Basal and Luminal A
subtypes were enriched for putative oncogenes and oncomirs. The mRNA tar-
gets are involved in a number of important signaling pathways including PI3K-
AKT, JAK-STAT, and Ras. Many of these highly differential links involved the
miR-16 family of miRNAs which are known tumor suppressors. miR-16 shows
signifıcantly lower activity in basal tumors than other subtypes. Conclusions: By
looking at changes in miRNA-target links between tumor subtypes, our algo-
rithm was able to identify both miRNAs and target genes involved in pathways
relevant to breast cancer. Our predictions of overall RNA-induced silencing
activity showprognostic value in both determining subtype andpredicting over-
all survival within subtypes.
#480 Novel miRNA regulation in an early progression model of PDA.
Nina J. Chu, Todd D. Armstrong, ElizabethM. Jaffee. The Sidney Kimmel Com-
prehensive Cancer Center, Johns Hopkins University School of Medicine, Balti-
more, MD.
The success of immunotherapy is dependent on infıltration and function of T
cells within the tumor microenvironment. However, for many cancers, inflam-
matory and stromal cells provide formidable barriers to T cell access. Emerging
data suggests that the cellular barriers to T cell access and function are regulated
by both genetic and epigenetic factors. Identifıcation of these regulators should
provide new targets for enhancing immunotherapy. The overall goal of this
research is to construct a comprehensive profıle ofmiRNAexpressionwithin the
inflammatory and stromal cells that develop in the earliest pre-malignant pan-
creatic intraepithelial neoplasias (PanINs) in theKrasG12D/;Trp53R172H/;Pdx-
1-Cre (KPC) mouse model, a spontaneous model of pancreatic ductal adeno-
carcinomas (PDA) tumorigenesis. Specifıally, we aim to investigate the
functional roles of key differentially expressed miRNAs in propagating the tu-
mormicroenvironment viamodulating the signaling between transformed duc-
tal epithelial cells and the recruited cancer associated fıbroblasts (CAFs) that
comprise the majority of the desmoplastic stroma that characterizes PDA. Al-
though numerous studies have describedmolecular alterations that are involved
in pancreatic cancer development and progression, little is known about the
miRNA regulatory profıle and the associated inflammatory changes within the
tumor microenvironment in the earliest PanIN lesions. We conducted miRNA
microarray analysis to determine the levels of 750 unique miRNAs in the pan-
creata of KPC mice ranging from 4 to 12 weeks of age (pre-PanIN1 to PDA).
miRNA was isolated from normal pancreatic ducts, PanIN grades 1 through 3,
and PDA via laser capture microdissection. miRNA expression was quantifıed
by Taqman miRNA OpenArrays and confırmed by qPCR analysis. Out of the
750 rodentmiRNAs, 4miRNAs (miR-21, miR-16, miR-19b, andmiR-224) were
signifıcantly upregulated throughout PDA development. miR-21 and miR-224
are of particular interest for their regulation of targets in cancer promoting
inflammatory pathways and epithelial-mesenchymal transition (EMT). To in-
vestigate the roles that miR-21 and miR-224 play in the developing microenvi-
ronment, primary KPC pancreatic ductal epithelial and fıbroblast cell lines were
established via fluorescence activated cell sorting (FACS) in order to perform in
vitro miRNA knock-in and knock-out studies. Additionally, miRNA fluores-
cence in situ hybridization (miR-FISH) was performed to examine the spatial
expression of miR-21 throughout progression of the early microenvironment.
miR-21 is expressed at low levels in wildtype pancreata, but is highly expressed
particularly in ductal epithelial cells of late stage KPC pancreata. Additional
studies are underway to determine the functional role of this miRNA in PDA
development and progression.
#481 Diminished microRNA-29b results in overexpression of BRD4 and
BRD4-regulated oncogenes in cutaneous T-cell lymphoma. Rebecca
Kohnken,1 Jing Wen,1 Bethany Mundy-Bosse,1 Max Yano,1 Leah Grinshpun,1
Kathleen McConnell,1 Ashleigh Keiter,1 Alex Hartlage,1 James Bradner,2 Mi-
chael Caligiuri,1 Pierluigi Porcu,1 Anjali Mishra1. 1Comprehensive Cancer Cen-
ter, The Ohio State University, Columbus, OH; 2Dana-Farber Cancer Institute,
Harvard Medical School, Boston, MA.
Cutaneous T-cell lymphoma (CTCL) is a CD4 T-cell malignancy that af-
fects the skin but may disseminate systemically, and there are no long-term
effective therapeutic strategies.Here,we characterized the therapeutic effıcacy of
manipulating the tumor suppressor microRNA-29b (miR-29b) and its target
bromodomain-containing protein 4 (BRD4) in CTCL pathogenesis. Using pri-
mary CD4 T-cells we determined that miR-29b expression is signifıcantly
decreased in patients compared to healthy controls (0.0070.002, n9 vs
1.0080.052, n6, p0.0001). We utilized miR-29b-/- mice and bortezomib, a
proteasome inhibitor known to increase miR-29b levels, to confırm the inverse
relationship between miR-29b and BRD4 (Mishra, A. et al. Cancer Cell, 2012).
Diminished miR-29b level resulted in increased BRD4 protein expression
(1.870.29, p0.014), while increase in miR-29b, as in bortezomib-treated
CTCL cell lines, results in nearly undetectable BRD4 protein. We also observed
increased genome-wide occupancy of BRD4 at regulatory regions in CTCL pa-
tients, an effect that is reversed with BRD4 inhibitor, JQ1, to similar levels as
observed in healthy control CD4 T-cells. Specifıcally, oncogene loci of
NOTCH1 and RBPJ demonstrated enhanced BRD4 binding in CTCL patients,
with resultant increases in mRNA in patient vs normal donors (4.160.98,
p0.024; 3.020.54, p0.012). Further, in vivo treatment of interleukin-15
(IL-15) transgenic mice (Mishra, A. et al. Cancer Discovery, 2016) with JQ1
preventedCTCLdevelopment and decreased lesion severity (3.370.49, n8 vs
6.00.45, n5, p0.004). Skin from JQ1-treatedmice demonstrated decreased
protein expression of BRD4, NOTCH1, and RBPJ, consistent with our fındings
in patients and CTCL cell lines. Bortezomib treatment of CTCL mice yielded
similar results to JQ1 in vivo, while miR-29b levels were elevated in treatedmice
vs control animals. Since IL-15 signals through its receptor complex, we evalu-
ated and observed increased BRD4 binding at IL-15 receptor  gene loci in
CTCL patients, which was reversed with both JQ1 and bortezomib treatment.
Thus, we conclude that diminishedmiR-29b results in increased expression and
subsequent binding of BRD4 at regulatory regions of knownoncogenes inCTCL
cells including NOTCH1, RBPJ, and the IL-15 receptor complex. We confırm
the potential therapeutic utility of targeting this pathway in vivo, by direct dis-
placement of BRD4 by JQ1, or by rescue of miR-29b expression by bortezomib.
We therefore describe a novel targetable oncogenic pathway featuring IL-15,
miR-29b, and BRD4 in CTCL.
#482 miRNAs involved in LY6K and estrogen receptor- contribute to
tamoxifen susceptibility inbreast cancer.YesolKim,DasomSon,KyungHyun
Yoo, JongHoonPark. SookmyungWomen’s University, Seoul, Republic of Korea.
Estrogen receptor-alpha is a clinically important therapeutic target for breast
cancer.However, tumors that lose ER are less responsive to anti-estrogens such
as tamoxifen. MicroRNAs are small RNAs that regulate expression of their tar-
get gene and dysregulations of miRNA has been identifıed in many diseases
including human cancer. However, only a few miRNAs associated with tamox-
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ifen resistance has been reported. In this study, we found that lymphocyte anti-
gen 6 complex, which is a member of the Ly-6/PAR superfamily and related to
breast cancer progression and metastasis, is inversely correlated with ER ex-
pression. We, for the fırst time, found miRNAs involved in the regulatory mo-
lecular mechanism between ER and LY6K and related to tamoxifen suscepti-
bility in breast cancer. miR-192-5p, induced by LY6K, downregulates ER
directly and induced tamoxifen resistance in ER-positive breast cancer cells. In
addition, re-expression of ER in ER-negative breast cancer cells increased
miR-500a-3p expression and directly inhibits LY6K expression. Ectopic expres-
sion of miR-500a-3p sensitized ER-negative cells to tamoxifen by increasing
apoptosis. Finally, we observed an inverse correlation between LY6K andER in
primary breast cancer samples. We found that patients with recurrence showed
high expression of miR-192-5p after tamoxifen treatments. In addition, expres-
sion of miR-500a-3p was signifıcantly correlated to survival outcome. As miR-
NAs involved in the regulatory mechanism between LY6K and ER can affect
tamoxifen resistance, downregulating miR-192-5p or re-expressing miR-
500a-3p could be a potential therapeutic approach for treating tamoxifen resis-
tant patients.
#483 Differential expression of miR-34b and androgen receptor pathway
regulate prostate cancer aggressiveness betweenAfricanAmericans andCau-
casians. Marisa Shiina, Yutaka Hashimoto, Taku Kato, Soichiro Yamamura,
Yuichiro Tanaka, Shahana Majid, Sharanjot Saini, Shahryari Varahram, Pri-
yanka Kulkarni, Prita Dasgupta,Mitsuho Sumida, GuorenDeng, Rajvir Dahiya.
UCSF/VA Medical Center, San Francisco, CA.
African-Americans are diagnosed with more aggressive prostate cancers and
have worse survival than Caucasians, however a comprehensive understanding
of this health disparity remains unclear. To clarify the mechanisms leading to
this disparity, we analyzed the potential involvement of miR-34b expression in
African-Americans andCaucasians.We found thatmiR-34b expression is lower
in human prostate cancer tissues from African-Americans compared to Cauca-
sians. DNA hypermethylation of the miR-34b-3p promoter region showed sig-
nifıcantly highermethylation in prostate cancer compared to normal tissues.We
found that AR andETV1 genes are differentially expressed inMDA-PCa-2b and
DU-145 cells after overexpression of miR-34b. Direct interaction of miR-34b
with the 3’ untranslated region of AR and ETV1 was validated by luciferase
reporter assay.We found thatmiR-34b downregulation inAfrican-Americans is
inversely correlated with high AR levels that lead to increased cell proliferation.
Overexpression of miR-34b in cell lines showed higher inhibition of cell prolif-
eration, apoptosis and G1 arrest in African-American cells (MDA-PCa-2b)
compared to the Caucasian cell line (DU-145). Taken together, our results show
that differential expression of miR-34b and AR are associated with prostate
cancer aggressiveness in African-Americans.
#484 Epigenetic regulation of hsa-miR-3663 in colon cancer. Laia Pique,
Humberto Jorge Ferrerira, Manel Esteller. Bellvitge Biomedical Research Insti-
tute (IDIBELL), Barcelona, Spain.
Colon Cancer is the third most common cancer in the world and a major
cause of morbidity and mortality. Molecular mechanisms of colon carcinoma
have been deeply studied and current evidences indicate that microRNAs play a
pivotal role in its tumorigenesis and progression. MicroRNAs (miRNAs) are
small 19 to 22 nucleotides of RNA classifıed as non-coding RNAs that negatively
regulate gene expression at the post-translational level controlling numerous
biological processes including development, cell proliferation, apoptosis, differ-
entiation and cell migration. Aberrant expression of miRNAs due to epigenetic
alterations has been associatedwith carcinogenesis. Aimed to identify epigeneti-
cally regulated miRNAs involved in colon cancer, we analyzed DNA methyl-
ation profıles available in The Cancer Genome Atlas. One of the main hits iden-
tifıed was hsa-miR-3663, hypermethylated in 26% of colon cancer patients
(n286, p 0.001) in comparison with complete lack of methylation in normal
tissues (n38), suggesting its potential function as a putative tumor suppressor.
In order to study the role of DNA methylation controlling hsa-miR-3663,
HumanMethylation450K methylation profıles were generated for a panel of
colon cancer cell lines (n10), including the HCT116-DNA methyltransferase
knock-out model (DKO, double knockout of DNMT1 and DNMT3B). We
found a signifıcant correlation betweenmethylation status of hsa-miR-3663 and
expression in colon cancer cell lines. Furthermore, epigenetic regulation of hsa-
miR-3663was confırmed inHCT116methylated cell line by restored expression
upon treatment with DNA demethylating agent 5-aza-2=-deoxycytidine and in
the HCT116-DKO model. In order to elucidate the function of hsa-miR-3663,
we stably expressed hsa-miR-3663 in a panel of fıvemethylated colorectal cancer
cell lines (HCT116, RKO, DLD1, SW48 and SW480). Our initial functional
assays revealed that hsa-miR-3663 is not involved in cell proliferation or migra-
tion. We are now performing additional assays to further study hsa-miR-3663
and its potential role in colon cancer.
#485 Epigentic silencing of miR-142-3p promotes metastasis by targeting
ZEB2 in NPC. Yingqin Li, Na Liu, Jun Ma. Sun Yat-sen University Cancer Cen-
ter, Guangzhou, China.
Metastasis is the major cause of cancer-related death in nasopharyngeal car-
cinoma (NPC). However, the molecular mechanisms governing metastasis re-
main poorly understood in NPC. Here, we demonstrated that miR-142-3p was
downregulated and signifıcantly suppressed NPC cell migration, invasion in
vitro and in vivo.We identifıed zinc fınger E-box binding homeobox 2 (ZEB2) as
a direct target of miR-142-3p, and its overexpression rescued the inhibitory
effects of miR-142-3p in NPC. Importantly, miR-142-3p downregulation was
associated with DNA methylation within the miR-142 locus. Enhancer of zeste
homologue 2 (EZH2) suppressedmiR-142methylation andmiR-142-3p expres-
sion. Systemic reversal of miR-142 silencing suppressed lung metastasis of NPC
cells. Furthermore, miR-142 hypermethylation was associated with poormetas-
tasis-free survival. This study demonstrates a suppressive role of miR-142-3p in
metastasis and uncovers an epigenetic mechanism for miR-142-3p silencing in
NPC, suggesting a potential prognostic factor and therapeutic target to combat
metastasis in NPC.
#486 Production of an unbiased, highly reproducible small RNA library
for NGS using a novel circularization technology. Marta Gonzalez-Plasky,
Amanda McNulty, Konstantinos Charizanis, Jing Ning, Edward Jan, Matthew
Carroll, Emmanuel Kamberov, Karl Hecker. Rubicon Genomics, Inc., Ann Ar-
bor, MI.
MicroRNA sequencing (miRNA-Seq) is a useful tool for aiding researchers in
the examination of miRNA expression patterns, the characterization of novel
miRNAs, and for uncovering miRNA-disease associations. Since miRNAs are
also unusually well-preserved in a range of samples (e.g. urine, FFPE tissue,
plasma), profıling their expression is becoming a powerful diagnostic tool.How-
ever, current methods for sequencing miRNA require large amounts of total
RNA, are not very reproducible and, more importantly, have considerable sys-
tematic bias resulting in loss of many prospective biomarkers. This bias severely
affects the trustworthiness of results as libraries are not a true representation of
the biological state of the sample. We have recently developed a technology that
effıciently capturesmiRNA species with extremely low bias. Through a circular-
ization approach, Illumina P5 andP7 adapters are ligated tomiRNA, resulting in
sequenceable libraries in under 5 hours in a single tube. These libraries are then
purifıed and size-selected prior to sequencing. Analysis of read distributions of
libraries prepared from an equimolarmixture of 963miRNAs demonstrated the
technology is able to effıciently capture all species with high reproducibility
between replicates and input amounts (correlation coeffıcient of 	0.97). Fur-
thermore, 80-86% of these captured miRNA read numbers fall within a /-
2-fold variation of the expected read number demonstrating unbiased represen-
tation. In contrast, frequency distribution analyses for other technologies reveal
that 47-56% of miRNAs are greatly under-represented (i.e. less than 2X fewer
reads than expected), 29-38% of miRNAs are represented within a /- 2-fold
variation of the expected read number, and around 15% are over-represented by
more than 2X. These fındings highlight the fact that the current technical state of
library preparation for miRNA sequencing fails to accurately represent miRNA
expression patterns. This in turn leads researchers to perform more costly vali-
dation experiments than necessary. Our product is designed and developed for
more accurately reflecting the true biological state of a sample. This will provide
researchers with a tool that can aid in advancing miRNA sequencing in transla-
tional research.
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#487 A comprehensive target enrichment panel for fusion detection.
Ashesh Saraiya,1 Brandon Young,2 Tobias Meißner,2 Brian L. Jones,2 Stephanie
C. Huelga,1 Doug A. Amorese1. 1NuGEN, San Carlos, CA; 2Avera Cancer Insti-
tute for Precision Oncology Genomics, San Diego, CA.
Growing interest in cancer classifıcation and progression has accelerated the
rate of novel gene fusions discovery with increasing recognition of their roles as
biomarkers. RNA-Seq is an attractive method for expressed fusion discovery
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and detection because of its ability to provide unbiased fusion sequencing infor-
mation. The ability to detect low expressing fusion transcripts, however, require
high sequencing depth and represents a signifıcant fınancial barrier and identi-
fıcation of clinically relevant fusion sequences from a large data set can be a
bioinformatics challenge. To address these challenges we have tested the Ova-
tion® Fusion Panel Target Enrichment System V2, a targeted RNA sequencing
methodusing the Single Primer Enrichment Technology (SPET), with a number
of control and clinical samples. Initial studies were performed using a compre-
hensive target enrichment panel targeting 502 genes with three samples from
Horizon DX containing known fusions. Target enriched libraries were con-
structed with 10 ng and 100 ng inputs and the data was analyzed using the
NuFuseDpipeline (available as a point and click BaseSpace application or down-
loadable linux package) which has been optimized for fusion analysis from this
data. Expected fusions were identifıed at both input levels, even when down
sampled to 500K reads, with fewer fusion calls compared to other publically
available fusion detection software (Chimerascan and SOAPFuse), suggesting a
lower false positive rate. NuFuseD fusion calls are provided with a P-value to
help prioritize the identifıed fusions for subsequent validation. Additionally,
NuFuseD detected novel fusions in the control samples demonstrating the ad-
vantage of a comprehensive panel compared to more restricted panels. We fur-
ther validated the target panel using control RNA (UHR andHuman Brain) and
fresh or FFPE cell lines (NCI-H2228, HCC1937) to further demonstrate our
ability to identify known fusions. Finally, the systemwas evaluated at an external
site using patient FFPE samples. These samples (N8) were from a set of breast,
liver and ovarian cancers, containing a unique fusion in 4 of the samples based
on DNA based sequencing. Only 1 of the 4 expected fusions were identifıed
using whole transcriptome data (100million reads) while 3 of the 4 fusions were
detected with this assay (10 million reads) demonstrating its ability to generate
targeted RNA sequencing libraries with increased sensitivity of gene fusion de-
tection and reduced sequencing costs compared to standard RNA-Seqmethods.
#488 E2F2-mediated copynumber changes drivemetastasis and therapeu-
tic response of HER2-positive tumors through Col1a1, CHAD, and AKT-
dependentmechanisms. Jonathan P. Rennhack, Kelian Sun, JordanHoneysett,
Eran Andrechek.Michigan State University, East Lansing, MI.
The E2F family of transcription factors is classically known to regulate G1 to
S-phase transition in cell cycle but has emerging roles in HER2 breast cancer.
A loss of E2F1 or E2F2, in a HER2 mouse model, MMTV-Neu, leads to a de-
crease in tumormetastasis1. It is not knownwhatmechanistic roles specifıc E2Fs
are playing in this process. To investigate this, we leveraged and bioinformatic
principles, including genomics and transcriptomics with traditional laboratory
science and high throughput drug screening projects. This experimental ap-
proach immediately revealed that loss of E2F2 is signifıcantly associated with a
more unstable tumor including an increase in copy number alterations, single
nucleotide variants, and translocations. Further analysis revealed a conserved
copy number alteration in both mouse and humans. Specifıcally we noted the
amplifıcation of 17q21.33 in 25% of HER2 patients. The analogous region
chromosome 11D was lost in 30% of the less metastatic MMTV-Neu E2F2
knockout mice indicating a role of the region in tumor metastasis. Transcrip-
tomic data revealed that two genes, CollagenType I, alpha 1 (Col1a1) andChon-
droadherin (CHAD), were potential genes of signifıcance in the amplifıcation
event. CRISPR mediated knockout studies were conducted to determine each
gene’s effect on tumor cell migration and metastasis in mouse and human de-
rived cell lines. Wound healing assays and tail vein injection have shown the
Col1a1 and CHAD KO cell lines have a delay in cell migration (P.01) and
reduced ability to colonize the lung (P.05) respectively. Oncogenic signaling
data shows that the 17q21.33 amplifıcation event has higher AKT and E2F2
signaling thanHER2 positive tumorswithout the event. It was hypothesized that
the tumors would be dependent on the signaling and perturbation of the net-
work might be an effective therapy for patients with the 17q21.33 amplifıcation
event. To investigate this we identifıed deferentially lethal siRNAs and com-
pounds between HER2 tumors with and without the 17q21.33 event in the
Achilles, CCLE, and PDX datasets. A String-DB analysis showed many of the
deferentially lethal genes and compounds centered around AKT. A decrease in
AKT signaling through siRNA or chemical compound results in the death of the
cell in the 17q21.33 amplifıed samples but not the HER2 samples without the
event. This study reveals that patients’ with a 17q21.33 amplifıcation event have
more metastatic tumors mediated through Col1a1 and CHAD and may be re-
sponsive to AKT targeting therapy. References1. Andrechek ER: HER2/Neu
tumorigenesis andmetastasis is regulated by E2F activator transcription factors.
Oncogene 2013.
#489 Mismatch repair defects and endocrine therapy resistance in estro-
gen receptorpositive breast cancer. SvastiHaricharan,1 Jacob Schmelz,1Cheryl
Schmidt,1 Purba Singh,1 Kimberly R. Holloway,1 Meenakshi Anurag,1 Shunq-
iang Li,2 Shyam M. Kavuri,1 Shixia Huang,1 Dean P. Edwards,1 Vera Suman,3
Kelly Hunt,4 John A. Olson,5 Jeremy Hoog,2 Cynthia X. Ma,2 Matthew N. Bain-
bridge,1 Matthew J. Ellis1. 1Baylor College of Medicine, Houston, TX; 2Washing-
ton University, St. Louis, MO; 3Mayo Clinic, Rochester, MB; 4UT MD Anderson
Cancer Center, Houston, TX; 5University of Maryland, School of Medicine, Bal-
timore, MD.
Estrogen receptor positive (ER) breast cancer is treatedwith endocrine ther-
apy but intrinsic resistance occurs in1/3 of patients and acquired resistance in
1/5 of the remainder.Whilemany resistancemechanisms have been explored,
therapeutic strategies to overcome resistance in the clinical setting have seen
mixed outcomes, and appear most effective in the acquired resistance setting.
Understanding mechanisms of resistance and fınding therapeutic strategies to
target them, therefore, remain important challenges facing breast cancer re-
searchers. In this study we systematically examine the role of DNA damage
repair defects in inducing endocrine therapy resistance, a relatively understud-
ied question of recent interest. We use in silico analysis of clinical datasets, in
vitro experiments evaluating endocrine therapy resistance in response to DDR
dysregulation in multiple breast cancer celllines, and in vivo validation using
cellline xenograft and patient-derived xenograft models. We also use gene ex-
pression microarrays and RPPA data from cell lines, patient-derived xenografts
and primary ER breast tumors to uncover therapeutic options that are vali-
dated in vitro and in vivo and corroborated by clinical trial data. The results of
this study uncover an intriguing link between mismatch repair (MMR) defı-
ciency, specifıcally of the MutL complex (MLH1/3, PMS1/2), and poor progno-
sis in ER disease. We fınd a direct role for MutL loss in endocrine therapy
resistance in vitro and in vivo by knocking down multiple MutL genes using
CRISPR and stable shRNA approaches validated using standard rescue experi-
ments. We identify the underlying mechanism: MutL defıciency in ER breast
cancer abrogates Chk2-mediated feedback inhibition of CDK4/6 that appears
necessary for endocrine therapy responsiveness. Consequently, pharmacologi-
cal targeting of CDK4/6 in vitro and in vivo signifıcantly inhibits growth of
endocrine therapy resistant MutL-defıcient ER breast cancer cells. These re-
sults are corroborated by data from a neoadjuvant clinical trial demonstrating
that cell cycle regulation ofMutL-mutant tumors tends to be estrogen-indepen-
dent but sensitive to CDK4/6 inhibitors. The results of this study provide im-
portant biological and clinically relevant insights. 1) MMR defıciency is unex-
pectedly causal to intrinsic endocrine therapy resistance 2) This causal effect
appears to be mediated by abrogation of cell cycle checkpoint activation in
response to endocrine therapy 3) MMR defıciency in a subset of ER tumors
explains why CDK4/6 inhibition is effective against some de novo endocrine
therapy resistant tumors. While there are currently no biomarkers to guide the
use of CDK4/6 inhibitors for ER breast cancer,markers ofMMRdysregulation
could identify patients in whom CDK4/6 inhibition should be used to prevent
disease recurrence.
#490 Identifıcation of oncogenic gene fusions in primary colon cancers.
Robert R. Coebergh van den Braak,1 Wigard P. Kloosterman,2 Mark Pieterse,2
Markus van Roosmalen,2 Anieta S. Sieuwerts,1 Christina Stangl,2 Ronne
Brunekreef,2 Zarina S. Lalmahomed,1 Salo Ooft,3 Anne van Galen,1 Marcel
Smid,1 Armel Lefebvre,2 Fried J. Zwartkruis,2 JohnW. Martens,1 John A. Foek-
ens,1 Katharina Biermann,1 Marco J. Koudijs,2 Jan N. IJzermans,1 Emile E.
Voest1. 1Erasmus University Medical Center, Rotterdam, Netherlands; 2Univer-
sityMedical Center Utrecht, Utrecht, Netherlands; 3Netherlands Cancer Institute,
Amsterdam, Netherlands.
Introduction: Fusion genes (such as ALK-EML) are potentially attractive tar-
gets for anti-cancer treatment. In the era of personalizedmedicine exploring the
identifıcation, incidence, and functionality of fusion genes may contribute to
effective treatment approaches. Methods: We performed a comprehensive and
unbiased screening for gene fusions in a clinically well-defıned prospectively
collected cohort of 278 primary stage I to III colon cancers. Illumina RNA se-
quencing was performed using RNA from the fresh frozen samples. The STAR
fusion gene detection pipeline and GATK RNA-seq variant calling were used to
identify fusion genes and detect somatic genetic variations. Gene fusions were
considered relevant when recurrent, when resulting in divergent expression
(outlier analysis) or when functional relevance was predicted (i.e. kinase fu-
sions). Results: 2.5% of all samples contained a relevant gene fusion. Kinase
fusionsweremost prevalent with a frequency of 1.8%. Three BRAF-fusionswere
identifıed, two known (TRIM24-BRAF & AGAP3-BRAF) and one novel fusion
(DLG1-BRAF). Co-expressionwith ERK1 inHEK293 cells resulted in enhanced
EKR1 phosphorylation. The outlier analysis revealed four unique fusions
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(EML4-NTRK3, RRBP1-RET, USPX9-ERAS & EIF3E-RSPO2). The EML4-
NTRK3 fusion led to increased expression of the tyrosine kinase encoding do-
main exons, which is retained in the fusion transcript. Co-expressionwith ERK1
in HEK293 cells resulted in enhanced EKR1 phosphorylation. The tumor with
the RRBP1-RET fusion was pan negative for known driver mutations, as re-
ported in literature. Mate-pair sequencing of the USPX9-ERAS fusion gene re-
gion revealed that the fusion gene was caused at the genomic level by a highly
local chromothripsis event on chromosome X spanning solely the region cov-
ered by USP9X and ERAS, leading to high ERAS expression. ERAS is a consti-
tutionally active RAS protein and normally only expressed in embryonic stem
cells. Analysis of phosphorylated AKT after expression of the USP9X-ERAS
fusion gene in NIH-3T3 A14 cells showed activation of AKT signaling. The
occurrence of one R-spondin fusion in our set (0.4%) is low compared to the
previously described 9.5%, whichmay be explained by difference in incidence of
KRAS- or BRAF-mutations in the two cohorts, since all R-spondin fusions oc-
curred in a tumor with a KRAS- or BRAF-mutation. All fusion genes were
expressed in cell lines resulting in the activation of AKT signaling. Finally, on-
cogenic fusions were only found in lymph node negative tumors and were not
observed in tumors with classical driver mutations in BRAF and KRAS except
for the R-spondin fusion. Conclusions: We found oncogenic gene fusions in-
cluding novel fusions with a frequency of 2.5%, including an USP9X-ERAS
fusion with strong oncogenic activity in vitro. Although recurrent fusion genes
are rare events in colorectal cancer they may represent functional drivers and
provide potential novel leads for personalized therapeutic strategies.
#491 Elucidating de novo PATRR-mediated t(3;8) balanced translocation
and clear cell renal cell carcinoma. Marilena Melas,1 Kevin J. McDonnell,1
Christopher K. Edlund,1 Sarah J. Tash,2 Duveen Y. Sturgeon,1 Chenxu Qu,1
Charalampos Lazaris,3 Peter J. Gruber,4 Thomas W. Glover,5 Beverly S.
Emanuel,2 Stephen B. Gruber1. 1USCNorris Comprehensive Cancer Center, Uni-
versity of Southern California, Los Angeles, CA; 2Division of Human Genetics,
Children’s Hospital of Philadelphia, Philadelphia, PA; 3Laura& Isaac Perlmutter
Cancer Center and Helen L. & Martin S. Kimmel Center for Stem Cell Biology
School of Medicine, New York, NY; 4Division of Cardiothoracic Surgery, Depart-
ment of Surgery, University of Iowa Carver College of Medicine, Iowa City, IA;
5Department of Human Genetics, University of Michigan Medical School, Ann
Arbor, MI.
Palindromic AT-Rich Repeat (PATRR) - mediated translocations entail ex-
change across chromosomes at sites enriched in palindromic repeats of the
nucleotides adenine (A) and thymine (T). Their precise embryologic origin and
associated pathobiology with clear cell renal cell carcinoma (ccRCC) remain
incompletely described. In the present study we document an individual with
familial non-VHL ccRCC (7 primary renal tumors) who harbors a germline de
novo PATRRmediated balanced translocation involving chromosomes 3 and 8
[t(3;8)] validated by spectral karyotyping (SKY). Using translocation specifıc
PCR and DNA sequencing we determined the chromosome 3 breakpoint to be
located in anAT-rich palindromic sequence in the third intron of the FHIT gene
(chr3p14.2) and the chromosome 8 breakpoint in the fırst intron of the TRC8
gene (chr8q24.1). Genotyping analysis, using a high density custom exomechip
array by Illumina, revealed a loss of the entire aberrant chromosome 8 carrying
the 3p segment [der(8)] in all renal tumors tested. We also determined that the
[46, XY, t(3;8), (p14.2, q24.1)] translocation was paternally derived by perform-
ing a genotypic assessment of the regions that differ between the parental alleles
and then establishing which haplotypes are associated with the translocation.
The somatic mutational landscape was assessed byWhole Exome sequencing of
the renal tumors and the proband’s germline DNA. No germline or somatic
deleterious mutations were detected in VHL gene suggesting that the ccRCC
phenotype is not associated with Von Hippel-Lindau disease. Furthermore,
we measured the transcriptomic profıles of the renal tumors and matched
normal tissues employing barcoded probe hybridization technology (Nano-
String) and RNASeq to fully characterize differential gene expression and
defıne gene ontology networks that are dysregulated. Most signifıcantly, no
difference in expression of the VHL gene was detected between tumors and
normal counterparts. Aberrant regulation was detected in members of WNT
signaling pathway, TGF-beta and MAPK pathways, in addition to NOTCH
signaling pathway genes and members of the VEGF family. In summary, in
this study we employed advanced genomic and transcriptomic techniques,
to delineate the embryologic origin and deleterious biological consequences
of the PATRR-mediated t(3;8) balanced translocation associated with clear
cell renal cell carcinoma.
#492 Chronic inflammation contributes toneoplastic progression inpros-
tate tissue: a needle biopsy study. Shardul C. Soni, Michael Glover, Qinghu
Ren, Gregory T. MacLennan, Pingfu Fu, Sanjay Gupta. Case Western Reserve
University, Cleveland, OH.
The relationship between inflammation and prostate cancer has not been
established, although chronic inflammation has frequently been identifıed in
prostate biopsies, radical prostatectomy and benign prostatic hyperplasia spec-
imens. In the peripheral zone of the prostate, sometimes adjacent to foci of
high-grade PIN and cancer, certain morphologic changes are often identifıed,
whichmay represent active and terminal phases of chronic inflammation. These
changes are designated as proliferative inflammatory atrophy (PIA) and post
atrophic hyperplasia (PAH), and their morphology is well documented. In our
previous studies, we have identifıed chronic inflammation as a putative contrib-
utor to neoplastic progression in prostate epithelial cells, and hypothesized that
its adverse effects were related to an increase in Bcl2, a survival protein involved
in cell survival and carcinogenesis. We hypothesize that changes in the stromal
microenvironment, characterized by infıltration of immune cells, with genera-
tion of reactive oxygen species, can induce oxidative stress in the surrounding
proliferating epithelium and cause permanent genomic alterations. In the pres-
ent study, we focused on several key proteins involved in the inflammatory
process, COX2 and iNOS; cell survival, Bcl2 and GSTP; and evaluated immu-
nohistochemical expression of alpha-methylacyl coenzyme A racemase
(AMACR) and basal cell-specifıc markers 34E12 and/or p63 to evaluate possi-
ble neoplastic alterations in epithelial cells in an inflammatory environment.We
evaluated 16 prostate core needle biopsy specimens that exhibited the presence
of chronic inflammation as well as PIA and PAH lesions along with immuno-
histochemical staining for various markers was performed in each set of biop-
sies. The integrity of the basal layer was maintained in the area of chronic in-
flammation with high expression of p63 in 72% of these cells. Approximately
68% of luminal cells expressed high to moderate levels of iNOS and COX-2,
whereas 55% of these cells express modest levels of GSTP1 and Bcl2. Interest-
ingly, prostatic glands near the areas of chronic inflammation in the PIA lesions
exhibit highAMACR expression in luminal cells andweak to patchy p63 expres-
sion in basal cells, which was associated with increased expression of the inflam-
matory markers COX2 and iNOS, as well as loss in pro-survival signal GSTP1
and Bcl2 in the adjacent luminal cells. These neoplastic alterations were ob-
served in 6/16 (38%) of the needle biopsy specimens. Our fındings suggest that
basal cells undergo alterations in a setting of chronic inflammation. This is
important because basal cells are considered to be progenitor cells capable of
differentiating into secretory luminal cells, but under the influence of chronic
inflammation, they may instead transform into the neoplastic cells that charac-
terize high grade prostatic intraepithelial neoplasia and prostatic adenocarci-
noma.
#493 Pathologic fındings at RRSO in germline BRCA mutation carriers
with breast cancer: signifıcance of bilateral RRSO at the optimal age in germ-
line BRCA mutation carriers. YoungJae Lee, YongMan Kim, ShinWha Lee.
Asan Medical Center, Seoul, Republic of Korea.
Objective: Most BRCA1/2 carriers do not undergo risk-reducing salpingo-
oophorectomy (RRSO) by the recommended age. This study aimed to fınd the
incidence of precursor lesions and cancer after RRSO. Methods: We retrospec-
tively reviewed breast cancer patients identifıed as BRCAmutation carriers who
underwent RRSO at Asan Medical Center, Seoul, Korea, from 2010 to 2014.
From 2013, all cases were examined according to the SEE/FIM protocol and
underwent immunohistochemically (IHC) staining. RRSOwas performed in 63
patients, 27 in 2010-2012 and 36 in 2013-2014. Results: Themedian age at RRSO
was 46.5 years (32-73 years). Occult invasive cancerwas detected in 8 patients, of
ovarian origin in 5 and of tubal origin in 3. All occult invasive cancer cases with
metastasis were detected in patients older than 40 years. Of the 36 patients from
the 2013-2014 cohort, 7 showed p53 overexpression, 1 showed Ki-67 overex-
pression, 2 showed serous tubal intraepithelial carcinoma (STIC), and 3 showed
occult cancer. The detection rate of precursor lesions or cancer was 36.1% (13/
36). In the analysis according to age, precursor lesions were more common in
BRCA1 mutation carriers younger than 40 years old (66.7% vs 20.0%). In
BRCA2 mutation carriers, precursor lesions were only detected in those older
than 40 years of age, indicating the possible faster occurrence of precursor le-
sions inBRCA1mutation carriers. Conclusions:Many patients still tend to delay
RRSO until after they are 40 years old. Our fındings support the signifıcance of
RRSO before the age of 40 in germline BRCA mutation carriers.
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#494 FrequentNRG1 genomic rearrangements in invasive mucinous ade-
nocarcinoma from caucasian patients. Domenico Trombetta,1 Giulio Rossi,2
Angelo Sparaneo,1 Federico P. Fabrizio,1 Maria C. Manzorra,1 Evaristo Mai-
ello,1 Vito M. Fazio,1 Paolo Graziano,1 Lucia A. Muscarella1. 1IRCCS Casa Sol-
lievo della Sofferenza, San Giovanni Rotondo, Italy; 2Azienda USL Valle d’Aosta
Hospital Parini, Aosta, Italy.
Invasive Mucinous Adenocarcinoma (IMA) accounts for 2-5% of lung ade-
nocarcinomas and it is associated with an unfavorable clinical course, mainly
due to lack of effective treatments. Current knowledge of the molecular altera-
tions involved in IMAs is limited. Recently, the NRG1 genomic rearrangement
was identifıed as a subtype-specifıc molecular feature of Asiatic IMA cohorts
since it acts as a strong inductor of the aberrant tyrosine kinase activity of ErbB2/
ErbB3 heterodimers through PI3K–AKT and MAPK cellular cascades. In light
of these premises we explored the occurrence and frequency of NRG1 fusions in
a cohort of 90 Formalin Fixed Paraffın Embedded (FFPE) lung adenocarcinoma
fromCaucasian patients (35 non-IMAs and 55 IMAs) by performing FISH anal-
ysis to study theNRG1 genomic region (-III isoform, chr 8p12). In total, 16 out
of 55 (29%) IMAs showed NRG1 rearrangements, whereas in non-mucinous
lung adenocarcinoma group it was found with a frequency of 3% (1/35). The
functional effect of the genomic rearrangement was confırmed by RT-PCR and
sequencing in three cases with available RNA, where NRG1-CD74 fusion tran-
scripts were identifıed. An aberrant expression of pErbB3 was also observed in
these threeNRG1 rearranged cases by performing immunohistochemistry anal-
ysis, thus confırming the ErbB3 cascade activation. Our results strongly confırm
NRG1 rearrangements as potentially treatable oncogenic driver alterations as-
sociated with a defınite lung adenocarcinoma subtype in Caucasian population
and support a clear molecular rationale to novel therapeutic opportunity for
these aggressive tumors.
#495 Somatic copy number variants detection using the NEBNext Direct
target enrichment method. Kruti M. Patel,1 Sarah K. Bowman,1 Noa Henig,1
Amy B. Emerman,1 Andrew Barry,2 Charles Elfe,1 Scott Adams,1 Salvatore Rus-
sello,2 Ted Davis,2 Cynthia L. Hendrickson1. 1Directed Genomics, Ipswich, MA;
2New England Biolabs, Ipswich, MA.
Variations in copy number are the most common type of DNA structural
variations. Many of these alterations are associated with disease or indicate dis-
ease susceptibility. Detection of copy number variants (CNVs) for clinical ap-
plications requires effıcient, fast and cost effectivemethods.Herewedescribe the
use of the NEBNext Direct® hybridization-based target enrichment method to
identify somatic CNVs with high sensitivity. This approach begins with target
enrichment followed by enzymatic digestion of off-target sequences and ligation
of adapters that contain unique molecular identifıers (UMIs). The UMIs en-
hance the identifıcation of duplicate reads and further increase the fınal number
of on-target reads used for variant detection. We used a cell line known to
contain a deletion in the CDKN2A gene and spiked DNA isolated from the cell
line into a HapMap DNA sample that contains full diploid copies of CDKN2A.
We were able to detect the gene deletion as a somatic CNV in a dose dependent
manner with high sensitivity. Thus, we demonstrate that the NEBNext Direct
approach is an effıcient technique to detect somatic CNVs of high and low
frequencies.
#496 Ubiquitin specifıc peptidases 37 promotes constitutive replication
fork movement by stabilizing Chk1 via its deubiquitination.Mayank Singh,1
Amy C. Burrows,2 Andrew Dickson,2 Komal Komal,1 Debjani Pal,1 Matthew K.
Summers1. 1Ohio State University, Columbus, OH; 2Cleveland Clinic, Cleveland,
OH.
Protein deubiquitination controlsmany intracellular processes, including cell
cycle progression, transcriptional activation, and signal transduction. Ubiquitin
specifıc peptidases (USPs) remove ubiqiuitin tags from target proteins to control
both protein fate and function.USP37 (Ubiquitin specifıc peptidase 37) has been
implicated in cancer and we have previously shown that antagonizes the tumor
suppressor APCCDH1and promotes S phase entry. However, the role of USP37
during S-phase was unknown. Here, we report that in cells experiencing repli-
cation stress USP37 overexpression confers survival advantage while its deple-
tion enhances sensitivity. USP37 overexpressing cells were able to resolve differ-
entDNAdamagemarkersmuchmore effectively then the control cells or cells in
which USP37 was depleted.Mechanistically, our data indicate that USP37 binds
and stabilizes the active form of CHK1 and deubiquitinates Chk1 to increase its
stability and promote the checkpoint response. USP37 overexpression results in
constitutive replication fork movement and long tract DNA synthesis while
USP37 depleted cells were unable to carry out long tract DNA synthesis. Nota-
bly, expression of low level of Chk1 in USP37 depleted cells rescues cell survival
and DNA damage response. Overall our data suggest that inhibition of USP37
may represent a novel mechanism to modulate Chk1 activity.
#497 Higher nucleolar index of nucleolin as an indicator of aberrant cel-
lular DNA damage response (DDR). Iqra Nadeem,1 Amna Aslam,2 Jingyuan
Wang,1 Anna Kozlova,1 Danielle Gordon,1 Rumsha Javed,2 Ruchama Stein-
berg,1 Rachele Dolce Rameau,3 Xinyin Jiang,1 Anjana D. Saxena3. 1CUNY,
Brooklyn College, New York, NY; 2Midwood High School, Brooklyn, New York,
NY; 3CUNY, Brooklyn College and Graduate Center, New York, NY.
Nucleoli provide a survival advantage for various tumor types, exemplifıed in
prostate neoplasia, leukemia, lung, and breast carcinomas. Unregulated expres-
sion and increased nucleolar localization ofmany stress-responsive factors often
correlate with hyper-proliferative status. Therefore, nucleolar changes in cancer
cells are the fırst cytological indicators that can serve as an index for diagnostic
and prognostic purposes. In this study, we examine an abundant nucleolar stress
factor, nucleolin (NCL) for its sub-nuclear localization under normal and DNA
damage conditions. NCL is a multifunctional RNA-binding phosphoprotein
that plays critical role/s in many cellular processes including regulation of gene
expression during normal cell cycle as well as in the cellular DNA damage re-
sponse (DDR). NCL-mediated DDR involves changes in its phosphorylation
status, sub-nuclear translocation and amulti-level regulation of p53-checkpoint
signaling. However, the role/s of p53 status and the signaling pathways triggered
during NCL-mediated stress response remain elusive, and forms the focus of
this study. Taking advantage of two human ductal breast epithelial tumor cell
lines with different genetic backgrounds (wild type, wt-p53 and mutant, mut-
p53 L194F), we demonstrate that NCL is predominantly nucleolar in unstressed
conditions irrespective of the p53 status. Upon genotoxic stress, however, wt-
p53 is required for NCL to mobilize from nucleoli to the nucleoplasmic region.
We observed a signifıcant increase in nucleoplasmic index for NCL that is wt-
p53 dependent and specifıc to the type of DNA damage. In contrast, in the
presence of mut-p53, NCL failed to translocate even under various DNA dam-
age conditions, resulting in a higher nucleolar index. Interestingly, another nu-
cleolar factor, nucleophosmin (NPM) remained unaltered upon stress condi-
tions even in the presence of wt-p53. This study corroborates the previous
research that suggests NCL translocation requires wt-p53 and provides new
insights into the role of p53-mutations (e.g. the zinc fınger mutation in the
central DNA binding region-L194F) in NCL-mediated DDR. Further, we also
assessed the role of NCL and p53 (wt vs. mut) in regulating stress signaling
(ATM/ATR and p38-kinase) pathways and gene expression in apoptosis. To-
gether, our study elaborates a novel approach that correlates NCL sub-nuclear
localization, downstream signaling pathways and gene expression during the
cellular DDR.
#498 Attenuation of polycyclic aromatic hydrocarbon (PAH)-mediated
pulmonary carcinogenesis in mice by omega-3-fatty acids. Bhagavatula
Moorthy,1 Weiwu Jiang,1 Lihua Wang,1 Sudha R. Kondraganti,1 Guodong
Zhou2. 1Baylor College ofMedicine,Houston, TX; 2TexasA&MUniversity,Hous-
ton, TX.
3-Methylcholanthrene (MC) and benzo[a]pyrene (BP) are potent polycyclic
aromatic hydrocarbons (PAHs) carcinogens. PAHs are present in cigarette
smoke, diesel exhausts, and charcoal broiled meats, etc. Cytochrome P450
(CYP) 1A/1B1 enzymes play key roles in the activation of PAHs to carcinogenic
metabolites, which initiate carcinogenesis by binding covalently to DNA, and
the adducts, if not repaired, could lead to tumorigenesis. In this study we tested
the hypothesis that pre-treatment of mice with omega-3-fatty acids, i.e. [eicosa-
pentaenoic acid (EPA) anddocosahexaenoic acid (DHA)will lead to attenuation
of PAH-mediated pulmonary DNA adduct formation and pulmonary tumori-
genesis. Twelve week old male and female A/J mice received EPA (60 mg/kg)
and DHA (40 mg/kg) from day 1 to day 24. Control mice were treated with
vehicle corn oil. On day 3, mice were treated with BP (40 mol/kg) or 3-meth-
ylcholanthrene (MC, 40 mol/kg) by i.p. In the short-term experiment (DNA
adduct studies), 3-5 mice from each group were terminated at day 10 (7 days
after BP or MC treatment). EPA/DHA signifıcantly suppressed formation of
BP-DNA andMC-DNA adducts in lung and liver of bothmale and femalemice.
In the long-term experiment (tumor studies), 8 mice for each group continued
to receive EPA/DHA twice per week till end of experiment (16 weeks). Pulmo-
nary tumor incidence and multiplicity was signifıcantly suppressed in mice
given EPADHA, compared to those given the PAHs, BP or MC alone. These
studies suggest that the omega 3-fatty acids could be developed as novel candi-
dates for the prevention of PAH-mediated lung cancers in humans.
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#499 IgH enhancers hs3b/hs4 are dispensable for c-Myc deregulation in
mouse plasmacytomaswith T(12;15) translocations.Alexander L. Kovalchuk,
Herbert C. Morse. NIH-NIAID, Rockville, MD.
c-Myc deregulating t(12;15) chromosomal translocation is the hallmark cy-
togenetic abnormality of murine plasmacytomas (PCTs). In the great majority
of PCTs, the immunoglobulin heavy chain (IgH) locus is broken between E
enhancer and the 3’ regulatory region (3’RR), making the latter the major can-
didate for orchestrating c-Myc deregulation. To elucidate the role of 3’RR in
tumorigenesis, we induced PCTs in mice defıcient for the major 3’RR enhancer
elements, namely hs3b and hs4 (3’KO). Unexpectedly, and contrary to the pre-
vious observations made in a mouse lymphoma model, Hs3b/Hs4 3’KO mice
did develop t(12;15)-positive PCTs, although with a lower incidence than wild-
type controls. In heterozygousmice, there was no allelic bias in targeting IgH for
the t(12;15).Molecular analysis of IgH/Myc junctions revealed dominance of S
region breakpoints compared to the prevalence of hits into S or S in the
controls. Analysis of c-Myc expression as well as Ig secretion in 3’KO PCT cell
lines revealed no signifıcant differences from the controls. Our current fındings
highlight the complexity of the 3’RR and the potential of its components to
compensate for each other in the context of differentiation from B-lymphocyte
to plasma cell. We next extended our observations to include a PCT model
where Cre-mediated deletion can remove all four 3’IgH enhancers: hs3a, hs1,2,
hs3b and hs4. In PCT cell lines where c-Myc is translocated to an IgH BAC
transgene with a floxed 3’IgH enhancer region, induction of retrovirally-ex-
pressedCre-recombinase causes gradualMyc downregulation and complete cell
deathwithin 96 hours. The later observation confırms the requirement of the full
3’RR for c-Myc deregulation by T(12;15).
#500 Impairment of DNA double strand break repair in human primary
alveolar type II cells in emphysema. Beata Kosmider, Liudmila Vlasenko, Na-
thaniel Marchetti, Sudhir Bolla, Chenna Mandapati, Nathaniel Xander, Gerard
Criner, Karim Bahmed. Temple University, Philadelphia, PA.
Rationale: Emphysema is caused by the destruction of alveolar wall septa.
The major risk factor for this disease is cigarette smoke and effective thera-
pies are very limited. Alveolar type II (ATII) cells are in the gas exchange
portion of the lung. They make and secrete pulmonary surfactant, and pro-
liferate to restore the epithelium after damage to the more sensitive alveolar
type I cells. Methods: Control ATII cells were isolated from deidentifıed
control non-smoker and smoker organ donors whose lungs were not suitable
for transplantation and donated for medical research. Furthermore, as a
unique approach, we have developed a new method on how to isolate ATII
cells from excess tissue from lung transplants obtained from patients with
emphysema using magnetic microbeads. We determined DNA damage,
DNA repair, oxidative stress, injury, and inflammation in human primary
ATII cells isolated from these individuals in comparison with controls.
Results: Our data indicates high oxidative stress in human ATII cells induced
by cigarette smoke extract in vitro as measured by 4-HNE staining by im-
munocytofluorescence. We also observed DNA double strand breaks, high
DNA damage, and low DNA repair in these cells. Moreover, we found
greater proinflammatory response as determined by IL-8 and IL-6 levels by
ELISA. Furthermore, ATII cells obtained from patients with emphysema had
greater injury compared to cells obtained from control non-smokers and
smokers. Conclusion: Our results indicate oxidative ATII cell damage in-
duced by cigarette smoke and in emphysema. Observed DNA damage/repair
imbalance may contribute to cell death in this disease. The study of ATII cell
injury may improve our knowledge on this disease pathogenesis and may
lead to novel therapeutic strategies to slow the progression of emphysema.
#501 Tyrosyl-DNAphosphodiesterase I cellular functiondependent on its
N-terminal residues. SelmaM. Cuya, Robert C.A.M. VanWaardenburg.Univ.
of Alabama at Birmingham, Birmingham, AL.
Tyrosyl-DNA phosphodiesterase I (Tdp1) is a highly conserved eukaryotic
DNA repair enzyme that catalyzes the resolution of 3’ and 5’ phospho-DNA
adducts. Tdp1 has been implicated in the repair of DNA topoisomerase I
(Top1)-DNA covalent complexes reversibly stabilized by FDA approved camp-
tothecins (CPTs) derivatives topotecan and irinotecan. Tdp1 activity relies on
two catalytic histidines that function as a nucleophile and an acid-base residue.
A mutation of the acid-base His to Arg (H493R) in human Tdp1 is associated
with the rare recessive ataxia SCAN1. We defıned alternative substitution of
either catalytic histidine that induce cytotoxicity, reduce catalytic activity and
enhances the requisite Tdp1-DNA covalent adduct lifetime in the cell. The phe-
notypes of the catalytic mutants provide excellent tools to study Tdp1 cellular
function. Biochemical studies revealed that Tdp1 catalysis in vitro is indepen-
dent of the N-terminal domain. Among Tdp1 proteins, the N-terminal domain
is poorly conserved in sequence and size (79aa for yeast and 148aa for human
Tdp1). Conversely, theN-terminal domain regulates the in vitro activity of these
Tdp1 mutants. Additionally, we investigated the role of the N-terminal domain
for Tdp1 activity in the yeast and human cell models. Expression of N-terminal
truncated proteins showed similar cellular distribution as the full-length pro-
teins. However, these N-terminal truncated Tdp1 mutants did not display the
toxicity that was observed with the full-length Tdp1 mutant proteins. Our data
suggests that the N-terminal domain is required to resolve protein-DNA cova-
lent complexes, such as Top1. Indeed, preliminary results suggest that this do-
main is also critical to process Top2-DNA covalent complexes, but only in the
presences of etoposide. We are currently investigating other protein-DNA ad-
ducts that are resolved by Tdp1. These results suggests that the N-terminal
domain is a critical determinate of Tdp1 cellular function. However, further
studies are necessary to ensure that these constructs are properly distributed and
retain their catalytic activity. Additionally, the N-terminal domain of human
Tdp1 is post-translational modifıed, while our preliminary results suggest that
this domain is important for protein-protein interaction and Tdp1 recruitment
to its substrates. Understanding Tdp1 substrate and protein-interactions are
important in the development of Tdp1 as therapeutic target. This work is in part
supported by the ADDA, UABCancer Comprehensive Center (P30CA013148),
ACS-IRG-60-001-53, DOD OCRP (W81XWH-15-1-0198).
#502 Electronic cigarette aerosols increase cellular reactive oxygen species
and induce signifıcant oxidativeDNAdamage.VengateshGanapathy,1 Jimmy
Manyanga,1 Dehra McGuire,1 Daniel Brobst,1 Theodore Wagener,1 David
Rubenstein,1 Ilangovan Ramachandran,2 Lurdes Queimado1. 1Univ. of Okla-
homaHealth Sciences Ctr., Oklahoma City, OK; 2University of Madras, Chennai,
India.
Background: E-cigarettes (ECs), also known as electronic nicotine delivery
systems (ENDS) are battery-operated devices that deliver nicotine through in-
haled aerosols. The health risks associated with EC use are unclear, but ECs have
been promoted as a safer alternative to tobacco smoking and a smoking cessa-
tion aid. Currently, more than 13% of American high school students and 10%
adults report using ECs. EC aerosols contain unique constituents (e.g. silicate
beads, tin and flavorants), as well as other toxicants also present in tobacco
smoke, including carcinogens and reactive oxygen species (ROS). The potential
of EC aerosols to induce DNA damage has not been fully characterized. Aims:
(1) To examine the effects of EC aerosol exposure in the levels of cellular reactive
oxygen species (ROS); and (2) To evaluate the potential of EC aerosols to cause
oxidative DNA damage. Methods: EC aerosols and mainstream smoke extracts
were generated from distinct brands of ECs containing diverse nicotine concen-
trations and a reference combustible cigarette, in controlled conditions using a
modifıed smoking apparatus.Humannormal epithelial and oral cancer cell lines
were exposed up to 2 weeks to diverse doses of EC aerosol extracts equivalent to
1 to 100 EC puffs. Levels of ROS were evaluated using the 2’,7’ -dichlorofluores-
cin diacetate (DCFDA) cellular ROS detection assay kit (Abcam). Overall DNA
damage was quantifıed using two distinct assays q-PADDA and Comet assay.
8-Oxoguanine, one of the most common DNA lesions resulting from ROS, was
quantifıed using a commercially available ELISA kit. Data were analyzed by
Student’s t-test. Results: Exposure to EC aerosols caused a signifıcant increase in
ROS levels. Exposure to EC extracts induce signifıcantDNAdamagemeasurable
by q-PADDA and Comet assay. Overall, EC aerosol extracts induced signifı-
cantly less DNA damage than mainstream smoke extracts. Yet, a signifıcant
increase in 8-oxoguanine lesions was observed after acute and long-term expo-
sure to EC extracts compared to the control. Conclusion: Both short- and long-
term exposure to EC aerosols can increase cellular ROS levels and cause signif-
icant DNA damage. Moreover, EC aerosols cause oxidative DNA lesions which
are highly mutagenic, and can lead to tumor initiation and progression. Our
study emphasizes the urgent need to further investigate the potential short- and
long-termhealth effects of EC aerosols. Grant support: This workwas supported
by the Oklahoma Tobacco Research Center (LQ). Dr. Queimado holds a Pres-
byterian Health Foundation Endowed Chair in Otorhinolaryngology.
#503 Enhanced repair of bulkyDNA adducts induced by a tobacco carcin-
ogen and UV light in human oral epithelial cells by black raspberry extract.
Joseph B. Guttenplan,1 Kun-Ming Chen,2 Yuan-Wan Sun,2 Ross Teicher,3 Wi-
eslawa Kosinska,3 Krishne Gowda,2 Shantu Amin,2 Gary D. Stoner,4 Karam
El-Bayoumy2. 1New York University Dental andMedical Schools, New York, NY;
2Penn State College of Medicine, Hershey, PA; 3New York University Dental
School, New York, NY; 4Medical College of Wisconsin,, Milwaukee, WI.
We were the fırst to report that an anthocyanin-enriched black raspberry
extract (BE) inhibitedmutagenesis, and reduced levels of DNA adducts induced
bymetabolites of the tobacco carcinogen dibenzo(a,l)pyrene (DBP), in a rat oral
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fıbroblast cell line, by enhancing removal of DNA adducts (Guttenplan, et al.,
Cancer Prev Res; 9(8) August 2016). Here we extend these fındings to the repair
of DBP-induced DNA damage in a human oral leukoplakia cell line (MSK
leuk1), and a reduction in the toxicity (assayed by dead cell numbers and cell
survival) of DBP diolepoxide (DBPDE) in these cells. In addition, we examined
the effect of BE onDNAdamage and toxicity induced byUV light. Treatment of
theMSK cells with DBP, and 2 of its metabolites, DBP-dihydrodiol and DBPDE
led to a major adenine adduct, (-)-anti-trans-DB[a,l]PDE-dA (DBPDE-dA).
The order of potency wasDBPDEDBPDBP-dihydrodiol with oneMDBP,
producing adduct levels of about 20/10E6 dA. BE in the range of 75-150 g/ml
signifıcantly inhibited adduct formation when cells were pretreated with BE
before addition of DBP. However, when cells were fırst treated with DBP and
one day later BE was added, adduct levels were reduced by about 50% two days
after treatment with DBP, indicating that the BE was enhancing DNA repair.
This conclusion results from the fact that BE was not present during the meta-
bolic activation of DBP to DBPDE, and hence couldn’t modulate the activation
steps.We also tested whether BE, added 4 hr after treatment with the short-lived
DBPDE, inhibited toxicity toMSK cells. Initial toxicity was measured by count-
ing the numbers of dead cells in themedium 24 hr after addition of DBPDE; and
the relative levels of surviving cells were determined using anMTT cell viability
assay. It was found that 100ug/ml BE reduced toxicity induced by 25 - 200 nM
DBPDE by about 50%, with a concomitant increase in survival in the BE-treated
cells. AsDBP produces bulkyDNAadducts we also investigated the effects of BE
on toxicity and levels of DNA adducts produced by UV light. Cells were irradi-
ated for 30 - 120 seconds with 254 nm light and 15minutes later, treated with 50
- 150 g/ml BE. Toxicity was measured, as above, and a logarithmic decrease in
cell death was observed with increasing concentration of BE. Similar to results
withDBPDE, BE increased cell survival. The effects of BE on relative levels of the
UV-light-induced cyclopyrimidine adducts were also determined, using an
ELISA assay. BE at levels of 150 - 300 g/ml reduced adduct levels by 30 - 60%.
These results indicate that BEmayprovide chemopreventive effects on initiation
of carcinogenesis by environmental agents that produce bulkyDNAadducts - by
enhancing DNA repair, likely via the nucleotide-excision repair pathway. Sup-
ported by NIH grant #CA173465.
#504 Quantifıcation of nucleic acid quality in postmortem tissues from a
cancer research autopsy program. Jun Fan,1 RayaKhanin,1Hitomi Sakamoto,1
Yi Zhong,1 Chelsea Michael,1 Derwin Pena,1 Breanna Javier,1 Laura Wood,2
Christine Iacobuzio-Donahue1. 1Memorial Sloan Kettering Cancer Center, New
York, NY; 2Johns Hopkins Hopital, New York, NY.
The last decade has seen a marked rise in the use of cancer tissues obtained
from research autopsies. Such resources have been invaluable for studying can-
cer evolution or the mechanisms of therapeutic resistance to targeted therapies.
Degradation of biomolecules is a potential challenge to usage of cancer tissues
obtained in the post-mortem setting and remains incompletely studied. We
analysed the nucleic acid quality in 371 different frozen tissue samples collected
from 80 patients who underwent a research autopsy, including eight normal
tissue types, primary and metastatic tumors. Our results indicate that RNA
integrity number (RIN) of normal tissues decline with the elongation of post-
mortem interval (PMI) in a tissue-type specifıc manner. Unlike normal tissues,
the RNA quality of cancer tissues is highly variable with respect to post-mortem
interval. The kinetics of DNA damage also has tissue type-specifıc features.
Moreover, while DNA degradation is an indicator of low RNA quality, the con-
verse is not true. Finally, we show that despite RIN values as low as 5.0, robust
data can be obtained by RNA sequencing that reliably discriminates expression
signatures. Based on this promising pilot data, we are currently identifying sam-
ples formultiregion RNA sequencing of pancreatic cancers with divergentmor-
phologies within the primary and/or metastatic sites. Thus far we have screened
554 RNA samples from 10 autopsy cases. These samples represent 198 geo-
graphically distinct regions of tumor with duplicate or triplicate RNA extrac-
tions. The number of samples per patient ranges from17 to 86with an average of
55. Our data shows that high quality RNA can be acquired from cases with long
PMI (48h). While extensive screening of samples is required to identify those
with optimal quality, the downstream data produced is of high quality and can
support novel hypotheses or validations of experimental data.
#505 Somatic and inherited riboSnitches in TPT1 and LCP1 mRNA sec-
ondary structures. Lela L. Lackey,1 Aaztli Coria,1 Chanin Tolson,1 Evonne
McArthur,2 Alain Laederach1. 1University of NC, Chapel Hill, Chapel Hill, NC;
2Vanderbilt University, Nashville, TN.
RiboSnitches are single nucleotide variants that change the secondary structures
of RNA. These structural changes can have a regulatory or functional impact on the
RNA. Many inherited single nucleotide variants function as riboSNitches. We
wanted to investigate the potential of somaticmutations to act as riboSNitches.We
determined the secondary structure of two cancer-associated mRNAs, TPT1 and
LCP1, using the chemical probing SHAPE-Map technique. Both of these mRNAs
are highly structured and have similar folds in vivo and in vitro. We analyzed the
structural impact of all the synonymous somatic mutations identifıed in the COS-
MICcancer sequencingdatabase forbothTPT1andLCP1mRNAs. InTPT1wealso
tested several inherited variants.We found that both somatic and inherited variants
can be riboSNitches, at approximately the same ratio.Our results are in accordwith
previous work indicating that15% of SNVs are capable of acting as riboSNitches.
Although the impact of non-coding and synonymous somatic mutations are diffı-
cult to measure, it is becoming clear that these mutations can contribute to cancer
progression and phenotype. The majority of our identifıed riboSNitches are detri-
mental according to FATHMM-MKL functional impact prediction. Our experi-
ments indicate that a substantial fraction of somaticmutations can cause ameasur-
able change to RNA structure, potentially changing the regulatory or functional
behavior of that mRNA.
#506 The role of Nek2 in hepatocellular carcinoma. Chan Shing Ho Vin-
cent. The University of Hong Kong, Hong Kong, Hong Kong.
Cancer is a disease of aging. Among different types of cancer, liver cancer
is one of the most prevalent cancers over the world and particularly affects
people in some East Asia countries such as Korea, Japan and China. The
NIMA-related kinase 2 (Nek2), which regulates centrosome cohesion, is a
potential player in carcinogenesis. Our evidence showed Nek2 mRNA and
protein levels are overexpressed in liver cancer cells and promotes HCC cell
growth. Since Nek2 is pertinent to centrosome, we speculated that it might
take part in centrosome regulation. To study the effect of Nek2 in chromo-
somal instability, centrosome splitting and cell cycle, a stable isoformNek2A
overexpression inducible system was generated in different Hepatocellular
Carcinoma cell lines for investigations through immunofluorescent staining
and cell-cytometry. For the study of centrosome, we observed that higher
proportion of cells with centrosome splitting occurred in the Nek2A over-
expressing cells in both HepG2 and SMMC-7721 inducible cell lines. More-
over, cell cycle analysis showed an increased content of DNA when Nek2A is
overexpressed, suggesting that Nek2A induces more aneuploidy cells. To
conclude, overexpression of Nek2 exacerbates chromosomal instability.
Dysregulation of centrosomemay be the key for understanding of regulatory
mechanism of chromosomal instability by Nek2.
#507 A signature of stress-induced mutagenesis in cancer. Kimberly J.
Bussey, Luis Cisneros. NantOmics, LLC, Tempe, AZ.
The action of the AID/APOBEC family of cytosine deaminases contributes to
mutational clustering but fails to explain 50% of the clusters observed in cancer
genomes. Stress-inducedmutagenesis inbacteriaoccurswhendouble-strandbreaks
(DSB)happen inDNAin the context of additional cellular stress suffıcient to initiate
the SOS response. This results in mutational clustering driven by DinB where mu-
tational abundance decays as a function of the distance from the DSB, but remains
above background rates of mutagenesis up to 1MB away. In humans, the ortholo-
gous genes to DinB have become specialized for translesion synthesis (TLS). The
dysregulation of cell cycle and DNA repair that characterizes most tumors would
logically increase theneed forTLS in cancer. Therefore,wehypothesized that stress-
induced mutagenesis in cancer would result in peaked clusters of SNVs driven by
TLS.Weuseddata from764caseswith somaticmutationandstructural variant calls
from WGS from the ICGC database, release 19, and private de novo mutations
derived from 130 trios in the 1000 Genomes project with WGS. SNV context was
determined based both on the reference and themutant allele, and calledwhenonly
onemechanism (TLS, APOBEC, or AID) could be assigned, thereby underestimat-
ing the actual number of TLS events.We observed that as the total number of SNVs
increases so does thenumber of clusters, the proportionof SNVs in clusters, and the
average size of clusters in both de novo privatemutations and somaticmutations in
cancer. In normal, a median of 15.2% of the SNVs occurring in clusters occur in a
sequence context indicative of TLS, compared to 0.53% and 1.6% for APOBEC and
AID, respectively. In contrast, in cancer, TLS accounts for a median of 30.6% of
SNVs in clusters. APOBEC and AID account for 2.3% and 2.6%, respectively. We
devised a measure of cluster shape based on empirical cumulative distributions,
termed the Stress-IntroducedHeterogeneity (SItH) score. It ranges from -1 to 1 and
quantifıes how sharply peaked clusters arewithmorepositive numbers indicative of
a faster decay in mutational load over distance relative to the putative DSB. In nor-
mal, SItH scores range from 0.457 to 0.578 with a median of 0.504. In cancer, SItH
scores ranged from 0.17 to 0.999 with a median of 0.46 and vary signifıcantly by
organ site (ANOVA, F44.96, p2.2x10-16).We assessed the contribution of TLS,
APOBEC, and AID to SItH score using an additive, linear model of SItH scores
derived solely from SNVs in that specifıc context and including organ site as a
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variable. We found that in both normal and cancer that TLS was the only context
that contributed signifıcantly to SITH score. Therefore, we conclude that the clus-
tering seen incancer is beingdrivenprimarilybyTLSand these clustershavea shape
characteristic of a process of stress-inducedmutagenesis.
#508 DNA repair status in a patient derived ovarian cancer xenobank.
Federica Guffanti,1 Maddalena Fratelli,1 Monica Ganzinelli,1 Francesca Ricci,1
Roberta Affatato,1 Maria Rosa Cappelletti,2 Daniele Generali,2 Francesca Biz-
zaro,1 Massimo Broggini,1 Raffaella Giavazzi,1 Giovanna Damia1. 1IRCCS - In-
stitute for Pharmacological Research Mario Negri, Milan, Italy; 2Azienda Socio-
Sanitaria Territoriale di Cremona, Cremona, Italy.
Epithelial ovarian cancer (EOC) is the most lethal gynecological malig-
nancy with a 5-year relative survival rate of 45%. The high mortality rate is in
part due to the development of platinum chemoresistance occurring in more
than 70% of patients after the fırst-line therapy. DNA repair capacity has
been reported to be a key determinant for the cellular response to platinum
agents. Since half of the high grade serous EOCs lacks Homologous Recom-
bination repair, we aimed to profıle the DNA repair status in a panel of well
characterized 42 ovarian patient derived xenografts (PDXs) recently estab-
lished in our laboratory and to correlate it with the in vivo response to a
platinum based therapy. We evaluated by real time PCR (ABI-7900, Applied
Biosystems) the mRNA levels of genes with a key role in Base Excision Repair
(OGG1, POLB and PARP1), Homologous Recombination (BRCA1, PALB2,
TP53BP1 and RAD51), Nucleotide Excision Repair (ERCC1, XPA, XPF,
XPD and XPG), Fanconi Anemia pathway (FANCA, FANCC, FANCD2 and
FANCF), Translesion Repair (POLEta), Mismatch Repair (MLH1), Micro-
homology End Joining (POLQ), Non Homologous End Joining (XRCC4,
XRCC5, XRCC6 and XRCC7) and CDK12, a kinase regulating the transcrip-
tion of some DNA repair genes. The methylation status of BRCA1, ERCC1,
MLH1, XPA, XPG and FANCFwas investigated by standard techniques. Our
results show that the DNA repair genes considered were variably expressed
in all the 42 PDXs analyzed, with no specifıc histotype-specifıc cluster of
expression. The expression of PALB2, FANCC, FANCD2, OGG1, POLQ and
RAD51 was found to correlate with the expression of at least six other genes.
In high grade serous/endometrioid PDXs, the CDK12 mRNA expression
levels positively correlated with the expression of TP53BP1, PALB2, XPF and
POLB. BRCA1 was found to be hypermethylated in 51% of the xenografts.
TP53 mutated PDXs showed statistically signifıcant higher levels of POLQ,
FANCD2, RAD51, and POLB genes. The expression of CDK12 [p0.017],
PALB2 [p0.019] and XPF [p 0.016] was negatively associated with the in
vivo response to DDP, with resistant PDXs showing higher mRNA levels
than responsive ones. We looked for association with overall survival in the
TCGA data set and we found that high levels of CDK12 were associated with
a worse overall survival in patients with a residual tumor after surgery minus
than 2cm. These data suggest that some DNA repair genes can have a role in
EOC patients’ response to DDP therapy. Particularly, CDK12 was signifı-
cantly able to predict worse survival in patients undergoing optimal debulk-
ing surgery. Our xenobank will be a valid instrument to set up functional
DNA repair assays, as suggested by preliminary data on primary cultures.
#509 Genomic profıling of acute lymphoblastic leukemia in ataxia telan-
giectasia patients reveals tight linkbetweenATMmutations and chromothri-
psis. Manasi Ratnaparkhe,1 Mario Hlevnjak,1 Thorsten Kolb,1 Anna Jauch,2
KendraMaass,1 Frauke Devens,1 Agata Rode,1 Volker Hovestadt,1 Andrey Kor-
shunov,1 Agata Pastorczak,3 Wojciech Mlynarski,3 Stephanie Sungalee,4 Jan
Korbel,4 Jessica Hoell,5 Ute Fischer,5 Till Milde,1 Christof Kramm,6 Michaela
Nathrath,7 Krystyna Chrzanowska,8 Eugen Tausch,9 Masatoshi Takagi,10
Takashi Taga,11 Shlomi Constantini,12 Jan Loeffen,13 Jules Meijerink,14 Stefan
Zielen,15 Gudrun Goehring,16 Brigitte Schlegelberger,16 Eberhard Maass,17
Reiner Siebert,18 Joachim Kunz,2 Andreas Kulozik,2 Barbara Worst,1 David
Jones,1 Stefan Pfıster,1 Marc Zapatka,1 Peter Lichter,1 Aurelie Ernst1. 1German
Cancer Research Center, Heidelberg, Germany; 2University Heidelberg, Heidel-
berg, Germany; 3Medical University of Lodz, Lodz, Poland; 4EMBL, Heidelberg,
Germany; 5Heinrich Heine University, Duesseldorf, Germany; 6University of
Halle, Halle, Germany; 7Technical University Munich, Munich, Germany; 8The
Children’sMemorial Health Institute,Warsaw, Poland; 9University of Ulm, Ulm,
Germany; 10Graduate School of Medical and Dental Sciences, Tokyo, Japan;
11Shiga University of Medical Science, Japan; 12Tel-Aviv Medical Center, Israel;
13Sophia Children’s Hospital, Rotterdam, Netherlands; 14Princess Máxima Cen-
ter for Pediatric Oncology, Netherlands; 15Goethe-University, Frankfurt, Germa-
ny; 16HannoverMedical School, Germany; 17Children’s Hospital, Klinikum Stutt-
gart, Germany; 18University Hospital Schleswig-Holstein Campus Kiel/Christian-
Albrechts University Kiel, Germany.
Recent developments in sequencing technologies lead to the discovery of a
novel form of genome instability, termed chromothripsis. This catastrophic
genomic event, involved in cancer formation, is characterized by tens to
hundreds of locally clustered rearrangements on one chromosome, acquired
simultaneously. We hypothesized that leukemias developing in individuals
with Ataxia Telangiectasia, who are born with two mutated copies of the
ATM gene, essential guardian of genome stability, would show a higher
prevalence for chromothripsis due to the defect in DNA double-strand break
repair. Using whole-genome sequencing, fluorescence in situ hybridization
and RNA sequencing, we characterized the genomic landscape of Acute
Lymphoblastic Leukemia (ALL) in patients with Ataxia Telangiectasia. We
detected a high frequency of chromothriptic events in these tumors, specif-
ically on acrocentric chromosomes, as compared to tumors from individuals
with other types of DNA repair syndromes (27 cases in total, of which 10 with
Ataxia Telangiectasia). Our data show that the genomic landscape of Ataxia
Telangiectasia ALL is clearly distinct from that of sporadic ALL. Mechanis-
tically, short telomeres and compromised DNA damage response in cells of
Ataxia Telangiectasia patients are linked with frequent chromotripsis. Ad-
ditionally, we show that ATM loss is associated with increased chromothri-
psis prevalence in further tumor entities.
#510 Topoisomerase II silencing increases R loops at specifıc genomic
loci associated with an increase of H2AX and cell cycle progression delay in
human cancer cells.Maria Delcuratolo, JessicaMarinello, Giovanni Capranico.
University of Bologna, Bologna, Italy.
DNA topoisomerases (Top) are important players inmaintaining the genome
stability of cells by removing negative and positive DNA supercoils during tran-
scription, replication and other DNA transactions. Recent evidence demon-
strated that Top 1 silencing and poisoning by camptothecin affect the formation
of R-loops, which are RNA/DNA hybrid structures involved in genome insta-
bility and are favored by negative supercoils of the DNA. The fındings overall
demonstrate that Top 1 reduces R loop levels during transcription whereas it
favors R loop formation at early origins of DNA replication. Here, we address
the question of whether DNA topoisomerase II can also contribute to steady-
state levels of R loop structures in the genome of U2OS cancer cells. We have
then investigated the effects of Top2 silencing and Top2 poisons, doxorubicin
and etoposide, on R loops and DNA damage in human U2OS cancer cells.
Similarly to published data with camptothecin (Marinello et al., Nucleic Acids
Research, 2013), Top2 poisons increase cellular R loops by IF after short treat-
ment times and reduce them after 1 hour of treatment. The bi-phasic effect of
poisons is mainly dependent on transcription. Moreover, we have determined
the changes of R-loop levels by IF after Top2 silencing and the fındings dem-
onstrate that the enzyme can stronglymodulate the formation of R loops as a full
Top2 depletion increases nuclear R-loop levels. In addition, Top2 depletion
leads to a slight increase of phosphorylation of H2AX histone along with cell
cycle delay and eventually cell death. Thus, Top2depletion can trigger genomic
DNAbreakage through alterations ofR-loops. In order to establishwhich are the
genomic regions of altered R loop levels, we have mapped Top2-dependent R
loop alterations by the DRIP method showing that specifıc genomic sites are
affected by Top2. Bioinformatic analyses of R loop maps in U2OS cells will be
presented and discussed at the meeting. Altogether the fındings demonstrate a
critical role of Top2 in governing R loop structures in human cancer cells
indicating that DNA torsional tension is a main driving factor of R loop forma-
tion and hence genome instability in cancer cells.
#511 Chromosome instability mechanisms in breast cancer among Afri-
can Americans and Caucasians. Jose Thaiparambil, Oula Mansour, Susan Ha-
ley, Randa EL-Zein. Houston Methodist Research Institute, Houston, TX.
Signifıcant disparities exist in breast cancer among African Americans (AAs)
womencompared toCaucasians.Even thoughAAsare less likely toundergo regular
mammograms due to access barriers, it is unlikely that differences in screen based
detection accounts entirely for outcome disparities. While the current guidelines
recommend women begin mammography at age 40 or 50, AA women may be at
increased risk for delayed diagnosis since10% of breast cancer cases in AAs are
diagnosed in women younger 40 years compared with 5% of Caucasians. This
highlights the importance of defıning optimal ethnically appropriate age of screen-
ing especially given the disproportionate mortality among younger black women
patients. Therefore, an alternative approachusing biomarkers should be considered
in order to develop ethnically appropriate measures for detecting the disease in the
earliest stages. Genomic instability has long been recognized as a major driver of
carcinogenesis occurring early on and increasing in complexity with disease pro-
gression.However, to date little is known about the underlyingmechanisms associ-
ated with such instability among the different ethnic groups. In this study we hy-
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pothesized that alterations in telomere length and dysfunctional centrosome
apparatus are underlyingmechanisms associated with ethnic-based genomic insta-
bility. We investigated alterations in centrosome apparatus, misaligned chromo-
somes and spindle angle orientation in AA [HCC 70] and Caucasian [HCC1395]
cell lines using confocal microscopy. Our results demonstrated signifıcant differ-
ences in structural (30%) and numerical alterations (60%) in centrosome apparatus
between AA and Caucasian cell lines (p0.001). We also noticed a signifıcant in-
crease of misaligned chromosomes (35%) and (68 %) in the metaphase of Cauca-
siansandAA’s respectively (p0.002). Inaddition,a signifıcantdifference inspindle
orientationwas observed amongAAs andCaucasians suggesting thatmitotic phase
abnormalities may be, in part, responsible for the underlying genetic instabilities
associatedwith breast cancer.Using ingenuity pathway analysis, we compared gene
expressions in both AAs and Caucasian cell lines and observed a signifıcant change
in telomerase signaling expression between the cell lines, suggesting a role for telo-
mere lengths in the generation of genetic instability. Together, identifying the spe-
cifıc mechanisms that drive tumorigenesis may provide opportunities for future
targetedprevention efforts amonghigh risk cohorts. (Thiswork is supported inpart
by CA189240).
#512 Knockdown of the spindle assembly checkpoint gene Bub1b results
in increased cell death and cell cycle impairment in breast cancer. Dilara
Koyuncu, Erik T. Goka, Philip C.Miller,Marc E. Lippman.University ofMiami,
Miami, FL.
Genomic instability is an enabling hallmark of cancer that provides cancer cells a
replicative advantage. Accumulation of genomic aberrations can also compromise
the genomic integrity and put cells under mitotic stress. Maintaining balance be-
tween the instability that gives cancer cells a replicative advantage and the instability
that could lead them to mitotic catastrophe is crucial for survival of cancer cells.
Mitotic catastrophe can be caused by rapid progression throughmitosis before cru-
cial checkpoints aremet, resulting in cell death. To overcome this challenge, cancer
cells may acquire overexpression of spindle assembly checkpoint (SAC) genes,
which can prevent mitotic catastrophe that would occur if they undergo mitosis
prematurely. Bub1b is an important part of SAC and inhibits the onset of anaphase
until all chromosomes are aligned at the metaphase plate. Our analysis of clinical
datasets show Bub1b expression is elevated in breast cancer, compared to normal
breast, and is exemplifıed by a pattern of increasing overexpression inmore aggres-
sive variants, such as triple negative breast cancer (TNBC). Bub1b overexpression
also correlates with decreased overall survival in patients. Expression analysis of
breast cancer cell lines corroborates this clinical data. We hypothesize that the re-
quirement for Bub1b expression indicates a vulnerability of rapidly proliferating
breast cancers cells, and the inhibition of Bub1b will result in cell death through
mitotic catastrophe.UsingRNAinterferencewith siRNAsweknockeddownBub1b
expression in a variety of breast cancer cells. This resulted in signifıcant decrease in
cellular viability and clonogenicity in soft agar. Furthermore, analyses of apoptosis
using Annexin V and PI costaining showed that Bub1b knockdown results in sig-
nifıcantly increased apoptosis and cell death, especially in theTNBCcell lineMDA-
MB-468. However, the viability and apoptosis levels of the normal breast epithelial
cell line, MCF12A, were not affected. Bub1b knockdown resulted in silencing of
SAC activity, as measured by Cyclin B levels, and also signifıcantly impaired cell
cycle progression in breast cancer cell lines. Additionally, knockdown of Bub1b in
breast cancer cell lines demonstrated an additive effect when combinedwithDNA-
damagingagents.Ourdata support thatBub1b isacriticalplayer inbreast cancercell
survival, by enabling them toovercomemitotic stress.Wedemonstrate that impair-
ment of Bub1b has detrimental effects on cell cycle and progression of mitosis.
Further investigation of the role of Bub1b in promoting successful chromosome
alignment and proliferation of breast cancer cells with genomic instability could
provide a novel pathway on how cancer overcomes the mitotic stress caused by
genomic instability. These studies may also lead to novel therapeutic strategies that
combine SAC inhibitors with standard genotoxic treatments.
#513 The link between polyploidy and replication stress in melanoma.
Anna E. Vilgelm,1 C. Andrew Johnson,1 Kiran Malikayil,2 Dayanidhi Raman,3
David Flaherty,4 BrianHiggins,5 AnnRichmond6. 1Vanderbilt University, Nash-
ville, TN; 2MeharryMedical College, Nashville, TN; 3University of Toledo, Toledo,
OH; 4Vanderbilt University Medical Center, Nashville, TN; 5Roche Innovation
Center, New York, NY; 6Tennessee Valley Healthcare System, Nashville, TN.
Genomic instability is a hallmark of cancer implicated in tumor evolution and
resistance to therapy. However, the molecular mechanisms that underlie
genomic instability are still poorly understood. One common feature of cancer
cells is an elevated genomic content (polyploidy) which is also associated with
the acquisition of therapy resistance. Here we demonstrate a link between
genomic instability and polyploidization in melanoma cells. We show that
polyploidy induced by treatment with small molecule inhibitors of various mi-
totic kinases, such as AURKA, AURKB and PLK1, leads to DNAdamage in cells
with elevated (4n) DNA content. This DNA damage results from replication
stress exacerbated by limited activation of p53 in malignant melanocytes. Phar-
macological induction of p53 in polyploid cells using an MDM2 antagonist
reduced DNA damage by blocking re-replication of the polyploid genome as a
result of p53-mediated p21 activation and transactivation of DNA repair genes.
Notably we found that p21 blockade using siRNA knockdown or genetic knock-
out shifted polypoid cell response to p53 activation from cytostatic to cytotoxic.
As a result, p21-defıcient cells exhibited enhanced sensitivity tomitotic blockade
combined with p53 induction. Furthermore, TCGA dataset analysis showed
poor progression free survival in melanoma patients with high p21 protein ex-
pression. These data argue for administering mitotic inhibitors and MDM2
antagonists, which are currently in clinical development, in conjunction with
agents that target p21. In summary, our data here reveal that polyploidization
can be a mechanism for induction of DNA damage and genomic instability
associated with drug resistance in cancer and suggest a novel strategy for target-
ing these pathways to improve melanoma therapy.
#514 Genetic load in cancer cell populations. Yuezheng Zhang,1 Xu Shen,2
Yawei Li,2 Tianqi Zhu,2 Yong Tao,2 Tao Li,2 Di Wang,1 Xueying Li,3 Qin Ma,2
Xuemei Lu,2 Hurng-Yi Wang,4 Chung-I Wu2. 1University of Washington, Seat-
tle, WA; 2Beijing Institute of Genomics, Beijing, China; 3Peking University, Bei-
jing, China; 4Institute of Clinical Medicine, National Taiwan University, Tai Pei,
Taiwan.
Populations accumulate deleteriousmutations that have yet to be removed by
natural selection. This mutated portion of the population that does not contrib-
ute to its fıtness is called the genetic load and is proportional to the deleterious
mutation rate. Given the genomic instability of cancer cells, the genetic load
could be substantial if the instability indeed leads to loss of cell fıtness. We
hypothesize that because aneuploidy and copy number variations (CNVs) are
the most common forms of genome instability, their fıtness consequences may
determine the genetic load in cancer cells. To test this hypothesis, we randomly
selected single cells from a HeLa cell line and measured the cell growth rate via
daily cell counting and an MTT cell proliferation assay. We then measured the
genetic changes and resulting growth rate variation. We observed rapid gener-
ation of heterogeneity in the growth rate within the population. The growth rate
of different progeny cells was stable indicating that it is genetically determined.
Next, using whole genome sequencing of recently descended clones of a single
HeLa cell, we found that cells with fewer newly acquired CNVs have higher
proliferation rates vice versa. This indicated that CNV accumulation decreased
cell fıtness systematically. We next estimated the rate of CNVmutation bymea-
suring the growth rate of two daughter cells from single proliferation and found
that there is approximately 1 deleterious mutation in every 4 cell divisions. We
speculated that due to a high, deleterious CNVmutation rate, tumor cells inev-
itably accumulate deleterious CNVs and a large percentage of tumor cells are
genetically defective. Accordingly, we observed that the average growth rate of
tumor cell populations decreased in the short term since defective cells accumu-
lated in the population and the variation of cellular growth rates within the
population increased. By modeling the process of mutation accumulation and
measuring cell growth rate, we estimated that the deleterious mutation rate in
HeLa cells is about 0.26-0.31 per cell division, and thatHeLa cells reduce roughly
5%-6% of fıtness for every cell division. The observations of a high proliferation
rate and high genetic load in this representative tumor cell line indicates a “high
risk, high reward” evolution strategy for tumor cells and suggests that increasing
the level of genomic instabilitymay cause themeltdownof tumor cell population
by forcing cells to accelerate the cell cycle.
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#515 Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway
and cAMP pathway confırm poor prognosis and reduced overall survival
(OS) in a series of 209 acute myeloid leukemia patients. Mariachiara Ab-
benante,1Mariachiara Fontana,2 GiovanniMarconi,1 Giorgia Simonetti,1 Anto-
nella Padella,1 Elena Tenti,1 Eugenia Franchini,2 Anna Ferrari,2 Sarah Parisi,2
Emanuela Ottaviani,2 Nicoletta Testoni,2 Viviana Guadagnuolo,3 Chiara Sar-
tor,2 Silvia Lo Monaco,2 Cristina Papayannidis,1 Giovanni Martinelli2. 1Istituto
L. e A. Seragnoli, bologna, Italy; 2Istituto L. e A. Seragnoli, Bologna, Italy; 3Cellply,
Italy.
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Introduction: PI3P is a molecule that regulate cell growth and mediates cell
proliferation via PI3K/AKT/mTOR in response to various growth signals. Ab-
normal activation of genes in its pathway is associated to oncogenic activity and
poor Overall Survival (OS). AMPK plays a role as a regulator of cellular energy
homeostasis. Aims The aim of the this study is to defıne the role of PI3P path-
ways and AMPK pathway in AML. Methods: In this work we analyzed 208
consecutive newly diagnosed non M3 AML patients, screened for TP53, FLT3,
NMP1, IDH1, IDH2, and DNMT3A mutations. Remission status was assessed
with bone marrow biopsy. We performed Microarray-based Comparative
Genomic Hybridization with Affymetrix SNP array 6.0 or Cytoscan HD in all
the patients; we performedWhole Exome Sequencing (WES)in 80/208 patients.
Survival data were collected prospectively, with a median follow-up of 18
months. Survival analysis was performed with Kaplan Meyer method using log
rank test. Univariate and multivariable regression and Cox Hazard Ratio(HR)
model was performed. Correlation between variables was assessed with Fisher’s
exact test. Results: We selected genes in pathways basing on literature and GO
data. Alterations in these pathways involved 103/209 patients (48%). We ana-
lyzed the gene in two different pathways. PI3K/AKT/mTOR pathway includes
the following genes: pik3ca, cdkn1a, akt1, akt3, mtor and pten, pdk1,pik3r1 and
irs1. The second one is AMPK pathway and it include: sesn, prkaa1, prkab1,
prkag1, prkag3. Alterations in PI3K/AKT/mTORpathway conferworstOS (p
.035) when compared with unaltered patient, but events in these pathways did
not affect therapy response. Alterations in AMPK pathway confer worst OS
(p.001); Alteration of regulators in cAMP were related to lower CR% after
induction in univariate (p.001) andmultivariable analysis with age, karyotype,
secondary AML, TP53 mutation (p0.009). AMPc pathway alteration was sig-
nifıcantly associated with complex karyotype and TP53 mutation (p.001).
WES in a sub-cohort of patients did not found any signifıcant mutation in genes
we analyzed, according to literature. Conclusions:Ourwork investigates the role
of PI3P and cAMP pathways in AML. Surprisingly, it showed that alterations in
these pathways are associated with poor prognosis. Signifıcantly, alterations in
cAMP pathways were associated with therapy resistance. Acknowledgement:
ELN, AIL, AIRC, PRIN, Progetto Regione-Università 2010-12, FP7 NGS-PTL
project, HARMONY.
#516 High-throughput functional evaluation of variants of unknown sig-
nifıcance in EGFR. Shinji Kohsaka,1 Masaaki Nagano,1 Toshihide Ueno,1 Yo-
shiyuki Suehara,2 Takuo Hayashi,2 Naoko Shimada,2 Kazuhisa Takahashi,2
Kenji Suzuki,2 Kazuya Takamochi,2 Fumiyuki Takahashi,2 Hiroyuki Mano1.
1Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 2Juntendo
University Graduate School of Medicine, Tokyo, Japan.
Since transforming mutations in epidermal growth factor receptor gene
(EGFR) were fırst identifıed in non-small-cell lung carcinoma (NSCLC), ad-
vancement of diagnostics for such mutations, and evolution of targeted thera-
peutics against EGFR has driven unprecedented improvements in the manage-
ment as well as outcome of patients with this lethal disease. However, next-
generation sequencer (NGS)-driven extensive analyses onNSCLChave revealed
a large number of variants of uncertain signifıcance (VUS) in EGFR and other
regions in the cancer genome that await further investigation. Here we present a
mixed all nominated mutants in one (MANO) method to evaluate the trans-
forming potential and drug sensitivity of VUS of oncogenes, and applied this
method to 101 non-synonymous EGFRmutants in a high-throughput manner.
The sensitivity of individualmutants to tyrosine kinase inhibitors (TKIs) against
EGFR was shown diverged, ranging from relatively insensitive mutations such
asmissensemutations within exon 19 to a highly resistantmutationwithin exon
21. Our data thus support the importance of examining uncommon mutations
within EGFR, and also of functional evaluation of such mutations. Our MANO
method may become a novel foundation for in vitro and in vivo assessments of
variants of cancer-related genes to deliver precisionmedicine to individual can-
cer patients.
#518 Synergistic effects of dual inhibition of YAP1 and TAZ in non-small
cell lung cancer cells. Elaine Shum,1 Huijie Liu,2 Liang Zhu,2 Roman Perez-
Soler,1 BalazsHalmos,1HaiyingCheng1. 1MontefıoreMedical Center/Albert Ein-
stein College ofMedicine, Bronx, NY; 2Albert Einstein College ofMedicine, Bronx,
NY.
Background: The Hippo signaling pathway is associated with regulation of
cell growth and apoptosis. Downstream effectors of this pathway, YAP and its
paralog, TAZ, interact with TEA domain (TEAD) transcription factors leading
to cell proliferation and anti-apoptosis. As a result, YAP and TAZ have emerged
as attractive anti-cancer therapeutic targets. Several studies, including our pre-
vious report, have noted the individual effects of YAPor TAZ ablation; however,
consequences of dual inhibition have not yet been investigated in lung cancer.
We hypothesize that dual inhibition of YAP and TAZ will lead to more pro-
nounced cytotoxicity than each knockdown alone as a result of diminished com-
pensatory mechanism by the remaining family member. Methods: NSCLC cell
lines, such as PC9 and A549, were transfected with individual YAP1, TAZ
siRNA or a combination of both siRNAs. Western blotting was performed to
determine the levels of YAP1 and TAZ proteins following knockdown. Quanti-
tative RT-PCR was also performed to confırm effective YAP1 and TAZ knock-
down. In addition, gene and protein expression of downstream targets, such as
CTGF and Cyr61, were assessed. Clonogenic assays were performed to deter-
mine cell survival. Results: Successful siRNA-mediated YAP and TAZ ablation
were confırmed withWestern blot and qRT-PCR. The expression of the Hippo-
YAP/TAZ downstream targets, CTGF, Cyr61 and AXL, were also reduced ac-
cordingly. Moreover, dual knockdown of YAP and TAZ led to a more pro-
nounced inhibition of cell survival/proliferation than ablation of individual
genes alone. In addition, dual inhibition of YAP/TAZ exhibited signifıcantly
diminished levels of the mesenchymal markers, vimentin and N-cadherin, and
increased levels of the epithelial marker, E-cadherin. EMT has been recognized
as an essential process during lung cancer tumor migration and metastasis.
Conclusion: Our fındings show that dual inhibition of YAP1 and TAZ are syn-
ergistic in blocking NSCLC cell survival signaling. Thus, dual inhibition may
serve as a better therapeutic strategy in targeting the Hippo pathway than sole
YAP1 blockade in the management of NSCLC.
#519 Antitumor activity ofMET antibody emibetuzumab (LY2875358) in
combination with EGFR inhibitors in erlotinib resistant (ER) xenograft
mouse models. Suzane L. Um,1 Victoria L. Peek,1 Jennifer R. Stephens,1 Jessica
A. Baker,1 Holly K. Cannon,1 Joel D. Cook,1 Isabella H. Wulur,1 Roger Agyei,2
SudhakarChintharlapalli,1 Robert J. Evans,1William J. Feaver,2 LysianeHuber,1
LindaN. Lee,1 Ling Liu,1 LiandongMa,1 RuslanNovosiadly,2 VolkerWacheck,3
Sau-Chi Betty Yan1. 1Eli Lilly and Company, Indianapolis, IN; 2Eli Lilly and
Company, New York, NY; 3Eli Lilly and Company, Vienna, Austria.
Background: MET amplifıcation (amp) is a resistance mechanism to EGFR
TKI treatment. Emibetuzumab, a bivalent MET antibody (Ab) blocks HGF
binding to MET and internalizes the receptor. Combination of emibetuzumab
with EGFR TKIs (erlotinib, AZD9291, CO1686) or EGFR Ab (necitumumab,
cetuximab) was evaluated in 3 ER xenograft models. Methods: Model 1: ER cell
line HCC827ERL with high focal MET amp, high pMET, EGFR ex19 del (no
T790M) was created from parental HCC827 NSCLC (EGFR ex19 del, EGFR
amp, no MET amp) by increasing concentration of erlotinib in vitro over 7
months. Model 2: ER cell line HCC827-A8 was derived from HCC827 parental
xenograft tumor serially passed in vivowith long term treatment of gefıtinib and
erlotinib. HCC827-A8 cells express high focal MET amp, high pMET/AXL
(Western blot) while retaining EGFR ex19 del (no T790M). Model 3: LU0858
was anERpatient-derivedNSCLCxenograft tumor, with focalMET amp, EGFR
L858R (noT790M).MET amp and EGFRmtwas determined by FISH and LNA-
PCR sequencing respectively. Compound dosing: emibetuzumab 20 mg/kg qw;
necitumumab 4 mg/kg or 20 mg/kg biw; cetuximab 4 mg/kg biw; erlotinib 25
mg/kg qd; 5 mg/kg AZD9291 qd; 30 mg/kg CO1686 bid. Results: EGFR inhibi-
tors, but not emibetuzumab showed signifıcant single agent anti-tumor effect in
xenograft tumors derived from non-MET amp HCC827 parental cells. In MET
amp ER models, single agent emibetuzumab resulted in tumor growth inhibi-
tion in Model 1 (T/C 51.7%-61.0%, p0.05) and 3 (T/C2.8%, p0.05)] but
no tumor regression, and no anti-tumor effect in Model 2. Where evaluated,
EGFR inhibitors showed no anti-tumor effect in the 3 ER models as mono-
therapy, except necitumumab (20 mg/kg) in Model 1 (T/C  36.2%, p0.05).
However, combination of emibetuzumab with AZD9291, CO1686, necitu-
mumab (20 mg/kg), or erlotinib resulted in 80.4%, 58.2%, 44.4%, 69.1% tumor
regression respectively (p0.001) in Model 1, while emibetuzumab cetux-
imab (4 mg/kg) resulted in tumor stasis (T/C0.2%, p0.05). In Model 2, emi-
betuzumab AZD9291 resulted in tumor stasis (T/C  12.9%, p0.05). In
Model 3, emibetuzumab necitumumab (20 mg/kg) resulted in 80.1% tumor
regression (p0.001). Conclusion: The three erlotinib resistant models with
MET amp and retaining sensitizing EGFRmt (ex19 del or L858R), and no ac-
quired T790M were found resistant to other EGFR inhibitors (Abs and TKIs).
Emibetuzumab in combinationwith either EGFRTKI orAb showed anti-tumor
activity inMETampERxenograftmodels including tumor regression in 2 out of
3models. The combination of emibetuzumabwith erlotinib is being evaluated in
NSCLC patients with EGFR activating mutation (NCT01897480).
#520 Trim44 is overexpressed in colorectal cancerwith amplifıcation, pro-
moting degradation of SHP-1 and activating JAK/STAT pathway by ubiqui-
tin modifıcation. Jie Hong, Qian Liang, Haoyan Chen, Jing-Yuan Fang, Hua
Xiong. Shanghai Jiaotong Univ School of Med Renji Hospital, Shanghai, China.
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Tripartitemotif 44 (Trim44) was found to be expressed in several cancers, but
the exact roles of Trim44 in colorectal cancer (CRC) remain unclear. The objec-
tive of this study was to determine the functional and prognostic implications of
Trim44 in colorectal cancer. The Trim44 gene is recurrently amplifıed and up-
regulated in CRC. Trim44 overexpression and amplifıcation are associated with
poor survival in patients with CRC and the prognostic signifıcance was con-
fırmed by independent patient cohorts. High expression of Trim44 associates
with activation of the JAK/STAT3pathway inCRC tissues. TRIM44 knockdown
reduced proliferation, and invasion of colorectal cancer cells, as well as growth
and metastasis of xenograft tumors in nude mice; overexpression of TRIM44
had the opposite effects. TRIM44 interacted physically with Shp-1, increasing its
ubiquitination and degradation. Increased levels of TRIM44 in human colorec-
tal tumors correlated with reduced expression of SHP-1 and increased phos-
phorylation of STAT3. In a word, The putative ubiquitin ligase TRIM44 is up-
regulated in human colorectal tumors compared with nontumor tissues. Levels
of TRIM44 correlate with tumor progression and patient survival times.
TRIM44 interacts with SHP-1, promoting its ubiquitination and degradation,
andTRIM44might promote colorectalmalignant transformation via thismech-
anism.
#521 Dual-targeting of IGF-1R and ErbB3 pathways in Ewing’s Sarcoma
cellular models with istiratumab (MM-141), a bispecifıc, tetravalent mono-
clonal antibody. Isabel Yannatos, AdamCamblin, Zhenhua Li,Michael Curley,
Gege Tan, Chrystal U. Louis, Vasileios Askoxylakis, Greg Finn, Birgit Schoeberl,
Rachel Nering.Merrimack Pharmaceuticals, Cambridge, MA.
Ewing’s sarcoma family tumors (ES) are aggressive tumors that often present
as metastatic in bone and soft tissue and predominantly affect adolescents and
younger adults. Current treatment for ES includes surgical resection followed by
loco-regional radiotherapy and chemotherapy. Survival rates for patients with
metastatic disease continue to offer a particularly diffıcult clinical challenge,
with a fıve-year survival rate of 20-30% for these patients. ES is primarily a
genetic disease caused by fusion between the 5’ segment of the Ewing sarcoma
breakpoint region 1 gene (EWSR1) on chromosome 22 and the 3’ portion of
Friend leukemia virus integration site 1 (FLI1) on chromosome 11. Fusions of
EWSR1 and other ETS transcription factors result in dis-regulated transcription
factors which promotemalignant progression of ES tumors. Recent studies have
shown that most ES cell lines and clinical samples express IGF-1R. Importantly,
an activated IGF-1R pathway appears to be a prerequisite for malignant trans-
formation by the EWS-FLI1 translocation, presumably via activation of the
PI3K-AKT andMAPK pathways. These fındings have led to the preclinical and
clinical evaluation of multiple IGF-1R-targeted therapeutics with varying re-
sults. Clinical experience with anti-IGF1R targeting therapies has demonstrated
striking anticancer activity inminor subsets of patientswith ES. Importantly, the
paucity of a clinically useful biomarker to select patients continues to hinder
IGF-1R drug development in ES. Istiratumab is an investigational, bi-specifıc,
monoclonal antibody that acts as a tetravalent inhibitor of PI3K/AKT/mTOR, a
major pro-survival pathway tumor cells use as a resistance mechanism to anti-
cancer therapies. Istiratumab is designed to interferewith this pathway by block-
ing ligand-induced signaling through the IGF-1R andErbB3 receptors, based on
fındings that ErbB3 activation mediates resistance to the IGF-1R blockade. We
will present data in multiple ES models demonstrating the importance of both
IGF-1R and ErbB3 in this disease as a mechanism of growth and resistance.
Furthermore, preclinical xenograft studies demonstrate that the combination of
istiratumab with an irinotecan-based chemotherapy regimen offers signifıcant
benefıt over chemotherapy alone. These studies suggest that clinical evaluation
of istiratumab in ES is warranted.
#522 Expression and functional analysis of signal peptidase complex 18 in
bladder cancer. Yoshinori Shigematsu, Yohei Sekino, Naoya Sakamoto, Ka-
zuhiro Sentani, Naohide Oue, Tetsutaro Hayashi, Jun Teishima, Akio Mat-
subara, Wataru Yasui. Hiroshima Univ., Hiroshima City Hiroshima, Japan.
Urothelial carcinoma of the bladder is a common malignancy that causes
approximately 150,000 deaths per year worldwide. So far, no molecularly
targeted agents have been approved for treatment of the disease. In the
present study, we built an in-house oligonucleotide array, on which 394
genes were selected based on our SAGE data and previously reported array
data, in order to identify the genes of most relevance to gastric carcinogen-
esis. Among these genes, we focused on SEC11A, because it is frequently
overexpressed in gastric cancer (GC). SEC11A encodes the SPC18 protein,
which is one of the subunits of the signal peptidase complex (SPC). Most
secretory proteins contain amino terminal- or internal signal peptides that
direct their sorting to the endoplasmic reticulum (ER). From the ER, pro-
teins are transported to either the extracellular space or the plasma mem-
brane through the ER-Golgi secretory pathway. The ER signal peptides are
then cleaved by the SPC. In GC, SPC18 contributes to progression via EGFR
pathway associated with TGF-a secretion. However, the expression and
function of SPC18 have not been investigated in bladder cancer (BC). In this
study, we analyzed the expression and distribution of SPC18 in human BC.
Expression of SPC18 was observed in 44 (54.3%) out of 81 BC cases that was
associated with T category (p0.0002), Grade (p0.0425), vascular invasion
(p0.0112) and CK5/6 positive/ CK20 negative basal type BC (p0.0004).
The univariate analysis indicated that expression of SPC18 (HR, 3.14; 95%
CI, 1.47-7.47; P0.0027) was associated with overall survival. In the multi-
variate model, SPC18 expression was an independent prognostic indicator
(HR, 3.46; 95% CI, 1.35-10.00; P0.0087). BC cells KMBC2 transfected with
SPC18 expression vector signifıcantly induced the cell growth (p0.01) and
invasion (p0.01) activity. Western blot showed the overexpression of
SPC18 induced the phosphorylation of EGFR, Akt and Erk. Real-time re-
verse transcription PCR analysis revealed the SPC18 forced expression cells
induced mesenchymal character. These results suggest that SPC18 might
contribute to the progression of BC.
#523 HGFmediatedupregulationofPHLDA2 is associatedwith apoptosis
in gastric cancer. Sung Ae Koh, Kyung Hee Lee, Jae Ryong Kim, Sang Woon
Kim. Yeungnam University Hospital, Daegu, Republic of Korea.
Pleckstrin homology-like domain family Amember 2 (PHLDA2), a homolog
of the mouse TDAG51 gene, was the fırst apoptosis-related gene shown to be
imprinted and expressed from the maternal allele in normal development. It is
located within the tumor suppressor region of 11p15, and its expression was
reported to be suppressed in several cases of malignant tumors. But, the apopto-
tic regulatory mechanism and its role is not fully known in gastric cancer. The
purpose of the this study is to identify of function of PHLDA2 associated with
apoptosis in gastric cancer. We used cell culture, western blotting, RT-PCR,
MTT assays, PHLDA2 knock-down with short hairpin RNA (shRNA). First, we
confırmed that the expression level of PHLDA2was up-regulated byHGF(hepa-
tocyte growth factor). To identify associated pathway of HGF-induced LCN2,
the cells were treated with PI3-kinase inhibitor (LY294002) or MEK inhibi-
tor(PD098059) or p38 inhibitor(SB203580) and then analyzed byWestern blot-
ting. The HGF-mediated PHLDA2 protein level was only decreased with
LY294002. The role for PHLDA2 with was determined by knock down cell of
PHLDA2. PHLDA2-sh RNA cells showed a decreased level of P53 and a in-
creased level of pAKT. We also examined to confırm the role of HGF-mediated
PHLDA2. HGF-mediated cell proliferation and in vitro invasion was increased
in PHLDA2 knock down cell. Also, HGF-mediated cell apoptosis decreased in
PHLDA2knock down cell. Our study showed that PHLDA2upregulatedHGF is
regulated through PI3K/AKT pathway in gastric cancer, and PHLDA2 have a
role in cell apoptosis in gastric cancer, which may be a possible target for devel-
oping gastric cancer therapy.
#524 Characterizing the in vitro and in vivo effects of the PIM kinase
inhibitor HS140 in triple-negative human breast cancer.Michael Cobb,1 Lu-
cas Hunter,2 David Carlson,3 David Darr,2 Timothy Haystead,3 Antonio T.
Baines1. 1North Carolina Central Univ., Durham, NC; 2University of North Car-
olina at Chapel Hill, Chapel Hill, NC; 3Duke University, Durham, NC.
Triple-negative breast cancer (TNBC) lacks expression of the estrogen recep-
tor (ER), the progesterone receptor (PR) and the ERBB2 (also known as HER2)
receptor, making it the worse subtype of all breast cancers. Currently, there are
no molecular targeted therapies for this cancer and chemotherapy is only suc-
cessful in a limited number of patients. Recent studies suggest that members of
the oncogenic PIM kinase family, especially PIM-1, play a signifıcant role in the
growth of TNBC. However, there is very limited information on the role other
PIM family members have in the growth and development of TNBCs. As an
attempt to address this concern, we treated a panel of TNBC cell lines with
HS140, a PIM-2 kinase inhibitor developed in the laboratory. Using cytotoxicity
assays, we were able to demonstrate a decrease in anchorage-dependent growth
of cell lines at different concentrations of HS140. Also, a triple negative breast
cancer GEMM (C3TAg) was used for an effıcacy study. Mice (FVB/N back-
ground) have C(3)SV40 T-antigen resulting in inactivation of p53 and Rb. Nine
mice received HS140 treatment (80mg/kg BIW IP) and 14 left untreated for
control (non-treatment [NT]). All mice were monitored for weight loss and
timespan to tumor development 5 timesweekly. Tumor volumes at 21 days were
signifıcantly (Mann-Whitney, p0.0002) reduced in the treated cohort with a
mean of 109mm3 (range of 0-5000) compared to untreated 1393mm3 (0-239).
We observed no toxicities with body mass stable at the treatment dose of 80mg/
kg. Additionally, threemice fromuntreated and threemice from treated cohorts
were chosen for blood sampling pre- and post-treatment via a submandibular
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bleed; no signifıcant differences were noted in WBC, RBC, PLT, or HGB be-
tween untreated and treated cohorts. Overall, these results suggest that other
members of the PIM kinase family, including PIM-2, have an important func-
tion in the growth and development of TNBC and may serve as a potential
molecular target for future therapeutics.
#525 Role of CLCA2 in proliferation of certain growth-factor receptor
dependent cancers. Yufang Yin, Aarushi Sharma, Randolph C. Elble. Southern
Illinois Univ. School of Medicine, Springfıeld, IL.
The CLCA2 gene is downregulated inmost adenocarcinomas, suggesting it is
a tumor suppressor gene. However, we have observed that CLCA2 is upregu-
lated in squamous carcinomas and Her2 breast cancers. Such cancers also
upregulate the calcium-activated chloride channel Ano1 along with EGFR or
Her2. Others have reported that Ano1 enhances EGFR signaling and that Ano1
knockdown confers sensitivity to EGFR inhibitors. Both EGFR and Her2 are
known to transduce their mitogenic signal in part by causing release of intracel-
lular calcium. We have found that CLCA2 activates Ano1 by upregulating in-
tracellular calcium. Moreover, knockdown of CLCA2 reduced EGFR activation
and cell proliferation while it enhanced sensitivity to the tyrosine kinase inhib-
itor lapatinib. These observations suggest that EGFR/Her2, Ano1, and CLCA2
comprise a feed-forward loop that amplifıes growth factor signaling, so that
certain cancer cell types maintain expression of all three.
#526 NF	B p65 overexpression promotes bladder cancer migration via
FBW7-mediated degradation of RhoGDI protein. Yang Li, Junlan Zhu,
Jingxia Li, Chuanshu Huang. NYU Nelson Institute of Environmental medicine,
Tuxedo Park, NY.
Since bladder cancer (BC) is one of the most lethal urological malignant
tumors worldwide, understanding the molecular mechanisms that trigger the
migration, invasion and metastasis of BC has great signifıcance in reducing the
mortality of this disease. RelA/p65, a member of the NF-kappa B transcription
factor family, is increasingly recognized as a crucial player in many steps of
cancer initiation and progression. In this study, we unexpectedly found that p65
protein expression increased in the bladder carcinogen N-butyl-N-(4-hydroxy-
butyl)-nitrosamine (BBN)-induced high invasive bladder tumor tissues, and in
human bladder cancer cell lines. We also observed that p65 overexpression
promoted bladder cancer cell migration by inhibiting RhoGDI expression.We
further demonstrate that the regulatory effect of p65 on RhoGDI expression is
mediated by its upregulation of FBW7, which specifıcally interacted with
RhoGDI and promoted RhoGDI ubiquitination and degradation.Mechanis-
tic studies revealed that p65 stabilizing the E3 ligase FBW7proteinwasmediated
by its attenuating Pten transcription. Taken together, p65 overexpression results
in Pten downregulation, and FBW7 protein degradation, and in turn leading to
RhoGDI protein degration and promotings human BC cell migration. The
identifıcation of p65/PTEN/FBW7/RhoGDI axis provides a signifıcant insight
into understanding the nature of BC migration.
#527 Integrated genomic cfDNA/cfRNA profıling for AR-V7 liquid bi-
opsy test in prostate cancer. Shidong Jia. Predicine Inc, Irvine, CA.
The growth and survival of prostate cancer tumors relies primarily on the
functioning of the androgen receptor (AR) signaling pathway. Recent studies
suggested that the presence of AR-V7, a c-terminal truncated form of AR, in
circulating tumor cells (CTCs) of patients with castration-resistant prostate can-
cer (CRPC) is associated with inherent and/or acquired resistance to enzalut-
amide and abiraterone, the stand of care androgen deprivation therapies in
prostate cancer. A series of data also indicate that AR-Vs (eg, including AR-V7,
ARv567es, AR-T878A, AR-F876L etc) may drive resistance in CRPC. Expression
of AR-V7 has been shown to correlate with disease progression and shortened
survival. Considering that truncated AR splicing variants with C-terminal loss
lack a functional ligand-bingding domain (LBD) and are constitutively active,
C-terminal AR-directed therapies may not be effective for patients with AR
splicing variants. Circulating tumor cell (CTC)-based AR-V7 tests are currently
being tested in the clinic. However, nearly half of the CRPC patients do not have
enough CTCs for AR-V7 test, raising the request for a complementary, non-
CTC platform to detect AR variants as well as other resistance markers in circu-
lation. Here we report the development, validation and clinical application of
PrediSeq-Prostate, a non-invasive next generation sequencing-based diagnos-
tics platform that offers integrated genomic cell-freeDNA(cfDNA) and cell-free
RNA (cfRNA) profıling of prostate cancer, identifying known (such as AR-V7,
AR-V9, AR-V2, etc) and novel AR splicing variants, point mutation, copy num-
ber, and translocation (such as TMPRSS2-ERG) using a single tube of blood.
Using plasma samples from mCRPC patients that developed resistance to en-
zalutamide and/or abiraterone, PrediSeq-Prostate NGS test identifıed AR-V7,
AR-V2, AR-V3, AR-V4 and other splicing variants that impact diagnosis and
therapeutic selection.We also developed a Bio-Rad digital PCR assaymeasuring
AR-V7 andAR-FL (full length) simultaneously. Collectively, PrediSeqNGS and
ddPCR assays offer comprehensive genomic profıling of both cfDNA and
cfRNA in all patients with prostate cancer, regardless of their status of CTC
enumeration. The successful development and clinical validation of these tests
has potential to enable precision medicine in prostate cancer.
#528 Evaluation of single agent merestinib (LY2801653) or emibetu-
zumab (LY2875358) and the combination in a xenograft tumor model bear-
ing MET exon 14 skipping. Sau-Chi Betty Yan,1 Suzane L. Um,1 Victoria L.
Peek,1 Jennifer R. Stephens,1 Wei Zeng,1 Bruce W. Konicek,1 Ling Liu,1 Volker
Wacheck,2 Richard A. Walgren1. 1Eli Lilly and Company, Indianapolis, IN; 2Eli
Lilly and Company, Vienna, Austria.
Background: MET ex14 skipping, present in3% of lung cancer, is a strong
oncogenic driver which is further evidenced by case reports of patients response
to MET TKI treatment. 15% of tumors in patients that harbor MET ex14
skipping also haveMET amplifıcation (amp).Merestinib is a type IIMET kinase
inhibitor1. Emibetuzumab, a bivalentMETAb, internalizesMET receptor. Each
single agent and the combination were evaluated in the Hs746t gastric cancer
line bearing MET ex14 skipping and MET amp. Methods: Each agent was eval-
uated in vitro for inhibition ofHs746t cell proliferation and pMET levels. In vivo
study in Hs746t-derived xenograft mouse model (n7 mice/ arm, 28 day dos-
ing) initiated when tumors were 150-350mm3: merestinib at 6 mg/kg (subopti-
mal dose - insuffıcient target coverage for 24 hrs) or 12mg/kg (optimal dose) qd
orally, emibetuzumab at 10 mg/kg qw by IP. Results: Merestinib inhibited
Hs746t cell proliferation with IC5034 nM and totally eliminated pMET at
65-100 nM. Emibetuzumab slightly inhibited Hs746t cell proliferation
(IC50100 nM), reduced 10-20% cell surface MET, and no effect on pMET
expression (at 130-650 nM). In the Hs746t xenograft model, merestinib (12
mg/kg) treatment resulted in 91.8% tumor regression after 21 day dosing, while
6 mg/kg merestinib provided transient tumor regression followed by re-growth
while on treatment with T/C18.3% after 21 day dosing. No tumor re-growth
was observed in 6/7 mice in the 12 mg/kg merestinib cohort during the 5 weeks
post-treatment. Emibetuzumab treatment provided transient tumor regression
(37.7%) after 3 doses, but tumors re-grew while on treatment. Combination of 6
mg/kg merestinib and 10 mg/kg emibetuzumab resulted in 85% tumor regres-
sion for the duration of the 28 day dosing period and the treatment was well
tolerated. Tumors in animals re-grew upon termination of this combination
treatment. Conclusion:Merestinib (12mg/kg) treatment resulted in durable and
complete response in 6/7 mice bearing Hs746t tumors with MET ex14 skipping
and MET amp. When used singly, merestinib (6 mg/kg) or emibetuzumab (10
mg/kg) resulted in only transient tumor regression in this model, while the
combination resulted in substantial tumor regression while on treatment. This
combination treatment was however, not as durable as was observed with single
agent 12 mg/kg merestinib. Single agents and the combinations were well toler-
ated. As a type IIMET inhibitor, merestinibmay provide a therapeutic option to
treatment naïve patients or those who have progressed on type I MET inhibitor
treatment, whose tumors have MET exon 14 skipping and/or MET amplifıca-
tion 2,3. Data in this study support a clinical evaluation of merestinib in patients
with MET exon 14 skipping (NCT02920996). 1 - Yan et al. Invest New Drugs
2013;31:833-844 2 - Ou et al. J Thorac Oncol. 2016; PMID:27666659 3 - Heist et
al. J Thorac Oncol. 2016;11:1242-1245.
#529 The signifıcance of activated PI3K/AKT pathway in FGFR3-TACC3
fusion positive cervical cancer. Ryo Tamura,1 Kosuke Yoshihara,1 Tetsuya
Saito,2 Ryosuke Ishimura,2 Emmanuel Martínez-Ledesma,3 Yutaro Mori,1
Kaoru Yamawaki,1 Kazuaki Suda,1 Tatsuya Ishiguro,1 Yoichi Aoki,4 Seiya Sato,5
Hiroaki Itamochi,5Masaaki Komatsu,2 RoelandVerhaak,3 Takayuki Enomoto1.
1Niigata University Graduate School of Medical and Dental Sciences, Niigata,
Japan; 2Department of Biochemistry, NiigataUniversity Graduate School ofMed-
ical and Dental Sciences, Niigata, Japan; 3Department of Genome Medicine, The
University of Texas MD Anderson Cancer Center, Houston, TX; 4Department of
Obstetrics and Gynecology, Graduate School of Medicine, University of the
Ryukyus, Okinawa, Japan; 5Department of Obstetrics and Gynecology, Tottori
University School of Medicine, Tottori, Japan.
Uterine cervical cancer is one of the most common cancer in women world-
wide, and the prognosis in advanced or recurrent cases remains poor because of
no effectivemolecular target therapies for this disease. The aim of our study is to
identify and validate therapeutically targetable gene fusions in uterine cervical
cancer, leading to the development of new therapeutic strategies. We have ana-
lyzed RNA sequencing data of 253 TCGA cervical cancer samples to search for
gene fusions by using PRADA algorithm, and validated recurrent fusions in our
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Japanese dataset (n 100) by RT-PCR and sanger sequencing. In TCGA sam-
ples, we detected 358 fusion transcripts and extracted 3 kinds of recurrent in-
frame fusion transcripts (FGFR3-TACC3, ARL8B-ITPR1 and NXN-ABR). We
focused on FGFR3-TACC3 fusion as a candidate of therapeutic kinase fusion
and identifıed FGFR3-TACC3 fusion in 2 of 253 (0.8%) TCGA samples and 2 of
100 (2%) Japanese samples. All of fusion positive samples, which were histolog-
ically diagnosed as squamous cell carcinoma, showed high expression of both
FGFR3 and TACC3 genes. To evaluate the possibility as therapeutically tar-
getable fusions in uterine cervical cancer, we transfected FGFR3-TACC3, wild
type FGFR3 and TACC3 transcripts to normal immortalized cervical keratino-
cytes derived from ectocervix (Ect1/E6E7) and four uterine cervical cancer cell
lines (SiHa, ME180, HeLa, CaSki). Continuous expression of FGFR3-TACC3
fusion transcript led to anchorage-independent growth in Ect1/E6E7 and the
dramatically alteration of cell proliferation in all cancer cell lines. On the other
hand, no obvious phenotype change was observed in FGFR3 or TACC3 trans-
fected cells. Western blotting analysis demonstrated that MAPK pathway was
activated in all the fusion transfected cell lines but PI3K/AKT pathway was
activated only in ME180 and CaSki harboring PIK3CAmutation. Fusion trans-
fected cell lines exhibited high sensitivity to fusion specifıc siRNA and FGFR
inhibitor compared to control. Although PI3K/AKT activated cell lines (ME180
and CaSki) showed less effective against FGFR inhibitor compared to PI3K/
AKT neutral cell lines (SiHa andHeLa), combined inhibition of FGFR andAKT
had a synergic effect in PI3K/AKT activated cell lines. Our fındings suggest
FGFR3-TACC3 fusion gene is an oncogenic driver event and therapeutic target
in a fraction of cervical cancer. When FGFR3-TACC3 fusion positive cervical
cancer is treated by FGFR inhibitor, genomic background such as PI3K/AKT
status should be considered.
#530 The role of EGFR in c-fos-dependent osteosarcoma formation.
Markus Linder,1 Elisabeth Glitzner,1 Sriram Srivatsa,1 Parastoo Shahrouzi,1
Latifa Bakiri,2 Monika Dumanic,1 Markus Mitterhauser,1 Erwin F. Wagner,2
Maria Sibilia1. 1Medical University of Vienna, Vienna, Austria; 2Spanish Na-
tional Cancer Research Center (CNIO), Madrid, Spain.
The Epidermal Growth Factor Receptor (EGFR) is overexpressed or mutated
in human carcinomas and glioblastomas, which are tumors of epithelial and glial
origin, respectively. Some publications indicated that EGFR overexpression
could occur in human osteosarcomas (OS). Using EGFR knockout mice
(Egfr-/-), we have recently shown that EGFR plays a role in bone development
and osteoblast function, raising the possibility that EGFR is also involved in OS
formation. Here we show that Egfrf/f Runx2-Cre mice (Egfr	Ob), lacking the
EGFR in osteo-chondroprogenitor cells, develop an increased zone of hypertro-
phic chondrocytes in long bones and decreased bone formation. When bred to
c-fos transgenic mice (H2-c-fosLTR) that develop osteosarcomas with 100%
penetrance, Egfr	Ob mice show reduced tumor incidence and burden. At the
molecular level, tumors from Egfr	Ob mice exhibit decreased expression levels
of c-Fos andCyclinD1. In vitro experiments in primary bone tumor cells further
show that EGFR inhibition leads to reduced proliferation and increased apopto-
sis. Importantly, Egfr and c-Fos also play an important role in human OS, as
co-expression of both proteins in tumor sections correlated with signifıcantly
reduced survival in patients suffering fromprimaryOS. Taken together our data
suggest an essential role of EGFR signaling during both development and pro-
gression of c-Fos-dependent OS and newly identifıed molecular targets cur-
rently under investigation will be presented.
#531 Activity of the selective FGFR 1, 2 and 3 inhibitor INCB054828 in
genetically-defıned models of triple-negative breast cancer. Phillip C.C. Liu,1
Brian D. Lehmann,2 Bruce Ruggeri,1 Darlise DiMatteo,1 Johanna M. Schafer,3
Jin Lu,1 Sang Hyun Lee,1 Luping Lin,1 Timothy C. Burn,1 Melody Diamond,1
AllaVolgina,1 LiangxingWu,1GregoryHollis,1 ReidHuber,1 Jennifer A. Pieten-
pol,2 Peggy Scherle1. 1Incyte, Wilmington, DE; 2Vanderbilt University Medical
Center, Nashville, TN; 3Vanderbilt University, Nashville, TN.
Activation of the Fibroblast Growth Factor (FGF)-FGF Receptor (FGFR) sig-
naling axis occurs in many human cancers. In preclinical models, cell lines with
genetic aberrations in FGF/FGFR genes are preferentially inhibited by com-
pounds that selectively target the FGFR kinase. INCB54828 is a potent, selective,
and reversible inhibitor of FGFR1, 2 and 3 that is currently in Phase 2 clinical
trials for advancedmalignancies characterized by FGF-FGFR alterations. In this
study, we investigated the effıcacy of INCB054828 in models of triple-negative
breast cancer (TNBC). FGFR1 and FGFR2 are amplifıed in approximately 4%
and 5% of TNBC, respectively, and oncogenic fusion proteins including
FGFR3-TACC3 have also been identifıed in some TNBC specimens. To pro-
fıle the activity of INCB054828, we screened a panel of diverse TNBC cell
lines that are representative of each of the four subtypes of TNBC. Three
human TNBC lines MFM223, SUM185 and SUM52PE were highly sensitive
to INCB054828 in viability assays. Each of these responsive cell lines has a
known alteration in FGFR, whereas TNBC lines lacking any aberrations in
FGF/FGFR genes were refractory to growth inhibition. Inhibition of cell
viability was associated with suppression of growth promoting pathways
including Ras-MAPK. To confırm this association in vivo, four PDX models
of TNBC were tested: two chemo-refractory models with FGFR1 amplifıca-
tion (CNV  4 and 6) and two without any known FGF/FGFR alterations.
Both of the models with FGFR1 copy number gain showed a response to
INCB054828 as monotherapy with 36 and 78% tumor growth inhibition that
was statistically signifıcant vs vehicle control (P0.05 and p0.001, respec-
tively). At the maximally effıcacious dose of 1 mg/kg daily, neither PDX
model lacking FGF/FGFR alteration responded to the treatment. Finally to
assess the effect of the microenvironment on drug sensitivity, mouse 4T1
breast cancer cells were orthotopically implanted into the mammary fat pad;
under these conditions, 4T1 tumors retained sensitivity to a standard dose of
INCB054828. In summary these results demonstrate that the FGFR1/2/3
inhibitor INCB054828 is highly active against models of TNBC with genetic
alterations in FGFR genes, and confırms the importance of patient stratifı-
cation strategies for clinical trials with FGFR targeted therapies.
#532 Identifıcation of unpaired cysteine-mediated gain and loss of func-
tion CSF3R extracellular mutations.Haijiao Zhang,1 Sophie Means,1 Anna R.
Schultz,1 Kevin Watanabe-Smith,1 Bruno C. Medeiros,2 Tim Kükenshöner,3
Oliver Hantschel,3 Daniel Bottomly,1 Beth Wilmot,1 Shannon K. McWeeney,1
JeffreyW. Tyner1. 1Oregon Health & Science University Knight Cancer Institute,
Portland, OR; 2Stanford University School of Medicine, Stanford, CA; 3School of
Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Swit-
zerland.
Mutations in the CSF3R extracellular domain have been reported so far only
in neutropenia patients. These extracellular mutations are loss of function mu-
tations, which interrupt ligand binding. Here we screened CSF3R extracellular
domain variants in a variety of hematological malignances and described for the
fırst time the identifıcation of an activating CSF3R extracellular mutation
W341C in a leukemia patient. Functional assays revealed that this mutation
conferred Ba/F3 cell cytokine-independent growth and induced constitutive
JAK-STAT activation. We further characterized that cysteine substitutions at
other amino acid positions (342, 356 and 477) and other amino acid substitutes
of W341 (A/G/K/R/S) did not transform cells, indicating that both the amino
acid position and cysteine substitution are essential for the transforming capac-
ity. In agreement, increased dimer formation of W341C was observed in the
co-immunoprecipitation assay and non-reducing condition immunoblot,
which could be abrogated in an immunoblot run under reducing conditions,
highly suggesting that dimerization is mediated by the formation of intermolec-
ular disulfıde bonds. Surprisingly, W356C demonstrated loss of function prop-
erties, however, showed increased dimer formation similar to W341C, indicat-
ing that only the increased dimerization is not suffıcient for transforming
capacity. Computational modeling based on IL6ST showed opposite directions
of W341 and W356, which may orientate the cytoplasmic domain towards or
away fromone another. Interestingly, aCSF3R cytoplasmic truncationmutation
at amino acidW791was found to be on the same allele asW341C in this patient.
TheW341C/W791X compoundmutation transformed Ba/F3 with faster kinet-
ics comparing to theW341C single mutation. Furthermore, the compoundmu-
tation, but not W341C alone demonstrated delayed receptor degradation, indi-
cating enhanced oncogenic potential. Notably, the primary patient sample and
the Ba/F3 cells transformed by W341C or the compound mutation were all
sensitive to JAK inhibitors. The patient harboring these CSF3R mutations dis-
played myelodysplastic morphology with BCOR mutation at disease diagnosis,
and showed good response to Azacytidine treatment. However her white blood
count (mature neutrophils in particular) increased after 15-18 months’ treat-
ment, which was concomitant with the acquisition and expansion of CSF3R
W341C andW791X and disease progression.We further investigated the onco-
genic potential of disrupting original cysteine pairs in the CSF3R extracellular
domain. Increased dimers are observed in these mutations, whereas two func-
tional consequences were observed: loss of function and constitutive activity.
This, therefore, represents the fırst characterization of unpaired cysteines that
mediate both loss and gain of function phenotypes. This paradigmmay apply to
other cytokine receptors.
#533 XIAP BIR domain suppresses miR-200a expression and subse-
quently promotes EGFR protein translation and anchorage-independent
growth of bladder cancer cell. Xin Liao,1 Chao Huang,2 Jingxia Li,2 Chuanshu
Huang2. 1New York University School of Medicine and Wuhan Tongji Hospital,
Tuxedo Park, NY; 2New York University School of Medicine, Tuxedo Park, NY.
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The X-linked inhibitor of apoptosis protein (XIAP) is a well-known potent
apoptosis suppressor, and also participates in cancer cell biological behaviors,
therefore attracting great attentions as a potential antineoplastic therapeutic
target for past years. We found here that lacking of XIAP expression resulted in
a remarkable suppression of EGFR expression, consequently leading to the de-
fıcient of anchorage-independent cell growth. Further study demonstrated that
BIR domain of XIAP was crucial for regulating the EGFR translation by sup-
pressing the transcription and expression of miR-200a. Mechanistic studies in-
dicated that BIR domain activated the PP2A activity by decreasing the phos-
phorylation of PP2A at Tyr307 in its catalytic subunit, PP2A-C. Such activated
PP2A prevented the deviant phosphorylation and activation of MAPK kinases/
MAPKs, their downstream effector c-Jun, and in turn inhibiting transcription of
c-Jun-regulated the miR-200a. Collectively, our study uncovered a novel func-
tion of BIR domain of XIAP in regulating the EGFR translation, providing sig-
nifıcant insight into the understanding of the XIAP overexpression in the cancer
development and progression, further offering a new theoretical support for
using XIAP BIR domain and EGFR as targets for cancer therapy.
#534 PDGFRB gain-of-function mutations in multifocal infantile myofı-
bromatosis: Implications for diagnosis & therapy. Florence A. Arts,1 Raf
Sciot,2 Bénédicte Brichard,1 Marleen Renard,2 Laura A. Noël,1 Amélie I. Vel-
ghe,1 Christine Galant,1 Maria Debiec-Rychter,2 An Van Damme,1 Miikka Vik-
kula,1 Raphaël Helaers,1 Nisha Limaye,1 Hélène A. Poirel,1 Jean-Baptiste B. De-
moulin1. 1University of Louvain, Brussels, Belgium; 2KU Leuven, Leuven,
Belgium.
Myofıbromas and infantile myofıbromatosis are among the most prevalent
soft tissue tumors of infancy and childhood. They are characterized by the pres-
ence of solitary ormultiple nodules in the skin, subcutaneous soft tissues, bones,
muscles and viscera. Multifocal myofıbromatosis with visceral lesions is associ-
ated with a poor prognosis. The pathogenesis of sporadic myofıbromatosis is
unknown. A few familial cases have been linked to mutations in various genes
including PDGFRB, which encodes a receptor tyrosine kinase that is highly
expressed in fıbroblasts, pericytes and other cells of mesenchymal origin. In the
present study, we investigated whether the sporadic form of the diseasemay also
be associated with PDGFRB mutations. We sequenced the whole coding se-
quence of PDGFRB in 20 cases ofmyofıbromatosis or solitarymyofıbromausing
the Ion AmpliSeq technology at high coverage (Life Technologies). Six different
mutations in the coding sequence of PDGFRB were identifıed in seven patients,
six ofwhomhad the sporadicmulticentric formof the disease, with amedian age
at diagnosis of 13 months [range: 0 to 7 years]. Mutations were located in four
different exons: the classical hotspot exons 12 and 14, encoding the juxtamem-
brane and the kinase domains, but also the exons 11 and 18, encoding the trans-
membrane domain and the activation loop respectively. The percentage of mu-
tated reads varied between 4 and 33%, suggesting that the mutations were
somatic, except for one patient who had a germline R561C substitution and a
somatic second hit. Two patients had the same mutation in multiple separated
lesions, suggesting an early post-zygotic mutation in a progenitor cell. By con-
trast, a third patient had three different PDGFRBmutations in the three nodules
analyzed.We showed that these mutations constitutively activated receptor sig-
naling in the absence of ligand and stimulated fıbroblast proliferation in vitro.
Furthermore, the mutant receptors were sensitive to the tyrosine kinase inhibi-
tor imatinib, except D850V, which was inhibited by dasatinib and ponatinib,
suggesting a treatment for severe myofıbromatosis. In conclusion, we identifıed
activating PDGFRBmutations in 66%of sporadicmultifocal infantilemyofıbro-
matosis cases, shedding light on the mechanism of disease development. Our
results provide a genetic test to facilitate diagnosis, and preclinical data for de-
velopment of molecular therapies.
#535 Paving the path to metastasis/invasion through GIV: Identifıcation
of a polarized ex(o)citing machinery for cancer invasion. Cristina C. Rohena,
NinaN. Sun, Nicolas Aznar, Pradipta Ghosh.University of California SanDiego,
San Diego, CA.
Polarized exocytosis is a fundamental process involving the delivery of mem-
brane and cargo proteins to target sites the plasma membrane (PM) and it is
essential for a wide range of biological functions such as cell growth, morpho-
genesis, and polarized cell migration. Polarized exocytosis requires precise spa-
tial control of vesicle tethering to target sites at the PM. This is mediated by the
octameric exocyst complex that is conserved fromyeast toman.How the exocyst
complex imparts polarity during exocytosis remained a mystery until recent
insights emerged from studies on budding yeast. A functional interaction be-
tween exocyst component Exo70p and the yeast polarity determinant scaffold
protein Bem1p was reported, and it was shown that Bem1p regulates the target-
ing of Exo70p to polarized exocytic sites. Despite these insights, the counterpart
of Bem1p in higher species remained elusive. Here we demonstrate that a novel
polarity-determinant protein calledGIV (G-interacting vesicle associated pro-
tein/Girdin) fulfılls the key criteria and functions of its yeast counterpart Bem1p.
GIV provides an evolutionary upgrade to the process of polarized exocytosis by
making it responsive to growth factors and other external cues and by modulat-
ing it through G protein signaling that is unique to mammalian cells. GIV was
originally identifıed in a yeast-2 hybrid screen as a binding partner of EXOC1,
and subsequently validated by us as a PI4P-binding protein that is a direct bind-
ing partner of mammalian Exo70. Biochemical assays have confırmed that the
mechanism of GIV:Exo70 interaction bears close semblance to the Bem1p:
Exo70p interaction. Sequence alignment studies led to the identifıcation of sin-
gle point mutants in Bem1p and GIV that are selectively defective in binding to
Exo70. Using genetic manipulation of cancer cells we have observed that GIV is
essential for polarized tethering of Exo70-coated vesicles at the cell periphery.
Consistent with the previously described prometastatic role of GIV, we found
that GIV is required for EGF-stimulated exocytosis of matrix metalloproteases
that aid in cancer invasion inMDA-MB-231 breast cancer cells and that specifıc
point mutants of GIV that interrupt the interaction with Exo70 cause a reduc-
tion in the ability of these breast cancer cells to invade and degrade components
of the extracellular matrix. Furthermore, GIV interacts specifıcally with TC-
10●GTP[active], a monomeric GTPase that regulates fusion of exocytic vesicles
at the plasma membrane. Insights gained continue to provide an in-depth un-
derstanding of how GIV affects a fundamental process of exocytosis, and what
impact that may have on cancer invasion and metastasis.
#536 Novel identifıcation of STAT1 as a crucial mediator of ETV6-
NTRK3-induced tumorigenesis. Jinah Park,1 Junil Kim,2 Poul H. Sorensen,3
Seong-Jin Kim1. 1Seoul National University, Gyeonggi-do, Republic of Korea;
2Perelman School of Medicine, Philadelphia, PA; 3British Columbia Cancer Re-
search Centre, Vancouber, British Columbia, Canada.
Chromosomal rearrangements that facilitate tumor formation and progres-
sion through activation of oncogenic tyrosine kinase are frequently observed in
cancer. The ETV6-NTRK3 (EN) fusion has been implicated in various cancers,
including infantile fıbrosarcoma, secretory breast carcinoma and acute myelo-
blastic leukemia, and has exhibited in vivo and in vitro transforming ability. In
the present study, we analyzed transcriptome alterations using RNA-Seq in EN-
transduced NIH3T3 fıbroblasts to identify the mechanisms that are involved in
EN-mediated tumorigenesis. Through functional profıle assessment of EN-reg-
ulated transcriptome alterations, we found that EN up-regulated genes mainly
associated with cell motion, membrane invagination, and cell proliferation,
while down-regulated genes are involved in cell adhesion, which described the
transforming potential and increased proliferation in EN-transduced cells. No-
tably, KEGG pathway analysis identifıed the JAK-STAT signaling pathway with
the highest statistical signifıcance. Moreover, Ingenuity Pathway Analysis and
gene regulatory network analysis identifıed the Stat1 transcription factor and its
target genes as top EN-regulated molecules. We further demonstrated that EN
enhanced STAT1 phosphorylation but attenuated STAT1 acetylation, thereby
inhibiting the interaction between NF-B p65 and acetylated STAT1. Conse-
quently, nuclear translocation of NF-B p65 and subsequent anti-apoptotic
NF-B activity were increased by EN. Taken together, here we report, for the
fırst time, STAT1 as a signifıcantly EN-regulated transcription factor and a cru-
cial mediator of EN-induced tumorigenesis. [This work was supported by a
National Research Foundation grant of Korea (NRF-2014M3A9B5073918)
funded by the Korea government.]
#537 TRAF3 serves as a tumor suppressor in HPV-associated head and
neck squamous cell carcinomas. TonyW. Chen, Jialing Zhang, Xinping Yang,
Zhong Chen, Carter Van Waes. NIH/NIDCD, Bethesda, MD.
The molecular mechanisms that control transformation and tumorigenic-
ity of human papillomavirus-associated (HPV) head and neck squamous
cell carcinomas (HNSCCs) are currently being investigated. The number of
HPV HNSCC cases has increased sharply in recent years, especially in
tonsil and oropharyngeal cancers. These HPV HNSCCs often respond
differently to treatments. Recently, The Cancer Genome Atlas (TCGA, 2015)
identifıed novel loss-of-function genomic alterations of TNF receptor-asso-
ciated factor 3 (TRAF3) in HPVHNSCCs. TRAF3 is a ring-fınger E3 Ubiq-
uitin Ligase which inhibits downstream alternative NF-B signaling and
promotes anti-viral immunity by promoting degradation of ubiquitinated
proteins. To assess TRAF3’s role in HPV HNSCCs, we identifıed cell lines
with lower level of TRAF3 protein, consistent with defıcient TRAF3 expres-
sion identifıed in TCGA data. Functional studies showed that TRAF3 expres-
sion led to decreased steady-state protein levels of the alternative NF-B
pathway components RELB and NF-B2/p52, as assessed by Western blot,
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reporter assays and immunofluorescence. Additionally, TRAF3 expression
led to decreased cell proliferation, tumorigenic activity and migration, and
increased sensitivity to chemotherapy agent cisplatin. Interestingly, TRAF3
increases the steady state protein level of the classical tumor suppressors RB
and p53 in HPV HNSCC cell lines as assessed by Western blot. Further in
vitro characterization of TRAF3’s function in HPV HNSCCs was assessed
using clinically identifıed TRAF3 loss-of-function mutagenic isoforms,
mimicking both TCGA data and HNSCC cell line data for TRAF3 defects. In
contrast to wtTRAF3, these mutant forms of TRAF3 do not as strongly
restore p53 or inhibit RELB and NF-B2/p52 protein levels. One specifıc
mutation which causes a frameshift at residue 210 greatly inhibits TRAF3
function as assessed by Western blot. To further assess effects of wt or
TRAF3 loss-of-function mutants in vitro and in vivo, an inducible HPV
HNSCC line expressing TRAF3 using the TET-ON system, and TRAF3
knockout in HPV HNSCC line and Human Oral Keratinocyte (HOK) line
using CRISPR-Cas9 genomic editing are generated. In conclusion, the ring-
fınger E3 ubiquitin ligase TRAF3 inhibits the pro-survival alternative NF-B
signaling pathway and restores TP53 and RB, thereby serving as a tumor
suppressor in HPV HNSCCs. (Supported by NIDCD intramural project
ZIA-DC-000016, 73 and 74).
#538 The cytosolic domain of a disintergrin andmetalloprotease (ADAM)
15 promotes non-small cell lung cancer (NSCLC) anti-apoptosis ability.
Hsin-Han Hou, Chong-Jen Yu. National Taiwan University Hospital, Taipei,
Taiwan.
Emerging evidence has indicated that proteins of a disintergrin and metallo-
protease (ADAM) family contribute to cancer progression and metastasis. One
member of this family, ADAM15, has been shown to be upregulated inmultiple
cancers, including gastric, lung, breast, and prostate cancers, and the enzymatic
activities of its extracellular metalloprotrease domain promote breast cancer
proliferation and migration through mediating ErbB signaling pathway. The
patients with ADAM15 high-expressing lung tumors have shorter survival time
and ADAM15 has been proved to enhance synovial fıbroblasts anti-apoptosis
ability via focal adhesion kinase signaling pathway. We fırstly demonstrated
other than extracellular enzymetic activity, the longest isoform of ADAM15
(ADAM15 i6), which contains the most cytoplasmic Src homology 3 (SH3)
binding motifs, signifıcantly upregulated in primary lung cancer tissues and
promoted NSCLC proliferation via growth factor receptor-bound protein 2
(Grb2) and Src homolog 2 domain containing (Shc) association. In this study,
we further explore the roles of ADAM15 cytosolic domain in NSCLC apoptosis
resistance. Overexpression of ADAM15 i6 promoted CL1-0 cell anti-apoptosis
ability according to the trypan blue inclusion assay. Ablation of nephrocystin
(NPHP1) attenuated theADAM15 i6-promoted anti-apoptosis ability. Thus, we
identifıed a novel mechanism of the ADAM15 cytoplasmic domain in NSCLC
tumor progression, which will shed light on the molecular mechanisms of
ADAM proteins, and facilitate development of novel therapy in NSCLC.
#539 MAEL promotes colorectal cancer cell growth and migration by ac-
tivating EGFR pathway. Lulu Liu, Zhou Tong, Weiqin Jiang, Yi Zheng, Peng
Zhao,Weijia Fang.The First AffıliatedHosipital, ZhejiangUniversity,Hangzhou,
China.
Colorectal cancer (CRC) is one of themost commonmalignant tumors of the
digestive system. It is generally accepted that CRC pathogenesis is a long-term
process involving accumulation of multiple genetic alterations. Herein, we aim
to explore the molecular biological mechanisms of CRC initiation and progres-
sion. We have been committed to investigating MAEL function in digestive
neoplasms and have found MAEL is a new candidate oncogene. Previously,
overexpression of MAEL was frequently detected in CRC tissues and signifı-
cantly associated with poor 5-year outcome. By MTT assay and transwell assay,
functional study demonstrated that overexpression of MAEL promoted cell
growth and cell migration in DLD1 and THC8307 cell lines. Furthermore over-
expression of MAEL in DLD1 cell line could promote tumor formation in nude
mice. Further study found that MAEL overexpression in DLD1 and THC8307
elevated the protein expression of p-EGFR, p-Raf-1, p-ERK 1/2, p-PI3K and
p-AKT. These data indicated that MAEL enhanced the activity of EGFR/Ras/
Raf/MEK/ERK1/2 and EGFR/PI3K/Akt pathways. However, more effort is
needed to investigate MAEL function and howMAEL activate EGFR pathways.
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#540 Deep learning to determine breast cancer estrogen receptor status
from nuclear morphometric features in H&E images. Rishi R. Rawat, Daniel
Ruderman, David B. Agus, Paul Macklin. Ellison Institute for Transformative
Medicine of USC, Los Angeles, CA.
We hypothesized that the spatial arrangement of nuclei in a hematoxylin and
eosin (H&E) stained image contains a vast quantity of latent information that is
currently underutilized. We tested this hypothesis on the classifıcation of breast
cancer biopsies as estrogen receptor (ER) positive or negative. While determin-
ing ER status typically requires immunohistochemistry (IHC) staining, we
aimed to recapitulate this step by predicting ER status directly fromH&E stained
slides. By training a deep neural network on nuclear-morphometric features, we
demonstrate the power of machine learning to provide insights about cancer
biology, and aim to scale precision oncology for the developing world. We con-
structed a learning pipeline that segments nuclei from H&E stained slides
scanned into digital images, extracts shape and orientation descriptors, and uses
a deepneural network to learn spatial features to predict ER status. After training
the pipeline on 57 tissue cores of invasive ductal carcinoma (IDC), we were able
to predict ER status in patients with IDC in a statistically signifıcant manner
(AUC0.72, 95%CI0.55-0.88, n56) and ductal carcinoma in situ
(AUC0.82, 95%CI0.74-0.89, n106). To our knowledge, this is the fırst
work to show that nuclearmorphometric information can be used to predict the
molecular status of a breast cancer tumor. An initial analysis of the features
learned by the deep neural network provides a glimpse into the mechanistic
differences between ER and ER- cancers: suggesting the importance of spatial
heterogeneity in distinguishing between ER and ER-. We anticipate that fur-
ther analysis will provide deeper insights about the morphological differences
between ER and ER- cancers, and that this type of analysis can be applied to
othermarkers and cancers.Moreover, an optimized version of this pipelinemay
serve patients in the developing world by providing a means to predict marker
status directly from H&E images.
#541 A comprehensive analysis delineating the immunotherapeutic ter-
rain of cancer-related clinical trials. Cara M. Statz, Sara E. Patterson, Taofei
Yin, SusanM.Mockus.The Jackson Laboratory for GenomicMedicine, Farming-
ton, CT.
Technological innovations have facilitated a greater understanding of how the
tumor microenvironment contributes to cancer, leading to rapid FDA approval
of four immunotherapies. To assess how these therapies are being further inves-
tigated in combination with other therapies and in tumor types outside of the
current FDA approval, we performed a comprehensive analysis of the curated
clinical trials in the JAX Clinical Knowledgebase (JAX-CKB). In brief, clinical
trials investigating Atezolizumab, Nivolumab, Pembrolizumab, and Ipili-
mumab, curated from clinicaltrials.gov, were queried in the JAX-CKB and then
analyzed for comparison. Further analyses were executed to illustrate possible
unmet needs within the fıeld of cancer therapeutics. Of the four immunothera-
pies, Pembrolizumab was identifıed with the greatest number of clinical trials
overall, with 305 compared to Atezolizumab, 79, Nivolumab, 183, and Ipili-
mumab, 126. Of these trials the number of trials investigating Pembrolizumab,
Atezolizumab,Nivolumab, or Ipilimumab in combinationwith another therapy
was higher than those investigating one of the four immunotherapies as amono-
therapy. Phase II trials for both single therapy and combinatorial therapies were
greater than both Phase I and Phase III for the same groups, regardless of ther-
apy. On average, 12% 3.8% of the combined trials for all four drugs included
any advanced solid tumor. Nivolumab combined with Ipilimumab demon-
strated the greatest number of trials (61) investigating an immunotherapy in
combination with another immunotherapy. Among those, 30 were Phase II
trials, 16 were Phase I, and 14 were Phase III. Across fıve cancer indications
(lung, pancreatic, ovarian, prostate, and colon), lung cancer was most com-
monly indicated in the trials, among all four drugs. Prostate was indicated in the
least number of trials, with Ipilimumab ranking the highest (10). The recent
success with immunotherapies has garnered signifıcant interest in understand-
ing how these therapies will perform in different tumor types and whether spe-
cifıc combinations will have a greater impact. Interrogation of the clinical trial
terrain in the JAX-CKB provides a basis for determining additional investiga-
tions that might be warranted.
#542 Genomic and clonal characterization of immunogenic epitope land-
scape across The Cancer GenomeAtlas.HoJoon Lee,1 Stephanie Greer,1 Susan
M.Grimes,1 Jae-HoCheong,2Hanlee P. Ji1. 1StanfordUniv., Stanford, CA; 2Yon-
sei University, Seoul, Republic of Korea.
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Recent advances in cancer immunotherapy and genomic sequencing technol-
ogies have created promising opportunities for precision cancer medicine. So-
matic mutation in coding regions of cancer genomes may lead to amino acid
alterations that generate immunogenic peptides, called neoantigens. These
novel peptides are tumor-specifıc. An individual’s ownMHCgenotypes restricts
the presentation of these tumor-specifıc peptides and thus there are a limited
number of candidate epitopes for immune cellular recognition. Current studies
have not comprehensively studied howMHC-restricted neoantigens are present
across tens of thousands of cancer. Nor have these studies determined how
somatic mutations and their associated neoantigens are represented among dif-
ferent subclonal populations existingwithin individual tumors. To address these
limitations, we have mapped the complex immunogenomic topology of neoan-
tigen epitopes across 8,000 tumors representing 18 different cancer types. This
neoantigen landscape accounts for how neoepitope candidates are distributed
among the various clonal subpopulations existing within any given tumor.Our
study utilized genomic data from the Cancer Genome Atlas (TCGA). Our auto-
mated pipeline provides results from 8,000 samples from 18 cancer types that
have somatic variant calls, copy number variation, whole exome sequence, and
RNA-Seq data. Identifıcation of somatic mutations that lead to highly immuno-
genic antigens involved fıve different steps; i) in-silico translation of identifıed
mutations, ii) expression as measured per RNA-Seq, iii) patient’s own major
histocompatibility complex genotype, iv) binding affınity specifıc to the MHC
alleles for any given patient and v) occurrence of clonal subpopulations as dem-
onstrated by intratumoral genetic heterogeneity. We mapped the neoantigen
landscape with quantitative representation of the genetic clonal diversity exist-
ing within individual tumors. In average, 2% of missense mutations from a
patient are detected in RNA-Seq, with binding affınity to own HLA genotypes,
and from the dominant clonal subpopulation.In summary, our study demon-
strates the various relationships among the number of optimal antigens, the
number of clonal subpopulations, the number ofmutations, and clinical pheno-
types such as tumor stage. Our automated bioinformatics process facilitates the
use of exome andRNA-Seq as potential diagnostic analytic process for precision
immunotherapy.
#543 Harnessing synthetic lethality to predict clinical outcomes of cancer
treatment. Joo Sang Lee,1 Avinash Das,1 Livnat Jerby-Arnon,2 Seung Gu Park,1
Matthew Davidson,3 Dikla Atias,4 Arnaud Amzallag,5 Chani Stossel,4 Ella Bu-
zhor,4 Welles Robinson,1 Kuoyuan Cheng,1 Joshua J. Waterfall,6 Paul S. Melt-
zer,6 SridharHannenhalli,1 Cyril H. Benes,5 Talia Golan,4 Emma Shanks,3 Eytan
Ruppin1. 1University of Maryland, College Park, MD; 2Tel Aviv University, Tel
Aviv, Israel; 3Beatson Institute, Glasgow, United Kingdom; 4Sheba Medical Cen-
ter, RamatGan, Israel; 5HarvardMedical School, Boston,MA; 6National Institute
of Health, Bethesda, MD.
Signifıcance: The identifıcation of Synthetic Lethal interactions (SLi) has
long been considered a foundation for the advancement of cancer treatment.
The rapidly accumulating large-scale patient data now provides a golden
opportunity to infer SLi directly from patient samples. Here we present a new
data-driven approach termed ISLE for identifying SLi, which is then shown
to be predictive of clinical outcomes of cancer treatment in an unsupervised
manner, for the fırst time. Methods: ISLE consists of four inference steps,
analyzing tumor, cell line and gene evolutionary data: It fırst identifıes pu-
tative SL gene pairs whose co-inactivation is underrepresented in tumors,
testifying that they are selected against. Second, it further prioritizes candi-
date SL pairs whose co-inactivation is associated with better prognosis in
patients, testifying that they may hamper tumor progression. Finally, it elim-
inates false positive SLi using gene essentiality screens (testifying to causal
SLi relations) and prioritizing SLi paired genes with similar evolutionary
phylogenetic profıles. Results: We applied ISLE to analyze the TCGA tumor
collection and generated the fırst clinically-derived pan-cancer SL-network,
composed of SLi common across many cancer types. We validated that these
SLi match the known, experimentally identifıed SLi (AUC0.87), and show
that the SL-network is predictive of patient survival in an independent breast
cancer dataset (METABRIC). Based on the predicted SLi, we predicted drug
response of single agents and drug combinations in a wide variety of in vitro,
mouse xenograft and patient data, altogether encompassing 700 single
drugs and 5,000 drug combinations in 1,000 cell lines, 375 xenograft
models and 5,000 patient samples. Of note, these predictions were per-
formed in an unsupervised manner, reducing the known risk of over-fıtting
the data commonly associated with supervised prediction methods. Our
prediction is based on the notion that a drug is likely to be more effective in
tumors where many of its targets’ SL-partners are inactive, and drug syner-
gism may be mediated by underlying SLi between their targets. Most impor-
tantly, we demonstrate for the fırst time that an SL-network can successfully
predict the treatment outcome in cancer patients in multiple large-scale
patient datasets including the TCGA, where SLis successfully predict pa-
tients’ response for 75% of cancer drugs. Conclusions: ISLE is predictive of
the patients’ response for the majority of current cancer drugs. Of para-
mount importance, the predictions of ISLE are based on SLi between (po-
tentially) all genes in the cancer genome, thus prioritizing treatments for
patients whose tumors do not bear specifıc actionable mutations in cancer
driver genes, offering a novel approach to precision-based cancer therapy.
The predictive performance of ISLE is likely to further improve with the
expected rapid accumulation of additional patient data.
#544 Hypoxia response signaling is linked to TACE resistance in hepato-
cellular carcinoma (HCC) patients. Valerie Fako,1 Joyce Lee,2 Tan-To
Cheung,2 Irene O. Ng,2 Xin W. Wang1. 1National Cancer Institute, Bethesda,
MD; 2University of Hong Kong, Hong Kong, Hong Kong.
Hepatocellular carcinoma (HCC) is one of the most common cancers world-
wide, and outcome is dismal, due to tumor heterogeneity and lack of effective
treatment options for patients with later stage disease. Transcatheter arterial
chemoembolization (TACE) is the gold standard of therapy for patients with
intermediate to locally advanced tumors. TACE delivers a high dose of chemo-
therapy directly to the tumor via the hepatic artery, followed by an embolizing
agent to restrict tumor blood supply. However, tumor hypoxia is linked to alter-
ations in metabolism, such as increased glycolysis (theWarburg effect), and can
lead to enhanced cell survival. Several randomized control trials (RCTs) showed
a survival benefıt with TACE, but only with strict patient selection criteria. In
Asia, TACE is also commonly used as adjuvant therapy after surgical resection,
yet RCTs evaluating adjuvant TACEhave shown conflicting results, likely due to
patient selection and stratifıcation. We hypothesize that tumor gene expression
is predictive of response following TACE, and that differential cellular metabo-
lism resembling a hypoxic phenotype prior to treatment is responsible for TACE
resistance.We retrospectively analyzed gene expression data in treatment-naive
tumor tissue from a cohort of Chinese patients who received TACE. Using
hierarchical clustering, followed by class comparison and survival risk predic-
tion, we identifıed a 14-gene signature that is predictive of response vs. non-
response toTACE, asmeasured by overall survival, independent of other clinical
variables. We found that hypoxia- and glycolysis-related genes are enriched
among differentially expressed genes in TACEResponders vs. Non-Responders,
and that hypoxia master regulator HIF-1 and hypoxia target gene VEGF are
signifıcantly up-regulated in Non-Responders.We determined that a key glyco-
lysis gene is up-regulated in Non-Responders, and conversely, two rate-limiting
genes involved in gluconeogenesis, the pathway opposing glycolysis, are up-
regulated in Responders. We also examined metabolomic data from the TACE
cohort, and found an enrichment of glycolysis-related metabolites in Non-Re-
sponders, and gluconeogenesis-related metabolites in Responders. Further in-
vestigation will be required to connect altered glucose metabolism to TACE
resistance and to determine driver genes linking hypoxia and metabolism,
which, together with our 14-gene signature, may serve as a stratifıcation tool to
guide personalized treatment modalities for HCC patients.
#545 Prognostic alternative mRNA splicing signature in non-small cell
lung cancer.Yuan Li,1 Nan Sun,2 Zhiliang Lu,1 Shouguo Sun,1 JianbingHuang,1
Zhaoli Chen,1 Jie He1. 1National Cancer Center/Cancer Hospital, Chinese Acad-
emy of Medical Sciences and Peking Union Medical College, Beijing, China; 2De-
partment of Clinical Cancer Prevention, UTMDAnderson Cancer Center, Hous-
ton, TX.
Alternative splicing provides a major mechanism to generate protein di-
versity. Increasing evidence suggests a link of dysregulation of splicing asso-
ciated with cancer. However, alternative splicing in non-small cell lung can-
cer (NSCLC) is largely unstudied. In this study, seven types of alternative
splicing were profıled in 491 lung adenocarcinoma (LUAD) and 471 lung
squamous cell carcinoma (LUSC) patients in TCGA using RNA sequencing
data. Prognostic predictors for LUAD, LUSC and merged NSCLC patients
were built by integrated survival analysis. Gene network and splicing corre-
lation network analyses were also conducted. Overall, we detected 45,062
and 50,732 alternative splicing events in LUAD and LUSC, respectively,
almost half of them were exon skipping events. A total of 3,691 and 2,403
alternative splicing events were signifıcantly associated with patient survival
in LUAD and LUSC, respectively. Gene network analysis uncovered impor-
tant hub genes or nodes such as EGFR, CD44, PIK3C3, RRAS2, MAPKAP1
and FGFR2. The area under the curve (AUC) of the receiver-operator char-
acteristic (ROC) curve for prognostic predictors in LUAD and LUSC were
0.960 and 0.940 at 2000 days of overall survival. Most relevant for clinical
application, we also built the prognostic predictor for NSCLC patients with
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high performance. The AUC of ROC curve in NSCLC was 0.817 which were
also over 0.8 in LUAD and LUSC, separately. Moreover, expression of 49 and
9 survival associated splicing factors were signifıcantly correlated with 75
survival associated alternative splicing events in LUAD and LUSC, respec-
tively. Interestingly, splicing correlation networks uncovered that “onco-
genic“ splicing factors were up-regulated in LUAD while “tumor suppres-
sor” splicing factors were down-regulated in LUSC. Survival associated
splice factors might have opposite roles in the regulation of RNA splicing in
LUAD and LUSC. In conclusion, we created prognostic predictors based on
alternative splicing events with high performances for risk stratifıcation in
NSCLC patients and uncovered interesting splicing networks in LUAD and
LUSC which could be underlying mechanisms.
#546 Supporting neoantigen identifıcation for personalized cancer vac-
cines trough analytical validation of an augmented content enhanced (ACE)
transcriptome. Jennifer L. Yen, Sean Boyle, Ravi Alla, Jason Harris, Martina
Lefterova, Richard Chen. Personalis, Menlo Park, CA.
The identifıcation of neoantigens has become a critical step in the develop-
ment of neoantigen-based personalized cancer vaccines and other immunother-
apy applications. Since neoantigens can be generated from tumor specifıc mu-
tations in any expressed gene, the fırst step in neoantigen identifıcation typically
involves deep sequencing of the tumor exome and transcriptome combinedwith
exome sequencing of the matched normal. As personalized vaccines enter clin-
ical trials, there is a growing need for strong analytical validation of these plat-
forms. To address this, we have developed the ACE Exome (200X) and Tran-
scriptome platforms for neoantigen identifıcation which harness an augmented
exome approach specifıcally designed to increase sensitivity for neoantigens in
low complexity, diffıcult to sequence regions. To enable this platform for neo-
antigen based personalized cancer vaccines, we have performed a validation of
both ourACEExome (tumor andnormal) andACE transcriptomeplatforms for
detecting DNA-based SNVs and Indels, as well as for RNA based small variant
and fusion calls, variant types that are especially important for neoantigen iden-
tifıcation. In this abstract, we describe the ACE Transcriptome validation. To
validate the ACE Transcriptome, we assessed analytical sensitivity (AS) and
positive predictive accuracy (PPA). ASwas calculated from a reference set of 894
SNVs and 19 indels across 11 tumor cancer cell lines withmatched normals. The
reference set was constructed based on previously observed variants in CCLE,
COSMIC or had been validated by Sanger sequencing. PPA and limit of detec-
tion (LOD) were calculated in a series of tumor-normal dilutions representing
allele frequencies ranging from 10% to 100%. For fusions, we further selected an
additional 10 cell lines to test the detection of 16 previously characterized fusion
events including several clinically actionable fusions (ALK and BCR-ABL1).We
report an analytical sensitivity for SNVs of99%, and a PPA of96% for small
variants with 10% minor allele frequency (MAF). For fusion events, we
report an analytical sensitivity of99%,with the detection of all 16 fusion events
supported by at least 5 reads. We demonstrate that our ACE Transcriptome
assay and RNA cancer pipeline is a highly sensitive and robust platform for
detecting small variants and fusions in the RNA.
#547 Novel algorithms for spatial modeling of cellular interactions in the
tumor microenvironment. Yiyi Yan,1 Alberto Santamaria-Pang,2 Michael
Gerdes,2 Fiona Ginty,2 Anup Sood,2 Svetomir N. Markovic,1 Alexey Leontov-
ich1. 1Mayo Clinic, Rochester, MN; 2GE Global Research, Niskayuna, NY.
Background: Understanding the spatial interactions between tumor and im-
mune cells in the heterogeneous tumormicroenvironment is pivotal to improve
clinical outcomes of immunotherapy. Various multiplexed imaging platforms
have been recently developed to visualize the different immune cell subtypes
with various distribution patterns that can impact the antitumor immunity.
However, the lack of tools that allow for the spatial pattern modeling remains a
major barrier for systematic analysis of cellular interactions in the TME.
Methods: We used multiplexed immunohistochemistry (mIHC) to understand
the cellular interplays in metastatic melanoma TME using FFPE section. This
platform allows in situ quantitative single cell analysis with high-level of multi-
plexing while preserving the tumor heterogeneity. Single cell spatial data (posi-
tion and location) in the context of TMEcanbe obtainedduringmIHC, enabling
further spatial modeling to characterize the cellular interactions between tumor
immune cells. Novel spatial analysis algorithms are developed taking advantages
of these spatial data. Results: Using R programming language, we developed two
novel analytical approaches to reveal the spatial distributions of various immune
cell subtypes relative to tumor cells. The cell neighborhood analysis algorithm
uses the “applynbd()” function to traverse through every cellular point on a
two-dimensional plane and creates neighborhoods of 24um in diameter cen-
tered by a tumor cell. This algorithm captures the counts of a specifıc type of
immune cells that are in direct contact with a tumor cell, allowing the visualiza-
tion and statistical analysis of cellular attraction/repulsion patterns. The cell
aggregate analysis algorithm uses a sliding-window based approach to capture
cell aggregates with certain densities and the areas within the TME covered by
specifıc cell aggregates. Combined with the Ripley K-function, the cell aggregate
algorithm captures the aggregation vs. segregation pattern between different cell
types, enabling the clustering and distance analysis of immune cells relative to
tumor cells. Our algorithms demonstrate that tumor cells either attract CD3
tumor-infıltratingT cells or favor the aggregation ofCD20Bcell in peri-tumor
areas depends on the levels of tumor cell human leukocyte antigen-1 (HLA-1)
expression. Conclusion: Our novel spatial analysis algorithms enable the mod-
eling of different interaction patterns between tumor and immune cells (direct
contact vs. aggregation) at both single cell and TME level. It demonstrates that
tumor cells with heterogeneous properties can impact the immune cells’ distri-
butions in the TME with various biological outcomes. It also establishes tools
that are necessary for systematic analysis of the TME, allowing the elucidation of
the “homogeneous patterns” within the heterogeneous TME.
#548 RNAseq analysis of infıltrating immune cells in liver cancer.Krithika
Bhuvaneshwar,1 Coleman I. Smith,2 Alexander H. Kroemer,2 Aiwu Ruth He,2
Yuriy Gusev1. 1Georgetown University, Washington, DC; 2Medstar Georgetown
University Hospital, Washington, DC.
Hepatocellular carcinoma (HCC) has emerged as second most common
cause of cancer deaths worldwide. During the last 10 years, there has been a clear
delineation of landscape of genetic alterations in HCC and deregulated path-
ways inHCC.However, the treatment for patientswith advancedHCC is limited
despite of great effort developing therapeutic targeting the deregulated pathways
in HCC. Recent studies reveal a direct causal relationship between cancer &
immune dysfunction, whereby tumor cells and theirmicroenvironment are able
to evade immune attack by exploiting various immunoregulatory mechanisms
in a process termed cancer immune editing. Methods: In this poster, the objec-
tive is to perform exploratory analysis of TCGA liver cancer data to see if im-
mune infıltrates matter, and if they offer anti-tumor immunity to a cell. For this
purpose, we analyzed RNA-seq data for a cohort of 75 liver cancer samples from
TCGA collection. We obtained the gene expression data from a pre-selected
group of specifıc markers for infıltrating lymphocytes (several subtypes), and
explored the association of expression of these markers with clinical out-
come.We downloaded raw RNA-seq data from the TCGA Liver cancer collec-
tion from 75 patients. These included 25 patients who had Hepatitis B virus
(HBV), 25 patients who had Hepatitis C virus (HCV) and 25 patients who had
both viruses. After processing of raw data, we extracted isoform expression
(TPM values) from specifıc markers for infıltrating lymphocytes. This data was
stratifıed into ‘high’ and ‘low’ expression based on median cutoff.We compared
the ‘high’ and ‘low’ expression groups of patients by performing differential
expression & pathway analysis, to see if the differentially expressed results were
linked to immune pathways. We then performed survival analysis tests (Log
rank, Cox regression) and Kaplan Meier (KM) survival graphs to explore the
association with overall survival outcome. ResultsWe found 14 of 75HCC cases
expressed CD8B isoform, while 61 of 75 HCC cases did not express CD8B iso-
form. The Log Rank survival test showed a signifıcant association between the
expression of CD8B isoform and overall survival (Chisq 5.2 on 1 degrees of
freedom, p 0.0222). The survival test using a Cox model on the same CDBB
isoform, showed that samples that expressed CD8B isoform were at higher risk
of event compared to those that did not express the isoform. Other markers that
showed good separation of survival curves included CD3 & CD8A. Conclusion
Additional immune cell subtype specifıc transcripts are being tested. Based on
our preliminary analysis, we saw that most of the affected pathways were highly
relevant to lymphocyte signaling & immune response and infıltration. Hence,
exploring infıltrating lymphocytes can give evidence of immune surveillance
against HCC. Testing immune cell specifıc transcript in tumor samples may
service as predictor to treatment targeting immune evasion in cancer patients.
#549 Clustering analysis of next-generation sequencing T cell repertoire
data in sipuleucel-T treated prostate cancer patients. Li Zhang,1 Sounak
Chakraborty,2 Jason Cham,1 David Oh,1 Nadeem Sheikh,3 Lawrence Fong1.
1University of California, San Francisco, San Francisco, CA; 2University of Mis-
souri-Columbia, Columbia, MO; 3Dendreon Pharmaceuticals Inc, Seattle, WA.
Immunotherapy has demonstrated signifıcant clinical benefıt in different
cancers. T cells are a crucial component of the adaptive immune system and
mediate anti-tumoral immunity. Antigen-specifıc recognition by T cells is via T
cell receptor (TCR) which is the product of somatic V(D)J gene recombination
with the addition/subtraction of nontemplated bases at recombination junc-
tions. Next generation TCR sequencing effectively profıles the TCR repertoire.
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Currently TCR analyses quantify diversity across single clones, however, due to
the low overlap of clones across samples, such analyses are limited to a single
sample. Here we extend our previous analysis pipeline to track and examine
TCR repertoire across time by focusing on V and J gene segments, overcoming
the limitation of contemporary analytical approaches and thus obtain statistical
inference across subjects directly. The published data of TCR profıling of serial
peripheral blood mononuclear cells (PBMC) from three healthy subjects and
fıve prostate cancer patients enrolled in an open-label, Phase II clinical trial of
neoadjuvant sipuleucel-T (sip-T) were used as the basis of this analyses. After
consolidating the clonal abundance for each combination of V and J gene seg-
ments, we calculated Pielou’s evenness, which demonstrates that sip-T treated
subjects displayed greater clonal expansion compared to healthy subjects
(P0.001). The Circos table viewer was used to circularly visualize the distribu-
tion of the combination of V and J gene segments. Sip-T treated subjects were
successfully distinguished from healthy subjects with 12 V and J gene combina-
tions explaining the majority of variance of the patients by applying principle
components analysis (PCA). Furthermore, we developed a customized cluster-
ing workflow to cluster the combination of V and J gene segments based on the
change in abundance over time, with gap statistics employed to estimate the
optimal number of clusters and k-means algorithm used for partitioning. We
found that for all the prostate cancer patients assessed, TCRBV06/TCRBJ01,
TCRBV05/TCRBJ02 and TCRBV06/TCRBJ02, which were in the same cluster
with the highest frequencies, expanded after fırst treatment and were main-
tained at high frequencies at later time points. The results demonstrate that in
the setting of immune modulation after sip-T treatment, the V(D)J recombina-
tion is not entirely random, and that this non-randomness can be used to dis-
tinguish T cell repertoires from sip-T treated subjects versus healthy subjects.
The use of additional information of V and J gene segments enables to investi-
gate the profıling of TCR repertoire from a different angle and add another layer
of understanding of TCR repertoire. The application of PCAand the customized
clustering complete our initial workflow for TCR sequencing data.
#550 Predictive value of co-expression network consisting of FOXM1 and
its neighbor genes in cancers. Bic-Na Song, In-Sun Chu. Korea Research Insti-
tute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Purpose: Forkhead box proteinM1 (FOXM1) is a key regulator of tumorigen-
esis. Previous studies demonstrated that FOXM1 expression was strongly cor-
related with poor prognosis of various cancers. The aim of this study is to defıne
a signature consisting of FOXM1 and its associated genes and assess its prog-
nostic potential in cancers including hepatocellular carcinoma (HCC) and oth-
ers. Experimental procedures: We analyzed a gene expression profıle of 100
patients withHCC to identify FOXM1-correlated genes (the FOXM1 signature)
associated with the prognosis of HCC patients. The validity of the FOXM1
signature was verifıed in an independent HCC cohort (n  242). Using the
signature, we also analyzed different cancer types including pancreatic adeno-
carcinoma, lung adenocarcinoma, breast carcinoma, and bladder urothelial car-
cinoma to verify the association between the FOXM1 signature and prognosis.
Various statistical methods were applied to signature fınding and validation.
Upstream regulator and gene-to-gene network analyses were performed to
identify potential key mediators of the FOXM1 signature. Results: Through a
gene expression profıling in 100 patients with HCC, we identifıed a gene set
consisting of FOXM1 and its co-expressed genes for predicting poor prognosis.
A predictive value of the signature was validated in an independent cohort con-
taining 242 HCC patients. In multivariate analysis, the FOXM1 signature
showed the most signifıcant prognostic value (HR  1.706, 95% CI  1.176-
2.475, P 0.005). By directly applying the signature to four data sets in different
cancer types, our signature showed a consistent prognostic signifıcance, regard-
less of tumor types. Finally, upstream regulator and gene-to-gene network anal-
yses found an interconnection of network hubs composed by FOXM1, MYC,
and E2F1 that might be common key mediators of patient survival in cancer.
Conclusions: The FOXM1 signature represents a promising commondiagnostic
tool to identify high-risk cancer patients and may extend treatment options in
various cancers.
#551 Assessment of computational approaches for quantifıcation of im-
mune cell infıltration from gene expression profıles of complex biological
samples.BrendanP.Hodkinson,Michael E. Schaffer,MichaelGormley. Janssen
Research & Development, Spring House, PA.
Anticancer immunotherapies target immune cells to block immune suppres-
sion and/or promote immune activation in order to eliminate cancer cells. Ipi-
lumumab and Nivolumab, targeting CTLA4 and PD1 respectively, have dem-
onstrated dramatic responses in melanoma and lung cancer (Hodi et al. 2010;
Risvi et al. 2015). However, poor response rates in other types of cancer under-
score the need to better understand immunomodulatorymechanisms (Topalian
et al. 2012). Examination of immune cell specifıc signals, in either the tumor
microenvironment or the periphery, has proven to be a useful tool in developing
prognostic biomarkers (Chi et al. 2014; Gentles et al. 2015), inferring mecha-
nisms of action (Krejcik et al. 2016), and discerning immune-based predictors of
drug response (Tumeh et al. 2014). In this study we evaluate various gene ex-
pression-based computational approaches for inferring immune cell identity in
complex cellular mixtures in order to rank their relative utility for illuminating
the details of the tumor microenvironment and potentially revealing new bio-
markers for prognosis and response prediction. Immune cell identity has been
inferred by previous researchers using a variety of mathematical approaches,
including least squares (Abbas et al. 2009), quadratic programming (Gong et al.
2011; Zhong et al. 2013), maximum likelihood (Qiao et al. 2012; Liebner et al.
2013),machine learning (Newman et al. 2015), and enrichment type approaches
(Angelova et al. 2015).We used publically-available gene expressionmicroarray
data from blood, normal tissue, and tumor samples to assess the effectiveness of
these methods in sample types relevant to oncology research. The results from
comparisons of these differentmethods demonstrate that certain approaches are
signifıcantly more robust to noise, and are therefore more suitable for complex
cellular mixtures such as tumor samples. The discerning use of methods to infer
immune cell type proportions from gene expression profıles may lead to im-
proved prognosis, predictive biomarkers for immunotherapy to assist in patient
stratifıcation, and new immunoncology targets by indicating immunosuppres-
sive mechanisms.
#552 Multi-scale omics integration using parallel heatmap clustering for
the systemic analysis and biomarker discovery of drug sensitivity in lym-
phoma cell lines. Ivo Kwee,1 Andrea Rinaldi,2 Alberto J. Arribas,2 Eugenio
Gaudio,2 Chiara Tarantelli,2 Filippo Spriano,2 Petra Hillmann,3 Francesco Ber-
toni2. 1Institute of Oncology Research & Dalle Molle Institute for Artifıcial Intel-
ligence, Bellinzona, Switzerland; 2Institute of Oncology Research - IOR, Bellin-
zona, Switzerland; 3PIQUR Therapeutics AG, Basel, Switzerland.
Background. Pharmacogenomics studies the role of genomics in drug re-
sponse. By measuring the individual genome, it is hoped that pharmaceutical
drug treatments can deviate from a ‘one-dose-fıts-all‘ approach to a more ‘per-
sonalized‘ treatment. To achieve this goal, we need to explain which genomic
differences cause the lack of response and to be able to predict the response from
baseline omics data, that is from data available before starting treatment. Here,
we present an integrated omics approach to analyze drug sensitivity based on in
vitro experiments. Methods. We measured the drug response in 61 lymphoma
cell lines for a number of anti-cancer drugs using a standard MTT cell prolifer-
ation assay. The baseline genomics of these cell lines were fully profıled for gene
expression, copy number and methylation. Pathway and gene set signatures
were computed using GO, KEGG, Biocarta and lymphoma databases to provide
gene set level features. Additionally, we computed high level ‘biological concept‘
features. Thesemulti-scale featureswere directly correlatedwith drug sensitivity
but also correlated between the multiple data types. Using a novel parallel clus-
tering approach, we integrated our data for the different omics types and at
different scales: gene, gene set and concept level. Finally, a shortest path algo-
rithm extracted the most probable explanation between genotype and response
phenotype. Results. As a proof of concept, we fırst applied our method to the
classifıcation of activated B- cell like (ABC) and germinal center B (GCB) sub-
types in diffuse large B-cell lymphomas (DLBCL). In accordance to previous
knowledge, our method showed the MYD88/CD40/NFKB axis as strongly up-
regulated in the ABC, while, albeit less pronounced, the PI3K/MTOR and
NOTCH signalling pathways were more enriched in the GCB subtype. We then
applied ourmethod to the drug sensitivity data of our lymphoma cell line panel.
The analysis showed that drug response was largely driven by differential meth-
ylation rather than copy number aberrations. We found that B cell receptor
signaling (BCR) and CD40 signalling were among the most correlated to drug
sensitivity in a drug-specifıc manner. Genes in these pathways (such as SYK,
SPIB and CD79A) appeared as good biomarkers for drug-specifıc response in
lymphoma. Conclusion. Using an integrated analysis of multiple omics data at
multiple scales, we successfully identifıed functional modules related with drug
sensitivity in lymphoma cell lines. The samemethod can be applied to study the
sensitivity to other drugs in either hematological and/or solid cancer types.
#553 Microsatellite genotyping enables precision lung cancer risk classifı-
cation. Robin T. Varghese,1 Karthik Raja Velmurugan,1 Natalie C. Fonville,2
Harold R. Garner1. 1Edward Via College of Osteopathic Medicine (VCOM), Ro-
anoke, VA; 2Riverside Law, LLP, VA.
There remains a large discrepancy between the known genetic contributions
to cancer and that which can be explained by genomic variants, both inherited
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and somatic. Recently, understudied repetitive DNA regions called microsatel-
lites have been identifıed as genetic riskmarkers for a number of diseases includ-
ing various cancers (breast, ovarian and brain). In this study we demonstrate an
integrated process for identifying and validatingmicrosatellite based risk mark-
ers for lung cancer using data from the cancer genome atlas (TCGA) and the
1000 genomes project. Comparingwhole exome germline sequencing data from
488 TCGA lung cancer samples to germline exome data from 390 control sam-
ples from the 1000 genomes project, we identifıed 119 potentially informative
microsatellite loci. These loci (riskmarkers) were found to be able to distinguish
between cancer and control samples with sensitivity and specifıcity ratios over
0.8. Then these loci, supplemented with additional loci from other cancers and
controls, were evaluated using a custom target enrichment kit and sample-mul-
tiplexed nextgen sequencing. Thirteen of the 119 risk markers were validated
using high-depth (579x315) nextgen sequencing of 30 lung cancer and 89
control samples, resulting in sensitivity and specifıcity ratios were 0.90 and 0.94,
respectively. When 8 loci harvested from the bioinformatic analysis of other
cancers are added to the classifıer, then the sensitivity and specifıcity rise to 0.93
and 0.97, respectively. Analysis of the genes harboring these loci revealed two
genes (ARID1B and REL) and two signifıcantly enriched pathways (chromatin
organization and cellular response to stress) which suggest that the process of
lung carcinogenesis is linked to chromatin remodeling, inflammation, and tu-
mor microenvironment restructuring. We illustrate that high-depth nextgen
sequencing enables a high precision microsatellite-based risk classifıer.
#554 Accurately identifying neoantigens utilizing both DNA and RNA
somatic variants in an enhanced platform. SeanM. Boyle, JasonHarris, Gabor
Bartha, Ravi Alla, Mirian Karbelashvili, Steve Chervitz, Aldrin Montana, Craig
Rowell, Patrick Jonganeel, Scott Kirk, Rena McClory, John West, Rich Chen.
Personalis, Menlo Park, CA.
The identifıcation of neoantigens is a crucial step in the development of neo-
antigen-based personalized cancer vaccines and other immunotherapies. Accu-
rately predicting which neoantigens are likely to be immunogenic remains a key
challenge owing to the complex processes involved in determining neoantigen
immunogenicity including the antigen presenting machinery, likelihood of
MHC class I and II binding, similarity to self, and ability to interact with the
TCR. We have developed a neoantigen detection pipeline built upon our ana-
lytically validated Accuracy and Content Enhanced (ACE) Exome and Tran-
scriptome sequencing platform and somatic variants calling pipeline through
combined DNA and RNA analysis. The analytical performance of these pipe-
lines is greater than97% sensitivity for small variants (RNA and DNA) with a
specifıcity of98% (DNA) and a fusion sensitivity of99% (RNA).Within our
neoantigen pipeline, variants that are detected by our DNA and RNA cancer
analysis pipelines are processed for antigen identifıcation, including SNVs, in-
dels, and fusion events. Importantly, both in-frame and out-of-frame events are
accurately considered by transcript, allowing for detection of a wealth of candi-
date neoantigens. Our pipeline includes assessment of important immunologic
components including HLA prediction, MHC binding (class I and II), immu-
nogenicity, similarity to self, and similarity to known antigens. Additionally,
peptides are evaluated for variant allele frequency in both the RNA and DNA of
the tumor sample and gene expression level is considered. Collectively, our
ImmunoID product provides a comprehensive assessment of features that may
be used for identifying and ranking potentially immunogenic neoantigens. To
assess the effectiveness of this pipeline in predicting immunogenic neoantigens,
we assembled a gold-set of 23 known, previously experimentally-validated im-
munogenic neoantigens from the literature.We spiked in these neoepitopes into
exome data and assessed the ability of our neoantigen pipeline to fınd and rank
these immunogenic known neoantigens. Preliminary results show our neoanti-
gen pipeline is able to accurately identify 22 out of 23 (96%) of the spiked in
neoantigens as being potentially immunogenic.
#555 Examination and evaluation ofMR radiomics features for character-
ization of dominant intraprostatic lesions. Hassan Bagher-Ebadian, Janic
Branislava, Chang Liu, Milan Pantelic, David Hearshen, Indrin Chetty, Mo-
hamed Elshaikh, Benjamin Movsas, Ning Wen. Henry Ford Hospital, Detroit,
MI.
Purpose: This pilot study investigates a set of radiomics features extracted
from fast relaxation fast spin echo (FRFSE) T2 pulse sequences for normal tissue
and Dominant Intraprostatic Lesions (DILs) in twenty prostate cancer patients.
Material and Methods: Twenty patients with prostate cancer were studied. All
patients had axial FSRFSE T2 scans using a 3 Tesla scanner. A radiologist inter-
preted MR examinations, and contoured the suspicious DIL and the contralat-
eral section of the prostate gland (normal) on the T2 weighted MR images.
Patients underwent a 14-core transrectal Ultrasound Guided Biopsy and local-
ization of positive cores, Gleason score and clinical tumor stage were recorded.
167 radiomics features were extracted from normal and DIL zones. These fea-
tures were categorized into 8 different sets as following: Intensity Histogram
Based (IHB), Gray Level Run Length (GLRL), Law’s Textural Information
(LAWS), Discrete Orthonormal Stockwell Transform (DOST), Local Binary
Pattern (LBP), Two Dimensional Wavelet Transform (2DWT), Two Dimen-
sional Gabor Filter (2DGF), and Gray Level Co-Occurrence Matrix (GLCM)
with 8, 7, 18, 18, 6, 48, 40, and 22 features in each category respectively. A
Welch’s test and the Fisher method were used to test for signifıcant differences
among the 167 radiomics features and their subcategories. For all patients, cor-
relation coeffıcients between the extracted features in the normal andDIL zones
were also calculated. Results: According to the Fisher combined p-values,
among the eight categories of radiomics features, only 5 feature categories
showed a signifıcant difference (IHB, GLRL, DOST, LBPF and GLCM with
pFisher 2.0x10-6, 0.02, 12 x10-4, 3.7 x10-3, and 1.5 x10-6 respectively). Among all
167 features, only 7 showed a signifıcant difference (D100x[DIL/NP-1]) and
small correlation between normal and DIL zones: IHB-Skewness (r0.19,
p0.03, and D50.3%), GLCM-Contrast (r0.12, p0.03, and D-67.5%),
GLCM-Dissimilarity (r0.12, p0.01, and D-67.5%), GLCM-Entropy
(r0.07, p0.01, and D-67.1%), GLCM-Difference-Variance (r0.12,
p0.01, and D-67.1%), GLCM-Difference-Entropy (r0.10, p0.01, and
D-60.4%), and GLCM-Information-Measure-of-Correlation (r0.25,
p0.01, and D-65.1%). Conclusion and Discussion: This pilot study demon-
strates the feasibility of using radiomics features fromMR images to characterize
DILs in prostate cancer patients. Among 167 radiomics features extracted from
axial MR T2 FRFSE, 7 features were shown to be potentially signifıcant for
distinguishing normal tissue from DILs. This research supports an integrated
decision making system, combining clinical factors and radiomics features ex-
tracted fromMR images, for increasing the DIL detection performance in pros-
tate cancer studies.
#556 CDD: functional insights into orphan GPCRs via subfamily domain
architectures. James S. Song, Noreen R. Gonzales, Roxanne A. Yamashita, Ste-
phenH. Bryant, AronMarchler-Bauer.National Center for Biotechnology Infor-
mation, National Library of Medicine, National Institutes of Health, Bethesda,
MD.
NCBI’s Conserved Domain Database (CDD, https://www.ncbi.nlm.nih.gov/
Structure/cdd/cdd.shtml) is a resource that aims at classifying ancient conserved
domain families and capturingwhat is known about their functional diversity. It
is a collection of multiple sequence alignments (MSAs) and derived position-
specifıc score matrices (PSSMs). RPS-BLAST allows for the rapid identifıcation
of conserved protein domain footprints in protein sequences along with the
location of annotated functional sites. CDD is a redundant collection, it imports
external domain model collections (Pfam, COGs etc.) and supplement these
withmanually-curated domainmodels that are organized into hierarchical clas-
sifıcations, which facilitate annotation of functionally distinct protein families
and subfamilies. More recently CDD has been curating information on con-
served domain architectures to support functional labeling of proteins that fall
into characterized families: SPARCLE (Subfamily Protein ArCHitecture Label-
ing Engine) is both a curation tool and a public service available at https://
www.ncbi.nlm.nih.gov/sparcle. Architecture summaries provide interactive in-
terfaces to lists of proteins that share the same characteristic domain
architecture, and to their assigned names, functional labels, and supporting ev-
idence. Here we present the functionally annotated, evolutionary hierarchical
classifıcation of the seven-transmembrane G-protein coupled receptors (7TM
GPCRs), which includes the largest family of promising therapeutic targets, with
more than 140 human orphan GPCRs of unknown function. Across the three
kingdoms of life, GPCRs are involved in a wide array of critical physiological
processes, and have been implicated in tumor initiation, tumor progression,
angiogenesis and metastasis. Orphan subfamilies with unknown endogenous
ligand/function are often found to have poor sequence similarity to canonical
GPCRs. They have been assigned putative functionswith predicted ligand-bind-
ing sites, downstream interacting partners, and/or the location of 7TM helices
annotated by inference from the molecular and physiological functions of
known related GPCR proteins, utilizing more than 25 available 3D-structures,
phylogenetic relationships, and the published literature. We hope that this up-
dated classifıcation, together with NCBI’s software tools (Cn3D/CDTree and
SPARCLE), will aid researchers in the discovery ofmolecular therapeutic targets
for cancer treatment by providing insights regarding as-yet-unidentifıed intra-
and intermolecular interactions as well as functional mechanisms of GPCR sig-
naling. Acknowledgement: This research was supported by the Intramural Re-
search Program of the National Library of Medicine, NIH.
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#557 SPOP mutant subclass prediction and its impact on prostate cancer
prognosis. Deli Liu.Weill Cornell Medicine, New York, NY.
SPOP mutations defıne a distinct and key molecular class of prostate cancer,
but there is no signature to identify SPOP mutant subclass based on transcrip-
tional data, and its impact on prognosis and clinical outcomes of prostate cancer
patients is unknown. We developed the SPOP mutant transcriptional signature
with high sensitivity and specifıcity based on transcriptional data. After we pre-
dicted SPOP mutant subclass from a large cohort project with transcriptional
signature, we studied its association with clinicopathologic variables and prog-
nosis in prostate cancer patients. On univariate analysis, SPOPmutant subclass
was associated with lower preoperative serum prostate-specifıc antigen, ex-
traprostatic extension and older patients (p0.05). On multivariate analysis,
SPOP mutant subclass was associated with metastasis (p0.05). Combined
SPOP mutant status and CAPRA-S models have slightly better prediction for
metastasis. On Kaplan-Meier analysis, we found the signifıcant association of
SPOP mutant subclass with better patient outcomes of metastasis, and patients
without radiation therapy with even better metastatic outcomes. The SPOPmu-
tant subclass could be predicted by using our SPOP mutant signature purely
based on transcriptional data. Clinical and prognosis difference were found
among SPOP mutant subclass.
#558 Computational analysis of clinically actionable genomic features:
precision heuristics for interpreting the alteration landscape (PHIAL).Bren-
dan Reardon,1 Nathanael Moore,2 Eliezer VanAllen1. 1Dana-Farber Cancer In-
stitute, Broad Institute, Harvard Medical School, Boston, MA; 2Dana-Farber
Cancer Institute, Broad Institute, Indiana University School of Medicine, Har-
vard Medical School, MA.
Background: PHIAL (Precision Heuristics for Interpreting the Alteration
Landscape) was developed as a heuristic clinical interpretation algorithm for
cancer genomic data to inform treatment decisions at the point of care and
provide researcherswith rapid assessment of tumor actionability. This approach
used somatic whole exome sequencing data and a database of tumor alterations
relevant for genomics driven therapy (TARGET). However, PHIAL was limited
to fırst order genomic relationships, could not distinguish relative actionability
given multiple actionable variants, did not maximize the richness of somatic-
germline interactions, and could not leverage both exome and transcriptome
data to move towards feature-based actionability. Towards that end, we devel-
oped a new interpretation methodology to address these areas and improve
clinical actionability algorithms.Methods:We revised PHIAL to predict action-
able alterations based on the presence of SNVs (in the context of allele specifıc
expression from RNA-seq), indels, SCNAs, fusions, and global features (e.g.,
context-specifıc mutational burden) that imply actionability. Additionally, we
refıned and expanded the TARGETdatabase to enable PHIAL to produce scores
on multiple dimensions and reflect newly discovered relationships between
genomics and clinical actions. Predictive implication values were assigned to
reflect the validities of TARGET’s drug sensitivity, drug resistance, and prognos-
tic claims. Results: We applied both the original (PHIAL1) and an updated
version of PHIAL (PHIAL2) to a 255 patient cohort with whole exome/tran-
scriptome sequencing data (146 castration-resistant prostate cancer and 109
metastatic melanoma samples). PHIAL1 identifıed 1,342 clinically actionable/
biologically relevant events across the cohort with a median of 3 events per
patient and 95% of patients having at least one event. PHIAL2 identifıed 2,508
events, with a median of 6 events per patient and 98.5% of patients harboring at
least one event. Of these events, 8.12% were associated with an FDA-approved
therapy and 2.09% with a clinical trial. PHIAL2 identifıed events in 9 patient
samples that PHIAL1 associated with no events. Conclusion: PHIAL2 was able
to identify and rank more putatively actionable alterations than PHIAL1, and
effectively transitioned from a variant-based to a feature-based approach. This
strategy may inform the utility of point-of-care whole-exome/transcriptome
sequencing in larger contexts as these data emerge in clinical settings, and may
bridge towards machine learning based approaches as patient outcomes are
linked to genomic and transcriptomic features. Finally, PHIAL2may ultimately
provide a deeper understanding of, and suggest clinical actions for, cases in
which there is no clear single genomic alteration associated with oncogenesis.
#559 Estimation of immune cell content in bulk tumour tissue using ref-
erence profıles from single-cell RNA-seq data. Max Schelker,1 Jinyan Du,1
Sonia Feau,1 Edda Klipp,2 Birgit Schoeberl,1 Gavin MacBeath,1 Andreas Raue1.
1Merrimack Pharmaceuticals, Inc., Cambridge, MA; 2Humboldt-Universität zu
Berlin, Germany.
Although therapeutics thatmodulate the immune systemprovide remarkable
benefıt for many cancer patients, predicting who will respond remains an un-
solved problem. As interactions between the immune system and cancer are
governed by a complex network of cell-cell interactions, knowing the specifıc
immune cell composition of a solid tumour may be essential in predicting re-
sponse to immunotherapy. Here, we describe how to derive the cellular compo-
sition of a solid tumour from bulk gene expression data bymathematical decon-
volution, using consensus cell type-specifıc gene expression profıles from
recently published tumour-derived single-cell RNA sequencing data. Notably,
successful deconvolution depends on these new data, as previously-available
profıles fromperipheral blood are insuffıcient. The presentedmethodmakes the
problemof obtaining a patient’s tumour immune cell composition from existing
databases like The Cancer Genome Atlas as well as in the clinical setting com-
putationally tractable.
#560 A pan-inflammatory and precancerous disease analysis reveals key
biological characteristics in chronic inflammatory diseases with high onco-
genic risk.Chi Zhang,1 Fang Yao,2 Sha Cao,1 Tao Sheng,1 Sen Liang,3Wei Du,3
Ying Xu1. 1Univ. of Georgia, Athens, GA; 2College of Life Science and Oceanog-
raphy, Shenzhen, China; 3Jilin University, Changchun, China.
It has long been observed that cancer development tends to be associatedwith
chronic inflammation. Recent epidemiology studies have suggested chronic in-
flammation may be causally linked to a larger number of sporadic cancers. In
this work, we have conducted a Pan-inflammatory and precancerous diseases
analysis by comparing the 173 transcriptomics data sets consisting 4073 disease
and 2669 normal human tissue samples of 10 cancer prone and 8 cancer inde-
pendent inflammatory diseases, 11 precancerous diseases or benign tumors and
20 cancer types, aiming to identify fundamental differences between cancer-
prone chronic inflammations and cancer-independent chronic inflammations
and what biological characteristics cause cancer initiation or increased onco-
genic risk. By applying differential gene expression, co-expression network, our
in-house immune cell deconvolution and machine learning based hypoxia/oxi-
dative stress prediction methods on the collected data, we have discovered the
cancer prone chronic inflammatory diseases consistently have: (1) elevated rel-
ative proportion of CD4 T, Macrophage, and Neutrophil cells, (2) decreased
CD8 T, adipocyte, monocyte and B cells, (3) highly disorder tissue repair
phase I - IV related pathways, (4) increased oxidative stress level associated with
Macrophage and Neutrophil proportions, (5) elevated iron ion metabolism, (6)
over expressed extracellular glycosaminoglycan metabolism and (6) suppressed
mitochondrial activity. These analyses results strongly suggest that there is a
necessary pathway for the majority or all chronic inflammatory diseases to be-
come cancerous, namely consecutively dysregulated tissue repair process, in-
creased reactive oxygen species producing immune cells, damage of extracellu-
larmatrix, Fenton reaction and production of hydroxyl radical and dysregulated
mitochondrial activity. We believe these new insights could provide highly use-
ful information in guiding future studies of inflammation associated cancers.
#561 Does molecular staging trump clinical staging: a pan-cancer, big-
data analysis of TCGA data. Nicholas Shannon, Melissa Ching Ching Teo,
Narayanan Gopalakrishna Iyer. National Cancer Centre Singapore, Singapore,
Singapore.
True integration of clinical staging and molecular prognostic biomarkers has
been hampered by a lack of comprehensive data sets with adequate power. In the
last two years, The Cancer Genome Atlas (TCGA) has generated and made
available a repository of rich, high volume -omics datasets including molecular
profıling together with matched clinical data. Methods: Clinical and transcrip-
tomics data were downloaded for TCGA datasets (38 projects) representing a
total of 14,043 patients.Matched expression and clinical datawas available for 34
cohorts, covering 10554 patients (median n270, range 15-1091) and survival
data was available for 24 cohorts (7854 patients, median 294 per cohort), with a
median follow-up of 10.7 months (range 1.9 to 61 months). Prediction models
were constructed based on the latest AJCC staging guide, a novel fıve gene
molecular prognostic signature specifıcally derived for each cancer type, and a
combined model utilising both. Accuracy of survival prediction was calculated
as the area under the receiver operator characteristic curve (AUC), based on
2-year overall survival prediction. Results: Pan-cancer analyses demonstrate ac-
curacy of clinical staging from 0.55-0.91 (median 0.72), while molecular prog-
nostication varies from 0.7-0.99 (median 0.84). The combined model is consis-
tently more accurate, 0.71-0.99 (median 0.89, p0.01), where the benefıt of
adding molecular data improved accuracy (median 0.13, 0.03-0.36). The
absolute benefıt of adding molecular data to clinical staging correlated more
closely with strength of clinical prediction (R20.35) than strength ofmolecular
prediction (R20.08). When clinical staging was more less accurate (clinical
prediction 0.7), there was a greater contribution of molecular data, compared
to cancers with more accurate clinical staging (mean 0.15 vs 0.07, respec-
tively; p0.015). Interestingly, of the six tumours with poor clinical prediction
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(AUC 0.7), three were squamous cell carcinomas (SCC) arising from the head
and neck, cervix or lung respectively. The fact that there were no datasets rep-
resenting SCC in the good clinical prediction group (AUC  0.7) suggests an
important need for more accurate prognostic models in this subtype. Conclu-
sion: The potential role for molecular staging as an adjunct to clinical staging
remains undefıned. In this study, we demonstrate for the fırst time the impor-
tance of molecular prognostication across a range of cancer sub-types, but espe-
cially where conventional staging performs poorly. The latter sub-group is fur-
ther enriched for squamous cell cancers, where molecular information offers
dramatic improvement in accuracy (0.15 to AUC), and hence, should be pri-
oritized for assessment of molecular signatures. The lack of integrating molec-
ular data could also reflect limitations in our understanding of tumour biology,
which in turn needs to be translated into potential actionable targets and thera-
peutic benefıt.
#562 Oncovirus detection and integration analysis from human tumor
samples using targetedmassively parallel sequencing.Robert T. Burns,1 Sam-
uel S. Hunter,2 Matthew D. Ducar,1 Aaron R. Thorner,1 James A. Decaprio,1
Paul Van Hummenlen,1 Alexander Frieden,1 Anwesha Nag,1 Haley A. Cole-
man,1 Michael K. Slevin,1 Andrea Clapp,1 Samantha D. Drinan,1 Suzanne R.
McShane,1 Edwin Thai,1 Priyanka Shivdasani,1 Joshua Bohannon,1 Johann
Hoeftberger,1 Reuben Jacobs,1 Bruce M. Wollison,1 Neil A. Patel,1 Monica D.
Manam,1 Phani Davineni,1 MatthewMeyerson,1 Laura E. MacConaill1. 1Dana-
Farber Cancer Institute, Boston, MA; 2University of Idaho, ID.
Viruses are a major contributor to oncogenesis, causing 10-15% of human
cancers. Molecular pathways involved in malignant transformation are fre-
quently activated by genetic alterations, including but not limited to, somatic
mutations, copy number aberrations, structural variants, and oncoviruses. Pre-
cision cancer medicine aims to classify tumors by site, histology, and molecular
tests to determine an “individualized” profıle of cancer alterations. However,
clinical tests for these various alterations are sequential, time consuming, and
use a lot of material, which is often quite limited (e.g., biopsies). Moreover, tests
for the presence of viral sequence are generally performed separately to tests
(such as massively parallel sequencing) to detect human genomic alterations.
Here we present a hybrid capture andmassively parallel sequencing approach to
detect viral infection concurrently with targeted genomic analysis, which may
decrease assay costs, increase sensitivity and scalability, and detectmany types of
alterations, thereby providing a more complete tumor genetic profıle all from a
single sample. We have created a custom hybrid capture probeset for targeted
Illumina sequencing to determine whether oncoviruses are present in tissue
samples and also determine if the virus has integrated into the host’s genome.
We have created both ’detection’ and ’integration’ baits for several oncoviruses,
including polyomaviruses, human papilloma viruses, Epstein-Barr virus, hu-
man cytomegalovirus, Kaposi sarcoma herpesvirus, human T-lymphotropic vi-
rus, and hepatitis B virus. To distinguish between different strains of a single
virus, strain-specifıc detection baits were created to bind to variable regions of
viral genomes. The integration bait was designed to bind to regions of the viral
genomes that are commonly integrated into the human genome. This baitset can
also be combined with other capture panels targeting oncogenes to simultane-
ously determine infection and integration statuses, as well as somaticmutations,
copy number and structural variants. To detect virus presence, reads were
aligned to a hybrid reference of both the human, and targeted virus genomes.
Viral integration status and integration loci were determined by leveraging dis-
cordant read pairs that aligned to both the human genome and a viral genome.
We have tested our techniques on tissue samples that were infected with either
Merkel Cell Polyomavirus or Epstein-Barr virus, as determined using quantita-
tive polymerase chain reaction (qPCR) or immunohistochemistry (IHC) tech-
niques, and have successfully detected these viruses and identifıed viral integra-
tion loci. Overall, this viral hybrid capture probeset provides the ability to
simultaneously determine a tissue sample’s infection and viral integration status
alongside other somatic genomic analyses, saving both time and sample mate-
rial.
#563 Quantitative EMT expression score for predicting survival outcome.
Jason T. George, Mohit K. Jolly, Herbert Levine. Rice University, Houston, TX.
Tumor aggressiveness and subsequent metastasis still remain as major limi-
tations to curative treatments for cancer patients. The epithelial tomesenchymal
transition (EMT) is a process that occurs naturally during embryogenesis and
has been linked to metastasis in many cancer types. EMT is characterized by
phenotypic changes that allow for tissue extravasation and migration of cancer
cells into the bloodstream. These changes may be linked to specifıc patterns in
the gene expression signature of cells undergoing EMT. Recent theoretical ef-
forts have predicted the existence of a stable, hybrid (E/M) phenotype which has
also been observed experimentally in single cells. However, the effects of this
hybrid phenotype on cancer patient survival have not been well characterized.
The ability to quantify a patient’s EMT status via a simple test involving a small
collection of prognostic genes would provide an important tool for clinical risk
stratifıcation and treatment in the context of many cancer types. Here, we apply
iterative statistical methods to generate an EMT score based on gene expression
samples. We use this score to characterize the degree of the hybrid phenotype
signature present in test samples. Predictions from our model are verifıed
against cell lines with known EMT status. Lastly, we apply our model to clinical
samples in order to assess survival differences in various EMT groups.We dem-
onstrate that in many cases, EMT status successfully classifıes patients into
groupswith statistically signifıcant differences in survival, which is of immediate
clinical relevance.
#564 Binary classifıcationof superparamagnetic relaxometrydata for can-
cer screening. Javad Sovizi, Sara L. Thrower, David Fuentes, Wolfgang Stefan,
John D. Hazle, Kelsey Mathieu. The University of Texas MD Anderson Cancer
Center, Houston, TX.
Introduction: Superparamagnetic relaxometry (SPMR) is an emerging tech-
nology that holds potential for use as a second-line screening modality to im-
prove early cancer detection. During SPMR scanning, targeted superparamag-
netic iron oxide nanoparticles (SPIONs) specifıcally bind to cancer cells and
their spatial distribution can be characterized by measurement of the magnetic
fıeld relaxation following a brief excitation pulse. Highly sensitive supercon-
ducting quantum interference devices (SQUIDs) detect relaxation of clusters of
SPIONs bound to small tumors. Challenges inherent to the SPMR technology
includemeasurement noise, as well as the competing influence of SPIONuptake
by healthy organs (namely the liver), which also contributes to the overall SPMR
signal. Hence, manual and stand-alone classifıcation of the SPMR data into
positive (i.e., the subject has cancer) or negative (i.e., the subject does not have
cancer) screen results can be erroneous. Methods: We employed a data-driven
approach based on Gaussian process (GP) formulation tailored to SPMR data-
sets to systematically quantify the probability of cancer. In silico, we simulated
the SPION uptake process and generated SPMR signals that closely resembled
experimental data collected in mouse models of cancer. We investigated the
classifıcation accuracy for different amounts of SPION accumulation within the
tumor, as well as different levels of measurement noise (coeffıcient of variation
(CV)). In a phantom study, a mouse liver was simulated by clustering together
nine cotton swabs containing a total of 150 g of immobilized SPIONs, while a
mouse tumor was simulated by a single cotton swab containing either 9.4 g or
14.4 g of immobilized SPIONs. An additional nine cotton swabs containing
32.3 g of immobilized SPIONs (5 g per phantom) were evenly distributed
within the scan plane to represent background SPIONs not bound to the tumor
or liver. For each of the tumor phantoms, 18 datasets were collected using a
magnetic relaxometry device (Senior Scientifıc LLC) by moving the phantom to
18 different locations. Moreover, 10 datasets were collected without using the
tumor phantom to represent the expected signal from healthy mice. In each
iteration, the background SPIONphantomswere randomly relocatedwithin the
scan plane. Results: Our in silico analysis for tumor accumulations of 3% and 5%
of the injected SPION dose achieved 87% and 97% classifıcation accuracies,
respectively, when CV0 and 75% and 93% when CV0.015. Similarly, in our
phantom study, classifıcation accuracies of 87.5% and 96.4%, respectively, were
reported for the 9.4 g and 14.4 g tumor phantoms. Conclusion: Using a
data-driven GP model, tumor-status classifıcation accuracies of up to 96.4%
were achieved in SPMR phantom datasets. In the future, we plan to evaluate the
accuracy of our classifıer in preclinical settings using animal datasets.
#565 Analytical performance of TruSight® Tumor 170 in the detection of
gene fusions and splice variants using RNA from formalin-fıxed, paraffın-
embedded (FFPE) solid tumor samples. Tingting Du, June Snedecor, Jennifer
S. LoCoco, Xiao Chen, Laurel Ball, Allan Castaneda, Danny Chou, Katie Clark,
Brian Crain, Anthony Daulo, Manh Do, Sarah Dumm, Yonmee Han, Mike
Havern, Chia-LingHsieh, Tingting Jiang, Suzanne Johansen, Scott Lang, Rachel
Liang, Jaime McLean, Yousef Nassiri, Austin Purdy, Jason Rostron, Jennifer
Silhavy, Natasha Talago, Li Teng, Kevin Wu, Clare Zlatkov, Chen Zhao, Ali
Kuraishy, KarenGutekunst, SohelaDe Rozieres,Matthew Friedenberg, AnneC.
Jager, Han-Yu Chuang. Illumina, San Diego, CA.
Recent studies have highlighted the importance of gene fusions and splice
variants in solid tumor profıling1. Next-generation sequencing can be an
effective means of detecting these alterations in FFPE samples using RNA
rather than DNA, as a single chimeric RNA transcript could result from
numerous alterations in DNA2. To that end, Illumina developed TruSight®
Tumor 1703, a comprehensive, hybrid capture-based NGS assay targeting
BIOINFORMATICS AND SYSTEMS BIOLOGY: Bioinformatics and Analysis for Therapy and Immune System
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 141
170 key cancer genes. Along with a DNA workflow, the assay includes a RNA
workflow for the identifıcation of splice variants and gene fusions. Following
sequencing on the NextSeq® or HiSeq® instruments, TruSight® Tumor 170
offers an analytical pipeline which initiates variant calling. These algorithms
were fırst optimized against the simulated read data from 350 fusions and
splice variants reported in the RNA content of the gene panel. A hybrid
approach of read alignment and assembly was used to enhance the fusion
calling sensitivity. Deliberate fılters were designed to reduce false positive
calling from sequence homologs, polymerase read-through, or FFPE arti-
facts. For splice variant calling, a panel of FFPE non-cancerous samples were
used to capture false positive mutation calls. With endogenous RNA splicing
in cellular physiology, exon-boundary probes were added in the hybrid cap-
ture to enhance enrichment effıciency. To the best of our knowledge, there is
not yet a standard defınition for the limit of detection (LoD) in detecting
gene fusions and splice variants from NGS data. We propose to defıne the
LoD of a fusion calling and splice variant NGS panel as the lowest molecule
count of a chimeric transcript that could be reliably detected with a suffıcient
number of supporting sequencing reads. To determine the LoD of TruSight®
Tumor 170 using this defınition, we mixed cell lines expressing a panel of
known fusions and splice variants to measure the copy number of each
chimeric transcript. Using these samples we examined the ability of the assay
to confıdently detect the alterations using 40 ng of RNA input. To demon-
strate the analytical sensitivity and specifıcity of this NGS based assay, we
compiled a panel of 49 mixed samples and validated the molecule count to be
near the LoD of 5 copies per ng RNA input by PCR. The sensitivity was98%
for fusions and 100% for splice variants. For understanding the limit of blank
(LoB) of the assay, another panel of 40 samples not harboring fusions and
splice variants was also assessed by TruSight® Tumor 170. These samples
demonstrated a97% specifıcity for fusion calling and95% specifıcity for
splice variant calling. These results indicate that the TruSight® Tumor 170
panel analysis can identify lowly expressed fusions and splice variants from
a small amount of compromised RNA from solid tumor samples at high
analytical sensitivity and specifıcity. 1 Klijn et al. (2015) 2 Maher et al. (2009)
3 For Research Use Only.
#566 A pathway based drug selection for cancer precision medicine.
Varshini Vasudevaraja, Lijun Cheng, Sai Mounika Inavolu, Milan Radovich.
Indiana University, Indianapolis, IN.
BackgroundandPurpose:Precisionmedicine tailors the right therapy to the right
patient based on his/her tumor molecular profıles. In clinic and ongoing clinical
trials, drug-targeted selection schemes dependsmore or less on drug targets’ muta-
tions or expression status. However, there is a lack of systematic pathway based
method to connect individual genomics information with properly drug target and
treatment in precision medicine. The paper aims to integrate various knowledge-
bases, including cancer drugs, drug-targets and gene-gene regulatory pathway, to
construct a drug target and properly drug selection algorithm for individual patient
inprecisionmedicine.Materials andMethods: In thedrug selectionalgorithm,drug
targets and properly drugs recommendation are based on the patient specifıc mo-
lecular profıle data, including copy number variation, mutation, and gene expres-
sion. Our target and drug selections are based on whether these drug targets act as
hub genes that either regulate or control the signaling pathways for many other
genes in the biological pathways. Only those patients whose molecular profıles do
not show targets, the usual chemotherapy treatment will be recommended. This
novel algorithm is applied to individual Pancreatic Adenocarcinoma (PAAD) for
drug target and drug selection. All of patients’ genomic data obtained from the
Cancer Genome Atlas (TCGA). The pathway information is from Pathway Com-
mons and FDA approved cancer drugs and their targets is from DrugBank. The
Cancer Cell Line Encyclopedia (CCLE) 46 pancreases cancer cell line are used to
validate the algorithm result reliability. Results: Our algorithm identifıes targets,
such as ERBB2, CDK2, SRC, CDK9, SMAD2, CDK4, HDAC1, PPP1CA, AKR1B1,
EGFR, IGF1R, AKT and MEK, for pancreatic adenocarcinoma cancer patients. In
which, they cover the clinic fırst line effective drug targets, such as Gemcitabine for
the Akt-mTOR signaling pathway (AKT) and CDK4/6 inhibitor and Erlotinib for
HER2 Kinase Family (ERBB2, EGFR) activation inhibitor. In addition, new inhibi-
tors include Src inhibitors (dasatinib, saracatinib andbosutinib), TGFbeta inhibitor
for target SMAD2 (galunisertib) and IGF-1R/insulin receptor inhibitors (ceritinib,
brigatinib) are recommended accordingly and validated in pancreatic cancer cells.
Conclusion: This novel algorithm might act as a better source for off-label drug
selection and further cell line validations may help in providing a better treatment
strategy in precisionmedicine.
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#567 CD38 blockade overcomes the immune resistance to anti-PD-L1
therapy by boosting CD8 T cell response. Limo Chen, Lixia Diao, Yongbin
Yang, Xiaohui Yi, Jaime Rodriguez, Youhong Fan, Leticia Rodriguez, Jared Fra-
dette, Christin Ungewiss, Jonothan Roybal, Jingfen Zhu, Jing Wang, Lauren
Byers, Stephen Ullrich, Ignacio Wistuba, John Heymach, Xiao-Feng Qin, Don
Gibbons. UTMD Anderson Cancer Ctr., Houston, TX.
Although strategies incorporating immune checkpoint inhibition, e.g. PD-1/
PD-L1blockade, are achievingunprecedented successes and increasingly becoming
incorporated into standard of care regimens for cancer patients, high rates of resis-
tance still limit thepotential effıcacy.Therapeutic improvement requires a thorough
understanding of the biological process of resistance. To date there have been few
studies reporting mechanisms of resistance to PD-L1 blockade. We have explored
the resistancemechanisms to functional PD-L1 loss in preclinical lung cancermod-
els by using pharmacological and genetic approaches (PD-L1 blocking antibody
treatment or CRISPR/Cas9-mediated deletion of PD-L1 on tumor cells). The mo-
lecular and immune profıles of the tumor microenvironment were evaluated in
mutant K-ras/p53 (KP)GEM lung cancermodels andmultiple immunocompetent
syngeneic models (both KP and Lewis lung cancer). Additionally, to determine the
applicability of the results to patients with lung cancer, we analyzed 259 patient
tumor specimens with IHC staining and evaluated the immune markers in TCGA
datasets (adenocarcinoma and squamous) and the MDAnderson PROSPECT da-
taset.Weobserved that lung tumors gained resistance to anti-PD-L1 antibody treat-
mentover time, and that theup-regulationofCD38ontumorcells accounted for the
treatment resistance. We also observed the same resistance mechanism caused by
CD38 up-regulation in PD-L1 KO mice bearing PD-L1 KO Lewis lung tumors
generatedwith the CRISPR/Cas9 system.Manipulation of CD38 on a panel of lung
cancer cell lines, demonstrated that CD38 inhibits CD8 T cell proliferation, anti-
tumor cytokine secretion, and tumor cell killing capability in vitro and in vivo.
Furthermore, to testwhetherCD38blockademight be therapeutically effıcacious to
counter anti-PD-L1 resistance, we applied the combination therapy of anti-CD38
and anti-PD-L1 in lung cancer animal models and demonstrated dramatic thera-
peutic benefıt on primary tumor growth and metastasis. Bioinformatic analyses of
the patient tumor databases revealed a strong correlation betweenCD38 expression
and an immune suppressive inflammatory signature. Finally, in 259 lung cancer
specimens, 18.5%of cases exhibitedpositive staining forCD38on tumorcells.Based
upon our studies, we conclude that the up-regulation of CD38 on tumor cells is a
major mechanism of resistance to anti-PD-L1 therapy, and that CD38 is a novel
immune checkpoint that inhibits CD8T cell function. The blockade of CD38 and
PD-L1 is a rational combination to prevent immune resistance and increase the
response rate for lung cancer patients.
#568 Regulatory T cell recruitment limits the effectiveness of checkpoint
inhibition for claudin-low breast cancer. Sarah C. Vick, Nicholas A. Taylor,
Michael D. Iglesia, W June Brickey, Lisa A. Carey, Bentley R. Midkiff, Karen P.
McKinnon, Shannon Reisdorf, Joel S. Parker, Charles M. Perou, Benjamin G.
Vincent, Jonathan S. Serody. University of North Carolina, Chapel Hill, NC.
Introduction: Breast cancer can be separated into fıve intrinsic subtypes
based on differences in the transcriptome of the tumor. We propose that the
intrinsic differences of specifıc tumor subytpes lead to extrinsic differences
in the tumor microenvironment. Methods: We utilized human clinical and
genetically engineered mouse model (GEMM) samples of the intrinsic sub-
types luminal A, basal-like, and claudin-low breast cancers to evaluate the
immune landscape in the tumor microenvironment by histology and mi-
croarray analysis. Our claudin-low GEMMwas derived from BRCA-/-/p53-/-
mice. The HER-2 overexpressing, basal-like, and luminal A models have
been previously descried. We utilized the FoxP3-DTR transgenic mouse
model as a method of regulatory T cell (Treg) depletion to evaluate their
function in these GEMMs. Results: The claudin-low human tumors were
heavily infıltrated with immune cells, with CD4 T cells being the most
prominent, when compared to the luminal A subtype (P 0.01). There were
also increased focal areas of Tregs in human claudin-low tumors. To evaluate
the mechanism for these fındings, we utilized a GEMM of claudin-low tu-
mors in addition HER-2 overexpressing, basal-like, and luminal A models.
Mice with claudin-low tumors recruited elevated numbers of immune cells
to the tumor microenvironment when compared to other breast cancer sub-
types (P0.01). Additionally, there was increased expression of multiple
chemokine ligands in the tumor microenvironment among claudin-low tu-
mors, with CXCL12 being the most highly overexpressed. Because the clau-
din-low tumors were heavily immune infıltrated, we hypothesized that
blockade of the inhibitory checkpoint receptors programmed death-1
(PD-1) and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) could
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delay tumor growth and improve anti-tumor immune response. Surpris-
ingly, we saw no delay in tumor growth in the claudin-low model using
checkpoint inhibition. To investigate if presence of Tregs limited the func-
tion of checkpoint inhibitors, mice with claudin-low tumors were treated
with AMD3100, a CXCR4 inhibitor. This decreased Treg infıltration into the
tumor but did not alter tumor growth. We then utilized the FoxP3-DTR
transgenic mouse model, where depletion of Tregs alone resulted in a very
modest decrease in tumor growth, while depletion of Tregs plus checkpoint
inhibition signifıcantly improved survival (P 0.03) and increased cytokine
production by CD8 T cells. Conclusion: We found that an effective anti-
tumor immune response in claudin-low tumors is inhibited by the recruit-
ment of Tregs to the tumor microenvironment. These data highlight early
Treg recruitment as a possible mechanism for the lack of response to im-
mune checkpoint inhibition therapy for claudin-low breast cancer.
#569 Dexamethasone inhibits T-cell proliferation through a CTLA-4 me-
diated pathway.Marsha-Kay N. Hutchinson, Amber J. Giles, Heather M. Son-
nemann, Caitlin M. Reid, Deric M. Park, Mark Gilbert. National Institute of
Health, Bethesda, MD.
BACKGROUND: The use of corticosteroids for therapeutic benefıt has to be
weighed against the risks of adverse consequences associated with these drugs.
Brain tumor patients in particular, are routinely prescribed dexamethasone (a
glucocorticoid) to reduce edema associated with their lesion. Checkpoint block-
ade, a type of immune therapy, is currently being investigated as a potential
treatment for brain tumors. However, glucocorticoid signaling has been shown
to attenuate the immune response through several mechanisms including the
repression of transcription of genes controlling pro-inflammatory cytokines and
chemokines. HYPOTHESIS: Here, we propose that dexamethasone’s ability to
upregulate inhibitory T-cell molecules such as CTLA-4 and PD-1 might be an
additional immunosuppressive mechanism. METHODS: Healthy donor T cells
were tested for response to dexamethasone. T cell proliferation, cell cycle anal-
ysis, apoptosis, and protein expression were assessed with flow cytometry. Pro-
tein expression was also measured withWestern blots. Transcriptional changes
were assessed with qPCR. A monoclonal antibody, ipilimumab, was used to
block CTLA-4 binding. RESULTS: Unexpectedly, dexamethasone did not elicit
a direct lymphotoxic effect on T cells as measured by absolute cell number.
However, we found that dexamethasone signifıcantly reduced T cell entry into
the cell cycle, but did not impact cells already undergoing mitosis. Checkpoint
molecules CTLA-4 and PD-1 were increased with dexamethasone treatment
when cells are stimulated. Blockade of CTLA-4 with Ipilimumab resulted in a
substantial reversal of cell cycle entry inhibition that was induced by dexameth-
asone. CONCLUSIONS: These results suggest that dexamethasone impairs T
cell expansion by inhibiting cell cycle entry. Upregulated CTLA-4 expression
contributes to cell cycle entry blockade which is reversed by inhibiting CTLA-4
with ipilimumab. These fındings indicate that administration of ipilimumab
before dexamethasone diminishes the negative proliferative effect on anti-tu-
mor T cells suggesting that when needed, corticosteroids can be used after im-
mune checkpoint blockade has been established.
#570 Transparent tumor tomography (T3): 3D spatial immunoanalysis
for PD-L1 immune checkpoint blockade therapy. Steve Seung-Young Lee,
Vytautas P. Bindokas, Stephen J. Kron. The University of Chicago, Chicago, IL.
Untangling the complexity of programmed death-ligand 1 (PD-L1) expres-
sion within a heterogeneous tumormicroenvironment is an urgent challenge in
PD-1/PD-L1 immune checkpoint blockade therapy. Here, we address this chal-
lenge with a method, termed transparent tumor tomography (T3), facilitating
three-dimensional (3D) visualization and spatial analysis of distributions of
multiple biomarkers regarding to cancer cells, vasculature, and immune cells in
context in the tumor microenvironment. With T3 analysis of transgenic mouse
mammary tumors immunostained against Her2, CD45, Ki-67, CD31, and PD-
L1, we reveal that PD-L1 expression within the tumor microenvironment is
highly adaptable for effıciently preventing immune cell infıltration into the tu-
mor. Stronger correlation ofHer2 and PD-L1 expression in the tumor periphery
where has a highCD45 immune infıltrate density is determined by tumor-wide
analysis. Also, tomographic analysis shows blood vessels expressing PD-L1 in
the tumor core, where PD-L1 expression is lower. Furthermore, high-resolution
T3 image localizes PD-L1 expression to a region between the endothelium and
the surrounding smooth muscle cells in blood vessels. We investigate spatial
pharmacokinetics of anti-PD-L1 antibody in the wholemousemammary tumor
in the context of hypoxia, CD31 blood vessels, and target PD-L1 cells. The 3D
anti-PD-L1 antibody distribution is fıt to a two-compartment pharmacokinetic
model, yielding estimated distribution half-life of 4.7 min and terminal half-life
of 2.5 days. We also evaluate anti-tumor immune responses after PD-L1 block-
ade therapy using T3. We observe broad distribution of tumor infıltrating
CD3CD8 cytotoxic T cells in 3D tumor section following combination ther-
apy of radiation and anti-PD-L1 antibody compared to PBS, anti-PD-L1 anti-
body alone, or radiation alone treatment group. Moreover, we apply T3 for
immunoanalysis of whole core needle biopsy. We spatially map PD-L1 expres-
sion and granzymeB-producing CD3CD8 cytotoxic T cells in pre-treatment
and in-treatment core needle biopsies at cellular resolution and in three dimen-
sions. Meanwhile, T3 analysis is nondestructive, allowing secondary analysis by
IHC and/or IF. We anticipate that T3 can be applied broadly to facilitate pre-
clinical studies of immunotherapy and also fınd use in spatial, multiparameter
analysis of patient biopsies, particularly to improve predictive testing and anal-
ysis of immune responses to tumor immunotherapy.
#571 Meta-analysis of genomic predictors of response to immune check-
point therapy in metastatic melanoma.DianaMiao,1 David Liu,1 Daniel Keli-
her,1 Sachet Shukla,1 Bastian Schilling,2 Claire Margolis,1 Alicia Smart,1 Levi
Garraway,1 Stephen Hodi,1 Dirk Schadendorf,2 Eliezer M. Van Allen1. 1Dana-
Farber Cancer Institute, Boston, MA; 2University Hospital Essen, Essen, Ger-
many.
Introduction: Immune checkpoint therapies benefıt a subset of patients with
metastatic melanoma, but ability to predict clinical outcomes is limited. This
meta-analysis of genomic predictors of outcomes to aPD1 and aCTLA4 in mel-
anoma combines 220 sequenced tumors from 3 published cohorts, aiming to
validate existing hypotheses regarding response to immune checkpoint thera-
pies and discover new relationships with greater power.Methods: Genomic data
and clinical annotations from published cohorts were analyzed with standard-
ized pipelines for somatic variant calling, mutational signature deconvolution,
and neoantigen prediction. Patients were stratifıed into clinical benefıt (CB) and
no clinical benefıt (NCB) as described in Van Allen et al. 2015. Analyses were
repeated using two other published response metrics (CBPFS6 months;
CBCR or PR). Results: Nonsynonymous mutational burden was signifıcantly
higher in CB vs. NCB using all 3 response metrics, though signifıcance was less
pronounced using PFS alone (p0.01 vs. p0.0001; Wilcoxon rank sum), par-
tially due to 3 patients with highmutational burden who experienced PR for6
months, potentially representing early acquired rather than intrinsic resistance.
To assess the impact of mutational processes contributing to overall mutational
burden, we used a non-negative matrix factorization framework to infer muta-
tional activity in tumors from 6 signatures previously seen in melanoma: aging
(S1), TC substitutions (S5), mismatch repair (S6), alkylating agents (S11), UV
(S7), and TG substitutions (S17). The proportion of mutations in S7 or S11
was positively correlated withmutational burden (Spearman’s rho0.66), while
S5 and S1 were anti-correlated (rho-0.62). In a multivariate logistic model, S7
and S11 activity were independent predictors of CB adjusting for mutational
load (p0.05), with the sum of S7 and S11 activity being a strong predictor
(p0.001). Of the patients with low mutational burden (median) with CB, a
large majority (23/29) had 1/2 of mutations in S7 or S11, compared to only
36/71 of low-mutation NCB (p0.01; Pearson’s chi-squared). Neoantigen bur-
denwas strongly correlatedwithmutational burden, and did not improve ability
to predict CB. In examining mutations in specifıc genes,500 genes were mu-
tated more frequently in either CB or NCB (p0.05, Fisher’s exact). Restricting
analysis to genes recurrently mutated in cancer and correcting for patient mu-
tational burden by permutation, nonsynonymous mutations in ACSL3 and
MET and truncating alterations in ARID2 were signifıcantly enriched in CB.
Conclusions: In this meta-analysis of 220 patients, harmonized clinical and
whole exome analysis confırmed that mutational burden correlates with CB
from aPD1 and aCTLA4 therapy, while mutational signatures and alterations in
specifıc genes potentially provide additional predictive power.
#572 Inhibition of IDO1with epacadostat enhances anti-tumor effıcacy of
PD-1 blockade in a syngeneic glioblastoma (GBM)model.DavidA. Reardon,1
Prafulla C. Gokhale,1 Sarah R. Klein,1 Kristen L. Jones,1 Paul T. Kirschmeier,1
Maria Speranza,1 Holly Koblish,2 Peggy Scherle,2 Lance Leopold,2 Robert New-
ton,2 Gordon J. Freeman1. 1Dana-Farber Cancer Inst., Boston, MA; 2Incyte Cor-
poration, Wilmington, DE.
Purpose: To determine if epacadostat, an oral indoleamine 2,3-dioxygenase
(IDO1) inhibitor has therapeutic benefıt against GBM when administered as
single agent and with PD-1 blocking antibody. Methods: An initial survival
experiment was performed to assess effıcacy and was followed by an identical
repeat experiment for validation. 1X105 luciferized GL261 cells, a murine GBM
tumor line derived from intracerebral methylcholanthrene implantation, were
stereotactically implanted intracranially in albino syngeneic C57BL/6 mice.
Mice with increasing bioluminescence on days 3 and 6 were randomized (n8/
group) to receive treatment beginning on day 6: anti-PD-1 (332.8H3, mouse
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IgG1; 500 g intraperitoneal (IP) on day 6, 250 g q 3 days X 7); epacadostat
(Incyte Corporation, orally dosed at 300mg/kg/day for 5 days on/2days off for 3
weeks); anti-PD-1 epacadostat; and control therapy (isotype IgG antibody IP
and 0.5% methocel in water). Tumor response assessments were performed by
quantifying bioluminescence and survival. A re-challenge experiment was per-
formed in long-term survivors to assess for tumor immune responses capable of
preventing relapse. All long-term surviving mice (defıned as	 100 days) from
the effıcacy experimentwere injectedwith 1X105GL261 cells in the contralateral
hemisphere and followed for survival. Results: In both preclinical effıcacy exper-
iments, median survival in the epacadostat monotherapy group did not differ
from controls (approximately 30 days). Four of 8 mice (50%) treated with anti-
PD-1 were long-term survivors in both effıcacy experiments. In the epacadostat
plus anti-PD-1 combination group, 81%of themicewere long-term survivors (7
of 8 in experiment 1 and 6 of 8 in experiment 2). Of note, none of the long-term
surviving mice developed evidence of tumor; thus the median survival among
the anti-PD-1 and epacadostat plus anti-PD-1 combination groups were both
100 days. In the re-challenge study, all of the mice who underwent GL261 re-
inoculation survived  100 more days with no evidence of tumor recurrence.
Conclusions: IDO1 inhibitionwith epacadostat increased the eradication rate of
anti-PD-1 therapy in an orthotopic syngeneic GBM model and long term sur-
vivors rejected tumor following orthotopic re-challenge. Further combinatorial
studies incorporating IDO inhibitor therapy for GBM, including mechanistic
studies, are warranted.
#573 Metabolism as checkpoint: Induction of anti-tumor immune re-
sponse with the novel glutamine antagonist JHU-083. Robert D. Leone, Jud-
son M. Englert, Min-Hee Oh, Chih-Hsien Cheng, Rana Rais, Barbara Slusher,
Jonathan D. Powell. Johns Hopkins Hospital, Baltimore, MD.
The metabolic characteristics of the tumor microenvironment (eg, hypoxia,
acidity, nutrient depletion, elevated adenosine) present a signifıcant hurdle for
immunotherapy. Dysregulated glutamine metabolism plays a crucial role in es-
tablishing this environment. We previously demonstrated that the novel glu-
tamine antagonist, JHU-083, profoundly alters tumor metabolism and inhibits
growth withminimal toxicity. Further studies have demonstrated that JHU-083
can reprogram the immune contexture of the TME leading to decreased regu-
latory T cells (Treg), increased CD8:Treg ratio, decreased MDSCs, suppressed
adenosine, and decreased acidifıcation and hypoxia. We now report that JHU-
083 not only markedly enhances antitumor response to anti-PD-1 and adoptive
cellular therapy (ACT) but also generates potent immune-mediated responses
as a single agent. In an MC38 tumor model C57BL/6 mice treated from day 10
with concurrent JHU-083 and low-dose anti-PD-1 therapy showed robust anti-
tumor activity with complete rejection and normal lifespan in 9/10 mice (vs.
0/10 complete responses with anti-PD-1 monotherapy). The combination regi-
men was well tolerated, causing only minimal, transient weight loss. In other
studies, a therapeutic ACT model with OVA-expressing B16 melanoma cells
was employed and showed that low-dose JHU-083 and adoptive transfer of
activated OVA-specifıc T cells led to markedly suppressed tumor growth and
increased survival versus vehicle treated controls. In the course of these studies
we found that incrementally increasing the dose of single agent JHU-083 gener-
ated 100% complete response rates (5/5) with 60% ofmice rejecting tumor upon
rechallenge, strongly suggesting an immune-mediated rejection had been estab-
lished. Indeed, subsequent tumor studies in WT and RAG-/- mice confırmed
that anti-tumor response to single agent JHU-083 was critically dependent on
the adaptive immune system. This was unexpected as glutamine is known to be
essential for T cell expansion. To this end, we used a vaccinia-OVA model and
found that low-dose JHU-083 administered in the peri-vaccination period had
minimal suppressive effect on OVA-specifıc CD8 expansion, but importantly,
promoted generation of robust memory T cells with higher T-Bet expression
and increased mTORC1 activity upon rechallenge. These studies demonstrate
that, while the dosing and schedule of JHU-083 employed can disrupt tumor
metabolism andmarkedly inhibit tumor growth, these same doses can promote
long-lived changes in T cells that enhance memory response. Overall, our stud-
ies indicate that glutamine antagonismwithin tumors ameliorates critical check-
points to immune function, dissipating metabolic suppression of immune-me-
diated anti-tumor responses. As such, targeting tumor metabolism can
“unleash” endogenous anti-tumor responses asmonotherapy and canmarkedly
enhance anti-PD1 checkpoint blockade and adoptive cellular therapy.
#574 Phosphatidylserine targeting antibody in combination with tumor
radiation and immune checkpoint blockade promotes anti-tumor activity in
mouse B16melanoma. Sadna Budhu,1Olivier DeHenau,1 Roberta Zappasodi,1
Rachel Giese,1 Luis F. Campesato,1 Christopher Barker,1 Bruce Freimark,2 Jeff
Hutchins,2 Jedd D. Wolchok,1 Taha Merghoub1. 1Memorial Sloan Kettering
Cancer Center, New York, NY; 2Peregrine Pharmaceuticals, Inc., Tustin, CA.
Phosphatidylserine (PS) is a phospholipid that is exposed on surface of apo-
ptotic cells, tumor cells and tumor endothelium. PS has been shown to promote
immunosuppressive signals in the tumor microenvironment. Antibodies that
target PS have been shown to reactivate anti-tumor immunity by polarizing
tumor associated macrophages into a pro-inflammatory M1 phenotype, reduc-
ing the number ofMDSCs in tumors and promoting thematuration of dendritic
cells into functional APCs. In a mouse B16 melanoma model, targeting PS in
combination with immune checkpoint blockade promoted greater anti-tumor
activity than either agent alone. This combinationwas shown to enhance CD4
and CD8 T cell infıltration and activation in the tumors of treated animals.
Radiation therapy (RT) is an effective focal treatment of primary solid tumors,
but is less effective in treating metastatic solid tumors as a monotherapy. There
is evidence that RT induces immunogenic tumor cell death and enhances tu-
mor-specifıc T cell infıltration in treated tumors. The abscopal effect, a phenom-
enon in which tumor regression occurs outside the site of RT, has been observed
in both preclinical and clinical trials when RT is combined with immunother-
apy. In this study, we show that irradiation treatment of B16 melanoma causes
an increase in PS expression on the surface of viable tumor and immune infıl-
trates.We subsequently examined the effects of combining RTwith an antibody
that targets PS (mch1N11) and immune checkpoint blockade (anti-PD-1) inB16
melanoma. We found that treatment with mch1N11 synergizes with RT to im-
prove anti-tumor activity and overall survival in tumor bearing mice. In addi-
tion, the triple combination ofmch1N11, RT and anti-PD-1 treatment displayed
even greater anti-tumor and survival benefıt. Analysis of local immune re-
sponses in the tumors of treated animals revealed an increase in tumor-associ-
ated macrophages with a shift towards a pro-inflammatory M1 phenotype after
treatment with RT and mch1N11. In addition, analysis of the systemic immune
responses in the spleen and tumor draining lymph nodes revealed an increase in
CD8 T cell activation, effector cytokine production and differentiation into ef-
fector memory cells in the triple combination. This fınding highlights the po-
tential of combining these three agents to improve outcome in patients with
advanced-stage melanoma and other cancers and may inform the design of
clinical studies combining PS-targeting antibodies with RT and/or checkpoint
blockade.
#575 PD-L1 positive tumor-infıltrating lymphocytes andmutational load
in breast cancer.Marcelo Sobral-Leite,1 KoenVan deVijver,1MagaliMichaut,1
Hugo M. Horlings,1 Tesa M. Severson,1 Philip C. Schouten,1 Rianne van der
Linden,1 Kelly Kersten,1 Anna Marie Mulligan,2 Nayana Weerasooriya,2 Joyce
Sanders,1 Ashley Cimino-Mathews,3 Dennis Peters,1 Gerrit K. Hooijer,4 Erik
Hooijberg,1 Annegien Broeks,1 Rene Bernards,1 Sabine Linn,1 Irene L. Andru-
lis,2 Marc J. van de Vijver,4 Lodewyk F. Wessels,1 Marleen Kok,1 Karin E. de
Visser,1 Marjanka K. Schmidt1. 1The Netherlands Cancer Institute, Amsterdam,
Netherlands; 2University of Toronto, Toronto, Ontario, Canada; 3The JohnsHop-
kins Hospital, Baltimore, MD; 4Academic Medical Center, Amsterdam, Nether-
lands.
Background: PD-1 blockade has emerged as an effective treatment for a subset
of cancer patients. Studies have shown that PD-L1 expression is associated with
likelihood of response to PD-1 blockade. In order to select the right breast cancer
patient for immunotherapy, characterization of the immune landscape of breast
tumors is required. Therefore, we assessed PD-L1 expression and tumor-infıl-
trating lymphocytes (TILs) in different breast tumor subtypes and the link with
prognosis. We also sequenced a panel of genes to assess the mutational load in
triple negative tumors (TNBC) and investigate the association with PD-L1 pos-
itive TILs. Material and methods: We analyzed 438 tumor samples from breast
cancer patients of all ages treated between 1986 and 2007 with surgery, with or
without adjuvant therapy. PD-L1 was stained using whole slide specimens
(E1L3N® antibody) after methodological validation. Pathologists quantifıed
TILs based on International TILsWorkingGroup recommendations and scored
PD-L1 based on the percentage of positive (tumor and/or immune) cells; as
negative if 0%, positive if	1%, and high if50%.Mutational load was assessed
based onDNAkinome sequencing. Associations weremeasured byCox/logistic
regressionmodel, including pathological variables. Multiplex imaging of 20 im-
mune-infıltrated areas from four ER negative tumors were performed using the
Vectra® system based on immunofluorescence staining panel of: CD4, CD68,
CD8, FOXP3 and PD-L1. Results: PD-L1 expression and TILs were higher in
ductal (comparedwith lobular), high grade and estrogen receptor (ER)-negative
tumors (p0.001). TILs (density	5%) were signifıcantly associated with worse
distant metastasis-free survival (DMFS) only in ER-positive tumors (n204):
HR2.72; 95%CI: 1.07-6.94. PD-L1 positivity (	1%) followed the same trend:
HR1.66; 95%CI: 0.87-3.15. However, in ER-negative tumors (n171), high
PD-L1 expression (50%) was signifıcantly associated with better DMFS:
HR0.51; 95%CI: 0.27-0.98. TNBC with high PD-L1 expression of TILs
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(50%) showed an association with increased mutation load (p0.019) and a
trend for better DMFS (HR0.41; 95%CI: 0.16-1.04) compared with tumors
lacking TILs. Further characterization of PD-L1 positivity in the immune-infıl-
trated cells was conducted by a multiplex imaging analysis. Preliminary results
indicated that PD-L1 is expressed in CD68, CD4, FOXP3 and CD8
immune-cells. Conclusion: Our fındings suggest that PD-L1 positive TILs are
associated with worse prognosis in ER-positive breast cancer and with better
outcome in ER-negative group. In TNBC, high mutational load correlates with
high PD-L1 positive TILs.
#576 Neoadjuvant immunotherapy improves effıcacy of image-guided
thermal ablation to generate curative responses in a murine breast cancer
model.Matthew T. Silvestrini, Elizabeth S. Ingham, Lisa M. Mahakian, Azadeh
Kheirolomoom, Yu Liu, Brett Z. Fite, SarahM. Tam, Samantha Tucci, Katherine
D. Watson, AndrewW. Wong, Arta M. Monjazeb, Neil E. Hubbard, William J.
Murphy, Alexander D. Borowsky, Katherine W. Ferrara. UC Davis, Davis, CA.
Magnetic resonance-guided focused ultrasound (MRgFUS) facilitates local
tumor control via thermal ablation, however, the anti-tumor immune effects
induced are weak and unable to consistently generate robust objective responses
in distant lesions. Here, we set out to optimize a therapeutic approach for em-
ploying immunotherapy with thermal ablation for systemic cancer treatment.
We assessed the effıcacy of implementingMRgFUS ablationwith blockade of the
PD-1/PD-L1 axis (anti-PD-1) and activation of TLR9 (CpG oligonucleotide)
under various protocols and in multiple models of murine cancer. Anti-PD-1
(200 g, i.p., days 21 & 28) and CpG (100 g, i.t., days 21, 24 and 28) were
administered coincidentally with MRgFUS ablation (3 MHz central frequency,
circular pattern with R2mm, 1 revolution per second, 65ºC for 1 min, days 21
and 28) over the course of a week in bilateral syngeneic neu deletion line (NDL),
4T-1 and B16 tumor bearing mice. Additionally, we evaluated the administra-
tion of immunotherapy prior to a course of thermal ablation (i.e., “primed ab-
lation”), where anti-PD-1 (as above on days 21, 28 & 35), CpG (as above on days
21, 24, 28, 31, 38 and 45) andMRgFUS ablation (as above on days 31, 38 and 45)
were administered in bilateral NDL tumor-bearing mice. Primed ablation gen-
erated a robust anti-tumor immune response in distant lesions two weeks after
the start of treatment, where a threefold increase in tumor infıltrating leukocytes
(reaching 40% CD8 and 20% CD4 T-cells) was observed. This led to a com-
plete response in 80% of treated mice within 70 days after treatment com-
menced. This effect was also observed in animals with high tumor burden and
when thermal ablation was performed sequentially at multiple independent
sites; 80% of untreated lesions were eradicated at 50 days after the start of treat-
ment. However, therapeutic effıcacy was limited when thermal ablation was
performed coincident with the fırst dose of immunotherapy; this protocol was
not curative in anymurinemodel. To elucidate themechanism for this effect, we
employed tumor histology and positron emission tomography immediately af-
ter MRgFUS ablation. We found that thermal ablation induced stromal inflam-
mation, and the loss of cell-cell adhesion and local vascular integrity, which
impacted the intratumoral transport of small molecules and proteins for 48
hours post treatment. These data suggest that tumor debulking using image-
guided thermal therapy can be successfully incorporated within a curative pro-
tocol in which immunotherapy is initiated before ablation.
#577 Antagonismof the co-inhibitory receptor BTLA enhances effıcacy of
anti-PD-1 treatment in murine syngeneic tumor models.Nathan R. Miselis,1
Douglas Linn,1 Clifford Restaino,1 Toya Baral,2 Jane Xia,2 Roanna Ueda,2
Anandi Sawant,2 Jeanne Baker,2 Gopalan Raghunathan,2 Xinzhong Wang1,1
Edward Bowman,2 Selvakumar Sukumar2. 1Merck & Co., Inc.,, Boston, MA;
2Merck & Co., Inc.,, Palo Alto, CA.
Anti-PD1 therapies show a remarkable improvement in response over many
standard of care regimens, but there is a signifıcant need to further increase
patient responses. Recent clinical studies show improved response rate when
combining anti-PD1 and anti-CTLA4 therapies. This provides “proof of con-
cept” that the combination of two immunotherapies can enhance effıcacy. The
goal of our work was to evaluate the anti-tumor effıcacy of B and T lymphocyte
attenuator (BTLA) antagonism with anti-PD1 therapy in preclinical mouse tu-
mor models. BTLA is an inhibitory co-receptor that modulates T cell function
and is a marker of “exhausted” T cells. The inhibitory signal mediated by BTLA
is initiated following engagement with herpesvirus entry mediator (HVEM), a
ubiquitous receptor that is highly expressed onmalignant cells. One of the chal-
lenges to evaluating BTLA in mouse models is the presence of strain-specifıc
allelic polymorphisms. These sequence differences occur adjacent to theHVEM
binding sites and can interfere with the ability of certain antibodies to recognize
BTLA in different strains of mice or block the HVEM-BTLA signaling. C57BL/
6-specifıc and strain agnostic BTLA binding antibodies are commercially avail-
able, but none antagonize HVEM signaling through BTLA in BALB/c mice. To
more comprehensively evaluate the anti-BTLA/anti-PD1 combination regimen
we generated a fırst-in-class BALB/c strain polymorphism specifıc BTLA antag-
onist monoclonal antibody (40E4) and identifıed clone PJ196 as a C57BL/6
strain polymorphism specifıc antagonist.We show that 40E4 and PJ196 not only
block BTLA:HVEM interaction as measured by cell ELISA, but also reverse
HVEM-mediated suppression in primary T cells from the appropriate mouse
strain. An effector function reduced mouse IgG1 (D265A) chimeric form of
40E4 was generated for in vivo use. In combination with anti-PD1 (mDX400),
40E4 mIgG1 (D265A) shows improved tumor growth inhibition (TGI) over
mDX400 alone in preclinical subcutaneous mouse models of breast cancer
(EMT6) and colon cancer (CT26). To show that anti-BTLA enhancement of the
anti-tumor response to mDX400 is not unique to BALB/c mice, we tested the
combination of a C57BL/6 BTLA strain-polymorphism specifıcmonoclonal an-
tibody (PJ196) with mDX400. Using the subcutaneous MB49 model of bladder
cancer, we show that treatment with PJ196 andmDX400 signifıcantly improved
TGI over mDX400 alone. This is the fırst report evaluating a BTLA antagonist
monoclonal antibody in preclinical mouse tumor models and the fırst report to
show BTLA antagonism enhances the effect of anti-PD1 therapy.
#578 Discovery and characterization of novel antagonistic antibodies that
bind with high affınity to human, cynomolgus, and murine TIGIT, an im-
mune checkpoint receptor. Julia C. Piasecki,1 Kenneth Brasel,2 Robert Rosler,1
Kevin M. Klucher,3 Scott R. Peterson1. 1Cascadian Therapeutics, Inc., Seattle,
WA; 2Unaffıliated, Seattle, WA; 3Unaffıliated, CA.
TIGIT is a recently identifıed coinhibitory immune checkpoint receptor ex-
pressed onNK, effector T, and regulatory T cells. In the oncology setting, TIGIT
is upregulated on tumor infıltrating immune cells and is co-expressed with ex-
haustionmarkers including PD-1, TIM-3 and LAG-3 on infıltrates. TIGIT binds
at least two ligands, CD155 andCD112, which are expressed on antigen present-
ing cells and other tissues, including tumor cells. These ligands also bind the
activating receptor CD226, often co-expressed with TIGIT, creating a network
that modulates adaptive and innate immune response in a manner analogous to
the CD28-CTLA4-CD80-CD86 network. The absence of TIGIT signaling, re-
sulting from genetic defıciency or blockade, enhances anti-tumor immunity in
murinemodels, suggesting that disruption of TIGIT signalingmay have clinical
utility. To explore this concept, yeast antibody display was used to identify fully
human, anti-TIGIT antibodies that block binding to ligands.Multiple rounds of
selection with human and mouse TIGIT protein were performed to promote
species cross-reactivity, diversity and affınity. A pool of 695 unique clones were
screened for binding to TIGIT protein; 65 clones were then selected for further
evaluation. Of the 65, 63 competed with CD155 for binding to TIGIT in a For-
teBio screen. Fifty-three clones bound cynoTIGIT and 25 boundTIGIT from all
three species (human, cyno, mouse). Antibodies bound endogenous TIGIT on
primaryT cells and blocked binding of ligands to cell surface expressedTIGIT in
a dose dependent manner. Twelve clones showed functional activity in a TIGIT
blockade bioassay and showed synergy with anti-PD-1 antibody in a PD-1/
TIGIT combination bioassay. Activity in the bioassays correlated with affınity
for recombinant and cell surface expressed TIGIT. Based on species cross-reac-
tivity, binding affınity and activity in the bioassays, a lead candidate antibody
was selected and produced as mouse IgG1 and IgG2a chimeras for testing in
mouse tumor models. The chimeric antibodies behaved similarly to the parent
clone in vitro exhibiting high affınity for TIGIT, competition with ligand for
binding to TIGIT, and functional blockade of CD155-TIGIT interaction. Eval-
uation of the chimeric anti-TIGIT candidates alone and in combination with
anti-PD-1 antibody in mouse syngeneic tumor models is ongoing, and results
will be reported at the meeting. Antibody mediated blockade of coinhibitory
immunoreceptors has proven clinically effıcacious and supports the develop-
ment of antibodies that target TIGIT. The unique human, non-human primate,
andmurine cross-reactive TIGIT-specifıc antibodies described here offer a sim-
plifıed preclinical development path and the functional activity of these mole-
cules supports their consideration as candidates for therapeutic development.
#580 Nivolumab treatment of metastatic renal cancer patients impairs
Tregs and potentiates NK function: The role of CXCR4 inhibition (“REVO-
LUTION Trial”). Sara Santagata, Anna Maria Trotta, Maria Napolitano, Luigi
Portella, Sabrina Rossetti, Sisto Perdona, Sandro Pignata, Stefania Scala. Na-
tional Cancer Inst. Pascale, Naples, Italy.
Despite encouraging results,Nivolumab response is not aswide as expected in
renal cancer ( RCC). Among mechanisms of immunoresistance T-regulatory
cells(Tregs) activity plays a central role. We previously showed that tumoral
Tregs in RCC patients are more suppressive than healthy donors Tregs. Since
tumoral Tregs express high level of CXCR4, the receptor antagonism was eval-
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uated on patients Tregs revealing that CXCR4 antagonism reverted Treg sup-
pressive activity( Santagata et al, submittedmanuscript). To identify biomarkers
informative and predictive of nivolumab effıcacy Treg function, tumoral access
and NK interactions was determined in nivolumab treated mRCC patients (“
Revolution” trial). At today eleven patients were analyzed for Tregs and NKs
function at time 0-2-4 weeks-3-6 months of treatment. 2 patients died for unre-
lated causes, 5 Patients showed PR, 4 SD and 1 PD at sixmonths. At time 0 Tregs
function, evaluated as inhibition of T-effector (Teff) proliferation, varied among
patients; two patients showed anergy reversed byNivolumab treatment.Overall,
increase in Teff proliferation, compatible with a decreased Tregs activity, was
revealed during nivolumab treatment and, while the total peripheral Tregs was
unaffected, a decrease in CD4CD25127lowFOXp3 highCD45RA - (suppressive
Tregs) was detected. NK activity, evaluated as CD107a exposure, increased with
nivolumab treatment with a concomitant reduction in the inhibitory receptors
CD158a, PD-1 andCXCR4.Moreover patients Tregs andNKswere evaluated in
vitro for the effıcacy of CXCR4 inhibition in affecting cell function. CXCR4
antagonists suppressed the Treg mediated inhibition of Teff proliferation. In
conclusion the evaluation of 11 patients enrolled in the REVOLUTION study
revealed detectable variations on Tregs and NKs function relatively to Niv-
olumab treatment to be correlated with clinical outcome. Tregs suppressive
function was impaired by inhibition of CXCR4 receptor.
#581 Discovery and development of COM701, a therapeutic antibody tar-
geting the novel immune checkpoint PVRIG. Ofer Levy,1 Chris Chan,2 Gady
Cojocaru,1 Spencer Liang,2 Eran Ophir,1 Sudipto Ganguly,3 Maya Kotturi,2 Tal
Friedman,1 Benjamin Murter,3 Liat Dassa,1 Ling Leung,2 Shirley Greenwald,1
Meir Azulay,1 Sandeep Kumar,2 Zoya Alteber,1 Xiaoyu Pan,3 Andy Drake,2 Ran
Salomon,1 Arthur Machlenkin,1 John Hunter,2 Zurit Levine,1 Drew Pardoll,3
Mark White2. 1Compugen Ltd., Holon, Israel; 2Compugen Inc, USA, SSF, CA;
3BloombergKimmel Institute for Cancer Immunotherapy, Johns Hopkins Uni-
versity, Baltimore, MD.
Background: While blockade of the CTLA4 and PD1 pathways has emerged
as an effective treatment of cancer, the majority of patients do not derive long
term benefıt. This provides a rationale for identifying and targeting additional
checkpoints. Employing our unique computational algorithms, we identifıed
PVRIG, a new member of the B7/CD28 family. We report here the expression
pattern, functional characterization, and anti-tumor activity of blocking anti-
bodies targeting PVRIG as well as characterization of PVRIG KOmice. Materi-
als and Methods: PVRIG is expressed by T and NK cells within the tumor mi-
croenvironment. We identifıed PVRL2 as its counterpart and characterized the
PVRIG-PVRL2 interaction. Antibody discovery was carried out with phage dis-
play and hybridoma platforms and antibodies against the human protein were
screened for their ability to enhance T-cell activity in vitro, while surrogate
antibodies targeting the mouse protein were assessed in syngeneic models for
effects on tumor growth. PVRIG -/- KOmice were generated and characterized
including phenotyping and anti-tumor immune response. Results: PVRIG is
expressed on different T cell subsets and on NK, NKT and  T-cells. Within T
cells, memory subsets possess the highest level of PVRIG and its expression is
induced upon long term activation with different stimuli. Within tumor mi-
croenvironment, PVRIGwas found to be expressed onNK and CD8T cells in
multiple cancers. A high affınity lead Ab was selected, COM701, for further
clinical development and demonstrated blockade of the interaction of PVRIG
with PVRL2 as well as enhancement of activation of both primary and tumor-
derived effector immune cells through a PVRL2-dependent mechanism. More-
over, COM-701 showed notable enhancement of T cell function in-vitro when
combined with PD1 or TIGIT Ab blockade. The lead antibody, COM-701, is
currently in preclinical development. A surrogate antibody, that blocks PVRIG-
PVRL2 interaction, was shown to inhibit growth of colon carcinoma and mela-
noma in syngeneic models upon combined treatment with anti-PDL1 antibody.
Comparative analysis of PVRIG KO versus WT derived T cells revealed en-
hanced reactivity of PVRIGnull T cells uponpolyclonal activation in presence of
PVRL2-Ig. Accordingly, MC38 tumors grew slower in PVRIG KO than in WT
mice and ex vivo analysis pointed to the quantitative and functional differences
in anticancer immunity developed in these mice. Conclusion: We describe the
identifıcation of PVRIG as a novel T cell immune checkpoint. We further dem-
onstrate that antibody blockade of the PVRIG-PVRL2 interaction has the po-
tential to be effıciently combined with PD1 or TIGIT blockade for enhancing
anti-tumor immunity. COM-701 is a high affınity antagonistic antibody that is
currently in preclinical development. Taken together, these data demonstrate
the utility of targeting PVRIG in addition to other B7 family checkpoints for the
treatment of cancer.
#582 Circulating tumor DNA (ctDNA) variant allele frequencies are re-
duced in responders to durvalumab and low baseline variant allele frequen-
cies are associatedwith improvedoverall survival inNSCLCpatients.Michael
A. Kuziora, Brandon W. Higgs, Philip Brohawn, Rajiv Raja, Koustubh Ranade.
Medimmune, Gaithersburg, MD.
Mutations can influence patient responses to treatment in non-small cell lung
cancer (NSCLC). Monitoring such mutations can be critical to guiding treat-
ment decisions, however, accessing suffıcient biopsymaterial formutation anal-
ysis can be challenging. Circulating tumor DNA (ctDNA) in the plasma offers a
robust and highly sensitive approach to identifying mutations. Further, variant
allele frequencies (VAFs) in individual mutations represent the number of can-
cer clones harboring a mutation, thus providing an indicator of tumor burden.
Here we evaluated baselinemutation spectrum in genes implicated in cancer for
association with clinical outcomes to durvalumab, an anti-PDL1 molecule, and
examined changes in VAFs, as a surrogate for tumor burden, after treatment
with durvalumab in NSCLC patients. CP1108/NCT01693562 was a nonran-
domized phase 1/2 trial evaluating durvalumab in patients with advanced
NSCLC or other solid tumors. By 29APR2016, 304 NSCLC pts received 10
mg/kgQ2WofD12monthswithmedian 18.8months followup.Apanel of 70
genes was assayed for nonsynonymous mutations and copy number (CN) vari-
ants using the Guardant360 cancer panel in plasma ctDNA from 115 NSCLC
patients pre-treatment and 28 patients pre and 8 weeks post-treatment with
durvalumab (Q2W). The mean VAF of all mutations harbored by a patient was
correlated with clinical outcomes. Objective response rate (ORR) was calculated
according to RECIST v1.1 and a Cox proportional hazardsmodel was calculated
adjusting for baseline ECOG, gender, age, smoking status, therapy lines, histol-
ogy, and number of metastases. Partial responders (PRs) showed a signifıcant
decrease (	 -2.7%, p0.005) in ctDNA mean VAF post-treatment with dur-
valumab (i.e. reduction in tumor burden) compared to an increase inmeanVAF
(i.e. increase in tumor burden) in progressive disease (PD) patients (	1.7%,
p0.17). This correlation was also observed in total mutation count in PR (	-
5.3, p0.037) compared toPDpatients (	2.7, p0.003). In a PDpatient, the
VAF of T790MEGFRmutation doubled after 6weeks of durvalumab treatment.
Patients with VAFs below the median VAF or no CN gains had longer median
overall survival (15.7 months, 95% CI[11.2,not reached] ) compared to those
with VAFs above the median or CN gains (5.1 months 95% CI[3.8,9.4];
HR0.29; p0.0005), even after adjustment for clinical covariates. CtDNA
VAFs were consistently reduced in responders but not non-responders after
eight weeks of durvalumab. Below median pre-treatment VAFs or no CN gains
in ctDNA correlated with longer overall survival in patients treated with dur-
valumab. Because we examined oncogenes and tumor suppressors, increased
VAF in ctDNA of these genes may help to identify aggressive, and diffıcult to
control tumors.
#583 The CDK4/6 inhibitor abemaciclib induces synergistic immune ac-
tivation and antitumor effıcacy in combination with PD-L1 blockade. Jack
Dempsey,1 Lysiane Huber,1 Amelie Forest,2 Jennifer R. Stephens,1 Thompson
N. Doman,1 Jason Manro,1 Andrew Capen,1 Robert S. Flack,1 Gregory P.
Donoho,1 Sean Buchanan,1 Alfonso De Dios,1 Kyla Driscoll,2 Michael Kalos,2
Ruslan Novosiadly,2 Richard P. Beckmann,1 David A. Schaer2. 1Eli Lilly, India-
napolis, IN; 2Eli Lilly, New York, NY.
Targeting cyclin dependent kinases 4 and 6 (CDK4/6) with inhibitors such
as abemaciclib has shown promise in early and late phase clinical trials in
both breast cancer and NSCLC. While there is evidence that patients benefıt
from single-agent abemaciclib, combination strategies leveraging this com-
pound together with immunotherapy are of interest for the treatment of
these and other cancers. Consequently, it is important to understand if and
how a cell cycle inhibitor can be combined with immunotherapy. However,
because most preclinical studies have been performed using xenograft tu-
mors in immune-compromised mice, the potential immunomodulatory ef-
fects of abemaciclib have not been adequately ascertained. To investigate the
immune combinatorial potential of abemaciclib, we studied the effects of
treatment alone and in combination with checkpoint immunotherapy in a
murine syngeneic tumor model sensitive to abemaciclib using immuno-
competent mice. Abemaciclib monotherapy of established murine CT26 tu-
mors, which harbor KRAS G12C mutation and CDKN2A deletion, caused a
dose-dependent delay in tumor growth. Surprisingly, gene expression anal-
ysis showed that treatment was associated with an increase in intra-tumor
immune inflammation without major alteration in immune subset frequen-
cies. Testing of various dosing regimens in this preclinical model found that
monotherapy abemaciclib pretreatment followed by combination with anti-
PD-L1 antibody therapy, induced an enhanced anti-tumor response com-
pared to abemaciclib and anti-PD-L1 monotherapies. Optimal combination
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therapy exhibited superior anti-tumor effıcacy, resulting in complete tumor
regression (CR) in 50-60% of mice in a setting where anti-PD-L1 mono-
therapy showed little or no effıcacy (0% CRs). Mice which maintained CRs
after cessation of combination therapy were able to resist later CT26 rechal-
lenge, demonstrating that abemaciclib in combination with anti-PD-L1 en-
abled the generation of an immunologic memory. Examination of intra-
tumor gene expression during treatment found that combination therapy
further amplifıed the immune/T cell activation signature compared to both
monotherapies. Intra-tumoral suppression of cell cycle genes, which are
indicative of inhibition of CDK4/6, was also greater during the combination
therapy, suggesting that the effects anti-PD-L1 therapy may augment the cell
cycle arrest induced by abemaciclib. Although it was uncertain if agents that
inhibit cell proliferation could be combined with immunotherapy, these
preclinical results demonstrate that it is possible to combine CDK4/6 inhi-
bition by abemaciclib with checkpoint immunotherapy to improve tumor
effıcacy. The synergistic responses observed in terms of tumor effıcacy, im-
mune activation, and cell cycle control provides support for the clinical
investigation of this combination.
#584 From code to cure: Computational discovery of novel immune
checkpoints. Yair Benita, Amit Novik, Gady Cojocaru, Itamar Borukhov, Assaf
Wool, Yossef Kliger, Tomer Zekharya, Zurit Levine, Sergey Nemzer, Ofer Levy,
Amir Toporik. COMPUGEN, Holon, Israel.
Antibody blockade of CTLA4 and PD-1 immune checkpoints emerged as an
effective treatmentmodality for cancer.However, themajority of patients donot
achieve sustained long term benefıt, suggesting a need for targeting of additional
immune checkpoints. To identify additional B7/CD28 immune checkpoint tar-
gets, we developed a unique compendium of computational algorithms that
identifıed multiple novel targets including TIGIT in 2008, which was an un-
known protein at the time of discovery [Proc Natl Acad Sci U S A. 2009 Oct
20;106(42):17858-63], and PVRIG which we recently disclosed. Since their ini-
tial discovery, these targets have been functionally validated and anti-tumor
activity was demonstrated with antibodies that target them. In this presentation,
we will describe the computational algorithms that led to the discovery of these
novel immune checkpoints. These algorithms combine two complementary as-
pects: (i) endogenous immune checkpoint function prediction and (ii) predic-
tion of immuno-modulatory activity in cancer. Immune checkpoint function
was predicted based on gene structure similarity to B7/CD28 family members
that is reminiscent of ancient common evolutionary origins. A gene structure
alignment tool was developed to identify functional homologs of B7/CD28
genes even in the absence of sequence similarity. Next, the expression profıle of
these candidates was modeled and compared to profıles of known immune
checkpoints in normal and cancer tissues. We will review the details of TIGIT
and PVRIG discovery, which were among the immune checkpoints predicted in
this process. Our approach demonstrates the powerful ability of computational
biology to translate genomic knowledge into rational and reliable drug target
discovery.
#585 Chromosome 9p24.1 deletions as a determinant of tumor im-
mune surveillance and immune checkpoint blockade therapy in non-
small cell lung cancer. Tao Shen, Jie Wu. Stephenson Cancer Center,
OUHSC, Oklahoma City, OK.
Anti-PD-1/PD-L1 immune checkpoint blockade therapy requires the pres-
ence of PD-L1/PD-L2 and MHC class I antigens on the tumor cell surface. We
previously found JAK1 truncating mutations in endometrial cancer cells that
impairs JAK1/JAK2-STAT1-IRF1-mediated signaling pathway, which regulates
MHC class I antigen presentation. To determine the potential role and genetic
defects in the IFN--IRF1 pathway in non-small cell lung cancer (NSCLC), we
analyzed the Cancer GenomeAtlas (TCGA) data. Expression of IRF1 correlated
with cytolytic activity markers GZMA and PRF1. Loss-of-function (LOF) ge-
netic alterations in the IFN--IRF1 pathway genes were found in 64 cases (6.3%)
among 1016 patients. These genetic defects occurred prevalently in the JAK2
gene (33 cases) and often through deletions (29 cases) of chromosome 9p24.1.
JAK2 gene deletions were frequently associated with deletions of CD274 and
PDCD1LG2 genes that encode PD-L1 and PD-L2, respectively, whereas CD274
and PDCD1LG2 deletions were always accompanied by JAK2 deletions. Chro-
mosome 9p is frequently deleted in NSCLC. This has been attributed to
CDKN2A/CDKN2B and PTPRD tumor suppressor genes located at the chro-
mosome 9p21.3-9p24.1. Interestingly, JAK2, CD274, and PDCD1LG2 genes are
co-localized at chromosome 9p24.1 near the CDKN2A/CDKN2B and PTPRD
genes. JAK2, CD274, and PDCD1LG2 deletion often but not always coincided
with CDKN2A/CDKN2B and PTPRD deletions. IFN- induced IRF1 expres-
sion and cell surface HLA-ABC levels in A549 cells that contain wildtype JAK2
but not inH1573 cells that had a truncating JAK2.Deletion of JAK2or inhibition
of JAK2kinase activity inA549 cells resulted in loss of IFN--regulated IRF1 and
cell surface HLA-ABC, whereas expression of exogenous JAK2 in H1573 cells
restored IFN- responses. These fındings reveal a previously unrecognized sig-
nifıcance of chromosome 9p deletion in NSCLC and point to chromosome
9p24.1 as a determinant of immune checkpoint therapy.
#586 Ionizing radiation-induced PD-L1 upregulation in glioma: a crucial
role for the molecular chaperone FKBP5. Paolo D’Arrigo, Michele Russo, Elia
Guadagno, Roberto Pacelli, Maria Laura Del Basso De caro, Anna Rea, Martina
Tufano, Stefania Staibano, Gennaro Ilardi, Maria Fiammetta Romano, Simona
Romano. University of Naples Federico II, Naples, Italy.
Glioblastoma can avoid immune surveillance and induce tumor tolerance,
through inhibitory molecules, e.g. PD-L1. Ionizing radiation (IR), used to treat
this tumor, is known to increase tumor expression of PD-L1, thus inducing
resistance mechanisms. Finding molecular determinants involved in IR-in-
duced PD-L1 may provide a target for preventing such an effect and improve
radiotherapy outcomes.We demonstrated that the short isoform of the cochap-
erone FKBP51 (FKBP51s) regulated PD-L1 expression inmelanoma. In glioma,
FKBP51s was expressed at high levels, together with PD-L1 and its silencing
reducedPD-L1 levels. Conversely, overexpression of FKBP51s increased PD-L1.
Different PD-L1 isoforms were observed by immunoblot. A lower band (37
kDa) corresponding to the naïve protein and two upper bands (50,68 kDa)
ascribable to post-translationally modifıed isoforms. FKBP51s was found
mainly bound to the heaviest bands of PD-L1, reasonably mature protein, while
the canonical isoform FKBP51 appeared to bind only the naïve protein. Mature
PD-L1 protein consists in carbohydrates addition, the principal chemical mod-
ifıcation tomost plasmamembrane proteins, and, particularly, N-glycosylation.
Treatment of immunoprecipitated PD-L1 protein with PNGaseF produced a
decrease of the highest band and the appearance of a lower band, corresponding
to the naïve PD-L1, in accordance with the concept that the heaviest band of
PD-L1 is a glycosylated form. Moreover, following subcellular fractionation to
obtain extracts from ER and Golgi compartments, we found that naïve 37 kDa
PD-L1 was detectable in the ER, but not in the Golgi. The PD-L1 glycosylated
band was expressed in ER in a small proportion and mostly in the Golgi.
FKBP51s, but not the canonical FKBP51, was found in ER. Co-IP of FKBP51s
and PD-L1 from ER extract confırmed the two proteins interacted each other in
ER. Our results show that naïve PD-L1 colocalized in the ER of glioma cell
complexed with FKBP51s, while the PD-L1 glycosylated form was measured in
the Golgi apparatus. Treatment of glioma cell with increasing doses of IR up-
regulated PD-L1 expression, in a dose-response manner. Particularly, we found
a signifıcant increase in PD-L1 expression at 4 and 8 Gy, in comparison with
unirradiated glioma cell. Moreover, IR induction of mature PD-L1 was effı-
ciently counteracted by FKBP51s silencing. Subcellular fractionation of glioma
cell subjected to IR in kinetics showed an early and transitory decrease in
FKBP51s ER levels at 3hrs, in line with a reduction of the glycosylated band in
the whole lysate. After 8 hrs from IR, FKBP51s rose up again in the ER inducing
a full maturation of PD-L1. These fındings suggested that FKBP51s has a role in
catalyzing PD-L1 folding, an essential step to glycosylation, through which it
controls the affınity for PD1. This study identifıes FKBP51s as an essential ele-
ment that regulates PD-L1 expression on glioma cell, which is exploited by the
tumor to resist to IR.
#587 HMBD002, a novel neutralizing antibody targeting a specifıc epitope
on the co-inhibitory immune checkpoint receptor VISTA, displays potent
anti-tumor effects in pre-clinical models. Piers J. Ingram, Dipti Thakkar, Je-
rome D. Boyd-Kirkup. Hummingbird Bioscience, Singapore.
V-domain immunoglobulin (Ig)-containing suppressor of T-cell activation
(VISTA) also known as PD1homolog (PD1H) is a co-inhibitory immune check-
point receptor. VISTA is predominantly expressed on hematopoietic cells, par-
ticularly myeloid derived suppressor cells and antigen presenting cells, and at
lower levels onCD4 andCD8T cells and Foxp3Tregs.Multiple studies have
demonstrated VISTA can strongly suppress human T-cell activation, and the
presence of high VISTA expressing cells in the tumor microenvironment has
been postulated as playing a critical role in tumorigenesis and resistance to
immunotherapy. VISTA neutralizing antibodies have been previously observed
in pre-clinical models to increase the abundance of tumor infıltrating effector T
cells as well as their effector functions, resulting in enhanced control of tumor
growth, even in the absence of detectable expression of VISTA on the tumor
cells, a potential advantage over PD1 or PDL1 blockade. There is an urgent need
to develop the most clinically effective anti-VISTA antibodies however the lim-
ited characterization of the VISTA pathway and the uncertainty around the
cognate VISTA ligand has limited the extent to which in vitro studies can sup-
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port the selection of optimal antibodies for development. Hummingbird Biosci-
ence’s proprietary Rational Antibody Development platform to the design of
neutralizing antibodies against specifıc epitopes on VISTA. Extensive in silico
analyses of the VISTA structure and comparative structural modeling against
other B7 protein familymembers has enabled the prediction of key binding sites
where antibody binding will inhibit function, while preserving necessary safety
and developability profıles. Subsequently, a directed evolution strategy was used
to isolate monoclonal antibodies specifıcally targeting these key predicted func-
tional domains on the native folded VISTA protein. Hummingbird’s anti-
VISTA antibodies bind human and murine VISTA protein with high affınity
(kD5nM) and with high specifıcity. Antibody HMBD-002, targeting a region
on VISTA predicted to be critical to ligand binding, was given as single dose
monotherapy to wildtype BALB/C mice, 3 days after inoculation with CT26
syngeneic colon cancer cells. Induction of cytokine release was observed in the
mouse sera (up to 4 fold increase in IL-2, IL17 and IFNmeasured at 24 and 72
hrs after dosing), confırming robust activation of the immune response. This
was associated with signifıcant effects on tumor progression including delay in
progression free survival and 60% inhibition of tumor growth (after 15 days)
with no observable toxicity. Further in vitro and in vivo validation experiments
in other cancer models are ongoing, both as monotherapy and in combination
with other immune therapies. The fırst in-human trial of HMBD-002 is planned
for 2018.
#588 Advanced molecular characterization of severe autoimmune toxici-
ties associatedwith checkpoint inhibitor therapies. JustinM.Balko,1Daniel Y.
Wang,1 Yu Wang,1 Rami Al-Rohil,1 Margaret Compton,1 Jeffery A. Sosman,2
Igor Puzanov,3 Bret Mobley,1 Robert D. Hoffman,1 Yaomin Xu,1 Javid J.
Moslehi,1 Chanjuan Shi,1 Douglas B. Johnson1. 1Vanderbilt University Medical
Center, Nashville, TN; 2Northwestern University, Chicago, IL; 3Roswell Park
Medical Institute, Buffalo, NY.
Immune checkpoint inhibitors (ICIs) have made a profound impact on the
treatment of a variety of cancers. However, as with any systemic treatment,
toxicities are inevitable. With most classes of cancer therapies, toxicities are
relatively predictable based on clinical trial safety data and therefore can be
handled with prophylactic or supportive care measures. However, ICIs are
unique in their ability to cause rare but severe auto-immune toxicities. The
molecular underpinnings of these toxicities, as well as unique features of the
patient, tumor, or affected tissue, have not been extensively explored. We re-
cently reported a small case series of two patients with myocarditis resulting in
death arising following combination ICI therapy (Johnson et al, N Engl J Med,
2016). High lymphocytic infıltration, coupled with PD-L1 expression was pres-
ent in the affectedmyocardium and skeletalmuscle. CommonT cell clones were
identifıed between the affected tissue and tumor, and abnormal expression of
muscle-specifıc transcripts was identifıed in the associated tumor, suggesting
release of peripheral tolerance to tumor-expressed self-antigens.To expand
upon our reported study, we collected healthy and afflicted tissue froma series of
cancer patients with immune-related colitis, myocarditis (MC), and encepha-
lopathy following ICI treatment. We hypothesize that molecular analysis of
these tissues will identify causal factors in the etiology of these toxicities, and
how to better predict, prevent, and treat them. Thus, we performed molecular
characterization of the immune infıltrate and diseased tissue microenviron-
ment. A total of 20 affected (colon, cardiac, brain) and non-diseased control
specimens were examined by spatial digital profıling (nanoString). This process
generates a spatial heatmap of digital counts of 20 selected immunology and
cellular markers and proteins across each specimen. Using this technology, the
landscape of inflammation in ICI-affected organs can be resolved for insights
into the mechanism whereby ICI-mediated auto-immunity occurs. Targeted
RNAseq for selected immuno-oncology mRNA targets was also performed. In
initial RNA sequencing analyses of MC cases, affected myocardium, skeletal
muscle, and patient-matched tumors all demonstrated expression of immune
activation markers (e.g. interferon-gamma and granzyme B), expression of PD-
L1, and muscle-specifıc genes. In the expanded population, including colitis,
digital spatial profıling analyses and targeted NGS (RNAseq) are underway.
Although data analyses are incomplete at the time of this abstract, this work will
be the largest andmost comprehensive analysis of the molecular underpinnings
of ICI-mediated auto-immune toxicity reported to date. These data should offer
clarity in themechanisms and features of these adverse events, how to prevent or
predict them with precision medicine, and how to treat them when they do
occur.
#589 Hedgehog signaling augments PDL-1 expression in cancer cells un-
der hypoxic condition to inhibit antitumor effects by activated lymphocytes.
Hideya Onishi, Akiko Fujimura, Yasuhiro Oyama, Makoto Kawamoto, Akio
Yamasaki, Takashi Morisaki. Kyushu University, Fukuoka, Japan.
[Background] Hedgehog (Hh) signaling is activated under hypoxic condition
in cancerous tissue. This is thought to be one of themechanisms of the induction
of malignant phenotype of cancers. We have shown that Hh inhibitor decreases
proliferation, invasiveness, and tumorigenesis. We have also revealed that Hh
signaling plays pivotal roles for the maintenance of function in activated lym-
phocytes and dendritic cells under hypoxia. Recently, immune checkpoint in-
hibitor takes much attention, however, response rate is still limited. The mech-
anisms regulating PDL-1 expression also remains unclear. In this study, to
increase reponse rate of immune checkpoint inhibitor, we investigated whether
hypoxia-induced activation of Hh signaling contributes to PDL-1 expression in
cancer and whether it affects the antitumor function of activated lymphocytes.
[Materials and Methods] Pancreatic cancer cell line, Panc-1, gallbladder cancer
cell line, NOZ and GBd, and lung small cell cancer cell line, SBC-5 were used as
target cancer cells. Human lymphocytes derived from PBMC were activated by
using anti CD3 mAb and IL-2, and were used as effector cells. For normoxic
conditions, cells were cultured in 5% CO2 and 95% air. For hypoxic conditions,
cells were cultured in 1% O2, 5% CO2, and 94% N2 using a multigas incubator.
For Hh signaling inhibition, cyclopamine, polysaccharide-K (PSK), and small
interfering RNA targeting Gli1, Smo, MAML3, and RBPJ were used. Cell num-
bers were counted by light microscope. Expression of cell surface molecules was
estimated by FACS. [Results] 1) Hypoxia augmented PDL-1 expression in all 4
cancer cell lines. 2) Inhibition of Hh signaling using MAML3 siRNA, cyclo-
pamine and PSK reduced PDL-1 expression under hypoxia in all 4 cancer cell
lines. 3)When activated lymphocytes were cocultured with cancers treated with
a Hh inhibitor, activated lymphocyte cell numbers signifıcantly increased under
hypoxia. 4) In contrast, this increase was abrogated when cancer cells were
treated with a PDL-1 neutralizing antibody. 5) When activated lymphocytes
were coculturedwith cancers treatedwith aHh inhibitor and/or anti-PDL-1Ab,
the percent of CD8 lymphocytes decreased in both the cyclopamine- and anti-
PDL-1-treated groups under hypoxic conditions, while there was no signifıcant
change in CD3 expression. 6) NKG2D expression increased on activated lym-
phocytes in anti PDL-1Ab-treated group. [Conclusion] These results suggest
that Hh signaling is one of regulatory pathways of PDL-1 expression under
hypoxia and that inhibiting Hh signaling may induce lymphocyte antitumor
activity. Therefore, Hh inhibition could be a promising drug target, not only as
a direct tumor suppressor agent, but also as a PDL-1 inhibitor.
#590 A new standardized CD8 and PD-L1 dual assay. Florence Monville,1
Emmanuel Prestat,1 Nadia Yessaad,2 Marine Villard,1 Luciana Batista,1 Jerome
Galon,3 Julien Adam,4 Jacques Fieschi1. 1HalioDX, France; 2Mi-mAbs-CIML,
France; 3INSERM, France; 4Institut Gustave Roussy, France.
PD1/PD-L1 pathway blockade results in a durable clinical response in a frac-
tion of the non-small cell lung cancer (NSCLC) patients. Today, the expression
of PD-L1, detected by immunohistochemistry (IHC) at the surface of tumor or
tumor-infıltrating immune cells, is used to select patients that may respond to
immune checkpoint inhibitors (ICI). However the predictive value of that bio-
marker alone is questioned. In order to better stratify NSCLC patients, we have
developed a new dual-staining IHC assay of PD-L1 and CD8 cells (TILs)
present in the tumor microenvironment on a single slide prepared from FFPE
tissue. The assay was optimized and fully automated on the Benchmark XT
platform (Roche Ventana) with anti-PD-L1 (HDX3) and anti-CD8 (HDX2)
monoclonal primary antibodies, respectively revealed with DAB and fast red
substrates. Stained slides are analyzed by a pathologist like any other existing
IVD test together with the TILs information. In addition, after digitization, the
samples are analyzed to quantify brown and red cells with a newly developed
digital Pathology (DP) tool. The following parameters are reported by the DP
tool: (1) CD8 cell density (cells/mm²) ; (2) PD-L1 cell density (cells/mm²) ;
proximity between CD8 and PD-L1 cells, either centered on CD8 or on
PD-L1 cells and fınally cluster indexes for CD8 cells and PD-L1 cells.
HalioDx DP analysis tool can calculate these parameters on any Regions Of
Interest (ROI) defıned by the user. Accuracy of the automated numeration of
CD8 and PD-L1 cells was validated by an expert pathologist. Cell-to-cell
distances were validated with an independent DP tool. Variability was assessed
for all parameters using adjacent dual-stained slides on complete tissue sections.
The concordance with main IVD approved PD-L1 methods was established on
a representative set of 55NSCLC tumours.HalioDxhas developed an innovative
assay based on the dual staining of CD8 and PD-L1 cells associated to a DP
tool to standardize the evaluation of the tumor microenvironment. This assay
could have higher predictive performance than existing IVD tests used to iden-
tify ICI resistant NSCLC patients.
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#591 Effıcacy of ALKS 4230, a novel immunotherapeutic agent, inmurine
syngeneic tumormodels alone and in combination with immune checkpoint
inhibitors.Heather C. Losey, Jared E. Lopes, Reginald L. Dean,Michael R.Huff,
Rosemarie A. Moroso, Juan C. Alvarez. Alkermes, Waltham, MA.
ALKS 4230 is a novel immunotherapeutic agent being tested in an ongoing
phase 1 study to evaluate safety and tolerability in the treatment of patients with
refractory solid tumors. ALKS 4230 is a selective agonist of the intermediate-
affınity interleukin 2 (IL-2) receptor that when administered to mice results in a
signifıcant increase in numbers of memory CD8 T cells and NK cells with no
expansion of CD4 regulatory T cells (Tregs). The selectivity achieved by ALKS
4230 is due to the fact that themolecule is a fusion of circularly permuted IL-2 to
the extracellular portion of the IL-2 receptor , and the resulting fusion protein
is sterically prevented from binding to the high-affınity IL-2 receptor expressed
on Tregs. The effıcacy of ALKS 4230 was compared to recombinant human IL-2
in a B16F10 lung tumor metastasis model. ALKS 4230 treatment resulted in
dose-dependent reduction of lung tumor colonization, with 100% inhibition at
the highest dose tested. In contrast, while IL-2 was able to reduce lung tumor
colonization, the maximal level of inhibition achieved was 60-70% at multiple
dose levels such that increasing doses did not result in greater inhibition. Thus,
the activation and expansion of effector cells without expansion of Tregs in re-
sponse to ALKS 4230 treatment correlates with its improved effıcacy over IL-2,
which non-selectively expands both effector cells and Tregs. The antitumor effı-
cacy mediated by ALKS 4230 was further evaluated in several murine subcuta-
neous syngeneic tumormodels, includingB16F10,MC38 andEMT6.Treatment
with ALKS 4230 or its murine ortholog resulted in inhibition of tumor growth
and improved survival in multiple models. When dosed in combination with
anti-CTLA-4 or anti-PD-1 antibodies, ALKS 4230 resulted in further improve-
ment of tumor growth inhibition and survival. These results demonstrate the
murine antitumor effıcacy of ALKS 4230 alone and in combination with im-
mune checkpoint inhibitors and support the ongoing clinical evaluation of
ALKS 4230 as an immunotherapy for cancer.
#592 Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1
checkpoint blockade. Spencer C.Wei,1 Jacob H. Levine,2 Dana Pe’er,2 James P.
Allison1. 1UT MD Anderson Cancer Ctr., Houston, TX; 2Sloan Kettering Insti-
tute, New York, NY.
Checkpoint blockade is able to achieve durable responses in a subset of patients,
however the biological variables that distinguish responders from non-responders
are not well understood. Furthermore, we lack a satisfying comprehension of the
underlying mechanisms of anti-CTLA-4 and anti-PD-1 induced tumor rejection.
Given that PD-1 andCTLA-4 attenuate T cell activity through distinctmechanisms
that are separated spatially and temporally, we hypothesized that responses to anti-
CTLA-4 and anti-PD-1 are driven by distinctmechanisms. To address this hypoth-
esis we utilized mass cytometry to comprehensively profıle the effect of checkpoint
blockade on tumor immune infıltrates in murine tumor models. This approach
allows for the interrogation of greater than 40 analytes at single cell resolution. We
demonstrate that high dimensional mass cytometry analysis enables unsupervised
identifıcation of biologically relevant tumor infıltrating immune populations with
high sensitivity and specifıcity. Using this approachwe analyzed immune infıltrates
ofMC38 andB16BL6murine tumors inmice treatedwith anti-CTLA-4, anti-PD-1,
or control antibodies. In both tumor models we identify 15 distinct T cell popula-
tionswith 0.5%or greater frequency. TheT cell populations identifıed inMC38 and
B16BL6 tumors were highly congruent. Notably, some but not all of these T cell
populations were responsive to checkpoint blockade. A subset of tumor infıltrating
CD8Tcell populations expanded followingbothanti-CTLA-4andanti-PD-1.Con-
versely, a subset of regulatory T cell populations contracted following both anti-
CTLA-4 and anti-PD-1. Interestingly, we observed expansion of a Th1-like CD4
effectorT cell population only in response to anti-CTLA-4 treatment. Thus,we fınd
that anti-PD-1 predominantly engages subsets of tumor infıltrating CD8 T cells
whereas anti-CTLA-4 engages both the CD4 andCD8 effector compartments. Our
fındings indicate that anti-CTLA-4 and anti-PD-1 utilize distinct cellular mecha-
nisms to induce tumor rejection. These fındings highlight the importance of ex-
panding ourmechanistic understanding of immunotherapeutic approaches for the
rational designof combinatorial therapeutic approaches. Furthermore, these results
demonstrate that mass cytometry analysis can be utilized to identify biologically
relevant tumor infıltrating T cell populations. We acknowledge the MDACC core
facility NCI Support Grant P30CA16672.
#593 Cross-platform integrative analysis of NSCLC reveals association
between PD-L1 expression patterns and tumor genetic profıle. Robin Ed-
wards, Patrik Vitazka, Peter Szabo, Han Chang, John Cogswell, Hao Tang,
Kaushal Desai, Darren Locke, Qiuyan Wu, Joseph Szustakowski, Steven Bern-
stein, Michele Cleary. Bristol-Myers Squibb, Princeton, NJ.
Background: Immunotherapy with PD-1 inhibitors is associated with in-
creased survival in NSCLC. While PD-L1 expression enriches for clinical bene-
fıt, additional predictive biomarkers are critically needed to further defıne pa-
tient subsets associated with specifıc response/resistance profıles and to develop
optimal combination strategies. We hypothesized that integration of pathology
features derived from H&E and PD-L1 immunohistochemistry with genetic/
genomic data from NSCLC could identify phenotypic/genotypic associations
that highlight specifıc immunosuppressive mechanisms. Towards that end, we
present data from an initial pilot analysis. Methods: Twenty-nine NSCLC (23
adenocarcinoma; 6 squamous cell carcinoma) were included. H&E-stained sec-
tions were scored for tumor grade (1-3), relative proportion of tumor stroma
(stroma score 1-3), percent necrosis and intensity of chronic inflammatory in-
fıltrate (1-3). PD-L1 immunohistochemistry was performed using the DAKO
28-8 antibody. PD-L1 expression was scored in tumor cells bymodifıedH-score
and by the predominant pattern observed - diffuse, heterogeneous, tumor-
stroma interface or negative, and in immune cells using a semi-quantitative
intensity scale (1-3). DNA and RNA extracts from FFPE tissue were subjected
to whole exome sequencing and RNAseq fromwhichmutation load, oncogene/
tumor suppressor genotypes and inflammation signatureswere derived. Results:
The highest PD-L1 H-scores were associated with diffuse expression patterns
and were observed in high grade tumors (Grade 3). Deleterious mutations in
TP53, STK11, KEAP1, KRAS, EGFR andMEToccurred at expected frequencies.
Thesemutations occurred acrossmultiple PD-L1 expression patterns except for
STK11 which was restricted to PD-L1 negative tumors (p0.077, Fisher exact
test). STK11-mutant tumors also displayed a lower PD-L1 inflammation score
(p0.046, Fisher exact test). Trends toward an increase in mutation load with
increasing levels of chronic inflammation onH&E stain as well as with PD-L1
chronic immune infıltrates were noted. Inflammation signatures derived from
RNAseq showed an association between diffuse PD-L1 expression by IHC and
the highest levels of inflammation mRNA signatures comprising T-cells (CD8,
Tregs), B-cells, macrophages and MDSCs. Conclusions: The potential associa-
tion between tumor grade, PD-L1 expression, intensity of the immune infıltrate
and mutation load raise the possibility that tumor morphology predicts muta-
tion load and associated immune response. The fınding that STK11 mutation is
restricted to PD-L1 negative tumors suggests an immunosuppressive mecha-
nism is invoked in this setting. This dataset is currently being expanded to
establish the signifıcance of these fındings.
#594 Dual targeting of TGFb and PD-L1 promotes potent anti-tumor ef-
fıcacy in multiple murine models of solid carcinomas. Karin M. Knudson,1
Sofıa R. Gameiro,1 Kin-Ming Lo,2 Jeffrey Schlom1. 1NCI-CCR, Bethesda, MD;
2EMD Serono, Billerica, MA.
Tumors evade host immune surveillance throughmultiple mechanisms, includ-
ing promoting a tumor microenvironment able to effectively suppress immune ef-
fector functions. Secretion of cytokines such as TGFb and upregulation of immune
checkpoint molecules are two main contributors to immune evasion and tumor
progression. TGFb is an important immunosuppressive cytokine with pleiotropic
actions in cancer, including promotion of epithelial tomesenchymal transition and
metastasis. It promotes tumor immune evasion by impairing T and NK cell matu-
ration, recruitment, and function. Tumors also inhibit antitumor immune re-
sponses through tumor cell-immune cell interaction, in which the negative regula-
tory checkpoint PD-L1/PD-1 interaction plays a major role. Therapies that
independently target TGFb signaling or PD-L1/PD-1 interaction demonstrate lim-
ited clinical effıcacy. Anti-PD-L1/TGFbTRAP (M7824) is a novel immunothera-
peutic agent designed to simultaneously block the PD-L1 and TGFb immunosup-
pressive pathways. It is comprised of the extracellular domain of human TGFbRII
(TGFbTRAP) linked to the C-terminus of human anti-PD-L1 heavy chain (anti-
PD-L1). M7824 has shown potent anti-tumor activities in preclinical models1 and
some evidence of clinical effıcacy in a phase 1 study2. Here, we demonstrate that
anti-PD-L1/ TGFbTRAP neutralizesmurine TGFb-induced signaling and binds to
murine PD-L1 in multiple murine breast and colon carcinoma models. In non-
tumor bearing mice, anti-PD-L1/TGFbTRAP increases the number of CD8 T
cells in the lymphnodes, and elicits splenicCD8TandNKcellswith amore active
phenotype. Initial examination of peripheral immune subsets in tumor-bearing
mice indicates that anti-PD-L1/TGFbTRAP induces CD8 T cells and NK cells
with amore active, less exhaustedphenotype. Furthermore, dual targeting of PD-L1
and TGFb increases tumor expression of MHC-I, MHC-II, and PD-L1, suggesting
additional immune effects in the tumormicroenvironment. Importantly, anti-PD-
L1/TGFbTRAP displays potent anti-tumor effıcacy against various murine models
ofbreast andcolorectal carcinomas.This response isdurable, preventing relapsesup
to 7 months. Anti-PD-L1/TGFbTRAP also decreases spontaneous metastasis in a
murine model of triple-negative breast cancer. Taken together, these fındings sup-
port the preclinical proof of concept for dual targeting of TGFb and PD-L1/PD-1
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pathwayswithanti-PD-L1/TGFbTRAP, itsmodeof action, and its potential clinical
use as amonotherapy or in combinationwith other immunotherapies or standards
of care. 1 Lan Y et al, Preclinical evaluation of M7824 (MSB0011359C), a novel
bifunctional fusion protein targeting the PD-L1 and TGFb pathways. Keystone
Symposium, Jan 2017. 2 Strauss J et al, Phase I trial of M7824 (MSB0011359C), a
bifunctional fusion protein targeting PD-L1 and TGFb, in advanced solid tumors.
Keystone Symposium, Jan 2017.
#595 Heterogeneity of immune checkpoint expression in lung cancer identi-
fıed throughrapid tissuedonation.TheresaBoyle,AndreaShaffer, JanellaN.Hud-
son, Luisa D. Arevalo, Matthew Schabath, TeresitaMuñoz-Antonia, Christie Pratt,
Gwendolyn P. Quinn, Eric B. Haura.Moffıtt Cancer Center, Tampa, FL.
Background: Translational research in advanced lung cancer is hindered by the
limitedavailabilityof specimens foradvancedmolecular techniques.Althoughhelp-
ful, the standard practice to biopsy a small amount of tissue from a single site of
cancer provides limited information.We launched a thoracic rapid tissue donation
(RTD) program to enable lung cancer research with collection of tissue at multiple
tumor sites within hours after death. Many patients chose to enroll in the RTD
programas anopportunity to contribute to cancer research.RTDtissuewill support
multiple research projects, such as studying differential expression of immune
checkpoint proteins in immune oncology or understanding resistance to targeted
agents. Methods: The RTD program for patients with stage IV lung cancer was
approved in June 2015 by the Moffıtt Cancer Center institutional review board.
Tissue specimens from multiple tumor sites from consented donors are collected
rapidly (aim 24 hours) after death and are frozen and/or preserved in formalin.
Hematoxylin and eosin (H&E) staining is performed with evaluation of the histo-
pathology and quality of the specimens. Immunohistochemistry is performed to
evaluate expression of immune checkpoint biomarkers (PD-L1, CTLA4, LAG3,
TIM3, BTLA, A2aR and iNOS). Results: Between June 26, 2015 and November 16,
2016, 18 patients with stage IV lung cancer consented to the RTD program. Post-
mortem tissue has been collected from multiple tumor sites for three cases. H&E
staining of 25 tissue blocks from the fırst case showed minimal evidence of post-
mortem tissue damage by autolysis, confırminghighRTD tissue quality. Biomarker
studies, such as immunohistochemistry for immune checkpoints, such as PD-L1,
CTLA4, LAG3, TIM3, BTLA, A2aR and iNOS are ongoing. Preliminary analysis of
PD-L1 expression in the fırst patient revealed heterogeneous PD-L1 expression
within and between eight tumor sites (both lungs, liver, both kidneys, left adrenal
gland, mediastinal and retroperitoneal lymph nodes). Conclusions: Rapid tissue
donationwith collectionof amplepost-mortemtumor tissue is feasible andvaluable
for cancer research.Aheterogeneous pattern of PD-L1 immune checkpoint expres-
sion was observed between multiple sites of tumor. Post-mortem tissue collection
frommultiple tumor sites facilitates understanding changes in tumor behavior and
biomarker expression at metastatic sites, especially in the context of treatment fail-
ures. Acknowledgements: NIHSponsor #R21CA194932-01 andTissueCore Facil-
ity at the H. LeeMoffıtt Cancer Center & Research Institute (P30-CA076292).
#596 eFT508, a potent and highly selective inhibitor ofMNK1/2 regulates
immune checkpoint and cytokine expression promoting anti-tumor immu-
nity. Kevin R. Webster,1 Vikas K. Goel,1 Jocelyn Staunton,1 Craig R. Stumpf,1
Rajesh Sharma,1 Ivy N. Hung,1 Gregory S. Parker,1 Jolene Molter,1 Gary G.
Chiang,1 Christopher J. Wegerski,1 Samuel Sperry,1 Vera Huang,2 Joan Chen,1
Peggy A. Thompson,1 Chinh Tran,1 Justin T. Ernst,1 Paul A. Sprengeler,1 Sieg-
fried H. Reich1. 1eFFECTOR Therapeutics, San Diego, CA; 2Molecular Stetho-
scope, San Diego, CA.
Dysregulated translation of messenger RNA (mRNA) plays a role in the
pathogenesis of multiple solid tumors and hematological malignancies. MNK1
and MNK2 integrate signals from several oncogenic and immune signaling
pathways (including RAS, Toll-like receptors and T cell receptor) by phosphor-
ylating eukaryotic initiation factor 4E (eIF4E) and other key effector proteins
including hnRNPA1 and PSF. Phosphorylation of these RNA-binding proteins
by MNK1 andMNK2 selectively regulates the stability and translation of a sub-
set of cellular mRNA that control tumor/stromal cell signaling, the tumor mi-
croenvironment and immune cell function. eFT508 is a potent and highly selec-
tive inhibitor of both MNK1 andMNK2. Ribosome profıling has demonstrated
that inhibition of MNK1 and MNK2 by eFT508 selectively regulates the trans-
lational effıciency and mRNA stability of a subset of genes that include inflam-
matory cytokines/chemokines, regulators of stress response, and effectors of
anti-tumor immune response. Given the importance of MAPK signaling and
translational control to immune cell activation and differentiation, the immu-
nological effect of eFT508was further evaluated in both normal human immune
cells in vitro and immunocompetent syngeneic cancer models in vivo. eFT508
treatment of normal donor T cells has no deleterious effect on CD3/CD28
stimulated IL-2 production, T cell proliferation or T cell viability. However,
eFT508 selectively down regulates the induction of IL-10 and specifıc immune
checkpoint receptors, including PD-1 and LAG3. Further evaluation of the
mechanism of translational regulation has shown LAG3 mRNA contains spe-
cifıc sequence elements in the 5’-untranslated region (UTR) that confer sensi-
tivity to eFT508. In addition, IL-10 mRNA is destabilized upon treatment with
eFT508 leading to signifıcant inhibition of IL-10 production in activated T cells.
Furthermore, eFT508 treatment results in upregulation of MHC class II mole-
cules on tumor cells, macrophage and dendritic cells through an IL-10/
MARCH1 dependent mechanism. The in vivo antitumor effect of eFT508 was
assessed in the CT26 BALB/C syngeneic tumor model. CT26 mouse tumor cell
proliferation and survival are insensitive to eFT508 in vitro. In vivo, daily oral
treatment with 1 mg/kg eFT508 results in signifıcant anti-tumor activity, mod-
ulation of tumor infıltrating lymphocytes and establishment of immune mem-
ory. In addition, combination of eFT508 with either anti-PD-1 or anti-PD-L1
monoclonal antibodies results in marked effıcacy, signifıcantly increasing the
percentage of responder animals. eFT508 is currently under evaluation in two
phase I/II clinical trials for patients with advanced solid tumors and patients
with advanced lymphoma respectively. These fındings support further clinical
evaluation of eFT508 in combination with checkpoint blockade.
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#597 Bispecifıc anti-CD123 x anti-CD3 ADAPTIR™ molecules for redi-
rected T-cell cytotoxicity in hematological malignancies. Michael R.
Comeau, Danielle Mitchell, Rebecca Gottschalk, Lynda Misher, Mollie
Daugherty, Lara Parr, Peter Pavlik, Brian Woodruff, Hang Fang, Megan
Aguilar, Jeannette Bannink, Starrla Johnson, Gary Li, Robert E. Miller, Rob-
ert Bader, Nicole Zhang, Toddy Sewell, Maria Dasovich, Gabriela H. Hoyos,
JohnW. Blankenship, CatherineMcMahan, David Bienvenue, Jane A. Gross.
Aptevo Therapeutics, Seattle, WA.
Introduction: CD123 is a component of the IL-3 receptor expressed in
several hematological malignancies including AML, ALL, HCL, and MDS.
CD123 is a compelling target in AML due to its overexpression on AML
blasts as well as leukemic stem cells, which are thought to be resistant to
chemotherapy and may be responsible for relapse of disease following treat-
ment. While CD123 is expressed by some normal leukocyte populations in
circulation and hematopoietic progenitor cells in the bone marrow, the low
frequency of expression on normal cell types provides a therapeutic window
for targeting CD123 in tumor settings with the potential for durable response
and reversible side effects. We have developed bispecifıc anti-CD123 x anti-
CD3 ADAPTIR molecules APVO436 and APVO437 for redirecting T-cell
cytotoxicity to CD123-expressing tumor cells. Results are presented that
examine the in vitro and in vivo activity of these molecules in preclinical
models of AML. Methods: APVO436 and APVO437 proteins were expressed
in CHO cells. Affınity SPR studies were performed using recombinant
CD123-ectodomain. In vitro functional studies were conducted with
CD123 AML tumor cell lines and primary human and cynomolgus ma-
caque T-cell populations. Cytotoxic activity was determined using chro-
mium release assays. On-cell binding, T-cell activation and proliferation
were assessed using multi-color flow cytometry. Pharmacokinetic parame-
ters were determined in BALB/c mice using a single IV dose of approxi-
mately 10mg/kg. In vivo studies to examine tumor growth inhibition activity
were performed with NOD/SCID mice co-implanted subcutaneously with
AML tumor cells and human T-cells followed by treatment with APVO436
or APVO437. Tumor growth was assessed by measuring tumor volume and
Bioluminescent Imaging. Results: APVO436 and APVO437 bound human
CD123 protein with high affınity and binding to CD123 and CD3 expressing
cell lines was confırmed by flow cytometry. Both APVO436 and APVO437
induced concentration-dependent lysis of CD123 AML cell lines with pri-
mary human effector T-cells, accompanied by T-cell activation and prolif-
eration. Comparable redirected T-cell cytotoxicity function was observed
using primary cynomolgus macaque T cells. These activities were dependent
on the expression of CD123 by the tumor target cells. APVO436 and
APVO437 demonstrated an extended elimination half-life in mouse serum,
typical of molecules capable of binding the neo-natal Fc receptor. In vivo,
growth of AML tumor cells was inhibited by treatment with low doses of
APVO436 and APVO437, signifıcantly improving host survival. Conclusion:
Taken together these data demonstrate potent in vitro and in vivo activity of
APVO436 and APVO437 against CD123 expressing tumor cells and are
supportive of further investigation of this approach as a potential treatment
option for AML and other hematological malignancies.
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#598 APOBECmutagenesis: a link between innate immunity and cancer.
ARouf Banday, OlusegunO. Onabajo, Krizia-Ivana Udquim, Adeola Obajemu,
Ludmila Prokunina-Olsson. NCI/NIH, Bethesda, MD.
Introduction: Cytidine deaminase activity of APOBEC3 enzymes generates
mutations that restrict viral infection and eliminate tumor cells but also contrib-
ute to viral and tumor evolution. For example, human immunodefıciency virus
(HIV) is hypermutated by APOBEC3G (A3G), and human papilloma virus
(HPV) can be hypermutated by APOBEC3s, including A3A and A3B. In many
human tumor types explored by TheCancerGenomeAtlas (TCGA), C to T orG
substitutions in the TCA or TCT motifs are predominantly attributed to the
activity of A3A and A3B enzymes. In bladder tumors more than 60% of all
exonic mutations are of the APOBEC-signature type, with nearly 100% of all
bladder tumors carrying these mutations. Previously, we reported that two
germline genetic variants – a single nucleotide polymorphism (SNP) rs1014971
and a 30Kb germline deletion that eliminatesA3B and creates anA3AB chimera,
are the strongest factors associated with bladder and breast cancer risk, expres-
sion of A3A and A3B, and APOBEC mutagenesis in human tumors. Other
factors affecting the source of APOBEC mutagenesis in human tissues are not
well understood. Because some APOBEC3s can be induced in the course of
antiviral response, we hypothesized that APOBECmutagenesis might be a mis-
fıred innate immune response. Methods: We used TaqMan-based expression
analysis for selected APOBECs (A3A, A3B, and A3G) to explore expression in
bladder (HT-1376, HTB-9, and RT-4) and breast cancer (MCF-7, MDA-MB-
231, andT-47D) cell lines infectedwith Sendai virus (SeV). SeV is amurineRNA
virus that results in self-limiting infection in a wide range of human cells, effı-
ciently controlled by innate immune response of the host. The strong induction
of APOBEC3s in RT-4 andMDA-MB-231 was followed-up by global transcrip-
tome analysis with RNA-seq and pathway analysis. Cell lines were also treated
with IFN-, IFN-, IFN-3 and IFN-4 and tested for induction of A3A, A3B
and A3G by TaqMan assays. Results: A3A, A3B and A3G are interferon-stimu-
lated genes (ISGs) because they were induced in the course of innate antiviral
response to SeV infection and by IFNs in some conditions. Specifıcally, A3Awas
most strongly induced by SeV, with 32, 51 and 12,000-fold induction in 3 breast
cancer cell lines, and 4, 5 and 167-fold induction in 3 bladder cancer cell lines.
A3B was also induced by SeV but only in the range of 1-5 fold in all cell lines
tested. Conclusion: APOBEC3s can be strongly induced in the course of innate
immune response even to transient and self-limiting viral infections. In the
presence of single-stranded DNA (ssDNA), the APOBEC3 substrate generated
by different cellular and environmental conditions, strong induction of some
nuclear APOBEC3s, such as A3A and A3B, may result in mutation of human
genomic DNA. In turn, accumulation of these mutations can lead to tumor
initiation and evolution, particularly in individuals with germline APO-
BEC3 risk variants.
#599 Pharmacodynamic biomarkers for anti-TIGIT treatment and prev-
alence of TIGIT expression in multiple solid tumor types. Fiore Cattaruzza,
Pete Yeung, Min Wang, Alayne Brunner, Erwan Le Scolan, Jennifer Cain,
Gretechen Argast, Gilbert O’Young, YuWang Liu, Belinda Cancilla, Austin
Gurney, Tim Hoey, John Lewicki, Ann Kapoun. OncoMed Pharmaceuticals,
Redwood City, CA.
TIGIT (T cell immunoreceptor with Ig ITIM domain) is a co-inhibitory re-
ceptor and its signaling axis inhibits T cell andNatural Killer (NK) cell activity in
the healthy immune system. In tumors TIGIT is highly expressed on a subset of
dysfunctional T andNK cells and of highly suppressive regulatory T cells (Treg).
Loss of TIGIT signaling enhances NK cell activity, CD4 T cell priming and
CD8 T cell effector functions, suggesting a role in anti-tumor immunity. We
have developed an anti-TIGIT blocking antibody that shows potent antitumor
effıcacy in in multiple syngeneic mouse models, including CT26WT colon,
B16F10 melanoma and 4T1 breast cancer. Dose-dependent (12.5-0.1 mg/Kg)
single agent effıcacy was demonstrated in established tumors, and pharmacody-
namic (PD) biomarkers in blood and in tumors were identifıed. Consistent with
TIGIT’s role as a co-inhibitory receptor, anti-TIGIT promoted a dose-depen-
dent increase in activation of CD8 and CD4 tumor infıltrating leukocytes
(TIL) and NK cells, as shown by increased staining of IFN- and CD69 by flow
cytometry, when compared to controls. Anti-TIGIT also increased CD4 and
CD8 T cell frequency in the tumor, measured by immunohistochemistry (IHC).
Furthermore, anti-TIGIT caused an increase in splenic NK cell cytotoxicity,
which correlated with dose and effıcacy. To identify gene expression biomarkers
in tumor and in blood, we used microarray analysis, and found similar immune
gene changes between the two tissues. As expected, anti-TIGIT increased the
expression of genes associated with CD8 T cells, CD4 T cells, and NK cells.
Markers indicative of cytotoxic activity and Th1 response were also induced by
anti-TIGIT. The microarray data were validated by qRT-PCR and results were
consistent with flow cytometry and cytotoxicity results, and underlie the mech-
anism of action of anti-TIGIT. We have developed an IHC assay to evaluate
TIGIT expression patterns in tumor and the associated stroma and TILs. Using
this assay, we profıled 17 tumor types to evaluate patterns of TIGIT expression.
Expression was high on immune cells in the stroma and on TILs in 8 tumor
types, while it was generally low on tumor cells. TIGIT expression was also low
on tumor cells in a panel of 27 PDX models. Consistent with the IHC results,
analysis of 33 tumor types in the TCGA by RNA-Seq showed a good correlation
of the expression levels of TIGIT and T cell markers, suggesting that TIGIT is
mostly expressed on immune cells in tumors. In conclusion, we have identifıed
PD biomarkers for anti-TIGIT in tumors and in surrogate tissues in syngeneic
mousemodels. Analysis of the biomarkers demonstrates activation ofT cells and
NK cells upon inhibition of TIGIT signaling. These biomarkers can be used in
the clinic to demonstrate target engagement. In addition, we have profıled the
expression of TIGIT inmultiple solid tumor types and characterized prevalence
of TIGIT-positive cells.
#600 A cellular platform enables targeted brain delivery of T cells to
glioblastoma. Heba Samaha,1 Antonella Pignata,2 Tiara Byrd,2 Kristen
Fousek,2 Fong Lam,2 Thomas Shum,2 Fabio Stossi,2 Sean Marrelli,1 Micheal
Mancini,2 Meenakshi Hedge,2Wayne smith,2 Nabil Ahmed1. 1Baylor College
of Medicine, Texas Children’s Hospital, Children’s Cancer Hospital Egypt
(CCHE 57357), Houston, TX; 2Baylor College of Medicine, Texas Children’s
Hospital, Houston, TX.
BACKGROUND: Cancer renders the endothelium anergic, abrogating T cell
homing and hindering cell therapy for central nervous system (CNS)malignan-
cies. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is a pathological
adhesion molecule upregulated in the endothelium of Infıltrative CNS diseases.
ALCAM in these conditions leads to overexpression of Intercellular Adhesion
Molecule-1 (ICAM-1) and vascular CAM-1 (VCAM-1); mediating fırm leuko-
cyte anchorage . Antibodies blocking ALCAM decrease leukocyte BBB access
and are currently in a clinical trial for Multiple Sclerosis (MS). METHODS/
RESULTS:We studied the difference in the dynamic signature of adhesionmol-
ecules GBM tumor endothelium. ALCAM is expressed on primary glioblastoma
(GBM) endothelium,while ICAM-1 andVCAM-1 are paradoxically downregu-
lated. We saw induction of vascular ALCAM alone under tumor condition.
Thus, GBM endothelium fails to launch the second wave of adhesion molecules
necessary for BBB transmigration. Then, we mapped the ALCAM minimal
binding region and created an artifıcial molecule with the intent of creating a
novel cellular platform to reverse endothelial anergy, through ALCAM specifıc
anchorage. The exodomain is composed of domain 3 (D3) of CD6 , a stalk and a
CD6 endodomain. D3 on T cells crosslinked to ALCAM in proximity ligation
assay (PLA; 40nm) during TEM. Under shear stress, D3 T cells showed a
global improved traffıcking kinetics: higher capture, more rolling with slower
velocity, arrest and eventually better TEM. This was not seen on ALCAM (-)
normal endothelium or with non-transduced (NT) control T cells. In an ex vivo
model of BBB,D3T cells exhibited higher transmigratory ability overNTT cells.
Signaling through the D3 endodomain phosphorylated ZAP70 recruiting Talin
that enables LFA-1 open confırmation, mediating TEM. D3 T cells had higher
F-actin/FAK colocalization using TIRF microscopy at its interface with AL-
CAM. In an orthotopicmodel of GBM,D3T cells homed signifıcantlymore and
accumulated at the tumor site. This was confırmed by the detection of D3 T cells
in brain explants. CONCLUSION: We created a cellular platform that enables
targeted brain delivery of T cells. This platform serves as a gateway to the effec-
tive cellular therapeutics for brain malignancies but potentially as a delivery
system for complex biologics.
#601 Oncolytic and immune effects of RAPTOR: a novel oncolytic
Herpes Simplex Virus 1 expressing PTEN-L for brain tumor therapy. Luke
Russell,1 Alexander Sprague,1 Alena Cristina Jaime-Ramirez,1 Chelsea
Bolyard,2 Yeshavanth Banasavadi-Siddegowda,1 JiYoung Yoo,1 Pin Yi
Wang,3 Timothy Cripe,3 Balveen Kaur1. 1Ohio State University, Columbus,
OH; 2OhioHealth Research Institute, Columbus, OH; 3Nationwide Childrens
Hospital, Columbus, OH.
Glioblastoma (GBM) is a World Health Organization grade IV astrocytoma
with poor patient survival, characterized by extreme heterogeneity and invasive-
ness, and by resistance to radiation and chemotherapeutic drugs. Brain metas-
tases are 2-3x more frequent than GBM, with breast cancer among the top 3
brainmetastasizing tumor types. The tumor suppressor phosphatase and tensin
homolog on chromosome ten (PTEN) is mutated or deleted in50% of all high
grade gliomas and is lost in 33-49%of all breast cancers.Wepropose to target the
dysregulated PTEN pathway in brain tumors to enhance patient survival. On-
colytic viruses are engineered to destroy tumor cells while sparing non-neoplas-
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tic cells, and can be designed to incorporate payloads that enhance their onco-
lytic effects. PTEN-L is a recently discovered, longer form of PTEN which is
secreted and membrane permeable, and retains its phosphatase activity after
secretion and re-entry into cells. We have generated a novel oncolytic herpesvi-
rus (RAPTOR) that secretes PTEN-L from infected cells for the treatment of
GBM and breast cancer brain metastases (BCBM). In vitro assays to evaluate
virally mediated tumor cell killing, virus replication, transgene expression, and
flow cytometry to evaluate intracellular pAkt and cell surface programmeddeath
ligand 1 (PD-L1) were performed. In vivo studies usingmice bearing orthotopic
human GBM (nude mice) or murine BCBM (nude and FVB/N) were used to
evaluate brain immune infıltrates and survival.Western blot analyses of infected
cell lysates and conditioned media show that RAPTOR produces functional
secreted PTEN-L, as confırmed by intracellular pAkt FACS. Tumor cell killing
and replication were equivalent between RAPTOR and control HSVQ. In vivo,
treatment of mice bearing established orthotopic BCBM revealed improved an-
ti-tumor effıcacy of RAPTOR. Signifıcantly, 9/10 RAPTOR treated mice were
long term survivors in immunocompetent FVB/N mice vs. 4/10 HSVQ treated
mice (p0.044). Treatment of nude mice bearing the same tumors did not
produce long term survivors, implicating the development of antitumor immu-
nity in RAPTOR treated animals. Flow cytometry revealed signifıcant down
regulation of the T-cell repressor PD-L1 on RAPTOR vs. HSVQ treated cells.
Consistent with this, FACS of virus treated tumor bearing brain hemispheres
revealed RAPTOR induced a signifıcant influx in antigen presenting, NK, and
CD8 T cells 7 days post treatment. Our fındings demonstrate that RAPTOR
enhances survival of brain tumor bearing mice using a two-pronged approach:
lytic tumor cell death and immune cell education and activation against the
brain tumor. RAPTOR inhibits virally induced PD-L1 expression on tumor
cells, and could pave the way for a paradigm shift in immune therapy where
immune checkpoint inhibition occurs locally within the tumor rather than glob-
ally, overriding toxicity of neutralizing antibodies.
#602 A novel TGF-/IL-12R signal conversion platform that protects
CAR T cells from TGF--mediated immune suppression and concurrently
amplifıes effector function. Benjamin Boyerinas, Sara Miller, Ryan Murray,
Stacie Seidel, Geoffrey Parsons, Kathy Seidl, Kevin Friedman, Richard Morgan.
bluebird bio, Inc., Cambridge, MA.
Numerous immune-suppressivemechanisms exist within the tumormicroenvi-
ronment thatmayhinderchimericantigenreceptor (CAR)Tcell effıcacy.One such
mechanism is mediated by TGF-, a cytokine secreted by tumor cells and infıl-
trating suppressive immune cells that directly inhibits effector T cell activity.
Effector T cells express the TGF- receptors TGFBR1 and TGFBR2, and expo-
sure of T cells to TGF- induces phosphorylation of the major TGF- signal
mediators SMAD2 and SMAD3. Phosphorylated SMAD proteins (pSMADs)
induce a suppressive transcriptional program that ultimately leads to reduced
cytokine production, reduced cytotoxicity, and a failure to proliferate in re-
sponse to antigen stimulation. A dominant negative receptor version (DNR) of
TGFBR2 that does not contain signaling domains protects T cells from the
impacts of TGF- by blocking the ability of TGF- to induce pSMADs.Here, we
report the development of a novel TGF- signal conversion platform that pro-
vides a T cell stimulatory signal upon exposure to TGF-. This platform utilizes
co-expression of chimeric variants of TGFBR2 and TGFBR1 where the TGF--
binding domain of each receptor is fused to the transmembrane and intracellular
signaling domains of the T cell simulating IL-12 receptors IL-12R-2 and IL-
12R-1, respectively. Using a single lentiviral vector encoding both chimeric
TGF- receptors (CTBR) and a CAR, we demonstrated that CAR-CTBR T cells
were completely protected from TGF--mediated SMAD phosphorylation. In
addition, CAR-CTBR T cells generated signifıcant amounts of pSTAT4 and
pSTAT5 in response to TGF- exposure, a response that mimics the T cell
stimulation effects of IL-12. To further demonstrate successful signal conver-
sion, we evaluated the impact of TGF- exposure on the secretion of IFN, a
major downstream target of IL-12 signaling. CAR-CTBR cells secreted signifı-
cantly greater amounts of IFN than either control CAR T or CAR-DNRT cells
following activation in the presence of TGF-. Lastly, we utilized a serial re-
stimulation assay to expand CAR, CAR-DNR, and CAR-CTBR T cells in the
presence or absence of TGF-. As expected, TGF- exposure resulted in a sig-
nifıcant inhibition of T cell proliferation in control CAR T cells. By contrast,
both CAR-DNR and CAR-CTBR cells were protected from TGF--mediated
inhibition of expansion. Gene expression analysis following 21 days of weekly
antigen-driven expansion revealed specifıc TGF--mediated gene expression
changes in CAR-CTBR cells consistent with increased T cell potency, including
signifıcant upregulation of IFN, IL10, IL18RAP, IL18R1, IL21R and CD62L
transcripts. These data demonstrate the successful development of a TGF-
signal conversion platform that transforms the inhibitory effects of TGF- ex-
posure into an IL-12R-like T cell stimulatory signal that has the potential to
produce superior CAR T cell responses in vivo.
#603 Evaluation of CD19 targeted T cells in relapsed or refractory ALL
patients unable to afford allogenic bone marrow transplant in India. Alka
Dwivedi,1 Sushant Kumar,1 Terry Fry,2 GauravNarula,3 Rahul Purwar1. 1Indian
Institute of Technology Bombay (IIT Bombay),Mumbai, India; 2National Cancer
Institute (NCI), National Institute of Health (NIH), Bethesda,MD; 3TataMamo-
rial Hospital, Mumbai, India.
CAR-T cell therapy has demonstrated remarkable success in long-term re-
mission of relapsed or refractory B-ALL. Unlike western countries, most of the
relapsed/refractory B-ALL patients in India are unable to afford allogeneic stem
cell transplant (allo-SCT), and simply choose palliation. To assess the potential
use of CAR-T cells as a fırst line therapy, it is critical to evaluate CAR-T cell
effıcacy in patients unable to undergo allo-SCT.As a fırst step, a novel anti-CD19
CAR was designed and CD19-vector was produced using lentiviral mediated
gene delivery system. To generate CD19CAR T cells, T cells from healthy
subjects were transduced and expanded either with rIL-2 or rIL-15. Almost
20-50% transduced T cells express CD19-CAR on their surface as analysed by
flow cytometry. Next, effıcacy of CD19-CAR-T cells was examined by cytotox-
icity assay usingCD19malignant B cell lines (Raji cells) and autologousB cells.
CAR-T cells were able to kill majority of CD19B cells effectively (100% kill-
ing). In addition, CAR-T cells secreted high levels of IFN and IL-2. TheCAR-T
cells expanded in presence of rIL-15 showed fewer Treg compared to CAR-T
cells expanded using rIL-2, however, there were no differences in numbers of T
stem cells (TSC) and central memory T cells (TCM). In addition to data on
healthy volunteers reflected above, results of above tests in relapsed/ refractory
B-ALL patients is ongoing and being collated for inclusion in the fınal analysis.
In conclusion, our data demonstrate the successful development of an indige-
nous CAR-T cell platform for subsequent use in clinical trials of CD19B cell
malignancies.
#604 Accurate identifıcation and prioritization of candidate neoantigens
from integrated cancer exome and transcriptome sequencing of FFPE sam-
ples. Marián Novak, Sam Angiuoli, Luis A. Diaz, Andrew Georgiadis, Sian
Jones, Peter R. Loverso, Sonya Parpart-Li, Maria Sevdali, Victor E. Velculescu,
Ellen L. Verner, James White, Theresa Zhang, Mark Sausen. Personal Genome
Diagnostics, Inc., Baltimore, MD.
Precise identifıcation and characterization of candidate neoantigens is
important for the development of effective cancer vaccines, adoptive T-cell
transfer, and prediction of response to checkpoint inhibitors. The candidate
tumor neoantigens are actionable only when expressed, however, current
prediction methods lack the capacity to evaluate neoantigen expression. Se-
quencing both DNA and RNA from a patient’s tumor tissue enables identi-
fıcation of mutations and evaluation of their expression leading to accurate
identifıcation of putative neoantigens. The purpose of this study was to de-
velop and validate a methodology for co-extraction and sequencing of DNA
and RNA from formalin-fıxed paraffın-embedded (FFPE) samples to enable
a robust neoantigen prediction protocol that integrates whole exome and
transcriptome data to identify and prioritize tumor neoantigens for applica-
tion in immuno-oncology research and clinical trials. In order to prepare
high-quality sequencing libraries from FFPE specimens, the tissue was ma-
crodissected to enrich for tumor-specifıc material, and improve the overall
accuracy of next-generation sequencing for detection of somatic alterations.
Total DNA and RNA was co-extracted and purifıed. The DNA was used to
prepare whole exome sequencing (WES) libraries, while the co-extracted
RNA was ribosome-depleted, and reverse-transcribed to prepare RNA se-
quencing (RNAseq) libraries. The WES and RNAseq data was then analyzed
using a multi-algorithm HLA typing and neoantigen prediction protocol
(ImmunoSelect-RTM). ImmunoSelect-R evaluates somatic genomic altera-
tions identifıed from WES of tumor and matched normal tissue to ensure
appropriate prediction of candidate neoantigens. The process of neoantigen
prediction was then refıned by integration of patient tumor-matched
RNAseq data, which allowed for removal of non-expressed putative neoan-
tigens. To further validate the approach, we applied the methodology to a set
of experimentally validated neoantigens. In this setting, ImmunoSelect-R
correctly classifıed 18 out of 19 as strong neoantigen candidates, suggesting
a sensitivity of greater than 90%. Moreover, in a set of 10 patients, Immu-
noSelect-R consistently ranked experimentally validated neoantigens within
the top 20% of all neoantigen candidates derived fromwhole exome sequenc-
ing. In summary, our combined tissue processing, macrodissection, co-ex-
traction, and neoantigen prediction methodology is able to identify and
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prioritize candidate neoantigens. Our approach is unique in combining
high-fıdelity sequencing (WES) and expression (RNAseq) data to accurately
inform the selection of actionable tumor neoantigens for immuno-oncology
applications.
#605 Potency of Gp96-Ig/Fc-OX40L cell-based combination vaccine in
cancer immunotherapy. Xin Xu, Louise E. Gonzalez, George J. Fromm, Suresh
de Silva, Louise Giffın, Jason Rose, Taylor H. Schreiber. Heat Biologics, Inc.,
Durham, NC.
The breakthrough discoveries of checkpoint inhibitors in the fıeld of tumor
immunology have driven the clinical success of immunotherapies for cancer,
despite their benefıcial effıcacy in only a small portion of patients. This is due in
part to immuno-evasive mechanisms and the inability of the immune system to
recognize tumor antigens as foreign. As a therapeutic approach to effectively
present these tumor antigens in order to elicit an anti-tumor immune response,
we previously designed and characterized an allogenic, gp96-Ig secreting, cell-
based vaccine (ImPACT); currently being assessed in a phase II study in non-
muscle invasive bladder cancer and a phase Ib study in non-small cell lung
cancer – the latter, in combination with the PD-1 antagonist Nivolumab. We
recently characterized a ’next-generation’ vaccine (ComPACT) that combines
the tumor antigen chaperone Gp96-Ig along with the T cell costimulator Fc-
OX40L, which are both secreted from the same cell (Fromm et. al. Cancer Im-
munology Research. 2016). In preclinical assays, ComPACT is effective at stim-
ulating CD4 andCD8 antigen-specifıc T cell expansion, the programing of a
durable memory T cell phenotype, and the elimination of melanoma and colon
tumors. This anti-tumor effıcacy is enhanced when ComPACT is combined
with checkpoint inhibition (anti-PD1 or anti-PDL1). To supportmanufacturing
and clinical efforts of both ImPACT andComPACT, in anticipation of phase III
expansion and/or new trial initiation, we have developed novel potency assays to
quantify the biologically active form of Gp96-Ig and the in vitro activity of
Fc-OX40L onT cell costimulation. It has been shown that gp96 can interact with
toll-like receptors (TLR) and that this interaction results in the activation of the
NF-B pathway. Since THP1 cells express abundant TLR2/4, we engineered a
THP1 cell line to express luciferase that is regulated by NF-B response ele-
ments. Furthermore, we utilized the human T cell line; Jurkat, as host cells in
which we also express NF-B-luciferase, to quantify Fc-OX40L costimulation.
Jurkat/NF-B-luciferase cells primedwith either CD3/CD28 or TNF, and sub-
sequently culturedwithComPACT-secreted Fc-OX40L, results in a dose depen-
dent increase in NF-B (luciferase) expression. Our current data in both assays
shows a linear correlation with the input of Gp96-Ig and Fc-OX40L, and may
serve as an effective potency assay to facilitate the manufacturing of our vaccine
product as it transitions into more advanced cancer immunotherapy clinical
studies.
#606 Targeting multiple immune checkpoints and their ligands using a
humanized mouse model of ovarian cancer. Ruea-Yea Huang, Kunle Odunsi.
Roswell Park Cancer Inst., Buffalo, NY.
We have recently reported that multiple immune checkpoints are expressed
in the TILs (tumor infıltrating T lymphocytes) and TALs (tumor associated T
lymphocytes) from a murine ovarian cancer model and that blockade of one
checkpoint pathway induces an upregulation of the other unblocked check-
points.We hypothesized that resistance to single agent blockade (e.g. anti-PD1)
is resulted from the compensatory upregulation of the other pathways (e.g.
CTLA4 or LAG-3). To test this hypothesis in human ovarian cancer, we fırst
examined the level of several immune checkpoints and their ligands in TILs or
TALs fromovarian cancer patients. In addition to the highly expressedPD-1 and
CTLA4, other checkpoint molecules such as TIM3, LAG3, VISTA, and TIGIT
are also elevated inTALs as comparedwith control PBMC.The levels ofmultiple
ligands for the immune receptors in the tumor samples were also analyzed. To
translate the results from mice to humans, we developed several aggressive hu-
man ovarian cancer cell lines from patient derived xenografts to test the combi-
natorial checkpoint blockade strategies. Using a humanized mouse model of
ovarian cancer we observed that adaptive transfer of autologous T cells in com-
bination with checkpoint blockade of PD1mildly delays ovarian tumor growth.
The effect of blocking PD-1 and CTLA-4 pathways on tumor growth and the
upregulation of other checkpoints are currently underway.
#607 PDL1 expression associated with triple negative breast ductal carci-
nomas inAfricanAmericanwomen.FarhanKhan,1YasmineKanaan,1 Luisel J.
Ricks-Santi,2 Rabia Zafar,1 Hagos Aymut,1 TammeyNaab1. 1HowardUniversity
Hospital, Washington, DC, DC; 2Hampton University Hospital, Hampton, VA.
Background: Tumor cells avoid host immune response through expression of
inhibitory T cell regulator, Programmed cell death ligand (PDL1).Our objective
was to evaluate PDL1 expression by immunohistochemistry in the four major
subtypes of breast carcinoma (Luminal A, Luminal B, HER2, and Triple Nega-
tive) in a population of 202 African-American (AA) women with other clinico-
pathological factors. Design: Tissuemicroarrays (TMAs)were constructed from
FFPE tumor blocks from primary ductal breast carcinomas in 202 African-
American females. Two separate 1 mm cores represented each case. Five micro-
meter sectionswere stainedwith rabbitmonoclonal antibody against PDL1. The
sections were evaluated for the percentage and intensity of membrane staining
in both tumor and immune cells. Cut off was 1%. Bivariate analysis was done
via 2 analysis and survivability data was calculated via the generation of Ka-
plan-Meier curves (SPSS v19). Statistical signifıcance was assumed if p  0.05.
Results: PDL1 expression in only tumor cells, only immune cells and in combi-
nation was associated with ER negative (p0.0001), PR negative (p0.0001),
Triple negative subtype (p0.0001) and high grade (p0.0001) breast ductal
cancers. Conclusion: Our study fınding of selective expression of PDL1 in triple
negative breast ductal cancers (TNBC) in AAwomen suggests that inhibition of
adaptive immune response is involved in the progression of these cancers.
PDL1/PD1 is the inhibitory check point of immune response resulting in de-
creased T cell activation and cytokine production. Some studies have shown that
PDL1 expression is associated with loss of PTEN and phosphatide inositol 3
kinase pathway (PI3K) activation. Our previous study showed loss of PTEN in
TNBC. Combining PDL1 inhibitors with PI3K inhibitors may be useful therapy
for aggressive TNBC.
#608 Augmenting and broadening T cell responses against mutated tu-
mour neo-antigens. Bruce W. Robinson,1 Shaokang Ma,1 Jonathan Chee,1
Craig Rive,1 Paula Van Miert,1 Rob A. Holt,2 Jenette Creaney1. 1University of
Western Australia, Western Australia, Australia; 2University of British Colum-
bia, Vancouver, British Columbia, Canada.
Cytotoxic T lymphocytes (CTLs) recognize mutated tumor proteins (neo-
antigens) and are important for anti-tumor immunity, especially in the context
of immune checkpoint blockade immunotherapy (ICPB). Positive outcomes to
ICPB are associated with high neo-antigen loads and with neo-antigen specifıc
CTL responses. However only around 20%of patients respond to ICPB. In order
to examine ways in which the non-responders might become responders we
examined several strategies to improve response rates, using anti-CTLA4 ini-
tially as the ICPB therapy in BALB/c mice in which Uqcrc2 has been defıned as
a DNA/RNAseq-identifıed neo-antigen in AB1 tumor lines induced by a rele-
vant human carcinogen(1). a) We fırst examined therapy-induced changes in
T-cell responses against Uqcrc2. Anti-CTLA4 alone increased the magnitude of
responses against Uqcrc2. Anti-CTLA4 combined with anti-GITR induced de-
terminant spreading, unmasked responses against a new neo-antigen UNC45A
that was undetectable during normal tumour growth. Immunogenic chemo-
therapy also unmasked responses against UNC45A, suggesting that subdomi-
nant neo-antigens can be unmasked by the appropriate immunotherapy. b)We
then evaluated neo-antigen vaccination strategies. Uqcrc2 vaccination only pro-
tected against tumor growth when administered in combination with partial
Treg depletion (Foxp3.DTRmice), suggesting that neo-antigen vaccination will
only be maximally effective when administered in combination with therapies
that modulate existing immune restraints, including Tregs. c) We determined
optimal anatomical location for tracking neo-antigen CTL responses and iden-
tifıed the draining lymph node as an optimal, though not exclusive, location for
response testing compared to blood or tumor.We are currently examining these
observations using sequencing-defıned neo-antigens in our patients and will
present data on changes in human neo-antigen responses to therapy. These
observations have important translational implications for identifıcation of key
neo-antigens, choice of therapy and monitoring of anti-tumor responses. 1. J.
Creaney et al., Strong spontaneous tumor neoantigen responses induced by a
natural human carcinogen. Oncoimmunology 4, e1011492 (2015).
#609 Overcoming host histocompatibility barrier to create a renewable
source of off-the-shelf effector lymphocytes for adoptive immunotherapy.
Raedun L. Clarke, Matthieu Bauer, Ryan Bjordahl, Jeffrey Sasaki, Brian Groff,
Svetlana Gaidarova, Tom Tong Lee, Weijie Lan, Michelle Burrascano, Ramzey
Abujarour, Greg Bonello, Megan Robinson, Stewart Abbot, Scott Wolchko,
Daniel Shoemaker, Bob Valamehr. Fate Therapeutics, Inc., San Diego, CA.
Encouraging clinical outcomes in autologous cellular immunotherapy have
garnered hope and excitement. However, limitations of patient-derived cancer
immunotherapies remain to be addressed to deliver reliable and effıcacious ther-
apies with broader applicability. Induced pluripotent stem cells (iPSCs) are a
unique, renewable source for the continuous generation of cellular therapeutics
and represent a highly promising approach for overcoming many of the limita-
tions of autologous therapy. To advance the promise of iPSC technology as an
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“off-the-shelf” (OTS) source of cellular therapeutics, several considerations
need to be addressed. Ensuring the persistence of allogeneic OTS therapies after
adoptive cell transfer across histocompatibility barriers is a key requirement.
Establishing amaster cell line from genetically engineered clonal iPSC lines with
the capacity to continuously generate homogenous populations of highly func-
tional effector cells will also be necessary.Herewe demonstrate a comprehensive
approach for the generation of immune tolerant effector cells derived from a
genetically engineered iPSCmaster cell line.We successfully combined deletion
of classical human leukocyte antigenmolecules with expression of immunosup-
pressive proteins to generate clonal iPSC lines with the ability to escape immune
rejection. Utilizing in vitro quantitative live cell analysis we show that OTS-
iPSCs elicit a signifıcantly decreased cytotoxic response from both peripheral
blood (PB)-NK cells (47.9 vs. 91.4% survival at 3:1 E:T ratio) and PB-T cells
(2.7-fold greater number of OTS-iPSC derived cells remaining at 88 hrs).
Additionally, mixed lymphocyte reactions employing unfractionated PBmono-
nuclear cells resulted in signifıcantly decreased activation and proliferation of
CD8 T cells (63.4 vs. 29.6%), CD4 T cells (70.9 vs. 17.3%) and NK cells (46.8
vs. 11.6%). In preclinical mousemodels we demonstrate that OTS-iPSCs exhibit
improved persistence in vivo. Bilateral engraftments were established in non-
conditioned, fully immune-competent recipientmice using luciferized wildtype
and OTS-iPSCs. Daily bioluminescence imaging revealed a signifıcant increase
in persistence of OTS-iPSCs during the 48-196 hour post injection window
(5.5 fold greater luminescence at 96 hrs). Using our potent chemically-defıned
stage-specifıc monolayer hematopoietic differentiation platform, we demon-
strate that OTS-iPSC derived CD34 expressing hematopoietic cells are repro-
ducibly scaled and readily give rise to functional lymphocytes carrying the en-
gineered targetedmodality in a homogenousmanner (95 /- 5%). The outlined
preclinical data illustrate that iPSCs are an ideal renewable source for OTS he-
matopoietic cell-based immunotherapies and represent a potentially exponen-
tial advancement in adoptive immunotherapy.
#610 Blockade of tumor expression of PD-1 promotes lung cancer growth
in a murine model. Shisuo Du,1 Qing Guan,2 Adam P. Dicker,1 Bo LU1.
1Thomas Jefferson University, Philadelphia, PA; 2Fudan University, Shanghai,
China.
Lung cancer remains one of themost prevalent and fatal malignancies world-
wide. There are substantial evidences that immunotherapies offer signifıcant
benefıts among lung cancer patients. Pembrolizumab, a humanized pro-
grammed death receptor-1(anti-PD-1) antibody is now approved by FDA as a
fırst-line treatment of patients with metastatic non-small cell lung cancer
(NSCLC). Recent data demonstrate that PD-1 is not only expressed by immune
cells, but also by human melanoma cells. However, little is known about the
biological signifıcance of PD-1 pathway in cancer including NSCLC. Thus, we
examined PD-1 expression in a series of established murine lung cancer cell
lines. RT-PCR amplifıcation and sequencing of the full coding sequence of the
murine PD-1 (PDCD1) gene revealed the presence of PDCD1 mRNA in the
M109 lung cancer cells. Flow cytometry and immunofluorescence analysis dem-
onstrated PD-1 protein expression in these murine lung cancer cells. To deter-
mine the molecular function of tumor PD-1 in lung cancer survival, we treated
M109 cells in culturewith either anti-mouse PD-1(100ug/ml) or isotype control
antibody and found that PD-1 inhibition signifıcantly enhanced cancer cell vi-
ability asmeasured byMTTand clonogenic assay. Alternative PD1 inhibition by
either knockdown of PDCD1 via siRNA or knockout of PDCD1 by CRISPR-
Cas9 all lead to increased survival of M109 cells. Furthermore, PDCD1-knock-
outM109 cells had no survival difference in the presence of anti-PD1 compared
to its PD1-expressing parental cells. Conversely, treatment with recombinant
PD-L1 fusion protein exhibited signifıcantly increased apoptotic rates
(7.53.2% vs 2.11.2%) suppressing the tumor cell growth in the wild-type
M109 in culture. To validate these results in in vivomodels, NSGmicewere used
to determine the direct impact of anti-PD1 on M109 xenografts without the
interplay of host immune system. M109 xenografts treated with antiPD-1
(10mg/kg i.p.) antibodies showed accelerated growth compared to those treated
by IgG control (2487473 vs 1499292mm3at days 21 after tumor inoculation,
p0.013). M109 subcutaneous tumors in the PD-1 knockout mice also mani-
fested more rapid growth than the same tumors implanted in wild-type mice.
Taken together, our results uncover a novel function of PD-1/PD-L1 axis in lung
cancer survival and implicate possible tumor-promoting effects from anti-PD-1
therapy upon PD1-expressing lung cancer in the absence of effective immune
response.We plan to interrogate bio-specimens collected throughNRG trials to
establish the translational potential of these fındings.
#611 Reversion of mesenchymal features in NSCLC cells using M7824, a
fırst-in-class bi-functional immunotherapeutic agent targeting PD-L1 and
TGF① (TGF TRAP). Justin M. David,1 Jeffrey Schlom,1 Yan Lan,2 Claudia
Palena1. 1National Cancer Institute, Bethesda, MD; 2EMD Serono, Billerica, MA.
Background: Evasion of antitumor immunity is widely regarded as a hallmark
of cancer. Tumor cells can avoid immune destruction by upregulating the im-
mune checkpoint molecule PD-L1, and antibodies targeting the PD-1/PD-L1
axis have demonstrated clinical effıcacy in several tumor types. Antitumor im-
munity can also be suppressed by TGF, a pleiotropic cytokine that reduces
innate and adaptive antitumor immune responses. Additionally, TGF impacts
tumor cells by activating a differentiation program called epithelial-mesenchy-
mal transition (EMT), in which tumor cells lose epithelial features and gain
mesenchymal characteristics. The gain of mesenchymal traits is associated with
metastasis, stemness, and resistance to multiple therapeutic modalities, includ-
ing chemotherapy and radiation. The objective of this work is to investigate the
therapeutic potential of M7824 in non-small cell lung cancer (NSCLC). M7824
is a fırst-in-class bi-functional immunotherapeutic agent designed to target two
negative regulatory pathways in immunosuppression. It is a novel fusion protein
comprised of the extracellular domain of human TGFRII covalently linked to
the C-terminus of the Fc domain of the fully human anti-PD-L1 IgG1 antibody
avelumab. Methodology: In vitro assays were conducted using NSCLC cell lines
treated with TGF1 alone or in combination with avelumab or M7824 to assess
the ability of M7824 to revert features of tumor cell EMT, including molecular
marker expression, cell proliferation, and response to various chemotherapies.
The ability ofM7824 tomediate antibody-directed cellular cytotoxicity (ADCC)
of TGF1-treated cells in vitro was also assessed. Results: Treatment with
TGF1 induced mesenchymal marker expression, reduced cell proliferation,
and enhanced resistance to docetaxel, paclitaxel, and gemcitabine. Treatment
withM7824, but not avelumab, was able to both prevent and revert these effects
of TGF1.M7824 also exhibited the ability tomediate ADCC of TGF1-treated
cells in vitro. Conclusions: M7824 effectively antagonizes TGF1-mediated tu-
mor cell mesenchymalization, including resistance to chemotherapy. These re-
sults suggest that M7824 has the potential to relieve immunosuppression and
block treatment-resistance induced by TGF1 in patients with NSCLC.
#612 Methylation changes in DNA of CD8 T cells following CD137 co-
stimulation. M. Angela Aznar,1 Sara Labiano,1 Angel Diaz-Lagares,2 Manel
Esteller,2 Juan Sandoval,3 Ignacio Melero1. 1Center for Appplied Medical Re-
search University on Navarra (CIMA), Pamplona, Spain; 2Bellvitge Biomedical
Research Institute (IDIBELL), Barcelona, Spain; 3Medical Research Institute La
Fe, Valencia, Spain.
Introduction: CD137 ligation imprints long term changes in the behavior of
costimulated T-cells (1). There is not a satisfactory mechanistic explanation yet.
Experimental procedures: to determine the specifıc DNA methylation changes
occurring uponCD137 costimulation, purifıed humanCD8T cells from three
healthy donors were activated in vitro for 5 days with anti-CD3 monoclonal
antibody and either with an anti-CD137 monoclonal antibody or its corre-
sponding isotype (huIgG4). Activated lymphocytes were left 5 days in culture
with huIL-7 without further stimulation. Such back-to-resting CD8 lympho-
cytes were reestimulated with anti-CD3 for 12, 24 and 36h to validate the ex-
pression of the genes differentially methylated upon primary stimulation at
mRNA and protein levels. DNAmethylation profıles of both activated and rest-
ing cell subsets were characterized with Infınium 450K DNAmethylation array
(Illumina). To further confırm our observations, identical experimental proce-
dure was performed with a different anti-CD137 agonist antibody (mIgG1 iso-
type) in a CD8 T-cell donor. Differentially methylated genes between anti-
CD3anti-CD137 versus their corresponding control counterparts were
validated by pyrosequencing on activated and resting CD8 from independent
group of healthy donors (n8 for hIgG anti-CD137 and n 11 for mIgG anti-
CD137). Expression changes were confırmed by qRT-PCR and flow cytometry
in activated, rested and reestimulated CD8 lymphocytes. Results: 853 genes
were differentially methylated in hIgG4 anti-CD137-treated CD8 T cells as
comparedwith their controls, 52 ofwhichwere sharedwithmIgG1 anti-CD137-
costimulated CD8 T lymphocytes. A number of differentially methylated
genes are involved in i) T cell migration, ii) T cell activation, survival and ho-
meostasis and iii) regulation of gene expression including key T-cell transcrip-
tion factors. Conclusions: CD137 costimulation induces CD8 T lymphocytes
that are poised to respond more effectively to a second antigen exposure. These
acquired functions are imprinted in the genomic DNA of the CD8 T cells by
DNA methylation changes upon CD137 co-stimulation, and involve key genes
for CD8 T cells. References: 1. Hendriks, J., Y. Xiao, J.W. Rossen, K.F. van der
Sluijs, K. Sugamura, N. Ishii, and J. Borst, During viral infection of the respira-
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tory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8
memory T cells and their capacity for secondary expansion. J Immunol 2005,
175: p. 1665-76.
#613 Development of FPA154, a novel tetravalent anti-GITR antibody,
for the treatment of solid tumors. SusannahD. Barbee,1 AmandaChen,1 Susan
Johnson,1 David I. Bellovin,1 John C. Timmer,2 Nebiyu Wondyfraw,1 Mikayel
Mkrtichyan,1 Amir S. Razai,2 Kyle S. Jones,2 Chelsie Y.Hata,2 Denise Gonzalez,1
Quinn Deveraux,2 Brendan P. Eckelman,2 Luis Borges1. 1Five Prime Therapeu-
tics, South San Francisco, CA; 2Inhibrx, San Diego, CA.
Glucocorticoid-induced TNFR-related (GITR, TNFRSF18) is a member of
the TNFR superfamily with pleiotropic T cell modulatory activity. We are de-
veloping a novel anti-GITR antibody with enhanced agonist activity for the
treatment of solid tumors. Our candidatemolecule, FPA154, is constructedwith
single-domain antibodies (sdAbs) in a tetravalent format, with an effector-com-
petent IgG1 Fc domain. Both FPA154 and the mouse-reactive surrogate mole-
cule (cmFPA154, mIgG2a isotype) bind to cell-surface GITR with high affınity.
GITR is most highly expressed in vivo on activated and intratumoral Treg, and
our data indicates that FPA154 and cmFPA154 potentlymediate ADCC activity
against Treg expressing high levels of GITR. In contrast, activated effector T cells
express modest levels of cell-surface GITR, and FPA154 and cmFPA154 drive
GITR-induced NF-B activation. This activity is independent of Fc-mediated
crosslinking, which is normally required for bivalent GITR antibodies to induce
GITR signaling. cmFPA154 has potent antitumor activity in several syngeneic
mouse tumors, both as a monotherapy treatment and in combination with anti-
PD-1. In summary, FPA154 is a promising candidate withmultiplemechanisms
of action that contribute to generation of an antitumor immune response me-
diated by different T cell subsets.
#614 VB4-845 tumor cell killing in a combination study with the anti-
PD-1, Nivolumab. Rachelle Lee Dillon,1 Shilpa Chooniedass,1 Arjune Prem-
sukh,1 Glen MacDonald,2 Jeannick Cizeau,1 Gregory A. Adams3. 1Viventia Bio
Inc., Winnipeg, Manitoba, Canada; 2Eleven Biotherapeutics Inc., Winnipeg,
Manitoba, Canada; 3Eleven Biotherapeutics Inc., Philadelphia, PA.
VB4-845 is a Targeted Protein Therapeutic (TPT) comprised of a scFv frag-
ment specifıc for the Epithelial Cell Adhesion Molecule (EpCAM) genetically
fused to a truncated form of Pseudomonas exotoxin A (ETA), via a flexible
linker. Due to the inherent immunogenicity of the ETAmoiety, VB4-845 is only
used for the treatment of loco-regionally accessible tumors and is currently in a
Phase III clinical trial for the treatment of high grade, non-muscle invasive
bladder cancer. In a Phase I study in late stage squamous cell carcinoma of the
head and neck, direct injection of VB4-845 led to shrinkage of the principal
injected tumor, as well as non-targeted tumors in some patients, suggesting the
activation of a T cell-mediated anti-tumor response through cross-priming.
Only cells undergoing immunogenic cell death, or ICD, are capable of stimulat-
ing cross-priming. ICD is characterized by distinct “eat-me” signals such as the
release of ATP and HMGB1, and cell surface translocation of calreticulin, an
endoplasmic reticulum chaperone protein. To evaluate whether VB4-845-me-
diated cell killing results in ICD events, treated tumor cell lines were assessed for
these distinct signaling molecules. In vitro studies using flow cytometry and
ELISA showed both translocation of calreticulin and release of ATP and
HMGB1 by VB4-845-treated tumor cells. Immune T cell activation via an ICD
pathway suggests a complimentary outcome when combined with checkpoint
inhibitors. A study was performed in PDX tumor-bearing NOG mice reconsti-
tuted with a human immune system to assess the combination of intratumoral
injection ofVB4-845with an anti-PD1 antibody,Nivolumab, given i.p. VB4-845
showed growth suppression of the injected tumor whereas the growth delay of
the contralateral, non-injected tumor was more pronounced with the addition
of Nivolumab. In summary, the data presented suggests that VB4-845 mediates
tumor cell killing by an ICD pathway and that the resulting cross-priming effect
can enhance the anti-tumoral activity of immune checkpoint inhibitors.
#615 Local irradiation with systemic anti-PD1 antibody may effectively
suppress the micrometastasis in distant organ through the induction of ab-
scopal effects. Hidenori Tsukui, Rihito Kanamaru, Ai Sadatomo, Daishi Naoi,
Tetsuichiro Shimizu, Makiko Tahara, Katsusuke Mori, Homare Ito, Mitsuaki
Morimoto, Yoshihiko Kono, Yoshiyuki Inoue, Hiroyuki Maruyama, Koji Koi-
numa,HisanagaHorie, Yasunaru Sakuma, YoshinoriHosoya,Naohiro Sata, Joji
Kitayama. Jichi Medical University, Shimotsuke Tochigi, Japan.
Background: Tumor shrinkage in response to radiotherapy (RT) is partially
dependent on host immunity. Recent clinical results have suggested that PD-1/
PD-L1 blockademarkedly augments the antitumor immune response especially
in case of numerous genetic mutations. Here, in this study, we evaluated if
anti-PD-1 mAb can induce abscopal effects of local RT in murine model.
Method: Murine colon cancer cell, LuM-1, is a highly metastatic clone of colon
26. After subcutaneous (s.c) inoculation of LuM-1, micro- andmacro- metasta-
ses were observed in bilateral lung at 1 and 2 weeks, respectively. Then, LuM-1
(2105 per mouse) was s.c implanted subcutaneously in the left flanks of
BALB/c mice. At day 8, mice were divided into 4 (control, RT, anti-PD-1 mAb,
RTanti-PD-1 mA) groups with each group containing 5 mice. In RT group,
mice received local RT at day 9 and 17. In brief, anesthetized mice were held in
the decubitus position, with the whole body except left flank tumor protected by
a lead shield and the ionizing irradiation (X-ray, 8Gy) was selectively delivered
to s.c. tumor usingMBR-1505R2 (HitachiMedical Co.) Anti-PD-1mAb (J43) or
control hamster mAb (0.5mg) was given at day 9,11,13 and 17,19,21 At day 28,
mice were sacrifıced and s.c tumor and lung metastases were quantifıed with
tumor size and lung weight, respectively. Results: S.c tumor was signifıcantly
reduced byRT and/or PD-1mAbwith additive effects. Thewhole lungweight in
PD-1 mAb group was 12064.0 gr, which was signifıcantly less than control
mAb group (30638.4 gr, p0.05) RT alone did not affect the lung weight
(29840.0 gr), however, RT if combined withPD-1 mAb, tended to further
reduce the lung metastases (69.031.5gr,. p0.12). Conclusion: Local RT and
PD-1 mAb is effective to prevent the growth of micrometastasis in non-irradi-
ated sites through the augmentation of abscopal effects. Combination of RT and
immune checkpoint inhibitors can be a new treatment strategy for locally ad-
vanced rectal cancer.
#616 The novel -Gal-based immunotherapy AGI-134 invokes CD8 T
cell-mediated immunity by driving tumor cell destruction, phagocytosis and
tumor-associated antigen cross-presentation via multiple antibody-medi-
ated effector functions. Jenny L. Middleton,1 Oliver Schulz,2 Amber Charle-
magne,1 Sascha A. Kristian,1 Stephen Michael Shaw1. 1Agalimmune Limited,
Sandwich, United Kingdom; 2The Francis Crick Institute, London, United King-
dom.
Background: AGI-134 is a fully synthetic -Gal (Gal1-3Gal1-4GlcNAc-R)
glycolipid that is being developed for the treatment of solid tumors. The -Gal
epitope is not expressed in humans, who, as a result of constant antigenic stim-
ulation by -Gal-bearing commensal bacteria, develop high titer natural anti-
bodies to -Gal. We have previously demonstrated that AGI-134 recruits anti-
Gal antibodies to tumor cells in vitro, activating complement and driving
phagocytosis by antigen presenting cells. AGI-134 also confers systemic protec-
tion from distal lesion development in a mouse model of melanoma and syner-
gizes with anti-PD-11. Here we present further data characterizing the multiple
pathways activated by the anti-Gal subclasses to drive AGI-134-mediated anti-
tumor immunity. Results: Using quantitative methods, we demonstrate that
human anti-Gal is composed of a diverse repertoire of effector antibodies in a
panel of serum samples, with IgM, IgG1 and IgG2 being the major subclasses.
Polyclonal anti-Gal IgG purifıed from human IVIG was, like human serum,
comprised mainly of IgG1 and IgG2. When AGI-134 treated cells were incu-
bated with human serum, binding of all anti-Gal subclasses was detected by flow
cytometry, demonstrating that all anti-Gal subclasses can interact with AGI-134
treated cells and are available to activate downstream effector functions. When
human serumwas depleted of IgG, AGI-134 stimulated complement dependent
cytotoxicity (CDC) was still effective, indicating that anti-Gal IgM is primarily
responsible for deposition of complement on AGI-134 treated cells. AGI-134
treated cells incubated with purifıed polyclonal anti-Gal IgG activated FcRIIIA
on a reporter cell line and promoted natural killer cell-mediated antibody-de-
pendent cell-mediated cytotoxicity (ADCC). Opsonization of AGI-134 treated
human cancer cells with human anti-Gal and complement stimulated their
phagocytosis by human monocyte-derived macrophages. Ovalbumin-express-
ing cells treated with AGI-134 and then incubated with human serum to initiate
CDC were specifıcally phagocytosed by murine CD8 dendritic cells and the
immunodominant antigen of ovalbumin, SIINFEKL, was cross-presented to
CD8 T cells. In conclusion, AGI-134 stimulates adaptive anti-tumor immu-
nity through immune activation and antigen cross-presentation, which is driven
by the diverse repertoire of anti-Gal antibodies. 1. Shaw, S. et al. Abstract 4862:
AGI-134: a fully synthetic alpha-Gal glycolipid that prevents the development of
distal lesions and is synergistic with an anti-PD-1 antibody in a mouse mela-
nomamodel. [abstract]. AACR;Cancer Res 2016;76(14 Suppl):Abstract nr 4862.
#617 Evaluating the in-vitro effects of tumor treating fıelds on T cell re-
sponses. Gil Diamant, Ilan Volovitz, Zvi Ram. Tel Aviv Sourasky Medical Cen-
ter, Tel Aviv, Israel.
BACKGROUND: Tumor Treating Fields (TTFields) are low-intensity elec-
trical fıelds that target proliferating cells by hindering formation ofmitotic spin-
dle and translocation of charged organelles. TTFields have been recently ap-
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proved for the treatment of both recurrent and newly diagnosed Glioblastoma
(GBM). Immunotherapeutic approaches for treatment of GBM are considered
promising, and multiple strategies are currently being evaluated in basic re-
search and clinical trials. Combining TTFields and immune-based therapies is a
rational approach as they possess markedly different mechanisms of action
(MOA). Conversely, TTFields may potentially abrogate various cellular func-
tions required for effective T cell responses. We performed an in-vitro evalua-
tion on the effect ofTTFields on select humanTcell functions that are pivotal for an
effective anti-tumoral response. The study objective was to evaluate the potential
compatibility between immune-based therapies and TTFields. METHODS: Pe-
ripheral blood mononuclear cells were isolated from healthy donors. Cells were
cultured under normal versus TTFields conditions using the inovitro TTFields
system, either with or without Phytohemaglutenin (PHA - a super antigen).
Cellular responses were monitored using an 8-color flow cytometry panel that
concurrently evaluated proliferation (CFSE dilution), cytokine secretion
(IFN), cytotoxic degranulation (CD107a surface presentation), and T cell ac-
tivation/ exhaustion (PD1 expression). The effect on T cell viability was assessed
in a separate assay, by comparing the live-to-dead ratio of cells cultured in
normal versus TTFields settings.RESULTS:TTFieldsdidnot alter the functionality
of non-activated T cells. Viable PHA-activated T cells cultured under TTFields ex-
hibited no change in PD1 up-regulation, IFN secretion and CD107a surface-ex-
pression.TheTcells exhibited reducedproliferation,which is in linewith theknown
MOAof TTFields. As the presence of polyfunctional T cells is associatedwith effec-
tive anti-tumoral responses, a single-cell level polyfunctionality analysis of activated
T cells was performed. The analysis demonstrated that under TTFields conditions
non proliferating cells retained all other combinations of immune functions. TT-
Fields were found to have a minor effect on the viability of un-activated T cells. In
activatedcells, therewasamoderate effectoncells thatdidnot attempt toproliferate,
but TTFields substantially reduced the viability rate of cells that had proliferated.
These fındings were true for both helper and cytotoxic T cells. CONCLUSIONS:
Pivotal T-cell response parameters, but not proliferation, were found to be unhin-
dered by TTFields. Our current data suggests that the integration of TTFields with
various immunotherapeutic approachesmaybe a rational strategy to explore for the
treatment of brain tumors.
#618 Toll-like receptor 2 costimulation potentiates the antitumor effıcacy of
CARTcells.PengLi,1XinDu,2YunXin,1 JianyuWeng,2 PeilongLai2. 1GIBH,CAS,
Guangzhou, China; 2Guangdong General Hospital, Guangzhou, China.
Chimeric antigen receptor (CAR) T cell immunotherapies have shown un-
precedented success in treating leukemia but lack effıcacy in solid tumors. Here,
we generated 1928zT2 and m28zT2, targeting CD19 and mesothelin, respec-
tively, by introducing the Toll/interleukin-1 receptor (TIR) domain of Toll-like
receptor 2 (TLR2) to 1928z and m28z. T cells expressing 1928zT2 or m28zT2
showed enhanced effector function, expansion and persistency against CD19
leukemic or mesothelin lung cancer cells in vitro and in vivo. In a patient with
relapsedB cell acute lymphoblastic leukemia, a single dose of 5104/kg 1928zT2
T cells resulted in robust expansion and leukemia eradication and led to com-
plete remission. Hence, our results demonstrate that TLR2 signaling is a con-
tributing component to CAR T cells for both leukemia and solid tumors and is
capable of increasing the effıcacy of CART cells and facilitating low dose clinical
usage.
#619 Effect of anti-PD-1 therapy on immune cells in the peripheral blood of
non-small cell lung cancer patients. Eleni-Kyriaki Vetsika,1 Galatea Kallergi,2 De-
spoina Aggouraki,1 Zaharoula Lyristi,1 Aristeidis Koukos,1 Despoina Kourougki-
aouri,1 FilipposKoinis,1VassilisGeorgoulias,1AthanasiosKotsakis1. 1Laboratory of
Translational Oncology, University of Crete, Heraklion, Greece; 2Department of Bio-
chemistry, University of Crete, School of Medicine, Heraklion, Greece.
Background: Programmed cell death-1 (PD-1), an inhibitory immune check-
point, plays a pivotal role in tumor immune escape. The interaction of PD-1with its
ligand (PD-L1) results inT cells exhaustion, and the blockade of this interaction can
partially restoreTcell function.Recently, antibodies targetingPD-1andPD-L1have
beenapproved for treatmentof advancedNonSmallCell LungCancer (NSCLC). In
this pilot study, we aimed to investigate the effect of anti-PD1 treatment or chemo-
therapy on the frequencies of circulating PD-1 T cells and PD-L1 immunosup-
pressive cells in NSCLC patients. Patients & Methods: Peripheral blood samples
were collected from35 advancedNSCLCpatients before initiation of treatment and
after 3 cycles. Twelve treatment-naïve patients received front-line chemotherapy,
whereas 23 patients received anti-PD1 treatment in the second-line setting. Flow
cytometry was used to quantify PD-1- and PD-L1-expressing immune cells.
Changes in the frequencies of these cells were compared between the two settings
and correlated with the clinical outcome. Results: Chemotherapy had no effect on
the percentages of PD-1CD4 and PD-1CD8 T cells after 3 cycles, whereas
therewas a signifıcant decrease inPD-1CD4 andPD-1CD8Tcells in patients
whoreceived3administrationsofanti-PD1antibody(p0.007andp0.05, respec-
tively). Moreover, the levels of PD-1-CD4 (p0.009) and PD-1-CD8 (p0.009)
were augmented in response to anti-PD-1 therapy. The frequencies of both periph-
eral CD4Tregs (CD3CD4CD25highCD127-/lowCD152FoxP3) and granulo-
cytic MDSCs (G-MDSC; CD14-CD15CD33CD11bHLA-DR-Lin-) expressing
PD-L1 were decreased following anti-PD1 therapy (p0.01 and p0.02, respec-
tively). Incontrast, chemotherapyaffectedonly thePD-L1CD4Tregs,butnot the
PD-L1G-MDSC, by increasing their levels after 3 cycles (p0.04). Anti-PD-1
treatment induced a superior reduction of the PD-1CD4, PD-1CD8 T cells,
PD-L1CD4 Tregs and PD-L1G-MDSCs percentages compared to the effect of
fırst line chemotherapy (p0.04, p0.05, p0.002 and p0.01, respectively). Fur-
thermore, a signifıcant decrease in PD-1CD8 T cells, PD-L1CD4 Tregs and
PD-L1G-MDSCs after 3 doses of anti-PD-1 was observed in patients who experi-
enced stable disease compared to baseline (p0.006, p0.05 and p0.03, respec-
tively). At the time of response evaluation to chemotherapy, the percentage of the
PD-L1CD4Tregsafter3cycleswas signifıcantly inferior compared tobaseline, in
disease progressors (p0.04). Conclusion: These data indicate that although che-
motherapy affected the levels of PD-L1CD4 Tregs, anti-PD1 therapy seems to
exert an effect on both PD1 T cells and PD-L1 immunosuppressive cells. Addi-
tional studies are needed in a larger cohort in order to document its impact on their
clinical relevance inNSCLCpatients. This study is ongoing andupdateddatawill be
presented at the meeting.
#620 Tumor microenvironment heterogeneity is not identifıed across
multiple histologically similar tumors from the same patient. Carl D. Morri-
son,1 Jeffrey Conroy,1 Sean Glenn,1 Blake Burgher,1 Sarabjot Pabla,1 Maochun
Qin,1 Antonios Papanicolau-Sengos,1 Jon Andreas,1 Vincent Giamo,1 Mary
Nesline,1 Shipra Gandhi,2 Manu Pandey,2 Nischala Ammannagari,2 Kunle
Odunsi,2Marc Ernstoff,2Mark Gardner1. 1OmniSeq, LLC, Buffalo, NY; 2Roswell
Park Cancer Institute, Buffalo, NY.
Introduction: Tumor heterogeneity has beenwell documented formutational
analysis in virtually all types of tumors and is accepted as a true fınding. Heter-
ogeneity of the tumor microenvironment (TME) in the context of response to
checkpoint inhibitors has not beenwell studied; the belief is that variationwill be
identifıed across multiple tumors from the same patient. The expectation is that
multiple tumors from a single patient would demonstrate extensive TME heter-
ogeneity driven by the neoplasm.Methods:We validated and utilized a targeted
RNA-seq immune panel of 350 genes to interrogate the TME of 49 different
tumors from 17 unique patients. These samples for one patient represented
primary and metastatic tumors that were separated by multiple years. Prior to
this study we built a reference database of RNA-seq immune results for this
panel of 167 samples. An in-depth analysis of genes associated with checkpoint
inhibition (CPI) and tumor infıltrating lymphocytes (TILs) were the focus of the
comparative analysis. Unsupervised analysis and gene rank by RNA-seq were
the primary modes of comparison. Results: For more than one-half of these
patients the different tumors for a single patient separated by multiple years
more closely resembled the other tumors from that patient than the reference
population by unsupervised clustering. When ranked by LOW, MODERATE,
or HIGH expression of genes associated with TILs or CPI the results for the
majority of patients were highly concordant: LOW TILs / LOW CPI associated
gene expression. Conclusion: Our results support a paradigm shift in the influ-
ence of the host on TME heterogeneity with evidence that the host and not the
neoplastic cells are the primary determining factor. TME heterogeneity is not
identifıed across multiple tumors of the same histology collected from different
sites across time points from the same patient. This study does not evaluate
multiple primary tumors from the same patient, but is an additional study we
have planned.
Subject
ID M-Path T-Path PMR
Specimen
Year
TILs
Score
TILs
Interpretation
CPI
Score
CPI
Interpretation
1 Melanoma Lymph node NOS Metastatic 2009 45 LOW 13 LOW
1 Melanoma Subcutaneous
tissue NOS
Metastatic 2010 8 LOW 2 LOW
2 Bladder cancer Urinary bladder
NOS
Primary 2012 37 LOW 16 LOW
2 Bladder cancer Urinary bladder
NOS
Primary 2013 10 LOW 11 LOW
2 Bladder cancer Soft Tissue Metastatic 2014 14 LOW 23 LOW
3 Melanoma Brain NOS Metastatic 2010 58 MODERATE 37 LOW
3 Melanoma Duodenum NOS Metastatic 2012 51 MODERATE 41 LOW
4 Melanoma Soft Tissue NOS Metastatic 2005 98 HIGH 88 HIGH
4 Melanoma Soft Tissue NOS Metastatic 2005 22 LOW 3 LOW
5 Melanoma Mesentery NOS Metastatic 2012 45 LOW 35 LOW
5 Melanoma Peritoneum NOS Metastatic 2014 87 HIGH 86 HIGH
6 Bladder cancer Urinary bladder
NOS
Primary 2009 5 LOW 4 LOW
6 Bladder cancer Lung NOS Metastatic 2012 43 LOW 41 LOW
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Subject
ID M-Path T-Path PMR
Specimen
Year
TILs
Score
TILs
Interpretation
CPI
Score
CPI
Interpretation
7 Melanoma Skin of Trunk
NOS
Metastatic 2011 4 LOW 4 LOW
7 Melanoma Chest wall NOS Metastatic 2012 2 LOW 1 LOW
7 Melanoma Soft Tissue Metastatic 2012 25 LOW 25 LOW
8 Lung
adenocarcinoma
Lung right upper
lobe of, NOS
Primary 2009 99 HIGH 88 HIGH
8 Lung
adenocarcinoma
Lung right upper
lobe of, NOS
Primary 2016 88 HIGH 80 HIGH
9 Melanoma Lymph node NOS Metastatic 2009 2 LOW 5 LOW
9 Melanoma Small intestine
NOS
Metastatic 2011 0 LOW 1 LOW
10 Melanoma Skin of Lower
Extremity NOS
Metastatic 2012 16 LOW 8 LOW
10 Melanoma Lymph node NOS Metastatic 2012 43 LOW 31 LOW
10 Melanoma Skin of Lower
Leg NOS
Metastatic 2013 4 LOW 13 LOW
11 Melanoma Lung left lower
lobe of, NOS
Metastatic 2012 14 LOW 5 LOW
11 Melanoma Skin of Scalp
NOS
Primary 2010 22 LOW 20 LOW
12 Lung
adenocarcinoma
Lung NOS Primary 2010 89 HIGH 77 HIGH
12 Lung
adenocarcinoma
Brain NOS Metastatic 2014 41 LOW 13 LOW
13 Melanoma Liver NOS Metastatic 2011 66 MODERATE 51 MODERATE
13 Melanoma Lymph node NOS Metastatic 2011 47 LOW 13 LOW
14 Renal cell
carcinoma
Lung right lower
lobe of, NOS
Metastatic 2013 95 HIGH 87 HIGH
14 Renal cell
carcinoma
Adrenal gland
NOS
Metastatic 2014 65 MODERATE 71 MODERATE
15 Lung
adenocarcinoma
Lung right
middle
lobe of, NOS
Primary 2014 88 HIGH 75 HIGH
15 Lung
adenocarcinoma
Brain NOS Metastatic 2015 26 LOW 1 LOW
16 Melanoma Tonsil NOS Metastatic 2014 62 MODERATE 53 MODERATE
16 Melanoma Soft Tissue Metastatic 2015 13 LOW 1 LOW
17 Melanoma Dura Mater NOS Metastatic 2015 53 MODERATE 16 LOW
17 Melanoma Lymph node NOS Metastatic 2015 99 HIGH 88 HIGH
#621 Tumor suppressor TUSC2 immunogene therapy is synergistic with
anti-PD1 in lung cancer syngeneic mouse models. Ismail M. Meraz, Mourad
Majidi, RuPing Shao, Meng Feng, Xiaobo Cao, David Rice, Boris Sepesi, Lin Ji,
Jack Roth. UTMD Anderson Cancer Ctr., Houston, TX.
TUSC2, a pro-apoptotic tumor suppressor gene whose expression is lost or de-
creased inmost lung cancers, activates the innate immune system through initiation
of broad spectrumcytokine secretion andnatural killer (NK) cell activation.TUSC2
delivered systemically by nanovesicles hasmediated tumor regression inmetastatic
non-small cell lungcancer clinical trials.Westudied theeffectofTUSC2on immune
cell populations and the anti-tumor activity of TUSC2 in combination with anti-
PD1 checkpoint blockade in two syngeneicmousemodels: C57BL/6mice subcuta-
neously injected with murine lung adenocarcinoma cell line CMT/167-luc cells
(KrasG12V mutation) and 344SQ (KrasG12D allele and a knock-in
Trp53R172H	G allele) adenocarcinomas which metastasize to the lung in 129S2
mice.Tumorgrowthwasmonitoredbyscoringex-vivo luminescenceusing the IVIS
Imaging System 200.Multi-color flow cytometry was used for immune profıling of
circulating immune cells after nanovesicle mediated TUSC2 intravenous injection.
Cytokine gene expression in response to TUSC2 in sorted immune subpopulations
was determined by real-time PCR. Tumor growth was signifıcantly reduced with
TUSC2 treatment compared with no treatment in both subcutaneous and meta-
staticmousemodels. Synergistic anti-tumoractivitywasobservedwhenTUSC2was
combined with anti-PD1 verifıed in fıve independent experiments. In the lungme-
tastasismodel,mice treatedwithTUSC2 anti-PD1 lived signifıcantly longer than
with single agent treatment. Circulating NK cells increased three fold following
TUSC2 nanovesicle intravenous injection both in tumor free and tumor bearing
micewhich correlatedwith tumor regression and survival. Cytotoxic T lymphocyte
responses were increased whereas Tregs andMDSCs decreased with TUSC2 alone
and TUSC2anti-PD1 treatment. The levels of T cell checkpoint markers PD1,
CTLA-4, LAG-3, and TIM-3 evaluated by flow cytometry were decreased after
TUSC2 treatment. TUSC2 anti-tumor response was abolished when NK cells were
depleted indicatingNKcells are importantmediatorsof theTUSC2treatmenteffect.
Single cell suspension analysis by flow cytometry showed high numbers of NK cells
infıltrating lung tumor metastases after TUSC2 treatment. The number of tumor
nodules in the lung was signifıcantly less following treatment with TUSC2 nano-
vesicles comparedwith control. IL-15 gene expressionwhichmediatesNK cell pro-
liferation, was increased by TUSC2. In conclusion, systemic TUSC2 nanovesicle
immunogene therapy combinedwith checkpoint blockade showed synergistic anti-
tumor effıcacy and activated the immune system through upregulation of NK cells
and CTL and downregulation of regulatory cells.
#623 Identifying candidate antigens for a ductal carcinoma in situ vaccine
that are essential to breast cancer survival across multiple subtypes. Sasha
Elizabeth Stanton, Erik Ramos, James Annis, Andrew Timms, Tessa Rue, Mary
L. Disis. Univ. of Washington, Seattle, WA.
Vaccine therapy may be ideal to destroy ductal carcinoma in situ (DCIS) and
prevent recurrence. A vaccine can induce type 1 T-cells against DCIS antigens
that could migrate from the circulation to invade and destroy the tumor as well
as generate immunologic memory to provide long lasting protective immunity.
One of the limitations to developing a DCIS vaccine is identifying antigens that
target all subtypes of DCIS. DCIS hasmany of the samemolecular abnormalities
as invasive breast cancer (IBC), including overexpressed proteins that may be
drivers of progression to invasive disease. Eliminating cells that are overexpress-
ing driver proteins by vaccination may prevent progression to IBC if such pro-
teins could be determined. In this study, we identifıed proteins that were over-
expressed from normal breast in both DCIS and IBC across fıfteen Geo and
Array Express data sets. From 68 candidate proteins, we identifıed twelve whose
expression was necessary for cancer cell survival across breast cancer subtypes.
We selected overexpressed proteins necessary for cancer survival using a high
throughput siRNA screen and chose candidates that increased apoptosis and
decreased cell survival in HER2 positive (HER2), triple negative (TN), and hor-
mone receptor positive HER2 negative (HR) human breast cancer cell lines with
decreased expression of the target protein. For example, decreased expression of
NDC80 caused decreased cell survival to 563% in HR, 463% in TN, and
772% in HER2 breast cancer cell lines and increased apoptosis by 1.40.03
fold in HR and 1.20.03 fold in TN breast cancer cell lines. Decreased expres-
sion of RRM2 caused decreased cell survival to 663% in HR and 892% in
HER2 breast cancer cell lines and increased apoptosis by 1.60.08 fold in HR,
1.40.07 fold in TN, and 2.40.3 fold in HER2 breast cancer cell lines. Twelve
proteins (AURKA, KIF11, NDC80, RRM2, SDC1, UBE2C, HJURP, CENPA,
CENPF, HIST2H2AA3, HIST1H2BD, and TOP2A) were essential for cancer
cell survival in at least 2 breast cancer subtypes. These protein targets are immu-
nogenic in patients with DCIS. In the sera of women without breast atypia
(n36), autoantibodies toNDC80were detected with amean of 5.31.8 ng/mL
while inwomenwith fıbroadenoma (n36) autoantibodies were detectedwith a
mean of 8.31.5 (p0.05). In the sera of women without breast atypia (n36),
autoantibodies to RRM2were detected with amean of 0.160.7 ng/mLwhile in
womenwith fıbroadenoma (n36) autoantibodieswere detectedwith amean of
7.22.1 (p0.05) and in women with DCIS (n59) autoantibodies were de-
tected with a mean of 2.60.6 ng/mL (p0.0003). These proteins represent
DCIS antigens of biologic importance in tumor growth and, potentially, pro-
gression to IBC and are candidate immunogens for a vaccine to treat DCIS.
#624 Characterization of PD-L1 expression and the immune cellmicroen-
vironment in hepatocellular carcinoma (HCC) and non-cirrhotic liver tissue
adjacent to HCC. Christian Ihling,1 Sienna Yoast,2 Yue Zhang,3 Bartholomew
Naughton,3 Miriam Urban,1 P. Alexander Rolfe,3 Eveline Frick-Krieger,1 Isa-
belle Dussault3. 1Merck KGaA, Darmstadt, Germany; 2Dako North American,
Carpinteria, CA; 3EMD Serono Research and Development Institute Inc., Bil-
lerica, MA.
Still-emerging evidence suggests that HCC is at least moderately responsive to
therapeutic agents that target tumor immune suppression pathways, specifıcally the
programmed death 1/programmed death ligand 1 (PD-L1) pathway. Prior studies
raise the possibility that PD-L1 is a prognostic biomarker inHCC,where its expres-
sion levelshavebeenreported tocorrelatewith tumoraggressivenessandrecurrence
followingsurgical resection.Thepurposeof this studywas toevaluate theexpression
of PD-L1 in non-cirrhotic liver tissue adjacent to HCC and HCC itself in 68 pro-
cured tissue samples, as well as elucidate the immune cell composition of the HCC
tumor microenvironment. All cases showed the typical morphology of HCC and
were classifıed as low- to high-grade trabecular, pseudoglandular, or solid with the
common cytoplasmic features. Immunohistochemical (IHC) staining for PD-L1 in
tumor-free liver (TFL) revealed PD-L1 staining in sinusoidal lining cells (macro-
phages [M] and endothelial cells [EC], as confırmed by double labeling for CD68
and CD31), although there was considerable heterogeneity in the extent of PD-L1
staining.More specifıcally, in TFL, some but not all CD68Mwere also PD-L1,
whereas most CD31 EC were also PD-L1. Furthermore, we evaluated PD-L1
staining qualitatively and semiquantitatively in HCC. Only few tumor cells dis-
played membranous PD-L1 staining, and 62/68 of the cases (91.2%) were catego-
rized as PD-L1- vs 6/68 (8.8%) PD-L1 (	1% and 25%  PD-L1); instead,
PD-L1 expression within the tumor microenvironment predominantly emanated
from immune cell infıltrates (as confırmed by PD-L1/pan-cytokeratin double label-
ing). Then we assessed the immune milieu in HCC tissue specimens using quanti-
tative IHC. We found considerable interspecimen variation in the number of
CD68 M, CD8 cytotoxic T lymphocytes, and FoxP3 regulatory T lympho-
cytes. Comparing the number of immune cells in different tumor compartments
showed that the prevalence of CD68 cells (p.0005), CD8 cells (p.0004), and
FoxP3

cells (p.05)was signifıcantly higherwithin the invasivemargin vs the cen-
ter of the tumor. Quantitative analysis of the immune cell content also showed that
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there was no correlation between T lymphocyte infıltration (CD8/FoxP3) and
M infıltration in any compartment. Taken together, our fındings confırm the in-
tertumoral heterogeneity of the immune cell microenvironment inHCC; however,
future studies are needed to correlate these fındings to the clinical setting with im-
munooncologic treatments.
#625 Eradication of cancer cells by T-cell receptor-engineered T cells tar-
geting neoantigens/oncoantigens. Tatsuo Matsuda,1 Taigo Kato,1 Yuji Ikeda,1
Matthias Leisegang,2 Sachiko Yoshimura,3 Tetsuro Hikichi,3 Makiko Harada,1
Makda Zewde,1 Jae-Hyun Park,1 Hans Schreiber,1 Kazuma Kiyotani,1 Yusuke
Nakamura1. 1University of Chicago, Chicago, IL; 2Charité Campus Buch, Ger-
many; 3OncoTherapy Science Inc, Japan.
Cytotoxic T lymphocytes (CTLs) play critical roles in cancer-immune responses,
and functional characterization of CTLs and their cancer-specifıc antigens will fa-
cilitate cancer immunotherapies. Immunogenic peptides, which can be derived
from oncogenic proteins specifıcally expressed in cancer cells but not expressed in
normal organs except testis (oncoantigens), or frompeptides with somatic nonsyn-
onymousmutations (neoantigens), are known as good targets forCTLs to eradicate
cancer cells. In this study, we aimed to establish a method to effıciently identify
oncoantigen/neoantigen-specifıc CTLs. Firstly, we screened candidate HLA-
A2402-restricted oncoantigen/neoantigen peptides by in silico prediction of their
binding affınity toMHCclass Imolecules.We conducted an in-vitro stimulation of
CD8 lymphocytes carryingHLA-A24:02 allele by each peptide, and then confırmed
clonal expansion of the peptide-specifıc CTLs by TCR repertoire sequencing analy-
sis, interferon- enzyme-linked immunospot (ELISPOT) and/or peptide-HLA
multimer assays. After identifıcation of TCR alpha-beta pairs, we conducted retro-
viral transduction and prepared the TCR-engineered T cells to evaluate their cyto-
toxic activities against cancer cells. As oncoantigens, we isolated the CTLs for
FOXM1 and UBE2T from healthy donors, and found these CTLs showed strong
cytotoxicity againstHLA-A2402-positive cancer cells expressing targetproteins, but
not against HLA-unmatched cancer cells. Similarly, the TCR-engineered T cells for
FOXM1 and UBE2T showed killing effects for only HLA-A2402-positive cancer
cells. Neoantigen-specifıc TCR-engineered CTLs also exhibited the mutated pep-
tide-specifıc response, but did not cross-react to the nonmutated peptide. In addi-
tion, neoantigen-specifıc cytotoxicity was observed against HLA-A2402-positive
cancer cells expressing theproteinswith target somaticmutations. Inconclusion,we
developed the pipeline to screen possible onconatigens/neoantigens and establish
antigen-specifıc TCR-engineered CTLs from peripheral blood lymphocytes. Our
approach provides a promising strategy to develop personalized immunotherapies
using onconatigen/neoantigen-reactive TCR-engineered T cells to treat cancer.
#626 BGB324, a selective smallmolecule inhibitorof receptor tyrosinekinase
AXL, abrogates tumor intrinsic andmicroenvironmental immune suppression
and enhances immune checkpoint inhibitor effıcacy in lung andmammary ad-
enocarcinoma models. Katarzyna Wnuk-Lipinska,1 Kjersti Davidsen,2 Magnus
Blø,1 Agnete Engelsen,2 Jing Kang,2 LinnHodneland,1 Maria Lie,2 Sebastien Boug-
naud,2 Kristina Aguilera,1 Lavina Ahmed,1 Agata Rybicka,1 Eline Milde Nævdal,1
PaulinaDeyna,1 Anna Boniecka,1 StraumeOddbjørn,3 SalemChouaib,4 Rolf Brek-
ken,5 Gro Gausdal,1 James B. Lorens2. 1BerGenBio AS, Bergen, Norway; 2University
ofBergen,Bergen,Norway; 3HaukelandUniversityHospital andUniversityofBergen,
Bergen, Norway; 4Institut Gustave Roussy, Université Paris-Sud, Paris, France; 5UT
SouthwesternMedical Center, Dallas, TX.
The AXL receptor tyrosine kinase is associated with poor overall survival in a
wide spectrum of cancers including lung and breast adenocarcinomas. AXL
signaling is an important regulator of tumor plasticity related to epithelial-to-
mesenchymal transition (EMT) and stem cell traits that drive metastasis and
drug resistance. Signaling via AXL is also a key suppressor of the anti-tumor
innate immune response, and AXL is expressed on several cells associated with
the tumor immune microenvironment including natural killer (NK) cells and
tumor-associated macrophages. Hence AXL resides uniquely at the nexus be-
tween tumor and microenvironmental anti-tumor immune suppression mech-
anisms. We report that BGB324, a selective clinical-stage small molecule Axl
kinase inhibitor, enhances the effect of immune checkpoint blockade in aggres-
sive adenocarcinoma models with limited immunogenicity by targeting both
tumor intrinsic and microenvironmental immune suppression. Immune ther-
apy with anti-CTLA4/PD1 in the 4T1 model increased AXL and EMT-marker
expression correlating with a lack of response. Combination with BGB324 re-
sulted in durable primary tumor clearance versus anti-CTLA4/PD1 alone. In a
separate study, BGB324 anti-CTLA4 treatment resulted in signifıcant long-
termprimary tumor clearancewhile no responsewas observedwith anti-CTLA4
treatment alone. The extensive metastasis to the lung, liver and spleen charac-
teristic of the 4T1 model was not detected in animals responding to the combi-
nation treatment. Importantly, responding animals rejected orthotopic 4T1 tu-
mor cell re-challenge, demonstrating sustained tumor immunity. In the LL2
Lewis Lung model, BGB324 in combination with anti-PD1/PDL1 signifıcantly
prevented tumor growth compared to treatment with anti-PD1/PDL1. Tumors
from mice treated with BGB324 in combination with immune checkpoint in-
hibitors displayed reduced EMT traits, altered cytokine expression, enhanced
tumor infıltration of effector cells and decreased number of mMDSC. Also,
BGB324 signifıcantly reduced IL10 secretion by isolated human macrophages
and enhanced human NK-cell mediated NSCLC tumor cell lysis. Collectively
these results support a prominent role for AXL in resistance to immune therapy
and support clinical translation of combining BGB324with immune checkpoint
inhibitors to improve cancer treatment.
IMMUNOLOGY: Tumor Antigens and Adaptive Immunity
#627 NLRC5 co-mutations are associated with impaired antigen presen-
tation and immune exclusion inKRAS-mutant lung adenocarcinoma. Ferdi-
nandos Skoulidis, Taghreed Hirz, Xiang Dong Lee, Jaime Rodriguez Canales,
Edwin R. Parra, Pan Tong, Carmen Behrens, Vassiliki A. Papadimitrakopoulou,
Jing Wang, Ignacio Wistuba, John V. Heymach. UTMD Anderson Cancer Ctr.,
Houston, TX.
Background: We recently reported that co-occurring genetic events consti-
tute major determinants of the molecular diversity of KRAS-mutant lung ade-
nocarcinoma (LUAC) (Skoulidis et al., CancerDiscovery, 2015).However, com-
prehensive evaluation of the functional impact of KRAS co-mutations on key
cancer hallmarks is thus far lacking. Here, we fınd that inactivatingmutations in
NLRC5, a major transactivator of MHC class I molecules, are signifıcantly en-
riched in KRAS-mutant LUAC and examine the impact of NLRC5 loss on the
composition of the tumor immune microenvironment. Methods: Our cohorts
consist of 513 LUACs from the TCGA (145 KRAS-mutant), 152 chemotherapy-
naïve surgically resected LUAC from the PROSPECT cohort, 20 platinum-re-
fractory KRAS-mutant LUAC from the BATTLE-2 clinical trial, as well as a
panel of 31 KRAS-mutant NSCLC cell lines. Analysis of immune cell sub-pop-
ulationwas performedusing automated IF-based enumeration.Antigen presen-
tation score was defıned as the geometric mean mRNA expression of HLA-A,
HLA-B, HLA-C and 2M. Results: In an unbiased analysis for genes signifı-
cantly co-mutated with KRAS in LUAC (TCGA cohort) we identifıed NLRC5
(NLR family, CARD domain containing 5), encoding a recently discovered ma-
jor transactivator of MHC class I genes (11% of KRAS-mutant LUAC, odds
ratio 2.99, P0.0197).The spectrum of NLRC5 somatic mutations includes sev-
eral nonsense and frameshift mutations, as well as missense mutations, many of
which are predicted to abrogate normal NLRC5 function. In the TCGA cohort,
KRAS/NLRC5 co-mutated tumors exhibited lower antigen presentation score
compared to KRAS-mutant NLRC5 wild-type tumors (P0.0369, t-test).
AmongKRAS-mutant LUAC from the TCGA, PROSPECT, BATTLE-2 cohorts
expression of NLRC5 mRNA correlated tightly with the expression of core an-
tigen presentation pathway components including HLA-A, HLA-B, HLA-C,
2M, TAP1, TAP2, PSMB8 and PSMB9 [in BATTLE-2: HLA-A r0.7616,
P9.572e-05, HLA-B r0.834, P4.884e-06, HLA-C r0.8029, P2.036e-05,
TAP1 r0.8189, P1.009e-05 ]. Similar results were obtained in a panel of 31
KRAS-mutant NSCLC cell line. Thus, both mutational and non-mutational
mechanisms can account for NLRC5 inactivation. Finally, in a tumor microar-
ray encompassing surgically resected, chemotherapy naïve LUAC (PROS-
PECT), NLRC5-low tumors (lower tertile for NLRC5 mRNA expression,
N34), exhibited reduced density of infıltrating CD3 (P0.0001, Mann-
Whitney U test), CD8(P0.0001, Mann-Whitney U test) as well as PD-1
cells (P0.0001, Mann-Whitney U test) and PD-L1 Histo-score (P0.0036,
Mann-Whitney U test) compared to NLRC5-high tumors (N41). Conclu-
sions: Co-mutations in NLRC5, are enriched in KRAS-mutant LUAC and are
associated with immune exclusion. KRAS co-mutations can shape the tumor
immune micro-environment and may therefore predict for response - or lack
thereof- to immunotherapy.
#628 Neoantigens predicted by clonalmutation analysis in lung adenocar-
cinoma patients. Dapeng Zhou,1 Weijing Cai,1 Deng Pan,1 Tan Wen Ling,1
Jiaqian Wang,1 Caichun Zhou,1 Yanyan Lou2. 1Shanghai Pulmonary Hospital
affıliated with Tongji University School of Medicine, Shanghai, China; 2Mayo
Clinic, Jacksonville, FL.
Mutant peptides presented in cancer are superior vaccine candidates than self
peptides. The effıcacy ofmutant K-Ras, P53 andEFGRpeptides have been tested
as cancer vaccines in pancreatic cancer, colorectal cancer, and lung adenocarci-
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noma. However, the occurrence of these mutations in cancer is limited. Further
more, these mutant peptides can only be presented by certain MHC alleles.
Neoantigens expressed by passenger mutations which are not involved in com-
mon proliferative molecular pathways are potential candidates for personalized
vaccine design. Such passenger mutations have drawn attention by the recent
clinical data that colorectal cancerwith a large number of somaticmutations due
to mismatch-repair defects are more susceptible to immune checkpoint block-
ade by PD1 antibody therapy. In this study, we analyzed the next generation
sequencing data of 147 lung adenocarcinoma patients from The Cancer Ge-
nome Atlas and predicted neoantigens presented by MHC Class I and Class II
molecules. We found 18175 expressed clonal somatic mutations, with an aver-
age of 124 per patient. Based on such somatic mutations, we predicted 8731
neo-peptides, among which 3888 strong-binders and 4843 weak-binders to
MHC Class I molecules were found by NetMHCPan. For HLA-A*02:01, 778
strong binding and 822 weak binding neo-peptides were found. In average, 11
neo-antigen peptides of mutations were predicted per individual patient with
HLA-A*02:01 allele. Smokers expressed 5.73 fold higher mutant neo-antigen
peptides than non-smokers. The 20 most commonly mutated genes with pre-
dicted neo-antigens are TTN, RYR2, MUC16, KRAS, ZFHX4, TP53, USH2A,
NAV3, KEAP1, ANK2, DNAH9, ADAMTS12, CSMD1, CSMD3, SPTA1,
FAT3, ZNF804A, PAPPA2, PCLO, EGFR.As a positive control, the frequency of
known proliferation-related mutations (KRAS, P53, and EGFR) were deter-
mined in 147 patients, which are consistent with previously next generation
sequencing studies of lung adenocarcinoma. Mutation hotspots were found in
proliferation-related mutations (KRAS), but not in passenger mutations. 6950
neo-peptides, including 259 strong binders and 6691 weak binders were found
for HLA DRB1, an MHC Class II molecule. INDEL mutation type of neo-
epitopes were found in 119 of 147 patients, with an average of 4.34 INDEL
mutations presented by MHC Class I and 0.86 INDEL mutations presented by
MHC Class II molecule HLA DRB1 in every patient. Our results support the
feasibility of discovering individualized mutant peptides as candidates for im-
munodiagnosis and immunotherapy of lung adenocarcinoma. Neo-epitopes
which can be presented by both MHC Class I and MHC Class II molecules are
attractive targets for designing long-peptide vaccines.
#629 An integrated genomic and proteomic analysis of human tumors
reveals key factors in neoantigen identifıcation and enables epitope predic-
tion for cancer immunotherapy. Brendan Bulik-Sullivan, Jennifer Busby,Mat-
thew Davis, Andrew Clark, Tyler Murphy, Michele Busby, Fujiko Duke, Jessica
Smith, Jason Hudak, Adnan Derti, Josh Francis, Roman Yelensky. Gritstone
Oncology, Inc, Cambridge, MA.
Background: Immunotherapy has become essential in the treatment of ad-
vanced cancer, with the advent of drug approvals in multiple indications and
functional cures for a minority of patients. However, overall survival gains from
immunotherapy have been limited and substantial progress remains. The dis-
covery of tumor-specifıc neoantigens as principal targets of T cells unleashed by
immune checkpoint blockade was a key breakthrough in immunotherapy re-
search. Although example neoantigens have been reported, the impact of
genomic features on HLA presentation and neoantigen identifıcation has not
been comprehensively assessed. Moreover, in silico methods for predicting
which mutations lead to neoantigens are currently inadequate for most thera-
peutic applications, with a false positive rate of95%. Methods: We performed
deep tumor/normal exome sequencing (Illumina-based, average unique depth
557x/149x), tumor transcriptome sequencing (avg. 111M unique reads), and
mass spec HLA class I peptide sequencing (Thermo Lumos, avg. 3,482 peptides)
on fresh-frozen primary tumor specimens from 23 patients (22 NSCLC, 1 OC).
Somatic mutations were called with a custom GATK-based pipeline, gene ex-
pression assessed with RSEM, and peptides matched to mass spectra using
COMET/Percolator. We examined the effect of NGS parameters on neoantigen
identifıcation, analyzedHLApresentation as a function of genomic features, and
created a novel deep learning model for epitope prediction. Results: We identi-
fıed 6,252 nonsynonymous somatic mutations across the cohort (avg. 272 per
patient) and found 3,874 (62%) transcribed in mRNA. Down-sampling tumor
DNANGSdata to amore typical average unique coverage of200x andRNA to
60M reads revealed 3,275 transcribed mutations, an overall 15% loss of can-
didate neoantigens and25% loss in low tumor content samples, demonstrat-
ing the importance of sequencing depth. Gene expression measurement at the
RNA level predicted HLA presentation more strongly than expected, with pep-
tides from genes detected in RNA found presented20X more often than pep-
tides from non-detected genes.With this and public datasets we trained amodel
to predict HLA presentation and compared it to standard binding affınity pre-
diction (e.g., NetMHC or MHCflurry) at the strong-binder 50nM threshold for
well-characterized alleles.Whereas binding affınity-based prediction gave a pos-
itive predictive value (PPV) of only 3%, our integrated deep learning approach
showed a PPV of25% at equivalent recall, a near ten-fold gain. Conclusions: A
novel genomic and proteomic analysis of human tumors establishes NGS re-
quirements for neoantigen identifıcation, characterizes key correlates of HLA
presentation, and enables prediction for personalized cancer immunotherapy
research.
#630 Inactivation of DNA repair triggers dynamic neoantigen evolution
and impairs cancer growth. Giovanni Germano, Simona Lamba, Giuseppe
Rospo, Alessandro Magrì, Federica Maione, Mariangela Russo, Nabil Amir-
ouchene Angelozzi, Ludovic Barault, Monica Montone, Federica Di Nicolanto-
nio, EnricoGiraudo,Alberto Bardelli.Candiolo Cancer Institute, Candiolo (TO),
Italy.
Colorectal, ovarian, endometrial and other tumors carrying defects in DNA
mismatch repair often show favorable prognosis and indolent progression. The
genomes of these tumors -also known as microsatellite unstable (MSI) cancers-
bear hundreds of thousands of somaticmutations, a featurewhich fosters cancer
progression and rapid evolution of resistance to targeted therapies. The molec-
ular bases for the favorable outcome of MMR defıcient cancers have long re-
mained amystery. Recent evidences that a subset ofMSI tumors respond prom-
inently to anti-immune checkpoint blockade led to the seminal hypothesis that
the presence of high number of somatic mutations may be responsible for effec-
tive immune-surveillance.However, several reports indicate that a relevant frac-
tion of hyper-mutated tumors have unfavorable prognosis and do not respond
to immune-modulators. Intrigued by these contradictory fındings, we used the
CRISPR system to genetically inactivated MutL homolog 1 (MLH1) in colorec-
tal, breast and pancreaticmouse cancer cells. The growth ofMMRdefıcient cells
was comparable to their profıcient counterparts in vitro and upon transplanta-
tion in immune-compromised mice. Strikingly however, isogenic MMR defı-
cient colorectal, breast and pancreatic cancer cells were largely unable to form
tumors when injected subcutaneously or orthotopically in syngeneic mouse
models. MMR defıcient tumors initially established in immunodefıcient mice
continued to grow exponentially when transplanted in syngeneic animals but
regressed promptly when immune checkpoint inhibitors (anti PD-1 and anti
CTLA-4) were administered. Exome sequencing of MMR profıcient cells re-
vealed mutational loads and neo-antigen profıles that were stable over time.
MMR inactivation further increased the mutation burden and led to highly
dynamic mutational profıles, resulting in persistent renewal of neoantigens.
These results led us hypothesize that enforced increase of the number of muta-
tions in cancer cells could be -paradoxically- benefıcial for therapeutic purposes.
We therefore performed a pharmacological screen to identify agents capable of
permanent inactivation of MMR in colorectal, breast and PDAC cancer cells.
We found that temozolomide triggers MLH1 inactivation and leads to rapid
clonal evolution and dynamic neoantigen profıles. Temozolomide-treated cells
were unable to form tumors in syngeneic animals, while cells treated with other
alkylating agents did. Genomic analysis of these tumor models revealed that
fluctuating levels of neoantigens, rather than the absolute number of mutations
is critical to provoke immune surveillance. These results provide the rationale
for developing innovative anticancer therapies that target DNA repair proteins.
#631 Dual-specifıc T cells are highly effective in eradicating solid tumors.
Clare Y. Slaney, Bianca von Scheidt, Phillip K. Darcy,Michael H. Kershaw. Peter
MacCallum Cancer Centre, Melbourne, Australia.
Chimeric antigen receptor (CAR) T cell therapy is a novel form of adoptive
cellular therapy and has recently generated remarkable effects in patients with
hematological cancers. However, the success against solid cancers has been
modest. The major challenges are the hostile tumor microenvironment and the
low effıciency of CAR T cells infıltrating the tumor. Here, we present a major
advancement in CAR T therapy that eradicated large established solid cancers,
some in excess of 150mm2, in immunocompetentmice.We hypothesized that a
vaccine composed of a recombinant poxvirus could be used as an antigen deliv-
ery vehicle to specifıcally activate CAR T cells through their T cell receptor
(TCR) and simultaneously change the tumor microenvironment, allowing the
recruitment and activation of CAR T cells. The approach involves adoptive cell
transfer incorporating vaccination (ACTIV) therapy. We generated dual-spe-
cifıc T cells expressing a CAR specifıc for the tumor antigen Her2 and a TCR
specifıc for the melanocyte protein (gp100). Injection of T cells, together with
recombinant vaccinia virus expressing gp100, induced durable complete remis-
sion of a variety of Her2 tumors and established metastases, some in excess of
150mm2, in immunocompetentmice expressingHer2 in normal tissues, includ-
ing the breast and brain. Tumor destruction mediated by dual-specifıc T cells
occurred rapidly over a period of seven days and was associated with an exten-
sive proliferation and infıltration of the dual-specifıc CAR T cells. Mice that had
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rejected tumors were resistant to rechallenge with the same Her2 tumor cells
and partially resistant to rechallenge with Her2- tumor cells, indicating the for-
mation of immune memory and epitope spreading. This mouse model study
supports the view that it is possible to design a highly effective CAR T cell
therapy for solid cancers and metastases, even when the target antigen is also
expressed in vital tissues. To explore the translational potential for using the dual
specifıc CAR T cell strategy, we established methods to transduce the T cells
from human peripheral blood with both a TCR specifıc for gp100 and a CAR for
Her2. From as little as 1 ml of human buffy coat, we could generate more than
109 dual-specifıc CAR T cells, which is suffıcient for a course of treatment. The
human dual-specifıc CAR T cells were functional in secreting IFN- and killing
human cancer cells when co-cultured with the gp100 orHer2 expressing human
cancer cells. The stimulation of gp100 through TCR enhanced the dual-specifıc
CAR T cell proliferation, secretion of IFN- and killing of Her2 human cancer
cells in vitro. These characteristics were identifıed to be important for eradicat-
ing tumors in the mouse models. Taken together, our data provide valuable
information for the development of CAR T cell therapies for patients with solid
cancers.
#632 Genome-scale neoantigen screening using ATLAS™ prioritizes can-
didate antigens for immunotherapy in a non-small cell lung cancer patient.
Lila Ghamsari,1 Emilio Flano,1 Judy Jacques,1 Biao Liu,1 Zheng Yan,1 Aula
Alami,1 Christine Kelley,1 Theresa Zhang,1 Jonathan Havel,2 Vladimir Ma-
karov,2 Taha Merghoub,2 Jedd D. Wolchok,2 Matthew Hellman,2 Pamela Car-
roll,1 Timothy Chan,2 Jessica B. Flechtner1. 1Genocea Biosciences, Cambridge,
MA; 2Memorial Sloan Kettering Cancer Center, New York, NY.
Despite the unprecedented effıcacy of checkpoint blockade (CPB) therapy
in treating some cancers, the majority of patients fail to respond. Several
lines of evidence support that the combination of CPB and neoantigen vac-
cine prolongs survival curves in cancer patients. Capitalizing on neoantigens
derived from non-synonymous somatic mutations is a good strategy for
therapeutic immunization. Current approaches to neoantigen prioritization
involve mutanome sequencing, in silico epitope prediction algorithms, and
experimental validation of cancer neoepitopes. Even the best in class in silico
epitope prediction algorithms lack the accuracy necessary for effıcacious
personalized cancer vaccines. We sought to circumvent some of the limita-
tions of currently available prediction algorithms by prioritizing neoanti-
gens empirically using ATLAS™, a technology developed to screen T cell
responses from any subject against their entire complement of potential
neoantigens. Exome sequences were obtained from peripheral blood mono-
nuclear cells (PBMC) and tumor biopsies from a non-small cell lung cancer
patient who had been successfully treated with pembrolizumab. The tumor
exome was sequenced and somatic mutations were identifıed. Individual
DNA sequences (399 nucleotides) spanning each mutation site were built,
cloned and expressed in E. coli co-expressing listeriolysin O. Polypeptide
expression was validated using a surrogate T cell assay or by Western Blot-
ting. Frozen PBMCs, collected pre- and post-therapy, were used to derive
dendritic cells (MDDC). Both CD4 and CD8 T cells were enriched and
expanded using microbeads. The E. coli clones were pulsed onto MDDC in
an ordered array, then co-cultured either with CD8 or with CD4 T cells
overnight. T cell activation was detected by analyzing cytokines in superna-
tants. Antigens were identifıed as clones that induced a cytokine response
that exceeded three standard deviations of the mean of all negative control
wells, then their identities compared with T cell epitopes predicted using
previously described algorithms. We found biological evidence for neoanti-
gens that were specifıcally responsive to peripheral CD8 and CD4 T cells,
derived from the patient’s tumor, pre- and post-CPB intervention. Some of
these neoantigens were identifıed as a T cell target both pre- and post-CPB
therapy. We identifıed neoantigens for which no epitopes were predicted by
in silico methods. These data represent evidence that multiple patient-spe-
cifıc neoantigens can be identifıed through functional evidence of T cell
response from peripheral blood without epitope prediction. By profıling
natural and CPB-enhanced immunity to neoantigens, a broad catalog of T
cell targets can be identifıed for development of immunotherapies that en-
gage T cells against cancer to improve outcomes for patients for whom
current therapies are ineffective.
#633 Induction of ADCC resistance profoundly alters tumor cell pheno-
type and stress response. Dalal S. Aldeghaither,1 Joseph C. Murray,2 Sarah M.
Roth,1 Elana J. Fertig,2 Shaojun Tang,1 Sandra A. Jablonski,1 Louis M.Weiner1.
1GeorgetownUniversity,Washington, DC; 2JohnsHopkins University, Baltimore,
MD.
Antibody dependent cellular cytotoxicity (ADCC) is one mechanism by
which monoclonal antibodies (mAb) work. In addition to ADCC, mAbs act on
their target by causing signal perturbation and complement activation. Cetux-
imab is an EGFR targeting mAb used to target EGFR overexpression and am-
plifıcation seen in many types of cancer. While mechanisms of resistance to
EGFR targeted therapy have been extensively studied, resistance to ADCC has
not,mainly due to the lack ofADCC-resistancemodels for study. To address this
limitation we established a model system for anti-EGFR ADCC using NK92-
CD16V effector cells, cetuximab, and the high EGFR-expressing squamous cell
carcinoma cell line A431. Continuous A431 exposure to ADCC yielded an
ADCC resistant phenotype (ADCCr) that exhibits a stable phenotype in the
absence of continued ADCC selection. We have explored: ADCCr cell gene
expression profıle, NK cell activation, metabolic signature and subsequent
RPPA analysis to further understand the causes and properties associated with
this resistance. This ADCCr cell line has a distinctive transcriptional profıle
highlighted by overexpression of histone- and interferon-related genes, reduced
sensitivity to antimetabolites, DNA-intercalating and ABC transporter-regu-
lated cytotoxic agents. Intense ADCC selection causes epigenetic modifıcation
and stress response characterized by the transcriptional overexpression of PCAF
(KAT2B), which initiates histone hyper-acetylation and epigenetic changes, in-
ducing DNA replication arrest, DNA damage and stress responses that activate
checkpoint signaling in the cell cycle. The pharmacologic inhibition of KAT2B
reverses the ADCCr phenotype. Immune checkpoints such as PD-L1 do not
modulate ADCC in this model system. These results shed light on new mecha-
nisms of ADCC resistance and inform future combinatorial treatments formAb
therapy. We are exploring the possibility that stress response mechanisms are
responsible for resistance for diverse selection pressures imposed by immune
synapse-mediated cytotoxic attack.
#634 RNAi-mediated -catenin inhibition promotes T-cell infıltration
and anti-tumor activity in combination with immune checkpoint blockade.
Shanthi Ganesh, Serena Shui, Weimin Wang, Bob D. Brown, Marc Abrams.
Dicerna Pharmaceuticals, Inc, Cambridge, MA.
Recent research strongly suggests an important role for Wnt/-catenin sig-
naling in mediating cancer immune evasion and resistance to immune check-
point therapy, including anti-PD-1, anti-PD-L1, and anti CTLA-4 antibodies.
ThemechanismbywhichWnt/-catenin signaling causes checkpoint resistance
is believed to involve blocking of specifıc cytokines which trigger immune cell
recruitment to the tumor, resulting in the phenomenon of T-cell exclusion and
rendering the tumor to a non-inflamed state. Inhibition of -catenin may be an
effective strategy for increasing the low response rate to these effectivemedicines
in numerous cancer populations. DCR-BCAT is a potent and specifıc chemical-
ly-optimized RNA interference (RNAi) trigger targeting CTNNB1, the gene
which encodes -catenin, formulated in a tumor-selective EnCore lipid nano-
particle. In syngeneic mouse tumor models, -catenin inhibition promoted T-
cell infıltration and signifıcantly improved the sensitivity of the tumors to check-
point inhibition. The combination of DCR-BCAT and IO therapy yielded
signifıcant tumor growth inhibition compared to monotherapy in B16F10 mel-
anoma, 4T1 mammary carcinoma, Neuro2A neuroblastoma and Renca renal
adenocarcinoma. Importantly, a signifıcant increase in CD8 T-cells after
DCR-BCAT monotherapy was observed in all models evaluated, including ge-
netically-driven spontaneousMMTV-Wnt1 tumors. These data support clinical
development of these combination approaches for this fırst-in-class RNAi ther-
apeutic.
#635 CD8 tumor-infıltrating T cells before and after neoadjuvant ther-
apy correlates with the pathological response in rectal cancer. Shinji Matsu-
tani, Masatsune Shibutani, Kiyoshi Maeda, Hisashi Nagahara, Tatsunari Fu-
kuoka, Ryosuke Amano, Hiroaki Tanaka, Kazuya Muguruma, Kosei Hirakawa,
Masaichi Ohira. Osaka City University Graduate School of Medicine, osakasi,
Japan.
Background: Recently, neoadjuvant therapy (ie. neoadjuvant chemotherapy,
neoadjuvant chemoradiationtherapy) for locally advanced rectal cancer has
been generally performed. Although in unresponsive cases it may have disad-
vantages such as tumor progression or delaying surgery, factors predicting the
clinical response to neoadjuvant therapy have not been adequately defıned.
Meanwhile CD8Tumor-infıltrating lymphocytes (TILs) have been reported to
have a crucial effect in tumor progression and outcome as primary host immune
response in various types of cancer, and antitumor immune effect has been
reported to contribute to the response to radiotherapy and chemotherapy. The
aim of this study was to elucidate the correlation between the local immune
status and the effectiveness of the neoadjuvant therapy for locally advanced
rectal cancer. Patients andmethods: A total of 51 patients who underwent cura-
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tive operation for locally advanced rectal cancer after neoadjuvant therapy were
enrolled. We retrospectively examined the number of CD8 tumor-infıltrating
lymphocytes (TILs) using immunohistochemical staining of pretreatment bi-
opsy samples and resected specimens, and assessed the correlation with patho-
logical response. The grade of tumor response was evaluated according to the
defınitions in the Japanese Classifıcation of Colorectal Carcinoma. Grade0-1a
were defıned as “poor response” and Grade1b-3 were defıned as “good re-
sponse”. We set each median value of the number of CD8 TILs as the cut-off
value. Results: For the 26 patients with pretreatment biopsy samples, we classi-
fıed the the patients into the poor response group (n14) and the good response
group (n12). Thenwe set 6.0 as the cut-off value and classifıed the patients into
the high pretreatment CD8 TILs group (n14) and the low pretreatment
CD8 TILs group(n12). Low pretreatment CD8 TILs were associated with
poor response to neoadjuvant therapy (p0.036). For resected samples (n51),
we classifıed the patients into the poor response group (n25) and the good
response group (n26). Then we set 10.8 as the cut-off value and classifıed the
patients into the high posttreatment CD8 TILs group (n28) and the low
posttreatment CD8 TILs group(n23). Low posttreatment CD8 TILs were
also associated with poor response to neoadjuvant therapy (p0.001). Addi-
tionally, the number of pretreatment CD8 TILs tend to be related to the num-
ber of posttreatment CD8 TILs. Conclusion: In locally advanced rectal cancer
patients, T lymphocyte-mediated immune reactions play an important role in
tumor response to neoadjuvant therapy, and the quantitative measurement of
CD8 TILs in pretreatment biopsy samples may be a predictor of the clinical
effectiveness of neoadjuvant therapy for locally advanced rectal cancer. More-
over, low posttreatment CD8 TILs were associated with poor response to neo-
adjuvant therapy.
#636 Comprehensive analysis of T cells responsive to neoantigens derived
from tumor-specifıc geneticmutations.Tetsuro Sasada, JunyaOhtake, Satoshi
Wada, Erika Yada, Shintaro Yoshida. Kanagawa Cancer Center, Yokohama,
Kanagawa, Japan.
Neoantigens derived from tumor-specifıc genetic mutations can be recog-
nized as foreign by the host immune system, and might be suitable as target for
cancer immunotherapy possibly due to their higher immunogenicity. In this
study, to really know the immunogenicity of tumor-specifıc neoantigens, we
comprehensively investigated T cell responses against neoantigens derived from
geneticmutations in gastric cancer. Using next-generation sequencing, 156mis-
sense mutations were identifıed in tumor cells from two gastric cancer patients.
From them, we selected 30 potentially immunogenic amino acid sequences,
which were derived from the mutations and predicted to potentially bind to
HLA-class I (A*0201,A*0206, orA*2402) by an epitope prediction server, IEBD.
We synthesized 30 kinds of 27mer long peptides, in which the mutated se-
quences were located in the center, and then cultured peripheral blood mono-
nuclear cells (PBMC) from healthy donors in the presence of the synthetic pep-
tides to evaluate whether they could really induce antigen-specifıc T cell
responses. In the analysis with PBMC from 18 healthy donors, 27/30 (90%)
synthetic peptides showed an ability to induce antigen-specifıc T cell responses
in at least one donor, assessed by cytokine production assay. Among them, 15
peptides were immunogenic inmore than one donor. The antigen-specifıc T cell
responses were detected more frequently in CD4 T cells (70%) than in CD8
T cells (43%). The specifıcity of T cell responses tomutated sequences, but not to
the corresponding wild type sequences, were confırmed in 5 of 8 (63%) peptides
examined. In addition, antigen-specifıc T cell responses induced by mutated
peptides were shown to be much higher than those induced by the correspond-
ing wild type peptides. These fındings clearly demonstrated high immunogenic-
ity and specifıcity of neoantigens derived from tumor-specifıc genetic muta-
tions. Further studies would be recommended to develop a novel
immunotherapeutic approach, “personalized cancer vaccination”, targeting
mutation-derived neoantigens.
#637 The class I HDAC inhibitor mocetinostat augments checkpoint in-
hibitor therapy via direct up regulation of antigen presentation transcrip-
tional programs in tumor cells and increased T-cell clonality in tumors.Da-
vid M. Briere, Niranjan Sudhakar, Peter Olson, Jamie Christensen. Mirati
Therapeutics, San Diego, CA.
Mocetinostat is a spectrum-selective class I/IV histone deacetylase (HDAC)
inhibitor that augments checkpoint inhibitor therapy through enhanced antigen
presentation capacity and a pro-immunogenic shift in the tumormicroenviron-
ment (TME).Mocetinostat up-regulated tumor antigen presentationmachinery
(i.e. major histocompatibility complex (MHC) genes and co-presentation mol-
ecules) and programmed cell death-ligand 1 (PD-L1) expression in a panel of
non-small cell lung cancer (NSCLC) cell lines. Surprisingly, some of the most
highly up regulated genes following mocetinostat treatment were MHC class II
genes (20 fold), which are normally expressed by antigen-presenting cells, but
are silenced in most epithelial tissues and solid tumors. To elucidate the molec-
ular mechanisms whereby mocetinostat regulates MHC class I and class II tran-
scriptional programs in tumor cells, we performed chromatin immunoprecipi-
tation DNA sequencing (ChIP-Seq). HDAC2 was detected at the promoters of
many mocetinostat-regulated immune pathway genes. Further, mocetinostat
treatment increased histone 3 lysine 27 acetylation and histone 3 lysine 4 trim-
ethylation indicating an induction of active transcription at these loci. Class II
transactivator (CIITA) is an interferon gamma (IFN)-sensitive regulator of
MHC class II gene expression and was one of the top HDAC2/mocetinostat
target genes based on ChIP-Seq data. In addition, CIITA and a representative
MHC class II gene, HLA-DRA, were synergistically up regulated following mo-
cetinostat and IFN treatment. To investigate the impact of Class I HDAC
inhibition on the TME, syngeneic mouse tumor models were utilized. Moceti-
nostat treatment decreased intratumoral immune suppressive T regulatory cells
(Tregs) and increased intratumoral CD8 T cells. To gain additional insight
into the functional effects of mocetinostat in the TME, we performed deep se-
quencing of the T-cell receptor in vehicle, mocetinostat, PD-L1 or combination-
treated tumors. Mocetinostat-treated tumor cohorts exhibited increased T-cell
clonality which likely reflects expansion of a subset of activated, antigen-specifıc
T cells. Together, these data provide molecular insight into the mechanism
whereby mocetinostat augments checkpoint inhibitor therapy by directly regu-
lating tumor antigen presentation and through functional effects on the T cell
repertoire.
#638 Epigenetic reprograming of immune cells through selective inhibi-
tion of HDAC6 reduces suppressive phenotypes and augments anti-tumor
properties of T-cells. Andressa L. Sodre,1 David M. Woods,1 Amod Sarnaik,2
Brian C. Betts,2 Steven Quayle,3 Simon Jones,3 Jeffrey Weber1. 1NYU Langone
Medical Center, New York, NY; 2Moffıtt Cancer Center, Tampa, FL; 3Acetylon
Pharmaceuticals, Boston, MA.
Alteration of the epigenetic landscape of immune cells canmodify the pattern
of gene expression, thus resulting in phenotypic and functional changes. Small
molecule inhibitors targeting epigenetic modifıers, such as histone deacetylases
(HDACs), have been shown to reduce tumor growth. Besides promoting direct
anti-tumor effects, HDAC inhibitors also target immune cells and alter their
gene regulation. Here, we demonstrate that the HDAC6 selective inhibitors
ACY-241 andACY-1215 (ricolinostat) decrease the function ofmyeloid derived
suppressor cells (MDSC) and T regulatory (Treg) cells, maintain an effector
phenotype by CD8 T cells, and do not reduce viability of immune cells. First,
peripheral blood mononuclear cells derived from melanoma patients were
treatedwithACY-241, and the phenotype ofMDSCswas assessed. Expression of
the suppressive molecules ARG1 (p0.01) and NOS2 (p0.05) was decreased
in CD14HLA DR lo CD11b and CD14HLA DR lo CD33MDSC popu-
lations, suggesting less potent MDSCs. To gain insight into other suppressive
populations, we evaluated the phenotype and function of Treg cells derived from
melanoma patients. Cultures of CD3 T-cells treated with ACY-1215 or ACY-
241 resulted in decreased expression of FOXP3 and reduced frequency of Tregs
(CD4CD25CD127-; p0.001). ACY-1215 pre-treated Tregs exhibited less
suppressive activity against responding conventional T-cells in standard assays,
compared to Tregs pre-treated with DMSO control (p0.01). CD3 T-cells
exposed toACY-241 orACY-1215were activated viaCD3/CD28 co-stimulation
to assess effects on cytokine production. Selective HDAC6 inhibition shifted
T-cell differentiation towards Th1-type (Tbet) over Th2-type (GATA3),
compared toDMSO (p0.05). Additionally, Th2 cytokines (e.g. IL-4, IL-5, IL-6,
IL-10, IL-13) were signifıcantly decreased (p0.05). In accordance with de-
creased Th2 differentiation, mTORC signal transduction, including phosphor-
SGK1, was similarly reduced (p0.05). Targeted inhibition of mTORC signal-
ing (i.e. SGK1 inhibitor) recapitulated decreased Th2 cytokine production
(p0.05). In order to address effector immune function, tumor infıltrating lym-
phocytes (TILs) were harvested frommelanoma biopsies and expanded in vitro
in the presence of ACY-1215 or ACY-241, and IL-2. Measuring CD45RA,
CD45RO,CD62L and/orCCR7, an accumulation of centralmemoryCD4 and
CD8 T-cells was observed (p0.05). Activated TILs treated with ACY-241 or
ACY-1215 displayed higher expression of IFN-gamma and CD107a. Collec-
tively, these data indicate that epigenetic reprograming of immune cells by
HDAC6 selective inhibitors may decrease the function of suppressive subsets
(e.g. Tregs, MDSCs), while enhancing the accumulation of anti-tumor memory
and effector T-cell subsets.
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#639 Morphological changes inmitochondria induced by CD137 (4-1BB)
co-stimulation on CD8 T cells. Sara Labiano, Álvaro Teijeira, Arantza Azpili-
kueta, Ángela Aznar, Elixabet Bolaños, IgnacioMelero.Center for AppliedMed-
ical Research, Pamplona, Spain.
Metabolism has emerged as a fundamental biological process in the control of
immunological functions of T cells, playing essential roles in survival and dif-
ferentiation of these immune cells. Mitochondria are key organelles in control-
ling these processes by performing fundamental steps in aerobic respiration,
fatty acid metabolism and in the control of apoptosis. Recently, Carl June and
colleagues showed thatCARs engineeredwith the cytoplasmic tail of 4-1BBwere
able to promote oxidative phosphorylation in T cells as a result of enhanced
mitochondrial biogenesis. CD137 (4-1BB) is an immunostimulatory receptor of
the TNFR family expressed on the surface of antigen-activated T cells. Treat-
ment with agonistmonoclonal antibodies targeting 4-1BB is showing promising
results for immunotherapy of cancer. In this work, we observed that stimulation
of 4-1BB with agonistic mAbs was able to raise the mitochondrial membrane
potential on human CD8 T cells. 4-1BB co-stimulated CD8 T cells showed en-
larged mitochondria (up to 3m diameter) with a round shape when observed
by confocal or transmission electronmicroscopy.We observed that CD8 T cells
from DLNs (drainig lymph nodes) of tumors in mice treated with agonistic
anti-4-1BB antibodies also contained enlargedmitochondria. By double fluores-
cence labeling ofmitochondria prior and after activation,we could ascertain that
enlarged mitochondria were a product of preexisting mitochondria rather than
de novo generated organelles. This observation prompted us to study the regu-
lation ofmitochondrial dynamics by 4-1BB receptor. 4-1BB stimulation induced
an increase in expression of themitochondrial fusion protein OPA-1. By Super-
resolution microscopy with AiryScan detectors we observed more pronounced
co-localization of OPA-1 with mitochondrial membrane in 4-1BB co-stimu-
lated T cells than in T cells activated only by CD3 crosslinking. Our results
indicate an important role of 4-1BB in the regulation ofmitochondrialmorphol-
ogy and performance in such a way that can be relevant for various T cell func-
tions.
#640 Subsets of HLA alleles are capable of binding neoantigens derived
from mutations within cancer driving genes such as KRAS and EGFR. An-
drew Nguyen, J Zachary Sanborn, Charles J. Vaske, Shahrooz Rabizadeh, Kay-
van Niazi, Patrick Soon-Shiong, Steve Benz. NantOmics, Santa Cruz, CA.
Background: Immunoncology has shown great promise as a low toxicity tool
to combat several cancers. Use of checkpoint inhibitors against PD1 or CTLA4
unlocks the immune system’s ability to recognize tumor antigens and, more
specifıcally, neoantigens caused by random mutations within cancers. The vast
majority of neoantigens consist of privatemutations unique to a patient’s tumor
genome, but several cancers harbor recurrent mutations. Mutations in the
KRAS gene, such as p.G12V, occur in roughly 25% of colorectal cancers. Muta-
tions in EGFR occur in 10% and 35% of patients with non-small cell lung cancer
in the US and East Asia, respectively. Evenmore prevalent are mutations within
the TP53 tumor suppressor gene, with roughly 23000 unique protein variants
reported to date. If these mutations in cancer driving genes are so prevalent in
cancers, why are neoantigens against these targets not more readily available?
Results: We collected recurrent mutations across a variety of cancer driving
genes such as KRAS, EGFR, TP53 and MYC and performed binding analysis
using netMHC 3.4 to see which HLA alleles are capable of binding specifıc
cancer mutations such as KRAS p.G12V. Using this method, we report all pos-
sible HLA alleles capable of binding these recurrent mutations within cancer
genes. We further performed 3-dimensional modeling to determine whether
complexes created by the HLA alleles and cancer neoepitopes are stable. Con-
clusions: Several HLA alleles are capable of binding recurrent cancer mutations.
These include both MHC Class 1 and Class 2 alleles. The variation in alleles
capable of binding commonly mutated genes such as EGFR may explain the
difference in prevalence of these mutations between geographic populations.
Determining whether a certain HLA allele confers resistance to common cancer
gene mutations may lead to identifıcation of immune cells within these popula-
tions that can recognize neoantigens from commonly mutated cancer genes.
#641 PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances
tumor infıltrating CD8 T cell accumulation and improves checkpoint in-
hibitor effıcacy inmurine syngeneic breast cancer models. Renee Clift, Jisook
Lee, Curtis B. Thompson, YujunHuang.Halozyme Theraputics, Inc., San Diego,
CA.
Hyaluronan (HA) is an extracellular glycosaminoglycan that accumulates in
the tumor microenvironment (TME) of many solid tumors and is associated
with rapid tumor progression and poor prognosis. In preclinical studies, enzy-
matic degradation of TME HA by intravenous PEGylated recombinant human
hyaluronidase PH20 (PEGPH20) remodels the TME, reduces tumor interstitial
fluid pressure, decompresses tumor blood vessels, and facilitates delivery of
chemotherapeutics. We have previously shown that PEGPH20-mediated HA
degradation enhances anti-PD-L1 and anti-PD1 effıcacy in anHAaccumulating
murine pancreatic tumor model (Rosengren, AACR 2016 poster #4886). Ac-
cordingly, we aimed to extend these checkpoint blockade studies into orthotopic
breast cancermodels; while further elucidating the effect of PEGPH20-mediated
HA degradation on modulating tumor infıltrating lymphocytes (TILs). The
mammary fat pads of BALB/c mice were inoculated with either EMT-6 cells or
4T1/HAS3, a 4T1 cell line engineered to over-express hyaluronan synthase-3.
During tumor progression, both EMT-6 and 4T1/HAS3 mammary carcinomas
accumulate high levels ofHA (average 730ng/mg and1408ng/mg, respectively).
When treated with PEGPH20 alone (0.0375mg/kg), EMT-6 tumor growth was
inhibited by 	30% (p0.01). Additional EMT-6 studies were conducted to
evaluate PEGPH20 in combination with anti-PD-L1. PEGPH20 increased anti-
PD-L1 effıcacy by 38% relative to anti-PD-L1 alone (86%vs 62.4% tumor growth
inhibition (TGI), p0.0024). Comparable tumor growth experimentswere con-
ducted in the 4T1/HAS3 model. TILs were evaluated by flow cytometry.
PEGPH20-mediatedHA removal enhanced both checkpoint effıcacy andCD8
T cell recruitment. Specifıcally, PEGPH20 alone (1mg/kg) increased anti-PD-L1
effıcacy by 411% relative to anti-PD-L1 alone (93% vs 18.2% TGI, p0.0001)
and increased the accumulation of CD8 TIL by 176% (p0.0025). Taken to-
gether, the data suggest that tumor HA accumulation may act as a barrier to
immune cell access and negatively modulate CD8 TILs, and that PEGPH20-
mediated HA reduction facilitates increased access of CD8 T cells. This in-
creased recruitment may contribute to the enhanced anti-PD-L1 effıcacy ob-
served when combined with PEGPH20. A Phase 1 trial is ongoing to evaluate
PEGPH20 plus checkpoint blockade in patients with advanced or metastatic
non-small cell lung cancer and in patients with locally advanced or metastatic
gastric adenocarcinoma (NCT02563548).
#642 Detection of circulating antibodies against KRAS in patients with
advanced cancers. Ed Kheder,1 Helen J. Huang,1 Alice Wu,2 David S. Hong,1
Sarina A. Piha-Paul,1 Daniel D. Karp,1 Siqing Fu,1 Vivek Subbiah,1 ApostoliaM.
Tsimberidou,1 Aung Naing,1 Adi Diab,1 Milind Javle,1 Scott Kopetz,1 Anil K.
Sood,1 Jonathan M. Kurie,1 Funda Meric-Bernstam,1 Martin Gleeson,2 Filip
Janku1. 1The University of Texas MD Anderson Cancer Center, Houston, TX;
2Genalyte INC, San Diego, CA.
Introduction: KRAS gene plays a major role in tumorigenesis, cell prolifera-
tion and survival. Yet, there has been no effective targeted therapy against KRAS
mutation-mediated tumors. We hypothesized that KRAS can induce humoral-
mediated immune response. Methods: Plasma or serum samples from patients
with progressing advanced cancers with orwithout KRASmutationswere tested
for the presence of circulating KRAS antibodies. We used the Maverick Detec-
tion System (Genalyte, San Diego, CA), which can perform real-time detection
of macromolecules in crude samples using biologically functionalized silicon
photonic biosensors lithographically printed on disposable silicon chips. Re-
sults: We collected serum or plasma samples from 213 patients with advanced
cancers (KRAS-mutant, N100; KRAS wild-type, N113) and 50 (23%) were
found to have circulating KRAS antibodies. There was no association between
KRAS antibodies and tumor KRAS mutation status (21/100, 21% for KRAS-
mutant vs. 29/113, 26% for KRAS wild-type; P0.52). In addition, there was no
difference in detection of KRAS antibodies in colorectal cancer (21/89, 24%)
compared to other cancers (29/124, 23%; P1.00). There was no difference in
the median survival in patients with KRAS antibodies compared to patients
without KRAS antibodies (9.0 months vs. 10.1 months; P 0.825). Similarly,
there was no difference in the median survival according to the presence of
circulating KRAS antibodies in subgroups of patients with tumor KRAS muta-
tions (P 0.96) andwithout tumorKRASmutations (P0.63). On the contrary,
the median survival of patients with tumor KRAS mutation was shorter com-
pared to patients with KRAS wild-type (7.2 months vs. 11.5 months; P0.001).
Conclusion: Circulating KRAS antibodies can be detected in 23% of patients
with advanced cancers. Biological implications of circulating KRAS antibodies
remain to be understood.
#643 Induced MHCII expression on breast cancer cells broadens the re-
sponding T cell repertoire, delays tumor-specifıc T cell exhaustion, and im-
pairs tumor growth. Tyler R. McCaw,1 Mei Li,1 Selene Meza-Perez,1 Donald J.
Buchsbaum,1 Dmytro Starenki,2 Sara Cooper,2 Andres Forero,1 Troy D. Ran-
dall1. 1University of Alabama at Birmingham, Birmingham, AL; 2HudsonAlpha
Institute for Biotechnology, Huntsville, AL.
We recently reported that the aberrant expression of Major Histocompatibil-
ity Class II (MHCII) molecules on human triple negative breast cancer (TNBC)
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cells correlates with prolonged progression-free survival and increased tumor
infıltrating lymphocytes. We hypothesized that the expression of MHCII en-
hances the intratumoral CD4 T cell response, thereby bolstering the tumor-
specifıc CD8T cell response, resulting inmore effective tumor control. To test
our hypothesis, we created bothMHCII-expressing andMHCII-negative tumor
cells by transfecting murine breast cancer (TS/A) cells with the human class II
transcriptional activator (hCIITA) or empty vector, respectively. Transfected
cells were then injected into BALB/c mice and the resulting immune response
analyzed by flow cytometry at four time points.We found that hCIITA-express-
ing tumors grew slower than control tumors in immunocompetent recipients,
but that this difference was nullifıed in immunocompromised and markedly
reduced in CD4 T cell depleted mice. CD4 T cells isolated from hCIITA-
transfected tumors produced more IFN, IL-17A, and surprisingly granzyme B
for longer times than their counterparts in control tumors. Similarly, CD8 T
cells isolated from hCIITA-transfected tumors displayed a more activated phe-
notype and produced more IFN and granzyme B for longer times. Neverthe-
less, bothCD4 andCD8T cells eventually became exhausted in both groups.
In addition to enhanced effector functions, TCR repertoire analysis demon-
strated that both the breadth and magnitude of expansion of responding T cell
clones were increased in hCIITA-transfected tumors. Interestingly, TS/A-
hCIITA tumors harbored more regulatory T cells (Tregs) with a more suppres-
sive phenotype than Tregs from control tumors. Finally, we show that the his-
tone deacetylase inhibitor (HDACi) Entinostat is capable of robust and dose-
dependent induction of MHCII on tumor cells in vivo, an effect that correlates
with dramatic reduction in tumor size. These results suggest that the clinical
benefıt associated withMHCII expression on TNBC cells is mediated by a delay
in T cell exhaustion and increased intratumoral CD4 T cell activation, which
enhances the cytotoxic capacity of CD8 T cells. Entinostat, and potentially
other epigenetic modifying agents, may enable induction of MHCII expression
on TNBC cells clinically and allow more patients to benefıt from an augmented
T cell response. These effects may be magnifıed by combinatorial therapy with
checkpoint inhibitors to promote durable anti-tumor immune responses.
#644 CA125/MUC16 suppresses antibody-dependent cellular cytotoxicity
of IgG1-based therapies via perturbation of antibody Fc-Receptor engage-
ment on immune effector cells. J. Bradford Kline, Rina Kennedy, Shawn Fer-
nando, Jennifer McDonough, Earl Albone, Elizabeth B. Somers, Wenquan
Wang, Charles Schweizer, Luigi Grasso, Nicholas C. Nicolaides. Morphotek,
Inc., Exton, PA.
Background: Human cancers employ a number of mechanisms to evade host
immune responses. Here we report the effects of the tumor-shed antigen CA125
(MUC16) on suppressing IgG1-mediated antibody-dependent cellular cytotox-
icity (ADCC). This evidence stems from prespecifıed subgroup analysis of an
1100 patient Phase 3 clinical trial testing the investigational agent farletuzumab,
a monoclonal antibody (mAb) to folate receptor alpha, plus standard-of-care in
patients with recurrent ovarian cancer. In this study, patients with low levels of
CA125 [no greater than 3X the upper limit of normal ( 3XULN)] treated with
farletuzumab compared to placebo demonstrated improvements in both pro-
gression free survival (HR 0.49, p 0.0028) and overall survival (HR 0.44, p
0.0108). Farletuzumab’s pharmacologic activity is mediated in part through
ADCC. Here we show that CA125 inhibits farletuzumab’s ADCC activity by
suppressing antibody interaction with the CD16a Fc-Receptor on effector cells.
Methods: Functional assays employing Jurkat-hCD16 reporter cells as well as
primary NK cells were used to measure ADCC activity. CA125 isolates from
various patients and cell lines were used in ADCC assays to monitor CA125
effects on immune-effector function. Multiple isogenic tumor cells expressing
endogenous CA125 and their CA125-null counterparts were also used to mon-
itor CD16a-mediated ADCC activity. CD16a cell binding assays were used to
measure the effects of CA125 inhibition on CD16a Fc-Receptor interaction and
activation. Recombinant CD16a and humanized mAbs were used in ELISA for-
mat to measure molecular binding. Results: Functional assays showed that ex-
ogenously added tumor-shed CA125 was able to suppress ADCC mediated by
IgG1-type mAbs against several target cell lines. This CA125-mediated ADCC
suppression was also observed in cells naturally expressing membrane-bound
CA125 but not in isogenic CA125-null cells. Molecular studies suggest that
CA125-mediated immunosuppression is caused by the perturbation of antibody
interaction with the CD16a Fc-Receptor and that this effect is specifıc to IgG-
type mAbs. Conclusions: Here we demonstrate that the tumor-shed antigen
CA125 can elicit immunosuppression by blocking the interaction of tumor-
targeting mAbs and CD16a Fc-Receptor on immune effector cells. This effect
appears to be through a direct interaction of CA125 with antibody-CD16a pro-
teins. These fındings support a biologicalmechanism for the clinical observation
that relapsed ovarian cancer patients with low CA125 blood levels have im-
proved clinical responses to the experimental agent farletuzumab. These fınd-
ings also provide new insights on the potential biological mechanisms for which
tumors produce tumor-shed antigens such as CA125 to suppress host anti-
tumor immune responses.
#645 Immunological landscape of non-small cell lung cancer (NSCLC):
PD-1 expression in lung TILs correlate with co-expression of other check-
point inhibitor molecules. Se W. Jeong, Timothy Bullock. University of Vir-
ginia, Charlottesville, VA.
Lung cancer is the leading cause of annual cancer related mortality in the
United States. More than 150,000 people in the U.S. will die from lung cancer
this yearwhichwill lead to roughly asmany deaths as breast, prostate, colon, and
pancreatic cancers combined. Lung cancer is also of global concern as tobacco
and cigarette use, a signifıcant known risk factor, in developing countries have
risen signifıcantly. Stage II and III non-small cell lung cancer (NSCLC) patients
often have a 5-year disease free survival of less than 50% even after surgical
resection and post-operative chemotherapy and a dismal 5% overall survival for
patients with stage IV metastatic disease. Even with the advent of PD-1/PDL-1
checkpoint blockade immunotherapies, only about 20% of patients are respon-
sive to the treatment. This limited scope of success may be due to our lack of
understanding the immune landscape ofNSCLCs. Therefore, we set out to char-
acterize the immune composition from surgical lung resections via flow cytom-
etry. We found that NSCLCs have a diverse set of checkpoint inhibitor and
co-stimulatory molecules expressed by T cells, including PD-1, TIM-3, and
TIGIT. Interestingly, even though PD-1 was elevated compared to a normal
donor, the expression level was lower than either breast or melanoma tumor
samples. We also discovered that PD-1 heavily correlates with co-expression of
other checkpoint inhibitor molecules. In our regulatory T cell analysis, FoxP3
populations have a profound presence in these lung tumors suggesting there is a
highly suppressive environment for tumor infıltrating lymphocytes (TILs). Our
lung resection screenings furthermore suggests a dynamic range of both fre-
quency and proportion of CD3-CD56 natural killer (NK) cells. Finally, our
data indicates there is a large population of CD11bCD33 myeloid-derived
suppressor cells (MDSCs) in the tumors, with varying degrees of arginase-1
expression, a functional marker for MDSCs. Altogether, these fındings in con-
cert suggest there are potential goldmine of opportunities to targetmolecules on
different immune cell populations. This multi-modal approach, directing com-
bination of immunotherapies that influences multiple immune compartments
yet complement each other, may have signifıcant implications for future clinical
studies.
#646 Targeting MHC class I molecules and immune checkpoints as key
immune evasion strategies in EBV-associated nasopharyngeal carcinoma.
Sharie Pui-Kei Siu,1 Ka Fai To,1 Grace Tin-Yun Chung,1 Vivian W.Y. Lui,1
YvonneY. Li,1 Peter S.Hammerman,2KwokWai Lo1. 1TheChineseUniversity of
Hong Kong, Hong Kong, Hong Kong; 2Dana-Farber Cancer Institute, Boston,
MA.
Nasopharyngeal carcinoma (NPC) is a distinct type of head and neck
cancer that is consistently associated with intensive lymphocytes infıltration
and Epstein-Barr virus infection. This study aims at elucidating the mecha-
nism contributing to immune evasion in NPC. During NPC tumorigenesis,
multiple intrinsic mechanisms are acquired to escape cellular immune re-
sponse for the tumor and viral antigens. By genome sequencing, somatic
alterations of multiple MHC class I genes including NLRC5, HLA-A,
HLA-B, HLA-C and B2M were detected in 30% of primary NPC. Signifıcant
correlation of MHC class I gene alterations and poor survival rate in the
patients was also shown. The fınding suggested that the defıciency of antigen
presentation mechanism represents a common strategy for immune evasion
in NPC and favors rapid tumor progression. Losses of HLA-A, HLA-B and
NLRC5 expression were validated in a panel of NPC tumor lines and selected
primary tumors. The role of NLRC5 as key transcription regulator of HLA-A
and HLA-B expression was demonstrated in the nasopharyngeal epithelial
cells. To further evaluate the mechanisms contributed to immune evasion in
NPC, we have elucidated immunosuppressive molecules involved in im-
mune surveillance in Epstein Barr Virus (EBV)-associated NPC and its as-
sociation with EBV-encoded LMP1 in an independent cohort of primary
NPCs. By immunohistochemistry, the expression of EBV-encoded LMP1,
MHC class I genes and various immunosuppressive molecules including
PDL1, PDL2 and IDO1was examined in 98 primary tumors. PDL1 and PDL2
were found to be over-expressed in 50% and 33.7% of NPC cases while IDO1
was found to be expressed in 28.8% of cases. Primary NPC cases expressing
either PDL1 or PDL2 accounted for 64.3%. A signifıcant association between
LMP1 and PDL1 and PDL2 expression was also found. The correlation of
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PDL1, PDL2 and/or MHC class I molecule expression with the outcome of
the patients was determined. The high incidence of MHC class I defıciencies
and PDL1/PDL2 overexpression imply that EBV-associated NPC escape
from the host immune response by targeting both antigen presentation
mechanisms and immune checkpoints. Our fındings also suggested that the
expression of MHC class I molecules and PDL1/PDL2 is a potential bio-
marker for immunotherapy in NPC patients.
#647 Bortezomib enhances CD8 T Lymphocyte antitumor effector
function: Potential mechanism(s) via notch regulation. Ariana N. Ren-
rick,1 Menaka C. Thounaojam,2 Portia Thomas,1 Samuel T. Pellom,1 Anil
Shanker1. 1MeharryMedical College, Nashville, TN; 2Medical College of Geor-
gia, Augusta, GA.
The immunosuppressive tumor microenvironment disturbs host antitu-
mor immunity by multiple mechanisms including interference with the
Notch system, which is important for various metazoan cell fate decisions
and hematopoietic cell differentiation and function. We observed that treat-
ment with the proteasome inhibitor bortezomib in mice bearing various
solid tumors resulted in an upregulated expression of various Notch signal-
ing components in lymphoid tissues, thereby increasing CD8T lymphocyte
IFN secretion and expression of effector molecules, perforin and granzyme
B, as well as the T-box transcription factor eomesodermin. Of note, bort-
ezomib reversed tumor-induced downregulation of Notch receptors,
Notch1 and Notch2, as well as increased the levels of cleaved Notch intra-
cellular domain (NICD) and downstream targets Hes1 and Hey1 in tumor-
draining CD8 T cells. Moreover, bortezomib promoted CD8 T cell nu-
clear factor-B (NFB) activity by increasing the total and phosphorylated
levels of the IB kinase and IB as well as the cytoplasmic and nuclear levels
of phosphorylated p65. Even when we blocked NFB activity by Bay-11-
7082, or NICD cleavage by -secretase inhibitor, bortezomib signifıcantly
increased expression of Notch Hes1 and Hey1 genes as well as perforin,
granzyme B and eomesodermin in activated CD8 T cells. Data suggest that
bortezomib can rescue tumor-induced dysfunction of CD8 T cells by its
intrinsic stimulatory effects promoting NICD-NFB crosstalk. We are also
elucidating components of microRNA regulation affecting NICD-NFB
crosstalk. Our preliminary data suggest that bortezomib is also able to pos-
itively regulate miR-155 expression in CD8 T cells from mice bearing tu-
mor. As well as, miR-155 suppression downregulates bortezomib-induced
increase in Notch target genes in T cells. We are currently investigating
alternative proteasome inhibitors in order to understand whether bort-
ezomib’s effect on miR-155 expression in CD8 T cells is specifıc to bort-
ezomib or primarily conducive to a proteasome inhibition effect. These fınd-
ings provide novel insights on using bortezomib not only as an agent to
sensitize tumors to cell death, but also to provide lymphocyte-stimulatory
effects, thereby overcoming immunosuppressive actions of tumor on anti-
tumor T cell functions.
#648 Interferon-gamma induces PD-L1 expression via IFNGR-JAK-
STAT pathway in ovarian cancer. Tat-San Lau, Loucia Kit-Ying Chan, Tak-
Hong Cheung, So-Fan Yim, Jacqueline Ho-Sze Lee, Joseph Kwong. The Chinese
University of Hong Kong, Shatin, New Territories, Hong Kong.
The purpose of this study is to investigate underlying mechanism of how
cytokine interferon-gamma (IFN-) regulates PD-L1 expression in ovarian
cancer cells.We treated a panel of human andmouse ovarian cancer cell lines
with recombinant human/mouse IFN-. Our data showed that IFN- up-
regulated mRNA and protein expression of PD-L1 signifıcantly in a majority
of ovarian cancer cells. The functional IFN- receptor is comprised of two
ligand-binding IFNGR1 chains associated with two signal-transducing IF-
NGR2 chains and associated signaling machinery. Here we found that the
mRNA expression levels of IFNGR1 and IFNGR2 were abundant in all hu-
man ovarian cancer cell lines being tested, while their expressions were not
affected by IFN- treatment. After knocking down the expression levels of
IFNGR1 and IFNGR2 in a ovarian cancer cell line by target gene-specifıc
siRNA, our data showed that the IFN--mediated induction of PD-L1 were
diminished in the ovarian cancer cells when compared to those with non-
targeting scrambled siRNA controls, indicating the induction of PD-L1 by
IFN- is dependent on the presence of IFN- receptors in the ovarian cancer
cells. Although abundant expression of IFNGR1 and IFNGR2 were found in
all human ovarian cancer cell lines being tested, the IFN--mediated induc-
tion of PD-L1 was not detected in a few of the human ovarian cancer cell lines
(namely IGROV-1, TOV21G and SKOV3). We further investigated the in-
tegrity of IFN- signaling in the human ovarian cancer cell lines by examin-
ing activation of STAT1 protein and induction of IRF-1 gene in human
ovarian cancer cell lines after IFN- treatment. Our data showed that phos-
phorylated-STAT1 protein and IRF-1 gene expression were up-regulated
signifıcantly in a majority of human ovarian cancer cells after IFN- treat-
ment, except IGROV-1 and TOV21G cells. These results suggested that
IGROV-1 and TOV21G cells might harbor defects in intracellular JAK-
STAT1 signaling. We then examined the presence of JAK1 truncating mu-
tations in human ovarian cancer cell lines by Sanger sequencing, and con-
fırmed that IGROV-1 and TOV21G cells, but not the others, have JAK1
truncating mutations. Since our data showed that SKOV3 cells have wild
type JAK1, we further investigated other possible defects in IFN- signaling
in SKOV3 cells. We investigated the IFN--induced STAT3 protein activa-
tion in human ovarian cancer cell lines, and defects were found in Y705
STAT3 phosphorylation in SKOV3 as well as in IGROV-1 and TOV21G
cells. To summarize, our results showed that IFN- induces PD-L1 expres-
sion in ovarian cancer cells via IFNGR-JAK-STAT pathway. The failure of
IFN--mediated induction of PD-L1 in a minority group of human ovarian
cancer cell lines is due to defective IFN- signaling, including JAK1 truncat-
ing mutations and impaired STAT3 activation. This work is supported by
Hong Kong Research Grants Council General Research Fund (467713 and
14109515).
#649 Emigrant pre-REP tumor infıltrating lymphocytes profoundly differ
from remnant T-cells.Michelle R. Simpson-Abelson, Christopher Mosychuk,
Maria Fardis, Michael T. Lotze. Lion Biotechnologies, Tampa Bay, FL.
Adoptive T cell therapywith autologous tumor infıltrating lymphocytes (TIL)
provides up to 56% objective response rates and a complete response in 24% of
patientswithmetastaticmelanoma. The process of generatingTIL from resected
tumor involves morcellating the tumor into 1-3 mm3 fragments and expanding
TIL in the presence of Interleukin 2 (IL-2) in a pre-Rapid Expansion Protocol
(pre-REP). During the ’pre-REP’, tumor-resident immune cells emigrate (eTIL)
and proliferate. The length of the pre-REP varies between 11-21 days, depending
on cell growth. Residual tumor fragments (remnants) are discarded and the
expanded eTIL are subjected to a Rapid Expansion Protocol (REP) with irradi-
ated PBMC feeders, anti-CD3 and IL-2. Viable cells remaining in the tumor
remnants (rTIL) following the pre-REP were investigated to assess their func-
tion and phenotype. We evaluated and compared the rTIL and eTIL in mela-
noma, breast, renal, pancreatic, lung and colorectal tumors (n9). Tumor rTIL
are consistently phenotypically distinct from eTIL, as determined by differential
expression of various markers (Table 1). The fundamental differences in rTIL
were: Increased CD69 (7 fold MFI in CD4) (p.001); diminished LAG3 (2
fold MFI in CD8) (p.05); TIM3 (3 and 2 fold MFI in CD8 and CD4 respec-
tively) (p.05/.01); CD154 (3 fold MFI in CD4) (p.01); and CD56 (5%)
(p.05). Surprisingly, a REP of rTIL and eTIL resulted in comparable expan-
sion. The phenotypic signature of TIL was sustained post-REP with fıdelity of
the individual expression of LAG3, Tim3, and CD28. These studies have iden-
tifıed signifıcant differences in the biology of cell populations in terms of tissue-
resident T cells and the signals associated with emigration and retention. These
data provide additional insights on the individual TIL populations that could be
utilized for adoptive T-cell therapy in patients and raise important questions
about the nature of tissue-resident T cells in sites of chronic inflammation such
as tumor.
Table 1: Tumor resident remnant T cells are phenotypically distinct
from emigrating T cells (N9)
Marker
Expression
LAG3
(CD8/ CD4)
MFI
Tim3
(CD8/ CD4)
MFI
PD-1
(CD8/ CD4)
%
CD69
(CD8/ CD4)
MFI
CD154
(CD8/ CD4)
MFI
CD28
(CD8/ CD4)
MFI
CD57
(CD8/CD4)
%
CD56
%
eTIL 507/ 144 2832/ 1756 36.95/ 47 1320/ 1543 1498/ 3751 1163/ 5036 18.76/ 19.6 5.615
rTIL 209/ 106 877/ 742 42.8/ 48 3437/ 223.4 1034/ 1167 458.3/ 2795 9.16/8.5 1.027
*P-values
(CD8/ CD4)
0.05/ 0.21 0.05/ 0.01 0.38/ 0.89 0.11/ 0.001 0.55/ 0.01 0.05/ 0.11 0.05/ 0.06 0.05
_______
#650 B lymphocytes promote upregulation of an IL-1-NfkB dependent
signaling and increase invasiveness of triple negative breast cancer. Nicole
Flynn,1 Rajasekharan Somasundaram,2 Jennifer Sims-Mourtada3. 1University of
Delaware, Newark, DE; 2The Wistar Institute, Philadelphia, PA; 3Helen F. Gra-
ham Cancer Ctr., Newark, DE.
Triple negative breast cancer (TNBC) is an aggressive form of breast can-
cer that progresses quickly from a non-invasive carcinoma in situ to an
invasive state. Chronic inflammation associated to humoral immune re-
sponses has been found to promote aggressiveness in a number of solid
tumor types. In breast cancer, B lymphocytes are associated with microin-
vasive disease and correlate with expression of inflammatory genes. The
purpose of our work is to study the impact of B lymphocytes on the tumor
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microenvironment and increased invasiveness of TNBC cells. Through real-
time PCR, we demonstrate that co-culture of B lymphocytes and TNBC cells
leads to increased mRNA levels of IL1 and its downstream target interleu-
kin 8 (IL8) in both B lymphocytes and in TNBC cells. Western Blot analysis
shows that co-culture also leads to increased phosphorylation of p65, indi-
cating IL-1  activation of NFB signaling. Additionally, co-culture of B
lymphocytes with TNBC cells leads to increased expression of matrix met-
alloproteinases (MMPs) and cellular invasion through a matrigel invasion
chamber. Gelatin zymography reveals increased functional MMP2 and
MMP9 in tumor cell supernatant following co-culture with B lymphocytes.
To complement our in vitro studies, we examined the presence of CD20 B
cells and expression of inflammatory cytokines IL-1 and IL-8 by immuno-
histochemistry in serial sections of tissue microarrays from patients with
estrogen receptor (ER) positive and negative ductal carcinoma in situ (DCIS)
and invasive carcinoma. Large areas of densely populated B cells were ob-
served in ER-DCIS and in invasive TNBC compared to ER DCIS. Further-
more, in ER- DCIS and TNBC, both B lymphocytes and tumor cells are found
to express IL1 whereas IL8 is found more specifıcally to be expressed by
tumor cells. Our fındings support the hypothesis that B lymphocytes pro-
mote a chronic inflammatory environment leading to increased invasion of
TNBC cells.
#651 Evaluation of the expression and function of TIM-3 relative to PD-1
in human tumors. Kristen McEachern,1 Srimoyee Ghosh,1 Yonghong Zhao,1
Qiyao Zhang,2 Norman Zhang,2 David W. Jenkins1. 1TESARO, Waltham, MA;
2Wuxi AppTec, China.
While immunotherapies directed against PD-1 and PD-L1 have proven effec-
tive across multiple indications, there is still a large unmet medical need for
therapies for patients who do not respond or who develop acquired resistance
during the course of treatment. There are several emerging hypotheses to ex-
plain the lack of response, including the overall presence and localization of
immune cells, as well as the up-regulation of additional T-cell checkpoints, in-
cluding TIM-3 in tumor infıltrating lymphocytes. To investigate the potential
role of TIM-3, we set out to evaluate the expression and function of TIM-3 and
the relationship to PD-1 in several systems. Firstly, we developed a flow cytom-
etrymethodology to enumerate T-cell, including CD4 and CD8 positive cells, as
well as other immune cell populations in a panel of human tumor samples,
includingnon-small cell lung cancer (NSCLC). In these samples, we investigated
the expression profıles of TIM-3 and PD-1 in both T-cell and non-T-cell popu-
lations. In addition, we performed complementary genomic studies to explore
gene expression profıles of not only the bulk tumor samples but also of isolated
PD1 positive/TIM-3 negative versus PD1 and TIM-3 double positive cell popu-
lations. The profıling identifıed tumors with a range of tumor infıltrating lym-
phocyte content and also differences in PD1 andTIM-3 expression. It was found
that in addition to T-cells, TIM-3was expressed onmyeloid cell populations and
furthermore, that there were distinct differences in the gene expression profıles
of PD1 single positive versus PD1 and TIM-3 double positive cells. Building on
the expression studies, the functional role of Tim-3 in T-cells and also on my-
eloid-derived cells was explored. Taken together, these studies provide further
evidence for TIM-3 as an important immunological checkpoint and as a relevant
therapeutic target for the treatment of cancer with the potential for biological
effects in both the T-cell and myeloid compartments of the tumor microenvi-
ronment.
#652 PD-L1 and MHC class 1 expression levels are modulated by MEK
inhibition on head and neck squamous cell carcinoma. Seong-Ho Kang,1
Bhumsuk Keam,2 Soyeon Kim,1 Miso Kim,2 Yong-Oon Ahn,1 Tae Min Kim,2
Dong-Wan Kim,2 Dae Seog Heo2. 1Cancer Research Institute, Seoul National
University, Seoul, Republic of Korea; 2Department of Internal Medicine, Seoul
National University Hospital, Seoul, Republic of Korea.
Background: To overcome immunosuppression, multiple pathways can be
targeted by counter strategies, including elimination of suppressive signals (such
as PD-L1 and CTLA-4) and promotion of antigen presentation from tumor
cells, and of T cell infıltration into tumor sites. The purpose of this study is to
investigate the change in expression of PD-L1 andMHCclass I aswell as of T cell
chemoattractants, CXCL9 andCXCL10, in human head and neck squamous cell
carcinoma (HNSCC) cell lines after treatment with MEK inhibitor. In addition,
for evaluation of immunologic effects of MEK inhibitor in vivo, we employed
SCC VII mouse squamous cell carcinoma (SCC) model. Methods: Six human
HNSCC cell lines (SNU-1041, SNU-1066, SNU-1076, Detroit 562, FaDu, and
HN31) and a mouse squamous cell carcinoma cell line (SCC VII) were used.
Trametinib was purchased from Selleckchem.We conducted cell viability assay
using these cell lines after 72 h incubation with MEK inhibitor trametinib.
PD-L1 andMHC class I expression levels were analyzed by flow cytometry after
treatment with trametinib and/or interferon-gamma (IFN-). Expression of
PD-L1, p-Erk1/2, and p-STAT1/3 were analyzed by western blot. STAT3 was
knocked down by siRNA transfection. To determine the levels of CXCL9 and
CXCL10 transcripts after trametinib treatment, reverse-transcription PCR was
carried out. Results: The growth inhibition by trametinib treatment was variable
between cell lines with moderate sensitivity (10 nM IC50 100 nM in fıve of
seven cells). IC50 values were over 10 M in Detroit 562 and FaDu. All the cell
lines have no upstream RAS or RAF mutation. Although trametinib treatment
was not shown to be enough for inhibiting growth of these cell lines, it up-
regulated MHC class I expression in all cells either alone ( 2-fold) or when
combined with IFN- ( 2-fold of IFN- alone). At the same time, we observed
PD-L1 expression was elevated by trametinib treatment when combined with
IFN- in all cells except SNU-1066, in which trametinib treatment down-regu-
late IFN--induced increase of PD-L1 expression. Furthermore, we observed
that trametinib alone and/orwith IFN- enhancedmRNAexpression of CXCL9
andCXCL10 in all human cells.Mechanistically, trametinib treatment enhanced
STAT1 phosphorylation by IFN- in fıve of six human cells, and directly phos-
phorylated STAT3. When we silenced STAT3, enhanced expression of MHC
class I by trametinib treatment was not observed in SNU-1041 cell. Conclusion:
Our results suggest that MEK pathway is closely related with modulating the
expression of PD-L1 and MHC class I as well as of CXCL9 and CXCL10 in
HNSCC cell lines. Up-regulated levels of MHC class I and T cell-recruiting
chemokines imply that MEK inhibitor may mediate potentiating T cell re-
sponses. Moreover, simultaneous increase of PD-L1 expression suggests the
possible synergistic role of MEK inhibitor when combined with anti-PD-1/
PD-L1 immunotherapy in HNSCC.
#653 Inhibition of MMP9 improves anti-tumor immunity by changing
the tumor microenvironment to promote T cell traffıcking and activa-
tion. Vladi Juric, Amanda Mikels-Vigdal, Chris O’Sullivan, Andrew Green-
stein, Erin Stefanutti, Vivian Barry-Hamilton, Igor Mikaelian, Ted Sullivan,
Erik Huntzicker, Jeremiah Degenhardt, Peng Yue, Victoria Smith. Gilead
Sciences, Foster City, CA.
Background: Matrix metalloproteinase 9 (MMP9) acts via diverse mecha-
nisms to promote tumor growth, invasion, and metastasis. It activates growth
factors and signaling pathways, promotes angiogenesis, and impedes anti-tumor
immune responses. We developed a monoclonal antibody that inhibits mouse
MMP9 (AB0046) and assessed its mechanism of action in immunocompetent
mouse tumor models and in vitro assays. Methods: We examined MMP9 ex-
pression in a variety of human tumor tissues via immunohistochemistry. Hu-
manmonocytes were differentiated in vitro and protein expression was assessed
via enzyme-linked immunosorbent assay. Primary tumor growth in orthotopic,
syngeneic tumor models was examined following anti-MMP9 antibody treat-
ment. RNA sequencing, immunohistochemical and flow cytometry analyses
were performed on tumor tissues to assess gene expression, stromal remodeling
andmacrophage polarization in response to AB0046 treatment. Results: MMP9
levels are elevated in human tumors compared to healthy tissues. The protein is
expressed predominantly in stromal cells, including macrophages and neutro-
phils, with more occasional heterogeneous expression in tumor epithelia. Dif-
ferentiation of humanmonocyte-derivedmacrophages in vitro revealed thatM2
polarization is associated with increased expression of MMP9 and Th2 markers
CCL18 and TGF. Anti-MMP9 treatment in three independent mouse tumor
models (HC11-NeuT, CT26, Lewis lung carcinoma (LLC)) resulted in decreased
primary tumor growth (p0.001 and p0.018 for HC11-NeuT and CT26 re-
spectively) and increased animal survival (p0.024 for LLC). Gene expression
profıling of tumors from the various models demonstrated that inhibition of
MMP9 resulted in elevated expression of genes associated with immune cell
activation pathways (Hallmark Interferon Gamma Response, p0.05,
FDR0.001). Additional analysis in the HC11-NeuT model revealed a signifı-
cant decrease in M2 macrophages in the tumor microenvironment (p  0.05)
with AB0046 treatment, as well as reductions in tumor-associated fıbrillar col-
lagen as assessed by Picrosirius red staining. Conclusions: These analyses show
that MMP9 is expressed in a variety of human tumors. Our data suggest that
inhibition of MMP9 promotes anti-tumor immunity and enhances a Th1 im-
mune response.GS-5745, a humanized anti-MMP9 inhibitory antibody, is being
evaluated in gastric cancer in phase 3 and 2 studies with chemotherapy and
nivolumab, respectively (NCT02545504, NCT02864381).
#654 The epigenetic landscape of T cell exhaustion. Debattama Sen. Dana
Farber Cancer Institute/Harvard Medical School, Cambridge, MA.
Exhausted T cells in cancer and chronic viral infection have distinctive pat-
terns of gene expression, including sustained expression of the inhibitory recep-
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tor PD-1, but the regulation of gene expression in exhausted T cells is poorly
understood. Here we defıne the accessible chromatin landscape in mouse and
human exhausted CD8 T cells and show that it is profoundly different from
functional memory CD8 T cells. Exhausted CD8 T cells in a mouse model of
chronic viral infection acquire an extensive, state-specifıc pattern of enhancers,
which are organized into functional modules. One enhancer, -23.8kb from the
Pdcd1 locus, is found only in exhausted T cells and other lymphocytes with
sustained PD-1 expression. Genome editing shows it to be required for high
PD-1 expression. Cas9-mediated in situ saturationmutagenesis of the enhancer
pinpoints critical minimal sequences that correspond to bound transcription
factor motifs for RAR, T-bet and Sox3 in exhausted CD8 T cells. State-specifıc
enhancer profıles identifıed in mouse exhausted CD8 T cells are conserved in
human exhausted antigen-specifıc CD8 T cells responding to HIV and HCV
infection. Detailed functional enhancer maps of T cell exhaustion reveal state-
specifıc regulatory sequences and offer targets for genome editing that could
alter gene expression preferentially in exhausted CD8 T cells.
CLINICAL RESEARCH: Checkpoint Inhibitor and Prognostic
Biomarkers
#655 Development of IHC staining protocols for assessment of PD-L1
expression in cytological samples. Christine Boyiddle,1 Mark Ruboyianes,1 Ed
Del Valle,1 Lukas Bubendorf,2 Kerstin Trunzer,3 Judith Pugh,1 Jennifer Boone1.
1Ventana Medical Systems, Oro Valley, AZ; 2University Hospital Basel, Basel,
Switzerland; 3F. Hoffmann-La Roche, Basel, Switzerland.
Immunohistochemistry (IHC) staining of non-small cell lung cancer
(NSCLC) samples for programmed cell death ligand 1 (PD-L1) can help identify
patients thatmay benefıt from anti-PDL1 therapy. However, resection or biopsy
samples cannot be obtained for some patients with NSCLC. Fine needle aspira-
tion (FNA) is a less invasive method for obtaining samples in such patients, and
it is yet to be determined if PD-L1 can be assessed using cytological samples. In
this study we had three objectives 1. Develop staining protocols on the VEN-
TANA BenchMark ULTRA automated staining platform for cytology samples
fıxed with the most common methods using cell lines as a model. 2, Determine
the optimal cytology fıxationmethod for VENTANAPD-L1 (SP142) IHCAssay
(PD-L1 (SP142)) staining, and 3. Assess PDL1 expression in tumor cells (TC)
and tumor-infıltrating immune cells (IC) in cytological samples prepared from
NSCLC patients. KARPAS 299 cell line was used as a model system for the
fıxation studies. Liquid-based preparations (LBPs) fıxed in PreservCyt, conven-
tional smears (unstained and pap-stained) fıxed in 95% ethanol, and paraffın
embedded cell blocks (CBs) fıxed in 95% ethanol, 10% neutral buffered formalin
(NBF), PreservCyt, and SurePath preservative were optimized on the Bench-
MarkULTRAusing PD-L1 (SP142) antibody andOptiViewDABDetection and
Amplifıcation Kits. NSCLC FNACBs fıxed in 10%NBF (N69) and a subset of
FNAs with matched resections (N20) were stained with the optimized proto-
col. FNAs and resections were assessed for percentage of TC and IC with PD-L1
staining. Staining parameters were optimized on the BenchMark ULTRA for all
sample types tested, and they all produced a range of moderate to strong PD-L1
expression. CBs fıxed in 95% ethanol and 10% NBF produced the highest per-
centage of staining, with expression in 90% of cells. CBs fıxed in PreservCyt and
SurePath preservative had a lower percentage of staining, 40% and 75% respec-
tively. LBPs had 25% cells staining and smears ranged from 20%-60%. NSCLC
FNA CBs fıxed in 10% NBF produced interpretable results when stained with
PD-L1 (SP142). IC staining was seen in 8.7% (6/69) of samples, TC staining was
seen in 8.7% (6/69) of samples, both IC and TC staining was seen in 14.5%
(10/69) of samples. The subset of FNAs with matched resections showed con-
cordance with PD-L1 IC staining in 60% (12/20) of samples and TC staining in
75% (15/20) of samples. The discordant cases showed that FNAs were negative
for IC when the resection was negative and positive for TC in 5% of cases when
the resection was negative. The VENTANA PD-L1 (SP142) Assay staining pa-
rameters were found to be optimal for staining NSCLC FNA CB fıxed in 10%
NBF. PD-L1 staining was detected in both TC and IC in FNA samples and
concordance of FNA and matched resections was high for both IC and TC. A
larger study is necessary to validate the use of FNAs for assessment of PD-L1
expression in a clinical setting.
#656 PD-L1 expression in primary lesions vs metastatic sites and by de-
mographics in advanced urothelial carcinoma samples. M Zajac,1 A M.
Boothman,1 Y Ben,2 A Gupta,3 X Jin,3 J Antal,3 A Sharpe,1 M Scott,1 M Rebe-
latto,3 J Walker1. 1AstraZeneca, Cambridge, United Kingdom; 2AstraZeneca,
Gaithersburg, MD; 3MedImmune, Gaithersburg, MD.
Background:Determination of programmed cell death ligand-1 (PD-L1) expres-
sion levels in tumorsmay help physicians understandwhich patients (pts) aremost
likely to respond to anti-PD-1/PD-L1 therapies in urothelial carcinoma (UC). Un-
derstanding the impact of different sample types and demographics on PD-L1 ex-
pression is important to determine suitability of tumor biopsies for testing.
Methods: As of July 24, 2016, 363 pts screened in the UC cohort of Study CD-ON-
MEDI4736-1108 (NCT01693562) had tissue available for analysis and 47 pts had
provided paired primary and metastatic samples. FFPE samples were tested in a
central laboratory with the VENTANA PD-L1 (SP263) Assay using a BenchMark
ULTRA instrument. Ptswere classifıed as having either PD-L1high (PD-L1 expres-
sion	25% either on tumour cells [TC] or immune cells [IC]) or PD-L1 low/nega-
tive (25%onTCand IC) tumors. PD-L1 high prevalencewas reported in primary
vsmetastatic sites, and by age, sex and race. Results: PD-L1 status was evaluable for
332/363 (91.5%)pts (175/332 [52.7%]PD-L1high and157/332 [47.3%]PD-L1 low/
negative) whose UC specimens were tested (intent to diagnose [ITD] population).
Overall percentage agreement between paired primary and metastatic samples,
based on combined TC/IC scoring	25%, was 74.5% (95%CI 59.7 - 86.1%). In the
ITDpopulation,usingonly the samples fromwhichpatientPD-L1expressionstatus
was determined, PD-L1 high prevalence in primary and metastatic samples was
57.1%and50.9% respectively (p0.343, not signifıcant). Theproportionof ptswith
PD-L1 high status was not enriched in any demographic group (Table). Conclu-
sions: Initial data fromUCpts in Study 1108 showed similar PD-L1highprevalence
in primary and metastatic lesions and good concordance between paired primary
and metastatic samples. These results build optimism that samples obtained from
either location could be used to determine PD-L1 status. Further data are needed to
confırm these fındings.
Patients screened for UC cohort with evaluable PD-L1 result - ITD
population (n 332)
Parameter PD-L1 high, n (%) P value
Age, years 65 (n131) 73 (55.7%) 0.438
	65 (n201) 102 (50.8%)
Sex Male (n236) 127 (53.8%) 0.610
Female (n96) 48 (50.0%)
Race Asian (n52) 23 (44.2%) Asian vs White: 0.406
Black or African American
(n10)
6 (60.0%)
White (n218) 113 (51.8%)
Other (n9) 4 (44.4%)
#658 Association of tumor mutational burden (TMB) with DNA repair
mutations and response to anti-PD-1/PD-L1 therapy in non-small cell lung
cancer (NSCLC).Andrew A. Davis, Young Kwang Chae, Sarita Agte, Alan Pan,
Nisha Mohindra, Victoria Villaflor, Kirtee Raparia, Francis J. Giles. Northwest-
ern University, Chicago, IL.
Background: Identifying optimal biomarkers for response to anti-PD-1/
PD-L1 therapies in non-small cell lung cancer (NSCLC) is critical. Tumor mu-
tational burden (TMB) is a potential biomarker of genomic instability and neo-
antigen binding sites to activated effector T cells. The goal of this study was to
examine the association of TMB with overall survival for patients treated with
checkpoint blockade and to correlate TMB with mutational status, including
DNA repair mutations. Methods: We retrospectively examined TMB using
next-generation sequencing (FoundationOne) for 82 patients with NSCLC in
our institution. TMB included coding base substitutions and indel alterations,
but excluded potentially functional mutations. TMB high versus low was strat-
ifıed based on 15 mutations per megabase pair. We correlated TMB with DNA
repair mutations, mutational status, and smoking history. In addition, survival
data were obtained for 35 patients who were treated with anti-PD-1/PD-L1
therapy. Results: TMB was associated with signifıcantly longer overall survival
for patients treated with checkpoint blockade (Table 1, p  0.04). In addition,
TMB was independently correlated with direct and indirect (Chae et al. 2016)
DNA repair mutations (p  0.03). TMB was also signifıcantly associated with
smoking, number of coding region mutations, and treatment with at least two
prior lines of therapy (p  0.02). A trend toward lower TMB was found for
patients with mutations in EGFR, ALK, or KRAS (p  0.06). Conclusions:
Higher TMB was associated with improved survival for patients treated with
anti-PD-1/PD-L1 therapies. In addition, TMB was correlated with DNA repair
mutations, number of coding mutations, prior treatment, and smoking. Our
results indicate that TMB can be used as a biomarker for response to checkpoint
blockade in NSCLC.
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Table 1. Tumor mutational burden (TMB) by patient characteristic and
mutation status
Patient Characteristic TMB (mutations per megabase) P
TMB
(<15)
TMB
(>15) All
Smoking History Minimal/
Never (N)
25 1 26 P 0.011
Current/
Former (N)
38 18 56
All (N) 63 19 82
Number of Treatment
Lines Prior to
Checkpoint Blockade
(Excluding
Targeted Therapy)
0-1 (N) 20 4 24 P 0.017
2 (N) 4 7 11
All (N) 24 11 35
Presence of EGFR/ALK/
KRAS Mutations
Yes 27 3 30 P 0.061
No 36 16 52
All (N) 63 19 82
Number of Potentially
Functional Direct
Indirect DNA
Repair Mutations
Mean (N) 0.76
(N63)
1.26
(N19)
0.88 (N82) P 0.027*
Number of VUS
Direct Indirect
DNA Repair
Mutations
Mean (N) 1.30
(N63)
2.26
(N19)
1.52 (N82) P 0.011*
Number of Direct DNA
Repair Mutations
Mean (N) 1.08
(N63)
2.42
(N19)
1.39 (N82) P 0.001*
Number of Total DNA
Repair Mutations
Mean (N) 2.06
(N63)
3.53
(N19)
2.40 (N82) P 0.005*
Number of Potentially
Functional Mutations
Mean (N) 4.79
(N63)
8.00
(N19)
5.54 (N82) P 0.002^
Number of VUS Mutations Mean (N) 9.13
(N63)
25.00
(N19)
12.80 (N82) P 0.001^
Total Reported Mutations Mean (N) 13.92
(N63)
33.00
(N19)
18.34 (N82) P 0.001^
Overall Survival Kaplan-Meier Log-Rank Test P 0.020
Cox Proportional Hazards Regression Model HR 0.19
95% CI:
[0.04 - 0.88]
P 0.034
VUS, Variant of Unknown Signifıcance; HR, Hazard Ratio; Pearson’s Chi-Squared; *
Logistic regression; ^ Welch’s two-sample t-test
#659 Multiplex cocktails for immunotherapy targets: PD-L1 with tumor
specifıc transcription factors. David Altree-Tacha, Wei Yuan, George Yang.
Biocare Medical, Concord, CA.
Introduction: Blocking the interaction between the programmed cell death
(PD)-1 protein and one of its ligands, PD-L1, has been reported to generate
impressive antitumor responses. Therapeutics targeting PD-L1 in several can-
cers are currently in clinical trials, and the U.S. FDA has granted accelerated
approval for Keytruda (pembrolizumab) to treat patients with advanced (meta-
static) non-small cell lung cancer (NSCLC). Various pathology scoring and in-
terpretation methods have been put forth to assay PD-L1 expression, and vari-
ability of non-PD-L1 staining across tumors may have important prognostic
aspects. PD-L1 expression on tumor cells can be upregulated via activation of
CD8 cytotoxic T lymphocytes. PD-L1 expression is also associated with cer-
tain subtypes of tumor-associated lymphocytes, macrophages and dendritic
cells. In certain cancers, the cross reactivity of PD-L1 can make interpretation
and scoring diffıcult. Thus, a strategy using IHC multiplex stains could help
resolve challenging cases by cocktailing PD-L1 with target tissue transcription
factor antibodies along with other potential markers. Method and Materials:
Formalin-fıxed paraffın-embedded tissues and tissue microarrays for various
tumor types including lung, bladder and melanoma were processed and cut at
4-5microns. PD-L1 rabbitmonoclonal antibodywas cocktailed with the follow-
ing antibodies: TTF-1 (lung cancer); CD163 (lung cancer); p40 GATA3
(bladder cancer); and SOX10 (melanoma). Cocktails were detected with double
stain detection systems using brown, red and blue chromogens for visualization.
Sections were counterstained with a standard hematoxylin or Wiegert’s iron
hematoxylin. Results PD-L1 and TTF-1 with or without CD163 (macrophage)
and PD-L1 CD163 were used in lung cancers. The nuclear staining of TTF-1
in lung adenocarcinoma (blue chromogen) helped defıne tumor positive PD-L1
(DAB) positive cells and CD163 (Fast Red) marked macrophages. PD-L1 com-
bined with p40 and GATA3 was deployed for bladder cancers. PD-L1 membra-
nous expression in tumor cells and co-expression of p40 and GATA3 gave ro-
bust nuclear staining in bladder tumor cells. Finally, SOX10nuclear stainingwas
observed in most melanoma cells and could be easily separated from PD-L1
membrane staining. Conclusion: PD-L1 cocktailed with strategic nuclear or cy-
toplasmic antibodies can help discriminate tumor cells from non-tumor cells,
and may facilitate quantitation or scoring methods for more accurate assess-
ment of this key immunotherapy marker.
#660 Pre-symptomatic detection and early treatment ofmammary cancer
with anti-PD-L1 in a mouse mode. Hu Duan, Stephen Albert Johnston, Shen
Luhui. Biodesign Institution, ASU, Tempe, AZ.
Cancer kills8M people/year and the WHO predicts an epidemic of cancer
in the developing world over the next 20 years due to increased longevity. De-
velopment of a simplemethod to detect and treat cancer early could be a solution
to this challenge. Here we test this approach in principle in a transgenic mouse
mammary tumor model by immunosignature (IMS) diagnostics. IMSs are pro-
fıles of antibodies in the blood displayed on a high density peptide array. As
previous published data showed, the IMS can distinguish different diseases
based on the disease specifıc antibody profıle in the patient, including different
cancers and infectious diseases. According to the immune surveillance theory,
the immune system, including the humoral immune response, starts to interact
with cancer cells as soon as they are transformed. First, we tested if the IMS is
sensitive enough to detect the antibody profıle change caused by the early tumor
development in the FVB-NeuN (MMTVneu/202Mul/J) mammary cancer
model. In the FVB-NeuN model, the MMTV promoter activates the wild type
rat ERBB2 gene in mammary cells, and every mammary cell potentially can
convert into a cancer cell. The transition from normal mammary glands to
hyperplasia of FVB-NeuN inmouse starts at 8.6 to 15weeks after birth. Themice
develop the fırst palpable tumor in one of the ten mammary glands by 19-45
weeks of age with an average age of 321.2 weeks in our hands. We collected
serum every 4 weeks from the FVB-NeuNmice and the wild type FVB mice for
the IMS analysis. The IMS can distinguish the FVB-NeuN mouse from the age
matched wild type FVBmouse as early as 12 weeks (Stage-1) before the onset of
the fırst palpable tumor. We also analyzed the IMSs from the Stage-2 (8 weeks
before the palpable tumor and so on) to Stage 4. Different IMS of each stage has
only partial overlap with the other stages. The cross-stage prediction analysis
showed the accuracy of the cancer detection by using different IMS is from 75%
to 93%. Second, we determined if early treatment at the time of diagnosis with
the checkpoint blockade, anti-PD-L1, would inhibit the tumor growth. A course
of 3 injections at the time of diagnosis signifıcantly retarded tumor growth
relative to untreated controls. The early treatment elicited long-term protection
which could restrict the tumor growth even fourmonths after the treatment. The
treatedmice presented a specifıc IMS at 28 days post treatment and 35 days post
the fırst palpable tumor, compared to the untreatedmice. This indicates that the
early treatment elicited an anti-tumor immune response that could inhibit tu-
mor growth. This preliminary experiment suggests that early diagnosis com-
binedwith systemic treatmentmight be amethod to control or eliminate cancer.
#661 Evaluating “harmonization” of PD-L1 assays using image analysis.
Nathan T. Martin, Joshua C. Black, Zachary Pollack, Famke Aeffner, Joseph
Krueger. Flagship Biosciences, Westminster, CO.
The current diagnostics landscape for therapeutics that target the PD1/PD-L1
pathway is highly complex. Four different companion or complementary diag-
nostics have been developed for pembrolizumab in NSCLC, nivolumab in
NSCLC and melanoma, and atezolizumab in urothelial carcinoma. The need to
reconcile diagnostics for this class of targeted therapies has been recognized by
the creation of the FDA-AACR-ASCO “PD-L1 Blueprint” working group to
explore means to “harmonize” PD-L1 testing in tissue based IHC assays. The
results reported from this working group noted similarities, but also several
important discrepancies, between the current assays. Since each test uses a spe-
cifıc interpretation for each assay and indication, this creates a highly complex
diagnostic landscape, which is likely to continue to increase in complexity as
more PD-1/PD-L1 therapeutics and potentially novel diagnostics continue to be
approved in additional indications. To address the need for adaptive, sustainable
harmonization for PD-L1 diagnostics, Flagship Biosciences evaluated the utility
of image analysis-based methods to harmonize multiple PD-L1 tests. We exe-
cuted a proof-of-concept study utilizing a cohort of serial tissue sections from
the same NSCLC patients, stained with the FDA approved Dako PD-L1 tests
(28-8 and 22C3 clones), and our in-house PD-L1 assays (SP142 and E1L3N
clones) for comparison. We digitized the tissue slides using a whole slide scan-
ner, and evaluated the sampleswith our tissue ImageAnalysis (tIA™) technology.
As expected, the patient samples stained with the separate PD-L1 assays yielded
differences in staining and, thus, the reported scores for PD-L1 expression based
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on each test used, despite serial sections being derived from the same patient. To
attempt to harmonize the scoring approaches for each test, we leveraged our
computational Tissue Analysis (cTA™) platform to create a mathematically-de-
rived “virtual slide score” for each sample, which enabled calibration of the
various tests to deliver cross PD-L1 comparative scores. Based on the proof-of-
concept demonstrated in this study, the cTA™ approaches could enable harmo-
nization of the various PD-L1 tests through use of a digital pathology platform.
The data presented provides a foundation for potential application of the cTA™
platform in the clinical laboratory setting to achieve harmonization of multiple
PD-L1 tests.
#662 The differential association of PD-1, PD-L1, and CD8 cells with
response to pembrolizumab and presence of Merkel cell polyomavirus
(MCPyV) in patients withMerkel cell carcinoma (MCC).Nicolas A. Giraldo,1
Genevieve J. Kaunitz,1 Tricia R. Cottrell,1 Sneha Berry,1 Joel C. Sunshine,1 Peter
Nguyen,1 Haiying Xu,1 Aleksandra Orgutsova,1 Candice D. Church,2 Natalie J.
Miller,2 Jennifer H. Yearley,3 Evan J. Lipson,1 Ludmila Danilova,1 Paul T. Ng-
hiem,2 Suzanne L. Topalian,1 Janis M. Taube1. 1Johns Hopkins Medical Institu-
tions, Baltimore, MD; 2University of Washington, Seattle, WA; 3Merck Research
Labs, Biologics Discovery, Palo Alto, CA.
We recently reported a 56% objective response rate in patients with advanced
MCC receiving pembrolizumab (anti-PD-1) as fırst-line therapy. However, a
tumor biomarker predicting clinical response was not defıned. The purpose of
this study was to determine potential associations of anti-PD-1 response (RE-
CIST 1.1, analysis 8/1/16) and the presence of MCPyV, with the density and
distribution of CD8, PD-1 and PD-L1 cell populations in the tumor mi-
croenvironment (TME). Pretreatment FFPE tumor specimens were stained for
CD8 (n23) and PD-L1 (n16, 22C3 assay) with immunohistochemistry
(IHC). Immunofluorescence (IF) was used to detect PD-1 (n16). Intratumoral
(IT), peritumoral (PT, 100 um zone) and total (PTIT) densities of PD-1 and
CD8 immune cells (IC) were determined with digital image analysis. PD-L1
cases had1% tumor cells (TC) expressing PD-L1. Tumors from patients who
responded to anti-PD-1 showed higher densities of PD-1 cells in the IT, PT,
and ITPT regions when compared to non-responders (Mann-Whitney test,
p-value0.03, 0.06, 0.03, respectively). There was no signifıcant association of
response with CD8 IC densities (IT, PT or total) or TC PD-L1 expression.
Similarly, when we quantifıed the number of PD-1 IC located within 15 um
from a PD-L1 cell (TC or IC), an association was observed between PD-1 and
PD-L1 proximity and clinical response (Mann-Whitney test, p-value 0.04),
but not CD8 and PD-L1 proximity. Because viral neoantigens can elicit a strong
immune response, we also studied these TME factors for their potential associ-
ations withMCPyV.We found the presence of virus was signifıcantly associated
with increased densities of PTCD8 cells (Mann-Whitney test, p-value0.008)
and TC PD-L1 expression (Fisher’s test, p-value0.04), but not PD-1 IC. A
more extensive multiplex IF panel (CD8, PD-1, PD-L1, CD68, FoxP3, NSE)
analysis was performed on select pre-treatment specimens using the Vectra
multispectral imaging system (Perkin Elmer) to explore this divergence. We
found that only 60% of observed total PD-1 expression was displayed by
CD8 cells. Although preliminary, our results suggest a relationship between
PD-1 cells and response to anti-PD-1 therapy and highlight that lymphocyte
subsets other than CD8 T-cells may contribute to the observed response. Fur-
ther studies in larger cohorts are needed to validate these results.
#663 Clinical performance andutilization of 3 PD-L1 immunohistochem-
ical assays. Steven M. Anderson,1 Bruce Horten,2 Bryan McCune,3 Ronald
Paler4. 1Covance, Durham, NC; 2Integrated Oncology, New York, NY; 3LabCorp,
Research Triangle Park, NC; 4Covance, Phoenix, AZ.
Three different PD-L1 immunohistochemical (IHC) assays have recently
been approved to help guide treatment decisions regarding anti-PD-1
(Keytruda®, Opdivo®) and anti-PD-L1 (Tecentriq®) immuno-oncology based
therapies. The three assays differ in the primarymonoclonal antibodies used, the
assay platform (Dako, Ventana), scoring and interpretation criteria, and in-
tended use. Our clinical laboratories currently offer all 3 assays (pharmDx™
22C3, pharmDx™ 28-8, and SP142) because they are associated with different
intended uses, companion and complementary diagnostics for non-small-cell
lung cancer (NSCLC), and complementary diagnostic for urothelial carcinomas
(UC). In the NSCLC samples evaluated in the fırst year since the approval of the
two pharmDx™ assays, we have noted a higher percentage of positive samples
with the pharmDx™ 28-8 assay (50%) compared to the pharmDx™ 22C3 assay
(30%). This difference is mainly due to the use of different assay cutoffs associ-
atedwith the two assays, as there is good correlation between the overall staining
patterns, including the distribution of the percentage of tumor cells exhibiting
positive staining. For the SP142 assay tested on UC samples, 22% of the cases
were considered positive. All 3 assays are robust, with a limited number of
samples considered inconclusive (10%), mainly due to an inadequate number
of tumor cells. The companion diagnostic PD-L1 assay (pharmDx™ 22C3) has
had the greatest utilization of the 3 assays, as it is required for the use of the
Keytruda® in NSCLC samples. The performance features of the 3 different
PD-L1 assays in the clinical laboratory setting has shown that all assays are
robust and can be readily scored and interpreted by the pathology team. The
utilization of the 3 assays correlateswith respective intendeduse, tumor type and
companion versus complementary diagnostic application, for each assay.
#664 Analytical validation and clinical utility of an immunohistochemical
PD-L1 diagnostic assay for treatment with durvalumab in urothelial carci-
noma patients.MZajac,1 A M. Boothman,1 Y Ben,2 A Gupta,3 J Antal,3 X Jin,3
A Nielsen,4 GManriquez,4 C Barker,1 PWang,4 P Patil,4 N Schechter,4 M Rebe-
latto,3 J Walker1. 1AstraZeneca, Cambridge, United Kingdom; 2AstraZeneca,
Gaithersburg, MD; 3MedImmune, Gaithersburg, MD; 4VentanaMedical Systems
Inc., Tucson, AZ.
Background: A high quality programmed cell death ligand-1 (PD-L1) diag-
nostic may help to identify patients (pts) most likely to respond to anti-PD-L1/
programmed cell death-1 (PD-1) therapy. Here we describe a PD-L1 immuno-
histochemical (IHC) diagnostic test developed for urothelial carcinoma (UC)
pts treated with durvalumab. Methods: The IHC assay uses an anti-human
PD-L1 rabbit mAb optimized for detection of both tumor cell (TC) and tumor-
associated immune cell (IC) PD-L1 expression with the OptiView DAB IHC
Detection Kit on the automated VENTANABenchMark ULTRA platform. The
assay was validated for intended use in UC formalin-fıxed, paraffın-embedded
samples in a series of studies that addressed sensitivity, specifıcity, robustness
and precision and implemented in Study CD-ON-MEDI4736-1108
(NCT01693562). Ptswere evaluated using theVENTANAPD-L1 (SP263)Assay
at a prespecifıed PD-L1 expression cut-off. Effıcacy was analyzed in pts with
PD-L1 low/negative (defıned as TC 25% and IC 25%) UC and in pts with
PD-L1 high (defıned as TC 	25% or IC 	25%) UC. Results: The VENTANA
PD-L1 (SP263)Assaymet all the predefıned acceptance criteria (average positive
agreement and average negative agreement85%), showing analytical specifıc-
ity, sensitivity and precision. It demonstrated 	97% and 	85% inter-reader
precision agreement for TC and IC respectively. For intra-reader precision, it
demonstrated 96% and 87% agreement for TC and IC respectively. For
intra-day performance, the assay demonstrated	96% agreement for TC and IC
and for inter-day performance, it demonstrated	98% and 100% agreement for
TC and IC respectively. Precision studies for inter-antibody lot, inter-detection
kit lot and intra-platform demonstrated97% agreement for both TC and IC.
Inter-laboratory testing was performed at 3 external laboratories and demon-
strated an overall agreement rate of 92.3%. The VENTANA PD-L1 (SP263)
Assay was implemented in Study CD-ON-MEDI4736-1108 and durvalumab
demonstrated clinical activity anddurability of response in bothPD-L1high and
PD-L1 low/negative subgroups, yet with different response rates. In addition,
given the high negative predictive value of the assay, it is especially helpful in
evaluating the likelihood of response to durvalumab; pts who were classifıed as
PD-L1 high with the VENTANA PD-L1 (SP263) Assay tended to have a higher
objective response rate per RECIST v1.1 than pts whowere PD-L1 low/negative.
Conclusions: These data show that determination of PD-L1 expression in TC
and IC in UC pts using the VENTANA PD-L1 (SP263) Assay is precise and
highly reproducible and highlight the utility of the assay in a clinical setting. The
VENTANASP263Assay is especially helpful in informing pts and physicians on
the likelihood of response to durvalumab, but not for the purpose of restricting
treatment to only PD-L1 high pts.
#665 Molecular and clinical analyses of patients with gynecologic malig-
nancies treated with PD-1 directed immunotherapy. Young Kwang Chae,1
Sabina Murshudova,1 William H. Bae,2 Jonathan F. Anker,1 Mario J. Pineda,1
Wilberto Nieves-Neira,1 Daniela E. Matei,1 John R. Lurain,1 Shohreh Shahabi,1
Francis J. Giles1. 1Northwestern University, Chicago, IL; 2Yonsei University Col-
lege of Medicine, Seoul, Republic of Korea.
Long term responses are seldom seen in treatments of advanced or recurrent
gynecologic cancers. In contrast, immunotherapeutic strategies targeting im-
mune checkpoints such as programmed cell death-1 (PD-1) are currently in
active development in platinum resistant gynecologic malignancies with prom-
ising durable responses observed in subset of patients. We analyzed all 14 pa-
tients with gynecology malignancies that were treated with PD-1 directed im-
munotherapy, nivolumab or pembrolizumab at the developmental therapeutics
program (DTP) clinic in Northwestern University during 2015 till 2016. Seven
patients had ovarian/fallopian/peritoneal cancer; six, endometrial cancer; 1,
squamous cell carcinoma (SCC) of cervix that are refractory to standard-of-care
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chemotherapies. Comprehensive genomic profıling including microsatellite in-
stability (MSI) status and tumor mutational burden (TMB) analyses was per-
formed using next generation sequencing (NGS) (FoundationOne). Among 7
patients with ovarian/fallopian/peritoneal cancer (median age, 62 years), objec-
tive response rate (ORR) was 20%. One patient had partial response (PR), an-
other one had stable disease (SD), and 3, progressive disease (PD). Two patients
were uable to be evaluated. In a patient with PR, CA 125 level normalized from
426.2 to 10.8U/mL.Her tumor had very lowTMB (1/Mbp). In all patients, TMB
level varied from very low to low (1-5 mut/Mbp) with MSI status being stable.
Progression free survival (PFS) ranged from 14 to 196 days; overall survival (OS)
varied from 60 to 199 days. Among 6 patients with endometrial cancer (median
age, 68 years), ORR was 20%. One patient had PR while four experienced PD.
One patientwhose disease could not be assessed due to early death froman event
unrelated to treatment had a remarkable chemical response with a decrease in
CA125 level from 5,889 to 182.1 U/mL after one single dose. Her tumor had
MSI-stable status and intermediate TMB (6 mut/Mbp). In a patient with PR,
CA125 level decreased from 1,216 to 226.5 U/mL. Her tumor had MSI-high
status with unknown TMB. Of note, one of four patients with PD hadMSI-high
status and intermediate level of TMB.Other patients had tumorwithMSI-stable
status and low level of TMB (3-4 mut/MB). PFS ranged from 23 to 258 days; OS
varied from73 to 265 days.OnepatientwithHPVpositive SCCof cervix (34 year
old) experiencedPD.Her tumor hadMSI-stable statuswith unknownTMB. PFS
was 88 days; OS, 132 days. In summary, patients with ovarian and endometrial
cancer treated with PD-1 directed immunotherapy demonstrated ORR of 20%.
One additional patient with endometrial cancer had an exceptional chemical
response. None of the tumors had high TMB (6/Mbp). No clear associations
between genomic traits including TMB and MSI staus and responses were
found. Further larger prospecitve studies are warranted to explore potential
biomarkers for response with immunotherapy in gynecologic malignancies.
#666 CD37 tetraspanin as a novel biomarker for PD-1 blockade in diffuse
largeB-cell lymphoma.ZijunY. Xu-Monette, KenH. Young.UTMDAnderson
Cancer Ctr., Houston, TX.
PD-1 immune checkpoint blockade reconstituting antitumor immunity has
changed the cancer treatment paradigm. PD-1 blockade has been successful in
many types of solid tumors andHodgkin lymphoma, but not yet for diffuse large
B cell lymphoma (DLBCL), the most common aggressive B-cell lymphoma.We
found several biomarkers including loss of CD37 tetraspanin expression in DL-
BCL correlated with increased PD-1 expression suggesting potential sensitivity
of these DLBCL subsets to PD-1 blockade. CD37 (TSPAN26) is amember of the
tetraspanin superfamily, widely expressed on normal and malignant mature
B-cells and downregulated in plasma cells. It has been documented that CD37
plays important roles in T-cell-B-cell interactions, B-cell humoral response trig-
gered byB-cell receptor cross-linking, and a balance between immune responses
and tolerance. Interestingly, in a large cohort of DLBCL patients, we found that
loss of CD37 expression in DLBCL predicts strikingly decreased overall and
progression-free survival rates, and that PDCD1 gene expression was upregu-
lated in CD37-negative activated B-cell-like (ABC) DLBCL by gene expression
profıling, whereas the costimulatory molecule ICOSLG was upregulated in
CD37 germinal center B-cell-like (GCB) DLBCL. Using the new fluorescent
multiplex technology, we further measured PD-1 and PD-L1 expression at the
protein level on lymphoma cells and immune cells in the tumor microenviron-
ment, and found that PD-1 protein levels were increased on both cytotoxic and
helper T-cells infıltrating in CD37-negative DLBCL either of GCB or ABC sub-
type. These novel discoveries suggest that CD37 is important for sustained an-
titumor adaptive immunity, that immune dysregulation plays an important role
for poor clinical outcomes in DLBCL, and that CD37-negative DLBCL may be
sensitive to PD-1 blockade. In summary, loss of aCD37 tetraspaninwas found to
correlate with PD-1 overexpression in DLBCL clinical samples, and CD37 may
serve as a novel biomarker for anti-PD-1 immunotherapy clinical trials in DL-
BCL.
#667 Immunoprofıling circulating blood as a means to early detection of
solid tumors. Amit Kumar,1 Dimitry Gabrilovich,2 Frank J. Rauscher,2 George
Dominguez,2 Cyrus Sholevar,1 John Roop,1 Anthony Campisi,1 Alexander
Polo2. 1Itus Corporation, Los Angeles, CA; 2Wistar Institute, Philadelphia, PA.
Our goal was to evaluate whether profılingMyeloid Derived Suppressor Cells
(MDSCs) in circulation correlated with the existence and stage of multiple,
biopsy-verifıed solid tumor types and to evaluate whether such analyses could
enable early detection. The tumor micro-environment (TME) is replete with
numerous immune cells, and the type and concentration of such cells can pro-
vide prognostic information. The link between high concentrations of MDSCs
and poor prognosis is most likely due to the immuno-suppressive effects of such
cells. Some fraction of these cells spill into the blood stream. We utilized flow
cytometry to phenotypically quantify subsets ofMDSCs and other leukocytes in
the circulation of biopsy-verifıed cancer patients, as well as in age and sex
matched healthy donors. Our results indicate amarked increase inMDSC levels
in the circulation of tumor patients relative to healthy donors.We have analyzed
patients presenting over a dozen solid tumor types (lung, breast, ovarian, colon,
melanoma, liver, thyroid, pancreatic, uterine, osteosarcoma, appendiceal, leio-
myosarcoma, liposarcoma, and vulvar) and found notable differences in the
immune-profıles of circulating blood in these patients. It appears that the im-
mune response, as measured by our flow cytometry technique, is general for
most tumor types. We will present correlations and inter-relations between
different cell types and evidence of tumors. While our studies to date have been
performed in an unblindedmanner, we will present performance data (specifıc-
ity and sensitivity) for our approach.
#668 Evaluation of -1-acid glycoprotein as a prognostic marker and as a
predictive biomarker for severe neutropenia induced by docetaxel in esoph-
ageal carcinoma patients. Yusuke Sasaki,1 Ken Kato,2 Hidekazu Hirano,2 Hi-
rokazu Shoji,2 Yoshitaka Honma,2 Satoru Iwasa,2 Atsuo Takashima,2 Tetsuya
Hamaguchi,2 Kengo Nagashima,3 Narikazu Boku2. 1National Cancer Center
Hospital, Hakodate Central General Hospital, Tokyo, Japan; 2National Cancer
Center Hospital, Tokyo, Japan; 3Chiba University Graduate School of Medicine,
Chiba, Japan.
Background: Serum -1-acid glycoprotein (AAG) level is an independent
predictor of response and a prognostic factor of survival in patients with non-
small cell lung cancer treated with docetaxel chemotherapy. However, whether
AAG is associated with the outcomes of esophageal cancer patients treated with
docetaxel remains unclear. Methods: Between August 2009 and April 2014, pre-
treatment serum samples were obtained from patients with clinical stage II/III
esophageal cancer. Individuals were subsequently treated with neoadjuvant
DCF or CF followed by surgery. DCF consisted of docetaxel and cisplatin on day
1, and continuous infusion of 5-fluorouracil on days 1-5, with this regimen
repeated every 3 weeks for up to three cycles. CF consisted of cisplatin and
5-fluorouracil. Patients were divided into groups based on the median value of
baseline AAG levels. Response to chemotherapy, survival, and the most severe
grade of neutropenia were compared between the high and low AAG groups at
each regimen. Results: A total of 129 patients were enrolled (44 received neo
DCF and 85 neo CF). The median serum AAG level was 95 g/L (range 57-228
g/L) and 95 g/L (range 46-197 g/L) in the patients with neoDCF and CF, respec-
tively. For all patients, overall survival (OS) was signifıcantly shorter in the high
AAGgroup (AAG 95 g/L) than the lowAAGgroup (AAG 95 g/L) (HR2.18,
p0.03). Both in the neo DCF and neo CF patients, there was a similar trend in
OS between individuals with high and low AAG levels. Multivariate analysis
demonstrated that AAG level (HR 1.98) and performance status (HR 2.20) were
independent prognostic factors. However, the relationship between response to
chemotherapy and AAG level were similar both in DCF and CF patients. In
addition, grade 4 neutropenia was observed in 50% of patients with low AAG
level and 23%with high AAG (p 0.06) in DCF patients. A correlation analysis
revealed a statistically signifıcant correlation between serum AAG level and
nadir absolute neutrophil count caused by DCF chemotherapy. However, in CF
patients, there was no difference in the frequency of severe neutropenia between
individuals with high and low AAG level, and there was no correlation between
AAG and nadir neutrophil count. Conclusions: Serum AAG level may be a
prognostic marker for survival in stage II/III esophageal cancer patients treated
with neoadjuvant chemotherapy. In addition, low serumAAG level is a potential
predictive biomarker of docetaxel-induced severe neutropenia.
#669 Quantifıcation of estrogen (ER) and progestin receptor (PR) as well
as HER2/neu proteins and gene expression improves discrimination of clin-
ical behavior by triple positive breast carcinomas.Zohair R. Hameed,Michael
W. Daniels, D. Alan Kerr, James L. Wittliff. University of Louisville, Louisville,
KY.
IHC analyses of ER, PR andHER2 proteins are used as clinical biomarkers for
breast cancer management. However, IHC provides semi-quantitative results
sometimes complicated by variation in methods and interpretation. Our goal
was to ascertain clinical use of these three analytes to predict breast cancer
recurrence when analyses for gene expression and protein products were quan-
tifıed. Procedures: We examined ER and PR protein in 1059 de-identifıed carci-
noma biopsies previously quantifıed by radio-ligand binding and/or enzyme
immunoassay (EIA) using FDA approved reagents and HER2 oncoprotein de-
termined by EIA to assess relationships between biomarker profıles and disease-
free (DFS) and overall survival (OS) for 123 patients. Our comprehensive, IRB-
approved Database also contained de-identifıed Microarray results obtained
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for 22,000 genes from LCM-procured breast carcinoma cells of 247 primary
breast biopsies. ESR1, PGR and ERBB2 gene expression levels were validated
previously in 278 cancers by qPCR. Results: Generalized Pair Plots of the three
protein biomarkers indicated a relationship only between ER andPR supporting
evidence that ER complexed with estrogenic ligands promotes synthesis of PR.
Of the 8 possible combinations of the 3 protein biomarkers, only breast cancers
exhibiting ERPRHER2 (triple positive breast cancer, TPBCa) exhibited
increased OS, whereas those with triple negative breast cancers (TNBCa) had
decreased OS. TPBCa was exhibited by 32.5 % of specimens compared to TN-
BCa, which represented 7.3% of biopsies when biomarker proteins were quan-
tifıed. Number of TPBCa was less when expression of the 3 genes (ESR1/
PGR/ERBB2) was measured by microarray or by qPCR while those of
TNBCa increased. Furthermore,whenTPBCawere identifıed by eithermicroar-
ray or by qPCR measurements, collectively increased ESR1, PGR and ERBB2
expression was associated with increased PFS and OS of patients. In contrast,
biopsies that were ESR1-/PGR-/ERBB (14.1%) correlatedwith poor prognosis
and overall survival using qPCR data, while those exhibiting ESR1-
PGRERBB2- (14.1%) profıles by microarray results exhibited decreased PFS
and OS. Influence of patient menopausal status on biomarker profıles was ex-
amined. Conclusions: Quantitativemeasurements of ER, PR andHER2 proteins
as well as microarray and qPCR assessment of ESR1, PGR and ERBB2 gene
expression were correlated with prediction of clinical outcomes of breast carci-
nomas exhibiting Triple Positive Breast Cancers (TPBCa). Results reinforce im-
portance of assessing levels of the three biomarkers in a quantifıed fashion to
enhance their use in breast cancer management and prediction of risk of recur-
rence.
#670 Integrative genomic analysis of alterations driving anti-androgen
treatment resistance in vitro. Dong Shen,1 Brendan Hodkinson,1 Deborah
Ricci,1 Karin Verstraeten,2 Michael Schaffer,1 Michael Gormley,1 Shibu
Thomas1. 1Janssen Research & Development, Spring house, PA; 2Janssen R&D
BE, Beerse, Belgium.
Prostate cancer is one of the most frequently diagnosed cancers in the world.
It is the secondmost common type of cancer and the fıfth leading cause of cancer
death in Americanmen. Enzalutamide (MDV) and apalutamide (ARN-509) are
selective competitive antagonists of the androgen receptor (AR). Abiraterone
acetate (ABI) is an androgen biosynthesis inhibitor which is used in combina-
tion with prednisone in metastatic castration-resistant prostate cancer. Al-
though the anti-androgen and AR inhibitors provide breakthrough treatments
of metastatic castration-resistant prostate cancer, approximately a third of pa-
tients fail to show PSA response (50% decline from baseline after 12 weeks of
treatment), while another third of patients progress after a few cycles of treat-
ment. Recently, the acquired F876Lmutation of the androgen receptor (AR)was
identifıed in advanced prostate cancer cells with acquired resistant to enzalut-
amide and apalutamide. To systematically identify and understand the mecha-
nisms of resistance, we evaluated 22RV1 and LNCaP prostate cancer cells which
were resistant to the treatment of enzalutamide (MDV), apalutamide (ARN-
509), and abiraterone acetate (ABI). We isolated the DNA and RNA from both
resistant cells and their parent cells. We did RNAseq for gene expression analy-
sis, whole exome sequencing to identify theDNAalterations, and array CGH for
copy number change analysis. We confırmed the acquired F876L mutation of
the AR identifıed in LNCaP cells resistant to apalutamide. We identifıed the
novel G644R and R630Q mutations of AR, R213* mutation of TP53, N372H
mutation of BRCA1, and E2621Gmutation of ATM in LNCaP cells which were
resistant to the treatment of enzalutamide and apalutamide. For copy number
alterations, we identifıed acquired copy number gain on chromosome 3, 8, and
18 on 22RV1 resistant cells, and acquired copy number loss on LNCaP resistant
cells. Besides acquired DNA alterations, we identifıed 16 up-regulated and 24
down-regulated genes which are common in both 22RV1 and LNCap cells re-
sistant to enzalutamide and apalutamide. Through pathway enrichment analy-
sis, we identifıed the Wnt/B-catenin, cAMP signaling, and TREM1 signaling
pathways were up-regulated in 22RV1 and LNCap cells resistant to enzalut-
amide and apalutamide. Detection of acquired genetic alterations in cells resis-
tant to anti-androgen treatment provides us with important insights into the
mechanisms of their resistance. Further testing of clinical samples collected at
disease progression after treatmentwith these agents is required to validate these
fındings.
#671 Prognostic importance ofEGFRexpression andKras genemutations
in gallbladder carcinoma.Anjali Singh,1 Abul KalamNajmi,1 PramodMishra,2
Majid Talikoti1. 1Jamia Hamdard, New Delhi, India; 2MAMC, Delhi University,
New Delhi, India.
Gallbladder carcinomas involve multiple cascades of oncogenes like EGFR
andKras. Activation of Kras downstreampathways predict the sensitivity to anti
EGFR treatment. In 2012, for the fırst time it was established that GBC and
cholangiocarcinomas have their unique somatic genomic landscape and thus be
studied independently. This study evaluateswhether EGFR is a prognostic factor
in GBC and identifıes the frequency of codon 12 and codon 13 Kras mutations
along with its association with subject survival. Seventy twoGBC curative resec-
tions from North India were immunostained with anti EGFR monoclonal anti-
body and assessed for codon 12 and 13KRASmutation by real time PCR. Strong
EGFR expression was observed in 25.4percent cases. About 28/72; G12C, 17/72;
G12R, 10/72; G12D and 18/72; G13D cases harboured point mutations in Kras
gene, whichwas signifıcantly higher as compared to control tissues.Multivariate
analysis revealed that EGFR expression (p0.01; HR3.14; 95percent
CI1.28-7.71) and codon-13 mutation (p0.001; HR38.34; 95percent
CI4.90-300.01) had a signifıcant impact on survival and were independent
prognostic factors in GBC. Our study suggests that EGFR expression and codon
13mutations are independent prognostic factors in the selectedGBC cohort and
showed a high frequency of Kras codon 12 mutations as well.
#672 Baseline serum albumin as a prognostic factor in patients with stage
I and II colon adenocarcinoma. Luis F. Onate-Ocana. Instituto Nacional de
Cancerologia, Mexico City, Mexico.
Background: Patients with stage I or II colon carcinoma (CC) have a signifı-
cant risk of recurrence after adequately performed curative resection. Adjuvant
chemotherapy has not improved recurrence or survival in such patients. In this
study, a prognosticmodel in patients with stage I or II CC is presented.Methods:
Consecutive cases with CC treated at a cancer center in Mexico City from Jan-
uary 2008 toDecember 2014, with diagnosis of adenocarcinoma by colonoscopy
and biopsy were included in this cohort. Patients were treated according to
standard guidelines. Follow-up continued until June 2016; the Kaplan-Meier
method and the Cox model were used to analyze the association of prognostic
factors and overall survival (OS). Results: 1,259 cases of CC were treated; only
496 patients have stage I and II CC and were included in the database: 234
women (47.2%) and 262 males (52.8%) and their mean age was 59.9 years (SD
14.9); 96, 339, 31 and 30 cases were pTNM stages I, IIa, IIb and IIc, respectively.
Multivariate analysis of prognostic factors is depicted below. Predicted survival
functions using this model, defıned 4 risk groups that showed better prognostic
value than simple TNM stages I-IIc. Conlusion: BSA is an independent, signif-
icant, simple, cheap and widely available prognostic factor in patients with CC.
BSA and other clinical factors add signifıcant prognostic information to TNM
classifıcation. Feasibly, it can be used to developmultivariate prognostic models
with clinical impact defıning the use of adjuvant chemotherapy. The use of
histopathological and immunohistochemical markers could improve the prog-
nostic information of this model.
Multivariate análisis of prognostic factors
Beta SE p HR 95% CI
Male gender 0.355 0.166 0.032 1.426 1.031-1.973
Hemoglobin -0.088 0.038 0.02 0.916 0.85-0.986
Platelet count -0.002 0.001 0.001 0.998 0.996-0.999
Neutrophil count 0.082 0.028 0.004 1.085 1.027-1.147
Albumin 0.782 0.228 0.001 2.185 1.397-3.417
Albumin/Globulin -1.624 0.488 0.001 0.197 0.076-0.513
BMI -0.042 0.022 0.051 0.958 0.918-1.0
TNM 0/I 0.054 1
TNM IIa 0.554 0.255 0.03 1.74 1.056-2.869
TNM Iib 0.734 0.404 0.069 2.083 0.944-4.597
TNM IIc 0.95 0.367 0.01 2.586 1.26-5.305
Chemotherapy -0.765 0.2 0.0001 0.465 0.315-0.688
R0 0.0001 1
R1 0.267 0.475 0.574 1.306 0.515-3.311
R2 0.936 0.348 0.007 2.551 1.29-5.044
No Resection 1.936 0.288 0.0001 6.932 3.944-12.18
Platelet/Lymphocute ratio 0.001 0.001 0.08 1.001 1.0-1.002
#673 Exploration of tissue morphologies in breast cancer samples using
unsupervised machine learning. Riku Turkki,1 Dmitrii Bychkov,1 Nina
Linder,1 Jorma Isola,2 Heikki Joensuu,3 Johan Lundin1. 1Institute for Molecular
Medicine Finland, Helsinki, Finland; 2BioMediTech, University of Tampere,
Tampere, Finland; 3Translational Cancer Biology Research Program, Helsinki,
Finland.
We applied a machine learning approach for exploration of tissue morphol-
ogy in hematoxylin and eosin (H&E) stained breast cancer tissue microarray
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(TMA) samples. We then investigated whether the morphological categories
produced were associated with clinically relevant molecular biomarkers and
10-year overall survival. The data set comprises digitized (0.22 m/pixel) and
H&E stained TMA spots from tumor samples of 490 women who were diag-
nosed with primary breast cancer within a Finnish breast cancer database (Fin-
Prog) collected in 1991 and 1992. In order to quantitatively describe the tissue
morphologies of the TMA spots, we divided the tissue images into rectangular
sub-images (224x224 pixels), and extracted features with a pre-trained convo-
lutional neural network. We then clustered the sub-images (n147,266) with a
non-linear data embedding algorithm that creates a two-dimensional mapping
of the tissue morphologies. Lastly, we defıned a quantitative profıle for each
tumor, describing themorphologies within the tissue spot image by dividing the
two-dimensional map ofmorphologies into 128 separate clusters with k-nearest
neighbor clustering. Visual inspection of the two-dimensional embedding of
tissue spot images verifıed that the morphologies clustered coherently, i.e. sim-
ilar looking sub-images formed distinct clusters in the map. Interestingly, some
morphological patterns were strongly associated with tumor estrogen receptor
content, progesterone receptor content, human epidermal growth factor recep-
tor 2 status, and the proliferation marker Ki-67 status (p0.0001 for each com-
parison). In exploratory analyses we identifıed one morphological category that
was associated with a favorable 10-year overall survival with a risk ratio of 0.68
(CI95% 0.53-0.89, p0.002, power 0.87). Our work demonstrates that unsu-
pervised machine learning can be applied to explore and better understand the
role of morphological patterns in breast cancer. Methods that quantitatively
assess the morphology of cancer tissue may complement molecular biomarkers
and potentially reveal novel prognostic and predictive factors.
#674 HPV16 was the preponderant type of HPV infection in cutaneous
squamous cell carcinoma. Gang Shi,1 Anne C. Fischer,2 Jonathan M. Ze-
nilman,1 Patti E. Gravitt,3 Max Fischer,4 Inbal B. Sander,1 Jonathan D. Cuda,1
Janis M. Taube,1 Mohammed Lilo,1 W P Andrew Lee,1 Anthony P. Tufaro1.
1Johns Hopkins University School of Medicine, Baltimore, MD; 2Florida Atlantic
University, Boca Raton, FL; 3Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD; 4University of Maryland School of Medicine, Baltimore, MD.
Purpose: Human papillomavirus (HPV) has been well established as a caus-
ative factor in mucosal oropharyngeal cancer and anogenital surface malignan-
cies. However, its etiological role in cutaneous squamous cell carcinoma (cSCC)
is still debated. The aim of this study is to identify the presence of HPV types in
cSCC and identify their associations with cSCC. Methods: 77 cSCC blocks from
54patients underwentDNA isolation and a broad spectrumofHPVPCR tests to
detect the presence of HPV genotypes by the use of a universal primer pair
GP5/GP6. The resultant PCR products were cloned to T Vectors and sub-
sequently underwent DNA sequencing and Nucleotide BLAST search to iden-
tify the HPV types in cSCC. To ensure the accuracy of the HPV PCR test, 16
blocks from 10 head and neck SCC (oropharyngeal) patients were also included
in theHPVpresence and type analyses. Cutaneous SCC patients’ demographics,
pathology and clinical parameters were compared and analyzed statistically in
conjunction with the HPV test results. Results: HPVDNAwas found in 37 of 77
(48.1%) blocks representing 32 of 54 (59.3%) cSCC patients. HPV16 was the
preponderant type of HPV Infection, accounting for 28 of 32 (87.5%) and 30 of
37 (81.08%) HPV positive patients and blocks. Other HPV genotypes found
included HPV18, 57, 10, 2, accounting for 4 of 32 (12.5%), 2 of 32 (6.25%), 2 of
32 (6.25%), 2 of 32 (6.25%) of the HPV positive patients and 4 of 37 (10.81%), 2
of 37 (5.41%), 2 of 37 (5.41%), 2 of 37 (5.41%) of the HPV positive blocks,
respectively. HPV infection was signifıcantly associated with the cSCC tumor
size in this cohort of patients. Tumors with a size of 20mm were more fre-
quently associated with HPV. Moreover, the average tumor size of the HPV
positive group was also signifıcantly smaller than that of the HPV negative
group. Conclusions: HPV infection is very commonly found in cSCC patients
andHPV16 is themajor type of HPV involved in cSCC oncogenesis, accounting
for80% of HPV infections. HPV is a contributing factor, which appears to be
contributing to a smaller size of cSCC, which may improve the prognostic clas-
sifıcation of patients to provide a new insight into tumorigenesis.
#675 The interaction between hedgehog and EMT pathway in non-small
cell lung cancer and its prognostic implication.Ho Jung An,1 Tae-Jung Kim,2
Young Jo Sa,2 Chang Suk Kang2. 1St. Vincent’s Hospital, The Catholic University
of Korea, Suwon, Republic of Korea; 2Yeouido St. Mary’s Hospital, The Catholic
University of Korea, Seoul, Republic of Korea.
Introduction: The Hedgehog (Hh) signaling plays essential role in transcrip-
tion regulation and embryonic development. In many cancers including lung
cancer, it is related to carcinogenesis and poor prognosis. This signaling also
mediates epithelial to mesenchymal transition (EMT) by paracrine mechanism
in various diseases. We aim to study the interaction between Hedgehog and
EMT pathway and its clinical implication in non-small cell lung cancer
(NSCLC).Method: Total 271 cases of NSCLCwho received surgical resection in
Yeouido St. Mary’s Hospital between 1997 and 2011 were included. For immu-
nohistochemical analysis of Hh and EMT related proteins, 4um sections were
sliced from tissue microarray. Hh signaling proteins including Sonig hedgehog
(Shh), Patched (Ptch), Smoothened (Smo), Glioma-associated oncogene (Gli-1)
and Suppressor of fused (Sufu), and EMT associated molecules including E-
cadherin and vimentin were analyzed. Staining intensity (IS) was estimated as
follows 0 (no staining), 1 (weak), 2 (distinct), 3 (strong). Intensity score
(IS) 	1 was defıned as positive. Medical record was retrospectively reviewed.
The study was approved by the institutional review board the hospital. Result:
The median age was 63 (18-84) years, and 65.3% were male. Squamous cell
carcinoma was diagnosed in 113 (41.7%), adenocarcinoma in 153 (56.5%), and
mixed type in 153 (56.5%). Stage 1 and 2were 46.9% and 30.6%, respectively, and
8 cases had distantmetastasis. TheHhproteins showed positive correlation each
other. For EMT, the expressions of Hh protein was signifıcantly correlated with
tumoral and stromal positivity of vimentin, and inversely with positivity of E-
cadherin (P 0.002 and P 0.028, respectively). The expression ofHh proteins
were signifıcantly associatedwith lymph nodemetastasis alongwith large tumor
size (P 0.021 and P 0.035, respectively). In survival analysis, expressions of
Shh and Gli1 were independent predictor of disease free survival and cancer-
specifıc survival (P 0.007 andP 0.025, respectively). Conclusion: Expression
of Hh protein is associated with epithelial-mesenchymal transition and associ-
ated with poor prognosis in NSCLC.
#676 Nuclear expression of insulin receptor (InsR) adds prognostic infor-
mation in primary breast cancer patients with high BMI. Sofıe Björner, Ann
H. Rosendahl, Maria Simonsson, Andrea Markkula, Karin Jirström, Signe
Borgquist, Carsten Rose, Christian Ingvar, Helena Jernström. Lund University,
Lund, Sweden.
Aim and introduction: The aim of this study was to elucidate the prognostic
importance of nuclear expressionof the insulin receptor (nucInsR) inprimary breast
cancer. The InsR is important for themetabolism, for the insulin-like growth factor
(IGF) signaling network and is implicated in breast cancer. Insulin and InsR are
interlinkedwith obesity and bodymass index (BMI), which are also associatedwith
breast cancer. The InsR is present both in the membrane and cytoplasm and can
additionally translocate to the nucleus. The role of nucInsR is not well understood
and the prognostic importance is unclear. Methods: The tumor-specifıc expression
of nucInsRwas evaluated by immunohistochemistry on invasive breast cancer tissue
microarrays from 984 primary breast cancer patients included in a population-
based cohort in Sweden. Patients were followed for up to 11 years, the median
follow-up for patients still at riskwas fıve years. nucInsR in relation to prognosis was
analyzed using Cox regression, adjusted for age, invasive tumor size, axillary lymph
node involvement, histological grade, estrogen receptor (ER) status, BMI, tumor
storage time, and treatment.Results: Status for nucInsRwas available for 900patients
(91.5%). nucInsRpos staining was present in 214 patients (23.8%) andwas associated
with lower age (P0.004), and lower waist-to-hip ratio (P0.006), but not with
BMI, ERorPR status.During follow-up, 107 patients had a fırst breast cancer event.
nucInsRhadnoprognostic signifıcant impactamongallpatients.However, therewas
a signifıcant effect modifıcation of BMI on nucInsR regarding event-free survival
(Pinteraction0.006). Patients with nucInsRpos-expressing tumors and higher BMI
(	25 kg/m2) had lower risk for any breast cancer event, adjustedHR (0.49; 95%CI
0.26-0.93),while patientswith nucInsRpos-expressing tumors andnormalBMI (25
kg/m2) were associated with a non-signifıcant higher risk of events, adjusted HR
(1.72; 95%CI0.93-3.17).Conclusions:These results indicate that nucInsR statusmay
add prognostic information in primary breast cancer depending on BMI.
#677 Progranulin/GP88 tumor tissue expression further stratifıes survival
outcomes of patients classifıed by their Nottingham Prognostic Index. Gi-
nette Serrero,1 Douglas Hawkins,2 Olga Ioffe,3 Pablo Bejarano,4 Binbin Yue1.
1A&G Pharmaceutical, Inc., Columbia, MD; 2University of Minnesota, Minne-
apolis,MN; 3University ofMarylandGreenebaumComprehensiveCancerCenter,
Baltimore, MD; 4Cleveland Clinic Florida, Weston, FL.
Background: TheNottinghamPrognostic Index (NPI) combines nodal status,
tumor size and histological grade and is used to provide predictive value infor-
mation on survival for patients with primary breast cancer. Attempts to improve
the performance of NPI have been carried out by inclusion of other factors, such
as biomarker expression as well as addition of other structural features such as
vascular invasion. In the present study, we investigated whether expression of
the survival factor GP88 (progranulin), known to be overexpressed in breast
cancer, would improve NPI’s predictive value. GP88/Progranulin is an 88 kDa
autocrine growth and survival factor that is overexpressed in estrogen receptor
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positive (ER) invasive ductal carcinoma (IDC) in associationwith resistance to
anti-estrogens and aromatase inhibitor while the cells remain ER. Previous
training and validation pathological studies totaling 600 cases of ER IDC had
demonstrated that GP88/Progranulin tissue expression was an independent
prognostic marker od recurrence and mortality for early stage ER IDC.
Methods: We examined by immunohistochemistry the GP88 tumor tissue ex-
pression of 508 formalin fıxed paraffın embedded cases of ER IDCwith known
clinical outcomes and for which NPI had been determined. GP88 IHC expres-
sion was scored by two board certifıed pathologists and classifıed into two score
groups of GP88  3 (0, 1, 2) and GP88  3. The correlation between
GP88 scoring, NPI and disease-free (DFS) and overall survival outcomes (OS)
was then examined by Kaplan Meier analysis, Cox proportional Hazard ratio
and Pearson’s 2 test. Results: Patients were categorized into three NPI groups
( 3.4, 3.4-5.4, 5.4). Kaplan-Meier survival graphs of cases categorized by
their NPI scores and GP88 expression showed that for each NPI subgroup,
patients having tumors with a high GP88 expression (GP88 IHC score of 3)
had a worse DFS than patients within the same NPI subgroup with low GP88
expression (GP88 IHC score  3). When adjusted for NPI, high GP88 score
was highly signifıcantly associated with recurrence. Its hazard ratio is 3.30 (95%
CI 2.12 to 5.14). Conclusions: These data suggest that the determination GP88
tumor expression at time of diagnosis for early stage breast cancer patients could
provide additional survival information than the ones provided by NPI alone
that maybe useful for improving the risk management of patients.
#678 A strategy to overcome the interfering problem of tissue embedding
OCT compound in activity based multiplex profıling of tyrosine kinase sub-
strates. Stephan Arni, Claudio Caviezel, Walter Weder, Sven Hillinger.Univer-
sity Hospital Zürich, Zürich, Switzerland.
Introduction: The analysis of clinically relevant human tissue preserved in
optimal cutting temperature (OCT) medium with activity based proteomic ap-
proaches are promising for the discovery of novel druggable disease biomarkers
for the diagnosis, prognosis and prediction of response to therapeutic interven-
tions. Nonetheless, and for many different proteomic approaches, there are im-
portant signal interferences observed in the presence of the OCT compound.
Methods:We tested activity basedmultiplex profıling tyrosine kinase substrates
in a large batch of neoplastic and non-neoplastic lung resection specimen em-
bedded with or without OCT. We observed signifıcant differences in overall
phosphorylation levels and searched for reasons explaining such a large effect.
Results: We ruled out the implication of either short versus long storage time
after sample extraction or of nonhomogeneous batch processing of samples.We
documented that the clear downward shift in overall phosphorylation levels
coincidedwith the introduction ofOCT as an improved embeddingmedium for
resection specimen. For all the kinomes extracted, we developed a corrective
procedure where a median centering was performed on the values of each pep-
tide, separately for the with or without OCT samples. Conclusions: We applied
corrective fıltering of data to the multiplex profıling approach of well character-
ised tyrosine kinase substrates obtained in lung resection specimen embedded
with or without OCT. With the OCT correction parameters applied, the quan-
titation of molecular prognosis signature based on tyrosine kinase activity dif-
ferences found in lung adenocarcinoma resection specimens may result in the
identifıcation of novel targets for future anti-lung cancer therapies.
#679 Serine/threonine kinase inhibitors on improving symptoms of neu-
roendocrine tumor. I-Hua Liu, Yusian Ding, Chiung-Wen Liou, Jia-Ming
Chang. Development Center for Biotechnology, New Taipei City, Taiwan.
Recently, neuroendocrine tumors (NETs) are increased and mostly occurred in
gastrointestinal tract and lung in theworldwide. It secretes functionalhormonesand
non-functional neural transmitters to affect patients unwell so called carcinoid syn-
drome. In clinically, surgical removal and somatostatin treatment are used to ease
the syndrome by NETs. A new strategy for advanced NETs is used by targeting
mTOR signaling and neovascularization. In 2011, Everolimus, anmTOR inhibitor,
was approved for the treatment of progressiveNETs of pancreatic origin in patients
withunresectable, locallyadvancedormetastaticdisease,but safetyandeffectiveness
of everolimus have not been established. In this study, low dose ofmTOR inhibitor
was investigated for capability in modifying the carcinoid syndrome. In an NCI-
H727NET xenograftmodel, the level of chromograninA (CgA)was determined in
accordance with tumor volume. With multiplexing the serum hormones, alpha-
melanocyte-stimulating hormone (alpha-MSH) and beta-endorphin were lowered
in tumor-bearing mice, but they were rebound when animals treated with Everoli-
mus. Another mTOR inhibitor INK 128 had no apparent tumor inhibition in the
samemodelwith doses ranged from0.25-1mg/kg. Therewas no change in the level
of CgA in INK128-treated tumor-bearing mice but alpha-MSH level was restored
compared with normal mice at a dose-dependent manner. In conclusion, we dis-
covered that low dose of mTOR inhibitor could modify the carcinoid syndrome,
where alpha-MSH and beta-endorphin may serve as biomarkers for prognoses of
mTOR treatment.
#680 Prognostic impact of OPN and DKK1 in patient of hepatocellular
carcinoma after hepatectomy. YunSung Seo, Hye Rim Byeon, In Hae Park,
Seung Duk Lee. National Cancer Center, Goyang-si, Gyeonggi-do, Republic of
Korea.
The new biomarkers are essential for improving the survival and prognosis of
hepatocellular carcinoma(HCC) patients. Alpha-fetoprotein(AFP) is the most
widely used biomarker. But the low sensitivity and specifıcity limits its clinical
application. Recent study validated the diagnostic capability of osteoponti-
n(OPN) and dickkopf-1(DKK1) and assessed the combination of AFP, DKK1,
and OPN as a panel for the diagnosis of HCC. Based on these previous studies,
we hypothesized that combination ofOPNandDKK1 can be used to as amarker
for prognosis to patient of HCC after hepatectomy. From January 2006 to De-
cember 2008, patients undergoing hepatectomy for hepatocellular carcinoma
were screened serum that has been stored in the Bank of tumor. To target the
selected patient, it was confırmed that the remaining tissue specimen is stored
after diagnosis. Serumof the patientswas used to investigate theOPNandDKK1
by ELISA. In the paraffın block were prepared unstained slide and OPN
andDKK1 level checked by IHC. It examined the correlation between prognosis
and biomarkers through statistical analysis. AFP, OPN(serum level) and
DKK1(serum level) are an independent prognostic factor for overall surviva-
l(OS) in HCC after hepatectomy(n60, P0.0204, 0.0167 and 0.0455 respec-
tively). New biomarkers combinations based on the AFP existing biomarker are
showed a falling curve of the overall survival(OS) and disease-free survival(DFS)
in Kaplan Meier curve. In conclusion, combination of OPN, DKK1 and AFP as
a biomarker could support the correct diagnosis for HCC after hepatectomy.
#681 Methylomics profıling reveals epigenetically silenced HS3ST2 sensi-
tize IL6 signaling and confers poor prognosis of ovarian cancer. Rui-Lan
Huang,1 Hsiang-Ju Chan,2 Lin-Yu Chen,3 Yaw-Wen Hsu,3 Tai-Kuang Chao,4
Po-Hsuan Su,1 Yu-ChunWeng,1 Chiou-Chung Yuan,1 Hung-Cheng Lai1. 1Tai-
pei Medical University-Shuang Ho Hospital, New Taipei, Taiwan; 2Taiwan In-
ternational Graduate ProgramMolecular and Cell Biology, Ph.D. Program, Aca-
demia Sinica, New Taipei, Taiwan; 3Graduate Institute of Life Sciences, National
DefenseMedical Center, Taipei, Taiwan; 4Tri-Service General Hospital, National
Defense Medical Center, Taipei, Taiwan.
The attempts of target therapy in ovarian cancer therapy mostly fail. There is
a need of biomarkers for better patient stratifıcation in clinical trials. Epigenetics
is a driving force for cancer development andmay serve as amolecularmarker of
disease. The present study was to analyze the clinical relevance of methylation
phenotypes and fıgure out the mechanism in ovarian cancer. We integrated the
analysis using public dataset of epigenomics and transcriptomics, and our hos-
pital-based methylomic database and tissue arrays of patients diagnosed with
epithelial ovarian cancers (EOC). Bioinformatics results were verifıed and vali-
dated in cell lines and clinical samples. From 25 genes, we identifıed even genes,
ADRA1A, CD248, HS3ST2, NEFH, IGSF21, POU4F2, and TWIST1, of which
hypermethylationwas signifıcantly related to the poor overall survival (OS). The
association of NEFH and HS3ST2 hypermethylation and poor 5-year OS was
validated in our independent dataset and TCGA database. The NEFH/HS3ST2
hypermethylated signature was an independent risk factor for 5-year OS (ad-
justed Hazard ratio 2.93, 95% confıdence interval 1.25 to 6.85, P 0.013).
In vitro experiment re-expressing HS3ST2 repressed migration and invasion,
and suppressed IL-6 signaling pathways. The combination of hypermethylation
of HS3ST2 and high expression of IL-6 confers the worse outcome. Our data
suggested that methylation of NEFH/HS3ST2 constituted a poor prognostic
signature of ovarian cancer. The sulfation status of proteoglycan modifıed by
HS3ST2 implicates an intrinsic sensitivity of ovarian cancer cells to IL-6, which
shed a new light on the application of HS3ST2 as a biomarker for personalized
medicine of targeting IL-6.
#682 Novel Mesenchyme Homeobox2-target transcription axes are in-
volved in cancer-drug resistance, overall survival and therapy prognosis in
lung cancer patients: a functional epigenome wide study. Federico Avila
Moreno,1 Leonel Armas lopez,1 Patricia Piña-Sánchez,2 Oscar Arrieta,3 Enrique
Gúzman de Alba,4 Abril Marcela Herrera-Solorio,1 Blanca Ortiz-Quintero,4
Patricio Santillán-Doherty,4DavidCChristiani,5 JoaquínZúñiga4. 1Universidad
Nacional Autónoma de México (UNAM), Mexico City, Mexico; 2Instituto Mexi-
cano del Seguro Social (IMSS), Mexico City, Mexico; 3Instituto Nacional de Can-
cerología (INCAN), Mexico City, Mexico; 4Instituto Nacional de Enfermedades
Respiratorias (INER) Ismael Cosío Villegas., Mexico City, Mexico; 5Harvard
Medical School, Boston, MA.
CLINICAL RESEARCH: Checkpoint Inhibitor and Prognostic Biomarkers
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017172
Lung cancer remains the most progressive malignant disease strongly resis-
tant to oncological therapies including platinum-derived cancer drugs and Epi-
dermal Growth Factor Receptor (EGFR)-Tyrosine Kinases Inhibitors (TKIs).
Homeobox-related gene (HOX) transcription factors as Mesenchyme HOX-2
(MEOX2) have previously been associatedwith cancer-drug resistance, progres-
sion and/or clinical prognosis in lung cancer patients. However, transcriptional
mechanisms epigenetically modulated have not totally been elucidated in lung
cancer therapy resistance. Here an epigenomic strategy was conducted to iden-
tify a novel MEOX2 gene sequence-promoter targets profıle, associated or in-
volved in therapy resistance mechanisms in human lung cancer. For that chro-
matin from human non-small cell lung carcinomas (NSCLC), MEOX2 versus
RNAPol II immunoprecipitation and hybridization assays using gene promoter
tiling-arrays and bioinformatics analyses were performed, while a set of quanti-
tative and functional assays with clinical-outcome prognosis validation predic-
tions analyses, were assessed. Stringent bioinformatics results identifıed a com-
mon profıle of 13 gene promoter sequences, which included in others Sonic
Hedgehog-GLI-1, ALDH1A2, MMP24, RUFY3 and ZEB1 (FDR0.1) in
NSCLC patients with different clinical outcome data. GLI-1 gene promoter-
sequences upstream -2,192 to -109 quantitatively validated, were occupied by
MEOX2 andRNAPol II in bothNSCLC cell lines andNSCLCpatients, as well as
consistently enriched with the histone activation marks H3K27Ac and
H3K4me3, in addition, confırmed by the ENCODE database bioinformatics
analyses. Furthermore, a set of genetic silencing functional assays validated a
novel transcriptionalMEOX2-GLI1 axis in a cisplatinum dose-dependentman-
ner, involved in cellular migration, invasion, and proliferation capacity. Finally,
MEOX2-GLI1 axis expression was clinically validated and analyzed using Ka-
plan-Maier survival analyses on an independent cohort of 90 NSCLC patients,
identifying a signifıcant MEOX2-dependent GLI-1 overexpression statistically
associated with clinical poorer overall survival prognosis and treatment re-
sponse into cisplatinum-based fırst-line therapy and/or second-line EGFR-TKIs
target therapy protocols. In conclusion, a chromatin-immunoprecipitation and
epigenome-wide analysis based on the MEOX2-transcriptional occupation
study, identifıed novel MEOX2-transcriptional gene promoter axes involved in
embryonic development, oxidoreductase activity, matrix metalloprotease, cel-
lular polarity, epithelial-mesenchyme phenotype, cancer cell migration and in-
vasion pathways. Promoting cisplatinum-based resistance mechanisms and
EGFR-TKIs based therapy response prognosis in human lung cancer.
#683 Quantifıcation of rare PD-L1 expressing leukocytes and CTCs in
peripheral blood of cancer patients. Adam Jendrisak, Jiyun Byun, Mahipal
Suraneni, David Lu, Rachel Krupa, Sarah Orr, Ryon Graf, Yipeng Wang, Mark
Landers, Ryan Dittamore. Epic Sciences, San Diego, CA.
Background: Expression of PD-L1 on tumor tissue is associated with im-
proved response to PD-1 and PD-L1 checkpoint inhibitors. Additionally, ex-
pression of PD-L1 on infıltrating T cells is associated with immune exhaustion.
Currently, PD-L1 analysis as well asmeasures of infıltrating T cells are examined
in surgically removed or biopsied samples, usually taken long before clinical
decision points. Additionally, given tumor heterogeneity, metastatic lesions are
likely to be under-sampled. We sought to examine expression of PD-L1 on
circulating tumor cells (CTCs) and leukocytes cell populations with a non-inva-
sive liquid biopsy. Examining dynamic biomarker changes in longitudinal sam-
ples could enable the development of novel diagnostic tools for response predic-
tion and pharmacodynamics studies related to immunotherapy. Methods:
Blood samples from cancer patients were received and shipped to Epic Sciences.
Contrived blood samples were also developed utilizing spike-in of cancer cell
line controls into healthy blood samples. RBCs were lysed, and nucleated cells
plated onto glass slides utilizing the Epic Sciences process. Slides are stainedwith
an IF cocktail (CK, DAPI, CD45, PD-L1) and scanned. Approximately 3million
nucleated cells are examined through advanced Digital Pathology pipelines to
detect rare CTCs (CK/-, cancer morphology, CD45-) and leukocytes (CK-,
CD45, leukocyte morphology) and analyze for PD-L1 expression. Results: A
limit of detection of 1 cell/mL of blood was analytically validated. Using Epic’s
rare cell detection platform, we could detect a wide range of PD-L1 leukocyte
counts in a subset of peripheral blood of cancer patients, observed as low as
0.003% (110 of 3,192,263) of total leukocytes. PD-L1 CTCs were observed in
the presence of both high and low counts of PD-L1 leukocyte populations.
Conclusions: Epic Sciences CTC platform’s low limit of detection coupled with
ability to archive patient blood samples allowed precise quantifıcation of PD-L1
expression on CTCs and leucocytes retrospectively. In addition, we have previ-
ously demonstrated the platform’s ability to detect leucocyte subtypes such as
CD3, CD4 and CD8 cells, which will allow us to further characterize PD-L1
expression in T-lymphocytes and other immune cell types. Development of a
liquid biopsy based platform that is capable of simultaneously measuring im-
mune biomarkers inCTCs aswell as leucocyteswill allow real time assessment of
response to immune checkpoints inhibitors.
#683A Mechanism of liver metastasis induced systemic suppression of
checkpoint inhibitor response. James C. Lee, Adil Daud, Jeff Bluestone.UCSF,
San Francisco, CA.
Introduction: In stage IV melanoma and NSCLC, PD-1 checkpoint inhibitor
therapy is effective and now FDA approved as fırst-line therapy. However, de-
spite these rationally designed strategies to manipulate immune cells, curative
responses remain rare, and the majority of metastatic cancer patients ultimately
succumb to their disease. Emerging potential biomarkers of response have re-
quired specialized technologies such as next-generation sequencing or flow cy-
tometry, which are diffıcult to access, costly, and not immediately clinically
applicable. To this end, we have previously reported that presence of liver me-
tastasis was signifıcantly associated with the lack of antitumor immune infıl-
trates at distant biopsy sites as well as poor clinical response to PD-1 blockade.
Here, we sought to study the mechanism of liver metastasis related non-re-
sponse to PD-1 blockade using a syngeneic immunocompetent murine tumor
model. Methods: C57BL/6 mice were implanted with a ‘primary” subcutaneous
tumor as well as a secondary “metastatic” tumor in the liver or the lungs (con-
trol), and given systemic PD-1 blockade therapy to mimic the clinical observa-
tion and study the effects of liver tumor involvement on systemic antitumor
immunity. Animals are monitored for survival and tumor growth. The immune
infıltrates of both the primary and metastatic sites are phenotypically analyzed.
Results: Animals with liver tumor involvement appear to have signifıcantly
shortened survival as well as diffıculty rejecting tumors, both at the primary and
secondary site of implantation, when compared to non-liver involved controls.
The lack of response to PD-1 blockade in the liver cohort is correlated with a
signifıcant decrease in CTLA4/PD-1/CD8 “exhausted” antigen experi-
enced T cells (TEx) within the tumor microenvironment of the subcutaneous
and liver-embedded sites. The deleterious effect on TEx appears to be liver-
specifıc and not tumor cell-line dependent, as delivery of different tumor cells to
the liver reproduces the same effect while delivery of tumor cells to other organs
does not change the quantity of TEx at the subcutaneous site. Lastly, liver asso-
ciated deletion of TEx appears to be a an antigen dependent process, as delivery
of mismatched tumor cell line to the liver abrogates this effect and restores TEx
within the tumor microenvironment at the distant subcutaneous site. Conclu-
sions: Using an immunocompetent checkpoint blockade animal tumor model,
we recapitulated the clinically observed difference in response to PD-1 blockade
treatment that is associated with liver metastasis. Our studies suggest that
the liver is capable of suppressing effective T cell mediated antitumor response
systemically, rendering checkpoint blockade less effective. The fındings here
propose a novel mechanism for which non-responsiveness to PD-1 blockade
therapy could occur and may impact the treatment decision for cancer patients
with liver metastasis.
CLINICAL RESEARCH: Childhood Cancer Clinical Translational
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#684 Integrative proteomics and transcriptomics to defıne the cell surface
landscape of neuroblastoma. Amber K. Weiner,1 Simone Sidoli,1 Tina Gliso-
vic-Aplenc,2 John M. Maris,2 Benjamin A. Garcia,1 Sharon J. Diskin2. 1Univ. of
Pennsylvania School of Medicine, Philadelphia, PA; 2Children’s Hospital of Phil-
adelphia, Philadelphia, PA.
BACKGROUND.Neuroblastoma (NB) is an embryonal tumor of the sympa-
thetic nervous system that accounts for 12% of childhood cancer deaths. Despite
intense multimodal therapy, survival probability for high-risk NB patients re-
mains below 50% and relapsed NB is essentially incurable. To date, the cell
surface landscape of NB at diagnosis and relapse is currently unknown. An
unbiased survey of these proteins and their isoforms will greatly facilitate the
identifıcation of candidate immunotherapeutic targets for preclinical valida-
tion. METHODS. To identify proteins on the cell surface of NB, we performed
plasma membrane protein extraction utilizing an optimized sucrose density
gradient methodology followed by nano-liquid chromatography coupled to
mass spectrometry (nLC-MS/MS) in NB cell lines. Proteomic data is integrated
with RNA-sequencing data to assess the correlation between these data types,
determine differential expression between NB (n2242) and normal tissues
(n7859), and investigate NB-specifıc isoforms. In parallel, we have developed
a software tool to aid in proteomic data analysis and interpretation. RE-
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SULTS. To date, we have applied our proteomic approach to nine NB cell lines
stratifıed by MYCN amplifıcation. This methodology has yielded on average
66% (range: 60-68%) membrane protein enrichment with high reproducibility
between biological replicates (80%; range: 78-84% ). This has allowed us to
confırm known cell surface proteins that are currently being developed as im-
munotherapeutic targets (ALK, GPC2 andNCAM1).We are currently integrat-
ing the mass spectrometry based proteomics data, where we identifıed 4826
membrane proteins, with RNA-sequencing data to evaluate proteins expressed
uniquely in neuroblastoma and those that correlate with MYCN amplifıcation.
We are further determining how RNA and protein levels correlate on the cell
surface and will utilize these data to detect NB-specifıc isoforms. In parallel, we
have also created GiaPronto, an effıcient tool for data analysis and visualiza-
tion. After normalization, our program outputs several plots and fıgure legends
that assess data quality, regulated or abundant proteins, and Gene Ontology.
CONCLUSION. We have developed robust methodology for cell surface pro-
tein isolation and quantifıcation along with a software package to facilitate
downstream analyses. Parallel proteomic and transcriptomic studies in patient
derived xenografts (PDX) and patient tumors are ongoing to defıne the cell
surface landscape in both diagnostic and relapsed NB.
#685 GPC2 is an oncogene and immunotherapeutic target in high-risk
neuroblastoma. Kristopher R. Bosse,1 Pichai Raman,1 Maria Lane,1 Robyn T.
Sussman,1 Jo LynneHarenza,1DanielMartinez,1 SabineHeitzeneder,2 Zhongyu
Zhu,3 Komal Rathi,1 Michael Randall,1 Laura Donovan,4 Sorana Morrissy,4
Doncho V. Zhelev,3 Yang Feng,3 Jennifer Hwang,3 Yanping Wang,3 Bruce
Pawel,1 Tricia Bhatti,1 Mariarita Santi,1 Javed Khan,3 Michael Taylor,4 Dimiter
S. Dimitrov,3 Crystal Mackall,2 JohnM.Maris1. 1Children’s Hospital of Philadel-
phia, Philadelphia, PA; 2Stanford University, Stanford, CA; 3National Cancer
Institute, MD; 4Hospital for Sick Children, Toronto, Ontario, Canada.
Background: GD2-directed immunotherapeutic strategies have improved
outcomes in neuroblastoma; however, the majority of patients treated suffer
relapse and GD2 expression on pain fıbers causes dose-limiting toxicities.
Methods: To identify alternative cell surface immunotherapeutic targets, we
compared high-risk neuroblastoma (n126 tumors) and normal tissue RNA
sequencing data (GTEx; n7859 samples from 31 normal tissues) and priori-
tized genes by differential and absolute expression and cell surface prediction.
Genes were further surveyed for somatic copy number gain and correlative
expressionwithMYCNamplifıcation. Differential protein expression and local-
ization were confırmed in neuroblastoma primary tumors (n98), patient-de-
rived xenografts (n32; PDXs), cell lines (n23), and normal pediatric tissues
(n36). Cell lines were subjected to candidate gene gain and loss of function
studies (n11). Additional pediatric tumor RNA sequencing data was surveyed
followed by confırmatory immunohistochemistry (IHC). Finally, candidate spe-
cifıc antibodies were isolated from a human Fab phage library and utilized for
antibody-drug conjugate (ADC) engineering followed by cytotoxicity studies.
Results: We identifıed 33 differentially expressed cell surface molecules from
which we prioritized glypican-2 (GPC2) for validation given GPC2’s robust
differential expression (log-fold change tumor vs. normal tissue  1.71-9.22;
p1.99 x 10-9-1.88 x10-300), high-level absolute RNA expression (median
FPKM60), and frequentDNA copy number gain associatedwith higherGPC2
expression (35%, n182 tumors; p0.005). GPC2 expressionwas also higher in
MYCN amplifıed neuroblastomas (p0.05), MYCN binds the GPC2 promoter
shown by chromatin immunoprecipitation (ChIP) sequencing and reporter as-
says, and MYCN depletion resulted in decreased GPC2 expression. Immuno-
blot, flow cytometry, immunofluorescence, and IHCanalysis of primary tumors,
PDXs, and cell lines confırmed dense cell surface GPC2 expression. Medullo-
blastomas (n62) were also found to have high GPC2 expression that positively
correlatedwithMYC,MYCN, andGPC2 loci gain (p0.0001). Pediatric normal
tissues had very restricted cell surface GPC2 expression, with only low levels
found in the esophagus and skin. GPC2 depletion in neuroblastoma cell lines
resulted in apoptosis and growth inhibition and GPC2 forced over-expression
increased neuroblastoma cell proliferation (p0.001 for all assays). Finally, a
humanGPC2 antibody,D3-GPC2-Fab,was developed and shown to bindGPC2
with high affınity and specifıcity. D3-GPC2-IgG1 induced internalization of
GPC2 and was conjugated to pyrrolobenzodiazepine (PBD) dimers to form an
ADC which induced potent and specifıc cytotoxicity to GPC2 expressing neu-
roblastoma cells (IC50  1.7-11 pM). Conclusions: GPC2 is an oncogene and
immunotherapeutic target in neuroblastoma and potentially other cancers.
#686 onTARGET: a new computational strategy to predict in vivo relevant
targets against neuroblastoma. Elin Almstedt, Ingrid Lönnstedt, Cecilia
Krona, Sven Nelander. Uppsala University, Uppsala, Sweden.
One of the main bottlenecks of anticancer drug development is the assess-
ment of the in vivo relevance of emerging therapies. Previously, drugs that sup-
press the in vivo progression of neuroblastoma have been hard to identify. To
address this problem, we propose a new computational technique, onTARGET,
that enables researchers to select, with good accuracy, compounds that are likely
to induce changes in cellular pathways that are consistent with specifıc clinical
outcomes and subgroups. onTARGET prediction is based on an integration of
massive expression and other data resources, including the NIH LINCS dataset
(with 1,300,000 expression profıles), the NIH TARGET and R2-AMC neuro-
blastoma cohorts, andour own in-house databases. In a fırst step, the datasets are
preprocessed by factor analysis to remove systematic bias in these large data sets.
In a second step, Bayesian statistics are applied to prioritize compounds whose
cellular responses match clinically relevant differences between patient subsets,
such asMYCN status, survival hazard ratio, or histopathological assessment. To
evaluate the method, we used onTARGET prediction to identify compounds
and gene targets relevant for clinical outcomes in the NIH-TARGET (n249)
and R2-AMC (n98) neuroblastoma cohorts. The algorithm confırmed exist-
ing targets andmade interesting predictions. Of 50 the top-ranking compounds
associated with a survival outcome, agents targeting the mTOR/PI3K axis are
highly prevalent. The algorithm correctly predicts targeting of the MYC path-
way, and predicts possible modulators of MYC signaling, such as TRRAP, AU-
RKAandBMP2. In addition to nominating agents with a favorable outcome, the
algorithm can also flag compounds that might worsen prognosis, further facili-
tating the prioritization of targets for evaluation. In summary, onTARGETmay
guide target selection for neuroblastoma studies and can be adapted for other
cancers as well. The many targets that were identifıed immediately suggest an
opportunity for continued evaluation in cells and in vivo models. This work has
been initiated in collaboration with researchers at Lund University.
#687 Targeting tumor-promoting neuroblastomamicroenvironment: in-
hibiton of tumor development and progression by targeting mPGES-1 ex-
pressed by cancer associated fıbroblasts. Anna Kock,1 Karin Larsson,2 Nina
Eissler,1 Filip Bergqvist,2 Joan Rauf,2 Marina Korotkova,2 John-Inge Johnsen,1
Per-Johan Jakobsson,2 Per Kogner1. 1Women’s and Children’s Health, Stock-
holm, Sweden; 2Medicin, Stockholm, Sweden.
Background:High-risk neuroblastomas present a tumor promotingmicroen-
vironment with infıltrating cancer associated fıbroblasts (CAFs) expressing the
mPGES-1 enzyme, essential for prostaglandin E2 (PGE2) synthesis regulating
tumor inflammation and immune suppression, angiogenesis, genetic instability,
tumor progression and therapy resistance. We investigated the impact of novel
therapy targeting the COX/mPGES-1/PGE2 pathway. Methods: Human neuro-
blastomaswere investigated for immunosuppressivemicroenvironment and ex-
pression of the COX/mPGES-1/PGE2/EP-receptor pathway. High-risk in vivo
models, human 11q-deleted xenografts and transgenic MYCN-driven tumors,
were treated with a novel specifıc mPGES-1 inhibitor. Tumor-fıbroblast co-
cultures examined cell migration. Inflammatory lipid mediators were analyzed
by LC-MS/MS. Tumor tissues were analyzed by immunohistochemistry, immu-
nofluorescence and FACS. Results: Tumor microenvironment in human high-
risk neuroblastomas and both 11q-deleted xenografts andMYCN-driven trans-
genic mice displayed mPGES-1 expression in PDGFRb cancer associated
fıbroblasts. MPGES-1 expression correlated with high-risk neuroblastoma
prognosis and infıltration of tumor-promotingmacrophages withM2-polariza-
tionmarkers CD163 andCD206. The inflammatory regulator STAT3was active
in mPGES-1 expressing CAFs. Expression of the inflammatory COX/mPGES-
1/PGE2/EP-receptor pathway in experimental tumors resembled high-risk pri-
mary human neuroblastomas. Targeting mPGES-1 with a novel compound de-
creased PGE2, induced M1 polarization of macrophages, decreased cancer
associated fıbroblasts and reduced angiogenesis signifıcantly in treated tumors.
Tumor development in the xenograft model was delayed and growth of estab-
lished xenografts and transgenic tumors was signifıcantly decreased by non-
toxic treatment in vivo when compared to neuroblastoma tumors in untreated
animals. Tumor cell stimulated CAFmigration and infıltration was inhibited by
targeting mPGES-1. Conclusions: Tumor-promoting inflammation and sup-
pression of anti-tumor immunity in neuroblastoma is mediated through pros-
taglandin E2 and STAT3 expression in cancer associated fıbroblasts in the tumor
microenvironment. Early targeting of mPGES-1 may inhibit CAF infıltration
and tumor development. This novel tumor treatment targeting mPGES-1 de-
creases inflammatory mediators, modulates tumor-promoting microenviron-
ment and inhibits signifıcantly aggressive tumor growth and progression. We
conclude that treatment targeting non-malignant cells in the neuroblastoma
microenvironment may constitute a novel clinical therapeutic approach.
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#688 Meta-[211At]astatobenzylguanidine ([211At]MABG) is a potent al-
pha particle emitting systemic targeted radiotherapeutic in preclinical mod-
els of neuroblastoma.Vandana Batra,1 Jimmy Elias,1MehranMakvandi,2Mat-
thew Tsang,1 Pietro Ranieri,1 Catherine Hou,2 Yimei Li,1 Daniel A. Pryma,2
JohnM.Maris1. 1Children’s Hospital of Philadelphia, Philadelphia, PA; 2Univer-
sity Of Pennsylvania, Philadelphia, PA.
BACKGROUND: The alpha particle emitting radiotherapeutic [211At-
]MABG theoretically has superior radiobiological properties for anti-tumor ef-
fıcacy compared to the currently used agent ([131I]MIBG). Specifıcally,
[131I]MIBG does not target microscopic deposits due to the long path length of
the beta particles, while alpha particles have both a short path length and higher
linear energy transfer to induce clustered double strand breaks. Here we sought
to defıne the anti-tumor activity of [211At]MABG in preclinical models of hu-
man neuroblastoma (NB). METHODS: 211At was synthesized using a bismuth
target via the 209Bi(,2n)211At reaction and used for solid-phase radiosynthesis
of [211At]MABG (Ultratrace, Progenics, NY). We determined NET (SLC6A2)
mRNA and protein expression in 35 NB cell lines and created isogenic pairs by
overexpression of NET in 5 NB cell models. We performed uptake, cytotoxicity
and biodistribution studies using these models with [131I]MIBG and [211At-
]MABG and extrapolated human dosimetry. Additionally, dose escalation stud-
ieswith [211At]MABG (n10 at each dose, range 10-100 uCi)were performed to
determine toxicity in SCIDmice. Therapeutic in vivo trials were conductedwith
NET transfected xenografts and patient derived xenograft (PDX) models in-
jected intravenously with escalating doses of [211At]MABG, [131I]MIBG or ve-
hicle (n10 respectively). RESULTS: We now routinely synthesize [211At-
]MABG with a radiochemical yield of 50-70% and radiochemical purity99%.
NET-overexpressing cell lines showed 4-10 fold higher uptake of NET ligands
than parental isogenic lines, and tumor-specifıc [211At]MABG uptake (tumor-
muscle ratios of 7.37). Estimated dosimetry confırmed the potential to deliver
therapeutic doses to tumors. Intravenous [211At]MABG was well tolerated in
murinemodels at doses of 10 and 25Ci except for transient thrombocytopenia
(nadir at 6 weeks; p0.001 and p0.0005 respectively) while doses higher than
50 uCi caused signifıcantweight loss. [211At]MABGwas a potent cytotoxic agent
in vitro (EC50’s ranged from 0.0006-0.1 uCi/ml compared to 0.25-46 uCi/ml
with [131I]MIBG). Single dose therapeutic trials showed signifıcant regression of
established NET overexpressing SKNSH xenograft and COG-N-453x PDX
models (p0.0001) sustained for a median of 14.5 days, comparable to single
dose [131I]MIBG therapy and prolonged survival was noted in mice receiving
[211At]MABG. CONCLUSIONS: The biodistribution and uptake of [211At-
]MABG is similar to [131I]MIBGand therewas no unanticipated toxicity. [211At-
]MABG is more potent than [131I]MIBG in vitro and the two agents showed
similar activity in bulky xenograft models, remarkable due to the several log
difference in half-life (7.2 hours for [211At]MABG, 8.04 days for [131I]MIBG).
Additional studies exploring fractionated dosing of [211At]MABG are ongoing
and will be reported.
#689 Immune checkpoint targeting to improve immunotherapy in neuro-
blastoma.Myrna L. Ortiz-Ruiz.H. Lee Moffıtt Cancer Ctr. & Res. Inst., Tampa,
FL.
Neuroblastoma (NB) is the most common extracranial solid tumor in chil-
dren. Current treatments accounts only for at the most 40% of survival rate in
high-risk NB patients. Hence, there is a need to develop new strategies that
disrupt immunosuppressive signals in the tumormicroenvironment in order to
achieve robust anti-tumor immune responses. Co-inhibitory signals through
receptors such as PD-1 can lead to the inactivation of T cells. On the other hand,
co-stimulatory signals through receptors such as 41BB can enhance T cell activ-
ity against tumors. These receptors can serve as tools to develop strategies to
optimize and enhance T cell anti-tumor functions. In this study, we used 9464D
NB tumor mouse model to evaluate antibody treatment as a possible immuno-
therapy strategy.We further examine the infıltration and function of T cells after
targeting checkpoints in 9464D NB tumor bearing mice. Blockade of various
receptors in mice bearing 9464D tumor showed that anti-PD1 and anti-41BB
delayed tumor growth. Combination therapy with anti-PD1 and anti-41BB an-
tibodies signifıcantly delayed tumor growth compared to single antibody treat-
ment. This combination therapy led to a higher infıltration of CD8 cells within
the tumor. Splenocytes from 9464D tumor bearing mice treated with anti-PD1
and anti-41BB are tumor specifıc. In conclusion, our fındings intend to design
the best complement therapy to improve survival of patients with advanced NB.
Our data demonstrates that tumor reactive T cells in NB tumors may express
different checkpoint receptors including PD1 and 41BB. 9464D tumor bearing
mice that received a combination of anti-PD1 and anti-41BB antibodies have
smaller tumor size compared to single antibody therapy. Future direction in-
cludes examine T cells activation after combination therapy of BMT and immu-
necheckpoint targeting. Alsowewant to test adoptive transfer of T cells in tumor
bearing mice after BMT. Further we want to measure the infıltration of other
immune cells, such as myeloid cells and Tregs, in the tumor environment and
possible target immune suppressive populations to see the effects in tumor
growth.
#690 Identifying the genetic basis of stage 4S neuroblastoma. Zalman
Vaksman, Lee D. McDaniel, Maura Diamond, JohnM.Maris, Sharon J. Diskin.
Children’s Hospital of Philadelphia, Philadelphia, PA.
Introduction: The 5 year mortality rate for stage 4 metastatic neuroblas-
toma (NBL) is 50%; however, the stage 4S subset of NBL is typically clas-
sifıed as low-risk with tumors exhibiting spontaneous regression. To date,
the underlying genetic mechanisms influencing this distinct phenotype re-
main unknown. Method: To identify genetic determinants specifıc to the 4S
phenotype, we performed genome-wide association study (GWAS) analyses.
Blood DNA samples from 6,195 NBL patients and 11,384 non-NBL controls
were genotyped using Illumina SNP arrays. European ancestry subjects were
selected for inclusion in a discovery [stage 4S (n148), stage 4 (n996),
non-NBL controls (n9,923)] or replication cohort [stage 4S (n76), stage
4 (n608), non-NBL controls (n1,461)]. Following imputation using 1KG
Phase 3, we conducted case:case comparisons including stage 4S vs. 4 and
stage 4S vs. 1, followed by comparisons of NBL cases in each group to
matched non-NBL controls. Variants uniquely associated with 4S NBL were
defıned as those meeting the following criteria: (1) stage 4S vs. 4 meta P 
5.0 x 10-5 and P  0.005 in the discovery cohort (2) 4S vs. non-NBL control
P 0.05 and (3) either not signifıcant (P 0.05) or odds ratio in the opposite
direction in 4 vs. non-NBL controls. Results: 4S-specifıc variants that met
our criteria spanned multiple regions with several harboring genes impor-
tant to neuronal function including 9q34 (SARDH/DBH; rs2502746), 1p32.2
(KCNH1; rs12122529), 1p34 (KCNQ4; chr 1:41317634), 7q34 (CNTNAP2;
rs79403134) and 2q24.1 (KCNJ3; rs78829625). At the 9q34 locus, rs2502746
showed further evidence as an expression quantitative trait locus (eQTL) for
Dopamine Beta-Hydroxylase Antisense RNA1( DBH-AS1 P  1.9 x 10-5
sun-exposed skin) and Sarcosine Dehydrogenase SARDH expression (P 
2.5 x 10-6 whole blood). Other 4S-specifıc loci observed include 3q27.3
(rs113207181), 8p21.3 (rs12548388), and 15q12 (rs62189512). Notably, none
of the previously identifıed NBL susceptibility loci were found to be associ-
ated with 4S NBL in the 4S vs. non-NBL control comparison, suggesting a
unique genetic basis for this enigmatic subset. Discussion: Although a uni-
fying mechanism underlying 4S NBL has yet to be identifıed, our results
suggest a potential role for ion-channel and neuronal function genes. Ongo-
ing efforts include investigating the role these genes and associated pathways
play in NBL, including an integrative genomic, epigenomic and transcrip-
tome analysis of stage 4 and 4S NBL.
#691 DFMO synergizes with BET inhibitors targetingODCandMYCN to
impede neuroblastoma cell proliferation and tumor initiation. SarahDeCou,
Ping Zhao, TraceyAvequin, AbhinavNagulapally, Jeffrey Bond,Giselle Saulnier
Sholler. Helen DeVos Children’s Hospital, Spectrum Health, Grand Rapids, MI.
Background: Neuroblastoma (NB) is the most common extracranial solid
pediatric tumor and is associated with MYCN amplifıcation. MYCN is a
regulator of ornithine decarboxylase (ODC), the rate-limiting enzyme of
polyamine biosynthesis. Inhibition of this pathway in MYCN-amplifıed NB
tumors has been shown to be a target for treatment. Alpha-difluoromethyl-
ornithine (DFMO) inhibits ODC and is currently being used in a Phase II
clinical trial for NB. BET inhibitors JQ1 and OTX-015 have been shown to be
effective against MYCN-amplifıed cancers; it is hypothesized that they
downregulate MYCN as well as cancer stem cell (CSC) signaling. We pro-
pose that inhibiting MYCN with a BET inhibitor, coupled with inhibition of
ODC with DFMO, will result in enhanced inhibition of NB growth and
tumor-initiating properties. Methods: Single and combination drug treat-
ments were conducted on BE(2)-C, SMS-KCNR, CHLA90, and one patient-
derived cell line. CellTiter-Glo Luminescent Cell Viability Assay was used to
determine cell viability in 96-well plates. IC50 values were calculated with a
four-parameter variable-slope dose response curve using GraphPad Prism
v.5 software. Drug combination studies were conducted in MYCN amplifıed
tumors BE(2)-C and SMS-KCNR using ray designs to evaluate for syner-
gism. IncuCyte ZOOM Live-Cell Imaging system was used for kinetic mon-
itoring of cytotoxicity and apoptosis in NB cells. Western blots measured
protein levels of apoptosis markers (cleaved caspase 3 and cleaved PARP)
and CSCmarkers (Nanog, Sox2, NF-kB, CXCR4, Lin28B, andMYCN). Neu-
rosphere assays were used to evaluate tumor initiation via sphere formation.
Results: Cell viability of MYCN amplifıed NB showed an IC50 range of
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1.48-1.69 M for JQ1 and 839.3 nM-2.36 M for OTX-015; MYCN non-
amplifıed NB showed an IC50 range of 4.22-11.58M for JQ1 and 2.99-11.03
uM for OTX-015. Combination treatment in MYCN NB had a synergistic
effect, based on Loewe-additivity as the null hypothesis, for cell viability
suppression by ray design experiments for BE(2)-C and SMS-KCNR. West-
ern blots showed greater expression of apoptosis markers and decreased
expression of CSC markers in combination relative to single drug treat-
ments. A greater than 50% decrease in neurosphere formation with combi-
nation treatment in BE(2)-C, SMS-KCNR, and the patient cell line provides
evidence for reduced CSC activity. IncuCyte imaging showed an increase in
cell death with time post-treatment. Conclusion: The combination of DFMO
with BET inhibitors has a synergistic effect in treating MYCN amplifıed NBs
as shown by a decrease in cell viability. This combination targets CSC path-
ways and decreases tumor-initiating ability. Given the lack of effective treat-
ment options for children with relapsed or refractory high-risk NB, this
combination may be a promising novel therapy.
#692 Pappalysin-1 is a suitable target for T cell receptor transgenic T cells
to kill Ewing sarcoma in vivo and in vitro. Uwe Thiel,1 Andreas Kirschner,1
Melanie Thiede,1 Thomas GP Grünewald,2 Rebeca Alba Rubio,2 Günther Rich-
ter,1 Thomas Kirchner,2 Dirk Busch,3 Poul Sorensen,4 Stefan Burdach1. 1Labo-
ratory for Functional Genomics and Transplantation Biology,Munich, Germany;
2Institute of Pathology of the LMU, Munich, Germany; 3Technische Universität
München, München, Munich, Germany; 4BC Cancer Research Centre, Vancou-
ver, British Columbia, Canada.
Pregnancy-associated plasma protein-A (PAPPA), also known as pappalysin,
is a member of the insulin like growth factor (IGF) family. PAPPA acts as a
protease, cleaving IGF inhibitors, i.e. IGF binding proteins (IGFBPs), thereby
releasing IGFs from IGFBPs. The insulin/IGF-axis is involved in cancer in gen-
eral and in Ewing sarcoma (ES) in particular. ES is a highly malignant bone
tumor characterized by earlymetastatic spread. PAPPA stimulates normal bone
growth, and is also associated with various cancers. In particular, PAPPA is
overexpressed and required for proliferation in ES.We isolatedHLA-A*02:01/
peptide restricted T cells fromA*02:01- healthy donors directed against PAPPA,
generated by priming with A*02:01 PAPPA peptide-loaded dendritic cells.
After T cell receptor (TCR) identifıcation, retrovirally TCR transduced CD8 T
cells were assessed for their in vitro specifıcity and in vivo effıcacy in human ES
bearing Rag2-/-c-/- mice. Engraftment in mice and tumor infıltration of TCR
transgenic T cells in the mice was evaluated. The TCR transgenic T cell clone
PAPPA-2G6 demonstrated specifıc reactivity towards HLA-A*02:01/
PAPPA ES cell lines. We furthermore detected circulating TCR transgenic T
cells in the blood in Rag2-/-c-/- mice and in vivo engraftment of the in bone
marrow. Tumor growth in mice with xenografted ES was signifıcantly reduced
after treatment with PAPPA-2G6 TCR transgenic T cells compared to controls,
and tumors from treated mice revealed tumor infıltrating PAPPA-2G6 TCR
transgenic T cells. In summary, we demonstrate that PAPPA is a promising
target for TCR based immunotherapy of ES. We demonstrate that TCR trans-
genic T cells recognize this target, home to the tumor, and causes tumor regres-
sion in a preclinical mouse model.
#693 Antibody-based targeting of the cell surface receptor tyrosine kinase
FGFR4 in rhabdomyosarcoma and other cancers. Martin Skarzynski,1 Nitya
Shivaprasad,1 Baskar Subramanian,1 David Azorsa,2 Zhongyu Zhu,3 Dimiter
Dimitrov,3 Javed Khan1. 1Oncogenomics Section, Genetics Branch, National
Cancer Institute, Bethesda, MD; 2The Translational Genomics Research Institute
(TGen), Scottsdale, AZ; 3Protein Interactions Section, Cancer and Inflammation
Program, National Cancer Institute, Frederick, MD.
Fibroblast Growth Factor Receptor 4 (FGFR4) is a receptor tyrosine kinase
that is highly expressed in rhabdomyosarcoma (RMS), an aggressive soft tissue
sarcoma originating from skeletal muscle in children and adolescent young
adults. FGFR4 is expressed during development in myoblasts, but not in termi-
nally differentiated skeletal muscle. Of note, FGFR4 is directly induced by the
chimeric fusion oncogene PAX3-FOXO1 found in the most aggressive fusion-
positive RMS and is mutationally activated in approximately 10-13% of the
remaining fusion-negative RMS. High FGFR4 expression is associated with ad-
verse outcome and is a driver oncogene in RMS. Metastatic RMS has a dismal
outcome in the clinic with30% survival. Novel treatments are needed for this
devastating disease of children and young adults. Given that FGFR4 is function-
ally important and differentially overexpressed in RMS, we therefore hypothe-
sized that FGFR4 is an ideal target for antibody-based therapeutics. To test our
hypothesis, we fırst generated 15 binders against FGFR4: 3 murine monoclonal
antibodies (mAbs), 2 rabbit mAbs and 10 fully human mAbs. We then assessed
the specifıcity and affınity of these binders for FGFR4 by ELISA and surface
plasmon resonance. Using flow cytometry and confocal microscopy, we next
evaluated whether the mAbs internalized upon binding FGFR4. We then se-
lected the internalizing binders from our panel for development of antibody-
drug conjugates (ADCs). To investigate the ability of internalizing anti-FGFR4
mAbs to deliver cytotoxic payloads to RMS cells, we used a rapid screening
method which employs drug-conjugated secondary antibodies (2°ADC), and
thus circumvents the need for direct conjugation of cytotoxic small molecules to
mAbs. When the anti-FGFR4 primary antibody and 2°ADC are co-adminis-
tered, target cells internalize both antibodies in complex with the antigen. In
addition to rapid screening of binders, this method facilitates comparison of
various cytotoxic payloads, such as DNA alkylating and tubulin polymerization
inhibiting agents. From the internalization and cytotoxicity screening data, we
identifıed two murine mAbs that bound FGFR4 with low nanomolar affınity,
readily internalized and killed RMS cells when paired with an anti-murine
2°ADC carrying MMAF or DMDM. In summary, we have determined that our
anti-FGFR4 ADCs can deliver cytotoxic payloads to target cells through recep-
tor-mediated endocytosis. We will next convert the two internalizing murine
mAbs into mouse/human chimeric mAbs, directly conjugate them with a cyto-
toxic payload and test them in vitro and in vivo against RMS cell lines and RMS
patient derived cells. The ultimate goal of these studies is to demonstrate the
potential for clinical utility of FGFR4 targeting and develop novel therapeutics
that can make a clinical impact on RMS and other FGFR4 overexpressing can-
cers, such as hepatocellular carcinoma, breast and lung cancers.
#694 TK-216: a novel, fırst-in-class, smallmolecule inhibitor of EWS-FLI1
in early clinical development, for the treatment of Ewing Sarcoma. Saravana
P. Selvanathan,1 Eric Moseley,1 Garrett T. Graham,1 Katti Jessen,2 Brian Lan-
nutti,2 Aykut Üren,1 Jeffrey A. Toretsky1. 1Georgetown University, Lombardi
Comp. Cancer Center, Washington, DC; 2Oncternal Therapeutics, Inc., San Di-
ego, CA.
One of the most signifıcant challenges in creating more potent, less toxic
treatments for patients is to identify new cancer therapeutic targets that distin-
guish the malignant from normal cells. EWS-FLI1 is a well-established Ewing
sarcoma (ES) oncogene that has the potential to be an ideal therapeutic target by
directly impacting malignant cells. We have previously reported the discovery
and characterization of YK-4-279, an enantiomer-specifıc inhibitor of EWS-
FLI1, which has been demonstrated to induce apoptosis, inhibit EWS-FLI1 tran-
scription, block RNA helicase A co-immunoprecipitation with EWS-FLI1, and
result in alternative splicing to mimic EWS-FLI1 knockdown. Continuous ef-
forts in structure-guided medicinal chemistry has yielded TK-216, an analog of
YK-4-279 inhibitor of EWS-FLI1, which is 3-4 fold more potent with excellent
drug-like properties. TK-216 potently inhibits the proliferation of ES cells. In-
duces apoptosis in a dose -dependent manner as measured by caspase-3 activity
in multiple ES cell lines with distinct translocation variants. The effects of TK-
216 on alternative splicing (AS) were further validated using genes including
ARID1A,CLK1,CASP3, PPFIBP1 andRUNX2. The splicing patternwas similar
betweenTK-216 andYK-4-279. In addition to the in vitro activity of TK-216 ,we
show that TK-216 displays anti-tumor activity in a number of ES xenograft
models. In summary, TK-216, a novel, fırst-in-class therapeutic which directly
inhibits EWS-FLI1, offers a promising approach for the treatment of Ewing
Sarcoma and is currently in Phase 1 clinical trials in patients with relapsed or
refractory Ewing Sarcoma (clinicaltrials.gov - NCT02657005).
#695 Targeted nanoparticle therapy for poor prognosis Ewing’s sarcoma.
HyungGyoo Kang,1 Jon Nagy,2 Julia Samulak,1 Timothy Triche1. 1USC/Chil-
dren’s Hospital Los Angeles, Los Angeles, CA; 2Nano Valent Phamaceuticals,
Bozeman, MT.
Targeted nanoparticles have shown the potential to deliver anticancer drugs
to cancer cells selectively and thus to overcome unexpected cytotoxicity and
limited effıcacy of chemotherapy caused by non-selective delivery to normal
cells. However, the optimal formulation of targeted nanoparticles for actual
translational applications has not been established. By refıning early formula-
tions and after extensive testing, we have created an optimized targeted delivery
system, HPLNs (Hybrid Polymerized Liposomal Nanoparticles) and demon-
strated that this new, targeted nanoparticle technology overcomesmany of these
defıciencies. This technology has tremendous potential for treating virtually any
type of cancer. The goal of our present study was to determine the effıcacy and
toxicity of this novel targeted nanoparticle in the treatment of Ewing’s Sarcoma,
a rare and highly lethal cancer of children and young adults. The effıcacy of this
targeted delivery systemwas compared to 1) administration of the free drug and
2) the drug in untargeted nanoparticle form. Our studies have shown that
HPLN-Dox targeted with human antiCD99 antibodies can successfully inhibit
the growth of Ewing’s Sarcoma in murine models without any detectable off-
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target toxicity. The deliverable for our study was to demonstrate that the effec-
tiveness of doxorubicin in the treatment of recurrent Ewing’s sarcoma could be
dramatically improved when encapsulated in human antiCD99 antibody tar-
geted HPLNs. At the same time, toxic side effects normally seen with free drug
was not detectable. Success with human anti-CD99 antibodies targeted HPLNs
containing Doxorubicin was then easily adapted to other tumor types (Leuke-
mia, Prostate or Pancreatic cancers) and other payloads such as irinotecan,
EWS-FLI1 specifıcASOs, siRNAandCRISPR/Cas9 targeting the ETS domain of
the chimeric EWS-ets gene found in all Ewing sarcoma. In conclusion, our study
showed a potential of targeted HPLN as a selective delivery vehicle of cytotoxic
payloads to cancers and this technology is then easily adapted to other tumor
types and virtually any small molecule therapeutic.
#696 Inhibition of Ewing sarcoma cell growth by targeting Sp1 and sur-
vivin with the small molecule clotam. Sagar Shelake,1 Umesh T. Sankpal,1 W.
Paul Bowman,1 MatthewWise,2 Anish Ray,3 Riyaz Basha1. 1University of North
TexasHealth Science Center, FortWorth, TX; 2Texas College of OsteopathicMed-
icine, Fort Worth, TX; 3Cook Children’s Medical Center, Fort Worth, TX.
Ewing sarcoma (ES) is the most common soft tissue and bone tumor in ado-
lescents and young adults. The survival rate of patients withmetastatic disease is
poor suggesting an urgent need for the development of more effective therapeu-
tic options.Our aimwas to investigate novel targets and identify less toxic agents
to improve therapeutic effıcacy in ES patients. Specifıcity protein 1 (Sp1) tran-
scription factor regulates critical genes involved in cell proliferation. Sp1 also
mediates the expression of survivin, an inhibitor of apoptosis protein. Overex-
pression of Sp1 and survivin is linked to aggressiveness and poor prognosis in
several cancers; however, their precise association is not adequately evaluated in
ES. Previously, we showed that tolfenamic acid (TA) inhibits leukemia, medul-
loblastoma and neuroblastoma cell proliferation by targeting Sp1. In this study,
we investigated the anti-cancer activity of this small molecule using human ES
cell lines. CHLA-9 and TC-32 cells were treated with vehicle (DMSO) or TA
(2.5-20g/ml) and cell viability wasmeasured at 24, 48 and 72 h post-treatment
using CellTiter Glo kit. ES cells were treated with vehicle or TA (15 g/ml) for
48 h. ThemRNA and protein expression of Sp1 and survivin was determined by
quantitative polymerase chain reaction (qPCR) and Western blot analysis re-
spectively. Flow cytometry was used to measure apoptotic cell population using
Annexin-V staining and cell cycle phase distribution with propidium iodide.
Markers of apoptosis (caspase 3/7 activity using caspase Glo kit and cleaved
PARP by Western blot) and cell cycle arrest (Cyclin D1 and p21 expression by
Western blot) were also determined. Sp1 DNA-binding was evaluated by gel
shift assay. TA treatment inhibited ES cell viability in a dose and time-dependent
manner which is accompanied by the inhibition of Sp1 and survivin protein
expression and a 2-3 fold increase in apoptotic markers, caspase 3/7 activity,
Annexin-V staining, and c-PARP expression. Interestingly, TA inhibited
mRNA expression of survivin but not Sp1, suggesting it has post-translational
effects, perhaps proteasome-dependent degradation of Sp1. Gel shift assay re-
vealed a decrease in Sp1DNA-binding, indicating that TA could directly disrupt
the binding of Sp1 with its consensus binding site in the promoter of target
genes. Cyclin D1 is crucial for moving the cells from G0/G1 to next phases and
induction of p21 is known to inhibit Cyclin D1. In this study, TA up-regulated
p21, reducedCyclinD1 expression and accumulated cells inG0/G1phase. These
results demonstrate that TA induces apoptosis and causes cell cycle arrest in ES
cells by targeting Sp1 and survivin.
#697 Stage 1 in vivo evaluation ofmulti-receptor tyrosine-kinase inhibitor
lenvatinib in osteosarcoma patient derived mouse xenograft models. Wen-
dongZhang,1Michael E. Roth,2 JonathanGill,2 Sajida Piperdi,1 E. Anders Kolb,3
David S. Geller,4 Bang Hoang,4 Rui Yang,4 Richard Gorlick2. 1Albert Einstein
College of Medicine, Bronx, NY; 2Albert Einstein College of Medicine/Children’s
Hospital at Montefıore, Bronx, NY; 3Nemours/A.I. duPont Hospital for Children,
Wilmington, DE; 4Albert Einstein College of Medicine/Montefıore Medical Cen-
ter, Bronx, NY.
Background:Osteosarcoma (OS) is themost commonprimary bone tumor in
children and young adults. Over the past three decades improvement in out-
comes for children withOS have remained stagnant. Novel therapies are needed
to improve outcomes for these patients. Lenvatinib is an oral small-molecule
tyrosine-kinase inhibitor (TKI), targeting multiple receptors including
VEGFR1-3, FGFR 1-4, PDGFR, RET, and c-kit. Prior studies have shown that
PDGFR-VEGF/VEGFR and FGFR3 are overexpressed in human OS cell lines.
Lenvatinib is FDA-approved for the treatment of differentiated thyroid cancer,
and, in combinationwithmTOR inhibitor everolimus, for the treatment of renal
cell carcinoma. The current study assessed the in vivo effıcacy of lenvatinib in
osteosarcoma xenograftmodels.Materials andMethods: Single agent lenvatinib
was tested against 5 well-established osteosarcoma patient derivedmouse xeno-
graft models. Lenvatinib was administered using a dose of 7.5mg/kg given by
oral route daily (5/7 days) for 6 weeks or until study endpoints weremet. Tumor
volume and mouse body weight were measured bi-weekly. Tumor volume was
compared to baseline tumor volume to calculate the relative tumor volume
(RTV). The RTV was compared between the control and experimental groups
utilizing the student t-test. P-values0.05 were considered statistically signifı-
cant. Additional statistical analyses were conducted as per the Pediatric Preclin-
ical Testing Program analysis plan. Results: Lenvatinib was generally well toler-
ated in vivo, without noted toxicity in any of the treated animals. Lenvatinib
treatment led to delayed tumor progression in 4/5models tested. Relative tumor
volumes in the treatment group compared to the control group at week 3 in
xenografts OS1, OS2, OS17, OS31, and OS33 were 0.77 (p0.013), 0.88
(p0.147), 0.49 (p0.001), 0.66 (p0.001), and 0.40 (p0.001), respectively.
Despite delayed progression observed in the OS xenografts treated with lenva-
tinib, all groups experienced progressive disease by the end of the study period.
Conclusions: Single agent lenvatinib demonstrates consistent anti-tumor activ-
ity in osteosarcoma patient derivedmouse xenograftmodels. Preclinical studies,
as well as clinical trials, have demonstrated the effıcacy of tyrosine kinase inhi-
bition in combinationwith inhibition ofmTOR in a variety ofmalignancies. The
current study, along with prior data, suggests that targeting receptor tyrosine
kinases, in addition tomTOR,may lead tomore effective inhibition of osteosar-
coma cell growth. Ongoing studies are assessing the effıcacy of lenvatinib, ad-
ministered in combination with mTOR inhibitor, everolimus, in osteosarcoma
patient derived mouse xenografts.
#698 Functional outcome and socio-psychological problems for bone &
soft tissue sarcoma patients in childhood&AYAgeneration.KanyaHonoki,1
Toshiaki Shinomiya,1 Hiromasa Fujii,1 Takashi Ishihara,1 Shinji Tsukamoto,1
Shingo Kishi,1 Yumiko Kondo,1 Akira Kido,1 Toshifumi Tsujiuchi,2 Midori
Shima,1 Yasuhito Tanaka1. 1Nara Medical Univ., Nara, Japan; 2Kindai Univ.,
Higashiosaka, Japan.
[Objective] To elucidate the problems between functional and sociological
outcomes in patients of bone and soft tissue sarcomas in childhood and adoles-
cent/young adult (AYA) generation. [Method] Clinical (prognostic and func-
tional) and socio-psychological outcomes were retrospectively analyzed in 50
patients with bone and soft tissue sarcomas under 29 years old treated in our
institute from 1998 to 2014. [Results] Twenty-two patients under 15 and 28 of
AYA generation (15 to 29 years old) (28 male and 22 female) were subjected,
including 35 cases of bone and 15 cases of soft tissue sarcomas, and 39 of ex-
tremity cases. Most common diagnosis was osteosarcoma of 27 cases. Limb-
sparing surgery was performed in 30 cases, including 14 of prosthetic and 8 of
biological reconstruction for bone tumors. Overall Survival rates were 79% for 2
year and 61% for 5 year follow-up periods. 70% of the patients experienced
limited activities; 50% in high school and college students experienced drop-out
or delay, suspension and repeating the same class; 56% faced to their job lost or
limitation of job search; 20% experienced changes of relationship with families
and partners (Table). Most taken palliative care intervention was the counseling
for familymembers and caregivers, besides painmanagement and psychological
care. Correlation coeffıcient failed to show a signifıcant correlation between
functional score and sociological disability score both in all limb sparing cases
(R2  0.2664) and in osteosarcoma cases ((R2  0.1757) . [Conclusion] The
sociological problems for patients in this particular group could be focused on
school life, job search and relationship with families and partners. QOL is a
multidimensional measure with various domains, such as physical, psychologi-
cal, social well-being, spiritual health as well as functional ability, therefore,
multi-disciplinary care for socio-physiological and psychological disadvantage
must be taken for this group of patients at earliest convenience.
Reletionship between physiological and socio-psychological problems
Subject All patients Limb-spared patinets
Limitation of activities 70% (30/43) 75% (21/28)
School dropout/delay in
high-schoolers & college students
50% (14/28) 32% (8/25)
Lost jobs/job search diffıculties 56% (9/16) 33% (3/9)
Changing social reletions
with families & partners
20% (8/40) 21% (3/28)
#699 Clinical feasibility of chemotherapy monitoring for bone sarcoma
patients with diffuse optical spectroscopic imaging. Hannah M. Peterson,1
Bang H. Hoang,2 David Geller,2 Richard Gorlick,2 Rui Yang,2 Jeremy Berger,2
Janet Tingling,2 Michael Roth,2 Jonathan Gill,2 Darren Roblyer1. 1Boston Uni-
versity, Boston, MA; 2Montefıore Medical Center, Bronx, NY.
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Background: Sarcomas account for almost 15% of all childhood cancers
and 40-60% of these patients develop locally recurrent or metastatic disease.
Currently in many sarcomas, the only clinically accepted prognostic marker
in patients with localized disease is the percent of tumor necrosis at the time
of surgery. Diffuse Optical Spectroscopic Imaging (DOSI) is an emerging
near-infrared (NIR) imaging technique that non-invasively measures quan-
titative functional information andmay provide a newmeans tomonitor and
predict chemotherapy response in sarcoma which could impact treatment
decisions. Here we evaluate the feasibility of measuring pediatric sarcomas
with DOSI. Methods: Patients diagnosed with either Ewing’s Sarcoma or
osteosarcoma underwent DOSI measurement at multiple time points during
their course of neoadjuvant chemotherapy. A handheld probe was used to
take point measurements in a 1 cm spaced grid at tumor and contralateral
normal locations. The measurement area was approximately 6 x 7 cm and a
single point measurement typically took 15-30 s, which includes the time it
takes to position the probe, ensure good contact between the probe and the
skin, and acquire data. The optical properties, and absolute concentrations
of oxyhemoglobin (ctHbO2), deoxyhemoglobin (ctHb), water (ctH2O), and
lipids were compared between tumor and normal measurements. Results: To
date, one osteosarcoma and two Ewing’s sarcoma patients have been mea-
sured. At baseline and early in treatment, all subjects had a statistical differ-
ence in total hemoglobin concentration between the affected and contralat-
eral normal tissues (p 0.05 for Student’s t-test, Kolmogorov-Smirnov test,
and Mann-Whitney rank test). Statistical differences also appeared in oxy-
hemoglobin, deoxyhemoglobin, oxygen saturation, water, lipids, scattering
amplitude, and scattering power although longitudinal trends varied across
patients. Conclusions: DOSI can be utilized to measure optical properties
and to obtain functional information in bone sarcoma patients. It can detect
differences between affected and normal tissue. A better understanding of
the optical properties in this patient population is needed. Larger data sets
are needed to characterize and quantify sarcoma optical properties and treat-
ment response dynamics, ideally fınding a functional biomarker associated
with pathologic response. Additional accrual of primary bone sarcoma pa-
tients and normal volunteers is ongoing.
#700 Characterization of the mode of action of Fenretinide treatment
in alveolar rhabdomyosarcoma cells. Eva Brack, Marco Wachtel, Beat W.
Schaefer. University Children’s Hospital Zurich, Zurich, Switzerland.
Alveolar rhabdomyosarcoma (aRMS) is a highly malicious childhood malig-
nancy characterized by a specifıc chromosomal translocation encoding the on-
cogenic transcription factor PAX3-FOXO1. As aRMS cells are addicted to the
tumor-specifıc fusion protein, it may serve as an ideal therapeutic target. Previ-
ously, we have identifıed from a large drug library screen the compound Fen-
retinide (retinoic acid p-hydroxyanilide), which is already in clinical use, to
affect both PAX3-FOXO1 expression as well as aRMS cell viability. The aim of
this study was therefore to characterize the mode of action of Fenretinide in
more detail. First, we were able to show that Fenretinide induced the generation
of reactive oxygen species (ROS) in mitochondria. A more detailed character-
ization revealed that the Fenretinide-induced ROS derived from an interaction
of Fenretinide around complex II of the mitochondrial respiratory chain, lead-
ing to the production of superoxides. ROS scavenging as well as complexing of
iron ions completely abolished cell death. To identify the mode of cell death
involved, we then used a range of pharmacological inhibitors of specifıc cell
death pathways including Z-vad (pan -caspase inhibitor), Necrostatin-1
(necroptosis pathway inhibitor (RIP-1 kinase inhibitor)), 3-Methyadenine (3-
MA) (autophagy pathway inhibitor (phosphatidylinositol 3-kinase inhibitor))
and Ferrostatin (ferroptosis pathway inhibitor) during Fenretinide treatment.
Surprisingly, none of these inhibitors alone was able to prevent cell death and
even different combinations were not suffıcient to completely inhibit cell death.
CRISPR/Cas9 mediated depletion of key players in the apoptotic and necrop-
totic pathway (Bak, Bax and RIPK1) confırmed the pharmacological data. We
therefore conclude that other, less characterized cell death pathways or a com-
bination of several pathways including apoptosis and necroptosis might be cru-
cial. Interestingly, electronmicroscopic examination of cells pointed towards an
excessive accumulation of vacuoles to be characteristic. Taken together, our data
show that Fenretinide shows high potential for the treatment of aRMS, inducing
several forms of cell death mediated through the production of ROS. These
properties open the search for additional compounds acting in a combinatorial
manner.
#701 Pazopanib synergizes with clofılium tosylate in the treatment ofma-
lignant rhabdoid tumors. Celine Chauvin,1 Aurianne Lescure,1 Wilfrid
Richer,1 Arnault Tauziède-Espariat,2 Amaury Leruste,1 Zhi-Yan Han,1 Didier
Surdez,1 Stefano Cairo,3 ElaineDel Nery,1 Olivier Delattre,1 Franck Bourdeaut1.
1Curie Institute, Paris, France; 2Sainte-Anne Hospital, Paris, France; 3XenTech,
Evry, France.
Background: Rhabdoid tumors (RTs) are rare, highly aggressive pediatric
malignancies which occur in kidney, soft-parts and brain of young children.
They are characterized by a complete inactivation of the SMARCB1 tumor sup-
pressor gene encoding a core subunit of the chromatin remodeling SWI/SNF
complex. Prognosis for children with RTs is poor as, in many instances, these
tumors are resistant to conventional type chemotherapy. Hence, new therapies
should be designed and biologically-driven strategies targeting the SMARCB1-
defıciency or its biological consequences have to emerge. Methods: For this
purpose, we realized a high-throughput screening by using the PrestwickChem-
ical Library of 1200 FDA-approved drugs on two rhabdoid tumor cell lines and
one SMARCB1-reexpressing cell line. Cell count was assessed by automatic cell
counting using DAPI. Results: Among 10 drugs that showed cytotoxic activity
specifıcally in SMARCB1-defıcient cell lines, we identifıed vatalanib, a broad
receptor tyrosine kinase (RTK) inhibitor. This prompted us to analyse the re-
sponse to a wider number of 9 RTK inhibitors on 7 SMARCB1-defıcient cell
lines compared to 6 SMARCB1-expressing cell lines. This “supervised” screen-
ing confırmed the activity of vatalanib but showed that pazopanib had an even
greater cytotoxic ability. Interestingly, the screening also identifıed a potassium
channel inhibitor (clofılium tosylate), that showed among the strongest cyto-
toxic activity as a single agent, and also synergistically reduced viability and
induced apoptosis, when combined with vatalanib and pazopanib. With in vivo
experiments on two patient-derived xenograft (PDX) models of rhabdoid tu-
mor, we notably showed that pazopanib is effective in reducing tumor growth
and that combinationwith clofılium tosylate enhanced the anti-tumor activity of
pazopanib in the two PDXmodels. Interestingly, we also highlighted that pazo-
panib combined to conventional chemotherapies is even more effıcient than
chemotherapy alone. Finally, to identify candidate kinases that confer pazo-
panib sensitivity to rhabdoid tumor cell lines, we performed a phosphoarray
experiment and found PDGFRa, PDGFRb and FGFR2 as pazopanib targets,
RTK that were among the most highly expressed in our expression profıling
dataset. Conclusion: To conclude, our fındings demonstrate that targeting
PDGF and FGF axis is an effective means of therapy against rhabdoid tumors.
We therefore propose that pazopanib should be tested in childrenwith rhabdoid
tumors in which there is a dire need for an effective therapy.
#702 A novel cell-penetrating ATF5 antagonist peptide CP-d/n-ATF5 ex-
erts in vitro and in vivo anti-tumor effects in a broad spectrum of pediatric
cancers.Debarshi Banerjee,1 Shuobo Boboila,1 Cherease Street,1 Shunpei Oko-
chi,1 Filemon S. Dela Cruz,2 Eileen Connolly,1 Angela Kadenhe-Chiweshe,1
Darrell Yamashiro3. 1Columbia Univ. Medical Ctr., New york, NY; 2Columbia
Univ. Medical Ctr, New york, NY; 3Columbia Univ. Medical Ctr., New York, NY.
Purpose: Activating transcription factor 5 (ATF5), a member of the ATF/
CREB family transcription factor, has been implicated in the pathogenesis of
glioblastoma and other adult tumors. Recently, a novel cell penetrating (CP-d/
n-ATF5) peptide has been developed to antagonize ATF5 function. The goal of
the current study is to test the effıcacy of CP-d/n-ATF5 in several children
tumors including neuroblastoma, hepatoblastoma, Ewing sarcoma, and rhab-
doid tumor, in vitro and in vivo. Methods: A panel of neuroblastoma cell lines:
SK-N-Be(2)C, SK-N-DZ, NGP, IMR-32, NGP, SHEP-21N, KELLY, CHP-212,
CHLA-20, CHLA-15 and SK-N-SH; hepatoblastoma cell lines HUH 6 andHep-
G2; Ewing sarcoma cell lines A673, SKNMC, SKNEP1, and TC32; and the rh-
abdoid cell G401, were treated with vehicle or 50, 100 and 200 M of CP-d/n-
ATF5. Cell viability and apoptosis were assessed after 72 hr by WST-8 and
TUNEL assays, respectively. To test in vivo effıcacy, SK-N-Be(2)C kidney xeno-
graft tumorswere treatedwith the peptide at dose 50mg/kg, IP injection once per
day for fırst three days and then twice per week. Tumor growth was monitored
by bioluminescence imaging and mice were sacked when flux reached a thresh-
old value. Organ metastases were determined by ex vivo imaging. A patient-
derived xenograft (PDX) model of rhabdoid tumors was employed where PDX
tumors, at 150-200 mm3 size, were enrolled in the penetratin (control) and
CP-d/n-ATF5 treatment (samedose as above). Tumorsweremeasured biweekly
with a calipers andmicewere sacrifıcedwhen tumor volume reached a threshold
(1500 mm3). Results: CP-d/n-ATF5 exerted cytotoxicity or apoptosis, in a dose
dependent manner, across a wide panel of pediatric tumor cell lines. In vitro,
tumor cell viabilities were reduced 40-70% (P0.05) and apoptosis was in-
creased 50-80% at 200 M of CPd/nATF5. In vivo, CP-d/n-ATF5 signifıcantly
inhibited SK-N-Be(2)C xenograft growth in nude mice, with a median survival
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of 35 days for control against 21 days for CPd/nATF5, P0.0013. CP-d/n-ATF5
also reduced SK-N-Be(2)C metastatic burden in the liver (P0.05) and bone
marrow (P0.01). In the rhabdoid PDX model, there was a signifıcant inhibi-
tion of tumors treated with CP-d/n-ATF5 as compared to Penetratin treatment,
with a mean tumor volume of control 1283 266.6 mm3 (n5) vs CPd/nATF5
234.2 50.66 mm3 (n6), at day 10 post treatment. Penetratin treated tumors
showed a median post-treatment time of 13 days to reach threshold volume.
None of the CP-d/n-ATF5 treated tumors reached the threshold after 28 days of
treatment with some tumors demonstrating regression, indicating a profound
anti-tumor effect of the peptide. Conclusion: Our study shows that a novel
ATF5-targeting peptide CP-d/n-ATF5 has broad and profound cytotoxic and
apoptotic effects in several pediatric tumors in vitro and in vivo. Our study also
indicates that CP-d/n-ATF5 has the potential to act as an anti-metastatic agent.
#703 Combinatory treatment for pediatric low grade gliomawith the dual
mTORC1/2 inhibitor TAK228 and MEK inhibitor Trametinib. Antje Ar-
nold,1 Fausto Rodriguez,1 CharlesGeorge Eberhart,1 EricHuttonRaabe2. 1Johns
Hopkins University School of Medicine; Division of Neuropathology and Sidney
Kimmel Comprehensive Cancer Center, Baltimore, MD; 2Johns Hopkins Univer-
sity School of Medicine; Division of Neuropathology and Sidney Kimmel Compre-
hensive Cancer Center; Division of Pediatric Oncology, Baltimore, MD.
Pediatric low grade glioma (PLGG) is one of the most common childhood
tumors. If the tumor is located in a region of the brain that is not accessible for
surgical resection or if the tumor recurs after surgery, additional therapies are
needed. Recent studies highlighted the important role of mTORC and MEK-
activation in PLGG. The dual mTORC1/2-inhibitor, TAK-228, and the FDA
approved MEK-inhibitor, Trametinib, have good brain penetration and are
promising candidates for targeted therapy PLGG. We hypothesized that TAK-
228 and Trametinib would show synergistic effects both in vitro and in vivo in
PLGGmodels. We treated the PLGG derived cell lines Res186 and Res259 with
TAK-228, Trametinib, and vehicle. Cell growth was investigated using MTT-
assay over different days and compared to the treatment with the vehicle. DNA
replication was measured through bromodeoxyuridine (BrdU) incorporation
assay and apoptosis was evaluated through cleaved caspase 3 (CC-3) staining.
Cells were analyzed and countedwith ImageJ. Activation ofMAPKpathwaywas
detected via Western Blot by phosphorylated pERK compared to total pERK,
and -actin. Treatment of Res186 and Res259 with TAK-288 or Trametinib
reduces cell growth and proliferation in a dose and time depended manner.
Res186 have a signifıcant reduction in cell growth after 4 days treatment (TAK-
288: 20nM, **p0.01; Trametinib: 20nM, **p0.01). Res259 showed a signifı-
cant cell reduction at the same time point, but with a higher drug dose (TAK-
288: 50nM, *p0.05; Trametinib: 50nM, **p0.01). IC50 values for TAK-288
was 15nM for Res186 and 20nM for Res259 cells on day 4. IC50 values for
Trametinibwas 50nM for Res186 and 100nM for Res259 cells. Staining for CC-3
showed a signifıcant increase for apoptosis in Res259 cells after treatment with
TAK-288 or Trametinib (**p 0.01). No positive CC-3 staining was detected in
Res186 cells after drug treatment. MAPK pathway was activated in a dose-de-
pendent manner as determined by phosphorylated pERK Western Blot after
TAK-288 and inactivated after Trametinib treatment. No change in total ERK
concentration was detected, suggesting that cells attempt to compensate for loss
of mTOR signaling by upregulating MAP kinase signaling. Our preliminary
results show that the PLGG-derived cell lines are sensitive to TAK-228 and
Trametinib treatment. All cell lines showed decreased proliferation at various
doses of either inhibitor. The increased MAP kinase activity we identifıed after
TAK-228 treatment suggests a compensatory mechanism that may render these
cells especially sensitive to treatment with both TORC1/2 and MEK inhibitors.
We will now investigate both drugs in vivo. Evidence of activity in murine
models will be necessary to provide a pre-clinical rationale for combination
therapy of these agents in aggressive PLGG.
#704 Therapeutic potential of Delta24-ACT, a novel immunostimula-
tory oncolytic adenovirus, for the treatment of pediatric solid tumors:
Initial study in pHGG, DIPG and osteosarcoma. Marc Garcia Moure,1
Naiara Martínez-Vélez,1 Enric Xipell,1 Marisol González-Huarriz,1 Ana
Patiño,1 Oren J. Becher,2 Cande Gómez-Manzano,3 Juan Fueyo,3 Marta M.
Alonso1. 1University Hospital of Navarra, Pamplona, Spain; 2Duke Univer-
sity School of Medicine, Durham, NC; 3The University of Texas MD Anderson
Cancer Center, Houston, TX.
Pediatric High Grade Glioma (pHGG), including Diffuse Intrinsic Pon-
tine Glioma (DIPG), and osteosarcoma are amongst the most common and
lethal pediatric solid tumors. Despite improvements in surgery, radiother-
apy and chemotherapy, the outcome for children affected with these malig-
nancies remains dismal since the current treatments are ineffective and in-
flict severe side effects. Thus, it is critical to implement novel and radically
different therapeutic approaches to improve the survival and quality of life of
these children. Delta24 is a modifıed adenovirus with a tumor dependent
replication, and its antitumor effect has been tested in preclinical and clinical
models of both high grade glioma and osteosarcoma. The adenovirus de-
stroys the tumor mass as it replicates within the tumor. Additionally, the
adenovirus infection triggers the recruitment of lymphocytes to the tumor.
However, tumors are often characterized by an immunosuppressive envi-
ronment that hampers the synergistic effect mediated by the virus and the
immune system. Here we describe the generation of a new oncolytic adeno-
virus Delta24-ACT, based on the Delta24 platform, encoding an immunos-
timulatory protein. For this project we used relevant immunocompetent
pediatric solid models. The toxicity of the virus was assessed by dose-esca-
lation experiments. Delta24-ACT was well tolerated and did not lead to
important adverse effects. The antitumor effect of Delta24-ACT was evalu-
ated in immunocompetent mice bearing orthotopic supratentorial glioma,
DIPG or local osteosarcoma that spontaneously metastasize to lungs, obtain-
ing signifıcant tumor shrinkage or complete elimination in some of them.
Delta24-ACT also promoted an increased T-cell infıltration within the tu-
mor and an enhanced antitumor immune response. Of importance, treat-
ment with Delta24-ACT led to a signifıcant increase in median survival in all
the tumor models tested and resulted in long-term survivors free of disease.
Furthermore, in our osteosarcoma model local treatment of primary tumors
led to the regression of spontaneous lung metastases, which are usually the
leading cause of death in most of the patients affected by osteosarcoma.
Currently, we are performing re-challenge experiments to evaluate a possible
memory effect mediated by the virus andmechanistic studies to elucidate the
mechanism of action. Altogether, these results demonstrate the potential
therapeutic benefıt of Delta24-ACT adenovirus in the treatment of pediatric
solid tumors such as pHGG, DIPG and osteosarcoma, representing an im-
portant milestone in the fıght against cancer.
#705 Elucidating pediatric brain tumor pathophysiology by assessing sig-
nal transduction pathway activation. Laurent Holtzer, Wim Verhaegh, Anja
Van de Stolpe. Philips Research, Eindhoven, Netherlands.
A major problem in pediatric neuro-oncology is lack of insight into un-
derlying tumor biology, making treatment with targeted therapy challenging
for this group of patients. To enable targeted therapy choice, understanding
of underlying signal transduction pathway activity is required, as well as
availability of appropriate diagnostic tests to predict therapy response. We
have developed a novel method to identify activity of the ER, AR, HH, Wnt,
TGFbeta, NFB, and PI3K signal transduction pathways in an individual
tissue sample. Our method is based on measuring mRNA levels of the path-
way transcription factor target genes and interpreting these expression levels
using a knowledge-based Bayesian network computational model which in-
fers the probability of activity of the respective transcription factor (Ver-
haegh et al, Cancer Res. 2014). Public patient sample datasets from the GEO
database were used to investigate pathway activation in pediatric brain tu-
mors. In normal brain tissue from medulla, cerebellum, cerebral cortex and
thalamus (GSE50161), pathway analysis showed no signifıcant oncogenic
pathway activation. Observed pathway activity in medulloblastoma was
strongly correlated with known pathway-activating mutations, which was
used as initial validation of these models for use in pediatric brain tumor
diagnostics. In ependymoma (GSE66354), three distinct subtypes were ana-
lyzed: infratentorial posterior fossa A (PFA), PFB and supratentorial. These
tumors are known to have a subtype-dependent prognosis; mainstay of ther-
apy is surgery and radiation. Tumor driving pathway identifıcation in pedi-
atric ependymoma using mutation analysis is usually not helpful because
epigenetic mechanisms prevail (Mack et al, Brain Pathology 2013). Using
our pathway activity analysis, we fınd remarkable differences between dif-
ferent types of ependymoma with respect to signal transduction pathway
activity. For PFA we fınd high NFB and Wnt pathway activity. The domi-
nant NFB activity is in agreement with the described inflammatory pheno-
type. On the other hand, for PFB we fınd low NFB and Wnt pathway
activity. Finally, for supratentorial ependymoma we fınd almost all samples
to have an active Hedgehog and Wnt pathway. We also analyzed multiple
other pediatric tumors for pathway activity, for which data will be presented.
The above pathway activity results provide highly interesting leads for tar-
geted therapy selection, and we expect that such pathway analysis will have
clinical utility in a neoadjuvant setting to reduce tumor size prior to surgery,
and possibly also in an adjuvant setting to prevent recurrences.
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#706 Combination ionizing radiation and oncolytic Seneca Valley virus
injection enhances tumor cell killing of pediatric gliomas.YuchenDu. Baylor
College of Medicine, Houston, TX.
Background and Purpose: Radiation therapy is the traditional and only
therapy that offers benefıts to patients with diffuse intrinsic pontine gliomas
(DIPG) which are highly aggressive pediatric central nervous system tumors
without known curative therapies. However, unfortunately, effıcacy of radi-
ation therapy is transient. Seneca Valley virus-001(SVV-001) is a novel non-
pathogenic oncolytic piconavirus that can be systemically administered and
pass through brain blood barrier (BBB). Phase I clinical trial of SVV has
proven its effıcacy in adults patients with cancers with neuroendocrine fea-
tures and in pediatric patients with non-central nerve system (CNS) tumors.
We sought to examine if combining ionizing radiation with an oncolytic
virus SVV-001 would lead to synergistically enhanced tumor cell killing and
signifıcantly improve therapeutic effıcacy in vivo in DIPG patient tumor-
derived intra-brain stem orthotopic xenograft mouse models (PDOX).
Methods: By infecting PDOX derived tumor cells with green fluorescent
protein (GFP)-coupled SVV (SVV-GFP) or SVV-001, in vitro virus infection
and anti-tumor activity of SVV were examined by cell viability assay, West-
ern Blotting for apoptosis and autophagy-related protein and immunohis-
tochemistry (IHC) staining or Flow cytometry for cell mitochondria content.
In vivo therapeutic effıcacy was evaluated by systemic administration of SVV
into PDOX derived DIPG xenografts alone or in combination with irradia-
tion. Results: We fırst had established a novel panel of nine PDOX derived
orthotopic xenograft mouse models of DIPG. Our data confırmed that SVV
can infect and effıciently kill DIPG tumor cells in vitro by inducing apoptosis
and autophagy, leading to improved animal survival in a subset of DIPG
xenograft models. We found that the lack of mitochondria in the xenograft
tumor cells in vivo impaired the intracellular replication of SVV-001 and
subsequently compromised its oncolytic cell killing of tumor cells in vivo.
Radiation induced elevatedmitochondria biogenesis in tumor cells therefore
boosted SVV oncolysis of tumor cells. Moreover, combining fractionated
radiation with single i.v.injection of SVV led to signifıcant improvement of
animal survival in a subset of DIPG models. Conclusion: SVV-001 killed
DIPG xenograft cells in vitro. Radiation activated mitochondria content of
tumor cells in vivo, which restored impaired SVV oncolytic function.Com-
bining radiation with single systemic administration of SVV synergistically
enhanced animal survival in a subset of DIPG xenograft models.
#707 Personalization of dexamethasone in acute lymphoblastic leukemia.
Rosanna K. Jackson,1 Ali Alhammer,1 Zach Dixon,2 Gareth J. Veal,1 Julie AE
Irving1. 1Newcastle University, Newcastle, United Kingdom; 2Bristol University,
Bristol, United Kingdom.
Synthetic glucocorticoids, such as dexamethasone (Dex), are pivotal in the
treatment of childhood acute lymphoblastic leukemia (ALL) but are associated
with signifıcant variability, both in terms of toxicity and effıcacy. We aimed to
investigate three key variables to better understand how Dex personalization
may be achieved: pharmacokinetics (PK), intracellular Dex accumulation, and
cellular response, following Dex binding to the glucocorticoid receptor (GR) in
ALL cells. For Dex PK studies, blood samples were collected post oral adminis-
tration on one of the fırst three days of induction chemotherapy in 99 patients on
the UKALL 2011 trial receiving either 6mg/m2 for28 days (standard arm) or
10mg/m
2
for 14 days (short arm). Plasma Dex levels were analysed using a vali-
dated LC/MSmethod, and a non-compartmental pharmacokinetic analysis. To
assess intracellular Dex levels, cell lines, primagraft (n9) and primary patient
samples (n6) were studied. The plasma Dex LC/MSmethod was optimized to
quantify Dex in ALL cell lysates. Dex accumulation was also assessed using flow
cytometric analysis of Dex conjugated to FITC. Cellular Dex sensitivity was
assessed using Alamar Blue assays. There was a wide Dex PK variability, with
AUC0-12h, and Cmax signifıcantly higher on the short compared to the standard
arm; 564 (202-1606) versus 408 (142-1009), median (range), p0.0003 and
0.0006, respectively. However there was substantial overlap between the two
arms, with a number of patients on the standard arm exhibiting higher expo-
sures than those on short therapy. DexGI50 values ranged from 37 - 1000 nM
and 2 - 1000 nM in cell lines and patient samples respectively. Western blot-
ting indicatedwildtypeGR in all samples, withR3D11 andREHcell lines serving
as hemizygous deleted and GR negative controls. Dex accumulation in cell lines
was 2.1 and 1.8 (range 1.2 - 2.1) pmol/106 cells in PreB697 and Dex resistant
sub-lines, respectively. While patient samples exhibited greater variability, Dex
accumulation was not signifıcantly different between sensitive and resistant
cells;mean of 1.0 versus 1.4 (range 0.1-2.3, 0.4-4.4 pmol/ 106 cells, p0.17). Flow
cytometry Dex FITC accumulation confırmed these data, with a mean fluores-
cence intensity of 4.2 versus 4.1 (range 1.5-5.9, 2.0 - 9.1, respectively; p0.97).
Thesedata suggest thatwhilePKandcellular responsearehugelyvariable, variations
in drug accumulation do not appear to play a key role inDex response in ALL cells.
Importantly, 62% of patient cell samples had Dex GI50 values greater than plasma
concentrations observed in any patient, on both arms on the UKALL 2011 trial. A
combined approach incorporating PK assessments and cellular response in ALL
cells should be further investigated, to allow a comprehensive understanding ofDex
pharmacology with a view to optimizing its clinical utility.
#708 Prohibitin is a prognosticmarker of treatment failure and therapeu-
tic target to block chemotherapy resistance inWilms tumor.Michael Vincent
Ortiz,1 Melissa Burns,2 Amy Eisenberg,3 Saima Ahmed,2 Lyvia Gaewsky,2 Gary
Bradwin,2 Paolo Cifani,1 AntonHenssen,1 IanMacarthur,1Michael LaQuaglia,1
Anthony Letai,4 Arlene Naranjo,5 Samantha Gadd,6 Yueh-Yun Chi,5 Jeffrey
Dome,7 Elizabeth Perlman,6 Elizabeth Mullen,2 Hanno Steen,2 Alex Kentsis1.
1Memorial Sloan Kettering Cancer Center, NY; 2Boston Children’s Hospital, MA;
3University of California, Berkeley, CA; 4Dana Farber Cancer Institute, MA;
5University of Florida, FL; 6Lurie Children’s Hospital of Chicago, IL; 7Children’s
National Medical Center, DC.
Wilms tumor (WT) is the most common kidney tumor of children. Over
the last three decades, clinical trials employing multi-modality therapies
have resulted in overall survival of greater than 90% for patients with low-
risk disease. In spite of these advances, treatment of patients with advanced,
anaplastic, and relapsedWilms tumors remains challenging, with substantial
rates of treatment failure and death. To improve risk stratifıcation and iden-
tify novel therapeutic targets, we used high-accuracy mass spectrometry
urine proteomics to identify urine tumors markers associated with relapsed
WT and non-WT renal tumors. We measured urine proteomes at diagnosis
of 54 patients with renal WT, clear cell sarcoma, rhabdoid tumor, and age-
matched controls, leading to the quantitation of 6,519 urine proteins. In
particular, we identifıed specifıc urine WT markers, including those that
were enriched in patients with relapsed WT, such as mitochondrial regula-
tors prohibitin and DAD1, -catenin antagonist DACT2, and DNA repair
factor SUN1. Using a specifıc enzyme-linked immunosorbent assay (ELISA)
developed to measure urine prohibitin in an independent cohort of 139 WT
and control samples, we found that urine prohibitin concentrations over
1000 ng/mL were signifıcantly associated with the risk of disease relapse,
with an odds ratio of relapse of 153 and receiver operating characteristic area
under the curve of 0.77 (95% confıdence interval of 0.64-0.99). Immunohis-
tochemical tumor analysis revealed that prohibitin was highly expressed in
primaryWilms tumor specimens. Importantly, using loss- and gain-of-func-
tion genetic experiments, we found that prohibitin was required for the
growth and survival of Wilms tumor cells, and its overexpression conferred
concomitant resistance to vincristine, doxorubicin and actinomycin D. Con-
sistent with prohibitin’s functions in mitochondria, we are using BH3 pro-
fıling to elucidate specifıc intrinsic apoptotic dependencies in distinct sub-
sets of refractory Wilms tumors, as a prelude to rational combination
blockade of chemotherapy resistance, such as blockade of BCL2 dependence
using venetoclax. In all, the use of urine prohibitin measurements may im-
prove initial therapy stratifıcation, and enable monitoring of response to
therapy and early detection of relapse. In addition, therapeutic targeting of
chemotherapy resistance induced by prohibitin overexpression may offer
improved therapies for patients with relapsed or refractory Wilms tumors.
#709 Incidence and mortality of diethylstilbestrol-related clear-cell ade-
nocarcinoma of the vagina and cervix: 40 years of long-term follow-up. De-
zheng Huo, Diane Anderson, Arthur L. Herbst. Univ. of Chicago, Chicago, IL.
Objective: Women exposed to diethylstilbestrol (DES) in utero are at in-
creased risk for the development of vaginal and cervical clear cell adenocarci-
noma (CCA), and possibly of breast cancer, diabetes, and cardiovascular dis-
eases as well. A peak in the age-incidence curve in DES- related CCA has been
documented at ages 19 to 24. It is unknown if a second peak will occur in later
life, the ages when CCA developed spontaneously in the pre-DES era. In addi-
tion, the long-term prognosis and health impact for adolescents and young
adults who have DES-related CCA are unknown. Methods: 720 cases of CCA
were reviewed from the CCA Registry at the University of Chicago through
2014. Rates and cumulative risks for CCA were calculated based on white
women born in the U.S. from 1948 through 1971. Kaplan-Meier method was
used to estimate survival probability amongwomenwithCCA.Coxmodelswere
used to identify independent prognostic factors. To gauge the relative impact of
young-onset clear-cell adenocarcinoma on mortality, we compared their mor-
tality hazards with mortality hazards of the U.S. female population, and calcu-
lated standardized mortality ratio (SMR). Results: In 420 CCA cases there was
documented evidence of prenatal DES exposure. 80% patients had a CCA be-
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tween ages 15 and 31 but some occurred as late as age 55. A small second peak
occurred around age 40. The risk of U.S. born, white DES-related CCA was
highest in the 1951-1956 birth cohort, and this birth cohort effect correlatedwith
DES use in the U.S. By age 50, the cumulative risk of CCAwas 1 per 750 exposed
women. A total of 695 CCApatients were included in the survival analysis. After
a median follow-up of 22.7 years (interquartile range: 10.8-35.1 years), 219 pa-
tients died. The 5-year, 10-year, and 20-year survival probabilities were 83%,
75%, and 69%, respectively. As expected, tumor stage was a strong prognostic
factor for survival among DES-related CCA cases. Tubular-cystic histology was
associated with better survival compared with papillary, solid, or a combination
of these histological patterns. Adolescent patients (18 years old) had worse
survival than young adult patients. Compared with general U.S. female popula-
tion, womenwithDES-related CCAhad 27-fold increased risk of death between
10 and 35 year of age (SMR 27.06, 95% CI: 23.04-31.58), 5-fold increased risk
between 35 and 50 year of age (SMR 5.07, 95% CI: 3.59-6.95), 2-fold increased
risk after age 50 (SMR 2.03, 95% CI: 1.22-3.18). Conclusion: Our study drew a
relatively complete epidemic curve of DES-related CCA. There existed late-
onset CCA among women with prenatal exposure of DES. DES-related CCA
increased mortality not only during early life among exposed women, but also
impacted life after age 50. These results suggest continued close health follow-up
of this population.
CLINICAL RESEARCH: Early Detection
#710 Identifıcation of autoantibody to ECH1&HNRNPA2B1 as potential
biomarkers in the early detection of lung cancer. Liping Dai,1 Jitian Li,2 Jun-
Chieh J. Tsay,3 Xiao Wang,1 John S. Munger,3 Harvey Pass,3 William N. Rom,3
EngM. Tan,4 Jian-Ying Zhang1. 1Zhengzhou University, Zhengzhou, China; 2the
University of Texas at El Paso, El Paso, TX; 3NewYork University, New York, NY;
4The Scripps Research Institute, San Diego, CA.
Background: Identifıcation of biomarkers for early detection of lung can-
cer (LC) may lead to more effective treatment and reduction of mortality.
Methods: Serological proteome analysis (SERPA) was used to identify pro-
teins around 34 kDa, which had been previously recognized by autoantibody
in sera from LC patients. We have validated autoantibody response in sera
from 90 LC patients, 89 normal controls by using immunoassay. Another
independent cohort of 25 LC patients with 219 serial serum samples and 56
matched normal controls were examined to evaluate whether the autoanti-
body can be detected in the preclinical stage. Results: The proteins with
molecular weight of 34 kDa were identifıed as ECH1, GAPDH and
HNRNPA2B1. In the validation study, autoantibody to ECH1 achieved an
area under the curve (AUC) of 0.799 with sensitivity of 62.2% and specifıcity
of 95.5% in discriminating LC from normal individuals, and showed nega-
tive correlation with tumor size (rs0.-256, p0.023). Autoantibody to
HNRNPA2B1 performed an AUC of 0.874 with sensitivity of 72.2% and
specifıcity of 95.5%, and showed negative correlation with lymph node me-
tastasis (rs0.-279, P0.012). By using longitudinal preclinical samples,
autoantibody to ECH1 showed an AUC of 0.763 with sensitivity of 60.0% and
specifıcity of 89.3% in distinguishing LC with matched normal controls, and
elevated autoantibody levels could be detected greater than two years prior
to LC diagnosis. Conclusions: ECH1 and HNRNPA2B1 are autoantigens
that elicit autoimmune responses in LC and can be used as potential bio-
markers for the early detection of LC. Funding support: This work was
supported by the National Natural Science Foundation of China (81672917,
81372371) and the National Institutes of Health (SC1CA166016 and
U01CA086137).
#711 Mechanistic implications ofCOL1A1as aprostate cancer biomarker.
Andrej Jedinak,1 Camille Vuichoud,2 Andrew El-Hayek,2 Katherine Kaplan,2
Jason Savage,3 Sarah Prophet,4 Adam S. Feldman,4 Kevin A. Camphausen,3
Kevin R. Loughlin,5 Marsha A. Moses1. 1Boston Children’s Hospital, Harvard
Medical School, Boston,MA; 2Boston Children’s Hospital, Boston,MA; 3National
Cancer Institute, Bethesda, MD; 4Massachusetts General Hospital, Boston, MA;
5Brigham and Women’s Hospital, Boston, MA.
Prostate cancer (PCa) is the second most frequently diagnosed form of male
cancer and shares similar symptoms with BPH (Benign Prostate Hyperplasia), a
disease characterized by prostate enlargement. Elevated levels of prostate-spe-
cifıc antigen (PSA) can be observed with either benign or malignant growth of
the prostate and therefore cannot effectively discriminate between these two
prostate diseases. Currently, a test that sensitively and accurately distinguishes
between BPH and localized prostate cancer does not exist creating an urgent
need for novel biomarkers that can successfully distinguish between these two
prostate diseases. The goal of this studywas to identify and validate non-invasive
urinary biomarkers that distinguish between BPH and PCa. Our previous pro-
teomic study identifıed elevated levels of several proteins, including EGF (epi-
dermal growth factor), HE-4 (human epididymis protein 4), COL1A1 (collagen,
type I, alpha 1) and other proteins in the urine of PCa patients compared to urine
samples from patients with BPH. In this current study we have analyzed and
validated the presence of EGF, HE-4 and COL1A1 by enzyme-linked immu-
nosorbent assay (ELISA). Our ELISA experiments revealed that COL1A1 was
signifıcantly (P 0.002) elevated in the urine of patients diagnosedwith early or
localized PCa vs. BPH. In vitro experiments performed on seven different pros-
tate cell lines identifıed cells from the tumor microenvironment that secrete the
highest levels of COL1A1. Expression of COL1A1 by these cells was confırmed
by immunohistochemistry (IHC) using prostate tissue microarrays (TMA). In
addition, protein array experiments identifıed elevated levels of several proteases
in the urine of PCa patients, including MMP-9, uPA, ADAM-TS1 and several
cathepsins. Substrate gel electrophoresis (zymography) revealed elevated activ-
ity of both MMP-9 and MMP-2 in urine from PCa patients. These data suggest
that MMP-9 and MMP-2 may participate in the cleavage of collagen type 1,
resulting in elevated levels of COL1A1 in urine of PCa patients.We are currently
testing this hypothesis. In summary, COL1A1 may represent a novel non-inva-
sive urinary biomarker that can effectively discriminate between BPH vs. local-
ized PCa. (Supported by The Ellison Foundation).
#712 Detection of lung cancer by assay of novel methylated DNAmarkers
in plasma. Hatim T. Allawi,1 Maria Giakoumopoulos,1 Evan Flietner,1 Austin
Oliphant,1 Carla Volkmann,1 Brian Aizenstein,1 Tamara Sander,1 Drew Eck-
mayer,1 Ashley Poenitzsch Strong,1 Melissa Gray,1 Barry Berger,1 Tracy Yab,2
William Taylor,2 DouglasMahoney,2 John B. Kisiel,2 David E.Midthun,2 David
A. Ahlquist,2 Graham P. Lidgard1. 1Exact Sciences Corporation, Madison, WI;
2Mayo Clinic, Rochester, MN.
Purpose: Lung cancer is the leading cause of cancer deaths worldwide. Most
present symptomatically at late stage with high lethality. Early detection reduces
mortality but accurate and readily accessible tools for population screening are
limited. By whole methylome sequencing, we have identifıed novel methylated
DNAmarkers (MDMs) for lung cancer in tissue (Giakoumopoulos et al. ASCO
2016). Using top candidate MDMs in the present study, we now explore their
clinical accuracy for lung cancer detection when assayed from plasma. Experi-
mental Procedures: Archival plasmas from two independent study groups were
tested in blinded fashion. Lung cancer cases and controls (apparently healthy
smokers) for each group were balanced on age and sex (Group 1: 64 cases, 231
controls; Group 2: 23 cases, 80 controls). Using multiplex PCR followed by
QuARTS (Quantitative Allele-Specifıc Real-time Target and Signal amplifıca-
tion) assay, a post-bisulfıte quantifıcation of MDMs on DNA extracted from
plasmawas performed.We selected 31MDMcandidates for initial evaluation in
Group 1 (1 ml plasma/patient); top individual MDMs were subsequently tested
in Group 2 to identify optimal MDM panels for lung cancer detection (2 ml/
patient). Results: From Group 1 analyses, 13 high performance MDMs were
selected for further testing (CYP26C1, SOBP, SUCLG2, SHOX2, ZDHHC1,
NFIX, FLJ45983, HOXA9, B3GALT6, ZNF781, SP9, BARX1, EMX1) with indi-
vidual areas under the receiver operator curve (AUCs) ranging from 0.593 to
0.939. Discrimination by individual MDMs was corroborated in Group 2 in
which data was analyzed using two methods: a logistic regression fıt and a re-
gression partition tree approach. The logistic fıt model identifıed a 4-marker
panel (ZNF781, BARX1, EMX1, and SOBP) with an AUC of 0.96 and an overall
sensitivity of 91% and 90% specifıcity. Analysis of the data using a regression
partition tree approach identifıed 4 markers (ZNF781, BARX1, EMX1, and
HOXA9) with AUC of 0.93 and an overall sensitivity of 96% and specifıcity of
94%. For both approaches, B3GALT6 was used as a standardizing marker of
total DNA input. Conclusion: A panel of MDMs assayed in plasma achieved
high sensitivity and specifıcity for all types of lung cancer. Further clinical eval-
uation and validation of this promising panel in larger patient groups are clearly
indicated.
#713 Proteomic early detection biomarkers for ER breast cancer to im-
prove mammography screening. Carly B. Garrison,1 Tracey Marsh,1 Matthew
Buas,2 Yuzheng Zhang,1 Margaret Pepe,1 Paul D. Lampe,1 Christopher I. Li1.
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2Roswell Park Cancer
Institute, Buffalo, NY.
There are clear clinical and public health needs to improve the early detection
of breast cancer in order to save lives. Breast cancer is the leading cause of cancer
death in women worldwide and is the second leading cause of cancer mortality
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in women in the United States. Although mammography is widely used to
screen for breast cancer, it suffers both from false negative and false positive
readings resulting in later diagnoses or unnecessary follow-up (e.g., biopsies),
respectively. Improvement of breast cancer early detection may be possible
through the measurement of minimally invasive, easy to perform blood based
biomarkers. Our studies were performed on pre-clinical plasma samples col-
lected up to 12.5months before breast cancer diagnosis from cases andmatched
controls obtained from the Women’s Health Initiative (WHI) Observational
Study (a prospective cohort of 93,676 post-menopausal women). We utilized
high-density antibodymicroarraymethods for both discovery and preliminarily
validation on distinct sample sets for early detection biomarkers of estrogen
receptor positive (ER) breast cancer (around 70% of all breast cancers are
classifıed as ER). Antibodymicroarray features (i.e., spots) identifıed as having
	30% sensitivity at 80% specifıcity were considered to have met the cutoff cri-
teria and identifıed as potential markers. A total of 129 features, corresponding
to 101 proteins, were identifıed as potential markers in one WHI dataset (90
cases vs. 90 controls). Of the 129 features (101 proteins), 47 (34 proteins) vali-
dated by our cutoffs and demonstrated over or under-expression in cases com-
pared to controls consistent with the fırst dataset in the second set of WHI
samples (121 cases vs. 121 controls). Given this level of reproducibility, we be-
lieve these biomarkers could be used to improve early detection of ER breast
cancer for these clinical scenarios: 1. Informing timing of a subsequent mam-
mogram in women with a negative screening mammogram; 2. Informing con-
tinuation of mammographic screening among women 75-79 years; 3. Prioritiz-
ing women who should be screened with mammography in areas with limited
resources. We are currently performing further validation of the protein
markers in Early Detection Research Network (EDRN) specimen reference
set from patients at the time of diagnosis. We plan to test our markers on a
pre-diagnostic cohort from the Cardiovascular Health Study using a differ-
ent, more clinically applicable platform. We used the same high-density
antibody microarray platform to measure autoantibody-autoantigen com-
plexes and sialyl Lewis-A and –X modifıcations in one of the WHI sample
sets and are now testing these markers in the EDRN set for validation. Given
the strength of our biomarker candidates, the high quality sets of biospeci-
mens we used, the study designs employed, and the clearly delineated clinical
applications proposed, we believe these markers could have near-term clin-
ical impact.
#714 Human transcriptome alterations in pre-cancer and cancer epithe-
lium identify candidate biomarkers of progression to pancreatic cancer.
Elena V. Komissarova, Jorge Sepulveda, Sarawut Kongkarnka, Maryam Shirazi,
Brynn Levy, Claudia Cujar, Antonia R. Sepulveda. Columbia University, New
York, NY.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common can-
cers in the United States. The fıve-year survival rate for patients with PDAC
remains dismal. Identifıcation of biomarkers for early diagnosis of PDAC and
pre-cancer pancreatic intraepithelial neoplasia (PanIN) lesions with risk of pro-
gression to PDAC is critically needed. We hypothesized that differentially ex-
pressed genes and regulatory pathways in PanIN and PDAC compared to nor-
mal duct epithelium (ND) may represent biomarkers of development of
malignancy.We used Affymetrix Human Transcriptome Arrays 2.0 to establish
gene expressionprofıles in ND, low-grade PanIN, and PDAC epithelium. Total
RNA was isolated after laser capture microdissection (LCM) of frozen tissue
sections and then used for producing hybridization-ready DNA. Hybridization
quality control was performed with Expression Console 1.4 software and back-
ground corrected/normalized data were analyzed with Transcriptome Analysis
Console (TAC) 3.1 and the ASSIGN algorithm. We tested RNA from 22 LCM
samples (9 PDACs, 5 PanINs, and 8 ND), including 4 matched trios of ND,
PanIN and PDAC from the same patients. Differential expression analysis with
one-way between subject ANOVA revealed over 2000 genes differentially ex-
pressed in PDAC and PanIN vs. ND group (fılter criteria up/down2; ANOVA
p0.05). The most frequent alteration in PanIN compared to ND samples was
upregulation of 433 genes and in PDAC compared to ND downregulation of
566. We found 60 (40 coding) upregulated genes and 750 downregulated genes
(fılter criteria up/down 1.5; ANOVA p0.05) in both PanIN and PDAC vs.
ND epithelium. Signaling pathway analysis of WikiPathways showed a num-
ber of signifıcantly altered pathways in PDAC and PanIN compared to ND
including the Gastric Cancer Network 1 with upregulated S100P in both
PanIN and PDAC whereas other genes including CENPF, KIF20B,TPX2,
and UBE2C were upregulated in PDAC only. Using the ASSIGN algorithm
and the Kruskal-Willis test for analysis of difference in pathway activity, we
found additional regulatory pathways with altered activity including Nuclear
Receptor meta-pathway with reduced overall score in PDAC compared to
PanIN and ND samples. In summary, over 400 genes were signifıcantly up-
regulated in pre-cancer PanIN lesions compared to normal duct epithelium,
whereas gene down-regulation was the most frequent alteration in PDAC.
Sixty genes, including 40 coding genes were up-regulated in both PDAC and
PanIN. The altered pathways associated with the differentially expressed
genes may represent an approach for integrated biomarker testing of neo-
plastic progression.
#715 The AroCell TK 210 ELISAmay complement Pro PSA and the Pros-
tate Health Index in differentiating pre cancerous and cancerous conditions
in prostate cancer. Jagarlamudi Kiran Kumar,1 Staffan Eriksson,1 Zupan
Moca,2 Kumer Kristina,3 Josko Osredkar,3 Fabjan Teja,3 Hlebic Gregor,4
Smrkolj T4. 1Swedish Agricultural University, Uppsala, Sweden; 2Blood transfu-
sion unit, Lubjliana, Slovenia; 3Institute of Clinical Biochemistry, Lubjliana, Slo-
venia; 4University Medical Centre, Lubjliana, Slovenia.
Background: Thymidine Kinase 1 (TK1) is a cytosolic enzyme that plays an
important role inDNAprecursor synthesis and TK1 enzyme activity in serum is
an established biomarker for prognosis and treatment monitoring, particularly
for haematological malignancies. The AroCell TK 210 ELISA determines TK1
protein levels, in contrast to TK1 activity, and it has demonstrated superior
sensitivity in distinguishing between subjects with solid tumours and controls.
Pro PSA, free PSA and the prostate health index (PHI) have been proposed as
more discriminating tests than PSA in distinguishing between benign and can-
cerous prostate changes. The purpose of this study was to compare the AroCell
TK 210 ELISAwith PSA, free PSA, pro PSA and PHI inmenwith pre-cancerous
conditions, and patients with confırmed prostate cancer. Experimental Proce-
dures: Serum samples from 94 patients with knownPSA values (in the range 2 to
10 g/L) that were under investigation for prostate cancer were collected at the
UniversityMedical Centre, Ljubljana. TK1 protein levels were determined using
the AroCell TK 210 ELISA. PSA, fPSA and pro PSA levels were analysed with
commercial assays (Hybritech PSA, Hybritech Free PSA and Access 2pPSA -
Beckman Coulter USA) analysed on the Access 2 Beckman Coulter analyzer.
Results: Overall, 16/94 patients had serum TK1 protein levels above the esti-
mated cut-off value for age-matched healthy men (0.45g/L). 65/94 men had
pre-cancerous prostate conditions, including benign prostate hyperplasia, pros-
tatitis and high grade prostatic intraepithelial neoplasia, while 29 patients had
confırmed prostate cancer (PCa). Only 7 /65 in the pre-cancerous group (11%)
had TK1 protein levels above the cut-off, whereas in the prostate cancer group 9
out of 29 (31%) were positive. Moreover, the TK1 protein values in the PCa
group (mean0.41g/L) differed signifıcantly from those with pre-cancerous
conditions (mean0.31g/L, P0.01). Further analysis showed that pro PSA
and PHI also differentiated the prostate cancer group from those with pre-
cancerous conditions (P 0.01 and P0.001, respectively). This was not ob-
served for fPSA and PSA. Overall, the AroCell TK 210 ELISA showed signifıcant
correlation with PHI (r0.32, P0.0017) and pro PSA (r0.21 P0.044) but
not with fPSA or PSA. Conclusions: This preliminary study has demonstrated
that serum TK1 assayed with the AroCell TK 210 ELISA can differentiate be-
tween pre-cancerous and prostate cancer patients with a similar accuracy to that
of pro PSA. Further clinical studies will establish the capacity of the AroCell TK
210 ELISA to complement pro PSA and PHI in distinguishing between pre-
cancerous and prostate cancer, potentially providing another tool in prostate
cancer management.
#716 Genomic classifıcation of longitudinally observed small colorectal
polyps. Meta C. van Lanschot,1 Beatriz Carvalho,1 Charlotte J. Tutein Nolthe-
nius,2 Christian R. Rausch,1 Ernst J. Kuipers,3 Jaap Stoker,2 Evelien Dekker,2
Gerrit A. Meijer1. 1Netherlands Cancer Institute, Amsterdam, Netherlands; 2Ac-
ademic Medical Center, Amsterdam, Netherlands; 3Erasmus Medical Center,
Amsterdam, Netherlands.
Introduction: Colorectal polyps are very common in elderly people with a
prevalence of 15-30% reported in screening series. However, only a minority of
5% of these lesions is estimated to develop into invasive cancers, whereas others
will remain stable or regress over time. In standard practice all polyps observed
during colonoscopy are removed by polypectomy and therefore, knowledge
about their natural history is limited. In this study, small (6-9mm) colorectal
polyps were followed over time and subsequently resected during colonoscopy.
Aim: The prevalence of DNA copy number alterations (CNAs), a feature asso-
ciated with adenoma to carcinoma progression, was compared in polyps that
morphologically progressed versus those that did not. Methods: In the CT-
colonography (CTC) arm of the COCOS-trial1 small 6-9mm polyps were left in
situ. After a three-year surveillance interval, growth according to CTC of 95
small polyps wasmeasured. Based on overall volumetric change onCTC, polyps
were classifıed as either progressed (30%growth), stable (30% to -30%growth)
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or regressed (-30% growth). From 65 resected polyps, formalin-fıxed paraffın-
embeddedmaterial was retrieved and reviewed by an expert pathologist (GAM).
Of these polyps, 48% (31/65) progressed, 41% (27/65) remained stable and 11%
(7/65) regressed. Seventy-two percent (47/65) were tubular adenomas, 14% (9/
65) tubulovillous adenomas, 3% (2/65) sessile serrated lesions and 11% (7/65)
hyperplastic polyps. Subsequently, the samples that yielded suffıcient quality
DNA were analyzed with low-coverage whole genome sequencing (HiSeq, Illu-
mina, San Diego, CA, USA). DNA copy number status was called with the
R-package QDNAseq. Results: From 50/68 resected polyps, originating from 38
individuals (mean age of 66.8 years (s.d. 7.0); 63% male), suffıcient DNA was
available. The mean surveillance interval of these polyps was 3.27 years (s.d.
0.29). The mean number of CNAs per sample was 0.8 (range 0-8), the most
frequently observed was 13q gain (20%). No signifıcant differences in number,
or regions of CNAs were observed between polyps that progressed and the ones
that did not change or diminished in size (stable or regressed). Larger polyps
showedmore CNAs, of which specifıcally 13q gain wasmore often present (43%
in 	10mm and 8% in 10mm polyps). Of note, no serrated lesions were
	10mm. No differences in CNAs were found between the different histological
subtypes. Conclusions: In a series of colorectal polyps left in situ for an average
3.27 years, no difference in prevalence of DNA copy number alterations was
observed between polyps that volumetrically progressed and those that did not.
Of the CNAs observed, 13q gain was most prevalent and found in 43% of the
	10mm polyps. 1. Stoop, E. M. et al. Participation and yield of colonoscopy
versus non-cathartic CT colonography in population-based screening for colo-
rectal cancer: A randomised controlled trial. Lancet Oncol. 13, 55-64 (2012).
#717 Diagnosis of basal like breast cancer using DNAmethylation mark-
ers at the promoters of long noncoding RNAs.Yoo J. Han, SonjaM. Boatman,
Jing Zhang, Albert C. Yeh, Yonglan Zheng,Olufunmilayo I. Olopade.University
of Chicago, Chicago, IL.
Background: Patients with basal-like breast cancer (BLBC) have poor overall
survival and suffer a high rate of metastasis to the brain or lung within three to
fıve years of initial presentation. Absence of a cure for advanced BLBC warrants
early detection of BLBC,whichmight savemore lives, especially those of women
of African ancestry who are disproportionately affected by young onset BLBC.
Aberrant DNAmethylation is frequently observed in BLBC. DNAmethylation
is themost robust epigeneticmarks and can be analyzed using clinical specimens
including FFPE, tumor biopsies and liquid biopsies. Because expression of long
non-coding RNAs (lncRNAs) is controlled temporally in response to neoplastic
stimuli, we investigated the potential for lncRNA promoter methylation marks
to be used for detection andprediction of BLBCdevelopment andprogression in
African Americans. Methods: To identify lncRNAs dysregulated in BLBC, we
performed a Ribo-Zero RNA-seq or microarray analysis on breast tissues iso-
lated fromAfrican American (n63) and European American patients (n14).
Differentially methylated and hydroxymethylated regions of lncRNA genes
were identifıed in African American samples (n30) using our chemical meth-
ods to assay 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC).
The Cancer GenomeAtlas (TCGA) datasets were utilized to validate our results.
To functionally annotate lncRNAs, we knocked down lncRNAs using LNA-
antisense oligonucleotides (ASO) and performed Caspase 3/7 assays, flow cy-
tometry, and qRT-PCR. We also utilized the CRISPR-Cas9 editing tools to
knock out lncRNAs. Results: LncRNAs displayed distinct expression patterns
between tumors and normal breast tissues. Out of hundreds of lncRNAs specif-
ically expressed in BLBC tumors, we selected two lncRNAs, lnc19 and lnc98,
which represent, respectively, a signifıcantly increased and decreased lncRNA in
BLBC tumors, compared to normal breast tissues and other subtype tumors.
Lnc19 is highly up-regulated (a 39-fold increase) whereas lnc98 is dramatically
down-regulated (a 59-fold decrease) in BLBC tumors. Methylation analysis
showed signifıcantly lower levels of promoter methylation for lnc19 and higher
levels for lnc98 in BLBC tumors. A signifıcant inverse correlation betweenmeth-
ylation and expression of lnc19 was observed. Depletion of lnc19 resulted in
rapid cell death of BLBC cells, with increased sensitivity to chemotherapy drugs.
The data suggests that chemo-resistance of BLBC might be partly due to lnc19
overexpression, which is mediated through epigenetic control. Conclusion: We
identifıed two epigenetically dysregulated lncRNAs inBLBC tumors,which con-
tribute to chemo-resistance of these tumors. Our fındings on the regulation of
lncRNAs by cytosine methylation raise the possibility of new epigenetic bio-
markers for diagnosis and prognosis of aggressive BLBC tumors.
#718 Biomarkermonitoring by quantitativeMALDI imaging; application
to the tryptophan-kynurenine pathway in immuno-oncology. Rima Ait
Belkacem,1 Vanessa Bol,2 Gregory Hamm,1 Stefan Linehan,1 Bruno Gomes,2
Jonathan Stauber1. 1Imabiotech, Loos, France; 2iTeos Therapeutics SA, Gosselies,
Belgium.
Tryptophan is an essential amino acid for cell proliferation and survival that
can bemetabolized through different pathways, amajor route being the kynure-
nine pathway. The fırst and rate-limiting enzyme of this pathway is the in-
doleamine-2,3-dioxygenase 1 (IDO1), that is a natural endogenous molecular
mechanism of immune suppression acting through modulation of the Trp deg-
radation pathway. Inhibition of T-cell functions, activation of the regulatory
T-cells, and inhibition of Natural Killer cells are among the important immu-
nosuppressive effects of IDO1. IDO1 enzyme is proposed to have a therapeutic
potential in immunodefıciency-associated abnormalities, including cancer.
IDO1 over expression has been described in multiple cancer indications and
IDO1 inhibitors are being developed to stimulate the anti-tumor immune re-
sponse. The existing and standard quantitation methods are based on the total
level of Trp and its metabolites determined by LC-MS/MS analysis in human
plasma, cerebrospinal fluid and brain. We describe the setup, development and
application of a new method based on MSI to detect, localize, and quantify Trp
and Kyn in biological tissues. This method allows both the study of the sub-
tissular localization and the detection/quantitation of metabolites of interest in
tumor tissues. In the present study, an experimental tumor model overexpress-
ing IDO1 and its wild-type counterpart were implanted in mice. Tissue sections
of different tumorswere realized and used forMSI analysis.MALDI FTICRhigh
resolution imaging followed by data analysis enabled an absolute on tissue quan-
titation. Internal standards of tryptophan (Trp-d5) and kynurenine (Kyn-d4)
metabolites were used for normalization. As expected, our results showed an
increase of Kyn in parallel to a decrease of Trp amount in IDO1-positive tumors.
Following, immunostainings of IDO1 and Trp-depletion sensor pathways were
carried.Overlaying images between the immunostainings and themolecularMS
images allowed co-localization studies and underlined both the biology and the
tumor heterogeneity. This study allowed us to highlight key metabolites of the
Trp pathway that are responsible for the immunosuppressive tumor microen-
vironment. It illustrated the heterogeneity of tumor immune areas.The devel-
opment of immunotherapies such as IDO1 inhibitors requires a deep under-
standing of the interplay between the immune system and cancer cells, these
immune endogenous metabolites can now be followed by QMSI and as bio-
markers towards enhancing immunotherapies effıciency.
#719 Pathobiological implications of Trefoil Factors in the progression
and metastasis of pancreatic cancer. Rahat Jahan, Sukhwinder Kaur, Muzafar
A.Macha, Yuri Sheinin, Lynette Smith, JaneMeza, Surinder K. Batra.University
of Nebraska Medical Center, Omaha, NE.
Background: Pancreatic cancer (PC) is a highly lethal malignancy and the
disastrous statistics warrants an urgent need to develop new diagnostic and
prognostic marker(s) and therapeutic target(s) for its better management. Tre-
foil factors (TFF 1/2/3) are a family of small, stable molecules observed to co-
express withmucin and secreted bymucus-producing cells that facilitate muco-
sal repair after injury. Recent studies have shown that TFF1 and TFF3 can
differentiate between molecular subtypes of PC. Based on this, we hypothesized
that differential expression of TFF1 and TFF3 could predict pancreatic intraepi-
thelial neoplasia (PanIN) as well as the early stage of PC. The present study
explores the diagnostic and functional signifıcance of TFF in PC. Material and
Methods: Immunohistochemistry was used to determine the expression status
of TFF1 and TFF3 in PC tissue microarray containing normal pancreatic
(n40), pancreatic intraepithelial lesion 1, 2, 3 (PanIN 1- 3, n13) and well,
moderately and poorly differentiated PC tissues (n149). Sandwich ELISA was
used to detect TFF1 levels in serum. The diagnostic signifıcance of TFF1 was
evaluated in the sample set (n331) comprising of benign control (BC, n104),
chronic pancreatitis (CP, n47), early stage PC (EPC, Stage 1 and 2, n78) and
late PC (LPC, Stage 2-3, n69). RT-PCR and ELISA were carried out to profıle
levels of TFF1 and TFF3 in PC cell lines and cell supernatants respectively.
Recombinant treatment with TFF3 was performed to observe the impact on of
transmembrane (MUC4) and secretedmucins (MUC5AC) stability and expres-
sion. Results: Differential expression of TFF3 was observed in PanIN precursor
lesion, pancreatic cancer tissue in comparison to normal pancreatic tissue (p
0.0003). Furthermore, the TFF3 expression was signifıcantly higher for well-
differentiated tumor in comparison to poorly differentiated cases (p  0.006).
For TFF1, expression was signifıcantly higher in PanIN lesions compared to
normal pancreas (p  0.0001), and PC versus normal pancreatic tissue (p 
0.0001). In serum, signifıcantly increased expression of TFF1 was observed in
EPC serum samples compared to BC (p-value  0.035) and CP (p-
value0.0058) cases. RT-PCR analysis revealed positive expression of TFF1 and
TFF3 in themajority of the PC cell lines. Treatment of PC cells with recombinant
TFF3 lead to differential expression ofMUC4 andMUC5AC.Conclusion:Over-
all, both tissue and serum based studies show that TFF1 and TFF3 are differen-
tially expressed in early PanIN lesions as well early stage of PC tissues compared
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to normal pancreas. Overall, these results suggest a potential implication of
TFF1 and TFF3 in PC pathogenesis and provide a basis for functional impact of
TFF 1 and 3 on mucins stability and downstream signaling in PC pathogenesis.
#720 Systematic discovery and evaluation of tumor-associated antigens
(TAAs) as biomarkers in cancer immunodiagnosis. Jianxiang Shi,1 LuZhang,1
Peng Wang,1 Hua Ye,1 Liping Dai,1 Pei Li,2 Chenglin Luo,2 Chuhua Song,1
Kaijuan Wang,1 Xiao Wang,1 Jun Ouyang,1 Zhenyu Ji,1 Jianying Zhang1.
1ZhengzhouUniversity, Zhengzhou, China; 2TheUniversity of Texas at El Paso, El
Paso, TX.
Proteins aberrantly over-expressed in tissues from nineteen types of cancers
have been identifıed from the Human Protein Atlas (HPA) database. Among
these proteins, somewere overexpressed in several types of cancers while certain
proteins were found only overexpressed in certain type of cancers. It is demon-
strated that aberrantly overexpressed proteins might shed into the blood and
trigger the immune system to produce autoantibodies during the process of
oncogenesis. Autoantibodies are more stable and often have higher titer com-
pared to autoantigens. Therefore, we hypothesize that autoantibodies against
these aberrantly overexpressed proteins may have the potential to serve as diag-
nostic biomarkers in certain type of cancers. In current study, we have selected
11 proteins, including EDNRB, KRT4, PLAT, MSLN, WFDC2, F5, FOXA1,
AURKC, STC1, CAB39L, and SFTPA1, to further evaluate the diagnostic values
of their corresponding serum autoantibodies in fıve types of cancers, including
hepatocellular carcinoma, lung cancer, gastric cancer, breast cancer and ovarian
cancer. Sera from 470 patients (94 per cancer type), 94 hepatitis patients and 192
age- and gender-matched normal controls were used in current study. Serum
autoantibodies were detected by ELISA. Receiver operating curve (ROC) anal-
ysis was used to evaluate the diagnostic value of serum autoantibodies against
these potential TAAs. The data indicates that several anti-TAA autoantibodies
can be found to have diagnostic value for certain types of cancers. Autoantibod-
ies against PLAT can distinguish breast and ovarian cancerwhile autoantibodies
against SFTPA1 and CAB39L can distinguish cancers both in male and female.
However, none of these serum anti-TAAs was found to be specifıc to a single
type of cancer. In summary, HPA database has made systematic discovery of
cancer biomarkers possible. Whether these in silicon biomarkers can be used to
distinguish normal and cancer still needs to be evaluated inmore serum samples
from normal controls and cancer patients.
#721 Minimally invasive test and composite biomarker for early detection
of serous ovarian carcinoma. Keren Bahar-Shany,1 Georgina D. Barnabas,2
Limor Helpman,3 Ariella Yakobson-Siton,4 Tamar Perri,1 Ram Eitan,4 Jacob
Korach,1 Tamar Geiger,2 Keren Levanon1. 1Sheba Medical Center, Ramat Gan,
Israel; 2Tel Aviv University, Tel Aviv, Israel; 3Meir Medical Center, Kfar Saba,
Israel; 4Rabin Medical Center, Petach Tikva, Israel.
Background: Current screening programs for early detection of high grade
epithelial ovarian cancer (HGOvC) among high-risk populations have failed to
show improvement in HGOvC mortality, therefore these women are offered
risk-reducing bilateral salpingo-oophorectomy (RRBSO) at 35- 40 years. Strat-
ifıcation of high-risk population, especially BRCAmutation carriers,may enable
personalized risk counseling and individualization of timing of RRBSO. Inmost
cases, the precursor lesions of HGOvC arise in the epithelium of the fallopian
tube (FT) fımbriae rather than intra-peritoneally. It is therefore plausible that
proteins, RNA or DNA from early-stage tumor cells may be identifıable in fluid
samples obtained from the lumen of the gynecological tract, thus making it
possible to identify curable, early stage lesions. Aims: (1) Test the feasibility of
uterine lavage as a minimally invasive test for early detection of ovarian cancer,
and (2) Identify novel early-detection biomarkers in the uterine lavage fluid
(UtLF). Methods: We developed a method for sampling of gynecologic tract
fluid termed uterine lavage fluid (UtLF), which is a simple, reproducible, low-
cost offıce procedure that can be performed routinely during gynecologic fol-
low-up visits. We have already collected UtLF from 140 HGOvC patients and
control women undergoing gynecologic surgical procedures for non-malignant
indications. Deep proteomic profıling of UtLF is performed by isolation of mi-
croparticles from body fluids, followed by solubilization, trypsin digestion and
high resolution mass spectrometric (MS) analysis (on the Q-Exactive MS). Ma-
chine learning algorithms have been used to extract a classifıer that can predict
the diagnosis of ovarian cancer. Results: Uterine lavage appears to be a feasible,
low burden procedure. TheMS approach has identifıed thousands of proteins in
eachUtLF specimen, in a high throughputmanner. The label-free quantifıcation
algorithm (MaxQuant) enables a quantitative comparison between samples
from cases and controls. We have derived a 20-protein classifıer with an area
under the curve (AUC) of Receiver Operating Characteristics (ROC) curve of
0.91 at 20% error. The composite biomarker has been applied to an independent
validation set with a negative predictive value (NPV) of 92% and positive pre-
dictive value (PPV) of 45%. Conclusions: A minimally invasive technique of
uterine lavage to collect unique diagnostic samples, coupled with state-of-the-
art proteomics methods, results in a highly sensitive and specifıc composite
biomarker which may be developed in to a screening tool for early detection of
serous ovarian cancer in high-risk populations.
#722 Circulating EBV microRNA BART2-5p helps to diagnose nasopha-
ryngeal carcinoma< screen for high risk individuals precisely. Chen Jiang,1
Lei Li,2 Li Jiangchao,3 Shang-hang Xie,2 Su-mei Cao,2 Xin-yuan Guan1. 1The
University of Hong Kong, Hong Kong, China; 2Sun Yat-Sen University Cancer
Center, Guangzhou, China; 3Guangdong Pharmaceutical University, Guang-
zhou, China.
Nasopharyngeal carcinoma is an EB-virus associated malignancy which is
highly prevalent in Southeast Asia. If diagnosed early, the 5 year disease-free
survival rate is about 90%. However, most patients have already developed local
or regional invasion when diagnosed, which results in poor prognosis. So it is
essential to develop biomarkers to screen high risk individuals or diagnose the
disease at early stages. As nasopharyngeal carcinoma is closely related to EBV
infection andmicroRNAs encoded byBART region (BamHIARightwardTran-
scripts) is abundant in NPC, we propose to identify biomarkers from those
BARTmicroRNAs. To quantify the copy number of microRNAs in serum sam-
ples, we usedTaqmanProbe-based qPCR.After adding Spiked-inControl (Mix-
ture of Cel-39,Cel-54, Cel-238) to each 100ul serum sample, we extracted total
RNA and reverse transcribed microRNA into cDNA with corresponding Taq-
man primers. Meanwhile, microRNA mimics with known copy number were
serial diluted and reverse transcribed along with the samples. qPCR was per-
formed to quantify the level of microRNAs in these samples with diluted cDNA
and Taqman Probe. All data was normalized by Spiked-in controls and exact
copy number of each microRNA was calculated through the standard curve
generated by the serial diluted microRNAmimics. Here, we screened 17 BART
microRNAs in discovery stage and found BART 2-5p as a candidate biomarker.
In training cohort consisting of 266 patients with nasopharyngeal carcinoma
and controls from Hong Kong, the sensitivity, specifıcity and AUC is 93.2%,
89.8%,0.976 respectively. The results are similar in validation cohort 1 consti-
tuted by 376 patients and controls from Guang Zhou. To evaluate the ability of
BART 2-5p to distinguish preclinical NPC patients from healthy high risk indi-
viduals, we established a nested case-control study with serum samples prospec-
tively collected from 10 NPC patients at least one year prior to their clinical
diagnosis and 92 matched healthy high risk controls from a screening scheme
conducted in South China. The sensitivity and specifıcity is 90.0% and 31.5%.
Taken together, EBV microRNA BART2-5p is a promising biomarker to im-
prove NPC diagnosis and target preclinical patients more precisely than sero-
logic test.
#723 Improved detection of cancer specifıc serum exosomal aspartyl (as-
paraginyl) beta hydroxylase (HAAH).MarkA. Semenuk, Anokhi S. Cifuentes,
Eleanor R. Ghanbari, Michael S. Lebowitz, Hossein A. Ghanbari. Panacea Phar-
maceuticals, Inc., Gaithersburg, MD.
Bymeans of an ELISA, we have found the pan-cancer biomarkerHAAH to be
closely associated with serum exosomes primarily in cancers of the breast, lung,
colon, and prostate. This new understanding of the HAAH target has led to a
dramatically improved serological detection assay, and in turn diagnostic re-
agent kit. In keeping with the multivalent particulate nature of exosomes, ap-
propriately reformatting the ELISA assay has yielded a simplifıed so-called si-
multaneous-homologous format. Currently in this format, a single monoclonal
anti-HAAH antibody (FB50) serves both as microplate capture and as a biotin-
ylated detector. All reagents, including peroxidase-streptavidin, are co-incu-
bated in the FB50- coatedmicroplate simultaneously with serum samples, in the
absence of intervening sequential steps. This considerably shorter exosome-
enabled ELISA format requires half the time and yields generally on average a
two-fold or higher increase in detection of HAAH. This format was evaluated
with over 100 banked serum samples from several early stage cancers. While
increasing the sensitivity for HAAH in cancer samples, the improved detection
and performance has not caused any undesirable increases in false positives
among more than 30 normal serum samples from healthy subjects. The reagent
kit components include recombinantHAAHcalibrators, positive /negative con-
trols, vialed detection reagents and a Mylar packaged FB50 pre-coated micro-
plate. The simplifıed reagent kit format has yielded close inter-operator and day
to day trending consistency with a limit of detection (LOD) of 3 ng/mL. Recog-
nizing the exosomal nature of the HAAH target has resulted in some changes in
blood sample procurement, sample processing, and sample shipping. Such fıeld
testing of the HAAH reagent kit was recently done with serum samples from 48
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high risk ormildly symptomatic volunteers with general concerns about cancer.
Upon testing these samples 9 had anHAAH level greater than 3.0 ng/mL (range
4.2 to 116.7) and 39 had less than 3.0 ng/ mL. Based upon the post-analysis
diagnostic determination, there were two false negatives and one false positive,
hence an overall accuracy of 93.8%.
#724 Clinical impact of modifıed telomerase-specifıc adenovirus-based
identifıcation of viable-peritoneal tumor cells in peritoneal lavage fluid in
patients with potentially resectable pancreatic cancer.Masahiro Tanemura,1
Kenta Furukawa,1 Soichiro Mori,1 Masahisa Otsuka,1 Youzo Suzuki,1 Mitsuyo-
shi Tei,1 Toru Masuzawa,1 Kentaro Kishi,1 Yasuo Urata,2 Hiroki Akamatsu1.
1Osaka Police Hospital, Osaka, Japan; 2Oncolys BioPharma Inc., Tokyo, Japan.
Pancreatic cancer (PC) is a highly aggressive disease with dismal prognosis.
Although only a surgical resection can offer the chance of a cure, the 5-year
survival rate after a potentially curative resection have been reported to be a low
as 10-30 %. In PC, the presence of peritoneal carcinomatosis preclude the pos-
sibility of surgical cure, irrespective of the resectability of the primary tumor.
Peritoneal lavage cytology (CY) is used widely in the diagnosis and staging of
gastric and pancreatic cancer. Positive CY fındings (CY) in PC is defıned as
stage IV disease, however, the true value of CY for the patient’s prognosis
remains controversial. We rise the question of whether CY status has predic-
tive value for survival and early intraperitoneal recurrence. The aim of this study
was to evaluate use of a new genetically modifıed telomerase-specifıc replica-
tion-selective adenovirus, expressing GFP (TelomeScan F35) in rapid detection
of viable peritoneal tumor cell (v-PTC) dissemination of PC. This human clin-
ical trial sought to determine if the presence of virally-detected, rare v-PTC
predict peritoneal recurrence and patient outcome. This study was approved by
theOsaka PoliceHospital IRB. Patients with resectable cytologically or histolog-
ically proven ductal adenocarcinoma of the pancreas were enrolled. Peritoneal
lavage fluid was harvested just after a laparotomy in 27 patients with PC. Half of
the fluid was examined by cytology with papanicolau staining and MOC-31
immunostaining and the remaining half was used to detect v-PTC with Telom-
eScan F35. To distinguish between leucocyte and cells with epithelial origin, cells
were stained with anti-CD45 Ab. To further distinguish cells with primary tu-
mor origin, cells were labeled with anti-CEA and anti-CA19-9 Abs. GFP-posi-
tive andCD45-negative, and either CEA- or CA19-9-positive cells were counted
as v-PTC. Patients were followed after surgery to evaluate its clinical signifı-
cance. Among 27 patients aged 57-91 years (16 males and 11 females), 3 were
cytologically positive (CY), other 3 were virally positive by TelomeScan F35
(v-PTC). All 27 patients underwent a surgical resection (PD/DP/TP/H-
PD13/7/6/1). One patient was double positive (CY/v-PTC), and postop-
erative peritoneal recurrence early occurred at 5 month after resection despite
adjvant chemotherapy. 2 were CY, but v-PTC-, and no recurrence in the
abdominal cavity were observed (0%). On the other hand, other 2 were CY-, but
v-PTC, and one of these 2 patients occurred local recurrence in the abdominal
cavity (50%). Remaining 22 patients (CY-/v-PTC-) were observed with neither
local recurrence nor distant metastasis. In conclusion, the TelomeScan F35-
based v-PTCdetectionmay be an independent prognostic factor in patientswith
resectable PC and had close association with local or peritoneal recurrence.
#725 Feasibility and evaluation of exosomal RNAs as novel diagnostic
biomarkers for high grade serous epithelial ovarian cancer. Emily N. Pren-
dergast, Xianzhi Lin, Rosario I. Corona, Dennis J. Hazelett, Beth Y. Karlan, Kate
Lawrenson. Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: High-grade serous ovarian cancer (HGSOC) survival has been
essentially unchanged over the last ten years despite new therapeutic strategies.
In order to make a large-scale impact on overall survival, early detection strate-
gies are imperative. Exosomes are cell-derived vesicles derived from multive-
sicular bodies or the plasma membrane that carry a variety of biomolecules,
including protein, DNA, and RNA. Exosomal contents represent a novel and
underexplored source of tumor biomarkers, in particular for HGSOC. This
study aimed to fırst evaluate approaches to exosomal RNA purifıcation and to
then compare the exosomal RNA profıles from serum of patients with benign
ovarian disease andHGSOC to determine if unique profıles exist, and to identify
biomarkers useful for early detection. Methods: Cell free serum was obtained
from patients in each of the following categories: HGSOC with early (n24) or
late stage (n24) disease, benign ovarian masses (n24) and healthy age-
matched controls (n24). We compared ultracentrifugation and a commercial
precipitation solution to enrich and isolate exosomes. Exosomal enrichmentwas
confırmed by both transmission electron microscopy (TEM) and western blot
using anti-CD63 antibodies. RNA was extracted for each and deep sequencing
analysis was performed for 12 candidates within each group. A second cohort of
48 samples will be used for validation of the best performing candidate biomark-
ers from the discovery cohort via RT-qPCR. Results: Enrichment of exosomes
was confırmed via qualitative assessment using TEM andWestern blot analysis.
RNA quality was superior when RNA isolations were performed using the QIA-
gen RNeasy kit compared to the AllPrep kit. Mean RNA yield for each group
ranged from 10.3-28.6ng/l and RNA yield and quality was independent of
sample age. RNAseq analyses are ongoing to identify biomarkers specifıc to
HGSOC that can be detected at the earliest stages. The top differentially
RNAs for the ovarian cancer groups will be validated in an independent
cohort of specimens. A panel will then be generated in combination with
CA125 to determine the clinical utility of an integrated -omics approach in
early stage detection of HGSOC. Conclusions: Effıcient isolation of exo-
somes and RNA can be achieved from archived specimens 10 years old.
Evaluation of exosomal RNA in HGSOC provides a novel method for bio-
marker discovery.
#726 Ultrasensitive quantifıcation of promoter methylation in cell-free
circulating DNA for early detection of lung cancer.Delphine Lissa.NIH/NCI,
Bethesda, MD.
Lung cancer is the leading cause of cancer-related deaths worldwide. Early
detection of lung cancer using Low Dose Computed Tomography (LDCT)
screening has been shown to decrease themortality rate.However,most nodules
found are deemed to be benign upon further invasive testing. Thus, complemen-
tary minimally-invasive tests are being sought that will help discriminate malig-
nant from benign nodules. Molecular biomarkers are increasingly becoming
part of routine clinical practice for the diagnosis, prognosis or prediction of
treatment response, with improved disease management and survival outcome.
Cell-free circulating DNA (cfDNA) in body fluids, including serum, plasma and
urine, has recently emerged as a surrogate for tumor DNA. In addition to pro-
viding a minimally-invasive source of tumor DNA, cfDNA reflects molecular
alterations and tumor heterogeneity. Epigenetic changes, including DNAmeth-
ylation, occur early in carcinogenesis. Cancer cells are characterized both by
global hypomethylation and hypermethylation of CpG islands in gene promoter
regions. Analysis of tumor-specifıc DNA methylation in cfDNA is a promising
strategy for applying epigenetic biomarkers to the detection of cancers at an
early-stage. In a prior genome-wide analysis of DNAmethylation, we identifıed
a locus methylated de novo in fresh frozen tumor tissues resected from stage I
lung cancer patients, that had high discriminatory power to distinguish tumor
fromnon-tumor tissues inmultiple patient cohorts.High promotermethylation
was also associated with shorter cancer-specifıc survival. The present study aims
at evaluating the diagnostic signifıcance of promotermethylation in cfDNA, and
the prognostic value in formalin-fıxed paraffın-embedded (FFPE) tissues. We
developed amethylation-specifıc droplet digital PCR (ddPCR) assay to quantify
rare methylation events. DNA was subjected to bisulfıte treatment to convert
unmethylated cytosine residues to uracil. We designed specifıc primers and
probe containing 7 CpGs to only amplify themethylated promoter. Experimen-
tal conditions were fırst optimized using fully methylated and unmethylated
control DNAs, DNA extracted from lung cancer cell lines, germline cells and
lung tissues (paired tumor and non-tumor). The ddPCR assay has a limit of
detection of 30 haploid genomes equivalent of methylated promoter DNA, and
a limit of quantifıcation of a single methylated allele present at 0.2% (i.e., 1
methylated copy among 500 unmethylated copies). We demonstrated the assay
linearity, reproducibility and specifıcity for the methylated locus. Differences in
methylation levels between tumors and adjacent tissues were also observed. We
have thus established a robust and ultrasensitivemethod for standardized deter-
mination of promotermethylation status in cfDNA.We are currently evaluating
its potential value for noninvasive diagnosis and prognosis of lung cancer pa-
tients.
#727 Prospective lung cancer diagnostic screening using whole, unstimu-
lated saliva versus stool. Yosef Y. Tobi,1 Fadi Antaki,2 MaryAnn Rambus,2
Martin Tobi3. 1R&D Detroit VA Medical Ctr, Detroit, MI; 2Detroit VA Medical
Ctr., Detroit, MI; 3Saginaw VA Medical Ctr., Saginaw, MI.
Current screening for lung cancer (LC) reduces mortality but tests are not
ideal. Low-dose CT scans are expensive, incur radiation exposure, and high
false positive rates. Although sputum cytology is unhelpful, saliva biomarker
testing is promising but no prospective data are available. Methods: In con-
ducting a study using stool markers in a high risk colorectal neoplasia pop-
ulation we prospectively collected saliva and stool samples. Subsequently, 11
with available saliva; 8 with stool specimens but without signifıcant personal
or family history of GI neoplasia or symptoms, had contracted LC. We used
3 monoclonal antibodies to test reactivity in saliva (Adnab-9, BAC 18.1,
COX-2). These are biomarkers of innate immune system, cell-mediated im-
munity, and inflammation, respectively. We used ELISA with either alkaline
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phosphatase (ALP) or immunoperoxidase (IMP) substrate and contrasted
reactivity in LC patients and asymptomatic controls with no advanced pol-
yps, and chemiluminescent dot blots with manual or Bel-blotter 96-well
replicating tool. Results: Saliva IMP testing was positive in 73% of 11 LC
patients and 50% of 8 controls contrasted with ALP ELISA for stool Adnab-9
in 75% of 8 LC patients and 32% in 34 controls (OR 6.27:CI1.09-36.25;
p0.05).Specifıcity was 68%. Sensitivity for Adnab-9 for IMP manual and
bel-blotting was 73 and 9% respectively; specifıcities were 37 and 64% re-
spectively. BAC 18.1 sensitivities were 73 and 55% respectively; specifıcities
13 and 29%. COX-2 sensitivity for bel-blotting only was 27% and specifıcity
was 71%. Inherent salivary peroxidase activity (OD0.1/1g protein) was
negative in all 7 LC versus 9 of 23 (39%) of non-LC patients (p0.07). The
peroxidase absorbance means[SD] were signifıcantly different (0.077[0.014]
versus (0.116[0.056];p0.007). Equivalent inherent alkaline phosphatase of
saliva samples was negative in both groups and means were not signifıcantly
different. The approximate time from saliva collection to diagnosis of LCwas
3.76 years and 3.89 for stool. Conclusions: Adnab-9 sensitivity was moderate
but promising due to the ability to make an early preclinical diagnosis. While
this was only signifıcantly different from controls in stool ALP ELISA, in-
herent IMP activity could be blocked to improve specifıcity. Signifıcantly
suppressed inherent peroxidase activity in LC saliva may explain the insen-
sitivity of the Bac18.1 and Cox2 inflammatory biomarkers. The Bel-blotter
volume capacity is 4-10l/blot and may explain the lower sensitivity using
this tool. A battery of tests, including Adnab-9 in an ALP ELISA format may
allow for early disease intervention.
#728 Development and validation of ColoScape™ - a new colorectal cancer
mutation detection assay.Michael J. Powell, Elena Peletskaya, Anne Vallerga,
Qing Sun, Larry Pastor, Aiguo Zhang. DiaCarta, Richmond, CA.
Introduction: Colorectal cancer is a highly preventable disease as early
detection increases rates of patient survival to near 100%. Herein we report
the development and validation of a novel multigene mutation biomarker
real-time PCR based assay for qualitative detection of colorectal cancer as-
sociated biomarkers that comprise tumor specifıc mutations in the following
genes: APC (Exon 15), KRAS (Exon 2), BRAF (Exon 15) and CTNNB1 (Exon
3) called ColoScapeTM . The assay allows the sensitive detection of the pres-
ence or absence of mutations in the targeted regions of the genes interro-
gated. Methodology: The high sensitivity of this multigene biomarker assay
is achieved due to xenonucleic acid (XNA) probe technology. XNA probes
are novel backbone modifıed oligomers having natural nucleoside bases
(A,T,C and G) that hybridize by Watson-Crick base pairing to natural DNA
and RNA with much higher binding affınity than natural deoxyribonucleic
acid oligomers of the same sequence. XNA probes are designed that bind to
the selected wild-type sequences at the respective genetic loci in the target
genes. These XNA probes have a much higher Tm than the primer annealing
temperature and suppress amplifıcation of WT DNA templates and only
allow amplifıcation of the target mutant DNA templates in the sample. Both
single nucleotide polymorphisms (SNP’s) and insertion/deletions (indels)
mutations can be detected. For each of the selected mutation sites primers
and FAM-labeled TaqMan hydrolysis probes were designed and tested to-
gether with the selected XNA oligomers and analytical assay performance
confırmed. An internal PCR control amplicon selected in the Human -Ac-
tin (ACTB) gene was employed utilizing a HEX-labeled TaqMan probe.
Performance parameters of the assay were established on DNA of colorectal
cancer patients extracted from FFPE as well as reference DNA materials
(synthetic and cell line derived DNA). The assay demonstrates high sensi-
tivity and specifıcity in detection of colon cancer and adenoma samples
based on the set of biomarkers involved in colorectal cancer neogenesis and
disease progression. Conclusion: The ColoScapeTM Colorectal Cancer Mu-
tation Detection assay is shown to be a sensitive tool intended to facilitate
research in colon cancer development, early detection, disease monitoring
and therapeutic interventions.
#729 A novel cancer-stem-cell biomarker, DCLK1-S, traffıcs to nuclei of
colon cancer cells: potential use as a biomarker for assessing colon cancer risk
after screening colonoscopy. Shubhashish Sarkar, Vsevolod L. L. Popov,
Malany O’Connell O’ Connell, Heather L. Stevenson, Brian S. Lee, Robert A.
Obeid, Pomila Singh. UTMedical Branch, Galveston, TX.
DCLK1 expression is critically required for maintaining growth of human
colon cancer cells (hCCCs). We and others recently reported that the
5’promoter of hDCLK1-gene gets hypermethylated and silenced in human colo-
rectal tumors (hCRCs) during adenoma-carcinoma sequence of colon carcino-
genesis (Reviewed by Singh et al. SCI, 2016). We also made the discovery that
hCRCs and hCCCs express a novel short isoform of DCLK1 (DCLK1-S) (iso-
form2) from -promoter in intron V of hDCLK1-gene, while normal-colons
express the canonical long-isoform (DCLK1-L) (isoform1) from 5’()-pro-
moter, suggesting that DCLK1-S, and not DCLK1-L, marks cancer-stem-cells
(CSCs) (O’Connell et al, Sci Rep, 2015). Even though DCLK1-S differs from
DCLK1-L by only six amino-acids, we succeeded in generating a mono-specifıc
DCLK1-S-Antibody (PS41014), which does not cross-react with DCLK1-L, and
specifıcally detects DCLK1-S in several assay platforms, including westerns and
IHC. Sub-cellular localization of S/L isoforms was examined by immune-elec-
tron-microscopy (IEM). Surprisingly, besides plasma membrane and cytosolic
fractions, S/L also localized to nuclear/mitochondrial fractions, with pro-
nounced localization of S-isoform in the nuclei and mitochondria of hCCCs.
Sporadic CRCs develop from adenomas (Ads). Screening colonoscopy is used
for detection/resection of growths, and morphological/pathological criteria are
used for risk assessment and recommendations for follow-up colonoscopy. But,
these features are not precise and majority of the patients with adenomas will
never develop CRC.We hypothesized that antibody-based assay(s), which iden-
tify CSCs, will signifıcantly improve prognostic value of morphological/patho-
logical criteria. We conducted a pilot retrospective study with PS41014-Ab, by
staining archived adenoma specimens from patients who developed (High-risk)
or did not develop (Low-risk) adenocarcinomas within 10-15 years.
PS41014-Ab stained adenomas from initial and follow-up colonoscopies of
high-risk patients, at signifıcantly higher levels (3-5X) than adenomas from low-
risk patients, suggesting that PS41014-Ab could be used as an additional tool for
assessing CRC-risk. We previously reported that CRC-patients, whose colonic
tumors were positive for relatively high levels of DCLK1-S expression (by qRT-
PCR), had a worse overall survival and disease free interval than low-expressers
(O’Connell et al, Sci Rep 2015). We now report that DCLK1-S-Antibody may
help to identify patients at high-risk for developing CRCs within 10-15 years, at
the time of index/screening colonoscopy, and thus serve as a useful biomarker at
early time points of colon carcinogenesis, unlike the currently available fecal/
blood tests.
#730 High sensitive detecting procedure of circulating repetitive RNA as
novel early marker of pancreatic cancer. Takahiro Kishikawa, Motoyuki Ot-
suka, Kazuhiko Koike. University of Tokyo, Tokyo, Japan.
Pancreatic ductal adenocarcinoma (Pdac) is one of the most intractable ma-
lignancies due to diffıculties in early detection. Although promising biomarkers
are increasingly reported, such methods are not yet easy to apply clinically,
mainly due to their low reproducibility or technical diffıculties. In this study, we
developed a convenient and sensitive method for quantifying aberrantly ex-
pressed satellite repeat RNAs in sera, which can be used to effıciently detect
patients with Pdac. It is diffıcult to correctly quantitate repeat arrays because its
repetitive nature makes it diffıcult to establish appropriate primers that amplify
a single product using simple PCR procedures. Here, we introduce a Tandem
Repeat Amplifıcation by nuclease Protection (TRAP) method combined with
droplet digital PCR (ddPCR) to detect human satellite II (HSATII) RNAs, which
are specifıcally expressed in human Pdacs at greater levels than normal tissues.
HSATII RNA core sequence levels in sera were signifıcantly higher in Pdac
patients compared with non-cancer patients (median copy number: 14.75 and
3.17 per l in the training set and 17.35 and 2.9 in the validation set, respec-
tively). In addition, patients with intraductal papillary mucinous neoplasm
(IPMN), a precancerous lesion of Pdac, could also be effıciently detected. This
method can be routinely applied to screen patients with Pdac and high-risk
patients, facilitating the development of preventive medicine for this disease.
#731 Stool DNA testing of Fusobacterium nucleatum for detection of
colorectal tumors.Yutaka Suehiro, Kouhei Sakai, ToshihikoMatsumoto, Taka-
hiro Yamasaki. Yamaguchi Univ. Graduate School of Medicine, Ube, Japan.
Background: Accumulating evidence shows an overabundance of Fusobacte-
riumnucleatum (Fn) in colorectal tumor tissues. Although stool DNA testing of
Fn might be a potential marker for the detection of colorectal tumors, the diffı-
culty in detecting Fn in stool by conventional methods prevented further explo-
rations. Therefore, we developed a droplet digital PCR assay for detecting Fn in
stool and investigated its clinical utility in the management of colorectal tumors
in a Japanese population. Methods: Feces were collected from 60 healthy sub-
jects (control group) and from 11 patients with colorectal non-advanced adeno-
mas (non-advanced adenoma group), 19 patients with colorectal advanced ad-
enoma/carcinoma in situ (advanced adenoma/CIS group), and 158patientswith
colorectal cancer (CRC) of stages I to IV (CRC group). Absolute copy numbers
of Fn were measured by droplet digital PCR. Results: The median copy number
of Fn was 17.5 in the control group, 311 in the non-advanced adenoma group,
122 in the advanced adenoma/CIS group, and 317 in the CRC group. In com-
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parisonwith that in the control group, the Fn level was signifıcantly higher in the
non-advanced adenoma group, the advanced adenoma/CIS group, and theCRC
group. Conclusions: This study illustrates the potential of stool DNA testing of
Fn by droplet digital PCR to detect individuals with colorectal tumors in a
Japanese population.
#732 Potentials of some serum proteins and urinary molecular biomark-
ers for early diagnosis of prostate cancer in Nigeria patients. Oluyemi Akin-
loye,1 Aniebietabasi S. Obot,2 Taiwo A. Adewole2. 1University of Lagos, Lagos,
Nigeria; 2Ladoke Akintola University of Technology, Osogbo, Nigeria.
Background: Prostate cancer (PCa) an adenocarcinoma is the most common
cancer diagnosed in African men today. At present, the only widely accepted
screening tools for prostate cancer are prostate specifıc antigen (PSA) and digital
rectal examination. There is controversy regarding the appropriate level of se-
rum PSA that should trigger a biopsy. This study is aimed at fınding a better
marker/panel of markers for prostate cancer. Methods: 150 consented patients
requiring a prostate biopsy and 100 agematched controls were recruited for this
study. Genetic materials were found in 132 (88%) of the samples. Serum Total
PSA (TPSA) , and free PSA were assayed using ELISA method, % free/total
PSA(%f/tpsa) was obtained statistically, prostatic volume was determined using
TRUS. In addition, selected urinary RNA’s were assayed; transmembrane serine
protease (TMPRSS2:ERG and TMPRSS2:ETS) fusion genes, PSA gene and
PCA3 (prostate cancer antigen 3) , using standard polymerase chain reaction
(PCR) protocols. Results: TMPRSS2:ERGwas detected in 9 (7 %) of the samples
and limited to biopsy positive for PCa. Similarly, TMPRSS2:ETS was found in
only 4 (3%) of the samples and also restricted to biopsy positive for PCa. PCA3
score had the best discriminatory accuracy in diagnosing PCa amongst patients
with serum Total PSA in the range of 4 - 10 ng/ml with AUC of 0.705 compared
to Total PSA, f/t PSA ratio, and PSADensity which were 0.365, 0.695, and 0.541
respectively. At the cut off value of 24.6, PCA3 score yielded its best sensitivity of
0.615 and specifıcity of 0.630. At the cutoff of 18, free/total PSA ratio (0.615,
0.77), at the cutoff of 0.14 PSAD yielded its best (0.538, 0.704.) respectively.
Direct logistic regressionwas performed to access the predictability of PCa using
differentmodels comprising of three (3) covariates, themodel comprising PCA3
Score, f/t PSA ratio and PSAD had the best discriminating accuracy in the sub-
group with TPSA range of 4 - 10ng/ml, with the sensitivity, specifıcity, positive
predictive value, and negative predictive values of 0.59, 0.93, 71.4% and 75.8%
respectively, over models comprising PCA3 Score ,TPSA and %f/t PSA, and
PCA3 Score, TPSA and PSAD with these values (0.23, 0.85, 42.9 % and 70.1%),
(0.39, 0.89, 62.5%, and 75 %) and ( 0.15, 0.85,66.7% and 67.6%) respectively.
Conclusions: In predicting PCa amongst patients with serum total PSA in the
grey area of 4 - 10 ng/ml, the model comprising PCA3 Score, f/t PSA ratio and
PSAD had the best discriminating accuracy.
#733 DetectionofHCC-derivedmajorHBV integration junctions inurine
and their implications for driver identifıcation. Selena Y. Lin,1 Jamin D. Stef-
fen,2 Yih-Ping Su,3 Surbhi Jain,2 Ting-Tsung Chang,4 Wei Song,1 Ying-Hsiu
Su3. 1U-Screen Dx, Inc., Doylestown, PA; 2JBS Science, Inc, Doylestown, PA; 3The
Baruch S Blumberg Institute, Doylestown, PA; 4National Cheng Kung University
Medical College, Tainan, Taiwan.
Chronic Hepatitis B Virus (HBV) infection is a major etiology of hepatocel-
lular carcinoma (HCC), a leading cause of cancer mortality worldwide. Integra-
tion of HBV DNA into the host genome occurs during the course of chronic
infection. Integrated HBV DNA is observed in most of HBV-associated HCC.
The integration junctions derived from the original tumor cell become abun-
dant (referred to as major integration junctions) in the infected liver because of
clonal expansion during tumor development. Detection of circulating DNA
containing these tumor-derived integration junctions may therefore be useful
for cancer detection. We have adapted a method known as Primer Extension
Capture (PEC) to enrich integrated HBV DNA for next-generation sequencing
(NGS). Our initial studies using this approach to enrich the HBVDR1-2 region
(a common site for HBV integrated breakpoints) identifıed major integration
junctions from HBV-HCC tissue samples and matched urine. Further analysis
revealed that most recurrently targeted integrations from these HCC tumors
have previously reported involvement in cancer. This suggested that identifıca-
tion of recurrently targeted genes is applicable for driver identifıcation. Interest-
ingly, we show how HBV targets the TERT promoter in a localized region even
though no two TERT junctions examined are identical. We have further devel-
oped this PEC to enrich for the entire HBV genome and applied it to (i) liver
tissue DNA from 20 matched HCC and adjacent non-HCC samples, and (ii)
DNA from urine of 20 hepatitis, 20 cirrhosis and 20 HCC patients. The HBV
enriched libraries were sequenced by NGS and the integration events were an-
alyzed using the in-house developed software. The complexity of HBV junction
sites in HCC and non-HCC tissue and urine derived circulating DNA is re-
ported. Our approach has potential to be used for liquid biopsies to study the
complexities of HBV integrations in chronic HBV infection and carcinogenesis,
and to identify HCC-related DNAmodifıcations for early detection and disease
management.
#734 Improved detection of salivary glands’ RNA markers in saliva
samples. Adrian D. Schubert, Evgeny Izumchenko, Piotr T. Wysocki, David
Sidransky, Mariana Brait. Johns Hopkins University, School of Medicine, Bal-
timore, MD.
RNA based liquid biopsy in saliva could be part of the diagnostic process and
surveillance in patients with Salivary Gland Tumors. There is no established
approach for saliva markers in salivary gland tumors. These tumors occur ap-
proximately in one out of 100,000 adults per year in theUSA.We aim to develop
a method to identify RNA shed specifıcally from the salivary glands.The two
most common salivary glandmalignancies harbor frequent gene fusions, which
may be candidate RNA based markers. In mucoepidermoid carcinoma, the
MECT1-MAML2 fusion. In adenoid cystic carcinoma, either a MYB-NFIB or
MYBL1-NFIB fusion. We identifıed collection and processing methods to be
tested on healthy individuals’ saliva samples. We compared three saliva stimu-
lation methods: Chewing Gum, Tabasco and Vitamin C powder with unstimu-
lated collected saliva; and also utilized different processing and RNA extraction
procedures: Trizol based: QIAzol method (Qiagen), RNEasy saliva protecting
reagent (Qiagen), OrageneRNA (DNA Genotek), and mirVana Kit (Thermo-
Fisher). We evaluated the RNA´s quantity and quality with Spectrophotometer
and Agilent’s 2100 Bio analyzer. We identifıed two salivary gland specifıcally
highly expressed genes (HTN3 and CA6) to be analyzed by quantitative RT-
PCR.We have collected and processed 221 samples and analysis is ongoing. Bio
analyzer showed that RNA from the unstimulated collected saliva has a higher
concentration than stimulated saliva. Unstimulated saliva is expected to contain
mucosa cells, bacteria and rests of food, therefore those could also be RNA
sources. When saliva’s RNA is protected by either of the buffers tested, the RIN
scores (RNA Integrity Number) obtained by Bio analyzer are higher. Based on
our preliminary data, stimulation with either Tabasco, Chewing Gum or Vita-
min C followed by RNA stabilization with the OrageneRNA kit and extraction
with Trizol resulted in the highest quality and specifıcity of the RNA for its
salivary gland origin. Unstimulated collection followed by the same processing
generates a greater RNA yield. This saliva RNA is likely contaminatedwith RNA
form squamous cells, bacteria and food residues, which may decrease the sensi-
tivity of the specifıc gene expression ofHTN3 andCA6.Once established how to
best collect and protect saliva for the extraction of nucleic acids originated from
the salivary glands, we anticipate accelerating the path to clinically highly de-
manded kits for the surveillance of salivary gland cancer patients. We plan to
prospectively collect samples from Salivary gland tumor patients with the cho-
sen method and evaluate tumor related markers. The detection of tumor mark-
ers in bodily fluids will open a new avenue for the diagnosis and the clinical
management of patients with this type of tumor.Moreover, our work creates the
possibility of a liquid biopsy-based detection of several disease-specifıc altera-
tions identifıed in different types of salivary gland tumors.
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#735 HER2 protein quantifıcation in multiple cancer indications identi-
fıes candidates for HER2 targeted therapies. Shankar Sellappan,1 Sarit
Schwartz,1 Ellen Wertheimer,1 Fabiola Cecchi,1 Steven W. Mamus,2 Daniel VT
Catenacci,3 Todd Hembrough1. 1NantOmics, Rockville, MD; 2Cancer Center of
Sarasota-Manatee, Sarasota, FL; 3University of Chicago, Chicago, IL.
Background: Anti-HER2 therapy in cancer indications other than breast and
gastric cancers is the subject of ongoing clinical trials. We previously used mass
spectrometry to identify HER2 protein expression level cutoffs that correlate
with standard measures of HER2 positivity (740 and 750 amol/g in breast and
gastric cancers, respectively). These studies also demonstrated that trastu-
zumab-treated patients whose tumors express high levels of HER2 (	 2200 and
	 1825 amol/g in breast and gastric cancers, respectively) survived much lon-
ger than patients with lower HER2 levels. We hypothesized that targeted pro-
teomics would reveal high HER2 levels in indications other than breast and
gastric cancers, thus identifying patients likely to benefıt from anti-HER2 ther-
apy. Methods: We summarized results from samples processed in our CAP/
CLIA-certifıed laboratory. Tumor areas fromFFPE tissue blocks (N3828) rep-
resenting multiple cancer indications were marked by a pathologist,
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microdissected, and solubilized to tryptic peptides. In each liquefıed tumor sam-
ple, HER2 and other protein targets were quantifıed with mass spectrometry-
based proteomic analysis. Results: HER2 superexpression ( 2200 amol/g)
was found in 0.64% (12/1891) of patients with non-breast, non-gastroesopha-
geal cancers. Among indications with 50 patients tested, the highest rates of
HER2 superexpression were in gynecological cancers (3/124; 2.4%) and bladder
cancer (1/51; 2.0%). Treatment and outcome data are largely unavailable, but we
are aware of 3 anecdotes: In a 74-year-oldmale with invasive adenocarcinoma of
the gallbladder who had disease progression on gemcitabine cisplatin, pro-
teomic testing found high HER2 protein expression (3105 amol/g). The pa-
tient responded to trastuzumab FOLFIRI for 5 months. In a uterine cancer
patient whose HER2 status was equivocal by genomic analysis, proteomics
found high HER2 expression (4995 amol/g). Proteomics also revealed the ab-
sence of a resistance marker for taxane (TUBB3) and high levels of the response
marker for antifolate agents (FRalpha  10500 amol/g). The patient re-
sponded to trastuzumab taxol for 9months before developing resistance and
responding to trastuzumab antifolate. Lastly, a cervical cancer patient whose
disease had progressed on chemotherapy showedHER2 superexpression (11322
amol/g). She was treated with anti-HER2 combinations for  12 months.
Conclusions: Patients with high HER2 protein expression as measured by tar-
geted mass spectrometry in multiple cancer types have benefıtted from anti-
HER2 therapy. Only small numbers of patients with non-breast, non-gastric
tumors have HER2 protein levels indicative of survival benefıt from anti-HER2
therapy.However,multiplexed targeted proteomics offers simultaneous, precise
quantifıcation of other biomarkers (eg, ERCC1, TUBB3, FRalpha) to guide ther-
apy selection for multiple cancer types.
#736 Cell lineage-oriented clinical sequencing unveils distinct clonal on-
togeny of acute myeloid leukemia with myelodysplasia-related changes. Ka-
zuaki Yokoyama,1 Nozomi Yusa,2 Sousuke Nakamura,3 Mika Ito,3 Asako Ko-
bayashi,3 Masayuki Kobayashi,3 Rika Kasajima,4 Hiroaki Yui,4 Eigo Shimizu,4
AtushiNiida,4 RuiYamaguti,4 Tsuneo Ikenoue,5 Seiya Imoto,6 Yoichi Frukawa,2
Satoru Miyano,7 Arinobu Tojo8. 1Department of Hematology/Oncology, Re-
search Hospital, The Institute of Medical Science, The University of Tokyo (IM-
SUT), Tokyo, Japan; 2Department of Applied Genomics, Research Hospital, IM-
SUT, Japan; 3Division ofMolecular Therapy, Advanced ResearchCenter, IMSUT,
Japan; 4Human Genome Center, ISMUT, Japan; 5Division of Clinical Genome
Research, ISMUT, Japan; 6Health Intelligence Center, IMSUT, Japan; 7Human
Genome Center, ISMUT, Tokyo, Japan; 8Department of Hematology/Oncology,
Research Hospital, IMSUT, Japan.
Acutemyeloid leukemia (AML) is characterized by unregulated clonal expan-
sion and maturation arrest of myeloid committed progenitors (MP). AML gen-
erally represents de novo onset or evolves from preceding myelodysplastic syn-
drome (MDS), which is defıned by refractory cytopenias, clonal hematopoiesis,
and/or multi-lineage dysplasia. The WHO classifıcation 2008 includes this en-
tity as “AMLwithmyelodysplasia-related changes (AML-MRC)”, and currently,
diagnosis of AML-MRC is based on either previous history of MDS, multi-
lineage dysplasia, or MDS-related cytogenetic abnormality. However, AML-
MRC often represents de novo onset without these MDS-compatible clinical
features. Considering that AML-MRC exhibits rather poor prognosis with re-
fractoriness to conventional chemotherapy against AML, more accurate and
objective diagnostic approach is requisite to unveil hidden “MDS signatures” in
patientswith apparently de novoAML.A certain set of genemutations is specifıc
and recurrent in MDS. Given the pre-existing “MDS signatures”, the founder
gene mutations might be detected in not only blast cells but also neutrophils
and/or T cells in AML-MRC. To test this hypothesis, we performed FACS sort-
ing of neutrophils, T cells, and blasts fractions, respectively, followed by muta-
tion screening using targeted deep sequencing, namely, cell lineage-oriented
sequencing (CLS). Genomic DNA both from each cell fraction and buccal swab
was subjected to screening mutations in 54 genes which are tightly involved in
MDS and AML. Pair-end deep sequencing was performed on an Illumina
MiSeq, using library prepared by TruSight Myeloid Panel (Illumina, San Diego,
CA). Bioinformatic analysis was performed by in-house pipeline.We performed
CLS of clinically diagnosed AML-MRC (n7), suspected AML-MRC (n2), de
novo AML (AML with t(15;17) or AML with inv16, n4), MDS (RAEB-1 and
RAEB-II, n3), and familial MDS (n1). As expected, in a familial MDS case,
overlapping germline RUNX1 driver mutation was demonstrated in granulo-
cytes, blast cells and T cells, supporting that it would be originated from a he-
matopoietic stem cell. Notably, inMDS, AML-MRC, and suspected AML-MRC
cases with no germ-line mutations, the founder mutations present in neutro-
phils were also retained in the AML blast cells, irrespective of a history of MDS,
suggesting that these are derived from a myeloid progenitor cell. In marked
contrast, there were no overlapping driver mutations between blast cell and
neutrophil fractions in de novo AML characterized by recurrent chromosomal
abnormalities. In summary, CLS revealed that founder mutations are shared by
neutrophils and AML blast cells in AML-MRC, but not in de novo AML. Al-
though our data should be validated in a larger cohort of AML cases, CLS is a
promising approach to molecular diagnosis of latent AML-MRC which require
distinct therapeutic options from de novo AML.
#737 Signfıcant DLX4 expression in inflammatory breast cancer tumors
from African American patients. Jaehong Jeong,1 Tammey Naab,2 Martin
Ongkeko,1 Kepher Makambi,1 Farhan A. Khan,2 Jan Blancato1. 1Georgetown
Univ., Washington, DC; 2Howard Univ., Washington, DC.
Purpose: To examine protein expression characteristics of Distal-less homeo-
box4 (DLX4) in inflammatory breast cancer (IBC) cases from anAfrican-Amer-
ican population to determine if a) DLX4 over-expression occurs in IBC vs. nor-
mal mammary tissue and b) over-expression is associated with clinico-
pathologic features such as ER, PR, HER2. Experimental Design: Twenty nine
blocks of formalin-fıxed paraffın-embedded (FFPE) tissues fromwell-character-
ized human IBC cases were used for immuno-histochemical staining (IHC).
Tumor tissues were fromAfrican American subjects seen at Howard University
Hospital. Normal breast tissues from 30 mammoplasties were controls. IHC
results were assigned intensity and percentage scores based upon intensity of
positive staining and % of stained cells. Percentage scores were assigned as 0, 1
(0%-25%), 2 (26%-50%), 3 (51%-75%) or 4 (76%-100%) and intensity scores
were assigned 0, 1, 2 or 3. For the analysis of the IHC, a percentage score of
3 or 4was considered high and an intensity score of 2 or 3was categorized as
high. Chi-square and Fisher’s exact tests were used for analysis. Results: The
staining pattern for the categorized cohort in which 82.8% (24 out of 29) of IBC
cases showed high percentages of positive cells staining for DLX4 protein, while
40.0% (12 out of 30) normal breast tissues demonstrated DLX4 expression
(P0.001). In terms of staining intensity, 75.9% (22 out of 29) of IBC cases
showed a high level of intensity, compared to 20.0% (6 out of 30) of normal
breast tissues (P0.001). In terms of the association between breast cancer char-
acteristics and IHC staining, intensity of DLX4 was higher in HER2- (87.0%, 20
out of 23) than HER2 (33.3%, 2 out of 6; P0.018). Other associations were
not statistically signifıcant in this pilot study. Conclusions: DLX4 expression is
signifıcantly higher in this pilot study of IBC cases from AA patients than in
normal breast tissue cases. In addition, HER2- is associated with high intensity
of DLX4 expression in IBC.
Associations DLX4 protein expression (IHC) In IBC and normal breast tissues
Low High P-value
Percent positivity n (%) n (%)
Controls (n30) 18 (60.0) 12 (40.0) 0.001
IBCs (n29) 5 (17.2) 24 (82.8)
Staining intensity n (%) n (%)
Controls (n30) 24 (80.0) 6 (20.0) 0.001
IBCs (n29) 7 (24.1) 22 (75.9)
#738 Highly multiplexed and precisely calibrated reference materials for
copy number variation detection.Catherine Huang, Yves Konigshofer, Jessica
Dickens, Bharathi Anekella. Seracare Life Sciences, Gaithersburg, MD.
Introduction: Genomic instability is a hallmark of cancer, and copy number
variation (CNV), including gene duplication and deletion, can be a key driver of
oncogenesis. Detection of CNV is needed for personalized treatment, and may
involve microarray analysis or Next Generation Sequencing. Often, DNA from
patient-derived cell lines is used as positive control material in these assays.
However, these materials are often poorly characterized, may change over time,
and have additional confounding genetic alterations. Here we describe the de-
velopment of new reference materials that are highly characterized by digital
PCR and can aid in the validation and calibration of new diagnostic assays for
CNV. Methods: The GM24385 reference cell line has been extensively charac-
terized by the Genome in a Bottle project1 and originates from a participant in
the Personal GenomeProject. DNA from this cell line was used tomake a library
of full-length gene inserts. The library had 12X coverage of the GM24385
genome and an average insert size of135Kb. PCR based screening was used to
identify and isolate full lengthMYC, FGFR3 and ERBB2 genes. Next Generation
Sequencing, using IlluminaNextera library preparation kits and aMiSeq instru-
ment, was used to verify the gene of interest. The genomicDNAand gene inserts
were then formulated into reference materials, in purifıed DNA format to am-
plify the copy numbers of these key genes. Digital PCR was used to control the
mixing and verify the number of copies of genes and/or mutations within the
referencematerial. Results: The sequence confırmed genes were formulated into
GM24385 genomic DNA at levels consistent with 5X and 10X amplifıcation.
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Testing on the ArcherDx VariantPlex™ Solid Tumor Kit indicated that each
amplifıcation could be detected at the expected level. Conclusions: Highly char-
acterized and consistently manufactured reference materials for copy number
detection are currently lacking. The described SeraseqCNVReferenceMaterials
provide proof of concept for a biosynthetic, engineeredmaterial that uses digital
PCR as an orthologous reference method and provides a “ground truth” copy
number level for key oncogenes.
#739 Orthogonal validation of oncomine cfDNA panel data with digital
PCR using TaqMan Rare Mutation Assays. Vidya Venkatesh, Marion Laig,
Kamini Varma, Yanchun Li, Kelli Bramlett, Dalia Dhingra, Richard Chien.
Thermo Fisher Scientifıc, South San Francisco, CA.
The discovery of circulating tumor DNA (ctDNA) in the blood, urine and
other bodily fluids of cancer patients has led to a new type of non-invasive
method of characterizing cancer-causing mutations, the liquid biopsy. With
NGS technologies becoming increasingly sensitive, down to a 0.1% Limit of
Detection (LOD), they are rapidly gaining traction as a valid assay for cancer
genotyping and have potential to direct cancer treatment plans. The wide-angle
view provided by NGS panels, combined with dPCR’s zoomed-in precision de-
tection of DNA provide a comprehensive picture of a cancer’s genetic makeup.
By applying these complementary techniques at the appropriate time based on
the disease type and stage, cancer treatment will become quicker, more precise
and more cost-effective in the future. NGS and digital PCR together provide a
complete picture of the cancer genome. As part of our research, we wet-lab
tested a subset of RareMutation Assays corresponding to theOncomine cfDNA
panel for next generation sequencing. Synthetic plasmid (GeneArt) carrying the
mutation was spiked into wild-type genomic DNA to reflect a mutation rate of
0.1%. Wild-type genomic DNA was used as negative control. Thermal cycling
was performed according to protocol for digital PCR using theQuantStudio 3D.
In this study, we tested a pilot set of samples using AcroMetrix Oncology Hot-
spot Control and Horizon cfDNA Reference Standard with both NGS using
Oncomine cfDNA panel and digital PCR with Rare Mutation Assays. Compar-
ison of NGS and digital PCR results for the same sample showed excellent cor-
relation in the lowmutation range around 0.1%. This study confırms that digital
PCR using QuantStudio 3D and Rare Mutation Assays is effective as a method
for orthogonal validation of NGS data using the Oncomine cfDNA panel. Ad-
ditionally, TaqMan Rare Mutation Assays offer a sensitive and precise solution
for downstream mutation tracking over a time course. For Research Use Only.
Not for use in diagnostic procedures.
#740 Rapid detection of IDH1/2 mutations using RNaseH2 dependent,
multiplex quantitative PCR Assays. Yun Bao,1 Aymen Baig,2 Yu Wang,1 A.
John Iafrate,2 Caifu Chen,1 Darrell R. Borger2. 1Integrated DNA Technologies,
Redwood City, CA; 2Massachusetts General Hospital Cancer Center, Boston,MA.
Isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are enzymes that normally
catalyze the oxidative decarboxylation of isocitrate to -ketoglutarate during
glucosemetabolism.Heterozygousmutations in the IDH1 and IDH2 genes have
been identifıed in a specifıc subset of cancers. Mutations typically affect the
enzyme active sites at codon R132 in the IDH1 gene, and R140 or R172 in the
IDH2 gene. This confers neomorphic enzyme activity that produces the onco-
metabolite 2-hydroxyglutarate that is involved in cancer initiation and progres-
sion. The detection of IDH1/IDH2 mutations has important diagnostic, prog-
nostic, and therapeutic implications and testing for these variants is being
incorporated in clinical settings. In fact, the identifıcation of IDH1or IDH2 gene
mutations is now required for the classifıcation of tumors of the central nervous
system under the 2016 WHO guidelines. Therefore, there is a signifıcant need
for an IDH1 IDH2 test that can be performed in a rapid manner to support
clinical diagnosis and treatment decisions. A strategy utilizing allele-specifıc
quantitative PCR (qPCR) is well suited for evaluating a small number of hotspot
variants in IDH1 and IDH2 from clinical tissue samples in amatter of few hours.
Using RNase H2-dependent PCR (rhPCR) and a universal reporter system, we
have developed new multiplex qPCR assays that effectively discriminate be-
tween closely related sequences that differ by only a single nucleotide base at the
same position or adjacent position in a single tube reaction. In addition, the
rhPCR mechanism of the assays also greatly reduces the impact of primer-
primer interactions, further improving the multiplex capability of the assays.
During initial testing, specifıcity, accuracy, and sensitivity were evaluated. Mu-
tations present in patient samples at frequencies as low as 2% were identifıed
with high reproducibility. The assays have been tested across 49 patient samples
that included FFPE tissue, blood, and bonemarrow aspirate with results that are
concordant to those found using an orthogonal method of next generation se-
quencing. Our study showed that this assay provides a rapid method for detec-
tion of multiple IDH1 or IDH2 mutations in single rhPCR reactions with high
accuracy, specifıcity, and sensitivity.
#741 Rapid detection of necrosis in breast cancer with ex vivo and in situ
mass spectrometry analysis methods. Arash Zarrine-Afsar,1 Bindesh Shres-
tha,2 Alessandra Tata,1 Michael Woolman,1 Manuela Ventura,3 Nicholas Ber-
nards,1 Milan Ganguly,3 Howard Ginsberg,4 Jinzi Zheng,3 Emma Bluemke1.
1Techna Institute for the Advancement of Technology for Health, University
Health Network, Toronto, Ontario, Canada; 2Waters Corporation, Milford, MA;
3University Health Network, Toronto, Ontario, Canada; 4St. Michael’s Hospital,
Toronto, Ontario, Canada.
Necrosis is a form of cell death that is often associated with highly aggressive
forms of cancer, is of prognostic value in treatment planning. Mass Spectrome-
try (MS) is a highly sensitive analytic platform capable of providing a molecular
profıle of cancer on the basis of mass to charge (m/z) ratio of tissue constituent
molecules. MS analysis of ex vivo tissue slices frommetastatic murine xenograft
tumors from LM2-4 cell line with Desorption Electrospray Ionization Mass
Spectrometry (DESI-MS) allowed direct comparisons with histology images to
determine the molecular profıle of necrotic tissues. The necrotic tissue is char-
acterized by the presence of a ceramide absent from the viable cancer regions.
The spatial distribution of this ion fully correlated to necrotic areas from pathol-
ogy in additional independent tumor samples examined. The same ion was
detected from in situ necrotic tissue using tissue aerosols generated by hand-
held ablation probes coupled to evaporative ionization interface in only a few
seconds of sampling. These developments further establishMSas a novel tool for
rapid pathology that is highly complementary to current histology based meth-
ods widely used in characterization of cancer in both imaging mode (to provide
spatial information on cancer border) and profıling mode (to provide informa-
tion on cancer type and subtype); all based on unique molecular profıle associ-
ated with each cancer type and subtype. Current efforts in creating cancer mo-
lecular profıle libraries will facilitate translation.
#742 Comprehensive detection of all major classes of MET deregulation
by Anchored Multiplex PCR and next-generation sequencing. Brian A. Kud-
low,1 Josh Haimes,1 Marc Bessette,1 Namitha Manoj,1 Laura M. Griffın,1 Dan-
ielle Murphy,2 Robert Shoemaker,2 Jason Amsbaugh,1 Joshua Stahl1. 1Ar-
cherDX, Boulder, CO; 2Ignyta, San Diego, CA.
Introduction: Deregulation of the proto-oncogene, MET, confers an aggres-
sive phenotype in a variety of human cancers, promoting proliferation, invasive
growth and angiogenesis. MET deregulation can be driven by gene amplifıca-
tion, overexpression, exon 14 skipping, gene fusions and single nucleotide vari-
ants (SNVs), such as kinase-activating point mutations. MET is a target of in-
tensive drug development efforts, although the various mutated forms of MET
exhibit unique drug sensitivities. Therefore, detection of these mutations has an
important role in the development of drugs targetingMET, and has the potential
to guide treatments for cancers driven by MET deregulation. Next-generation
sequencing (NGS) enables comprehensive detection of all mutation types from
whole genomes and transcriptomes. However, low detection sensitivity, high
input requirement and high costs render these approaches impractical for rou-
tine detection of mutations from low-input clinical sample types.We developed
a targeted NGS assay based on Anchored Multiplex PCR (AMP™) to detect all
types of mutations driving MET deregulation from a single sample. Methods:
AMP only requires a single gene-specifıc primer for amplifıcation, enabling
open-ended capture of DNA and cDNA fragments for NGS-based detection of
known and unknown mutations. We developed AMP-based Archer® Variant-
Plex™ and FusionPlex® library preparation assays to detectmutations fromDNA
and RNA, respectively. AMP probes were designed to cover the MET gene for
detection of copy numbers variants (CNVs) and SNVs from DNA, and known
and novel fusions, exon skipping and expression levels from RNA. Results: We
show that the VariantPlex assay enables NGS-based detection of MET amplifı-
cations from DNA in concordance with FISH results. Further NGS analysis of
RNA from the same sample using the FusionPlex assay revealed the resulting
overexpression of MET. We also demonstrate that AMP-enabled open-ended
capture of cDNA fragments allows for reliable detection of exon 14 skipping in
FFPE samples and in cells, consistent with RT-PCR results. Parallel analysis of
DNA from the cell samples revealed splice site mutations that have been previ-
ously reported to drive exon 14 skipping. Furthermore, this open-ended capture
also permitted identifıcation of a novel GTF2I:MET gene fusion in a patient-
derived xenograft model. Finally, we detected an kinase-activating point muta-
tion inMET, p.Y1253D, by analysis of genomic DNAwith the VariantPlex NGS
assay. Conclusions: These results show that AMP-based VariantPlex and Fu-
sionPlex Assays enable comprehensive detection of multiple mutation types
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from low-input clinical sample types, such as FFPE specimens. As MET dereg-
ulation can be driven by many different genetic aberrations, this allows for
NGS-based characterization of MET deregulation from a single sample.
#743 Detection of TERT C228T and C250T promoter mutations in mela-
noma tumor and plasma samples using novel mutation-specifıc droplet dig-
ital PCR assays.Broderick Corless,1 Gregory Chang,1 SamanthaCooper,2Mah-
rukh Syeda,1 Iman Osman,1 George Karlin-Neumann,2 David Polsky1. 1New
York Univ. School of Medicine, New York, NY; 2Bio-Rad Laboratories, Pleasan-
ton, CA.
Purpose: Detecting mutations in the plasma of patients with solid tumors is
becoming a valuable method of diagnosing and monitoring cancer. Mutations
in 1 of 2 hot spots in the TERT promoter sequence are found in several cancers,
including up to 85% of melanomas and the majority of cases that lack BRAF or
NRASmutations (about one-third of melanomas). Due to the high G-C content
of the TERT promoter sequence these mutations can be diffıcult to detect using
NGS approaches. We developed novel droplet digital PCR (ddPCR) assays to
detect these 2 mutations with high sensitivity and specifıcity, and demonstrate
the application of these assays in melanoma clinical samples. Methods: Assays
were optimized using cell lines with Sanger sequencing-confırmed mutations:
glioblastoma A172 (C228T), and melanoma NYU12-126 (C250T). We varied
assay designs and amplifıcation conditions to optimize probe-based detection
using the Bio-RadQX-200 ddPCR system. Assay sensitivities and specifıcities at
variousDNA input levels were determined using serial dilutions with 3 replicate
wells for each condition. Sensitivity is defıned as the lowestmutant allele dilution
for which the confıdence interval did not overlap with that of the 0% mutant
wells.Weused normal and cancer-derivedDNAsources of different quality (e.g.
normal human DNA (Promega), cancer cell lines, plasma and FFPE-derived
DNAs) with and without the mutations, and compared the effıciency of detec-
tion of amplicons of 88, 113 and 163 base-pairs. We compared effıciencies to
assays of similar size for RPP30, a housekeeping gene. Patient-matched meta-
static melanoma tumors and plasma samples were analyzed to explore the clin-
ical utility of these assays. Results: The assays showed greater sensitivity when
higher amounts of DNAwere analyzed. For C228T the limit of detection (LOD)
of the mutant allele was 1%, 0.25% and 0.1% for 6.6ng/well, 33ng/well and
66ng/well respectively; for C250T the LODs were 0.25%, 0.05% and 0.05% re-
spectively. Using normal human DNA, the effıciency of the TERT assays aver-
aged approximately 90% of that for RPP30 across assays of similar size, and no
decrease in assay effıciency was observed as amplicon length increased. In con-
trast, whereas amplicon size had only a modest effect on assay effıciency in
plasma cfDNA, it gave amore pronounced effect on FFPEDNA’s, decreasing to
38% for the 163bp amplicon. We observed 100% concordance between TERT
mutation detection by SNaPshot and ddPCR in 10 FFPE tumor samples, and in
plasma samples from 4 metastatic melanoma patients with matching tumor
samples. Conclusion: We developed robust ddPCR assays to detect TERT pro-
moter mutations with high sensitivity and specifıcity. Mutated TERT DNA can
be detected and quantitated in the plasma of patients withmetastaticmelanoma,
and is likely to be present in the plasma of other cancer patients in whom TERT
mutations occur.
#744 ctDNA use in molecular diagnostics. Gilda Magliacane, Greta
Grassini, Ilaria Francaviglia, Elena DalCin, Chiara Lazzari, Alessandra Bulotta,
Monika Ducceschi, Vanesa Gregorc, Lorenza Pecciarini, Claudio Doglioni,Ma-
ria Giulia Cangi. San Raffaele Scientifıc Inst., Milano, Italy.
The analysis of circulating cell-free tumor DNA (ctDNA), which can be ob-
tained from plasma by non-invasive procedures, is expected to provide useful
biomarkers in themanagement of non-small-cell lung cancer (NSCLC) patients.
Indeed, several studies have assessed ctDNA prognostic and predictive value as
source of key data for therapeutic targets and drug resistance in carcinoma
patients. The expanding number of targeted therapeutics for NSCLC always
expects a real-time wider tumor genotyping, and the use of ctDNA as either a
complement or an alternative to tumor tissue DNA (ttDNA) could be a valid
option for Next-Generation Sequencing (NGS) of key cancer genes. However,
isolation and enrichment of ctDNA is a big challenge because of its high degree
of fragmentation and its low concentration against the normally occurring back-
ground of cell-free DNA derived from healthy cells. Therefore standardized
methods for ctDNA extraction and analysis are crucial aspects in the setting-up
of a molecular diagnostic approach. In this study we aimed to evaluate the
ctDNA use for molecular profıling, also analyzing the impact of both pre-ana-
lytical and analytical variables on DNA yield and mutation detection. Matched
ttDNA and ctDNA from 30 NSCLC patients were extracted, quantifıed and
quality-controlled, and then investigated by different standard methods (real-
time PCR, digital PCR, Mass Spectrometry genotyping) for EGFR, KRAS,
BRAF, PIK3CA status. Mutational screening of ctDNA samples by IonTorrent
NGS (Oncomine™ Lung cfDNAAssay, ThermoFisher) was also performed. Fur-
ther, we extended ctDNA evaluation to additional 30 lung cancer patients with
no available tumor sample. We found that cell free DNA concentration in
plasma correlated with both stage and number of metastatic sites. Analyzing
matched ttDNA and ctDNA by standard methods, we identifıed mutations in
EGFR,KRAS, PIK3CAgenes, with an overall concordance of 77%. Interestingly,
Oncomine Lung cfDNA assay detected these same mutations with the same
allelic frequency of standard methods; mutations in TP53 and ALK genes were
also found. In the 30 patients with no available tumor sample, we found EGFR
(10%) andKRAS (7%)mutations on ctDNAby standardmethods; NGS analysis
is under evaluation. This study evaluated the use of multiple different methods
to detect mutations in NSCLC and showed that ctDNA can be a feasible option
for clinical monitoring of lung cancers, including for those patients who cannot
undergo invasive diagnostic procedures, due to either comorbidities or absence
of biopsable tumor lesions.
#745 Interleukin-13 conjugated quantum dots to identify glioma initiat-
ing cells and exosomes.Achuthamangalam B. Madhankumar,1 Oliver Mrowc-
zynski,1 Brad Zacharia,1 Michael Glantz,1 Lichong Xu,1 Becky Webb,1 Christo-
pher Siedlecki,1 Akiva Mintz,2 James R. Connor1. 1Penn State Univ. College of
Medicine, Hershey, PA; 2Wake Forest University Baptist Medical Center, Win-
ston Salem, NC.
High grade brain tumors like glioblastoma multiforme (GBM) and certain
other brainmetastatic cancers possess high tumor invasive and infıltrating prop-
erties making them harder to detect. Identifıcation of cancer stem cells and
exosomes secreted by them in the biofluids like cerebrospinal fluid (CSF) will be
an ideal way of detecting the presence of residual cancer after therapy. In the
current approach, a ligand conjugated quantum dot (QD) was utilized to spe-
cifıcally label the cancer stem cells and exosomes to identify the presence of
IL13R2 a tumor invasive marker. Human glioma initiating cells were cultured
in adherent form and were exposed to interleukin-13 conjugated quantum dots
(IL13QD), which binds the glioma initiating cells expressing IL13R2 receptor.
Similarly the exosomes isolated from cancer stem cell condition media and CSF
was briefly incubated with IL13QD, before analyzing their complexing pattern.
Exosomes that were isolated from glioma stem cells and patients CSF were
demonstrated to express IL13R2 receptor. Fluorescent microscopy, transmis-
sion electron microscopy and flow cytometry were performed on the exosomes
after complexing with IL13QD. IL13QD was demonstrated to specifıcally bind
glioma stem cells both in the monolayer and spheroid culture. The binding
affınity of the exosomes to the quantum dots were quantitatively and qualita-
tively confırmed by atomic force microscopy (AFM). The morphology and size
of exosomes before and after complexing with exosomes were confırmed by
electronmicroscopy and AFM. The density plot from the flow cytometry exper-
iments with IL13QD-exosomes complex indicates a possibility to identify the
tumor associated exosomes. Our experiment infers that tumor targeted quan-
tum dots can selectively bind with glioma stem cells and extracellular vesicles
(exosomes) that are secreted by cancer cells. This binding profıle could be uti-
lized to identify the expression of certain tumor promoting receptors and anti-
gens on the surface of exosomes present in the CSF and cancer stem cells from
the glioma patients. Experiments are in progress to identify the tumor initiating
cells in an orthotopic mouse glioma tumormodel after intravenous administra-
tion of wild type IL13 and certain high affınity mutated IL13 conjugated quan-
tum dots, by non-invasive way.
#746 TaqManRareMutationAssays targeting theTERTpromoter region.
Marion Laig, Kamini Varma, Vidya Venkatesh. Thermo Fisher Scientifıc Inc.,
South San Francisco, CA.
The enzyme Telomerase maintains telomeres at the ends of chromosomes.
The Telomerase Reverse Transcriptase (TERT) gene codes for the enzyme’s
catalytic domain and is not expressed in normal somatic cells. As a consequence,
normal cells acquire senescence by shortening of their telomeres during cell
division and eventually undergo apoptosis. In contrast to normal somatic cells,
expression of TERT is reinstated in cancer cells causing escape from senescence
and apoptosis by maintaining the telomeres. It has recently been shown that
mutations in the TERT promoter region play a key role in regulating and rein-
statingTERTexpression. 90%of cancers carry amutation in theTERTpromoter
region. Mutations like C228T and C250T create new binding site for the E26
transformation-specifıc (ETS) transcription factor that regulates TERT expres-
sion. Experimental evidence showed that the ETS factor GA-binding protein,
alpha subunit (GABPA) binds to the de novo ETS motif and activates TERT
transcription in cancer cells. We undertook a project designing TaqMan Rare
Mutation assays addressing mutations in the TERT promoter. These assays are
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TaqMan SNP Genotyping assays that are optimized for use in digital PCR with
theAppliedBiosystemsQuantStudio 3D. In digital PCR, partitioning the sample
into many individual reaction wells facilitates detection and quantifıcation of
rare mutant alleles. TaqMan SNP Genotyping Assays ensure reliable discrimi-
nation of mutant and wild-type allele. This will enable easy and sensitive detec-
tion of TERT promoter mutations in cancer research samples. These assays are
suitable for detection in liquid biopsy applications with cell free DNA (cfDNA).
Assay design proved to be challenging due to high GC content and repetitive
elements in this region of the TERT gene and required varying both the assay
design and experimental cycling conditions. Template for wet-lab testing was
synthetic plasmid carrying the mutation spiked into wild-type genomic DNA
and wild-type genomic DNA control. The result was a TaqMan Rare Mutation
assay detecting the C228T mutation in the TERT promoter region. We showed
that designing TaqMan Rare Mutation Assays for digital PCR is feasible for the
challenging TERT promoter region. Work addressing additional mutations in
this region is ongoing. For Research Use Only. Not for use in diagnostic proce-
dures.
#747 An improved fıxative for histomorphology, recovery of nuclic acids
and proteins. Stephen M. Hewitt,1 Joon-Yong Chung,1 Candice Perry,1 Kris
Ylaya,1 William M-A Smith,1 Robert A. Star2. 1National Cancer Inst., Bethesda,
MD; 2National Institute of Diabetes andDigestive andKidneyDiseases, Bethesda,
MD.
Neutral Buffered Formalin (NBF) has been the primary diagnostic fıxative for
histopathology for nearly a century. The limitations of NBF are well known,
especially with reference to the analysis of RNA and proteins. Alternative fıxa-
tives have been proposed, but not been widely adopted. Recently, the US Envi-
ronmental Protection Agency (EPA) classifıed formaldehyde as a carcinogen,
further tilting the balance away from the continued use of NBF. We recently
described a fıxative based on 70% ethanol and phosphate buffered saline, called
BE70. Using BE70 as the base fıxative, we have developed a modular fıxative in
which different chemicals can be supplemented for “fıt for purpose” applica-
tions. The addition of guanidinium salts to BE70 , termed BE70G results in a
fıxative in which both proteins and nucleic acids are improved in quantity and
quality after extraction from the paraffın block. The guanidinium replaces non-
freezable water, and prevents hydrolysis and oxidation of the biomolecules. His-
tomorphology is not disrupted at lower concentrations, with only alterations of
hematoxylin intensity at higher concentrations. Studies are underway to evalu-
ate the stability of RNA and protein in the tissue block as well as on cut sections.
This fıxative, BE70G has the potential to address a number of challenges facing
the development of precision biomarkers, while preserving histomorphology,
and improving the safety of pathology staff. Other formulations are currently
being evaluated thatmay support applications for cytology and electronmicros-
copy. The goal is a well characterized fıxative, in which modifıcations to the
chemistry are defıned and can be applied to obtain the optimal pathology spec-
imen for both histomorphologic and molecular analysis.
#748 A rapid and accurate nucleic acid amplifıcation and detection
method for KRAS mutation testing in colorectal cancer specimens. Choong
Eun Jin, Seung-Seop Yeom, Yong Shin, Seok-Byung Lim. University of Ulsan
College of Medicine, Seoul, Republic of Korea.
Colorectal cancer (CRC) is one of themost common type of cancers bothmen
and women in worldwide. Fortunately, overall death rates of CRC have been
decreasing for the last two decades due to the improvement of screening test
assays that detect early-stage cancer and pre-cancerous polyps. Nevertheless, the
most common treatment for CRC is surgery, because it may completely elimi-
nate the cancer region. In case of the cancer with systemic metastasis, chemo-
therapy is required before or after surgery for primary or metastatic lesions.
Among the regimens for the chemotherapy, both monoclonal antibodies (Ce-
tuximab and Pantitumumab) against the epidermal growth factor receptor have
been shown to improve survival for only patients with lack of RAS mutations.
Thus, the KRAS gene mutations (codons 12 and 13) in CRC patients have been
extensively studied as a strong negative predictive biomarker to indicate
whether a CRC patient responds to the treatment. Therefore, testing the KRAS
mutational status of tumor samples is becoming an essential tool for managing
patients with CRCs. Although a myriad of nucleic acid testing methods have
been developed to analyze the mutation status in the key regions of the KRAS
gene of CRC, several obstacles still remain related to low sensitivity, time con-
suming, and required large instruments including thermal cyclers. Here, we
present a novel nucleic acid amplifıcation and detection method for KRAS mu-
tations (G12D and G13D) testing that enable rapid and accurate detection. This
method is based on combination of isothermal DNA amplifıcation method and
bio-photonic silicon sensor that can be detected themutations in a label-free and
real-time manner. The proposed method can detect the mutant cell present at
1% in amixture of wild type cells, while both PCR and sequencing can detect the
mutations in a sample containing approximately 30% of mutant cells. We used
60 tissue samples from CRC patients (22 samples with G12D mutations, 23
samples withG13Dmutation, and 15 samples with nomutation) to compare the
clinical utility of three methods including PCR, Sanger sequencing and the pro-
posed method. The proposed method with both G12D and G13D showed a
value of 100% and 100% for sensitivity and specifıcity, respectively. One the
other hand, the sensitivity and specifıcity of PCR (90.5% and 100%) and se-
quencing (95% and 100%) were lower than that of the proposedmethod. There-
fore, the proposed method was found to be a rapid ( 30 min), highly sensitive
and specifıc method for KRAS mutation testing. We believe that this rapid and
accurate method will enable proper treatment for CRC patients.
#749 Novel ALK specifıc mRNA in situ hybridization assay for non-small
cell lung carcinoma. Noriko Hirai, Takaaki Sasaki, Yoshinobu Ohsaki. Asa-
hikawa Medical Univ., Asahikawa, Japan.
A recent technical advance in the mRNA in situ hybridization (mRNA-ISH)
assay provides simultaneous signal amplifıcation and background suppression
with a unique probe design to achieve singlemolecule visualization.We assessed
the utility of the mRNA-ISH assay as a diagnostic tool to detect anaplastic lym-
phoma receptor tyrosine kinase (ALK)mRNA innon-small cell lung carcinoma.
We compared the mRNA-ISH assay with immunohistochemistry (IHC) and
fluorescence in situ hybridization (FISH). The study included 279 surgically
resected lung adenocarcinomas and 44 transbronchial biopsied (TBB) adeno-
carcinomas. mRNA-ISH was conducted using the RNAscope 2.0 system which
includes pre-designed detection probes for the tyrosine kinase domain of ALK
mRNA. IHC was conducted on all of the 323 samples using ALK-specifıc anti-
bodies. mRNA-ISHwas performed on 279 surgical samples and 6 TBB samples.
Break-apart FISHwas used to assess cases thatweremRNA-ISHor IHCpositive.
ALK protein expression was detected in 11/279 (3.9%) specimens. ALK mRNA
was also detected bymRNA-ISH in these cases, and 9 of the 11 specimens (81%),
were also positive by ALK FISH. Using the IHC results as a reference, the sensi-
tivity and specifıcity of mRNA-ISH was 100%. In the TBB cohort, ALK protein
expression was observed in 3/44 (6.8%) of specimens, in which ALK mRNA
expression was also detected. ALKmRNA-ISH data were highly correlated with
the IHC data, and ALK mRNA-ISH was able to identify every FISH-positive
sample.We conclude that mRNA-ISH could play an alternative or complemen-
tary role in ALK genetic diagnosis in NSCLC.
#750 Detection of mutations in single circulating tumor cells using
MALDI-TOF mass spectrometry. Jackie L. Stilwell,1 Ryan T. Birse,2 Arturo
Ramirez,1 Melinda Duplessis,1 Brennan Enright,1 Darryl Irwin,2 Eric Kaldjian1.
1RareCyte, Inc., Seattle, WA; 2Agena Bioscience, Inc., San Diego, CA.
Background: As cancer therapeutics are increasingly selected based uponmo-
lecular genetic information, having reliable, accurate, rapid and inexpensive
methods formutational analysis are extremely desirable. Circulating tumor cells
(CTCs) allow non-invasive “liquid biopsy” access to intact cells for molecular
analysis. Here we demonstrate the successful detection of mutations in model
CTCs individually isolated from blood (AccuCyte® - CyteFinder® system, Rare-
Cyte) using MALDI-TOF Mass Spectrometry (MassARRAY, Agena Biosci-
ence). Methods: Breast (MDA-MD-231) and lung (NCI-H1975) cancer cells
with a set of known mutations were spiked into blood and processed by Ac-
cuCyte onto microscope slides and stained on an automated immunostainer.
Slides were imaged using the CyteFinder digital fluorescence scanning micro-
scope andmCTCs were identifıed by positive nuclear, EpCAM, and cytokeratin
staining, and negative CD45 staining. mCTCs and white blood cell (WBC) neg-
ative controls were picked from the slides and put into PCR tubes using the
CytePicker® module. DNA from individual or small pools of cells (3-5) was
amplifıed using the PicoPLEX® (Rubicon) whole genome amplifıcation (WGA)
kit; alternatively cells were lysed and directly entered into the ensuing iPLEX®
Pro workflow. Specifıc regions surrounding 5 different mutations in each of the
mCTC lines were amplifıed from the WGA product or the lysed cells and the
products were detected and scored for themutations using a single PCR reaction
iPLEX® Pro panel that includes a combination of 10 common lung and breast
cancer mutations using the MassARRAY® platform. Results: Five point muta-
tions in four different genes (CDKN2A, EGFR, PIK3CA, and TP3) were mea-
sured in the NCI-H1975 lines and four point mutations in four genes (BRAF,
KRAS,NF2, andTP53) and a deletion in one gene (CDKN2A)weremeasured in
the MDA-MB-231 cells by iPLEX® Pro chemistry on the MassARRAY® system.
All mutations were accurately detected in theWGA single and pooled cell sam-
ples andmost were also detected in cells that did not undergoWGA before PCR
with with iPLEX Pro panel. Allelic frequency observed was consistent with
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known zygosity of the mutation. Conclusions: MassARRAY successfully de-
tected mutations in single model CTCs that were individually picked from a
blood sample processed by the AccuCyte - CyteFinder system. Integrating CTC
isolation with MassARRAY may be a practical way to identify and monitor
known cancer mutations non-invasively.
#751 Characterization of STAT3 activation in human prostate cancer.
Marco A. De Velasco,1 Yuji Hatanaka,1 Yurie Kura,1 Naomi Ando,1 Kazuko
Sakai,1 Koichi Sugimoto,1 Masahiro Nozawa,1 Kazuhiro Yoshimura,1 Kazuhiro
Yoshikawa,2 Kazuto Nishio,1 Hirotsugu Uemura1. 1Kindai University Faculty of
Medicine, Osaka-Sayama, Japan; 2Aichi Medical University, Nagakute, Japan.
Signal transducers and activators of transcription (STATs) were initially as-
sociatedwith cytokine signal transductionpathways but are nowalso recognized
as key modulators of key survival processes in in various cancers. Activation of
STAT3 occurs by the binding of various cytokines to its receptors leading to the
activation of the JAK/ STAT3 signaling pathway. Interleukin-6 (IL-6) has been
implicated in regulating growth of variousmalignant tumors. Activated IL-6 has
also been shown to be elevated in the sera from patients withmetastatic prostate
cancer, and persistent activation of STAT3 is a common feature. To better char-
acterize the potential role of JAK/STAT3 as a therapeutic target for advanced
prostate cancer, we examined expression patterns of activated STAT3 in 111
cases of localized prostate cancer from patients who underwent radical prosta-
tectomy. Association studies were conducted with clinicopathological charac-
teristics and biochemical recurrence. We also analyzed the expression of IL-6/
KAK/STAT3 genes from RNA-sequencing data form the Cancer Genome Atlas
Prostate Adenocarcinoma (TCGA-PRAD) data set and its association to long-
term outcomes. Immunohistochemical analysis revealed that 11.7%, 42.3% and
45.9% of patients had high, moderate or low/negative expression of phosphor-
ylated-STAT3 (Tyr705). Cancerous glands tended to have higher STAT3 ex-
pression compared to paired normal adjacent tissue, P0.088. No correlations
were observed between STAT3 expression and clinicopathological parameters.
Patients with moderate-high p-STAT3 expression tended to experience shorter
times to biochemical recurrence (median time, 15 months) compared to pa-
tients with low/negative STAT3 activity, (median time to recurrence not
reached, P0.064). Cluster analysis suggested a trend for decreased disease-free
survival for patientswith high IL-6/KAK/STAT3gene expression signature.Our
data suggests an association between STAT3 signaling and prostate cancer re-
currence and provides clinical evidence to support JAK/STAT3 as a potential
therapeutic target for patients with advanced prostate cancer.
#752 Evaluation of VENTANA BenchMark ULTRA and Roche cobas® z
480 analyzer for detection of EGFR mutations. Lorraine Stewart, Chunyan
Liu, Judith Pugh, Heather Gustafson. Ventana Medical Systems, Tucson, AZ.
Research has shownnon-small cell lung cancer (NSCLC) is themost common
type of lung cancer, accounting for 85% cases. Exon 19 deletion and L858R
mutation in exon 21 account for approximately 90% of EGFR mutations in
adenocarcinoma NSCLC1. Accuracy and sensitivity in detection of these mark-
ers aids the selection of patients with NSCLC for therapy with an EGFR tyrosine
kinase inhibitor (TKI). This study demonstrates how validated Immunohisto-
chemistry (IHC) and real-time PCR testing can be used to aid one another in
detection of epidermal growth factor receptor (EGFR) mutations in formalin-
fıxed, paraffın embedded biopsies in our CAP/CLIA laboratory. Evaluation of
IHC detection was completed on the VENTANA BenchMark ULTRA Auto-
mated IHC/ISH slide stainer and PCR testing was performed using the Roche
cobas® z 480 analyzer. The IHC diagnostic markers selected were the two most
common EGFR mutations, E746-A750del (SP111) and L858R (SP125). Sample
preparation and real-time PCR testing was done using the cobas® DNA Sample
Preparation Kit and cobas® EGFR Mutation Test v2 utilizing a custom, auto-
mated plate preparation program on the Perkin Elmer NGS Express Platform.
Analytical data from the BenchMark ULTRA platform staining and the cobas® z
480 analyzer correlated in the majority cases. Out of 32 specimens tested, we
observed a 100% concordance between IHC and PCR for L858R exon 21 muta-
tion, whereas EGFR exon 19 deletion concordance between IHC and PCR was
90%. This decrease in concordance was due to 3 specimens with indeterminate
IHC staining results with weak staining in a small tumor area. Use of a custom
automated workflow for PCR plate preparation demonstrated successful facili-
tation of sample preparation and tracking. Evaluation of results indicate that not
only is10% tumor content important for detection of mutations via PCR (as
directed by the IVD package insert), but heterogeneity within the tumor can
further decrease sensitivity of PCR. However weak or low IHC staining in only
small areas of the tumor may prove to have less clinical relevance. For the most
comprehensive results, IHC staining in addition to molecular testing provides
better characterization of tumor profıles. Preliminary results suggest that auto-
mated dissection of tumor with the Roche Automated Dissection instrument
prior to PCR increases sensitivity. In conclusion, IHC and real-time PCR should
be used together to detect not only the array of mutation available in the PCR
test, but also to confırm the two most common mutations by IHC and increase
sensitivity of testingwhichmay be strongly impacted by heterogeneity. 1. -Marc
Ladanyi andWilliam Pao: Lung adenocarcinoma: guiding EGFR-targeted ther-
apy and beyond. Modern Pathology (2008)21, S16-s22; doi:10.1038/mod-
pathol.3801018.
#753 Human epidermal growth receptor-2 immunohistochemistry in gas-
tric cancer. Babatunde M. Duduyemi,1 Mary Y. Afıhene,1 Emmanuel A. Asia-
mah2. 1Kwame Nkrumah University of Science and Technology, Kumasi, Ghana;
2Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Introduction:Gastric cancer is the secondmost commonGI cancers and third
leading cause of cancer-related deaths worldwide. In Ghana, gastric cancer con-
tributes signifıcantly to cancer morbidity and mortality. The recent develop-
ment on the benefıt of targeted therapy in the management of gastric cancer
using HER-2 monoclonal antibody in combination with chemotherapy has
greatly improved the overall survival of patients. This study therefore aims at
determining the frequency of Her-2 over-expression in gastric carcinomas in
Kumasi, Ghana and comparing with other prognostic factors. Methodology:
Demographic data and histological diagnosis were retrieved from the surgical
day book of the Department of Pathology, Komfo Anokye Teaching Hospital,
Kumasi. The slides were retrieved and reviewed to confırm diagnosis, grading
and classifıcation of gastric cancer. Immunohistochemistry was done with anti-
HER-2 antibody to confırmHER-2 over-expression. The data was analysedwith
SPSS version 17. Results: Of the 99 cases of gastric cancer seen over the 8 year
period, there were 57males and 42 females, adenocarcinoma (91), GIST (5) and
Non Hodgskin Lymphoma (3). The age range of the study population was 8-90
years with modal age group in the 6th decade. There were more biopsies (63)
than resections (36). Of the adenocarcinomas, 45 were poorly differentiated, 38
moderately differentiated and 8 well differentiated. Diffuse type is most com-
mon with 47 cases followed by intestinal 41cases and mixed type 3 cases. Three
of the 4 patients under the age of 30 years had lymphoma. HER-2 over-expres-
sion was seen in 14 out of the 47 tested and all were intestinal type. Conclusion:
HER -2 over-expression was seen a small cohort of our patients with gastric
cancer especially those with intestinal type.
#754 Treatment decision-making of rare ERBB2 (HER2) mutations in
lung cancer; a role for multidisciplinary molecular tumor boards. Arja ter
Elst,1 Nils A. ’t Hart,1 Anthonie J. van der Wekken,1 Wim Timens,1 Lucie B.
Hijmering-Kappelle,1 Geke A. Hospers,1 Hilde Jalving,1 Elise M. van der Logt,1
Leon C. van Kempen,1 Sjoukje F. Oosting,1 Matthew R. Groves,2 T Jeroen Hil-
termann,1 Anke van den Berg,1 Harry J. Groen,1 Ed Schuuring1. 1University
Medical Center Groningen, Groningen, Netherlands; 2University Medical Center
Groningen, University of Groningen, Groningen, Netherlands.
Introduction: Breakthroughs in cancer research have resulted in mutation-
specifıc targeted therapies (precision medicine). Most of these new drugs are
only effective in patients with an actionable molecular profıle. Thus, predictive
molecular testing enables oncologists to select individual patients for the most
appropriate (targeted) therapy and to reduce the burden of overtreatment. The
number of clinically relevant predictive markers that are routinely analyzed is
growing rapidly, resulting in the identifıcation of raremutations,mutationswith
unknown relevance and coexistence of two or more mutations in the same
sample. Incorporating these into the optimal treatment for the individual pa-
tient can be complex. Methods: A total of 2461 sequential tumor biopsies were
analyzed at our institute using targeted next generation sequencing (IonTorrent
platform). 230 of these patients were discussed at a weekly Molecular Tumor
Board (MTB)meeting. Cases involved 170 lung and 21 colorectal carcinomas, 24
melanomas, 1GIST and a range of othermalignancies with uncommon and rare
mutations. The board is composed of pulmonologists, medical oncologists, pa-
thologists and clinical scientists in molecular pathology. The goal of the MTB is
to discuss the biological and clinical relevance of rare mutations or uncommon
profıles and to suggest treatment options based on registered, off-label or trial-
based drugs presently available in the Netherlands. Results: In this abstract we
report on four patients with an ERBB2 exon 20 mutation and 1 patient with
ERBB2 amplifıcation received anti-HER2 treatment after an MTB consensus
decision. Two patients with an insertion in exon 20 of ERBB2: (c.2313_2324dup;
p.(Y772_A775dup)) received fırst line therapywith afatinib and showed a partial
response and stable disease respectively. One patient with a c.2524GA;
p.(V842I) mutation received afatinib and showed stable disease for 3 months. A
patient with another ERBB2 exon 20 insertion (c.2326_2327insTAT:
p.(G776delinsVC)) received afatinib but had progressive disease within two
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months. One patient with an ERBB2 amplifıcation by FISH and high (3)
HER2(ERBB2) expression, showed a partial response to trastuzumab. All pa-
tients had stage IV and would without genomic knowledge been treated with
chemotherapy. Conclusion: Lung cancer patients with sporadic ERBB2 muta-
tions might benefıt from targeted ERBB2 therapy. For an optimal treatment
decision, patients with raremutations in general, may benefıt fromdiscussion in
a multidisciplinary molecular tumor board. In the future, both the consider-
ations for targeted therapy as well as treatment response and toxicity should be
registered in an open-access database and shared with other national and inter-
national Molecular Tumor Board initiatives to allow comparison with tradi-
tional treatments.
#755 Supporting precision cancer treatment decision with functional
evaluation of cancer gene mutations and variants. Jingjing Jiang,1 Zhong-
guang Luo,2 JiaWei,3 Guanglei Zhuang,4 Song Yi,5 Ying Yan,6 Tengfei Yu,6Wei
Du,6 Tingting Tan,6 Ling Qiu,6 Jiali Gu,6 Xin K. Ye,6 Jie Liu,2 Zhenyu Gu6.
1GenenDesign USA Co, Ltd., Menlo Park, CA; 2Huashan Hospital, Shanghai,
China; 3Nanjing University, Nanjing, China; 4Shanghai Jiao Tong University,
Shanghai, China; 5MDAndersonCancer Center, Houston, TX; 6GenenDesignCo,
Ltd., Shanghai, China.
Precision oncology requires identifying and understanding of cancer genome
changes in a patient tumor tissue and fınding the best cancer therapy targeting
the changes. Although many cancer gene targets have been validated so far,
next-generation genomic profıle analyses have uncovered much more cancer
gene variants with unconfırmed functions. Developing methods to functionally
evaluate mutations/variants and understand their roles in cancer development
and drug responses, such as drug resistance or synthetic lethality, will be critical
in cancer treatment decision support. In addition, in some clinical cases, multi-
ple treatment choices such as multiple drug combinations exist. Developing
cancer models which can test multiple treatments will provide direct compari-
son of those therapies and select the best options. At GenenDesign, we have
performed drug tests on mouse “avatars”, which are also known as Patient-
Derived Xenograft (PDX)models. They are personalized cancermodels derived
from patient tumor samples with cancer mutation profıles and drug responses
very similar to the corresponding cancer patients. Drug screenings were carried
out in avatars by testing chemotherapies or targeted drugs against specifıc cancer
gene mutations and variants. Selected drugs or drug combinations from avatar
studies have been applied to corresponding patientswith highly consistent treat-
ment outcome. From genomic profıle analysis of our near 1500 PDX tumor
models in cancer types such as lung, colorectal, gastric, liver, and esophageal, we
are able to identify a large number of cancer gene mutations/variants, gene
fusions, as well as gene copy number and RNA expression changes in major
cancer signal pathways such as EGFR,Her2, c-Met/ALK, Ras/Raf, FGFRs, PI3K/
Akt,Wnt, Notch, DNA repair, cell cycle regulation, angiogenesis. Many of these
gene aberrations are potential drug targets and have been functionally tested in
PDX models with approved drugs or clinical drug candidates. The mutation/
variant information and drug response information generated from PDXmod-
els have been organized into our Precision Cancer Information Lab database.
Patient tumor DNA test results have been used for searching genetically
matched PDX models in our database. Once matched PDX models are identi-
fıed, the available drug response information can be used as evidence for clinical
treatment decision. In addition, the matched PDXmodels can also been used to
test more treatment options such as different combinations and new clinical
drug candidates.
#756 Molecular characterization of triploid and tetraploid urine FISH
samples. Lorenza Pecciarini, Valeria De Pascali, Ilaria Francaviglia, Anna Tala-
rico, Chiara Iacona, Massimo Freschi, Maria Giulia Cangi, Claudio Doglioni.
San Raffaele Hospital, Milano, Italy.
Urothelial carcinomas (UC) are characterized, among other aberrations, by
chromosome 3, 7, 17 gains and 9p21 (p16) loss. Since UC cells readily exfoliate
into the urine, molecular cytogenetics techniques have been used to detect cells
consistent with UC diagnosis and follow-up: a multitarget Fluorescence In Situ
Hybridization (FISH) test, composed of 3, 7 and 17 centromeres and 9p21 locus
multicolor probes, has been proved useful for atypical cells identifıcation in both
void urine and lower and upper urinary tract samples before morphological
changes are apparent through cytological and histological examination. To date,
there are no uniform criteria for urine FISH scoring though the test is commonly
considered positive following the UroVysion Bladder Cancer Kit criteria (Ab-
bott Molecular): 4 or more cells with a gain of 2 or more chromosomes (poly-
somy), and/or 12 or more cells with 9p21 homozygous deletion. This defınition
of polysomy includes trisomy and tetrasomy classes, but, as tetraploidy may
represent cells at S/G2 phase, this criterionmay lead to false-positives; moreover
it has been described that also inflammation induces tetraploidy, and that small
percentages of normal urine cells show trisomy/tetrasomy. On the other hand,
triploidy and tetraploidymay have a direct role in tumorigenesis, as an interme-
diate state in the development of cancer aneuploidy. At the moment little is
reported about the clinical correlations of urine FISH cases showing only tri-
somy/tetrasomy and more data are needed to clarify the diagnostic value of
triploid and tetraploid urothelial cells. Aiming to better classify patients with a
trisomy/tetrasomy urine FISH result, we extracted genomic DNA from 50 fıxed
urine cell suspensions, previously tested by urine FISH, and investigated them
for the presence of fıbroblast growth factor receptor 3 (FGFR3) and telomerase
reverse transcriptase (TERT) promoter mutations, which constitute the most
recurrent somatic alterations in BC. In particular frequentmutations in exons 7,
10 and 15 of FGFR3 characterize non-muscle invasiveUCwhilemutations in the
core promoter region of TERT gene, mainly at -124 and -146 positions from the
ATG start site, have emerged as the most frequent somatic genetic alteration in
both non-muscle invasive and muscle invasive UC. All specimens were sub-
jected to PCR amplifıcation and Sanger sequencing for FGFR3 exon 7 and 10,
and for the C228T and C250T TERT promoter mutations. A preliminary anal-
ysis of 20 urine FISH cases showed 4 samples with trisomy/tetrasomy, and 1 of
these 4 had a mutation of the TERT promotor. Complete results of the FGFR3
and TERT promoter molecular analysis will be presented and correlated to both
FISH results and patients clinical data, in order to evaluate if the presence of
FGFR3 and/or TERT promoter mutations in urine samples with FISH detected
trisomy/tetrasomymay help to identify patients with a higher risk of recurrence
and progression.
#757 Development and validation of theActionSeqTM test system. Saman-
tha Helm, Vanessa Spotlow, Aleksandra Ras, Kevin Kelly, Guruprasad Ananda,
Sara Patterson, Honey V. Reddi. Jackson Laboratory for Genomic Medicine,
Farmington, CT.
Introduction In the constantly changing fıeld of oncology precisionmedicine,
it is exceedingly important to keep diagnostic and therapeutic assays clinically
relevant. Next generation sequencing (NGS) panels in oncology are greatly im-
pacted by new fındings in clinical actionability. In order to ensure that cancer
panels continue to provide the most benefıcial results to patients, they must be
regularly updated. In keeping with this idea, JAX has launched a new 212 oncol-
ogy gene panel which focuses on genes and variants with documented action-
ability, referred to as ActionSeq. Methods Development of ActionSeq included
the optimization of a new targeted capture assay. This process included running
multiple batches of samples through the assay to determine appropriate DNA
input, ligation times, PCR cycles, and pooling conditions. The fully optimized
assay was then validated using 24 uncharacterized FFPE samples. The validation
was executed in 5 phases: (1) confırm that assay optimizations yielded suffıcient
wet lab results; (2) LOD&sensitivity (3) inter-assay concordance; (4) intra-assay
concordance; (5) specifıcity and accuracy. Results During development, the
standard protocol was optimized using a 200ng input, 30minute ligation period,
5 cycles of pre-PCR, and the pooling of 4 samples per hybridization reaction.
Wet lab processing results of the fırst validation batch can be seen inTable 1. The
inter- and intra-assay concordances were found to be 	 96% for variants and
100% for CNVs. The sensitivity was calculated to be 98.92% at a LOD of 3% for
SNVs, 100% at a LOD of 8% for INDELs, 100% at a LOD of 6 copies for CNV
amplifıcations, and 100% at a LODof 0 copies for CNVdeletions. The specifıcity
and accuracywere found to be 100% for allmutation types. ConclusionBased on
the success of this validation ActionSeq has been incorporated into the JAX
clinical test menu. This addition accomplished the goal of providing a more
clinically relevant (actionable) somatic tumor profıling assay to patients and
clinicians.
Sample
Post
Prep ng/ul
Capture
Pool ng/ul
Average Base
Pair Size
Mean
Target Coverage
Percent
Duplication
1 27 1.41 309 511 23%
2 24 1.41 309 594 23%
3 24 1.52 302 659 22%
4 29 1.52 302 652 21%
5 21 2.22 290 535 16%
6 35 2.22 290 560 13%
7 29 2.23 299 530 17%
8 72 2.58 304 1196 14%
9 65 2.58 304 732 14%
10 43 2.58 304 571 13%
11 42 2 303 722 18%
12 37 2.0 303 611 16%
13 27 2.0 303 735 18%
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Sample
Post
Prep ng/ul
Capture
Pool ng/ul
Average Base
Pair Size
Mean
Target Coverage
Percent
Duplication
14 42 1.9 309 731 20%
15 40 1.9 309 683 19%
16 67 1.9 309 675 16%
17 48 1.9 309 573 20%
18 53 1.89 301 655 19%
19 31 1.89 301 763 22%
20 82 1.89 301 761 17%
21 56 1.89 301 877 19%
22 34 1.99 329 771 18%
23 48 1.99 329 886 16%
24 78 1.99 329 841 15%
Established Quality Control Cut Offs:
Post Library Prep ng/ul: 	20
Post Capture Pool ng/ul: 	0.5
PC Average Base Pair Size: 250-350
Mean Target Coverage: 	 500
Percent Duplication: 25%
Table 1: This table displays the wet lab processing results for the 24 samples used to
confırm the effıciency of the developmental optimizationsmade to the assay prior to begin-
ning the clinical validation.
#758 Capture and characterization of circulating tumor cell clusters in
patients with metastatic castrate-resistant prostate cancer. Samantha L.
Savitch,1 Stephanie S. Yee,1 Devon Soucier,1 Denis Smirnov,2 Chandra Rao,2
Steve Gross,2 Ravi K. Amaravadi,1 David J. Vaughn,1 Naomi B. Haas,1 Erica L.
Carpenter1. 1Division of Hematology and Oncology, Department of Medicine,
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;
2Janssen Pharmaceutical, Johnson & Johnson, Huntington Valley, PA.
Introductory Sentence indicating purpose of study: Circulating tumor cell
(CTC) clusters have been shown to have higher metastatic potential than single
CTCs in breast, pancreatic, and other cancers, yet these clusters have not been
extensively described inmetastatic castrate-resistant prostate cancer (MCRPC).
Herewe sought to determine the feasibility of capturing and characterizingCTC
clusters in prostate cancer patients. Description of Experimental Procedures:
Fifty-fıve blood samples from 29 MCRPC patients, ages 50 to 81 (median age
68), were obtained prior to the patient starting or switching to androgen recep-
tor inhibitor or 17 alpha lyase inhibitor therapies. Eighteen patients received
enzalutamide and 11 received abiraterone. The majority of patients had a Glea-
son score 7 (22; 75.9%), bone metastases (19; 65.5%), and an ECOG status of
0 (21; 72.4%). All patients had previously undergone, orwere receiving at time of
enrollment, androgen deprivation therapy. Eleven patients (37.9%) had been on
a prior 2nd generation anti-androgen therapy. CTC single cells and clusters (2 or
more cells together in one image) were enumerated using the CellSearch system
and stained to detect expression of androgen receptor (AR), glucocorticoid re-
ceptor (GR), andneuroendocrine (NE)markers. Summary ofData: Five ormore
single CTCs, a measure which has previously been associated with an unfavor-
able prognosis, were detected in 13 of 29 patients (44.8%), and in 19 of 55 blood
samples (34.5%). Altogether, a total of 282 CTC clusters was detected, with 1 or
more clusters found in 10 patients (34.5%) and 13 samples (23.6%). The number
of clusters per 7.5ml of blood ranged from 0-150, and clusters contained any-
where from 2 to 16 cells. Most CTC clusters (268; 95.0%) contained only CTCs
and no leukocytes. Just over half the detected clusters (162; 57.4%) contained
only 2 CTCs. Cluster staining patterns were fairly homogenous with 29.4% of
clusters having uniform expression of either AR, GR, or NE markers, i.e., all
CTCs in the cluster expressed themarker of interest. Most clusters (67.7%) were
uniformly marker negative and the remaining 2.8% demonstrated a mix of
marker positive and marker negative CTCs. Serum Chromogranin A levels, as
determined by standard of care clinical blood testing, were found to be positively
associated with the number of CTC clusters per 7.5ml of blood (p0.0001).
Statement of Conclusions: The capture and characterization of CTC clusters in
the blood of MCRPC patients can be successfully performed using the Cell-
Search system. Further investigation into the clinical implications of these clus-
ters is warranted, including whether cluster characteristics are associated with
more aggressive disease.
#759 Highly-sensitive detection of EGFRmutation in non-small cell lung
cancer using mutant-enrichment method. Hung-Chi Chien. Industrial Tech-
nology Research Institute, Hsinchu, Taiwan.
Detectionofmutations inEGFRinnon-small cell lungcancer is important for the
clinical decision-making process of molecularly targeted therapies, including Ir-
essa®, Tarceva®, and Tagrisso®. In this study we developed an assay allowing the
detection of EGFR gene mutations being conducted in the routine diagnostic pro-
cedure and its analytic andclinical performancewere evaluatedusingdifferent types
of specimens. The EGFR mutation assay in this study allows for detecting EGFR
exon 19 deletion (Del), exon 20 insertion (Ins), and mutation in T790M, L858R,
S768I andL861Qof rare amounts in anormal genetic background.Enhancementof
detection sensitivity was achieved with the developed mutant enrichment method
which combines mutation-specifıc primers and 3’-phosphorylation oligonucleo-
tides as blockers for inhibiting wild-type gene from DNA amplifıcation. Analytic
performance for each mutant was assessed using the control plasmids containing
the mutant genes of known amounts as well as the genomic DNA extracted from
mutant cell lines and Horizon FFPE samples. The assay performance were also
evaluated using clinical samples in parallel with the FDA-approval companion di-
agnostic product therascreen® EGFR RGQ PCR Kit . The sensitivity of the assay
evaluated using control plasmids for Del, T790M , L858R, S768I, L861Q mutation
andInswas5%,0.5%,1%,0.5%,0.1%and0.5%respectively, andwas1%,0.5%,0.5%,
0.5%, 0.1% and 0.5% respectively when applying on HDx reference standards. Di-
agnostic results for the 116 clinical samples for identifyingmutations of del, T790M,
L858R, S768I, L861Q and Ins was 92.2%, 100%, 99.1%, 100%, 97.4% and 100%
respectively concordance with the therascreen® EGFR RGQ PCR Kit, including 17
cases of multiple mutations. The overall diagnostic results for all mutations evalu-
atedwith PPA (positive percent agreement), NPA (negative percentage agreement)
and OPA (overall percentage agreement) were 83.3%, 98.2% and 90.5%, respec-
tively. The three samples fırstly diagnostic as false positive were retested and con-
fırmed to be Exon 19 del by DNA sequencing. The assay demonstrated good sensi-
tivity when compared with commercial product. More clinical studies are being
performed to establish relationship between drug effıcacy and different mutation
combinations.
#760 Detection of EGFRT790Mmutation by ddPCR in untreatedNSCLC
patients: Correlationwith clinical outcome.MonicaGanzinelli,1 Eliana Rulli,2
Elena Tamborini,1 Adele Busico,1 Giuseppe Lo Russo,1 Giulia Corrao,1 Milena
Vitali,1 Marina Chiara Garassino,1 Massimo Broggini,2 Mirko Marabese2.
1Fondazione IRCCS Istituto Tumori Milano, Milan, Italy; 2IRCCS - Istituto di
Ricerche Farmacologiche Mario Negri, Milan, Italy.
Background: Activating EGFR mutations are associated with response to fırst
generation tyrosine kinase inhibitors (TKI) that signifıcantly increased PFS andOS
inNSCLCpatients. However, almost invariably, patients relapse while in treatment
withTKI,mostly for the presence of EGFRT790Mmutation.New second and third
generationEGFR inhibitors active againstT790Marenowunder developmentwith
very promising results. To date it is not known if the presence of T790M (and its
amount) at diagnosis influences clinical outcome of patients with activating EGFR
mutation. Methods: We analysed 50 cases with NSCLC. 48 patients harbour TKI
sensitizing mutation in either exon 19 (N24) or 21 (N19). 2 EGFR wt patients
(blinded to the investigator) were analysed in parallel. These patients were screened
byddPCR for thepresenceofT790MmutationusingBioradQX200DropletDigital
PCR System.We used rough DNA extract from FFPE sections after deparaffıniza-
tion and proteinase K digestion, as available in pathology unit for daily diagnosis.
Results: 12 samples failed to amplify, maybe due to the poor quality of DNA. 13
samples produced results, but were excluded for the analysis because of too low
number of calls retrieved. T790Mmutationwas detected in a signifıcant proportion
of remaining cases. Among the latter, 4 patients were sampled after TKI treatment
and here the percentage of T790M were higher compared to those patients not
treated [0.65% - 28%vs 0.019% - 1.65%, respectively].One out four of these patients
was not detected by routinely method of sequencing (Sanger or RT-PCR). T790M
positive samples harboured mutations affecting exon 19 or 21 in equal manner.
Conclusions:ddPCRhasproventobeasensitivemethodtodetectT790Mmutation,
although thequalityofDNAcouldaffect the results.The systemhasbeenchallenged
for specifıcity an sensitivity and the results proved to be clinically relevant. The
correlation between theT790Mpositivity and clinical outcomewill be available and
weplan todefıne addPCR threshold valuewhich canhelp in selecting thosepatients
who are likely to have early recurrence under fırst generation TKI and that could
therefore be directly shifted to second or third generation inhibitors.
#762 A concordance study of the ArcherDX RevealTM ctDNA 28 NGS
panel andBiocept’s Target SelectorTMmutation assay using ctDNA collected
in Biocept CEE-sureTM blood collection tubes. Jason C. Poole,1 Brian Kud-
low,2 Jill Stefanelli,2 Skyler Mishkin,2 Anh Pham,1 Jeff Chen,1 Veena M. Singh,1
Josh Stahl,2 Lyle J. Arnold1. 1Biocept, Inc., San Diego, CA; 2ArcherDX, Inc., Boul-
der, CO.
Biocept’s Target Selector technology is a targeted hotspot mutation panel
designed to enrich for mutant targets in a large excess of WT DNA. The test is
specifıc to small regions of interest, is highly sensitive, validated down to 7
mutant copies in a background of 14,000 WT at 98% sensitivity. The Ar-
cherDX Reveal ctDNA test is a 28 gene NGS panel that targets key oncogene
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activating mutations, drug resistance mutations, in addition to full coverage of
TP53. The Reveal ctDNA assay utilizes Anchored Multiplex PCR to enrich, tag,
and effıciently capture short ctDNA fragments. Both technologies are designed
specifıcally for use with plasma associated ctDNA.We undertook to evaluate the
feasibility of using the ArcherDX Reveal ctDNA 28 NGS panel with the DNA
extracted from plasma collected with Biocept’s patented blood collection tube
which has been validated at room temperature for 4 days for circulating tumor
cells and 8 days for ctDNA. The ability to build complex, targeted libraries, free
of chemically induced mutations is of major importance for the detection of the
vanishingly rare mutations that can be present in the plasma of cancer patients.
We found that high quality NGS libraries were produced from plasma collected
and stored in the Biocept blood tube, indicating that little damage occurred to
the DNA during preservation. In addition, the two methods were found to be
highly concordant and complementary when using both mutation positive and
negative patient samples. TheTarget-Selector assaywas themore sensitive, how-
ever, the ArcherDX panel revealed several additional mutations not targeted by
the Biocept Target Selector assay.
#763 Analytical validation of Ki67/CD8 duplex IHC assay using compu-
tational tissue analysis (cTATM). Staci J. Kearney, Joshua C. Black, Benjamin J.
Landis, Sally Koegler, Brooke Hirsch, Roberto Gianani. Flagship Biosciences,
Inc., Westminster, CO.
Chromogenic multiplex immunohistochemistry (IHC) assays enable investi-
gation of the spatial relationships between tumor and immune cells, which is
thought to be important for understanding and predicting therapeutic response.
Development and analytical validation of multiplex IHC assays enables the use
of such assays to simultaneously investigatemultiple biomarkers as predictors of
clinical response. In this study, we analytically validated a chromogenic duplex
IHC assay that quantifıes Ki67 and CD8 in formalin-fıxed, paraffın-embedded
non-small cell lung cancer tissues. Five performance criteria were selected and
evaluated based on Clinical Laboratory Standards Institute guidelines: report-
able range, analytical sensitivity, analytical specifıcity, accuracy, and precision.
Similar to analytical validation studies for monoplex IHC assays, this study
utilized a referencemethod andmultiple days of staining. The percentage of cells
positive for Ki67 nuclear staining and/or CD8 membrane staining were quanti-
fıed using our computational Tissue Analysis (cTATM) platform. Performance
of the Ki67/CD8 chromogenic duplex IHC assay was considered acceptable for
the fıve criteria evaluated. Once the performance of the assay was established,
additional exploratory cTA-based endpoints were examined, including the
quantifıcation of each biomarker in the tumor compartment and the tumor
microenvironment, and analysis of the spatial arrangement of immune cells
relative to tumor cells. In conclusion, Flagship’s cTA platform allows for more
consistent quantifıcation of individual analytes on dual-stained tissue sections,
enabling investigation of complex biological questions that cannot be achieved
with traditional tissue-based manual endpoints.
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#764 Survival analysis for the elderly esophageal cancer patients (>80
years) with surgery and non-surgery treatments. Dan Feng Du,1 Dan Feng
Du,2 Fu You Zhou,3 Lian Qun Zhang,3 Xue Na Han,1 Yuan Yuan,3 Zong Min
Fan,1 Jian PoWang,3 YaoWenZhang,3 Tai Jiang Liu,4 GuoHua Liu,4 Yi JunQi,5
Yan Rui Zhang,6 Li Dong Wang1. 1The First Affıliated Hospital of Zhengzhou
University, Zhengzhou, China; 2Basic Medical College of Zhengzhou University,
Zhengzhou, China; 3AnyangTumorHospital, China; 4Huojia RedCrossHospital,
China; 5The First Affıliated Hospital of Henan University of Science and Technol-
ogy, China; 6Henan Provincial People’s Hospital, Zhengzhou, China.
With the aging of population, the elderly esophageal cancer patients are in-
creasing. However, the optimal treatment methods have not been well charac-
terized for the elderly esophageal cancer patients because of that most random-
ized studies have excluded the elderly. The aim of this study was thus to analyze
the outcomes of surgery and non-surgery therapy on the elderly patients aged 80
years or older with esophageal squamous cell carcinoma (ESCC) to provide
more evidences for optimal treatment design on the elderly patient. The enrolled
1,143 ESCC cases in this study were from the ESCC database in Henan Key
Laboratory for Esophageal Cancer Research. Of the 1,143 patients, there were
614 males with a mean age of 82.452.64 and 529 females with a mean age of
82.442.61. The age ranged from80 to 96 years old at diagnosed.All the patients
were confırmed as ESCC by histopathology. The patients were classifıed into
four groups based on treatment methods, i.e., radical esophagectomy (group I),
esophagectomy plus radiochemotherapy (group II), radiochemotherapy only
(group III), and symptomatic treatment (group IV). Radical esophagectomywas
performed on 304 patients (26.6%), including 134 males and 97 females. In
addition, of the 304 patients with radical esophagectomy, there were 73 patients
who were received radichemotherapy after surgery. 518 patients received only
radiochemotherapy (45.3%). Radiochemotherapy included 50-60 Gy of radia-
tion concurrentwith orwithout 5-fluorouracil alone or combinedwith cisplatin.
Moreover, there were 321 patients (28.1%) who did not receive either surgery or
radiochemotherapy, but only with symptomatic treatment. The Kaplan-Meier
analysis indicated that there was no signifıcant difference in gender, age or his-
tology between patients in the different groups. The overall 1-, 3- and 5-year
survival rates were 56%, 31% and 19%, respectively, with amedian survival time
of 2.5 years. In group I, the overall 1-, 3- and 5-year survival rates were 68%, 48%
and 30%, respectively, with a median survival time of 3.8 years. In group II, the
overall 1-, 3- and 5-year survival rateswere 48%, 32%and 14%, respectively, with
a median survival time of 1.9 years. In group III, the overall 1-, 3- and 5-year
survival rates were 58%, 28% and 18%, respectively, with amedian survival time
of 2.5 years. In group IV, the overall 1-, 3- and 5-year survival rates were 39%,
18% and 0.08%, respectively, with a median survival time of 1.6 years. The log
rank survival analysis showed that the surgery group had better prognosis than
surgery plus radiochemotherapy or radiochemotherapy alone group (P0.002)
and the symptomatic treatment group (P0.000). The present results demon-
strate the benefıt of esophagectomy on the elderly ESCC patients in terms of
survival. [Supported by the Joint Funds of NSFC (U1301227), Natural Science
Foundation of Henan Province (20161110) and Correspondence to: Li Dong
Wang, Email: ldwang2007@126.com].
#765 Prognostic impact of Philadelphia chromosome in elderly acute lym-
phoblastic leukemia patients ineligible for hematopoietic stem cell trans-
plantation. Ja Min Byun. Seoul National University Hospital, Seoul, Republic of
Korea.
Elderly acute lymphoblastic leukemia (ALL) patients are often unfıt for nei-
ther dose-intensive chemotherapy nor stem cell transplantation, thus their clin-
ical outcomes have been dismal. The increased incidence of BCR-ABL translo-
cation with increasing age also contributed to poor prognosis but, it was our
conjecture that the introduction of potent tyrosine kinase inhibitors (TKI) tar-
geting ABL, BCR-ABL translocation might not deliver negative prognostic im-
pact in elderly ALL. Considering that many elderly Ph- ALL patients do not
tolerate cytotoxic chemotherapy required for effective tumor control, we sup-
posed that effıcacy of ABL TKIs and their combination strategy with low dose
cytotoxic chemotherapy would result in better survival for elderly Ph ALL
compared to their Ph- counterparts. This study was a multicenter longitudinal
cohort study of elderly de novo ALL (	 60 years) recruited from 11 hospitals in
Korea from January 2005 to December 2015. We considered Ph if it was
positive in at least one of three techniques: conventional cytogenetics, fluores-
cence in situ hybridization, or quantitative real-time polymerase chain reaction
(qRT-PCR). Among the 96 patients enrolled, there were 50 Ph- ALL patients
(52.1%) and 46 Ph ALL patients (47.9%). There were no differences between
the 2 groups regarding age, sex distribution, performance status, and induction
regimens. For treatment outcomes evaluation, the 5 Ph ALL patients not re-
ceiving TKI were eliminated and 41 Ph ALL patients treated with TKI were
compared with 50 Ph- ALL patients (Table). Complete remission (CR) was
attained in 27 (54.0%) of patients in the Ph- group versus 35 (85.4%) in the Ph
group (P0.001). The median RFS was signifıcantly longer in the Ph group
(3.1 months for Ph- vs. 8.9 months for Ph, P0.017). Induction death and
induction failure occurred signifıcantly more often in the Ph- group. The me-
dian OS was 6.3 months for Ph- group versus 10.3 months for Ph group
(P0.033). In conclusion, using real world data, this study reports the possible
favorable impact of Ph in TKI-era for elderly patients.
#766 Comorbidities limiting recruitment of non-small cell lung cancer
(NSCLC) patients in early phase trials. Narjust Duma, Yucai Wang, Aaron
Mansfıeld.Mayo Clinic, Rochester, MN.
Background: Early phase trials (EPCT) provide signifıcant value by evaluating
the possible benefıts of new agents. The eligibility criteria in EPCT are usually
rigorous and may exclude many patients (pts) commonly seen in clinical prac-
tice. Our objective was to identify the most common comorbidities excluded in
EPCT for NSCLC. Methods: ClinicalTrials.gov was queried on August 1st of
2016. 299 interventional drug trials were extracted from 2010 to 2016. We stud-
ied the trial characteristics including: experimental therapy, location, funding
and eligibility criteria. Exclusion of CNSmetastasis was treated as a binary vari-
able (strict exclusion vs. allowed). Logistic regressions were used for statistical
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analysis. Results: Of the 299 trials, 164 (55%)were phase II, 81 (27%) phase I and
54 (18%) phase Ib/II. 164 (55%) were conducted in the United States (US), 45
(15%) in Asia, 39 (13%) in Europe and 51 (17%) were international. 171 (57%)
trials were funded by the industry, 54 (18%) by government agencies and 74
(25%) were investigator initiated. Survival was an end-point in 97 (32%)
trials. 70 (23%) trials required a repeat lung biopsy. 54 (18%) trials excluded
pts 75 years of age. 99 (33%) trials required creatinine levels 1.5 mg/dl,
132 (44%) liver enzymes 2.5 and total bilirubin 1.5 of the upper limit of
normal. 88 (29%) trials required Hgb9 g/dl and 141 (47%) excluded pts
with platelets 100,000/dl. In terms of comorbidities, 84 (28%) trials ex-
cluded pts with atrial fıbrillation, 94 (31%) with any anticoagulation therapy
and 120 (40%) HIV positive pts. CNS involvement was a signifıcant exclu-
sion factor, 123 (41%) trials excluded pts with CNSmetastasis. On univariate
analysis, the odds of CNS metastasis exclusion were signifıcantly higher in
immunotherapy trials (OR 1.72, 95%CI 1.2-2.4, p0.01) and lower in Euro-
pean trials (OR 0.76, 95%CI 0.6-0.9, p0.005). In multivariate analysis, US
based trials had higher odds of exclusion of CNS metastasis (OR: 3.2, 95%CI
1.4-7.5, p0.05). Conclusions: Many of the EPCTs excluded pts with ad-
vanced age, cytopenias and other common comorbidities, eliminating the
possibility of many of our aging pts from participation. Regarding CNS
disease, our analysis suggests the type of agent and location may influence
the trial design about CNS metastasis inclusion. Investigators should review
whether suffıcient justifıcation exists for every exclusion criterion before
their incorporation in future trial protocols.
#767 Breast cancer in sub-SaharanAfrica: a histopathologic review from a
tertiary hospital in Northern Nigeria. Saad A. Ahmed, Balarabe Kabir, Nasiru
Abubakar. Ahmadu Bello University, Zaria, Nigeria.
Introduction: Breast cancer is the commonest cancer in women world-
wide, however, there are discrepancies in the incidence among different
geographical regions. The highest incidence rate is in North American,
Northern and Western European, while the lowest rate is found among
Asian and sub-Sahara African women. Breast cancer is undoubtedly heter-
ogeneous in terms of its presentation, morphology and molecular profıles.
Studies from the developing countries suggested that there are differences
between the biology of BC in the developing and developed countries. Meth-
ods: This is a retrospective histopathologic review of breast cancer cases
between 1st January 2003 and 31st December 2015 from the Ahmadu Bello
University Teaching Hospital Zaria - Nigeria. Results: A total of 784 breast
cancer cases were seen during the study period and majority of the cases
(99.4%) were females. The prevalence of breast cancer was found to be 12.6%.
Triple-negative breast cancers (TNBC) constitute 67.7% of cases. The mean
age was 45.8 12.0 years and the youngest patient was 18 years while the
oldest was 90 years. Out of the 784 cases, 208 were mastectomies while the
remaining were incisional, trucut needle and excisional biopsies. Infıltrating
ductal carcinoma NST was the most common histologic variant seen (94.7%)
and most of these cases (59.1%) were Grade II tumors. The Nottingham
Prognostic Index (NPI) shows that 91.4% of the cases have NPI Score of	3.5
with attendant poor 5-year survival rate. Conclusion: This study found that
breast cancer is common and affects mostly women in fıfth decade of life.
There is a high TNBC among the population studied and therefore androgen
receptor profıle and genomic studies may be useful to determine the course
of therapy.
#768 The utility of a breast cancer registry for improved cancer manage-
ment in developing countries. DeAnna McGarity,1 Brandon Epps,1 Alexis
Maynor,2 Tania Anderson,2 Ernest Alema-Mensah,1 Delroy Fray,3 Maung
Aung,3 Kisha Holden,1 James Lillard,1 Brian Rivers,1 Derrick Beech1. 1More-
house School of Medicine, Atlanta, GA; 2Tuskegee University, Tuskegee, AL;
3Western Regional Health Authority and Cornwall Regional Hospital, Montego
Bay, Jamaica.
Background Breast cancer is one of the leading causes of cancer related deaths
in the island nation of Jamaica, West Indies. Cancer and other non-communi-
cable diseases have increased in many developing nations in the Caribbean as
well as Central and South America. The health systems of these developing
countries continue to provide care to patients with limited resources. The use of
a breast cancer registry can assist in care coordination of these patients and allow
targeted screening and treatment programs in under-resourced environments.
Methods In collaboration with theWestern Regional Health Authority, a breast
cancer registry database was developed in RedCap to provide a comprehensive
analysis of breast cancer in under resourced environment. 53 patients from
Atlanta were compared to 78 patients from Jamaica These patients were entered
into the breast cancer registry from June 1, 2014 to March 31, 2015 by the
attending physician and de-identifıed. Demographics, tumor related factors,
treatment, survival and health behavior informationwas collected by the attend-
ing physician. The fındings were then analyzed using Statistical Analysis System
(SAS) and Data Analysis and Statistical Analysis (STATA): Fisher Exact test,
chi-square andmultiple regressions. Results Themedian of patient ages were 61
years old (range 38 - 81 years) for the U.S. patients and 53 years old (range 26 -
84 years old) for Jamaican women. For the U.S. patients, 84% were Black, 4%
White, and 12.24% were Latin or Asian. The majority of the patients were diag-
nosed with stage 1 invasive ductal breast cancer. In contrast, the majority of the
Jamaican patients were diagnosed with late-stage breast cancer. Utilizing the
data from the breast cancer registry, we were able to identify parishes (counties)
with disproportionately high rates of late-staged cancer at the time of diagnosis.
Conclusion The use of a disease specifıc registry can improve care coordination
and identify actionable target areas for enhanced screening and treatment. It is
our hope to frequent review the dashboards associated with the registry data by
providers, medical centers and health systems. This will optimize care coordi-
nation and allow timely improvements in cancer diagnosis and management in
developing countries.
#769 Matched-pair comparisons of chemotherapy plus bevacizumab ver-
sus chemotherapy alone as third-line treatment or beyond for advanced non-
small cell lung cancer. Binbin Hu,1 You Lu,1 Xiaojuan Zhou,1 Qian Li,2 Meng-
meng Xiang2. 1West ChinaHospital, SichuanUniversity, Chengdu, China; 2West
China School of Medicine, Sichuan University, Chengdu, China.
Background: The addition of bevacizumab to chemotherapy has proven
effıcacy as fırst-line treatment for advanced NSCLC. Whether this combina-
tion still be effıcient as salvage treatment for NSCLC patients who have not
received bevacizumab previously remains unclear. This retrospective
matched-pair study was designed to compare the effıcacy and safety of che-
motherapy plus bevacizumab with chemotherapy alone as third-line treat-
ment or beyond for NSCLC patients. Methods: Patients with stage IV
NSCLC who had received single-agent chemotherapy plus bevacizumab af-
ter failure of at least two prior regimens were enrolled in this study. Each of
them was matched with two patients who had received chemotherapy alone
(1:2) by age (within5 years), sex, smoking history, histology, EGFR muta-
tion status and number of prior regimens. Tumor response rate, survival and
toxicity analyses were performed. Results: Between January 2011 and June
2016, a total of 40 patients who had received chemotherapy plus bevaci-
zumab (chemotherapy-bevacizumab group) were matched with 80 patients
who had received chemotherapy alone (chemotherapy-alone group) as
third-line treatment or beyond. Objective response rate (ORR) and Disease
control rate (DCR) were improved for chemotherapy-bevacizumab com-
pared with chemotherapy alone (ORR, 22.5% v 6.2%, respectively, p .014;
DCR, 62.5% v 40.0%, respectively, p .032). Progression-free survival was
prolonged for chemotherapy-bevacizumab compared with chemotherapy
alone (median, 3.9 v 2.5 months, respectively; HR, 0.64; 95%CI, 0.43 to 0.97;
p .032). Incidence of severe (	 grade 3) adverse events was low and similar
across groups. Conclusion: The combination of chemotherapy and bevaci-
zumab can be an effıcient alternative salvage treatment for NSCLC patients
who have not received bevacizumab previously. But taking this combination
as fırst-line treatment for advanced NSCLC still should be a priority.
#770 Colorectal cancer screening in rural community health clinics using
the fecal immunochemical test (FIT). Connie L. Arnold,1 Terry C. Davis,1
AlfredW. Rademaker,2 JamesMorris,1 GlennMills1. 1LSUHealth Sciences Cen-
ter - Shreveport, Shreveport, LA; 2Northwestern University, Chicago, IL.
Introduction: Colorectal cancer (CRC), the second leading cause of cancer
death in the United States, can be signifıcantly reduced if it is detected early.
Although overall CRC screening rates have increased signifıcantly, dispari-
ties persist among low income individuals, adults with low literacy and those
living in rural areas. These groups all have screening completion rates below
50%. Objectives: To assess patient knowledge, beliefs, and self-effıcacy about
CRC screening and compare the effectiveness of two health literacy in-
formed telephone follow-up strategies to improve initial and annual repeat
screening with Fecal Immunochemical Test (FIT) in rural community clin-
ics. Methods: A two-arm, randomized controlled trial is being implemented
in four community clinics. Clinics reported CRC baseline screening rates of
1% to 3%. Eligible patients, age 50-75, are recruited at the clinic prior to a
scheduled appointment. A research assistant (RA) conducts a baseline struc-
tured interview measuring CRC screening knowledge, beliefs, and self-effı-
cacy. The RA then recommends screening and gives brief literacy and cul-
turally appropriate education using a pamphlet (4th grade level), the FIT kit
with pre-addressed envelope, simplifıed instructions (3rd grade level) and a
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demonstration of how to use it, At four weeks patients who have not returned
their kit receive either 1) a personal follow-up call (PC) from a central pre-
vention coordinator using motivational interviewing skills and reminding
them to complete and mail FIT kits; or 2) an automated follow-up call (AC)
using plain language andmotivational messages encourages patients to com-
plete and mail the FIT. Outcomes include FIT completion after intervention,
and again at 12 and 24 months. 650 patients will be enrolled. Results: To
date 599 patients not up-to-date with screening have been enrolled; 64%
African American, 56% women; 40% inadequate literacy. Although 90%
reported having heard of CRC, only 64% knew a test to check for CRC. 70%
reported a provider had recommended CRC screening in the past and
91% reported they would want to know if they have CRC. Self-effıcacy was
high with over 90% indicating they would return the kit to the lab. Screening
results: 599 patients enrolled to date (AC: n300 / PC: n299); 412 (69%)
completed tests (AC: n210 (70%) / PC: n202 (68%)). Follow-up calls for
Unreturned Kits - AC: 113 people called - 26 returned FIT (23% of people
called completed FIT). PC: 115 people called - 22 returned FIT - (19% of
people called completed FIT). 2nd Year Screening: 129 Second kits mailed out
to-date. AC (n61): n29 (48%) completed kits. PC (n68): 28 (41%) com-
pleted kits. Discussion: Implementing literacy and culturally appropriate
CRC education and screening strategies using the FIT and phone reminders
has the potential to increase CRC screening rural community clinics and
address public health disparities.
#771 Cervical cancer: Our experience in Sudan. Kamal Eldein H. Mo-
hamed, Dr Ammar Ashmeig Ahmed Ashmeig. Faculty of Medicine, Univ of
Khartoum, Khartoum, Sudan.
Introduction:Cervical cancer is the secondmost prevalent cancer in Sudanese
Women; breast cancer forms between 29 - 35% of female cancers while Ca
Cervix forms 12 - 16%.There are limited screening activities in the country using
VIA, andPap smears inObs. andGyn. clinics.With themain emphasis onhealth
education programs, teaching women the early symptoms of ca cervix and early
detection. Due to lack of awareness themajority of women don’t know anything
about screening, so there is limited demand. Method: This is a retrospective
study of 405 Cases of Ca Cervix treated during the period between 2000—2013
at the Radiation and Isotopes Center of Khartoum, RICK. Data was collected
from patients records. Results: Age distribution showed,40 years 8  2 %,
41 -50 9423.2%, 51—60 187 46.2%, 61—70 102 25.2%,70 14 
3.5%. Age range28—79, mean age47 years. Residence distribution was as
follows, western Sudan 48 %, central Sudan 41.%, North 7%, East 4%.
Length of duration of symptoms, range between 1—10 months, mean of 5
months. FIGO Stage distribution: Stage 1 6%, Stage 2 A 13%. Stage 2
B23%, Stage 3 A18%, Stage 3B34%, Stage 4 A, B7%,. Pathology: poorly
dif. Squamous ca 38%, moderately dif. Squamous 26%, well dif 25%, Adenocar-
cinoma 9%, others 2%. Treatment: external Radiotherapy, 45-50 Gy in 20—25
fractions, by 2 or 4 fıelds, using Co 60 or lineacs 6,9 Mv, concurrent chemo
radiotherapy was given to patients with stage 2B, 3A, 3B, and 4A. Using weekly
Cisplatinum, this was given to 32% of patients. 60 %% of the patients had Brach
therapy, 34% with Low Dose Rate, LDR, Manual Brachy therapy, 35Gy to point
A,and 66% had High Dose Rate Brachy, HDR, 9 Gy x 2 sessions, using a cobalt
source. Results: 175 patients (43.3%) survived for 5 years and more, mostly
patients with stage one and two 158  39% survived for 3-4 years after treat-
ment,39 patents 9.6 %, mostly patients with stage four, died during follow up
due to the disease and 33 patients 8.2% disappeared after treatment. The poor
outcome is attributed to the advanced stages at presentation, lack of screening
and awareness about cervical cancer, poverty, illiteracy, the large size of the
country and the poor distribution of the limitedmedical resources. The patients
treatedwith LDRorHDRhave equal outcome andmorbidity. Conclusion:Most
of Ca Cervix Patients present with advanced disease, hence the poor prognosis,
due to lack of awareness and screening, illiteracy and poverty, the majority are
poorly differentiated squamous cancers. There is a need for increasing public
awareness about ca cervix and its early symptoms, and provision of a pap smear
and VIA services in the primary health care facilities.
#773 Optimizing drug regimens in oncology by clinical trial simulations:
Why and how. Jocelyn Gal,1 GerardMilano,1 Julien Viotti,1 Renaud Schiappa,1
Audrey Dugue,2 Agnes Paquet,3 Sylvie Chabaud,4 Jean-Marc Ferrero,1 Emman-
uel Chamorey1. 1Ctr. Antoine Lacassagne, Nice, France; 2Ctr. Francois Baclesse,
Caen, France; 3Molecular and Cellular Pharmacology Institute, Sophia Antipolis-
Valbonne, France; 4Léon Bérard Cancer Center, Nice, France.
Introduction: In therapeutic research, the safety and effıcacy of pharmaceu-
tical products are necessarily tested on humans via clinical trials after a very long
and expensive development period. Alternative methodologies such as com-
puter modeling and Clinical Trial Simulation (CTS) are a valuable option to
reduce animal and human assays. The relevance of these methods is well recog-
nized in pharmacokinetics and pharmacodynamics from the pre-clinical phase
to post-marketing. However, they are seldom used and are poorly regarded for
drug approval, despite FDAandEMArecommendations.Wepropose to discuss
the principle behind, and the interest of, CTS approaches in drug development
in oncology. Our work is based on a systematic review using two electronic
literature databases (Medline andWeb of Science). Key components of CTS:We
will explainwhy and how to successfully developCTS.Why developingCTS? To
obtain a better knowledge of pharmacology and/or better prediction of safety
and effıcacy To evaluate disease progression dynamics and to test the potential
impact of biomarkers To analyze subpopulations and extend the post-marketing
authorization to help in the choice of the best outcome To optimize experimen-
tal designs in order to better anticipate the progress of the studyHow to develop
CTS? CTS project must follow three steps: 1/The constitution of pharmacome-
tricians team who elaborates clinical model and simulation plan that must con-
tain three components: Input/output model: How do covariates impact out-
comes? Covariate distribution Model: How can we generate virtual patients?
Execution model: What can happen during the clinical trial? 2/Obtaining data
for simulations. We will present the contribution of machine learning for CTS
3/The use of specialized software to realize simulations Limitations of CTS: We
will present the features that can slow down or accelerate the development of
CTS. The generalization of CTS could be greatly facilitated by the availability of
software for modeling biological systems, by the clinical trials studies and hos-
pital databases. Data-sharing and data-merging raise legal, policy and technical
issues that will need to be addressed. CTS challenges and prospects: Develop-
ment of future molecules will have to use CTS for faster development and thus
enable better patient management. Drug activity modeling coupled with disease
modeling, optimal use of medical data and increase of the computing speed
should allow this leap forward. The realization of CTS requires not only the
bioinformatics tools to allow interconnection and global integration of all clin-
ical data, but also a universal legal framework to protect the privacy of every
patient. CTS will have to be used to provide quantitative support for drug devel-
opment decisions butwill never replace real clinical trials. This in silicomedicine
opens the way to the 4P medicine: predictive, preventive, personalized and par-
ticipatory.
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#774 Notch pathway activation predicts resistance to bevacizumab ther-
apy in glioblastoma. Norihiko Saito, Kazuya Aoki, Nozomi Hirai, Satoshi Fu-
jita, Junya Iwama, Masashi Ikota, Haruo Nakayama, Morito Hayashi, Keisuke
Ito, Takatoshi Sakurai, Satoshi Iwabuchi. Toho University Ohashi Medical Cen-
ter, Tokyo, Japan.
Glioblastoma, the most common adult glioma, is associated with a dismal
prognosis. Treatment with bevacizumab has not signifıcantly prolonged overall
patient survival times. Glioblastoma resistance to angiogenesis inhibitors is at-
tributed tomultiple interactingmechanisms.We have thus embarked on a com-
prehensive effort to detecting expression signatures that are associated with
response to the therapy and these signatures may allow prospective selection of
patients with high likelihood of responding to therapy. Notch signaling pathway
is an evolutionarily conserved pathway that plays an important role in multiple
cellular and developmental processes including cell fate decision, differentia-
tion, proliferation, survival, angiogenesis andmigration. Analysis of TheCancer
Genome Atlas expression dataset identifıed a group (43.9%) of tumors with
proneural signature showing high Notch pathway activation. In this study, we
compared CD133, Notch, and VEGF expressions in histological sections of pri-
mary and recurrent glioblastomas after radiotherapy and chemotherapy. Tumor
samples were collected from 27 patients at the time of tumor recurrence. We
used immunohistochemical techniques to compare expression of CD133,
Notch-1 and VEGF. Expressions of CD133-, Notch-1-, and VEGF-positive gli-
oma cells were higher in recurrent glioblastoma after radiotherapy and chemo-
therapy. To determine the clinical importance ofNotch-1 expression in glioblas-
toma, we analyzed 15 patients who had received bevacizumab therapy followed
by a second surgery at recurrence. OS was signifıcantly longer in cases with
Notch-1 negativity (8.8 months) than in those with Notch-1 positivity (6.8
months). Electron microscopic observation of two autopsy cases revealed the
effects of blood vessel normalization in Notch-1 positive glioblastoma. Electron
microscopic images confırmed the presence of pericytes surrounding the vascu-
lar endothelium. Autopsied tumors exhibited marked proliferation of Notch-1
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and VEGF positive cells around vessels. In tumor angiogenesis, vascular endo-
thelial growth factor and Notch signaling induce sprouting angiogenesis and
recruitment of vascular endothelial cells such as tip cells, stalk cells, and phalanx
cells. Fully mature phalanx cells are in close contact with pericytes. These fınd-
ings indicate that bevacizumab treatment promotes vascular normalization by
recruiting mature pericytes and associated with resistance to bevacizumab ther-
apy in glioblastoma with high Notch pathway activation.
#775 Identifıcation of activated signal transduction pathways and mole-
cules in theHMGB-1 induced angiogenesis.YujinKwon, Sujin Shin,WonKyu
Kim, Hoguen Kim. Yonsei Univ. College of Medicine, Seoul, Republic of Korea.
High-mobility group box-1 (HMGB-1) is a highly conserved protein playing
various roles both in the nucleus and cytosol and known to be expressed in
almost all types of mammalian cells. Secreted HMGB-1 has been most inten-
sively studied and reported as an immune cell derived cytokine regulating sys-
temic inflammation, signal transduction, and activation of endothelial cells
(EC). Especially, HMGB-1 over-expression is now considered as a hallmark in
cancers based on its involvement in cell proliferation, inflammatory microenvi-
ronment, invasion, metastasis, and sustained angiogenesis. Numerous studies
have shown that secreted HMGB-1 directly or indirectly promotes angiogenesis
by activation of ECs. However, mechanisms of HMGB-1mediated angiogenesis
have not yet been fully understood, especially, in terms of genomic changes
caused by HMGB-1 treatment. Moreover, differences between vascular endo-
thelial growth factor (VEGF) mediated and HMGB-1 mediated angiogenesis
have not been studied. To explore the roles of HMGB-1 in angiogenesis, we fırst
confırmed whether HMGB-1 treatment renders ECs angiogenic by evaluating
proliferation, migration, wound-healing, and tubule formation of ECs after
HMGB-1 treatment. In addition, we performed gene expression microarray to
clarify how HMGB-1 treatment induced EC activation at various time points
and subsequent angiogenic features according to time-dependent gene expres-
sion changes.We show that HMGB-1 treatment induces proangiogenic features
to ECs such as stimulation of tubule formation, promotion of proliferation, and
accelerated wound healing. By analysis of microarray data, we found that VEGF
and HMGB-1 commonly promoted the activation of MAPK, cell proliferation,
and wound healing pathways which directly regulate angiogenesis. On the other
hand, axon guidance, gap junction, P53 signaling, cell cycle, and cell differenti-
ation pathways were specifıcally up-regulated by HMGB-1. Taken together,
HMGB-1 leads to angiogenesis via upregulation of both angiogenic and nonan-
giogenic genes.
#776 Acquired platinum resistance enhances tumour angiogenesis
through activation of vascular mimicry. Aya El Helali,1 Nuala McCabe,1
Naomi Dickson,1 Lara Dura Perez,1 Denis P Harkin,2 RichardWilson,1 Richard
Kennedy1. 1Centre for Cancer Research and Cell Biology, Belfast, United King-
dom; 2Almac Diagnostics, Craigavon, United Kingdom.
Introduction: Platinum resistant High Grade Serous Ovarian Cancer (HG-
SOC) has a poor outcome with limited treatment options. Angiogenesis is a key
pathological feature of ovarian cancer and anti-angiogenics have dominated the
fıeld of drug development in EOC, particularly in the second-line setting (Mara-
chini et al 2013). In this studywe asked if platinum resistance could be associated
with an improved response to anti-angiogenic agents. Method: A review of
phase III anti-angiogenic clinical trials was used to investigate the association
between platinum resistance and response to anti-angiogenic agents. To inves-
tigate the effect of chemotherapy on predefıned ovarian cancer molecular sub-
groups (Gourley, et al. J Clin Oncol 32:5s, 2014), we analysed 35 matched pre-
and post-chemotherapy samples by gene expression. Novel isogenic cisplatin-
resistantHGSOCcell lineswere established to study themechanisms of cisplatin
section pressure and shift to an angiogenic phenotype. This was further vali-
dated in novel ascites-derived primary cell lines from HGSOC patients with
known outcomes following platinum-based chemotherapy. Results: Critical re-
view of 22 phase III anti-angiogenic trials suggested that there was a better
response to anti-angiogenics following previous platinum-based chemotherapy.
Our analysis demonstrated that 67% of treatment naïve tumours that were ini-
tially classifıed as non-angiogenic shifted to an angiogenic biology, which was
associated with platinum resistance. Additionally we found that cisplatin resis-
tant cancer cell lines demonstrated hallmarks of vascular mimicry and an asso-
ciated increase in vessel density using an angiogenesis Matrigel plug assay in
Athymic nudemice (p-value0.0001). In addition, cell lines established from
platinum-resistant patients as well as cell lines made platinum resistant in-vitro,
demonstrated overexpression of VEGFa which would be expected to stimulate
angiogenesis. Conclusion: We have demonstrated that platinum-resistance in
HGSOC is associated with angiogenic biology supporting the use of anti-angio-
genic agents in this setting.
#777 ELTD1/ADGRL4, a novel adhesion GPCR regulator of tumour an-
giogenesis, suppresses lipid metabolism in endothelial cells, and is upregu-
lated in breast cancer endothelium and epithelium. David M. Favara,1 Mad-
hulika Nambiar,2 Helen Sheldon,1 MassimoMasiero,1 Demin Li,1 Ali Jazayeri,2
Alison H. Banham,1 Adrian L. Harris1. 1University of Oxford, Oxford, United
Kingdom; 2Heptares Therapeutics, Welwyn Garden City, United Kingdom.
Background:We identifıed ELTD1/ADGRL4, an orphan GPCR belonging to
the adhesion GPCR family (aGPCR), as a novel regulator of angiogenesis and a
potential anti-cancer therapeutic target. ELTD1 is normally expressed in both
endothelial cells & vascular smooth muscle cells. Expression in the tumour vas-
culature is signifıcantly increased.Our aimswere to analyse ELTD1’s function in
endothelial cells & its role in breast cancer. Method: After ELTD1 silencing,
mRNA array profıling was performed on primary human umbilical vein endo-
thelial cells (HUVECs) & validated with qPCR & confocal microscopy. We in-
vestigated ELTD1 signalling by applying the aGPCR ’Stinger/tethered-agonist
Hypothesis’. For this, truncated forms of ELTD1 & peptides analogous to the
proposed tethered agonist region were designed. FRET-based 2nd messenger
(Cisbio IP-1; cAMP) & luciferase-reporter assays (NFAT; NFKB; SRE; SRF-RE;
CREB) were performed to establish canonical GPCR activation. To investigate
ELTD1 in breast cancer, a panel of cell lines representative of all molecular
subtypes were qPCR screened. Furthermore, primary human breast cancers
(n245) & matched primary & nodal secondary breast cancers (n79) were
stained for ELTD1 expression. Staining intensity was then scored & compared
with survival. Results: HUVECmRNA expression profıling after ELTD1 silenc-
ing showed upregulation of SLC24A1, which transports citrate from the mito-
chondria to the cytoplasm&ACLY,which converts cytoplasmic citrate toAcetyl
CoA, feeding fatty acid and cholesterol synthesis, and acetylation. We validated
this at RNA & protein expression level & showed that ELTD1 inhibited lipid
droplet formation. Signalling experiments revealed that unlike other aGPCRs,
ELTD1 does not couple to any canonical GPCR pathways (Gi; Gs; Gq;
G12/13). In breast cancer, we found that no representative cell line screened
expressed ELTD1. Breast cancer immunohistochemistry revealed higher inten-
sity vascular ELTD1 staining within the tumour stroma contrasted to normal
stroma & expression within tumour epithelial cells (15%). Higher ELTD1 ex-
pression in both the tumour stroma vasculature (n241; HR0.68; p0.04) &
within the subset of tumour positive cases (n24; HR0.3; p0.02) correlated
with improved relapse free survival (RFS). Conclusion: ELTD1’s regulation of
lipid synthesis through suppression of ACLY & SLC25A1 highlights ELTD1’s
role as a novel regulator of endothelial metabolism. Unlike other aGPCRs,
ELTD1 does not signal through canonical G protein pathways. The good prog-
nosis of ELTD1 expression may be related to inducing a quiescent endothelial
population. It will be of interest to relate this to activity of anti-angiogenic ther-
apy. Nevertheless, a relevant fraction of patients expressing ELTD1 still relapsed
& this may be a suitable target for this population.
#778 Identifying, subtyping and classifying tumor associated circulating
endothelial cells in patients with solid tumors.Daniel L. Adams,1 R. Katherine
Alpaugh,2 Steven H. Lin,3 Jeffrey R. Marks,4 Raymond Bergan,5 Stuart S. Mar-
tin,6 SaranyChumsri,7MassimoCristofanilli,8 Cha-Mei Tang,9 Steingrimur Ste-
fansson10. 1Creatv MicroTech, Inc., Monmouth Junction, NJ; 2Fox Chase Cancer
Center, Philadelphia, PA; 3MD Anderson Cancer Center, Houston, TX; 4Duke
University, Durham, NC; 5Oregon Health and Science University, Portland, OR;
6University of Maryland, Baltimore, MD; 7Mayo Clinic Cancer Center, Jackson-
ville, FL; 8Northwestern University, Chicago, IL; 9Creatv MicroTech, Inc., Po-
tomac, MD; 10HeMemics Biotechnologies, Inc., Rockville, MD.
Background: Tumor endothelial cells (ECs) are a population of stromal cells
required for tumor growth that cooperatewith tumors to form angiogenic struc-
tures. In blood, circulating ECs (CECs) are normal constituents of healthy indi-
viduals, although a Cancer Associated Vascular Endothelial cell (CAVE) sub-
type has been observed in cancer patients. The CAVE population has been
isolated and identifıed using their large size or multicellular clustering and a
pooled mixture of classical EC markers (i.e. CD31 and CD146). However, there
has been no attempt to differentiate CAVEs from themany EC subtypes. This is
not surprising as in-depth phenotyping of ECs requires an array of biomarkers
that until recently has not been feasible. A multi-phenotypic screening of EC
markerswas tested onCAVEs from116 blood samples in 3 types of solid tumors.
This data suggests that CAVEs exist as a common and diverse subtype of tumor
derived CECs that may express cytokeratin (CK) and various EC biomarkers,
correlating to disease stage.Methods: Peripheral blood samples from 116 cancer
patients (stage I-IV) were drawn from 2012-2014 including breast (n42), lung
(n39) and prostate (n35), as well as blood from 34 healthy controls. Blood
was processed by an established fıltration approach, i.e. the CellSieveTMmicro-
fıltration technique (Creatv MicroTech), fıltering blood by size exclusion and
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staining cells for CK 8, 18 & 19, EpCAM and CD45. After identifıcation and
imaging, the QUAS-R (Quench, Underivatize, Amine-Strip and Restain) tech-
nique was used to remove fluorescence signal and restain all cells with CD31,
CD146, CD144, & DAPI. After reimaging, QUAS-R was again used to remove
fluorescence and restain the cells for CD14, CD105, CD34, &DAPI. Results: Out
of 116 patient samples, we identifıed CAVEs in 63 patients (54%) based on
positivity of CD31, CD144 or CD146, but none were found in healthy controls.
CAVEs per 7.5mL sample in patients averaged 5.1 (breast), 5.6 (prostate) and 7.9
(lung). Presence of CAVEs appeared related to stage with 26% in stage 1, 61% in
stage 2, 68% in stage 3, and 74% in stage 4 patients. No CAVEs were positive for
CD14 or CD45. CD31 was the most present marker, found on 93% of CAVEs,
followed by CD144 (85%), CD34 (64%), CD146 (45%), & CD105 (4%). In con-
trast with the previous study on this topic, CK was found in 67% of CAVEs, but
was not a universal marker. Conclusions: It has been reported that CK and
CD45- CECs are isolated from the blood of cancer patients in colon and lung
cancers, prompting some to classify them as circulating tumor cells. However,
subtyping these CECs is incomplete when characterized with only 3-4 biomark-
ers. A multi-phenotypic subtyping technique was used to properly identify and
subtype these CECs in cancer patients. This data suggest that a subset of CECs,
e.g. CAVEs, are found in circulation as CK/CD45-, but exist as a heteroge-
neous population of cancer specifıc circulating cells that require further study.
#780 In vitro screening of individual human neuroendocrine tumors for
their angiogenic response to tyrosine kinase inhibitors. Tanja Milosavljevic,1
Elise J. Chouest,1 Catherine E. Anthony,2 ArianaDirige,1 Yi-ZarnWang,1 Philip
J. Boudreaux,1 Thiagarajan Ramcharan,1 Eugene A. Woltering1. 1LSU Health
New Orleans, New Orleans, LA; 2Merkey Cancer Center, University of Kentucky,
Lexington, KY.
Background: Human neuroendocrine tumors (NETs) are highly vascular in
nature and reliant on multiple receptor tyrosine kinases (TKs) for their neovas-
cularization, growth, and, metastasis. These tumors most commonly originate
in the small bowel (SB) and frequentlymetastasize to the lymph nodes and other
organs. Current treatment of metastatic NETs involves a variety of approaches
including antiangiogenesis therapies. In this study we tested effectiveness of six
TK inhibitors (TKIs) [Dovitinib lactate, Regorafenib, Erlotinib, Imatinib, Vata-
lanib, and Sunitinib] on individualNETs angiogenic response in vitro.Methods:
Specimens were obtained from NET patients who underwent removal of their
primary tumor (small bowel/pancreas/stomach), nodal, and organ (i.e. liver/
ovary/omentum/mesentery) metastasis. Fresh tumors were minced, embedded
in a fıbrin-thrombin clot and supplemented with nutrient culture media per the
in vitro human tumor angiogenesis model protocol. Neovessels were visually
scored and evaluated for angiogenic parameters: percent initiation (%I), angio-
genic growth (AI), and overall angiogenic response (OAR). All TKIs were pre-
pared consistent withmanufacturer’s instructions and their effective concentra-
tion was determined by dose response experiments. The selected TKI dose
reflected the clinically achievable plasma level. A large group of NETs was tested
for their antiangiogenic response to six TKIs [Dovitinib lactate (D): n164,
Regorafenib (R): n163, Erlotinib (E): n35, Imatinib (I): n51,Vatalanib (V):
n163, Sutent (S): n164)]. Paired samples t-test was used to compare TKI to
control results for each angiogenic parameter, and independent samples t-test to
compare TKI-response of primary andmetastatic sites (MedCalc). Results: Each
selected dose [D: 82nM, R: 1100nM, E: 100M, I: 2.5M, V: 20M, S: 188nM]
achieved statistically signifıcant inhibition of OAR (D:94.23%, R:35.58%,
E:52.07%, I:59.77%,V:76.65%, S:64.79%) in allNETs (p0.0001). This is accom-
plished by the simultaneous statistically signifıcant decrease of %I by at least
3.47% (p0.0164) and AI by at least 34.03% (p0.0001). Comparison of OAR
between the primary and metastatic tumor sites revealed no differences in their
response to each tested TKI (p0.2119). In all NETs, TKIs inhibited bothmech-
anisms of angiogenesis, but preferentially targeted growth (all TKIs: p0.0001)
over %I (D, I, V, S: p0.0001; E: p0.0072; R: p0.0164). Conclusions: In vitro
screening of individual tumors revealed that TKIs effectively inhibited all pa-
rameters of angiogenesis in all NETs, primary and metastatic tumors. Selected
TKIs preferentially inhibited angiogenic growth rather than initiation in all
NETs. Our preclinical results show that Dovitinib inhibits angiogenesis most
effectively in human NETs compared to other TKIs in vitro.
#781 Functional consequence of the p53 codon 72 polymorphism in colo-
rectal cancer.Venkat R.Katkoori,1UpenderManne,2Harvey Bumpers1. 1Mich-
igan State Univ., East Lansing, MI; 2University of Alabama at Birmingham, Bir-
mingham, AL.
Background: The codon 72 polymorphism in p53 has been implicated in
colorectal cancer (CRC) and CRC health disparities. In this study, we deter-
mine the functional consequence of this polymorphism in CRC following
both in-vitro cell based and in-vivo mouse model studies. Experimental
Design: Plasmids (pCMV6) that express different phenotypes of p53 [p53
wild type (wt) at codon 72 (R72wt), R72wt with mutation at codon 273 cys-
teine (R72273Cys), p53 mutation at codon 72 (P72wt) and P72wt with mutation
at codon 273 (P72273Cys)] were constructed. We selected a CRC cell line
Caco2, which does not express p53 for in vitro studies. Severe combined
immunodefıcient mice were inoculated with CRC cells (HT29, SW480, and
LS174) to establish tumor xenografts (tumors). Tumor angiogenesis was
assessed in tumors by immunostaing for CD31. Sequencing analysis for
codon 72 polymorphism of p53 was performed using genomic DNA purifıed
from tumors.Western blot (WB) or immunostaining analyses for proteins of
signaling mechanisms were performed to assess the functional consequence
of P72 phenotype of p53. Results: Our study demonstrated that P72 tumors
had well established vascularity, while R72 tumors had very poor vascular-
ization. Indeed, themeanmicro vessel density was higher in P72 tumors than
in R72 tumors. WB analyses revealed that P72wt or mutant phenotypes ef-
fectively induced the activation of p38 and RAF/MEK/ extracellular signal-
regulated kinase (ERK) MAP kinases. Up-regulation of phosphorylated
SEK1/MKK4, an upstream kinase of p38MAPKwas associated with P72wt or
mutant phenotypes. This activation was accompanied by up-regulation of
phosphorylated-MAPKAPK-2, -Hsp27, and -CREB, downstream targets of
p38 MAPK. Increased activation of CREB was found to be higher in tumors
that exhibit P72 phenotype. Metastatic lesions of CRC expressed more phos-
pho-CREB than non-metastatic lesions. Furthermore, suppression of RAF/
MEK/ERK activation was signifıcantly higher in cells that express R72wt
phenotype compared to cells that express P72wt or mutant phenotypes. The
expression of P72wt or mutant phenotypes displayed decreased expression of
E cadherin and/or an increased expression of vimentin, fıbrinectin, CD44,
thereby promoting CRC metastasis. Conclusions: These fındings offer sig-
nifıcant novel insights into the mechanism by which P72 contributes to the
aggressiveness of CRC. Because P72 is over-expressed in CRC, specifıcally in
African-American patients, these studies suggest a role for P72 in cancer
health disparities. This work was supported by NIH/NCI Workforce Diver-
sity Grant R21-CA171251.
#782 Revisiting the angiogenic switch:Host geneticmodifıers induce non-
productive angiogenesis and inhibit breast cancer.Michael Flister, Cody Plas-
terer, Shirng-Wern Tsaih, Angela Lemke, Dana Murphy, Amit Joshi, Peter
LaViolette, Carmen Bergom.Medical College of Wisconsin, Milwaukee, WI.
Purpose: Multiple aspects of the tumor microenvironment (TME) impact
breast cancer risk, yet the genetic modifıers of the TME are largely unknown,
including those that modify tumor vascular formation and function. Methods:
To discover host TME modifıers, we developed a system called the Consomic/
Congenic Xenograft Model (CXM). In CXM, human breast cancer cells are
orthotopically implanted into genetically-engineered consomic/congenic xeno-
graft host strains that are derived from two parental strains with different sus-
ceptibilities to breast cancer. Because the host strain backgrounds are different,
whereas the inoculated tumor cells are the same, any phenotypic variation is due
to TMEmodifıer(s) on the substituted chromosome (i.e., consomic) or subchro-
mosomal region (i.e., congenic) of the host’s germline DNA. Here, we assessed
TMEmodifıers on rat chromosome 3 (RNO3) that impact growth, angiogenesis,
vascular function, and hematogenous metastasis of tumors implanted in the
SSIL2R and SS.BN3IL2R CXM strains. Results: Breast cancer xenografts im-
planted in SS.BN3IL2R (consomic) had signifıcant inhibition of tumor growth
and hematogenousmetastasis comparedwith SSIL2R (parental control), despite
a paradoxical increase in the density of blood vessels in the SS.BN3IL2R tumors.
We hypothesized that decreased growth of SS.BN3IL2R tumors might be due to
nonproductive angiogenesis. To test this possibility, SSIL2R and SS.BN3IL2R
tumor vascular functionwas examined by dynamic contrast-enhancedmagnetic
resonance imaging (DCE-MRI), micro-computed tomography (micro-CT),
and ex vivo analysis of primary blood endothelial cells; all of which revealed
altered vascular function in SS.BN3IL2R tumors compared with SSIL2R. Gene
expression analysis also revealed a dysregulated vascular signaling network in
SS.BN3IL2R tumors, amongwhichDLL4was localized to RNO3 and downregu-
lated on the vasculature of SS.BN3IL2R tumors compared with SSIL2R. CXM
congenic mapping confırmed that the DLL4 modifıer allele is physically linked
with breast cancer inhibition by inducing non-productive angiogenesis. Finally,
using whole genome sequencing of the germline DNA, we have identifıed mul-
tiple polymorphisms in the DLL4 promoter and a proximal regulatory lncRNA
that likely alter DLL4 expression and function. Conclusions: Collectively, these
data suggest that DLL4 can function as a heritable modifıer of non-productive
angiogenesis that inhibits breast cancer growth and metastasis.
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#783 Cancer cell-derived extracellular vesicles stimulate tumor angiogen-
esis by delivering VEGF to endothelial cells. Song Yi Ko, Honami Naora. UT
MD Anderson Cancer Ctr., Houston, TX.
Angiogenesis is essential for tumor growth andmetastasis, and is orchestrated
by a repertoire of growth factor signaling pathways that stimulate endothelial
cell growth, migration and vessel formation. Recent studies have shown that
angiogenesis can also be regulated by cell-derived extracellular vesicles. Exo-
somes are small endosomal-derived membrane vesicles that contain various
biomolecules such as RNA and proteins, and are increasingly thought to play
important roles in transferring informational cargo between cancer cells and
stromal cells. In the majority of studies to date, the effects of cancer cell-derived
exosomes have been attributed to their RNA cargo. In this study, we identifıed
that exosomes derived from ovarian, colon and renal cancer cells contain abun-
dant vascular endothelial growth factor (VEGF). Cancer cell-derived exosomes
were found to activate the VEGF signaling pathway in endothelial cells and to
stimulate endothelial cellmigration and tube formation. Furthermore, our stud-
ies using inhibitors of VEGF signaling demonstrated that the stimulatory effects
of cancer cell-derived exosomes on endothelial cells depend on the presence of
VEGF in exosomes and are mediated via the VEGF signaling pathway. These
fındings indicate that cancer cell-derived exosomes promote tumor angiogene-
sis by delivering VEGF to endothelial cells.
#784 Pharmacodynamic biomarkers in metronomic chemotherapy: Mul-
tiplex cytokinemeasurements in gastrointestinal cancer patients.PalomaVa-
lenzuela,1 Karla Parra,1 Derrick Oaxaca,1 Luis Reza,1 Jose Lopez,1 Montserrat
Garcia Arreguin,1 Diana Garcia,1 Georgialina Rodriguez,1 Alfredo Falcone,2
Giacomo Allegrini,2 Teresa Di Desidero,2 Guido Bocci,2 Robert Kirken,1 Giulio
Francia1. 1UT El Paso, El Paso, TX; 2University of Pisa, Pisa, Italy.
Metronomic chemotherapy has shown promising antitumor activity in a
number of malignancies. For example, we previously reported (Allegrini et al.,
Angiogenesis (2012) 15(2):275-86) a phase II clinical trial ofmetronomicUFT (a
5-fluorouracil prodrug; 100 mg/twice per day p.o.) and cyclophosphamide
(CTX; 500 mg/mq2 i.v. bolus on day 1 and then 50 mg/day p.o.) plus celecoxib
(200 mg/twice a day p.o.) in 38 patients with advanced refractory gastrointesti-
nal tumors. The mechanisms of action of metronomic chemotherapy include
upregulation of the angiogenesis inhibitor Thrombospondin-1, the suppression
of bone marrow derived endothelial progenitor cells and, at least for drugs such
as CTX, activation of the immune system. To further evaluate the latter, we
carried out an immune system multiplex 14-cytokine profıling of plasma sam-
ples that were available (for day 0, day 28, and day 56) from 31 of the 38 patients
in the above noted (Allegrini et al) clinical trial. Our results show that pre-
treatment plasma level cut-offs of interferon-gamma (12.84pg/ml), sCD40L
(2168pg/ml), interferon-alpha2 (55.11pg/ml), and IL-17a (15.1pg/ml)
were predictive markers for those patients with better progression-free survival
(p.05 for each cytokine). After 28 days of metronomic therapy, the plasma
levels of sCD40L, IL-17a, and of IL-6 (130pg/ml) could serve as predictors of
improved progression-free survival, as could levels interferon-gamma and
sCD40L after 56 days of therapy. We observed minimal changes in cytokine
profıles, from baseline, as a consequence of the metronomic therapy, with the
exception of an elevation of IL-6 and IL-8 levels 28 days (and 56 days) after
treatment started (p0.05). Our results indicate that a selective cytokine eleva-
tion, involving IL-6 and IL-8, followingmetronomic chemotherapy administra-
tion. In addition, interferon-gamma and sCD40L may be potential biomarkers
for gastrointestinal cancer patients that are likely to benefıt from metronomic
chemotherapy. Our study contributes to our understanding of the mechanisms
of action of metronomic chemotherapy, and may guide future patient selection
criteria for metronomic chemotherapy for gastrointestinal cancers.
#785 Molecular profıle of sunitinib resistance in clear-cell renal cell carci-
noma. Oscar Reig Torras,1 Mercedes Marin-Aguilera,2 Natalia Jiménez,2 Paré
Laia,2 Patricia Galvan,2 CarmeMallofre,1 Aleix Prat,1 BegoñaMellado1. 1Hospi-
tal Clínic de Barcelona, Barcelona, Spain; 2Fundació Clínic per a la Recerca
Biomèdica, Barcelona, Spain.
Background: Sunitinib (SU) is a tyrosine kinase inhibitor used in the fırst line
setting in metastatic clear-cell renal cell carcinoma (ccRCC). Recently, niv-
olumab, a checkpoint inhibitor, has been approved as a second line therapy. The
identifıcation of biomarkers of resistance to these drugs may be useful to select
patients’ treatment. In this study we investigated the molecular and immune
profıle associated to SU resistance. Methods: Forty-four patients (pts) withmet-
astatic ccRCC treated with SU were included. A global transcriptome analysis
(Affymetrix Human Gene 2.0 ST array) on 6 extremely sensitive (ES; progres-
sion-free survival (PFS) 24 months) and 8 refractory (R; ; progression disease
as best response) ccRCC pts treated with SU was performed. Differentially ex-
pressed geneswere tested in thewhole cohort by qPCR. In silico validation using
the microarray data from 53 SU-treated pts (Beuselinck et al, Clin Cancer Res
2015) was performed. In addition 730 immune-related genes were tested in the
same cohort and in 10 additional pts treated with anti-PD1/PD-L1 therapies as
an exploratory analysis. Results: Differential expression analysis between R and
ES pts showed 330 differentially expressed genes: 148 were overexpressed and
182 underexpressed in R pts. Top two deregulated networks were centered in
LYN and NR3C1 (Network 1), and in chemokine ligands and receptors (e.g.
CCL5, CCRL1 and CXCL10) (Network 2). In Beuselinck dataset, 9 genes were
differentially expressed between R and ES pts. The expression of 7 genes (BST2,
CD44, ELK1, FADS2, LYN,NKAPandVEGFC)was correlatedwith a lower PFS
in both cohorts (Table 1). A different immune-related molecular profıle was
shown between resistance to SU and to anti-PD1/PD-L1 therapies. TIM-3 was
overexpressed in SU-sensitive pts and in anti-PD1/PD-L1 refractory pts. Con-
clusions: We described a gene expression profıle of SU resistance in ccRCC pts.
The value of TIM-3 as a potential biomarker in ccRCC merits further explora-
tion.
Survival analysis of selected genes in the training and validation set.
*High vs low expression.
HR
(Training set) P
Median
PFS,
months*
HR
(Validation set) P
Median
PFS,
months*
ELK1 2.66 (1.1 - 6.2) 0.022 5.2 vs 17.2 2.47 (1.2 - 5.1) 0.014 12 vs 24
BST2 4.87 (1.5 - 15.7) 0.008 4.6 vs 10.6 2.22 (1.1 - 4.6) 0.031 11 vs 15
CD44 2.55 (1.2 - 5.6) 0.023 5 vs 18.9 2.47 (1 - 6) 0.046 9 vs 14
FADS2 2.84 (1.1 - 7.7) 0.039 4.2 vs 6.9 2.1 (1.1 - 4) 0.025 11 vs 19
LYN 5.38 (1.6 - 18.1) 0.006 4.5 vs 17.2 2.35 (1.1 - 4.9) 0.024 8.5 vs 16
NKAP 3 (1.3 - 7.1) 0.012 5.1 vs 17.2 2.27 (1.1 - 4.8) 0.031 11 vs 16
VEGFC 3.02 (1.2 - 7.5) 0.016 4.5 vs 17.2 1.97 (1 - 3.8) 0.045 12 vs 25
#786 Vascularity and vascular maturity in breast cancer: a comparative
analysis of the different molecular subtypes.Nehad M. Ayoub,1 Ahmed Y. Al
Husban,1 Hussein M. Al Husban,2 Abdul Rahman N. Al Khatib,1 Alaa O. Al-
Mesleh,1 Ekhlas A. Al-Majali2. 1Jordan University of Science and Technology
(JUST), Irbid, Jordan; 2Royal Medical Services, Amman, Jordan.
Currently, angiogenesis inhibitors lack considerable activity and did not re-
sult in survival advantage in breast cancer. The goal of this study is to evaluate
vasculature in terms of vascularity and vascular maturity among breast cancer
subtypes. Archived tumor samples for breast cancer patients were retrieved
fromPathologyDepartment at RoyalMedical Services in Jordan. Tissue sections
were stained for the expression of basementmembrane laminin using immuno-
histochemical analysis. Endothelial cell andpericytewere identifıed and counted
based on the shape of the nuclei as visualized with DAPI stain. Demographic,
clinical, and pathological data were retrieved from patient medical records at
time of diagnosis. Vascularity was obtained by counting the number of blood
vessels and maturity of blood vessels is represented by the ratio of the average
number of endothelial cell to average number of pericytes. A total of 60 patients
were enrolled in this study in which 34 patients (56.7%) have hormone-depen-
dent disease, 14 patients (23.3%) determined to haveHER2-positive disease, and
12 cases (20.0%) were classifıed as triple-negative. Results showed a signifıcant
difference for the mean number of blood vessels (p0.008) and endothelial cell
to pericyte ratio (p0.000) among the different molecular subtypes of breast
cancer. Post hoc analysis indicated statistically signifıcant difference in mean
number of blood vessels between hormone-dependent and HER2-positive tu-
mors (p0.015). In addition, ratio of endothelial cells to pericytes was signifı-
cantly different between hormone-dependent cases and each of HER2-positive
and triple-negative cases (p0.000 and 0.014, respectively). Size of tumor was
signifıcantly correlated to endothelial cell to pericyte ratio for the population
examined (r0.345, p0.007). A signifıcant correlation was found between the
number of blood vessels and number of involved lymph nodes among all pa-
tients (r0.271, p0.038). Independent samples t–test analysis comparing
mean number of blood vessels and endothelial to pericyte ratio according to
hormone receptor status showed signifıcant difference between hormone recep-
tor negative and positive cases for both estrogen and progesterone receptors
(p0.05). No signifıcant differencewas found for the vascular parameters tested
according to tumor stage, grade, and lymphovascular invasion (p0.05). Col-
lectively, these fındings showed that the degree of tumor vascularity and vascular
maturity are not uniform among breast cancer subtypes. Vascular maturity was
remarkably higher for hormone-dependent breast tumors compared to both
HER2-positive and triple-negative cases. It is critical that a careful assessment of
tumor vasculature is being considered in breast cancer patients in order to de-
termine responsiveness to chemotherapy and anti-angiogenic treatment among
the different molecular subtypes.
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#787 Vascular mimicry mediated mechanisms drive therapy resistance in
glioblastoma. Kartik Angara, Mohammad Rashid, Thaiz Borin, Bhagelu
Achyut, Meenu Jain, ASM Iskander, Roxan Ara, Ali Arbab. Augusta University,
Augusta, GA.
Therapy resistance in solid tumors is of growing concern due to the failure of
multiple therapeutic approaches. Targeting tumor cells alone with chemother-
apy, tumor vasculature with antiangiogenic therapies (AAT) and tumor-infıl-
trating myeloid cells with CSF1R inhibitor have all lead to the development of
refractory tumors with greater relapse rates. There is an urgent need to under-
stand molecular mechanisms of therapy resistance in cancer. There could be
tumor cell extrinsic and intrinsic mechanisms in the tumor microenvironment.
We focused our study to investigate tumor cell intrinsic pathways using glioblas-
toma (GBM) as a model tumor and AAT (antiVEGF-VEGFR) as a model ther-
apy. The benefıts of AAT are transient with increased relapse owing to adaptive
responses by the GBM. Our preclinical study and in vitro data, for the very fırst
time, identifıed that AAT induces transdifferentiation of tumor cells into endo-
thelial-like cells, capable of forming functional blood vessels in the growing
tumors, termed as vasculogenicmimicry (VM).We observed that anti-VEGFR2
(Vatalanib) induced VM vessels are positive for periodic acid-Schiff (PAS) ma-
trix but devoid of any endothelium on the inner side and lined by tumor cells on
the outer-side. The PASmatrix is positive for basal laminae (laminin) indicat-
ing vascular structures. Vatalanib treated GBM displayed various stages of VM
such as initiation (mosaic), sustenance, and full-blown VM. In addition to this,
vatalanib treated tumors show signifıcantly increased Laminin positive loops
characteristic of VM in tumor center as well as at the periphery. A positive
correlation was observed between the VM-like structures and the tumor size.
We also performed in vitro tube formation assays with AAT treated GBM cells
alone and HUVEC cells (co-culture) to confırm the role of GBM cells in the
formation of mosaic vessels in normoxic conditions. Interestingly, tumor cells
are incorporated into the tubes formed by HUVEC cells. We found a higher
number of complete tube like structures with AAT treated tumor cells as com-
pared to control. Cytokine array with the condition media from tumor cells
treated with AAT showed a signifıcant upregulation in the levels of IL8. We
observed a signifıcant increase in the CXCR1 and CXCR2 endothelial-like
GBM cells following treatment with AAT. Ongoing investigations are focused
on study of IL8-CXCR1/2 pathway in VM regulation using loss or gain of func-
tion approaches. The study will identify critical mediators of VM in GBM. In
clinics, discovering novel targets causing VM associated therapy resistance is
essential for identifying subset of patients that could be treated with alternate
regimens.
#788 Less is more: macrophage depletion via CSF1/CSF1R pathway im-
proves anti-VEGF therapy after adaptive resistance. Yasmin A. Lyons, Sunila
Pradeep, Jean M. Hansen, Michael J. Wagner, Robert L. Dood, Sherry Y. Wu,
RebeccaA. Previs,WeiHu, Robert L. Coleman,Anil K. Sood.University of Texas
MD Anderson Cancer Center, Houston, TX.
Objectives: Anti-angiogenesis therapy shows clinical benefıt in patients with
high-grade serous ovarian cancer (HGSC), but adaptive resistance typically oc-
curs. Thus, approaches to overcome such resistance are needed. Here, we sys-
tematically assessed immune cell populations enriched during adaptive resis-
tance and identify novel therapeutic avenues.Methods: A series of in vitro and in
vivo (immune competent and nude mice) experiments were carried out. Ani-
mals were treated with anti-VEGF antibody continuously until resistance
emerged, at which point full immune profıling was performed. Based on these
results, effıcacy of AC708 (CSF1R inhibitor to target tumor-associated macro-
phages)was tested in the adaptive-resistancemodels. F4/80 antibodywas used as
a macrophage marker. Results: On the basis of full immune profıling, we de-
tected signifıcantly increased macrophage infıltration in tumors with anti-
VEGF antibody resistance compared to tumors from sensitivemice (p0.0001).
Given the dominant role of CSF1R in macrophage function and overexpression
ofCSF1R inHGSC,we addedAC708 following emergence of adaptive resistance
to anti-VEGF antibody. Mice treated with AC708 after anti-VEGF antibody
resistance demonstrated complete response upon completion of the experiment,
while those that did not receive AC708 still had abundant tumor. To mimic
treatment with the AURELIA regimen, we next treated mice with anti-VEGF
antibody and paclitaxel until resistance emerged, and then AC708 was added.
The addition ofAC708 restored response to anti-angiogenesis therapy, resulting
in 82% lower tumor burden compared to treatment with anti-VEGF antibody
and paclitaxel alone (p  0.0001), and a substantial decrease in macrophages
(p0.0004). Conclusions: The addition of CSf1R inhibitor to anti-VEGF ther-
apy and taxane chemotherapy results in robust anti-tumor effects. To confırm
these fındings, a clinical trial at our institution is nearing activation. The REDI-
RECT (RandomizEd Induction DIscontinuation TRial of EmaCTuzumab) trial
will randomize patients to continueweekly paclitaxel andbiweekly bevacizumab
with or without a CSF1R inhibitor (emactuzumab) following an induction
phase.
#789 Establishment of an in vitro model for the study of vasculogenic
mimicry in ovarian and gastrointestinal cancer cells.AndresValdivia,1 Dusan
Racordon,2 Raul Aravena,3 Gabriel Mingo,2 Alejandra Sandoval,1 Maria Loreto
Bravo,4 Mauricio A. Cuello,2 Sumie Kato,2 Rafaela Erices,2 Carolina Ramirez,2
Pamela Gonzalez,2 Beatriz Sanchez,2 Alejandro H. Corvalan,5 Gareth I. Owen6.
1Pontifıcia Universidad Catolica de Chile, Advanced Center of Chronic Diseases
(ACCDis), Santiago, Chile; 2Pontifıcia Universidad Catolica de Chile, Santiago,
Chile; 3Pontifıcia Universidad Catolica de Chile, Universidad Santo Tomas, San-
tiago, Chile; 4PontifıciaUniversidadCatolica de Chile, Center UC Investigation in
Oncology, Millennium Institute on Immunology and Immunotherapy, Santiago,
Chile; 5Pontifıcia Universidad Catolica de Chile, Center UC Investigation in On-
cology, Advanced Center of Chronic Diseases (ACCDis), Santiago, Chile; 6Pontifı-
cia Universidad Catolica de Chile, Center UC Investigation in Oncology, Millen-
nium Institute on Immunology and Immunotherapy, Advanced Center of
Chronic Diseases (ACCDis), Santiago, Chile.
Introduction: A key step in cancer progression is tumor irrigation. The pro-
cess of angiogenesis can be complemented in sub-sets of highly aggressive can-
cers by the process of vasculogenic mimicry, which is the formation of tubular
structures by tumor cells. Herein, we sought to establish an in vitro assay of
vasculogenicmimicry and determine the percentage of ovarian and gastrointes-
tinal primary cultures capable of undergoing this process. Materials &Methods:
Gastric cancer cell lines, AGS and Hs746T, and the ovarian cancer cell lines
SKOV-3 and HEY were used in conjunction with gastrointestinal and ovarian
primary cultured cancer cells extracted from peritoneal fluid. Cells were seeded
on matrigel and monitored for a week. Hollow channels formation was evalu-
ated by fluorescent dye microinyection, periodic acid Schiff staining, confocal
microscopy and X-Ray microtomography (Micro-CT). Results: SKOV-3, HEY
and AGS cell lines underwent the process of vasculogenic mimicry. Both confo-
cal microscopy andMicro-CT reconstruction were able to show the presence of
a lumen of the structures in 3D. In 22 primary cancer cultures (Ovarian, Colon
and Gastric) only 38% could underwent vasculogenic mimicry. Discussion: We
have standardized an in vitro assay to assay and quantify vasculogenic mimicry.
Regardless of origin, only a low percentage of cultures have the ability to un-
dergo vasculogenic mimicry. An understanding of this process could shed light
on new therapies for this sub-set of highly aggressive cancers. Funding: FOND-
ECYT 1120292, 3150028 & 1140970. CORFO L2 13IDL2-18608, BMRC 13CTI
21526-P6, IMII P09/016-F, CONICYT-FONDAP #1513001.
#790 Regulation of tumor angiogenesis by low dose Aspirin. Jinia
Chakraborty,1 Gargi Maity,2 Snigdha Banerjee,2 Sushanta K. Banerjee2. 1VA
Medical Center/Blue Valley West High School, Kansas City, MO; 2VA Medical
Center, Kansas City, MO.
Background and Objective: Tumor angiogenesis is a pathophysiological pro-
cess in which new blood vessels are formed in the primary tumor site or distant
organs for the nourishment of cancer cells and metastatic growth. Thereby,
targeting tumor angiogenesis is an important area of research for cancer therapy.
Abnormal structure of blood vessels (i.e. leakiness due to abnormal lining of
pericytes on the microvessels) is one of the critical features of tumor angiogen-
esis that sensitizes vascular cells to cytokines and helps circulating tumor cells to
metastasize to distant organs. Our long term goal is to repurpose the drugs that
may prevent tumor angiogenesis or normalize the vessels by repairing leakiness
via recruiting pericytes or both. Our recent studies found that Aspirin (ASA) has
the potency to inhibit breast cancer growth andmetastasis, as well as reprogram
the mesenchymal to epithelial transition (MET). Given the importance of ASA,
we testedwhetherASAmaybe able to regulate tumor angiogenesis.Methods: To
do so, we determined the effect of low dose ASA (1mM, which is equivalent to
80mg human dose), ASA-treated (2.5mM) conditioned media (231-CMASA) or
vehicle-treated conditioned media (231-CMVT) of MDA-MB-231 cells on dif-
ferent endothelial cell physiology. These include endothelial cells’ migration
towards serum using 3Dmodifıed Boyden chamber assay, in vitro capillary-like
structure formation on Matrigel, cell permeability using in vitro endothelial
permeability assay and interactions of pericytes-endothelial cells.We also deter-
mined the effect of ASA on various angiogenic factors associated with tumor
angiogenesis. Finally, we determined the effect of ASA on in vivo tumor angio-
genesis using in vivo Angiogenesis Assay (Trevigen) Results and Conclusions:
We found that 231-CMASA signifıcantly blocks in vitromigration, the formation
of in vitro capillary-like structures parallel with leakiness via incomplete inter-
action of pericytes and endothelial cells as compared to 231-CMASA. The anti-
angiogenic effect ofASAwas also documented in in vivo assays.Mechanistically,
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ASA treatment blocks several angiogenic factors including VEGF-A that are
associated with these three events, implicating a low dose of Aspirin is poten-
tially therapeutic for breast cancer via blocking and normalizing tumor angio-
genesis.
#791 Inhibitory effects of theaflavin-3, 3=-digallate (TF3) on ovarian can-
cer cells.YiC.Chen,1GaryO. Rankin2. 1AldersonBroaddusUniv., Philippi,WV;
2Marshall University, Huntington, WV.
Theaflavin-3, 3’-digallate (TF3) is a black tea polyphenol produced from po-
lymerization and oxidization of green tea ployphenols epicatechin gallate and
()-epigallocatechin-3-gallate (EGCG) during fermentation of fresh tea leaves.
TF3 has been reported to have anti-cancer properties.However, the effect of TF3
on tumor angiogenesis and the underlying mechanisms are not clear. In the
current research, TF3 was verifıed to inhibit tumor angiogenesis. Compared
with EGCG, TF3 was more potent. TF3 inhibited human ovarian carcinoma
OVCAR-3 cells induced angiogenesis in human umbilical vein endothelial cell
model and in chick chorioallantoic membrane model. TF3 reduced tumor an-
giogenesis by down-regulating HIF-1 and VEGF. One of the mechanisms was
TF3 inactivated Akt/ mTOR/ p70S6K/ 4E-BP1 pathway and Akt/ c-Myc path-
way. Besides, TF3 suppressed the cleavage of Notch-1, subsequently decreased
the expression of c-Myc, HIF-1 and VEGF, and fınally impaired cancer cells
induced angiogenesis. Nevertheless, TF3 didn’t have any influence on MAPK
pathways. Taken together, these fındings suggest that TF3 might serve as a po-
tential anti-angiogenic agent for cancer treatment.
#792 Development of high-throughput cell-based co-culture angiogenesis
assay system using hTERT immortalized cells. CHAOZHONG ZOU,1 Chia-
Wen Hsu,2 Menghang Xia,2 Metewo S Enuameh1. 1ATCC, Gaithersburg, MD;
2National Institutes of Health, Bethesda, MD.
Angiogenesis is amulti-step physiological process which is involved in a large
number of normal and disease state processes; In vitro angiogenesis models
provide very useful tools to study these processes, one of which is the analysis of
tubule formation. Tubules formed in co-culture assays were signifıcantly more
heterogeneous and more closely resembled capillaries than Matrigel® tubules.
Current co-culture models using primary cells have donor variability, and in-
consistent results due to lot to lot variation. In this study, we established an in
vitro co-culture model system consisting of an assay ready mixture of an aortic
endothelial cell line TeloHAEC-GFP (hTERT immortalized human aortic en-
dothelial cell line) and a hTERT immortalized adipose-derived mesenchymal
stem cell line (hTERT-MSCs) in a specially formulated medium containing
VEGF supplement (Angio-Ready™ Angiogenesis Assay System). Both cell lines
were immortalized by hTERT (human telomerase reverse transcriptase) alone
and have been well-characterized showing that the cells retain the most impor-
tant characteristic of their parental counterparts. The new co-culture system
forms functional tubular structures in less than 7 days, and in addition, the
hTERT-MSC cells which surround the tubular structures have undergone trans-
formation indicated by elevated positive SMA staining (a marker of smooth
muscle cells), indicating that the system has physiological relevance. Notably,
our results showed the co-culture system has minimal lot-to-lot variation indi-
cated by the treatment of three lots with the anti-cancer drug, Ramucirumab
(Cyramza®), which also targets the VEGF pathway. Next, we tested the new
systemwith compounds that impact angiogenesis, results demonstrated that the
angiogenesis system responds positively to elevated doses of VEGF and nega-
tively to increasing concentrations of suramin; more importantly, the tubular
formation effıciency is reduced or blocked by well-known anti-cancer drugs
such as Sunitinib (SUTENT®) and Bevacizumab (Avastin®), both of which target
the VEGF pathway. Finally, we used the Angio-Ready™ system validated 4 HIF-
1(hypoxia inducible factors-1) inhibitors which have anti-angiogenic properties
identifıed by high-throughput screeningmethods; data showed the results of the
new system match with other screening methods including a system screening
time as short as 3 days. Therefore, the co-culture model developed by using
hTERT-immortalized cell lines described in this report provide a consistent and
robust in vitro system for studying cardiovascular biology, drug screening and
tissue engineering.
#793 Human endothelial progenitor cells: A new target for anti-vascular
therapy. Ghada Ben Rahoma, Neha Tuli, Rachana Maniyar, Sanjukta
Chakraborty, Sarnath Singh, Abraham Mittelman, Raj K. Tiwari. New York
Medical College, Valhalla, NY.
Breast cancer affects one in eight women in the USA. Early diagnosis and
newer treatment modalities have rendered breast cancer manageable. However,
triple negative breast cancer is still diffıcult to treat and warrantes a search for
newer targets. One strategy that has emerged in cancer research involves target-
ing of tumor associated blood vessels which provide growing tumors with oxy-
genated blood and growth factors necessary for maintenance and metastasis.
Antiangiogenic drug therapy is transient and has not been able to gain main-
stream therapeutic modality. We discovered that endothelial progenitor cells
(EPCs) are mobilized from the bonemarrow to the tumor site and contribute to
the development of breast tumor vessel formation in an estrogen dependent
manner. Therefore, characterization of tumor associated endothelial progenitor
cells in breast cancermayprovide amore specifıc antivascular therapy.Using the
highly proliferative human umbilical cord blood derived EPCs, having the phe-
notype (CD133, CD34, VEGFR-2), the effect of growth factor and chemo-
kine rich EPCs conditioned medium (CM) was assessed in luminal (MCF-7),
and post-EMT (MDA-MB-231) breast carcinoma cell lines. We observed an
initial halt in cellular proliferation inMCF-7 followed by a signifıcant increase in
proliferation after forty eight hours of treatment. On the other hand,MDA-MB-
231 showed decreased proliferation even after forty eight hours of treatment.
Treating the EPCs with breast cancer conditionedmedium resulted in morpho-
logical and cellular growth changes in the EPCs. MDA-MB-231 CM resulted in
an increase of the EPCs proliferation and differentiation by increasing the num-
ber of spindle shaped attaching cells, andMCF-7CMresulted only in an increase
in the differentiation rate by increasing the number of cell clusters. This increase
in EPCs proliferation and differentiation associated with MDA-MB-231 CM
treatment might explain the invasiveness of this breast cancer cells through the
increase in the tumor associated neovascularization. The analysis of the para-
crine interaction between breast cancer cells and EPCs along with the associated
cellular changes will facilitate identifıcation of the interactive mediators and
subsequent development of effective antivascular therapy.
#794 Potential role of DLL4 in uveal melanoma vascular mimicry. Julia
Escandon,MatthewG. Field, Stefan Kurtenbach, Jeffım Kuznetzov, Christina L.
Decatur, J William Harbour. Univ. of Miami, Miami, FL.
Uveal melanoma is the most commonmalignancy of the eye. Thanks to gene
array analysis it is possible to classify uveal melanoma in Class 1 (lowmetastasis
risk) and Class 2 (high metastasis risk) tumor. This classifıcation will ultimately
determine the tumor treatment, risk of metastasis and patient surveillance. Pro-
gression to metastasis remains by far the greatest problem in uveal melanoma
and is associated with loss of BAP1 tumor suppressor. Bioinformatic analyses of
RNA-Seq indicated that pro-angiogenic genes such as DLL4, VEGFA, VEGFC
and HIF1a are overexpressed in Class 2 compared to Class 1 uveal melanoma
while angiogenic inhibitors such as ZFP36L1, HIF1AN, VEGFB, VHL and
HIF3A are downregulated. Further, we found that DLL4 is among the 5 most
highly overexpressed genes associated with BAP1 loss in clinical specimens and
in uveal melanoma cell lines induced to deplete BAP1. DLL4 is a Notch ligand
known to regulate endothelial cells, bone marrow endothelial cell progenitors
and angiogenesis.We hypothesize that DLL4 contributes to vascularmimicry in
uveal melanoma. To test this hypothesis, we will test uveal melanoma cell lines
induced to deplete BAP1 using shRNA in cell culture-based and in vivomodels.
The results of this research have the potential to elucidate the mechanism by
which vascular mimicry occurs in uveal melanoma.
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#795 The capacity of high-grade serous ovarian cancer cells to form spon-
taneousmulticellular structures (SMCS) in vitropredicts their in vivo tumor-
igenicity.Alicia A. Goyeneche, Zu-hua Gao, Carlos M. Telleria.McGill Univer-
sity, Montreal, Quebec, Canada.
High grade serous ovarian cancer (HGSOC) is the most frequent histopatho-
logical subtype among epithelial ovarian cancers (OC). While an increase in
concentration of CA125 in the blood anticipates clinical remission following
standard of care, we lack biomarker/s to diagnose early disease stage or predict
progression speed. In this work we question whether the capacity of HGSOC
cells to form Spontaneous Multi-Cellular Structures (SMCS) when incubated
under culture conditions that promote, not prevent, adherence to a plastic sur-
face, correlates with their degree of tumorigenicity. We studied 3 HGSOC cell
lines developed from the same patient’s ascites: longitudinally along disease
progression—established at platinum-sensitive relapse (PEO1); from further
progressive disease 10months (mo.) later (PEO4); and after failure to respond to
high-dose cisplatin 3 mo. later (PEO6). We noticed all cell types developed an
adherent phenotype and a differential capacity to form SMCS. This capacity was
more evident in PEO6 cells having high SMCS forming ability, followed by
PEO4 cells denoting some SMCS forming capacity, while PEO1 cells depicted no
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apparent capability to form SMCS. Next, 2x106 PEO1, PEO4 or PEO6 cells were
implanted into the abdominal cavity of nude mice; the animals were sacrifıced
either after having met an end-of-wellness endpoint criterion, or after a maxi-
mum of 14 mo. if no such criteria were met. PEO6-injected mice reached the
humane endpoint due to accumulation of ascites 6-7 mo. following injection,
and presented discrete yet visible solid tumors in the omentum, pancreatic-
spleen region, liver base and diaphragm. Animals injected with PEO4 or PEO1
cells, however, did not develop any apparent disease 14 mo. following injection.
Yet, when a 10-fold higher load of PEO4 cells but not PEO1 cells (i.e., 20x106)
were injected, animalsmet euthanasia criteria due to ascites accumulation 6mo.
later and displayedmacroscopic disease similar to that caused by 1/10 of the load
of their successors (PEO6 cells) within the same timeframe. Furthermore, the
anatomical localization and histopathological aspect of the lesions generated
with PEO6 cells were similar from that generated with PEO4 cells, suggesting
that themore aggressive PEO6 cells were likely present, although in fewer quan-
tities, within the less aggressive PEO4 cell population. Our data demonstrate,
then, that the in vitro SMCS forming capacity of HGSOC cells has a positive
correlation to their capacity to sicken the animals. Moreover, this study suggests
that the in vitro SMCS forming capacity of epithelial OC cells obtained from
ascites of patients diagnosed with HGSOC may be used to predict their aggres-
siveness and, consequently, guide prognosis.
#796 Reproductive hormonesmodulate cardioprotection from doxorubi-
cin-induced cardiomyopathy in female spontaneously hypertensive rats.
Kaytee Pokrzywinski,1 Elliot T. Rosen,1 Julia L. Bonanno,1 Baikuntha Aryal,1
Thomas Biel,1 DelaramMoshkelani,1 StevenMog,2 Ashutosh Rao1. 1FDA, Silver
Spring, MD; 2FDA, College Park, MD.
Doxorubicin (Dox) causes cardiomyopathy, partially driven by the excess
generation of mitochondrial reactive oxygen species (ROS). The incidence of
Dox-induced cardiac stress is greater in prepubescent and postmenopausal fe-
males compared to reproductivelymature women, suggesting that reproductive
hormonesmaymediate cardioprotection.We investigated the role of exogenous
hormone replacement therapy (HRT) and naturally cycling reproductive hor-
mones in providing cardioprotection from Dox chemotherapy. Mammary ade-
nocarcinoma SST-2 cells were implanted in spontaneously hypertensive rats
(SHRs) thatwere either ovariectomized and receivedHRT, or left reproductively
normal and maintained natural hormone cycling. HRT animals received time-
release pellets containing 17--estradiol (E2), progesterone (P4), Tamoxifen
(Tam) or combinations thereof, and were subsequently treated with Dox. Nat-
urally cycling animals were treated with Dox, the iron chelator Dexrazoxane
(Drz), orDoxDrz. Tumor sizewas used to evaluate anticancer activity.Vaginal
cytologies and circulating E2 and P4 levels were obtained. Serum cardiac tro-
ponin I (cTnI), histopathology and echocardiogramswere used to assess cardiac
health. Dox treated animals supplemented with E2 and P4 (alone) showed car-
dioprotection relative to the Dox treated animals. Dox/-Drz exhibited sus-
tained anti-tumor activity independent of endocrine status. After 13 days with
Dox, all naturally cycling animals arrested in diestrus (lowest hormone levels).
These results demonstrate that E2 and P4 have a role in providing cardioprotec-
tion fromDox therapy in SHRs, and that estrous cycle stagemay provide a safety
treatment window, potentially reducing the risk of cardiomyopathy in repro-
ductively normal females.We are also currently analyzing RNA sequencing data
obtained from heart tissues to achieve a better understanding of the molecular
mechanisms of cardioprotection.
#797 Glioblastoma animalmodel usingCRISPR-Cas9 technology.DaEun
Jeong,1 Kee Hang Lee,1 Sung Soo Kim,1 Yoon Kyung Bae,1 HyunNam,2 Ji Yoon
Hwang,3 Hee Jang Pyeon,2 Hye Jin Song,2 Kyeung Min Joo1. 1SAIHST, Sung-
kyunkwan University, seoul, Republic of Korea; 2Sungkyunkwan University,
seoul, Republic of Korea; 3Samsung Medical Center, seoul, Republic of Korea.
Current in vivo model system poses limitation on fully recapitulating
genomic characteristics of a tumor due to high complexity and poor under-
standing of the heterogeneous microenvironment conditions in cancer patho-
genesis. In an effort to address such issues, strategic models are required. In
present study, we propose that themost representative cancer models have con-
sistent tumor microenvironments and genomic mutations. The Clustered reg-
ularly interspaced short palindromic repeats (CRISPR)-Cas9 system is a power-
ful genome editing tool for effıcient and precise genome engineering. Here, we
employed CRISPR-Cas9 system in vivo to generate Cre-dependent Cas9
knock-in mouse (B6;129-Gt(ROSA)26Sortm1(CAG-cas9*,-EGFP)Fezh/J, Jack-
son lab.). The Cre-dependent Cas9 mouse models harbor combinations of
genomic alterations including well-established oncogenes such as EGFRviii, c-
MET, PDGFRa, IDH1 R132H andKRAS, EGFR, ALK, BRAF in Brain and Lung
cancer models, respectively. While, they also consist of tumor suppressor genes
including PTEN, NF1, Ink4a/ARF, Rb, TP53 and TP53, PTEN, NKx-1, APC in
both Brain and Lung models, respectively. Cre-dependent model allows us to
study in-depth into the tumor initiation and progression, while able to follow up
in the role of tumor microenvironment in cancer maintenance. A better under-
standing of cancermodels for preclinical research including their uses, as well as
their limitations, may aid future potential studies regarding the development
and implementation of new immune targeted therapies and potential validation
of novel therapeutic biomarkers.
#798 Label-free enrichment and detection of circulating tumor cells in
metastatic breast cancer patients show 82% of cohorts have detectable tar-
gets. Yu-Jen Chang,1 Chen-Lin Chen,1 Wei-Fan Hsu,1 Meng-Ze Li,1 Wei-Yuan
Ma,1 Ken-Chao Chen,1 Guan-Syuan Huang,1 Wai-Sang Wong,1 Jhan-Yu Syu,1
Thomas, Yo-Yan Huang,2 Ching-Hung Lin,3 Andrew M. Wo,1 Chiun-Sheng
Huang3. 1National TaiwanUniversity, Taipei, Taiwan; 2University of California,
San Diego, CA; 3National Taiwan University Hospital, Taipei, Taiwan.
Circulating tumor cells (CTC) are believed to be the culprit of metastasis and
studies have shown that their enumeration has prognostic value inwide range of
solid tumors. Althoughmuch progress has beenmade in CTC technology, their
rarity in blood and their inherent heterogeneity still provide much challenge
towards maturity of the technology. This paper presents semi-automated en-
richment of CTC via density-based approach in a novel microfluidic disk, fol-
lowed by multi-step on-disk immunofluorescence staining (pan-CK, EpCAM,
Hoechst and CD45), fluorescence microscopy for image capture, and software
image analysis. To characterize the performance of the system, we spiked 1 to
300 cells (mean 105, median 125) from six cell lines (DLD-1, Huh-7, MCF7,
PC3,MDA-MB-231 and PC-9) from fıve cancers into whole blood from healthy
donors. The recovery rate of the system is 87.4%3.7% (R20.958) regardless of
EpCAM expression levels of the cell lines. To interrogate the limitation of the
technology, this data set included ultra-low cell counts spiked of 1 to 13 cells
(mean 5.7, median 5) which might be indicative of CTC from metastatic breast
cancer (MBC) patients. The recovery rate for this low cell count is 90%10%.
Notably, one single cell was spiked into healthy whole blood, processed via the
technology, and one target cell was detected. This test was repeated in triplicate
with all three tests recovered one cell each. Furthermore, the microfluidic disk
technology enables operation over a range of blood volume (from 2 to 7.5ml)
with no statistically signifıcant difference in recovery rate. Recovered MCF-7
cells spiked in blood were subsequently cultured for 6 days and showed good
viability with cell proliferation.We tested the technology inMBC patients along
with CA15-3 and CT imaging. A total 34 of blood samples were collected from
21 patients over the course of their systemic treatment. Results showed CTC
were detected in 28 samples (82%). The target CTC detected ranges from 0 to
138 (mean 16, median 4 CTCs per 7.5mL). 15 out of 34 samples (44%) had CTC
number	 5/7.5mL). In one patient with triple negative diagnosis, CTC count,
CA15-3 and CT imaging were monitored during the course of chemotherapy.
The CTC count remained zero at the end of the fırst and second treatment
course, elevated to 24 CTCs at the end of the third course, and continued its
elevation to 31 by the end of the fourth treatment course. During this entire
treatment course, CA15-3 did not vary signifıcantly. However, CT image con-
fırmed the metastasized liver tumor grew from 6.15cm at the beginning of the
second chemo course to 8.09cm at the beginning of the fourth course. Taken
together, our label-free CTC enrichment technology has high analytical sensi-
tivity (87%) over a wide range of cancers, able to handle a flexible blood volume
(2mL to 7.5mL), and amenable to detect a high percentage (82%) of CTC in
MBC patients.
#799 Tumourmicro-environmental factors and the development ofmam-
mary calcifıcations: Recent fındings from an in-vitromodel. Shane O’Grady,
Maria P. Morgan. RCSI, Dublin 2, Ireland.
The presence of microcalcifıcations on mammographic images represents a
highly valuable tool in the early detection of breast cancer, often allowing ra-
diographers to diagnose mammary tumours at an early, in-situ stage. The pres-
ence of microcalcifıcations has also been linked to a number of unfavourable
prognostic factors including decreased survival and an increased probability of
relapse. Despite their long history of use in the clinic, the precisemechanisms by
which microcalcifıcations are formed remains poorly understood. Pathological
soft-tissue calcifıcation is often considered the result of an imbalance between
pro- and anti-calcifying factors. However, the possible impact of such an imbal-
ance has not been studied in the context of breast calcifıcation. We have estab-
lished an in-vitro model of microcalcifıcation formation using the triple-nega-
tive adenocarcinoma cell line MDA-MB-231. When cultured in the presence of
the osteogenesis-promoting reagents -glycerophosphate, ascorbic acid and
dexamethasone, calcifıed deposits begin to form by Day 14, as verifıed by Aliz-
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arin Red staining and the quantitative o-cresolphthalein assay. Following the
establishment of our model, we set out to identify the underlying molecular
triggers initiating the calcifıcation process, in particular the role of micro-envi-
ronmental factors. Altered magnesium homeostasis has been suggested as an
important mediator of tissue calcifıcation. We found that a slight increase in
magnesium concentration almost completely blocked calciumdeposition in our
model. Previous studies in other tissues have shown this protective effect to be
dependent on the cation channel TRPM7 which is increased in breast cancer
patientswith calcifıcations compared to thosewithout.Unexpectedly, inhibition
of the TRPM7 channel by two separate compounds (2-APB and NS-8593) not
only failed to reverse the inhibition of microcalcifıcation formation by exoge-
nous magnesium, but actually further decreased calcium deposition by Day 28,
suggesting that calcium influx via the TRPM7 channel may be promoting devel-
opment of mammary calcifıcations. Finally, we investigated the effect of several
tumour associated cytokines on the rate of calcium deposition and found that
IL-1 and TNF- blocked mineralisation whilst IL-6 and BMP2 lead to an
increase. Interestingly, co-administration of IL-6 alongside a soluble form of its
receptor (sIL-6R)was observed to promotemineralisation even in the absence of
dexamethasone, which had previously been essential to the formation of calci-
fıcations in our model. To date, our model has yielded a number of important
insights into the formation of calcifıcations in breast cell lines, many of which
recapitulate observations from patient studies. It is hoped that this work will
contribute to our understanding of the origin of these pre-invasive diagnostic
clues.
#800 Enhancing tumor killing abilities of NK cells by targeting CD16
shedding, and ADAM17. Hemant K. Mishra,1 Jianming Wu,1 Dan S. Kauf-
man,2 Bruce Walcheck1. 1University of Minnesota, St. Paul, MN; 2University of
California, San Diego, CA.
CD16 consists of two isoforms (CD16a and CD16b) encoded by two highly
homologous genes that differ by only 6 amino acids in their extracellular regions.
CD16b is expressed by human neutrophils and CD16a by human natural killer
(NK) cells. The ectodomain regions of bothCD16 isoforms are cleaved proximal
to the cell membrane by a proteolytic process referred to as ectodomain shed-
ding. We demonstrate that the membrane metalloprotease ADAM17 cleaves
CD16 in isolated leukocytes and in human patients. Bymass spectrometry anal-
ysis, we determined 3 adjacent cleavage sites in neutrophil CD16b and one
cleavage site inNK cell CD16a that occurred at the same location as the predom-
inant cleavage site inCD16b,which is interesting consideringCD16b is linked to
the plasmamembrane via a GPI anchor andCD16a is a transmembrane protein.
Antibody-dependent cell cytotoxicity (ADCC) by NK cells is a key mechanism
in the anti-cancer effects of therapeutic antibodies, and CD16a exclusively rec-
ognizes tumor-bound antibodies. Surface levels of CD16a are rapidly down-
regulated upon NK cell activation by cytokines, target cell interaction, and tu-
mor infıltration, which is associated with impaired ADCC. Thus blocking this
process has important clinical signifıcance. We contend that maintaining high
surface levels ofCD16aduringNKcell-based immunotherapywill enhance their
killing of antibody-bound tumor cells. In ongoing studies, we are examining
pharmaceutical and gene-targeting means of preventing CD16a cleavage as a
novel therapeutic strategy to enhance the anti-cancer effects of NK cells.
#801 A zebrafısh model of NF1-mutant melanomas that lack activating
mutations of BRAF or NRAS. Shuning He,1 Marc R. Mansour,2 Hillary M.
Layden,1 Scott J. Rodig,3 E. Elizabeth Patton,4 A. Thomas Look1. 1Dana-Farber
Cancer Institute, Boston, MA; 2University College London, London, United King-
dom; 3Brigham and Women’s Hospital, Boston, MA; 4University of Edinburgh,
Edinburgh, United Kingdom.
Cutaneous melanoma is the most lethal type of skin cancer, with 76,380
newly diagnosedmelanoma and10,130 melanoma-associated deaths per year
in the US. Thus, there is a need for improved understanding of the molecular
pathogenesis and more effective targeted therapies for this devastating disease.
The recent work of The Cancer Genome Atlas Network has defıned melanoma
as an RTK/RAS-driven solid tumor that can be classifıed into four genomic
subtypes: BRAF-mutant, RAS-mutant, NF1-mutant, and triple-wild-type. This
landmark study highlighted the important role of the previously understudied
NF1 tumor suppressor in melanoma pathogenesis, especially for the 9% of mel-
anoma patients who have acquired inactivating NF1-mutations, but lack hot-
spot mutations that activate BRAF or RAS. To date, animal models have not
been developed for the NF1-mutant subtype of melanoma, which has signifı-
cantly impaired the development of novel therapeutic strategies for this subtype.
Here we report the fırst zebrafısh model for NF1-mutant melanoma, which we
generated by combining the loss of nf1 with loss of both pten and p53. The
resultant compound mutant zebrafısh develop aggressive melanomas from the
age of 7 weeks and the tumor penetrance is 80% by the age of 18 weeks. We
demonstrate further that these high-risk zebrafısh melanomas were exclusive of
hotspot mutations of braf and nras. Sustained inhibition of bothMEK and PI3K
suppressed tumor progression in vivo, whereas inhibition ofMEKor PI3K alone
was insuffıcient to suppress the growth of these tumors. Surprisingly, single
agent therapywith rapamycin, anMTOR inhibitor, proved evenbetter for short-
and long-term suppression of tumor cell growth in nf1/pten-mutant melano-
mas. Thus our model appears ideal for the testing of drugs that will prove
uniquely active for the signifıcant subset of NF1-mutant, BRAF/NRAS-wildtype
human melanomas.
#802 Loss of function of Arid1a synergizes withMYCN in neuroblastoma
pathogenesis. Hui Shi, Ting Tao, Cigall Kadoch, Thomas Look. Dana-Farber
Cancer Inst., Boston, MA.
ARID1A is a key component of the SWI/SNF-A (BAF) chromatin-remodel-
ing complex that is known tomodulate chromatin structure and gene transcrip-
tion. Recent exome and whole-genome resequencing has identifıed SWI/SNF as
the most frequently mutated chromatin remodeler in human cancers, and
ARID1A as themost highlymutated component among the SWI/SNF subunits,
primarily in solid tumors. In high-risk neuroblastoma, ARID1A is mutationally
inactivated in one allele in 1% of patient tumors. In addition, ARID1A is
deleted in one allele in at least 85% of cases with chromosome 1p deletions,
which is the most common deletion found in neuroblastoma. Thus, ARID1A
appears to function as a haploinsuffıcient tumor suppressor in a substantial
fraction of high-risk neuroblastomas. The arid1a gene is duplicated in zebrafısh,
and the two genes are hence named arid1aa and arid1ab.We targeted each allele
of the two genes using CRISPR/Cas genome editing system and recovered stable
lines with loss-of-function mutations in each arid1a gene. arid1ab but not
arid1aa homozygous mutation showed embryonic lethality.We bred these lines
with a transgenic zebrafısh line expressing high levels ofMYCN in the peripheral
sympathetic nervous system driven by the dopamine beta-hydroxylase pro-
moter. Loss of one copy of either arid1aa or arid1ab dramatically accelerated the
onset and increased the penetrance of MYCN-induced neuroblastoma. Loss of
additional copies of arid1aa or arid1ab accelerated the tumor onset even futher,
with the most rapid onset in compound heterosygotes of both genes. The com-
pound heterosygotes showed increased fraction of sympathoadrenal cells in ac-
tive cell cycle compared to the MYCN transgenic fısh with wild type arid1a
allales. Our long-term goal is to use the zebrafısh model to elucidate the mech-
anisms underlying the highly dose-dependent tumor suppressor role of this
component of the BAF chromatin remodeling complex in neuroblastoma, as a
fırst step toward designing targeted therapies synthetic lethal with reduced ex-
pression levels of ARID1A.
#803 Targeting -catenin/CBP signaling in OSCC. Khalid Alamoud,1 Kh-
ikmet Sadykov,1 Vinay Kartha,2 Stefano Monti,2 Anna Belkina,2 Jennifer Sny-
der-Cappione,2 Sara Pai,3 Maria Kukuruzinska1. 1Boston University Henry M.
Goldman School of Dental Medicine, Boston, MA; 2Boston University School of
Medicine, Boston, MA; 3Massachusetts General Hospital, Boston, MA.
Objectives: Oral squamous cell carcinoma (OSCC) is an aggressive malig-
nancy characterized by molecular heterogeneity and locoregional spread asso-
ciated with high morbidity. Aggressive cancers are thought to arise from popu-
lations of cancer initiating cells (CICs) that exhibit the properties of stem cells
and drive tumor development, recurrence and resistance to therapy. The tran-
scriptional regulator, -catenin, has been implicated in OSCC CICs. Nuclear
-catenin has been shown to recruit the chromatin remodeling CREB binding
protein (CBP) to drive expression of proliferation and survival genes, as well as
genes that maintain stem-like phenotypes. We hypothesized that targeting
-catenin-CBP interaction will inhibit CICs in oral tumors and restore an epi-
thelial phenotype. Methods: To test tumor aggressive potential of OSCC CICs,
we used zebrafısh as a model system. We isolated CD44CD24hiCD29hi cells
fom aggressive HSC-3 OSCC cells by FACS and assayed their ability to drive
tumor growth and metastases in zebrafısh compared to unsorted and
CD44CD24lowCD29low cells. In addition, we examined the role of the
-catenin/CBP axis in the aggressive phenotype of these cells. We also assessed
whether the -catenin/CBP axis affected CICs in tumors from immune compe-
tent HPV mice. Results: Zebrafısh injected with subpopulation of cells co-
expressing CD44CD24hiCD2hi primitive cell surface markers drove rapid tu-
mor growth and metastases, followed by unsorted and sorted CD44
CD24lowCD29low. Treatment of CD44CD24hiCD29hi cells with a small mole-
cule inhibitor of the-catenin-CBP interaction, ICG-001, interferedwith tumor
growth andmetastases in zebrafısh. Further, ICG-001 inhibited tumor growth in
immunocompetent HPV murine model. On a cellular level, ICG-001 pro-
motedmembrane localization of -catenin, enhanced E-cadherin adhesion and
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restored epithelial phenotype. Signifıcantly, ICG-001 gene signatures tracked
with reduced overall patient survival in the cancer genome atlas, TCGA. Con-
clusion: Our studies indicate that the -catenin/CBP axis promotes OSCCCICs
and that ICG-001 may be an effective therapeutic agent for this malignancy.
Support: Evans Center for Interdisciplinary Biomedical Research ARC funding
AU 5303015 8000000.
#804 Zebrafısh as a model organism to study human pancreatic CSC’s.
Laura E. Sanchez,1 Pablo Cabezas Sainz,1 Bruno Sainz,2 Laura Muinelo,3 Rafael
Lopez4. 1University of Santiago de Compostela, Lugo, Spain; 2Autonoma de Ma-
drid University, Madrid, Spain; 3IDIS, Santiago de Compostela, Spain; 4Univer-
sity of Santiago de Compostela, Santiago de Compostela, Spain.
Zebrafısh is establishing itself as a powerful animal model for understanding
human disease, including cancer. Xenotransplantation of human cancer cells
into zebrafısh is becoming an attractive research tools for studying cancer be-
haviour, both for established lines and primary tumours, however, its utility as a
model for cancer stem cells (CSCs) is still in its infancy. In addition, only when
the differences between primary tumours and established cancer cell lines are
minimized will we be truly one step closer to developing biologically relevant
personalized medicine platforms for cancer. To address these two limitations,
we set out to achieve a deeper behavioral understanding of pancreatic CSCs
inside the zebrafısh embryo. Themainmethodology of this studywas focused on
the xenotransplantation of human primary pancreatic ductal adenocarcinoma
(PDAC) cells (185 scd line) into zebrafısh embryos using two different condi-
tions: adherent cells (non-CSCs) vs sphere-derived cells (CSCs). Marked with a
lipophilic dye, cells were injected into zebrafısh embryos and incubated at 36ºC
during 48h/72h to assess the proliferation of the injected cells. Self-developed
Matlab software was used to analyze the intensity and area of the injected cells in
order to give a ’proliferation ratio’. Results obtained indicated that the sphere-
derived cells proliferated and migrated at a higher rate than adherent cells. This
is likely due to the different CSC content present between the two conditions
tested: adherent pancreatic 185 cells contain 1% CSCs versus the 15% enrich-
ment of CSCs in sphere-derived 185 cells. Apart from the differential CSC con-
tent, we also hypothesize that the 3D environment afforded by the yolk sac of the
zebrafısh embryo additionally favors the expansion of CSCs. Importantly, sim-
ilar results were obtained with CSCs isolated via FACsorting, using autofluores-
cence as a marker for CSCs. This work not only contributes to the behavioral
understanding of pancreatic CSCs using the zebrafıshmodel organism butmore
importantly concludes that 1) PDAC CSC proliferation and migration can be
studied in zebrafısh, 2) the zebrafısh model represents a potentially powerful
surrogate model for the study of PDAC CSC biology in vivo, and 3) this model
can potentially be adapted for to test chemotherapeutics that specifıcally target
PADCCSCs, the cell type considered to be themost chemoresistant and tumor-
igenic in pancreatic cancer.
#805 KRASG12D andTP53R167H cooperate to induce pancreatic carcinoma
in conditional transgenic Sus scrofta .Daniel Principe,1 NanaOvergaard,2 An-
drew Diaz,3 Carolina Torres,3 Ronald McKinney,3 David Dawson,4 Laurie
Rund,5 Regina Schwind,3 Paul J. Grippo,3 Lawrence Schook5. 1University of
Illinois-Rockford, Rockford, IL; 2Technical University of Denmark, Denmark;
3University of Illinois-Chicago, Chicago, IL; 4University of California-Los Ange-
les, Los Angeles, CA; 5University of Illinois-Urbana Champaign, Urbana, IL.
Although survival has improved in recent years, pancreatic ductal adenocar-
cinoma (PDAC) remains remarkably virulent with a median survival time of
only fourmonths. As there is no effective strategy for themanagement of PDAC,
there is a need for the development of new preclinical strategies. Themajority of
this work is being done in genetically modifıed mice, which faithfully recapitu-
late a variety of pancreatic cancer histotypes. While mice have allowed for un-
precedented insight into pancreatic cancer etiology, due to fundamental differ-
ences in anatomy and physiology, mouse models of PDAC often fail to
accurately predict responsiveness to therapy. As the pig pancreas has more sim-
ilar anatomical orientation and localization to humans than that of rodents, pigs
may serve as a more relevant model for PDAC and other malignancies of the
pancreas. AsKRAS andTP53mutations are observed in approximately 95% and
70%of PDACpatients, respectively, we generatedCre/lox transgenic Sus scrofta
expressing a LSL-KRASG12D-TP53R167H cassette and administered an Adeno-
Cre particle to the pancreas glandparenchyma. This resulted in amixedhistoype
of metastatic leiomysarcoma and neoplastic disease of the pancreas. To produce
a similar pancreas histoype while avoiding the leiomyosarcoma, we next re-
stricted the Adeno-Cre administration to the main pancreatic duct, which re-
sulted in both PDACandneuroendocrine carcinomawith no abnormality of the
smooth muscle. This serves as the fırst large animal model of pancreatic carci-
nogenesis, and given the anatomical/physiological similarity of pigs and hu-
mans, may allow for insight into new avenues of research not before possible in
rodents.
#806 MGA is a potential tumor suppressor in acute myeloid leukemia.
Qiaoyang Sun,1 Lingwen Ding,1 Kar-Tong Tan,1 Wenwen Chien,1 Xinyi Loh,1
Jinfen Xiao,1 Anand Mayakonda,1 Dechen Lin,1 Yanyi Jiang,1 Henry Yang,1
Sigal Gery,2 H. Phillip Koeffler1. 1Cancer Science Institute of Singaore, Singapore,
Singapore; 2Cedars-Sinai Medical Center, Los Angeles, CA.
MGA is an incompletely studied gene with a high mutation frequency in
MLL-PTD AML (9%) and in core bind factor AML (8%). This gene encodes a
MAX-interacting protein and is believed to act as a transcription factor that
suppresses MYC binding to its target. By in silico analysis, we found that MGA
is expressed in normal myeloid hematopoietic cells and AML, and the expres-
sion level is comparable with TET2 orDNMT3A. Further datamining of TCGA
revealed a high frequency of inactivatingmutations of theMGAgene in a variety
of cancers such as various adenocarcinomas. To interrogate functionally its role
in leukemogenesis, lentiviral constructs containing either shRNA or CRISPR-
sgRNA targeted to different regions of the MGA gene were generated. MGA
expressing AML cell line EOL-1 was silenced by shRNA or CRISPER system.
Silencing was confırmed by western blot (shRNA) and Sanger Sequencing
(sgRNA). An increase of methylcellulose colony number (30%) was observed
in MGA silenced cell lines. Control EOL-1 cells or EOL-1 cells silenced with
MGA CRISPR sgRNAs were injected into both flanks of NSG mice, and tumor
masses were harvested 21 days after injection. Silencing of MGA by CRISPR-
sgRNAconsistently enhanced in vivo xenograft cell growth. In addition,western
blot analyses revealed silencing of MGA in EOL-1 cells increased protein levels
of Cyclin E1 and phos-RB (S807 phosphorylation inhibits the ability of RB to
target protein allowing cell cycle progression), indicative of a proliferative ad-
vantage conferred by the silencing ofMGA.MGAmaybe a potential regulator of
the MYC pathway. We, therefore, examined whether silencing of MGA alters
MYC transcriptional activity. Luciferase reporter assay was carried out in 293FT
cells stabilized with either scramble or shRNA- targeting MGA. Luciferase ac-
tivities weremeasured 48 h after transfection of cells withMYC activity reporter
pMyc4ElbLuc and normalized to the corresponding co-transfected Renilla lu-
ciferase activity. A fourfold increase in luciferase activity was observed in MGA
silenced cells when compared with non- targeting shRNA controls. Further-
more, Kaplan–Meier survival analysis was performed in the TCGA-AML pa-
tients by comparison of cases with highest versus lowest expression of MGA.
P-values were calculated by log-rank test. MGA expression data and patient
survival data were retrieved from TCGA-AML patients RNA seq, or microarray
(70AMLpatients). TheMGAexpression ’high’ and ’low’ groupswere defıned by
15% higher than the median or 15% lower than the median, respectively. AML
patients with lower levels of MGA in their leukemic samples had a worse out-
come compared with those whose leukemic cells expressed higher levels of
MGA. Collectively, our results suggest that MGA may function as a potential
tumor-suppressor in AML.
#807 A novel immunodefıcient rat for modeling human cancer. Fallon K.
Noto, Angela Arey, Christopher McClain, Wei Zhang, Tseten Yeshi. Hera Bio-
Labs, Lexington, KY.
Animal models of human cancer offer the potential to study human tumor
growth kinetics, genetic variance among human cancers, and provide in vivo
platforms for drug effıcacy testing. In particular, immunodefıcient mouse mod-
els have been invaluable in modeling a wide range of human cancers. However,
some cancer lines don’t grow well in the available mouse models or show vari-
ability in growth kinetics from mouse to mouse, making drug effıcacy studies
diffıcult due to differences in tumor size at the onset of treatment. These chal-
lenges are also seen in patient derived xenograft (PDX) models, in addition to
long timeframes to obtain suffıcient mice with PDX tissue growth for drug
effıcacy studies. Mice are also limited in tumor growth potential with regard to
humane endpoints and small size also limits the volume of blood that can be
collected for analysis. An immunodefıcient ratmodel could provide a solution to
some of these issues. A rat model would allow for larger tumor size, easier
surgical manipulation, and greater volume of tissue and blood sampling for
downstream analysis. In addition, large tumors from rats could be serially trans-
planted into mice for drug effıcacy testing and could provide a large number of
transplantedmice in a shorter period of time compared with serially transplant-
ing frommouse to mouse.We have created an immunodefıcient rat model with
a functional deletion of the Rag2 gene. This knockout, created using spermato-
gonial stem cells, lacks mature B and T cells. To assess the capability of the Rag2
knockout rat to accept human xenografts, we transplanted 2 commercially avail-
able human cancer cell lines into our animals. The human REH acute lympho-
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cytic leukemia cell line was transplanted via intravenous injection and the hu-
man glioblastoma cell line U87MG was transplanted subcutaneously. Both cell
lines survived in the Rag2 knockout rat and resulted in the growth of tumors
comprised of human cells. Studies are underway to characterize the Rag2 knock-
out rat’s ability to grow other human cell lines, including those that do not grow
well in mice, and PDX tissues.
#808 PDGF-A overexpression and p53 depletion in rat neural precursor
cells induces large brain tumors that resemble human glioblastoma.Nina P.
Connolly,1 Craig S. Schneider,1 Amol Shetty,1 Su Xu,1 Tatsuya Ozawa,2 An-
thony J. Kim,1 Jeffrey A. Winkles,1 Eric Holland,2 Graeme F. Woodworth1.
1University of Maryland, Baltimore, Baltimore, MD; 2Fred Hutchinson Cancer
Research Center, Seattle, WA.
One of themajor obstacles in developing new therapeutics for glioblastoma is
testing these agents in reliable models that recapitulate the tumor biology of
human disease. The RCAS/tv-a system enables spatial, temporal, and cell-type
specifıc control of oncogenic transformations in the brain. In this study, we
sought to develop a rat RCAS-TVAmodel of glioblastoma to eventually facilitate
translational studies using magnetic resonance imaging (MRI), targeted radia-
tion, focused ultrasound, and local drug delivery strategies.We developed a high
copy number nestin-promoter driven tv-a (Ntv-a) transgenic Sprague-Dawley
rat line. To initiate tumors, RCAS PDGF-A and p53 shRNA constructs were
injected intracranially. The tumors were followed over time usingMRI andMR
proton spectroscopy. Animal survival was monitored and histopathology and
gene expression analyses were performed. All animals (n8) developed tumors
that could be visualized with MRI throughout the tumor formation process.
Early stage tumors showed relatively homogenous characteristics with minimal
mass effect. Later stage tumors demonstrated large heterogeneous lesions with
evidence of necrosis, increased vascularity, and signifıcant mass effect. MR pro-
ton spectroscopy revealed increases in choline to creatinine ratio (Cho/Cr) and
decreases in NAA, consistent with aggressive tumor progression. Immunohis-
tochemistry revealed pseudopallisading necrosis, brain invasion, and vascular
proliferation, all key features of human GBM. Immunohistochemistry con-
fırmed a high proliferative index within the tumor core as well as neovascular-
ization as evidenced by positive Ki67 and Smooth Muscle Actin (SMA) respec-
tively. Gene expression analysis revealed approximately 1000 differentially
expressed transcripts between the normal and tumor tissue. In addition to typ-
icalmarkers such asKi67 andPDGFR-Aoverexpression, SPP1 andPOSTNboth
ofwhich are linked to glioma and tumor-associatedmacrophages, were found to
be differentially expressed in the tumor. Comparisons between the rat gene
expression profıle and published human TCGA data indicated that the RCAS/
tv-a tumors appear to align with the proneural GBM subtype. In summary,
transgenic Ntv-a rats generate reproducible brain tumors following combined
PDGF-A and p53 genetic alterations. The tumor progression process from low-
grade tumor to high grade malignancy can be visualized withMRI. Histopatho-
logical features strongly resemble human GBM, and gene expression analysis
suggests these tumors correspond to the proneural subtype.
#809 A novel woodchuck model of hepatic artery infusion (HAI) with
FACTcomplex targeted drugCBL0137.MinhyungKim, Leslie I. Curtin, Colin
A. Powers, Sandra Sexton, Katerina V. Gurova, Andrei V. Gudkov, Renuka V.
Iyer. Roswell Park Cancer Institute, Buffalo, NY.
Background: The liver has unique anatomy in that most blood flow to normal
hepatocytes is derived from the portal venous system, while liver tumors obtain
their nutrient blood supply exclusively from the hepatic artery. Hepatic artery
infusion (HAI) concentrates chemotherapy agents delivering them directly to
the tumor bed with the fırst-pass effect. Although, HAI chemotherapy as a re-
gional therapy has been used clinically for decades in the treatment of both
primary and metastatic cancers of the liver, signifıcant toxicity remains a con-
cern, and clinical results have been mixed. The purpose of this study was to
establish preclinical HAI model in a woodchuck and administer the FACT (fa-
cilitates chromatin transcription) complex targeted drugCBL0137.Material and
methods: Woodchuck hepatitis virus infected Eastern Woodchucks (Marmota
monax) were used for the study. Hepatocellular carcinoma (HCC) developed
spontaneously about 18months after birth. The size ofHCCwasmonitoredwith
ultrasound every 2 weeks, and 4 woodchucks bearing over 2 cm tumors were
used for the experimental group. Prophylactic cholecystectomy was performed
fırst, and then a 2Fr. (ID0.012”, OD0.025”) vascular access port (VAP) was
implanted in the gastroduodenal artery (GDA) after collateral vessel ligations.
HAI was performed at room temperature via a VAP using 15mg/kg of CBL0137
at a volume of 3 mL/kg for 30 minutes, and tumor responses were investigated
with MRI on day 0 (the surgery day of HAI port) and day 7 after HAI. Results:
Anatomy variations existed in the size and location of the supraduodenal artery
or pancreatico-duodenal artery. 4/4 success rate of a port implantation was
achieved without mortality, but 1/4 animals suffered post-operative bleeding at
the port head site, attributed to coagulopathy secondary to hepatic dysfunction.
And, 4/4 animals were partially anorexic for up to 7 days post-surgery. De-
creased tumor volume and Ktrans (a measure of capillary permeability) were
detected 7 days after single HAI with CBL0137. Conclusion: Although the anti-
cancer effect of CBL0137 on HCC was not clear because of a lack of the control
group, we successfully implanted a VAP into the GDA of 4 woodchucks bearing
unresectable HCC for HAI. The described woodchuck model may serve as a
platform for identifying novel drugs and optimal conditions for the treatment of
primary and metastatic liver tumors.
#810 Establishing patient derivedpreclinical in vitro and in vivomodels of
pediatric brain cancers. Sridevi Yadavilli, Madhuri Kambhampati, Jamila Git-
tens, Eshini Panditharatna, Mojca Stampar, Lindsay B. Kilburn, Suresh Magge,
Roger J. Packer, JavadNazarian. children’s National Health System,Washington,
DC.
The recent surge in understanding genomic aberrations of some of the dead-
liest childhood brain cancers has highlighted the need for robust preclinical
models. Such models will allow for robust drug screening and preclinical eval-
uation of effıcacy, toxicity, and tumor penetrance in vivo. Given the rarity and
importance of patient derived specimens, handling and processing methods are
perhaps the most critical steps for successful establishment of viable and repro-
ducible in vitro and in vivo models. Since specimen source varies (biopsy, au-
topsy, or cryo-preserved), processing methods should be refıned to allow for
optimal extraction of maximum numbers of viable cells from each specimen
type. We have developed standardized procedures for handling and processing
of tissue samples obtained frombiopsy, autopsy, or cryo-preserved specimens as
well as necropsy tissue obtained fromexisting xenograftmodels. Twoprocessing
methods for generating viable cell suspensions are described. The fırst method,
which uses collagenase-DNAse mediated digestion of the tissue is effıcient with
bulky samples and can be used with tissues obtained at autopsy. The second
method uses a commercially available enzymatic dissociation kit optimal for
small volume samples such as biopsy, cryo-preserved andmouse necropsy spec-
imens. We show that obtaining viable cell suspension from precious tumor
tissue by these methods results in successful generation of pre-clinical in vitro
and in vivo models of DIPG, pilocytic astrocytoma and medulloblastoma that
represent the exact genetic makeup of the original patient tumor. We further
demonstrate intracranial injections of these cells into P2 mice for generating
orthotopic xenograft models of brainstem or cortical tumors. Our methods and
results allow for rapid establishment of preclinical models using rare and valu-
able childhood brain tumor specimens. These pre-clinical models serve as valu-
able tools for understanding the molecular mechanisms of the disease, identify-
ing targetable molecules, and screening of novel therapeutics.
#811 Histological heterogeneity contributes to sunitinib resistance in
clear cell renal cell carcinoma. Zsuzsanna Lichner, Rola Saleeb, Henriett Butz,
Roy Nofech-Mozes, Sara Riad, Mina Farag, Andras Kapus, George Yousef.
Keenan Biomedical Research Centre, St Michael’s Hospital, Toronto, Ontario,
Canada.
Introduction: The receptor tyrosine kinase (RTK) inhibitor sunitinib is the
fırst line treatment for advanced clear cell renal cell carcinoma (ccRCC).
Sunitinib inhibits angiogenesis via blocking signaling through VEGFR. About
80% of patients develop resistance after a drug-sensitive period. Molecular
changes early in treatment may impact drug resistance, but are poorly under-
stood. Experimental Procedures: ACHN, 786-O and Renca cell lines were
treated with 1Msunitinib. NSGmice were s.c. xenografted with themodel cell
lines and were treated with sunitinib at 40 mg/kg/day dose. mRNA expression
was screened using IlluminaHT-12 bead chip array andmiRNA expression was
assessed byNanostring nCounter assay. R statistical packages were used for data
processing. Reactome and miRPath softwares were used for downstream anal-
ysis. Results: Sunitinib treatment of ccRCC xenografts led to several early
changes in tumor histology, such as the emergence of live tumor areas within the
necrotic spaces. These areas showed membranous staining for E-cadherin, and
-catenin, while the rest of the tumor and vehicle-treated tumors were negative.
In vitromodel cell lines developed cancer spheroidswhen treatedwith sunitinib.
Cancer spheroidswere highly tumorigenic andmetastatic, and expressed several
established cancer stem cell markers. ccRCC cancer spheres, but not the 2D
adherent cells, showed membranous staining for E-cadherin and -catenin;
similarly to the live tumor areas observed in in vivo sunitinib treatment. In vitro
inhibition of E-cadherin by EGTA or by siRNA, interfered with viability of
sunitinib treated ccRCC cell lines. Conclusions: Sunitinib treatment causes early
phenotypic changes of the tumor in vivo and in vitro. The formation of highly
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metastatic and tumorigenic cancer spheres in model cell lines is the most prom-
inent effect in vitro. We provide preliminary evidence that sunitinib induced in
vitro cancer spheres and the live tumor areas that survivewithin necrotic patches
of the sunitinib-treated xenografts, are related. Finally, membranous expression
of E-cadherin enhances the survival of ccRCC cell lines under sunitinib treat-
ment.
#812 Multiplatform modeling of pancreatic cancer using patient-derived
cells: A new approach for defıning drug resistance mechanisms. Erika Maria
Parasido,1 Praathibha Sripadhan,1 George Avetian,1 Richard Schlegel,1 Jona-
than Brody,2 Jordan Winter,2 Charles J. Yeo,2 Michael J. Pishvaian,1 Erik Glas-
gow,1 Stephen Byers,1 Christopher Albanese1. 1Georgetown University, Wash-
ington, DC; 2Thomas Jefferson University, Philadelphia, PA.
Background: Pancreatic adenocarcinoma (PA) is the fourth leading cause of
cancer-related death in the USA. Current treatments utilize Gemcitabine alone
or in combination with other drugs, such as nab-paclitaxel, however, a growing
number of patients have shown resistance to these regimes. In order to enhance
clinical response, it is important to better understand the mechanisms of drug
resistance. To date, one of the main limitations in PA research has been the
reliance on a few commercially available PA cell lines or a limited number of
genetically engineered or PDXmouse models for in vitro and in vivo studies. It
was therefore imperative to develop more accurate cellular models that better
represent a given patient’s tumor. In our current study, we present the use of
patient-derived primary PA cells as a model system for basic and translational
research, and for personalized medicine. Methods: Patients’ biopsies were col-
lected after surgery, and long-term cultures of PA cells were established using
the conditional reprogramming of cells (CRC) approach we developed. KRAS
and p53 sequencing verifıed the PA origin of both the patient samples and the
matched CRC lines. The IC50s for Gemcitabine and Abraxane were determined
and used to establish drug resistant clones. Our two dimensional (2D) CRC
cultures have shown to be adaptable to different platforms, such as 3D spheroid
cultures as well as zebrafısh- and mouse- PDX models. Results: We established
KRAS-mutant primary cell lines derived from patients’ PA samples. From two
different parent cell lines we created fıve nab-paclitaxel and two Gemcitabine
resistant clones. The clones were 3-1000 times less sensitive to the drugs as
compared with the parent lines. Drug resistance ratios between parent and re-
sistant clones were confırmed both in 3D cultures and our zebrafısh PDX plat-
form. The injection of both parent and resistant clones into NCI/nude mice
induced tumor masses in 100% of the cases. Unlike the parent cell-derived tu-
mors, the nab-paclitaxel clone-derived tumors exhibited a metastatic pheno-
type. Histological analyses of these PDX models recognized the presence of
morphological features of human PA, including ductal acinar structures com-
prised of pleomorphic epithelial cells with extensive stromal desmoplasia sur-
rounding the tumors, and thereby represent a fundamentally important ad-
vancement in the PDX modeling fıeld. Conclusion: Overall, the ease of culture,
the genetic stability and the high-throughput ability to identify differences be-
tween patients sensitivity to FDA approved drugs confırm the power of this
technology for on-demand in vitro use in PA research. The in-vivo approach
demonstrated the accuracy of our model system in recapitulating the patient
tumor. Our method now enables the high-resolution experiments necessary to
better understand the resistance mechanisms that directly affect clinical out-
comes.
#813 Development of a porcine model for pancreatic cancer. Neeley A.
Remmers,1 Jesse L. Cox,1 PaulM.Grandgenett,1 JamesA.Grunkemeyer,1 Laurie
A. Rund,2 Lawrence B. Schook,2 Michael A. Hollingsworth,1 Mark A. Carlson3.
1University of Nebraska Medical Center, Omaha, NE; 2University of Illinois, Ur-
bana, IL; 3University of Nebraska Medical Center; NE-Western IA VA, Omaha,
NE.
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a
5-year survival rate of 4%. Without signifıcant advances in early detection and
treatment, PDAC is estimated to become the second leading cause of cancer
deaths in the United States by 2020. Many advancements in PDAC have come
frommurine models and retrograde studies of patient samples. A supplemental
pig model would allow such studies as noninvasive image-guided technologies,
radiation oncology, drug metabolism, surgical experimentation/training, and
early detection screening to be more readily performed. Here, we sought to
develop an orthotopic model of porcine pancreatic cancer using transformed
pancreatic tumor cells to help address some of these issues.We isolated primary
porcine epithelial cells from pancreatic ducts harvested from a normal pig. We
isolated epithelial cells from fıbroblasts by serial dilutions and stained our fınal
population with cytokeratin 19 (specifıc for pancreatic ductal epithelium), E
cadherin, alpha-SMA, and collagen I to show that our population of primary
cells were indeed of epithelial origin and not mesenchymal. We used these cells
to generate 3 different tumorigenic cell lines: PGKP (containsmutated Kras and
p53), PGKPS (PGKP SMAD4 shRNA), and PGKPSC (PGKPS p16
shRNA).We tested these cell lines using in vitro assays to test their tumorigenic
properties. The PGKP cells outperformed the primary cells in proliferation,
population doubling time, and soft agar growth with p-values0.03. The addi-
tional hits in the PGKPS and PGKPSC cells generated more pronounced inva-
sion through matrigel, migration rate, anchorage-independent growth, prolif-
eration capacity, and population doubling times with p0.01 when compared
both to primary cells and the PGKP cells. We used all three cell lines in a subcu-
taneous injectionmodel in nudemice to determine if they could produce tumors
in vivo. We injected 5x106 cells into the hind flanks of mice with groups of 10
mice/cell line.Of the 30mice injected, 28 grew tumors thatwere	1.8 cm2 in size
within 5weeks. All of the tumors had large necrotic centers, were hypervascular,
and mucous producing. Upon H&E analysis, all tumors displayed an undiffer-
entiated morphology with mild desmoplasia. Representative tumor sections
were stained for the samemarkers as used above in the primary cell isolates with
the addition of vimentin. These stains indicate that our tumorigenic cells formed
undifferentiated carcinomas with mild desmoplasia. Here, we demonstrate for
the fırst time development of porcine pancreatic tumor cells that can induce
tumors in vivo. The expression of vimentin in our tumor slides indicates that our
cells may have the potential to recapitulate metastatic disease when orthotopi-
cally injected into the pancreas of syngeneic pigs. We feel that this model could
greatly supplement the existing murine models of pancreatic cancer to help
improve imaging, surgical, and future diagnostic techniques.
#814 NOTCH1 regulates head and neck cancer cell growth and invasion.
Andrew C. Birkeland, Megan Ludwig, Jacqueline Mann, Samantha Devenport,
Rebecca C. Hoesli, Chloe Matovina, Matthew E. Spector, Carol R. Bradford,
Thomas E. Carey, Mark E. Prince, J. Chad Brenner.University of Michigan, Ann
Arbor, MI.
Introduction: NOTCH1 has recently been identifıed as a frequently mutated
gene in head and neck squamous cell carcinoma (HNSCC). However, its role in
HNSCC is poorly understood. Creation of genetic models investigating the role
of NOTCH1 in HNSCC behavior will be crucial to further characterize its func-
tion, and to potentially modify treatment paradigms in NOTCH1 mutant HN-
SCCs. To date, no syngeneic HNSCC cell line knockout models of NOTCH1
have been created to specifıcally study the effects of NOTCH1 in HNSCC phe-
notypes. Methods: We transfected a NOTCH1 gRNA-CRISPR-Cas9 lentiviral
construct into a HNSCC cell line with wildtype NOTCH1 (UMSCC-49) and
selected knockout clones. Whole exome sequencing, qRT-PCR, and Western
blotting were performed to validate the cell line knockout. Invasion chamber
and growth assays were performed to assay for cell line phenotypes. Immuno-
fluorescence staining and proteomic analysis were performed to study expres-
sion changes in various invasive markers. Results: We successfully created a
NOTCH1 knockout cell line (UMSCC-49N1KO) with an otherwise identical
genetic architecture as its parent line (UMSCC-49). Knockout statuswas verifıed
via exome sequencing, qRT-PCR and Western blotting. Analysis of UMSCC-
49N1KO suggested an increased aggressive and invasive phenotype. Cell prolif-
eration assays demonstrated an increased cell proliferation in UMSCC-
49N1KO. Invasion chamber assays demonstrated increased invasion in the
NOTCH1defıcient cell line. Proteomic analysis demonstrated increased expres-
sion of proteins associated with invasion and cell proliferation and decreased
expression of cell differentiation markers in UMSCC-49N1KO, consistent with
an aggressive and invasive phenotype in the NOTCH1 defıcient line. These
phenotypes were validated with subsequently generated UMSCC-49 NOTCH1
knockout lines. Conclusions: NOTCH1 acts as a key tumor suppressor gene in
HNSCC and regulates cell proliferation and invasion. We have created a useful
genetic model to study effects NOTCH1 in tumorigenesis, proliferation and
metastasis with a wildtype NOTCH1 parent (UM-SCC49) and mutant
NOTCH1, otherwise syngeneic cell line (UM-SCC49N1KO). NOTCH1mutant
status correlates with worse outcome in HNSCC patients. Further characteriza-
tion of the role of NOTCH1 in cell proliferation, invasion and metastasis may
provide insight into treatment stratifıcation paradigms, targetable options and
predictive biomarkers for patients with NOTCH1 mutant HNSCCs.
#815 Using CRISPR/Cas9 to generate isogenic cell lines and reference
standards for applications in cancer diagnostics. Xin Cheng, Nga Nguyen, Qi
Zheng, Mi Shi, Andrew Hilmer, Huanyu Jin, Ruby Yanru Chen-Tsai, Ling-Jie
Kong. Applied StemCell, Inc., Milpitas, CA.
We are entering an era of precision medicine, in which there are signifıcant
initiatives to employ companion diagnostics and molecular profıling to inform
clinical decisions in therapeutic treatment. In order for these initiatives to work
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as effectively as possible, there is a need for molecular reference materials that
can help facilitate precision assay development. Cell-line based reference stan-
dards are ideal for such applications because they represent a reproducible and
renewable source of control materials that can be employed for assay develop-
ment, quality control, or lead compound discovery. With this in mind, we have
used the CRISPR/Cas9 platform to engineer series of isogenic cell lines that
feature 51 recurrent mutations in theMAPK signaling pathway. These cell lines
contain footprint-free, homozygous mutations in the kinase domains of the
EGFR, KRAS, and BRAF genes in HCT116 and RKO cancer cell lines, with 32
mutations in EGFR, 12 mutations in KRAS, and 7 mutations in BRAF. The
mutations include precise deletions, point mutations and small fragment inser-
tions, and these engineered cell lines have been further employed for the devel-
opment of derivative referencematerials, including genomic DNA (gDNA) and
FFPE cell line blocks. Such materials can be employed as positive and negative
controls in diverse assay platforms, including next generation sequencing
(NGS), quantitative PCR (qPCR), in situ hybridization (ISH), and others. We
present quality control data for these reference materials, which demonstrate
excellent consistency and uniformity, as well as examples of the application of
these materials in molecular assay validation. We conclude that using CRISPR/
Cas9 technology to generatemolecular reference standards is a very effıcient and
precisemethod in generating footprint-free, biorelevantmutations for compan-
ion diagnostic assays.
#816 Molecular and genomic characterization of a newly establishedmale
breast cancer cell line. Tereza Vaclova,1 SarahMaguire,1 Matthew Pugh,1 Peter
Barry,2 Nick Orr1. 1ICR, London, United Kingdom; 2The Royal Marsden NHS
Foundation Trust, London, United Kingdom.
Although the majority of breast cancers affect women, approximately 1% of
cases occur inmen.At present comparatively little is known about themolecular
mechanisms that influence male breast cancer predisposition and tumorigenic-
ity. This is largely due to the current unavailability of an established cell line
model in which to study male breast cancer. Development of in vitro models of
the disease is therefore warranted, not least because growing evidence indicates
that it is suffıciently different from female breast cancer such that extrapolating
knowledge from one to the other may be misleading. Here we report the estab-
lishment and characterisation of a male breast cancer cell line derived from a
primary tumor arising in a 61-year old male patient. We used 3T3-J2 mouse
fıbroblast co-culture in the presence of a ROCK inhibitor to conditionally re-
programepithelial cells from freshly resected tumor tissue.Once established, the
cell line showed a rapid proliferation rate and growth in full conditioned media
without the support ofmouse fıbroblasts. Immunohistochemical profıling dem-
onstrated expression of epithelium-specifıc antigens AE1/AE3, breast epithelial
markerCK7 and confırmed estrogen receptor positivity in concordancewith the
primary tumor. Germline sequencing detected no pathogenic germline predis-
position mutations in either BRCA1 or BRCA2. There was no evidence of so-
matic mutation in any of the established female breast cancer driver genes.
Somatic whole genome sequencing of early and late passages indicated a paucity
of structural aberration and little evidence for obvious accumulation of gross
genetic alterations. In conclusion, we have established a novel in vitromodel for
studying male breast cancer. That the cell line genome displays minimal evi-
dence of signifıcant acquired genetic changes arising due to reprogramming
suggests that it will be of value in future studies of the biology of male breast
cancer.
#817 Unbiased discovery of exosome-associated biomarkers using xeno-
graft models. Milcah C. Scott,1 John R. Garbe,1 Hirotaka Tomiyasu,1 Alicia
Donnelly,1 Brad A. Bryan,2 Subbaya Subramanian,1 Jaime F. Modiano1. 1Univ.
of Minnesota, Minneapolis, MN; 2Texas Tech University Health Sciences Center,
El Paso, TX.
We developed a novel, genome-wide method for biomarker discovery that is
able to separate intrinsic markers of disease from markers of host response.
Specifıcally, we implanted cell lines derived from two primary canine osteosar-
coma tumors with different biological behavior into the tibiae of athymic nude
mice. Both cell lines formed orthotopic tumors, and each recapitulated the bio-
logical behavior of the original primary tumor in terms of growth rate and
metastatic potential (1,2).We also developed a cross-species hybrid genome that
allowedus to identify separate canine andmouse transcripts in tumor xenografts
(2). In otherwords, wewere able to determine the contribution of caninemRNA
sequences (derived from the implanted tumor cells) and mouse mRNA se-
quences (derived from infıltrating stroma) to defıne tumor-intrinsic features
and host-specifıc features that contribute to osteosarcoma progression. When
we applied this analysis method to exosome-derived mRNAs, we found canine-
derived transcripts that were only present in exosomes of tumor-bearing mice
that were associated with functions such as protein kinase A (PKA) and actin
cytoskeleton signaling, and with upstream transcriptional regulators such as
FOXF1, ESR1, and TP53. We also found tumor-specifıc, canine-derived tran-
scripts thatwere associatedwith functions such as caveolae-derived endocytosis,
energy utilization andmetabolism, immune interactions, and G-coupled recep-
tor signaling, and with upstream transcriptional regulators such as HNF1A,
ESR1, NIPR1, and HNF4A. This method has the potential to reduce the statis-
tical uncertainty that arises from the use of pre-selected molecules among the
background of thousands of genomic features in patient samples. Using ge-
nome-wide analyses, we are able to combinemultiple, highly correlated genes to
manage this problem, increase markers’ robustness, and avoid random correla-
tions. In conclusion, this technology is useful to identify nucleic acids that serve
as cancer biomarkers with high precision, and inter-species sequence conserva-
tion can be used to further improve its predictions. References 1. Scott MC,
Sarver AL, Tomiyasu H, Cornax I, Van Etten J, Varshney J, et al. Aberrant
Retinoblastoma (RB)-E2F Transcriptional Regulation Defınes Molecular Phe-
notypes of Osteosarcoma. J Biol Chem 2015;290(47):28070-83. 2. Scott MC,
Tomiyasu H, Garbe JR, Cornax I, Amaya C, O’Sullivan MG, et al. Heterotypic
models of osteosarcoma recapitulate tumor heterogeneity and biological behav-
ior. Disease Models & Mechanisms 2016, doi: 10.1242/dmm.026849.
#818 Unravelling the role of androgen targeted therapies in epithelial
plasticity during prostate cancer progression. Ellca Ratther, Katrina G.
Sweeney, Nataly Stylianou, Qiuhua Hu, Gregor Tevz, Colleen C. Nelson, Eliza-
beth D. Williams, Brett G. Hollier. Queensland University of Technology, Insti-
tute of Health & Biomedical Innovation, Australian Prostate Cancer Research
Centre – Queensland, Translational Research Institute, Brisbane, Australia.
Recent evidence suggests that the use of potent androgen receptor (AR) an-
tagonists have contributed to the increased prevalence of prostate cancer (PCa)
tumors exhibiting therapy resistance. Androgen targeted therapies (ATT) in-
hibit the androgen/AR axis which PCa cells rely on for growth. ATT are initially
effective however most men progress to metastatic castration resistant prostate
cancer (mCRPC).Mechanisms of resistance include programs of epithelial plas-
ticity (EP) such as epithelial-to-mesenchymal transition (EMT) and neuroen-
docrine transdifferentiation (NEtD). EMT enables PCa cells to become more
motile and invasive. PCa cells that undergo NEtD gain neuroendocrine (NE)-
like traits. Patients withNEprostate cancer (NEPC) usually presentwith visceral
metastasis, are refractory to ATT and have short response to chemotherapies.
We aim to characterizemodels of therapy-inducedNEtD (tNEPC) and to inves-
tigate the role of tumor plasticity in the progression to mCRPC. To recapitulate
ATT in vitro, androgen-dependent LNCaP cells were treatedwith either enzalu-
tamide (Enz) (10M) or shRNA targeting AR in culture medium containing
fetal bovine serum (FBS) or charcoal stripped serum (CSS) with or without
10nM dihydrotestosterone (DHT). To model EMT, LNCaP cells were engi-
neered to express doxycycline (Dox) inducible overexpression of EMT tran-
scription factor Snail. Androgen deprivation in vitro induced expression of NE
markers in LNCaP cells compared with FBS treated cells (mean fold increase
SEM): neuron specifıc enolase (ENO2) (6.0  2.5), neural cell adhesion mole-
cule (NCAM) (10.4  6.8) and midkine (MDK) (13.2  2.4). Cells co-treated
with Enz and DHT had increased expression of NE markers compared to DHT
alone: ENO2 (2.7 0.6), NCAM (2.9 0.3) and MDK (2.3 1.8). AR knock-
down resulted in a potent induction of NEmarkers compared with control cells:
ENO2 (8.3 1.4), NCAM (8.3 2.4) andMDK (9.0 2.2). Dox-induced Snail
enhanced androgen deprivation-mediated upregulation of NE markers com-
paredwith no-Dox cells: ENO2 (1.3 0.1), NCAM (8.3 2.4) andMDK (9.0
2.2). Tomore accurately model a preclinical setting, LNCaP tumors were grown
subcutaneously in severe combined immune defıciencymice.Once tumors grew
to 200mm3, mice were castrated and upon tumor recurrence mice were treated
with Enz (10mg/kg). At the ethical endpoint, expression of EMT and NEmark-
ers will be assessed. Patients treated with ATTs show an increase in NE-like
traits. Thus, there is a need to identify molecular mechanisms involved in this
adaptive response. In vitro, we havemodelled the acquisition ofNE-like features
in PCa cells usingATTs, EMTdrivers andARknockdown. Further investigation
using these models may lead to the development of biomarkers and therapeutic
targets for the clinical management of advanced PCa.
#819 Transcriptomic profıling of two canine mammary cancer cell lines
for translational oncology studies. Heidge Fukumasu,1 Yonara G. Cordeiro,1
Pedro L. Xavier,1 Arina L. Rochetti,1 Pamela A. Alexandre,1 Claudia C. Mori,2
Silvio H. Freitas,1 Ricardo F. Strefezzi1. 1Univ. of São Paulo, Pirassununga - São
Paulo, Brazil; 2Univ. of São Paulo, São Paulo, Brazil.
Dogs develop spontaneous cancers as humans and shares a variety of features
including histology, genomic alterations, molecular targets, biological behavior
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and response to conventional therapies. Although dogs can be considered good
models for translation of new cancer treatments, there is a lack of established
preclinical in vitro models of canine cancers. Therefore, our aim here was to
establish two caninemammary cancer cell lines and characterize their transcrip-
tomic profıle to speed the translation of new cancer treatments from dogs to
humans.Mammary cancer samples were obtained from female dogs that under-
went surgery. Pieces of the tumors were FFPE for histopathology and the other
fragments were washed with PBS, minced and dissociated with hyaluronidase
and collagenase. Cells were fıltered and put in culture with DMEM-F12, 5%FBS
and 1% pen-strep. After 5 passages, FBS was increased to 10%. After passage 15,
cells were characterized for doubling time, karyotype, immunocytochemistry
for cytokeratin, vimentin and -smooth muscle actin, matrigel-invasion assay
and tumor growth in nude mice. At last, RNA-seq was performed on total RNA
extracted with TRIZOL for functional enrichment analysis of differentially ex-
pressed (DE) genes from cancer cell lines. From 49 tumor samples, we charac-
terized 2 cell lines namedM5 andM25, originally from a comedocarcinoma and
a mixed carcinoma, respectively. Both cell cultures showed spindle-shape cells
and were positive for cytokeratin, vimentin and -smooth actin, suggesting
myoepithelial origin. The doubling time was 26.0h for M5 and 42.8h for M25
cells. Karyotyping analysis showed moderate aneuploidy for both cell cultures.
M25 cell line presented signifıcant higher invasion potential than M5 cells and
formed tumors in mice but the latter didn’t. Histopathology of these tumors
resembled the original tumor in the dog. An average of 16.2 million paired-end
100 bp reads were sequenced per replicate (three for each cell culture) with an
average of 81.1% alignment to the reference genome. A total of 11,260 and
11,476 genes with more than 1 count per million were detected in M5 and M25
cell lines. M5 cell line have 404 and 394 up- and downregulated genes in com-
parison to M25 cell line, respectively. Gene ontology of DE genes showed the
more malignant cell (M25) signifıcantly enriched for pathways related to drug
metabolism, ECM-receptor interaction, cell cycle, DNA replication, focal adhe-
sion and cell differentiation. In conclusion,M25 cell line ismoremalignant than
the M5 which is supported by their transcriptome. Thus, it is possible to use
these cells as a comparative translational model for drug development especially
if one wishes to work with molecular targets as described above.
#820 Potential pro-proliferative role of SIRT6 in melanoma. Liz Garcia-
Peterson, Mary A. Ndiaye, Chandra K. Singh, Wei Huang, Nihal Ahmad. Uni-
versity of Madison Wisconsin, Madison, WI.
Melanoma is one of the deadliest form of skin cancer that can rapidly metas-
tasize to become lethal, if not diagnosed early or left untreated. In 2016, approx-
imately 76,380 new melanoma cases and 10,130 melanoma-related deaths are
predicted in the United States. Current preventive and therapeutic strategies
have not been suffıciently effective in themanagement of melanoma. Therefore,
novel molecular targets and treatments are required for an effective manage-
ment of this neoplasm. In our laboratory, we are assessing the role and func-
tional and therapeutic signifıcance of sirtuin family of proteins in melanoma.
Sirtuins (SIRTs) have been conserved through evolution from prokaryotic to
eukaryotic cells. SIRTs are nicotinamide adenine dinucleotide (NAD) depen-
dent protein deacetylases and belong to class III of the histone deacetylase
(HDAC) family. Seven members of the mammalian SIRT family are known to
date, and despite structural similarities, each SIRT has their own biological
niche, performing unique functions via regulating critical mechanisms in the
cell. The role of SIRTs in cancer is somewhat controversial, as they have exhib-
ited conflicting functions (tumor promoter vs. tumor suppressor) depending on
cell and tissue contexts. The sirtuin SIRT6, a predominantly nuclear protein, has
been shown to conduct ADP-ribosyl transferase and histone deacetylase activi-
ties. SIRT6 plays key roles in DNA repair, inflammation and metabolic diseases
such as cancer. Currently, the role of SIRT6 in melanoma is not known. The
objective of this study was to determine the role of SIRT6 in melanoma. Using a
panel of human melanoma cell lines (A375, Hs 294T, G361, SK-MEL-2, SK-
MEL-28, SK-MEL-31, WM115 andWM35) differing in genetic complexity and
disease progression stage, and normal human epidermal melanocytes
(NHEMs), we determined the endogenous expression levels of SIRT6.We found
that compared to NHEMs, SIRT6 is signifıcantly upregulated in melanoma cell
lines, at mRNA as well as protein levels, as shown by quantitative Real-Time
PCR and western blot analyses. Further, employing a human tissue microarray
(TMA) coupled with quantitative Vectra™ analysis, we determined the expres-
sion profıle of SIRT6 protein in human melanoma and melanocytic nevus tis-
sues. Our data demonstrated that SIRT6 is signifıcantly overexpressed in human
melanoma tissues when compared to nevi. Furthermore, lentiviral short hairpin
RNA-mediated knockdown of SIRT6 in human melanoma cells was found to
result in a marked anti-proliferative response in melanoma cells. Taken to-
gether, our data suggest that SIRT6 overexpression could potentially be a con-
tributing factor in melanoma progression. Further detailed studies are under-
way to understand the functional signifıcance of SIRT6 in melanoma
development and progression.
#821 Loss and retention of mutations in cell culture model systems. Pa-
mela S. Shaw,1 Rick Nicoletti,1 Naghmeh Salimi,1 Helen L. Yang,1 Abigail E.
Witt,1 Agoston T. Agoston,2 Elin S. Agoston1. 1Cellaria Biosciences, Cambridge,
MA; 2Brigham and Women’s Hospital, Boston, MA.
Although relevant, the genomic and proteomic alterations between original
tumor tissue and newly established cell lines are frequently uncharacterized. In
developing a novel cell model (Powder) of high grade serous carcinoma
(HGSC), we followed the status of clinically relevant biomarkers to identify
changes taking place between the tissue and cultured cell population. Under-
standing these changes enables proper utilization of newmodels and continued
model optimization. Using a validated panel, we analyzed 592 genes in the Pow-
der cell model and tumor from which it was derived, detecting several classes of
genomic alterations. This included point mutations, indels, copy number vari-
ations, fusions, and variant transcripts. p53 mutation status of Powder was
matched to a panel of previously reported HGSC cell lines. We further subdi-
vided the panel by p53 protein expression level by reanalyzing previously pub-
lished reverse phase protein array (RPPA) data. Signifıcance of differential ex-
pression between groups was determined with a Welch’s t-test. A majority
(14/21 or 67%) of themutations detected in the HGSC tumor were conserved in
the Powder cell model. Two additional mutations, undetected in the tumor,
were found in the cell model. The tumor exhibited moderate to strong diffuse
positive p53 immunostaining, and p53 mutations were measured in 79% of
alleles. While the p53 mutation did not carry to the cell model, the cells were
positive for CK7 and PAX8, consistent with ovarian cancer cells. In the panel of
HGSC cell lines, we examined p53mutation status and protein level, identifying
3 groups: (1) p53-mut/high protein, (2) p53-mut/low protein and (3) p53-WT/
low protein. Powder identifıed with the p53-WT/low protein group. Previous
work identifıes the p53-WT/low protein group of cell models as part of a larger
set of novel ovarian cell models with a stem-like molecular profıle and higher
drug resistance. Analysis of differential protein expression revealed upregula-
tion in the p53 low protein group of both normal cell cycle genes and of notable
cancer-related proteins. This included p21 and BAD, which are upregulated in
cells with functional p53, eIF4E, a candidate cancer therapeutic target, and
BOP1, which is disregulated in multiple solid cancers, including ovarian. These
results underscore the need for further characterization of the Powder cellmodel
to clarify its applications to specifıc research questions. Continued examination
of Powder and other p53-WT cell models derived from HGSC tumors may
uncover independent pathways driving disease. Additionally, understanding
which mutations are underrepresented by cell models is necessary for ongoing
methods development.
#822 Simple and easymonitoring of tube formation andmigration assays
with the CytoSMARTTM Live Cell Imaging System. Stefanie Buesch,1 Sabine
Schaepermeier,1 Theresa D’Souza,2 Bodo Ortmann,1 Claudia Schwartz,1 Jenny
Schroeder1. 1LonzaCologneGmbH,Cologne,Germany; 2LonzaWalkersville Inc.,
Walkersville, MD.
Movement of cells plays a critical role in the development of cancer. Analyz-
ing the motility of cells in appropriate cell culture models is therefore an impor-
tant tool for cancer researchers. Live cell imaging is particularly well suited to
capture dynamic processes in cell culture. The CytoSMART™ Device is an easy-
to-use, small and affordable live cellmonitoring system suitable for the label-free
analysis of cell motility within a standard cell culture incubator. Label-free ap-
proaches offer the benefıt of cell analysis without potential cytotoxic or other
side-effects of the usedmarkers or dyes on the cells. This presentation shows the
suitability of the CytoSMART™ Device for the analysis of different cancer-rele-
vant assays. The formation of new blood vessels is required to ensure suffıcient
nutrient and oxygen supply and to allow solid tumors to grow beyond a certain
size. This process can be mimicked in cell culture models in so-called tube
formation assays. In this study, Human Umbilical Vein Endothelial Cells
(HUVEC) were seeded on Engelbreth-Holm Swarm Sarcoma derived Basement
Membrane Extract (BME). The resulting formation of endothelial tubes was
monitored with the CytoSMART™ Device. Subsequently, the average length of
the formed tubes as well as the number of closed tube circles was quantitatively
determined. In addition, the impact of Suramin on tube formation was evalu-
ated as an example for a tube formation inhibiting compound. Themigration of
cancer cells is also required for the growth and in particular the metastasis of
tumors. In a fırst example, the closure of a so-called wound or scratch in a
confluent monolayer of cancer cells was monitored with the CytoSMART™ De-
vice. Determining the migration speed of the cells by measuring the speed of
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wound closure is a simple assay to determine the migration potential of cancer
cells. Modifying the cancer cells, e.g. by knocking down specifıc genes with
siRNA, can help to identify genes that play a role in cell migration. Compounds
that are expected to reduce cell motility and therefore reduce the metastasis
potential of cancer cells can be easily tested. In a second example, the invasion of
cancer cells into a three-dimensional (3D) matrix was analyzed. Tumor cells
were embedded in a cancer-relevant matrix and their invasion into the 3D ma-
trix was documented with the CytoSMART™Device.While this type of model is
slightly more diffıcult in set-up and analysis compared to simple scratch assays,
it may reflect better the in vivo situation where solid tumors develop within
three-dimensional tissues. The images captured with the CytoSMART™ System
were quantitatively analyzed using appropriate software. Overall, the Cyto-
SMART™ System is an easy-to-use, small and affordable live cell imaging system
suitable for the label-free analysis of different cancer-relevant assays.
TUMOR BIOLOGY: Cellular Responses to Ionizing Radiation
#823 Inhibition of focal adhesion kinase (Fak) leads to sensitization of p53
mutant head and neck cancer to genotoxic stress.Manish Kumar, Liang Yang,
David Molkentine, Jeffrey Myers, RaymondMeyn, Curtis Pickering, John Hey-
mach, Heath Skinner. UTMD Anderson Cancer Center, Houston, TX.
Head andneck squamous cell carcinoma (HNSCC) ismost commonly treated
with DNA-damaging therapies such as cisplatin and/or radiation. However, a
signifıcant proportion of HNSCCs are resistant to this therapy. Recently, we
have identifıed focal adhesion kinase (Fak) as a targetable biomarker of thera-
peutic resistance in this disease. Additionally, utilizing in vivo shRNA screening
of druggable targets in a panel of HNSCC cell lines, Fak was one of the most
signifıcant genes related to radiosensitization. Additional investigations utiliz-
ing a combination of in vivo and in vitro assays have shown that inhibition of Fak
either chemically or via shRNA leads to dramatically increased sensitivity to
DNA damage. This effect is primarily found in p53-mutant tumors and cell
lines, which are known to be resistant to DNA-damaging therapies. DNA dam-
age due to radiation appears to be potentiated in p53 mutant HNSCC cell lines
following Fak inhibition, but less so in matched p53 wild type HNSCC. More-
over, basal Fak activity is higher in HNSCC cell lines engineered to express
missense p53 mutations compared to either wild type or p53 null cells. We also
found that several forms of mutant p53 bind to Fak and may alter its activity
directly. Taken together, our data suggest a targetable nexus of mutant p53 and
Fak that can be directly modulated to improve the effıcacy of DNA-damaging
therapy.
#824 Reduction in prostate tumor growth and induction of anti-tumor
immunity after combined treatment with oncolytic VSV and radiation.
Thirupandiyur S. Udayakumar, Dillon Betancourt, Glen Barber, Anis Ahmad,
Brian Marples, Alan Pollack. University of Miami, Miami, FL.
Androgen deprivation therapy (ADT) is amainstay of treatment for high-risk
non metastatic and metastatic prostate cancer. Patients initially respond to
ADT, but eventually develop resistance to treatment. To overcome these limita-
tions, we have used oncolytic virotherapy which has the potential to influence
both local and systemic disease through direct cytotoxic and immune mecha-
nisms. Here, we investigated the effectiveness of radiation therapy (RT) com-
bined with Vesicular Stomatitis Virus (VSV) vector expressing interferon 
(IFN) in VSV resistant prostate xenografts. In initial cell culture experiments,
microarray analysis indicated that PC3 cells treated with VSV-hIFN and RT
displayed several genes known to directly inhibit VSV replication (e.g., MX2,
OAS2, TRIM25, IFITM1) were downregulated compared with VSV-hIFN
therapy alone. Additionally, many apoptotic pathway-associated genes (e.g.
IL24, GADD45B, KLF4&10, TNF, EGFR) were upregulated several fold during
combination therapy. Gene expression changes were confırmed by RT-PCR.
Further, immunoblot analysis demonstrated expression levels of IFNAR, BCL-
XL, phosphorylatedAKT, JAK2 and STAT3were alsomarkedly decreasedwhen
VSV-hIFN was combined with RT. However, RIG-I was not signifıcantly al-
tered after VSV-hIFNRT treatment. A marked decrease in MAVS, NFKB
(p50), IRF7 and antiviral protein PKR was seen after combined treatment. The
role of IFN pathway in viral response was investigated using an interferon-
inducible promoter ISRE-luciferase (ISRE-Luc) reporter construct. A signifıcant
difference (600 fold) in the ISRE-Luc activationwas seen for PC3 compared to
LNCaP cells, indicating that the IFN pathway is highly active in PC3 cells after
VSV infection alone. The activation of ISRE-mediated transcription of lu-
ciferase was signifıcantly attenuated (p0.05) in both the cell lines after com-
bined treatment with VSV-hIFN and RT. In subsequent in vivo studies, we
determined that radiation treatment combined with intratumorally-delivered
VSV-mIFN function synergistically to induce oncolysis in both PC3 and LN-
CaP xenografts and a syngeneic RM9 murine model. In the syngeneic model,
combination therapy resulted in a robust anti-tumor immune response with
CD8 and CD4 T-cell expansion and resistance to tumor rechallenge compared
to either therapy alone. These studies demonstrate that two mechanisms are
involved in combined RT andVSV-mediated oncolysis. These are, (1) the atten-
uation of the antiviral response which increases the direct oncolytic effect of
VSV on the tumor cells and (2) improved generation of an adaptive immune
response earmarked by CD8 lymphocyte expansion and anti-tumor activity.
Our study demonstrates that the combined strategy of RT plus VSV-IFN,
affects tumor cell death that are resistant to VSV through direct and systemic
activity that includes a pronounced enhancement of anti-tumor immunity.
#825 Cetixumab enhanced apoptosis effects of radiation on human pros-
tate cancer cell line PC-3.Chia-lun Chang, Szu-YuanWu.Wan Fang Hospital,
Taipei, Taiwan.
Prostate cancer is a leading cause of cancer death in men in developed coun-
tries. Radiotherapy is the main treatment to prostate cancer. Dose escalation of
irradiation with image guide rasdiotherapy and intensity modulated radiother-
apy were used with more and more evidences in prostate cancer patients and
bring in longer PSA-free survival time. Although the evolution of radiation
techniques bring better outcomes, but modern modalities were not avaliable in
non-western world. Radiation enhancement is still an improtant issus in pros-
tate cancer in non-western world, especially in androgen independnt prostate
cancer. The epidermal growth factor receptor (EGFR) network has rich targets
for prostate cancer killing. The chimeric monoclonal antibody Cetuximab
(IMC-A12, Erbitux®) binds to EGFR and prevents its intracellular signaling.
Currently, it is approved for treatment of wild-type KRAS colon and head and
neck cancer. The effect andmechanisms of Erbitux and radiotherapy are still not
clear. In this study, we evaluated the effects of combining the EGFR inhibition
and radiation on PC-3 prostate cancer cells. PC-3 cells were treated with various
doses(1,2.5,5 and 10 ug/ml) of anti-EGFR antibody (CETUXIMAB) and irradi-
ation(5, 7.5 Gy). The results revealed that 5 and 10 ug/ml of CETUXIMAB
signifıcnatly reduced the colony formation. The cell cycle analysis revealed that
CETUXIMAB signifıcnatly enhanced the radiation induced G2/M phase arrest
and subG1 peak increasing. The Hoechst staining and DNA laddering analysis
revealed radiation and CETUXIMAB combined use will induced more apopto-
tic bodies or DNA fragmentation than radiation alone use. By using a apaptosis
protein array, we found that several apaptosis related protein (Catalase, cIAP-1,
Clusterin, Fas, HIF-1, HSP27, HSP60, HSP70, SMAC and Survivin) were sig-
nifıcantly downregulated in radiation and CETUXIMAB combined group.
Taken together, our results demonstrated that Erbitux enhanced apoptosis ef-
fects of radiation on PC-3.
#826 Nrf2 confers radioresistance by regulating cancer stem trait in lung
cancer cells . Xiaoqing He,1 Alex Chi,1 LiyingWang,2 Yon Rojanasakul1. 1West
Virginia Univ., Morgantown, WV; 2National Institute for Occupational Safety
and Health, Morgantown, WV.
Lung cancer is the leading cause of cancer-related death accounting for more
than 1.3 million deaths worldwide annually. Despite advances in treatment, the
fıve-year survival rate is 2% if the cancer has metastasized to other organs. The
major cause of poor prognosis of advanced lung cancer is multi-resistance to
chemo/radio therapy. Therefore, it is crucial to understand the underlying
mechanisms of chemo/radio resistance and develop therapeutic strategies to
overcome the resistance. Transcription factor Nrf2 is a key regulator of cytopro-
tective genes which facilitate cellular defense against harmful insults. We found
that Nrf2 and its downstream target NQO1 are highly upregulated in lung can-
cer patient tumor tissues as well as in lung cancer cell lines compared to adjacent
normal tissues or normal cell lines. We hypothesized that the upregulated Nrf2
may be responsible for radio/chemo resistance and malignancy in lung cancer.
RNA interference studies showed that knockdown of Nrf2 substantially in-
creased the sensitivity of human lung cancer H460 and A549 cells to radiation-
induced cell death. Knockdown of Nrf2 also decreased tumor sphere formation,
suggesting its role in cancer stemcell (CSC) regulationwhichmaybe responsible
for the radioresistance. Analyses of CSC markers including ALDH and Oct4 in
control and Nrf2-knockdown H460 and A549 cells support this fınding. To-
gether, our results indicate an essential role of Nrf2 in the control and regulation
of CSCs and radioresistance. Since CSCs are widely believed to be responsible
for cancer chemoresistance and relapse, our novel fınding on the role of Nrf2 in
radiation resistance may aid in the design of novel therapeutic strategies for
resistant cancers.
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#827 Statistical analyses of stable housekeeping gene expression in cancer
post-irradiation. Albert R. Wang, Gopal Iyer, Sean Brennan, Shay Bourgeois,
Eric Armstrong, Pari Shah, Paul M. Harari. University of Wisconsin-Madison,
Madison, WI.
Ionizing radiation (IR) can induce DNA damage in human cells and result in
changes in gene expression. The changes could also include some of the com-
monly used housekeeping genes (HKG), and thus making them unstable over
the time period after being exposed to radiation.Normalization of housekeeping
genes is critical for understanding gene expression post-irradiation. Toward the
validation of stable HKGs, cancer cell lines from head and neck, non-small cell
lung and pancreas were irradiated to 2, 4 and 6Gy IR doses. Statistical analysis of
RNA expression of fourteen HKGs measured at 5 min to 48hrs post-irradiation
reveal tradition HKGs such as beta-actin (ACTB) and glucose-6-phosphate-
dehydrogenase (G6PD) to be unstable, while TATA-Box Binding Protein (TBP)
and Importin 8 (IPO8) was identifıed as stable HKGs in non-small lung and
pancreas cell across all IR doses and time. Interestingly in head and neck cancer,
TBP is also found stable across all IR doses and time. The statistical framework
used for identifıcation and validation of HKGs can serve as a reliable metric for
quantifying gene expression post-irradiation.
#828 Radiosensitization of glioblastoma stem-like cells by Selinexor, a
selective inhibitor of nuclear export (SINE) compound.AmyWahba, JohnW.
O’Neill, Kevin Camphausen, Philip J. Tofılon. NIH/NCI, Bethesda, MD.
Radiation therapy remains a primary treatment modality for glioblastoma
(GBM). Recently, radiation-induced translational control has been implicated
in regulating processes involved in the cellular radioresponse of GSCs. Reac-
tome analysis disclosed that onemajor pathway under translational control after
irradiation in GSCs is the nuclear export pathway, specifıcally by the nuclear
export receptor Exportin 1 (XPO1, also referred to as CRM1). XPO1 transports
over 200 cargo proteins from the nucleus to the cytoplasm via the nuclear pore
complex, including several tumor suppressor proteins and it is dysregulated in
multiple types of cancers. Selinexor (KPT-330), a SINE compound, is an XPO1
inhibitor that has shown antineoplastic activity in preclinical and clinical mod-
els, both alone and in combination with other treatments. In this study, we
investigated the effect of XPO1 inhibition by Selinexor in combination with
radiation on GSCs. To determine whether XPO1 could serve as a target for GSC
radiosensitization we focused on the GSC cell line NSC11. Based on clonogenic
survival assay, addition of Selinexor 1h before irradiation signifıcantly enhanced
the radiosensitivity of NSC11 cell as compared to controls. To begin to investi-
gate the mechanism behind Selinexor-mediated radiosensitivity, H2AX foci
dispersal, a surrogate marker for DNA double strand breaks (DSB) was evalu-
ated. NSC11 cells treated with Selinexor 1h before irradiation (2Gy) and col-
lected 1-24h later for analysis of H2AX demonstrated a signifıcant delay in
DNADSB repair 24h after irradiation. BecauseXPO1 is responsible for export of
various cargo proteins out of the nucleus, including several ribosomal subunits,
it is predicted to play a role in global translation. To evaluate the effects of XPO1
inhibition onGSCs, the polysome profıles of NSC11 treated with Selinexor were
evaluated. Polysome profıles of NSC11 cells demonstrated signifıcant attenua-
tion of the polysome portion of the profıle as early as 1h after treatment with
Selinexor. After 24h of Selinexor treatment, polysomes were almost undetect-
able with a decrease in translational effıciency (TE) by more than half. This
attenuation is not accompanied by a change in themonosomal peaks, suggesting
that poly-ribosome binding tomRNA is specifıcally affected by radiation. Taken
together, these data suggest that XPO1 plays a role in translation as well as in
cellular radioresponse, and inhibition of XPO1 by Selinexor enhances GSC ra-
diosensitivity, possibly by inhibiting global translation.
#829 MicroRNA regulation of radiation sensitivity in colorectal cancer.
Shushan Rana, Katherine Kelley, Rebecca Ruhl, Charles Thomas, Liana Tsikitis,
Sudarshan Anand. Oregon Health & Science University, Portland, OR.
Background Patients with locally advanced rectal cancer receive neoadjuvant
chemoradiation therapy (CRT) and subsequent surgery. While 10-25% of pa-
tients have complete response toCRT, the remaining patients undergo extensive
tumor excision resulting in signifıcant quality of life issues. Response to CRT is
an independent predictor of overall survival highlighting the importance of
improving CRT response rates. Several tumor intrinsic factors govern responses
to CRT including specifıc gene expression programs. Emerging evidence sug-
gests that microRNAs (miRs) modulate gene expression programs in response
to radiation and have been implicated in several pathological processes associ-
ated with colorectal cancer progression. In this context, we hypothesized that
differential expression of miRs regulates colorectal cancer radiation sensitivity
and can be used as a biomarker to predict radiation effıcacy. Methods To inves-
tigate the differences in miR profıles between rectal cancer patients that had
either a pathological partial response (PR) or no response (NR), we isolated
RNA fromFFPE biopsies using themiRvanamicroRNA isolation kit (Life Tech-
nologies). We used the Nanostring miR profıling platform and obtained abso-
lute counts for 700 human miRs. We performed in vitro gain and loss of
studies with candidate miR transfections in human CRC cell lines and used a
luminescence-based assay for proliferation (Cell titer glo, Promega). Surviving
fraction assays were performed by seeding cells and counting colonies stained
with Crystal Violet. Eight distinct miR bioinformatic target prediction algo-
rithms initiated miR target identifıcation, and a RISC-Trap assay was imple-
mented to confırmmiR-target interactions. The Cancer Genome Atlas (TCGA)
datasets were accessed to acquire provisional survival data on 639 colorectal
adenocarcinoma patients. ResultsWe identifıed 17miRs that were differentially
expressed, and miR-451a, among the most upregulated miRs, inhibited prolif-
eration and colony formation in 2D and 3D assays in the presence of radiation.
Target prediction algorithms highlighted CAB39, EMSY, EREG, and
MEX3C as prominent miR-451a targets in colorectal cancer and/or radia-
tion. TCGA subset anaylsis found CAB39 and EMSY protein levels were
found to be upregulated in 14% and 6% of cases, respectively, and upregu-
lated co-expression of these genes signifıcantly reduced 3 year overall sur-
vival (69% vs 78%, p  0.05). miR-target interaction was confırmed via the
RISC-Trap assay with miR-451a mimic transfection resulting in robust 2.4-,
1.2-, and 2.8-fold enrichment of EREG, CAB39, and EMSY, respectively. In
our partial responders patient cohort possessing upregulated miR-451a,
there was signifıcant downregulation of CAB39 and EMSY mRNA and pro-
tein compared to non-responders. Conclusions miRs alter cell survival net-
works affecting radiation sensitivity and serve to identify pathways amenable
to alternative therapeutic modulation.
#830 MiRNA-106a and LITAF are novel modulators of prostate cancer
radioresistance.ChristianneHoey,1 Jessica Ray,1 Paul Boutros,2 StanleyK. Liu3.
1University of Toronto, Toronto, Ontario, Canada; 2Ontario Institute for Cancer
Research, University Health Network, Toronto, Ontario, Canada; 3Sunnybrook
Research Institute, Toronto, Ontario, Canada.
Prostate cancer (PCa) is the second most prevalent cancer affecting men
worldwide, with radiotherapy being a primary treatment modality. PCa recur-
rence is amajor clinical problemwith up to a 40%biochemical recurrence rate at
fıve years after external beam radiotherapy (ionizing radiation, IR). Therefore,
there is an unmet need to characterize radioresistance in order to improve ther-
apy and patient outcomes. MicroRNAs (miRNAs) are small non-coding RNAs
that regulate gene expression. MiRNAs are aberrantly expressed in cancer, spe-
cifıcally, miR-106a has been found to be overexpressed in various cancer types.
The purpose of this study is to determine whether miR-106a confers IR resis-
tance and tumor aggression in PCa. Utilizing The Cancer Genome Atlas Data
Portal, bioinformatics analysis discovered that miR-106a was signifıcantly over-
expressed in PCa samples relative to normal prostate. This suggests that miR-
106a is involved in prostate carcinogenesis. Clonogenic survival assays revealed
that cells overexpressing miR-106a had increased survival after IR treatment
compared to control cells. Proliferation assays showed that miR-106a cells had a
higher proliferation rate than control cells in both unirradiated and IR-treated
cells. Affymetrix gene array analysis was used to identify possible targets of
miR-106a. Combining results from the gene array, in silico prediction algo-
rithms, and in vitro analyses, we identifıed lipopolysaccharide-induced TNF
factor (LITAF) as a target of miR-106a. In addition, LITAF knockdown lead to
increased proliferation and clonogenic survival following IR, recapitulating the
phenotype of miR-106a overexpression. Cells were stained for -galactosidase
expression following IR to assess senescence, as a mode of cell death. We found
that both miR-106a overexpression and LITAF knockdown resulted in signifı-
cantly fewer senescent cells post-IR. Upon examination of critical DNA damage
response genes, we found thatmiR-106a overexpression and LITAF knockdown
increased expression of ATM mRNA and protein. Upregulation of ATM is
associated with IR resistance, elucidating the mechanism by which miR-106a
overexpression and LITAF knockdown are involved in radioresistance. Tumor
xenograft experiments, using a PCa cell line stably overexpressing miR-106a,
confırmed that miR-106a increases proliferation compared to control tumors
before and after IR. Thus, our results strongly suggest that miR-106a is involved
in PCa aggression and confers a radiation-resistant phenotype, by targeting the
novel radiation response gene LITAF.
#831 TGF controls theDNAdamage response viamiR-182 regulation of
BRCA1 and ATM. Qi Liu,1 Haydeliz Martinez-Ruiz,2 John Murnane,1 Simon
N. Powell,3 Mary Helen Barcellos-Hoff1. 1University of California, San Fran-
cisco, San Francisco, CA; 2Eli Lilly, Indianapolis, IN; 3Memorial Sloan Kettering
Cancer Center, New York, NY.
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Transforming growth factor  (TGF) is a well-documented tumor sup-
pressor; a poorly studied aspect of TGF biology is its control of genomic
stability. Our prior work showed that TGF compromises ATM (ataxia tel-
angiectasia mutated) kinase activity, which mediates recognition and repair
of DNA damage. Consequently, inhibiting TGF following ionizing radia-
tion increases clonogenic death in vitro and tumor control in vivo in breast,
brain, and lung cancer preclinical models. As yet unknown is how TGF
controls ATM kinase. We recently determined that TGF regulates mam-
mary lineage commitment by post-transcriptional control of BRCA1 mRNA
and protein by its suppression of miR-182 (Martinez-Ruiz et al., Science
Signaling, in press). miR-182-mediated downregulation of BRCA1 impacts
DNA repair and sensitivity to PARP inhibitors in cancer cell lines (10.1016/
j.molcel.2010.12.005) Here we used two cell culture models to investigate the
effect of TGF regulation of BRCA1 andmiR-182 onDNA damage response.
Spontaneously immortalized Tgfb1 heterozygote and wild type fıbroblasts
from primary mammary epithelial preparations were synchronized in S-
phase and exposed to UV radiation before fıxation to detect unrepaired DNA
damage by quantitative image analysis of 53BP1 foci. Consistent with com-
promised BRCA1 function, more than twice as many cells with 53BP1 foci
were evident in Tgfb1 heterozygote fıbroblasts compared to wild type cells
(p0.01). The second model consisted of non-malignant human breast ep-
ithelial cell line, MCF10A, stably transduced with a scrambled or miR-182
antagomir, grown under serum free conditions and treated with a small
molecule inhibitor of TGF type I receptor kinase, LY364937. FOXO3 is a
target of miR-182 and thus also regulated by TGF. and FOXO3 association
with ATM is required for its kinase activity (10.1038/ncb1709). As reported,
FOXO3 and ATM co-immunoprecipitated, but was eliminated by TGF
inhibition and this effect was lost in MCF10A cells expressing a miR-182
antagomir. The impaired DNA repair phenotype induced by TGF inhibi-
tion can be fully rescued by antagonizing miR-182. These studies support
TGF as stringent regulator of the DNA damage response via suppression
miR-182, which directly targets BRCA1 and indirectly affects ATM activity
via FOXO3. We predict that cancers that have lost TGF signaling capacity
will be genomically unstable due to defective DNA damage control, which is
consistent with our studies showing that TGF inhibition sensitize cancers
to radiation therapy.
#832 In vitro characterization and clinical correlation of BRCAness as a
personalized biomarker for radiosensitizationwith homologous recombina-
tion-directed therapies. Jennifer Ma,1 Andrew C. Bell,1 Jeremy Setton,1 Justin
Haseltine,1Marcher Thompson,1 Rachna Shah,1 BenjaminH. Lok,1 Robert Del-
site,1 Rebecca Aft,2 Nadeem Riaz,1 Simon Powell1. 1Memorial Sloan Kettering
Cancer Center, New York, NY; 2Washington University, School of Medicine, St.
Louis, MO.
Introduction: BRCA1 and BRCA2 are involved in double-strand break
(DSBs) repair via homologous recombination (HR). Clinically, BRCA1/2 mu-
tant tumors show sensitivity to cisplatin, a cross-linking agent, but only mild
sensitivity to ionizing radiation (IR). The addition of cisplatin to IR has been one
of the largest advances in improving patient outcomes with radiotherapy in the
past 50 years. Recently, BRCAness has been described wherein sporadic defıcits
inHR are observed in the absence of germline BRCA1/2mutations.We hypoth-
esize that BRCAness tumors also exhibit sensitivity to the combination of cis-
platin IR, and are a signifıcant driver of the observed clinical benefıt of com-
bination therapy. Methods: Sensitivity to cisplatin IR was examined in vitro
and correlated with clinical data. Functional HR defıciency (HRD) was assessed
in isogenic BRCA1 (H1299; lung) and BRCA2 (DLD1; colon) knockout pairs
using 3 assays: the Rad51 foci assay, a flow-based DRGFP assay (DSB reporter
assay) and clonogenic survival assays (CSA) with cisplatin /- IR. Cancer Cell
Line Encyclopedia (CCLE) data was used to identify breast cancer cell lines with
sporadic, non-BRCA1/2mutations. Functional HRD in 4 breast cancer cell lines
was assessedwith the same 3 assays used for theBRCA1/2 isogenic pairs.We also
examined 14 triple-negative breast cancer (TNBC) patients treated with neoad-
juvant cisplatin IR. Nine of the 14 had available tissue, which was stained for
Rad51 foci. Results: Functional HRD is observed in the BRCA1/2 isogenic pairs,
as demonstrated by the Rad51 foci andDRGFP assay results. Increased sensitiv-
ity to cisplatin IR is observed in the BRCA1/2 knockout lines in CSA results
compared to isogenic controls. A genomic scar score, LST (large scale transi-
tion), was generated for each line based on CCLE data, with higher LST scores
suggesting increased genomic instability and therefore HRD. Four cell lines
were selected for further study. Similar functional HRD and cisplatin IR
sensitivity is observed in 2 breast cancer cell lines with high LST scores, as
compared to 2 with low LST scores. Epistasis was observed upon siBRCA1
knockdown in the 2 cell lines with high LST scores. Half of the 14 TNBCpatients
demonstrated pathological complete response to neoadjuvant cisplatin IR.
Nine of the 14 patients had available tissue, of which 4 demonstrated functional
HRD by the Rad51 foci assay. Conclusions: Multiple in vitro assays suggest that
HRD tumors are muchmore sensitive to the widely used combination of cispla-
tin IR as comparedwithHRprofıcient tumors. Data fromour small cohort of
triple-negative breast cancer patients appear concordant with these fındings.
Reliable determination of “BRCAness” tumors should identify a subpopulation
of non-germline BRCA1/2-mutated breast cancer patients who may benefıt
from targeted therapy with cisplatin IR.
#833 Alginate hydrogels for three-dimensional culture and real-time
monitoring of cancer cell metabolism and radiation response. Aparna H.
Kesarwala, Jenna L. Carter, Graham H. Read, Natsuko Miura, Kazutoshi
Yamamoto, James B. Mitchell, Murali C. Krishna. National Cancer Institute,
Bethesda, MD.
The purpose of this study was to characterize a three-dimensional calcium
alginate culture system for real-time monitoring of cancer cell metabolism and
radiation response. HCT116 colorectal cancer cells were encapsulated in 2.5%
calcium alginate using a custom electrostatic rig adapted from a previously pub-
lished system. Bead diameter was a function of voltage and alginate concentra-
tion: 4 x 107 cells/mL encapsulated at 4 and 8 kV resulted in mean diameters of
880 and 584 m, respectively. The distribution of bead radii for all voltages
showed positive excess kurtosis (4 kV 1.6, 8 kV 3.0) and 72.9% of 4 kV and
77.2% of 8 kV bead diameters fell within one standard deviation of the mean.
Encapsulated cell viability was assessed by staining with Trypan Blue and clono-
genic survival assays (CSAs). The baseline viability of cells immediately after
encapsulation was 93.2%, which decreased 2 days after a single 10 Gy dose
(90.7%, p0.05). After two weeks of continuous culturing, 84.1% of non-irra-
diated and 73.8% of irradiated encapsulated cells remained viable (p0.003).
Pimonidazole staining demonstrated the presence of hypoxic cores propor-
tional to bead size. CSAs of 8 kV beads showed a dose modifying factor (DMF)
of 1.06 relative to cells grown in a monolayer, while larger 4 kV beads showed a
DMF of 1.58. Mean oxygen consumption rate rose with increasing number of 8
kV beads/well: 1 bead, 35.5; 2 beads, 97.4; 3 beads, 175.5; 4 beads, 209.9; 2.0 x 104
monolayer cells, 92.6 (all pmol/min,8.2 x103 cells/bead, p0.005). Hyperpo-
larized 13C-NMR spectroscopy of 400 uL of 8 kV beads containing 1.2 x 108
cells/mL showed a detectable conversion of [1-13C]-pyruvate to [1-13C]-lactate;
1 hour after a single 10 Gy dose, the lactate:pyruvate ratio decreased by 25%.
Unpaired 2-tailed Student’s t-tests were used to determine signifıcance between
and one-way ANOVAwas used to determine signifıcance among groups with 
set at p0.05. These data demonstrate the versatility of alginate hydrogels for
real-time metabolic and radiation response studies which are non-invasive,
higher throughput, and lower cost compared to in vivo systems. Future direc-
tions include additional metabolic flux analysis and hyperpolarized 13C-NMR
spectroscopy to further investigate the cancer cell metabolic response to drug
and/or radiation therapy.
#834 Formation of DNA double-strand breaks in colon tumors after tar-
geted alpha therapy with 211At-mAb. Sophie E. Eriksson,1 Erika Elgström,1
Sture Lindegren,2 Tom Bäck2. 1Lund University, Lund, Sweden; 2Univeristy of
Gothenburg, Gothenburg, Sweden.
Introduction: Targeted alpha therapy has shown promising results in preclin-
ical and clinical studies. Alpha particle irradiation gives a high fraction of DNA
double-strand breaks (DSB), as shown in vitro, resulting in a high probability of
cell death.We have previously examined the therapeutic effects of 211At on solid
colon carcinoma tumors (diameter approximately 1 cm), with tolerable activi-
ties (5MBq/animals) resulting in non-palpable tumors within one week p.i. The
aim of the present study was to investigate the formation of DNA DSB during
tumor regression after radioimmunotherapy with 211At-mAb in a syngeneic rat
colon carcinoma model. Methods: 18 rats bearing solid colon tumors (1 cm in
diameter) between peritoneum and the abdominal muscle were injected intra-
venously with 5 MBq/animal 211At-BR96. Tumors were excised and paraffın-
embedded after 10 min, 2 h, 8 h, 18 h, 24 h, and 48 h p.i. (3 tumors per time
point). 53BP1 was stained by immunohistochemistry and used as a marker for
DNA DSB. Untreated tumors were used as controls (n9). DNA DSB were
counted in central and peripheral tumor areas selected at random.Results: A few
DNADSBwere detected in untreated tumors.Already 10minp.i., the number of
DNADSBhad increased slightly in peripheral tumor tissue. The number peaked
8 h p.i., when the number of DNA DSB had increased 50 times in the tumor
periphery and 24 times in the tumor center. The number of DNA DSB then
declined, but the difference between center and periphery remained, as expected
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considering the intratumoral distribution of radioimmunoconjugate. This cor-
relates with the 211At half-life of 7.2 h. Conclusion: DNA DSB are formed early
after injection of 211At-mAb and follows the intratumoral distribution of mAbs.
#835 Sensitivity of PTEN defıcient non-small cell lung cancer to ionising
radiation through inhibition of ataxia terangiectasia related 3 kinase (ATR).
Victoria Louise Dunne, Kelly Redmond, Caroline Coffey, Karl Butterworth,
Kevin Prise, GerardHanna.Centre for Cancer Research and Cell Biology, Queens
University, Belfast, United Kingdom.
This study sought to determine the therapeutic effıcacy of AZD6738, a small
molecule inhibitor of ataxia telangiectasia related 3 kinase (ATR), in combina-
tion with ionising radiation (IR) for the treatment of PTEN defıcient non-small
cell lung cancer (NSCLC). An isogenic PTEN defıcient cell model were gener-
ated in H460 and A549 cell lines by HuSH PTEN shRNA constructs in pGFP-
V-RS vectors fromOrigene. Radiosensitivity was determined at various concen-
trations of AZD6738 by clonogenic assay following IR with 225 kV X-rays.
Target validation and mechanistic evaluation of the ATR radiation treatments
was performed by western blotting. Cell cycle distribution was obtained using
propidium iodine flow cytometry analysis which was performed 48 hours fol-
lowing treatment with AZD6738 alone or in combination with IR. In vivo effı-
cacy was determined using cell line derived xenografts in female SCID mice
treated with AZD6738 at a concentration of 25mg/kg per day by oral gavage for
28 days. Animals were exposed to size fraction and hypofractionated radiation
dose under CBCT image guidance using the small animal radiotherapy research
platform (SARRP). Radiation induced toxicity in normal lung tissue effects was
investigated in amodel of radiation induced fıbrosis in C57BL6/J mice. In-vitro,
combined treatment with AZD6738 and IR selectively targets PTEN-defıcient
tumour cells causing a signifıcant reduction in clonogenic survival for both
H460- and A549-PTEN KO cell models (p0.05 at 8Gy). Following 2 Gy IR
exposure therewere signifıcantly highermean foci per cell in bothH460-KOand
A549-KO cells in comparison toWT cells (p0.05 at 2, 4 and 8 hours follow-
ing treatment). Both PTEN-KO cell lines exhibited increased sub G0/G1 and
G2/M populations in comparison to PTEN-WT cell lines when treated with
AZD6738 and IR. Minimal toxicity was observed in both normal HBE and
BEAS-2B cell lines. Currently in vivo tumour response experiments are under-
way to investigate IR and ATR kinase inhibitor AZD6738 using H460-WT and
H460-PTEN KO cell models as well as determining the effects of AZD6738 in a
radiation induced model of lung fıbrosis. Approximately 10% of NSCLC pa-
tients have mutations in PTEN. This research therefore elucidates PTEN loss as
a therapeutic target for combined IR with pharmacological inhibition of ATR in
NSCLC. Targeting ATR inhibition in PTEN-defıcient NSCLC may serve to in-
crease radiation sensitivity in an in vivo model thus highlighting its clinical
relevance as a potential personalisedmedicine approach for patients with PTEN
defıcient NSCLC.
#836 ATR inhibitor BAY 1895344 shows potent anti-tumor effıcacy in
monotherapy and strong combinationpotentialwith the targeted alpha ther-
apy Radium-223 dichloride in preclinical tumor models. Antje Margret
Wengner, Gerhard Siemeister, Ulrich Luecking, Julien Lefranc, Philip Lienau,
Gesa Deeg, Eleni Lagkadinou, Li Liu, Sven Golfıer, Christoph Schatz, Arne
Scholz, Franz vonNussbaum,Michael Brands, DominikMumberg, Karl Ziegel-
bauer. Bayer Pharma AG, Berlin, Germany.
The integrity of the genome of eukaryotic cells is secured by complex signal-
ing pathways, known as DNA damage response (DDR). Recognition of DNA
damage activates DDR pathways resulting in cell cycle arrest, induction of DNA
repair, or cell death. Proteins that directly recognize aberrant DNA structures
recruit and activate kinases of the DDR pathway, such as ATR (ataxia telangiec-
tasia and Rad3-related). ATR responds to a broad spectrum of DNA damage,
including double-strand breaks (DSB) and lesions derived from interference
with DNA replication as well as increased replication stress. Therefore, inhibi-
tion of ATR kinase activity could be the basis for a novel anti-cancer therapy in
tumors with increased DNA damage, defıciency in DNA damage repair or rep-
lication stress. Radium-223 dichloride (Xofıgo®) is the fırst and only approved
targeted alpha therapy so far. It is indicated for the treatment of patients with
castration-resistant prostate cancer (CRPC), symptomatic bone metastases and
no known visceral metastatic disease, based on improvement of overall survival.
It exhibits strong cytotoxic effects on adjacent cells via the induction of DNA
DSB. Here, we disclose for the fırst time the structure and functional character-
ization of the novel ATR kinase inhibitor BAY 1895344. In vitro, BAY 1895344
is a selective low-nanomolar inhibitor ofATRkinase activity, potently inhibiting
proliferation of a broad spectrum of human tumor cell lines (median IC50 of 78
nM). A clear separation between highly sensitive (IC5010 nM) and less sen-
sitive cell lines was observed. The majority of the sensitive cell lines are charac-
terized bymutations affecting theATM(ataxia telangiectasiamutated) pathway.
In cellular mechanistic assays BAY 1895344 inhibited hydroxyurea-induced
H2AX phosphorylation demonstrating the anticipated mode of action. BAY
1895344 is an ATR inhibitor that exhibits strong in vivo anti-tumor effıcacy in
monotherapy in a variety of xenograft models of different indications that are
characterized by DDR defıciencies, inducing stable disease in ovarian and colo-
rectal cancer or even complete tumor remission in mantle cell lymphomamod-
els. In addition, we could demonstrate that combination treatment with BAY
1895344 andRadium-223 exhibits clear synergistic anti-tumor activity in a bone
metastases xenograft model of CRPC. Our fındings validate the concept of syn-
thetic lethality of genetically determinedDNA repair defıciency andATR block-
ade by demonstrating strong monotherapy effıcacy of the highly potent ATR
inhibitor BAY 1895344 in a variety of tumor indications. Furthermore, the
mechanism-based combination potential of DNA damage induction by Radi-
um-223 with BAY 1895344 creates a powerful new treatment option for CRPC
patients with bonemetastases. The start of clinical investigation of BAY1895344
is planned early 2017.
#837 PSMB8 as a candidate marker of responsiveness to preoperative ra-
diotherapy in rectal cancer patients.YejinHa,1 Ka hee Tak,1 ChanwookKim,1
Seon Ae Roh,1 Eun Kyung Choi,1 Dong Hyung Cho,2 Jeong-Hwan Kim,3 Seon-
KyuKim,3 Seon-YoungKim,3Yong SungKim,3 Jin-CheonKim1. 1AsanMedical
Ctr., Seoul, Republic of Korea; 2KyungHee University, Yongin, Republic of Korea;
3Korea Research Institute of Bioscience & Biotechnology, Daejeon, Republic of
Korea.
Prediction of individual responsiveness is urgently needed, specifıcally in lo-
cally advanced rectal cancer (LARC) patients who underwent preoperative che-
moradiotherapy (CRT). The present study, RNA-Seq was used to compare the
basal expression profıle between responders and non-responders to preopera-
tiveCRT, in correlationwith the tumor regression grade (TRG) among 22LARC
patients. Eight differentially expressed genes (B3GALT4, HSPA1B, KRBOX1,
PPBP, PPP1R18, PSMB8, SLC39A7, and TAP2) associated with preoperative
CRT responses were primarily identifıed among the 22 LARC patients by RNA-
Seq (p0.0005 and 16-fold difference). Among these genes, PSMB8 and
SLC39A7 were upregulated in the responsive group in the other 40 LARC pa-
tients (p0.05). PSMB8 overexpression signifıcantly reduced colony formation
and increased apoptosis-inducing molecules like cleaved caspase-3 and cleaved
PARP in irradiated CRC cells after 6 Gy irradiation. PSMB8 knockdown in-
creased colony formation and decreased caspase-3 activation and cleaved PARP
levels after irradiation. In mice treated with ionizing radiation, tumor growth
suppressionwas signifıcantly greater inHCT116/PSMB8-xenografts (81%) than
in HCT116/vector-xenografts (53%) (p0.001). However, SLC39A7 overex-
pression had no signifıcant effect on irradiated CRC cells. These results suggest
that PSMB8 appears to predict radiosensitivity in LARC patients with preoper-
ative CRT, although further clinical validation is needed in a larger cohort.
#838 Effect of tumor treating fıelds on cell proliferation and synergistic
antitumor effıcacy in combination with ionizing radiation. Eun Ho Kim,1
Yunhui Jo,2 Jiwon Sung,2 Hyo Sook Song,2 Myonggeun Yoon2. 1Korea Institute
of Radiological & Medical Sciences, Seoul, Republic of Korea; 2Korea University,
Seoul, Republic of Korea.
Alternating electric fıelds at an intermediate frequency (100300 kHz), called
tumor treating fıelds (TTFs), are reported to interrupt the process of mitosis via
apoptosis and to act as an inhibitor of cell proliferation.Although the presence of
an antimitotic effect of TTFs has beenwidely reported, the effıcacy of TTFs is still
controversial issue among medical experts. To resolve this controversial issue,
the comparison study between the effects of TTFs and the effect of other con-
ventional cancer treatment techniques need to be carried out. In this study,
experimental evidence of the synergistic antimitotic effect of TTFs in combina-
tion with ionizing radiation (IR) is reported. For these experiments, aggressive
brain cancer cells, glioblastoma multiforme (GBM) cells (U373 and U87), were
treated either with TTFs alone, with IR alone or with TTFs followed by ionizing
radiation (IR). The percentages of cell apoptosis, DNA damage, and mitotic
abnormalities were increased by the application of TTFs alone and its quantity
was markedly increased when TTFs were combined with IR. Our results also
suggested that radiotherapy togetherwithTTFsmay be clinically benefıcial since
the combination treatment seemed to synergistically suppress both cell migra-
tion and invasion, based on the inhibition of MMP-9 and vimentin.
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#839 Network-driven analytics of published tissue-based biomarkers to
predict response to neoadjuvant therapy in rectal cancer. Liam R. Poynter,1
Kirill Veselkov,1 Dieter Galea,1 James Kinross,1 Alexander Mirnezami,2 Jeremy
Nicholson,1 Zoltan Takats,1 Reza Mirnezami,1 Ara Darzi1. 1Imperial College
London, London, United Kingdom; 2University of Southampton, United King-
dom.
Introduction Neoadjuvant chemoradiotherapy (nCRT) plays a central role in
the management of locally advanced rectal cancer. For many, nCRT leads to
clinically meaningful tumour regression. However, up to 20% exhibit little to no
response and, in this group, nCRT results in unnecessary delays to defınitive
treatment. There is a critical need for development of robustmolecularmethods
to predict response to nCRT, to allow for more precise treatment stratifıcation.
Although numerous molecular pathways and biomarkers have been implicated
in radiosensitivity, the lack of a unifying interpretation of these fındings has
restricted translational deployment. The aim of the current studywas to develop
a ’knowledge network’ with which to visualise and interpret published, quanti-
tative, biomarker data relating to radiosensitivity in rectal cancer, beyond the
conventional format of a systematic review.Methods Existing data on predictive
biomarkers were retrieved by way of a systematic review of electronic biblio-
graphic databases. Biomarkers were classifıed according to biological function
and built into a hierarchical Gene Ontology tree. Signifıcance was binarized
based on p-values or multivariate statistics. An interactive, direct acyclic graph
was developed using theDagre-D3 JavaScript library. Nodes were sized by num-
ber of studied biomarkers and color-coded according to their signifıcance
scores. The scores reflect the ratio of signifıcant versus non-signifıcant evidence
across studied biomarkers. A negative score range indicates more non-signifı-
cant biomarker fındings for that ontological term (node). Weightings were ap-
plied to reflect those biomarkers confırmed as signifıcant across two or more
studies. p-values of 0.05 or less (adjusted for multiple comparative analysis
where appropriate) were considered to be statistically signifıcant. Results 72
individual biomarkers were identifıed through review. On highest order classi-
fıcation, the domains of response to stress and factors inhibiting apoptosis were
found to be most signifıcant (aggregate signifıcance scores across identifıed bio-
markers, 0.75 and 0.714 respectively). A predictive power was not reached for
the majority of prognostic biomarkers; rather, the levels of their statistical sig-
nifıcancewere assessed. Conclusions Building a knowledge-based network anal-
ysis of published data identifıes promising areas for further research into cellular
mechanisms, whichmay aid in biomarker discovery. Regarding signifıcant node
clusters within a network of published data on predictive biomarkers, modifıca-
tions in cellular metabolic responses to the insult posed by nCRT appear to hold
promise in developing a panel of biomarkers with a predictive capacity for re-
sponse. Network-based analytics takes into account the complex nature of re-
sponse to therapy, and is a novel way of presenting results obtained from a
systematic review.
#840 Polymorphism in DNA repair gene XRCCI leading to nonconserva-
tive amino acid substitution and its role in susceptibility to lung cancer risk.
Gh Rasool Bhat, Rakesh Kumar. Shri Mata Vaishno Devi University, Katra,
India.
Lung cancer is a heterogeneous disease and major global health concern ac-
counting for more than a million annual deaths worldwide. Histologically, 85%
of lung cancers are non-small cell lung cancer (NSCLC) and the other 15% are
small cell lung cancer (SCLC). In India, it is the most common cause of cancer-
related mortality in both men and women. According to the Indian Council of
Medical Research cancer registry, 57,795 new caseswere reported in 2010,which
is projected to increase up to 67,000 new cases annually by the year 2020. Studies
revealed that in Srinagar (Jammu and Kashmir) the incidence of lung cancer
among males is highest and recent investigation by Global Adult Tobacco Sur-
vey (GATS) declared Jammu and Kashmir as the lung cancer capital of India
with 26.6% smokers. Lung cancer remains the biggest health concern and chal-
lenge for society. Various factors being responsible for lung cancer, but among
them smoking is the main cause of lung cancer. However, not all of cigarette
smokers develop this disease. This depicts the signifıcance of genetic makeup in
predicting individual’s susceptibility towards lung carcinoma. This genetic sus-
ceptibility may result from the inherited polymorphisms in genes responsible
for DNA damage repair mechanism and carcinogen metabolism. DNA repair
mechanism plays a very critical role in protecting the genome from insults of
cancer causing agents and maintaining genomic integrity. XRCC1 (X-Ray Re-
pair Cross Complementing group 1) is a major DNA repair gene, acts as a
scaffold of different activities involved in repair by interacting with components
of base excision repair (BER) at the site of damage. Functional polymorphisms in
XRCC1 gene, codon 399 (Arg/Gln), 194 (Arg/Trp) have been known to effect
the repair effıciency which might predispose an individual to lung cancer risk.
However, such studies are completely lacking in the region of Jammu andKash-
mir. With this background, we elected to screen these functional variations in
Patients and Healthy Individuals in a case-control based study design in popu-
lation group from JammuandKashmir. In the pilot study, we have observed that
both the variations are present in the population group of Jammu and Kashmir
and hence can be screened for the case-control association. Further, preliminary
analysis showed a difference in the frequency distribution of the variations in
Cases and controls. However, a larger sample size is required to reach a conclu-
sion regarding the association. We are working on increasing the sample size of
the patient and double the number of controls, from where a real picture of the
association can emerge.
#841 UTR analysis identifıes Musashi1 as a translational regulator of ra-
diation-induced Golgi-related gene expression. Stacey L. Lehman, John W.
O’Neill, Kevin Camphausen, Philip J. Tofılon. National Cancer Institute,
Bethesda, MD.
The cellular radioresponse is regulated by post-translational modifıcation of
constitutively expressed proteins and by changes in gene expression. Although
the role of constitutively expressed proteins, such as those involved in the DNA
damage response and cell cycle checkpoints, is well-understood in the context of
the radioresponse, radiation-induced changes in gene expression are not as
clearly defıned. We have previously demonstrated that glioblastoma stem-like
cells (GSCs) alter their gene expression at the translational level in response to
ionizing radiation (IR). In particular, the NSC11 GSC line demonstrated thou-
sands of genes differentially translated at one hour after a dose of 2 Gy, while
considerably fewerweremodifıed at the transcriptome level. Furthermore, there
was little overlap between the transcriptome and the translatome. Genes under-
going translational regulation in response to IR fell into distinct functional cat-
egories, including mitochondrial structure and function, Golgi function, and
translational regulation. Here, we aimed to elucidate the mechanism by which
IR induces translational changes in theNSC11GSC line.NSC11 cells were either
exposed to 2 Gy or mock irradiated, and polysomes were isolated by sucrose
gradient fractionation one hour later. Polysome-boundmRNAwas purifıed and
analyzed bymicroarray. The 5’ and 3’ untranslated regions (UTRs) of the top 75
up- and down-regulated genes were analyzed for the presence of regulatory
elements. The most frequently occurring element in the UTRs of both the top
up- and down-regulated genes was the Musashi1 binding site. Musashi1 is an
RNA binding protein that typically binds to 3’ UTRs to regulate mRNA trans-
lation. It is a neural stem cell marker, and its expression is correlated with the
grade of malignancy in glioma. GO term analysis of known Musashi1 target
genes that were translationally regulated in response to IR revealed an enrich-
ment of genes involved in Golgi function and vesicular traffıcking. Knockdown
of Musashi1 prevented IR-induced Golgi dispersal in NSC11 cells. Musashi1
knockdown also radiosensitized NSC11 cells, indicating a role for the protein in
the cellular radioresponse. Together, these data demonstrate that in the NSC11
GSC line, Musashi1 contributes to radiation-induced translational regulation,
specifıcally in the context of Golgi-related genes, and suggests thatMusashi1 is a
novel target for radiosensitization.
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#842 Breast cancer: Relationship between GPC3 and EMT process. Lilian
F. Castillo, Gisela V. Novack, Elisa Bal de Kier Joffé,María G. Peters. Instituto de
Oncologia Angel H. Roffo, CABA, Argentina.
Epithelial-mesenchymal transition (EMT) is a processwhereby epithelial cells
acquire mesenchymal fıbroblast-like properties and display reduced intracellu-
lar adhesion and increased motility. Glypican-3 (GPC3) is a heparan sulfate
proteoglycan associated with cancer. We have established that GPC3 regulates
the EMT process underwent by breast cancer cells. However, cellular and mo-
lecular events underlying this modulation are not completely described. At the
present workwe analyzed the effect of GPC3 on cell adhesion and on the expres-
sion of molecules associated with this property. In addition, molecular regula-
tors of EMT were also studied. We employed a murine breast cancer cell line
(LM3: GPC3-) as well as human lines (MDA-MB231: GPC3- and MCF-7:
GPC3). We have blocked GPC3 expression in MCF-7 cells, while it was over-
expressed in MDA-MB231 and LM3 ones. It is know that EMT depends on a
reduction in cell adhesion. We determined that GPC3 overexpression induced
an increase in the homotypic adhesion ofMDA-MB231 and LM3 cells, although
GPC3 silencing did not lead signifıcant changes in the organization of MCF-7
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spheroids. GPC3 was also able to modulate the adhesion to extracellular matrix
components. GPC3 overexpressing cells weremore adherent to fıbronectin than
controls, but no changes were observed in their adhesion to laminin. E-Cad-
herin, amolecule involved in homotypic adhesion, is considered a suppressor of
invasion and growth of many epithelial cancers. Here, we have corroborated by
WB that GPC3 overexpression induces the E-Cadherin upregulation in LM3
and MDA-MB231 cells, whereas GPC3 silencing inhibits the expression of this
epithelialmarker inMCF-7 cells.We also confırmed the called ‘cadherin switch‘,
sinceN-Cadherinwas downregulated inGPC3overexpressing cells and upregu-
lated in GPC3 silenced ones. -Catenin is a key downstream effector in theWnt
pathway. We confırmed that GPC3 expressing breast cancer cells exhibit a ca-
nonicalWnt signaling inhibition.-Catenin also activates Slug. Similar to Snail,
Slug binds to the E-Cadherin promoter to repress transcription. By WB and
qPCR we demonstrated that GPC3 induces a decrease in Slug and Snail levels.
Surprisingly, Twist expression was higher in GPC3 expressing cells. It was re-
ported that Slug is able to represses integrins expression. However, 1-Integrin
levels were decreased in GPC3 overexpressing MDA-MB231 cells, while they
were increased in GPC3 blocked MCF-7 sublines. Our results suggest the key
role of GPC3 in the EMT regulation. GPC3 would modulate cell adhesion and
expression of E-Cadherin, N-Cadherin and 1-Integrin. In addition, GPC3
would regulate the expression of different EMT molecules (as Slug, Snail and
Twist) as well as signaling pathways involved in that process (like canonical
Wnt). The set and balance of these regulations would result in the reversal of
EMT, reinforcing the function of GPC3 as an inhibitor of mammary tumor
progression.
#843 CLDN1 mediates tumor invasion in HNSCC by regulation of EMT
through AMPK-TGF- signalling. JaeWon Chang,1 Seung-Nam Jung,1 Lihua
Liua,1 Jin Man Kim,1 Myung Jin Ban,2 Yeon Soo Kim,3 Bok-Soon Lee,4 Yang
Eun Kim,4 Ho Ryun Won,4 Chul-Ho Kim,4 Bon Seok Koo1. 1Chungnam Na-
tional Univ. College of Medicine, Daejeon, Republic of Korea; 2Soonchunhyang
University College ofMedicine, Cheonan, Republic of Korea; 3KonyangUniversity
College ofMedicine, Daejeon, Republic of Korea; 4Ajou University School of Med-
icine, Suwon, Republic of Korea.
Background: Claudin-1 (CLDN1), amajor component of tight junction com-
plexes in epithelium, maintains cellular polarity and plays critical roles in cell-
to-cell communication and epithelial cell homeostasis. Although, the role of
CLDN1 in cancer has been generally studied in cancers, the exact regulatory
mechanisms and downstream pathways in cancer have been controversial and
are not completely understood. Materials and Methods: After, analysed muta-
tional profıling of tumor/non-tumor paired tissue in the patients with head and
neck squamous cell carcinoma (HNSCC) bynext-generation sequencing (NGS),
CLDN1 expression levels weremeasured in humanHNSCCcell lines and tissues
fromHNSCCpatients using next-generation sequencing. For functional in vitro
analysis, cell proliferation testing using a WST-1 assay, an invasion assay, and
Western blotting was performed after CLDN1 expression regulation. In vivo
validations were performed using nudemouse and patient-derived tumor xeno-
graft (PDTX) model. Results: Mutational profıling of tumor/non-tumor paired
HNSCC tissue by NGS revealed that HNSCC tumor tissues and cell lines had
relatively high levels of CLDN1 expression. Although, CLDN1 regulation did
not affect proliferation of HNSCC cell lines, knock down of CLDN1 inhibited
invasive characteristics (migration/invasion) with down-regulation of EMT as-
sociated proteins (vimentin and slug). We also found that CLDN1 negatively
correlated with AMPK phosphorylation and AMPK activator (AICAR) showed
the same effect with CLDN1 suppression on HNSCC cells without change in
CLDN1 expressionwhich lead to inhibition of TGF--induced Smadphosphor-
ylation and their transcriptional activity, suggesting that CLDN1/AMPK/
TGF- cascade. Then, we confırmed antitumorigenic effects of suppression of
CLDN1 in HNSCC in a nude mouse and PDTXmodel. Conclusions: Our fınd-
ings suggest thatCLDN1 acts as oncogenic driver inHNSCCvia regulating EMT
through AMPK/TGF- signalling and if validated in further studies, a CLDN1-
targeting agent partneredwith an existing anti-TGF-modality could be a novel
tactic to overcome HNSCC.
#844 PPARD downregulation in cancer cells suppresses metastases by in-
hibiting tumor angiogenesis and EMT.Xiangsheng Zuo,Weiguo Xu,Min Xu,
Rui Tian, Micheline J. Moussalli J. Moussalli, Fei Mao, Mihai Gagea, Daoyan
Wei, Anil K. Sood, Imad Shureiqi. UTMD Anderson Cancer Ctr., Houston, TX.
PPARD is upregulated in many major human cancers, but the role that its
expression in cancer cells has inmetastasis remains poorly understood.Here, we
show that specifıc PPARD downregulation or genetic deletion of PPARD in
cancer cells signifıcantly repressed metastasis in various cancer models in vivo.
Mechanistically, PPARDpromoted angiogenesis via interleukin 8 in vivo and in
vitro. Analysis of transcriptome profıling of HCT116 colon cancer cells with or
without genetic deletion of PPARD and gene expression patterns in The Cancer
Genome Atlas colorectal adenocarcinoma database identifıed novel pro-meta-
static genes (GJA1, VIM, SPARC, STC1, SNCG) as PPARD targets. PPARD
expression in cancer cells drastically affected epithelial-mesenchymal transition,
migration, and invasion, further underscoring its necessity to metastasis. Clini-
cally, high PPARD expression in various major human cancers (e.g., colorectal,
lung, breast) was associated with signifıcantly reduced metastasis-free survival.
Our results demonstrate that PPARD, a druggable protein, is an important mo-
lecular target in metastatic cancer.
#845 A clinically validated multiplex immunofluorescence assay for the
quantitative assessment of changes in EMT phenotypes in FFPE tumor tis-
sues in response to cancer therapeutics. Tony Navas,1 Melinda G. Hollings-
head,2 Suzanne Borgel,3 John P. Carter,3 Angelena Millione,3 Brad A. Gouker,4
Donna Butcher,4 Susan Holbeck,5 Apurva K. Srivastava,1 Robert J. Kinders,1
Donald P. Bottaro,6 Shivaani Kumar,5 Alice Chen,5 James H. Doroshow,5 Ralph
E. Parchment1. 1Clinical Pharmacodynamics Program, Applied/Developmental
Directorate, Leidos Biomedical Research, Frederick National Laboratories, Fred-
erick, MD; 2Biological Testing Branch, Developmental Therapeutics Program Di-
rectorate, NCI-Frederick, Frederick, MD; 3Biological Testing Branch, Develop-
mental Therapeutics ProgramDirectorate, Leidos Biomedical Research, Frederick
National Laboratories, Frederick, MD; 4Pathology/Histotechnology Laboratory,
Animal Sciences Program, Leidos Biomedical Research, Frederick National Lab-
oratories, Frederick, MD; 5Division of Cancer Treatment and Diagnosis and Cen-
ter for Cancer Research, NCI, Bethesda, MD; 6Urologic Oncology Branch, Center
for Cancer Research, NCI, Bethesda, MD.
Epithelial-mesenchymal transition (EMT) is a critical process implicated in
metastasis. Despite extensive research, the clinical signifıcance of EMT remains
unclear, and a quantitative evaluation of this process in human tumors has yet to
be demonstrated. We previously reported a validated EMT immunofluores-
cence assay (EMT-IFA), that utilizes-catenin as a tumor segmentationmarker
to delineate tumor tissue from surrounding stroma in FFPE tumor biopsies. The
assay accurately quantifıes individual expression and co-localization of E-cad-
herin (E) and vimentin (V) in tumor cells (Navas et al. NCI-EORTC 2015). We
used this assay tomeasure changes in both the total number and the correspond-
ingEMTphenotypes of tumor cells in xenograft tissues following treatmentwith
various anticancer agents currently in clinical trials at the NCI. Daily treatment
for 14 days with the multikinase inhibitor pazopanib caused signifıcant tumor
regression and delayed regrowth in the epithelial (E) gastric cancer xenograft
modelMKN45, and the tumor cells remaining after treatment were signifıcantly
shifted toward a mesenchymal (V) phenotype. In contrast, pazopanib
(QDx15) had less anti-tumor effıcacy in the mesenchymal gastric cancer xeno-
graft model SNU5. In another instance, daily treatment of the MDA-MB-468
breast cancer xenograft model with the BCR-Abl kinase inhibitor nilotinib for
19 days did not demonstrate any signifıcant anti-tumor effıcacy or change in the
predominance of the E phenotype, whereas a cycle of treatment with the anti-
tubulin agent paclitaxel (Q3Dx4) led to MDA-MB-468 tumor regression and
delayed tumor regrowth after completion of the treatment cycle. Furthermore,
the combination of nilotinib with paclitaxel not only signifıcantly diminished
the total MDA-MB-468 tumor cell number compared to single-agent arms, but
also effectively transformed the EMTphenotype of the tumor, with only a subset
of cancer cells surviving by the last day of treatment, which were mostly
CD44CD133 mesenchymal cells and potential cancer stem cells. The
changes in EMT phenotype brought on by effective drug treatments occurred
via preferential killing of cells with E phenotype, suggesting that V and
VE tumor cells may be more resistant to therapy. The EMT-IFA provides a
much-needed analysis tool suitable for clinical investigation of the proposed role
of EMT in tumor progression, metastasis, and acquired drug resistance, and is
able to detect changes in EMT signature which may serve as early indicators of
treatment effıcacy and tumor resistance. Funded by NCI Contract No.
HHSN261200800001E.
#846 A novel high-throughput 3D screening system for EMT inhibitors.
Kazuya Arai,1 MMamunur Rahman,2Manabu Itoh,1 NorioMasuda,1 Takanori
Eguchi,3 Tetsuya Nakatsura,4 Stuart K. Calderwood5. 1ORGANOGENIX, Inc.,
Kanagawa, Japan; 2MBL international, Woburn, MA; 3Okayama University
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama,
Japan; 4National Cancer Center, Chiba, Japan; 5Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, MA.
EMT (epithelial-mesenchymal transition) is a signifıcant event in tumor me-
tastasis and malignancy. Therefore, inhibition of EMT is considered to enable
controlling of malignant transformation. In this study, we introduce an innova-
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tive three-dimensional (3D) high-throughput (HTS) system that leads to an
identifıcation of EMT inhibitors. At fırst, we established 3D-HTS EMT model
withNanoCulture Plate (NCP) that provided a gel-freemicro-patterned scaffold
for cells forming spheroids naturally. In the NCP-based 3D cell culture system,
A549 lung cancer cells migrated, gathered, and then formed multiple spheroids
within 7 days. Live cell imaging experiments showed that an established EMT-
inducer TGF- promoted peripheral cells around the core of spheroids to ac-
quiremesenchymal spindle shapes, loss of intercellular adhesion, andmigration
from the spheroids. Along with such morphological change, EMT-related gene
expression signatures were altered, particularly alteration of mRNA levels of
ECAD/CDH1, NCAD/CDH2, VIM and ZEB1/TCF8. These EMT-related
phenotypic changes were blocked by SB431542, a TGF-receptor I
(TGFR1) inhibitor. Inside of the spheroids were highly hypoxic; in con-
trast, spheroid derived peripheral migrating cells were normoxic, revealed by
visualization and quantifıcation using Hypoxia Probe. Thus, TGF--trig-
gered EMT caused spheroid hypoplasia and loss of hypoxia. Spheroid EMT
inhibitory (SEMTIN) activity of SB431542 was calculated from fluorescence
intensities of the Hypoxia Probe, and then was utilized in a drug screening of
EMT-inhibitory small molecule compounds. In a pilot screening, 9 of 1,330
compounds were above the thresholds of the SEMTIN activity and cell via-
bility. Finally, two compounds SB-525334 and SU9516 showed SEMTIN
activities in a dose dependent manner. SB-525334 was a known TGFR1
inhibitor. SU9516 was a cyclin-dependent kinase 2 (CDK2) inhibitor, which
we showed also had an EMT-inhibitory activity. Taken together, it was
shown that this 3D NCP-based HTS system was useful for screening of
EMT-regulatory drugs.
#847 Anti-cancer effects of selective Cox-2 and EP2 inhibition through
suppression of EMT and the clinical implications of overexpression of Cox-2
and downregulation of E-cadherin in pharyngeal squamous cell carcinoma.
Yoshihiro Watanabe,1 Yorihisa Imanishi,2 Hiroyuki Ozawa,3 Kaori Ka-
meyama,3 Koji Sakamoto,3 Ryoichi Fujii,3 Seiji Shigetomi,3 Noboru Habu,3
Kuninori Otsuka,3 Yoichiro Sato,3 Mariko Sekimizu,3 Fumihiro Ito,3 Yuichi
Ikari,3 Shin Saito,3 Kaoru Ogawa3. 1Keio University, School of Medicine/Tokyo
Saiseikai Central Hospital, Tokyo, Japan; 2Keio University, School of Medicine/
Kawasaki Municipal Kawasaki Hospital, Tokyo/Kawasaki, Japan; 3Keio Univer-
sity, School of Medicine, Tokyo, Japan.
Background: Overexpression of cyclooxygenase 2 (Cox-2), an inducible prosta-
glandin (PG) synthetase, is assumed to promote cancer progression through its
multifaceted function, including induction of angiogenesis, stimulation of cell pro-
liferation, restraint on apoptosis, and immunosuppression. Furthermore, recently
its inverse relationship with E-cadherin expression was reported. The epithelial-to-
mesenchymal transition (EMT) accompanied by the downregulation of E-cadherin
is supposed to promotemetastasis. However, neither the anti-cancer effect of selec-
tiveCox-2 inhibitors on the regulationof E-cadherinnor its specifıcmechanismhas
been examined in pharyngeal squamous cell carcinoma (PhSCC). In addition, the
anti-tumor effect of EP2 antagonist, a possibly more selective inhibitor of PGE2,
remains to be elucidated.Methods:Weused quantitative real-timePCR to examine
the effects of a selective Cox-2 inhibitors, Celecoxib, and a selective EP2 antagonist,
PF-04418948, on the gene expressions of CDH-1, its transcriptional repressors
(snail, ZEB1, twist), and vimentin in the human PhSCC cell lines BICR6 and FaDu.
Alteration in E-cadherin expression on the cell surface was evaluated by immuno-
fluorescent staining. In vitro proliferation and migration assays were performed to
assess cellular behaviors. Clinicopathological factors and immunohistochemical ex-
pressionsofCox-2 andE-cadherinwere evaluatedusing surgical specimens from54
patients with PhSCC who underwent transoral resection. Results: Both Celecoxib
and PF-04418948 upregulated the CDH-1 expression and themembranous E-cad-
herin expression and downregulate the vimentin expression in the PhSCC cells
throughthesuppressionof snail,ZEB1,andtwist expression.Theextentof this effect
dependedonthebaselineexpression levelsofbothE-cadherinandCox-2 ineachcell
line. Additionally, the cell migration was attenuated by both Celecoxib and PF-
04418948, whereas the cell proliferation was not affected. Univariate analysis
showed that differentiation, overexpression of Cox-2, and decreased expression of
E-cadherin were signifıcantly correlated with lymph node metastasis. Multivariate
logistic regression revealed that overexpression of Cox-2 (odds ratio [OR]53.49,
P0.001) and decreased expression of E-cadherin (OR0.06, P0.016) were the
independent risk factors affecting lymph nodemetastasis. Conclusions: These fınd-
ings suggest that the appropriately selective administration of the Cox-2 inhibitor
andEP2 antagonistmayhave an anti-metastatic effect through suppressionof EMT
by restoring E-cadherin expression. In addition, overexpression of Cox-2 and
downregulation of E-cadherinmay be closely implicated in lymph nodemetastasis
in PhSCC.
#848 Netropsin blocks EMT of murine BRAF mutated melanoma cells.
Juliano Freitas, Fenfei Leng, Lidia Kos. Florida International University, Miami,
FL.
Melanoma is the most aggressive and deadliest type of skin cancer due to its
high propensity to metastasize. Despite current progress in the identifıcation of
promising drugs for treating melanoma, drug resistance has emerged as a seri-
ous issue indicating that novel therapeutic strategies may be required. It is well
documented that the process of converting the epithelial tumorigenic cell to a
mesenchymal phenotype, the epithelial-mesenchymal transition (EMT), is re-
sponsible for conferring an invasive phenotype to cancer cells. An EMT-like
process has been shown to occur duringmelanoma progression.High-mobility-
protein AT-hook 2 (HMGA2) is a multi-function transcription factor linked to
oncogenesis and EMT in a variety of cancers. HMGA2 is a small DNA-binding
protein with three “AT-hook” DNA-binding motifs that specifıcally recognize
the minor groove of AT-rich DNA sequences. HMGA2 is signifıcantly upregu-
lated in human primary melanoma and metastases, including those with BRAF
mutations.We accessed the potential application of netropsin, a potent inhibitor
of HMGA2-DNA interactions, as an EMT blocking agent of BRAF mutated
melanoma cells. Three murine melanoma cells lines that carry mutations in the
BRAF gene and show resistance to vemurafenib (D4M, YUMM1.1, and
YUMM1.7) were used. Cells were treated with EMT Inducing Media Supple-
ment along with Netropsin and the expression of E-cadherin as well as their
migratory behavior were evaluated. Netropsin treatment of EMT induced cells
was not cytotoxic, prevented changes in cellmorphology,maintained high levels
of E-cadherin expression and decreased migratory behavior. All three cell lines
express HMGA2 which continues to be expressed in the tumors resulting from
subcutaneous injections in mice. YUMM1.1 cells showed the highest levels of
expression of HMGA2 amongst the three cell lines. Interestingly, in our prelim-
inary study only YUMM1.1-derived tumors generated overt metastasis in the
lung 30 days after the injections. Altogether our data showed that Netropsin is
capable of blocking EMT of murine BRAFmutated melanoma cells. The results
of this studywill contribute to the development of strategies to prevent EMT that
may result in the implementation ofmore effective therapies to treat melanoma.
#849 Molecular characterization of primary tumor& the paired livermet-
astatic biopsies of colorectal cancer reveals a critical role of immunosuppres-
sion, EMT & angiogenesis in cancer metastasis. Jiangang Liu,1 Yong Beom
Cho,2 Hye kyung Hong,3 Song Wu,1 Philip J. Ebert,1 Steven M. Bray,1 Swee
SeongWong,1 Jason C. Ting,1 John N. Calley,1 Catherine F.Whittington,1 Shri-
pad Bhagwat,1 Emma Bowden,1 Amit Aggarwal,1 Christoph Reinhard,1 Robert
Wild,1 Do-Hyun Nam,2 Woo Yong Lee,2 Sheng-Bin Peng1. 1Eli Lilly and Com-
pany, Indianapolis, IN; 2Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, Republic of Korea; 3Samsung Biomedical Research
Institute, Seoul, Republic of Korea.
Colorectal cancer (CRC) is one of the leading causes of cancer-related mor-
tality worldwide. In United States alone, it was estimated that nearly 137,000
people were diagnosed, and more than 50,000 were dead from the disease each
year. CRC primary tumors oftenmetastasize to liver which accounts for most of
CRC death. The molecular mechanism of tumor metastasis is complicate and
remains poorly understood. In this study, we have collected 79 human CRC
samples, and 60 of them are paired primary tumor and livermetastatic surgically
resected samples.Molecular characterization of these samples was conducted by
exome and RNA sequencing, as well as SNP6.0 analysis. Genetic analysis re-
vealed no signifıcant difference in genetic alterations including common onco-
genicmutations, whole genomemutations and copy number variations between
primary and their matched liver metastatic tumors. To further characterize the
molecular mechanism of metastatic progression, we have assembled gene cor-
relation networks by utilizing a genome-wide interrogation of co-regulated net-
works based on RNA sequencing data of these CRC samples. Computational
analysis of these correlation networks has identifıed gene signatures of immune-
suppression, epithelial-mesenchymal transition (EMT) and angiogenesis as the
key events and potentially synergistic drivers associated with CRC metastasis.
Further independent cohort validation using published datasets verifıed that
these specifıc gene networks of tumor microenvironment were progressively
up-regulated throughout the carcinogenesis, and represented distinct biological
processes. These gene networks were capable of discriminating the previously
categorized CRC molecular subclasses. In addition, we also showed an associa-
tion of type I interferon network with good clinical outcome of CRC, and gene
networks of EMT, angiogenesis, immune-suppression and T cell exhaustion are
closely associated with the poor patient outcome.We further demonstrated that
the networks of EMT and angiogenesis were related to innate anti-PD-1 resis-
tance, and the networks of immunosuppression and T cell exhaustion were
associated with resistance to radiation and checkpoint blockade. Overall, we
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conclude that a genome-wide interrogation of co-regulated networks utilized in
this study represents a valuable strategy to identify molecular mechanisms of
cancer metastasis, and gene networks of immune-suppression, EMT and angio-
genesis are among the key events associated with CRC metastasis.
#850 The Pi3K/Akt pathway mediates epithelial-mesenchymal transition
(EMT) andmalignant progression in BRCA-defective epithelial ovarian can-
cer. Mehida Alexandre, Z Ping Lin, Elena S. Ratner. Yale University School of
Medicine, New Haven, CT.
Objectives: Despite improvement in therapy, the majority of patients with
ovarian cancer relapses and eventually succumbs to the disease. Therefore, there
is an urgent need for further understanding the development and progression of
ovarian cancer. It is well established that the phosphatidylinositol 3-kinase
(Pi3k/Akt) pathway is activated in 70% of ovarian cancers. We have previously
shown that in AKT activity is up regulated in BRCA1 and BRCA-2 defıcient
cancer. Epithelial-mesenchymal transition (EMT), a process by which cells ac-
quire motility and lose their intercellular adhesions, plays an important role in
normal development. Cancer cells have been shown to exhibit similar EMT-like
process during invasion andmetastasis. Recently, the activation of the Pi3k/Akt
pathway is emerging as a central feature of EMT. This study aims to investigate
whether activation of the Pi3k/Akt pathway is necessary for promoting EMT
and malignant progression in BRCA-defective ovarian cancer. Methods:
BRCA2-mutated PEO1 and BRCA2-wild type PEO4 epithelial ovarian cancer
cell lines were derived from the same patient at fırst and second relapse, respec-
tively, following platinum-based chemotherapy. Non-targeted siRNA control
(NTC) and BRCA1-knockdown (BRCA1-kd) SKOV3 cell lines were previously
established in our laboratory.Western blot analysis and luciferase reporter assay
were performed to determine EMT markers (snail, slug, fıbronectin) in BRCA
defective ovarian cancer cells. Scratch wound assays were conducted to deter-
mine the ability of cells tomigrate. Clonogenic and apoptosis assayswere carried
out to determine cell survival in response to various concentrations of carbopla-
tin and olaparib with or without MK-2206, a small molecule inhibitor of AKT.
Results: PEO1 cells exhibited an increase in mesenchymal markers Snail and
fıbronectin, whereas PEO4 cells exhibited an increase in the epithelial marker
E-cadherin. PEO1 cells also exhibited an increase in cell migration compared
with PEO4 cells. In the luciferase reporter assay, BRCA2- mutated PEO1 and
BRCA-1 Kd SKOV3 cells exhibited lower levels of the epithelial maker, E-cad-
herin compared to their BRCA-wild type counterparts, PEO4 and SKOV3NTC,
respectively. Treatment with MK-2206 caused increased susceptibility of
BRCA1-kd SKOV3 cells to olaparib compared with BRCA1-wild type SKOV3-
NTC cells. Conclusions: BRCA2-mutated PEO1cells manifested an increase in
mesenchymal markers and invasive phenotypes. BRCA1-Kd SKOV3 cells man-
ifested a decrease in the epithelial trait, E-cadherin activity. In addition, AKT
inhibition heightened susceptibility of BRCA-1Kd SKOV3 cells to DNA dam-
aging agents such as olaparib. These fındings suggest that BRCA-defective cells
rely on the induction of EMT via activation of AKT to survive DNAdamage and
develop therapeutic resistance during malignant progression.
#851 Reversion of epithelial to mesenchymal transition under androgen
deprived conditions promotes chemoresistance in prostate cancer.Akanksha
Upadhyaya,1 Nataly Stylianou,1 AnthonyM. Davies,2 Sarah-Louise Ryan,2 Brett
G.Hollier,1 ElizabethD.Williams1. 1Australian Prostate Cancer ResearchCentre
– Queensland, Institute of Health and Biomedical Innovation, School of Biomed-
ical Sciences, Queensland University of Technology and Translational Research
Institute, Australia, Brisbane, Australia; 2Australian Prostate Cancer Research
Centre – Queensland, IHBI, School of Biomedical Sciences, Queensland Univer-
sity of Technology and Translational Research Institute, Australia, Translational
Cell Imaging – Queensland, Brisbane, Australia.
Introduction: Metastatic prostate cancer (PC) is one of the leading causes of
cancer related male deaths in Australia. Radical prostatectomy followed by an-
drogen deprivation therapy (ADT) upon recurrence of disease is the conven-
tional form of treatment. Upon relapse, administration of androgen targeted
therapy (ATT) and subsequent chemotherapy improves quality of life and over-
all survival of patients. However, it is not curative and the disease ultimately
progresses. Epithelial to mesenchymal transition (EMT) is a process that can
facilitate tumour growth and progression to metastasis and has also been asso-
ciated with chemoresistance. We therefore aim to determine how EMT and
resultant reversal of this state (MET) influences the chemoresistance profıle of
PC cells and further determine if and how specifıc genetic regulators are in-
volved in this process. Methods: Doxycycline hyclate (Dox) inducible Snai1 and
Zeb1, LNCaP EMTmodels were used to determine the effect of the EMT status
in response to a clinically relevant panel of drugs using cellular and molecular
assays. All assays were performed in both fetal bovine serum (FBS) and charcoal
stripped serum (CSS) supplemented culture media. CSS media was used to
mimic an ADT-like environment. Using 2D monolayer and 3D spheroid
[Happy Cell©] formats. Cells were induced for 5 days of EMT in the presence of
Dox and were allowed to revert for 14 days of MET (absence of Dox) before the
drug assays were carried out over a period of 72 hours. Live/dead cell staining
was used to determine viability percentage in both models. Flow cytometry was
used for 2D assays and 3D assays were analysed using either a GE IN Cell
Analyzer live cell imaging system or confocal microscopy. Results: Induction of
Snai1 and Zeb1 induced an elongated cell shape and increased mRNA and pro-
tein expression of mesenchymal markers such as vimentin during EMT. This
was associated with a decrease in expression of epithelial markers E-cadherin
and EpCam,. An eventual drop in the expression levels of vimentin at around 14
days of dox removal along with an increase in epithelial markers was observed.
These changes were also associated with a gradual reversal in the phenotype of
these cells. However, this reversal in phenotype and expression of EMTmarkers
was not as striking in cells grown in CSS compared to cells in FBS media (both
2D and 3D). Mitoxantrone concentration-response assays in a 2D format
showed that cells that undergo a subsequentMET aremore chemoresistant than
uninduced or EMT cells when grown in CSS media. This was however, not
observed in cells undergoing similar transitions in the FBS media. Conclusions:
The chemoresistance profıle of prostate cancer cells is altered by their EMT
status. This effect is enhanced in the context of ADT. Cells that revert back to a
more epithelial phenotype after undergoing an EMT exhibit higher resistance
towards chemotherapy drugs.
#852 Bromodomain and extraterminal proteins regulate the epithelial-
mesenchymal transition in breast cancer. Guillaume Andrieu, Gerald V. De-
nis. Boston Univ. School of Medicine, Boston, MA.
The epithelial-mesenchymal transition (EMT) is a developmental program
that cancer cells often activate to acquire a highly plastic phenotype that pro-
motes invasion, metastasis, but also chemoresistance and cancer stem cell gen-
eration. As readers of epigenetic marks, bromodomain and extra-terminal
(BET) proteins BRD2, BRD3 and BRD4 participate in the regulation of multiple
transcriptional programs implicated in cancer progression. We sought to un-
ravel the roles of BET proteins in EMT in breast cancer. Despite their homology,
we report that BET proteins differentially regulate EMT. Based on an EMT PCR
array, we identify a BRD2-specifıc transcriptional profıle that promotes EMT,
whereas BRD3 and BRD4 signatures repress this program. These individual
signatures are unidentifıable upon pan-BET inhibition using JQ1, reinforcing
the necessity to target each BET member separately to better understand their
functions. Upon BRD2 depletion, basal-like breast cancer cells, which present a
mesenchymal phenotype, exhibit a reduced expression of mesenchymal mark-
ers (N-cadherin, vimentin) and re-express epithelial markers (E-cadherin, cyto-
keratins). Moreover, a large panel of EMTmaster transcription factors is down-
regulated in BRD2-depleted cells, including the Snail and ZEB families or Twist.
Interestingly, we found that BRD3 or BRD4 depletion leads to the opposite
phenotype: an increase ofmesenchymalmarker expression and repression of the
epithelial markers. In luminal A breast cancer cells which present an epithelial
phenotype, BRD2overexpression leads to the expression ofmesenchymalmark-
ers. Similar results were obtained by depleting BRD3 or BRD4 in these cells,
confırming the differential roles of BET proteins in EMT regulation. Taken
together, our results establish that BRD2 positively regulates EMT, whereas
BRD3 and BRD4 repress this program. BET proteins possess separate and op-
posite biological functions, reinforcing the relevance of an individual targeting
instead of a pan-BET inhibition using JQ1. We hypothesize that BET proteins
modulate EMT through the regulation of its master transcription factors. We
propose that the balance of BET proteins presence at the promoters of the EMT
genes is a novel mechanism of regulation of this program in breast cancer cells.
#853 C1orf116, a gene with unknown function, is a novel driver of epithe-
lial phenotype in epithelial-to-mesenchymal transition in human cancer.
Sarah R. Amend, James Hernandez, Princy Parsana, Kenneth J. Pienta. Johns
Hopkins Univ., Baltimore, MD.
Metastatic prostate cancer is an incurable lethal disease and is the cause of
death for 28,000men in theUS annually. In order for a cancer cell tometastasize
from the primary tumor, it must move. In a critical early event of metastasis, a
rare population of cells in the primary tumor undergoes a phenotype switch
from a proliferating epithelial cell to gaining the migratory capacity of a mesen-
chymal cell, a process, termed epithelial-to-mesenchymal transition (EMT). To
identify previously overlooked regulators of EMT, we undertook a multi-study
gene expression array analysis (15 published gene expression studies; 95 total
samples; 6 cancer types) and identifıed C1orf116 as a candidate driver of the
epithelial phenotype in EMT across multiple cancer types. Of note, C1orf116 is
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an unnamed gene of unknown function that is largely uncharacterized in any
setting, including in cancer biology or in EMT. To substantiate its potential role
in EMT, we queried the NCI-60 cell line collection gene expression dataset and
found that C1orf116 shared a similar expression pattern with epithelial marker
genes (ESRP1, ESRP2, OVOL1, OVOL2) and a converse expression pattern to
mesenchymal marker genes (CDH2, SNAI2, VIM). Moreover, we found that
C1orf116 expression is decreased in metastatic prostate cancer tumors com-
pared to localized disease (Oncomine), suggesting the potential for clinical
translation. To specifıcally interrogate the role of C1orf116 in EMT, we utilized
the PC3 cell line, an in vitromodel of prostate cancer EMT.We found that C1orf
116 expression was higher in an epithelial PC3 cell line (PC3-epi) compared to
PC3 cells that had undergone a stable EMT (PC3-emt). Moreover, shRNA-
mediated knockdown of C1orf116 expression in PC3-epi cells resulted in de-
creased gene expression of canonical epithelial markers (OVOL1, ESRP1,
CDH1) and elevated expression of standard mesenchymal markers (CDH2,
ZEB1, VIM), suggesting a role as a driver of the epithelial phenotype. Interest-
ingly, the sole publication specifıcally studying C1orf116 describes it as Specifı-
cally Androgen Regulated Gene (SARG). The authors demonstrate the presence
of an androgen response element upstream of the C1orf116 start site the in
androgen-responsive prostate cancer cell line LNCaP. Our data indicate a role
for C1orf116 in the androgen receptor-negative prostate cancer cell line PC3,
suggesting a non-androgen-mediated role for C1orf116 in prostate cancer. In
addition to elucidating its role in EMT, work is underway to characterize the
RNA and protein products of C1orf116. Alternative splicing results in two tran-
scripts of varying length that likely give rise to at least two protein product sizes.
RNA sequencing andmass spectrometry will reveal transcript and protein iden-
tity and provide insight into potential isoform switching regulating EMT and
other processes.
#854 Human tissue Kallikrein 6 enzyme activity regulates epithelial-mes-
enchymal transition in colon cancer. Hwudaurw Chen,1 Earlphia Sells,2 Hai-
yan Cui,1 Ritu Pandey,2 George Pampalakis,3 Georgia Sotiropoulou,3 Thomas
Doetschman,2 Natalia A. Ignatenko2. 1Univ. of ArizonaCancer Ctr., Tucson, AZ;
2Univ. of Arizona, Tucson, AZ; 3Univ. of Patras, Patras, Greece.
Background: Kallikrein-related peptidase 6 (KLK6) belongs to the family of
human tissue kallikrein genes, majority of which are shown to be differentially
expressed in cancers. Clinical studies have demonstrated that upregulation of
KLK6 in primary colorectal tumors and lymph nodes correlates with serosal
invasion, liver metastasis and indicative of poor prognosis in patients. It has
been reported that KLK6 protein is involved in regulation of the epithelial-
mesenchymal transition (EMT) program in an organ-specifıc context. The
aim in this study was to investigate contribution of KLK6 enzyme in the EMT
during neoplastic transformation in the colon. Results: We expressed enzymat-
ically active or inactive KLK6, using pcDNA3.1()preproKLK6 and
pcDNA3.1()preproKLK6 Ser197Alamutant plasmids, in Caco-2 colon cancer
cell line, which has been characterized before as a very low KLK6 expresser with
an undetectable secreted KLK6. Stable isogenic clones were selected and further
evaluated for their ability to migrate and invade using in vitro assays and to
metastasize in vivo using SCID orthotopic mouse model. We found no effect of
KLK6 enzyme activity onmigration of Caco-2 cells, expressing the empty vector
(Caco-2 mock), and Caco-2 cells, expressing an enzymatically active KLK6
(Caco-2 KLK6 wt) or inactive KLK6 (Caco-2 KLK6 mut). But Caco-2 KLK6 wt
cells demonstrated the invasive phenotype in Matrigel invasion assays
(p0.001, compared to Caco-2 mock and Caco2 KLK6 mut cells). The Caco-2
mock and Caco-2 KLK6 mut cells, injected in SCID mice orthotopically, devel-
oped primary colon tumors but no metastatic lesions were identifıed. In con-
trast, Caco-2 KLK6 wt cells formed primary colon tumors and metastasized
locally, although they failed to form the distantmetastasis (lung andmesentery).
Animals, growing the Caco-2 KLK6 wt tumors, displayed a signifıcant decrease
in their survival rates, compared to other groups (p0.02). In Caco-2 KLK6 wt
cells TGF- protein expression and secretion was induced, which resulted in
activation of TGF--SMAD2/3 signaling pathway. This phenotype was associ-
ated with the elevated expression of known regulator of the EMT, zinc-fınger
protein Snail. In addition, the expression of a high-mobility group AT-hook 2
(HMGA2) protein was induced in Caco-2 KLK6 wt cells. The HMGA2 expres-
sion is implicated in the EMT program, acting through the TGF- signaling
pathway and is associated with a poor survival in colorectal cancer. Conclusion.
These fındings demonstrate that KLK6 enzyme activity is required for colon
cancer progression via induction of the EMT program. We identifıed the
TGF-- signaling pathway as a mechanism driving the EMT in colon cancer
cells expressing KLK6 enzyme.
#855 Ube2v1 promotes epithelial mesenchymal transition and metastasis
in colorectal cancer by epigenetically transcriptional suppression of au-
tophagy.Tong Shen,1Dong LingCai,1HongYuLiu,2 JuanWenGan,1Ming Li,1
Ru Jing Wang,1 Da Peng Guo,1 Qun Zhou,1 Xing Xing Lu,1 Shi Li,1 Na Li Sun,1
Ming Jian Li1. 1SoochowUniversityMedical School, Suzhou, China; 2BaoanHos-
pital, Shenzhen, China.
Ubiquitination is one of the basic post-translationalmodifıcations for cellular
homeostasis. The conjugating enzyme (E2) family plays as a bridge linking the
fırst step mediated by E1 with the fınal step mediated by E3 in the ubiquitin-
proteasomesystem. However, the role of Ube2v1, one of Ubiquitin-conjugating
E2 enzyme variant proteins (Ube2v), in colorectal cancer (CRC) and autophagy
is unclear. Here, we found that Ube2v1 is elevated in tumor samples of CRC
patients and correlated with poorer survival of CRC patients. Furthermore,
Ube2v1 promotesmigration and invasion ofCRCcells in vitro and boosts tumor
growth and metastasis of CRC cells in vivo. Interestingly, Ube2v1 suppresses
autophagy program and promotes EMT and metastasis of CRC cells in an au-
tophagy dependent pattern in vitro and in vivo. Moreover, Rapamycin attenu-
ates the enhanced in vitro migration and invasion and in vivo lungmetastasis of
Ube2v1 overexpression by inducing the autophagy pathway. Mechanistically,
Ube2v1 increases histone H4 lysine 16 acetylation by down-regulating expres-
sion of Sirt1 and epigenetically suppresses gene expression of autophagy genes in
colorectal cancer. In conclusion, Ube2v1 functions as a globalregulator for au-
tophagy by epigenetically transcriptional suppression of autophagy, and conse-
quently promotes EMT and metastasis of CRC. Our study functionally links
Ube2v1, one member of E2 family in the ubiquitin-proteasome system toau-
tophagy program in CRC progression and metastasis.
#856 Notch-1 promotes a mesenchymal phenotype in colon cancer cells
via Notch-3 and Smad-3 activation. George Sigounas,1 Fred E. Bertrand,2
Douglas A. Weidner,1 Kaitlyn E. Vinson,1 Alexander G. Clark,1 Azeem Khan1.
1East Carolina Univ. School of Medicine, Greenville, NC; 2University of Alabama
at Birmingham, Birmingham, AL.
A role for cancer initiating cells (CIC) in tumor growth, drug resistance,
relapse, andmetastasis via epithelial tomesenchymal transition (EMT) has been
supported by experimental evidence. It is well-documented that Notch-1 recep-
tor signaling participates in stem cell maintenance and lineage commitment in
various organs, including the colon, and can regulate EMT. The function of
Notch signaling in colorectal cancer (CRC) is not clear. We have reported that
Notch-1 activation in the human colon tumor cell line HCT-116 resulted in
upregulation of Jagged-1, Smad-3, CD44, and Slug proteins. These changeswere
accompanied by acquisition of a mesenchymal cell phenotype that included
increased anchorage independent growth and migratory activity. Experiments
with a -secretase inhibitor (DAPT) and soluble Jagged1-Fc protein demon-
strated that Notch-1 signaling activates CD44 and Slug via other Notch recep-
tors. In subsequent experiments, we observed an increase inNotch-3 expression
in the presence of activated Notch-1. Herein, we tested the hypothesis that the
stem cell-like mesenchymal phenotype induced by Notch-1 signaling in colon
cancer cells is mediated by the Notch-3 receptor and Smad-3. The human colon
tumor cell lineHCT-116was transducedwith constitutively activeNotch-1, and
a Notch-3 shRNA to produce a Notch-3 null cell line with activated Notch-1
(ICN1-shN3 cells). ICN1-shN3 cells exhibited a 2.5-fold lower plating effıciency
than the HCT-116/ICN1 cell line (p0.01) that expresses constitutively active
Notch-1 in the presence of Notch-3. In addition, Notch-3 null cells with consti-
tutively active Notch-1 (ICN1-shN3 cells) were slower by 29% in completing
wound healing as compared with the HCT-116/ICN1 cell line (p0.05). Con-
sistent with the lower plating effıciency, a 37% decrease in colosphere formation
was observed with ICN1-shN3 cells as compared with the HCT-116/ICN1 cell
line (p0.001). These data indicated that loss of Notch-3 abrogated theNotch-1
induced mesenchymal cell phenotype. Western blot analysis demonstrated that
the HCT-116/ICN1 cells with intact Notch-3 exhibited increased levels of the
EMT associated proteins Smad-3, CD44 and Slug as compared to the parental
HCT-116 cell line. Expression of CD44 and Slug inNotch-3 receptor null ICN1-
shN3 cells was highly reduced compared with HCT-116/ICN1 cells and was
similar to that detected in the parental HCT-116 cells. Treatment of HCT-116/
ICN1 cells with a Smad-3 inhibitor resulted in signifıcant reduction of the CD44
and Slug proteins. Meanwhile, Notch-3 receptor null ICN1-shN3 cells were also
more sensitive to chemotherapy treatment than the HCT-116/ICN1 cell line
(p0.05). Collectively, our data provide evidence for a novel pathway in which
Notch-1 signaling in colon tumor cells promotes a mesenchymal phenotype via
activation of Jagged-1, Notch-3 and Smad-3, followed by expression of CD44
and Slug.
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#857 ELF3 modulates mesenchymal to epithelial transition through reg-
ulation of CD44 variant isoform expression in pancreatic cancer cells.Ayano
Kabashima-Niibe,1 Hiromasa Takaishi,2 Takanori Kanai,2 Hideyuki Saya,2
Gregory J. Gores,1 Hajime Higuchi3. 1Mayo Clinic, Rochester, MN; 2Keio Uni-
versity School of Medicine, Tokyo, Japan; 3International University of Health and
Welfare, Tokyo, Japan.
BACKGROUND: Epithelial to Mesenchymal Transition (EMT) and Mesen-
chymal to Epithelial Transition (MET) may participate in pancreatic ductal
adenocarcinoma (PDAC)metastasis. CD44proteins are cellmembrane proteins
which function as co-receptors regulatingmany cellular functions. Some reports
have shown that isoform switching from CD44 variant form (CD44v) to CD44
standard form (CD44s) takes place during the EMT. (Brown et al., J. Clin. Invest,
2011, Yae et al., Nat Commun., 2012). The AIM of this study was to explore the
regulation of CD44 isoform switching in PDAC cells. Methods: The expression
levels of CD44v and CD44s in PDAC cell lines were assessed by immunohisto-
chemistry and immunoblot analysis. PDAC cell lines were implanted into im-
munodefıciency mice and treated with sulfasarazine for 14 days. Sulfasarazine,
which inhibits glutamate-cysteine transport, reduces CD44v-dependent cell
growth. CD44v or CD44s positive cells were isolated using flow cytometry and
induced to undergo the EMT by TGF- treatment (7.5ng/mL) for 72 hours. A
doxycycline inducible system was employed to overexpress Slug, which pro-
motes the EMT phenotype. To induceMET, the cells were released fromTGF-
treatment and cultured for an additional 72 hours. E74-like ETS Transcription
Factor 3 (ELF3) expression was knocked-down by siRNA transfection. RE-
SULTS: Immunohistochemistry analysis revealed that CD44v protein is ex-
pressed specifıcally by PDAC with ductal structures within the complex tumor
environment of these cancers. However, in contrast, CD44v expression was not
observed in solitary infıltrating cancer cells. PANC-1, AsPC-1 and SUIT-2
PDAC cell lines expressed both CD44v and CD44s isoforms. Tumor mass in
implanted PANC-1, AsPC-1 and SUIT-2 cells were reduced 69%, 50% and 36%
respectively by sulfasarazine treatment following 2 weeks of therapy. However,
CD44v null HPAC cells were resistant to sulfasarazine therapy following im-
plantation. E-cadherin was expressed in CD44v positive cells but not in CD44s
positive cells, and both CD44v and E-cadherin protein were reduced by TGF-
treatment. Slug over expressed cells were resistant to sulfasarazine treatment
compared to non-Slug-induced cells. Removal of TGF- restored both CD44v
and E-cadherin expression levels which consistently occurs with MET. How-
ever, restoration of CD44v expression was diminished when ELF3 expression
was reduced by siRNA transfection. CONCLUSION: The isoform switching
between CD44v and CD44s was reversible. The expression of CD44v isoform
appears to be controlled by ELF3 during MET.
#858 The circadian clock of glioma cells undergoing epithelial-mesenchy-
mal transition. Arpan De, Dilshan Harshajith Beligala, Vishal Premdev
Sharma, Benjamin Ryan Fry, Michael Eric Geusz. Bowling Green State Univer-
sity, Bowling Green, OH.
Highly invasive gliomas contain many cells that have changed to an en-
hanced migratory state through an epithelial-mesenchymal transition
(EMT). These cells have the phenotype of glioma stem cells (GSCs). Similar
to GSCs, glioma cells undergoing EMT show phenotypic heterogeneity, al-
tered gene expression, and resistance to anticancer drugs along with in-
creased invasiveness. Circadian rhythms in tumor cells influence the pro-
gression and severity of cancer and appear to regulate cell division cycles.
Increased cancer incidence and progression have often been linked to dis-
ruption or deregulation of the molecular mechanism of the circadian clock.
One of the major clock proteins, PER2, has been shown to play a regulatory
role as a tumor and EMT suppressor in metastatic breast cancer cell lines.
GSCs in tumorsphere cultures contain circadian clocks that may regulate
their cancer properties. The possibility of a regulatory role for circadian
rhythms in EMT was examined here. We used a standard method to induce
EMT in the C6 rat glioma cell line that has known circadian rhythms in gene
expression generated by the circadian clocks within its cells. EMT was in-
duced by exchanging the cell culture medium with a serum-free stem cell
medium (SCM) containing growth factors (EGF, FGF2, PDGF-alpha-beta).
Cell cultures were imaged continuously with a microscope and digital cam-
era in a cell incubator to monitor cell shape, cell death, migration, and
apoptosis. During EMT, cells changed from an extended flat state to rounded
and spindle shapes, ceased proliferating, and expressed EMT markers ZEB1
and vimentin. At the end of two days in SCM, 33.4% of the cells were ZEB1-
positive and only 1.26% were GFAP-positive (n3 cultures). Cell diameters
after EMT were within the size range of C6 GSCs described as Hoechst-
negative cells positive for stem cell markers nestin and CD133. Following
EMT, small tumorspheres began to form. After initiating EMT, the rounded
cells were counted at hourly intervals for up to four days after the medium
exchange. As the number of post-EMT cells increased, the population size
oscillated, and when examined by Lomb-Scargle periodogram analysis, four
cultures had a signifıcant period within the circadian range, 19-29 hours,
(average 22.202.45 SD, p0.05). One had a 16-hour period and one lacked
a signifıcant rhythm. Rhythms were present even when circadian clocks in
the cultures were not synchronized with an initial forskolin treatment. We
conclude that EMT may be timed by endogenous circadian oscillators in
gliomas that favor larger numbers of post-EMT cells at a particular time of
day. These results suggest that pharmacological treatments that suppress
EMT or target GSCs would be more effective when delivered at particular
times during the circadian cycle of the tumor.
#859 Epigenetic regulation of epithelial-mesenchymal transition in
esophageal squamous cell carcinoma. Chen Chen,1 Ming Zhao,1 Xiaojie
Huang,1 XiangWang,1 Wenliang Liu,1 Mingjiu Chen,1 Bangliang Yin,1 Zhi Li,2
Yunchang Yuan,1 Qianjin Lu,1 Fenglei Yu1. 1The Second Xiangya Hospital of
Central South University, Changsha, China; 2Beijing Genomics Institute at Shen-
zhen, Shenzhen, China.
Epithelial-mesenchymal transition (EMT) is a developmental program,
which is associatedwith tumor progression andmetastasis.Herewe investigated
the DNA methylation and histone modifıcations in the regulation of EMT in
esophageal squamous cell carcinoma (ESCC). The RNA-Seq analysis identifıed
a total of 6150 differentially expressed genes (3423 up-regulated and 2727 down-
regulated). TheGO terms showed that these genes belonged to severalmolecular
functions and biological pathways. The abnormal expression of key EMT genes,
some of Sox family genes and EZH2 signifıcantly related to patient survival. The
MeDIP-Seq analysis identifıed differentially methylated regions (DMRs) on the
whole genome level with focal hypermethylation and widespread global DNA
hypomethylation. The gene ontology analysis showed that the DMRs related
genes belonged to several different ontological domains, such as EMT progres-
sion, cell cycle, adhesion, proliferation, and apoptosis. The results of the bisul-
fıte-sequencing confırmed theEMTgeneDMRs identifıed byMeDIP-Seq.How-
ever, further analyses showed that the EMT gene DMRs only related to gene
expression, but not the patient survival. ChIP-Seq was then performed to ob-
serve the relationship between histonemethylation and gene expression. A total
of 295 genes were found to correlate with H3K27 tri-methylation (H3K27me3)
, and a certain number of key EMT genes, such as ZEB1/2,AREG, GATA4,and
CDH8 were identifıed. Further study showed that Ezh2-mediated H3K27me3
regulate the expression of key EMT genes. Ablation of Ezh2 expression prevents
EMT,whereas forced expression of Ezh2 restores EMT. Sox4 gene could directly
regulate Ezh2 expression, tri-methylated H3K27me3 for EMT gene repression.
Taken together, our results suggest that both of the DNA methylation and
H3K27me3 modifıcation involved in the regulation of EMT in ESCC. Sox4-
Ezh2-mediatedH3K27me3marks associate with key EMT gene regulation, rep-
resenting an important epigenetic EMT signature.
#861 Olfactomedin 4downregulation is associatedwith enhancing epithe-
lial-mesenchymal transition in human benign prostate cells and prostate
cancer cells. Hongzhen Li,1 Wenli Liu,1 Jianqiong Zhu,1 Kay Chin,1 Jaime Ro-
driguez-Canales,2 Griffın P. Rodgers1. 1NIH-NHLBI, Bethesda, MD; 2UT - MD
Anderson Cancer Center, Houston, TX.
We have previously reported that lost or reduced olfactomedin 4 (OLFM4)
expression is caused by deletions within the OLFM4 gene in 10-25% of all hu-
man prostate-cancer samples, and that its expression is lost inmore than 58% of
advanced prostate-cancer samples. Therefore, we sought to study the role of
epigenetic factors in the regulation of OLFM4 gene expression in normal pros-
tate, as well as prostate-cancer, cell lines. Pyrosequencing of genomic DNA
extracted fromnormal prostate or prostate-cancer tissue cells demonstrated that
three of the eight CpG sites in the OLFM4 gene promoter were signifıcantly
hypermethylated in prostate cancer compared with normal tissue. Exposure to
the methylation inhibitor 5-azadeoxycytidine (5-Aza 5 M) signifıcantly in-
creased OLFM4 expression in RWPE1 benign prostate cells. Knockdown of
OLFM4 expression in RWPE benign prostate cells reduced autophagy and en-
hanced the epithelial-mesenchymal transition (EMT). Restoration of OLFM4
expression in metastatic prostate-cancer cells lacking OLFM4 inhibited cell
growth in both in vitro culture models and an in vivo xenograft tumor model,
and also inhibited EMT marker gene expression in these cells. 5-Aza induced
OLFM4 expression in PC-3 prostate cancer cells and OLFM4 shRNA trans-
fected PC-3 cells affects 5-Aza mediated cell proliferation compared to control-
shRNA transfected PC-3 cells. Taken together, our results suggest that OLFM4
inhibits the EMT program in both normal prostate and prostate-cancer cells,
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and may play a critical role in regulating the EMT program during the progres-
sion of cancer. They also suggest that modulation of OLFM4 expression might
be a novel molecular target for advancing prostate-cancer therapies.
#862 Atypical protein kinase c inhibitors can repress epithelial to mesen-
chymal transition (type III) in malignant melanoma. Wishrawana Sarathi
Ratnayake, Mildred Acevedo-Duncan. Univ. of South Florida, Tampa, FL.
Melanoma is a type of cancer occurs in melanocytes. Approximately 90% of
melanoma occurs in skin (cutaneous melanoma) but can rarely arise from the
mucosal surfaces or areas which neural cellsmigrate. Examples are eye, intestine
and mouth [Eur. J. Cancer, 69: 39-42 (2016)]. 76,380 of new cases and 10,130
number of deaths are expected in 2016 in the USA due to melanoma [http://
seer.cancer.gov/statfacts/html/melan.html (11/05/2016)]. Atypical PKCs con-
tains two structurally and functionally distinct isozymes in human which are
PKC- (iota) and PKC- (zeta). They are believed to be involved in cell cycle
progression, tumorigenesis, cell survival and cell migration. We believe that
atypical PKCs play an important role in cell motility of melanoma by involving
the signaling pathways which induces EMT-type III (Epithelial toMesenchymal
Transition). In normal melanocytes, PKC- was found in low levels and PKC-
was not detected. But both proteins are detected in very high levels in malignant
melanoma [Melenoma Res. 12:201-209 (2002)]. In the current study, we have
investigated the effects of novel atypical PKC inhibitors [4-(5-amino-4-carbam-
oylimidazol-1-yl)-2, 3-dihydroxycyclopentyl] methyl dihydrogen phosphate
(ICA-1)which is specifıc to PKC- and 8-hydroxy-1, 3, 6-naphthalenetrisulfonic
acid (Compound-50) which is specifıc to PKC- on the cell proliferation, apo-
ptosis and cell migration of two malignant melanoma cell lines (SK-MEL-2 and
MeWo) compared to a normal melanocyte cell line (PCS-200-013). We showed
that both inhibitors can decrease the levels of total and phosphorylated levels of
PKC- and PKC-. Furthermore, both inhibitors increased the levels of E-cad-
herin and decreased the levels of Vimentin which is a mesenchymal marker
associated with EMT. Treatments with inhibitors altered the levels of CD44, a
cell-surface glycoprotein involved in cell-cell interactions, cell adhesion, migra-
tion and tumor cell homing during metastasis. These results suggest that both
PKC- and PKC- are involved in signaling pathways which upregulate EMT
and which can be effectively suppress using ICA-1 and Compound-50. Further-
morewe established that treatmentwith ICA-1/Compound-50 induced apopto-
sis as shown by increasing Caspase-3 levels and decreasing Bcl-2 levels.
#863 Neuronal splicing regulatory factors are upregulated in models of
epithelial-mesenchymal transition. Yevgenia L. Khodor,1 Julia Froese,2 Frank
Gertler,1 Robert A. Weinberg,2 Christopher B. Burge1. 1MIT, Cambridge, MA;
2Whitehead Institute, Cambridge, MA.
Epithelial-mesenchymal transition (EMT) is an essential developmental pro-
gram through which epithelial cells lose their polarity and junctions with neigh-
boring cells and acquiremigratory and invasive properties. Cancer cells hijack at
least a portion of the EMTprogram to increase their invasive properties, acquire
resistance to senescence, and metastasize. Major changes in cell signaling, tran-
scriptional and post-transcriptional regulation occur during EMT. To study
post-transcriptional changes we characterized gene expression and splicing
across EMT in 3 cell culture models of EMT: the luminal epithelial MCF7ras
breast cancer cell line with EMT induced by SLUGSOX9 and in basal human
mammary epithelial (HMLEras) cells, with EMT induced by either SNAIL or
ZEB1. RNA-seq was performed at 2-day intervals across these transitions. We
observed broad overlaps between these systems, with 821 genes that changed
signifıcantly in all three. In all three time courses, genes associatedwith cell cycle
and growth decreased in expression, while genes associated with signaling, cell
motion, adhesion, extracellular matrix organization, and differentiation in-
creased. Intriguingly, genes associated with neurogenesis and angiogenesis were
also induced in the MCF7 and HMLER-Snail time courses. Those include
known axon guidance and angiogenic factors in the Robo and Slit families. We
also foundmany alternative splicing events shared in all 3 systems, including 272
skipped exons. Sequence analysis of regions around these exons revealed bind-
ingmotifs for canonical splicing regulators, including ESRP1 andESRP2 and the
RBFOX protein family, which are known to play a role in EMT. While most
genes encoding RNA binding proteins decreased in expression in EMT, a small
subset consistently increased in expression, including some that matched our
motif analysis. Specifıcally, several splicing factors associated with nervous sys-
tem development were upregulated, including factors of the QKI and NOVA
families. We have validated the increased expression of QKI and NOVA1 pro-
teins during EMT in vitro, and of QKI and NOVA2 in tumor sections. Further,
we found that perturbation of QKI expression affects the motility of mesenchy-
mal cancer cells in culture. Together, our results point to the existence of a
program of alternative splicing shared between neuronal and mesenchymal
cells.
#864 Alternated activation of TGF pathway and differential expression
of epithelial to mesenchymal transition transcription factors in relation to
lymph node metastasis in two subtypes of breast cancer tumors. Victoria
Ortega-Hernandez,1 Patricia Gajardo-Meneses,1Wanda Fernandez,2 Pilar Car-
vallo1. 1Pontifıcia Universidad Catolica de Chile, Santiago, Chile; 2Hospital San
Borja Arriaran, Santiago, Chile.
Breast cancer is the leading cause of cancer death among women worldwide,
being distant metastases the main cause of death. Epithelial to mesenchymal
transition (EMT) has been implicated in promoting cancer invasion andmetas-
tasis. This process can be induced by TGF through the expression of transcrip-
tion factors: TWIST, SNAIL, SLUG and ZEB1, which expression may be pro-
moted by different signaling pathways such as SMAD2/SMAD3, PI3K/AKT and
ERK/MAPK. The expression of EMT transcription factors has been previously
studied in several cancer cell lines, although no studies have been performed in
breast cancer tumors. In this study, we analyzed by immunohistochemistry the
expression of the four transcription factors, and the signal transduction key
proteins p-SMAD2 (ser465/467), p-SMAD2L (ser245/250/,255) and p-AKT
(ser473), in 107 breast cancer tumors. We found expression of at least one tran-
scription factor in all triple negative tumors (n24), while only 70% luminal
tumors showed expression of at least one of these proteins. Expression of ZEB1,
SNAIL and SLUG was observed in tumors with metastases to lymph node,
whereas the majority of tumors expressing TWIST were negative for lymph
node status. All triple negative tumors with an active state of the signal trans-
duction pathway TGF/SMAD showed expression of at least one transcription
factor, whereas 65% of luminal tumors with an active state of the same pathway
showed no expression of these transcription factors. Active state of PI3K/AKT
pathway was observed only for luminal tumors as it has been described. Sixty-
three percent of tumors having this pathway active showed expression of at least
one transcription factor. In conclusion we found differential expression of EMT
transcription factors in relation to lymph node status and a differential active
state of signaling pathways in relation to tumoral subtype of breast cancer tu-
mors. Our results suggest a different mechanism of EMT induction by TGF in
relation to two tumor’s subtypes and lymph node metastasis.
#865 Cytoplasmic polyadenylation element binding protein 2 splice vari-
ants have opposing functions in the epithelial to mesenchymal transition
pathway. James T. DeLigio, Charles E. Chalfant, Margaret A. Park. Virginia
Commonwealth University School of Medicine, Richmond, VA.
Alternative splicing of cytoplasmic polyadenylation element binding protein
2 (CPEB2) generates two isoforms, CPEB2B and CPEB2A, through inclusion/
exclusion of exon 4, respectively, inmaturemRNA.We previously reported that
CPEB2B is essential to establish anoikis resistance (AnR), and promotes metas-
tasis using in vivo orthotopic models. In contrast, CPEB2A decreases AnR and
metastatic transformation. In the current studies, we examined the function of
CPEB2 isoforms using next generation sequencing analysis of downstream sig-
naling pathways. We found that CPEB2B expression upregulated AnR in breast
cancer cells and induced key genes/proteins in the epithelial to mesenchymal
transition (EMT) and hypoxic response (hypoxia inducible factor 1 (HIF1)-
dependent) pathways. Inhibition of either TWIST1 or HIF1 reduced the
CPEB2B-mediated AnR in cells ectopically expressing CPEB2B, confırming a
link between CPEB2 alternative splicing and the induction of the EMT/hypoxia
pathways. We then extended our fındings, and demonstrated that CPEB2 alter-
native splicing induced de novo translation of both HIF1 and TWIST1,
whereas CPEB2A decreased translation of these factors. Furthermore, CPEB2
isoforms were found to modulate differential polyadenylation site selection of
the TWIST1 3’UTR and competed for binding to HIF1 and TWIST1 3’UTR
cytoplasmic polyadenylation element (CPE) site sequences. These results dem-
onstrate that CPEB2A and CPEB2B modulate the translation of factors in the
EMT/hypoxia pathways in an opposing fashion via differential polyadenylation
site selection and subsequent translation.
#866 The epithelial-to-mesenchymal transition regulates E-selectin li-
gand activities of breast cancer cells. Grady E. Carlson, Alexander O. Oster-
mann, Venktesh S. Shirure, Fabian Benencia, MonicaM. Burdick.Ohio Univer-
sity, Athens, OH.
The epithelial-to-mesenchymal transition (EMT) leads to specifıc stem-like
and invasive properties in breast cancer cells. However, it remains unclear
whether the EMT modifıes sialofucosylated ligands that circulating tumor cells
use to attach and adhere to vascular endothelial E-selectin duringmetastasis. To
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address this issue, immunohistochemistry and E-selectin microsphere dynamic
adhesion assays were initially used to assay 110 cases of breast cancer for EMT
biomarkers and E-selectin ligand activity. The expression of E-cadherin, but not
N-cadherin or vimentin, directly correlatedwith E-selectin ligand activity. Thus,
it was hypothesized that the EMT, and in turn the mesenchymal-to-epithelial
transition (MET), regulate expression of functional E-selectin ligands in breast
cancer cells. The ectopic expression or shRNA knockdown of transcription fac-
tors (i.e., Snail and Twist) in target cell lines were used to induce EMT or MET,
respectively. Shear flow adhesion assays and flow cytometry demonstrated that
cells with epithelial phenotypes had greater E-selectin ligand activities and
greater expression of sialofucosylated carbohydrates compared to cells with
mesenchymal phenotypes.Moreover, glycoprotein E-selectin ligand activities of
breast cancer cells were more affected by the EMT compared to glycolipid E-
selectin ligand activities. Assessing expression of 1,3- and 1,4- fucosyltrans-
ferases (FUT) at the RNA level using qRT-PCR revealed that FUT3 and FUT6
gene expression were decreased via the EMT, corresponding to the lowered
E-selectin ligand activities observed in mesenchymal phenotype cells. Alto-
gether, the results of this investigation demonstrate that the EMT, as well as the
MET, mechanistically regulate the expression of functional E-selectin ligands
expressed by breast cancer cells.
#867 Circulating lung tumor cells capture extracellular vesicles conferring
resistance phenotype by the occurrence of epithelial-mesenchymal transition
reprogramming. Josephine Zangari,1 Marius Ilie,2 Simon Heeke,1 Véronique
Hofman,2 Baharia Mograbi,1 Sophie Raynaud,3 Salome Lalvee,2 Nathalie Yaz-
beck,1 Charles-Hugo Marquette,2 Sylvie Leroy,2 Patrick Brest,1 Paul Hofman2.
1Université Côte d’Azur, Nice, France; 2Université Côte d’Azur/FHU Oncoage,
Nice, France; 3CHU Nice, Nice, France.
Background: The overall prognosis of lung cancer patients remains dismal, in
particular at advanced stages. Only complete surgical resection of early-stage
tumors improves the prognosis of certain non-small cell lung cancer (NSCLC)
patients. However, migration of circulating tumor cells (CTCs) into the blood
stream is probably an early event of carcinogenesis inducingmetastases. The fact
that some of these CTCs could survive within this “liquid environment” suggest
that they acquire phenotypic changes that would confer them improved resis-
tance against anoikis. In this context, we looked if immune blood cells could
transfer to CTCs some factors associated with this increased resistance. Materi-
als andMethods: Lung cancer cells (A549 cell line)were incubatedwith different
sub-population of blood cells (PBMCs, granulocytes, platelets) and serum to
look for potential transfer of extracellular vesicles (EVs) into the cancer cells. To
assess the inter-cell transfer we looked for the presence of a validated blood cell
specifıcmarker themiR-223 that should not be expressed in lung cancer cells. By
using a direct method for CTCs detection and characterization, we looked for
these biomarkers within CTCs of lung cancer patients with early and late stages.
Moreover the quantifıcation of these biomarkers was correlatedwith the expres-
sion of vimentin, cytokeratin and E-cadherin Results: First, A549 cells were able
to quickly capture microRNA (in particular miR-223) within the control blood
samples. We then identifıed neutrophils as a major source of these miRNA. The
inter-cell transfer was EVs dependent and promoted improved resistance and
survival of A549 cells cancer cells. In NSCLC patients with different stages, the
presence of some specifıc miRNAs for blood cells was detected in a subpopula-
tion of CTCs showing epithelial to mesenchymal phenotype, in particular an
increase of vimentin expression and loss of E-cadherin expression. Conclusion:
These results tend to prove that CTCs may capture extracellular vesicles from
immune blood cells within the bloodstream and this phenomenonmay be asso-
ciated with a more aggressive phenotype. Inhibition of specifıc EVs transfer
could be on interest for development of new targeted immunotherapies.
#868 GRK5promotes amesenchymal transition in prostate cancer. Joseph
B. Black, Iqbal Mahmud, Hamsa Thayele Purayil, Yehia Daaka. University of
Florida, Gainesville, FL.
Locally advanced andmetastatic prostate cancer is incurable, despite decades
of research targeting the activity of the androgen receptor (AR). Our lab previ-
ously identifıed G protein-coupled receptor 5 (GRK5) for its ability to regulate
PCa progression, independent of AR activity. GRK5 partially partitions to the
nucleus, wherein it has been shown to regulate the transcriptome in non-PCa
models. To globally elucidate the mechanistic impact of GRK5 on PCa progres-
sion, we are investigating the impact of GRK5 on the PCa transcriptome. We
hypothesize that GRK5’s regulation of the PCa transcriptome promotes tumor
progression. To assay the effect of GRK5 on the PCa transcriptome, RNA se-
quencing was performed in two cell lines: PC3 Control (PC3 shGFP) and PC3
GRK5 Knockdown (PC3 shGRK5). Ontologic analysis identifıed the epithelial–
mesenchymal transition (EMT) as being affected when GRK5 is depleted. The
epithelial–mesenchymal transition (EMT) is highly associated with promoting
PCa progression and chemoresistance, thus we selected this pathway for further
investigation. Confırmatory western blot analysis and quantitative PCR (qPCR)
validated that depleting GRK5 suppresses the expression of the mesenchymal
markers Vimentin and N-Cadherin. Similarly, overexpression of GRK5 in-
creases the expression of these mesenchymal markers. Stable overexpression of
GRK5 promotes cells to develop a spindle-like morphology, indicative of a mes-
enchymal state. GRK5 mediates this mesenchymal transition through increas-
ing the expression of the EMT transcription factor, Twist1. Further analysis
identifıes that GRK5 activity promotes in vitro invasion. Cell lines overexpress-
ing GRK5 demonstrate an increase in resistance to docetaxel, the mainstay che-
motherapy for advanced PCa. Overexpression of mutated forms of GRK5 that
are relegated to the nucleus are able recapitulated all aforesaid changes, arguing
that the nuclear activity of GRK5 mediates this effect. Collectively, this data
presents a novel mechanism promoting PCa progression, independent of AR
activity. Future work seeks to assay the ability of GRK5 to promotemetastasis in
vivo in mouse models.
#869 Mesenchymal identity of breast cancer promotes brain metastases
and therapeutic resistance through MLK4/NFkB signaling Pathway. Heba
AllahM. Alsheikh, MutsukoMinata, Shinobu Yamaguchi, Ichiro Nakano.Uni-
versity of Alabama at Birmingham, BIRMINGHAM, AL.
Patients with breast cancer brain metastases (BCBM) suffer from a devastat-
ing outcome despite recent progress in a variety of therapeuticmodality. Among
the four major molecular subtypes, breast cancers that are either human epider-
mal growth factor receptor (HER) 2- positive or triple-negative breast cancer
(TNBC) patients have a higher risk of BCBM compared with the luminal cancer
patients. The mechanisms by which the disseminated cancer cells overcome the
multistep defense mechanism in the brain, adapt the microenvironment, and
subsequently initiate metastasis remain elusive. Recently, we identifıed a set of
genes that contribute to initiate Glioblastoma (GBM) and at least some of them
are functionally essential for GBM establishment and the therapy resistance.
Mixed lineage kinase 4 (MLK4) is a relatively poorly characterized serine/thre-
onine kinase, which is largely expressed in various cancers including GBM.We
recently found a critical role of MLK4 in controlling the mesenchymal identity
inGBMstem cells and plays a role inGBM initiation through direct activation of
NF-kB signaling. Our preliminary data indicates MLK4 is also highly expressed
in patient-derived hormone receptor (HR)-negative breast cancer cells in com-
parison with the other HR-positive counterparts. For therapeutic development
purpose, we performed the structure-based drug design, which has led to iden-
tify two small molecule MLK4 inhibitor candidates to test effıcacy on a set of
patient-derived breast cancer cells in vitro and their xenografted tumors in vivo.
Results will be presented in the conference.
TUMOR BIOLOGY: Imaging Cancer Immunotherapy, Tumor
Microenvironment, and Other Aspects of Tumor Biology
#870 Radiation-induced PD-L1 upregulation can be detected by Zr-89-
PD-L1 PET/CT in the tumor micro-environment of murine HPV positive
HNSCCmodel andmelanomamodel.Masahiro Kikuchi, RaghvendraM Sriv-
astava, David A Clump, Julio A Diaz-Perez, Lingyi Sun, Dexing Zeng, W. Barry
Edwards, Carolyn J Anderson, Robert L Ferris. University of Pittsburgh, Pitts-
burgh, PA.
Background: Radiation therapy (RT) can induce upregulation of pro-
grammed death ligand 1 (PD-L1) on tumor cells or myeloid cells, which might
affect the response to RT with or without anti-PD-1/PD-L1 blockade. RT-in-
duced PD-L1 expression during therapy could be a predictive marker for the
therapy response, however, serial biopsies to monitor its distribution may be
unreliable because its expression is heterogeneous. Therefore, non-invasive im-
aging of tumor PD-L1 expression could be more helpful. Materials and Meth-
ods: Two different murine tumor models (MEER and B16F10) were established
in two locations, at the back of the neck and at the right flank of C57BL/6mouse.
Then fractionatedRT (2Gyx4or 2GyX10)with orwithout anti PD-1 therapywas
delivered only to the neck tumor. PD-L1 expression was measured by PET/CT
and biodistrubtion with Zr-89-DFO-anti-mouse PD-L1 monoclonal Ab (clone
10F.9G2) and the results were corroborated by flow cytometric analysis and
immunohistochemistry. PET/CT imaging and biodistributions were performed
48 or 96 hours after tracer-injection. The change of PD-L1 expression on irra-
diated neck tumor was evaluated using non-irradiated flank tumor as a control.
Endothelial cell morphology in tumor vessels was also analyzed by CD31 stain-
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ing to determine whether RT-induced increased permeability of tumor vessels
might result in increased non-specifıc tracer accumulations in the irradiated
tumors. Results: PET/CT imaging and biodistribution study of ex-vivo tracer
uptake values demonstrated signifıcant increased tracer uptake in irradiated
neck tumor compared to non-irradiated flank tumor in either case ofMEER and
B16F10. Tracer uptakes in the spleenswere signifıcantly decreased if high dose of
non-labeled anti-mouse PD-L1 monoclonal Ab was given in advance before
tracer-injection, which indicates the tracer is fully functional. Flow cytometry
and immunohistochemistry showed PD-L1 upregulation in both irradiated tu-
mors corroborating PET/CT imaging of RT-induced PD-L1 upregulation. Flow
cytometry also revealed RT-induced PD-L1 upregulation on myeloid cells is
more prominent than that of tumor cells in both MEER and B16F10. CD31-
positive staining in the irradiated tumors was not different from that of non-
irradiated tumors, which shows RT did not induce alterations in tumor blood
vessels. PD-L1 upregulation of MEER was not seen unless it was performed
2GyX10 RT, however, that of B16F10 could be seen at an earlier time-point of
2GyX4. Combination therapy of anti PD-1 with RT did not show further PD-L1
upregulation compared to RT without anti PD-1 therapy. Conclusion: RT-in-
duced PD-L1 upregulation in different tumormodels ofMEER and B16F10 was
identifıed by PET/CT using Zr-89 labeled PD-L1monoclonal Ab and its validity
was corroborated by flow cytometric analysis and immunohistochemistry.
#871 [18F]BMS-986192 as a novel PET imaging agent for assessment of
PD-L1 expression in vivo. Ralph A. Smith,1 David Donnelly,1 Paul E. Morin,1
Dasa Lipovsek,2 Jochem Gokemeijer,2 Daniel Cohen,1 Joonyoung Kim,1 Adri-
enne Pena,1 Olufemi Adelakun,1 Xi-Tao Wang,1 Patrick Chow,1 Samuel J. Bo-
nacorsi,1 Wendy Hayes1. 1Bristol-Myers Squibb, Princeton, NJ; 2Bristol-Myers
Squibb, Waltham, MA.
Objectives Inhibition of the Programmed Death Ligand-1 (PD-L1)/PD-1 in-
teraction allows for potent anti-tumor activity and antibodies that disrupt this
interaction have been approved for the treatment of multiple cancer types.
PD-L1 expression has been investigated clinically as a potential biomarker to
predict response to anti-PD-1/PD-L1 therapy. BMS-986192, an Adnectin with
high affınity and specifıcity for human PD-L1, was selected in vitro from a
complex library. Here we report the discovery and fırst preclinical evaluation of
[18F]BMS-986192 as a PET imaging agent to detect PD-L1 expression in vivo.
Methods [18F]BMS-986192was radiolabeled via copper-free click chemistry and
assessed for its ability to detect PD-L1 expression. Tracer binding to human
L2987 (PD-L1) and HT-29 (PD-L1-) xenografts as well as human non-small
cell lung cancer (NSCLC) tissue samples was assessed by autoradiography
(ARG). Tracer binding was compared to PD-L1 expression assessed indepen-
dently with anti-PD-L1 immunohistochemistry (IHC). In vivo performance of
the tracer was also assessed by PET imaging in mice bearing bilateral L2987 and
HT-29 xenografts, and tracer biodistribution was further assayed in these ani-
mals ex vivo by gamma counter. Finally, initial in vivo biodistribution and radi-
ation dosimetry was measured by PET in cynomolgus monkey. Results ARG
studies showed increased [18F]BMS-986192 total binding to PD-L1() L2987
xenograft compared to PD-L1(-) HT-29 xenograft tissue. Radiotracer binding
was higher in all tested human NSCLC tissue samples compared to xenografts.
Dose-dependent blockade was seen in all PD-L1() tissues co-incubated with
cold BMS-986192, and binding was unaffected by co-incubation with cold non-
PD-L1 binding control. Visual comparison of tracer binding aligns closely with
PD-L1 IHC both spatially as well as in intensity. Preferential accumulation of
[18F]BMS-986192 was noted in PD-L1() L2987 compared to PD-L1(-) HT-29
xenografts in tumor-bearing mice. PET studies in cynomolgus monkeys con-
fırmed binding to PD-L1() tissue (e.g. spleen) withminimal nonspecifıc back-
ground signal exclusive of primary clearance organs. Radiation dosimetry of
[18F]BMS-986192 indicates an estimated single administration dose limit of 6.2
mCi for an average human subject. Conclusions ARG, PET studies, and ex vivo
measurements in rodent and cynomolgus monkey demonstrated sensitive and
specifıc [18F]BMS-986192 binding to PD-L1. Low background signal in cyno-
molgus monkey in the context of endogenous PD-L1 expression further sup-
ports the potential of this tracer for sensitive detection of PD-L1() lesions in
vivo. Radiation dosimetry suggests that [18F]BMS-986192 can be safely admin-
istered in human trials, with estimated absorbed radiation doses well within safe
parameters for human administration. [18F]BMS-986192 has potential as a sen-
sitive PD-L1 imaging agent for same-day imaging in patients.
#872 Noninvasive monitoring of endogenous Pdl1 expression by using a
dual reporter system. Min Zhou, Xinjian Liu, Fang Li, Chuan-Yuan Li. Duke
University Medical Center, DURHAM, NC.
Programmed death-ligand 1 (Pdl1) is a key immune checkpoint protein fa-
cilitating tumor escape fromhost immune system.Clinical approval of anti-PD1
and anti-PDL1 antibodies for the treatment of a variety of malignancies under-
scores the promise of immune checkpoint therapy. Further progress in this
promising area of research is likely to come from better understanding of the
mechanisms for regulation of immune checkpoint proteins such as PDL1. In the
present study, we designed a dual reporter imaging system to monitor Pdl1
expression by use of theCRSPR-Cas9 technology. A fusion reporter that consists
of eGFP and Luc2 was introduced into downstream of the endogenous Pdl1
gene, right before the stop codon, through CRISPR-Cas9mediated homologous
recombination. A P2A self-cleaving motif is inserted between the fusion re-
porter gene (eGFP-Luc2) and Pdl1. The reporter system was introduced into
two murine tumor cell lines, 4T1 and B16F10. In vitro, an increase in eGFP
intensity and bioluminescence of the reporter cells was observed after exposure
to ionizing radiation or IFN-gamma, which has been reported to upregulate the
expression of Pdl1. In vivo, wewere able to observe radiation induced increase in
bioluminescence signals from tumor established by use of the reporter cells. Our
study therefore provided proof of principle for the use of our endogenous Pdl1
reporter imaging system to monitor the expression levels of Pdl1 in vitro and in
vivo noninvasively and serially.
#873 Evaluating immunotherapy effects using preclinical molecular im-
aging tools for quantitative immune cell tracking.Marie-LaurenceTremblay,1
Zoe O’Brien-Moran,2 Christa Davis,1 Kimberly Brewer1. 1IWK Health Center,
Halifax, Nova Scotia, Canada; 2Dalhousie University, Halifax, Nova Scotia, Can-
ada.
Immunotherapies are a promising class of cancer therapeutics, but clinical
translation is often hampered by a lack of understanding regarding optimal
therapy administration, combination, and reliable biomarkers of success. Tra-
ditional metrics such as RECIST, and modern metrics like irRC and PERCIST
used formonitoring cancer therapy outcome, have limitations for immunother-
apy evaluation and are not always reflective of the underlying immune mecha-
nisms.We aim to better characterize andmonitor these immunotherapies, with
focus on combination therapy optimization, by tracking immune cell migration
in response to these therapies using preclinical magnetic resonance imaging
(MRI). MRI is used to obtain anatomical tumor changes, detect and quantify
superparamagnetic iron oxide (SPIO)-labeled cells in vivo. Goal: To link
immune cell migration to early prognostic biomarkers for immunotherapy
success. Methods: C57/BL6 mice (n40) received an implant of 5x105 C3
cancer cells in the left flank. Mice (n10/group) were i) untreated or treated
with ii) 200g of anti-PD1/day on days 7, 9, 11, 21 and 25, iii) the peptide-
based vaccine DepoVaxTM (DPX) on day 15, or iv) with anti-PD1 and DPX.
CD8 cytotoxic T cells (CD8) and suppressive regulatory T cells (Tregs)
were isolated from diseased-matched & treated donor mice for expansion in
culture before labeling with SPIO for adoptive cell transfer into mice receiv-
ing scans. PET/MRI Data: Anatomical and qualitative SPIO data is collected
using a balanced steady-state free precession (bSSFP) sequence. Iron quan-
tifıcation is done using R2* maps from a multi-echo single point imaging
sequence (TurboSPI). Tumor metabolism was assessed by 18F-fluorodeoxy-
glucose uptake during simultaneous acquisition of positron emission to-
mography (PET) with MRI. Imaging was done 21 and 28 days post-implant.
Results: CD8 and Treg cells are consistently recruited to both the tumor and
vaccine draining inguinal lymph nodes. CD8 T cells are primarily recruited
to the tumor periphery and do not always penetrate the tumor core. Positive
therapy outcomes are correlated with an increasing CD8/Treg ratio in the
tumor, particularly at earlier time points (21 vs 28 days). In certain cases,
CD8 T cells were found within the fat pad between the tumor and lymph
node. As expected, DPX & anti-PD1 combination therapy resulted in the
best prognosis. Simultaneous acquisition of PET/MRI demonstrated large
areas of necrosis in tumor cores. Using TurboSPI, we have begun quantifying
CD8 and Tregs cells, evaluating if volumetric tumor changes due to pseudo-
progression correlate with Treg or CD8 T cell migration and comparing
results to pre-existing biomarkers. Conclusions: Using MRI/PET with quan-
titative immune cell tracking results in more in-depth, longitudinal, charac-
terization of immunotherapies at the preclinical level, which can be used to
optimize therapy combinations.
#874 Lifting the iron curtain: Imaging cellular barriers to combination
chelation-immune checkpoint therapy. Avigdor Leftin, Suresh Veerape-
rumal, Huiyong Zhao, Sadna Budhu, Elisa de Stanchina, Jedd Wolchok,
Taha Merghoub, Jason Koutcher. Memorial Sloan Kettering Cancer Center,
New York, NY.
Iron accumulation in cancer cells and macrophages can result in a tumor
microenvironment that is unfavorable for checkpoint immune therapy. Che-
lation is a safe approach of reducing cellular iron accumulation that while
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affecting all cells biochemically, has been shown to also regulate tumor
growth via specifıc “off-label” effects on macrophages that can hypotheti-
cally support an immune therapy responsive microenvironment. To further
investigate the connection between infıltration of macrophages, iron chela-
tion therapy, and synergy with immune therapy, we used established ortho-
topic Myc-CaP and TRAMP-C2 prostate cancer models and quantitative
iron and cellular MRI, histology, and FACS to evaluate pre-treatment and
post-chelation macrophage/immunological status, and MRI to monitor tu-
mor growth. Quantitative assessment of cellular iron from MRI and histol-
ogy of tumors, livers, and spleens revealed differences in tissue iron levels
between host mouse strains, and enabled us to correlate these differences
with extent of iron-macrophage infıltration in the tissues. To see if we could
reduce these cells metabolically we administered the oral chelator defer-
iprone at tumor onset which resulted in reductions in endpoint tumor vol-
ume in both prostate tumor models with the largest response to chelation
being observed in low-iron C57BL6 model backgrounds; a result subse-
quently confırmed in MMTV-PyMT orthotopic breast cancer models. Even
in cases of complete tumor growth inhibition, systemic iron-load was not
signifıcantly affected, indicating that chelation achieved these therapeutic
gains without harmful side-effects. Reduction of iron-macrophages and tu-
mor volume accompanied shifts in macrophage surface receptor presenta-
tion and T-cell repertoire indicating that pro-tumor (M2) macrophage de-
polarization to anti-tumor (M1) phenotypes occurred with chelation
therapy. As these changes can potentially support improved action of check-
point PDL-1 inhibitors, we then tested the combination chelation-check-
point therapy approach in the prostate tumor models. These trials showed a
modest reduction in tumor growth with either chelation or immune check-
point therapy alone. A notable synergistic effect was observed using combi-
nation chelation-checkpoint therapy that accompanied a shift in macro-
phage polarization suggesting that chelation was suffıcient to enhance
checkpoint response. These therapeutic imaging studies demonstrate how
tumor infıltration of iron-macrophages can be used as a biomarker of the
immune-microenvironment, and how by using iron-chelation immunother-
apeutic response can be enhanced.
#875 Improved resection and prolonged overall survival with PD-1-
IRDye800CW fluorescent probe-guided surgery and PD-1 adjuvant immu-
notherapy. Yang Du, Jie Tian. Institute of Automation, Chinese Academy of
Sciences, Beijing, China.
Purpose: An intraoperative technique to accurately identify microscopic
tumor residuals could be applied to decrease the risk of positive surgical
margins. Several lines of evidence support the expression and immunother-
apeutic effect of PD-1 in breast cancer. Here, we sought to develop a fluo-
rescence labeled PD-1 probe for in vivo breast tumor imaging and image-
guided surgery. The effıcacy of PD-1 monoclonal antibody (mAb) as
adjuvant immunotherapy after surgery was also assessed. Experimental De-
sign: A near-infrared dye labeled PD-1-IRDye800CW probe was developed
and examined for its application in tumor imaging and image-guided tumor
resection in an immunocompetent 4T1 mammary mouse tumor model that
recapitulates clinical metastatic cancer. Fluorescence molecular imaging
(FMI) was performed to monitor probe biodistribution and intraoperative
imaging. Bioluminescence imaging (BLI) was carried out concurrently to
monitor tumor growth and evaluate post-surgical tumor residuals, recur-
rences, and metastases. Results: The PD-1-IRDye800CW probe exhibited a
specifıc and stable signal at the tumor region compared to the IgG control,
and exhibited the highest tumor-to-background ratio (TBR) 8 h post-injec-
tion (11.62 0.79), approximately 5 fold higher than the IgG control (2.13
0.30). Furthermore, PD-1-IRDye800CW guided surgery combined with
PD-1 adjuvant immunotherapy inhibited tumor regrowth and microtumor
metastases, as determined by BLI imaging, and thus improved survival rate
with no obvious side effects. Conclusions: Our study demonstrated the fea-
sibility of using PD-1-IRDye800CW for breast tumor imaging and image-
guided tumor resection. Moreover, we found that PD-1 mAb adjuvant im-
munotherapy reduces cancer recurrences and metastases emanating from
minimal tumor residuals.
#876 Imaging the interaction of leukemia and bone marrow microenvi-
ronment in murine model of ALL. Karine G. Harutyunyan,1 Saradhi Mallam-
pati,1 Anna Zal,1 Mateusz Rytelewski,1 Michael C. Gutkin,2 Jason M. Butler,2
Tomasz Zal,1 Marina Konopleva1. 1MD Anderson Cancer Ceter, Houston, TX;
2Weill Cornell Medical College, New York, NY.
Interactions of leukemia and the bone marrow (BM) microenvironment are
known to play a key role in the survival and growth of leukemic cells, and we
have shown that HIF-1 stabilization in BM stromal cells facilitates leukemia
homing and progression (Chen et al. Blood 2012, 119:4971). Leukemic cells have
been shown to hijack the homeostatic mechanisms of normal hematopoietic
stem cells (HSCs) and take refuge within the BM niche. This mechanism is
pivotal during chemotherapy and contributes to disease relapse. In this study,
we aimed to characterize the time-dependent progression of BM hypoxia in-
volving both acute lymphocytic leukemia (ALL) cells and components of the BM
niche, using multiphoton intravital microscopy (MP-IVM) . We generated a
transplantable, fluorescent leukemia model by retrovirally transducing C57Bl6-
Ai14murine BM cells that express red fluorescing tdTomato with the p190-Bcr/
Abl oncogene (KG Harutyunyan et al, Blood 2014 124:2396). The resulting
p190-Bcr/Abl tdTomato cells caused rapid development of ALL in non-irradi-
ated C57Bl6 immunocompetent mice, manifested by infıltration of multiple
organ and BM sites, followed by death within 14-18 days. We utilized Col2.3-
GFPemd transgenic mice as recipients of leukemia to highlight the osteoblastic
niche, and visualized vasculature by injection ofTRITC-dextran.We showed the
dynamic of homing and engraftment of ALL leukemic B cells (LBC) in OB-GFP
recipient mice, with homing in the vicinity of blood vessels visualized by MP-
IVM, followed by proliferation and leukemia expansion. This was accompanied
by invasion of both vascular and osteoblastic components of BMmicroenviron-
ment. Longitudinal assessment of hypoxia utilizing pimonidazole staining
showed progressive development of BM hypoxia starting from Day 10 p.i., par-
alleling leukemia progression, despite the abundant vascularization of the BM.
To assess the integrity of the BMvascular niche during leukemia progression the
experimental mice were intravitally injected with low doses of an Alexa-Fluor-
647-conjugated VE-cadherin antibody (MG. Poulos et al, Epub 2013 Sep 5) to
visualize the number andmorphology of the perfused vessels and to analyze the
architecture of the hematopoietic compartment. We observed that at late stage
of leukemia progression (day 12-14 p.i) BMvessels are disorganized as a result of
expansion of leukemic B cells. Ongoing longitudinal imaging experiments will
characterize the cellular origin of hypoxic niche cells and the dynamic of vascu-
lature alteration in ALL. In summary, these fındings demonstrate rapid devel-
opment of intra-BM hypoxia that parallels leukemia progression and involves
interactions between leukemia cells and BM niche cells, as well as disordered
vasculature.
#877 Real-time imaging of adherent and non-adherent cell interactions:
utility of an automatedmicrofluidic trap platform to recapitulate in vivo cell
culture microenvironment. Rekha Kannan, Victor Yeh, James Helton,
Amedeo Cappione.Millipore Sigma, Hayward, CA.
The study of dynamic cell processes and their interactions is of crucial impor-
tance to understand the complexities of tissue microenvironments. Simulation
of in vivo cell culturemicroenvironments can greatly improve biologic relevance
of cell-cell interaction studies, and so there is an ongoing demand for heuristic
optimization of cell co-culture devices and protocols. One particularly challeng-
ing task is establishing real-time image analysis while co-culturing non-adher-
ent cells in contact with adherent cell layers under precisely controlled environ-
mental parameters. To address this challenge, we present a novel
microfluidic approach to trap two different cell types in precise locations in
order to image and study their interactions over time. The platform utilizes
a well plate format that contains multiple microfluidic units. Each unit con-
sists of a 3 mm x 3mm x 40m (L xW xH) chamber for culture, and an array
of microscopic trap areas tailored to the dimensions of the cells of interest,
typically15m. Themicro-scale geometries of the traps physically confıne
non-adherent cells, and co-cultures can be achieved by trapping the non-
adherent cells over a monolayer of cells. The microfluidic plate is integrated
with a system which enables perfusion-based nutrient supply along with gas
and temperature control for long-term cell culture. Each chamber within the
plate can be addressed by programmable and on-demand perturbation of up
to 6 reagents, enabling uninterrupted real-time live cell imaging assays. We
present here the use of this microfluidic platform to replicate tumor mi-
croenvironment by maintaining adjacent co-cultures of cancer and immune
cells. We have successfully imaged and cultured monolayers of tumor cell
lines for 7 days followed by subsequent loading and trapping of immune
(non-adherent) cells. In conclusion, the microfluidic platform enables
unique co-cultures with environmental control and real-time imaging to
facilitate the investigation of cell-cell interactions in a wide range of appli-
cations such as drug response and screening in tumor microenvironments,
invasion, evasion pathways and other mechanisms governing cell-cell inter-
actions.
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#878 A new SOX2/OCT4 stem cell biosensor reveals the mechanism of
cancer stemcell dissemination in humanbreast cancer.VedP. Sharma,1 Sonia
Voiculescu,1 Yarong Wang,1 George S. Karagiannis,1 Binwu Tang,2 Lalage
Wakefıeld,2 David Entenberg,1 Sumanta Goswami,3 Maja Oktay,1 John Cond-
eelis1. 1Albert Einstein College of Medicine, Bronx, NY; 2National Cancer Insti-
tute, Bethesda, MD; 3Yeshiva University, New York, NY.
There is increasing consensus that cancer stem cells (CSC) play an important
role duringmetastatic progression of breast cancer. Previous studies have shown
that stem cells display a pro-invasive phenotype in breast cancer. However, the
phenotypes specifıc to breast cancer stem cells have not been evaluated at single
cell resolution in vivo. Here, we employ high-resolution intravital two-photon
microscopy in both orthotopic xenograft tumors, and their metastases, formed
from human breast cancer cell lines expressing a previously characterized
SOX2/OCT4 transcription-based fluorescent stem cell biosensor (SORE6). Us-
ing this high resolution imaging technology we found that SORE6 stem cells:
(a) constitute aminority population of the primarymammary tumors, (b)move
approximately ten times slower than non-stem breast cancer cells (0.1 vs 1.1
m/min, respectively), (c) are migratory toward blood vessels and, (d) com-
pared to non-stem cells, they are enriched for invasive cellular protrusions called
invadopodia. This is important because we have shown that these phenotypes
are specifıcally associated with the disseminating population of tumor cells in
the primary tumor site and, in addition, invadopodia are required for transen-
dothelialmigration during intravasation. Stem cells also have a three-fold higher
incidence of direct contact with macrophages compared to non-stem cells. In
fact, stem cells were frequently seen to be part of the tripartite macrophage-
tumor cell- endothelial cell complex called TMEM,whichwas previously shown
to be the doorway for intravasation of tumor cells in primary mammary tumors
and is validated as a prognostic of metastasis in human breast cancer patients.
Furthermore, we followed breast cancer stem cell dissemination to the lung by
using a novel lung window for high resolution imaging of the lung (WHRIL),
which allows visualization of the same lung tissue in a singlemouse, serially, over
days to weeks. Using WHRIL, in combination with intravital multiphoton mi-
croscopy and the above biosensor, we visualized the arrival, extravasation and
outgrowth of spontaneously arriving breast tumor cells in the lung. We report
here for the fırst time, the kinetics and stemness state of the spontaneously
metastasizing tumor cells and, the record at single cell resolution, of their fate
and metastatic outgrowth in the lung over time.
#879 Multi-scale time-lapse intravital imaging of soft tissues tomap single
cell behavior. JessicaM. Pastoriza,1Maria Soledad Sosa,2KathrynHarper,2 Julio
Aguirre-Ghiso,2 Maja H. Oktay,1 David Entenberg,1 Yarong Wang,1 John S.
Condeelis,1 Aviv Bergman,1Mihaela Skobe,2 Benedicte Lenoir2. 1Albert Einstein
College of Medicine, Bronx, NY; 2Icahn School of Medicine at Mount Sinai, New
York, NY.
After more than 10 years of research into the tumor micro-environment and
the sources of tumor micro-heterogeneity, it is becoming increasingly clear that
in addition to driver mutations, the tumor microenvironment determines tu-
mor metastatic phenotype. This research has led to a new understanding of the
impact of tumor microenvironments and their heterogeneity upon tumor cell
proliferation, dissemination, dormancy, and survival. A full understanding of
this heterogeneity, both temporally and spatially, how it supports tumor cell
dissemination, dormancy and eventual further metastatic growth, and how it
responds to therapeutic interventions, is crucial. Traditional single parameter
studies have not been as productive as hoped in revealing the above relationships
and have highlighted the need to understand tumors as integrated systems of
genes, gene networks, and intracellular interactions, particularly with regard to
the interplay between cells and their immediate microenvironment. To accom-
plish this, we have developed a new technology in the form of large volume
intravital imaging using multiphoton intravital microscopy (MIVM) where im-
ages of large tumor volumes are stitched together to form a comprehensive
record of the genes, gene networks, and intracellular interactions that occur
throughout many tumor microenvironments at single cell resolution. Here, we
report a protocol for obtaining large area high-resolution mosaic imaging in
living animals. The protocol is composed of surgical techniques for the stabili-
zation of soft tissues includingmammary gland, lymph node, liver, and lung and
the acquisition of multiple high-magnifıcation tiles that are stitched together to
form a large-area low-magnifıcation image. We have developed specifıc proto-
cols for the surgery as well as tools for tissue stabilization and the acquisition and
stitching of the images to generate very large MVIM data sets. We have inter-
faced these very large MVIM image data sets with support vector machine
(SVM) classifıcation, a nonlinear, multiparametric classifıcation algorithm suit-
able for analysis of systems with arbitrary distributions and/or non-linear para-
meter’s correlations. To defıne the combinations of microenvironment param-
eters where tumor cell phenotypes of interest are likely to occur, we used these
microenvironment parameters as an “input” for the SVM classifıer to identify
associated tumor cell phenotypes as the classifıer’s “output”. Using this ap-
proach at widely varying temporal and spatial scales (fromminutes toweeks and
from sub-cellular to tissue wide) and at different stages (early carcinoma on to
metastasis), has resulted in a catalog of associations betweenmicroenvironment
conditions and tumor cell phenotypes associated with progression. These asso-
ciations resulted in new insights into the mechanisms of metastasis.
#880 A computational and statistical approach for interpreting real-time
in-vitro gene reporter data. Alexander T. Pearson,1 Dan Sun,2 Zhengda Li,2
Jacques Nor,3 Qiong Yang,2 Laura Buttitta2. 1Univ. of Michigan Health System,
Ann Arbor, MI; 2Univ. of Michigan, Ann Arbor, MI; 3Univ. of Michigan Dental
School, Ann Arbor, MI.
We have developed a new computational approach to track and analyze data
from cells engineered with fluorescent cell cycle gene reporters. Gene reporters
are a rapidly growing tool to gather information captured with time-lapse im-
aging, and can give insights to real-time metabolic conditions, cell cycle state,
cancer stem cell state, and many other applications. Gene reporters may reflect
cellular conditions that are cyclical rather than monotonic. Currently, the pri-
marymechanism for interpretation of time lapse gene reporter data is reporting
the mean fluorescence of images over time. This simplistic analysis discards
information such as the cycle length and variation between of gene reporters
between cells, and can be biased due to the overall fluorescence shift from pop-
ulation growth. More nuanced data acquisition and analysis approaches have
been limited due to requirement of laborious hand-on data analysis. We have
implemented a high-throughput computational pipeline for interpretation of
cell cycle information using a combination of commercial and newly developed
software to partition the activities of individual cells. The fluorescence informa-
tion for each cell is smoothed and the cycle states for each cell are assigned
adaptively. Our approach captures and quantifıes the total time each individual
cell spends in each presumptive state, and then analyses state information from
the cohort of observed cells using censored survival time data methods such as
the Cox Proportional HazardsModel to account for cell death ormovement out
of the observed area. As a proof of concept for our pipeline, we engineered 3T3
fıbroblast cellswith a cell cycle reporter construct includingmCherry-CDT1 and
mVenous-p27K- reporters which can discriminate cells in G0 phase from G1
phase. We calculated the sample size required for statistical power of 80% to
detect a hazard ratio (HR) of 0.8 between groups at  0.05 at 386 tracked cells
per group. As our treatment model, we used the Protein Phosphatase 2A inhib-
itor Okadaic Acid (OA) an agent known to promote departure from G0. We
captured a distinct total of 601 vehicle cells and 479 treatment cells in a 24 hour
monitoring period with 20 minute capture intervals. We were able to discern
subtle differences between control and treatment G0 time, including a subtle,
statistically signifıcant decrease in G0 time after treatment with OA (p0.0166,
HR  0.84). Here we have developed a computational pipeline with the capa-
bility for high-throughput image-stack data processing and nuanced quantifı-
cation. Our approach assigns cycling cell states adaptively and the time until
each cell departs its current state is tallied and interpreted statistically with sur-
vival time statistical analysis. The cell-level analysis affords a high degree of
statistical power to discriminate group differences. Our pipeline is highly adapt-
able and has a multitude of applications in cancer biology research.
#881 CD44-specifıc supramolecular hydrogels for fluorescencemolecular
imaging of EMT induced BRAF <V600E> mutant thyroid cancer cells.
Hyung Kwon Byeon,1 Minhee Ku,1 Yeon Ju Yang,1 Min Hee Cho,1 Yoojung
Oh,1 Jae Wook Kim,2 Myung Jin Ban,2 Ji-Hoon Kim,3 Da Hee Kim,1 Joo Hyun
Kim,1 Jaemoon Yang,1 YoonWoo Koh1. 1Yonsei University College of Medicine,
Seoul, Republic of Korea; 2Soonchunhyang University College of Medicine, Seoul,
Republic of Korea; 3Yonsei UniversityWonju College ofMedicine,Wonju, Repub-
lic of Korea.
Previously, the authors have identifıed that the acquired drug resistance to BRAF
inhibitor, PLX4032 in BRAF (V600E) mutant anaplastic thyroid cancer promotes
not only tumor progression and proliferation, but also migration and invasion of
cancer through upregulated epithelial-to-mesenchymal transition (EMT). The un-
derlyingmechanism to the acquired resistance to BRAF inhibition involves c-Met-
mediated reactivation of PI3K/AKT pathway. Therefore combinatorial dual tar-
geted therapy of BRAF and c-Met inhibition has shown to reverse EMT and show
maximal antitumor effect. Previously, the authors have developed a novel in vivo
imaging strategy using CD44-targetable near-infrared (NIR)-sensitive supramo-
lecular hydrogels (NIRSHs) for the recognition of CD44-expressing cancer cells. In
the present study, we applied thisNIR-sensitivemolecular imaging probe in detect-
ing the upregulated EMT changes in PLX4032-treated 8505C cells. The CD44-tar-
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getable NIRSHs were fabricated by polyplexing Cy5.5-conjugated polyethyleimine
and hyaluronic acid in an aqueousmedium. Ectopic xenograft mousemodels were
prepared by injecting 8505C cells at the flank of male athymic nude BALB/c mice,
aged 6weeks.After confırming tumor formation at 3weeks post-injection, themice
were randomly divided into four groups andwere each treated under different con-
ditions; DMSO, PLX4032, PHA665752, PLX4032 and PHA665752. After 3 weeks,
the pre-established NIRSH probes were injected and confırmed by IVIS imaging.
The injectedNIRSHprobes showedhighest uptake in thePLX4032 single treatment
groupand lowestuptake in thePLX4032andPHA665752combinationgroup. Sizes
of tumor were verifıed byMRIwhich showed correlations with theNIRSH fluores-
cence imagings. The results suggest that CD44-targetable NIRSHs imaging shows
potential as a non-invasive in vivo imaging tool in detecting the increased invasion
potential of cancer cells andmonitoring appropriate therapeutic effects.
#882 Interpreting gliomaMR imaging and somatic mutations in a cancer
hallmark context. JohnGraf,1Mirabela Rusu,1 Yunxia Sui,1Dattesh Shanbhag,2
Uday Patil,2 Jeffrey Kiefer,3 Jill Barnholtz-Sloan,4 Michael Berens,3 Fiona
Ginty,1 Sandeep Gupta,1 Chinnappa Kodira,1 Lee Newberg,1 Anup Sood1. 1GE
Global Research, Niskayuna, NY; 2GEGlobal Research, Bangalore, India; 3Trans-
lational Genomics Research Institute, Pheonix, AZ; 4Case Comprehensive Cancer
Center, Cleveland, OH.
Extracting biologically relevant data from radiology images can enable better
monitoring of disease progression and therapy response. The fıeld of radiog-
enomics is providing new approaches for such genomic/radiology correlations.
However, there are several challenges in validation and clinical translation in
that few DNAmutations are shared between tumors from different individuals
and the differences in scale between imaging and genomic features can limit
interpretation of underlying mechanisms. The goals of this work were to i)
analyze correlations between low grade glioma (LGG) DNA somatic mutations,
using a novelDNA impact scoring approach, andMRI derived imaging features;
and ii) to interpret results in context of cancer hallmarks1. Multi-parametric
MRI and corresponding DNA data from 32 LGG patients were extracted from
The Cancer Genome Atlas (TCGA) and The Cancer Imaging Archive (TCIA).
The cohort included 18 males (56%), with mean age of 44 years (range: 21-74
years). An expert radiologist outlined the normal and tumor regions of interest
using ITK-Snap tool. The normal region was used as a reference to normalize
image intensities in the tumor region. Tumormean intensity andmean variance
were computed from Apparent Diffusion Coeffıcient (ADC), T1 enhancement
ratio (derived from T1 pre- and post- contract MRI), and Fluid-Attenuated
Inversion Recovery (FLAIR) images. A novel algorithm was used to compute
DNA impact scores for each somatic mutation. The score represents the prob-
ability of a DNA variant being pathogenic vs. nonpathogenic. First, the scoring
algorithm computes a score for nucleotide base insertions, deletions, or single
base changes and then computes the consequence of such changes on amino
acid coding, binding sites, splice sites and protein phosphorylation sites. An
impact score was then computed based on the individual DNA impact scores of
mutations within the gene. Finally, an averageDNA impact score was computed
at the Cancer Hallmark level using a gene-cancer hallmark map. At gene level,
signifıcant positive correlations were found between the ATRX (p0.0002),
TP53 (p0.02) and ADC mean intensity. At pathway level, regulation of TP53
expression and degradation, andDNA damage response, signal transduction by
p53 classmediator, andDNA translocase activitywere found to be enrichedwith
genes that correlated with ADC and FLAIR. These pathways also contained
genes that were enriched in the following cancer hallmarks: replicative immor-
tality, evading growth suppression and genome instability. The ATRX gene is a
member of all three hallmarks and TP53 a member of two. Since ADC is a
measure of water diffusion and hence an indirect measure of cellularity, these
fındings demonstrate thatmutations in replication and repair pathways are con-
tributing to imaging features at the tumor level.1 Hanahan, D. and Weinberg,
R.A. (2011). Hallmarks of cancer: the next generation. Cell 144(5):646-74.
#883 Elucidating cancer hallmark context from glioma MR imaging and
RNA expression data . Yunxia Sui,1 Mirabela Rusu,1 Dattesh Shanbhag,2 Uday
Patil,2 Jeffrey Kiefer,3 Jill Barnholtz-Sloan,4Michael Berens,3 Fiona Ginty,1 Graf
John,1 Sandeep Gupta,1 Chinnappa Kodira,1 Lee Newberg,1 Anup Sood1. 1GE
Global Research, Niskayuna, NY; 2GEGlobal Research, Bangalore, India; 3Trans-
lational Genomics Research Institute, Pheonix, AZ; 4Case Comprehensive Cancer
Center, Cleveland, OH.
Radiogenomics or radiomics is an emerging fıeld where tumor genomic data is
correlated with radiology image features, thereby potentially providing more bio-
logical information about the tumor phenotype. A central challenge is the potential
for model over-fıtting due to analysis of many thousands of genomic data-points
with hundreds of corresponding patient image features. Biological interpretation of
the imaging feature correlations is also challenged by overlapping pathways and
common gene effects. Our goals were: i) to explore correlations between gene ex-
pression and corresponding Magnetic Resonance (MR) Apparent Diffusion Coef-
fıcient (ADC) derived imaging features in low grade glioma (LGG); ii) to classify
signifıcant gene and imaging correlates by cancer hallmark1. RNA expression data
from32 LGGpatients were extracted fromTheCancerGenomeAtlas (TCGA) and
matched with corresponding MR image data from The Cancer Imaging Archive
(TCIA). Among 32 patients, 18 were males (56%), and ages ranged from 21 to 74
years (mean age 44). Tumor and normal regions in theMR images were annotated
by an expert radiologist using ITK-Snap. The normal reference region was used
normalize image intensities in corresponding tumor regions. Tumor texture fea-
tureswere computed onADCMaps at each voxel locationwithin the disease region
(including fırst and second order statistics, Run Length and co-occurrence matrix
derived measures features. The voxel features were fınally aggregated within the
tumor region using statistical measures of mean, variance, median, kurtosis, and
skewness. ADC imaging features (n310) were correlated with each single gene
expression value (11614 genes after MAD0.4 fıltering). Only image features and
genes with pairwise correlations higher than 0.68 (0.68 is the 3-standard deviation
above average correlation) and FDR (False Discovery Rate) 0.1 were used for
follow-up analyses. Signifıcant genes andMR image featureswere aggregated into 3
groups based on gene expression and correlated with cancer hallmarks. Seven
Haralick image features (reflecting the average level of image intensity heterogene-
ity) were independently, signifıcantly correlated with the Angiogenesis Hallmark
(FDR all 0.001). Three Haralick image features (reflecting asymmetric distribu-
tion of intensity)were signifıcantly correlatedwith theActivating Invasion andMe-
tastasisHallmark (FDR all 0.001). Validation of these fındings in additional LGG
cases with additional imaging protocols and features is ongoing. Radiogenomics
informed by genomic profılingmay usher in processes to infer cancer hallmarks to
aid treatment planning and prognosis of glioma patients.1 Hanahan D and Wein-
berg RA (2011). Hallmarks of cancer: the next generation. Cell 144(5):646-74.
#884 Detection of intratumoral heterogeneity using MR-defıned tumor
habitats in breast cancermodel undermelatonin treatment.BrunaV. Jardim-
Perassi,1 William Dominguez-Viqueira,2 Asmaa El-Kenawi,2 Dominique F.
Abrahams,2 Mikalai Budzevich,2 Epifanio Ruiz,2 Suning Huang,2 Pedro M. En-
riquez-Navas,2 Gary Martinez,2 Debora Aparecida Pires de Campos Zuccari,1
Robert J. Gillies2. 1Faculdade de Medicina de São José do Rio Preto, São José do
Rio Preto, Brazil; 2Moffıtt Cancer Center, Tampa, FL.
Breast cancer shows high intratumoral heterogeneity, which can be visualized
as localized sub-populations of tumor cells with different malignancy potential
and treatment responsiveness. These regions are like “habitats” that contain
different combinations of environmental selection forces, such as hypoxia, aci-
dosis, or nutrient availability. Thus, agents that can perturb these forces may be
useful in limiting cancer progression. Studies have shown that melatonin can
affect tumor metabolism and we hypothesize that this may be a mechanism by
which the disruption of circadian melatonin production by light exposure at
night (LAN) promotes breast cancer initiation and progression. The aim of this
study was to evaluate the effect of melatonin on intratumoral heterogeneity
measured by non-invasive MR imaging in a syngeneic mouse model of breast
cancer (4T1). To visualize habitats, clusters were generated from combinedMR
images generated by different pulse sequences. These were co-registered with
histology using tumor specifıc 3-D printed cradles to classify these tumor habi-
tats.Methods:Micewere exposed to LAN (Control) or LANplusmelatonin. The
melatonin metabolite 6-sulfatoxymelatonin (6-SMT) was assessed in urine as a
measure of melatonin production. Mice were imaged in a 7T MRI system with:
1) anatomical T2 images, 2) T2*, 3) diffusion-weighted MRI (DWI); and 4) T1
weighted dynamic contrast enhanced (DCE). DCEmaps were obtained through
semi-quantitative analysis of the pre- and post-contrast agent bolus time-series
on a pixel-by-pixel basis. These were combined to the corresponding T2, T2* and
Apparent Diffusion Coeffıcient (ADC) values to generate parameter maps. Pa-
rameter maps were used to classify multiple clusters, based on a Gaussian mix-
ture model. Following euthanasia, a 3D printed mold based on the T2 tumor
isosurface was created in order to co-register the MRI and histology. Tumors
were stained with H&E and for pimonidazole (hypoxia) by immunohistochem-
istry. Results: Melatonin treatment increased the 6-SMT in urine of mice ex-
posed to LAN and statistically reduced tumor growth by day 15 (p0.05). Dis-
tinct hypoxic habitats have been observed by MRI. Habitat clusters with low
values in ADC (high cellularity) and low contrast enhancement were associated
with positive staining of pimonidazole. Initial results suggest that themelatonin-
treatedmice hadmore homogeneous tumors, although additional numbers will
be needed to reach statistical signifıcance. Conclusion: These data indicate that
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the spatial heterogeneity of breast tumors, corroborated by histological features,
may be used as a non-invasive imaging method for monitoring the changes in
intratumoral heterogeneity following cancer therapy.
#885 Live-imaging reveals the correction of skin deformities within two
tumor-associated mutational models. Cristiana Pineda, Samara Brown, Val-
entina Greco. Yale University, New Haven, CT.
Healthy tissues are frequently subject to oncogenic mutations that fail to
produce malignancy. Such mutations can lead to aberrant cellular behaviors
such as abnormal differentiation or hyperproliferation and the subsequent for-
mation of aberrant tissue growths and cancer. However, it remains unclear how
phenotypically normal tissue is capable of harboring mutations and raises the
question as to how the switch from normal to malignant is initiated. One chal-
lenge to understanding the initiating events towards malignancy is the inability
to follow the same cells over time in an intact mammal. Specifıcally, this road-
block hinders the ability to understand both the role of specifıc cells and how
their location contributes to their growth, whether that growth be normal or
cancerous. To overcome this, we have established a novel live imaging approach
to perform in vivo lineage tracing of the samemutant cells over time within two
distinct mutational systems in the skin epithelium. To begin, we turned to the
pro-differentiation pathway Wnt/-catenin, which when mutated is known to
drive benign growths in the skin, and activated this mutant form in skin stem
cells.We show that the resulting growths that deform the skin tissue architecture
spontaneously regress, irrespective of their size. Endogenous behaviors such as
differentiation and apoptosis as well as ectopic cell extrusions are employed to
eliminate mutant cells from the tissue and dismantle the aberrant structures.
Following regression, the remaining structures are either completely eliminated
or converted into functional skin appendages in a niche-dependent manner.
While these results demonstrate the remarkable capacity to reverse aberrant
phenotypes, the question remained whether this phenomenon was Wnt/-
catenin specifıc. To address this, we next turned to mutant Hras, which is well
established to cause a hyperproliferative, pro-growth advantage and frequently
found mutated in malignant skin tumors such as cutaneous Squamous Cell
Carcinoma. Activation of mutant Hras in the skin epithelium produced a range
of phenotypes from hyperthickening to follicular structural deformities to mac-
roscopic skin growths, all of which demonstrated the capacity to correct. Cur-
rently, we are utilizing a combination of extensive biochemical characterization
together with targeted cellular ablations to investigate the mechanisms at play
both within themutant pool and the surrounding normal tissue that leads to the
reversibility and integration observed within the Hras model. Altogether, this
study reveals an unanticipated plasticity of adult skin epithelium when faced
with mutational insult and elucidates the dynamic cellular behaviors employed
for its return to a homeostatic state.
#886 An integrative platform for three-dimensional quantitative anal-
ysis of spatially heterogeneous metastasis landscapes. Ian H. Guldner, Lin
Yang, Fang Liu, Danny Z. Chen, Siyuan Zhang. University of Notre Dame,
Notre Dame, IN.
Metastatic microenvironments are spatially and compositionally heteroge-
neous. This seemingly stochastic heterogeneity provides researchers great chal-
lenges in elucidating factors that determine metastatic outgrowth. Herein, we
develop and implement an integrative platform that will enable researchers to
obtain novel insights from intricate metastatic landscapes. Our two-segment
platform begins with whole tissue clearing, staining, and imaging to globally
delineate metastatic landscape heterogeneity with spatial and molecular resolu-
tion. The second segment of our platform applies our custom-developed
SMART 3D (Spatial fıltering-based background removal and Multi-chAnnel
forest classifıers-based 3D ReconsTruction), a multi-faceted image analysis
pipeline, permitting quantitative interrogation of functional implications of het-
erogeneousmetastatic landscape constituents, from subcellular features tomul-
ticellular structures, within our large three-dimensional (3D) image datasets.
Coupling whole tissue imaging of brain metastasis animal models with SMART
3D,we demonstrate the capability of our integrative pipeline to reveal and quan-
tify volumetric and spatial aspects of brain metastasis landscapes, including
diverse tumor morphology, heterogeneous proliferative indices, metastasis-as-
sociated astrogliosis, and vasculature spatial distribution. Collectively, our study
demonstrates the utility of our novel integrative platform to reveal and quantify
the global spatial and volumetric characteristics of the 3D metastatic landscape
with unparalleled accuracy, opening new opportunities for unbiased investiga-
tion of novel biological phenomena in situ.
#887 Magnetic relaxometry detection of stealth, antibody-targetedmicel-
lar iron oxide nanoparticles in-vivo. Rebeca Romero Aburto,1 Konstantin
Sokolov,1 AdamM. Kulp,1 Erika C. Vreeland,2 Zhen Lu,1 Robert C. Bast,1 John
D. Hazle,1 Kelsey B. Mathieu1. 1MD Anderson Cancer Center, Houston, TX;
2Senior Scientifıc LLC, Albuquerque, NM.
Magnetic relaxometry (MRX) has the potential to provide unprecedented
sensitivity in early detection of cancer by sensing changes inmagnetic relaxation
of iron oxide (Fe3O4) nanoparticles targeted to cancer biomarkers and is ex-
pected to exceed the detection limits of established clinicalmodalities.MRXuses
superconducting quantum interference device (SQUID) sensors to measure
Neél relaxation of bound particles. Our strategy was to develop molecular spe-
cifıc Fe3O4 nanoparticles using amphiphilic functionalized phospholipids that
allow for clinical translation of the MRX technology. To accomplish this, we
used automated, controlled rate, direct infusion of an organic phase mixture of
phospholipids and nanoparticles into water to produce monodisperse micellar
nanoparticles with amean diameter of 7512 nm and surface charge of -10mV.
The particles were determined to be stable in various biologicalmedia, including
humanplasma, formore than 24 hourswith no detectable formation of a protein
corona. Furthermore, in-vivo studies in healthy mice showed blood circulation
times of more than 2 hours, as well as minimal MRX signals during this time.
Additionally, we developed maleimide conjugation chemistry for epidermal
growth factor receptor (EGFR) antibody attachment to micellar nanoparticles.
We have achieved molecular specifıc labeling of cancer cells over-expressing
EGFR. In the future, we will evaluate the MRX signal impact from injecting
EGFR-conjugated nanoparticles into tumor-bearing mice.
#888 Volumetric reconstruction of targeted nanoparticles for superpara-
magnetic relaxometry. Sara L. Thrower,1 Kelsey Mathieu,2 Wolfgang Stefan,2
Zhen Lu,2 Robert C. Bast,2 Javad Sovizi,2 David Fuentes,2 John D. Hazle2. 1The
University of Texas Graduate School of Biomedical Sciences at Houston; The
University of Texas MD Anderson Cancer Center, Houston, TX; 2The University
of Texas MD Anderson Cancer Center, Houston, TX.
Superparamagnetic relaxometry (SPMR) is an emerging technology that uses
the unique magnetic properties of superparamagnetic iron oxide nanoparticles
(SPIONs) to detect cancer cells. In order to estimate tumor locations from raw
MRX data, we developed an L1 reconstruction algorithm under the assumption
that early stage disease is sparsely distributed throughout the anatomy. The
approach was previously validated in phantom datasets of known signal loca-
tions. Advantages of our method are that the solver does not require the user to
input prior information regarding the expected number of tumors or their ap-
proximate locations. Additionally, the solver reconstructs a volumetric distribu-
tion of detected sourceswithin the fıeld of view. To validate the algorithm for use
in preclinical settings, SPMR was performed on SKOV3 ovarian tumor bearing
mice (n 3) with theMRXdevice over time following an intratumoral injection
of anti-Her2 antibody-conjugated 25nm SPIONs (Senior Scientifıc LLC). The
SPMR data was reconstructed with our sparse solver and was found to be highly
correlated (r  0.9978) with the results generated by the commercial software
that accompanies the MRX instrument (MSA). Additionally, segmentation of
the reconstruction revealed a strong signal (2.0·106 pJ/T) in the area of the tumor
and almost no signal in areas outside of the tumor (0.077 pJ/T) at four hours after
injection. This result was consistent with our prior observations which have
revealed that a large fraction of intratumorally-injected nanoparticles remain
localized within the tumor for several hours after injection. Furthermore, these
results were consistent with SPMR data collected by measuring tissue samples
excised 24 hours after injection, of which the tumor had the highest signal. Thus,
our sparse reconstruction algorithm was able to return the expected results
without prior information regarding the location of nanoparticles. Future work
will focus on quantifying the uncertainty in our reconstruction method, as well
as characterizing its stability with increasingly complex nanoparticle distribu-
tions and detectability limits. In conclusion, this work represents an important
advancement of the SPMR technology by allowing for volumetric reconstruc-
tions of bound nanoparticles from in vivo data.
#889 A comparison between quantitative ultrasound and histology in het-
erogeneous tumor structure. Jerome Griffon,1 Delphine Le Guillou-Buffello,1
Oumeima Laifa,1 Alexandre Dizeux,1 Micheal Oelze,2 Lori Bridal,1 Michele
Lamuraglia1. 1Laboratoire d’Imagerie Biomedicale (UPMC, CNRS, INSERM),
Paris, France; 2Bioacoustics Research Laboratory, University of Illinois at Urbana-
Champaign, Urbana-Champaign, IL.
Background: To investigate howQUS (QuantitativeUltrasound)maps reflect
regional variations in heterogeneous tumor microstructure, we compared like-
regions of QUS effective scatterer diameter (ESD, m) and effective acoustic
concentration (EAC, dB/cm) maps to whole-slice, virtual histology sections
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stained for vascular, cellular and other microstructural features. Methods: An
ectopic model of murine colorectal carcinoma (CT26) was implanted in 7 mice
(BALB/c). US radiofrequency data were acquired for the longitudinal plane of
tumors in vivo (SSI, Aixplorer, SL15-4 probe, research mode) on days 6 and 14
after start of therapy with an anti-angiogenic (AA: n 3) or placebo (P: n 4).
The AA used is Pazopanib, an oral tyrosine kinase inhibitor of VEGF receptors
1/-2/-3, platelet-derived growth factor receptors (PDGFR) -alfa/-beta, and c-
KIT. A daily dose of 2 mg of AA, diluted in 100l of solution, was administered
per os. Average backscattered power spectra were calculated (FFT, 512 pts, Rect-
angular gated RF), normalized with respect to a reference phantom and cor-
rected for attenuation (0.4 dB/cm/MHz). ESD and EACweremapped (2 x 2mm
blocks, with 75% axial and lateral overlap). Tumors were excised andmarked to
conserve orientation and approximate position relative to US imaging plane.
Whole-slice, histological sections were prepared with fluorescent immunohis-
tochemical markers at D6 and D14 for invasive assessment of cell nuclei, apo-
ptosis and vascular endothelium. The Number of Nuclei (NU), the % area of
Apoptosis (AP) and% area of Vascular (VA)marker were calculated with image
analysis processing for each 333m by 333m region of histological sections.
QUS and histological maps of each tumor were manually segmented and coreg-
istered using an affıne registration method so that matched regions could be
compared. Results: The absolute value of the non-parametric Spearman corre-
lation coeffıcient (RS) was computed separately for each mouse to study the
correlation between histological parameters and QUS parameters. Two mice of
the AA group showed amoderate correlation (0.4RS0.6) betweenNU and
EAC. Only onemouse in the P group showed strong correlation (0.6RS) for
[AP vs. ESD], [AP vs. EAC], [VA vs. ESD] and [VA vs. EAC]. The other tumors
(1 from AA group and 3 from P group) showed poor correlation (RS0,4).
Additional data is available from 14 other mice (7 from AA group and 7 from P
group) and will be analyzed to more fully investigate correlation between the
QUS parameters and the histological parameters. Conclusions: This original
technique to compare QUS parameter maps and whole slice histology analysis
shows a promising evolution for this non-invasive imaging technique. Complete
results on 21 mice will be presented in April.
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#890 The role of calpastatin isoforms in breast cancer progression. Bhud-
saban Sukkarn, Sarah Storr, Ian O. Ellis, Kirsty Jewell, Tim Parr, Stewart G.
Martin. The University of Nottingham, Nottingham, United Kingdom.
Calpastatin is the endogenous inhibitor of the ubiquitously expressed m-
calpain and-calpain. Both of them are important regulators of various cellular
pathways including proliferation, apoptosis, adhesion, andmigration. Dysregu-
lation of the calpain system is associated with a wide range of pathologies in-
cluding tumour invasion and metastasis. In breast cancer, down-regulation of
calpastatin mRNA, in particular an exon 3 containing variant, is associated with
lymphatic vessel invasion which is the predominant form of lymphovascular
invasion (LVI) (96%), a critical initial step of metastases. The current project
seeks to determine the role that individual calpastatin isoforms play in regulat-
ing breast cancer cell migration and endothelial interactions to understand pro-
cesses involved in regulating LVI. Seven breast cancer cell lines were assessed for
calpain system protein expression (calpain-1, -2, -4 and calpastatin) and cal-
pastatin (CAST) mRNA expression (total CAST, CASTexon3, CAST I, II and
III) by Western blotting and qRT-PCR, respectively. T47D and MDA-MB-231
cell lines showed low calpastatin but high calpain expression. From haptotaxis
cell migration data, T47D migrated more slowly than MDA-MB-231
(35.496.14 and 80.345.52 percent wound closure at 24 hours post-scratch
respectively) (P value0.0233). These cell lines, that represent different sub-
types of breast cancer (luminal and basal respectively), were therefore selected to
study the role of differential calpastatin type/isoform expression. GFP-tagged
XL and Leader domains of calpastatin type I, II and III, with or without exon 3
were overexpressed in each cell line. The different calpastatin types show differ-
ential subcellular localization. In MDA-MB-231, type I, III, I	3, III	3 were
expressed generally in cytoplasmwhereas type II and II	3were located as punc-
tate nuclear invaginations. To assess if overexpression of the different calpasta-
tin types cause phenotypic changes, full length HA-tagged calpastatin type I, II
and III were transfected into MDA-MB-231 and T47D and stable clones pro-
duced. Thus far stable type II overexpression in MDA-MB-231 and type III in
T47D have been obtained with others under single cell selection. The localiza-
tion of full length type II in MDA-MB-231 was similar to the localization of the
truncated form that showing a strong single perinuclear signal. In T47D, the full
length and truncated type III also show similarly localization that expressed
throughout the cytoplasm. For the effect of calpastatin types on cell prolifera-
tion, calpastatin type II in MDA-MB-231, and type III in T47D, had no signifı-
cant effect on cell doubling time when compared to respective controls (P
value0.6400 and 0.8874, respectively). According to preliminary studies, cal-
pastatin type II seems to have no effect on clonogenicity ofMDA-MB-231. Such
effect on T47D and other phenotypic changes involved in regulating LVI of
transfected cell are being examined.
#891 Annexin A2 (ANXA2) promotes migration and invasion of esopha-
geal cancer cells via stabilizing c-Myc and promoting HIF-1 transcription.
SaiMa, Yan-Yi Jiang, Li-FeiWu, Jia-Jie Hao, Yu Zhang, Xin Xu, Yan Cai, Ming-
Rong Wang. State Key Laboratory of Molecular Oncology Cancer Institute, Na-
tional Cancer Center/Cancer Hospital, Chinese Academy ofMedical Sciences and
Peking Union Medical College, Beijing, China.
Purpose:Wepreviously revealed that the expression ofAnnexinA2 (ANXA2)
was increased in ESCC by two-dimensional electrophoresis and MALDI-TOF
and LC-ESI-IT MS. This study aims to investigated the implication of Annexin
A2 in ESCC. Annexin A2 (ANXA2) promotes migration and invasion of esoph-
ageal cancer cells via stabilizing c-Myc and promoting HIF-1 transcription.
Experimental Design: Immunohistochemistry was performed to analyze the ex-
pression of ANXA2 in esophageal squamous cell carcinomas (ESCC). siRNA
knockdown, transwell assay and wound-healing assays were used to investigate
the function of ANXA2 in cells. Quantitative reverse-transcription polymerase
chain reaction, Western blot analysis were used to seek the potential effector
molecule of ANXA2. Chromatin immunoprecipitation, and reporter gene as-
says were used to confırm the relationship between c-Myc and HIF-1 alpha.
Co-immunoprecipitation assay was performed to demonstrate the relationship
between ANXA2 and c-Myc. Immunofluorescence was used to reveal the loca-
tion of ANXA2. Results: Knockdown of Annexin A2 signifıcantly inhibited the
migration and invasion of ESCC cells. At the molecular level, VEGF, MMP-2,
MMP-9, p-MEK and p-ERK were down-regulated in ANXA2-siRNA cells. The
HIF-1 alpha mRNA and protein levels were signifıcantly lowered after knocked
down the Annexin A2. HIF-1 alpha is the effector molecule of ANXA2 in ESCC
cells, and that ANXA2 affects the expression of HIF-1 alpha at the transcription
level because when knocking down HIF-1 alpha, the level of VEGF, MMP-2,
MMP-9, p-MEK and p-ERK reduced as well. c-Myc is a transcription factor for
HIF-1 alpha. ANXA2 has a direct protein interaction with c-Myc and knock-
down of ANXA2 down-regulated the expression of c-Myc. The Tyr 24 phos-
phorylation form of Annexin A2 (Y24D-ANXA2) was located in the nucleus,
and the non-phosphorylation form (Y24A-ANXA2), in the cytoplasm and cell
membrane. Transfection of pcDNA3.1-ANXA2-Y24D enhanced the migration
and invasion as compared with that of pcDNA3.1-ANXA2-Y24A in esophageal
cancer cells. A treatment with the Annexin A2 phosphorylation inhibitor, Da-
satinib, changed the location of Annexin A2 and lowered the expression of
c-myc and HIF-1 alpha. Conclusions: These results suggest that in esophageal
cancer cells, phosphorylated Annexin A2 could enter into nucleus, which stabi-
lizes c-myc and promotes the transcription of HIF-1 alpha, and the activates
MAPK pathway, increases matrix metalloproteinase (MMP) activity and vascu-
lar endothelial growth factor (VEGF) expression, which results in the enhance-
ment of cell invasion and migration.
#892 ROCK dependent signalling pathways contribution to collective in-
vasion of colorectal carcinoma. Fotine Libanje, Joel Raingeaud, Zoé ap
Thomas, Fatiha Sangar-Mavouna,AnneChauchereauChauchereau, Fanny Jau-
lin. Gustave Roussy, Villejuif, France.
Metastatic progression of cancer, which is responsible for 90% of patients
death, results from tumor cells dissemination out of the primary tumor through-
out the body. During the fırst step of this process -that consists in invasion of the
peritumoral stroma- cancer cells can adopt 1) a single cell mode of invasion, in
which cell have lost cell-cell junctions to move individually, 2) or a collective
mode of invasion where cells maintain their cell-cell junctions to move as a
cohort in which Leader cells at the front drag the follower cells at the rear.
Although tumour histology data from cancer patients show that invasion occurs
predominantly in a collective manner, this mode of cell invasion remains un-
derinvestigated. My work aims at identifying the molecular and cellular mech-
anisms underlying colorectal carcinoma (CRC) collective invasion. I use 3D
organotypicmodels of CRC: Caco-2 cell lines or organoids generated fromCRC
patients derived xenografts (PDX) and assess invasion in collagen-I based gels
using microscopy approaches on fıxed or live samples. Knowing its central role
in the cytoskeleton dynamics which is themotor of cell motility, we hypothesize
that RhoGTPases signaling pathways could control the collective mode of inva-
sion.We therefore performed a siRNA based screen targeting the 98 effectors of
TUMOR BIOLOGY: Imaging Cancer Immunotherapy, Tumor Microenvironment, and Other Aspects of Tumor Biology
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 227
the pathway and found ROCK to be an anti-invasive protein. Although it had
been described as a proinvasive protein in the single cell mode of invasion, we
confırmed using pharmacological inhibitors (Y27632 and H1152), that ROCK
activity inhibition triggered collective invasion. Using a ROCK2 dominant neg-
ative mutant specifıcally targeting ROCK2 isoform but not ROCK1, I demon-
strated that ROCK2 inhibition was suffıcient to induce leader cell formation
leading to collective invasion. In contrast, depletion of MyosinII -ROCK’s most
common effector- was not suffıcient to induce effıcient protusive leader cells.
However I found RAC1 to be necessary and in a 2nd siRNA based screen target-
ingGEFs, we identifıed FARP2, aGEF for Rac1, as themediator of ROCK-RAC1
crosstalk in collective invasion. Even though the activation of FARP2 alone or
RAC1 alone were not suffıcient to induce leader cell formation, the concomitant
inhibition of MyosinII recapitulated the collective invasion induced by ROCK
inhibition. Altogether these results show a new anti-invasive role of ROCK2
kinase in collective invasion as it controls the formation of leader cells, through
1) the negative regulation of RAC1 and its GEF FARP2, and 2) the positive
regulation of MyosinII.
#893 Systematic assessment of spliceosome components as drivers of
breast cancer progression. Esmee Koedoot, Sylvia Le Dévédec, Bob van de
Water. Leiden University, Leiden, Netherlands.
Accumulating evidence indicates that RNA splicing is involved in different
steps of carcinogenesis. Although the critical role of a limited number of splicing
factors has been demonstrated in several cancer studies, the function of many
spliceosome components is still unknown. In breast cancer samples higher ex-
pression levels of a subset of spliceosome components consistently correlated
withmore aggressive tumor types in patientmicroarray aswell as RNA sequenc-
ing data from The Cancer Genome Atlas (TCGA). We further systematically
evaluated the effect of siRNA-mediated knockdown of 244 individual splicing
factors on both cell migration and proliferation in two aggressive breast cancer
cell lines MDA-MB-231 and Hs578T using high throughput microscopy. Pri-
mary candidates were validated with four single siRNAs and classifıed based on
their effects on migration and proliferation. Knockdown of validated spliceo-
some factors such as SNRPG and SNRPA1 affected the levels of small nuclear
RNAs, the main catalyzers of the spliceosome. Moreover, high expression of
these key candidate hits is associated with poor breast cancer metastasis free
survival. To investigate the downstreammechanisms and splicing patterns con-
trolled by our candidate genes we performed RNA sequencing on both control
and siRNA mediated knockdown cells. Interestingly, knockdown of our hits
affect extracellular matrix pathways that are essential in tumor cell migration
and invasion. Altogether our data indicate a key role for spliceosome factors in
the control of breast cancer progression which provide new leads for future
therapeutic intervention.
#894 Heparanase-induced shedding of syndecan-1 promotes cancer cell
invasion : prevention by inhibitory synstatin peptide. Oisun Jung, Alan Ra-
praeger. University of Wisconsin-Madison, Madison, WI.
Syndecan-1 (Sdc1, CD138) is highly expressed in multiple myeloma (MM).
Heparanase (HPSE), an enzyme that cleaves heparan sulfate (HS) chains on
Sdc1, induces shedding of the Sdc1 ectodomain; this is associated with poor
prognosis in this disease. However, the link between Sdc1 shedding and poor
prognosis remains unclear.Wenow show thatHPSE-induced shed Sdc1 (sSdc1)
engages 41 integrin (VLA-4) and vascular endothelial cell growth factor re-
ceptor-2 (VEGFR2) to form a ternary receptor complex on the cell surface. This
coupling of VEGFR2 to clusters of VLA-4 via sSdc1 leads to autoactivation of
VEGFR2 and the subsequent activation of protein kinase A (PKA) bound to the
VEGFR2 cytoplasmic domain. PKA activation proceeds via VEGFR2-mediated
stimulation of the G-protein coupled cytokine receptor CXCR4 and the subse-
quent generation of cAMP by its activation of adenylate cyclase 7. This mecha-
nism is prevented by SSTNVEGFR2, a peptide that competes for the VEGFR2
docking site in the Sdc1 ectodomain, thereby disrupting VEGFR2 binding to
sSdc1. VLA-4 has been shown to mediate the polarized invasion of a variety of
cells due to 4 integrin phosphorylation on Ser988 by PKA, followed by Rac
GTPase activation, a process that is restricted to the leading edge of the cell. But
how this is confıned at the leading edge is wholly unknown.We fınd that HPSE-
mediated shedding of Sdc1 promotes an invasive phenotype by re-localizing
VLA-4 and VEGFR2 to the leading edge of migrating myeloma cells as well as
humanT-acute lymphoblastic leukemia,melanoma, and endothelial cells where
VEGFR2-dependent PKA activation causes 4 integrin phosphorylation. These
results reveal a novel mechanism in which the expression of HPSE, acting by
causing Sdc1 shedding, potentially regulates angiogenesis and the extravasation
and invasion of cancer cells and identifıes SSTNVEGFR2 as a promising cancer
therapeutic.
#895 Fucosylation inhibits invadopodia formation and melanoma inva-
sion. Tyler S. Keeley,1 Eric Lau,2 Shengyu Yang1. 1Penn State University, Her-
shey, PA; 2Moffıtt Cancer Center, Tampa, FL.
Background: Melanoma is the most deadly skin cancer and metastasis is es-
sentially responsible for all melanoma related death. Recently, fucose treatment
has been shown to inhibit melanoma cell migration and invasion in vitro, and
melanoma metastasis in a mouse model, suggesting that protein fucosylation
could be exploited to prevent or suppress melanoma metastasis. Invadopodia
are proteolytic actin-rich protrusions used by metastatic melanoma cells to de-
grade extracellularmatrix and to promote invasion andmetastasis. In this study,
we investigated the mechanisms by which fucosylation regulate melanoma in-
vasion and invadopodia formation Method: The melanoma cells were treated
with L-fucose-supplemented medium or infected with fucokinase-expressing
lentivirus to increase protein fucosylation. shRNAs were also employed to
knockdown fucokinase and to inhibit fucosylation in melanoma cells. The ef-
fects of fucosylation on invadopodia formation and extracellular matrix degra-
dation were determined by phalloidin staining and degradation of fluorescently
labeled gelatin thin fılm. Results: Here, we show that the addition of L-fucose to
complete media inhibits the ability of melanoma cells to form invadopodia in a
dose-dependent manner. The overexpression of hFUK inWM793 cells showed
a similar result as L-fucose treatment, where invadopodia formation was signif-
icantly reduced. In addition,we observed a signifıcant decrease in the percentage
of cells that have invadopodia during L-fucose supplementation or hFUK over-
expression. In an invadopodia precursor assay, the hFUK-overexpressing cell
line exhibited delayed FBS-stimulated invadopodia formation. Conclusions:
Our data suggest that fucose or the overexpression of hFUK reduces melanoma
invasion by inhibiting invadopodia formation. Given that invadopodia forma-
tion was hindered within an hour after stimulation, we believe that invadopodia
initiation is affected by increased fucosylation, resulting in fewer invadopodia
and slower extracellular matrix degradation.
#896 Long term exposure to Oroxylin A inhibits cell migration via sup-
pressing CCL2 in oral squamous cell carcinoma cells. Jiun-Jia Tung,1 Tony
Jer-Fu Lee,2 Wei-Ting Ku,1 Kuo-Chu Lai1. 1Tzu Chi University, Hualien, Tai-
wan; 2Buddhist Tzu Chi General Hospital, Hualien, Taiwan.
Oral squamous cell carcinoma (OSCC) is the sixth most common cancer in
the world. Like other cancers, the major causes of OSCC-related death are cer-
vical node and distant metastasis. Therefore, it is a critical need to identify new
potential therapeutic agents against OSCC migration, invasion, and metastasis.
Oroxylin A, a main bioactive flavonoids extracted from Scutellaria radix, has
been reported to inhibit migration in breast and non-small-cell lung cancer. In
this study, we explored the anti-migration effects of oroxylin A on OSCC cells
and investigated its underlying mechanisms. A 24-hour exposure (short-term)
of OSCC cells to oroxylin A at noncytotoxic concentrations (5-20 M) signifı-
cantly suppressed cell migration using the wound healing assay. Furthermore, a
30-days exposure (long-term) to oroxylin A (20 M), which still had no cyto-
toxic effect onOSCC cells, but signifıcantly suppressedmore cell migration than
that of short-term oroxylin A exposed OSCC cells. To uncover the molecular
mechanisms involved in the inhibitory effect of oroxylin A onOSCCmigration,
cDNAmicroarray technique and Ingenuity software were used. There were 468
differentially expressed genes, including 112 upregulated and 356 downregu-
lated genes identifıed in long-term oroxylin A exposed cells compared to un-
treated OSCC cells. Among them, 77 genes have been reported to be associated
with cancer cell migration. Consistent with results from cDNA microarray, we
revealed that the expressions of several cell migration-related genes, such as
CCL2, S100A9, LCN2, and THBS1 were signifıcantly decreased in long-term
oroxylin A exposed OSCC cells using QPCR assay.Western blotting and ELISA
results also demonstrated that CCL2 expressions at mRNA and protein levels
were signifıcantly decreased in long-term oroxylin A exposed OSCC cells com-
pared to untreatedOSCC cells. In themeantime, the expressions of downstream
targets of CCL2, including p-ERK, NFB, MMP2, and MMP9 were also de-
creased in long-term oroxylin A exposed OSCC cells. These results suggest that
long-termoroxylinA treatment inhibitsmigrationmay via suppressingCCL2 in
OSCC cells.
#897 PEA-15 regulates epithelial-mesenchymal transition and invasive
behavior through its phosphorylation in triple-negative breast cancer. Jihyun
Park,1 Evan N. Cohen,2 Gaurav Chauhan,1 Jangsoon Lee,1 Naoto T. Ueno,1
Debu Tripathy,1 James M. Reuben,2 Chandra Bartholomeusz1. 1Department of
Breast Medical Oncology, The University of Texas MD Anderson Cancer Center,
Houston, TX; 2Department of Hematopathology, The University of Texas MD
Anderson Cancer Center, Houston, TX.
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Triple-negative breast cancer (TNBC) is an aggressive subtypewith noproven
active targeted therapies available. Patients with TNBC have a very poor prog-
nosis because the disease often metastasizes. Newer approaches to preventing
metastasis and inhibiting tumor growth, are crucial to improving prognosis for
these patients. Previously it has been shown that PEA-15 binds to ERK, prevent-
ing ERK from being translocated to the nucleus and hence blocking its activity.
Our previous studies showed that overexpression of wild type PEA-15 inhibited
ERK activity and reduced tumor volume in a TNBC xenograft model. We also
showed that PEA-15 being unphosphorylated at both Ser104 and Ser116 inhib-
ited ovarian cancer cell tumorigenicity. However, the function and impact of
PEA-15 phosphorylation on TNBC is not well understood. From these observa-
tions,we hypothesized that unphosphorylatedPEA-15will preventmetastasis in
TNBC through the inhibition of EMT. To study the effect of the phosphoryla-
tion status of PEA-15 on metastasis in TNBC, we established stable cell lines
overexpressing nonphosphorylatable (PEA-15-AA) and phosphomimetic
(PEA-15-DD) mutants in MDA-MB-468 cells. The clonogenic growth of PEA-
15-AA was signifıcantly reduced by 80% compared with vector control, PEA-
15-V. Anchorage-independent growth of PEA-15-AA was inhibited by 60%
compared with PEA-15-V (P0.05). PEA15-AA upregulated the expression of
E-cadherin, a key epithelial molecular marker and decreased expression of vi-
mentin suggesting that PEA-15-AA reverses EMT. Moreover, compared with
PEA-15-V, migration and invasion of PEA-15-AA were signifıcantly reduced.
To determine themechanism of how PEA-15 regulates EMT andmetastasis, we
performed RT-PCR immune and metastasis arrays. We found that expression
levels of IL-6, IL-8 and PDGF-BB were greatly decreased in PEA-15-AA. Upon
stimulation of the PEA-15-AA with these cytokines, mesenchymal characteris-
tics were partially rescued indicating that PEA-15-AA may inhibit the expres-
sion of these cytokines, thereby reversing EMT. Further, to determine the in
vivo effect of PEA-15-AA, we injected stable transfectants of MDA-MB-468
cells into the mammary fat pad of NOD/SCID mice. The PEA-15-DD-in-
jected group showed an increase (P0.05) in tumor volume compared with
PEA-15-V and PEA-15-AA groups. Additionally, immunohistochemical
data revealed that vimentin and p--catenin (Ser675) expression was greatly
decreased in PEA-15-AA tissues, suggesting that PEA-15-AA has antitumor
effects. Further studies are warranted to evaluate the impact of PEA-15 phos-
phorylation on metastasis in vivo using mice bearing highly metastatic hu-
man breast tumor and determine the mechanism underlying decreased cy-
tokine expression in PEA-15-AA. Together, this study highlights the
potential for overexpression of unphosphorylated PEA-15 as an approach
for TNBC-targeted therapy.
#898 Elucidation of the molecular mechanism ofMenaINV expression, in-
vadopodium maturation and tumor cell intravasation during breast cancer
disseminationbyTMEM.MaxwellD.Weidmann,1ChinmayR. Surve,1 Jeanine
Pignatelli,1 Javier J. Bravo-Cordero,2 George S. Karagiannis,1 Maja H. Oktay,1
John S. Condeelis1. 1Albert Einstein College of Medicine, Bronx, NY; 2Icahn
School of Medicine at Mount Sinai, Manhattan, NY.
Numerous clinical studies have identifıed Tumor MicroEnvironment of Me-
tastasis (TMEM) andMenaCalc as distinct but functionally interrelated prognos-
tic indicators of distant metastasis in breast cancer patients. TMEM sites are the
only sites where tumor cells intravasate in mammary tumors. TMEM score is
calculated histologically as the density of tripartite microanatomical structures
involving a perivascular macrophage, a Mena-expressing tumor cell and an en-
dothelial cell, all three in direct physical contact. On the other hand, MenaCalc
represents the pattern of Mena splice-isoforms present in a tumor sample. Me-
naINV is the key metastasis-promoting Mena splice-isoform driving tumor cell
migration toward blood vessels, intravasation and dissemination. However, the
precisemolecularmechanisms relating TMEM formation and function andMe-
naINV expression in these critical steps of the metastatic cascade have not been
elucidated. Here we show that MenaINV promotes invadopodium-based prote-
olysis, which is required for tumor cell invasion and transendothelial migration,
by preventing the localization of the phosphatase PTP1B to invadopodia. Inter-
estingly, PTP1B regulates invadopodiummaturation by limiting cortactin phos-
phorylation at a key residue (Y421) that is necessary for actin polymerization
during invadopodiummaturation. Additionally, we demonstrate that MenaINV
expression, invadopodium activity, and subsequent transendothelial migration
are induced in tumor cells via Notch1-mediated signaling induced by contact of
tumor cells with macrophages. Knock-down of MenaINV expression in tumor
cells leads to a proportional decrease inmature invadopodium formation. Com-
plete knock-out ofMena inmousemammary tumors (PyMT-MMTV) abolishes
TMEM assembly and TMEM functions, including TMEM-dependent vascular
permeability, circulating tumor cells and lung metastases. In summary, our
work shows that macrophage contact of TMEM-associated tumor cells during
TMEM assembly stimulates Notch1 to drive expression of MenaINV in tumor
cells. MenaINV expression then inhibits PTP1B at invadopodia to promote cor-
tactin phosphorylation at invadopodium precursors, driving invadopodium
maturation and promoting transendothelial migration. These fındings provide,
for the fırst time, an integrative molecular mechanism for two clinically vali-
dated prognostic indicators of metastatic risk, TMEM and MenaCalc, and iden-
tify new drug targets for limiting the metastatic spread of breast cancer.
#899 CD99 plays an important role in glioblastoma cell migration. Lais C.
Cardoso,1 Antonio M. Lerario,2 Suely K. Marie,1 Roseli S. Soares,1 Sueli M.
Oba-Shinjo1. 1School of Medicine of University of São Paulo, São Paulo, Brazil;
2University of Michigan, Ann Arbor, MI.
Glioblastoma (GBM) is the most common and aggressive malignant brain
tumor in adults and the standard treatment consists of surgical resection of the
tumor followed by radiation and chemotherapy with temozolomide. A combi-
nation of standard therapy with other biologically-based therapies is necessary
to improve the survival of patients with GBM, which currently stands only to
15-17 months. In this sense many studies have been developed in pursuit of
expressed membrane proteins in GBM, which are potential targets for immu-
notherapy. Our laboratory demonstrated increased CD99 mRNA and protein
expression in GBM samples. CD99 has a key role in several biological processes,
including cell adhesion, migration, apoptosis, differentiation of T cells and thy-
mocytes, diapedesis of lymphocytes to inflamed vascular endothelium, mainte-
nance of cellular morphology and regulation of intracellular membrane protein
traffıcking. In this study, the transcriptome of two GBM cell lines (U87MG and
A172) transfected with siRNA for CD99 were analyzed in relation to the non-
target control (NTC). A total of 728 genes (hypoexpressed with fold change
-1.5 relative toNTCor hyperexpressedwith fold change	1.5 relative toNTC)
were observed in both cell lines. An enrichment analysis by MetaCoreTM re-
vealed the following processes as the most signifıcant: (1) Cytoskeleton_Regu-
lation of cytoskeleton rearrangement, (2) Cell adhesion_Cell-matrix interac-
tions (3) Development_Blood vessel morphogenesis. Further, both cell lines
were silenced forCD99 expression by shRNA(two clones) to perform functional
assays, as wound healing (migration assay), adhesion, invasion and apoptosis.
The CD99 knockdown reduced migration in both cell lines, with the highest
decrease of the migration observed in the highest CD99 knockdown. Adhesion
assay was performed using fıbronectin as an extracellular matrix substrate.
U87MG cells showed greater adhesion to fıbronectin than the control (scram-
bled shRNA). On the other hand, A172 cells knocked down for CD99 presented
lower adherence to fıbronectin than the control. Apoptosis analysis with
shCD99 U87MG cells showed a tendency of cells entering into late apoptosis
when treated with temozolamide for 48 hours, but the same was not observed
in shCD99 A172 cells. Additionally, CD99 (RPE) and phaloidin (Alexa Fluor
488) colocalized at lamellipodia, suggesting that CD99 is related to cytoskel-
eton rearrangement in both GBM cell lines. The different phenotypic behav-
ior of migration and apoptosis observed in these two GBM cell lines with
different somatic mutation background may be due to distinct signaling
activation. Migration/invasion is the major characteristics of GBM which
limits the surgical tumor resection, and consequently leads to tumor recur-
rence. Therefore, further analysis of CD99 activating pathways in the context
of cell migration is worthwhile to unveil new therapeutic strategies to halt
GBM progression.
#900 Tumor Treating Fields (TTFields) affect human glioma cell migra-
tion, invasion and adherence properties in vitro. Dario Garcia-Carracedo,1
Rosa S. Schneiderman,2 Einav Zeevi,2 Anna Shteingauz2,2 Moshe Giladi,2 Tali
Voloshin,2 Yaara Porat,2 Mijal Munster,2 Roni Blat,2 Eilon D. Kirson,2 Uri
Weinberg,3 Yoram Palti2. 1Novocure, New York, NY; 2Novocure, Haifa, Israel;
3Novocure, Luzern, Swaziland.
TTFields, an approved treatment modality for glioblastoma, are delivered via
continuous, noninvasive application of low intensity, intermediate frequency
alternating electric fıelds. The antimitotic effects of TTFields have been exten-
sively investigated. We investigated other processes that may be affected by
TTFields such as human glioma cell migration and cellular invasion properties.
Four human glioma cell lines were treated with TTFields using the inovitro
system. Cell migration rates were measured using wound healing assays. Inva-
sion assays were performed using a modifıed Matrigel coated Boyden chamber.
Cell adhesion assays were performed during TTFields treatment and compared
to untreated controls. At the end of TTFields’ treatment, adhered cells were
trypsinized and counted. A cells de-adhesion assay was performed following 24
and 72 hours of TTFields applicationwith the outcomebeing the number of cells
removed after varying times of trypsinization. Application of TTFields in-vitro
led to a signifıcant reduction in cell migration velocity compared with untreated
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control cells. Furthermore, comparison of the anti-migratory effıcacy of TT-
Fields applied from 2 directions vs. a single direction revealed that the single
direction approach applied perpendicularly to the course ofmigrationwasmore
effective than TTFields applied in 2 directions or in a single parallel direction.
Glioma cells invasion was signifıcantly reduced compared to untreated cells in
all tested cell lines. Cell adhesion to the substrate (fıbronectin) was signifıcantly
reduced when exposed to TTFields. On the other hand, cell de-adherence fol-
lowing TTFields treatment took signifıcantly longer time of trypsinization. Our
results suggest that human glioma cell motility is impaired by exposure to TT-
Fields. Both alterations in cells adherence and de-adherence during exposure to
TTFieldsmay contribute to reduction in cellmotility. Further studies are needed
to elucidate the mechanism by which TTFields disrupts cellular motility in gli-
oma cancer cells.
#901 The mechanobiome of pancreatic cancer: a viable, targetable drug
space. Alexandra Surcel, Eric S. Schiffhauer, Dustin Thomas, Qingfeng Zhu,
Robert Anders, Douglas Robinson. Johns Hopkins Univ. School of Medicine,
Baltimore, MD.
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an
annual mortality rate of 37,000 in the US alone. Its 5-year survival rate of6%
remains relatively unchanged over the past 4 decades. Because PDAC has ele-
vated rates of de novo and acquired resistance to traditional chemotherapies, we
are exploring new drug spaces that targetmetastatic hepatic disease, the primary
mortality factor for patients. Specifıcally, we have identifıed the cluster of pro-
teins that sense and respond to mechanical stimuli - collectively known as the
mechanobiome. This cytoskeletal machinery is responsible in large part for en-
dowingmetastatic cells with the ability to navigate throughdifferent tissue types.
Based on theirmechanoresponsiveness profıle, we have predicted and identifıed
via western blot and immunohistochemistry proteins in themechanobiome that
are upregulated in patient-derived pancreatic tissues. These proteins include
non-muscle myosin IIA and IIC, alpha-actin-4, and fılamin B.We are perform-
ing knockdown and overexpression studies of these isoforms on 2D and 3D
behaviors - cell mechanics, migration, invasion, and tissue sphere formation
and are poised to begin mouse studies on the metastatic suffıciency in alter-
ing the expression of these proteins. In addition, we are testing 4-HAP, a
small molecule mechanics modulator that we previously identifıed that tar-
gets myosin IIC, thus affecting PDAC mechanics in PDAC murine models.
Limited studies reveal that 4-HAP reduces metastasis. These data suggest
that direct targeting of the mechanobiome may eventually expand treatment
strategies for pancreatic cancer.
#902 Cancer-stem-cell (CSC)marker,DCLK1-S, enhances invasive poten-
tial of cancer cells by phosphorylating/activating NFATc2: role of COL3A1
and SPARC in mediating metastatic effects of DCLK1-S/NFATc2. Malaney
O. Connell, Shubhashish Sarkar, Heidi Spratt, StevenWiden, ThomasG.Wood,
Pomila Singh. UTMB, Galveston, TX.
DCLK1 expression is critically required for colon carcinogenesis inmice, and
for maintaining tumorogenic potential of human colon cancer cells (hCCCs)
(Singh et al, 2016). Down-regulation of DCLK1, combined with chemopreven-
tion, eliminates CSCs, and avoids colon cancer relapse (Kantara et al, 2014).We
recently discovered that long (L) and Short (S) isoforms of DCLK1 (DCLK1-L/
DCLK1-S) are transcribed by two separate promoters (5’()/IntronV()) in the
hDCLK1-gene (O’Connell et al, 2015). During adenoma-carcinoma sequence of
colon-tumorigeneses, L-isoform becomes silenced by DNA-methylation while
S-isoform gets upregulated by many fold (O’Connell et al, 2015). S-isoform
specifıcally imparts invasive potential to cancer cells, unlike L-isoform (Singh et
al, 2016); others have similarly reportedmetastatic potential of DCLK1 express-
ing cancer cells (Ito et al, 2016). Thus the goal of our studies was to evaluate
molecular/genetic pathways mediating invasive effects of DCLK1-S in cancer
cells. Isogenic clones of HCT116-cells, wild-type or down-regulated for
DCLK1-S (HCT-C/HCT-D), were subjected to next generation sequencing and
pathways analysis. SPARC and COL3A1 emerged as two candidate genes/pro-
teins, which were decreased/increased by several fold in response to loss/over-
expression of DCLK1-S, respectively. We present data confırming a critical role
of COL3A1 and SPARC in mediating metastatic effects of DCLK1-S expression
in hCCCs. We additionally discovered that DCLK1-S functions as a specifıc
kinase for the transcriptional factor, NFATc2, and phosphorylates 53SPPS56mo-
tif of NFATc2, resulting in activation of NFATc2 and increased expression of
COL3A1. Conclusions. Our novel fındings, suggest for the fırst time, that
DCLK1-S expression by colonic tumors in humans, mediates invasive potential
of colon cancer cells by phosphorylation/activation of NFATc2, resulting in
up-regulation of COL3A1/SPARC; the latter proteins re-model extracellular
matrix, assisting unhindered invasion of colon cancer cells.
#903 CXCR4 and CXCR7 play distinct and overlapping roles in prostate
cancer dissemination to bone. SounakRoy,1KennethC.Valkenburg,2Kenneth
J. Pienta2. 1Johns Hopkins University, Baltimore, MD; 2Johns Hopkins School of
Medicine, Baltimore, MD.
Approximately 28,000 men die of prostate cancer (PCa) each year in the US,
and 90-100% of them will be due to bone metastasis. It has been demonstrated
that PCa cells detach from the primary tumor and “home” to bone. Osteoblasts
(bone-forming cells) secrete the chemoattractant stromal-derived factor 1
(SDF-1, also known as CXCL12), and PCa cells express the receptors for SDF-1,
C-X-C chemokine receptors 4 and 7 (CXCR4 and CXCR7). PCa cells use these
receptors to enter the chemoprotective bonemicroenvironment, specifıcally, the
hematopoietic stem cell (HSC) niche in the endosteum. While small molecule
inhibition of CXCR4 can mobilize PCa cells from the bone marrow microenvi-
ronment, it is unknown whether CXCR7 plays a compensatory role when
CXCR4 is antagonized. SDF-1 is known to bind with greater affınity to CXCR7
compared to CXCR4 indicating a possible role of CXCR7 in tumormigration to
the endosteal niche. Therefore, it is crucial to determine the individual and
combined roles of CXCR4 and CXCR7 in the formation and treatment of PCa
bone metastases. To answer these questions, fırst we assessed CXCR4 and
CXCR7 expression across a panel of prostate cancer cell lines. We then tran-
siently overexpressed and knocked down CXCR4 and CXCR7 in PCa cells and
found CXCR4 and CXCR7 expression in vitro to directly correlate to cell viabil-
ity andmigration in PC3 PCa cells. To further test dissemination andmetastasis
in bone, we are making stable overexpression and knockout cells and will per-
form in vivo metastasis experiments. We have developed a novel immunofluo-
rescence protocol for detecting and quantifying tumor cells inmurine blood and
bone marrow and will use this technique to determine the ability of PCa cells to
disseminate to bone in the presence or absence of CXCR4 and/or CXCR7. This
will be quickly translatable because we are currently running a fırst-in-prostate
cancer clinical trial to determinewhether smallmolecule inhibition ofCXCR4 to
mobilize PCa tumor cells from the bone marrow, combined with docetaxel, will
benefıt metastatic PCa patients. If we determine that CXCR7 plays a compensa-
tory role in dissemination and/or metastasis, we will need to add CXCR7 inhi-
bition to our treatment strategy to obtain the most effıcient benefıt for patients.
#904 Podocyte-specifıc SMPDl3bmodulates radiation-induced renal dys-
function. Anis Ahmad,1 Alla Mitrofanova,1 Saba Ansari,1 Thirupandiyur
Udayakumar,1 Jacek Bielawski,2 Alan Pollack,1 Alesia Fornoni,1 BrianMarples,1
Youssef Zeidan1. 1UM, Miami, FL; 2MUSC, Charleston, SC.
Background: The underlying mechanisms responsible for the renal failure
and proteinuria in radiation nephropathy remain largely unknown. Radiother-
apy with or without chemotherapy may result in radiation-induced kidney in-
jury in pelvic malignancies such as gynecologic cancers, lymphomas, gastroin-
testinal cancers, sarcomas of the upper abdomen and during total body
irradiation. The current study investigates the role of sphingolipids in radiation-
induced podocytopathy using a murine model. The molecular and functional
effects of kidney irradiation were evaluated after single-dose exposures. Materi-
al/Methods: In cell culture, SMPDL3b expression post radiation (8Gy) was de-
termined by real-time PCR (RT-PCR) and Western blotting. Morphological
changes and DNA damage were detected post radiation using immunofluores-
cence microscopy.Wild-type C57BL/6 male and female mice (age 10-14 weeks)
were irradiated with a single dose of X-ray (14 Gy) using an image guided small
animal arc radiation treatment system (iSMAART). Rituximab/IgGwas admin-
istered (50 mg/kg, intraperitoneal injection) 30 min before the single dose of
irradiation. Functional kidney parameters, kidney histology, and gene expres-
sion were analyzed at 20, 30 and 40 weeks after irradiation. Results: Following
irradiation, SMPDL3b expression at protein level was signifıcantly reduced in
vitro and in vivo. However, no signifıcant changes were observed at the tran-
scriptional level. Podocyte number also decreased signifıcantly post radiation in
vivo. iSMAART dynamic contrast enhanced (DCE) imaging data analysis
showed reduced glomerular fıltration rate post radiation. In agreement with the
functional data, hematoxylin and eosin staining of kidney sections showed a
multifocal increase in the number of pericytes, tubular atrophy, and glomerular
damage. Periodic Acid-Schiff (PAS) staining showed an increase in glomerular
mesangial matrix accumulation post radiation. Sirius red staining showed dif-
fuse intertubular fıbrosis, especially in the renal cortex post radiation. These
histological changes were paralleled by the change in serum Creatinine, urine
albumin. Rituximab pretreatment to mice, improved kidney functional param-
eters, vascular structure, normalization of pericyte coverage, suppress the devel-
opment of fıbrosis and tubular damage post irradiation. Conclusion: This study
shows that rituximab pretreatment protects mice against radiation-induced
nephrotoxicity, whichmay have therapeutic implications for radiation-induced
injuries in cancer patients.
TUMOR BIOLOGY: Migration and Invasion 1
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017230
#905 Lysyl oxidase is required for chemotaxis. Haoran Tang, Nathalie
Dhomen, Richard Marais. CRUK Manchester Institute, Manchester, United
Kingdom.
Purpose: Lysyl oxidase (LOX) increases extracellularmatrix stiffness by cross-
linking collagen. A stiffermatrix drives integrin activation, and therefore LOX is
believed to promote cancer cell invasion through enhanced integrin signaling.
However increased matrix stiffness does not necessarily lead to a more permis-
sive environment for invasion. Fibrillar collagenmatrix orientation, density and
porosity also determine how well cells can invade. Assays based on collagen
gel-covered transwell systems have previously been used to show that LOX is
required for invasion. These systems are driven by a chemoattractant gradient,
and thus a role for LOX in chemotaxis could not be excluded. In this study we
aimed to clarify whether LOX was required for matrix invasion or chemotaxis.
Experimental procedures: To set up a 3D invasion assay that was not driven by a
chemoattractant gradient, spheroids from multiple LOX expressing cancer cell
lines were embedded into a thick 3D collagen gel. Cells were then allowed to
randomly invade into the surrounding collagen. Alternatively, cancer cells were
allowed to invade a fıbroblast-modifıed 3D collagen gel in an organotypic assay.
In this assay the invasion was driven by a strong chemoattractant gradient
through a dense collagen gel, with cancer cells cultured atop the collagen gel at
the air-medium interface. A Dunn chemotaxis chamber or a transwell tissue
culture insert was used to investigate chemotaxis towards serum or EGF. Small
interfering RNA (siRNA) or short hairpin RNA (shRNA) specifıc to human
LOX was used to deplete LOX expression in the cancer cells, to test potential
LOX functions in the above assays. Results: LOX depletion in parental MDA-
MB-231 cells,MDA-MB-231 brain or bonemetastatic sub-population cells, U87
and U118 cells did not impact 3D collagen gel invasion. LOX inhibition by
BAPN also did not impact collagen gel invasion inMDA-MB-231, LN229, U87,
U118 andU138 cells. The data indicated that LOXwas not required for invasion
through a thick 3D collagen gel in vitro. However, in the chemotactic-driven
organotypic assay, loss of LOX in MDA-MB-231 cells completely abolished
invasion. When the chemotactic potential towards serum and EGF of LOX de-
pleted MDA-MB-231 and U87 cells was tested using Dunn chemotaxis cham-
bers, we observed strong chemotactic defects in both cell lines. The chemotactic
defects of these cells were also observedwhen a transwell based chemotaxis assay
was used. Randomcellmigration ofMDA-MB-231 andU87 cellswere otherwise
not affected by LOX depletion. Conclusions: LOX is not required for collagen
matrix invasion per se. Instead LOX is important for cells to sense chemoattrac-
tants and to maintain directional cell migration. The molecular mechanisms
underlying these observations are now the subject of further investigation.
#906 PATZ1 promotes migration and invasion of thyroid cancer cells
through upregulation of the activity of plasminogen activator and matrix
metalloproteinases. Asumi Iesato,1 Teruo Nakamura,1 Tsuyoshi Uehara,1 Hi-
roto Izumi,2 Ken-ichi Ito1. 1Shinshu University School of Medicine, Matsumoto-
city, Nagano-Prefecture, Japan; 2University of Occupational and Environmental
Health, Kitakyusyu-city, Japan.
Background: PATZ1, a transcription regulator, has been reported to function
as oncogene or tumor suppressor in several human malignant neoplasms. The
aim of the study was to examine involvement of PATZ1 in carcinogenesis and
progression of thyroid cancer.Materials andmethods: PATZ1 expression in 165
clinical thyroid specimens obtained from87 patients were evaluated by IHC.We
examined the function of PATZ1 using an immortalized normal thyroid follic-
ular epithelial cell line (Nthy-ori 3-1), and four thyroid cancer cell lines; TPC-1
(papillary cancer), FTC-133 (follicular cancer), FRO and ACT-1 (anaplastic
cancer). Knockdown of PATZ1 inNthy-ori 3-1 and thyroid cancer cell lines was
performedwith siRNA-PATZ1, and overexpression of PATZ1 in thyroid cancer
cell lines was performedwith pcDNA3-FLAG-PATZ1. Results: In the IHC anal-
ysis of clinical specimens, nuclear PATZ1 expression in anaplastic carcinoma
was signifıcantly less frequently than that in normal thyroid tissue or well-dif-
ferentiated carcinoma (Table 1). Knockdown of PATZ1 in Nthy-ori 3-1 and
differentiated thyroid cancer cell lines (TPC-1, FTC-133) induced morphologi-
cal change of the cells and signifıcant increase of cell proliferation andmigration
as well as moderate increase of invasion. Furthermore, the expression of u-PA,
MMP2 and MMP11 was increased by inhibition of PATZ1 in TPC-1 and FTC-
133. On the other hand, overexpression of PATZ1 in anaplastic cancer cell lines
(FRO and ACT-1) decreased proliferation and migration of the cells along with
the decreased expression of u-PA, MMP2, MMP9 and MMP11. Conclusion:
Our study suggests that PATZ1 might play an important role as a tumor sup-
pressor in thyroid follicular epithelial cells andmight be involved in progression
of thyroid cancer.
Expression of nuclear PATZ1 in thyroid tumor
type
Normal
thyroid/
goiter
(N68)
Follicular
adenoma
(N5)
Papillary
cancer
(N39)
Follicular
cancer
(N8)
Poorly
differentiated
cancer
(N12)
Anaplastic
cancer
(N28)
Medullary
cancer
(N5)
positive (%) 68 (100%) 4 (80.0%) 35 (89.7%) 5 (62.5%) 7 (58.3%) 3 (10.7%) 4 (80.0%)
negative (%) 0 (0%) 1 (20.0%) 4 (10.3%) 3 (37.5%) 5 (41.7%) 25 (89.3%) 1 (20.0%)
#907 Uptake of lung cancer exosomes inducesmigratory and invasive phe-
notypic changes in lung epithelial cells in an oncogene context dependent
manner. Yoshihisa Shimada, Paul Yenerall, Kimberly Avila, Hyunsil Park,
Brenda Timmons, KennethHuffman, Boning Gao, DhrubaDeb,Maithili Dalvi,
John D. Minna. University of Texas Southwestern Medical Center, Dallas, TX.
Cancer-derived exosomes are intracellular signaling organelles that can act
via inter-cellular communication to help cancer cells invade neighboring tissues
and prime metastatic sites for cancer cell spread. Lung cancer is a highly meta-
static disease, with metastases often occurring when tumors are in a clinically
early stage. Little is known of how lung cancer exosomes influence the migrato-
ry/ invasive phenotype of lung cancer cells. We studied migration and invasion
mechanisms by transferring cancer-derived exosomes to recipient cells includ-
ing cancer cells, human bronchial epithelial cells (HBECs) cells, andHBECs that
we had modifıed with common lung cancer oncogenic changes. Exosomes iso-
lated from lung cancer line H1299 cells (p53null, NRAS mutant) and non-ma-
lignant, immortalized HBEC3-KT cells were characterized for exosome content
and type by nanoparticle tracking analysis, electron microscopy, western blot-
ting with antibodies directed at HSP70 and CD63, and generation of H1299 and
HBEC3-KT derivatives stably transfected with CD63-GFP, releasing green flu-
orescence exosomes for tracking purposes. Exosomes were isolated using a va-
riety of published methods and the amount quantifıed: 106 H1299 and HBEC-
3KT cells produced 9 109 and 7 109 exosomes of similar size (125.4nm and
129.8nm). Effect of exosomes from cancer and HBECs were tested on: 1. cell
motility and invasiveness of HBECs and their oncogenic derivatives determined
by transwell chamber migration assay and scratch assay; 2. vascular leakiness
properties in the lung by evaluating mouse lung endothelial permeability after
exosomes were injected (an early event in metastatic spread for the migrated
cells); and 3. xenograft tumor formation. We found CD63-GFP exosomes from
H1299 and HBEC3-KT are actively incorporated by all of the cell types. How-
ever, only H1299 exosomes (but not HBEC3-KT exosomes) inducedmigratory/
invasive phenotypic and morphologic changes and they did this in a concentra-
tion-dependentmanner in lung cancer cells andHBECswith oncogenic changes
(HBEC sh-p53KRASv12 and sh-p53KRASv12c-MYC manipulated
HBECs) but not in the parental HBEC3-KT cells. Also, H1299 exosomes but not
HBEC3-KT exosomes enhanced the lung endothelial permeability as evaluated
by the extravasated dextran leaking. NSCLC H1299 cells when injected with its
own exosomes produced better xenograft takes compared to H1299 cells alone.
Lung cancer-derived exosomes compared to exosomes derived from immortal-
ized but non-malignant human bronchial epithelial cells induced an increased
migratory/invasive phenotypewith lung vascular leakiness and higher xenograft
tumor take rates.However, they induced these changes only in the context of key
oncogenic changes. These results suggest understanding and targeting the
mechanism of such lung cancer derived exosome behavior could lead to novel
therapeutic strategies.
#908 A role for MST4 in organelle organization and breast cancer cell
vascular invasion. Eric B. Berens,1 Mara Gilardi,2 Matteo Moretti,3 Anna T.
Riegel,1 Anton Wellstein1. 1Georgetown University, Washington, DC; 2Univer-
sity of Milano-Bicocca, Milan, Italy; 3IRCCS Istituto Ortopedico Galeazzi, Italy.
There exist 5 Mammalian Sterile20-like (MST) kinases that are broadly
distributed into two subgroups. While MST1 and MST2 have established
roles in the canonical Hippo signaling pathway, MST3, MST4, and YSK1 are
known to regulate the actin cytoskeleton and cell polarity. Here we clarify
distinct roles for MST3 vs. MST4 in breast cancer cell lines. Stable knock-
down of MST4, but not MST3, enhances the ability of breast cancer cells to
disrupt an endothelial monolayer as well as invade from an endothelial net-
work formed within a microfluidic device. In addition, depletion of MST4 in
MDA-MB-231 cells alters their morphology, induces abnormalities in nu-
clear structure, and affects the organization of cellular organelles like the
Golgi apparatus. We conclude that, despite their relative homology, MST4
versus MST3 uniquely impacts the intracellular organelle status and vascular
invasive behavior of breast cancer cells.
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#909 Tracking of migration using digital holography to monitor drug-
induced phenotypic shifts in breast cancer cells. Sofıa Kamlund, Stina
Oredsson. Lund University, Lund, Sweden.
This study aims to investigate the migration behaviour of individual JIMT-1
breast cancer cells during the cell cycle. Mechanisms behind cell migration are
important to unravel in the context of cancer relapses caused by distant metas-
tases. JIMT-1 cells were cultivated in normoxia or hypoxia and treated with 0.5
M of the cancer stem cell inhibiting compound salinomycin. The cells were
imaged in a digital holographymicroscope placed in a regular cell culturingCO2
incubator (normoxia) or in a hypoxia chamber (1%O2). In digital holography, a
laser beam is split into two beams - the reference beam and the object beam. The
object beam is directed through the sample, where the difference in refractive
index between air, the cell medium, and the cell body induces a phase shift in the
laser beam.After having passed the object, the beam ismergedwith the reference
beam giving an interference pattern, which is used to construct a three-dimen-
sional image of the cells in a software program. The laser is non-phototoxic and
therefor it can be used for long-term studies. In our study, images were acquired
every 5th minute during a 72-hour incubation period. After acquisition, the
individual cells in the imageswere tracked throughout the time lapse. Cellmove-
ment is described by three parameters: motility, which is the length of the total
cell movement path, migration, which is the shortest distance from the start to
the end position, and migration directness, which is migration divided by mo-
tility. When cells were exposed to hypoxia and/or treated with salinomycin, the
cell cycle time increased compared to non-treated cells in normoxia. When the
cell cycle time increased, motility increased as well. However, migration direct-
ness decreased despite increase in motility implying increased local movement
of cells treated with salinomycin compared to control cells. We have previously
shown that salinomycin-treated JIMT-1 cells obtain an epithelia phenotype
(Huang et al., 2016). Thus, we decided to investigate a breast cancer cell linewith
epithelial traits i.e, the MCF-7 cells. The MCF-7 cells behaved like the JIMT-1
cells treated with salinomycin i.e. the motility was high and the migration di-
rectness was low. Thus, we suggest that cells with mesenchymal and epithelial
traits can be distinguished using digital holographic imaging based on motility
and migration directness and that drug-induced phenotypic shifts can be stud-
ied using this technique. References: Xiaoli Huang, Björn Borgström, Sebastian
Kempengren, Lo Persson, Cecilia Hegardt, Daniel Strand and Stina Oredsson.
Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin
analogs. BMC Cancer (2016) 16:145. DOI 10.1186/s12885-016-2142-3.
#910 Phloridzin docosahexaenoate (PZ-DHA) inhibits breast cancer cell
invasion and angiogenesis. Wasundara Fernando,1 Emma MacLean,1 Krysta
Coyle,1 Paola Marcato,1 David W. Hoskin,1 H. P. Vasantha Rupasinghe2. 1Dal-
housie University, Halifax, Nova Scotia, Canada; 2Dalhousie University, Truro,
Nova Scotia, Canada.
In our previous studies, we showed the selective cytotoxicity, in vitro anti-
proliferative and anti-metastatic activities of phloridzin docosahexaenoate (PZ-
DHA). PZ-DHA combines phloridzin (PZ), a dihydrochalcone found in apple
peels, and docosahexaenoic acid (DHA), an -3 fatty acid found in fısh oil,
through an acylation reaction. Signifıcant suppression of tumor growth resulted
from the intratumoral administration of PZ-DHA to non-obese diabetic severe
combined immunodefıcient (NOD-SCID) femalemice xenografted withMDA-
MB-231 breast cancer cells. Examination of haematoxylin and eosin-stained
tumor sections confırmed that PZ-DHA caused tumor cell death. PZ-DHA also
suppressed the invasion ofMDA-MB-231 cells throughmembranes coatedwith
extra cellular matrix proteins, fıbronectin and gelatin, in a Boyden chamber
assay. The effect of PZ-DHA on the mRNA transcription of the gelatinase, ma-
trix metalloproteinase-2 (MMP-2,) was measured in RT-qPCR analysis, which
showed thatMMP-2mRNA expression was inhibited at 12 h and 24 h following
PZ-DHA treatments. Furthermore, suppression of MMP-2 protein expression
was shown by western blot analysis of cell lysates of PZ-DHA-treated MDA-
MB-231 cells. Intraperitoneal administration of PZ-DHA suppressed the
growth of primary tumors andmetastasis of 4T1 and green fluorescence protein
(GFP)-tagged-MDA-MB-231 cells to lungs of BALB/c and NOD-SCID female
mice, respectively. Anti-angiogenic activity of PZ-DHA was investigated using
human umbilical vein endothelial cells (HUVECs). PZ-DHA suppressed the
metabolic activity of HUVECs in MTS assays and the cell death was confırmed
using flow cytometric analysis of 7-AAD and Annexin-V-FLUOS/propidium
iodide-stained HUVECs. Anti-proliferative activity of PZ-DHA was shown us-
ingOregonGreen 488 stained-HUVECs by flow cytometry. PZ-DHA treatment
arrested the HUVEC cell cycle at S-phase. PZ-DHA also suppressed the migra-
tion of HUVECs in a gap closure assay and inhibited HUVEC tubule formation
on a matrigel matrix. For comparison purposes, PZ and DHA were included in
all experiments, but in all cases were less effective than PZ-DHA. Taken to-
gether, these fındings reveal the potential of PZ-DHA to inhibit triple-negative
breast cancer progression. We are currently working on identifying potential
phase I and II metabolites of PZ-DHA and understanding its pharmacokinetic
parameters.
#911 Destabilizing -catenin and Ras could be an ideal therapy for treat-
ing metastatic colorectal cancer. Yong-Hee Cho, Jeong-Soo Yoon, Kang-Yell
Choi. Yonsei University, seoul, Republic of Korea.
INTRODUCTIONAberrant activations ofWnt/-catenin and Ras signaling
pathways by APC (90%) and K-Ras (40-50%) mutations are closely interacted
and accelerate CRC tumorigenesis. Protein level of -catenin as well as Ras is
increased by APC loss via inhibiting GSK3B-mediated poly-ubiquitination de-
pendent Ras degradation through recruitment of -TrCP E3 linker. Moreover,
additional K-Rasmutation results in the livermetastasis by secondary activation
of the Wnt/-catenin signaling pathways via Ras-ERK and -AKT pathways in
addition to the initial activation by APC loss. Consequently, both -catenin and
Raswere highly increased in humanCRCpatient tissues, especially inmetastatic
tumor. EXPERIMENT PROCEDURES To investigate the synergistic effects of
aberrant Wnt/-catenin and Ras signaling pathways on tumor development to
metastasis, we established the APCMin//K-RasG12DLA2 compoundmouse that
harbor APC and K-Ras mutations in animal model. We also analyzed Ras pro-
tein level using human CRC patient tissues of normal mucosa and adenocarci-
noma (N24) and metastatic adenocarcinoma (N26) and tumor budding
(N10). To recapitulate the metastatic tumor environment which have en-
riched receptor tyrosine kinases (RTKs), wemaintained and experimented with
EGF (20ng/ml) in every in vitro studies. RESULTS We observed that both
-catenin and Ras were increased in adenocarcinoma andmetastatic adenocar-
cinoma of human CRC compared with normal mucosa. Interestingly, both
-catenin and Ras were most signifıcantly increased in tumor budding regions
which histopathologically represent epithelial mesenchymal transition (EMT).
Inmurinemodel, the EMTphenomenonwas effectively induced and invasion of
small intestinal tumors were occurred in APCMin//K-RasG12DLA2 with in-
creased level of -catenin and Ras compared with APCMin/. However, EMT
phenomenon and its following events such as migration and invasion of CRC
cells induced by APC and K-Ras mutations were abolished by destabilization of
-catenin and Ras. CONCLUSION Our results show that destabilizing
-catenin andRas could be effective therapeutic targets for inhibitingmetastasis
in the early stage of CRC development.
#912 ADAM9-plectin interaction involved in prostate cancer malignancy
progression. Che-Ming Liu,1 Chia-Ling Hsieh,2 Shian-Ying Sung2. 1China
Medical University, Taiwan; 2Taipei Medical Univ., Taipei, Taiwan.
Introduction: To identify a specifıc biomarker for malignant prostate cancer
progression and therapeutic target, we had demonstrated the correlation of
ADAM9 expression and cancer progression. The aim is to clarify the association
of ADAM9 and interactive proteins in malignant phenotypic progression.
Methods: Knockdown of ADAM9 expression was conducted to explore its role
in cell motility and metastasis activities. Pull-down assays were performed to
identify the proteins that interact with ADAM9 during cancer cell migration.
Proximity ligation assay (PLA) was carried out to validate the protein-protein
interaction. Transmission electron microscope (TEM) analysis to confırm
ADAM9 and plectin interaction. Protein degradation test was conducted to
determine the regulation pathway. Results: Our study demonstrated that
ADAM9 play an important role in the regulation of prostate cancer migration,
invasion and metastasis in the in vitro assay and xenograft animal models. The
combination of ADAM9 pull-down assays and mass spectrum analysis demon-
strated hemidesmosome components, plectin, ladinin, and cytoskeleton were
pull-down with ADAM9. However, the key element of hemidesmosome, integ-
rin 64, did not pull-down together. Both TEM and PLA confırmed the inter-
action of ADAM9 and plectin in the protrusion end of migrating cells. This
interaction can be strengthened after knockdown integrin 4; and vice verse,
knockdown of ADAM9 increased interaction of integrin 4 and plecin. These
results indicated ADAM9 and integrin4 compete for plectin binding. Further-
more, shADAM9 attenuated the degradation of integrin 4. Clinical evaluation
of 96 patient samples in TMU demonstrated increased of ADAM9 and plectin
interaction in tumor region when compared to the benign part of the same
patient. Conclusions: Our studies demonstrated that ADAM9 promotes cancer
metastasis through alteration of hemidesmosome dynamic by enhancing of in-
tegrin 4 degradation. Therefore, these results indicated possible to use AD-
AM9-plectin interaction to predict prostate cancer malignancy progression.
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#912A Cadherins control Src kinase induced fıbroblast cell motility.
Stephanie A. Sheehan, Edward P. Retzbach, Yongquan Shen, Gary S. Goldberg.
Rowan University, Stratford, NJ.
Cancer associated fıbroblasts (CAFs) are a part of the tumor microenviron-
ment, and help remodel the extracellular matrix to pave the way for tumor cells
to forge invasive fronts. Src tyrosine kinase activity is often increased in the
tumor microenvironment, and has been shown to induce cell motility and dis-
rupt adherens junctions. Adherens junctions are formed by cadherin proteins
that mediate intercellular adhesion and control cell migration. Previous studies
have found correlations between cadherin expression and cancer cell motility.
However, effects of cadherin expression on CAF motility have not been thor-
oughly elucidated. We are investigating how junctions formed by E-cadherin
(ECAD) and N-cadherin (NCAD) affect individual and collective migration of
fıbroblasts expressing different levels of Src kinase activity. We are utilizing
fluorescently tagged ECAD or NCAD to study the localization and effects of
cadherin proteins in real time by live cell imaging along with wound healing and
Transwell migration assays. Results from these studies indicate that ECAD and
NCAD have different effects on migration of cells depending on Src kinase
activity. Src kinase activity did not affect collective cell migration, but increased
individual cell migration by over 4 fold (p0.0001 by t-test) in the absence of
forced cadherin expression. In addition, our data indicate that ECAD increases
collective cell motility, while NCAD decreases collective cell migration in the
absence of strong Src kinase activity. Collective migration by ECAD expressing
cells was over 4 fold higher than cells expressing NCAD or control transfectants
(p0.0001 by t-test) in the absence of strong Src activity. Conversely, collective
migration of cells expressing NCAD was over 5 fold lower than control trans-
fectants, and over 30 fold lower than cells expressing ECAD (p0.005 by t-test)
without strong Src kinase activity. In contrast, both cadherins decrease individ-
ual cell motility promoted by Src kinase activity. ECAD and NCAD transfected
cells migrated over 4 fold less than control transfectants with high levels of Src
kinase expression (p0.0001 by t-test). Interestingly, human oral squamous cell
carcinoma (OSCC) cells that express high levels of both ECAD and NCAD
exhibit collective migration equal to cells with low Src kinase activity, but indi-
vidual migration over 5 fold higher than nontransformed cells (p0.0001 by
t-test). This system should prove useful to elucidate how cadherins and Wnt
signaling pathways affect motility of CAFs and tumor cells. For example, west-
ern blotting analysis suggest that both ECAD andNCADmay protect-catenin
from destruction initiated by Src kinase activity. Taken together, this work
should elucidate how cadherins affect the ability of the Src kinase to increase
CAF motility, and identify mechanisms that can be exploited to identify poten-
tial chemotherapeutic targets.
TUMOR BIOLOGY: Stem Cell Heterogeneity
#913 Wnt signaling promotes mouse and human gastric stem cell prolif-
eration. Elise Susan Demitrack, Linda C. Samuelson. University of Michigan,
Ann Arbor, MI.
Background: The Wnt signaling pathway is required for proliferation of in-
testinal stem cells and activating mutations in the Wnt pathway can promote
colorectal cancer. The requirement forWnt to support gastric stem cell function
is much less clear, despite recent reports showing that activating Wnt pathway
mutations occur in human gastric cancer. Here we tested the role of Wnt to
support stem cell proliferation in the mouse stomach and in human stem cells
cultured from control or gastric cancer tissues. Methods: Wnt signaling in the
mouse stomachwas detected usingTCF/Lef:H2B-GFP reportermice, andWnt
gastric cells were identifıed via GFP immunostaining. Wnt function in SOX2
gastric stem cells was tested with Sox2-CreER; Apcfl/mice, 1-month post-Apc
deletion. Wnt regulation of human gastric stem cells was tested in organoid
cultures derived from paired control (non-cancer) and gastric cancer tissues.
Established organoids were treated with the Wnt inhibitor IWR-1-endo and
growth was assessed by quantifıcation of organoid size. Results: GFP cells were
observed in the gastric epithelium of TCF/Lef:H2B-GFPmice, located through-
out corpus glands and at the gland base in antral glands. Interestingly, GFP
epithelial cells were largely post-mitotic although in the antrum, a subset of
GFP cells at the gland base co-localized with the antral stem cell marker LGR5.
In both corpus and antrum, a subset of GFP epithelial cells co-stained with the
pan-endocrine marker Chromogranin A and in the antrum, a subset also co-
stained with the deep mucous cell marker GSII, suggesting Wnt may regulate
gastric cell fate. Analysis of Sox2-CreER; Apcfl/ mice revealed that Wnt path-
way activation in SOX2 gastric stem cells led to increased epithelial cell prolif-
eration in both corpus and antrum. In the antrum, this incease in proliferation
was also accompanied by increased expression of the cancer stem cell marker
CD44 at the gland base. Wnt activation also perturbed epithelial cell differenti-
ation in the gastric antrum, with expansion of GSII deep mucous cells. Wnt
inhibition reduced growth of human gastric organoids derived fromnon-cancer
and gastric cancer tissues. Interestingly, organoids derived from gastric cancer
tissue were signifıcantly larger than control organoids and required a 5-fold
increase in IWR-1-endo to achieve signifıcant growth inhibition, implying that
gastric cancer organoids are somewhat resistant to Wnt inhibition to slow
growth. Conclusion:Wnt signaling is a critical pathway for regulation of mouse
and human gastric stem cell homeostasis, promoting cellular proliferation.
Thus,Wnt may represent an effective therapeutic target for gastric cancers with
Wnt-activating mutations.
#914 Age-associated neoplastic transformation of mammary stem cells.
Xiang Gu, Hakim Bouamar, Kyle Pressley, LuZhe Sun. University of Texas
Health Science Center San Antonio, San Antonio, TX.
Incidence rate of breast cancer increases signifıcantly with age. However, the
mechanism of age-associated mammary tumorigenesis is unknown. Although
mammary stem/progenitor cells have been proposed as the cells of origin for
breast cancer, the mechanism remains largely elusive. Previously we discovered
that in the old (28 to 30month-old) mousemammary gland, the luminal cells in
the hyperplastic lesions elevated expression of CD49f, which is a basal cell
marker. This led to an increased percentage of mammary stem cells (MaSCs)
marked by CD49fhi in the old in comparison to the young (3 to 6 month-old).
Similarly, old (60 yr) human mammary ducts in the adjacent normal tissues
from patients with breast cancer showedmore hyperplastic lesions and CD49fhi
luminal cells than young (40 yr) tissues. Regenerated mammary glands by the
old CD49fhi MaSCs through in vivo transplantation in cleared mammary fat
pads showedmore hyperplastic and dysplastic lesions than those regenerated by
the young CD49fhi MaSCs, suggesting the old CD49fhi MaSCs contain trans-
formedMaSCs. Moreover, gene set enrichment analysis of whole genome tran-
scriptome data showed that they also have elevated expression of luminal cell
specifıc genes and reduced expression of basal cell specifıc genes. Through large
scale screeningwith flow cytometry guided by bioinformatics analysis, we found
that Lin- CD24med CD49fhi CD13 CD73- mammary epithelial cells had in-
creased number of MaSCs. By comparing young (3 to 6 months old) and old
Balb/C mice, we found that the frequency of this specifıc MaSCs was signifı-
cantly increased by four folds in old mammary epithelial cells (young: 4%, old:
16%). In contrast, relative percentage of Lin- CD24med CD49fhi CD13- CD73
cells signifıcantly decreased (young: 46%, old: 16%) during agingwhile theCD13
and CD73 double positive or double negative subpopulations remained un-
changed. CD13 CD73- cells generated signifıcantly many more mammo-
spheres (around 40 spheres per 1,000 cells) in suspension culture than other
three types of cells (around 2 spheres per 1,000 cells). However, there was no
signifıcant difference between the young and old in terms of sphere formation
effıciency for any of the four subpopulationsmarked byCD13 andCD73.We are
studyingwhether anyone of these four subpopulation fromCD49fhi old cells will
generatemore hyperplastic and dysplastic lesions in regenerated glands than the
other subpopulations as well as than the corresponding young subpopulation.
Our study show that CD13 and CD73 may be the markers for the identifıcation
of tumor-initiating MaSCs.
#915 Thrombomodulin expression regulates the tumor stroma differen-
tiation of mesenchymal stem cells for controlling tumor growth. Tsung-
Hsien Shih,1 Jhy-Ming Li,1 Guey-Yueh Shi,2 Hua-Lin Wu2. 1Chang Gung Uni-
versity, Taoyuan City, Taiwan; 2Cheng Kung University, Tainan City, Taiwan.
Introduction: Thrombomodulin (TM), a thrombin receptor on endothelial
cell surface, acts as an anti-coagulant factor in thrombin-catalyzed protein C
activation and inhibits the pro-coagulant functions of thrombin. Owing to TM’s
widely expression patterns on various cell types, our studies have demonstrated
that beside anti-coagulation, TM also participates in controlling cell-cell adhe-
sion, tumor growth, inflammation, angiogenesis, and atherosclerosis. However,
the signifıcance of TM expression in mesenchymal stem cells (MSCs) has never
been investigated. The non-hematopoietic MSCs could specifıcally home into
the developing tumors and becomes the active components of tumor stroma,
which affects tumor’s growth, immunity, progression, and therapeutic resis-
tance. Recently, we investigated the role of TMon the tumormicroenvironment
differentiation of MSCs for establishing the active stroma that assists tumor
growth. Materials &methods: Normal and TM gene-targeting transgenic mice-
isolated bone marrow-derivedMSCs were used as the research models to inves-
tigate the expressing signifıcance of TM on MSC’s biological activities and dif-
ferentiations duringmousemelanomaB16F10 cell’s conditioning in vitro and in
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vivo. Results: Our data showed that MSC’s TM expression was low in the quies-
cent state but was up-regulated while treating with B16F10 cell’s conditioned
medium in themechanismof plate-derived growth factor signaling dependence.
Accordingly, using conditional gene knockout strategy, under the condition of
tumor cell other than normal culture resulted in that TM gene knockout signif-
icantly affected MSC’s proliferation, migration, interleukin-6 secretion, angio-
genic activity, and tumor-associated fıbroblast differentiation in vitro. Further-
more, TM knockout notably reduced the capacity of MSCs on regulating the
growth, vasculogenesis, and active stroma establishment of B16F10 melanoma
xenograft in vivo. Conclusion: These results indicate that the secretion of tumor-
associated plate-derived growth factor is a critical event for MSC’s TM expres-
sion that controls MSC’s stroma differentiation for developing active tumor
microenvironment, which promotes tumor progression. This study further sug-
gests that themodulation of TM expression onMSCs has the therapeutic poten-
tial via diminishing the establishment of functional tumor stroma that sensitizes
tumor for the therapies.
#916 Asymmetric cell division regulator prevents hyperproliferation in
glioma cell-of-origin.Mathieu Daynac, Claudia K. Petritsch. UCSF, San Fran-
cisco, CA.
In the past, we demonstrated that adult oligodendrocyte progenitor cells
(OPC) undergo asymmetric cell division (ACD) to self-renew and generate
functional cells by unequally distributing active EGFR and the OPC-specifıc
marker NG2.Moreover, premalignant OPC switch from an asymmetric to sym-
metric, self-renewing division mode at premalignant stages, and exhibit aber-
rant proliferation and impaired differentiation (Sugiarto S et al Cancer Cell
2011). OPC are the cell-of-origin of glioma in genetically engineered mouse
models (Persson A et al Cancer Cell 2010) and OPC-like glioma cells have high
tumor-initiating potential in some glioma types. These data contribute to the
emerging evidence that asymmetric cell division (ACD) has tumor suppressive
activity. Whether the loss of ACD directly promotes tumor initiation is unclear,
because the detailed mechanisms of mammalian ACD have not been elucidated
(Gomez-Lopez S et al. Cell Mol Life Sci 2014). Lethal giant larvae 1 (Lgl1) was
initially identifıed as a tumor suppressor in Drosophila and has been implicated
in the asymmetric localization of cell fate determinants in mammalian neural
progenitor cells (Klezovitch et al., Genes Dev, 2004). Others have shown also
that human Lgl1 is inhibited by PTEN loss, which is common in glioblastoma,
and Lgl1 depletion in human glioblastoma cells increases their invasive proper-
ties (Gont et al, Oncotarget, 2013 and 2014). Whether Lgl1 restricts prolifera-
tion, promotes differentiation and prevents neoplastic transformation of OPC,
by regulating their asymmetric division, is unknown. We developed a flow cy-
tometry method to isolate proliferative and differentiation-committed OPC
(COP) and showed that Lgl1 expression is elevated in differentiation. Using a
Cre-conditional knock-out allele (Klezovitch et al., Genes Dev, 2004), we show
that Lgl1 knockout OPC proliferate more and differentiate less when compared
with Lgl1 wildtype OPC. Lgl1 depletion increases symmetric, self-renewing di-
visions and reduces the frequency of ACD. Lgl1 appears to control the expres-
sion of several conserved ACD regulators, as revealed by comparative Taqman
expression analyses of Lgl1 knockout versus control OPC. Ongoing studies are
aimed to investigate the link of Lgl1 depletion, alteredACD regulator expression
and observed OPC phenotypes. Data derived from this work are expected to
provide further insights into the extent to which defective ACD contributes to
neoplastic transformation in all cancers.
#917 CD82/KAI1 maintains the dormancy of long-term hematopoietic
stem cells through interaction with DARC-expressing macrophages. Jae-Il
Choi,1 Jin Hur,1 Hwan Lee,1 Pniel Nham,1 Cheong-Whan Chae,1 Young-Eun
Choi,1 Taewan Kim,1 Ga-Young Lee,1 Sung Hee Baek,2 Hyo-Soo Kim1. 1Seoul
National University Hospital, Seoul, Republic of Korea; 2Creative Research Ini-
tiative Center for Chromatin Dynamics, Seoul, Republic of Korea.
Hematopoiesis is regulated by crosstalk between long-term repopulating he-
matopoietic stem cells (LT-HSCs) and supporting niche cells in the bone mar-
row (BM). Here, we examine the role of CD82/KAI1 (CD82 hereafter) in niche-
mediated LT-HSC maintenance. We found that CD82 is expressed
predominantly on LT-HSCs and rarely on other hematopoietic stem-progenitor
cells (HSPCs). InCd82-/-mice, LT-HSCswere selectively lost as they exited from
quiescence and differentiated. Mechanistically, CD82-based TGF-b1/Smad3
signaling leads to induction of CDK inhibitors and cell-cycle inhibition. The
CD82 binding partner DARC/CD234 is expressed on macrophages and stabi-
lizes CD82 on LT-HSCs, promoting their quiescence. When DARC BMmac-
rophages were ablated, the level of surface CD82 on LT-HSCs decreased, leading
to cell-cycle entry, proliferation, and differentiation. A similar interaction ap-
pears to be relevant for human HSPCs. Thus, CD82 is a functional surface
marker of LT-HSCs thatmaintains quiescence through interactionwithDARC-
expressingmacrophages in the BM stem cell niche. Finally, we hope that further
development of our study will allow us to improve leukemia treatment by awak-
ening not only “good” stem cells to keep benefıcial stem cell functions, but also
“bad” stem cells (e.g. cancer stem cells) in order to increase the sensitivity to
treatment and avoid relapse.
#918 Cdc42 is crucial for intestinal stem cells survival by regulating Wnt
and YAP signaling. Xiao Zhang,1 Nan Gao2. 1Rutgers Newark, Harrison, NJ;
2Nan Gao, Harrison, NJ.
Strictly defıned architectureof intestinal epithelial cells and the gradient of signal-
ing cues along the villus-crypt axis ensure the maintenance of adult intestinal stem
cells, as well as proper regeneration and differentiation of all intestinal epithelial cell
types. The Rho family small GTPase Cdc42 controls the polarized division of intes-
tinal stemcells, and affects subsequent fate-determinationof theprogenitor cells.As
we previously described in Cdc42 Villin-Cre knockout mice, loss of Paneth cells
from crypt bottom and emergence of Goblet cell-like intermediate cells at the villus
indicate possible compromise of the canonical Wnt signaling during Paneth cell
differentiation.Herewe further characterized theunderlyingmolecularmechanism
of Cdc42 regulating intestinal stem cell survival, proliferation, and differentiation.
IHC of the intestinal tissue in Cdc42 Villin-Cre knockout mice suggests greatly
reducedOlfm4 level in the stemcells,whichare abnormallypositioned in the crypts,
along with a reduction of both transcription co-factors beta-Catenin and YAP.
However, the Notch signaling, which is required for stem cells and the differentia-
tionof absorptive linage, seems intact. The autonomous regulationofCdc42onYap
signaling is probably through its specifıc role in stabilizing cell-cell junction and
actin fılaments in the epithelium, both of which are known regulatory inputs of the
Hippo-YAP pathway. Both Wnt/beta-Catenin and Yap signaling are required for
the initiationandprogressionof colorectal cancer, and the regenerationof stemcells
post radiation. Given that Cdc42 is overexpressed in multiple types of cancers, es-
pecially colorectal cancer, our fınding that Cdc42 regulates both Wnt and YAP
pathways in the homeostasis of adult intestinal tissue sheds new light on themolec-
ular mechanism of its pathological involvement, and potential therapeutic target.
#919 Identifıcation of stem cells in stomach corpus and antrum. Junichi
Matsuo, Akihiro Yamamura, Khay Guan Yeoh, Motomi Osato, Yoshiaki Ito.
National University of Singapore, Singapore, Singapore.
Gastric cancer is still relatively poorly understood, because of the lack of
knowledge on stem cells in stomach. By radio-labeling experiments and electron
microscopy, rapidly proliferating stem cells have been suggested in isthmus of
both corpus (which is just below pit cell zone) and antrum (which is a quarter
above the base) (1). In addition, there have been reports indicating the prolifer-
ation capacity under certain conditions in a subset of chief cells present at the
base in corpus (2). We reported earlier that 270 bp Runx1 enhancer element
(termed aR1) that drives the expression ofRunx1 inhematopoietic stemcells (3).
We found that eR1 alsomarks the cells in these three locations of stomach (4). In
antrum, the stem cell marker, Lgr5, has been reported to mark the cells at the
base of antrum but not in corpus (5). eR1 and Lgr5 stem cell in antrum
appears to be different. It will be interesting to fınd out the difference between
these two types of stem cells. Transgenic mouse was generated that harbors eR1
linked to heterologous promoter and Cre recombinase (eR1-CreERT2). By
treating themousewith tamoxifen, we showed lineage tracing fromeR1 cells in
the isthmus of both corpus and antrum that replenish entire glands. We ex-
pressed K-rasG12D in eR1 cells in isthmus and observed antralization of corpus
epithelium that is similar to precancerous lesion in human stomach after H
pylori infection. On the other hand, eR1 chief cells rarely multiply. However,
they robustly proliferate after tissue damage or oncogene expression. When
K-rasG12D is activated in eR1 chief cells, they show retrodifferentiation to show
SPEM (spasmolytic polypeptide expressing metaplasia) phenotype. eR1 chief
cells appear to be reserve stem cells that can replace cells after tissue damage.We
now have capability to activate or inactivate genes of interest in the stomach
stem cells. We are examining stepwise carcinogenesis in stomach. From eR1
cells in isthmus of both corpus and antrum, we are generating organoids. We
will describe interesting difference in the properties of organoids generated from
eR1 cells from corpus and those from antrum. Reference(1) Karam and
Leblond., The Anatomical Record 1993; 236: 259-273. (2) Goldenring et al.,
Gastroenterology 2011; 138: 2207-2210. (3) Ng et al., Stem Cells 2010; 28: 1869-
81. (4) Matsuo et al., Gastroenterology 2016; PMID: 27670082. (5) Barker et al.,
Cell Stem Cell 2010; 6: 25-36.
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#920 ICAM-1(CD54) is involved in the osteogenic differentiation of mes-
enchymal stem cells and affects the progression of osteosarcoma cells. Yidan
Zhang,1 Sajida Piperdi,1 Nikolas Zaphiros,1 Pratistha Koirala,1 Tingting Ren,2
Michael Roth,1 Jonathan Gill,1 Bang Hoang,1 David Geller,1 Rui Yang,1 Wen-
dong Zhang,1 Xiuquan Du,1 Jinghang Zhang,1 Richard Gorlick1. 1Montefıore
Medical Center, Albert Einstein College of Medicine, Bronx, NY; 2Peking Univer-
sity People’s Hospital, Beijing, China.
Purpose: The aim of this study is to validate the relationship between the
expression of ICAM-1(CD54), a cell surface glycoprotein, and osteogenic dif-
ferentiation of mesenchymal stem cells (MSCs) and the role of ICAM-1 in the
progression of osteosarcoma (OS) cells. Experimental Design: To compare the
gene expression profıles betweenMSCs andMSCs after osteogenic induction, a
microarray analysiswas fırst performed. The differences in expression of specifıc
genes including ICAM-1were confırmedusingwestern blot and flow cytometry.
MSCs were sorted into two groups of cells by CD105CD44CD54 and
CD105C44CD54- and properties of these cells were compared. Expression
of ICAM-1 among tumor cell lines and xenograft OS cells were tested at the
protein level. ICAM-1 was stably, constitutively overexpressed in multiple cell
types. Differences in osteogenic differentiation potential between normal cell
lines and transformed cell lines were studied using alizarin red S staining. Mo-
tility, proliferation and invasion as well as the metastatic potential of the trans-
formed and normal cells were evaluated. Results: The initial microarray analysis
revealed that ICAM-1 expression was signifıcantly increased in MSCs after os-
teogenic induction for 15 days (p0.042). Consistent results were achieved in
western blot and flow cytometry analysis. Further microarray analysis between
CD105CD44CD54 and CD105C44CD54- groups determined that
NF-kB signaling pathwaywas differentially activated. As forOS cells, ICAM-1 is
not expressed at high level among OS tumor cell lines and is inconsistently
expressed in xenograft OS cells. Enhanced osteogenic differentiation potential
was observed in ICAM-1 overexpressing cells. Although there were no major
difference in in vitro motility, proliferation or invasion tests, substantially less
lung nodules occurred with transformation as compared to the normal control.
Conclusions: ICAM-1 is involved in the osteogenic differentiation ofmesenchy-
mal stem cells and its down regulation may be involved in the progression of
osteosarcoma cells.
#921 Cdyl2 is a chromodomain protein involved in the maintenance of
pluripotency of stem cells. Naoko Hattori,1 Kana Kimura,1 Jumpei Taguchi,2
Toshio Imai,1 Yasuhiro Yamada,2 Toshikazu Ushijima1. 1National Cancer Cen-
ter Research Institute, Tokyo, Japan; 2Kyoto University, Kyoto, Japan.
Reader proteins of histone modifıcations are required to translate the infor-
mation of histone marks into the cellular phenotypes, including pluripotency
and malignancy. For example, a reader protein BRD4 has its target specifıcity
and becomes a target of cancer therapy. Here, we aimed to identify reader pro-
teins involved in the pluripotency of stem cells. Using the UCSC database, 11
genes coding chromo- or PHD-domain proteins were isolated as actively tran-
scribed in mouse ES cells (ESCs). Among the 11 genes, Cdyl2, chromodomain
proteinY-like2, was found to be down-regulated uponESCdifferentiation using
RT-qPCR. Immunofluorescence and ChIP assay revealed that Cdyl2 recognized
H3K27me3 of the specifıc regions, including differentiation-associated genes.
Cdyl2-knock-out ESCs could not survive after differentiation induced by LIF
removal or retinoic acid because of the induction of apoptosis, indicating that
Cdyl2 is important for normal differentiation of ESCs. ESC expressing exoge-
nous Cdyl2 showed incomplete down-regulation of Oct-4 and Nanog by reti-
noic acid, and generated teratomaswith an abnormal composition of three germ
layers, showing perturbation of differentiation ability. Pathologically, aberrant
expression of human CDYL2 was observed in breast cancer cell lines and pri-
mary breast cancers. Two breast cancer cell lines (MDA-MB-231 and MDA-
MB-468) expressing exogenous CDYL2 showed enhanced attachment ability
along with the up-regulation of integrin alpha-6 and integrin beta-1. The pop-
ulation of cancer stem cells, defıned as ALDH positive cells, were increased in
CDYL2-expressing MDA-MB-468 cells, showing that human CDYL2 is in-
volved in proliferation of cancer stem cells. From these data, we conclude that,
between self-renewal and differentiation of stem cells,mouse and humanCdyl2/
CDYL2 is necessary for the implementation of the initial step of differentiation.
#922 Delta133p53 represses p53-inducible senescence genes and enhances
the generation of human induced pluripotent stem cells. Izumi Horikawa,1
Kye-yoon Park,2 Han Li,3 Kazunobu Isogaya,1 Yukiharu Hiyoshi,1 Katsuhiro
Anami,1 Ana I. Robles,1 Abdul M. Mondal,1 Kaori Fujita,1 Manuel Serrano,3
Curtis C. Harris1. 1National Cancer Inst., Bethesda, MD; 2NIH, Bethesda, MD;
3Spanish National Cancer Research Center, Madrid, Spain.
p53 functions to induce cellular senescence and apoptosis, which can be in-
compatible with self-renewal of pluripotent stem cells such as induced pluripo-
tent stem cells (iPSC) and embryonic stem cells (ESC). On the other hand, p53
regulates DNA damage response and repair and thus plays an essential role in
maintaining genomic integrity and suppressing malignant transformation in
iPSC and ESC. It remains to be elucidated whether and how p53 and its regula-
tors contribute to balanced regulation between the self-renewing capacity and
the genomic and functional integrity in these pluripotent stem cells.We hypoth-
esized the involvement of 	133p53, a physiological p53 protein isoform that
inhibits the activity of full-length p53 (FL-p53), and here examined 12 lines of
human iPSC and their original fıbroblasts, as well as 3 human ESC lines, for
endogenous protein levels of 	133p53 and FL-p53, and mRNA levels of p53
target genes of different functions. While FL-p53 levels in iPSC and ESC widely
ranged from below to above those in the fıbroblasts, all iPSC and ESC lines
expressed elevated levels of 	133p53. The p53-inducible genes that mediate
cellular senescence (e.g., p21WAF1 andmiR-34a), but not those for apoptosis and
DNA repair, were downregulated in iPSC and ESC. Consistent with these en-
dogenous expression profıles, overexpression of 	133p53 in human fıbroblasts
preferentially repressed the p53-inducible senescence mediators and signifı-
cantly enhanced their reprogramming to iPSC. The iPSC clones derived from
	133p53-overexpressing fıbroblasts, when injected into immunodefıcientmice,
formed well-differentiated, benign teratomas, suggesting that 	133p53 overex-
pression is non- or less oncogenic than total inhibition of p53 activities. Over-
expressed	133p53 prevented FL-p53 from binding to the regulatory regions of
p21WAF1 and miR-34a, providing a mechanistic basis for its dominant-negative
inhibition. This study supports the hypothesis that upregulation of 	133p53 is
an endogenous mechanism that facilitates human somatic cells to become plu-
ripotent without malignant transformation.
#923 Human embryonic stem cells exhibit altruistic cell death that release
death signals having potent anti-cancer activity.Bidisha Pal,1 Seema Bhuyan,2
Jaishree Garhyan,1 Herman Yeger,3 Bikul Das1. 1The Forsyth Institute, Cam-
bridge, MA; 2KaviKrishna Laboratory, Indian Institute of Technology (IIT), Gu-
wahati, India; 3Hospital for Sick Childern, Toronto, Ontario, Canada.
Background: We recently described the altruistic stem cell (ASC) phenotype
in human embryonic stem cells (hESCs) as well as inmesenchymal stem cells (1,
2). The ASC phenotype was characterized by altered state of p53/MDM2 feed-
back system that permitted the cells to transiently acquire an unstable state of
low p53 allowing the cells to survive in extrememicroenvironment (1). Interest-
ingly, we noted that ASCs spontaneously returned to its basal state of high p53
after a period of two weeks (1, 2). In this study, we speculate that this return of
p53 levels to basal state could be a safetymechanism to preventmalignant trans-
formation of ASCs.We also speculate that ASCs may release soluble factors like
high mobility group protein B1 (HMGB-1) that could selectively target the cells
exhibiting abnormal p53 e.g. cancer cells. Here, we further characterized ASC
phenotype and its fate. Methods: hESC, BG01 cells were exposed to extreme
hypoxia followed by reoxygenation and then ABCG2/SSEA3 cells were flow
cytometry sorted. This specifıc subpopulation is enriched in ASCs and could be
cultured in vitro for two weeks (1). The post- hypoxia treated ABCG2/
SSEA3 cells were maintained in serum free media, and subjected to apoptosis,
and senescence assays. The conditionedmedia (CM) of these cells and subjected
to HMGB-1 measurement by ELISA. To measure bystander apoptosis, terato-
carcinoma cells (Tera-2) were treated with the CM followed bymeasurement of
apoptosis. Results: Here we confırmed that p53 and MDM2 in ABCG2/
SSEA3 cells exhibited return of oscillation between days 19-24. This was asso-
ciated increase in apoptosis, and senescence of these cells. Apoptosis/senescence
was decreased when treated with either Pifıthrin , an inhibitor of p53, or by
siRNA silencing of p53, suggesting p53-dependent apoptosis. Additionally,
treatment with Nutlin-3, an inhibitor of MDM2 (1) led to a 10-fold increase in
apoptosis indicating that high MDM2 was required to prevent the apoptosis of
ASCs. Thus, ASCs underwent spontaneous apoptosis (altruistic cell death) due
to the return of p53/MDMD2 oscillation.We suggest that this return of p53 and
associated apoptosis could be a safety mechanism to prevent malignant trans-
formation of ASCs. Next, we found that the CM of ABCG2/SSEA3 cells
contained high levels of HMGB-1 compared to the parental BG01 cells. Impor-
tantly, CM treatment led to p53 dependent apoptosis of Tera-2 cells. Further-
more, CM treatment also inhibited the growth of Tera-2 xenografts in NOD/
SCIDmice. Conclusion: Our results indicate that ASCs undergoes altruistic cell
death, and releases death signal mediated by HMGB1 that can target neighbor-
ing cells exhibiting abnormal p53 including cancer cells. We suggest that this
unique property of ASCs could be exploited as a novel cancer therapeutic. 1. Das
B et al, Stem Cells, 2012; 30(8):1685-95. 2. Pal B et al, Cancer Research, 2016;
Volume 76, Issue 14 Supplement, pp. 251.
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#924 Dedifferentiation into polyploid blastomere-like cancer stem cells
via formation of polyploid giant cancer cells. Na Niu, Jinsong Liu. UT MD
Anderson Cancer Ctr., Houston, TX.
Wehave recently shown that polyploid giant cancer cells (PGCCs) are capable
of tumor initiation and acquisition of embryonic-like stemness and thus repre-
sent a novel type of cancer stem cells. However, two important questions remain
to be answered from this surprising fınding: (1) how PGCCs acquire such stem-
ness; (2) onwhich stage of normal development PGCCs correspond to. Here, we
tracked the fate of single PGCCs induced via mitotic failure by paclitaxel. Mor-
phologically, early spheroids derived from PGCCs were indistinguishable from
human embryos at the polyploid blastomere, compaction, morula, and blasto-
cyst-like stages by scanning electron microscopy. PGCCs showed time- and
space-dependent activation of expression of the embryonic stem cell markers
OCT4, NANOG, SOX2, and SSEA-1 and lacked expression of Xist. PGCCs also
showed time-dependent activation of expression of the germ layer-specifıc
markers alpha-fetoprotein, smooth muscle actin, and 3-tubulin and were ca-
pable of redifferentiation into three germ layers in vitro. PGCCs-derived daugh-
ter cells showed attenuated invasive ability and increased resistance to paclitaxel.
PGCCs-derived spheroids grew into a wide spectrum of human neoplasms,
includingmalignant dysgerminoma and embryonic carcinoma, poorly differen-
tiated or well-differentiated carcinomas, and benign squamous tissue. We also
observed PGCCs in ovarian cancer from patients treated with chemotherapy.
Thus, our data demonstrated that PGCCs acquired novel cancer stem cell prop-
erties and capability to redifferentiate into different tumors including the germ
cell tumors, which are at the topmost developmental hierarchy. Our studies, for
the fırst time, link PGCCs to the polyploid blastomere-like cancer stem cells and
thus offer a new paradigm for the origin of cancer.
#925 Tumorigenesis ofmurine iPS cell is prevented by iron depletionwith
downregulation of stemnessmarkers.YukiKatsura,1 ToshiakiOhara,1Hajime
Kashima,1Hiroaki Sato,1 TakuyaKato,1 TakayukiNinomiya,1KazuhiroNoma,1
Yasuko Tomono,2 Hiroshi Tazawa,1 Shunsuke Kagawa,1 Yasuhiro Shirakawa,1
Toshiyoshi Fujiwara1. 1Okayama Univ., Okayama, Japan; 2Shigei Medical Re-
search Institute, Okayama, Japan.
Background: Iron plays a crucial role in the variousmetabolic pathways and it
is essential for life. However excess of iron is known to cause cancer. There are
many reports that iron depletion treatment indicates antitumor effect. Previ-
ously, we have confırmed that iron depletion treatment indicates antitumor
effect against Cancer stem cell (CSC) model, miPS-LLCcm, which was con-
verted from murine induced pluripotent stem cell (miPS cell) in Okayama uni-
versity (Chen at el. PLOS ONE 2012), and also suppresses CSC markers. Many
tumors contain phenotypically and functionally heterogenous cancer cells due
to pluripotency of CSC. Although there are various theories about the origin of
CSC, miPS has a pluripotency and regarded as the top of the hierarchy, it can be
the candidate of the origin of CSC. miPS cell is known to form teratoma when
inoculated into nude mouse because of its undifferentiated status. We hypoth-
esized if we could suppress the stemness and tumorigenicity of miPS cell by iron
depletion treatment, it can be applied to the therapy for CSC and undifferenti-
ated status cancer cell. In this study, we investigated the stemness and tumori-
genecity of miPS cell with iron depletion treatment. Methods: We used miPS
cell(cell name : iPS-MEF-Ng-20D-17) purchased from Riken Cell Bank(Japan).
Deferasirox (DFX), an popular commercial available oral iron chelator was used
for iron depletion treatment. Western blot analysis was done to examine the
expression of the stemnessmarkers includingNanog,Oct3/4, Sox2, Klf4, c-Myc.
Subcutaneous model of miPS cell and miPS cell treated with DFX (50M) were
used in vivo study. Tumors were harvested for immunohistochemistry. Results:
Stemnessmarkers of miPS cell were suppressed strongly by DFX in western blot
analysis. DFX also suppressed the subcutaneous tumor growth. The average
tumor volume of the control group was 665.3430.8mm3 while that of the DFX
treated groupwas 204.376.2mm3(p0.05) on day 20. Immunohistochemistry
of the tumor revealed the suppression of the stemness markers in the DFX
treated group compared with the control group.
#926 Generationof a potential breast cancer stemcellmodel from induced
pluripotent stem cells. Neha Nair,1 Anna Sanchez Calle,1 Maram Hussein
Zahra,2 Aung Ko Ko Oo,1 Arun Vaidyanath,1 Tomonari Kasai,1 Shinobu
Masuda,3 Masaharu Seno1. 1Okayama University, Okayama, Japan; 2Menoufıa
University, Shebin El-Koam, Egypt; 3NihonUniversity School ofMedicine, Tokyo,
Japan.
The role of cancer stem cells (CSC) in the present scenario of breast cancer
research is perceived as indispensable in the development and progression of the
disease. The CSC niche maintains a heirarchy of heterogeneous cells, which
facilitates the inception of the tumor until its invasion. Therefore, our study
focuses on the development of an effective breast cancer stem cell model from
mouse induced pluripotent stem cells (miPSCs). Taking into consideration the
intertumor heterogeneity of breast cancer, three human breast cancer cell lines,
namely BT549, SKBR3 and T47D representing three major hormone subtypes
were used to derive respective conditioned medium. The miPSCs were treated
with these conditionedmedia separately for a period of onemonth following the
protocol previously established by our laboratory. The resulting survived cells
were subcutaneously and orthotopically transplanted into Balb/c nude mice.
Within a short span of 15-20 days, both subcutaneous and orthotopic tumors
were developed. Serial transplantations in to nude mice also generated malig-
nant tumors with same vigor. Histopathological studies of these tumors con-
fırmed a malignant infıltrating ductal carcinoma with apparent desmoplasia in
orthotopic tumor and Her2 expression in comparison with subcutaneous ones,
all of which confırmed us the conversion of miPSCs to CSCs. Presence of lung
metastatic nodes further ascertained the invasiveness of this in vitro generated
CSCs. Marked expression of prominent CSC markers namely CD44, Nanog,
Sox2 and CD49f were observed in primary cells generated from these tumors.
Tumor sphere formation assay further confırmed the presence of a good popu-
lation of self renewing CSC population in the tumor tissues. This study attempts
to recapitulate human breast cancer disease in mice without any genetic manip-
ulation, but by exploiting the tumor microenvironment in the form of condi-
tioned medium. This should pave the way for the establishment of personalized
therapy and a model to assess effective therapeutic interventions.
#927 Cancer stem cell proliferation in human prostate cancer cells utiliz-
ing a new defıned 3D spheroid culture system. Nick Asbrock, Vi Chu, Kan
Saito.MilliporeSigma, Temecula, CA.
Solid tumors grow in a three-dimensional (3D) spatial conformation, result-
ing in a heterogeneous exposure to oxygen and nutrients as well as to other
physical and chemical stresses. To mimic the 3D spatial conformation, 3D in
vitro culture models have been used in cancer research since the diffusion-
limited distribution of oxygen (hypoxia), nutrients, metabolites, and signaling
molecules is not mimicked in conventional two-dimensional (2D) monolayer
cultures. One of the 3D in vitro culture models, the tumorsphere culture is an
emerging model for studying and expanding the cancer stem cell (CSC) popu-
lation. E006AA cell line is a spontaneously immortalized cell line derived from a
Gleason 6 localized prostate cancer in a hormone-naive prostate cancer patient
of AfricanAmerican descent. This cell line expresses androgen receptor andwas
repeatedly reported to be non-tumorigenic in nude mice. However this cell line
forms continuously growing tumor in NOG-SCID triple-defıcient mice (i.e.,
NOG-SCIDmice not having NK, B, and T-cells) and an establishment of highly
tumorgenic subline E006AA-hT was reported suggesting this cell line has a
potential for CSC proliferation by 3D sphere cultures. Here we report tumors-
phere cultures of E006AA cells by a new 3D spheroid culture media system. The
cells showed continuous proliferation supported during serial passage of 3D
tumorsphere cultures. In addition to the stable proliferation, increases of Alde-
hyde Dehydrogenase (ALDH) expressing CSC population were observed with
the increase of passages of 3D tumorsphere cultures.
#928 Combined treatment by manuka honey and metformin inhibited
growth and inducted apoptosis in CD133and CD90 subpopulation hepa-
tocellular carcinoma cancer stem cells. Amira S. Fyala, Ahmed S. Sultan. Fac-
ulty of Science, Alexandria University, Alexandria, Egypt.
Manuka honey is well known for its anti-bacterial and wound healing prop-
erties but its anticancer role against cancer stem cells (CSC) in hepatocellular
carcinoma (HCC) cell lines and the underlying molecular mechanisms remain
uninvestigated. Recently, we identifıed a CSC subpopulation in HCC cell lines
characterized by their CD133 and CD90 phenotype. The CD133/
CD90cells demonstrated a more aggressive phenotype than the CD133-/
CD90- counterpart and formed metastatic lesions in the lung of immunodefı-
cientmice. In order to evaluate the effect ofManuka honey alone or in combined
treatment withMetformin, a biguanide that has been widely used to treat type 2
diabetes, on cell viability and apoptosis induction in human HCC cell lines,
isolated and identifıed CD133/ CD90subpopulation CSC were used. Cell vi-
ability wasmonitored using anMTT assay. In addition, apoptosis inductionwas
labeled by Annexin Vfluorescein isothiocyanate/propidium iodide and mea-
sured using flow cytometry. Western blotting was used to examine the protein
expression of p53, Bcl2, Bax, Bcl2associated death promoter (Bad), Bcl2 homol-
ogous antagonist/killer (Bak) and cleavedcaspases3 and 9. The results of the
present study revealed thatManuka honey alone or in combined treatment with
Metformin suppressed the cell viability of CD133/CD90cells in a concentra-
tiondependent manner and the maximum effect was detected in combined
treatment after 24 h. In addition,Manuka honey alone or in combined treatment
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withMetformin induced a signifıcant apoptosis in the tested cells. Furthermore,
it was demonstrated that combined treatment increased the expression of pro-
apoptotic proteins, including p53, Bax, Bad and Bak, while it decreased the
protein level of antiapoptotic protein Bcl2 compared to control, Manuka honey
or Metformin alone. Furthermore, the combined treatment strongly inhibited
stemness characteristics of CSC subpopulation, colony formation and dramati-
cally inhibited CD133/CD90tumor growth in vivo. Our data demonstrated
that combined treatment induced apoptosis in CD133/CD90 subpopulation
through G1 arrest in the cell-cycle and regulating p53/Bcl2/caspase3 signaling
pathway. In conclusion, our results suggested thatMonuka honey alone or com-
bined treatment with Metformin may be a potential treatment for apoptosis
induction in CSC and may provide a novel therapeutic model for HCC.
#929 Dissecting heterogeneity and population dynamics in breast cancer
stem cells.Michael D. Brooks, Max S. Wicha. University of Michigan, Ann Ar-
bor, MI.
The CSC hypothesis posits that there is a subset of tumors cells driving tumor
growth andmetastasis and that by targeting this population, tumors can bemore
effıciently eradicated. Recently it was shown that there are two types of CSCs in
breast cancer, mesenchymal CSC’s characterized as CD44/CD24- and an ep-
ithelial type marked by ALDH expression. The cellular plasticity of these CSC
statesmay contribute to theirmetastatic capacity.However, little is known about
the heterogeneity of these CSC populations or how they are regulated by the
tumormicroenvironment. To address these issues we have utilized Drop-Seq to
generate single cell RNA-Seq data from thousands of cells across patient derived
xenografts from various molecular subtypes of breast cancer. In order to moni-
tor real-time state transitions between the determined cellular populations, we
have also designed and constructed fluorescent reporter constructs for genes
specifıc to critical cell populations and cancer stem cells.We used CRISPR/Cas9
to introduce these reporters into the native loci of the genes in order to recapit-
ulate native gene expression patterns. Single cell transcriptomics will help to
characterize the molecular heterogeneity of CSC populations. The addition of
fluorescent reporters will help to elucidate the mechanisms that regulate breast
CSC’s as well as their interaction with the tumor microenvironment and to
identify potential therapeutic targets.
#930 Role of DLK1 in sarcoma stem cells. Ilkyu Han, Sun Hee Ahn, Han-
Soo Kim. Seoul National Univ. Hospital, Seoul, Republic of Korea.
Sarcoma is a rare form of cancer that comprises about 1% of all malignancies.
A large proportion of deaths by sarcomas are caused by tumor metastasis, of
which the biological basis remains obscure. A signifıcant body of evidence sug-
gests that only a small population of sarcoma cells possess the ability to initiate
andmaintain tumors. These tumor-initiating cells have the ability to self-renew,
recapitulating the cellular heterogeneity of the original cancer, and thus are often
referred as cancer stem like cells (CSLCs).Delta-like factor 1 (DLK1) was cloned
in the preadipocyte cells 3T3-L1 cDNA library. Previous studies reported on the
role of DLK1 in mesenchymal stem cell differentiation, adipogenesis, myogen-
esis, and osteoblastogenesis. It was reported that DLK1 liver cancer cells have
characteristics similar to those of CSLCs and that DLK1 could be a potential
therapeutic target against the liver CSLCs. However, little is known about role of
DLK1 in CSLCs of sarcoma. The mRNA (real time PCR) and protein (Western
blot) expression of DLK1 from 13 sarcoma cell lines was examined. CSLCs from
sarcoma cell lines were isolated using FACS with CD133 and sphere forming
assay. The effect of DLK1 on sarcoma tumorigenesis was examined using cell
proliferation and cell invasion assays by DLK1 siRNA treatment.Real-time PCR
showed the increased expression of DLK1 mRNA in sarcoma cell lines. In par-
ticular, DLK1 mRNA was highly expressed in U2OS (osteosarcoma), SW872
(liposarcoma), A204 (rhabdomyosarcoma), and HS-SYII (synovial sarcoma)
cells.We observed a reduction in cell proliferation and invasion in U2OS, A204,
and sw872 cells treated with DLK1 siRNA. CSLCs were isolated from U2OS,
A204, and sw872 by the FACS sortingmethod using the CD133, a CSLCmarker
in sarcoma. The number of active sarcoshperes in CD 133 cells were signifı-
cantly higher than that in CD133- cells by sphere forming assay. Soft agar assays
revealed the presence ofmanymore colonies inCD133 cells than inCD133- or
wild type cells. To investigate the effect of DLK1 on sarcoma CSLCs, sw872 cells
were categorized into four groups: wild type, CD133-, CD133 and spheres.
Real-time PCR and western blot were used to detect the DLK1 gene in all four
groups. We observed that DLK1 expression in sw872 CSLCs (CD133 and
spheres) were relatively low. We found that suppression of DLK1 by siRNA
inhibited the invasiveness of CSLCs although it inhibited more effectively to
activation of invasive cells as well as cell proliferation in sw872 non-
CSLCs.These results suggest that DLK1 may play a role in tumorigenesis of
CSLCs and cancer cells in various sarcomas.
#931 Extracellularmatrix stimuli regulate cancer stemcell population and
migratory potential in glioblastoma. Jee-wei E. Chen,1 JanC. Lumibao,1HRex
Gaskins,1 Jann N. Sarkaria,2 Brendan A. Harley1. 1University of Illinois at Urbana-
Champaign, Urbana, IL; 2Mayo Clinic, Rochester, MN.
Introduction Glioblastoma (GBM) is the most common and lethal form of
brain cancer. Poor survival is linked to diffuse infıltration throughout the brain,
suggesting the need to examine the effect of the tissue environment at the mar-
gins of the GBM tumor on processes of GBM invasion. Further, the presence of
GBM cancer stem cells (GSCs) in primary tumor specimens is believe to play a
signifıcant role inGBMspreading, recurrence, and therapeutic resistance.While
biophysical properties of the tumormicroenvironment, such as spatial gradients
inmatrix stiffness and hyaluronic acid (HA) content as well as regional hypoxia,
may affect GBM invasive phenotypes, limited tools are available to rigorously
examine the relationship between tissue microenvironment and tumor growth,
invasion, and therapeutic outcomes. This work focuses on the integration of
HA-functionalized gelatin hydrogels with 3D cell invasion assays to investigate
the impact of tissue microenvironment on GBM invasion and GSC population.
Methods Hydrogels are generated from methacrylamide functionalized gelatin
(GelMA) and methacrylated HA. Prepolymer mixture was crosslinked under
UV light in the presence of a photoinitiator. GBM cells, either U87 cell lines or
patient-derived xenografts (PDX), were mixed with prepolymer solution prior
to polymerization and collected for up to 7 days in culture. To assess invasion,
cells were seeded onto dextran beads overnight, with populational invasionmet-
rics calculated after 3 and 7 days, while live cell tracing via confocal microscopy
was employed for single cell invasion metrics. Samples were cultured with 5%
CO2 and20%O2 (normoxia) or 1%O2(hypoxia). Results The invasion of U87
and U87viii (constitutively active EGFR) cells increased signifıcantly in GelMA
hydrogels lacking HA, consistent with our previous fındings that compensatory
secretion of soluble HA in the absence of matrix-boundHAwas associated with
upregulated invasion. HeightenedU87 invasion was observed in the presence of
hypoxia for all hydrogel compositions, and was associated with upregualted
markers of invasion (gene expression: MMP-2, VEGF; protein expression:
ERK1/2) while PI3Kwas downregulated, suggesting cells respond to hypoxia by
alternating invasion andproliferation behaviors.We subsequently examined the
effect of matrix biophysical properties and hypoxia on the expansion of GSC
populations within PDX cells (a gift of Jann Sarkaria, Mayo Clinic). Here, the
expansion of the GSC population in EGFRviii mutant GBM6 was a function of
hypoxia as well as matrix-boundHA. Conclusions This work demonstrates that
GBM cells respond dynamically to their matrix biophysical (Stiffness, HA con-
tent, hypoxia) properties. Using PDX cells, we provide evidence that the expan-
sion of GSC is related with both metabolic environment (O2%) and matrix
composition (/- HA). Ongoing work seeks to understand how GSCs contrib-
ute to the invasive phenotype of GBM.
#932 Wnt antagonist, secreted frizzled-related protein 4 (SFRP4) and pep-
tides from its associated domains, increases chemotherapeutic response of can-
cer stem cells of malignant mesothelioma cell lines. Vanathi Perumal,1 Senthil
Kumar,2 Frank Arfuso,3 Simon Fox,1 Arunasalam Dharmarajan2. 1School of Phar-
macy, Curtin University, Perth, Australia; 2School of Biomedical Sciences, Curtin
University, Perth, Australia; 3Curtin University, Perth, Australia.
Malignant mesothelioma (MM) is a highly aggressive cancer associated
with past asbestos exposure that is characterized by rapid progression, late
metastases and poor prognosis. There is a need formuch improved and novel
therapies for this cancer through improved biological understanding of the
disease.Previous studies have shown that SFRPs in general and SFRP4 in
particular are down regulated in mesothelioma tissue and cell lines 1-4. Based
on our own study and previously demonstrated a role for sFRP4 in making
chemoresistant tumours amenable to chemotherapeutics 5-16. We have now
progressed our work into the effects of peptides derived from the cysteine-
rich domain and the netrin-like domain of sFRP4 on tumour initiating cells
derived from MM cell lines.We examined the effect of secreted frizzled-
related protein 4 (sFRP4), a Wnt signaling antagonist and its associated
peptides, in chemosensitizing the MM cell line ONE 58 and JU77 and MM
cancer stem cells (CSCs) enriched from these two cell lines to chemothera-
peutics.We found tumorspheres exposed to sFRP4 and peptides alone and in
combination with cisplatin induced cell death and decreased CD133 and
ALDH1 expression.We thus identifıed for the fırst time that sFRP4 and as-
sociated peptides could help to sensitise to chemotherapeutics and destroy
cancer stem cells of MM cell line, which would lead to effective treatment
regimen to combat malignant mesothelioma. Our initial in vitro data exem-
plify the ability of these peptides in diminishing the numbers of therapy-
resistant Tumor initiating cells (TICs). References: 1. Lee et al, 2004, Onco-
gene, 23(39), 6672-6676. 2. He et al, 2005 Cancer research, 65(3), 743-748. 3.
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Kohnoe et al 2010; Oncology reports, 24(2), 423 4. S.A. Fox et al., 2013
Biochem Biophys Res Commun. 2013 Oct 11;440(1):82-7 5. Perumal V et al.,
2015 Int J Biochem Cell Biol, Mar 21;64:91-96 6. Wolf V et al., FEBS Lett
1997. 385-9 7. Hsieh M, et al., Endocrinology 2003, 144:4597-4606 8. Drake
JM, et al., Apoptosis 2003, 8:389-397 9. Constantinou T, et al., J Mol Signal
2008, 3:10 10. White L, et al., Reprod Biomed Online 2009, 18:104-110 11.
Muley A et al., Am J Pathol 2010, 176: 1505-1516 12. Longman D,et al.,
Oncology Research 2012, 20: 1-6 13. Uttara S, et al., BMC Cell Biology
2012,13: 25 14. Warrier A, et al., Cancer Gene Therapy 2014, 21: 381-388 15.
Warrier S, et al., Oncology Research 2014 21: 9 16. Perumal V, et al, Exp Cell
Res. 2016 Feb 15;341(2):218-24.
#933 Bcl-xL overexpression promotes tumor aggressiveness.Maria Grazia
Tupone, Daniela Trisciuoglio, Marianna Desideri, Marta Di Martile, Chiara
Gabellini, Simonetta Buglioni, Laura De Salvo, Gabriele Alessandrini, Simona
D’Aguanno, Donatella Del Bufalo. Regina Elena National Cancer Institute,
Rome, Italy.
Bcl-xL is an antiapoptotic protein highly expressed in cancer and contributes to
tumor initiation andprogressionbypromoting cell survival. It also promotes tumor
angiogenesis and metastasis. By using M14 melanoma and ADF glioblastoma cell
lines and their derivative bcl-xL overexpressing clones, in the current study, we
investigated the role of bcl-xL in aggressive features ofmelanoma and glioblastoma
models.We found that in bothmodels, bcl-xL overexpression increased in vitro cell
migration and invasion and facilitated tumor cells to form de novo vasculogenic
structures. Furthermore, bcl-xL overexpressing cells exhibited signifıcantly higher
tumorsphere formation capacity, reflecting the self-renewal activity, and expressed
high levels of some stem cell markers, supporting the concept that bcl-xL plays
essential roles in themaintenanceof cancer stemcells phenotype. Forced expression
of bcl-xL in melanoma cells also increased vascular endothelial growth factor
(VEGF) and matrix metalloprotease-2 (MMP-2) expression, and the activation of
hypoxia-inducible factor 1 (HIF-1), a key pathway involved inmelanoma vascular-
ization and aggressiveness. On the contrary, no differences were observed after
bcl-xL overexpression in glioblastoma model, in terms of HIF-1 expression and
activity, and VEGF protein secretion. Immunohistochemical analysis revealed that
the expression of the vascularmarkers, and the vasculogenicmimicrywere upregu-
lated in the bcl-xL overexpressing xenografts derived from both tumor histotypes.
The work presented here brings further support to the understanding of themalig-
nant actions of bcl-xL both inmelanoma and glioblastoma, and in particular to the
concept that bcl-xL contributes to the aggressiveness of these two tumor histotypes
bypromoting invasion,migration, vasculogenicmimicry andcancer stemcells phe-
notype. It also indicates a cell type-specifıc effect of bcl-xL onHIF-1/VEGF axis.
#934 EGFR induces ILF3 andG9a expressions tomaintainOct4-mediated
stemness property in lung cancer. Chun-Chia Cheng,1 Jungshan Chang,2
Huan-Chau Lin,1 Ai-ShengHo,3 Ken-Hong Lim,1 Chun-ChaoChang,4 Yi-Fang
Chang,1 Cheng-Wen Wu5. 1Mackay Memorial Hospital, New Taipei City, Tai-
wan; 2Taipei Medical University, Taipei, Taiwan; 3Cheng Hsin General Hospital,
Taipei, Taiwan; 4Taipei Medical University Hospital, Taipei, Taiwan; 5National
Yang-Ming University, Taipei, Taiwan.
Cancer stem cells survive and lead to tumor recurrence in tumor therapeutic
treatments. Lung cancer cells highly express epidermal growth factor receptor
(EGFR), which is critical for tumor progression. We hypothesized that EGFR
may play a pivotal role in the induction of cancer stemness cells (CSCs). The aim
of this study attempted to investigate the molecular mechanism of EGFR-medi-
ated cancer stemness, and to discover the potent therapeutic agents. A high
expression level of cancer stemness markers, ALDH1, CD133, Oct4, and Nanog
was observed in tumorspheres derived from HCC827. External EGF further
elevated the expression of Oct4 in HCC827 cells. Moreover, chemical inhibition
and genetic knockdown of EGFR reduced the Oct4 expression and also tumor-
sphere formation. We found that inhibitors targeting to EGFR (afatinib), ILF3
(YM155), andG9a (UNC0642) are potential to reduce the formations of tumor-
spheres. The results revealed that EGFR triggered the formation of tumors-
pheres through elevating the activations of G9a-mediated stemness genes. In
addition, YM155 effectively inhibited tumor growth and formation of tumors-
pheres as an anti-lung cancer agent blocking the EGFR-G9a cell initiating pro-
gram pathway. This study demonstrated that EGFR participated in maintain of
cancer stemness property through expressing ILF3 andG9a expressions. YM155
inhibited the EGFR-G9a stemness pathway, and reduced the formation of tu-
morspheres as a potent anti-lung cancer agent.
#935 CD133 cancer stem cells promoted by VEGF accelerate the recur-
rence of hepatocellular carcinoma. Dexi Chen,1 Kai Liu,1 Meijun Hao,1 Yabo
Ouyang,1 Jiasheng Zheng,1 Kishore Babu. Challagundla2. 1Beijing You An Hos-
pital, Capital Medical University, Beijing Institute of Hepatology, Beijing, China;
2Children’s Center for Cancer and Blood Diseases and The Saban Research Insti-
tute, CA.
The function of cancer stem cells (CSCs) on inducing HCC recurrence after
radiofrequency ablation (RFA) is still unclear. Here, 19 RFA-treated primary
HCC patients were enrolled.We identifıed a dramatic increase of plasma VEGF
in some patients (termed type II, n9) after RFA, who suffered early HCC
recurrence; the other patients (termed type I, n10) had no increased plasma
VEGF but had longer interval for HCC recurrence. Moreover, the expression of
CSCs marker, CD133, was dramatically increased in recurrent HCC tissue of
Type II in comparison with type I, suggesting induction of CD133 CSCs may
contribute to early HCC recurrence. In vitro studies demonstrated that VEGF
stimulus enhanced the level of CD133 CSCs and their self-renewal ability by
inducing Nanog dependently on activation of VEGFR2. In vivo studies further
demonstrated that CD133CSCswithVEGF stimulus formed larger tumor size
in comparison with non-stimulus; and VEGF stimulus increased the tumori-
genic cell frequency of primaryHCCcells dependently on the presence ofNanog
and VEGFR2. In recurrent HCC tissue of type II, but not type I, almost all
CD133 cells were Nanog and p-VEGFR2 positive cells, suggesting that activa-
tion VEGFR2 is critical for RFA-induced tumor stemness in HCC. Taken to-
gether, RFA-induced VEGF promotes tumor stemness and accelerates tumori-
genesis in HCC dependently on Nanog and VEGFR2, which is valuable for the
prediction ofHCC recurrence after RFAanddevelopment of novel therapeutics.
#936 Single cell analysis reveals cancer stem cell heterogeneities in hepa-
tocellular carcinoma. Hongping Zheng, Yotsawat Pomyen, Maria Hernandez,
Caiyi Li, Ferenc Livak, Tim Greten, Anuradha Budhu, Xin Wang. NIH,
Bethesda, MD.
Tumor heterogeneity represents a major obstacle to effective cancer treat-
ment and personalized medicine. Hepatocellular carcinoma (HCC) is clinically
and biologically heterogeneous, which is partly attributed to the presence of
hepatic cancer stem cells (CSCs). CSC surface makers can have overlapping
expression or exclusive expression of different subpopulations of hepatic CSCs,
and these cells may contain different oncogenic changes. The existence of vari-
ousCSC surface-marked subpopulationsmight pose a problem forCSC targeted
therapeutics. Little is known aboutwhether there are shared or distinct pathways
in different subpopulations. Moreover, it remains unknown whether heteroge-
neity exists within certain subpopulations. Thus, we propose to profıle the global
transcriptome of surface-marked CSCs (EpCAM, CD133 and CD24) at
the single-cell level using index flow cytometric sorting and single-cell RNA
sequencing technology.We statistically comparedmRNA transcriptomes of in-
dividual single cells of triple positive (EpCAM/ CD133 /CD24) CSCs and
triple negative (EpCAM-/ CD133- /CD24-) cells. Further, we compared the
triple positive and the triple negative cells at the single cell level in terms of their
self-renew capability in both normoxic and hypoxic conditions. Our results
show that at the single cell level, the transcriptomic profıles show a high-degree
of heterogeneity in HCC cell lines, meanwhile, there is a dramatic difference
between triple positive and triple negative cells in their transcriptomic profıles.
There is a high-degree of intra-tumor and inter-tumor heterogeneity observed
in single cell transcriptomes of HCC patients’ samples. Triple positive CSC
single cells show continuous rather than discrete stemness-related gene expres-
sion patterns. In parallel, the self-renewal capability of triple positive cells also
exhibits heterogeneity, while triple negative cells show little self-renewal capa-
bility. Thus, our single cell analysis study reveals molecular and biological het-
erogeneity of cancer stem cells in HCC, which may provide insight into the
underlying mechanisms of how CSCs contribute to tumor heterogeneity and
underscore key pathways and novel targets for hepatic CSC therapy.
#937 Plasticity in heterogenous cancer stem cells promotes glioblastoma
radioresistance. Mutsuko Minata,1 Alessandra Audia,2 Junfeng Shi,3 Songjian
Lu,4 Marat Pavlyukov,1 Yancey Gillespie Gillespie,1 Krishna Bhat,2 Ichiro Na-
kano1. 1University of Alabamaat Birmingham, Birmingham,AL; 2TheUniversity
of Texas, M.D. Anderson Cancer Center, Houston, TX; 3The Ohio State Univer-
sity, Columbus, OH; 4University of Pittsburgh School ofMedicine, Pittsburgh, PA.
Some cancers includingGlioblastoma (GBM)have hierarchical cellular archi-
tecture with cancer stem cells (CSCs) as a minor tumorigenic subpopulation.
While CSCs have been touted to contribute to initiate recurrence, post-surgical
therapy-induced phenotypic changes in CSCs remain elusive. Here we report
that treatment of GBM cells with ionizing radiation (IR) promotes a wound-
healing mesenchymal signature, accompanied by conversion of naïve CSCs ex-
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pressing CD133 to post-treatment more radioresistant CSCs expressing the
GPI-anchored, TGFb-inhibitory protein CD109 in an ATM, NF-kB, CEBP-b
dependent manner. In post-IR GBM, these therapy-escaped CD133-/CD109
GBM cells, but not the rest of the tumor, uniquely retain clonogenic, tumori-
genic, and multi-potent capacities both in vitro and in vivo. CD109 silencing
unexpectedly eliminates cancer stemness via controllingYAP/TAZas the down-
stream target and this CD109-YAP/TAZ signaling axis is evolutionally con-
served between drosophila and human brain tumors. Clinically, both CD133
and CD109 are independently associated with poorer prognosis of GBM pa-
tients, while the poorest prognosis group of GBM expressed both CD133 and
CD109 at higher rates. These data indicate a possibility of the post-IR CSC
plasticity and subsequent heterogeneity, and the activation of the CD109-YAP/
TAZ signaling axis as previously unidentifıed therapeutic targets for post-IR
recurrent GBM.
#938 Estrogen induced NRF1 signaling is a molecular mechanism under-
lying the generation of different breast cancer stem cell subpopulations lead-
ing to intratumoral heterogeneity. Jayanta Kumar Das, Deodutta Roy. Florida
International University, Environmental and Occupational Health, Bruce W
Carter VA Medical Center, Research Service Laboratory, Miami, FL.
Life time exposure to elevated levels of estrogen (E2) is a major risk factor for
breast cancer. Among women with ER/PR positive tumors, only 50 to 60% of
women respond to endocrine therapy. Intra-tumoral heterogeneity of breast
cancer cells may be one of the reason for unresponsiveness to endocrine therapy
in more than 40% of ER-positive breast cancer cases. In this study we examined
that heterogeneous breast cancer stem cells (BCSCs) are produced by exposure
to E2 and/or ectopic expression of molecular risk factor - nuclear respiratory
factor 1 (NRF1). To elucidate this, we used single cell confocal imaging, flow
sorting, ChIP and qRT-PCR approaches.We alsomeasured the key regulators of
pluripotency, epithelial-mesenchymal transition (EMT), stemness, cell apopto-
sis and cell cycle regulation. The functional assay for cancer stem cells enrich-
ment employed were selection of cells in B27 medium as spheroids, anchorage-
independent growth and mammosphere formation assays. Carcinogenic
treatments of E2 to MCF10 A CD24- cells induced formation of 1.46%
CD44/CD24 and 26.02% of CD44/CD24- subpopulations, which are a
typical phenotypes associated with human breast tumor-initiating cells (BTICs)
or BCSCs. These subpopulations are capable of forming self-renewingmammo-
spheres. In contrast, CD24 or CD24-/CD44- cells did not form mammo-
spheres. Stable NRF1 overexpression induced formation of 2.36% CD44/
CD24 and of 64% CD44/CD24- subpopulations. Carcinogenic treatments
of E2 to stable NRF1 overexpressing MCF10 A cells, induced to acquire 21.54%
CD44/CD24 and 44.54% CD44/CD24- subpopulations. E2 treatment to
NRF1 overexpressing BSCSs markers signifıcantly increased mammosphere
forming capability, compared to NRF1 alone. The dominant negative form of
NRF1 diminished the effects of E2 and/or NRF1 induced acquiring of BCSCs
antigen markers and their capability of forming mammospheres. E2 induced
BTICs/BCSCs were heterogeneous. Each subpopulation was characterized by a
different transcriptional and biomarker profıles of CD24, CD44, CD49f, CD133,
ALDH1A1, CXCR4, and NRF1. The expression of different markers for pluri-
potency (OCT4, SOX2 andNanog), EMT (E-cadherin, N-cadherin and Vimen-
tin), stemness (CD24, CD44, CD39f, CD133, ALDH1A1), cell cycle
(p16,CDC2,CDC25C, cyclinB1) and metastasis (CXCR4), were associated with
BTICs produced by E2 and/or NRF1. In summary, we observed new roles of
NRF1 in contributing to acquire breast tumor initiating stem-like cells and in
regulating EMT and invasiveness of BCSCs, thus opens a new direction of
NRF1’s role in breast cancer research. A better understanding of how E2 depen-
dent breast neoplasm heterogeneity depends on NRF1 network may open new
avenues for therapeutic strategy against breast cancer. This work was supported
partly by VAMERIT Review (VA BX001463) grant to DR.
#939 Single cell mRNA expression profıling reveals heterogeneity of nor-
mal and malignant breast stem cell populations. Shamileh Fouladdel,1 Justin
Colacino,2 EbrahimAzizi,1Max S.Wicha1. 1University ofMichigan, Department
of Internal Medicine, Division of Hem/Onc, and Comprehensive Cancer Center,
School of Medicine, Ann Arbor, MI; 2University of Michigan, Department of
Environmental Health Sciences, School of Public Health, Ann Arbor, MI.
The normal breast contains epithelial populations which are hierarchically orga-
nized, a profıle recapitulated in breast cancer. At the apex of these hierarchies are
‘stem like‘ cells defıned by their capacity to self-renew as well as to generate more
differentiated progeny. In breast cancer these ‘cancer stem cells‘ (CSCs) have been
shown to be important mediators of tumor metastasis and treatment resistance.
Although the phenotypes of normal rodent and human mammary stem cells have
been characterized, CSC populations are operationally defıned by their capacity for
tumor initiation. In addition, putative breast CSC markers such as CD44/
CD24low/- andorALDHhaveprovenuseful in enriching for cells capable of tumor
initiationandprevious studieshave suggested that thesemarkers identify alternative
mesenchymal and epithelial stem cell states, respectively. However, it remains un-
clear whether CSCs exist in discrete states orwhether these cells actually represent a
continuum reflected in heterogeneity of cell populations defıned by expression of
these markers. To address this question we utilized single cell mRNA expression
profıling of normal andmalignant breast stem cells.We fırst generated a panel of 96
genes representing stem cell and developmental pathways and analyzed expression
of these 96 genes utilizing Fluidigm’s C1 and BioMark HD technologies and Taq-
Mangene expression assays.We also utilizedFluidigm’s Polaris to selectively isolate
single cells that were then analyzed by illumina RNA-Seq method. Utilizing these
advanced technologies, we demonstrated that both normal and malignant breast
stem cells characterized byCD44/CD24low/- and orALDH expression are highly
heterogeneous. For example, the ALDH isoforms ALDH1A1 and ALDH1A3 were
each expressed in some single cells and co-expressed in others. ALDH1A1 express-
ing single cells appeared to express a unique gene pattern characterized by SLIT/
ROBO, PLXNA2, RHOU and HNF1a. These results suggest that at the level of
mRNA expression, normal andmalignant breast stem cells display a greater heter-
ogeneity than has previously been reported. These results have important implica-
tions for breast carcinogenesis as well as for the development of therapeutic strate-
gies designed to target CSCs in breast cancer.
#940 Altering intratumoral heterogeneity in HER2 breast cancers with
PTEN inactivation and trastuzumab therapy. Joseph P. Burnett, Shamileh
Fouladdel, Nathan Truchan, EbrahimAzizi, MaxWicha, Duxin Sun.University
of Michigan, Ann Arbor, MI.
Within the context ofHER2breast cancer, PTENmutationhasbeenassociated
with poor patient survival, trastuzumab resistance, and inductionof the epithelial to
mesenchymal transition. Accumulating evidence supports the theory that breast
cancers are organized in ahierarchicalmannerwith thepresence of cancerous stem,
lineage restricted progenitor, and differentiated-like cells. Recent literature has also
indicated that CSCs may exist in distinct epithelial and mesenchymal states which
retain unique properties. In order to understand the influence of PTEN inactivation
within thecontextof ahierarchicalmodelof cancer, andexaminewhichpopulations
themselves are targeted by trastuzumab, we have performed analysis of traditional
CSC markers and single cell lineage tracing experiments. Here, a lentiviral vector
containingshPTENanddsRedreporterare introduced intoHER2cell lineBT474.
Following bulk sorting of dsRed cells, long term culture of parent and shPTEN
cells with and without trastuzumab for 4 weeks reveal no obvious changes in tradi-
tionalEMT-CSCmarkersCD44/CD24-andonlymodest changes inAldefluor
cells. In order to take a CSC-marker agnostic approach we performed a single cell
colony formation assay and identify that trastuzumab enriches for rare cells with
colony forming potential. Themajority of single cell derived colonies exhibited dis-
tinct morphologies stable with long term culture which are similar regardless of
PTEN knockdown or trastuzumab therapy. However, quantifıcation reveals PTEN
knockdown results in a higher frequency of colonies which exhibit distinctly mes-
enchymal morphology and less of those with epithelial morphology. Interestingly
rare colony forming cells could recapitulate allmorphologies present in the parental
cell line, suggesting they were derived from a true CSC. Single cell multiplex RT-
qPCRof 96 target geneswas performedonmixed anddistinctmorphology colonies
using Fluidigm’s C1 and BioMark HD instruments and TaqMan gene expression
assays. Principal component and t-SNE analysiswas capable of separatingmorpho-
logically distinct colonies and revealed multiple cell clusters within each colony.
Using hierarchical clustering it is evident that a minority of cells which appear as
uniqueclusters inPCAanalysis are thosewhichareproliferative andexpressdistinct
lineage markers reflective of the colony itself. Taken together these results suggest
that PTEN knockdown shifts the equilibrium from primarily epithelial lineage dif-
ferentiation to amoremesenchymal differentiation while trastuzumab enriches for
stem and progenitor cells.
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#941 CXCL1-CXCR2 signaling might recruit the bone marrow-derived
mesenchymal cells to the carcinoma-associated fıbroblasts of gastric cancer.
Masakazu Yashiro, Tomohisa Okuno, Hiroaki Kasashima, Yuichiro Miki, Hi-
rohisa Nakamae, Kisyu Kitayama, Toshiyuki Kawashima, Takaharu Hatano,
Heishiro Fujikawa, TsuyoshiHasegawa, TakahikoNakane,MasayukiHino, Ko-
sei Hirakawa, Masaichi Ohira. Osaka City Univ. Grad. School of Medicine,
Osaka, Japan.
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Background & Aims: Activated fıbroblasts in the tumor stroma, also termed
carcinoma-associated fıbroblasts (CAFs), play a critical role in the progression
of cancer. In our previous studies, we identifıed CAFs as playing an important
role in cancer progression in the development of gastric cancer. However, it
remains unclear which factor recruit and promoteCAFs. The aimof this study is
to clarify from where CAFs originate and which factor recruits them into the
gastric cancer microenvironment. Methods: In vitro study analyzed the che-
motaxis-stimulating factor from gastric cancer cells using bonemarrow-derived
mesenchymal cells (BM-MCs). The nude mice with bone marrow transplanta-
tion fromCAG-EGFPmicewere used for the in vivo gastric cancer experiments.
The influences of chemokine (C-X-C motif) receptor 2 (CXCR2) inhibitor on
themigration of BM-MCswere examined in vitro and in vivo. Results: BM-MCs
migrated into tumor stroma of in vivo gastric cancer. The number of BM-MCs
wasmuch greater in the gastric tumor than innormal tissue from three days after
inoculation of cancer cells. C-X-C motif ligand 1 (CXCL1) from gastric cancer
cells signifıcantly (p0.001) stimulated the chemoattractant ability of BM-MCs
in vitro. Anti-CXCL1 antibody and CXCR2 inhibitor signifıcantly (p0.05)
decreased the migration-stimulating activity of gastric cancer cells. A CXCR2
inhibitor, SB225002, decreased tumor size and lymph nodemetastasis of gastric
tumor, and signifıcantly (p0.039) prolonged survival of gastric-tumor bearing
mice. The histologic fındings indicated that SB225002 decreased the recruitment
of BM-MCs into the tumor stroma, resulting in the reduction of CAFs. Conclu-
sions: BM-MSCs recruit into gastric tumor and differentiate into CAFs. CXCL1
from gastric cancer cells stimulates the recruitment of BM-MCs into gastric
cancer locus via CXCR2 signalling. Inhibition of BM-MCs’ recruitment appears
a promising therapy for gastric cancer.
#942 CXCR2 acts as a checkpoint regulator of the pancreatic stellate cells
activity within pancreatic cancer tumor microenvironment. Mohammad
Awaji, Michelle Varney, Abhilasha Purohit, Surinder K. Batra, Rakesh K. Singh.
University of Nebraska Medical Center, Omaha, NE.
Pancreatic cancer (PC) is a grotesque disease featured by an inflamed complex
tumor microenvironment (TME) that contribute to advancing tumor progress-
ing. Oncogenic K-ras, the most common mutation in PC, amplifıes inflamma-
tion within TME through overexpression of multiple immune factors such as
CXCR2 and its ligands. K-ras induced overexpression of CXCR2 axis, made
CXCR2 seem intuitively a good target for PC treatment. In KC, a spontaneous
PCmouse model with oncogenic K-ras, genetic ablation of CXCR2 caused anti-
tumor events such as increased apoptosis and decreased angiogenesis; and also
presented pro-tumorigenic events; most notably was the increased fıbrosis and
metastasis to the liver. These observations have shed light on the possible role the
CXCR2 on the other TME component especially pancreatic stellate cells (PSCs).
The aim of this study is to determine the differential effect of K-ras status and
CXCR2 chemokines expression in the PC cells on their interaction with PSCs.
Unidirectional segregated co-culture studies were conducted using conditioned
media (CM). CM collected from PSCs were used to grow multiple PC cell lines,
andCMobtained fromdifferent PC cell lines were used to culture PSCs. Cellular
proliferation and gene expression were analyzed. Furthermore, PSCs prolifera-
tion potentials were assessed as those cells treated with exogenous CXCL1 and
CXCL8, or PC cell lines derived-CM in the presence or absence of CXCR2
antagonists. Co-culture studies revealed that PSC-derived CM had increased
proliferation of PC cell lines positive to oncogenic K-ras as well as increasing
their expression ofmultiple chemokines such as CXCL1, CXCL5, andCCL2.On
the other hand, PC cell lines with a wildtype K-ras were inhibited by PSC-
derived CM treatment. PSCs proliferation potentials were decreased with CM
derived from oncogenic K-ras positive PC cell lines and increased with CM
derived from PC cell lines with wildtype K-ras. Furthermore, CM from onco-
genic K-ras PC cell lines has increased the expression of multiple pro-tumori-
genic genes in the PSCs including cytokines such as IL-10, IL-4 and IL-13, and
chemokines such as CXCL2 and CXCL7. Also, treating PSCs with exogenous
CXCL1 and CXCL8 exhibited a similar proliferation inhibition to that observed
with oncogenic K-ras PC derived CM treatment. CXCR2 antagonists have
shown rescued inhibition or enhanced proliferation of PSCs when incorporated
with CXCR2 chemokine or PC cell line derived CM treatment. These observa-
tions suggest that K-ras status of PC dictates their interaction with PSCs within
the TME. We have demonstrated that oncogenic K-ras through increased pro-
duction of CXCR2 chemokine would dampen PSCs proliferation and further
orient them to support tumor progression by increased expression of pro-tu-
morigenic genes. Besides, we observed that CXCR2 inhibition in PSCs would
increase their proliferation which may further their fıbrogenic activity.
#943 RelA regulates CXCR5/CXCL13 transcription and associated im-
mune response in breast cancer. Sougata Roy Chowdhury, Subir Biswas, Gun-
jan Mandal, Arindam Bhattacharyya. University of Calcutta, Kolkata, India.
It is evident from research outcomes that metastases-associated deaths are
predominant in breast cancer. Recent developments on early diagnosis using
mammographic screening and the implementation of adjuvant therapies may
have reduced breast cancer associated deaths in decent numbers, although new
markers for prognosis are of utmost importance for patients with higher risk of
developing metastases or recurrence. Chemokines are the key messenger of
cellular immune response and can be targeted to reduce the intratumoral regu-
latory T cells (Treg) for antitumor immunity. Targeting either specifıc immuno-
modulators and/or interveningmolecularmechanisms is thought to be a poten-
tial therapeutic option. In our previous study, we have found that co-expression
of CXCR5 and CXCL13 is signifıcantly associated with epithelial to mesenchy-
mal transition (EMT) of cells and lymph node metastasis (LNM) during breast
cancer progression. In this study, we are aiming to investigate how the transcrip-
tional regulation of this receptor-ligand pair directs the process of disease devel-
opment. Interestingly, it was found that RelA (p65), a subunit of NFkB protein,
promoted the transcription of both CXCR5 and CXCL13. The putative RelA
binding sites were validated using sequential deletion of respective promoter
regions of CXCR5 and CXCL13.We observed that expression of CXCR5 signif-
icantly (p0.05) increased with RelA and Nrf2 overexpression and CXCL13
co-stimulation in MDA-MB-231 cell line. RelA was also found to induce the
expression of CXCL13 in T-47D and MDA-MB-231 cell line. Signifıcantly,
SNAIL, a key EMT regulatory element, was found to be highly expressed in
RelA-transfected MDA-MB-231 cell line with or without CXCR5 and CXCL13
co-stimulation. We also observed CXCR5 T follicular helper (Tfh) and Treg
sub-population within the tumor microenvironment, although numbers varied
with stages and molecular subtypes. In chemotaxis assay, CXCR5 Treg cells
were found to be predominant among migratory T-cell subsets against RelA
overexpression and/or CXCL13 stimulation. Simultaneously, CCL2, a pro-in-
flammatory chemokine, inducedmacrophages to secrete CCL22, which in turn,
might attract CXCR5 Treg and Th2 cells into the tumor microenvironment.
Study in 4T1-BALB/c breast cancer mouse model demonstrated signifıcant
(p0.05) increase in CXCR5 and CXCL13 expression levels upon immunos-
timulation. The study may help to understand the prognosis value of CXCR5
and CXCL13 considering the impact of this receptor-ligand pair on the regula-
tion of Tfh/Treg ratio, EMT and LNM. We believe that this investigation may
lead to a comprehensive prediction of the tumor fate as well as to explore pos-
sible markers for breast cancer prognosis and future chemotherapy with more
precision.
#944 Chemokine receptor signaling as a new tool to improve lung cancer
diagnostics and therapy. Katalin Nagy-Major,1 Jörg Sänger,2 Harshad R.
Kulkarni,2 Peter Fix,2 Almut Kunze,2 Amelie Lupp,3 Reiner Bonnet,2 Werner
Seeger,4 Richard P. Baum,2 Patricia Grabowski,1 Rajkumar Savai4. 1Charité
Campus Benjamin Franklin, Berlin, Germany; 2Zentralklinik Bad Berka, Bad
Berka, Germany; 3Jena University Hospital, Jena, Germany; 4Max Planck Insti-
tute for Heart and Lung Research, Bad Nauheim, Germany.
Background: The tumor microenvironment plays a critical role in cancer
development, progression, and control. We demonstrated in vitro and in vivo
that a bidirectional crosstalk between tumor-associated macrophages and can-
cer cells via CCR2-CCL2 and CX3CR1-CXCL1 signaling is fundamental for
lung cancer growth and metastasis offers new treatment concepts. Aim: Our
working hypothesis is to develop a newplatform for specifıc chemokine receptor
(CCR2) PET imaging and a range of theranostic applications in lung cancer. For
this purpose, we planned to defıne the CCR2 expression in NSCLC as well as in
SCLC, tumor cells aswell as immune/inflammatory cells.Material andMethods:
This is a multicenter trial with patients from Zentralklinik Bad Berka GmbH (n
100 NSCLC, n100 SCLC). All patients gave informed consent according to
the declaration of Helsinki. FFPE material was available in all cases. CCR2
CXCR4 and CX3CR1 expression was determined by immunohistochemistry
with the avidin-biotin-peroxidase-complex. Results: Analyzing 96 NSCLC (47
adenocarcinoma, 49 squamous cell carcinoma) and 45 SCLC tumor samples, we
found CXCR4 and CCR2 chemokine receptor expression in tumor, immune
and inflammatory cells. In NSCLC, co-expression between CCR2 and CXCR4
staining was very high concerning their expression on tumor cells rising with
higher tumor stages, proliferation rate and grading. CCR2 expression in im-
mune cells was restricted to lower stages; the same pattern could be observed in
45 SCLC tumor samples where CCR2 expression on immune cells was found
especially in limited disease rather than inmetastatic disease; CXCR4 expression
in tumor cells was found to be high in all stages of SCLC. To evaluate the ther-
apeutic effıcacy ofCCR2 antagonism in vivo,we injected LLC1 s.c. intoWTmice
treated with CCR2 antagonist (RS504393) or vehicle. Notably, tumor growth
was signifıcantly inhibited in CCR2 antagonist-treated mice as compared with
vehicle-treated mice. Discussion: Our preliminary results show a signifıcant
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portion of CCR2 positive tumors - NSCLC as well as SCLCwhich would qualify
for a CCR2-based imaging as well as - demonstrated in ourmicemodels - CCR2
inhibitory strategies. This should be evaluated in further preclinical trials.
#945 Oligodendrocytes might up-regulate the Invasiveness of glioblas-
toma cells via angiopoietin-2 signaling.Toshiyuki Kawashima.Osaka city uni-
versity school of medicine, osaka, Japan.
Background & Aims: Glioblastoma (GBM,WHOGrade IV) is considered as
the most lethal neoplasm of all solid cancers due to its inherent intensive inva-
siveness. GBM may arise de novo, or following progression from lower grade
gliomas. Recently, solid tumor progression has been recognized as the product
of an evolving crosstalk between the cancer cells and its surrounding glial cells.
The intensive invasion activity of GBM cells might be regulated by surrounding
normal cells such as oligodendrocytes or fıbroblasts. In this study, we evaluated
the interactive factors betweenGBMcells and normal glial cells to determine the
role of oligodendrocytes in regulating the invasiveness of glioblastoma cells.
Methods: TwoGBMcell lines, T98G andU251, were used. Twooligodendrocyte
cell lines, ODC1 and ODC2, were derived one each from surgical tissues of
patients with low-grade glioma (WHOGrade II). Two fıbroblasts cell lines, GF1
and GF2, were derived one each from surgical tissues of patients with GBM.
Oligodendrocytes and fıbroblasts were confırmed by immuno-histochemical
staining. The invasive property of GBM cells was analyzed in the presence or
absence of conditioned medium from oligodendrocytes or fıbroblasts by
wound-healing assay and Boyden chamber invasion assay. The proliferation
ability of GBM cells was examined by MTT assay. Subsequently Cytokine array
was used to examine the cytokines and growth factors in the conditioned me-
dium from oligodendrocytes or fıbroblasts. Results: Oligodendrocyte cells,
ODC1 and ODC2 cells, signifıcantly (p0.01) increased the migration and in-
vasion ability of GBM cells, T98G and U251. In contrast, fıbroblasts, GF1 and
GF2 cells, did not affect the migration and invasion ability of GBM cells. Cyto-
kine array indicated that Angiopoietin-2 was found in the conditioned medium
from oligodendrocytes, but not that from fıbroblasts. Angiopoietin-2 signifı-
cantly (p0.01) increased the invasiveness of GBM, but not their proliferation
ability. Conclusion: Oligodendrocytes might up-regulation of the invasiveness
of GBM cells via angiopoietin-2 signaling pathway. Hence, angiopoietin-2 can
be considered as a promising target for the treatment of malignant gliomas.
#946 Characterize and identify secreted high molecular weight hepara-
nase from PC3M conditionedmedium.Donghong Ju, Mary A. Kosir. Barbara
Ann Karmanos Cancer Inst., Detroit, MI.
Introduction: Neutrophils, platelets, lymphocytes are typical sources of
NAP-2 which is associated with heparanase activity. Heparanase degrades poly-
meric heparan sulfate molecules into shorter oligosaccharides, participating in
extracellular matrix degradation. It is active under acidic conditions during tu-
mor invasion and inflammatory processes. Our lab previously found that some
cell lines like androgen independent prostate cancer cells (PC3M) can secrete a
protein that reacts with anti-NAP-2 antibody, but has a much higher molecular
weight(50KD) thanNAP-2 (MW6-14KD), andhas heparanase activity. The
purpose of this study is to characterize and identify this protein. Procedures:
Immunoprecipitation was performed using Pierce DirectIP kit according the
manufacturer’s instructions. Heparin binding affınity column used HiTrap™
Heparin HP column from GE Healthcare Bio-Sciences. The binding buffer was
10mM NaAcetate pH 5.0, the eluting buffers were 0.5M-2M NaCl in 10mM
NaAcetate pH 5.0. The mass spectrometry was done by KCI Proteomics Core
facility. Data: The immunoprecipitationmethod confırmed that this highermo-
lecular weight protein indeed can be pulled down by the NAP-2 antibody, and
after using heparin binding affınity column to purify, we can still get the 50KD
band on the western blot for NAP-2, meaning it is a heparin binding protein.
Conclusions: A protein identifıed with NAP-2 antibody, but with higher molec-
ular weight than native NAP-2 is found in the conditioned medium of PC3M
cells that binds heparin, further confırming a potential role in tumor progression
for prostate cancer.
#947 CXCR4 in combination with immune check point inhibition in
ovarian cancer mouse model demonstrates potential for novel therapeu-
tic strategies. Kristen Starbuck, Robert McGray, Samar Masoumi-Moghad-
dam, Ariel Francois, Kunle Odunsi, Emese Zsiros. Roswell Park Cancer In-
stitute, Buffalo, NY.
Chemokine CXCL12 and its receptor CXCR4 are the most highly expressed
chemokine axis in serous ovarian cancer. CXCR4 promotes tumor growth, an-
giogenesis, andmetastasis. High CXCR4 expression is associated with poor sur-
vival,making it an attractive therapeutic target. The objective of this studywas to
establish an immune competentmurine ovarian cancermodelwith highCXCR4
expression and to test single agent CXCR4 blockade and combination therapy to
optimize emerging treatment strategies for future clinical trials. CXCR4 expres-
sion was evaluated by flow cytometry in ID8, ID8-VEGF, IE9-MP1, BR5, BR5-
Akt, BR5-C2k, and BR5-Krasmouse ovarian cancer cell lines as well as IE9-MP1
tumor samples. Subsequently an exploratory study was undertaken utilizing the
ID8 immune competent mouse model to assess the effıcacy of AMD3100, the
only commercially available CXCR4 inhibitor, alone and in combination with
bevacizumab and anti-PD-1. Immune analysis of circulating lymphocytes by
flow cytometry was performed during treatment tomonitor changes of immune
cell subsets. Surface expression of CXCR4 receptor was minimal in ID8 (1.6%),
ID8-VEGF (0.9%), IE9-MP1 (1.8%), BR5 (0.9%), BR5-Akt (1.2%), BR5-C2k
(2.3%), and BR5-Kras (1.1%), however intracellular staining revealed wide-
spread CXCR4 expression in ID8 (99.6%), ID8-VEGF (99.7%) BR5 (96.7%),
BR5-Akt (94.3%), BR5-C2k (98.2%), and BR5-Kras (98.7%) cell lines. Using the
ID8 intraperitoneal ovarian cancer mouse model in C57BL/6J mice, treatment
with immunotherapy signifıcantly increased cell surface expression of CXCR4
from 2% in the control group to 79.6-91.8% in the treatment group. Treatment
with AMD3100 as a single agent showed no improvement in survival over con-
trol. However, AMD3100 in combination with anti-PD-1 therapy signifıcantly
improved survival. The addition of bevacizumab demonstrated no further sur-
vival benefıt and bevacizumab as a single agent showed no improvement in
survival over control, either alone or in combinationwith anti-PD-1. Analysis of
circulating lymphocytes revealed a trend toward higher CD4 to CD8 ratio in
mice who were treated with anti-PD1 therapy. Targeting the CXCL12-CXCR4
axis in combination with other immunotherapies such as immune checkpoint
inhibitors is a novel therapeutic strategy which may provide benefıt over single-
agent immunotherapy and warrant investigation in a clinical trial.
#948 Characterization of themicroenvironment ofmurine primary triple
negative breast cancer. Kassondra Balestrieri, Keith Pittman, Mohamed Ra-
mez, Nasreen Vohra, Kathryn Verbanac. East Carolina University/Brody School
of Medicine, Greenville, NC.
The purpose of this study was to investigate the role of inflammatory cells in
the metastatic process using reliably metastatic murine models of Triple Nega-
tive Breast Cancer (TNBC). We have previously selected, developed and char-
acterized two reliably metastatic TNBC mouse models for our investigations.
The T11 (claudin-low) and 2225LM (basal-like) Balb/c-derived transplantable
tumors display molecular profıles that mirror human TNBC. Here we report
characterization of the inflammatory cells and microenvironment in these pri-
mary TNBC tumors and at metastatic sites in both heterotopic and orthotopic
models. Tumors were implanted in the s.c. flank or mammary fat pad and re-
sected 1-2 weeks later to promote the growth of seeded metastases, when vol-
umes reached700 mm3 or 300 mm3, respectively. Both flow cytometric anal-
ysis and immunohistochemistry of primary tumors demonstrated high
infıltration bymyeloid-derived cells (CD11b) and low levels of lymphoid cells
(CD3). Myeloid cells were also the major infıltrating cells in lung metastases
and were signifıcantly elevated compared to normal lung. The granulocytic sub-
set (CD11bLy6G) predominated, consistent with an immunosuppressive
role for cells with this phenotype (N2, G-MDSC, etc.). Primary 2225LMandT11
tumors and metastatic lung tumor homogenates were assayed for immuno-
modulators and compared to normal breast and lung tissue from age-matched
contemporary controls. G-CSF was signifıcantly increased in tumors and levels
(pg/mg protein) were correlated with tumor burden. VEGF was signifıcantly
elevated in all tumors, as were chemoattractants for granulocytic cells (KC/
CXCL1, MIP-2/CXCL2), monocytic cells (MCP-1/CCL2), eosinophils (Eo-
taxin/CCL11) and T cells (MIG/CXCL-9). In the heterotopic model, lung levels
ofKC/CXCL1 andMCP-1/CCL2were signifıcantly increased prior to frank lung
metastasis (5-30 days post-implant). These data suggest that TNBC-derived G-
CSF may play a role in the mobilization of CD11bLy6G granulocytes and
progenitors from the bonemarrow and key chemokinesmaymediatemigration
of these cells to metastatic sites. Future studies will defıne phenotypic and func-
tional characteristics of the G-MDSC that are promoting tumor progression in
these murine TNBC models.
#949 Resistin potentiates stemness and chemoresistance of breast cancer
cells through STAT3 activation: implications in breast cancer health dispar-
ity. Sachin Kumar Deshmukh,1 Arun Bhardwaj,1 Sanjeev K. Srivastava,1 Nikhil
Tyagi,1 Ahmed Al-Ghadhban,1 Ajay P. Singh,1 Donna L. Dyess,1 James E.
Carter,2 Seema Singh1. 1Mitchell Cancer Institute, Mobile, AL; 2College of Medi-
cine, Mobile, AL.
Breast cancer (BC) is most frequently diagnosed cancer and remains the sec-
ond leading cause of cancer-related deaths in women in the United States. Afri-
can American (AA) women bear an additional burden of BC with early onset of
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disease, poorer prognosis, higher risk of recurrence, and worst clinical outcome
as compared to Caucasian American (CA) women. Emerging evidence strongly
argue the role of tumor-microenvironment (TME) in BC of AA and CA racial
backgrounds. On the similar line, our earlier fındings suggested that serum
levels of resistin; an inflammatory cytokine are signifıcantly elevated in AA BC
patients compared to their CA counterparts. Furthermore, we demonstrated
that resistin promoted growth and aggressiveness of BC cells. In the present
study, we investigated the role of resistin in stemness and chemoresistance of BC
cells. For this, two BC cells of CA (MDA-MB-231) and AA (MDA-MB-468)
origin were treated with resistin and sphere-forming ability, a key characteristic
of cancer stem cells, was determined. Data demonstrate that number of spheres
is signifıcantly enhanced in both the BC cells upon resistin stimulation. Immu-
noblot analyses reveal that resistin-induced sphere-forming ability is associated
with enhanced levels of stemness-associated transcription factors (Nanog and
KLF4) in BC cells. We next examined if resistin conferred chemoresistance to
BC cells. Our data suggest that resistin-treated MDA-MB-231 and MDA-MB-
468 BC cells develop greater resistance against doxorubicin-induced cytotoxic-
ity. Notably, the effects conferred by resistin were more prominent in AA BC
cells comparing to CA BC cells. Our mechanistic studies unveiled an important
role of STAT3 activation in the resistin-induced stemness and chemoresistance
of BC cells. Taken together, our fındings provide novel insight into the role of
resistin in BC biology and further strengthen its role in racially disparate clinical
outcomes.
#950 Involvement of proinflammatory chemokine network between adi-
pocytes and triple negative breast cancer cells. Rosa Mistica Coles Ignacio,1
Hyeongjwa Choi,1 Carla Gibbs,1 Eunsook Lee,2 Samuel Adunyah,1 Deok-Soo
Son1. 1Meharry Medical College, Nashville, TN; 2Florida A&M University, Tal-
lahassee, FL.
Obesity has become a global epidemic and causes a chronic low-grade inflam-
mation. This poses a large health burden because excess adiposity can lead to
chronic diseases such as type 2 diabetes, cardiovascular disease and some can-
cers. Obese individuals get higher incidence, progression and mortality of can-
cers compared to lean ones. Particularly, breast cancer (BC) in women is closely
associated with obesity. Despite an epidemiological link between obesity and
low cancer survival rates, little is known about the molecular mechanisms by
which obesity promotes BC progression. Obesity-derived chronic low-grade
inflammation involves alteration of a chemokine network thatmay contribute to
the cancer progression and metastasis. Herein, we proposed the novel concept
that the chemokine network between obesity and BC builds an inflammatory
burden via proinflammatory chemokines to promote cancer progression. We
employed mesenchymal BC cell PY8119 and epithelial-like BC PY230 for triple
negative BC (TNBC) cell model, andmouse 3T3-L1 preadipocyte and adipocyte
conditioned media (CM) to mimic lean and obese conditions in vitro. We ex-
amined the profıles of chemokine signature of PY8119 and PY230 treated with
preadipocytes and adipocytes CM using PCR array. Both preadipocytes and
adipocytes CM-treated PY8119 and PY230 cells absent or low levels in chemo-
kine receptors. On the other hand, the chemokines CCL2, 5, 7 and CXCL10
showed higher expression in both preadipocyte and adipocyte CM-treated
PY8119. Interestingly, adipocyte CM-treated PY8119 cells dominantly ex-
pressed CXCL1-3 compared to preadipocyte CM-treated cells. In addition,
CCL2, 5, 7, 20, andCXCL1, 5, 10were highly expressed in both preadipocyte and
adipocyte CM-treated PY230 cells. Moreover, CXCL2 and 3 were signifıcantly
induced in PY230 cells after treatment with adipocyte CM compared to preadi-
pocyte CM. Taken together, the results indicate that dominant chemokines
CXCL1-3 expressed in adipocyte CM-treated TNBC cells promote a pro-tumor
inflammatory network. Hence, these proinflammatory microenvironment aug-
mented by adipocytes might contribute to TNBC progression.
#951 Induction of COX-2 and NF	B activation represent TLR3-indepen-
dent undesirable aspects of poly-I:C activity.Marie-Nicole Theodoraki,1 Ravi
Muthuswamy,2 Jamie Voyten,2 Francesmary Modugno,2 Natasa Obermajer,2
Robert P. Edwards,2 Pawel Kalinski2. 1University of Pittsburgh, Pittsburgh, PA;
2University fo Pittsburgh, Pittsburgh, PA.
Background: Infıltration of cytotoxic T-cells (CTL) in tumors is known to be
associated with improved patient’s clinical outcomes. In contrast, local infıltra-
tion with regulatory T-cells (Treg) predicts accelerated progression and shorter
overall survival. The above observations highlight the need for newmeasures to
promote selective accumulation of CTLs but not Tregs in tumor microenviron-
ments (TME). Here we compare the TME-modulating impact of poly-I:C with a
selective TLR3 ligand, rintatolimod showing an induction of CCL22, CXCL12
and expression of COX-2 and downstream suppressive factors, selectively by
poly-I:C. Finally, we report on the optimized combinatorial adjuvant to repro-
gram tumormicroenvironment.Materials andMethods: Twelve ovarian cancer
specimens were cultured in the presence of IFN, indometacin (COX-1/2 in-
hibitor) or/and one of two synthetic TLR3 ligands, poly-I:C (non-selective acti-
vator of TLR3 and helicases) or rintatolimod (selective TLR3 ligand). Biopsies
were harvested for mRNA measurements and culture supernatants were ana-
lyzed for CCL5, CXCL10 and CCL22 concentrations. Alternatively, established
ovarian cancer cell lines, monocyte-derived macrophages, THP1 cells or adult
fıbroblasts were used in analogous experiments. Chemotaxis assays were per-
formed using pre-activated CD8 T-cells (top chamber) and supernatants from
the differentially treated ovarian cancer specimens. Western blot experiments
were used to evaluate the impact of NFB. Blocking experiments using soluble
TNF receptor inhibitor were performed. Results: Both, Poly-I:C and rintatoli-
mod, induced CTL attractant CXCL10. Unexpectedly, poly-I:C but not rinta-
tolimod promoted the expression of theMDSC/Treg attractant CXCL12, which
was reversed by addition of indometacin. Furthermore, poly-I:C induced ex-
pression of COX-2 and COX-2-dependent suppressive factors (IDO, IL-10).
Evaluating the COX-2 cascade, TNFwas found to be increased in the presence
of poly-I:C but not rintatolimod. Additionally, Western Blot analysis showed
I-B degradation (as a marker of NF-B activation), selectively in response to
poly-I:C. We observed that the combination of both TLR-3 ligands with IFN
and indomethacin selectively induced the desirable chemokines CCL5 and
CXCL10 and suppressed CCL22 in tumor samples with similar results in the
macrophages and fıbroblasts. The ovarian cancer cell lines showed onlyminimal
expression of chemokines. Conclusion: We demonstrate the feasibility of selec-
tive modulation of TME, using different clinically applicable factors and their
combinations.We show for the fırst time, that poly-I:C, but not a selective TLR3
ligand, induces NFB and undesirable COX2-dependent suppressive factors,
which though can be eliminated through addition of aCOX-1/2 inhibitor. These
effects may be avoided using a selective TLR3 ligand.
#952 Modulation of immune cell traffıcking into human colorectal cancer
by gut microbiota. Eleonora Cremonesi,1 Jesus G. Garzón,2 Valeria Governa,1
Valentina Mele,1 Francesca Amicarella,1 Elisabetta Padovan,1 Manuele Mu-
raro,1 Paul Zajac,1 Daniel Oertli,3 Lubor Borsig,2 Giandomenica Iezzi1. 1Univer-
sitat Spital, Basel, Switzerland; 2Istitute of Phisiology, University of Zürich,
Zürich, Switzerland; 3Department of Surgery, Universitat Spital, Basel, Switzer-
land.
Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related
death. CRC infıltration by immune cells, including cytotoxic CD8 T cells
(CTLs), IFN-gamma-producing T-helper 1 cells (Th1), Foxp3 regulatory T
cells (Tregs) and CD16 MPO neutrophils, is associated with favorable
prognosis. However, chemokines driving these cell populations into the tu-
mor site, their cellular sources and their microenvironmental triggers re-
main to be elucidated. Aim: We investigated the chemokine/chemokine re-
ceptor network promoting CRC infıltration by immune cells associated to
favorable prognosis. Results: CRC infıltration by immune cells was associ-
ated with defıned chemokine gene signatures, including CCL5, CXCL9 and
CXCL10 for cytotoxic T lymphocytes and T-helper 1 cells, and CCL17,
CCL22 and CXCL12 for T-helper 1 and regulatory T cells. Most of these
chemokine genes were expressed by tumor cells upon exposure to gut bac-
teria in vitro and in vivo. Indeed, chemokine expression levels were signifı-
cantly higher in orthotopic xenografts than in intraperitoneal tumors, and
were drastically reduced by antibiotic treatment of tumor-bearing mice. Im-
portantly, in human CRC samples, extents of chemokine production and
immune cell infıltration was signifıcantly associated with bacterial loads.
Conclusion: Gut microbiota stimulates chemokine production by CRC cells,
thus favoring T cell recruitment into tumor tissues.
#953 Atypical chemokine receptor 1 (ACKR1/DARC) expressing tumors
are associated with distinct recruitment of immune cells and increased pro-
inflammatory chemokines. Brittany D. Jenkins,1 Rupali Hire,1 Elizabeth How-
erth,1 Michele Monteil,2 Rachel Martini,1 Melissa B. Davis1. 1Univ. of Georgia,
Athens, GA; 2AU/UGAMedical Partnership, Athens, GA.
Interactions between chemokines and their receptors can improve a host’s
anti-tumor response by influencing the targetedmigration of immune cells via a
chemokine gradient. Atypical Chemokine Receptor 1 (ACKR1/DARC), a genet-
ically diverse transmembrane GPCR, acts as a decoy receptor for a variety of
CXC and CC chemokines, including those with pro-malignant and pro-inflam-
matory effects, such as CCL2 (MCP-1, MCAF, JE) and CXCL8 (IL-8). The pur-
pose of this study is to determine if the migration of tumor-associated immune
cells is unique based on epithelial ACKR1 expression on breast cancer cells, and
if this association is correlated to an increase in pro-malignant chemokines,
better survival odds, and differences in race. Immunohistochemistry techniques
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were used to determine expression levels of ACKR1 on primary breast tumors,
along with relative expression of T-cells, B-cells, dendritic cells, and macro-
phages. Concentrations of pro-inflammatory chemokines in circulation were
determined using a Luminex-based immunoassay and matched patient periph-
eral blood samples. In silco analyses were performed to determine associations
between ACKR1 tumor expression status, race, and survival. Finally, using hu-
man breast cancer cell lines and immunofluorescence techniques, co-localiza-
tion between ACKR1 and selected pro-inflammatory chemokines was investi-
gated. Results from these tests indicate that there is differential expression of
immune cell types in tumors expressing ACKR1, and this difference was asso-
ciated with the migration of B-cells and dendritic cells, which were not detected
in ACKR1 negative tumors. Signifıcantly increased circulating CCL2 and
CXCL8 chemokine levels we also determined to be positively correlated with
ACKR1 expression in primary breast tumors. Survival analyses showed a signif-
icantly increased relapse free survival in patients having tumors with high
ACKR1 expression, while investigations into racial differences revealed a signif-
icant race effect, with Caucasians having higher ACKR1 levels on their tumors
than African-Americans. Finally, co-localization between ACKR1 with CCL2
and CXCL8 is observed in cultured human breast cancer cells. Given that the
data collected shows a tendency for those tumors positively expressing ACKR1
to have a more favorable prognosis, we suggest that a partial role of ACKR1 on
breast tumor cells is to sequester pro-inflammatory chemokines in the tumor
microenvironment, indirectly recruiting a distinct subset of tumor-associated
immune cells.
#954 TGF-ß signaling inhibition counteracts myelofıbrosis inMPN.Mat-
thias Bartenstein,1 Lanzhu Yue,2 Wanke Zhao,3 Wanting Tina Ho,3 Cem Mur-
dun,2 Adam W. Mailloux,2 Ling Zhang,2 Anjali Budhakoti,1 Kith Pradhan,1
Franck Rapaport,4 Huaquan Wang,5 Zonghong Shao,5 Ulrich Steidl,1 Ross L.
Levine,4 Zhizhuang Joe Zhao,3 Amit K. Verma,1 Pearlie K. Epling-Burnette2.
1Albert Einstein College of Medicine, Bronx, NY; 2Moffıtt Cancer Center and
Research Institute, Tampa, FL; 3Oklahoma University Health Sciences Center,
Oklahoma City, OK; 4Memorial Sloan Kettering Cancer Center, New York, NY;
5Tianjin Medical University General Hospital, Tianjin, China.
Myelofıbrosis (MF) is a common feature of the Philadelphia-Chromo-
some negative (Ph-) myeloproliferative neoplasms (MPN), a group that in-
cludes Primary Myelofıbrosis (PMF), Essential Thrombocytosis (ET) and
Polycythemia Vera (PV). Current treatment with Jak2 inhibitors reduces
splenomegaly, but does not eliminate malignant clones nor improve bone
marrow (BM) or spleen fıbrosis, underlining the need for alternative thera-
pies. One promising target is TGF-1, a cytokine crucial for the development
of myelofıbrosis that is elevated in PMF patient plasma, progenitors and
megakaryocytes (MK), and is known to promote fıbrosis through stimula-
tion of fıbroblasts and their progenitors, mesenchymal stroma cells (MSC).
Dysregulation of TGF-1 signaling has been described in a number of mouse
models of myelofıbrosis exhibiting aberrant megakaryopoiesis, one of the
hallmarks of MPNs. Preliminary data from 93 MPN patients showed over-
expression of TGF-ß in PMF samples (p0.001), with increased activation of
the canonical target SMAD2 (p0.005). We tested the effıcacy of the orally
available TGF-1 signaling inhibitor Galunisertib (LY2157299) in counter-
acting fıbrosis in two MF mouse models of common MPN oncogenes Jak2
and Mpn. Mice in the fırst model express the constitutively active human
Jak2V617F mutant under the control of the ubiquitous hematopoietic pro-
moter vav1 and show a PV-like phenotype at 6 weeks old, progressing to
fıbrosis of bone marrow (BM) and spleen around 25-30 weeks. Thirty week
old mice were treated with Galunisertib for 4 weeks and showed a signifıcant
decrease in fıbrosis compared to control mice. Similar results were observed
in 50 week old mice treated with a murine antibody against TGFRII (IMC-
TR1,LY3022859) for 4 weeks.Our second model relies on transplantation of
mice with BM cells transduced with MPLW515L, a mutant mpl variant that
is active in the absence of TPO. These mice rapidly develop MF, myelopro-
liferation and splenomegaly. Flow cytometry showed an expansion of imma-
ture and mature megakaryocytes with overexpression of TGF-1 in
MPLW515L cells. Treatment from day 12 to day 26 after transplantation
reduced both white blood cell counts (a measure of myeloproliferation) and
fıbrosis as measured by reticulin staining. In vitro, Galunisertib counteracted
the pro-fıbrotic effects of TGF-ß1 on both murine and human MSC by an-
tagonizing its stimulatory effects on collagen I and III production. Analysis
of MSCs from Galunisertib-treated mice also showed reduced collagen I and
III production compared to controls. In conclusion, we offer further evi-
dence that aberrant megakaryopoiesis drives TGF-1 overproduction in
MPN by increasing megakaryocyte numbers and overexpressing TGF-1 in
mutant MKs. Galunisertib counteracts TGF-ß1 induced fıbrosis in twoMPN
mouse-models and is a promising candidate for symptomatic treatment of
myelofıbrosis.
#955 LY3200882, a novel, highly selective TGFRI small molecule inhib-
itor. Huaxing Pei,1 Saravanan Parthasarathy,1 Sajan Joseph,1 William McMil-
len,1 Xiaohong Xu,2 Stephen Castaneda,2 Ivan Inigo,2 Karen Britt,1 Bryan An-
derson,1 Gaiying Zhao,1 Scott Sawyer,1 Douglas Beight,1 Talbi Kaoudi,2
Chandrasekar Iyer,1 Huimin Bian,1 Amy Pappas,1 David Surguladze,2 David
Schaer,2 Karim Benhadji,2 Michael Kalos,2 Kyla Driscoll2. 1Eli Lilly, Indianapo-
lis, IN; 2Eli Lilly, New York, NY.
The transforming growth factor  (TGF) signaling pathway is a pleiotropic
cellular pathway that plays a critical role in cancer. In fact, aggressive tumors are
typically associated with high ligand levels and thus associated with poor
prognosis in various tumor types. Cancer cells use autocrine and paracrine
TGF signaling to modulate tumor cells and the tumor microenvironment
leading to a highly invasive and metastatic phenotype, inducing and increas-
ing tumor vascularization, modulating the extracellular matrix in the
stroma, and inhibiting immune surveillance and antitumor immunity. Clin-
ical studies with galunisertib (aka LY2157299 monohydrate), a small mole-
cule inhibitor targeting the TGF pathway, have provided proof of concept
data supporting the role of TGF in cancer and the utility of targeting the
TGF pathway. Here we describe the identifıcation of LY3200882, a next
generation small molecule inhibitor of TGF- receptor type 1 (TGFRI).
The molecule is a potent, highly selective inhibitor of TGFRI embodied in
a structural platform with a synthetically scalable route. It is an ATP com-
petitive inhibitor of the serine-threonine kinase domain of TGFRI. Mech-
anism of action studies reveal revealed that LY3200882 inhibits various pro-
tumorigenic activities. LY3200882 potently inhibits TGF mediated SMAD
phosphorylation in vitro in tumor and immune cells and in vivo in subcuta-
neous tumors in a dose dependent fashion. In preclinical tumor models,
LY3200882 showed potent anti-tumor activity in the orthotopic 4T1-LP
model of triple negative breast cancer and this activity correlated with en-
hanced tumor infıltrating lymphocytes in the tumormicroenvironment. Du-
rable tumor regressions in the orthotopic 4T1-LP model were observed and
rechallenge of congenic tumors resulted in complete rejection in all mice. In
in vitro immune suppression assays, LY3200882 has shown the ability to
rescue TGF1 suppressed or T regulatory cell suppressed naïve T cell activity
and restore proliferation. Therefore, LY3200882 shows promising activity as
an immune modulatory agent. In addition, LY3200882 has shown anti-met-
astatic activity in vitro in migration assays as well as in vivo in an experimen-
tal metastasis tumor model (intravenous EMT6-LM2 model of triple nega-
tive breast cancer). Finally, LY3200882 shows combinatorial anti-tumor
benefıts with checkpoint inhibition (anti-PD-L1) in the syngeneic CT26
model. In conclusion, we have developed a novel potent and highly selective
small molecule inhibitor of TGFRI for the treatment of cancer.
#956 Novel oral small molecule CXCR4 inhibitor improves activity of
immune checkpoint blockade in ovarian cancer mouse model. Kristen
Starbuck, Robert McGray, Samar Masoumi-Moghaddam, Ariel Francois,
Kunle Odunsi, Emese Zsiros. Roswell Park Cancer Institute, Buffalo, NY.
Ovarian cancer continues to be the most lethal gynecologic malignancy
with no real cure for patients presenting with advanced stage disease. Im-
mune check point blockade showed modest clinical response in patient with
recurrent ovarian cancer, thus additional therapeutic strategies for combi-
nation therapy are needed. As chemokines and their receptors drive both
immune cell migration and tumor growth, angiogenesis and metastasis for-
mation, they are an attractive target for combinatorial cancer therapy.
CXCR4 is the most highly expressed chemokine receptor in advanced stage
high grade serous ovarian cancer, thus the objective of this study was to
evaluate the effıcacy of a novel oral small molecule CXCR4 inhibitor (X4-
136) alone and in combination with immune checkpoint inhibition and the
anti-angiogenic agent bevacizumab, and characterize the changes in circu-
lating immune cells during treatment in murine ovarian cancer model. The
ID8 cell line was used in C57BL/6J mice to establish an immune competent
murine model and to compare single agent and combination therapy with
oral X4-136 CXCR4 inhibitor, bevacizumab, and anti-PD1. During treat-
ment blood sampling was performed and immune cells were analyzed by
flow cytometry. Our results demonstrated that single agent therapies alone
with either drug had no signifıcant effect on tumor progression or survival.
Combination therapy with the CXCR4 inhibitor and anti-PD1 improved
survival compared to control animals and the other combination therapy
groups. The addition of bevacizumab to the dual combination did not fur-
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ther prolong survival. Analysis of circulating immune cells revealed eleva-
tions in CD11bLy6C and the ratio of CD11bLy6C to
CD11bLy6G in groups treated with the CXCR4 inhibitor, indicating an
increase in circulating myeloid cells. Bevacizumab had no activity in this
mouse model as a single agent, and did not have synergistic effect in combi-
nation therapy. For the fırst time we demonstrated that novel CXCR4 inhib-
itor X4-136 in combination therapy with anti-PD1 showed improved sur-
vival in murine ovarian cancer model. CXCR4 blockade increased the
proportion of circulating myeloid cells during active treatment, thus further
investigation into this novel therapeutic approach is warranted.
#957 Use of angiotensin system inhibitors is associatedwith longer overall
survival in pancreatic ductal adenocarcinoma patients who underwent pan-
createctomy.Hao Liu,1 Matthias Pinter,1 Joao Incio,1 Hang Lee,1 William Ho,1
Jonathan Crain,1 Kamila Naxerova,1 Mengyang Di,2 Alex Jacobson,1 Daniella
Dias Santos,1 Andrea Zanconato,1 VikramDeshpande,1 Keith Lillemoe,1 Carlos
Fernandez del Castillos,1 Michael Downes,3 Ronald Evans,3 James Michael-
son,1 Cristina Ferrone,1 Yves Boucher,1 Jain K. Rakesh1. 1Massachusetts
General Hospital, Boston, MA; 2Brown University, Providence, RI; 3Salk In-
stitute, La Jolla, CA.
Introduction: Angiotensin system inhibitors (ASI) are widely used tomanage
hypertension. Laboratory and retrospective clinical data suggests that ASIs can
improve cancer prognosis. The aim of this study is to investigate the effect of
ASIs on overall survival in pancreatic ductal adenocarcinoma (PDAC) patients.
Methods: We performed a retrospective review of the clinicopathologic records
of patients with PDAC seen at the Massachusetts General Hospital (MGH) be-
tween 1/2006 - 12/2010. Patients on angiotensin converting enzyme inhibitors
(ACEi) or angiotensin receptor blockers (ARB) were included as ASI users. We
performed RNAseq and Gene Set Enrichment Analysis (GSEA) of primary tu-
mor samples from patients with or without chronic ASI use. We also identifıed
a surrogate signature of differentially expressed genes and we measured the
extent of angiotensin inhibition in GEO and TCGA datasets. The extent of
inhibition was used to correlate with survival. Statistical analysis was performed
using Kaplan-Meier estimator and Cox proportional hazards ratio model. Re-
sults: A total of 794 consecutive PDAC patients were included, of whom 297
(37.4%) were on ASIs and 183 (23.0%) were on non-ASI antihypertensive drug
therapy. In resected patients, ASI users had a signifıcantly longer overall survival
on univariate (median OS: 36.3 vs. 19.3 months, p0.011) and multivariate
analysis (HR, 0.49; 95%CI, 0.333-0.734; p0.001). In our sub-group analysis of
resected hypertensive patients treated with chemotherapy, chronic ASI users
had a signifıcantly longer overall survival than ASI-naïve patients (p0.048)
(28.7 vs 12.3 months, p 0.05). Gene Set Enrichment Analysis revealed that the
ASI lisinopril down-regulated geneswhich stimulate themitotic cell cycle,WNT
and Notch signaling and the interaction between integrins and the extracellular
matrix. Lisinopril also enhanced gene sets linked with oxidative phosphoryla-
tion, antigen processing and presentation and the cytotoxic activity of T cells. In
unresected patients, the effect of ASI was only signifıcant in patients with locally
advanced disease in multivariate analysis (HR, 0.572; 95%CI, 0.386-0.847;
p0.005), but not in metastatic patients. The low expression of genes down-
regulated by ACEi was also signifıcantly associated with longer survival in the
TCGA and GSE71729 datasets. Conclusion: In patients with PDAC, ASI use is
associated with longer overall survival in resected patients and may benefıt pa-
tients with locally advanced disease. These fındings suggest the need for a pro-
spective study to determine the effıcacy of ASI in PDAC patients.
#958 Blocking CD70 cancer associated fıbroblasts: Are we paving the
way towards immunotherapy in colorectal cancer. Julie Jacobs,1 Vanessa De-
schoolmeester,1 Karen Zwaenepoel,2 Christophe Hermans,1 Christian Rolfo,2
Marc Peeters,2 Filip Lardon,1 Vasiliki Siozopoulou,2 Evelien Smits,3 Patrick
Pauwels2. 1University of Antwerp, Wilrijk, Belgium; 2Antwerp University Hospi-
tal, Edegem, Belgium; 3Vaccine and Infectious Disease Institute, Edegem, Bel-
gium.
Introduction: Numerous studies have reported that tumor progression and
invasiveness are determined not only by the malignant cancer cells themselves
but also by the surrounding tumor microenvironment, including cancer-asso-
ciated fıbroblasts (CAFs). Although CAFs are implicated in tumor progression,
their total depletion of CAFs has been demonstrated to induce more aggressive
tumors, indicating that different CAF subpopulations have opposing tumor-
promoting or tumor-inhibitory roles. Unfortunately, specifıc markers to target
these subsets of CAFs are lacking. Expression of the immune checkpoint CD70
is normally tightly regulated and limited to cells of the lymphoid lineage only.
Instead, tumors hijack CD70 to facilitate immune evasion by increasing the
amount of suppressive regulatory T cells (Tregs), inducing T cell apoptosis and
skewing T cells towards T cell exhaustion. Recently, a lot of clinical successes
have been generated by the blockade of immune checkpoints. However, in colo-
rectal cancer (CRC) the effıcacy remains limited to a small subset of patientswith
mismatch repair-defıcient (MSI) tumors which might be caused by the intense
dialogue between stroma and malignant cells. Therefore, we have explored the
expression patterns of the immune checkpoint molecule CD70 in CRC, with a
particular focus on CAFs.Methods: The prognostic value of CD70 was analyzed
by immunohistochemistry on 51 CRC specimens. In addition, the relationship
with Tregs and microsatellite instability was explored. Furthermore, primary
CAF cell lines were successfully cultured from 20 different primary resection
specimens. These cell lines were used to study the effect of CD70 on the tumor
microenvironment in vitro. Results: We revealed expression of CD70, not just
on the malignant cells but on the majority of CAFs in invasive CRC specimens.
Thereby, CD70-expression was signifıcantly correlated with negative clinico-
pathological parameters such as metastasis (P0.007), differentiation
(P0.053) and advanced stage (P0.001). Moreover, CD70-positive CAFs
proved to be a poor prognostic marker by univariate as well as multivariate
analysis. We have also detected a signifıcant association between elevated Treg
amounts and CD70-expressing CAFs (P0.012). In vitro data on the effects of
CD70 on CRC behavior and immune escape are currently being analyzed. Con-
clusion:We have identifıed a new targetable CAF subpopulation, marked by the
expression of CD70 and equipped with strong tumor-promoting properties.
Thereby, we have found evidence of a potential cross talk between CD70CAFs
and Treg, paving the way towards immune escape. The lack of association of
CD70 expression andMSI-status, which highlights the potential of this target in
CRC subsets that do not benefıt from immune checkpoint blockade.We believe
that targeting CD70 holds great potential in CRC, especially in light of the lim-
ited immunotherapeutic options available.
#959 Targeting neuronal activity regulated neuroligin-3 dependency for
high-grade glioma therapy. Humsa S. Venkatesh, Lydia T. Tam, Pamelyn J.
Woo, Michelle Monje. Stanford University, Stanford, CA.
Neuronal activity promotes high-grade glioma (HGG) growth. An important
mechanism mediating this neural regulation of brain cancer is activity-depen-
dent cleavage and secretion of the synaptic molecule and glioma mitogen neu-
roligin-3 (Nlgn3), but the therapeutic potential of targeting Nlgn3 in glioma
remains to be defıned. Here, we demonstrate a striking dependence of HGG
growth on microenvironmental Nlgn3 and determine a targetable mechanism
of secretion. Patient-derived orthotopic xenografts of pediatric glioblastoma
(pGBM) and diffuse intrinsic pontine glioma (DIPG) fail to grow in Nlgn3
knock outmice. Using genetic mousemodels, we illustrate that Nlgn3 is cleaved
from both neurons and oligodendrocyte precursor cells via the ADAM10 shed-
dase.Administration of anADAM10 inhibitor robustly blocks pGBMandDIPG
xenograft growth via modulation of the tumor microenvironment. This work
defınes the therapeutic potential of and an effective strategy for targeting Nlgn3
secretion in the glioma microenvironment, which could prove transformative
for treatment of HGG.
#960 Mechanisms underlying primary ibrutinib sensitivity in CLL. Shih-
Shih Chen,1 Priyadarshini Ravichandran1,1 Yasmine Kieso,1 Jacqueline C. Bar-
rientos,1 Jan Burger,2 Kanti R. Rai,3 Nicholas Chiorazzi1. 1The Feinstein Institute
for Medical Research, Manhasset, NY; 2The University of Texas MD Anderson
Cancer Center,Houston, TX; 3Karches Center for Chronic Lymphocytic Leukemia
Research, The Northwell Health System, Manhasset, NY.
The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is effıcacious in B cell
malignancies including chronic lymphocytic leukemia (CLL). Although thema-
jority of CLL patients respond to ibrutinib, CLL clones with unmutated IGHV
gene (U-CLL) are signifıcantly more sensitive to ibrutinib than clones with mu-
tated IGHV (M-CLL). About 77% of U-CLL but only 33% M-CLL patients
experience a partial or complete response. Since ibrutinib resistance occurs,
understanding the molecular mechanisms underlying this difference will im-
prove clinical practice. Here we hypothesized that the difference in ibrutinib
sensitivity between U-CLL and M-CLL was due to a greater vulnerability of
U-CLL B cells to the loss of environmental prosurvival signals. We fırst evalu-
ated 28 treatment naive CLL cases receiving ibrutinib. We defıned not only the
characteristic CLL B cell but also T cell lymphocytosis and the latter resolved
faster in patients with good prognosis. After 1 treatment cycle, CLL T cells failed
to proliferate upon mitogenic stimulation and to home to solid tissues after
transfer into NSG mice. Without BCR signaling and T cell support, the CLL B
cell proliferative fraction was diminished and the remaining B cells had elevated
but dysfunctional surface membrane (sm) CXCR4 based on impaired recycling,
internalization and signaling. Ibrutinib also inhibited CXCR4 phosphorylation
at ser324/325/339 at a greater level in U-CLL. We then investigated ibrutinib
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mediated changes in microenvironment in a xenograft mouse model using pri-
mary cells from 3 U-CLL and 3 M-CLL cases. Ibrutinib signifıcantly inhibited
CLL cell growth in spleen; the treated CLL cells developed elevated but dysfunc-
tional smCXCR4. The inhibition on tumor growth and impaired CXCR4 oc-
curred to much greater extent in U-CLL. Notably, ibrutinib also signifıcantly
inhibited T cell growth only in U-CLL cases. Thus, ibrutinib inhibited CXCR4
signaling and CLL B-T cell crosstalk essential for tumor growth in tissue niches,
especially in U-CLL cases that has limited B-lymphocytosis. Finally, molecules
controlling the vulnerability of U-CLL B cells to death in the absence of envi-
ronmental prosurvival signals were examined in 15 patients. Ibrutinib reduced
BCL2 protein levels in U-CLL but not M-CLL; levels of BCL-XL and MCL-1
were unchanged. Consistent with these results, U-CLL but not M-CLL cell sur-
vival in vitro was promoted by T cell stimulation that led to upregulation of
prosurvival BCL2. These fındings suggest enhanced CLL B cell death by inhib-
iting BCL2 in U-CLL after the loss of environmental prosurvival signals. Alto-
gether, ibrutinib inhibits CLL-microenvironment crosstalk by blocking CXCR4
signaling andT cell support. U-CLL cells had a greater vulnerability to the loss of
environmental prosurvival signals after ibrutinib inhibition. Our data demon-
strate mechanisms underlying the differences in primary ibrutinib sensitivity
between U- and M- CLL patients, supporting the use of inhibitors of BTK and
BCL2 in CLL.
#961 Inhibitors of fıbrosis and TGF-beta delay tumor xenograft growth
and reduce ascites in ovarian cancermodels.QingZhang, XiaonanHou, Brad-
ley J. Evans, John J. Weroha, William A. Cliby.Mayo Clinic, Rochester, MN.
Background: Most ovarian cancer (OC) patients present with advanced dis-
ease and ultimately develop chemo-resistant relapses. Stroma plays a signifıcant
role in OC behavior including invasiveness, fıbrosis and chemoresistance.
TGF- is important for crosstalk between stroma and cancer cells, and stromal
activation in cancer has similarities to matrix remodeling in fıbrosis. We have
shown that TGF- and fıbrosis-inhibitors can suppress OC cell proliferation,
migration and invasion. Such inhibitors are available for clinical use, and we
have begun to test their effıcacy in OC in vivo. Methods: Animal experiments
were approved by Mayo Clinic IACUC. Intraperitoneal xenograft models were
derived from OVCAR8 (5106) cells (OV8-CDX) or 0.1 gm OC patient tumor
tissue (PDX) in NSG mice. OV8-CDX and PDX PH003 (an aggressive,
chemoresistant and ascites-pronemodel) (n5-10mice/arm) were treated with
2 agents and compared to untreated controls (C): 1) C vs. the fıbrosis inhibitor
Pirfenidone (P, 200mg/kg, BID, provided byGenentech); 2) C vs. TGF- recep-
tor I inhibitor Galunisertib (G, 75 mg/kg, BID, provided by Eli Lily). Mice were
pretreated for 2 days before xenografting and treated for 4 weeks with ultra-
sound (US) to measure tumor growth. At day (d) 28, we i) collected tumor
(OV8-CDX); or ii) observed until progression (PH003, PH053). OV8-CDX tu-
mors were used for target gene analysis. Results: P treatment delayed tumor
growth inOV8-CDX relative to control (C): tumors established in 0/5 (P) vs. 1/5
(C), and 1/5 (P) vs. 4/5 (C) of mice at d14 and d28, respectively. The reduced
tumor weight (g) at d28 was also confırmed (0.200.10 vs. 0.540.23, p0.02).
Similarly, P treatment in PH003 inhibited the tumor growth (tumor area (cm2)
at d28: 0.740.43 vs. 1.040.51, p0.28), ascites development (volume (ml):
1.140.54 vs. 3.370.62, p0.05) and prolonged survival time (p0.04). G
treatment was also associated with delayed tumor establishment in OV8-CDX
relative to C: tumors presented in 0/5 (G) vs. 1/5 (C), and 1/5 (G) vs. 4/5 (C) of
mice at d14 and d28, respectively. Associated d28 tumorweightwas signifıcantly
reduced (0.200.10 vs. 0.540.23, p0.02) aswell. For PH003,G treatmentwas
associated with delayed tumor growth (tumor area at d28: 0.570.27 vs.
1.040.51, p0.05), a marked reduction in ascites (volume: 1.250.56 vs.
3.370.62, p0.05) and a prolonged survival time (p0.04) We identifıed
down-regulation of TGF- signaling-related genes (e.g. TGFB1, TGFBR2) and
fıbrosis-related biomarkers (e.g. FAP, COL11A1) following drug treatment con-
fırming inhibition of relevant pathways. Conclusion:We report that 2 currently
available inhibitors targeting either fıbrosis or TGF- appear to have effıcacy in
vivo and delay tumor growth in OC PDXmodels. These results suggest promise
for a strategy of targeting the stromal component of OC.
#962 Novel targeting of tumor-infıltrating TNFR2 Tregs: removing sup-
pression with microenvironment-specifıc antibodies. Heather Torrey, John
Butterworth, Toshiyuki Mera, Yoshiaki Okubo, Limei Wang, Danielle Baum,
Audrey Defusco, Sara Plager, Sarah Warden, Daniel Huang, Eva Vanamee,
Rosemary Foster, Denise L. Faustman.Massachusetts General Hospital & Har-
vard Medical, Charlestown, MA.
Background: A recognized and potent subtype of regulatory T cells (Tregs)
expresses tumor necrosis factor receptor 2 (TNFR2), a member of the tumor
necrosis factor (TNF) superfamily. TNFR2 expressing Tregs are overabundant
in human and murine tumors and are the most potent suppressors of host
immune responses. In addition, recent data in diverse human tumors show that
TNFR2-expressing host T cells are the dominant Tregs in the tumor microen-
vironment, expressed far in excess of OX40 and GITR. Unlike many tumor
markers, TNFR2 has limited expression in the immune system and almost no
expression on parenchymal cells. This makes TNFR2 Tregs an attractive target
for anticancer therapy. Methods: We produced monoclonal antibodies to hu-
man TNFR2 with the goal of inactivating the potent host Tregs that express
TNFR2, competing with the agonism of TNF and inactivating infıltating Tregs
of human tumors. Tregs from fresh ovarian ascites fluidwere compared to Tregs
from normal human blood donors for antibody potency. Results: Using a 48-hr
cell-based Treg assay, we showed that TNFR2 antagonistic antibodies can in-
hibit Treg proliferation, suppress soluble TNFR2 secretion on normal cells and
allowT effector expansion. The antagonism is dominant, succeeding even in the
presence of TNF, which is a TNFR2 agonist. Furthermore, the structural biology
of dominant TNFR2 receptor antagonism uncovers a unique conformation that
equally inhibits downstream NFkB signaling. We also showed that dominant
TNFR2 antibodies in a dose dependent fashion kill Tregs in ovarian cancer
infıltrates more strongly than Tregs from healthy donors. Treg killing in the
cancer microenvironment was dependent on cell proliferation and turnover the
Tregs. Conclusion: In sum, blocking TNFR2 signaling on themost potent Tregs
of the tumor microenvironment with a dominant antagonist antibody selec-
tively heightens death of the immunosuppressive Tregs in the tumor microen-
vironment, at least in ovarian cancer. With the expanding knowledge that
TNFR2 Tregs are the most potent host cells of the immune response, their
dominance in diverse human tumor infıltrates and the natural low expression of
this marker on normal lymphoid cells makes targeting of TNFR2 in the tumor
microenvironment attractive.
#963 Ovarian-dependent SSM2ucd mouse mammary carcinoma cells de-
pend onCyp3a11 epoxygenase activity for proliferation.ZhijunGuo,1 Patrick
McGrarrah,1 Ted Bebi,2 Ashley Mooneyham,1 Alejandra Osorio,3 Cesar Her-
rera,4 Victor Arrieta,4 Sebastian Mohar,4 Irwin Hernandez,4 Robert Klink,1
Robert Cardiff,5 David A. Potter1. 1Univ. of Minnesota, Minneapolis, MN; 2Ma-
calester College, Saint Paul,MN; 3Univ. of Central Florida, Olando, FL; 4Instituto
Nacional de Cancerologia, Mexico City, Mexico; 5Univ. of California, Davis, CA.
Introduction: Silencing of the human cytochrome P450 (CYP)monooxygen-
ase enzymeCYP3A4 in the ERMCF-7 tumor cell line inhibits tumor growth in
the mammary fat pad, but the relative roles of tumor cell intrinsic CYPs vs.
vascular/microenvironment CYPs remain to be determined and a syngeneic
animal model is needed to answer this question. The SSM2ucd ovarian depen-
dent mouse mammary carcinoma cell line forms a transplantable estrogen-re-
ceptor positive (ER) mousemammary tumor in which growth dependence on
cell intrinsic CYPs may be tested in vitro and in vivo. The SSM2ucd cell line is
derived from 129SvJ: homozygous Stat1-null female mice, which develop ER
mammary tumors (1,2). Expression profıling of spontaneously arising mouse
mammary carcinomas in a TP53 KOmodel revealed that the CYP3A4 ortholog
Cyp3a11 is up-regulated in these tumors. Methods: Cyp3a11 bactosomes were
used to assay for NADPH dependent biosynthesis of EETs from arachidonic
acid using an LC-MS/MSmethod. siRNA silencing andCRISPR/Cas9 knock out
of the Cyp3a11 exons 2 and 3 was performed and the cell lines were character-
ized for EET dependence using an MTT assay. The highly potent inhibitor and
chemical probe of CYP epoxygenase activity, hexyl-benzyl-biguanide (HBB),
was used to test dependence of SSM2ucd cells onCYP epoxygenase activity. Total
cellular EETs in SSM2ucd cells exposed to HBB at the IC50were measured by the
LC-MS/MS method. Results: Cyp3a11 was shown to have robust NADPH de-
pendent epoxygenase activity, while SSM2ucd cells were EET dependent for
growth. Silencing of Cyp3a11 was demonstrated to inhibit proliferation of the
SSM2ucd cell line, which was partly abrogated by EETs. CRISPR/Cas9 knock out
of the Cyp3a11 in the SSM2ucd cell line was performed and exon 2 and exon 3
deleted cell lines were derived. SSM2ucd Cyp3a11 knock out cell lines were more
sensitive to EET-induced proliferation under serum free condition than control
lines. HBB potently inhibits the SSM2ucd cell line in vitro (IC5025 uM) and
reduces total cellular EET levels in this cell line at IC50. These results suggest that
we may see inhibitory activity of HBB in a syngeneic 129/SvJ tumor transplan-
tation model. Conclusions: The Cyp3a11 gene can be silenced in the SSM2ucd
cell line, without disrupting cell viability, allowing further study of the roles of
EETs in mouse mammary carcinoma proliferation, survival and clonogenicity.
The Cyp3a11 gene has been knocked out in the SSM2 ucd cell line, allowing in
vitro and in vivo studies of the roles of Cyp3a11 in the growth of ovarian depen-
dent mouse mammary carcinoma. 1. Breast Cancer Res. 2012 Jan 20;14(1):R16
2. PLoS One. 2015 Jun 15;10(6):e0129895].
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#964 A quantitative flow cytometric assay for the simultaneous detection
of PD-L1 in tumor and immune infıltrate present in NSCLC. Ryan T. Rodri-
guez,1 Amanda Chargin,1 RianMorgan,1 Randall K. Wetzel,2 Reginaldo Prioli,2
Bruce Patterson,1 Keith Shults1. 1IncellDx,Menlo Park, CA; 2Cell Signaling Tech-
nology, Danvers, MA.
As our understanding of the inherent complexity of the immune checkpoints
becomes clearer, we must understand the expression of immune modulators
such as PD-L1within the context of the tumormicroenvironment. This includes
measures of immune infıltrate, levels of expression of immunemodulators, such
as PD-L1, on lymphocytes and tumor cells, as well as DNA heterogeneity within
tumor cells. We show here characterization of the rabbit anti-PD-L1 clone
E1L3N compared to other commercial sources of antibody for use in a flow
cytometric assay. First we demonstrate specifıc fluorescence and sensitivity in
tumor derived cell lines and then combine cell lines and PBMCs to form a tumor
microenvironment mimic. When E1L3N was combined with antibodies di-
rected toward CD45, CD3, and CD8, the cellular subsets known to be present in
the tumor micro environment, including cytotoxic lymphocytes, T- helper cells
and CD45 negative tumor derived cells are readily detected. The use of sequen-
tial gating strategies allows the assay to detect PD-L1 on each of these subsets
which, when combined with quantitative MESF beads (Bangs Laboratories)
along with the known fluorescence-to-protein ratio of each antibody, allows the
calculation of the average relative PD-L1 receptors bound for each cell type. This
assay further segregates cells using the DNA-specifıc dye (DAPI) allowing the
measurement of proliferation and delineation of the mutated aneuploid frac-
tion. We demonstrate the assay’s ability to measure quantitative PD-L1 expres-
sion, immune infıltrate, and tumor ploidy inNSCLC tumor samples.We believe
this will be a valuable assay in the clinician’s toolbox tomake informed decisions
for patients who may respond best to PD-1 pathway inhibitors.
#965 Two in one: nanotechnology based strategies for the treatment of
ER breast cancer. Maria Ines Diaz Bessone,1 Lorena Simón-Gracia,2 Pablo
Scodeller,2 Tambet Teesalu,2 Marina Simian1. 1Universidad Nacional de San
Martín, Buenos Aires, Argentina; 2University of Tartu, Tartu, Estonia.
Understanding endocrine resistance mechanisms is key to develop new ther-
apeutic strategies. We focus on the role the tumor microenvironment plays as a
modulator of endocrine therapy resistance in breast cancer, in particular asso-
ciated to Tamoxifen. Studies show that the use of nanoparticles (NPs) as antitu-
mor drug delivery systems is a good strategy to improve the effıcacy anddecrease
secondary effects of conventional chemotherapies. In this context we hypothe-
size that a therapeutic strategy based on the use of Tamoxifen carried in NPs
coated with the tumor penetrating peptide iRGD, would be more effective than
conventional Tamoxifen. Neuropilin-1, that mediates iRGD induced endocyto-
sis, has been shown to be associated to breast cancer stem cells. Thus, we postu-
late that our multifunctional NPs would be effective in reducing this cell popu-
lation, contrary to what is observed with free Tamoxifen. Moreover, iRGD
blocks the interaction between integrin 1 and fıbronectin, a mechanism we
have previously shown induces Tamoxifen resistance (Pontiggia et al. 2012).
NPs were synthesized with polyethyleneglycol and polycaprolactone and coated
with the iRGDpeptide. This peptidewas constructedwith a FAM fluorophore in
order to track the NPs. To evaluate the cell uptake, MCF-7 cells were incubated
for 5 h with iRGD-NP or FAM-NP as a control. NP entry was higher when the
NPs were coated with iRGD, both in 2D and in 3D cultures. Cell viability exper-
iments revealed that Tamoxifen encapsulated inNPswasmore effective than the
free drug (p0,05), and NPs coated with iRGD had an even stronger effect
(p0,01). Moreover, resistance to Tamoxifen induced by fıbronectin was re-
versed with the iRGD-coated NPs, contrary to what is observed with the free
drug. Previously, we demonstrated that treatment with Tamoxifen enhances the
stem cell population in estrogen receptor-positive breast cancer cell lines (Raffo
et al. 2013). In this context iRGD coated NPs lead to a decrease in breast cancer
stem cells as evaluated bymammosphere assays (p0,01). Finally, in vivo tumor
homing was evaluated to test whether the iRGD peptide affected the biodistri-
bution of the NPs. Nude mice carrying MCF-7 breast tumors were treated with
iRGD-NP and control NPs. Tumors were collected at 4 and 24 hrs post inocu-
lation. Frozen sections were analyzed by confocal microscopy revealing that
only the mice treated with the iRGD-NPs had high levels of NPs in the tumor,
compared to the control group. Moreover, frozen sections of kidneys, livers,
lungs and spleen showed very low levels of iRGD-NPs, confırming that the
targeting was effective. In vivo experiments of the impact of iRGD-NPs on tu-
mor growth, metastasis and the stem cell population are ongoing. These results
suggest that iRGD-NPs carrying Tamoxifen could be an effective strategy to
avoid the development of endocrine resistance in breast cancer.
#966 Phase II clinical trial patient responses to themacrophage activating
agent RRx-001 correlate to TGF-  pathway activation and markers for fı-
brosis. Saheli Jha,1 Thomas A. Summers,2 Karen Zeman,3 Christine Brzezniak,3
Corey Carter,3 Lindsey Ferry,3 Jan Scicinski,1 Bryan Oronsky,1 Scot Caroen,1
Jane B. Trepel,4 Pedro Cabrales,5 Regina Day2. 1Epicentrx, Mountain View, CA;
2USUHS, Bethesda, MD; 3Walter Reed National Military Medical Center ,
Bethesda, MD; 4NCI NIH, Bethesda, MD; 5UCSD, La Jolla, CA.
Introduction: RRx-001 is a novel systemically non-toxic small molecule
macrophage stimulating agent with promising activity in an ongoing clinical
trial in small cell and non-small cell lung cancer and in neuroendocrine
tumors. In preclinical studies, RRx-001 activated normally immune-sup-
pressive M2-like Tumor Associated Macrophages (TAMs) to express a series
of pro-inflammatory cytokines and chemokines such as transforming growth fac-
tor-1 (TGF-1), tumor necrosis factor- TNF-), inducible nitric oxide synthase
(iNOS), and interleukins-10 and -12, a profıle that resembles theM1 activatedmac-
rophagestate.Due to its chemotacticactivity formacrophages,TGF-1washypoth-
esized to be involved in the antitumor mechanism of RRx-001. We therefore com-
pared expression patterns of TGF-1 and TGF-RI in patient-derived biopsy
samples obtained at screening and post RRx-001. As TGF-1 is closely associated
with the induction of fıbrosis, we also examined key fıbrosis markers. Methods:
Tumor biopsies before and after treatment with RRx-001 were obtained from con-
sented patientswithNSCLC, SCLC, andneuroendocrine tumors in theQUADRU-
PLE THREAT Phase II clinical trial (NCT02489903). Post treatment biopsies were
obtained following 6 weeks of once-weekly RRx-001 treatment co-incidental with
the fırston-studyCTscan.Tumorsampleswereevaluated immune-histochemically
with putative markers for TGF pathway activation (TGF-1, TGF-R1), fıbrosis
(alpha-smooth muscle actin [-SMA], Matrix metallopeptidase-9 [MMP-9], and
Collagen III deposition), and macrophage activation. Patients were subsequently
followed for tumor progression. Results: Positive immune-histochemical staining
for TGF-1 and TGF-R1 was seen in all responding patients, and in none of the
non-responding patients to date. In responders we also found that MMP-9 and
-SMA activity was down regulated post RRx-001. The down-regulation of these
fıbrosis markers is suggestive of less invasive malignancy. The number of tumor
associated macrophages and their activation was related to the activity of RRx-001.
Conclusions: Our pre and post dose patient derived data to date indicate a correla-
tion between TGF- signaling activation and a response to RRx-001 that may also
correlatewith increasednumbers ofmacrophages, and their activation status, in the
vicinity of the tumor. These data suggest that activation of the TGF-1 pathway, as
evidentby expressionofTGF-1andTGF-R1by tumorcells, couldbeapredictive
biomarker for RRx-001 treatment.
#967 Development of fluorescent-cell based high throughput assay to
identify novel therapeutics of bladder cancer cells through upregulation of
SPARC expression. Chirayu M. Patel. Wake Forest Health Sciences, Winston-
Salem, NC.
Bladder cancer is the most common malignancy affecting the urinary
system with an estimated 76,960 new cases and projected 16,390 deaths in
2016 in the United States. The role of SPARC in various cancers is contextual
and differs based on the tumor classifıcation, malignancy and progression.
We have recently reported the tumor suppressor effect of SPARC in urinary
bladder cancer. We have shown that the loss of SPARC in bladder cancer
resulted accelerated bladder carcinogenesis and metastasis multiple path-
ways involving cell cycle deregulation, inflammation and angiogenesis. We
have also reported that SPARC protein expression signifıcantly decreased in
the cancerous compartment in advanced human bladder cancer as well as in
carcinogen-induced murine urothelial cancer. However, the mechanism of
the downregulation of SPARC expression in cancer in general and in bladder
cancer in particular is still unraveled. The purpose of our study is to develop
a robust, high throughput assay to identify therapeutic candidates as regu-
lators of SPARC expression in bladder cancer. We cloned SPARC promoter
in a third generation lentiviral vector coupled with fluorescent GFP or
mCherry fluorescent protein to quantitatively measure SPARC expression.
We generated stable bladder cancer cell lines expressing SPARC expression
in bladder cancer cell lines. UMUC3 bladder cancer cells were transduced
with lentiviral vector to generate SPARC-promoter reporter system to screen
regulators of SPARC expression. Reporter cells were plated in 96 well plates
and treated with 10uM of FDA-approved and natural product drug libraries.
Real time monitoring of changes in SPARC expression was done by measur-
ing GFP fluorescence intensity using IncuCyte® ZOOM Live Imaging Anal-
ysis System. We identifıed drugs that consistently exhibited dosage-depen-
dent augmentation or down-regulation of SPARC expression in UMUC3
cells. Our screens identifıed novel up-regulators of SPARC expression that
are both standard of care and novel bladder cancer therapeutics. Our efforts
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produced an effıcient robust assay to identify novel therapeutics and regula-
tors of the tumor suppressor SPARC in the bladder cancer ecosystem that
can be used in the adjuvant and neoadjuvant settings.
#968 Podoplanin’s diverse potential as a chemotherapeutic target for oral
squamous cell carcinom. Edward P. Retzbach,1 Harini Krishnan,1 Jhon A.
Ochoa-Alvarez,1 Yongquan Shen,1 Evan Nevel,1 David J. Kephart,1 Evelyne Ka-
lyoussef,2 Soly Baredes,2 Mahnaz Fatahzadeh,3 Kingsley Yin,1 Alan J. Shien-
baum,1 Yukinari Kato,4 Lasse Jensen,5 Gary S. Goldberg1. 1Rowan University,
Stratford, NJ; 2Rutgers New JerseyMedical School, Newark, NJ; 3Rutgers School of
Dental Medicine, Newark, NJ; 4Tohoku University Graduate School of Medicine,
Sendai, Japan; 5Linkoping University, Linkoping, Sweden.
Oral cancer is diagnosed in over 300 thousand people, and kills over 100
thousand people, around the world each year. Current treatments rely on radi-
ation and surgery procedures that often decrease the quality of life for oral
cancer survivors. There is a clear need to improve treatments for these patients.
Over 90%of oral cancers are oral squamous cell carcinoma (OSCC).MostOSCC
cells express the transmembrane receptor podoplanin (PDPN), which has
emerged as a promising target for OSCC treatment. The PDPN receptor pro-
motes tumor cell invasion and metastasis which leads to the vast majority of
cancer deaths. Here, we describe efforts to target PDPN in order to prevent and
treat oral cancer. PDPN can be targeted with Maackia amurensis seed lectin
(MASL) to inhibit tumor cell migration and viability. Recent evidence also sug-
gests that PDPNmay undergo cancer specifıc changes, which indicates another
potential route for targeting PDPN in oral cancer. Taken together, these data
indicate that PDPN can serve as a functionally relevant target to prevent and
combat oral cancer.
#969 Expression of membrane-type matrix metalloproteinases (MT-
MMPS) in head and neck squamous cell carcinomas, a target for prodrug
development. Rene Ankrah,1 Steve D. Shnyder,1 James A. McCaul,2 Phil A.
Batman,1 Robert Falconer,1 Paul M. Loadman1. 1Univ. of Bradford, Bradford,
United Kingdom; 2Royal Marsden Hospital and Northwick Park Hospitals, Lon-
don, United Kingdom.
Introduction: Head andNeck Squamous Cell Carcinomas (HNSCC), a group
of highly aggressive heterogeneous epithelial malignancies, are considered the
fıfth most common cancer with the seventh highest cancer mortality. Despite
advances in treatment, low fıve-year survival rates of around 30% still remain.
Several studies have implicated the actions of matrix metalloproteinases
(MMPs) in HNSCC progression. Their role in mediating extracellular matrix
remodeling is paramount to tumour progression, as they facilitate invasion,
angiogenesis and metastasis. In contrast, expression of active MMPs in normal
tissues is largely absent. MT1-MMP (MMP14) expression is known to correlate
with poor clinical response in several tumour types, but little is known about the
expression of other MT-MMPs in HNSCC. We have assessed the protein ex-
pression of the entire MT-MMP complement in matched tumour and normal
tissues of clinical HNSCC cases by immunohistochemistry, supported byWest-
ern Blot and gene expression data andwill ultimately demonstrate translation of
protein expression into MT-MMP-specifıc proteolytic activity. Differential ex-
pression would support the development of prodrugs specifıcally activated in
the tumour by MMPs. Methods: 32 clinical cases (matched normal & tumour
tissues) were assayed for gene expression of the 6 members of the MT-MMP
family (MMP14,15,16,17,24,25). Expression profıling was carried out using
quantitative real-time reverse transcription-PCR analysis. Analysis of protein
expression used IHC on fıxed sections used withmonoclonal antibodies specifıc
for MT1 to MT6 MMP and Western blot analysis with monoclonal antibodies
optimized for western blotting. Results: The protein expression of all six MT-
MMPs has been characterised in clinical HNSCC samples and related to
matched normal tissue controls. A differential in gene and protein expression
levels exists between theMT-MMPprofıles across the normal and cancer tissues
examined. MT1-, MT3- and MT6-MMP in particular were shown to be highly
overexpressed at both gene and protein level in the majority of tumours. MT2,
MT4 and MT5-MMP expression was low or undetectable in all normal tissue
and low in tumour tissue Conclusion: The existence and demonstration of dif-
ferential MT-MMP protein expression in HNSCC relative to normal tissues is a
valuable tool for prodrug development.MT1-,MT3- andMT6-MMP are highly
expressed in the majority of tumour samples compared to matched normal
control tissue. However, further work to elucidate the proteolytic activity of the
expressed proteins and therefore the proteolytic capacity of tumours is needed to
determine the suitability of HNSCC for prodrug therapy.
#970 Probing the expression and function of aldehyde dehydrogenases in
prostate cancer using ALDH-affınic compounds and siRNA. Maria Sadiq,1
Ali I. Ibrahim,1 Fiona Frame,2 Simon J. Allison,3 Mark Sutherland,1 Roger M.
Phillips,3 Norman J. Maitland,2 Klaus Pors1. 1University of Bradford, Bradford,
UnitedKingdom; 2University of York, York,UnitedKingdom; 3University ofHud-
dersfıed, Huddersfıeld, United Kingdom.
The human aldehyde dehydrogenases (ALDHs) play a major role in detoxi-
fying highly reactive aldehydes into carboxylic acids. Deregulation of ALDHs
have implications in a number of cancers including prostate cancer. They play
an important role as a cancer stem cell (CSC) marker due to high activity found
in CSCs while high expression is also known to lead to resistance to drugs
including docetaxel. Although the exact role of ALDHs is not fully understood,
emerging information indicates several isoforms including ALDH1A3 and
ALDH7A1 play a key role in cancer. To further elucidate the role of ALDHs in
prostate cancer, we here report on the perturbation of ALDH expression and
function using chemical probes and siRNA. Primary prostate epithelial cells
cultured from patient tissue were used for this study. Cancer samples were ob-
tained from radical prostatectomies and benign samples from transurethral re-
section of the prostate. qPCR analysis showed ALDH1A3 to be more highly
expressed than ALDH7A1 in the primary prostate epithelial cultures in 18 pa-
tient samples. Expression of ALDH1A3 was 3-fold higher in the cancer samples
compared to the benign samples. The RNA data correlates with protein expres-
sion in 6 patient samples by immunofluorescence. qPCR analysis also showed
that knockdown of ALDH7A1 resulted in an increase in the expression of
ALDH1A3 suggesting a compensatorymechanism. Trypan blue exclusion assay
showed that knockdown of ALDH1A3, ALDH7A1 or a combination of both
resulted in a reduction in cell numbers. Flow cytometry was used to study cell
differentiation upon knockdown of ALDH1A3, ALDH7A1 or both. In all 7
samples studied there was a reduction in CD49b expression indicating cell dif-
ferentiation. ALDH7A1 knockdown showed a higher level of cell differentiation
in all cases. The colony forming ability of primary cells was also investigated
post-transfection of siRNAs against ALDH1A3, ALDH7A1 or both using the
colony formation assay which resulted in a lower number of colonies in all 7
samples tested. The effect wasmore pronounced in benign prostatic hyperplasia
(BPH) than in malignant cancer samples and patient variability was observed.
ALDH-affınic probe compounds (DEAB and three derivatives, Ali-9, Ali-14 &
Ali-18) were tested against 5 patient samples to investigate if they have an effect
on cell viability. All four compounds showed reduction in cell viability at the
highest concentration while Ali-14 and Ali-18 showed a synergistic effect in
combination treatmentwith docetaxel. In conclusion, knockdownofALDH1A3
andALDH7A1 reduce cell number, induce cells to differentiate and reduce their
colony forming ability. Novel ALDH-affınic probe compounds reduced cell vi-
ability alone and in combination with docetaxel, therefore these compounds
may be of value both as single treatments and to provide a strategy to enhance
taxane-based therapy such as docetaxel.
BIOINFORMATICS AND SYSTEMS BIOLOGY: Computational
Cancer Biology
#971 Genome directed diagnosis informs clinical cancer care. Alexander
Penson, Niedzica Camacho, Anna M. Varghese, Adam Abeshouse, Pedram
Razavi, Aijazuddin Syed, Ahmet Zehir, Nikolaus Schultz, David B. Solit, David
Hyman, Barry S. Taylor, Michael F. Berger.MSKCC, New York City, NY.
Cancer treatment is primarily guided by the organ of origin, which despite
extensive histopathological and clinical evaluation, remains ambiguous inmany
cases andmay be inaccurate in cases of occult primary.We determine the extent
to which routine prospective tumour sequencing, combined with conventional
histopathology, can be used to infer the tumor type and thereby direct clinical
decisions. Characteristic patterns of somatic mutations, broad and focal copy
number alterations, structural rearrangements, mutational signatures, and
other facets acquired from prospective tumor sequencing can inform the tissue
of origin classifıcation of patient disease. Such prospective sequencing of active
cancer patients presents an opportunity to guide diagnosis and therapy beyond
the identifıcation of individual biomarkers of treatment response. Probabilistic
classifıcation allows for systematic combination of genome-directed diagnosis
with conventional histopathology and clinical history in the course of disease
management. Using more than 10,000 tumors collected from advanced cancer
patients at our institution and sequenced using a comprehensive cancer panel
(MSK-IMPACT) encompassing 341 genes, we have developed a probabilistic
classifıer that infers the tumor type from nine broad categories of genomic ab-
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errations. Scores from a RandomForest classifıer are calibrated to correspond to
the probability for each of the 22 interrogated tumor types. In 18% of all cases, a
prediction is made with very high confıdence (greater than 99%), of which just
over 99% agree with the existing diagnosis. The classifıer has been used to guide
clinical decision making, including re-diagnoses that distinguish between a re-
currence and a new primary, spare or encourage surgery, facilitate access to
FDA-approvedmolecularly targeted drugs andprompt germline genetic testing.
We demonstrate that genome-directed diagnosis, based on alterations routinely
identifıed from prospective sequencing, can inform clinical cancer care with the
potential to improve patient outcomes.
#972 Improving pre-clinical cancer pharmacogenomics with novel drug
sensitivity metrics based on growth rate inhibition.Marc Hafner, Mario Nie-
pel, Peter K. Sorger. Harvard Medical School, Boston, MA.
Drug sensitivity in growing cells is conventionally quantifıed by IC50, AUC, or
Emax values, but these metrics suffer from a fundamental flaw: they highly de-
pend on the division rate of cell lines. This dependency creates artefactual cor-
relations between genetic alterations and drug sensitivity which impede bio-
marker discovery. To address this issue, we recently developed novel drug
response metrics insensitive to the number of divisions occurring during the
assay. These are based on estimating growth rate inhibition (GR) under treat-
ment using fıxed assays. Here, we illustrate the flaws of using IC50 values for
pharmacogenomic studies by reanalyzing a recently published large dataset of
drug sensitivity and showing cases in which differences in division rates drive
associations between IC50 values and tissue type or genetic alterations. Using
GR50 values prevents these artifıcial correlations and restores known associa-
tions between drug resistance and genomic markers such as PTEN loss driving
lapatinib resistance in breast cancer cell lines. We also show how use of GRmax
values, a measure of drug effıcacy, allows quantifying differences in the pheno-
types and distinguishing cytostatic from cytotoxic response. For drugs that have
a narrow range of GR50 values like taxanes, effıcacy is the most relevant metric:
in many ovarian BCL2-deleted cell lines, docetaxel induces a cytotoxic response
(negative GRmax values), whereas wild-type lines elicit a cytostatic response
(positive GRmax values). Because effıcacy (GRmax) varies independently of po-
tency (GR50), we conclude that bothmetrics are complementary for pharmacog-
enomics and should be studied jointly. AdoptingGRmetrics requires onlymod-
est changes in experimental protocols and analysis is facilitated by our
interactive website: GRcalculator.org. We expect GR metrics to improve the
identifıcation of reliable drug response biomarkers and enhance the reproduc-
ibility of large-scale sensitivity studies.
#973 Methylation accurately predicts age of cancer onset in patients with
Li Fraumeni Syndrome. BenjaminM. Brew,1 DavidMalkin,1 Lauren Erdman,1
Andrea Doria,1 Jason Berman,2 Adam Shlien,1 Tanya Guha,1 Ana Novokmet,1
Anna Goldenberg1. 1The Hospital for Sick Children, Toronto, Ontario, Canada;
2IWK Health Centre, Toronto, Ontario, Canada.
Introduction: Li Fraumeni Syndrome (LFS) is a rare hereditary genetic
cancer predisposition syndrome. Germline mutations of the TP53 tumor
suppressor gene are the underlying cause in80% of patients with LFS, and
are associated with an increased risk of second tumors and a spectrum of
early onset cancers, even in the absence of a family history of cancer.We have
previously developed and implemented a comprehensive life-long clinical
surveillance protocol for individuals with a germline TP53 mutation. We set
out to make this screening process more targeted by building a predictive
model of age of onset. We accomplished this goal by implementing machine
learning methods on germline methylation data. Methods: We made use of
the Toronto Hospital for Sick Children (SickKids) LFS family cohort in our
predictive model of age of onset. In all, we have 74 patients with germline
methylation data, consisting of450,000 probe sites. We subset this data by
identifying probes that fall into differentially methylated regions between
LFS and cancer patients with wild-type TP53. The probes identifıed in these
regions were used in our predictive model of age of onset. Because age of
sample collection was highly correlated with age of onset (r2  .90), we
corrected for confounding using a strategy that is two-fold: (1) we extracted
the variation of each probe that is independent of the age of sample collection
(the residual after regressing on the age of sample collection) and use these as
predictors in our model, and (2) we test our models on the task of predicting
the age of sample collection for LFS patients that do not have cancer. The
former provided us with more robust predictions while the latter verifıed
that we are in fact predicting age of onset, rather than simply predicting age
at which the sample was collected. Results: Our machine learning model was
able to achieve 86% correlation between true and predicted values of the age
of onset. Additionally, we have tested the ability of our models to predict
whether an individual will be diagnosed before or after the age of 4. Our
classifıcation machine learning model achieved 91% accuracy on average.
We verifıed that our model does not simply predict age of sample collection
by using our cohort of LFS patients that do not have cancer (n  37). The
distribution of the age of sample collection matched those of the patients
used in our model. The model has no predictive power on the age of sample
collection, thus confırming that our model is highly predictive of the age of
cancer onset in LFS TP53Mutation patients. Conclusions: We identifıed two
predictive models for age of cancer onset in LFS patients that achieve high
accuracy, both when predicting the age of onset as a continuous variable
(86% correlation) and whether cancer onset will occur before or after the age
of 4 (91% accuracy). Our model will assist clinicians in targeting high risk
patients for screening, lower the cost of treatment, and raise the likelihood of
survival among LFS patients.
#974 Automating deconvolution of heterogeneous bulk tumor genomic
data. Theodore Roman, Brenda Xiao, Russell Schwartz. Carnegie Mellon Univ.,
Pittsburgh, PA.
Tumor heterogeneity has been linked to many measures of poor patient out-
come. Despite numerous recent methodological advances, though, reliable esti-
mates of clonal and subclonal architecture remain elusive. We present advances
in computational deconvolution of tumor heterogeneity, aimed at better han-
dling complex substructure,more automated inference, and increased flexibility
to heterogeneous genomic data sources. Our methods make use of geometric
models of mixture substructure, a specialized form of a strategy called manifold
learning, to better resolve clonal substructure shared across genomic samples.
We validate themethods onbreast tumor dataset from theCancerGenomeAtlas
(TCGA).We fınd statistically signifıcant Spearman correlation between inferred
mixture models and independently derived clinical subtype across DNA, RNA,
and combined datasets. DAVID tissue term enrichment, applied to inferred
amplifıed gene sets, further yields signifıcant correlation (p 0.01) with various
ontological terms expected for breast tumors, for example, ‘Breast Carcinoma‘.
We further verifıed the ability of the mixture modeling to classify tumors by
progression state, showing cross-validated k-fold loss of 0.2538 in separating
tumors by early (Stage I - II) vs. late (Stages III-IV) stage, corresponding to
signifıcant (p0.001) separation by chi-squared test. The results demonstrate
the effectiveness of our improved geometric deconvolution approach in resolv-
ing clonal structure to separate tumors by biologically relevant pathways and
degrees of progression.
#975 A multiscale computational model for spatio-temporal tumor im-
mune response. Chang Gong,1 Oleg Milberg,1 Bing Wang,2 Paolo Vicini,3
RajeshNarwal,4 LorinRoskos,4Aleksander S. Popel1. 1JohnsHopkinsUniversity,
Baltimore, MD; 2MedImmune, Mountain View, CA; 3MedImmune, Cambridge,
United Kingdom; 4Medimmune, Gaithersburg, MD.
When the immune system responds to tumor development, patterns of im-
mune infıltrates emerge, highlighted by expression of immune checkpoint-re-
latedmolecules such as PD-L1 on cancer cells and its receptor PD-1 on cytotoxic
T cells. Pre-treatment tumor spatial heterogeneity could bear information on
intrinsic characteristics of the tumor lesion for individual patient, and thus has
the potential to comprise biomarkers for anti-tumor therapeutics. We devel-
oped a systems biology computational multiscale agent-based model to capture
the interactions between immune cells and cancer cells during tumor progres-
sion. Cytotoxic T cells and cancer cells are modeled as free-moving agents in a
3-dimensional grid, where each cell acts in response to its local microenviron-
ment and carries out functions such as division, apoptosis, cytotoxic killing and
switching between states with different PD-1 or PD-L1 expression levels. Sub-
sequently, we analyzed the emergent behavior of tumor progression by looking
at all these local interactions as a whole. Using this model, we are able to repro-
duce temporal dynamics of cytotoxic T cells and cancer cells during general
tumor progression, as well as 3-dimensional spatial distributions of these cells
over the time course of the simulation. By varying the characteristics of the
neoantigen profıle of individual patients, such asmutational burden and immu-
nogenicity, a spectrum of pre-treatment spatial patterns of PD-1/PD-L1 expres-
sion is generated in our simulations, resembling immune-architectures ob-
tained via immunohistochemistry from patient biopsies. We evaluate potential
prognostic biomarkers by correlating these spatial characteristics with in silico
treatment results with immune checkpoint inhibitors. Simulation results dem-
onstrate that the percentage of PD-L1 positive cancer cells which are not in close
proximity of the tumor boundary or vasculature is more indicative of successful
anti-PD1/anti-PD-L1 treatment. Our fındings suggest that tumor spatial heter-
ogeneity, especially its immune-architecture, reflects the course of tumor pro-
gression as well as patient-specifıc properties, and is thus likely to carry impor-
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tant information about tumor susceptibility to treatment such as with immune
checkpoint inhibitors. We demonstrated how prognostic biomarkers could be
realistically simulated in a general cancer scenario. The model is further refıned
for use to predict treatment/biomarker combinations in specifıc cancer types.
#976 ImmunoMap: a novel bioinformatics tool for immune cell repertoire
analysis. John-William Sidhom,1 Catherine A. Bessell,1 Jonathan J. Havel,2
Timothy A. Chan,2 Jonathan P. Schneck1. 1Johns Hopkins University, Baltimore,
MD; 2Memorial Sloan Kettering Cancer Center, New York City, NY.
Background: There has been a dramatic increase in T-cell Receptor (TCR)
sequencing spurred, in part, by the clinical demand in Immuno-oncology and
technological advances in TCR sequencing. However, there has been little in the
way of approaches to parse the data in a biologically meaningful fashion. The
ability to parse this data to understand the T-cell repertoire in a structurally
relevant manner has the potential to open new discoveries about how the im-
mune system responds to insults such as cancer and infectious diseases. Meth-
ods: Here we describe a novel method to visualize and quantify TCR repertoire
sequence diversity. This method includes metrics such as visualization of reper-
toire with: 1) weighted phylogenetic trees that display relatedness and frequency
of the sequences; 2) dominant motif analyses identifying clusters of highly ho-
mologous sequences that contribute signifıcantly to response and; 3) TCR di-
versity score measuring the average relatedness (by sequence homology) of all
TCR’s in a sample. To demonstrate the power of the approach, we have applied
it to understanding the CD8 T Cell response to model self (TRP2) and foreign
(SIY) antigens in naïve and tumor-bearing (B16melanoma) B6mice. Addition-
ally, this method was applied to tumor infıltrating lymphocytes, TIL, taken pre-
andon-therapy, frompatients undergoingNivolumab (-PD1) therapy formet-
astatic melanoma. Results: Analysis of the naïve CD8 response demonstrated a
highly conserved (measured by the TCRdiversity score) and less clonal response
to SIY whereas the response to TRP2 was less conserved and highly clonal.
Dominant motif analysis demonstrated highly rich motifs consisting of many
homologous sequences in the SIY response but few sequences per motif in the
TRP2 response. This may reflect the outcome of tolerance mechanisms to self-
antigens. Presence of tumor demonstrated differential immune pressure on the
TRP2 vs SIY response. Tumor primed novel SIY motifs but constricted the
number of dominantmotifs in the TRP2 responsewhile additionally altering the
sequence of the motifs. In patients undergoing -PD1 therapy, we identifıed
signatures in pre- and post-therapy TCR repertoires that correlated with clinical
outcome response. Prior to therapy, patients whose dominant motifs were rich
with many sequences responded favorably to checkpoint inhibition over those
with less rich motifs. After four week on therapy, patients whose TCR reper-
toires became more conserved responded more favorably to PD1 treatment
while those who did not respond had no change in their TCR diversity score.
Conclusions: In summary, we have developed and demonstrated a novel
method to meaningfully parse and interpret TCR repertoire data and have ap-
plied it to yield a novel insight of CD8 T Cell responses to different types of
antigens in model systems as well as key characteristics of TIL repertoires from
patients who respond clinically to -PD1 therapy.
#977 Phenotypic analysis of single-cell breast cancer inhibition data re-
veals insights into EMT. William S. Chen,1 Nevena Zivanovic,2 Dana Pe’er,3
Bernd Bodenmiller,2 Smita Krishnaswamy1. 1Yale School of Medicine, New Ha-
ven, CT; 2University of Zurich, Zurich, Switzerland; 3Columbia University, New
York, NY.
Background: A leadingmodel of cancer metastasis is epithelial-to-mesenchymal
transition (EMT). We sought to determine whether single-cell inhibition data tar-
geting potential mediators of EMT could uncover mechanistic insights into the
EMTprocess.Methods: EMTwas artifıcially inducedonPy2Tmurinebreast cancer
cells by TGFb treatment. Additionally, a unique drug inhibitor was added to each
well of a multiplexed CyTOF experiment. 37 transcription factors and cell surface
markers were measured in each cell to assess epithelial and mesenchymal states,
SMAD, AKT, and MAPK signaling activity, cell cycle regulation, and apoptosis
pathway activation.The fınal single-cell dataset consisted of 300 inhibition and con-
trol conditions (cell populations), whichwe aimed to characterize in relation to one
another with respect to effect on EMT. Analyzing the similarity between drug inhi-
bitions amounts to a novel type of clustering problem that involves computing the
similarity between diverse cell populations generated by each inhibitor. Traditional
methods for comparing cell populations are not robust to the intra-population het-
erogeneity we observed amongst cells undergoing EMT. Thus, we developed Phe-
notypic Earth Mover’s Distance (PhEMD). This method for comparing cell popu-
lations leverages the insight that only a limited number of “cell subtypes” (e.g.
mesenchymal, epithelial, transitional) are observed in unperturbed and perturbed
EMT. By classifying each cell as one of these distinct subtypes using community-
detection based clustering, PhEMDrepresents an inhibition or control condition as
its relative abundance of each cell subtype. It then uses Earth Mover’s Distance
(EMD) to compare two relative abundance distributions (i.e. heterogeneous cell
populations). PhEMD thus derives a single value representing the dissimilarity be-
tween two inhibitionconditions.UsingPhEMDasmeasureofdissimilaritybetween
eachpairof inhibitionandcontrol conditions,weconstructedan inhibitor-inhibitor
graph and used graph clustering to identify groups of inhibitors that had similar
effects to one another. Results: PhEMD analysis revealed that MEK, EGFR and Src
inhibitors signifıcantly halted EMT by generating far fewer mesenchymal cells and
maintaining a large epithelial cell subpopulation. PhEMD also revealed that differ-
ent mTOR, PI3K, and Akt inhibitors tended to have similar effects to one another
and collectively generated adistinct, transitional cell subpopulationwith alteredpS6
expression. The pS6 dysregulationmay be explained by the fact that ribosomal pro-
tein S6 is downstream of PI3K/AKT/mTOR, and the intermediate levels of both
E-cadherin and vimentin suggest that this subset of cells may have been halted
mid-transition. Finally, several Aurora Kinase and CDK inhibitors resulted in a
relatively high percentage of apoptotic cells, suggesting these kinasesmay be impor-
tant cell cycle regulators in the context of EMT.
CANCER CHEMISTRY: Novel Therapeutic Targets, Molecules,
and Approaches for the Treatment of Cancer
#978 Spatial-temporal delivery of OX40 agonist and PD-1 inhibitor using
nanoparticles improves therapeutic effıcacy of cancer immunotherapy. Yu
Mi,ChristofC. Smith, Feifei Yang, Jonathan Serody, BenjaminVincent, Andrew
Z. Wang. UNC Chapel Hill, Chapel Hill, NC.
Background:Cancer immunotherapy isanexcitingnewapproach tocancer treat-
ment and there is strong interest in strategies to improve the long-term durable
response rates of cancer immunotherapy. One approach is to combine checkpoint
inhibitors such as aPD-1 with T cell activator such as OX40 agonist to further in-
crease immune activation. We hypothesized that we can improve the therapeutic
effıcacyof this approachby temporallycontrol theactivationofOX40and inhibition
of PD-1 pathways. To accomplish this, we utilized nanoparticles that can deliver
anti-OX40 and anti-PD1 antibodies simultaneously to T cells. Methods: Agonist
antibody (anti-OX40) and antagonist antibody (anti-PD1) were conjugated to
PLGA-PEG-Maleimide nanoparticles (AANPs) with precise ratio control and
quantifıedbyELISA.Their specifıc binding to the target proteinswas shown invitro
by flow cytometry. The tumor inhibition effıciency was assessed on mice bearing
different tumor models. Two tumors were inoculated subcutaneously (105 B16F10
cells) or on fourthmammary fat pad (105 4T1 cells) onboth flanks ofmice.One side
of tumor was irradiated once and AANPs were injected twice every 3 days. In vivo
depletion experiments were tested on C56Bl6 mice and CD11b/c mice. Different
populations of T cells in tumor and spleen were analyzed by flow cytometry and by
fluorescent IHC staining. T cell killing assay and IFN- ELISpot were studied. Co-
localization was demonstrated with fluorescent labeled antibodies and the corre-
spondingAANPs.Results:AANPs showeda30%cure rate, compared to10%of free
antibodies, 0% of anti-PD1 conjugated NPs, and 0% of anti-OX40 conjugated NPs
in B16F10 melanoma model. We then re-challenged the cured mice with 2105
B16F10 cells and none of the mice developed another tumor. In 4T1 breast cancer
model, the survival rate on day 39 was 50% with AANPs treatment, compared to
22% in the mixture of anti-PD1 conjugated nanoparticles and anti-OX40 conju-
gatednanoparticles, and0%of free antibodies.Wedemonstrated thatAANPs led to
a higher medium TCD8/Treg ratio in tumors. The therapeutic effect was medi-
ated by CD8T cells as elimination of these cells abrogated the therapeutic effects.
In vitro study confırmed that AANPs were able to improve T cell stimulation com-
pared to free antibodies by increasing IFN- excretion (2x). We further confırmed
co-localization of antibodies with AANPs on tumor infıltration T cells in vivo. Our
data demonstrated that spatial-temporal delivery of agonist and antagonist could
improve T cell activation and cancer immunotherapy. Conclusions: Our data dem-
onstrates that spatial-temporal deliveryof agonist andantagonist can improveTcell
activation and cancer immunotherapy.
#979 Discovery of the JAK1 selective kinase inhibitor AZD4205. Jason G.
Kettle,1 Qibin Su,2 Neil Grimster,2 Sameer Kawatkar,2 Scott Throner,2 Richard
Woessner,2 Huawei Chen,2 Geraldine Bebernitz,2 Kristen Bell,2 Erica Ander-
son,2 Linette Ruston,1 JonWinter-Holt,3 Paul Lyne,2 Melissa Vasbinder,2 Clau-
dio Chuaqui2. 1AstraZeneca, Stockport, United Kingdom; 2AstraZeneca,
Waltham, MA; 3AstraZeneca, Cambridge, United Kingdom.
Janus kinases are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine
kinase 2 (TYK2) that are critical in cytokine signalling, with constitutive activa-
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tion of JAK/STAT pathways associated with a wide variety of malignancies.
Elevated JAK/STAT signalling leading to increased activation of STAT3 is re-
ported in a wide variety of cancers, including breast, liver, prostate, colorectal,
head and neck, oesophageal, pancreatic, bladder, and non-small cell lung, and is
implicated in the pathogenesis of diffuse large B-cell lymphoma and nasopha-
ryngeal carcinomas. Overall, up to 70% of human tumours are linked to persis-
tent elevated STAT3 activity which can be associated with poorer prognosis in
many of these settings. In addition, elevated pSTAT3 is observed in response to
chemotherapy treatment, and also in response to treatment with inhibitors of
oncogenic signalling pathways such as EGFR,MAPKandAKT, and is associated
with resistance or poorer response to agents targeting these pathways. In many
of these cases, JAK1 is believed to be a primary driver of STAT3 phosphorylation
and signalling, suggesting inhibition of JAKs as a therapeutic approach to treat
these potential resistance mechanisms. The mixed JAK1/2 kinase inhibitor rux-
olitinib is approved for the treatment ofmyeloproliferative neoplasms including
intermediate or high risk myelofıbrosis and polycythemia vera and has been
tested in a variety of tumor settings. Since JAK2 is essential for the signal trans-
duction downstream of erythropoietin, thrombopoietin and related receptors
that control erythrocyte andmegakaryocyte expansion, dosing of inhibitors that
target JAK2 can be limited by toxicities such as thrombocytopenia and anaemia.
Starting from a non-kinome selective screening hit, structure-based design was
used to optimise a series of aminopyrimidines that led to JAK1-selective candi-
date drug AZD4205. This compound demonstrates ATP competitive binding
with IC50’s in a high ATP concentration enzyme assay against JAK1 of 73 nM
(Ki 2.8 nM), with high selectivity against JAK2 and JAK3with IC50’s of 13,233
nM and 30,000 nM respectively. In addition it showed potent inhibition of
p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and
excellent selectivity across the kinome. In summary, AZD4205 is a highly potent
JAK1-selective kinase inhibitor with excellent preclinical pharmacokinetics
with potential for further clinical development. The optimization from screen-
ing hit to fırst disclosure of this candidate drug will be presented.
#980 BAY-299, a novel chemical probe for in-depth analysis of the func-
tion of the bromodomain proteins BRPF2 and TAF1. Léa Bouché,1 Clara D.
Christ,1 Stephan Siegel,1 Cynthia Tallant,2 Amaury E. Fernández-Montalván,1
Kilian V. Huber,2 Verra Pütter,1 Susanne Müller,2 Oleg Fedorov,2 Antonius ter
Laak,1 Tatsuo Sugawara,1 Detlef Stöckigt,1 Julia Meier,3 Simon J. Holton,1 Ingo
V. Hartung,1 Bernard Haendler1. 1Bayer Pharma AG, Berlin, Germany; 2Struc-
tural Genomics Consortium, Oxford, United Kingdom; 3Merck, Germany.
With the exception of the bromodomain and extra-terminal domain BET
subgroup, little is known about the role of bromodomain (BD) containing pro-
teins in cancer so that there is a dire need for chemical probes addressing other
family members. The bromodomain and PHD-fınger (BRPF) family encom-
passes three paralogs, BRPF1, BRPF2 and BRPF3, which are all found in histone
acetyltransferase (HAT) complexes. BRPF2 is a scaffold protein and its knock-
out leads to embryonic lethality at E15.5, potentially due to its role in embryonic
stem cell differentiation. Here we present the structure-activity relationship
(SAR) and characterization of the fırst selective BRPF2 chemical probe BAY-
299, with additionnal strong activity at TAF1, a major component of the basal
transcription initiation complex TFIID. BAY-299 shows in vitro activity for
BRPF2 (IC50 67 nM) and TAF1 second bromodomain (BD2; IC50 8 nM) in
the TR-FRET assay, as well as in the cellular NanoBRET assay [IC50 (BRPF2)
575 nM; IC50 (TAF1 BD2) 825 nM]. To the best of our knowledge BAY-299 is
the only disclosed inhibitor showing BRPF2 selectivity over its two paralogues
BRPF1 and BRPF3. It belongs to the 1,3-benzimidazolone scaffold and bears a
novel substitutionwhich is responsible for its high BRPF2 selectivity and also for
its inactivity on BET BDs. The dual inhibitory properties of BAY-299 against
BRPF2 and TAF1make it an ideal research tool for further investigation of these
two proteins in physiological and pathological processes.
#981 The design and characterization of a selective TRIM24 degrader.
Lara N. Gechijian,1 Dennis Buckley,1 Matthew Lawlor,2 Thomas Scott,2
Joshiawa Paulk,1 Jaime Reyes,1 GeorgWinter,1 Michael Erb,1 Chris Ott,1 Sirano
Dhe-Paganon,2 James Bradner1. 1Harvard Medical School, Boston, MA; 2Dana
Farber Cancer Institute, Boston, MA.
A fundamental biological understanding of the individual contributions of
functional domains within multidomain proteins is critical to inform therapeu-
tic approaches to targeting mechanisms driving human disease. TRIM24 is a
multi-domain protein that has been broadly characterized as a co-regulator of
transcription. It is therapeutically relevant as it is implicated as a dependency in
many human cancers, however, the potent and selective inhibitors of the
TRIM24 bromodomain do not have well-characterized phenotypic conse-
quences. Where inhibition of one activity of a protein does not appear to be
effıcacious, chemical knockdown tools allow for the acute depletion of the entire
protein, therefore eliminating all protein activities. In this study, we have used
chemical degradation as one strategy to target the entire TRIM24 protein, where
we have shown that a bifunctional degradermolecule hijacks the ubiquitin ligase
machinery for targeted TRIM24 degradation. We have shown that TRIM24
degradation is required to perturb the oncogenic state in leukemia. In this con-
text, TRIM24 degradation rather than bromodomain inhibition alone is re-
quired to displace TRIM24 from chromatin. Using this probe, a further under-
standing of the contribution ofTRIM24domains to its transcriptional activation
function will provide mechanistic insight as to how TRIM24 promotes a gene
expression program permissive of the oncogenic state, as well as inform a ther-
apeutic approach to target multidomain proteins, such as TRIM24, that are
tightly linked to disease.
#982 Development of homogeneous dual-drug ADCs: Application to the
co-delivery of auristatin payloads with complementary antitumor activities.
Matthew R. Levengood, Xinqun Zhang, Kim K. Emmerton, Joshua H. Hunter,
Peter D. Senter. Seattle Genetics, Inc., Bothell, WA.
A common theme in treating cancer is the use of combination chemother-
apy, where multiple drugs with different mechanisms of action are combined
to elicit synergistic activity or overcome differential drug sensitivities. Anti-
body-drug conjugates (ADCs) have emerged as a powerful approach for
treating cancer, combining the tumor targeting specifıcity of monoclonal
antibodies with the potent cell-killing activity of cytotoxic drugs. Like other
therapies, these agents are increasingly being tested in combination with
unconjugated, clinically approved anticancer agents. In addition, emerging
data demonstrates that insensitivity to a particular ADC can be overcome
through delivery of a different payload using the same antibody. For these
reasons, the development of ADCs that can deliver two complementary pay-
loads to a tumor would likely be a signifıcant advancement in ADC technol-
ogy. To enable dual-drug conjugation, we utilized a multiplexing drug car-
rier that contains cysteine residues with orthogonal protecting groups and
identifıed novel conditions for utilization of these protecting groups on a
folded protein. Sequential cysteine unmasking enables discrimination be-
tween conjugation sites to allow for site-specifıc drug conjugation. This
strategy provides homogeneous ADCs bearing 16 total drugs per antibody,
split evenly between the two drug linkers. Importantly, this strategy is flex-
ible, as it does not require engineered antibodies or custom enzymes for
drug-linker conjugation. To demonstrate the potential benefıts of ADC dual
drug delivery, this strategy was applied to the construction of ADCs bearing
two classes of auristatin drug linkers that have different physiochemical
properties and complementary anti-cancer activities. Dual-auristatin ADCs
were tested in cell line and xenograft models that have differential sensitiv-
ities to the individual auristatin components, including those with hetero-
geneous antigen expression or high levels of drug efflux transporters. The
data from these studies demonstrate that the dual-auristatin ADCs were
active on cells and tumors that are refractory to treatment with either of the
individual component drugs. This work highlights the potential for deliver-
ing two synergistic or complementary payloads on a single ADC and pres-
ents a flexible method for constructing dual-drug ADCs with site-specifıc
and homogeneous drug loading.
#983 Identifıcation of potent, highly selective and orally available ATR
inhibitor BAY 1895344 with favorable PK properties and promising effıcacy
in monotherapy and combination in preclinical tumormodels.Ulrich T. Lu-
ecking,1 Julien Lefranc,1 AntjeWengner,1 LarsWortmann,1Hans Schick,2Hans
Briem,1 Gerhard Siemeister,1 Philip Lienau,1 Christoph Schatz,1 Benjamin
Bader,1 Gesa Deeg,1 Franz von Nussbaum,1 Michael Brands,1 Dominik Mum-
berg,1 Karl Ziegelbauer1. 1Bayer Pharma AG, Berlin, Germany; 2ASCA GmbH,
Berlin, Germany.
The integrity of the genome of eukaryotic cells is secured by complex signal-
ing pathways, known as DNA damage response (DDR). Recognition of DNA
damage activates DDR pathways resulting in cell cycle arrest, suppression of
general translation, induction of DNA repair, cell survival or even cell death.
Proteins that directly recognize aberrant DNA structures recruit and activate
kinases of the DDR pathway, such as ATR (ataxia telangiectasia and Rad3-
related). ATR responds to a broad spectrum of DNAdamage, including double-
strand breaks (DSB) and lesions derived from interference with DNA replica-
tion as well as increased replication stress (e.g. in oncogene-driven tumor cells).
Therefore, inhibition of ATR kinase activity could be the basis for a novel anti-
cancer therapy in tumors with increasedDNAdamage, defıciency inDNAdam-
age repair or replication stress. Herein we report the identifıcation of the potent,
highly selective and orally available ATR inhibitor BAY 1895344 by a collabor-
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ative effort involving medicinal chemistry, pharmacology, DMPK and compu-
tational chemistry. The chemical structures of lead compound BAY-937 and
clinical candidate BAY 1895344 as well as themain SAR trends within this novel
class of naphthyridine derivatives will be disclosed for the fırst time. The novel
lead compoundBAY-937 revealed promising inhibition ofATR (IC50 78nM)
and high kinase selectivity in vitro. In cellular mechanistic assays BAY-937 in-
hibited hydroxyurea-induced H2AX phosphorylation (IC50  380 nM) dem-
onstrating the anticipated mode of action. Moreover, BAY-937 was shown to
inhibit proliferation of a variety of tumor cell lines with low- to sub-micromolar
IC50 values. In initial xenograft studies, BAY-937 revealed moderate activity in
monotherapy and in combination with cis-platin. However, BAY-937 also re-
vealed low aqueous solubility, low bioavailability (rat) and activity in the hERG
patch clamp assay. Extensive lead optimization efforts led to the identifıcation of
the novel, orally available ATR inhibitor BAY 1895344. In vitro, BAY 1895344
was shown to be a very potent andhighly selectiveATR inhibitor (IC50 7 nM),
which potently inhibits proliferation of a broad spectrum of human tumor cell
lines (median IC50  78 nM). In cellular mechanistic assays BAY 1895344
potently inhibited hydroxyurea-induced H2AX phosphorylation (IC50  36
nM). Moreover, BAY 1895344 revealed signifıcantly improved aqueous solubil-
ity, bioavailability across species and no activity in the hERG patch-clamp assay.
BAY 1895344 also demonstrated very promising effıcacy in monotherapy in
DNA damage defıcient tumor models as well as combination treatment with
DNA damage inducing therapies. The start of clinical investigation of BAY
1895344 is planned for early 2017.
#984 Identifıcation of potent and highly selective PTEFb inhibitor BAY
1251152 for the treatment of cancer: from p.o. to i.v. application via scaf-
fold hops. Ulrich T. Luecking,1 Arne Scholz,1 Dirk Kosemund,1 Rolf Bohl-
mann,1 Hans Briem,1 Philip Lienau,1 Gerhard Siemeister,1 Ildiko Terebesi,1
Kirstin Meyer,1 Katja Prelle,1 Ray Valencia,2 Stuart Ince,2 Franz von Nuss-
baum,1 Dominik Mumberg,1 Karl Ziegelbauer,1 Michael Brands1. 1Bayer
Pharma AG, Berlin, Germany; 2Bayer HealthCare Pharmaceuticals Inc.,
Whippany, NJ.
PTEFb/CDK9 mediated transcription of short-lived anti-apoptotic sur-
vival proteins like Mcl-1 and Myc plays a critical role in cancer cell growth
and survival in various tumor entities including AML. In addition, these
survival proteins play important roles in the development of resistance to
chemotherapy. We previously disclosed the preclinical profıle of BAY
1143572, the fırst selective, orally available PTEFb/CDK9 inhibitor that en-
tered clinical development 1
3
. BAY 1143572 had low nanomolar activity
against PTEFb/CDK9, an at least 50-fold selectivity against other CDKs in
enzymatic assays and broad anti-proliferative activity against a panel of tu-
mour cell lines with sub-micromolar IC50 values. BAY 1143572 also showed
single agent in vivo effıcacy at tolerated doses in various xenograft tumour
models in mice and rats upon once daily oral administration. To fully ex-
plore future treatment options using selective PTEFb/CDK9 inhibitors we
initiated a follow-up program to identify novel PTEFb/CDK9 inhibitors for
treatment of cancer with increased potency enabling i.v. treatment of pa-
tients. Extensive lead optimisation efforts, including various scaffold hops,
led to the identifıcation of BAY 1251152. In comparison to oral BAY
1143572, BAY 1251152 shows signifıcantly increased biochemical (IC50
CDK9  3 nM) and cellular potency (IC50 MOLM13  29 nM), increased
selectivity against CDK2 as well as high permeability and no efflux. The
signifıcantly reduced therapeutic dose and high solubility of BAY 1251152
enable the desired i.v. application. BAY 1251152 demonstrated excellent
effıcacy upon i.v. treatment in xenograft models (e.g. MOLM13) in mice and
rats. BAY 1251152 is currently being evaluated in Phase I studies
(NCT02635672; NCT02745743) to determine the safety, tolerability, phar-
macokinetics and initial pharmacodynamic biomarker response in patients
with advanced cancer. This presentation will highlight the key learnings
from our PTEFb/CDK9 i.v. lead optimization program and disclose the
structure of BAY 1251152 for the fırst time. [1]: Proceedings of the 107th
Annual Meeting of the American Association for Cancer Research; 2016 Apr
16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14
Suppl):Abstract nr 3022. [2]: Proceedings of the 106th AnnualMeeting of the
American Association for Cancer Research; 2015 Apr 18-22; Philadelphia,
PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr
DDT02-02. doi:10.1158/1538-7445.AM2015-DDT02-02. [3]: Proceedings of
the 106th Annual Meeting of the American Association for Cancer Research;
2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res
2015;75(15 Suppl):Abstract nr 2828. doi:10.1158/1538-7445.AM2015-2828.
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#985 Adipose tissue inflammation in breast cancer survivors: effects of a
16-week aerobic and resistance exercise intervention.ChristinaM.Dieli-Con-
wright,1 JeanHughes-Parmentier,2 Kyuwan Lee,1 Darcy Spicer,1WendyMack,1
Fred Sattler,1 Steven D. Mittelman2. 1University of Southern California, Los An-
geles, CA; 2Children’s Hospital Los Angeles, Los Angeles, CA.
BACKGROUND AND PURPOSE: Obesity is a leading modifıable contribu-
tor to breast cancer mortality due to its association with increased recurrence
and decreased overall survival rate. There are over 2.5 million breast cancer
survivors, 64% of whom are overweight/obese (BMI 25 kg/m2). A central
mechanism by which obesity stimulates cancer progression is through chronic,
low-grade inflammation in white adipose tissue, leading to accumulation of
adipose tissue macrophages (ATMs), in particular the pro-inflammatory M1
phenotype macrophage. Exercise has been shown to reduce M1 ATMs, and
increase the more anti-inflammatoryM2 ATMs in obese adults. The purpose of
this study was to determine whether a 16-week exercise intervention would
positively alter adipose tissue inflammation by changing ATM phenotype and
cytokine secretion in obese postmenopausal breast cancer survivors. EXPERI-
MENTAL DESIGN: Twenty obese postmenopausal breast cancer survivors
were recruited fromUSC and randomized to either the exercise (EX) or control
(CON) group. The EX group participated in 16 weeks of supervised exercise
sessions 3 times/week. Sessions included total-body resistance training consist-
ing of 8 exercises with a rest period of 45 seconds between each set of resistance
exercise followed by 30 minutes of moderate-vigorous intensity (65-80%
HRmax) aerobic exercise. The CON group was asked to maintain their current
activity levels. Superfıcial subcutaneous abdominal adipose tissue biopsies were
performed at baseline and following the 16-week study period. Adipose tissue
samples were analyzed using fluorescence-activated cell sorting (FACS) to char-
acterize ATM characterization (M1 vs M2). Portions (100 mg) of each biopsy
were incubated inmedia overnight to measure cytokine secretion. A 2x2 (group
x time) repeated measures ANOVA was used to evaluate changes in adipose
tissue and systemic inflammation. SUMMARYOFRESULTS: At baseline, there
were no group differences (p0.05) in age (55.15.2 yrs), BMI (34.47.5 kg/
m2), percent body fat (36.24.9%), or ATM M1 (25.46.7%) and M2
(4.20.9%) levels. EX was associated with a signifıcant decrease in ATM M1
(-18.87.3%) and increase in ATMM2 (9.61.6%; p0.01). EX increased ad-
ipose tissue secretion of the anti-inflammatory cytokines, adiponectin
(14.65.2%), IL-12 p40 (2.40.8), IL-12 p70 (2.81.8%) and decreased secre-
tion of IL-6 (-4.82.0%), and TNF-a (-2.00.7; p0.01). The CON group did
not experience any changes in ATM characterization and cytokine secretion
during the study period (p0.01). CONCLUSIONS: A 16-week aerobic and
resistance exercise intervention attenuates adipose tissue inflammation in obese
postmenopausal breast cancer survivors. Future large randomized controlled
trials are warranted to investigate the impact of exercise-induced reductions in
adipose tissue inflammation and breast cancer recurrence.
#986 Targeting nicotinic acetylcholine receptors for the prevention and
reversal of chemotherapy-induced peripheral neuropathy. S Lauren Kyte,1
Wisam Toma,1 Ganeshsingh Thakur,2 M Imad Damaj,1 David A. Gewirtz1.
1Virginia Commonwealth Univ., Richmond, VA; 2Northeastern University, Bos-
ton, MA.
While chemotherapy has played a signifıcant role in the survival of cancer
patients, exposure to drugs such as the taxanes, platinum-based compounds,
and bortezomib often results in chemotherapy-induced peripheral neuropathy
(CIPN), a consequence of peripheral nerve fıber dysfunction or degeneration.
CIPN is characterized by sensory symptoms such as numbness, burning pain,
and allodynia, resulting in an overall decrease in quality of life. Paclitaxel
(Taxol), a taxane that is commonly used to treat breast, lung, and ovarian can-
cers, has been found to cause CIPN in 59-78% of cancer patients. There is cur-
rently no effective preventative or therapeutic treatment for this side effect,
which can be a dose-limiting factor or delay treatment. Our studies have estab-
lished that the prototypical nicotinic acetylcholine receptor (nAChR) agonist,
nicotine, is capable of preventing and reversing the development of paclitaxel-
induced CIPN, and does not stimulate tumor growth or interfere with the cyto-
toxic properties of paclitaxel.MaleC57BL/6Jmicewere treatedwith paclitaxel (8
mg/kg, i.p.) every other day for a total of four injections. Nicotine was either
infused via a subcutaneous 7-day osmoticminipump (24mg/kg/day) starting 48
hours prior to paclitaxel treatment, or acutely injected (0.9mg/kg, i.p.) following
paclitaxel treatment. Von Frey fılament testing revealed that nicotine can pre-
vent and reverse paclitaxel-induced mechanical allodynia; the latter effect of
nicotine can be inhibited by the 7 nAChR antagonist methyllycaconitine (10
mg/kg, s.c.). Also,7 nAChRknockoutmice exhibit a greater sustained decrease
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in mechanical threshold after paclitaxel administration than wild-type mice,
suggesting the involvement of this receptor in CIPN development and mainte-
nance. This hypothesis was supported by the reversal of paclitaxel-induced me-
chanical allodynia by the7 nAChR silent agonist R-47.While nicotine activates
its receptors in the tumors cells, based on stimulation of the PI3K/Akt pathway,
MTT/MTS colorimetric assays showed that concentrations of nicotine ranging
from 0.1 to 10 M fail to signifıcantly increase the viability of A549 or H460
non-small cell lung cancer cells, murine Lewis lung carcinoma cells, or primary
human lung cancer cells. Most importantly, the paclitaxel-induced decreases in
H460 proliferation and LLC viability are not signifıcantly attenuated by 1 M
nicotine. Moreover, 1 M nicotine does not interfere with paclitaxel-induced
apoptosis of A549 cells. Finally, R-47 also suppresses CIPN without increasing
lung tumor cell viability and colony formation, or interfering with the cytotox-
icity of paclitaxel. Our in vitro fındings are supported by studies demonstrating
that nicotine does not enhance tumor volume or cause premature death in
tumor-bearing mice. These data suggest that nAChRs may be promising drug
targets for the prevention and treatment of CIPN.
#987 Unanticipated cardiotoxicity due to targeted anti-cancer therapy in
hematologicmalignancies patients: Natural history and risk factors.Chintan
Shah, Yan Gong, Anita Szady, Qian Sun, carl J. Pepine, Taimour Langaee, Alex-
andra R. Lucas, Jan S. Moreb. Univ. of Florida, Gainesville, FL.
INTRODUCTION: Unanticipated cardiotoxicity is now identifıed as a signifı-
cant clinical problem associated with new anti-cancer targeted agents. Risk factors
and natural history are still poorly understood.We aim to determine potential clin-
ical risk factors for cardiotoxicity among patients with hematologic malignancies
(HM)whowere treated with targeted therapies over a 10-year period.METHODS:
We used 114 diagnosis codes for HM and 17 codes for cardiac diseases in order to
identify patients in our electronicmedical records (EPIC) and identify patientswith
HM who met above criteria. Cardiotoxicity was defıned mainly by left ventricular
ejection fraction (LVEF) of 50%, arrhythmias, or ischemic cardiovascular event
that occurred after initiation of the drug of interest. The targeted agents of interest
include tyrosine kinase inhibitors (TKIs), proteasome inhibitors, monoclonal anti-
bodies, hypomethylating agents, and immunomodulatory agents.Multivariable lo-
gistic regression was performed to estimate the odds ratios (ORs) and 95% confı-
dence intervals (95% CI) of the potential risk factors. Kaplan-Meier analysis and
log-rank test were used to evaluate the effect of cardiotoxicity on the overall survival
of the patients. RESULTS: Of 820 patients with both HM and cardiac diagnosis, 29
patients developed cardiotoxicity after initiation of targeted therapies. We selected
70 matched controls based on type of targeted therapy. In the study group, the
median time from exposure to cardiac event was 120 days (range, 1-1176). Signifı-
cantly higher number of patients had prior exposure to anthracyclines in study
versus control group (65.5% vs 42.8%, P0.04), however, this was not signifıcant in
multivariable analysis.Multiple other variables, including traditional risk factors for
heart disease,were analyzed anddidnot differ signifıcantly between the two groups.
Only two variables remained signifıcant in the multivariable analysis, including
prior history of DVT/PE (OR 4.88, 95% CI: 1.44-16.54, P0.011), and Karnofsky
scoreof	80%(OR3.99,95%CI:1.51-10.6,P0.005).Withmedian follow-upof27
months (range, 1-120), 17 patients in the study group died, but only 2 of cardiac
causes. Repeat echocardiograms showed worsening of LVEF in 4 patients while
stable/improved in 23 patients, and 21 patients were able to receive further chemo-
therapy. There was a trend towards worse overall survival in the study group (P
0.071). CONCLUSIONS: About 3.5% of patients with HM experience unantici-
pated cardiotoxicity due to targeted anti-cancer agents with relatedmortality of 6.8
%.Most patients dowellwith stable compensated cardiac function and35%have an
objective improvement in LVEF. Risk of cardiotoxicity was signifıcantly higher in
patients with known history of DVT/PE. Future studies of possible underlying ge-
netic predisposition will be of great importance.
#988 Effect of a supervised exercise interventionon sarcopenic obesity and
metabolic syndrome in prostate cancer patients: A randomized pilot study.
Jacqueline L. Kiwata, Tanya B. Dorff, E. T. Schroeder, Christina M. Dieli-Con-
wright. University of Southern California, Los Angeles, CA.
Purpose: Prostate cancer survivors (PCS) on androgen deprivation therapy
(ADT)experienceadverse sideeffects suchas skeletalmuscle lossandadipositygain,
together called sarcopenic obesity, and changes in cardiometabolic factors that in-
crease risk of metabolic syndrome (MetS). Resistance exercise can increase skeletal
muscle mass, but no exercise interventions to date in PCS on ADT have concomi-
tantly improved sarcopenic obesity and cardiometabolic risk factors. Utilizing a
12-week intervention of progressive resistance exercise designed to target skeletal
musclemass, this ongoingpilot trial investigates sarcopenic obesity andas a second-
ary analyses,MetS components, inPCSonADT.Methods: EighteenPCS (65.68.8
yr) on current or previous ADT were recruited from the USC Norris Comprehen-
sive Cancer Center and randomized to resistance training (RT; n9) or a control
stretching program (CS; n9). Body composition, measured through dual-x-ray
absorptiometry, and MetS outcomes, including waist circumference, blood pres-
sure, fasting blood glucose, triglycerides and HDL, were assessed at baseline and
after the 12-week intervention. Appendicular skeletalmuscle index (ASMI), a com-
mon index of sarcopenia, was calculated from body composition. RT performed a
supervised total-body resistance exercise and stretching program 3 times/week. CS
performed home-based stretching 3 times/week. Baseline differences were tested
with univariate ANOVA. Differences in all outcomes were tested with 2(group) x
2(time) ANOVA. Results: No signifıcant differences in ADT duration, Gleason
score, body fat, skeletal muscle mass, or MetS components were found between
groups at baseline (P0.05).RTprogramcompliancewas 98.3%,whileCSprogram
compliancewas 75.5%.Post-intervention, signifıcant increaseswere observed inRT
compared toCS for appendicular skeletalmass (meanSE; 0.8.4 kg; P0.04) and
ASMI (0.3.1 kg/m2; P0.041). A nonsignifıcant decrease in body fat (%) was
observed in RT compared to CS (1.3.7 %; P.067; d0.89). No differences were
found in MetS components. Conclusions: While 12 weeks of resistance exercise in
PCS on ADT improved skeletal muscle mass, no changes in adiposity and MetS
variables were observed. Future interventions are needed for PCS to determine the
optimal exercise prescription to target both sarcopenic obesity and cardiometabolic
risk factors.
#989 Do physician-reported toxicities accurately reflect patient-reported
symptom burden? An analysis of ESAS and CTCAE for patients with lung
cancer. Bansi Savla,1 Thomas Dilling,2 Syeda Mahrukh Naqvi,2 Jae K. Lee,2
Hsiang-HsuanM. Yu2. 1University of South Florida, Tampa, FL; 2Moffıtt Cancer
Center, Tampa, FL.
Purpose/Objectives: Symptomadverse events canbequantitativelymonitoredby
oncologists with theU.S. National Cancer Institute’s CommonTerminology Crite-
ria for Adverse Events (CTCAE). Symptoms can also be reported by patients
through the Edmonton Symptom Assessment Scale (ESAS). There is increasing
recognition of the importance of assessing patient-reported symptoms as part of
clinical care. The aim of this study is to examine correlation between patient-re-
ported and physician-graded symptoms in patients with lung cancer who under-
went external beam thoracic radiotherapy, in an attempt to identify gaps between
these parameters.Materials/Methods: Between August 2015 and July 2016, 265 pa-
tientswithdiagnosis of lung cancerhad completedESASandCTCAEdata obtained
during weekly clinic visit while undergoing thoracic radiotherapy.The following
stratifıcation for symptomseveritywasused:ESAS (none, 0;mild1-3,moderate 4-6,
severe 7-10) andCTCAE scores (none, 0;mild, 1;moderate, 2; and severe, 3-4). Five
associated symptoms were compared: tiredness, nausea, shortness of breath, and
other (cough and dysphagia) from ESAS and fatigue, nausea, dyspnea, cough and
esophagitis fromCTCAE. Frequency tables and boxplots combinedwith the scatter
plots were used to assess the distribution, correlation and to identify possible outli-
ers. Spearman correlation coeffıcients were analyzed to evaluate rank-associated
correlations between associated ESAS domains and CTCAE toxicities. Results: Sta-
tistical analysis showed that the associated ESAS symptoms and CTCAE toxicity
pairs (tiredness/fatigue, nausea, shortness of breath/dyspnea, dysphagia/esophagi-
tis, cough) were highly correlated (p0.05), However, analysis showed that ESAS
reportedbypatients screens formore severe symptoms than the toxicities gradedby
physicians using the CTCAE; this includes fatigue (16.1% as opposed to 0.5%),
nausea (5.0%asopposed to0.0%),dyspnea (11.8%asopposed to2.4%), cough(2.1%
as opposed to 0.2%), and esophagitis (1.5% as opposed to 0.5%). ESAS collected
additional symptom domains including overall wellbeing symptoms, depression,
anxiety, and spiritual wellbeing, which are not included on CTCAE. ESAS detected
6.2% of patients reporting severe depression, 8.3% with severe anxiety, 9.7%mark-
ing severe for poor overall wellbeing, and 8.3% marking severe for poor spiritual
wellbeing. Conclusion: This studied demonstrated that while ESAS and CTCAE
reports are correlated,patients reportedmore severe symptoms throughESAScom-
pared to physician-graded toxicities from CTCAE in this group of lung cancer pa-
tients who underwent thoracic radiotherapy. Systematic acquisition of patient-re-
ported symptoms is important tooptimize clinical care and symptommanagement.
#990 Patterns of racial disparities in health-related quality of life among
colorectal cancer patients and relationship with survival.Michelle A. T. Hil-
debrandt, Alem A. Belachew, Monica E. Reyes, Yuanqing Ye, Xifeng Wu. UT
MD Anderson Cancer Center, Houston, TX.
Distinct racial disparities are evident in CRCprognosis with Black patients expe-
riencing worse outcomes than Hispanics and Whites. In a prior study of Health
Related Quality of Life (HR-QoL) in a cohort of CRC patients, we observed that
racialminoritypatients experienced lowerHR-QoLscores compared toWhiteCRC
patients. Therefore, in this study, we focused on the identifıcation of patterns of
racial disparities in HR-QoL scores and relationship to differences in prognosis.
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White (N450), Hispanic (N366), and Black (N316) CRC patients within 1
yearofdiagnosis atMDAndersonCancerCenter completed theSF-12quality of life
questionnaire todetermineMentalCompositeSummary (MCS)andPhysicalCom-
posite Summary (PCS) scores. Participants also completed aquestionnaire to collect
epidemiology and sociodemographic variables. Vital status and histology informa-
tion was obtained from the institutional tumor registry. Racial disparities were re-
ported inHR-QoLwithbothBlackandHispanicpatients reporting lowermeanPCS
and MCS scores compared to White patients, suggesting poorer HR-QoL in these
populations. We observed differences in patterns of association between epidemi-
ology and sociodemographic variables and poor HR-QoL by race. Hispanics who
never married were at higher risk of poor physical HR-QoL (OR: 2.55(1.15-5.67),
P0.021) compared tomarriedpatients,whichwasnotobserved forWhiteorBlack
CRC patients. Similarly, CRC patients with some college education was associated
with a decreased risk of poor PCS, but only in Hispanics (OR: 0.26(0.13-0.52),
P0.0001).White femaleshaveabout two-fold riskofpoorPCS(P2.00x10-4) and
MCS (P2.21 x 10-4) scores compared to White males. This relationship was also
observed for Black females OR: 2.28(1.35-3.84), but not Hispanic females. Among
CRC patients reporting poor PCS (50), signifıcant differences inmedian survival
times (MSTs) were observed by race. Hispanic patients had the highestMST at 85.4
months followed by Blacks (47.8 months) and Whites (43.2 months). A similar
relationshipwas observed for poorMCS (50) stratifıed by racewithMST times of
81.9months for Hispanics, 40.8months for Blacks, and 54.1months forWhites. In
conclusion, we identifıed patterns of racial disparities in epidemiology and sociode-
mographic factors that correspond to poor baseline HR-QoL in CRC patients. We
also demonstrated that a prognostic correlation exists between baseline HR-QoL
and patient overall survival, and that this relationship is influenced by race. The
patterns of racial disparity identifıed in this study can be an important tool for
assessing theunderlyingmediators ofHR-QoL inCRCpatients and to further iden-
tify those who are particularly at risk for poor prognosis.
#991 Association of high-sensitivity C-reactive protein with health-re-
lated quality of life among breast cancer survivors. Hyun Jeong Cho,1 Zisun
Kim,2 Hyun Jo Youn,3 Jihyoung Cho,4 Jung Eun Lee5. 1Sookmyung Women’s
University, Seoul, Republic of Korea; 2Soonchunhyang University Bucheon Hos-
pital, Bucheon, Republic of Korea; 3ChonbukNational UniversityMedical School,
Jeonju, Republic of Korea; 4Keimyung University School of Medicine, Daegu, Re-
public of Korea; 5Seoul National University, Seoul, Republic of Korea.
Backgrounds/AimsDecline inhealth-relatedqualityof life (HRQoL) isassociated
with worse prognosis among patients with breast cancer. Increased risk of inflam-
mationwithcancer-relatedsymptomssuchas lowphysical function,depressionand
pain could be a potentialmechanism.We aimed to examinewhether high-sensitiv-
ity C-reactive protein (hs-CRP)were related toHRQoL among breast cancer survi-
vors.MethodsThis cross-sectional studyofKoreanbreast cancer survivors included
a total of 165women aged 29 to 63 years who had been diagnosedwith stage I to III
breast cancer and survived six months or more after surgery. Post-diagnostic
HRQoL levels weremeasured using the 36-Item Short FormHealth Survey (SF-36)
containing eight components: physical functioning, role-physical, body pain, gen-
eral health, vitality, social functioning, role-emotional, and mental health. The
higher scores indicated betterHRQoL. Circulating levels of hs-CRPweremeasured
usingparticle-enhanced immunoturbidimetric assay.Wecategorizedhs-CRP levels
to four groups;0.4, 0.4-0.6, 0.6-1.0 mg/L (low risk), and	1.0 mg/L (average
or high risk) on the basis of the Centers for Disease Control/AmericanHeart Asso-
ciation criteria (low risk;1.0mg/L, average risk; 1.0-3.0mg/L, and high risk;3.0
mg/L).We calculated the least squaremeans (LS-means) and 95%confıdence inter-
vals (CIs) using generalized linear models (GLM) to examine the associations of
eachcomponentwithcategoriesofhs-CRPaccording toHRQoLlevels.Weadjusted
for ageatdiagnosis, bodymass indexatdiagnosis,weight change, income level, stage
at diagnosis, time since surgery, tumor size andplasma vitaminD levels. ResultsWe
found that increasing levels of physical functioning and role-physical components
were associated with decreasing levels of hs-CRP; according to0.4, 0.4-0.6, 0.6-
1.0, and	1.0 mg/L of hs-CRP, LS-means (95% CIs) were 78.1 (73.2-83.0), 75.2
(69.6-80.8), 76.1 (69.5-82.7), 70.1 (64.5-75.7), respectively (p for trend 0.05) for
physical functioning and 77.5 (70.6-84.4), 81.0(73.2-88.8), 79.4(70.2-88.7),
66.6(58.7-74.4), respectively (p for trend 0.05) for role-physical. Higher scores of
mental components were also associated with lower levels of hs-CRP; LS-means
(95% CIs) of0.4 and	1.0 mg/L of hs-CRP levels were 84.6 (77.8-91.4) and 67.1
(59.4-74.9; p for trend 0.002) for role-emotional, 87.4 (82.3-92.6) and 77.4 (71.5-
83.4; p for trend 0.03) for social functioning, 62.4 (56.4-68.4) and 53.3 (46.5-60.2;
p for trend 0.05) for vitality. Conclusions High circulating levels of hs-CRP, an
inflammation biomarker, were associated with lower levels of HRQoL among Ko-
rean breast cancer survivors. Funding information This research was supported by
the Basic Science Research Program through the National Research Foundation of
Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-
2014R1A2A2A01007794)
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#992 Patient-derived tumor organoids of neuroendocrine prostate can-
cer. Loredana Puca,1 Rohan Bareja,1 Reid Shaw,2 Wouter Karthaus,3 Dong
Gao,3 Chantal Pauli,1 Juan Miguel Mosquera,1 Joanna Cyrta,1 Rachele Rosati,4
Rema Rao,1 Andrea Sboner,1 Carla Grandori,4 Giorgio Inghirami,1 Yu Chen,3
Mark A. Rubin,1 Himisha Beltran1. 1Weill Cornell Medicine, New York, NY;
2Cure First, seattle, WA; 3Memorial Sloan Kettering, New York, NY; 4Cure First,
Seattle, WA.
Background: The development of neuroendocrine prostate cancer (NEPC) is
one mechanism of treatment resistance to androgen receptor (AR)-targeted
therapies for a subset of patients with advanced prostate cancer. This is associ-
ated with transition from a prostate adenocarcinoma to small cell/NEPC histol-
ogy, low AR signaling signaling, and expression of neuroendocrine markers as
Chromogranin A (CGHA), Synaphophysin (SYP) and CD56). Patient derived
preclinical models recapitulating the NEPC phenotype may be used to address
NEPC pathogenesis and test emerging therapeutic targets. Methods: Tumor
organoids were developed according to protocols previously described (Gao et
al, Cell 2015). Briefly the tissue biopsies (liver and bone biopsy) were washed,
enzymatically digested and then seeded in Matrigel (BD) droplets. Organoids
were characterized at genomic (WES), RNA and protein level (IHC) to confırm
the expression of specifıc markers. Lentiviral infections were performed using
shRNAs against EZH2 to knock down EZH2 in organoids. Organoids were also
subcutaneously injected in NSG mice to generate patient derived xenografts
(PDXs) for drug treatment in vivo. Results:We developed and characterized two
NEPC tumor organoids from tumor biopsies (liver and bone) of two patients
both in vitro and in vivo (as PDXs). NEPC tumor organoid models retained the
molecular and histological characteristic of their matched patient samples. We
successfully manipulated the activity of the histone methyltransferase EZH2 by
using a catalytic inhibitor and its expression by infecting organoids with
shEZH2. We showed that the absence of EZH2 affects the expression of neu-
roendocrine-associated programs as stem cell and neuronal pathway.Moreover
treatment with EZH2 inhibitor decreased tumor organoids viability and
PDXs tumor volume. Drug screening approaches on NEPC organoids were
used to discovery novel drug targets and combinations that could potentially
benefıt NEPC patients. Top single agent hits included previously identifıed
targets such as EZH2, AURKA, as well as novel synergies. Conclusions NEPC
patient tumor organoids are clinically relevant tumor models to study the
NEPC phenotype in advanced prostate cancer and may be used to elucidate
novel drug targets.
#993 Diagnostic leukapheresis (DLA):Molecular characterisation and or-
ganoid culture of circulating tumor cells (CTC) from metastatic castration
resistant prostate cancer (mCRPC). Maryou B. Lambros,1 Veronica S. Gil,1
Mateus Crespo,1 Mariane S. Fontes,2 Rui N. Neves,3 Niven Mahra,1 Gemma
Fowler,1 Berni Ebbs,1 Penny Flohr,1 George Seed,1 Wei Yuan,1 Joanne Hunt,2
Deirdre Moloney,2 Dionne Ayanda,2 Joost F. Swennenhuis,4 Kiki C. Andree,4
Semini Sumanasuriya,1 Matthew Clarke,1 Pasquale Rescigno,2 Zafeiris Zaf-
eiriou,2 Joaquin Mateo,2 Diletta Bianchini,2 Nikolas H. Stoecklein,3 Leon W.
Terstappen,4 Gunther Boysen,1 Johann S. De Bono1. 1The Institute of Cancer
Research, London, United Kingdom; 2The Royal Marsden NHS Foundation
Trust, London, United Kingdom; 3University Hospital of the Heinrich-Heine-
University Düsseldorf, Düsseldorf, Germany; 4University of Twente, Enschede,
Twente, Netherlands.
Introduction: CTC count is an independent predictor of overall survival in
mCRPC. Isolation of CTC from peripheral blood (PB) for genomic and func-
tional analysis is challenging, especially in patients (pts) with low CTC count. It
has been shown that DLA increases CTC yield. However, it has yet to be proven
whether CTC isolation fromDLA can be used in complementary studies such as
molecular characterization and growth of organoid culture for drug sensitivity
studies. Here we present preliminary data of an on-going study, which evaluates
DLA in mCRPC pts, focusing on safety, CTC enrichment, molecular character-
ization and feasibility for organoid culture.Methods:mCRPCpts considered for
clinical trials were selected according to performance status (ECOG 0-1) and
number of CTC found in 7.5ml PB (20 cells/7.5mL). DLA products (200x106
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cells) were processed using the CellSearch CTC kit (Janssen Diagnostics, LLC)
according to manufacturer procedures. The contents of CellSearch cartridges
were sorted into single cell by fluorescence activated cell sorting (FACS) and
subsequently assessed by array comparative genomic hybridization (aCGH) for
copy number aberrations (CNA). Enrichment of CTC for organoid culture was
performed by density gradient of mononuclear cells followed by positive selec-
tion usingmagnetic beads. Results: Overall 12mCRPCpatients underwentDLA
without any complication or toxicity. The mean CTC count was 90 CTC/7.5 ml
peripheral blood (median  31) and ranged from 20 to 324. CellSearch CTC
count in the DLA yielded a mean of 466 (median203) and ranged from 60 to
2496 with an up to 40-fold increase (mean  13, median  6) in CTC count
separation when comparing 1mL of PB to 1mL of DLA. Molecular analyses of
FACS single CTC from the DLA by aCGH showed that these CTC genomic
profıles had the typical hallmarks ofmCRPCwithCNAs includingAR andMYC
locus (8q) amplifıcation, and PTEN, RB1, TP53, CHD1 loss. Additionally, ex
vivo culture of CTC-derived organoids was successfully achieved. aCGH of
these organoids matched the genomic profıle that of the CTC from the same
patient. Conclusion: DLA frommCRPC pts was well tolerated and yields higher
CTC capture than PB and may provide an alternative to tissue biopsy and rou-
tine blood volumes. Our strategy allowed us to isolate genomic DNA with good
quality for molecular characterization and viable CTC for organoid culture and
functional studies.
#994 Diagnosing leukemia structural variations via a novel genomemap-
ping approach.Christopher Pool, JieXu,DarrinBann,DavidGoldenberg,Arati
Sharma, David Claxton, Feng Yue, James Broach. Penn State Hershey Medical
Center, Hershey, PA.
Identifıcation of structural variants (SVs) is critical to the prognosis of AML.
SVs are not readily identifıed by next generation sequencing methods and are
currently diagnosed by cytogenetics, an intrinsically low resolution tool. We
have adapted a new method for determining large SVs as a clinical tool for
evaluating AML and other cancer genomes. The Bionano Irys images in micro-
fluidic nanochannels large (150Kb) segments of genomicDNA that have been
bar coded by site specifıc nicking and local incorporation of fluorescent label.
The complement of individual molecules can be assembled through matching
bar codes to create a de novo map of the genome from which, by matching to a
reference genome, identifıes and catalogs structural variants at resolution of ca.
1 Kb. With this technology, we characterized structural variants signatures in
breast cancer, renal clear cell carcinoma, and CML cell lines. Structural variants
were then validated via PCR/Sanger sequencing, fluorescent in situ hybridiza-
tion and whole genome sequencing. We identifıed a thorough compendium of
consistent false positive rearrangements identifıed by this technology, most of
which reflect errors in the reference human genome assembly. We then applied
this methodology to ten AML patient samples, seven from archived blood sam-
ples and three directly obtained from newly diagnosed patients. Karyotyping on
one archived sample identifıed a t(6:9) translocation in the majority of cells. We
identifıed that rearrangement at a much higher resolution than cytogenetics,
which allowed us to map the breakpoint via PCR/Sanger sequencing to nucleo-
tide resolution and confırm a fusion ofNUP214 toDEK, a known oncogene.We
also discovered the reciprocal t(9:6) translocation, which had not been identifıed
by cytogenetics. In the six other cases from archived samples, we have confırmed
the translocation identifıed by cytogenetic karyotyping and in several cases
found additional rearrangements.Moreover, in the fırst pediatric case, whichwe
completed within fıve days of obtaining the sample, we have identifıed four
distinct translocations, all of which have been associated previously with AML.
Overall, this is technology has the ability to quickly and accurately identify SVs
in cancer cell lines and AML patient samples with higher resolution than cyto-
genetics, demonstrating its clinical usefulness in the diagnosis and subsequent
treatment of leukemia.
#995 Impact of molecular subtypes on predicting chemotherapy response
and survival in muscle invasive bladder cancer.Woonyoung Choi,1 Debasish
Sundi,1 Michael Metcalfe,1 i-ling Lee,1 Shanna Pretzsch,1 Jolanta Bondaruk,1
Elizabeth Plimack,2 Arlene Odelia Siefker-Radtke,1 Bogdan CzerniaK,1 Colin
Dinney,1 DaivdMcConkey3. 1UTMDAnderson Cancer Ctr., Houston, TX; 2Fox
Chase Cancer Center, Philadelphia, PA; 3Johns Hopkins, Baltimore, MD.
Usingwhole genomemRNAexpression profılingwe reported the existence of
molecular subtypes (basal, p53-like and luminal) characterized by distinct gene
expression patterns and clinical outcomes in muscle invasive bladder cancer
(MIBC). To further explore the potential clinical signifıcance of the molecular
subtypes,wemeasured the relative clinical impact of neoadjuvant chemotherapy
(NAC) in each of the subtypes. We created a meta-dataset using 148 transure-
thral resection (TUR) specimens from patients who received NAC followed by
radical cystectomy (RC) within the context of 5 separate Phase II clinical trials
and another consisting of 127 TURs from patients who were treated with RC
without NAC. We used TCGA’s complete MIBC dataset as a validation cohort.
We assigned the tumors to subtypes using a published one nearest neighbor
(oneNN) classifıer, and the relationship between subtype assignment andoverall
survival (OS) was assessed by Kaplan-Meier analysis with log-rank test. In the
NAC cohort, chemotherapy was active as measured by an overall pathological
downstaging rate (pT1 at cystectomy) of 47% (70/148). Based on pathological
downstaging, p53-like tumors were resistant to chemotherapy (response rate;
28%, p0.009). Patients with basal tumors had the best survival (median OS:
211 months, p 0.033) compared to p53-like (45 months) and luminal tumors
(85 months). In contrast, in the RC without NAC cohort, patients with basal
tumors had the shortest survival (17 months, p0.001) compared to p53-like
(110months) and luminal tumors (108months).Whenwe compared the impact
of NAC on OS within each subtype, patients with basal tumors obtained sub-
stantial clinical benefıt (p0.0001), whereas NAC produced no signifıcant dif-
ferences in OS in patients with p53-like or luminal tumors. These results were
confırmed in independent analyses of TCGA’s dataset, where patients with basal
tumors were the only ones who received signifıcant survival benefıt from che-
motherapy (median OS with chemotherapy-undefıned; without chemotherapy
-17 months, p0.027). Our results demonstrate that the molecular subtypes of
MIBC are associated with differential benefıt from chemotherapy. If validated
prospectively, the data suggest that basal tumors should be identifıed at diagno-
sis so that patients with these tumors can be aggressively managed with neoad-
juvant chemotherapy. The molecular mechanisms that probably underlie the
preferential impact of chemotherapy in basal tumors will be discussed.
#996 A translational phosphoproteomic approach to study differences in
KRAS signaling in pancreatic, colorectal and lung cancers. Adam Stewart,1
Elizabeth A. Coker,1 Anna Minchom,2 Sebastian Pölsterl,1 Alexandros Geor-
giou,2 Paul Huang,1 Bissan Al-Lazikani,1 Udai Banerji2. 1The Institute of Cancer
Research, London, United Kingdom; 2The Institute of Cancer Research and The
Royal Marsden, London, United Kingdom.
Aims To understand any context-dependent differences in signaling path-
ways between pancreatic (PAN), colorectal (CR) and lung (LU) cancers with
KRAS mutations using a targeted phosphoproteomic approach in cell lines and
patient-derived cancer cells exposed to targeted anticancer drugs ex-vivo. Ma-
terials andMethodsWe studied a panel of 30KRASmutant cell lines: 10 PAN, 10
CR and 10 LU cell lines. Cancer cells were also immuno-magnetically isolated
from pleural effusions and ascites of patients with KRAS mutant CR and LU
cancer and exposed to a DMSO control and clinically relevant concentrations of
PI3K (pictilisib), AKT (AZD5363), mTOR (everolimus), EGFR (gefıtinib),
BRAF (vemurafenib),MEK (trametinib) andHSP90 (luminespib) inhibitors for
1 hr. Dynamic changes in a panel of 52 relevant phosphoproteins were studied
using the Luminex 200 platform. Hierarchical clustering and logistic regression
were used to fınd differences in dynamic changes in phosphoproteins between
KRAS mutant, PAN, CR and LU cancer cells. Results Supervised clustering
studying exposure to different drugs revealed that when exposed to the PI3K
inhibitor, pictilisib, KRAS mutant LU cancers did not signifıcantly cluster to-
gether; p0.008, p0.104 following Benjamini-Hochberg correction. Indepen-
dently, logistic regression showed signifıcant differences in signaling of KRAS
mutant cells when exposed to the PI3K inhibitor, pictilisib. PAN andCR cancers
showed an increase in p-MEK while LU cancer cells did not; p0.0195. LU
cancer cell lines showed signifıcantly more reduction of p-AKT compared to
PAN and CR cell lines when exposed to the PI3K inhibitor; p0.0423. As ex-
pected, exposure to vemurafenib increased p-MEK levels across the majority of
the KRASmutant cell lines, however compensatory reductions in p-mTOR lev-
els were seen signifıcantlymore in PANandCR cell lines and not in LU cell lines;
p0.0084. The dynamic phosphoprotein changes caused by pictilisib were val-
idated in cancer cells isolated from serous effusions of 3 KRASmutant LU and 4
KRAS mutant CR cancer patients. Validation of these fındings using multiple
other inhibitors and time-points is ongoing. Interpretation/conclusionsWe hy-
pothesise that the signifıcantly greater reduction in p-AKT and less increase of
compensatory p-MEK caused by PI3K inhibition in KRAS mutant LU cells
compared to KRAS mutant PAN and CR cell lines represents preferential sig-
naling of these cells through the PI3K pathway. Increase in p-MEK driven by
BRAF inhibitors caused a reduction in p-mTOR in PAN and CR but not in LU
cell lines also indicating preferential dependence of signaling in KRAS mutant
lung cancer cells through the PI3K pathway. These fındings are important while
designing clinical trials of KRAS mutant cancers and more broadly to precision
medicine where mutation status independent of tissue context is often used.
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#997 Impact of a personalizedmedicine research program (PMRP), using
targeted tumor profıling and a cloud based clinical trialsmatching platform,
on clinical decision-making. Thomas D. Brown,1 Paul D. Tittel,1 Philip J.
Gold,1 Charles W. Drescher,1 John M. Pagel,1 J D. Beatty,1 Patra Grevstad,1
Desiree Iriarte,1 Shlece Alexander,1 Madeleine Brindle,1 Xiaoyu Liu,1 Donielle
O’connor,1 Mariko Tameishi,1 Danbin Xu,2 Anna B. Berry3. 1Swedish Cancer
Inst., Seattle, WA; 2CellNetix Pathology and Laboratories, Seattle, WA; 3Swedish
Cancer Inst., CellNetix Pathology and Laboratories, Seattle, WA.
Background: Cancer care is evolving to a model of precision medicine where
genomic changes in a patient’s tumor are used to inform individualized man-
agement (mgmt). The optimal approach and impact of tumor profıling on can-
cer care remain important research questions. We report the impact on clinical
decision-making by results from a PMRP in a research practice. Methods: A
custom designed next generation sequencing (NGS) 68 gene alteration (GA)
panel, covering clinically relevant genes and regions was developed in 2014. The
NGS results were used to: 1) prioritize standard therapies; 2) match patients
(pts) with clinical trials (CT); and 3) serve as a datamining resource.NGS testing
was offered early in the course of mgmt. An Institutional Review Board ap-
proved prospective registration protocol (PMRP)was activated in 2014, with the
objective of establishing a centralized longitudinal, molecular phenotypic, and
research data repository. Primary endpoints include proportion of pts where
NGS impacted mgmt, to include enrollment onto CT. A cloud-based informat-
ics platform was developed to: manage PMRP; facilitate CT matching; perform
quality assurance/quality improvement; pursue research initiatives. Results: As
of 11/15/2016, 869 pts gave informed consent, with 844 pts enrolled. The top
primary sites included: breast (115); colorectal (111); central nervous system
(103); lung (91); ovary (49); hematologic malignancies (46); pancreas (37);
uterus (28); esophagus (25); skin (21). Of solid tumor pts with documented
clinical stage, 130 (40%) pts had early stage cancer (I, II and III), and 193 (60%)
pts had advanced stage (IV) cancer. NGS results: 739 (88%) pts with GA found;
27 (3%) pts without GA. Of pts with GA, 178 (24%) pts had actionable (on-label
drugs) GA and 476 (64%) pts had applicable (off-label or CT) GA, for a total of
546 (74%) pts with actionable and/or applicable GA. The top actionable GA
were: KRAS (125); PIK3CA (17); BRAF (13); EGFR (12); NRAS (11); AKT1 (3);
TET2 (2); ERBB2 (2); HRAS (2). The top applicable GA, included: TP53 (225);
TPMT (78); TYMS (78); PIK3CA (77); APC (56); PTEN (52); IDH1 (34);
CDNK2A (22); CTNNB1 (18); TET2 (16). Care mgmt impact was reported by
physicians for 508 pts with actionable/applicableGA. Physicians reportedmgmt
impact, at time of reporting, for 105 (21%) pts, to include: new treatment (Tx) in
30 (6%) pts; no Tx given in 18 (4%) pts; Tx changed in 12 (2%) pts; Tx stopped in
1 (1%) pt; 6 (1%) pts enrolled onto CT. In 403 (79%) pts, physicians reported
no mgmt impact, to include: insuffıcient evidence in 294 (58%) pts; drugs/CT
access in 91 (18%) pts; refused Tx in 17 (3%) pts. Conclusions: NGS profıling of
tumors with this 68 GA panel has an impact on clinical decision- making in a
minority, though substantial number, of pts. Impact on CT participation re-
mains modest. Access to drugs and CT remains an important barrier.
#998 OPeN: the oncology precision network data sharing consortium.
LincolnNadauld,1 DerrickHaslem,1 Paul D. Tittel,2Mariko Tameishi,2 Thomas
Brown,2 James Ford3. 1Intermountain Healthcare, St. George, UT; 2Providence
Health and Services, Seattle, WA; 3Stanford, Palo Alto, CA.
Background: The advent of Next-Generation Sequencing (NGS), and other
molecular diagnostic technologies, has enabled the use of genomic information
to guide targeted treatment in cancer patients. While this precision oncology
approach can yield exciting clinical outcomes, the innumerable genomic vari-
ants identifıed in individual tumors effectively establishes each case as a unique
N1 clinical presentation. This scenario is contrary to a basic dogma ofmedical
practice where historical cases and treatment outcomes guide future manage-
ment and therapeutic decisions. Aggregation of large data sets, on a multi-insti-
tutional basis, has the potential to overcome the N1 paradox and yield man-
agement insights in the implementation of precision oncology. Methods: We
have formed the Oncology Precision Network (OPeN), an oncology data shar-
ing consortium, to aggregate big data sets consisting of clinical, genomic, phar-
macological, and treatment response data from diverse patient cases. Data from
Intermountain Healthcare, Stanford University, and Swedish Cancer Institute-
Providence St. Joseph Health, as well as other institutions, comprises the data-
base and is derived from 79 hospitals, over 800 physician clinics and more than
50,000 annual cases. Results: The OPeN database can be interrogated by variant
type, specifıc therapeutics, clinical outcomes, and by grouped variables, in a
structured data format. The overarching IT platform is a cloud based, open
source, triple store precision oncology solution, Syapse. These data are yielding
valuable insights, including tumor mutational burden (TMB) scores and their
correlation to immunotherapy response, clinical response in various drug-gene
combinations, and therapy-specifıc adverse events. Conclusions: We anticipate
this resource will be used by the Molecular Tumor Boards of contributing insti-
tutions for clinical interpretation, and by treating providers to overcome the
N1 challenge associated with precision oncology.
ENDOCRINOLOGY: Estrogen Receptor in Cancer Progression
and Therapies
#999 ESR1 mutations activate and confer hormone resistance via distinct
mechanisms.Weiyi Toy,1 Kathryn E. Carlson,2 Teresa A. Martin,2 Christopher
G.Mayne,2 SeanW.Fanning,3 PedramRazavi,1 José Baselga,1 Yang Shen,4Geof-
frey Greene,3 Benita Katzenellenbogen,2 John Katzenellenbogen,2 Sarat Chan-
darlapaty1. 1Mem. Sloan Kettering Cancer Ctr., New York, NY; 2University of
Illinois at Urbana-Champaign, Urbana, IL; 3University of Chicago, Chicago, IL;
4Texas A & M University, College Station, TX.
Mutations in the ligand-binding domain (LBD) of ESR1 have been identifıed
in the tumors and plasma of hormone-resistant, metastatic ER breast cancer
patients. The most prevalent alterations are Y537S and D538G, and both mech-
anistic and clinical investigations have focused on the implications of these 2
mutations. Through large-scale clinical sequencing efforts, we have examined
the coding region of ESR1 from over 1000 cases of metastatic breast cancer and
found a diversity of ESR1 mutations. These have included a number of never
before reported alterations including mutations in the DNA binding domain
and dimerization interface. The biochemical and biologic impact of many of
thesemutations is unknown. In this study, we have examined the impact of these
alterations on ER conformation, transcriptional activity, breast cancer growth,
and drug sensitivity. Using transcriptional assays, we found several classes of
mutation including: (1) mutations that weakly promoted ligand-independent
activity, (2) mutations that led to ligand-independent activity comparable to
estradiol stimulation, and (3) mutations that impaired transcriptional activity.
Among mutations that promoted some level of ligand-independent activation,
we examinedwhether they had similar effects on receptor conformation in vitro.
First, we characterized a subset using a FRET-based co-activator recruitment
assay and found that, unlike Y537S andD538G, severalmutants (e.g. E380Q and
S463P) were unable to recruit SRC in the absence of estradiol. In keeping with
this observation, trypsin digestion assays also revealed differences in the local
structure within helix 11 between these mutants. To further characterize the
molecular basis for these differences, we conducted molecular dynamic (MD)
modeling of mutants and compared these with the MD and crystal structure
models of apo Y537S andD538Gmutants. These studies further revealed differ-
ences in overall receptor conformation including localization of H12. From a
therapeutic point of view, we examined the effect of different mutants on sensi-
tivity to various ER antagonists. Once again, we observed important differences
between mutants, with several mutants of class 2 exhibiting reduced sensitivity
to SERDs compared to mutants of class 1. Nevertheless, it appeared that all
mutants could be effectively antagonized by more potent SERDs, implying a
continued ability of the mutant ERs to become distorted into the antagonist
conformation. Taken together, the data reveal distinct conformational restric-
tions on ER activity that can be relieved by different ESR1mutations. These data
also imply the value of more broad coverage of ER in clinical sequencing efforts
in order to effectively capture all potential resistance alleles.
#1000 Estrogen receptor coactivator MED1 in breast tumorigenesis
and therapeutic resistance. Xiaoting Zhang. University of Cincinnati, Cin-
cinnati, OH.
Recent studies have established Mediator Subunit 1 (MED1) as a key ER
transcriptional coactivator for in both normal mammary gland development
and breast cancer. Signifıcantly, the MED1 gene is located at the chromosome
17q12 region, also known as theHER2 amplicon, and co-amplifıes withHER2 in
almost all instances. Importantly, we found that MED1 serves as a key crosstalk
point for theHER2 andERpathways in anti-estrogen resistance of breast cancer.
Signifıcantly,MED1 expression highly correlates with poor disease-free survival
of breast cancer patients; and most recent studies have discovered increased
frequency of MED1 mutations in circulating tumor cells of human patients
following anti-estrogen and anti-HER2 treatments. To determine the role of
MED1 in HER2-driven tumorigenesis, we have crossed the MMTV-HER2
mammary tumormodel with our establishedMED1mutant knockin and newly
generated MED1 mammary specifıc overexpression mouse models. Collec-
tively, our studies revealed critical roles forMED1 in tumor progression, metas-
tasis, cancer stem cell formation and therapeutic resistance in HER2-mediated
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mammary tumorigenesis. These studies not only for the fırst time reported key
roles for aHER2 amplicon co-amplifıed gene inHER2-driven tumorigenesis but
also support MED1 as a potential therapeutic target. To test that, we have as-
sembled highly innovative RNA nanotechnology-based pRNA-HER2apt-
siMED1 nanoparticles.We found these RNAnanoparticles have a very high Tm
value, and is ultra-stable under RNase A, 8 M urea, serum and PBS conditions.
Importantly, pRNA-HER2apt-siMED1 nanoparticles could specifıcally target
HER2 human breast cancer, effıciently deplete the expression of MED1 and
decrease ER-mediated gene transcription both in vitro and in vivo. Most signif-
icantly, pRNA-HER2apt-siMED1 nanoparticles not only greatly reduce the
growth, metastasis and cancer stem cell formation of HER2 breast cancer, but
are also able to overcome their therapeutic resistance. (Thiswork is supported by
Susan G. Komen for the Cure Foundation Career Catalyst Grant, American
Cancer Society Research Scholar Grant and NIH/NCI Grant Number
R01CA197865).
#1001 ESR1 mutations confer novel metastatic functions in genome-ed-
ited breast cancer models. Zheqi Li,1 Amir Bahreini,1 Peilu Wang,2 Kevin
Levine,1 Nilgun Tasdemir,1 David Chu,3 Ben Ho Park,3 Adrian Lee,1 Steffı Oes-
terreich1. 1University of Pittsburgh, Pittsburgh, PA; 2Tsinghua University, Bei-
jing, China; 3Johns Hopkins University, Baltimore, MD.
Background: Estrogen receptor alpha (ER), encoded by the ESR1 gene, is
expressed in approximately 70% of breast cancers. Recent studies conducted by
us and others have shown that somaticmutations in ESR1 gene play a key role in
conferring endocrine resistance in ER breast cancer. These hotspot mutations
mainly occur on the ligand binding domain of ER, leading to poor outcomes in
25-30%of patientswith ERmetastatic breast cancer in clinic. Themechanisms
behind the potential enhanced metastasis of these mutations have become an
urgent issue to be addressed, but they are not well understood due to a lack of
ESR1mutantmodels.Methods:We generated and characterized genome-edited
T47D and MCF7 breast cancer cell lines with the two most common ESR1
mutations (Y537S and D538G), using CRIPSR/Cas9 and rAAV systems respec-
tively.Multiple clones for eachmutantwere sorted and themutation frequencies
were detected using digital droplet PCR (ddPCR). We subsequently performed
an RNA-sequencing to deeply differentiate the gene expression patterns in these
mutants. The growth of these pooled mutant-cells was determined in both 2D
and 3D plates. The cell-matrix adhesions were measured based on ECM array,
and 84-ECM adhesion related genes were further tested by qPCR array. In-
cuCyte real-time image system was used to monitor the cell migration based on
the wound-scratching assay. Results: We fırst identifıed the robust mutation
frequencies at both RNA and DNA levels in our cell models. The RNA-seq
exhibits multiple ligand-independent genes overlapping between either cell
lines or mutants, which were further conformed by qPCR. We also found that
both Y537S and D538Gmutants present ligand-independent growth in 2D and
3D ultra-low attachment plates. Using wound-scratching assay, we observed
signifıcant higher migration rate in D538G mutant of T47D cell lines on both
matrigel and type I collagen, indicating a cell-line and mutant-specifıc pheno-
type. We also detected lower attachment of both mutants on type I collagen in
both cell lines, and our qPCR array revealed that alterations in the MMP path-
ways could be one of themajormechanism causing this phenotype. Conclusion:
In sum, our study presents the fırst in-depthmetastatic functional analysis of the
biology of ESR1 mutations in genomic knock-in cell models, pointing out the
enhanced migration and decreased cell-matrix adhesion as a potential novel
gain-of-function of the Y537S and D538G mutant-cells. These fındings suggest
the potential role of enhanced metastasis of these ESR1 mutations through re-
modeling of transcriptional profıles, shedding lights towards the development of
effıcient therapies of ESR1 mutant breast cancer.
#1002 An epigenetic strategy to degrade the estrogen receptor in breast
cancer.Huili Li,1 Foteinos-Ioannis Dimitrakopoulos,2Meredith Stone,1 Lauren
Murphy,1 Stephen Baylin,1 Cynthia A. Zahnow1. 1Sidney Kimmel Comprehen-
sive Cancer Center at Johns Hopkins, Baltimore, MD; 2University of Patras, Med-
ical School, Rion, Greece.
Epigenetic changes in DNA methylation can lead to altered gene expression
and the development and progression of breast cancer. Luminal breast tumors
are associated with increased DNA hypermethylation of CpG islands while
basal, triple negative tumors more commonly have lower levels of DNA meth-
ylation. Increasing evidence suggests that aberrant epigenetic alterations in
DNA methylation and chromatin structure may also contribute to endocrine
resistance in luminal breast cancers. We thus asked whether epigenetic therapy
using the demethylating agent, 5-Azacytidine (AZA) is an effective anti-tumor-
igenic agent in luminal breast cancers, what epigenetic mechanisms might be
involved in the response and whether AZA could play a role in the sensitization
of tamoxifen resistant cells. We have demonstrated using 26 breast cancer cell
lines that luminal B, ER breast cancer is more responsive to treatment with
AZA than areHer2 or triple negative (TN) breast cancers. Cells were treated in
culture with low nanomolar doses of AZA for 72 hrs, followed by transplanta-
tion intomice andweekly palpation of tumors. Tumorgraftmeasurements show
that 67% of luminal B, ER cells are sensitive to AZA, whereas only 22% of TN
and 25% of Her2 cells exhibit an anti-tumorigenic response to AZA in mice.
Expression data showed that AZA leads to decreases in ER mRNA and protein
expression in 50% and 67% of luminal B lines respectively. Further investigation
showed that a longer AZA treatment led to lower ER protein levels and stron-
ger tumor growth inhibition. Protease inhibitor (MG132) treatment rescued
ER protein reduction in 50% of the luminal B cell lines, suggesting that an
AZA-mediated, ubiquitin-26S proteasomal pathway may be responsible for the
degradation of ER. Gene expression analysis demonstrated that the E1 ubiqui-
tin-activating enzyme, (UBA7-UBE1L) was up-regulated at themRNA and pro-
tein levels by AZA. UBA7 has been suggested to function as a tumor suppressor
in lung cancer and elevations in UBA7 have been correlated with longer overall
survival in breast cancer. The interaction of UBA7 with ER protein was vali-
dated by immunoprecipitation and over-expression of UBA7 in ZR-75-1 cells
led to a reduction in ER protein. We further analyzed the UBA7 promoter
region by Illumina 450K array and bisulfıte sequencing in our cell lines and
identifıed two CpG rich sequences in the promoter that may be important for
AZA induced UBA7 promoter demethylation and gene re-expression. We also
demonstrated in both tamoxifen sensitive and resistant cells that combination
therapy with both AZA and tamoxifen was more effective at inhibiting tumor
growth than the single agents. Studies are ongoing in our lab to better under-
stand this response.Our data suggest that AZAmay be clinically useful to inhibit
the growth of some luminal breast tumors via its actions to increase expression
of UBA7 and to degrade ER and may have effıcacy in combination with anti-
estrogen treatments.
#1003 Extranuclear ER-mTOR signaling rewires cancer cell metabolism
during obesity-associated breast cancer. Zeynep Madak Erdogan, Yiru C.
Zhao, Gianluigi Rossi, Kinga Wrobel, Eylem Kulkoyluoglu, Sung Hoon Kim,
John A. Katzenellenbogen, Jodi Flaws, Rebecca Smith. Univ. of Illinois at Urba-
na-Champaign, Urbana, IL.
Obesity is a preventable risk factor for post-menopausal ER-() breast can-
cer. We hypothesized that serum from obese post-menopausal women contain
factors that would increase tumorigenicity of breast cancer cells and increase
risk of ER-() breast cancer. Using whole metabolite profıling and OLINK
biomarker panel of about 400 proteins associatedwith cancer, inflammation and
cardiovascular disease, we identifıed biomarkers that were differentially present
in serum from 50 obese v.s. 50 non-obese postmenopausal women. Next, using
in vitro cell based assays as proxy we identifıed certain free fatty acids (FFAs) as
factors from serum that correlate with increased cell proliferation, motility and
mTOR activation in ER() breast cancer cells. We performed RNA-Seq, ER
ChIP-Seq and metabolomics analysis in breast cancer cells that are exposed to
conditions thatmimic serum from obese postmenopausal women. This integra-
tive -omics approach enabled us to uncover ER and mTOR pathway-depen-
dent metabolic rewiring in breast cancer cells under these conditions. Pathway
preferential estrogens (PaPEs), which target ER and mTOR signaling, were
able to block free fatty acid-dependent proliferation of breast cancer cells. In fact,
effıcient cancer cell killing by PaPEs was achieved only in the presence of FFAs,
suggesting a role for obesity-associated metabolic rewiring in providing new
vulnerabilities for the breast cancer cells. In summary, we uncovered a novel role
for extranuclear-initiated ER signaling in rewiring breast cancer cell metabo-
lism in response to obesity-associated factors in the serum.Our fındings provide
a basis for preventing or inhibiting obesity-associated breast cancer by using
PaPEs thatwould exploit newmetabolic vulnerabilities of breast tumors in obese
postmenopausal women.
#1004 LDLR knockdown reduces the growth of Her2 overexpressing
breast cancer inmousemodels of hyperlipidemia. Emily J. Gallagher, Brian A.
Neel, Zara Zelenko, Irini Markella Antoniou, Nathan Kase, Derek LeRoith.
Icahn School of Medicine at Mount Sinai, New York, NY.
Women with higher circulating low density lipoprotein (LDL) cholesterol
levels are more likely to have advanced HER2 positive breast cancers. The LDL
receptor (LDLR) is the main receptor for cholesterol uptake into cells from
circulating LDLand its expression is higher inHER2positive breast cancers than
other subtypes. The aim of our study was to understand the importance of the
LDLR in the progression of HER2 positive breast cancer growth in the setting of
hyperlipidemia. To study the role of hyperlipidemia in HER2 cancer progres-
sion, we used twomousemodels with elevated LDL cholesterol: Apolipoprotein
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E knockout (ApoE-/-), and LDLR knockout (LDLR-/-) mice on an FVB/n back-
ground. ApoE-/-, LDLR-/- and control (WT)micewere placed on awestern diet
at 8-10 weeks of age. After 2 weeks on the diet, serum cholesterol concentrations
were measured and demonstrated signifıcantly higher cholesterol levels in the
ApoE-/- and LDLR-/- mice compared with WT mice (WT: 20819mg/dL;
LDLR-/-: 48837mg/dL; ApoE-/- 66039mg/dL). We used the MCNeuA
(MMTV-Neu derived) breast cancer cells to study the effect of hyperlipidemia
on Her2/Neu positive breast cancer in this model, as the MCNeuA cells were
found to have high levels of LDLR protein expression compared with other
murine breast cancer cell lines. To study the importance of the LDLR in medi-
ating the effects of hyperlipidemia, we knocked down the LDLR in theMCNeuA
cells using shRNA, and selected two cell clones with successful gene knockdown
confırmed by RNA and protein analysis. ApoE-/-, LDLR-/- andWTmice on the
western diet were injected into the 4th mammary fat pad with 2 x 106 MCNeuA
(MMTV-Neu derived) control shRNA or MCNeuA LDLR knockdown clone 1
or clone 2 cells (n6-10 mice per group). Tumor growth was measured for 30
days. Control shRNA tumors in both hyperlipidemic mouse genotypes grew
more rapidly than in the WT mice. 30 days after injection the control tumor
volumes were: WT 51466.5mm3; LDLR-/- 76778.2mm3; ApoE-/-
118994mm3. The LDLR knockdown clones 1 and 2 had a reduction of tumor
volume of 11% and 30% in the WT mice, 28% and 62% in LDLR-/- mice, and
26% and 53% in the ApoE-/- mice, respectively compared with the control
shRNA cells. Western blot analysis of tumor protein lysates showed an increase
in p19 cleaved caspase 3 in the tumors with LDLR knockdown, compared with
the control cells. In vitro studies demonstrated a decrease in survival of MC-
NeuA cells with LDLR knockdown in serum starved conditions, and an increase
in caspase 3 cleavage. These data demonstrate that hyperlipidemia promotes the
growth of Her2/Neu overexpressing breast cancer cells and the LDLR plays an
important role in protecting Her2 / Neu tumors from apoptosis. Therefore,
targeting cholesterol uptake and metabolism may be an important strategy for
women with HER2 positive breast cancers.
#1005 Interaction between the estrogen receptor and fıbroblast growth
factor receptor pathways in non-small cell lung cancer. Laura P. Stabile,1 Nat-
alie J. Rothenberger,1Mariya Farooqui,2 SanjaDacic,1 JillM. Siegfried2. 1Univ. of
Pittsburgh School of Medicine, Pittsburgh, PA; 2University of Minnesota, Minne-
apolis, MN.
The estrogen receptor (ER) promotes cell proliferation in non-small cell lung
cancer (NSCLC). Since fıbroblast growth factors (FGFs) are known regulators of
stem cell markers in ER positive breast cancer, we investigated whether a link
between the estrogen pathway, FGFs, and stem cell markers could be demon-
strated in NSCLC animal models, human cells lines and tumor tissue. In the
lungs of female FVB/Nmice exposed to the tobacco carcinogen 4-(methylnitro-
soamino)-1-(3-pyridyl)-1-butanone, NNK, treatment with the anti-estrogen
fulvestrant and/or the aromatase inhibitor anastrozole blocked secretion of both
FGF2 and FGF9, and reduced expression of the stem cell markers SOX2 and
nanog. These effectswere observed in the normal airway epiltheliumaswell as in
both lung preneoplasias and lung adenomas. To investigate the effects of -es-
tradiol (E2), male mice were administered E2 in the drinking water during
exposure toNNK for 4weeks. In thismousemodel, the incidence of carcinogen-
induced lung preneoplasias increased 1.8-fold (p0.05) with E2 exposure ac-
companied by increased expression of FGF2, FGF9, SOX2, and nanog in airway
preneoplasias demonstrating a relationship between activation of the FGF path-
way in the lungs, expansion of cells with a stem cell phenotype, and promotion of
pre-cancerous changes. In FGFR1 normal copy number NSCLC cell lines that
express multiple FGFR family members and secrete several FGFs, E2 treatment
caused a signifıcant increase (up to 4-fold; p0.05) in release of FGF2, an effect
that was completely blocked by fulvestrant. Treatment with fulvestrant also re-
sulted in a 30% reduction in phosphorylation of fıbroblast growth factor recep-
tor substrate 2, the FGFR docking protein. Upon co-inhibition of ER and FGFRs
using fulvestrant and the pan-FGFR inhibitor AZD4547, signifıcantly enhanced
(p0.01) anti-proliferative effects were observed in FGFR1 normal copy num-
ber NSCLC cells that show low sensitivity to FGFR inhibitors as single agents. In
NSCLC xenografts, the combination of AZD4547 (daily 12.5mg/kg) and fulves-
trant (30 mg/kg twice weekly) resulted in a signifıcantly greater inhibition (67-
85% decrease; p0.05) of tumor growth and decreased expression of Ki67 and
stem cellmarkers compared to each single agent treatment. Furthermore, tumor
histology appeared more differentiated and up to a 25% decrease in malignant
cellularity was observed with combination treatment compared to each single
agent treatment. In NSCLC patient tumors, high ER
 expression correlated
with high FGFR1 expression (p0.001). Taken together, these results suggest
that interaction between the ER and FGFR pathways in NSCLC promotes a
stem-like state. Combining an FGFR inhibitor with an ER pathway inhibitor
could be exploited to increase the effıcacy of FGFR inhibitors for NSCLC pa-
tients who lack FGFR genetic alterations. Supported by P50 CA090440 and the
V-Foundation.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Novel
Mechanisms of Drug Resistance
#1006 Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibi-
tion. Matthew J. Hangauer,1 Vasanthi S. Viswanathan,2 Matthew J. Ryan,2
DhruvBole,1 Jake Eaton,2 Stuart L. Schreiber,2 FrankMcCormick,1McManusT.
Michael1. 1University of California, San Francisco, San Francisco, CA; 2Broad
Institute/Harvard University, Cambridge, MA.
Acquired drug resistance prevents chemotherapy and targeted therapy from
achieving stable and complete responses. Emerging evidence implicates a key
role for nonmutational mechanisms during early stages of acquired drug resis-
tance. Drug-tolerant “persister” cells are a model of nonmutational cancer drug
resistance inwhich small fractions (5%) of cells within cancer cell lines survive
cytotoxic drug exposure despite lacking resistance-conferring mutations. These
residual surviving cells are quiescent, occupy a unique chromatin state, and
exhibit reversible drug resistance: removal of drug allows regrowth of cellswhich
become resensitized to drug treatment. Importantly, this phenomenon has been
observed across a wide range of cancer lineages with both chemotherapy and
targeted therapy. Persister cells remain quiescent for weeks to months during
constant drug exposure, however some persister cells eventually regrow and
acquire irreversible drug resistance-conferring mutations that did not preexist.
This model mirrors the common clinical scenario in which tumor response is
followed by relapse with acquired resistance-conferring mutations. Targeting
nonmutational resistance may therefore present a therapeutic opportunity to
eliminate residual surviving tumor cells to prevent relapse. We have performed
anunbiased functional genomics analysis ofHER2 breast cancer persister cells
which survive HER2 targeted therapy. Utilizing RNAseq, pathway analysis,
RNAi screens and chemical inhibitor screens, we discovered that persister cells
undergo a switch to mesenchymal gene expression and are uniquely susceptible
to inhibition of the phospholipid hydroperoxidase GPX4. This fınding is not
restricted to breast cancer, rather we have observed that all persister cells tested
including those derived from melanoma, lung, ovarian and pancreatic cancer,
from either targeted therapies or chemotherapies, are each specifıcally sensitive
to loss of GPX4 function. Parental, drug naive cancer cells and normal human
cells are insensitive to GPX4 inhibition. Mechanistically, we found that GPX4
dependency in persister cells is due to a disabled antioxidant program charac-
terized by global downregulation of antioxidant genes, decreased levels of re-
ducing cofactors glutathione and NADPH, and immediate ROS increase upon
GPX4 inhibition. These fındings point toward a GPX4 inhibition strategy to
prevent tumor relapse by inducing ferroptosis in the residual pool of surviving
persister cells.
#1007 SHP2 inhibition restores sensitivity to ALK inhibition in resistant
ALK-rearrangednon-small cell lung cancer (NSCLC).LeilaDardaei,1HuiQin
Wang,2 Paul Fordjour,2 Manrose Singh,1 Grainne Kerr,2 Satoshi Yoda,1 Jinsh-
eng Liang,2 Yichen Cao,2 Yan Chen,2 Justin F. Gainor,1 Luc Friboulet,3 Ibiayi
Dagogo-Jack,1 David T. Myers,1 Emma Labrot,2 David Ruddy,2 Melissa Parks,1
Dana Lee,1 Richard H. DiCecca,1 Susan Moody,2 Huaixiang Hao,2 Morvarid
Mohseni,2 Matthew LaMarche,2 Juliet Williams,2 Keith Hoffmaster,2 Giordano
Caponigro,2 CyrilH. Benes,1 Alice T. Shaw,1AaronN.Hata,1 Fang Li,2 JeffreyA.
Engelman2. 1Massachusetts General Hospital Cancer Center, Charlestown, MA;
2Novartis Institutes for BioMedical Research, Cambridge, MA; 3Gustave Roussy
Cancer Campus, Paris, France.
Despite development of highly potent and selective inhibitors (e.g., ceritinib,
alectinib, lorlatinib) targeting anaplastic lymphoma kinase (ALK), resistance
invariably develops and limits the effıcacy of these inhibitors in the clinic. The
major classes of resistance are on-target genetic alterations (e.g., secondary ALK
kinase domainmutations) and activation of alternative or bypass signaling path-
ways. While most patients are responsive to sequential treatment with two or
more ALK inhibitors, ALK-independent resistance eventually emerges and
leads to failure of furtherALK-directedmonotherapy.Weused a synthetic lethal
pooled shRNA screen to discover loss-of-function events that could sensitize
resistant patient-derived cell lines to ALK inhibition. In addition to identifying
known bypass targets such as FGFR, EGFR and SRC, we also identifıed PTPN11
(which encodes SHP2, a non-receptor protein tyrosine phosphatase that mod-
ulates signaling downstreamof growth factor receptors) as a commonhit shared
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by cell lines exhibiting different mechanisms of bypass activation. In parallel
with the shRNA screen, we also performed a high throughput combination
compound screen in the same patient-derived models, and identifıed activation
of the same bypass signaling pathways. We showed that the highly potent and
selective small-molecule SHP2 inhibitor SHP099 could sensitize resistant cell
lines to ALK inhibition. In biochemical studies, co-targeting of ALK and SHP2
overcame resistance mediated by ALK-independent bypass mechanisms by de-
creasing RAS-GTP loading potential of cells and inhibiting phospho-ERK re-
bound. These results suggest that dual ALK and SHP2 inhibition may represent
a new therapeutic strategy for ALK-positive patients, whose lung cancers have
evolved ALK-independent mechanisms of resistance, including activation of
bypass signaling pathways.
#1008 Gain-of-function kinase library screen identifıes FGFR1 amplifıca-
tion as amechanism of resistance to antiestrogens and CDK4/6 inhibitors in
ER breast cancer. Luigi Formisano,1 Yao Lu,1 Valerie M. Jansen,1 Joshua A.
Bauer,1 Ariella B. Hanker,1 Melinda E. Sanders,1 Paula González-Ericsson,1
Sunkyu Kim,2 Monica Arnedos,3 Fabrice André,3 Carlos L. Arteaga1. 1Vander-
bilt University, Nashville, TN; 2Novartis Pharmaceuticals Corporation, NJ; 3In-
stitute Gustave Roussy, France.
The CDK4/6 inhibitor palbociclib was recently approved in combination
with endocrine therapy for treatment of ER metastatic breast cancer. The
goal of this study was to discover mechanisms of resistance to ER antagonists
alone and in combination with CDK4/6 inhibitors. To achieve this goal, we
used lentiviral vectors to individually express 559 human kinase open read-
ing frames (ORFs) in ER MCF7 human breast cancer cells treated with
fulvestrant  the CDK4/6 inhibitor ribociclib (Novartis). In MCF7 cells
treated with fulvestrant alone or with ribociclib, we identifıed 21 and 17
kinases, respectively, which induced a 30% increase in cell viability com-
pared to control cells; 11 of these kinases overlapped in both treatment
groups. In a secondary screen, MCF7 cells were stably transduced with V5-
tagged lentiviruses expressing the positive ’hits’ for treatment with fulves-
trant/ribociclib. Five of 11 kinases (FGFR1, FRK, HCK, FGR, CRKL) were
confırmed to induce resistance to fulvestrant/palbociclib and fulvestrant/
ribociblib. Survey of TCGA for copy number alterations and/or expression
of these fıve genes showed only FGFR1 to be amplifıed/overexpressed in 17%
of ER breast cancers. Experiments in vitro showed that ER/FGFR1-am-
plifıed (amp) MDA-134, CAMA-1 and HCC1500 human breast cancer cells
and MCF7 cells stably transduced with FGFR1 were relatively resistant to
estrogen deprivation, fulvestrant and fulvestrant/palbociclib compared to
non-FGFR1 amp MCF7 cells. This resistance was abrogated by treatment
with the FGFR tyrosine kinase inhibitor (TKI) lucitanib. Treatment with
fulvestrant or palbociclib, each alone, modestly delayed growth of ER/
FGFR1-amp breast cancer patient-derived xenografts (PDX) established in
nude mice. However, addition of the FGFR TKI erdafıtinib to fulvestrant/
palbociclib resulted in marked PDX regressions in all mice without associ-
ated toxicity. Treatment of FGFR-amp cells with FGF-2 strongly induced
CCND1 (cyclin D1) expression. Downregulation of CCND1 with CCND1
RNAi oligonucleotides or kinase inhibition with erdafıtinib restored sensi-
tivity of FGFR1-amp cells to fulvestrant/palbociclib. Conversely, overex-
pression of CCND1 in MCF7 cells induced resistance to estrogen depriva-
tion and fulvestrant  palbociclib. At this time, we are examining whether
FGFR1 amplifıcation measured by FISH correlates with maintenance of pro-
liferation (Ki67) in 110 patients with ER/HER2- breast cancer treated with
palbociclib for 14 days immediately before surgery (Arnedos et al. ASCO
2016). In summary, using a gain-of-function ORF kinome screen, we identifıed
FGFR1 amplifıcation as amechanism of resistance to anti-ER therapiesCDK4/6
inhibitors. Based on these data we propose FGFR inhibitors should be tested in
combination with ER antagonists and CDK4/6 inhibitors in patients with ER/
FGFR amplifıed breast cancer.
#1009 Comprehensive ctDNA sequencing reveals mechanisms of resis-
tance to rociletinib in EGFR T790M-mutated NSCLC. Elena Helman,1 An-
drew D. Simmons,2 Chris A. Karlovich,2 Thomas C. Harding,2 Mitch Raponi,2
Darya I. Chudova,1 Daniel A. Simon,1 Richard B. Lanman,1 AmirAli Talasaz1.
1Guardant Health, Redwood City, CA; 2Clovis Oncology, San Francisco, CA.
Background: First and second-generation EGFR tyrosine kinase inhibitors
(TKIs) have benefıted patients with EGFR-mutated non-small cell lung cancer
(NSCLC), but resistance invariably develops after a median of 9-16 months. In
60% of patients, resistance ismediated by a secondmutation in EGFR, namely
T790M.Hence, third-generation EGFRTKIs such as osimertinib and rociletinib
were developed to target both activating EGFR mutations as well as T790M.
Unfortunately, patients also develop resistance to these therapies throughmech-
anisms that have not yet been thoroughly explored. Since repeat tissue biopsies
pose potential complications from invasive procedures, circulating tumor DNA
(ctDNA) testing is increasingly used in the clinical setting to identify potentially
targetablemechanisms of resistance.Methods:Matched pre-treatment and pro-
gression plasma from 57 patients with EGFR-mutatedNSCLC treatedwith roci-
letinib were profıled using a 70-gene ctDNA targeted next-generation sequenc-
ing panel (Guardant360) that detects somatic single nucleotide variants, short
insertions and deletions, fusions, and copy number variants. Pre-treatment
EGFR ctDNA allele fractions were also determined by BEAMing, a technique
based on droplet digital PCR followed by flow cytometry. Pre-treatment tumor
EGFR status was assessed by the therascreen EGFR test. Results: In all 57 pre-
treatment samples profıled, plasma-based ctDNA analysis detected the initial
EGFR driver and T790M resistance mutations that were identifıed in the
matched tumor. Interestingly, we found that 12% (7/57) of patients had evidence
of compound EGFR driver mutations at baseline, including E709A-L858R,
K860I-L858R, and L718V-L858R. EGFR T790M mutations in plasma were ob-
served subclonally (present on average at 40% of the allele fraction of the driver
mutation), suggesting tumor heterogeneity at baseline. The correlation coeffı-
cients (r) between Guardant360 and BEAMing for EGFR L858R, Exon19Del,
and T790Mwere 0.90, 0.92, 0.95, respectively. Upon progression on rociletinib,
5% of patients (3/57) developed the EGFRC797S resistancemutation, 5% (3/57)
developed focal MET amplifıcation, and 2% (1/57) developed a NTRK1 fusion
thatwere not present in thematched baseline plasma.Additionally, 4 deleterious
BRCA1/2 alterations (2 germline and 2 somatic) were identifıed, with the so-
matic alterations emerging at progression. In 14% (8/57) of the patients, muta-
tions in genes involved in the RAS/RAF signaling pathway, including KRAS
Q61H, KRAS K117N and NF1 Q1822*, emerged or increased at progression.
Conclusions: Plasma ctDNA revealed heterogeneity and multiple mechanisms
of resistance in rociletinib treated patients. Thus comprehensive ctDNA se-
quencing allows for the identifıcation of potentially actionable alterations and
may help inform the choice of next therapy for patients progressing on a third-
generation EGFR TKI.
#1010 Genomic analysis of recurrent ovarian cancer in patient-derived
xenografts treated with platinum and taxane chemotherapy. Elizabeth
Stover,1 Ali Amin-Mansour,2 Sangeetha Palakurthi,1 Sanam Dharma,1 Qing
Zeng,1 Shan Zhou,1 Palak Desai,1 Levi Garraway,1 Ursula Matulonis,1 Joyce
Liu1. 1Dana-Farber Cancer Institute, Boston, MA; 2Broad Institute, Cam-
bridge, MA.
Introduction: Many women with advanced ovarian cancer (OC) are ini-
tially sensitive to platinum and taxane chemotherapy, but subsequently de-
velop recurrent disease which is often incurable. OC chemotherapy resis-
tance mechanisms are incompletely understood. We used patient-derived
xenografts (PDX) to model OC recurrence following chemotherapy and to
analyze genomic evolution of recurrent tumors. Approach: We leveraged
PDX derived from human OC ascites that accurately represent high-grade
serous OC. We used two PDX models: PDX-A derived from a chemothera-
py-naive patient with WT BRCA1/2; PDX-B derived from a chemotherapy-
resistant patient with a BRCA1 mutation. Using luciferase-labeled tumor
cells, we generated intraperitoneal disease in multiple recipients. We treated
cohorts of 5-10 animals with vehicle, carboplatin, paclitaxel, or carbopla-
tin  paclitaxel (C/T) for 3 cycles followed by observation with biolumines-
cence imaging of tumor burden. Results: While vehicle- and paclitaxel-
treated animals exhibited rapid disease outgrowth, carboplatin- and C/T-
treated animals showed disease regression, followed by recurrence after 90-
300 days. Median survival was signifıcantly increased in carboplatin- and
C/T-treated animals. Recurrent tumors were histologically similar to vehi-
cle-treated tumors. We performed whole-exome sequencing and whole-
transcriptome sequencing on ascites cells from 4 animals in each treatment
group. We used a decontamination algorithm to remove stromal mouse
reads from our tumor samples, resulting in a highly pure (over 99%) human
tumor sequence data. Mutations, insertions/deletions, and copy number al-
terations were identifıed and compared among treatment groups. Known
TP53 mutations were present at 100% frequency across samples. Average
mutation frequencies were similar across all groups. We identifıed several
mutations and copy number variants present in the carboplatin or C/T re-
current tumors that were distinct from the vehicle groups, including putative
alterations in chemoresistance pathways such as DNA repair (BRCA1/2),
apoptosis (BCL2L1), drug transport (ABC transporters), and PI3K signaling
(EEF2K). In model PDX-A, all four carboplatin and one C/T treated recur-
rent tumors exhibited a similar copy-number profıle, suggestive of subclonal
expansion, which included an increase in WT copies of PTEN relative to the
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vehicle tumors. Phylogenetic analysis and whole-transcriptome analysis are
ongoing. Conclusions: Our study models recurrent ovarian cancer in PDX
and identifıes potential features of in vivo chemotherapy resistance.
#1011 RNAseq analysis obtained from on-purpose tumor biopsies of pa-
tients in the MATCH-R trial allows the identifıcation of potential mecha-
nisms of acquired resistance to PD(L)1 therapies. Loic Verlingue, LindaMah-
joubi, Sandrine Aspeslagh, Marion Pedrero, Giulia Buzzatti, David Brandao,
Zsofıa Balogh, Etienne Rouleau, Ludovic Lacroix, Rastislav Bahleda, Christophe
Massard, Antoine Hollebecque, Anas Gazzah, Céline Lefebvre, Serge Koscielny,
Jean Yves Scoazec, Eric Angevin, Fabrice André, Aurélien Marabelle, Jean
Charles Soria. Gustave Roussy, Villejuif, France.
Background: MATCH-R is a prospective molecular characterization trial
(NCT02517892) aiming at defıning themolecular basis of acquired resistance to
targeted agents and immune checkpoint blockers. RNA sequencing (RNAseq)
has been used to identify mechanisms of secondary resistance to immunother-
apy. Patients andmethods: Patients’ metastatic tumors were multi-site biopsied
at relapse under immunotherapies after a period of clinical benefıt, defıned by a
partial response or a stable disease of more than 6 months. Genome-wide
RNAseq counts were intra-patient normalized and a score of each gene’s expres-
sion was computed in comparison to a cohort of 450 metastatic cancer patients
with RNAseq available at the time of analysis. Results: To date, 10 patients
treated by immunotherapies have had a successful RNAseq in the MATCH-R
trial. Five patients were treated with PD-1 inhibitors and 5 with PD-L1 inhibi-
tors. Three patients had NSCLC, 2 MSI high endometrial carcinoma, 2 anal
carcinoma, 2 urothelial carcinoma and 1TNBC. Eight out off ten patients had an
expression of IDO1 higher than the median expression of IDO1 in our 450
controls (p value 0.005). A patient with endometrial carcinoma had one of the
highest expressions of IDO1 in the cohort. Consistently, IDO1 activation has
previously been reported as a mechanism of secondary resistance to immuno-
therapies. A 40 year old smoker NSCLC patient with a TP53 mutation has been
treated during 11 months with anti-PD1. RNAseq analysis on the biopsy of a
progressive lesion showed decreased expression of different actors of the JAK-
STAT pathway (biopsy composed of 40% tumor cells and 60% microenviron-
ment). Of the 78 genes signatures used (including 52 immunogenes signatures),
the interferon gamma signature had the lowest expression (p value  0.004),
consistent with a previous report of JAK-STAT-induced resistance to immuno-
therapy. Two more patients had an altered immune profıle that could be in-
volved in resistance to immunotherapies, but was not yet reported in the littera-
ture. Confırmation of the RNAseq analysis with immunohistochemistry is
currently ongoing. The gene signatures of the 10 patients, composed of immu-
nogenes, DNA repair genes and epigenes, were compared to the whole cohort in
order to deduce corresponding false discovery rates. As such we could identify 2
gene clusters, one enriched in T cells, dendritic cells and macrophages, and the
other enriched in epigenes and DNA repair genes. Analysis of more patients is
currently ongoing in order to cluster the results with clinical characteristics.
Conclusion: Gene expression in the biopsy of patients that relapsed after initial
benefıt to immunotherapy is informative and helps to identify themechanismof
acquired resistance.
#1012 Patient-derived tumormicroenvironmentmodels uncover non-au-
tonomous TKI resistancemechanisms inNSCLC.HaichuanHu, HillaryMul-
vey, SundusNoeen, KodackDavid, AaronHata,MatthewNiederst, Cyril Benes,
Jeffrey Engelman.MGH Cancer Center, Charlestown, MA.
Background: Tyrosine kinase inhibitors (TKI) have yielded great responses in
non-small-cell lung cancer (NSCLC) with EGFRmutations and ALK transloca-
tions, however these and other targeted therapies are limited by intrinsic and
acquired drug resistance. Previous study fromour groupwas looking into tumor
autonomous resistancemechanisms by developing patient-derived cancermod-
els (PDCs). In this study, we aimed to decipher the non-autonomous resistance
mechanisms via tumormicroenvironment by developing patient-derived fıbro-
blast (PDF) cell lines. Method: Cancer-associated fıbroblast cells are isolated
directly from EGFR mutant and ALK translocated NSCLC biopsies. Over 30
PDFs models have been established, which represent different clinical features
and response profıles. Result: By co-culturing the PDCs with PDFs, we found
that there is considerable variability in both models for their magnitude and
mechanism by which the TKI treatment is desensitized. Both HGF dependent
andHGF independent resistancemechanisms can be overcome by specifıc ther-
apeutic combinations. Conclusion: Together, our results indicate that PDFs are
clinically relevant models for deciphering non-autonomous resistance mecha-
nisms, that they are heterogeneous in protecting cancer cells from TKI treat-
ment, and that the resistance mediated by PDFs can be overcome by specifıc
therapeutic combinations.
IMMUNOLOGY: Novel Insights into Mechanisms of Response to
Immunotherapy
#1013 Location matters: unique functional and transcriptional, but not
flow cytometric, characteristics of intratumoral FOXP3 Tregs vs. Tregs
from other sites of patients with lung tumors. Wayne W. Hancock, Tatiana
Akimova, Tianyi Zhang, Evgeniy Eruslanov, Sunil Singhal, Steven M. Albelda.
CHOP/U Penn, Philadelphia, PA.
FOXP3 Tregs are considered important to limiting antitumor immunity but
are rarely characterized clinically. We studied 227 samples from 66 lung cancer
patients using blood, lymph node (LN), tumor and distant lung samples, with a
mean age of 67.81.1 years, 67%males, 62% adenocarcinoma, 31% squamous cell
carcinoma, 7%miscellaneous tumors,mean tumor sizeof 3.40.3 cm, and21%rate
ofmetastases. In addition to quantitating FOXP3CD4Tregs,we evaluated their
expression of 35 markers by flow cytometry: CD15s, CD25, CD26, CD27, CD39,
CD40L, CD45RA/RO, CD62L, CD69, CD101, CD120b, CD161, CCR4, CTLA4,
GARP,GITR,Helios,HLA-DR, ICOS,LAP,neuropilin,PD-1,TIGIT,Tim3,CCR4,
CCR5, CCR7, CXCR3, CXCR4 and CCR8, and tested Treg suppressive function.
We used PrimeFlow to evaluate mRNA expression of target genes in 100% pure
human Treg cells, gated on CD4FOXP3 cells. FOXP3 Tregs (%) in the CD4
celsof tumors andLNwere signifıcantly increased (p0.0001Kruskal-Wallis) com-
pared to other sites; tumors 19.28.5%, LN 14.78.5%, healthy PBMC donors
7.22.5%,PBMClungcancer7.22.7%, and lungs6.63.2%.Tregsof lung tumors
were remarkably suppressive vs. all other sites (p0.0001 vs. PBMC & LN,
p0.0106 vs. lungTregs).Noneof the 35markers evaluatedby flowcytometrywere
statistically signifıcantly different for tumor Tregs vs. other sites. However, Prime-
Flow showed tumor Tregs, but not FOXP3- T cells or Tregs from other sites, had
upregulated mRNA expression of 4 transcription factors (TF): Eos, Irf4, Satb1 and
Gata1. These 4 TFs plus LEF1 were recently described as a quintet of Treg self-
locking signature TF; expression of any 2 TF plus FOXP3 promoted full Treg gene
expression and function. Tumor Tregs also showed signifıcant upregulation of
FOXP3mRNAand protein. Tumor and lungTregs expressedmore Eos, Irf4, Satb1
and Gata1 mRNA, and much higher levels of FOXP3 protein per cell, while in
PBMC, LNs and healthy donor Tregs upregulation of TFs did not correspond with
increase of FOXP3 protein, indicating the “Treg self-locking signature” is subject to
regulation by local factors. Indeed, cultured tumor Tregs downregulated FOXP3
protein,mRNA andTF expression, while PBMC and LNTreg incubated in tumor-
conditioned media upregulated FOXP3 mRNA and protein, and Treg TF expres-
sion, moving toward the tumor Treg-like phenotype. We found signifıcantly in-
creased numbers and suppressive function of FOXP3 Tregs within lung tumors
vs. other sites in the same patients. In addition, while large-scale flow cytometric
studies were not useful in identifying key features of tumor Tregs vs. Tregs at other
sites, PrimeFlow showed that tumor Treg have a unique phenotype with upregu-
lated expression of FOXP3mRNAandprotein, as well as Eos, Irf4, Satb1 andGata1
mRNAs. These features appear to be malleable and associated with features of the
local tumormicroenvironment.
#1014 Selective impairment of intratumoral regulatory T cells by target-
ing Ezh2 enhances cancer immunity.David Q.Wang, Jason R. Quiros, Chien-
Chun S. Pai, Lawrence H. Fong, Jeffrey A. Bluestone, Michel J. DuPage.Univer-
sity of California, San Francisco, San Francisco, CA.
Highnumbersof tumor infıltratingregulatoryT(Treg)cells are indicativeofpoor
outcome in several malignancies, including ovarian cancer, colorectal cancer, and
melanoma.Thus, selectively abrogating intratumoralTreg cell functionwhilemain-
taining systemic immune tolerance remains an attractive, albeit elusive, strategy for
cancer immunotherapy.Wehave identifıed the epigenetic enzymeEzh2, anH3K27
methyltransferase, to be a critical mediator of lineage stability and function in acti-
vatedTregcells.Consequently,defıciencyofEzh2 inTregcells strongly impairs their
function in non-lymphoid tissues. We hypothesized that this phenomenon might
translate to a similar defect that is restricted to the tumormicroenvironment. Here
we tested this hypothesis in three transplantable syngeneic tumor models in mice
(MC38coloncarcinoma,TRAMP-C2prostate cancer, andB16F10melanoma).We
observed that constitutive deletion of Ezh2 in Treg cells resulted in potent anti-
tumor activity, signifıcantly impaired tumor outgrowth, and in many instances,
complete tumor rejection. These results were also recapitulated when Ezh2 was
temporally deleted in the vastmajority ofTreg cells at the timeof tumor inoculation.
Functional analyses at early timepoints after Ezh2deletion revealed enhanced func-
tionality of effector CD4 and CD8 populations, as evidenced by increased IFN-
production. These effects were evident without reduction of intratumoral Treg cell
frequenciesanddespitepresenceof residualwild typeTregcells.Mechanistic studies
showed that Ezh2-defıcient Treg cells were destabilized and produced pro-inflam-
matory cytokines IL-2 and IFN- selectively within the tumor microenvironment,
suggesting a direct contribution of Ezh2-defıcient Treg cells to tumor clearance. To
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more directly address this hypothesis, we generatedmice that harbored both Ezh2-
defıcient and wild type Treg cells and observed anti-tumor activity similar to mice
that exclusively harbored Ezh2-defıcient Treg cells. In stark contrast to Ezh2 defı-
ciency,micewhoseTreg cellswere completely depleted, using aFoxp3-drivendiph-
theria toxin receptor allele, were unable to reject tumors, further supporting a dom-
inant role of Ezh2-defıcient Treg cells in driving anti-tumor immunity. Finally,
tumor protection in the presence of Ezh2-defıcient Treg cells occurred without sig-
nifıcant morbidity due to autoimmune pathologies, which were prevalent in mice
withsystemicTregcelldepletion.Theseresults suggest that targeteddeletionofEzh2
in Treg cells drives a unique phenotype among tumor infıltrating Treg cells, repro-
grammingthe tumormicroenvironmentandselectivelyaugmenting theanti-tumor
immune response. Cancer therapies that pharmacologically inhibit Ezh2 to target
tumor cells are under investigation, going forward it will also be important to assess
the potential for benefıcial effects via modulating the immune response.
#1015 Directionality of T-cell-mediated cross-protection against the same
tumor in lungs versus skin. Jessica J.O’Konek, ElenaAmbrosino,AnjaBloom,Liat
Izhak, Jay A. Berzofsky, Masaki Terabe.National Cancer Inst., Bethesda, MD.
Immunotherapy is a new pillar of cancer therapy. One theoretical advantage of
immunotherapy of cancer is that effector cells induced at one site should be able to
kill metastatic cancer cells in other sites or tissues. On the other hand, it has been
recognized that each tissue has unique immune components that play critical roles
in protection against pathogens. However, very little is known whether effector T
cells inducedagainst tumors inone tissue canworkagainst the same tumors inother
tissues. To address this question, we compared the effect of effector cells induced
against the same tumor cells growing in either the skin or the lung by using CT26
murine tumormodels. Rejection of s.c. CT26 tumorswas achieved by pretreatment
with anti-CD25, which blocks the function of Treg cells. BothCD4 andCD8T cells
were necessary for the protection. When anti-CD25-pretreated mice challenged
with s.c. CT26 were simultaneously inoculated i.v. with CT26, they also rejected
tumors in the lung,whileanti-CD25-pretreatedmicewithout s.c.CT26didnot.This
observationsuggested thatTcellmediatedanti-tumorprotective immunity induced
against s.c. tumors can also protect against lung metastases of the same tumors. In
contrast to Treg depletion which allowed for the induction of protective immunity
in the s.c. tumormodel, NKT cell-defıciency in CD1dKOmice induced signifıcant
CD8Tcell-mediatedprotectionagainst lungmetastasisofCT26buthadnoeffecton
the growth of s.c. CT26 tumors. When CD1d KO mice rejecting i.v. CT26 were
simultaneously challenged with s.c. CT26, the development of s.c. tumors was not
affected, indicating that tumor rejection induced against the CT26 in the lung did
not confer protection for the same tumor cells in the skin. Since the protection
against CT26 in the lung in CD1d KOmice is mediated by CD8 T cells, we trans-
ferred T cells fromCD1dKOmice inoculated i.v. with CT26 into RAG1KO recip-
ients, and challenged the recipient mice with the CT26 tumor cells. The recipient
RAG1KOmicewere highly resistant toCT26 inoculated i.v. but not s.c. confırming
that the CD8 T cells protective in the lung are not protective in the skin. These data
indicate the effector cells against the same tumor do not work in all tissues, and the
induction site of the effector T cells is critical to control metastasis.
#1016 Evaluation of progression associated neoepitopes and immune
contexture in pulmonary premalignancy. Kostyantyn Krysan, Linh M. Tran,
Brandon S. Grimes, Tonya C. Walser, William D.Wallace, Steven M. Dubinett.
UCLA David Geffen School of Medicine, Los Angeles, CA.
Lung cancer is the leading cause of cancer death in theUS and in theworld.Over
thepast 30 years, the fıve-year survival rate for lung cancerhas increasedbyonly 5%.
With the widespread implementation of screening programs, detection of prema-
lignant and early stage disease is increasing. A better understanding of genomic
alterationsand themicroenvironmentalong the spectrumofearlydiseasecould lead
to identifıcation of progression-associated mutations (PAMs), defıned as those
shared between premalignant lesions and invasive cancer, and their neoepitopes.
Unleashing the immune response against pulmonary premalignancy could trans-
form therapy and outcomes. FFPE tissue blocks from patients with resected lung
adenocarcinoma (ADC) were obtained from the UCLA Lung Cancer Tissue
Repository. For each patient, the following regions were dissected from dis-
tal airways utilizing Laser Capture Microdissection: a) normal airway epi-
thelial cells (1-3 regions), b) premalignant atypical adenomatous hyperplasia
(AAH, 2-4 regions), c) adenocarcinoma in situ (AIS, when present) and d)
ADC, 1-3 regions followed by whole exome sequencing. Forty-one complete
cases have been sequenced to date. Our data suggest that premalignant le-
sions from the same patient may a) have different mutational profıles and b)
bear progression-associated mutations, common with the primary lung tu-
mor. This inter-lesion heterogeneity suggests that a progression-associated
mutational landscape could be defıned in longitudinal studies of pulmonary
premalignancy which will be the focus of future investigations. Next, utiliz-
ing the mutational data, we performed in silico neoantigen analysis to iden-
tify potential neoepitopes among the genes mutated in premalignant lesions.
The neoantigen analysis demonstrated that among the top 11 peptides with
high binding avidity for autologous MHC, 9 were derived from PAMs. This
suggests that neoepitopes exist in premalignancy that could serve as targets
for development of future vaccines. Finally, we performed the quantitative
immunohistochemical (IHC) and immunofluorescence (IF) staining for
Granzyme B, PD-1, PDL-1, CD4, CD8 and FOXP3 to evaluate cell-me-
diated immunity on the same samples that were utilized for WES. We found
both infıltration of T effector cells as well as upregulation of checkpoints in
premalignancy and detected a signifıcant inter-lesional heterogeneity. Our
studies lay the ground work for identifıcation of neoepitopes that can be
targeted before the development of invasive lung cancer, thus shifting the
approach to disease interception through immunoprevention and treatment
of the very earliest phase of the disease.
#1017 Lipidmetabolic reprogramming drives resistance to PD1 blockage.
Maria A. Cortez, Sharareh Niknam, Efrosini Cuko, Jonathan E. Schoenhals,
HampartsoumBarsoumian, Ahmed I. Younes, Ailin Li, JodyV. Vykoukal, Cris-
tina Ivan, George A. Calin, Patrick Hwu, James W. Welsh. UT MD Anderson
Cancer Ctr., Houston, TX.
The mechanisms underlying immunosuppression and resistance to PD1 inhibi-
tors in cancer are not well understood. We attempted to fıll this gap with an inte-
grated analysis ofmRNA,microRNA, and protein expression in an anti-PD1-resis-
tant lung adenocarcinomamousemodel. Themodel was created by in vivo passage
of 344SQ murine lung cancer cells (p53R172H	g/K-rasLA1/) in a syngeneic host
repeatedly dosed with anti-mouse PD1 antibodies. Anti-PD1-resistant 344SQ
(344SQ_R) and 344SQ parental (344SQ_P) cells were then inoculated into synge-
neic 129Sv/ev mice, which were then dosed twice with anti-PD1 or control IgG
antibodies. Tumor tissues were collected and analyzed as follows: transcriptome
with Affymetrix; protein levels by reverse phase protein array analysis; signature
enrichment by gene set enrichment analysis; metabolome by mass spectrometry;
and lipid content with fluorescent probes Oil O rad and BODIPY.We also isolated
tumor-infıltrating immune cells for flow cytometry and gene expression analyses.
We identifıed lipid-relatedmetabolic pathways as being themost highly enriched in
anti-PD1-resistant tumors (344SQ_R) vs. their 344SQ_P counterparts; the resistant
cells also had more lipid droplets than the 344SQ_P cells. The anti-PD1-resistant
tumors overexpressed several genes involved in lipogenesis and fatty acid pathways
(e.g., fatty acid binding proteins [FABPs], fatty acid synthase, acetyl-coA-acyltrans-
ferase2, fatty acid elongases). Specifıcally, FABPoverexpressionpromoted fatty acid
uptake and lipid-droplet accumulation in resistant tumors. Lipid-sensitive targets
linked to inflammation and insulin signaling (e.g,. stress-activated kinases such as
JNK and NFB) were altered in 344SQ_R vs. 344SQ_P tumors. Mechanistically,
JNK downregulation by NFB-regulated microRNAs protected PD1-resistant tu-
mors from lipotoxicity caused by FABPs upregulation and fatty acid uptake. FABP
levels were higher in plasma from 344SQ_R than from 344SQ_P tumors. Tumor-
infıltrating macrophages from 344SQ_R tumors had 4 times the amount of FABP
mRNA than parental tumors and a correspondingly higher percentage of M2-like
macrophages. 344SQ_R tumors promoted immune suppressive cells by upregulat-
ing FABPs expression in M2-like macrophages, marked by increased fatty acid in-
take and fatty acid oxidation. Conversely, percentages of CD4 andCD8 tumor-
infıltrating lymphocytes were reduced in the resistant tumors. These results suggest
that lipid metabolic rewiring drives resistance PD1 inhibitors supporting the accu-
mulation of immunosuppressive cells, includingM2-likemacrophages, preventing
type I immune responses elicited by T cells. Collectively, these fındings reveal new
potential lipid-related targets for drug development or new treatments combining
inhibitors of these targets with anti-PD1 therapy.
#1018 High-resolution microbiome profıling and genome wide arrays un-
cover bacteria driven alterations of oncogenic and immune pathways in head
andneckcancerpatients treatedwith surgery, chemo-radiationandPD-1check-
point blockade therapy. Rafael E. Guerrero-Preston,1 James RobertWhite,2 Filipa
Godoy-Vitorino,3 Herminio Gonzalez,3 Arnold Rodríguez-Hilario,3 Kelvin Na-
varro,3GustavoA.Miranda-Carboni,4ChristinaMichailidi,1AnneJedlicka,5 Steph-
anie Hao,6 Sierra Canapp,1 Jessica Bondy,1 Amanda Dziedzic,5 Barbara Mora La-
gos,7 Gustavo Rivera-Alvarez,8 Winston Timp,6 William Westra,1 Wayne Koch,1
Hyunseok Kang,1 Luigi Marchionni,1 Young Kim,9 David Sidransky1. 1Johns Hop-
kinsUniv. School ofMedicine,Baltimore,MD; 2RespheraBiosciences,Baltimore,MD;
3Inter American University of Puerto Rico, San Juan, PR; 4University of Tennessee
Health Science Center,Memphis,MD; 5JohnsHopkinsUniv. School of PublicHealth,
Baltimore,MD;6JohnsHopkinsUniv.WhitingSchoolofEngineering,Baltimore,MD;
7UniversidaddeLaFronteraSchool ofMedicine,Temuco,Chile; 8University ofPuerto
Rico School of Medicine, San Juan, PR; 9Vanderbilt University School of Medicine,
Nashville, TN.
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Previous microbiome studies at the genus level have described altered
microbiota in head and neck squamous cell carcinoma (HNSCC), both in
terms of taxonomic composition and metabolic capacity. We applied high-
resolution microbiome profıling (Resphera Insight) to analyze 16S rRNA
sequencing data in saliva and tissue samples from HNSCC patients and
healthy controls. DNA extraction and amplicon library preparation was per-
formed for saliva samples fromHNSCC (n38) and controls (n25), as well
as tissue samples from HNSCC (n25) and controls (n8). Raw sequences
were processed for quality and length, screened for chimeras and fıltered for
contaminant human and chloroplast DNA. High-quality passing sequences
were submitted to Resphera Insight for species-level taxonomic assign-
ments, followed-by differential abundance analysis with the DESeq package.
Samples from a subset of HNSCC patients were signifıcantly enriched with
commensal species from the vaginal flora, including Lactobacillus gasseri/
johnsonii (710x higher in saliva and 1990x higher in tissue) and Lactobacillus
vaginalis (52x higher in saliva). These species were not observed in normal
saliva or tissue samples from Hopkins patients (n33) nor in normal saliva
samples (n292) from the Human Microbiome Project (HMP). Interest-
ingly, both species were only observed in saliva from Human Papilloma
Virus positive (HPV) and HPV negative (HPV-) oropharyngeal cancer
patients, and we confırmed their representation in vaginal samples from the
HMP (n249). We also found that Fusobacterium nucleatum (F.nuclea-
tum), an oral cavity flora commensal bacterium linked to colon cancer, is
enriched (600x higher in saliva and 51x higher in tissue) in a subset of
HNSCC patients with advanced tumors (T3 or above). F. nucleatum was
detected in samples obtained before and after treatment with chemo-radia-
tion, but not with surgery alone. Interestingly, we identifıed upregulation of
the oncogenic Wnt/Beta catenin pathway (Wnt7B, FZD6, SFRP4) and down
regulation of immune system pathways (TLR10, IRF8) with genome-wide
mRNA arrays (Affymetrix) in HNSCC samples enriched for F.nucleatum.
Using fluorogenic quantitative PCR we confırmed that F.nucleatum and Fu-
sobacterium spp. are enriched in saliva samples collected prior to treatment
in another cohort of HNSCC patients, and in post-treatment saliva samples
obtained from HNSCC patients treated with PD-1 checkpoint blockade. We
also found enrichment of HPV oropharyngeal tumors with F.nucleatum
and Fusobacterium spp., prior to therapy, while some recurrent HPV- oro-
pharyngeal tumors are enriched only with Fusobacterium spp. Together,
these results suggest that bacteria may impact therapy in HPV and HPV-
oropharyngeal and oral cavity cancer by altering oncogenic and immune
system pathways.
#1019 In vivo CRISPR screening identifıes Ptpn2 as a target for cancer
immunotherapy. Robert T. Manguso,1 Hans W. Pope,1 Margaret D. Zim-
mer,1 Flavian D. Brown,1 Kathleen B. Yates,1 Brian C. Miller,1 Natalie B.
Collins,1 Kevin Bi,1 Martin W. Lafleur,1 Vikram R. Juneja,2 Sarah A. Weiss,1
David E. Fisher,3 David E. Root,4 Arlene H. Sharpe,2 John G. Doench,4 W
Nicholas Haining1. 1Dana-Farber Cancer Institute/Harvard Medical School,
Boston, MA; 2Harvard Medical School, Boston, MA; 3Massachusetts General
Hospital, Boston, MA; 4Broad Institute of Harvard andMIT, Cambridge, MA.
Despite the dramatic clinical success of cancer immunotherapy with PD-1
checkpoint blockade, most patients don’t experience sustained clinical ben-
efıt, suggesting that additional therapeutic strategies are needed. Functional
genomic screens in cancer cells to discover new therapeutic targets are usu-
ally carried out in vitro where interaction with the immune system is absent.
Here we report a pooled, loss-of-function genetic screening approach using
CRISPR/Cas9 genome editing that is conducted in vivo in mouse transplant-
able tumors treated with vaccination and PD-1 checkpoint blockade. We
tested 2,400 genes expressed by melanoma cells for those that synergize with
or cause resistance to checkpoint blockade, and recovered the known im-
mune evasion molecules, PD-L1 and CD47. Loss of function of multiple
genes required to sense interferon-y caused resistance to immunotherapy.
Deletion of Ptpn2, a pleotropic protein tyrosine phosphatase improved re-
sponse to immunotherapy. In vivo, Ptpn2 defıcient tumors showed increased
infıltration of activated CD8T cells. In vitro, Ptpn2 loss by tumor cells
increased antigen presentation to T cells. Biochemical, transcriptional and
genetic epistasis experiments demonstrated that loss of function of Ptpn2
sensitizes tumors to immunotherapy by enhancing interferon-y-mediated
effects on the tumor cell. Thus, augmenting interferon-y signaling in tumor
cells could increase the effıcacy of immunotherapy. More generally, in vivo
genetic screens in tumor models can identify new immunotherapy targets
and rationally prioritize combination therapies.
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#1020 BRD9 defınes a novel mammalian SWI/SNF (BAF) complex con-
fıguration which supports proliferation in AML. Brittany C. Michel,1 Joshua
Pan,1 Robin M. Meyers,2 Paola Grandi,3 Phillip G. Humphreys,4 Neil G. Gar-
ton,4 Rab K. Prinja,4 Cigall Kadoch1. 1Dana-Farber Cancer Institute and Har-
vard Medical School, Boston, MA; 2Broad Institute of MIT and Harvard, Boston,
MA; 3Cellzome, Heidlberg, Germany; 4GlaxoSmithKline, Hertfordshire, United
Kingdom.
Genes encoding subunits of the mammalian SWI/SNF (BAF) ATP-depen-
dent chromatin remodeling complexes are mutated in over 20% of human can-
cer. Specifıc subunits are mutated in specifıc malignancies, highlighting their
tissue-specifıc protective roles; moreover, synthetic lethal screens have uncov-
ered genetic- and lineage-based features which confer dependence on specifıc
mSWI/SNF subunits. As combinatorial complexity represents a major chal-
lenge, identifıcation of specialized mSWI/SNF confıgurations, subunit-specifıc
functions, binding restrictions, and exclusivity relationships is critical for un-
derstanding oncogenic mechanisms and for the selection of appropriate thera-
peutic agents targeting mSWI/SNF complex subunits. Here, we discover that
BRD9, a recently identifıed mSWI/SNF subunit, defınes a novel complex con-
fıguration distinct from BAF and PBAF, which we term non-canonical BAF, or
ncBAF. We used biochemical methods to isolate BRD9-containing complexes
and fınd that BRD9 selectively marks a sub-stoichiometric group of mSWI/SNF
complexes of smaller molecular weight that lack several members of canonical
BAF complexes such as BAF47 and ARID1A. Moreover, chemoproteomics us-
ing a BRD9 inhibitor (GSK) isolates only ncBAF and does not resolve BAF-
specifıc or PBAF-specifıc components, including the highly related bromodo-
main-containing subunit BRD7. We further identifıed regions of BRD9 and
BRD7 that confer specifıcity of these subunits to ncBAF and PBAF complexes,
respectively, resolving their mSWI/SNF binding domains. Using genome-wide
ChIP-seq and RNA-seq experiments, we determined that ncBAF complexes
target a distinct subset of all mSWI/SNF complex target genes and, consistent
with previous studies, maintain proliferation of AML cells. Finally, we applied a
newly- generated approach to deriving functional relationships within and be-
tween protein complex families from shRNAandCRISPR-based genetic screen-
ing datasets across hundreds of cancer cell lines to explore ncBAF-specifıc sub-
units. We fınd that ncBAF-specifıc complex subunits form a distinct functional
module, supporting biochemical studies and pointing to the specifıc and diver-
gent functions of the ncBAF confıguration. Cancers of hematologic origin col-
lectively exhibit the most signifıcant responses to perturbation of three ncBAF
subunits including BRD9, substantiating previous small molecule screening ef-
forts using BRD9 bromodomain inhibitors. These data demonstrate that ncBAF
complexes represent a novel BAF complex compositionwith distinct function in
cancer.
#1021 Mutations in SWI/SNF chromatin remodeling complex sensitizes
tumors to OXPHOS inhibition. Yonathan Lissanu Deribe. UT MD Anderson
Cancer Ctr., Houston, TX.
Recent large-scale cancer genomic studies have established a framework in
which biological functions and genetic interactions of established and novel
cancer genes can be explored.One of themajor fındings of these studies has been
the discovery of frequent genetic alterations in chromatin and epigenetic regu-
lators including inactivatingmutations in components of the SWI/SNF chroma-
tin remodeling complex. In lung adenocarcinoma in particular, a quarter of
tumors have inactivating mutations in the SWI/SNF components Smarca4,
ARID1A or the histone modifıer SETD2. With the aim of understanding the
mechanism of tumor development and identifying potential vulnerabilities of
SWI/SNF mutant tumor, we developed a genetically engineered mouse model
(GEMM) of lung adenocarcinoma by selectively ablating Smarca4 in the respi-
ratory epithelium. We demonstrate that Smarca4 acts as a bona fıde tumor
suppressor and cooperates with p53 loss. Cross species integrative gene expres-
sion analyses revealed signatures of enhanced oxidative phosphorylation and
reactive oxygen species (ROS) response in Smarca4 mutant murine and human
lung tumors.We further show that Smarca4mutant cells have increased oxygen
consumption, enhanced basal andmaximal respiratory capacity and production
of ROS. This is primarily driven by activation of the mitochondrial master reg-
ulator, PGC1alpha. Finally, we show that Smarca4 and other SWI/SNF mutant
lung cancer cell lines have exquisite sensitivity to inhibition of oxidative phos-
phorylation using a novel small molecule that is under development. These
fındings provide a mechanistic basis for further development of OXPHOS in-
hibitors as therapies in SWI/SNF mutant tumors.
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#1022 Chromatin remodeler HELLS is an epigenetic driver for hepatocel-
lular carcinoma progression.Cheuk-Ting Law, Larry L.Wei, Felice HCTsang,
Iris MJ Xu, Robin KH Lai, Daniel WH Ho, Joyce MF Lee, Carmen CL Wong,
Irene OLNG, Jack CMWong, The State Key Laboratory for Liver Research.The
University of Hong Kong, Hong Kong Island, Hong Kong.
Hepatocellular carcinoma (HCC) is the major type of liver cancer and the
second leading cause of cancer death worldwide. Every year, more than six
hundred thousand people are newly diagnosed. For the advancedHCCpatients,
only one FDA-approved drug is currently available. Therefore, there is an urge
to delineate the molecular mechanism of HCC progression for developing new
therapeutics. Increasing evidence showed that epigenetic alterations play an
important role in the carcinogenesis process. The epigenetic regulatory mecha-
nism is accomplished by DNAmethylation, histone modifıcation, and chroma-
tin remodeling. Deregulation of DNA methylation and histone modifıcations
have recently been characterized in HCC, but the signifıcance of chromatin
remodeling in liver carcinogenesis remains to be explored. In this study, we
employed RNA-seq to investigate the expression of chromatin remodelers in
human HCCs. We found that HELicase, Lymphoid-Specifıc (HELLS), a SWI2/
SNF2 chromatin remodeling enzyme, was remarkably overexpressed in HCC.
Overexpression of HELLSwas correlated withmore aggressive clinicopatholog-
ical features and poorer patient prognosis. We further showed that up-regula-
tion ofHELLS inHCCwas conferred by hyper-activation of transcription factor
SP1. To investigate the functions ofHELLS inHCC,we generated both gain- and
loss-of-function models by CRISPR activation system, lentiviral shRNA, and
CRISPR/Cas9 genome editing system.We demonstrated that overexpression of
HELLS augmented HCC cell proliferation andmigration. In contrast, depletion
of HELLS reduced HCC cell growth and motility. Moreover, inactivation of
HELLS induced apoptosis in HCC cells. Coherently, ablation of HELLS also
mitigated tumorigenicity and lungmetastasis in vivo as demonstrated with both
subcutaneous and orthotopic tumor implantation models. Mechanistically, by
using RNA-seq and MNase-seq, we revealed that HELLS controls the nucleo-
some occupancy at gene enhancer and transcription start site (TSS). Overex-
pression of HELLS increased nucleosome occupancy that obstructed the acces-
sibility of enhancers and hindered the formation of nucleosome-free region
(NFR) at TSS of its target genes, thereby blocks the binding of transcription
factors for activating gene expression. Consequently, though this mechanism,
up-regulation of HELLS mediated epigenetic silencing of multiple tumor sup-
pressor genes including E-Cadherin, FBP1, IGFBP3, XAF1 and CREB-H in
HCC. In conclusion, our data unravel that HELLS is a key epigenetic driver of
HCC. By altering the nucleosome occupancy at NFR and enhancer, HELLS
epigenetically suppresses numerous tumor suppressor genes to promote HCC
progression.
#1023 Activation of proto-oncogenes by enhancer-hijacking in high
risk
neuroblastoma.Daniel Dreidax,1 Moritz Gartlgruber,1 Sebastian Steinhauser,1
Larisa Savelyeva,1 Ron Schwessinger,1 Umut Toprak,1 Nati Ha,1 Dilafruz Ju-
raeva,1 Martin Peifer,2 Matthias Fischer,2 Stefan Gröschel,1 Kai-Oliver Hen-
rich,1 Young-Gyu Park,1 Benedikt Brors,1 Matthias Schlesner,1 Carl Herr-
mann,1 Frank Westermann1. 1German Cancer Research Center (DKFZ),
Heidelberg, Germany; 2University of Cologne, Cologne, Germany.
Background: Neuroblastoma (NB), a neural crest-derived tumor of the sym-
pathetic nervous system, is the most common extracranial solid tumor in chil-
dren. We have previously shown that genomic rearrangements activate proto-
oncogenic telomerase by juxtaposing active enhancer elements to the TERT
gene in a large fraction of high-riskNBs. In the present study, we applied a global
approach integrating whole genome sequencing (WGS), Chromatin immuno-
precipitation sequencing (ChIP-seq) and RNA sequencing (RNA-seq) data of
NB cells and tumors to identify further key oncogenes activated by enhancer-
hijacking in NB. Methods: WGS was applied to search for structural rearrange-
ments in 120 NB tumors and fıve NB cell lines. Corresponding RNA-seq data
were used to discover mono-allelic and/or outlier expression of candidate genes
potentially involved in enhancer hijacking events. ChIP-seq of 34 NB tumors
and 17 NB cell lines was applied to identify active enhancer elements in NB.
Circular chromatin conformation capture sequencing (4C-seq)was used to con-
fırm physical promoter-enhancer interactions in NB cell lines. Results: WGS
analyses revealed that chromosomal rearrangements are common events in NB
tumors and cell lines and frequently affect regions harboring proto-oncogenes
and lineage specifıc enhancers. ChIP-seq analyses of the chromatin mark his-
tone 3 lysine 27 acetylation (H3K27ac), surrogate for enhancer activity, con-
fırmed that these rearrangements recurrently juxtapose active enhancer ele-
ments to oncogenes including MYCN and MYC in NB. Intriguingly,
quantifıcation of H3K27ac ChIP-seq profıles uncovered that the enhancer ele-
ments translocated toMYCwere among themost active ones within the respec-
tive epigenomes. 4C-seq analyses proofed physical interactions between trans-
located enhancer elements and promoters of the respective oncogenes, which is
in line with their elevated expression in rearranged cases. Conclusions: Our
study reveals that structural rearrangements in high-risk neuroblastoma fre-
quently juxtapose strong enhancers to key oncogenes, including MYCN and
MYC, leading to physical promoter-enhancer interactions which likely drive
overexpression of the oncogenes observed in rearranged cases. The common
mechanismof oncogene activation by enhancer-hijackingmay open a therapeu-
tic window for epigenetic drugs including BET or CDK7 inhibitors in high-risk
NBs.
#1024 Genome-wide examination of topological variability reveals cell
type-specifıc mechanisms of oncogene activation. Caleb Lareau, Martin
Aryee. Harvard University, MA.
INTRODUCTION: The organization of chromatin within the nucleus into
hierarchical three-dimensional (3D) structures plays a key role in the regulation
of gene expression. Differences in 3D architecture, such as the presence or ab-
sence of “loops” between specifıc enhancers and their target genes, are a major
driver of transcriptional and phenotypic variation. By determining the accessi-
bility of genes to transcriptional machinery and distal regulatory regions, mech-
anisms mediating oncogene activation can be discerned. Recent studies have
implicated pathogenic alterations in genome topology with the activation of
proto-oncogenes in a multitude of cancers. METHODS: To characterize the
topological changes associated with different cancer states, we developed a com-
putational suite of tools that facilitates the systematic discovery, annotation, and
visualization of features in chromatin topology and assigns statistical confıdence
estimates to regions with variability between cellular phenotypes. Our frame-
work facilitates the integration of heterogeneous genomic data, including gene
expression, histone modifıcation, DNA methylation, open chromatin, and ge-
netic variation, to further characterize changes in 3D genome. Ultimately, we
propose a joint model that functionalizes the effect of epigenetic modifıcations
on transcription as mediated through hierarchical chromatin structure. RE-
SULTS: We identify regions of topological variation unique to breast cancer,
cervical cancer, glioblastomas with and without an IDH1 mutation, melanoma,
and leukemia. Patterns of disrupted insulation and subsequent localization of
enhancers to proto-oncogenes can be attributed to variation in the epigenome,
including variation in DNA methylation and open chromatin, at distal regula-
tory regions. These 3D alterations provide amechanism for activation of specifıc
oncogenic pathways, including signaling mediated by p38, PLK3, and BRCA.
CONCLUSIONS: Variable patterns of chromatin topology provide a unique
signature and mechanism of oncogenes for the cancer phenotypes considered.
Additionally, our framework provides a novel means for interpreting epigenetic
variability, particularly at distal regulatory regions, and explaining transcrip-
tional variation associated with cancer phenotypes as mediated through struc-
tural changes in the DNA.
#1025 Controlled and endogenous depletion of a synthetic lethal target in
human cancer cell lines via SMASh degron engineering. Florencia Rago,Mat-
thew T. Dimare, Geoffrey Bushold, Avnish Kapoor, Hyo-eun C. Bhang, Zainab
Jagani. Novartis Institutes for Biomedical Research, Cambridge, MA.
The SWI/SNF multi-subunit complexes play an important role in regulating
processes such as gene transcription through ATP-dependent remodeling of
chromatin. The importance of this role is highlighted by the prevalence of mu-
tations in various SWI/SNF subunits across approximately 20% of cancers en-
compassing various lineages and subtypes. Functional genomics screening via
pooled shRNAs has led to the discovery of distinct vulnerabilities of SWI/SNF
mutant cancers to loss of mutually exclusive subunits. In particular, cancer cells
with BRG1 loss become exquisitely dependent on the remaining BRG1 counter-
part, BRM. To further understand the synthetic lethal relationship between
BRM and BRG1, we have adapted a recently described degron, the small mole-
cule assisted shutoff (SMASh) tag, showing for the fırst time the ability to apply
this system to control endogenous levels of target protein, in this case BRM.We
used the SMASh tag to target the endogenous BRM locus in both a BRG1 wild-
type and mutant cancer cell line. Using these engineered cell lines, we were able
to show that we can achieve tunable protein levels by varying the concentration
of the effector molecule. The ability to tune BRM depletion allowed us to inves-
tigate the nature of the BRG1/BRM synthetic lethal relationship. Our data inter-
estingly suggests that while modest depletion of BRM is suffıcient to observe
changes in the expression of a target gene regulated by SWI/SNF in a dose-
dependentmanner, a higher level of BRMdepletion is required to elicit a growth
arrest phenotype in the BRG1-mutant non-small cell lung cancer line. Together
these results uncover a novel relationship between the catalytic SWI/SNF sub-
unit and gene expression, where we fınd that the latter responds in a dose de-
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Chromatin Structure and Function
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017262
pendent manner to BRM levels. Additionally, we elucidate the level of BRM
depletion required to observe the synthetic lethal phenotype, providing insight
and informing on strategies for therapeutic targeting whether by protein degra-
dation approaches, such as PROTAC, or other small molecule approaches. Fi-
nally, having provided a proof-of-concept, such tools can be readily adapted for
application to endogenous degradation of other target proteins in different sys-
tems.
#1026 Identify BRD4 as a facilitator of replication stress response signal-
ing. Jingwen Zhang,1 Brandon Willis,1 Maureen Hattersley,1 Alan Lau,2
Corinne Reimer,1 Michael Zinda,1 Stephen Fawell,1 Gordon Mills,3 Austin Du-
lak,1 Huawei Chen1. 1AstraZeneca Pharmaceuticals, Waltham, MA; 2AstraZen-
eca Pharmaceuticals, Macclesfıeld, United Kingdom; 3The University of Texas
MD Anderson Cancer Center, Houston, MA.
BRD4 is a member of the BET (bromodomain and extraterminal domain)
family of chromatin readers that recognize acetylated-lysines on histones and
nuclear proteins. Previous reports have demonstrated that select cancers depend
on BRD4 to regulate oncogenic gene transcriptional programs. However,
whether BRD4 contributes to cancermalignancy through othermechanisms has
not been extensively evaluated. Here, we show that BRD4 is important formain-
taining an intactDNA replication checkpoint in cancers. Displacement of BRD4
by BET bromodomain inhibitor AZD5153 in cell lines under intrinsic or exog-
enous replication stress led to a time-dependent reduction in phospho-Chk1
fırst detected within 30 minutes, and reaching maximum phospho-Chk1 inhi-
bition (85%) at an hour after AZD5153 treatment in U2OS cells. The decrease
in Chk1 phosphorylation was observed without a concomitant decrease in total
Chk1, and this was not replicated by treatment with pan-transcriptional inhib-
itors, suggesting a non-transcriptional mechanism linked to BRD4. Further-
more, BRD4 interacts with the DNA pre-replication complex and inhibition of
BRD4 leads to hyperactivation of the pre-replication complex and aberrant
DNA replication re-initiation under replication stress conditions. Consistent
with a role in S-phase signaling, BETi treatment sensitizes replicating cells to
replication stress-inducing agents. Finally, we observed that ovarian cancer cell
lines are highly-sensitive to the combined inhibition of BRD4 and ATR. Coad-
ministration of AZD5153 and AZD6738 (ATR inhibitor) signifıcantly inhibited
tumor growth in OVCAR3 ovarian xenograft model (TGI after 21 day dosing:
AZD5153, 52%; AZD6738, 46%; Combo, 84%). Sustained tumor growth delay
was observed after combination treatment cessation. Together, our study un-
covered a novel function for BRD4 in regulating DNA replication stress re-
sponse, and provide mechanistic rational for combining BETi with DNA dam-
age-targeted agents for cancer therapies.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Oncogenes and Tumor Suppressors 1: Function and Therapeutic
Vulnerabilities
#1027 Development of orthotopically grafted organoid models to study
pancreatic cancer progression. Chang-Il Hwang, Eunjung Lee, Brandon Da
Silva, Kevin Wright, Youngkyu Park, David A. Tuveson. Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY.
Pancreatic ductal adenocarcinoma (PDA) is one of the most diffıcult human
malignancies to treat. The 5-year survival rate of PDA patients is 7% and PDA is
predicted to become the second leading cancer-related cause of death in the
USA. A subset of potential tumor suppressor genes was identifıed by genome-
wide analysis of human PDA and insertional mutagenesis in genetically engi-
neered mouse models (GEMMs). Since the functional validation of these genes
in GEMMs is time-consuming and labor-intensive, we have developed a rapid
and effıcient ’orthotopically grafted organoid’ (OGO) models in conjunction
with RNAi andCRISPR/Cas9 technology to study PDAprogression. Previously,
we showed that OGOmodel represents the full spectrum of PDA progression in
vivo upon orthotopic engraftment. Here, as a proof-of-concept experiment, we
demonstrate that ablation of Trp53 by viral introduction of shRNA or gRNA in
PanIN-derived organoids accelerates PDAprogression upon transplantation. In
addition, we engineered tetracyclin-inducible shRNA against Trp53 in ColA1
locus by Flpe recombinase-mediated cassette exchange in organoids derived
from Kras /G12D ; Rosa26-rtTA ; ColA1-homing cassette mouse. Orthotopic
transplantation followed by doxycycline administration resulted in rapid PDA
progression with metastases. Isolated tumor organoids were re-transplanted to
evaluate the effect of p53 restoration in PDA progression. Restoration of p53 by
doxycycline withdrawal led to reduced liver metastases, although there was no
difference in survival and primary tumor growth. This will provide a new insight
how p53 regulates PDA metastasis. Therefore, OGO models should provide an
excellent platform to study the functional role of genes in PDA progression in
vivo.
#1028 Genetic disruption of Kras sensitizes lung cancer cells to Fas-medi-
ated apoptosis.HaiweiMou,1 Jill Moore,1 SunilMalonia,1 Yingxiang Li,1 Deniz
Ozata,1 Soren Hough,1 Chunqing Song,1 Jordan Smith,1 Has Yin,2 Andrew
Fisher,1 Daniel Anderson,2 Shipping Weng,1 Michael Green,1 Wen Xue1.
1Univ. of Massachusetts Medical School, Worcester, MA; 2David H. Koch
Institute for Integrative Cancer Research, Massachusetts Institute of Technol-
ogy, Worcester, MA.
Genetic lesions that activate KRAS account for30% of the 1.6 million annual
cases of lung cancer. Despite clinical need, KRAS is still undruggable using tradi-
tional smallmoleculedrugs/inhibitors.WhenoncogenicKras is suppressedbyRNA
interference, tumors initially regress but eventually recur and proliferate despite
suppression of Kras. Here we show that tumor cells can survive CRISPR-mediated
knockout of oncogenic Kras, indicating the existence of Kras-independent survival
pathways. Thus even if clinical KRAS inhibitors were available, resistance would
remain an obstacle to treatment. Kras-independent cancer cells exhibit decreased
colony formation in vitro but retain the ability to form tumors inmice. Comparing
the transcriptomes of oncogenic Kras cells and Kras knockout cells, we identifıed
603genes thatwere specifıcallyupregulated inKrasknockoutcells, including theFas
gene, which encodes a cell surface death receptor involved in physiological regula-
tionof apoptosis.Antibodies recognizingFas-receptor effıciently induced apoptosis
ofKrasknockoutcellsbutnotoncogenicKrasexpressingcells. IncreasedFasexpres-
sion in Kras knockout cells was attributed to decreased association of repressive
epigenetic marks at the Fas promoter. Concordant with this observation, treating
oncogenicKras cells with histone-deacetylase inhibitor and Fas-activating antibody
effıciently induced apoptosis, thus bypassing the need to inhibit Kras. Our results
suggest that activation of Fas could be exploited as an Achilles’ heel in tumors initi-
ated by oncogenic Kras.
#1029 MAPK-mediated immunomodulation in disseminated murine
Emu-TCL1 chronic lymphocytic leukemia. Aparna Lakshmanan, Yo-Ting
Tsai, Amy Lehman, Ellen J. Sass, Minh Tran, Fabienne Lucas, Meixiao Long,
Bonnie K. Harrington, Krista La Perle, Vincenzo Coppola, Gerard Lozanski,
Natarajan Muthusamy, John C. Byrd, Michael R. Grever, David M. Lucas. The
Ohio State University, Columbus, OH.
Work in melanoma and other solid tumors shows mutations activating MAPK
pathway not only promotemalignancy by promoting survival and proliferation but
also are immunosuppressive than wild-type (WT) counterparts. However, rele-
vance ofMAPK-activatingmutations to immunemodulation in disseminated can-
cers such as leukemia is uncertain, and the mechanisms by which this occurs are
likely to differ. BRAF activating mutation is found in nearly all hairy cell leukemia
cases, 4%of chronic lymphocytic leukemia (CLL) and9%CLLcaseswhen including
other MAPK-activating mutations such as KRAS and NRAS. To assess immuno-
modulatory effects of BRAF-mutant CLL cells, we co-cultured dox-inducibleOSU-
CLL cells transfected withWT or BRAFV600E constructs with healthy donor T cells
incubated with anti-CD3/anti-CD28 antibodies, and T cell proliferation, cytokine
production and expression of surface proteinswere assessed by flow cytometry.We
also employed a transgenic mouse model of BRAF B cell leukemia. CD19-Cre x
BRAFV600E or CD19-Cre onlymice were crossed with the well-characterized Emu-
TCL1 model of CLL to obtain mice with spontaneous B cell leukemia expressing
either WT BRAF (CD19-Cre xTCL1) or mutant BRAF (BRAFV600E xCD19-Cre
xTCL1) under the native BRAF promoter. For adoptive transfer (AT) experiments,
leukemia cells (2e7) from transgenicmice were engrafted intravenously into synge-
neichealthy adult animals. Bloodand spleencellswere examinedby flowcytometry.
OSU-CLL cells expressing BRAFV600E more strongly inhibited anti-CD3/CD28-
induced proliferation of normal donor T cells. Transwell assays showed this effect
was due both to soluble and contact-dependent factors. TNF levels were higher in
BRAFV600E-expressing cells and reduced by vemurafenib, but a TNF neutralizing
antibody did not alter the inhibitory effect of BRAFV600E-expressing cells on T cell
proliferation. Proliferationwas rescued by theBRAFV600E inhibitor dabrafenib, fur-
ther supporting the contribution of mutant BRAF to this effect. Impact of
BRAFV600Emutationonmyeloid compartmentwas also evaluatedusingATmodel.
Mice were engrafted with BRAFWT or BRAFV600E leukemia cells, and upon achiev-
ing similar disease loads, BRAFV600E leukemic B cells caused 2.2-fold increase in
PD-L1 expressing-peripheral myeloid cells (p0.001; n25WT; 11 mutant). Ad-
ditionally, there was an increase in F4/80 macrophages (11%; p0.002),
CD11bLy6CintLy6Ghi MDSCs (8.5%, p0.014) and decrease in
CD11bLy6CloLy6Glo patrolling monocytes (11%; p0.031; n33 WT; 40 mu-
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tant) in spleens of mice with BRAFV600E leukemia, indicating that this mutation
influences the myeloid cell compartment as well. Ongoing studies are investigating
the mechanism of these effects and the potential for pharmacologic reversal. To-
gether, these results demonstrate immunosuppressive impact of BRAF in B-cell
leukemia.
#1030 Metabolic reprogramming caused by mutations of the Fbw7 ubiq-
uitin ligase in colorectal cancer.Ryan J. Davis,1Mehmet Gonen,2 DavidHock-
enbery,1 Adam Margolin,2 Bruce E. Clurman1. 1Fred Hutchinson Cancer Re-
search Ctr., Seattle, WA; 2Oregon Health Sciences University, Portland, OR.
Fbw7 is an evolutionary conserved F box protein that functions as a substrate
adapter for the Skp1-Cullin 1-F box (SCF) E3 ubiquitin ligase complex. Fbw7 is
also a tumor suppressor gene that is mutated in diverse human cancers. Many
Fbw7 substrates are oncogenic transcription factors, including c-Myc, Notch,
and Jun. Cancer-associated Fbw7 mutations diminish its ability to interact with
substrates, which results in inappropriate oncoprotein accumulation.One of the
signifıcant challenges for understanding the consequences of Fbw7mutations in
tumors is that Fbw7 coordinately regulates approximately two dozen broadly-
acting transcription factors. To address this problem, we used novel computa-
tional methods to analyze TCGA gene expression datasets to derive transcrip-
tional signatures that could predict a tumor’s Fbw7 mutational status; these
signatures were then analyzed for enrichment of genes involved in specifıc bio-
logical processes. We found that genes associated with mitochondrial function
were highly predictive of Fbw7mutations across several tumor types, suggesting
that metabolic reprogramming is a crucial oncogenic consequence of Fbw7mu-
tations. We validated this prediction by creating isogenic colorectal cancer cells
with normal or mutant Fbw7 alleles. We found that mitochondrial signature
genes are elevated in Fbw7 mutant cells, which also exhibit increased oxidative
metabolism. Moreover, metabolomic studies revealed deregulation of other
metabolic pathways in Fbw7-mutant cells, including amino acid and nucleotide
biosynthesis. These data suggest that metabolic vulnerabilities may represent
novel therapeutic targets in Fbw7-associated cancers.
#1031 Nuclear relocalization of NPM1c induces terminal differentiation
and cell growth arrest. Lorenzo Brunetti,1 Michael C. Gundry,1 Anna G. Guz-
man,1 Ilaria Gionfriddo,2 Federica Mezzasoma,2 Francesca Milano,2 Maria
Paola Martelli,2 Brunangelo Falini,2 Margaret A. Goodell1. 1Baylor College of
Medicine, Houston, TX; 2University of Perugia, Perugia, Italy.
NPM1 mutated acute myeloid leukemia (AML) is a distinct entity in the
WHO classifıcation of hematopoietic cancers. It displays a specifıc phenotype
characterized by favorable prognosis and upregulation of HOX cluster genes.
NPM1 is a multifunctional nucleolar chaperone. Mutations in NPM1 result in
cytoplasmic protein localization (NPM1c) through the acquisition of a nu-
clear export signal (NES) at the C-terminus. Themost frequent NPM1mutation
is a heterozygous 4bp insertion in exon 12 (mutA). The role of NPM1 in leuke-
mogenesis is still a matter of debate and there is no direct proof that cytoplasmic
localization of mutant NPM1 is necessary for maintenance of leukemia. We
recently developed a CRISPR strategy for highly effıcient gene editing in hema-
topoietic cells. We hypothesized that NPM1mutA could be specifıcally targeted
due to its 4bp insertion, avoiding the WT allele. Using an sgRNA spanning the
insertion site (NPM1c sgRNA), we aimed to introduce indels adjacent to the
mutation and disrupt the C-terminal NES. To test our hypothesis, we used the
NPM1 mutated OCI-AML3 cell line. After transfection of OCI-AML3 with
NPM1c sgRNA, while NPM1mutA allele showed 70-90% indel frequencies, the
NPM1wt allele was intact. To determine whether the novel edited alleles gener-
ated NPM1 that was re-localized to the nucleus, we cloned the alleles into a
GFP-NPM1 fusion construct and observed nuclear localization after transfec-
tion. Consistent with this fınding, immunofluorescence revealed that edited
OCI-AML3 cells had lost nearly all cytoplasmicNPM1. Return ofNPM1protein
to the nucleuswas followed by terminal differentiation and cell cycle arrest inG1
phase (controls 453%, NPM1c sgRNA 681.5%). Cell growth (3.7-4 fold de-
crease in cell counts in NPM1c sgRNA samples), colony forming ability (16-20
fold reduction in colonies in NPM1c sgRNA samples) and engraftment in xeno-
graft models (signifıcant loss of indels at NPM1mutA allele in engrafted cells)
were also signifıcantly impaired after NPM1mutA targeting. Furthermore, RNA
sequencing on NPM1mutA-targeted and control OCI-AML3 cells revealed al-
most complete loss of expression of the HOXA and HOXB cluster genes as well
asMEIS1 in treated cells (4.5 average fold reduction ofHOXA9-A13; 5.6 average
fold reduction of HOXB7-B13; 5 fold reduction of MEIS1). Allele-specifıc edit-
ing is a powerful tool to probe mechanistic aspects of oncogene dependencies.
By achieving nuclear re-localization of mutant NPM1, we demonstrated that
cytoplasmic localization of NPM1c is necessary for OCI-AML3 cells to main-
tain their leukemic phenotype. Drugs promoting mutant NPM1 nuclear local-
ization such as CRM1 inhibitors are attractive candidates for clinical success in
NPM1-mutated AML.
#1032 Identifıcation of Ran binding protein 6 as a novel negative regula-
tor of EGFR and candidate tumor suppressor in glioblastoma. Wan-Ying
Hsieh,1 Barbara Oldrini,2 Hediye Erdjument-Bromage,3 Paolo Codega,1 Maria
S. Carro,4 Igor Vivanco,5 Dan Rohle,1 Carl Campos,1 Craig Bielski,1 Barry Tay-
lor,1 Paul Tempst,1 Massimo Squatrito,2 Ingo K. Mellinghoff1. 1Memorial Sloan
Kettering Cancer Center, New York, NY; 2Spanish National Cancer Research
Centre, Madrid, Spain; 3New York University School of Medicine, New York, NY;
4Medical Center University of Freiburg, Freiburg, Germany; 5The Institute of
Cancer Research, London, United Kingdom.
Amplifıcation and overexpression of the epidermal growth factor receptor
(EGFR) are common in glioblastoma (GBM) and frequently associatedwith silenc-
ing of the phosphatase and tensin homologue (PTEN) tumor suppressor. PTEN
silencing has been associatedwith clinical resistance to EGFR tyrosine kinase inhib-
itors, in part by raising EGFR levels.Here, we investigated the effect of PTENon the
EGFRsignalingcomplexbyEGFRaffınity immunopurifıcationandmass spectrom-
etry with and without PTEN knockdown. We identifıed Ran binding protein 6
(RanBP6), a125-kDaproteinofpreviouslyunknownfunctions, asEGFRinteracting
protein in PTEN expressing, but not PTENknockdown cells. Further studies of the
effect of RanBP6 on EGFR revealed that RanBP6 depletion by shRNA or CRISPR/
Cas9-mediated gene silencing resulted in increased EGFR mRNA levels and up-
regulation of EGFR promoter activity. Consistent with amodel of a negative EGFR
regulation by RanBP6, we observed an inverse correlation between RanBP6 and
EGFRmRNA levels in PTENwildtype but not PTEN altered cancer cells in a large
panel of humancancer cell lines (CancerCell LineEncyclopedia). To further under-
stand the mechanism of how RanBP6 negatively regulates EGFR mRNA level, we
found that RanBP6 interactedwith nuclear Ran-GTPase and repressed EGFR tran-
scription by promoting nuclear import of Signal transducer and activator of tran-
scription 3 (STAT3). Lastly, RanBP6 appeared to be frequently deleted on chromo-
some 9p in GBM.We showed that RanBP6 silencing raised EGFR levels and signal
output andaccelerated in-vivogliomagrowth.Our results establish anovel function
of RanBP6 as a link between EGFR signaling and the Ran-mediated nuclear import
pathway, and identify RanBP6 as candidate tumor suppressor on chromosome 9p.
#1033 Estrogen receptor gene fusions drive endocrine therapy resistance
in estrogen receptor positive breast cancer. Jonathan T. Lei,1 Jieya Shao,2 Jin
Zhang,3 Michael Iglesia,4 Doug W. Chan,1 Ryoichi Matsunuma,1 Xiaping He,4
Purba Singh,1 YoshimasaKosaka,5 RobertCrowder,2 SvastiHaricharan,1 Shyam
Kavuri,1 Jeremy Hoog,2 Chanpheng Phommaly,2 Rodrigo Goncalves,6 Susana
Romalho,7Wei-ChuLai,2OliverHampton,1AnnaRogers,2 EthanTobias,2 Poo-
jan Parikh,2 Sherri Davies,2 Cynthia Ma,2 Vera Suman,8 Kelly Hunt,9 Mark
Watson,2 Katherine A. Hoadley,4 Aubrey Thompson,10 Charles Perou,4 Chad J.
Creighton,1 Chris Maher,3 Matthew J. Ellis1. 1Baylor College of Medicine, Hous-
ton, TX; 2Washington University School of Medicine in St. Louis, MO; 3Washing-
ton University in St. Louis, MO; 4University of North Carolina Chapel Hill, NC;
5KitasatoUniversity School ofMedicine, Japan; 6University of Sao Paulo School of
Medicine (FMUSP), Brazil; 7State University of Campinas, Brazil; 8Mayo Clinic,
Rochester,MN; 9MDAndersonCancer Center, Houston, TX; 10MayoClinic, Jack-
sonville, FL.
Dysregulation of estrogen receptor gene (ESR1) is an established mechanism
of inducing endocrine therapy resistance. We previously discovered a chromo-
somal translocation event generating an estrogen receptor gene fused in-frame
to C-terminal sequences of YAP1 (ESR1-YAP1) that contributed to endocrine
therapy resistance in estrogen receptor positive (ER) breast cancer models.
This current study compares functional and pharmacological properties of ad-
ditional ESR1 gene fusion events of both early stage (ESR1-NOP2) and advanced
endocrine therapy resistant (ESR1-YAP1 and ESR1-PCDH11x) breast cancers.
The YAP1 and PCDH11x fusions conferred estrogen-independent and fulves-
trant-resistant growth in T47D, an ER breast cancer cell line in vitro and in
vivo, in contrast to the NOP2 fusion which was sensitive to hormone depriva-
tion. Immunohistochemical (IHC) staining of mouse lungs revealed signifı-
cantly higher numbers of micrometastatic ER cells from the T47D tumors
expressing the YAP1 and PCDH11x fusions thanYFP control andNOP2 fusion.
Estrogen response element (ERE) reporter and pull down assays revealed that
although all ESR1 fusions studied bound EREs, only the YAP1 and PCDH11x
caused ERE activation. Cell lines containing these “canonical” ESR1 fusions
upregulated expression of ER responsive genes such as TFF1 and GREB1 in
hormone deprived conditions. In contrast, the NOP2 fusion neither induced
ERE activity nor upregulated TFF1 and GREB1 gene expression. The prolifera-
tive ability of canonical fusion-containing T47D cells was inhibited by palboci-
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clib, a CDK4/6 inhibitor, in a dose-dependent manner. In vivo growth of pa-
tient-derived xenograft tumors naturally harboring the ESR1-YAP1 fusion
(WHIM18) was signifıcantly reduced in mice fed palbociclib-containing chow.
Mice transplantedwithWHIM18 also formed lungmicrometastases, with anER
IHC staining pattern similar to lungs fromYAP1 and PCDH11x fusion express-
ing T47D xenografts. In conclusion, in-frame ERE activating canonical fusions
occur in end-stage, drug resistant, advanced breast cancer and can be added to
ESR1 point mutations as a class of somatic mutation that may cause acquired
resistance. Endocrine therapy resistant growth induced by these fusions can be
treated with CDK4/6 inhibition, using an FDA approved drug, palbociclib,
which could potentially improve outcomes in patients with ESR1 translocated
tumors.
TUMOR BIOLOGY: Animal Models of Human Oncogenesis
#1034 Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell
carcinomadevelopment and radiation resistance.Youngtae Jeong,1NgocHo-
ang,2 Henning Stehr,1 Alexander Lovejoy,1 Andrew Gentles,1 Aadel Chaud-
huri,1 Billy Loo,1AshAlizadeh,1MaximilianDiehn1. 1StanfordUniversity School
of Medicine, Stanford, CA; 2San Francisco State University, CA.
Although lung squamous cell carcinomas (LSCC) comprise a large fraction of
non-small cell lung cancers (NSCLCs), their pathogenesis and cell of origin
remain incompletely understood and biomarkers that predict therapeutic re-
sponses are lacking. Here we describe novel, clinically relevant murine LSCC
models driven by inactivation of Trp53with orwithoutKeap1, both ofwhich are
frequently mutated in human LSCCs. Homozygous inactivation of Keap1 or
Trp53 promoted airway basal stem cell (ABSC) self-renewal both in vitro and in
in vivo, suggesting that Trp53 or Keap1 mutations lead to expansion of mutant
stem cell clones. Deletion of Trp53 with or without Keap1 in ABSCs, but not
more differentiated tracheal cells, produced tumors recapitulating histologic
and molecular features of human LSCCs. However, deletion of Trp53 with or
without Keap1 in type II pneumocytes (ATIIs) or bronchioalveolar stem cells
(BASCs) produced tumors with the features of adenocarcinoma, indicating that
ABSCs represent the likely cell of origin for LSCC in this model. Deletion of
Keap1 promoted tumor growth, metastasis and resistance to oxidative stress.
N-acetylcysteine (NAC) treatment enhanced tumorsphere formation and me-
tastasis in Keap1WT LSCCs, but not in Keap1-/- LSCCs, suggesting that NRF2-
ROS pathway activation is the main mediator of Keap1 loss. Finally, Keap1
deletion induced radioresistance in vitro and in vivo in both LSCCs and lung
adenocarcinomas (LUADs). Congruous with these fındings, KEAP1/NRF2mu-
tation status strongly predicted risk of local recurrence in NSCLC patients
treated with RT and these mutations could be non-invasively identifıed in cir-
culating tumor DNA. These data suggest that Trp53 and Keap1 mutations in
ABSCs play important roles in LSCC initiation and progression and identify
KEAP1/NRF2 mutations as predictive biomarkers that could be used for per-
sonalization of therapeutic strategies for NSCLCs, and likely other cancers in
which they are recurrently mutated.
#1035 Direct evidence for a pro-tumor role of APOBEC3A in cancer ini-
tiation andprogression in vivo: enhancedmutagenesis and immune suppres-
sion in a novel humanized autochthonous model of pancreatic cancer. Sonja
Woermann,1 Robert Cowan,1 Susan M. Ross,2 Andrew D. Rhim1. 1MD Ander-
son Cancer Center, Houston, TX; 2University of Illinois, Chicago, IL.
Introduction: The apolipoprotein B editing complex 3 (APOBEC3) family of
enzymes are possible candidates for inducing mutations across a number of
tumors, including pancreatic ductal adenocarcinoma (PDA; Alexandrov et al,
2013; Roberts et al, 2013). APOBEC3A (hA3A) is one of eight identifıed iso-
forms in humans and known to deaminate cytidines in genomic ssDNA at a
specifıc sequence motif. Large scale sequencing studies demonstrate signifıcant
enrichment of this signature in a number of human cancers. Furthermore, hA3A
is overexpressed in a variety of solid tumors, including PDA. Taken together,
these data suggest that hA3A may catalyze point mutations in cancer and drive
cancer initiation and progression. However, direct evidence to support this hy-
pothesis in vivo are lacking. Here, we utilize a novel genetically engineered
mouse model to determine the precise effects of hA3A on PDA initiation and
progression.Methods:As opposed to humans,mice only contain oneAPOBEC3
isoformwhich has limited to no deaminating activity on genomicDNA.Thus, to
delineate the function of hA3A on PDA initiation and progression, we ex-
changed the murine APOBEC3 protein coding sequence for hA3A, leaving the
murine 5’ and 3’ endogenous regulatory sequences intact to ensure physiologic
expression (murine APOBEC3 and hA3A reflect similar expression kinetics
during PDA development). We then bred these mice to a well-established
GEMM of PC (Rhim et al., Cell 2012) to yield LSL-KrasG12D; p53fl/; Pdx1-
Cre; RosaLSL-YFP; hA3A/- (KPCY;hA3A) mice. We compared these mice to
KPCY mice. We genotyped tumors from both cohorts with Ilumina exome
capture sequencing with variant calling by a custom caller based on VarScan.
Results: All KPCY; hA3A (n11) mice developed tumors and expired signifı-
cantly faster compared to KPCY (n18) controls (3.9 v. 7.0 mo; p0.01). One
third of the KPCY; hA3Amice developedmacrometastatic disease compared to
3/12 in the KPCY control. Interestingly, KPCY; hA3A tumors contained dra-
matic desmoplasia, far surpassing the KPCY controls. Moreover, comparative
RNAseq and histologic analyses revealed dramatic differences in the number
and distribution of various T-cell and B-cell subsets. Finally, we found that
KPCY; hA3Amice contained signifıcantlymore single nucleotide variants com-
pared to KPCY controls (51.3 v. 8.4; p0.05). Conclusions: These data show for
the fırst time that physiologic expression of hA3A in vivo leads to increased
mutations, altered immune response andmore aggressive cancer. Future studies
will address the precise mechanisms by which hA3A catalyzes tumorigenesis
using our novel gain of function model. Furthermore, our data suggest that
incorporating our humanized A3A germline allele may provide amore genomi-
cally recapitulative model of cancer.
#1036 Non-myogenic origin of embryonal rhabdomyosarcoma.Catherine
J. Drummond, Matthew R. Garcia, Daniel J. Devine, Jennifer Peters, Victoria
Frohlich, David Finkelstein, Mark E. Hatley. St Jude Childrens Research Hospi-
tal, Memphis, TN.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in chil-
dren. Despite aggressive chemotherapy, radiotherapy and surgery, clinical out-
comes for RMS have not improved for three decades, emphasizing the need to
uncover the molecular underpinnings of the disease. RMS includes two histo-
pathologic subtypes: alveolar RMS, driven by the fusion protein PAX3/7-
FOXO1, and embryonal RMS (ERMS), which is genetically heterogeneous. RMS
has been presumed to originate from derailed muscle progenitors based on the
histologic appearance and gene expression pattern of the tumors. However, an
origin restricted to skeletal muscle does not explain RMS occurring in tissues
devoid of skeletalmuscle such as the prostate, bladder, biliary tree and the omen-
tum. Previously, we showed that activation of Sonic Hedgehog signaling
through expression of a conditional, constitutively active Smoothened allele,
SmoM2, under control of an adipocyte-restricted adipose protein 2 (aP2)-Cre
recombinase transgene in mice gives rise to aggressive skeletal muscle tumors
that display the histologic andmolecular characteristics of humanERMS. In this
model, tumorigenesis occurs with high penetrance (80%), is early onset (by 2
months of age), and is restricted to the head andneck.Also, unlike previousRMS
models, this model requires no additional background mutations, such as inac-
tivation of p53, and results in only ERMS neoplasia.We illustrated that the gene
expression signature of the aP2-Cre;SmoM2 tumors recapitulates both other
mouse ERMS models as well as human ERMS. With the short latency and ana-
tomic restricted tumor location, we sought to leverage this model to explore the
cell of origin. Here, we use genetic fatemapping of aP2-cre with reportermice to
determine the effect of constitutive hedgehog activation on the identity and
localization of aP2-Cre expressing cells. aP2-cre expressing cells are found in
both brown and white adipose and to be localized within the muscle intersitium
but not beneath the laminin sheath of the muscle fıbers. These aP2-cre express-
ing cells are distinct from Pax7-positive skeletal muscle stem cells or satellite
cells and do not contribute to myofıber formation. Instead these cells were con-
fırmed to be endothelial by gene expression analysis. Colocalization between
aP2-cre expressing cells and CD31 was also observed. When compared to aP2-
Cre;R26-Tom mice, the addition of oncogenic SmoM2 (aP2-Cre;R26-Tom;
SmoM2) resulted in embryonic expansion of these aP2-lineage interstitial mus-
cle cells and formation of ERMS. Our fındings suggest that non-skeletal muscle
progenitors are a cell of origin for Sonic Hedgehog-driven ERMS.
#1037 Progression frommelanocytic nevi to melanoma is associated with
increased genomic mutations in a UV-induced mouse model of humanmel-
anoma.HelenMichael, Chi-Ping Day, Howard Yang, AleksandraMichalowski,
Maxwell Lee, Glenn Merlino. National Institutes of Health, Bethesda, MD.
Melanoma is the deadliest form of skin cancer with approximately 132,000
cases worldwide each year. Benign melanocytic nevi are nearly universal, and
although progression of nevi to melanoma is very rare, 20-50% of melanoma
appear to arise from a pre-existing nevus. UV exposure, particularly childhood
sunburn, is believed to play an important role in the development ofmelanocytic
nevi andmelanoma, but the exactmechanism is unknown.Alterations inMAPK
pathway genes, especially NRAS and BRAF, are common in both benign nevi
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and melanoma, but approximately 1/3 of melanomas do not have an identifıed
driver mutation. Studying nevus initiation and progression prospectively in the
human population is impractical due to the long latency to progression and
repeated UV exposures Our laboratory has developed a hepatocyte growth fac-
tor (HGF) genetically engineered mouse model with “humanized” junctional
distribution of melanocytes on an iDCT-GFP background with melanocyte-
specifıc GFP expression, allowing melanocytic lesions to be tracked through
percutaneous GFP imaging. Following a single relevant dose of UV modeling
childhood sunburn, HGF iDCT-GFP develop discrete, small melanocytic le-
sions consistent with nevi. Most nevi remain stable over the lifetime of the
mouse, but around 1 in 30 progress to melanoma usually starting at 6-12
months. The melanocytic lesions are histologically similar to human nevi and
melanoma, label with melanocyte markers and tumors are transplantable into
syngeneic mice. Melanomas that arise in the model are heterogeneous and in-
clude radial growth phase and vertical growth phase tumors and sometimes
metastasize to liver and lung. Exome sequencing of 28 nevi and melanomas
show that vertical growth phase melanomas have approximately 3xmore muta-
tions than radial growth phase melanomas or nevi. The increased number of
mutations in vertical growth phase tumors is due to an increase in CT transi-
tions despite the lack of additional UV exposure. Interestingly, melanocytic nevi
and melanomas with DNA repair pathway mutations average 3x more muta-
tions than lesions without mutations in these pathways. Melanomas sometime
contain mutations in hotspot locations from human melanomas, including
GNAQ, but most do not have a previously identifıed dominant driver. Genes
potentially involved in the initiation of melanocytic lesions or progression to
aggressive melanomas and relevant to human melanoma have been identifıed
and are being functionally tested using CRISPR to introduce point mutations or
knock out genes and in vitro skin reconstitution assays. Identifıcation of novel
drivers and pathways involved in non-BRAF, non-NRAS melanoma has the
potential to uncover biomarkers and new therapeutic targets to improve clinical
outcomes for melanoma patients.
#1038 The KIT-V654A second site mutation confers perinatal lethality
and increased oncogenesis in a mouse model of GIST. Jennifer Q. Zhang,
Benedikt Bosbach, Cristina Antonescu, Peter Besmer, Ronald DeMatteo.
MSKCC, New York, NY.
Tyrosine kinase inhibitors have revolutionized the treatment of gastrointes-
tinal stromal tumor (GIST), which are mostly driven by mutations in the recep-
tor tyrosine kinase KIT. However, resistance commonly develops, which is as-
sociated with second site mutations in KIT. Here, we created the fırst genetically
engineered mouse model of the most common second site mutation, KIT-
V654A (mouse KIT-V653A), to study in vivo its oncogenic properties and
mechanisms of resistance in order to develop next-generation GIST therapies.
The knock-in strategy consisted of inserting into the endogenous murine Kit
locus a targeting vector containing both the KitV558	 exon 11 mutation and the
KitV653A exon 13 mutation under the control of a floxed neomycin-resistance
gene-expression cassette which acts similar to a loxP-STOP-loxP cassette. Treat-
ments included imatinib 45 mg/kg i.p., sunitinib 40 mg/kg p.o., and cabozan-
tinib 60mg/kg p.o. Tumors were assessed by histology, immunohistochemistry,
and western blot. In contrast to our previously published GIST model with a
single mutant KitV558	 allele, the double knock-in KitV558	; V653A-neo allele
caused perinatal lethality when activated in pre-implantation embryos with
a germline EIIa-Cre approach. We therefore sought to restrict the induction
of the KitV558	;V653A double mutation to the interstitial cells of Cajal (ICC),
the cell of origin of GIST, via the essential ICC lineage survival factor ETV1.
The KitV558	; V653A-neo/ mouse was crossed with the Etv1Cre-ERT2/ mouse
expressing Cre recombinase under the Etv1-specifıc promoter. Systemic ad-
ministration of tamoxifen at birth in KitV558	; V653A-neo/; Etv1Cre-ERT2/
mice resulted in cecal GIST development with full penetrance. The tumors
were histologically similar to human GIST, stained positive for KIT, and
displayed active p-KIT signaling. As expected, high-dose imatinib treatment
did not inhibit p-KIT Y719 in these GISTs and did not induce a histologic
response. Sunitinib and cabozantinib each had signifıcant anti-tumor ef-
fects, as assessed by decreased Ki67 index and increased histologic response.
Compared to single mutant KitV558	-neo/; Etv1Cre-ERT2/mice, double mu-
tant KitV558	; V653A-neo/; Etv1Cre-ERT2/ mice developed larger cecal GISTs
and had decreased survival. The KitV558	; V653A-neo/; Etv1Cre-ERT2/ mouse
is the fırst in vivo model of the most common secondary mutation in GIST
and the fırst in vivo demonstration that cell-autonomous expression of mu-
tant KIT in the ICC lineage gives rise to GIST. We have found cabozantinib,
an FDA-approved drug, to be an effective therapy in GISTs harboring the
V653A mutation. Furthermore, our results suggest the addition of the KIT-
V653A second site mutation leads to increased oncogenesis.
#1039 Disruption of circadian clockwork in in vivo reprogramming in-
duced mouse kidney cancer and human Wilms tumor. Munehiro Ohashi,1
Yasuhiro Umemura,1 Yoichi Minami,1 Hitomi Watanabe,2 Tomoko Tanaka,3
Tsuneharu Miki,4 Osamu Ukimura,4 Tatsuro Tajiri,3 Gen Kondoh,2 Yasuhiro
Yamada,5 Kazuhiro Yagita1. 1Department of Physiology and Systems Bioscience,
Kyoto Prefectural University of Medicine, Kyoto, Japan; 2Laboratory of Animal
Experiments for Regeneration, Institute for Frontier Medical Science, Kyoto Uni-
versity, Kyoto, Japan; 3Department of Pediatric Surgery, Kyoto Prefectural Uni-
versity of Medicine, Kyoto, Japan; 4Department of Urology, Kyoto Prefectural
University of Medicine, Kyoto, Japan; 5Center for iPS Research and Application,
Kyoto University, Kyoto, Japan.
Most organisms have evolved intrinsic circadian clock to optimize their be-
havior and physiology for diurnal environmental changes. The circadian clock
exists not only in the organismal level but also in the peripheral organs and
cellular levels, and regulates the various physiological aspects. Among these
regulation systems, the relationship between circadian clock and cancer has
been enthusiastically investigated in this decade. However, the mechanistic link
connecting circadian clock and cancer has not been fully understood. Recently,
we have clarifıed that circadian clock is tightly connected with cellular differen-
tiation using the in vitro mouse embryonic stem cells (ESCs) differentiation
model, and in addition, misregulation of differentiation leads to the circadian
clock disruption via highly expression of KPNA2 and suppression of CLOCK
protein. On the other hand, it was revealed that altered dedifferentiation leads to
cancer development using in vivo reprogramming mouse model. So we consid-
ered that the viewpoint of dysdifferentiation can help to provide signifıcant
pathophysiological implications for the relationship of circadian clock and can-
cer. Firstly, we established Rosa26:M2-rtTA TetO:OSKM ES cells carrying cir-
cadian rhythm reporter mPer2:luc, and generated chimeric mice. The chimeric
mice were treated with doxycycline (Dox) for transient in vivo reprogramming.
The Dox treatment inducedWilms tumor-like kidney tumors and we sectioned
the kidney tumor for monitoring real time bioluminescence signals, and exam-
ined the RNA and protein expression profıles. Here, we showed that the circa-
dian clock was disrupted in the Wilms tumor-like mouse kidney tumor tissues,
while the control mouse kidney exhibited the obvious circadian biolumines-
cence oscillation. And the gene expression signature of the circadian clock
development correlated gene set in the tumor was similar to the dysdiffer-
entiation-mediated circadian clock disrupted cells. Moreover, the highly ex-
pressed KPNA2 and suppression of CLOCK protein were also observed in
the mouse tumor cells. Next, we examined human Wilms tumor gene and
protein expression profıles. Astonishingly, the transcriptional signature of
the circadian clock development correlated genes was similar to the mouse
kidney tumor induced by dedifferentiation. Furthermore, the protein ex-
pression patterns of KPNA2 and CLOCK coincided with them. These fınd-
ings suggest that the severely dedifferentiated cancers may lose their circa-
dian clocks and the mechanism is common with the suppression mechanism
during differentiation coupled circadian clock development. Moreover, cir-
cadian clock functionality may reflect the etiology of cancer development
including dedifferentiation. In future prospects, a new view point of the
circadian clock may help to evaluate the type of cancer cells, and it leads to
more improved therapeutic strategy.
#1040 LIN28B-mediated let-7 independent activation of AKT promotes
neuroblastoma pathogenesis. Ting Tao,1 John T. Powers,2 Hui Shi,1 Pavlos
Missios,2 Antonio R. Perez-Atayde,2 Shizhen Zhu,3 George Q. Daley,2 Thomas
A. Look1. 1Dana-Farber Cancer Institute, Boston, MA; 2Boston Children’s Hos-
pital, Boston, MA; 3Mayo Clinic, Rochester, MN.
LIN28 is well known as a RNA-binding protein and a suppressor of mi-
croRNA biogenesis, by selectively blocking the processing of let-7 precursors. It
plays diverse functions in cellular reprogramming, development, metabolism
and tumorigenesis. Many of these functions are executed through its ability to
inhibit let-7 maturation. However, little is known about its function indepen-
dent of let-7. Here we made zebrafısh transgenic lines expressing high levels of
either wild-type or mutant LIN28B (does not block the maturation of let-7) in
the peripheral sympathetic nervous system driven by the dopamine beta-hy-
droxylase promoter. We bred these lines with a transgenic zebrafısh line over-
expressing the MYCN oncogene in these cells. Either wild-type or mutant
LIN28B overexpression accelerated the onset and increased the penetrance of
MYCN-induced neuroblastoma, despite the fact that only wild-type LIN28B
blocked let-7 maturation compared to MYCN-only tumors. Mechanistically,
both wild-type and mutant LIN28B overexpression enhanced MYCN-induced
hyperplasia by increasing cell proliferation in the sympathoadrenal lineage. Fur-
ther studies revealed that overexpression of either wild-type or mutant LIN28B
resulted in hyperphosphorylation of AKT on both Ser473 and Thr308 in ze-
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brafısh tumors and also serum-deprived human neuroblastoma cell lines. Both
wild-type and mutant LIN28B interacted with IGF2BP1, a known interactor
that increases stability and translation of a subset of RNAs. We found IGF2
RNA levels to be increased in response to either form of LIN28B. Coincident
with IGF2 overexpression, IGF1R was phosphorylated, providing an expla-
nation for PI3K-AKT activation in LIN28B overexpressing cells. Finally,
overexpression of a constitutively active, myristoylated murine Akt2 (myr-
mAkt2) alone in zebrafısh induced ganglioneuroma in the interregnal gland
(the zebrafısh equivalent of the human adrenal medulla), without a require-
ment for MCYN overexpression. Thus, our studies indicate that overexpres-
sion of LIN28B leads to AKT activation mediated through its interaction
with IGF2BP1 and subsequent upregulation of IGF2. This pathway provides
a mechanism underlying enhanced transformation in LIN28B overexpress-
ing neuroblastomas, which is independent of the inhibitory activity of
LIN28B on let-7 maturation.
TUMOR BIOLOGY: Niches and Routes of Metastasis
#1041 Binding of soluble DC-HIL to endothelial cell creates immunosup-
pression on premetastatic niches.Vijay Ramani,1 Takahiro Teshima,2 Kyoichi
Tamura,2 Jin-Sung Chung,1 Ponciano Cruz,1 Kiyoshi Ariizumi1. 1UT South-
westernMedical Center, Dallas, TX; 2NipponVeterinary and Life Science Univer-
sity, Tokyo, Japan.
Highly metastatic attribute of melanoma can be recapitulated in a mouse
model by high potential of B16 melanoma-derived soluble factors that form
more premetastatic niches (PMNs) in distal organs than those of LL2 lung car-
cinoma. Having shown that the T cell-inhibitory receptor DC-HIL is a potent
promoter of B16 melanoma growth and that B16 cells secrete it into blood
circulation as a soluble receptor (sDC-HIL), we hypothesized that sDC-HIL
accounts for the metastatic nature. We tracked sDC-HIL in various organs of
melanoma-bearing mice by immunoblotting and showed that sDC-HIL was
expressed in particular organs; at highest levels in bone marrow (BM) and lung;
and no-to-little in lymphoid organs and liver.We next examined effects of sDC-
HIL on LL2 cells (noDC-HIL expression). In amodel of spontaneousmetastasis
quantifıed by colonogenic assay, syngeneicmice implanted subcutaneously with
LL2- transfected-sDC-HIL cells produced 6-foldmore lungmets thanmicewith
LL2-transfected-GFP. We obtained similar results in a model of experimental
metastasis (EM), in which LL2 cells injected i.v. in tumor-bearing mice. To
establish specifıcity, similar mice were treated i.v. with anti-DC-HIL mAb 2 h
before and 24 h after infusion of LL2 cells: ThemAb led to 80% reduction in lung
mets in mice with sDC-HIL-LL2 tumor. Next we infected tumor-free mice with
lentiviruses for sDC-HIL/GFP or GFP gene and then performed the EM assay:
lung mets in mice expressing sDC-HIL were 5-fold greater than control. To
determine whether sDC-HIL is responsible for the ability of B16-conditioned
media (CM) to induce metastasis, tumor-free mice were injected i.p. daily with
CM from LL2, B16, or DC-HIL-knocked down (KD) B16 cells and then assayed
for EM. B16-CM induced signifıcantlymore lungmets than LL2-CM, withmets
almost corresponding to that produced by KD-B16-CM.We tracked the fate of
sDC-HIL in lung by immunofluorescence and showed sDC-HIL accumulated
on particular (not all) endothelial cells (EC), at sites where LL2 and BM-cells
migrated. Kinetic studies in BM-chimera mice showed that sDC-HIL arrives at
lung sites before VEGFR1BM-progenitors, which initiate formation of PMNs.
Since the mets-enhancing effect of sDC-HIL was not seen in immunodefıcient
mice, we asked whether lungs expressing sDC-HIL were immunosuppressive.
CFSE-labeled CD8 T cells were infused into mice with sDC-HIL- or GFP-LL2
tumors, and their proliferation assayed by FACS: T-cell proliferation in lungs
expressing sDC-HIL was reduced signifıcantly (28%) vs. control (81%). Because
sDC-HIL by itself is not suppressive, we asked whether binding of sDC-HIL by
EC makes immunosuppressive. CD8 T cells were co-cultured with sDC-HIL-
bound EC and then co-stimulated: sDC-HIL-bound EC completely suppressed
the IFN- response. Thus, sDC-HIL critically contributes to the highly meta-
static potential by making PMNs immunosuppressive even before the arrival of
tumor cells.
#1042 CLIC4 is incorporated into extracellular vesicles of murine breast
cancer cells and may influence metastatic burden. Alayna B. Craig-Lucas,
Vanesa C. Sanchez, Abigail Read, Ji Lou, Anjali Shukla, Stuart H. Yuspa. NCI,
Bethesda, MD.
Chloride intracellular channel 4 (CLIC4) is an evolutionarily conserved,
29kD, dimorphic protein that contributes to TGF- signaling by preventing the
de-phosphorylation of phospho-SMAD2/3 upon nuclear translocation. In sev-
eral cancer types, CLIC4 is excluded from the nucleus and downregulated in the
cytoplasm of the tumor cells as the tumor progresses, suggesting that CLIC4 acts
as tumor suppressor. In a parallel sequence, CLIC4 becomes upregulated in the
stromal compartment, where it enhances tumor growth and invasion. Recent
reports have suggested that CLIC4 is detectable in the serum of cancer patients
and incorporated into extracellular vesicles, and has potential as a biomarker.
Wehope to gain a better understanding of the role that CLIC4 plays in the tumor
stromal and epithelial compartments as well as their respective release of extra-
cellular vesicles. Using in-vitro and in-vivo assays, we have conducted experi-
ments using the FVB mouse MMTV-c-MYC 6DT1 breast cancer model. By
CRISPR/ Cas9 system, CLIC4 was deleted from wild type 6DT1 cells. Following
clonal selection, the loss of the CLIC4 protein at both the cellular and released
vesicle level was validated. Both functional assays on CLIC4 deleted clones and
evaluation of their extra-cellular vesicles were undertaken in order to further
understand their tumorigenic and metastatic capabilities. In-vitro, CLIC4 was
not necessary for vesicle biogenesis and its deletion did not have a signifıcant
effect on cellular proliferation. In vivo, selected clones were orthotopically in-
jected into the 4th mammary fat pad of wild type FVB mice. Compared to wild
type 6DT1 clones, CLIC4 deleted clones formed primary tumors that had
greater mass but a fewer number of lungmetastasis. Future studies are designed
to isolate vesicles circulating in tumor bearing hosts to determine their stromal
or epithelial origin and to provide a better understanding of the role that CLIC4
may play in tumor growth, creating a metastatic niche and as a potential sero-
logical biomarker.
#1043 CSF-1R inhibitor prevented pre-metastatic lung niches in meta-
static mammary tumor. Thaiz F. Borin, Kartik Angara, Mohammad Rashid,
Adarsh Shankar, Asm Iskander, Roxan Ara,Meenu Jain, Bhagelu R. Achyut, Ali
S. Arbab. Augusta University, Augusta, GA.
Exosomes are small vesicle cellular products originating from the endocytic
pathway abundantly secreted by tumor cells. These exosomes have the ability to
alter their immediate microenvironment (ME) through cell-cell interaction by
fusion with plasma membrane and subsequent endocytosis or release of their
cargo. Exosomes are critical modulators of pre-metastatic niche creation by
increasing the recruitment of inflammatory cells. In breast cancer, tumor-de-
rived exosomes recruit myeloid derived suppressor cells in the creation of an
immunosuppressive pro-tumorigenic lung niches. Colony stimulating factor
1-receptor (CSF1R), which is a key regulator of myeloid cell proliferation, sur-
vival, and differentiation can be blocked by a selective inhibitor GW2580. Over-
expression of CSF-1 has been implicated in the creation of increased number of
metastatic niches in numerous cancers. In our study, we have demonstrated that
the exosomes secreted under hypoxic conditions can initiate early pre-meta-
static niche creation in lungs in a metastatic breast cancer model compared to
normoxia-secreted exosomes. Exosomeswere injected intravenously intoBalb/c
femalemice three days after the implantation of 4T1breast tumor and continued
for a week with injections on alternated days. The animals were pre-treated with
GW2580 the day before tumor implantation and continued for a week concom-
itantly with exosomes on alternate days. Lungs, bone marrow, spleen and brain
tissues were collected and analyzed by flow cytometer to detect myeloid and
angiogenic cells populations. GW2580 was able to prevent myeloid cell infıltra-
tion in lungs and bone marrow. Further, we observed signifıcant increase in
anti-tumorigenic M1-macrophage population in the lungs of exosome treated
animals pre-treated with GW2580. However, these fındings were not observed
in the bonemarrows of the same group. Vasculogenic leukocyte and angiogenic
myeloid cell populations were signifıcantly decreased in the lung of exosome
treated animals pre-treated with GW2580. A similar decrease in these popula-
tions of cells was not seen in the lungs of animals pre-treatedwithGW2580 only.
These surprising results have led us to hypothesize that GW2580 treatment can
prevent the effects of exosomes, which causes infıltration of myeloid cells in the
lung to create metastatic niche. These observations indicate a role of CSF1R
inhibitor in preventing the distant metastatic niche formation.
#1044 Development of amiRNA-based signature to predict human cancer
metastasis. Lian Willetts, Konstantin Stoletov, Juan Jovel, Emma Woolner,
John D. Lewis. University of Alberta, Edmonton, Alberta, Canada.
Metastasis is the primary cause of death for cancer patients, and invasive cancer
cell migration is required atmultiple steps duringmetastasis (e.g. intravasation and
extravasation). SincemicroRNAs (miRNAs) have been implicated as key regulators
of metastatic spread of cancer cells, we sought to develop a miRNA signature that
canbeused to predict cancermetastasis.Wehypothesized that themiRNAs that are
functionally required for invasivecellmigrationcould serveasbiomarkers topredict
human cancer metastasis. We developed an intravital imaging-based approach
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combinedwithNGS to screen formiRNAs that are required for invasive cellmigra-
tion of human HT1080 fıbrosarcoma cells. The screen-identifıed miRNAs were
validated in a panel of in vitro and in vivo assays for invasivemigration.Microarray
analysis identifıed genes downregulated in transfected HT1080 cells. Publically
available databases were used to correlate the expression of screen-identifıed miR-
NAsand theprogressionofmultiplehumancancers.WeusedaqRT-PCRapproach
combined with machine learning to develop a miRNA signature to predict metas-
tasis in a 66-patient cohort of prostate cancer. We identifıed over twenty novel
miRNAs that regulate directional cancer invasion. Microarray analysis in HT1080
cells revealed that the altered expression ofmetastasis-regulatingmiRNAs is associ-
ated with 50% reduction in gene expression of migration and adhesion gene net-
work components such as integrin a4, CDC42, and transgelin). We evaluated the
potential of screen-identifıedmiRNAs to serve as biomarkers to predict cancerme-
tastasis.Using publically available databases,we found thatmajority of screen-iden-
tifıed miRNAs are dysregulated in multiple human cancer types (e.g. prostate,
breast, ovarianand lung) and theexpressionof thesemiRNAscorrelatedirectlywith
patient disease progression.We analyzed the expression of the top two screen-iden-
tifıed miRNAs in plasma samples from the PCa patient cohort. A signature was
generatedusing aweightedK-nearest neighbor algorithm that provided aROCarea
under the curve of 0.79 for predicting metastatic disease. We identifıed a panel of
novel metastasis-regulatingmiRNAs that is functionally involved in human cancer
metastasis. ThesemiRNAs have the potential to serve as both biomarkers to predict
metastasis and potentially as therapeutic targets to blockmetastasis.
#1045 Understanding breast cancermetastasis through circulating tumor
cells. Remi Klotz, Thomas Amal, Alan Wang, Matthew Mackay, Kathleen
Heller, Lin Li,Maxwell Serowoky, Grace Lee, JaneHan, Andrew Smith,Min Yu.
USC, LOS ANGELES, CA.
Due to the advance in technologies for rare cell isolation, circulating tumor
cells (CTC) have recently received vast interest. During tumor progression tu-
mor cells invade the primary tumor microenvironment and intravasate into
blood vessels, where they are referred as CTCs. TheseCTCs disseminate to other
organs and a subset of these cells will be able to form metastasis. The growing
interest for CTC is confronted with the diffıculty associated with their isolation
and characterization. To address this challenge, our lab has recently optimized
the ex vivo culture condition and was able to establish CTC lines from breast
cancer patients. These CTC lines constitute a unique cell population in the
metastatic process and gave us a rare opportunity to investigate the signal path-
ways involved in each step of the metastatic cascade. To assess the metastatic
potential of breast cancer patient-derived CTC lines we utilized an experimental
mouse model for metastasis by injecting CTCs directly into the left ventricle of
the heart in female immuodefıcient NSG mice. The ability of 4 CTC lines to
arrest and colonize in organ was monitored by bioluminescence imaging once
every 2 weeks for 5 months. CTC lines were capable of generating brain, lung,
bone and ovarymetastases.Most of those organs are common sites ofmetastases
in breast cancer patients. Two patient-derived CTC lines have a high metastatic
potential (over 80% of mice had metastases after 3 months) with generation of
simultaneousmetastases inmultiple organs such as bone, lung andOvary. These
mice remained brain-metastases free for up to 8 months. However, two other
patient-derived CTC lines demonstrated the brain as preferential site of metas-
tasis despite their overall lowmetastatic potential. Interestingly, of 4 breast can-
cer patients where CTC lines were generated, one developed a metastatic brain
tumor and her CTC line has the highest risk of brain metastases in our mouse
model. We further investigated genetic and epigenetic determinants that regu-
late the organotropism of CTCs. We isolated metastatic variants corresponding
to a subpopulation of CTCs with a preferential tropism for the brain, lung and
bone. Gene expression analysis (RNA-seq) of these variants identifıed potential
gene signatures of breast cancer metastasis. The pathways with the highest en-
richment scores were glioblastoma multiform, ceramide biosynthesis and PCP
pathway for the brain metastatic variants and were interferon and mTOR sig-
naling for the lung metastatic variants. Next we used a method for assaying
chromatin accessibility (ATAC-seq) and identifıed potential regulatory regions
mediating the organ tropism in breast cancer. Together our data provide the
evidence of a promising role of CTC as an early prognostic factor in metastasis.
Additionally, we expect to develop novel organ tropism associated markers,
which can be considered for potential therapeutic targets in breast cancers.
#1046 Conditional knock out of N-Myc and STAT Interactor disrupts
normal mammary development and enhances metastatic ability of mam-
mary tumors. Hawley Christine Pruitt, Brandon J. Metge, Shannon E. Weeks,
Dongquan Chen, ShiWei, Lalita A. Shevde, Rajeev S. Samant.Univ. of Alabama
at Birmingham, Birmingham, AL.
The process of development requires a delicate balance between plasticity and
differentiation. This balance is disrupted in cancer initiation and progression, ulti-
mately ending in metastasis and plummeting rates of patient survival. Recent fınd-
ings fromour lab have revealed that protein expression of evolutionarily conserved,
N-Myc and STAT Interactor (NMI) is decreased in 70% of primary patient speci-
mens with metastatic breast cancer. To study how Nmi loss facilitates metastatic
behavior and gain insight into its role in normal mammary biology, we created a
novel mammary specifıc Nmi knock out mouse model, which we then challenged
withcarcinogenandoncogene induced tumorigenesis.Ourstudies showthatNmi is
induced at the onset of pregnancy and its expression remains throughout lactation.
Furthermore, prolactin stimulation and differentiation ofHC11murinemammary
epithelial cells is accompanied by up-regulation of Nmi. STAT5 is the downstream
effector of prolactin and is essential for differentiation of secretory alveolar epithe-
lium.NMI interactswithSTAT5and this interactionappears tobecritical tonormal
differentiation of mammary epithelium. Indeed, loss of Nmi in vivo caused a de-
crease in STAT5activity and a subsequent transcriptomic shift inmammary epithe-
lial andbreast cancer cells.Moreover, knockdownofNmi inHC11cells impedes the
expression of beta-casein upon differentiation with prolactin. Concurrently, Nmi
knock out alveoli exhibit an extensive presence of nuclear beta-catenin, a mediator
of stem cell maintenance in the mammary gland. As a result, mice exhibit an in-
creasednumberof alveoli andmoreproliferatingmammary epithelial cells (MECs).
The Nmi knock out pubertal ductal tree extends into the mammary fat pad at an
accelerated rate and exhibits enhanced terminal endbudnumbers, a phenotype that
mirrors mice altered forWnt signaling. Tumors derived fromNmi null mammary
epithelium contain signifıcantlymore cells with stem and progenitormarkers, indi-
cating that these tumors are less differentiated than their littermate counterparts. In
addition, Nmi null mammary tumors exhibit invasive morphology as well as en-
hanced distant metastasis. We observe that conditional Nmi loss disrupts differen-
tiation in themammary gland andpromotes the progressionof tumorswith aggres-
sive metastatic characteristics.
#1047 Role of endocytosis inNM23mediatedmotility suppression. Imran
Khan, Patricia S. Steeg. National Institute of Health (NIH), Bethesda, MD.
NM23 has been identifıed as a metastasis suppressor gene and is known to
inhibit motility of cancer cells and suppressmetastasis inmultiple in vivomodel
system. Biochemically,NM23 is a nucleoside diphosphate kinase (NDPK).As an
NDPK, NM23 is fırst autophosphorylated on its histidine 118 before transfer-
ring its phosphate to anNDP.NM23 is also known to trans-phosphorylate other
proteins to act as a protein histidine kinase (PHK) using same histidine H118
phosphorylation intermediate. In spite of many studies on NM23 in different
cancers, the molecular mechanism of NM23 action has not been well worked
out. Studies on Drosophila homologue of the NM23, awd, highlights its role in
regulating cell differentiation and motility by influencing endocytosis. We now
hypothesize that NM23 mediated motility/metastasis suppression could be due
to increased endocytosis of cell surface receptors, needed for cellular motility.
We over expressed NM23 (human H1 and H2 and murine h1) in MDA-MB-
231Tbreast cancer cells and observed that themotility suppression phenotype (4
fold, p0.0001) of NM23 correlates with increase in NM23 histidine auto phos-
phorylation, as observed by using a new anti-histidine 1-phosphate (1-pHis)
antibody. NM23 over expressing cells were studied for the level of endocytosis
using Transferrin-Alexa-594 and pHrodo-Red-EGF labelled dyes. It was ob-
served that NM23 over expression causes increased endocytosis of both the
above labelled ligands. Based on the literature, Dynamin is known to be involved
in endocytosis and is also an interacting partner of NM23. We validated NM23
and Dynamin interactions by pulldown studies (using both anti-NM23 and
anti-Dynamin antibodies) in NM23 over expressing cells. We also observed
reduced endocytosis with Dynamin inhibitors. Further, when a series of Dy-
namin inhibitors (MiTMAB, OcTMAB, Dynole-34-2 and Iminodyn-22) were
used inmotility assays, theywere found to be inhibitory tomotility.However, no
further decrease in motility was observed upon NM23 overexpression, high-
lighting the reversal of NM23 mediated motility suppression in absence of Dy-
namin. To further address the role of endocytosis in NM23 mediated motility
suppression, two crucial mutants of NM23 namely; P96S (has NDPK activity
with very low HPK activity) and H118F (has no NDPK and HPK activity) were
made and stable cells were generated.We observed that themotility suppression
phenotype of NM23 was reverted to normal in both the mutants, highlighting a
possible role of HPK activity in motility suppression. Similarly, endocytosis
studies on these cells shows loss of increased endocytosis in both themutants. To
date, the data indicate that NM23 phosphohistidine levels, motility suppression
and increased endocytosis are well correlated and is being influenced by Dy-
namin signaling. Different approaches to further understand the physiological
meaning of NM23-dynamin interactions are underway.
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EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Combination Strategies: Novel Agents and Standard Therapies
#1048 Reactive oxygen species-mediated synergistic and preferential in-
duction of cell death and reduction of drug resistance in oncogenic H-Ras-
expressing bladder cancer cells by combined romidepsin and cisplatin with
gemcitabine. Lenora A. Pluchino, Hwa-Chain R. Wang. Univ. of Tennessee,
College of Veterinary Medicine, Knoxville, TN.
Human urinary bladder cancer is the fıfth most commonly diagnosed
cancer in the United States and is often associated with induction of onco-
genic H-Ras. Long-term survival of patients is suboptimal with the current
chemotherapeutic regimen of combined cisplatin and gemcitabine and oth-
ers due to acquired drug resistance and recurrence. Thus, it is urgent to
develop new regimens effective in control of tumor growth, drug resistance,
and recurrence to reduce the morbidity and mortality of this disease. We
used our cellular system, consisting of human urinary bladder cancer J82
cells paired with its derived oncogenic H-Ras-expressing J82-Ras cells, to
investigate the effıcacy of a novel combination regimen in treating bladder
cancer cells. Our studies revealed, for the fırst time, the ability of a combi-
nation of cisplatin and romidepsin with gemcitabine to synergistically and
preferentially induced cell death and reduced drug resistance in J82-Ras
versus J82 cells. The Ras-ERK-Nox pathway played an essential role in me-
diating signals to elevate reactive oxygen species (ROS), leading to enhanced
caspase activation, DNA damage, and DNA oxidation, as well as reduced
glutathione, to synergistically increased cell death and reduced drug resis-
tance in cells treated with combined romidepsin, cisplatin, and gemcitabine.
Preferentially induced Ras-ERK-Nox-ROS pathway, caspase activation, and
DNA damage/oxidation, as well as reduced glutathione, contributed to the
preferentially induced cell death and reduced drug resistance in J82-Ras
versus J82 cells. Synergistically induced death and reduced drug resistance
were also detected in human bladder cancer SW780 cells treated with com-
bined romidepsin, cisplatin, and gemcitabine. Hence, our results lead us to
suggest that a combination of romidepsin, cisplatin, and gemcitabine should
be seriously considered as a new therapeutic regimen for controlling the
development and recurrence of human urinary bladder cancer, especially
Ras-ERK-activated cancers.
#1049 Combinatorial effects of thymoquinone on the anticancer activity
of doxorubicin in adult T-cell leukemia. Hala Gali-Muhtasib,1 Isabelle Fak-
houry,1Maamoun Fatfat,1 RashaMismar,1 Regine Schneider-Stock2. 1American
University of Beirut, Beirut, Lebanon; 2University Erlangen, Nuremberg, Ger-
many.
Doxorubicin (Dox) is a clinically approved drug which suffers from drug
resistance and cardiotoxicity. Recent studies have shown that thymoquinone
(TQ) in combination with Dox can reduce Dox toxic side effects in vitro as
well as in vivo. Both TQ and Dox have shown promising anticancer effects
against aggressive adult T-cell leukemia (ATL), however, the anticancer po-
tential of TQ and Dox combination treatment has never been tested against
ATL. We hypothesized that co-treatment with TQ could enable the use of
lower doses of Dox to achieve similar or enhanced anticancer activity. The
effects of TQ and Dox combination on cell death and cell cycle were evalu-
ated by trypan blue and propidium iodide. TUNEL assay was used to inves-
tigate the mode of cell death. The levels of reactive species (ROS) were de-
termined using DCFH assay, and mitochondrial membrane potential was
measured by rhodamine assay. The regulation of key proteins involved in cell
cycle regulation and cell death was determined by Western blot. The results
reveal that the human T-lymphotropic virus (HTLV-1) positive HuT-102
cells are more resistant to treatment with Dox alone, than the HTLV-1 neg-
ative Jurkat cells. However, treatment with high doses of TQ and low doses of
Dox simultaneously, enhances cell death in both cancer cell lines as com-
pared to treatment with Dox alone. TUNEL assay on Jurkat and HuT-102
cells further indicated that the combination of TQ and Dox caused cell death
by apoptosis. An increase in ROS production was noted in response to treat-
ment with TQ alone and with TQ and Dox combination in both Jurkat and
HuT-102 cells. The oxidative stress; however, was only shown to play a role
in the disruption of the mitochondria of Jurkat cells. Similarly, caspase acti-
vation was involved in the disruption of the mitochondria of Jurkat cells. The
expression levels of key regulatory proteins were modulated in response to
treatment with the combination. In conclusion, the combination of TQ and
Dox effectively inhibits ATL leukemic cancer cell growth at lower doses of
Dox which can potentially lower the side effects of the drug. In vivo studies
are still warranted to assess the adjuvant chemotherapeutic potential of TQ
in combination with Dox.
#1050 Mefloquine enhances the cytotoxic effects of tyrosine kinase inhib-
itors in blast phase chronic myeloid leukaemia by lysosome membrane dis-
ruption. Wei Xiang,1 Yi Hui Lam,1 Colin Sng,2 May Anne Cheong,1 Hein
Than,1 William YK Hwang,1 Charles Chuah1. 1Singapore General Hospital, sin-
gapore, Singapore; 2Duke-NUS Medical School, Singapore, Singapore.
Despite the remarkable clinical responses achieved with BCR-ABL ty-
rosine kinase inhibitors (TKIs) in the treatment of chronic phase-chronic
myeloid leukaemia (CML), these TKIs have been less effective as single
agents in blast phase (BP) CML. Identifıcation of new therapeutic strategies
is needed for the better clinical management of BP-CML. Given the known
pharmacokinetics and toxicity profıle, drug repurposing represents an alter-
native therapeutic strategy for CML. Mefloquine is a FDA-approved antima-
larial drug that has been recently reported to have anti-cancer activities. In
this work, we investigated the effect of mefloquine and its underlying mech-
anisms in CML. We show that mefloquine inhibits proliferation and induces
apoptosis of CML cells in a dose-dependent manner. In addition, mefloquine
is also effective in targeting BP-CML CD34 progenitor cells. It induces
apoptosis, inhibits colony formation and self-renewal capacity of CD34
cells derived from a TKI-resistant BP-CML patient. Mefloquine signifıcantly
enhanced anti-proliferative and pro-apoptotic effects of imatinib and dasat-
inib in CML cell lines (eg, K562, LAMA84 and KU812) as well as BP-CML
CD34 cells, suggesting that mefloquine augments the effects of BCR-ABL
TKIs. Mechanistically, mefloquine increases lysosome biogenesis in various
CML cell lines. The action of mefloquine on lysosome is further confırmed by
our observation that the lysosomal vacuolar ATPase bafılomycin A1 rescues
mefloquine-induced CML cell death. Mefloquine also induces oxidative
stress in CML cells as shown by the increased mitochondrial superoxide
levels. Importantly, -tocopherol (known to inhibit lysosomal lipid-medi-
ated ROS production) but not N-acetyl-L-cysteine (NAC, known to inhibit
thiol redox-mediated ROS production) protects against mefloquine-medi-
ated cell death, suggesting that oxidative stress induced by mefloquine in
CML cells is lysosome-mediated. It is known that the length of isoprenoid
side chain of -tocopherol is important for the stabilization of biological
membranes. Interestingly, -tocopherol analog Trolox, which differs from
-tocopherol by decreasing isoprenoid side chain fails to rescue mefloquine-
induced cell death, suggesting that mefloquine may destabilize lysosome
membrane in CML cells. In addition, we show that mefloquine decreases
phosphorylation of S6 and increases LC3B II levels, suggesting that mTOR
inhibition and autophagy induction might be involved in the action of me-
floquine in CML cells. Taken together, our work suggests that mefloquine
has a potential to be repurposed for CML treatment, given its effıcacy as a
single agent and synergism as combination with BCR-ABL TKIs in CML
primary progenitors and cell lines. Our work also highlights the therapeutic
value of targeting the lysosome in the treatment of CML.
#1051 Preclinical analyses of synergistic effect of eribulin and paclitaxel
for triple-negative breast cancer. Takaaki Oba, Ken-ichi Ito. Shinshu Univer-
sity, Matsumoto, Japan.
Purpose: There is an urgent need to develop novel therapeutic strategies
for triple negative breast cancer (TNBC). To explore the antitumor effect of
combination of eribulin (ERI) and paclitaxel (PTX) for TNBC, we conducted
preclinical experiments. Materials & methods: Combinational effects of ERI
and PTX were analyzed both in vitro and in vivo using two TNBC cell lines
(MDA-MB-231, Hs578T). Results: When ERI was added simultaneously
with PTX to TNBC cells, the sensitivity to PTX was increased synergistically.
On the other hand, synergistic increase of sensitivity to ERI was observed in
the presence of PTX. When the TNBC cells were treated with each drug
subsequently, pretreatment with ERI for 96 hours enhanced the sensitivity to
PTX administrated subsequently. In contrast, pretreatment of TNBC cells
with PTX enhanced the sensitivity to the subsequently administrated ERI.
When the TNBC cells were treated with ERI, the expression of epithelial
marker, E-cadherin was increased, while the expression of mesenchymal
markers, pSmad2, ZEB1, Slug, and vimentin were decreased. In contrast,
when the cells were treated with PTX, the expressions of mesenchymal mark-
ers were increased. When epithelial-mesenchymal transition (EMT) was in-
duced by TGF- in the TNBC cells, the sensitivity to ERI was enhanced,
while TGF- receptor inhibitor (LY2157299) reduced the sensitivity to ERI.
Furthermore, knockdown of ZEB1 by small interfering RNA conferred re-
sistance to ERI in both TNBC cell lines. In the mouse xenograft model
bearing MDA-MB-231, ERI plus PTX combination therapy signifıcantly in-
hibited tumor growth compared with either PTX or ERI monotherapy. Fur-
thermore, prior treatment with ERI signifıcantly enhanced the antitumor
activity of PTX in the mouse xenograft model. Conclusions: Our fındings
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demonstrate an EMT-mediated synergistic antitumor effect by combination
of two tubulin inhibitors. This combination therapy may serve as a novel
therapeutic strategy for TNBC.
#1052 Aldose reductase inhibitor increases doxorubicin-sensitivity of co-
lon cancer cells and decreases cardiomyopathy.Himangshu Sonowal, Pabitra
B. Pal, Satish K. Srivastava, Kota V. Ramana.UTMedical Branch, Galveston, TX.
Chemotherapy is one of the most common option for colorectal cancer
(CRC), specifıcally at the advanced stages and after surgical resection of the
tumor. Anthracycline drugs such as doxorubicin, daunorubicin are the most
commonly used for the therapy of leukemia, lymphoma andbreast cancer.How-
ever, doxorubicin is not a very effective drug to kill CRC cells since a high
amount of doxorubicin is required for colon cancer therapy, which leads to
unwanted side effects like cardiac toxicity and cardiomyopathy. Therefore, bet-
ter adjuvant therapies are required to increase sensitivity of CRC to doxorubicin
aswell as to decrease the associated cardiomyopathy.Our recent studies indicate
that aldose reductase (AR; AKR1B1) inhibitors such as fıdarestat prevent CRC
growth as well as metastasis in nude mice xenograft models. We now examined
our hypothesis that AR inhibition increases the sensitivity of CRC to doxorubi-
cin and decreases its cardiotoxicity by modulating oxidative stress-mediated
signaling pathways. We have investigated the effect of co-administration of
doxorubicin along with AR inhibitor fıdarestat in in vitro and in vivo CRC cells
growth and toxicity. Our results suggest that treatment of CRC cells with fıdar-
estat increases the effıcacy of doxorubicin-induced death of HT-29 and SW-480
colon cancer cells. Flow cytometric analysis indicates that in fıdarestat doxo-
rubicin -treated CRC cells, the intracellular accumulation of doxorubicin is in-
creased as compared to doxorubicin alone-treated cells. Further, AR inhibition
prevents doxorubicin-induced increase in the expression of drug transporter
proteins such as MRP-1 and ABCG-2 in CRC cells. In addition, combination of
fıdarestat with doxorubicin signifıcantly prevented the growth of CRC cells in
nude mice xenografts as compared to doxorubicin alone. Fidarestat also pre-
vented the doxorubicin-induced cardiac toxicity as measured by serum tro-
ponin-I levels and inflammatory cytokines and chemokines in the serum and
heart of doxorubicin-treated mice in combination with fıdarestat. Most impor-
tantly, fıdarestat protects the cardiac damage and dysfunction in doxorubicin-
treated mice. Thus, our results suggest that fıdarestat could be used as a novel
adjuvant therapy in enhancing doxorubicin sensitivity of CRC cells and to re-
duce the doxorubicin-associated cardiotoxicity.
#1053 Synergistic anticancer effects of combined -tocotrienol and
pterostilbene is associated with a suppression in Rac1/WAVE 2 signaling in
highly malignant breast cancer cells. Ibrahim G. Algayadh, Paul William Syl-
vester. Univ. of Louisiana at Monroe, Monroe, LA.
Breast cancer is the most common cancer and the second leading cause of
cancer death in American women. RhoGTPases play a crucial role in regulating
different cellular functions, including cell proliferation, gene expression, cell
morphology, actin polymerization, cell motility, metastasis and apoptosis. Wis-
kott-Aldrich syndrome protein family verprolin-homologous protein2
(WAVE2) is a member within the Wiskott-Aldrich syndrome protein (WASP)
family displays a signifıcant role in actin polymerization and cytoskeletal orga-
nization which, are essential for cellular migration and invasion. -Tocotrienol
is a natural isoform within the vitamin E family that displays anticancer activity
against a variety of cancer cell types. Pterostilbene is a natural dimethyl ether
analog of resveratrol that has several benefıcial effects such as anticancer activity.
Studies were conducted to examine the effects of combined -tocotrienol and
pterostilbene on Rac1/WAVE 2 signaling in mouse SA and human MDA-
MB231 breast cancer cells and cellular migration. Results show that combined
treatment of -tocotrienol and pterostilbene caused a synergistic inhibition of
both mouse SA and human MDA-MB231 breast cancer cells growth, and
corresponding reduction in Rac1/WAVE2 signaling as characterized by a sig-
nifıcant inhibition in the levels of phospho-Rac1/cdc42, WAVE2, Arp2, and
Arp3 expression. Additional studies indicated that this combination resulted in
a signifıcant inhibition in mammary cancer cell migration. In summary, these
fındings strongly suggest that combined treatment of -tocotrienol with pteros-
tilbene may provide great benefıt as a therapeutic approach in the treatment of
metastatic breast cancer. Supported by a grant from the Louisiana Cancer Foun-
dation.
#1054 Nobiletin synergizes cytotoxicity of antimicrotubule agents by in-
hibiting Pin1 pathway. Kazunori Kato, Takumi Yamazaki, Masaaki Honma.
Toyo Univ., Saitama, Japan.
Nobiletin is a citrus polymethoxy flavonoid that suppresses cell proliferation,
angiogenesis and metastatic properties in various cancer cells. In this study, we
investigated the combined effects of nobiletin and various chemotherapeutic
agents on the cytotoxicity of human colon and esophageal cancer cells. We
cultured cancer cells at serial dilution of chemotherapeutic agents with or with-
out nobiletin and assessed cell cytotoxicity at 5 days after drug treatment. The
addition of a suboptimal dose of nobiletin did not alter the growth of cancer
cells, however cytotoxic effect of antimetabolites (gemcitabine and 5-FU) and
DNA-platinating agent (cisplatin) were markedly attenuated by nobiletin. By
contrast, nobiletin markedly enhanced antitumor effect of antimicrotubule
agents such as docetaxel, paclitaxel, vincristine and MMAE. Moreover, en-
hanced cytotoxicity by nobiletin was also verifıed in the combination with
MMAE- or DM1-conjugated antibodies to EpCAM and EphA2. We found the
inhibition of phosphorylation andnuclear translocation of Pin1 (peptidyl-prolyl
isomerase) by nobiletin, suggesting a rational molecular target of nobiletin is
Pin1. Overall, these data suggest that nobiletin might useful for the chemother-
apeutic treatment of microtubule inhibitors.
#1055 Enhanced effıcacy of trifluridine for ionizing radiation in human
colorectal cancer cell lines.Kazuaki Matsuoka,1 Mamoru Nukatsuka,1 Takashi
Kobunai,2 Teiji Takechi2. 1Taiho Pharmaceutical Co., Ltd., Tokushima, Japan;
2Taiho Pharmaceutical Co., Ltd., Tokyo, Japan.
Background: Trifluridine/tipiracil is a combination of trifluridine (FTD),
a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase
inhibitor, in a molecular ratio of 1:0.5. Trifluridine/tipiracil is indicated for
the treatment of patients with metastatic colorectal cancers refractory to
standard chemotherapies. Chemotherapy can make radiation therapy more
effective against some colorectal cancers. In this study, we investigated
whether cytotoxicity was enhanced when FTD was sequentially used with
ionizing radiation (IR). Method: The colorectal cancer cell lines HT-29,
HCT-15, and HCT 116, showing low, middle and high sensitivity for IR,
respectively, were treated with the combinations of FTD and IR as follows, 1)
sequence 1 (pre-radiation): exposure to 2-8 Gy radiation alone and no treat-
ment for 24 h followed by exposure to 0, 2.0, or 4.0 M FTD for 24 h, 2)
sequence 2 (post-radiation): exposure to 0, 2.0, or 4.0 M FTD for 24 h
followed by 2-8 Gy radiation alone and no treatment for 24 h. Cells were
irradiated using a cabinet X-ray irradiation system and all treatments were
evaluated by the clonogenic survival assay. The dose modifıcation factors
(DMFs) were calculated from clonogenic survival curves as the ratio of ra-
diation doses (control radiation dose divided by the FTD-treated radiation
dose). To evaluate DNA strand-breaks, alkaline comet assays were per-
formed and the comet tail moment was determined. Results: DMFs of se-
quence 1 at 8 Gy for 2.0 M FTD were 1.55, 1.24, and 1.03 and for 4.0 M
FTD were 1.75, 1.26, and 1.02 for HT-29, HCT-15, and HCT 116, respec-
tively, and of sequence 2 at 8 Gy for 2.0MFTDwere 1.82, 1.38, and 1.03 and
for 4.0MFTDwere 2.73, 1.41, and 1.09 for these cell lines, respectively. The
DMFs increased in an FTD dose-dependent manner compared with IR-only
treatment. In particular, FTD enhanced the effıcacy of radiation in HT-29
and HCT-15 indicating low and middle sensitivity to IR. Compared with
IR-only treatment, the median comet tail moments of sequence 1 at 8 Gy for
2.0 M FTD, respectively, were 13.8-, 14.4-, and 2.0-fold and for 4.0 M
FTD were 16.6-, 12.6-, and 3.6-fold in HT-29, HCT-15, and HCT 116, re-
spectively, and of sequence 2 at 8 Gy for 2.0 M FTD were 4.8-, 4.3-, and
1.8-fold and for 4.0 M were 7.5-, 14.3-, and 2.6-fold in these cell lines,
respectively. Taken together, FTD promoted DNA strand-breaks and en-
hanced the effıcacy of radiation in these three cell lines, regardless of both
sequential treatments. Conclusion: Sequential combination of FTD and ra-
diation was more effective than radiation alone against colorectal cancer cell
lines with different radiosensitivities. These results suggest that combination
therapy of radiation with trifluridine/tipiracil might be useful for colorectal
cancer even with low sensitivity to radiation alone.
#1056 Volasertib in combinationwith radiotherapy: The perfectmatch in
non-small cell lung cancer. Jolien Van den Bossche,1 Ines De Pauw,1 Hilde
Lambrechts,1 Céline Merlin,1 Christophe Deben,1 Vanessa Deschoolmeester,1
Pol Specenier,2 Patrick Pauwels,2 Marc Peeters,2 Filip Lardon,1 An Wouters1.
1Antwerp University, Wilrijk, Belgium; 2Antwerp University Hospital, Edegem,
Belgium.
Background: Polo-like kinase 1 (Plk1), a master regulator of mitosis and
the DNA damage response, is overexpressed in several human malignancies,
making it a promising therapeutic target. Monotherapy of Plk1 inhibition
has shown only a moderate effect in clinical trials, indicating the need to
combine with other therapies. Remarkably, Plk1 inhibition arrests cancer
cells in mitosis, which is the most radiosensitive cell cycle phase. Hence, we
are the fırst to investigate the effect of volasertib, the lead agent in category of
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Plk1 inhibitors at themoment, on the radiosensitivity of a panel of non-small
cell lung cancer (NSCLC) cell lines with a different p53 background under
both normal and reduced oxygen conditions. Material and methods: Three
isogenic NSCLC cell lines (i.e. A549 (p53 wt); A549-NTC (non template
control, p53 wt); and A549-920 (p53 defıcient)) and one TP53 mutant cell
line (NCI-H1975, R273H mutation) were included. Cell survival after vola-
sertib monotherapy (0-85 nM, 24h) was assessed using the sulforhodamine B
assay. The effect of volasertib (0-20 nM, 24h) on cell cycle distribution was
determined flow cytometrically using the Vindelov method. The clonogenic
assay (24h 0-10 nM volasertib followed by 0-8 Gy irradiation) was performed
to evaluate the radiosensitizing effect of volasertib. Cells were incubated
under normoxia or hypoxia (1% O2) during the treatment period. Data anal-
ysis was done using WinNonlin and FlowJo software. Results: Plk1 inhibi-
tion by volasertib established a dose-dependent growth inhibition in all cell
lines under both normoxia and hypoxia. Cell survival was signifıcantly in-
fluenced by the p53 status, with a reduced sensitivity to volasertib in p53
defıcient/mutant cells compared to p53 wild type cells (p0.001). Except for
the TP53 mutant NCI-1975 cell line, IC50-values were signifıcantly higher in
hypoxic cells compared to their normoxic counterparts (p0.001). Treat-
ment with increasing concentrations of volasertib induced a strong G2/M
phase block (p0.001), which was most pronounced in p53 defıcient A549-
920 cells, accompanied by a signifıcant decrease in the number of G1 and S
phase cells (p0.001). Under hypoxia, a mitotic arrest was only detected
when high volasertib concentrations were used. Intriguingly, the radiosen-
sitizing effect of the Plk1 inhibitor was more pronounced in p53 wild type
cells than in p53 defıcient cells. For example, the dose enhance factor (DEF)
for volasertib treatment ranged from 1.60 to 2.13 in A549-NTC cells and
from 1.18 and 1.22 in A549-920 cells, respectively. Importantly, radiosensi-
tivity was retained when cells were treated and irradiated under hypoxia.
Conclusion: Our in vitro data confırm the therapeutic potential of volasertib
in NSCLC cells. Pretreatment with the Plk1 inhibitor enhanced radiosensi-
tivity, especially in cells with functional p53, suggesting a potential role for
p53 in radiosensitization by volasertib.
#1057 Co-treatment with fenretinide and safıngol induced p38 MAPK
and/or FOXO3a activated pro-survival autophagy in glioblastoma multi-
forme cells.NikhilVad,DongWang,Charlie Linch, Barry J.Maurer.TexasTech
Univ. Health Sciences Ctr., Lubbock, TX.
Cytotoxicity of the synthetic retinoid, fenretinide (4-HPR), is associated
with increased reactive oxygen species and/or de novo synthesized
D-erythro-dihydroceramides. Co-treatment with L-threo-sphinganine (saf-
ingol, S), synergistically increased fenretinide cytotoxicity in cell lines of
many cancer types coincident with increase of safıngol-derived, L-threo-
dihydroceramides. Previously, we showed that 4-HPRS induced ER stress,
unfolded protein response (UPR), pro-survival autophagy, and mixed non-
apoptotic and apoptotic cell death in glioblastoma multiforme (GBM) cells
in vitro. However, the mechanisms regulating such activity remained un-
clear, including the role of ceramide-activated signal transducers, such as
ASK1. We now report that 4-HPRS activated stress kinase ASK1 via phos-
phorylation at Thr845 (1-6 hrs), an event known to induce p38 MAPK
phosphorylation. Furthermore, 4-HPRS induced an increase in the nu-
clear localization of transcription factor FOXO3a coincident with decreased
Akt signaling and increased phosphorylated levels of JNK1/2, p38 MAPK,
ERK1/2, and autophagy regulator, AMPK (1-6 hrs). 4-HPRS caused a
time-dependent (6-24 hrs) increase of GRP78 protein levels, a key regula-
tor of ER stress response and UPR, and increased levels of pro-apoptotic
transcription factor, CHOP. GRP78 increase was p38 MAPK-dependent, as
p38 MAPK inhibitor, SB203580, greatly reduced GRP78 increase. Interest-
ingly, 4-HPRS induced cytotoxicity was unchanged in the presence of an
inhibitor of ERK 1/2 (PD98059) but signifıcantly decreased when cells were
concurrently treated with p38 MAPK inhibitor, SB203580, or JNK1/2 inhib-
itor, SP600125 (24-72 hrs, p 0.05). Signifıcantly, co-treatment with dor-
somorphin, an AMPK inhibitor, increased and accelerated 4-HPRS cyto-
toxicity (24-72 hrs, p  0.05). Moreover, 4-HPRS treatment induced
FOXO3a Ser7 phosphorylation (1-6 hrs) and a corresponding decrease in
levels of nuclear E3-Ub protein ligase, Skp2. The decrease of SKp2 protein
was coincident with increased levels of CARM1 protein, a known transcrip-
tional activator of autophagy-related genes. Activation of ASK1, JNK1/2,
p38 MAPK and ERK1/2 by 4-HPRS occurred earlier, and to a greater
extent, than single agent 4-HPR and S exposures at all time points (1-24
hrs). Together, these results support that 4-HPRS induced both pro-sur-
vival autophagy and cell death at least partly through activation of FOXO3a
and ASK1-dependent activation of p38 MAPK, possibly in response to the
known progressive increase of de novo synthesized D-erythro and L-threo
dihydroceramides. A Phase I trial of intravenous 4-HPRS in adult solid
tumors (ClinicalTrials.gov Identifıer:NCT0155307) is currently open in the
Texas State-supported, South Plains Oncology Consortium (SPONC.org).
#1058 Synergistic activity of p97 inhibitors with histone deacetylase 6
inhibitors inmantle cell lymphoma.RekhaM. Rao,1 PratikkumarH. Vekaria,1
Trisha Home,1 Anusha Vallurupalli,1 AbdulraheemYacoub,1 Frank Schoenen,2
Joseph McGuirk1. 1Univ. of Kansas Medical Ctr., Kansas City, KS; 2Univ. of
Kansas, Lawrence, KS.
p97, or valosin-containing protein (VCP), is an ATPase whose function is
essential to restore protein homeostasis in cells. Working in concert with the
ubiquitin proteasome system, p97 promotes the retrotranslocation of misfolded
proteins from the endoplasmic reticulum and/or their degradation. Conse-
quently, p97 inhibition has emerged as a novel therapeutic target in cancer cells,
especially those that depend on high protein turnover and/or ER function. p97 is
also present in a complex with many protein complexes including the HSP90,
histone deacetylase (HDAC) 6 and heat shock factor 1 (HSF1)-also called the
repressive complex. p97 participates in the disaggregation of the repressive com-
plex to regulate HSP90 and HSF1 function under stressed conditions. Accumu-
lation of misfolded polyubiquitylated proteins in the cytosol or on damaged
organelles promotes the binding of p97 to polyubiquitylated proteins in an
HDAC6-dependent manner and promotes their turnover by autophagic degra-
dation. Given that perturbation of protein homeostasis and ER function induces
apoptosis as well as autophagy in B cell malignancies such as multiple myeloma
andmantle cell lymphoma (MCL), we hypothesized that inhibition of p97 func-
tion in combination with HDAC6 inhibitors would induce proteotoxic stress
and/or apoptotic cell death in MCL cells. In this study, we report that the p97
inhibitors DBeQ, ML240 and NMS-873 induce a dose-dependent loss of cell
viability in cultured and primary MCL cells. Treatment of MCL cells with
ML240 induces the accumulation of polyubiquitylated proteins and induces
markers of ER stress such as glucose regulated protein 78 (GRP78) and phos-
phorylated eukaryotic initiation factor 2 (eIF2) aswell as the autophagicmark-
ers LC3-B and p62 (protein whose accumulation is suggestive of reduced au-
tophagic clearance of misfolded proteins). Co-treatment with ML240 and the
HDAC6 inhibitor ACY-1215 induces more accumulation of polyubiquitylated
proteins and markers of enhanced ER stress as well as autophagy, than either
agent alone. Mechanistically we determined that co-treatment with ML240 and
ACY-1215 inhibits the binding of p97 to polyubiquitylated proteins and
HDAC6, resulting in the reduced clearance of cytotoxic protein aggregates in the
cells. Co-treatment with ML240 and ACY-1215 also induces the accumulation
of cytosolic polyubiquitylated proteins and their co-localization with LC-3B
puncta as demonstrated by immunofluorescentmicroscopy. These observations
are suggestive of enhanced initiation of autophagy but not its completion. Con-
sequently, treatment of MCL cells with ML240 and ACY-1215 resulted in en-
hanced proteotoxic stress and synergistic apoptotic cell death in MCL cells.
Collectively our studies create a strong rationale to test effıcacy of the combina-
tion of p97 inhibitors in combination with HDAC6 inhibitors in MCL.
#1059 Enhanced anti-tumor effıcacy of a checkpoint inhibitor in combi-
nation with the HDAC inhibitor belinostat in a murine hepato-cellular car-
cinoma preclinical model. Diana Llopiz,1 Marta Ruiz,1 Perrine Pivette,2 Véro-
nique Trochon-Joseph,2 Bérangère Vasseur,2 Caroline Lemarchand,2 Graham
Dixon,2 Pablo Sarobe,1 Bruno Sangro3. 1CIMA (Centro de Investigación Médica
Aplicada), Pamplona, Spain; 2Onxeo, Paris, France; 3Clínica Universidad de Na-
varra, Pamplona, Spain.
Introduction Belinostat is an HDAC inhibitor currently marketed in the
US for the treatment of PTCL. A new oral formulation is under development
(positive PoC in preclinical PK study) and provides an increase potential to
develop new indications of belinostat in combination with other drugs. It has
been extensively demonstrated that some anti-tumor agents, besides their
direct anti-tumor effect, may induce additional mechanisms involving acti-
vation of immune responses. Thus, combination of these drugs with other
immunotherapeutic protocols may yield improved therapeutic benefıts. The
objective of the present study is the characterization of the therapeutic effı-
cacy of a combination of checkpoint inhibitors (anti-CTLA-4 antibodies)
with belinostat in a murine HCC model. In addition, immunoprofıling was
performed in order to assess the associated immune response. Methods In
vivo effıcacy was performed in a Hepa 129 murine hepatocellular carcinoma
model implanted subcutaneously in immune-competent C3H mice using
anti-CTLA4 alone, belinostat alone or in combination. Treatments were
optimized to be able to demonstrate positive effect of the combination. Tu-
mor volume was the primary endpoint. Samples from the spleen were taken
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to analyze immune mechanism mediating the antitumor activity. Percent of
CD4, CD8 T cells and regulatory T cells were determined by flow cytometry.
Anti-tumor T cell response was measured by IFN-gamma ELISPOT assay.
Results Belinostat improved anti-tumor therapeutic response induced by the
anti-CTLA4 checkpoint inhibitor with a signifıcant superior tumor growth
inhibition compared to control groups. Treatment with the combination
resulted in a complete cessation in tumor growth in all mice during the
belinostat treatment period which continued for 1 week after the fınal dose.
Mechanistic studies showed that the underlying immune response corre-
lated with the observed therapeutic effect of the combination with enhance-
ment of IFN-gamma production as antitumor T cell response and decrease
in regulatory T cells in the spleens of treated animals. Conclusion These
results provide a rational for using belinostat in combination with check-
point inhibitors to reinforce therapeutic response. Currently only approx.
20% of patients respond to check point inhibitors alone. The oral formula-
tion of belinostat will allow greater flexibility in dosing schedule and use in
multiple clinical situations. Further studies are ongoing in order to fully
characterize this fınding and to facilitate its translation into patients.
#1060 Identifıcation and validation of repurposed drugs for treating head
and neck cancer. Jennifer L. Bryant, Nikolaos Batis, Baksho Kaul, Margaret
Hartley, Gordon B. Ryan, Rachel J. Spruce, Hisham Mehanna. University of
Birmingham, Birmingham, United Kingdom.
Background: Head and neck squamous cell carcinoma (HNSCC) prevalence
is rising and new treatments are urgently required. Repurposing existing, clini-
cally approved drugs to be used for cancer therapy is appealing due to the re-
duced time and cost required to achieve patient benefıt. Aim: The aim of this
study was to identify repurposed drugs for use in HNSCC and to validate these
drugs and their targets in vitro and in vivo. Methods: A library of 100 BNF-
approved drugs were screened against HNSCC cell lines using high-throughput
AlamarBlue proliferation assays and the drug combination IHN56 and IHN29
was identifıed. To validate this fınding, AlamarBlue assays were repeated using a
range of concentrations either alone or in combination with cisplatin. In addi-
tion, the ability of IHN56  IHN29 to reduce colony formation and promote
apoptosis of HNSCC cell lines was quantifıed using clonogenic survival assays
and Annexin V/PI FACS analysis. To determine the mechanisms of action of
IHN56  IHN29, CAL27 cells were exposed to drugs for 24 hours and the
expression of STAT3, pSTAT3-Y705, pSTAT3-S727, EGFR, pEGFR, p21, p53,
LC-3 and Ki67 were visualized by Western blot. Finally, in vivo mouse models
were employed to confırm our in vitro fındings. 5  105 CAL27 cells were
injected into male NSGmice and allowed to reach 150mm3.Mice then received
IP injections of 310 mg/kg INH29 on days 3-14 after escalating doses on days
1-2, 40 mg/kg INH56 days 3-14, 2 mg/kg cisplatin days 3, 5 and 7, or vehicle
control days 1-14. Weights and tumors were measured at least 3 times a week.
Results: The initial screen identifıed two promising drugs in combination;
INH56 and INH29, originally used to treat helminthiasis and epilepsy. The IC50
of INH56 in CAL27 cells utilising the AlamarBlue assay was 1.47 M and re-
duced to 0.66M in the presence of 0.9 mM INH29. Clonogenic assays demon-
strated the ability of INH56 to reduce colony formation by 55% at 2 M and by
85% when combined with 0.9 mM INH29. Furthermore, a dose-dependent in-
crease in apoptosis was observed with INH56 treatment, which was markedly
increased following the addition of INH29.Western blot analysis supports these
observations through decreased Ki67 (proliferation), reduced STAT3 activation
(oncogenic signaling), increased p21 (apoptosis) independent of p53, and in-
creased LC3 (autophagy) protein levels. In vivo, CAL27 xenograft tumor growth
was signifıcantly impaired by IP administration of INH29 alone (P0.002) and
in combination with INH56 (P0.002) after 11 days, without any obvious tox-
icity. Conclusion: The combination of INH56  INH29 demonstrates strong
promise as a novel treatment for HNSCC. This study reveals that INH56 
INH29 alone and in combination with standard treatment (cisplatin and irradi-
ation) reduces proliferation, impedes colony formation and increases apoptosis
in vitro, and reduces tumor growth in vivo. We are progressing to a phase I/II
trial in HNSCC patients starting in the new year.
#1061 Modulation of death pathways by TRAILR2 agonist antibody and
NF-B pathway by NIK inhibitor in HPV-positive head and neck squamous
cell carcinomas. Yi An, Lillian Sun, Adeeb Derakhshan, Sophie Carlson, Rita
Das, Zhong Chen, Carter Van Waes. NIDCD/NIH, Bethesda, MD.
Head and neck squamous cell carcinomas (HNSCC) induced by human pap-
illoma virus (HPV) have increased recently in the US, and exhibit a different
prognosis and response to therapies from HPV(-) cancers. Analysis of HNSCC
TCGA datasets provide evidence for distinct alterations in expression of com-
ponents of theNF-B and death pathways inHNSCCwith differentHPV status.
Previously, we have found that birinipant, a novel SMAC mimetic that inhibits
inhibitor of apoptosis proteins (IAPs), sensitizes a subset of HPV() HNSCC
cell lines to death agonists like TNF- and TRAIL. In this study, we have ob-
served that birinipant also sensitizes most HPV() cell lines to TRAIL and
TNF- in vitro. The IC50 of birinipant was under 50nM for HPV() UPCI-
SCC-90 and UM-SCC-47 cell lines, when combined with TNF- or TRAIL. To
explore the therapeutic potential of enhancing TRAILR mediated death signal-
ing in HPV() HNSCC cells, we investigated the effects of an agonistic poly-
clonal TRAILR2 antibody. Treatment of cells with TRAILR2 antibody alone
shows little or no inhibitory effect on UPCI-SCC-90 and UM-SCC-47 cells in
vitro. However, a combination of birinipant and TRAILR2 antibody, or triple
combination of birinipant, TRAIL, and TRAILR2 antibody shows additive or
synergistic effects to inhibit cell proliferation and induce cell death in a dose
dependent manner. In addition, our preliminary data suggested that the non-
canonical NF-B pathway is predominately activated in HPV() HNSCC cells,
and that NF-B inducing kinase (NIK) is a key component of this pathway.
When we tested the NIK inhibitor 4H-isoquinoline-1,3-dione in UPCI-SCC-90
cells, we found it reduced cell proliferation in a dose-dependent manner
(IC50 1.5M). Taken together, these results indicate that TNF-, TRAIL, and
TRAILR2 agonist antibody sensitized birinipant anti-tumor activity, and triple
combination exhibited synergistic effects in HPV() HNSCC cell lines. NIK
inhibitor alone inhibits cell proliferation of HPV() cells, supporting the hy-
pothesis of aberrant activation of alternative pathway in HPV() HNSCC cells.
(Supported by NIDCD intramural projects ZIA-DC-000016, 73, 74).
#1062 The combination ofmetformin and valproic acid induces synergis-
tic apoptosis of prostate cancer cells via p53 activation and the intrinsic path-
way. Linh N.K. Tran, Ganessan Kichenadasse, Katherine L. Morel, Pamela J.
Sykes. Flinders University and Medical Centre, Adelaide, Australia.
The anti-diabetic drug metformin (MET) and the anti-epileptic drug valproic
acid (VPA), when used alone, have demonstrated anti-cancer effects in prostate
cancer (PCa). We have demonstrated that the combination of MET and VPA
(METVPA) can induce synergistic apoptosis in the human prostate cancer cell
line LNCaP (p53) but not in PC3 (p53-), and that the response is dependent on
functional p53. Here, we aimed to (1) investigate the mechanism of synergistic ap-
optosis induced byMETVPA in LNCaP and (2) propose patient subsets for clin-
ical applicationsofMETVPAbasedon themechanism involved. LNCaPandPC3
cells were treatedwith vehicle, 2.5mMMET, 2.5mMVAL, or 2.5mMMETVAL
and proteins extracted from cell fractions. Western blots were used to confırm cy-
toplasmic andmitochondrial fractions bymeasuring the presence of-actin, pyru-
vate dehydrogenase subunit E1-, and ATP synthase subunit- protein, as well as
the release of cytochromec frommitochondria to the cytoplasm.Themechanismof
apoptosis via p53 activation is proposed based on our fındings and current under-
standing from literature. The release of cytochrome c from themitochondria to the
cytoplasm was signifıcantly increased up to 12-fold (p0.05) in LNCaP, but not in
PC3, in response toMETVPA compared to vehicle, MET alone, and VPA alone.
This fınding suggests that both MET and VPA are required to induce an intrinsic
apoptosis response in LNCaP via p53. The mechanism proposed is that MET can
inhibit the activity of mitochondrial complex 1 which alters the AMP/ATP ratio.
This change can activate adenosine monophosphate protein kinase which phos-
phorylates p53 at Ser15 and leads to p53-dependent cell death. As a non-specifıc
histone deacetylation inhibitor, VPA causes protein acetylation including p53 at
lysine residues 373 and 382. By combining metformin and VPA, increased p53
protein activation can occur through phosphorylation of p53 at different sites driv-
ingp53-dependentcell apoptosisvia the intrinsicpathway, asevidencedbyreleaseof
cytochrome c into the cytoplasm. Our results suggest that METVPA provides a
useful treatment for PCa at a clinically localized stage where p53 is present in most
patients or advanced stage where p53 has not been mutated. Additionally,
METVPA is potentially an alternative to androgen deprivation therapy, particu-
larly in tumorswith functional p53. A phase I neo-adjuvant clinical trial will start in
early 2017 to evaluate the response of high risk localized PCa toMETVPA (AN-
ZCTR trial ID: ACTRN12616001021460).
#1063 Benefıt from combination cancer therapy arising from patient-to-
patient variability rather than additive or synergistic drug action. Adam C.
Palmer, Peter K. Sorger. Harvard Medical School, Boston, MA.
Combination cancer therapy is an important means to increase rates and dura-
bility of drug response. Superior responses to combination therapies are commonly
interpreted as evidence that individual tumors respond more strongly to a combi-
nation than to a monotherapy, and combinations are often developed based on
pre-clinical observations of drug additivity or synergy. Here we explore an alterna-
tive hypothesis, namely that combination therapy can confer benefıt simply by pro-
vidingmultiple chances of an above-average response tomonotherapy. The benefıt
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Combination Strategies: Novel Agents and Standard Therapies
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017272
conferred by two-drug combination therapy in human clinical trials and PDX ani-
mals was compared with a model of independent drug action postulating that net
response in each patient equals the better of two potential responses to drugs given
individually with no benefıt from the second agent. Data were derived from clinical
trials of drug combinations inmelanoma, ovarian, colorectal, pancreatic, andbreast
cancers treated with immunotherapies, chemotherapies and inhibitors of kinases,
growth factor receptors, angiogenesis, and DNA repair enzymes; as well as analysis
of 4,500 drug response measurements in patient-derived tumor xenografts, and a
fırst-principlesmodel of tumor kinetics and variability in drug response.Amajority
of approved combination cancer therapies analyzed confer benefıts consistent with
independent drug action. This benefıt arises from high inter-subject variability,
which can be assessed from clinical trials, and low correlation in responsiveness to
different drugs, assessed fromPDX studies. In aminority of cases responses exceed
this expectation, sometimesdramatically, and are likely to represent truedrug inter-
action. Therefore, independent drug action,without any assumption about additive
or synergistic effects, provides a suffıcient and more parsimonious explanation for
the superiority of many clinically approved combination cancer therapies and
changes how such data are interpreted mechanistically. Optimization of indepen-
dent action also provides an alternative means for designing new drug combina-
tions.
#1064 STAT3 NH2-terminal domain inhibition sensitizes medulloblas-
toma cells to chemotherapy. Sutapa Ray,1 Don W. Coulter,1 Shawn D. Gray,2
Jason A. Sughroue,2 Nagendra K. Chaturvedi,3 Shantaram S. Joshi,3 Kishor K.
Bhakat,3 Timothy R. McGuire,2 John G. Sharp3. 1Pediatrics, University of Ne-
braskaMedical Center, Omaha, NE; 2Pharmacy Practice, University of Nebraska
Medical Center, Omaha, NE; 3Genetics, Cell Biology and Anatomy, University of
Nebraska Medical Center, Omaha, NE.
Medulloblastoma (MB) is the most common malignant brain tumor in chil-
dren that arises from cerebellar neuronal progenitor cells. Despite aggressive
treatment involving radiation and chemotherapy, the prognosis for high-risk
MB remains poor and long-term complications from current therapies are com-
mon. Therefore, new effective therapies based on the molecular features of MB
are needed to improve therapeutic outcomes. The STAT3 transcription factor is
known to be constitutively activated in a variety of human cancers, including
MB and functions as an oncoprotein, mediating cancer cell survival, prolifera-
tion, migration and drug-resistance. We have delineated the functional role of
STAT3NH2-Terminal Domain (NTD) inMB by using a cell permeable peptide
derivative of the STAT3 second helix that specifıcally binds and perturbs the
structure/function of STAT3 and interferes with tetramerization of STAT3
dimers, protein-protein interactions and target genes transcription. Herein, we
report that treatment of MB cells with STAT3-NTD inhibitor (S3-NTDi) leads
to growth inhibition, cell cycle arrest and apoptosis. The inhibition of STAT3
signaling was also confırmed by downregulation of its downstream targets, in-
cluding MYC, CCND1, BCl2L1, BCL2, PIM1 and APEX1. Moreover, we ob-
served that S3-NTDi exposure attenuated themigration ofMB cells in a wound-
healing assay, a prerequisite for tumor invasion and metastasis. We also found
that S3-NTDi abrogated IL-6 induced epithelial-mesenchymal transition
(EMT) marker protein expression and inhibition of EMT-related transcription
factors SNAIL and TWIST. Most importantly, we observed that combination
therapywith S3-NTDi and cisplatin signifıcantly decreased the highly aggressive
MYC-drivenMB cell growth in a dose dependent manner and induced apopto-
sis by downregulating STAT3 regulated anti-proliferative and anti-apoptotic
gene expression. To elucidate themechanisms of S3-NTDimediated inhibition,
we showed that S3-NTDi upregulated expression of pro-apoptotic gene C/EBP-
homologous protein (CHOP) and concomitantly decreased association of the
STAT3 transcription factor to endogenous proximal promoter of CCND1 and
BCL2 in chromatin immunoprecipitation assay. Furthermore, we determined
that S3-NTDimediated downregulation ofmiRNA-21 inMB cells, de-repressed
Protein Inhibitor of Activated STAT3 (PIAS3), a negative regulator of STAT3
which, in turn, attenuated STAT3 signaling pathway. Overall, our results re-
vealed an important role of STAT3NTD and its downstream effector molecules
in regulating MB pathogenesis and disruption of this pathway with S3-NTDi
may serves as a promising new candidate for therapeutic interventions in MB
therapy, thereby improving the outcomesin high-risk pediatric MB patients.
#1065 MMP sensitive liposomes followed by radiotherapy improves tu-
mor control in head andneck cancermicemodels.Rikke Y. Brogaard,1 Allison
Khoo,2 Rasmus Eliasen,1 Fredrik Melander,1 Awalpreet Chadha,2 Kathryn
Aziz,2 Sunil Krishnan,2 Thomas L. Andresen1. 1Technical University of Den-
mark, Kongens Lyngby, Denmark; 2MD Anderson Cancer Center, Houston, TX.
Many cancers at advanced stages require a combination of chemotherapy and
radiotherapy. A big challenge with this approach is accumulated toxicity because
both of these treatment modalities are non-selective and inevitably damage non-
target tissues. Nanoparticles such as liposomes provide the ability to differentiate
between healthy and cancerous tissues and thus offer effıcient delivery of chemo-
therapy to cancerous tissues. Recently, we developed a matrix metalloproteinase
(MMP)-sensitive liposomal platform to carry anticancer agents to the tumor. High
local expression of MMPs within the tumor microenvironment ensures bioavail-
ability of the carried agent by converting a polyethylene glycol (PEG)ylated anionic
liposome into a dePEGylated cationic liposome that is readily internalized by cells.
Using oxaliplatin-loaded MMP-sensitive liposomes, we previously demonstrated
great in-vivoeffıcacy inmicebearingCT26 tumors. In thepresent study,weassessed
the combinatorial effect ofMMP-sensitive liposomes and radiotherapy in head and
neck squamous cell carcinoma models. Using a clonogenic cell survival assay, we
evaluatedMMP-sensitive liposomes combined with radiotherapy. A slightly sensi-
tizing effect was produced by oxaliplatin-loaded MMP-sensitive liposomes while
freeoxaliplatinproducedanadditive effect. Similarly, levels of platinumintercalated
into DNA were three times higher in cells treated with oxaliplatin-loaded MMP-
sensitive liposomes than in those treatedwith freeoxaliplatin.The in-vivo effıcacyof
oxaliplatin-loaded MMP-sensitive liposomes combined with radiotherapy was
studied in the same tumor models, FaDu and HN5, where zymogram gels con-
fırmed anMMP-positive tumormicroenvironment.MMP-sensitive liposomes and
radiation had a much greater anti-tumor effect than any of the monotherapies or
free oxaliplatin combined with radiation. In FaDu, the mean tumor size between
liposomes  radiation and liposomes only were signifıcantly different (p0.05).
Thus, our preliminary results suggest that MMP-sensitive liposomes in combina-
tionwith radiationholdagreatpotential for clinical translation.TheMMP-sensitive
liposomeoffers a valuable tool to deliver the payload in a controlled fashion into the
tumor microenvironment, where radiation can potentially amplify the therapeutic
index.
#1066 Imipridone ONC201 effıcacy in refractory multiple myeloma via
Erk1/2 inhibition and pro-apoptotic Bim upregulation: single agent and
combinatorial approaches. Yongsheng Tu,1 Jin He,1 Huan Liu,1 Richard Eric
Davis,1 Robert Z. Orlowski,1 Varun Vijay Prabhu,2 Joshua Allen,2 Jing Yang1.
1The University of TexasM.D. Anderson Cancer Center, Houston, TX; 2Oncoceu-
tics, Inc, Philadelphia, PA.
Disease relapse and drug resistance occurs in the majority of multiple myeloma
(MM)patients despite improvements offered bynew treatments. There is anurgent
unmet need for new therapies that can overcome drug resistance and prolong pa-
tient survival after failure of standard-of-care. ONC201, founding member of the
impridone class of compounds, has robust preclinical effıcacy in a variety of tumor
types.Afırst-in-humanONC201clinical studyhasdemonstratedexceptional safety,
therapeutic pharmacokinetics and evidence of tumor engagement that has led to
several Phase I/II advanced cancer studies. Given the pronounced sensitivity of B-
cell lymphomas toONC201, we assessed the effıcacy ofONC201 inMMpreclinical
models. We treated human MM cell lines and patient-derived cells isolated from
bone marrow aspirates with ONC201 for 72 hours. ONC201 treatment decreased
MM cell viability in CellTiter-Glo assays, with IC50 values that were 1 M to 1.5
M, even in high risk MM cell line RPMI8226. Consistent with prior reports, the
effıcacy of ONC201 was independent of TP53 status, as MM.1S or NCI-H929 cells
with wild-type TP53 and OPM-2 or RPMI8226 with mutated TP53 had a similar
sensitivity towards ONC201. Additionally, ONC201 was equally effective in paired
MM cell lines with TP53 wild type or knockout. Western blot analysis showed in-
creased apoptosis, cleavage of caspase-9, caspase-3, and PARP.We also found that
ONC201 induced expression of the pro-apoptotic protein Bim inMM cells, which
can occur downstream of ERK inactivation. shRNA knockdown of Bim expression
in MM cells abrogated ONC201-induced apoptosis in annexin-V binding assays.
PhosphorylationofBimatSer69byErk1/2hasbeen shown topromoteproteasomal
degradationofBim. In accordancewith thismechanism,weobserved thatONC201
treatment reduced levels of phosphorylated Erk1/2, an indicator of Erk1/2 kinase
activity, anddownregulatedBimpSer69. In addition,ONC201 inducedapoptosis in
dexamethasome-, bortezomib-, and carfılzomib-resistant MM cell lines with the
same effıcacy as in wild-type cells. As a rational strategy to increase the effıcacy of
ONC201 by enhancing its inhibition of proteasome-mediated Bim degradation,
we tested combinations of ONC201 with proteasome inhibitors. Synergistic re-
duction in cell viability and enhanced Bim expression and PARP cleavage was
observed with ONC201 in combination with bortezomib or carfılzomib in MM
cells. The combination of ONC201 and bortezomib enhanced the levels of Bim
and cleaved PARP in MM cells. Overall, these fındings demonstrate that
ONC201 inhibits the Erk1/2 signaling pathway and induces Bim expression to
induce apoptosis in MM regardless of p53 status and resistance to standard-of-
care therapies. Our studies provide a strong rationale for clinical trials of
ONC201 as a single agent or in combination with approved drugs in relapsed/
refractory MM.
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#1067 Anti-cancer effıcacy of imipridones in pancreatic cancer: single
agent ONC212 or combination of ONC201 with IGF1-R inhibition. Avital
Lev, Amriti R. Lulla, Jessica Wagner, David T. Dicker, Wafık S. El-Deiry. Fox
Chase Cancer Ctr., Philadelphia, PA.
Pancreatic cancer is a highly chemo-resistant tumor type known to aggres-
sivelymetastasize at an early stage with an overall fıve-year survival rate of6%.
In this study we tested the effıcacy of ONC201 and ONC212 in a panel of pan-
creatic cancer cell lines andpatient-derivedmodels in vitro and in vivo.ONC201
is the founding member of the imipridone class of small molecules with anti-
proliferative and pro-apoptotic effects in various tumor types. Kline et al. and
Allen et al. previously showed that ONC201 stimulates the integrated stress
response by up-regulating ATF4, CHOP and DR5 followed by induction of
apoptosis by up-regulating TRAIL. While the spectrum of ONC201 effıcacy is
broad among tumor types, pancreatic cancer cells are relatively insensitive.
ONC201 exhibits lowmicromolarGI50 values in 3 out of 7 pancreatic cancer cell
lines and 2 out of 9 patient-derived cells that were most sensitive among the
pancreatic cell lines and samples tested. ONC201 induces the integrated stress
response in bothONC201-sensitive and –insensitive pancreatic cancer cell lines.
Interestingly, ONC201-treated resistant cells arrest in G1 and do not go through
apoptosis. In order to address insensitivity to ONC201 in pancreatic cancer we
explored two approaches. The fırst approach included treatingwith theONC201
analogue ONC212, an imipridone that is currently under pre-clinical develop-
ment. In vitro and in vivo studies consistently show a higher potency ofONC212
as compared toONC201 in pancreatic cancer, especially inONC201-insensitive
models. We are currently investigating the mechanism of action of ONC212 in
comparison to ONC201. The second approach to address ONC201-insensitive
pancreatic cancer was combination treatment with the IGF1-R inhibitor
AG1024. Western blot analysis of receptor tyrosine kinase expression levels in
the panel of pancreatic cancer cell lines revealed a strong correlation between
resistance to ONC201 and high expression of IGF1-R. Therefore we hypothe-
sized that IGF1/IGF1-R might play a role in the resistance of pancreatic cancer
cells to ONC201. Indeed, treatment of resistant pancreatic cancer cells with the
IGF1-R inhibitor AG1024 sensitized the cells to ONC201. We are currently
further exploring the involvement of IGF1-R in the ONC201 resistance mecha-
nism. Furthermore, in-vivo studies are ongoing to validate the effıcacy of the
combination treatment. In summary, although pancreatic cancer is known to be
refractory to many drugs, this study introduces two different approaches with
imipridone small molecules ONC212 and ONC201 that show promising thera-
peutic potential for pancreatic cancer.
#1068 Driver pathway blockage synergizes with PLK1 inhibition in ana-
plastic thyroid cancer. Daniela De Martino, Emrullah Yilmaz, Arturo Orlac-
chio, Antonio Di Cristofano. Albert Einstein College of Medicine, Bronx, New
York, NY.
Anaplastic thyroid cancer (ATC) is one of the most lethal malignancies, with
a median survival of less than 6 months from the time of diagnosis. Molecular
changes that characterize ATChave been recently well defıned and involvemost
often p53mutations, and activation of PI3K, RAS and BRAF. PLK1, an essential
mitotic regulator, has been found overexpressed inATC. Previous data fromour
lab have shown that PLK1 inhibitors are effective in ATC cell lines. However
PLK1 inhibition often results in escape from growth arrest through mitotic
slippage. This leads to the generation of polyploid, genetically unstable, cell
populations. We have tested the effect of combining PLK1 and PI3K inhibitors
in ATC cell lines. Combined treatment with the PLK1 inhibitor BI6727 and the
PI3K inhibitor BKM120 resulted in a signifıcant synergistic effect in ATC cell
lines with high levels of AKT activity, but not in those with undetectable pAKT.
Combination of the two drugs enhanced the G2/M arrest at doses in which the
single drugs showed no effect. In addition, it led to a massive reduction of the
tetraploid cells population. Furthermore, combined treatment with BI6727 and
BKM120 in PI3Khigh cell lines showed a signifıcant induction of apoptosis in a
time- and dose-dependentmanner. Combined inhibition of PI3K andPLK1was
extremely effective in inhibiting tumor growth in vivo, in an immunocompetent
allograft model of ATC. Our results show that combination of PLK1 and PI3K
inhibitors is an effective treatment for ATC cells with high levels of PI3K signal-
ing. This combination results in cell cycle arrest, inhibition of of tetraploid cell
generation, and induction of apoptosis, suggesting a clear therapeutic potential.
#1069 Inhibition of the nuclear import receptor, KpnB1 synergizes with
cisplatin toxicity in cervical cancer cells. Ru-pin Chi,1 Wei Wei,2 Michael
Birrer,2 Virna D. Leaner1. 1Univ. of Cape Town, Cape Town, South Africa; 2Har-
vard University, Cambridge, MA.
Elevated expression of members of the nuclear transport protein family has
been reported in multiple cancers and presents as novel anticancer therapeutic
targets. Using a cervical cancer model system, we have previously shown that
inhibition of the nuclear import receptor, KpnB1 by siRNA and a novel small
molecule, Inhibitor of Nuclear Import (INI-43) resulted in cancer cell death via
apoptosis. In this study, we investigated the cancer cell killing effects of KpnB1
inhibition in combinationwith Cisplatin (CDDP), a fırst-line chemotherapeutic
agent used in the treatment of many cancers. KpnB1 siRNA and INI-43 treat-
ment at sub-lethal concentrations enhanced cancer cells’ sensitivity to CDDP.
Our data shows that the combination treatment of INI-43 and CDDP signifı-
cantly decreases CDDP IC50 compared to CDDP treatment alone. Increased
PARP-cleavage was observed in combination treated cells and this correlated
with increased H2A.X, indicating increased apoptosis and DNA damage. Fur-
thermore, INI-43 treatment reduced the nuclear import of NFB, a stress-reg-
ulated response transcription factor known to be a KpnB1 cargo protein that
promotes cancer cell survival. Decreased levels of downstream pro-survival and
DNA-repair targets of NFB were observed, including cyclinD1, c-Myc and
XIAP, which correlated with increased DNA damage and apoptosis. Taken to-
gether, results suggest increased Cisplatin sensitivity of cervical cancer cells
when nuclear import via KpnB1 is inhibited.
#1070 Role of FOXO1 in response of ovarian carcinoma cells to theXPO1/
CRM1 inhibitor KPT-330/selinexor in combination with cisplatin. Simone
Stucchi,1 Michelandrea De Cesare,1 Cristina Corno,1 Nives Carenini,1 Emilio
Ciusani,2 Nadia Zaffaroni,1 Laura Gatti,1 Paola Perego1. 1Fondazione IRCCS
Istituto Nazionale dei Tumori, Milan, Italy; 2Fondazione IRCCS Istituto Neuro-
logico C. Besta, Milan, Italy.
Ovarian carcinoma is a major cause of cancer-related death in women. Be-
sides late diagnosis, treatment often fails to produce a persistent disease control.
The effıcacy of the platinum drug-based therapy is limited by drug resistance.
Thus, an ideal therapy for women with ovarian carcinoma is still missing. Be-
cause the karyopherin XPO1/CRM1 contributes to the regulation of the cellular
localization of the transcription factor FOXO1 which participates in apoptosis
regulation, the aim of this study was to examine if interference with XPO1 to
improve FOXO1 nuclear localizationmay be exploited to kill effıciently ovarian
carcinoma cells and to improve cisplatin effıcacy. Here, we employed preclinical
pharmacology approaches including growth inhibition assays, western blot
analyses, gene knockdown by siRNA, quantitative Real-time PCR, immunoflu-
orescence analyses and tests in in vivo models. The drug interaction was ana-
lyzed using the Chou and Talalaymethod.When cell sensitivity to KPT-330 of a
panel of ovarian carcinoma cell lines was examined a marked sensitivity to the
XPO1 inhibitor was found. The effect of the combination of cisplatin and KPT-
330 was investigated in the IGROV-1 cells, using simultaneous or sequential
schedules. According to the combination index values, whenKPT-330 exposure
followed cisplatin exposure the most favourable drug interaction was observed.
In IGROV-1 cells, amodulation of proteins involved in apoptosis (p53, Bax) and
in cell cycle progression (p21) was found, besides G1 and G2/M accumulation
after exposure to KPT-330 and to the cisplatin/KPT-330 combination, respec-
tively. KPT-330-treated cells exhibited FOXO1nuclear staining, in keepingwith
the capability of the compound to inhibit FOXO1 nuclear export. Knock-down
experiments by RNA interference indicated that FOXO1-silenced cells dis-
played a reduced sensitivity to KPT-330, but no signifıcant changes in cisplatin
sensitivity. FOXO1 silencing tended to reduce the effıcacy of the drug combina-
tion at selected cisplatin concentrations. An analysis of the antitumor effıcacy of
KPT-330, indicated the capability of KPT-330 to signifıcantly inhibit tumor
growth when IGROV-1 cells were subcutaneously injected in immunodefıcient
mice or growth intraperitoneally. Our fındings support that the XPO1 inhibitor
KPT-330 is a promising agent for the treatment of ovarian carcinoma. The effect
of theKPT-330-cisplatin combination appears to be dependent on the treatment
schedule, as a synergistic interaction occurs when cells are treated with cisplatin
followed by KPT-330. Such an interaction can be modulated by silencing of
FOXO1, which results in reduced sensitivity to KPT-330. Our results suggest
that therapeutic regimens selected on the basis of the molecular tumor features
should be used to achieve a personalized therapy tailored to the specifıc charac-
teristics of each patient.
#1071 Effıcacy of trifluridine/tipiracil anti-mouse PD-1 antibody com-
bination on mouse colorectal cancer model and related tumor immuno-
modulatory effects. Norihiko Suzuki, Hiroshi Tsukihara, Fumio Nakagawa,
Takashi Kobunai, Teiji Takechi. Taiho pharmaceutical CO., LTD., Tokushima,
Japan.
Background: Trifluridine/tipiracil (FTD/TPI) is an oral nucleoside anti-
tumor agent that is composed of trifluridine and tipiracil hydrochloride at a
molecular ratio of 1:0.5. Checkpoint-blockade immunotherapies are partic-
ularly effective in patients with tumor T cell infıltrations. In this study, the
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antitumor effects of FTD/TPI  anti-mouse PD-1 antibody combination
were studied in a syngeneic mouse model and the tumor-infıltrating lym-
phocyte (TIL) subsets were evaluated. Method: The mouse colorectal cancer
cell line CMT-93 was subcutaneously implanted into C57BL/6 mice. Vehicle
(0.5% Hydroxypropyl methylcellulose, 10 mL/kg, p.o.), FTD/TPI (75, 100,
and 150 mg/kg/day, twice daily, days 1-14, p.o.), anti-mouse PD-1 antibody
(clone RMP1-14; 0.1 mg/body; once daily, days 1, 5, and 9; i.p.), and FTD/
TPI  anti-mouse PD-1 antibody combination were administered, and in-
hibitory activity was evaluated according to tumor-volume changes. Single-
cell suspensions were prepared from collected tumors. Based on cell marker
expression, CD4 T cells, CD8T cells, and regulatory T cells (Tregs) were
identifıed using antibodies against CD4, CD8, CD25, and Foxp3, and subsets
of TILs were evaluated by flow cytometry. Results: Both anti-mouse PD-1
antibody and FTD/TPImonotherapies were effective in vivo. Tumor-growth
inhibition by anti-mouse PD-1 antibody was 81.7% at 0.1 mg/kg/day and
that by FTD/TPI was 33.4%, 46.1%, and 59.5% at 75, 100, and 150mg/kg/day,
respectively. FTD/TPI  anti-mouse PD-1 antibody combination using
FTD/TPI (75, 100, and 150 mg/kg/day) with anti-mouse PD-1 antibody (0.1
mg/kg/day) inhibited tumor growth at signifıcantly higher rates (P  0.05;
91.8%, 95.7%, 98.4%, respectively) than monotherapy. Remarkably, the 150-
mg/kg/day FTD/TPI 0.1-mg/kg/day anti-mouse PD-1 antibody combina-
tion caused complete tumor regression in four/fıve mice without body-weight re-
duction or drug-related deaths; however, none of the monotherapies caused
complete tumor regression. Flow cytometric analysis revealed a higher
CD8 T cell percentage among total lymphocytes and a lower Treg percent-
age in CD4 T cells after combination therapy compared with the controls.
Conclusion: FTD/TPI  anti-mouse PD-1 antibody combination was syn-
ergistically effective on CMT-93 mouse colon tumor. This combination in-
creased CD8 T cell percentages in whole lymphocyte and decreased Treg
percentages in CD4 T cell. This suggests that FTD/TPI anti-mouse PD-1
antibody combination modulates tumor T cell populations and improves
their antitumor activity.
#1072 Synergistic effect of gemcitabine and a Dclk1 inhibitor on pancre-
atic cancer cell survival. Daichi Kawamura, Yoshihiro Takemoto, Arata
Nishimoto, Toshiki Tanaka, Yukari Hironaka, Kumiko Yoshida, Junichi Mu-
rakami, Naruji Kugimiya, Eijiro Harada, Koji Ueno, Tohru Hosoyama, Kimi-
kazu Hamano. Yamaguchi University, Ube, Japan.
Pancreatic cancer has the highestmortality rate of allmajor cancers and is one
of themost lethal malignancies. There is a constant upward trend in the number
of patients diagnosed with pancreatic cancer and the number of deaths due to
pancreatic cancer. Gemcitabine (GEM) is often used in the treatment of pancre-
atic cancer (PDAC), but has limited effects. Doublecortin-like kinase 1 (Dclk1)
is important in the progression of early pancreatic neoplastic lesions and PDAC.
However, the functional role of Dclk1 in PDAC is unknown. To identify the
substrate protein phosphorylated by Dclk1, we performed a protein microarray
analysis on Dclk1 knockdown cells. The results of this analysis directed our
studies toward Chk1, which is known to be a potential regulator of the cell cycle
and experiences upregulation of phosphorylation after GEM treatment. In gen-
eral, GEM treatment results in DNA damage to pancreatic cancer cells, an in-
crease in phosphorylated Chk1 (p-Chk1), and arrests the cell cycle progression
to repair the damaged DNA. On the basis of the preliminary data, we hypothe-
sized that the decrease in Chk1 phosphorylation by Dclk1 inhibition circum-
vents cell cycle arrest and impairs the subsequent DNA repair. The aim of this
study was to evaluate the synergistic effect of Dclk1 inhibition and GEM treat-
ment on pancreatic cancer cell survival. We used the human pancreatic cancer
cell line MIA PaCa-2 and LRRK2-IN-1 (LRRK) as the Dclk1 inhibitor for this
study. First, we examined the effects of GEM or the Dclk1 inhibitor or both on
cancer cell proliferation and the expression of p-Chk1. Signifıcantly decreased
cell proliferationwas observed on co-treatment of GEMand LRRK compared to
GEM treatment alone. In addition, the expression of p-Chk1 signifıcantly de-
creased on co-treatment compared to GEM treatment alone. Second, we used
flow cytometry to analyze the cell cycle after treatment with GEM and/or LRRK.
Almost all cancer cells treatedwithGEMalonewere arrested in the S phase of the
cell cycle. The addition of LRRK allows the cell cycle to proceed in the same
manner as untreated control cancer cells do.We also evaluatedDNAdamage by
measuring the intensity of gamma-H2AX. Cancer cells that were co-treated
experienced more DNA damage than with GEM treatment alone. The co-treat-
ment induced apoptosis without the repair of DNA damage in the cancer cells.
In conclusion, the combined treatment with GEM and a Dclk1 inhibitor de-
creased the cell survival rate compared to treatment with GEM alone through
the suppression of p-Chk1. Targeting Dclk1 in combination with GEM might
offer an excellent opportunity for future pancreatic cancer treatments.
#1073 Increased internalization andprocessing of theCD37-targeting an-
tibody-drug conjugate, naratuximab emtansine (IMGN529), in the presence
of rituximab leads to enhanced potency in diffuse large B-cell lymphoma
models. Stuart W. Hicks, Katharine C. Lai, Yong Yi, Prerak Shah, Cristina L.
Gavrilescu, Joe Ponte, Callum M. Sloss, Angela Romanelli. Immunogen, Inc.,
Waltham, MA.
Naratuximab emtansine (IMGN529) is an investigationalCD37-targeting an-
tibody-drug conjugate (ADC) that has shown both preclinical and clinical ac-
tivity in DLBCL. We have shown that rituximab, an anti-CD20 monoclonal
antibody, enhances the preclinical activity of IMGN529. The combination of
IMGN529 and rituximab is more active than either agent alone, and this benefıt
is associated with an increase in apoptosis and cell death, resulting in enhanced
potency in DLBCL models. Effıcacy of ADCs, such as IMGN529, relies on the
internalization, intracellular traffıcking and degradation of the ADC leading to
the release of the cytotoxic catabolite. To explore themechanism underlying the
enhanced activity of the combination, we investigated the effect of rituximab
treatment on the binding, internalization and processing of IMGN529 in vitro.
To evaluate the effect on the internalization of IMGN529, DLBCL cell lines were
incubated with fluorescently-labeled K7153A antibody (the CD37 targeting
moiety of IMGN529) alone or in combinationwith rituximab or a non-targeting
control antibody. K7153A internalization was similar whether incubated alone
or with the non-targeting control. However, when cells were co-incubated with
K7153A and rituximab, the internalization of K7153A signifıcantly increased.
This increase was also observed with other anti-CD20 antibodies suggesting an
anti-CD20 class effect. Radiolabeled processing studies were performed to de-
termine if the observed increase in internalization led to a corresponding in-
crease in antibody degradation, which is required for the release of the cytotoxic
agent in IMGN529. By trace-labeling the K7153A antibody with tritiated propi-
onate (3H-K7153A), we were able to follow binding, uptake, and degradation of
the antibody component of IMGN529 in DLBCL cell lines. Following pulse
exposure, the amount of 3H-K7153Adegraded after 24 hours remained the same
whether treated alone or in combination with other B-cell targeting antibodies.
However, when combined with rituximab the percentage of degraded 3H-
K7153A increased as much as 3-fold and a similar increase of 3H catabolite was
generated. When compared, the combination of K7153A and rituximab pro-
duced considerably more catabolite (6-fold, p-value0.0001) than the com-
bination of rituximab and a CD19-targeting antibody. These fındings suggest a
novel mechanism where the increased potency of IMGN529 and rituximab can
be explained by CD20 binding resulting in an increase in internalization and
degradation of IMGN529, leading to generation of greater amounts of cytotoxic
agent. Overall, these data provide a biological rationale for the enhanced activity
of the rituximab plus IMGN529 combination, further supporting the clinical
development strategy of this combination in DLBCL.
#1074 Combining forces: Synergy of erlotinib and crizotinib in a wild-
type squamous non-small cell lung cancer cell line. Nele Van Der Steen,1
Christian Rolfo,2 Patrick Pauwels,2 Godefridus J. Peters,1 Elisa Giovannetti1.
1VU University Medical Center, Amsterdam, Netherlands; 2Antwerp University
Hospital, Antwerp, Belgium.
Oncogenic drivers are often overexpressed in adenocarcinoma non-small cell
lung cancer (NSCLC) patients, so this tumor type is often sensitive to targeted
therapies. Sensitizingmutations in the epidermal growth factor receptor (EGFR)
are good predictive biomarkers for response to EGFR-smallmolecule inhibitors,
eg erlotinib. Amplifıcation or exon 14 skipping of cMET are good biomarkers
for cMET-small molecule inhibitors, eg crizotinib. In other subtypes of NSCLC,
eg squamous, targeted therapy is not considered to be active. We tested the
combination of erlotinib and crizotinib on a panel of squamousNSCLCcell lines
that were wild-type for both EGFR and cMET. The effect of this drug combina-
tion was tested with different assays. The sulforhodamine B-assay was used to
determine growth inhibition and combination indexes (CI)were calculatedwith
the method of Chou&Talalay. A CI 0.8 was synergistic, 0.8CI1.2 was ad-
ditive and CI1.2 was antagonistic. With flow cytometry the cell cycle was
studied. With the wound-healing assay we determined the effect on cell migra-
tion. A 3D spheroid assay was performed to determine the effect of limited
nutrient availability and hypoxia. Protein phosphorylation was studied with a
pathscan array andphospho-specifıcwestern blotting. TheLUDLUcell line gave
a synergistic CI of 0.39	0.07, whereas the Calu1 (CI 0.81	0.04), H520 (CI
0.87	0.06) and SKMES1 (CI  0.81	0.02) were additive and the H1703 cell
line (CI  1.20	0.15) was antagonistic. Cell cycle analysis revealed that erlo-
tinib monotherapy caused a G1 phase arrest (38 to 76%) and crizotinib caused a
G2/M (13 to 64%) phase arrest. In cells treated with the combination, the effect
of crizotinib was dominant (13 to 52%). In the wound-healing assay the LUDLU
cells were not migratory. The pathscan revealed a decrease in the phosphoryla-
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tion of pERK1/2 (Thr202/204), pPRAS40 (Thr246) and pGSK3 (Ser9). West-
ern blotting showed that the levels of pPRAS40 were decreased in the LUDLU
cells after treatment with erlotinib or crizotinib, and almost gone when treated
with the combination. In the SKMES1 cells only the combination decreased
pPRAS40. H1703 cells showed no change in pPRAS40. These changes in phos-
phorylation make us hypothesize that Her3 and PI3K/Akt signaling may be
important in the interaction of both drugs. Her3 is a promiscuous receptor that
is able to heterodimerize with EGFR and cMET. When blocking one of these
receptors, Her3 is still able to continue downstream PI3K/Akt signaling. When
both EGFR and cMET are blocked, Her3 and PI3K/Akt signaling is inhibited,
leading to synergy. The expression of total-Her3 was lowest in the antagonistic
cell line. The combination of both inhibitors lead to a complete inhibition of
pHer3 (Tyr1289). In conclusion: Blocking both EGFR and cMET signaling
causes inhibition of Her3 downstream signaling through PI3K/Akt, leading to
synergy in wild-type squamous NSCLC cells.
#1075 JQ1 induces DNA damage, inhibits expression of DNA repair pro-
teins, and synergizes with PARP inhibitors in pancreatic cancer cells.Aubrey
Lynn Miller,1 Tracy Gamblin,1 Leona Council,1 Robert van Waardenburg,1
Eddy Yang,1 James Bradner,2 Karina Yoon1. 1Univ. of Alabama at Birmingham,
Birmingham, AL; 2Novartis Institutes for Biomedical Research, Cambridge, MA.
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pan-
creatic cancer. PDAC is a highly aggressive tumorwith a 5-year survival of6%.
Surgery remains the only curative treatment for PDACpatients, but only 20% of
newly diagnosed patients have resectable disease. The remaining 80% present
with locally advanced or metastatic disease, and receive systemic chemotherapy
with gemcitabine. Themedian survival of this patient population is6months.
Development of more effective therapy for this chemorefractory disease is im-
perative. The goal of the current study was to develop effective combination
therapy for PDAC by identifying agents that might be combined with the BET
bromodomain inhibitor JQ1, which we have shown to inhibit the growth in vivo
of PDAC patient derived xenografts (PDX). Expression profıle analysis of tu-
mors from vehicle control and JQ1 treated mice revealed that JQ1 inhibited the
expression of multiple gene products involved in DNA repair. Notably, JQ1
inhibited expression ofDNAdouble-strand break (DSB) repair proteins BRCA2
and Ku80. Immunohistochemical staining confırmed down-regulation of ex-
pression of both proteins in tumors of mice treated with JQ1. Further, immu-
noblot and immunofluorescence analyses demonstrated that decreased expres-
sion of BRCA2 and Ku80 was coincident with increased levels of DNA damage,
as reflected by expression of the DNA DSB marker gamma-H2AX. Data gener-
ated in vivo in three independent PDX models corroborated in vitro data gen-
erated using pancreatic cancer cell lines BxPC3 and Panc1. The data suggest that
JQ1 induces DNA damage by inhibiting DNA repair. Because DNA repair de-
fıciency sensitizes cells to PARP inhibitors, we hypothesized that JQ1-induced
DNA repair defıciency would sensitize PDAC cells to PARP inhibitors. To ad-
dress this hypothesis, we exposed Panc1 and BxPC3 to JQ1 or to a PARP 1/2
inhibitor (veliparib or olaparib) or to the combinations, and assessed the effıcacy
of each. Growth inhibition data, analyzed using Compusyn software and re-
ported as combination indices, demonstrated that the combinations of JQ1 
veliparib or olaparib exert synergistic cytotoxicity. Further, the combination of
JQ1  a PARP inhibitor increased the accumulation of DNA damage in vitro,
compared to either agent alone. We conclude that JQ1 induces DNA damage
due at least in part to DNA repair defıciency, and propose that this mechanism
sensitizes PDAC cells to PARP inhibitors.
#1076 Potent antitumor activity of artemisinin.Mounir Tilaoui. Faculty of
Science and Technology Beni-Mellal, Béni Mellal, Morocco.
Cancer is a leading cause of death worldwide and remains a therapeutic
enigma. Phytochemical compounds are emerging as a new generation of anti-
cancer agents with limited toxicity in cancer patients. The purpose of this study
was to investigate the potential impact of artemisinin, the main active com-
pound of the Chinese herb Artemisia annua L, on survival cancer cells and
tumor growth in vivo. Exposure of tumor cells P815 (murinemastocytoma) and
BSR (kidney adenocarcinoma of hamster) to increasing artemisinin concentra-
tions resulted in a signifıcant inhibition of viability, as revealed by the respective
IC50 values (12 M for P815 and 52 M for BSR cells). Interestingly, no cyto-
toxic effect was observed of artemisinin on peripheral blood mononuclear cells.
The in vitro cytotoxicity studies were complemented by the determination of
apoptotic DNA fragmentation and Annexin V- Streptavidin-FITC assay. Our
results provide evidence that artemisinin leading to apoptotic pathway on P815
but not on BSR cancer cell lines. Moreover, we demonstrate that artemisinin
synergizes with microtubule - damaging agent vincristine to inhibit cellular
viability. The in vivo anticancer activity of artemisinin was also evaluated using
the DBA2/P815 (H2d) mouse model inoculated with the P815 mastocytoma
cells. Our in vivo data clearly showed that the oral administration of artemisinin
inhibited solid tumor development. In view of the available experimental fınd-
ings, we contend that artemisinin could have clinical potential as an anticancer
drug alone or in combination with chemotherapeutic agents such as vincristine.
#1077 Extra-virgin olive oil Met inhibitor oleocanthal-lapatinib: a novel
synergistic combination for HER2-dependent breast malignancies. Abu Ba-
kar Siddique, Hassan Y. Ebrahim, Mohamed R. Akl, Mohamed M. Mohyeldin,
Khalid A. El Sayed. Univ. of Louisiana College of Pharmacy, Monroe, LA.
Breast cancer (BC) is themost commonly diagnosed cancer in women, claim-
ing the lives of hundreds of thousands of women each year. The Mediterranean
diet is known to reduce BC and colon cancer incidence. Extravirgin olive oil
(EVOO) represents a main ingredient in this diet. The EVOOderived
()oleocanthal was shown to target the Receptor tyrosine kinases (RTK) cMet.
Oleocanthal exerted potent invivo effıcacy in an orthotopic athymic nude
mouse breast cancer xenograft model much greater than its modest invitro
potency. Dysregulation of RTKs, specifıcally EGFR/HER2 pathways, correlates
with poor prognosis and more aggressive breast cancer phenotypes. Dysregula-
tion of hepatocyte growth factor (HGF) and its receptor c Met correlates with
aggressive proliferation, invasive character, and pathological motility. cMet
amplifıcation correlates with escape from the anticancer effects of EGFR/HER2
inhibitors and cetuximab. ()Oleocanthal (OC) is a naturally occurring pheno-
lic secoiridoid from EVOO showed signifıcant in vivo activity against invasive
breast cancers through targeting HGF/Met axis. The Dual EGFR/HER2 inhib-
itor lapatinib (LP) has already been in clinical practice for HER2amplifıed
breast cancer, which occasionally develops resistance through cMet upregula-
tion. Lapatinib’s therapeutic dose induced signifıcant hepatotoxicity. The com-
bined use of OC and LP was hypothesized not only for therapeutic synergy but
also to notably reduce LP’s effective doses and thereforeminimize its hepatotox-
icity. Combined treatment of subeffective doses of lapatinib and OC caused
signifıcant in vitro and in vivo synergistic antiproliferative effects against the
HER2dependent BT474 and SKBR3 BC cells. Interestingly, OC induced
4fold lapatinib dose reduction index with improved potency. Protein microar-
ray andWestern blot analyses of OCLP combination treatments synergistically
reduced EGFR, HER2, FAK, JAK1, MEK, and cMet activation. These results
proposeOCuse as dietary supplement to synergize the chemotherapeutic effects
of LP, reduce its therapeutic dose to¼ and therefore canminimize itsmorbidity.
Combinatorial inhibition of cMetHER2EGFR is an effective strategy for the
control of HER2 positive breast cancer. This study was supported by NIH/NCI
project 1R15CA16747501.
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#1078 Dinaciclib overcomes resistance to BKM120 in triple negative
breast cancer patient-derived xenograftmodels. SandeepRajput, FangGuo, Li
Shun, Cynthia Ma.Washington University St. Louis, St. Louis, MO.
Purpose: Triple negative breast cancer (TNBC) is one of the most lethal sub-
types of breast cancer with limited therapeutic options. Development of molec-
ularly targeted agents for TNBC is an unmet clinical need. The phosphoinositide
3-kinase (PI3K) pathway, which is a major cell growth and survival pathway, is
frequently activated in TNBC as a result of genetic aberrations such as loss of the
negative regulator PTEN or gain of functionmutations in PIK3CA, therefore an
attractive therapeutic target. However, single agent PI3K inhibitors have shown
limited anti-tumor activity in both preclinical models and in clinical trials. One
of the most important mechanisms of resistance to PI3K inhibitor is amplifıca-
tion ofMyc.Dinaciclib, a potent inhibitor of cyclin-dependent kinases (CDKs)1,
2, 5 and 9, has shown to be particularly effective in Myc dependent tumors in
preclinical studies and in TNBC. We therefore hypothesized that dinaciclib
could overcome tumor cell resistance to PI3K inhibitors and improve the ther-
apeutic effıcacy in TNBC. In this study, we evaluated the anti-tumor andmolec-
ular effect of dinaciclib and BKM120 (Pan-PI3K inhibitor), either alone or in
combination, in a panel of patient derived xenograft (PDX) models of TNBC.
Methods: Four TNBC PDXs models were selected for the study for in-vivo and
ex-vivo response to vehicle, BKM120, dinaciclib, or the combination of BKM120
and dinaciclib. Tumor volume changes over time in each group were docu-
mented to calculate the percentage of tumor growth inhibition by either agent
alone or in combination. Tumor tissues harvested post treatment were exam-
ined by immunohistochemistry for cleaved PARP to determine the extent of
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apoptosis and phospho-Histone H3 for G2 to M phase cell cycle progression.
Western blot analysis and reverse protein phase array (RPPA) were also per-
formed to determine treatment effect on PI3K downstream targets and cell cycle
molecules. Results: The combination of BKM120 and dinaciclib induced signif-
icantly greater growth inhibitory effect on tumor growth than either single agent
alone in TNBC PDX models. This is accompanied by an enhanced apoptotic
induction and reduced cell cycle progression. In addition, the combination of
dinaciclib and BKM120 signifıcantly reduced the level of cyclin B and the key
anti-apoptotic protein survivin as well as signifıcant downregulation of pAKT,
and pS6. Conclusions: These data suggest that dinaciclib and BKM120 combi-
nation is an effective approach in treating TNBC. Additional mechanistic inves-
tigation for the effıcacy of this combination is underway.
#1079 Preclinical activity of the FGFRinhibitor BAY 1163877 alone or in
combinationwith antihormonal therapy inbreast cancer.Oliver Politz,1 Peter
Ellinghaus,2 Sebastian Bender,2 Sylvia Gruenewald,1 Franziska Siegel,1 Marie-
Pierre Collin,2 Sabine Zitzmann-Kolbe,1 Dominik Mumberg,1 Karl Ziegel-
bauer1. 1Bayer AG, Berlin, Germany; 2Bayer AG, Wuppertal, Germany.
BAY 1163877 is an orally available, highly potent and selective pan fıbroblast
growth factor receptor (FGFR) inhibitor. In an ongoing Phase 1 clinical trial
(NCT01976741) BAY 1163877 showed clinical responses at exceptional tolera-
bility in patients suffering from different tumor types including urothelial blad-
der carcinoma or lung tumors, which were selected based on elevated FGFR1-3
mRNA expression. In the preclinical phase, the compound demonstrated sig-
nifıcant single agent anti-tumor activity in various tumor models with different
FGFR alterations leading to FGFR overexpression (e.g. FGFR gene amplifıca-
tions or mutations). Genetic alterations of FGFRs can also be found in breast
cancer with 7.5 - 17% of all tumors harboring a FGFR1 gene amplifıcation.
Elevated FGFR1 mRNA levels can be found in up to 22% of breast cancer cell
lines as well as clinical samples. Other FGFR alterations include FGFR2 or
FGFR4 gene amplifıcations as well as elevated FGFR mRNA levels, which were
reported in all breast cancer subtypes. We therefore investigated BAY1163877
monotherapy in various breast cancer models. Due to the favorable clinical
safety profıle of BAY1163877, we also examined a combination treatment with
early line antihormonal therapies in hormone receptor positive breast cancer. In
vitro profıling of BAY 1163877 in a number of breast cancer cell lines showed a
clear association of effıcacy with expression levels of different FGFR isoforms.
The effıcacy was further investigated in several patient- or cell line-derived
breast cancer in vivo models. For instance, BAY 1163877 alone dosed 38mg/kg
twice daily induced tumor growth inhibition of greater than 90% in a subcuta-
neous mouse syngeneic 4T1 breast cancer model expressing elevated levels of
FGFR2. Resistance to endocrine therapy appears associated with FGFR1 gene
amplifıcation and may explain the poor prognosis of FGFR1 overexpressing
tumors treated with adjuvant tamoxifen. We therefore investigated the combi-
nation of the panFGFR-inhibitor BAY 1163877 with the clinically used antihor-
monal compound fulvestrant in selected luminal breast cancer PDX models.
Some of these models showed resistance to antihormonal treatment in mono-
therapy but improved in vivo effıcacy in combined treatment using BAY
1163877 and fulvestrant. These data may warrant further clinical investigation
of BAY1163877alone or in combination with antihormonal therapy in patients
with FGFR overexpressing breast cancer.
#1080 Targeting the PI3K-Akt and NF-B pathways as a combination
therapy in blocking prostate cancer progression.Eswar Shankar,1 RajneeKan-
wal,1 Aditi Goel,1 Xiaoping Yang,2 Sanjeev Shukla,1 Gregory T. MacLennan,1
Pingfu Fu,1 Anant Madabhushi,1 Parameswaran Ramakrishnan,1 Sanjay
Gupta1. 1Case Western Reserve Univ., Cleveland, OH; 2VA Medical Center,
Cleveland, OH.
Akt/protein kinase B and transcription factor NF-KB are important signaling
molecules and key survival factors involved in the control of cell proliferation,
apoptosis and oncogenesis. Although Akt and NF-KB are components of sepa-
rate signaling pathways, Akt can induce cell survival signal through NF-B ac-
tivation. Previous studies from our laboratory have shown constitutive activa-
tion of NF-KB/p65 and PI3K-Akt in clinical prostate cancer specimens and in
autochthonous mouse model of prostate cancer. In this study we investigated if
these two signaling pathways converge and whether dual targeting is effective in
blocking disease progression. Using tissue samples obtained during transure-
thral prostatic resection and paraffın-embedded sections of benign and malig-
nant prostate tissue, we fırst analyzed nuclear levels of NF-KB/p65, native/acti-
vated Akt levels, and evaluated co-localization of these two proteins. Compared
to benign tissue, cancer specimens exhibited constitutive Akt and NF-KB/p65
activation which was more pronounced in high-grade cancer (Gleason grade
7-10). Immunohistochemical analyses further confırmed a progressive increase
in the activated form of Akt and NF-KB/p65 in the nucleus of cancer tissues
compared to benign specimens, and exhibited co-localization of these proteins
in a subset of aggressive cancer. Utilizing androgen-responsive prostate cancer
LNCaP cells, with increased Akt activity, and androgen-refractory PC-3 cells
harboring high levels of Akt and NF-KB. Individual treatment of cells with Akt
Inhibitor VIII (0.075-1.8M) and NF-KB inhibitor Parthenolide (0.32-60M)
for 24-72 h demonstrated partial suppressive effect in cell growth. Strikingly,
concurrent blocking of Akt and NF-B/p65 at 1:10 molar ratio resulted in po-
tentiated toxicity with marked inhibition in proliferation and induction of cell
cycle arrest. Interruption of Akt activation using dominant-negative approach
resulted in signifıcant inhibition in Akt-phosphorylation (Ser473) and induc-
tion of apoptosis in LNCaP cells, whereas ectopic expression of NF-B/p65
increased doubling time and invasiveness in these cells, which was abrogated by
combinational treatment. Furthermore, combination treatment decreased the
expression of p-IKK (Ser176/180), p-NF-B/p65 (Ser536), and p-Akt (Ser473)
and downstream targets viz. cyclin D1, Bcl-2, VEGF and MMP9 in both cell
lines. In vivo administration of Inhibitor VIII and Parthenolide at 1:10 ratio to
PC-3 tumor xenograft for 8 weeks resulted inmarked decrease in tumor volume
and reduced expression of target genes, compared to individual treatments.
These results suggest that nuclear co-localization of Akt andNF-KB/p65may be
developed as prognostic biomarker and concurrent targeting of these molecules
by combination of pharmacological inhibitors is an effective approach and is
more effıcacious than use of single agent blocking prostate cancer progression.
#1081 APC regulation of breast cancer therapeutic resistance. Anne Ar-
nason,1 Monica VanKlompenberg,2 Jenifer R. Prosperi2. 1University of Notre
Dame, Notre Dame, IN; 2Indiana Univ. School of Medicine-South Bend, South
Bend, IN.
Resistance to chemotherapy is one of the leading causes of death from breast
cancer. Our lab discovered that Adenomatous Polyposis Coli (APC) loss in
breast cancer cells results in an elevation of tumor-initiating cells (TICs) and
resistance to chemotherapy-induced apoptosis. Given that TICs are often most
resistant to standard chemotherapeutic compounds, we sought to understand
the mechanism responsible for APC-mediated TIC enhancement. Our hypoth-
esis is that the molecular mechanism involved in chemotherapeutic resistance
parallels that promoting the TICs. APC-mutant cells have amplifıed activation
of signal transducer and activator of transcription 3 (STAT3). Interestingly,
inhibition of STAT3 with a small molecule inhibitor A69 decreases the TIC
population and restores drug sensitivity. Studies are ongoing in the laboratory to
investigate other molecular signaling pathways involved in APC-mediated en-
hanced TIC population and therapy resistance. These data have begun to reveal
the molecular mechanisms of APC loss in breast cancer that can guide future
treatment plans to counteract chemotherapeutic resistance.
#1082 MerTK promotes resistance to irreversible EGFR TKIs by activa-
tion of the PI3K-AKT pathway in NSCLCs expressing wild-type EGFR. Dan
Yan,1 Xiaodong Wang,2 Stephen V. Frye,2 Shelton H. Earp,3 Deborah DeRyck-
ere,1 Douglas K. Graham1. 1Aflac Cancer and Blood Disorders Center, Atlanta,
GA; 2Center for Integrative Chemical Biology and Drug Discovery, Chapel Hill,
NC; 3UNC Lingerger Comprehensive Cancer Center, Chapel Hill, NC.
Lung cancer is the leading cause of cancer-related death with poor survival
rates worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all
lung cancers and 60% of these have overexpression of wild-type EGFR
(wtEGFR),which portends a poor prognosis. In addition, in a recent clinical trial
6 of 12 lung cancer patients whose tumors acquired a resistance-conferring
T790M EGFR mutation during treatment with an EGFR TKI reverted to
wtEGFR after treatment with Rociletinib/CO-1686, an irreversible EGFR TKI
that is selective for the T790M mutant. These data suggest that targeting
wtEGFR may improve treatment outcomes; however, to date single agents that
target wtEGFR have not been effective in large scale clinical trials and new ways
to target wtEGFR in this context are needed. Our laboratory previously identi-
fıed the MerTK receptor tyrosine kinase as a potential therapeutic target in
NSCLC and developed MRX-2843 as a novel MerTK-selective small molecule
tyrosine kinase inhibitor with favorable properties for clinical translation. Irre-
spective of driver oncogene status, treatment with a MerTK inhibitor yields
potent anti-tumor effects in NSCLC cell culture models and blocks tumor
growth in xenografts of the MerTK-dependent wtEGFR-expressing A549 cell
line. In an attempt tomore potently blockA549 lung cancer cell proliferation,we
screened a library of 378 kinase inhibitors that are in various stages of develop-
ment and identifıed synergy betweenMRX-2843 andmultiple irreversible EGFR
TKIs, including CO-1686 and Osimertinib/AZD-9291. Further, we found that
wtEGFR andMerTKwere frequently co-expressed and co-immunoprecipitated
with each other in NSCLC cancer cell lysates. Synergistic inhibition of cell ex-
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pansion was observed in a spectrum of NSCLC cell lines with wtEGFR expres-
sion treated with the combination therapy, including H1299 (NRASmutation),
H157 (KRASmutation),H3122 (ALK fusion), andColo699 (FGFR1overexpres-
sion). On a mechanistic level, combined treatment with 1MCO-1686 and 100
nM MRX-2843 dramatically inhibited phosphorylation of both MerTK and
EGFR and downstream signaling through the PI3K-AKT and MAPK-ERK
pathways, while treatment with equivalent doses of either single agent did not
effıciently inhibit MerTK, EGFR or downstream signaling. Additionally, CO-
1686 mediated synergistic inhibition of A549 expansion in combination with a
PI3K or AKT inhibitor, suggesting a role for PI3K-AKT activation downstream
of MerTK contributing to the resistance of wtEGFR NSCLCs to irreversible
EGFR TKIs. Taken together, our data provide rationale for a novel strategy for
treatment of NSCLC with wtEGFR overexpression by combining MRX-2843
and an irreversible EGFR inhibitor.
#1083 Synergistic drug combination prediction through drug differential
dependency network analysis. Seungchan Kim, Gil Speyer, Harshil Dhruv, Jeff
Kiefer,Michael Berens.The Translational Genomics Research Institute, Phoenix,
AZ.
In an effort to discover strategies which identify effective drug combinations,
we analyzed 39 of the 480 compounds screened in the Cancer Therapeutics
Response Portal (CTRP) where combinations of two compounds were tested
against 860 cancer cell lines; this enabled a comparison of the drug sensitivity of
the combinations versus that of the individual compounds.More than half of the
drug combinations (n21) did not signifıcantly improve the drug sensitivity,
compared to individual compounds alone. In fact, some of the combinations
showed reduced drug sensitivity. In EDDY-CTRP* analysis, the Cancer Cell
Line Encyclopedia (CCLE) RNAseq data and CTRP compound response mea-
surementswere analyzed to discover both 1) pathways enrichedwith differential
dependencies between sensitive and non-sensitive cell lines for each compound
and 2) the mediators of cell line response to a drug. A mediator is a gene in a
pathway that plays a signifıcantly different role between sensitive and non-sen-
sitive conditions. The signifıcance is assessed for either essentiality, measured as
a node’s centrality change, or specifıcity,measured as the difference in condition
specifıc edges. These drug-pathway-mediator connections are predicted to re-
veal crucialmolecular determinants of drug sensitivity that otherwise are hidden
in the complexities of the molecular networks of the cell (Speyer et al., PSB
22:497-508, 2017). We further investigated whether mediators identifıed for
single compounds could predict sensitivity to drug combinations. This analysis
revealed that if two single compounds share the same specifıcity mediators, i.e.
the genes with the most signifıcant re-wiring of gene dependencies between
sensitive and non-sensitive cell lines, combination of these two compounds
correlate with improved sensitivity. The converse was also found: compounds
that do not share mediators rarely show synergy. Further analysis and empirical
testing of predicted combinations promises to prioritize synergistic drug com-
binations. We believe that this methodology may predict synergistic drug com-
binations from cancer cell line drug screening data. Supported by NIH
U01CA168397. *available at http://biocomputing.tgen.org/software/EDDY/
CTRP
#1084 Combination of eribulin and AURKA inhibitor prevents meta-
static colonization and eradicates established metastases in breast cancer.
Elena N. Pugacheva, Varvara Kozyreva, Anna Kiseleva, Ryan Ice, Brandon
Jones, Yuriy Loskutov.WVU Cancer Institute, Morgantown, WV.
The majority of cancer-related deaths (90%) are happened due to metastasis
from the primary tumor site to distant organs. MLN8237 is a small, highly
selective molecule inhibitor of Aurora A kinase (AURKA), which results in
disruption of the mitotic spindle, chromosome segregation collapse, and inhi-
bition of cell proliferation.Numerous studies have showed that levels ofAURKA
are elevated in many types of cancer, including breast cancer. Our previous
studies indicated that MLN8237 is extremely potent against pulmonary metas-
tasis, but not the primary tumor in orthotropic xenograft model. To further
enhance MLN8237 based regiment, its combination with other therapeutic
compounds can be used.As a potential partnerwe chose eribulin - fully synthetic
macrocyclic analogue of the marine natural product halichondrin B. Eribulin
belong to the class of non-taxanemicrotubule destabilizingmolecules, currently
used in clinic to treat taxol resistantmetastatic breast cancer. In present studywe
have investigated the effect of MLN8237 and eribulin against breast cancer in
vivo and in vitro. The results showed that combination of drugs possess a syn-
ergistic effect on both primary tumor and metastases, through inducing cyto-
toxic autophagy and apoptosis. This data clearly indicate great potential behind
the MLN8237 based therapies and introduce a new hope for the eradication of
metastatic breast cancer.
#1085 Time dependent analysis for the combination of standardized An-
nona cherimola and Solanum nigrum extracts with 5-FU against head and
neck cancer cells. Serag Eldin I. Elbehairi,1 Aly F. Mohamed,1 Nahla G. Mo-
hamed,1 Mohammad I. Basuony,2 Mahmoud M. Salem,1 Metwally M. Mon-
taser,2 Mohammad Y. Alfaifı,3 Ayman M. Noreddin,4 Ahmed M. Al-Abd5.
1Egyptian Organization for Biological Products and Vaccines (VACSERA), Giza,
Egypt; 2Azhar University, Cairo, Egypt; 3King Khalid University, Abha, Saudi
Arabia; 4Chapman University School of Pharmacy, Irvine, CA; 5National Re-
search Centre of Egypt, Giza, Egypt.
Phytochemicals of natural origin constitutes very initiative fıeld of anticancer
drug discovery. Annona sp. and Solanum nigrum are folk herbs with reported
use for the treatment of several neoplasias. Natural herb products and folkmed-
icine might not be potent anticancer remedies and are recommended for com-
bination therapy. In the current work, we mathematically evaluated the influ-
ence of combining standardized extracts of A. cherimola and S. nigrum to the
cytotoxic profıle of 5-FU against head and neck cancer cells (HEP-2). Cytotox-
icity assessment and combination analysis were calculated after MTT assays
followed by fıtting to Emax model and calculating the combination index (CI-
value). After 24 h exposure, bothA. cherimola and S. nigrum extracts weremore
potent than 5-FU with IC50 of 29.4	4.4, 7.3	1.3 and 3.4	4.4 g/ml, respec-
tively. Both A. cherimola and S. nigrum extracts signifıcantly decreased the IC50
of 5-FU to 5.2	0.55 and 7.6	0.85 g/ml, respectively; however the CI-values
were indicative of additive and antagonistic interactions, respectively (0.91 and
2.49, respectively). After 48 h of exposure, the IC50 of 5-FU, A. cherimola and S.
nigrum extracts were 3.1	0.45, 0.87	0.22 and 7.2	0.65 g/ml, respectively.
Similarly, combination of A. cherimola and S. nigrum extracts with 5-FU
showed additive and antagonistic interaction with CI-values of 1.05 and 3.37,
respectively. After 72 h of exposure, the IC50 of 5-FU, A. cherimola and S. ni-
grum extracts were 1.9	0.1, 2.1	0.24 and 2.1	0.1 g/ml, respectively. Simi-
larly, combination of A. cherimola and S. nigrum extracts with 5-FU showed
additive and antagonistic interactionwithCI-values of 1.2 and 2.21, respectively.
Then, CnTmodel was used to assess the relative influence of drug concentration
and exposure time on the cytotoxic profıle of treatments under investigation.
For S. nigrum and its combination with 5-FU, n-values were 0.9 and 0.63 which
is indicative of relatively high influence of drug concentration. On the other
hand, n-value for 5-FU treatment was 0.37; this indicates higher influence of
drug exposure time compared to other treatment. The n-values of A. cherimola
and its combination with 5-FU were 0.51 and 0.54, respectively; this indicate
comparable influence of both drug concentration and exposure time. As a con-
fırmatory measure, expression of the apoptotic gene, BAX, was increased after
5-FU combination with A. cherimola and decreased after combination with S.
nigrum. In conclusion, some natural herb remedies such as A. cherimola might
influence the cytotoxic profıle of 5-FU and particularly after short exposure
time; while on the other hand, some herb remedies such as S. nigrum signifı-
cantly antagonizes its cytotoxic activity against head and neck cancer cells.
#1086 Vitamin D3 increases the response to cisplatin in bladder cancer
through VDR and TAp73 pathway crosstalk. Brittany L. Bunch,1 Donald
Trump,2 Candace S. Johnson1. 1Roswell Park Cancer Institute, Buffalo, NY;
2Inova Dwight and Martha Cancer Institute, Falls Church, VA.
Neoadjuvant cisplatin-based chemotherapy is used to treat muscle invasive
bladder cancer (MIBC); however the relative 5-year survival of advanced disease
is only 15%. The two major pitfalls of neoadjuvant chemotherapy are delaying
cystectomy in patients with poor response to cisplatin, and the lack of available
biomarkers to identify these patients. Previous studies in our lab showed that
pretreatment of preclinical bladder cancer models with 1,25 dihydroxyvitamin
D3 (1,25D3), the active metabolite of vitamin D3, enhances the apoptotic re-
sponse to cisplatin. Mechanistic understanding can provide insight into poten-
tial markers for response to 1,25D3 and cisplatin combination therapy in pa-
tients. Greater than 50% of MIBCs harbor p53 mutations; however p53 status
has not been linked to clinical response to cisplatin. We previously determined
that TAp73, a pro-apoptotic p53 family member protein induced after DNA
damage, is required for the response to 1,25D3 and cisplatin. In two bladder
cancer cell lineswithmutant p53, T24 andRT-112, we identifıed signaling cross-
talk between the vitamin D receptor (VDR) and TAp73. Treatment with 1,25D3
and cisplatin, compared to either alone, results in greatest increase of TAp73
mRNA and protein, 2-fold (T24) and 15-fold (RT-112), as well as TAp73 tran-
scriptional target BAX, 3-fold (T24), and 4-fold (RT-112). TAp73 and BAX
induction is lost in cells transfected with VDR siRNA, indicating a requirement
for VDR. Cells treated with 1,25D3 and cisplatin, compared to either alone, also
show the greatest increase of VDR mRNA and protein, 3-fold (T24) and 4-fold
(RT-112). CYP24A1, a VDR target gene, has the greatest induction after the
combination treatment as well, with an increase of approx. 60-fold (T24), and
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100-fold (RT-112). CYP24A1 induction requires TAp73, determined using
TAp73 shRNA. These data demonstrate that VDR signaling is enhanced by
cisplatin treatment, and TAp73 signaling is enhanced by 1,25D3. We expanded
these fındings in vivo by treating mice on a vitamin D3 suffıcient diet (1,000 IU)
or a vitamin D3 defıcient diet (25 IU) with 5 mg/kg of cisplatin (IP, q.wk for 3
weeks). Initially, mice on both diets respond to cisplatin treatment, as evidence
by a 30% reduction in tumor volume. After the second cycle of treatment, tu-
mors in the defıcient mice stopped responding and returned to their initial
tumor volume within 24 days. In the suffıcient mice, tumors continued to re-
spond to cisplatin with a maximum reduction of 50%. This was maintained for
approximately 40 days after treatment. Further study will determine the molec-
ular response to confırm our in vitro mechanism. Our work suggests that vita-
minD3 is important in and can increase the response to cisplatin, it also provides
rationale for investigating TAp73 protein levels and serum vitamin D3 levels as
potential markers to determine patients’ likelihood of responding to cisplatin.
#1087 CPX-351 works synergistically in combination with FLT3 inhibi-
tors against AMLwith FLT3-ITD.David K. Edwards,1 Nathalie Javidi-Sharifı,1
Angela Rofelty,1 Max Gordon,1 Riley Roth-Carter,1 Paul Tardi,2 Lawrence
Mayer,2 Jeffrey W. Tyner1. 1Oregon Health & Science University, Portland, OR;
2Jazz Pharmaceuticals, Vancouver, British Columbia, Canada.
Introduction: CPX-351 (Vyxeos) is a liposomal combination of cytarabine
and daunorubicin at a synergistic 5:1 molar ratio. Recently, CPX-351 has been
shown to be signifıcantly more effective than the 73 standard of care chemo-
therapy in treating high-risk AML patients, including patients with the FLT3-
ITDmutation.We previously treated primary patient samples with CPX-351 ex
vivo and found that FLT3-ITD samples were signifıcantly more sensitive to
CPX-351 and showed enhanced drug uptake. We hypothesized that dysregu-
lated FLT3 signaling results in an activation of liposome uptake pathways, lead-
ing to increased sensitivity to CPX-351 and ultimately cell death. Furthermore,
we examined the effect of combining CPX-351 with existing FLT3 inhibitors
(e.g. quizartinib and midostaurin). Methods: To examine drug uptake dynam-
ics, we exposedAML cell lines (includingMOLM-13 andMOLM14 that contain
FLT3-ITD, and ME1 that contains an activating FLT3 mutation) to varying
concentrations of CPX-351, with or without pre-treatment of quizartinib and
midostaurin. We evaluated cell viability using a colorimetric assay and mea-
sured intracellular daunorubicin fluorescence, an indicator of drug uptake, by
flow cytometry. Additionally, we analyzed the synergy of exposing these cell
lines to CPX-351 and FLT3 inhibitors in combination and at different dose
schedules, followed by measuring cell viability and daunorubicin fluorescence.
Results: We observed that cell lines containing FLT3-ITD or FLT3-activating
mutation were more sensitive to CPX-351 and exhibited increased drug uptake
compared to cell lines with other genetic abnormalities. Interestingly, we ob-
served that pre-treatment with quizartinib for 16 hrs produced a population of
cells (approximately 50% of the total population) that exhibited decreased
daunorubicin fluorescence, suggesting that prolonged FLT3 inhibition may de-
crease CPX-351 uptake. Consistent with this, we observed robust synergy when
combining CPX-351 with FLT3 inhibitors simultaneously or with CPX-351 ex-
posure scheduled 24 hours prior to FLT3 inhibitor exposure.However, exposure
to FLT3 inhibitors 24 hours prior to CPX-351 administration was less synergis-
tic and even antagonistic at certain doses. Conclusions: These data provide ad-
ditional supportive evidence that FLT3 activation results in increased uptake of
CPX-351. This is consistent with results from the CPX-351 Phase III trial in
which FLT3-ITD patients survived signifıcantly longer when treated with
CPX-351 compared to 73 chemotherapy.We also show that combining CPX-
351 with existing FLT3 inhibitors can elicit a synergistic response when admin-
istered in dosing regimens where FLT3 inhibition does not precede CPX-351
treatment. Cumulatively, our data support further testing of CPX-351 in com-
bination with FLT3 inhibitors for treating AML patients with genetic dysregu-
lation of FLT3 signaling.
#1088 Metronomic therapy of doxorrubicin and molecular iodine in ca-
ninemammary cancer.Xochitl Zambrano Estrada,1 Brianda Landaverde,2 An-
drés A.Dueñas,2MarcoA.De Paz,2 GerardoA.Hernández,2 Benjamín Solorio,3
Manuel Trejo,3 Laura Pérez,3 Carmen Aceves1. 1Instituto de Neurobiología, Ju-
riquilla, México, Mexico; 2Facultad de Estudios Superiores Cuautitlán, Estado de
México, Mexico; 3Facultad de Ciencias Naturales, Juriquilla, México, Mexico.
Introduction: Conventional chemotherapy is administered at the maximal
tolerated dose (MTD), usually every 21 days, and the drug-free period allows the
patient to recover from the adverse effects secondary to the treatment. However,
this period also enables tumor cells to reinitiate growth through induced tu-
moral revascularization. In recent years, a new strategy known as metronomic
chemotherapy explored the scheme of long-lasting low-dose administration of
antineoplastic drugs, which results in the attenuation or interruption of tumor
growth by inhibition of angiogenesis and/or reactivation of anti-tumoral im-
mune system. Moreover, the use of combination therapies including cell re-
differentiation messengers are currently being tested to provide a better quality
of life. In this sense, it has been demonstrated that the supplement of molecular
iodine (I2) induces apoptotic and cellular re-differentiation effects, and its com-
bination with doxorubicin (DOX) promotes a cytotoxic effect and generates
cardioprotection. In this study, canine mammary cancer is used as a model of
spontaneous carcinogenesis. Objective: Determine the effıcacy of metronomic
therapy of DOX in combination with I2 analyzing the clinical, pathological, and
molecular effects involved in proliferation, invasion, and chemoresistance.
Methods: 27 female dogs with mammary cancer were given daily I2 (10 mg)
supplements or placebo (colored water) in conjunction with four cycles of DOX
(30mg/m2, intravenous). Two protocols were carried out: the standard protocol
with a 21-day interval and 20-minute infusions, and the metronomic protocol
with a 15-day interval and 60-minute infusions (DOX-M). Results: The metro-
nomic scheme (DOX-M) attenuated the severity of side effects, but it showed no
difference in tumor response (size, gene expression). The I2 supplement signif-
icantly improved the quality of life in both schemes, and it exerted synergistic
effects on the tumor response in DOX-M, decreasing the epithelial component
as well as markers of chemoresistance (MDR1 and Survivin) and invasion
(uPA). The antitumor immune response (lymphocytic infıltration) in this
schemewas signifıcantly activated, and all these responses were accompanied by
a major increase in peroxisome proliferator-activated receptor type gamma
(PPARy) expression. Endocrine evaluation showed that I2 supplements do not
alter thyroid function or estrogen response. Conclusions: Combination of
DOX  I2 in a metronomic scheme exerts synergistic effects that prevent
drug resistance and invasion and greatly improve the patient’s quality of life.
Studies are underway to decrease the dose of DOX. Key words: Molecular
Iodine, Doxorubicin, Canine Mammary Cancer, Metronomic Therapy. The
authors appreciate the technical support of Alexander Bontempo, Evange-
lina Delgado and María Juana Cardenas. Investigation supported by PA-
PIIT-UNAM IN200813 and 201516; CONACYT 245255.
#1089 Anti-tumor activity of selinexor is enhanced by palbociclib in pre-
clinical models of HER2 breast cancer. Hua Chang, Sharon Friedlander,
Trinayan Kashyap, Boris Klebanov, Christian Argueta, Oscar A. Gonzalez, Er-
kan Baloglu, Yosef Landesman, Sharon Shacham, Margaret Lee, William Sena-
pedis. Karyopharm Therapeutics, Inc., Newton, MA.
Introduction: XPO1 (exportin-1/CRM1) inhibitor selinexor (KPT-330) is the
fırst-in-class, orally bioavailable, clinical stage SINE (Selective Inhibitor of Nu-
clear Export) compound with marked anti-tumor activity towards solid and
hematologicalmalignancies. This activity can be further enhanced by other ther-
apeutic agents. We have previously shown strong synergistic preclinical activity
of selinexor plus trastuzumab againstHER2 breast cancer. In cancermodels of
acquired resistance to HER2-targeted therapies, G1/S phase cell cycle regulators
Cyclin D1 and CDK4/6 are inappropriately activated.We therefore investigated
the combinatorial effect of selinexor plus palbociclib, a CDK4/6 inhibitor, in
HER2 breast cancer models as a treatment option for recurrent and relapsed
HER2 breast cancers. Methods: The effects of selinexor or palbociclib single
agents or in combination were tested in vitro with BT474 HER2 breast cancer
cell line. Total RNA and protein was extracted from cell lysates and analyzed by
qPCRand immunoblots. In vivo, a subcutaneous BT474 xenograftmousemodel
was treated with selinexor (5 mg/kg or 15 mg/kg; qodx3) or palbociclib (50
mg/kg or 150 mg/kg; qd) single agents or in combination. Tumor growth and
body weights were monitored for 60 days. Tumors were harvested and analyzed
by immunohistochemistry (IHC). Results: Selinexor plus palbociclib was highly
effective in vitro and in vivo in BT474 breast cancer cells. In in vitro assays,
selinexor or palbociclib single agents demonstrated inhibitory effects on cell
proliferation and showed strong synergy when combined. In vivo, the combina-
tion resulted in signifıcant survival benefıt and enhanced tumor growth inhibi-
tion compared to vehicle or either single agent. IHCanalysis of xenograft tumors
showed synergistic inhibition of cell proliferation by selinexor plus palbociclib.
The Ki67 proliferation index determined by IHC was 25% for vehicle control,
20% for selinexor, 7% for palbociclib and 2% for the combination. Based on IHC
analysis, the synergistic anti-tumor activity of selinexor plus palbociclib was
achieved at multiple levels of the CDK4/6 pathway. Selinexor treatment in-
creased p21, p27 and Rb nuclear staining. Both p21 and p27 are inhibitors of
CDK4/6while Rb is a negative regulator of cell cycle progression. CDK4/6 phos-
phorylates and inactivates Rb, which allows cell cycle progression. In selinexor
as well as palbociclib treated samples, phosphorylated Rb in the nucleus de-
creased, indicating a down-regulation of the CDK4/6 pathway. Conclusion: Se-
linexor plus palbociclib shows synergistic inhibition of cell proliferation in vivo
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and in vitro in HER2 breast cancer cell line BT474 by down-regulation of
CDK4/6 pathway. This combination therapy warrants further investigation as
an effective treatment option for recurrent and relapsed HER2 breast cancer.
#1090 Preclinical evaluation of combination therapy with dasatinib and
sorafenib for the treatment of brain metastases. Qingyu Stephanie Zhou,
Xiaofang Guo. Univ. of South Florida College of Pharmacy, Tampa, FL.
Brain metastases, the most common type of intracranial tumors in adults,
carry a dismal prognosis with a median survival of less than 18 months regard-
less of primary status or treatment given. As part of an ongoing project, this
study is concerned with the preclinical evaluation of targeted combination ther-
apy for the treatment of brainmetastases. The cell line used in this study was the
H1915 (ATCC®CRL-5904TM) human lung cancer cell line, whichwas originally
derived from a brain metastasis from primary lung adenocarcinoma. The cell
line was stably transfected with a plasmid that allows expression of fırefly lu-
ciferase (i.e., H1915-luc) so that the tumor growth in a mouse orthotopic model
of brain metastases can be assessed in real time using the Xenogen in vivo bio-
luminescence imaging (BLI). Our previous study has demonstrated that the
synergistic effect of combined dasatinib and sorafenib treatment was cell-line
dependent. In this study, the cytotoxicity of dasatinib and sorafenib, when used
alone or in combination at the fıxed molar ratios of 3:1, 1:1 and 1:3 (dasatinib:
sorafenib), was further examined in H1915-luc cells using the MTT assay. The
results demonstrated that simultaneous and continuous exposure of H1915-luc
cells to dasatinib and sorafenib at the fıxed concentration ratio of 1:1 and 1:3 for
72 h showed synergism (the combination index value between 0.7 and 0.8) at
effect levels of 40 and 80% inhibition of cell viability. For the in vivo study, an
orthotopic mouse model of brain metastases was established by injecting
H1915-luc cells into the right general carotid artery of individual athymic nude
mice followed by permanent ligation. The preliminary study showed that fol-
lowing the intracarotid injection of H1915-luc cells, brain metastases were
formed and readily to be detected by BLI. The obtained whole brain samples
were fıxed in OCT and stored at -80oC. The brain sections are to be subjected to
the immunofluorescence double staining of CD31 and fırefly luciferase to assess
the potential effect of the dasatinib-sorafenib combination onmicroscopic brain
metastasis formation and progression and vessel co-option. Given the fact that
brain metastases usually have a poor response to chemotherapeutic agents in
part due to the presence of blood-brain barrier, a pharmacokinetic study is
underway to characterize the distribution of sorafenib and dasatinib in normal
brain tissues and brain metastases using the serial blood sampling and brain
microdialysis technique. Overall, results from the in vitro cytotoxicity study
demonstrated the synergistic effect of dasatinib and sorafenib on H1915-luc
human lung cancer cells, providing a rationale for the in vivo evaluation the
potential of this combination for the treatment of brain metastases from lung
carcinomas.
#1091 Paclitaxel-loadedmicroparticles in combinationwith gemcitabine-
loaded microparticles decreases gemcitabine resistance and promotes cell
death in pancreatic cancer cell lines.MariaMunoz-Sagastibelza, AriellaMosh-
chinsky, Oluwafeyikemi Okome, Jenny E. Paredes Sanchez, Raavi Gupta, Laura
Martello-Rooney. SUNY Downstate Medical Ctr., Brooklyn, NY.
Pancreatic cancer is the fourth leading cause of cancer death in the United
States with only 7% of diagnosed patients surviving 5 years. Current systemic
chemotherapies have not been very effective at decreasing tumor burden, but
nonetheless expose patients to the adverse side effects of treatment. Poly(lactic-
co-glycolic acid)-based microparticles (MPs) are a promising tool for localized
drug delivery within the tumor due to their high biocompatibility, flexibility in
drug encapsulation and extended drug release. A previous in vivo experiment
from our laboratory demonstrated minimal penetration of systemic gemcit-
abine into the tumor resulting in low levels of apoptosis compared to locally
injected gemcitabine-loaded microparticles (GMPs), which demonstrated
much higher levels of intratumoral apoptosis. The present study investigated
whether paclitaxel-loadedmicroparticles (PMPs), alone or in combination with
GMPs, decreased gemcitabine resistance, colony formation and promoted cell
death in two human pancreatic cancer cell lines, PANC-1 and MIAPaCa-2. In
vitro studies with PANC-1 cells treated with PMPs or GMPs showed enhanced
cell killing and a signifıcant decrease in colony formation in the higher MPs
volume groups. Moreover, the combination treatment of PMPs followed by
GMPs, showed a greater decrease in colony formation in comparison with the
single treatments. Subsequently, we tested the effect of single and combination
treatments on two well-known resistance markers for gemcitabine, ribonucle-
otide reductase catalytic subunitM1 (RRM1) and cytidine deaminase (CDA), as
well as on the promotion of cell death measuring cleaved caspase-3 (CC3). In-
terestingly, PANC-1 cells treated with PMPs alone showed an increase in CC3
expression and a signifıcant decrease in the expression of both markers when
treated with different volumes of PMPs. MIAPaCa-2 cells exhibited similar re-
sults. The combination treatment also showed amodulation in RRM1 and CDA
proteins and an increase in CC3 expression. However, when PANC-1 cells were
treated with GMPs alone, both markers went up suggesting an increase in resis-
tance against gemcitabine. These experiments are in progress for the MI-
APaCa-2 cells. In addition, preliminary drug release studies with GMPs demon-
strated detection of gemcitabine up to 14 days. In conclusion, our data
demonstrated that PMPs and GMPs promote an increase in cancer cell death.
Furthermore, the combination of the drug-loadedMPs indicated a reduction in
drug resistance and clear impairment in colony formation. Further studies are in
progress to investigate combination MPs injections in a mouse model of pan-
creatic cancer to confırm in vivo effıcacy. The described drug delivery method
has the potential to be a more effıcient local treatment modality than systemic
drug against pancreatic cancer.
#1092 PF562271, a Pyk2 inhibitor, reduces glioma tumor growth and in-
vasion in C57Bl6-Gl261 mouse glioma model. Jescelica Ortiz-Rivera,1 Kim-
berleve Rolón-Reyes,2 Alejandro Albors,1 Luis Cubano,1 Lilia Kucheryavykh1.
1Universidad Central del Caribe, Bayamon, PR; 2University of Puerto Rico, Rio
Piedras, PR.
Glioblastoma is an extraordinarily aggressive type of brain cancer due to its
invasive and proliferative nature. The tumormicroenvironment, withmicroglia
as a critical player, has an important role in tumor progression. Microglia infıl-
trate majority of gliomas and release factors, which favor tumor growth and
invasion. Previously we demonstrated that microglia residing within the tumor
stimulate glioma cell invasion through the proline rich tyrosine kinase 2 (Pyk2)
signaling cascade. We hypothesize that the use of pharmacological inhibitors of
Pyk2 together with currently applied chemotherapy can signifıcantly reduce
invasiveness of glioblastoma tumor and improve the outcome of the treatment.
Using C57Bl/6-Gl261 mouse glioma implantation model we investigated the
effect of the combined treatment for glioblastomawith temozolomide (TMZ, 50
mg/kg, once/day, orally) together with a Pyk2 inhibitor PF562271 (twice/daily,
25 mg/kg, orally) vs. TMZ monotherapy. Treatment was provided during 14
days, beginning the 5th day after glioma implantation. For the assessment of the
effectiveness of treatment animals’ survival, tumor size, and invasion area were
evaluated. Western blot were used for the evaluation of the level of Pyk2 phos-
phorylation in tumor cells. For the purifıcation of glioma cells from total tumor
tissue Percol gradients were used. The study revealed that treatment with
PF562271 reduced invasion of glioma cells at the tumor edge, while TMZ re-
duced the tumor growth. Combined treatment showed signifıcantly more
prominent effect on reduction of tumors growth compared to TMZ mono-
therapy and additionally reduced invasiveness of tumors similar to PF562271
monotherapy. In both PF562271 monotherapy and combined treatments the
downregulation of Pyk2 phosphorylation in glioma cells has been recorded.
Survival analysis demonstrated a signifıcance increase of survival of animals
received combined treatment compare to TMZmonotherapy. In conclusion, we
can state that combined treatment with TMZ together with PF562271 reduced
Pyk2-related tumor growth and invasiveness and increased animal survival.
This research was made possible by NIH grant numbers: 1SC2GM102040,
G12MD007583, R25GM110513, Puerto Rico Science, Technology, and Re-
searchTrust grant number 2016-00157, andUSDepartment of EducationGrant
number P031S130068.
#1093 Synergistic action of sorafenib and carfılzomib against hepatocel-
lular carcinoma in vitro and in vivo. Chao Jiang,1 Rui Xu,2 Xiao-Xing Li,1
Hui-Yun Wang,1 X.F. Steven Zheng1. 1Sun Yat-sen University Cancer Center,
Guangzhou, China; 2Cancer Center of Guangzhou Medical University, Guang-
zhou, China.
Background: Sorafenib, a multikinase inhibitor, is currently the only ap-
proved systemic drug for advanced hepatocellular carcinoma (HCC), but has
demonstrated limited survival benefıts for patients. Carfılzomib (CFZ) is a sec-
ond-generation proteasome inhibitor approved for the treatment of multiple
myeloma. In this study, we aim to investigate the synergistic antitumor effect of
the combined treatment of sorafenib and CFZ in hepatocellular carcinoma and
the underlyingmolecularmechanisms.Methods: Hep3B and Bel-7402HCC cell
lines were treated with sorafenib and/or CFZ at clinically relevant concentra-
tions, after which effects on cell viability and proliferation were analyzed using
MTSmethod; cell migration and invasion were evaluated in transwell assay; cell
apoptosis were monitored by flow cytometry. Western blot assay was used to
investigate the potential molecular mechanism of the synergistic antitumor ef-
fect of the combined treatment. In vivo effıcacy was determined in nude mice
with Hep3B xenografts. Results: MTS results showed that CFZ could improve
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the drug sensitivities of sorafenib in Hep3B and Bel-7402 cells when combined
these two drugs together. Moreover, cell proliferation was more signifıcantly
suppressed in combinational treatment compared to single agent (p 0.01) in
the two tested cell lines. The colony formation assay showed similar results with
the MTS assay. The results from flow cytometry showed that sorafenib or CFZ
alone induced about 11% apoptotic cells in Hep3B, when administered in com-
bination the percentage of apoptotic cells signifıcantly increased to about
20.78% (p 0.01). Similar results were observed in Bel-7402. Results of trans-
well assay demonstrated that cell migration and invasion ability were inhibited
when treated with sorafenib or CFZ alone; and cells treated with the combina-
tional therapy migrated and invaded even less (p 0.05). The in vivo xenograft
tumor model showed that treatment with sorafenib or CFZ inhibited Hep3B
tumor growth (p  0.05); moreover, treatment with the combination more
signifıcantly inhibited tumor growth (p  0.01). Mechanistically, combined
treatment of the two drugs suppressed the epithelial-mesenchymal transition
process by increasing E-cadherin and decreasing N-cadherin and -catenin.
Furthermore, the drug combination activated themitochondria-related apopto-
sis pathway, showing up-regulation of cleaved caspase 3/7/9. Up-regulations of
PERK/eIF2/ATF4/CHOP pathway implicated the involvement of ER stress-
mediated apoptotic pathway following the drug combination treatment. Con-
clusion: In conclusion, these fındings suggest that the combination of sorafenib
and CFZ shows synergistic antitumor activities in HCC, potentially providing a
novel therapeutic strategy for patients with advanced hepatocellular carcinoma.
#1094 Combining the pan-FGFR inhibitor AZD4547 with radiation in
lung and head and neck squamous cell carcinoma. Andrew M. Baschnagel,
Chunrong Li, Alecia M. Morgan, Sean R. Brennan, Kalley A. Russo, Paul M.
Harari. Univ. of Wisconsin School of Medicine, Madison, WI.
The fıbroblast growth factor receptors (FGFR1, FGR2, FRG3, FGR4) are fre-
quently altered or overexpressed in both lung and head and neck squamous cell
carcinomas (SCC). Amplifıcation of FGFR1 has been reported to be as high as
22% in lung SCC and 17% in head and neck SCC (HNSCC). FGFRs have been
identifıed as a potential therapeutic target in lung and head and neck cancers. In
addition, FGFRs activate multiple pathways involved in the radiation response
including RAS/RAF/MAPK, PI3K/AKT and STAT. AZD4547 is a potent and
selective tyrosine kinase inhibitor of the FGFR family and is currently being
investigated in clinical trials. Since a substantial portion of lung cancer and
HNSCC patients are treated with radiotherapy, we examined the anti-tumor
effects of AZD4547 in combination with radiation in both lung and head and
neck cancer model systems. FGFR protein and RNA expression and cell prolif-
eration with AZD4547 were evaluated in 8 lung and 8 head and neck cancer cell
lines. Clonogenic survival assays were performed on 4 lung and 4 head and neck
cancer cell lines and xenograft experiments were performed on oneHNSCC cell
line. These cell lines demonstrated varying levels of FGFR1, 2 and 3 protein and
RNA expression. The half maximal inhibitory concentration (IC50) of
AZD4547 in these cell lines ranged from 0.05 to 128 uM. Sensitivity to AZD4547
did not correlate directly with protein or RNA expression. In vitro clonogenic
survival assays showed limited effects of combining AZD4547 with radiation.
However, signifıcant tumor growth delay was observed with the combination of
radiation and AZD4547 compared to radiation or drug alone in the SCC1483
FGFR2 expressing HNSCC xenograft model. These fındings suggest that
AZD4547 can augment the response of radiation in an in vivo model system.
Further studies are underway to test these fındings in additional cell lines includ-
ing FGFR dependent amplifıed cancer cell lines.
#1095 A combination of suberoylanilide hydroxamic acid and quinacrine
is an effective therapeutic approach in preclinical settings of upper gastroin-
testinal cancers. Shoumin Zhu, Wael El-Rifai. Surgery, Nashville, TN.
Background: Quinacrine (QC), an antimalarial drug, has been shown to pos-
sess anticancer effects. Suberoylanilide hydroxamic acid (SAHA) inhibits class I
and class II HDACs and is approved for cancer therapy. Developing novel ap-
proaches to overcome cancer drug resistance could signifıcantly enhance cur-
rent therapeutic approaches and improve patient care. Methods: ATP-GLO,
clonogenic survival, Annexin-V apoptosis assay, comet assay and DNA double-
strand breaks (DSB) kits were used. The mRNA and protein levels were evalu-
ated by quantitative real-time PCR and Western blot analyses. Results: A com-
bination of QC/SAHA signifıcantly increased cell death in all cancer cell lines
and had no effect on immortalized non-cancer cell lines (HFE145,NIH-3T3 and
EPC2) (P0.01). Clonogenic survival assay indicated that QC/SAHA co-treat-
ment led to signifıcantly lower number of cancer cell colonies, as compared to
single agents and controls (P0.01). Of note, the QC/SAHA combination led to
an increase in the the sub-G0 population in AGS (9-fold), MKN-28 (14-fold),
FLO1 (5.6-fold), and SNU1 (4-fold) cells (P0.01). These results were con-
fırmed using the Annexin V apoptosis induced signifıcantly higher levels of
apoptosis (10 - 20 fold) as compared to single agent and control (P0.01).
Treatment with QC/SAHA combination induced high levels of DSB (20 fold,
P0.01). Comet assay data showed increased DNA damage compared with
vehicle-treated cells (8-fold, P0.01). Western blot analysis demonstrated a
notable increase in activation of PARP, caspases 3, 9 and -H2AX following
QC/SAHAco-treatment in all cancer cell lines. Interestingly, the combination of
QC/SAHA substantially decreased the protein levels of both wtP53 andmutP53
in these cells. Tumor xenograft data confırmed that a combination ofQC/SAHA
is more effective than a single agent in abrogating tumor growth (P0.05).
Conclusion: Our novel fındings show that QC and SAHA have a synergistic
effect on cancer cell death. The results provide compelling evidence that in-
creased DNA damage mediates the cytotoxic effect of combined QC/SAHA.
Such effect is likely related tomutP53 andwtP53 protein degradation induced by
QC/SAHA combination. Our fındings provide a rationale for a clinical evalua-
tion of combined QC/SAHA therapy in gastro-esophageal cancers. Ongoing
studies are currently being undertaken to understandmechanisms that regulate
the degradation of wtp53 and mutp53 proteins.
#1096 Co-targeting of AKT and Pim kinases in mouse PTEN-defıcient
prostate cancer.Marco A. De Velasco,1 Koichi Sugimoto,1 Yurie Kura,1 Naomi
Ando,1 Noriko Sato,1 Kazuko Sakai,1 Barry R. Davies,2 Dennis Huszar,2 Masa-
hiro Nozawa,1 Kazuhiro Yoshimura,1 Kazuhiro Yoshikawa,3 Kazuto Nishio,1
Hirotsugu Uemura1. 1Kindai University Faculty of Medicine, Osaka-Sayama,
Japan; 2AstraZeneca, Macclesfıeld, United Kingdom; 3Aichi Medical University,
Nagakute, Japan.
AKT and Pim kinases modulate programmed cell death by the phosphoryla-
tion of common substrates that regulate apoptosis and other survival processes.
Evidence suggests that the antitumor effects of targeted Akt inhibition can be
inhibited or diminished by the JAK/STAT-dependent induction of Pim kinases.
In this study we examined the therapeutic potential of co-targeting AKT and
Pim in a genetically engineered mouse model of prostate cancer driven by the
conditional inactivation of PTEN. The antitumor effects of AZD5363, a pan
AKT inhibitor, and AZD1208, a highly potent Pim kinase inhibitor, were inves-
tigated as monotherapy or in combination on mice harboring castration-naïve
prostate tumors andmice that developed castration-resistant disease.Mice were
randomized treated for four weeks. Safety and tolerability was assessed by body-
weight changes. Antitumor activity was determined by differences in tumor
burden, proliferation and apoptosis and histology. Molecular activity was as-
sessed by examining the phosphorylation of common substrates by western blot
analysis. Treatments were well-tolerated and no signifıcant differences in body-
weight changes were observed. In castration-naïve prostate tumors, treatments
with AZD5363, AZD1208 and AZD5363/AZD1208 resulted in 11.9%, 13.5%
and 36.9% reductions of tumor burden compared to vehicle treated controls,
respectively, P0.001. The treatment combination of AZD5363/AZD1208
demonstrated signifıcant antitumor activity compared to monotherapy,
P0.001. In the castration-resistant tumors, treatments with AZD5363,
AZD1208 andAZD5363/AZD1208 resulted in 21%, 9.5% and 27% reductions of
tumor burden compared to vehicle treated controls, respectively, P0.004. Al-
though the differences in in tumor burden were not statistically betweenmono-
therapy and combination therapy, a notable degree of tumor gland regression
was observed in tumors treatedwithAZD5363/AZD1208. Overall, combination
therapy showed a synergistic effect by inhibited or impaired phosphorylation of
PRAS40, eIF4B and BAD in both castration-naïve and castration-resistant tu-
mor models. Inhibition of both pathways enhanced the reduction of tumor cell
proliferation and increased apoptosis. Overall, our fındings provide in vivo data
to support redundancy between AKT/Pim survival pathways and suggest that a
therapeutic approach of combined AKT/Pim kinase inhibition may be possible
therapeutic approach for AKT-driven prostate cancer.
#1097 Enhancing the effıcacy of Temozolomide with Biochanin A: Mech-
anistic and metabolic effects. Vilas Desai,1 Aditi Jain,2 Maryna Perepelyuk,1
Annie Chhun,1 Christopher Farrell,1 James C. K. Lai,3 Alok Bhushan1. 1Thomas
Jefferson University, Philadelphia, PA; 2University of Kentucky, Lexington, KY;
3Idaho State University, Pocatello, ID.
Enhancing the effıcacy of Temozolomide with Biochanin A: Mechanistic and
Metabolic effects Glioblastoma multiforme (GBM) is the most frequent, pri-
mary malignant brain tumor prevalent in humans. GBM is characterized by
aggressive cell proliferation and rapid invasion of normal brain tissue resulting
in poor patient prognosis. Furthermore, the current standard therapy of surgical
resection followed by radiotherapy and chemotherapy with Temozolomide is
not very effective. The ineffıcacy of the currently available chemotherapeutic
agents forGBMcan be attributed to the challenges of drug delivery to the tumor.
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Our laboratory has previously reported the anticancer potential of isoflavones
like Biochanin A against oral, pancreatic, breast and brain cancers. In this study,
we tested our hypothesis that, Biochanin A sensitizes the GBM cells to Temozo-
lomide, thereby increasing its effıcacy in combination treatment. We used the
MTT assay to determine the effects of Biochanin A alone and in combination
with Temozolomide on survival of U-87 MG cells. Furthermore, two different
nanoformulations of Single Walled Carbon Nanotubes (SWCNTs) functional-
ized with Biochanin A and Atorvastatin and SWCNTs functionalized with Te-
mozolomide were synthesized and their effects on cell viability of U-87 MG
glioblastoma cells tested. The cell viability results indicate a decrease in cell
proliferation with the combination treatment as compared to the individual
drug treatment. Similarly, the flow cytometry analysis showed an increased in-
duction of apoptosis with combination treatment as compared to the drugs
alone. Western-blot analysis and Immunofluorescence imaging methods were
used to elucidate some of the cell survival/proliferation mechanisms involving
EGFR, p-AKT, MMP-2, MT-MMP1. The effects of the drugs on U-87 MG cell
metabolism (parameters like ECAR &OCR) studied using Seahorse XFp analy-
ser, suggest an increase in the mitochondrial respiration. Our results provide
support for our hypothesis and the data shows that it may have implications in
increasing the effıcacy of the conventional treatments for GBM. These results
will potentially aid in designing new therapies that can improve the outcome of
GBM.
#1098 Delta-tocotrienol chemosensitizes humanpancreatic tumormetas-
tasis to gemcitabine targeting cancer stem cells. KazimHusain, Said M. Sebti,
Mokenge P. Malafa.Moffıtt Cancer Center, Tampa, FL.
Background: Pancreatic cancer, a lethal malignancy is the fourth leading
cause of cancer-related deaths in the United States. The standard chemotherapy
with gemcitabine is ineffective in patients with metastatic tumors. Pancreatic
cancer stem cells (CSCs) have been implicated in the development of pancreatic
cancer metastasis, resistance to chemotherapy and its recurrence following sur-
gical extirpation. We have shown that natural vitamin E 	-tocotrienol is the
most bioactive tocotrienols against pancreatic cancer in vitro as well as in vivo
models. The purpose of this study was to evaluate the chemosensitization of
pancreatic tumormetastasis by 	-tocotrienol to gemcitabine in vitro as well as in
vivo. Methods: In vitro human metastatic pancreatic cancer cells L3.6pl and
pancreatic cancer stem cells (PCSC) were treated with gemcitabine (5 M) and
	-tocotrienol (50 M) alone and in combination. Treated cells used for epithe-
lial to mesenchymal transition (EMT), migration/invasion, microsphere/spher-
oid, and signaling markers assays. PCSC expressing luciferase was orthotopi-
cally implanted into pancreas of Athymic nudemice (n 20) and after oneweek
they were randomized into four groups: 1) vehicle control (ethanol extracted
olive oil), 2) gemcitabine (100 mg/kg, IP, twice a week), 3) 	-tocotrienol (200
mg/kg, orally twice a day) and 4) gemcitabine  	-tocotrienol. The treatment
was continued for 4 weeks. The tumor volume, tumor weight, metastasis were
recorded. Results: Gemcitabine slightly inhibited the growth, migration/inva-
sion of L3.6pl and PCSC in vitro and PCSC tumor growth (tumor volume and
weight) in vivo. 	-tocotrienol signifıcantly inhibited the growth, microsphere/
spheroid, migration/invasion, EMT(E-cadherin to vimentin), angiogenesis
(VEGF), PCSC transcription factors (Nanog, Oct4, and Sox2), tumor growth
and liver/lung metastasis compared to control. The combination of both drugs
synergistically inhibited the cancer and stem cell growth, EMT, migration/inva-
sion, microsphere/spheroid, metastasis, angiogenesis, and PCSC transcription
factors in vitro as well as in vivo. Conclusion: Vitamin E 	-tocotrienol chemo-
sensitizes human pancreatic tumor metastasis to gemcitabine through inhibi-
tion of EMT, migration, invasion, angiogenesis, cancer stem cell self-renewal,
tumor growth and metastasis.
#1099 Testosterone abolishes cabazitaxel effıcacy in an in vivo model of
prostate cancer and affects intratumoral concentrations. LisanneMout, Cor-
rina de Ridder, Debra Stuurman, Peter Bruijn, Ron H. Mathijssen, Ronald de
Wit, Martijn P. Lolkema, Wytske M. Weerden. Erasmus MC, Rotterdam, Neth-
erlands.
Introduction Docetaxel combined with castration provides a major survival
benefıt in newly diagnosed metastatic PCa. Conversely, docetaxel without cas-
tration in high-risk localized PCa is not active. Cabazitaxel is a new taxane
retaining its activity in tumors resistant to docetaxel and new hormonal thera-
pies. We aimed at better characterizing in vivo the relationship between cabazi-
taxel and circulating androgens in a preclinical human-derived xenograftmodel
of castration-resistant prostate cancer (CRPC). Material and methods Athymic
nudemice were inoculated with the androgen receptor wt, PSA secreting CRPC
cell line PC346C-DCC-K. Mice were surgically castrated when tumors were
established (tumor volume (TV) of 150 mm3). After 7 days, mice were random-
ized to receive testosterone (40mg) or empty pellet. The following daymicewere
injected with one bolus injection of cabazitaxel (33 mg/kg) or NaCl intraperito-
neally. Mice were sacrifıced when tumors exceeded a volume of 1,500 mm3 or
the maximum follow-up of 90 days after cabazitaxel treatment. Blood was sam-
pled biweekly for PSA and testosterone and analyzed by an immunoassay. In a
second in vivo experiment intratumoral uptake of cabazitaxel was determined in
the presence and absence of testosterone using a similar experimental set-up,
with the exception that mice were sacrifıced 7 days after cabazitaxel treatment.
Here, intratumoral cabazitaxel concentrations were determined in snap frozen
tumors by LC/MS-MS and corrected for tumor weight. Results Cabazitaxel
treatment of castrated male mice bearing PC346C-DCC-K tumors resulted in a
complete or near-complete antitumor response. In contrast, in mice supple-
mented with testosterone the anti-tumor effect of cabazitaxel was not signifı-
cantly different from placebo (median time till TV 1,500 mm3 48 and 45 days
resp.). Importantly, testosterone supplementation alone did not signifıcantly
affect tumor growth, confırming the CRPC nature of the (PC346C-DCC-K)
xenograft. Interestingly, in tumors of testosterone supplemented castrated mice
the intratumoral cabazitaxel concentrations were signifıcantly decreased com-
pared tomice that did not receive testosterone (0.39 ng cabazitaxel permg tumor
tissue vs. 1.36 ng/mg, t-test p0.0032). Conclusions These fındings indicate that
circulating testosterone signifıcantly impairs the effıcacy of cabazitaxel. Testos-
terone supplementation may alter the metabolism of cabazitaxel, or may inter-
ferewith uptake and/or accumulation of cabazitaxel in PCa cells.Wewill further
investigate the relationship between circulating androgens and intratumoral
cabazitaxel accumulation as well as anti-tumor effıcacy. The study was sup-
ported by a research grant from Sanofı
#1100 Synergistic interaction between gemcitabine and PD-0325901 in
C-33A cervical carcinoma cell line. Macarena Irigoyen, Gonzalo Castillo.
BIOENSIS, LLC., Bellevue, WA.
Cervical cancer affects over half amillionwomenworldwide, and is one of the
most common causes of death in women. Treatment of cervical cancers consists
of surgery, radiation, chemotherapy, or combination of therapies. However,
about half of patients with advance cancer will show recurrent tumors. Signaling
cascades are often dysregulated in human cancer cells making them attractive
targets for combination drug therapies. PD-0325901, an inhibitor of the mito-
gen-activated protein kinase, is a promising target for metastatic cancer. An-
other drug used to treat cervical carcinoma is gemcitabine, a nucleoside analog
inhibitor of the ribonucleotide reductase and DNA damage inducible protein
45a (Gadd45a). This drug is generally used in combination with other drugs,
after reoccurrence of the disease state. We decided to evaluate the effıcacy of
gemcitabine in combination with PD-0325901 in C-33A, a metastatic cervical
cancer-derived cell line. We evaluated the potency of gemcitabine and PD-
0325901 alone and in combination. Cell viability after incubation with the drugs
was determined at 72 hours and at 7 days by measuring ATP content. Synergy
was determined assessed utilizing BIOENSIS’s suite of drug combination anal-
ysis tools including: isobologram, combination index (CI) and Bliss analysis.
Isobologram analysis at 72 hours of incubation revealed that the mean values of
the observed data were signifıcantly smaller than those of the predicted maxi-
mum additive values, indicating synergy. Bliss and combination index analysis
confırmed the observation, showing a synergistic effect at concentrations be-
tween 2 - 200 nM PD-0325901 and 0.3 - 3 nM gemcitabine. Similar patterns of
synergy were observed with 7 day incubations of C-33A with gemcitabine and
PD-0325901. These results indicate that gemcitabine and PD-0325901 showed
signifıcantly more growth inhibition than either drug alone in the C-33A tumor
cell line, suggesting that the combination of gemcitabine - PD-0325901 could be
used in cervical cancer therapy.
#1101 Telomerase inhibitor imetelstat in combination with the BCL-2
inhibitor venetoclax enhances apoptosis in vitro and increases survival in
vivo in acute myeloid leukemia. Joshua J. Rusbuldt, Leopoldo Luistro, Diana
Chin, Melissa Smith, AmyWong, Margarita Romero, Aleksandra Rizo, Jacque-
line Bussolari, Fei Huang, Amy (Kate) Sasser. Janssen Research & Development,
LLC, Spring House, PA.
Background/Aims: Acute myeloid leukemia (AML) is an aggressive can-
cer with limited treatment options outside of chemotherapy. Improved ther-
apies with novel mechanisms of action are desperately needed to fıll this
need. Both hTERT, the catalytic subunit of telomerase, and BCL-2, an apo-
ptotic regulator, are overexpressed in AML, correlating with disease severity
and poor prognosis respectively. Imetelstat is a novel, fırst-in-class compet-
itive inhibitor of telomerase with clinical activity in hematologic malignan-
cies. Venetoclax, an approved BCL-2 inhibitor for CLL, has shown a prom-
ising clinical benefıt in AML patients. Preclinical evidence shows that
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downregulation of hTERT induces apoptosis via disruptions of hTERT and
BCL-2 interaction; we hypothesize that inhibiting both targets would yield
greater anti-tumor activity in AML compared to treatment with either agent
alone. Methods: AML cell lines and AML patient’s PBMC samples were
treated with imetelstat or venetoclax alone, or in combination, and viable
and apoptotic populations of cells were evaluated by flow cytometry. Telom-
erase activity, hTERT expression andmitochondrial dysfunction were inves-
tigated for mechanism of action. Furthermore, an in vivo study in the
MOLM-13 AML disseminated model was conducted to assess effıcacy and
survival. Results: A dose-dependent synergistic activity in inducing apopto-
sis was observed in multiple AML cell lines when combining imetelstat with
venetoclax. In theMOLM-13 cell line, single-agent imetelstat and venetoclax
had modest apoptotic activity after 48 hours (22% and 30% respectively), but
the combination achieved 88% at 48 hours and nearly 100% at 96 hours.
Similarly enhanced apoptotic activity was also observed in PBMCs purifıed
from 4 AML patient whole blood samples. Molecular analyses showed com-
bining imetelstat with venetoclax reduced hTERT expression and telomerase
activity much more strongly than either agent alone. Furthermore, in vivo
studies showed all mice tolerated the combination of imetelstat with ABT-
199 well, with increased life span as compared to the vehicle control (68.1%,
p0.0001), to imetelstat (39.6%, p0.0011) alone, or to venetoclax (23.3%,
p0.0001) alone. In the combination group, 40% of treated mice were alive
77-days after treatment discontinued whereas all mice of the other single
agent arms died within two weeks, demonstrating a signifıcant survival ben-
efıt. Conclusions: To our knowledge, this is the fırst investigation combining
imetelstat with venetoclax in AML, and the results demonstrated a synergis-
tic effect on induction of apoptosis in cell lines and patient samples in vitro,
which translated into prolonged survival in xenograft models, thus provid-
ing a strong rationale for clinical exploration of this combination.
#1102 Anti-tumor effects of imipridone ONC201 in combination with
anti-angiogenic agents signifıcantly impact on colorectal cancer growth in
vivo. Jessica Wagner, Wafık El-Deiry. Fox Chase Cancer Center, Philadelphia,
PA.
Small molecule imipridone ONC201 is an investigational anti-tumor agent
with a wide therapeutic index and broad-spectrum effıcacy in vivo. ONC201
upregulates intratumoral TRAIL expression and the integrated stress response
pathway. A Phase I clinical trial using ONC201 as therapy in advanced cancer
patients has been completed and the drug has progressed into several Phase II
trials in multiple cancer types. Colorectal cancer (CRC) remains one of the
leading causes of cancer worldwide and metastatic disease continues to have a
poor prognosis. Clinical trials in CRC and other tumor types have demonstrated
that therapeutics targeting the vascular endothelial growth factor (VEGF) path-
way, such as bevacizumab, are effective in combination with certain chemother-
apeutic agents. Bevacizumab is a humanized monoclonal antibody that targets
VEGF and is an FDA-approved treatment for advanced CRC patients, in addi-
tion to other tumor types. We are investigating the potential combination of
VEGF inhibitors such as bevacizumab andONC201 in both CRC xenograft and
patient-derived xenograft (PDX) studies. Our results demonstrate signifıcant
tumor regression and occasional tumor ablation in human xenografts with the
combination of ONC201 with bevacizumab, and in syngeneicMC-38 colorectal
cancer xenografts using amurineVEGF-A inhibitor.Non-invasive angiogenesis
imaging demonstrated the impact of this combination on decreasing tumor
growth and tumor metastasis. With the use of both a murine VEGF inhibitor in
syngeneic models, and bevacuzimab in human cell line-derived xenografts, we
have demonstrated that combining anti-angiogenic therapies with ONC201
could enhance antitumor effıcacy. Thus, ONC201 in combination with anti-
angiogenic therapies such as bevacizumab represents a promising combinatorial
approach that may be exploited in the clinic for the treatment of CRC.
#1103 Novel theranostic strategy against scirrhous gastric cancer; combi-
nation of chemotherapy and fluorescence oncolytic adenovirus. Wataru
Ishikawa, Satoru Kikuchi, Hiroshi Tazawa, Shinji Kuroda, Kazuhiro Noma, Hi-
royuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa,
Toshiyoshi Fujiwara. Okayama University, Okayama, Japan.
Background: Gastric cancer is one of the most common cancers worldwide,
especially inEasternAsia. Scirrhous gastric cancer (SGC),which is characterized
by poorly differentiated tumor cells that diffusely infıltrate the gastric wall, ac-
counts for 10% of all gastric cancers, and often causes peritoneal metastasis.
Peritoneal carcinomatosis shows the worst prognosis among various metastatic
patterns. Since it is diffıcult to detect peritoneal micrometastasis preoperatively
or intraoperatively, SGC patients with peritoneal micrometastasis show the re-
currence and refractory to conventional systemic chemotherapy after surgery.
In recent year, intraperitoneal (i.p.) administration of paclitaxel (PTX) has been
shown to have therapeutic effects against ovarian cancer with peritoneal metas-
tasis. However, the effective treatment option to overcome peritonealmetastasis
of SGC has not been developed yet, although i.p. administration of some che-
motherapeutic agents has been attempted to SGC. Therefore, a novel therapeu-
tic strategy is required for the treatment of peritoneal metastasis of SGC. Meth-
ods: We previously developed a telomerase-dependent replication-selective
adenovirus OBP-401 (TelomeScan), which can replicate within the tumor cells
selectively and express green fluorescent protein (GFP). Moreover, OBP-401
infection also induces tumor-specifıc cell death inmonotherapy or combination
therapywith chemotherapy. In this study, we assessed synergistic effects in com-
bination with novel theranostic agent OBP-401 and chemotherapeutic agent
paclitaxel (PTX) using human SGC cell lines (GCIY and KATO III). In vitro
experiment, SGC cells and normal human lung fıbroblast (NHLF) cells were
infectedwithOBP-401 at various doses. PTXwas administrated after 48 hours of
virus infection. Twenty-four hours after PTX administration, we evaluated the
anti-tumor effect by XTT assay, and analyzed the synergistic effect by CalcuSyn
Software. Results: SGC cells were visualized as GFP-positive cells selectively by
the infection of OBP-401, whereas NHLF cells were not visualized with OBP-
401. In both SGC cell lines, the suppression of cell viability dose-dependently by
administration of OBP-401 or PTX alone was confırmed. OBP-401 synergisti-
cally suppressed the viability of SGC cells in combinationwith PTX as compared
to monotherapy. Conclusions: These results suggest that OBP-401 has a prom-
ising potential to detect peritoneal micrometastasis of SGC intraoperatively and
combination of OBP-401 and PTX would be a novel theranostic strategy for the
treatment of peritoneal metastasis of SGC.
#1104 Novel specifıc RTK targeting of EGFR/FAK axis in glioblastoma
invasion. Raghupathy Vengoji, Satyanarayana Rachagani, Suprit Gupta, Kavita
Mallya, Maneesh Jain, Moorthy Ponnusamy, Surinder Batra, Nicole Shonka.
University of Nebraska Medical Center, Omaha, NE.
Background: Glioblastoma (GBM) is the most aggressive primary brain tu-
mor with a median survival rate of 14.6 months. Currently, the fırst-line treat-
ment includes surgical resection, chemoradiation, and adjuvant chemotherapy
with temozolomide. However, GBM recurs most often within 6.9 months. Re-
ceptor tyrosine kinases are dysregulated in GBM, with epidermal growth factor
receptor (EGFR) representing 57.4% of the deleted/mutated GBM. In addition,
30 - 40% of GBM patients with EGFR amplifıcation carry an oncogenic gene
rearrangement EGFR variant III (EGFRvIII) which is constitutively active. Yet
most EGFR inhibitors have shown very little clinical effıcacy in GBM.Methods:
Afatinib, blood-brain barrier penetrant pan-EGFR inhibitor, covalently binds
and irreversibly inhibits signaling fromEGFR. Afatinib also persistently inhibits
ErbB homo and hetero-dimers. Using GBM cell lines U87MG and U87MG
transfected with wild type EGFR, EGFRvIII and EGFRvIII with dead kinase
domain, we evaluated the effıcacy of afatinib alone and in combination with
temozolomide. Results: Afatinib treatment resulted in a dose dependent de-
crease in the proliferation of U87MG cells transfected with EGFRvIII. The IC50
value for this cell line is 2M (afatinib). 50M temozolomide inhibited cell
proliferation by 50%. We evaluated the combinational effıcacy of IC25 of both.
Afatinib effectively blocked EGFR signaling even 72 hours after treatment in the
U87MG cell line transfected with either wild type EGFR or EGFRvIII. This was
evidenced by decreased phosphorylation of EGFR (Tyr 1068) and its down-
stream signaling. Focal adhesion kinase (FAK) signaling in EGFRvIII expressing
cells, largely responsible for the invasiveness of GBM, was abolished by afatinib.
Furthermore, treatment with afatinib and temozolomide signifıcantly decreased
the in vitro tumorigenicity (anchorage dependent growth - colony formation
assay as well as anchorage independent growth - soft agar assay) of EGFRvIII
expressing GBM cells. Conclusion: Altogether, these results support synergistic
effıcacy of afatinib and temozolomide in EGFRvIII expressing GBM.
#1105 A chemotherapeutic approach to kill cancer stem cell rich ovarian
ascites. Siddik Sarkar, Obeid M. Malekshah, Arash Hatefı. Rutgers University,
Piscataway, NJ.
Purpose: More than one third of ovarian cancer patients present with cancer
cells in the abdomen (also known as ascites) at diagnosis, and almost all have
ascites at recurrence (Ahmed and Stenvers 2013). It is well-documented that
subpopulations of the ascites show cancer stem cell-like characteristics which
possess enhanced resistance to chemotherapies and the capacity for distal met-
astatic spread and recurrent disease. Therefore, ascites are a major source of
morbidity and mortality for ovarian cancer patients. The major defıciency that
currently exists is that there is no effective and safe therapy for ascites since they
are rich in cancer stem cells (CSCs) and resistant to chemotherapy. To overcome
this defıciency, it is our objective to develop an effective chemotherapy approach
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that can destroy the CSC-rich ascites and inhibit recurrence. Methods: Several
established human ovarian cancer cells as well as ascites obtained from the
abdomen of an ovarian cancer patient (ASCITES) were cultured. Cells were
sorted by FACS Cell Sorter to determine the percentage of cancer stem cells
(CSCs) in each cell line. Dose response curves of different chemotherapeutic
drugs such as Cisplatin (CDDP), 6-Methylpurine (6-MP), 5-Flurouracil (5-FU),
SN-38, Monomethyl auristatin E (MMAE) and Etoposide were studied in sus-
pension culture enriched with cancer stem cells. The relative change in total
CSC-rich spheroidmass which considers both number and volume of spheroids
was used to determine Killing Index for each chemotherapeutic drug. To inves-
tigate inhibition of recurrence, the spheroids were monitored for 30 days post
treatment and the viability of CSC-rich spheroids were studied by fluorescent
microscopy. Results: Primary human ovarian A2780 and ASCITES (derived
from ovarian cancer patient Ascitic fluid) were found to have CSCs with unlim-
ited renewal capacity in suspension culture. While Cisplatin, 5-FU, 6-MP and
Etoposide showed effıcacy in killing CSC spheroids at effective doses around
1-10 M, but MMAE and SN-38 showed the ability to either signifıcantly di-
minish or completely eradicate CSC spheroids with effective doses as low as 10
nM. Importantly, no evidence of recurrence (repopulation of spheroids) was
observed in MMAE and SN-38 treated group even after 30 days of post treat-
ment. Conclusion: These promising results with the two chemotherapeutic
drugs that show their ability to kill highly drug-resistant CSC-rich ovarian
spheroids open the door to further investigate their use in the clinic. Currently,
we are investigating the potential use of these two drugs in combination but at
very low concentrations for the treatment of abdominal ovarian metastasis.
#1106 Alvocidib potentiates the activity of venetoclax in preclinical mod-
els of multiple myeloma. Mark Livingston, Wontak Kim, Hillary Haws, Peter
Peterson, Clifford J. Whatcott, Adam Siddiqui-Jain, Steven Weitman, David J.
Bearss, Steven L. Warner. Tolero Pharmaceuticals, Inc., Lehi, UT.
The proteasome inhibitor bortezomib is widely used in the treatment of pa-
tients with multiple myeloma (MM). The expression levels of many proteins
increase as a result of bortezomib treatment, including the pro-apoptotic protein
NOXA.NOXA functions to sequester the anti-apoptotic BCL-2 familymember,
MCL-1. High levels of MCL-1 and/or low levels of NOXA have been implicated
in bortezomib resistance and negative patient outcomes, including short dura-
tion of treatment response. The BCL-2-specifıc BH3mimetic venetoclax (ABT-
199) has also been explored in multiple hematological malignancies, including
the treatment ofMM. Venetoclax induces apoptosis in a BCL-2 specifıc manner
by directly inhibiting BCL-2 function. However, intrinsic resistance to veneto-
clax treatment observed in MM patient samples has been attributed to a low
BCL-2-to-MCL-1 gene expression ratio, suggesting a central role for MCL-1 in
cell survival in this context as well. Increased MCL-1 expression is a known
resistancemechanism to venetoclax treatment in a variety of cell types including
chronic lymphocytic leukemia and lymphomas. Considering the central role of
MCL-1 to treatment effıcacy in MM, we investigated the ability of an MCL-1-
lowering agent, namely the CDK9 inhibitor alvocidib, to potentiate the activity
of venetoclax inMM. Alvocidib suppresses MCL-1 expression via CDK9-medi-
ated regulation of RNA polymerase II. Alvocidib has achieved robust improve-
ments in the clinical response rates of high-risk, newly diagnosed acute myeloid
leukemia (AML) patients as part of the time-sequential ACMregimen (alvocidib
 cytarabinemitoxantrone).We therefore hypothesized that alvocidibwould
potentiate the activity of venetoclax in MM through an MCL-1-dependent
mechanism. In this report, we demonstrate that alvocidib inhibits the protein
expression of MCL-1 in MM cells in a time-dependent fashion, up to 96 hours.
In cell viability assays, the addition of up to 100 nM venetoclax resulted in a
2.8-fold reduction in the IC50 of alvocidib in the cultured OPM-2 cell line.
Conversely, the potentiation of venetoclax activity with the addition of alvocidib
resulted in a more than 500-fold decrease in IC50 in the relatively venetoclax-
resistant OPM-2 cells. Additional studies are currently underway to investigate
the effıcacy of alvocidib and venetoclax in the context of bortezomib resistance
where low NOXA may contribute to enhanced cell survival via MCL-1. Taken
together, our data suggest that the combination of alvocidibwith venetoclaxmay
constitute a novel therapeutic regimen in the treatment of MM. Further, it sug-
gests that CDK9-mediated targeting of MCL-1 may offer a clinical route to
addressing intrinsic resistance in MM patients.
#1107 Co-treatment with a C1B5 domain peptide of protein kinase C
and a low dose of gemcitabine effectively inhibited pancreatic cancer growth
in mouse peritoneal cavity. Alejandro Zulbaran, Kelsey Monson, Susumu
Ishiguro, Atsushi Kawabata, Deepthi Uppalapati, Naomi Ohta, Masaaki Ta-
mura. Kansas State University College of Veterinary Medicine, Manhattan, KS.
Although the gemcitabine is an effective chemotherapeutic agent for pancre-
atic cancer, unacceptable side effects often accompany. Since we have previously
discovered that PKC C1B domain peptides effectively control tumor growth
without any side effect (Kawabata et. al, Cancer Biol Ther, 2012), we sought to
examine the effıcacy of co-treatment with this peptide and a low dose of gem-
citabine on the growth of pancreatic cancer. Although individual and co-treat-
ment with C1B5 peptide (1M) and gemcitabine (20 nM) weakly inhibited
growth of PAN02 murine pancreatic acinar cell carcinoma in 2D culture, either
treatment effectively attenuated spheroid growth on PAN02 cells in 3D culture
with 48.2% and 35.8% inhibition, respectively. Combination treatment with the
C1B5 peptide and gemcitabine further attenuated the growth of PAN02 cells
(69.5% inhibition). In mice bearing peritoneal allograft tumors of PAN02 cells
(2.5 x 105 cells/mouse), combination treatment with C1B5 peptide at 20 mg/kg
(every other day) and gemcitabine 15 mg/kg (every three days) markedly inhib-
ited tumor growth of PAN02 allografts (94% inhibition) more than individual
treatment with gemcitabine (76% inhibition) or C1B5 peptide (39% inhibition).
The tumor growth inhibition by the combination treatment was similar to the
higher dose (50 mg/kg) of gemcitabine alone treatment. Peritoneal cavity infıl-
trated neutrophils and granzime B lymphocyte numbers were signifıcantly
higher in combination treatment group than in control group. In cell culture
study, the treatment with C1B5 peptide alone (1M) signifıcantly increased
INF-, IL-2, and TNF- mRNA levels, suggesting that C1B5 peptide directly
stimulated Jurkat cell activation. These studies suggest that stimulation of leu-
cocyte migration toward cancer tissues and activation of cytotoxic T cells may
play important roles in tumor growth attenuation by the combination treatment
of C1B5 peptide and gemcitabine. Taken together, the current study suggests
that C1B5 peptide offers an effective combination treatment strategy to reduce
side effects associated with gemcitabine without losing tumoricidal effect of this
agent. Thiswork is supported in part byKansas StateUniversity JohnsonCancer
Research Center, NIH grants P20 GM103418, and Kansas State Bioscience Au-
thority Collaborative Cancer Research grant.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
DNA Repair
#1108 A novel, selective inhibitor of DNA-dependent protein kinase
(DNA-PK) potentiates the effects of DNA-damaging therapies in hepatocel-
lular carcinoma. Catherine E. Willoughby,1 Huw D. Thomas,1 Tommy Renni-
son,2 CelineCano,2Helen L. Reeves,3 StephenR.Wedge1. 1Northern Institute for
Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
2School of Chemistry and Northern Institute for Cancer Research, Newcastle Uni-
versity, Newcastle upon Tyne, United Kingdom; 3Liver Unit, Freeman Hospital,
Newcastle uponTyneHospitalsNHSFoundationTrust andNorthern Institute for
Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
DNA-dependent protein kinase (DNA-PK) is a key component in the repair
of DNA double-strand breaks via non-homologous end-joining. Studies have
found elevated DNA-PK expression and activity in hepatocellular carcinoma
(HCC) to be strongly correlatedwith increased tumor grade, resistance toDNA-
damaging therapies and poor survival (1,2). We have explored the selective
inhibition of DNA-PK in combination with DNA-damaging agents as a poten-
tial therapeutic approach in HCC using NDD0004 - a novel, orally-bioavailable
small molecule inhibitor of DNA-PK (in vitro IC50  8 nM). NDD0004 was
evaluated in a panel of DNA-PK overexpressing humanHCC cell lines (Hep3B,
HepG2, Huh7) in combination with ionizing radiation or the topoisomerase II
poison doxorubicin. DNA-PK activity was determined by Ser2056 phosphory-
lation status, DNA damage quantifıed by H2AX levels, cell proliferation deter-
mined by SRB assays and cell survival assessed using clonogenic assays. In vivo
effıcacy was evaluated using a novel murine model of localized and sustained
doxorubicin therapy, involving intra-tumoral injection of doxorubicin-loaded
DC M1 polymer beads into established Huh7 human HCC xenografts in CD1
nude mice. Oral twice-daily treatment with 30 mg/kg NDD0004 or vehicle con-
trol was commenced 1 hour following bead implantation and continued for up
to 20 days (6 mice per group). NDD0004 dose-dependently inhibited activation
of DNA-PK in HCC cell lines in vitro in response to ionizing radiation, and
signifıcantly increased and sustained DNA damage following treatment. Fur-
thermore, NDD0004 sensitized DNA-PK overexpressing HCC cell lines to
doxorubicin and ionizing radiation in proliferation and survival assays by 

5-fold. Combining NDD0004 with doxorubicin-loaded beads in vivo signifı-
cantly inhibited the rapid growth of HCC tumors when compared to treatment
with doxorubicin-loaded bead monotherapy, with the time taken for tumor
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volumes to quadruple (RTV4) being extended from 11 to 18 days (P0.01,
Mann-Whitney). Individual and combination treatments were well tolerated
throughout. Immuno-histochemical analysis revealed H2AX levels in hepato-
cytes surrounding doxorubicin-loaded beads to be signifıcantly increased by
NDD0004 co-treatment for 72-hours (P0.02, 2-way ANOVA). In conclusion,
selective inhibition of DNA-PK catalytic activity sensitized DNA-PK overex-
pressing HCC cell lines to doxorubicin chemotherapy and ionizing radiation in
vitro, and augmented the anti-tumor activity of localized chemotherapy inHCC
xenografts in vivo. These data support the concept of combining a DNA-PK
inhibitor with localized DNA-damaging therapies in the treatment of HCC. 1.
Cornell et al. (2015)ClinCancer Res. 21: 925-33 2. Evert et al. (2013) Br J Cancer.
109: 2654-64
#1109 MutS andMutSmismatch repair complexes differentially regu-
late temozolomide effıcacy & sensitizing effects of veliparib in glioblastoma
cells. Shiv K. Gupta, Emily J. Smith, Ann M. Tuma, Brett L. Carlson, Mark A.
Schroeder, Gasper J. Kitange, Jann N. Sarkaria.Mayo Clinic, Rochester, MN.
Mismatch repair (MMR) is essential for temozolomide (TMZ) sensitivity, and
MMR defıciency causes TMZ resistance and disease recurrence. However, the
role MMR in TMZ response has been linked with Msh2/Msh6 (MutS), while
role of Msh3, a component of MutS remains unclear. To delineate role of
MutS and MutS in TMZ response, we used siRNA to disrupt MSH6 and
MSH3 expression. As expected, silencing of MSH6 led to resistance in a TMZ-
sensitive U251 cell line. In contrast, silencing ofMSH3 enhanced TMZ sensitiv-
ity as compared to the control cells. These results support established role of
MutS in TMZ response via replication stress and DNA double strand breaks
(DSB), and reveal thatMutSmay potentially influence TMZ response bymod-
ulating DSB repair. Consistently, host cell reactivation (HCR) assays in U251
expressing DRGFP reporter showed decreased homologous recombination
(HR) after MSH3 knockdown (KD), while Msh6 KD had no effect on HR effı-
ciency. Supporting the concept of synthetic lethality of HR with PARP inhibi-
tion, clinically relevant dose of veliparib (1M) showed amodest but consistent
increase in TMZ sensitization measured in terms of potentiation factor (PF,
ratio of relative growth with TMZ alone/ TMZ and veliparib) in MSH3 KD (PF
1.6	0.2) as compared to control cells (PF 1.1	0.2). Sensitizing effect of 1 M
veliparib in MSH6 KD (PF 1.7	0.5) was comparable to that in MSH3 KD cells.
Interestingly, supra-therapeutic dose of veliparib (10 M) induced more pro-
nounced sensitization in MSH6 KD cells (PF 2.6	0.3) as compared to MSH3
KD (PF 2.4	0.3) or control cells (PF 1.6	0.2). Consistently, veliparib (10 M)
alone had no impact onDNAdamage signaling, while TMZ induced prominent
increase in phosphorylation of KAP1, Chk1 and Chk2 in control andMSH3KD
cells, but not in MSH6 KD cells; veliparib/TMZ co-treatment led a robust sig-
naling in all 3 types of cells. Increased sensitization by veliparib after MSH3 KD
was also examined in a TMZ-resistant (GBM22TMZ) PDX model carrying re-
sistance due to a homozygous mutation in MSH6, and a 4-fold increase in HR
effıciency. In clonogenic assays silencing of MSH3 or BRCA1 had no effect on
TMZ sensitivity in GBM22TMZ cells. However, veliparib alone (10 M) de-
creased colony formation with relative colony formation 0.54	0.03 and
0.32	0.06 in MSH3 and BRCA1 KD cells, respectively as compared to
0.82	0.04 in controls. TMZ/veliparib co-treatment in GBM22TMZ led to fur-
ther decrease in colony formation in MSH3 KD and BRCA1 KD cells with
relative colony formation of 0.30	0.04 and 0.19	0.02, respectively versus
0.46	0.03 in control. Taken together, our results suggest that MutS and
MutS differentially regulate cytotoxic effects of TMZ. Decreased HR effıciency
and enhanced sensitizing effects of veliparib in MSH3 KD cells partially defıne
synthetic lethality ofMMRdefıciency with PARP, andmay help development of
PARP inhibitors as sensitizer of TMZ therapy in GBM.
#1110 AsiDNA induce tumor sensitivity to PARP inhibitors in homolo-
gous recombination profıcient breast cancerAsiDNA induce tumor sensitiv-
ity to PARP inhibitors in homologous recombination profıcient breast can-
cer.marie DUTREIX,1Wael Jdey,2 sylvain Thierry,1 Inna Kuperstein,3 Graham
Dixon4. 1Institut Curie, Orsay, France; 2Institut Curie, Onxeo, Orsay, France;
3Institut Curie, Paris, France; 4Onxeo, Paris, France.
Purpose: PARP inhibitors (PARPi) have shown signifıcant benefıts in cancer pa-
tients with BRCAmutations. However, their major limitations are the necessity of
homologous recombination (HR) defıciency and the rapid emergence of resistance.
In the current study, we propose a novel therapeutic strategy, based on drug com-
bination to promote sensitivity to PARPi independently of the tumor genetics. Ex-
perimental design: We used AsiDNA, a DNA repair pathways agonist (Dbait con-
cept), consisting in small molecules mimicking double-strand DNA breaks to
activate ectopic signaling of DNA damage and prevent recruitment at damage sites
of HR repair enzymes. We characterized the DNA repair inhibition activity of
AsiDNA by monitoring repair foci formation and DNA damage and analyzed the
cell survival toAsiDNAmonotherapy and combinationwith thePARPiOlaparib of
21 tumor cell lines, and 3 non-tumor cell lines. Effıcacy of the combination treat-
ment was analyzed in tumor xenografts derived from the MDA-MB-231 cell line
showing reduced sensitivity to AsiDNA andOlaparib in vitro.We screened for the
frequency of clones resistant to two weeks treatment with AsiDNA or Olaparib in
the 4NQO-mutagenized haploid KBM7 cells. Results: Molecular analyses of repair
foci formed after irradiation demonstrate that AsiDNA inhibits recruitment of
RAD51 and 53BP1whereasOlaparib prevents XRCC1.Combination of both drugs
increases the accumulation of unrepaired spontaneous damage resulting in an in-
crease of cell death in all tumor cell lines. The synergy of the association of AsiDNA
with PARPi was also confırmed with 6 other PARPi. AsiDNA do not induce any
increase inDNAdamageor lethality innon-tumor cellswhenused inmonotherapy
aswell as in associationwithPARPi.Multi-omics analysis of tumor cells highlighted
a correlation between similarity to normal cells profıle and AsiDNA resistance. Se-
lection of resistant clones allowed the emergence of resistance to Olaparib (1.45%),
Imatinib (0.6%) and 6-Thioguanine (1.6%) but not to AsiDNA (0.07%), indicat-
ing that the drug acts through multiple targets. In the MDA-MB-231 xenograft
model, whereas Olaparib failed to prevent tumor growth and AsiDNA provided
only a 62% increase in tumor growth delay, the combination of Olaparib and
AsiDNAincrease 215%days themean tumorgrowthdelay.Conclusion:Our results
highlight the therapeutic interest of combining AsiDNA and PARPi to recapitulate
synthetic lethality in all tumors independently of theirHR status.Moreover, the low
frequency of appearance of resistant clones toAsiDNA suggests a sustained effıcacy
during treatment unlike most targeted therapies.
#1111 The chromatin remodelers RUVBL1 and RUVBL2 are prognostic
factors and therapeutic targets innon-small cell lung cancer due to their roles
inDNA replication, repair, and radiosensitization.Paul Yenerall,1 Rahul Kol-
lipara,1 Amit Das,1 Pamela Villalobos,2 Long Shan Li,1 Brenda Timmons,1 Luc
Girard,1 Jaime Rodriguez-Canales,2 Ignacio Wistuba,2 John Minna,1 Ralf Kit-
tler1. 1Univ. of Texas SouthwesternMedical, Dallas, TX; 2UT-MDAndersonCan-
cer Center, Houston, TX.
Despite advances in targeted agents and immunotherapy, non-small cell lung
cancer (NSCLC) remains the number one cause of cancer-related death. To
identify new therapeutic targets in NSCLC, we performed an siRNA screen
directed against genes involved in chromatin remodeling. This screen showed
that RUVBL1 and RUVBL2 (herein collectively referred to as RUVBL1/2) were
universally but differentially required for the viability of 24 NSCLC cell lines,
which was an on-target effect. Various independent gene expression datasets/
platforms show that NSCLC patient tumors have increased levels of RUVBL1
and RUVBL2 mRNAs, in comparison to normal lung, and that patients with
high levels of RUVBL1 or RUVBL2 have a poorer prognosis, suggesting that
RUVBL1/2may play an important role inNSCLC tumors. To confırm this at the
protein level, we validated an antibody against RUVBL1 for immunohistochem-
istry, stained clinically annotated NSCLC tissue microarrays for RUVBL1, and
found that patients with higher levels of RUVBL1 protein also have a poorer
prognosis. To better understand the role of RUVBL1/2 inNSCLC at amolecular
level, wemeasured the distribution of cells in the cell cycle following RUVBL1/2
KD, determined RUVBL1/2 interacting proteins by immunoprecipitation fol-
lowed by tandem mass-spec (IP-MS/MS), and measured gene expression
changes following RUVBL1/2 KD by RNA-seq. Depletion of RUVBL1/2 ar-
rested cells in S-phase and promoted pan-H2AXpositivity, IP-MS/MS showed
an over-representation of proteins involved in DNA repair and replication, and
gene set enrichment analysis of the RNA-seq data displayed a downregulation of
transcripts involved in DNA replication and repair, strongly implicating RU-
VBL1/2 in these processes. To further probe the effects of RUVBL1/2 loss, we
performed low-level knock down (KD) of RUVBL1/2, such that viability is
largely unaffected, and thenmeasured the viability of cells in response to various
drugs (n35). These drugs target a wide variety of biological processes; how-
ever, the only drugs with increased effıcacy in the presence of RUVBL1/2 KD
were those that damageDNA, target ATR or its downstreampartner CHEK1, or
target somemitotic proteins, further implicatingRUVBL1/2 inDNA replication
and/or repair. Due to their roles in replication, we reasoned that RUVBL1/2 KD
may enhance the effects of ionizing radiation, a treatment frequently given to
NSCLCpatients. Low level KDof RUVBL1/2 decreased the clonogenic potential
of multiple NSCLC cell lines, which can be phenocopied by depleting indepen-
dent subunits of RUVBL1/2-containing chromatin remodeling complexes. Fi-
nally, we show that RUVBL1/2 depend upon their ATPase activity to support
NSCLC viability, suggesting that small molecule inhibitors of this protein may
be effıcacious in the treatment of NSCLC, especially when combined with radi-
ation therapy.
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#1112 Forced reduction of DSS1, a member of TREX2 complex, highly
sensitizes chemotherapy to breast cancer cells in a BRCA2-independent
manner. Kazuhiko Kuwahara,1 Naomi Gondo,2 Andri Rezano,3 Zhenhuan
Zhang,4 Yukari Hato,5 Kiyotaka Kuzushima,2 Hiroji Iwata,6 Tatsuya Toyama,5
Eisaku Kondo1. 1Niigata University Graduate School of Medical and Dental Sci-
ences, Niigata, Japan; 2Aichi Cancer Center Research Institute, Nagoya, Japan;
3Universitas Padjadjaran, Bandung, Indonesia; 4University of Florida, Gaines-
ville, FL; 5Nagoya City University Graduate School of Medical Sciences, Nagoya,
Japan; 6Aichi Cancer Center Hospital, Nagoya, Japan.
[Introduction] DSS1 (deleted in split-hand/split-foot malformation 1) was
originally identifıed as a BRCA2-associated/stabilizing protein. By comparison
ofDSS1mRNA level, we reported that the highDSS1 expression groups in breast
cancer patients showedworse prognosis in relapse-free survival (RFS); however,
DSS1 expression per se was not correlatedwith other clinical parameters includ-
ing cellular proliferation or tumor grade, suggesting that the level of DSS1 af-
fected the sensitivity of DNA-damage agents in breast cancer cells (Rezano et al.,
2013). It still remains unclear why the expression level of DSS1 is associatedwith
chemosensitivity, because DSS1 has multifunctional properties regulating ho-
mologous recombination and RNA-mediated genomic stability. In this study,
we investigated if the effect of DSS1 in chemosensitivity is influenced by two
representative DSS1-associated molecules, BRCA2 and PCID2. [Methods] We
established MCF7 overexpressing DSS1 (MCF7/DSS1) by retroviral transfec-
tion. DSS1, BRCA2, or PCID2 knockdown in MCF7 was performed using
siRNA transfection. The susceptibility to the cytotoxic chemotherapy such as
doxorubicin and paclitaxel in breast cancer cells was evaluated by flow cytom-
etry to detect apoptosis and colony assay. In addition, we compared patient
survival by dividing patients into high or low expression group of BRCA2 or
PCID2 using cohort studies. [Results] BRCA2 depletion inMCF7/DSS1 did not
alter the chemoresistance. Although DSS1 knockdown induced the downregu-
lation of BRCA2, direct depletion of BRCA2 did not show marginal effect to
chemosensitivity, suggesting that the enhancement of chemosensitivity byDSS1
knockdown was not related to BRCA2 expression. Importantly, over- and un-
der-expression of PCID2 induced similar effect to chemosensitivity compared
to those of DSS1. There was a trend that high PCID2 expression group in breast
cancer patients showed worse prognosis in RFS. [Conclusion] DSS1 could be a
molecular target to increase chemosensitivity, which is independent of BRCA2
expression. Rather, the transcription-coupled DNA damage induced by im-
paired TREX2 complexmight be associated with induction of chemosensitivity.
#1113 Inhibition of DNA repair by NR1D1 enhances chemosensitivity of
breast cancer cells. Na-Lee Ka, Tae-Young Na, Hyelin Na, Mi-Ock Lee. Seoul
National University, Seoul, Republic of Korea.
Most chemotherapeutic agents exert cytotoxic effects by inducing excessive
DNA lesions in cancer cells. Therefore, regulating DNA repair networks is a
critical factor that determines sensitivity of cancer cells to chemotherapeutic
drugs. In this study, we identifıed the role of nuclear receptor NR1D1 in DNA
repair, which enhanced chemosensitivity in breast cancer cells. NR1D1 inhib-
ited recruitment of the DNA repair complex to damaged DNA sites, thereby
impaired proper DNA repair upon doxorubicin treatment in breast cancer cells.
Interaction with Poly(ADP-ribose) polymerase-1 and subsequent PARylation
were critical steps that allow NR1D1 to translocate to DNA double-strand
breaks. In agreement, depletion of NR1D1 in MCF-7 cells resulted in resistance
to a chemotherapeutic drug, doxorubicin, in both in vitro and in vivo experi-
ments. Further, NR1D1 expression level was correlated positively with clinical
outcomes in breast cancer patients who received chemotherapy. Thus, NR1D1
and its ligands may provide better therapeutic options that could enhance the
outcomes of adjuvant chemotherapy in breast cancer patients.
#1114 Combining anti-androgen therapy and PARP inhibition results in
synergistic cytotoxicity of metastatic castration-resistant prostate cancer
(mCRPC) cells. Sahithi Pamarthy, Vinay Sagar, Rajita J. Vatapalli, Zachary Re-
instein, Muhammad Zayd Ansari, Benedito A. Carneiro Filho, Francis J. Giles,
Sarki A. Abdulkadir. Northwestern University, Chicago, IL.
Androgen deprivation therapy is an effıcient fırst line therapy for advanced
prostate cancer. However, in most cases resistance inevitably develops resulting
in metastatic castration-resistant prostate cancer (mCRPC). Abiraterone and
enzalutamide are approved to treat mCRPC and act by inhibiting androgen
biosynthesis and androgen receptor (AR) signaling, respectively. Poly (ADP-
ribose) polymerase 1 (PARP1) is a key enzyme in the DNA damage repair path-
way and has also been implicated in AR signaling cascade. Recent reports sug-
gest signifıcant effıcacy combining anti-androgens and inhibitors of Poly (ADP-
ribose) polymerase (PARP) particularly against cells harboringmutations in the
DNArepair pathway.Here, we provide evidence of synergistic cytotoxicity com-
bining PARP inhibition and androgen signaling ablation in the AR positive
human CRPC cell line 22RV1 harboring mutation in the DNA repair gene
BRCA2. The PARP inhibitor talazoparib (IC50 - 0.05 M) was upto 20 times
more potent than olaparib (IC50 – 1.0 M) in inducing cell death in 22RV1 as
seen by cell viability and clonogenic assays.When combinedwithAR antagonist
enzalutamide (IC50 – 0.25 M) or androgen synthesis inhibitor abiraterone
(IC50 – 1.25 M) both PARP inhibitors showed signifıcant synergy, although
talazoparib was more prominent owing to its superior potency. Higher concen-
trations of enzalutamide and abiraterone (10M) induced PARP cleavage and
increased expression of-H2AX, amarker forDNAdamage.Our results suggest
that AR signaling inhibition involves PARP mediated apoptosis and highlight
the crosstalk between PARP and AR pathways. In summary, combining anti-
androgen therapy and PARP inhibitors carry signifıcant therapeutic potential
for CRPC patients harboring mutations in DNA repair pathway.
#1115 Germline single nucleotide polymorphisms inDNA repair genes in
urothelial cancer patients.BishoyM. Faltas, Panagiotis J. Vlachostergios, Linda
Lam, Tuo Zhang, Olivier Elemento, Mark A. Rubin.Weill Cornell Medical Col-
lege, New York, NY.
Introduction: Germline single nucleotide polymorphisms (SNPs) have been in-
vestigated in several cancers. Repair of DNA damage is a key cellular process in-
volved in the development of chemotherapy-resistance. The role of germline SNPs
inDNAdamage repair genes (DRGs) in determining resistance toDNA-damaging
agents in urothelial carcinoma (UC) patients is not completely understood. Meth-
ods:We examined a cohort of 53UCpatients (median age 67, 42males) enrolled in
our IRB-approved Precision Medicine program. Patients had histologically con-
fırmed UC (43 bladder, 10 upper tract UC) and received treatment with platinum-
based chemotherapy. We isolated germline DNA from peripheral blood lympho-
cytes or buccal swabs, and used whole exome sequencing (WES) to examine
germline SNPs. As a reference for SNP frequencieswe used the ExomeAggregation
Consortium (ExAC) database, which represents the largest, randomly selected,
germline WES database in the general population, including 60,706 individuals,
among which 7,601 patients with multiple cancer types from the Tumor Cancer
GenomeAtlas (TCGA) cohort. Results: Twelve differentDRGSNPswere identifıed
in germlineDNAsamples from53patients, affecting genes involved innon-homol-
ogous end-joining (RECQL4, n 18, 54.50%; POLQ, n 2, 6%), nucleotide exci-
sion repair (ERCC6, n 2, 6%; XPA, n 1, 3%; CCNH, n 1, 3%; POLK, n 1,
3%), homologous recombination (RNF168, n 1, 3%; RAD17, n 1, 3%; POLE,
n 1, 3%), Fanconi anemia pathway (POLN, n 1, 3%), mismatch repair (EXO1,
n 1, 3%) and mitochondrial DNA repair (POLG, n 2, 6%). The frequency of
rs11342077 of the DNA helicase RECQL4 was signifıcantly higher in our cohort
(18/53,34%)compared to its frequency in theExACdatabase (p0.01%).Therewas
no signifıcant difference in overall survival (OS) between patients with andwithout
DRG SNPs (log-rank p0.46). There was no signifıcant association between the
most commonly identifıed SNP, rs11342077, and overall survival among UC pa-
tientswithDRGSNPs (log-rankp0.39).Overall, thepresenceofDRGSNPs inour
cohort occurred at a signifıcantly higher frequency (33/53, 62.3%) compared to the
ExAC database (0.56%, chi-square p0.01). Conclusions: Germline SNPs in DNA
repair pathway genes are common inUC.Additional studyof the role of these SNPs
as potential biomarkers of response DNA damaging chemotherapeutic agents, in-
cludingplatinum-based chemotherapyor/andPARP inhibitors is needed in a larger
cohort.
#1116 Targeting replication stress by carbazole blue- A novel strategy to
treat triple negative breast cancers. Subapriya Rajamanickam,1 Kaitlyn Bates,1
Santosh Timilsina,1 JunHyoung Park,2 Benjamin Onyeagucha,1 Panneerdoss
Subbarayalu,1 Nourhan Abdelfattah,1 KwangHwa Jung,2 Edward Favours,1 Ta-
brez A. Mohammad,1 Hung-I Harry Chen,1 Benny A. Kaipparettu,2 Yidong
Chen,1 Jack L. Arbiser,3 Manjeet K Rao1. 1University of Texas Health Science
Center San Antonio, San Antonio, TX; 2Baylor College of Medicine, Houston-
77030, TX; 3Emory University School of Medicine, Atlanta-30322, GA.
Background: Triple-negative breast cancers (TNBC) are the most aggressive
forms of breast cancer and almost 60% of patients with TNBCs develop chemo-
resistance, leading to recurrence, poor prognosis and poor survival. TNBCs have
been reported to have high levels of replication stress, which plays pivotal role in
genomic instability, and therapy resistance. Targeting replication stress is an emerg-
ing approach for better TNBC treatment.Here, we evaluated the anticancer effıcacy
of carbazole blue (CB), a synthetic analogue of carbazole that we recently synthe-
sizedonTNBCcells growthandprogression.ExperimentalDesign:Theeffect ofCB
on breast cancer growth was assessed in vitro as well as in orthotopic mouse xeno-
graft and PDX-models of breast cancer. In addition, the therapeutic effıcacy and
safety ofCBwasdetermined in long term toxicity studies inmice and also in ex-vivo
explants frombreast cancer patients. Themechanismof action of CBwas evaluated
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by performing gene expression, cell cycle, apoptosis andDNA repair studies as well
as proteins involved in the abovementionedmechanisms.Results:Our results dem-
onstrated that CB inhibits short and long term viability of TNBC cells in a dose
dependent manner without affecting normal mammary epithelial cells. We show
that the systemic delivery of CB using nanoparticle-based delivery approach sup-
pressed breast cancer growth without inducing toxicity in preclinical and PDX
mousemodelsof triplenegativebreast cancer.Our long termtoxicity studies reveled
thatCB treatmentdidnot induce any toxicity inBalb/cmice.Using ex-vivo explants
from breast cancer patients, we demonstrated that CB modulated breast cancer
growth. Consistent with that, our results revealed that CB treatment induced G1/S
cell cycle arrest and apoptosis in TNBCs. Interestingly, our gene expression analysis
revealed that CB modulates expression and activity of several genes known to be
involved inDNA replication andDNA repairmachinery. Conclusions: Our results
for the fırst time showed theCBcan serve as anovel andpotent therapeutic agent for
treating breast cancer in general and TNBC in particular. These fındings highlight
the potential ofCB tobe applied as a safe regimen for treating breast cancer patients.
As exploiting replication stress to treat cancer is gainingmajor interest, compound/s
thatmay induce replication stress and inhibit DNA repair ability of cancer cells, has
immense translational potential.
#1117 Triple negative breast cancer patient-derived xenografts as a trans-
lational model for discovery of novel therapeutic targets. Margarite D. Ma-
tossian,1 Hope E. Burks,1 Annie C. Bowles,1 Rachel A. Sabol,1 Van T. Hoang,1
Bruce Bunnell,1 William J. Zuercher,2 David H. Drewry,2 Carrow Wells,2
Krzysztof Moroz,3 Matthew E. Burow,1 Bridgette Collins-Burow1. 1Tulane Uni-
versity School ofMedicine, NewOrleans, LA; 2University of North Carolina, Cha-
pel Hill, NC; 3Louisiana Cancer Research Center, New Orleans, LA.
Triplenegativebreast cancers (TNBCs)constitute12%ofall breast cancers, and is
approximately twice more prevalent in African-American populations. Louisiana
hasahighproportionofAfrican-Americanresidents (32.5%in2015), andthushosts
a higher population of TNBCpatients. TNBCs have an aggressive phenotype that is
elusive to the targeted therapeutics used to treat other breast cancer subtypes. The
claudin-lowmolecular subtype has higher rates of metastases and recurrence. Cer-
tain kinase families have been extensively studied as regulators of epithelial-mesen-
chymal transition (EMT), a process involved in the initiation of cancer metastasis.
Discovery of novel kinase targetswithin the subset of uncharacterized kinases could
provide important insight into future targeted therapies. However, current models
utilized in target discovery research are limited by the inability to accurately recapit-
ulate the complex stromal architecture and heterogenous genetic and molecular
composition of breast cancer. Furthermore, immortalized cell lines are limited to a
2D environment and over time acquire mutations that may not reflect the primary
tumor. Recently, our laboratory has successfully established two TNBC patient-
derivedxenograft (PDX)modelsderived fromAfrican-Americanpatients, andgen-
erated cell lines (TU-BCx-2K1, TU-BCx-2O0) and mammospheres. One of these
models, 2O0, presents tumor architecture, cellular composition, genomic (qRT-
PCR) andprotein (westernblot) expressions that are concordantwith a claudin-low
subtype. Furthermore, we show that both TNBC models metastasize to the lungs,
andexhibitmolecular characteristics consistentwithmesenchymalphenotypes.We
utilized these translational PDXmodels to screen a library of small molecule inhib-
itors that represent a variety of kinase pathways to identify novel therapeutic targets
and/or pathways that are specifıc toTNBC subtypes.We found in a preliminary cell
morphologyscreenusing threeTNBCcell lines (MDA-MB-231,BT549,MDA-MB-
157), two small molecule inhibitors that increased epithelial marker (CDH1) gene
expression, suppressed mesenchymal (VIM, c-FOS, SNAI1, ZEB1) expression
and/or suppressed cellularmotility in transwellmigration assays.Weobserved after
ex vivo treatmentswith our PDX tumors the two compounds increase the epithelial
marker CDH1 expression, and suppress mesenchymal markers (VIM,MMP2) ex-
pressions.Weconfırm these fındings in theTU-BCx-2K1cell line.Kinase arraydata
revealed candidate kinases responsible for the observed EMT changes in the two
compounds of interest (NEK5, NEK9, NEK1 potentially affect cell motility; SRC-
family kinases, TAOK2, STK10 potentially affect EMT gene changes); we plan to
utilize the PDXcell lines to characterize these kinases in EMT.We aim to ultimately
discover novel therapeutic targets specifıc to different TNBCmolecular subtypes.
#1118 Synthetic lethality of CDK12 inhibition in tumors with EWS/FLI
rearrangements. Amanda L. Balboni,1 Bjorn Stolte,1 Amy Saur Conway,1 Ga-
brielaAlexe,1 Emily JueWang,1NicholasKwiatkowski,1 TinghuZhang,1 Brian J.
Abraham,2 Peter Kalev,1 Dipanjan Chowdhury,1 Cyril H. Benes,3 Richard A.
Young,2 Nathanael S. Gray,1 Kimberly Stegmaier1. 1Dana-Farber Cancer Insti-
tute, Boston,MA; 2Whitehead Institute, Cambridge,MA; 3Massachusetts General
Hospital, Boston, MA.
THZ1 is a potent, covalent inhibitor of the transcriptional CDKs, CDK7/12/
13. Chemical genomic profıling of THZ1 across1,000 diverse cancer cell lines
revealed that EWS/FLI- rearranged Ewing sarcoma cells were remarkably sen-
sitive to this molecule. We demonstrated that THZ1 inhibits the phosphoryla-
tion of the C-terminal domain of RNA Polymerase II, decreased colony forma-
tion capacity, and induced apoptosis in a dose-dependent manner in Ewing
sarcoma cell lines. Using selective CDK7 and CDK12/13 inhibitors, we revealed
that the primary target of THZ1 in Ewing sarcoma is CDK12/13. Genetic sup-
pression of CDK12, but not CDK13, induced strong anti-viability effects, con-
fırming CDK12 as the primary target. Treatment of Ewing sarcoma cell lines
with THZ531, a novel CDK12/13 selective inhibitor, preferentially repressed
genes involved in DNA damage repair. Additionally, suppression of EWS/FLI
rendered Ewing sarcoma cells resistant to THZ531 and partially rescued the
anti-viability effects of CDK12 knockdown. These results suggest that EWS/FLI
imparts vulnerability toDNAdamage repair inhibition and implicate a synthetic
lethal relationship between the tumor-specifıc expression of EWS/FLI and
CDK12 inhibition. Furthermore, we demonstrated that CDK12 and PARP in-
hibitors are highly synergistic in vitro, inducing widespread yH2AX foci forma-
tion. Interestingly, THZ531 impairs the ability of the PARP inhibitor, olaparib,
to induce RAD51 foci formation, suggesting that THZ531 specifıcally causes a
defect in homologous recombination repair. Moreover, we observed striking
synergy of THZ1 and olaparib in two mouse models of Ewing sarcoma with
limited toxicity observed. These fındings have important translational signifı-
cance as clinical trials with PARP inhibitors as single agents in Ewing sarcoma
failed to demonstrate effıcacy, highlighting the need to identify combination
therapies that will enhance the activity of PARP inhibition. We anticipate that
CDK12 andPARP inhibitor combinationswill be of therapeutic interest in other
ETS-rearranged tumors, as well as tumors with defects in DNA repair.
#1119 Targeting tankyrases as a therapeutic strategy for triple-negative
breast cancer.Maya Mathew, Loredana Campo, Jung-Lye Kim, Geun-Hyoung
Ha, Eun-Kyoung Breuer. Loyola University Medical Center, Maywood, IL.
Tankyrases (TNKS1 and TNKS2) are members of the human poly(ADP-
ribose) polymerase (PARP) family and catalyze PARsylation by usingNAD as
a substrate to modify various proteins in order to regulate various cellular pro-
cesses including Wnt/-catenin signaling. TNKS1 has been shown to be over-
expressed and to be correlated with highly aggressive disease and prognosis in
various types of human cancers. A smallmolecule inhibitor of TNKS1,XAV-939
has been proven to be a potent inhibitor ofWnt/-catenin signaling by stabiliz-
ing Axin. However, the effect of tankyrase inhibitors as potential breast cancer
therapy is still under investigation. In this study, we found that TNKS1 is highly
expressed in breast cancer cell lines, particularly in triple-negative breast cancer
(TNBC) cells and that the expression of TNKS1 correlateswith anti-proliferative
effıcacy of tankyrase inhibitors, XAV-939 and JW55. Also, XAV-939 treatment
suppressed cell migration and invasion capabilities and epithelial-mesenchymal
transition (EMT) signaling in triple-negative breast cancer cell lines. Moreover,
XAV-939 reduced expression of stemness markers. It was shown that polo-like
kinase 1 (PLK1) functions as a positive regulator of TNKS1 protein stability.
Interestingly, we found that combination treatment of XAV-939 with PLK in-
hibitor GW843682X signifıcantly suppressed cell growth, clonogenic potential,
migratory and invasive capabilities of breast cancer cells. The combination of
XAV-939 with ionizing radiation (IR) also showed an additional therapeutic
effect. Therefore, our fındings highlight the important value of TNKS1 as a
therapeutic target and suggest the potential for improving the clinical effıcacies
of tankyrase inhibitors in combination with either PLK inhibitors or radiother-
apy for patients with triple-negative breast cancer.
#1120 Chronopharmacology of cisplatin: role of the circadian rhythm in
modulating cisplatin-induced toxicity in melanoma mouse model. Panshak
Dakup, Kenneth Porter, Rajendra Gajula, Shobhan Gaddameedhi.Washington
State Univ. College of Pharmacy, Spokane, WA.
Purpose: The goal of this research is to highlight novel and divergent molec-
ularmechanisms of the circadian system inmodulating the response of cisplatin
therapy against melanoma tumors. Cisplatin is one of the most commonly used
chemotherapeutic drugs in treating a variety of tumors including cancers of
ovaries, testis, lungs, blood and solid tumors of the head and neck, and is more
recently under clinical trials for potential application in melanoma tumors.
However, the major limitation of cisplatin as a chemotherapeutic drug is its
tumor resistance and nephrotoxicity. Hence, improving the effectiveness and
reducing the toxicities associated with cisplatin therapy are desirable outcomes.
Studies on human models have shown decreased renal and blood toxicity by
time-of-the-day. Consequently, our project seeks to study the chronopharma-
cological effects and understand the mechanisms that have been successfully
demonstrated in human models. We hypothesize a mechanistic, circadian
rhythm-based cause for these outcomes. Experimental Design: Studies were
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done on B16F10melanomamouse models of wild-type and circadian disrupted
Per1/2 -/- animals treated with 3 doses of 5 mg/kg cisplatin in the morning (7
AM) and evening (5 PM). Animal weights and tumor sizes were measured reg-
ularly post-treatment. Upon sacrifıce, tissues (skin, kidney, and tumor) were
harvested and analyzed for cisplatin-induced toxicities and DNA damage re-
sponses using H & E staining, western blot, and KIM-1 and immuno-slot blot
assays. Results: Weight measurements show a clock-regulated response to cis-
platin toxicity. AM-treated wild-type animals showed signifıcant weight loss
compared to PM-treated wild-type animals. This treatment time differential is
lost in the Per1/2 -/-. On a molecular level, kidney tissue DNA samples showed
clock-controlled cisplatin-DNA repair activity in wild-type animals compared
toPer1/2 -/-. These initial fındings strongly suggest that nephrotoxicity andDNA
damage response functionmight be regulated by the circadian rhythm. Conclu-
sions: These fındings indicate a possible mechanism for the chronopharmacol-
ogy of cisplatin in minimizing the toxicity associated with it and reveal a target
for future study of additional mechanistic causes of circadian dosing changes in
cisplatin and other genotoxic stress-mediated anti-cancer agents.
#1121 Redox-mediated inactivation of MGMTDNA repair through thio-
lation or nitrosylation of the active site cysteine145 sensitizes humangliomas
to alkylating agents in vitro and in xenograft models. Debasish Basak,
Kalkunte S. Srivenugopal. Texas Tech University Health Sciences Center, Ama-
rillo, TX.
O6-Methylguanine-DNAmethyltransferase (MGMT) is a simple andunique an-
timutagenic DNA repair protein that plays a crucial role in conferring tumor resis-
tance to various alkylating agents in brain tumor therapy.MGMT repairs O6-alkyl-
guanines by transferring the alkyl groups to its active site cysteine (Cys145) in a
stoichiometric/suicidal reaction thereby restoring the original nucleotide sequence
in a single step.AlthoughO6-benzylguanine (BG), a pseudosubstrate inhibitor, cur-
rently in clinical trials, potently inhibits MGMT and improves the effıcacy of alky-
lating agents, unacceptable levels of bonemarrow toxicity has been a great concern.
FordevelopingnewMGMTinhibitors,we exploited the reactivenatureof the active
site Cys145 (pKa 4.5) and its susceptibility for thiolation and nitrosylation, both of
which inactivate theMGMT. A new strategy involving inhibition of S-nitosogluta-
thione reductase (GSNOR) was also explored to increase the steady-state levels of
nitrosylated MGMT. First, we designed a redox perturbing glutathione mimetic, a
homoglutathione disulfıde (hGTX) that has been stabilized with the addition of
small amounts of cisplatin (1000:10). Spermine NONOate and S-nitroso penicilla-
mine (SNAP) served as the protein-nitrosylating agents. N6022, a specifıc and re-
versible inhibitor of GSNOR was used with nitrosylators in some assays. Both the
hGTXandspermineNONOateat100-400Mconcentrations for24h inhibited the
repair activity of MGMT 75% in HT29, SF188, and T98G cells. The NONOate
strongly curtailed theDNA repair activity of recombinantMGMT showing a direct
interaction. The inactivatedMGMT protein was promptly eliminated from glioma
cells. MGMT disappeared from cells much faster in spermine NONOateN6022
treated cells, suggesting an extended steady-state of nitrosylated MGMT and its
subsequent degradation. MGMT depletion was accompanied by 4-6 fold increases
in cell killing by BCNU or temozolomide (TMZ). Binding of the biotinylated-O6-
benzylguanine to the MGMT protein was prevented by hGTX and spermine
NONOate treatments indicating the Cys145 was indeed the site of modifıcation. In
the nudemice bearing T98G orHT29-luc2 xenografts, combinations of hGTX and
TMZor spermineNONOateTMZproducedmarkedly synergistic tumor regres-
sions compared with TMZ alone. A reduction of MGMT protein as by immuno-
blotting and diminished MGMT activity levels in tumor tissues was verifıed. Apo-
ptosis regulatory proteins were upregulated in excised tumors and H&E staining
confırmednodiscernible host organ toxicities.Our studies highlight the options for
redox-driven therapeutic strategies for MGMT [supported by CPRIT grants
RP130266 and RP170207 to KSS].
#1122 ATR inhibitors synergize with PARP inhibitors in killing glioblas-
toma stem cells and treating glioblastoma. Jianfang Ning, Hiroaki Wakimoto,
Robert L.Martuza, SamuelD.Rabkin.MassachusettsGeneralHospital, Boston,MA.
PARP inhibitors (PARPi) have been used alone or in combination with other
agents for the treatment of tumors with homologous repair (HR) defıciencies.
However, challenges remain for the treatment of tumors that are PARPi-resis-
tant or HR-profıcient. Glioblastoma (GBM) is an invariably lethal tumor that is
not associated with HR defıciencies. GBM stem cells (GSCs), thought to be
critical for tumor growth and resistance to therapy, can be isolated from GBM
specimens and are representative of the patient’s tumors. GSCs exhibit variable
PARPi sensitivity, with at least half being resistant. In order to enhance the
antitumor effıcacy of PARPi for GBM, we examined the combination of PARPi
with inhibitors of oncogenic or DNA damage pathways, including inhibitors of
PTEN, PI3K,ATM,ATR, and temozolomide, some ofwhich have been reported
to sensitize cancer cells to PARPi. Only inhibitors of ATR (VE821, VE822,
AZ20) synergized with PARPi in killing GSCs in vitro. VE822 inhibited ATR
activity both in vitro and in vivo, and modestly, but signifıcantly, extended
survival in mice bearing GSC-derived tumors. However, ATR inhibitor (ATRi)
in combination with PARPi further prolonged survival, compared to each drug
alone, even in mice bearing PARPi-resistant GSC-derived tumors. This is the
fırst report that ATRi alone or in combinationwith PARPi is effective in treating
GBM and provides a rationale for clinical trials for GBM.
#1123 Sphingolipids transfer proteins (GLTP and CPTP) regulate the
neoplastic progression of colon and breast cancer cells. Shrawan K. Mishra,
Rhoderick E. Brown. Hormel Institute, University of Minnesota, Austin, MN.
Sphingolipids have previously been shown to affect cancer progression by
regulating cell death (apoptosis) and survival (autophagy). While apoptosis
is promoted by elevations in sphingosine and ceramide, increases in sphin-
gosine-1-phosphate and ceramide-1-phosphate can tip the balance toward
survival. Changes in the expression of sphingolipid transfer proteins such as
GLTP (glycolipid transfer protein) and CPTP (ceramide-1-phosphate trans-
fer protein) have been shown to modulate cell shape change and regulate
pro-inflammatory cytokine release, respectively, in human cancer epithelial
cell lines. To gain a better understanding of the situation, we investigated
further. We discovered that GLTP overexpression inhibits the growth of
human colon carcinoma cell lines (HT-29; HCT-116), but spares normal
colonic epithelial cells (HCEC) largely due to growth arrest at the G0/G1 cell
cycle checkpoint. Mechanistically, we found that GLTP overexpression
modulated cell cycle progression by upregulating Kip1/p27 and Cip1/p21
protein and mRNA levels, while decreasing CDK2, CDK4, cyclin E and cy-
clin D1 protein levels. The cell cycle arrest and growth inhibition induced by
GLTP overexpression led to apoptotic cell death of HT-29 cells. Neither
GLTP nor CPTP overexpression induced apoptosis in breast cancer cell lines
(T47D and HTB-126). However, depletion of CPTP, but not GLTP, induced
autophagy as indicated by increased LC3 transcript and autophagosome
levels (GFP-LC3-II puncta). In the breast cancer cell lines, increased tran-
script levels of cPLA2 and CERK were detected consistent with the earlier
pro-inflammatory effect reported for CPTP depletion in A549 lung epithelial
carcinoma cells. Our fındings shed light on the mechanistic ways by which
GLTP and CPTP affect apoptosis and autophagy to impact cancer progres-
sion. Future in vivo studies are planned to ascertain the role(s) of these new
players in cancer development and therapy. [Support: NIH GM45928, HL-
125353, Paint-the-Town-Pink (PTTP) Cancer Funds, Hormel Fdn]
#1124 Assessment of HRD score as predictor of chemosensitivity of
PDAC PDX xenograft models to DNA-damaging chemotherapy. Vladimir
Khazak,1 Natalia Skobeleva,2 Anastasiia Vetkina,2 Ilya Serebriiskii,2 Kirsten M.
Timms,3 Angela Davies,4 Igor Astsaturov2. 1NexusPharma Inc., Philadelphia,
PA; 2Fox Chase Cancer Center, Philadelphia, PA; 3Myriad Genetics, Inc., Salt
Lake City, UT; 4Champions Oncology, Inc., Hackensack, NJ.
Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy
that affects 44,000 individuals annually in the US, with almost 90% lethality
even when diagnosed prior to metastasis. There is an urgent unmet medical
need both for new therapies as well as better matching of existing therapies to
patients. To address this emergency, we are assessing the feasibility of im-
plementing a strategy of using HRD (Homologous Recombination Defı-
ciency) scores for better therapy matching in PDAC patients. Using a panel
of 77 patient-derived xenograft (PDX) models that were developed from
fresh surgical PDAC tumor samples, HRD scores were generated based on
analysis of three biomarkers (LOH, TAI and LST) and mutational data for 45
genes. All 77 samples met inclusion criteria, 75 FFPE specimens generated
mutation data. HRD analysis was successful for 71 specimens (range 1 - 63
(median22)), with the primary cause of failure identifıed as high non-
tumor content. 53 PDXmodels had mutations in KRAS gene and 45 in TP53.
We have also identifıed 4 PDX models with mutations in BRCA2, 3 models
with mutations in ATM, 4 models with mutations in RAD51. We have also
found frequent mutations in several other DNA repair genes (ATR, PALB2,
MLH1, MSH2, MSH3, MSH6, FANCM), but most of these models retained
one functional allele and were not associated with a high HRD score. Using
this genomic analysis, all 71 PDX models were stratifıed into three clusters
with high, medium and low HRD scores. Three PDXmodels with the highest
and lowest HRD scores each were selected for an in vivo study with DNA-
damaging platinum-based chemotherapeutic agents Cisplatin and Carbo-
platin, as well as with a clinically relevant PARP inhibitor Niraparib. The
results of the PDX study will be reported and compared with responses to
chemotherapy using RECIST V1.1 in patients.
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#1125 Eukaryotic Elongation Factor 2 Kinase (eEF-2K) is a novel thera-
peutic target in BRCA1 mutated breast cancer. Elif Asik,1 Nermin Kahra-
man,1 Tulin Guray,2 Murvet Volkan,2 Gabriel Lopez-Berestein,1 Bulent Ozpo-
lat1. 1MD Anderson Cancer Center, Houston, TX; 2METU, Ankara, Turkey.
BReast CAncer 1 and 2 (BRCA1/2) tumor suppressor genes are frequently
mutated in familial breast and ovarian cancers. Recent clinical trials in breast
cancers with BRCA1/2mutations indicate that 50-75% of patients may not have
response to poly (ADP-ribose) polymerase inhibitors (PARP) inhibitors. Thus,
identifıcation of novel molecular targets and therapeutic interventions are
needed to improve poor clical outcome and patient survival. Here we report that
Eukaryotic Elongation Factor-2 Kinase (EF2K), an atypical kinase, is highly
upregulated in BRCA1 mutated cell lines and involved in colony formation,
migration/ invasion and enhances the effect of PARP inhibitors. Furthermore,
in vivo therapeutic targeting of EF2K by once a week systemic injections with
magnetic nanoparticles (MNPs) incorporating EF2K siRNA signifıcantly inhib-
its growth of BRCA1 tumors in orthotopic xenograft models in mice by inhi-
bition of tumor cell proliferation, angiogenesis and induction of robust apopto-
sis, whichwere associatedwith in vivo inhibition of clinically relevantmolecular
pathways including, proliferation, survival/drug resistance (PI3K/Akt, c-Myc),
cell cycle (Cyclin D1), motility/invasion (Src/FAK/Paxillin), translation (4E-
BP1), angiogenesis (VEGF) and stem-cell markers. No toxicity was detected
during the study and by postmortem analysis of major organs, indicating that
targeting EF2K is safe. The combination of PARP inhibitor (AZD2281, Olepa-
rib) withMNP-EF2K siRNA enhanced signifıcantly growth inhibition inMDA-
MB-436 cells indicting EF2K siRNA sensitize BRCA1mutation breast cancer
cells to PARP inhibitors. Collectively, our results suggest, for the fırst time, that
EF2K is involved in tumorigenesis and progression andmay serve as a potential
therapeutic target in BRCA1mutated breast cancers.
#1125A -hydroxybutyrate inhibits histone deacetylase activity and ra-
diosensitizes malignant glioma cells. Eric C. Woolf,1 Alex P. Rossi,1 Helena B.
Silva-Nichols,1 Kara D. Gardner,1 Nelofer Syed,2 Adrienne C. Scheck1. 1Barrow
Neurological Inst., Phoenix, AZ; 2Imperial College London, United Kingdom.
Several preclinical studies support the use of the therapeutic ketogenic diet
(KD) and/or caloric restriction (CR) as an adjuvant to cancer therapy. This data
not only suggests that this approach alters multiple hallmarks of cancer growth,
but that it may also enhance other therapeutic modalities. We have demon-
strated that the unrestricted KD greatly increases survival in a mouse model of
malignant glioma when administered in combination with radiation, yet the
underlying mechanisms are not fully elucidated. Mounting evidence suggests
that the abnormal epigenetic landscape in tumors may, among other things,
impact radiosensitivity. Specifıcally, many cancers exhibit increased histone
deacetylase (HDAC) activitywhich contributes to the epigeneticmilieu found in
tumors and alters DNA damage repair. It was recently demonstrated that the
ketone body -hydroxybutyrate (BHB) inhibits HDAC activity in normal
mouse tissue. As the use ofHDAC inhibitors as anti-cancer agents has generated
great interest, we examined the effect of BHB on HDAC activity and radiosen-
sitivity in the context of malignant glioma. We found that BHB radiosensitizes
mouse glioma, human glioma and human glioma stem-like cells in vitro. We
also demonstrate that BHB inhibits HDAC activity in a dose dependent manner
and alters key components of DNA damage repair. Taken together this data
opens up another avenue for understanding themechanisms underlying the KD
and its impact on radiation therapy, ultimately helping us better understand
how to implement it for clinical use in oncology.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: New
Targets 1
#1126 Potent inhibition of HCMV by modulating the cellular SNARE
syntaxin 5.DhimantH.Desai,1 LindaCruz,1Nicholas T. Streck,1 TrishaD.Desai,2
Aron Lukacher,1 ShantuG.Amin,1Nicholas J. Buchkovich1. 1Penn StateUniv. Col-
lege ofMedicine,Hershey, PA; 2CumberlandValleyHigh School,Mechanicsburg, PA.
Human cytomegalovirus (HCMV), also referred to as human herpesvirus-5
(HHV-5), can cause serious and even fatal disease in immunocompromised
individuals and newborns, namely individuals with AIDS, solid organ trans-
plant recipients, chemotherapy patients and recipients of bone marrow and
stem cell transplants. HCMV is a ubiquitous virus found throughout all geo-
graphic regions and socioeconomic groups, infecting greater than 50% of adults
in industrialized countries and as many as 100% in developing countries. Al-
though current therapeutics improves clinical outcomes, they are limited by
toxicity, intravenous infusion and the development of resistance by the virus.
Thus, there is a pressing need to develop novel therapeutics to prevent HCMV
infections with concomitant organ toxicity. Formation of the cytoplasmic viral
assembly compartment (cVAC) is an important step for effıcientHCMVassem-
bly. To do this, the virusmust alter and repurpose the normal cellular balance of
membrane and protein flux, a process that is not well understood. We have
identifıed a compound Retro94, which potently inhibits production of infec-
tious HCMV virions in cells by operating against a host cell process, rather than
directly targeting the virus. The presence of Retro94 results in the severely im-
paired production of infectious virions, as great as 5 logs (99-99.99%). Here we
discuss in vitro, in vivo, stability, and binding study of Retro94. Overall, our
fındings have identifıed Retro94, as novel agent that affects key cellular traffıck-
ing factors important for supporting HCMV infection.
#1127 Aberrant nuclear expression ofGSK-3beta in humanhead andneck
carcinoma.Maria Matsangou,1 Andrey Ugolkov,2 Timothy J. Taxter,3 Sandeep
Samant,4 Andrew P. Mazar,2 Francis J. Giles1. 1Robert H Lurie Comprehensive
Cancer Center, NorthwesternUniversity, Chicago, IL; 2Chemistry of Life Processes
Institutue, Northwestern University, Chicago, IL; 3Department of Pathology,
Northwestern University, Chicago, IL; 4Department of Otolaryngology, North-
western University, Chicago, IL.
Background: Recurrent/metastatic head and neck squamous cell carcinoma
(SCCHN) and salivary gland malignancies are diffıcult to treat with limited
standard of care options at the present time. Glycogen Synthase Kinase-3beta
(GSK-3beta), a serine/threonine protein kinase, has been implicated as a poten-
tial therapeutic target in human cancer. Our in vivo studies demonstrated that
our novel GSK-3 inhibitors signifıcantly potentiated the effects of conventional
chemotherapy in patient-derived xenograft models of glioblastoma and breast
cancer leading to regression of tumors. In order to develop a rationale to test our
novel GSK-3 inhibitors in head and neck (H&N)malignancies, we evaluated the
expression pattern of GSK-3beta in human H&N benign tissue and malignant
tumors. Methods: We used immunohistochemical staining of H&N tumor tis-
sueMicroarray (TMA), 48 total cases (20 benign tissues, 28malignant), to study
the expression pattern of GSK-3beta. GSK-3beta nuclear accumulation was de-
fıned as positive staining of more than 50% of cancer cell nuclei throughout the
tumor regardless of cytoplasmic staining. Results: Of the 20 malignant H&N
samples (15 SCCHN, 1 nasopharyngeal and 5 other histology), 13 (65%) were
found to have aberrant nuclear accumulation of GSK-3beta. Amongst SCCHN,
73% (11 of 15 samples) had aberrant nuclear accumulation of GSK-3beta. In
contrast, none (0%) of the 11 benignnon-salivaryH&N tissue showeddetectable
expression of GSK-3beta. Of interest, 60% of salivary adenoid cystic carcinoma
specimens and 44% of benign salivary gland tissue showed GSK-3beta expres-
sion. Conclusions: Our results demonstrate for the fırst time, that there is aber-
rant nuclear expression of GSK-3beta in SCCHN. This fınding supports further
exploring of our novel GSK-3beta inhibitor as a potential therapeutic target for
recurrent/metastatic SCCHN and also, as a potential prognostic and predictive
biomarker for risk of recurrent disease and chemo- or radio-resistance. Its role
in salivary gland malignancies requires further studying.
#1128 Identifıcation of arginine methyltransferase PRMT5 as a novel
therapeutic target in T-cell acute lymphoblastic leukemia. Yunyue Wang,1
HuiHuang,2 Daniel Diolaiti,3Marta SanchezMartin,1 BeataModzelewski,3 Lianna
J. Marks,3 Allison R. Rainey,3 Ervin S. Gaviria,3 Maria L. Sulis,1 Filemon S. Dela
Cruz,3 Adolfo A. Ferrando,1 Andrew L. Kung3. 1Columbia University, New York,
NY; 2EMD serono, CT; 3Memorial Sloan Kettering Cancer Center, New York, NY.
Advances in risk-adapted cytotoxic chemotherapy, hematopoietic stem cell
transplantation and supportive care have contributed to signifıcant improvements
in the survival of patients with acute lymphoid leukemia (ALL) and acute myeloid
leukemia (AML) over the past few decades. However, despite such progress, a sig-
nifıcant percentage of both adult and pediatric leukemia patients become refractory
to therapy or relapse and eventually die of disease. Hence, there remains an urgent
need for the development of effective and targeted therapies for acute leukemia.
Recent genetic profıling of solid andhematologicmalignancies has identifıed epige-
netic factors as a critical groupof genes recurrentlymutated in cancer. Additionally,
epigenetic dysregulation has been shown to play an important role in the develop-
ment, progression andmaintenance of leukemia. Therefore, pharmacological inhi-
bition of epigenetic factors represents a potential avenue for the development of
novel epigenetic-targeted therapies. In order to identify epigenetic vulnerabilities in
leukemia, we developed an epigenetic-focused shRNA screen to search for novel
therapeutic targets in human leukemia cell lines both in vitro and in vivo. Specifı-
cally,T-andB-ALLcell lineswere transducedwitha libraryof shRNAstargeting449
genes including epigenetic readers, writers and erasers and other chromatin-related
factors. Selected cells were subsequently cultured in vitro and concurrently injected
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intomice. Engraftment of inoculated cells and disease progression weremonitored
through bioluminescence imaging. Amongst the universe of epigenetic regulatory
proteins, the argininemethyl transferase, PRMT5, emergedas themost signifıcantly
depleted factor in both in vitro and in vivo screenings. Chemical inhibition of
PRMT5enzymatic activity effectively reducedprotein symmetric dimethyl arginine
methylation, altered splicing, inhibited cell growth and promoted apoptosis of both
ALL and AML cell lines in vitro. In addition, inhibition of PRMT5 in vivo using
patient-derived xenograft (PDX) T-ALL mouse models demonstrated diminished
tumor growth and prolonged survival. Notably, quantifıcation of peripheral blood
cell numbers showed that pharmacologic PRMT5 inhibitionwas well tolerated and
did not affect normal hematopoiesis in mice suggesting that a therapeutic window
exists for anticancer drugs targeting PRMT5 in acute leukemia. Overall, our data
indicates that pre-mRNA processing and in particular RNA splicing modulation
may represent novel therapeutic targets in leukemia.
#1129 Sigma receptors: Novel targets for the treatment of highly malig-
nant tumors. Michela Cortesi,1 Sara Pignatta,1 Simona Collina,2 Andrea
Rocca,1 Alice Zamagni,1 Chiara Arienti,1 Michele Zanoni,1 Luigino Tosatto,3
Daniela Bartolini,3 Evandro Nigrisoli,3 Annamaria Marra,2 Marta Rui,2 Anna
Tesei1. 1Istituto Scientifıco Romagnolo per lo Studio e la Cura dei Tumori
(I.R.S.T.) IRCCS, Meldola (FC), Italy; 2University of Pavia, Pavia, Italy, Pavia,
Italy; 3M. Bufalini Hospital, Cesena, Italy.
Introduction.More than 7million patients are diagnosedwith cancer every year,
and approximately 24 million new cases of cancer will probably be registered by
2035. Over the past decades, numerous cancer targets have been identifıed and,
despite promising results in this fıeld, thediscoveryofnovel targeted therapies is still
a largely unmet need. Sigma receptors (SRs), more highly expressed in tumor cells
than innormalcells,havearoused the interestof the scientifıc communitybecauseof
increasing evidence of their involvement in proliferation and survival signaling
pathways of cancer cells. Glioblastoma (GBM) and pancreatic cancer (PCa) are two
of themost aggressive and lethal solid tumors. GBMpatients usually relapse within
7-10 months of the end of fırst-line treatment with median survival of about 14.6
months while PCa is the fourth most fatal cancer in both men and women, with
median survival of 6-12 months. Little or no improvement in prognosis has been
obtained over the past 20 years. Thus, new approaches to the treatment of both
tumors are urgently needed. In the present work, 3D GBM primary cultures en-
dowedwith stemness features andPCacell lineswereused to evaluate the antitumor
activity of a dual S1R and S2R ligand RC-106, a novel sigma receptor modulator.
Methods. RC-106 tissue distribution studies were performed inmice. PCa cell lines
were assessed by cytotoxic assay (CellTiter 96® AQueous One Solution Cell Prolifer-
ation Assay). Molecular analyses were performed by qRT-PCR and Western blot.
Apoptosis and cell cycle were analyzed by flow cytometry. GBM primary cultures
were isolated from surgical tumor samples. A rotatory cell culture system (RCCS)
was used to obtain 3D cell cultures. Growth and morphology of the colonies were
monitored by open-source AnaSP and ReViSP software tools. Molecular analyses
were performed by flow cytometry and qRT-PCR. 3D cell viability was measured
usingCellTiter-Glo®3DCellViabilityAssay.Apoptosis andcell cyclewere analyzed
by flow cytometry. Results. RC-106 preferentially accumulate inmice pancreas and
brain after intravenous administration, supporting the use of sigma receptor mod-
ulators as a novel therapy for these tumors. Treatment with RC-106 strongly inhib-
ited cell proliferation and survival regardless of the type of cancer investigated. 25
M of the drug impaired the in vitro clonogenic ability of tumor cells, an effect
lasting for up to 42 days, the longest time tested. RC-106 also led to the induction of
substantial apoptosismediatedby caspase 3 and9 activation, and to amodulationof
the Akt pathway. Furthermore, treatment with RC-106 signifıcantly reduced the
growth of human GBM and PCa spheroids. Conclusions. (RC-106) represents the
hit compoundofanewclassofdual-action ligands targetingS1RandS2Rpotentially
useful for the treatment of cancer disease.
#1130 Targeting the tumor-associated autoantigen alpha-enolase in pros-
tate cancer. Tino Wilson Sanchez,1 Guangyu Zhang,1 Jitian Li,2 Liping Dai,2
Saied Mirshahidi,1 Nathan R. Wall,1 Clayton Yates,3 ColwickWilson,4 Susanne
Montgomery,4 Jian-Ying Zhang,2 Carlos A. Casiano1. 1Loma Linda University
School of Medicine, Loma Linda, CA; 2University of Texas, El Paso, El Paso, TX;
3TuskegeeUniversity, Tuskegee, AL; 4LomaLindaUniversity School of Behavioral
Health, Loma Linda, CA.
Prostate cancer (PCa) is the most commonly diagnosed cancer and second
leading cause of cancer-related deaths in American men. African American
(AA) men are more likely to be diagnosed with aggressive PCa at a younger age
and twice as likely to die from the disease as European American (EA) men. In
order to reduce PCa mortality and its associated racial disparities, there is a
critical need to identify and target pathways responsible for PCa aggressiveness.
An unexplored target is the plasminogen system, which is key to cancer cell
migration and tissue invasion during metastasis. During inflammation, activa-
tion of the plasminogen pathway degrades extracellular fıbrin networks; how-
ever, in the context of cancer, this activation promotes cancer tissue invasion
and metastasis. Mounting evidence shows that the glycolytic enzyme alpha-
enolase (ENO1) plays a vital role in both increased energy metabolism and
plasminogen activation during cancer progression andmetastasis. Using immu-
noseroproteomic profıling of anti-tumor autoantibody responses in AA and EA
men with PCa, we identifıed several tumor-associated autoantigens with func-
tions in glycolysis and plasminogen signaling, including ENO1, annexin A2,
fructose bisphosphate aldolase, glucose-regulated protein 78, glyceraldehyde-3-
phosphate dehydrogenase and phosphoglycerate kinase. In a cohort of PCa
(N157) and non-PCa sera (N183), we found a signifıcantly higher frequency
of autoantibodies to ENO1 in patients with PCa (p0.05). Surprisingly, when
we probed a panel of non-PCa and PCa cell lines with anti-ENO1 positive sera
from AA and EA patients with PCa, we observed that AA patients showed
increased immunoreactivity to this protein in metastatic PCa cells, with de-
creased reactivity in docetaxel-resistant cell lines. By contrast, the anti-ENO1
EA-PCa sera and a monoclonal mouse anti-ENO1 showed relatively uniform
immunoreactivity across the same panel cell lines. This suggested that the AA-
PCa patients are producing antibodies to a different ENO1 variant than EA-PCa
patients. Proteomic analysis of post-translationalmodifıcations (PTM) inENO1
showed differences in ENO1 PTM profıles between the parental PC3 bone met-
astatic cell line and the PC3 docetaxel-resistant cell line, which could explain the
differential autoantibody reactivity observed in AA men. Given that ENO1 is
up-regulated in PCa tissue, plays a role in glucose metabolism and plasminogen
activation during cancer progression, and that the immune system of a cohort of
AA-PCa patients recognizes an alternately modifıed variant of ENO1 that is
upregulated inmetastatic PCa,we elected to target this protein inmetastatic PCa
cell lines. ENO1 depletion via siRNA knockdown in PC3 cells led to increased
cell death, with concomitant decrease in PCa proliferation. Taken together,
these results highlighted the value of immunoproteomics as a tool to identify
novel therapeutic targets, with ENO1 as a promising target in metastatic PCa.
#1131 O-GlcNAc transferase inhibition in breast cancer cells.Anna Bark-
ovskaya,1 Lina Prasmickaite,1 Damien Y. Duveau,2 Ian G. Mills,3 Gunhild M.
Mælandsmo,1 Siver A. Moestue,4 Harri M. Itkonen5. 1Oslo Univ. Hospital Inst.
for Cancer Res., Oslo, Norway; 2Division of Preclinical Innovation, National Cen-
ter for Advancing Translational Sciences, National Institutes of Health, Rockville,
MD; 3PCUK/Movember Centre of Excellence for Prostate Cancer Research, Cen-
tre for Cancer Research and Cell Biology (CCRCB), Queen’s University Belfast,
Belfast, United Kingdom; 4NTNU, Department of Circulation andMedical Imag-
ing, Trondheim, Norway; 5Department of Microbiology and Immunobiology,
Harvard Medical School, Harvard Institute of Medicine, Boston, MA.
O-linked-N-acetylglucosamination (O-GlcNAcylation) is a post-transla-
tional modifıcation that occurs on serine and threonine amino acid residues of
the intracellular proteins. O-GlcNAcylation of numerous targets is catalyzed by
a single enzyme -O-GlcNAc-transferase (OGT).O-GlcNAcylation impacts pro-
tein activation and stability thereby regulating several key biological functions,
and is heavily involved in cancer development and progression.OGTexpression
and total protein O-GlcNAcylation are elevated in many cancers compared to
non-malignant adjacent tissues. In breast cancer, this increase also has a positive
correlation with the tumor grade suggesting a possible link to metastasis and
disease progression. Here we investigated the effects of OGT inhibition in two
triple-negative (TNBC) and two receptor-positive luminal breast cancer cell
lines. Treatment of cells with an OGT inhibitor as well as OGT knockdown led
to a strong decrease in viability and proliferation of the TNBC cells, but signifı-
cantly less so in the luminal receptor-positive cell lines. This differential re-
sponse was evaluated using analysis of apoptosis, cell cycle, gene expression and
a reverse-phase antibody-based protein array (RPPA). We found that cell cycle
progression was affected by OGT inhibition. In addition, proteomics data
pointed towards the transcription factor hairy and enhancer of split-1 (HES1) as
a possible mediator of the cytotoxicity observed in the TNBC cell lines. We
currently work to elucidate the molecular mechanisms of HES1 regulation by
OGT and its effect on TNBC cell survival and apoptosis. In conclusion, OGT
inhibition has a pronounced cytotoxic effect on the TNBC cells and may have
some potential for therapeutic use in the future.
#1132 Lactate dehydrogenase expression in African American women
with triple-negative breast cancer. Odalys J. Torres-Luquis, Sulma Moham-
med. Purdue University, West Lafayette, IN.
The incidence of breast cancer in African American women (AAW) is much
lower than those of their Caucasian counterparts. However, the age adjusted mor-
tality rates are much greater for AAW compared to Caucasian American women
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(CAW). These differences in survival between AAW and CAWwere attributed to
socioeconomic factors and access to health care. Yet, after adjusting these differ-
ences, AAW still had lower survival rates than CAW. Genetic and immunohisto-
chemical studies have revealed that biological variations may account for this dis-
parity. These studies have suggested as a causative: a higher prevalence of basal-like
tumors in premenopausal AAW and low prevalence of luminal tumor. These are
characterizedbybeinghigh-grade aggressive tumors that are estrogen receptorneg-
ative (ER-), progesterone receptor negative (PR-), human epidermal growth factor
receptor-2 (HER-2)/; with high rate of lymph node involvement. Despite this
understanding, there is little evidence to indicate which genetic or non-genetic fac-
tors contribute to causingaggressivebreast cancer thereby limiting thedevelopment
of prevention and treatment option. We proposed that the phenotypic diversity of
breast cancermight be accompaniedby a correspondingdiversity inprotein expres-
sionpatterns that canbe reveal usingproteomic technologies.Wehypothesized that
in addition to ER- and PR-, and the absence in expression of HER-2, the protein
composition of triple-negative tumors varies amongAfrican-American andCauca-
sian. Two-dimensional gel electrophoresis, mass spectrophotometry and data anal-
ysis of protein from breast cancer tissues were used to identify differentially ex-
pressed proteins from African American and Caucasian women. Western blot of
luminal and TNBC cell lines were used to confırm the expression of identifıed pro-
teins. We have found that many proteins were differentially expressed in AAW
breast cancer tissues compared to CAW. One of these is lactate dehydrogenase
which was found to be overexpressed in tissues from AAW.Western blot analysis
confırmed expression.
#1133 Discovery of novel small molecule inhibitors of RNA-binding pro-
teinMusashi-1.LanLan,1Amber Smith,1XiaoqingWu,1AnuradhaRoy,1 Ragul
Gowthaman,1 John Karanicolas,2 Amber D. Somoza,3 Clay C.C. Wang,3 Berl
Oakley,1 Roberto De Guzman,1 Kristi Neufeld,1 Liang Xu1. 1University of Kan-
sas, Lawrence, KS; 2Fox Chase Cancer Center, Philadelphia, PA; 3University of
Southern California, Los Angeles, CA.
1) Background and Objective: Musashi-1(Msi1) is an RNA-binding protein
that negatively regulates translation by binding to the 3
-UTRs of targetmRNAs
including Numb, APC and p21WAF-1, key regulators of Notch, Wnt signaling
and cell cycle progression, respectively. We aim to identify small molecule in-
hibitors of Msi1’s mRNA-binding activity thus blocking the growth of a broad
range of cancer cells. 2) Methods: Fluorescence polarization assay was used to
screen for smallmolecules that disrupt the binding ofMsi1 to its consensus RNA
binding site. Hits were validated by surface plasmon resonance, amplifıed lumi-
nescent proximity homogeneous assay and nuclear magnetic resonance. 3) Re-
sults: Among2,000 small molecules we screened, we found several clusters of
compounds that disrupt the Msi1-numb RNA binding potently, including nat-
ural products, herbal extracts and fungal metabolites. One of the clusters is the
derivatives of the secondary metabolites fromAspergillus nidulans. The top hit,
Aza-9, from this cluster was validated by amplifıed luminescent proximity ho-
mogeneous assay. Further validation by surface plasmon resonance and nuclear
magnetic resonance indicate that Aza-9 binds to Msi1 directly, in the RNA
binding pocket. 4) Discussion andConclusions: Our study supports the hypoth-
esis that Msi1 inhibition is a viable and effective anti-cancer strategy. More
target validation assays will be carried out for the compounds from other clus-
ters.
#1134 Tissue transglutaminase is a new therapeutic target to overcome
steroid resistance inT cell acute lymphoblastic leukemia.Hyun Joo Jung.Ajou
University Hospital, Suwon, Republic of Korea.
Background: The treatment response to steroid is themost important predic-
tive factor for treatment outcome of T-cell acute lymphoblastic leukemia (T-
ALL). To improve survival for steroid-resistant T-ALL patients, it is necessary to
develop innovative therapeutic strategies to overcome steroid resistance. This
study attempts to determine new therapeutic strategies to overcome steroid
resistance for patients with T-ALL. Tissue transglutaminase (TG2) is a intracel-
lular calcium-dependent protein cross-linking enzyme reported to be highly
expressed in various metastatic or drug-resistant cancer cells, and chronic ex-
pression of TG2 constitutively activates nuclear factor kappa B (NF-kappaB).
Methods: We used biochemical and molecular methodologies to demonstrate
that TG2 modulation leaded to overcome the steroid resistance in T-ALL. Re-
sults: We generated the steroid-adapted subclones of T-ALL cell lines that were
extremely less sensitive to steroid than their parent T-ALL cells. We found that
steroid-resistant subclones of T-ALL cells expressed much higher levels of TG2
than their parent cells and the modulation of TG2 activities altered NF-kappaB
expression in this steroid-resistant cells. Inhibition of TG2 suppressed steroid
resistance and improved the cytotoxicity of leukemia cells in steroid-adapted
subclones of T-ALL. Conclusion: This study shows that TG2 expression is ele-
vated with steroid resistance in T-ALL and the modulation of TG2 induces the
cytotoxicity of steroid-adapted T-ALL. TG2 could be a new therapeutic target to
overcome steroid resistance in T-ALL. Furthermore, change of TG2 expression
could serve as markers of induced steroid resistance in T-ALL.
#1135 DRD2 is critical for pancreatic cancer and promises pharmacolog-
ical therapy by already established antagonists. Pouria Jandaghi,1 Hamed S.
Najafabadi,1 Andrea Bauer,2 Andreas I. Papadakis,1 Matteo Fassan,3 Anita
Hall,1 AnieMonast,1MaryamSafısamghabadi,1Magnus vonKnebelDoeberitz,4
John P. Neoptolemos,5 Eithne Costello,6 William Greenhalf,6 Aldo Scarpa,7
Bence Sipos,8 Daniel Auld,1 Mark Lathrop,1 Morag Park,1 MarkusW. Büchler,9
Oliver Strobel,9 Thilo Hackert,9 Nathalia Giese,9 George Zogopoulos,1 Veena
Sangwan,1 Sidong Huang,1 Jörg D. Hoheisel,4 Yaser Riazalhosseini1. 1McGill
University, Montreal, Quebec, Canada; 2Deutsches Krebsforschungszentrum
(DKFZ), Heidelberg, Germany; 3ARC-NET Center for Applied Research on Can-
cer, University and Azienda Ospedaliera Universitaria Integrata, Verona, Italy;
4Deutsches Krebsforschungszentrum (DKFZ), Germany; 5National Institute for
Health Research, Liverpool Pancreas Biomedical ResearchUnit, Liverpool, United
Kingdom; 6National Institute forHealth Research, Liverpool Pancreas Biomedical
ResearchUnit, UnitedKingdom; 7ARC-NETCenter for Applied Research onCan-
cer, University and Azienda Ospedaliera Universitaria Integrata, Italy; 8Institute
for Pathology and Neuropathology, Universitätsklinikum Tübinge, Germany;
9Department of Surgery, University Hospital Heidelberg, Germany.
Introduction and aims:Although the overall fıve-year survival of all patientswith
cancer stands at 63%, for pancreatic cancer patients, it is a disheartening 8% - a
number that remains largelyunchanged for threedecades.Of thepatientsdiagnosed
with pancreatic cancer, about 85% exhibit pancreatic ductal adenocarcinoma
(PDAC). Most of these patients die within 4 to 6 months after diagnosis. The poor
prognosis is caused by the detection at only late stages, and lack of effective options
for chemotherapy. Thewidely used chemotherapeutic agent gemcitabine, confers a
median survival advantage of only 6 months, and resistance to therapy develops in
thevastmajorityofpatients.Given thispoorprognosis ofpatientswithPDAC, there
is an urgent need to fınd more effective therapies. Experimental procedures: Mi-
croarrays were used to perform global gene expression profıling in 195 PDAC and
41 normal pancreatic tissue samples. Using these profıling data, we undertook
an extensive analysis of PDAC transcriptome by superimposing the pathway
context and interaction networks of aberrantly expressed genes to identify fac-
tors with central roles in PDAC pathways. Next, tissue microarray analysis
(TMA)were used to verify the expression of the candidate target in independent
set of 152 samples comprising 40 normal pancreatic tissues, 49 chronic pancre-
atitis sections (CP) and 63 PDAC samples. We further validated the functional
relevance of the candidate molecule through RNA interference (RNAi) and
pharmacological inhibition in vitro and in vivo. Results: We identifıed dopa-
mine receptor D2 (DRD2) as a key modulator of cancer pathways in PDAC.
DRD2 up-regulation at the protein level was validated in a large independent
sample cohort. Most importantly, we found that blockade of DRD2, through
RNAi or pharmacological inhibition using FDA-approved antagonists hampers
the proliferative and invasive capacities of pancreatic cancer cells while modu-
lating cAMP and endoplasmic reticulum stress pathways. Also, we observed a
potent effect ofDRD2antagonists on inhibition of cancer cell proliferationusing
differentmodel of primary andmetastatic tumor cells derived from spontaneous
pancreatic cancer mouse models and patient-derived pancreatic adenocarci-
noma mouse xenograft (PDX) models. Conclusions: Our fındings demonstrate
that inhibiting DRD2 represents a novel therapeutic approach for PDAC. Since
DRD2 inhibitors are already in the clinic for the management of schizophrenia,
our results from this study could support a drug repurposing strategy to expedite
clinical evaluation of these agents as novel therapy against pancreatic cancer.
#1136 Heat shock protein 90 inhibitors suppress PDGFRA reactivation
and other receptor tyrosine kinase activation important in drug resistant
gastrointestinal stromal tumors. Masahiro Yamamura, Akira Yamauchi,
Naoki Katase, Makoto Okawaki, Yousuke Katata, Futoshi Kuribayashi, Junichi
Kurebayashi, Yoshiyuki Yamaguchi. Kawasaki Medical School, Kurashiki,
Japan.
Background: Inhibition of KIT oncoproteins by imatinib induces clinical re-
sponses inmost gastrointestinal stromal tumor (GIST) patients.However,many
patients develop imatinib resistance due to secondary KIT mutations. The drug
resistance mechanism has only been partially elucidated, and the sunitinib re-
sistance mechanism is also unknown. In this study, we elucidate the new ima-
tinib resistant mechanism and fınd effective inhibitors. Methods: We have es-
tablished imatinib-resistant cells GIST-T1R by culturing cells with increasing
concentrations of imatinib. We analyzed receptor tyrosine kinase and intracel-
lular signal protein strongly expressed in resistant cells using Western blotting
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and Phosphorylation Array. Then, the antitumor effect was examined using an
agent that inhibits strongly expressed molecules of the resistant cells. Results:
The IC50 of imatinib in the sensitive cells(GIST-T1) and the resistant cells(GIST-
T1R) was 10 nM and 20 M, respectively, which demonstrated 2000-fold dif-
ference. These imatinib resistant cells were also cross-resistant to sunitinib. In
western blotting, PDGFRA phosphorylation and protein expression were en-
hanced in GIST-T1R compared to GIST-T1. When GIST-T1 was treated with
imatinib, KIT phosphorylation was suppressed but PDGFRA phosphorylation
was enhanced. Imatinib treatment of GIST-T1R enhanced PDGFRA phosphor-
ylation and protein expression as compared to before imatinib treatment. Phos-
phorylation of PDGFRA in these resistant cells could not be suppressed by
regorafenib. Furthermore, in the protein phosphorylated array, in addition to
phosphorylation of PDGFRA in resistant cells, phosphorylation of multiple
RTKs was also enhanced. An HSP90 inhibitor AUY922 capable of simultane-
ously suppressing a plurality of proteinswas used. AUY922 suppressedGIST-T1
and GIST-T1R cell proliferation at low concentrations and was more effective
than regorafenib. Furthermore, AUY922 inhibited phosphorylation and protein
expression of PDGFRA in drug-resistant cells, as well as phosphorylation of
other several receptor tyrosine kinases. Conclusion: Activation of PDGFRAwas
considered to be important for the mechanism of drug resistance of GIST. Fur-
thermore, since activation of multiple receptor tyrosine kinases can be observed
simultaneously in drug resistance, it is considered that inhibiting a single target
is not effective. Since HSP90 inhibition suppresses PDGFRA protein expression
and possibly inhibits multiple target proteins at the same time, it is the most
effective treatment for drug resistant GIST.
#1137 ADAM8 drives aggressive phenotype of triple-negative inflamma-
tory breast cancer & constitutes a novel therapeutic target.Mathilde Romag-
noli,1 Stefania Pianetti,1 Sonia G. Das,1 Delphine Loussouarn,2 Carole Gour-
melon,2 Mario Campone,2 Sophie Barillé-Nion,3 Giang T. Nguyen,1 Srimathi
Srinivasan,1 Gail E. Sonenshein,1 Nora D. Mineva1. 1Tufts Univ. School of Med-
icine, Boston, MA; 2Institut de Cancérologie de l’Ouest, Saint-Herblain, France;
3UMR 892 INSERM, Nantes, France.
Inflammatory Breast Cancer (IBC) is a rare, highly aggressive form of
cancer that is frequently locally advanced or metastasized at the time of
diagnosis. The Triple-Negative subtype of IBC (TN-IBC), in particular, is
characterized by very poor overall survival. TN-IBC lacks targeted therapies
and is primarily treated with radiation or chemotherapy, which are ineffı-
cient. Recently, we identifıed the cell surface transmembrane ADAM8 (A
Disintegrin and Metalloproteinase) protein as a driver of Triple-Negative
Breast Cancer (TNBC) growth andmetastasis via its Metalloproteinase (MP)
and Disintegrin (DI) domains, respectively. In in vivo proof-of-concept ex-
periments with a prototype reagent, we demonstrated that simultaneous,
antibody-based, targeting of the ADAM8MP and DI domains is an effective
therapeutic approach for TNBC (Romagnoli et al., EMBO Mol. Med. 6:278,
2014). The aggressive behavior of IBC cells has been attributed to a stem-like
cancer cell compartment with high ALDH activity (ALDH). Our studies of
the green tea compound epigallocatechin-3 gallate (EGCG) revealed that it
reduced growth of tumors derived from ALDH SUM-149 TN-IBC cells.
We now report that EGCG concurrently decreases tumor levels of ADAM8
mRNA. This led us to assess the role of ADAM8 in TN-IBC. Tumor biopsies
from 15 patients taken at the time of diagnosis and/or after neo-adjuvant
treatment with chemotherapy, as well as paired lymph node and skin sam-
ples (when available) were analyzed by immunohistochemistry for ADAM8
expression. We report that 45.5% of primary TN-IBC patient tumors and
50.0% of metastases within the axillary lymph nodes express high levels of
ADAM8 and its expression is largely unaffected by chemotherapy. In addi-
tion, ADAM8 expression was higher in the aggressive ALDH stem-like
SUM-149 cell compartment. Consistently, knockdown of ADAM8 dramat-
ically reduced the ability of SUM-149 cells to grow in an anchorage indepen-
dent fashion and to migrate throughMatrigel. A newly prepared anti-human
ADAM8 mouse monoclonal antibody (ADP13) inhibited the MP and DI
domains of ADAM8 on SUM-149 cells. ADP13 reduced orthotopic growth
of tumors derived from SUM-149 cells by 40% in mice treated by i.p. injec-
tion 2 days a week with a dose of 4.5 mg/kg (n7). Dose-response curves and
survival experiments are in progress. Conclusions: ADAM8 expression is
present in almost half of TN-IBC patient tumors and their metastases, and
promotes aggressive phenotype of TN-IBC cells in in vitro 3D-assays. A
pre-clinical mouse model of TN-IBC validated ADAM8 as an accessible and
promising new target for therapeutic intervention against this highly aggres-
sive disease.
#1138 The protein disulfıde isomerase inhibitor XCE853 inhibits in vitro,
ex-vivo and in vivo growth of human tumors. Gregoire Pierre Prevost,1 Anne
Chauchereau,2 Patrick Ladam,3 Renaud Seigneuric,4 Denis Carniato,5 Marc-
Henry Pitty,6 Paul Foster7. 1CIPREVO, Antony, France; 2Gustave Roussy, Ville-
juif, France; 3Université Paris XIII, Bobigny, France; 4Université de Bourgogne,
Dijon, France; 5DC2, Marcoussis, France; 6Oregon Therapeutics, Paris, France;
7University of Birmingham, Birmingham, United Kingdom.
Protein disulfıde isomerase (PDI) is a chaperone protein that regulates
oxidative protein folding as well as cell viability. Increased PDI levels have
been documented in a variety of human cancers associated with a poor
overall survival, including ovarian, prostate, brain and lung cancers. Inhibi-
tion of PDI activity leads to apoptosis in cancer, suggesting that PDI is a
promising druggable target. XCE853 is a synthetic small molecule displaying
an excellent docking with the catalytic domain of the human PDI. XCE853
inhibits in vitro recombinant PDI enzymatic activity. In addition, the pro-
liferation of a large panel of human tumor cells is blocked by XCE853 with
IC50s in the nanomolar range through an irreversible cytolysis leading to a
tumor cell death by autophagy and particles release (vesicles or protein ag-
gregates). XCE853 is also active on a large panel of drug resistant human
cancer cells. XCE853 induced an irreversible cytolysis of human tumor cells
after a short in vitro exposure independently of efflux pumps. In addition,
the ex-vivo approach using fresh human tumor explants cultivated in 3 di-
mensions with low concentrations of XCE853 has shown a strong decrease of
the proliferation (KI-67 labeling) in several tumor types. Finally, XCE853
displayed excellent oral bioavailability in mice and was able to block the
growth of several human cancers using in vivo xenograft models leading to a
complete tumor growth arrest even after the cessation of the treatment.
Altogether, these data strongly support further efforts to move this drug
candidate to the preclinical studies to access advanced cancer patients.
#1139 G protein-coupled receptors (GPCRs): unrecognized potential
therapeutic targets in cancer. Paul A. Insel, Krishna Sriram, Shu Z. Wiley,
Thalia McCann, Randall P. French, Andrew M. Lowy. UCSD, La Jolla, CA.
G protein-coupled receptors (GPCRs) are the largest class of signaling recep-
tors in humans and other species and in addition, the most widely targeted class
for FDA-approved therapeutics. However, GPCRs are not commonly targeted
in cancers other than endocrine tumors. We hypothesize that GPCRs may have
been “missed” as targets in cancer, perhaps in part because they have not been
frequently identifıed as driver mutations; however, GPCRs may have unappre-
ciated utility as therapeutic targets in a variety of tumors. To test this hypothesis,
we have used unbiased approaches (Taqman GPCR arrays and RNA-seq), min-
ing of publicly available datasets (e.g., The Cancer Genome Atlas, TCGA), and
validation studies (e.g., protein and functional analyses) to assess GPCRs in a
variety of human tumors, cancer cells and stromal cells (cancer-associated fıbro-
blasts, CAFs). Amajor focus of our efforts has been on pancreatic ductal adeno-
carcinoma (PDAC) cells/tumors and pancreatic CAFs (PCAFs). We fınd that
PDAC cells and PCAFs express70 different GPCRs, including many orphan
GPCRs (receptors without known physiologic agonists) and that numerousGP-
CRs are expressed at much higher levels than in normal precursor cells (pancre-
atic ductal epithelial cells for PDAC cells and pancreatic stellate cells and pan-
creatic fıbroblasts for PCAFs). We fınd that a cluster of GPCRs is overexpressed
in PDAC tumors. Two such receptors are orphanGPCRs,Orphan 1 andOrphan
A, neither of which is mutated but each has high expression, respectively, in
PCAFs and PDAC cells. Orphan 1 and Orphan A have at least 2-fold higher
expression in 90% of PDAC tumors in TCGA compared to that in normal
pancreatic tissue (compiled from the GTEX database). Higher expression of
orphan A is associated with decreased survival and remission, while Orphan 1
expression correlates with that of numerous fıbrotic genes. Importantly, both
Orphan 1 and Orphan A are functional and appear to contribute to the malig-
nant phenotype. For example, siRNA knockdown of Orphan 1 in PCAFs blunts
production of profıbrotic markers and decreases ability of conditioned media
from PCAFs to enhance proliferation of PDAC cells while transfection of Or-
phan A increases DNA synthesis of normal pancreatic ductal epithelial cells.
Taken together, these and other results suggest that in addition to their role in
endocrine tumors, GPCRs represent previously unrecognized contributors to
cancer through actions on tumor cells and stromal cells. These data suggest the
possibility that highly expressed GPCRs (such as Orphan A) may function as
oncogenes. Thus, GPCRs may be druggable, novel targets for the treatment of
cancer, including pancreatic cancer, a tumor for which new therapeutics are an
important, unmet need.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: New Targets 1
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017292
#1140 Characterization of a novel PDE10 inhibitor in lung tumor cells
and an orthotopicmousemodel of lung cancer.Veronica Ramirez-Alcantara,1
Bing Zhu,1 Xi Chen,1 Rajkumar Savai,2 Prema Subbarayal,2Michele A. Schuler,3
Kevin J. Lee,1 Ashley S. Lindsey,1 Kristy L. Berry,1 Dennis Otali,4 Joshua Canzo-
neri,5 Jacob Valiyaveettil,1 Adam Keeton,1 Lori Coward,6 Gregory Gorman,6
WilliamGrizzle,4Michael Boyd,5 Gary A. Piazza1. 1University of South Alabama
Mitchell Cancer Institute, Drug Discovery Research Center, Mobile, AL; 2Max
Planck Institute for Heart and Lung Research, Molecular Mechanism in Lung
Cancer, Bad Nauheim, Germany; 3University of South Alabama, Department of
Comparative Medicine, Mobile, AL; 4University of Alabama at Birmingham, De-
partment of Pathology, Birmingham, AL; 5ADT Pharmaceuticals, Inc., Orange
Beach, AL; 6Samford University, Pharmaceutical Sciences Research Institute,Mc-
Whorter School of Pharmacy, Birmingham, AL.
BACKGROUND: Screening a focused library of indene derivatives for PDE10
inhibitory activity identifıed novel leads with potent and selective tumor cell
growth inhibitory activity. ADT-030 emerged from lead optimization chemistry
with excellent drug-like properties and oral bioavailability. Here we characterize
the anti-tumor activity of ADT-030 in human lung tumor cells and an ortho-
topic mouse model of lung cancer. METHODS: Growth inhibitory activity of
ADT-030 was measured in a panel of human lung tumor cell lines by ATP
quantifıcation following 72 h of treatment. The effect of ADT-030 on intracel-
lular cGMP/cAMP was measured in whole cell lysates using a competitive
ELISA assay. PDE inhibitory activity of ADT-030 was evaluated in lysates of
human lung tumor cells and by recombinant PDE isozymes using the IMAP
fluorescence polarization PDE assay. Activation of PKG signaling and suppres-
sion of -catenin levels in response to ADT-030 treatment was evaluated by
Western blot using whole cell lysates of human lung tumor cells. ADT-030 was
orally administrated to C57BL/6 mice and free levels quantifıed in plasma and
tissues by LC-MS. Anti-tumor activity of ADT-030 was evaluated in athymic
nude-Foxn1nu mice after inoculating the left lung with 1x106 A549 lung tumor
cells and treating once daily by oral administration at dosages ranging from 25 -
125mg/kg. Tumor growthwasmonitored by in situ bioluminescence using IVIS
as well as necropsy and pathological grading after 4 weeks of treatment. RE-
SULTS: ADT-030 inhibited the growth of human lung tumor cell lines with IC50
values in the low micromolar range by inducing apoptosis, while appreciably
higher concentrations were required to affect the growth of normal human
airway epithelial cells. ADT-030 treatment of human lung tumor cells increased
both intracellular cGMP and cAMP levels, activated PKG and suppressed
-catenin within the same concentration range as required for tumor cell
growth inhibition. Pharmacokinetic studies in mice demonstrated a half-life
suitable for once a day dosing. Tissue distribution studies revealed appreciably
higher concentrations of ADT-030 in lungs relative to plasma and other tissues,
with the highest accumulationmeasured in the parenchyma. ADT-030 was well
tolerated in mice implanted with A549 tumor cells and displayed strong anti-
tumor activity as evident by reduced luminescence, tumor grading, and double-
blinded pathological evaluation. CONCLUSIONS: ADT-030 represents a pro-
spective drug development candidate with favorable drug-like properties that
concentrates in lung after oral administration exhibiting a strong anti-tumor
activity in a pre-clinical mouse model. The mechanism of lung tumor cell
growth inhibition involves PDE10 inhibition, elevation of cGMP, activation of
PKG, and attenuation of -catenin.
#1141 Evaluation of GABRP as a novel therapeutic target in triple nega-
tive breast cancer.VikramB.Wali, Gauri A. Patwardhan, ChristosHatzis, Lajos
Pusztai. Yale Univ. School of Medicine, New Haven, CT.
TripleNegative breast cancers (TNBC) represent nearly 20%of all breast cancers
butdonothaveany targeted therapies availabledue to lackof amplifıcationofHER2
andexpressionof estrogenandprogesterone receptors.To identifypotentiallydrug-
gable targets for TNBC, we compared TNBC to non-TNBC tumors in large inde-
pendent gene expression clinical datasets to identify highly expressed genes in
TNBC that encode for proteins expressed on the cell surface. We found gamma-
aminobutyric acid typeA receptor pi (GABRP) to be themost overexpressed recep-
tor protein gene in TNBC, while its expression in normal tissues was low and com-
parable to that of proteins targeted by drugs or therapeutic antibodies already in
clinical testing.We compared GABRPmRNA and protein expression across panel
of breast cancer cell lines and found it to be particularly elevated in HCC1143 and
MDA-MB-468TNBCcells.KnockdownofGABRPusing siRNAsuppressedTNBC
cell growthand stableGABRPknock-downby shRNAsuppressedgrowthofMDA-
MB-468 xenografts in nudemice. Sub-cellular fractionation of TNBCcells and sub-
sequent Western blot analysis confırmed that GABRP is located predominantly in
the cell membrane. GABRP protein expression on cell surface was also detected by
flowcytometry. Interestingly, treatment with 5-100g/ml of anti-GABRP antibody
that binds to the extracellular domain (ECD) itself inhibited growth of TNBC cell
lines expressing higher GABRP, while the same doses of a control antibody had no
effect in these cells in culture. Our goal is to generate an antibody drug conjugate
(ADC) for TNBC by conjugating anti-GABRP antibody with a maytansinoid such
as DM1, which has proven cytotoxicity in breast cancer cells. Together, our results
suggest that GABRP is a potential therapeutic target for triple-negative breast can-
cers.
#1142 Novel target discovery for glioblastoma using chemical biology fın-
gerprinting.Darren Finlay,1 Pedro Aza-Blanc,1 Harshil Dhruv,2 Alexey Erosh-
kin,1 Craig Hauser,1 Jeff Kiefer,2 Seungchan Kim,2 Tao Long,1 Robert G. Os-
hima,1 Sen Peng,2 Gil Speyer,2 Michael Berens,2 Kristiina Vuori1. 1Sanford
Burnham Prebys Med Discovery Institute, La Jolla, CA; 2TGen, Phoenix, AZ.
Themost common adult brain tumor is GlioblastomaMultiforme (GBM), an
extremely aggressive cancer with only scant treatment options. Even with stan-
dard of care most patients present with a recurrence and the median survival is
only circa 15months. The need, therefore, for new therapeutic targets and treat-
ment options is pressing. Here we describe here a multipronged approach to
identifying said targets.We present an establishedmethodology for the isolation
and culture of patient derived GBM samples that retain the “stem-like” fraction
thought to underlie resistance and recurrence. Furthermore we show genomi-
cally that these samples represent specifıc subtypes of the disease yet still form
distinct groups in unbiased clustering analysis. Thus we havemultiple represen-
tative patient derived cultures that are suitable for our drug discovery and chem-
ical biology analyses. Using a process we term Chemical Biology Fingerprinting
(CBF) we utilize small focused, and clinically relevant, chemical collections in
order to identify patterns of chemovulnerabilities across multiple samples. This
allows an unbiased yet cancer relevant sub-stratifıcation and the identifıcation of
agents, and therefore targets, which may be relevant for GBM patient subtypes.
Indeed our use of the highly annotated NCI CTD2 Informer Set of chemicals
allows ready drug-to-target mapping and facilitates data sharing across the
CTD2 network. Moreover, already defıned subgroups can be clustered to fınd
agents, or groups of agents, that show selective activity against traditional clas-
sifıcations (e.g. proneural, mesenchymal etc.). Finally our strategy is permissive
for the identifıcation of “exceptional responders”. That is, individual patient
samples that respond to a specifıc drug whilst most samples are refractory. In
sum we demonstrate generation of patient derived models and identify specifıc,
and novel, drugs that may be relevant for specifıc GBM subtypes. Supported by
NIH U01CA168397
#1143 Targeting the transcriptional kinases CDK12 and CDK13 in breast
and ovarian cancer. Michael Bradley, Jason Marineau, Yoon Choi, Kristin
Hamman, Goran Malojcic, David Orlando, Yixuan Ren, Nan Ke, Shanhu Hu,
Eric Olson, Christian Fritz, Christopher Roberts. Syros Pharmaceuticals, Cam-
bridge, MA.
CDK12 and CDK13 regulate expression of large transcripts requiring sub-
stantial processing to produce mature mRNA. This transcriptional regulation
includes coordinated phosphorylation of specifıc repeats within the C-terminal
domain of RNA polymerase II and association with RNA processing factors
(Chila, 2016). RNAi knockdown of CDK12 in cell culture decreases expression
of DNA damage response genes, including BRCA1 and ATR, while enhancing
sensitivity to DNA damaging agents (Blazek, 2011; Liang, 2015). Recently
THZ531, a selective covalent inhibitor of CDK12 and CDK13, was shown to
decrease expression of DNA damage response genes in cell culture (Zhang,
2016). Here we present further studies with THZ531 to guide our discovery
program toward molecules suitable for clinical development and to explore
mechanistic rationales for combining a CDK12/13 inhibitor with PARP inhibi-
tors or DNA damaging agents for diffıcult-to-treat cancers such as high-grade
serous ovarian cancer and triple-negative breast cancer. Using THZ531 as a
benchmark, we developed assays capable of discriminating sub-nM inhibitors,
including quantifying time-dependent covalent inhibition and cell-based CDK
occupancy. Since CDK7, like CDK12 and CDK13, contains a cysteine residue
proximal to the kinase active site, these approaches are critical to understand
covalent inhibitor selectivity. Furthermore, we performed kinome paneling
studies to better understand selectivity of this scaffold in support of our ongoing
efforts to optimize CDK12/13 potency and selectivity. To pharmacologically
investigate the previously reported effects of CDK12RNAi, growth inhibition of
a panel of ovarian and breast cancer cell lines was assessed following treatment
with THZ531 (OVA EC50  50-200 nM (n6); BRCA EC50 50 nM (n4)).
Expression profıling revealed that THZ531 treatment resulted in different sets of
genes being affected than was observed following treatment with inhibitors tar-
geting CDK7, CDK9 or BET-bromodomain proteins. Additionally, CDK12/13,
CDK7 and CDK9 inhibitors were profıled in a broad cell line panel (n400) to
reveal relationships between inhibitor sensitivity, mutation status, gene expres-
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sion, andpotential oncology indications thatmay be addressed by these different
mechanisms. Finally THZ531 was synergistic with both PARP inhibitors and
DNA damaging agents in ovarian and breast cancer cell lines. These data high-
light cancer indications and combinations that may be particularly amenable to
treatment with CDK12/13 inhibitors. While the pharmacokinetic properties of
THZ531 preclude adequate target engagement in tumor tissue at tolerated doses
inmousemodel systems, our ongoingmedicinal chemistry program is progress-
ing to identify and optimize CDK12/13 inhibitors suitable for clinical evalua-
tion.
#1144 Dual inhibition ofMEK1/2 andPLK1 specifıcally targets aggressive
breast cancer cell population with CEP55 elevated expression. Debottam
Sinha, Murugan Kalimutho, J. Alejandro Lopez, Kum Kum Khanna. QIMR
Berghofer Medical Research Institute, Brisbane, Australia.
Triple negative breast cancers (TNBCs), lacking the expression of ER, PR and
HER2 amplifıcation, are the most aggressive form of breast cancer (BC). Due to
their heterogeneity influenced by high level of genomic instability and aneu-
ploidy, treatment of TNBC patients is one of the biggest challenges faced in the
clinics. CEP55, discovered fırst by our laboratory, is a key regulator of cytokine-
sis malfunction of which has been shown to cause multinucleation. Further-
more, ERK2/PLK1 critically regulates the functional role of CEP55 via phos-
phorylation of CEP55 at particular stages of mitosis, allowing it to localize to the
midbody for accurate cytokinesis. Research has demonstrated association of
CEP55with various cancers especially BCas over-expression ofCEP55mRNA is
associated with worse BC prognosis and poor survival. We hypothesized that,
CEP55 regulates the fate of aneuploid cell population, which are highly depen-
dent on mitotic genes for tumor progression among aggressive BC, thus can be
targeted for therapy development.We have performed a series of in vitro studies
demonstrating that depletion of CEP55 sensitizes cells to anti-mitotic drugs like
PLK1 inhibitor (BI2536) and leads to unscheduled CDK1/Cyclin B activation
and favor CDK1-Caspase 3-dependent mitotic catastrophe. We also demon-
strate that ERK1/2 transcriptionally controls CEP55mRNA and due to lack of a
specifıc smallmolecule inhibitor against CEP55, inhibition ofMEK1/2 using the
small molecule inhibitor Selumetinib, can mimic depletion of CEP55 in vivo.
Thus, we rationalized the usage of a MEK1/2 inhibitor in combination with a
PLK1 inhibitor across a series of BC cell lines. We observed synthetic lethality
among the aggressive hormone receptor negative cell lines, which expressed
higher expression of CEP55 compared to normal like and hormone receptor
positive BC cell lines with lower CEP55 level. The combination synergistically
increased apoptosis of aneuploid population via premature entry of these cells
intomitosis in the presence of antimitotic drugs due to exhaustion ofCEP55.We
have also validated this synergistic effect of MEK1/2 and PLK1 inhibition using
xenograft models, results of which imitated the in vitro fındings. Therefore, we
propose a novel treatment strategy of MEK1/2-PLK1 dual combination for se-
lectively targeting CEP55 over-expressing BC in the clinics.
#1145 Overcoming chemoresistance and blocking metastasis in breast
cancer by targetingHuR.XiaoqingWu,1 RebeccaMarquez,1 ShuangHan,1 Lan
Lan,1 Dan A. Dixon,2 Jeffrey Aubé,3 Danny R.Welch,2 Liang Xu1. 1University of
Kansas, Lawrence, KS; 2University of Kansas Medical Center, Kansas City, KS;
3University of North Carolina, Chapel Hill, NC.
Patients with metastatic breast cancer have a dismal 5-year survival rate of
only 24%. Chemoresistance is another contributor to the high mortality of ad-
vanced breast cancer. The RNA-binding protein, Hu antigen R (HuR), is over-
expressed at all stages of breast cancer development. CytoplasmicHuR accumu-
lation correlates with high-grade malignancy, poor distant disease-free survival
and serves as a prognostic factor for poor clinical outcome in breast cancer. HuR
promotes tumorigenesis by promoting mRNA stability and translation of pro-
teins implicated in proliferation, survival, angiogenesis, invasion, and metasta-
sis.HuRalsomodulates sensitivity of breast cancer cells to chemotherapy. Taken
together, HuR is an emerging target for breast cancer therapy, especially meta-
static breast cancer. Using shRNA and CRISPR technologies to modulate HuR
expression in breast cancer cells, we found that cells with HuRKD/KOwere less
invasive and more sensitive to chemotherapy. In an effort to discover small
molecules that disrupt the HuR-mRNA interaction and block HuR functions in
breast cancer progression, metastasis and chemoresistance, high throughput
screening (HTS) was carried out in several chemical libraries (23,000 com-
pounds) using fluorescence polarization (FP) assay, which identifıed several
initial hits with sub-micromolar inhibitory constants (Ki). Those potential inh-
bitors were then validated by ALPHA assay (Amplifıed Luminescent Proximity
Homogeneous Assay), confırmed by Surface Plasmon Resonance (SPR). In cell-
based assays, top hit KH-3 and its optimized analogs, specifıcally shortenedHuR
target mRNA half-lifes and decreased the level of the encoded proteins. More-
over, those compounds inhibited invasion and restored chemosensitivity. qPCR
arrays focusing on specifıc pathways revealed that HuR inhibitors potently up-
regulated metastatic suppressors and downregulated genes frequently overex-
pressed in lung metastases. In animal studies, KH-3 not only exhibited potent
antitumor effıcacy in orthotopic xenografts of breast cancer, but also effıciently
blocked experimental metastasis. In conclusion, we identifıed potent and spe-
cifıc small molecule inhibitors of HuR-mRNA interaction for potential anti-
metastatic therapy for breast cancer with HuR overexpression.
#1146 Biomarker-driven targeted oral treatment strategy for bladder can-
cer. Daley S. Morera, Andre Jordan, Vinata B. Lokeshwar. Augusta University,
Augusta, GA.
INTRODUCTION ANDOBJECTIVE: Hyaluronic acid (HA) family of mol-
ecules, HA-synthases (HAS-1,2,3), HA-receptors (CD44, RHAMM) and hyal-
uronidase (HYAL-1) are markers for bladder cancer (BCa) diagnosis and pre-
dicting prognosis. HA-family promotes tumor growth and metastasis by
inducing epithelial mesenchymal transition (EMT). 4-Methylumbelliferone (4-
MU) is an orally bioavailable dietary supplement that inhibits HA synthesis.We
evaluated the expression of HA family and EMT markers in bladder tissues as
well as the antitumor effects of 4-MU as a potential targeted therapeutic agent in
preclinical models of BCa. METHODS: Quantitative PCR was used to measure
mRNAexpression ofHA-family andEMTgenes (-catenin, Twist, and Snail) in
72 bladder tissue specimens (28 normal; 44 tumor); follow-up: 20.3	2.5
months; median 17 months. The effect of 4-MU (0-0.6 mM) on cell prolifera-
tion, apoptosis, intracellular signaling, and the expression of HA receptors, and
EMT genes were examined in BCa cell lines by Q-PCR, immunoblotting, prox-
imal ligation and PI-3K activity assays. Mechanism of action was analyzed by
HA addition and mAkt overexpression. Effect of oral administration of 4-MU
(100, 200-mg/kg) on tumor growth was analyzed in subcutaneous xenografts.
RESULTS: HAS-1, -2 -3, HYAL-1 and Snail levels were 10-20-fold elevated in
BCa tissues as compared to normal bladder (P0.001). In univariate analysis,
HAS-1, -2, HYAL-1 and Twist levels correlated with metastasis (P0.001);
HYAL-1 was an independent predictor of metastasis. 4-MU inhibited cell pro-
liferation, chemotactic motility and invasion in a dose-dependent manner; 50-
70% inhibition at IC50 (0.4 mM) for HA-synthesis inhibition. 4-MU induced
apoptosis (3-fold) via the death receptor pathway. 4-MU downregulated HA-
signaling, specifıcally transcript and/or protein levels of CD44, RHAMM, p-Akt,
-catenin, p-catenin(S552). Snail and twist were downregulated by 2-5-fold,
but pcatenin((T41/S45), pGSK-3/ and E-cadherin levels were increased.
4-MU also inhibited CD44/PI-3K complex formation and PI-3K activity. HA
addition or myristoylated Akt expression attenuated 4-MU effects. In xenograft
studies, 4-MU oral treatment abrogated tumor growth of established tumors
(vehicle, day 50: 766	221 mm3; 4-MU: 128	61, day 50) by abrogating HA-
synthesis. No weight loss or serum or organ toxicity was observed in treated
mice. CONCULUSION: This study demonstrates that HA-family signaling is
upregulated in BCa and can be specifıcally targeted for treatment by a non-toxic
dietary supplement. Support: 7R01 CA072821-16; 7R01CA176691-03
#1147 Probing the roles of SUMOylation in cancer cell biology using a
selective SUMO activating enzyme inhibitor. Sai M Pulukuri, Xingyue He,
Stephen Grossman, Jessica Riceberg, Erik Koenig, Teresa Soucy, Keli Song,
Anna Kreshock, Dylan England, Hirotake Mizutani, Larry Dick, James
Brownell, John Newcomb, Steve Langston, Eric Lightcap, Katherine Galvin.
Takeda Pharmaceuticals, Inc, Cambridge, MA.
SUMOylation has been implicated inmany cellular processes that are impor-
tant for cancer cell survival, including cell cycle, chromosome structure and
segregation, nuclear and subnuclear organization, transcription andDNAdam-
age repair. However, a potent and selective inhibitor to target the SUMO path-
way has been lacking. The SUMO-activating enzyme (SAE) is an essential en-
zyme in the pathway that initiates the SUMOylation process. Here we report the
identifıcation of the fırst mechanism-based SAE inhibitors with nanomolar po-
tency in cellular assays. These inhibitors selectively block SAE enzyme activity
and total SUMOylation in cells, which leads to reduced cancer cell proliferation.
Moreover, SAE inhibition resulted in disruption of PML nuclear bodies and
redistribution of DAXX. In vivo administration of SAE inhibitor into tumor
bearingmice results inmodulation of several biomarkers including a signifıcant
reduction in SUMO-conjugates and E2 Ubc9 thioesters, demonstrating SUMO
pathway inhibition. Our results demonstrate the feasibility of inhibiting the
SUMO pathway with small molecule inhibitors and provide tools to study the
SUMO biology in cancer.
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#1148 Bazedoxifene as a novelGP130 inhibitor for the treatment of triple-
negative breast cancer. Jilai Tian,1 Yang Cao,2 Xiang Chen,1 Hui Xiao,3 Chen-
glong Li,4 Jiayuh Lin1. 1University ofMaryland, Baltimore,MD; 2HuazhongUni-
versity of Science and Technology, Wuhan, China; 3The Ohio State University,
Columbus, OH; 4University of Florida, Gainesville, FL.
Triple negative breast cancer (TNBC) is the only subtype of breast cancer still
lacking effective therapeutic options. Thus, fınding novel targets and therapies
to treat TNBC is an urgent clinical issue. IL-6 is one of the principal oncogenic
mediators in breast cancer and systemic IL-6 levels correlates with poor prog-
nosis, advanced disease, and metastases. Importantly, growth of TNBC cells are
replied on autocrine cytokines including IL-6. Therefore, IL-6 signaling repre-
sents a novel approach with a potential to improve the therapeutic effıcacy. To
date, however, no small molecules that target IL-6 signaling are available for
clinical cancer therapy. IL-6 binds to IL-6 R, then recruits GP130 to form the
IL-6/IL-6 R/GP130 heterotrimer and triggers a signaling cascade downstream
including JAK/STAT3, PI3-K/AKT/mTOR, andMEK/ERK.Therefore, it is pos-
sible to target IL-6 signaling by blocking IL-6 binds to GP130 or IL-6 R and
thus inhibiting its signaling cascade downstream.To effectively target IL-6 sig-
naling, we have utilized a novel drug discovery approach combining Multiple
Ligand Simultaneous Docking and drug repurposing to target GP130, since its
structure is more druggable than IL-6 R. We have identifıed a FDA-approved
drug Bazedoxifene (for the prevention of the postmenopausal osteoporosis in
postmenopausal women) with a novel function to inhibit IL-6 and GP130 pro-
tein-protein interactions and thus blocking IL-6 signaling cascade downstream.
In this study, we examined the therapeutic effect of Bazedoxifene on TNBC,
aiming to verify Bazedoxifene as a Novel IL-6/GP130 Inhibitor for TNBC treat-
ments.Our data of western blot showed Bazedoxifene inhibited increased
STAT3 phosphorylation induced by IL-6. In addition, Bazedoxifene inhibited
phosphorylation of AKT and ERK in TNBC cells that were also produced by
IL-6. Furthermore, combination of Bazedoxifene with paclitaxel exhibitedmore
signifıcant inhibition than single agent alone on cell viability in TNBC cells
either in 2D or 3D culture model in vitro. Results of colony formation showed
that Bazedoxifene could signifıcantly inhibit cell survive and proliferation at 20
M,which weremore effective than Evista and SC144.Moreover, Bazedoxifene
could inhibit cell migration.We tested the increased proliferation of TNBC cells
using BrdU with the added IL-6, which were then inhibited by Bazedoxifene,
demonstrating the Bazedoxifene could achieve a competed inhibition of IL6.
The result of signifıcant inhibition of tumor growth in vivo furtherly verifıed the
therapeutic effects of Bazedoxifene. All results showed the signifıcant therapeu-
tic effects of Bazedoxifene in TNBC cells by competed blocking IL6 signaling.
Thus, Bazedoxifene holds a great potential for TNBC therapy.
#1149 Targeting Rad6B suppresses melanomagenesis.Ashapurna Sarma,1
Sarah Petit,1 Fangchao Liu,2 Pratima Nangia-Makker,1 Guangzhao Mao,2 Mal-
athy Shekhar1. 1Wayne State University and Karmanos Cancer Institute, Detroit,
MI; 2Wayne State University, Detroit, MI.
Active -catenin signaling inmelanoma is associated with aggressive disease.
We have previously shown that Rad6B, an ubiquitin conjugating enzyme, is a
positive regulator of -catenin stability and transcriptional activity, and is itself
a transcriptional target of -catenin. This stabilization is mediated by Rad6B-
induced K63-linked polyubiquitination of -catenin that renders it insensitive
to 26S proteasomal degradation. Immunohistochemical analysis of human cu-
taneous melanoma samples showed the fırst detectable expression of Rad6B in
melanocyte hyperplasia and continued Rad6B and -catenin overexpression in
primary and metastatic melanomas. These data implicate a critical role for
Rad6B in melanocyte transformation and a continuing role in melanoma pro-
gression. To analyze the role of Rad6B in melanomagenesis, we targeted Rad6B
expression/activity in human M14 metastatic melanoma cells by using a Rad6-
selective small molecule inhibitor SMI#9 and the CrispR/Cas9 gene editing sys-
tem. Immunoblot analysis showed that compared to controls, M14 cells treated
with SMI#9 showed decreased levels of -catenin, and -catenin driven tran-
scriptional targets Rad6, vimentin, Mitf-M, and Melan A. Although Snail levels
were not altered, SMI#9 treated cells showed increase in phosphorylated Snail.
Immunocytochemical staining verifıed the western blot data and showed cyto-
plasmic relocalization of PCNA and Snail in SMI#9 treated cells which is con-
sistent with increase in phosphorylated Snail. Concordant with the decrease in
vimentin and unphosphorylated Snail levels, Rad6B-inhibited cells display poor
capacity to migrate as compared to controls. Whereas Rad6B knockout cells
were severely growth impaired, Rad6B edited clones showing partial expression
(potentially fromonly one allele) similarly showed decreased levels of-catenin,
vimentin, andMitf-M. Similar to Rad6B-inhibited cells, Rad6B edited cells were
migration- and invasion-impaired. Whereas control cells produced robust tu-
mors and overt lungmetastases, the Rad6B gene edited cells were poorly tumor-
igenic. Rad6B gene edited clones showed complete loss of Melan A. Since
Mitf-M is a transcriptional regulator of Melan A and a key player in melanocyte
lineage specifıcation, our data suggest that targeting Rad6B could potentially
inhibit melanomagenesis by reprogramming melanoma cells. Supported by
NIH CA178117 and 3Balls Racing.
#1150 Downregulation of Hedgehog signaling via Sirt6 activation is im-
portant to docosahexaenoic acid-induced cell death in human EGFRmutant
non-small cell lung cancer. Soyeon Jeong,1Kaipeng Jing,1 Soyeon Shin,2 Seung-
HyeonHan,3 Yoon-Seon Yoo,3 Prashanta Silwal,3 Young-Joo Jeon,3 Jun-Young
Heo,4 Gi-RyangKweon,4 Seung-Kiel Park,5 Jong-Il Park,5 TongWu,6 Kyu Lim7.
1Dept. of Biochemistry, Infection Signaling Network Research Center, Chungnam
National University, Daejeon, Republic of Korea; 2Dept. of Biochemistry, Cancer
Research Institute, Chungnam National University, Daejeon, Republic of Korea;
3Dept. of Biochemistry, Dept. of Medical Science, School of Medicine, Chungnam
National University, Daejeon, Republic of Korea; 4Dept. of Biochemistry, Dept. of
Medical Science, School of Medicine, Infection Signaling Network Research Cen-
ter, Chungnam National University, Daejeon, Republic of Korea; 5Dept. of Bio-
chemistry, ChungnamNational University, Daejeon, Republic of Korea; 6Depart-
ment of Pathology and Laboratory medicine, Tulane University School of
Medicine, New Orleans, LA; 7Dept. of Biochemistry, Dept. of Medical Science,
School of Medicine, Cancer Research Institute, Infection Signaling Network Re-
search Center, Chungnam National University, Daejeon, Republic of Korea.
Docosahexaenoic acid (DHA) induces apoptotic cell death through several
mechanisms in cancer cells. Here we report that DHA-induced apoptotic cell
death is related to the inhibition of Hedgehog signaling via SIRT6 activation in
human PC9 and H1975 nonsmall cell lung cancer (NSCLC). DHA-induced cell
death was confırmed increase of the protein levels of cleaved PARP and
caspase-3 Bax as well as the number of TUNEL positive cells and the Sub-G1
proportion in PC9 and H1975. DHA signifıcantly increased the SIRT6 levels.
Knockdown of SIRT6 by siRNAs inhibited apoptosis induced by DHA, while
SIRT6 overexpression increased apoptotic cell death, indicating that DHA-in-
duced SIRT6 activation results in apoptosis. In addition, SIRT6 activation by
DHA treatmentwas associatedwith downregulation ofHh signaling and knock-
downof SIRT6 resulted in augmentation ofHh signaling, suggesting elevation of
SIRT6 levels in DHA-treated NSCLC cells leads to downregulate the Hh signal-
ing. Smo activator SAG increased the protein levels ofHh signalingmolecules by
DHA, and SAG plus DHA treatment decreased cleaved PARP levels, implying
that DHA-inhibitedHh signaling is related to apoptotic cell death. To unveil the
effects of endogenous DHA on apoptosis via SIRT6-mediated Hh signaling
downregulation, we used PC9 stable cell lines of fat-1 (3-desaturase) gene. The
SIRT6 levels were signifıcantly increased and Hh signaling molecules were di-
minished in fat-1 stable PC9 (f-PC9) cells, compared with the cells transfected
with the control vector (c-PC9).Moreover, SIRT6 expression was elevated and
Gli and smo levels were inhibited in tumor tissues from f-PC9 cells-injected
mice, demonstrating that DHA regulates SIRT6 and Hh signaling in vivo.
Taken together, these results suggest that DHA may induce apoptotic cell
death through SIRT6-modulated Hh signaling suppression in human
NSCLC cells. These fındings implicate that 3-PUFAs may represent a po-
tential effective therapy for the chemoprevention and treatment of human
NSCLC. [This work was supported by the National Research Foundation of
Korea (NRF) grant funded by the Korea government (MEST) (2007-
0054932, NRF-2015R1D1A1A01056887) and by the framework of interna-
tional cooperation program managed by National Research Foundation of
Korea (2015K2A2A6002008)].
#1151 SY-1365, a potent and selectiveCDK7 inhibitor, exhibits promising
anti-tumor activity inmultiple preclinicalmodels of aggressive solid tumors.
Shanhu Hu, Nan Ke, Yixuan Ren, Sofıja Miljovska, Nisha Rajagopal, Michael
McKeown, David Orlando, Kevin Sprott, Yoon J. Choi, Eric Olson, Christian C.
Fritz. Syros Pharmaceuticals, Cambridge, MA.
CDK7 has recently emerged as an attractive target in cancer since its inhibi-
tion decreases the transcript levels of oncogenic transcription factors, especially
those driven by super-enhancers (SEs). Cancers have been hypothesized to be
addicted to SE regulated genes and simultaneous suppression of multiple SE
associated genes through CDK7 inhibition might represent a novel, powerful
way to selectively kill cancer cells. Previously, we reported that SY-1365, a highly
selective covalent CDK7 inhibitor, induces apoptosis in leukemia cells, but not
in non-malignant cells, and demonstrates anti-tumor activity in in vivo models
of leukemia. In this study, we extend these fındings to the identifıcation of mul-
tiple solid tumors that are susceptible to SY-1365 and compare the effects of
SY-1365 on gene expression to other gene control agents. SY-1365 was screened
in a panel of solid tumor cell lines, revealing activity in breast, ovarian, colorectal
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and lung cancer cells with low nM EC50 and rapid induction of apoptosis. In
breast cancer, a subset of triple negative breast cancer (TNBC) cell lines were
found to be more sensitive than luminal breast cancer cell lines, so we extended
our studies to in vivomodels and showed substantial tumor growth inhibition in
multiple patient-derived xenograft (PDX) models of TNBC. Since other com-
pounds have been reported tomodulate the expression of SE regulated genes, we
compared the transcriptional effects of SY-1365 treatment with those of a pan-
CDK inhibitor (flavopiridol), a CDK9 inhibitor (NVP2) and a BRD4 inhibitor
(JQ1) using microarray analysis. Applying principal component analysis, we
observed a unique transcriptional response elicited by SY-1365 compared to the
other inhibitors. NVP2 and flavopiridol inhibited an overlapping and much
larger gene set than either JQ1 or SY-1365. Interestingly, SY-1365 treatment
decreased the expression of oncogenic transcription factors, cell cycle check-
point regulators andDNAdamage response genes. The downregulation of tran-
scripts involved in apoptosis and DNA damage response by SY-1365 suggests
that CDK7 inhibition might synergize with targeted agents that affect these
processes. Indeed, we observed that SY-1365 was synergistic with the PARP
inhibitor niraparib and the Bcl-2 inhibitor venetoclax in triple negative breast
cancer and AML cell lines, respectively. In summary, we have identifıed TNBC,
ovarian and small cell lung cancer cell lines as highly sensitive to SY-1365 in vitro
and have observed substantial tumor growth inhibition in PDX models of
TNBC. SY-1365 induced a distinct transcriptional response compared with
other transcriptional inhibitors, with apoptotic and DNA damage pathways be-
ing central. Finally, these mechanism of action studies support a rationale for
investigating combinations of SY-1365 with inhibitors of PARP and Bcl-2.
#1152 Lipid elongation: an unexplored therapeutic target in prostate can-
cer. Zeyad D. Nassar,1 Margaret M. Centenera,1 Jelle Machiels,2 Samuel J.
Polacek,1 KatarzynaBloch,2WayneD. Tilley,1 LukeA. Selth,1 JohannesV. Swin-
nen,2 Lisa Butler1. 1University of Adelaide, Adelaide, Australia; 2KU Leuven -
University of Leuven, Leuven, Belgium.
Dysregulated lipid metabolism is one of the hallmarks of cancer, particularly
for prostate cancer (PCa). PCa cells exhibit distinctivemetabolic features such as
upregulation of enzymes involved in de novo synthesis, uptake and beta-oxida-
tion of lipids, which promote prostate cancer growth, metastasis, and drug re-
sistance. Androgen signalling is a major driver of both PCa growth and lipid
metabolism in PCa cells, however the precise effects of androgens on cellular
lipid composition and the molecular pathways by which androgens regulate
lipid metabolism in PCa cells are yet to be elucidated. In this study we investi-
gated the effect of androgens on the lipid composition of PCa cell membranes
and the enzymes involved in lipid metabolism, and explored the influence of
these enzymes on tumour cell behaviour such as cell migration, proliferation
and attachment. PCa cell lines (AR positive and negative) were cultured in the
absence or presence of androgens or the anti-androgen enzalutamide, and
changes in intact phospholipid species were assessed by ESI-MS/MS-based lip-
idomics. This analysis revealed a complexity of changes in phospholipid profıles
in response to androgen treatment. Strikingly, elongation of the fatty acyl chains
was consistently observed for multiple phospholipid classes in response to the
androgens mibolerone or 5-dihydotestosterone, whereas inhibition of elonga-
tion was observed in the presence of enzalutamide. Transcriptional analysis of
critical lipid metabolism pathways revealed that the enzymes that catalyse lipid
elongation (ELOVLs) weremarkedly induced by androgens inmultiple PCa cell
lines, and siRNA depletion of these enzymes, either alone or in combination,
reversed the androgen-induced fatty acyl elongationphenotype. The androgenic
regulation of ELOVL enzymes was confırmed in clinical PCa cohorts and in
primary tumours cultured as explants. Targeting ELOVL gene expression also
signifıcantly attenuated the tumorigenic properties of PCa cells. ELOVL down-
regulation decreased LNCaP cell migration, and adhesion to fıbronectin. Fur-
thermore, ELOVL knock down signifıcantly decreased three-dimensional
spheroid growth of LNCaP cells using a hang drop assay. The impact of these
enzymes on the lipid profıle of PCa cell membrane and cell viability, adhesion
and migration suggests that they may represent promising and previously un-
explored therapeutic targets.
#1153 Heparan sulfate proteoglycans as novel target in cancer precise
therapy.Chiara Falciani, Jlenia Brunetti, Lorenzo Depau, Alessandro Pini, Giu-
lia Riolo, Elisabetta Mandarini, Luisa Bracci. University of Siena, Siena, Italy.
Heparan sulfate proteoglycans (HSPGs) have crucial regulatory roles in tu-
mor onset and progression. HSPGs are composed of a core protein and glycan
chains characterized by repeated disaccharide units which can be sulfated at
different amount and position. HSPG have enormous structural diversity due to
the different possible modifıcations of the single saccharide units within the
polysaccharide, such as position, sulphation and acetylation. As a result HSPG
can bind and modulate their binding to signaling molecules such as growth
factors, morphogens and chemokines1. HSPG proved to be important in medi-
ating cancer development and progression by enhancing the binding of growth
factors, morphogens and cytokines to their cognate receptors, thus activating
signaling pathways that give rise to angiogensis, cell growth and proliferation,
togetherwith invasion andmetastasis 2-3.NT4 is a branchedpeptides that targets
HSPGs. NT4 specifıcally binds to sulfated glycosaminoglycans on cancer cells
and tissues.NT4 can be conjugated tomanydifferent cytotoxic units and tracers.
NT4 conjugated to paclitaxel produced tumor regression in a breast cancer
orthotopic mouse model 4. NT4 conjugated to tracers can discriminate between
tumor andhealthy tissue in different human cancer specimen5.Wewill show the
ability of NT4 to drive tracers onto tumor lesions by means of Qdots and in
vivo imaging, proving their promising features as theranostics. We will also
show NT4 ability to interfere with HSPG-modulated activities such as: tu-
mor cell proliferation, migration and invasion of matrix; as well as endothe-
lial cells proliferation, migration and tube formation. NT4-HSPG interac-
tions and consequent modulation of signaling pathways will prove the
importance of this versatile tool, NT4, in addressing tumor cells and inter-
fering in their cell-cell and cell-matrix communications. Bibliography 1.
Gharbaran R. et al. Tumour Biol. 2016; 37:11573-11588. 2. Purushothaman
A et al. Blood. 2010; 115:2449-57. 3. Lee JH et al. J Biol Chem. 2009; 284:
27167-75. 4. Brunetti, J. et al. Scientifıc Reports. DOI:10.1038/srep17736 5.
Falciani C. et al. J Med Chem. 2013; 56:5009-18.
#1154 Targeted silencing of elongation factor 2 kinase (EF2K) suppresses
invasion, cell proliferation and growth in an orthotopic model of ovarian
cancer.Mumin Alper Erdogan, Bulent Ozpolat.UTMDAnderson Cancer Cen-
ter, Houston, TX.
Ovarian cancer (OCa) is one of the most aggressive and deadliest cancer
and is currently incurable disease with the poorest prognosis and survival
rates (4%, 5year survival rates). One of the hallmarks of OCa is its early
invasion and metastasis, resistance to chemotherapeutics and radiotherapy
and aggressive tumor progression. These features contribute to a poor prog-
nosis of this highly complex malignancy with many molecular alterations
and mutations involving multiple genes. The major reason for patient death
is due to metastasis and resistance to current therapies that include chemo-
therapy, hormonal therapy and radiation. Therefore, novel molecular targets
and therapeutics strategies are urgently needed to enhance the effıcacy of
current therapies and prolong patient survival. Recently, we discovered that
Eukaryotic elongation factor-2 kinase (EF2K), an atypical kinase, is dramat-
ically up-regulated in cells and promotes cell survival and proliferation, its
inhibition signifıcantly reduces cell growth and colony formation. However,
the role that EF2K in OCa and pathways regulating cell proliferation, colony
formation, survival, invasion/metastasis and resistance remains is largely
unknown. Here, we show that specifıc inhibition of EF2K by siRNA-medi-
ated knockdown markedly inhibits OCa (HeyA8 and SKOV3ip1) cell prolif-
eration, colony formation and invasion/migration in vitro. This targeting
resulted in a substantial decrease in eEF2 phosphorylation in the tumors, and
led to the inhibition of tumor growth and metastasis. Lack of function dem-
onstrated that EF2K regulates Beta1-integrin, p-SRC, p-FAK, p-AKT,
p-IF2alpha, p-ERK expression. Our western blot data suggested that EF2K
may enhance tumorigenesis and metastasis through the upregulation of pro-
tumorigenic, metastatic proteins and pathways in OCa. Furthermore, we
found that therapeutic inhibition of EF2K by systemically administered (i.v)
nanoliposomal EF2K siRNA inhibited growth SKOV3 tumor xenografts and
intraperitoneal tumor nodules (intraperitoneal metastatic model) in nude
mice (p0.05), demonstrating the role of EF2K in tumorigenesis and meta-
static phenotype. We also found that treatment with EF2K siRNA resulted in
signifıcant decrease in mean tumor weight, induced apoptosis (as judged by
a positive TUNEL assay) and the downregulation of the proliferative marker
Ki-67. Collectively, our data suggest, for the fırst time, the pivotal role of
eEF2K in OCa cell proliferation, invasion and tumor progression and estab-
lish eEF2K as a novel potential therapeutic target in highly aggressive and
lethal ovarian cancer.
#1155 Potent anti-cancer effects of selective GPR132/G2A agonist imipri-
done ONC212 in leukemia and lymphoma. Varun Vijay Prabhu,1 Neel Mad-
hukar,2 Rohinton Tarapore,1 Mathew Garnett,3 Ultan McDermott,3 Cyril
Benes,4 Neil Charter,5 Sean Deacon,5 Wolfgang Oster,1 Michael Andreeff,6 Ol-
ivier Elemento,2 Martin Stogniew,1 Joshua Allen1. 1Oncoceutics, Inc, Philadel-
phia, PA; 2Weill Cornell Medicine, New York, NY; 3Wellcome Trust Sanger Insti-
tute, Hinxton, United Kingdom; 4Massachusetts General Hospital, Boston, MA;
5DiscoverX Corporation, Fremont, CA; 6The University of Texas M.D. Anderson
Cancer Center, Houston, TX.
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ONC201, foundingmember of the imipridone class of compounds, is a highly
selective small molecule G protein-coupled receptor (GPCR) antagonist that is
in Phase I/II advanced cancer clinical trials. In this study, we evaluated GPCR
engagement and antitumor activity ofONC212, an imipridone that is a chemical
analogue of ONC201. Experimental GPCR profıling using the PathHunter®
-Arrestin assay, determined that ONC212 is a selective agonist of the orphan
GPCRGPR132/G2A.Multidose validation confırmed nanomolar GPR132 ago-
nist activity (EC50400nM). GPR132 is a stress-inducible orphan GPCR that
causes G2/M arrest. The tumor suppressive role of GPR132 has been demon-
stratedmost notably in lymphoid leukemia. Gene expression analysis of samples
in the CancerGenomeAtlas (TCGA) revealedGPR132 is expressed in a range of
tumor types with highest expression in leukemia and lymphoma. The in vitro
effıcacy of ONC212 was assessed in the Genomic of Drug Sensitivity in Cancer
(GDSC) collection of cell lines (1,000 cell lines). Cell viability assays were
performed at 72 hours post-treatment to generate dose responses curves at con-
centrations from 78nM up to 20M. ONC212 was broadly effıcacious across
most solid tumors and hematological malignancies in the low nanomolar range.
Ranking the sensitivity of cancer lines to ONC212 by tumor type revealed that
leukemia and lymphoma are the most responsive tumor types based on com-
pleteness of response (area under the dose-response curve). Interestingly, we
also observed that high expression of GPR132 signifıcantly correlated with
ONC212 effıcacy in GDSC cell lines, suggesting the importance of GPR132
agonist activity for ONC212 effıcacy. ONC212was tested in 62 human leukemia
cell lines that included acute myeloid leukemia (AML), acute lymphoblastic
leukemia (ALL), chronicmyelogenous leukemia (CML) and hairy cell leukemia.
ONC212 demonstrated broad spectrum anti-leukemic activity and was equally
effıcacious across all leukemia subtypes tested. Most cell lines (60/62) were re-
sponsive to ONC212 with GI50 ranging from78nM to 456nM. Within ALL,
both B-cell and T-cell ALL were highly sensitive to ONC212. ONC212 reduced
cell viability inAML independent of complex karyotypes andp53mutations that
are associated with poor clinical prognoses. ONC212 was also tested in 58 lym-
phoma cell lines comprised of anaplastic large cell lymphoma, Burkitt’s lym-
phoma, cutaneous T-cell lymphoma (CTCL), diffuse large B-cell lymphoma
(DLBCL), Mantle cell lymphoma (MCL), Follicular Lymphoma and Hodgkin’s
lymphoma. ONC212 reduced cell viability in most cell lines (56/58) and was
equally effıcacious regardless of subtypes with GI50 ranging from 78nM to
261nM. Thus, GPR132 agonist ONC212 possesses robust anti-cancer activity in
hematological malignancies irrespective of leukemia and lymphoma subtype
and provides further validation of the anti-cancer effıcacy of the novel imipri-
done class of small molecules.
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#1156 Epigenetic re-wiring of breast cancer by pharmacological targeting
of C-terminal binding protein. Jung S. Byun, Samson Park, Dae IK Yi, Mo-
hamed Kabbout, Genqing Liang, Kevin L. Gardner. National Institutes of
Health, Bethesda, MD.
TheC-terminal binding protein (CtBP) is a family of dimeric nuclear proteins
whose levels are increased in cancers of the colon, ovaries, prostate and breast.
Elevated CtBP expression is associated with poor cancer survival and can also
distinguish those node negative breast cancer patients who will show worse
survival. This implicates CtBP as both a biomarker and a promising candidate
for therapeutic intervention. As a dimer, CtBP provides a scaffold that couples
multiple different DNA-binding transcriptional regulators with a variety of
chromatin modifying protein complexes to alter the epigenetic landscape
throughout the nucleus. These properties provide the rationale for pharmaco-
logical targeting of CtBP to change epigenetically regulated gene expression in
cancer cells. In this study, we employ computer assisted drug design to screen for
optimal quantitative structure-activity relationships (QSARs) between small
molecules and CtBP to identify 24 potential CtBP inhibitors. Functional screen-
ing of these compounds identifıes 4 lead compounds with low toxicity and high
water solubility. Treatment of breast cancer cells at micro-molar concentrations
of these small molecular inhibitors induces signifıcant de-repression of epige-
netically silenced pro-epithelial genes in themesenchymal, triple negative breast
cancer cell line, MDA-MB-231. This re-activation is associated with eviction of
CtBP from the respective gene promoters, disrupted recruitment of CtBP-chro-
matin modifying protein complexes, increased deposition of activating epige-
netic histone marks, and upregulation of both pro-epithelial gene mRNA and
protein expression. In functional assays, CtBP inhibition by these small molec-
ular inhibitors decreases cellular invasion, and improves DNA repair. FRET
(Förster resonance energy transfer) analysis demonstrates that CTBP inhibition
results in decreased FRET intensity, suggesting that CTBP dimerization is re-
pressed by CTBP inhibition. In addition, pharmacological inhibition of CtBP
combines with established epigenetically targeted drugs to synergistically de-
crease cell migration and potentiate the reactivation of silenced pro-epithelial
gene expression in triple negative cancer cells. Finally, CTBP inhibition results
in transcriptional repression ofMDR1 expression and reduces the population of
Doxorubicin resistant cells in the triple negative breast cancer cell lines. These
fındings implicate the possible use of this class of compounds in strategies for
therapeutic intervention that may increase the effıcacy and decrease the ac-
quired resistance to targeted therapeutic intervention in breast cancer.
#1157 Screening and identifıcation of new generation glucose transporter
inhibitors as anticancer therapeutics. Yanrong Qian, Pratik Shriwas, Xuan
Wang, Dennis Roberts, Emma Kessler, Stephen Bergmeier, Xiaozhuo Chen.
Ohio Univ., Athens, OH.
Cancer is a top killer second only to cardiovascular diseases. Cellular meta-
bolic reprogramming and altered energetics are key features of cancer. Oppor-
tunistic uptake of extracellular nutrients has recently been named as an emerg-
ing hallmark of cancer metabolism. Glucose is a key nutrient taken in by cancer
cells for satisfying their high energy and biosynthesis needs. Drastic upregula-
tion of glucose uptake and glycolytic activity, a phenomenon called theWarburg
effect, is prevalent in cancers. Cancer cells overexpress specifıc glucose trans-
porters (Gluts), particularly Glut1, on cell membranes for taking in glucose via
facilitated diffusion. Considering the addiction of cancer cells for glucose and
their sensitivity and vulnerability to changes in glucose supply, Gluts, especially
Glut1, have been recognized as an attractive anticancer target. We previously
reported the identifıcation of fırst generation lead Glut1 inhibitor WZB117 (1).
WZB117 treatment of human nonsmall cell lung cancer (NSCLC) A549 cells
resulted in inhibition of glucose uptake, glycolysis and induction of apoptosis
and necrosis. In addition,WZB-117 reduced tumor growth by70% in anA549
tumor mouse model. WZB117 inhibit cell growth of 7 cancer cell lines in 4
cancer types with IC50 values lower than 10 M. Through a structure activity
relationship (SAR) study of WZB117, a second generation lead, DRB18, has
been identifıed. DRB-18 ismuchmore stable and 5 to 10 timesmore potent than
WZB117 in inhibiting growth and proliferation in about 90% of the 60 different
cancer cell lines in 9major cancer types as revealed inNCI-60 screenings.And its
IC50s in many cancer cell lines are in the high nM range. In this study, we also
report new compounds screening results for the objective of identifying novel
compounds with higher glucose transport-inhibitory and cancer cell growth-
inhibitory activities using nonsmall cell lung cancer cell lines as models. Refer-
ences: 1. Liu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin,
R., Ding, J., Tong, L., Wu, S. and Hines, J., 2012. A small-molecule inhibitor of
glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and
inhibits cancer cell growth in vitro and in vivo. Molecular cancer therapeutics,
11(8):1672-1682.
#1158 Modulation of splicing by inhibiting the kinase SRPK1 as a novel
therapeutic strategy inmyeloid leukemia.Konstantinos Tzelepis,1 Etienne De
Braekeleer,1 Michael Seiler,2 Isaia Barbieri,3 Sam Robson,3 Yu Hsuen Yang,4
MalgorzataGozdecka,1MonikaDudek,1GraceCollord,1OliverM.Dovey,1 Em-
manouil Metzakopian,1 Dimitrios Garyfallos,1 Jonathan L. Cooper,1 Silvia
Buonamici,2 Hannes Ponstingl,1 Michael R. Stratton,1 Allan Bradley,1 Brian J.
Huntly,5 Cristina Pina,6 Tony Kouzarides,3 Kosuke Yusa,1 George S. Vassiliou1.
1Sanger Institute, Cambridge, United Kingdom; 2H3 Biomedicine, Boston, MA;
3Gurdon Institute, Cambridge, United Kingdom; 4University College of London,
London, United Kingdom; 5Cambridge University Hospitals NHS Trust, Cam-
bridge, United Kingdom; 6NHS Blood and Transplant, Cambridge Biomedical
Campus, Cambridge, United Kingdom.
Acutemyeloid leukemia (AML) is an aggressive cancerwith a poor prognosis,
for which the therapeutic landscape has changed little for decades. Aberrant
mRNA splicing plays a key role in cancer development and genes coding for
several of the major components of the spliceosome are targeted by somatic
mutations in numerous cancers including myelodysplastic syndromes and
AML. Recently, myeloid neoplasms bearing spliceosome gene mutations were
shown to be preferentially susceptible to pharmacological disruption of the spli-
ceosome. Here we report that targeting the spliceosome can also be an effective
therapeutic strategy in other types of AML. Recently, we generated a compre-
hensive catalogue of genetic vulnerabilities in AML using CRISPR-Cas9 ge-
nome-wide recessive screens and reported several novel intuitive and non-intu-
itive therapeutic candidates. Amongst these we identify SRPK1, the gene coding
for a serine-threonine kinase that phosphorylates themajor spliceosome protein
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SRSF1.Here, we demonstrate that targeted genetic disruption of SRPK1 inAML
driven by MLL-fusion genes, led to differentiation and apoptosis. Additionally,
mice transplanted with human AML cell lines carrying the MLL-AF9 fusion
gene, namely MOLM-13 and THP-1, presented a signifıcant prolongation of
survival when SRPK1 was genetically disrupted by CRISPR-Cas9 editing. Simi-
lar effects were seen with pharmacological inhibition of SRPK1 in vitro and in
vivo. At the molecular level we show that genetic or pharmacological inhibition
of SRPK1was associatedwith profound changes in the splicing ofmultiple genes
involved in the MLL leukemogenic program in association with signifıcant
changes in enzymatic modifıcations of core histone tails. We proceeded to per-
form a genome-wide CRISPR drop-out screen for sensitizers of MOLM13 cells
to pharmacological inhibition of SRPK1 and identifıed, amongst other genes,
BRD4 as a sensitizer. We go on to show that the BRD inhibitor iBET-151 syn-
ergizes with SRPK1 inhibition to kill MOLM-13 both in vitro and in vivo. Pre-
liminary data indicates that SRPK1 inhibition has overlappingmolecular effects
to BRD inhibition. We are currently investigating the molecular bases of this
observation. Our work identifıes SRPK1 as a novel therapeutic target in AML
that can be used alone or in conjunctions with drugs targeting epigenetic mod-
ifıcations to improve their anti-leukemic effects.
#1159 Targeting novel mucin synthesis pathway for pancreatic cancer
treatment. Altaf Mohammed, Naveena B. Janakiram, Venkateshwar Madka,
Gaurav Kumar, Scott Edgar, Gopal Pathuri, Taylor Bryant, Yuting Zhang,
Hariprasad Gali, Yan Daniel Zhao, Stan Lightfoot, Chinthalapally V. Rao.Univ.
of Oklahoma Health Sciences Ctr., Oklahoma City, OK.
Pancreatic cancer (PC) is most fatal and is the fourth leading cause of cancer
related deaths inUSAwith a least fıve year survival of7%. Although several over-
expressed mucin subtypes (MUC1, MUC4, MUC5AC, and MUC16) that impede
drug delivery to PC have been targeted with limited results, core enzymes involved
inmucin biosynthesis have yet to be evaluated as potential targets. The core 2 1,6
N-acetylglucosaminyltransferase (GCNT3/C2GNT) plays a signifıcant role in mu-
cin glycan biosynthesis. We analyzed GCNT3 expression on 180 specimens from
individuals with PC (90) or matched controls (90). Patients with low GCNT3 ex-
pression survived longer than patients with high GCNT3 expression (median sur-
vival: 17.5 vs. 10.5months, p0.036).Weobserved a signifıcant increase inGCNT3
mRNA expression (103.16 folds; p0.0001) in correlation with increased mucins
subtypes (p0.05) in the pancreatic tumors from genetically engineered mouse
(GEM) compared with pancreata from wild-type mice, as determined by Next-
generation Sequencing/RNAseq analysis. In in silico studies, blind docking simula-
tions revealed that a novel drug talniflumate binds toGCNT3with a better docking
affınityof -8.3kcal/mol.Wesynthesized talniflumate anddeterminedquality/purity
using NMR, HRMS, and HPLC for in vitro and in vivo studies. Pancreata from
6-week-old KrasGEM (N6/group) treatedwith talniflumate showed a signifıcant
decrease inGCNT3andmucinexpression inPanIN lesions. InhumanPCMiaPaCa
cell line, talniflumate reduced GCNT3 expression and the number of mucin-posi-
tive cells (38% p0.0001). Further, PC cells (BxPc3 and Panc1) were treated with
talniflumate for 24hrs formucindisruption followedby radioactive 3Hgemcitabine
treatment for 2 hrs. The cells treated with talniflumate showed 40% (p0.03) and
50% (p0.025) increased 3H gemcitabine uptake in BxPc3 and Panc1 cells com-
pared to respective controls. GCNT3 CRISPR knock out PC cells and talniflumate
treated PC cells showed a reduction in cell proliferation and signifıcantly reduced
spheroid formation (p0.05). In in vivo,wedidnot observe any overt toxicity upon
talniflumate treatment as determinedby liver enzyme toxicity andbodyweight gain
(N5 mice/group). BxPC3 cells implanted nude mice (N5 mice/group) treated
with talniflumate or GCNT3 siRNA showed a marked reduction in xenograft tu-
mors comparedwith untreated controls. Both talniflumate andGCNT3 siRNA sig-
nifıcantly inhibited xenograft tumor weight (48% p0.002 with siRNA, 63%
p0.0001 with talniflumate) and tumor volume (75% p0.0001 with both siRNA
and talniflumate) andGCNT3 enzyme activity (28%p0.03). Transcriptome anal-
ysis of xenograft tumors (N3/group) treated with GCNT3 SiRNA or talniflumate
showed reduced GCNT3 and top hits related to mucin expression. These results
justify the use of talniflumate formucin synthesis disruption, thereby enhancing the
uptake of gemcitabine and thereby effıcacy for PC treatment.
#1161 Dimethylaminoparthenolide (DMAPT), an oral nuclear factor
kappa B inhibitor (NFB), enhances radiation therapy and enhances epider-
mal growth factor tyrosine kinase inhibitor (EGFRTKI) activity.Katherine L.
Morel,1 Pamela J. Sykes,1 Prafulla C. Gokhale,2 Gwo-ShuMary Lee,2 Hong Tiv,2
Christopher J. Sweeney2. 1Flinders University, Bedford Park, Australia; 2Dana-
Farber Cancer Institute, Boston, MA.
Introduction: NFB can promote cancer and resistance to therapy as well as
mediate tissue injury in response to radiation (XRT). We assessed DMAPT
effıcacy alone and in combination with XRT, and also with an EGFR TKI, and
assessed whether it can mitigate XRT side effects. Methods: Six-week old male
TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice received
DMAPT (100 mg/kg) orally or vehicle control 3x/week until palpable tumors
formed and lungmetastases were analyzed histologically. In separate studies, 16
week old TRAMP mice were treated with 100 mg/kg DMAPT 3x over 1 week
before 6 Gy whole-body XRT. Cancer and normal tissues were analyzed for
apoptosis for up to 72 hours post-XRT. NCr nude mice were inoculated with
H1975 (T790M mutation non small cell lung cancer, NSCLC) subcutaneously.
When tumors reached 200 mm3, treatment (Rx) commenced: vehicle, DMAPT
100mg/kg/day, EGF TKI-AZD9291 25mg/kg/day, combination. Results: Long-
term Rx with DMAPT extended the median time to palpable prostate tumor by
41.3 (p 0.0013) days. Chronic DMAPT Rx reduced the number of metastatic
lesions/mm2 in TRAMP lungs 20-fold (0.077	 0.12 SD) compared to a vehicle
control (1.47 	 1.28 SD) (p  0.0004). XRT-induced apoptosis doubled in
TRAMP prostates (with moderate to high grade PIN lesions) treated with
DMAPT prior to 6 Gy XRT (101.3 % increase, p 0.039). DMAPT induced the
greatest radiosensitivity in TRAMP prostates with higher grade PIN (R2 0.79,
p 0.0001), while apoptosis frequency in tissues with lower grades of PIN was
the same as vehicle control TRAMP mice (R2  0.024, p  0.3). DMAPT also
reduced XRT-induced apoptosis in healthy TRAMP spleen (32.9 % reduction,
p 0.003) and rectum (28.7% reduction, p 0.0001). In theH1975 experiment,
DMAPT monotherapy did not differ from the vehicle controls. In the single
agent AZD9291 group, 2 of the 8 mice had resistance emerge during Rx and
adding DMAPT to AZD9291 reversed resistance in one of these. Rx was held at
Day 220 in 3 remaining AZD9291 treated mice with no evidence of tumor and
only 1 mouse was alive with no tumor at day 260. For mice receiving Rx with
AZD9291 andDMAPT fromD1, resistance emerged in 1mouse, and atD140 all
remainingmice with no evidence of tumor had Rx stopped, and 3mice were still
tumor free at D260. Two mice had regrowth, were retreated, and at D200 with-
out evidence of tumors had Rx held, and one had no tumor at D260 at the end of
the experiment. In total, 4 of 8mice in the AZD9291 andDMAPT had no tumor
off therapy at D260. Conclusion: Radiation and EGFR TKI resistance has been
linked to NFB activation. DMAPT slows down cancer progression and de-
creases metastatic lesions in a prostate cancer mouse model, protects normal
tissue from radiation induced apoptosis, augments radiation induced apoptosis
in prostate cancer and augments EGFR TKI effıcacy in T790Mmutant NSCLC.
#1162 The evaluation of INCB059872, an FAD-directed covalent inhibi-
tor of LSD1, in preclinicalmodels of Ewing sarcoma.Valerie Dostalik Roman,
Min Ye, Huiqing Liu, Melody Diamond, Antony Chadderton, Yvonne Lo, Xue-
song M. Liu, Jin Lu, Chunhong He, Liangxing Wu, Timothy Burn, Richard
Wynn, Wenqing Yao, Gregory Hollis, Gregory Hollis, Peggy Scherle, Bruce
Ruggeri, Sang Hyun Lee. Incyte Corporation, Wilmington, DE.
Ewing sarcoma is a rare bone cancer affecting predominantly children. The
chromosomal translocation of chromosomes 11 and 22 results in the EWS/FLI
gene fusion oncoprotein that is associated with85% of Ewing sarcoma cases.
The EWS/FLI fusion protein is involved in deregulating gene expression and
consequently causing cellular transformation. It was previously reported that
lysine specifıc demethylase 1 (LSD1) regulates EWS/FLI transcriptional activity
via its functional interaction through the NuRD co-repressor complex. We
therefore evaluated whether inhibition of LSD1 could have anti-tumor effects in
Ewing sarcomas that express the EWS/FLI fusion oncoprotein. INCB059872 is a
potent, selective, and orally available FAD-directed covalent inhibitor of LSD1.
To investigate the potential utility of INCB059872 in Ewing sarcoma, the A673
cell line having the characteristic chromosomal translocation was chosen as the
experimental model system. INCB059872 inhibition of LSD1 did not signifı-
cantly alter A673 proliferation in vitro. However, INCB059872 inhibited onco-
genic transformation as determined by colony formation clonogenicity assays.
NKX.2.2 was previously identifıed as a critical downstream target molecule of
the EWS-FLI fusion oncoprotein that is required for transformation. A signifı-
cant downregulation of NKX2.2 was observed in A673 cells treated with
INCB059872, suggesting that INCB059872 mediates its effects through modu-
lation of the EWS/FLI -NKX2.2 axis. Oral administration of INCB059872 sig-
nifıcantly suppressed the growth of both A673 and SK-ES Ewing sarcoma xeno-
grafts in vivo. In addition, in vivo effıcacy was evaluated in patient derived
xenograft (PDX) models that were developed from relapsed tumor tissues of
Ewing sarcoma patients. Notably, a subset of PDX models having EWS/FLI
translocations (3/6) exhibited signifıcant tumor growth inhibition at well-toler-
ated doses of INCB059872. Molecular signatures obtained from RNA-Seq data
with these PDX models exhibited intrinsic differences between responders and
non-responders, suggesting additionalmolecular or genetic variationsmay con-
tribute to their sensitivity to INCB059872. Studies identifying potential candi-
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date molecular mechanisms are underway. Together, these data suggest that
INCB059872 may be therapeutically effıcacious in a subset of Ewing sarcoma
patients.
#1163 Non clinical pharmacology, pharmacokinetics and safety profıling
of CB-103: A novel fırst-in-class small molecule inhibitor of the NOTCH
pathway. Rajwinder Lehal,1 Viktoras Frismantas,2 Charlotte Urech,1 Maximil-
ien Murone,1 Dirk Weber,1 Michael Bauer,1 Jean-Pierre Bourquin,2 Freddy
Radtke3. 1Cellestia Biotech AG, Basel, Switzerland; 2Univeristy Children’s Hospi-
tal, Zurich, Switzerland; 3Ecole Polytechnique Federale de Lausanne, Lausanne,
Switzerland.
NOTCH signaling is a developmental pathway known to play critical roles
during embryonic development as well as for the regulation of self-renewing
tissues. Aberrant activation of NOTCH signaling leads to deregulation of the
self-renewal process resulting in sustained proliferation, evasion of cell death,
loss of differentiation capacity, invasion and metastasis, all of which are hall-
marks of cancer. Over activation of NOTCH in human cancers can be a conse-
quence of over expression of NOTCH ligands/receptors, GOF mutations in
NOTCHreceptors aswell as chromosomal translocations leading to constitutive
activation of the pathway by producing truncated version of NOTCH1 or
NOTCH2. Over activation of NOTCH and its oncogenic role in various cancers
is prognostically relevant with shorter survival seen in patients harbouring these
genetic alterations. Given the importance of Notch signaling in human cancers,
several therapeutic approaches have been utilized to block NOTCH signaling.
Two of these strategies are; a) the use ofmonoclonal blocking antibodies (mAbs)
against NOTCH ligands and receptors and b) the use of small molecule -secre-
tase inhibitors (GSIs). However, these approaches can only be effective if tumor
cells express full-length ligand or receptormolecules. On the contrary, in human
cancers harbouring NOTCH gene fusion due to chromosomal translocations,
the use of mAbs andGSIs will have very limited clinical benefıts. A third, yet not
fully explored approach would be the blockage of NOTCH signalling by target-
ing the most downstream complex in the NOTCH signal transduction cascade,
the NOTCH transcriptional activation complex, using small molecule inhibi-
tors. Previously we have reported the discovery and characterization of CB-103,
a novel fırst-in-class orally-active small molecule inhibitor of the NOTCHpath-
way. CB-103 inhibits NOTCH signaling by targeting the NOTCH transcrip-
tional activation complex in the nucleus. CB-103 has shown the ability to block
NOTCH signalling in various human cancer cell lines with activeNOTCHpath-
way. CB-103 has also been tested in in vivo models. In a GSI/mAb resistant
model of human triple negative breast cancer, CB-103 has demonstrated excel-
lent anti-tumor effıcacy. In this study we present additional pharmacology,
pharmacokinetics data and provide an overview of the good safety and tolera-
bility seen with CB-103 in the non-clinical studies. Based on these fındings
CB-103 has been selected as clinical candidate to be investigated in a FIM, phase
I/IIA clinical study in advanced cancer patients.
#1164 A novel hypoxia-inducible factor-1 inhibitor IDF-11774 regulates
cancer metabolism, thereby suppressing tumor growth. Misun Won,1 Hyun
Seung Ban,1 Kyeong Lee,2 Hongsub Lee,3 Bo-Kyung Kim,1 Hwan Mook Kim,4
Ravi Naik,2 Song-Kyu Park,5 Joon-Tae Park,3 Inhyub Kim,1MisoNam,6 Geum-
Sook Hwang6. 1Korea Research Inst. of Biosci. & Biotech., Daejeon, Republic of
Korea; 2DonggukUniversity-Seoul, Republic of Korea; 3ILDONGPharmaceutical
Co. Ltd, Republic of Korea; 4Gachon University, Republic of Korea; 5Korea Uni-
versity, Republic of Korea; 6Korea Basic Science Institute, Daejeon, Republic of
Korea.
HIF-1 is associated with poor patient prognosis and therapeutic resistance of
cancer. We have developed a novel hypoxia-inducible factor (HIF)-1 inhibitor,
IDF-11774, as a clinical candidate for cancer therapy. Under hypoxic condition,
IDF-11774 inhibited the accumulation of HIF-1 in vitro and in vivo in colo-
rectal carcinoma HCT116 cells. IDF-11774 suppressed the angiogenesis of can-
cer cells by reducing the expression ofHIF-1 target genes.Moreover, IDF-11774
reduced glucose uptake, leading sensitizing cell growth on low glucose condi-
tion. IDF-11774 also decreased the extracellular acidifıcation rate (ECAR) and
oxygen consumption rate (OCR). Metabolic profıle of IDF-11774-treated cells
revealed low levels of NAD, lactate, and intermediates in glycolysis and tricar-
boxylic acid (TCA) cycle. More importantly, we observed elevated AMP and
diminished ATP level, leading high AMP/ATP ratio. Apparently, phosphoryla-
tion of AMPK increased, leading inhibition of mTOR signaling in cells. In vivo
xenograft assays demonstrated that IDF11774 has signifıcant anti-cancer effı-
cacy by targeting cancer metabolism in mouse models containing the KRAS,
PTEN or VHL mutation, which often occurs in many malignant cancers. Col-
lectively, IDF-11774 suppresses the hypoxia-induced HIF-1 accumulation,
thereby repressing tumor growth by regulating cancer metabolism.
#1165 Plitidepsin targets themoonlighting functions of eEF1A2 in cancer
cells. Alejandro Losada, Maria Jose Muñoz, Juan F. Martínez-Leal, Juan M.
Domínguez, Carlos M. Galmarini. PharmaMar S.A., Colmenar Viejo, Spain.
Plitidepsin, a cyclic depsipeptide of marine origin, has shown potent antican-
cer activity in preclinical assays and recently fınished with positive results a
pivotal phase III trial (clinicaltrials.gov identifıer: NCT01102426) for the treat-
ment of multiple myeloma patients. We have recently found that eukaryotic
elongation factor 1A2 (eEF1A2), one of the two isoforms of the alpha subunit of
eEF1, is the pharmacological target of plitidepsin. Although it shares 96% ho-
mology with eEF1A1 (the other isoform), they display an exclusive pattern of
expression, being eEF1A2 solely expressed in brain and muscle in healthy indi-
viduals. However, it has been found that many tumors abnormally overexpress
this protein, including multiple myeloma, prostate, pancreatic, ovarian, breast,
lung and liver cancers. Furthermore, although eEF1A2 canonical function con-
sists in the delivery of aminoacyl-tRNAs to theA site in the ribosome, it has been
shown to have pro-oncogenic moonlighting activities, including inhibition of
apoptosis, protein degradation by the proteasome, heat shock response, cyto-
skeleton organization and regulation of oxidative stress. We now investigated
several of the pro-oncogenic activities of eEF1A2 to analyze the impact that
plitidepsin could have preventing them. Indeed, we observed that plitidepsin
interfered with the interaction between eEF1A2 and Peroxiredoxin 1 (PRDX1),
a complex that allosterically enhances the enzymatic activity of PRDX1. This
way, plitidepsin would diminish PRDX1 antioxidant activity, possibly originat-
ing the oxidative stress that has been described in the bibliography as one of the
fırst effects triggered by the drug in cancer cells. PRDX1 only interacts with the
GDP-bound form of eEF1A2, while plitidepsin exclusively binds to the GTP-
bound form, most probably sequestering this protein from the pool that could
interact with and activate PRDX1. Furthermore, we have confırmed that
eEF1A2 interacts with Sphingosine kinase 1 (SPHK1), a complex that has been
described in the bibliography as having enhanced SPHK1 activity. SPHK1 phos-
phorylates sphingosine producing sphingosine-1-P, second messenger that
binds to its receptors in the cell membrane and conveys growth and survival
signals to the cell. We could see that plitidepsin treatment reduced the produc-
tion of sphingosine-1-P in HeLa cells, destabilizing the equilibrium towards the
pro-apoptotic ceramide/sphingosine side and promoting cell death. Thus,
through its binding to eEF1A2, plitidepsin derails a series of its moonlighting
functions that are essential for the survival of tumor cells, driving them into
apoptosis.
#1166 Identifıcation of a novel quinoxaline-isoselenourea targeting
STAT3 pathway as a potential melanoma therapeutic. Verónica Alcolea,1
Deepkamal Karelia,2Manoj K. Pandey,3 Daniel Plano,1 Parvesh Singh,4 Rosalyn
B. Irby,2 Juan Palop,1 Shantu Amin,2 Carmen Sanmartín,1 Arun K. Sharma2.
1Univesrsity of Navarra, Pamplona, Spain; 2Penn StateUniv. College ofMedicine,
Hershey, PA; 3Cooper Medical College of Rowan University, Camden, NJ; 4Uni-
versity of Kwa-Zulu Natal, Durban, South Africa.
The prognosis for patients with metastatic melanoma remains very poor.
Constitutive STAT3 activation has been correlated to larger tumor size, metas-
tasis, acquired resistance against vemurafenib (PLX-4032), and poor patient
survival suggesting its potential as a molecular target. We recently designed a
series of isoseleno- and isothio-urea derivatives of several biologically active
heterocyclic scaffolds. The cytotoxic effects of lead isoseleno-/isothio-urea de-
rivatives (compounds 1/3) were studied in a panel of fıve melanoma cell lines,
including B-RAFV600E mutant and wild type (WT) cells. Compound 1 (IC50
range 0.8-3.8 M) showed lower IC50 values than 3 (IC50 range 8.1-38.7 M)
and the mutant B-RAF specifıc inhibitor PLX-4032 (IC50 range 0.4-50 M),
especially at shorter treatment time (24 h). These effects are long-lasting since
melanoma cells did not recover their proliferative potential after 14 days of the
treatment. In addition, we confırmed that compound 1 induces cell death by
apoptosis using Live and Dead, Annexin V and Caspase3/7 apoptosis assays.
Furthermore, compound 1 reduces protein levels of STAT3 and its phosphory-
lation, as well as decreases the expression of STAT3 regulated genes involved in
survival and metastasis such as survivin and c-myc. Compound 1 also upregu-
lates the cell cycle inhibitor p21. Docking studies further revealed the favorable
binding of 1 with SH2 domain of STAT3 suggesting its activity through STAT3
inhibition. Taken together, our results suggest that compound 1 induces apo-
ptosis by means of the inhibition of STAT3 pathway to non-specifıcally target
both B-RAFmutant andWTmelanoma cells withmuch better cytotoxicity than
the current therapy PLX-4032.
#1167 Development of BT1718, a novel Bicycle Drug Conjugate for the
treatment of lung cancer. Gavin Bennett, Robert Lutz, Peter Park, Helen Har-
rison, Kevin Lee. Bicycle Therapeutics Ltd, Cambridge, United Kingdom.
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BT1718 is a Bicycle Drug Conjugate (BDC®) comprising a constrained bicy-
clic peptide (Bicycle®) that binds with high affınity and specifıcity to membrane
type 1-matrixmetalloprotease (MT1-MMP;MMP14) covalently linked through
a hindered disulfıde linker to the potent anti-tubulin agent DM1. MT1-MMP is
involved in normal tissue remodeling and is also expressed in tumor associated
stromal cells. However, overexpression is linked to increased tumor aggression
and metastasis. Specifıcally, over-expression of MT1-MMP is also associated
with poor clinical prognosis and shorter survival times in patients with NSCLC
and a range of other solid tumors. The Bicycle MT1-MMP binding element
within BT1718was identifıed using a proprietary phage display peptide technol-
ogy consisting of highly diverse phage libraries of linear amino acid sequences
constrained into two loops by a central tri-functional chemical scaffold. These
MT1-MMP binding Bicycles exhibit a profound affınity and specifıcity, more
often associated with monoclonal antibodies, whilst their low molecular weight
(1.5-3 kDa), akin to that of a small molecule, aids in rapid extravasation and
tumor penetration. Together these attributes make Bicycles an ideal format for
the targeted delivery of cytotoxic payloads.We evaluated the ability of BT1718 to
bind to and kill tumor cells in vitro and in vivo in a panel of tumor cells. BT1718
demonstrated MT1-MMP target-specifıc binding and MT1-MMP-dependent
cell killing of lung tumor cells in vitro as well as effıcacy across a panel of lung
tumor xenograft mouse models. For example, in the Met-amplifıed squamous
NSCLC lung EBC-1 model, complete regressions were observed in all mice at
doses as low as 5 mg/kg (iv) twice weekly and across a range of other dosing
schedules, from daily to weekly. MT1-MMP-dependent activity was demon-
strated by blocking target specifıc interactions through co-administration of an
excess of unconjugated Bicycle binder, which inhibited tumour regression, or a
non-binding Bicycle, which had no effect. Further evaluation in patient-derived
lung xenograft (PDX) models indicates a similar activity to that seen in cell-line
derived xenografts, with effıcacy seen from 3mg/kg twice weekly and rapid full
regression of tumors at higher doses. The molecular attributes of these Bicycles:
rapid tumor penetration and specifıc binding,makes them ideal therapeutics for
targeted delivery of toxins as Bicycle drug conjugates (BDCs). The small size of
the BDC may offer a signifıcant advantage to other targeted cytotoxic ap-
proaches such as antibody-drug conjugates due to rapid extravasation and im-
proved tumor penetration. BT1718, a Bicycle Drug Conjugate, shows potent
anti-tumor activity in human lung tumor xenograft models and IND-enabling
studies are underway.
#1168 Effıcacy of the IRAK4 inhibitor CA-4948 in patient-derived xeno-
graft models of diffuse large B cell lymphoma. Robert N. Booher, Maria Elena
Samson, Guang-Xin Xu, Hongsheng Cheng, David P. Tuck. Curis, Inc, Lexing-
ton, MA.
IRAK4 kinase activity is required for toll-like receptor (TLR) and interleu-
kin-1 receptor (IL-1R) signaling in a variety of myeloid and lymphoid cell types.
Recruitment of IRAK4 to these receptors and its subsequent activation is facili-
tated by the MYD88 adaptor protein, which is mutated in 22% of DLBCL
cases. TheMYD88 L265P activatingmutation is found in30% of the activated
B-cell (ABC) and6% of germinal center B-cell (GCB) subtypes of DLBCL and
leads to constitutive activation of NF-B signaling that is associated with worse
prognosis. Thus, the development of small molecule inhibitors targeting IRAK4
is an attractive anticancer strategy for MYD88 mutation-containing cancers
such as DLBCL. We are developing an IRAK4 inhibitor, CA-4948, as a thera-
peutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4
signaling. CA-4948 (previouslyAU-4948) is a selective and potent IRAK4kinase
inhibitor with in vivo activity in a TLR4-induced cytokine release model. CA-
4948 exhibits favorable DMPK properties, oral bioavailability, and is well toler-
ated in mice. Furthermore, CA-4948 was previously shown to exhibit dose-
dependent effıcacy in ABC-DLBCL MYD88-L265P xenograft tumor models
using cell lines OCI-LY3 and OCI-LY10. Here, we report the effıcacy results
from testing CA-4948 in a panel of well characterized, patient-derived DLBCL
tumor xenograft (PDX) mouse models. CA-4948 exhibited the greatest effıcacy
in four of the fıveABC-DLBCLPDXmodels tested as compared toGBC-DLBCL
and ABC/GCB DLBCL PDX models. Furthermore, CA-4948 was effıcacious in
ABC-DLBCL PDX tumors containing activating mutations in both TLR/IL-1R
and BCR signaling pathways (MYD88 and CD79B double mutants). Interest-
ingly, the one ABC-DLBCL PDXmodel that failed to respond to CA-4948 treat-
ment contained a MYD88 L265P mutation as well as a BCL6 translocation.
While this particular PDXmodel was resistant to CA-4948, and showed a weak
anti-tumor response to single-agent ibrutinib, the combination treatment of
ibrutinib andCA-4948 exhibited a synergistic tumor growth inhibition effect. In
summary, CA-4948 exhibited anti-tumor activity in ABC-type DLCBL PDX
tumormodels including those containing combinations of activatingmutations
in the TLR/IL-1R and BCR signaling pathways. These results underscore the
therapeutic potential of IRAK4 kinase inhibition by CA-4948, as a single-agent
or in combination with BCR inhibitors, for the treatment of DLBCL.
#1169 mtTERT promoter as a target for treatment of glioblastoma.
Saumya R. Bollam,1 Harshil D. Dhruv,1 Hyun-Jin Kang,2 Sen Peng,1 Vijay
Gokhale,2 Laurence Hurley,2 Michael Berens1. 1Translational Genomics Re-
search Institute, Phoenix, AZ; 2University of Arizona, Tuscon, AZ.
Approximately 86% of GBM tumors exhibit mutation at -124 or -146 bases
upstream of the ATG start site in the transcription activating promoter re-
gion of Human telomerase reverse transcriptase (hTERT). Mutation in the
promoter region of hTERT impairs repression, leading to overexpression of
hTERT; inappropriate hTERT is associated with oncogenesis, tumor main-
tenance, and resistance to apoptosis. We surveyed long-term glioma cell
lines and glioma PDXmodels for mt-hTERT; mRNA and protein expression
of hTERT were assessed by qPCR and western blot. The -124 and -146 mu-
tations are located in the major 5-12 G-quadruplex and result in misfolding
of the silencer element and consequent over-expression of hTERT. Using a
diverse small molecule library, we identifıed a small drug-like pharmacolog-
ical chaperone (pharmacoperone) molecule, TG-4260, which binds to the 26
mer base-pair heteroduplex loop, which is the nucleation site for cooperative
folding of the major 5-12 G-quadruplex. The chaperone effect of TG-4260
corrects DNA hTERT G-quadruplex misfolding resulting from the somatic
mutations and restores the silencer function of the G-quadruplex thereby
reducing hTERT activity. TG-4260 directly decreases the transcription ac-
tivity of the WT and the 124, 124/125, 138/139, and 146 mutants to
a similar extent and suppresses the downstream gene BCL2, which activates
caspase-3 and produces cell-cycle arrest, leading to cell death. Finally, TG-
4260 signifıcantly inhibits telomerase and shortens telomere length after fıve
days of treatment and induces a senescence-like phenotype. This is the fırst
example of the use of a pharmacoperone molecule to correct the misfolding
of a DNA G-quadruplex element resulting from mutations in an early fold-
ing intermediate. Finally, we screened GBM cell models against a novel small
molecule inhibitor that interferes with mutated hTERT promoter and dem-
onstrated that TG-4260 selectively suppresses glioma cell viability without
affecting non-transformed normal human astrocytes.
#1170 Notch pathway is overexpressed and is a therapeutic target in clear
cell renal cancer.Tushar D. Bhagat,1 Yiyu Zou,1 ShizengHuang,2 Jihwan Park,2
MatthewB. Palmer,2 CarolineHu,1Weijuan Li,1 Niraj Shenoy,1OrsolyaGiricz,1
Yiting Yu,1 Yi-An Ko,2 María Concepción Izquierdo,2 Esther Park,2 Nishanth
Vallumsetla,1 Remi Laurence,1 Robert Lopez,1 Masako Suzuki,1 James Pull-
man,3 JustinKaner,1 BenjaminGartrell,1 A. AriHakimi,4 JohnGreally,1 Bharvin
Patel,5 Karim Benhadji,5 Kith Pradhan,1 Amit Verma,1 Katalin Susztak2. 1Albert
Einstein College of Medicine, Montefıore Medical Center, Bronx, NY; 2University
of Pennsylvania, Perelman School of Medicine, Philadelphia, PA; 3Montefıore
Medical Center, Bronx, NY; 4Sloan Kettering Cancer Center, New York, NY; 5Eli
Lilly, Indianapolis, IN.
Clear cell renal cell carcinoma (CCRCC) is an incurable malignancy in ad-
vanced stages and needs newer therapeutic targets. We conducted a transcrip-
tomic analysis of CCRCCs and matched microdissected renal tubular controls
and observed an overexpression of NOTCH ligands [JAGGED1, JAGGED2)
and Delta like (DLL3) family of ligands] and receptors (NOTCH1, NOTCH2,
NOTCH3 andNOTCH4) in tumor tissues. Examination of the TCGARNA-Seq
dataset also revealedwidespread activation ofNOTCHpathway in a large cohort
of CCRCC samples. Samples with NOTCH pathway activation were also clini-
cally distinct and were associated with better overall survival. Parallel high res-
olution DNAmethylation and copy number analysis with the HELP assay dem-
onstrated that both genetic and epigenetic alterations led to NOTCH pathway
activation in CCRCC. NOTCH ligands, JAGGED1was overexpressed and asso-
ciated with loss of methylation of its intronic enhancer. The other NOTCH
ligand, JAGGED2 was overexpressed in and associated with gene amplifıcation
in distinct CCRCC samples. To test the causality, we transgenically expressed
the intracellular domain of NOTCH1 in mice renal tubules with tubule specifıc
deletion of VHL. The Kspcre VHLf/f ICNotch1 mice exhibited dysplastic hyper-
proliferation of tubular epithelial cells confırming the procarcinogenic role of
NOTCH in vivo. Alteration of cell cycle pathways was seen in murine renal
tubular cells with NOTCH overexpression and molecular similarity to human
tumors was observed, demonstrating that humanCCRCC recapitulates features
and gene expression changes observed inmicewith transgenic overexpression of
the Notch intracellular domain. Finally, treatment with clinical, gamma secre-
tase inhibitor, LY3039478, led to inhibition of CCRCC cells in vitro and in vivo
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in CCRCC xenografts. In summary, these data reveal the mechanistic basis of
NOTCH pathway activation in CCRCC and demonstrate this pathway to a
potential therapeutic target.
#1171 Therapeutic applications of the selective high affınity ligand
SH7139 may extend beyond NHL to many other types of solid tumors.Mo-
nique Cosman Balhorn, Rod Balhorn. SHAL Technologies, Inc., Livermore, CA.
SH7139, the fırst of a new class of cancer therapeutics developed for treat-
ing non-Hodgkin’s lymphoma, is unusual in that both targeting and pro-
drug functionalities have been incorporated into the same small molecule.
Functioning similar to an antibody-drug conjugate, SH7139 targets a unique
structural epitope within the antigen-binding pocket of HLA-DR10. HLA-
DRs containing this epitope within the -subunit are reported to be over-
expressed in approximately 85% of B-cell lymphomas. Upon binding to
HLA-DR molecules located on the tumor cell’s surface, SH7139 is trans-
ported into the cytoplasm where it is concentrated and subsequently metab-
olized. A series of metabolic products derived from the SHAL’s recognition
elements (three small molecules that are linked together to create SH7139
and to provide targeting selectivity) are generated as the drug is broken
down, each of which inhibits one or more activities required for tumor cell
survival. Preclinical studies with SH739 have demonstrated remarkable effı-
cacy in treating B-cell lymphoma xenografts in mice, providing permanent
cures for up to two-thirds of the animals at a human equivalent dose as low
as 0.41 g/kg. Biopsy tissue binding studies conducted with SH7129, a bio-
tinylated form of SH7139, and streptavidin-horse radish peroxidase detec-
tion have shown the drug binds to a signifıcant fraction of tumors obtained
from patients diagnosed with multiple myeloma and each of the B-cell lym-
phoma subtypes tested to date (DLBC, Burkitt’s, Mantle Cell, Follicular,
MALT, and CLL). SH7129 was also observed to bind to tumor biopsies
obtained from of a number of patients diagnosed with peripheral T-cell and
nodular sclerosis Hodgkin’s lymphomas, a result consistent with observa-
tions reported by others that HLA-DRs are expressed in a subset of these
lymphomas. HLA-DR expression has also been reported to occur in or be
linked to a number of other types of cancer, including melanoma, cervical,
ovarian, pancreatic and lung cancers. SH7129 staining of tumor microarrays
have shown biopsy cores from a subset of patients diagnosed with each of
these cancers also bind SH7139.While in vivo effıcacy has only been tested in
Burkitt’s (Raji), Mantle cell (Granta-519), and T-cell (Jurkat, a cell line con-
trol lacking HLA-DR and showing no effıcacy) lymphoma xenografts, these
tissue binding results suggest that in addition to the majority of the NHL
subtypes, nodular sclerosis Hodgkin’s lymphoma, multiple myelomas, as
well as a subset of melanomas, ovarian, cervical, pancreatic, and lung cancers
may also respond to SH7139 therapy. This research was supported by the
National Cancer Institute Phase II SBIR Award R44CA159843.
#1172 In vivo pharmacokinetic properties and antitumor effıcacy of por-
cupine lead inhibitors in the orthotopic murine MMTV-Wnt1 breast tumor
model and the human HPAF-II pancreatic xenograft mouse model. Vishal
Pendharkar,1 Yun Shan Chew,1 Vithya Manoharan,1 Choon Bing Low,1 Hon-
gqian Esther Ong,1 Soo Yei Ho,1 Wei Ling Wang,1 Jeyaraj Duraiswamy Athi-
sayamani,1 Babita Madan,2 David Virshup,2 Thomas Hugo Keller,1 May Ann
Lee,1 Alex Matter,1 Jeffrey Hill,1 Kanda Sangthongpitag1. 1Experiemental Ther-
apeutic Centre, Singapore, Singapore; 2Duke-NUS Medical School, Singapore,
Singapore.
Porcupine (PORCN), a muti-pass integral membrane-bound-O-Acyl acyl-
transferase (MBOAT), resides in the in the endoplasmic reticulum (ER) and is
required for biogenesis ofWnt ligands. The secretedmatureWnt ligands bind to
their cognate receptors (Frizzled, LRP5/6 and transmembrane receptor ROR) to
form the ligand - receptor complex which is capable to activate the Wnt--
catenin signalling cascade and downstream signalling pathways such as mTOR,
GSK3, Akt, and PKC. The deregulation of and aberrant activation of the various
components of Wnt--catenin signalling pathway have been implicated in tu-
morigenesis, cell proliferation, survival and differentiation. Hyperactivity of
PORCN is found to be associated with cancerous cell growth. Knockdown of
Porcn mRNA signifıcantly reduced the proliferation of breast cancer cells and
resulted in the delay of MDA-MB-231 tumor formation in mouse xenograft
models (Covey et al 2012). Loss of function mutations of RNF43, a negative
regulation of Wnt-signalling via Frizzled receptor, is recently reported to be
involved with pancreatic ductal adenocarcinoma. Inhibition of the PDAC cell
lines bearing RNF43 mutations enhanced Wnt--catenin signalling and re-
sulted in suppression of proliferation and differentiation of PDAC tumor cells
(Jiang et al 2013). Taken together porcupine could be an attractive therapeutic
approach for a particularWnt-driven cancer population.We have identifıed the
porcupine lead compounds (ETC-159, ETC-535, ETC-611 and ETC-539) from
different novel chemical scaffolds. The aim of this study was to evaluate their
pharmacokinetic properties and antitumor effıcacy in different cancer mouse
models, the murine MMTV-Wnt1 breast cancer and the human pancreatic
HPAF-II cancer. All porcupine lead compounds had good oral pharmacokinetic
properties with the absolute oral bioavailability greater than 42%. They had the
maximum tolerated dose (MTD-7d) up to 200mg/kg. They produced antitumor
effıcacy ranging from 24% to 79% at 1 mg/kg, 38% to 89% at 3 mg/kg, and 58 to
97% at 10 mg/kg in MMTV-Wnt1 tumor mouse model. In vivo inhibition of
PORCN led to reduce the expression level of Axin2 inMMTV-Wnt tumors upto
8h. At 100mg/kg, they produced antitumor effıcacy ranging from 34% to 91% in
human HPAF-II pancreatic xenograft mouse model. Of 4 porcupine lead com-
pounds, ETC-159 demonstrated great oral pharmacokinetic properties and pro-
duced signifıcantly antitumor effıcacy (p value 0.0001) in both cancer mouse
models. ETC-1922159 was selected as the preclinical development candidate
and currently is under investigation in Phase 1 clinical trial.
#1173 A novel selective Mcl-1 inhibitor exhibits in vitro and in vivo effı-
cacy in melanoma. Karson J. Kump, Lei Miao, Ahmed S. Mady, Katherine Lev,
William Giblin, Mary E. Skinner, David B. Lombard, Zaneta Nikolovska-
Coleska. University of Michigan, Ann Arbor, MI.
Metastatic melanoma is the deadliest form of skin cancer that still has limited
treatment options and dismal 5-year year survival rates as low as 15%. Only
recently has there been signifıcant progress in the treatment of metastatic mel-
anoma, advent by molecular targeted drugs and immunotherapy, but their lim-
itations are exposed as these cancers are quickly able to develop resistance. Dys-
regulation of apoptotic machinery in melanoma allows the cancer cells to evade
cell death and contributes to treatment resistance. Up-regulation of Mcl-1, a
member of the Bcl-2 family of anti-apoptotic proteins, has been correlated with
melanoma progression and metastasis. Mcl-1 amplifıcation is one of the most
common genetic aberrations found in human cancers and has been labeled as a
marker of aggressive oncogenesis and poor patient prognosis. Previous studies
have pointed to Mcl-1 as a viable therapeutic target for the treatment of mela-
noma and conclude that small moleculeMcl-1 inhibitorsmay appeal this unmet
medical need. We have discovered and characterized a new class of selective
small molecule Mcl-1 inhibitors using various biochemical, functional, and cell
based assays; further development of these compounds allowed us to achieve
potent low-nanomolar binding affınity for Mcl-1 and more than 300-fold selec-
tivity over Bcl-2/Bcl-xL. Our most potent inhibitor, 483-LM, was screened
across a panel of humanmelanoma cell lines using a cell proliferation assay and
revealed varying levels of sensitivity. A BH3 profıling assay demonstrates that
C8161, the cell line most sensitive to our inhibitor, solely relies on Mcl-1 for
survival. The Mcl-1 dependence of C8161 might contribute to the known met-
astatic nature of this cell line. Mechanistic studies revealed that 483-LM effec-
tively engaged the endogenousMcl-1 protein after treatment of C8161, as deter-
mined by a CETSA assay, and prompted disruption of protein-protein
interactions between Mcl-1 and several pro-apoptotic proteins, including Bax,
Bak and Bim. This was followed by induction of Bax/Bak dependent apoptosis
and activation of hallmarks of the intrinsic apoptotic pathway, including mito-
chondrial outer membrane depolarization, caspase activation, and PARP cleav-
age. Importantly, treatment with 483-LM caused massive up-regulation of the
pro-apoptotic BH3-only protein Noxa, an effect apparent after an 8 hour treat-
ment, which contributes to the induction of cell death. The in vivo effıcacy
studies with 483-LM showed signifıcant effect on tumor growth and caspase-3
activation in tumor samples. Overall, our data indicate that Mcl-1 inhibitors are
a promising treatment option for aggressive metastatic melanoma and warrant
further preclinical investigation of 483-LMas a promising selectiveMcl-1 inhib-
itor to be used as a single agent and in combination with chemotherapy and
immunotherapy.
#1174 CT179 degrades the olig2 transcription factor in glioblastoma
stem-like cells and prolongs survival. Gordon R. Alton,1 Graham Beaton,1
Susan Knowles,1 Gregory Stein,1 Santosh Kesari2. 1Curtana Pharmaceuticals,
Austin, TX; 2Pacifıc Neuroscience Institute, Santa Monica, CA.
Olig2 is a bHLH transcription factor that has been shown to be a key driver of
glioblastoma (GBM) tumorigenesis.Olig2 is expressed in human tumor-derived
glioma stem-like cells. A growing body of evidence suggests that glioma stem-
like cells (GSCs) are more representative of their parent tumors when cultured
under defıned serum-free conditionswith themitogens epidermal growth factor
(EGF) and fıbroblast growth factor (FGF). Furthermore, recent research has
indicated that human Proneural GSCs grown in vitro in PDGF aremore tumor-
igenic in vivo.We have designed and synthesized a potent inhibitor ofOlig2 that
possesses all the necessary properties for clinical development as an important
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newGBM therapeutic. CT179 dose dependently causes the degradation ofOlig2
in multiple GBM cell lines and this correlates to G2/M arrest and increased
apoptosis. CT179 also induces the loss of expression of EGFR and PDGFR in
human GSCs. CT179 achieves high concentrations in the CNS with a long du-
ration of pharmacologic action. Furthermore, CT179 signifıcantly extends sur-
vival of mice implanted orthotopically with patient-derived human tumor
GSCs. Immunohistochemistry demonstrates a marked reduction of Olig2 pos-
itive cells in the tumor bearing animals. Together, these results indicate that
CT179 has signifıcant promise as a new therapeutic for the treatment of human
GBM.
#1175 Inhibition of NAMPT as a novel therapeutic strategy for infant
leukemia. Klaartje Somers,1 Shiloh Middlemiss,1 Asel Biktasova,1 Mawar
Karsa,1 Leanna Cheung,1 Angelika Kosciolek,1 Kathryn Evans,1 Chelsea
Mayoh,1 Ursula R. Kees,2 Lioubov Korotchkina,3 Olga B. Chernova,3 Richard B.
Lock,1 Andrei V. Gudkov,4 Michelle Haber,1 Murray D. Norris,1 Michelle
J. Henderson1. 1Children’s Cancer Institute, University of New South Wales,
Randwick, Australia; 2Telethon Kids Institute, University of Western Australia,
Perth, Australia; 3Tartis, Inc., Buffalo, NY; 4Roswell Park Cancer Institute, Buf-
falo, NY.
Novel targeted therapies are urgently needed for infant leukemia as this dis-
ease is highly aggressive and refractory to treatment resulting in poor survival
rates. The NAD (Nicotinamide Adenine Dinucleotide) producing enzyme
NAMPT (Nicotinamide Phosphoribosyltransferase) has been considered an at-
tractive selective target for anti-cancer therapy due to the high dependency of
tumor cells on NAD for energy metabolism and activity of NAD-dependent
enzymes such as poly-ADP-ribose polymerases (PARPs) and sirtuins that play
key roles in cancer cell survival. A newly developed NAMPT inhibitor, OT-82,
was initially isolated for its high selective toxicity against a panel of adult leuke-
mia cell lines. Here we investigated NAMPT inhibition as a therapeutic strategy
for infant leukemias characterized by rearrangement of the MLL gene (MLL-r),
by testing the potency of OT-82 in a panel of preclinical in vitro and in vivo
models ofMLL-r leukemia that are based on the use of patient-derived xenograft
(PDX) cells. OT-82, as a single agent, dramatically reduced the viability of all
tested MLL-r leukemia cell lines (n9) and MLL-r leukemia PDX (n6) with
IC50s ranging from 0.15 to 3.82nM. While the IC50 for OT-82 correlated sig-
nifıcantly with the IC50 of other NAMPT inhibitors STF-118804 and FK866,
OT-82 was the most potent compound. When combining OT-82 with chemo-
therapeutic agents currently used to treat infants with leukemia, we observed
signifıcant synergy between OT-82 and cytarabine indicating the potential of
OT-82 for chemosensitization. Consistent with NAMPT inhibition, OT-82 re-
duced cytosolic NAD levels inMLL-r leukemia cells and inhibited the activity
of the NAD-requiring enzymes PARP-1 and SIRT-1, as exemplifıed by a de-
crease in PARylated PARP-1 levels and a p53-mediated increase in p21 levels,
leading to apoptosis induction. Interestingly, despite the remarkable potency of
OT-82 in killing MLL-r leukemia cells, a 25-fold difference in IC50 levels was
noted across the cell line panel, with those lines harboring the MLL transloca-
tionsmost prevalent in infants, namely t(4;11) and t(11;19) translocations, being
the most sensitive to the compound. A positive correlation was noted between
baseline NAMPTmRNA levels and OT-82 IC50 (r0.7712, P0.015). Further
in vivo testing of OT-82 showed impressive effıcacy of the compound in MLL-r
leukemia PDX-based animal models (n6). OT-82 (p.o. 3x week, 40-50 mg/kg,
for 3 or 6 weeks) was well tolerated and signifıcantly delayed leukemia progres-
sion in 6/6 MLL-r leukemia xenografts with 5/6 achieving objective responses.
OT-82 given as monotherapy was as effective as the routinely used triple com-
bination treatment of vincristine, L-asparaginase and dexamethasone. Overall,
these results demonstrate that NAMPT inhibition using OT-82 is highly effec-
tive against MLL-r leukemia and when combined with current chemotherapies
may offer a more selective and potent therapeutic option for infants suffering
from this disease.
#1176 Preclinical characterization of the pharmacokinetic-pharmacody-
namics-effıcacy relationship of novel allosteric SHP2 inhibitors.Minying Pu,
Laura R. La Bonte, Stan Spence, Kathy Hsiao, Shumei Liu, Brant Firestone, Ping
Wang, Pascal D. Fortin, Ying-Nan P. Chen, Matthew J. LaMarche, Matthew J.
Meyer. Novartis Insts. for BioMedical Research, Cambridge, MA.
SHP2 is a non-receptor protein tyrosine phosphatase downstreamof receptor
tyrosine kinases (RTK). Mutations yielding constitutive activation of SHP2 pri-
marily lead to activation of theMAPK pathway and have been found inmultiple
tumor types. These observations make SHP2 a potentially promising therapeu-
tic target for the treatment of cancers with RTK dependence. Recently, a novel
allosteric mechanism of SHP2 inhibition was identifıed where the autoinhibited
formof SHP2 is stabilized via smallmolecule binding.Hereinwe describe efforts
to characterize the pharmacokinetic (PK)/pharmacodynamic (PD)/effıcacy re-
lationship of orally bioavailable novel allosteric SHP2 inhibitors. Single dose
PK/PD studies were conducted in nudemice engraftedwith the EGFR amplifıed
esophageal squamous cell carcinoma cell line, KYSE520. The allosteric SHP2
inhibitor SHP099 achieved time and dose dependent increases in plasma con-
centrations and concomitant reductions in tumor pERK that could be described
by an Emaxmodel. Tumor pERK levels were reduced by 50 to 70%when SHP099
unbound plasma concentrations exceeded the in vitro cellular PD IC50, suggest-
ing that exposure above this threshold was required for pathway inhibition in
vivo. A second allosteric SHP2 inhibitor, SHP065, was also profıled in vivo and
yielded data consistent with this hypothesis. Two additional allosteric SHP2
inhibitors (SHP156, SHP393) that achieved unbound plasma concentrations
approximating their cellular IC50s failed to modulate tumor pERK. The totality
of these data support the hypothesis that unbound plasma concentrations in
excess of the cellular IC50 is required for allosteric SHP2 inhibitors to inhibit the
MAPK pathway in vivo. We further demonstrated that SHP099 achieves dose
dependent inhibition of KYSE520 tumor xenograft growth in nude mice. Inte-
gration of the antitumor effıcacy data and pERK inhibition data revealed a direct
linear relationship between tumor growth inhibition and the fraction of time
between dosing intervals in which pERK is inhibited by at least 50%. To test this
model, SHP099 PK data from nude rats was applied to the Emax model and the
resulting predicted PD responses were applied to the PD/effıcacy model to pre-
dict SHP099 anti-tumor effıcacy in nude rats. Data generated from a SHP099
KYSE520 effıcacy study in nude rats demonstrated that the exposure/response
model was remarkably robust. Doses of 8 mg/kg qd, 25 mg/kg qd, or 75 mg/kg
q2d yielded observed T/C of 70, 14, and 18%, respectively; versus a model pre-
dicted T/C of 75, 6, and 6%, respectively. In summary, we describe for the fırst
time successful efforts to characterize the PK/PD/effıcacy relationship of novel
allosteric SHP2 inhibitors. These exposure/responsemodels served as a basis for
further allosteric SHP2 inhibitor drug discovery efforts and begin to inform
rational approaches to dose and schedule selection in clinic.
#1177 Targeting NEDD8 to uncover an exceptional responder molecular
subtype in glioblastoma. Lauren K. Hartman,1 Darren Finlay,2 Peiwen Pan,2
Seungchan Kim,1 Gil Speyer,1 Jeff Kiefer,1 Harshil Dhruv,1 Kristiina Vuori,2
Michael Berens1. 1Translational Genomics, Phoenix, AZ; 2Sanford BurnhamPre-
bys Medical Discovery Institute, La Jolla, CA.
Neddylation is a post-translational mechanism that marks proteins for deg-
radation through activity of NEDD8 Activating Enzyme (NAE). NAE blocks
cullin-RING ligases from initiating proteosomal degradation of select substrates
including cell cycle regulators and apoptosis modulators. MLN4924, or Pevone-
distat, targets NAE and inhibits Neddylation and induces apoptosis in sensitive
cells. We have discovered, in a cohort of glioblastoma PDX models, an excep-
tional responder to MLN4924 (GBM102). Most pertinently the effects we ob-
serve are in a PDX cultured as 3D neurospheres that more closely resemble the
true tumor architecture, heterogeneity, and “stem-like” phenotype characteris-
tic of tumor growth. We have leveraged RNAseq expression data from Cancer
Cell Line Encyclopedia (CCLE) and Pevonedistat response data from The Can-
cer Therapeutics Response Portal (CTRP) to apply a network-based analysis to
identify pathways enriched with differential dependencies between cell lines
sensitive and non-sensitive to MLN4924. The analysis also identifıes potential
mediating genes that appear to play critical roles in such differential dependency
networks. Identifıed differential networks and mediators provide insight for
cellular mechanisms underlying drug response. Additionally, we also investi-
gated the effıcacy ofMLN4924 against orthotopic gliomaPDXmodels (GBM102
and GBM116) in vivo to validate our fındings in vitro. Thus genomic character-
ization of patient samplesmay lead to the identifıcation of amolecular signature
which is associated with a subset of GBMs vulnerable to MLN4924. As the
treatment options for GBM are extremely limited, this may highlight a novel
alternative opportunity to treat a select fraction of patients with this aggressive
disease.
#1178 Unbiased effıcacy-based screening of small molecules highly selec-
tive against hematologicalmalignancies revealed inhibitor ofNADsynthesis.
Lioubov Korotchkina,1 Sangeeta Joshi,1 Slavoljub Vujcic,1 Ilya Toshkov,1
Mikhail Chernov,2 Denis Kazyulkin,1 Katerina Andrianova,1 Alexander Polin-
sky,1 Olga Chernova,1 Andrei V. Gudkov2. 1Oncotartis Inc., Buffalo, NY; 2Ro-
swell Park Cancer Inst., Buffalo, NY.
Effective anticancerdrugs canbedirected against cell lineage-specifıc, rather than
tumor-specifıc, targets (i.e., androgen receptor, CD20, etc.). We sought to conduct
systematic search for novel agents that are selectively cytotoxic to hematopoietic
(HP) malignancies presumably targeting HP lineage-specifıc survival factors. Cell-
based screening and subsequent validation of small-molecules in a broad panel of
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HP and non-HP cancer cell lines followed by a hit-to lead optimization of the se-
lected class of compounds has led to a molecule named OT-82 characterized by
highly selective cytotoxicity against all HP-derived cancers tested (14 cell lines, rep-
resenting humanAML, ALL, CML and lymphoma cells) active within single nano-
molar rangeof concentrations.OT-82killed sensitive cells by inductionof apoptosis
and was up-to 20-fold more toxic to HP-derived than to solid tumor-derived cell
lines and normal primary cells of HP and non-HP origin. OT-82-based affınity
chromatography of cell lysates followed bymass spectrometry led to the identifıca-
tion of nicotinamide phosphorybosyltransferase (NAMPT) as the OT-82 target.
NAMPTcatalyzes the rate limiting step in amajor pathway of synthesis ofNAD, an
energymetabolismmediator and essential cofactor of PARP and sirtuins. NAMPT
treatment caused dramatic reductions in cellular NAD levels. Nicotinic acid (NA,
vitamin B3), a substrate for the alternative NAD synthesis pathway, protected cells
fromthe cytotoxic effects ofOT-82.Oral administrationofOT-82was effıcacious in
subcutaneous and systemic xenograft models of human AML, ALL, erythroleuke-
mia and multiple myeloma including complete response in several models. Thera-
peutic doses ofOT-82 inmicewere signifıcantly lower thanmaximal tolerated dose
(MTD); toxicities observed at doses above MTD were largely limited to HP and
lymphoid organs. Toxicity profıle of OT-82 determined in GLP in mice and non-
human primates was favorably different from that reported for other reported clin-
ical stage NAMPT inhibitors and did not involve any detectable retinal or cardiac
toxicity. These results indicate high lineage specifıc andmalignant transformation-
specifıc dependence of HP neoplastic cells on NAMPT, presumably due to the
strong addiction of this cell type on the NAD levels, and highlight OT-82 as a pro-
spective clinical candidate for the treatment of hematological malignancies.
#1179 EP4 receptor antagonism in paclitaxel-resistant ovarian clear cell
carcinomas that overexpress class III -tubulin. Dana M. Roque,1 Danielle
Meir-Levi,1 Gautam G. Rao,1 Paul Staats,2 Amy Fulton,2 Jocelyn Reader1. 1Di-
vision of Gynecologic Oncology, University of Maryland School of Medicine-
Greenebaum Cancer Center, Baltimore, MD; 2Department of Pathology, Univer-
sity of Maryland School of Medicine, Baltimore, MD.
OBJECTIVES: Advanced ovarian clear cell carcinoma (OCCC) is associated
with a survival disadvantage relative to ovarian serous carcinoma following plat-
inum/taxane-based chemotherapy and optimal cytoreduction. Prostaglandin
E2 (PGE2) contributes to disease progression through modulation of several
G-protein coupled receptors (EP1-4) [Fig.1a]. The addition of upstream COX
inhibition to platinum/taxane-based chemotherapy in the fırst-line phase II set-
ting in ovarian cancer has been disappointing,a possibly due to compensatory
upregulation of COX isoenzymes and negation of protective effects of EP1.
Selective antagonism of EP4 may therefore pose a more rational strategy than
global COX inhibition. Paclitaxel administration has been shown to upregulate
components of the COX pathway.b Class III -tubulin is a marker for paclitaxel
resistance and is widely overexpressed in OCCC. The purpose of this study is to
demonstrate that EP4 inhibition may overcome paclitaxel resistance in OCCC
that overexpress class III -tubulin. METHODS: Expression of EP4 receptor
and class III -tubulin was quantifıed using immunohistochemistry and West-
ern blot in solid tissues and cell lines. Standardmetabolic growth andmigration
assays were employed to test the effects of drug treatment (paclitaxel and EP4
inhibitors RQ-15986/AH-23848) with and without EP4 silencing using siRNA.
RESULTS: OCCC overexpress class III -tubulin/EP4 relative to normal ovary
[Fig. 1b/c]. EP4 staining intensity was 2 in 100% OCCC using an ovarian
cancer tissue microarray (62 cores, 13% OCCC); this rate was only 26-56%
among other histologies. EP4 inhibition reduces growth of paclitaxel-resistant
cells [Fig. 1d]. Likewise, treatment with EP inhibitors [Fig.1 e-top] and silencing
of EP4 resulted in reducedmigration [Fig.1 e-bottom]. CONCLUSIONS: Selec-
tive antagonism of PGE2 through EP4 receptor inhibitionmay represent a pow-
erful targeted therapy for paclitaxel-resistant OCCC. Further study including
simultaneous treatment (EP4 inhibitorpaclitaxel) and larger samples sizes is
required. REFERENCES: a Reyners et al. A randomized phase II study investi-
gating the addition of the specifıc COX-2 inhibitor celecoxib to docetaxel plus
carboplatin as fırst-line chemotherapy for stage IC to IV epithelial ovarian can-
cer, fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann
Oncol 2012; 23:2986-902. b Moos et al. Effects of taxol/taxotere on gene expres-
sion inmacrophages: induction of the PGH synthetase-2 isoenzyme. J Immunol
1999;162:476-73.
#1180 Targeting the HSP40/HSP70 chaperone axis as a novel strategy to
treat castration-resistant prostate cancer. Michael A. Moses,1 Yeong Sang
Kim,1 Genesis Rivera-Marquez,1 Matthew J. Watson,1 Sunmin Lee,1 Andrea
Kravats,1 SueWickner,1 JasonGestwicki,2 Jane Trepel,1 LenNeckers1. 1National
Cancer Institute, Bethesda, MD; 2University of California, San Francisco, San
Francisco, CA.
Castration-resistant prostate cancer (CRPC) is frequently characterized by ele-
vated expressionof nuclear receptors able to at least partiallymaintain the androgen
receptor (AR) transcriptional program. Elevated expression of a number of consti-
tutively active AR splice variants lacking the ligand binding domain (LBD) (e.g.,
ARv7, which is ligand-independent and correlates with poor prognosis, reduced
survival, and resistance to existing LBD-targeted standard of care therapy) is a fre-
quent occurrence inCRPC. Thus, alternative approaches to disruptAR signaling in
CRPC are of great clinical importance, and a single strategy able to target AR and
ARv7 remains a critical unmet need.As a steroid hormonenuclear receptor, theAR
exists inan interactiveanddynamiccyclewith themolecularchaperones (heat shock
proteins,HSPs)HSP40/HSP70/HSP90 forproper foldingandremodelingof theAR
LBD to bind ligand. Notably, HSP90 inhibitors promote AR degradation and dis-
play effıcacy in prostate cancer xenograft models. Although it has been shown that
ARv7 functions independently of HSP90, additional chaperone requirements of
LBD-defıcient ARv7 are not known. Thus, we tested the hypothesis that both AR
andARv7aredependentonHSP40/HSP70andthat targeting thesechaperoneswith
specifıc inhibitors (C86 and JG98, respectively)will lead toAR/ARv7destabilization
and loss of transcriptional activity inmodels of CRPC. To determine if AR proteins
associate with HSP40/HSP70, 22Rv1 CRPC cells (expressing endogenous AR and
ARv7)were fırst transfectedwith FLAG-HSP40 or FLAG-HSP70. Immunoprecipi-
tation with FLAG beads revealed AR and ARv7 associated with both chaperones,
indicating potential functional dependence of these nuclear receptors on HSP40/
HSP70. To further characterize these interactions, 22Rv1 lysate was probed with
biotinylated-C86 and subjected to IP with streptavidin beads. C86 bound a signifı-
cant fraction of HSP40 complexed with HSP70, AR, and ARv7. Excess unlabeled
C86 or JG98 effectively competed away binding of HSP40/HSP70 to biotinylated-
C86 with concomitant loss of associated AR and ARv7. Treatment of 22Rv1 cells
with C86 or JG98 led to a time and dose-dependent decrease in AR and ARv7
protein, concomitant with a signifıcant loss of viability. We also observed that
HSP40/HSP70 inhibition markedly reduced AR and ARv7 transcriptional activity,
as indicated by decreased AR (KLK3, TMPRSS2) and ARv7 (UBE2C) target gene
expression. Finally, treatment of mice bearing 22Rv1 xenografts with JG231 (an
analog of JG98 with enhanced PK properties) led to signifıcantly smaller tumors
relative to vehicle treated mice. Together, these data confırm the continued depen-
dence of AR and ARv7 on HSP40/HSP70 molecular chaperones and they demon-
strate the feasibility of targeting the HSP40/HSP70 axis to abrogate sustained AR-
mediated signaling in CRPC.
#1181 Discovery and development of novel highly potent and selective
inhibitors of USP19 usingUbiPlexTM.Gerald Gavory, ColinO’Dowd, Ewelina
Rozycka, Anthony Dossang, Ashling Henderson, Caroline Hughes, Hugues
Miel, Oliver Barker, Joana Costa, Peter Hewitt, Mary McFarland, Lauren Proc-
tor, Tim Harrison. Almac Discovery, Belfast, United Kingdom.
Over the past decade, protein ubiquitination has emerged as an important
post-translational modifıcation with regulatory functions in all important cellu-
lar processes. Deubiquitinating enzymes (DUBs) including ubiquitin specifıc
proteases (USPs) are cysteine proteases that catalyse the de-ubiquitination of
protein substrates including tumor suppressors and oncogenes, hence regulat-
ing their levels and/or function. As a result of their increasing implications in the
etiology of numerous pathological conditions including cancer, DUBs are
emerging as an attractive and promising target class for the development of 1st in
class medicines with high therapeutic impact. However, despite 15 years of in-
tense research DUBs have proved largely refractory to drug discovery efforts.
Herein, we further describe the application of Ubi-PlexTM, our drug discovery
platform for the identifıcation and optimisation of DUB inhibitors. In particu-
lar, we will highlight the versatility and robustness of Ubi-PlexTM by describing
the outcome of our focussed library screening, hit identifıcation, hit validation
and elaboration activities onUSP19. A series of novel, highly potent (e.g. IC50
10 nM) and reversible USP19 inhibitors have been identifıed. Further profıling
has also demonstrated excellent selectivity against a large panel of DUBs and
other non-related enzymes (e.g. kinases, proteases). These inhibitors are cell-
permeable and exhibit potent target engagement in cells with EC50 values 30
nM. Finally, we will describe our progress towards the development of lead
molecules with drug-like properties with the aim to rapidly establish in vivo
proof-of-concept studies. In summary, this work further exemplifıes the tracta-
bility of theDUB target family and reports the discovery and detailed profıling of
the fırst highly potent and selective inhibitors of USP19. These molecules may
provide opportunities for the development of new anticancer therapeutics as
well as for the treatment of muscle wasting disorders including cachexia.
#1182 A novel curcumin derivative inhibits active ras and its downstream
pathway in pancreatic cancer. Naveen Mallangada,1 Gerardo G. Mackenzie2.
1Stony Brook University, Stony Brook, NY; 2University of California, Davis, Da-
vis, CA.
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Pancreatic Cancer’s (PC’s) 5-year survival rate of only 6.7% indicate the need
to improve treatment modalities. Despite decades of research, current chemo-
therapy and radiation therapy regimens offer minimal or no help. It is critical to
develop new agents for the effective management of PC. Given that Kras muta-
tions initiate andmaintain PC, inhibition of this pathway is widely considered a
therapeutic target of exceptional importance.Our laboratory is currently explor-
ing the chemotherapeutic effıcacy of a novel Chemically-Modifıed Curcumin
(CMC2.24) as a potential chemotherapeutic agent for PC. Preliminary studies
have shown thatCMC2.24 has higher bioavailability than curcumin, as shown in
pharmacokinetic studies in rats, and inhibits PC growth in vitro and in vivo.
However, the exact mechanism on how CMC2.24 reduces cell growth remains
unidentifıed. The objective of this work was to determine the mechanism of
CMC2.24 in PC. Using human PC MIA PaCa-2 and Panc-1 cell lines and pan-
creatic acinar explants from Kras mutant mice, we explored the effects of
CMC2.24 on Ras activation, ERK phosphorylation, mitochondrial reactive ox-
ygen species,mitochondrial ATP production, and intrinsic apoptosis. In human
PCMIA PaCa-2 cells CMC2.24 inhibited Ras activation by 90% (p0.05). This
was confırmed in primary acinar explants isolated from Kras mutant mice in
which CMC treatment reduced Ras activation by 70%, compared to control.
Furthermore, CMC2.24 treatment reduced the phosphorylationMEK, ERKand
c-Raf, down-stream pathway of Ras, both in vitro and in vivo. The effect of
CMC2.24 on ERK phosphorylation was confırmed by Immunofluorescence,
showing a signifıcant decrease in ERK phosphorylation (47.8%; p0.05). More-
over, CMC2.24 treatment enhanced the levels of superoxide anion inmitochon-
dria by 200% (p0.02), decreased ATP levels in a concentration-dependent
manner (p0.05), and induced intrinsic apoptosis, as shown by the increase in
caspase 9 and Parp cleavage downstream of cytochrome C cytosolic release. In
conclusion, our results indicate that theRas pathway is a keymolecular target for
CMC2.24 and that CMC induces apoptosis in PC cells through the intrinsic
pathway. This research was supported by the Stony Brook Cancer Center and a
URECA Summer Grant.
#1183 Structure-activity studies and biological evaluations of ERGi-USU,
a highly selective inhibitor for ERG-positive prostate cancer cells. Ahmed A.
Mohamed,1 Charles P. Xavier,1 Gauthaman Sukumar,2 Samuel D. Banister,3
Vineet Kumar,3 Shyh-Han Tan,1 Shilpa Katta,1 Lakshmi Ravindranath,1 Mu-
hammad Jamal,1 Taduru Sreenath,1 David G. McLeod,1 Gyorgy Petrovics,1 Al-
bert Dobi,1 Meera Srivastava,2 Sanjay Malhotra,3 Clifton Dalgard,2 Shiv Srivas-
tava1. 1Uniformed Services Univ. of the Health Sci., Rockville, MD; 2Uniformed
Services Univ. of the Health Sci., Bethesda, MD; 3Stanford University, Standford,
CA.
Introduction and objectives: While new prostate cancer (CaP) treatments
(Abiraterone and Enzalutamide) have improved survival in castration-resistant
prostate cancer (CRPC), their benefıts are short-lived and drug resistance devel-
ops likely due to numerous adaptive mutations. Therefore it is a critical to de-
velop effective novel inhibitors to target other signaling pathways that promote
or contribute to prostate tumorigenesis. Accumulating evidence has established
the androgen regulated TMPRSS2-ERG fusion as a common oncogenic driver
that contributes to the early development and progression of over half of CaP.
Therefore, ERG oncoprotein and ERG dependent pathways are promising tar-
gets for CaP therapy in early stages when cancer ismost responsive to treatment.
We previously identifıed a small molecule inhibitor, ERGi-USU, which selec-
tively inhibits ERG protein and cell growth in ERG positive tumor cell lines and
mouse xenograft models. In an effort to further develop ERGi-USU with en-
hanced effıcacy we performed detailed structure-activity relationship (SAR)
evaluation of ERGi-USU core structure and developed new derivatives. Meth-
ods: Based on SAR of the core structure of ERGi-USU, 48 new derivatives were
designed and synthesized by substitutions with alkyl, alkoxy, cycloalkyl, hetero-
cycloalkyl, aryl, heteroaryl or hydroxyl groups. The new ERGi-USU derivatives
were evaluated for inhibition of cell growth and ERG protein levels in the TM-
PRSS2-ERG fusion harboring CaP cell line, VCaP. Four of these compounds
have been selected for evaluation of ERG selectivity by defıning IC50 in ERG
positive malignant cells (VCaP, KG1, MOLT-4 and COLO320), ERG negative
CaP cell line (LNCaP) or ERG positive normal primary endothelium-derived
cells (HUVEC). Result: Like parental compound, four new ERGi-USU deriva-
tives exhibited inhibition of cell growth and ERG protein levels in ERG positive
VCaP, KG1, MOLT-4 and COLO320 cell lines, with no or minimal effects on
LNCaP and HUVEC cells. One of the new derivatives (ERGi-USU#6) showed
increased effıcacy for cell growth inhibition (IC500.074M) compared to the
parental ERGi-USU (IC500.200M). Other three new compounds showed
similar IC50 as the ERGi-USU. Conclusion: Comprehensive evaluation of
ERGi-USU derivatives along with parental compound has continued to under-
score selective inhibition of ERG positive tumor cells by these small molecules.
#1184 Characterization of novel STAT5 inhibitors to interfere with the
oncogenic activities of STAT5 in hematopoietic diseases. Bettina Wingel-
hofer,1 Barbara Maurer,1 Elizabeth C. Heyes,1 Patricia Freund,1 Abbarna A.
Cumaraswamy,2 Jisung Park,2 Stefan Kubicek,3 Peter Valent,4 Patrick T. Gun-
ning,2 Richard Moriggl1. 1Ludwig Boltzmann Institute for Cancer Research, Vi-
enna, Austria; 2University of Toronto Mississauga, Mississauga, Ontario, Can-
ada; 3CeMMResearch Center forMolecularMedicine of the Austrian Academy of
Sciences, Vienna, Austria; 4Medical University of Vienna, Vienna, Austria.
Activation of the transcription factor STAT5 is essential for the pathogenesis
of acute myeloid leukemia (AML) containing the FLT3 internal tandem dupli-
cation (ITD). FLT3 ITD is a constitutively active tyrosine kinase (TK) that drives
the activation of STAT5 leading to the growth and survival of AML cells. Al-
though there has been some success in identifying TK inhibitors that block the
function of FLT3 ITD, treatment options are still limited. This is mainly due to
drug resistance development by mutations that allow for the continued activa-
tion of STATs. Since STAT5 represents a critical mediator of malignant cellular
behavior and sits at the convergence point of many kinase pathways, the direct
targeting of STAT5 may be an effective means of overcoming this resistance to
TK inhibitors. First, we screened a library of potential STAT5 inhibitors for
specifıc SH2 domain binders using a fluorescent polarization assay. Thereby, we
identifıed small inhibitory molecules, called AC-3-019 and AC-4-130, that bind
to the SH2 domain of STAT5, subsequently resulting in the disruption of the
reciprocal STAT5-phosphopeptide interactions. They effıciently blocked ki-
nase-mediated phosphorylation, dimer formation, nuclear translocation, DNA
binding and STAT5 mediated target gene expression. Further, we observed a
time- and dose-dependent impairment of proliferation, blocked cell cycle pro-
gression and increased apoptosis. Studies with human AML patient-derived
samples similarly showed an induction of apoptotic cell death and decreased
colony forming capabilities. A combinatorial drug screen revealed synergistic
effects with TK inhibitors, as well as with drugs standardly used in the treatment
of AML patients, e.g. Cytarabine. Finally, AC-3-019 and AC-4-130 signifıcantly
suppressed tumor growth in vivo without general toxicity in healthy organs.
Overall, our fındings indicate that AC-3-019 and AC-4-130 are potent and se-
lective inhibitors of STAT5. These compounds provide lead structures for fur-
ther chemical modifıcations and clinical development for the identifıcation of
compounds to improve existing therapies.
#1185 H3B-8800, a novel orally available SF3bmodulator, shows preclin-
ical effıcacy across spliceosome mutant cancers. Silvia Buonamici,1 Akihide
Yoshimi,2 Michael Thomas,1 Michael Seiler,1 Betty Chan,1 Benjamin Caleb,1
Fred Csibi,1 Rachel Darman,1 Peter Fekkes,1 Craig Karr,1 Gregg Keaney,1 Amy
Kim,1 Virginia Klimek,3 Pavan Kumar,1 Kaiko Kunii,1 Stanley Chun-Wei Lee,2
Xiang Liu,1 Crystal MacKenzie,1 Carol Meeske,1 Yoshiharu Mizui,1 Eric Pad-
ron,3 Eunice Park,1 Ermira Pazolli,1 Sudeep Prajapati,1 Nathalie Rioux,1 Justin
Taylor,2 John Wang,1 Markus Warmuth,1 Huilan Yao,1 Lihua Yu,1 Ping Zhu,1
Omar Abdel-Wahab,2 Peter Smith1. 1H3 Biomedicine, Cambridge, MA; 2Memo-
rial Sloan Kettering Cancer Center, New York, NY; 3Moffıtt Cancer Center and
Research Institute, Tampa, FL.
Genomic characterization of hematologic and solid cancers has revealed re-
current somatic mutations affecting genes encoding the RNA splicing factors
SF3B1, U2AF1, SRSF2 and ZRSR2. Recent data reveal that these mutations con-
fer an alteration of function inducing aberrant splicing and rendering spliceo-
somemutant cells preferentially sensitive to splicingmodulation comparedwith
wildtype (WT) cells. Here we describe a novel orally bioavailable small molecule
SF3B1 modulator identifıed through a medicinal chemistry effort aimed at op-
timizing compounds for preferential lethality in spliceosomemutant cells. H3B-
8800 potently binds toWTormutant SF3b complexes andmodulates splicing in
in vitro biochemical splicing assays and cellular pharmacodynamic assays. The
selectivity of H3B-8800 was confırmed by observing lack of activity in cells
expressing SF3B1R1074H, the SF3B1 mutation previously shown to confer resis-
tance to other splicing modulators. Although H3B-8800 binds both WT and
mutant SF3B1, it results in preferential lethality of cancer cells expressing
SF3B1K700E, SRSF2P95H, or U2AF1S34F mutations compared to WT cells. In an-
imals xenografted with SF3B1K700E knock-in leukemia K562 cells or mice trans-
planted with Srsf2P95H/MLL-AF9 mouse AML cells, oral H3B-8800 treatment
demonstrated splicing modulation and inhibited tumor growth, while no ther-
apeutic impact was seen inWT controls. These data were also evident in patient-
derived xenografts (PDX) from patients with CMML where H3B-8800 resulted
in a substantial reduction of leukemic burden only in SRSF2-mutant but not in
WT CMML PDX models. Additionally, due to the high frequency of U2AF1
mutations in non-small cell lung cancer, H3B-8800 was tested in U2AF1S34F-
mutant H441 lung cancer cells. Similar to the results from leukemia models,
H3B-8800 demonstrated preferential lethality of U2AF1-mutant cells in vitro
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and in in vivo orthotopic xenografts at well tolerated doses. RNA-seq of isogenic
K562 cells treated with H3B-8800 revealed dose-dependent inhibition of splic-
ing. Although global inhibition of RNA splicing was not observed; H3B-8800
treatment led to preferential intron retention of transcripts with shorter and
more GC-rich regions compared to those unaffected by drug. Interestingly,
H3B-8800-retained introns commonly disrupted the expression of spliceosomal
genes, suggesting that the preferential effect of H3B-8800 on spliceosome mu-
tant cells is due to the dependency of these cells on expression of WT spliceo-
somal genes. These data identify a novel therapeutic approach with selective
lethality in leukemias and lung cancers bearing a spliceosomemutation. Despite
the essential nature of splicing, cancer cells without a spliceosome mutation
were less sensitive to H3B-8800 compared with potent eradication of mutant
counterparts. H3B-8800 is currently undergoing clinical evaluation in patients
with MDS, AML, and CMML.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Reversal of Drug Resistance
#1186 Propranolol could overcome BRAF inhibitors resistance by multi-
ple mechanisms in melanoma. Chengfang Zhou,1 DongYa Shen,1 WeiLi
Wang,1 Shangchen Xie,1 Ping Liao,1 Xiang Chen,2 Howard L McLeod,3 Yijing
He2. 1Department of Clinical Pharmacology, XiangYa Hospital, Central South
University, Institute of Clinical Pharmacology, Central South University, Hunan
Key Laboratory of Pharmacogenetics, Changsha, China; 2Department of Derma-
tology, XiangYaHospital, Central SouthUniversity, Changsha; ChinaHunanKey
Laboratory of Skin Cancer and Psoriasis, Changsha, China; 3Moffıtt Cancer Cen-
ter, Tampa, FL.
BRAF(V600E) is the most common oncogenic mutation in melanoma and
leads to constitutive activation of the MAPK pathway, which results in uncon-
trolled cell growth. Selective BRAF inhibitors such as vemurafenib have been
observed to neutralize oncogenic the signaling, inhibit cellular growth, and im-
prove patient outcome. Although these mechanisms of vemurafenib resistance
have been reported, few studies focused on how to overcome the resistance.
Propranolol, a non-selective -blocker, was confırmed to involve in multiple
anticancer effects. Our previous study also showed propranolol inhibited mela-
noma by suppressing MAPK and AKT pathways in vitro an in vivo. But its
effıcacy and mechanism of overcoming vemurafenib still remain unknown in
melanoma. Here, we explored the effect of propranolol on the A375, P-8 (pa-
tient-derivedmelanoma cell line) vemurafenib resistance cell line and resistance
mice xenografts. Cell viability assay demonstrated that 2M -20M vemu-
rafenib couldn’t decrease the proliferation but 24h-120h of incubation of 2M-
200Mpropranolol inhibited viabilitywith a concentration and timedependent
manner in the two resistance cell line. TUNEL staining showed 24h incubation
of 20M propranolol alone or plus 4M vemurafeinb obviously increased cell
apoptosis. Mice received daily ig. administration of propranolol at the dose of 2
mg/kg alone or plus 10 mg/kg for 21days. The mean tumor volume at day 21 in
resistance A375 xenografts was 221.13 	 7.65mm3vs. 904.12 	 70.57mm3 vs.
2021 	 316.24mm3for the propranolol plus vemurafenib, propranolol alone,
vemurafenib alone, respectively. Propranolol improved mice survival, 28.6%
animal dead in plus group, 57.1%mice dead in the propranolol group, and 71.5%
animal dead in vemurafenib at end of treatment. IHC showed propranolol also
reduced Ki67 index both in propranolol and plus group when compared with
vemurafenib treated mice. Furthermore, RNA sequencing was performed to
explore the mechanism of propranolol overcoming the resistance, the data
showed propranolol largely reduced mRNA levels of IGF family (IGFBP3, IG-
FLR1, IGFBP6, IGF2, IGF1R.etc.) but elevated the expressions of innate im-
mune related genes (NKG7, TLR9, NCR3.etc.) in A375-vemr cell line. These
results provide a strategy of therapeutic resistance for the clinic, importantly,
this study also provide a clue targeting IGF family and regulating innate immune
might be a potential strategy to suppress resistance in BRAF inhibitor therapies
in melanoma.
#1187 Synthetic lethality screening reveals ATR as responsible for oxalip-
latin resistance in colorectal cancer cells. Eve Combes,1 Augusto Faria-An-
drade,1 Diego Tosi,1 Pierre Martineau,1 Maguy Del Rio,1 Roderick Beijersber-
gen,2 Nadia Vie,1 Céline Gongora1. 1IRCM, INSERM U1194, Montpellier,
France; 2The Netherlands Cancer Institute, Amsterdam, Netherlands.
Despite the recent advances achieved in the treatment of colon cancer, tumor
resistance is a frequent cause of chemotherapy failure. Our work was aimed to
determine the molecular mechanisms involved in the resistance to oxaliplatin,
an anticancer agent widely used in colorectal cancer treatment. To this end, we
establish an oxaliplatin-resistant cellularmodel from the colon adenocarcinoma
cell lineHCT-116. Among cellular clones obtained, we used one displayingmild
resistance (10 fold calledHCT116-R1) to perform short hairpin RNA-based loss
of function genetic screen in order to identify genes that can modulate the cel-
lular response to oxaliplatin by revealing genes the silencing of which causes
drug sensitivity (synthetic lethal interactions with the drug). Using this screen,
we have identifıed ATR (Ataxia-telangiectasia mutated and rad3 related), a pro-
tein that plays a key role in the repair of DNA double-strand breaks induced by
various DNA damaging agents, including platinum derivatives. We further val-
idated ATR implication in oxaliplatin resistance by showing that (i) shRNA-
mediated repression of ATR in HCT116-R1 oxaliplatin-resistant CRC cells sen-
sitizes such cells to the drug; (ii) co-incubation with the ATR inhibitor VE-822
(or VX-970) and oxaliplatin led to a dramatic synergistic effect in six different
CRC cell lines (two oxaliplatin-sensitives: HCT116 and SW48; and four oxalip-
latin-resistant: HCT116-R1, HCT116-R2, SW48-R1 and SW48-R2) using 2D
and 3D cell growth inhibition assays and in vivo. The synergistic effect was
evaluated using dose matrix data (an algorithm that was implemented in our
group); (iii) the synergistic effect of oxaliplatin andVE-822was accompanied by
an increase of ssDNA, DNA double-strand breaks, growth arrest and apoptosis
induction. In conclusion, our preliminary data confırm the results of our screen
by demonstrating for the fırst time the functional role ofATR in the sensitivity to
oxaliplatin.
#1188 Sodium phenylbutyrate has an antineoplastic effect and enhances
the cytotoxicity of 5-fluorouracil and irinotecan in colorectal cancer cell
lines.Maha Al-Keilani, Ruba Darweesh. Jordan University of Science and Tech-
nology, Irbid, Jordan.
Colorectal cancer is the third most common cancer in the world and it is the
second leading cause of cancer-related deaths in theUnited States. About 25%of
colorectal cancer cases present with metastases at time of diagnosis and 50% of
patients who undergo surgery will ultimately develop metastatic disease. Con-
sequently, adjuvant chemotherapy is required in many cases and it aims to
prevent tumor progression and metastasis. Resistance to chemotherapy is the
biggest obstacle in the treatment path of advanced colorectal cancer. Thus, high-
lighting the urgent need for the identifıcation of new therapeutic agents that can
enhance the cytotoxicity of the currently approved anticancer drugs. Sodium
phenylbutyrate (NaPB), a salt of a short chain fatty acid that is used for treatment
of urea cycle disorders, is under investigation for its antineoplastic potential.
NaPB acts as a histone deacetylase inhibitor and it has been shown to be associ-
atedwith reducedER stress and enhanced JNK signaling pathway. This indicates
that NaPB may enhance the cytotoxicity of the currently approved agents for
colorectal cancer including oxaliplatin, 5-fluorouracil, and irinotecan. The aims
of this study were to identify the antineoplastic potential of NaPB in colorectal
cell lines, and to identify its effect on the cytotoxicity of oxaliplatin, 5-fluorou-
racil, and irinotecan. MTT proliferation assay showed that NaPB possessed a
concentration dependent killing effect against HCT-116 and HT-29 colorectal
cancer cell line (IC50 values were 5 and 10 mM respectively). Moreover, at
clinically achievable and nontoxic concentration (2.5 mM), NaPB showed a
synergistic effect in HCT-116 on 5-fluorouracil (R14.176, p0.006), on irino-
tecan (R53.86, p0.0117), and on oxaliplatin (R20, p0.004), but resulted
in extensive cytotoxicity when used at 5 mM and 10 mM. In HT-29 cells, NaPB
at concentrations 5 mM and 10 mM, showed a synergistic effect on 5-fluorou-
racil (R5.5, p0.001; and R125, p0.001 respectively), on irinotecan
(R5.7, p0.016; and R21.3, p0.018 respectively), and on oxaliplatin
(R2.4, p0.003; and R3, p0.002 respectively). The addition of NaPB at
concentration of 20 mM to the previous drugs resulted in profound cytotoxic
effect toward HT-29 cells. As a conclusion, NaPB is a promising new adjuvant
antineoplastic agent that can be used to enhance the cytotoxicity of 5-fluorou-
racil, irinotecan, and oxaliplatin in colorectal cancer.
#1189 Enhanced YAP expression leads to EGFR TKI resistance in lung
adenocarcinomas. Ting-Fang Lee, Yu-Chi Tseng, Cheng-Wen Wu. National
Yang-Ming University, Taipei, Taiwan.
Epidermal growth factor receptor (EGFR) mutation is prevalently expressed
in lung adenocarcinoma cases and acts as one of the major driving oncogenes.
EGFR tyrosine kinase inhibitors (TKIs) have been used in patients with EGFR-
mutant as an effective targeted therapy in lung adenocarcinoma, but drug resis-
tance and tumor recurrence inevitably occurs. Recently, Yes-associate protein
(YAP) has been reported to promote multiple cancer cell properties, such as
promoting cell proliferation, EMT and drug resistance. This study investigated
the roles of YAP in TKI-resistant lung adenocarcinoma. In TKI-sensitive cells,
enhanced YAP expression leads to TKI resistant. Also, upregulated YAP expres-
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sion and activationwere detected in long termTKI-induced resistant cells.With
reduced YAP expression using shRNA or YAP inhibitors, TKI-resistant cells
become TKI-sensitive. Moreover, combined EGFR TKI and an YAP inhibitor
statin, prolonged survival among lung cancer patients analyzed by Taiwan Na-
tional Health Insurance Research database. These observations revealed the im-
portance of YAP in promoting TKI-resistance and combined YAP inhibition
can be a potential therapy delaying the occurrence of TKI-resistance in lung
adenocarcinoma.
#1190 Comprehensive high-throughput screen for combination therapies
to block acquired resistance to targeted drugs. Izhak Haviv. Bar Ilan Univ.,
Zfat, Israel.
Background - Genetic and epigenetic alterations provide the selective advan-
tage for cancer cell acquired drug resistant (ADR). A bottleneck in implement-
ing drug combination is the challenging task of identifying combinations with
acceptable risk benefıt ratio. High throughput functional genomic (RNAi)
screen is an ideal tool to comprehensively identify double and triple inhibitor
combinations to prevent ADR. Unfortunately, most anticancer agents are an-
tagonists (antagonists operate in the same direction as the RNAi), therefore
RNAi hits with possible clinical value are the ones that disappear during the
screen. Materials and Methods - We use lentiviral-borne shRNA libraries
(mainly kinome collection) to transduce the different RNAis into patient-de-
rived cancer cells. The resulting mixed cancer cell population (each lost one
gene) is subject to negative screen, to identify mediators of ADR. This process
was performed with approved cancer drugs, such as erlotinib, olaparib, pazo-
panib, etc. We developed a proprietary unique way to identify the RNAi clones
that disappear/extinct, specifıcally in the presence of the investigated drug.
RNAi clones are tracked using next generation sequencing, and quantifıed in
treated and untreated cancer cell cultures or xenografts. The resulting drug
combinations identifıed through this screen are tested directly on a platform of
patient-derived xenografts. Results -We identifıed known boosters of the EGFR
activity, such as DYRK1 (maintains level of EGFR protein), IKBKE (down-
stream survival mediator), which when reduced by their RNAi, enhance the
response to erlotinib. Consequently, known inhibitors of JAK1, CDK4/6, and
PI3K combined to egfr inhibitors generated more durable remissions in egfr
positive cells. Remarkably, even tumors without egfrmutations were sensitive to
the combinations. A similar discovery of novel combinations were found for
olaparib and pazopanib. Mouse harboring patient derived xenografts tolerated
combination therapy fairly well. Conclusion - Our fındings demonstrate the
value of clinically testing the effıcacy of drug combinations empirically designed
to block ADR. Animal model support our fındings with acceptable toxicity.
#1191 The dopamine (DA)D3 receptor antagonists (PG01037, NGB2904,
SB-277011A, and U99194) signifıcantly attenuate ABCG2-mediated multi-
drug resistance. Noor Hussein,1 Haneen Amawi,1 Charles R. Ashby,2
Karthikeyan Chandrabose,3 Roopali Mittal,4 Ryann Christman,1 Piyush
Trivedi,3 Amit Tiwari1. 1University of Toledo, Toledo, OH; 2St. John’s University,
Queens, NY; 3Rajiv Gandhi Proudyogiki Vishwavidyalya, Bhopal, India; 4OU
Medical Center, Oklahoma City, OK.
ATP-binding family G2 (ABCG2) transporters are known to produce multi-
drug resistance (MDR) and limit successful cancer chemotherapy. Usingmolec-
ular modeling, we obtained data indicating that highly potent and selective do-
pamine (DA) D3 receptor antagonists had signifıcant docking scores for the
active site of the ABCG2 transporter. In this in vitro study, we determined the
effect of the D3 receptor antagonists (PG01037, NGB2904, SB-277011A, and
U99194) on MDR resulting from the overexpression of ABCG2 transporters.
The D3 receptor antagonists alone did not signifıcantly affect the viability of
HEK293/ABCG2, H460/MX-20, S1-M1-80 or A549-MX-10 cells, which over-
express ABCG2 transporters. However, the D3 receptor antagonists (PG01037,
NGB2904, SB-277011A, and U99194) signifıcantly increased the effıcacy of the
anticancer drugs mitoxantrone and doxorubicin in the above mentioned cell
lines. Efflux studies indicated that both PG01037 and NGB2904 signifıcantly
decreased the efflux of rhodamine 123 from H460-MX20 cells. Interestingly,
PG01037 and NGB2904 signifıcantly decreased the expression levels of the
ABCG2protein levels as shownby immunocytochemical andWestern blot anal-
ysis. This suggests that D3 antagonists inhibit both function and expression of
ABCG2 transporters at relevant non-toxic concentrations. In conclusion, our in
vitro results indicate that PG01037,NGB2904, SB-277011A, andU99194 reverse
resistance to mitoxantrone and doxorubicin mediated by overexpression of
ABCG2 transporters. Further mechanistic and animal studies are warranted to
establish the clinical use of D3 receptor antagonists in reversing ABCG2-medi-
ated MDR.
#1192 Regorafenib (Stivarga®) reverses BCRP-mediated multidrug resis-
tance in vitro and in vivo. Yun-Kai Zhang,1 Yi-JunWang,1 Guan-Nan Zhang,1
Wen-Ji Zhang,2 Meng-Ning Wei,2 Zhi Shi,2 Zhe-Sheng Chen1. 1St. John’s Uni-
versity, Jamaica, NY; 2Jinan University, Guangzhou, China.
Overexpression of breast cancer resistance protein (BCRP) has been shown to
producemultidrug resistance (MDR) in various kinds of cancers, such as breast,
colon, lung and ovarian cancers. Regorafenib, an oral multi-kinase inhibitor,
was found to have inhibitory effects on BCRP-mediatedMDR both in vitro and
in vivo. Regorafenib signifıcantly sensitized BCRP-overexpressing cancerous
cells to BCRP substrates by increasing their intracellular accumulation. There
are no signifıcant changes in the expression level or the subcellular distribution
of BCRP in the cells exposed to regorafenib. Our mechanism studies revealed
that regorafenib inhibited the ATP-driven efflux function of BCRP. Our in-
duced-fıt docking and molecular dynamics simulations suggested the existence
of strong and stable interactions between regorafenib and BCRP protein. Ani-
mal study revealed that the combination of regorafenib and topotecan resulted
in great inhibitory effects on the growth of S1-M1-80 xenograft tumors. Rego-
rafenib signifıcantly increased the intratumoral concentration of topotecan but
had no signifıcant effects on topotecan plasma concentration. In conclusion, our
study indicated that regorafenib could be useful in combating multidrug resis-
tance in cancer treatments.
#1193 DS-8201a, a novel HER2-targeting ADC with a novel DNA topo-
isomerase I inhibitor, abrogates the resistance to T-DM1 in HER2-positive
gastric cancer: a preclinical study. Yoshikane Nonagase,1 Naoki Takegawa,1
Kimio Yonesaka,1 Kazuko Sakai,1 Yusuke Ogitani,2 Junji Tsurutani,1 Kazuto
Nishio,1 Kazuhiko Nakagawa1. 1Kindai University Faculty Of Medicine, Osaka-
sayama, Osaka, Japan; 2Daiichi-Sankyo Co., Ltd., Tokyo, Japan.
Background: Anti-HER2 therapies are benefıcial for patients withHER2-pos-
itive breast and gastric cancer. T-DM1 is an HER2-targeting antibody-drug
conjugate (ADC), which is structurally composed of the anti-HER2 antibody
trastuzumab and the tubulin inhibitor DM1. T-DM1 has shown effıcacy in pa-
tients with advanced breast cancer, but all patients eventually develop resistance
to T-DM1. DS-8201a is a novel ADC composed of an anti-HER2 antibody and a
novel potent topoisomerase I inhibitor DX-8951 derivative. DS-8201a achieved
a high drug-to-antibody-ratio (DAR: 7-8) and homogeneous drug conjugation.
The aim of this studywas to elucidate themechanisms of T-DM1 resistance, and
evaluate the effıcacy of DS-8201a in a T-DM1-resistant HER2-positive gastric
cancer cell line.Materials andmethods: The T-DM1-resistant NCI-N87 cell line
(N87-TDMR) was established by a step-wise method—the parent HER2-posi-
tive N87 cell line was exposed to up to 4 g/ml of T-DM1. The profıle of N87-
TDMR was assessed by immunoblotting, DNA microarray, and quantitative
reverse transcription-PCR (qRT-PCR). The sensitivity of parent N87 and N87-
TDMR cells to T-DM1 orDS8201awas assessed by an in vitro growth inhibition
assay as well as through the mouse xenograft model study. Results: N87-TDMR
cells were found to be resistant to T-DM1 in the in vitro growth inhibition assay
(50% growth inhibitory concentration;10g/ml in N87-TDMR, 0.055g/ml
inN87) as well as in the in vivo xenograftmodel study, butHER2 expressionwas
maintained in the N87-TDMR cells. A comprehensive expression analysis re-
vealed that N87-TDMR cells showed increased ATP-binding cassette (ABC)
transporter expression such as ABCC2 and ABCG2 compared with N87 cells
(50.2 times; 8.0 times higher than that measured by qRT-PCR relatively). Inhi-
bition of ABCC2 and ABCG2 by MK571 recovered the sensitivity to T-DM1 in
N87-TDMR cells. Since DS-8201a has higher DAR than T-DM1 and the unique
topoisomerase I inhibitor, this resistance was expected to be abrogated. DS-
8201a showed anti-tumor effıcacy against N87-TDMR xenograft cells in the
mouse model (relative tumor growth rate: 244.2% with T-DM1, -39.2% with
DS-8201a; n10 for each treatment). Conclusions: The HER2-positive gastric
cancer cell line used in this preclinical study acquired resistance to T-DM1
depending on the up-regulation of ABCC2 and ABCG2 expression. However,
DS-8201a could abrogate this T-DM1 resistance. These results provide a ratio-
nale for DS-8201a to be investigated for its effıcacy in patients with T-DM1-
resistant breast or gastric cancer.
#1194 Neutralization of IGF-I and -II ligands with the fully humanized
bispecifıc monoclonal antibody xentuzumab inhibits AR-V7-induced en-
zalutamide resistance in castration-resistant prostate cancer. Gang Liu,1
Holly M. Nguyen,1 Kristine van Maltzan,1 Shihua Sun,1 Cynthia Sprenger,1 Ul-
rikeWeyer-Czernilofsky,2 Eva Corey,1 Stephen R. Plymate1. 1Univ. ofWashing-
ton, Seattle, WA; 2Boehringer Ingelheim, Ingelheim, Germany.
Background: Recent data from multiple investigators have shown that an
increase in constitutively active androgen receptor (AR) variants such as AR-V7
is associated with more aggressive prostate cancer and a signifıcantly shortened
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overall survival. Additionally, expression of AR-V7 in circulating tumor cells or
increased expression in metastatic tissue is a biomarker for resistance to cur-
rently available anti-androgen therapies, including enzalutamide (ENZA) and
abiraterone, resulting in castration resistant prostate cancer (CRPC). Insulin-
like growth factor (IGF) signaling pathways have been incriminated as mecha-
nisms of resistance but little is known about the potential role of IGFs in CRPC
growth in relation to AR variants. In this preclinical study we examined the
effects of IGF-I and -II inhibition in LuCaP 96CR, an ENZA resistant prostate
cancer patient-derived xenograft. Hypothesis: IGF-I and -II neutralization will
block AR-V7 activity and inhibit castration-resistant prostate cancer growth.
Study procedures: LuCaP 96CR was implanted s.c. into castrate SCID mice (15
mice per group). When tumors exceeded 150mm3 animals were randomized
into groups: 1) Control; 2) ENZA (50 mg/kg, QD, po), 3) xentuzumab (BI
836845[1], 200 mg/kg QW IP) in combination with ENZA. At the end of the
study, tumors were collected for preparation of RNA and protein lysates and
histology. Results: ENZA did not show signifıcant inhibitory effects on LuCaP
96CR, but the combination of xentuzumab and ENZA resulted in signifıcant
tumor inhibition (p0.001) vs. ENZAalone.AR full length (AR-FL)mRNAand
protein increased after ENZA treatment (p0.001) but did not further rise sig-
nifıcantly when xentuzumab was co-administered. In contrast, signifıcantly el-
evated AR-V7 mRNA and protein levels were detected in tumors from mice
treated with the xentuzumab and ENZA combination (p0.001). Downstream
markers of AR-V7 activity, UBE2C and UGT2B17 mRNA, increased after
ENZA treatment when compared to vehicle (UGT2B17, p0.01); no further
signifıcant increase of UGT2B17 was detected after combination treatment and
UBCE2C signifıcantly decreased (p0.001). Summary: These data show that
addition of xentuzumab provides tumor inhibition of ENZA-resistant CRPC.
Interestingly, associated with a signifıcant decrease in tumor growth, this treat-
ment resulted in increased AR-V7mRNA and protein expression but no signif-
icant increases in downstream markers of AR-V7 activity, UBE2C and
UGT2B17. Conclusion: Our results suggest that the IGF-I and -II neutralizing
antibody xentuzumab may reverse AR-V7-mediated ENZA resistance.
#1195 TNF induces multiresistance to HER2-targeted TNF induces
multiresistance to HER2-targeted therapies in HER2-positive breast cancer.
María F. Mercogliano,1 Mara De Martino,1 Sofıa Bruni,1 Leandro Venturutti,1
Martín Rivas,2 Matías Amasino,1 Cecilia J. Proietti,1 Patricia V. Elizalde,1
Roxana Schillaci1. 1IBYME-CONICET, CABA, Buenos Aires, Argentina; 2Weill
Cornell Medical College, Manhattan, NY.
HER2 positive (HER2) is a breast cancer (BC) subtype characterized by
HER2 overexpression/amplifıcation that affects nearly 15% of BC patients and
correlates with poor prognosis. These patients receive trastuzumab (T), an anti-
HER2 monoclonal antibody, but resistance events (40-60%) hamper its clinical
benefıt. Previously we have demonstrated that TNF (TNF) induced mucin 4
(MUC4) expression and turned T-sensitive cell lines and tumors into resistant
ones. Nowadays, new anti-HER2 therapies are being used in the clinical setting,
such as lapatinib (a dual inhibitor of EGFR and HER2), and antibodies like
T-DM1 (combines TZ with the anti-microtubule agent emtansine), and pertu-
zumab (P) that impeds HER2 dimerization. The aim of this work was to study
the role of TNF in resistance to the new HER2-targeted therapies. We used
BT-474-C (control cells) and BT-474-T2, engineered in our lab to stably over-
express TNF, andwere proven to be sensitive and resistant to T, respectively.We
performed dose-response curves for T-DM1, they show that inhibits prolifera-
tion of BT-474- C cells at 0.01 g/ml. On the other hand, BT-474-T2 cells were
resistant in the same experimental conditions and they exhibited reduced
T-DM1 binding with respect to BT-474-C. BT-474-C cells were sensitive to low
concentrations of T-DM1with 0.51 nmol/L, but in BT-474-T2 cells T-DM1was
10 times less potent than control cells (IC 50 3.34 nmol/L). When we abro-
gated MUC4 expression, BT-474-T2 cells were sensitized to T-DM1, showing
that TNF-inducedMUC4 expression is responsible for T-DM1 resistance in this
cell line. We assessed the effect of lapatinib performing a dose-response curve.
Results shown a similar IC50 for BT-474 C and T2 cells (0.26 M and 0.28 M,
respectively). When we studied P effect, we observed that the combination of
TP wasmore effective inhibiting proliferation in BT-474-C cells than T alone,
despite these results binding of the antibody showed no change between the cell
lines. In BT-474-T2 cells proliferation was slightly inhibited by the combined
treatment. In vivo experiments showed that BT-474-C tumors were sensitive to
T and the combination of TP, but BT-474-T2 tumors did not respond to any of
these treatments. These results suggest that TNF plays an important role in
multiresistance to HER2-targeted therapies, specifıcally T-DM1 and P, but not
in lapatinib resistance. We propose TNF as an attractive target and we suggest
that HER2 patients resistant to T could be eligible for a combination ofHER2-
targeted therapies and a TNF-blocking treatment to overcome resistance.
#1196 Epigenetic drugs modulate long noncoding RNAs expression in
BRAF inhibitor-resistant melanoma. Barbara Montico,1 Giorgio Giurato,2
Katy Mastorci,1 Aurora Rizzo,1 Maria Ravo,2 Francesca Rizzo,2 Alessandro
Weisz,2 Riccardo Dolcetti,3 Francesca Colizzi,1 Luca Sigalotti,4 Elisabetta
Fratta1. 1Centro di Riferimento Oncologico, Aviano, Italy; 2University of Salerno,
Salerno, Italy; 3University of Queensland Diamantina Institute, Brisbane, Aus-
tralia; 4University Hospital of Udine, Udine, Italy.
Emergence of drug resistance is the major cause of failure of BRAF inhibitors
(BRAFi) treatment in cutaneous melanoma (CM). Epigenetic modifıcations are
known to physiologically trigger massive modifıcations in cellular commitment
and several studies report a correlation between the drug-resistant phenotype
and epigenetic alterations of tumor cells. In this setting, long noncoding RNAs
(lncRNAs) represent a class of gene regulators acting at epigenetic, transcrip-
tional and post-transcriptional level. Several studies have implicated lncRNAs in
chemoresistance through their ability to impair cell cycle arrest and apoptosis,
but also to induce and modulate epithelial-mesenchymal transition and cell
adhesion-associated signaling pathways. LncRNAs interact with histone modi-
fying complexes and/or DNA methyltransferases, being also targets of these
epigenetic mediators. Furthermore, epigenetic drugs have been recently identi-
fıed asmodulators for lncRNAs function aswell as their related targeting signals.
Starting from these evidences, we asked the question whether epigenetic drugs
could differentially affect the survival of BRAFi-resistant (VR) and -sensitive
CM cells, investigating the mechanistic network involved, with a specifıc focus
on the role of lncRNA. A panel of BRAFi-sensitive and VR CM cell lines was
treated with the FDA-approved HDAC inhibitor vorinostat (SAHA). FACS
analysis of annexin V-FITC/propidium iodide stained cells showed that SAHA
cytotoxic activity was more pronounced on VR CM cells than on their parental
counterparts. RNA-Seq analysis revealed that a large number of differentially
expressed lncRNAs was modulated in VRCM cells treated with SAHA. Intrigu-
ingly, the expression of severalVRup-regulated lncRNAswas decreased to levels
similar to those observed in the matched parental cells. Functional analysis in-
dicated these lncRNAs were statistically enriched in pathways involving cellular
growth and proliferation, but also cellular assembly and organization. Though
additional studies are required, epigenetic modulation of VR-associated ln-
cRNAs promises to have signifıcant therapeutic potential to restore BRAFi sen-
sivity in CM, being concomitantly effective in killing VR cells as monotherapy.
Based on our preliminary data, we could anticipate that the combined use of
epigenetic and targeted drugswould increase therapeutic effıcacy inCMpatients
relapsing to BRAFi.
#1197 Endothelin-1 receptor/-arrestin1 is an actionable node that regu-
lates YAP/TAZ signaling and chemoresistance in high-grade ovarian cancer.
Piera Tocci,1 Roberta Cianfrocca,1 Laura Rosanò,1 Rosanna Sestito,1 Valeriana
Di Castro,1 Giovanni Blandino,2 Anna Bagnato1. 1Preclinical Models and New
Therapeutic Agents Unit - Regina Elena National Cancer Institute, Rome, Italy;
2Oncogenomic and Epigenetic Unit - Regina Elena National Cancer Institute,
Rome, Italy.
The widespread activation of YAP and TAZ transcriptional regulators has been
shown to promote tumor progression and resistance to anti-cancer therapies. Ex-
tensive studieshave identifıeddifferentupstreamregulatorsofYAP/TAZ, including
G-protein coupled receptor (GPCR). However how GPCR signals regulate YAP/
TAZpuzzles have remained elusive. Among theGPCR, we reveal that the endothe-
lin-1 (ET-1) receptor activates YAP/TAZ pathway in high-grade serous ovarian
cancer (HG-SOC) sensitive and resistant cell lines and primary cultures. In HG-
SOCcells, the aberrant activation of ET-1 receptor (ET-1R), promotes an enhanced
nuclear shuttling of dephosphorylated YAP and TAZ in a time-dependent
manner, through the scaffold protein -arrestin1 (-arr1). Interestingly,
ET-1-induced YAP/TAZ nuclear accumulation is further improved in plat-
inum-resistant cells and is prevented by expressing a mutant -arr1 incapa-
ble of nuclear distribution.Moreover, the ET-1/ETAR axis activation induces
the co-localization of -arr1, YAP and TAZ in the nucleus. Mechanistically,
in sensitive and to a greater extent in resistant cells, ET-1 induces the forma-
tion of a complex -arr1/Trio, a Rho-Guanine nucleotide exchange factor
family member, which dephosphorylates YAP, inducing its nuclear accumu-
lation and the transcription of YAP/TAZ target genes. -arr1, RhoA or Trio
depletion, as well as the treatment with the dual ETAR/ETBR antagonist
macitentan, signifıcantly reduces RhoA GTPase activity and YAP nuclear
translocation, suggesting that ET-1/ETAR axis regulates YAP/TAZ activity
by driving -arr1/Trio/RhoA pathway. According with these results, the
ET-1-induced upregulation of YAP/TEAD target genes, such as CYR61,
CTGF, ANKRD1 and EDN1, as well as TEAD transcriptional activity and
cell invasion, are inhibited upon -arr1, Trio, or YAP silencing, or maciten-
tan treatment, demonstrating that -arr1-mediated intersections are re-
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quired for ET-1-induced YAP signaling. At the chromatin level, the activa-
tion of ET-1 axis promotes the recruitment of YAP, TEAD and -arr1 on
TEAD binding sites of CTGF, ANKRD1 and EDN1 promoters, an effect
inhibited by macitentan treatment. These results indicate that -arr1 can act
as a transcription co-activator that bind TEAD thereby activating transcrip-
tion of EDN1, which in turn, can sustain persistent YAP/TAZ activity
through an autocrine loop. In murine orthotopic model of patient-derived
xenograft (PDX) of HG-SOC, ET-1R blockade bymacitentan, inhibits tumor
growth, enhances the sensitivity to chemotherapy and reduces YAP and
TEAD transcriptional activity. Altogether our results establish for the fırst
time YAP/TAZ as critical downstream effectors of ET-1R/-arr1 signaling,
providing mechanistic insights that targeting ET-1R signaling overcomes
YAP/TAZ driven platinum-based therapy failure in HG-SOC.
#1198 Neuropilin-1 blockade chemosensitizes pancreatic cancer cells via
dual inhibition of epithelial-mesenchymal transition and autophagy. Pratiek
N. Matkar, Krishna K. Singh, Gerald Prud’homme, David Hedley, Howard Le-
ong-Poi. Univ. of Toronto, Toronto, Ontario, Canada.
Introduction:Fibroticandmalignantpancreaticductal adenocarcinoma(PDAC)
tumorsareoftenresistant tochemotherapy, andremaina leadingcauseofmorbidity
and mortality. Epithelial–mesenchymal transition (EMT), a process by which epi-
thelial cells lose their cell polarity and adhesion to become migratory and invasive
mesenchymal stemcells, contributes to chemoresistance inPDAC.Likewise, PDAC
tumors benefıt from autophagy, a self-degradation pathway that confers a survival
benefıt against metabolic stress. Over-activation of EMT and autophagy has been
linked to increased drug resistance in PDAC. Both these processes are largelymedi-
ated by TGF1. Recently, we demonstrated the role of neuropilin-1 (NRP-1) in
TGF1-dependent endothelial-mesenchymal transition and fıbrosis in PDAC.
However, the potential mechanisms linking NRP-1 with EMT and autophagy-me-
diated chemoresistance remain unexplored.Wehypothesized thatNRP-1 blockade
will enhance chemotherapeutic effect, by suppressing EMT and autophagy in
PDAC. Methods: Human PDAC cells (BxPC-3) or serially gemcitabine exposed
chemoresistant (CR-BxPC-3) cellswere transfectedwith siNRP-1or scrambleusing
DharmaFECT-2. ForEMTandchemotherapy studies, transfected cellswere treated
with TGF1 (5ng/mL, 24h), followed by gemcitabine (1M) for 48h. RNA (24h)
and protein (48h) was isolated using TRIzolTM andRIPA, respectively. EMTmark-
ers were evaluated by RT-PCR and immunoblotting/immunostaining. For au-
tophagy studies, cells were serum starved post NRP-1 silencing and protein was
isolated. For autophagy inhibition, cells were treatedwith bafılomycin-A1 (100nM)
for 24h post NRP-1 silencing and protein was isolated. Autophagy flux (LC3-II/I)
and P62 were measured by immunoblotting/immunostaining. Cell viability was
evaluated by MTT assay. Results: SiNRP-1 treatment in BxPC-3 and CR-BxPC-3
cells resulted in NRP-1 knockdown and promoted cell-death after chemotherapy.
TGF1-stimulated BxPC-3 cells demonstrated a morphological change consistent
with EMT that was revoked by siNRP-1. Also, siNRP-1maintained epithelial cellu-
larmorphologyviagainof epithelial and lossofmesenchymalmarkers.Remarkably,
CR-BxPC-3 cells exhibited enhanced EMT features. SiNRP-1 inhibited EMT and
promoted cell-death by overcoming gemcitabine resistance in CR-BxPC-3 cells,
possibly through reduced ERK signaling. Moreover, siNRP-1 inhibited autophagy
(decreased LC3-II/I ratio and increased P62 levels) following starvation or chemo-
therapy stress, and enhanced cell-death after chemotherapy and autophagy inhibi-
tion in BxPC-3 cells. Conclusions: Our fındings defıne a previously undetermined
role of NRP-1 in regulating autophagy and TGF1-induced EMT in PDAC, sug-
gesting thatNRP-1may represent a novel therapeutic target to overcome chemore-
sistance through reduced EMT and autophagy.
#1199 Overcomes AXL and Met mediated erlotinib/gefıtinib cross resis-
tance in non-small cell lung cancer cells by Marsdenia tenacissima extract.
Shu-Yan Han, Hong Sun, Dong Xue, Wei Zhao, Yan-Na Jiao, Ping-Ping Li.
Peking University Cancer Hospital & Institute, Beijing, China.
Apart from EGFR T790M mutation, the bypass activation of c-Met and Axl
kinase also can lead to the resistance to tyrosine kinase inhibitors (TKIs) in
NSCLC. Axl and c-Met share same downstream pathways with EGFR, thus
combined treatments of EGFR inhibitors with Axl or Met inhibitor are promis-
ing to overcome acquired resistance of TKIs. Our previouswork showed that the
water extract of Marsdenia tenacissima (MTE), which used to treat cancer in
clinics for decades, restored gefıtinib sensitivity in resistant NSCLC cells with
EGFR T790M mutation or K-ras mutations in vitro and in vivo. However, the
potential effeicacy of MTE on Axl and c-Met mediated resistance has not yet
been fully understood, and the related molecular mechanisms also need to be
elucidated. The present study was performed on HCC827/ER cells, which was
established by exposing parental HCC827 cells to erlotinib. HCC827/ER cells
are with Axl activiation and c-Met amplifıcation, and show dual-resistance to
erlotinib and gefıtinib. We evaluated the effects of MTE to restore erlotinib/
gefıtinib sensitivity with three different combinations. Cell viability and cell
apoptosis were determined byMTT and flow cytometry, respectively. The c-Met
amplifıcation was assessed with TaqMan real-time PCR. Signaling pathways
were examined by Western blotting to reveal the possible mechanisms. The in
vivo effects of MTE combined with erlotinib/gefıtinib were tested on
HCC827/ER xenograft mice, and tumor tissues were subjected to immunohis-
tochemistry analysis and Western blotting. Our results indicated the
MTE¡MTEErlotinib/Geftinib (M¡ME/G) treatment was themost potent
combinations. Compared with control group and each single, M¡ME/G
treatment induced signifıcant apoptosis, obviously inhibited EGF-induced
phosphorylation of PI3K/Akt/mTOR and ERK1/2, down-regulatedHGF/c-Met
activation in HCC827/ER cells. Axl is a receptor tyrosine kinase which strongly
associated with EMT phenotype. The M¡ME/G treatments could not re-
strainAxl expressions but remarkably reduced phospho-Axl levels and inhibited
EMT phenotype in HCC827/ER cells. Surprisingly, MTE alone caused promi-
nent p-Axl inhibition, along with up-regulated E-cadherin and decreased mes-
enchymal markers. The mouse tumors were remarkably restrained by the
M¡ME/G combinations, and it was signifıcant compared with each drug
alone (P0.05). Accordingly, cell apoptosis was extended, PCNA expression
and tumor angiogenesis (VEGF and CD105) were reduced and EMT phenotype
were regulated in tumor tissues. The p-Met and p-AXL were also considerably
suppressed by the combined treatments. The present data revealed that MTE
restored TKIs such as erlotinib and gefıtinib effıcacy in resistant NSCLC cells
with Axl activation and c-Met amplifıcation in vitro and in vivo. It suggests that
the addition ofMTEmay be a promising therapeutic strategy to overcome TKIs
resistance in NSCLC.
#1200 Novel strategy to overcome platinum resistance in uterine leiomy-
osarcoma; blocking ATP7B by copper ion. Mamoru Kakuda, Shinya Matsu-
zaki, Ruriko Nakae, Yusuke Tanaka, Eiji Kobayashi, Yutaka Ueda, Kiyoshi Yo-
shino, Tadashi Kimura. Osaka University, Suita-City, Japan.
Objective: Resistance to platinum drugs remains a signifıcant problem. Our
objective is to elucidate the role of ATP7B, a copper transporter which excretes
intracellular platinum giving drug resistance, in gynecologic malignancies and
to develop amethodwhich can overcome the platinum resistance.Methods: The
expression of ATP7B was evaluated in 3 uterine leiomyosarcoma (LMS) cell
lines (SK-LMS, SK-UT1 and SKN) and 26 clinical samples of LMS by immuno-
histochemical (IHC) staining, respectively. The IC50 values of cisplatin were
measured by modifıed MTT assay. Intracellular platinum accumulation was
determined by ICP-MS analysis in SK-LMS cells and ATP7B-stably suppressed
cells (SK-LMS-7B cells), which transfected the pRS ATP7B shRNA vector. To
analyze in vivo platinum sensitivity, SK-LMS and SK-LMS-7B cells were subcu-
taneously injected into nudemice. Cisplatin (3mg/kg) or PBS was administered
i.p. to xenograftedmice twice weekly for 28 days. Further, we attempted to show
the improvement of platinum sensitivity by using premedication for CuSO4
before cisplatin treatment in vitro and in vivo model. Results: Expression of
ATP7Bwas observed in all 3 LMS cell lines. In clinical samples, ATP7Bwas over
expressed in 14 of 26 (53.8%) cases. In drug resistance analysis, signifıcantly
lower IC50 values of cisplatin were observed in SK-LMS-7B cells (4.3M, p 
0.01) compared with SK-LMS cells (17M) indicating knockdown of ATP7B
improved platinum sensitivity. Also, signifıcantly higher platinum accumula-
tion was detected in SK-LMS-7B cells (7.2ng/dish, p  0.01) compared with
SK-LMS cells (52ng/dish). In in vivo analyses, a signifıcantly higher anti-tumor
effect of cisplatinwas observed in SK-LMS-7B-xenograftedmice comparedwith
SK-LMS-xenografted mice (56	27 g vs 214	68 g, p0.05). Pretreatment
with CuSO4 (15M) before cisplatin treatment for SK-LMS cells signifıcantly
reduced IC50-values (17 M to 3.9 M, p0.05). In addition, an elevated intra-
cellular platinum accumulation was observed in cells from pretreatment group
(15.0 to 68.4 ng/dish, p0.05). A signifıcant improvement of platinum sensitiv-
ity was observed in the premedication group (CuSO4 premedication group;
65	40g vs no pretreatment group; 230	60g, p0.05). Conclusion: ATP7B
contributes platinum resistance in LMS. Presumably, ATB7B preferentially ex-
crete copper ion thereby platinum can be accumulate in cells. Thus, pretreat-
mentwithCuO4 effectively improvedplatinumsensitivity in vitro and in vivo by
blocking ATP7B.
#1201 Disrupted endoplasmic reticulum-mitochondria contacts promote
multidrug resistance. Jorida Coku,1 Madison C. Pedrotty,1 David M. Booth,2
Sharon Kim,1 Annette Vu,1 C. Patrick Reynolds,3 György Hajnóczky,2 Michael
D. Hogarty1. 1University of Pennsylvania, Philadelphia, PA; 2Thomas Jefferson
University, Philadelphia, PA; 3Texas Tech University Health Sciences Center,
Lubbock, TX.
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Background: Most high-risk neuroblastoma patients succumb to lethal ther-
apy resistant disease acquired during the course of intensive multimodality
treatment. This acquired therapy resistance is largely attributed to insensitivity
to drug-induced apoptosis, however the exact mechanisms remain unknown.
Apart from integrating death signals, mitochondria (mito) interact with the
endoplasmic reticulum (ER) at close contact sites known as mitochondria asso-
ciated membranes (MAM) of the ER to regulate calcium and lipid transfer and
apoptotic sensitivity, a process often derailed in therapy resistant cancers. ER-
mito contact sites are juxtaposed by various tethering protein complexes that
include MFN2 and PACS2. Pathologic deregulation of these contact sites has
been implicated in the genesis of neurodegenerative and metabolic disorders.
Here, we show that disruption of bona fıde ER-mito tethering proteins in ther-
apy sensitive neuroblastomas induces apoptotic insensitivity and a drastic shift
towards a resistance-like phenotype. Methods and Results: Previously we
showed that isolated mitochondria from tumors at relapse resist induction of
mitochondrial apoptosis when primed with the terminal death effectors that are
downstream of therapeutic stress (tBid and Bim-BH3 peptide). We isolated mi-
tochondria from seven matched isogenic tumor pairs obtained at diagnosis
(DX) and relapse (REL) and quantifıed their apoptotic response to tBid and Bim
bymeasuring cytochromeC release by ELISA. Electronmicroscopy (EM) image
analyses of ER-mito contact sites revealed that REL tumors contain up to 70%
fewer ER-mito interactions than their matched DX tumors, as confırmed by IB
for organelle-specifıc proteins. Here, we recapitulate the post-therapy resistance
phenotype in DX therapy sensitive cells by shRNA silencing ofMFN2 or PACS2
and confırm their apoptotic resistance by BH3 profıling and drug response in
vitro. A 60% decrease in MFN2 protein in DX cells partially phenocopied the
resistance profıle of isogenic REL cells. The degree of apoptotic resistance cor-
related with the extent of protein knockdown forMFN2. Treatment of shMFN2
and shPACS2 DX cells with ABT-737, a BH3mimetic, or carboplatin, increased
their IC50s multiple-fold compared to control cells, paralleling their blunted
mitochondrial apoptotic response. Conclusions: Our data implicate ER-mito
contact sites as positive regulators of apoptosis, whose disruption may be nec-
essary for apoptotic attenuation in therapy resistant cancer cells to enable apo-
ptosis evasion and survival.Wepresent a potentialmechanism for broad therapy
resistance arising under therapeutic stress that selects for reduced communica-
tion of ER with mitochondria.
#1202 Targeting PIK3C3 to overcome drug resistance resulted from pro-
survival autophagy in cancer cells. CHUN-HAN CHEN. Taipei Medical Uni-
versity, Taipei, Taiwan.
Autophagy is an important cellular recyclingmechanism inwhich portions of
cytosol or organelles are sequestered into a double-membrane structure and
delivered to lysosome for degradation. PIK3C3 is the only class III PI3K, which
specifıcally generates phosphatidylinositol 3-phosphate (PtdIns3P). It in turn
recruits proteins containing FYVE or PX domains, thereby initiating various
complexes at the membranes of endosomes, phagosomes and autophagosomes.
Recently, several studies have shown that autophagy is upregulated in cancer
cells when exposing to chemotherapy and radiotherapy. Therefore, the rationale
of targeting autophagy addiction in cancer was proposed by combining au-
tophagy inhibitionwith agents that induce autophagy as a pro-survival response
to increase their therapeutic effıcacy.We stably knocked downPIK3C3 in cancer
cell lines and combined with clinical therapeutic agents reportedly induce pro-
survival autophagy. Cell viability was examined byMTT assay and combination
indexwas determined byCompusyn software. The autophagy fluxwas evaluated
by detecting protein levels of LC-3II and p62 through western blot analysis. The
results showed PIK3C3 knockdown synergistically sensitize the killing effects of
gefıtinib and gemcitabine in A549 cells and Panc1 cells, respectively. Both of
gefıtinib and gemcitabine increased autophagy flux, as evidence by the increase
of LC3-II and decrease of autophagy substrate, p62. However, the combination
of PIK3C3 knockdown and therapeutic agents increased both of the protein
levels of LC3-II and p62. These data suggest incomplete autophagy when the
function of PIK3C3was inhibited. The phenomenonwas confırmedby bombing
autophagy inducer and PIK3C3 inhibitors. Moreover, no appreciable apoptotic
cell death was observed. Taken together, our study revealed a potential strategy
by targeting PIK3C3 to overcome drug resistance associated with the pro-sur-
vival autophagy in cancer.
#1203 MiR-25 can sensitize cisplatin-resistant ovarian cancer cells to cis-
platin through enhancing cisplatin-mediated G2/M arrest. Huaping Chen,
Adam Steg, Zachary C. Dobbin, Ashwini A. Katre, Ronald D. Alvarez, Charles
N. Landen. University of Alabama at Birmingham, Birmingham, AL.
Recurrent chemoresistant ovarian cancer is responsible for the highmortality
rate in ovarian cancer patients. The molecular mechanisms underlying the
chemoresistant ovarian cancer are not fully understood. MicroRNAs (miRs)
expression has been recognized as one of the core regulators of gene expression
in recent years. However, whether miRs are involved in chemoresistance of
ovarian cancer has not been fully elucidated. Current study was performed to
interrogate the role of a number of critical miRs in chemoresistance of ovarian
cancer. These miRs include miR-21, miR-25, miR-128a, miR-141, miR-182,
miR-214, miR-29c, miR-200a, miR-506 which have been identifıed to play key
roles in ovarian cancer by previous study. The association between expression
pattern of these miRs and chemoresistance of ovarian cancer was revealed
through comparing their expression in chemosensitive versus -resistant ovarian
cancer cell lines or chemosensitive and treated recurrent chemoresistant patient
derived xerograph (PDX) samples via Taqman real-time quantitative PCR. In-
volvement of aberrant expressied miRs in chemoresistant ovarian cancer was
further validated through treating cells with antagomers or mimics for corre-
sponding miRs. Cell cycle analysis was performed to study the role of miRs in
cell cycle progression. We demonstrate that miR-21, miR-25, miR-128a, miR-
141, miR-182, miR-214 and miR-506 are upregulated, while miR-29c and miR-
200a are downregulated in chemoresistant ovarian cancer cells or PDX samples.
Inhibiting miR-21, miR-128a, miR-182 or overexpression of miR-101 does not
lead to signifıcant sensitization, suggesting the differential expression of these
miRs in chemoresistant cells does not contribute directly to ovarian cancer cell-
mediated chemoresistance. However, inhibiting miR-25 leads to a 3-fold de-
crease in the IC50 to cisplatin in A2780CP20 cells (from 1 M to 0.333 M),
indicating sensitization to chemotherapy. Furthermore, inhibiting miR-25 can
arrest more cells in G2/M phase by itself or in combination with cisplatin. Col-
lectively, these data indicate that miR-25 could be a potential therapeutic target
for treating cisplatin resistant ovarian cancer patients.
#1204 Enhanced effıcacy of selumetinib by pretreatment of 5-FU in pre-
clinical Ras/Raf-mutant colorectal cancer models. Hye Yeon Jang,1 Haeng
Jung Lee,2 Yeo Jin Nam,1 Won Dong Kim,3 Yong Ju Bae,3 Jin Hwang Jung,4
Seung Jin Lee,1 Dae Hyuk Moon5. 1Chungnam National University, Daejeon,
Republic of Korea; 2Asan Institute for Life Sciences, Asan Medical Center, Seoul,
Republic of Korea; 3Gachon University, Incheon, Republic of Korea; 4Asan Med-
ical Center, University of Ulsan, College of Medicine, Seoul, Republic of Korea;
5Asan Medical Center, University of Ulsan, Seoul, Republic of Korea.
Optimal strategy for the application ofMEK inhibitor as combination therapy
has not been established in Ras/Raf-mutant colorectal cancer (CRC). As we
preliminary observed that 5-FU-induced pharmacodynamic changes were re-
stored by ERK inhibition, we hypothesized that post-treatment of MEK inhibi-
tor would enhance antitumor activity of 5-FU. Treatment of 5-FU for 2 days
followed by selumetinib for another 2 days (FS schedule) exhibited synergism
for cell viability, whereas reverse or concomitant combination showed antago-
nism or inconsistent response, respectively, in 8 kinds of CRC cell lines includ-
ing BRAFV600E colo205, BRAFV600E RKO, or KRASG13D HCT8 cells. Combina-
tion as FS schedule persistently down-regulated the phosphorylation of ERKand
pS6 throughout treatment period, whereas selumininib alone or reverse combi-
nation transiently decreased within 24 hr. The cells treated as FS schedule ex-
hibited higher apoptosis and lower capacity of anchorage-independent cell
growth than the cells under single or reverse combination. Microarray analysis
revealed the distinct groups of genes underlying different effıcacy by schedule-
dependent treatment. Tumor growth in mice administered 5-FU at 10 mg/kg/
day for colo205 and at 30 mg/kg/day for HCT8 for 7 days followed by selu-
metinib at 10 mg/kg/day for colo205 and 25 mg/kg/day for HCT8 for another 7
days was signifıcantly retarded than that in mice treated with single agents. But
the combination in reverse sequence induced comparable tumor growth to sin-
gle agents. Decreased expression of Ki67 was observed in tumors from mice
treated as FS scheduling. Our results suggest that the schedule-dependent com-
bination of 5-FU and selumetinib may be benefıt in patients having CRC with
hyper-activation of Ras/RAF pathway.
#1205 Rubrofusarin and toralactone sensitize resistantMCF-7adr cell line
to paclitaxel via inhibitingP-glycoprotein efflux activity. SalwaD.Alqahtani,1
Hanan A. Assiri,1 Fahad A. Al-Abbasi,1 Ali M. El-Halawany,2 Ahmed M. Al-
Abd3. 1King Abdulaziz University, Jeddah, Saudi Arabia; 2Cairo University,
Cairo, Egypt; 3National Research Centre of Egypt, Giza, Egypt.
The use of anti-cancer adjuvant therapy is rationalized by potentiating the
effıcacy and/or protecting from major side effects of chemotherapeutics. Pacli-
taxel is an effective spindle toxin anticancer agent used for the treatment of
breast cancer. Rubrofusarin and toralactone are naturally occurring structurally
related naphthopyrones with potent antioxidant and hence chemoprotective
activity. The purpose of this study is to investigate the influence of rubrofusarin
and toralactone on the cytotoxic profıle of paclitaxel (PTX) against chemo-
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resistant breast cancer cell line (MCF-7adr) compared to parent MCF-7 cells.
MCF-7adr was prepared by continuous culturing of MCF-7 cells in media con-
taining subcytotoxic concentration of doxorubicin (IC10%) for two months du-
ration. Toralactone and rubrofusarin showedmoderate cytotoxic effects against
MCF-7 cells with IC50’s of 32.4	4.2 M and 13.9	6.1 M, respectively. Inter-
estingly, toralactone and rubrofusarin showed stronger cytotoxicity against
MCF-7adr cells with IC50’s of 7.3	0.7 M and 7.8	0.6 M, respectively. PTX
treatment was opposed by signifıcant resistance fromMCF-7adr cells compared
to parent MCF-7 cells having IC50’s of 4.9	0.9 M and 57.7	4.5 nM, respec-
tively. Combination of torolactone or rubrofusarin with PTX did not signifı-
cantly improve its cytotoxicity against MCF-7; IC50’s were 24.2	2.2 nM and
69.7	6.6 nM, respectively compared to 57.7	4.5 nM for PTX alone. Surpris-
ingly, combination with either torolactone or rubrofusarin abolished the resis-
tance ofMCF-7adr to PTX resulting in IC50’s of 3.4	0.2 nM and 4.9	0.5 6 nM,
respectively compared to 4.9	0.9 M for PTX alone. Using flowcytometric
analysis, rubrofusarin and toralactone increased median intracellular fluores-
cence signal count of rhodamine dye (non-cytotoxic P-gp substrate) within
MCF-7adr from 1794.7	21.5 to 2003.3	12.5 and 2113	10.5 cellular events,
respectively. Using purifıed membrane bound humanized recombinant P-gp
molecules; it was found that both rubrofusarin and toralactone might be inhib-
iting P-gp efflux activity via dual interaction with both P-gp ATPase enzyme
subunit and P-gp active binding site. In both MCF-7 and MCF-7adr cells, PTX
exerted signifıcant cell cycle block at G2/M-phase with signifıcant increase in the
pre-G dead cell fraction from 3.4	0.9% to 23.6	2.1% and from 1.4	0.6% to
17.2	3.2%, respectively. Neither rubrofusarin nor toralactone exerted any sig-
nifıcant influence for PTX induced cell cycle interruption in both normal
(MCF-7) and resistant (MCF-7adr) cell lines. In conclusion, rubrofusarin and
toralactone can enhance the cytotoxic profıle of P-gp substrates, such as PTX, via
inhibiting P-gp efflux activity and enhancing the intracellular entrapment of
P-gp substrates.
#1206 miR-205 replenishment in prostate cancer cells: A novel nanopar-
ticle approach. Prashanth K. Nagesh, Pallabita Chowdhury, Vijayakumar N.
Boya, Vivek K. Kashyap, Sheema Khan, Bilal B. Hafeez, Nadeem Zafar, Stephen
W. Behrman, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu.University
of Tennessee Health Science Center, Memphis, TN.
Introduction Prostate cancer (PrCa) is the most common male malignancy
among men in the United States. Recent studies suggest that low expression of
miR-205 is seen in PrCa cell lines and tumors in comparison to normal prostatic
epithelial cells. A numer of studies have shown that restoration of miR-205 in
PrCa cells resulted in supression of cell growth, epithelial-to-mesenchymal tran-
sition, and chemosensitization. However, due to the poor pharmacological ki-
netics and low in vivo stability of miR-205, serious limitations are being experi-
enced at the clinical level. Therefore, we have chosen a novel nanoparticle-based
approach to deliver miR-205, for improved therapeutic benefıts in PrCa. Meth-
ods A novel miR-205 nanoparticle formulation (named miR-MPG) was gener-
ated which is composed of an iron oxide core layered with polyethylene imine
(PEI), and NHS-PEG-NHS (PEG) polymer. The miR-205 withholding and re-
lease characteristic ofmiR-PEGwere examined through fluorescence quenching
and agarose gel electrophoresis. Hemocompatibility of this formulation was
examined using a hemolysis assay. Cellular uptake of miR-MPG formulation
was evaluated using flow cytometry and confocal studies. Further, therapeutic
and chemosensitization activity of miR-205 were assessed using cell-culture
based assays. Molecular effects associated with the PrCa cells growth inhibiton
were evaluated through protein profıling and qRT-PCR analyses. Results and
Dissusion miR-MPG formulation exhibited optimal particle size and zeta po-
tential, which are suitable for cancer therapeutics. Agarose gel electrophoresis
binding studies suggested 5 g of nanoparticle formulation is optimum to hold
1 g of miR-205 mimic. Release of miR-205 from miR-MPG was determined
with respect to concentration of anionic molecules and in a time-dependent
manner. We observed no hemolysis during miR-MPG interaction with the red
blood cells indicating its hemocompatibility. In addition, miR-MPG particles
exhibited superior internalization and endosmal escape in PrCa cells. This for-
mulation displayed enhanced sensitization of PrCa cells to docetaxel. Addition-
ally, it induced the expression of apoptotic proteins (Bax, Bim, cleaved PARP,
and caspase 3), and downregulated the anti-apoptotic proteins (Bcl-2 and sur-
vivin). Moreover, the expression of the chemoresistance-associated proteins
(PSMA andMDR1) was profoundly inhibited in cells treated with miR-MPG in
the presence of docetaxel. Further dataset of qRT-PCR studies showed induced
expression of the miR-205 and affected the expression of its downstream genes.
These results suggest that miR-MPG formulation may serve as an ideal delivery
vehicle to deliver miR-205. Conclusion Results from this study suggests that
successful delivery of miR-205 through miR-MPG nanoparticles can induce
sensitization potential for docetaxel treatment. This novel therapeutic modality
might be effective for PrCa patients undergoing chemotherapy.
#1207 SNS-062 demonstrates effıcacy in chronic lymphocytic leukemia in
vitro and inhibits C481S mutated Bruton tyrosine kinase. Catherine A. Fa-
bian,1 Sean D. Reiff,1 Daphne Guinn,2 Linda Neuman,3 Judith A. Fox,3 Wendy
Wilson,3 John C. Byrd,1 Jennifer A.Woyach,1 Amy J. Johnson1. 1The Ohio State
University, Columbus, OH; 2Georgetown University, Washington, DC; 3Sunesis
Pharmaceuticals, South San Francisco, CA.
Introduction: In order to address the issue of acquired resistance to ibrutinib,
we sought to characterize the Bruton agammaglobulinemia tyrosine kinase
(BTK) inhibitor SNS-062 in preclinicalmodels of chronic lymphocytic leukemia
(CLL). Methods: Primary CLL B cells were isolated from the whole blood of
consented patients by fıcoll density centrifugation and Rosette-Sep negative se-
lection. Annexin V and propidium iodide flow cytometry was used to measure
patient CLL cell viability and 7-AAD was used to measure viability in stromal
co-culture. CD40 and CD86 expression was evaluated via flow cytometry sub-
sequent to sustained 3.2uM CpG stimulation. BCR signaling in primary CLL
cells was investigated by immunoblot following 1 hour treatment and following
1 hour or 24 hours of incubation with SNS-062 in XLA cell lines. ITK inhibition
was investigated via immunoblot after stimulation with anti-CD3 and anti-
CD28 and incubation with SNS-062 for 1 hour. SNS-062 was used at a concen-
tration of 1uM in preclinical studies unless otherwise noted. Measurement of
kinase activity in human recombinantWTBTKorC481SBTKwas performed in
a FRETkinase assay. Results: Immunoblots of BTK andERKphosphorylation of
XLA cells transfected withWT or C481S BTK demonstrated that SNS-062 inhi-
bition is comparable to that of ibrutinib in WT BTK and greater than that of
ibrutinib inC481SBTK.Using a recombinant kinase assay, we found the IC50 of
SNS-062 againstWT BTK to be 4.6nM and C481S BTK to be 1.1nM, suggesting
that SNS-062 retains activity against the mutated BTK variant. Additionally,
SNS-062 was found to be six times more potent than ibrutinib and greater than
640 timesmore potent than acalabrutinib against C481S BTK. SNS-062 demon-
strates dose-dependent inhibition of BTK in primary patient CLL cells compa-
rable to ibrutinib via immunoblot for BTK phosphorylation. The viability of
primary patient cells treated with 0.1uM, 1.0uM, and 10.0uM SNS-062 for 48
hours was measured to be 96.7%, 96.1%, and 88.1%, respectively, that of the
untreated condition. At 48 hours, SNS-062 decreased viability of primary CLL
cells in the presence of HS5 stromal protection by 5.5%. SNS-062 was found to
decrease CpG induced CD40 and CD86 expression by 8.7% and 15.7%, respec-
tively. Using an in vitro kinase assay, SNS-062 inhibited ITK with an IC50 value
of 24nM. An immunoblot of anti-CD3/CD28 stimulated Jurkat cells revealed
that SNS-062 decreased the phosphorylation of ERK, implying inhibition of
ITK. Conclusion: Unlike ibrutinib, SNS-062 inhibits BTK signaling in the pres-
ence of the C481S mutation and may address acquired resistance to covalent
BTK inhibitors. SNS-062 decreases B cell activationmarkers, viability, and stro-
mal cell protection in primary patient CLL cells and was shown to inhibit ITK,
suggesting support of T cell mediated antitumor activities. These data support
further investigation of this molecule and advancement into clinical trials.
#1208 Analysis of the combinatorial antiproliferative effect of pan RAF
inhibitor AZ-628 and MEK1-inhibitor AZD-6244 on a large panel of tumor
cell lines. Alokta Chakrabarti, Daniel Feger, Sarah Umber, Orysya Stus, Mari-
anne Birkle, Oliver Siedentopf, Jan E. Ehlert. ProQinase GmbH, Freiburg, Ger-
many.
Cancer is a highly complex, multigenic disease with tumor cells underlying
constant transition. Single drug treatments against specifıc targets frequently
result in only partial success because mutations and redundant pathways cause
drug resistance. Therefore, drug combinations that effect different synergisti-
cally acting targets in the cancer cell in parallel have become a promising strategy
to improve the success inmany fıelds of cancer therapy.One example for such an
approach is the co-treatment of B-Raf driven tumors with Raf andMEK1 inhib-
itors. In our study, we determined the combinatorial effect of the pan-Raf inhib-
itor AZ-628 and the MEK1 inhibitor AZD-6244 on the viability of a large panel
of more than 100 tumor cell lines. Whittaker et al. (Mol.CancerTher, 2015)
could already show that this drug combination has a signifıcant synergistic effect
in several melanoma and colon cancer cell lines. The authors showed evidence
that synergistic activity was correlated with enhanced mutation-triggered RAS/
RAF/MAPK signalingwith a special role forC-Raf in resistance due to a negative
feedback mechanism. We here applied the combination of AZD-6244 and AZ-
628 in a broad checkerboard pattern to a multitude of cell lines from other
entities beyond melanoma and colorectal cancer. Based on these results we cor-
related the observed synergistic and non-synergistic effects with gene expression
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profıles of these cell lines and analyzed the requirement of a MAPK activating
signaling. Our approach revealed that synergistic activity is not confıned to
melanoma and colon cancer but is observed in tumors from other entities as
well. This observation may expand the usefulness of MEK/Raf inhibitor co-
treatment to a larger panel of cancer types.
#1209 FGFR inhibition re-sensitizesBRAF/MEKdual resistant cells to the
BRAF/MEK inhibitor combination. Victoria E. Wang,1 Jeffrey Settleman,2
FrankMcCormic1. 1UCSF, San Francisco, CA; 2Genentech, South San Francisco,
CA.
The BRAF-MEK pathway is frequently mutated in humanmelanoma. Inhib-
itors of these kinases have proven to prolong survival in melanoma patients.
However, clinical benefıt is relatively short-lived due to acquired drug resis-
tance. To explore mechanisms of resistance in melanoma cells treated with dual
BRAF and MEK inhibitors, A375, a cell line harboring the BRAF V600E muta-
tion, was treated with escalating doses of vemurafenib and cobimetinib to gen-
erate a cellular population resistant to combination therapy. These cells display
a reversible resistance phenotype. Upon initial treatment of the drug combina-
tion, upregulation of pSTAT3 is observed but the cells lose dependency on the
pSTAT3 pathway upon prolonged drug treatment. A pharmacological synthetic
lethal screen was performed and the FGFR inhibitor class re-sensitizes the cells
to BRAF and MEK inhibition through inhibitions of pERK. The dual resistant
cells also displayed hyperactivation of the PI3K-AKT pathway. Interrogation of
patient samples confırmed these fındings. These fındings provides a biological
rationale for a polytherapy strategy using a FGFR inhibitor in patients with
resistance to dual BRAF and MEK inhibition.!–EndFragment–
#1210 Hederagenin overcomes the cisplatin resistance of head and neck
cancer by targeting the antioxidant defense mechanisms. Daiha Shin,1 Eun
Hye Kim,1 Hyejin Jang,1 Jaewang Lee,1 Ji Won Kim,1 Jae Ryung Lee,1 Minsu
Kwon,2 Seungho Baek,3 Jong-Lyel Roh1. 1Asan Medical Center, Univ. of Ulsan
College of Medicine, Seoul, Republic of Korea; 2Gyeongsang National University
School ofMedicine andGyeongsang National University Hospital, Jinju, Republic
of Korea; 3College of Korean Medicine, Woosuk University, Wanju, Jeonbuk,
Republic of Korea.
Background: Cisplatin is a fırst-line chemotherapeutic agent for head and
neck cancer (HNC). Acquired resistance to cisplatin is themost common reason
for the failure of cisplatin chemotherapy. Hederagenin is extracted from the
leaves of Cyclocarya paliurus, also known as sweet tea, which is one of the most
popular teas utilized in traditional Chinese medicine. There is accumulating
evidence it exhibited signifıcant cytotoxicity against several types of cancers,
however, which has been rarely tested in HNC cells. Herein, we examined the
potential utility of hederagenin for overcoming cisplatin resistance inHNC cells
and further clarifıed its molecularmechanisms of action.Methods: Parental and
cisplatin-resistant HNC cells, and Nrf2 or SLC7A11 gene overexpressed HNC
cell lines and other humanHNC cells were used. The cells were used to examine
the effects of hederagenin treatment in HNC cell lines by measuring cell viabil-
ity, cell cycle, cell death, reactive oxygen species (ROS) production, glutathione
level, mitochondrial membrane potential (m), and protein expression. The
anti-tumor effect of hederagenin in mouse tumor xenograft models was also
tested. Results: Hederagenin induced cell death in both cisplatin-sensitive and
-resistant HNC cells. Hederagenin treatment resulted in effective death of cis-
platin-resistant HNC cells in a form of apoptotic cell death with the m
change. Hederagenin inhibited Nrf2 and SLC7A11 resulting in an increased
ROS accumulation in HNC cells, of which effects were reversed by the pretreat-
ment of antioxidant trolox. In addition, hederagenin caused the apoptosis effec-
tively induced by targeting the antioxidant defense mechanisms in HNC cells.
Subsequently, hederagenin activated signaling pathways of cell death involving
caspase-3, PUMA, and PARP in the cells. The growth inhibitory effects of he-
dragenin were also confırmed in the tumor xenograft model implanted with
cisplatin-resistant HNC cells. Conclusions: Our data suggests that hederagenin
can overcome the resistance of cisplatin in resistant HNC cells via targeting
antioxidant systems.
#1211 Lurbinectedin reverses platinum dependent IRF1 overexpression
and nuclear localization, partially responsible for resistance to platinum
drugs in ovarian cancer. Gema Santamaria Nuñez, Maria Jose Guillén, Juan F.
Martínez-Leal, Pablo Avilés, Carlos M. Galmarini. PharmaMar S.A., Colmenar
Viejo, Spain.
Lurbinectedin (PM1183) is a new synthetic compound from the tetrahy-
droisoquinoline family, which has demonstrated a strong antiproliferative ac-
tivity against a panel of human tumor models in preclinical assays and is cur-
rently being evaluated in phase III clinical trials in platinum-resistant ovarian
cancer and small cell lung cancer. Lurbinectedin binds to DNA, inhibits trans-
activated transcription, induces the degradation of elongating RNA Pol II and
fools nucleotide excision repair to produce dsDNA breaks that need to be re-
paired mainly by homologous recombination (HR)1,2. Nearly 70% of patients
diagnosed with ovarian cancer are in advanced stage, and the vast majority of
them will eventually relapse after a primary cytoreductive surgery and several
cycles of standard adjuvant chemotherapy including a platinum drug and a
taxane. After a period of treatment with platinum drugs, patients will fınally
develop resistance, usuallymediated bymechanisms such as drug detoxifıcation
or efflux and enhanced DNA repair. IRF-1 transcription factor expression has
been shown to be up-regulated by cisplatin (CDDP) in ovarian cancer cells and
might be limiting the response to the drug, likely by inhibiting cell proliferation3.
Here we took advantage of the A2780/A2780cis human ovarian cancer cell lines,
the second being a cisplatin resistant derivative, to investigate the role of IRF1 in
the response of human ovarian cancer cells to cisplatin and lurbinectedin.
A2780cis cells are, indeed, more resistant to cisplatin that their parental cell line
but they do not differ in their resistance to lurbinectedin. Basal IRF-1 protein
levels were actually higher in A2780cis cells than in their parental cell line,
contributing to their resistance to cisplatin. Furthermore, cisplatin treatment
induced the overexpression andnuclear localization of IRF-1 both, inA2780 and
A2780cis cell lines. Contrarily, lurbinectedin did not induce the overexpression
of IRF-1 neither in A2780 nor in A2780cis, explaining why this latter cell line is
not resistant to the compound. Furthermore, lurbinectedin co-treatment with
cisplatin reduced the expression of IRF-1 in A2780 and, more importantly, in
A2780cis cells, explaining the synergism the combination has on these tumor
cell lines. Thus, lurbinectedin not only did not activate the samemechanisms of
resistance as cisplatin in ovarian cancer cells, but even reversed the resistance of
these resistant cells to platinum drugs. 1 Santamaría Nuñez et al, 2016. Mol
Cancer Ther 15(10):2399-2412 2 Romano et al, 2013. Int J Cancer. 2013 Nov;
133(9):2024-33 3 Pavan et al, 2013. Eur J Cancer 49(4):964-973
#1212 Co-targeting epidermal growth factor receptor (EGFR) and ana-
plastic lymphoma kinase overcomes EGFR inhibitor resistance in head and
neck squamous cell carcinoma patient-derived models. Xiaoming Ouyang,
Ashley Barling, Aletha Lesch, Jeffrey Tyner, Sophia Jeng, Christina Zheng, Sara
A. Courtneidge, Shannon McWeeney, Molly Kulesz-Martin. Oregon Health &
Science University, Portland, OR.
Background: HNSCC is the sixth most common cancer worldwide. EGFR is
overexpressed in up to 90% of HNSCC and associated with poor outcome. An
EGFRmonoclonal antibody is the only approvedmolecular targeted therapy for
HNSCC, however, resistance eventually occurs in all patients. Methods: Func-
tional screens including a small-molecule kinase inhibitor panel and an RNAi
screen panel were used to identify agents that synergized with EGFR inhibitors
in reducing cell viability in HNSCC patient-derived tumor cells. Effective com-
bination therapies were validated in scale-up experiments in 2D and 3D, and
their true targets were evaluated using siRNAs to rule out off-target effects of the
drugs. Cell viability, cell number and cell colony formation ability were tested
upon siRNA treatment. qRT-PCR and immunofluorescent staining was used to
test ALK expression in tumor cells before and after anti-EGFR treatment. Re-
sults: Two ALK inhibitors on the drug screen panel showed synergistic effects
with EGFR inhibitors in 6/8 HNSCC patients’ tumor cells, despite ineffective-
ness of single drug. Scale-up dose-response experiments confırmed patient cell
sensitivity to 4 different ALK inhibitors in combinationwith the EGFR inhibitor
Gefıtinib. siRNA targeting ALK synergized with Gefıtinib in reducing cell via-
bility in the patient cells that responded to EGFR/ALK inhibitor combinations,
indicating specifıcity to ALK. Scale-up RNAi experiments confırmed synergy
between siRNAs targetingALKandEGFR in reducing cell viability, cell number,
and colony formation ability. Inhibition of EGFR by siRNA or Gefıtinib each
increased ALK expression at the mRNA level and protein level, suggesting in-
duction of ALK as a novel mechanism of EGFR inhibitor resistance in HNSCC.
Conclusion: We identifıed EGFR/ALK inhibitor combinations as a potential
strategy for treating EGFR inhibitor resistant HNSCC.
#1213 Nuclear export ofE2F7 in squamous cell carcinoma in anactionable
event that reverses resistance to anthracyclines. Alba Natalia Saenz Ponce,1
Yosef Landesman,2 Trinayan Kashyap,2 Alexander Guminski,3 Orla Gannon,1
Nicholas Saunders1. 1University of Queensland, Brisbane, Australia; 2Karyop-
harm Therapeutics, Newton, MA; 3Royal North Shore Hospital, NSW, Australia.
Objectives and Background: Squamous cell carcinoma (SCC) of the skin or head
and neck region is a major cause of cancer death in the western world. Patient with
advanced SCC have few therapeutic options and SCC remains resistant to current
treatments. Overcoming drug resistance in SCCwould signifıcantly change patient
outcomes and treatment strategies. We previously showed that SCCs express the
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activating transcription factor E2F1 and the inhibitory transcription factor E2F7,
which are mutually antagonistic. We showed that E2F1/7 controlled the sensitivity
to anthracyclines in SCCcells via E2F-dependent regulationof sphingosine kinase 1
(Sphk1) and its product sphingosine-1-phosphate (S1P). In addition, we showed
that S1P treatment of cells induces profound anthracycline resistance. However, it
was consistently diffıcult to reconcile the mutual overexpression of E2F1 and E2F7
with a seemingly pro-E2F1 environmentwithin the SCCcells (i.e. pro-proliferation,
differentiation-suppressive and pro-survival). In this study we have examined the
role of nuclear export pathways in determining nuclear E2F activation in SCC.
Methods:We have interrogated human tissuemicroarrays of normal stratifıed epi-
thelia and SCC of the skin or head and neck tumours from patient samples. To
validateour invivo fındingsweusedasuiteofSCCcell linesandexamine thenuclear
andcytoplasmic localizationofE2F1andE2F7by immunofluorescenceandwestern
blotting.We deployed inhibitors of the Exportin 1 (XPO1) pathway and have used
siRNA against XPO1 to confırm a functional role of XPO1 in the nuclear export of
E2F7.We have used inhibitors of XPO1 in vitro and in vivo to examine their ability
to enhance the cytotoxic responses to anthracyclines. Results & Conclusions: We
report that E2F7 is selectively localized to the cytoplasm of SCC cells and tumors
but is exclusively nuclear in normal cells and tissues. In contrast, E2F1 is almost
exclusively localized to the nucleus in normal and SCC cells and tissues. The
localization of E2F7 to the cytoplasm could be reversed using inhibitors of the
nuclear export protein XPO1 and siRNA against XPO1. XPO1-dependent nu-
clear export of E2F7 shows that this pathway is selectively activated in SCC. The
inactivation of XPO1 is now possible using selinexor, a Selective Inhibitor of
Nuclear Export (SINE) compound currently in advanced clinical trials to treat
solid and hematologicalmalignancies.We show that treatment of SCC cells with
selinexor reverses anthracycline resistance. Signifıcantly, we show that a combi-
nation of selinexor doxorubicin in vivo induces profound anticancer activity.
Signifıcance: Our studies show that i) E2F7 is selectively mislocalized in SCC, ii)
E2F7 nuclear export is XPO1-dependent, iii) dysregulation of XPO1 causes de-
repression of S1P-mediated anthracycline resistance and iv) anthracycline resis-
tance is reversed with inhibitors of XPO1 in vivo.
#1214 The polymeric fluoropyrimidine F10 is effective towards cell and
organoid models of 5-FU-resistant colorectal cancer. William H. Gmeiner,1
Anthony Dominijanni,1 Olcay Boyacioglu,2 Steven Forsyth,1 Aleks Skardal,1
Boris Pasche1. 1Wake Forest Univ. School ofMedicine,Winston-Salem, NC; 2Ad-
nan Menderes University, Aydin, Turkey.
Background: Fluoropyrimidine drugs (FPs, e.g. 5-fluorouracil (5-FU)) con-
stitute the backbone of most chemotherapy regimens for treating locally-ad-
vanced and metastatic colon cancer (e.g. FOLFOX, FOLFIRI, FOLFOXIRI).
While current FPs improve survival and are the preferred drugs for most colo-
rectal (CRC) cases, drug resistance is a serious problem. One of the most prev-
alent causes of 5-FU resistance is mutation in TP53 which occur in more than
one-third of stage III CRC tumors. 5-FU requires wtp53 for initiation of apo-
ptosis and CRC cells with mtp53 are markedly less sensitive to 5-FU. Methods:
To test if F10 induced p53-independent apoptosis in CRC cells, we obtained
p53-/- and p53/ HCT-116 cells from Professor Vogelstein (Johns Hopkins)
and evaluated drug-response in cell-based, organoid, and xenograftmodels. Cell
viability and apoptosis were assessed using Cell-Titer Glo and Caspase Glo as-
says (Promega). Cell-cycle distributionwas evaluated by flow cytometry analysis
of propidium iodide stained cells. Thymidylate synthase (TS) activity was as-
sessed using a 3H-release assay andTopoisomerase 1 cleavage complex (Top1cc)
formation was assessed using an in vivo complex of enzyme (ICE) bioassay. Cell
division was quantifıed by time-lapse video microscopy. Organoids were devel-
oped by bioprinting cells on a biogel matrix to produce a center comprised of
tumor cells encompassed by stromal cells. Drug effects in each cell type were
evaluated using a “Live-Dead” assay. Drug effects in vivo were evaluated using
xenograft models. Results: p53-/- HCT-116 cells were resistant to 5-FU, but
sensitive to F10 and underwent p53-independent apoptosis. While F10 is more
effıcient than 5-FU at inhibiting TS, it uniquely supported continued DNA syn-
thesis, mitosis, and cell division in p53-null cells while 5-FU-treated cells under-
went S-phase arrest under thymineless conditions. Following cell division, F10
induced high levels of Top1cc in daughter cells causing massive DNA damage.
Using a DT40 knockout system we determined that Tdp1 and PARP-1 were
important for F10-induced DNA damage. Organoid models demonstrated se-
lective killing of malignant cells relative to stroma by F10, but not 5-FU. Xeno-
graft models are in progress. Conclusions: F10 is much more potent than 5-FU
and induces p53-independent apoptosis. F10 differs from 5-FU in supporting
continued DNA synthesis under thymineless conditions leading to Top1-medi-
ated DNA damage, Top1 depletion, genomic instability and activation of the
extrinsic apoptotic pathway.
#1215 Apigenin overcomes drug resistance by blocking signal transducer
and activator of transcription 3 (STAT3) signaling in breast cancer. Hye-
Sook Seo,1 Jin Mo Ku,1 Se Hyang Hong,1 Hyeong Sim Choi,1 Jong-Kyu Woo,2
Bo-Hyoung Jang,1 Yong Cheol Shin,1 Seong-Gyu Ko1. 1Kyung Hee University,
Seoul, Republic of Korea; 2Seoul National University, Seoul, Republic of Korea.
Drug resistance in chemotherapy is a major obstacle for successful treatment
of cancer.Drug resistance is caused by various reasons including the overexpres-
sion of P-glycoprotein (P-gp, MDR1). Development of new useful compound
which overcomes drug resistance is urgent. Apigenin, a dietary flavonoid, is
reported as an anti-cancer drug in vivo and in vitro. In the present study, we
investigated whether apigenin is able to reverse drug resistance using adriamy-
cin-resistant breast cancer cells (MCF-7/ADR) and xenograft mouse model. As
a result, apigenin signifıcantly decreased cell growth and colony formation in
MCF-7/ADR and its parental MCF-7 cells. This growth inhibition was related
with accumulation of subG0/G1 apoptotic population and increase of apoptosis
cell number. Apigenin reduced the mRNA expressions of multi-drug resistance
1 (MDR1) and multi-drug resistance associated proteins (MRPs) in MCF-7/
ADR cells. Apigenin also down-regulated the expression of P-gp. Apigenin re-
versed drug efflux from MCF-7/ADR cells resulting in Rho123 accumulation.
Inhibition of drug resistance by apigenin is related with suppression of STAT3
signaling pathway. Apigenin decreased STAT-3 activation (p-STAT3) and its
nuclear translocation, and inhibited the secretion of VEGF and MMP-9 which
are STAT3 target genes. STAT3 inhibitor, JAK inhibitor I and HIF-1 inhibitor
decreased cell growth inMCF-7 andMCF-7/ADR cells. In conclusion, apigenin
overcomes drug resistance, and this study advances human health.
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#1216 Overcoming cisplatin resistance through the combination treat-
ment with CK2 inhibitor, CX-4945, in gastric cancer. Hyun Myong Kim,1
Inhye Jeong,1 Kyu Hyun Park,2 Tae Soo Kim,2 Woo Sun Kwon,2 Hei-Cheul
Jeung,2 Minkyu Jung,3 Sun Young Rha4. 1Song-dang Institute for Cancer Re-
search, Brain Korea 21 PLUS Project for Medical Science, Yonsei University Col-
lege of Medicine, Seoul, Republic of Korea; 2Song-dang Institute for Cancer Re-
search, Yonsei University College of Medicine, Seoul, Republic of Korea; 3Song-
dang Institute for Cancer Research, Division of Medical Oncology, Department of
InternalMedicine, Yonsei CancerCenter, YonseiUniversityHealth System, Seoul,
Republic of Korea; 4Song-dang Institute for Cancer Research, Brain Korea 21
PLUS Project for Medical Science, Department of Internal Medicine, Yonsei Uni-
versity College of Medicine, Seoul, Republic of Korea.
Platinum-based antineoplastic drugs are chemotherapeutic agents to usually
treat gastric cancer (GC) include cisplatin. However, the majority of cancer
patients will eventually relapse with cisplatin-resistant disease. Especially, in-
creased DNA repair is drug targetable mechanism and useful in the treatment
strategy of cisplatin-resistant cancer. Casein kinase 2 (CK2) has critical role of
multiple cellular processes with DNA repair. For this reason, research for CK2
expression correlated with DNA repair mechanism is important in gastric can-
cer. Combination of cisplatin andCK2 inhibitor (CX-4945, also known as Silmi-
tasertib, Senhwa Biosciences, USA) may improve cisplatin-induced DNA dam-
age for GC treatment. In this study, we screened sensitivity of cisplatin and
CX-4945 in 49 GC cell lines byMTT assay. Formolecular profıling, we analyzed
variants and gene expression using whole exome sequencing and RNA sequenc-
ing. RNA and protein expression of CK2 subunits (/’) using real-time RT-
PCR andWestern blot. Also, activity of CK2was measured by ELISA. Combi-
nation treatment performed different schedules including concurrent and
sequential. Synergistic effectwas analyzed byBliss Independencemodel. AsCK2
profıling, CK2’ mRNA expression was a tendency to correlated with CX-4945
sensitivity(p0.0504). Moreover, CK2’ protein expression was a correlated
with CX-4945 sensitivity(p0.0252). Other molecular profıling did not reveal
any clear correlations. Twenty one (Group1: cisplatin extremely resistant and
CK2 high, Group2: cisplatin intermediate resistant regardless of CK2 expres-
sion) cell lines were performed combination treatment. Both YCC-21 and
YCC-28 cell lines show synergistic effect (20% and 22%, respectively) in
concurrent schedule. Only MKN-74 cell line show synergistic effect (11%) in
Pre-addition. The 4 cell lines (YCC-18, YCC-38, SNU-1 and -216) were show
synergistic effect (10%,37%,11% and19%, respectively) in Post-addi-
tion. In conclusion, early inhibition of CK2 shows synergistic effect in group 1,
because CK2 is high expression. In group 2, late inhibition of CK2 demonstrated
synergistic effect. It means CK2-related DNA repair is up-regulating for repair
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to cisplatin-induced DNA damage. Personalized the treatment schedule for in-
hibit CK2-induced DNA repair is a new strategy to restore cisplatin resistant in
GC.
#1217 Blockade of Aurora kinase A synergizes with platinum and radia-
tion in non-small cell lung cancer cells. Huijie Liu,1 Dongwei Zhang,2 Alain
Borczuk,3 Vincent Chau,4 Roman Perez-Soler,5 Balazs Halmos,5 Haiying
Cheng5. 1Albert Einstein College of Medicine, Bronx, NY; 2Columbia University
Medical Center, New York, NY; 3Weill Cornell Medical College, New York, NY;
4Montefıore Medical Center, Bronx, NY; 5Albert Einstein College of Medicine
/Montefıore Medical Center, Bronx, NY.
Background: Most patients with advanced lung cancer will receive platinum-
based therapy during their treatment course despite limited clinical benefıts.
Thus, strategies to improve platinum-based therapy continue to be needed.
Through a functional genetic screen, we have identifıed Aurora kinase A as a
potentially actionable candidate that canmodulate the activity of platinum com-
pounds. Aurora A is a serine/threonine kinase and a key regulator of themitotic
process. Through its mitotic and non-mitotic roles, the aberrant activation of
Aurora A can lead to oncogenic transformation and has emerged as a promising
therapeutic target in cancer. METHODS: High-throughput RNAi screen was
used to identify potential candidates for cisplatin resistance. Cell proliferation/
viability was determined byMTS assays and colony formation assays. Immuno-
histochemistry was performed to determine the overexpression of Aurora A in
specimens from lung cancer patients. Western blot was used to explore the cell
signaling mechanisms in cisplatin, radiation, and/or MLN8237 (alisertib)
treated NSCLC cell lines. -Galactosidase staining was performed to determine
the senescence following cisplatin and/or MLN8237 treatment in NSCLC cell
lines. RESULTS: Aurora Kinase A is widely expressed in lung cancer specimens.
The expression of AuroraA is upregulated following treatment with Cisplatin in
NSCLC cells, such as PC9, A549, H1703, and H460. Inhibition of Aurora A
activity with either siRNA-mediated knockdown or pharmacological blockade
(MLN8237) signifıcantly improved sensitivities to cisplatin and ionizing radia-
tion, both of which cause DNA damage and cell death. On the other hand,
inhibition of Aurora A activity by itself was associated with reduced cell prolif-
eration and survival of NSCLC cell lines. Moreover, co-administration with
Cisplatin and AURKA siRNA resulted in sustained DNA double strand breaks
and more pronounced apoptosis. The combination of AURKA inhibitor
(MLN8237) with Cisplatin similarly led to enhanced DNA damage. Similar ef-
fects were observed with radiation concomitant with inhibition of Aurora A.
Furthermore, MLN8237 induced marked apoptosis in the p53 mutant cell line,
PC9, whereas more senescence was noted in p53 wild type A549 cells. CON-
CLUSIONS: Our study indicates a signifıcant role for Aurora Kinase A as a
common modulator of p53-dependent resistance in the context of DNA-dam-
aging platinum and radiation therapy. Aurora A inhibition can potentially im-
prove the effıcacy of these common treatment modalities in lung cancer man-
agement.
#1218 Synthetic lethal targeting of p53 mutant cells with prenylation in-
hibitors. Shay R. Ferdosi,1 Benjamin Katchman,2 Jia Loo,1 Harneet Grewal,1
Seron Eaton,1 Shanshan Yang,1 Jin Park,1 Joshua Labaer,1 Karen S. Anderson1.
1Arizona State University, Tempe, AZ; 2Eccrine System Inc, Cincinnati, OH.
Introduction: TP53 is mutated in 30-40% of breast cancers and is associ-
ated with poor prognosis. Mutation of TP53 causes increased cellular pro-
liferation, migration and invasion, and downstream activation of multiple
pathways. HMG CoA reductase inhibitors, such as simvastatin, inhibit tu-
morigenic properties induced by TP53 mutation. Mechanism of this re-
sponse is an important question in targeted cancer therapy. It is well known
that HMG CoA reductase inhibitors block cholesterol production and pre-
nylation. Therefore, we hypothesized that prenylation inhibitors would tar-
get p53 mutant cells primarily by inhibiting activation of the ras family
induced by TP53 mutation. Method: We generated 5 MCF10A stably trans-
duced cell lines over-expressing each of the common TP53 point mutations,
R273H, G245S, R248Q, Y234C, or wild type p53. Total Ras, Ras-GTP, total
RhoA and RhoA-GTP was measured by immunoprecipitation and immuno-
blot. Proliferation was measured using CellTiterGlo. The functional effects
of a panel of prenylation inhibitors was measured using a caspase3 reporter
assay, and migration was measured with a scratch assay. Illumina mRNA
sequencing was performed to measure gene expression of mutant and wild
type cells before and after simvastatin treatment (2.5l, 48 h). The RNAseq
was analyzed with the DAVID Enrichment tool to evaluate ras pathway
activation induced by TP53 mutation. Results: Mutation in TP53 was asso-
ciated with signifıcant activation of both wild-type Ras and RhoA. Prolifer-
ation of cells expressing mutant TP53 was sensitive to a panel of prenylation
inhibitors, including simvastatin. Growth inhibition by simvastatin corre-
lated with induction of apoptosis, and could be fully rescued by addition of
farnesylpyrophosphate or geranylgeranylpyrophosphate, suggesting that
simvastatin functionally blocks both prenylation pathways which are acti-
vated in the presence of mutant p53 (IC50(wt/mut)  4). RNAseq analysis
confırms that Ras signaling pathways, including GAPs and GEFs are en-
riched in the presence of mutant TP53, and FOXO signaling is signifıcantly
targeted post statin treatment (P0.01). Conclusion: p53 mutant breast can-
cer cells are highly sensitive to prenylation inhibition due to activation of
both ras and rhoA. Simvastatin inhibits both farnesylation and geranylgera-
nylation, effectively blocking ras pathway activation and induction of pro-
liferation in p53 mutant cell lines. A gene expression panel associated with
ras pathway activation was identifıed and may be predictive biomarkers for
sensitivity to statin therapy.
#1219 Integrative kinome exome sequencing and copy number profıling
of ovarian clear cell carcinoma. J.j. Caumanns,1 G.b.a Wisman,1 K Berns,2 T.
Tomar,1 R.s.n. Fehrmann,1 R Bernards,2 A.g.j. Van der Zee,1 S De Jong1. 1Uni-
versityMedical Centre Groningen, Groningen, Netherlands; 2Netherlands Cancer
Institute, Amsterdam, Netherlands.
Introduction: High stage ovarian clear cell carcinoma (OCCC) is less re-
sponsive to chemotherapy and has a worse prognosis than other ovarian
cancer subtypes. The most frequently mutated genes in OCCC have been
characterized in recent years. These include deleterious mutations in the
tumor suppressor gene ARID1A, epigenetic silencing and deleterious muta-
tions in the PI3K antagonist PTEN as well as activating mutations in the
PI3K catalytic subunit PIK3CA. Yet, therapeutic strategies that utilize these
genetic aberrations are lacking. In the present study, we aimed to identify
and validate new kinase targets in OCCC. Methods: To determine new mu-
tations and copy number gains and losses, kinome sequencing was per-
formed on DNA isolated from tumor samples (n124) and matched con-
trols (n47) and high-coverage SNP analysis was implemented for 109 of the
collected OCCC tumor samples. Inhibitor sensitivity screening was per-
formed on 17 OCCC cell lines to validate potential kinase targets, following
in vivo validation in OCCC patient-derived xenografts (PDX). Results: Mu-
tations in ARID1A, PIK3CA, PTEN, KRAS and TP53 corresponded to fre-
quencies found in literature. Most identifıed mutations could be designated
to the PI3K/Akt/mTOR and MAPK signal transduction pathway, and HER
family of receptor tyrosine kinases. The PI3K pathway related genes PIK3R1,
ERBB3 andAKT1were signifıcantlymutated in our dataset and not described in
OCCC before. EGFR, ERBB2 and PIK3CA emerged as most frequently ampli-
fıed kinases. Combining mutations and copy number alterations in these path-
ways, 91% of all tumors were affected. The highly positive staining of p-S6 (90%
of OCCC tumors) indeed suggests high mTORC1/2 activity in these tumors.
Inhibitor screening demonstrated subsets of cell lines to be sensitive to EGFR or
ERBB2 inhibition. Furthermore, the vast majority of OCCC cell lines was sus-
ceptible to inhibition of PI3K andMAPK downstream target mTORC1/2 using
AZD8055,which effıcacywas further demonstrated in severalOCCCPDXmod-
els. In contrast, mTORC1 inhibition alone was less effective. Conclusion: Most
kinase mutations and copy number alterations in OCCC can be related to PI3K
and MAPK pathway activation. In vitro and in vivo data suggest mTORC1/2
inhibition as a novel treatment strategy in OCCC. Combinations of EGFR or
ERBB2 inhibition with mTORC1/2 targeted therapy can be envisioned for
OCCC tumors with EGFR or ERBB2 alterations. Supported by a grant from the
Dutch Cancer Foundation: RUG 2012-5477.
#1220 Coordinated chemical-genetics approach identifıes PTP4A3-medi-
ated regulation of colon cancer cell migration and extracellularmatrix inter-
actions.Kelley E.McQueeney,1 JosephM. Salamoun,2 Isabella K. Blanco,1 Paula
Pekic,1 Jennifer Ahn,1 Elizabeth R. Sharlow,1 Peter Wipf,2 John S. Lazo1. 1Uni-
versity of Virginia, Charlottesville, VA; 2University of Pittsburgh, Pittsburgh, PA.
Aberrant regulation of protein phosphorylation is an exceedingly common
driver of human cancers. It is notable that we understand much less about the
role of protein tyrosine phosphatases in human malignancies compared to ty-
rosine kinases. The membrane-associated, intracellular, protein tyrosine
PTP4A3 is highly overexpressed in multiple tumor types including colorectal
cancer and has been associated with tumor metastases. We have, therefore, in-
vestigated the role of PTP4A3 in colon cancer migration and invasion. The
Ptp4a3 gene was expunged from colon tumor cells derived from Ptp4a3flox/flox
mice and the resulting cells exhibited impaired migration, invasion, and colony
formation compared to the wildtype isogenic cells. We characterized a potent,
selective, and noncompetitive small molecule inhibitor of PTP4A3, JMS-631-
053, which also disrupted colon cancer cell migration, invasion, and colony
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formation. PTP4A3 deletion increased the expression of extracellular matrix
and adhesion genes, including the tumor suppressor Emilin 1. Expression of
these extracellular matrix genes is mutually exclusive with PTP4A3 expression
in tumors derived from patients with colorectal cancer. These chemical and
biological reagents reveal a previously unknown communication between the
intracellular PTP4A3phosphatase and the extracellularmatrix and support con-
tinued efforts to pharmacologically target PTP4A3 for cancer therapy.
#1221 Triple-negative breast cancer (TNBC) phosphoproteomics. Sara
Fernandez Gaitero,1 Ivana Zagorac,1 Jose Francisco Lopez-Acosta,1 Gonzalo
Gomez-Lopez,1 David González Pisano,1 Javier Muñoz Peralta,1 Luis Manso,2
Soledad Alonso,3 Renske Penning,4 Maarten Altelaar,4 Albert JR Heck,4 Miguel
Quintela-Fandino1. 1Spanish National Cancer Research Center (CNIO),Madrid,
Spain; 212 de Octubre University Hospital, Madrid, Spain; 3Hospital Universita-
rio de Guadalajara, Guadalajara, Spain; 4Netherlands Proteomics Centre,
Utrecht, Netherlands.
Background: We hypothesized that the biphasic relapse pattern of TNBC could
be explained by a limited number of activation patterns of signaling nodes. In addi-
tion, we sought to determine whether the hyperactive signaling nodes, distinguish-
ing the caseswith favorable vs adverseoutcome, couldbepotential targets.Methods:
Training set of 34 frozen tumor samplesdivided in twosets, (A)13patients, relapsed
in4 years; (B) 21 patients relapse-free12 years, (mimicking the percentage and
relapse patterns of unselected TNBC, but paired for T, N, G and Ki67). TNBC cell
lines: 7 indolent (no metastases in 60 weeks) and 3 aggressive, develop metastases
and kill recipient mice in 4 months. Shotgun phosphoproteomics and TiO2-
IMAC phosphopeptide enrichment coupled with mass spectrometry runs in a Or-
bitrap Elite Mass Spectrometer was performed. Spectra were processed with Max-
Quant software. Differentially expressed phosphopeptides were obtained by
applying linear models R limma package. Differential kinase activation driving the
profıles segregating cured vs. relapsing cases was done using linear sequence motif
analysis. The hyperactivated kinases were validated in an independent set of 113
consecutive TNBC cases with 12 years of follow-up spotted in TMAs by using an
in-house algorithm for immunohistochemistry coupled with computer-aided
quantitationusing anAriol scanning,we took thekinases in theupperquartile (high
activity). Survival analysiswasperformedwithKMcurvesand log rank test; andCox
proportionate hazards model was used for multivariate models. Results: 11405
phosphopeptideswere identifıed and quantifıed in the training set. Supervised clus-
teringof relapsedvs. curedcases showedthat161and541peptideswere signifıcantly
up-regulated in the A and B groups, respectively (FDR0.15). After kinase-to-ki-
nase co-linearity was ruled-out , gathering the high activity (upper quartile) of six
kinases (a combined variable, herein Var1) showed statistically signifıcant associa-
tionwith relapse, being these: PRKCE, pERK, c-KIT, CDK6, pP70S6K and pPNKP.
Cox proportional hazards model of any of the six probes high (var1) vs rest: 9.9 vs.
not reachedyears (P0.001). Patients that had anyof the 6kinases highhave 47%of
chance to relapse (only 2 out of 42 relapsed patients have 0/6 active kinases) vs
patients with Var1 negative, 7% of chance (29 patients out of 72 have 0/6 active
kinases) we also observed constants patterns of activations in the different sets ex-
pressions of kinases. We considered the kinases at Var1 as a potentially targets and
we developed a pharmacological in vitro assay, testing pairs inhibitors on 10
TNBC cell lines; 99.3% of the combinations were supra-additive. Conclu-
sion: High throughput p-proteomics allows a parsimonious segregation of
early TNBC cases, easily detecting the cases with long-term cure vs the re-
maining while identifying potential therapeutic solutions for the patients
falling in the adverse prognostic subgroups.
#1222 Developingkinase inhibitorswithpolypharmacological profıles for
the treatment of resistant cancers. Suman Rao,1 Tan Li,1 Robert Everley,2
Guangyan Du,1 Peter Sorger,2 Nathanael Gray1. 1Dana Farber Cancer Institute,
Harvard Medical School, Boston, MA; 2Harvard Medical School, Boston, MA.
Smallmolecule kinase inhibitors targeting a specifıc oncoprotein driving can-
cer cells have shown great clinical success in the past (e.g. imatinib against
leukemia). However, resistance to targeted therapies quickly arises due to plas-
ticity associated with cancer cell signaling and tumor heterogeneity. One way to
overcome this problem is to rationally design drugswith polypharmacology that
can target multiple signaling pathways engaging in cancer cell proliferation and
survival. To this end, we have developed a strategy based on combining pheno-
typic screens of small molecule inhibitors and affınity-based mass spectrometry
to identify drugs with multi-targeted properties and piloted this approach using
the highly resistantKRASmutant non-small cell lung cancer cell lines.Webegan
this study by screening kinase inhibitors targeting MEK, ERK, PI3K, Akt and
mTOR and found that the lung cancer cells were largely resistant to single drugs
but showed enhanced sensitivity towards triple inhibition of MEK, ERK and
PI3K. These cell lines were then screened with a library of covalent and non-
covalent kinase inhibitors in an attempt to identify a small molecule inhibitor
that could mimic the activity of the triple drug combination. This led to the
discovery of SM1-71 that not only recapitulated the growth inhibitory activity of
MEKERKPI3K inhibition, but also blocked phosphorylation of ERK, Akt,
mTOR and S6K in cells. Target profıling of the drug was carried out using
chemoproteomics, which revealed that SM1-71 inhibited 55 kinases at a 1M
concentration. Dose-dependent evaluation further determined the IC50 of in-
hibition across the 55 kinases and rank ordered them based on binding affınity.
Top hits including MEK1, MEK2, ERK1, ERK2, AURKA, SRC and RPS6KA3
were confırmed using alternate kinase screens and cellular assays. Growth factor
receptors such as IGF1R, MET and EGFR were also identifıed and further vali-
dated using cell-based assays. Taken together, these results elucidated the polyp-
harmacology associated with SM1-71 and uncovered key targets responsible for
inducing strong cytotoxicity in KRAS mutant lung cancer cells. Through the
combination of phenotypic screens and mass spectrometry-based target identi-
fıcation, we have demonstrated the proof of principle for developing kinase
inhibitors with polypharmacology targeting resistant cancers.
#1223 Evaluation of the dual p38/NLK kinase inhibitor as potential new
therapeutic agent for tamoxifen-resistant breast cancer. XIANWANG,1 Xixi
Cao,2 Jamunarani Veeraraghavan,2 Lanfang Qin,2 Jin-Ah Kim,2 Ying Tan,2 Su-
san G. Hilsenbeck,2 Rachel Schiff,2 Xiaosong Wang1. 1University of Pittsburgh,
Pittsburgh, PA; 2Baylor College of Medicine, Houston, TX.
Background: Endocrine therapy has been considered an effective initial treat-
ment for ER positive breast cancer and tamoxifen is the most commonly used
endocrine agent. However, about half of the patients develop resistance or re-
lapse eventually. No effective targeted therapy exists to overcome it. In our
previous study, we have identifıed the role of nemo-like kinase (NLK) in breast
cancer endocrine resistance – a serine-threonine kinase that functions in stress
response and neurite outgrowth. In addition to NLK, activation of the other
stress kinases such as p38 MAPK has been reported to modulate ER signaling
and promote endocrine resistance. In this study, we have identifıed a highly
selective dual p38 and NLK kinase inhibitor (PNKI). This study aimed to eval-
uate the therapeutic effect of the PNKI inhibitor in tamoxifen-resistant breast
cancers using in vitro and preclinical mouse models. Experimental design and
methods: To determine the effect of PNKI on tamoxifen-resistant breast cancer
cells, we treated a primary tamoxifen-resistant breast cancer cell line
MDAMB415 and an acquired-resistant line MCF7 TamR, with 0.5 uM PNKI in
the presence of different doses of Tamoxifen. To evaluate the therapeutic effect
of PNKI in a T47D-derived xenograft tumor model with acquired tamoxifen
resistance, we administered PNKI alone or in combination with Fulvestrant, or
with the mTOR inhibitor Everolimus. Mice bearing T47D-TamR xenografts
were randomized into six treatment groups (Vehicle, PNKI, Fulvestrant, Fulves-
trant  PNKI, Everolimus, Everolimus  PNKI). Tumor growth was tracked
closely. The tumors harvested 2 weeks following treatments were profıled with
Reverse Phase Protein Array (RPPA) to assess the early signaling changes after
treatments. Furthermore, the therapeutic effect of PNKIwere also evaluated in a
patient-derived xenograft (PDX) model of de novo endocrine resistant breast
cancer.Mice bearing the PDX tumorswere randomized to one of four treatment
groups (Vehicle, PNKI, Everolimus, Everolimus  PNKI) and tumor growth
curve wasmeasured. Summary of the Results: Breast cancer cell lines with either
de novo or acquired Tamoxifen resistance became more sensitive to tamoxifen
when treated with 0.5 uM PNKI. The concomitant treatment of PNKI and
Everolimus results in signifıcant decrease of tumor growth in the T47D-TamR
xenograft tumor compared to Fulvestrant, Fulvestrant  PNKI, PNKI, or
Everolimus treatments. RPPA data revealed that a majority of key survival sig-
naling in breast cancer are repressed only when PNKI are combined with
Everolimus. The de novo endocrine-resistant PDX tumors showed diverse re-
sponse to PNKI mono-treatment, whereas the combination of PNKI and
Everolimus resulted in signifıcantly decreased tumor growth. Conclusion: The
PNKI exhibited potential therapeutic value as adjuvant agent to the mTOR
inhibitor everolimus for acquired or de novo tamoxifen-resistant breast cancer.
#1224 Combination of rapamycin and crizotinib induces partial remis-
sion of pleural mesothelioma in a patient-derived xenograft model. Dina
Mönch,1 Sabine Bode-Erdmann,1 Jörg Kalla,2 Jörn Sträter,3 Carsten Schwänen,3
Roger-Fei Falkenstern-Ge,4 Martin Kimmich,4 Martin Kohlhäufl,4 Godehard
Friedel,4 German Ott,1 Claudia Kalla1. 1Department of Clinical Pathology, Rob-
ert-Bosch-Krankenhaus, Dr. Margarete Fischer-Bosch-Institute of Clinical Phar-
macology, University of Tübingen, Stuttgart, Germany; 2Institute of Pathology,
Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany; 3Ambulantes
Onkologiezentrum, Klinikum Esslingen and Institute of Pathology, Esslingen,
Germany; 4Center for Pulmonology and Thoracic Surgery, Klinik Schillerhöhe,
Stuttgart, Germany.
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Introduction: Malignant pleural mesothelioma (MPM) is a neoplasm with
inferior prognosis and notorious chemotherapeutic resistance. New treatment
approaches may be based on specifıc inhibitors against kinases that are overex-
pressed in MPM, such as mTOR and MET. Here we examined the tyrosine
kinaseALKas a potential therapeutic target and the combinatorial effıcacy of the
ALK/MET inhibitor crizotinib and the mTOR inhibitor rapamycin. Methods:
We investigated the ALK status and the expression of mTOR and MET in 145
primary MPM and 8 murine patient-derived xenograft models. ALK overex-
pression, rearrangement andmutationwere studied by qRT-PCR, FISH, immu-
nohistochemistry and sequence analysis. Expression of mTOR and MET was
analyzed by qRT-PCR and immunohistochemistry. The combined anti-tumor
effect of crizotinib and rapamycin was evaluated in a patient derived xenograft
model. Effects of single drug vs. combination treatment on proliferation, apo-
ptosis and autophagy were assessed using Ki-67 immunohistochemistry,
TUNEL assay and LC3B immunofluorescence, respectively. Results: Overex-
pression of ALK transcripts was detected in 25 (19.5%) of 128 interpretable
primary MPM and two xenograft tumors and was neither associated with ALK
rearrangement nor with mutation of the kinase domain. ALK protein was ex-
pressed in 8.3%MPM and the two xenograft tumors expressing ALK transcript.
mTOR protein expression was detected in 28.7%MPM, co-expressed with ALK
and/orMET in 17.8%MPM.Applied to a patient derivedMPMxenograftmodel
that co-expressed ALK, MET and mTOR, crizotinib alone did not exert anti-
tumor growth activity, but enhanced the anti-tumor effect of rapamycin: Rapa-
mycin was effective in 3 of 5 tumors (pathological partial remission in 1, stable
tumor in 2 cases). Combination treatment was active in all 5 tumors (partial
remission in 4, stable tumor in 1 case). Simultaneous treatment with rapamycin
and crizotinib, however, signifıcantly suppressed tumor proliferation compared
to rapamycin-single treatment. Autophagy was induced by both single drug
treatments and distinctly enhanced by combination treatment, while apoptosis
was not promoted. Conclusion: Dual combinatory treatment of rapamycin and
crizotinib is more effective than rapamycin as single agent in suppressingMPM
tumor growth and therefore merits further investigation.
#1225 A unifıed model of RAF inhibitor action determines inhibitor ac-
tivity in BRAF-dependent tumors. Zoi Karoulia,1 Yang Wu,2 Tamer A.
Ahmed,1 Qisheng Xin,2 Julien Bollard,1 Clemens Krepler,3 Xuewei Wu,1 Chao
Zhang,4GideonBollag,4MeenhardHerlyn,3 JamesA. Fagin,5 Amaia Lujambio,1
Evripidis Gavathiotis,2 Poulikos I. Poulikakos1. 1Icahn School of Medicine at
Mount Sinai, New York, NY; 2Albert Einstein College of Medicine, Bronx, NY;
3The Wistar Institute, Philadelphia, PA; 4Plexxikon, California, CA; 5Memorial
Sloan Kettering Cancer Center, New York, NY.
The FDA approved RAF inhibitors vemurafenib and dabrafenib have elicited
profound responses in melanoma patients with tumors harboring BRAFV600E
mutation, but resistance limits their effectiveness. Furthermore, RAF inhibitors
exhibit only modest effıcacy in colorectal and thyroid BRAFV600E tumors and
they are not effective in tumors harboring non-V600 BRAF mutations. While
RAF/MEK inhibitor combinations demonstrate increased clinical effıcacy, drug
resistance develops as well, through similar mechanisms to those identifıed in
RAF inhibitor monotherapy. This suggests that insuffıcient RAF inhibition lim-
its treatment effıcacy and indicates the need for more effective therapeutic ap-
proaches to potently and durably target RAF/ERK signaling. Although the
unique biochemical properties of RAF inhibitors have been a topic of intensive
investigation, a unifıed model of RAF inhibitor action has been lacking. Our
biochemical and structural analysis in a panel of RAF inhibitors with different
structural properties revealed that they exert their effects via the combined out-
come of two distinct allosteric mechanisms. RAF priming and dimerization are
the result of RAF/RAS-GTP interaction upon inhibitor binding to RAF and
stabilization of theC-helix in the IN (active) position. Resistance of the dimeric
RAF to vemurafenib and dabrafenib is the result of stabilization of the C-helix
of the drug-bound protomer towards the OUT (inactive) position, a conforma-
tion that sterically prevents occupancy of both RAF protomers. Next generation
RAF inhibitors that stabilize the C-helix of RAF towards the IN position
(C-IN RAF inhibitors) allow occupancy of both RAF protomers and thus ac-
complish potent inhibition of the dimeric form of RAF. We further provide
structural, biochemical and cell-based evidence that next generation C-IN
RAF inhibitors (such asMLN480, TAK632, LY3009120, AZ628 and others) will
bemore effective for the treatment of patientswith tumors expressing non-V600
BRAF mutants and in BRAFV600E colorectal and thyroid tumors. However,
C-IN RAF inhibitors are predicted to have a low therapeutic window, since
they inhibit dimeric wild-type BRAF also in normal cells. Together our fındings
provide a blueprint for the development of RAF inhibitors with defıned bio-
chemical properties and support therapeutic strategies inwhich relatively lower,
non-toxic concentrations of C-IN inhibitors will be administered in combina-
tion with currently approved RAF and MEK inhibitor regimens for the treat-
ment of BRAFV600E melanoma, colorectal and thyroid cancers, as well as for
tumors with BRAF mutations other than V600.
#1226 Targeting BTK family in ER breast cancer with Ibrutinib for per-
sonalized precision medicine: a double-edged sword. Yesim Gökmen-Polar,
Xiaoping Gu, Edyta Vieth, Sunil Badve. Indiana Univ. School of Medicine, Indi-
anapolis, IN.
Background: Metastasis is the principal cause of morbidity and mortality
from breast cancer. Although current therapies are effective in early-stage of
breast cancer, resistance to therapy is common leading to the development of
metastasis. The commonest site of metastases is the regional lymph nodes. The
presence and the number of involved lymph nodes remains the single best pre-
dictor of metastases and an important guide for the use of systemic adjuvant
therapy. Identifıcation of the underlying molecular targets of lymph node me-
tastasis and a better understanding how to therapeutically target these will be a
signifıcant step in the goal of prevention ofmetastases. Experimental Design: To
determine the key players associated with the development of metastasis in
breast cancer, we performed RNA sequencing (Illumina Paired-end RNA-seq)
analysis in a cohort of matched pairs of primary and (nodal) metastatic tumors
(n18). Gene expression profıles were analyzed using DESeq2. For targeted
therapeutics, we performed orthotopic tumor implantation into mammary fad
pads of athymic nude mice of breast cancer models. Results: Our results identi-
fıed signifıcant differential expression of the Bruton’s tyrosine kinase (BTK)
family members in nodal metastasis. Among the family members, BTK, BLK,
RLK/TXK and JAK3 are expressed at very high levels in themetastatic lesions as
compared to matched primary tumors. Among the 51 breast cancer cell lines
analyzed, the BTK genes were signifıcantly upregulated in luminal, but not basal
cell lines. Categorized by the molecular subtypes of breast cancer, hormone
receptor- positive (HR) and /or HER2 overexpressing breast cancer cell lines
present higher BTK expression. Among the 51 breast cancer cell lines analyzed,
the BTK genes were signifıcantly regulated in both ER HER2- (T47D and
ZR75.1) and ERHER2 (BT-474 and ZR75.30) breast cancer cell lines. Ibru-
tinib, a selective and irreversible inhibitor of BTK targeting the cysteine-481
residue in the active site, exhibited potent activity in preclinical models of BTK-
expressing targets. Ibrutinib decreased primary tumor growth signifıcantly in
ERHER2 (BT-474)mouse xenograftmodel in a dose dependentmanner (10
mg/kg vs 25 mg/kg; P 0.05), whereas it promoted the tumor growth in a
signifıcant manner in ERHER2- xenograft models (T47D and ZR75.1;
P0.05). The differences might be due to the differences in model systems due
to the HER2 presence. Conclusion: Our data suggests that differential expres-
sion of target genes can be used to select agents as treating breast cancer. How-
ever, caution is necessary, as, in some situations, thismight lead to enhancement
of the growth in in vivo in subsets of breast cancer.
#1227 Angiotensin-(1-7) reduces triple negative breast cancer brain met-
astatic growth in association with decreased c-Met signaling. E. Ann Tallant,
Guorui Deng, Wenhong Chen, Linda J. Metheny-Barlow, Patricia E. Gallagher.
Wake Forest School of Medicine, Winston-Salem, NC.
Patients with triple negative breast cancer often develop metastatic brain dis-
ease and have limited treatment options due to the lack of targeted therapeutics
that effıciently cross the bloodbrain barrier. In the current study,we investigated
the effect of angiotensin-(1-7) [Ang-(1-7)], a heptapeptide hormone with anti-
proliferative and anti-metastatic activities, on the growth of murine brain tu-
mors using brain trophic BR.5-4T1 cells in a model of metastatic triple negative
breast tumor growth. BR.5-4T1 cells (1.25 x 104) were injected into the internal
carotid artery of female BALB/c mice; after two days, mice were implanted with
osmotic mini-pumps to deliver 24 g/kg/h Ang-(1-7) and all mice were sacri-
fıced after 20 days of treatment. Ang-(1-7) treatment signifıcantly reduced met-
astatic tumor number in the brain; an average of 20metastatic lesions permouse
was observed in the brains of an untreated control cohort while an average of 3
metastatic tumors per mouse was observed in the Ang-(1-7)-treated cohort.
Tumor size was also reduced 17-fold by treatment with Ang-(1-7). Ki67, a
marker of proliferation, was decreased from 29.1	6.7% to 6.4	2.2% in tumors
from mice treated with Ang-(1-7), indicating that the heptapeptide hormone
decreased metastatic tumor burden in the brain. Aberrant activation of the c-
Met receptor tyrosine kinase signaling pathway facilitates tumor cell invasion
and metastasis. Treatment with Ang-(1-7) signifıcantly reduced the percentage
of metastatic tumor cells exhibiting phospho-c-Met immunoreactivity, from
20.8	3.4% in tumors from untreated mice to 6.7	2.6% in mice treated with
Ang-(1-7). Protein phosphatase 1b (PTB1b), which dephosphorylates and neg-
atively regulates phospho-c-Met, was increased in the tumor cells ofmice treated
with Ang-(1-7) compared to tumor cells from untreated animals, from
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4.1	1.4% in sections of tumors from control mice compared to 8.8	0.9% in
sections of tumors frommice treated with Ang-(1-7). These results suggest that
Ang-(1-7) increases PTP1b to antagonize c-Met signaling and decrease triple
negative breast cancer brain metastasis. In support of a role for c-Met signaling
in the regulation of metastatic brain disease in breast cancer patients, analysis of
publicly available breast cancer cohort databases demonstrated a signifıcant cor-
relation between low c-Met/high PTP1b expression and improved survival out-
come, including an increase in brainmetastasis-free survival and distant-metas-
tasis free survival. This is the fırst report to demonstrate that Ang-(1-7) reduces
metastatic triple negative breast cancer localized to the brain in association with
increased protein phosphatase PTP1b and decreased phospho-c-Met, suggest-
ing that the heptapeptide hormone may serve as a novel targeted therapy to
reduce metastatic brain tumor burden in triple negative breast cancer patients.
#1228 Nintedanib selectively inhibits the activation and tumor-promot-
ing effects of fıbroblasts from lung adenocarcinoma patients. Jordi Alcaraz,1
MartaGabasa,2 Rafael Ikemori,1NoemíReguart3. 1University. of Barcelona, Bar-
celona, Spain; 2University of Barcelona, Barcelona, Spain; 3Hospital Clínic de
Barcelona, Barcelona, Spain.
Nintedanib (BIBF 1120) is a multikinase inhibitor recently approved to treat
lung adenocarcinoma (ADC)patients based on the therapeutic benefıts reported
in clinical trials on ADC but not on squamous cell carcinoma (SCC), which are
the two most common lung cancer subtypes. However, the biological processes
underlying the selective anticancer function of nintedanib in ADC remain ob-
scure. To shed light on this gap of knowledge, we examined the role of tumor-
associated fıbroblasts (TAFs) in the differential effects of nintedanib inADCand
SCC. BecauseTAFs are largely quiescent and activated in vivo,we focused on the
antifıbrotic effects of nintedanib on TAFs stimulated with TGF-1, which is a
potent fıbroblast activator frequently upregulated in lung cancer. Nintedanib
dose-dependently inhibited the TGF-1-induced expression of activation
markers in both ADC-TAFs and control fıbroblasts derived from uninvolved
parenchyma, whereas such inhibiton was very modest in SCC-TAFs, thereby
suggesting that TAF activation is regulated by differentmechanisms inADCand
SCC. Remarkably, nintedanib abrogated the stimulation of growth and invasion
in a panel of carcinoma cell lines induced by secreted factors from activated
TAFs in ADC but not SCC. These results reveal that nintedanib is a potent
inhibitor of fıbrosis and its associated tumor-promoting effects in ADC, and
strongly suggest that the subnormal antifıbrotic response of SCC-TAFs to nint-
edanib may underlie the lack of therapeutic benefıts of this drug in SCC. Our
fındings also support that preclinical models based on carcinoma-TAF interac-
tions may help unraveling the resistance mechanisms of SCC-TAFs to nint-
edanib and testing new combined therapies to further expand the therapeutic
effects of this drug.
#1229 RNAi-based -catenin inhibition in combination with MEK inhi-
bition promotes synergistic anti-tumor effıcacy and overcomes resistance
with MEK inhibition promotes synergistic anti-tumor effıcacy and over-
comes resistance. Shanthi Ganesh, Serena Shui, Girish Chopda, Martin Koser,
Kevin Craig, Chaitali Dutta, Cheng Lai, Hank Dudek, Weimin Wang, Bob D.
Brown, Marc Abrams. Dicerna Pharmaceuticals, Inc, Cambridge, MA.
Despite recent advances in early detection and therapeutic intervention, colo-
rectal cancer (CRC) remains one of themost deadly cancers in theUnited States.
TheWnt/-catenin andKRAS/BRAF-drivenMAPK pathways were reported to
cooperate in inducing CRC initiation and progression. Several studies have also
identifıedWnt signaling as a resistancemechanism inMAPKpathway-activated
CRCs. Thus far, independent targeting of these single oncogenic events in CRC
has yielded limited therapeutic success. RNA interference (RNAi) triggers are
capable of silencing any expressed mRNA with high potency and specifıcity,
including previously un-druggable targets such as -catenin, an oncogene fre-
quently dysregulated in CRC. DCR-BCAT is a chemically-optimized DsiRNA
targeting CTNNB1, the gene which encodes -catenin, formulated in a second-
generation EnCore lipid nanoparticle. We have previously reported extensive
preclinical pharmacology for DCR-BCAT in mouse tumor models of diverse
origin. (Ganesh et al,Mol Cancer Ther 2016). Herewe demonstrate that the dual
inhibition of -catenin and MEK demonstrates synergistic effıcacy in not only
primary CRC, but also in aggressive liver metastases of CRC in preclinical mod-
els. This combination ofDCR-BCATand theMEK inhibitor trametinibwas also
effıcacious in tumors which are known to be resistant to trametinib, as well as
tumors which acquire resistance due to drug exposure. These data support clin-
ical development of these combination approaches for this fırst-in-class RNAi
therapeutic.
#1230 Talazoparib, a second generation PARP inhibitor, is a novel ther-
apy for PTEN mutants in prostate cancer. Zachary Z. Reinstein, Rajita Vata-
palli, Jonathan Anker, Sahithi Pamarthy, Benedito Carneiro, Sarki Abdulkadir.
Northwestern University, Chicago, IL.
Prostate cancer is the most common cancer among men, other than skin
cancer, in the United States. When the cancer enters into the metastatic castra-
tion resistant stage (mCRPC), few treatment options are currently available and
the disease is considered incurable. The purpose of this study is to investigate a
new, targeted therapy against prostate cancers, including mCRPC. Talazoparib
is a novel PARP inhibitor with up to 100-fold higher potency and PARP affınity
when compared to PARP inhibitors such as olaparib, veliparib, and rucaparib.
Current literature suggests that PTEN mutants have high sensitivity to talazo-
parib. PTEN is a tumor suppressor gene that is commonly lost in prostate can-
cers. A murine prostate cancer cell line, Myc-CaP, which has been modifıed to
overexpress the oncogeneMyc, was edited by the CRISPR-Cas9 system to knock
out the PTEN gene. Myc-CaP and Myc-CaP PTEN KO cells were treated with
olaparib, an FDA approved, fırst generation PARP inhibitor, and talazoparib.
Talazoparib decreased cell viability signifıcantly more in PTEN KO cells versus
PTEN wild-type (WT) cells. No such trend was observed when these cells were
treated with olaparib. In addition, IC50 values in prostate cancer cell lines with
heterozygous or homozygous deletion of PTEN were up to 20 times lower with
the talazoparib treatment when compared to olaparib. Not only does this indi-
cate that talazoparib is much more potent than olaparib, but also preferentially
impairs cell growth in PTENmutants. PTEN’s signal transduction prevents the
phosphorylation of AKT, which is necessary for cell proliferation. When cells
were treated with an AKT inhibitor, MK2206, alone or in combination with
talazoparib, pAKTprotein levels decreased, but the greatest effectwas seenwhen
MK2206was used in combinationwith a lowdose of talazoparib in theMyc-Cap
cell line with wt PTEN. Western blot analysis showed that PTEN was upregu-
lated following talazoparib treatment. These results indicate synergy of talazo-
parib and MK2206 in reducing the phosphorylation of AKT in a dose-depen-
dentmanner. Talazoparib is by far themost potent PARP inhibitor developed to
date. With talazoparib potentially acting on prostate cancer with PTEN muta-
tions, talazoparib treatment may expand current PARP inhibitor treatment in
advanced prostate cancers and thereby elicit a response in as many as 80% of
patients. Thus, talazoparib has vast therapeutic potential in prostate cancer.
#1231 Restoration of tumor suppression in vivo by systemic delivery of
PTEN mRNA nanoparticles. Yingjie Xu,1 Mohammad Ariful Islam,2 Harshal
Zope,2 Morteza Mahmoudi,2 Robert S. Langer,3 Jinjun Shi,2 Bruce R. Zetter,1
Omid C. Farokhzad2. 1Boston Children’s Hospital, HarvardMedical School, Bos-
ton,MA; 2BrighamandWomen’sHospital,HarvardMedical School, Boston,MA;
3Massachusetts Institute of Technology, Cambridge, MA.
PTEN (phosphatase and tensin homolog on chromosome ten) is one of the
most common lost or mutated tumor suppressor genes in human cancers, in-
cluding 50% of metastatic castration-resistant prostate cancer (mCRPC). By
catalyzing PIP3 dephosphorylation, PTEN negatively regulates the PI3K-AKT-
mTORpathway, which is frequently altered inmCRPC. Reintroduction of func-
tional PTEN for mCRPC treatment has proven diffıcult. By employing self-
assembled lipid-polymer hybrid nanoparticle platforms, we successfully
reintroduced PTENmRNA to PTEN-null prostate cancer cells both in vitro and
in vivo. These mRNA-loaded nanoparticles demonstrate high protein expres-
sion effıciency, low toxicity and good stability in serum and tumor accumula-
tion.We confırmed that restoration of PTEN in PTEN-null prostate cancer cells
inhibits the PI3k-AKT pathway, reduces cell viability and enhances apoptosis in
vitro. Systemic delivery of PTENmRNA-loaded nanoparticles in prostate xeno-
graft tumors results in85% inhibition of tumor growth and leads to tumor cell
death without toxic side effects in vivo. In summary, this work provides proof of
concept of mRNA-based gene therapy for systemic restoration of functional
PTEN for tumor suppression in vivo. It represents a novel approach to PI3K-
AKT pathway inhibition, with the potential to specifıcally target cancers with
loss of PTEN function.
#1232 Development of novel therapeutic splice-switching oligonucleo-
tides targeting oncogenic RNA isoforms driving race-related aggressive
prostate cancer. Jennifer A. Freedman, Timothy Robinson, Bonnie LaCroix,
Brendon Patierno, Daniel George, Bruce Sullenger, Steven Patierno.Duke Can-
cer Inst., Durham, NC.
Background: Age-adjusted incidence and mortality rates for prostate cancer
(PCa) among African American (AA) men are 1.6- and 2.4-fold greater, respec-
tively, than among white men. More aggressive characteristics of AA PCa account
for a signifıcant component of the PCa disparity, in addition to social determinants
of health. Previous work from our laboratory and others have identifıed deregula-
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tion of the androgen receptor (AR) and epidermal growth factor receptor (EGFR)
pathways in AA versus white PCa. Thus, there is an urgent need to develop a novel
therapeutic strategy capable of inhibiting oncogenic AR and EGFR RNA isoforms
enriched for in AA PCa.Methods:We have designed and synthesized novel chem-
icallymodifıed splice switchingoligonucleotides (SSOs) to: 1) correct aberrant splic-
ing leading to production of AR-V7 (AR-V7 SSO), an AR variant that lacks the
ligand binding domain, is constitutively active and associates with castration-resis-
tant PCa, poorer clinical outcomes and resistance to androgen ablation/AR inhibi-
tion therapies, 2) drive production of AR45 (AR45 SSO), an AR variant that has a
unique, non-functional transactivation domain and acts in a dominant-negative
mannerand3)driveproductionof inhibitoryordominant-negativeEGFRisoforms
(EGFR-TMor EGFR-TK SSOs), lacking the transmembrane or tyrosine kinase do-
main, respectively.Results:Transfectionof apanel ofPCacell linesderived fromAA
and white patients with AR-V7 SSO decreases AR-V7 RNA and protein in a dose-
dependent manner. Preliminary data suggests this biochemical response correlates
withabiologically signifıcantphenotype, asAR-V7SSOalsodecreasesproliferation,
proliferation in thepresenceofenzalutamideandcolony formingabilityofPCacells.
Following transfectionof PCa cell lineswithAR45SSO, an increase inAR45RNA is
seenand simultaneousdecreases inwild typeARRNAandAR-V7RNAare seen. In
addition, modulation of AR signaling is detected, with decreases in RNAs corre-
sponding toAR-induced target genes and increases in RNAs corresponding toAR-
repressed target genes. Transfection of PCa cell lines with EGFR-TM or EGFR-TK
SSOs increase RNA corresponding to these isoforms in a dose-dependent manner.
Furthermore, a decrease in phosphorylated EGFRprotein is detected. Further stud-
ies to examine theeffectsof theseSSOson transactivationactivity, signalingandPCa
cell biology and the therapeutic effıcacy of these SSOs inAAandwhite PCa patient-
derived explants are underway.Conclusions: These studies suggest that SSOs canbe
developed tomodulate AR and EGFR signaling. Such SSOs could represent a novel
therapeutic strategy with the potential to reduce PCa disparities for AA men and
improveoutcomes formenof all raceswith aggressivediseasedrivenby thesemech-
anisms.
#1233 WNT inhibitor ICG-001 prevents visceral metastatic triple nega-
tive breast cancer in a chemo-resistant patient derived xenograft -PDX-
model. IramFatima, Ikbale El Ayachi, Chidi Zacheaus, JosephKerbyGray, Raya
Krutilina, Tiffany N. Seagroves, Susan A. Krum, Gustavo A. Miranda-Carboni.
University of Tennessee Health Science Center, Memphis, TN.
Triple negative breast cancer (TNBC) is characterized by absence of the estrogen
receptor (ER) andprogesterone receptor (PR), andhuman epidermal growth factor
receptor 2 (HER2) amplifıcation. Such cancers are highly aggressive and frequently
metastasize to the lungandbrain.Unlikeotherbreast cancer subtypes suchas, ER,
PR and/or HER2, TNBCs have no specifıc targeted-therapeutics; therefore,
studies should be directed for development of targeted therapies to treat this condi-
tion.Recent studies indicate thatWnt/-catenin signaling isparticularlyactivated in
TNBC and is associated with reduced overall survival in all patients. Therefore,
pharmacological targeting ofWnt signaling pathway constitutes an ideal approach
for treating TNBC and variousWnt inhibitors are currently in use in clinical trials,
such as; ICG-001 inmetastatic colon cancer. The inhibitory effects of ICG-001 have
notbeen tested inchemoresistantTNBCPDXtumors.Herein,we report for the fırst
time that ICG-001 compound selectively inhibited the growth of several European
American (EA) and African American (AA) triple negative breast cancer subtypes
MSL andBSL-1 cell lines both in vitro and in vivomodels. To further investigate the
precisemechanisms of action in the regulation ofWnt/-catenin signaling by ICG-
001, we performed Western blot analysis, apoptosis assays, cell cycle assays and
quantitative real-time reverse transcriptase- polymerase chain reactions in human
triplenegativebreast cancer cells.This compoundsignifıcantly interferedwithWnt/
-catenin signaling, and its inhibition led to downregulation of important down-
stream targets such asAxin2,HMGA2, PCNA, c-myc andCyclinD1,which in turn
led to inhibition of proliferation, cell cycle progression and metastasis confırming
our previous results too. In addition ICG-001 inhibited the invasion andmotility of
tumor cells and showed inhibition and prevention of visceral metastatic PDX tu-
mors from both chemoresistant EA andAAwomen. These results indicate that the
Wnt inhibitor ICG-001 could constitute a powerful new chemotherapeutic agent
against triple negative breast cancer.
#1234 The novel FGFR4-selective inhibitor INCB062079 is effıcacious in
models of hepatocellular carcinoma harboring FGF19 amplifıcation. Bruce
Ruggeri, Matthew Stubbs, Yan-ou Yang, Ashish Juvekar, Liang Lu, Sindy Con-
don, Darlise DiMatteo, Xiaoming Wen, Paul Collier, Timothy Burn, Liangxing
Wu, Daniel Wilson, Swamy Yeleswaram, Alan Roberts, Wenqing Yao, Gregory
Hollis, ReidHuber, Peggy Scherle, Phillip CC Liu. Incyte Corporation,Wilming-
ton, DE.
Hepatocellular carcinoma (HCC) is the most common form of primary liver
cancer with limited treatment options for advanced stage disease. Thus, there is
a critical medical need for improved therapies. In approximately 10% of HCC, a
focal amplicon at 11q13 harboring FGF19 has been reported. High levels of
FGF19 have been shown to drive HCC tumor development and progression in
preclinical models, suggesting that selective targeting of FGFR4, a high affınity
receptor for FGF19, may be effıcacious in these HCC tumors. INCB062079 a
potent and selective irreversible inhibitor of FGFR4 (250-fold vs FGFR1/2/3)
suppresses the growth ofHCC cell lines driven by amplifıcation and overexpres-
sion of FGF19. In subcutaneous xenograft models of HCC, oral dosing of
INCB062079 at tolerated doses resulted in dose-dependent inhibition of tumor
growth with regressions observed at higher doses consistent with inhibition of
FGFR4 signaling in the tumors. In combination with sorafenib, the only ap-
proved targeted therapy for HCC, FGFR4 inhibition exhibited additive tumor
growth inhibition in the Huh7 model. To assess exposure of INCB062079 in
orthotopic tumors after oral dosing, Hep3B tumors were implanted surgically
into the liver and their development monitored by analysis of plasma alpha-
fetoprotein (AFP). At effıcacious doses, INCB062079 strongly suppressed the
levels of AFP and FGF19 secreted by the tumors, and their levels correlated well
with the reduction in terminal liver tumor mass, suggesting that these may be
surrogate markers for response of HCC tumors to INCB062079. In two PDX
models of HCC with amplifıcation of FGF19 (4-6 CNV), INCB062079 admin-
istration reduced tumor growth by 50-66% at doses that were well tolerated.
Additional surrogate markers for FGFR4 inhibition were explored including
several parameters related to FGF19 regulation of bile acid metabolism. The
mRNA levels of CYP7A1, encoding cholesterol 7a-hydroxlyase, the rate limiting
enzyme in bile acid synthesis, were induced in the livers of cynomolgusmonkeys
upon dosing with INCB062079. Correspondingly there was a dose-dependent
increase in fecal bile acids. In summary these data demonstrate that
INCB062079 is highly and selectively effıcacious inmodels ofHCCwith FGF19-
FGFR4 oncogene addiction and elicits pharmacodynamic responses in primates
providing support for the clinical evaluation of INCB062079 in genetically se-
lected liver cancer patients.
#1235 EPHA2-targeted therapy enhances the cytotoxicity of eicosapenta-
enoic acid against triple-negative inflammatory breast cancer.AngieM. Tor-
res-Adorno,1 Heidi Vitrac,2 Yuan Qi,3 Yiwen Yang,4 Peiying Yang,5 Bedrich L.
Eckhardt,6NaotoT.Ueno6. 1TheUniversity of TexasGraduate School of Biomed-
ical Sciences at Houston, Breast Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, TX; 2Center for Membrane Biology, Univer-
sity of Texas Health Science Center, Houston, TX; 3Bioinformatics & Computer
Biology, The University of Texas MD Anderson Cancer Center, Houston, TX;
4Biostatistics, The University of Texas MD Anderson Cancer Center, Houston,
TX; 5General Oncology Research, The University of Texas MD Anderson Cancer
Center, Houston, TX; 6Breast Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, TX.
Background: Inflammatory breast cancer (IBC) is themost aggressive form of
breast cancer. We have previously reported that mediators of inflammation,
such asCOX-2, promote the growth ofTriple-Negative receptor (TN) IBCxeno-
grafts; therefore, inflammation in TN-IBC has a unique opportunity as a thera-
peutic strategy. Eicosapentaenoic acid (EPA), a non-toxic omega-3 fatty acid
with anti-inflammatory properties, has partially reduced tumor growth in pre-
clinical models of TN-IBC. Therefore, our goal is to develop a novel non-toxic
approach that enhances EPA effıcacy against TN-IBC in combination with tar-
geted therapy. Methods and Results: Using a high-throughput, siRNA screen
(939 genes) in the TN-IBC cell line SUM149PT, we identifıed Ephrin type-A
receptor 2 (EPHA2), an oncogenic cell-surface receptor tyrosine kinase, as a
target that modulates the sensitivity of TN-IBC cells to EPA treatment. To de-
termine the clinical relevance of EPHA2, we interrogated a meta-analysis of
breast cancer mRNA expression data sets, and found that high EPHA2 tumor
expression was signifıcantly correlated with poor overall survival in TN-IBC
patients, compared to low EPHA2 expressing tumors (P 0.01). We observed
no signifıcant correlations to other breast cancer subtypes. Similar fındings were
observed in vitro were EPHA2 expression predominantly occurred in the TN-
IBC subtypes (19 of 30) among 49 breast cancer cell lines. Gain/loss-of-expres-
sion studies were performed to functionally validate EPHA2 as a synergistic
combinational target with EPA in two EPHA2-expressing TN-IBC models,
SUM149PT and BCX010, using proliferation and apoptosis assays in vitro and
established tumor xenografts in vivo. EPHA2 gene silencing signifıcantly re-
duced cell growth and induced apoptosis in combination with EPA when com-
pared with untreated control and monotherapy in vitro (P 0.05) and in vivo
(P  0.001), while vector-induced EPHA2 expression reversed cell growth re-
duction and apoptosis induction following combination treatment with EPA in
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vitro (P 0.05). To translate our fındings to the clinic, we validated that dasat-
inib, a small molecule inhibitor of EPHA2, in combination with EPA signifı-
cantly enhanced cell death of SUM149PT and BCX010 cells in vitro when com-
pared to non-treated and monotherapy (P  0.05). Finally, using membrane
fluidity assessment and reverse-phase protein array (300 antibodies), we deter-
mined that combination treatment effıcacy depended on EPA/EPHA2 inhibi-
tion-mediated increase in cell membrane rigidity (P  0.001, compared to
monotherapy), which subsequently inhibited receptor tyrosine kinase signaling
activity, potentially resulting in induction of apoptosis. Conclusions: Our pre-
clinical fındings provide a rationale for the development of a phase 1 clinical trial
investigating combination EPA andEPHA2-inhibitors in patients with EPHA2-
positive TN-IBC.
#1236 Novel androgen receptor inhibitors in triple negative breast cancer.
Saswati Bhattacharya, Yuanqi Cai, Steven Kurina, PamelaWestmark, Benjamin
Hokanson, Matthew Anderson, Ruth O’Regan. UWMadison, Madison, WI.
Triple negative breast cancer (TNBC), which lacks expression of hormone
receptors and human epidermal growth factor receptor 2, has the worst prog-
nosis of all breast cancer subtypes, due to inherent chemo-resistance and a lack
of therapeutic targets. A subset of TNBC has been shown to express androgen
receptor (AR) but despite promising pre-clinical data, clinical trials evaluating
the use of approved anti-androgens (bicalutamide, enzalutamide) in AR-posi-
tive TNBC has shown modest effıcacy to date. In prostate cancer, bicalutamide
binds to AR with low affınity and in the presence of AR gene amplifıcation or
mutation, can exhibit partial agonist activity leading to resistance. In order to
increase affınity for AR and to avoid AR antagonist to agonist conversion syn-
thesized 7-substituted umbelliferones (UMB) derivatives with a distinct scaffold
modifıed from available AR antagonists (Kandil et al Bioorganic & Medicinal
Chemistry Letters, 2016). These agents exhibited inhibitory activity in human
prostate cancer cells lines at sub-micro molar level, a 50-fold and 30-fold im-
provement over bicalutamide and enzalutamide, respectively. We hypothesized
that these novel AR antagonists would be effective in inhibiting the growth of
AR-positive TNBC cells. Methods: TNBC AR negative mesenchymal MDA-
MB-231 (as control) and AR positive MDA-MB-231 cells were utilized for de-
termination of the effıcacy of the UMB derivatives. For proliferation assays,
viability of the cells wasmonitored over a period of 72 hours with redox dye Cell
Titer-Blue. Standard Western blotting techniques were used for protein detec-
tion. For apoptosis analysis, standard flow cytometry reagents, FITC labelled
Annexin V and Propidium Iodine(PI) mix were utilized. Results: UMB deriva-
tives decreased the expression of AR in AR-positive MDA-MB-453 in a dose
dependent manner. UMB derivatives, at micro Molar concentration decreased
cell proliferation of AR-positive and interestingly AR-negative cell lines by 20 to
50%, also in a dose dependent manner. UMB derivatives induced apoptosis in
both cell lines. Interestingly, UMB derivatives induced a change from a mes-
enchymal to epithelial phenotype in AR-negative MDA-MB-231 cells, which
was confırmed by decreased expression of vimentin and other mesenchymal
markers. Conclusions: Novel UMB derivatives inhibit growth and cause ap-
optosis in TNBC cells and inducemesenchymal-to-epithelial transition in an
AR-negative mesenchymal TNBC cell line. Targeting AR with novel AR
antagonists seem to be a promising therapeutic approach for AR-positive
TNBC and further evaluation of AR antagonists in AR-negative mesenchy-
mal TNBC is warranted.
#1237 PDGF induces cell growth and changes in glucose metabolism in
colon cancer in the absence ofPDGFreceptors.RomanaMoench, TanjaGrim-
mig, Christoph-Thomas Germer, Ana Maria Waaga-Gasser, Martin Gasser.
Univ. of Würzburg, Wuerzburg, Germany.
Background: ThePlatelet derived growth factor (PDGF) and its receptors play
amajor role in inducing proliferation,migration, and angiogenesis by activating
intracellular PI3K/Akt/mTOR signaling events in different solid tumors and
therefore represent attractive targets in tumor therapy. Recently we showed a
PDGF-induced activation of metabolism and proliferation in HT29 colon can-
cer cells in the absence of specifıc PDGF receptors. The aim of this study was to
analyze PDGFR and VEGFR expression and possible alternative PDGF binding
partners in colorectal cancer (CRC). Methods: Human HT29 colon cancer cells
were cultured and stimulated with PDGF in a time-dependent manner. Addi-
tionally, VEGFR2 and EGFR inhibition was performed to analyze alternative
PDGF signaling events. Whole cell or RNA extracts were analyzed by Western
Blot and RT-q-PCR for receptors and PI3K/Akt/mTOR signaling. To investi-
gate the effects of specifıc receptor inhibition on proliferation, MTS prolifera-
tion assays were performed. Moreover, mRNA levels of PDGFR and VEGFR in
tumors from patients with CRC were analyzed by RT-qPCR. Results: Human
UICC stage I-IV tumors exhibited a signifıcantly increased PDGFR and
VEGFR1,2 gene expression. As observed previously, HT29 colon cancer cells
showed only positivity for VEGFR1,2, but no PDGFR protein expression. De-
spite that, stimulation with PDGF resulted in increased proliferation and meta-
bolic changes. In contrast, Caco-2 and SW480 colon cancer cells showedPDGFR
and VEGFR expression on protein level. Interestingly, PDGF stimulation in-
creasedVEGFR1 and 2 gene expression inHT29 colon cancer cells and secondly
inhibition of VEGFR2 and EGFR showed alterations in proliferation and Akt
signaling in PDGF stimulated cancer cells. Conclusion: Despite the absence of
PDGF receptors in HT29 colon cancer cells, PDGF induced proliferating and
metabolic effects in the tumor cells, suggesting an alternative binding partner on
the tumor cell surface. Further investigation of the alternative PDGF binding
partners could be of clinical relevance in CRC.
#1238 Targeting the platelet derived growth factor receptor (PDGFR)
with the receptor tyrosine kinase inhibitor ponatinib in small cell carcinoma
of the ovary, hypercalcemic type. Jessica Diane Lang,1 William Hendricks,1
Pilar Ramos,1 Holly Yin,1 Chris Sereduk,1 Jeffrey Kiefer,1 Yemin Wang,2 An-
thony N. Karnezis,2 Bernard Weissman,3 David Huntsman,2 Jeffrey Trent1.
1Translational Genomics Research Institute, Phoenix, AZ; 2British Columbia
Cancer Agency, Vancouver, British Columbia, Canada; 3University of North Car-
olina at Chapel Hill, Chapel Hill, NC.
Subunits of the SWI/SNF chromatin-remodeling complex are tumor suppres-
sors that are inactivated in20% of all cancers, yet few targeted treatments have
shown selective activity in SWI/SNF-mutant cancers. Small cell carcinoma of
the ovary, hypercalcemic type (SCCOHT) is a rare, aggressive ovarian cancer in
young women that is universally driven by SWI/SNF dysregulation. Given that
two-year survival following standard high-dose chemotherapy and radiation in
SCCOHT is less than 35%, a great need exists for effective targeted therapies to
improve outcomes for these women. We previously demonstrated that SC-
COHT tumors are driven by inactivating mutations in SMARCA4, one of two
mutually exclusive SWI/SNF ATPases. In addition, we have shown that SC-
COHT lacks expression of the alternative SWI/SNF ATPase, SMARCA2. We
have now found through integrated genomic and functional analyses in SC-
COHT tumors and cell lines that SMARCA4 loss correlates with increased ex-
pression of receptor tyrosine kinases (RTKs) including the platelet derived
growth factor receptors (PDGFRs). Through integration of high-throughput
RNA interference and drug screens in SCCOHT cells we have identifıed sensi-
tivity to RTK knockdown and RTK inhibitors including the FDA-approved
oncology drug, ponatinib. These data corroborate prior studies showing RTK
dependence in rhabdoid tumors, rare cancers that are also driven by mutations
in the SWI/SNF complex. Of the known ponatinib targets, PDGFR-alpha and
FGFR1 were highly expressed in SCCOHT tumors, as confırmed in RNA-Seq
data (four tumors) and a SCCOHT tissue microarray (TMA; ten tumors). Fur-
thermore, PDGFR-alpha and -beta phosphorylation and downstream signaling
are inhibited by ponatinib in SCCOHT cells, suggesting that these tumors are
sensitive to ponatinib due to dependence on signaling through these RTKs.
Finally, given ponatinib’s potency in vitro and the proposed mechanism of ac-
tion, we tested this agent in xenograft models of SCCOHT. In addition to con-
fırming effıcacy in a SCCOHT cell line xenograft model, superior effıcacy was
demonstrated in two patient-derived xenograft (PDX)models of SCCOHTwith
ponatinib. Thus, ponatinib effectively targets SWI/SNF-mutant SCCOHT tu-
mors through inhibition of PDGFR signaling and may have clinical utility for
the treatment of these cancers.
#1239 The expression of salvage pathway enzymes in non-small cell lung
cancer cells. Michelle H. Townsend, Evita G. Weagel, Michael D. Anderson,
Edwin Velazquez, Richard A. Robison, Kim L. O’Neill. Brigham Young Univer-
sity, Provo, UT.
The aim of this study is to evaluate the expression of the salvage pathway
enzymes DCK, APRT, and HPRT in lung cancer cells to determine if they could
serve as biomarkers for lung cancer diagnosis and potential treatment. In both
men andwomen, lung cancer is themost lethal cancer in theworld, and accounts
for more than 30% of cancer-related deaths. We chose to evaluate the salvage
pathway enzymes due to an established relationship between the serum bio-
marker Thymidine Kinase 1 (TK1) and lung cancer. Two non-small cell lung
carcinoma cell lines were utilized for this analysis (NCI-H460 and A549) along
with cancer tissue and healthy tissue from 27 lung squamous carcinoma pa-
tients. The surface localization of these enzymes was determined utilizing flow
cytometry, confocal microscopy, and scanning electron microscopy, while up-
regulation within tissue was assessed using immunohistochemistry (IHC).
Throughout our investigation, we found no signifıcant expression of DCK or
APRT on the surface of non-small cell lung cancer cells, but found a signifıcant
presence of HPRT on the plasma membrane of both NCI-H460 and A549 cells.
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The average population florescence of cells treated with HPRT antibodies in-
creased by 24.3% and 12.9% in NCI-H460 and A549 cells, respectively, in com-
parison to controls. To ensure expression was not attributed to cytoplasmic
HPRT, confocal microscopy was performed to visualize HPRT binding on the
plasma membrane. After staining NCI-H460 cells treated with both fluorescent
antibodies and a membrane-specifıc dye, we observed direct overlap between
HPRT and the membrane of the cancer cells. Additionally, gold conjugated
antibodies were used to label and quantify the amount of HPRT on the cell
surface using scanning electron microscopy and EDAX. Further confırming
HPRTpresence, the goldweight percentage of the sample increased signifıcantly
when NCI-H460 cells were exposed to HPRT antibody (p-value 0.012) in com-
parison to isotype controls. Finally, the general upregulation of the protein was
observed in patient tissue samples, with approximately 44% of lung cancer tis-
sues showing signifıcant HPRT upregulation when compared to healthy tissue
samples. This differential upregulation shows an altered HPRT expression
within some patients, which may help explain the presence of this presumed
cytosolic enzyme on the surface of lung cancer cells. These results strongly in-
dicate a unique relationship between cancer cells and HPRT and suggest HPRT
as a possible biomarker for the detection and treatment of non-small cell lung
cancers.
#1240 Evaluating clinically relevant pharmacological agents in a rat am-
bulation model to ameliorate PEGylated recombinant hyaluronidase PH20
(PEGPH20)-mediatedmusculoskeletal adverse events. LiMa,1Marc R. Azar,2
Michael Shepard,1 Ya Huang,1 Piet A. Vervaet,1 Daniel C. Maneval,1 Curtis B.
Thompson,1 Rudy Paladini1. 1Halozyme Therapeutics Inc., San Diego, CA; 2Be-
havioral Pharma, La Jolla, CA.
Some cancers accumulate high levels of the glycosaminoglycan hyaluronan
(HA)within the tumormicroenvironment (TME), and this HA accumulation is
associatedwith rapid tumor progression and poor clinical outcomes. As preclin-
ical data have demonstrated that enzymatic degradation of HA, via intravenous
(IV) administration of PEGylated recombinant human hyaluronidase PH20
(PEGPH20), increases therapeutic effıcacy in HA-accumulating tumors, several
clinical trials evaluating PEGPH20 in combination with anti-cancer therapies
are ongoing. The most advanced clinical trial (Phase 3) is evaluating PEGPH20
plus Abraxane® (nab-paclitaxel)/gemcitabine (AG) in patients with stage IV
untreated pancreatic ductal adenocarcinoma (PDA)(NCT02715804). The safety
profıle of PEGPH20/Abraxane/gemcitabine (PAG) was generally similar to AG
alone in an interim analysis of the Phase 2 data, with the exception of a potential
imbalance of thromboembolic events (TEs), and an increased incidence ofmus-
culoskeletal events (MSEs) in the PAG arm, with the predominant MSE being
muscle spasms (55.4%PAGvs. 1.6%AG, all grades)(Bullock, ASCO2016). In an
effort to fınd pharmacological agent(s) that might decrease MSEs in PAG-
treated patients, a rat locomotor activity assay was developed. In brief, locomo-
tor activity of male Sprague Dawley rats wasmeasured with an automated infra-
red photobeam monitoring apparatus (Hamilton/Kinder®, San Diego) during
the 12h dark cycle when rats are normally active. Any PEGPH20-mediated de-
crease in rat locomotor activity was interpreted as MSE-like effects. In response
to PEGPH20 (1 mg/kg) the locomotor activity of male rats was reduced by
75% for the fırst 2 dark cycles post-treatment (48h), and then gradually re-
turned to vehicle baseline levels by days 4-5. FDA approved drugs used clinically
to alleviate pain were subsequently tested for their ability to ameliorate the ef-
fects of PEGPH20 on locomotor activity. Agents included anti-inflammatories,
anti-spasmodics, neuropathic pain medications, neuroleptics, diuretics, anti-
hypertensives, anti-fıbromyalgics and opioids. The steroid dexamethasone, cur-
rently being used in the Phase 2 and Phase 3 PDA clinical trials tomanageMSEs,
was the positive control. As a class, nonsteroidal anti-inflammatory drugs
(NSAIDs), including ketorolac, ketoprofen, diclofenac, and piroxicam, in-
creased rat ambulation by 40% on the fırst night following PEGPH20 treat-
ment compared to PEGPH20 alone. Mobility in rats treated with NSAIDs/
PEGPH20 increased60% on the second night compared to PEGPH20 alone.
No other drug classes increased rodent ambulation. These data suggest that
NSAIDs may be useful in partially alleviating the MSEs experienced by patients
receiving PEGPH20.
#1241 A preclinical study of the combined treatment of arginase and ca-
navanine in pancreatic cancer.Tsz Tung Kwong, Chi HangWong, Herbert Ho
Fung Loong, Stephen Lam Chan. The Chinese University of Hong Kong, Hong
Kong, Hong Kong.
Background:Arginine deprivation is a novel approach for cancer treatment as
some cancerswere found to be arginine auxotrophic. PEG-BCT-100, a pegylated
form of recombinant human arginase, was used to investigate the effect of argi-
nine deprivation onpancreatic cell lines.On the other hand,Canavanine (CAV),
a natural toxic analog of arginine isolated from leguminous plant, has also dem-
onstrated its ability in inhibiting cancer cell proliferation. It alters the protein
structure and causes critical metabolic defects in the cells by replacing arginine
into newly synthesized proteins during translation. In this study, we have also
tested the effıcacy of combined arginase and CAV treatment on pancreatic cell
lines.Methods: Pancreatic cell lines (MIA PaCa-2, CFPAC-1) and normal fıbro-
blast cell line (WI-38), were either incubated in normal or arginine free condi-
tion. The corresponding IC50 of CAV was determined by cell viability assay. To
evaluate the responsiveness to the combined treatment, cells weremonitored by
live cell imaging under the conditions of PEG-BCT-100 treatment alone (0.3IU/
ml) or in combination with CAV (10M or 50M). The apoptotic effect of the
combined treatment was examined by Western blotting and Annexin V assay.
Results: Either arginase or CAV treatment could inhibit pancreatic cancer cell
growth. The cells treated with CAV in arginine free condition demonstrated an
inhibition of cell proliferation and its corresponding IC50 was signifıcantly low-
ered from millimolar to micromolar concentration when arginine was with-
drawn. Strong synergismofCAVandPEG-BCT-100was observed after 48-hour
treatment with enhanced apoptosis in pancreatic cell lines, but not in normal
fıbroblast cells. Both early and late apoptosis were observed in co-treated pan-
creatic cancer cells as indicated by Annexin V assay and the detection of poly-
ADP ribosyl polymerase (PARP) in Western blot. Conclusion: Arginine depri-
vation by PEG-BCT-100 combined with CAV treatment showed a strong
synergetic effect on inducing cell death in pancreatic cell lines, suggesting that
the supplement of CAV could facilitate the treatment outcome of arginine de-
privation by arginase. This combined treatment may serve as a treatment strat-
egy for pancreatic cancer.
#1242 Ornithinedecarboxylase as a therapeutic target in endometrial can-
cer. Hong Im Kim,1 Chad R. Schultz,1 Andrea L. Buras,1 Elizabeth Friedman,2
Alyssa M. Fedorko,1 Leigh G. Seamon,3 Gadisetti Chandramouli,4 André S.
Bachmann,1 John I. Risinger1. 1Michigan State University, Grand Rapids, MI;
2Grand Rapids Medical Education Partners, Grand Rapids, MI; 3Spectrum
Health, Grand Rapids, MI; 4GenEpria, Columbia, MD.
Endometrial cancer is the 4th most common cancer and the 6th deadliest
cancer in US women. The American Cancer Society estimates there will be
60,050 new endometrial cancers in 2016, an increase of more than 10% from the
previous year highlighting the need for more effective treatments and preven-
tion. Ornithine Decarboxylase (ODC) a key enzyme in polyamine synthesis is
often overexpressed in cancers and contributes to cell proliferation and tumor
growth. Therefore, ODC and the polyamine pathway are considered rational
targets for cancer treatment or prevention. We noted ubiquitous expression of
ODC1 in our previously published endometrial cancer gene array data and con-
fırmed this in the cancer genome atlas (TCGA), fınding expression in all four
molecular sub-typeswith highest expression in copynumber high cancerswhich
have the worst clinical outcomes. Therefore, we explored the association of
ODC1 gene expression with clinical outcomes of overall survival (OS) and re-
currence in the TCGA cohort and noted that elevated ODC1 was signifıcantly
related to OS (Wald test p0.001) and recurrence (p0.01). Importantly, we
confırmed these observations using QRT-PCR in a validation cohort of 60 en-
dometrial cancers and found that endometrial cancers with elevated ODC1 had
signifıcantly shorter recurrence-free intervals (p5.59x10-5) and elevated haz-
ard ratio3.72. Similar to TCGA data we also noted a strong trend to worse OS
( p0.00014) with elevated hazard ratio 3.81. Numerous studies including clin-
ical trials have examined the chemopreventive and anti-tumor effects of difluo-
romethylornithine (DFMO), a specifıc inhibitor of ODC.We found that DFMO
treatment signifıcantly reduced cell proliferation, cell viability, and colony for-
mation in human cell line models derived from undifferentiated, endometrioid,
serous,MMTand clear cell endometrial cancers. In contrast, immortalized uter-
ine endometrial epithelial cells (EME6/E7TERT1)were less sensitive toDFMO.
To confırm the signifıcant effects of DFMO in vitro we performed an in vivo
study with human endometrial cancer (ACI-98) tumor-bearing athymic nude
mice. Xenografted mice were either treated with 2% (w/v) DFMO supplied in
drinking water or water only (n10/group). DFMO signifıcantly reduced the
tumor burden in mice compared to controls (p0.0023). ODC-regulated poly-
amines (putrescine [Put] and spermidine [Spd]) known activators of cell prolif-
eration were strongly decreased in response to DFMO, in both tumor tissue
([Put] (p0.0006), [Spd] (p0.0001)) and blood plasma ([Put] (p0.0001),
[Spd] (p0.0049)) of treated mice. Results of these studies indicate that some
endometrial cancers appear particularly sensitive to DFMO. Our fındings indi-
cate that the polyamine pathway in endometrial cancers in general and specifı-
cally those most clinically relevant endometrial cancers could be targeted for
effective treatment, chemoprevention or chemoprevention of recurrence.
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CANCER CHEMISTRY: Cheminformatics and Computational
Strategies for Drug Discovery
#1243 FAM134B mutation in esophageal squamous cell carcinoma: Its
clinical signifıcance and quantifıcation by electrochemicalmethods.Md.Ha-
kimul Haque,1 Vinod Gopalan,1 Muhammad J. A. Shiddiky,2 Alfred K. Lam1.
1GriffıthUniversity, Southport, Australia; 2GriffıthUniversity, Nathan, Australia.
Aim: The aim of this research was to detect novel sites of FAM134B muta-
tions, copy number variations and their clinicopathological signifıcance in
esophageal squamous cell carcinoma (ESCC) patients. Also, this study was in-
tended to develop a simple and inexpensive electrochemical detection method
for the analysis of FAM134Bmutations using a single-use anddisposable screen-
printed electrode.Method:Approximately 102 fresh tissue samples of ESCC and
matched non-cancer adjacent tissues were recruited. TheDNAcopy numbers of
FAM134B were initially studied by qRT-PCR. The FAM134B mutations were
then quantifıed via high resolution melt curve (HRM) and Sanger sequencing
analysis. In order to quantify the level of point mutation or SNPs in FAM134B
gene, a new electrochemical method was also developed. The underlying work-
ing principle of the method is relied on the base dependent affınity interactions
towards gold electrode. Since two DNA sequences with different DNA base
compositions (i.e., amplifıed mutated sequences will be distinctly different than
itswild type sequence)will have different adsorption affınity towards anunmod-
ifıed gold electrode, accurate measurement of adsorbed DNA on the electrode
surface will give the measure of point mutation or SNPs present in the DNA
sequences. Target DNA sequences were fırst extracted from clinical samples and
then PCR amplifıed and purifıed prior to adsorption on a single-use screen-
printed gold electrode. The amount of mutation sites on a DNA sequence is
quantifıed by monitoring the Faradaic current generated by the [Fe(CN)6]3-/4-
system present in the electrolyte solution. Result: Amplifıcation of FAM134B
DNA was noted in 37% of ESCC tissues whereas 35% cases showed loss of
FAM134B copies compared to matched non-tumor tissues. Overall, thirty-
seven FAM134Bmutationswere documented in exons 4, 5, 7, 9 aswell as introns
2, 4-8 of FAM134B. Also, FAM134B mutations were detected in all the meta-
static ESCC cases and in 14% (8/57) of the primary ESCC. Using the new elec-
trochemical method, we were able to detect mutations in 50 ng of target PCR-
amplifıed product within 1 h with high reproducibility (% RSD 2) and
specifıcity. Conclusion:DNAcopynumber variations and frequentmutations of
FAM134B inmetastatic lymph node tissues in ESCC patients indicate its critical
role in the pathogenesis of ESCCs. Also themutation detection via electrochem-
ical methods was successful distinguishing single point mutation in DNA from
oesophageal cancer implying its potential application in point mutation detec-
tion in clinical diagnostics.
#1244 An in vitro biological assay to identify small molecule upregulators
of let-7 miRNA in LIN28- positive ovarian cancer cells. Miriam-Rose Me-
nezes,1 Goeun Bae,2 Yong Sung Park,2 Julien Balzeau,1 Clifford C. Stephan,2
John P. Hagan1. 1University of Texas Health Science Center Houston, Houston,
TX; 2TAMHSC Institute of Bioscience and Technology, Houston, TX.
Onco-fetal LIN28, present in two isoforms A and B and expressed in cancer
cells, promotes tumorigenesis by suppressing the biogenesis of the tumor sup-
pressor microRNA, let-7, thereby activating an array of oncogenes including
RAS, MYC, HMGA2 and Cyclin D1. Studies have demonstrated a positive cor-
relation between LIN28A/B expression and advanced epithelial ovarian cancers
(Histological grade 2 or 3). Correlation of LIN28 expression to a poor progres-
sion-free survival and resistance to platinum-based therapiesmakes LIN28-let-7
pathway an attractive target for ovarian cancer chemotherapy. The overall goal
of this study was to identify small molecules that upregulate let-7 levels in
LIN28A or LIN28B positive ovarian cancer cells.We hypothesize that induction
of let-7 levels would potentially improve prognosis for ovarian cancer patients
bearing LIN28 positive tumors. To test this hypothesis, we developed a dual
luciferase let-7 reporter assay in which let-7 binding sites found in the 3’ UTR of
the HMGA2 gene were cloned downstream of the nanoluciferase reporter gene.
In this assay, elevated let-7 levels would result in repression of the nanoluciferase
signal. Data obtained was normalized to Firefly luciferase activity. We tested
effıcacy of the assay system using let-7 mimics and inhibitors in LIN28A (OVK-
18) and LIN28B (TOV-112D) positive ovarian cancer cell lines stably expressing
the reporter cassette that were generated in house. Transfection of the let-7
mimic resulted in a 0.5 fold decrease in both cell lines relative to the negative
controls, whereas transfection of the let-7 inhibitor resulted in a two-fold in-
crease in relative luminescence. We miniaturized the assay to 384-well format
for small molecule screening. The Z prime (Z’) scores for both cell lines was 0.58
and 0.84 respectively, indicating that the assay was robust to carry out the
screens. We performed a primary screen using the Prestwick and LOPAC1280
libraries for each cell line in duplicate as well as a counter screen using a reporter
cassette that lacked let-7 binding sites. A compound was identifıed as a hit if it
ranked within the top 100 compounds in the primary screen and outside the top
250 compounds in the counter screen. The hit rate for LIN28A positive cell line
was 80 % for the Prestwick and 74 % for the LOPAC1280 libraries. For the LIN28
B positive cell line, the hit rate was 73 % and 53 % for the Prestwick and LOPAC
libraries. The hits were validated by assaying for let-7 levels using qRTPCR. The
hits identifıed included compounds that inhibited PI3K-mTOR, nFkB, c-MYC,
CyclinD1, BET1 aswell as aurora kinase. These targets have been reported in the
literature to downregulate let-7 levels. In conclusion, our assay-system is the fırst
to utilize a biological assay of let-7 levels for small molecule library screening
thus serving as a valuable tool for cancer drug discovery.
#1245 Screening methodologies for the discovery of small molecule mel-
anoma therapeutics targeted at the ErbB4 receptor tyrosine kinase. Richard
L. Cullum,1 John T. Piazza,1 Jared I. Senfeld,1 Logan T. Neel,1 Ram B. Gupta,2
Allan E. David,1 David J. Riese1. 1Auburn University, Auburn, AL; 2Virginia
Commonwealth University, Richmond, VA.
Introduction: Gain-of-function mutations in the ErbB4 receptor tyrosine ki-
nase have been found in a signifıcant fraction of melanoma cell lines that are
dependent on ErbB4 for proliferation. However, there is a scarcity of therapeu-
tics for treating these ErbB4-dependent tumors. Consequently, we have devel-
oped high-throughput screening assays to identify small molecule ErbB4 antag-
onists that may hold promise as targetedmelanoma therapeutics. Our approach
is based on the observation that theQ43Lmutant of the ErbB4 agonist Neuregu-
lin 2beta (NRG2b) functions as a partial agonist at ErbB4. NRG2b/Q43L stim-
ulates ErbB4 tyrosine phosphorylation, fails to stimulate ErbB4-dependent cell
proliferation, and competitively antagonizes agonist stimulation of ErbB4-de-
pendent cell proliferation. Experimental procedures: Therefore, we have devel-
oped three high-throughput screening assays to identify ErbB4 partial agonists
that function as antagonists. The primary screen identifıes molecules that stim-
ulate ErbB4 tyrosine phosphorylation. The secondary screen identifıes mole-
cules that stimulate or fail to stimulate ErbB4-dependent cell proliferation. The
tertiary screen identifıes molecules that antagonize agonist stimulation of
ErbB4-dependent cell proliferation. Results: A phospho-ErbB4 sandwich ELISA
assay identifıes molecules that stimulate ErbB4 tyrosine phosphorylation with
high sensitivity and fıdelity (Z’0.5). IL3-independence assays in conjunction
with MTT assays using a cell line that displays ErbB4-dependent cell prolifera-
tion distinguish between molecules that stimulate and fail to stimulate ErbB4-
dependent proliferation (Z’0.5) and identify molecules that antagonize ago-
nist stimulation of ErbB4 dependent proliferation. These assays have been used
to identify small molecules that stimulate ErbB4 tyrosine phosphorylation.
Efforts to determine whether these hits function as ErbB4 full agonists or
partial agonists (antagonists) are underway and will be reported. Structures
of these small molecule ErbB4 full and partial agonists may be reported,
pending submission of a provisional patent application. Conclusions: We
have validated an HTS strategy for identifying ErbB4 partial agonists that
function as ErbB4 antagonists and deployment of that strategy has led to the
identifıcation of several hits (20 from the primary screen). Such molecules
may hold promise as targeted therapeutics for melanoma and other ErbB4-
dependent tumors.
#1246 Development of a novel KRAS-targeting agent: systematic valida-
tion using in silico, in solution, cellmodels, PDX and transgenicmousemod-
els. Arsheed Ahmad Ganaie,1 Hifzur R. Siddique,1 Ishfaq Sheikh,1 Lei Wang,1
Aijaz Parray,1 Jayanth panyam,2 Peter Villalta,1 Joshua Liao,1 Yibin deng,1 Mo-
hammad saleem1. 1Univ. of Minnesota Hormel Inst., Austin, MN; 2Univ. of Min-
nesota Hormel Inst., Minneapolis, MN.
Aberrant KRAS signaling plays an important role in the pathogenesis of ma-
lignancies including pancreatic (PDAC), colon and lung cancer. Because thera-
pies targeting either downstream or associated factors of KRAS pathway have
shown dismal results in clinics, there is a need to identify effective agents target-
ing active KRAS (GTP-KRAS) protein. In this study, we screened a chemical
library for their effıcacy to inhibit KRAS activity using in silico methods. Based
on their binding energy, we selected a candidate agent (LP1) that exhibited high
potential of binding to KRAS protein at a region where KRAS-activator protein
“SOS1” binds to, and GDP-GTP exchange takes place. We next investigated if
LP1 exhibits the effıcacy of KRAS binding in biological solution using recombi-
nant proteins and employing drug development techniques i.e., florescence
(FL)-based competition, Isothermal Titration Calorimetry (ITC) and Surface
PlasmonResonance (SPR) assays. The FL-based study show that LP1 inhibits the
binding of SOS1 protein andGTPmolecules to KRAS protein. The ITC and SPR
analysis showed that LP1 binds to the KRAS protein (at 10M).We next deter-
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mined the KRAS-inhibitory potential of LP1 in activated-KRAS cells represent-
ing premalignant and malignant models of PDAC, colon and lung cancer. Dis-
sociation study involving incubation of KRAS/SOS1 proteins showed the LP1
inhibits the binding of SOS1 to KRAS. Notably, LP1 therapy signifıcantly de-
creased the (i) KRAS-GTP protein levels (ii) growth and (iii) proliferation of
activated-KRAS single cell and 3D Organoid cultures. We next tested KRAS-
inhibitory effıcacy of LP1 in PDAC patient-derived (PD) tumor explants and
found that LP1 therapy (10 days) signifıcantly decreased growth of, and KRAS-
GTP levels in PD explants. Based on the in silico, in solution, cell model and
PD-explant data, we determined the effıcacy of LP1 as a KRAS inhibitor in in
vivo conditions. We fırst performed the pharmacokinetic study of LP1 in mice
and observed that LP1 is physiologically available in the blood (peak of 15-20
M) after oral and intraperitoneal administrations and detectable up to 24h
post-administration.Wenext tested LP1 therapy in tumor xenograftmodels and
show that LP1 therapy signifıcantly reduces the tumorigenicity of KRAS-acti-
vated PDAC and colon cell-derived tumors implanted in athymicmice.We next
tested effıcacy of LP1 administration on the developmental phases of PDAC
disease (from normal to high grade neoplasia/early stage carcinoma) and show
that LP1 feeding for six months caused a signifıcant inhibition of PanIN devel-
opment in KPCG12D transgenic mouse model. Notably the analysis of tumors
xenograftmodels and pancreatic tissues of KPCG12Dmice receiving LP1 therapy
exhibited reducedKRAS-GTP levels. Taken together, these data show that LP1 is
a potentKRAS activity inhibitor and a potential candidate for clinical use against
KRAS-driven cancers.
#1247 Identifying novel regulators of the Unfolded Protein Response
(UPR) by genome-scale CRISPR-Cas9 knockout screens.NektariaMaria Leli,
SouvikDey, Lauren Brady, Constantinos Koumenis.University of Pennsylvania,
Philadelphia, PA.
Development and growth of a tumor as well as its ability to metastasize in-
volves a complex relationship with its tissue microenvironment. A proliferating
tumor encounters several microenvironmental stress conditions such as hyp-
oxia, lack of nutrients and acidosis. To cope with these conditions, cancer cells
have developed elaborate cytoprotective mechanisms which provide them with
distinct advantages to thrive. Thus, deciphering the signaling pathways which
get activated in the tumor microenvironment has been paramount to develop
new therapeutic strategies for treatment. TheUnfolded ProteinResponse (UPR)
is an adaptive prosurvival pathway elicited by stresses in the tumor microenvi-
ronment (e.g., hypoxia, low glucose) and involves translational and transcrip-
tional activation of effector genes which act to relieve cellular stress and block
cancer cell death. We developed a strategy to comprehensively analyze critical
mediators of cell fate in response to UPR activation. We have delivered a lenti-
viral genome-scale CRISPR Cas9 knockout (GeCKOv2) library to Sq20B cells
(human squamous head and neck carcinoma) and A375 (human melanoma)
cells. The library is targeting 19,050 genes with 123,411 unique guide sequences
and enables both negative and positive selection screening.We used theGeCKO
v2 library to identify genes essential for triggering the UPR in response to thap-
sigargin and tunicamycin, known specifıc activators of ER stress. Our highest-
ranking candidates include BIRC5/Survivin, a well-studiedmolecule that acts as
an inhibitor of apoptosis and is highly expressed in cancer cells and eukaryotic
translation initiation factor eIF6, whose overexpression increases motility and
invasiveness of cancer cells. Our preliminary results indicate that loss of Survivin
and eIF6 dramatically enhance sensitization of cells to various ER stress condi-
tions.Moreover, this synergistic outcome is observedwhen cells are treatedwith
YM155, a small molecule that selectively suppresses Survivin and is used in
phase I/II clinical trials. Lastly, morphological changes like endoreduplication
are observed after long term absence of Survivin indicating its endogenous ER
stress inducing role. Taken together, Survivin and eIF6 are importantmediators
of survival following ER stress and characterizing the pathways involved can
lead to the development of novel targeted agents and therapeutic approaches.
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#1248 Adult calorie restriction reduces weight gain andmammary tumor
incidence in obesity prone MMTV-TFG  mice. Michael E. Grossmann,
Nancy K. Mizuno, Da-Qing Yang, D. Joshua Liao, Margot P. Cleary. Univ. of
Minnesota Hormel Inst., Austin, MN.
Obesity is associated with increased risk of postmenopausal breast cancer
resulting in recommendations for weight gain prevention and/or weight loss.
However, there is little experimental data indicating if calorie restriction (CR)
initiated in adulthood impacts mammary tumorigenesis. We have used female
MMTV-TGF-mice which develop mammary tumors in the 2nd yr of life as a
model of postmenopausal breast cancer. From 10-30 weeks of age (woa) mice
were fed a diet with 33% fat calories. At 30 woa based on body weight mice were
classifıed as Obesity-Prone (Ob-Pr), Overweight (Ow) or Obesity-Resistant
(Ob-R). Half in each weight category were then fed a 25% CR diet with reduced
carbohydrate content (43% fat calories). The remaining mice continued on ad
libitum (AL) feeding of the 33% fat diet. This resulted in six experimental groups
(n 26-31/group). Food intakes were monitored and body weights and mam-
mary tumor status were determined weekly. Mice were sacrifıced either at 90
woa or earlier if tumor size dictated.Mice in theCR-Ob-Pr group lost an average
of 1.12 grams while mice in the AL-Ob-Pr group gained 16.03 grams from 30
woa until euthanasia. CR-Ob-Pr mice had a reduced palpable tumor incidence
as compared to AL-Ob-Pr mice prior to euthanasia (12.90% versus 61.54% P
0.0002). Indolent tumorswere discovered at euthanasiawith theCR-Ob-Prmice
having a larger number than AL-Ob-Pr mice resulting in fınal tumor positive
mice in these groups of 54.84% vs 65.38%, respectively. Interestingly, the Ob-R
mice had fınal tumor incidence of 38.71% and 73.08% for the CR-Ob-R vs the
AL-Ob-R (P0.01). Average tumor weight was highest in the AL-Ob-Pr group
with CR resulting in a signifıcantly lower tumor weight (P 0.01). The AL-
Ob-Pr group had the shortest average survival time of 82.96 woa while CR of the
Ob-Pr mice resulted in increased survival to 89.77 woa (P 0.001). A compar-
ison of the survival curves of these two groups showed that CR resulted in
signifıcantly increased survival (P 0.0001). Results of this study indicate that
initiation of moderate 25% CR during adulthood reduces weight gain, mam-
mary tumor incidence, and tumorweight as well as increases lifespan evenwhen
a moderately high fat diet was consumed. This information supports further
efforts to be made to prevent weight gain as women approach menopause to
delay or prevent breast cancer development. Support: NIH-CA157012, The
Hormel Foundation and Paint the Town Pink.
#1249 Procyanidin B2-3,3=-di-O-gallate targets cancer cell metabolism in
its effıcacy against human prostate carcinoma cells. Chapla Agarwal, Dileep
Kumar, Alpna Tyagi, Natalie Serkova, Michael Wempe, Komal Raina, Rajesh
Agarwal. Univ. of Colorado Denver, Aurora, CO.
The metabolic profıle of various cancerous tissues can be correlated with cell
growth and death, specifıc tumor type as well as the pathological stage of tumor.
In recent times, prostatic tissue metabolomics using spectroscopy methods has
helped to identify and establish the metabolic profıles specifıc to prostate cancer
(PCa)malignancy. Thus, the evaluation of the anticancer effıcacy of an agent can
be considered incomplete without assessing its effect on the metabolic profıle of
the tumor tissue. With this rationale, herein, we carried out a metabolomics
study on human PCa cell lines after procyanidin B2-3,3=-di-O-gallate (B2G2)
exposure, which was recently identifıed by us as most effective agent in grape
seed extract for growth inhibition and apoptotic death of human PCa cells.
Specifıcally, we employed quantitative high-resolution nuclear magnetic reso-
nance spectroscopy (1H-, 13C- and 31P-NMR) to assess themetabolic profıle and
energy state of the B2G2-treated human PCa cell lines PC3 and C42B. This
approach helped us assess global metabolic profıle, including glucose metabo-
lism, energy state, and lipid metabolism in these cells after B2G2 treatment. We
also studied the time-course (4-72 hrs) of B2G2 effect on glucose uptake and
lactate release in themedia of B2G2-treated PCa cells. Our results indicated that
there was differential effect of B2G2 on mitochondrial glucose metabolism in
these cells. While glucose uptake was markedly reduced as a function of time,
there was also a signifıcant decrease in extracellular lactate export with increased
B2G2 exposure-time. Importantly, B2G2 preserved citrate concentration in the
PCa cells as indicated by an increase in citrate levels after treatments; citrate
generation is indicative of normal secretion functions of the prostate epithelial
cells. The fact that the citrate was not further utilized for cholesterol synthesis
was also confırmed by a decrease in cholesterol levels in these cells, indicating
decreased cholesterogenesis by B2G2. Together, these results suggest that B2G2
differentially inducesmetabolic alterations in various PCa cell lines, which could
be associated with its effects on cell growth, proliferation and death, as well as
androgen dependency (or lack of it). In in vivo study examining B2G2 effect on
PCa PC3 tumor xenograft growth in athymic nu/nu mice, B2G2 treatment
(dose: 5mg/kg body weight of mice; given daily as intraperitoneal injections)
signifıcantly decreased tumor volume and tumor weight by 61% and 52%
(both P 0.01), respectively, after 5 weeks of treatments. Taken together, these
studies indicate anti-PCa effıcacy of B2G2 under both in vitro and in vivo sce-
nario and warrant further extensive studies to establish its effıcacy in other PCa
models.
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#1250 Curcumin inhibits migration and growth of human colon cancer
cells through covalent modifıcation of oncogenic SIRT1: Cysteine 67 as a
potential binding site. Yeon-Hwa Lee,1 Na-Young Song,1 Do-Hee Kim,1 Hye-
Kyung Na,2 Young-Joon Surh1. 1Tumor Microenvironment Global Core Re-
search Center, College of Pharmacy, Seoul National University, Seoul, Republic of
Korea; 2College of Human Ecology, SungshinWomen’s University, Seoul, Repub-
lic of Korea.
Silent mating type information regulator 2 homolog 1 (SIRT1), an NAD-
dependent histone/protein deacetylase, has diverse physiological functions, in-
cluding metabolic regulation and stress response. Despite extensive research,
however, the role of SIRT1 in tumorigenesis remains controversial. Recent stud-
ies have demonstrated that SIRT1 is abnormally overexpressed in several human
malignancies, and elevated levels of SIRT1 are correlated with the tumor inva-
sion and metastasis. Curcumin (diferuloymethane), a major component of the
spice turmeric (Curcuma longa L.), has been reported to possess anti-inflamma-
tory and anti-carcinogenic properties. In the present study, we found that SIRT1
is predominantly overexpressed in the cytoplasm of several colorectal cancer
cells as well as colon tumors. Curcumin abrogated migration and colony form-
ing capability of human colon cancer (HCT-116) cells. This prompted us to
investigate the effect of curcumin on the expression of SIRT1 and underlying
molecular mechanisms in the context of its inhibition of the migration and
growth of these cells. When HCT-116 cells were treated with curcumin, the
protein expression of SIRT1was signifıcantly reduced, but the level of itsmRNA
transcript remained unchanged. The curcumin-induced suppression of SIRT1
protein expression was abrogated by the proteasomal inhibitor, MG-132.When
HCT-116 cells were treated with curcumin, ubiquitination of SIRT1 was ele-
vated. Notably, tetrahydrocurcumin, a non-electrophilic analogue of curcumin
that lacks the ,-unsaturated carbonyl moiety, failed to ubiquitinate and de-
grade SIRT1. Nano-LC-ESI-MS/MS analysis revealed the modifıcation of the
SIRT1 cysteine 67 residue. In line with this observation, the protein stability of a
mutant SIRT1 in which cysteine 67 was replaced by alanine (SIRT1-C67A) was
unaffected by curcumin treatment. Furthermore, migration and anchorage-in-
dependent growth of cells expressing SIRT1-C67A were barely inhibited by
curcumin compared with those in cells harbouring wild-type SIRT1. Lysates of
HCT-116 cells incubated with curcumin-conjugated Sepharose 4B beads exhib-
ited covalent binding of curcumin to SIRT1. However, such direct interaction
wasmarkedly reduced in cells with SIRT1 cysteine 67mutation. Taken together,
these fındings suggest that curcumin exerts inhibitory effects on progression of
colon cancer through destabilization of oncogenic SIRT1. The electrophilic,-
unsaturated carbonyl group present in curcumin can covalently modify SIRT1,
preferentially at the cysteine 67 residue, facilitating its degradation via the ubiq-
uitin-proteasome pathway in HCT-116 cells.
#1251 Pioglitazone inhibits periprostatic white adipose tissue inflamma-
tion in obesemice.MikiMiyazawa,1Kotha Subbaramaiah,1 Priya Bhardwaj,1 Xi
Kathy Zhou,1 Hanhan Wang,1 Domenick J. Falcone,1 Dilip D. Giri,2 Andrew J.
Dannenberg1. 1Weill Medical College of Cornell University, New York, NY; 2Me-
morial Sloan Kettering Cancer Center, New York, NY.
Obesity is associated with an increased incidence of high-grade prostate can-
cer (PC) and poor prognosis for PC patients. Recently, we showed that obesity-
related periprostatic white adipose tissue (WAT) inflammation, characterized
by crown-like structures (CLS) consisting of dead or dying adipocytes sur-
rounded by macrophages, was associated with high-grade PC in men. It’s pos-
sible, therefore, that agents that suppress periprostatic WAT inflammation will
alter the natural history of PC. Pioglitazone, a ligand of PPAR, is used to treat
diabetes and possesses anti-inflammatory properties. Here our main objectives
were to determine if pioglitazone inhibited obesity-related periprostatic WAT
inflammation in mice and then to elucidate the underlying mechanism. Mice
were fed either a high fat (HF) diet or low fat (LF) diet to determine if obesity
caused periprostatic WAT inflammation as defıned by the presence of CLS. To
determine if pioglitazone inhibited obesity-associated periprostatic WAT in-
flammation, obese HF diet fed mice were either continued on HF diet alone or
treated with HF diet containing two doses (0.005% or 0.05% w/w) of pioglita-
zone. Treatment with pioglitazone reduced the density of CLS in periprostatic
WAT, and suppressed levels of TNF-, TGF- and the chemokine monocyte
chemoattractant protein-1 (MCP-1). Importantly, the ability of pioglitazone to
suppress periprostatic WAT inflammation was abrogated in MCP-1 knock out
mice. Pioglitazone caused dose-dependent induction of both adiponectin, an
anti-inflammatory adipokine, and its receptor AdipoR2 in cultured 3T3-L1 cells
and in periprostaticWATof obesemice. Pioglitazone blocked TNF--mediated
induction of MCP-1 in 3T3-L1 cells, an effect that was attenuated when either
adiponectin or AdipoR2 were silenced. Taken together, pioglitazone-mediated
induction of adiponectin suppressed the elevation in MCP-1 levels thereby at-
tenuating obesity-related periprostatic WAT inflammation. These fındings
strengthen the rationale for future efforts to determine whether targeting the
PPAR-adiponectin-MCP-1 axis will decrease periprostatic adipose inflamma-
tion and thereby reduce the risk of high-grade PC or improve outcomes formen
with PC.
#1252 A pre-clinical model for lung cancer interception: gene expression
similarities between human and mouse bronchial premalignant lesions.
SarahA.Mazzilli,1 AnnaTassinari,1 XiaohuiXiao,1Gang Liu,1 SamjotDhillon,,2
Candace Johnson,2Mary Reid,2Marc Lenburg,1 Avrum Spira,1 Jennifer Beane1.
1Boston University, Boston, MA; 2Roswell Park Cancer Institute, Buffalo, NY.
The molecular events that drive the development of the premalignant lesions
(PMLs) that precede lung squamous cell carcinoma (SCC) are poorly under-
stood. Amajor limitation to understanding PMLs and developing interventions
is the lack of preclinical models to test candidates derived from human studies.
Previous work by our group and others suggests that the N-nitroso-tris-chloro-
ethylurea (NTCU) mouse model of lung SCC may be a candidate for modeling
human PMLs based on histologic similarities, but its molecular relationship to
human disease is limited. In this study, we investigate the transcriptomic simi-
larities between PMLs from the NTCU treated mice and humans. RNA from 40
whole lung sections (curls) and laser capture microdissected (LCM) of PMLs of
varying histology fromSWR/J andA/Jmice treatedwithNTCUwere profıled by
RNA-Seq. RNA from 131 human endobronchial biopsies representing analo-
gous histological gradeswere also profıled byRNA-Seq as part of the Pre-Cancer
Genome Atlas (PCGA). Linear modeling was used to identify gene expression
differences associated with increasing histological severity, mouse strain and
sample type. Concordance of gene expression associated with histology between
species was investigated using GSEA and GSVA. Biological pathways were in-
ferred using EnrichR and GSEA. A gene expression signature associated with
increasing histological severity across all mouse samples was identifıed (1195
genes, FDR0.05), which was concordant with gene expression differences as-
sociated with increasing histological severity of human PMLs (FDR0.05). We
identifıed a 51-gene (p0.001) and a 178-gene (p0.001) signatures associated
with increasing histology in the all SWR/J and A/J samples respectively. These
gene expression signatures are enriched for biological pathways involved in
immune modulation, occurring with progressing lesions. Conversely, genes
whose expression changed with increasing histology in a model that included
only LCM samples (153 genes at p0.001) revealed epithelial-specifıc processes
including the up-regulation of KRT5 and p63 and loss of TTF1. Additionally, in
the LCM samples, we identifıed up-regulation of genes involved in proliferation
including a number of genes involved in cell structure, metabolism, transcrip-
tion and translation, anti-apoptosis as well as several immunosuppressive genes.
The major fınding of these studies is that there are molecular similarities be-
tween PMLs from human and NTCU treated mice, which suggest that this
mouse model may be useful to investigate targeted early intervention to halt or
reverse PML progression towards lung cancer.
#1254 Mechanistic interrogation of pre-treatment lowdose aspirin effects
in HER 2 positive breast cancer. Ian S. Miller,1 Sonja Khan,2 Liam P. Shiels,3
Sudipto Das,1 Bruce Moran,3 Finbarr P. Leacy,1 Paul M. Loadman,4 Robert S.
Kerbel,5 Darran O’ Connor,1 Kathleen Bennett,1 Róisín M. Dwyer,2 Annette T.
Byrne1. 1Royal College of Surgeons in Ireland, Dublin, Ireland; 2National Univer-
sity of Ireland, Galway, Galway, Ireland; 3University College Dublin, Dublin,
Ireland; 4University of Bradford, Bradford, United Kingdom; 5University of To-
ronto, Toronto, Ontario, Canada.
Background: Prior data (Barron et al. Cancer Res. 2014 74:4065-77) sug-
gests that pre-diagnostic exposure to aspirin can have signifıcant effects on
breast tumor biology and patient outcome. It has been proposed that aspirin
inhibition of COX-2 may suppress lymphangiogenesis and metastasis
(Karnezis et al Cancer Cell. 2014. 21:181-95). Here, we sought to recapitulate
pre-diagnostic aspirin exposure in rodent models of Her2 breast cancer
and elucidate mechanisms of action.We also determined the effect of aspirin
on tumor stroma, using a co-culture system of human tumor and mesenchy-
mal stem cells (MSC). Methods: NOD/SCID mice were orthotopically im-
planted with Her2 MDA-MB-231 or HCC1954 cells. 48hr later, animals
began a daily low dose [30mg/kg or 120mg/kg] of aspirin, until tumors
reached 250mm3. They were then resected. 3 weeks later, HCC1954 im-
planted animals were treated with trastuzumab (15mg/kg) and paclitaxel
(5mg/kg) for 6 weeks. Primary tissues were analysed by immunohistochem-
istry to assess VEGF-C, -D, COX-2, LYVE1 and CD31. RNAseq was per-
formed on tumours to identify aspirin perturbed molecular pathways. To
determine the stromal response to aspirin, patient derived MSCs were cul-
tured either alone or with HCC1954 cells and exposed to aspirin (2.5 or
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7.5mM). Secreted VEGF-C was quantifıed. A tubule formation assay was
performed to determine the impact of aspirin on angiogenesis. Pro-angio-
genic protein expression was investigated using a human angiogenesis array
platform. Results: A signifıcant delay in tumor growth was observed in both
tumor models following aspirin treatment (p.01). Assessment of meta-
static progression revealed that 120 mg/kg aspirin signifıcantly (p.05) in-
creased time to metastasis and reduced primary regrowth in the MDA MB
231 model (p.01). Immunohistochemical analysis of VEGF C, D and
LYVE1 showed a signifıcant dose dependant reduction (p.01) in both
models. RNAseq pathway analysis revealed a signifıcant over-representation
of mitochondrial electron transport chain genes. Downstream factors of
AMPK showed signifıcant (p.01) upregulation suggesting alterations in
metabolism. Aspirin (7.5mM) exposure resulted in loss of VEGF-C secretion
from co-cultured tumor / MSC cell populations. Conditioned media har-
vested following aspirin treatment limited support tubule formation. Ex-
pression of pro-angiogenic factors in HCC1954 cells showed alterations fol-
lowing treatment, with the greatest decrease seen in Urokinase Plasminogen
Activator (42%) and its inhibitor Serpine1 (55%). Conclusion: We have
successfully recapitulated pre-treatment aspirin response in surgical resec-
tion models of Her2 breast cancer, with IHC analysis confırming the im-
pact of treatment on angiogenic and lymphangiogenic factors. RNAseq anal-
ysis implicates aspirin mediated alterations in cellular metabolism. Our data
further reveals increased response to aspirin in stromal cell populations.
#1255 PhIP/DSS-induced colon carcinogenesis in CYP1A-humanized
mice and its prevention by tocopherols. Chung S. Yang,1 Jayson Chen,1 Anna
B. Liu,1 Mao-Jung Lee,1 HongWang,1 Guangxun Li,1 Lanjing Zhang,2 Kenneth
Reuhl,1 Nanjoo Suh1. 1Rutgers University, Piscataway, NJ; 2University Medical
Center of Princeton, Princeton, NJ.
In order to establish a more physiologically relevant colorectal cancer model,
we recently developed a colon-carcinogenesis model induced by the meat-de-
rived dietary carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
(PhIP), and promoted by dextran sodium sulfate (DSS)-induced colitis in the
cytochrome P450 1A-humanized (hCYP1A)mice. PhIP/DSS treatments caused
rapid destruction of the colonic mucosa with severe inflammation, followed by
the presence of reactive changes and low-grade dysplastic lesions, and then
manifestation of high-grade dysplastic lesions and fınally adenocarcinomas in
themiddle to distal colon of the hCYP1Amice after 10weeks.Molecular analysis
of the high-grade dysplastic lesions present at early time-points indicates Ct-
nnb1/-catenin mutations and -catenin nuclear accumulation in high-grade
dysplastic lesions, but not in low-grade dysplastic lesions or adjacent normal
tissues. Using hCYP1A/Lgr5-EGFP mouse, which harbors EGFP-tagged Lgr5
allele, we also investigated the role of Lgr5 colon stem cells in the PhIP/DSS-
induced colon carcinogenesis and found the presence of Lgr5-EGFP-expressing
cells amidst ulcerated mucosa, high-grade dysplastic lesions and adenocarcino-
mas, suggesting a possible role of Lgr5 stem cells in this colon-carcinogenesis
model. In addition, our study demonstrated strong cancer preventive effects of
tocopherols (T), the major forms of vitamin E, in PhIP/DSS-induced colon
carcinogenesis.Dietary supplementationwith 	-T and-T signifıcantly reduced
colon tumor formation and suppressed the expression of markers of oxidative
and nitrosative stress as well as pro-inflammatory mediators in tumors and
adjacent tissues. By administering 	-T at different time points, we found that the
inhibitory effect of 	-T against colon carcinogenesis was mainly due to protec-
tion against early cellular and DNA damages caused by PhIP. -T was found to
be ineffective in inhibiting colon tumorigenesis and less effective in attenuating
the molecular changes. Altogether, PhIP/DSS-induced colon carcinogenesis is
likely initiated from residual epithelial cells (possibly Lgr5 colon stem cells)
and promoted by colitis, and subsequently developed into high-grade dysplasia
and adenocarcinoma. These events are effectively inhibited by 	-T and -T, but
not -T. (This work was supported by the US NIH grants RO1 CA133021, RO1
AT007036, and F31 CA168333 as well as shared facilities funded by center grant
P30 CA72720 and P30 ES005022).
#1256 Non-steroidal anti-inflammatory drugs induce ER stress and have
an immunomodulatory role in the suppression of colorectal tumorigenesis.
Rochelle E. Fletcher,1 Lin Zhang,2 Brian Leibowitz,3 Jian Yu4. 1University of
Pittsburgh Cancer Institute, Pittsburgh, PA; 2University of Pittsburgh, Depart-
ment of Pharmacology, Pittsburgh, PA; 3University of Pittsburgh, Department of
Pathology, Pittsburgh, PA; 4University of Pittsburgh, School of Medicine, Pitts-
burgh, PA.
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths
in the United States. A number of epidemiological studies, clinical trials, and
animal studies have demonstrated the chemopreventive effect of non-steroidal
anti-inflammatory drugs (NSAIDs) on CRC. However, the exact mechanism by
which NSAIDs suppress colorectal tumorigenesis has remained unclear. Our
previous study showed that NSAID-induced death receptor signaling, along
with loss of the gatekeeper APC tumor suppressor, triggers a synthetic lethal
interaction and apoptotic death in an otherwise normal cell. In this study, we
determined how NSAIDs induce death receptor signaling, and found a critical
role of the endoplasmic reticulum (ER) stress response. Treating CRC cells with
the NSAIDs sulindac or indomethacin upregulated C/EBP homologous tran-
scription factor (CHOP), a key mediator of the ER stress response that is re-
quired for the induction of death receptor 5 (DR5) by NSAIDs. Blocking ER
stress abolished the apoptotic effect of NSAIDs in CRC cells and in normal
colonic epithelial cells with knockdown of APC, and also suppressed the che-
mopreventive activity ofNSAIDs inAPCMin/mice. Furthermore, we identifıed
plasma membrane translocation of calreticulin in cells undergoing NSAID-in-
duced apoptosis, suggesting the involvement of immunomodulation in this tu-
mor suppression. Our results provide novel insight into the chemopreventive
mechanism of NSAIDs, whichmay help designmore effective chemopreventive
strategies and agents.
#1257 Paternal sub-optimal nutrition leads to programming of daugh-
ters’ breast cancer risk in a mouse model. Raquel Santana,1 Elissa Carney,1
Hong Cao,1 Johan Clarke,1 M. Idalia Cruz,1 Lu Jin,1 Yi Fu,2 Zuolin Cheng,2
Joseph (Yue)Wang,2 Sonia deAssis1. 1GeorgetownLombardiComp.CancerCtr.,
Washington, DC; 2Virginia Tech University, VA.
Background: Dietary patterns are known to induce epigenetic changes in
paternal sperm. Acquired epigenetic traits have been shown to be transmitted
from parents to offspring via the germ-line (eggs and sperm) and modulate
disease risk in offspring.We have shown before that paternal overweight around
the time of conception leads to reprogramming of the mammary gland tissue
and breast cancer risk in the offspring. Here, we investigated whether paternal
sub-optimal nutrition (low protein diet) could epigenetically reprogram the
father’s germ-line and alter daughters’ likelihood of developing breast cancer,
using a mouse model. Methods: Male mice were fed control (Con) or low-
protein (LP) diets from weaning until sexual maturity; at this point, males were
housed together with female mice reared on control diet. Once a vaginal plug
was detected, males were euthanized for sperm collection. Pregnant dams were
fed the control diet throughout pregnancy and after giving birth. Pups were fed
the control diet throughout the experiment. A subset of female offspring was
euthanized for mammary tissue harvesting on post-natal day (PND) 50, which
was used for morphologic and molecular analyses. Another sub-set of female
offspring was treated with 9,12-dimethylbenz[a]anthracene (DMBA) to induce
mammary tumors. Results: We found that male LP consumption alters the
non-coding RNA content andDNAmethylation patterns of the sperm in agree-
ment with previous fındings.We also observed that, compared to Con offspring,
the female offspring of LP fathers had lower birth weight (p0.035). This de-
crease in body weight persisted through sexual maturity when females begun to
gainmore weight than their control counterparts (p0.001). In addition, mam-
mary glands of LP offspring were larger(p0.02) and had increased epithelial
density (p0.001) when compared to Con on PND50. In addition, we found
that LP mammary glands had epigenetic alterations, including in DNAmethyl-
ation and the miRNA expression profıles. These changes in normal mammary
tissue were associated with higher rates of DMBA-induced mammary tumor
(p0.04), increased tumor growth (p0.03) and reduced tumor latency in LP
offspring (p0.03). Mammary tumors of LP offspring had lower rates of apo-
ptosis, which may explain the increased tumor growth in this group. However,
the mechanisms mediating this effect still needs to be elucidated. Conclusion:
Paternal sub-optimal nutrition programs the female offspring mammary gland
development and breast cancer risk. Whether this increase in cancer risk is due
to local mammary tissue changes or whether systemic changes play a role re-
mains to be investigated. It also remains to be determined whether epigenetic
changes in paternal sperm are functionally linked to changes inmammary gland
development and cancer risk.
#1258 Lifestyle improvements delay cancer onset and progression by
adapting endocrine and immune signaling inmousemodels.Grant D. Fogle-
song, Stephen M. Bergin, Wei Huang, Michael A. Caligiuri, Lei Cao. The Ohio
State University, Columbus, OH.
Metabolic syndromes instigate substantial morbidity and mortality world-
wide via its negative effects of many diseases including cancer. Obesity in par-
ticular has been deemed a causative factor for breast cancer in post-menopausal
women, while worsening prognosis regardless of menopausal status. Impor-
tantly, progression of many metabolic syndromes can largely be slowed or re-
versed with aggressive lifestyle changes, thus also having the potential to miti-
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gate cancer onset. A mouse model of environmental enrichment (EE) to
improve motosensory, cognitive, and social stimulation by increasing physical
engagement and social interaction triggers vast improvements in overall health.
These include boosting mental health, reducing adiposity, prevention of diet-
induced obesity (DIO), promoting the white to brown fat transition, enhancing
insulin sensitivity, improving immune function, limiting inflammation, and in-
hibition of cancer growth.Wehave elucidated the centralmechanismof EE to be
the activation of the hypothalamic-sympathoneural-adipocyte (HSA) axis, a
specifıc neuroendocrine route in which the brain communicates with adipose
tissue via the sympathetic nervous system.Once activated, norepinephrine (NE)
is released directly onto adipose tissue which induces the observed metabolic
improvements. Breast cancer is uniquely exposed to this adipose-NE so we
sought to explore this distinctive microenvironment in the context of both local
and systemic endocrine and immune signaling in varied body mass states and
menopausal statuses. Our data showed that EE diminished leptin levels and
delayed cancer onset in the MMTV-PyMT spontaneous mouse model of breast
cancer and slowed growth in a DIO allograft model. In contrast, EE failed to
attenuate tumor progression in ob/ob mice in the absence of leptin, but rather
enhanced tumor growth, suggesting that the leptin-NE relationship is one of the
key peripheral mediators of the EE anti-breast cancer effects. We also observed
signifıcant immune cell modulation in the adipose tissue following EE. Initial
characterization revealed a decrease in the proportion of tumor-associatedmac-
rophages (TAMs) and an overall anti-inflammatory response which together
with the drop in leptin may contribute to the observed anti-cancer effects. We
plan to further elucidate this EE-induced adipose and immune cell modulation
with the ultimate goal of developing therapeutic strategies to treat both meta-
bolic syndromes as well as associated and possibly independent cancer types.
#1259 Stem cell property-suppressing microRNAs are stimulated and
their target proteins inhibited by vitamin D and progesterone in ovarian
cancer cells.Rebecca Rosales, Jane Turbov, Jennifer Yoo,GustavoC. Rodriguez,
Larry G. Thaete. NorthShore University HealthSystem, Evanston, IL.
Vitamin D (1,25(OH)2D3) and progesterone (P4) have both been shown to
reduce the incidence of ovarian cancer. Mechanisms involved in their actions
are not fully known but each one can enhance the effect of the other. Six micro-
RNAs (miRNAs), associated with suppression of cancer stem cell properties,
were investigated fırst in a screening array and then with a more defınitive
RT-PCR investigation of the response of thesemiRNAs to 100 nM1,25(OH)2D3
and 100 nM P4. These experiments were conducted in cells that do (OVCAR-
3-PGR) and do not (SKOV3) express nuclear progesterone receptors (PGR).
Let-7a and Let-7b are known to decrease expression of Ras and c-Myc and
reduce stem cell self-renewal. Let-7b expressionwas increased (p0.001) at 48 h
in response to combined 1,25(OH)2D3 and P4 when PGR were present, and in
response to individual and combined treatments at 72 h (p0.01). Correspond-
ingly, c-Myc expression was decreased (p0.001) by both P4 and combined P4
and 1,25(OH)2D3. Let-7a expression was not affected by these treatments. No
treatment-related change in the production of ras protein was observed com-
pared to controls. In the absence of PGR (SKOV3 cells), c-Myc was suppressed
by combined P4 and 1,25(OH)2D3 treatment at 24 h and 48 h. miR-26a and
miR-101 are known to downregulate EpCAM and EZH2, leading to decreased
invasion and metastasis and to reduced proliferation. miR-101 increased
(p0.001) at 48 h in response to combined 1,25(OH)2D3 and P4 in cells express-
ing PGR. It was increased (p0.05) at 36 h and showed synergy in the screening
array in the absence of PGR. Target proteins EZH2 and EpCAM decreased
moderately (p0.05) at 72 h combined treatment, both with and without PGR
present.miR-26a expressionwas not affected by these treatments.miR-200b and
miR-200c are known to suppress expression of ZEB1 which in turn decreases
Bmi1 and Sox2 to increase E-cadherin (epithelialmarker) anddecrease vimentin
(mesenchymal marker), thus inhibiting the epithelial-to-mesenchymal transi-
tion. Expression of miR-200b was increased (p0.05) at 24 h and 72 h in re-
sponse to P4 when PGR were present. miR-200c expression was not responsive
to these treatments. ZEB1 was decreased (p0.01) at 48 h in response to com-
bined 1,25(OH)2D3 and P4. These results point not only to differences among
cancer cell lines but they also emphasize a possible mechanism by which P4 and
1,25(OH)2D3 may work together to prevent the occurrence of ovarian cancer,
namely by suppressing stem cell renewal and the formation of neoplastic lesions.
The results also reveal that P4 may act via other signaling pathways than its
primary nuclear receptors to effect suppression of stemcell properties. Increased
expression of cancer stem cell-suppressingmiRNAsmay be an importantmech-
anism mediating the effıcacy of a progestin-based ovarian cancer prevention
strategy.
#1260 Diet and exercise-induced weight maintenance may be preventing
mammary tumor growth and metastatic burden by enhancing antitumor
immunity and/or reducing protumorigenic factors.William J. Turbitt, Yitong
Xu, Andrea M. Mastro, Connie J. Rogers. The Pennsylvania State University,
University Park, PA.
Two lifestyle factors that increase cancer risk and progression are weight gain
and sedentary behavior. Possible mechanisms underlying this relation include
changes in metabolic, inflammatory, and immune mediators. Few studies have
examined the effect of body weight and exercise on the effıcacy of immunother-
apeutic strategies. An emerging immunotherapeutic strategy is PD-1 check-
point blockade, which selectively targets the membrane protein programmed
cell death-1 (PD-1) on T cells to promote a sustained, antitumor effector re-
sponse. Thus, the goal of the current studywas to determine if preventingweight
gain through diet (10% reduction in calories) and exercise (voluntary running
wheel activity) will improve the response to the dual administration of a whole
tumor cell vaccine and PD-1 checkpoint blockade. Female BALB/c mice were
randomized to sedentary, weight gain (WG) or exercising, weight maintenance
(WM) groups (n32/group). After 8 weeks, all mice were orthotopically in-
jected with 5x104 luciferase-transfected 4T1.2 cells into the fourthmammary fat
pad and continued on their intervention for 35 days. After injection, WG and
WM mice were randomized into vaccination (VAX) or vehicle (VEH) groups,
and 1x106 irradiated 4T1.2 cells or HBSS vehicle control, respectively, was ad-
ministered at day 7 post-tumor injection. Mice were further randomized (n8/
group) to receive anti-PD-1 (10mg/kg/mouse) or isotype control at day 9 and 12
post-tumor injection. All WM groups, regardless of immunotherapy interven-
tion, weighed signifıcantly less than WG groups over the course of the study
(p0.001). Mean tumor volume (p0.001) and tumor weight at sacrifıce
(p0.076) were signifıcantly lower with PD-1 treatment in theWGbut notWM
groups. Furthermore, metastatic burden in the lung (p0.032) and the number
of splenic myeloid-derived suppressor cells (p0.058) was reduced with
VAXPD-1 treatment in the WG but not WM groups. Thus, the combination
of VAXPD1 was effective at reducing primary tumor growth and metastatic
burden and improving immune outcomes only in mice that gained weight over
the course of the study. However, diet and exercise alone was effective in reduc-
ing tumor growth and metastatic burden. The lack of responsiveness to vacci-
nation anti-PD-1 treatment inWMmice suggests thatWMachieved through
diet and exercise may be enhancing antitumor immunity and/or reducing pro-
tumorigenic factors (i.e. similar mechanisms mediated by vaccination  anti-
PD-1 therapy). These data demonstrate that preventingweight gain throughdiet
and exercise may be an important recommendation to maintain prolonged an-
titumor effector responses and improve clinical outcomes.
#1261 Lipid-peroxidation derived DNA damage is prevented in obesity-
related hepatocarcinogenesis through CD4mediated apoptosis in the liv-
ers ofmice on a green-tea diet.Heidi Coia, NingMa,MarcinDyba, Fung-Lung
Chung. Georgetown UNIV., Washington, DC.
Using a C57BL/6J bioassay, we assessed whether formation of a lipid-peroxi-
dation (LPO)-derivedDNAadductwould inducemutations during the progres-
sion of obesity-induced hepatocarcinogenesis and if its formation could be pre-
vented using a diet infused with Theaphenon E, a mixture of polyphenols
extracted from green tea. Obesity is now the leading risk factor for the develop-
ment of hepatocellular carcinoma in the United States. We have conducted a
life-time C57BL/6J tumor bioassay to assess the role of obesity in the formation
of -hydroxy-1,N2-propanodeoxyguanosine (-OHPdG), a promutagenic
DNA adduct formed endogenously by LPO. Previously, we have shown
-OHPdG was detected in FFPE liver tissues of patients with different stages of
liver disease, demonstrating that its formation is consistentwith LPO in the early
stages of liver disease and suggesting that itmay be a source of endogenousDNA
damage in hepatocarcinogenesis. Tea polyphenols, predominately EGCG, are
antioxidants that have been shown to prevent obesity and tumorigenesis. For the
bioassay, mice were fed either a high fat, low fat, or high fat 2% TE diet starting
at 4 weeks of age. Tissue and blood were collected over the course of 80 weeks at
11 separate time points. Health of the mice was assessed using serum concen-
trations of ALT and AST, gross morphology and immunohistochemistry of
TUNEL, Ki67 and CD4. In contrast to the high-fat and low-fat diet mice, the
TE treatedmicemaintained a healthy bodyweight, liver to bodyweight ratio and
low levels of AST and ALT enzymes which are elevated in liver disease. Addi-
tionally, the health of the liver appears to be maintained through increased
CD4 mediated apoptosis in TE treated mice as demonstrated through de-
creased Ki67 expression and TUNEL staining showing increased apoptosis in
TE treated mice livers in conjunction with increased CD4 cells. The CD4
immune response may, therefore, be targeting cells with mutagenic potential.
Similar to the trend indicated by the clinical samples, during hepatocarcinogen-
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esis in the high fat dietmice, adduct levelswere increased initially and likely fıxed
into mutation at later time points, where their levels decreased, as quantifıed by
LC-MS/MS. In contrast, in the TE treated mice, the average -OHPdG levels
remained consistently low. Further studies incorporating whole exome se-
quencing of the tumors that were formed during the life-time bioassay will
indicate whether -OHPdG may contribute to the mutations that occured. In
conclusion, our study has shown that a robust immune system response medi-
ated by TE may be an underlying mechanism to combat the DNA adduct-
induced DNA damage that may lead to HCC.
#1262 Aspirin inhibits the carcinogenesis of esophageal squamous cell
carcinoma and enhances its responses to cisplatin. Zhigeng Zou, Hongjun
Fan, Xiying Yu, Shuming Zhang, Liping Guo, Wei Jiang, Shih-Hsin Lu. Cancer
Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union
Medical College, Beijing, China.
Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malig-
nancies. Over 70% of ESCC cases occur in China. Unfortunately, the treatment
of ESCC has hardly been improved all these years. Several studies suggested that
aspirin (ASA) might decrease the risk of ESCC and prolonged the survival of
patients with ESCC. However, it is unclear if ASA could prevent ESCC and/or
enhance ESCC treatment by chemotherapy. In this study, a N-nitroso-N-meth-
ylbenzylamine (NMBzA) - induced ESCC model was employed to prove that
aspirin could prevent the growth of esophageal tumor. F344 rats were treated
with NMBzA by subcutaneous injection with or without ASA in drinking water
(2mg/ml). After 35 week ASA-NMBzA or NMBzA alone treatment, rats were
killed and esophageal tumor development were examined. The results showed
that F344 rats treated with NMBzA and receiving a daily intake of ASA devel-
opedmuch less tumors than F344 rats treatedwithNMBAalone both in amount
and in size (Tumor count: 2.40 	 1.57 vs 10.85 	 3.86 , P  0.001; Tumor
volume: 11.10	 13.38 mm3 vs 70.79	 41.65 mm3, P 0.001). Immunohisto-
chemical analysis indicated that a higher rate of apoptosis was observed in the
basal layer of esophageal epithelium in ASA-NMBzA treated rats than in
NMBzA alone treated rats. These results indicated that ASA prevented develop-
ment of esophageal tumors in rats induced byNMBzA.Moreover, using in vitro
humanESCC cell culture and in vivo xenograftmodels, we showed that ASAhas
strong benefıcial effects on inhibition of ESCC cell proliferation and colony
formation, reduction of ESCC cancer stem cells and enhance of ESCC cell cyto-
toxicity induced by cisplatin treatment. Biochemical analysis revealed that these
effects of ASA on human ESCC cells in vitro and in vivo were due to inhibiting
the repairing of DNAdamage, decreasing the efflux activity andALDH1 activity
of the tumor cells, and blockades of PI3K/Akt pathway. Thus, our results dem-
onstrated a positive role of aspirin in the prevention and treatment of ESCC.
#1263 Andrographolide inhibits prostate cancer by suppressing cytokine
involved in promoting epithelial to mesenchymal transition. Hina Mir,1
Neeraj Kapur,1 Guru Sonpavde,2 Shailesh Singh1. 1Morehouse School of Medi-
cine, Atlanta, GA; 2UAB Comprehensive Cancer Center, Birmingham, AL.
Mesenchymal phenotypes are responsible for cancer progression and poor
therapeutic response. Hence, approaches targeting mesenchymal phenotype or
inhibiting epithelial to mesenchymal transition will signifıcantly prevent cancer
progression or improve therapeutic outcome. Using in vitro models andmolec-
ular approaches we have shown that Andrographolide (AG), a compound iso-
lated from Andrographis paniculata, shows promising effect on mesenchymal
cells. It disposes PCa cells towards epithelial phenotype by modulating E-cad-
herin, ZEB-1, SNAIL and TWIST. In addition to these, signifıcant inhibition in
IL-6, which is known to be a poor prognostic maker, was observed in PCa cells
treatedwithAGcompared to untreated cells. This reduction in IL-6 could be due
to AG induced suppression of SOCS (Suppressor of cytokine signaling) mole-
cules. Therefore, our data underscores the ability ofAG to impede cancer growth
by impacting EMT and rationalizes its application as a potent therapeutic agent.
#1264 Studying senescence in prostate of selenium treated rats undergoing
carcinogen-induced, androgen-promoted prostate carcinogenesis. Kartick C.
Pramanik,1 Michael Schlicht,2 Maarten Bosland,2 Chang Jiang,1 Yibin
Deng,3 Junxuan Lu1. 1Penn State University, College of Medicine, Hershey,
PA; 2University of Illinois at Chicago, IL; 3The University of Minnesota
Hormel Institute, MN.
Preclinical studies from us and others have shown that oral intake of next-
generation selenium (Se) forms, especially methylseleninic acid (MSeA) and
Se-methylselenocysteine (MSeC) inhibits mouse prostate carcinogenesis. Our
recent study has shown that MSeA suppresses pten-defıcient mouse high grade
prostatic intraepithelial neoplasia progression to adenocarcinoma in association
with superactivating p53-p21mediated cellular senescence. To address the ques-
tion whether the activation of senescence is induced in prostate carcinogenesis
driven by different etiology, we sought to test the in vivo effect of different
selenium forms fed to rats undergoing chemically induced, androgen promoted
prostate carcinogenesis. Wistar-Unilever (WU) rats (10-12 wks) were sequen-
tially treated with androgen receptor blocker flutamide for 21 days (10 mg/kg/
day by gavage), followed by testosterone propionate (TP, 10 mg/kg, s.c) on day
22. Three days after TP, chemical carcinogenmethylnitrosourea (MNU, 30 mg/
kg/bw) was administered by i.p. injection. One week later, the rats received
testosterone-containing silastic implants. Rats were randomized to groups fed
the AIN-93M diet or supplemented with 3 ppm of Se as MSeA, MSeC, or sel-
enomethionine (SeMet). Separate groups of rats were fed these diets, but did not
receive the carcinogen treatment. After 16 weeks of this dietary treatment, rats
were euthanized. Blood, major organs and different prostate lobes were dis-
sected and weighed. The body weight of carcinogen-exposed rats was signifı-
cantly lower than their non-carcinogen-exposed counterparts. However, total
prostate complex weight was higher in carcinogen-treated groups than the non-
carcinogen groups, consistent with MNU and extra-testicular androgen pro-
moting prostate epithelial cell proliferation. There were no signifıcant organ-to-
body weight ratio differences of various prostate lobes in the different dietary
groups, regardless of the carcinogen exposure status. In order to test the involve-
ment of senescence in prostate of rats fed different Se diets, we have undertaken
steps to optimize staining method for senescence-associated -galactosidase
(SA-gal) activity in different lobes of prostate frozen sections. Together, with
whole slide imaging using anAperioDigital Pathology Scanner for quantitation,
we are afforded an approach for more objective interrogation of the role of
senescence in this carcinogenesis model and chemoprevention by selenium
compounds.
#1265 Mechanisms underlying genomic integrity in breast cancer-derived
dormant circulating tumor cells.Debasish Boral,1 Haowen N. Liu,1 Wei Yin,1
Monika Vishnoi,1 Marc L. Sprouse,1 Jenny C. Chang,2 Jean Paul Thiery,3 Sca-
mardo Antonio,4 David S. Hong,4 Dario Marchetti1. 1Houston Methodist Re-
search Institute, Houston, TX; 2Houston Methodist hospital, Houston, TX; 3Na-
tional University of Singapore, Singapore, Singapore; 4The University of Texas
MD Anderson Cancer Center, Houston, TX.
Patients with metastatic breast cancer have a fıve-year survival rate of 22%
compared to 99% in patients with cancer localized to the breast. This disparity in
clinical outcome is at least in part caused by the lack of diagnostic tools for early
detection of metastatic recurrence. This can be especially valid for breast cancer
patients having brain metastases (BCBM), 10-20% of whom are diagnosed only
at autopsy. The early detection of circulating tumor cells (CTCs) in peripheral
blood during the metastatic cascade provides a window of opportunity to pre-
vent BCBM onset. However, to target CTCs causing BCBM, one must dissect
mechanisms that allow CTCs to retain their brain metastatic potency while
remaining dormant in circulation. We hypothesized that hyperactive mecha-
nisms of DNA repair preserve the genomicmake-up of dormant CTCs allowing
them to maintain over time the potential for BCBM competence. Comprehen-
sive analyses of breast cancer patient-derived CTC transcriptomes showed that
CTC gene signatures closely relate to basal-like breast cancer cell lines rather
than the molecular subtype of the primary tumor. However, unlike actively
cycling cell lines, a large proportion of CTCs were mitotically dormant (Ki67-/
PCNA-) with low overall mRNA expression and transcriptional activity. Upon
systemic injection of patient-derived common lineage-depleted cells into im-
muno-compromised mice, the majority of CTCs were found at metastatic sites
in a state of mitotic/metabolic dormancy. Second, dormant CTCs had a lower
incidence of double-strand DNA breaks (DSB) than proliferating cells as as-
sessed by Serine139 phosphorylation status of gammaH2AX. Third, we discov-
ered that the human telomere-associated protein RIF1, amediator of alternative
non-homologous end joining repair of DNA DSB interplaying with BRCA1/2,
was signifıcantly up-regulated in the Ki67-/PCNA- CTC population. RIF1/
BRCA1 foci formation was confırmed in areas of DNA damage in these cells.
Lastly, shRNA-mediated RIF1 knockdown promoted dormant cell populations
to becomemore susceptible to UV and bleomycin-induced DNA damage while
activating p38 and ERK stress-response pathways as well as their phosphoryla-
tion ratio. Moreover, RIF1 knockdown in MDA-MB231BR clone attenuated its
metastatic competence to the brain. Collectively, these fındings suggest that
RIF1 regulates the genomic integrity of dormant CTCs allowing them to survive
over time while in circulation. Further elucidation of RIF1-mediated CTC path-
ways and its dynamicswith BRCA1/2may provide novel strategies for therapeu-
tic intervention. This can be clinically useful in breast cancer patients that are yet
to develop overt BCBM.
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#1266 Metformin represses esophageal carcinogenesis in NMBzA-treated
rat model through inhibiting AMPK/mTOR and Stat3 signaling pathways.
Hongjun Fan, Zhigeng Zou, Xiying Yu, Liping Guo, Wei Jiang, Shih-Hsin Lu.
National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences
and Peking Union Medical College, Beijing, China.
Esophageal cancer is one of the most aggressive tumor types because of its
invasiveness and metastatic potential. Metformin is one of the most used
diabetic drugs for the management of type 2 diabetes mellitus in the world.
The role of metformin in prevention of the development and progression of
a variety of human tumors has been studied. However, the detailed mecha-
nisms have not yet been fully understood. In the present study, we investi-
gated the effects of metformin on the suppression of esophageal carcinogen-
esis in a rat model, in which F344 rats were treated with N-nitroso-N-
methylbenzylamine (NMBzA 0.30 mg/kg s.c.) three times per week for 35
weeks to induce esophageal tumors. To monitor the effects of metformin in
this model, one group of rats were administered with metformin (3 g/L) in
the drinking water at the fırst NMBzA injection. Our results showed that
although there was no signifıcant difference in body weight in rats of differ-
ent groups, rats treated with NMBzA and metformin together signifıcantly
reduced the tumor formation and tumor volume when compared with rats
treated with NMBzA alone. Statistic analyses demonstrated that the tumor
numbers was reduced in NMBzA-treated rats received metformin to an av-
erage of 1.85 	 1.09 tumors per rat when compared with 10.85 	 3.86 (P 
0.001) in rats without metformin, while the tumor volume was decreased
from 70.79	 41.65mm3 per rat without metformin administration to 8.64	
13.45 mm3 (P 0.001) with metformin administration. In addition, 7 out of
24 rats in the NMBzA-treated group died before week 35 but no rats died in
the other groups. Furthermore, immunoblotting analysis indicated that p-
mTORSer2448, p-Stat3Tyr705, and Cyclin D1 protein levels signifıcantly de-
creased, while p-AMPKThr172 signifıcantly increased in tumors obtained
from rats treated with NMBzA and metformin when compared with tumors
obtained from rats treated with NMBzA alone. Thus, our results indicated
that metformin suppressed NMBzA-induced esophageal carcinogenesis via
inhibition of the AMPK/mTOR and Stat3 signaling pathways. Together, our
study suggested that metformin might have a potential use for treatment and
prevention of esophageal cancer.
#1267 Emodin exerts its anticancer effect on colon cancer cells by inhibit-
ing proliferation and inducing apoptosis. Ian T. Saunders, Hina Mir, Neeraj
Kapur, Shailesh Singh.Morehouse School of Medicine, Atlanta, GA.
Despite state of the art diagnostic and therapeutic options offered in the
clinics, colon cancer is still a major health care concern. Therapeutic out-
come is often compromised due to late diagnosis and development of resis-
tance against treatment options used to treat advanced disease. Hence, the
need to explore new avenue to treat/prevent colon cancer more effectively
still exist. In this study we have investigated potential impact of Emodin, an
anthraquinone derived from plant (Rheum rhabarbarum) on colon cancer
cell proliferation, survival and apoptosis. Our data show that emodin re-
duces the cell viability and inhibits proliferation of human colon cancer cell
(COLO-201 and DLD-1) in a time-dependent manner. Furthermore, FACS
analysis show higher percentage of apoptotic cells with Emodin treatment
compared to untreated cells. Interestingly, pro-inflammatory and anti-in-
flammatory cytokines produced by colon cancer cells were modulated with
Emodin treatment. Cancer cells often use these cytokines to achieve their
goal to progress and escape the treatment. Our data implies Emodin could be
a promising agent that could be used for chemoprevention as well as in
therapeutic combination to improve effıcacy of conventional therapy.
#1268 Bitter melon effıcacy against human pancreatic cancer cells: possi-
ble involvement of cellular stemness and metabolome targets. Deepanshi
Dhar, Gagan Deep, Sushil Kumar, Chapla Agarwal, Natalie Serkova, Michael
Wempe,KomalRaina, RajeshAgarwal.Univ. of ColoradoDenver School of Phar-
macy, Aurora, CO.
Pancreatic cancer (PanC) has a dismal 5-year survival rate of 5%. Symp-
tomless progression, late diagnosis and rising drug resistance to leading
chemotherapeutic agents like gemcitabine, add to PanC severity. Hence,
there is a critical requirement for identifying alternative novel non-toxic
agents (dietary/non-dietary) aimed at effective management of PanC with
minimal patient distress. Bitter melon (Momordica charantia), a dietary
agent, is actively being investigated for its anti-cancer potential against a
variety of malignancies, including our work in PanC. Recent studies by us
have shown bitter melon juice (BMJ) effıcacy against a panel of human PanC
cell lines in culture and tumor xenografts. For mechanistic studies, here we
evaluated the effıcacy of BMJ against cancer stem cells (CSCs) pool in PanC
cells. Results indicated that BMJ treatment (0.25-2% v/v) signifıcantly de-
creased CSC enriched (CD44CD24EpCAMhigh) PanC cell population. Suc-
cessive immunofluorescence/immunohistochemical analysis of BMJ exposed
cells, spheroids and MiaPaCa2 xenograft tumors showed a signifıcant reduc-
tion in CSC markers/ regulatory molecules. Since cancer cell metabolism is an
important component to be targeted to control cancer growth and progression,
we next assessed BMJ effıcacy in that direction. Indeed, BMJ mediated its anti-
PanC effect via activating the keymetabolic regulatorAMPK.Concomitantly, to
determine whether BMJ-effects were nutrient/energy stress dependent, we next
sought to determine the cellular energy profıle and major metabolic changes
induced by BMJ. PanC cell metabolome analysis was done, as a function of time,
to determine the shift in PanC cell metabolism on BMJ exposure. 1H-, 13C- and
31P-NMR spectra of PanC cell monolayers treated with BMJ (2% v/v) at early (
4h) and late (72h) time points showed signifıcantly altered energy status and
modulation of major metabolic pathways involved in PanC cell growth and
proliferation. A signifıcant reduction in glucose uptake and cellular energy levels
(ATP/ADP) ratiowas observed, but lactate export was increased. BMJ alsomod-
ulated nucleotides and aromatic amino acids involved in protein precursors/
synthesis for PanC growth and proliferation. Total fatty acids and phosphatidyl-
choline levels (a precursor of membrane lipids) were also downregulated by
BMJ. Glutamine and glutamate levels were constrained by BMJ, indicating that
it could potentially limit PanC cell ability for targeting an alternative energy
source. Furthermore, the cellular levels and membrane localization of GLUT1
(major glucose transporter overexpressed in PanC) were also suppressed after
BMJ treatment. Collectively, these results suggest that BMJ targets PanC CSCs
and cellularmetabolism in its effıcacy against this deadlymalignancy (supported
by CA195708).
#1269 Preventive potentials of the fruits of Detarium microcarpum on
N-methyl nitrosourea (MNU) induced colon carcinogenesis in rats.Mubarak
L. Liman,1 Sunday E. Atawodi2. 1Nuhu Bamalli Polytechnic, Zaria- Kaduna,
Nigeria; 2Ahmadu Bello University, Zaria- Kaduna, Nigeria.
Detaruim microcarpum Guill. & Perr is a leguminous African plant with
signifıcant nutritional and medicinal uses. In an experimental N-methyl
nitroso urea (MNU) induced colon carcinogenesis in rats, various concen-
trations of pulverized D. microcarpum fruits were included in diets of rats
and the chemopreventive effects of these supplemented diets were investi-
gated. The rats were divided into 10 groups (n7) and fed for 10 weeks with
diets containing 2.5%, 5.0% and 10.0% D. microcarpum. Subsequently, the
feeding continues for another 12 weeks but with concomitant intra-rectal
administration of MNU at every 72 hour interval. Respective control groups
fed similar concentrations of supplemented diets, normal diet with or with-
out MNU intoxication were also included. All rats were sacrifıced at the end
of the 22 weeks experiment; blood collected for hematological analysis and
serum was separated for carcinoembryogenic antigen (CEA) assay and other
biochemical tests. Liver, kidney and colon were also collected for antioxidant
and tissue peroxidation assays. Sections of the colon were subjected to his-
topathological studies and immunohistochemical (IHC) staining using
mutL homolog 1 (MLH1) antibody. A signifıcant (p0.05) elevation was
observed in levels of CEA (210 	 18 pg/ml) in the MNU positive control
group when compared with the test groups and the negative control group
(70	 6 to 140	11 pg/ml). There were signifıcant decreases (p0.05) in the
major hematological parameters (PCV, hemoglobin, WBC etc) levels, cata-
lase and superoxide dismutase (SOD) activities in the MNU control group
when compared to other groups. A concomitant signifıcant increases
(p0.05) was also observed in the levels of liver function enzymes and kid-
ney function biomarkers as well as thiobarbituric reactive substance (ma-
liondealdehyde) in the MNU control group when compared to the test
groups and other controls. It was further observed that these variations in the
CEA and antioxidant status markers were dose dependent in many in-
stances. Histopathological and IHC staining of the colons in the treated
groups showed mild changes in tissues with no expression of the MLH1
antibody when compared with the MNU control group having moderate
damage and expression of the antibody. Hence it was concluded that the
inclusion of fruits of D. microcarpum in the diet protected the organs and
tissues of the rats from induced MNU toxicity; ameliorated oxidative stress
in colon carcinogenesis model and possibly prevented the initiation of the
process of carcinogenesis implying that the fruits possess signifıcant health
benefıts which may have warranted their usage in foods and also in tradi-
tional medicine in Africa.
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EPIDEMIOLOGY: Genetic Variation (Non-GWAS) and Cancer
Risk, Prognosis, or Mechanisms
#1270 Vitamin E related genetic variants and prostate cancer risk: A
Mendelian randomization analysis. Tracy M. Layne, Shakira M. Nelson,
Stephanie J. Weinstein, Eric Karlins, Stephen J. Chanock, Demetrius Albanes,
The PRACTICAL Consortium. National Cancer Institute, Bethesda, MD.
Alpha-tocopherol is a highly biologically active form of vitamin E that has
been inconsistently associated with prostate cancer risk in cohorts and supple-
mentation trials. In order to further elucidate the association using aMendelian
randomization approach that avoids sources of bias common in observational
research, we examined genetic variants related to vitamin E status, including
those from GWAS analyses of circulating vitamin E, in relation to prostate
cancer risk in the Prostate Cancer Association Group to Investigate Cancer
AssociatedAlterations in theGenome (PRACTICAL)Consortium. The analysis
included 38,868 cases and 25,210 controls from 35 participating cohorts and
examined the association between 847 vitamin E-related single nucleotide poly-
morphisms (SNPs) in (or near) six genes and risk of prostate cancer. Logistical
regression was used to estimate meta-analyzed case-control odds ratios (OR)
and 95% confıdence intervals (CI) for the per allele risk associations. Both geno-
typed and imputed data were examined, and results for the latter are presented
based on the consistency between the two sets of fındings. In addition to exam-
ining SNPs demonstrating nominal signifıcance (alpha-error p0.05), a Bon-
ferroni threshold of 0.00006 was applied to adjust for multiple comparisons.
We found 89 SNPs were nominally signifıcantly associated with prostate cancer
risk. This included SNPs involved in vitamin E transport (i.e., SEC14L2 and
SCARB1) andmetabolism (i.e., BUD13/ZNF259). The top three risk-associated
SNPs (P 0.001) included rs141696823 (OR  0.59, P6.0x10-5) in CYP4F8
(cytochromeP450 family 4 subfamily Fmember 8) on 19p13.12which functions
as a prostaglandin hydroxylase in the seminal vesicles, and rs1915379 (OR 
1.04, P0.0002) in CYP4F3 (cytochrome P450 family 4 subfamily F member 3)
on 19p13.12 which oxidizes arachidonic acid and omega-hydroxylates tocoph-
erol phytyl side chains, and has been directly associated with higher circulating
alpha-tocopherol. The fınal SNP (r185614299, OR  1.19, P0.0004) is in
NKAIN3 on 8q12.3, which encodes theNa/K transportingATPase Interact-
ing Protein 3, a plasma membrane enzyme responsible for maintenance of in-
tracellular electrolyte gradients. Vitamin E has been shown to reduce cell mem-
brane lipid peroxidation, thereby promoting Na/K-ATPase activity. Other
variants on this gene have previously been associated with serum alpha-tocoph-
erol concentration in response to vitamin E supplementation in the ATBC
Study. The present Mendelian randomization analysis suggests genetic variants
related to vitamin E metabolism, its role as an antioxidant, and its function in
inflammatory processes, may be associated with prostate cancer risk.
#1271 Genetic variants in the 16q24.3 region of melanocortin-1-receptor
(MC1R) and prostate cancer risk: A Mendelian randomization analysis of
39,000 cases and 25,000 controls. Stephanie J.Weinstein, TracyM. Layne, Jiaqi
Huang, Eric Karlins, Stephen J. Chanock, Demetrius Albanes, the PRACTICAL
Consortium. National Cancer Inst., Bethesda, MD.
We previously reported that men with naturally red hair had a signifıcantly
lower risk of prostate cancer (HR0.46, 95% CI 0.24-0.89) compared with the
most prevalent hair color, light brown (Br J Cancer 2013;109(3):747-750). The
red hair phenotype is encoded by variants in the melanocortin-1-receptor
(MC1R) gene that controls expression of the eumelanin and pheomelanin pig-
ments. In order to re-examine this association through the relatively unbiased
Mendelian randomization approach, we examined single nucleotide polymor-
phisms (SNPs) in and near MC1R in relation to prostate cancer risk using data
from the Prostate Cancer Association Group to Investigate Cancer Associated
Alterations in the Genome (PRACTICAL) consortium. The analysis includes
38,868 men diagnosed with prostate cancer and 25,210 controls from 35 studies
participating in PRACTICAL Consortium (Nat Gen 2014;46(10)1103-1109).
Logistic regression modeling was used to estimate the odds ratio (OR) and con-
fıdence interval (CI) for the per allele prostate risk associations with 148 geno-
typed SNPs and 164 imputed SNPs. Variants demonstrating nominal signifı-
cance (alpha-error p0.05) as well as those reaching a stringent Bonferroni
threshold of p0.0003 adjustment for multiple comparisons were examined.
We identifıed prostate cancer risk associations with 30 genotyped and 36 im-
puted polymorphisms that were nominally signifıcant, three of which achieved
Bonferroni signifıcance and were in a region of 16q24.3 that includes MC1R,
GAS8 (growth arrest specifıc-8, an alleged tumor suppressor that is deleted in
some prostate cancers), and transcription factor-25 (TCF25). These were
rs4628973 and rs3743824 that were in high LD (r20.931; prostate cancer risk
associations p0.00029 and 0.00023, respectively), as well as rs6500461 that was
independently associated with risk (r20.20 with rs4628973; p0.00020). This
large-scale Mendelian randomization analysis suggests genetic variants near
MC1R, which directs melanocyte melanin synthesis, secretion and human pig-
mentation, may be associated with risk of prostate cancer.
#1272 Prostate cancer risk and vitamin a related genetic variants in the
PRACTICAL Consortium. Shakira M. Nelson,1 Tracy M. Layne,1 Stephanie J.
Weinstein,1 Eric Karlins,2 Stephen J. Chanock,1 Demetrius Albanes,1 PRACTICAL
Consortium. 1NCI, Rockville, MD; 2Cancer Genomics Research Laboratory,
Rockville, MD.
Vitamin A compounds including retinol are thought to play a protective role
in human carcinogenesis. However, recent studies have shown that men with
higher serum retinol concentrations are at increased risk of both overall and
aggressive prostate cancer, the most common cancer in men within developed
populations. The biological mechanism underlying this association remains un-
clear. In the present investigation, we examined the associations between com-
mon genetic variants related to serum retinol status and prostate cancer risk in
the Prostate Cancer Association Group to Investigate Cancer Associated Alter-
ations in the Genome (PRACTICAL) Consortium. The analysis includes 38,868
cases and 25,210 controls from 35 participating PRACTICAL studies. A Men-
delian randomization approach was used to examine the individual association
between 135 vitamin A-related single nucleotide polymorphisms (SNPs) and
risk of overall prostate cancer. Logistical regression was used to estimate the
odds ratio (OR) and confıdence interval (CI) for the per allele association be-
tween each SNP and risk. Associations were examined using both genotyped
and imputed data, and results for the latter are presented here based on their
substantial similarity. In addition to examining SNPs demonstrating nominal
signifıcance (alpha  0.05), a Bonferroni cut-point of  0.0003 was used to
adjust for multiple comparisons. Seven SNPs were found to be nominally sig-
nifıcant at the p 0.05 level; however, none remained signifıcant after Bonfer-
roni correction. Of these, fıve SNPs (rs4799751, OR  0.97; rs9963553, OR
1.03; rs9967180, OR1.03; rs2167689, OR 0.98; rs1941356, OR 0.98) are
located in or near three genes: transthyretin gene (TTR), traffıcking protein
particle complex 8 (TRAPPC8), and beta-1,4-galactosyltransferase 6
(B4GALT6). The carrier protein transthyretin is the only gene known to be
related to retinol status based onpriorGWASanalyses, while B4GALT6 encodes
type-IImembrane-bound glycoproteinswhichmay be used as a potential cancer
biomarker. The two other SNPs, rs1377189 (OR0.96) and rs117053512
(OR0.97), are located in desmoglein 3 (DSG3), whose encoded protein plays a
role in maintenance of tissue architecture which may be upregulated in malig-
nancies. Our large-scale Mendelian randomization analysis reveals some evi-
dence of a relativelyweak association between genetic variants related to vitamin
A status and prostate cancer risk. These associations should be further examined
in aggressive and fatal cancers.
#1273 Pathway analysis of insulin-like growth factor candidate genes and
risk of pediatric rhabdomyosarcoma. Libby Morimoto,1 XIaorong Shao,1
Anand Chokkalingam,1 Joseph Wiemels,2 Xiaomei Ma,3 Catherine Metayer1.
1University of California, Berkeley, Berkeley, CA; 2UCSF, San Francisco, CA;
3Yale University, New Haven, CT.
Pediatric rhabdomyosarcoma (RMS) is themost common soft tissue sarcoma
in children under 15 years of age. Due largely to its rarity, the etiology of pedi-
atric RMS is poorly understood. Patterns of fetal growth were previously shown
to be independent risk factors for RMS among non-Hispanic white (NHW)
children; however, the underlying biologic mechanisms remain unclear. Alter-
ations in the insulin-like growth factor (IGF) system, the primary regulator of
growth during the fetal and early life period, may provide clues. Using an inno-
vative linkage between the California birth records and cancer registry informa-
tion, we conducted a population-based case-control study (1982-2009) of can-
didate genes involved in IGF signaling and risk of pediatric RMS. Fifteen genes
involved in the IGF pathwaywere selected: IGF1, IGF2, IGF1R, IGF2R, IGFBP1,
IGFBP2, IGFBP3, IGFBP4, IGFBP5, IGFBP6, INS, INSR, IRS1, GH1, and
GHRH. DNA extracted from the archived newborn blood spots of all available
RMS cases (n644) was genotyped on the Illumina OmniExpress Exome array
(n964,043 SNPs); after stringent quality control (QC), a total of 633 RMS cases
(360 embryonal RMS [eRMS] and 197 alveolar RMS [aRMS]) were available for
analysis. A total of 815 controls genotyped on the IlluminaOmniExpress Exome
array and 3,922 controls genotyped on the Affymetrix Axion LAT array
(n801,830 SNPs) from the same base population of California children, with
no evidence of RMS, were included in this analysis. After imputation to increase
coverage of the genome and post-imputation QC to identify and remove plat-
form effects, a total of 5,556,335 SNPs were available for analysis. Among NHW
children, SNPs in IGF1 (rs10860869, p0.0031) and IGF1R (rs62023616,
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p0.00074; rs62023648, p0.00076) were signifıcantly associated with RMS
risk after adjustment for multiple comparisons. Analyses stratifıed by histologic
subtype showed that these associations were limited to eRMS, and of stronger
magnitude. Among Hispanic children, 12 SNPs in IGF1R (p-value range:
0.0007-0.0027) and 3 SNPs in IGFBP1 (p-values: 0.0016-0.0023) were signifı-
cantly associated with eRMS risk. The SNPs found to be associated with RMS
were located in intergenic and intronic areas of the genes, areas that may influ-
ence gene regulation.Our results support the hypothesis that genetic variation in
IGF1 signaling pathway modulate the risk of RMS, especially eRMS, among
NHW and Hispanic children.
#1274 Associations between genetic polymorphisms in genes related to
estrogenmetabolism and function and prostate cancer risk: results from the
Prostate Cancer Prevention Trial. Li Tang,1 Mary Platek,1 Song Yao,1 Cathee
Till,2 Phyllis Goodman,2 Catherine M. Tangen,2 Yue Wu,1 Elizabeth A. Platz,3
Marian L. Neuhouse,2 Frank Z. Stanczyk,4 Juergen K. Reichardt,5 Regina M.
Santella,6 Ann Hsing,7 William D. Figg,8 Scott M. Lippman,9 Ian M. Thomp-
son,10 Christine B. Ambrosone1. 1Roswell Park Cancer Inst., Buffalo, NY; 2Fred
Hutchinson Cancer Research Center, Seattle, WA; 3Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD; 4University of Southern California, Los
Angeles, CA; 5University of Sydney, Sydney, Australia; 6Columbia University,
New York, NY; 7Stanford University, Stanford, CA; 8National Cancer Institute,
Baltimore, MD; 9UC San DiegoMoores Cancer Center, San Diego, CA; 10Univer-
sity of Texas Health Science Center at San Antonio, San Antonio, TX.
Background: Substantial preclinical data corroborate the critical role of
estrogen in prostate cancer development; however, epidemiological studies
found no associations between circulating estrogen levels and prostate can-
cer risk. It was hypothesized that intraprostatic estrogen milieu may play a
more important role than circulating estrogen in prostate carcinogenesis.
Since it is diffıcult to obtain data on prostatic estrogen levels, we tested the
hypothesis indirectly by investigating associations of prostate cancer risk
with genetic variations of enzymes that are involved in estrogen synthesis,
metabolism and function, and may affect intraprostatic estrogen milieu.
Methods: A panel of 36 potentially functional single nucleotide polymor-
phisms (SNPs) in estrogen-related genes was assembled based on informa-
tion obtained in the literature. After removing SNPs with call rate 95% (1
SNP) orminor allele frequency3% (10 SNPs), a total of 25 SNPs in 13 genes
(PGR, ESR1, ESR2, CYP17A1, HSD17B1, CYP19A1, CYP1A1, CYP1B1,
COMT, UGT1A6, UGT1A10, UGT2B7, UGT2B15) were examined for asso-
ciations with prostate cancer risk using data and DNA samples from 1617
cases and 1731 controls in the Prostate Cancer Prevention Trial (PCPT).
Cases and controls were frequency-matched on age, treatment arm and fam-
ily history. Logistic regression was used to estimate odds ratios (ORs) and
95% confıdence intervals (CIs) separately in the placebo and fınasteride
arms, adjusting for age, race and family history. Results were similar when
restricting analysis to white men only. Results: Panels of SNPs that were
signifıcantly associated with prostate cancer risk were different according to
treatment arm, showing rs1801132 in ESR1, rs700518 in CYP19A1, and
rs4124874 in UGT1A6 in the placebo arm and rs2445765 in CYP19A1 and
rs4680 in COMT in the fınasteride arm. When stratifıed by circulating estro-
gen and androgen levels, signifıcant associations were only observed in ei-
ther the high or low category of serum hormone levels; no SNPs were signif-
icantly associated with prostate cancer risk in both categories. CYP19A1 was
the only gene harboring SNPs that were signifıcantly associated with prostate
cancer risk in both the placebo (rs700518) and fınasteride arms (rs2445765).
In haplotype analysis using all three CYP19A1 SNPs genotyped in the study
(rs700518, rs2445765 and rs700519), compared with non-risk haplotype
(GCC), certain CYP19A1 haplotypes were signifıcantly associated with in-
creased prostate cancer risk in both arms. Conclusion: Associations between
prostate cancer risk and SNPs in genes involved in estrogen metabolism and
function are complicated, and markedly modifıed by other factors such as
fınasteride treatment or circulating hormone levels. Supported by grant
U10CA37429, 5UM1CA182883 and P01CA108964 from the NCI.
#1275 Genetic variations in cancer-related signifıcantly mutated genes
and lung cancer susceptibility. Liren Zhang,1 Yanwei Zhang,1 Rong Li,1 David
W. Chang,1 Yuanqing Ye,1 John D.Minna,2 Jack A. Roth,1 Baohui Han,3 Xifeng
Wu1. 1UT MD Anderson Cancer Center, Houston, TX; 2University of Texas
Southwestern Medical Center, Dallas, TX; 3Shanghai Chest Hospital, Shanghai
Jiao Tong University, Shanghai, China.
Cancer initiation and development are driven by key mutations in driver
genes. Applying high-throughput sequencing technologies and bioinformatics
analyses, TheCancerGenomeAtlas (TCGA) project has recently identifıed pan-
els of genetic mutations that contributed to or associated with the etiology of
various cancers. However, there are few studies investigating the germline ge-
netic variations in these highly mutated genes and lung cancer susceptibility. In
thismulti-phase study, we aimed to comprehensively evaluate the 1655 tagSNPs
located in the 127 signifıcantly mutated genes (SMGs) identifıed by TCGA, and
test their association with risk of lung cancer in a total of 7355 patients and 7301
healthy controls. We found that 11 SNPs in 8 genes showed consistent associa-
tion (P0.1) and 8 SNPs signifıcantly associated with lung cancer risk (P0.05)
in both discovery and validation phases. The most signifıcant SNP A was asso-
ciated with a decreased risk of lung cancer (OR0.91, 95%CI: 0.87-0.96,
P2.310-4). Cumulative analysis of the 11 SNPs showed consistently elevated
risk with increasing number of unfavorable genotypes (P for trend1.210-10).
In stratifıed analyses, the association of SNP A and lung cancer risk appeared
stronger among population of younger age at diagnosis and never smokers. The
eQTL-analysis indicated that genotypes of four SNPs signifıcantly correlated
with the expression of their genes respectively. From TCGA data, expression
of the identifıed genes were signifıcantly different in lung tumors compared
with normal tissues, and the genes’ highest mutation frequency was found in
lung cancers. Integrative pathway analysis (IPA) indicated the identifıed
genes were mainly involved in major cell cycle regulatory pathway suggest-
ing the underlying biological processes. In summary, this study revealed
novel genetic variants in SMGs associated with lung cancer risk, whichmight
contribute to elucidating the biological network involved in lung cancer
development.
#1276 Gene-environment interaction relevant to estrogen and risk of
breast cancer. JooYong Park,1 Ji-Yeob Choi,1 Seokang Chung,1 Nan Song,2 Sue
K Park,3 Wonshik Han,4 Dong-Young Noh,4 Sei-Hyun Ahn,5 Mi-Kyung Kim,6
Keun-Young Yoo,3Wei Zheng,7 Daehee Kang3. 1Department of Biomedical Sci-
ences, Seoul National University College of Medicine, SEOUL, Republic of Korea;
2Cancer Research Institution, Seoul National University College of Medicine,
SEOUL, Republic of Korea; 3Department of Preventive Medicine, Seoul National
University College of Medicine, SEOUL, Republic of Korea; 4Department of Sur-
gery, Seoul National University College of Medicine, SEOUL, Republic of Korea;
5Department of Surgery, University of Ulsan College ofMedicine andASANMed-
ical Center, SEOUL, Republic of Korea; 6Division of Cancer Epidemiology and
Management, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Ko-
rea; 7Department of Medicine, Division of Epidemiology, Vanderbilt Epidemiol-
ogy Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of
Medicine, Nashvile, TN.
Introduction:Many established reproductive risk factors for breast cancer are
mediated byhormonalmechanisms, andmost parts are involved in estrogens. In
addition, the estrogen level controlled by genetic factors might be a sort of
determinants to breast cancer risk involving estrogen metabolism. This study
aims to examine gene and environment interaction (GxE) between candidate
genes which are involved in estrogen metabolism and environmental factors
which are related to estrogen exposure. Methods: GxE analyses were conducted
in the Korean 1,970 breast cancer cases and 2,052 controls which were recruited
in the Seoul Breast Cancer Study (SEBCS), a multicenter case control study. 137
candidate genes involved in estrogen metabolism were searched from couple of
databases and 11,555 SNPs (2,472 typed SNPs and 9,083 imputed SNPs) from
the range of candidate genes were included in GxE analyses with 8 established
environmental factors. Statistical analyses were performed by using GxEScan
(ver. Beta 0.4.0; http://biostats.usc.edu/software) for GxE test. Results: There
were three signifıcant interaction between 11,555 SNPs and 8 environmental
factors. Firstly, interaction rs851998 nearby ESR1 with height was shown in the
GE 2df model (p-2df  1.1x104) This SNP had protective effect marginally
(ORG 0.82, 95% CI: 0.75-0.90) and further protective effect for women whose
height is smaller than 160cm (OR G height
 160cm 0.78, 95%CI: 0.70-0.87, p
1.09x105). Second interaction was shown between rs13035764 of NCOA1 and
age at menarche in the GE 2df model (p-2df  1.2x103). This SNP also had
protective effect marginally (ORG 0.85, 95% CI: 0.77-0.97) and more protec-
tive effectwhenage atmenarche is 14 years andover (ORG age at menarche
 14 years
0.82, 95% CI: 0.73-0.97, p3.6x104). Lastly, there was marginally signifı-
cant interaction between rs4140979 of FSHR and age at fırst full term preg-
nancy (FFTP) in the EDGxE model. Although this SNP had no marginal
effect, qualitative interaction was shown with FFTP (OR G FFTP  27 years 
0.88, 95%CI: 0.78-1.00, p0.0482; OR G Nulliparity or FFTP
 27 years 1.30, 95%
CI: 1.10-1.53, p0.002). Conclusion: Three signifıcant interactions were
identifıed by focusing two step methods. Replication should be performed in
the independent and larger population due to statistical limitation.
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#1277 Interaction of insulin-like growth factor-I and insulin resistance-
related genetic variants with obesity and lifestyle factors on postmenopausal
breast cancer risk. Su Yon Jung,1 Gloria Ho,2 Thomas Rohan,3 Howard Strick-
ler,3 Jennifer Bea,4 Jeanette Papp,5 Eric Sobel,6 Zuo-FengZhang,7 CarolynCran-
dall6. 1University of California, Los Angeles, Los Angeles, CA; 2Hofstra Northwell
School of Medicine, Feinstein Institute for Medical Research, Great Neck, NY;
3Albert Einstein College of Medicine, Bronx, NY; 4University of Arizona Cancer
Center, Tucson, AZ; 5David Geffen School of Medicine, University of California,
Los Angeles, CA; 6David Geffen School of Medicine, University of California, Los
Angeles, Los Angeles, CA; 7Fielding School of Public Health, University of Califor-
nia, Los Angeles, Los Angeles, CA.
Objectives: Genetic variants and traits in metabolic signaling pathways may
interact with obesity, physical activity, and exogenous estrogen (E), influencing
postmenopausal breast cancer risk, but these inter-related pathways are incom-
pletely understood. Stratifying via obesity and lifestyle modifıers, we evaluated
the effects of insulin-like growth factor-I (IGF-I)/insulin resistance (IR)–related
traits on breast cancer risk as amediator or influencing factor in this case-cohort
study. Method: Using 75 single-nucleotide polymorphisms (SNPs) in genes re-
lated to IGF-I/IR traits and signaling pathways, and data from 1,003 postmeno-
pausal women in Women’s Health Initiative Observation ancillary studies, we
assessed the effects of IGF-I/IR-traits (fasting total and free IGF-I, IGF binding
protein-3, glucose, insulin, and homeostatic model assessment–insulin resis-
tance) by proportional change estimation. Using traits as mediators of the IGF-
I/IR–traits genetic variants-cancer relationship, we partitioned total effect of
these genetic variants on cancer risk into two putative mechanisms: 1) indirect
(mediated by traits) and 2) direct (through pathways other than traits). For the
effects of IGF-I/IR traits on IGF-I/IR signaling pathways–relevant genetic vari-
ants–cancer risk, we used the same algorithm as that for mediator, but inter-
preted as an influential factor. Results: Seven SNPs in IGF-I and INS genes were
associated with breast cancer risk. These associations differed between non-
obese/active and obese/inactive women and between exogenous E nonusers and
users. The mediation effects of IGF-I/IR traits on these SNPs–cancer relation-
ship differed between strata, but only roughly 35% of the cancer risk due to the
SNPs was mediated by IGF-I/IR traits. Similarly, carriers of 20 SNPs in PIK3R1,
AKT1/2, and MAPK1 genes (signaling pathways–related genetic variants) had
different associations with breast cancer between strata, and the proportion of
the SNP–cancer relationship explained by IGF-I/IR traits varied 45-50% be-
tween the strata. Conclusions: Our fındings suggest that IGF-I/IR genetic vari-
ants interact with obesity and lifestyle factors, altering cancer risk partially
through pathways other than IGF-I/IR traits.
#1278 Effect modifıcations of vitamin D receptor common polymor-
phisms association with prostate cancer by serum vitamin D related behav-
ioral and biological factors.Ken Batai,1 AdamB.Murphy,2 Ebony Shah,1 Chil-
edum Ahaghotu,3 Rick A. Kittles1. 1University of Arizona, Tucson, AZ;
2NorthwesternUniversity, Chicago, IL; 3CarneyHospital-StewardHealth System,
Dorchester, MA.
Background: Several roles have been proposed for vitamin D and the vitamin
D receptor (VDR) in prostate cancer (PCa) pathogenesis and progression.How-
ever, previous genetic epidemiologic studies have provided limited support link-
ing VDR polymorphisms to PCa due to complexity of vitamin D metabolism
and potential gene and environmental interactions. In this study, we investi-
gated the association of VDR genotypes with PCa incidence and aggressiveness
in African Americans (AAs) and European Americans (EAs) and if the associ-
ations were modifıed by behavioral and biological factors that influence serum
vitamin D levels. Methods: The total of 810 AAs and 487 EAs from Chicago, IL
andWashington,D.C.were included in this study. Seven single-nucleotide poly-
morphisms (SNPs) in and around the VDR gene and 105 ancestry informative
markers were genotyped. We performed logistic regression analyses adjusting
for relevant variables. Results: In EAs, TaqI (rs73136) and BsmI (rs1544410)
minor alleles revealed a protective effect against PCa, while in AAs, FokI
(rs2228570) was associated with overall PCa risk (OR0.74, 95% C.I.: 0.57-
0.96). The heterogeneous associations observed in our study could be due to
difference in prevalence of vitamin D defıciency between AAs and EAS and
effect modifıcations by behavioral and biological factors that affect serum vita-
min D levels. Therefore, we investigated if behavioral and biological factors that
influence serum vitamin D modifıed the associations between VDR polymor-
phisms and PCa, and we found evidence suggesting that these behavioral and
biological factors modify the effect of VDR on PCa. In AAs, we observed statis-
tically signifıcant interaction between twoVDRpolymorphisms, FokI and TaqI,
and vitamin D intake (PInteraction0.01 and PInteraction0.03 respectively). We
also observed evidence of interactions between VDR gene variants and other
behavioral and biological factors that lower serum vitamin D levels in both AAs
and EAs. In AAs, calcium intake and skin pigmentation may modify the effects
of VDR on PCa. In EAs, BMI may modify the effect of VDR. Conclusions:
Although a larger sample size is necessary to confırm the observation, we dem-
onstrated that vitamin D related behavioral and biological factors modify the
effect of VDR genotypes on PCa. Impact: The VDR gene is involved in PCa
pathogenesis and progression, and polymorphisms in VDR gene and vitamin D
are likely to alter the function of the gene.
#1279 A polymorphism of VEGF -2489C/T is associated with prostate
cancer susceptibility inMexicans.AbrilMartínez-Rizo,1 XaviCasillas-Rangel,1
Cuerpo Académico Investigación Bioquímica (UAN-CA-266), Hilda Andrade-
Madrid,2 Veronica Benites-Godinez,2 Nallhely Rodríguez-Ocampo1. 1Autono-
mous University of Nayarit, Tepic, Mexico; 2Mexican Social Security Institute,
Delegation Nayarit, Tepic, Mexico.
Introduction: Prostate cancer (CaP) encompasses a range of malignant pros-
tate tissue dysplasias that primarily affects men over 50 years, is the second
leading cause of cancer mortality in males. VEGF expression is associated with
tumor progression and metastasis in patients with CaP. The SNP -1154 G/A is
associated with the severity of CaP populations in Tunisia and the United King-
dom while -634 G/C alone has been associated in Tunisian population. It is
unknown whether these polymorphisms could serve as biomarkers in the Mex-
ican population. Aim: To associate VEGF polymorphisms -1154 G/A and - 634
G/Cwith the severity of prostate cancer in patients of westernMexico.Materials
and methods: The gDNA was analyzed a total of 525 men of whom 301 are
presented HBP and 224 patients with clinical diagnosis of prostate cancer. For
association with severity they were subclassifıed into high (
7) and low grade
(6) following theGleason scale. Genotypingwas performed by Real Time PCR
using TaqMan probes system. Results.When we compare the allelic frequencies
in the control group, they are in Hardy-Weinberg equilibrium. However, no
signifıcant association of the disease with polymorphisms or severity or progres-
sion was found. Conclusions: There is no association between prostate cancer
and genetic polymorphisms at -634 and -1154 position of the promoter region of
VEGF.
#1280 Functional characterizationof prostate cancer risk loci by SNPs-seq
and STARR-seq. Peng Zhang,1 Jing Zhu,2 Sufyan Suleman,3 Yong-Chen Guo,4
Mei-Jun Du,5 Li-DongWang,1 Gong-HongWei,3 LiangWang5. 1the First Affıl-
iated Hospital of Zhengzhou University, ZhengZhou, China; 2Harbin Medical
University, Harbin, China; 3University of Oulu, Oulu, Finland; 4Jining Medical
University, Jining, China; 5Medical College of Wisconsin, Milwaukee, WI.
Background. By SNPgenotyping andRNAsequencing of 471normal prostate
samples, we recently created a prostate tissue-based eQTL dataset and identifıed
signifıcant eQTL signals at 51 prostate cancer risk loci. To functionally charac-
terize these risk SNPs, we developed a massively parallel sequencing technology
to screen SNPs for their allele-dependent protein binding differences. We com-
bined this technology (called SNPs-seq) with another high throughput assay
(called STARR-seq) to screen the risk loci with signifıcant prostate-specifıc
eQTL signals. Methods. To select candidate functional SNPs in eQTL regions,
we took advantage of existing epigenomic datasets and available tools including
ENCODE, HaploReg, and Regulome. For all selected SNPs, we fırst made allele-
specifıc double-strand oligos and performed DNA-protein binding assays. We
then performed sequencing analysis on the protein-bound DNA oligos and
determined allele-specifıc protein binding differences. To evaluate reproducibil-
ity of SNPs-seq, we performed each assay in duplicates. We cloned SNPs-seq
screened SNP regions showing allele-specifıc protein binding differences into
the STARR-seq vector to further determine allele-specifıc enhancer activities.
Finally, we performed EMSA and luciferase reporter assays to validate a set of
promising candidate SNPs. Results. From 51 risk loci with strong eQTL signals,
we selected 374 SNPs with strong indication of regulatory potential, as evi-
denced by overlapping with epigenomic marks. When comparing technical du-
plicates, sequence read counts from the SNPs-seq showed signifıcant correlation
with r20.99. By normalizing input controls, we found 101 of the 374 SNPs
showing signifıcant allelic protein binding differences (1.5-fold binding dif-
ference between variant and reference alleles). Interestingly, three published
functional SNPs (rs12769019, rs10993994, and rs4907792) were also among the
signifıcant SNPs, validating SNPs-seq as functional SNP screening tool. To fur-
ther validate the candidate SNPs from SNPs-seq, we applied STARR-seq and
tested the 101 SNPs-containing sequences (371-686bp) in LNCaP cell line under
androgen treatment. This analysis revealed 11 SNPs that not only demonstrated
enhancer/repressor activity but also functioned with allelic differences. EMSA
and luciferase reporter assays confırmed 6 SNPs with allele-dependent enhanc-
er/repressor activity. Conclusions. We developed a high throughput sequenc-
ing-based technology to screen large number candidate SNPs for their allelic
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protein binding differences. The SNPs-seq coupled with STARR-seq will pro-
vide a powerful strategy for functionally characterizing risk loci in prostate can-
cer and other common diseases. Further understanding genetic role of prostate
cancer etiologymay facilitate the translation of population-based discovery into
biological mechanisms and eventually benefıt clinical practice.
#1281 Germlinemutations inNBN conferring DNA damage response de-
fects are found in patients with multiple cancer types. Sabine Topka, Michael
F. Walsh, Ann Maria, Annie Lincoln, Diana Mandelker, Liying Zhang, Marc
Ladanyi, Michael F. Berger, Mark E. Robson, Joseph Vijai, Kenneth Offıt. Me-
morial Sloan Kettering Cancer Ctr., New York, NY.
Nibrin, the protein encoded by the NBN gene forms a complex with Mre11
and Rad51 (MRN complex) that is crucial for DNAdamage repair.Mutations in
NBN are found in90% of patients with Nimjegen breakage syndrome (NBS),
an autosomal recessive disorder characterized by growth retardation, micro-
cephaly, radiosensitivity, immunodefıciency and increased cancer risk. Most of
NBS patients harbor the common founder mutation c.657del5 that leads to
expression of a hypomorphic 70kDa C-terminal fragment produced by alterna-
tive translation initiation. Cell lines derived from these patients show increased
sensitivity to DNA-damaging agents, chromosome instability, and abnormal
cell cycle checkpoint function. Several studies have addressed cancer incidence
in individuals with germline NBNmutations, showing increased cancer risk for
individuals harboring the c.657del5 founder mutation and for carriers of the
R215Wmissense mutation across multiple cancer types. For other NBN muta-
tions conflicting reports exist as to their association with cancer risk. Here, we
report newly identifıed NBN germline frameshift and truncating mutations in
patientswithmultiple cancer types, including prostate, lung, breast cancer, acute
lymphocytic leukemia, and chronic lymphocytic leukemia. Modeling these mu-
tations in an NBN-defıcient cellular background showed expression of a novel
C-terminal truncated fragment that can bind to Mre11. Cells expressing these
mutant proteins display attenuatedDNAdamage repair function and decreased
overall survival following induction ofDNAdamage. ImpairedChk2 phosphor-
ylationwas also observed, indicating cell cycle checkpoint defıciencies. Thus, the
NBNgermlinemutations identifıed here could contribute to genomic instability
predisposing to tumorigenesis. Further in vitro studieswith these and additional
germline mutations occurring in cancer patients are ongoing, in order to better
understand the role of this pathway of DNA damage repair in susceptibility to
malignancies.
#1282 Analysis of missense variants in BRCA1 BRCT domains. Giuliano
Di Pietro,1 Vanessa Camara Fernandes,2 Kwabena Amankwah,3 Cara Shields,3
Volha A. Golubeva,3 Carly Harro,3 Marcelo Alex Carvalho,4 Alvaro N. Mon-
teiro3. 1FederalUniversity of Sergipe, SaoCristovao, Brazil; 2InstitutoNacional de
Câncer, Rio de Janeiro, Rio de Janeiro, Brazil; 3Moffıtt Cancer Center, Tampa, FL;
4Instituto Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Currently, only ¼ (133/600) of documented single nucleotide variation
leading to missense changes in the BRCA1 gene have been characterized as
pathogenic or non-pathogenic (IARC Classes 4 & 5 and 1 & 2, respectively)
posing a challenge for carriers of these variants. A detailed understanding of
structure-function relationships is critical for the assessment of these variants in
the interpretation of data from functional assay and for the development of
functional impact predictors. Thus, we have systematically probed the C-termi-
nus of BRCA1 including the N-terminal border of the BRCT domains (M1650,
S1651), the BRCT linker region (G1738, D1739, V1740, G1743, H1746, G1748,
P1749, R1753, and D1757), and the alpha 1 and alpha’1 helices in BRCT[N] and
[C], respectively. We assessed the functional impact of 47 missense variants
using a validated transcriptional assay by a protein fusion of the GAL4 DNA-
binding domain to BRCA1 C-terminus (aa 1,396-1,863) in HEK 293FT cells.
Analysis of functional data redefıned the BRCTborder (previously thought to be
at S1651) at residue M1650. Overall, mutations in the BRCT linker had severe
impact on the function. Mutations in the alpha1 and alpha’1 helices also tended
to display impaired function despite the lack of functional impact of 16 out of the
17 variants previously analyzed. In summary, our study provides increased
granularity in our understanding of BRCA1 regions less tolerant to changes and
therefore more likely to contain pathogenic variants. This knowledge will be
critical for the assignment of different prior probabilities of pathogenicity given
the variant location, improving risk assessment and clinical management of
carriers of BRCA1 missense alleles
#1283 Mutations in the Duffy Antigen Receptor for Chemokines (DARC/
ACKR1) gene result in population-private variants. Rachel Martini, Brittany
Jenkins, Melissa Davis. University of Georgia, Athens, GA.
By studying the breast cancer microenvironment, we can specifıcally address
novel aspects of cancer development and progression at the molecular level.
Chemokines are small signaling molecules that are an important component of
thismicroenvironment, as they shape cellular composition of this space through
recruitment of immune cells, among other functions. DARC, the Duffy Antigen
Receptor for Chemokines, is an atypical chemokine receptor (ACKR1) that can
bind different classes of chemokines. It is a non-signaling receptor that mainly
acts as a regulator of chemokine homeostasis by removing them from circula-
tion to recruit appropriate immune cell types. The purpose of this study is to
determine how population-private variants of the DARC/ACKR1 gene across
global population render distinct function and defıne aspects of humandiversity
in immune responses. A well-studied example of this would be the Duffy-null
allele. This allele carries a mutation that is population-specifıc to recent dece-
dents of Sub-Saharan Africans, and removes expression of DARC on red blood
cells. Loss of expression on red blood cells presumably causes these “Duffy-Null”
individuals to lose the ability to sequester chemokines, therefore losing homeo-
static balance of these molecules in circulation. To identify additional muta-
tions, we completed in silico analysis of minor allele frequencies across the gene
in the 1000 Genomes Project data, and identifıed several other putative func-
tional mutations that likely result in additional gene variants, specifıc to geo-
graphic ancestry groups and likely under similar selection as the Duffy null
allele. We have prioritized our initial functional study to include mutations in
the regulatory regions of the gene, as thesemutations can change how andwhere
the gene is expressed. Future work is focused on investigating these functional
variants in situ, using human tissue and human breast cell lines, by isolating and
re-engineering ancestry-specifıc variants in these cell lines. By identifying and
determining functional outcomes of these population-specifıc mutation, we can
observe differences in immune responses across these global populations, fur-
ther defıning the role that DARC/ACKR1 plays in the breast tumor microenvi-
ronment.
#1284 Identifıcation of potential cancer regulatory germline single-nucle-
otide polymorphisms in the non-coding genome.Diptee A. Kulkarni, Kijoung
Song, Karl Guo. GlaxoSmithKline, King of Prussia, PA.
Tumorigenesis in sporadic cancers is mainly driven by somatic genetic
alterations such as driver mutations in protein coding genes or chromosomal
changes comprising deletions, amplifıcations or translocations resulting in
loss of tumor suppressor proteins, gain of oncogenic proteins or expression
of aberrant fusion proteins, respectively. Some cancers lack such somatic
changes, but are addicted to expression of certain genes for their sustained
proliferation and survival. There is evidence of such oncogenic addiction to
LIM domain only 1 (LMO1) expression in neuroblastoma (NB). Genome-
wide association studies (GWAS) have identifıed robust associations be-
tween germline single-nucleotide polymorphisms (SNPs) within LMO1 and
NB susceptibility with the causal SNP being rs2168101. Investigation of the
mechanism of NB dependency on LMO1 showed that LMO1 expression in
NB cells is regulated by rs2168101, which resides within a highly conserved
tissue-specifıc super enhancer in LMO1 intron 1 and drives LMO1 expres-
sion through GATA3 transcription factor binding. This makes LMO1-de-
pendent NB a unique example of sporadic cancer driven by germline genetic
variation. Numerous GWAS have identifıed signifıcant associations between
germline SNPs in the non-coding genome and cancer risk or outcomes. To
identify additional examples of regulatory SNPs as cancer drivers, we
merged published genome-wide signifıcant associations from cancer GWAS
with genome regulatory data from ENCODE (Encyclopedia of DNA Ele-
ments; Nature. 2012 Sep 6; 489 (7414): 57-74)) and searched for clusters of
cancer associated SNPs that resided within gene regulatory elements. Gene
regulatory elements were defıned as those marked by active epigenetic fea-
tures and chromatin accessibility in cancer cell lines. Of the1,600 unique,
genome-wide signifıcant SNPs from cancer GWAS with regulatory evidence,
we identifıed 46 clusters of 3 or more putative regulatory SNPs near 28 genes.
These clusters were particularly enriched within ovarian cancer associated
loci. Mechanistic studies such as reporter assays and genome editing in rel-
evant cell types are being considered to identify the causal SNPs from these
clusters regulating gene expression and driving tumorigenesis, which in turn
may lead us to new cancer targets.
#1285 Analysis of esophageal cancer SNPs and gene expression to predict
ESCC risk. Lilly A. Ding,1 Molly P. Ding,1 Xin Song,2 Lidong Wang,2 Liang
Wang3. 1None, Bethesda, MD; 2First Affıliated Hospital, Zhengzhou, China;
3Medical College of Wisconsin, Milwaukee, WI.
Esophageal cancer is one of most common cancers worldwide and its inci-
dence has increased rapidly over the past decades. The majority of esophageal
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cancers is the esophageal squamous cell carcinoma (ESCC),which is particularly
prevalent inAsian and SouthAfrican areas.Most cases of ESCC are diagnosed at
advanced stages, with an overall 5year survival rate of 10–20%. Currently, ge-
nome-wide association studies (GWAS) are used to identify high risk individu-
als for the development of ESCC. Many SNPs have been identifıed to associate
with a risk of ESCC. However, the effect size attributable to individual SNPs was
typically modest, suggesting that genetic variants may only account for a very
small amount of genetic risk and heritability of ESCC. The combined effect of
multi genetic variants with alteredmRNAexpression play critical roles in ESCC.
In this study, we used several existing bioinformatics databases (HaploReg,
GTEx Portal and cBio Portal). We fırst selected 450 potential ESCC risk SNPs
fromHaploReg and thendefınedwhich SNPs caused gene expression alterations
in the esophagus through expression quantitative trait loci (eQTL). Nine SNPs
in eight genes (MUC1, ALS2CR12, ADHB1, TMEM173, XBP1, PLCE1,
HEATR3 and SMG6) were identifıed as having altered mRNA expression. The
alteredmRNA expression of these seventeen genes are:MUC1, THBS3, GBAP1,
EFNA1, SCAMP3, CASP8, CASP10, ALS2CR12, STRADB, ADH4, TMEM173,
CYCTM1, DNAJC18, DNAJC20, NOC3L, HEATR3 and SRR. These altered
gene expressions in the mucosal layer of the esophagus metabolize enzymes,
repair DNA, and prevent cell death and inflammation, all of whichmay indicate
that the existing altered esophageal mRNA levels plus the predisposition of
normal esophageal epithelial cells can lead to harmful environmental carcino-
gens, thus attributing to ESCC development. In order to validate these gene
alterations related to ESCC SNPs in screening and early detection of high risk
individuals, DNA genotyping of this group of SNPs with a prospective cohort
(n5451) in a high risk area of ESCC will be tested in future studies.
#1286 Targeted deep sequencing of colorectal tumor tissues to study associ-
ationsof tumorsubtypeswithgermlinegenetic, lifestyle, andenvironmental risk
factors. Syed H. Zaidi,1 Wei Sun,2 Jeroen Huyghe,2 Catherine S. Grasso,2 Quang
Trinh,1 Charles Connolly,2 Amy French,3 Jasmine Mu,4 Marios Giannakis,5 Eve
Shinbrot,6 IvanBorozan,1Michael J.Quist,2HermannBrenner,7DanielBuchanan,8
PeterCampbell,9AndrewChan,10 JennyChang-Claude,7Vincent Ferretti,1 Charles
Fuchs,5 Andrea Gsur,11 Marc Gunter,12 Tabitha Harrison,2 Michael Hoffmeister,7
Wen-Yi Huang,13 Paul Krzyzanowski,1 Stephen Lee,1 Mathieu Lemire,1 Jessica
Miller,1 Danielle Pasternack,1 Cherie Teney,1 Elaine Mardis,14 Polly Newcomb,2
Lincoln Stein,1 Lee Timms,1 DavidWheeler,6 Christina Yung,1 Niha Zubair,2 Levi
Garraway,5 ShujiOgino,15LiHsu,2 StevenGallinger,1 StephenThibodeau,3Thomas
Hudson,1 Ulrike Peters2. 1Ontario Institute for Cancer Research, Toronto, Ontario,
Canada; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3Mayo Clinic,
Rochester, MN; 4Broad Institute, Cambridge, MA; 5Dana-Farber Cancer Institute,
Boston, MA; 6Baylor College of Medicine, Houston, TX; 7German Cancer Research
Center (DKFZ),Germany; 8TheUniversity ofMelbourne,Australia; 9AmericanCan-
cer Society, Atlanta, GA; 10Massachusetts General Hospital, Boston, MA; 11Medical
University of Vienna, Austria; 12International Agency for Research on Cancer,
France; 13NationalCancer Institute,NIH,DHHS,Bethesda,MD; 14WashingtonUni-
versity School of Medicine, St. Louis, MO; 15HarvardMedical School, Boston, MA.
The Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) in
collaboration with the Colorectal Cancer Family Registry (CCFR) aims to identify
genetic variants andenvironmental risk factors that impact colorectal cancer (CRC).
Over 30 studies fromNorthAmerica, Europe, andAustralia participate inGECCO.
These studies have collected clinical, epidemiological, and survival data, as well as
bloodandtumorbiospecimens, forover80,000CRCcasesandcontrols.Thecurrent
study aims to conduct targeted deep sequencing of tumors and matching normal
DNA to identify recurrent and novel somatic and germline variants in 4,200 CRC
cases. To achieve this goal, anAmpliSeq targeted sequencing panel of 1.12Mbpwas
constructed to sequence the coding regions of 190 signifıcantlymutated genes iden-
tifıed fromwhole exome sequencingdatasets generated by theNurses’Health Study
and Health Professional’s Follow-up Study, and The Cancer Genome Atlas. The
panel also covers coding regions of 15 genes with germline high penetrance muta-
tions in CRC, 54 regions to detect CRC-related copy number alterations (CNAs),
andmicrosatellite and homopolymer repeat regions to identify defectiveDNAmis-
match repair. Primerswere also included to detect FusobacteriumnucleatumDNA
in tumor biopsies, as F. nucleatum is thought to promote CRC carcinogenesis. Se-
quencingof theDNAlibrariesonIlluminaHiSeq2500producedameancoverageof
greater than 500X for tumor DNA and 100X for normal DNA, with85% of the
bases covered at the target at 50x. So far, targeted sequencing of1,500 DNA sam-
ples from CRC tumors and normal tissues has identifıed recurrent and novel so-
maticmutations, germline genetic variants, andhypermutation status of the tumors
due to defective DNAmismatch repair or pathogenicmutations in the POLE gene.
Targeted sequencing has also allowed quantifıcation of the F. nucleatum DNA in
tumor biopsies; the results were validated by amultiplexQPCRassay. At theAACR
annualmeeting, wewill present targeted sequencing results generated from the fırst
two GECCO-participating studies (n1,300 cases). These data will be valuable for
future association testingof somaticmutations,CNAs,hypermutation status, andF.
nucleatum with germline genetic variants, lifestyle, and environmental risk factors
and survival. This large studywill allowdevelopment of better strategies for diagno-
sis, treatment, and prevention of CRC.
#1287 Multigene panel testing and risk estimates in 10,233 ovarian cancer
cases. Jenna Lilyquist,1 Holly LaDuca,2 Eric Polley,1 Hermela Shimelis,1 Chunling
Hu,1 RaymondMoore,1 Steven N. Hart,1 Fergus J. Couch,1 Jill Dolinsky,2 David E.
Goldgar3. 1Mayo Clinic, Rochester, MN; 2Ambry Genetics, Aliso Viejo, CA; 3Univer-
sity of Utah School of Medicine; Huntsman Cancer Institute, Salt Lake City, UT.
Germline pathogenic variants in BRCA1 andBRCA2 account for 10%of ovarian
cancer (OC), including ovarian, fallopian tube, and primary peritoneal carcinomas.
Pathogenic variants in BRIP1, RAD51C,RAD51D, and other cancer predisposition
genes have been observed in another 2% to 5% of OCs. However, the specifıc genes
associated with OC and estimates of risk associated with pathogenic variants in the
individual genes are not well defıned. We sought to determine the relevance of
multigene panel testing results for OC cases. The study was focused on 140,449
individuals, including 10,233 OC cases, receiving clinical panel testing of cancer
predisposition genes. Standardized relative risks (SRR) for pathogenic variants in 18
cancer predisposition genes were estimated using reference controls from the Ex-
omeAggregation Consortium (ExAC). Themedian (range) age at diagnosis of OC
was57 (21-90) years.OCcaseswere 76.2%Caucasian, 3.6%AfricanAmerican, 4.6%
Asian, 4.7% Hispanic, and 10.9% unknown/other. Among the 10,233 OC cases,
1391 (13.6%) had pathogenic mutations, including 1032 pathogenic mutations
among the 7793 Caucasian OC cases (13.2%). Using the non-Finnish European
ExAC (excluding TCGA samples) reference controls, the allele frequency for all
pathogenic variants in each gene was summed and compared to the frequency of
mutations in theCaucasianOCcases. Pathogenic variants in the knownOCpredis-
position genes: BRCA1, BRCA2, BRIP1, MSH2, MSH6, RAD51C, and RAD51D
were associated with a high risk of OC (SRR4.0). Additionally, signifıcant associ-
ations were observed for pathogenic variants in suspected OC risk genes ATM and
PALB2 (SRR2.06 and 2.78, respectively). This study identifıed several genes rou-
tinely screenedonmultigene panel testing that confer highormoderate risks ofOC.
AssociationswithknownOCpredispositiongeneswere confırmed. Inaddition, this
studyprovides evidence that PALB2 is amoderate riskOCgene, and thatATMmay
confer lower to moderate risks of OC. If confırmed in future studies, these risks
should be carefully considered in future screening andmanagement ofOCpatients.
In contrast, BARD1 and genes in theMRN complex were not associated with clin-
ically relevant risks of OC.
#1288 Telomere length genetic risk score is associated with breast cancer
risk. Laurie Grieshober,1 Jean Wactawski-Wende,1 Rachael Hageman Blair,1
Lina Mu,1 Leah Preus,1 Jing Nie,1 Jiali Han,2 Jaymie R. Meliker,3 Thomas Ro-
han,4 Heather M. Ochs-Balcom1. 1University at Buffalo, Buffalo, NY; 2Indiana
University, Indianapolis, IN; 3Stony Brook University, Stony Brook, NY; 4Albert
Einstein College of Medicine, Bronx, NY.
Background: Genome-wide association studies (GWAS) have identifıed associa-
tions of telomeremaintenance genes with breast cancer risk. This, coupledwith the
recognized role of telomere dysfunction as a cancer hallmark, has motivated the
need for further study of telomeres and breast cancer. Further, the meta-GWAS
discovery of seven single nucleotide polymorphisms (SNPs) associated with telo-
mere length (TL) enables the use of an aggregated genetic risk score (GRS) for TL.
We hypothesized that a higher GRS (representing shorter TL) would be associated
with increased risk of breast cancer, and that a strengthened association may exist
between higher TL GRS and aggressive breast cancer risk. Methods: In a race/eth-
nically diverse sample of invasive breast cancer cases (N1,108) and non-cases
(N20,023) from the Women’s Health Initiative, we derived an unweighted TL
GRS using seven previously identifıed TL-associated SNPs. Women were post-
menopausal and the average age at enrollment was 63.9 years. We tested TL GRS
associations with overall breast cancer risk and for estrogen receptor (ER), proges-
terone receptor (PR), and her2/neu (HER2) status-specifıc breast cancer risk using
Cox proportional hazards models adjusted for age and race/ethnicity (in the entire
sample) and age in strata of EuropeanAmerican (EA;N9,796), AfricanAmerican
(AA; N7,504), andHispanic American (HA; N3,229) women.We also consid-
ered reproductive risk factors, family history of breast cancer, hormone therapy,
tumor characteristics, BMI, physical activity, smoking, alcohol, and US region as
potential confounders. Results: We observed a small but statistically signifıcant as-
sociation between higher TL GRS (shorter TL) and reduced risk of overall breast
cancer in the entire sample (HR0.96, 95%CI: 0.93-1.00). Results of race/ethnicity-
stratifıedanalyses forTLGRSandoverall breast cancer riskwerenot signifıcant.The
TL GRS was independently associated with decreased risk of ER-negative, PR-pos-
itive, andHER2-positive breast cancer risk in the entire sample (HR0.82, 95%CI:
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0.71-0.94, HR0.94, 95% CI: 0.89-0.99, and HR0.88, 95% CI: 0.79-0.99, respec-
tively). Similarly, the TL GRS was associated with a reduced risk of ER-negative
breast cancer in AA (HR0.79, 95% CI: 0.64-0.97) and independently with PR-
positive and HER2-positive breast cancer risk in HA (HR0.85, 95% CI: 0.75-0.97
andHR0.79, 95%CI: 0.58-0.99, respectively). Adjustment for other covariates did
not influence hazards. Conclusions: Our results suggest that higher TLGRS is asso-
ciatedwith reducedriskofoverall breast cancerandwith thedevelopmentof specifıc
breast cancer subtypes, such as ERnegativity and/or PR andHER2positivity.While
our focusonGWAS-implicatedSNPsmaynotencompass the full spectrumofgenes
involved in TL, further studies into the potential mechanism for shorter TL and
reduced breast cancer risk are needed.
#1289 Evaluation of vitamin D receptor regulated genes reveals EGFR poly-
morphism is associatedwithhigh-grade serousovarian cancer inAfricanAmer-
ican women. Delores J. Grant,1 Ani Manichaikul,2 Lauren C. Peres,2 Xin-Qun
Wang,2 Ann G. Schwartz,3 Anna Wu,4 Edward Peters,5 Patricia Moorman,6 Mi-
cheleL.Cote,7MelissaBondy,8 LindaE.Kelemen,9 Jill Barnholtz-Sloan,10Temitope
O. Keku,11 Cathrine Hoyo,12 Andrew Berchuck,6 Paul Pharoah,13 JoellenM. Schil-
dkraut,2 African American Cancer Epidemiology Study (AACES) and the Ovarian
Cancer Assoc Consortium (OCAC)2. 1North Carolina Central Univ., Durham, NC;
2University of Virginia, Charlottesville, VA; 3Wayne State University, Detroit, MI;
4KeckSchool ofMedicineofUSC,LosAngeles,CA; 5LouisianaStateUniversityHealth
Sciences, NewOrleans, LA; 6DukeUniversityMedical Center, Durham,NC; 7Wayne
State University School of Medicine, Detroit, MI; 8Baylor College of Medicine, Hous-
ton, TX; 9Medical University of South Carolina, Charleston, SC; 10CaseWestern Re-
serveUniversity School ofMedicine,Cleveland,OH; 11University ofNorthCarolinaat
Chapel Hill, Chapel Hill, NC; 12North Carolina State University, Raleigh, NC; 13Uni-
versity of Cambridge, Cambridge, United Kingdom.
Few studies have evaluated genetic risk factors for ovarian cancer in African
American women. In a previous study with small sample sizes, Vitamin D Re-
ceptor (VDR) variants were shown to increase risk of epithelial ovarian cancer
(EOC) in that population. This study sought to replicate those fındings and
assess gene variants from the VDR regulatory pathway. We assessed SNPs
(genotypedimputed) from 5 gene regions which included VDR and genes
regulated by VDR, including UGT1A, UGT2B, CYP3A4/5 and EGFR in 755
EOC cases and 1,235 controls amongwomen ofAfrican ancestry from theOvar-
ian Cancer Association Consortium (OCAC). We also performed analyses re-
stricted to 537 patients with HGSOC represented in the overall analysis of EOC.
SNPs were genotyped using the custom-designed 533,631 SNP Illumina On-
coArray with imputation to the 1,000 Genomes Phase 3 v5 reference set for
genotyped and imputed SNPs evaluated at the 5 gene regions (918 SNPs in
UGT1A, 6302 SNPs in UGT2B, 410 SNPs in CYP3A4/5, and 824 SNPs in
EGFR). Logistic regressionwas performed using an additive 1 degree of freedom
model for genetic inheritance with adjustment for two principal components of
ancestry to estimate odds ratios (OR) and 95 % confıdence intervals (CI). For
each gene region, we applied a gene-specifıc Bonferroni-threshold for statistical
signifıcance defıned as 0.05 / number of SNPs examined for that gene. Based on
this signifıcance threshold, a statistically signifıcant association with HGSOC
was identifıed in the EGFR region for the imputed SNP, rs114972508 (per allele
OR 2.32, 95% CI 1.58, 3.40 p1.6e-05, imputation R-squared0.89). We
further identifıed suggestive associations (P  1.0e-06) with EOC for 10 im-
puted SNPs located within the UGT2B4 gene. We did not replicate previous
associations in the 282 SNPs examined in the VDR gene for EOC overall or
among HGSOC. In summary, we identifıed statistically signifıcant association
for variants from the EGFR region, and suggestive evidence of association for
variants within the UGT2B region in genetic association analyses of ovarian
cancer in women of African Ancestry. Data from in vitro experiments suggest
that EGFR transcription and proliferative function is suppressed via VDR bind-
ing. Thus EGFR association with HGSOC may be a marker of VDR activity.
UGT2B4 variants have not been previously explored in ovarian cancer but
shown to be nominally associated with breast cancer in women of African an-
cestry. UGT2B4 enzymes, part of the phase II liver detoxifıcation pathway, are
important in the clearance of steroid hormones, bile acid and drug metabolism.
Alterations in EGFR and UGT2B4 could perturb enzyme effıcacy and prolifer-
ation in ovaries and impact susceptibility to ovarian cancer. Future studies will
be needed to validate the associations of the imputed SNPs and to determine the
impact of EGFR and UGT variants on cancer development.
#1290 Association of common genetic variants with TMPRSS2 ERG fu-
sion status in prostate cancer. Indu Kohaar,1 Lakshmi Ravindranath,1 Denise
Young,1 Amina Ali,2 Qiyuan Li,3 Albert Dobi,1 David McLeod,1 Inger L. Ros-
ner,2 Isabell Sesterhenn,1Matthew Freedman,4 Shiv Srivastava,1 Gyorgy Petrov-
ics1. 1CPDR/USUHS, Rockville, MD; 2WRNMMC/USUHS, Bethesda, MD; 3Xia-
men University, China; 4Dana-Farber Cancer Institute, Boston, MA.
Introduction and Objectives: Oncogenic activation of ERG resulting from
prevalent gene fusions is present in two thirds of prostate cancer (CaP) patients
of European Ancestry including Caucasian Americans (CA). Our laboratory
and others have recently reported that major cancer driver genes, including
ERG, show signifıcant racial/ethnic differences in CaPwith lower frequencies in
African Americans (AA), Africans and Asians. Racial differences of CaP associ-
ated SNPs have also been extensively described. However, there is limited data
on germline association with ERG fusion status. The goal of this study is to
identify germline molecular determinants associating with ERG status of CaP.
Methods: Blood derived genomic DNA samples were prepared from 270 AA
men and 129 CAmen treated by radical prostatectomy atWalter Reed National
Military Medical Center (WRNMMC). ERG status was determined in whole
mounted prostate specimens by immuno-histochemistry (IHC) for ERG pro-
tein expression as a surrogate for the TMPRSS2-ERG fusion. Blinded blood
samples were genotyped for SNPs on the Illumina Golden Gate platform using
Infınium Oncoarray, a 500K genome wide BeadChip kit from Illumina. Data
analysis approaches included association analyses based on logistic regression,
Principal Component Analysis (PCA) and Effıcient Mixed-Model Association
eXpedited (EMMAX) analysis. Genotype imputation analysis is being per-
formed by IMPUTE2 program. Results: After applying rigorous sample and
SNP QC steps on the datasets, SNP genotyping analysis was performed in 321
patients with 478,299 SNPs. Logistic regression, principal component analysis
by EIGENSTRAT and a variance component approach, EMMAX analysis were
performed to account for population structure. By EMMAXwe identifıed SNPs
associated with ERG status. The SNPs most signifıcantly (105) associated
with ERG fusion status included rs6698333, an intron variant of Kruppel-like
factor 17 (KLF17) and two SNPs (rs1889877, rs3798999) in the intron of adhe-
sion G protein-coupled receptor B3 (ADGRB3). Fine-mapping of SNPs is un-
derway by genotype imputation analysis (IMPUTE2) using the 1000 Genomes
reference dataset, followed by independent validation. Conclusions: This study
identifıed SNPs differentially associated with ERG status of CaP, a major driver
oncogene in CaP. Although the biological signifıcance as it relates to ERG status
of CaP still needs to be determined, these SNPs, with independent validation,
may help asmarkers in stratifying patients early (even beforeCaP is detected) for
targeted prevention and treatment options.
#1291 Mutation analysis of endometrial cancer in a population-based
study by targeted next-generation sequencing. Maxine Chen, Marta Crous-
Bou, Michael J. Downing, Evan L. Busch, Kimberley Glass, Jennifer Prescott,
George L. Mutter, Immaculata De Vivo. Brigham and Women’s Hospital and
Harvard Medical School, Boston, MA.
Endometrial carcinoma (EC), a malignancy that arises from the epithelial lining
of the uterus, is heterogeneous at histologic and molecular levels. Risk factors and
outcomes also differ by type. Though prior studies characterized the genomic land-
scape of endometrial carcinoma, few integrated histologic, clinical, and prospec-
tively collected epidemiologic data into the analysis. We collected formalin-fıxed
paraffın embedded tumor tissue fromwomen enrolled in the Nurses’ Health Study
whowere diagnosedwithECbetween1976 and2012.We targeted 50 cancer related
genes for high-throughput sequencing to identify genetic variants in 37 ECs and
correlate fındings with immunohistochemical, histologic, and epidemiologic data.
Case selection was designed to include maximal power to discover genetic changes
associated with p53 immunohistochemical status and clinical stage of disease at
diagnosis. Mutations most frequently occurred in TP53 (57%), PTEN (46%), and
PIK3CA (38%). TP53 mutations were seen in 83% of ECs that immunostained
positive formutant p53, with themost frequent TP53mutations occurring inR248.
Well-differentiated endometrioid tumors had elevated frequencies of PTEN and
PIK3CA mutations compared to less differentiated tumors (p 0.05). The muta-
tion profıles of these samples are consistent with previous studies, supporting the
viability of archival paraffın-embedded tissue in mutation detection. This study’s
interdisciplinary approach to tumor characterizationmayhelp inform future devel-
opment of personalizedmodels for EC.
#1292 Germline genetic, molecular and environmental factors modulate
APOBECmutagenesis in human tumors. A. Rouf Banday, Ariunaa Bayanjar-
gal, Krizia-Ivana Udquim, Olusegun O Onabajo, Ludmila Prokunina-Olsson.
National Cancer Institute, National Institutes of Health, Bethesda, MD.
Background:Activity ofAPOBEC3 enzymes has been identifıed as amain source
of somaticmutations of a specifıc type (C toTorG substitutions in theTCAorTCT
motifs). This mutation pattern, known as the APOBEC signature, has been de-
scribed in16of 30 tumor types exploredbyTCGA,withbladder cancer beingoneof
top cancers enriched with APOBEC-signature mutations. Recently, we demon-
strated that a risk allele of a bladder cancer GWAS SNP rs1014971was signifıcantly
associatedwith increasedAPOBEC3B (A3B)mRNAexpression andAPOBECmu-
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tagenesis in bladder tumors. Here, we aimed to further explore factors that can
modulate APOBECmutagenesis in human tumors. Methods: Isoform-specifıc ex-
pression analysis of all APOBEC3 genes (A3A, A3B, A3C, A3D, A3G, A3F, and
A3H) was performed in TCGA datasets for seven tumor types enriched for APO-
BEC mutations ( 25% of the samples) - bladder urothelial carcinoma (BLCA),
breast invasive carcinoma (BRCA), cervical and endocervical cancers (CESC), head
and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), lung
squamous cell carcinoma (LUSC), and ovarian serous cystadenocarcinoma (OV).
Expression andAPOBECmutagenesis patternwere analyzed bymultivariate linear
regression in relation to rs1014971 genotypes and adjusting for age, sex, race, DNA
CpG methylation, copy number alterations (CNA), and human papilloma virus
(HPV) infectionstatus (where relevant). Survival analysiswasperformedusingmul-
tivariate Cox regressionmodels that included age, sex, tumor stage, rs1014971, and
load of APOBEC mutations or mRNA expression of APOBEC3 splicing forms.
Results: Analysis of APOBECmutagenesis identifıed signifıcant interplay between
SNP rs1014971, expression of specifıc APOBEC3 splicing isoforms, and environ-
mental factors (such as HPV infection). For example, SNPwas important in BLCA
and sub-types of HNSC, while HPV infection status was themain factor associated
withAPOBECmutagenesis inCESCandHNSC. Importantly, variable contribution
ofmutagenic andnon-mutagenic isoformsofA3AandA3B,whicharegeneratedby
alternative splicing, emerged as signifıcant factors contributing to APOBEC mu-
tagenesis acrosshumantumors.Survivalof thecancerpatientswasalsodifferentially
influenced by these factors. Conclusions: These fındings suggest thatAPOBECmu-
tagenesis pattern is tissue-specifıcally affected by germline genetic, molecular and
environmental factors. Deeper understanding of these factors and their interplay
maypave theway forpreventive and treatmentmeasures of humancancers towards
precisionmedicine.
#1293 ABObloodtypeandcancerrisk:preliminaryfındingsfromaphenome
analysis.AliciaBeeghly-Fadiel,AyushGiri, LisaBastarache, Jill Pulley, JeremyWar-
ner, Josh Denny.Vanderbilt University Medical Center, Nashville, TN.
Introduction: ABO blood type has long been implicated in disease susceptibility,
including cancer. However, evidence for associations with many malignancies is
mixed. We applied a novel phenome approach to test to cancer codes from elec-
tronic medical records (EMR) in relation to ABO blood type in a large predomi-
nantly Caucasian study population. Approach: Among adults aged 18-100, cancer
case and control status were assigned using 58 general neoplasm related phenome
codes tode-identifıedEMRat theVanderbiltUniversityMedicalCenter. Blood type
from serologic assayswas ascertained fromEMR-linked laboratory reports. Associ-
ations between blood type and cancer phenomes were quantifıed with Odds Ratios
(OR) and corresponding 95%Confıdence Intervals (CI) from logistic regression in
models adjusted for sex and stratifıed by race/ethnicity. Only analyses with at least
100 cases per strata were conducted. Results: Among 221,015 Non-Hispanic Cau-
casians, 37,841 Blacks, 7,714 Hispanic Caucasians, and 3,616 Asian subjects with
ABObloodtypeavailable in linkedEMR,weevaluated56,37,4, and3general cancer
phenome codes, respectively. After employing Bonferroni corrections, ABO blood
typewassignifıcantlyassociatedwithcancersof thepancreas,ovary, cervix, skin, and
hematopoietic system.Caucasianswithblood typeOwere less likely tohaveovarian
cancer (OR: 0.82, 95%CI 0.73-0.91) and pancreatic cancer (OR: 0.83, 95%CI: 0.74-
0.92), andmore likely to have squamous cell or other skin cancer (OR: 1.08, 95%CI:
1.04-1.13)andmyeloid leukemia (OR:1.15,95%CI:1.06-1.25) than thosewithother
blood types (A, B, orAB).HispanicCaucasianswith blood typeOwere less likely to
have cervical cancer (OR: 0.56, 95%CI: 0.38-0.82) than thosewithotherblood types.
No associations surpassed correction for multiple comparisons among Blacks or
Asians. Conclusions: Our phenome approach confırmed known associations be-
tween blood type and risk of pancreatic and ovarian cancer, and adds to accumulat-
ing evidence supporting associations with skin cancer and leukemia. Our novel
cervical cancer association amongHispanicCaucasians and other nominally signif-
icant fındings, especially in understudied non-Caucasians, should be further evalu-
ated in large and diverse populations. In addition, research to determine howABO
blood type may influence cancer development and progression, and if such associ-
ations can be exploited for risk prediction or cancer prevention is warranted.
#1294 Prevalence and spectrumof germline rare variants inBRCA1/2 and
PALB2 among breast cancer cases in Sarawak, Malaysia. Xiaohong (Rose)
Yang,1 Beena Devi,2 Hyuna Sung,1 Jennifer Guida,1 Yanzi Xiao,1 Lisa Garland,3
Nan Hu,1 Maria Rodriguez-Herrera,1 Chaoyu Wang,1 Kristine Jones,3 Wen
Luo,3 Belynda Hicks,3 Tieng Swee Tang,2 Karobi Moitra,1 Mike Dean1. 1NCI/
NIH/DHHS, Bethesda, MD; 2Sarawak General Hospital, Kuching, Malaysia;
3Leidos Biomedical Research, MD.
Germlinemutations in the BRCA1 and BRCA2 genes result in predisposition to
breast and ovarian cancer. Detection of BRCA mutation carriers can lead to im-
proved prevention and therapeutic interventions such as the targeted therapy using
poly ADP ribose polymerase (PARP) inhibitors, which are particularly effective in
BRCA mutation carriers. The spectrum of BRCA mutations varies depending on
geographic origin, population, and ethnic group; however, the prevalence of BRCA
mutations in non-Caucasian populations has been poorly characterized, particu-
larly in a population-based setting. The goal of this study was to characterize the
spectrum of germlinemutations in BRCA1/2 and PALB2 in unselected breast can-
cer cases who were seen in Sarawak General Hospital, Malaysia, where 93% of the
breast cancer patients in Sarawak are treated. We performed targeted sequencing
using a validated AmpliSeq panel on 467 cases with available risk factor question-
naire and clinical follow-up data. Breast cancer subtypes were defıned by the joint
expression of ER, PR, and HER2. Common variants with frequency 1% in any
public database (1000 Genome, Exome Sequencing Project, The Exome Aggrega-
tion Consortium) were excluded. Pathogenic variants included known pathogenic
variants inClinVar, lossof functionvariants (frameshift andstop-gain), andvariants
that alter the fırst or second base of the splice site. Variants of unknown signifıcance
(VUS) were also defıned using the ClinVar classifıcation. We found 10 BRCA1
pathogenicvariants in12patients, 10BRCA2pathogenicvariants in15patients, and
4PALB2pathogenic variants in4patients,whichgave aBRCAmutationprevalence
of 5.78% among the unselected breast cancer cases in this population. All these
variants were extremely rare in the general population (0.05%). Only 4 of them
were recurrent variants (2 in BRCA1 and 2 in BRCA2) and all four are known
variants that were reported previously in other populations. In addition, we identi-
fıed a novel deleterious mutation (stop-gain) that has never been reported and a
number of VUS variants in this population. Patients with pathogenic BRCA and
PALB2 variants were associated with an earlier age at onset (7 years younger,
p0.0005), a positive family history (20% higher, p0.01), and the triple-negative
(TN) subtype (56% vs. 18%, p0.0001), compared to patients without mutations.
Mutation carrier cases had worse survival compared to non-carriers, however, the
association was mostly driven by the higher frequency of TN in mutation carriers.
Our study for the fırst time reported the prevalence of germlinemutations in BRCA
and PALB2 in a quasi-population-based case series unselected for age and family
history in anunder-studiedAsianpopulation.Our resultsmayhave important clin-
ical implications for performing genetic testing on selected patients in a low-re-
source setting.
#1295 Genomewide gene-diabetes and gene-obesity interaction scan in
7095 cases and 10710 controls from Pancreatic Cancer Cohort Consortium
and Pancreatic Cancer Case Control Consortium.Hongwei Tang,1 Lai Jiang,2
Laufey T. Amundadottir,3 Harvey A. Risch,4 Rachael S. Stolzenberg-Solomon,3
Alison P. Klein,5 Brian M. Wolpin,6 Gloria Petersen,7 Nilanjan Chatterjee,8
Donghui Li,1 Peter Kraft,2 PengWei1. 1UTMD Anderson Cancer Center, Hous-
ton, TX; 2Harvard T.H. Chan School of Public Health, Boston, MA; 3National
Cancer Institute, National Institutes of Health, Bethesda, MD; 4Yale School of
Public Health, New Haven, CT; 5Johns Hopkins School of Medicine, Baltimore,
MD; 6Dana-Farber Cancer Institute, Boston, MA; 7Mayo Clinic, Rochester, MN;
8The Bloomberg School of Public Health, Baltimore, MD.
Introduction:Obesity anddiabetes are twomajormodifıable risk factors for pan-
creatic cancer. Genetic variation affecting the risk of obesity- and diabetes-related
pancreatic cancer have yet to be comprehensively investigated at the genome-wide
level. Aims: To identify novel gene-environment interactions (GxE) of obesity/dia-
betesonpancreatic cancer risk.Methods:Weconductedamulti-stagegenome-wide
gene-diabetes and gene-obesity interaction study using GWAS data of 7095 cases
and10710controls fromPancreaticCancerConsortium(PanScan I,PanScan II and
PanScan III) and Pancreatic Cancer Case Control Consortium (PanC4). About
870,000SNPs,havingMAF
0.005andhavingbeengenotyped inat leastonestudy,
were analyzed. Missing genotypes were imputed using IMPUTE2 and the Haplo-
type Reference Consortium (HRC) reference panel. Case-control (CC) and case-
only (CO) methods were used for SNP-level GxE analysis. Fixed-, random- and
joint-effectmodels built in “rareGE”Rpackagewere used for gene-basedGxE anal-
ysis. About 20,000 genes that have at least one SNP genotyped were included in the
analysis. Age, gender and principal components accounting for subpopulation
structure were adjusted in both SNP-level and gene-level analyses. Obesity was de-
fıned as body mass index 
30 mg/m2. Diabetics with 3-year duration were ex-
cluded for gene-diabetes interaction analysis. The PanScan I, II, III and PanC4 da-
tasets were analyzed separately followed bymeta-analysis of the summary statistics.
Fixed-effect andFisher’s p-value basedmeta-analysiswas applied for SNP-level and
gene-level GxE analysis, respectively. Results: No genome-wide signifıcant (P5 x
108 ) interaction at the SNP level was detected in any of the PanScan or PanC4
datasets or in the meta-analysis. A signifıcant interaction of diabetes and FAM63A
(familywith sequence similarity63memberA)gene (P2.5x106)wasobserved in
themeta-analysis (PFixed3.4x105, PRandom1.9x106, PJoint6.8x107).This
interaction showed nominal signifıcance in all individual dataset analyses. The cor-
respondingP values for this interactionwere 4.2 x 102, 3.8 x 102 and 6.8 x 102 in
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PanScan I, 2.8 x 102, 3.9 x 102 and 6.5 x 102 9.1 x 103, 2.2 x 104 and 8.8 x 106
in PanScan III, and 3.1 x 103, 3.4 x 103 and 8.8 x 103 in PanC4, respectively.
Conclusions: In the largest genome-wideGxEanalysis for pancreatic cancer to date,
we identifıed a signifıcant diabetes interacting gene in pancreatic cancer, whichwas
consistently replicated in 4 individual GWAS studies. This observation identifıes
FAM63A as a candidate for future functional studies to understand its role in pan-
creatic cancer etiology. Further increasing the sample size may unveil additional
genetic loci that contribute to the susceptibility to pancreatic cancer via G x E.
#1296 Bayesian fıne-mapping using summary data of 145,000 subjects
refınes common risk associations, discovers secondary signals and novel can-
didate genes for prostate cancer. Zsofıa Kote-Jarai,1 Tokhir Dadaev,1 Ed Saun-
ders,1 Paul Newcombe,2 Ezequiel Anokian,1 Daniel Leongamornlert,1 Ali Amin
Al Olama,2 Christopher Haiman,3 Ros Eeles,1 David Conti,3 The PRACTICAL/
ELLIPSE Consortium. 1Inst. of Cancer Research, Sutton, United Kingdom; 2Uni-
versity of Cambridge, Cambridge, United Kingdom; 3University of Souther Cali-
fornia, Los Angeles, CA.
Genome-wide association studies (GWAS) have identifıed more than 160
prostate cancer (PrCa) genetic risk loci, however these variants rarely point
directly to the true underlying functional variant driving the association. In this
fıne-mapping study to narrow the credible causal variant set for 80 PrCa regions
representing 89 original independent GWAS signals, we performed Bayesian
variable selection in combination with functional annotation and quantile re-
gression. We used imputed data for 83,511 PrCa cases and 62,283 controls in-
vestigated with high-density genotyping arrays from the OncoArray, iCOGS
and 5 previous GWAS studies from the PRACTICAL/ELLIPSE consortia. To
facilitate fıne-mapping from one-at-a-time SNP associations meta-analyzed
over the consortia we fırst applied JAM, a novel Bayesian algorithm which
searches multi-SNPmodels in summary data by imputing the correlation struc-
ture according to a reference panel. JAM provides inference on the number of
independent signals, aswell as the set of potential SNPs driving those signals.We
utilized functional annotation and eQTL analysis (TCGA prostate tumor data)
in combination with quantile regression to further prioritize the most likely
causal variants within the credible set of SNPs and identify potential candidate
genes and functional mechanisms. The median credible set size from JAM was
17 SNPs per region, shrinking the post-QC input set of variants by about 98%. In
13 regions evidence was found for multiple independent signals, up to a maxi-
mum of 5 SNPs. Within the single hit regions, almost half had less than 10
variants selected. In 34 regions the credible set included at least one SNP thatwas
co-localized with a signifıcant eQTL. Quantile regression highlighted enrich-
ment for variants in promoters, DNase hypersensitivity site and eQTLs - repre-
senting candidate biological mechanisms underpinning disease development.
This study has substantially reduced and prioritized the candidate causal PrCa
risk variants within previously knownGWAS regions, identifying a small subset
of variants for further functional investigation and novel candidate genes at a
number of loci.
#1297 Genetic reclassifıcation of prostate-specifıc antigen levels for
personalized prostate cancer screening. Rebecca E. Graff,1 Thomas J. Hoff-
mann,1 Michael N. Passarelli,2 Nima C. Emami,1 Lori C. Sakoda,3 Eric Jor-
genson,3 Laurel A. Habel,3 Jun Shan,3 Dilrini K. Ranatunga,3 Charles P.
Quesenberry,3 Chun R. Chao,4 Nirupa R. Ghai,4 David Aaronson,5 Joseph
Presti,5 Tobias Nordström,6 Zhaoming Wang,7 Sonja I. Berndt,7 Stephen
J. Chanock,7 Jonathan D. Mosley,8 Robert J. Klein,9 Mridu Middha,9 Hans
Lilja,9 Olle Melander,10 Mark N. Kvale,1 Pui-Yan Kwok,1 Catherine
Schaefer,3 Neil Risch,1 Neil Risch,1 Stephen K. Van Den Eeden,3 John S.
Witte1. 1University of California, San Francisco, San Francisco, CA; 2Geisel
School of Medicine at Dartmouth, Hanover, NH; 3Kaiser Permanente North-
ern California, Oakland, CA; 4Kaiser Permanente Southern California, Pas-
adena, CA; 5Kaiser Oakland Medical Center Northern California, Oakland,
CA; 6Karolinska Institutet, Stockholm, Sweden; 7National Cancer Institute,
National Institutes of Health, Bethesda, MD; 8Vanderbilt University, Nash-
ville, TN; 9Memorial Sloan-Kettering Cancer Center, New York, NY; 10Lund
University, Malmö, Sweden.
Background: Prostate-specifıc antigen (PSA) screening for prostate cancer
results missed diagnoses as well as many unnecessary biopsies and their associ-
ated morbidities. Because PSA levels are heritable, traditional PSA screening
maybe improved by adjustment for constitutive germline genetics that influence
PSA independently of prostate cancer. Methods: In a previous genome-wide
association study in non-Hispanic white men without prostate cancer in the
Kaiser Permanente Research Program on Genes, Environment and Health co-
hort, we identifıed 40 single nucleotide polymorphisms (SNP) independently
and signifıcantly associated with PSA levels. Among them, 24 were not associ-
ated with prostate cancer risk. To calculate genetically normalized PSA (i.e.,
PSA’), we multiplied each man’s most recent PSAmeasurement by a factor that
adjusted for the amount by which his 24 PSA-specifıc SNPs may have increased
his PSA level. We then compared howmen without prostate cancer were classi-
fıed based on their PSA and PSA’ levels with regard to decisions for diagnostic
testing. Results: PSA and PSA’ were highly correlated among non-Hispanic
white men without prostate cancer (r2: 0.959; 95% CI: 0.958-0.960). Still, 4.6%
were reclassifıed from above to below a cutpoint of 2.5 ng/ml when using the
PSA’ measure, and 2.7% were reclassifıed from below to above this cutpoint
(4.6% - 2.7% 1.9%net reclassifıed to below the cutoff). The reclassifıcationwas
even more pronounced when restricting to controls with a negative prostate
biopsy: 5.0% downward and 1.5% upward (3.5% net reclassifıed to below the
cutoff). Conclusions: Normalizing PSA levels using germline PSA variants may
reduce the number of subjects without prostate cancer receiving unnecessary
biopsies.
#1298 Genetic variants related to longer telomere length are associated
with increased risk of renal cell carcinoma.Mitchell J. Machiela,1 Jonathan N.
Hofmann,1 RobertCarreras-Torres,2Nathaniel Rothman,1 Paul Brennan,2Mat-
tias Johansson,2 Stephen J. Chanock,1 KevinM. Brown,1 Ghislaine Scelo,2 Mark
P. Purdue1. 1National Cancer Institute, Rockville, MD; 2International Agency for
Research on Cancer, Lyon, France.
Telomere length in peripheral blood leukocytes has been evaluated as a
potential biomarker for renal cell carcinoma (RCC) risk in numerous obser-
vational studies, but association results have been inconsistent. These fınd-
ings may have been affected by several limitations, including bias from re-
verse causation, reliance on a single blood specimen, residual confounding
or measurement outside of the etiologically relevant time period. Germline
genetic variations associated with leukocyte telomere length are not affected
by an individual’s exposure to confounders and may act as unconfounded
markers of the relationship between telomere length and RCC risk. We per-
formed an analysis of genetic variants associated with leukocyte telomere
length to assess the relationship between telomere length and RCC risk.
Genotypes from nine telomere length associated variants were aggregated for
10,785 RCC cases and 21,579 cancer-free controls.We found that the number of
telomere length variants associated with RCC risk (P-value0.05) was signifı-
cantly higher than what would be expected by chance (5/9 variants, binomial
P-value3.32105). We aggregated the telomere length associated variants
into a weighted genetic risk score (GRS), where one GRS unit equals to an
inferred one Kb change in telomere length. Genetically inferred telomere length
was associated with an increased risk of RCC (OR2.07, 95% CI1.70-2.52,
P-value7.141013). This associationwas consistent across increasing deciles
of telomere length GRS (Trend P-value5.581012). As a sensitivity analysis,
we removed two telomere length variants in linkage disequilibrium with RCC
genome-wide associated regions (rs10936599 and rs9420907) from the telomere
length GRS, the association with RCC risk remained statistically signifıcant
(OR1.73, 95% CI1.35-2.20, P-value1.07105). When performing analy-
ses by RCC subtype (clear cell5,574 cases, papillary573 cases and chromo-
phobe203 cases), all subtypes investigated showed positive GRS effect esti-
mates, suggesting higher risk for longer telomeres, however, due to limited
sample sizes the estimates were only signifıcant for clear cell (OR1.93, 95%
CI1.50-2.49, P-value3.79107) and papillary subtypes (OR1.96, 95%
CI1.01-3.81, P-value0.046). In conclusion, our results suggest a genetic
background that favors longer telomeres is associated with increased RCC risk.
#1299 Common germline risk loci and the tumor anticancer immune re-
sponse in breast cancer. Siddhartha Kar, Jonathan Tyrer, Paul Pharoah, Breast
Cancer Association Consortium (BCAC). University of Cambridge, United King-
dom.
The relationship between common germline SNPs that predispose to cancer
and the anticancer immune response as measured in tumors is uncharacterized.
We investigated this relationship in breast cancer, leveraging availability of four
large-scale resources for this cancer type: (1) 159 independent SNP loci associ-
ated with overall breast cancer risk at P  5 x 108, including 65 unpublished
SNPs, identifıed by a recent meta-analysis of over 220,000 individuals of Euro-
pean ancestry (EUR) from existingGWAS and new studies from theOncoArray
Network (2) Matched germline genotype and tumor transcriptomic profıles
from 701 (EUR) breast cancer cases from TCGA (3) a general measure of anti-
cancer immunity - fraction of total immune cells in these TCGA tumors inferred
from gene expression signatures by ESTIMATE scoring (Yoshihara et al, Nat
Commun 2013) (4) specifıc measures of anticancer immunity - levels of 15
immune cell types and functions in these TCGA tumors inferred from gene
expression signatures by ssGSEA (Rooney et al, Cell 2015). Linear regression
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with and without adjustment for covariates (age at diagnosis, stage, tumor neo-
antigen load, tumor ESR1 expression) was used to test association between
germline SNP genotype and the tumor anticancer immune response measures.
SNPswere evaluated individually and collectively as a polygenic risk score (PRS)
weighted by the per-allele log OR derived from the OncoArray analysis. The
breast cancer risk-conferring allele for 9 of the 159 SNPs was associated with
reduced tumor general immune infıltration (ESTIMATE score) at P 0.05 both
before and after adjustment for covariates. The most signifıcant of these associ-
ations with ESTIMATE score (Punadjusted  0.0003; Padjusted  0.001) was for
rs71801447, the lead SNP at 2q13, a breast cancer risk locus identifıed by the
OncoArray. This SNP was associated at P  0.05 with 12 of the 15 specifıc
immune cell types and functions both before and after adjustment. The risk
allele correlated with reduction in each of these 12 tumor immune phenotypes,
with the strongest associations identifıed for CD4 regulatory T cell (Padj 
0.003) and CD8 T cell infıltrates (Padj  0.007). SNP rs71801447 lies in the
3’-UTR of BCL2L11 and its risk allele was associated with reduced expression of
BCL2L11 in the same set of TCGA breast tumors (P 0.002). Moreover, SNPs
in strong LD (r2 0.98) with rs71801447 overlapped enhancers in CD4 and
CD8 T cells and in HMEC and MCF7 breast cells that were predicted to
interact with the promoter of BCL2L11 in each of these cell types. Finally, as a
PRS, breast cancer risk was signifıcantly associated with reduced tumor type I
interferon activity (Punadj  0.006; Padj  0.02). Our fındings implicate
BCL2L11, a well-known regulator of T and breast cancer cell apoptosis, as a
potential link between germline risk SNPs and immune response to tumors in
breast cancer and suggest that modulating antitumor immunitymay be amech-
anism of action for some established risk loci.
EPIDEMIOLOGY: Genome-Wide Association Studies/Post-
GWAS Studies
#1300 Genetic predictors of gene expression associated with risk of colo-
rectal cancer. Stephanie A. Bien,1 Xingyi Guo,2 Yu-Ru Su,1 Tabitha A. Harri-
son,1 Conghui Qu,1 Yingchang Lu,2 Jiron Long,2 Sai Chen,3 Andrew T. Chan,4
David V. Conti,5 Hyun M. Kang,3 Michael Hoffmeister,6 Thomas J. Hudson,7
Mark A. Jenkins,8 Loic LeMarchand,9 Polly A. Newcomb,1Martha L. Slattery,10
Emily White,1 Goncalo R. Abeçasis,3 Stephen B. Gruber,5 Deborah A. Nicker-
son,11 Stephanie L. Schmit,12 Graham Casey,13 Li Hsu,1 Wei Zheng,2 Ulrike
Peters,1 GECCO-CCFR-AAAC-CORECT. 1Fred Hutchinson Cancer Research
Ctr., Seattle,WA; 2Vanderbilt University, TN; 3University ofMichigan,MI; 4Har-
vardMedical School, MA; 5University of Southern California, CA; 6German Can-
cer Research Center (DKFZ), Germany; 7Ontario Institute for Cancer Research,
Ontario, Canada; 8TheUniversity ofMelbourne, Australia; 9University ofHawaii
Cancer Center, HI; 10University of Utah Health Sciences Center, UT; 11University
of Washington, WA; 12Moffıtt Cancer Center, FL; 13University of Virginia, VA.
To date, genome-wide association studies (GWAS) have reported common
variants in over 50 loci withweak tomoderate effects onCRC risk. These genetic
factors in aggregate explain only a small fraction of familial risk of CRC. To aid
in the discovery of novel CRC loci, we integrated large transcriptome data,
including those generated in theGenotype-Tissue Expression (GTEx) Project in
genetic association analyses of CRC. The computational method, PrediXcan,
was used to predict transcript levels in relevant tissues and perform gene-level
association tests with CRC. Prediction models were developed using whole
blood transcriptomes (n922) from the depression genes and networks (DGN),
as well as colon transcriptomes (transverse n169 and sigmoid n124) from
GTEx datasets, alongwith high-density genotyping data from the same subjects.
Genetically determined expression levels were tested for association with CRC
in 12,186 cases and 14,718 controls from GECCO-CCFR and suggestive associ-
ations (false discovery rate  0.2) were evaluated in 7,481 cases and 17,796
controls from the Asia Colorectal Cancer Consortium (ACCC) and 22,974 cases
and 14,392 controls from the Colorectal Transdisciplinary (CORECT) study.
We attempted to replicate novel associations for eight genes and found sta-
tistically signifıcant associations with CXCR1 (OR1.21 (1.10-1.33),
p-value7.8x105) and CXCR2 (OR1.24 (1.11-1.38), p-value
9.9x105). We also recovered previous associations at six known GWAS loci,
thereby providing additional support for putative target genes. CXCR1 and
CXCR2 are therapeutic targets for the anticancer agent Reparixin, which is cur-
rently being investigated in a stage II clinical trial for triple negative breast
cancer. As such, these fındings provide preliminary support for new molecular
targets that could potentially repurpose a putative cancer therapeutic. These
fındings highlight the utility integrating transcriptome data for novel discovery
and biological insight of risk loci.
#1301 Identifıcationof novel susceptibility loci andgenes for prostate cancer
risk:A large transcriptome-wideassociationstudy inover143,000subjects.Lang
Wu,1 Jirong Long,1 Yingchang Lu,1 Xingyi Guo,1 Bogdan Pasaniuc,2 Kathryn L.
Penney,3 Zsofıa Kote-Jarai,4 Christopher A. Haiman,5 Rosalind A. Eeles,4 Wei
Zheng,1 the PRACTICAL consortium. 1Vanderbilt University Medical Center,
Nashville, TN; 2University ofCalifornia, LosAngeles, LosAngeles, CA; 3HarvardT.H.
Chan School of Public Health, Boston, MA; 4The Institute of Cancer Research, Lon-
don, United Kingdom; 5University of Southern California, Los Angeles, CA.
Common genetic variants in over 150 loci have been found to be associated with
prostate cancer (PrCa) risk throughGWAS.These variants, however, explain only a
small fraction of PrCa heritability, and the genes responsible for the detected asso-
ciations remain largelyunknown. Ithasbeensuggested thatmanyGWAS-identifıed
associations may be driven by the regulation of risk variants on the expression of
disease causal genes. To identify novel PrCa risk loci and possible causal genes at
known risk loci, we performed a transcriptome-wide association study (TWAS) to
evaluate associations of genetically predicted gene expressions with PrCa risk. We
usedRNAsequencing data fromnormal prostate tissues andhigh-density genotyp-
ing from 73 European descendants included in the Genotype-Tissue Expression
Project and established genetic models to predict gene expression level. Given that
the regulatorymechanisms formostgenesare similaracrossmosthumantissues,we
also built cross-tissue models using gene expression data generated in all tissues
from 369 European descendants to increase the statistical power. Based on predic-
tion performance, we selected 22,126 genes and conducted association analyses of
their predicted expression with PrCa risk using GWAS data obtained from more
than 143,000 subjects included in PRACTICAL/ELLIPSE consortia. We identifıed
140 genes showing an association of their predicted expression levels with PrCa risk
at P  2.26106, a Bonferroni-corrected signifıcance threshold, including 105
protein-codinggenes, 33 longnon-codingRNAs, and2processed transcripts. Seven
of these associated genes are located more than 1Mb away from any of the risk
variants identifıed in PrCa GWAS, representing potential novel risk loci. Of the
remaining 133 genes located in known risk loci, 100 have not been reported from
previous eQTL analyses. The associations for 25 of these genes remained signifıcant
at P  3.76104 (0.05/133) after adjusting for the risk variants reported in the
initial GWAS. Our study also identifıed 33 genes that were previously reported
based on eQTL and fıne-mapping analyses. For many of the identifıed genes, so-
maticchangesof indels,nonsensemutations, splice sitevariants, translationstart site
variants,ormissensemutationsweredetected inPrCapatients in theTCGA, includ-
ing known PrCa driver genes NKX3-1 and PLXNA1. Pathway enrichment analysis
showedthatcancerrelated functionsweresignifıcantlyenrichedfor the identifıedgenes.
The top canonical pathways identifıed included prostate cancer signaling, ATMsignal-
ing, AMPK signaling, protein ubiquitination pathway, and antigen presentation path-
way.Insummary,weconductedthefırst largePrCaTWASandidentifıedmultiplenovel
susceptibility loci andgenes forPrCarisk.Our studyprovided substantialnew informa-
tion towards the understanding of PrCa genetics andbiology.
#1302 Genome-wide association study of glioma reveals specifıc differences
in genetic susceptibility to glioblastoma andnon-glioblastoma.BenKinnersley,1
Beatrice S. Melin,2 Jill S. Barnholtz-Sloan,3 Margaret R. Wrensch,4 Christoffer Jo-
hansen,5Dora Il’yasova,6QuinnOstrom,3andmembersofGICC,KarimLabreche,7
Jeanette E. Eckel-Passow,8 Paul A. Decker,8Marianne Labussière,7 Ahmed Idbaih,7
Khe Hoang-Xuan,7 Anna-Luisa Di Stefano,7 Karima Mokhtari,7 Jean-Yves Delat-
tre,7 Pilar Galan,9 KonstantinosGousias,10 Johannes Schramm,10Minouk J. Schoe-
maker,1 Sarah J. Fleming,11 Stefan Herms,12 Stefanie Heilmann,13 Marcus M.
Nöthen,13 Heinz-Erich Wichmann,14 Stefan Schreiber,15 Anthony Swerdlow,1
Mark Lathrop,16 Matthias Simon,10 Marc Sanson,7 Preetha Rajaraman,17 Stephen
Chanock,17 Martha Linet,17 Zhaoming Wang,17 Meredith Yeager,17 Rose K. Lai,18
Elizabeth B. Claus,19 Sara H. Olson,20 Robert B. Jenkins,21 Richard S. Houlston,1
Melissa L. Bondy22. 1Institute of Cancer Research, Sutton, United Kingdom; 2Umea˚
University,Umea˚, Sweden; 3CaseWesternReserveUniversity, Cleveland,OH; 4Uni-
versity of California, SanFrancisco, CA; 5Institute of Cancer Epidemiology, Copenha-
gen, Denmark; 6Georgia State University, Atlanta, GA; 7Institut du cerveau et de la
moelle épinière (ICM), Paris, France; 8Mayo Clinic College of Medicine, Rochester,
MN; 9Université Paris 13 Sorbonne Paris Cité, Paris, France; 10University of Bonn
Medical Center, Bonn, Germany; 11Centre for Epidemiology and Biostatistics, Uni-
versity of Leeds, Leeds, United Kingdom; 12University of Basel, Basel, Switzerland;
13Institute of Human Genetics, University of Bonn, Bonn, Germany; 14Institute of
Medical Informatics, Ludwig Maximilians University, Munich, Germany; 15Univer-
sity Clinic Schleswig-Holstein, Kiel, Germany; 16Génome Québec, McGill University,
Montreal, Quebec, Canada; 17National Cancer Institute, Bethesda, MD; 18Keck
School of Medicine, University of Southern California, Los Angeles, CA; 19Brigham
and Women’s Hospital, Boston, MA; 20Memorial Sloan Kettering Cancer Center,
New York, NY; 21Mayo Clinic Comprehensive Cancer Center, Rochester, MN; 22Dan
L. Duncan Comprehensive Cancer Center, Baylor College ofMedicine, Houston, TX.
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BACKGROUND: Glioma accounts for27% of all primary brain tumors
and is responsible for 13,000 cancer-related deaths in the US each year.
Glioma tumors can be broadly classifıed into glioblastoma (GBM) and low-
er-grade non-GBM. Typically gliomas have a poor prognosis irrespective of
medical care, with the most common form, GBM, having a fıve-year survival
rate of only 5%.While genome-wide association studies (GWAS) have trans-
formed our understanding of glioma susceptibility, individual studies have
had limited power to identify risk loci. METHODS: We performed the larg-
est glioma GWAS to date, comprising a meta-analysis of six existing GWAS
(6,405 cases, 14,100 controls) as well as new GWAS from the Glioma Inter-
national Case Control Consortium (GICC; 4,572 cases and 3,286 controls)
and University of California, San Francisco (UCSF)-Mayo (1,519 cases, 804
controls), totaling 12,496 cases (6,191 classifıed as GBM, 5,819 as non-GBM)
and 18,190 controls. RESULTS: We identifıed fıve new risk loci for GBM at
1p31.3 (rs12752552; near JAK1, P2.04109, odds ratio (OR)1.22),
11q14.1 (rs11233250; P9.951010, OR1.24), 16p13.3 (rs2562152; near
MPG, P1.93x108, OR1.21), 16q12.1 (rs10852606; HEATR3,
P1.291011, OR1.18), 22q13.1 (rs2235573; P1.761010, OR1.15)
and eight for non-GBM at 1q32.1 (rs4252707; MDM4, P3.34109,
OR1.19), 1q44 (rs12076373; AKT3, P2.631010, OR1.23), 2q33.3
(rs7572263; near IDH1, P2.181010, OR1.20), 3p14.1 (rs11706832;
LRIG1, P7.66109, OR1.15), 10q24.33 (rs11598018; OBFC1,
P3.39108, OR1.14), 11q21 (rs7107785; P3.871010, OR1.16),
14q12 (rs10131032; P5.07x1011, OR1.33) and 16p13.3 (rs3751667;
P2.61109, OR1.18). Case-only analyses confırmed the specifıcity of
11q14.1, 16p13.3 and 22q13.1 associations for GBM and 1q44, 2q33.3,
3p14.1, 11q21 and 14q12 for non-GBM tumors. In the combined meta-
analysis, among previously published glioma risk SNPs, those for all glioma
at 17p13.1 (TP53), GBM at 5p15.33 (TERT), 7p11.2 (EGFR), 9p21.3
(CDKN2B-AS1) and 20q13.33 (RTEL1) and for non-GBM at 8q24.21
(CCDC26), 11q23.2, 11q23.3 (PHLDB1) and 15q24.2 (ETFA) showed even
greater evidence for association. SNPs at 10q25.2 and 12q12.1 for non-GBM
tumors retained genome-wide signifıcance (i.e. P5.0x108). Associations
at the previously reported loci for GBM at 3q26.2 (near TERC) and 12q23.33
(POLR3B) did not retain statistical signifıcance. CONCLUSIONS: Our fınd-
ings substantiate genetic susceptibility to GBM and non-GBM glioma being
highly distinct, consistent with their distinctive molecular profıles presum-
ably resulting from different etiological pathways. Functional analyses
should lead to further insights into the biological basis of the different glioma
histologies. Such information can inform gene discovery initiatives and
therefore have a measurable impact on the successful development of new
therapeutic agents.
#1303 A genome-wide association study of prostate cancer in Latinos.
Hannah Hopp,1 Sue Ingles,1 Chad Huff,2 Xin Sheng,1 BrandiWeaver,3 Mariana
Stern,1 Sara Strom,2 Ian Thompson,4 David Conti,1 Christopher A. Haiman1.
1Department of Preventive Medicine, Keck School of Medicine, University of
Southern California Norris Comprehensive Cancer Ctr., Los Angeles, CA; 2The
University of Texas MD Anderson Cancer Center, Houston, TX; 3University of
Texas Health Science Center, San Antonio, TX; 4University of Texas Health Sci-
ence Center, San Antonio, TX.
Recent studies estimate that individuals of African or Latin American
ancestry represent less than 4% of samples analyzed to date in genome-wide
association studies. The clinical value of genetic information in guiding per-
sonalized medicine in populations of non-European ancestry will require
additional discovery and risk locus characterization efforts in these popula-
tions. Here, we performed a genome-wide association study (GWAS) meta-
analysis of prostate cancer in Latino men to search for risk loci that may be
important in this population. We combined GWAS data for 1034 cases and
1046 controls genotyped with the Illumina 660 Beadarray with GWAS data
for 1235 cases and 1053 controls genotyped with the Illumina Oncoarray as
part of the ELLIPSE U19 GAME-ON Consortium. A total of 11 million
genotyped and imputed SNPs of 
1% frequency were tested for association
with prostate cancer risk in logistic regression models controlling for age,
study and genetic ancestry. Genome-wide signifıcant associations were ob-
served with 24 variants all located at 8q24 (128.484-128.548), and which
capture the fırst reported prostate cancer susceptibility locus in ’region 1’ of
8q24. The most signifıcant association genome-wide was with SNP
rs7824776 (risk allele frequency, 0.35; OR1.69, p3.4x1011). No novel
genome-wide signifıcant associations were noted outside of 8q24. We ob-
served a high degree of generalizability of known prostate cancer risk loci,
with 78 (76%) of the 103 known risk variants having effects that were direc-
tionally consistent in their association with prostate cancer risk as previously
reported, of which 31 (30%) were statistically signifıcant with p  0.05. In
addition to these fındings from the largest GWAS of prostate cancer in La-
tinos conducted to date, we will also present the results investigating effect
heterogeneity by local ancestry (i.e. proportion Native American vs. Euro-
pean). In addition, we will present a comparison of polygenic risk models
between Latinos, African Africans and men of European ancestry that incor-
porate the known risk loci to better understand how genetic risk tracks with
population differences in prostate cancer incidence.
#1304 The contribution of rare and low-frequency variants to colorectal
cancer heritability. Jeroen R. Huyghe,1 Sai Chen,2 Hyun M. Kang,2 Tabitha
Harrison,1 Sonja I. Berndt,3 Stephane Bézieau,4 Hermann Brenner,5 Graham
Casey,6 Andrew T. Chan,7 Jenny Chang-Claude,5 Steven J. Gallinger,8 Stephen
B. Gruber,9 Andrea Gsur,10 Michael Hoffmeister,5 Thomas Hudson,11 Mark A.
Jenkins,12 Loic Le Marchand,13 Polly A. Newcomb,1 John D. Potter,1 Conghui
Qu,1 Martha L. Slattery,14 Joshua D. Smith,15 Emily White,1 Goncalo R. Abeca-
sis,2 Li Hsu,1 Deborah A. Nickerson,15 Ulrike Peters,1 on behalf of CCFR and
GECCO. 1Fred Hutchinson Cancer Research Center, Seattle, WA; 2University of
Michigan, Ann Arbor, MI; 3National Cancer Institute, Bethesda, MD; 4Centre
Hospitalier Universitaire Nantes, Nantes, France; 5German Cancer Research
Center, Heidelberg, Germany; 6University of Virginia, Charlottesville, VA; 7Mas-
sachusetts General Hospital, Boston, MA; 8Mount Sinai Hospital, Toronto, On-
tario, Canada; 9USC Norris Comprehensive Cancer Center, University of South-
ernCalifornia, Los Angeles, CA; 10Medical University of Vienna, Vienna, Austria;
11Ontario Institute for Cancer Research, Toronto, Ontario, Canada; 12The Uni-
versity of Melbourne, Melbourne, Australia; 13University of Hawaii Cancer Cen-
ter, Honolulu, HI; 14University of Utah Health Sciences Center, Salt Lake City,
UT; 15University of Washington, Seattle, WA.
Studies that estimate complex disease heritability based on genome-wide
common SNP array data have shown that a large fraction of heritability is
contributed from variants that do not reach genome-wide signifıcance at
current genome-wide association study (GWAS) sample sizes. The contri-
bution of rare variants to heritability has yet to be explored for many com-
plex diseases. Despite the decreasing cost of sequencing, it still remains
prohibitively expensive to sequence suffıcient samples for well-powered ge-
netic association studies of rare variants. However, with increasingly large
and denser imputation reference panels it has become feasible to accurately
impute variants with minor allele frequencies (MAFs) as low as 0.1%, en-
abling study of a subset of rare risk variants. In previous work, we used
restricted maximum likelihood (REML) to estimate the total additive heri-
tability of colorectal cancer (CRC) based on common SNP array genotypes.
Here, we expand this work using imputed genotype data and a larger sample
size. We performed whole-genome sequencing of 1,961 CRC cases and 981
controls, and subsequently imputed these haplotypes into 11,895 unrelated
CRC cases and 14,659 unrelated controls that are part of the Colorectal
Cancer Family Registry (CCFR) and the Genetics and Epidemiology of Colo-
rectal Cancer Consortium (GECCO). We estimated heritability from indi-
vidual-level imputed genotype data using LD- and MAF-stratifıed GREML,
as implemented in GCTA. In total, we analyzed 17,649,167 imputed genetic
variants with minor allele count 3. Published heritability estimates for
CRC from family-based studies vary from 12% to 35%. Based on common
genotyped SNPs, we previously estimated heritability to be 7.42% (95% CI:
4.71-10.12%) on the underlying liability scale, assuming a population prev-
alence of 0.004. For imputed genotypes, we estimate the total heritability to
be 12.0% (95% CI: 9.65-14.35). Using a likelihood ratio test, we demonstrate
a signifıcant contribution of variants with MAF 1% to CRC genetic risk
(P0.003). Because of the imperfect imputation accuracy for very rare vari-
ants, their contribution is likely higher. These results suggest that with ad-
ditional sequencing, improved imputation accuracy, and larger GWAS, we
should expect to start discovering rare variant associations for CRC risk.
#1305 A genome-wide association study of prostate cancer in Uganda.
Zhaohui Du,1 Alexander Lubmawa,1 Susan Gundell,2 Peggy Wan,2
Nalukenge Cissy,1 Muwanga Proscovia,1 Lutalo Moses,1 Nansereko Debo-
rah,1 Ndaruhutse Olivia,1 Katuku Molly,1 Lubwama Alexander,1 Rosemary
Nassanga,1 Benson Masaba,1 Sam Kaggwa,1 Dan Namuguzi,1 Vicky Kiddu,1
Asiimwe Luke,1 Kuteesa J,1 Dabanja M. Henry,1 David Conti,2 Christopher
A. Haiman,2 Stephen Watya1. 1Mulago Hospital Department of Surgery,
Urology Unit, Uganda; 2Department of Preventive Medicine, Keck School of
Medicine, University of Southern California USC /Norris Comprehensive
Cancer Ctr., Los Angeles, CA.
The greater incidence of prostate cancer in men of African ancestry re-
mains one of the most important unanswered health disparities globally. No
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established environmental/lifestyle risk factors have been identifıed, with the
only established risk factors being age, race/ethnicity and family history, all
of which implicate genetic susceptibility. GWAS have clearly validated the
importance of genetic susceptibility in prostate cancer, with100 common
risk loci identifıed to date which in aggregate explain 33% of the familial risk.
Genetic studies in African ancestry populations have provided strong evi-
dence for genetic factors in contributing to the greater incidence of prostate
cancer in men of African ancestry. To further explore this hypothesis, we
conducted a genome-wide association study (GWAS) of prostate cancer
among Ugandan men. Specifıcally, we genotyped the Illumina OncoArray,
which includes a 260K GWAS backbone, in 560 prostate cancer cases (119
with Gleason score 
8) and 480 controls and tested the associations of
448,939 genotyped and 16,396,662 imputed variants with 1% frequency.
The most statistically signifıcant variants were observed at the 8q24 risk
locus (rs72725854, OR3.37, P2.14x1013). We also observed suggestive
signals with 106 variants outside of known risk regions with p-values105
and107. Of the 104 known risk variants, 100 are polymorphic in Uganda
men, of which, 66 (66%) had effects that were directionally consistent in their
association with prostate cancer risk as previously reported and 8 (8%) were
signifıcantly associated with risk at p  0.05, with the most statistically
signifıcant variants being rs16901979 at 8q24 (OR1.45, p0.0001) and
rs1512268 at 8p21.2 (OR1.31, p0.0087). In addition to these fındings, we
will also present the results from replication testing of the most signifıcant
associations from the GWAS in the Ghana Prostate GWAS Study and the
African Ancestry Prostate Cancer Consortium, as well as provide a detailed
comparison of polygenic risk models of the known prostate cancer variants
between these two African populations, African Africans and men of Euro-
pean ancestry.
#1306 Two distinct regulatory mechanisms underlie estrogen receptor
negative breast cancer susceptibility at the 2p23.2 locus. Carly M. Harro,1
Gustavo Mendoza-Fandino,1 Nicholas T. Woods,2 Xueli Li,1 Fergus J. Couch,3
Alvaro N. Monteiro1. 1H. Lee Moffıtt Cancer Center and Research Institute,
Tampa, FL; 2Eppley Institute for Research in Cancer, Omaha, NE; 3Mayo Clinic,
Rochester, MN.
GenomeWide Association Studies (GWAS) are designed to identify single
nucleotide polymorphisms (SNPs) mapping to genomic regions associated
with a particular trait or disease. Currently, 19 genomic loci associated with
risk for estrogen receptor negative breast cancer have been identifıed. How-
ever, for most of these loci the mechanisms driving susceptibility have re-
mained elusive. The 2p23.2 locus, defıned by SNP rs67073037 (p  4.76 x
109), contains 79 SNPs exhibiting genome-wide signifıcant associations as
well as four candidate genes: SPDYA, TRMT61B, WDR43, and FAM179A.
Post-GWAS functional analysis revealed two candidate causal regulatory
elements: an enhancer-like element defıned by SNP rs44017214 located in
the fırst intron of the WDR43 gene; and a segment in the 3’-UTR region of
WDR43 defıned by SNPs rs11680458 and rs11331880 which are predicted to
have allele specifıc binding of non-coding microRNAs miR-548 and miR-
376, respectively. We validated allele specifıc transcription factor binding to
rs44017214 using competitive binding of USF1/USF2 to the risk allele in
both MCF10A and CAL51 cell lines in Electrophoretic Mobility Shift Assays
(EMSA). Additionally, rs44017214 was removed using CRISPR-cas9, and
expression of neighboring genes was evaluated by qRT-PCR. No change in
expression was found for any gene in a 2 Mb region surrounding the SNP,
with the exception of PLB1. This suggests that the enhancer element in the
intron of WDR43 has PLB1 as its target. To assess the miRNA binding site
impact on WDR43 expression the pMIR-REPORT Luciferase allele-specifıc
vector was co-transfected with miR-141/200, miR548, or miR-376 in
MCF10A cells. The rs1131880 allele C in the WDR43 3=-UTR lead to the
suppression of luciferase expression by miR-376 compared to the G allele.
This study reveals two independent regulatory mechanisms within the
2p23.2 locus; (i) modulation of enhancer activity by allele specifıc binding of
transcription factors USF1/USF2 to rs4401714, and (ii) decreasing the ex-
pression of WDR43 through the formation of a miR-376 binding site at the
3’-UTR of the WDR43 gene. Elucidating the functional signifıcance of these
common variants in the novel susceptibility loci 2p23.2 furthers our knowl-
edge of the etiology of estrogen receptor negative breast cancer.
#1307 Identifıcation of novel epithelial ovarian cancer loci in women of
African ancestry from the Ovarian Cancer Association Consortium. Ani
Manichaikul,1 Lauren C. Peres,1 Xin-QunWang,1 Kate Lawrenson,2 Sarah Ab-
bott,1 Ann G. Schwartz,3 Anna H.Wu,4 Edward Peters,5 Patricia G. Moorman,6
Michele L. Cote,3 Melissa Bondy,7 Linda Kelemen,8 Ellen L. Goode,9 Jill Barn-
holtz-Sloan,10 Simon A. Gather,2 Andrew Berchuck,6 Jennifer A. Doherty,11
Paul Pharoah,12 Joellen Schildkraut1. 1University ofVirginia, Charlottesville, VA;
2Cedars-Sinai Medical Center, Los Angeles, CA; 3Wayne State University School
of Medicine, Detroit, MI; 4Keck School of Medicine of USC, Los Angeles, CA;
5Louisiana State University Health Sciences Center School of Public Health, New
Orleans, LA; 6Duke University Medical Center, Durham, NC; 7Baylor College of
Medicine, Houston, TX; 8College of Medicine, Medical University of South Caro-
lina, Charleston, SC; 9Mayo Clinic, Rochester, MN; 10Case Western Reserve Uni-
versity School of Medicine, Cleveland, OH; 11University of Utah, Salt Lake City,
UT; 12University of Cambridge, Cambridge, United Kingdom.
Epithelial ovarian cancer (EOC) is a rare but deadly disease for which there is
notably poorer survival in women of African Ancestry (AA) compared to
women of European Ancestry (EA). Previous EA-based genome-wide associa-
tion studies (GWAS) have identifıed 30 common, low penetrant EOC suscepti-
bility alleles. Using the custom-designed 533,631 SNP Illumina OncoArray and
imputation to 12 million genetic variants in the 1000 Genomes Phase 3, we
conducted a GWAS in 755 AA EOC cases, including 537 high-grade serous
ovarian cancer (HGSOC) cases, and 1,235AA controls from theOvarianCancer
Association Consortium (OCAC). We identifıed novel susceptibility loci with
suggestive evidence of associationwith EOC, based on a threshold of P1x106,
at three distinct loci including 10p15.1 (lead SNP rs4525119, intronic to
AKR1C3, P4.9 x 107,minor allele frequency [MAF]0.33), 3p25.3 (lead SNP
rs7643459, intronic to LOC101927394, P8.4 x 107, MAF0.36), and 4q13.3
(lead SNP rs4286604, 15 kb 3= of UGT2A1, P8.5x107, MAF0.27). In anal-
ysis of HGSOC, we identifıed suggestive evidence of association at six distinct
loci including 5q11.2 (lead SNP rs37792, 132 kb 5= of FST, P6.0x108,
MAF0.34), Xq27.2 (lead SNP rs57403204, 81 kb 3= of MAGEC1, P1.7x10-7,
MAF0.06), 10p15.1 (lead SNP rs79079890, LOC105376360 intronic,
P3.0x107, MAF0.03), 17p25.1 (lead SNP rs66459581, 5 kb 5= of PRPSAP1,
P5.1x107, MAF0.23), 15p12 (lead SNP rs116046250, GABRG3 intronic,
P8.7x107,MAF0.05), and 4q21.21 (lead SNP rs192876988, 30 kb 3= ofGK2,
P9.2x107, MAF0.05). These SNPs showed no evidence of association with
risk in the OCAC EA GWAS including up to 23,543 EOC cases and 29,444
controls. Of the SNPs identifıed with suggestive evidence of association in our
GWAS, two are located near genes known to regulate hormones and previously
reported in relation to diseases of the ovary (AKR1C3 and FST), two have been
linked to cancer (AKR1C3 and MAGEC1) and one represents testis-specifıc
expression (GK2). Of the 30 SNPs identifıed previously in a EA EOCGWAS, we
observed nominally signifıcant associations (P0.05) with consistent direction
of effect for eight SNPs inAAwomen.Our investigation presents evidence of (1)
variants for EOC shared among EA and AAwomen and (2) novel EOC risk loci
of importance for AA women.
#1308 Transcriptome-wide association study among 66,450 women to iden-
tify candidate susceptiblegenes forovariancancer risk.YingchangLu,1 JoellenM.
Schildkraut,2 Thomas A. Sellers,3 Lang Wu,1 Xingyi Guo,1 Bingshan Li,1 Y. Ann
Chen,3 Jennifer B. Doherty,4 Simon Gayther,5 Ellen L. Goode,6 Hae Kyung Im,7
Siddhartha Kar,8 Kate Lawrenson,9 Ani W. Manichaikul,2 Jennifer B. Permuth,3
BrettM. Reid,3 Jamie K. Teer,3 Paul Pharoah,8Wei Zheng,1 Jirong Long1. 1Vander-
biltUniversityMedicalCenter,Nashville, TN; 2University ofVirginia, Charlottesville,
VA; 3Moffıtt Cancer Center, Tampa, FL; 4University of Utah, Salt Lake City, UT;
5Cedars-SinaiMedical Center, Los Angeles, CA; 6Mayo Clinic, Rochester, MN; 7Uni-
versity of Chicago, Chicago, IL; 8University of Cambridge, Cambridge, United King-
dom; 9Cedars -Sinai Medical Center, Los Angeles, CA.
Background: Large-scale genome-wide association studies (GWAS) have identi-
fıed35 loci associated with epithelial ovarian cancer risk. However, these genetic
loci together explain only a small portion of the heritability of this malignancy. The
large majority of the GWAS-identifıed variants are located in non-coding regions,
thus possible causal genes in these loci remain largely unknown. We performed a
transcriptome-wide association study (TWAS) to search for novel genetic loci for
ovarian cancer risk and plausible causal genes at GWAS-identifıed loci. Method:
Transcriptome data fromnormal ovarian tissue samples (n68) and all tissue sam-
ples (n 369), along with their high-density genotyping data, obtained from only
European descendants included in the Genotype-Tissue Expression Project
(GTEx), were used to build ovarian linear predictionmodels and cross-tissuemod-
els (to increase statistical power) using the elastic net method. Based onmodel per-
formance, we evaluated 17,121 genes for their cis-predicted gene expressions in
relation to ovarian cancer risk using summary statistics data generated inGWAS of
EPIDEMIOLOGY: Genome-Wide Association Studies/Post-GWAS Studies
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 337
ovarian cancer from 25,509 cases and 40,941 controls. MetaXcan was used to inte-
grate gene expression prediction model with summary statistics. Results: We iden-
tifıed35geneswithpredicted expression levels associatedwithovarian cancer risk at
P value 2.2 106, the Bonferroni corrected signifıcance level formultiple com-
parisons.Of these, 12genesat4genetic loci are located
500kbaway fromriskSNPs
previously reported in GWAS, representing potential novel genetic loci for ovarian
cancer risk. The remaining 23 genes at 12 loci are located within known ovarian
cancer risk loci. Fifteen of these genes at the 12 loci have not been reported in
previous studies. Analyses by ovarian cancer histological subtypes showed that the
majority of these 35 genes are associated with serous invasive carcinoma. Several
newassociationswere identifıed inhistological subtypeanalyses.Conclusion: In this
TWAS we identifıed multiple genes with predicted expressions related to ovarian
cancer risk and provide substantial new information to enhance the understanding
of ovarian cancer biology and genetics.
#1309 Association between insulin resistance and breast cancer risk: A
Mendelian randomization analysis of data from228,000womenof European
descent. Xiang Shu,1 Lang Wu,1 Nikhil K. Khankari,1 Kyriaki Michailidou,2
Manjeet K. Bolla,2 Jean Wang,2 Joe Dennis,2 Xiao-ou Shu,1 Jacques Simard,3
Douglas F. Easton,2Wei Zheng1. 1Vanderbilt-IngramCancer Center, Vanderbilt
University School of Medicine, Nashville, TN; 2University of Cambridge, Cam-
bridge, United Kingdom; 3Centre Hospitalier Universitaire de Québec Research
Center, Laval University, Québec City, Quebec, Canada.
Background: Epidemiologic studies suggest that insulin resistance may be asso-
ciatedwith breast cancer risk.We conductedMendelian randomization (MR) anal-
yses to reduce the biases associated with previous studies and provide evidence for
causal inference. Materials and Methods: We used genetic variants identifıed in
genome-wide association studies for circulating fasting insulin (15 variants), early
insulin secretion (16 variants), fasting proinsulin (8 variants), fasting glucose (35
variants), and 2-hour glucose (8 variants) as instruments inMRanalyses. To reduce
possible pleiotropic effects, variants associated with obesity were removed from the
instruments. We fırst evaluated the association of these instruments with type 2
diabetes risk in 110,452 subjects to assess instrument validity.We then investigated
theassociationof these instrumentswithbreast cancer riskusingdataobtained from
122,977 cases and105,974 controls of Europeandescent included in theBreastCan-
cer AssociationConsortium (BCAC). Odds ratios (OR)were calculated tomeasure
the associations of instrumental variables with risk of overall breast cancer and its
subtypes defıned by estrogen-receptor [ER] status. Results: All instrumental vari-
ables constructed for this study were strongly associated with type 2 diabetes risk
with ORs of 3.01 (p7.86x105), 0.22 (p3.54x1014), 1.90 (p8.28x104), 6.11
(p3.59x1019), and 1.91 (p6.8x1016) for per unit increase of fasting insulin,
early insulin secretion, fasting proinsulin, fasting glucose, and 2-hour glucose levels,
respectively. Statistically signifıcant associationswith overall breast cancer riskwere
found for fasting insulin (OR1.36 for per unit increase, 95% CI1.09-1.70,
p0.011) and fasting proinsulin (OR1.21, 95% CI1.06-1.38, p0.011). These
associations were observed only for ER-positive breast cancer. No statistically sig-
nifıcant association at p0.05 was found for early insulin secretion, fasting glucose,
or 2-hour glucose levels. Conclusions: Our study provides strong support that cer-
tain insulin resistance traits may be causally associated with risk of breast cancer,
particularly ER-positive breast cancer.
#1310 Identifıcation of pleiotropic cancer susceptibility variants from ge-
nome-wide association studies reveals functional characteristics. Yi-Hsuan
Wu,1 Rebecca E.Graff,1MichaelN. Passarelli,2 Thomas J.Hoffmann,1 EladZiv,1
John S. Witte1. 1University of California, San Francisco, San Francisco, CA;
2Geisel School of Medicine, Dartmouth College, Hanover, NH.
Background: There exists compelling evidence that some genetic variants are
associatedwith the riskofmultiple cancers (i.e., pleiotropy).However, thebiological
mechanisms of the pleiotropic effects are unclear. Thus, we investigated the func-
tional effects for genetic variants associated with the risk ofmultiple cancers.Meth-
ods: The National Human Genome Research Institute-European Bioinformatics
Institute (NHGRI-EBI) GWAS Catalog contains 28,643 variant-trait associations
with p  105. We utilized the Experimental Factor Ontology (EFO) to classify
cancer traits andobtainedall associationsbetweenvariantsandcancer risk.Basedon
pairwise linkage disequilibrium (LD) determined from the European (EUR) popu-
lation of Phase 3 of the 1000 Genomes Project in LDlink, correlated variants (R-
squared
0.8)were clustered intogroups.Variantgroupsassociatedwith the riskof
multiple cancerswere annotated using the EnsemblVariant Effect Predictor (VEP),
and tested for functional enrichment using the DAVID Functional Annotation
Tool. Results: We identifıed 1,456 variant-cancer risk associations. The majority
(57.1%) of the associations were discovered in European ancestry populations,
19.0% in East Asians, 7.9% in an African Americans or Afro-Caribbeans, and 7.1%
inHispanics orLatinAmericans.Removingduplicates,we found1,034uniquevari-
ant-cancer risk associations for 1,005 unique variants and 27 unique cancer sites.
After clustering correlated variants, we identifıed 29 pleiotropic variant groups, of
which 2 were associated with risk of fıve different cancer sites. Variant group
rs10936599 and rs12696304 within the MYNN gene (7.8 kb from the TERC gene)
was associated with leukemia, multiple myeloma, and colorectal, skin, and bladder
cancer. Variant group rs31489, rs31490, rs401681, and rs4975616 within the
CLPTM1L gene (22.8 kb from the TERT gene) was associated with leukemia, and
lung, pancreatic, skin, and bladder cancer. Among the 42 unique variants that com-
posed the 29 pleiotropic variant groups, 41 variants were within a known gene, and
only 1 variant was in an intergenic region. The 41 variants mapped to 26 genes,
which were enriched in cellular response to hypoxia (p 0.0071), establishment of
protein localization to telomere (p 0.0071), and ubl conjugation (p 0.0072).
Conclusion: This study identifıed and functionally characterized genetic variants
showing pleiotropic effects on cancer risk.Our fındings improve the understanding
of sharedbiologicalmechanismscommontodifferent cancers.Clinical implications
could include the classifıcation of cancers based on etiology, genetic testing formul-
tiple cancers, and repurposing cancer treatments.
#1311 Germline variation at 8q24 and prostate cancer risk. Kan Wang,1 Ali
Amin Al Olama,2 Rosalind Eeles,3 David Conti,1 Zsofıa Kote-Jarai,3 Christopher A.
Haiman1. 1Department of Preventive Medicine, Keck School of Medicine, USC/Norris
Comprehensive Cancer Ctr., Los Angeles, CA; 2Centre for Cancer Genetic Epidemiology,
Department of Public Health and Primary Care, University of Cambridge, Cambridge,,
UnitedKingdom; 3The Institute of Cancer Research, London,UnitedKingdom.
The 8q24 region harbors multiple risk variants for distinct cancers including 7 for
prostate cancer, themajority of which lie in separate linkage disequilbrium blocks. It is
not known whether a common biological mechanism underlies the association of ge-
netic variation with cancer risk at 8q24, or whether there are site-specifıc functions of
regulatory elements that are affected in this region. Given the proximity, theMYC on-
cogene is a likely candidate as are multiple long non-coding RNAs in the region. To
further understand the contribution of germline variation to prostate cancer risk we
performed a comprehensive fıne-mapping analysis of the region in men of European
ancestry from the PRACTICAL/ELLIPSE Consortium. More specifıcally, we tested
1,731 genotype tag SNPs and 12,221 imputed variants spanning the risk region (127.3-
129.0Mb) in56,363prostate cancer cases and37,386 controls ofEuropeanancestry that
were genotyped with the Illumina OncoArray.We performed stepwise logistic regres-
sion and identifıed 13 variants with risk allele frequencies between 0.006 and 0.998 that
surpassed genome-wide statistical signifıcance (p-values between 3.2x108 and 8.0
x1078) and with per allele odds ratios ranging from 1.11(rs5013678) to
2.68(rs183373024).Ongoinganalyses thatwill bepresented include incorporatingexist-
ingGWASand fıne-mappingdata (iCOGs) formenof European andAfrican ancestry
(35,000 cases and 35,000 controls) using JAM, a Bayesian approach that investigates
multi-SNPmodels using marginal meta-analysis statistics. Leveraging the power from
theoverallmultiethnicmeta-analysis(93,000casesand72,000controls)willprovide
further insight into thenumberof independent signals in the regionand their contribu-
tion to prostate cancer risk in these populations.
#1312 Genetic variation in the Hippo pathway and breast cancer risk in
women of African ancestry in the ROOT Consortium. Shengfeng Wang,1
Yonglan Zheng,1 Temidayo O. Ogundiran,2 Oladosu Ojengbede,2 Wei Zheng,3
Katherine L. Nathanson,4 Barbara Nemesure,5 Stefan Ambs,6 Dezheng Huo,1
Olufunmilayo I. Olopade1. 1University of Chicago, Chicago, IL; 2University of
Ibadan, Ibadan, Nigeria; 3Vanderbilt University, Nashville, TN; 4University of
Pennsylvania, Philadelphia, PA; 5State University of New York at Stony Brook,
Stony Brook, NY; 6National Cancer Institute, Bethesda, MD.
Background: The Hippo pathway controls organ growth by regulating cell pro-
liferation and apoptosis. To our knowledge, it is still unclear about its role in the
development of breast cancer. Identifying the relevant genes and single-nucleotide
polymorphisms (SNPs) should shed light on the pathway’s mechanism in carcino-
genesis. Methods: We examined 47,419 SNPs in 37 Hippo pathway genes in the
genome wide association study of breast cancer conducted in the African Diaspora
(ROOT consortium), which included 3,686 participants of African ancestry from
Nigeria, USA, and Barbados (1,657 cases and 2,029 controls). Gene-level analyses
were conducted using the adaptive rank truncated product (ARTP) test for 10,771
SNPs that weren’t highly correlated (r2  0.8), and SNP-level analyses were con-
ducted with logistic regression. Results: The Hippo pathway was signifıcantly asso-
ciated with risk of estrogen receptor positive (ER) breast cancer (pathway-level
P0.028).Gene-basedanalysesrevealedthatWWC1(gene-levelP0.001)wasrespon-
sible for this association,withrs116516633 in thisgenebeingstatistically signifıcantafter
gene-leveladjustmentformultiplecomparisons[oddsratio(OR)0.53foreachGallele,
95%confıdence interval (CI)0.41-0.70,Padj0.002]. In addition, twoSNPs inLATS2
(rs142900440,OR0.42,95%CI:0.28-0.64;rs58674288,OR0.38,95%CI0.24-0.61)
were associatedwith riskofERbreast cancer. In the analysis ofER-breast cancer risk,
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rs2579161 in DLG5 (OR1.38, 95% CI: 1.17-1.63) and rs11062429 in TEAD4
(OR1.39,95%CI:1.17-1.64)werestatistically signifıcant.Theseassociationsremained
signifıcantafterBonferroni-correctionat thegene-wide level (allP0.05).Conclusions:
Wefoundevidenceofassociationsof theHippopathwaywithERbreastcancerrisk in
women of African ancestry. Our fındings supported the potential mechanism that
WWC1 functions as an upstreammember of the pathway, and highlighted the impor-
tance of further studies.
Table1:Gene-wide signifıcant testedSNPs for all breast cancer,ER tumorsorER- tumors
Gene-SNP Function
Major/minor
alleles
Minorallele
frequency
among
controls
All cases vs
controls
ER cases vs
controls
ER- cases vs
controls
OR(95%CI) Padj OR(95%CI) Padj OR(95%CI) Padj
Overall
TEAD1-
rs16911695
Intron G/A 0.24 1.24
(1.11-1.39)
0.10 1.30
(1.07-1.58)
1.00 1.34
(1.10-1.63)
1.00
ER
LATS2-
rs142900440
Intron T/C 0.04 0.78
(0.61-0.98)
1.00 0.42
(0.28-0.64)
0.01 0.80
(0.54-1.19)
1.00
LATS2-
rs58674288
Intron C/T 0.03 0.73
(0.56-0.95)
1.00 0.38
(0.24-0.61)
0.01 0.70
(0.45-1.08)
1.00
WWC1-
rs116516633
Non-
coding
transcript
variant
A/G 0.10 0.82
(0.71-0.96)
1.00 0.53
(0.41-0.70)
0.002 0.81
(0.62-1.06)
1.00
ER-
DLG5-rs2579161 Upstream
gene
variant
G/A 0.49 1.08
(0.98-1.19)
1.00 0.99
(0.85-1.17)
1.00 1.38
(1.17-1.63)
0.03
TEAD4-rs11062429 Downstream
gene
variant
C/G 0.43 1.01
(0.92-1.11)
1.00 0.94
(0.79-1.00)
1.00 1.39
(1.17-1.64)
0.047
#1313 Characterization of germline susceptibility to male breast cancer.
Eleni Perrakis, Sarah Maguire, Katarzyna Tomczyk, Anthony Swerdlow, Nick
Orr. ICR, London, United Kingdom.
Male breast cancer (MBC) accounts for approximately 1% of all breast cancer
cases. Family history is an established risk factor for MBC and 10% of cases have
germline BRCA2 mutations. We recently demonstrated that common germline
polymorphismscontribute toMBCpredispositionand that there is overlapbetween
genetic susceptibility loci forMBC and female breast cancer (FBC). Here we report
a comprehensive evaluation of all 107 known FBC predisposition loci in an associ-
ation analysis of 1,032MBCcases and2,795populationmatched controls.A total of
21FBCpredispositionsinglenucleotidepolymorphisms(SNPs) showedevidenceof
association with risk of MBC. For approximately a third of these SNPs, the risk
estimates were signifıcantly larger inMBC than FBC. The magnitude of effects ob-
served suggest that common susceptibility variants may be of value for risk stratifı-
cation inmenwho have a high absolute risk of breast cancer such as BRCA2muta-
tion carriers. Although our data suggests that MBC predisposition shares many
features in commonwith FBC, there are striking differences. Surprisingly, given the
predominance of hormone receptor positive tumors in MBC, we observed no evi-
dence of association between SNPs at FGFR2 and MBC risk suggesting that the
estrogen receptor status ofMBC tumors does not explain the observed SNP associ-
ations. In summary, the data presented in this abstract signifıcantly advance our
understanding of genetic factors that contribute toMBCpredisposition and further
underscore the growing consensus that male breast cancer is not simply analogous
to hormone receptor positive female breast cancer.
#1314 Trans-ethnic HLA fıne-mapping of the MHC region identifıed
several independent variants influencing susceptibility to lung cancer.
Aida Ferreiro-Iglesias,1 Corina Lesseur,1 James McKay,1 Rayjean J. Hung,2
Christopher I. Amos,3 Paul Brennan,1 on behalf of OncoArray consortium1.
1International Agency for Research on Cancer (IARC-WHO), Lyon, France;
2Lunenfeld-Tanenbaum Research Institute of Sinai Health System, University
of Toronto, Toronto, Ontario, Canada; 3Geisel School of medicine, Dartmouth
College, Lebanon, PA.
Background: Genetic variants within the major histocompatibility complex
(MHC) are associatedwith lung cancer.However, debate persists about the identity
of the true causal variants, in part due to the broad linkage disequilibrium (LD)
characteristic of the MHC and to the complexity and cost of complete HLA geno-
typing. Here, we assessed the role of the MHC in modulating lung cancer risk in
Asians and Europeans using a broad set of HLA variants to detect the main alleles
and the presence of independent effects elsewhere in this genomic region. Material
and methods: Association between the HLA variants and risk of lung cancer was
examined in two collections of samples of different ethnicity (18,686 cases / 15,190
controls and 2,324 cases / 1,646 controls of European and Asian ancestry, respec-
tively). Using existing genome-wide SNP data from the lung cancer OncoArray
study, we imputed and tested classical alleles and amino acid polymorphisms in
HLA-A,HLA-B,HLA-C,HLA-DQA1,HLA-DQB1,HLA-DRB1,HLA-DPA1 and
HLA-DPB1, aswell as 7,258 SNPs across theMHC.All the analyseswereperformed
assuming an additive genetic model adjusted for sex and principal components as
covariates. The study-wide signifıcant threshold was p6.03 x 106. Results: Con-
ditional, haplotype and stratifıed analyses identifıed two independent HLA allele
effects associated with lung cancer squamous cell carcinoma in Europeans. One is
HLA-DQB1*06 that showed a signifıcant protective effect (OR0.85, 95%CI 0.80-
0.90,p3.05x108).Theother effect is attributed to the longancestral 8.1haplotype
(OR1.30,95%CI1.18-1.42,p4.78x108),whichcontainsclass Iandclass IIHLA
alleles (A*0101 - B*0801 - C*0701 - DRB1*0301 - DQB1*0201 - DQA1*0501). In
addition, single-amino-acid polymorphisms inHLA-B (at positions 9, 156, 163 and
178) and HLA-DRB1 (at positions 26, 71 and 74) located in peptide-binding
grooves, suggest these proteins as possible functional contributors within the hap-
lotype. In Asians, we observed two independent HLA allele effects associated with
lung adenocarcinoma : HLA-DQB1*0401 (OR1.67, 95% CI 1.35-2.05, p1.59
x106), andHLA-DRB1*0701(OR1.62, 95%CI 1.31-2.01, p5.48 x106) as well
as an intronic SNP in HLA-A (rs2256919) (OR0.75, 95% CI 0.67-0.83, p1.75 x
107). Conclusions:We established an association betweenHLAhaplotype 8.1 and
squamous lung cancer risk in Europeans. In contrast, inAsianswe observed associ-
ations only with class II HLA alleles and risk of lung adenocarcinoma. We did not
observed sharedHLA alleles effects between populations. This ethnic heterogeneity
in classical HLA allelic associations with lung cancer may be explained by allele
frequencydifferencesbetweenpopulationsandalsodifferent exposures that interact
with HLA. Furthermore, our study illustrates the value of high-resolution imputa-
tion for fıne-mapping causal variants in theMHC.
#1315 Estimating sex-specifıc effects of genetic loci associatedwith glioma
risk.QuinnT.Ostrom,1 BenKinnersley,2MargaretWrensch,3 Jeanette E. Eckel-
Passow,4 Georgina Armstrong,5 Terri Rice,3 Yanwen Chen,1 John Wiencke,3
Lucie McCoy,3 Helen Hansen,3 Christopher Amos,6 Jonine L. Bernstein,7 Eliz-
abeth B. Claus,8 Dora Il’yasova,9 Christoffer Johansen,10 Daniel Lachance,11
Rose Lai,12 Ching C. Lau,5 Ryan T. Merrell,13 Sara H. Olson,7 Siegal Sadetzki,14
Joellen Schildkraut,15 Sanjay Shete,16 Richard S. Houlston,2 Robert B. Jenkins,11
Beatrice Melin,17 Melissa Bondy,5 Jill S. Barnholtz-Sloan1. 1Case Western Re-
serve University School of Medicine, Cleveland, OH; 2The Institute of Cancer
Research, Sutton, United Kingdom; 3University of California, San Francisco, San
Francisco, CA; 4MayoClinic College ofMedicine, Rochester,MN; 5DanL.Duncan
Cancer Center, Baylor College of Medicine, Houston, TX; 6Geisel School of Med-
icine at Dartmouth, Hanover, NH; 7Memorial Sloan Kettering Cancer Center,
New York, NY; 8Yale University, New Haven, CT; 9Georgia State University,
Atlanta, GA; 10Danish Cancer Society, Copenhagen, Denmark; 11Mayo Clinic
Comprehensive Cancer Center, Mayo Clinic, Rochester, MN; 12Keck School of
Medicine, University of Southern California, Los Angeles, CA; 13NorthShore Uni-
versity HealthSystem, Evanston, IL; 14School of Public Health, Sackler Faculty of
Medicine, Tel-Aviv University, Tel-Aviv, Israel; 15University of Virginia School of
Medicine, Charlottesville, VA; 16University of Texas MD Anderson Cancer Cen-
ter, Houston, TX; 17Faculty of Medicine, Umea˚ University, Umea˚, Sweden.
BACKGROUND: Incidence of glioma varies signifıcantly by sex, and most
glioma histologies occur with greater incidence inmales. Previous analyses have
examined the impact of estrogen exposure as a risk factor for these tumors, but
have found results of varying signifıcance and low effect size. There may be
differences in effect of previously discovered risk alleles that contribute to sex
differences. METHODS: Using data collected for three previous glioma GWAS
in European-ancestry populations (MDAndersonCancer Center, the San Fran-
ciscoAdult Glioma Study, and theGlioma International CaseControl Study)we
assessed sex-specifıc effects for 14 previously identifıed and 13 newly identifıed
glioma risk SNPs (27 total) overall and for glioblastoma (GBM) and non-GBM
tumors separately. There were 3,892 male cases (59% GBM), 4,522 male con-
trols, 2,500 female cases (52% GBM) and 4,940 female controls. Sex-specifıc
odds ratios (ORM andORF), 95% confıdence intervals (95%CI) and p values (pM
and pF) were generated using stratifıed logistic regression models. Data from
each study were analyzed separately and combined using inverse variance
weighted meta-analysis. Results were considered statistically signifıcant at
p6.2x104. RESULTS: In GBM, rs11979158 (7p11.2, pM1.01x1010,
ORM1.43 [95%CI: 1.28-1.59]; pF3.43x103, ORF1.22 [95%CI: 1.07-1.39])
and rs2562152 (16p13.3, pM5.59x104, ORM1.23 [95% CI: 1.09-1.39];
pF1.22x101, ORF1.12 [95% CI: 0.97-1.29]) had signifıcant effect in males
only. In non-GBMgliomas, rs12076373 (1q44, pM3.56x107,ORM1.41, 95%
CI: 1.23-1.61; pF1.76x102, ORF1.20, 95% CI: 1.03-1.38), rs11979158
(7p11.2, pM1.77x105, ORM1.32 [95% CI: 1.16-1.49]; pF2.73x101,
ORF1.08 [95% CI: 0.94-1.24]), and rs3751667 (16p13.3, pM9.44x107,
ORM1.30 [95%CI: 1.17-1.44]; pF5.18x102, ORF1.13 [95%CI: 1.00-1.28])
had signifıcant effect in males only. Effect size for rs55705857 (8q24.21) varied
signifıcantly by sex, with ORM2.63 (95% CI: 2.24-3.09, pM4.42x1032), as
compared to ORF3.95 (95%CI: 3.28-4.76, pF1.82x1047). A sensitivity anal-
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ysis was performeddue to allele frequency heterogeneity by study and results did
not change. CONCLUSIONS: Sex differences and other demographic differ-
ences in cancer susceptibility can provide important clues to etiology, and these
differences can be leveraged for discovery in genetic association studies. Signif-
icant differences in effect size may suggest variation in genetic effect of risk
alleles or in unidentifıed risk factors that vary in prevalence or effect by sex.
There may also be differences in the distribution of molecular subtypes within
each histology by sex. Further investigation using an agnostic approach may
further elucidate the relationship between effect of risk alleles and sex.
#1316 Germline genetic signals acrossmultiple aggressive prostate cancer
phenotypes. Caroline G. Tai,1 Nima C. Emami,1 Thomas J. Hoffmann,1 Lori C.
Sakoda,2 Eric Jorgenson,2 Laurel A. Habel,2 Jun Shan,2 Dilrini K. Ranatunga,2
Chun R. Chao,3 Nirupa R. Ghai,3 David Aaronson,4 Joseph Presti,4 Catherine
Schaefer,2 Neil Risch,1 Stephen K. Van Den Eeden,2 John S. Witte1. 1University
of California, San Francisco, San Francisco, CA; 2Kaiser Permanente Northern
California, Oakland, CA; 3Kaiser Permanente Southern California, Pasadena,
CA; 4Kaiser Oakland Medical Center, Oakland, CA.
Prostate cancer (PrCa) is documented to be highly heritable. Butmany known
prostate cancer loci are not associated with aggressive prostate cancer pheno-
types such as high-grade cancer or biochemical failure. Previous efforts have
been largely underpowered or not replicated. We conducted a study of 6,321
men with PrCa and 5,663 controls of European ancestry recruited from Kaiser
Permanente (KP) matched by age and self-reported race. Phenotype data com-
bined patient-level demographic, clinical, and tumor data from KP databases
with data from 1994 to 2016. High-grade PrCa was defıned using Gleason score:
low-grade defıned as 7 (34), high-grade defıned as
 7 (43). Biochemical
failure was defıned for cases using post-treatment prostate specifıc antigen
(PSA) values: post-surgery failure if PSA
 0.4 ng/mL; post-radiation failure if
PSA value 
 2 ng/mL  nadir; and no failure if PSA did not reach specifıed
threshold. Early-onset disease was defıned as age 55 years at diagnosis. Men
were genotyped for over 650,000 SNPs using an ethnic-specifıc Affymetrix Ax-
iom array and imputed to 1000 Genomes. We tested genetic associations for
multiple aggressive phenotypes (410 early-onset cases, 1324 biochemical failure
cases, and 886 high grade cases) in both a case-only (e.g., high vs. low grade) and
case-control (e.g., high grade vs. no prostate cancer controls) analysis using
logistic regression adjusting for ancestry principal components, age, BMI, and
kit for batch effects. PrCa specifıc mortality was too rare to be evaluated. We
identifıed several known and novel loci. Case-control analyses highlighted
known prostate cancer loci at 8q24, 10q11, 11q13, 16q22, and 19q13. Previous
reports of case-only analyses also identifıed 8q24, 20p13 and the gene, KLK3 in
19q13, to be associated with high-grade PrCa; we confırmed these signals in our
study. Previous family-based studies identifıed 15q11 as a familial or early-onset
prostate cancer locus. These aggressive-specifıc variants could perform better in
predicting clinically actionable prostate cancers than variants for overall pros-
tate cancer and can improve the predictive ability of pre-diagnostic PSA.
#1317 Simultaneous identifıcation of candidate melanoma risk variants
using massively parallel reporter assay. Jiyeon Choi, Tongwu Zhang, Michael
Kovacs, Mai Xu, Nghi Lam, Leandro Colli, Kevin Brown. NCI, Bethesda, MD.
Recent melanoma Genome-Wide Association Study (GWAS) has identifıed 20
common susceptibility loci viameta-analysis of15,000 cutaneousmalignantmel-
anoma cases. While GWAS is extremely powerful in identifying genomic regions
contributing tomelanoma risk, teasing out functional variants and unravelingmo-
lecularmechanisms bywhich the risk is conferred presents a tremendous challenge
due to limited resolution of genetic structure and lack of high-throughput assay
system. To simultaneously identify functional risk variants from multiple GWAS
loci, we employed recently developedMassively-Parallel Reporter Assays (MPRA).
Based on the hypothesis thatmanyGWAS functional variants regulate gene expres-
sion through transcriptionalmechanism,we systematically examined allele-specifıc
transcriptional activities of genetically indistinguishable candidate variants. Out of
2,800 melanoma-associated variants (r20.4, EUR) from 16 melanoma loci for
which transcriptional mechanism could be applied, 835 variants were prioritized
based on their relevance as melanocyte-/melanoma-specifıc cis-element repre-
sented by ENCODE annotation as open chromatin or putative promoter/enhancer
histone marks in melanocytes and melanoma cell lines. Pooled oligoes of 145bp
encompassing each variant with either melanoma risk or protective allele coupled
with10differentunique sequence tagswere cloned into luciferase vectors and trans-
fected to melanoma cell lines. Resulting expressed tag counts were subsequently
determined using massively parallel sequencing. We were able to identify 200
potentially functional variants displaying allelic transcriptional activity by combin-
ing transfections in a melanoma cell line and HEK293FT cell line. Top functional
SNPs from melanoma GWAS loci were also shown as signifıcant eQTL SNPs in
human melanocytes including MX2 on chromosome 21. Overlaying MPRA func-
tional SNPs with melanocyte eQTL SNPs further enabled isolation of a functional
risk variant among several highly linked MX2 eQTL SNPs. The results from this
analysis will greatly accelerate the identifıcation of functional melanoma risk vari-
ants and further shed light on molecular mechanisms of genetic susceptibility of
melanoma in population.
#1318 A genome-wide association study of Waldenström macroglobu-
linemia/lymphoplasmacytic lymphoma demonstrates association with chro-
mosome 6. Mary L. McMaster,1 Sonja I. Berndt,1 Shengchao A. Li,1 Susan
Slager,2 Joseph Vijai,3 Charles C. Chung,1 Bin Zhu,1 Laurie Burdette,1 Brenda
Birmann,4 Elizabeth E. Brown,5 James R. Cerhan,2 Karin Ekstrom-Smedby,6
Henrik Hjalgrim,7 Geffen Kleinstern,2 Brian K. Link,8 James McKay,9 Alain
Monnereau,10 Lindsay M. Morton,1 Alexandra Nieters,11 Nathaniel Rothman,1
Christine F. Skibola,12 Alex Smith,13 Lauren R. Teras,14 Claire M. Vajdic,15 Roel
Vermeulen,16 BelyndaHicks,1 LynnR.Goldin,1 Neil E. Caporaso1. 1NCI-DCEG,
Bethesda, MD; 2Mayo Clinic, Rochester, MN; 3Memorial Sloan-Kettering Cancer
Center, New York, NY; 4Brigham and Women’s Hospital and Harvard Medical
School, Boston, MA; 5University of Alabama at Birmingham, Birmingham, AL;
6Karolinska Institutet, Stockholm, Sweden; 7Statens Serum Institut, Copenhagen,
Denmark; 8The University of Iowa, Iowa City, IA; 9International Agency for Re-
search on Cancer, Lyon, France; 10Center of Research in Epidemiology and Statis-
tics Sorbonne Paris Cite, Paris, France; 11University Medical Center Freiburg,
Freiburg, Germany; 12Emory University, Atlanta, GA; 13University of York, York,
United Kingdom; 14American Cancer Society, Atlanta, GA; 15University of New
South Wales, Sydney, Australia; 16Utrecht University, Utrecht, Netherlands.
Waldenström macroglobulinemia (WM) is a unique subset of lymphoplas-
macytic lymphoma (LPL) that is defıned by the presence of an LPL infıltrate in
the bone marrow together with a monoclonal IgM protein in the serum. A
somatic activating mutation, MYD88 L265P, occurs in 85% of WM and in
25%-50% of patients with the precursor condition, IgMmonoclonal gammopa-
thy of undetermined signifıcance (MGUS); however, germline MYD88 muta-
tions have not been observed in WM patients, and the genetic basis for WM
predisposition remains undefıned. To identify novel WM susceptibility loci we
conducted a two-stage genome-wide association study (GWAS) in over 450
WMcases and 4300 controls of European ancestry. Discovery (stage 1) included
217 WM cases (40% familial) and 3798 controls genotyped on the Illumina
Omni Express or Illumina Omni2.5 platforms following standard quality con-
trol procedures. The genotyped data were imputed using the Haplotype Refer-
ence Consortium panel as a reference and analyzed using logistic regression. In
stage 1, we identifıed three loci on chromosomes 6, 14 and 3 signifıcantly asso-
ciated (P5.0x108) with risk of WM. Eleven promising SNPs in these and
other suggestive loci (P5.0x107) were selected for replication (stage 2) in 269
WMor LPL cases (4% familial) and 571 controls, and genotypingwas conducted
using standard methods on Taqman and Sequenom platforms or Sanger se-
quencing (1 SNP). Preliminary results confırm replication of the chromosome 6
locus. Stratifıcation on familial status will illuminate the contribution of familial
disease. These results will provide insight into the underlying genetic basis of
WM susceptibility.
#1319 Epigenome-wide association study reveals differential DNAmeth-
ylation consistent with progression ofmultiple myeloma. Stephen D. Gragg,1
Devin Absher,2 Xiangqin Cui,3 Christina Pillion,1 Richard Myers,2 Shaji Ku-
mar,4 Luciano Costa,1 Brian Chiu,5 Celine Vachon,4 Elizabeth Brown1. 1Univer-
sity of Alabama at Birmingham School of Medicine, Birmingham, AL; 2Hudson-
Alpha Institute for Biotechnology, Huntsville, AL; 3University of Alabama at
Birmingham School of Public Health, Birmingham, AL; 4Mayo Clinic, Rochester,
MN; 5University of Chicago, Chicago, IL.
Purpose:Multiplemyeloma (MM) is the secondmost commonhematological
malignancy in the US. It is characterized by a clonal expansion of plasma cells in
the bone marrow and extramedullary sites and is preceded by two precursor
conditions including monoclonal gammopathy of undetermined signifıcance
(MGUS) and smolderingmyeloma (SMM). Strong evidence suggests a germline
and environmental etiology. However, efforts to characterize heritable changes
in gene activity, such asDNAmethylation, have not beenwidely reported.Meth-
ods: We examined epigenome-wide DNA methylation as markers of MGUS,
SMM and MM in peripheral blood obtained from treatment-naïve European
American cases with heavy-chain IgG or IgAMGUS (n60), SMM (n31) and
MM (n54) and age- and sex-matched controls (n79) included from the
University of Alabama at Birmingham, University of Chicago and the Mayo
Clinic, Rochester [54.5%males; mean age, 64 years (range, 36 to 86)]. We quan-
tifıed DNA methylation of over 450,000 CpG and non-CpG loci using the In-
fınium HumanMethylation450 array (Illumina). Differentially methylated po-
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sitions were calculated using a general linear model framework adjusted for
confounders and cellular heterogeneity. Results: A total of 6 CpGs were differ-
entiallymethylated inMMcases compared to controls at a level of genome-wide
statistical signifıcance. MM was associated with hypomethylation at differen-
tially methylated positions inside SBNO2 (P3.37x1010), WIZ
(P1.12x108), CA6 (P4.29x108) and ADORA1 (P3.68x108) as well as
intergenic positions proximal to TNFRSF8 (Chr 1p36.22; P2.24x109) and
ENDOV (Chr 17q25.3; P2.74x108). Each of these loci, with the exception of
CA6 and ADORA1, were hypomethylated in each of the 3 plasma cell dyscrasia
phenotypes including MGUS and SMM and MM cases compared to controls
(P0.03), albeit not at a level of genome-wide statistical signifıcance. Conclu-
sions: These preliminary fındings suggest that differences in DNA methylation
may contribute to altered risk of MM, as well as its precursor conditions, and
mayplay a role in plasma cell dyscrasia progression as a consequence of heritable
changes in gene activity due to past exposures. Replication in a large yet similarly
well-characterized population is warranted.
#1320 Non-additive and interaction effects of HLA class 2 polymorphism
contributing to risk of glioma. Chenan Zhang, Kyle Walsh.University of Cali-
fornia, San Francisco, San Francisco, CA.
Although genome-wide association studies have identifıed a number of sus-
ceptibility loci for adult glioma, little is still known regarding whether polymor-
phisms in the human leukocyte antigen (HLA) region contribute risk. HLA
associations have previously been reported for a number of malignancies, with
selected HLA polymorphisms investigated in a subset of glioma studies. How-
ever, no systematic analysis has been conducted to date, and no investigation
into potential non-additive effects of such associations has been described. In
this study, we conducted comprehensive genetic analyses of HLA variants in the
major histocompatibility complex (MHC) region among 1,746 adult glioma
patients and 2,312 controls from the GliomaScan Consortium. Genotype data
were generated with the Illumina 660-Quad array, containing 1,822 SNP probes
across theMHCregion.We imputedHLAalleles using a reference panel of 5,225
individuals in the Type 1 Diabetes Genetics Consortium who underwent high-
resolution HLA typing via next-generation sequencing. Subjects were of Euro-
pean-ancestry, and case-control comparisons were adjusted for population
stratifıcation using ancestry-informative principal components. Because alleles
in different loci across the MHC region are linked, we created multi-locus hap-
lotypes consisting of genes DRB1, DQA1, and DQB1. Although none of the
haplotypes were associated with glioma in additive models, DRB1*15:01-
DQA1*01:02-DQB1*06:02 showed an improvement inmodel fıt after the inclu-
sion of a non-additive term, which was signifıcant after Bonferroni correction
(P  2.5x103). Furthermore, the interaction of DRB1*15:01-DQA1*01:02-
DQB1*06:02 with haplotype DRB1*04:01-DQA1*03:01- DQB1*03:01 resulted
in a 3.80-fold increase in the odds of glioma (P 8.8x103). Our results indicate
that the DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype contributes to the
risk of glioma via a dominant effect, with heterozygosity conferring greater risk
of glioma than expected from homozygote disease risk in an additive model.
#1321 Transcriptome-wide association study of prostate cancer risk.Maxine
Chen,1 Alexander Gusev,2 The PRACTICALConsortium,Massimo Loda,3 Lorelei
A.Mucci,2Meir J. Stampfer,1PeterKraft,2KathrynL.Penney1. 1BrighamandWom-
en’s Hospital andHarvardMedical School, Boston,MA; 2Harvard T.H. Chan School
of Public Health, Boston, MA; 3Dana-Farber Cancer Institute, Boston, MA.
Though more than 150 single nucleotide polymorphisms (SNPs) associated
with prostate cancer have been identifıed through GWAS, we still do not under-
stand the functional consequences of common genetic variation in this disease.
Genetic variants may influence complex diseases like prostate cancer through
gene expression.However, very large studies evaluating gene expression in pros-
tate cancer are currently infeasible due to the limited availability of prostate
cancer tissue and expense of collecting expression data. Alternative approaches
have been developed to identify expression-trait associations in study popula-
tions without directly measured expression data. One such approach (Gusev et
al. Nat Genet. 2016) uses a set of reference individuals with both gene expression
and SNP data to develop genetic prediction models of gene expression values.
Thesemodels are thenused to impute cis genetic components of gene expression
for a much a larger set of individuals with only genotype and phenotype infor-
mation. We used Affymetrix gene expression microarray data from normal
prostate and prostate tumor tissue and genotype data from prostate cancer pa-
tients in the Health Professionals’ Follow-up Study and the Physicians’ Health
Study (N187) as a reference panel for creating the predicted models of the
genetic components of expression. We imputed gene expression values into
Oncoarray GWAS summary statistics from the PRACTICAL consortium (N
75,000) to assess the association between predicted expression and prostate can-
cer risk. We present the results of our transcriptome-wide association study in
normal prostate and prostate tumor tissue, identifying genes signifıcantly asso-
ciated with prostate cancer risk after correcting formultiple testing. These genes
may provide insight into how genetic variants influence prostate cancer through
their effect on gene expression.
#1322 A meta-analysis of genome-wide association studies identifıes
novel loci that influence breast cancer prognosis. Latha Kadalayil,1 Sofıa
Khan,2 Heli Nevanlinna,2 Peter A. Fasching,3 Fergus J. Couch,4 John Hopper,5
Jianjun Liu,6 TomMaishman,1 Lorraine Durcan,1 Carl Bloomqvist,2 Andy Col-
lins,1 Dianna Eccles,1 William Tapper1. 1University of Southampton, Southam-
pton, United Kingdom; 2University of Helsinki, Helsinki, Finland; 3Friedrich-
Alexander University Erlangen-Nuremberg, Erlangen, Germany; 4Mayo Clinic,
Rochester, MN; 5University of Melbourne, Melbourne, Australia; 6Genome Insti-
tute of Singapore, Singapore, Singapore.
Familial studies were among the fırst to indicate that breast cancer prognosis
has a heritable component. Subsequently many variants associated with prog-
nosis have been identifıed using a range of techniques including genome-wide
association studies (GWAs). Despite these advances, much of the heritability
remains unexplained. In young women, breast cancer is characterised by a
higher incidence of adverse pathological features, unique tumour gene expres-
sion profıles and worse survival. In addition, the association of risk with con-
ventional epidemiological exposures is less clear in women with early onset. We
hypothesise that some of these difference between early and late onset could be
influenced by germline variation. To identify additional variants that influence
breast cancer prognosis we conducted a two stage meta-analysis of four GWAs
consisting of 6,042 patients from the UK (POSH), Finland (HEBCS), Germany
(SUCCESS-A) and Australia (ABCFS). Cox-regression analyses were used to
investigate overall survival (OS, n1,101 events) and disease-free survival (DFS,
n1,316 events) with correction for oestrogen status (ER). These survival anal-
yseswere repeated in a subset of patientswith early onset (aged40 at diagnosis,
n2,315 patients, OS n604 events, DFS n716 events). Meta-analysis iden-
tifıed two intronic SNPs in ADAMTSL1 that were associated exclusively
with early onset DFS, rs715212 (Pmeta3.54x105) and rs10963755
(Pmeta3.91x104) without heterogeneity between cohorts. Multivariable Cox-
regression demonstrated that the effect of these SNPs were independent of the
classical prognostic factors. Most importantly, rs715212 reached genome-wide
signifıcance (Pmultivariate5.37x108) in the multivariate model. ADAMTSL1
encodes a glycoprotein that forms part of the extracellular matrix (ECM) and
may function in cell-cell or cell-matrix interactions or may regulate other AD-
AMTS proteases. Previous studies have shown that ADAMTSL1 is hypermethy-
lated in ER positive breast cancer tumours. Using GTEx to perform eQTL anal-
ysis, we found that rs715212 is associated with the expression of several
biologically relevant genes AREG (P0.035), TNF (P0.015), FASLG
(P0.0031) and EGF (P0.0018) in breast mammary tissue. Interestingly, sep-
arate studies have shown that AREG is overexpressed in ER-positive breast
tumours from pre-menopausal women versus post-menopausal women. Fur-
thermore, AREG is differentially expressed between parous and non-parous
mammary glands and is persistently downregulated by parity, which suggests it
may contribute to the susceptibility of the nulliparous gland to breast cancer.We
conclude that rs715212 is associated with an increased risk of disease progres-
sion in patients with early onset and speculate that this could be due to an
interaction with the expression of AREG.
#1323 Genome-wide association study of energy intake and its relation-
ship to prostate cancer. Lai Jiang, Peter Kraft, Kathryn M. Wilson. Harvard
T.H. Chan School of Public Health, Boston, MA.
Background/Objectives: Previous studies suggested that high energy intake
may increase the risk of prostate cancer. However, the mechanisms remain
unclear. No genome-wide association studies (GWAS) have been conducted to
detect the genetic variations in total energy intake.We aimed to identify genetic
variants associated with total energy intake in men and women, and to deter-
mine the association between previously identifıed prostate cancer susceptibility
loci and total energy intake.Methods:We conducted a genome-wide study using
combined GWAS data from 12,031 European-ancestry women and 6,743 Euro-
pean-ancestry men from the Nurses’ Health Study, Nurses’ Health Study II,
Health Professionals Follow-up Study, and Physician’s Health Study. Total en-
ergy intake was measured through validated food-frequency questionnaires.
Missing genotypes were imputed usingMACHwith 1000Genomes Project ALL
Phase I Integrated Release Version 3 Haplotypes as the reference panel. We
stratifıed by sex and adjusted for age, weight, height, physical activity and three
principal components accounting for subpopulation structure. Meta-analysis
based on p-values across sex was implemented. SNP set analyses, including a
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weighted fıxed-effects (Mendelian randomization,MR) and an unweighted ran-
dom-effects approach (METASOFT), were used to test the association between
prostate cancer risk loci and total energy intake using summary statistics of total
energy intake from the combined GWAS and the summary statistics for ge-
nome-wide signifıcant SNPs (NSNPs 104) from a GWAS of prostate cancer in
43,303 cases and 43,737 controls [Al Olama (2014) Nat Genet]. Results: Three
SNPs near gene ANKRD33 were genome-wide signifıcantly (P  5.0108)
associated with the increase in total energy intake amongmen (rs10876214 [P
5.811010], rs9669605 [P 1.46108], and rs10783478 [P 2.42108]).
No signifıcant genome-wide association was found in women or the meta-anal-
ysis combining men and women. SNP set analyses did not fınd a statistically
signifıcant association between established prostate cancer SNPs and energy
intake (PMR 0.11 and PMETASOFT 0.09, respectively). Conclusions:We iden-
tifıed three signifıcant SNPs near geneANKRD33 associatedwith increased total
energy intake amongmen. Genetic alleles related to risk of prostate cancer were
not associated with total energy intake. Larger GWAS studies of total energy
intake are warranted to explore the genetic basis of energy intake, including
possible differences betweenmen andwomen, and the association between total
energy intake, prostate cancer, and other cancers and chronic diseases.
#1324 Profıle of common prostate cancer risk variants in an unscreened
Romanian population. Paul D. Iordache,1 Bjarni Halldórsson,1 Andrei Man-
olescu,1 DanaMates,2 RaduUrsu,3 Viorel Jinga4. 1Rekjavik University, Rekjavik,
Iceland; 2National Institute of Public Health, Bucharest, Romania; 3Genetics De-
partment University of Medicine and Pharmacy Carol Davila, Bucharest, Roma-
nia; 44Prof. Dr. Th. Burghele Clinical Hospital, Urology Department, University
of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
In the present study we investigated for the fırst time the profıle of common
prostate cancer risk variants in an unscreened Romanian population. The study
population consisted of 990 unrelated histopathologically confırmed prostate
cancer (PCa) cases and 1,034 male controls consisting of patients admitted for
urological and surgical conditions, excluding cancer. DNA was extracted from
whole blood at deCODE Genetics (Reykjavik, Iceland) and genotyped using
Illumina SNP arrays, 24.295.558 variants were imputed using the 1000Genomes
dataset in the 2,024 Romanian subjects. A systematic literature review for vari-
ants associated with prostate cancer identifıed in previous GWAS’ was done
using the NHGRI catalog as a starting point, identifying 238 unique variants
from 28 studies. None of the tested variants in a Romanian only GWAS reached
a genome wide signifıcance (p-value lower than 5x108) but 807 markers
reached p-values of 1x106. Thirty-one of the previously-reported SNPs repli-
cated in the Romanian cohort, with the strongest associations seen at: 8q24.21,
11q13.3, 6q25.3, 5p15.33, 22q13.2, 17q12 and 3q13.2. Themost signfıcantly rep-
licated variants in Romania are rs1016343 at 8q24.21 (P 2.2x104), rs7929962
at 11q13.3 (P 2.7x104) and rs9364554 at 6q25.2 (P 4.7x104). Our present
study is the fırst GWAS on prostate cancer performed on a Romanian cohort.
The high proportion of clinically signifıcant disease in the Romanian prostate
cancer caseswill allow the dissection of the association between genetic variation
and severe disease. Acknowledgements: This study was funded in part by the
European Union FP7 Program (ProMark project 202059) and by the EEA grant
(ROMCAN project RO14-0017; EEA-JRP-RO-NO-20131-10191).
#1325 Genome-wide association study of thyroid nodule in Korean pop-
ulation. Eun Kyung Lee,1 Yul Hwangbo,1 Young Joo Park,2 Jong-Il Kim,3 Yuh-
Seog Jung,1 Jun Sun Ryu1. 1National Cancer Center, Korea, Goyang, Republic of
Korea; 2Department of Internal Medicine, Seoul National University College of
Medicine, Seoul, Republic of Korea; 3Department of Biochemistry and Molecular
Biology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Thyroid nodule is very common. Several autopsy surveys reported that 30%
or more of patients had thyroid nodule. However, inherited genetic risk factors
for thyroid nodule remain unknown. Genome-wide association studies
(GWAS) are widely used in human genetics to identify genes associated with
various diseases. We aimed to fınd genetic factors for thyroid nodule and con-
ducted case-control GWAS. Objective: To identify genetic variants associated
with susceptibility to thyroid nodules Methods: We performed a two-stage
GWAS for thyroid nodule. The discovery stage involved a genome-wide scan of
713 subjects with thyroid nodule and 591 subjects with normal thyroid from a
population-based cohort. replication testing was conducted in an additional 600
cases and 600 controls from the participants of a health check-up. Results In
discovery stage, 21 candidate single nucleotide polymorphisms (SNP) in 20 loci
includingNKX2-1, ITGB1 andZBTB25were selected for replication. The stron-
gest signal located inNKX2-1 (P 9x107), which is known susceptibility locus
for differentiated thyroid cancer. However, no SNP showed signifıcant associa-
tion in replication test. In joint analysis, no association signals reaching genome-
wide signifıcance (P 5x108) were detected. Conclusion GWAS for thyroid
nodule have failed to identify susceptibility locus. Therefore, genetic effect for
development of thyroid nodule could be negligible.
#1326 A pooled genome-wide association study of pancreatic cancer sus-
ceptibility loci inAmerican Jews. SamanthaA. Streicher,1AlisonP.Klein,2 Sara
H. Olson,3 Robert C. Kurtz,3 Andrew T. DeWan,1 Hongyu Zhao,1 Harvey A.
Risch1. 1Yale School of Public Health, New Haven, CT; 2Johns Hopkins School of
Medicine, Baltimore, MD; 3Memorial Sloan Kettering Cancer Center, New York,
NY.
Jews are estimated to be at increased risk of pancreatic cancer compared to
non-Jews. The higher risk of pancreatic cancer in Jews can be partially explained
by the increased frequency of BRCA1 and BRCA2 mutations in the Ashkenazi
Jewish population; however, the remaining 40-70% excess risk of pancreatic
cancer in Jews is not explained by other established non-genetic and genetic risk
factors. The genetic origins of modern Ashkenazi Jews can be traced back to a
founder population bottleneck between the 11th and 15th centuries follow by a
rapid endogamous population expansion, making the Ashkenazi Jewish popu-
lation a genetic isolate ideal for exploring genetic contributions to pancreatic
cancer. We conducted a genome-wide association study (GWAS) in a case-
control sample of American Jews, largely Ashkenazi, including 406 pancreatic
cancer patients and 2,332 controls, identifıed in the database of Genotypes and
Phenotypes (dbGaP) Pancreatic Cancer Cohort and Case-Control Consortium
I/II (PanScan I/II), Pancreatic Cancer Case-Control Consortium (PanC4), and
Genetic Epidemiology Research on Adult Health and Aging (GERA) data sets.
We then examined those single nucleotide polymorphisms (SNPs)with P107
in an expanded sample set, of 539 full- plus part-Jewish pancreatic cancer pa-
tients and 4,117 full- plus part-Jewish controls from the same data sets. Jewish
ancestry was genetically determined using seeded fast principal component
analysis. In our data set, the part-Jewish subjects had mixed genetic ancestry
both from Jews and from non-Jewish white-Europeans. Among the full Jews, a
novel genome-wide signifıcant association was detected on chromosome 19p12
(rs66562280, OR1.55, 95% CI1.33-1.81, P2.30x108). A suggestive asso-
ciation was detected on chromosome 19p13.3 (rs2656937, OR1.53, 95%
CI1.31-1.78, P9.96x108). Similar associations were seen for these SNPs
among the full- plus part-Jews. No SNPsmeeting the quality control fılter inclu-
sion criteria were found in the full- plus part-Jewish subjects to be signifıcant at
the P107 level. Overall, we identifıed in Jews one novel susceptibility locus
and one suggestive novel susceptibility locus for pancreatic cancer that warrant
follow-up work. This is the fırst GWAS conducted for pancreatic cancer in the
increased-risk Jewish population. The novel susceptibility locus discovered on
chromosome 19p12 could explain up to15%, and the novel suggestive suscep-
tibility locus on chromosome19p13.3 could explain up to an additional15%of
the increased risk for pancreatic cancer in the Jewish population.
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#1327 CD147 contributes to extracellular matrix remodeling and degra-
dation. Tiffany Tan, Beata Kosmider, Nathaniel Marchetti, Sudhir Bolla,
Chenna Mandapati, Gerard Criner, Karim Bahmed. Temple University, Phila-
delphia, PA.
Chronic obstructive pulmonary disease (COPD) is an incurable, progressive
lung disease characterized by shortness and diffıculty in breathing. Patients with
COPD are at higher risk of developing lung cancer and often are associated with
poor outcome of lung cancer diagnosis and treatment. Extracellular matrix
(ECM) remodeling and degradation is one of the common hallmarks between
cancer and COPD. It contributes to degradation of air sacs (emphysema) or
small airways (obstructive bronchiolitis). It is also involved in cancer initiation
and progression to assist tumor expansion and cancer cell migration. In this
study, we analyzed lung tissue and primary alveolar type II (ATII) cells isolated
from patients with emphysema and control organ donors. ATII cells secrete and
store pulmonary surfactant and restore the epithelium after damage. We per-
formed RNA sequencing in ATII cells to identify dysregulated proteins, which
are involved in ECM degradation in emphysema. To further study the mecha-
nism involved in the ECM degradation in this disease, we analyzed the expres-
sion of selected proteins and we focused on the role of extracellular matrix
metalloproteinase inducer (CD147). CD147 is a cellmembrane protein involved
in inducing the production of extracellular matrix metalloproteinases (MMPs).
First, we found that cells isolated from patients with emphysema have higher
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expression of CD147 in ATII cells in comparison with controls as detected by
western blotting and RT-PCR. This may explain high ECM degradation in this
disease. Second, we observed higher MMPs levels in plasma obtained from in-
dividuals with this disease. Third, we found signifıcantly higher expression of
cathepsin B inATII cells isolated from emphysema in comparisonwith controls.
Cathepsin B is an enzyme that facilitates a direct degradation of ECM proteins
and activate other proteases capable of degrading ECM. Fourth, our data indi-
cate that CD147 interacts with cathepsin B, which may lead to the activation of
MMPs and emphysema progression. In summary, our results show for the fırst
time the important role of CD147 in emphysema development. Moreover, we
found that cathepsin Bmay contribute to CD147-mediated disease progression.
Further studieswill elucidate its role in lung cancer development in patientswith
emphysema.
#1328 Mechanism of transcriptional regulation of metabotropic gluta-
mate recepter-5 induced by the CXCR4 signaling pathway.Nobuyuki Kurib-
ayashi, Daisuke Uchida, Makoto Kinouchi, Sayaka Izumi, Kyoko Kuribayashi,
Hitoshi Kawamata. Dokkyo University School of Medicine, Tochigi, Japan.
We have previously demonstrated that stromal cell-derived factor (SDF)-1/
CXCR4 system enhances the metastases of oral cancer cells via induction of
mGluR5. In this study, we examined the transcriptional regulation of mGluR5
induced by the SDF-1/CXCR4 system, using oral cancer cells, B88, which ex-
press functional CXCR4 and have highly metastatic potentials. mGluR5 was
markedly induced both by the exogenous SDF-1 addition and overexpression of
SDF-1 in B88 cells. These induction was completely inhibited by a MEK inhib-
itor, U0126, and partially inhibited by a PI3K inhibitor, wortmannin. Further-
more, these inhibitors signifıcantly inhibited the SDF-1/CXCR4 dependent cell-
migration in the presence or absence of mGluR5 agonist, DHPG. Recently,
several investigators demonstrated that activation of the ERK1/2 pathway is
responsible for the transcription of several cancer-associatedmicroRNAs (miR-
NAs). Thus, we performed miRNA microarray in SDF-1 stimulated B88 cells.
we isolated miR-30 family which has predictive binding sites in 3=-UTR of
mGluR5 mRNA in silico analysis. We now analyze the regulation of these
miRNA by MEK/ERK1/2 and PI3K/Akt pathway.
#1329 Inhibition of papillary thyroid cancer cells progression by targeting
skp2 via ros-erk-chop-dr5pathways.Pratheeshkumar Poyil, Rong Bu, Abdul K.
Siraj, Sandeep Kumar P, Khawla S. Al-Kuraya. King Faisal Specialist Hospital
and Research Center, Riyadh, Saudi Arabia.
S-phase kinase protein 2 (SKP2), is an F-box protein with proteasomal prop-
erties andhas been found to be overexpressed in a variety of cancers.However its
role in papillary thyroid cancer (PTC) has not been elucidated. Therefore, inac-
tivation of SKP2 could be a viable strategy for the treatment of PTC. In the
present study, we investigated the role of SKP2 and its ubiquitin-proteasome
pathway in PTC using a tissuemicroarray cohort of 1022 PTC samples, PTC cell
lines and Nude mouse model. Our immunohistochemistry data showed that
SKP2 was over-expressed in 75.1% of PTC cases and was clinically, signifıcantly
associated with extra thyroidal extension (p0.0331), Tall cell variant
(p0.0070), andpresence in surgicalmargins (p0.0347). Bortezomib aswell as
SKP2 specifıc siRNAcaused downregulation of SKP2 leading to dose-dependent
growth inhibition and induction of apoptosis via mitochondrial apoptotic path-
way in PTC cell lines. Furthermore, we found that treatment of PTC cells with
Bortezomib caused up-regulation of DR5 via generation of reactive oxygen spe-
cies (ROS). Finally, Bortezomib treatment augmented TRAIL mediated anti-
cancer effect on PTC xenograft tumor growth in nude mice. These data suggest
that Bortezomib is a viable therapeutic option for the treatment of PTC either
alone or in combination with other apoptotic agents such as TRAIL.
#1330 HSP90 inhibitor has a possibility to overcome imatinib resistance
in gastrointestinal stromal tumors. Yurina Saito,1 Tsuyoshi Takahashi,1 Sa-
toshi Serada,2 Minoru Fujimoto,2 Koji Tanaka,1 Yasuhiro Miyazaki,1 Tomoki
Makino,1 Yukinori Kurokawa,1 Makoto Yamasaki,1 Kiyokazu Nakajima,1 Shuji
Takiguchi,1 Masaki Mori,1 Yuichiro Doki,1 Tetsuji Naka2. 1Osaka University,
Graduate School of Medicine, Suita, Osaka, Japan; 2National Institutes of Bio-
medical Innovation, Health and Nutrition, Ibaraki, Osaka, Japan.
[Background] Gastrointestinal stromal tumors (GIST) are the most common
mesenchymal tumors of the digestive tract and are reported to harbor gain-of-
function mutations in the KIT gene, which contribute to the development of
sporadic GISTs. This knowledge has facilitated the development of targeted
therapies with tyrosine kinase inhibitors and the revolutionary chemotherapeu-
tic drug imatinib mesylate (IM). In clinical trials, the disease control rate was
nearly 85%, and corresponding 2-year overall survival rates ranged from 70-
80%, indicatingmarkedly improved patient outcomes compared with anecdotal
data in the pre-IM era. Despite its effectiveness, half of GISTs treated with IM
develop resistance within 2 years, largely due to the accumulation of additional
kinase domainmutations accompanied by concomitant re-activation of the KIT
tyrosine kinase, even in the presence of IM. Heat shock protein 90 (HSP90) is
one of chaperonmolecules required for the proper folding, function, and stabil-
ity of various client proteins such as KIT. The aim of this study is to clarify the
effıcacy of HSP90 inhibitor against IM resistant GIST. [Material and Method]
We used the established human GIST cell line GIST-T1, and two IM-resistant
cell lines (GIST-T1R8, GIST-T1R9), which had additional kinase domain mu-
tations accompanied by concomitant re-activation of the KIT tyrosine kinase
same as clinical samples, by exposure to IM. These resistant cell lines exhibited
imatinib IC50 values (10 M) that were1000-fold higher than the parental
cell line. We investigated the cytotoxicity and signaling inhibition by HSP90
inhibitor using by the WST-8 assay, caspase3/7 apoptosis assay and western
blotting. Immunobolts for KIT and for KIT-depending signaling pathways were
observed at 12 hours of treatment. Caspase 3/7 apoptosis assay was measured
after 24h. [Result] HSP90 inhibitor showed growth inhibition not only for GIST
T1 but also GIST-T1R8 and GIST-T1R9. Apoptosis induction of these cell lines
were also confırmed by the exposure to HSP90 inhibitor in a dose-dependent
manner. To fınd the mechanism of apoptosis induced by HSP90 inhibitor, we
investigated the signaling pathway depending on KIT. HSP90 inhibitor showed
inhibition of phosphorylated-KIT, a client for HSP90, in both IM sensitive and
resistant GIST cell lines. And, it also inhibited downstream of KIT signaling, e.g.
p-ERK and p-AKT. [Conclusions]HSP90 inhibitor showed the anti-tumor effı-
cacy for imatinib resistant GIST in vitro. It might have a possibility to apply for
clinical use.
#1331 TGF1 induces breast tumor kinase overexpression in triple nega-
tive breast cancer via p38MAPKsignaling to glucocorticoid receptors.Carlos
J. Santos Perez, Tarah ReganAnderson, Carol A. Lange.University ofMinnesota
Twin Cities, Minneapolis, MN.
Triple negative breast cancer (TNBC) is the deadliest breast cancer (BC) sub-
type, accounting for 20-30% of all BCs. It has a heterogeneous pathology and
pathogenicity, but it is defıned by the lack of estrogen receptor, progesterone
receptor, and Her2 epidermal growth factor receptor expression. Because tar-
geted therapy through these receptors is not possible, treatment relies on che-
motherapy and surgery, which are often inadequate. Thus, the identifıcation of
possible molecular targets is critically important in TNBC. Breast tumor kinase
(Brk) is a soluble tyrosine kinase that is overexpressed in 85%of BCs and a driver
of aggressive and metastatic phenotypes. Overexpression of Brk mRNA and
protein occurs in TNBC by unknownmechanisms. The glucocorticoid receptor
(GR), a very potent modulator of cytokine mediated actions of the immune
system, is emerging as a mediator of chemoresistance and recurrence in TNBC.
We previously demonstrated that GR signaling cooperates with physiologic
stress signaling mediated by hypoxia inducible factors HIF-1a and HIF-2 to
modulate the expression of Brk mRNA and protein in TNBC cells. Moreover,
phosphorylation of GR at ser134 by p38MAPK is essential for GR regulation of
Brk expression. P38 is an essential Ser/Thr kinase that regulates cellular trans-
duction of growth factors, such as Hepatocyte Growth Factor (HGF), and cyto-
kines (e.g. TGF1) in TNBC cells, and was previously shown to be co-expressed
with Brk in human breast tumors. Herein, we further probed mechanisms of
crosstalk between key cytokines, GR, and p38 signaling in the regulation of Brk
overexpression.We hypothesize that TGF1 signalingmodulates EMT andme-
tastasis in part by increasing the expression of Brk in TNBC. Treatment of
MDA-MB-231 cells with TGF1 for 1, 2, 24 and 48 hours increased Brk protein
expression relative to vehicle controls. Additionally, TGF1 increased both
HIF1 andHIF2protein levels (at 24 and 48hours respectively). TGF1 regulated
Brk expression at the level of mRNA, as measured using RT-PCR. Moreover,
TGF1 synergized with activated GR to further increase Brk mRNA levels. In
contrast, mRNA levels of HIF1 and HIF2 were not modulated by TGF1, sug-
gesting that the observed protein increases are due to stabilization of HIFs.
Finally, TGF1 robustly induced p38-dependent phosphorylation of GR at ser-
ine 134. This phosphorylation event promoted ligand-independent GR tran-
scriptional activity at the Brk promoter. Human breast tumors signifıcantly co-
express active p38 MAPK and Brk. Our molecular model implicates TGF1
signaling (via p38 MAPKs) to phospho-GR in the aberrant overexpression of
Brk in TNBC.We conclude that blocking of the TGF1 pathway may provide a
strategy to inhibit Brk mediated TNBC tumor progression. This work was sup-
ported by NIH/NCI R01 CA192178 (to CAL) and T32 GM008244-24.
#1332 NOTCH -HEY1 pathway induces EMT in head and neck squamous
cell carcinoma. Takahito Fukusumi,1 Theresa W. Guo,2 Shuling Ren,1 Akihiro
Sakai,1 Mizuo Ando,1 Sunny Haft,1 Chao Liu,1 Joseph A. Califano1. 1UC SanDi-
ego, San Diego, CA; 2Johns Hopkins Medical Institutions, Baltimore, MD.
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Background Head and neck squamous cell carcinoma (HNSCC) is noted to
have a NOTCHmutation rate of 20%within the Cancer Genome Atlas (TCGA)
dataset consistent with tumor suppressor gene status. However, NOTCH genes
are also upregulated in wild type HNSCC and show signs of downstream acti-
vation in a substantial proportion of HNSCC. In this study, we aimed to further
explore the potential for NOTCH pathways to be activated in HNSCC.Material
andMethods mRNA sequence of TCGA data includes 520 HNSCC tumors and
46 normal tissues. We used 447 HNSCC excluding 73 tumors with NOTCH
mutations. The activated groups of NOTCH downstream genes were defıned as
tumors with expression 1 standard deviation above the mean of normal tissue.
We used four HNSCC cell lines (SKN3, Cal27, SCC61, SCC090) to ascertain the
results of the TCGA analysis in vitro. Result In TCGA analysis, HEY1 activated
HNSCC had signifıcant more expression of NOTCH pathway genes. In partic-
ularNOTCH4had themost signifıcant correlationwithHEY1 activation among
NOTCH receptors. To confırm this result in vitro, HEY1 expression was com-
pared between si-control and si-NOTCH4 of SKN3, Cal27, SCC61 and SCC090.
As expected, HEY1 expression in all si-NOTCH4 treated cell lines were signifı-
cant decreased. Next, we examined the relationship about NOTCH4 and an
epithelial mesenchymal transition phenotype (EMT). Using TCGA data, we
found that mesenchymal marker genes were signifıcantly increased in high
NOTCH4 group. In vitro experiments, si-NOTCH4 cells decreased mesenchy-
mal marker gene expression such as Fibronectin and TWIST1. We also exam-
ined HEY1 function. Similar to NOTCH4, it was found that HEY1 is signifı-
cantly related to EMT in silico and in vitro. Conclusion The NOTCH4-HEY1
pathway is signifıcantly upregulated in HNSCC and induces EMT.
#1333 Cross talk betweenmitogen-activated protein kinase signaling cas-
cades and Wnt/-catenin in HER2 overexpressing breast cancer cells.
Miguel Nava,1 Nwamaka A. Amobi,1 Yanyuan Wu,1 Robin Farias-Eisner,2 Jay
Vadgama1. 1Charles Drew University, Los Angeles, CA; 2University of California,
Los Angeles, Los Angeles, CA.
Introduction: The HER2-positive breast cancer is characterized by an ampli-
fıcation of the HER2 gene, resulting in an increase in HER2 presence on the
surface of cells and magnifıcation of downstream intracellular signaling. Treat-
ment of HER2 breast cancer with trastuzumab decreases tumor volume, re-
duces metastasis and increases overall survival. Unfortunately, HER2-positive
breast cancers develop resistance to trastuzumab. The mechanism of resistance
may involve the activation of compensatory networks of different cell signaling
pathways. The purpose of the study is to examine the crosstalk between HER2/
EGFR and Wnt signaling in HER2-positive breast cancer cells. Methods: In
order to address this, a HER2-positive breast cancer cell line (SKBR3) was used
and induced with EGF. The phosphorylation of p38 and ERK1/2 was deter-
mined by Western blot analysis. The cellular localization of proteins of interest
was examined using biochemically fractionated lysates followed by western blot
analysis. Results: Our data demonstrated an early and transient peak of phos-
pho-p38 at 30min post EGF treatment. Interestingly, both phospho-p38 and
phospo-ERK1/2 were detected in the nuclear compartment at this time.
-catenin, the major effector molecule in Wnt signaling, was stabilized 30min
post EGF treatment. -catenin protein levels remained higher in EGF treated
cells than untreated cells up to 4h post EGF treatment. It is likely that a stabilized
-catenin following EGF treatment potently modulates a subset of Wnt targets.
We are assessing this possibility using chromatin immunoprecipitation based
experiments for H3K18ac, H3K27ac, pol2 and -catenin. Taken together, our
data suggests that EGFR signaling promotes Wnt signaling in HER2-positive
breast cancer cells. We hypothesize that this promotes cancer stem cell niche
maintenance and an EMT phenotype.
#1334 Mesenchymal cell sub-populations selectively modulate paracrine
hedgehog signaling in triple negative breast cancer.Karla P. Ramos,Maribella
Domenech. Univ. of Puerto Rico-Mayaguez, Mayaguez, PR.
Recent studies correlate Hedgehog (Hh) signaling with reduced survival rates
in triple negative breast cancer (TNBC) patients. Activation of hedgehog signal-
ing in the adjacent mesenchyme has been shown to promote tumor growth and
it is a poor prognosis factor for TNBC.We developed a novel tumor-mesenchy-
mal in vitro model of hedgehog signaling in TNBC to evaluate the role of mes-
enchymal cell sub-populations in the proliferative potential and stem cell mark-
ers of breast cancer cells using a custom designedmultiwell array. As a source of
mesenchymal cell sub-populations we evaluated myofıbroblasts, mesenchymal
stem cells derived from bone marrow or adipose tissue and tumor cells that
undergo epithelial-mesenchymal transition (EMT). Tumor cells were culture
with 1 or 2 mesenchymal cell sub-populations in adjacent compartments/
SHH ligand for 72-96hrs. Active Hh signaling was confırmed by up-regulation
of main Hh target genes (e.g. Gli1, Patch1). Paracrine Hh signaling only in bone
marrow-derived mesenchymal stem cell and EMT signifıcantly increased pro-
liferation (10-15%) of TNBC and normal breast cancer cell lines. Addition of
adipose-derivedmesenchymal stem cells or pharmacologicalHh inhibitors (Cy-
clopamine and Gant61) partially abolished tumor growth indicating that other
non-canonical signals are involve in paracrine Hh-driven tumors. Cancer stem
cell markers were selectively modulated in co-cultures. Our results suggest that
paracrine Hh signaling-driven by bone marrow and EMT mesenchymal are
potential therapeutic targets to treating TNBC.
#1335 Deubiquitinase OTUD6B isoforms are important regulators of
growth and proliferation. Maurizio Bocchetta, Clodia Osipo, Anna Sobol.
Loyola University Chicago, Maywood, IL.
Deubiquitinases (DUBs) are increasingly linked to the regulation of funda-
mental processes in normal and cancer cells, including DNA replication and
repair, programmed cell death, and oncogenes and tumor suppressors signaling.
Here evidence is presented that the deubiquitinase OTUD6B regulates protein
synthesis in non-small cell lung cancer (NSCLC) cells, operating downstream
from mTORC1. OTUD6B associates with the protein synthesis initiation com-
plex and modifıes components of the 48S preinitiation complex. The two main
OTUD6B splicing isoforms seem to regulate protein synthesis in opposing fash-
ions: the long OTUD6B-1 isoform is inhibitory, while the short OTUD6B-2
isoform stimulates protein synthesis. These properties affect NSCLC cell prolif-
eration, since OTUD6B-1 represses DNA synthesis while OTUD6B-2 promotes
it. Mutational analysis and downstream mediators suggest that the two
OTUD6B isoforms modify different cellular targets. OTUD6B-2 influences the
expression of cyclinD1 by promoting its translationwhile regulating (directly or
indirectly) c-Myc protein stability. This phenomenon appears to have clinical
relevance as NSCLC cells and human tumor specimens have a reduced
OTUD6B-1/OTUD6B-2 mRNA ratio compared to normal samples. The global
OTUD6B expression level does not change signifıcantly between non-neoplastic
and malignant tissues, suggesting that modifıcations of splicing factors during
the process of transformation are responsible for this isoform switch. Because
protein synthesis inhibition is a viable treatment strategy for NSCLC, these data
indicate that OTUD6B isoform 2, being specifıcally linked to NSCLC growth,
represents an attractive, novel therapeutic target and potential biomarker for
early diagnosis of malignant NSCLC.
#1336 Signifıcance of SERPINE2 expression in peritoneal metastasis in
gastric carcinoma. Daisuke Kuroda,1 Junji Kurashige,2 Hiroshi Sawayama,1
Masaaki Iwatsuki,1 Tomoyuki Uchihara,1 Tasuku Toihata,1 Eri Oda,1 Taisuke
Yagi,1 Tsugio Eto,1 KeisukeMiyake,1MayukoOuchi,1 KenichiNakamura,1 Koi-
chi Kinoshita,1 Kousuke Mima,1 Takatsugu Ishimoto,1 Yasuo Sakamoto,1 Yo-
shifumi Baba,1 Naoya Yoshida,1 Koshi Mimori,3 Hideo Baba1. 1Kumamoto
Univ. Graduate School of Medical Sci., Kumamoto, Japan; 2Kyushu Univ. Grad-
uate School of Medical Sci., Fukuoka, Japan; 3Kyushu University Beppu Hospital,
Kumamoto, Japan.
Background: Peritoneal metastasis is one of themost frequent causes of death
in patients with advanced gastric carcinoma (GC). However, molecular mecha-
nisms driving peritoneal dissemination still remain poorly understood.Here, we
aimed to give new insights to the molecular mechanisms that drive the perito-
neal dissemination of GC. This study identifıed candidates of potential regula-
tors of peritoneal dissemination and focused on the signifıcance of one of them
in vitro experiments and clinical samples. Methods: We utilized previously re-
ported combined expression analysiswith two cell lines and samples and 200GC
patients to identify driver genes of peritoneal dissemination. The cell lines con-
sist of HSC58, an established cell lines from scirrhous type primary GC and its
progeny cell line, 58As9, with in vivo-selected highly peritoneal metastatic po-
tential. In vitro experiments, we utilized the two gastric cancer cell lines, 58As9
andNUGC4 and evaluated the effect of SERPINE2 knockdownon proliferation,
spheroid formation, invasion, andmotility. As for evaluation of clinical samples,
176 primary gastric carcinomas were included, which were obtained from pa-
tients who underwent curative gastrectomy in Kumamoto university between
2005 and 2015. We evaluated expression of SERPINE2 in immunohistochemis-
try and divided the cohort into two groups by SERPINE2 expression and ana-
lyzed relationship with clinicopathological factors and survival. Results: Enrich-
ment analyses of the profıle of the peritoneal dissemination-associated
expression signature revealed that poor prognosis and peritoneal metastasis was
related with the two pathways, focal adhesion (FDR q0.00195) and extracel-
lular matrix (FDR q0.00195). Among the genes related with extracellular ma-
trix, Serine Proteinase Inhibitor, Clade E, Member 2 (SERPINE2) was found to
be highly expressed in 58As9 compared with HSC58, and we focused on SER-
PINE2 as a candidate of potential regulators of peritoneal dissemination. In vitro
experiments, the SERPINE2 knockdown was related with decrease in cell mo-
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tility and invasion, but not with decrease in proliferation, spheroid formation.
Immunohistochemistry analysis of the clinical samples revealed higher SER-
PINE2 expression was signifıcantly related with invasion of serosa and lym-
phatic vessels, and lymph nodematastasis, and peritoneal metastatic metastasis.
Survival analysis also revealed SERPINE2 expressionwas relatedwith poor peri-
toneal recurrence-free survival (p0.038), and peritoneal metastasis-specifıc
survival (p0.036). Conclusion: We found SERPINE2 as a candidate of driving
molecules of peritoneal metastasis partly because it promotes invasive potential.
Further study including in vivo study is required to reveal relationship of SER-
PINE2 with the other molecules and pathways.
#1337 The distribution of the phosphorylated Parkin in lung carcinoma.
HongweiWang,1 Songlin Zhang,2 CatherineMa,1 Yuan Zhou1. 1AbboMax, Inc.,
San Jose, CA; 2UT Health Science Center at Houston, Houston, TX.
Parkin, also known as Parkinson Juvenile Disease Protein 2, together with
PINK1 and Ubiquitin, form a simple cascade in the clearance of damagedmito-
chondria. This cascade plays an important role in maintain mitochondral qual-
ity controls and is implicated in protesomal degradation of toxic substrates.
Recent studies have demonstrated that Parkin to be genetically altered, and
aberrantly expressed in a variety of human malignancies including lung, breast
and ovarian cancers, these may indicate that Parkin is a tumor suppressor gene
whose inactivation may play an important role in tumorgenesis. PINK1-depen-
dent phosphorylation of Parkin(pS65) is a required step in Parkin activation and
localization. The aims of this study were to investigate the expression of Parkin
and its phophorylated form in various type of lung carcinoma tissues and lung
cancer cell lines; the correlation of the protein expression level and the type of
the cancer.We choose two forms of the cancer materials. 1) A tissue microarray
(TMA) which contains 16 cases of lung carcinoma tissues consisting of 8x ade-
nocarcinoma (AC), 6x squamous cell carcinoma (SCC), and 2x small cell lung
carcinoma (SCLC); 2) FFPE slides which contains 9x lung cancer cell lines
(A549, H1703, H1975, H2228, H23, H838, HOP62, HOP92, and SKMES1). All
the tissues and cells were immunohistostained by Parkin and phospho-Parkin
polyclonal antibodies. The reference staining was performed by monoclonal
anti-Cytokaratin 7 (CK7) antibodies. From this study, we found Parkin expres-
sion level varies from TMA tissues and FFPE cell section which were not corre-
lated with tumor grade. Among the 8 cases of andenocarcinoma, only 3/8
showed marked Parkin expression, 3/8 moderate, and 2/8 mild; for
Parkin(pS65), only 1/8 demonstrated marked expression, 2/8 moderate, 2/8
mild, and no staining in 3/8 cases. In SCC cases, 2/6 demonstrated marked
Parkin expression, 2/6 moderate, 2/6 mild. The phosphorylated Parkin(pS65)
only expressed in 3/6 showedmild expression, not the others. Among 2 cases of
SCLC, only one showed marked Parkin expression and less extent of Parkin
(pS65), the other sample had no staining. In all FFPE cell sections, the strong
expression of Parkin and Parkin (pS65) was found in the lung cancer cell lines.
An interesting fınding was that Parkin(pS65) strongly presented in cells of mi-
totic phase in these cell lines exceptH1703 cell line. All the TMAand FFPE slides
were confırmed by CK7monoclonal antibody staining. In summary, Parkin and
its phophorylated Parkin (pS65)were found in adenocarcinoma, squamouse cell
carcinoma and small cell lung cancers with differentially expressed levels, the
degree of expression level was not correlated with tumor grade in these 16 cases.
Phosphorlated Parkin (pS65) was strongly expressed in FFPE cancer cell lines at
mitotic phase. It is concluded that the function of Parkin in tumor development
and the prognosis remain to be further evaluated; it may provide a potential
therapeutic approach for lung cancer.
#1338 Exosome secretion promotes proliferation of African American
prostate cancer cells under hypoxia: Role of HIF2 and RAB signaling. Ga-
tikrushna Panigrahi, Taylor C. Peak, Sierra L. Patterson, Nicole Kasica, Ravi
Singh, Ashok Hemal, Gagan Deep. Wake Forest Univ Bapt Med Ctr, Winston
Salem, NC.
Background and Objectives: African American men experience worse pros-
tate cancer (PCa) outcomes compared with those of Caucasian men not only in
incidence and mortality rates but also harbor higher grade tumors compared to
Caucasians. While the disparity is likely multifactorial, there may be biological
basis for such phenomenon. Hypoxia in the tumormicroenvironment is the key
determinant of disease aggressiveness regulating primary growth, angiogenesis,
metastasis and treatment outcomes. But role of hypoxia in the aggressiveness of
PCa in African-Americanmen has not been characterized yet. Here, we focused
on hypoxia signaling, exosome biogenesis and characterization in African-
American PCa cells compared to Caucasian PCa cells. Methods: We employed
several techniques (cell viability assays, ultracentrifugation, nanoparticle track-
ing analyses [NTA], electron microscopy, and western blotting) to compare
exosomes biogenesis and underlying molecular mechanisms in African-Amer-
ican and Caucasian PCa cells under normoxic and hypoxic conditions. Results:
Compared to normoxic condition, African-American PCa cells (E006AA-hT
and RC77T) either survived better or proliferated under hypoxia (1%O2), while
growth of Caucasian PCa cells (PC3 and LNCaP) was strongly inhibited under
hypoxia. NTA analyses showed that all PCa cells secretedmore exosomes under
hypoxia compared to normoxia, but more prominently in African-American
PCa cells (E006AA-hT: 4.4 fold, RC77T: 35 fold, PC3: 3 fold and LNCaP: 2 fold).
Exosomes secreted by E006AA-hT cells under hypoxia were loaded with higher
amount of HSP70, HSP90, IL6 and Annexin II, and lower TGF. These
exosomes also showed signifıcantly higher MMP9 loading compared to
E006AA-hT cell lysates. More importantly, under hypoxia, exosome biogenesis
inhibition by GW4869 (20 M) and 5-(N,N-dimethyl) amiloride (0.1-5 g/ml)
signifıcantly reduced the E006AA-hT cell viability by 30% (p0.0001) and 20-
60% (p 0.005 - 0.0001), respectively in 48 hrs. Further studies on hypoxia
signaling revealed that E006AA-hT cells have signifıcantly higher HIF2 and
HIF1 but low HIF1 expression compared to LNCaP cells. Interestingly,
HIF2 was present largely in nuclear fraction and its expression was similar
under both normoxic and hypoxic conditions in E006AA-hT cells. Studies on
the RAB and its effector proteins indicated that RabGAP5 expression was
strongly increased under hypoxia in both E006AA-hT andLNCaP cells. Further,
compared to LNCaP cells, E006AA-hT cells showed higher expression of Rab5
and Rabex5 but lower Rab4, and these molecules did not change signifıcantly
under hypoxia. Conclusion: African-American PCa cells have growth advantage
under hypoxia mainly through higher exosome secretion; and higher expres-
sion/activity of HIF2 and RAB-signaling molecules could be associated with
PCa aggressiveness in African-Americans.
#1339 Role of PTEN loss in basal-like 2 triple negative breast cancer. Er-
icka L. Smith, Christiana S. Kappler, Stephen P. Ethier. Medical University of
South Carolina, Charleston, SC.
Basal-like 2 (BL2) triple negative breast cancer (TNBC) is an aggressive mo-
lecular subtype of breast cancer with a poor clinical outcome. These cancers are
characterized by overexpression of epidermal growth factor receptor (EGFR),
loss of PTEN protein expression, and presence of mutated TP53. Despite over-
expression of EGFR, EGFR-targeted therapies have performed poorly in clinical
settings. Therefore, understanding the mechanisms of resistance in these cells is
critical for improved patient care. To understand the oncogenic signaling land-
scape in BL2 TNBC, our lab utilizes the BL2 cell lines SUM-149 and SUM-229,
which overexpress EGFR activated by an amphiregulin-mediated autocrine
loop, and are PTEN null. In addition, we utilize the BL1 subtype cell line MDA-
MB-468,which also exhibits overexpression of EGFRand loss of PTEN.Both the
BL1 and BL2 cell lines exhibit elevated levels of phosphorylated AKT (p-AKT)
compared to controlMCF-10Acells.However,while treatment of SUM-149 and
SUM-229 cells with inhibitors targeting EGFR (Gefıtinib), type-1 PI3K
(BKM120, BKM), mTOR (KU-0063794, KU) and pan-AKT (MK2206, MK) did
not reduce p-AKT levels, MCF-10A and MDA-MB-468 cell lines treated with
the same panel of targeted inhibitors showed marked inhibition of p-AKT. In
addition, re-expression of PTEN in SUM-149 and SUM-229 cells had little effect
on p-AKT but dramatically reduced p-AKT in MDA-MB-468 cells. Although
PTEN re-expression alone had little effect on p-AKT in SUM-149 and SUM-229
cells, these cells did display decreased AKT phosphorylation following treat-
ment with Gefıtinib, BKM, KU, and MK. There are three isoforms of AKT
(AKT1, AKT2 andAKT3) of which, AKT3 has been implicated in the aggressive
nature of some cancers. Previous studies in our lab showed that SUM-149 and
SUM-229 cell lines have higher levels ofAKT3message andprotein compared to
the other AKT isoforms. AKT3 expression was also higher in the BL2 cell lines
compared to BL1 and control cells. This differential expression of AKT isoforms
led us to examine the impact of AKT isoform-specifıc signaling. Using PTEN
re-expressing SUM-149 cells, we showed that PTEN re-expression resulted in
decreased phosphorylation of AKT1 but not of AKT3. However, PTEN re-ex-
pression combined with Gefıtinib treatment dramatically reduced phosphory-
lation of both AKT1 and AKT3. Interestingly, while neither re-expression of
PTENnorGefıtinib expression alone had an effect on colony-forming effıciency,
PTEN re-expression coupled with Gefıtinib treatment was able to reduce colony
formation effıciency in both SUM-149 and SUM-229 cell lines. Taken together,
these data indicate that BL2 breast cancers, with overexpression of EGFR and
loss of PTEN expression, have an oncogenic signaling network involving AKT3
that contributes to the aggressive and drug-resistant phenotype observed in this
subset of TNBC.
#1340 RAS pathway activation and sensitivity to therapeutic agents is
correlated with NF1 residual activity in malignant peripheral nerve sheath
tumors. Elliot Kahen, Darcy Welch, Diana Yu, Christopher Cubitt, Jae Lee,
Andrew Brohl, Damon R. Reed.Moffıtt Cancer Center, Tampa, FL.
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Background: Malignant Peripheral Nerve Sheath Tumor (MPNST) is a
malignant sarcoma that derives from a peripheral nerve or plexiform neuro-
fıbroma. Neurofıbromatosis type 1 (NF-1) patients are particularly suscep-
tible, with a higher risk, earlier onset, and worse prognosis. The major factor
associated with MPNST and NF-1 is Neurofıbromin 1, coded by the NF1
gene. NF1 mutation results in RAS hyperactivation. Chemotherapy for
MPNST is currently limited, with poor prognosis for metastatic or unresect-
able tumors. Thus, the development of promising treatment solutions for
MPNST to translate to clinical trials is required. Methods: Here, we seek to
identify effıcacious chemotherapeutic treatments for MPNST with a combi-
nation of drug screening and biological pathway analysis. We used our pre-
viously established preclinical system to test FDA approved or promising
developmental agents against fıve cell line models for MPNST. We screened
sixty agents with diverse mechanisms of action below published maximum
plasma concentrations, and measured effects with a CellTiter-Glo viability
assay. Promising agents were then tested in two-drug combinations, allow-
ing for determination of synergism. We then examined the molecular effects
of the top candidates with use of antibody arrays that permit detection of a
series of phosphorylated proteins. Results: The group of most effıcacious
drugs was enriched with agents that target factors downstream of RAS, in-
cluding MEK, mTOR, and PI3K inhibitors, with microtubule inhibitors,
genotoxics, and HDAC inhibitors also demonstrating good results. Strong
synergism was observed across our cell line models particularly in combina-
tions containing the dual mTORC1/2 inhibitor INK128. Interestingly, drug
sensitivity varied greatly between cell lines, correlating with relative NF1
protein and RAS-GTP levels. We analyzed the activation of the RAS pathway
in response to drug treatment with antibody arrays and found that, following
treatment, relative phosphorylation signal was more decreased compared to
controls in cell lines with lower relative NF1 protein levels. Doxorubicin was
able to reduce phosphorylation signal compared to controls to a level near
comparable to targeted inhibitors, which could contribute to doxorubicin’s
current usefulness against MPNSTs. Importantly, we identifıed combination
treatments that were able to greatly reduce the relative phosphorylation
signal of RAS pathway members versus control. Combinations containing
INK128 resulted in the most pathway shutdown. These fındings suggest that
MPNSTs may be susceptible to combination treatments targeting RAS path-
way members. Moreover, it may be possible to use pathway analysis as a
diagnostic tool to predict drug tolerance.
#1341 Talin plays an important role in cell-cell interactions. Devang M.
Patel, Akhilesh Kumar, William Morgan, Michael D. Birnbaum, Chaunhua Ji-
ang, Fangliang Zhang.Miller School of Medicine, Miami, FL.
Appropriate cell adhesion is necessary for numerous physiological pro-
cesses and can be deranged in many diseases, including cancer. It has long
been recognized that the cadherins mediated cell-cell adhesion receptor is an
important determinant of tumor progression, serving as a suppressor of
invasion and metastasis. Recently a role for the C-terminal region of talin
(the VAD fragment) in cadherin mediated cell-cell attachment has been
suggested, but its molecular mechanism remained unclear. Here, we identi-
fıed a small region of the VAD fragment required for its localization to
cadherin-mediated cell-cell junctions and also found that its localization to
cell-cell junctions is independent of its actin binding properties. To identify
the binding partner of the VAD fragment at cell-cell junctions we utilized
immune-pulldown and found that it interacts with catenins, an important
component of cadherin-mediated cell-cell junction. Based on our data, we
proposed that the VAD-fragment of talin stabilized and/or stimulated the
cell-cell junction by interacting with catenins.
#1342 Loss of claudin-3 expression induces IL6/gp130/Stat3 signaling to
promote colon cancermalignancy.RizwanAhmad,1 Balawant kumar,1 Zhimin
Chen,2 Steven(Xi) Chen,3 DominikMuller,4 SubodhM. Lele,1 Mary KayWash-
ington,5 Surinder K. Batra,1 Punita Dhawan,1 Amar B. Singh1. 1UNMC,Omaha,
NE; 2The First Affıliated Hospital of Zhengzhou University, China; 3University of
Miami, Miami, FL; 4Department of Pediatric Nephrology, Charité, and Berlin
Institute of Health,, Berlin, Germany; 5Vanderbilt University, Nashville, TN.
Genetic and epigenetic aberrations drive the formation of a benign colo-
rectal adenoma and its progression to the full-blown carcinoma. Hyperacti-
vated Wnt/-catenin signaling acts as a switch to induce EMT and promote
colorectal cancer. Additionally, IL-6/Stat-3 signaling, activated by microbial
translocation through the dysregulated mucosal barrier in colon adenomas,
facilitates the adenoma to adenocarcinomas transition. However, inter-de-
pendence between these signaling pathways in their capacity to communi-
cate with mucosal barrier to promote colon cancer remains unclear. In cur-
rent study, we have discovered, using a comprehensive investigative
regimen, a novel and tissue specifıc role of claudin-3, tight junction integral
protein, in inhibiting colon cancer progression by serving as the common
rheostat of Stat-3 and Wnt-signaling activation. Notably, in our analysis,
using mRNA and protein expression, and utilizing samples from a large
patient cohort (250 CRC specimen), we found claudin-3 expression to be
signifıcantly suppressed (p0.001 versus normal) in cancer tissues versus
normal mucosa. The colon tissues from the established mouse models of
colon cancer (APCminmice and Azoxymethane (AOM)-DSS-induced colon
cancer) demonstrated similar tumor specifıc decrease in claudin-3 expres-
sion. Interestingly, claudin-3 negative tumors retained E-cadherin expres-
sion. Most notably, we found a signifıcant and positive correlation (p0.05)
of the greater levels of claudin-3 expression with patient survival. These
fındings however contrasted an upregulated claudin-3 expression in other
cancer types and implicated differential epigenetic regulation. In further
studies, naïve claudin-3-/- mice revealed dedifferentiated {signifıcant down
regulation of P-27 (p0.05) and vimentin expression versus WT mice} and
leaky colonic epithelium. Moreover, claudin-3-/- mice demonstrated in-
creased colon tumor burden and invasive adenocarcinoma when subjected
to colon cancer. Wnt-signaling hyperactivation, albeit in GSK-3 indepen-
dent manner, characterized colon cancer in claudin-3-/- mice. Claudin-3
loss also upregulated the gp130/IL6/Stat3 signaling in colonic epithelium
potentially assisted by infıltrating immune organization. Genetic and phar-
macological studies confırmed that claudin-3 loss induces Wnt/-catenin
activation in Stat-3-dependent manner to promote colon cancer. Overall,
these novel fındings identify claudin-3 as a therapeutic target for inhibiting
overactivation of Wnt-signaling to prevent CRC malignancy.
#1343 DUOX1 silencing in lung cancer is associated with enhanced nu-
clear EGFR localization.Andrew C. Little, Karamathullah Danyal, David Hep-
pner, Milena Hristova, Albert van der Vliet. University of Vermont, Burlington,
VT.
Non-small cell lung cancer (NSCLC) remains to be one of the leading causes
of cancer-related mortalities worldwide. The NADPH oxidase homolog, Dual
Oxidase 1 (DUOX1), is an H2O2 producing enzyme located in the airway epi-
thelium with key roles in mucosal host defense and wound repair mechanisms.
Recent studies indicate that DUOX1 is epigenetically silenced in many forms of
NSCLC via hypermethylation of its promoter.We previously demonstrated that
DUOX1 silencing in lung cancer cells is closely associated with epithelial-to-
mesenchymal transition (EMT) and enhanced tumor invasiveness andmetasta-
sis. However, the mechanism(s) by which DUOX1 silencing promotes these
outcomes are not understood. Previous fındings indicate that DUOX1-depen-
dent epithelial host defense pathways are mediated by redox-dependent activa-
tion of epithelial signaling via the non-receptor tyrosine kinase, Src, and the
receptor tyrosine kinase, EGFR.We therefore hypothesized that loss of DUOX1
in lung cancer may be associated with aberrant regulation of Src and/or EGFR,
tyrosine kinases that are frequently overexpressed and activated in lung cancer
and strongly contribute to tumor growth and survival. In fact, recent studies
have indicated that nuclear localization of EGFR in cancer cells is associatedwith
metastatic cell behavior and poor clinical outcome, and the nuclear EGFR local-
ization depends on Src-dependent phosphorylation of EGFR at Y1101. We ob-
served that overexpression of DUOX1 in alveolar lung cancer A549 cells, which
possess EMT-like features and in which DUOX1 is normally silenced, results in
redistribution Src to the plasma membrane and decreased nuclear accumula-
tion. DUOX1 overexpression in A549 cells also suppressed EGF-stimulated nu-
clear translocation of EGFR, which was associated with reduced EGFR phos-
phorylation at Y1101. Conversely, RNAi-mediated silencing of DUOX1 in the
epithelial cancer cell line H292, which normally expresses DUOX1 expression,
was found to promote EGF-mediated EGFR nuclear translocation and Y1101
phosphorylation. Since nuclear EGFR is thought to enhance the transcription of
target genes related to cell cycle progression and proliferation (e.g. CDK1, Myc,
others), we evaluated gene expression of these target genes in our cell models.
Indeed, in cells lackingDUOX1, EGF stimulation signifıcantly enhancedmRNA
levels of CDK1, Myc, and other target genes for nuclear EGFR, whereas no such
induction was seen in cells that express DUOX1. Our fındings indicate that
DUOX1 silencing in lung cancermay be associated with worse prognosis, partly
due to altered spatiotemporal regulation of EGFR and Src and increased nuclear
targeting. Since both EGFR and Src are subject to redox regulation by cysteine
oxidation, we are currently aiming to elucidate the molecular mechanisms by
which these mechanism are affected by altered DUOX1 status.
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#1344 Progranulin promotes ubiquitination, sorting and lysosomal deg-
radation of sortilin in castration-resistant prostate cancer cells. Ryuta Tan-
imoto,1 Chiara Palladino,1 Simone Buraschi,1 Shi-Qiong Xu,1 Leonard G. Go-
mella,1 Renato V. Iozzo,1 Antonino Belfıore,2 Andrea Morrione1. 1Thomas
Jefferson University, Philadelphia, PA; 2Universita della Magna Graecia, Catan-
zaro, Italy.
Introduction andObjective: Despite extensive clinical and experimental stud-
ies over the past decades, the pathogenesis of prostate cancer remains largely
unknown. Furthermore, the mechanisms promoting the castration-resistant
stage of prostate cancer are still very poorly understood. We recently demon-
strated that progranulin acts as an autocrine growth factor and promotes cas-
tration-resistant prostate cancer cell motility, invasion and anchorage-indepen-
dent growth. Progranulin was also overexpressed in prostate cancer tissues vis-
à-vis non-neoplastic controls. Despite the strong connections with cancer,
progranulin’smode of action is not well understood. Furthermore, proteins that
regulate early stages of progranulin signaling have not been identifıed. Sortilin, a
transmembrane protein of the Vps10 family, binds progranulin and negatively
regulates progranulin action bypromoting progranulin uptake anddegradation.
Signifıcantly, castration-resistant DU145 and PC3 cells express very low sortilin
levels, which were associated with high progranulin production and enhanced
motility, suggesting that mechanisms regulating sortilin/progranulin levels may
contribute to prostate cancer progression. Methods: Progranulin-mediated
sortilin ubiquitination was assessed by transient ubiquitination assays in PC3
andDU145 cells either expressing or depleted of endogenous progranulin. Sorti-
lin stability was assessed by immunoblotting with or without protein synthesis
inhibitors and immunofluorescence microscopy with GFP-tagged sortilin. Pro-
granulin-dependent sortilin endocytosis and sorting for degradation were eval-
uated by confocal microscopy and colocalization with specifıc intracellular
markers. Results: Prolonged progranulin stimulation induced sortilin ubiquiti-
nation in PC3 and DU145 cells, which was associated with enhanced sortilin
internalization through a clathrin-dependent pathway. Upon progranulin stim-
ulation, sortilin was then sorted into early endosomes and subsequently targeted
for degradation in the lysosomal compartment as assessed by immunoblot and
IF experiments in the presence or absence of lysosomal inhibitors. Signifıcantly,
sortilin ubiquitination was signifıcantly inhibited in progranulin-depleted PC3
and DU145 cells, which showed enhanced sortilin stability when compared to
progranulin-expressing control cells. Conclusions: Our data demonstrate that
progranulin activates a feedback loop by inducing sortilin downregulation via
the lysosomal pathway. This novel regulatory mechanism would ensure the
maintenance of progranulin signaling in castration-resistant prostate cancer
cells by limiting sortilin-mediated progranulin uptake and degradation. Deci-
phering the cross-talk between sortilin and progranulin signaling could provide
avenues to design novel therapeutic strategies in prostate tumors.
#1345 Mutant IDH1 and tissue factor in gliomas.Dusten Unruh, Snezana
Mirkov, Charles D. James, Craig Horbinski. Northwestern University, Chicago,
IL.
Background: IDH1mutations (IDH1mut) occur in 20-30% of gliomas, induce
DNA hypermethylation, and are associated with a better prognosis than IDH1
wild-type (IDH1wt) gliomas, yet the basis for this remains unclear. Furthermore,
venous thromboemboli (VTE) are a serious complication in glioma patients,
and themechanism for this is also unclear.We recently discovered that IDH1mut
gliomas are much less likely to develop VTE compared to IDH1wt gliomas. Our
data suggests that suppression of Tissue Factor (TF), the primary initiator of
coagulation, is a key reason for this. TF also directly enhances tumormalignancy
via protease-activated receptor 2 (PAR2). In this study, we further explored the
signifıcance of TF on malignancy and thrombosis in IDH1wt and IDH1mut glio-
mas. Methods: Assays were performed using 6 patient derived glioma cells, 3
IDH1
wt
(GBM6, GBM12, GBM43) and 3 IDH1mut (TB09, BT142, GBM164).
DNA methylation was analyzed by Illumina Human 850K. TF procoagulant
activity (PCA) was determined by FXa generation, using preoperative glioma
patient arterial plasma, conditioned medium, or cells. In vivo models of cancer
induced thrombosiswere created via surgical stenosis of the inferior vena cava of
mice engrafted with IDH1wt or IDH1mut gliomas. In vitro markers of malig-
nancy were measured by BrdU incorporation for cell proliferation, serum gra-
dient Matrigel-coated transwell inserts for invasion, soft agar colony formation
for clonogenicity. Nude mice (N
6/group) were orthotopically transplanted
with IDH1wt glioma cells and monitored for growth using bioluminescence
imaging. Results: The TF gene, F3, was signifıcantly hypermethylated in
IDH1mut cells compared to IDH1wt cells, and IDH1mut glioma cells had lower
levels of TF protein and TF PCA compared to IDH1wt cells. Exogenous treat-
ment with the product of IDH1mut enzyme, D-2-hydroxyglutarate, directly sup-
pressed TF PCA by 38% in IDH1wt cells (P0.03), as did transgene IDH1mut
expression. Mice with IDH1mut glioma xenografts produced fewer and smaller
IVC thrombi than mice with IDH1wt xenografts (0.9	0.9 vs 10.3	3.6 mg,
P0.02). Patients whose gliomas contained IDH1mut had lower TF PCA com-
pared to IDH1wt (0.5	0.2 vs 1.2	0.2 pg/mL, P0.04), and there was a strong
link between levels of TF PCA and subsequent development of VTE (P0.03).
TF knockdown greatly reduced cell proliferation, invasion, and colony forma-
tion of IDH1wt cells. Likewise, the PAR2 antagonist, GB83, inhibited IDH1wt cell
proliferation by 54% (P0.001) and reduced cell invasion by 25% (P0.05). TF
knockdown also reduced in vivo growth of IDH1wt gliomas by 96% at 28 days
post engraftment (P0.03), and extended median survival of engrafted mice by
86% (P0.001). Conclusions: IDH1mut mediated suppression of TF expression
and PCAmay be a critical component of the less thrombogenic, and less malig-
nant, IDH1mut phenotype. Targeting TF-PAR2 signaling may therefore repre-
sent a novel therapeutic strategy to reduce IDH1wt glioma malignancy.
#1346 Pan-ERBB inhibitor blocks tumor growth and metastasis. Joyce A.
Schroeder,1 Sabrina Maisel,1 Derrick Broka2. 1University of Arizona, Tucson,
AZ; 2Arizona Cancer Therapeutics, Tucson, AZ.
The Epidermal Growth Factor Receptor family of transmembrane tyrosine
kinases (ErbB) is over-expressed, correlates with poor prognosis and negatively
correlates with disease free survival in many cancer types. EGFR, HER2 and
ErbB3 are known to be highly expressed and active, and have been targeted by
both kinase inhibitors and monoclonal antibodies, both with disappointing re-
sults. Importantly, though, these therapeutics only target either a single receptor
or the kinase domain alone. It is well known that these receptors function as
heterodimers, and blocking of a single receptor will only promote the hetero-
dimerization of the remaining familymembers. Furthermore, while the tyrosine
kinase activity of these receptors is well known, less appreciated are the kinase-
independent mechanisms by which they drive cancer progression. These in-
clude themodulation of calcium signaling andmitochondrial and nuclear trans-
location and activity as transcriptional co-factors. The highly conserved juxta-
membrane domain (JD) of the ErbB receptors regulates these kinase-
independent functions, as well as receptor homo- and hetero-dimerization.
Upon ligand binding, the JD forms anti-parallel dimers between the receptors,
resulting in receptor dimerization and intracellular traffıcking. These protein-
protein interactions result in cell growth, survival, migration and invasion.
We have previously shown that peptides mimicking this JD can act in a
dominant-negative fashion, promoting the formation of non-functional ErbB
dimers (consisting of EGFR, HER2 and ErbB3) that induce rapid, ErbB-depen-
dent cell death. Using Cell Penetrating Peptides synthesized in tandemwith the
JD, these peptides (called EJ1) rapidly cross the plasma membrane, bind the
ErbB receptors, and induce cell death in cell lines and PDX lines grown in
culture. Death results from a combination of apoptotic and necrotic mecha-
nisms, due to inactivation of mitochondrial function and calcium signaling (as
well as kinase inhibition). Although EJ1 peptides display rapid ErbB-dependent
cell death in vitro, they are rapidly cleared in vivo, limiting their effıcacy. To
stabilize in vivo activity, the active peptide (which is an alpha-helix) was stabi-
lized with hydrocarbon staples. Based on this, we hypothesized that SAH-EJ1
would be an effective targeted therapeutic for the treatment of ErbB-dependent
cancer. We therefore tested SAH-EJ1 in 3 different ErbB-dependent models of
cancer, including EGFRvIII-driven glioblastoma, a PDX model of basal-like
breast cancer with EGFR and ErbB3 amplifıcation, and a PDX model of lung
cancer with EGFR kinase domain mutations driven by Erlotinib treatment. In
each of these models, substantial inhibition of tumor growth was observed, as
well as extended survival.
#1347 In vivo effıcacy of eflapegrastim in ratswith chemotherapy-induced
neutropenia. Young Hoon Kim,1 InYoung Choi,1 Prasad Kolli,2 Guru Reddy2.
1Hanmi Pharmaceuticals, Seoul, Republic of Korea; 2Spectrum Pharmaceuticals,
Inc., Irvine, CA.
Introduction: Eflapegrastim (SPI-2012, HM10460A) is a novel, long-acting
recombinant human granulocyte colony-stimulating factor (rhG-CSF). Eflape-
grastim consists of an rhG-CSF conjugated to a recombinant E. coli derived Fc
fragment of IgG4 via a polyethylene glycol linker. Eflapegrastim is in clinical
development for the treatment of chemotherapy-induced neutropenia in cancer
patients. The purpose of this study was to evaluate and compare the effıcacy of
eflapegrastim, pegfılgrastim and fılgrastim in rats with chemotherapy-induced
neutropenia. Methods: Rats were treated with 50 mg/kg of cyclophosphamide
(CPA) intraperitoneally to induce neutropenia. Pegfılgrastim was administered
subcutaneously as a single dose of 100 g/kg on Day 1 and fılgrastim was ad-
ministered subcutaneously at a dose of 20 g/kg daily for fıve days on days 1 to
5. Eflapegrastim was administered subcutaneously as a single dose on day 1, at
doses ranging from 32 g /kg to 322 g/kg (or 8.8 g/kg to 88 g/kg as G-CSF
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equivalent). Blood samples were collected for 8 days after drug administration
for the measurement of neutrophil counts and the Duration of Severe Neutro-
penia (DSN). Results: The DSN in neutropenic rats treated with eflapegrastim
was compared with the DSN in neutropenic rats treated with pegfılgrastim or
fılgrastim. The DSN was 0.2 days when eflapegrastim was administered as a
single dose at 88g/kg (asG-CSF equivalent) 24 hours after administeringCPA.
In contrast, the DSN was 3.04 days with fılgrastim administered at a dose of 20
g/kg for 5 days from Day 1 to Day 5 and 2.8 days with pegfılgrastim adminis-
tered as a single dose of 100 g/kg 24 hours after administering CPA. At the
lowest eflapegrastim dose of 8.8 g/kg that was about 1/10 of G-CSF equivalent
dose for pegfılgrastim, theDSN in eflapegrastim treated rats was 2.94 days. Thus,
eflapegrastim was found to be more potent in shortening the DSN with a lower
G-CSF equivalent dose when compared to either pegfılgrastim or fılgrastim.
Conclusion: Eflapegrastimwas about 10 timesmore potent than pegfılgrastim at
G-CSF equivalent doses in this neutropenic rat model
#1348 GDC-0032, a p110 beta sparingPI3K inhibitor is highly effıcient on
PIK3CA-mutated and HER2-amplifıed breast cancer model. Pradip De,1
Yuliang Sun,1 Jennifer Carlson,1 Lori Friedman,2 Casey Williams,1 Nandini
Dey,1 Brian Leyland-Jones1. 1Avera Research Inst., Sioux Falls, SD; 2Genentech,
San Francisco, CA.
Background: HER2 amplifıcation/overexpression frequently co-occurs with
PI3K pathway activation in breast tumors. Mutations in PIK3CA are known to
be involved in a wide range of human cancers including HER2 breast cancer,
and mutant PIK3CA is thought to act as an oncogene. Here, we evaluate the
effıcacy of GDC0032, a p110 beta-sparing PI3K inhibitor against HER2 or
HER2/PIK3CAmutated breast cancer cells. MATERIALS ANDMETHODS:
Four HER2 breast cancer (BC) cell lines consisting of three activating (either
helical or kinase domain) PIK3CA mutation (HER2/ER and HER2/ER-)
were analyzed for proliferation, apoptosis, cell cycle and signaling pathway ac-
tivation assays. Preclinical effıcacy of GDC-0032 was also evaluated in vivo in a
mousemodel. RESULTS: 1) All HER2 andHER2/PIK3CAmutant cell lines
exhibited low IC50 values (ranging from 0.1 M-1.5 M) irrespective of ER-
positive or not. 2) GDC-0032 caused a strong differential growth inhibition in
both HER2 and HER2/ /PIK3CA mutated breast cancer cell lines when
compared to lines that were HER2- and PIK3CA wild type by 3D-ON-TOP
clonogenic assay. 3) Administration of GDC-0032 induced cell cycle G0/G1
arrest and resulted in increased apoptosis in a dose-dependentmanner. Further-
more, induction of apoptosis was more with GDC-0032 when combined with
RAD001. 4) GDC0032 also blocked expression of CYCLIN D1. 5) Investigation
of the signal transduction revealed that the treatment of GDC-0032 reduced the
level of p-AKT (Ser473 and Thr308), and p-S6 expression is indicating the
down-regulation of downstream signaling of PI3K and mTOR pathway. 6)
GDC-0032 was highly active at reducing established tumor growth in vivo in
BC mouse xenografts harboring PIK3CAmutation and HER2 amplifıcation.
CONCLUSION: Our in vitro or in vivo data showed that GDC-0032 was
highly effıcient either as a single agent as well as with RAD001 in HER2/
PIK3CA mutated breast cancer cell lines. Our data suggest that GDC-0032
represents a novel therapeutic option in patients harboring PIK3CA muta-
tions and/or HER2/neu gene amplifıcation in breast cancer.
#1349 NSAIDs: Multiple roles in multiple environments. Gloria M Calaf1
and Debasish Roy2. 1Instituto de Alta Investigación, Universidad de Tarapacá,
Arica, Chile; 2Department of Natural Sciences, Hostos College, The City Univer-
sity of New York, Bronx, NY.
Non steroidal drugs are mainly known for their activities and use as anti-
inflammatory, antipyretic compounds. But, in recent observations, they are
exposed to use as an effective alternative compounds to prevent or stimulate
different metabolic activities and help in preventing various neoplastic pro-
gression. They have specifıc role in controlling estrogen metabolism during
breast cancer progression. Sometimes, they are used as an apoptotic induction in
various cancers. Their role in hypoxia induced proliferation is also showing
promising results. Different NSAIDs will help to induce the activities of various
tumor suppressor genes. As chronic inflammation increases the risk for various
cancers, therefore, it is important to eliminate inflammation through anti-In-
flammatory compoundswhereNSAIDs are playing a vital role.Most of them are
acting to prevent inflammation either via selective or non-selective COX based
mechanism. The non-selective COX inhibitor sulindac and the COX-2 selective
inhibitor etodolac etc. have been shown to prevent the formation and cause
regression of adenomas in patients with familial polyposis. Unfortunately,
COX-1 and/or COX-2 inhibition and depletion of physiologically important
prostaglandins is associated with gastrointestinal, renal and cardiovascular tox-
icities that limit the use of NSAIDs and COX-2 inhibitors for cancer chemopre-
vention In this particular study, we are using various NSAIDs in a radiation-
induced estogren treated breast cancer model to establish their role in
differential expression of various cancer related genes selected from different
cell cycle pathwaysmicroarray. Selection of biomarkers from these altered genes
will help to develop a valid strategy for cancer prevention through precision
based molecular targeted therapy. Supported by Offıce of Academic Affairs,
Honors Program, COBI, Hostos-CUNY, NY, USA (DR) and Tarapacá Univer-
sity, Arica, Chile (GMC).
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#1350 Direct pharmacological targeting of Gq/11 in uvealmelanoma.Mi-
chael D. Onken, Carol M. Makepeace, Shiqi Wang, Kevin M. Kaltenbronn, S.
Michinobu Kanai, Tom J. Broekelmann, John A. Cooper, Kendall J. Blumer.
Washington Univ. School of Medicine, St. Louis, MO.
Uveal (eye) melanoma is a highly aggressive cancer, in which almost half of
patients develop distant metastases that are refractory to therapy. In particular,
metastatic uveal melanoma has been clinically unresponsive to the immuno-
therapeutic agents that have shown success in skin tumors, making the need for
novel therapeutic approaches to uveal melanoma all the more urgent. Unlike
skin melanomas, which are driven by BRAF and NRAS mutations, uveal mela-
nomas arise typically from mutations that result in constitutive activity of the
alpha subunit of the heterotrimeric G-protein, Gq, or its paralog G11. The prev-
alence of constitutively active Gq/11 in uveal melanoma suggests a dependence
of these tumors on Gq/11 activity that could be exploited therapeutically. To
address this hypothesis, we are using a potent, bioavailable small molecule that
binds to and inhibits Gq/11 to target constitutively active Gq/11 in uveal mela-
noma cells. This inhibitor functions by sequestering wild type or constitutively
active Gq/11 in an inactive state. We fırst used inositol phosphate accumulation
assays and confırmed inhibition of both wildtype and constitutively active
Gq/11 by the inhibitor in all uveal melanoma cells.We then assayed the affect of
Gq/11 inhibition on overall viability of uveal melanoma cells, and found that
uveal melanoma cells with mutant Gq/11 were highly sensitive to the small
molecule; whereas, uvealmelanoma cells with wildtype Gq/11 showed no loss of
viability, even at 1000-fold higher concentrations of inhibitor. In Gq-mutant
uveal melanoma cells, Gq/11 inhibition caused cell cycle arrest in G1, and dys-
regulation of several cell cycle regulatory pathways. Inhibitor treatment also
caused Gq/11-driven uveal melanoma cells to become more differentiated, as
indicated by increased pigmentation, elevated expression of melanin synthesis
and melanosome markers, changes in cell morphology and changes in melano-
cytic versus melanoma gene programs. None of these phenotypic changes were
seen in BRAF-driven uveal melanoma cells treated with the Gq/11 inhibitor,
demonstrating that the effects of this inhibitor were exquisitely dependent on
the constitutively active Gq/11 oncogene. These results establish that Gq/11 is a
druggable target in uveal melanoma cells, and show that Gq/11-mutant uveal
melanoma cells are exquisitely sensitive to inhibition by small molecule inhibi-
tors. We are currently transitioning these studies to animal models to establish
drug effıcacy and toxicity and explore treatment and delivery options.
#1351 Alternative splicing of neurofıbromin 1 is associated with elevated
MAPKactivity andpoor prognosis in glioma.Robert Siddaway,ArunRamani,
Man Yu, Michael Brudno, Cynthia Hawkins. The Hospital for Sick Children,
Toronto, Ontario, Canada.
High-grade gliomas (HGG) are invasive with poor prognosis regardless of
age: diffuse intrinsic pontine gliomas (DIPG), arising in the brainstem, are al-
most universally fatal and the leading cause of brain-tumor death in children;
while adult anaplastic astrocytoma and glioblastoma multiforme (GBM) have
median survivals of 1-3 years. The mutational spectra of adult and pediatric
HGG differ, with pediatric tumours containing recurrent mutations of H3F3A
andHIST1H3B. However, alterations leading to RAS/MAPK/PI3K pathway ac-
tivation, including PDGFRA amplifıcation, EGFRvIII, BRAF-V600E, NF1 dele-
tion, are frequently found, although not all tumours will have mutations in this
pathway. The neurofıbromin 1 (NF1) gene negatively regulates RAS signalling
by stimulating RAS-GTP turnover, thereby leading to RAS-inactivation. The
two major isoforms, NF1-I and NF1-II, differ only by inclusion of the 21 aa
exon23a in the GAP-related domain of NF1-II. Exon23a-inclusion has been
shown to render NF1 10 times less active towards RAS, leading to elevated
MAPK signalling. The brain expresses predominantly NF1-I, while the major
isoform elsewhere is NF1-II. Here we used RNA-Seq to identify genes alterna-
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tively spliced between DIPG and normal brain, identifying an isoform switch
from NF1-I in normal brain to NF1-II; we additionally found the same isoform
switch in the TCGA adult GBM and LGG cohorts. For both GBM and LGG,
RAS/MAPK/PI3K wild-type tumors with elevated NF1-II conferred signifı-
cantly reduced patient survival compared to RAS/MAPK/PI3Kmutant tumors.
NF1-exon23a inclusion is known to be repressed in cell model systems by the
CELF and ELAV-like families of splice regulators. We further show that mem-
bers of these gene families are downregulated in HGG. Together, our results
indicate a novel mechanism by which gliomas can activate signaling down-
stream from RAS independent of mutations and tumor grade, which promotes
tumorigenesis by regulating pathways such as proliferation and invasion.
#1352 The importance of the RASA1/R-Ras/Ral-A signaling axis in mel-
anoma tumorigenesis.Kristen SuzanneHill, XueWang, Youngchul Kim,Min-
jung Kim.Moffıtt Cancer Ctr., Tampa, FL.
The Ras family of small GTP binding proteins are frequently activated by
mutations in melanoma, as shown for NRAS (20%), KRAS (2%) and HRAS
(1%). Ras isoforms can also be activated by inactivation of RasGTPase activating
proteins (RasGAPs), such as NF1, RASA1, and RASA2. In our recent study, we
observed that inactivation of RASA1 (RAS p21 protein activator 1, also called
p120RasGAP) suppressed melanoma via its RasGAP activity toward the R-Ras
(related RAS viral (r-ras) oncogene homolog) isoform and that R-Ras was re-
quired to promote anchorage-independent growth driven by RASA1 inactiva-
tion. Moreover, a low level of RASA1 mRNA expression is associated with de-
creased overall survival in melanoma patients with BRAF mutations. Based on
these observations, we hypothesized that, although not mutated, R-Ras is acti-
vated in melanoma by inactivation of RasGAPs and that BRAF activation coop-
erates with this RasGAP/R-Ras pathway activation inmelanoma tumorigenesis.
In this study, we addressed the importance of R-Ras, a previously less appreci-
ated member of the Ras small GTPases family, in melanoma tumorigenesis. We
observed frequent activation of R-Ras in BRAF mutant human melanoma cell
lines. In addition, RNAi-mediated reduced expression of R-Ras suppressed an-
chorage-independent colony growth and tumor growth.Moreover, among the 3
major RAS effector pathways, reduced R-Ras expression suppressed Ral-A acti-
vation, which may explain the mechanism of Ral-A activation in BRAF mutant
melanoma. Interestingly, anchorage-independent growth driven by R-Ras acti-
vation downstream of RASA1 inactivation was suppressed by both genetic
(siRNA targeting Ral-A) and pharmacological (Ral inhibitor BQU57) inhibition
of Ral-A. To further investigate the impact of RASA1 loss, and thus R-Ras acti-
vation, on BRAF mutant melanoma development in vivo, we generated a
RASA1L/L; BRAFCA/CA; Tyr-CreERT2 mouse model in which treatment with
4OHT results in expression of constitutively activated mutant BRAF and dele-
tion of RASA1 in melanocytic lineage cells. Preliminary analysis shows hyper-
pigmentation of the ear, tail, and foot pad in RASA1L/L BRAFCA/CA mice com-
pared to RASA1/ BRAFCA/CA littermates. Tumors generated in this animal
model will be analyzed to determine the extent of R-Ras and Ral-A activity in
vivo. This study demonstrates the importance of the RASA1/R-Ras/Ral-A sig-
naling pathway in BRAFmutantmelanoma and supports the possible combina-
torial treatment strategy targeting both the BRAF/MAPK and Ral signaling
pathways.
#1353 Polyisoprenylated cysteinyl amide inhibitors disrupt actin cyto-
skeleton organization, induce cell rounding, and block invasion of NSCLC.
Elizabeth Ntantie, Jerrine Fletcher, Felix Amissah, Olufısayo O. Salako, Augus-
tine T. Nkembo, Rosemary A. Poku, Nazarius S. Lamango. Florida A&M Uni-
versity, Tallahassee, FL.
Non-small Cell Lung Cancer (NSCLC) malignancy is dependent on cellular
processes that promote metastasis. F-actin organization is central to cell migra-
tion, invasion, adhesion and angiogenesis which are all processes involved in
metastasis. F-actin remodeling is enhanced by the overexpression and/or hyper-
activation of some members of the Rho family of small GTPases. Therefore
agents that mitigate hyperactive Rho proteins may be clinically relevant for
controlling metastasis. We previously reported the synthesis and characteriza-
tion of polyisoprenylated cysteinyl amide inhibitors (PCAIs) as potential inhib-
itors of the cancer phenotype. In this report, we investigate the potential role of
PCAIs against NSCLC malignancy and show that as low as 0.5 M PCAIs sig-
nifıcantly inhibit 2D and 3DNCI-H1299 cellmigration by 48% and 45%, respec-
tively. PCAIs at 1 M inhibited 2D and 3D NCI-H1299 cell invasion through
Matrigel by 50% and 85%, respectively. Additionally, exposure to 5 M of the
PCAIs, NSL-BA-040 caused a 38% drop in F-actin intensity at the cell mem-
brane 24 h post treatment. Importantly, this drop in F-actinwas accompanied by
a 73% reduction in the number of fılopodia per cell. Interestingly, the polyiso-
prenyl group of the PCAIs is essential for these effects, as NSL-100, an analog
that lacks the farnesyl moiety, does not elicit similar effects on F-actin assembly
and organization. Put together, our fındings indicate that PCAIs disrupt F-actin
assembly and organization to suppress cell motility and invasion and point
towards a potential role of PCAIs as effective therapies for NSCLC metastasis
and invasion.
#1354 The role of RALA in soft tissue sarcoma tumor growth and metas-
tasis. Steven T. Sizemore,1 Gina M. Sizemore,1 Reena Shakya,1 Peter Amaya,1
Anisha M. Hammer,1 Alexander H. Rice,2 Jeffrey J. Chalmers,1 Michael C. Os-
trowski,1 Arnab Chakravarti1. 1The Ohio State University, Columbus, OH;
2Denison University, Granville, OH.
Soft tissue sarcomas (STS) are a diverse collection of cancers of mesenchymal
origin arising from the connective and supportive tissues of the body. While
localized STS arewellmanaged by surgery and radiation;metastasis, particularly
to the lung, is frequent. More than 30% of adult STS patients develop lung
metastases and the 5-year survival for these patients is a dismal 16%. Treatment
options for metastatic STS are limited, thus there is an urgent unmet need for a
better understanding of the keymolecular pathways that drivemetastatic spread
in STS and identifıcation of inhibitors of these pathways for clinical application.
Through analysis of gene expression data from metastatic STS patient samples,
we identifıed decreased expression of PPP2R1B as a hallmark of metastatic STS.
To directly test its function as a suppressor of tumor growth and metastasis in
STS, PPP2R1B was stably over-expressed in HT1080 cells, a model of metastatic
STS. PPP2R1B expression almost completely abolished HT1080 tumor growth
in nude mice. PPP2R1B is a subunit of the PP2A protein phosphatase complex
that negatively regulates numerous cancer signaling pathways. However, the
functional consequences of decreased PPP2R1B expression in STS are un-
known. A combination of high-throughput and targeted approaches were uti-
lized to identify 37 phosphoproteins that are signifıcantly dephosphorylated
following PPP2R1B expression in HT1080 cells. One of these phosphoproteins,
the small GTPase RALA, exhibited decreased phosphorylation on Ser194 fol-
lowing PPP2R1B expression. RALA is signifıcantly prognostic of STSmetastasis
and is elevated in more aggressive STS subtypes relative to less aggressive sub-
types and normal tissue. RALA knockdown in HT1080 signifıcantly slowed
tumor growth and decreased the incidence of pulmonary metastasis, mirroring
PPP2R1B overexpression. Importantly, RALA is an actionable therapeutic tar-
get for improved treatment of STS. Aurora A inhibitors indirectly inhibit RALA
function by preventing RALA Ser194 phosphorylation by aurora A. We found
that RALA expression and activity predicted response of STS cell lines to aurora
A inhibition. Excitingly, the aurora A inhibitor alisertib nearly eradicated
growth of HT1080 tumors in vivo. Exploration of the biological mechanisms
through which RALA regulates STSmetastasis identifıed regulation of vesicular
traffıc as a likely critical function of RALA in this process. These fındings identify
PPP2R1B, RALA, and aurora A as members of a key molecular pathway that
drives STS progression and advocate the use of treatments targeting this path-
way to improve outcome for STS patients with advanced disease.
#1355 Linking AP/MS-derived protein-protein interaction networks and
pairwise sgRNA screens defınes new KRAS effectors in non-small cell lung
cancer.Marcus R. Kelly. Stanford University, Stanford, CA.
The KRAS oncogene ismutated in over one fourth of human cancers. Despite
decades of work studying known effector pathways, no drugs in clinical use
specifıcally target KRAS-mutant tumors. Uncharacterized feedback mecha-
nisms and parallel pathways have stymied the treatment of KRAS-mutant tu-
mors in patients, and theKRas protein does not easily accommodate the binding
of inhibitory small molecules. These challenges demand better characterization
of the physical and genetic relationships between Ras regulators and effectors.
To that end, we used tandem affınity purifıcation of Kras, Hras and Nras and
twelve proteins with known regulatory or effector roles to generate a high-con-
fıdence protein-protein interaction (PPI). Interactions were cross-referenced
with public PPI, genetic susceptibility, and patient data to assemble a physical
PPImap annotatedwith important functional determinants. The fınalmap con-
tains 287 genes and 990 physical interactions among them. Thismapwas used to
construct a library of1000 sgRNAs covering100 genes of probable relevance
to the Ras pathway. This library was screened for pairwise genetic effects in a
dual sgRNA vector system to identify quantitative changes in the growth of the
A549 NSCLC line. We will present the quantitative results of this screen and
additional validation studies on several previously undescribed regulators and
effectors of the Ras proteins. In particular, we highlight unknown interactions
between KRAS and the cell adhesion regulator RADIL, and the specifıcity of
Ras-family protein interaction with the Raf and Ral GEF family proteins. These
data underscore the limitations of our current understanding of Kras-driven
cancers and reveal their genetic vulnerabilities.
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#1356 Variable drug responses characterize the functional heterogeneity
of Nf1 null tumors. Daniela Pucciarelli, Ganesh Krishnamurthi, Steve Braun-
stein, Jean L. Nakamura. UCSF, San Francisco, CA.
Introduction: Neurofıbromatosis type 1 (NF1) is a autosomal dominant dis-
ease with a predisposition to cancer. Biallelic inactivation of the NF1 gene in-
creases risk of developing brain tumors, leukemia, neurofıbromas and malig-
nant peripheral nerve sheath tumors (MPNSTs). Somatic mutations in the NF1
gene are also associated with sporadic malignancies including glioblastoma,
neuroblastoma, and melanoma. The NF1 tumor suppressor gene encodes the
RAS GTPase-activating protein (GAP) neurofıbromin. Loss of NF1 results hy-
peractivation of Ras, MAPK and PI3K signaling pathways components, repre-
senting potential therapeutic targets. However, the variable response of NF1
mutant tumors to MAPK andmTOR inhibitors suggests the intrinsic heteroge-
neity of NF1 mutant tumors. We hypothesized that defıning alternative mech-
anisms and functional sub-classes of Nf1-mutant tumors on the basis of their
variable drug sensitivity will produce pre-clinical therapeutics data that will
inform clinical trials. Methods: We previously generated mouse models in
whichwemutagenizedNf1 heterozygousmicewith radiation, recapitulating the
susceptibility of patients with NF1 to radiation-induced cancers. These models
produced solid tumors such as mammary carcinomas, squamous cell carcino-
mas, and soft tissue sarcomas, which we determined to be Nf1 null. Cell lines
established from these tumors were characterized by a drug sensitivity screen
using a custom 94 compound drug library. Drug responses indicate that Nf1
mutant tumor cell lines organize into functional groups sharing similar drug
sensitivities. Six candidate drugs each targeting distinct components of MAPK
and PI3K signaling pathways were selected from the drug library. After 24 hours
of exposure to each inhibitor or control, cells were analyzed for cell proliferation,
cell cycle changes, and cell death.Western blottingwere performed to determine
whether drug exposures produce alterations in their predicted biochemical
pathways such as PI3K/Akt, and MAPK pathways. Results: Nf1 loss did not
predict uniform sensitivity of cell lines to treatment with MAPK and mTOR
inhibitors. Each compound induced differential effects on viability of Nf1 null
tumors cell lines. High variability and cell line-dependent cytotoxic and cyto-
static effects were also observed. Although phosphorylated Akt(S473), S6, and
p44/42MAPK varied widely among all untreated Nf1 null cell lines, this did not
predict their drug sensitivity. In vitro drug sensitivity data indicates heteroge-
neous differential sensitivities of Nf1 mutant tumor cells to different drug
classes, independent of tumor histology, permitting segregation into functional
groups. Conclusion: Tumor cell lines driven by Nf1 loss demonstrate heteroge-
neous responses to Ras pathway inhibition, which may be explained by mecha-
nisms of tumor formation after Nf1 loss involve multiple alternative pathways.
#1357 The small GTPase Arf6 potentiates melanoma metastasis by acti-
vating Akt. Lehi Acosta,1 Aaron Rogers,1 Jae H. Yoo,1 Shannon J. Odelberg,1
Dean Y. Li,1 Sheri Holmen,2 Allie H. Grossmann1. 1University of Utah, Salt Lake
City, UT; 2Hunstman Cancer Institute, Salt Lake City, UT.
Arf6 is amember of the Ras-superfamily of small GTPases and controlsmem-
brane traffıcking and cytoskeletal remodeling, functioning mainly in endocyto-
sis pathways at the cell periphery. Arf6 is activated by various extracellular sig-
nals and oncogenic events and has been shown to promote cell migration and
pro-invasive phenotype in human cancer cells. Small molecule inhibition of
ARF6 reduces spontaneousmetastasis in xenograft models of human cutaneous
melanoma, suggesting that ARF6 is necessary for disease progression. Using a
genetically-engineered mouse model of BRAF-mutant melanoma, we deter-
mined whether activation of Arf6 is suffıcient to induce spontaneous metastasis
in vivo. Formelanocyte-specifıc primary tumor induction, Cre recombinasewas
delivered via local injection of RCAS virus into DCT-TVA;Cdkn2alox/lox;
BRAFV600E mice. In the experimental mice, a constitutively active mutant form
of Arf6 (Q67L) was virally delivered with Cre. In this study, we observed a
signifıcant increase in spontaneous metastatic disease burden in Arf6 Q67L
mice. Likewise, tail vein injection of melanoma cell lines derived from Arf6
Q67L tumors consistently show a diffuse pattern of pulmonary metastasis com-
pared to controls that show rare, microscopic metastasis. Recently, it has been
demonstrated that activation of Akt, but not Pten loss, leads to an aggressive
phenotype in melanoma that includes the acquisition of brain metastases. Im-
munohistochemical analysis of phospho-Akt revealed that Arf6 Q67L is suffı-
cient to induceAkt activation in tumors. In addition, ARF6 is necessary for AKT
activation in human melanoma lines. We did not observe brain metastasis in
DCT-TVA;Cdkn2alox/lox;BRAFV600EArf6 Q67L mice. When we added Pten-
lox/lox allele to this genetic background, however, we observedmicroscopic brain
metastases at a low frequency, suggesting that the combination of Pten loss and
Arf6 activation reaches a threshold level of Akt activation that is suffıcient to
cause brain metastasis. Taken together our data indicate that activation of Arf6
is suffıcient to potentiate melanoma metastasis, consistent with the proinvasive
cellular phenotype attributed to Arf6. In addition, our data suggests a novel
signaling mechanism by which Arf6, a small GTPase involved in traffıcking, is
somehow involved in Akt activation and that this step may be important for the
acquisition of metastatic capacity.
#1358 p21 activated kinase 4 (pak4) as a novel therapeutic target for non-
hodgkin’s lymphoma. Asfar S. Azmi,1 Amro Aboukameel,1 Irfana Muqbil,1
Yiwei Li,1 William Senapedis,2 Erkan Baloglu,2 Yosef Landesman,2 Michael
Kauffman,2 Sharon Shacham,2 Ayad Al-Katib,1 Ramzi M. Mohammad1.
1Wayne State Univ., Detroit, MI; 2Karyopharm Therapeutics, Newton, MA.
Objective: The p21-activated kinase 4 (PAK4) is a key downstream effector of
the Rho GTPase family and is over-expressed in many different cancer types.
PAK4 protein, by virtue of its ability to engage multiple ligands, regulates a
repertoire of signaling pathways. A survey of non-Hodgkin’s lymphoma (NHL)
cell lines shows that there is increase in PAK4mRNA and/or protein expression
when compared to normal peripheral lymphocytes (PBL). Considering PAK4
RNA interference suppresses lymphoma cell proliferation, these fındings point
to a novel role for PAK4 in promoting NHL cell growth. To this end we exam-
ined the impact of the newly developed PAK4 allosteric modulators (PAMs) on
NHL proliferation both in vitro and in vivo. Methods:WSU-FSCCL (represent-
ing follicular small cell cleaved lymphoma) and WSU-DLCL2 (diffused large
B-cell lymphoma) were exposed to increasing concentrations of different PAM
analogs (KPT-7523, KPT-7189, KPT-9037, KPT-9274, or KPT-7010 [inactive])
or the Pan-PAK inhibitor, PF-3758309, in the presence or absence of CHOP
(used at IC25) for 72 hrs. Following combination treatment viability was evalu-
ated using TrypanBlue, apoptosis was analyzed using 7AAD, tetrachrome stain-
ing, Annexin V FITC and cell cycle arrest was accessed by flow cytometry. Pro-
tein and mRNA expression changes were evaluated using immunoblotting and
RT-PCR. The toxicity and effıcacy of PAMs were evaluated in sub-cutaneous
and disseminated xenograft models of NHL. Results: As single agents, PAMs
show anti-proliferative activity in vitro against NHL cell lines (IC50s for: WSU-
FSCCL 50 nMandWSU-DLCL2 250 nM)while sparing normal PBL (IC50s
in M range). There was a statistically signifıcant dose-dependent difference in
apoptosis induction in NHL cell lines treated with PAMs when compared to
vehicle control. PAMs reduced total p-PAK4 and downstream signaling pro-
teins involved in proliferation and apoptosis. In R-CHOP combination studies
we observed enhanced viability suppression, increased apoptosis, and concur-
rent down-regulation of PAK4 signaling pathway proteins when compared to
any single agent alone. The clinical compound, KPT-9274, is well tolerated and
showed remarkable anti-tumor activity in WSU-DLCL2 sub-cutaneous xeno-
graft inmice (p 0.01 at 140mg/kg/bid for 4weekswith no loss in bodyweight).
Residual tumors analysis showed suppression of PAK4 signaling pathways. Sin-
gle agent and R-CHOP combination effıcacy is currently being evaluated in
subcutaneous and systemic WSU-FSCCL and in primary patient derived xeno-
grafts inmice. Conclusions: This is the fırst study demonstrating a role for PAK4
in diffused largeB-cell and follicular small cell cleavedNHL.Our data shows that
inhibition of PAK4 could become a viable therapy for NHL either alone or in
combination with R-CHOP. Our data is directly applicable to the current Phase
1 trial of KPT-9274 in patients with advanced solid malignancies or NHL.
#1359 How does RAC1 GTP-ase signal Wnt-beta-catenin pathway-medi-
ated integrin-directed metastasis-associated tumor cell phenotypes in
TNBC. Nandini Dey, Jennifer H. Carlson, Casey Williams, Tyler Jepperson,
Pradip De, Brian Leyland-Jones. Avera Research Inst., Sioux Falls, SD.
Introduction: We reported that Wnt Pathway (WP) upregulation, one of the
salient genetic features of metastatic TNBC, controls the acquisition of integrin-
directed metastasis-associated (ID-MA) phenotypes of TNBC cells (Dey et al.,
2013). RAC-GTPases, small G-proteins which transduce signals from cell sur-
face proteins including integrins, have been implicated in tumorigenesis and
metastasis by their role in essential cellular functions likemotility. Aim:Here we
tested the role of the mechanism of involvement of RAC1 in the regulation of
WP-mediated ID-MAphenotypes in TNBC cells and examined howWP signals
are transduced via RAC1 in the context of ID-MA phenotypes in TNBC. Meth-
od: Oncoprints showed that the major alterations of RAC1 gene in TNBC were
constituted by the amplifıcation/gain of the gene. The collective percentage of
alteration(s) in RAC1 in ERve BC was 35% as compared to 57% in ER-ve BC
(brca/tcga/pub2015). Using pharmacological agents (sulindac sulfıde), genetic
tools (siRNA), WP modulators (Wnt-C59, XAV939), RAC1 inhibitors
(NSC23766,W56) andWP stimulations (LWnt3ACM,Wnt3A recombinant) in
a panel of 6-7 TNBC cell lines, we studied fıbronectin-directed migration and
variousmotility parameters (actin dynamics, fılopodia and lamellipodia by con-
focal microscopy) in the context of fıbronectin-directed RAC1 and Cdc42 acti-
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vation. Result: Breaking down by molecular subtypes of BC, RAC1 gene altera-
tions are observed in 20% in PAM50 Luminal A, 35% in PAM50 Luminal B, 37%
in PAM50 HER2 enriched and 40% in PAM50 Basal-like. For the samples set of
TCGA,Cell 2015, RAC1 genewas altered in 42% total while it was altered 37% in
PAM50 Luminal A, 57% in PAM50 Luminal B, 55% in PAM50 HER2 enriched
and 60% in PAM50 basal-like. An attenuation of WP, which (a) decreased cel-
lular levels of beta-catenin, as well as its nuclear active-form, (b) decreased fı-
bronectin-induced migration, (c) altered actin dynamics and (d) decreased po-
dia-parameters was successful in blocking fıbronectin-mediated RAC1/Cdc42
activity. Both Wnt-antagonists and RAC1 inhibitors blocked fıbronectin-in-
duced RAC1 activation and inhibited the fıbronectin-induced ID-MA pheno-
types following specifıc WP stimulation. To test a direct involvement of RAC1-
activation inWP-mediated ID-MA phenotypes, we stimulated brain-metastasis
specifıc MDA-MB231BR cells with LWnt3ACM. LWnt3ACM-stimulated fı-
bronectin-directed migration was blocked by RAC1 inhibition in MDA-
MB231BR cells. In the light of our previous report (De et al., 2016) that WP
upregulation stimulates ID-MA phenotypes in TNBC tumor cells, here we pro-
vide the fırst mechanism based evidence to demonstrate that WP upregulation
signals ID-MA tumor cell phenotypes in an RAC1-GTPase dependent manner
involving exchange-factors like TIAM1 and VAV2.
#1360 Novel function of p21-activated kinase 3 (PAK3) in regulating Akt
phosphorylation and pancreatic cancer stem cell phenotypes.Hsing-YuWu,1
Ming-Chen Yang,2 Po-Chen Chu,1 Samuel K. Kulp,2 Ching-Shih Chen1. 1Aca-
demia Sinica, Taipei, Taiwan; 2The Ohio State University, Columbus, OH.
p21-activated kinases (PAKs) are important effectors of the Rho family GT-
Pases and has been implicated in cytoskelestal remodeling, cell proliferation,
apoptosis, and transformation. Based on the sequence, structure homology, and
activation mechanism, six PAKs are classifıed into two groups, PAK 1-3 (group
I) and PAK 4-6 (group II). PAK kinases are frequently overexpressed in various
human tumors and represent therapeutically relevant targets for cancer treat-
ments. Previous studies have shown that PAK1 and PAK4 are upregulated
and/or hyperactivated in pancreatic cancer, and promotes pancreatic cancer cell
motility and invasion. In our study, we showed that knockdown of PAK3, but
not that of PAK1 or PAK2, inhibited pancreatic cancer cell proliferation in vitro,
and tumor growth in vivo. In addition, our data showed that PAK3 regulated the
protein stability of -catenin via Akt/GSK-3 signaling pathway in pancreatic
cancer cells. The role of PAK3 in regulating Akt/GSK-3 phosphorylation was
further confırmed by the ectopic expression of wild-type versus kinase-dead
(K297L) PAK3. Equally important, the mammosphere formation, aldehyde de-
hydrogenase (ALDH) activity and cancer stem cell-associated markers, were
also down-regulated in PAK3 knockdown cells, suggesting the involvement of
PAK3 in regulating cancer stem cell-like properties in pancreatic cancer cells.
Together, these fındings suggested that PAK3 as a primary regulator of Akt/
GSK-3/-catenin signaling for maintaining cancer stem cell phenotypes and
promoting tumor growth, which underlies the potential of targeting PAK3 in
fostering new therapeutic strategies for pancreatic cancer.
#1361 Characterization of TpeL, a RAS specifıc clostridial toxin.Maria T.
Abreu-Blanco. Cancer Research Technology Program, Leidos Biomedical Re-
search, Inc, Frederick, MD.
Clostridium perfringes lethal toxin (TpeL) belongs to the family of large clos-
tridial glycosylating cytotoxins. Clostridial toxins are glycosyltransferases that
modify and deactivate small GTPases of the RHO and RAS subfamily. TpeL
mono-glycosylates in the switch I domain (Thr35) of RAC and RAS small GT-
Pases. Glycosylation of RAS at Thr35 prevents binding to the primary effector,
RAF kinase and results in a blockade RAS signal transduction. RAS family pro-
teins function as key regulators of cell proliferation, differentiation, survival and
gene expression. Moreover, mutations in RAS proteins are highly prevalent in
human cancers. Considering the specifıcity of TpeL for RAS, we decided to
investigate the biochemical interaction between TpeL and RAS, and potentially
develop tools to disrupt the RAS signaling pathway. In order to assess the effect
of TpeL in vivo, we use RAS-dependent MEFs expressing different KRAS mu-
tations and BRAF V600E. We expect that proliferation should be inhibited in
MEF cells expressing RAS isoforms, but MEF cells expressing BRAF V600E
should not be affected by any toxin.We found that TpeL treatment did not affect
the viability of the BRAF V600E cells and only induced toxicity in RAS express-
ing cells. Consistent with this result, TpeL treatment inhibited MAPK signal
transduction in the RAS expressing cells, but not in the BRAF V600E cells.
Surprisingly, both cell viability as well as pERK levels remained unaffected in the
KRAS Q61R MEF cells treated with TpeL, suggesting that KRAS Q61R is resis-
tant to glycosylation. This may be due in part to the relatively slow intrinsic rate
of GTP hydrolysis and very high levels of KRAS-GTP in KRAS Q61R cells. We
also developed and adapted biochemical assays to study TpeL-KRAS interaction
in vitro. Based on Alpha Assay and UDPGlow, TpeL activity does not appear to
be nucleotide specifıc, in contrast to previously reported fındings. We are cur-
rently testing if TpeL RAS glycosylation is competitive with or is inhibited by
other molecules that bind to switch I, such as the RBD domain of RAF1 or
GEF/GAP proteins. These data may indicate that the lack of activity in KRAS
Q61R expressing MEF cells is due not to the high levels of RAS-GTP, but to the
constitutive binding to effector molecules, which prevent TpeL from accessing
KRAS. We also hope to identify the critical residues required for TpeL binding
and catalysis. By elucidating the mechanism of substrate binding and substrate
specifıcity we may gain insight into novel binding pockets that could be ex-
ploited therapeutically.
#1362 Argonaute 2 controls RAS activation in mouse embryonic fıbro-
blasts. Ronald F. Siebenaler, Sunita Shankar, Vijaya L. Dommeti, Malay Mody,
Arul Chinnaiyan. University of Michigan Medical School, Ann Arbor, MI.
The RAS gene family is among the most commonly mutated genes within
cancer, and while much research has elucidated the major downstream path-
ways, including MAPK and PI3K, little progress has been made in successfully
targeting mutant RAS in cancer. We recently identifıed an interaction between
the N terminal domain of Argonaute 2 (AGO2), a core component of RNA-
induced silencing complex (RISC), and the Switch II domain of KRAS. Further-
more, this interaction was found in all cell lines tested, expressing either wild-
type (WT) or mutant KRAS. We found that stable knockdown of AGO2 in
KRAS dependent cell lines lead to a decrease in KRAS protein expression with a
subsequent decrease in cellular proliferation. Conversely, the overexpression of
AGO2 in these cells lead to both an increase in KRAS expression and oncogen-
esis. In addition, this interaction inhibits the RNAi function of AGO2 by pre-
ventingmicroRNA unwinding in the presence of oncogenic KRAS compared to
WT-KRAS. Despite a clear association between mutant KRAS and AGO2 me-
diating increased KRAS mediated oncogenesis, the precise function of this in-
teraction remains unclear in normal physiology. In order to better assess the
endogenous function of the KRAS-AGO2 interaction, we analyzed two mouse
embryonic fıbroblast cell lines (NIH 3T3 and MEF) with complete knockout of
AGO2. Utilizing a Raf-1 RAS binding domain (RBD) pulldown method, we
assessed activated WT-RAS levels in AGO2 null NIH 3T3 and MEF cells. We
found that knockout of AGO2 lead to an increase in WT RAS-GTP activation
compared to normal control cells. Immunoblot analysis also indicates that
AGO2null fıbroblasts lead to increase inRASdownstream signaling through the
MAPK/ERK and PI3K/AKT pathways. Furthermore, rescue of AGO2 knockout
using full lengthmouseAGO2decreasedwild type RAS activation and its down-
stream signaling. Taken together, these observations suggest that the AGO2
interactionmay suppressWT-KRAS activation, leading tomaintenance of RAS-
GDP levels. Using RNA-seq, proteome and microRNA analysis, we have begun
to identify the pathways that may be involved in RAS activation in AGO2 null
cells. Early analyses indicate that AGO2 controls WT-KRAS levels and activity
throughmultiple mechanisms, laying the foundation for a better understanding
of the RAS-AGO2 interaction in normal physiology.
#1363 RSK2 provokes invasive signaling in glioblastoma through LARG-
dependent activation of Rho GTPases. Geng-Xian Shi,1 Ling Jin,1 Michelle L.
Matter,1 Santosh Kesari,2 Joe W. Ramos1. 1Univ. of Hawaii Cancer Ctr., Hono-
lulu, HI; 2John Wayne Cancer INstitute, Honolulu, HI.
Malignant gliomas are one of the most aggressive and deadly forms of cancer
and can affect any age group. In glioblastomamultiforme (GBM), infıltration of
primary tumor cells into the normal tissue and dispersal throughout the brain is
a central challenge to successful treatment that remains unmet. Patients with
malignant gliomas respond poorly to the standard therapeutic regimen of radio-
therapy and chemotherapy that follow tumor resection and have only a 16-
month median survival. It is therefore imperative to identify new approaches to
specifıcally attack GBM cell survival, proliferation and invasion. The cellular
mechanisms driving GBM-mediated migration and invasion are not fully un-
derstood. RSK2 (p90 ribosomal S6 kinase 2) is a kinase that regulates prolifera-
tion and adhesion and can promote metastasis. We fınd that RSK2 is signifı-
cantly upregulated in vivo in human GBM patient tumors, and that high RSK2
expression signifıcantly correlates with advanced tumor stage and poor patient
survival. We demonstrate that active RSK2 regulates GBM adhesion and is es-
sential for cell motility and invasion of patient-derived GBM neurospheres.
Importantly, inhibition of RSK2 by either RSK inhibitors or shRNA silencing
impairs invasion and combining RSK2 inhibitors with temozolomide improves
effıcacy in vitro. We further show that the effects of RSK2 on GBM invasion are
mediated in part through activation of RhoGTPases. Rho family of GTPases are
key regulators of cell polarity, migration and invasion. Here, we identify Rho A,
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B andC as downstream effectors of (RSK2) inGBMcell migration and invasion.
Here, we identifıed a unique signaling pathway in which RSK2 confers invasive-
ness through leukemia-associatedRhoGEF (LARG)-dependent RhoGTPase ac-
tivation. RSK2 directly interacts with LARG and nucleotide-bound Rho iso-
forms, but not Rac1 and Cdc42. Our data support a fundamental importance of
residue of Thr577 to the invasive signaling of RSK2. The invasive signaling of
RSK2 appears to depend on RhoA and B, but not RhoC. RSK2 activates RhoA
through activation of LARGby phosphorylation at Ser1288. Intriguingly, LARG
activity is only required for RSK2-T577E, but not RSK2-Y707A-mediated RhoA
activation and cell invasion. This further supports a pivotal role of Thr577 in
invasive RSK2 signaling. These results establish a unique RSK2-dependent
LARG-Rho signaling cascade as an uncompensated factor key to GBM cell mi-
gration and invasion. Together, our data provide strong evidence that RSK in-
hibitors could enhance the effectiveness of existingGBMtreatment, and support
RSK2 targeting as a promising approach for novel GBM therapy.
#1364 Direct phosphorylation and attenuation of the DLC1 tumor sup-
pressor by SRC kinase: a new mechanism of SRC-dependent activation of
Rho with translational implications. Brajendra K. Tripathi,1 Xiaolan Qian,1
Ming Zhou,2 DunruiWang,1 Marian Durkin,1 Alex G. Papageorge,1 Douglas R.
Lowy1. 1National Institutes of Health, Bethesda, MD; 2National Cancer Institute,
Frederick National Laboratory for Cancer Research, Frederick, MD.
Many tumors have high SRC activity and constitutive up-regulation of Rho-
GTP, which is frequently implicated in the neoplastic process and tumor pro-
gression to metastasis, but the mechanistic link is unclear. Here we identify the
DLC1 tumor suppressor, which encodes a RhoGAP, as a previously unrecog-
nized direct target of the SRC kinase, in untransformed cells and in tumor-
derived cell lines, which upregulates Rho-GTP. SRC kinase directly phosphor-
ylates two Tyrosines in DLC1: Y451 and Y701. SRC phosphorylation of DLC1-
Y701, which is located in the DLC1 RhoGAP domain, attenuates its RhoGAP
activity and tumor suppressor function by inhibiting the binding of active Rho-
GTP to the RhoGAP domain, reducing the hydrolysis of active Rho-GTP to
inactive Rho-GDP and resulting in an increase in Rho-GTP. The role of SRC
phosphorylation of DLC1-Y451 is to diminish DLC1 binding to tensin, which
further reduces the tumor suppressor functions, as measured by cell migration
rate, anchorage-independent growth, and tumor formation in nude mice, inde-
pendently of Rho-GTP.We also found that ERK1 cooperates with SRC by phos-
phorylatingDLC1-S129, which enhances the binding of the SRC SH3 domain to
this region of DLC1, and increases SRC-dependent phosphorylation of Y451
and Y701. The cooperative effects reduce RhoGAP activity, increase Rho-GTP
and Rho/ROCK/MRLC signaling, and attenuate DLC1 tumor suppressor func-
tions. DLC1 preferentially binds active SRC, which reduces overall SRC activity.
Therefore, SRC activity tends to be lower in cells that express high levels of
endogenous DLC1, compared with cells in which DLC1 expression has been
down-regulated. Although SRC targets two DLC1 functions that contribute to
its tumor suppressor activity, DLC1 binds several ligands in addition to tensin
that also contribute to its tumor suppressor functions. Therefore, it would not be
surprising if high SRC activity were associated with selective pressure for down-
regulation of DLC1 expression. Consistent with this hypothesis, the combina-
tion high SRC expression and low DLC1 expression was associated with a poor
prognosis in lung adenocarcinomas (p0.005) in TCGA. The potentially re-
versible nature of the SRC-induced attenuation of DLC1 function can be ex-
ploited therapeutically. In two systems that have high SRC activity and express
DLC1 - the mouse MMTV-PyMT cancer model and a human lung cancer cell
line - the Src inhibitor PP1 has potent antitumor activity, as it reduces DLC1
Tyrosine phosphorylation, reactivates DLC1, and reduces Rho-GTP. However,
PP1 has marginal antitumor activity an isogenic DLC1-negative strain of the
lung cancer line, as the inhibitor does not reactivate DLC1 and does not alter
Rho-GTP levels. The results highlight the potential importance of tumor sup-
pressor reactivation as a biomarker for predicting and monitoring the response
to SRC inhibitors.
#1365 Sensitivity of oncogenic KRAS to adenosine triphosphate suppres-
sion. Matthew Holderfıeld, Kanika Sharma. Frederick National Laboratory for
Cancer Research, Frederick, MD.
KRAS proteins regulate many cellular processes including initiation of cell
division in response to mitogens. Gain of function KRAS mutations appear in
approximately 30% of all human cancers and activate effector signal transduc-
tion pathways independent of mitogenic stimuli. KRAS driven cancers also fre-
quently have high metabolic rates and may have increased sensitivity to meta-
bolic inhibitors but the underlying mechanism is not fully understood. In this
study, we characterized the cellular mechanism of a small molecule inhibitor
identifıed using a transgenic Drosophila melanogaster model that expresses hu-
man KRAS-G12V in the fly wing. The compound partially restored wing devel-
opment in theKRAS-G12V flies and inhibited growth and signal transduction in
multiple KRAS driven cancer cells and KRAS-G12V dependent MEF cells but
not in MEF cells expressing BRAF-V600E. The compound also had a profound
impact on mitochondrial function by inhibiting electron transport (ETC) com-
plex I. Multiple other ETC or ATP synthase inhibitors similarly impaired onco-
genic KRAS signal transduction. ATP production through glucose metabolism
was suffıcient to rescueKRAS function and cellular growth after ETC inhibition,
suggesting that inhibition of MAPK signaling is due to low ATP levels rather
than a direct consequence of ETC or complex I inhibition. These data indicate
that oncogenic KRAS signal transduction requires high cellular ATP levels and
suggests a synthetic lethal interaction between KRAS and multiple metabolic
targets that could be exploited to target KRAS driven cancers.
#1366 Structural basis of impaired GTP hydrolysis in oncogenic mutants
of KRAS. Timothy Tran,1 Sathiya Dharmaiah,1 Oleg Chertov,1 Timothy Way-
bright,1 William Gillette,1 Dominic Esposito,1 Dwight Nissley,1 Frank McCor-
mick,2 Andrew Stephen,1 Dhirendra Simanshu1. 1NCI RAS Initiative, Frederick
National Laboratory for Cancer Research, Frederick, MD; 2Diller Family Com-
prehensive Cancer Center, University of California San Francisco, San Francisco,
CA.
RASmutations are found in one-third of all human cancers. Among the three
RAS isoforms - HRAS, KRAS and NRAS, KRAS is the most commonly mutated
gene (in 86% of RAS-driven cancers) and the mutations are often detected in
pancreatic, colorectal and lung cancers. RAS proteins function as molecular
switches by alternating between inactive GDP-bound and active GTP-bound
states. The active or inactive state of RAS proteins is regulated by guanine nu-
cleotide exchange factors (GEFs) andGTPase-activating proteins (GAPs). In the
GTP-bound state, RAS proteins interact with a variety of effector proteins, such
as Raf, PI3K, and RalGDS, leading to activation of several signaling cascades
within the cell. In 98%of the cases, oncogenic RASmutations are found at amino
acid positions G12, G13, and Q61 which impair intrinsic and GAP-mediated
GTPase function resulting in accumulation of constitutivelyGTP-boundRAS in
cells. To gain insights into the effect of oncogenicmutations on overall structure
and GTP hydrolysis, we solved high-resolution crystal structures of wild type
and six oncogenic mutants (G12C, G12D, G12V, G13D, Q61L and Q61R) of
KRAS4b in complexwithGMPPNP (a non-hydrolysableGTP analog) andmag-
nesium.Comparison ofGDP andGMPPNPbound structures of wild type (WT)
KRAS4b suggests conformational changes that occur when KRAS4b transitions
from inactive to active state. Comparison of mutant and wild-type KRAS struc-
tures has shown the appearance of new pockets in some cases that could be
exploited for structure-based drug design. Structural superposition of mutants
vs. wild type KRAS4b in complex with GMPPNP/Mg2, and KRAS4b mutants
vs.WT-HRASbound toRASA1-GAPprovides a rationale for impaired intrinsic
and GAP-mediated GTP hydrolysis in the KRAS mutants.
#1367 The dynamic mechanism of SARAH domain in RASSF5 activation
byK-Ras4B.Tsung-Jen Liao,1Hyunbum Jang,2 Chung-Jung Tsai,2 David Fush-
man,1 Ruth Nussinov2. 1University of Maryland, College Park, MD; 2National
Cancer Institute at Frederick, NIH, Frederick, MD.
RASSF5 is a tumor suppressor, which acts as an adaptor linking Ras and
the Hippo pathways. RASSF5 activates MST1/2, a key upstream protein of the
Hippo pathway, through SARAH domain heterodimerization, resulting in
Hippo signaling. Signaling stimulates YAP1 phosphorylation, leading to its deg-
radation and thereby cell apoptosis. Association with K-Ras4B promotes
RASSF5 to release its SARAH which heterodimerizes with MST1/2. We aim to
reveal how K-Ras4B regulates the Hippo pathway through RASSF5 by resolving
the structure and conformational dynamics of RASSF5 complexes. Our model-
ing and simulations help elucidate the intrinsic dynamic interactions of RASSF5
RA (Ras binding) and SARAH domains. Surprisingly, we found that the residue
E388 on RASSF5 SARAH plays a signifıcant role in the dynamic mechanism of
SARAHhomo-/hetero- dimerization and the RA-SARAH association. Themu-
tants E388A and E388K dramatically decrease the strength of RASSF5 homo-
SARAH and RASSF5-MST2 hetero-SARAH, suggesting that the E388mutation
may be oncogenic. Simulations of selected RASSF5 confıgurations with GTP-
bound K-Ras4B indicate that the interactions between RA and SARAH are re-
duced. We conclude that Ras binding weakens the RA-SARAH association,
increasing the SARAH dynamic fluctuation. The released RASSF5 SARAH has
high propensity to dimerize with MST1/2 SARAH, activating Hippo signaling
thus cancer suppression. Funded inwhole or in part with Federal funds from the
Frederick National Laboratory for Cancer Research, NIH under contract
HHSN261200800001E.
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#1368 RABL6A, a novel critical regulator of Akt-mTOR signaling in pan-
creatic neuroendocrine tumor cells. Shaik Amjad Ume Salma, Jussara Hagen,
Jacki Reilly, Ryan Sheehy, Nitija Tiwari, Jackson Nteeba, Scott K. Sherman,
Thomas M. 0’Dorisio, James R. Howe, Andrew M. Bellizzi, Benjamin W. Dar-
bro, Dawn E. Quelle. Univ. of Iowa College of Medicine, Iowa City, IA.
Introduction: A better molecular understanding of pancreatic neuroendo-
crine tumors (PNETs) is needed to improve patient diagnosis and treatment.
Everolimus (mTOR inhibitor) is a standard-of-care therapy for PNET patients
based on aberrant activation of the PI3K/Akt/mTOR kinase pathway in tumors.
However, sustained mTOR inhibition paradoxically promotes Akt kinase hy-
peractivation due to loss of negative feedback regulation and tumors become
drug resistant. Our data reveal that RABL6A, a novel oncoprotein amplifıed in
PNETs, is a key regulator of this clinically relevant pathway. Methods: RABL6A
and Akt protein levels were manipulated using viral shRNAs in BON1 PNET
cells. Transcript levels were assayed by microarray and qRT-PCR, proteins as-
sessed by western blotting, and cell proliferation and survival measured by cell
counts, trypan blue exclusion andEdU incorporation. Effect of RABL6A expres-
sion on sensitivity to clinically relevant drugs, MK2206 (Akt inhibitor) and
everolimus, were tested. Results: Silencing of RABL6A in PNET cells causes G1
and G2/M cell cycle arrest, and pathway analysis of microarray data suggested
inactivation of Akt signaling in the arrested cells. Immunoblotting confırmed
dramatic loss of Akt phosphorylation at Ser-473 along with impaired phosphor-
ylation and activation of its targets, PRAS40 and FOXO-1/3. Phosphorylation of
S6K, a downstream target ofAkt-mTOR signaling, was also reduced byRABL6A
defıciency. The mechanism by which RABL6A controls Akt-S473 phosphoryla-
tion is currently not known although we demonstrated that mTORC2 (the ki-
nase that phosphorylates Akt at Ser473) remains active in RABL6A defıcient
cells since the phosphorylation of other mTORC2 substrates (SGK1 and PKC)
is unaffected. Given the central role of Akt1 in tumorigenesis, we hypothesized
that reinstating its activity may rescue the arrest phenotype caused by RABL6A
loss. Restoration of Akt1 in RABL6A-depleted cells partially rescued the G1
phase arrest and induced S phase entry but was insuffıcient to allow mitosis,
suggesting RABL6A regulates other factors required for cell division. Finally,
drug response assays showed that RABL6A loss desensitizes PNET cells to Akt
and mTOR inhibitors. Conclusion: Our previous work showed RABL6A pro-
motesG1progression in PNET cells by inactivatingRb1, an established suppres-
sor of PNET pathogenesis. We now show that RABL6A also controls Akt phos-
phorylation and is essential for Akt-mTOR activation. Thus, RABL6A controls
multiple cancer pathways necessary for PNET cell cycle progression and sur-
vival. We are testing if RABL6A status in PNETs predicts responsiveness to
combination therapies targeting Akt and mTOR. Overall, this work identifıes
RABL6A as a new essential activator of Akt1-mTOR signaling, suggesting it is a
new potential biomarker and target for anticancer therapy in PNET patients.
#1369 DNA, protein, and cell line reagents to facilitate RAS pathway drug
discovery efforts. Dominic Esposito. Frederick National Laboratory for Cancer
Research, Frederick, MD.
The RAS Reagents Core within the NCI RAS Initiative produces and distrib-
utes qualifıed DNA vectors, cell lines, and protein production reagents to the
external community to facilitate research into RAS biology and development of
RAS cancer therapeutics. DNA vectors representing a variety of RASmutations,
as well as a complete collection of 180 genes in the RAS pathway are available as
Gateway-compatible Entry clones. These clones represent the most commonly
expressed transcript forms of the 180 genes, many of which were not previously
available in full-length, wildtype forms. The vectors can be usedwith the FNLCR
combinatorial cloning library to easily generate a large number of different types
of expression clones with various promoters, fusion tags, and plasmid back-
bones. Cell line reagents include a variety of Ras-dependent mouse embryonic
fıbroblasts (MEFs) which have a defınedmutant allele of KRAS and which serve
as isogenic cell lines for investigating allele and mutant specifıc RAS biology, as
well as for valuable screening tools. Protein reagents include E. coli and insect
cell constructs and cell lines for production of a variety of Ras-related proteins.
In particular, we have materials for the high yield production of properly pro-
cessed, prenylated KRAS protein using a unique engineered insect cell expres-
sion system. This system can also be used to produce other prenylated small
GTPases at levels not previously attainable. Many of the resources of the RAS
Reference Core are readily available to the academic community through repos-
itories ormaterial transfer agreements, and can be licensed to industry scientists
as well. The program is also interested in identifying the needs of the community
for additional RAS-related resources, and is developing methods for vetting
requests from the outside to provide additional reagents.
#1370 EGFR-mediated Spred1 phosphorylation inhibits NF1 to sustain
constitutive Ras/MAPK signaling. Evan Markegard, Ellen L. Mercado, Jillian
M. Silva, Jacqueline Galeas, Marena I. Trinidad, Anatoly Urisman, Frank Mc-
Cormick. UCSF, San Francisco, CA.
Spred proteins negatively regulate Ras/MAPK signaling following growth fac-
tor stimulation. Inhibition of Ras primary occurs through Spreds ability to bind
and localize NF1, a RasGAP and major tumor suppressor, to the plasma mem-
brane. Spred1 andNF1 loss-of-functionmutations occur across multiple cancer
types including non-small cell lung carcinoma, glioblastoma, melanoma, stom-
ach carcinoma, and uterine carcinosarcoma. Here we demonstrate that EGFR
signaling disrupts Spred1-NF1 binding. Mass spectrometry was performed on
cells overexpressing EGFRL858R to identify potential phosphorylation sites on
Spred1 and NF1 that could disrupt Spred1-NF1 binding by steric hindrance. A
serine phosphorylation site on Spred1 was identifıed in which a phosphomi-
metic and phosphodefıcient mutant decreased or increased Spred1-NF1 bind-
ing, respectively. Phosphomimetic Spred1 is unable to suppress Ras-GTP fol-
lowing EGF stimulation. Therefore, phosphorylation of Spred1 at this site by a
serine kinase downstream of EGFR may disrupt Spred1-NF1 binding. To iden-
tify the Spred1 kinasewe are performing an in vitro kinase assay and anunbiased
CRISPRa screen. Our fındings provide one potential mechanism by which
EGFR signaling disrupts negative feedback to sustain constitutive Ras signaling.
Furthermore, this work may elucidate a novel therapeutic target for restoring
NF1-mediated inhibition of Ras.
#1371 Isoprenylcysteine carboxylmethyltransferase (ICMT) function is
critical for epithelial malignant transformation by mutant-Ras. Hiu Yeung
Lau, Jingyi Tang, Patrick J. Casey, MeiWang.Duke-NUSMedical School, Singa-
pore, Singapore.
Purpose Limited progress has been made in the development of direct inhib-
itors of Ras. Therefore, targeting isoprenylcysteine carboxylmethyltransferase
(ICMT), the fınal enzyme in the prenylation pathway for Ras and other proteins
containing the so-called CaaX-motif, remains an important strategy to inhibit
Ras function in cancers. In this study, we investigate the role ICMT plays in the
initiation of human epithelial cancers involving constitutively-active mutant
Ras using genetic manipulation strategies. Methods Small T antigen and a
shRNA against p53 (shp53) were sequentially expressed in human mammary
epithelial cells immortalized by hTERT (HME1-hTERT) to create pre-malig-
nant HME1-shp53 cells. All 4 isoforms of wild-type or mutant Ras, namely
H-Ras, N-Ras, K-Ras-4A and K-Ras-4B, were independently introduced into
HME1-shp53 cells to determine their transforming ability. Using CRISPR-Cas9
genome editing technology, ICMT-null HME1-shp53 cells were generated and
mutant Ras isoforms were subsequently introduced; tumor formation abilities
of thus generated cells were determined using soft-agar anchorage-independent
colony formation assay and subcutaneous xenografts in mice. ICMT knock-out
was also performed in MiaPaCa-2 and MDA-MB-231 cells, both expressing
mutant K-Ras, and subcutaneous xenograft tumor formation in mice was mea-
sured. Results Pre-malignant HME1-shp53 cells can be transformed by all mu-
tant Ras isoforms but not by any wild-type Ras. ICMT loss-of-function dramat-
ically reduced anchorage-independent colony formation caused by all mutant
Ras isoforms in HME1-shp53 cells, and in vivo xenograft formation was com-
pletely abolished. ICMT loss-of-function also dramatically reduced in vivo
xenograft formation for mutant K-Ras-expressing MiaPaCa-2 and MDA-MB-
231 naturally-occurring cancer cells. Conclusion ICMT function is essential for
the malignant transformation of HME1 cells by all isoforms of Ras. Further-
more, ICMT function is also crucial for the maintenance of the malignant phe-
notype in mutant K-Ras-expresing cells such as MiaPaCa-2 and MDA-MB-231
cells.
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#1372 Towards novel strategies of targeting specifıc vulnerabilities of T-
PLL cells. Sabine Puetzer1, Emma Andersson2, Alexandra Schrader1, Lesley
Varghese1, M. Hülsemann1, Petra Mayer1, Marc-Henri Stern3, Sebastian Newr-
zela4, L. Frenzel1, SatuMustjoki2, Marco Herling1. 1Center for Integrated Oncol-
ogy (CIO) Köln-Bonn, University of Cologne, Cologne, Germany; 2University of
Helsinki and Department of Hematology, Helsinki, Finland; 3Institute Curie,
Paris, France; 4Institute of Pathology University of Frankfurt, Frankfurt, Ger-
many.
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T-cell prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm usually
presenting at an aggressive phase and amarked resistance to conventional cyto-
statics, i.e. alkylators. The monoclonal antibody alemtuzumab induces high re-
sponse rates, but virtually all patients relapse and the mostly elderly individuals
are often ineligible for allogeneic stem cell transplantation. Overall, the treat-
ment options for T-PLL are scarce and its general prognosis, with average sur-
vival times of3 yrs, remains poor. In agreement with the pronounced amena-
bility of T-cell tumors to intervention in the altered epigenetic code, recent
reports also implicate a high potential of epigenetic targeting in T-PLL. In fact,
profıling of antinucleoside sensitivities, including clinically used agents like flu-
darabine or nelarabine, revealed that the purine analog cladribine showed the
highest T-PLL specifıc activity (LD50s: 0.16 M in T-PLL; 2.95 M in healthy-
donor T-cells, 2.81 M in PBMC), potentially through its epigenetically active
pyrimidine function. Fittingly, high-throughput genomic analysis of 95 T-PLL
revealed alterations enriched in DNA repair genes and histone/DNA epigenetic
modifıers. Extensive ex vivo drug screens (306 substances, 39 T-PLL) corrobo-
rated the genomic data and identifıedmajor clusters of T-PLL-active substances.
The CDK inhibitor SNS-032 induced the highest T-PLL specifıc responses, fol-
lowed by p53 activators, BCL2-family antagonists, and modulators of protein
acetylation and chromatin accessibility, all surpassing the effects of JAK/STAT-
inhibitors. The BCL2 inhibitor ABT199 (Venetoclax) profoundly affected T-
PLL cell viability (LD506.9nM), although apoptosis was induced more effı-
ciently in CLL cells (LD502.4nM). This slightly lower cytotoxicity in T-PLL
might be explained by the more heterogeneous BCL2 expression in this disease
than in CLL (flow-cytometry and gene expression arrays; 70 T-PLL). The best-
performing substance of the set, SNS-032, selectively and profoundly induced
apoptosis in T-PLL (LD500.19Mvs 0.47Minnormal T-cells vs 0.88Min
PBMC). Recognized as a CDK inhibitor, it antagonizes transcription via target-
ingCDK7and -9.We identifıed associations of protein levels of the transcription
factor MYC with the in vitro responses to SNS-032. Amplifıed cMYC is one of
the genomic hallmarks of T-PLL and implicated in its aggressive phenotype.
Hence it may be a target of SNS-032 or serve as a biomarker for SNS-032 sensi-
tivity. In summary, we identifıed several substances with marked antileukemic
activity in T-PLL. In vitro studies confırmed their potency and selectivity that
could be aligned with identifıed protein and genomic-lesional target patterns.
Follow-up studies of members of the major clusters of most T-PLL-active com-
pounds, including their best-informed combinations and preclinical in-vivo
testing, will guide in the design of promising clinical trials in T-PLL.
#1373 The role of the ASH1L SET domain in leukemogenesis. David Ro-
gawski,1 Hongzhi Miao,1 Katarzyna Kempinska,1 Lili Chen,1 Jen Chase,1 Ann
Friedman,1 Xiaomei Yan,2 Kenichi Nishioka,3 Gang Huang,2 Patricia Ernst,4
AndyMuntean,1 IvanMaillard,1 Tomasz Cierpicki,1 Jolanta Grembecka1. 1Uni-
versity of Michigan, Ann Arbor, MI; 2Cincinnati Children’s, Cincinnati, OH;
3Saga University, Saga, Japan; 4University of Colorado Denver, Aurora, CO.
ASH1L (absent, small, or homeotic-like 1) is a histone lysine methyltrans-
ferase (KMTase) specifıc for histone 3, lysine 36 that has an emerging role in
multiple types of cancer. During development, ASH1L activates HOX genes and
regulates self-renewal potential of long-term hematopoietic stem cells. Interest-
ingly,HOXgenes are oncogenic drivers in a variety of cancer types. For example,
overexpression of HOXA9 is highly associated with a poor prognosis in acute
myeloid leukemia (AML). In addition, ASH1L is overexpressed in a variety of
cancers, including breast and thyroid cancer, but its role in cancer remains
poorly characterized. Recent data suggest thatASH1Lpromotes leukemogenesis
in mixed-lineage leukemia by recruiting the MLL epigenetic regulator to target
genes. However, ASH1L is a large protein with multiple chromatin-interacting
domains, and which regions of the ASH1L protein are important in leukemia
has not been reported. Specifıcally, the role of ASH1L’s KMTase activity in
leukemogenesis remains unknown. To further investigate the function of
ASH1L in leukemia, we knocked down expression of ASH1L in leukemia cell
lines. We found that ASH1L knockdown slowed cell growth and caused a de-
crease in expression of HOXA genes and their collaborator MEIS1. To specifı-
cally investigate the role of ASH1L KMTase activity in leukemia, we used a
mouse model with a targeted in-frame deletion of the ASH1L SET domain
(SET).SET cells express a shorter version of ASH1L that does not contain the
SET domain. We transduced bone marrow cells (BMCs) isolated from SET
and WT mice with several oncogenes relevant to AML to determine the role of
the ASH1L SET domain in leukemic transformation. We found that SET
BMCswere signifıcantly impaired in leukemic transformation compared toWT
BMCs, as manifested by decreased colony-forming ability and reduced expres-
sion of HOXA genes. These fındings suggest that the ASH1L SET domain plays
an important role in leukemogenesis mediated bymultiple different oncogenes.
Future studies will further characterize ASH1L’s role in leukemia by identifying
the complete set of genetic loci that it methylates and regulates, and will deter-
mine whether the ASH1L SET domain represents a viable therapeutic target.
#1374 Frequent up-regulation of histone methyltransferase G9a contrib-
uted to liver carcinogenesis by epigenetically silencing of tumor suppressor
RARRES3. lai wei, Felice Ho-Ching Tsang, Dicky Cheuk-Ting Law, Sandy
Leung-Kuen Au, Joyce Man-Fong Lee, Carmen Chak-Lui Wong, Irene Oi-Lin
Ng, Jack Chun-Ming Wong. The University of Hong Kong, Hong Kong, Hong
Kong.
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death
worldwide and is the most common type of cancer in sub-Saharan Africa and
Southeast Asia area where hepatitis B infections are common. The initiation and
progression ofHCCwas attributed to alternations in genetics and disruptions of
epigenetic processes which lead to altered gene functions in both oncogenes and
tumor suppressors. Recent advancements in the fıeld of cancer epigenetics in-
creasingly emphasize the important role of every component in the epigenetic
machinery. However, the alternations of epigenetic mechanisms involved in
HCC are still largely unknown. Using transcriptome sequencing, we examined
the expression of 591 epigenetic regulators in hepatitis B-associated human
HCC and found thatmost of the epigenetic regulators are deregulated especially
the histone modifıcation enzymes. Among all of them, we identifıed G9a (Eu-
chromatic histone-lysineN-methyltransferase 2, EHMT2), a histoneH3 lysine 9
(H3K9) specifıc histone methyltransferases, as one of the most signifıcantly up-
regulated epigenetic regulators in human HCCs. Previous studies about epige-
netic alternations primarily focused on promoter DNA hypermethylation.
However, little is known about the pathological implications of histone modifı-
cations. Herein, we hypothesis the frequent up-regulation of G9a causes epige-
netic aberrations which contribute liver carcinogenesis, and targetingG9a could
be a potential epigenetic therapeutic method for HCC treatment. In this study,
we found that G9a was frequently up-regulated in different HCC sample co-
horts. Up-regulation of G9a was signifıcantly associated with HCC disease pro-
gression, cancer aggressiveness, and more malignant tumor phenotypes. Func-
tionally, we demonstrated that shRNAknockdown andCRISPR/Cas9 knockout
of G9a suppressed HCC cell proliferation in vitro and inhibited subcutaneously
xenograft HCC tumorigenicity in vivo. Depletion of G9a signifıcantly reduced
HCC cell migration ability and induced cell senescence. Pharmacological inhi-
bition of G9a by small molecule inhibitors, UNC0638 and BIX01294, also sup-
pressed HCC cell growth and altered cell morphology. Mechanistically, we
showed that the frequent up-regulation of G9a in humanHCCwas attributed to
gene copy number gain at chromosome 6p21 and loss of miR-1. Furthermore,
up-regulation of G9 also epigenetically repressed miR-1 expression and thus
formed a feedforward regulation loop between them. By utilizing RNA-Seq and
GSEA analysis, we identifıed a potential tumor suppressor RARRES that was
epigenetically silenced byG9a and promoted tumor cells proliferation in human
HCC.Taken together, we showed thatG9a are novel oncogenes in humanHCCs
and G9a could be novel therapeutic targets for HCC treatment.
#1375 Loss of C-MYCand chromatin acetylation induce epigenetic repro-
gramming in acute lymphoblastic leukemia. Elodie M. Da Costa, Gregory
Armaos, Simon Jacques-Ricard, Annie Beaudry, Pascal St-Onge, Maxime Ca-
ron, Daniel Sinnett, SergeMcGraw, Noël J. Raynal.CHU Sainte-Justine research
center, Montreal, Quebec, Canada.
Epigenetic modifıcations play a key role in establishing andmaintaining gene
expression. In cancer, they are highly altered and responsable of gene expression
deregulation. Epigenetic drugs have the ability to reset cancer cell epigenome
producing cancer cell differentiation and apoptosis. In a drug screening initia-
tive, we recently reported a series of FDA-approved drugs with unsuspected
epigenetic and anticancer activities. Here, we tested in a secondary screen the
activity of these drugs against acute lymphoblastic leukemia (ALL) cell lines
(MOLT-4 and NALM-6). We found that Proscillaridin A, a cardiac glycoside
used for heart failure treatment, was the most active with IC50 values in the low
nanomolar range, suggesting drug repositioning potential. Proscillaridin treat-
ments induced a signifıcant decrease in RNA and protein levels of C-MYC, a
master oncogenic driver in ALL. Shortly after proscillaridin A treatment, C-
MYC exhibited a 75% reduction in lysine acetylation, a post-translational mod-
ifıcation known to prevent its degradation. Loss of acetylation was associated
with down-regulation of lysine acetyltransferases CBP, P300 and Tip60, which
also correlated with a reduction in histone 3 and 4 acetylation levels (H3K14ac,
H3K9ac,H3K27ac andH4K5ac). Preliminary analysiswith si-RNAexperiments
reveal that independent HAT activities are not responsible of C-MYC down-
regulation. RNA sequencing and gene set enrichment analysis in proscillaridin-
treated ALL cells (5 nM for 48h) showed that genes associated with cell differ-
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entiation and apoptosis pathways were up-regulated whereas down-regulated
genes were associated with C-MYC target genes. Altogether, our fındings show
that acetylation through lysine acetyltransferase down-regulation simultane-
ously induces loss of C-MYC and H3 acetylation leading to epigenetic repro-
gramming in ALL cells. This drug repositioning strategy, using proscillaridin A,
has the potential to reprogram cancer cells that are driven by MYC overexpres-
sion or hyperactivation.
#1376 Novel HDAC inhibitor SBAK-GHA: potential therapuetic mole-
cule for lymophocytic leukaemia. Javeed Ahmad Bhat,1 Mudassier Ahmad,1
Nawab John Dar,1 Aashiq Hussain,1 Rauf Ahmad Najar,1 Simmi Sharma,2
Mubashir Javeed Minto,1 Dilip Manikrao Mondhe,1 Vaqar M. Adhami,3 Bhah-
wal Ali Shah,2 Neena caplash,4 Abid Hamid*1. 1Cancer Pharmacology Division-
,Indian Institute of integrative Medicine,Canal Road, Jammu, India; 2Natural
product Microbes, Indian Institute of integrative Medicine,Canal Road, Jammu,
India; 3School of Medicine and Public Health University of Wisconsin-Madison
1300 University Ave MSC 4385 Madison, WI 53706., Wisconsin, WI; 4Depart-
ment of Biotechnology,Panjab University, Chandigarh, U.T. – 160014 India,
Chandigarh, U.T., India.
In cancer cells, an imbalance exists between Histone acetylase(HAT) and
Histone deacetylase(HDAC) activities and current research focuses actively on
seeking competitive HDAC inhibitors (HDACi) for chemotherapeutic inter-
vention.We have designed and synthesized a library of novel HDACi molecules
from naturally occurring boswellic acids as an alternate CAP for already vali-
dated pharmacophore of suberanilohydroxamic acid (SAHA).Novel HDACi
molecules were screened against a panel of cancer cell lines. A lead HDACi
i.e.N1-hydroxy-N5-(3--hydroxy-11-oxo-24-norurs-12-en-4-yl) glutaramide
(SBAK-GHA) having IC50 of 1.5Magainst leukaemiaHL-60 cell line and 6M
in enzyme based assay was obtained. Further HDACi, isoform evaluation was
done for SBAK-GHA and it was found to be HDAC Class 1 Specifıc, especially
against HDAC 2 (IC50 of 200 nM) and HDAC 8(IC50 of 250 nM). Acetylation
level of different histone residues on H3 andH4 upon SBAK-GHA treatment in
HL-60 cell line was studied by immunoblotting. HDACi, SAHA and Sodium
Butyrate (NaB) were used as positive controls to compare acetylation levels of
different H3 and H4 residues.SAHA and NaB showed signifıcant increase in
H3K9, H3K14, H3K27, H4K5, H4K12, and H4K16 acetylation levels while
H3K18 showed mild change in acetylation levels. On the other hand SBAK-
GHA showed signifıcant increase in acetylation levels of all the lysine residues of
histoneH3 andH4 especiallyH4K16 in comparison to SAHA andNaB. In order
to analyse varied expression of cyclins and their corresponding control of dif-
ferent phases of cell cycle, we performed chromatin immunoprecipitation assay
(ChIP) and observed acetylation pattern of different histone (H3 and H4) resi-
dues regulates cyclins differently. In order to analyse the correlation of acetyla-
tion on different H3 and H4 residues and their varied pattern of regulation of
cyclins, we next analyzed the effect of SBAK-GHA on different cell cycle events
in HL-60 cells and found G1 phase cell cycle arrest at signifıcantly low concen-
tration (1M).We further observed SBAK-GHA induced apoptosis at lower
concentrationswhile as autophagywas found at higher concentrations. Further-
more,we conducted mitochondrial membrane potential studies of SBAK-GHA
in HL-60 cells and observed signifıcant loss in mitochondrial membrane poten-
tial. We took our fındings from in vitro studies and analysed effect of SBAK-
GHAon different in vivomurinemodels. SBAK-GHA showed signifıcant activ-
ity especially against P388 lymphocytic leukemia compared to SAHA and 5-FU.
Moreover, SBAK-GHA showed promising activity against Ehrlich Ascites Car-
cinoma (EAC). In conclusion our fındings indicate that our lead molecule of
interest have great therapeutic potential singly or in combination, however fur-
ther mechanism of action needs to be elucidated before taking it from Bench to
Bedside.
#1377 Set7 is a novel histone methyltransferase in Schizosaccharomyces
Pombe. Eric Di Luccio, Yunpeng Shen, Damiaan E.H.F Mevius, Yeon Jeong
Noh, Jihyeon Kim, Masayo Morishita. Kyungpook National University, Daegu,
Republic of Korea.
Dynamics and plasticity of chromatin regulation is mediated by a molecular
ballet of writers, readers and erasers of epigenetic marks on both DNA and
histones. The pattern of histonemodifıcations may defıne a histone code, which
is part of intricate networks that ultimately regulate transcriptional events. Dys-
function of histone methylation affects chromatin regulation and is involved in
an increasing number of pathologies from cellular transformation to tumor
progression and other diseases. However, histone methyltransferase (HMTase)
pathways remain to be further explored and better understood. Fission yeast
(Schizosaccharomyces pombe) is an ideal model organism to investigate the
fundamental mechanisms of chromatin dynamics. Fission yeast possesses 13
SET-containing proteins (Set1 to 13), several of which methylate histones or
ribosomes. The catalytic SET domain is highly conserved across eukaryotes (e.g.
Set2, a homologue of the oncoprotein NSD2/MMSET/WHSC1 in human).
Structure-function studies of HMTases are essential from basic science to trans-
lational research. However, full-length structures of fıssion yeast methyltrans-
ferases are still scarce. Here, in a bid to better understand histone methylation
and to gain insight for drug-design, we report the identifıcation and structural
characterization of a novel histone methyltransferase Set7 (SPCC297.04c), in
Schizosaccharomyces Pombe. In this study, we investigated Sp.Set7’s cellular
localization and the effect of Sp.Set7 knock-out on the cell cycle and sporulation.
Next, we elucidated Sp.Set7’s Lysine substrate specifıcity on histone H3 and H4
by biochemical assays andmass spectrometry. Finally, we solved theX-ray struc-
ture of the apo Sp.Set7 at 2.0 Å resolution. In summary, we report the biochem-
ical and structural characterization of a novel histone methyltransferase in fıs-
sion yeast, which has implications for better understanding the fundamental
mechanism of HMTases.
#1378 Identifıcation of genomic regions associated with temozolomide
resistance in glioblastoma through analysis of histone marks on chromatin.
Xiaoyue Chen,1 HaiyunGan,2 JeongHeong Lee,1 Dong Fang,2 Gaspar Kitange,1
Jann Sarkaria,1 Zhiguo Zhang2. 1Mayo Graduate School, Rochester, MN; 2Co-
lumbia University, New York, NY.
Glioblastoma (GBM) is an aggressive and fatal primary brain tumor. Temo-
zolomide (TMZ) is a critical component of the standard care of newly diagnosed
GBMpatients, but unfortunately preexisting primary resistance and rapid emer-
gence of secondary resistance invariably limits the therapeutic benefıt of TMZ in
GBM. Prior studies have identifıed genetic and epigenetic alterations that can
modulate TMZ sensitivity and treatment outcome. However, comprehensive
analysis of histone marks and knowledge of epigenetic regulation of genes asso-
ciated with TMZ sensitivity or resistance is lacking. To identify epigenetic states
associated with TMZ resistance, we performed an epigenetic profıling of eight
different histone marks in GBM xenografts. Using chromatin immunoprecipi-
tation combined with high throughput sequencing (ChIP-seq), distribution of
H3K4me1, H3K4me3, H3K9ac, H3K9me2, H3K9me3, H3K27ac, H3K27me3
andH3K36me3 histonemarkswas compared in a panel of GBMpatient-derived
xenograft sub-lines derived by treating TMZ sensitive GBM12 tumors with pla-
cebo (n2 sublines) or temozolomide (n6 sub-lines) and then propagating
resulting recurrent tumors. Our analysis revealed that H3K4me1 and H3K27ac
modifıcation patterns varied globally across individual sub-lines, while distribu-
tion of H3K4me3, H3K36me3 histone marks was specifıcally altered in discrete
genomic regions in resistant sub-lines depending on the mechanisms of resis-
tance. To fınd how epigenetic modifıcations affect TMZ sensitivity, we analyzed
ChIP-Seq data using Hidden Markov Model to test if one or a combination of
histone marks relates to TMZ resistance. The effect of histone modifıcations on
transcription was simultaneously determined by RNA sequencing. These anal-
yses helped identify specifıc histone modifıcations which could be functionally
related to TMZ resistance. Through these analyses we have identifıed 1142
genomic regions governed by a specifıc epigenetic pattern. We subsequently
analyzed a candidate genomic region on top of the list. By using Clustered
Regularly Interspaced Short Palindromic Repeats/CRISPR associated nucleases
9 system (CRISPR/Cas9 system), we have generated clones from an intrinsically
TMZ resistant SKMG3 cell line with deletion up to four-kilo base genomic
region. Clonogenic growth assays showed that deletion of this genomic region
enhanced TMZ sensitivity, reducing the IC50 from 186 M to less than 60M,
p0.05. This fınding indicates that this genomic region is functionally related
with TMZ sensitivity. Taken together, our study reveals epigenetic modifıca-
tions related to TMZ resistance in GBM cells and a specifıc genomic region
involved in regulating TMZ sensitivity. The analysis of epigenetic state at this
genomic region could potentially be useful in predicting treatment response and
may help in designing TMZ sensitizing therapy in GBM.
#1379 Histone demethylase KDM6 as a target for glioblastoma radiosen-
sitization. Barbara Helen Rath, Marzia F. Shah, Kevin Camphausen, Philip J.
Tofılon. National Cancer Institute, Bethesda, MD.
Radiotherapy is a primary treatment modality for glioblastomas (GBMs).
Because post-translational histone modifıcations have been implicated in the
regulation of radiosensitivity, as a potential strategy for enhancing the response
of GBMs to radiotherapy we have evaluated the effect of radiation on histone
methylation in glioblastoma stem-like cells (GSCs) and the established glioma
cell line (U251). For these studies we focused on histone H3K27 tri-methylation
(H3K27me3), whose opposing site H3K36me2 has already been linked to DNA
repair. Exposure of GSCs and U251 to 10Gy decreased H3K27me3 by 30min,
reaching a cell line dependedmaximumbetween 1h and 3h, followed by a return
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to control levels at 6h. According to immunoblot analysis, GSCs and U251 had
signifıcant higher levels of KDM6A compared to KDM6B, suggesting a more
prominent role for KDM6A in the demethylation of H3K27me3 after irradia-
tion. To determine whether KDM6 could serve as a target for GBM radiosensi-
tization, we focused on GSKJ4, which is an inhibitor for KDM6A and KDM6B.
GSKJ4 treatment (4uM) of GSCs andU251 increased the amount of H3K27me3
within 1h of exposure and was found to block the radiation-induced decrease of
H3K27me3. Based on clonogenic survival analysis addition of GSKJ4 immedi-
ately prior to irradiation signifıcantly enhanced the radiosensitivity of GSCs and
U251. To begin to investigate the mechanism responsible for this radiosensiti-
zation,GSCs andU251were irradiated (10Gy), treatedwithGSKJ4 and collected
at 0.5-24h later for neutral comet assay, ameasure ofDNAdouble strand breaks.
GSKJ4 had no effect on the initial comet-tailmoment, yet signifıcantly increased
the comet tail-moment up to 24h after radiation, suggestive of an inhibition of
DSB repair. To further investigate the potential role of histone demethylase as a
potential target to radiosensitizeGBM, siRNAwas used to knock downKDM6A
expression. Cells treated with siKDM6A showed a signifıcant increase in
H3K27me3 and the radiation-induced decrease of H3K27me3 was abolished.
Analysis ofH2AXnuclear foci after irradiation (2Gy) of siKDM6A treated cells
showed a signifıcant delay in foci dispersal, consistent with an inhibition of DSB
repair. To investigate whether similar changes in histone methylation occurred
in an in vivo setting, H3K27me3 levels were determined in GSC orthotopic
xenografts as a function of time after brain irradiation. Similar to in vitro con-
ditions, radiation reducedH3K27me3 levels at 1h, with a decrease still present at
6h. Taken together, these results suggest that the histone demethylaseKDM6A is
a target for GBM radiosensitization.
#1380 Expression and functions of ASH1L in liver cancer. Lai Wei, Felice
H. Tsang, Daniel Ho, Cheuk-Ting Law, Mengnuo Chen, Long-Hin Tsang, Car-
menClWong, IreneOl Ng, Chun-MingWong.Univ.of Hong Kong, Hong Kong.
Hepatocellular carcinoma (HCC) is a common cancer and ranks the third
lethal cancer worldwide. However, the detail molecularmechanisms underlying
the initiation and progression of HCC remain poorly understood. Liver carci-
nogenesis is amultistep process that is driven by the accumulation of genetic and
epigenetic alterations.Mutational landscape and drivermutations have recently
been delineated by high-throughput sequencing studies. On the other hand, our
current knowledge about epigenetic deregulation in human HCC is limited.
Histonemodifıcation is amajor component of epigenetic regulation, and dereg-
ulation of histone medication could alter local chromatin structure and gene
expression. We hypothesized that deregulation of histone methyltransferases
might contribute to HCC development. In this study, we showed that trithorax-
group proteinASH1Lwas frequently up-regulated in humanHCC.Overexpres-
sion of ASH1L was detected in 40% of primary HCCs and signifıcantly associ-
ated with larger tumor size, present of venous invasion and tumormicrosatellite
formation. Up-regulation of ASH1L also correlated with increased Ki67 expres-
sion. ASH1L is a histonemethyltransferase specifıc for catalyzing transcription-
al-active H3K4 and H3K36 methylation. We showed that stable knockdown of
ASH1L signifıcantly suppressed HCC cell proliferation and colony formation.
We further demonstrated that knockdown of ASH1L inhibitedHCC cell migra-
tion. In addition, we investigated the underlying mechanisms contribute to
ASH1L up-regulation.We showed that up-regulation of ASH1L in humanHCC
was contributed by chromosome amplifıcation at chromosome 1q22. Further-
more, we showed that ASH1L was negatively regulated by miR-142. Therefore,
down-regulation of miR-142 contributed to ASH1L up-regulation in HCC. In
summary, our fındings suggested that ASH1L was frequently up-regulated in
human HCC due to chromosome amplifıcation and miRNA deregulation.
#1381 Human CRL4DDB2 E3 ubiquitin ligase regulates post-repair chro-
matin restoration of epigenetic marker H3K56Ac through recruitment of
histone chaperon CAF-1. Qianzheng Zhu, Nidhi Sharma, Jinshan He, Gulzar
Wani, Altaf A. Wani. Ohio State University, Columbus, OH.
Epigenetic marker acetylated histone H3 lysine 56 (H3K56Ac) diminishes as
an early DNA damage response but is restored in chromatin after DNA repair.
Here, we report that human CRL4DDB2 ubiquitin ligase regulates the DNA re-
pair-driven chromatin restoration of H3K56Ac by monitoring the recruitment
of histone chaperon CAF-1. We show that the H3K56Ac accumulates at DNA
damage sites. The post-repair H3K56Ac restoration depends on CAF-1 and
CBP/p300 function. The CRL4DDB2 components DDB1, DDB2 and CUL4A are
required not only for maintaining the H3K56Ac level in chromatin, but also for
restoring H3K56Ac following the repair of DNA photolesions and strand
breaks. Depletion of CUL4A decreases the recruitment of CAF-1 p60 and p150
to ultraviolet radiation (UVR)- and phleomycin-induced DNA damage. Inhibi-
tion of neddylation renders CRL4DDB2 inactive and concomitantly diminishes
the recruitment of CAF-1 and prevents post-repair H3K56Ac restoration. Ad-
ditionally, a PCNA-interacting protein (PIP) motif is shown to exist within
DDB2. The mutation in the PIP box of DDB2 compromises its capability to
maintain theH3K56Ac level but does not affect CRL4DDB2-mediated XPC ubiq-
uitination. These results suggest a novel role of CRL4DDB2 in regulating post-
repair chromatin restoration, which differs from its canonical role in the process
of nucleotide excision repair.
#1382 A novel BET family bromodomain inhibitor NHWD-870 repre-
sents a promising therapeutic agent for a broad spectrumof cancers.Nenghui
Wang,1 Mingzhu Yin,2 Qin Yan2. 1Ningbo Wenda Pharma, Ninghai, China;
2Yale School of Medicine, New Haven, CT.
Small molecule inhibitors of the bromodomain and extraterminal domain
(BET) proteins have emerged as a promising option for cancer therapy.NHWD-
870 is a potent and selective BET family bromodomain inhibitor and only binds
bromodomains of BRD2/3/4/T. NHWD-870 exhibited robust single agent ac-
tivity in cell viability assay across cancer cell lines derived from solid tumors,
leukemia and lymphomas. Further characterization of cancer cell responses to
NHWD-870 indicated that NHWD-870 manifested diverse mechanisms of ac-
tion in different cancer settings. These include: 1) inhibition of tumor cell
growth by downregulating the PDGFR, MEK1/2 and STAT1/MYC signaling
in tumor cells; 2) inhibition of tumor angiogenesis by decreasing PDGF produc-
tion in tumor cells and the PDGFR andMEK1/2 signaling in endothelial cells.
Consistent with its broad spectrum of activities in vitro, NHWD-870 has potent
tumor suppressive effıcacies in xenograft mouse models of small cell lung can-
cer, triple negative breast cancer and ovarian cancer. These results support its
further development for diverse solid tumor indications in the clinic.
#1383 HistoneH3 lysine 9methyltransferase SUV39H1 is associated with
clinical outcome of renal clear cell carcinoma patients. Wei Meng, Ri Cui,
Saikh Jaharul Haque, Carlo M. Croce, Arnab Chakravarti. The Ohio State Uni-
versity, Columbus, OH.
Background: Epigenetic alternations have three important components in-
cluding DNA methylation, histione modifıcations, and non-coding RNA. The
epigenetic changes are highly dynamic and also reversible, which regulate a
variety of biological processes. Euchromatin which is a loosely packed form of
chromatin is highly associated with active gene expression. In contrast, hetero-
chromatin is associated with high histone methylation and DNA methylation
but low RNA transcription. SUV39H1 catalyzes the histone 3 lysine 9 trimethy-
lation (H3K9me3) in heterochromatin regions, which alsomediatesDNAmeth-
ylation at pericentric heterochromatin. Currently, the oncogenic role of
SUV39H1 in renal cell carcinoma (RCC) pathogenesis is poorly understood. To
this end, we assessed the role of SUV39H1 in renal RCC cells and association
with clinical outcome of RCC patients. Results: In SUV39H1 knocked down
cells, we observed global H3K9me3 level reduction and cell growth inhibition.
Proximal ligation assay was used to determine the H3K9me3 and 5-methylcy-
tosine (5mC) interaction in RCC cells. Knocking down of SUV39H1 gene sig-
nifıcantly reduced the co-localization of H3K9me3 and 5mC in pericentric re-
petitive sequences. Moreover, Southern blot demonstrated that expansion of a
pentanucleotide (GGAAT) repeats was associated with upregulation of
SUV39H1, which is linked to SUV39H1 function with microsatellite instability
and rearrangement. In The Cancer Genome Atlas (TCGA) database, we found
that SUV39H1 gene expression was upregulated in RCC tissues compared to
normal tissues, andhigh SUV39H1 expression predicted aworse overall survival
outcome (p 0.002) in RCCpatients. Conclusion: SUV39H1 upregulation pro-
motes cell proliferation and microsatellite instability. SUV39H1 expression
could serve as a prognostic biomarker for RCC patients.
#1385 New insights into the roles of histone lysine-specifıc demethylase 2
(LSD2) in breast cancer. Lin Chen, Shauna N. Vasilatos, Ye Qin, Steffı Oester-
reich, Nancy E. Davidson, Yi Huang. University of Pittsburgh, Pittsburgh, PA.
Background: Epigenetic modifıers have been emerging as new players in
breast cancer development. FAD-dependent histone demethylases have been
proved to play important roles in regulating breast tumor initiation and devel-
opment.While the role of histone lysine-specifıc demethylase 1 (LSD1) in breast
cancer progression has been well characterized, the activity of its homolog,
lysine-specifıc demethylase 2 (LSD2), in breast cancer is still a riddle that needs
to be uncovered. Methods: To explore the precise role of LSD2 in breast cancer,
we overexpressed LSD2 protein inMDA-MB-231 cells (LSD2-OE). The pheno-
typic effect of LSD2-OE on MM231 cells was characterized by proliferation
assay, soft agar assay (3D growth), trans-well cell migration and invasion assay
and mammosphere formation assay. To extend stem cell-like features study of
LSD2 overexpressedMM231 cells, we examined CD44/CD24- subpopulation
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by flow cytometry and the expression of several stem cell markers by qPCR and
western blot. In addition, we also investigated the potential altered phenotypes
of LSD2 knockdown inMM231 cells via RNAi. Results: Results fromOncomine
database show that LSD2 expression level is greatly increased in invasive ductal
carcinoma (IDC) vs. non-invasive breast cancers. The cellular proliferation as-
say revealed that LSD2-OEpromotedMM231 cell growth. Similarly, LSD2 over-
expressed MM231 cells were capable of forming large colonies in soft agar.
Trans-well cell migration and invasion assay results indicated LSD2-OE signif-
icantly decreased both migration and invasion in MM231 cells. Mammosphere
formation assay results showed LSD2 overexpression increased the number of
primary and tertiary mammospheres in MM231 cells. Consistent with increase
of mammosphere forming effıciency, NANOG and SOX2 were increased by
LSD2 overexpression at the protein level. However, LSD2-OE signifıcantly de-
creased CD44/CD24- subpopulation. Moreover, siRNA mediated LSD2 de-
pletion signifıcantly decreased cell growth in multiple breast cancer cell lines
without altering migration and invasion in MM231 cells. Finally, no obvious
phenotypic changes were observed in MM231 cells expressing stable LSD2
shRNA. Conclusion: The multifaceted effects of LSD2 on breast cancer pheno-
types may reflect the profound influence of LSD2 activity on chromatin struc-
ture and gene expression in the breast cancer genome. Our studies suggest that
overexpression of LSD2 facilitates growth and confers stem cell-like traits to
breast cancer cells, and transient LSD2 inhibition by siRNA hinders breast can-
cer cell growth. These results suggest that LSD2 might be a valuable therapeutic
target in breast cancer.
#1386 Effects of histone deacetylase inhibitors on differentiationmarkers
and growth of colon and bladder cancer cells. Michael A. Lea, Lauren Cué,
Elizabeth Batista, Erik Lew, Charles desBordes. Rutgers New Jersey Medical
School, Newark, NJ.
Alkaline phosphatase and dipeptidyl peptidase are markers of differentiation
in colon cancer cells. In colon cancer cells differentiation canoften be induced by
treatmentwith inhibitors of histone deacetylase (HDAC) activity. In some colon
cancer cells butyrate causes a several-fold induction of alkaline phosphatase but
onlymodest effects on dipeptidyl peptidase. There is relatively little information
on changes in activity of cell surface hydrolases in bladder cancer. However,
there is some evidence for decreased alkaline phosphatase activity in bladder
cancer. We tested the hypothesis that there may be retention of activity in more
slowly growing cancer cells and the activity will be regulated by HDAC inhibi-
tors in amanner similar to that in colon cancer. In our initial studieswe screened
seven human bladder cancer cell lines for alkaline phosphatase activity. We
identifıed three cell lines (5637, HT1197 and HT1376) with activity comparable
to that inmore differentiated colon cancer cell lines. The response to incubation
with the HDAC inhibitors butyrate and valproate was compared with effects in
three colon cancer cell lines Caco-2, HT29 and SW1116. In all six cell lines there
were growth inhibitory effects that tended to be a little greaterwith butyrate than
with valproate. Induction of alkaline phosphatase activity was generally greater
with butyrate than with valproate and was apparent even without normalizing
the activity on a protein basis. After determining the activity per unit protein
there were increases in dipeptidyl peptidase activity after treatment with the
HDAC inhibitors that were smaller than for alkaline phosphatase. Growth inhi-
bitionwas observedwith all theHDAC inhibitors examined including LMK235,
nicotinamide, RGFP966, romidepsin and tubacin but increased activity of alka-
line phosphatase was not always seen. Activities of the enzymes were very low in
CRL1790 human colonocytes of fetal origin and there was little or no induction
with HDAC inhibitors. Although pyruvate and carnitine have been reported to
be HDAC inhibitors, incubation with colon and bladder cancer cells did not
cause induction of alkaline phosphatase activity. It was concluded that regula-
tion of alkaline phosphatase and dipeptidyl peptidase by HDAC inhibitors can
be similar in bladder and colon cancer cells.
#1387 Target RNA sequencing revealed the expression profıle of cancer
genes in response to deacetylase inhibitor in primary culture of prostate can-
cer cells.Hong Yin, Adam H. Greer, Glenn Mills. Louisiana State Univ. Health
Sciences Ctr., Shreveport, LA.
Histone acetylation is a dynamic event to optimize cell functions through the
control of RNA transcription and gene expression. In cancer, the histone
deacetylation is a therapeutic target. Suppression of histone deacetylase in-
creased the growth arrest, apoptosis, and senescence in cancer cells. Several
histone deacetylase inhibitors (HDACis) have been developed and applied as a
target therapy of various types of cancer, including the prostate cancer. How-
ever, the altered gene expression in HDACis treated prostate cancer cells is less
reported. Little is known about the gene expression profıles of primary cultures
of prostate cancer. In this study, we examined the cancer gene expression profıle
in primary cultures of human prostate cancer. Cells were isolated from two
patient’s prostate cancer samples. Isolated cells were cultured in prostate epithe-
lium culture medium CnT-52. After 24 hours of exposure to 400nM of Tricho-
statin A (TSA), an inhibitor of histone deacetylase I and II. RNA was extracted
and quantifıed. The library was prepared with Illumina’s TruSight RNA Pan-
Cancer Panel. The sequencing was performed on NextSeq 500 platform with
NextSeq 500/550 mid output v2 kit (150cycles). FastQ fıles were generated by
BaseSpace Onsite and analyzed further by TopHat alignment (Illumina) and
Partek Flow (Partek). The Trusight RNA Pan-Cancer panel targets 1385 cancer
genes and covers 21043 exonic regions with 57010 probes. The results showed
that 59 of the 1385 cancer genes were signifıcantly changed (FDR p-value0.05,
fold change 4 fold) in TAS treated cells. In the treated cells 49 genes were
unregulated and 10 genes were down-regulated. The altered expression of 59
genes is involved in multiple cell functions. Genes that were upregulated in-
cluded apoptosis associated genes (MAP2K6 and BIRC3), tumor suppression
genes (DIRAS3, PEG3, PTPRO, and DNM3), and P53-target gene (CYFIP2).
The genes that were down-regulated included cell cycle regulation genes (CDK1
and CCNA2), DNA damage response genes (BRCA1 and BRIP1), as well as cell
proliferation marker Ki67 gene (MKI67). However, the gene expression re-
sponse to TSA is complicated. Some altered gene expression favors tumor
growth and progression while other gene expression changes inhibit tumor
growth and promote apoptosis. In conclusion, we identifıed the gene profıle in
primary culture of prostate tumor in response to a histone deacetylase inhibitor,
TSA. The therapeutic effects of HDACis could be influenced by the summation
of contradicting tumor promoting and suppression gene expression profıle
changes.
#1388 SphK2/S1P axis regulates hypoxia-mediated HIG- synthesis in
breast cancer cells. Nitai C. Hait, Aparna Maiti. Roswell Park Cancer Institute,
Buffalo, NY.
The hypoxia-inducible transcription factors (HIF)-1 and -2 play a critical
role in cellular response to hypoxia in solid tumors. Elevated HIF- expression
correlates with poor patient survival in a large number of cancers including
breast cancers. HIF- activates expression of genes promoting angiogenesis,
metastasis, increased tumor growth and resistance to treatments. Understand-
ing transcriptional regulation HIF- under physiologically relevant hypoxic
conditions would be helpful to reduce breast cancer growth. Our recent studies
identifıed that intracellular bioactive sphingosine-1-phosphate (S1P) generated
from nuclear sphingosine kinase 2 (SphK2) acts as an endogenousmodulator of
histone deacetylases (HDACs) epigenetically regulates gene transcription in
breast cancer cells. We wonder whether nuclear S1P epigenetically regulates
acetylated histones, positive transcription marks in hypoxia and regulate tran-
scription ofHIF- and target genes in breast cancer cells.We have used estrogen
receptor positive human breast cancer MCF-7 cells, triple-negative human
breast cancer MDA-231 cells and lung metastatic LM-2-4 cells derived from
MDA-231 cells for our studies. We found that hypoxic condition enhances nu-
clear bulk histone acetylation in breast cancer cells and enhances HIF- synthe-
sis. Down regulation of SphK2 with siRNA or using selective inhibitor of SphK2
(K145 compound) reduces nuclear S1P as well as bulk histone acetylation and
consequently reduces nuclearHIF- synthesis in breast cancer cells. Downregu-
lation of cytosolic sphingosine kinase 1 (SphK1) with siRNA reduces cytosolic
S1P does not alter nuclear bulk histone acetylation neither signifıcantly alter
nuclear HIF- synthesis in breast cancer cells. We also found that targeting
SphK2 with K145 compound dramatically reduces in vitro tumorosphere for-
mation in breast cancer cells. Our data suggested that targeting the SphK2/S1P
signaling could represent an attractive strategy for therapeutic intervention in
hypoxic breast cancers. Supported by Health Research, Inc. (HRI) Grant 71-
4084 (NCH), National Cancer Institute Grant R01CA160688 (KT).
#1389 Effects of geinstein on histone modifying enzyme expression in
prostate cancer.LanniAquila,Nick Smothermon, LisaMorey.Canisius College,
Buffalo, NY.
The present study sought to examine the expression of two histonemodifying
enzymes, SET8 and SIRT1, in human prostate cancer cell model when exposed
to increasing concentrations of genistein. Genistein is a phytoestrogen found
mainly in soy-based foods and is of importance due to the varying intake levels
worldwide. This compound is thought to have chemopreventive properties and
it is hypothesized to exert its affects by epigenetically modifying chromatin or-
ganization within cells. As an estrogen-like compound, genistein may exert ef-
fects similar to that of estrogen. For this reason, SET8, a histone methyltrans-
ferase, and, SIRT1, a histone deacetylase, were studied. Previously, these histone
modifying enzymes were found to play a role in estrogen signaling. In the pres-
ent study, cells were treated either for 24 hours (acute) or 5 days (chronic), total
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RNA was extracted, followed by an RT-PCR, and amplifıcation of the genes of
interest via PCR. Changes in gene expression were quantitated using ImageJ.
Overall, it was concluded that the exposure to genistein impacts the gene expres-
sion of both SET8 and SIRT1 within human prostate cancer cells.
#1390 DeregulationofRNAN6-adenosinemethylation contribute to liver
carcinogenesis. Mengnuo Chen, Larry L. Wei, Cheuk Ting Law, Felice HC
Tsang, Iris MJ Xu, Joyce Lee MF Lee, Carmen Wong CL Wong, Irene OL Ng,
Chun-Ming Wong. The University of Hong Kong, Hong Kong, Hong Kong.
Primary liver cancer, particularly the most common type hepatocellular car-
cinoma (HCC), is the third leading cause of cancer death worldwide. Case is
even worse in Asia due to extremely high prevalence of HBV/HCV infection,
which enhances the risk of HCC. However, the exact mechanism of how HCC
develops is still not clearly defıned. Previous studies have shown strong evidence
for epigenetic alterations in human carcinogenesis, which mainly focus on ab-
normal DNA methylation, histone modifıcations, and chromatin remodeling.
Recent studies suggest that diverse chemical modifıcations on RNAs, also
known as “epi-transcriptome”, constitute another layer of gene expression reg-
ulation. N-6-methyladenosine (m6A) is the most abundant modifıcation on
eukaryotic mRNA, which has been found to functionally influence mRNA sta-
bility, alternative splicing, and translation effıciency. However, the roles of m6A
deregulation in human carcinogenesis remain unclear. Through whole-tran-
scriptome sequencing, we identifıed that METTL3, the major component of
m6A methyltransferase, was signifıcantly up-regulated in human HCC. Up-
regulation of METTL3 negatively associated with poor patient overall and dis-
ease free survival. Functionally knockdown/knockout of METTL3 dramatically
inhibited HCC proliferation, migration and colony formation abilities in vitro
and signifıcantly suppressed in vivo tumorigenicity. In contrast, overexpression
of METTL3 using CRISPR/dCas9 SAM system modestly but signifıcantly en-
hanced HCC proliferation, migration, anchorage-independent growth in vitro
and tumor formation in vivo. In order to fınd the downstream mechanisms
whichmight attributed toMETTL3 oncogenic functionwe performedRNA-Seq
on two independent METTL3 knockdown cell lines to interrogated their tran-
scriptome changes. Based on RNA-Seq data, we identifıed a prominent tumor
suppressor SOCS2 as a potential down-stream target of METTL3. With m6A-
RNA immunoprecipitation (RIP) assay, we confırmed that SOCS2 mRNA was
subject tom6Amodifıcation in cancer cells. Inactivation ofMETTL3byRNAi or
treatment ofmethylation inhibitor (DAA) impairedm6AmediatedmRNAdeg-
radation and thereby stabilized SOSC2 mRNA. We further confırm SOCS2 tu-
mor suppressor function in HCC. Downregulation of SOCS2 was associated
with poor patient overall survival and disease free survival of HCC patients.
Knockdown of SOCS2 signifıcantly promoted HCC proliferation, migration in
HCC cells. In conclusion, our fındings suggested that deregulation of METTL3
and its associated m6Amodifıcation could contribute to human carcinogenesis
by imposing an epigenetic control on the stability and expressions of critical
tumor suppressor genes.
#1391 The epigenetic regulator, G9a, is a KRAS-inducible protein and its
inactivation inhibits PanIN formation by this oncogene. Angela Mathison,1
Ann Salmonson,1 Brooke Paradise,1MckennaMissfeldt,1 Juan Iovanna,2 Daniel
Billadeau,1 Raul Urrutia,1 Gwen Lomberk1. 1Mayo Clinic, Rochester, MN; 2Can-
cerology Research Center of Marseille (CRCM); INSERM U1068, Marseille,
France.
Pancreatic ductular adenocarcinoma (PDAC) ranks fourth as a cause of
cancer death in the USA and is almost universally fatal, with the annual
number of deaths equivalent to the number of newly diagnosed cases. Valu-
able research in the fıeld has revealed genetic aberrations that contribute to
PDAC development and progression, with KRAS being one of the most
frequent mutations in more than 90% of patient samples. However, to date,
any efforts to directly target KRAS have failed in the clinic. Thus, there is
indisputably an urgent need to further improve our understanding of mo-
lecular mechanisms underlying PDAC development as to identify novel
therapeutic targets, including druggable important downstream targets and
nodes orchestrated by oncogenic KRAS. In particular, we are interested in
epigenetic pathways involved in PDAC development and progression due to
the potential reversibility of any alteration, unlike genetic mutation. In the
current study, using a cell model that allows inducible expression of mutant
KRASG12D, we fınd that protein levels of the dimethyl-K9H3 histone methyl
transferase (HMT), G9a, and its complex partners are increased in response
to activation of the oncogenic Kras pathway. Furthermore, the activation of
this oncogenic pathway results in the formation of the G9a-GLP-Wiz trimer
complex, as determined by affınity protein purifıcation, combined with mass
spectrometry. In vivo experiments involving the cross of the Pdx1-CRE/LSL-
KRASG12D mice with G9afl/fl animals demonstrate that a loss of the
H3K9Me2 mark in the nucleus of exocrine cells is accompanied by a signif-
icantly reduced number of PanIN lesions. RNA-Seq experiments from these
animals reveal that these mice have reduced levels of typical molecular mark-
ers of PanINs. In addition, these experiments show changes in the levels in
several genes, which have been previously been shown to synergize with Kras
to mediate pancreatic cancer initiation. Congruently, pharmacological inhi-
bition of G9a using BRD4770 displays an inhibitory effect on KRASG12D-
induced cell proliferation. Combined, these data provide evidence for a key
role of the meK9H3-G9a pathway as a mediator of the oncogenic Kras re-
sponse and defınes a novel point of potential therapeutic intervention for
PDAC.
#1392 Development of a novel mouse model for intrahepatic cholangio-
carcinoma. Rebecca Marcus,1 Wai Chin Foo,2 Anirban Maitra,1 Sonal Gupta1.
1SheikhAhmedBin ZayedAlNahyanCenter for Pancreatic Cancer Research, The
University of Texas MD Anderson Cancer Center, Houston, TX; 2The University
of Texas MD Anderson Cancer Center, Houston, TX.
Cholangiocarcinoma (CCA) is a poorly understood cancer of the biliary epi-
thelium and the second most common type of liver cancer. Surgery currently
offers the only potential for cure; however, most patients present with advanced
disease and are therefore unresectable. TheCancerGenomeAtlas (TCGA) anal-
ysis and other recent genomic studies have revealed discrete epigenetic pertur-
bations amongst CCAs originating from different anatomic sites. Intrahepatic
cholangiocarcinoma (ICC) arises from the intrahepatic bile ducts, and a subset
of ICCs is characterized by loss-of-function mutations in the gene encoding for
the chromatin regulatory factor BRCA associated protein 1 (BAP1). Loss of this
protein may be associated with global epigenomic and transcriptomic altera-
tions that ultimately contribute to tumor progression andmetastasis dissemina-
tion. While elucidating the molecular pathogenesis of ICC may identify poten-
tial targeted therapies and improve early detection, inquiry into this disease has
been hampered by a lack of genetically faithful animal models. We developed a
genetically engineered mouse model (GEMM) of ICC that incorporates an in-
activating mutation in BAP1 combined with Kras activation. An Albumin-Cre
promoter was used to induce hepatoblast-specifıc mutations. Mutant Kras co-
operates with loss of BAP1 and results in lethal hepatic transformation and
dose-dependent survival. Kras activation alone results in extended disease la-
tency and survival 50weeks. Loss of BAP1 alone or heterozygous loss of BAP1
combined with mutant Kras shortens disease latency, with mice surviving 39
weeks on average. A signifıcant reduction in survival is seen with homozygous
loss of BAP1 andKras activation (Kras BAP1L/L). Thesemice survive on average
23 weeks (p 0.0045). Histopathologic evaluation of Kras BAP1L/L mice dem-
onstrates focal biliary precursor lesions, frank ICC, and hepatocellular carci-
noma (HCC). Mice with heterozygous deletion of BAP1 and Kras activation,
loss of BAP1 alone, or Kras activation alone develop HCC only. Given the bipo-
tential nature of hepatoblasts, the ICC phenotype of our GEMM may be en-
hanced by inducing biliary tree-specifıcmutations.Adenoviral Cre enzyme (Ad-
Cre) is used to achieve such combinatorial specifıcity, and a novel surgery was
developed whereby retrograde biliary tree administration of this enzyme is per-
formed. Surgery utilizing GFP-tagged adeno-associated virus confırms admin-
istration targeted to the biliary tree. Retrograde biliary tree injection of Ad-Cre
into ROSAmT/mG mice demonstrates Cre recombinase expression within
cholangiocytes, thereby establishing proof-of-principle. Ad-Cre injection in
Kras BAP1L/L mice to induce cholangiocyte-specifıc BAP1 deletion and Kras
activation is ongoing.
#1393 Chromatin remodelers as potential new targets for therapy of pe-
diatric sarcoma. Joana G. Marques,1 Berkley Gryder,2 Marco Wachtel,1 Javed
Khan,2 Beat Schaefer1. 1University Children’sHospital, Zurich, Switzerland; 2Na-
tional Institutes of Health, Bethesda, MD.
Fusion-positive rhabdomyosarcoma (FP-RMS) is a pediatric malignancy
driven by the fusion transcription factor PAX3-FOXO1, which generates an
aberrant gene expression signature leading to cell transformation. Since FP-
RMS cells are highly addicted to the fusion protein, it is in focus as target for
alternative therapies. Nevertheless, PAX3-FOXO1, as a transcription factor,
does not contain structural cavities and has a low druggability. We therefore
hypothesize that we can affect this aggressive subtype of RMS by targeting the
co-regulators that collaborate with the fusion protein in regulating transcrip-
tion. Recently, we have identifıed the NuRD (Nucleosome Remodeling and
Deacetylase) complex as a potential partner of PAX3-FOXO1 in gene expression
modulation. The NuRD complex is unique among chromatin remodeling com-
plexes due to its dual enzymatic activity (histone deacetylation through
HDAC1/2 and nucleosome positioning byCHD4 - chromodomain-DNA-bind-
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ing protein 4), offering new possible therapeutic targets. Silencing of two core
members of NuRD, CHD4 and RBBP4, led to a drastic decrease in FP-RMS cell
viability. Additionally, CHD4 depletion caused a complete regression of mouse
tumor xenografts, but it did not affect proliferation of myoblasts, fıbroblasts or
fusion negative RMS cells, despite the fact that these cells also carry high CHD4
expression levels.We further investigated the nucleosome remodeler CHD4 and
learnt that it affects the expression of approximately 50% of PAX3-FOXO1 tar-
get genes with most of these genes being upregulated, suggesting an activating
role for CHD4 in these cases. Consistent with a positive effect of CHD4 on gene
expression, ChIP-seq experiments with FP-RMS cell lines demonstrated that
NuRD occupies promoter and enhancer regions of highly expressed genes and
co-localizes with the fusion protein at regulatory regions of a subset of its target
genes. Next, we studied the influence of this nucleosome remodeler on the chro-
matin status by DNase hypersensitivity assays and determined that the presence
of aDNase signal at PAX3-FOXO1binding sites is concordantwith the presence
of CHD4. Hence, we suggest a scenario where CHD4 plays an essential role on
FP-RMS tumorigenesis by allowing chromatin to acquire an open architecture
that enables PAX3-FOXO1 mediated gene expression. In summary, our data
propose that CHD4 has a crucial role as a co-regulator of PAX3-FOXO1 driven
gene expression. To our knowledge, CHD4 is the fırst identifıed chromatin re-
modeler associated with PAX3-FOXO1 transcriptional activity, thus highlight-
ing the relevance of epigenetic regulation in FP-RMS tumor development and
opening chromatin remodelling as a possible new fıeld of action against this
tumor, which is driving ongoing work aimed at fınding fırst-in-class small mol-
ecules to inhibit CHD4 function.
#1394 Bioorthogonal Profıling of ProteinMethylation (BPPM) identifıed
MCM5 as a new substrate for SETD8 in DNA replication. Fabio Pittella Silva,
Gil Blum, Chamara Senevirathne, Luo Minkui.Memorial Sloan Kettering Can-
cer Center, New York, NY.
SETD8 is the only member of the SET domain containing methyltransferase
family, which catalyzes mono-methylation of K20 on histone H4 (H4K20me1).
Lysine residues of non-histone proteins such as p53 and proliferating cell nu-
clear antigen (PCNA) are also monomethylated, while lysine residues in Numb
were found to be dimethylated. As a consequence, SETD8 methyltransferase
activity is implicated in several fundamental cellular processes such as transcrip-
tional regulation and heterochromatin formation as well as processes that en-
sures genomic stability including DNA replication and the DNA damage re-
sponse. Although it has been suggested that SETD8 is involved in DNA
replication as a positive regulator of origin licensing throughH4K20methyation
and by supportingOkazaki fragment processing through PCNAmethylation, to
date, there is no evidence whether other key protein in the replication fork is
directly modifıed by SETD8. To address this question, we used Bioorthogonal
Profıling of ProteinMethylation (BPPM)with engineered enzyme and synthetic
SAM analogues to profıle new substrates for SETD8.We genetically engineered
SETD8 and identifıed mutants amenable to accommodate non-native SAM an-
alogues containing a terminal alkynemoiety for click chemistry. The engineered
SETD8 can transfer this distinct chemical moiety into target proteins for subse-
quent pulldown and identifıcation of the modifıed substrates. Among the new
substrates discovered, we identifıed MCM5, a subunit of the hexameric
minichromosomemaintenance (MCM)DNAhelicase complex.MCM5directly
interactswithMCM2and 3 to form theMCM2-7 hexamerwhich associateswith
the origins of DNA replication to form part of the pre-replicative complex
(preRC), playing a key role during replication initiation and elongation. We
found that SETD8 can mono-methylate MCM5 directly affecting its binding
affınity toMCM2 and 3. In addition, MCM5mutations at the methylated lysine
further evidenced a stronger binding to its interacting partners contributing to
the formation of the MCM hexamer. Taken together our results indicate that
MCM5 methylation contributes to the assembly of the MCM complex suggest-
ing an important role for SETD8 in replication initiation. Our fındings may
bring new perspectives on the biological importance of SETD8 during DNA
replication.
#1395 Deciphering inosinome in glioblastoma versus normal cortex. An-
gela Gallo,1 Alessandro Silvestris,1 Valeriana Cesarini,1 Valentina Tassinari,1
Nicolò Mangraviti,1 Ernesto Picardi,2 Graziano Pesole2. 1Ospedale Pediatrico
Bambino Gesu, Roma, Italy; 2Università di Bari, Bari, Italy.
Cancer is driven by alterations of the genomic information, which carries
mutations in key genes providing selective advantage for clonalmultiplication of
cancer cells. However, mutations within DNA are not the only source for cell
alteration. RNAmolecules are targets of a series of post-transcriptional modifı-
cations, such as splicing andRNAediting, that can affect sequence, structure and
stability. Themost common type of RNAediting in humans converts Adenosine
in RNA targets into Inosine (A-to-I) and is catalyzed by two adenosine deami-
nases that act on dsRNA (ADARs) family of enzymes (ADAR and ADARB1).
Inosines are subsequently interpreted as guanosines by several cellular proteins
and could ultimately lead to a genomic mutations (A-to-I/G). At present, it has
been estimated that over 4 millions editing sites exist in our transcriptome in-
volving coding and non-coding RNAs. These huge amounts of Inosine at RNA
level are necessary for our survival and their levels is highly regulated in different
tissues and during development. Considering the importance of ADAR activity
in our cells we believe that if ADARare notwell regulated theymay contribute to
cancer on set and/or progression. The advent of high-throughputRNAsequenc-
ing has enabled identifıcation of RNA editing sites and global analyses of cancer
transcriptomes demonstrate that ADAR-mediated RNA editing dynamically
contributes to genetic alterations in cancer, including high-grade gliomas. Gli-
oblastoma (GBM) is one of the most common and aggressive primary brain
tumor in humans and despite advances in understanding the molecular mech-
anisms underlying these tumors, current treatments are ineffective. In order to
elucidate the glioma-specifıc RNA editing signature, we analyzed 146 RNA-Seq
of primary glioblastomas from the TCGAdataset compared to 132 normal brain
cortex RNA-Seq from the GTEx database and purifıed pools of normal cortex
astrocytes. A-to-I editing events has been detected using a collection of more
than 4 million annotated edited substrates and the REDItools suite of python
scripts with stringent fılters. By means of the Cuffquant/Cuffdiff tools, we have
also compared global transcriptome profıles and ADAR genes expression pat-
terns at gene level isoform level and using IHC at protein level. We found that a
general down regulation of editing events at both recoding and non -recoding
(Alus) sites that correlate with a down expression of ADARB1 enzyme. No
differences were observedwithADAR expression. Overall, we observed a strong
editing landscape perturbation in glioblastoma that could be important for iden-
tifying the most effective target genes for possible therapeutic intervention.
#1396 Role of epigenetic reader and alternative mRNA splicing variant
MBD2 variant 2 in triple-negative breast cancer. Emily A. Girsch,1 Bin Bao,1
CristinaMitrea,1 Gregory Dyson,1 Julie Boerner,1 Lisa Polin,1 Stan R. Terlecky,2
Aliccia Bollig-Fischer1. 1Wayne State University, Detroit, MI; 2Seton Hall Uni-
versity, South Orange, NJ.
Background: Among all breast cancer patients, those diagnosed with the tri-
ple-negative breast cancer (TNBC) subtype have the worst prognosis, in part
attributable to the fact that TNBC lacks targets for effectivemolecularly-targeted
therapies. The concept that EGFR inhibitor drugs could be used as a targeted
treatment against TNBC has been put forth because roughly 50% of TNBC
express high levels of EGFR. However clinical trials targeting EGFR did not
signifıcantly improve patient outcomes. Our recent work offers a potential ex-
planation as to why EGFR inhibitors failed and supports an innovative thera-
peutic approach combining an EGFR tyrosine kinase inhibitor with the novel
antioxidant biologic, CAT-SKL.Our data indicate that inhibition of cancer stem
cell-like cells depends on antioxidant-induced downregulation of an alternative
mRNA splice variant of the methyl-CpG binding domain 2 gene, MBD2_v2.
Objective and Methods: The purpose of the present study was to evaluate the
importance of MBD2_v2 in TNBC and better understand how CAT-SKL regu-
lates its expression. Using TNBC cell lines we investigated the effects of
MBD2_v2 expression on tumor initiation capacity. Furthermore we studied
MBD2_v2 mRNA levels in an in vivo tumor xenograph mouse model of TNBC
and in human TNBC samples using an existing database. Then by RNA-seq
analysis we assessed how CAT-SKL regulates MBD2_v2 expression in TNBC
cells through differential gene expression. Results: The results support that
MBD2_v2 expression is regulated by redox signaling in TNBC cells, which is
tightly linked to TNBC cell tumor initiation capacity. Furthermore, MBD2_v2
was upregulated in tumors harvested from overweight mice, which also dis-
played increased tumor take rate, suggesting that a pro-inflammatory tumor
microenvironment could play a role in promoting MBD2_v2 expression. In
addition, RNA-seq analysis identifıed an overrepresentation of mRNA splicing
factors with expression downregulated by CAT-SKL treatment of TNBC cells.
From this gene set two splicing co-factors are highlighted: SRRM1 and CPSF3.
These co-factors are critical for splicing factor function, 3= end formation and
polyadenylation; and both have been linked via protein-protein interaction to a
relevant exonic splicing enhancer site in exon 3 of the MBD2 _v2 transcript.
Finally, according to the KaplanMeier Plotter database highMBD2_v2 levels in
BC were associated with shorter relapse free survival. Conclusion: Our investi-
gation sheds light on the relevance of MBD2_v2 expression in TNBC, and how
a select antioxidant regulates its expression. The application of which holds
promise of a novel, targeted therapeutic modality for TNBC, the subtype with
the worst prognosis and highest need for treatment options.
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#1397 Antisense oligo nucleotide of Annexin A4 improved platinum re-
sistance in ovarian clear cell cancer. Reisa Kakubari,1 Satoshi Nakagawa,2 Ta-
dashi Iwamiya,1 Eiji Kobayashi,1 Shinnya Matsuzaki,1 Yutaka Ueda,1 Kiyoshi
Yoshino,1 Yuya Kasahara,1 Satoshi Obika,1 Tadashi Kimura,1 Satoshi Serada,3
Tetsuji Naka,3Minoru Fujimoto3. 1OsakaUniversity, OSAKA, Japan; 2Sakai city
medical center, OSAKA, Japan; 3National institute of Biomedical Innovation,
OSAKA, Japan.
Introduction: Ovarian cancer in Japan are classifıed as clear cell carcinoma
(CCC) more than 20 %, this percentage is higher than in Europe and United
States. Besides, it is well known that CCC of ovary is highly resistant to cancer
chemotherapy including carboplatin and paclitaxel treatment.We reported that
Annexin A4 protein was overexpressed in ovarian CCC tissues by immunohis-
tochemical analysis. Elevated Annexin A4 level has been detected in various
epithelial cancer cell lines and have reported associating with chemoresistance
to platinum-based cancer drugs. To overcome the platinum chemoresistance,
we thought antisense oligonucleotides (ASOs) to be a good therapeutic option in
a way of highly specifıc therapy for improving chemoresistance by suppressing
the expression of Annexin A4 in cancer cells. Methods: We generated ASO
targeting Annexin A4 with 2=, 4=-bridged nucleic acid. And we analyzed sup-
pression of Annexin A4 in ASO-transfected RMG-I cell line (CCC) in vitro
using real timePCRandwestern blotting. In 16 types ofASOs targetingAnnexin
A4, 2 ASOs were eligible. Cells were seeded in 96-well plates (2,000 cells per
well). Next day, cells were transfected with ASOs using lipofectamine 2000 and
were exposed to various concentrations of cisplatin (0 - 100M) for 72 hr. Then,
drug concentrations resulting in a 50% inhibition of cell growth (IC50 values)
were calculated. Intracellular platinum accumulation in Annexin A4 overex-
pressing cells was analyzed. To assess the improvement of platinum resistance in
vivo, we used ICR nu/nu mice xenografted subcutaneously with RMG-I cells.
Intraperitoneal injection of cisplatin 3mg/kg after intratumoral administration
of ASO 1mg/kg each twice a week were given to xenograft mice. Results: By
realtime PCR analysis, among strong 16 types of ASOs targeting Annexin A4, 2
ASOs showed strong knockdown effıciency (about 80% knockdown) compared
to negative control ASOs. Western blotting analysis showing knockdown of
AnnexinA4 expressionwas observed inAnnexinA4ASO transfected cells com-
pared to no treatment or control ASOs in vitro. ASO-transfected RMG-I cells
was less resistant to cisplatin (IC50 3.3M) compared with control cells (IC50
 5.2M) Same result were obtained with carboplatin. Platinum resistance was
signifıcantly improved in treated with Annexin A4ASO and cisplatin compared
to control ASO and cisplatin treated group in vivo. Conclusion: By transfection
of ASOs targeting Annexin A4, platinum resistance have improved in vivo and
in vitro, AnnexinA4 have associatedwith efflux of platinum anti-tumor drug. In
conclusion, antisense oligonucleotides for Annexin A4 will be a therapeutic
option for ovarian clear cell carcinoma with chemoresistance to platinum anti-
tumor drug.
#1398 Loss of PIWIL4 and piRNAs attenuate somatic methylome and
genome stability. Syuan-Cih Lin,1 Chia-ChenChiu,1 Shou-TungChen,2 Yao-Li
Chen,3 Ping-Yi Lin,3 Shu-Huei Hsiao,1 Yu-Wei Leu1. 1National Chung Cheng
Univ., Chia-Yi, Taiwan; 2Comprehensive Breast Cancer Center, Changhua, Tai-
wan; 3Transplant Medicine & Surgery Research Centre, Changhua, Taiwan.
Piwi-like RNA-mediated gene silencing 4 (PIWIL4) is expressed in somatic
tissues and is proposed to silence the transposition of repetitive elements like
long interspersed nuclear elements (LINEs) through DNA methylation and
maintain the genome stability. Through the knockout of PIWIL4 gene by
CRISPR/Cas9 system inmesenchymal stemcells (MSCs),MDA-MB-231 (breast
cancer cell line), HT29 (colon cancer cell line) andAGS (gastric cancer cell line),
the piRNA biogenesis was decreased and so was the methylation within LINE1
target loci and global methylation. The recruitment of SUV39H1, a histone H3
methyl-transferase, into nucleus was blocked, leading to the reduction of silenc-
ing tri-methylation of histoneH3 at lysine 9. Concurrently, the active H3K4me3
mark increased after knockout. Also, global CTCF bindings were distorted after
the knockout of PIWIL4 especially at the bindings franking the piRNA clusters.
This distortion implied the disorganization of genomic conformationwhichwas
validated by karyotyping. Through chromosomal G-banding, aneuploidy was
observedwhich indicated the loss of genomic stability. The knockout of PIWIL4
also results in disorganized cytoskeleton, therefore, changed cell stiffness as
measured by atomic force microscopy. Neural and hepatic induction of MSCs
were also blocked by the knockout of PIWIL4. In correlation, tissue arrays de-
tected abnormal PIWIL4 expression in gastric (n45), colon (n30) and breast
cancers (n30). In conclusion, we found that PIWIL4-piRNA interaction helps
to maintain somatic DNAmethylome, genome stability and stiffness in somatic
stem cells. The loss of PIWIL4 expression might then a candidate for cancer
biomarker. (Supported by: MOST-105-2314-B-371 -008, MOST-105-2320-B-
194 -004, MOST Taiwan)
#1399 In vitro characterization of several enzymes of the Fe(II)/2-oxoglu-
tarate-dependent dioxygenase superfamily using a universal succinate detec-
tion assay. Juliano Alves, Said Goueli, Hicham Zegzouti. Promega Corporation,
Madison, WI.
The covalent modifıcation of histone proteins, DNA and RNA by Fe(II)/2-
oxoglutarate-dependent dioxygenases are key to the modulation of biological
processes such as epigenetics, hypoxic signaling andDNA/RNArepair.Of these,
JumonjiC domain-containing histone lysine demethylases (JMJCs), the ten-
eleven-translocation (TET)DNAdioxygenases, theALKBDNA/RNAhydroxy-
lases and the prolyl hydroxylases EGLN1-3 have generated increased interest as
potential drug targets for the treatment of a number of pathological conditions,
including cancer. Since succinate is a common product to all Fe(II)/2-oxogluta-
rate-dependent dioxygenases, we determined the substrate specifıcities, the ap-
parent kinetic constants for several JMJCs and members of the dioxygenase
superfamily (i.e.: TET1, EGLN1, ALKBH3 and FTO), as well as inhibition pro-
fıles of reported inhibitors using a novel bioluminescent and homogenous suc-
cinate detection assay. Our results demonstrate that succinate detection is a
useful strategy for the characterization ofmultiple Fe(II)/2-oxoglutarate-depen-
dent dioxygenases with distinct substrate requirements, enabling the investiga-
tion of a large number of enzymes that cannot be evaluated in a miniaturized or
high-throughput manner with the methods currently available.
#1400 Using tumor spheroids to evaluate the effıcacy of EZH2 inhibitors
in clear cell renal cell carcinoma (ccRCC). Darmood Wei, Youfeng Yang,
Christopher J. Ricketts, Carole Sourbier, Laura S. Schmidt,WilliamM. Linehan.
NCI, Bethesda, MD.
Enhancer of zeste homolog 2 (EZH2) is a key component of the polycomb
repressive complex 2 (PRC2). EZH2 is frequently overexpressed in a wide vari-
ety of human malignancies including non-Hodgkin lymphoma, gastric cancer,
pancreatic cancer, and lung cancer. Thus it has potential to become a therapeutic
target. Characterization of EZH2 as a therapeutic target in clear cell renal cell
carcinoma (ccRCC) has not been fully explored. ccRCC have been defıned by
mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in combina-
tion with chromosome 3p loss. Recent sequencing efforts have revealed that
several chromatin remodeling genes encoded on chromosome 3p are often mu-
tated, of which PBRM1 is the most frequent (41%). The PBRM1 gene codes for
the BAF180 protein, a SWI/SNF chromatin remodeling complex subunit. Loss
of BAF180 in ccRCC may disrupt the PBAF variant of the SWI/SNF complex.
The SWI/SNF complex remodels the chromatin landscape by either sliding or
evicting the nucleosomes from the chromatin. This chromatin remodelingmod-
ulates the accessibility to promoter regions by transcriptional machinery. It is
through this mechanism that the SWI/SNF complex can regulate a range of
cellular processes. It has been demonstrated that the SWI/SNF complex can act
antagonistically to the PRC2 complex by evicting PRC2 complex from the pro-
moters of tumor suppressors. Disruption of the SWI/SNF complex would im-
pede the eviction of the PRC2 complex, similarly observed in SNF5-defıcient
malignant rhabdoid tumors. Therefore, we hypothesize that PBRM1 inactiva-
tion disrupts specifıc SWI/SNF complexes allowing EZH2 to bind and repress
target tumor suppressor genes. Thus inhibition of EZH2 in ccRCCmay present
as a targeted therapeutic option in tumors with PBRM1 mutations. We have
investigated EZH2 in ccRCCcell lineswith PBRM1mutations and observed that
these cells lines have overexpression of EZH2 in comparison to RPTEC (renal
cortex proximal tubule epithelium cell line). We examined the effects of two
EZH2 inhibitors (GSK126 and EPZ6438) on ccRCC tumor spheroids. Our pre-
liminary data suggests EZH2 inhibition results in reduced growth of PBRM1
mutant cell lines grown as tumor spheroids.
#1401 Deterring breast cancer progression. The critical role of a lipid-
sphingolipid epigenetic mechanism of cell fate. Stefano Rossetti, Vincenzo
Gagliostro, Nicoletta Sacchi. Roswell Park Cancer Inst., Buffalo, NY.
Genetic and environmental factors cooperate to assure precise genome-wide
epigenetic regulation of the mammary epithelia cell transcriptome. Our interest
in regulatory epigenetic mechanisms that, by determining mammary epithelial
cell decisions, are pivotal to deter the onset and progression of breast cancer, let
us identify a regulatory epigeneticmechanism ofmammarymorphogenesis that
links a physiological regulatory lipid of environmental origin (all-trans retinoic
acid, RA) with sphingolipids capable of determining either cell death (ceramide,
CER) or cell life (sphingosine 1 phosphate, S1P). Whenever RA, for different
reasons, fails to perform the epigenetic transcriptional control of neutral sphin-
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gomyelinase 2 (nSMase2/SMDP3), involved in the synthesis of pro-apoptotic
CER, S1P fosters both pro-proliferative and pro-invasive activity. Apparently, in
the absence of epigenetic control of CER production by RA, S1P contributes to
determine RA tumorigenic action. This study provides the rationale for combi-
nation therapeutic approaches with epigenetic drugs and inhibitors of either
sphingosine kinase, the enzyme involved in S1P synthesis, or S1P receptors. This
study was supported by the NCI R01 CA127614 grant (NS).
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Genomic Instability and Cancer Therapy
#1402 NME3 links mitochondrial fusion to DNA repair in nuclear ge-
nome. Zee-Fen Chang. National Taiwan University, Taipei, Taiwan.
Inmammals, there are 10 isoforms of NME (NDPKinase), which catalyze the
reversible reaction of NTPs formation from NDP and ATP. By RNA interfer-
ence, NME3was found critical forDNA repair. Data from analysis of the steady-
state levels of rNTPs and dNTPs suggest that NME3 does not play a critical role
in determining the total pools of these nucleotides. However, its mitochondrial
localization and catalytic function are necessary for its function in DNA repair.
Super-resolution microscopy analysis indicates the localization of NME3 at mi-
tochondrial outermembrane.We further used APEX-mediated biotinylation to
identify proteins interacting with NME3. Among them, Mfn1 is validated to
associate with mitochondrial NME3 in vitro and in vivo. We provide evidence
thatNME3 is required forDNAdamage-inducedmitochondria fusion viaGTP-
mediated fueling of Mfn1. The lack of this process increased nucleotide oxida-
tion and sustained DNA damage in nuclear genome. These data highlight the
function of NME3 in mitochondrial fusion, which is required for the mainte-
nance of genome integrity.
#1403 PCNA-dependent cleavage and degradation of SDE2 regulates re-
sponse to replication stress.Ukhyun Jo,1 Winson Cai,1 JingmingWang,1 Yoo-
jin Kwon,1 Alan D. D’Andrea,2 Hyungjin Kim1. 1Stony Brook University, Stony
Brook, NY; 2Dana-Farber Cancer Institute, Boston, MA.
Maintaining genomic integrity during DNA replication is essential for cellu-
lar survival and for preventing tumorigenesis. Proliferating cell nuclear antigen
(PCNA) functions as a processivity factor for DNA replication, and posttrans-
lational modifıcation of PCNA plays a key role in coordinating DNA repair
against replication-blocking lesions by providing a platform to recruit factors
required forDNArepair and cell cycle control.Here, we identify humanSDE2 as
a new genome surveillance factor regulated by PCNA interaction. SDE2 con-
tains an N-terminal ubiquitin-like (UBL) fold, which is cleaved at a diglycine
motif via a PCNA-interacting peptide (PIP) box and deubiquitinating enzyme
activity. The cleaved SDE2 is required for negatively regulating ultraviolet dam-
age-inducible PCNA monoubiquitination and counteracting replication stress.
The cleaved SDE2 products need to be degraded by the CRL4CDT2 ubiquitin E3
ligase in a cell cycle- and DNA damage-dependent manner, and failure to de-
grade SDE2 impairs S phase progression and cellular survival. Collectively, this
study uncovers a new role for CRL4CDT2 in protecting genomic integrity against
replication stress via regulated proteolysis of PCNA-associated SDE2 and pro-
vides insights into how an integrated UBL domain within linear polypeptide
sequence controls protein stability and function. Knowledge on such mecha-
nism will be useful to identify novel cancer therapeutic interventions exploiting
deregulated ubiquitin signaling and SDE2 activities in cancer.
#1404 Regulation of 53BP1 by the structural nuclear protein NuMA.
Naike Salvador Moreno. Wake Forest Baptist Medical Center, Winston Salem,
NC.
Cells repair DNA double-strand breaks (DSB) through two major pathways:
homologous recombination (HR) and non-homologous end joining (NHEJ).
The choice between these two pathways is critical to cell survival and is altered in
cancers. 53BP1 is a protein with an important role in this choice: it promotes
NHEJ by blocking CtIP-dependent DNA resection. Here, we present a new
negative regulation mechanism of 53BP1 that relies on the structural protein
NuMA. This protein participates in mitotic spindle assembly, influences chro-
matin organization during the interphase and modulates the chromatin re-
sponse to DNA damage. We identifıed NuMA in a proteomics analysis of a
53BP1-interacting proteins. The interactionwas confırmed by reciprocal immu-
noprecipitation andwith a FRETassay. In response toDSB,wemeasured greater
than 50% decreased 53BP1-NuMA binding, which suggests that NuMA may
restrain 53BP1 diffusion in the absence of DNA damage. Fluorescence correla-
tion spectroscopy (FCS) measurements in cells expressing GFP-tagged 53BP1
support this hypothesis. Moreover, NuMA overexpression inhibited 53BP1 re-
cruitment atDNAdamage sites in lasermicroirradiation assays, whereasNuMA
silencing had the opposite effect. 53BP1 plays an essential role in B cell class
switch recombination and mediates PARP inhibitor sensitivity in BRCA1-null
cells. NuMA overexpression prevented immunoglobulin switching, and over-
wrote cancer cell sensitivity to PARP inhibitors to the same extent as 53BP1 loss
of function.Our results help understand how 53BP1 is controlled, and shed light
on the mechanisms regulating PARPi sensitivity.
#1405 A novel chemotherapeutic agent to treat tumors with DNA mis-
match repair defıciencies. Kyungjae Myung,1 Yongliang Zhang,2 Young-Un
Park1. 1Institute for Basic Science, Ulsan, Republic of Korea; 2NIH, MD.
Impairing the division of cancer cells with genotoxic smallmolecules has been
a primary goal to develop chemotherapeutic agents. However, DNA mismatch
repair (MMR)-defıcient cancer cells, are resistant to most conventional chemo-
therapeutic agents. Here we have identifıed baicalein as a small molecule that
selectively kills MutS-defıcient cancer cells. Baicalein binds preferentially to
mismatched DNA and induces a DNA damage response in a mismatch repair-
dependent manner. In MutS-profıcient cells, baicalein binds to MutS to dis-
sociateCHK2 fromMutS leading to S phase arrest and cell survival. In contrast,
continued replication in the presence of baicalein in MutS-defıcient cells re-
sults in a high number of DNA double-strand breaks and ultimately leads to
apoptosis. Consistently, baicalein specifıcally shrinks MutS-defıcient xeno-
graft tumors and inhibits the growth of AOM-DSS-induced colon tumors in
colon-specifıc MSH2 knockout mice. Collectively, baicalein offers the potential
of an improved treatment option for patients with tumors with a DNA MMR
defıciency.
#1406 Towards an RNA expression-based signature for oncogene-in-
duced replication stress. Sergi Guerrero, Rudolf Fehrmann, Marcel ATM van
Vugt. University Medical Center Groningen, Groningen, Netherlands.
Introduction Certain tumor subgroups, including triple negative breast can-
cers (TNBCs), are characterized by high levels of genomic instability (GI). These
tumors are typically very aggressive and diffıcult to threat. Increasingly, we re-
alize that GI is fueled by replication stress (RS). RS can be induced by expression
of oncogenes, including CCNE1, MYC and CDC25A, which perturb initiation,
elongation and/or termination phases of DNA replication. RS poses a threat to
cellular viability, and tumor cells with high levels of RS will therefore increas-
ingly depend for their survival on DNA damage checkpoint and repair path-
ways. Possibly, this increased dependence creates therapeutic opportunities.
Unfortunately, it is currently diffıcult to determine levels of RS in tumors, a
requirement to effıciently select patients for novel treatments. The aim of this
work is to develop an RNA expression-based signature for oncogene-induced
replication-stress. Material & Methods A panel of cell lines (RPE-1, RPE-1-
P53/, MDA-MB-231, BT-549 and HCC-1806) was engineered to doxycy-
cline-inducibly express a set of oncogenes (CDC25A, CCNE1 or MYC). Single
DNA fıber replication analysis in combination with immunoblot analysis of RS
markers was used to validate the cell linemodels.MTT assays were performed to
assess sensitivity to ATR and Wee1 inhibitors. RNA-sequencing was used to
uncover expression changes upon RS induction. Results Treatment with doxy-
cycline resulted in high expression levels of CDC25A, CYCLINE or MYC. Ex-
pression was heterogeneous but present in the far majority of RPE-1 cells (40%
CDC25A, 88% CCNE1 and 93% MYC). DNA fıber analysis was subsequently
used to study the alteration of DNA replication dynamics. Severe reduction on
ongoing DNA synthesis velocity was shown in engineered cells (RPE-1 and
MDA-MB231) under doxycycline treatment, confırming prominent RS. In line
with elevated levels of RS, oncogene induction resulted in elevated levels of ATR
activity, as judged by phospho-CHK1 and phospho-RPA levels. Importantly,
oncogene-expression enhanced sensitivity toWee1 and ATR checkpoint inhib-
itors. Subsequently, RNA samples were harvested under the presence and ab-
sence of doxycycline. In parallel to oncogene-expression, hydroxyurea, a chem-
ical agent known to increase stalled replication forks was applied as a DNA
damage control. RNA-sequencing analysis will be performed to identify differ-
entially expressed genes upon oncogene expression. Commonly identifıed genes
over multiple cell lines and shared between the different oncogenes will be used
to build a ’RS’ profıle. ConclusionOur results indicate that oncogene expression
provokes RS in multiple cell line models and induces impaired replication fork
stability and sensitivity to cell cycle checkpoint inhibitors. These models are
therefore valid to develop an RNA expression-based qualifıer in order to facili-
tate patient selection towards novel therapeutics.
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#1407 Translational regulation of RPA2 via IRES by UNR and eIF3a. Jia-
Jia Cui, Lei-Yun Wang, Ji-Ye Yin. Department of Clinical Pharmacology,
Xiangya Hospital, Central South University, Changsha, China.
Purpose: Translation is a critical step in the process of genetic information
expression. Internal ribosome entry site (IRES) element is a RNA sequence with
a complex structure, which plays an important role in cap independent transla-
tion regulation. The activation of RPA2 IRES element can cause its abnormal
expression and fınally effects DNA repair pathway. We conducted series of as-
says to explore the mechanism of translation initiation regulation of RPA2 via
IRES by UNR and eIF3a Methods: Biotin pull down assay was taken to investi-
gate the physical interaction between RPA2 IRES and UNR. UNR was knocked
down and overexpressed in H1299, A549 and SK-MES cell lines. Western blot
and real-time PCR were used to detect protein level and mRNA level respec-
tively. For interaction of eIF3a withUNR, CO-IP assay and co-localization assay
were conducted. And GST pull down assay was carried out to further identify
their exact binding domains. RPA2 IRES-interacting domains ofUNRand eIF3a
were explored with EMSA assay. Results: UNR protein could directly bind to
RPA2 IRES as well as to eIF3a, and UNR regulated the protein expression of
RPA2 in H1299, A549 and SK-MES cells, while the mRNA level of RPA2 re-
mained no change. UNR interacted with the fırst domain of eIF3a and with
RPA2 IRES via its own fırst domain. However, we have not found a clue for the
direct interaction of eIF3a with RPA2 IRES yet. Conclusion: UNR cooperated
with eIF3a to regulate the RPA2 IRES activity and hence to regulate the RPA2
protein expression. This might be a regulation mechanism of cellular internal
ribosomal entry site affecting translation initiation, the rate-limiting step of
translation.
#1408 LIM protein Ajuba participates in the ATR response by direct in-
teraction with RPA70. SandyWan S. Fowler,1 Diego Loayza,1 Pascal Maguin2.
1Hunter College, Graduate Center City University of New York, New York, NY;
2Rockefeller University, New York, NY.
DNA damage response (DDR) pathways are essential for genome stability
and cell survival. Specifıcally, the ATR kinase is activated by DNA replication
stress or UV irradiation. An early event in this activation is the phosphorylation
and local recruitment of RPA, a single strand DNA binding protein. Our lab has
shown that the LIM protein Ajuba associates with RPA, an OB fold-containing
protein, and this interaction prevents an unscheduled ATR response. We hy-
pothesize that Ajuba represses the ATR pathway through direct interactionwith
RPA, thereby preventing activation of ATR. To test this hypothesis, we em-
ployed E. coli and in vitro translation system for the production of recombinant
proteins. Our data show that Ajuba directly associates with the large subunit of
RPA, RPA70. The domains involved in the interaction were the C-terminal OB
folds of RPA70, and the region between the PreLIM and LIM domains in Ajuba.
We speculate that this interaction mediates the association of Ajuba with the
RPA complex in cells. Understanding the implication of the Ajuba and RPA
interaction will allow us to gain insights on the regulation of DDR, which is
involved in early events of cellular transformation and tumorigenesis in human
cells.
#1409 Analysis of 16,172 patient-derived tumor samples indicate TPX2 as
being essential for survival of genomically instable cancer cells. Stephanie E.
vanGijn,1 EllesWierenga,1 AnneMargrietHeijink,2 Rudolf S. Fehrmann,1Mar-
cel A. van Vugt1. 1University Medical Center Groningen, Groningen, Nether-
lands; 2European Research Institute for the Biology of Ageing, Groningen, Neth-
erlands.
Mutations in homologous recombination (HR) genes, including BRCA1 and
BRCA2, compromise DNA repair and lead to genomic instability (GI). GI is
lethal to normal cells but is a characteristic of many cancers. Apparently, these
cancers are somehow re-wired to survive high levels of GI. Identifıcation of the
genetic alterations that allow viability of genomically instable tumor cells may
uncover novel therapeutic targets. To elucidate how these tumor cells are re-
wired, we analyzed publically available mRNA expression data of 16,172 human
cancer samples. Functional genomicmRNAprofıling (FGmRNA-profıling) was
applied on these samples to infer levels of GI and to capture the downstream
effects of somatic copy number alterations on gene expression. A genome-wide
association analysis was subsequently performed to assess the correlation be-
tween FGmRNA signals of individual genes with the degree of GI. From the top
250 genes with strong positive correlation with GI, 11 genes were prioritized
based on a co-functionality network in which genes are co-regulated and share
similar predicted biological function. The 11 genes that were identifıed in this
cluster were: BIRC5, UBE2C, CENPA, CDCA3, DEK, SKP2, TPX2, KIF2C,
RAD21, MYBL2 and WDR67. To validate these fındings in genetically-defıned
models, we engineered a panel of 5 triple negative breast cancer (TNBC) cell
lines with doxycycline-inducible shRNAs targeting BRCA2. BRCA2 depletion
resulted in a failure of RAD51 foci to localize to DNA double strand breaks
which generated isogenic cell line pairs profıcient and defıcient of HR repair.
First, we depleted each of the identifıed 11 genes using RNA interference in
BT-549 cells and observed that depletion of TPX2, a microtubule-associated
protein, led to largest differential levels of cell death when comparing the
BRCA2-defıcient with the BRCA2-profıcient context (86.6% vs 32.9% cell death
in BRCA2-depleted vs controlled depleted cells respectively). Subsequently, we
could replicate this decreased survival with TPX2 depletion in a BRCA2-defı-
cient context in an additional 2 out of 4 other TNBC cell lines. Furthermore, we
investigated whether BRCA2-depleted cells were also more sensitive to deple-
tion ofAurora kinaseA, a substrate of TPX2. For this purpose,mousemammary
tumor cell lines, derived from Tp53/ or Brca2/;Tp53/mice, or a Brca2-
reconstituted version thereof were treated with an Aurora A inhibitor, Alisertib.
Again, we found that the BRCA2-defıcient cell line wasmore sensitive toAurora
A inhibition than the two BRCA2-profıcient cell lines. In conclusion, FGm-
RNA-profıling of mRNA expression data of human cancer samples identifıed
TPX2 as an essential gene for survival of BRCA2-defıcient breast cancer cells,
when compared to BRCA2-profıcient cells. Thus, targeting the TPX2/AURKA
axis could potentially act as a novel therapeutic target in the treatment of
genomically instable cancers.
#1410 Proliferation during epithelial-to-mesenchymal transition induces
genomic instability. Valentine Comaills, Lilian Kabeche, Robert Morris, Min
Yu, Marissa Wells Madden, Joseph A. LiCausi, Nicola Aceto, Yu Zheng, David
T. Miyamoto, Sridhar Ramaswamy, Lee Zou, Daniel A. Haber, Shyamala Ma-
heswaran.Massachusetts General Hosp. Cancer Ctr., Charlestown, MA.
Epithelial to mesenchymal transition (EMT), a morphogenetic process re-
quired for proper embryonic development, is adopted by cancer cells during
tumor progression. We show that induction of EMT by TGFß or other EMT-
inducers such as Snail leads to genomic instability, associated with failed cyto-
kinesis and chromosome missegregation resulting in aneuploidy and polyp-
loidy. These defects are dependent on persistent proliferation of cells
undergoing EMT and are absent in normal cells that growth arrest during EMT.
While EMT and the associated mitotic abnormalities are reversible upon re-
moval of the EMT-inducer, the resulting chromosomal abnormalities are inher-
ited. TGFß-induced genomic instability is associated with the acquisition of
tumorigenic phenotypes and the resulting tumors are enriched for a genomi-
cally-altered tumor cell population, which exhibits differential drug sensitivity.
In breast and prostate cancer cells circulating in the blood, TGFß and EMT gene
signatures are signifıcantly correlated with aneuploid gene signatures. Analysis
of single circulating tumor cells (CTC) fromwomen with metastatic breast can-
cer reveals increased in genomic instability in mesenchymal CTCs. Together,
these fındings identify a novel mechanism whereby tumor microenvironment-
derived signals impact heritable genetic changes within cancer cells.
#1411 Differential mismatch repair-dependent damage responses in sub-
populations of cells from human intestinal organoids. Bo Lin, Qingfen Yang,
Abhijit Rath, Christopher D. Heinen. University of Connecticut Health, Farm-
ington, CT.
Hereditary mutations in DNAmismatch repair (MMR) genes cause the can-
cer predisposition syndrome called Lynch syndrome. Patients predominantly
develop colorectal cancer and some extracolonic cancers at a young age. The
MMRpathway repairsmismatches created duringDNAreplication, but also can
induce apoptosis and cell cycle arrest in response to certain DNA damaging
agents as a protective mechanism to eliminate cells at risk of accumulating mu-
tations. Our understanding of this MMR-directed DNA damage response has
come primarily from studies in human cancer cell lines. We wished to examine
the role of the MMR-dependent damage response in a model that may be more
relevant to the human intestine. Therefore, we have created human intestinal
organoids (HIOs) in vitro either by directing the differentiation of human em-
bryonic stem cells (hESCs) or through culturing of adult intestinal tissue sam-
ples.Wehave used theseHIOs to specifıcally study theMMRdependent damage
response to DNA alkylation damage. We have found that whereas hESCs un-
dergo rapid apoptosis in response to alkylation damage, the differentiated HIOs
or those created from adult tissues undergo not only apoptosis, but also senes-
cence and accelerated differentiation following damage. Using CRISPR-Cas9
gene editing in hESCs, we also created MMR-defıcient HIOs that failed to re-
spond to the drug indicating that these responses areMMR-dependent.We then
determined that the cells undergoing apoptosis followingDNAdamage aremost
likely the intestinal stem cells suggesting that different cell types in the intestine
have different MMR-dependent responses to damage. Together these results
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suggest that loss ofMMR function in the intestinal cryptsmay provide a selective
advantage particularly in an environment conducive with DNA damage that
promotes tumorigenesis.
#1412 High EGFR somatic mutation frequency targeting the TK domain
in colorectal cancer patients with microsatellite instability (MSI). Safoora
Deihimi,1 Michael Slifker,2 Eric A. Ross,2 Wafık S. El-Deiry1. 1Department of
Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer
Ctr., Philadelphia, PA; 2Department of Biostatistics, Fox Chase Cancer Ctr., Phil-
adelphia, PA.
CRCs arise through genetic changes that impact various driver genes and in
some tumors increased mutation rate in microsatellite unstable tumors. The
hypermutable phenotype associated with microsatellite instability (MSI) results
from loss of themismatch repair system (MMR) activity. MSI is detected in 15%
of all CRCs, and such tumors have a better prognosis and different chemother-
apeutic outcome patterns, including high clinical benefıt from immune check-
point therapy or relative resistance to 5-FU as compared to microsatellite stable
(MSS) tumors. The epidermal growth factor receptor (EGFR) signaling pathway
plays an essential role in carcinogenesis of CRCs and is known to be overex-
pressed in MSI CRCs while highly mutated in Lung cancer. We analyzed the
mutation frequency of deregulated pathways including EGFR and its down-
stream genes KRAS andBRAF inCRCs.We found a signifıcantly elevated EGFR
mutation frequency in CRC MSI-H subtype (45.5% vs. 6.5% in MSS CRCs,
p0.0000001). Although KRAS and NRAS are mutated with high frequency in
both MSI-H and MSS groups, BRAF corresponding to RTK-RAS pathways is
more altered inMSI-H thanMSSCRCs (32.67%vs 13.10%; p0.001), consistent
with the known association between MSI-H CRCs and BRAF mutations. We
hypothesized that there might be a mutation pattern in EGFR in CRC subtypes
that provide a rationale for EGFR-targeted therapy for a subtype of CRC. Of
1104 profıled CRCs in the COSMIC v73 database, somatic EGFR mutations
were mapped for 101 MSI-High versus 916 MSS CRCs. EGFR mutations
mapped on the protein structure revealed that mutations are mainly targeting
tyrosine kinase (TK) domain while the extracellular domain remained mostly
wild-type with potential for targeting by anti-EGFRmonoclonal antibodies. It is
known that downstream genes such as KRAS as well as expression levels of
EGFR ligands can affect the sensitivity of CRCs to anti-EGFR therapy.We didn’t
detect any difference inmRNA expression level betweenMSI-H andMSS group
but our analysis is indicative of the presence of G12D mutations in a high pro-
portion of KRAS-mutated MSS CRCs, therefore resistance to anti-EGFR anti-
bodies such as cetuximab would be expected. However, EGFR tyrosine kinase
inhibitors such as erlotinib and gefıtinib could be considered for further testing
in patients with MSI-H tumors that have a lower frequency of G12D KRAS
mutations and may have mutant EGFR.
#1413 Replication obstacles formed within common fragile sites under
replication stress are targeted by the global genomic nucleotide excision re-
pair pathway.MartinMistrik,1 Lucie Beresova,1 EvaVesela,1 Ivo Chamrad,2 Jiri
Voller,1 Masayuki Yamada,1 Tomas Furst,1 Rene Lenobel,2 Katarina Chroma,1
Jan Gursky,1 Jiri Bartek1. 1Palacky University in Olomouc, Faculty of Medicine
and Dentistry, Olomouc, Czech Republic; 2Palacky University in Olomouc, Fac-
ulty of Science, Olomouc, Czech Republic.
CFS’s are genomic loci present in higher vertebrates that are particularly sen-
sitive to various forms of replication stress and suffer from increased breakage
and rearrangements in tumors. They have rather enigmatic evolutionary role
and employ various DNA repair and checkpoint mechanisms promoting their
stability. We used an original approach for identifıcation of CFS’s associated
factors based on DNA probe designed to match the high flexibility island se-
quences typically present in some of the highly expressed CFS’s. This probe was
used as affınity bait for fıshing specifıcally enriched proteins which were further
identifıed using SILAC and quantitative mass spectrometry. Among already
known CFS’s stabilizers we identifıed also hits so far not implicated in CFS’s
maintenance. Interestingly, most of these novel hits are components of the
global genomic nucleotide excision repair pathway (GG-NER). Knock down-
based functional experiments revealed that GG-NER works most likely as an
important trigger turning the CFS’s-associated replication obstacles into DNA
lesion further recognized by theATR-promoted cellular checkpointwhich func-
tion is to block an escape of DNA replication intermediates into mitosis and the
next cell generation. Work was supported by the Grant Agency of the Czech
Republic 13-17555S, Czech-BioImaging project (LM2015062 funded byMEYS,
CR) and Ministry of Education of the Czech Republic (LO1304).
#1414 Chromatin remodeling histone chaperone FACT complex modu-
lates AP site damage repair in chromatin and sensitizes cancer cells to che-
motherapeutic drugs.Heyu Song, Shrabasti Roychoudhury, Dan Feng, Kishor
Bhakat. University of Nebraska Medical Center, Omaha, NE.
Recognition and repair of DNA lesions in the genome are critical for main-
taining genomic stability and reducing the generation of mutations that lead to
cancer development. The most frequently formed DNA lesion in the genome is
the apurinic/apyrimidinic (AP) sitewhich ismutagenic and blocks transcription
and replication. The primary enzyme to repairAP sites inmammalian cells is the
AP endonuclease (APE1), which often overexpresses in diverse cancer types and
its overexpression is associated with patients’ resistance to chemotherapeutic
drugs. The repair of AP sites by APE1 through the Base Excision Repair (BER)
pathway is extensively investigated in vitro. However, howAP site is recognized
by APE1 in the context of highly complex nucleosome structure in chromatin is
unknown. Because DNA is packaged tightly in nucleosome, the ability of repair
proteins to access sites of DNA damage and facilitates repair of the damage
requires chromatin remodeling activities. Here, we show that APE1 interacts
with chromatin remodeling histone chaperone complex, FACT (facilitates of
chromatin transcription) via its N-terminal domain in cells. By immunoprecipi-
tation of endogenous APE1 from chromatin fraction and separation of protein
bands in SDS-PAGE followed byMALDI-TOF-TOF analysis, we have identifıed
both subunits (SPT16 & SSRP1) of FACT as the prominent APE1 interacting
partners. Subsequently, we confırmed the interaction of APE1 with FACT com-
plex byCo-IP and immunofluorescence analysis and found that both SPT16 and
SSRP1 interact with APE1 in the nucleus and in chromatin. Interestingly, we
found rapid eviction of histones with concomitant degradation of FACT com-
plex upon induction of DNA damages. Downregulation of FACT complex ab-
rogates the nucleosome eviction, the recruitment of repair protein APE1 in
chromatin and the repair of AP sites, demonstrating the functional importance
of nucleosomes disruption in BER pathway and identifying chromatin remod-
eling protein required for the process. Notably, knock-down of FACT showed
increased sensitivity of cancer cells to many chemotherapeutic drugs. We also
found that FACT down-regulated cells have much higher accumulation of AP
site damages in the genome compared to control cells. Our study revealed a key
role of nucleosome remodeling complex FACT in DNA damage repair in BER
pathway. This study also suggests that histone chaperone complex could be a
potential target for enhancing sensitivity of tumor cells to chemotherapy.
#1415 SAN1: a novel senataxin associated nuclease required for the repair
of interstrand crosslinks. Alex Andrews, Ian Macara. Vanderbilt University,
Nashville, TN.
The DNA damage response (DDR) is a set of complex signaling pathways
capable of sensing DNA damage, and activating a large number of enzymes
involved in the remodeling and repair of the genome. Mutations in the genes
involved in the DDR lead to DNA damage, genomic instability, and various
cancers. One particularly dangerous type of DNA damage that can occur is an
interstrand crosslink (ICL). ICLs can lead to the development of double strand
breaks through the blockage of DNA replication and transcription. Although
ICLs can arise endogenously frommolecules such as aldehydes,most commonly
they are induced from chemotherapeutic drugs such as Cisplatin and Mitomy-
cin C (MMC). These drugs are commonly used in the treatment of breast and
ovarian cancers. A better understanding of which proteins are involved in the
repair of ICLs is critical for understanding resistance, toxicity, and response in
patients treated with ICL inducing agents. The repair of ICLs requires the coor-
dination of several DNA repair pathways including the Fanconi Anemia path-
way, homologous recombination (HR), and nucleotide excision repair (NER).
The Fanconi Anemia pathway is essential for the repair of these lesions as it is
responsible for the recognition of the ICL lesion, as well as the recruitment of
several nucleases responsible for unhooking and removal the cross-linked nu-
cleotides. Recently, we identifıed an uncharacterized 5= nuclease that interacts
with the RNA/DNA helicase Senataxin, which we have named senataxin-asso-
ciated nuclease 1 (SAN1). Senataxin has been shown to act on R loops, RNA/
DNA hybrids that are a source of endogenous DNA damage. Deletion of the
SAN1 gene in HeLa cells or in mouse embryonic fıbroblasts leads to the sensiti-
zation of cells to Cisplatin and Mitomycin C (MMC), but not to ionizing radia-
tion that induces double strand breaks. Importantly, the defect in ICL repair can
be restored using WT SAN1 but not with a mutant that is catalytically inactive.
Treatment of SAN1 -/- HeLa cells with MMC also leads to radial chromosome
formation, a characteristic of cells defıcient in ICL repair. Additionally, SAN1
partially colocalizes with Fancd2MMC induced foci, and treatment with MMC
results in increased DNA damage and R loops in SAN1-/- cells. In conclusion,
this study highlights the discovery of a novel nuclease involved in the repair
ICLs, a process critical for understanding resistance and response to chemother-
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apies such as Cisplatin and MMC. Future work is aimed at determining the
specifıc step of ICL repair that SAN1participates in, howandwhenduring repair
SAN1 is recruited to ICL sites, and which other DNA repair proteins SAN1
functions with.
#1416 Development of small molecule inhibitors for cancer therapy by
targeting RPA and XPA nucleotide excision repair proteins. Navnath S. Ga-
vande,1 Pamela S. VanderVere-Carozza,1 Tyler L. Vernon,1 Katherine Pawelc-
zak,2 John J. Turchi1. 1Indiana University School of Medicine, Indianapolis, IN;
2NERx BioSciences Inc, Indianapolis, IN.
Targeting DNA repair and the DNA damage response for cancer therapy has
recently gained increasing attention with inhibitors of the PARP enzyme show-
ing a therapeutic effıcacy in various cancers. Solid tumors of the lung, pancreas,
breast, and ovary represent a continuing clinical challenge in treatment and
together account for over 250,000 deaths in the US alone, representing over 40%
of all cancer deaths. There are limited therapeutic options for these patients, and
targeted and combination therapies remain necessary for treating these aggres-
sive cancers. The opportunity exists to exploit recent scientifıc advances in our
knowledge of the underlying biology behind these cancers to create novel tar-
geted therapeutics to dramatically enhance patient response to therapy and ul-
timately survival. To this end, we have developed a series of novel small chemical
molecules that disrupt critical protein-DNA interactions in the nucleotide exci-
sion repair (NER) pathways. It is well understood that various cancer treatments
like cisplatin, etoposide and ionizing radiation impart their chemotherapeutic
effect by the formation of direct DNAdamagewhich blockDNA replication and
transcription culminating in apoptosis. It is also well established that repair of
this DNA damage by nucleotide excision repair (NER) or homologous recom-
bination repair (HRR) reduces the effectiveness of chemo- or radio- therapy.
Replication protein A (RPA) and Xeroderma Pigmentosum Group A (XPA)
plays a crucial role in the NER pathway and makes them a novel drug target to
develop novel cancer therapy. We anticipate both direct mechanisms of action
on the repair pathways and synthetic lethal interactions can be exploited for
therapeutic benefıt. The series of novel small molecule inhibitors that we have
developed targeting RPA and XPA proteins independently exhibit single-agent
anti-cancer activity in cancer cell lines, and potentiate cellular sensitivity to
chemotherapeutic agent. Data demonstrate that these novel inhibitors do not
interact with DNA but directly bind the corresponding NER proteins. Our data
demonstrate that this class of inhibitors can be further developed as an anti-
cancer therapeutic with considerable potential to be used in conjunction with
radiation therapy and other cancer therapies that induce DNA damage. This
workswas supported byNIHgrants R01-CA180710 andR41-CA162648 and the
Tom and Julie Wood Family Foundation.
#1417 Expression of BARD1 induces genetic instability and is associated
with cervical carcinogenesis. Maxim Pilyugin,1 Pierre-Alain André,1 Nicole
Concin,2 Gerda Hofstetter,2 Irmgard Irminger-Finger1. 1University of Geneva,
Geneva, Switzerland; 2University Hospital Innsbruck, Innsbruck, Austria.
Cervical cancer is always linked to infection with the human papilloma virus
(HPV), which causes hyper-proliferation of cervical epithelial cells and neopla-
sia and cervical cancer. The viral oncoprotein interaction with host tumor sup-
pressor proteins partially explains the uncontrolled proliferation, which ulti-
mately progresses to cervical cancer. However, little is known about the specifıc
factors that promote or inhibit the malignant transformation. Since a portion of
HPV infections never evolves into cancer, the identifıcation of discriminatory
factors would be an important step towards the development of prognostic and
therapeutic tools. Based on this notion, we investigated whether an isoform of
BARD1, BARD1	, which we found frequently expressed in cancer cells, plays a
role in the malignant transformation of cervical epithelial cells. Using immuno-
hystochemistry staining on tissue sections and RT-PCR we found that BARD1	
is expressed in proliferating cervical cancer cells, while normal BARD1 is re-
pressed. BARD1might be a driver of carcinogenesis andmight be a critical event
in the progression from hyper-proliferating cervical epithelium after HPV in-
fection to cervical cancer. Together, our results show that an isoform of BARD1,
BARD1	, is increasingly expressed in precancerous stages of cervical cancer and
the specifıc inhibition of BARD1	may represent a novel approach for therapeu-
tic interventions to prevent cervical carcinogenesis after HPV infection.
#1418 G9a methyltransferase plays a role in ATM-dependent DNA dam-
age response. Lizahira Rodriguez-Colon,1 Vasudeva Ginjala,2 Atul Kulkarni,2
Safıa Ansari,1 Shridar Ganesan2. 1Rutgers University, New Brunswick, NJ; 2Rut-
gers Cancer Institute of New Jersey, New Brunswick, NJ.
Induction of DNA damage leads to a choreographed set of local chromatin
changes that ensures an effıcient recruitment of DNA repair factors. One prin-
cipal regulator of the DNADamage Response (DDR) signaling pathway is ATM
kinase, which phosphorylates key factors at early stages of the response. G9a
protein methyltransferase has been identifıed as a novel substrate for ATM.We
have found that G9a localizes to sites of DNA damage in an ATM-dependent
fashion and that inhibition of its activity affects recruitment of multiple DNA
repair factors. Moreover G9a catalytic inhibition using UNC0638 leads to hy-
peractivation of ATM induced by DNA breaks. This was associated with an
increased ATM-dependent “spreading” of pH2AX and MDC1 signals seen at
regions of localized DNA breaks induced by UV-laser scissors. These data sug-
gest that G9a activity is required for regulating the extent of ATM activation as
well as for effıcient recruitment of downstreamDNA repair factors. Biochemical
data will be presented that explore potential mechanisms for these fındings.
Overall our data suggests that G9a plays a critical role in the regulation of ATM-
dependent signaling during the DNA damage response, and raises the possibil-
ity of using G9a inhibitors to target cancers with certain DNA repair defects.
#1419 Role of a novel Senataxin-associated nuclease in DNA repair.
Heather McCartney, Ian Macara. Vanderbilt University, Nashville, TN.
Yeast two-hybrid analysis has identifıed a novel, uncharacterized Senataxin-
interacting protein with 5= exonuclease activity, and homology to the FEN1
nuclease domain. Senataxin is an RNA/DNAhelicase that functions in resolving
R loop structures which occur as a result of normal replication and transcription
but can also persist resulting in genomic instability.We found that SAN1 (Sena-
taxin-Associated Nuclease 1) is unable to cut dsDNA or bubbles, but is active
against 5= overhangs and against ssDNAs of greater than 15 nucleotides. SAN1
cleaves 3 or 8 nt fragments from the 5= end of ssDNA and utilizes magnesium as
a cofactor. As the defınitive 5= nuclease responsible for unhooking ICLs has yet
to be identifıed we speculate that SAN1 might function in excising crosslinked
nucleotides that result from interstrand crosslink (ICL) damage.We generated a
SAN1 -/- HeLa cell line through CRISPR/Cas gene editing and found that SAN1
-/- cells are sensitized to ICL agents mitomycin-c and cisplatin. Interestingly,
colony survival assays have shown that SAN1 does not appear to be epistatic of
FANCD2, a key component of the classical pathway for resolving ICLs, the
Fanconi Anemia pathway. Additionally, although the nuclease domain of SAN1
is homologous to the FEN1 family of structure-specifıc nucleases, SAN1 also
possesses a unique and conserved C terminus of unknown function. Our goal is
to understand the relationship between the structure and nuclease activity of
SAN1 in DNA repair and how SAN1 relates to other known ICL-repair path-
ways. Understanding the components that regulate genome stability is crucial in
understanding how cancer occurs and what protein targets will be the most
advantageous to pursue in developing potential therapeutics. This study may
also provide a better understanding of a novel factor in resistance to ICL-induc-
ing chemotherapeutics such as cisplatin andMMCwhich are still widely used in
the treatment of breast and ovarian cancers.
#1420 The endonuclease Metnase promotes base excision repair of Clus-
tered abasic DNA lesions. Aruna S. Jaiswal, Elizabeth A. Williamson, Bhavita
Patel, Gayathri Srinivasan, SatyaNarayan, Robert A.Hromas.University of Flor-
ida, Gainesville, FL.
Metnase, a human SET-transposase fusion protein contains two functional
domains: a SET domain and transposase domain. Transposase domain exhibit
strand transfer and end joining activity while set domain is responsible for his-
tone lysine methyltransferase activity (KMT). Metnase also increases the effı-
ciency of double strand break repair by non-homologous end joining (NHEJ);
however, its role in the excision of clustered DNA damage remains to be inves-
tigated. We hypothesize that 5=-3= endonuclease activity of metnase could pos-
sibly substitute for APE1 in BER and serve as an alternative initiator of BER in
tumor cells lacking APE1. In the present study, we examined in vitro endonu-
clease activity of Metnase using abasic site containing artifıcial DNA, and de-
scribe its activity in BER. Its unique 5= endonuclease activity was selective only
for abasic lesions, but not other basemodifıcations such as 8-oxoguanine, uracil,
hypoxanthine or xanthenes. Metnase specifıcally initiates removal of reduced
abasic lesions from DNA, and allows completion of short-patch or long-patch
BER. APE1 has diffıculty cleaving 5= of clustered abasic lesions. This endonu-
clease that promotes BER in clustered oxidative DNA damage is not known.
Metnase also cleaves multiple abasic lesions (clustered DNA damage) and facil-
itates the repair of DNA if themultiple DNA damages are 3 ormore nucleotides
apart on the opposing strands. However, repair of multiple DNA damages re-
mains ineffıcient if these are in close proximity of each other ( 3nt apart on the
opposing strands) and results in DNA double strand break (DSB). These results
suggest that Metnase can promote BER of oxidative nucleotides, where APE1 is
unable to function.
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#1421 Evaluation of DDR-targeting strategy using ATR inhibitor in bili-
ary tract cancer. Ah Rong Nam,1 Ji Eun Park,1 Ju Hee Bang,1 Mei Hua Jin,1 Do
Youn Oh,2 Yung Jue Bang2. 1Cancer Research Institute, Seoul National Univer-
sity College of Medicine, Seoul, Republic of Korea; 2Deparment of Internal Medi-
cine, Seoul National University of Hospital, Seoul, Republic of Korea.
Background: The DNA damage response (DDR) is a multicomplex network
of signaling pathways involved in DNA damage repair, cell cycle checkpoints
and apoptosis. The ataxia telangiectasia and Rad3-related (ATR) protein kinase
is a key enzyme in the DDR that activates checkpoint kinase 1 (Chk1), resulting
in cell cycle arrest. Tumor types with loss of ATM function and/or high replica-
tion stress are expected to be more susceptible to DDR targeting. In biliary tract
cancer (BTC), DNA repair pathway, which includes BAP1, MSH6, BRCA1,
ATM,MLH1,MSH2, is altered in about 20 % of cases. TP53module is observed
in 33.9%of BTC cases (NatGenet 2015). The purpose of this study is to testDDR
targeting strategy using ATR inhibitor in biliary tract cancer. Methods: Using 9
kinds of BTC cells, MTT assay and colony formation assay were done for deter-
mining growth inhibitory effect of AZD6738, an ATR inhibitor. Cell cycle anal-
ysis was done by FACS Calibur flow cytometer and the methods described by
Chou and Talalay were used to determine whether a synergistic effect existed
between AZD6738 and cytotoxic chemotherapeutic agents (cisplatin, 5-FU,
gemcitabine). The alkaline comet assay was done tomeasure of DNA damage in
individual cells. Tumor xenografts model was used for in vivo test of AZD6738.
Results: Among 9 BTC cells, SNU478 and SNU869 were most sensitive to
AZD6738, which showed low expression of both ATM and p53. AZD6738
blocked ATR-mediated Chk1 phosphorylation and increased rH2AX, a marker
of DNA damage, in sensitive cells. AZD6738 signifıcantly increased apoptosis
(cleavage of PARP and caspase-7) and G2/M arrest, increased level of p21, and
decreased cdc2. In addition, combination of AZD6738 and cytotoxic chemo-
therapeutic agents demonstrated synergistic effects in colony formation assay,
cell cycle analysis and comet assay. In xenograft model of SNU478, AZD6738
monotherapy decreased tumor growth. The combination of AZD6738 and cis-
platin showed more potent growth inhibitory effects, decreased Ki67, increased
Tunel than monotherapy of each drug. Conclusion: In BTC, DDR targeting
strategy using ATR inhibitor demonstrated promising antitumor activity alone
or in combination with cytotoxic chemotherapeutic agents. This supports fur-
ther clinical development of DDR targeting strategy in BTC.
#1422 Enhancing the therapeutic effects of PARP inhibitors in combina-
tion DNA methyl transferase inhibitors, using low doses of ionizing radia-
tion in non small cell lung cancers. Christopher Biondi,1 Daniel Fontaine,1
Lora Stojanovic,1 Pratik Nagaria,1 Rena Lapidus,1 Eun Yong Choi,1 Javed Mah-
mood,1 Stephen Baylin,2 Feyruz V. Rassool1. 1Univ. of Maryland School of Med-
icine, Baltimore, MD; 2Johns Hopkins University, Baltimore, MD.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related
deaths in the US. Treatment most commonly relies on ionizing radiation (IR)
and platinum-based DNA damaging agents, but long-term survival is poor and
patients tend to suffer chronic side-effects due to the high radiation dose to the
surrounding normal tissues. Therefore, new treatments are needed that can be
used in combination lower radiation doses. We have recently reported that low,
non-cytotoxic doses Poly ADP ribose polymerase inhibitors (PARPi) Talazopa-
rib in combination with DNA methyltransferase inhibitors (DNMTi) Decit-
abine (DAC) or azacytidine (AZA) signifıcantly increase cytotoxicity in acute
myeloid leukemia and breast cancer models in vitro and anti-tumor effects in
vivo. Simultaneous administration of both inhibitors result in increased PARP
binding in DNA, leading to higher levels of DNA double strand breaks (DSBs),
yielding increased cytotoxicity, compared with each agent treatment alone. We
fırst studied the effıcacy of Talazoparib and AZA combination therapy in mul-
tiple NSCLC cell lines (A549, H358 and H838) in vitro through colony forming
assays. Results showed, compared to single agent treatments, combination drug
treatment signifıcantly decreased colony formation. Cell viability was also sig-
nifıcantly decreased with the drug combination in MTS assays (P0.05). These
results also showed synergistic activity between the two drugs, with a combina-
tion index of less than 1 for all tested NSCLC cell lines. Importantly, the drug
combination increased PARP trapping in chromatin and DSB formation, as
measured by immunofluorescent staining for H2AX. We next determined
whether AZA/Talazoparib in combination with a single dose of radiation (2Gy)
had an increased anti-cancer effect compared to each modality alone in in vivo
mouse xenografts of NSCLC A549. While the combination of PARPiDNMTi
with radiation treatment decreased tumor growth, compared to PARPi/DNMTi
alone or RT alone, no signifıcant enhancement with radiation was observed.We
next determined whether low doses of fractionated IR (2Gy 3 fractions) would
improve the effıcacy of DNTMi and PARPi combination treatment. In vitro
studies with colony forming assays of NSCLC cell line A549 show that IR doses
in combinationwith PARPi andDNMTi decrease clonogenicity, comparedwith
non-IR controls. Furthermore, A549 xenografts were treatedwith the drug com-
bination and then irradiated 1 week later with 2Gy daily for 3 consecutive days.
Mice treatedwith the drug combination followed by IR had signifıcant decreases
in tumor volume and survival (P0.05). This suggests that low doses of PARPi
and DNMTi therapy in combination with low dose IR can potentially target
NSCLC tumors. This represents a novel treatment approach forNSCLCpatients
that may reduce chronic side-effects of high dose IR.
#1423 Nedd8-activating enzyme inhibitor pevonedistat synergizes with
cisplatin and carboplatin through interference with nucleotide excision re-
pair and interstrand cross-link repair mechanisms in non-small cell lung
cancer.Xiaozhen Liu,1 David Bouck,1 Khristofer Garcia,2 Jonathan Blank,1 Hu-
gues Bernard,1 Allison Berger,1 Mike Kuranda,1 Erik Koenig,1 Eric Lightcap1.
1Takeda, Cambridge, MA; 2Genentec, San Francisco, CA.
Platins are one of the most widely used classes of chemotherapeutic drugs.
Although used as part of fırst-line standard of care regimens for advanced non-
small cell lung cancer (NSCLC), their effectiveness remains limited, with a
5-year survival rate of 18%. Therefore, combination therapy to overcome resis-
tance and improve survival is needed. Pevonedistat (TAK-924/MLN4924) is an
investigational fırst-in-class Nedd8-activating enzyme (NAE) inhibitor that
blocks activation of the cullin family of E3 ubiquitin ligases by preventing cullin
conjugation with Nedd8, a ubiquitin-like protein. In vitro, pevonedistat is syn-
ergistic with carboplatin in a cell viability assay in 6 out of 20 NSCLC cell lines
either with or without paclitaxel. In vivo studies using patient-derived xenograft
(PDX) models showed a combination effect in a carboplatin-insensitive but not
carboplatin-sensitivemodel. To evaluate themechanism of the synergy between
pevonedistat and platinum, RNAi of 320 DNA-damage response genes was per-
formed in 4 cell lines in vitro. Depletion of genes involved in TC-NER (tran-
scription-coupled nucleotide excision repair) and ICR (interstrand crosslink
repair) reduced the synergy between pevonedistat and platinum, with the con-
tribution of each pathway varying by cell line. Since TC-NER and ICR are also
involved in the repair of DNA damage by platins, the results suggest that delay-
ing completion of platin induced DNA repair by pevonedistat results in en-
hanced cell death. Pevonedistat may impede TC-NER by inhibition of neddyla-
tion of the E3 ubiquitin ligase CUL4-RBX1-DDB1-ERCC8, thereby possibly
providing a direct reversal of resistance to platins.
#1424 DNA repair capacity in colon cancer patients - The effect on the
response to treatment and long-term survival. Sona Vodenkova,1 Michal
Kroupa,2 Katerina Jiraskova,3 Alessio Naccarati,4 Alena Opattova,5 Pavel Vod-
icka5. 1Third Faculty of Medicine, Charles University, Prague, Czech Republic;
2Faculty of Medicine and Biomedical Center in Pilsen, Charles University, Pilsen,
Czech Republic; 3First Faculty of Medicine, Charles University, Prague, Czech
Republic; 4Human Genetics Foundation, Turin, Italy; 5Institute of Experimental
Medicine, The Czech Academy of Sciences, Prague, Czech Republic.
Colorectal carcinoma (CRC) is the third most common cancer worldwide
with the highest incidence in Central Europe. It is the fourth leading cause of
cancer related deaths mainly due to the late diagnosis and low effıcacy of treat-
ment. CRCdiagnosed in early stage has a fıve-year survival rate about 90%which
drops to near 12% once distant metastases occur. It is a heterogenous disease
with different molecular and clinicopathological features depending on the tu-
mor location. Therefore, different treatment strategies are required. A standard
treatment of locally advanced rectal cancer includes neoadjuvant chemoradio-
therapy followed by surgery, whereas colon cancer treatment consists of surgical
resection of the tumor and/or subsequent adjuvant chemotherapy based on
disease characteristics. 5-fluorouracil (5-FU) alone or in combinationwith other
compounds is the most used treatment in CRC. The mechanism of 5-FU on
molecular level is either its incorporation into DNA or it imbalances the synthe-
sis of thymidine from uracil resulting in false uracil DNA incorporation. These
DNA lesions are repaired by base excision (BER) and mismatch repair (MMR)
pathways. An effective DNA damage response (DDR) is essential for the main-
tenance of genome stability in healthy cells, whereas in malignant cells, the
suppression of DNA repair capacity (DRC) would increase the effectiveness of
chemotherapy through DNA damage accumulation and consequent apoptosis.
In contrary the cells with high DRC may show better survival and therefore
patients with these molecular characteristics may contend with poor response,
resistance to treatment and decreased survival. The aim of our present studywas
to investigate DRC of BER and MMR in target tissue as a predictive marker for
a treatment strategy and long-term survival. In order to minimize a bias by
heterogenous therapy we focused only on patients with newly diagnosed colon
cancer. Our set of patients was selected based on the criteria of follow-up at
minimum30months, subsequent treatment with 5-FU andmicrosatellite stable
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tumor tissue characteristics. Tumor and adjacent non-affected tissue samples
were obtained from one hundred patients at surgical resection. Protein extracts
from tissues were isolated both for protein expression analysis and for measure-
ment of DRC. DNA repair and DDR protein expression levels were tested by
Western Blot. Functional assessments of DRC were performed by comet assay-
based in vitro DNA repair assay. The analysis is running and the data will be
statistically analyzed and compared with clinical data (TNM stage, type and
course of treatment, presence of recurrence, patient´s performance, etc.). Un-
derstanding DRC effect on the treatment response might contribute to the con-
cept assuming that targeted modulating of DNA repair processes can achieve
clinical benefıt in cancer treatment. Acknowledgements: GAUK 800216, COST
LD14050, GACR P303/15/14789S and AZV 15-27580A.
#1425 Targeting cell cycle dependencies in CCNE1 amplifıed tumors. Kai
Doberstein,1 Alison Karst,2 Paul Jones,2 Azra Ligon,2Michelle Hirsch,2 Dariush
Etemadmoghadam,3 William Hahn,2 David Bowtell,3 Ronny Drapkin1. 1Univ.
of Pennsylvania School of Medicine, Philadelphia, PA; 2Harvard Medical School,
Dana-Farber Cancer Institute, Boston,MA; 3University ofMelbourne PeterMac-
Callum Cancer Center, Melbourne, Australia.
Genomic instability is a hallmark of high grade serous ovarian carcinoma
(HGSOC). Based on The Cancer Genome Atlas (TCGA), it is estimated that
approximately 50% of HGSOCs harbor a defect in the homologous recombina-
tion (HR) pathway of DNA repair. In contrast, the 20% that harbor CCNE1
amplifıcations appear to have an intact HR pathway. These tumors are associ-
atedwith shorter overall survival and resistance to chemotherapy. Cyclin E is the
activating partner of cyclin-dependent kinase 2 (CDK2) which controls cell
cycle progression from G1 to S phase. Our previous data showed that CCNE1
amplifıcation and overexpression occurs early in serous tumorigenesis. Impor-
tantly, in immortalized human fallopian tube secretory epithelial cells (FTSEC),
constitutive Cyclin E overexpression imparts malignant characteristics to these
cells. This leads to an accumulation ofDNAdamage and altered gene expression
of genes involved in DNA replication and fork protection. However, in the
setting of hTERT expression and a p53 mutant, Cyclin E overexpression alone
was not capable of fully transforming the FTSECs. Therefore, in order to identify
cooperating genetic alterations, we performed an in vitro gain-of-function
(GOF) screen. One of those identifıed hits was the RAD51 paralog XRCC2,
which is known to be involved in the HR DNA repair pathway and in fork
protection.We could show that XRCC2 expression is upregulated in response to
Cyclin E overexpression in FTSECs and we found a strong correlation between
RNAseq expression of XRCC2 and Cyclin E in the TCGA patient cohorts. We
could further demonstrate that the knock down of XRCC2 is synthetic lethal in
CCNE1 amplifıed ovarian cancer cell lines but not in cells that harbor noCCNE1
amplifıcation, indicating that the upregulation of XRCC2 creates a dependency
in CCNE1 amplifıed tumors. Since overexpression of Cyclin E leads to unsched-
uled S-phase entry and stress on the replication fork, we speculated that one of
the roles of XRCC2might be to stabilize the replication fork in Cyclin E overex-
pressing cells. We found that the knock down of XRCC2 in Cyclin E overex-
pressing cells leads to a strong reduction in fork speed and fork recovery. To
further understand thismechanismwe analyzed the binding partners of XRCC2
in CCNE1 amplifıed cells by mass spectrometry. Interestingly, we found that
XRCC2 interacts with the minichromosome maintenance defıcient 7 (MCM7)
protein. MCM7 is part of the MCM complex that unwinds the DNA during
replication. Surprisingly, the downregulation XRCC2 also led to a strong reduc-
tion inMCM7protein expression indicating that XRCC2may play an important
role in stabilization the MCM complex. This is especially interesting since
CCNE1 amplifıed cells are more dependent on active MCM complexes and are
more sensitive to MCM complex reduction compared to normal cells. Further
defıning the factors that contribute to the XRCC2-MCM7 interaction at the
replication fork may defıne novel vulnerabilities in CCNE1 amplifıed tumors.
#1426 Blinding the CYCLOPS - Cancer vulnerabilities unveiled by
genomic loss. Alica Torkov,1 Kai-Oliver Henrich,1 Chunxuan Shao,2 Moritz
Gartlgruber,1 Frank Westermann1. 1DKFZ, Heidelberg, Germany; 2BioQuant,
Heidelberg, Germany.
Background: Heterozygous deletions within distal 1p are observed in 30% of
neuroblastomas. So far, several potential 1p tumor suppressor genes have been
identifıed. However, in this study we are focussing on 1p genes whose inactiva-
tion is not necessarily linked to tumor development but which mediate cell-
essential functions, rendering cells with copy number loss vulnerable to further
impairment. These genes are candidate therapeutic targets according to the con-
cept of CYCLOPS (copy number alterations yielding cancer liabilities owing to
partial loss). Methods: To identify a subset of 1p genes for which heterozygous
loss may be tolerated but further reduction leads to cell death, we performed
siRNA screens mediating the systematic knock-down of distal 1p genes in fıve
1p-deleted versus fıve non-1p-deleted neuroblastoma cell lines. We used 3 dif-
ferent siRNAs per gene in a liquid forward approach. After 96h Hoechst stained
nuclei were count. Among others, a neuron-related candidate gene has been
identifıed as a potential CYCLOPS. The candidate genewas validated by viability
assays, immunocytochemistry and cell cycle analysis via FACS. Results: We
identifıed many potential CYCLOPS genes mapping on the distal end of chro-
mosome arm 1p. One of these genes is involved in neuronal and embryonic
development and has been further validated. Knock-down of the gene impaired
cell viability in 1p-deleted cell lines but did not in 1p-non-deleted cells. G1/G0
phase arrest with corresponding S phase decrease was observed in both 1p-
deleted and 1p-non-deleted cells. Additionally, neurite-like outgrowth could be
observed in 1p-non-deleted cells indicating an induction of differentiation.
Conclusion: This study identifıed a candidate CYCLOPS gene in neuroblas-
toma. Heterozygous deletions of chromosome arm 1p are also frequently ob-
served in other cancers including melanoma, colorectal and breast cancer. We
hypothesize that this proof-of-principle opens a new therapeutic window for
tumors harbouring a heterozygous deletion of our candidate gene or other cell
essential genes on chromosome arm 1p.
#1427 Investigating role of RECQ1 in response to gemcitabine treatment
in triple negative breast cancer. Swetha Parvathaneni, Xing Lu, Sudha Sharma.
Howard University, Washington DC, DC.
The response of cancer cells to therapeutic drugs aimed at causing DNA
damage is dependent on proteins that play roles in DNA repair. Single nu-
cleotide polymorphism in RECQ1 (also known as RECQL or RECQL1), a
DNA helicase involved in DNA damage and replication stress response, is
reported to influence patient’s response to gemcitabine in pancreatic cancer
leading to poor survival. Gemcitabine is also used as a chemotherapeutic
against triple negative breast cancer; however resistance to gemcitabine is
reported. The mechanism by which gemcitabine chemoresistance is ob-
tained is poorly understood. Given the importance of RECQ1 in replication
fork restart and it being categorized as a breast cancer susceptibility gene, we
wish to investigate the role of RECQ1 in modulating cellular response to
gemcitabine in triple negative breast cancer cells. To study RECQ1 func-
tions, we developed isogenic pairs of RECQ1-profıcient and RECQ1-defı-
cient cells by CRISPR-Cas9-mediated targeted inactivation of RECQ1 in
breast cancer cell lines as in vitro model system. RECQ1-knockout MDA-
MB-231 cells displayed reduced cell growth and proliferation, and increased
DNA damage as compared to the MDA-MB-231 cells expressing wild type
RECQ1. As compared to RECQ1-profıcient MDA-MB-231 cells, RECQ1-
defıcient cells were more sensitive to gemcitabine treatment, incurred sig-
nifıcantly greater load of double strand breaks upon gemcitabine treatment,
and displayed aberrant cell cycle progression following recovery from gem-
citabine treatment. Our ongoing experiments are investigating the detailed
mechanism of RECQ1’s role in response to gemcitabine and its implications
in therapeutic response. Funding: This work was funded by the NIGMS/NIH
grant SC1GM093999 to Sudha Sharma. We also acknowledge support from
the NIMHD/NIH award number G12MD007597 and NIA/NIH award num-
ber 1R25 AG047843-02. We thank Drs. Ritu Chaudhary, Xiaoling Li and
Ashish Lal (NCI) for their help and support.
#1428 Single-cell transcriptomics reveals differential DNA repair signa-
tures after chemotherapy in high-grade serous ovarian cancer.Anniina Fark-
kila,1 Kaiyang Zhang,2 Katja Kaipio,3 Tarja Lamminen,3 Rainer Lehtonen,2 Jo-
hanna Hynninen,4 Seija Grénman,4 Olli Carpén,1 Sampsa Hautaniemi,2 Anna
Vähärautio2. 1Univ. of Helsinki and Helsinki University Hospital, Helsinki, Fin-
land; 2Univ. of Helsinki, Helsinki, Finland; 3University of Turku, Turku, Finland;
4University of Turku and Turku University Hospital, Turku, Finland.
Resistance to chemotherapy poses a major clinical problem in the treatment
of ovarian cancer. The effıcacy of platinum- based chemotherapy relies on de-
fective DNA repair mechanisms, and increased expression of homologous re-
combination (HR)/DNA repair genes in primary tumor samples is associated
with improved chemoresponse. However, the effects of neo-adjuvant chemo-
therapy (NACT) on the expression DNA repair genes in cancer cells are poorly
understood. In addition, high-grade serous ovarian cancers (HGSOCs) display
signifıcant inter- and intratumoral heterogeneity, and the identifıcation of
mechanisms of drug resistance has been hampered by the lack of data at the
single cell resolution. We collected 34 primary and 20 interval tumor samples
from 15 patients treated for HGSOC at the Turku University Hospital, Finland.
Tumor tissue total RNA was sequenced with Illumina HiSeq. For this study, we
selected 363 genes selected due to their validated role in DNA repair pathways
and compared their expression profıles between primary and interval samples.
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The treatment naïve primary tumor samples highly expressed genes related to
HR, such as BRCA2, RAD54, PARPBP, FANCD2, and POLQ. Whereas after
NACT the interval samples highly expressed genes regulating cell cycle, inflam-
matory response, and the drug efflux pump ABCB1. Moreover, higher expres-
sion of BRCA2 or POLQ in the interval samples correlated with poor primary
therapy outcome (p0.01). To reveal the transcriptomics landscapes of treat-
ment naïve and NACT treated HGSOCs at the single cell level, we performed
single cell mRNA sequencing of primary and interval samples using the Fluid-
igm C1 Platform. Unsupervised clustering revealed eight distinct cell subpopu-
lations, of which two clusters were annotated HGSOC cells based on enriched
expression of cancer specifıc genes. In global gene expression analysis of 98
HGSOC cells, the most differentially expressed genes in primary HGSOC
cells were heat shock proteins reflecting active protein synthesis. By contrast,
the cancer cells from interval samples highly expressed genes regulating the
cell cycle and immune response. Of the DNA repair pathway genes, the
interval samples expressed lower levels of HES1, a transcription factor that is
known to promote cancer progression and stemness. The herein elucidated
DNA repair pathway transcriptomics landscape at single-cell and whole tu-
mor level provides novel targets for overcoming chemoresistance in
HGSOC.
#1429 DNA damage response to dianhydrogalactitol (VAL-083) in p53-
defıcient non-small cell lung cancer cells. Anne Steino,1 Guangan He,2 Jeffrey
A. Bacha,1 Dennis M. Brown,1 Zahid Siddik2. 1DelMar pharmaceuticals, Inc.,
Vancouver, British Columbia, Canada; 2The University of Texas MD Anderson
Cancer Center, Houston, TX.
Non-small cell lung cancer (NSCLC) treatment usually involves surgery and
chemotherapy with tyrosine kinase inhibitors (TKI) in patients with EGFRmu-
tations (10-15% inWestern population, 40% in Asian populations) or with plat-
inum-based regimens. Response to TKI treatment is short lived, and tumors
recur with new mutations, primarily T790M. Recurrent NSCLC with T790M is
sensitive to third generation TKIs, but resistance usually emerges through new
mutations, including KRAS. Resistance to cisplatin and carboplatin, partly due
to p53 mutation, is also a major clinical limitation and long-term prognosis in
NSCLC is poor. Dianhydrogalactitol (VAL-083) is a bi-functional alkylating
agent with demonstrated clinical activity against NSCLC in historical NCI-
sponsored trials and VAL-083 is approved for lung cancer treatment in China.
However, themechanism-of-action of howDNAdamage signals are propagated
and their effects on NSCLC cells are not fully understood. Therefore, we exam-
ined VAL-083 in a panel of 11 humanNSCLC cell lines harboring wild-type p53
(H460,A549,H226),mutant p53 (H1975, SkLU1,H2122,H157,H1792,H23) or
null p53 (H838, H1299). Importantly, as determined by the 5-day MTT assay,
VAL-083 was cytotoxic against all 11 cell lines at low M concentrations and
cytotoxicity was independent of p53 status. We chose 3 TKI-resistant cell lines
with differentmutation profıles for cell cycle kinetics studies: i)H1975 (p53mut,
EGFR-T790M mut, KRAS wt) with IC50 0.9M, ii) A549 (p53 wt, EGFR wt,
KRAS mut) with IC50 1.8M, and iii) H157 (p53 mut, EGFR wt, KRAS mut)
with IC50 4.5M. In all 3 cell lines, early response at 18 hr showed dose-depen-
dent increase in cells in S-phase, with continued slow cell cycle progression
resulting in accumulation of cells in G2/M phase by 36 hr, suggesting persistent
cell cycle arrest. DNA damage signaling was examined by immunoblot analysis
in A549 andH1975 cells. In p53-wt A549, VAL-083 induced the phospho-Ser15
form of p53, total p53 and total p21, thus indicating that VAL-083 treatment
activated p53 function. On the other hand, in p53-mutant H1975, VAL-083
treatment did not result in consistent p53 or p21 increases, but did readily in-
duce phospho-Ser15 p53. This is consistent with a lack of p53 function, as an-
ticipated for mutant p53 cells. Interestingly, H1975 was 2-fold more sensitive to
VAL-083 thanA549, suggesting, that in p53-mutant cells, VAL-083 acts through
a p53-independent mechanism. Examination of ATR, ATM, Chk1 and Chk2
indicated that DNA damage by VAL-083 prompted phosphorylation of these
kinases. Notably, the total anti-apoptotic Chk1 was more prominently reduced
inH1975 thanA549, whichmay partly explain the stronger cytotoxicity of VAL-
083 in p53-mutantH1975. These preclinical data strongly support VAL-083 as a
potential treatment ofmutant p53 andTKI-resistantNSCLC, and indicateDNA
damage signaling is mediated via ATM, ATR, Chk1 and Chk2.
#1430 The spliceosome U2 snRNP factors promote genome stability
throughdistinctmechanisms; transcriptionof repair factors andR-looppro-
cessing.Michihiro Tanikawa. The University of Tokyo, Tokyo, Japan.
Objective: Recent whole-exome sequencing studies of malignancies have de-
tected recurrent somatic mutations in U2 snRNP components of the spliceo-
some. These factors have also been listed as novel players of DNA damage re-
sponse in several genome wide screens and proteome analysis for DDR genes.
Although accumulating evidences have implied that the spliceosome plays an
important role in genome stability and is an emerging hallmark of carcinogenic
pathways, its precise role in genome stability still remains ambiguous. The aim
of this study is to clarify the functions of U2 snRNP splicing factors, especially
SNRPA1 (Small Nuclear Ribonucleoprotein Polypeptide A1) in DDR pathway.
Methods: SNAPA1 and other U2 snRNP splicing factors were identifıed as HR
repair genes by genome-wide screens based on homologous recombination and
RAD51 immunofoci formation. Each splicing factor was depleted by siRNA
knockdown in USOS cells. The functions of SNRPA1 in DNA repair were ana-
lyzed byHR assay (DR-GFP assay), immunofluorescence, real-time lasermicro-
irradiation and comet assay (single cell gel electrophoresis). Results: HR assay
showed strong HR defıciencies in splicing factor’s depleted cells. In these cells,
accumulation of BRCA1 and Rad51, major HR factors, to DNA damage sites
were severely impaired. Especially, live cell imaging showed recruitment of
SNRPA1 to laser inducedDNAdamage sites and unveiled its direct involvement
to DNA damage repair. Comet assay also showed that depletion of SNRPA1
markedly caused DNA damage with the tail of broken DNA fragments. This
DNA damage was R-loop (DNA-RNA hybrid) mediated DNA damage and res-
cued by overexpression of RNAseH1.Conclusion:Herewe unveiled twodistinct
pathways how spliceosome U2 snRNP factors contribute to genome stability.
The main function is indirect, through transcription, to maintain the protein
levels of essential repair factors and contribute to homologous recombination
repair. Our data suggest that depletion of splicing factors can be onemechanism
for HR defıciency (i.e. BRCAness). In addition real-time laser microirradiation
analysis identifıed the rapid recruitment of SNRPA1 to DNA damage sites. In-
tensive functional analysis of SNRPA1 unveiled the other, more immediate and
direct effect to process R-loop structure, deleterious transcriptional by-products
for the genome, at sites of on-going transcription.
#1431 Therapeutic exploitation of mutant BRAF in childhood glioma.
Sudipa Saha Roy, Peter Houghton. UTHSCSA, San Antonio, TX.
Low grade gliomas (LGG) are the most common tumors of the central ner-
vous system in children, accounting for about 50% of all brain tumors. They
represent a heterogeneous group of grade I and II tumors according to theWHO
classifıcation. Pediatric LGG, is associated with activation of BRAF through a
tandem duplication that results in the KIAA1549-BRAF fusion or through an
activating point mutation of BRAF (predominantly V600E). More recent fınd-
ings suggest that the KIAA1549-BRAF fusion is restricted to Grade 1 tumors
(70-90%) whereas BRAF(V600E) occurs more frequently in Grade 2-4 tumors
(23%). Findings for BRAF mutation, similar to other tumors with activated
BRAF (e.g. melanoma), and the phase I activity of MEK inhibitor in the PBTC-
029 protocol, suggest that activated BRAF may provide a validated drug target.
Previous studies from our lab indicate that, in the context of mutant BRAF,
inhibition of MEK inhibits TORC1 signaling and may induce a ’BRCA-like’
phenotype, through depletion of FANCD2. Potentially suppression of TORC1
could have effects on other DNA damage response pathways that could com-
pensate for loss of FANCD2. To understand the consequences of MEK inhibi-
tion in the context of BRAF abreation in LGG we surveyed DNA repair genes
that may be regulated via the MEK/TORC1 pathway in BRAFmutant cells. The
objective of this particular studywas to examine themechanismand signifıcance
of MEK inhibition to the repair of DNA damage by the homologous recombi-
nation (HR) pathway. For this study, we have used glioma cell lines having
BRAF(V600E) mutation; the BT40 cell line was developed from patient-derived
astrocytoma xenograft (PDX) model in mice in our lab and AM38c1 and
DBTRG-05MG cells were generously provided by T. Nicolades. Annexin bind-
ing assay demonstrated thatMEKi treatment signifıcantly increased the percent-
age of apoptosis and necrosis of glioma cells. Human DNA repair PCR Array
analysis identifıed MEKi induced down regulation of genes involved in Base
Excision Repair (BER), Nucleotide Excision Repair (NER), Mismatch Repair
(MMR) and Double-Strand Break (DSB) repair pathways. DSB repair genes
were further validated by real time qPCR analysis. Immunoblot analysis of gli-
oma cell lines indicate that MEKi treatment enhanced the gamma-H2AX levels.
To elucidate themechanism of DSB repair pathway in presence ofMEKi, clono-
genic assay, nuclear foci formation assay, and GFP reporter assay for homolo-
gous recombination (HR) and non-homologous end-joining (NHEJ) are ongo-
ing. Collectively, these fındings demonstrate for the fırst time a previously
unknown role for MEKi in treatment of glioma cells that involves inhibition of
DNA double-strand break repair pathways. Further, we will examine the mech-
anism and signifıcance of MEK/ERK and TORC1 signaling axis in regulation of
DNA repair genes and its effect on LGG. Understanding howMEK plays a role
in DNA repair pathways will be useful in maximizing treatment opportunities
for childhood glioma.
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#1432 Precision lung cancer medicine based on information on cancer
and the host genomes. Takashi Kohno,1 Kouya Shiraishi,1 Kazushi Yoshida,2
Motonobu Saito,1 YukinoriOkada3. 1National CancerCtr. Research Inst., Tokyo,
Japan; 2National Cancer CtrHospital, Tokyo, Japan; 3OsakaUniversityGraduate
School of Medicine, Osaka, Japan.
Aberrations of oncogene, such as EGFRmutation; and ALK, RET, and ROS1
fusions, function as a driver in the development of lung adenocarcinoma
(LADC). They are a solid target of therapy using tyrosine kinase inhibitors, as
represented by a high response rate of RET-fusion positive LADC to vandetanib
(LURET study, Yoh et al., Lancet RespMed, 2016). Our genome-wide sequenc-
ing study revealed that oncogene aberration positive LADCs carry less numbers
of mutations in cancer-related genes than negative ones (Saito, Cancer Res,
2015), indicating a small mutation burden in the development of the formers.
Consistently, a clinical trial of anti-PD-1 therapy indicated that EGFR-mutation
positive cases do not benefıt well from the therapy (Borghaei et al., N Engl JMed.
2015). LADC driven by somatic EGFR mutations is more prevalent in East
Asians (30-50%) than in European/Americans (10-20%). We recently revealed
that variations inHLA-class II loci underlie the risk of the disease, by conducting
a genome-wide association study of 3,173 patients and 15,158 controls, com-
bined with imputation of HLA alleles using a Japanese-specifıc panel (Shiraishi
et al., Nature Comm, 2016). The result indicates that LADC develops in vivo
through interaction between somatic mutations and germline variations that
modulate immune reaction. Therefore, effıcacy of immune checkpoint blockade
targeting therapy might also be influenced by such germline variations. On the
other hand, oncogene-negative LADCs show a highmutation burden associated
with nonsynonymous mutations in chromatin remodeling and other cancer-
related genes. Thus, these cases would respond well to immune checkpoint
blockade targeting therapies. We would like to discuss here precision lung can-
cer medicine based on information on cancer and the host genomes.
#1433 Single cell RNA sequencing reveals smoking-associated alterations
in bronchial airway epithelial subpopulations. Grant E. Duclos, Joshua D.
Campbell, YaronGesthalter, PatrickAutissier, YvesM.Dumas, Robert Terrano,
Gang Liu, Marc E. Lenburg, Avrum Spira, Jennifer Beane. Boston University
School of Medicine, Boston, MA.
Rationale: We have previously shown that bronchial airway epithelial gene
expression reflects the physiologic response to cigarette smoke exposure. We
have also shown that gene expression differences in cytologically normal airways
cells can serve as a diagnostic biomarker for lung cancer. In this study, we use
single cell RNA-seq to profıle transcriptomes of individual bronchial epithelial
cells from current and never smokers in order to detect smoking-associated
alterations within specifıc epithelial cell types and to discover novel subpopula-
tions that develop as a result of smoke exposure. This approachmay be useful for
identifying cell type-specifıc transcriptomic changes in the airways of cancer
patients, which may lead to a better understanding of lung carcinogenesis and
new approaches to early lung cancer detection.Methods:We obtained bronchial
brushings from current smokers (n6) and never smokers (n6) and isolated
single cells by FACS. The CEL-Seq RNA library preparation protocol was used
to sequence the transcriptomes of 1,140 cells (n95/donor). Results: Distinct
populations of bronchial cells expressed known markers of basal (KRT5), cili-
ated (FOXJ1), secretory (SCGB1A1, MUC5AC) epithelial cells, as well as white
blood cells (CD45). In the airways of smokers, we observed an increase in abun-
dance of MUC5AC secretory cells as well as a decrease in abundance of
KRT5 basal cells and SCGB1A1 secretory cells. A novel subset of KRT8
cells that lacked expression of other known cell type markers was identifıed in
the airways of smokers and may represent a population previously described as
undifferentiated intermediate cells. Genes involved with metabolism of polycy-
clic aromatic hydrocarbons (CYP1B1) were detected in smoker secretory cells,
whereas genes involved in themetabolic response to cigarette smoke toxins such
as aldehydes (ALDH3A1) andquinones (NQO1),weremost highly expressed by
smoker ciliated cells. Interestingly, the novel KRT8 cells identifıed in smokers
expressed genes known to promote MUC5AC secretory cell differentiation
(SPDEF), but did not express MUC5AC itself, suggesting that these may be
pro-MUC5AC secretory intermediate cells. Furthermore, we found that genes
previously associated with higher expression in the airways of lung cancer pa-
tients were enriched among genesmost strongly associated with smoker ciliated
and secretory cells, whereas genes with lower expression in lung cancer were
enriched among genes most strongly associated with white blood cells. Conclu-
sion: We have identifıed cell type-specifıc transcriptomic alterations and shifts
in epithelial cell population abundance in smoker airways. In future studies,
profıling the transcriptomes of single cells from bronchial airways of smokers
with and without lung cancer may lead to the identifıcation of specifıc cellular
subpopulations contributing to the airway fıeld of lung-cancer associated injury.
#1434 Mutational landscape in the normal-appearing airway canceriza-
tion fıeld of early-stage non-small cell lung cancer. Smruthy Sivakumar,1 Yas-
minka Jakubek,2 Wenhua Lang,2 Tina McDowell,2 Melinda M. Garcia,2 Chi-
Wan Chow,2 ZacharyWeber,3 Carmen Behrens,2 Neda Kalhor,2 Cesar Moran,2
Randa El-Zein,4 Gareth Davies,3 Junya Fujimoto,2 Reza Mehran,2 Stephen G.
Swisher,2 Jing Wang,2 Avrum E. Spira,5 Jerry Fowler,2 F Anthony San Lucas,2
Ignacio I. Wistuba,2 Erik Ehli,3 Paul Scheet,2 Humam Kadara6. 1The University
of TexasGraduate School of Biomedical Sciences, Houston, TX; 2TheUniversity of
Texas MD Anderson Cancer Center, Houston, TX; 3Avera Institute for Human
Genetics, Sioux Falls, SD; 4Houston Methodist Research Institute, Houston, TX;
5School of Medicine, Boston University, Boston, MA; 6American University of
Beirut, Beirut, Lebanon.
Lung cancer, of which non-small cell lung cancer (NSCLC) is the most com-
mon form, is the secondmost prevalent cancer in the U.S. and the leading cause
of cancer mortality. Field cancerization phenomenon establishes that normal
appearing tissues surrounding a tumor will exhibit a fıeld effect – particularly in
smokers – with the tissues proximal to the tumor showing more, and even
sharing, alterations with the tumor. Previous studies in NSCLC provide evi-
dence for both complex progression trajectories, yet, precise mechanisms re-
main unknown. To investigate the fıeld cancerization phenomenon, we con-
ducted a genome-wide survey of acquiredDNAalterations in normal-appearing
tissues including small airways adjacent to NSCLC, mainstem bronchi (large
airways), nasal epithelium, distant normal lung and blood, along with multiple
samples from their surgically resected paired tumors, for a total of 500 samples
from 48 patients with early-stage NSCLC (11 squamous cell carcinomas and 37
adenocarcinomas). Since we expect lowmutation burdens andmutant cell frac-
tions in pathologically normal tissues, we assessed somatic point mutations via
deep targeted sequencing of 409 genes and paired these data with our recent
study of acquired copy number alterations (CNAs) inferred from high-density
whole-genome SNP microarrays, thus offering a deep and wide survey of so-
maticDNAalterations. After aggregating results frommultiplemutation callers,
we observed somatic mutations (exonic, splicing and UTRs) in 257 samples of
which 65 (in 35 patients) were from normal-appearing fıeld (non-tumor, non-
blood) samples. Tumor and fıeld samples in smokers showed a higher mutation
burden and large proportion of C:GA:T changes. We also observed concor-
dance of mutations in the airway and corresponding tumor profıles. Further, a
statistically signifıcant fıeld effect was established withmutational burden (mea-
sured by the variant allele frequency) increasing with proximity to the tumor.
Among the 35 NSCLC cases with fıeld mutations, the small adjacent (to tumor)
airways in six patients exhibitedmutations in lung cancer drivers such as KRAS,
STK11, TP53 and KEAP1. We also identifıed mutations in the large airway
(TP53, SETD2, CDKN2A), distant normal lung parenchyma (RB1, RET) and
nasal epithelium (AKT1). We then correlated point mutation and CNA muta-
tion profıles. Of eight cases showing a nonsynonymous or stopgain variants in
established lung cancer drivers in the airways, four exhibited putative “two-hit”
progressionmodels, e.g. both KEAP1 and STK11mutations with 19p loss, over-
lapping TP53 mutation/17p loss, or KRAS mutation/12p gain. Our fındings in
normal-appearing tissues of the respiratory epithelium offer insights into the
earliestmutational events in their progression toNSCLC and, possibly, in tumor
relapse and that may represent suitable targets for early detection and chemo-
prevention.
#1435 Immune/inflammatory polymorphisms predict lung cancer sur-
vival. Donovan Watza,1 Chrissy Lusk,1 Angie Wenzlaff,1 Christine Neslund-
Dudas,2GregoryDyson,1AymanSoubani,3 ShirishGadgeel,1AnnG. Schwartz1.
1Karmanos Cancer Institute, Detroit, MI; 2Henry Ford Hospital, Detroit, MI;
3Wayne State University School of Medicine, Detroit, MI.
Lung cancer is the leading cause of cancer related mortality in the United
States, with a median fıve year survival of 16%. Recent advancements in the
treatment of lung cancer focus on modulating the immune system to improve
patient outcomes with markedly reduced toxicity profıles. This study aims to
investigate single nucleotide polymorphisms (SNPs) within functional units of
the immune system genome to identify genetic markers indicative of overall
survival in a cohort of metropolitan Detroit lung cancer patients. This cohort
presents a unique population of lung cancer patients for analysis, consisting of
40% African Americans, whom are known to have worse outcomes than their
Caucasian counterparts. To assess SNPs within functional units of the immune
genome, a hierarchical immune system gene and pathway list was constructed,
incorporating genes and pathway identifıers from the Reactome database as well
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as previous genetic and inflammatory specifıc cancer studies to generate a well
curated gene and pathway dataset. Genomic locations for the genes, together
with proximal regulatory regions, were obtained from the UCSC genome
browser for cross-referencing with the Illumina MEGA SNP array to generate
SNPs for inclusion. Preliminary analysis of 848 NSCLC patients in association
with 29,126 immune specifıc SNPs identifıed six SNPs as signifıcantly associated
with survival (p-value104) in this lung cancer cohort, implicating the follow-
ing six genes, PXN, GFRA3, HLA-DQA1, KSR2, BTBD1, and ATF2; although
further gene/pathway analysis is necessary to elucidate how these associations
interact in the context of genes and pathways of the immune system. PXN over
expression has been previously implicated in both high risk lung epithelial dys-
plasia as well as in the development of lung adenocarcinoma in prior clinical
studies. Additionally, GFRA3 has been identifıed as an activator of the RET
kinase and increased GFRA3 activity in context of the Artemin pathway is a
known promoter of NSCLC progression. As well, select polymorphisms in the
HLA-DQA1 gene are known clinicalmodifıers of lung squamous cell carcinoma
risk. Finally, ATF2 is a broadly active transcription factor and ATF2 upregula-
tion has been associated with tumorigenesis and metastasis in both cell models
and patient tumor samples in multiple cancer studies. The previous association
of these genes in lung cancer is promising and further immune system gene/
pathway analysis is warranted.
#1436 Identifıcation of novel tumor suppressor candidates in familial
cholangiocarcinoma using sequencing-based Megabase-scale haplotypes
from germline and cancer genomes. Stephanie Greer,1 Lincoln Nadauld,2 Billy
Lau,1 LauraMiotke,1 ErikHopmans,1 ChristinaM.Wood,1 JohnM. Bell,1 David
A. Jones,3 Hanlee P. Ji1. 1Stanford Univ., Stanford, CA; 2Intermountain Health-
care, Salt Lake City, UT; 3Huntsman Cancer Institute, Salt Lake City, UT.
Cholangiocarcinoma (bile duct cancer) is a rare epithelial malignancywith an
extremely poor prognosis characterized by a 5-year survival of less than 10%.
While this tumor type can be amenable to specifıc combination chemotherapy
regimens, it is typically diagnosed at an advanced stage and inevitably progresses
towards distant metastasis. We identifıed a family with a predisposition to chol-
angiocarcinoma, having multiple affected family members, and sought to iden-
tify the underlying germlinemutation(s).We employed linked-read sequencing,
a microfluidic technology where high-molecular weight DNA molecules (20
kb) are partitioned into droplets and labeled with unique barcodes, enabling
computational reconstruction of the original large molecules following tradi-
tional short-read sequencing, to identify entire megabase-scale regions of the
genome that segregate with the disease. We applied this technology to an entire
generation of a family predisposed to cholangiocarcinoma, including a mix of 8
affected and unaffected siblings. We additionally utilized each affected individ-
ual’s cancer genome to search for a common second hit that would serve as
further confırmation. Our analysis yielded a small set of four candidate patho-
genic variants. Functional validation of the candidate genes in a zebrafıshmodel,
using morpholino-based gene silencing, identifıed one candidate whose silenc-
ing led to a reproducible phenotype consistent with known aspects of the can-
didate gene’s function. The candidate variant occurs in a TGF family-interacting
domain, and has not been extensively characterized in other cancers. Cross-
validation with TCGA datasets showed the gene was altered in 5% of cholangio-
carcinomas, all of which displayed homozygous deletions. This identifıcation of
a germline allele associated with familial cholangiocarcinoma represents a
unique discovery with clinical implications for the described family and war-
rants further investigation in other patients who display features of an inherited
cholagniocarcinoma. This fınding also raises the possibility of TGF pathway
targeting as a therapeutic strategy in select cholangiocarcinomas, and highlights
the power of whole-genome phasing to discover novel inherited tumor suppres-
sor variants.
#1437 Differential role of mutations in clonal evolution in esophageal
mucosa at risk for cancer. Akira Yokoyama,1 Hiromichi Suzuki,1 Tetsuichi
Yoshizato,1 Yuusuke Shiozawa,1 Yusuke Sato,1 Kosuke Aoki,1 Nobuyuki Kaki-
uchi,1 Yasuhide Takeuchi,1 Yoichi Fujii,1 Hideki Makishima,1 Kenichi Yo-
shida,1 Keisuke Kataoka,1 Yaichi Shiraishi,2 Masashi Sanada,3 Shigeru
Tsunoda,1 Sachiko Minamiguchi,1 Satoru Miyano,2 Manabu Muto,1 Seishi
Ogawa1. 1Kyoto university, kyoto, Japan; 2The University of Tokyo, tokyo, Japan;
3Nagoya Medical Center, nagoya, Japan.
Background: Esophageal squamous cell carcinoma (ESCC) develops in close
association with a chronic exposure to heavy drinking and smoking, frequently
in a metachronous manner, suggesting a strong fıeld effect on ESCC carcino-
genesis. However, it is poorly understood how the fıeld effect promotes clonal
evolution in esophageal mucosa to induce dysplasia, eventually leading to the
development of ESCC. Patients & Methods: A total of 221 samples were ob-
tained by multiple sampling from cancer tissues (n  53) as well as dysplastic
(n 12) andnon-dysplastic (n 156)mucosae from49 cancer-bearing patients
and 2 high-risk and 10 healthy patients either by endoscopy or surgery with
different sampling sizes (regular size: 4 - 8 mm2 and small size: 0.2 or 0.8 mm2).
All the samples were subjected to whole exome (WES) (n 99) and/or targeted-
capture (TS) (n 221) sequencing. Copy number alterations (CNAs) were also
investigated using SNP array- or sequencing-based karyotyping. Results: WES
and TS in regular size samples revealed clonal proliferation in most of the non-
dysplastic samples (98%), although the number of accompanyingmutations and
their clone size were signifıcantly lower compared to those in samples from
cancer and dysplasia (respectively, P  0.021 and P  0.001). Non-dysplastic
samples were most frequently accompanied by NOTCH1mutations (75%), fol-
lowed by TP53 mutations (50%). By contrast, cancer and dysplasia samples
showed much lower frequencies of NOTCH1 mutations (19% and 66%), but
instead characterized by higher frequency of TP53 mutations (100% and 92%),
andCNAs (83%and 17%), especially those focally involvingCCND1,CDKN2A,
PIK3CA, andEGFR, respectively.Mutation signatures also differed signifıcantly
between samples from non-dysplastic mucosa, and cancer/dysplasia tissues;
cancer/dysplasia samples exhibited an enhanced APOBEC-related and de-
creased transcription-coupled repair-related signatures, compared to non-dys-
plastic samples. In non-dysplasia samples, both NOTCH1 and TP53 mutations
were signifıcantly enriched in heavy drinkers compared to non- or occasional
drinkers (p 0.001 and p 0.023, respectively). To decipher the clonal archi-
tecture in more detail, we also sequenced 58 samples collected from non-dys-
plastic mucosae with a smaller sampling size. Clonal proliferation was con-
fırmed in all the samples analyzed; NOTCH1 andTP53mutationswere found in
79% and 55% of the samples, where 78% and 27% of the mutated area showed
biallelic alteration, respectively. Conclusions Clonal proliferation in non-cancer
esophageal epithelia is quite common even in non- or occasional drinkers and
could be extensive in heavy drinkers. NOTCH1 and TP53 mutations as well as
CNAs play major roles in clonal evolution but may have differential impacts on
esophageal carcinogenesis, where TP53 mutation and CNAs are likely to make
major contributions possibly under the influence of a higher APOBEC activity.
#1438 The dynamics of genetic aberrations in Crohn’s disease associated
colorectal carcinogenesis. Daniela D. Hirsch,1 Darawalee Wangsa,2 Yue Hu,2
Jack Zhu,2 David Petersen,2 Daniel C. Edelman,2 Paul S. Meltzer,2 Bao Tran,2
Kerstin Heselmeyer-Haddad,2 Thomas Ried,2 Timo Gaiser1. 1University Medi-
cal Center Mannheim, Mannheim, Germany; 2National Cancer Institute,
Bethesda, MD.
Crohn’s disease, a condition of chronic inflammation of the intestine,
signifıcantly increases the risk for the development of colorectal cancer
(CRC). Sporadic CRCs are characterized by a specifıc pattern of genomic
imbalances and a landscape of acquired gene mutations. In this study we
aimed to compare CRCs that arise as a consequence of chronic inflammation
in Crohn’s disease with sporadic CRCs. We analyzed 26 Crohn’s disease
associated CRCs, four matched dysplastic lesions, six matched inflamed mu-
cosa samples, and two matched lymph node metastases using array compar-
ative genomic hybridization, targeted sequencing (564 cancer related genes)
and gene expression profıling. As a control, we used normal intestinal mu-
cosa from the resection margin of these CRCs and 24 sporadic CRCs. In
general, CRCs that developed in patients with Crohn’s disease had a similar
distribution of genomic imbalances compared to sporadic CRC. However,
we identifıed distinct mutation signatures: in the Crohn’s disease associated
CRCs the most frequently mutated gene was TP53, which occurred in 65% of
the samples. The second, third and fourth most frequently mutated genes
were KRAS (27%), APC (23%) and PIK3CA (19%). In the control group of
sporadically arising CRCs, the most commonly mutated gene was APC
(75%), followed by KRAS (54%), TP53 (33%), SMAD3 (29%) and SMAD2
(25%). The genetic analyses of multiple lesions from individual patients
revealed a high degree of intertumoral heterogeneity with diverse patterns of
gene mutations and allowed the reconstruction of the sequence of genetic
events during Crohn’s disease associated tumorigenesis. In contrast to spo-
radic colorectal carcinogenesis, TP53 mutations were observed as early and
common events while APC mutations occurred rather late and were infre-
quent. Our comprehensive molecular profıling of Crohn’s disease associated
CRCs suggests that the genetic landscape of CRC is influenced by the acti-
vation of inflammation related pathways. Furthermore, our fındings offer
potential for establishing an early detection marker for dysplasia in patients
with Crohn’s disease.
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#1439 Genetic profıling of colitis-associated cancer indicates de novo car-
cinogenesis and the impact of chronic inflammation.Masashi Fujita,1 Naga-
hide Matsubara,2 Kazuhiro Maejima,1 Tomoki Yamano,2 Ikuo Matsuda,2 Seii-
chi Hirota,2 Hiroki Ikeuchi,2 Naohiro Tomita,2 Hidewaki Nakagawa1. 1RIKEN
Center for Integrative Medical Sciences, Tokyo, Japan; 2Hyogo College of Medi-
cine, Hyogo, Japan.
Background: Chronic inflammation is one of themajor causes of carcinogenesis.
Ulcerative colitis (UC) and Crohn’s disease (CD) increase the risk of colitis-associ-
ated cancer (CAC) development, and its biological and pathological characters are
also distinct. However, the genetic mechanism of how chronic inflammation leads
to CACs is still unclear. Methods: We obtained frozen tumor tissues from 21 CAC
patientsandperformedexomeorwhole-genomesequencingof thematched tumor-
normal samples. We enumerated recurrently mutated genes and selected 43 genes
among them for target capture. We then performed targeted resequencing of 84
FFPEspecimens fromCACtissues.Totally,wemadegenomicprofıles of 105CACs.
Results: Themost frequentlymutated genewasTP53,whosemutationwas found in
70 of 105 samples (67%),which ismore prevalent inCACs than commoncolorectal
cancers (CRCs). Somatic mutations of APC and KRAS were less prevalent (17 and
13 samples, respectively). Genes in the Wnt signaling pathway (APC, FBXW7,
TCF7L2, and RNF43) were mutated in 31 samples, whereas those in the TGF
pathway (TGFBR2, ACVR1B, SMAD2, SMAD4, LTBP4) weremutated in 25 sam-
ples. Mutational signature of CACs shows some differences from common CRCs.
Conclusion: Our results confırmed genetic differences for cancer development be-
tweenCACs and commonCRCs. Frequent TP53mutations and less frequent APC
mutations are consistent with the idea of “de novo” carcinogenesis than adenoma-
carcinoma sequence. The association between the mutations and clinical informa-
tion are also discussed.
#1440 Germline loss-of-function alleles in Finnish colorectal cancer pa-
tients.TomasTanskanen,UlrikaHänninen, TatianaCajuso, JohannaKondelin,
Riku Katainen, Jiri Hamberg, Niko Välimäki, Esa Pitkänen, Kimmo Palin, Lauri
A. Aaltonen. Genome-Scale Biology Research Program, Research Programs Unit,
University of Helsinki and Department of Medical and Clinical Genetics, Medi-
cum, University of Helsinki, Helsinki, Finland.
Colorectal cancer, a major cause of cancer deaths worldwide, is often
preventable by screening and surveillance, especially in patients at increased
risk; however, its heritability is incompletely understood, and studies in
isolated populations such as Finland may be valuable for gene discovery. We
analyzed whole-genome or whole-exome sequencing data in 322 Finnish
colorectal cancer cases of unknown etiology and 928 population-matched
controls. To enrich for susceptibility alleles, cases were selected on the basis
of early-onset colorectal cancer (age at diagnosis 50 years; 50/322, 16%),
synchronous or metachronous colorectal cancer (30/322, 9.3%), familial
colorectal cancer (134/322, 42%), personal history of noncolorectal cancer
(93/322, 29%), or family history of at least two noncolorectal cancers (124/
322, 39%). To increase the prior probability of pathogenicity of variants, the
study was restricted to rare and low-frequency protein-coding loss-of-func-
tion variants (nonsense, frameshift, and essential splice site variants; allele
frequency3%). Single-variant and gene-level associations were tested, and
genes with loss-of-function variants exclusively in cases were pinpointed. An
independent set comprising 1,257 cases and 2,638 controls were genotyped
using SNP arrays, and genotype imputation provided additional data on 225
(8.5%) of the 2,654 initially discovered loss-of-function variants. Principal
component analysis was applied to correct for population structure. In as-
sociation analyses, with a statistical power of at least 80% for a range of
moderate-to-high effect sizes and low allele frequencies (e.g., odds ratio of 3
and allele frequency of 0.5%) at p 0.15, a total of 35 candidate colorectal
cancer predisposition genes were identifıed, although none of them reached
exome-wide signifıcance. There were 21 genes with rare loss-of-function
alleles in at least two cases but none of the sequenced controls. Whole-
genome sequencing data from paired normal and tumor tissues were avail-
able in 243 cases, and potential second hits (wild-type allele losses or somatic
point mutations) were found in 15 genes. These results may, through further
analysis and replication, contribute to our knowledge of the genetic archi-
tecture and pathobiology of colorectal cancer susceptibility.
#1441 A comprehensive cis-eQTL analysis revealed target genes in breast
cancer susceptibility loci identifıed in genome-wide association studies.Xin-
gyi Guo,1 Weiqiang Lin,2 Qiuyin Cai,1 Jiajun Shi,1 Yaqiong Sun,1 Xiao Pan,2
Mi-Ryung Han,1 Wanqing Wen,1 Bingshan Li,1 Jirong Long,1 Jianghua Chen,2
Wei Zheng1. 1Vanderbilt University School ofMedicine, Nashville, TN; 2Zhejiang
University School of Medicine, Hangzhou, China.
Genome-wide association studies (GWAS) have identifıed approximately
107 common single nucleotide polymorphisms (index SNPs) for breast can-
cer risk. The target genes and underlying mechanisms for the large majority
of the identifıed associations remain unknown. We conducted a cis-expres-
sion quantitative trait loci (cis-eQTL) analysis using transcriptome data
from the Molecular Taxonomy of Breast Cancer International Consortium
(METABRIC) (N  1,981), The Cancer Genome Atlas (TCGA) (N  458),
and the Genotype-Tissue Expression (GTEx) project (N  183). We identi-
fıed a total of 58 genes including SSBP4 at Benjamini-Hochberg adjusted P
0.05 in at least one dataset and another gene, PAX9, at P 0.05 with consis-
tent association directions in all three datasets. Using data from the Ency-
clopedia of DNA Elements (ENCODE), we selected functional SNPs and
showed that some alternative alleles could signifıcantly change promoter
activities of their target genes compared to reference alleles using luciferase
reporter assays. The effects of target gene expression for those alleles were in
line with eQTL observations. In addition, we validated the genes SETD9 and
SSBP4 using Sequenom allelotype technique from 235 adjacent normal
breast tissues and observed the allelic-specifıc expression associated with
their index SNPs. This study revealed novel biological mechanisms for asso-
ciations of genetic susceptibility risk loci for breast cancer.
#1442 Analysis of cis-eQTLs in normal and tumor-derived pancreatic tis-
sues reveals functional insights, including for the 9q34.1 ABO pancreatic
cancer risk locus. Laufey T. Amundadottir,1 Soren LykkeAndresen,2Wenming
Xiao,3 Jason Hoskins,4 Ashley Jermusyk,4 Lauren Rost,4 Irene Collins,4 Jinping
Jia,4 Michael Mobaraki,4 Bin Zhu,4 Robert Kurtz,5 Hemang Parikh,4 Lei Song,4
Meredith Yeager,4 Torben Jensen,2 William Bamlet,6 Nilanjan Chatterjee,7
Brian Wolpin,8 Jill Smith,9 Sara Olson,10 Gloria Petersen,6 Jianxin Shi,4 Ming-
feng Zhang4. 1National Cancer Inst., Bethesda, MD; 2Aarhus University, Den-
mark; 3FDA, AR; 4National Cancer Inst., MD; 5Memorial Sloan Kettering Cancer
Center, NY; 6Mayo Clinic, MN; 7John’s Hopkins Univeristy, MD; 8Dana Farber
Cancer Institute, MA; 9Georgetown University, DC; 10MSK Cancer Center, NY.
Objective: To elucidate the genetic architecture of gene expression in pancre-
atic tissues. Design: We performed expression quantitative trait locus (eQTL)
and allele specifıc expression (ASE) analyses usingRNA-sequence data and 1000
Genomes (1000G) imputed GWAS genotypes from 95 fresh frozen histologi-
cally normal pancreatic tissue samples. Data from115 pancreatic tumor-derived
tissue samples from The Cancer Genome Atlas (TCGA) was included for com-
parison. Results: We identifıed 38,615 cis-eQTLs (corresponding to 484 Genes)
in histologically normal tissues and 39,713 cis-eQTL (corresponding to 237
Genes) in tumor tissues (FDR0.1), with the strongest effects seen near tran-
scriptional start sites (TSS). Approximately 23% and 42% of genes with signifı-
cant cis-eQTLs (eGenes) appeared to be specifıc for tumor and normal derived
tissues, respectively. Signifıcant enrichment of cis-eQTL variants was noted in
noncoding regulatory regions marked by modifıed histones, DNAse hypersen-
sitivity and bound transcription factors, in particular for pancreatic tissues
(1.53-3.12 fold, P0.0001), indicating tissue-specifıc functional relevance. A
common pancreatic cancer risk locus on 9q34.2 in theABOgene (rs687289) was
associated with ABO expression in histologically normal (P5.8x108) and
tumor-derived (P8.3x105) pancreatic tissues. The high linkage disequilib-
rium (LD) between this variant and the O blood group generating deletion
variant in exon 6 ofABO suggested that nonsense-mediated decay (NMD) of the
“O” mRNA could explain the eQTL. However, knock-down of crucial NMD
regulators did not influence decay of theABO “O”mRNA, indicating that a gene
regulatory element influenced by pancreatic cancer risk alleles may underlie the
eQTL. Conclusions: We have identifıed cis-eQTLs representing potential func-
tional regulatory variants in the pancreas and generated a rich dataset for further
studies on gene expression and regulation in pancreatic tissues.
#1443 Identifıcation of enhancer elements at kidney cancer susceptibility
loci using MPRA. Leandro Machado Colli,1 Lea Jessop,1 Mitchell Machiela,1
Jiyeon Choi,1 Timothy Myers,2 Stephen Chanock1. 1NCI, Rockville, MD; 2NCI,
Bethesda, MD.
GWAS is an important tool for discovering regions in the genome associated
with cancer susceptibility. For renal cell carcinoma (RCC), only two loci have
had their functional basis explained (11q13 and 12p12). Here, we used a mas-
sively parallel reporter assay (MPRA) to investigate enhancer activity in 20
GWAS regions that had anRCC association p-value of at least 107.We selected
784 SNPs with an r20.4 or D’0.5 and MAF0.05 that had evidence for en-
hancer activity based on available ENCODE transcription factor or histone
ChIP-seq, FAIRE, and DNase I hypersensitive data. The MPRA library was
composed of 47461 oligonucleotides 201 bp in length, compelled of 145 bps
contained the SNP in the forward or reverse orientation followed by 10 bp of
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barcode sequence to allow for identifıcation. Each of the 784 SNPs tested were
tagged 10 separate times for both orientations. Controls were constructed by
randomizing the 10 nucleotides centered on the SNP. TheMPRA librarywas the
cloned into a luciferase reporter vector that was transfected into HEK293T and
ACHN cell lines. NGS was performed on 5 replicates using the the Illumina
HiSeq 2500. After correcting formultiple comparisons, 50 SNPs from16 regions
showed signifıcant p-values. From these 50 SNPs, 29 showed enhancer activity
that was independent of the forward/reverse orientation and had the same effect
in both cell lines. This analysis has identifıed possible functional variants at RCC
risk loci and opens opportunities to discover new molecular mechanisms of
genetic susceptibility of RCC.
#1444 Validation of prostate cancer risk variants by CRISPR/Cas9 medi-
ated genome editing at theMSMB locus.XingWang,1 JamesHayes,1 XingXu,1
Dipti Mehtad,2 Xiaoni Gao,1 Hans Lilja,2 Robert Klein1. 1Icahn School of Medi-
cine at Mount Sinai, New York, NY; 2Memorial Sloan-Kettering Cancer Center,
New York, NY.
Genome wide association studies (GWAS) have identifıed nuermous sin-
gle nucleotide polymorphisms (SNPs) associated with prostate cancer risk.
While numerous in silico analyses suggest that the majority of these SNPs
may function through regulation of gene expression, wet lab experiments to
distinguish the causative variants from their linkage disequilibrium (LD)
partners is still needed. Here, we demonstrate how genome editing can in-
vestigate the role of individual polymorphisms on gene expression. Here, we
focus on the prostate cancer-associated SNP rs10993994, which is in the
promoter of the MSMB gene that encodes for the prostate-secreted protein
beta-MSP. This SNP is notable because it associates with seminal and serum
levels of beta-MSP, PSA, and hK2; mRNA levels of MSMB and the nearby
androgen receptor co-activator NCOA4 in the prostate; and mRNA levels of
MSMB in the stomach. Intriguingly, rs10993994 is not a gastric cancer risk
SNP suggesting that there may be other variants with prostate-specifıc func-
tion responsible for the observed prostate cancer association. Using data
from the FANTOM5 project, we show that rs7098889, in LD with
rs10993994, is located in one of the most prostate-specifıc enhancers. We
had previously shown that this SNP is associated with beta-MSP indepen-
dent of rs10993994. To distinguish the effects of these two SNPs on gene
expression, we generated a series of double gRNA mediated CRISPR/Cas9
deletions of the relevant regulatory elements. Removing the element con-
taining rs7098889 flanking region results in10 to 20 fold increase ofMSMB
expression in the prostate cancer LNCaP cell line but not in the gastric cancer
AGS cell line. There is no change in NCOA4 in either cell line. Removing
rs10993994 flanking region results in over 10 fold increase of MSMB expres-
sion and50% decrease of NCOA4 in LNCaP. As both LNCaP and AGS are
heterozygous for both SNPs, we then generated single clones in which only
one allele was removed. For rs7098889, an over 300 fold increase of MSMB
expression was observed in two out of the three clones with the T but not the
C allele. Transcripts from high expressers all came from one allele. Similarly,
single clone analysis showed 40 to 60 fold up-regulation ofMSMB expression
in two out of three clones with the C but not the T allele of rs10993994. This
is consistent with the observation for rs7098889 since rs7098889T and
rs10993994C are on the same haplotype. Our work demonstrates dramatic
and locus specifıc effect of individual polymorphisms on gene expression,
which strongly support the notion that an important function of disease risk
variants is through regulation of gene expression.
#1445 Understanding the 8q24 colorectal cancer risk locus via CRISPR/
Cas9 scarless genome editing. Nicole Coggins, Jacob Stultz, David Segal, Luis
Carvajal-Carmona. Univ. of California, Davis, Davis, CA.
Colorectal Cancer (CRC) is one of the leading causes of mortality in the
US, being the third most common cancer among both men and women.
While an exact cause of CRC has not yet been elucidated, the existence of a
clear heritable genetic component has been established. With the recent
surge of data from Genome-Wide Association Studies, a handful of CRC-
associated loci have been identifıed, each containing numerous Single Nu-
cleotide Polymorphisms (SNPs). We hypothesize that among the 25 loci
associated with increased risk for CRC, there are driver SNPs functioning to
contribute to initiation or progression of CRC development. It is crucial, in
order to enhance our understanding CRC tumorigenesis, to extract these
functional variants from the pool of associated SNPs and validate their caus-
ative signifıcance within the cell. To model these functional SNPs, we have
developed a novel “scarless” isolation pipeline for selecting isogenic clones
with the desired single-base edit without selection markers following
CRISPR-Cas9 mediated HDR.With this pipeline, we have successfully mod-
eled our fırst selected SNP, rs6983267, from the 8q24 risk locus in HCT-116
cells, producing the heterozygous genotype (G/T) from the parental ho-
mozygous risk (G/G) genotype. Rs6983267 is located within a known c-Myc
enhancer and has been shown to exert risk-allele specifıc increase in en-
hancer activity. Oncogenic c-Myc is known to play a signifıcant role in CRC
pathogenesis. In line with previous studies, we observe a slight decrease in
c-Myc expression in our heterozygous clones compared to wildtype ho-
mozygous risk. Moreover, we observe a preferential binding of the transcrip-
tion factor in control of c-Myc transcriptional regulation, TCF7L2, to the
risk allele over the reference allele while binding of proximal factors such as
CTCF show no allelic preference. Interestingly, we also see signifıcant
changes in expression of target genes of the WNT signaling pathway. Dys-
regulation of WNT is a hallmark characteristic of CRC. These changes indi-
cate there is indeed an effect of the risk allele of rs6983267 on overall WNT
activity in CRC cells due to increased binding of transcription factor
TCF7L2. This novel SNP editing pipeline provides a method to study precise
effects of single base changes located anywhere in the genome. Utilizing it to
model other risk SNPs will enable the enhancement of our current under-
standing of GWAS-identifıed risk loci in CRC pathogenesis at the molecular
level.
#1446 Super-enhancer identifıcation via Bru/BrUV-Seq and H3K27Ac
ChIP-Seq.Chunlao Tang, Vipin Yadav, Hui-RongQian, Jason B. Cunningham,
Hong Gao, Yushi Liu, Jason C. Ting, StevenM. Bray, Philip J. Ebert, Yuhao Lin,
Amit Aggarwal, John N. Calley, Bharvin K. Patel. Eli Lilly and Company, India-
napolis, IN.
Transcriptional super-enhancers (SEs) are large clusters of active enhancers
that drive expression of genes critical to cell identity and function. In cancer and
other human diseases, SEs can be acquired through somatic aberrations. Impor-
tantly, SEs and their target genes are particularly sensitive to perturbation, mak-
ing this mechanism a promising target for both diagnosis and therapy. Histone
modifıcation H3K27Ac is a good single predicative marker of active enhancers,
though additional marks would help. Accordingly, a common approach to SE
identifıcation is using H3K27Ac ChIP-Seq. The non-TSS (transcription start
site) histone binding sites (e.g., principally excluding TSS	2.5kb regions) are
mapped to genome and then subject to near-neighbor stitching (e.g., within
12.5kb). From the resulted relatively broad regions, SEs are identifıed by excep-
tional binding enrichment. Another potentially powerful approach is to use
Bru/BrUV-Seq in combination. By directional sequencing of bromouridine-
(Bru)-labeled nascent RNAs, Bru-Seq has been developed to study nascent tran-
scription. In the derivative BrUV-Seq, UV irradiation is additionally conducted
to stabilize transcripts prior to labeling, thereby allowing more sensitive detec-
tion of TSSs and unstable transcripts, including enhancer RNAs (eRNAs). It has
been shown that eRNAs indicate enhancer activity better than H3K27Ac bind-
ing. In this study, both approaches were used to identify SEs for three colon
cancer cell lines, HCT-116, SW48, and SW620. We have demonstrated that
Bru/BrUV-Seq has advantages in differentiating between mRNAs and eRNAs,
and between overlapping transcripts; the reduced complexity helps prevent false
identifıcations, which inflated our results obtained from ChIP-Seq.
#1447 Identifıcation of an oncogenic germlineKRAS truncatingmutation
in hereditary cancers.Moloy T. Goswami,1 Daniel H. Hovelson,1 Anna John-
son,1 Scott A. Tomlins,1 Lucy Wang,1 Kimberly Zhulke,1 Bhavneet Singh,1
Sharath Kumar Anand,1 Andi Cani,1 Albert Liu,1 Steven Kamberov,1 Yi-Mi
Wu,1 Dan Robinson,1 Arul Chinnaiyan,1 Kathleen A. Cooney2. 1University of
Michigan, Ann Arbor, MI; 2University of Utah, Salt Lake City, UT.
Somatic strongly activating KRAS mutations play an oncogenic role across
numerous human cancers, while less activating germline KRAS mutations are
associated with developmental disorders. KRAS encodes two splice variant
products—KRAS-4A and KRAS-4B—differing in their C-terminus through al-
ternative fourth coding exons. Though KRAS-4A is homologous to the original
transforming transcript identifıed inKirsten rat sarcoma virus, its role in human
cancer is less characterized compared to KRAS-4B. Here, through genetic anal-
yses of three cohorts of patients with hereditary and/or aggressive cancers, we
identifıed a rare KRAS-4A specifıc C-terminal truncating germline mutation
(KRAS-4A C180X; rs373169526) in affected men of three families with heredi-
tary prostate cancer and a patient with hereditary melanoma (minor allele fre-
quency [MAF] of 0.0014 in these combined cancer cohorts assessed vs. 0.000056
in the ExAC population database, odds ratio 24.6 [95% confıdence interval 5.1-
103.5], two sided Fisher’s exact test p 9.0E-5). The KRAS-4AC180Xmutation
truncates the C-terminus, removing the polybasic region and -CAAX motifs
previously demonstrated to be necessary for Ras family member membrane
association, MAP kinase signaling activation and transformation, suggesting a
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loss of function phenotype. However, in silico assessment of reported human
variation demonstrates truncating germline variants only in KRAS-4A and not
KRAS-4B, consistent with tolerance. Expression of KRAS-4A protein in
NIH3T3 andMDCK leads to loss of exclusive membrane association and inhib-
its GTP loading, as expected, but paradoxically resulted in modest but signifı-
cantly increased proliferation and soft agar colony growth compared to control
or wildtype KRAS expressing cells. Pro-oncogenic phenotypes were not depen-
dent on MAPK signaling, but showed sensitivity to AKT inhibition. In sum-
mary, we identifıed a germline truncating KRAS-4Amutation over-represented
in hereditary cancers that defınes a novel mechanism of KRAS activation not
dependent on the C-terminal polybasic and -CAAX motifs.
#1448 Unraveling the oncogenic pathway of serrated polyposis syndrome
driven byRNF43 germlinemutation.HelenHoiNingYan, JeffreyCWLai, Siu
Lun Ho, Anthony K W Chan, Wai Yin Tsui, Annie S Y Chan, Siu Tsan Yuen,
Suet Yi Leung.Dept. of Pathology, Univ. of Hong Kong, Hong Kong, Hong Kong.
Serrated polyps can arise in a sporadic or familial polyposis setting and
predispose to colorectal cancer (CRC). Recently, we have identifıed RNF43
germline mutation in a family with Serrated Polyposis Syndrome (Yan et al,
GUT 2016). The presence of second somatic hit in all serrated polyps exam-
ined from members of this family further confırmed the pathogenicity of
RNF43 germline mutation. In an attempt to further delineate the global
genomic alterations in these serrated polyps, so as to understand the RNF43
driven serrated neoplasia pathway for the development of colorectal cancer,
we performed whole exome sequencing (WES) on two sessile serrated ade-
nomas (SSAs) resected from an RNF43 germline mutation carrier, together
with the paired blood DNA. Consistent with the results from our previous
Sanger sequencing study, WES detected complete inactivation of RNF43
through a 2nd hit somatic mutation, c.461 CT P154L, or loss of heterozy-
gosity (LOH) in the two SSAs, respectively. We also identifıed 51 and 58
somatic mutations in the two SSAs, respectively. BRAFV600E mutation was
the only shared mutation between the two polyps. Interestingly, each of the
SSAs carried a truncating mutation in a histone-methyltransferase gene,
either PRDM9 or SETD1B, respectively. Other truncating or deleterious
mutations included chromatin modifıers (CHD2, CHD4, TSPYL2) or other
genes with methyltransferase activity (TRMT2B, METTL12, METTL14,
ECE2). In addition, we found few instances of chromosomal aberration or
LOH, apart from a region of LOH at chromosome 17 encompassing RNF43
in one of the SSAs. Overall, we have revealed the genomic landscape of two
sessile serrated adenomas resected from a germline RNF43 mutation carrier.
The results confırmed somatic RNF43 2nd hit and BRAFV600E mutation as
the key events, along with putative roles for histone methyltransferase, as
well as other chromatin modifıers. These fındings highlight the potentially
important role of an altered chromatin in the oncogenic pathway of serrated
neoplasia.
#1449 Germline mutation burden in an endometrial cancer cohort from
an integrated health care system. Raghu Metpally, Sarath Babu Krishnamur-
thy, Dokyoon Kim, Adam Cook, Ashlee Smith, John Nash, Marilyn Ritchie,
David Carey, Radhika Gogoi. Geisinger Medical Center, Danville, PA.
Endometrial cancer (EMCA) is the most common gynecologic malig-
nancy in the United States. We sought to explore germline mutations in 301
patients with a diagnosis of EMCA (EMCA cohort), who underwent whole
exome sequencing as part of the Geisinger Health System’s (GHS) MyCode
project. We additionally compared these mutations to germline and somatic
mutations in the TCGA array as well as a non-affected cohort at GHS.Whole
exome sequencing was performed using 75 bp paired-end sequencing on an
Illumina v4 HiSeq 2500 to a coverage depth suffıcient to provide greater than
20x haploid read depth of over 85% of targeted bases in 96% of samples
(approximately 80x mean haploid read depth of targeted bases). Control
groups consisted of 1150 female patients over the age of 85 with no cancer
diagnosis (Wellderly cohort) and the entire Geisinger’s MyCode population
of 50,000 patients (GHS cohort). Somatic and germline mutations in
EMCA were downloaded from the TCGA portal. We retrieved somatic mu-
tations from 248 patients as a mutation annotation format (MAF) that con-
sisted of 181,930 point mutations, while 2,931 indels were removed for the
comparison. In addition to somatic mutations, germline mutations with the
controlled access, obtained as a variant call format (VCF). Demographic
characteristics, treatment and outcomes were identifıed through a manual
chart review of the EHR. 2205 coding variants with 30 LOF and 802 missense
mutations were noted in the germline. Approximately 24.67% of patients in
the EMCA cohort had predictive pathogenic variants compared to control
cohort. Genes with most predictive pathogenic variants among EMCA co-
hort are ATM, TSC2, ROS1, NOTCH2, NOTCH1. LOF mutations were
found in 19 unique genes. When compared to pathogenic variants identifıed
in other hormone related cancers or a Wellderly cohort; 26 unique variants
were identifıed in the EMCA cohort. Overall 53.57% (2590/4836) of germline
mutations were found in EMCA Cohort when compared to the overlapping
mutations between DiscovEHR cohort and TCGA (5874 variants). In con-
trast, only (11/4836) 0.28% of germline mutations in EMCA Cohort overlap
with TCGA somatic mutations (3164 variants). Based on the results, cancer
predisposing germline mutations were found in a substantial number of
MyCode participants with EMCA. Knowledge of these mutations and poten-
tial integration with somatic information will help to improve our under-
standing of the disease. This will lead to more specifıc communication of
individual cancer risk and prognosis, cascade screening of their families and
more personalized and disease-specifıc care, an important step towards pre-
cision medicine.
#1450 Alternative splicing analysis identifıesmutation hotspots in hered-
itary breast and ovarian cancer genes. Suzette Farber-Katz, Vickie Hsuan,
JayneHoo, SitaoWu,HuyVuong, Dong Xu, Hsiao-Mei Lu, Phillip Gray, Aaron
Elliott, Rachid Karam. Ambry Genetics, Aliso Viejo, CA.
Genetic testing for hereditary breast and ovarian cancer (HBOC) is becoming
increasinglywidespread in the era of precisionmedicine. The implementation of
next-generation sequencing (NGS) has resulted in an explosion of genetic data.
While the majority of patients receive defınitive results, germline unclassifıed
variants with unknown function are regularly detected in thousands of patients.
In particular, variants of unknown signifıcance (VUS) in the HBOC susceptibil-
ity genes BRCA1 and BRCA2 pose a quandary tomedical providers and patients
because these genes are clinically actionable. A large percentage of VUS in
BRCA1/2 are predicted to affect splicing. Previous efforts have focused on in-
terrogating splicing VUS using low-throughput and/or imprecise techniques.
Therefore, we developed and validated a method for using RT-PCR NGS to
accurately and effıciently characterize germline splicing defects. The ENIGMA
(Evidence-based Network for the Interpretation of Germline Mutant Alleles)
consortium recommends capillary electrophoresis and Sanger sequencing of
subcloned transcripts as the gold standard to identify the BRCA1/2 transcripts
that are present in patient samples. We followed the recommendations of the
ENIGMA consortium and were able to largely replicate their results when we
analyzed the cDNA of lymphoblastoid cell lines (LCLs) generated by the kCon-
Fab consortium from carriers of BRCA1 or BRCA2 variants known to be asso-
ciated with splicing defects. In addition to LCLs, we analyzed RNA extracted
fromnormal blood controls and normal breast tissue for the entire BRCA1 gene.
We compared our capillary electrophoresis and Sanger sequencing results to our
newly developed RT-PCR NGS assay. For this assay, we used RT-PCR NGS
coupled to our custom in-house bioinformatics analysis to identify splicing
events including exon skipping, novel intron insertion, and alternative 5= donor
and 3= acceptor splicing sites. Capillary electrophoresis allowed us to roughly
visualize the various transcripts present in our samples, though sequencing was
needed to confıdently identify the exact splicing event. Similar to Sanger se-
quencing, our RT-PCR NGS assay detected all major splicing events. Interest-
ingly, we found that RT-PCR NGS allowed us to visualize more minor splicing
events present in the samples due to our high coverage. We sequenced tens of
thousands of reads with RT-PCRNGS, as opposed to Sanger sequencing, which
was limited to low-throughput sequencing of single colonies containing sub-
cloned RT-PCR products. In conclusion, RT-PCR NGS is a reliable high-
throughput alternative to the gold-standard splicing assays. Our assay will
greatly improve the interpretation of splicing VUS detected by clinical genetic
tests for BRCA1/2.
#1451 Search for new hereditary breast cancer genes by whole exome se-
quencing. Ekaterina Sh. Kuligina,1 Anna P. Sokolenko,1 Ilya V. Bizin,2 Alek-
sandr A. Romanko,3 Maria Anisimova,3 Evgeny N. Imyanitov1. 1N.N. Petrov
Research Inst. of Oncology, St. Petersburg, Russian Federation; 2St. Petersburg
State Polytechnical University, St. Petersburg, Russian Federation; 3St. Petersburg
Pediatric Medical University, St. Petersburg, Russian Federation.
Russian population is characterized by pronounced genetic homogeneity and
the increased occurrence of recurrent germ-line mutations, therefore it is par-
ticularly suitable for the whole exome sequencing (WES) studies. Exome se-
quencing was performed for 43 breast cancer (BC) cases, which demonstrated
evident clinical signs of the hereditary disease (family history and/or BC bilat-
erality and/or young onset) and lacked germ-linemutations in BRCA1, BRCA2,
CHEK2, NBS1/NBN and BLM genes. Approximately 52070 nonsynonymous
alternative variants were identifıed; 27503 (53%) of them were absent in 16
analyzed exomes from cancer-free controls. 2204 (4%) variants had suffıciently
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low allelic frequency (1%; ExACdatabase) and appeared to be functional upon
in silico assessment (CADDscore25); this list was composed of 186 frameshift
insertions/deletions, 152 stop-gains, 74 essential splice-site disruptions and
1792 potentially pathogenic missense mutations. Presumably causative muta-
tions in the BRCA1 network genes were revealed in 8 patients (truncating
mutations: PALB2 (p.Tyr1055*, p.Arg170Ilefs), RAD51C (c.9041GA),
FANCM (p.Ser497fs); overtly pathogenic missense mutations: FANCM
(p.Arg100Trp, p.Gln891Pro), ERCC4 (p.Arg799Trp), RAD51L (p.Arg394Trp)).
For the remaining 35 patients, 57 truncating variants and 109 presumably dele-
teriousmissensemutationswere further analyzed in a case-control study involv-
ing 550 hereditary BC cases and 450 elderly tumor-free controls. The most
promising results were obtained for several recurrent heterozygous mutations
(PZP p.Arg680* [OR  13.2; 95 % CI: 0.75 to 230.85]; LEPREL1 p.Pro636Ser
[OR 5.4; 95%CI: 0.28 to 104.77]; ING1 p.Pro319Leu [OR 3.8; 95%CI: 0.18
to 80.20]) as well as for homozygous missense substitution in BRCA1 gene
p.Gln356Arg [OR  6.7; 95 % CI: 0.82 to 54.83]. Conclusion: Although being
promising in the design, this study and several similar investigations failed to
identify novel breast cancer gene, whosemedical signifıcance is comparablewith
that for BRCA1, BRCA2, etc. This failure can be attributed either to the lack of
contribution of dominant highly-penetrant recurrent mutations in the missing
BC heritability or yet non-identifıed defıciency in the experimental approach.
This work has been supported by the Russian Scientifıc Fund (grant 16-45-
02011).
#1452 Interrogating the impact of pregnancy on breast cancer biology
using DNA copy number profıling. Bastien Nguyen,1 David Venet,1 Françoise
Rothé,1 ChristineDesmedt,1 SamiraMajjaj,1 Giancarlo Pruneri,2 David Brown,1
Fedro Peccatori,2 Hatem A. Azim,1 Christos Sotiriou1. 1Institut Jules Bordet,
Brussels, Belgium; 2European Institute of Oncology, Milan, Italy.
Background: Epidemiological evidence indicates a clear relationship between
pregnancy and breast cancer (BC) risk. However, little is known regarding the
impact of pregnancy on BC biology. DNA copy number aberrations (CNAs)
play an important role in breast carcinogenesis. BC during pregnancy is a rare
disease, however it can be used as a model to study the impact of pregnancy on
BC biology. Methods: We retrospectively included 54 pregnant and 113 non-
pregnant BC patients matched for age and stage with complete clinic-patholog-
ical, gene expression and 5-year follow-up data. CNAs were assessed using Af-
fymetrix OncoScan FFPE arrays. First, we fıltered genes whose expression was
driven by CNAs. Then, we identifıed genes that were differentially affected by
pregnancy both at the CNA and the gene expression level. Results: After quality
control, CNA profıles were obtained for 38 pregnant and 87 non-pregnant BC
patients. There were no signifıcant differences in classical clinic-pathological
features (pT, pN, grade, PAM50).We selected 1981 genes whose expression was
correlated with CNAs ( 
 0.4). Among these, 77 genes were altered at the
expression level (p 0.01) between pregnant and control patients, whereas 171
genes were altered at the CNA level (p  0.05). Twenty-eight genes were con-
comitantly altered at the expression and CNA levels which was signifıcantly
higher than expected (p 0.021, permutation test). These genes were mapped
on three different chromosomes. Genes located on chr7q and chr11q were as-
sociated with copy number gains and were up-regulated in pregnant patients
whereas genes located on chr22q were associated with copy number loss in
control patients. Of interest we identifıed 6 putative oncogenes (CDK6, ESRRA,
S6K2, LIMK2, MKL1) that were up-regulated in pregnant patients. A ’pregnan-
cy-associated breast cancer signature’ was computed from the expression of the
28 genes. There was a negative relationship between the signature and the ex-
pression of ESR1 and PGR genes. This signature was signifıcantly more corre-
lated with the proliferation-associated AURKA gene in pregnant patients as
compared to control (  0.73 vs   0.24, p  0.001). Conclusions: In this
study, we were able to identify several genomic alterations associated with preg-
nancy that could help elucidate the impact of pregnancy on BC risk. Moreover,
by combining CNAs with gene expression, we were able to identify genes that
could be responsible for the poorer prognosis seen in pregnancy-associated
breast cancer and could be potential drivers of this rare disease.
#1453 Transcriptoma analyses in triple-negative breast cancer with
BRCA1 germline mutation. Kivvi Duarte Nakamura, Elisa Ferreira, Rodrigo
Ramalho, Rafael Brianese, Dirce Carraro. A.C. Camargo Cancer Center, São
Paulo, Brazil.
Triple-negative breast cancer (TNBC), characterized by lack of expression of
the estrogen receptor (ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2), is associatedwith a higher prevalence of germ-
line BRCA1mutations, especially in younger women. TNBC comprises approx-
imately 15% of breast cancer cases and is considered one of the most aggressive
subtypes. BRCA1 protein plays a pivotal role in DNA damage repair, cell cycle
control and transcriptional regulation. In this context, we aimed to investigate
the transcriptional difference of paired tumor and adjacent normal tissue from
young patients in two TNBC groups - with or without BRCA1 germline muta-
tion. Fourteen early-onset patients (41 years), with TNBC previously evalu-
ated for BRCA1 and 2 germline mutation, were included. From these, nine
patients are BRCA1/2 wild-type and fıve patients were BRCA1 germline muta-
tion carriers. RNASeq librarieswere constructed from rRNAdepleted total RNA
extracted from paired tumor and normal adjacent samples and sequenced on
Illumina NextSeq 500 platform. Approximately 20 million reads aligned to hu-
man genomewere generated per sample, revealing about 14,500 expressed genes
with at least 10 copies per sample. Expression values were normalized by library-
size read counts followed by a gene-wise normalization. To explore similarity
level between samples we used the full matrix of the log2-transformed gene
expression values and calculated sample-to-sample distances for each tumor
compared to each normal sample, based on the Euclidian distances between
samples considering all available genes. We observed that 80% of the BRCA1-
mutated and 67% of the BRCA1/2 wild-type samples were clustered together.
Also, we detected that BRCA1-mutated TNBC showed, in general, less differ-
ence in transcriptional pattern related to normal breast tissue than the BRCA1/
2-wild type TNBC. Moreover, we compared differential expression between
normal and tumor samples of each group (BRCA1-mutated andBRCA1/2-wild-
type samples) using a linear-based model in DESeq2 program. Based on the
criteria of fold-change 
 |4| and FDR  0.01 we identifıed 2,809 DEGs, in the
group of BRCA1-mutated samples, being 722 up regulated and 2,087 down
regulated in the tumor and 904 DEGs in the group of BRCA1/2- wild-type
samples, 399 were upregulated and 505 downregulated in the tumor. Interest-
ingly, both lists of upregulated genes in TNBC of BRCA1-mutated and BRCA1/
2-wild type were signifıcantly enriched in the samemolecular pathway involved
with the cell cycle andmitosis, according to Reactome Pathways software. Over-
all, our fırst observation based on this preliminary data was that, in terms of
general gene expression analysis, BRCA1-mutated TNBC has less transcrip-
tional modifıcation in comparison to the normal tissue than the BRCA1/2-wild
type and that the tumorigenic process of both groups are similar in terms of
defective biological pathway.
#1454 Estrogen receptor signaling in FTE of BRCA mutation carriers.
Leah V. Dodds,1 Omar L. Nelson,1 Ramlogan Sowamber,2 Andres Rodrigues,1
Victoria de Castro,1 Wendell Henry,1 Guillermo Morales,1 Brian Slomovitz,1
Patricia Shaw,3 Sophia H. George1. 1LEONARD MILLER SCHOOL OF MEDI-
CINE, UNIVERSITY of MIAMI, MIAMI, FL; 2Princess Margaret Cancer Center,
Toronto, Ontario, Canada; 3University Health Network, Toronto, Ontario, Can-
ada.
Genetic and reproductive factors predicate epidemiological risk factors un-
derlying epithelial ovarian cancer. The fallopian tube epithelia (FTE), the pre-
sumptive etiological site of high-grade serous ovarian cancer (HGSC), is a hor-
monal responsive tissue. Estrogen is known to promote cell proliferation and its
metabolism produces reactive oxygen species that damage DNA and promote
tumorigenesis. Estrogen receptor (ER) is rarely mutated, amplifıed or deleted in
HGSC, yet only 10% of patients respond to anti-estrogen treatment, suggesting
that intrinsic variables to the ER pathway contribute to this clinical outcome.
TP53 mutations occur in almost 100% of HGSCs, indicating that mutated p53
supports a model as an early event in the pathogenesis of HGSC. We hypothe-
sized that in the presence of dysfunctional p53, subsequent promiscuous bind-
ing of ER will yield aberrant signaling, ultimately signifıcantly contributing to
cellular transformation. Mutant p53 and ER co-localize in FTE cells, suggesting
potential synergy.We established cell lines with p53mutations and treated them
with estradiol, an estrogen analog, to observe any changes in response. The
genome binding sites of ER-regulated transcription factors were then identifıed
and mapped by whole genome chromatin immunoprecipitation-deep sequenc-
ing (ChIP-Seq). The data generated will facilitate the development of gene sig-
natures that will predict response to anti-estrogen therapy in serous ovarian
cancer patients, and contribute to the discovery of biomarkers to more accu-
rately identify patients who will benefıt from hormonal therapies.
#1455 Vitamin D receptor (VDR) gene polymorphisms among Sudanese
femaleswith breast cancer attendingRadio and IsotopeCenter ofKhartoum.
Sara O. Yousif,1 Amar M. Ismail,2 Abdelrahim O. Mohamed,3 Abdelrahim O.
Mohamed4. 1Faculty ofMedical Laboratory Sciences, SudanUniversity of Science
and Technology, Khartoum, Sudan; 2Faculty of Science and Technology, Al-Nee-
lainUniversity, Khartoum, Sudan; 3Faculty ofMedicine, University of Khartoum,
Khartoum, Sudan; 4Neelain Institute for Medical Research, Al-Neelain Univer-
sity, Khartoum, Sudan.
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Background: Vitamin D Receptor (VDR) gene polymorphisms has been re-
ported to be associated with different cancers, including breast cancer. geo-
graphical and environmental factors have an impact on vitamin D (VD)metab-
olism. This study aims to evaluate VDR-gene polymorphisms (Fok1, Bsm1,
Taq1, Apa1) and its associationwith breast cancer risk among Sudanese females.
Materials andMethods: this is a case control study done in theRadio and Isotope
Center in Khartoum, Sudan. Hundred thirty seven patients and 69 healthy con-
trols were enrolled after informed consent. Blood genomic DNA was extracted
using quinidine chloroform method, and single nucleotide polymorphisms
(SNPs) Fok1 (T/C) [rs2228570], Bsm1 (G/A) [rs1544410], Taq1 (C/T)
[rs731236] and Apa1 (C/A) [(rs7975232] in VDR-gene were detected by PCR
and restriction fragment length polymorphism (PCR-RFLP) analysis. Results:
VDR-SNPs rs731236 correlated signifıcantly with low risk of breast cancer
(OR0.5, p 0.002). There was no signifıcant association observed with
rs1544410 and rs7975232. Although our study did not show an overall statisti-
cally signifıcant association of VDR-SNPs rs2228570 with the risk of breast
cancer, we found a 1.3 fold increased risk of breast cancer (OR 1.3) among
females with FF genotype when compared with ff genotype, suggesting that
females homozygous for F allele, might be at more risk than females carrying
homozygous f allele. Conclusions: These results suggested that, VDR-SNPs
rs2228570 may be related to higher risk of breast cancer and VDR-SNPs
rs731236 associated with lower risk of breast cancer in Sudanese females. Key
words: Breast Cancer, VDR, Polymorphisms, SNPs
#1456 Identifying early genetic steps inmalignant transformation of neu-
rofıbromatosis type 1- associated plexiform neurofıbromas. Alexander
Pemov,1 Nancy F. Hansen,2 Rajesh Patidar,3 Christine Higham,4 Eva Dombi,4
Joseph F. Boland,5 Settara C. Chandrasekharappa,2 NIH Intramural Sequencing
Center, James C. Mullikin,2 Margaret Wallace,6 Javed Khan,3 Eric Legius,7 Bri-
gitte Widemann,4 Douglas R. Stewart1. 1Clinical Genetics Branch, Division of
Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD;
2Cancer Genetics and Comparative Genomics Branch, National Human Genome
Research Institute, Rockville, MD; 3Genetics Branch, Center for Cancer Research,
National Cancer Institute, Bethesda,MD; 4Pediatric Oncology Branch, Center for
Cancer Research, NCI, Bethesda, MD; 5Cancer Genomics Research Laboratory,
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rock-
ville, MD; 6Departament of Molecular Genetics and Microbiology, UF Genetics
Institute, UF Health Cancer Center, University of Florida, Gainesville, FL; 7De-
partment of Human Genetics, Catholic University Leuven, Leuven, Belgium.
BACKGROUND: Neurofıbromatosis type 1 (NF1) is a genetic tumor predis-
position disorder caused by germlinemutations in tumor suppressor NF1. Plex-
iform neurofıbromas (PN) are benign tumors that arise prenatally or early in
childhood and affect 30-50% of NF1 population. Somatic inactivation of second
copy ofNF1 is believed to be primary genetic event leading to PN initiation. NF1
patients have 8-12% lifetime risk of developing malignant peripheral nerve
sheath tumor (MPNST), a highly aggressive soft tissue sarcoma, often arising
from pre-existing PN and atypical NF (ANF). ANF are pre-malignant tumors
that often arise within PN and can transform into MPNST. They are distinct
from both PN and MPNST clinically and histologically, thus representing an
intermediate step in malignant transformation. Several studies identifıed dele-
tion of the CDKN2A/2B locus as the most frequent genetic event in ANF, how-
ever it is not clear whether other genes or pathways play role in PN transforma-
tion into ANF and further into MPNST. In this study, we performed genomic
analysis of 16 ANF and 4MPNSTmatched with normal DNA obtained from 14
and 4 patients, respectively. METHODS:We performed whole exome sequenc-
ing and whole transcriptome RNASeq analyses on Illumina Hi-Seq 2500 plat-
form and copy-number variant (CNV) analysis on Illumina HumanOmniEx-
pressExome-8 SNP-arrays. In addition, we performed deep sequencing of NF1
and validation of selectmutations on IonTorrent platform. For select tumors we
estimated growth rate and metabolic activity by using volumetric MRI and
FDG-PET. RESULTS:We identifıed inactivation of NF1 in the majority of ANF
and all MPNST. We also detected CDKN2A/B locus deletion in the majority of
ANF and MPNST (heterozygous in ANF and mostly homozygous in MPNST).
We determined that PRC2 genes (EED and SUZ12) were mutated in multiple
MPNST but never in ANF. We identifıed a low number of point mutations and
small indels in the genomes of ANF (median 1, range 0-4) and somewhat ele-
vated mutation burden in MPNST (median 23, range 18-31), however none of
these mutations were recurrent and none of the mutant genes (other than NF1
and CDKN2A) were present in multiple samples. We found 93 CNV per tumor
(median) in ANF that constituted 2% of their genomes. In comparison, we
observed 2,249 CNV (median) in MPNST that comprised 75% of their ge-
nomes. We didn’t detect signifıcant correlation between growth rate or meta-
bolic activity and the degree of genomic instability or mutation burden in the
tumors, however the size of the sample set was modest. RNAseq data analysis is
pending. CONCLUSIONS: It appears that PN-ANF transition is predominantly
if not exclusively driven by heterozygous deletion of the CDKN2A/2B locus.
Further progression to MPNST likely involves homozygous loss of CDKN2A/B
and complete inactivation of the PRC2 complex. Widespread LOH in MPNST
may accelerate inactivation of key gatekeepers.
#1457 Somatic biallelic inactivation of fumarate hydratase (FH) in uterine
leiomyomas. Jaana Tolvanen,1 Netta Mäkinen,1 Hanna-Riikka Heinonen,1 Si-
mona Bramante,1 Miika Mehine,1 Nanna Sarvilinna,2 Jari Sjöberg,3 Oskari
Heikinheimo,3 Annukka Pasanen,4 Ralf Bützow,4 Lauri A. Aaltonen1. 1Depart-
ment ofMedical and Clinical Genetics, University of Helsinki; Research Programs
Unit, Genome-Scale Biology, University of Helsinki, Helsinki, Finland; 2Research
Programs Unit, Genome-Scale Biology, University of Helsinki; Department of
Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki,
Helsinki, Finland; 3Department ofObstetrics andGynecology,HelsinkiUniversity
Hospital, University ofHelsinki, Helsinki, Finland; 4Department of Pathology and
HUSLAB, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Uterine leiomyomas (ULMs) are highly common benign tumors that af-
fect the health of millions of women by causing a variety of symptoms.
Furthermore, ULMs are themost common indication for hysterectomy, gen-
erating considerable economic costs for the health care system. Recurrent
and mutually exclusive genetic aberrations leading to unique gene expres-
sion profıles have been identifıed in ULMs. Thus these tumors can be divided
into distinct subclasses according to their molecular genetic background.
The majority of ULMs (80-90%) have specifıc mutations in MED12 or aber-
rations in HMGA2. Somatic biallelic inactivation of FH can also, albeit
rarely, drive ULM tumorigenesis and has previously been detected in 1.3% of
sporadic ULM samples (2/153; Lehtonen et al, 2004). FH encodes the fuma-
rase enzyme that catalyzes the hydration of fumarate to L-malate in the
tricarboxylic acid cycle. Biallelic inactivation of FH leads to accumulation of
fumarate and aberrant succination of proteins. Heterozygous germline FH
mutations predispose to a rare autosomal dominant tumor predisposition
syndrome, hereditary leiomyomatosis and renal cell cancer (HLRCC). This
highly penetrant syndrome is characterized by uterine and cutaneous leio-
myomas and in some cases renal cell cancer. In this study, we re-evaluated
the frequency of somatic biallelic inactivation of FH in ULMs in the largest
sample set thus far. The study material consisted of 1167 fresh frozen ULM
and their respective normal myometrium tissue samples from 375 hysterec-
tomy patients. All samples were analyzed with high-throughput SNP array
(Infınium Human Core-24 Kit, Illumina Inc., San Diego, CA). All tumors
detected with somatic deletions or loss of heterozygosity (LOH) in the FH
locus were included in S-(2-succinyl) cysteine (2SC) immunohistochemistry
(IHC) to indirectly detect biallelic FH inactivation. Also samples without FH
double deletions were selected for Sanger sequencing of FH coding regions
to detect inactivating mutations. Somatic FH deletions or LOH were de-
tected in 30 tumors, of which 10 were identifıed FH defıcient by 2SC IHC. In
these samples, another deletion (a double deletion) in three ULMs and a
somatic nucleotide change in six ULMs was found to be the second hit
causing biallelic inactivation of FH. In one sample no second hit was detected
with these methods. From the six somatic nucleotide changes, four were
different FH missense mutations predicted to be damaging (SIFT, Poly-
Phen-2, Provean) and two were synonymous substitutions in the last nucle-
otide of different exons. Studies to determine the impact of these synony-
mous changes on splicing are underway. To conclude, in our sample set we
detected 0.9% (10/1167) of the ULMs to harbour somatic biallelic inactiva-
tion of FH.MED12 exon 1 or 2 mutations and HMGA2 rearrangements were
not detected in these tumors. Thus the previously published results were
validated in this study with the largest sample set so far.
#1458 Genome-wide association study of unselected prostate cancer cases
in Finnish population.Csilla Sipeky,1 Teuvo L. Tammela,2 Anssi Auvinen,2 the
PRACTICAL consortium, Johanna Schleutker3. 1University of Turku, Turku,
Finland; 2University of Tampere, Tampere, Finland; 3University of Turku and
Turku University Hospital, Turku, Finland.
Prostate cancer (PrCa) is the second most prevalent cancer in men world-
wide, representing the most common cancer in males in Finland with 5043
new cases and with over 850 annual deaths (2013). PrCa has a signifıcant
heritable component, with genetic factors accounting for 58% of the risk.
Accordingly, genome-wide association studies (GWAS) identifıed 104 low
penetrance PrCa susceptibility loci to date, predominantly in populations of
mixed European ancestry. However, effect allele frequencies (EAF) and
strength of association (Odds ratio, OR) are often variable across popula-
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tions. Our aim is to identify common PrCa susceptibility alleles specifıc for
Finnish population. Therefore, we conducted a meta-analyses of 200.000
single nucleotide polymorphisms (SNPs) in 2764 PrCa cases and 2401 con-
trols of Finnish origin. Germline DNA samples were genotyped within the
Collaborative Oncological Gene-Environment Study (COGS) using Illu-
mina iSelect custom SNP genotyping platform. Statistical analyses of uncon-
ditional case-control logistic regression model was performed by using
PLINK software. After FDR adjustment altogether 160 variants remain sig-
nifıcant on GWAS level (p5x108). The Finnish population specifıc PrCa
associated signals are concentrated on chromosomes (chr) 7, 8, 11, 17, 19,
and in close proximity to one another on the same chr. The strength of
association varies between 0.59-1.86. In our study we identifıed 101 risk
variants on chr 8, 11, 17 (OR 1.24-1.86) and 59 protective variants on chr 7,
8, 17, 19 (OR 0.59-0.80) with non-overlapping confıdence intervals (CIs).
The OR 1.86 is the highest by now found in GWAS studies examining com-
mon SNPs in non-familiar cases. Our data suggests that chromosome 11
seem to be risk conferring, whereas chromosomes 7 and 19 possess protec-
tive variants. The results facilitate population risk stratifıcation for screen-
ing, clinical studies, treatment choices and functional research of prostate
cancer in Finnish population.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
MicroRNA Regulation of Cancer Biology 2
#1459 Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and
miR-145-3p) are involved in castration-resistant prostate cancer pathogene-
sis.Mayuko Kato,1 Akira Kurozumi,1 Yusuke Goto,1 Nijiro Nohata,2 Takayuki
Arai,1 Atsushi Okato,1 Keiichi Koshizuka,1 Satoko Kojima,3 Tomohiko
Ichikawa,4 Naohiko Seki1. 1Department of Functional Genomics, Chiba Univer-
sity Graduate School of Medicine, Chiba, Japan; 2University of California, San
Diego, CA; 3Department of Urology, Teikyo University Chiba Medical Center,
Chiba, Japan; 4Department of Urology, Chiba University Graduate School of
Medicine, Chiba, Japan.
Prostate cancer (PCa) is themost frequently diagnosed cancer and the second
leading cause of cancer-related death among men in developed countries. An-
drogen signaling through the androgen receptor (AR) is an important oncogenic
pathway for PCa progression. Most patients initially respond to androgen-de-
privation therapy (ADT), but eventually acquire resistance and progress to cas-
tration-resistant prostate cancer (CRPC). Although several clinical trials for
CRPC have been carried out, resulting in the availability of novel chemothera-
peutic agents, these treatments provide limited benefıts and are not considered
curative. Therefore, identifıcation of effective biomarkers for detection of CRPC
andunderstanding themolecularmechanisms of androgen-independent signal-
ing and metastatic signaling pathways underlying PCa using current genomic
approaches would help to improve therapies for and prevention of the disease.
The discovery of microRNAs (miRNAs) has resulted in major advancements in
cancer research. miRNAs are small noncoding RNAs that function to fıne tune
the expression of protein coding/noncoding RNAs by repressing translation or
cleaving RNA transcripts in a sequence-depending manner. The unique char-
acteristic function of miRNAs is to regulate RNA transcripts in human cells.
Therefore, dysregulated expression of miRNAs can disrupt tightly regulated
RNA networks in cancer cells. miRNAs play critical roles in various biological
processes, and their dysregulation is shown in several human cancers. In this
study, we constructed the miRNA expression signature of CRPC using clinical
specimens because the development of therapeutic strategies is a central theme
in the advancement of PCa treatments. Using CRPC expression signature data,
we investigated the specifıc roles of miRNAs in PCa and CRPC oncogenesis by
examining differentially expressed miRNAs. Based on the CRPC signature, we
focused on the dual strand of pre-miR-145, miR-145-5p and miR-145-3p be-
cause these miRNAs were signifıcantly reduced in cancer tissues, suggesting
thesemiRNAs act as antitumormiRNAs in this disease. InmiRNAbiogenesis, it
is the general consensus that processing of the pre-miRNA through Dicer1 gen-
erates a miRNA duplex (a passenger strand and a guide strand), and that the
passenger strand has degradation and no regulatory activity and disintegrates in
cells. Our present data showed that bothmiRNAs,miR-145-5p andmiR-145-3p
signifıcantly suppressed cancer cell migration and invasion. Moreover, Kaplan-
Meier survival curves showed that low expression of miR-145-3p predicted a
short duration of progression to CRPC. Dual strand of pre-miR-145 functioned
as tumor suppressors based on themiRNA expression signature of CRPC. Iden-
tifıcation of miRNA-mediated cancer networks may provide novel molecular
pathogenesis of the disease.
#1460 miRNome analyses reveal that activity of CAF expressed podopla-
nin in tumormicroenvironment ismodulated by exosomemiRNAs involved
in the PTEN-PI3K-AKT-mTOR signaling. Anna Tejchman,1 Eric Mennes-
son,2 Isabelle Fixe,2 Alexandra Foucher,2 Simon Perera,3 Laura Artigas,3 Jose
Manuel Mas,3 Catherine Grillon,1 Maciej Ugorski,4 Nadia Normand,2 Claudine
Kieda1. 1Centre for Molecular Biophysics - CNRS, Orleans, France; 2tebu-bio, Le
Perray en Yvelines, France; 3Anaxomics Biotech, Barcelona, Spain; 4Institute of
Immunology and Experimental Therapy, Wroclaw, Poland.
In breast cancer, cancer associated fıbroblasts (CAF) express podoplanin but
little is known about its mechanism of expression and modulation. This might
be crucial for cancer cell movements and for the ability to escape from the tumor
site. Podoplanin showed anti-adhesive activity towards tumor and immune
cells. A key control of tumor microenvironment is exerted by microRNAs on
gene expression. Therefore miRNAs profıling was performed with 3D-Gene
microarray technology on a breast CAF model, on cell lysates and on secreted
exosomes, in hypoxia versus normoxia culture conditions. Systems biology en-
richment analyses were carried out through bioinformatics using mathematical
models that simulate in silico the behaviour of human physiology. Targets
linked to the set of differential miRNAs, both up-regulated and down-regulated,
have been analyzed with various methods including a hypergeometric distribu-
tion method. Processes linked to hypoxia, glycosylation, angiogenesis, extracel-
lular matrix and pathways associated with PI3K-AKT, mTOR, P53 and chemo-
kines signaling were studied. We showed that podoplanin expression strongly
affected miRNAs involved in these processes. Hypoxia increased expression of
miR-210, miR-21 and miR-29b in cells over-expressing podoplanin. miR-21 is
an oncogenic regulator in most cancer cells through its downstream target pro-
teins among which stands the tumor suppressor PTEN, a candidate to alleviate
hypoxia in tumors, regulating tumor angiogenesis and modulating tumor hyp-
oxia. miR-29b is a tumor suppressor, it also correlates with PTEN repression.
We highlighted miRNA regulation of podoplanin expression through down-
regulation of upstream genes for tumor suppressor PTEN. The combination of
miRNome analysis and systems biology bioinformatics uncovered potential
miRNAs involved in the regulation of podoplanin activity in CAF. Such data
analysismay be applied to protein andmRNAbiomarkers and extended to other
pathology pathways.
#1461 miR-424-cdc42, key signaling axis in hyperglycemic regulation of
stemness in triple negative breast cancer. Sushmita B.Nandy,1 AlexisOrozco,1
GauthamPrabhakar,1 Viktoria Stewart,1 Stephanie Jones,2 PalomaMunoz,1 Ra-
madevi Subramani,1 Diego Pedroza,1 Rajkumar Lakshmanaswamy1. 1Texas
Tech Univ. Health Sciences Ctr. El Paso, El Paso, TX; 2University of Texas at El
Paso, El Paso, TX.
Introduction: Meta-analysis shows women with diabetes have a 20% in-
creased risk of breast cancer. Diabetes increases the risk of breast cancer mor-
tality. Additionally, patients with breast cancer and preexisting diabetes have an
increased risk for distant metastasis compared with non-diabetic counterparts.
The molecular mechanisms for distant metastasis in breast cancer patients with
diabetes are not very well understood. Our preliminary data suggested that hy-
perglycemia enhances stem cell activity in triple negative breast cancer (TNBC)
cells. Here, we report miR-424 to be a key regulator of breast cancer stem cell
pool dynamics under hyperglycemic environment. Materials and Methods:
MDA-MB-231, TNBC cell line was maintained under euglycemic (5mM) and
hyperglycemic (10mM) culture conditions. RT-PCRbasedmicroRNAarraywas
performed followed by validation of signifıcantly altered microRNA to confırm
the effect of hyperglycemia on the global microRNA profıle. Flow cytometric
analysis for CD44/CD24 was performed to assess the alterations in breast
cancer stem cell population. In addition, sphere-forming assay were also per-
formed. Mir-424 over-expressing or knocked down cell lines were established
from parental MDA-MB-231 cells and maintained in hyperglycemic or eugly-
cemic condition respectively. Promoter analysis for PR/SET domain 14
(prdm14) was done. Western blotting and immunofluorescence assays were
performed for cdc42 (cell division control 42), pStat5 (phospho signal trans-
ducer and activator of transcription factor 5) and prdm14. Results: Loss of miR-
424 in TNBC cells under euglycemic conditions led to enhanced stem cell activ-
ity; whereas over expression of miR- 424 under hyperglycemic conditions
resulted in suppressed stem cell activity. Introduction of cdc42, (a miR-424
target gene) in miR-424 over expressing TNBC cells under hyperglycemic con-
ditions leads to increased stem cell activity demonstrating the signifıcance of
miR-424-cdc42 signaling in hyperglycemia. Over-expression of miR-424 in
TNBC dramatically reduced its metastatic abilities in vivo. Mechanistically, we
found that miR-424-cdc42 signaling in hyperglycemia promotes Prdm14
activation, a stem cell regulator through increased phosphorylation of Stat5.
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Conclusions: Our fındings establish a key molecular signaling cascade (miR-
424¡cdc42¡prdm14) that promotes TNBC stem cell activity under hyper-
glycemic conditions.
#1462 Exosome-derivedmiR-429 contributes to prostate cancer chemore-
sistance. Yang Liu,1 Liye Xie,1 Jing Li,1 Atsushi Mizokami,2 Evan T. Keller,3 Yi
Lu,1 Jian Zhang1. 1GuangxiMedical Univ., Nanning, China; 2Kanazawa Univer-
sity, Kanazawa, Japan; 3University of Michigan, Ann Arbor, MI.
Prostate cancer (PCa) is the most common cancer in men and the 2nd leading
cause of cancer-related death in theUnited States. CertainmiRNAs, act as tumor
promoting or inhibiting factors in tumor development, function primarily by
targeting specifıc mRNAs for degradation or inhibition of translation of their
targeted proteins. Emerging evidence indicates that exosomes play a key role in
tumor-host crosstalk, and exosome secretion, composition, and functional ca-
pacity are altered as tumors progress to aggressive phenotypes. From our prior
report, we have constructed a potential network of 29 deregulated miRNAs,
including 19 up and 10 down, in exosome samples derived from two kinds of
paclitaxel resistant PCa cells (PC3-TXR and DU145-TXR) compared with their
parental cells (PC3 and DU145). In this study, to further determine the roles of
certain miRNAs derived from exosomes in chemoresistant cells, we fırstly con-
fırmed the lower expression level of miR-429 miRNA in the exosomes derived
from the paclitaxel resistant PCa cells compared to their parental cells. In addi-
tion, when the miR-429 was over-expressed in PC3-TXR and DU145-TXR cells
by stable transfection, epithelial-to-mesenchymal transition (EMT) markers
signifıcantly altered together with morphological changes. Overexpression of
miR-429 decreased the tumor cell migration and invasion that associated with
inactivation of PI-3K/AKT and Notch signaling pathways since the pathway
specifıc inhibitors signifıcantly diminished the transfected tumor cell migration
and invasion. Finally, we found that overexpression ofmiRNA-429 signifıcantly
enhanced chemo-sensitivity of the chemoresistant PCa cells. These data sug-
gested that exosome-derived miR-429 contributes to PCa chemoresistance and
miR-429 may become a potential therapeutic target for PCa patients. This work
was supported by Natural Science Foundation of China (NSFC) Key Project
(81130046); NSFC (81171993; 81272415); Guangxi Projects of China (2013GX-
NSFEA053004; 2012GXNSFCB053004; 2013GXNSFBA019177; 1355004-5;
201201ZD004; GZPT13-35; 14122008-22; 11-031-05-K2; KY2015YB057; 14-
045-12-K2).
#1463 Intravital discovery of miRNA drivers of human cancer cell direc-
tional invasion.Konstantin V. Stoletov, LianWilletts, Juan Jovel, EmmaWool-
ner, John D. Lewis. Univ. of Alberta, Edmonton, Alberta, Canada.
Metastatic cancer cells often use directional ECM cues such as blood vessels
or collagen fıbers when invading through live tissue. Oncogenic miRNAs have
been implicated as key regulators of cancer progression yet the systemic discov-
ery of miRNAs that drive directional cancer cell invasion has not been achieved.
Here we describe the fırst in vivo quantitative whole humanmiRNAome screen
for miRNA drivers of directional cancer cell invasion using an ex ovo avian
embryo model of human cancer cell metastasis combined with high resolution
intravital imaging.We identifıedmore than twenty novelmiRNAs that promote
cancer cell invasion during the key rate-limiting step of cancer metastasis, the
initiation and expansion of overt metastatic lesions. In silico miRNA target
analysis (DIANA, Targetscan) showed signifıcant enrichment in gene targets/
pathways that control cancer cell-ECM adhesion and cancer cell contractility.
These fındings were further confırmed using Affymetrix gene expression anal-
ysis that showed signifıcant changes in the expression of genes that regulate actin
cytoskeleton rearrangement, cancer cell-ECM interaction and cell surface-re-
ceptor signaling. Public cancer gene expression database analysis (Oncoprint)
showed that these miRNA-mRNA networks deregulated in several deadly can-
cers (pancreas, prostate, breast) and negatively correlate with the cancer patient
survival. To elucidate potential mechanisms of these pro-metastatic miRNAs,
we utilized an intravital imaging approach. In vivo 4D cancer cell tracking re-
vealed that these pro-metastatic miRNAs are required for successful invasion
into collagen-rich tissue and for attachment to the outer surface of the vascular
wall. Deregulation of these miRNAs led to formation of loose contacts with the
vasculature and chaotic, non-directional cancer cell invasion patterns in living
tissue. Intravital second-harmonic microscopy analysis showed that inhibition
of the expression of thesemiRNAs blocked the ability of cancer cells to rearrange
the disorganized fıne collagen fıber network into thicker collagen bundles that
guide directional tumor cell invasion. In contrast to parental tumor cells that
persistently moved along the collagen bundles, miRNA-defıcient tumor cells
were observed to transiently associate with multiple collagen fıbers without es-
tablishing persistent collagen fıber-tumor cell protrusion contacts. Moreover,
miRNA-defıcient tumor cells failed to attach and protrude along preexisting
perivascular collagen bundles, resulting in the complete abrogation of cancer
cell/blood vessel co-option. In summary, we identifıed a novel panel of human
miRNAs that are functionally involved in the regulation of directional invasion
and metastasis. This work establishes these miRNAs as promising therapeutic
targets to block the metastatic spread of lethal cancers.
#1464 miR-6734 induces cell cycle arrest and apoptosis via up-regulation
of p21 expression in colon cancer cells. Jong Soon Kang, Moo Rim Kang.
KRIBB, Chungbuk, Republic of Korea.
Recently, microRNAs have been implicated in the regulation of gene expres-
sion in terms of both gene silencing and gene activation. Here, we investigated
the effects ofmiR-6734, which has a sequence homologywith a specifıc region of
p21WAF1/CIP1 (p21) promoter, on cancer cell growth and the mechanisms in-
volved in this effect. miR-6734 up-regulated p21 expression at both mRNA and
protein levels and chromatin immunoprecipitation analysis using biotin-labeled
miR-6734 confırmed the association of miR-6734 with p21 promoter. More-
over, miR-6734 inhibited cancer cell growth and induced cell cycle arrest and
apoptosis in HCT-116 cells, which was abolished by knockdown of p21. The
phosphorylation of Rb and the cleavage of caspase 3 and PARPwere suppressed
by miR-6734 transfection in HCT-116 cells and these effects were also reversed
by p21 knockdown. In addition, miR-6734 transfection caused prolonged in-
duction of p21 gene and modifıcation of histones in p21 promoter, which are
typical aspects of a phenomenon referred to as RNA activation (RNAa). Collec-
tively, our results demonstrated that miR-6734 inhibits the growth of colon
cancer cells by up-regulating p21 gene expression and subsequent induction of
cell cycle arrest and apoptosis, suggesting its role as an important endogenous
regulator of cancer cell proliferation and survival.
#1465 Regulatory role of miRNA-661 in triple-negative breast cancer of
AfricanAmericanwomen.Aline S. Fonseca,1 Selene Elifıo-Esposito,2Marilesia
F. Souza,3 Akanksha Mahajan,1 Yara R. Zabala,1 Bruna M. Sugita,4 Luciane R.
Cavalli1. 1Georgetown University, Washington, DC; 2Pontifícia Universidade
Católica do Paraná (PUC-PR), Curitiba, Brazil; 3Universidade Estadual de Lon-
drina (UEL), Londrina, Brazil; 4Universidade Federal do Paraná (UFPR), Cu-
ritiba, Brazil.
Triple negative breast cancer (TNBC) disproportionately afflicts young Afri-
can American (AA) women when compared to Non-Hispanic Whites (NHW),
being usually diagnosed in advanced stage, likely to experience metastasis and
often unresponsive to treatment. An increased number of studies have charac-
terized the differences in the tumor biology between AA andNHWpatients and
have shown that breast tumors from AA patients present increased cell prolif-
eration, elevated expression of angiogenesis markers and higher migration and
invasive properties, the fundamental hallmarks of cancer. MiRNAs are short
sequences of non-coding RNAs that act on gene expression regulation. In this
study, our main objective was to determine the expression levels of miRNA-661
in the TNBC of AAwhen compared to the NHWs and to verify it is directly role
in affecting the aggressive TNBC phenotype. MiRNA-661 expression analysis
was conducted by RT-qPCR in the tumor tissue of 31AA-TNBCpatients and 17
NHW-TNBCpatients. AA andNHWsamples of 40 and 20 non-TNBC subtype,
respectively, and 49 adjacent normal tissue (ANTs) were used as control for the
subtype and tumor specifıcity, respectively. Our results showed a signifıcant
down-regulation ofmiR-661 expression in TNBC of AA in relation to theNWH
(P0.0001) and between the AA-TNBC and non-TNBC subtypes (P0.001).
MiR-661 was also signifıcantly differentially expressed in the ANT when com-
pared to the tumor tissue (P0.001). In addition, ROC analysis showed a high
power of this miRNA in discriminating the TNBC genome of AA and NHW
women (AUC 0.79 (0.65-0.92), 95%CI). Modulation of the expression of this
miRNA in the HCC1806 and BT549 TNBC cell lines, derived from an AA and
NHWpatient respectively, using inducers/repressors systems, showed its direct
effect in cell proliferation, migration and cytotoxicity. Interestingly these effects
presented a higher impact in the HCC1806 cell line model. Altogether, our
fındings indicate thatmiRNA-661 dysregulation is associated with TNBC of AA
women, and directly impacts their tumor phenotype. The uncovering of the
molecular mechanisms that dictates these effects, specially the ones that modu-
late drug response, is critical for patient selection and stratifıcation into novel
and effıcient target therapies. This much needed knowledge would lead to pro-
found clinical benefıts, particularly to young AA patients, that are commonly
affected by the TNBC aggressive phenotype. Funding: This project was sup-
ported by theGeorgetownUniversityCenter of Excellence inRegulatory Science
and Innovation (CERSI U01FD004319), a collaborative effort between the uni-
versity and the U.S. Food and Drug Administration to promote regulatory sci-
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ence through innovative research and education. This research does not neces-
sarily reflect the views of the FDA. The authors thank the CNPq - Brazil for
scholarship (ASF).
#1466 QKI, amiRNA-200 target gene, suppresses epithelial-to-mesenchy-
mal transition in oral squamous cell carcinoma cells. Yoon Ho Ko,1 Eun Ju
Kim,2 Der Sheng Sun,1 Hye SungWon,1 Young-Ho Ahn2. 1Catholic University,
Uijeongbu-si, Republic of Korea; 2EwhaWomans University College of Medicine,
Seoul-si, Republic of Korea.
Objectives: The microRNA (miR)-200 family plays a major role in specifying
the epithelial phenotype by preventing expression of the transcription repres-
sors, ZEB1 and ZEB2, which are well-known regulators of epithelial-to-mesen-
chymal transition (EMT) in epithelial tumors including oral squamous cell car-
cinoma (OSCC). Here, we elucidated whether the miR-200 family members
control RNA-binding protein quaking (QKI) which is a newly identifıed tumor
suppressor and is regulated during EMT.Methods:We predicted thatmiR-200a
and miR-200b could recognize QKI 3=-UTR by analyzing TargetScan and
TCGAhead and neck SCC dataset. To further verify the role ofmiR-200 onQKI
in HNSCC, we carried out the functional study in CAL27 and HSC3 cells. Re-
sults: Forced expression of miR-200b/a/429 inhibited the expression of ZEB1
and ZEB2, and decreased cell migration in CAL27 and HSC3 cells. QKI expres-
sion was also suppressed by miR-200 over-expression, and the 3=-UTR of QKI
mRNA was directly targeted by miR-200 in luciferase reporter assays. Interest-
ingly, shRNA-mediated knockdown of QKI led to pronounced EMT and pro-
tumor effects in vitro and in vivo studies of OSCC. Conclusion: QKI increases
during EMT and is targeted by miR-200; while, it suppresses EMT and tumori-
genesis, contradictorily.We suggest that QKI andmiR-200 could form a balanc-
ing feedback loopmaintaining homeostatic responses to EMT-inducing signals.
#1467 A large set of miRNAs is deregulated since the earliest steps of
humanHCC. Francesca Rizzo,1 LucaDi Tommaso,2 Pia Sulas,3 ElenaCoviello,1
ChiaraNovello,2 AlessandroWeisz,1MassimoRoncalli,2 AmedeoColumbano3.
1University of Salerno, Salerno, Italy; 2Humanitas University, Rozzano, Italy;
3University of Cagliari, Cagliari, Italy.
Introduction: Hepatocellular carcinoma (HCC) is the result of a stepwise
process preceded by the development of premalignant lesions. To assess the
involvement of microRNAs (miRNAs) in hepatocarcinogenesis it is critical to
understand whether and which miRNAs are involved in the early stages of tu-
mor development. To this end, changes in expression of miRNAs were investi-
gated in low and high grade dysplastic nodules (LGDNs, HGDNs), early HCCs
(eHCCs) and progressed HCCs (pHCCs). Materials and Methods: Small RNA
sequencing (smallRNA-Seq) was applied to search for liver miRNAs and to
profıle their expression patterns in 14 cirrhotic nodules (CNs), 9 LGDNs, 6
HGDNs, 6 eHCCs and 20 pHCCs) from17 patients with liver lesions of different
etiology (HCV, HBV and alcohol). To investigate miRNAs differentially ex-
pressed in pHCCs towards their matched cirrhotic tissue, we applied the Ran-
dom-VarianceModel (F-test) andMultivariate Permutation Test (Fold Change,
FC
 2.0). QRT-PCR analysis was also performed on 14 additional patients with
the same etiology of the fırst cohort for validation of the smallRNA-Seq results.
Results: We identifıed a 62 miRNA expression signature that differentiates pH-
CCs from matched CNs. Notably, 52/62 miRNAs dysregulated in pHCCs were
likewise altered in LGDN and HGDN, suggesting their possible role in HCC
onset. Indeed, 28miRNAs showed lower expression in CN that was signifıcantly
increased in LGDNs and remained high up to pHCCs. In contrast, 24 miRNAs
displayed an opposite behavior, as their expression was very low or absent all
throughout the tumorigenic process, compared to CNs. Interestingly, 2 miR-
NAs (let-7a-5p, miR-101-3p) showed a progressive decrease, suggesting that
they are involved in later stages of the process. To further support the fınding
that dysregulation of miRNAs is a very early event in HCC development, we
performed qRT-PCR in a series of LGDN, HGDN, eHCC and pHCCs from 14
additional patients. We selected for this analysis a handful of miRNAs found
dysregulated by NGS analysis. The results demonstrate that all the 6 miRNAs
examined (miR-429, miR-141-3p, miR-200a-3p and miR-200b-3p, miR-375
and miR-21-5p), were dysregulated at all stages of the tumorigenic process as
compared to CNs. Conclusion: The results demonstrate that miRNAs deregu-
lationmay be a critical player in human hepatocarcinogenesis, from early stages
to pHCC. They also suggest that some miRNAs might represent biomarkers
useful for differential diagnosis of dysplastic and neoplastic liver lesions.
#1468 MiR-200b targets ARHGAP18 and suppresses triple negative
breast cancer metastasis. Chengfeng Yang,1 Brock Humphries,2 Yunfei Li,1
Zhishan Wang1. 1University Of Kentucky, Lexington, KY; 2Michigan State Uni-
versity, East Lansing, MI.
Triple negative breast cancer (TNBC) refers to a group of highly heteroge-
neous malignant tumors that lack estrogen receptor and progesterone receptor
expression, and human epidermal growth factor receptor 2 amplifıcation, ac-
counting for 10-20% of newly diagnosed breast cancer cases. Compared to other
subtypes of breast cancer, TNBCs usually show worse clinical features such as
rapid tumor growth, earlier recurrence, and more aggressive metastasis. Unfor-
tunately, the mechanism of TNBCmetastatic behavior has not been well under-
stood. Moreover, no effıcient targeted therapies for TNBCs are currently avail-
able, representing a real unmet need for effective new therapies. MiR-200 family
members are among the fırst miRNAs reported to function as potent inhibitors
of cancer metastasis. However, the mechanism of miR-200 family on cancer
metastasis has not been well understood. In this study, we investigated the effect
ofmiR-200b, onemember of themiR-200 family, onTNBCmetastasis using cell
culture and mouse orthotopic mammary xenograft tumor models. We found
that the expression level of miR-200b is signifıcantly lower in TNBC cells and
tissues than that in other types of breast cancer. Stably expressing miR-200b
signifıcantly reduced TNBC cell migration and invasion and suppressed TNBC
metastasis in a mouse orthotopic mammary xenograft tumormodel. Mechanis-
tic studies revealed that miR-200b overexpression in TNBC cells caused drastic
changes in cellular actin cytoskeleton organization patterns as evidenced by
reduced lamellipodia formation but increased stress fıber formation. In consis-
tent with these fındings, Rho GTPase pulldown assays demonstrated that stably
expressing miR-200b signifıcantly increased the Rho GTPase Rho A activation,
but reduced the Rho GTPase Rac1 activation. Moreover, inhibition of Rho A
signaling impaired the inhibitory effect of miR-200b on TNBC cell migration.
Bioinformatics analysis indicated that ARHGAP18, a specifıc Rho A GTPase
activating protein (GAP), is a predicate target of miR-200b. Further Q-PCR,
Western blot and 3=UTRreporter analysis confırmed thatARHGAP18 is a target
of miR-200b. Knocking down ARHGAP18 in TNBC cells using siRNAs signif-
icantly increased Rho A activation but reduced Rac1 activation. To further de-
termine the role of ARHGAP18 in TNBC, ARHGAP knockout TNBC cells were
generated using the CRISPR technology. It was found that knockout ARH-
GAP18 phenocopied the effect of miR-200b overexpression. Moreover, overex-
pressing ARHGAP18 in miR-200b stable expression cells overcome the inhibi-
tory effect of miR-200b on TNBC metastasis. Together, these fındings suggest
that miR-200b suppresses triple negative breast cancer metastasis by targeting
ARHGAP18 and enhancing Rho A activation.
#1469 Integrated analysis of microRNA, mRNA, and protein expression
utilizing MultiOmyxTM and NanoStringTM from formalin-fıxed paraffın-
embedded, lung, head and neck, breast, andmelanoma tumors.Qingyan Au,
RaghavKrishna Padmanabhan, Nam Tran, Lakshmi Chandramohan, Nicholas
Hoe. NeoGenomics, Aliso Viejo, CA.
Cancer is characterized as a loss of normal cellular regulation, due to accu-
mulation of mutations and disruption of complex biological pathways. MicroR-
NAs (miRNAs) regulation of co-stimulatory and immune checkpoint pathways
have been implicated as one of the potential mechanisms for cancer evasion in
immuno-oncology. It is estimated that 30% of all mRNA expression may be
regulated by miRNAs, and some are either oncogenic or tumor suppressive.
Complexity of miRNA regulation highlights the need for integrated assays, pro-
viding direct correlation between miRNA and mRNA, and protein expression.
From a single 4 m FFPE section, MultiOmyxTM hyperplexed immunofluores-
cent assay (demonstrated to stain up to 60 protein biomarkers) is utilized to
measure CD3, CD4, CD8, CD16, CD56, Granzyme B, FoxP3, ICOS, OX40,
OX40L, PD1, PDL1, HLA-DR, and Ki67 protein expression. From an adjacent
10 m section, NanoStringTM nCounter PanCancer Immune Profıling Panel
and Human v3 miRNA expression panel were utilized to comprehensively pro-
fıle the expression of 770 mRNA and 800 miRNA. Integrating MultiOmyx and
NanoString technologies, the current studymeasuredmiRNA,mRNA, and pro-
tein expression in lung, head and neck, breast, andmelanoma samples. For each
indication, three samples were selected from a larger sample set, based on high
protein expression of lymphocytes and macrophage markers (CD3, CD4, CD8,
CD56, CD16), co-stimulator markers (ICOS, OX40), and immune check-
point markers (PD1, PD-L1). Protein expression results indicate positive
correlation between expression of ICOS and OX40 with higher infıltration of
Thelper (CD3CD4), Tcytotoxic (CD3CD8), and effector T cells
(CD3CD8Granzyme B). NanoString normalizedmRNA counts for the pro-
tein biomarkers profıled indicate that all markers except for HLA-DR belong to
low expressers group with counts ranging from 20-700. Comparison of protein
expression to mRNA counts revealed inconsistencies in modulated markers
(PD1, PD-L1, ICOS, OX40) which are attributed to differences in population of
cells between the two sections.Direct assessment of up regulation ofmiRNAand
down regulation of target mRNA could not be made for miRNAs reported in
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literature as negative regulator of PD-L1 (miR-34a, 34b, 34c), PD1 (miR-28,
miR-107), FoxP3 (miR-210, miR-24, miR-31), and ICOS (miR-101). Analysis of
multiple miRNAs (combinatorial targeting) mapped in context to mRNA, and
their respective protein expression will be presented from lung, head and neck,
breast, and melanoma cancer samples.
#1470 Fine-tuning the expression of heterogeneous network of genes in-
volved in androgen signaling, aerobic glycolysis, apoptosis and epithelial-
mesenchymal transition by microRNA-644a in prostate cancer potentiation
of AR signaling therapy bymiR-644a: Selective manipulation of the prostate
cancer transcriptome by miR-644a. Jey Sabith Ebron,1 Jagjit Singh,1 Eswar
Shankar,2 Crystal Weyman,1 Sanjay Gupta,2 Daniel J. Lindner,3 Girish C.
Shukla1. 1Cleveland State Univ., Cleveland, OH; 2Case Western Reserve Univer-
sity, Cleveland, OH; 3Lerner Research Institute, Cleveland, OH.
Intratumoral Prostate cancer (PCa) heterogeneity is characterized by multi-
ple intrinsic mechanisms including Androgen signaling, aerobic glycolysis, ab-
errant transcriptional activation of c-Myc and dysregulation of miRNAs. The
ability of prostate cancer cells to alter growth and metabolism in a manner
distinct from benign cells is a major concern in the treatment of castration-
resistant prostate cancer. Therefore, targeting the diverse oncogenesis promot-
ing pathways involved in PCa progression and resistance at the posttranscrip-
tional level using micro RNAs (miRNAs) offers a novel therapeutic option.
Using a miRNA mimic screen, we identifıed a human-specifıc miRNA miR-
644a, whichmodulates expression of a diverse set of oncogenic pathways in PCa
including androgen signaling, AKT/IGF-1R signaling, c-myc mediated signal-
ing and EMT pathways.We have also demonstrated a potent tumor suppressive
function of miR-644a inmouse prostate cancer xenograft model. miR-644a also
sensitizes the PCa tumors to current therapeutic options including AR antago-
nist Enzalutamide by regulating the key modulators in development of drug
resistance. In conclusion, our study demonstrates that miR-644a is a novel tu-
mor suppressormiRNA regulating key prostate carcinogenesis promoting path-
ways.
#1471 miR-148a-3p regulation of OTX2 and PRC2 in group 3 and 4 me-
dulloblastoma. Qingfu Xu,1 Kimberly Wang,1 Sama Ahsan,2 Fausto Rodri-
guez,2 Charles Eberhart,2 Yugang Jiang,3 John Laterra,1 Yunqing Li1. 1Hugo W.
Moser Research Institute at Kennedy Krieger and Johns Hopkins School of Medi-
cine, Baltimore, MD; 2The Johns Hopkins School of Medicine, Baltimore, MD,
United States, Baltimore, MD; 3The Second Xiangya Hospital of Central South
University, Changsha, China.
Four different molecular subgroups are recognized in medulloblastoma
(MB). Among these subgroups, Group 3 and 4 tumors are the most aggressive
malignancies with few effective therapies. New therapies are likely to be most
effective if they target molecular alterations that mediate the formation and
growth of these malignancies. We searched the public cancer microarray data-
base Oncomine and found that the expression of OTX2, c-Myc, polycomb re-
pressor complex 2 (PRC2) subunits EZH2 and SuZ12 are signifıcantly higher in
Groups 3 and 4 as compared to the SHH subgroups. Moreover, Immunohisto-
chemical staining of a medulloblastoma tissue array showed that H3k27me3
expression is higher in Group 3 and 4 compared with the SHH groups. These
fındings suggest that these distinct molecular alterations could represent prom-
ising therapeutic targets. In this study, we identify miRNAs with the potential to
serve as therapeutic agents for Groups 3 and 4 by targeting oncogene pathway
OTX2 and c-Myc aswell as targeting PRC2 andmodulatingH3k27me3-targeted
tumor suppressors. Using TargetScan, Pictar and miRanda prediction algo-
rithms, miR-148a-3p is predicted to target OTX2. We show that enforced miR-
148a-3p potently inhibits protein expression of OTX2 and c-Myc in medullo-
blastoma cells. Luciferase reporter analysis shows that miR-148a-3p expression
downregulates OTX2 luciferase activities, and overexpressingOTX2 cDNA that
lack the respective 3=-UTR region recognized by miR-148a-3p signifıcantly res-
cues OTX2 downregulation bymiR-148a-3p. Furthermore, we show for the fırst
time that enforcedmiR-148a-3p expression can down-regulate the expression of
the PRC2methylase EZH2 and the PRC2 regulatory subunit SUZ12 in multiple
MB cell lines. Conversely, silencing endogenous miR-148a-3p expression up-
regulates the expression of EZH2 and SUZ12. Furthermore, enforced OTX2
expression attenuates the expression of miR-148a-3p-downregulated PRC2
subunit EZh2 and Suz12. Consistent with the effects of miR-148a-3p on EZH2
and SUZ12, miR-148a-3p was found to modulate H3k27me3 levels and restore
the expression of H3k27me3-targeted tumor suppressors. We also show that
enforced miR-148a-3p increases the sensitivity of Group 3 and 4 medulloblas-
toma cells to radiation and chemotherapy. Together, our fındings show that
miR-148a-3p has the potential to modulate Group 3 and 4 medulluloblastoma
malignancy and chemo/radiation sensitivity by (1) reversing H3k27me3 modi-
fıcations and thereby potentially restoring tumor suppressor expression; and (2)
down-regulating OTX2 and leading to the inhibition of c-Myc-dependent on-
cogenes.
#1472 Alternate translation initiation regulation of PRDX5 mRNA by
miR6855-3p in basal-like breast cancer cells.GautamChaudhuri, SmitaMisra.
Meharry Medical College, Nashville, TN.
Human peroxiredoxins (PRDXs) are a superfamily of six thiol-dependent
peroxidases that are able to reduce hydrogen peroxide, alkyl hydroperoxides and
peroxynitrite. Apart from the classical, apparently redundant function of mito-
chondrial and often peroxisomal peroxide neutralization shared by other per-
oxiredoxins, PRDX5 was initially discovered as a DNA binding transcriptional
repressor regulating the biosynthesis of cytotoxic Alu RNAs through a mito-
chondrial-localization signal-truncated mature form (SPRDX5] of this protein
that is accumulated in the nucleus and binds to a 60 bp nucleotide sequence at
the Alu gene promoters. Our data suggest that SPRDX5 also binds to the Alu-
sequence-containing BRCA2 gene silencer to prevent the binding of SLUG at
the silencer thus enhancing the BRCA2 gene expression leading to the genotoxin
and radiation-resistance of aggressive SLUG-high basal-like breast cancer cells.
PRDX5 mRNA contains two in-frame start codons (AUGs) that are condition-
ally used as alternate translation initiation sites. Translation from the fırst AUG
would result in the synthesis of a larger 214-residue protein (LPRDX5) whereas
the use of the second AUG would result in the production of a shorter 162-
residue polypeptide (SPRDX5). Since SPRDX5 lacks themitochondrial localiza-
tion signal, it is accumulated in the nucleus via its C-terminal bipartite nuclear
localization signal.Wepresent evidence here that amiRNA,miR-6855-3p, binds
the primary PRDX5 transcript between the two AUG codons and prevents the
translation of themRNA from the fırst AUG codon but not that from the second
AUG codon thus favoring the initiation of translation from the second AUG
codon. To characterize the effect of miR-6855-3p on Prdx5 mRNA translation,
we developed three different PRDX5-FLAG constructs in pCV3XFLAG14
(Sigma) that has Prdx5 ORF with or without mutation on the fırst or second
AUG codon. Transfection of these constructs into BT549 cells followed by treat-
ments with miR-6855-3p mimic or antagomiR and subcellular fractionation
further supported our notion.Wepropose here thatmiR-6855-3p acts as a tsmiR
by promoting the biosynthesis of the transcriptional regulator protein SPRDX5
which enhances the expression of the tumor suppressor protein BRCA2 leading
to the genotoxin and radiation-resistance of aggressive SLUG-high basal-like
breast cancer cells. Supported in part by DOD-CDMRP IDEA Expansion
Grant# BC103645 and NIH/NCI grant 1R21CA181920 01 to GC and
1U54RR026140 to SM.
#1473 miR-1207-3p regulates c-Myc in aggressive prostate cancer.Dibash
K. Das, Olorunseun O. Ogunwobi. CUNY Graduate Center/CUNY Hunter Col-
lege, New York, NY.
Prostate cancer (PCa) is the most common non-skin cancer and the second
leading cause of cancer-related death for men in the U.S. A major challenge is
understanding the molecular mechanisms involved in the progression from the
asymptomatic androgen-dependent PCa to the lethal castration resistant pros-
tate cancer (CRPC). The chromosomal region 8q24 is associated with aggressive
PCa and variants of this region have been identifıed to interact with the PVT1
non-coding gene in PCa. In previous work we demonstrated that microRNA-
1207-3p (miR-1207-3p) has prognostic value in PCa, and directly binds to the 3=
UTR of Fibronectin type III domain containing 1 (FNDC1) to regulate a novel
FNDC1/fıbronectin (FN1)/androgen receptor (AR) pathway upregulated in
metastatic PCa. miR-1207-3p is encoded at the PVT1 gene locus, which is lo-
cated downstream of c-Myc on the 8q24 human chromosomal region. Studies
have suggested amplifıcation at the 8q24 human chromosomal region, which
includes C-Myc, as a possible prognostic factor for CRPC. c-Myc is a well-
established proto-oncogene that is commonly found to be amplifıed in up to
72% of CRPCs signifıcant amplication of c-myc has been a consequence of
antiandrogen treatment, and c-Myc is downstreamofAR in somePCa.miRNAs
have also been implicated in the regulation of c-Myc. Nevertheless, the mecha-
nisms regulating c-Myc remain unclear in PCa. Using a panel of fıve PCa cell
lines we discovered that c-Myc expression is higher in aggressive CRPC cell lines
compared to non-aggressive CRPC and androgen-dependent prostate cancer
cell lines. Furthermore, our data reveals that c-Myc expression is higher in the
aggressive E006AA-hT PCa cell line when compared to the indolent E006AA
PCa cell line. This suggests that c-Myc is associated with aggressive PCa. More-
over, overexpression of miR-1207-3p suppresses the expression of c-Myc in
E006AA-hT PCa cells but not E006AA PCa cell line in which c-Myc is underex-
pressed compared to the normal prostate epithelial cell line, RWPE-1. Next,
using a synthetic biotinylated miR-1207-3p duplex, we discovered that overex-
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pression of miR-1207-3p more effıctively inhibited migration, inhibited prolif-
eration and increased apoptosis in the aggressive E006AA-hT PCa cell line with
increased c-Myc expression when compared to the indolent E006AA PCa cell
line with decreased c-Myc expression. These data demonstrate that the miR-
1207-3p/FNDC1/FN1/AR pathway may regulate c-Myc in aggressive PCa.
#1474 Epigenetic silencingofmicroRNA-137 enhancesASCT2expression
and tumor glutamine metabolism. Xiao Daibiao,1 Junli Dong,1 Zihan Zhao,2
Ping Ren,3 Cong Li,4 Yufeng Hu,1 Jianguo Shi,5 Hexiu Su,1 Zhaojing Wang,1
Hudan Liu,1 Bo Li,4 Peng Gao,6 Guoliang Qing1. 1Medical Research Institute of
WuhanUniversity,Wuhan, China; 2The SecondHospital of DalianMedical Uni-
versity, Dalian, China; 3Hubei University of Science and Technology, Xianning,
China; 4Zhongshan School of Medicine of Sun Yat-Sen University, Guangzhou,
China; 5Affıliated Union Hospital of Tongji Medical College,Wuhan, China; 6Af-
fıliated Dalian Sixth People’s Hospital, Dalian, China.
Cancer cells amplify the expression of ASC amino acid transporter 2 (ASCT2,
also called SLC1A5), a high-affınity glutamine carrier protein, to coordinate
metabolic reprogramming and malignant transformation. Yet genetic and/or
epigenetic mechanisms underlying the control of ASCT2-mediated glutamine
metabolism remain to be clarifıed. Combined in-silico algorithms with systemic
experimental screening, we herein identify the tumor suppressor miR-137 as an
essential regulator that targets ASCT2mRNA and cancer cell glutamine metab-
olism. Metabolic analysis shows that miR-137 derepression, similar to ASCT2
inactivation, signifıcantly inhibits glutamine consumption and TCA cycle
anaplerosis.Mechanistically,methyl-CpGbinding protein 2 (MeCP2) andDNA
methyltransferases (DNMTs) cooperate to promote active methylation of the
miR-137 promoter and its decreased transcription, which conversely enhances
ASCT2 expression and glutamine metabolism. As such, expression between
miR-137 and ASCT2 is inversely correlated in multiple human cancer types,
including colorectal carcinomas, glioblastomas, prostate andpancreatic cancers.
These fındings thus elucidate a universal mechanism responsible for ASCT2
deregulation in human cancers, revealing a molecular link between miR-137,
ASCT2 and tumor metabolism.
#1475 miRNA-450a suppresses adhesion but promotes invasion through
targeting of TMEM182 in oral squamous cell carcinoma. En-Wei Hsing,1
Shine-Gwo Shiah,1 Ching-Chuan Kuo,1 Jang-Yang Chang2. 1National Health
Research Institutes, Miaoli, Taiwan; 2National Health Research Institutes,
Tainan, Taiwan.
OurmicroRNA(miRNA)expression signatures of oral squamous cell carcinoma
(OSCC) revealed that miR-450a was signifıcantly increased in cancer tissues com-
pared with normal epithelium. In this study, we focused on the functional signifı-
cance of miR-450a in cancer cells and identifıcation of miR-450a-regulated novel
targets inOSCC.Overexpression ofmiR-450a inDOKandSAS cells showed signif-
icant inhibition of cell adhesion and induction of cell invasiveness, suggesting that
miR-450a functions as an onco-miRNA.Weperformed genome-wide gene expres-
sion analysis to search for miR-450a-regulated molecular targets. Gene expression
data and luciferase reporter assays revealed that TMEM182was directly targeted by
miR-450a.ThemiR-450a-reduced cellular adhesionwasblockedbyTMEM182 res-
toration, suggesting thatmiR-450aexhibits itsoncogenic activity throughnegatively
regulatingTMEM182 level. Furthermore,miR-450aexpressioncouldbe inducedby
the cytokine TNF- primarily through activating extracellular signal-regulated ki-
nase (ERK) signaling pathway. ERK inhibitor prevented the TNF--induced miR-
450a expression and enhanced adhesion ability. Taken together, these data indicate
that TNF-/ERK-dependent expression of miR-450a plays an important role in
mediating cellular adhesion and invasiveness, and scavenging miR-450a function
using antagomir may have therapeutic potential for the treatment of OSCC. (The
studywas supportedby the followinggrants:MOST103-2320-B-006-036-MY3and
MOST 105-2325-B-400-001 from the Ministry of Science and Technology of Tai-
wan, ROC)
#1476 Cell-freemiR-141 as amolecularmarker for prostate cancermetas-
tasis. Marilesia Ferreira de Souza,1 Ilce Mara de Syllos Cólus,1 Aline Simoneti
Fonseca,2HellenKuasne,3 Paulo Emilio Fuganti,4DeepakKumar,5 Silvia Regina
Rogatto,3 Luciane Regina Cavalli2. 1State University of Londrina, Londrina, Bra-
zil; 2Georgetown University, Washington, DC; 3AC Camargo cancer center, São
Paulo, Brazil; 4Londrina cancer hospital, Londrina, Brazil; 5University of the
District of Columbia, Washington, DC.
Prostate cancer is the secondmost commonly diagnosed neoplasia inmen. Cur-
rently, there is no available non-invasive tool to assist in the identifıcation of the
aggressive form of this disease. Cell-free nucleic acid has been tested as a potential
new molecular tool that can be useful in the diagnosis and prognosis of prostate
cancer. MicroRNAs are a class of non-coding RNAs, that are shown to impact the
development and progression of prostate cancer and their detection in plasma have
been indicated as a promisingnon-invasive tool for disease screening andprognosis
assessment. Among the several deregulated miRNAs that are observed in prostate
cancer, themiRNA-141-3pwasobservedwithupregulatedexpression levels inpros-
tate cancer, particularly in the metastatic lesions. Therefore, the main aim of this
studywas toverify thediagnosticpotentialofmiR-141asacirculating tumormarker
forprostate cancer anddetermine its functional role inmodulating tumorigenesis in
prostate cancermetastatic cell lines.MiR-141 expression analysis was performed in
plasma samples of 102 prostate cancer patients without treatment and of 50 health
controls by RT-qPCR. The experimental assays were performed by transfecting the
PC3 cell line using miRNA-141 mimic/ inhibitor systems and directly accessing
their effect in classical tumor phenotypes. Expression of the miR-141 were found
signifıcantly upregulated in the metastatic patients’ plasma specimens (FC9.11,
p0.04;AUC0.66)whencomparedto thepatientswithoutmetastasis, showing its
screening potential for prostate cancermetastasis. The in vitro ectopic expression of
miR-141 in PC3 cell line showed a signifıcant increased in cell proliferation, associ-
ated with changes in cell cycle (decreased number of cells in the G1 phase). Con-
versely, the inhibition of miR-141 showed an increase in the migratory ability, cell
adhesion and in the Docetaxel cytotoxicity of the PC3 cells. Western-blot analysis
showed that the inhibition of themiR-141 levels reduced the expression of the EMT
inducers markers E-CADHERIN and CLAUDIN, and up-regulated the levels of
ZEB-1, pAKT and VIMENTIN, consistent with their repression roles in the EMT
process. These fındings showed that miR-141 presents a direct function in control-
ling some of the in vitro metastatic phenotypes in prostate cancer, through the
regulation of the epithelial-mesenchymal transition expression proteins. In conclu-
sion,miR-141 presents a potential use as aminimally invasivemolecularmarker for
prostate cancer diagnosis and can be used as a druggable target for therapy, partic-
ularly in themetastatic clinical setting.
#1477 Melatonin regulates the tumor suppressor miR-148a-3p involved
in angiogenesis andmetastasis of breast cancer.Debora Zuccari,1 Jéssica Zani
Lacerda,2 Lívia Carvalho Ferreira,2 Beatriz Camargo Lopes,3 Andrés FelipeAris-
tizábal-Pachón,4Marcio ChaimBajgelman5. 1Faculdade deMedicina de São José
do Rio Preto - FAMERP, São José do Rio Preto, Brazil; 2Universidade Estadual
Paulista - UNESP, São José do Rio Preto, Brazil; 3Laboratorio de Investigação
Molecular do Cancer - LIMC/FAMERP, São José do Rio Preto, Brazil; 4Depart-
ment of Genetics/Faculdade de Medicina - USP, Ribeirão Preto, Brazil; 5Labora-
torio Nacional de Biociencias/Centro Nacional de Pesquisa em Energia e Materi-
ais - CNPEM, Campinas, Brazil.
Women with breast cancer has the tumor progression and angiogenesis-in-
duced metastasis as the main cause of death. MicroRNAs (miRNAs) are small
noncodingmRNAmolecules that play an important role in gene regulation and
once deregulated, these molecules may be involved with the progression of dif-
ferent human tumor types, including breast cancer. These miRNAs play an
oncostatic role on tumor suppressor genes and regulate the process of angiogen-
esis, tumor growth andmetastasis. So as newpossible adjuvant treatment against
breast cancer our group have shown melatonin, that is a hormone secreted by
the pineal gland, by exhibiting several anti-tumor and antiangiogenic effects.
Therefore, the aim of this study was to evaluate the potential therapeutic of
melatonin onmiRNAs regulation to verify breast cancer progression and potent
tumor suppressormiR-148a-3p. In silico analysis was performed for selection of
miRNAs involved in breast cancer. The MDA-MB-231 breast cancer cell line
(metastatic negative estrogen receptor) was grown and separated in two differ-
ent experimental conditions maintained for 24 hours: control group and mela-
tonin-treated group (concentration of 1mM). After this period the extraction of
total RNA was performed (Qiagen®) and the total concentration of miRNAs of
each sample was determined (NanoDrop Spectrophotometer 2000C - Thermo
Scientifıc®). Differential expressions of these miRNAs was evaluate using miS-
cript miRNA PCR-Array (Qiagen®) containing 84 miRNAs associated with
breast cancer. The overexpression of miR-148a-3p in MDA-MB-231 cells was
performed by bacterial cloning vector and the relative quantifıcation of gene
expression of their target IGF-1R and VEGF by real-time PCR. Moreover, the
quantifıcation of protein expression was performed by immunocytochemistry
of IGF-1R andVEGF. Lastly, themigration and invasion cell assays were carried
out to assess the potential capacity of these cells to undergo metastasis. The
analysis of miRNAs MDA-MB-231 cell line by PCR-array showed 24 upregu-
lated miRNAs and 8 miRNAs downregulated after the treatment with melato-
nin. Relative quantifıcation shows that the melatonin treatment increases the
gene expression of miR-148a-3p and decreases the gene and protein levels of
IGF-1R andVEGF. The capability ofmigration and invasion of the breast cancer
cells decreased after treatment withmelatonin and overexpression ofmiR-148a-
3p. Our results confırm the action of melatonin on the miR-148a-3p regulation
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known being involved in the progression of breast cancer. Thus the establish-
ment of this therapeutic protocols can control these cellular events essential for
the prognosis of patients with breast cancer.
#1478 Curcumin inhibits epithelial-mesenchymal transition and invasion
in breast cancer cells by controlling miR-34a expression. Marcela Gallardo,
Richard Ponce-Cusi, Gloria M. Calaf. Universidad De Tarapaca, Arica, Chile.
Breast cancer in advanced stages tends to developmetastases and/or chemoresis-
tance, in both cases therapeutic options are limited and have low probability of
success, which represents the biggest obstacle in reducing mortality from this dis-
ease. There is a close connection between the Epithelial-Mesenchymal Transition
(EMT) process of cancer cells and the acquisition of invasive andmetastatic ability.
Numerous EMT mediators have been described in cancer and among them miR-
NAsplay a fundamental role in regulating suchprocess, suggesting that it could be a
therapeutic target to address this phenotype. Curcumin (diferuloylmethane) is a
derivative compound of Curcuma longa that has therapeutic properties in various
cancers asblocking initiationand tumorprogression through its anti-inflammatory,
antioxidant, proapoptotic, antiangiogenic and antimetastatic effects. The role of
curcumin onEMT in non-cancerous breast cellsMCF-10F and in breast cancer cell
linesMCF-7andMDA-MB-231was evaluated.Thiswork shows that in all these cell
lines curcumin induced the expression of tumor suppressor microRNA miR-34a
andrepressed theexpressionof several genes involved inEMTandmetastasis asAxl,
Slug, Twist, N-cadherin, vimentin, fıbronectin, among others. Consequently, cur-
cumin inhibited the migration and invasiveness in these cells, irrespective of the
expression of estrogen and progesterone receptors and p53 mutational status.
Blockade of miR-34a by transfection with antagomiR-34a inhibited the effect of
curcumin onEMTgenes and on themigratory/invasive potential of cells indicating
that miR-34a plays a central role in the Curcumin-mediated suppression of EMT
and invasion.Therefore, results confırm the suppressive effect of curcuminonEMT
and invasion in breast cancer cells, showing that such substance exerts this effect by
inducing expression ofmiRNAmiR-34a and consequently the repression of several
of its target genes. Supported by Tarapacá University, Arica, Chile (GMC).
#1479 Differential expression of microRNAs in transformation of follicular
lymphoma to diffuse large B cell lymphoma.KaterinaMusilova,1 Gabriela Pavla-
sova,1 Vaclav Seda,1 Eva Vojackova,1 Katerina Cerna,1 Veronika Svobodova,1 Rob-
ert Pytlik,2 Vit Prochazka,3 Zuzana Prouzova,3 Sarka Pospisilova,4 Lenka Zla-
malikova,5 Heidi Mocikova,6 Lenka Kruzova,3 Marie Jarosova,3 Andrew Evans,7
Clive Zent,8 Leos Kren,5 Marek Trneny,2 Jiri Mayer,4 Andrea Janikova,5 Marek
Mraz1. 1CeitecMUandUniversityHospital Brno andFaculty ofMedicineMU,Brno,
Czech Republic; 2General University Hospital and Charles University in Prague,
Prague, Czech Republic; 3Palacky University and University Hospital Olomouc, Olo-
mouc, CzechRepublic; 4UniversityHospital Brno andFaculty ofMedicineMU,Brno,
Czech Republic; 5University Hospital Brno, Brno, Czech Republic; 6University Hospi-
tal Kralovske Vinohrady and Charles University in Prague, Prague, Czech Republic;
7University ofRochesterMedicalCenter, School ofMedicine andDentistry, Rochester,
NY; 8WilmotCancer Institute,UniversityofRochesterMedicalCenter, SchoolofMed-
icine and Dentistry, Rochester, NY.
MicroRNAs (miRNAs) are important post-transcriptional regulators of gene ex-
pression, and are frequently aberrantly expressed in cancer. We aimed to under-
stand their role in the transformation of indolent follicular lymphoma (FL) into an
aggressive diffuse large B cell lymphoma. This happens in 3% of cases per year
during the course of the disease, and is associated with median survival of only 2
years. The NGS revealed number of aberrations associated with transformed FL
(tFL), including frequent high-level activity ofMYC (amplifıcations, translocations,
and mutations) or loss of DNA damage regulators (p53, CDKN2A/B). Firstly, we
performed amiRNAprofıling (TaqManmiRNAArrays) in paired FL and tFL sam-
ples (N8 pairs). This revealed a relatively small group of 5 miRNAs that are con-
sistently differentially expressed in tFL (P0.05, fold-change1.5). Since themost
frequentlyacquiredaberration in tFL is thehigh-level activityofMYCweperformed
a correlation analysis of MYC levels and expression of these miRNAs in additional
samplesofFL, tFL, andCLLsampleswith/withoutMYCduplication(N40FL/tFL,
N39 CLL). This revealed that at least one of these miRNAs is signifıcantly down-
modulated (P0.05) in caseswith high-levels ofMYC. TheMYC-mediated repres-
sion of miRNA levels was also observed (P0.05) in B cells from transgenic MYC
over-expressingmice (MYC controlled by an Ig-alpha enhancer) in comparison to
wild-type animals (samples obtained from young animals before occurrence of any
malignancy). We have further shown that the levels of this miRNA affect B cell
proliferation in vitro, and its low-levels associate with percentage of Ki67 positive
cells in FL samples (P0.005).Moreover, low levels of tFL-associatedmiRNAwere
present in FL cases with a shorter overall survival (P0.01), and its expression di-
rectly affected BCR signalling (calcium flux assay after anti-IgM). We have shown
that the expression of this miRNA is not only down-modulated by high-levelMYC
expression, but also by B cell adhesion to stromal cells in co-culture in vitro (HS-5
stromal cells). This suggests that its normal physiological functionmight be related
to regulationofBcell functions in the contextof immuneniches, and thismightplay
a role in FL progression and transformation. It remains to be elucidated what other
molecular mechanisms ensure low-level expression of the studied miRNA in cases
that do not harborMYC over-expression, and what pool of target mRNAs is regu-
lated by thismiRNA in FL cells.This workwas supported by: theMinistry ofHealth
of the Czech Republic, grant nr. 16-29622A. All rights reserved. contact:
marek.mraz@email.cz
#1480 Mir-182 is involved in sulindac anticancer activity in colon cancer.
Hongyou Zhao, Bin Yi, Zhipin Liang, Ruixia Ma, Yaguang Xi. Louisiana State
University Health Sciences Center, New Orleans, LA.
Nonsteroidal anti-inflammatorydrugs (NSAIDs)displaypromisingantineoplas-
tic activity inmany human solid tumors including colorectal cancer. Previous stud-
ies reported that sulindac sulfıde (SS) can inhibit the growth of tumor cells through
cyclooxygenase-2 (COX-2) dependent or independent pathways. Obviously,
COX-2 independent pathway involves a low toxic property to support the clinical
potential for using sulindac as a chemoprevention drug. However, the molecular
mechanisms responsible for COX-2 independent pathway have not been com-
pletely elucidated. In this project, we employed two human colon cancer cell lines,
referred to HCT116 and HT29. HCT116 cells are characterized for low COX-2
expression,whileHT29 cells showrelatively highCOX-2 expression.We found that
SS could unbiasedly inhibit the growth ofHCT116 andHT29 cells by arresting cells
inG1/G2phases.CyclinG2was found tobeupregulated in response toSS treatment.
FOXO3a has been reported to regulate CyclinG2 expression at the transcriptional
level. Our results demonstrate that SS could also upregulate FOXO3a. By using the
loss-of-functionstrategy,we found thatSScouldnot effıcientlyupregulateCyclinG2
and lead to cell cycle arrest in cells with FOXO3a knockdown. In addition, we stud-
ied themechanismthat couldbe involved inSSregulationofFOXO3a.Ourprevious
studies reported that a panel of miRNAs could be altered by SS treatment in both
colon and breast cancer cells. In the downregulated miRNA list, we found that
miR-182 could potentially target FOXO3a. By using luciferase assay, we validated
the direct regulation ofmiR-182 on the expression of FOXO3a.WhenmiR-182was
downregulated, SS could neither effıciently upregulate the expression of FOXO3a
nor inhibit cell growthas itdid incontrol cells.Wegainedhighlyconsistent results in
HT29 andHT29 cells with COX-2 knockdown. Therefore, our study demonstrates
a pathway consisting of miR-182/ FOXO3a/ CyclinG2 as a novel mechanism re-
sponsible for SS anticancer activity in colon cancer, which may imply a COX-2
independent pathway.
#1481 Determination ofmicroRNAprofıle in lung cancer cell line treated
with chemotherapy cisplatin (C), pemetrexed (P) or PC with bevacizumab
(B) and its implication in resistance. Chao H. Huang,1 Hannah C. Motes,2
Siddarth Sharma,2 Jared Kevern,3 Emma Borrego-Diaz,4 Mukut Sharma2. 1Uni-
versity of Kansas Med Ctr, Lenexa, KS; 2Kansas City VAMedical Center, Kansas
City, MO; 3University of Kansas Med Ctr, Kansas City, KS; 4Eurofıns Lancaster
Laboratoris, Lancaster, PA.
Background: Cellular microRNAs (miRNAs) regulate gene expression
through modulation of messenger RNA transcription and are involved in epi-
genetic regulation, metastasis and cancer immunity. They have prognostic and
therapeutic signifıcance. The miRNAs associated with resistance in lung cancer
without EGFRmutation are not yet known. We sought to determine the profıle
of miRNA of lung cancer cell lines without EGFRmutation treated with chemo-
therapy. Methods: lung cancer cell lines HTB177 were treated with PC or PCB
(0.05mg/mL Cisplatin, 0.05 mg/mL pemetrexed, 6.25 mg/mL Bevacizumab) for
24, 48, 72 and 144hours.Weobtained baselinemiRNAprior to therapy and after
treatment to determine the changes in miRNA profıle using RT PCR technique.
After 144 hours, we obtainedmiRNA profıle of the cells that survived treatment
to assess change in themiRNA profıle.We chosemiRNA that has been reported
to influence on the outcome of lung cancer: Let 7 modulates RAS, miRNA 27 is
involved as tumor suppressor gene, mir212 negatively regulates antiapoptotic
protein PED, miR 375 down regulates ASH1 a transcription factor. Mir21 tar-
gets anti-apoptotic genes including PDCD4 and PTEN. Results: We observed
down regulation of these miRNA after 24h of treatment with PC and these
miRNA then became upregulated after 48 hours, especially let 7f. In contrast, the
treatment of PCwith B caused upregulation of thesemiRNA, especiallymiR 27b
and let 7f at 24 h and then decreased levels of upregulation at 48hours. These
miRNAwere not upregulated at 72h for both groups. The expression of miRNA
21 is upregulated 50 times in cells that survived treatment with PC or PCB at
144h. Conclusions: The treatment using PC and PC with B in lung cancer cell
lines regulates change in the profıle of miRNA at different time points. There is
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: MicroRNA Regulation of Cancer Biology 2
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017380
a difference of the miRNA profıle in these 2 treatment groups. miRNA 21 is
upregulated in cells resistant to therapy.miRNAcould be involved in the activity
of chemotherapy and development of resistance.
#1482 Triptolide inhibits the growth of osteosarcoma by regulating mi-
croRNA-181a via targeting PTEN gene in vivo and in vitro. Chunming Jiang,
Xiang Fang, Xuepeng Wang, Maoqiang Li, Wu Jiang, Liulong Zhu, Zhenyu
Bian.Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou,
China.
Objective: We aimed to study the effect of triptolide on OS and the related
molecular mechanism. Methods: The cell viability, apoptosis portion, tumor
size, tumorweight and invasion ofOS cellswere determined. The relative level of
miR-181 in OS tissues and the adjacent tissues was determined by qRT-PCR.
The target gene of miR-181a was determined and verifıed by luciferase report
assay. At last, OS cells were treated with triptolide and triptolide  miR-181a
mimics to verify the relationship between triptolide and miRN-181a. Results:
Triptolide inhibited the cell viability, promoted the apoptosis, decreased the
tumor size and weight, and reduced the invasion of OS cells. The level of miR-
181a in OS cells decreased signifıcantly after treating with triptolide, and the
relative level of miR-181a in OS tissues was markedly higher than that in the
adjacent tissues. PTEN was reported and verifıed the direct target gene of miR-
181a. The overexpression of miR-181a decreased the inhibition of triptolide on
OS proliferation and promotion onOS apoptosis. Conclusion: Triptolide inhib-
ited the proliferation of OS by regulating miR-181a via targeting PTEN gene in
vivo and vitro.
#1483 Alteration of miR-186 expression modifıes inflammatory markers
in normal epithelial and prostate cancer cell models. Suman Suman,1 Domi-
nique Z. Jones-Reed,1 M. L. Schmidt,1 Geoffrey J. Clark,1 Carolyn Klinge,1
Shirish Barve,1 Kevin S. Kimbro,2 La Creis R. Kidd1. 1University of Louisville,
Louisville, KY; 2North Carolina Central University, Durham, NC.
Dysregulation of miRNAs and chronic inflammation are strongly implicated
in the development of various malignancies, including prostate cancer (PCa).
Previously, our lab identifıed several inflammatory and immune response se-
quence variants inCCL5 andCCR5 signifıcantlymodifıedPCa risk. Recently, we
propose an oncogenic role for miR-186-5p based on its up-regulation in serum
from PCa patients and metastatic PCa cell lines. Moreover, miR-186-5p inhibi-
tion reduced proliferation, anchorage independent growth and invasion inmet-
astatic PC cells (PC3, MDA-PCA-2b). We hypothesize dysregulation of inflam-
matory and immune response markers may enhance immune surveillance
leading to a reduced aggressive tumor phenotype. Following modulations in
miRNA-186 levels in normal prostate epithelial (RWPE1) and metastatic PCa
(PC3) cell lines, we evaluated alterations inmRNAexpression usingmicro-array
analysis. Ectopic expression of miRNA-186 in the RWPE1 resulted in a 1.3-2.6-
fold down-regulation in TLR2, IRAK2, CCL20, IL1RAP, IL1RAP, IL15, and
IL17RD (FDR p-value 
7.8x1006). Whereas, inhibition of miR-186 in PC3
cells corresponded with a 1.4-fold up-regulation of IL18R1 (p0.0095). Nota-
bly, these inflammatory markers are involved in cell invasion (TLR2), apoptosis
(IL17RD), tumorigenesis (TLR2, IRAK2) and autoimmune diseases (CCL20).
Validation of these targets is underway using qRT-PCR, western blots and lu-
ciferase reporter assays. We will assess the mechanism by which these miR-186
targets suppress aggressive cancer behavior using knock-out and knock-in cell
and ultimately animalmodels. Future studiesmay identify inflammatory targets
that may guide immune therapies for the effective treatment of aggressive pros-
tate cancer.
#1484 Genome wide study reveal microrna based methylation phenotype
in oral cancer.Roshni Roy,1AniruddhaChatterjee,2NavonilDe Sarkar,3 Bidyut
Roy1. 1Indian Statistical Institute, Kolkata, India; 2Dunedin School of Medicine,
Dunedin, New Zealand; 3Fred Hutchinson Cancer Research Center, Seattle, WA.
Introduction: Oral cancer is one of the leading causes of cancer burden in
India. Studies over the years have enforced the role of deregulated microRNA
expression in oral cancer development and progression. Incidentally not much
is known about the cause of microRNA deregulation or to what extent can it be
attributed to methylation. Established genome wide microarray platforms like
450K Illumina Bead Chip have probes for very limited number of microRNAs
along with restriction on distance of the probes from microRNA transcription
start site.Wehave used genomewidemethylation sequencing approachRRBS to
get deeper insight on microRNA methylation. Aim: Genome wide methylation
profıle of 15 paired oral cancer and adjacent normal tissue was compared to
generate a detailed map of microRNA methylation in oral cancer. The methyl-
ation results were further correlated tomicroRNA expression data generated on
a subset of these samples. Methodology: RRBS based global methylation se-
quencing of 15 pairs of samples was conducted on HiSeq 2500 with an average
10X depth. Analyses were done using DMAP software. Previously generated
TLDA based microRNA expression data was used for correlation analysis. Re-
sult: Similar to protein coding genes, microRNAs also showed methylation
based clustering. Interestingly majority of methylation hits were more than 2kb
upstream of miRNA transcription start site which is generally not considered in
known microarrays. Distribution of hypo and hyper methylation sites is differ-
ent across the various CpG features like cores and shelves as well as across
chromosomes. MicroRNAs like mir-181c, miR-99b, miR-23a among others
showed signifıcant negative correlation between methylation frequency and ex-
pression level. IPA based pathway analysis emphasized repression of apoptosis
and cell death pathways along with activation of cell proliferation and colony
formation. Conclusion: Understanding the role of methylation in microRNA
deregulation could help us detect and possibly prevent a chain of events, which
lead to disrupted pathways eventually leading to cancer, at the onset.
#1485 Measuring relative utilization of aerobic glycolysis in breast cancer
cells by positional isotopic discrimination. Da-Qing Yang, Margot Cleary.
University of Minnesota, Austin, MN.
Cancer deaths, including breast cancer, are caused bymetastasis of themalig-
nant tumors to distant locations. However, currentmethods of detection cannot
distinguish pre-invasive breast cancer from noninvasive breast tumor or benign
breast disease. Population-wide mammographic screenings have led to in-
creased detection of ductal carcinoma in situ orDCIS, noninvasive, proliferative
cells contained by the basement membrane of the terminal ductal lobular unit.
DCIS is usually not associatedwithmetastasis and/or cancer death. Each year, in
the US alone, about 1.5 million of women who have been diagnosed with DCIS
or a suspicious lump/lesion by mammography will require resection or breast
biopsy after diagnosis for further pathologic analysis. However, 80-85% of
biopsies result in noninvasive breast disease or benign fındings. As a result, a
considerable number of patients suffer from side effects caused by breast biopsy
and/or overtreatment. Therefore, there is an urgent need to fınd a biomarker for
pre-invasive breast cancer. The ability of cancer cells to produce lactate through
aerobic glycolysis (the Warburg effect) is a consistent hallmark of cancer, in-
cluding breast cancer. Recent advancements in liquid chromatography-mass
spectrometry (LC-MS) technology have signifıcantly improved the sensitivity of
this method compared to traditional NMR or GC-MS-based technologies,
which make it feasible to detect very low concentrations of small molecules or
metabolites. We have recently established a positional isotopic labeling and LC-
MS-based targetedmetabolomics method that can directly measure the conver-
sion from [1-13C]glucose to [3-13C]lactate through glycolysis. Our results show
thatmetastatic breast cancer cells exhibit a dramatically increased production of
[3-13C]lactate from [1-13C]glucose even under aerobic conditions as compared
to low- or noninvasive breast cancer cell lines. We found that the rate of aerobic
glycolysis is closely correlated with glucose uptake and lactate production in
breast cancer cells. We have also observed signifıcantly elevated production of
[3-13C]lactate in serum samples of early stage metastatic mammary tumors de-
veloped inmice. Since elevated levels of lactate are closely correlated to increased
tumor aggressiveness, these results suggest that monitoring of lactate produc-
tion from glycolysis by targeted metabolomics may provide a biomarker for
pre-invasive breast cancer. These results will pave the way for further explora-
tion of the elevated production of lactate as a promising biomarker for pre-
invasive breast cancer and for assessment of therapeutic response in clinical
trials.
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#1487 ONC201 kills breast cancer cells by inhibitingmitochondrial respi-
ration.Yoshimi Greer,1 Samuel Gilbert,1 Celia Islam,1 Yun Ji,1 Luca Gattinoni,1
Christina Stuelten,1 Natalie Porat-Shliom,1 Roberto Weigert,1 Xiantao Wang,2
MarkusHafner,2 KunioNagashima,1DonnaVoeller,1 Stanley Lipkowitz1. 1NCI,
Bethesda, MD; 2NIAMS, Bethesda, MD.
Background: ONC201 is a small molecule originally identifıed as a TRAIL
inducing compound currently being tested in phase1/2 clinical trials inmultiple
cancer types. Two recent studies reported that ONC201 also induces an atypical
stress response mediated in part by ATF4 and CHOP. Methods: ONC201 was
obtained fromOncoceutics, Inc. Recombinant GST-TRAIL was prepared in the
laboratory. Cell viability was tested with MTS assay and CellTiter-Glo lumines-
cent cell viability assay. ATP level was measured with CellTiter-Glo 2.0 assay.
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RNAseq and western blotting were performed to investigate change of gene
expression. Mitochondrial respiration was monitored by Seahorse XF analyzer.
Live cell imaging was performed to examine the mode of cell death. Confocal
microscopy and electron microscopy analysis were performed to study mito-
chondrial morphology. Results: We tested the effects of ONC201 on 18 human
breast cancer cell lines that represent ER, HER2 amplifıed, TNBC basal A and
TNBC basal B breast cancer. ONC201 reduced cell viability in breast cancer cell
lines in all subtypes testedwith IC50s ranging from0.8-5M, similar towhat has
been reported for other cancer cell types. Unexpectedly, ONC201 toxicity was
not dependent on TRAIL receptors or caspases and live cell imaging revealed
ONC201 induces cell membrane ballooning followed by rupture. By contrast,
GST-TRAIL induced TRAIL-receptor dependent caspase mediated death and
classic apoptosis morphology. These results suggest that ONC201 kills breast
cancer cells via a caspase-independent, TRAIL-receptor-independent mecha-
nism distinct from TRAIL-induced apoptosis. Western blots revealed that
ONC201 induces the stress pathway proteins ATF4 and CHOP, consistent with
the recently published observations. ONC201 also induced phosphorylation of
AMP-dependent kinase (AMPK) and depletion of cellular ATP in multiple
breast cancer cell lines. Seahorse XF analysis found that ONC201 inhibited mi-
tochondrial oxygen consumption rate but did not inhibit glycolysis asmeasured
by the extracellular acidifıcation rate. Both ONC201-induced toxicity and ATP
depletion were enhanced when cells were cultured in non-glucose (galactose)
medium. Supplementing glucose to cells grown in galactose medium partially
prevented ONC201-dependent ATP depletion, induction of phospho-AMPK,
ATF4 and CHOP, and cell death. These data are consistent with an inhibition of
oxidative phosphorylation (OxPhos) by ONC201. RNAseq revealed ONC201
inhibits expression of multiple mitochondrial genes involved in OxPhos and
othermitochondrial functions, andwestern blot confırmed those fındings. Con-
focal and electron microscopic evaluation revealed abnormal mitochondrial
morphology. Conclusion: Our data demonstrate that ONC201 can kill breast
cancer cells by a novel mechanism involving disruption of mitochondrial mor-
phology and inhibition of mitochondrial respiration.
#1488 Altered skeletal muscle mitochondrial function and redox biology
with chemotherapy and exercise in a colorectal cancer mouse model. Mal-
colm Andrew West,1 Alexandrina Roman,1 Ronan Astin,2 Sian Pugh,1 Berna-
dette Fernandez,1 Annette Hayden,1 Judith Cave,3 Eleanor Jaynes,4 John N.
Primrose,1 Sandy Jack,1 Michael P. Grocott,1 Andrew Murray,5 Martin
Feelisch,1 Alexander Mirnezami,1 Timothy Underwood1. 1University of South-
ampton, Southampton, United Kingdom; 2University College London, London,
United Kingdom; 3University Hospital Southampton, Southampton, United
Kingdom; 4University Hospitals Southampton, Southampton, United Kingdom;
5University of Cambridge, Cambridge, United Kingdom.
Background: Chemotherapy improves outcomes for patients with gastroin-
testinal cancer, but carries associatedmorbidity. Platinum-based chemotherapy
adversely impacts fıtness, invivomitochondrial function, and cellular redox sta-
tus in humans, however the mechanisms are poorly understood. Exercise inter-
ventions mitigate against this, but interactions between the effect of the cancer,
chemotherapy, and exercise intervention are poorly understood. Using a colo-
rectal cancer (CRC) mouse model we investigated changes in skeletal muscle
oxidative phosphorylation (OxPhos) capacity and redox biology with chemo-
therapy and exercise. Method: SCID mice (n48) were randomized to laparot-
omywith (Ca) orwithout (NCa) orthotopic caecal injection ofDLD-1CRCcells.
CRC established over 8 weeks then mice were randomized to 1) 3 cycles of
intra-peritoneal (IP) chemotherapy (Chemo; 5FU 5mg/kg, Oxaliplatin 10mg/kg
and Leucovorin 90mg/kg) followed by interval exercise-training 2) Chemo and
no exercise 3) IP saline sham (Sal) with exercise or 4) Sal with no exercise. Blood
was collected pre and post-Chemo and at death (post-exercise), and markers of
oxidative stress measured. Soleus muscle mitochondrial function was analyzed
using high-resolution respirometry. Measurements included maximum Ox-
Phos capacity (PIII), Complex I and II capacities and the ratio of octanoyl-
carnitine to pyruvate-supported respiration (FAO). Histopathological cae-
cal examination was undertaken to determine cancer response. Results:
Chemotherapy alone resulted in 37% lower OxPhos capacities in sham mice
(p0.011), whilst FAOwas 40% lower (p0.004). Cancer alone resulted in 38%
lowerOxPhos capacities (p0.012). In combinationwith cancer, chemotherapy
resulted in OxPhos capacities that were 42% lower than in mice with cancer but
no chemotherapy (p0.007), along with 51% lower Complex I (p0.001) and
42% lower Complex II (p0.007) capacities. In sham mice (NCaSal), exercise
resulted in 33% greater Complex II activities (p0.042), but exercise did not
alter mitochondrial function in any other group. Total plasma protein content
(TPPC) increased with time in the CaSal (32%) and the NCaSal mice (23%),
whilst it decreased with chemotherapy (CaChemo -20%, NCaChemo -10%).
Oxidative stress increased with chemotherapy and exercise, however explor-
atory interaction analyses are ongoing. Complete histopathological response
was seen in 2 of 6 CaChemoEx animals. No other complete response was seen.
Conclusion: Chemotherapy and cancer alone were associated with a loss of
oxidative capacity, with a greater reduction when combined. Chemotherapy
alone and with cancer caused a shift away from FAO and reduction in TPPC.
Though we demonstrated an exercise effect in sham mice, exercise did not in-
crease OxPhos capacity, nor did it ameliorate the effects of cancer and chemo-
therapy. A more intense exercise intervention may be required.
#1489 Targeting themitochondrial enzyme proline dehydrogenase with a
mechanism-based irreversible inhibitor induces selective mitochondrial
stress and enhances breast cancer cell death under hypoxia. Gary K. Scott,
Katya Frazier, Christina Yau, Beatrice Becker, Mauricio Ortega, Christopher C.
Benz. Buck Inst. for Research on Aging, Novato, CA.
Proline dehydrogenase (PRODH) is a p53-inducible inner mitochondrial
membrane flavoprotein functionally linked to electron transport for proline
catabolism and intracellular ATP production, particularly under nutrient stress
conditions. We have previously shown that in breast cancer cells, PRODH and
glutaminase (GLS1) transcript levels are inversely correlated, supplying anaple-
rotic glutamate to triple-negative (GLS1) and luminal (PRODH) breast cancer
subtypes by different means; and that siRNA knockdown or competitive inhi-
bition of PRODH induces synthetic lethal interactions with both GLS1 inhibi-
tion and p53 upregulation in various malignant (ZR-75-1, DU4475, MCF7) but
not normal (MCF10A) breast epithelial models. In the present study we have
synthesized and structurally modeled a novel mechanism-based irreversible
(suicide) inhibitor of PRODH, N-propargylglycine (PPG), that shows more
than 2-fold greater capacity to inhibit PRODHactivity in isolatedmitochondrial
assays when compared to competitive PRODH inhibitors (L-tetrahydrofuroic
acid, THFA; or 5-oxo-2-tetrahydrofurancarboxylic acid, 5-oxo). Modeling hu-
man PRODHpredicts a post-reactive PPG structure with PPG covalently linked
to the enzyme pocket’s FAD moiety, producing pocket distortion that does not
occur with competitive PRODH inhibitors. Reflecting PPG’s irreversible bind-
ing to PRODH, mitochondria isolated from PPG treated ZR-75-1 cells are un-
able to catabolize proline despite being able to effıciently catabolize malate; in
contrast, isolated mitochondria from 5-oxo treated cells remain effıcient at ca-
tabolizing both proline andmalate. Unexpectedly, we observed that PPGbut not
the competitive inhibitors induces selective degradation of mitochondrial
PRODH protein levels within 24 h of cell culture treatment followed by loss of
other mitochondrial proteins like complex-I NDUFS1 but not by concomitant
loss of cytosolic FAD-containing proteins like MTHRF. MitoTracker assays
confırm the selective cellular loss of mitochondrial mass in ZR-75-1 cells within
24 h of PPG treatment. To confırm that suicide inhibition of PRODH can also
induce synthetically lethal metabolic interactions, breast cancer cells (MCF7)
were cultured under normoxic (20% O2) or hypoxic (1% O2) conditions and
then treated with PPG and a p53 upregulator known to induce PRODH expres-
sion (MI-63). Cell viability demonstrated that during hypoxia PPG with p53
upregulation synergistically reduces cell survival at 48 h, confırming the syn-
thetic lethality of this treatment combination. Altogether, these fındings support
the preclinical development of suicide PRODH inhibitors as potential cancer
therapeutics capable of inducing mitochondrial stress, exploiting synthetically
lethal metabolic conditions, and selectively enhancing cancer cell death.
#1490 Role of sub-cellular specifıc reactive oxygen species in heart regen-
eration after cancer therapy. Salim Abdisalaam, Souparno Bhattacharya, Kala-
yarasan Srinivasan, Shibani Mukherjee, Hesham A. Sadek, Aroumougame
Asaithamby. UT Southwestern Medical Center, Dallas, TX.
Introduction: Cardiovascular disease and cancer are the two leading causes of
morbidity andmortality worldwide. As advancements in radiation therapy (RT)
have signifıcantly increased the number of cancer survivors, the risk of radia-
tion-induced cardiovascular disease in this group is a growing concern. How-
ever, the molecular mechanism of radiation-induced heart failure is still elusive.
Recently, it has been discovered that the reactive oxygen species (ROS)-medi-
ated oxidative DNA damage is the primary upstream mechanism that prevents
cardiomyocyte proliferation. Therefore, elucidating the spatial and temporal
aspects of ROS production will lead to the development of countermeasures to
prevent heart injury following chest radiotherapy. Methods:We have generated
GSHredoxpotential (Grx-roGFP)ROSprobe targeted to cytoplasm, chromatin,
nucleolus, telomere, nuclear inner membrane and heterochromatin. These
probes have been inserted into cardiomyocytes specifıc AAV9 vectors which
were used to infect cardiomyocytes both in vitro an in vivo. For in vivo study, we
infected three months old mice with high-titer AAV particles via tail vein injec-
tion and then exposed to chest-only radiation (5-10 Gy). At different post-
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radiation times, fresh heart slices of 300-500M thickness were either mock- or
treated with mitochondrial electron transport complex (ETC) inhibitors and
then subjected to live tissue imaging using a confocal microscope. Results: In-
terestingly, our results showed that the distribution of basal ROS levels is not
uniform in different sub-nuclear compartments. Signifıcantly, upon the induc-
tion of oxidative stress, the ROS levels was elevated in all the cellular compart-
ments, but the extent of ROS level was signifıcantly higher in the cytoplasm.
Similarly, radiation altered ROS levels in all the cellular compartments; however
the effect of radiation on the ROS levels was sub-nuclear compartment-specifıc.
Intriguingly, we found that the complex IV of the ETCwas critical for themain-
tenance of ROS levels in different cellular compartments as compared with
complexes I and II. Conclusion and Future Directions: Our data clearly indicate
that the spatial and temporal levels of ROS are not uniformacross the cell and the
mitochondrial ETC plays a major role in regulation ROS levels in different
sub-nuclear compartments. The results obtained from this study can be utilized
to develop sub-cellular compartment specifıc targeted both genetic and pharma-
cological ROS scavengers that will help to regenerate adult heart by re-activating
the proliferative capacity of cardiomyocytes following cancer therapy. Finally,
our novel approach can be applied to assess alterations in ROS levels in different
cancers. Funding: This work was supported by the NASA (NNX13AD57G/
NNX15AE06G) CPRIT (RP160520) and NIH R01AG053341 grants.
#1491 Mitochondrial dysfunction from defective Cytochrome oxidase
complex induces tumorigenic phenotype. Satish Srinivasan,Manti Guha,Gor-
don Ruthel, Hiroshi Nakagawa, Narayan Avadhani.University of Pennsylvania,
Philadelphia, PA.
Mitochondrial defects that affect activity of the electron transport chain
(ETC) complexes are associated with several diseases including cancer. Dys-
functional mitochondria resulting from mitochondrial DNA (mtDNA) altera-
tions or exposure to xenobiotics have been shown to initiate retrograde signaling
pathway characterized by disruptedmembrane potential, elevated cytosolic cal-
cium and activation of Calcineurin, a calcium dependent phosphatase. In some
cell types these events form the basis for triggering transcriptional reprogram-
ming that converts non tumorigenic cells to tumorigenic phenotype. Cyto-
chrome oxidase (CcO) is the terminal enzyme of the ETC that catalyzes the
transfer of electrons from reduced cytochromeC to oxygen. All themutations of
CcO subunits identifıed as prevalent in various cancers like prostrate, pancre-
atic, colon and ovarian cancers have been found in mtDNA encoded subunits.
Effect of loss of nuclear subunits leading to reducedCytochrome oxidase activity
on tumor progression are notwell studied.Nuclear subunits IVi1 andVbofCcO
are susceptible to various stress conditions like exposure to long term hypoxia,
ischemia-reperfusion and treatment with ethanol resulting in selective degrada-
tion and loss of activity. Here we report the activation of retrograde signaling by
loss of these subunits. Genetic silencing of the subunits IVi1 and Vb, and loss of
activity resulted in metabolic shift to glycolysis and was accompanied by in-
creased glucose utilization. Disruption of the CcO complex activated many of
the hallmark factors of Ca2/Calcineurin mediated retrograde signaling. Im-
portantly, rescue of the CcO defıciency by overexpressing CcO subunits or by
inhibitors of retrograde signaling pathway attenuated the phenotypic changes
such as anchorage independent growth and increased invasive potential. Fur-
ther, esophageal tumor sections from human patients revealed reduced CcO
subunits IVi1 and Vb in the center of the tumor mass suggesting a pathological
signifıcance of these fındings. Our results show that mitochondrial ETC defect
initiates a retrograde signaling and induces genes with major roles in tumor
development. (Supported by NIH grants CA-22762 and GM-34883)
#1492 Chemical approaches to development of mitochondrial-targeted
Hsp90 inhibitor in anti-cancer therapeutics: Mechanism and structure
change ofmitochondrialHsp90. SungHu,NamGuYoon, ByoungHeonKang.
Ulsan National Institute of Science and Technology(UNIST), Ulsan, Republic of
Korea.
TumorNecrosis FactorReceptor-AssociatedProtein 1 (TRAP1), amember of
the heat shock protein 90 (Hsp90) which located in mitochondria, is thought to
promote tumor cell survival and to reprogram energy metabolism in cancer.
Previous studies have demonstrated that the inactivation of TRAP1 selectively
induced mitochondrial dysfunction and cell death in cancer cells. Therefore,
TRAP1 has been suggested as an emerging target protein for anti-cancer drug
development. Isopropyl amine of the Hsp90 inhibitor, PU-H71, was replaced
with themitochondria-targetingmoiety, triphenyphosphonium, to produce the
mitochondria-accumulating TRAP1 inhibitor, SMTIN-P01. To further opti-
mize SMTIN-P01, we have synthesized several SMTIN-P01 derivatives includ-
ing TPP-PU-X03 with potent TRAP1 inhibitory activities. TPP-PU-X03 in-
creased TRAP1 ATPase enzyme activity while suppressing chaperone activity,
suggesting asymmetric effect on dimeric TRAP1 chaperone functions. Electron
microscopic analyses showed TPP-PU-X03 shift TRAP1 conformation from
open to close conformation, while other TRAP1 or Hsp90 inhibitors stabilizes
open conformation. Importantly, TPP-PU-X03 showed improved mitochon-
dria dysfunction and enhanced cytotoxicity to various cancer cells in vitro and in
vivo. Collectively, the structure based optimization of current TRAP1 inhibitors
may generate potent anti-cancer drugs with novel mechanisms of action.
#1493 LonP1 is required for tumormaintenance and growth. Benjamin S.
Amidon, Dongyun Wu, John Bradley, Jingya Ma, Christopher Tsu, Elizabeth
Carideo-Cunniff, Vihren Kolev, James Garnsey, Pooja Shah, Erik Koenig, Hua
Liao, Courtney Cullis. Takeda Pharmaceuticals, Inc, Cambridge, MA.
Proper mitochondrial function is critical for energy production and the cy-
cling of metabolites required for tumor establishment and growth. LonP1 is an
ATP-dependent serine protease that is critical for maintaining mitochondrial
protein homeostasis by degrading misfolded and damaged proteins in the mi-
tochondrial matrix. Knockdown of LonP1 has been shown to reduce tumoro-
genesis and is consistent with the model that requires properly functioning
mitochondria for tumor establishment. It is unclear what the role of LonP1 is in
tumormaintenance and growth from an established tumor, therefore the LonP1
gene was mutated and complemented by a doxycycline-inducible copy of
LonP1. These complementation clones have the ability to establish tumors in
vivo in the presence of doxycycline, however upon doxycycline withdrawal the
tumors regress and show evidence of apoptosis. These xenograft lines permit
unique insight into not only potential LonP1 substrates but also the direct and
indirect effects from loss of mitochondrial matrix protein homeostasis. Com-
parison and contrast of these complemented cell lines in vitro and in vivo by
expression and proteomic analysis will be discussed.
#1494 Interethnic germline variants in mitochondrial DNA polymerase
(POLG1) inducemitochondrial dysfunction and confer tumorigenic proper-
ties. Prachi Bajpai,1 Bhupendra Singh,1 Kjerstin M. Owens,2 Vinodh Srinivasa-
sainagendra,3 Hemant K. Tiwari,3 Keshav K. Singh4. 1Department of Genetics,
University of Alabama at Birmingham, Birmingham, AL; 2Roswell Park Cancer
Institute, Buffalo, NY; 3Department of Biostatistics, University of Alabama at
Birmingham, Birmingham, AL; 4Department of Genetics, Pathology, Environ-
mental Health, Center for Free Radical Biology, Center for Aging, University of
Alabama at Birmingham, UABComprehensive Cancer Center, BirminghamVet-
erans Affairs Medical Center, Birmingham, AL.
Purpose: Germline variants contribute to large fraction of the diversity ob-
served among different ethnic groups and could give better insights in genetic
predisposition and susceptibility from one population to another for certain
disease including cancer. Decreased mitochondrial OXPHOS is one of the most
common phenotypes of cancer cells. Mitochondrial DNA (mtDNA) depletion
impairsOXPHOS and adaptivemetabolic responses. In this context, DNApoly-
merase  (POLG1) is known to function in human mitochondria and performs
critical function of mtDNA replication and repair. POLG1 is the most frequent
target of gene mutation and is involved in variety of mitochondrial diseases.
POLG1 protein consists of exonuclease, linker and polymerase domain, each
with distinct functions. Mutations in exonuclease domain leads to erroneous
proofreading and is responsible for increased mutations in mtDNA whereas
mutations in polymerase domain leads to erroneous replication and hence de-
pletion in mtDNA. Germline variants in these domains of POLG1 may serve as
important signature markers in association studies of individuals in a popula-
tion study. Through our present study, we identifıed germline variants, exam-
ined copy number variation, expression and regulation of POLG1 gene in hu-
man cancers. We provide evidence that altered POLG1 expression as well as
germline variations in POLG1 gene contribute to tumorigenesis. Methods: A
comprehensive race based bioinformatics analysis of POLG1 gene in European-
American and African-American was conducted and several unique germline
mutations were discovered. To analyze functional contribution of these unique
germline mutations in tumor progression, these unique prevalent mutations in
the evolutionary conserved regions of exonuclease and polymerase domains we
generated by site directed mutagenesis and functional and tumorigenic analysis
was performed. Results: We observed marked differences in copy number vari-
ation of POLG1 through cBioPortal and Cosmic databases and validated the
analysis in primary tumors and cancer cell lines. Our results also indicate that
mtDNA copy number in cancer cell is governed by regulation of POLG1 meth-
ylation and demethylation status, suggestive of epigenetic regulation of POLG1.
We identifıed amitochondrial disease causingmissense variation in polymerase
domain of POLG1 at amino acid 1143 (E1143G) to be 25 timesmore prevalent in
European-Americans when compared to African-Americans population. Ex-
pression of this germline variant (E1143G) increased glucose consumption, de-
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creased ATP production and increased matrigel invasion. Discussion/ Conclu-
sion: We demonstrate that POLG1 is epigenetically regulated and its unique
germline variants contribute to disruption ofmitochondrial function. Thus con-
tributes to differences in increased predisposition to cancer in inter-ethnic pop-
ulation.
#1496 Connecting themetallome withmetabolism in ovarian cancer. Eric
D. Shide, Lauren Amable. NIMHD, Bethesda, MD.
Ovarian cancer has historically been diagnosed late stage and lacks effec-
tive biomarkers for detection and prognosis. The deregulation of metabo-
lism and signaling cascades inherent of cancer may contribute to aberrant
levels of metal within cells. Biological processes essential for cell prolifera-
tion require metals for enzyme cofactors, signaling molecules, and structural
components. Metallomics is the study of the comprehensive, dynamic metal
profıle within cells. The goal of our study was to characterize the ovarian
cancer metallome at the level of whole cell and mitochondria in comparison
to non-cancer. Additionally, cellular metabolism was analyzed to connect
the mitochondrial (mito-)metallome to mitochondrial function. Ten human
ovarian cancer cell lines were used for experiments: A2780, CAOV3, A2780/
CIS, A2780/CP70, ES2, OVCAR3, OVCAR5, SKOV3, TOV112, and TOV21.
Three non-cancer human ovarian cell lines of epithelial and fıbroblast origin
served as controls. Inductively coupled mass spectrometry (ICP-MS) was
used to evaluate the metallome by measuring the following metals: calcium
(Ca), copper (Cu), iron (Fe), magnesium (Mg), manganese (Mn), molybde-
num (Mo), phosphorous (P), sulfur (S), selenium (Se), and zinc (Zn). An
XF24 Seahorse analyzer was used to measure cellular metabolism and mito-
chondrial function in the ovarian cancer and non-cancer cell lines. Our
results demonstrated that there was a distinct metal profıle at the level of the
whole cell and mitochondria in ovarian cancer cells compared to non-cancer
ovarian cells. The whole cell ovarian cancer metallome consisted of in-
creased Mg, P, and Cu, and decreased Fe, Mn, and Se in comparison to
non-cancer. The cancer mito-metallome consisted of increased Mg, P, Cu,
Zn, Se, and Ca. Referencing established literature of the known metals that
serve as cofactors for mitochondrial proteins, the relationship between the
mito-metallome and functional metabolic pathways was established.
Changes in cellular metabolism were reflected by changes in the mito-met-
allome. Our study was the fırst to evaluate an extensive panel of metals
simultaneously in themitochondria and bridge the uniquemetal signature of
ovarian cancer to cell metabolism. Future proteomics studies will be used to
further validate the connection of metals to cellular function. Metallomics
and the ovarian cancer cell metallome provide further understanding of how
cancer deregulates the metallome and how metallomics may provide an av-
enue for identifying new cancer biomarkers and allow for effective targeting
of cancer with chemotherapy.
#1497 BPM31510modulates mitochondrial complex activity to influence
oxidative stress in effectuating cell death in multiple cancers. Tulin Dadali,
Katerina Krumova, Anne R. Diers, Pallavi Awate, Ryan Ng, Arleide Lee,
Stephane Gesta, Vivek K. Vishnudas, Rangaprasad Sarangarajan, Niven R.
Narain. BERG, LLC, Framingham, MA.
Dysregulatedmitochondria play amultifaceted role in tumorigenesis through
regulation of energy production, biomass, redox state, and engagement of cell
death pathways. Perturbations inmitochondrial fluxes (i.e inhibition of electron
chain complexes activity, impaired electron flow) have substantial effects on cell
viability, suggesting that targeting mitochondrial function could be effective for
therapeutic response in cancer. BPM31510, containing oxidized coenzyme Q10
elicits an anti-Warburg effect is currently in phase II clinical trials for solid
tumors. Previously, we have demonstrated the anti-cancer properties of
BPM31510 in breast and pancreatic xenograft models. Here, we examined the
mechanism of action of BPM31510 in vitro. Using a multi-cancer cell panel,
BPM31510was shown to be consistently and selectively cytotoxic to cancer cells,
compared to normal and non-tumorigenic controls, and sensitivity did not cor-
relate to cell doubling time or mutational status. Treatment with BPM 31510
(EC50) in breast and pancreatic cancer cells resulted in a time- and dose-depen-
dent decrease inmitochondrialmembrane potential which preceded an increase
in early and late apoptosis cells, suggesting BPM31510 initiates a mitochondrial
mediated cell death pathway. Using a fluorescently labeled CoQ10 we were able
to trace the subcellular location of the CoQ10, which predominantly accumu-
lates inmitochondria and lipid droplets in a time dependent manner. Addition-
ally, themitochondrial enrichment of CoQ10 is accompanied bymorphological
changes that varied amongst the different cancer cell types. As CoQ10 is a redox
molecule required for electron transfer activity between complexes, we hypoth-
esized that disruption of Q-pool homeostasis would alter complex activity. To
investigate this, Complex driven respiration was measured in cells treated with
BPM31510 and compared to untreated. Alterations in mitochondrial respira-
tion characterized by a dose-dependent decrease in succinate (Complex II) and
glycerol-3-phosphate (Complex III)-fueled respiration were observed in cells
treated with BPM31510, while no changes were seen in pyruvate driven respira-
tion (Complex I), suggesting that BPM31510 specifıcally impairs respiration
responses that are more dependent on Q-pool functionality. As impairment of
the electron transport chain increases intracellular oxidative stress, we next in-
vestigated if BPM 31510 treatment increases ROS levels. After 24h treatment,
BPM31510 signifıcantly increasedROS levels in treated cancer cells compared to
untreated. Furthermore, BPM31510 induced death could be in part prevented
by co-treatment with antioxidants. Together, these data demonstrates
BPM31510 has anti-cancer activity in multiple cancer cell types and defıne a
unique and novel functional link betweenmitochondrial Q-pool disruption and
the mechanism of action of BPM31510.
#1498 Melatonin inhibits mitochondrial transcription factor A expres-
sion in glioblastoma U87MG cell culture inducing an anti-tumorigenic ef-
fect. Daiane G. Franco, Isabele F. Moretti, Suely K. Marie. University of Sao
Paulo, Sao Paulo, Brazil.
Melatonin, the major hormone of pineal gland, has been described to
induce intrinsic apoptosis in tumor cell, while it is inhibited in non-tumor
cell. In tumor cell, melatonin stimulates intracellular production of reactive
oxygen species (ROS) by a mechanism not completely understood. Here we
propose that melatonin inhibits the expression of the mitochondrial tran-
scription factor A (TFAM) in culture of glioblastoma (GBM) cell lineage,
leading to an increase of the production of ROS. TFAM is an important
mitochondrial protein that maintains the mitochondrial DNA (mtDNA)
integrity and consequently the oxidative phosphorylation. Human U87MG
GBM cell lineage was treated with melatonin (1 mM) for 72 h to evaluate the
expression of TFAM and the mtDNA copy number through Real Time PCR.
Proliferation, apoptosis, cell cycle and ROS production were also evaluated
by cytometry (Muse - Millipore Corporation) and the results were normal-
ized to control (vehicle: ethanol 0.3 %). Melatonin reduced the expression of
TFAM in 17.5 % compared to the control group, but had no effect on the
mtDNA copy number. Moreover, the incubation of U87MG with melatonin
induced a reduction in cell proliferation in 14.24 % 	 4.3 compared to
control, with an arrest of cell cycle in G0/G1 phase, which increased from
67.4 	 3.71 % to 72.78 	 3.18 % in the group treated with melatonin com-
pared to the control. Production of ROS presented an increase of 7.1 %, with
no signifıcant effect on apoptosis. These results suggest that TFAM maybe a
target for the melatonin function for an anti-tumorigenic effect through an
increase of ROS production, inducing a delay in the cell cycle and a reduction
of cell proliferation. The melatonin effect onTFAM maybe a novel signaling
pathway that could be explored for the control of GBM progression.
#1499 Role of mutations and expression change of mitochondrial func-
tion related nuclear genes in oral gingivobuccal squamous cell carcinoma.
Esita Chattopadhyay,1 Richa Singh,1 Roshni Roy,2 Bidyut Roy1. 1Indian Statis-
tical Institute, Kolkata, India; 2Baylor Research Institute, Dallas, TX.
Background: Mitochondria have long been suspected to have contribution in
progression and sustenance of cancer. But mitochondria related nuclear genes
have not been well-studied in oral cancer. The aim of this study is deciphering
the impact of somatic mutations and expression deregulation of mitochondria
related nuclear genes in oral gingivobuccal squamous cell carcinoma (GBSCC).
Methods: Nuclear-encoded genes which are functionally involved with mito-
chondria were enlisted from Mitocarta 2.0 and IMPI databases. Whole exome
sequencing was performed with 12 paired cancer-normal GBSCC samples and
somatic mutations in mitochondria related nuclear genes were extracted from
the data. Expression deregulation of mitochondria related nuclear genes were
quantifıed from whole transcriptome data of 12 paired cancer-normal GBSCC
samples. Expression was re-validated in another set of 12 cancer-normal paired
samples. 5 cancer-normal paired samples with whole transcriptome data were
also used for reduced representation bisulfıte sequencing (RRBS). Probable im-
pact of non-synonymous somatic mutations were predicted using SIFT and
POLYPHEN2 tools. Genes with possible damaging mutations and expression
deregulation were taken for literature search and KEGG pathway analysis to
understand their contribution in the function of mitochondria in GBSCC. Re-
sult: Total 1561 mitochondria related nuclear genes were identifıed from two
databases and included in the study. A total of 977 somatic mutations were
identifıed in 583 such genes in 12 oral GBSCC samples. These mutations were
distributed in exonic (346mutations), intronic (288mutations), splicing (4mu-
tations), UTR3= (270mutations) and UTR5= (69mutations) regions. Ten recur-
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rentlymutated genes (AK3,AK4,ATP10D,CASP8, ERBB4,MRPL10,NT5DC3,
RYR3, SMURF1and TP53) were identifıed in at least 25% (3/12) of samples.
Signifıcant expression deregulation in 147 mitochondrial related nuclear genes
was found from whole transcriptome data. Differential methylation was found
in some of these 147 genes in 5 oral GBSCC samples. Thirty-seven genes were
selected from147 genes for expression re-validation by qPCR and expressions of
32 genes were re-validated in another set of 12 GBSCC samples. Somatically
mutated and expression deregulated genes were different except two genes,
ACADMandNNT, which weremutated and deregulated. Literature survey and
KEGG pathway analysis revealed that most of the mutated or deregulated genes
were functionally involved with biological pathways like mitochondrial metab-
olism, oxidative phosphorylation, apoptosis and molecular transport. It indi-
cates possible disruption of these pathways in oral GBSCC. Conclusion: Mito-
chondrial function related nuclear genes may have signifıcant impact on oral
GBSCC in maintenance and progression, but needs to be validated in larger set
of samples.
#1500 Evaluating the effıcacy of limiting heme availability on growth and
progression of lung tumor. Poorva Ghosh, Sarada Preeta Kalainayakan,
Sanchareeka Dey, Sagar Sohoni, Li Zhang. UT Dallas, Richardson, TX.
Numerous studies support the importance of mitochondrial respiration in
tumorigenesis. Studies from our lab have demonstrated that mitochondrial res-
piration is intensifıed, and the levels of intracellular heme and hemoproteins are
elevated in Non-small cell lung cancer (NSCLC) cells. We also demonstrated
that lowering intracellular heme levels selectively decreases oxygen consump-
tion inNSCLC cells and inhibits cell migration and colony formation. Heme is a
central molecule for mitochondrial function and for all processes involved in
oxygen utilization. It serves as a prosthetic group in several oxidative phosphor-
ylation enzymes and other oxygen-utilizing hemoproteins. Most human cells
can synthesize heme de novo and uptake heme from the circulation. Further, a
number of epidemiological studies have shown that high heme intake is associ-
atedwith increased risk of several cancers, including lung cancer. The purpose of
the study is to determine the extent to which altering heme availability impacts
NSCLC tumor growth and development. To this end, we devised a two-pronged
approach to target both heme intake and heme synthesis to limit the heme
available to cells. Our lab synthesized a peptide to sequester heme from circula-
tion and thereby limit heme available for uptake. A well-known inhibitor of
heme synthesis is used to limit heme synthesis. NSCLC cells that express lu-
ciferase were implanted in NOD/SCIDmice to generate subcutaneous and lung
orthotopic xenografts. The mice were treated with the peptide alone and in
combination with an inhibitor. The tumor growth was monitored by non-inva-
sive bioluminescence imaging (BLI) using Perkin Elmer’s IVIS Lumina III Im-
ager. In subcutaneously implanted xenografts, our BLI data show that there is a
considerable reduction in radiance (total flux in photons per second) in the
treatment groups that received the peptide and a combination of peptide and
inhibitor. This trend was also observed in tumor volumes measured by calipers.
This observation is further corroborated in lung orthotopic xenografts, where
there is a signifıcant reduction in radiance in the treatment groups that received
the peptide and peptide-inhibitor combination. In all the cases the combination
of the peptide and the inhibitor had a greater effect than the peptide alone. Our
results indicate that combination of heme lowering agents works effectively in
limiting lung tumor growth and progression by limiting both heme uptake and
synthesis. Further studies are underway to discern the role of heme in lung
cancer growth and progression.
#1501 Sideroflexin4: Anovel regulator of ironmetabolism in ovarian can-
cer. Bibbin Paul,1 Miranda Lynch,2 Frank Torti,1 Suzy Torti1. 1University of
Connecticut Health, Farmington, CT; 2Los Alamos National Laboratory, Los
Alamos, NM.
The fıve year survival rate for women with ovarian cancer is 9-34%. This
high mortality is due to late stage diagnosis, marginally effective treatment
and frequent disease recurrence. Alterations in metabolism have been widely
recognized as an important hallmark of cancer. Metabolism of the micronu-
trient iron is signifıcantly altered in many cancers, including ovarian can-
cers. The expression of genes governing iron transport (TFR1 and FPN), iron
storage (FTL and FTH) and iron regulation (IRP1 and IRP2) are signifıcantly
altered in ovarian cancer compared to normal ovarian epithelial cells, result-
ing in higher intratumoral iron retention. However, specifıc pathways of
intracellular iron utilization that are altered in cancer cells, and the func-
tional consequences of disrupting these pathways, remain poorly under-
stood. To identify pathways of iron utilization that are perturbed in ovarian
cancer, we analyzed the expression of genes involved in iron metabolism
using a publicly available microarray database of ovarian cancer and normal
oviduct (GSE69428). We observed that sideroflexin4 (SFXN4), an inner mi-
tochondrial membrane protein that is essential for mitochondrial respira-
tory homeostasis, was signifıcantly upregulated (p 0.002) in ovarian cancer
patient samples. We screened several ovarian cancer cell lines and observed
that SFXN4 was similarly up-regulated both at the mRNA and protein level
when compared to normal human ovarian surface epithelial cells. To test the
role of SFXN4 in ovarian cancer cells we performed knockdown and over-
expression studies. Knockdown of SFXN4 induced S and G2-phase cell cycle
arrest and reduced the ability of MDAH2774 and SKOV3 ovarian cancer
cells to form colonies. Further investigation revealed that modulation of
SFXN4 alters mitochondrial respiration by affecting iron-sulfur cluster bio-
genesis. Thus, knock-out cells exhibited impaired respiratory activity and a
phenotype similar to cells with defects in iron-sulfur cluster biogenesis, in-
cluding increased IRP-IRE binding and a decrease in IRP1/ACO1 aconitase
activity. Furthermore, SFXN4 knock-out decreased the activity of iron-sul-
fur cluster-containing enzymes such as mitochondrial aconitase and succi-
nate dehydrogenase. Based on these observations, we postulate that SFXN4
acts as a molecular mediator that channels the excess iron present in ovarian
cancer cells to iron-sulfur cluster-dependent metabolic pathways that favor
growth andmetastasis. SFXN4may be a potential druggable target in ovarian
cancer.
#1502 The link between NRF2 and mitochondria through the regulation
of miR-181c/mitochondria-encoded cytochrome c oxidase subunit-1. Mi-
Kyoung Kwak, Kyeong-Ah Jung, Donghyeok Kim, Sujin Lee. The Catholic Uni-
versity of Korea, Gyeonggi-do, Republic of Korea.
The nuclear factor erythroid 2-related factor 2 (NRF2) pathway is involved in
the environmental resistance of cancers by enhancing the antioxidant capacity.
In the current study, we investigated the potential link between NRF2 and mi-
tochondrial function in cancer cells. GlobalmiRNAexpression analysis ofHT29
and HCT116 identifıed miR-181c as an NRF2-silencing-inducible miRNA, and
miR-181c elevation was associated with the decrease in mitochondria-encoded
cytochrome c oxidase subunit-1 (MT-CO1), a mitochondrial genome-encoded
complex IV subunit of the electron transport chain. As a result of decreased
complex IV activity, NRF2-silenced cancer cells exhibited reduced levels of mi-
tochondrial membrane potential (MMP), oxygen consumption rate, and ATP
production. Notably, these changes induced adaptive activation of AMP-acti-
vated protein kinase- (AMPK) and thereby, NRF2-silenced cells were more
vulnerable to AMPK inhibitor-induced growth suppression. Similarly, mouse
tumor xenografts derived fromNRF2-silencedHT29 exhibitedMT-CO1 reduc-
tion and AMPK activation, thereby increasing responsiveness to the AMPK
inhibitor treatment. Collectively, we showed a novel link of NRF2 to cancer
mitochondria and AMPK signaling by elucidating miR-181c/MT-CO1 signal-
ing as an underlying molecular mechanism. These results also suggest that it
may an effective strategy to inhibit both NRF2 and AMPK to control adaptive
tumor responses.
#1503 A physiologically-based pharmacokinetic (PBPK) model of hy-
droxychloroquine.Keagan P. Collins, KristenM. Jackson, Daniel L. Gustafson.
Colorado State Univ., Fort Collins, CO.
Hydroxychloroquine (HCQ) is a lysotropic autophagy inhibitor that is being
used in over 45 clinical trials either alone or in combination with another che-
motherapeutic. Pharmacokinetic (PK) and pharmacodynamic (PD) studies
with HCQ have shown that drug exposure in the blood does not correlate with
autophagy inhibition in either peripheral blood mononuclear cells (PBMCs) or
tumor tissue (Autophagy 10:1415). HCQ exhibits primarily pH-driven PK and
has been shown, by way of heightened levels of autophagy markers, to generate
a therapeutic effect longer than PK data suggests. A physiologically-based phar-
macokinetic model (PBPK) was developed for HCQ to describe the tissue-spe-
cifıc absorption, distribution, metabolism, and excretion as well as lysosome-
specifıc sequestration. Physiologic parameters were adapted from literature, or
obtained from experimental data when necessary, and used to simulate physio-
logically-based HCQ PK following designated dosing regimen in mice and rats.
Experimentally derivedPKdata from these specieswere compared to simulation
generated data to drive model development and subsequently determine model
accuracy, achieving statistically-similar PK predictions of blood and tissues.
Through allometric scaling and species-specifıc parameter modifıcations this
model can be easily adapted for accurate prediction of HCQ PK in dogs and
humans, as determined by comparisonwith respective blood levels. The value of
this model lies in its ability to simulate HCQ PK in cancer patients with tumor
types deemed autophagy-dependent. Model data simulating HCQ uptake in a
neutral tumor compartment (pH  7.2) shows that peak concentration in the
lysosomes, the active site of the drug, is roughly four-fold higher than the peak
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concentration of lysosomes in an acidic tumor compartment (pH  6.8), yet
there is only a small change betweenwhole-tumor concentrations. This suggests
that the ability of HCQ to inhibit autophagy in acidic tumors would be signifı-
cantly reduced,which is currently being investigated through in vitro and in vivo
uptake of HCQ in MDA-MB-231 and MCF-7 tumor cell lines. Additionally,
HCQ PK exhibits large interpatient variability, thus model utilization is benefı-
cial in determining if therapeutic levels of HCQ are achieved at the tumor site
and the impact of variability in the local tumor environment on HCQ disposi-
tion. The flexibility and simulation capabilities of the developed PBPK model
also allows for investigation of howHCQ PK and subsequent autophagy inhibi-
tion may potentially be modifıed by other treatment modalities and suggest
dosing schedules to optimize therapeutic response.
#1504 Tumor-treating fıelds (TTFields) interfere with biological key
properties of glioma cells in vitro. Manuela Silginer, Michael Weller, Roger
Stupp, Patrick Roth. University Hospital Zurich, Zurich, Switzerland.
Tumor-treating fıelds (TTFields) are low amplitude alternating electric fıelds
which are supposed to exert anti-tumor effects by targeting dividing tumor cells
while sparing cells in the brain not undergoing cell division. Although this novel
therapeutic approach has shown encouraging results in phase III trials in glio-
blastoma, its biological effects on tumor cells have only been poorly understood.
Here, we investigated the effects of TTFields on glioma cells in vitro using the
inovitroTM system that allows the application of TTFields to cell cultures. Expo-
sure to TTFields potently induce autophagy and necroptosis and interfere with
the migration and invasion of long-term glioma cell lines, but also of glioma-
initiating. The combination of TTFields with irradiation or temozolomide
(TMZ) reduced viability and clonogenic survival in an additive or synergistic
manner. Further studies suggest that theO6-methyl-guanineDNAmethyltrans-
ferase (MGMT) status does not influence the effıcacy of TTFields and TMZ-
resistant glioma cells remain responsive to TTFields application, thus making
TTFields particularly attractive for the majority of glioblastoma patients with
tumors that are unlikely to benefıt from TMZ treatment. In summary, these
fındings demonstrate that the application of TTFieldsmay interferewith various
biological key properties of glioma cells and may allow for a more detailed
clinical evaluation of TTFields beyond the clinical data available so far.
#1505 Breast cancer cells treated withmitochondria targeted redox active
agents inducemitophagy. Thomas Biel, Ashutosh Rao. Food and Drug Admin-
istration, Silver Spring, MD.
Triphenylphosphonium (TPP) conjugated agents induce mitochondrial dys-
function in cancer cells. However, the onset of mitophagy to remove the dys-
functional mitochondria is unknown. Here, a series of mitochondria targeted
redox active agents (MTA) that contain TPPwere used to investigatemitochon-
drial dysfunction and mitophagy in MDA-MB-231 cells as compared to MCF-
12A cells. Three different MTAs were identifıed to induced mitochondrial de-
polarization and enhanced autophagic flux selectively in MDA-MB-231 cells.
Mitochondrial reactive oxygen species generation and respiration indicated that
MDA-MB-231 cells had a heighten sensitivity to MTA treatments. Using stably
expressing mt-mKeimaMDA-MB-231 andMCF-12A cell lines, a non-cell type
selective decline in mitochondrial alkalinity and altered mitochondrial mor-
phology was detected. Furthermore, FACS analysis of mt-mKeima revealed
MTAs induced lysosomal dependentmitochondrial degradation in the presence
of Bafılomycin, a lysosomal inhibitor. To confırmMTAs inducedmitochondrial
autophagy in MDA-MB-231 cells, MitoTracker Red preloaded GFP-LC3 ex-
pressing MDA-MB-231 cells were used to identify autophagosomes containing
mitochondria using confocal microscopy, in addition to coimmunoprecipita-
tion for the detection of an endogenous autophagy-related protein complex, and
immunoblot to for mitochondrial PINK1 accumulation. To translate these in
vitro studies to an in vivo rat SST-2 xenograph breast cancer model, tumor
mitochondrial extracts from rats treated withMitoQ demonstrated an accumu-
lation of mitochondrial PINK1. Collectively, these data suggest that mitochon-
drial agents selectively caused mitochondrial depolarization, PINK1 accumula-
tion and mitophagy in MDA-MB-231 cancer cells as compared to MCF-12A
healthy cells.
#1506 The Wnt signature of melanoma cells predicts their invasiveness,
autophagy activity, and their response to pharmacologically mediated au-
tophagy inhibition.AbibatouM.N. Ndoye,1 Anna Budina,1 Amanpreet Kaur,1
CurtisH. Kugel,1MarieWebster,1 Reeti Behera,1 Vito Rebecca,2 Ling Li,1Meen-
hard Herlyn,1 Ravi Amaravadi,1 Maureen Murphy,1 Ashani Weeraratna1. 1The
Wistar Institute, Philadelphia, PA; 2The University of Pennsylvania, Philadel-
phia, PA.
Melanoma is the most aggressive type of skin cancer and the leading cause of
death from skin cancer. As the incidence of melanoma continues to increase, it
is crucial to investigate the cellular and molecular mechanisms that lead to in-
vasion and metastasis. High autophagy has been shown to correlate with mela-
noma tumor aggressiveness and poor survival in patients, and is a common
mechanism of resistance to therapy. Autophagy inhibition leads to reduced lev-
els in Wnt5A in a breast cancer model, suggesting a cross-talk between Wnt5A
and autophagy in cancer. Our laboratory showed that Wnt5A is a driver of
invasion andmetastasis inmelanoma.  catenin, a canonicalWntmediator, has
been shown to negatively regulate autophagy in a colorectal cancermodel. Given
that Wnt5A downregulates  catenin, we hypothesized that autophagy pro-
motesmelanoma tumor aggressiveness through the regulation ofWnt signaling
and that in turn the Wnt signaling status of melanoma cells affects their au-
tophagy activity. Our results demonstrate thatmelanoma cells with highWnt5A
and low  catenin have higher autophagy levels compared to less aggressive
melanoma cells that have lowWnt5A and high catenin. To determinewhether
there is a feedback loop between Wnt signaling and autophagy, we inhibited
autophagy in invasive melanoma cells using lentivirus-mediated shATG5
knockdown and evaluated the effects of autophagy inhibition onWnt5A and 
catenin expression. We found that the inhibition of autophagy results in a de-
crease in Wnt5A and an increase in  catenin. Our data also demonstrate that
the Wnt signature of melanoma cells greatly affects their response to Lys05-
mediated autophagy inhibition both in vitro and in vivo. Wnt5A decreased
sensitivity to autophagy inhibitionwhile catenin increased sensitivity to Lys05
both in vitro and in vivo. Pre-clinical models and clinical trials demonstrate a
potential of autophagy inhibition for melanoma therapy; however, the clinical
effects are not consistent and do not yield signifıcant anti-tumor effects. This
study will provide a rationale for the development of therapeutic strategies that
more effıciently target autophagy in aggressivemelanomaby taking into account
the Wnt signaling status of melanoma cells.
#1507 Fatty acid oxidation mediated autophagy regulation in triple neg-
ative breast cancer.KwangHwa Jung, JunHyoungPark, Tirupataiah Sirupangi,
Sajna Vithayathil, Lee-JunWong, Benny A. Kaipparettu. Baylor College of Med-
icine, Houston, TX.
Compared to hormone regulated/responsive (ER) breast cancer (BC), triple
negative BC (TNBC) patients have a worse overall survival, a signifıcantly
shorter disease-free survival, and a shorter post-recurrence survival. Using
transmitochondrial cybrid (cybrid) (compares different mitochondria under a
common defıned nuclear background)-based discovery and validation in cell
lines, patient derived xenografts (PDXs) andBCclinical tissues/data, we recently
published that fatty acid oxidation (FAO) is a major energy pathway in TNBC.
We also showed that FAO is a major regulator of Src activation by autophos-
phorylation at Src Y419 inmetastatic TNBC. Our data suggest that inhibition of
FAO induce cell growth inhibition. Short-term treatment of FAO inhibitors
induces both cell cycle arrest and apoptosis.Weobserved cell cycle arrest inG1-S
phase in FAO inhibitor treated TNBC cells. Apoptotic markers like cleaved
Caspase-3 and cleaved PARP induced in FAO inhibited cells. Short-term treat-
ment of FAO inhibitor also showed induction of AKT pathway. Further analysis
on the role of FAO in TNBC suggests that FAO is a critical player in autophagy
signaling in TNBC. Long-term treatment with FAO inhibitors or knockdown of
FAO rate-limiting proteins carnitine palmitoyltransferase I (CPT1) induce au-
tophagic cell death with beclin-1 and LC3-II induction in TNBC. However, no
such phenomenon observed in estrogen receptor positive (ER) breast cancer
cell lines. Treatment with autophagy inhibitor 3-methyladenine (3-MA) abol-
ished the FAO-induced cell growth inhibition and reduced beclin-1 and LC3-II
induction. Ongoing studies using knock-down and over expression approaches
focus on the role of specifıc pathways that are responsible for mitochondrial
energy reprogramming regulated autophagy signaling in metastatic TNBC.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Targeting Aberrant Transcription in Cancer
#1508 MTL-CEBPA activates the transcription factor CEBPalpha leading
to inhibition of hepatocellular cancer growth. Nagy Habib,1 Vikash Reebye,1
Xiaoyang Zhao,1 Jon Voutila,2 Robert Habib,2 Pål Sætrom,3 Hans Huber,4 Kai-
Wen Huang,5 John J. Rossi,6 David C. Blakey2. 1Imperial College London, Lon-
don, United Kingdom; 2MiNATherapeutics Ltd, London, United Kingdom; 3Nor-
wegian University of Science and Technology, Trondheim, Norway; 4BioTD
Strategies, LLC, Lansdale, PA; 5National Taiwan University, Taipei, Taiwan;
6Beckman Research Institute of City of Hope, Duarte, CA.
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CCATT/enhancer binding protein alpha (CEBPA) is a transcription factor
that can act as a tumor suppressor. Its expression is downregulated in a number
of cancers including hepatocellular carcinoma (HCC).We have investigated the
role of CEBPA in models of HCC using small activating RNAs (saRNA) to
transcriptionally upregulate its expression. Three liver tumor cell lines (HepG2,
Hep3B, PLCPRF5) were transfected with 20nM CEBPA-saRNAs (CEBPA51).
The transcriptional regulation of two key members of the CEBP family: CEBPA
and CEBPB and their protein expression level were measured. The impact on
cell growth was assessed by way of an SRB andWST-1 assay. To investigate the
role of CEBPB in protecting cells from the activity of CEBPA, siRNAs were used
to knock down CEBPB. Using i.v. delivery of CEBPA51 oligonucleotide, the
impact on tumor growth was investigated in a DEN (N-nitrosodiethylamine)
model of liver cancer. Rats were treated with DEN for 7 weeks, followed by a 2
week wash out and then treated with the CEBPA51 (3-4mg/kg) complexed
with PAMAM-dendrimers or encapsulated in a nanoparticle formulation
(SMARTCLES). The impact on CEBPAmRNA levels in the liver, tumor growth
and liver functions (including, bilirubin, ALT and AST) were measured. Trans-
fection of CEBPA51 into HepG2, Hep3B or PLCPRF5 cells after 72hr led to a
signifıcant increase in both CEBPA mRNA (1.7-2.5 fold by qPCR) and protein
expressionmeasured by western blot in all 3 cell lines. A signifıcant inhibition in
cell growth compared to either PBS or control oligonucleotide was observed in
HepG2 andHep3B but not in PLCPRF5 cells measured by both SRB andWST-1
assays. The levels of CEBPBmRNA and protein, whichmay act as an antagonist
of CEBPA, were found to be higher (1.4-2 fold) in PLCRF5 cells compared to
HepG2 and Hep3B cells. Co-transfection of PLCPRF5 cells with siRNAs to
CEBPB and CEBPA51 saRNA led to downregulation of CEBPB and senstized
the PLCPRF5 cells to growth inhibition by CEBPA51. Administration of
CEBPA51 complexed to either dendrimers or encapsulated in SMARTCLES
nanoparticle at doses of 3-4mg/kg i.v. over 2 weeks led to a signifıcant elevation
of CEBPAmRNA in the liver. This was accompanied by a reduction (80-90%) in
the size of DEN induced liver tumour nodules compared to a control oligonu-
cleotide using both delivery vehicles. The antitumor effects following treatment
withCEBPA51 using both delivery vehicles were also accompanied by reduction
in markers of liver injury (bilirubin, ALT and AST). These studies support an
important role for CEBPA in suppressing progression ofHCC. Activation of the
CEBP gene by saRNA leading to restoration of CEBPA levels in the liver rep-
resents a promising novel approach for inhibiting the growth of HCC whilst
improving normal liver function. The SMARTCLES formulation, MTL-
CEBPA,was chosen for clinical development and is currently in a Phase 1 trial in
patients with liver cancer (NCT02716012).
#1509 RUNX1 dosage dictates gene signature and in vitro response to
glucocorticoids in acute myeloid leukemia. Laura Simon, Vincent-Philippe
Lavallée, Marie-Eve Bordeleau, Jana Krosl, Irène Baccelli, Geneviève Boucher,
Bernhard Lehnertz, Tara MacRae, Réjean Ruel, Sébastien Lemieux, Anne
Marinier, Josée Hébert, Guy Sauvageau.University of Montreal, Montreal, Que-
bec, Canada.
Background: Poor prognosis subgroups of Acute Myeloid Leukemia (AML),
such as RUNX1-mutated (RUNX1mut) AML, would greatly benefıt frommore
effıcacious therapies that target leukemic stem cells (LSC) and improve patient
outcome. To understand factors that predict sensitivity to drugs, we used a
chemogenomic approach to interrogate primary AML specimens.Methods:We
performedRNAsequencing of 415 primaryAML specimens comprising various
cytogenetic subgroups. Using culture conditions that support LSC activity ex
vivo, we carried out a viability screen including 20 primary AML specimens and
5,100 low molecular weight compounds. RUNX1mut specimens showed in-
creased sensitivity to glucocorticoid compounds (GCs). Validation screens were
done in 248 primary AML samples and 32 AML cell lines treated with selected
GCs in a dose-response manner. The effect of RUNX1 dosage in the in vitro
response to drugs was assessed by shRNA gene knockdown. GCs target, the
glucocorticoid receptor (GR), was validated by chemical blockage and shRNA
silencing. Results: RUNX1mut specimens were associated with older age,
French-American-British (FAB) M0morphology, intermediate-risk cytogenet-
ics with abnormal karyotype and poor patient survival. RUNX1mut gene ex-
pression signature showed the overexpression of previously described genes
such as DNTT, BAALC and CD34, as well as novel genes such as PROM1 and
EGFEM1P. Most interestingly, the expression levels of these genes was influ-
enced by the nature of the RUNX1mutations, with levels progressively increas-
ing with mutations corresponding to decreased levels of functional RUNX1.
Chemical screens comprising 33 RUNX1mut specimens confırmed that
RUNX1mut are more sensitive to GCs than RUNX1 wild-type samples. In
agreement with the RUNX1mut gene signature, the anti-proliferative effect of
GCs anti-correlated with levels of functional RUNX1. Specimens harboring
loss-of-function and dominant-negative RUNX1 mutations showed increased
sensitivity to GCs when compared to samples carrying missense mutations ex-
pected to have little impact on RUNX1 function.Mutations in other genes, such
as CEBPA and SRSF2, had an additive effect on GC sensitivity when combined
withRUNX1mutations. In accordancewith our hypothesis, the downregulation
of RUNX1 could reverse GC-resistance in AML cell lines, and the sensitivity to
compounds was proportional to knockdown levels. Treatment of cell lines with
the GR antagonist RU486 blocked the inhibitory response induced by GCs and
GR silencing completely abrogated the anti-proliferative effects of GCs in GC-
sensitive cells, confırming that GCoperate through theGR inAML.Conclusion:
Altogether, these fındings highlight the impact of RUNX1 dosage on gene ex-
pression andGCs sensitivity in AML cells in vitro. Further studies should inves-
tigate the benefıts of repositioning GCs in the treatment of RUNX1mut AML
patients.
#1510 Selection inhibition of acute myeloid leukemia by targeting Taf12.
Yali Xu, Joseph Milazzo, Yusuke Tarumoto, Chris Vakoc. Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY.
Recent studies have suggested that co-activators are good drug targets for
cancer therapy, as exemplifıed by BRD4, the small molecule inhibitors of which
have already entered clinical trials. The high potency of targeting BRD4 in leu-
kemia cells mainly rises from suppressing the functions of multiple lineage spe-
cifıc transcription factors. However, such pleiotropic effects of Brd4 on different
transcription factors might be problematic, considering many of the perturbed
transcription factors are equally required by normal cells. This prompted us to
explore more co-activators as potential drug targets, aiming to identify the can-
didates that discretely disturb the function of oncogenic transcription factors
but not the general ones. In this study, we explored the roles of one of the largest
co-activator complexes TFIID in the maintenance of acute myeloid cells. To
address this, we designed an shRNA library targeting eachTAF subunit of TFIID
and tested the growth effect of these shRNAs in both mouse leukemia cell line
and primary bone marrow culture. We found that multiple shRNAs targeting
Taf12 shows strong toxicity in leukemia cells but not normal cells in vitro.
Knocking down Taf12 also inhibits leukemia progression in vivo. To gain in-
sight into the toxicity of inhibiting Taf12 in different organs, we generated doxy-
cycline inducible transgenic Taf12 shRNAmice, where Taf12 can be inhibited in
different tissues specifıcally at adult stage. In consistent to our in vitro observa-
tion, normal myeloid cells are not affected by Taf12 knockdown. Instead, the
lymphoid lineage cells are affected while removing doxycycline can reverse the
phenotype. To our surprise, all the other tissues that have been examined and
show signifıcant Taf12 knockdown do not have any defects. At molecular level,
we found that inhibition of Taf12 suppresses the transcription of core targets of
Myb, but not other transcription factors, like Pu.1, Erg, Fli-1, which is in contrast
to the pleiotropic effects of Brd4. Interestingly, it has been shown before that
leukemia cells are hypersensitive to Myb inhibition compared to normal cells.
Furthermore, similar to Taf12 mice, mice with hypomorphic level of Myb show
defects in lymphoid but not myeloid cells. Taf12 is a small protein with only one
histone fold domain (HFD), which can dimerize with the HFD of Taf4a within
TFIID complex. We found that the histone fold dimer of Taf12 and Taf4a can
physically interact with the transactivation domain (TAD) of Myb. Finally, we
showed that theHFDof Taf4a can be utilized to target Taf12 to inhibit growth of
leukemia cells. Similar to Taf12 shRNA, function of Myb is disturbed by over-
expressing Taf4a HFD. More strikingly, overexpressing Taf4a HFD is suffıcient
to cause regression of leukemia in vivo.
#1511 AML patient clustering by super-enhancers reveals an RARA asso-
ciated transcription factor signaling partner.Michael R.McKeown,1Matthew
L. Eaton,1 Chris Fiore,1 Emily Lee,1 Katie Austgen,1 Darren Smith,1 M. Ryan
Corces,2 Ravindra Majeti,2 Christian C. Fritz1. 1Syros Pharmaceuticals, Cam-
bridge, MA; 2Stanford University, Palo Alto, CA.
Prior studies have shown that the RARA gene is associated with a super-
enhancer (SE) and has upregulated mRNA expression in a subset of AML pa-
tients. Furthermore, this has been found to confer increased sensitivity to SY-
1425, a potent and selective RAR agonist. We sought to better characterize the
cell state and transcription factor circuitry in these RARA-highAML cells. Clus-
tering of 62 primary AML patient samples based on their genome wide SEmaps
identifıed six discrete clusters. RARA-high patients partitioned principally into
cluster 2, and to a lesser extent 1, suggesting that RARA upregulation is associ-
ated with a specifıc transcription factor (TF) network and cell state. To start
unraveling the TF circuitry in the RARA-high cluster, we investigated which
other TFs were SE associated with clusters 1 and 2. In particular, interferon
regulatory factor 8 (IRF8)was found to be strongly associatedwith clusters 1 and
2 by SE and mRNA expression, similar to RARA. Moreover, the expression of
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both genes is correlated in primary patient samples. IRF8 is involved in inter-
feron signaling and previous studies have shown crosstalk between interferon
and retinoic acid signaling. Furthermore, aberrant IRF8 pathway signaling is
implicated in AML and CML pathogenesis. The tight clustering of RARA and
IRF8 in patient subgroups defıned by genome wide enhancer maps suggests
RAR and IRF8 may form an integrated transcriptional circuit. Indeed, treat-
mentwith SY-1425was found to strongly induce interferon-like gene expression
changes in AML cells with high RARA or IRF8 levels, including the tumor
suppressive IFN responsive gene IRF1.While RARA-high AML cell linemodels
have been previously shown to respond to SY-1425, we found that models with
high IRF8 expression and low levels of RARA were also found to respond to
SY-1425. Such IRF8-high, RARA-low AML cell lines showed activation of sim-
ilar transcriptional pathways as RARA-high cell lines in response to SY-1425
based on GSEA. IRF8-high AML also had comparable low nM EC50 anti-pro-
liferative effects following SY-1425 treatment. In addition, SY-1425was found to
elicit differentiation in both RARA-high and IRF8-high AML cell lines based on
flow cytometry. While RARA and IRF8 expression appear correlated, this data
suggests that IRF8 levels may predict for sensitivity to SY-1425 in addition to
RARA levels, particularly in cases of AML with high IRF8 expression but low
RARA levels. Insights derived from enhancer analysis, transcriptional profıling
and differentiation response in preclinical models support the recently initiated
Phase 2 trial of SY-1425 (NCT02807558) inwhichwe are evaluating the SE based
patient selection strategies and gene circuitry derived pharmacodynamics clin-
icalmeasurements, including differentiationmarkers, in patients withAML and
MDS.
#1512 Functional characterization of novel transcription-regulating can-
cer drug targets, CDK8 and CDK19, using CRISPR/Cas9 knockout and a
highly selective CDK8/19 kinase inhibitor. Mengqian Chen,1 Bing Hu,2 Hao
Ji,1 SerenaAltilia,1 Jiaxin Liang,1MartinaMcDermott,1 Chang-uk Lim,1Donald
C. Porter,3 Eugenia Broude,1 Igor Roninson1. 1University of South Carolina,
Columbia, SC; 2Longhua Hospital, Shanghai University of Traditional Chinese
Medicine, Shanghai, China; 3Senex Biotechnology, Inc., Columbia, SC.
The Mediator complex-associated cyclin-dependent kinase CDK8 is an on-
cogenic transcription-regulating serine/threonine kinase thatmediatesmultiple
cancer-associated transcriptional pathways. Despite recent high-profıle atten-
tion to CDK8 as a novel cancer drug target, very little is known about the func-
tion of CDK8’s closely related paralog CDK19. Using CRISPR/Cas9n systemwe
generated CDK8/CDK19 single-knockout (CDK8-KO and CDK19-KO) and
double-knockout (CDK8/19-dKO) derivatives of HEK293 cells. RNA-Seq was
used to characterize the effects of a highly selective small-molecule CDK8/19
kinase inhibitor Senexin B on gene expression in the parental, single-knockout
and double-knockout cell lines. This analysis was conducted in the absence or in
the presence of TNF-alpha, an inducer of transcription factor NF-kappa-B that
we have previously shown to be potentiated by CDK8. The following results
were obtained. (1) CDK8 and CDK19 have complementary functions in stabi-
lization of their partner Cyclin C (independent of their kinase activity) and
phosphorylation of transcription factor STAT1 at S727 (dependent on the ki-
nase activity). (2) Senexin B treatment affected gene expression in wild-type 293
cells but had almost no effect in CDK8/19-dKO cells, indicating a very high
degree of target selectivity. (3) In contrast to the results with CDK8/19-dKO,
most of the genes affected by Senexin B in the wild-type cells were also affected
in CDK8-KO and CDK19-KO cells, indicating complementary functions of
CDK8 and CDK19. (4) Re-expression of either CDK8 or CDK19, but not of a
CDK8 kinase-dead (D173A) mutant, in CDK8/19-dKO cells restored CDK8/19
kinase-dependent gene expression as well as the regulatory effects of Senexin B.
(5) Many more genes were inhibited rather than induced by Senexin B, indicat-
ing that CDK8/19 act primarily as positive regulators of transcription. (6) The
total number of genes affected by Senexin Bwas greatly increased in cells treated
with TNF-alpha, suggesting that cooperation with other transcription factors
(such as NF-kappa-B) is the primary role of CDK8/19. Our results indicate that
complete suppression of cancer-relevant activities of CDK8 requires simultane-
ous inhibition of both CDK8 and CDK19.
#1514 A novel approach for targeting androgen receptor signaling axis in
prostate cancer. Salma Kaochar, Christopher Foley, Cristian Coarfa, Nicholas
Mitsiades. Baylor College of Medicine, Houston, TX.
Background andObjectives: The androgen receptor (AR) is a ligand-activated
transcription factor (TF) that plays critical oncogenic roles. Medical castration
therapy is the mainstay treatment for advanced PrCa, but the AR signaling axis
frequently remains active in castration-resistant PrCa (CRPC). Despite ad-
vances in AR targeting with abiraterone and enzalutamide, disease progression
re-occurs in the form of CRPCs that still express AR-dependent genes. This
highlights the need for novel approaches to block AR signaling and CRPC
growth. The GATA family of TFs contains six members in mammals, all of
which bind a consensus DNA sequence (A/T)GATA(A/G) to regulate gene ex-
pression. GATA2 is the predominant family member in prostate luminal epi-
thelial cells. In a search for TFs that control AR expression, we found that
GATA2 induces AR gene expression as well as promotes the recruitment of
coactivators to the AR transcriptional complex. We found that GATA2 protein
expressionwas strongly correlatedwithARprotein expression (Spearman’s cor-
relation coeffıcient: 0.323, p-value 0.0001) in our PrCa specimens (n383).
The intensity of GATA2 immunostaining in our BCM patient cohort positively
correlated with Gleason score (R0.37, p-value 0.01) and was a signifıcant
predictor of biochemical recurrence (p-value 0.001). We also demonstrated
that GATA2 directly promotes expression of both full-length and AR splice-
variant, resulting in a strong positive correlation between GATA2 and AR ex-
pression in both PrCa cell lines and patient specimens. Conversely, GATA2
expression is repressed by androgen and AR, suggesting a negative feedback
regulatory loop that, upon androgen deprivation, derepresses GATA2 to con-
tribute to AR overexpression in CRPC. Simultaneously, GATA2 is necessary for
optimal transcriptional activity of both full-length andAR splice-variants.Using
ChIP-Seq we found that GATA2 colocalizes with AR and Forkhead box protein
A1 (FOXA1) on chromatin to enhance recruitment of steroid receptor coacti-
vators (SRC1, SRC2, and SRC3) and formation of the transcriptional holocom-
plex. Lastly, we identifıed a GATA2 small molecule inhibitor (SMI) that can
suppress the expression and transcriptional function of both full-length and
splice-variant AR and exerted potent anticancer activity against PrCa cell lines.
We propose that the inhibition of GATA2 is a ’fırst-in-fıeld’ approach to target
AR expression and function, including ligand-independent AR, for the treat-
ment of CRPC.
#1515 Bromodomain and extra-terminal motif protein inhibitors (BETi)
in metastatic castration resistant prostate cancer (mCRPC): A novel mecha-
nism for regulating androgen receptor variant 7 (ARV7). Jonathan Welti,1
Adam Sharp,1 Ines Figueiredo,1 Wei Yuan,1 Daniel Nava Rodrigues,1 Veronica
S. Gil,1 Eleanor Knight,2 Jian Ning,2 Jeff Francis,2 Antje Neeb,1 Gunther Boy-
sen,1 Amanda Swain,2 Johann S. de Bono1. 1Institute of Cancer Research and the
Royal Marsden Hospital NHS Trust, Sutton, United Kingdom; 2Institute of Can-
cer Research, Sutton, United Kingdom.
Persistent androgen receptor (AR) signaling is key to the development and
progression of metastatic castration resistant prostate cancer (mCRPC). This is
in part due to expression of constitutively active AR splice variants like AR
variant 7 (ARV7), confering resistance to current anti-androgens including en-
zalutamide (E) and abiraterone (A). To improve the outcome for patients with
mCRPC, new therapeutic strategies to overcome AR and ARV7 oncogenic sig-
naling are urgently required. The inhibition of co-factors modulating AR sig-
naling are currently being investigated as novel strategies to treat mCRPC. One
promising candidate is BRD4, a member of the BET protein family, that binds
the AR on androgen response elements and facilitates the recruitment of the
transcriptional machinery. BET inhibitors (BETi) have been shown to regulate
AR and ARV7 signalling, however, the exact mechanism of ARV7 regulation
remains unclear. As BETi are currently being explored in clinical trials of un-
stratifıed patients with mCRPC, we investigated their potential mechanism of
action in CRPC cell lines, patient derived organoids (PDOs) and a patient de-
rived mouse xenograft (PDX). Here we demonstrate that nuclear expression of
BRD4 and ARV7 increases as patients develop resistance to E and/or A and
inhibition of BRD4 by BETi is suffıcient to block AR and ARV7 signalling in
mCRPC. Both inhibition of BRD4 by BETi and genetic knockdown of BRD4
reduced the growth of CRPC cell lines and led to down-regulation of AR and
ARV7 at the mRNA and protein level. To further investigate whether BETi is
suffıcient to inhibit ARV7 activity in patients with mCRPC, we treated patient
derived organoids (PDOs) and amouse xenograft (PDX) grown frommetastatic
biopsies of patients resistant to E and/or A with BETi. In this study 5 out of 10
PDOswere sensitive to BETi. Consistent with the cell culture experiments, BETi
treatment of the PDX led to down-regulation of both ARV7mRNA and protein
expression. Mechanistically, BETi might inhibit pre-mRNA splicing of AR re-
sulting in the observed decrease ofARV7 expression.However, RNAseq analysis
of the ARV7 expressing CRPC cell line LNCaP95 demonstrated an increase in
total splicing events including skipped exons, retained introns, mutually exclu-
sive exons, alternative 5= splice site and alternative 3= splice site after BETi treat-
ment. Despite this, focused analysis of splicing factors and spliceosome compo-
nents identifıed a subset of eight splicing factors being down-regulated by BET
inhibition including one yet uncharacterized factor that is crucial for ARV7
expression in LNCaP95 cells. Based on our results we propose amodel that BETi
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mediated inhibition of this novel ARV7-mRNA splicing factor may lead to de-
creased splicing and subsequent expression of ARV7 at bothmRNA and protein
level; providing a novel approach to target ARV7 in mCRPC.
#1516 Androgen-repressed and androgen-induced genes: challenging the
traditional dogma of prostate cancer therapy. Daniel P. Caley, Nasrin R.
Mawji, Marianne Sadar. BC Cancer Agency, Vancouver, British Columbia, Can-
ada.
Background: Benign and malignant prostate tissues are dependent upon the
activity of androgen receptor (AR). The primary function of full-length AR is as
a ligand activated transcription factor to increase or repress gene expression.
Many androgen-repressed genes regulate the cell cycle and proliferation. With
castration, the main therapeutic approach for advanced prostate cancer (PC),
these genes are believed to play a role in the initial clinical response. Current
approved therapies for advanced PC and castration-resistant PC (CRPC), target
the AR C-terminal ligand-binding domain (LBD), such as antiandrogens. Re-
cent antagonists of the ARN-terminal domain (NTD) have been described with
EPI-506, the prodrug of EPI-002, now in Phase 1 clinical trials. EPI-002 binds
tau-5 in activation function-1 (AF-1) of the NTD that is essential for AR tran-
scriptional activity. As expectedwith anAF-1 antagonist, EPI-002 is an excellent
inhibitor of androgen-induced gene expression and at blocking the transcrip-
tional activities of truncated AR splice variants lacking LBD, such as AR-V7.
EPI-002 blocks expression of genes regulated by truncated AR-V7 such as
UBE2C while antiandrogens have no effect. Here we reveal that the major dif-
ference in gene expression regulated by full-length AR between EPI-002 and
antiandrogens is their abilities to de-repress genes that are turned off by andro-
gen. Methods: The androgen sensitive human prostate cancer cell line LNCaP,
which expresses full-length AR, was treated with antiandrogens (bicalutamide
[BIC] and enzalutamide [ENZA]), EPI-002 and a control vehicle, with andwith-
out androgen. Gene expression was analysed using Affymetrix microarrays.
Bioinformatical analysis was completed and a selection of androgen-repressed
genes that were de-repressed with antiandrogens and/or EPI-002, were selected
for validation using qRT-PCR. Results: EPI-002 de-repressed known androgen-
repressed genes including SPLTLC3, ST7, PSAT1, TMEM140 and TNFRSF21.
EPI-002 was as effective or better than BIC or ENZA in de-repressing a subset of
androgen-repressed genes. Importantly, EPI-002 failed to de-repress expression
of many androgen-repressed genes that antiandrogens de-repressed, such as
SLITRK3, GPR63 andDAB1. Conclusions: EPI binds ARNTDwhich blocks the
transcriptional activities of full-length AR and truncated AR splice variants.
EPI-002 was excellent at inhibiting androgen-induced genes. However, EPI did
not broadly de-repress expression of genes turned off by androgen when com-
pared to antiandrogens. Such differences between EPI-002, a tau-5/NTD antag-
onist, and C-terminal LBD antiandrogens probably reflect the complexities of
the mechanisms of repression of gene expression that may involve different
domains of AR.
#1517 AKT inhibition induces neuroendocrine phenotype in prostate
cancer cells. RuiQi Chen, Yinan Li, Xuesen Dong. University of British Colum-
bia, Vancouver, British Columbia, Canada.
Androgen receptor (AR) signaling pathway inhibition (ARPI) is the primary
treatment for locally advanced, recurrent, or metastatic prostate cancer. While
ARPI is effective in short term, a fatal relapse is inevitable. The AKT signaling
pathway inhibition has been investigated under multiple ongoing clinical trials
as a co-therapeutic target withARPI. TheAKT signaling pathway is targeted due
to its role in tumorigenesis, prevalent over-activation, and reciprocal activation
uponARPI in prostate cancer. However, this novel combination therapymay in
fact facilitate PCa to progress into one of the most lethal subtypes called neu-
roendocrine (NE) prostate cancer (NEPC). Specifıcally, evidence has shown that
ARPI contributes to NEPC progression at least in part by down-regulating the
expression of RE-1 Silencing Transcription Factor (REST). Loss of REST is a
hallmark of NEPC progression because REST functions as a negative master
regulator in neurogenesis by suppressing genes required for neural differentia-
tion. Similar to ARPI, our studies found that AKT inhibition reduced REST
protein expression and increasedNEPCmarkers inmultiple prostate cancer cell
lines. We also showed that the loss of REST upon AKT inhibition was through
protein degradation mediated by an E3-ubiquitin ligase TRCP, which recog-
nizes a phosphorylated REST degron region to recruit ubiquitins. In vivo ubiq-
uitination assays confırmed the elevated REST ubiquitination after the treat-
ment of PI3K inhibitors. Furthermore, mutations within the REST degron
region reversed the TRCP-mediated REST ubiquitination and degradation. Fi-
nally, co-treatment of AKT pathway inhibition and ARPI showed aggravated
REST depletion and increased NE markers in the prostate cancer cell line LN-
CaP. Collectively, these fındings indicate that AKT pathway inhibition can in-
duce NE phenotype in prostate cancer cells via REST protein degradation. This
studymay provide a caution to the ARPI/AKT co-target strategy as this strategy
can potentially facilitate NEPC development.
#1518 Mechanisms of bromodomain and extra-terminal motif inhibitor
(BETi) sensitivity in triple-negative breast cancer (TNBC). Johanna Schafer,1
Brian Lehmann,2 Phillip Liu,3Matthew Stubbs,3 Peggy Scherle,3 Jennifer Pieten-
pol2. 1Vanderbilt University, Nashville, TN; 2Vanderbilt UniversityMedical Cen-
ter, Nashville, TN; 3Incyte Corporation, Wilmington, DE.
Triple-negative breast cancers (TNBCs) lack expression of estrogen receptor
(ER), progesterone receptor (PR), and amplifıcations in the human epidermal
growth factor receptor 2 (HER2). With currently no FDA-approved targeted
therapies for TNBC, patients with TNBC have a higher risk of local and distant
recurrence, and an overall increased rate of mortality. Recent studies have dem-
onstrated increased sensitivity of TNBC to the anti-proliferative effects of BETi
compared to the other breast cancer subtypes. To determine mechanisms of
sensitivity to BET inhibition, we analyzed the effect of two BET inhibitors,
INCB054329 and OTX-015, across a panel of TNBC cell line models and iden-
tifıed cell lines that were both sensitive and insensitive to BETi. With the intent
of identifying biomarkers of sensitivity, we performed RNA-seq and precision
nuclear run-on and sequencing (PRO-seq) on both sensitive and resistant cell
line models and data generated identifıed signifıcant differences in key growth
regulatory and apoptotic signaling pathways, including notable differences in
Myc-dependent signaling. Our data suggest potential biomarkers of BETi sen-
sitivity that may be of value in further pre-clinical studies. Further, our results
provide mechanistic rationale for combinations of BETi with select, targeted
therapies in a disease that is in need of new therapeutic intervention.
#1519 Estrogen receptor beta andp53 signaling crosstalk: implications for
ER beta as a potential therapeutic target in triple negative breast cancer.
Christina E. Adams, Gokul M. Das. Roswell Park Cancer Institute, Buffalo, NY.
Despite over 20 years of research, there is no current consensus on whether es-
trogen receptor  (ER) is pro- or anti-tumorigenic. With its expression found
amongall breast cancer subtypes, ER is a potentially valuable therapeutic target for
breast cancers that lack effective, targeted therapies, especially the triple negative
breast cancer (TNBC) subtype. In the published literature, there has been no con-
sensus as to whether ER functions as a pro- or anti-tumorigenic protein, although
a bifaceted role for ER has been proposed. Previous studies from our lab have
shown that ER candirectly bind and interactwith p53, resulting in inhibition of its
functions. Knockdown of ER in a breast cancer cell line with wild-type (wt) p53
(MCF-7) elicits opposite functional effects compared to knockdown of ER in a
TNBC breast cancer cell line with mutant (mut) p53 (MDA-MB-231). Therefore,
our hypothesis is that ER functions are dependent on p53 context. Besides having
different p53 statuses, these two cell systems also have many other genetic differ-
ences that may ormay not contribute to the opposing functions of ER. Currently,
we are using an isogenic cell system that allows for expression of different combina-
tions of ER andp53 (wt ormut) proteins.Here, we usedCRISPR/Cas9 technology
to knockout (KO) the TP53 gene in MDA-MB-231 cells, resulting in a complete
absence of the endogenous mut-p53 protein. By transiently transfecting back in
wt-p53, we can induce a prototypical wt-p53 response, which causes an increase in
p53 target genes accompanied by a decrease in cell growth.Meanwhile, the parental
cell line with endogenousmut-53 protein expression shows downregulation of p53
target genes and increases cell growth. This demonstrates that wt-p53 is still func-
tional in the context of a cell that originally expressedmut-p53, and thatwt-p53 and
mut-p53 have opposing functions. In this system, we demonstrate that ER de-
creases p53 target gene expression and apoptosis in thewt-p53 context. Conversely,
in themut-p53 context, ER increases p53 target gene expression, while decreasing
cell cycle progression. Taken together, these data support a pro-tumorigenic role of
ER in the wt-p53 context, and an anti-tumorigenic role of ER in the mut-p53
context in our isogenic system. Finally, we explore the ability of ER ligands to
modulate the ER-p53 interaction and subsequently affect p53 functions.We have
found that two ER antagonists, 4-hydroxytamoxifen and PHTPP, have opposite
effects on p53 target genes, suggesting a difference in their ability to modulate the
ER-p53 interaction. Our data show that p53 status of the tumor should be taken
into consideration for therapeutic targeting of ER in TNBC.
#1520 Down-regulation of c-MYC and hTERT gene expression in triple
negative breast cancer. Elaine Stur, Shelia Thomas, Francine Rezzoug, Donald
Miller. University of Louisville, Louisville, KY.
Breast cancer is themostcommoncanceraffectingwomen,withabout1.4million
newcasesdiagnosedeachyear.Triple-negativebreast cancer (TNBC)which is char-
acterized by lack of expression of estrogen, progesterone and human epidermal
growth factor receptors. Is the most aggressive group of tumors associated with a
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poor prognosis (15% of all mammary tumors). Previous studies have shown that
specifıc G-rich genomic sequences in the promoters of multiple human genes can
form G-quadruplex structures, resulting in decreased transcription and gene ex-
pression. These regions are generally found within gene promoters especially of
oncogenes such as c-MYC, KRAS, VEGF, BCL2 or hTERT.Most of these genes are
abnormally expressed in breast cancer. The c-MYC gene regulates a large array of
genes essential for cell functions including proliferation, metabolism, differentia-
tion, adhesion and apoptosis.Wehave recently shown that oligonucleotides encod-
ing the G-quadruplex sequence of the c-MYC, VEGF or hTERT promoters down
regulate expression of their respective genes and inhibit cell proliferation. We hy-
pothesized that such oligonucleotides could be applied to breast cancer cell lines in
order to inhibit cell proliferationandmetastasis. In this study,weevaluated theeffect
of oligonucleotides targeted to c-MYC (Pu27 and Pu27 Palmi), KRAS (KRASq),
VEGF (VEGFq), hTERT (Tert-FL) and BCL2 (BCL2q) in Breast cancer cell lines
(MDA-MB-231, SKBR3,MCF7) andMCF10A (non-transformedmammary cells).
Theeffectof eacholigonucleotideoncell growthwasevaluatedusing theMTTassay.
Our results reveal that all oligos inhibit cell growth ofMDA-MB-231. However, for
SKBR3andMCF7,onlyTert-FLhadgrowth inhibitoryactivity.Thecontrol cell line,
MCF10A, did not respond suggesting that the oligonucleotides affect preferentially
tumor cells. The effect of the oligonucleotides on gene expression (qRT-PCR) was
performed on MDA-MB-231 exposed for 3 days. The analysis of gene expression
shows the downregulation of c-MYC by Pu27 and hTERT by Tert-FL suggesting a
direct effect on gene expression. In addition, Pu27 downregulated hTERT and
VEGF which are both under c-MYC control. Since MDA-MB-231 is a TNBC cell
line overexpressing c-MYC and is highly enriched in cancer stem cells, we evaluate
the effect of Pu27 andTert-FL on the tumorsphere formation. The results showed a
very strong inhibition of tumorsphere formation in the cells treatedwith Pu27.Our
fındings suggest that oligonucleotideswhich target genes such as c-MYC,hTERTor
KRASvery effıciently inhibit the growthofBCcell lines inparticularMDA-MB-231
TNmost likely by downregulating target gene expression. In addition, we demon-
strate that downregulating c-MYCexpressionPu27dramatically reduces the cancer
stem cell numbers. The use of G-quadruplex forming oligonucleotides targeted to
c-MYC and /or hTERT may constitute a new therapeutic strategy especially for
TNBCwhere targeted therapy is lacking.
#1521 hTERT G-quadruplex-targeted oligonucleotides inhibit glioblas-
toma cell growth. Alex West. University of Louisville, Louisville, KY.
Glioblastoma is one of the most common and deadly forms of brain cancer,
representing roughly 75% of all brain malignancies. These tumors generally
have poor prognoses and are resistant to conventional therapy. It has recently
been shown that as many as 80% of all glioblastomas contain mutations in a
G-rich 68 base pair region of the hTERT promoter. hTERT is the catalytic sub-
unit of telomerase, a holoenzyme responsible for lengthening the ends of chro-
mosomes, thereby conferring immortality to cells. Normally, hTERT is not ex-
pressed in somatic cells and its expression is tightly controlled in stem cells.
However, hTERT is upregulated in up-to 95% of human tumors and is consid-
ered a key activator of cancer progression and a sign of poor clinical outcome.
Therefore, hTERThas been under investigation for the past decade as a potential
therapeutic target.Wehave shown that themutations in hTERTpromoter occur
in a G-rich region that is part of a silencer element which forms a secondary
G-quadruplex structure required for function, and that these mutations desta-
bilize the G-quadruplex structure, allowing hTERT expression. We have also
demonstrated that oligonucleotides encoding the G-quadruplex forming se-
quence in the c-MYC promoter can stabilize the G-quadruplex structure and
downregulate c-MYC expression. Therefore, we hypothesized that oligonucle-
otides targeted to theG-quadruplex of the hTERTpromoter could downregulate
this gene expression and inhibit glioblastoma cell proliferation in a similarman-
ner. We designed several G-quadruplex-forming oligonucleotides covering the
mutated sites in the hTERT promoter either in totality (68 nucleotides) or sep-
arately (25 nucleotides) to stabilize the G-quadruplex region. Two glioblastoma
cell lines (A172 and U87) and one neuroblastoma cell line (CHP134) were ex-
posed to these oligonucleotides and evaluated for growth inhibition using the
MTT assay and for gene expression by QRT-PCR. All oligonucleotides tested
were found to induce between 40 to 90%growth inhibition in the 3 cell lines. The
cell growth inhibition was both time and dose dependent and showed effective-
ness as early as 3 days suggesting that this effect is not solely due to telomere
shortening. Four oligonucleotides with the most consistent effıcacy in growth
inhibition were evaluated for their effect on hTERT gene expression in the 3 cell
lines at 4 day exposure and revealed that two of the G-quadruplex forming
oligonucleotides signifıcantly decreased hTERT expression compared to un-
treated cells. In conclusion, we have defıned G-quadruplex oligonucleotides
targeted to the hTERTpromoter that downregulate hTERT gene expression and
are effective growth inhibitors in glioblastoma cells. Our fındings indicate that
downregulation of hTERTwith targeted oligonucleotides affects non-canonical
functions of hTERT conferring an advantage to this therapeutic approach.
#1522 Targeted gene therapy · c-MYC and hTERT in the scope. Francine
Rezzoug, Shelia D. Thomas, Segen Tella, Donald M. Miller. Univ. of Louisville,
Louisville, KY.
In the past decade immunotherapy and kinase inhibitors have revolutionized
the approach for cancer therapy, particularly for melanoma which has benefıt
from this new therapy in the last 5 years. Although, new treatment increase
patient survival, there is no cure and treatments are often limited to a subtype of
patients. Therefore there is still an urgent need for effıcient therapy for mela-
noma. Among potential targets for cancer therapy, c-MYC and hTERT which
are overexpressed in up-to 85% of all cancers are the most promising. The over-
expression of hTERT provides indefınite division to cancer cells. Deregulation
of c-MYC affect a large array of genes involved in cell cycle, proliferation/differ-
entiation and apoptosis. Notably, both c-MYC and hTERT genes have in their
promoter area a G-rich sequence that form secondary structure called G-qua-
druplex. These G-quadruplex structures are part of the silencers and are re-
quired for the repression of c-MYC or hTERT transcription. Mutations in the
G-rich sequences of hTERT promoter destabilize the G-quadruplex and are
associated with incidence of melanoma. We have shown that oligonucleotides
encoding for theG-quadruples sequences of these genes promoter downregulate
their respective gene expression and inhibit cell growth in different cell lines.We
investigated the effect of targeting c-MYC or hTERT gene expression in mela-
noma cell lines using oligonucleotides targeted to the silencer G-quadruplex
sequence. Four cell lines where investigated (SK-Mel-2, SK-Mel-3, SK-Mel-28
and A375) for the effect of Pu27 (targeting c-MYC) and Tert-FL (targeting
hTERT) on cell proliferation usingMTT assay. The treatment for 6 days resulted
in 60% growth inhibition in the presence of Pu27 and 50% in the presence of
Tert-FL for SK-Mel-2, SK-Mel-3, SK-Mel-28whileA375was less sensitive. Gene
expression evaluated by QRT-PCR showed down-regulation of c-MYC and
hTERT in cell exposed to Pu27 and hTERT in cells exposed to Tert-FL. hTERT
expression is regulated by c-MYCand in our experiment the down-regulation of
c-MYC correlate with down-regulation of hTERT suggesting a cascade effect. In
addition, SOX2 gene expressionwas also down-regulated by Pu27 suggesting an
effect on the cancer stem cells (CSC). Our data demonstrate that oligonucleo-
tides targeted to c-MYC and hTERT down-regulate gene expression associated
with melanoma cell growth inhibition and possibly on metastasis.
#1523 The mechanism of action of BCL6 in glioblastoma. Nicole M.
Jones,1 Marie-Sophie Fabre,1 Dinindu Sachindra Senanayake,1 Katerina Hatzi,2
Ari M. Melnick,2 Melanie J. McConnell1. 1Victoria University of Wellington,
Wellington, New Zealand; 2Weill Cornell Medical College, Cornell University,
New York, NY.
Glioblastoma (GBM) is the most common and most deadly brain tumor to
occur in adults. Initially patients respond to radiation and chemotherapy, which
primarily work by causing large amounts of DNA damage, causing apoptosis of
the cells. However, this process does not happen effectively in GBM and under-
standing how these cells resist cell death in response to therapy is key to improv-
ing the effıcacy of treatment. BCL6 is a transcription factor that stops cell death
in response to DNA damage. Recent work in our lab has shown BCL6 to be
present in untreated GBM tumors and up-regulated in treated GBM cells. This
evidence indicates that BCL6may be used as a mechanism of therapy resistance
by GBM cells. In this study, the objective was to determine the mechanism of
action of BCL6 in GBM cells using luciferase reporter assays, quantitative chro-
matin immunoprecipitation (qChIP) and RNA sequencing. We observed that
BCL6 was transcriptionally active in GBM as shown by a reduction in luciferase
activitywhenBCL6was present. qChIP experiments revealed that BCL6 binding
changed over time and was different with different types of DNA-damaging
treatment. Preliminary analysis of our RNA sequencing data has identifıed a
unique subset of genes which are upregulated when BCL6 is inhibited and
downregulated in response to chemotherapy. These changes indicate that these
genes may be regulated by BCL6 in chemotherapy treated cells. All of these
results illustrate that BCL6 appears to have an active and relevant function in
GBM cells, which demonstrates that BCL6 is an attractive therapeutic target in
GBM.
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#1524 BCL6modulates theTP53 andSTATpathways in glioma.YeChen,1
LiangXu,1MarinaDutra-Clarke,2 AnandMayakonda,1De-Chen Lin,1 Lynnette
Koh,3 YukKienChong,3 Edwin Sandanaraj,3VikasMadan,1HenryYang,1Ngan
Doan,4 JonathanW. Said,4WilliamH. Yong,4MarkusMüschen,5 Beng Ti Ang,3
Carol Tang,3 Joshua J. Breunig,2 Phillip Koeffler1. 1National University of Singa-
pore, Singapore, Singapore; 2Cedars-Sinai Medical Center, UCLA, Los Angeles,
CA; 3National Neuroscience Institute, Singapore, Singapore; 4UCLA, Los Angeles,
CA; 5UCSF, San Francisco, CA.
Glioblastoma multiforme (GBM) remains the most aggressive brain malig-
nancy with little improvement in prognosis or therapy for decades. Recently, we
identifıed BCL6, also known as ZBTB27, to be a novel oncogene in GBM. In this
study, we performed IHC analysis of 153 primary human glioma specimens and
8 normal brain samples. BCL6 expression is robustly elevated in tumor samples
and positively correlated with glioma pathological grade. High BCL6 expression
strongly predicts a worse prognosis of GBM patients. Depletion of BCL6 in
human GBM cells reduced the incorporation of BrdU, promoted the cellular
senescence and inhibited the growth of human GBM cells in vivo. Next, ge-
nome-wide occupancy of BCL6 in GBM cells was characterized by ChIP-seq
assay. Genomic regions centered on BCL6 peaks are co-enriched with RNA-Pol
II and flankedwith strongH3K27ac andH3K4me3modifıcations.MYCand two
long non-coding RNAs MALAT1 and NEAT1 were identifıed as novel BCL6
targets in GBM. Moreover, pathway enrichment analysis of BCL6 peak-associ-
ated genes reveals a signifıcant enrichment of JAK-STAT, TP53, ERBB and
MAPK pathways. We demostrated further that BCL6 represses the TP53 path-
way and promotes the JAK-STAT pathway activation in GBM cells. Together,
our fındings uncover potential downstream targets and provide a better under-
standing of BCL6 function in GBM.
#1525 Chemically induced degradation of the oncogenic transcription
factor BCL6. Nina Kerres,1 Steffen Steurer,1 Stefanie Schlager,1 Gerd Bader,1
Helmut Berger,1 Sophia Blake,1 Maureen Caligiuri,2 John Engen,3 Peter Ett-
mayer,1 Thomas Gerstberger,1 Daniel Gerlach,1 Roxana Jacob,3 Simon Lucas,1
Moriz Mayer,1 Mischerikow Nikolai,1 Rumpel Klaus,1 Scharn Dirk,1 Schnitzer
Renate,1 Tilman Voss,1 Zoephel Andreas,1 Norbert Kraut,1 Darryl McConnell,1
Pearson Mark,1 Manfred Koegl1. 1Boehringer Ingelheim RCV GmbH & Co KG,
Vienna, Austria; 2FORMA Therapeutics, Watertown, MA; 3Northeastern Uni-
versity, Boston, MA.
The transcription factor BCL6 is a known driver of oncogenesis in lymphoid
malignancies, including diffuse large B-cell lymphoma (DLBCL). It is a DNA-
binding protein that represses gene transcription through the recruitment of
co-repressor proteins via its BTB domain. Disruption of the interaction of BCL6
with co-repressor proteins interferes with the physiological and oncogenic func-
tions of BCL6. We have used structure-based drug desgin to develop potent
compounds that block this interaction with half maximal inhibitory concentra-
tion values (IC50s) below 3 nM. In addition to inhibiting co-repressor binding, a
subset of the identifıed inhibitors also caused rapid disappearance of BCL6 pro-
tein in cells. This effect was mediated by compound-induced multi-ubiquityla-
tion of BCL6 and degradation by the proteasome and was dependent on the
presence of a functional DNA binding domain on BCL6. Compounds that in-
duced BCL6 degradation displayed signifıcantly stronger induction of expres-
sion of BCL6-repressed genes than compounds that merely inhibited co-repres-
sor interaction. BCL6-degrading inhibitors had anti-proliferative effects in
several DLBCL cell lines, while non-degrading BCL6 inhibitors only had minor
effects on proliferation. The fact that the magnitude of effects elicited by this
novel class of BCL6degrading compounds greatly exceeds that of our equipotent
classical co-repressor interaction inhibitors offers exciting new opportunities
for the development of BCL6-based lymphoma therapeutics.
#1526 Usp9x inhibition and depletion overcomes SOX2 dependent resis-
tance to BRAF inhibition inmelanoma.Harish Potu.Univ. ofMichigan Comp.
Cancer Ctr., Ann Arbor, MI.
Melanoma tumors often show limited response to BRAF/MEK/ERK pathway
inhibitors currently used in melanoma treatment. One mechanism of resistance to
currentmelanoma treatments is upregulation of SOX2, a transcription factor that is
essential for tumor growth and expansion, particularly in tumorswith BRAFmuta-
tion in melanoma. Targeting drugs to transcription factors has been elusive and
limits treatment options. Here we report that the deubiquitinating enzyme Usp9x
controls SOX2. We show that ubiquitin-specifıc peptidase 9, X-linked (Usp9x), a
deubiquitinases (DUB) enzyme, binds SOX2 in melanoma and deubiquitinates
SOX2 in vitro. Usp9x knockdown results in increased levels of ubiquitinated SOX2
inmelanoma, is coupled with depletion of SOX2 and promotes apoptosis synergis-
ticallywithvemurafenib inmelanomacell lines.Protein levels inprimarymelanoma
tumor samples demonstratedmoderately elevatedUsp9x/SOX2protein expression
in metastatic melanoma compared to primary melanoma patient tumors. Further,
Usp9x knockdown or inhibition with G9, a DUB inhibitor, blocked BRAF/MEK
kinase inhibitor-induced induction of SOX2 and fully suppressed in vitro colony
growth of BRAF-mutantmelanoma cells andpromoted apoptosis.Wediscovered a
novel mechanism of targeting SOX2, transcription factor by inhibition of Usp9x.
Thus, development of DUB inhibitors will add to the limited repertoire of current
melanoma treatments.
#1527 BRD3 as a specifıc vulnerable therapeutic target in neuroblastoma.
Kaat Durinck,1 Jolien Dewyn,1 Anneleen Beckers,1 Siebe Loontiens,1 Suzanne
Vanhauwaert,1 Daniel Carter,2 Belamy Chueng,2 Glenn Marshall,2 Katleen
Depreter,1 Frank Westermann,3 Frank Speleman1. 1Ghent University, Ghent,
Belgium; 2Children’s Cancer Institute Australia for Medical Research, Sydney,
Australia; 3DKFZ, Heidelberg, Germany.
Introduction: BET inhibitors have raised high expectations for cancer treatment
given their anti-proliferative effect by inhibiting BRD4 controlled enhancer activity
ofhighly transcribedgenes suchasMYC(N).However, current inhibitors also target
BRD2 and BRD3 which are functionally nonredundant with BRD4. In neuroblas-
toma only MYCN amplifıed tumors respond well to these drugs. Methods: We
performed an integrated bioinformatics approach to scrutinize BET family genes as
well as further candidate epigenetic regulators as targets for novel therapies in neu-
roblastoma. Results: First we performed a time-resolved expression data analysis of
week 1 and 2 hyperplastic lesions and tumors derived from the TH-MYCN trans-
genicmousemodel and confırmed dynamic regulation during tumor development
for established neuroblastoma oncogenes and tumor suppressor genes. Next, we
fıltered within the highest upregulated genes for Cancer Gene Census (CGC) genes
and identifıed21upregulatedCGCgenesmainly involved in chromatin remodeling
and DNA repair. Finally, after further selection based on expression in CCLE and
survival in neuroblastoma patients, BRD3 was identifıed as the top-ranked candi-
date. BRD3 exhibits drastic upregulation during tumor formation. Elevated BRD3
expression is thehighest expressed gene inneuroblastoma cell lines uponanalysis of
theCCLEpanel and associatedwith very poor prognosis. To explore the nonredun-
dant functions of BRD3 in relation to BRD4, we performed RNA-sequencing after
stable knockdown of BRD3 in neuroblastoma cell lines and compared the down-
stream effects on the transcriptome as well as the impact on cell viability to knock-
down of BRD4 and pharmacological treatment with BET-inhibitors (JQ1,
OTX015). In addition, we dissected the BRD3 protein complex by means of label-
freemass spectrometry analysis to gain further insights into theBRD3 specifıc func-
tions in relation to control of gene transcription and putative interaction with tran-
scription factors such as MYCN. Current efforts are ongoing to test cooperative
interaction of BRD3 versus BRD4 in dbh-MYCNdriven neuroblastoma formation
in zebrafısh as well as BRD3 and BRD4 ChIP-sequencing in neuroblastoma cells.
Conclusion:We identifıedBRD3as a candidate novel driver gene inneuroblastoma
and will present differential transcriptional control and protein interactions of
BRD3versusBRD4.This study canopen theway towardsdevelopingBRD3 specifıc
inhibitors for neuroblastoma and other BRD3 overexpressing cancers such as T-
ALL and small cell lung carcinoma.
#1528 Forecasting novel therapies by understanding the role BRD4 in
regulating the Notch3 signaling in ovarian cancer. Alejandro Villar-Prados,1
Sherry Y. Wu,1 Jason Roszik,1 Anil K. Sood,1 Margaret I. Engelhardt2. 1UT MD
AndersionCancer Center, Houston, TX; 2McGovernMedial School, Houston, TX.
Advances in cancer research have led to the rapid development of novel drug
therapies designed for optimal personalized patient care. Despite this surge of
treatments, there is still a challenge in accurately predicting the most effective
targeted therapy for a specifıc cancer. Additionally, the potential of systemati-
cally identifying and repurposing currently existing therapeutics designed for
one specifıc cancer to treat other malignancies remains understudied. To ad-
dress this problem, our group has developed an integrative computational ther-
apy-forecasting algorithm. This algorithm incorporates data from The Cancer
GenomeAtlas (TCGA) as well as molecular and survival correlations to identify
candidate anti-tumor drugs that can be re-purposed for other malignancies by
targeting novel pathways. Our computational analysis predicted that bromodo-
main inhibitors, which inhibit bromodomain-containing proteins such as
BRD4, would target the Notch3 pathway in high-grade serous ovarian carci-
noma (HGSC). Upregulation of Notch3 plays a crucial role in HGSC tumori-
genesis and is associated with worse patient survival. Current Notch3 targeted
therapies are not effective, thus designing therapeutic strategies to target Notch3
are critical for HGSC. We hypothesize that inhibition of BRD4 is an effective
therapeutic target in HGSC by downregulating the Notch3 pathway. Current in
vitro results demonstrated that BRD4 inhibition either by using chemical inhib-
itors or siRNA results in a decrease in HGSC cell viability by bothMTT and 2-D
colony formation assays. Furthermore, inhibition of BRD4 resulted in a decrease
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in bothNotch3 transcription and protein levels. Given that BRD4 regulates gene
transcription, we performed chromatin immunoprecipitation (ChIP) and ob-
served that BRD4 was present in the Notch3 gene promoter. These fındings
suggest that by inhibiting BRD4 inHGSC, we can target Notch3 and biologically
validates our initial in sillico analysis. The successful completion of this project
could have major implications for development of personalized therapies not
only for HGSC but for other cancers as well.
#1529 Scutellaria baicalensis targets the hypoxia-inducible factor-1 and
attenuates ovarian cancer growth. Imran Hussain,1 Sana Waheed,1 Kashif A.
Ahmad,2 John E. Pirog,3 Viqar Syed1. 1Uniformed Services Univ. of the Health
Sci., Bethesda, MD; 2University of Illinois College of Medicine-Urbana Cham-
paign, Urbana, IL; 3Northwestern Health Sciences University, Bloomington, MN.
Hypoxia-inducible factor-1alpha (HIF-1), a transcription factor important for
maintaining cellular oxygenhomeostasis, is aberrantly upregulated inmany tumors
and implicated in angiogenesis,metastasis and drug resistance. Therefore, develop-
ing treatments that target HIF-1may be a viable therapeutic approach. For centu-
ries, traditional Chinese medicine has used herbs, such as Scutellaria baicalensis
(SB), as a natural remedy for tumors.However, themechanisms bywhich SB inhib-
its tumor growth are not known. We have previously reported that SB inhibits
cancer cell proliferation and targets NF-B in endometrial and ovarian cancers and
TGF- in endometrial cancers. In this study, we examined the effects of SB on
HIF-1 protein levels in three ovarian cancer cell lines, SKOV3, OVCA 429, and
OVCA 420, grown under normoxic and hypoxic conditions. When treated daily
with SB, cancer cells showed a decrease inHIF-1 expression after 48 hours. Inves-
tigation into themolecular mechanisms of SB-induced inhibition revealed a signif-
icant reduction of HIF-1 accumulation in cells treated with cycloheximide, a pro-
tein synthesis inhibitor. Further decrease of HIF-1 accumulation was seen when
cycloheximide was combined with SB. Additionally, SB- induced HIF-1 protea-
somal degradation was prevented by treatment of cells with proteasomal inhibitor
MG132 and chloroquine, lysosome inhibitor, abrogated SB-induced inhibition of
HIF-1. Activation of PI3K/AKTandMAPK/ERK is shown in cancers. SB reduced
levels of phospho-AKT and phospho-extracellular signal-related kinase (ERK) in
ovarian cancer cells. Furthermore, pretreatment of cells with LY294002 (phospho-
inositide 3-kinase inhibitor) andPD98059 (mitogen-activatedproteinkinase kinase
inhibitor) reduced HIF-1 expression comparable to SB-treated cells. Hypoxia-in-
duced cisplatin resistance is a major challenge in therapy of ovarian tumors. SB
reduces the proliferation and reverses cisplatin resistance in ovarian cancer cells by
attenuating the expression of HIF-1. Taken together, the fındings suggest that
targetingHIF-1with SB couldbe an effective treatment strategy for ovarian cancer
and that SB can improve the sensitivity of cells to cisplatin.
#1530 RUNX1 positively regulates ErbB2/HER2 signaling pathway
throughmodulating the expression of SOS1 in gastric cancer cells.Yoshihide
Mitsuda, Ken Morita, Shintaro Maeda, Kensho Suzuki, Gengo Kashiwazaki,
Junichi Taniguchi, Toshikazu Bando, Hiroshi Sugiyama, Souichi Adachi, Ya-
suhiko Kamikubo. Kyoto University, Kyoto, Japan.
Although runt-related transcription factor 1 (RUNX1) is well known for its con-
text-dependent oncogenic properties in variousmalignancies, its role in gastric can-
cers has been poorly defıned. Up-regulation of receptor tyrosine kinase (RTK)
ErbB2/HER2 signalingpathway is encountered in the vastmajority of gastric cancer
cases and contributes to the initiation and maintenance of these cancer cells. This
signaling cascade is partly yet arbitrarymediated by son of sevenless gene 1 (SOS1),
which functions as an adaptor protein in RTK cascades. Herein we report that
RUNX1 regulates ErbB2/HER2 signaling pathway in gastric cancer cells through
transcriptionally regulating SOS1 expressions, rendering itself an ideal target in an-
ticancer strategies. Mechanistically, RUNX1 interacts with the consensus RUNX1
binding sequence (5=-TGTGGT-3=) located in the proximal promoter region of
SOS1andpositively regulates it. ShorthairpinRNA(shRNA)-mediatedknockdown
of RUNX1 in the gastric cancer cell lineMKN45 led to the decreased expression of
SOS1 and of phosphorylated form of ErbB2/HER2 as well as the deactivation of its
downstream targets such as AKT and ERK. RUNX1 knockdown subsequently in-
ducedcell cycle arrest atG0/G1phase and successive apoptotic cell death inMKN45
cells. Silencing of HER2 or SOS1 inMKN45 cells unalterably suppressed the prolif-
eration of these cancer cells, highlighting the importance of this ErbB2/HER2 sig-
naling cascade in themaintenanceof gastric cancer cells.Wealso found that SOS1 is
oneof themost consistentlyup-regulatedgenes inRUNX1-highexpressingprimary
gastric cancer cells derived frompreviously reported human clinical samples. These
data collectively indicates that inhibition of RUNX1 could be a legitimate therapeu-
tic choice in themanagement of gastric cancers. Lastly, we examined the effıcacy of
a novel smallmolecule specifıcally binds and inhibits RUNX1 (wenamed it asCM).
Intriguingly, CM was exceptionally effective against MKN45 cells (IC50 value at
403.5 nM). Besides, CM was well-tolerated in mice and fabulously suppressed the
growth of xenotransplantedMKN45 cells in immunodefıcient mice in vivo. Taken
together, our work identifıed a novel interaction of RUNX1 and ErbB2/HER2 sig-
naling pathway, paving a new way for the management of dismal-prognostic ad-
vanced stage HER2-positive gastric cancer patients.
#1531 Therapeutic strategies for osteosarcoma stem cells by regulating
adipocyte differentiation based on actin dynamics. Hiroyuki Nobusue,1
Nobuhiro Takahashi,1 Nobuyuki Onishi,1 Takatsune Shimizu,2 Eiji Sugihara,1
Yoshinao Oki,3 Koichi Akashi,4 Koichiro Kano,3 Hideyuki Saya1. 1Institute for
Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan;
2School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Tokyo, Ja-
pan; 3College of Bioresource Sciences, Nihon University, Tokyo, Japan; 4Kyushu
University Graduate School of Medical Science, Fukuoka, Japan.
We generated induced cancer stem cells that initiate osteosarcoma (OS) by
overexpression of c-MYC and loss of Ink4a/Arf in bone marrow-derived stro-
mal cells, and found that the loss of adipogenic potential is an essential event for
OS tumorigenesis. Therefore, our understanding of regulatory mechanisms of
adipocyte differentiateonwould greatly contribute to control OS tumorigenesis.
Here, we show that regulation of the transcriptional coactivator MKL1 (mega-
karyoblastic leukemia 1) by actin cytoskeleton dynamics drives adipocyte differ-
entiation mediated by PPAR. Exposure of preadipocytes to an adipogenic
cocktail results in the rapid disruption of actin stress fıbres as a consequence of
downregulation of RhoA-ROCK signaling, which regulates the formation of
actin stress fıbers and focal adhesions, and the consequent increase in mono-
meric G-actin levels. The resulting increase in the amount of G-actin leads to the
interaction of G-actin with MKL1, which prevents nuclear translocation of
MKL1 and allows expression of PPAR followed by adipogenic differentiation.
We further found that depletion of MKL1 can drive adipocyte differentiation in
preadipocytes and even in nonadipogenic fıbroblasts in the absence of an adi-
pogenic cocktail, and these data revealed that MKL1 functions as a gatekeeper
that controls adipocyte differentiation. In addition, we found that treatment
with ROCK inhibitors induced terminal adipocyte differentiateon even in OS
stem cells through regulation of MKL1 by actin cytoskeleton dynamics, which
resulted in a signifıcant suppression of tumorigenesis. Our fındings provide new
insight into the regulatorymechanismof adipogenesis, and trans-differentiation
approach by controlling actin cytoskeleton dynamics may provide a novel ther-
apeutic strategy for targeting cancer stem cells.
#1532 Mithramycin induces the antiproliferative activity of chemothera-
peutic agents in Ewing sarcoma cells.Anish Ray,1 Bhavani Nagarajan,2 Umesh
T. Sankpal,2 Sagar Shelake,2W. Paul Bowman,2Andras Lacko,2 RiyazM.Basha2.
1Cook Children’s Medical Center, Fort Worth, TX; 2University of North Texas
Health Science Center, Fort Worth, TX.
Ewing sarcoma (ES) is one of the most frequent primary bone and soft tissue
tumors that occur in pediatric and adolescent population. ES is often diagnosed
after the disease has already metastasized.With available treatment options, the
prognosis of metastatic ES patients is poor and the 5-year survival rate is less
than 20%.Therefore, identifying precise targeted therapies to induce therapeutic
response in ES patients is urgently needed. An oncogenic fusion protein and
transcription factor EWS-FLI1 is associated with more than 85% of ES tumors.
Mithramycin has been identifıed as an effective agent to target EWS-FLI1 and is
currently in clinical trials. In this study, we investigated the effıcacy of Mithra-
mycin to induce the anti-proliferative activity of chemotherapeutic agents com-
monly used for the treatment of this malignancy using human ES cell lines.
TC71, TC32, CHLA32, CHLA10 and TC205 cells were treated with increasing
concentrations of Mithramycin or Vincristine or Doxorubicin or Etoposide.
Cell growth inhibition was evaluated at 24 and 48 h post-treatment using Cell-
Titer Glo kit. Results showed a dose/time-dependent anti-proliferative effect for
all agents. To confırm the effect of Mithramycin on selected cell lines, mRNA
expression of downstream targets of EWS-FLI1 (ID2, LDB2, NROB1 and
RCOR1 genes) was determined by quantitative PCR following treatment with
Mithramycin. Mithramycin signifıcantly down-regulated all tested genes and
these results are in agreement with published work. In order to determine the
combination response, cell growth inhibition of the chemotherapeutic drugs
was assessed in the presence of addedMithramycin. The combination Indexwas
evaluated by Chou-Talalay method. Further studies were performed for the
combination ofMithramycin andVincristine to investigate its effect on apopto-
sis and cell cycle arrest using CHLA10 and TC205 cells. Apoptotic markers such
as the expression of cleaved Poly (ADP-ribose) polymerase (c-PARP) and sur-
vivin were determined by Western blot analysis. The apoptotic cell population
wasmeasured by Annexin-V staining using flow cytometry.When compared to
individual agents, the combination of Mithramycin and Vincristine showed
greater effect on apoptosis in both cell lines as evinced by an increase in An-
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nexin-V positive cells, decrease in survivin expression and up-regulation of c-
PARP. Overall, these results indicate the potential clinical advantage of combi-
nation treatment involving Mithramycin along with other chemotherapeutic
agents for inhibiting the growth of ES cells. Molecular profıling analysis is un-
derway to elucidate the candidate pathways associated with benefıcial effect of
this combination treatment.
#1533 Transcriptional inhibition of brachyury in chordoma is associated
with adoption of quiescent phenotype. Ashlee N. Seldomridge,1 Jinkyu Jung,1
Heather M. Sonnemann,1 Amber Giles,1 Kristan Meetze,2 Mark R. Gilbert,1
Claudia M. Palena,3 Deric M. Park1. 1Neuro-Oncology Branch, CCR, National
Cancer Institute, NIH, Bethesda, MD; 2Tragara Pharmaceuticals, Carlsbad, CA;
3Laboratory of Tumor Immunology and Biology, CCR, National Cancer Institute,
NIH, Bethesda, MD.
BACKGROUND: Brachyury is amesoderm specifıcation transcription factor
involved in notochord development and overexpressed in a variety of cancers,
including chordoma. High levels of brachyury protein expression in cancers is
associated with a poor prognosis in part due to its role in mediating epithelial-
mesenchymal transition (EMT). TG02 is a multikinase inhibitor that targets
transcriptional regulation of cyclin-dependent kinases (CDKs). Because chor-
doma is characterized by a relative paucity of genomic mutations and largely
driven by the super-enhancer activity of brachyury expression, we investigated
the downstream effect of a transcriptional inhibitor, TG02, in chordomas.
METHODS: Established chordoma cell lines, UCH-1 and UM-Chor1, were ex-
posed to increasing concentrations of TG02 to determine effect on brachyury
protein expression. qPCR was used to analyze brachyury mRNA expression as
well as themesenchymal proteins, vimentin and fıbronectin, typically associated
with brachyury expression in tumor cells. Cell migration was evaluated using
wound healing assay. CellTiterGlo Luminescence Assay was used to quantify
cell viability. RESULTS: TG02 down-regulated protein expression of brachyury
in a dose-dependent manner. Attenuation of brachyury expression was seen
within 4 hours and persisted for 5 days upon single exposure to a clinically
relevant concentration of TG02. Brachyury downregulation did not affect cell
count or viability, and was associated with a quiescent phenotype, including
impaired migration. Expression of vimentin and fıbronectin, both associated
with EMT, was also suppressed within 4 hours of TG02 treatment and persisted
for 24 hours. CONCLUSIONS: Inhibition of brachyury expression and its
downstream signaling is associated with quiescent behavior of chordoma cells.
Pharmacologically induced transcriptional targeting of brachyury usingTG02, a
potent CDK9 inhibitor, represents a potential therapeutic strategy.
#1534 The signifıcance of a p53 gain-of-functionmutation in the acquisi-
tion of metastatic traits in the SW13 cell line.McKaleMontgomery, Elizabeth
Hull.Midwestern University, Glendale, AZ.
The therapeutic potential of histone deacetylase inhibitors (HDACi), shown
to epigenetically regulate a variety of genes, has yet to be fully realized due to
their documented pleiotropic effects in vivo. Currently, four HDACi are FDA-
approved for the treatment of hematological malignancies, but their effective-
ness against other types of cancers have been shown to be limited at best and, as
a result, most of these clinical trials have failed. A comprehensive review of the
recent literature has identifıed that approximately 50% of all cell lines treated
with an HDACi demonstrate an increase in metastatic potential as measured by
increases in migration and invasion. Of these cell lines that respond with in-
creased metastatic potential to HDACi treatment, 60% have a gain-of-function
mutation within p53 (p0.03). As HDACi have been shown to destabilize mu-
tant p53, they have been used in studies to examine the effects of HDACi treat-
ment on cancers with an identifıed p53 mutation. This is concerning as the
specifıc p53 mutation in these cancers is not always known, and thus treatment
could potentially result in an increase in cancer cell growth. Previouswork in our
lab demonstrates that the human SW13 adrenal adenocarcinoma cell line, which
harbors a homozygous H193Y gain-of-function mutation, does have an
HDACi-inducedmetastatic phenotype; treated cells demonstrate signifıcant in-
creases in MMP activity and 50% reduction in p53 protein expression com-
pared to untreated cells. To investigate the role that a decrease in mutant p53
expression plays in the acquisition ofmetastatic characteristics we utilized stable
shRNA plasmids to knock-down p53 expression in the SW13 cell line. HeLa
cells, which possess a wild-type p53 gene, were used as a positive control. We
found that a decrease in p53 expression alone was not suffıcient to induce
changes in SW13 growth or invasiveness. In fact, even though p53 expression
was knocked down by70% in the shRNA lines, HDAC inhibition still induced
the acquisition of metastatic properties in these cells. Intriguingly, while the
DNA binding activity ofmutant p53 was correlated with protein expression and
was signifıcantly decreased following HDAC inhibition, the same response was
not observed in HeLa cells. These fındings suggest that p53 status may be an
important determinant of therapeutic response to HDAC inhibition.
#1535 Angiogenesis-related gene expression profıle of a novel antiangio-
genic agent F16 in human vascular endothelial cells. Khalid Alhazzani, Ali
Alaseem, ThiagarajanVenkatesan, AppuRathinavelu.Nova SoutheasternUniv.,
Davie, FL.
Angiogenesis is a key process in tumor propagation, progression, and metas-
tasis. This process is tightly modulated by a wide range of growth factors, recep-
tor tyrosine kinases, cytokines, matrix metalloproteinases, and transcription
factors. Distinctively, vascular endothelial growth factor (VEGF) and their re-
ceptors have been identifıed as prominent stimulators of tumor angiogenesis.
Therefore, inhibiting VEGF-induced tumor angiogenesis has been explored ex-
tensively for cancer therapy. In this context, F16, a novel small molecule pos-
sessing a unique molecular confıguration to block VEGFR2, has been subjected
to intensive preclinical investigations. The F16 molecule exhibits in vitro anti-
angiogenic activity via inhibiting endothelial cell proliferation, migration, and
tube formation. In addition, F16 was found to signifıcantly inhibit the in vivo
angiogenesis in chick chorioallantoic membranes as well as in athymic nude
mice with xenograft tumors. As a consequence of the antiangiogenic effects, F16
was able to effectively control the tumor growth in mice with xenograft tumors.
In the present study, we aimed to comprehensively interrogate the impact of F16
treatment on the expression of a panel of angiogenesis-related genes to gain
insight into the underlying molecular mode of action. We analyzed the expres-
sion of 84 genes that are known to be associated with angiogenesis in human
umbilical vein endothelial cells (HUVECs). Our pilot study identifıed upregu-
lation of some key genes in response to F16 treatment which include tissue
inhibitor of metalloproteinase 1 (TIMP1), angiopoietin-like 4 (ANGPTL 4),
chondromodulin 1 (LECT 1), and placenta growth factor (PIGF). On the other
hand, several genes involved in promoting angiogenesis were downregulated,
which include matrix metallopeptidase 9 (MMP9), integrin subunit beta 3
(ITG 3), insulin growth factor 1 (IGF 1), transforming growth factor alpha
(TGF), interleukin 6 (IL 6), leptin (LEP), thrombospondin -1, -2 (THBS -1, -2),
tyrosine kinase (TEK), VEGF B and C. The differential genes expression related
to pro- and anti-angiogenic growth factors coincide very well with our previous
observation of F16 inhibiting endothelial cell proliferation, migration and tube
formation. Based on the Gene Expression Profıle (GEP) observed in our exper-
iments, we speculate that F16 can induce TIMP1 which in turn could suppress
theMMP9 signaling leading to the inhibition of endothelial cell migration. This
disruption of TIMP1/MMP9 pathway offers an interesting foundation for func-
tional studies that can be performed to confırm the role of F16 as a potential
MMP9 inhibitor, which may provide extended benefıts during the use of this
drug for treating highly metastatic cancers. (This project was supported by The
Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida).
#1536 CRISPR/Cas9 biasedmutagenesis in themouse genome: Is it useful
or harmful for cancer therapeutics.Ha Youn Shin. NIH, Bethesda, MD.
Advances in CRISPR/Cas9 genome editing have provided unprecedented op-
portunities to interrogate the functional signifıcance of any given genomic site.
While this technology is rapidly spreading and extended to with almost 4,000
PubMed entries as of today, there is a paucity of data on the extent of unexpected
and undesired molecular consequences established upon targeting the mouse
genome.We have introduced deletions at more than 20 genomic sites including
CTCF and STAT5 transcription factor binding sites, screened over 500 founder
mice and established and analyzed more than 50 lines. These data sets revealed
hitherto unknown deletion patterns, unexpected large deletions using single
sgRNAs and the consistent deletion of sequences bridging distant loci that were
targeted simultaneously. Our fındings provide guidelines for the application of
CRISPR/Cas9 in the mouse germline and provide the insight into designing
CRISPR-based cancer therapeutics.
#1536A Progesterone receptor regulation of interferon signaling in
breast cancer. Katherine Walter, Merit Goodman, Gloria Trinca, Jade Hall,
Christy Hagan. University of Kansas Medical Center, Kansas City, KS.
Breast cancer is an extremely heterogeneous disease that affects close to two
million women across the globe each year. Of these breast tumors, approxi-
mately 70% express the progesterone receptor (PR), a nuclear receptor that is
activated in response to its ligand progesterone. Compelling clinical trial data
has suggested that progestins have a role in breast cancer development, inde-
pendent of the widely studied estrogen receptor. The mechanism by which this
occurs, however, is vastly understudied. Traditionally, PR exerts its effects fol-
lowing ligand activation by translocating to the nucleus and binding to DNA
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where it affects the transcription of a variety of genes involved in growth, sur-
vival and proliferation. Our lab, using microarray data combined with Gene Set
Enrichment Analysis, has identifıed a novel subset of genes that have altered
expression following PR activation. These genes are primarily involved in inter-
feron signaling—a pathway normally utilized in response to viral infection. Our
data show that many genes that are normally activated in response to interferon
signaling (interferon stimulated genes, ISGs) are repressed when PR is activated
by its ligand. Interestingly, this repression occurs even in the presence of inter-
feron alpha—the activating ligand of the interferon signaling cascade. Our lab
has also shown that when PR expression is transiently knocked down, ISG tran-
scriptional repression is lost, indicating that the repression of these genes is PR
dependent. In attempting to elucidate a mechanism by which PR exerts this
effect, we have performed chromatin immunoprecipitation experiments follow-
ing PR activation and observed PR recruitment to ISG enhancer regions. This
suggests PR is potentially interfering with normal transcription of these genes.
Wehypothesize that PR is functioning by either blocking normal transcriptional
machinery and co-activators or through the recruitment of transcriptional co-
repressors to these regions. Experiments to address these models are currently
underway. Evasion of the immune system has recently been added to the list of
Hallmarks ofCancer and our preliminary data suggest a potentialmechanismby
which breast cancer is able to accomplish this. Activation of type I interferon
signaling is an early step inmarking tumors for immune clearance. By repressing
ISG protein expression, it is possible that these tumors are able to avoid detec-
tion by host immune cells leading to tumor establishment and subsequent pro-
gression. Our preliminary data suggest that PR may be capable of aiding early
breast malignancies in evading immune recognition. This novel role of PR and
progestins offers insight that could aid in improving upon established estrogen
only-based therapies for prevention and treatment of hormone dependent
breast cancers.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Tumor
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#1537 3p13-14 FOXP1-SHQ1 deletion spanningmultiple potential tumor
suppressor genes cooperates with PTEN loss in cancer. Haley Hieronymus,
Philip J. Iaquinta, JohnWongvipat, AnuradhaGopalan, RajmohanMurali, Nin-
ghui Mao, Brett S. Carver, Charles L. Sawyers.Memorial Sloan Kettering Cancer
Center, New York, NY.
The recurrent 3p13-14 deletion spanning from FOXP1 to SHQ1 occurs fre-
quently in prostate cancer and is broadly lost in a range of cancer types, but this
deletion has unknown tumor suppressive potential. FOXP1-SHQ1 deletion sig-
nifıcantly co-occurs with PTEN loss in prostate cancer and other cancers. We
fınd that FOXP1-SHQ1 deletion cooperates with PTEN loss to accelerate pros-
tate cancer development in mice, resulting in tumors with increased prolifera-
tion and highly anaplastic dedifferentiation. FOXP1-SHQ1 deletion in these
PTEN null tumors results in selective mTORC1 pathway hyperactivation be-
yond that mediated by PTEN loss alone. FOXP1-SHQ1 deletion also partially
rescues AR target gene inhibition caused by PTEN loss, circumventing the re-
pression of the androgen axis seen upon PI3K pathway activation. Clinically,
combined FOXP1 and PTEN loss is associated with increased prostate cancer
recurrence, and this fınding extends to other cancer types, most notably breast
cancer.
#1538 Amouse model that mimics humanMEN1 tumor is effective in pre-
clinical neuroendocrine tumor therapeutics. Chung Wong,1 Richard Clausen,1
Laura Tang,2 Christian Davidson,3 Evan Vosburgh,1 Arnold Levine,4 Eugenia Xu1.
1Raymond and Beverly Sackler Foundation, New Brunswick, NJ; 2Memorial Sloan-
KetteringCancerCenter,NewYork,NY; 3RutgersCancer Institute ofNewJersey,New
Brunswick, NJ; 4Institute for Advanced Study, Princeton, NJ.
Conditional knockout of Men1 in  cells leads to development of pituitary ade-
nomas and pancreatic neuroendocrine tumors (PanNETs) by the age of eight to
twelve months. This suggests that other events, like loss of additional mutations,
may be required for development of tumors in the absence of MEN1. Since it was
reported that mutations in genes of PI3K/mTOR pathway are found in human
neuroendocrine tumors, we hypothesized that double deletion of PTENandMEN1
may accelerate neuroendocrine tumorigenesis.Mice with double deletion of PTEN
andMEN1 in cellswereproducedby crosses amongmicewithCre geneunder the
control of Rat Insulin promoter (Rip-Cre), floxed allele Men1 (Men1fl/fl), and Pten
(Ptenfl/fl). Thenmicewith the genotypeofMen1fl/fl Ptenfl/fl Rip-Creweremonitored
for development of tumors. Consistent with our hypothesis, mice with conditional
deletion of PTEN andMEN1 leads to fully developed PanNETs and pituitary ade-
nomasby three to fourmonthsold,muchearlier thanthatwithMen1deletionalone.
These tumors resemble humanMEN1 tumors at a histological andmolecular level.
Activation of phospho-AKT was observed in these tumors and Rapamycin treat-
ments lead to delayed PanNETs and pituitary adenomas for at least two months.
This mouse model (Men1fl/fl Ptenfl/fl Rip-Cre) directly supports that PI3K/mTOR
pathway plays a critical role in neuroendocrine tumorigenesis, and also provides a
platform to study new therapeutic opportunities for PanNETs and neuroendocrine
tumors of the pituitary through the targeting of PI3K/mTOR pathway and MEN1
pathway. This model represents an important tool for studying the biology and
preclinical therapeutics of human neuroendocrine tumors.
#1539 Investigating the mechanisms of tumor suppression mediated by
PTEN PDZ-binding domain in a murine breast cancer model. Mingfei Yan,1
Alexander Many,2 Hong Guan,3 Penelope M. Or,1 Andrew M. Chan1. 1School of
Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong,
Shatin, Hong Kong; 2Department of Oncological Sciences, Mount Sinai School of
Medicine, New York, NY; 3Department of Pediatrics, Medical College of Wisconsin,
Milwaukee,WI.
PTEN(Phosphatase and tensinhomolog) functions as a keynegative regulator of
PI3K-Aktpathway through its lipidphosphataseactivity.Mutationsor lossofPTEN
is frequently observed in brain, breast, prostate and endometrial cancer. PTENpos-
sesses a PDZ-binding domain (PDZ-BD) at the end of its carboxyl terminus. Func-
tionally, PDZ-BDmediates PTEN’s interactions with other PDZ domain-contain-
ing proteins, including ZO-1, PSD-95, DLG, etc, which are involved in the
formation of cell junctions, post-synaptic densities, and serves as scaffolding pro-
teins for multiple signaling complexes. However, whether the PTEN PDZ-binding
domain is required to suppress tumorigenesis still remains obscure. To study the
role of PTENPDZ-BD inbreast epithelial tumorigenesis, a PTEN-PDZmice lack-
ing this domain was generated. PTEN expression level and activity of PI3K-Akt
pathwayarenot changed in themammaryepithelial cells, indicating thatPDZ-BDis
dispensable for PTEN stability and negative regulation of the PI3K-Akt pathway.
Further, we crossed the PTEN-PDZ mice with the MMTV-PyMT breast cancer
model andobserved increased total tumorburdenaswell as higher tendencyof lung
metastasis in PTEN-PDZmice. This data indicates that PTENPDZ-BD is indeed
important for tumor suppression during breast cancer progression. Previously,
PTEN has been reported to govern the integrity of tight junctions and apical-basal
polarity of epithelial cells, which requires PTEN’s interactions with other proteins
through the PDZ-BD. However, through in vitro three-dimensional culture of pri-
marymousemammary epithelial cells, we failed to observe any disruption of either
apical-basal polarity or tight junction. Meanwhile, we investigated the alteration of
the transcriptomeofbreast cancer tissue inPTEN-PDZmicebyperformingRNA-
sequencing. Several enriched signaling pathwayswere identifıed by Ingenuity Path-
wayAnalysis (IPA),which seems tobemainly associatedwith cell skeleton signaling
aswell as signaling interactionbetweenextracellularmatrixand thecancer cell.A list
of geneswere validated byRT-PCR, and functional validation of these genes during
the tumorigenesis in our animal model is to be carried out in the near future. This
work was supported by a General Research Fund grant (#460713) from the Hong
KongUniversityGrantsCommittee toAC.YMwassupportedbyaHongKongPhD
Fellowship (PF12-13584), and a LoKwee-SeongBiomedical Research Seed Fund to
AC.
#1540 Creating faithful genetic zebrafısh models of pediatric high grade
gliomas and MPNSTs. Felix Oppel, Ting Tao, Shuning He, Mark W. Zimmer-
man, Dong H. Ki, Nina Weichert, A Thomas Look. Dana-Farber Cancer Insti-
tute, Boston, MA.
Pediatric high-grade gliomas (HGGs) are the leading cause of cancer-related
death in children. Despite a slight improvement of patient prognosis over the
past decades pediatric HGGs remain largely incurable. Thus, new experimental
models are needed to understand the mechanisms of the disease and fınd more
effective treatment options. We previously reported a model of HGGs and ma-
lignant peripheral nerve sheath tumors (MPNSTs) which is based on the com-
bined defıciencies in the tumor suppressor genes tp53 and nf1. However, HGG
penetrance is very low in this line and most fısh develop MPNSTs starting at
about 3 months of age. On top of the existing model we used CRISPR/Cas9 to
incorporate knock-out mutations in the tumor suppressor genes atrx or suz12
which are described to be involved in pediatricHGGbiology. Heterozygous atrx
loss-of-function (lof) did not impact tumor onset or penetrance of neither
HGGs nor MPNSTs. Since a total loss of atrx was lethal in development, we
re-injected effective atrx targeting gRNAs and Cas9 mRNA into the atrx/
line to create a mosaic atrx-/- genotype. Surprisingly, despite a high mutation
effıciency of the remaining atrx allele the re-injection strategy still did not alter
tumor onset and penetrance in that model. This suggests that loss of atrx is only
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effective inHGGs in cooperationwith additional hits other than tp53 and nf1. In
contrast, loss of suz12 cooperated well with the tp53/nf1-defıcient background.
As nf1, suz12 is duplicated in zebrafısh (suz12a and suz12b) resulting in 4 alleles
of each gene per cell. When at least 2 out of 4 alleles of either suz12a or suz12b
were lost, MPNST onset was accelerated. This effect was much stronger in
tp53-/-, nf1a/, nf1b-/- fısh (5-7 weeks) compared to tp53-/-, nf1a/,
nf1b-/- siblings (3-4 weeks). This indicates that the tumor supporting effect of
suz12 lof increases the more nf1 levels decrease. However, HGG onset still re-
mained unchanged. We hypothesize that effıcient onset of HGGs in our model
requires the presence of an activated oncogene. Specifıc missense mutations in
H3F3A are reported to be implicated inHGGprogression in children and young
adults. Thus, we overexpressed zebrafısh h3f3a-K27M or -G34R mutant se-
quences in the tp53/nf1/atrx/suz12-defıcient line and are currently investigating
possible changes in tumor biology. Our zebrafıshmodels of pediatric HGGs and
MPNSTs will be useful to dissect the mechanisms underlying the cooperation
among driver mutations and for small molecule screens to identify specifıc in-
hibitors of cell growth and survival in these malignancies.
#1541 The tumor suppressor BAP1 promotes a developmental switch
from pluripotency to differentiation. Jeffım N. Kuznetsov, Tristan Aguero,
Stefan Kurtenbach, Matthew G. Field, Mary Lou King, J WilliamHarbour.Uni-
versity of Miami Miller School of Medicine, Miami, FL.
Introduction: Our lab discovered that mutations in the tumor suppressor
BAP1 are strongly associated with metastasis and death in patients with uveal
melanoma. Subsequently, other cancers have been found to harbor BAP1 mu-
tations, including skin melanoma, kidney cancer, mesothelioma and others.
Germline BAP1 mutations are responsible for a newly described genetic cancer
syndrome. Therapeutic molecules that reverse the effects of BAP1 mutations
could represent a potent new treatment strategy for BAP1-mutant cancers. Un-
fortunately, there are several obstacles to developing such therapies. First, BAP1
is a tumor suppressor that is inactivated bymutations, such that targeted therapy
would need to be directed against downstream effectors that are deregulated by
BAP1 loss. Second, the effectors of BAP1 that are relevant to cancer are not
known. Interestingly, most known proteins that interact with Bap1 are develop-
mental epigenetic regulators such as Asxl1/2, Cbx1/3 and Kdm1b. Third, BAP1
is diffıcult to study in cultured cells because BAP1 loss results in cell cycle exit
and stemcell-like behavior. These obstacles led us to shift toXenopus laevis as an
in vivo developmental model to study the functions of BAP1. Results and con-
clusions: Loss of BAP1during embryodevelopment results in a failure to turn off
pluripotency genes such as ventx 1, ventx2 (Xenopus orthologues of the mam-
mal gene nanog), oct 25, oct 91 (Xenopus orthologues of the mammal gene
oct3/4) and pax3, and a failure to induce lineage specifıcation genes such as the
prospective epidermis marker keratin1 and the melanocyte precursor marker
sox10. This block in the shift from pluripotency to differentiation programs
results in a delay in gastrulation, neural crest specifıcation and migration, me-
sodermal differentiation and other phenotypes. The BAP1-defıcient phenotype
can be rescued by Xenopus or human wildtype BAP1 or by the histone deacety-
lase inhibitor SAHA (vorinostat). We conclude that BAP1 is a fundamental
regulator of multiple developmental lineages, including the neural crest from
which melanomas arises, and that this in vivo model can be used to screen for
novel therapeutic compounds that reverse the phenotypic effects of BAP1 loss.
#1542 Identifying genetic modifıers of PTEN using the Collaborative
Cross mouse panel. Amanda Lanier, William Barrington, David Threadgill.
Texas A&M University, College Station, TX.
Tumor suppressor genes code for proteins that limit cellular proliferation and
cancer progression, and are often exploited in cancer therapies. One such tumor
suppressor gene, Phosphatase and Tensin homolog deleted from Chromosome
Ten (PTEN),mediates cell growth through negative regulation of phosphatidyl-
inositol 3-kinase (PI3K) dependent pathways. PTEN is frequently deleted or
mutated in a variety of human cancers.Mice carrying a PTEN transgene (Super-
PTEN mice) were found to be resistant to tumor formation, and even small
changes in PTEN expression and activity have been shown to influence cancer
susceptibility and progression. We hypothesized that PTEN activity can be al-
tered by modifıer genes. To determine whether PTENmodifıers are influencing
its activity, we are using the Collaborative Cross (CC), a panel of inbred mouse
strains that has a similar amount of genetic variation as human populations. In
CC-Super-PTEN crosses, we are utilizing an easily measured phenotype of Su-
per-PTENmice, reduced body weight, to identify CC strains with altered PTEN
function. On average, weanlings carrying the PTEN transgene weigh 16% less
than their wild type littermates, but this weight difference varies signifıcantly
across strains, from no weight reduction to as much as a 29% difference. This
distribution of phenotypes has allowed us to use quantitative trait locus (QTL)
mapping to identify potential modifıers of PTEN. Through association map-
ping, we have determined that the loci with the highest LOD scores reside on
chromosomes 2, 12, 16, andX, andwe are now reviewing genes within those loci
to identify candidate modifıers of PTEN. Additionally, we are using several
cancer models to determine the effects of said candidate genes and confırm that
an altered PTEN weight phenotype correlates with changes in cancer suscepti-
bility and progression. Ultimately, this research will demonstrate the use of the
CC mouse panel to identify novel genetic modifıers and improve our under-
standing of PTEN regulation.
#1543 Caspase-10 suppresses tumorigenesis by targeting ATP-citrate
lyase. Rajni Kumari, Sanjeev Das.National Institute of Immunology, New Delhi,
India.
p53 fosters metabolic reprogramming, which restricts metabolic adaptation
of tumor cells under energy stress conditions. However, modulation and direc-
tionality of underlying cascades to induce or restrictmetabolism are determined
by the downstream target of p53. To explore the role of p53 in tumormetabolism
upon metabolic stress, we performed a microarray screen in the presence or
absence of p53 under glucose starvation. We observed caspase-10 to be upregu-
lated by p53 upon metabolic stress. Caspase-10 belongs to the class of initiator
caspases and is poorly understood in terms of substrate specifıcities. Emerging
evidences also suggest intrinsic activation of caspase-10, distinct from its homo-
logue caspase-8. Moreover, inactivating mutations as well as downregulation of
caspase-10 in several carcinomas are suggestive of its role in tumorigenesis.
Thus, we investigated the function of caspase-10 as a tumor suppressor. Our
results indicated that caspase-10, upregulated in a p53-dependent manner in
response to metabolic stress, was activated by homodimerization-induced in-
trinsic activation mechanism involving Adenylate Kinase 2 and FADD. We
further performed a proteomic screen to identify novel caspase-10 substrates.
We observed that several anabolic enzymes are caspase-10 interacting partners.
However, in vitro and in vivo assays confırmed only ATP-Citrate Lyase (ACLY)
as a novel substrate of caspase-10. Cleavage of ACLY by caspase-10 abrogates
enzymatic conversion of cytosolic citrate to acetyl-CoA, leading to overall de-
crease in nucleocytosolic acetyl-CoA pool. Decrease in cytosolic acetyl-CoA
levels suppress lipogenesis upon metabolic stress. Moreover, decreased levels of
nuclear acetyl-CoA alter global histone acetylation. Further studies using RNAi
established that alteration in histone acetylation is GCN5-dependent. Caspase-
10-dependent abrogation of histone acetylation reprograms the epigenetic pro-
fıle of metastatic and proliferative genes, leading to their diminished expression
under metabolic stress. Concomitant suppression of both cytosolic lipogenesis
and nuclear histone acetylation by caspase-10-mediated ACLY cleavage de-
creases proliferation capacity, migration potential and invasiveness of tumor
cells. Further, studies in mouse tumor models confırmed that caspase-10 re-
stricts tumorigenesis and metastases under metabolic stress via ACLY and
GCN5. Taken together, our fındings establish caspase-10 as a novel integrator of
metabolism and epigenetics, by regulating acetyl-CoA levels. Hence, it functions
as a tumor suppressor by disrupting lipogenesis-mediated metabolic repro-
gramming and GCN5-mediated epigenetic reprogramming.
#1544 MTAP insuffıciency promotesmetastasis in lung cancer via dimin-
ishing protein dimethylation. Wen-Hsin Chang,1 Bing-Ching Ho,1 Kang-Yi
Su,1 Jian-Wei Chen,2 Reen Wu,3 Pan-Chyr Yang,1 Sung-Liang Yu1. 1National
Taiwan University, College of Medicine, Taipei, Taiwan; 2National Chung Hsing
University, Taichung, Taiwan; 3University of California Davis, Davis, CA.
Genome instability, metabolic switch, and activating metastasis are three of
the cancer hallmarks,which always collectively contribute to cancermalignancy.
We identifıedmethylthioadenosine phosphorylase (MTAP) as ametastasis sup-
pressor in a series isogenic lung cell lines with different invasion ability by array
CGH. Using siRNA silencing and ectopic expression of MTAP, we found that
MTAPnot only inhibited invasion and colony forming in vitro, but also reduced
metastasis and tumorigenesis in vivo. Clinically, patients with low MTAP ex-
pression associated with poor overall survival and progression-free survival.
Furthermore, the metabolite analysis of clinical specimens showed that low
MTAP expression leads to MTA substrate accumulation and product decrease.
MTA accumulation in MTAP knockout cells reduced the level of symmetric
arginine dimethylation of proteins. By using LC/MS, we identifıed a novelmeth-
yl-protein, whose level is elevated inMTAP knockout cells with the depletion of
symmetric arginine dimethylation. Functionally, the unmethylated protein
would be protected from proteolysis via caspase 3 cleavage. Moreover, the un-
methylated mutant protein promoted migration and invasion in vitro strongly
than the wild-type one did. In conclusion, we identify a novel marker in low
MTAP expression or MTAP knockout cells, providing a potential therapeutic
candidate in lung adenocarcinoma.
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#1545 Loss of glycogen debranching enzyme (AGL) promotes rapid
growth of non-small cell lung cancer cells. David R. Meier, Benjamin Wein-
haus, Darby Oldenburg, Sunny Guin. Gundersen Medical Foundation, La
Crosse, WI.
Glycogen Debranching Enzyme (AGL) is involved in glycogen breakdown.
Compromise in glycogen breakdown due to loss of function mutations in the
AGL gene lead to metabolic disease - Glycogen Storage Disease Type III. We
have previously shown that loss of AGL results in rapid growth of bladder cancer
cells using extensive in vitro and in vivo experiments. Here we test whether AGL
regulate growth of non-small cell lung cancer (NSCLC) cells. We show that loss
of AGL promotes rapid growth of NSCLC cells using anchorage independent
growth assay. Loss of AGL also resulted in rapid xenograft growth of NSCLC
cells when injected subcutaneously in immunocompromised mice. Whereas
overexpression of AGL reduce the growth of these NSCLC cells. Further loss of
glycogen phosphorylase the other enzyme involved in glycogen breakdowndoes
not promote aggressive growth of these cancer cells. This observation is similar
to our fındings in bladder cancer which confırms that AGL regulates tumor
growth independent of its role in glycogen metabolism. Thus using in vitro and
in vivo experiments we show that AGL can regulate the growth of multiple
tumor types such as bladder cancer and NSCLC. The exact mechanism on how
AGL regulates NSCLC growth needs further investigation.
#1546 Contribution of heterozygous loss of ribosomal protein L5 as gen-
eral tumor suppressor in cancer. Kim R. Kampen, Laura Fancello, Jelle Ver-
beeck, Kim De Keersmaecker. KU Leuven, Leuven, Belgium.
The association between ribosome defects and cancer became clear with the
recent discovery of somatic mutations in ribosomal protein genes in several
cancers, such as lymphoid leukemia’s and glioblastoma (Nat Genet. 2013 Feb;
45(2):186-90 & Blood. 2016 Feb 25;127(8):1007-16 & Nature. 2014 Jan 23;
505(7484):495-501). To further delineate the role of ribosomal proteins in hu-
man cancer,we systematically screened theTCGAdatabase for genetic lesions in
ribosomal protein genes, confırmed the contributing capacity of the most com-
mon somatic ribosomal protein defect in cancer pathogenesis by molecular in-
terference, and explored the mode of action of this ribosomal protein defect.
Systematic analysis of TCGA mutation and copy number data of respectively
4926 and 7322 patients representing 16 cancer types for defects in all 81 ribo-
somal protein genes. After stringent fıltering, six ribosomal protein encoding
genes (RPL5, RPL11, RPL23A, RPS5, RPS20 and RPSA) were signifıcantly al-
tered and identifıed as candidate cancer driver genes. RPL5 was located at a
signifıcant peak of heterozygous deletion on chromosome 1p22 and showed
signifıcant mutations and deletions in 11% of glioblastoma (GBM), 28% of mel-
anoma, 34% of breast cancer (BRCA), and in 20% of multiple myeloma cases,
thereby supporting heterozygous RPL5 inactivation to be the most common
somatic ribosomal protein defect in human cancer. Human specifıc RPL5 doxy-
cycline inducible knockdown (sh-hRPL5) inTP53WTandTP53mutant human
breast cancer cell lines (MCF7 andMDA-MB-231) and in aTP53mutant human
glioblastoma cell line (U-118 MG) proved that RPL5 knockdown accelerated in
vivo tumor progression in NSG mice. This acceleration was associated with
reduced phosphorylation of CDK1tyr15, which is required for cell cycle progres-
sion from G2 to mitosis. Whereas RPL5 has been implicated in TP53 and MYC
regulation, no consistent effects of RPL5 downregulation on these proteins
could be detected in TP53 WT and TP53 homozygous R280K mutant breast
cancermodels (sh-hRPL5). Interestingly, partial RPL5 inactivationwas found to
be associated with PTEN protein suppression in these tumors. This observation
was confırmed in various cell models; in normal mouse neural stem/progenitor
cells andmouse bonemarrow cells (RPL5/lox by INF and poly I:C), and also in
GBM cancer pre-disposition mouse neural stem/progenitor cell model (sh-
mRPL5TP53 -/-). RPL5 downregulation also accelerated tumor formation in the
PTEN defıcient GBM cell line U-118MG, underscoring undefıned PTEN-inde-
pendent mechanisms of RPL5. Overall, we identifıed RPL5 as a new tumor
suppressor that shows heterozygous inactivation in 11-34% of multiple human
cancer types. Partialmolecular inactivation of RPL5 supported a tumor suppres-
sor function for RPL5 in accelerating breast cancer and glioblastoma progres-
sion in vivo, which may be, in part, due to a new function of RPL5 in regulating
PTEN.
#1547 BCCIPmodulates the ribosomal and extraribosomal function of
S7 through a direct interaction. Qian Ba, Hui Wang. Institute for Nutritional
Sciences, SIBS, CAS, Shanghai, China.
Extraribosomal functions of ribosomal proteins (RPs) have gained much at-
tention for their implications in tumorigenesis and progression. However, the
regulations of transition between the ribosomal and extraribosomal functions of
RPs are rarely reported. Herein, we identifıed a novel ribosomal protein S7-
interacting partner, BCCIP, which could modulate the functional conversion
of S7. Through the N-terminal acidic domain, BCCIP interacted with the cen-
tral basic region in S7 and regulated the extraribosomal distribution of S7.
BCCIP defıciency abrogated the ribosomal accumulation but enhanced the
ribosomal-free location of S7. This translocation further impaired protein syn-
thesis and triggered ribosomal stress. Consequently, BCCIP defıciency sup-
pressed the ribosomal function and launched the extraribosomal function of S7,
and eventually resulted in cell proliferation restriction. In conclusion, BCCIP,
as a novel S7 modulator, contributes to the delicate regulation of ribosomal and
extraribosomal functions of S7 and has implications in cell growth and tumor
development.
#1548 Down-regulation of 4-hydroxyphenylpyruvate dioxygenate (HPD)
contributes to the pathogenesis of hepatocellular carcinoma (HCC) through
ERK / BCL-2 signalling activation.ManTong,1 Tin LokWong,1 Steve Tin-Chi
Luk,1 Noélia Che,1 Kai Yau Wong,1 Tsun Ming Fung,1 Xin-Yuan Guan,1 Nikki
P Lee,1 Yun-Fei Yuan,2 Terence K Lee,3 Stephanie Ma1. 1The University of Hong
Kong, Hong Kong; 2State Key Laboratory of Oncology in Southern China, Sun
Yat-Sen University Cancer Center, Guangzhou, China; 3The Hong Kong Poly-
technic University, Hong Kong.
Hepatocellular carcinoma (HCC) is one of the most prevalent malignan-
cies in the world. Metastasis, recurrence and therapy resistance remain ma-
jor obstacles to the improvement of long-term survival and represent major
causative factors contributing to the rising mortality rates and poor progno-
sis of HCC. Identifıcation of key drivers important for clinical prognostic
utility and elucidation of mechanisms involved in hepatocarcinogenesis is
urgently needed to aid in the development of novel treatment modalities. To
this end, we began our study with an analysis of a publicly gene expression
dataset (GSE14520) comprising of transcriptomic profıles from a large co-
hort of human non-tumor liver and HCC clinical samples in hope to estab-
lish a prognostic gene signature associated with metastatic risk / recurrence
status so to identify novel driver genes responsible for HCC development
and progression. By this method, 4-hydroxyphenylpyruvate dioxygenase
(HPD) was identifıed as a candidate tumor suppressor gene in HCC. HPD
was found to be frequently down-regulated in primary HCC tumors as com-
pared with peri-tumor liver tissues. Its expression negatively correlated with
aggressive HCC pathological features, including tumor stage, metastasis,
recurrence and survival. Notably, down-regulated HPD expression in HCC
is in part a result of hypermethylation at the HPD promoter. The functional
effect of HPD was then examined in HCC cells with or without HPD stably
repressed or ectopically overexpressed. Upon knockdown of HPD, HCC
cells displayed signifıcantly enhanced abilities to form tumors, metastasize
and confer sorafenib resistance in vitro and in vivo. Conversely, overexpres-
sion of HPD in HCC cells led to an opposing effect. Consistently, sorafenib-
resistant HCC patient derived xenografts also displayed attenuated levels of
HPD as compared with parental sorafenib-sensitive counterparts. Mecha-
nistically, HPD down-regulation mediates aggressive cancer features in
HCC through activation of an ERK and BCL-2 pro-survival signaling path-
way, as evidenced by rescue experiments involving the ERK inhibitor U0126.
Collectively, our fındings suggest HPD down-regulation in HCC tumors to
promote tumorigenicity, metastasis and sorafenib resistance through ERK /
BCL-2 signaling activation and that HPD may represent a novel prognostic
biomarker for HCC.
#1549 Prognostic signifıcance and tumor suppressive functions of SDCT2
in renal cell carcinoma. Andre R. Jordan,1 Martin Hennig,2 Daley S. Morera,3
SoumD. Lokeshwar,1 Asif Talukder,3 Lokeshwar Vinata3. 1University ofMiami,
Miami, FL; 2University of Lübeck, Lübeck, Germany; 3Augusta University, Au-
gusta, GA.
Introduction: Five-year survival of metastatic renal cell carcinoma (mRCC)
patients is 10% andAfrican American (AA)males have the highest incidence.
Identifıcation of the molecular determinants of mRCC and racial disparity in
RCC is critical for biomarker development and targeted therapy. SDCT2 is ex-
pressed in kidney epithelial cells and is a succinate and citrate transporter, but its
role has not been examined in any benign diseases or cancer. We examined
SDCT2 expression in normal and RCC tissues and correlated it with clinical
outcome and racial disparity. We also evaluated the biological functions and
molecular signaling regulated by SDCT2 in RCC cells. Methods: Differential
gene expression in the matched normal and RCC tissues (n6/category) was
evaluated by microarray analysis; results were validated by quantitative-PCR
and immunoblotting in normal and RCC tissues from 53 patients (White21;
Hispanic19; AA13). VHL and VHL- RCC cells were stably transfected
with a Flag-tagged SDCT2 construct. Transfectants were characterized for cell
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proliferation, cell cycle, motility, succinate/citrate transport and reactive oxygen
species (ROS) measurement assays under normoxia and hypoxia (1% O2); cell
death and senescence pathway markers were also evaluated. SDCT2 induction
was evaluated following 5-azacytidine plus Trichostatin A treatment Results:
SDCT2 was 63- and 100-fold downregulated in low- and high-stage RCC
tissues, respectively. Q-PCR validation showed that SDCT2 levels were 40-
fold downregulated in tumor tissues when compared to normal kidney
(P0.0001 Mann-Whitney test). Downregulation was 40-fold in White and
Hispanic patients, but 198-fold in AA patients (P0.0049) and also corre-
lated with tumor stage and metastasis (P0.009). Under hypoxia, SDCT2
expression caused over 3-fold inhibition of proliferation, cell-cycle (G1-S
block), and motility in both VHL and VHL- cells (P0.01), only VHL
cells were inhibited under normoxia. SDCT2 expression induced ROS levels
and succinate transport by 3-fold in RCC cells (P0.01). SDCT2 expression
induced the p16INK4a-RB pathway and apoptosis (caspase-3 and PARP
activation). 5-AZATSA treatment caused a 50-fold induction (P0.0001)
of SDCT2 expression. Conclusion: This is the fırst study on a functional
biomarker in RCC, SDCT2, that is a possible novel tumor suppressor gene.
SDCT2 loss promotes RCC growth, survival and inhibits cellular senescence
and its downregulation correlates with metastasis and racial disparity. Sup-
port: Grant NCI/NIH 5R01CA72821; 5R01CA176691.
#1550 Epigenetic downregulation and growth inhibition of IGFBP7 in
gastric cancer. Jin Kim,1 Min A Kim,2 Sun-Ju Byeon,3 Woo Ho Kim4. 1Cancer
Research Institute, Seoul National University College ofMedicine, Seoul, Republic
of Korea; 2Seoul National University Hospital, Seoul, Republic of Korea; 3Asan
Medical Center, Seoul, Republic of Korea; 4Seoul National University College of
Medicine, Seoul, Republic of Korea.
Insulin-like growth factor-binding protein 7 (IGFBP7) has been found to be a
tumor suppressor in several human cancers, but the role of IGFBP7 in gastric
cancer has not yet been fully investigated. In this study, we examined the epige-
netic downregulation of IGFBP7 expression in gastric cancer. Analysis by qRT-
PCR, western blot, and methylation specifıc-PCR revealed that DNA methyl-
ation was inversely correlated with IGFBP7 expression, and the expression of
IGFBP7 was restored after treatment with 5-aza-2=-deoxycytidine. Immunohis-
tochemistry showed that IGFBP7 expression was downregulated in 47.5% of
advanced gastric cancer patients. Univariate and multivariate analysis showed
that IGFBP7 expression and tumor stage were independent prognostic factors.
In cell culture, IGFBP7 knockdown increased gastric cancer cell growth, inva-
sion, and migration, whereas IGFBP7 overexpression in gastric cancer cells
showed cell growth inhibition and apoptosis. Our data suggest that IGFBP7
functions as a tumor suppressor in gastric cancer via an epigenetic pathway.
#1551 GULP1 is an epigenetically altered and functional tumor suppres-
sor in urothelial carcinoma through regulation ofNrf2-Keap1 signaling axis.
Masamichi Hayashi, Elisa Guida, Rachel Goldberg, Yoshikuni Inokawa, Leon-
ardo Reis, Akira Oki, Evgeny Izumchenko, Leonel Maldonado, Luigi Mar-
chionni, Mariana Brait, Trinity Bivalacqua, Alexander Baras, George J. Netto,
Wayne Koch, David Sidransky, MohammadO. Hoque. The Johns Hopkins Uni-
versity School of Medicine, Baltimore, MD.
We identifıed GULP1 as a novel tumor suppressor gene (TSG) selectively
silenced during urothelial cancer (UC) progression through promoter hyper-
methylation (PH) analyzed by quantitative methylation specifıc PCR (QMSP)
and novel methylation specifıc digital droplet PCR (ddPCR) assay. Numerous
cell based assays revealed that GULP1 silencing confers growth advantage to
tumor cells. Correspondently, in vivo tumorigenicity after xenotransplantation
of GULP1 knockdown T24 cells was signifıcantly higher than control cells. Fur-
ther mechanistic analysis revealed that GULP1 has a crucial role in the regula-
tion of Nrf2-Keap1 axis, maintaining actin cytoskeleton architecture and help-
ing Keap1 to scaffold Nrf2 in the cytoplasm. Moreover, GULP1 silencing
induces constitutive activation of Nrf2 target signature, responsible for
chemoresistance of UCs. Additionally, we analyzed GULP1 PH and expression
in cisplatin-based therapy responsive and resistant primary UC samples, and in
isogenic cisplatin sensitive and resistant T24 cell lines. Interestingly, GULP1
expression at transcription level was lower in both resistant primaryUC samples
and resistant T24 cell line. Cell lines with lower expressions of GULP1 (SW780
andUM-UC-3) also showedhigher resistance to cisplatin than thosewith higher
expression (T24 and BFTC905). Altogether, our fındings determined that
GULP1 is an epigenetically silenced potential TSG inUCandGULP1 expression
and/or PH may guide in selecting candidate patients for cisplatin based neo-
adjuvant therapy.
BIOINFORMATICS AND SYSTEMS BIOLOGY: Functional and
Genomic Analysis of Cancer
#1552 Integrative bioinformatics analyses of ChIP seq and RNA seq data
reveals a complex regulatory landscape of NRF1 network involved in the
pathogenesis of breast cancer. Jairo Ramos, Deodutta Roy. Florida Interna-
tional University, Miami, FL.
The expression of redox sensitive transcription factor -nuclear respiratory
factor 1 (NRF1) expression signifıcantly correlates with histological grades and
prognosis of breast cancer. However, the molecular mechanism by which NRF1
may contribute in the development of breast cancer is not clear. In this study we
examined whether NRF1 is a molecular risk factor of breast cancer. We also
identifıed regulatory landscape ofNRF1network involved in the pathogenesis of
breast cancer. Steps followed for the investigation included the selection of
mRNA microarray dataset from TCGA and Metabric, selection and analysis of
ChIP-Seq datasets from different breast cancer cell lines to identify NRF1 target
genes possibly involved in breast cancer throughMolecular Pathway, Gene On-
tology and statistical analysis. Analysis of mRNA expression in breast cancer
patients showed that NRF1 was signifıcantly overexpressed in breast cancer
tissues compared to normal tissues. ChIP-Seq analysis of two different breast
cancer cell line - MCF7 and T7D showed that there are more than 8,000 genes,
which contain NRF1 binding DNA motif(s). The NRF1 binding to ChIP DNA
sequences of target gene is cell context dependent. High percentage of known
breast cancer (50%) susceptibility genes are transcriptional targets of NRF1.
Network analysis revealed that NRF1 regulates genes, which are key regulators
of epithelial-mesenchymal transition (EMT), stemness, cell apoptosis, cell cycle
regulation, chromosomal integrity, and DNA damage and repair. Furthermore,
we observed that NRF1 regulates target genes of both breast cancer and cancer
KEGG pathways. Many of the MicroRNAs involved in cancer and genes of
signaling pathways involved in cancer initiation and progression such asMAPK,
PI3K/AKT and Notch signaling are also transcriptional targets of NRF1. In
summary, this study reveals a complex regulatory landscape of NRF1 network
involved in the pathogenesis of breast cancer. Dysregulation of NRF1 signaling
pathways may contribute in the development of breast cancer. Clinical confır-
mation of our studywill have signifıcant impact on our understanding of the role
of NRF1 as a valuable biomarker for breast cancer diagnosis and prognosis and
will provide strong rationale for the future studies to further develop NRF1 for
breast cancer therapeutic target. This work was in part supported by a VA
MERIT Review (VA BX001463) grant to DR.
#1553 Delineating the role of multiple copies of RNA binding domains in
humannucleolin and its homologs using a computational approach.Kamrun
Begum, Ruchama Chaya Steinberg, Anjana Saxena, Shaneen Singh. CUNY
Brooklyn College, Brooklyn, NY.
All eukaryotes have nucleoli, the sub-nuclear compartmentswhere ribosomes
synthesis occur. Nucleolin (NCL), an abundant RNA binding phosphoprotein-
,constitutes 5-10%of total nucleolar proteins. Thismultifunctional protein plays
defıned role/s in many critical cellular processes e.g. chromatin remodeling,
ribosome biogenesis, transcriptional and translational regulation of various
non-coding as well as coding RNAs. NCL binds to its target RNAs via two or
multiple RNA binding domains (RBDs) to control gene expression during nor-
mal cell cycle as well as during cellular response to stress. A variety of tumors
express elevated levels of NCL where NCL plays a direct role/s in increasing
expressions of genes involved in cell survival, angiogenesis and metastasis. A
comparison of NCL in various organisms shows that it is highly conserved,
especially in its RNA binding domains that can vary in number (2 to 4 consec-
utive domains). Interestingly, the individual NCL-RBDs are more conserved
across different species rather than within the same protein. RBDs are known to
interact in pairs with RNA via RNA recognition motifs called RNP motifs, and
complementary nucleic acid motifs or elements in RNA allow interaction with
NCL. Vertebrate NCL proteins contains four RBDs, however most studies have
focused only on the role/s of RDB 1,2; none probing the possible functional
redundancy of the additional RBDs nor identifying any target-specifıcity for the
RBD3,4 in humanNCLandother homologs. Earlier data fromour lab suggested
RBD3,4 can bindRNA in a structurally analogousmanner toRBD1,2 albeit with
altered affınity. Here, we continue this research by investigating various ho-
mologs of human NCL to better understand the conserved mechanism of its
interactionwithRNAandwhether the additional RBDs, are in fact, redundant in
function. To test this hypothesis, RBDs from various homologs were modeled
using template based methods and analyzed by a combination of sequence and
structure analysis tools. We show that there are key residue differences in indi-
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vidual RBDs from various homologs that potentially manifest as differences in
binding affınities. This study reveals new insights into NCL RBD function and
describes the evolution of RBD function with respect to nucleic acid binding.
#1554 Development of a deconvolution algorithm for tissue-based gene
expression data. Sha Cao,1 Chi Zhang,2 Ying Xu1. 1University of Georgia, Ath-
ens, GA; 2Indiana University, Indianapolis, IN.
Tissue data provide substantially more information than cell-line data, and
offer new opportunities to study cancer biology and evolution in its actual mi-
croenvironment, when multiple tissue samples of the same cancer type are an-
alyzed together. However, it is very challenging to do information discovery
from tissue data because of their compositional complexity - each dataset rep-
resents a mixture of gene-expression data from multiple cell types. Hence,
meaningful tissue-data analyses require to fırst sort out the detailed contribu-
tions to the observed tissue-level data by different cell types. However, the com-
putational challenge in solving the tissue data deconvolution problem stems
from the reality: each cell type has a very large number of complex relations
among its expressed genes and pathways, which are preserved under different
conditions. To make deconvolution results meaningful, the co-expressions
among functionally closely related genes, must be captured and enforced in a
deconvolution problem formulation. We have a fundamentally novel formula-
tion of the tissue-data deconvolution problem, which is pathway instead of gene
based. It preserves co-expressions of genes of the same pathways through cap-
turing and using an expression signature among such genes, and allows differ-
ential expressions of pathways by giving them varying weights in different tis-
sues. In addition, this pathway-basedmodel substantially reduces the number of
free variables compared to gene-based models, making our problem formula-
tion effıciently solvable. The unique ideas of our approach are: (i) estimate the
proportion of each cell type within a mixture based on expression patterns of
cell-type specifıc genes; (ii) identify co-expressed gene clusters among genes
encoding each pathway (as defıned by REACTOME) in each cell type based on
cell line data; (iii) derive a condition-invariant expression signature for each of
the2,000 REACTOME pathways in each cell type; (iv) demonstrate that each
set of cell line gene-expression data can be uniquely represented as a weighted
sum of such signatures; and (v) formulate the deconvolution problem as to
estimate the weight of each pathway in each cell type that minimizes the Frobe-
nius norm of deviancematrix of estimated and observed gene expressionmatri-
ces. We demonstrated its effectiveness on simulated data, i.e., in silico mixtures
of gene-expression data from different cell types with varying proportions of
each cell type.We anticipate that the successful development and deployment of
the planned deconvolution method will enable and inspire a wide range of new
ways to study tissue-based expression data and uncover the very rich informa-
tion hidden in cancer tissues about the fundamental biology of cancer.
#1555 Pan-cancer patterns of synthetic lethality: statistical modeling of
genedependencyprofıles.HuwateYeerna,1 RamyaRangan,2AndrewAguirre,3
William Kim,3 Francisca Vazquez,3 Barbara Weir,3 Mahmoud Ghandi,3 Aviad
Tsherniak,3 Jesse Boehm,3 William Hahn,3 Jill Mesirov,1 Pablo Tamayo1. 1Uni-
versity of California, San Diego, La Jolla, CA; 2Harvard University, Cambridge,
MA; 3Broad Institute, Cambridge, MA.
We present a methodology to fıt statistical models of cell-viability profıles
from RNAi-gene knockdowns. This method allows us to classify genes accord-
ing to the degree of skewness in their viability distributions. The set of geneswith
the highest degree of skewness is highly enriched with many known oncogenes
and tumor suppressors. We characterize many of these genes, compare them
against the results of large sequencing efforts, and use themas inputs to amatrix-
decomposition procedure that identifıes the most salient cell viabilities shared
by different cancer types. We catalog these pan-cancer patterns of synthetic
lethality and characterize them by the genomic, transcriptional, and phenotypic
features. This analysis provides a rich catalog of the most salient Achilles’ Heels
of Pan-Cancer that can be helpful to identify new therapeutic strategies across
cancers.
#1556 Algorithms for discovery of somatic single nucleotide mutation
display specifıc artifacts and different detection capabilities under the effect
of read coverage and sample heterogeneity. Wenming Xiao,1 Leihong Wu,1
Gokhan Yavas,1 Huixiao Hong,1 Baitang Ning,1 Weida Tong,1 Eric F. Donald-
son,2 Zivana Tezak,3 Reena Philip,3 Howard Jacob,4 Louis M. Staudt5. 1FDA/
NCTR, Jefferson, AR; 2FDA/CDER, Silver Spring, MD; 3FDA/CDRH, Silver
Spring, MD; 4HudsonAlpha Institute, Huntsville, AL; 5NCI, Bethesda, MD.
Understanding the performance and capability of different bioinformatics
algorithms used for the discovery of somatic variants is very important for help-
ing scientists choose an appropriate tool for cancer research. In this study, we
developed a comparison approach and created a series of data sets that could be
used to provide such guidance. We mixed reads from two well characterized
individuals, NA12878 and NA24385, and generated a series of data sets with
different coverages and sample heterogeneity. We then used these data sets to
evaluate fıve commonly utilized somatic mutation detection tools. Our results
indicate that read coverage has a signifıcant impact on the accuracy and capa-
bility ofmutation calling by individual bioinformatics algorithms. Themutation
caller that performs well with high read coverage may perform poorly with low
read coverage.On the other hand, the tool that performedwell in calling variants
in a relatively higher homogeneity sample may not have the same power to
detect rare variants with lowmutation allele frequency. In addition, we demon-
strated that different mutation calling algorithms are associated with specifıc
artifacts that were sensitive to read coverage. Furthermore, there were large
numbers of false positives and false negatives shared by fıve callers, indicating
that other factors, such as read alignment, library preparation, and even the
properties of the sequencing platform could be the sources of false discovery for
somatic variants. We observed similar behavior of the fıve variant calling algo-
rithms using the sequencing data of a pair of matched tumor/normal cell lines,
confırming the fındings from the comparative analyses on the mixture of reads
from the twonormal individuals.Our fındings are expected to facilitate selection
of bioinformatics pipelines that fıt for specifıc purposes in cancer research based
on sequencing data.
#1557 Longitudinal expression response of glycosylation related genes,
regulators, and targets in cancer cell lines treated with eleven anti-tumor
agents. Julia Krushkal,1 Yingdong Zhao,1 Curtis Hose,2 AnneMonks,2 JamesH.
Doroshow,1 Richard Simon1. 1National Cancer Institute, Rockville, MD; 2Leidos
Biomedical Research, Inc., Frederick National Laboratory for Cancer Research,
Frederick, MD.
Cancer cells have profound alterations in glycosylation processes, which af-
fects the functioning of malignant cells and their interaction with surrounding
environment. We examined the effects of treatment of cancer cell lines with
eleven antitumor agents (bortezomib, cisplatin, dasatinib, doxorubicin, erlo-
tinib, gemcitabine, paclitaxel, sirolimus, sorafenib, sunitinib, and topotecan) on
transcriptional changes in 179 candidate genes involved in biochemical glyco-
sylation pathways or encoding glycosylation targets, regulators of glycosylation
processes, and components of cancer pathways affected by glycosylation. In
order to achieve this goal, we analyzed time course gene expression information
for the NCI-60 cancer cell line panel using the data from the NCI Transcrip-
tional Pharmacodynamic Workbench (NCI TPW), a resource developed at the
National Cancer Institute. Our analysis identifıed 145 glycosylation related
genes that responded to drug treatment in a concerted manner. Many of these
genes had a concerted response to multiple agents; however, the direction and
the magnitude of concerted response were specifıc to individual drugs. Expres-
sion of multiple genes prior to treatment and/or transcriptional changes in re-
sponse to treatment were signifıcantly correlated with drug chemosensitivity,
measured as log(GI50). Treatment with dasatinib resulted in the largest number
of signifıcant correlations of chemosensitivity with gene expression prior to
treatment and with gene expression changes in response to treatment. Signifı-
cant correlations of transcriptional changes after treatment and/or of pre-treat-
ment gene expression levels of glycosylation related genes and glycosylation
targets were also observed for other antitumor agents. Chemosensitivity to ki-
nase inhibitors and DNA damaging agents was signifıcantly correlated with
expression of genes involved in N- and O-glycosylation, fucosylation, biosyn-
thesis of poly-N-acetyllactosamine, removal of misfolded proteins, binding to
hyaluronic acid and other glycans, and cell adhesion. In particular, tumor cell
sensitivity or resistance to multiple agents were signifıcantly correlated with
changes in expression ofC1GALT1C1 (COSMC), FUCA1, SDC1,MUC1,mem-
bers of theMGAT,GALNT, B4GALT, B3GNT,MAN, and EDEMgene families,
and other genes involved in glycosylation processes or encoding glycosylation
targets and signaling regulators. We present a catalog of dynamic concerted
changes in expression of glycosylation related genes, their ligands, regulators,
and targets in response to chemotherapy, and provide a list of genes that influ-
ence the strength of response of cancer cells to treatment. These glycosylation
related genes may be considered as potential candidates for drug targeting in
combination therapy to enhance the effects of treatment. Funded by NCI Con-
tract No. HHSN261200800001E.
#1558 Data-driven approach to detecting novel gene interactions in can-
cer with applications to drug response prediction and cancer stratifıcation.
Assaf Magen, Avinash Das, Joo Lee, Sridhar Hannenhalli, Eytan Ruppin.UMD,
College Park, MD.
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The effect of a gene’s activity on a phenotype depends on the context of a
complex network of functionally interacting genes. Several genetic interactions
(GIs), such as Synthetic lethality and Synthetic Rescues, have been reported to
have a signifıcant functional role in cancer progression and provide potential
candidates for selective cancer treatments. However, numerous other types of
GIs with potential clinical signifıcance are yet to be explored. In this work we
generalize the concept of GI and detect70,000 GIs of different types with both
molecular and clinical signature. We demonstrate their clinical predictive value
as well as their ability to stratify breast cancer patients into refıned clinical sub-
types that might allow for better diagnosis and modifıed course of treatment.
These results compare favorably with previous sequence based approaches and
provide evidence for the importance of context specifıc genomic events and their
effect on tumor progression. Additionally, the GI network accurately predicts
patients’ drug response, where difference GI types are found to be predictive of
distinct drugs in a complementary manner. This work provides the basis for
future exploration of novel GI types as well as individual interactions withmajor
impact on cancer progression.
#1559 Proteogenomic analysis of alternative splicing in colorectal adeno-
ma-to-carcinoma progression. Malgorzata A. Komor,1 Thang V. Pham,2
Sander R. Piersma,2 Anne S. Bolijn,1 Tim Schelfhorst,2 Pien M. Delis-van Die-
men,1Marianne Tijssen,1 AnnemiekeC.Hiemstra,1Meike deWit,1 Beatriz Car-
valho,1 Gerrit A. Meijer,1 Connie R. Jimenez,2 Remond J. Fijneman1. 1Nether-
lands Cancer Insitute, Amsterdam, Netherlands; 2VUUniversity Medical Center,
Amsterdam, Netherlands.
Background: Early diagnosis of colorectal cancer (CRC) and identifıcation of
its precursor lesions (adenomas) is crucial in reducing CRCmortality rates. The
fecal immunochemical test (FIT) is a non-invasive CRC screening test that de-
tects human protein hemoglobin. Although FIT is benefıcial in its current form
with a sensitivity of 65% for detection of CRC and 27% for adenomas, its
performance is still suboptimal and needs to be further improved. Adenoma-to-
carcinoma progression is accompanied by alternative splicing, which results in
expression of tumor-specifıc protein variants. Thesemay yield novel biomarkers
suitable for improving detection of progressive adenomas and CRCs. Aim: We
aim to identify novel biomarkers to improve early detection of CRC. Materials
and methods: RNA was isolated from 3D organoid cultures derived from 5
adenomas and 4 CRC tissues. RNA and proteins were isolated from 18 healthy
human colon tissues, 30 adenomas and 30 CRCs. Samples were analyzed by
RNA sequencing (Illumina) and in-depth tandemmass spectrometry proteom-
ics (QExactive). For both organoid- and tissue-datasets differential splicing
analysis was performed on RNA level to enrich the sequence database, against
which mass spectra were searched, with predicted protein isoforms. Results:
Comparative splicing analysis between CRC and adenoma organoids revealed
90 differentially spliced genes, yielding candidate biomarkers from epithelial
origin. In the tissues, differential splicing analysis between CRCs and controls
and between CRCs and adenomas identifıed over 1000 of splice variants. These
include known alternatively spliced genes involved in cancer such as CD44 and
VEGFAand a number of candidates overlappingwith the isoforms derived from
the organoids. Proteomics analysis revealed that approximately 150 of the splice
variants were expressed on protein level. Conclusion and Discussion: We have
confırmed that adenoma-to-carcinoma progression is accompanied by aberrant
splicing. Analysis of the organoid cultures allowed us to identify gene isoforms
from (neoplastic) epithelial origin. Tissue analysis yielded tumor-specifıc splice
variants that represent novel protein candidate biomarkers for early detection of
CRC. The diagnostic performance of these splice variant proteins will be vali-
dated in series of stool and FIT samples.
#1560 Differential sensitivity analysis for resistant malignancies (DIS-
ARM), a novel approach for drug screen analysis, identifıes common candi-
date drugs across platinum-resistant cancer types. Carl M. Gay,1 Pan Tong,1
Robert J. Cardnell,1 Xiao Su,2 Nene N. Kalu,1 Upasana Banerjee,1 Rasha O.
Bara,1 FayeM. Johnson,1 JohnV.Heymach,1 JingWang,1 LaurenA. Byers1. 1The
University of Texas MD Anderson Cancer Center, Houston, TX; 2The University
of Texas Health Science Center at Houston, Houston, TX.
Resistance to therapy, including conventional chemotherapy, targeted ther-
apy and immunotherapy, continues to plague cancer treatment. Moreover,
mechanisms governing resistance are poorly characterized leading to a dearth of
rational combinatorial and sequential treatment strategies.While drug response
data is abundant across myriad tumor types and drug classes, there exists no
high-throughputmethod to probe such data with a query as simple as “If tumors
are resistant to drug X, to what drug(s) are they sensitive?”- a seemingly trivial
problem beset by immense data sets and imprecise defınitions of sensitivity and
resistance. Here, we present DISARM, a novel approach designed specifıcally to
screen for drugs that are active in spite of resistance to a reference drug. DISARM
selects candidates based on the proportion of samples that are resistant to a
reference drug but sensitive to a candidate drug with simultaneous consider-
ation to relatively lower IC50 values for candidate drugs and higher IC50 values
for reference drugs. As candidates may work in only a subset of resistant models
and precise delineation between sensitivity and resistance may vary between
experimental settings, DISARM permits flexibility in dichotomizing drug data
and uses grid search to optimize specifıcations. To illustrate, we analyzed pub-
lically available cell line data (IC50 data) from several cancer types for which
platinum-based therapy is a standard of care, identifying multiple drugs that
demonstrate activity in cisplatin-resistantmodels across tumor types such as the
BCL-2 inhibitor obatoclax in small cell lung cancer, lung adenocarcinoma, gas-
tric adenocarcinoma and bladder cancer, and the farnesyltransferase inhibitor
tipifarnib in small cell lung cancer, bladder cancer, esophageal cancer, colon
adenocarcinoma and head and neck squamous cell carcinoma. Frequently, mul-
tiple drugs from the same class were selected byDISARM for a single tumor type
and, in these cases, we found statistically signifıcant similarity between sensitive
cell lines suggesting a subset of cisplatin-resistant cell lines that are repeatedly
sensitive to a drug class. While translating preclinical observations into ap-
proved clinical use is often thwarted by an inability to identify predictive bio-
markers, DISARMalso allows us to select cell lines that are especially sensitive to
candidate drugs or drug classes on which to perform biomarker analysis. To
demonstrate this approach, we chose drugs with activity in multiple cancer
types and compared mRNA and protein expression data to highlight poten-
tially novel common and tumor-specifıc biomarkers for concomitant candi-
date drug sensitivity and cisplatin resistance. Thus, DISARM offers a simple
yet effective approach for both drug and biomarker discovery within a spec-
ifıed clinical niche.
#1561 Gene expression analysis identifıes heterogeneity in cutaneousmel-
anoma subjects with disruptiveMC1R alleles and BRAF hotspot mutations.
Piyushkumar A. Mundra, Candelaria Bracalente, Lucas Trucco, Nathalie
Dhomen, Richard Marais. Cancer Research UK Manchester Institute, Man-
chester, United Kingdom.
Background: Previous epidemiological and population sequencing studies
have established that subjects with melanocortin 1 receptor (MC1R) germline
mutations, associatedwith red hair and light skin phenotypes, have an increased
risk of melanoma. However, several conflicting reports about the role of BRAF
somatic mutations inMC1R subjects exist in the literature.We hypothesise that
this conflict is due to biological process driven heterogeneity withinMC1R sub-
jects carrying disruptive alleles. To understand the heterogeneity, we analysed
the TCGA cohort at the gene expression level using mRNA sequencing data.
Method: From the previously published studies, we identifıed 68 cutaneousmel-
anoma subjects who were of white ethinicity, had at least one disruptive allele of
MC1R, and had BRAF mutations. Associated clinical and mRNA sequencing
data were downloaded from the Firebrowse website. An unbiased hierarchical
clustering analysis was performed using the preprocessed mRNA data contain-
ing 14669 gene expressions. The resultant clusters were then characterised using
available clinical variables. A differential expression analysis was performed to
identify the genomic signatures of these clusters. The resultant p-values were
corrected for false discovery rate (FDR) using the Benjamini-Hochberg ap-
proach. Geneswith corrected p-values less than 0.01were further analysed using
gene set enrichment analysis (GSEA) preranked lists. Results: An unbiased clus-
tering identifıed two clear and separable clusters with 40 and 28 subjects respec-
tively. The UV-signature (dipyrimidine CT load) was correlated with these
clusters (p-value 0.047). However, no signifıcant differences in age at the time
of diagnosis, overall survival, and total mutation load between clusters were
observed. At the genomic level, 2588 genes were signifıcantly differentially ex-
pressed between two clusters (FDR corrected p- value less than 0.05). The top 10
differentially expressed genes included ATF2, MSH6, SP3, MAP3K2, and
VEGFB. Further GSEA revealed gene sets playing roles in several pathways and
biological processes, including oxidative phosphorylation, UV response in ker-
atinocytes, DNA repair, cell cycle, and cellular response to stress. Conclusion:
Cutaneous melanoma subjects with disruptive MC1R alleles and BRAF hotspot
mutations have heterogeneous gene expression profıles with several key onco-
genes differentially expressed. This suggests potential roles of other pathways,
either independently or in cooperationwith BRAFmutations, inmelanomagen-
esis in MC1R bearing patients.
#1562 Drug repurposing for hepatocellular carcinoma enabled via tran-
scriptomics data from experimental models of sorafenib resistance. Kelly
Regan,1 Ryan Reyes,1 Samson Jacob,1 Philip Payne,2 Tasneem Motiwala1. 1The
Ohio State University, Columbus, OH; 2Washington University in St. Louis, St.
Louis, MO.
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Hepatocellular carcinoma (HCC) is often diagnosed in patients with ad-
vanced disease who are ineligible for curative surgical therapies. Sorafenib is the
only approved drug for treating late stage HCC patients. However, patients
rapidly become unresponsive due to inherent and acquired drug resistance. The
promise of drug repurposing is that identifying new uses for existing drugs may
reduce the high costs and time required for drug discovery. This is the fırst study
employing connectivity mapping, a transcriptomics-based drug repurposing
method, to identify drugs for use against sorafenib resistant (SR)-HCC via re-
versal of gene expression patterns. As a fırst step, we characterized gene expres-
sion signatures of different models of sorafenib resistance. We obtained gene
expression signatures from an in vitro and an in vivo model of (SR)-HCC (pub-
licly available microarray data) as well as from sorafenib-resistant (pool and
clone) Huh7 cells generated in our lab. We determined the presence of the
SR-HCC gene signatures across six patient-derived HCC gene expression data-
sets from the Gene Expression Omnibus (GEO) database using the nearest tem-
plate method (FDR0.05), and found that the gene signatures performed sim-
ilarly in distinguishing tumor vs. normal liver tissue (FET p0.05). We also
analyzed RNAseq data from HCC patients (n423) in The Cancer Genome
Atlas (TCGA) for the presence of these SR gene signatures, and observed that
patients harboring the SR-HCC gene signatures generated by our lab had signif-
icantly reduced survival (log-rank p0.036 SR Huh7 pool; p0.009 SR Huh7
clone). Utilizing drug-induced gene expression profıles (n 3,740 drugs) in the
HepG2 HCC cell line from the Library of Integrated Network-based Cellular
Signatures (LINCS) database, we applied connectivity mapping analysis to the
SR-HCC gene signatures. Dasatinib, a Src family kinase inhibitor, was priori-
tized as a top drug candidate from our LINCS analysis to reverse HCC sorafenib
resistance.We confırmed up-regulated activity of Src family kinases in SR-Huh7
cells, as compared to sorafenib sensitive Huh7 cells (two-tailed t test, p0.05).
We validated the use of dasatinib against sorafenib-resistant HCC cells in vitro
alone and in combination with sorafenib using cell viability and clonogenic
survival assays. In summary, we provide physiological relevance of SR models
and proof of concept evidence for the validity of this novel drug repurposing
approach for SR-HCC with implications for personalized medicine.
#1563 A machine learning approach to predict platform specifıc gene es-
sentiality in cancer.CoryandarM. Gilvary, Neel S. Madhukar, KaitlynM. Gay-
vert, David S. Rickman, Olivier Elemento. Weill Cornell Medical College, New
York, NY.
Loss-of-function (LOF) screenings across a set of diverse cancer cell lines has
the potential to reveal novel synthetic lethal interactions, cancer-specifıc vulner-
abilities, and guide treatment options. These were traditionally done using shR-
NAs, but with the recent emergence of CRISPR technology there has been a shift
inmethodology. The Achilles project is to date the largest cancer LOF screening
effort undertaken, however we found a large amount of inconsistency between
their shRNA and CRISPR-Cas9 essentiality results for the same set of cell lines.
Here we characterize the differences between genes found to be essential in
either CRISPR or shRNA screens. We found that certain features such as gene
expression, network connectivity and conservation could accurately separate
out essential genes that were found exclusively in either one of these screens.
This information could be tremendously useful in understanding the differences
in the CRISPR and shRNA screening results. Furthermore, one limitation with
Project Achilles was that they conducted shRNA screens on 216 cell lines, but
only 33 cell lines in CRISPR. Therefore we developed a model that integrates
these genetic, network, and population features to predict CRISPR results from
shRNA screenings, and found that our model can accurately identify CRISPR
essential genes better than approaches just based on the shRNA results (p-
value  105, d-statistic 0.5 ). This potentially eliminates the need for a
costly CRISPR screen, predicts essential genes that would be missed in the
shRNA screen, and provides new data on thousands of genes in almost 200 cell
lines. Additionally we integrated prior screening results to build a second set of
models to predict gene essentiality for untested genes with no LOF screening
needed.We found this accurately predicted whether a gene would be marked as
essential as well as what type of platform (CRISPR or shRNA)wasmore likely to
accurately identify essentiality. When predicting genes which were exclusively
essential in CRISPR we observed an area under the receiver operating charac-
teristic curve (AUC) of 0.82. Overall, these methods allow for a more compre-
hensive essentiality analysis of genes; which is not possible by single screening
platforms.
#1564 Acomputational framework for removingmouse contamination in
tumors sequenced from patient-derived xenografts. Ali Amin-Mansour,1 Ju-
dit Jané-Valbuena,2 Xinmeng Jasmine Mu,1 Levi Garraway2. 1The Broad Insti-
tute of MIT and Harvard, Cambridge, MA; 2Dana-Farber Cancer Institute, Bos-
ton, MA.
Introduction: Using patient derived xenograft (PDX) models has become an
effective way for investigating response to standard or new therapeutics in can-
cer. Human cancer cells injected in mice are allowed to establish tumors and
subjected to desired treatments. The PDX tumors are later harvested and char-
acterized, often bymassive parallel sequencing.However, amajor challengewith
analyzing these data is the presence of stromal mouse genomic material, fre-
quently resulting in artifacts in downstream variant detection. We present a
computationalmethod to eliminatemouse contamination in PDX.Method:We
used the Burrows-Wheeler Aligner to map reads obtained from sequencing the
PDX samples to a combined human and mouse reference genome. We remove
reads that are mapped to the mouse reference. The remaining reads are then
processed through standard mutation calling pipelines for somatic mutation
detection. To test the effıcacy of our method, we created in silico mixtures of
human and mouse whole-exome sequencing reads from a melanoma patient’s
tumor and an immortalized mouse cell line captured with human exome baits.
We then carried out a sensitivity analysis to examine how changing the mean
target coverage of sequencing, ormouse contamination levels affects our results.
For each of the computational experiments, we evaluated somatic mutations
detected from the synthetic samples in comparison to the original human sam-
ple. Results: We calculated the sensitivity and specifıcity of detecting somatic
mutations to determine our algorithm’s performance. In all instances, we found
greater than 99% for both sensitivity and specifıcity. Conclusions: Our results
demonstrate that our method works accurately towards removing mouse reads
in PDX samples. This task could also be applied to separating sequence reads
from other species.
#1565 OnPLS-based integrative proteogenomics analysis of lung squa-
mous cell cancer. Fredrik Pettersson, Paul A. Stewart, Robbert J. Slebos, Eric A.
Welsh, Ling Cen, Yonghong Zhang, Zhihua Chen, Chia-Ho Cheng, Guolin
Zhang, Bin Fang, Victoria Izumi, Sean Yoder, Katherine Fellows, Y Ann Chen,
Jamie K. Teer, Steven Eschrich, John M. Koomen, Anders Berglund, Eric B.
Haura.Moffıtt Cancer Center, Tampa, FL.
Introduction:Multivariate projectionmethods such as PCAandPLS has been
widely applied for analysis of biological and chemical data. OnPLS is a recent
extension to these methods suitable for integrative analysis of omics data. With
OnPLS it is possible to compare multiple omics datasets to identify joint varia-
tion and variation locally unique for each of the studied datasets. OnPLS is a new
approach for truly integrative analysis of omics data to be contrasted to com-
monly applied approaches limiting analysis to 1) comparing fındings from in-
dividually analyzed blocks of data 2) pairwise comparison of individual probes.
Experimental: A Java based implementation of OnPLS was used for the statisti-
cal modeling. 116 lung squamous cell cancer samples were characterized using
gene expression profıling and global proteomics. TheOnPLSmodel was applied
to jointly model variation between mRNA and protein expression. Enrichment
analysis of factor loadings was performed using the Enrichr tools to identify
biological mechanisms explained by the different joint and unique components
of theOnPLSmodel. Results: Using a cross-validation procedure themodel with
the highest predictive ability was calculated having two joint components and
one locally unique component for each of the proteomics and gene expression
datasets. The model explained 21.9% of the variation in the expression data and
26.1%of the variation in the proteomics data. The fırst joint component captures
the highest degree of common variation between mRNA and protein activity.
From the mRNA data, this component is related to immune infıltrates, espe-
cially monocytes and B-cells, whereas this component is related to extracellular
matrix activity from the protein data. This suggests covariance of mRNA im-
mune-related gene expression and extracellular matrix-related protein expres-
sion. As expected, local variation specifıc to the protein measurements involved
regulation of protein activation and processing. mRNA-specifıc variation is re-
lated to keratinization, a key process in squamous cell cancer. Conclusion: On-
PLS offers an interesting approach for integrative analysis of omics data. Apply-
ing this approach to proteo-genomics data of lung squamous cell cancers suggest
similar patterns of activity is represented in protein and gene expression data,
however the biological processes associated with this activity may be distinct.
#1566 Differential expression of Epstein Barr virus miRNAs in triple-
negative breast cancer. Alexander Blanchard,1 Tiffany Walls,1 Ramon Vidal,2
Stefan Bonn,2 Scott Harrison,1 PerpetuaMuganda1. 1North Carolina A&T State
University, Greensboro, NC; 2German Center for Neurodegenerative Diseases,
Goettingen, Germany.
Triple-negative breast cancers (TNBC) accounts for up to 20% of breast can-
cer cases. These tumors are negative for estrogen, progesterone, and HER2 re-
ceptors, which are markers used for diagnosis and treatment of other types of
breast cancer. Clinically, TNBCs are notoriously aggressive, respond poorly to
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targeted therapies, have high rates of relapse, as well as poor prognosis. The
molecular basis of TNBC oncogenesis is currently unknown, but it is possible
that viral factors, such as Epstein-Barr Virus (EBV) miRNAs, play a role. EBV
miRNAs have been implicated in the oncogenesis of several forms of cancer,
including Burkitt’s lymphoma and nasopharyngeal carcinoma. The objective of
this study, therefore, was to determine the differential expression of EBV miR-
NAs in TNBC tumors as compared to normal breast tissue. We conducted a
comprehensive profıling of viralmiRNAs in 48TNBC tumors as compared to 15
control normal breast tissues, utilizing deep sequencing analysis software and
publically available deep sequencing data. Four EBV miRNAs (BART18-3p,
BART 8-5p, BART15, BART22) were signifıcantly expressed in 11-17% of the
TNBC tumors, and not in control normal breast tissue. Four novel putative EBV
miRNAswere found to be differentially expressed inTNBC tumors as compared
to control normal cells. Two of the novel putative EBV miRNAs were differen-
tially expressed above 125 reads permillion (RPM) in 20% and 27%of the TNBC
tumors as compared to 0% and 6.6% of normal breast tissues, respectively. One
novel putative EBV miRNA was expressed above 125 RPM in 83% of TNBC
tumors as compared to 13% of normal breast tissue. One novel putative EBV
miRNA was expressed above 125 RPM in 66% of the normal breast tissue as
compared to 2% of the TNBCs. These putative EBV miRNAs localize within
genomic regions of EBV, including the LMP-2 region. Ongoing work has so
far computationally validated one of these miRNAs as a novel EBV miRNA;
in vitro validation studies are in progress. This is the fırst report on the
differential expression of EBV miRNAs in TNBC tumors. Since TNBC tu-
mors are extremely heterogeneous, it is intriguing that 20% of TNBC tumors
specifıcally express the same EBV miRNA. Our fındings suggest that these
differentially expressed EBV miRNAs may potentially play a role in the
pathogenesis of TNBC.
#1567 Oncogenesis may result frommultiple different combinations of a
small number of tumorigenic mutations. Ramu Anandakrishnan, Robin Var-
ghese, Nick Kinney, Harold R. Garner. Edward Via College of Osteopathic Med-
icine, Blacksburg, VA.
Cancer is known to result from genetic mutations, both inherited and so-
matic. Yet, decades of investigation and the availability of extensive genomic
data, have failed to reveal the specifıc mutations that directly result in tumori-
genesis for most cancers. One possible reason is that tumorigenesis may result
from one or more of multiple different combinations of mutations, while inves-
tigators generally search for a single set of mutations. A mathematical model of
the probability of “hitting” one of many possible combinations of a small num-
ber of mutations was compared to the actual distribution of accumulated muta-
tions at diagnosis as reported on the cancer genome atlas (TCGA). This
“multi-combination multi-hit” model reproduces the distribution of accu-
mulated mutations from the TCGA database with surprising accuracy
(RMSD  1.5%) for a model where one or more of 100 different possible
combinations of three mutations result in tumorigenesis. We speculate that
each of the three mutations affects one of the several genes in three distinct
cell proliferation control pathways, such as senescence, apoptosis, autophagy
and necrosis, and different combinations of mutations affecting three of
these pathways may result in tumorigenesis. We have identifıed several such
combinations for further investigation.
#1568 Predicting stochastic proliferation and death in response to drugs
withmechanisticmodels tailored to genomic, transcriptomic, andproteomic
data.Mehdi Bouhaddou, AnneMarie Barrette, Rick J. Koch,Marc R. Birtwistle.
Icahn School of Medicine at Mount Sinai, New York, NY.
Over the past decade we have seen a shift in cancer therapy from broadly
cytotoxic drugs to molecular therapies targeting “driver” mutations. Although
targeted therapy has seen great success for some cancers (e.g. imatinib for leu-
kemia), it has struggled with poor effıcacy in treating other cancers that can
sometimes possess multiple “driver” mutations. This highlights the complex,
and at times non-intuitive, interplay between multiple players in a signaling
cascade, which can be highly dependent on the biological context – that is, gene
expression levels and mutational architecture – of a tumor or cell line. A quan-
titative, mechanistic, biologically-tailored understanding of how these signaling
dynamics drive proliferation and death could improve precision pharmacology
approaches to treat cancer. Here, we constructed the fırst highly detailed, large-
scale ordinary differential equation (ODE) mechanistic mathematical model
depicting themost commonlymutated cancer signaling pathways across human
cancers, as indicated by a pan-cancer analysis by The Cancer Genome Atlas
(TCGA). The model includes the RTK/Ras/MAPK, PI3K/AKT/mTOR,
CDK/RB cell cycle, p53/MDM2 DNA damage response, and BCL/Caspases ap-
optosis pathways. The adjustable parameters of the model can be informed by
measurements from patients or cell lines, including copy number alterations,
mutations, and gene expression levels. This single-cell model links stochastic
gene expression processes to quantitative signaling dynamics, and once tailored
to a biological context can be used to simulate the effect of various anti-cancer
therapies on cell fate behavior such as proliferation and death for a population of
cells. The fırst instance of the model integrated genomic, transcriptomic, and
proteomic data from the MCF10A cell line, a non-transformed cell line with
predictable phenotypic behaviors. We trained the model using western blot and
flow cytometry experiments to refıne various biochemical parameters and phe-
notypic outcomes. Many fundamental questions in signal transduction arose
during this process, such as how EGF and insulin synergize to drive S-phase
entry or how a specifıc biological context confers sensitivity or resistance to
inhibitors of the ERK and AKT pathways. Simultaneously, we are tailoring the
model to patient-derived genetic information from primary glioblastoma tu-
mors and screening brain-penetrable compounds in a patient-specifıc manner.
In conclusion, a quantitative, mechanistic, biologically-tailored mathematical
model depicting the major cancer pathways allows us to probe the mechanisms
that underlie how signaling dynamics drive proliferation and death in response
to various perturbations, and gain insight into their dependence on the biolog-
ical context of cell lines and patient tumors.
#1569 Optimizing transducer array confıguration for treatment of pan-
creatic cancer using Tumor Treating Fields (TTFields). Ariel Naveh,1 Ze’ev
Bomzon,1 Noa Urman,1 Ofır Yesharim,1 Eilon D. Kirson,1 UriWeinberg2. 1No-
vocure ltd., Haifa, Israel; 2Novocure GMBH, Lucerne, Switzerland.
Introduction: TTFields is an antimitotic cancer treatment that utilizes low
intensity (1-3 V/cm) alternating electric fıelds in the intermediate frequency
(100-300 kHz) that are delivered in two orthogonal directions using 2 pairs of
transducer arrays. TTFields are currently approved for Glioblastoma Multi-
forme (GBM). A phase II clinical trial (EF-20) showed that TTFields in combi-
nation with gemcitabine was safe in patients with locally advanced pancreatic
cancer. Preclinical studies show that the effect of TTFields is intensity-depen-
dent with a therapeutic threshold of 1V/cm. Simulation-based studies show that
the fıeld distribution changes with array placement. Treatment planning with
arrays positioned on the scalp to maximize fıeld intensity to the tumor is stan-
dard of practice when treating GBM. Studies to examine array layout on the
abdomen tomaximize the fıeld distribution in this region have not been done. In
the EF-20 study, a generic layout was used. We used computer simulations to
test how altering the transducer array layout on the mid-body alters the fıeld
distribution within the abdomen and pancreas. Methods: To simulate delivery
of TTFields to the abdomen, we used a realistic computerizedmodel of a human
male (DUKE 3.0 from ZMT-Zurich). Eight different layouts utilizing combina-
tions of arrays with either 13 or 20 disks placed at different locations on the
abdomen were simulated. In order to generate TTFields, an alternating voltage
difference with a peak to peak magnitude of 100V and a frequency of 150 KHz
was imposed on the outer surfaces of the disks of each pair of arrays. The simu-
lations were performed using ZMT’s Sim4Life V3.0 electro-quasi-static solver.
For each pair of transducer arrays, the mean fıeld intensity in the abdomen and
chest, and in the pancreas and liver, was calculated. Results: All eight layouts
delivered fıelds with mean intensities of about 2 V/cm to the abdomen. The
average fıeld intensity delivered to the pancreas and the liver exceeded the ther-
apeutic threshold of 1V/cm for all layouts. The highest intensitieswere delivered
to the pancreas by layouts in which a 20-disk array was placed at the middle of
the back, and either a 20 disk array placed at the middle of the abdomen or a 13
disk array placed on the front-left side of the abdomen over the pancreas. Gen-
erally, fıeld intensities in the pancreas are lower than in the rest of the abdomen
because of the high electric conductivity of this organ. Conclusion: This work
shows that TTFields can be delivered to the pancreas with intensities well above
the therapeutic threshold of 1 V/cm, and that altering the location of the arrays
on the abdomen can influence the fıeld intensity and distribution within the
body. This work forms the basis for developing optimal strategies for delivering
TTFields to the pancreas.
#1571 Decrypting the transcriptomeprofıle of Pak4usingnext generation
sequencing. Chetan Rane, Misaal Patel, Li Cai, Audrey Minden. Rutgers Uni-
versity, Piscataway, NJ.
The PAK4 (p-21 Activated Kinase 4) protein kinase has long been associated
with cancer because of its key roles in regulating cell proliferation, cell cycle
progression and cell morphology. The PAK4 gene is amplifıed in different types
of cancers, including breast cancer. PAK4 overexpression is associated with
oncogenic transformation in several breast cancer cell lines, while PAK4 inhibi-
tion has been shown to signifıcantly reduce their tumorigenic potential. How-
ever, there is limited information available on PAK4’s mechanism of action in
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promoting tumorigenesis. To gain an insight into PAK4 downstream signaling
pathways, we performed Next Generation Sequencing (NGS) on RNA samples
collected from non-transformed immortalized mouse mammary epithelial cells
(WT iMMECs) and iMMECs overexpressing PAK4. Research from our lab has
shown that unlikeWT iMMECs, iMMECs overexpressing PAK4 formed tumors
when injected into mammary fat pads of mice, suggesting a central role for
PAK4 in tumor formation. Previous studies to delineate PAK4 signaling path-
ways have mostly focused on substrates phosphorylated by PAK4. This study,
however, takes into account genes whichmay act downstream of PAK4 and play
an important role in mediating long term PAK4 function. RNA-seq analysis
offers the ability to discover new genes and splice variants and measure tran-
script expression. mRNA was isolated in triplicates from WT iMMECs and
iMMECs overexpressing PAK4; mRNA from each condition was then se-
quenced using Illumina NextSeq platform. The RNA-seq data generated was
analyzed using Top Hat and Cufflinks software, which created a list of genes
whose expression was signifıcantly different in these two cell types, and previ-
ously unknown to be regulated by PAK4 (26 genes were up regulated and 51
genes were down regulated by more than a log2 fold change of 3). A qPCR
analysis of 8 of these genes validated the sequencing data. Among the different
genes we identifıed, we chose to focus on ParvB, which is consistently down
regulated by almost seven fold in the iMMECs overexpressing PAK4. Previous
studies have suggested a tumor suppressor role for ParvB in regulating breast
tumorigenicity. We hypothesize that PAK4 mediates mammary tumor forma-
tion through ParvB downregulation. Additional studies investigating the role of
ParvB in the PAK4 signaling pathway are under investigation. Future studies
will also involve studying the other genes we found to be regulated by PAK4
overexpression and determining their role in tumorigenesis.
#1572 Transformation frommelanocytes or nevi into melanoma: models
based on a transcriptomemeta-analysis.Daniel Ortega-Bernal,1 Claudia Ran-
gel-Escareño,2 Elena Arechaga-Ocampo,1 Claudia H. Gonzalez-De la Rosa1.
1Universidad Autonoma Metropolitana, Mexico, Mexico; 2Instituto Nacional de
Medicina Genomica, Mexico, Mexico.
Background:Melanoma is themost aggressive skin cancer due to its ability to
rapidly metastasize and resist radio- and chemotherapy. The frequency of this
disease has increased 400% worldwide in the last 30 years. There are 2 ways to
develop melanoma: direct transformation of melanocytes into melanoma and
the nevus as an intermediary. Here, we used a computational strategy based on
transcriptome meta-analysis to identify the pathways involved in the 2 possible
ways by which cells may transform to melanoma. Methods: Affymetrix HU
133APlus 2.0microarray fıles (50 in total) were collected from theGene Expres-
sion Omnibus database for the meta-analysis, representing melanocytes, nevi
and stage I, II, and III melanoma. Differential expression was analyzed using
linear models and the limma library. The analysis focused on 3 comparisons:
nevi vs. melanocytes; melanoma vs. nevi; andmelanoma vs. melanocytes. Tran-
scripts with a log fold change of -1/1 (B-statistic 3) were included in the
study. Functional enrichment analysis identifıed the most deregulated pathway.
Genes resulting from the intersection of the melanoma vs. nevi and melanoma
vs. melanocytes comparisons were used as possible biomarkers of transforma-
tion and analyzed by IPA. Gene signature identifıcation: In melanoma vs. nevi
comparison, 1881 expressed genes were differentially expressed, of which only
888 were used to generate the transformation model and to perform functional
enrichment. Consistent with the phenomenon of malignant transformation, we
identifıed 3 pathways associatedwith cell cycle checkpoint control that exhibited
decreased activity. Conversely, the pathways that exhibited increased activity,
Estrogen-mediated S-phase Entry and Cyclins and Cell Cycle Regulation, pro-
mote cell cycle progression. In melanoma vs. Melanocytes comparison, 4112
expressed genes were differentially expressed (2310 downregulated and 1802
upregulated), 1099 of which intersected with the nevi vs. melanocytes compar-
ison. The 682 genes intersecting the melanoma vs. nevi comparison were re-
moved. Thus, 2331 genes were used to perform enrichment analysis. The main
result was the decreased activity of the cAMP-mediated signaling pathway. The
intersection of both comparisons (682 genes), was used to identify 22 genes
upregulated whose product is a secreted protein. Two of these genes were pre-
viously reported as potential biomarkers in neoplasia, cytokines CXCL8 and
CXCL16, supporting the quality of our analysis. Conclusions: Our analysis, in
agreement with previously reported results, identify CXCL8 as biomarker of
melanoma, and also identifıed new biomarkers, including CXCL16, MMP19,
BIVM, and FAM60A. A better understanding of the specifıc molecular altera-
tions causally involved in this diseasemay lead to new biomarkers and pathways
involved in the transformation for this currently incurable malignancy.
#1573 Detection of late-arising driver mutations using multi-sample tu-
mor sequencing data. Karen Gomez, Sayaka Miura, Sudhir Kumar. Temple
University, Philadelphia, PA.
Whole-genome sequencing of tumors has identifıed genetic mutations that
drive the origination, growth, and spread of cancer. Most driver mutations de-
tected from sequencing tumors have been categorized as early-occurring and are
believed to play a role in initial tumor formation. However, single-region pri-
mary tumor samples represent just one snapshot of the continuously changing
mutational landscape of a tumor. Drivers of initial tumor formation, occurring
early on in tumor development, are present in more tumor cells and are more
likely to be identifıed from a single tumor sample than drivers of later events like
metastasis, which are likely to be found in only one or a few tumor samples. We
analyzed 101multi-region and/ormulti-tumor sequencing data sets using driver
mutation annotation and phylogenetic inference to determine whether driver
mutations occur preferentially early on. We found driver mutations frequently
arise late in the course of tumor evolution, evenwhen statistically accounting for
small amounts of total drivers and many early total mutations. In addition, the
timing of driver mutation occurrence varies widely depending on cancer type as
well as among different individuals with a single cancer subtype. Finally, we
identify known cancer genes that are enriched in either early or late driver
mutations, reflecting different selective pressures at various stages of cancer
development. These results illustrate how drivers of primary tumorigenesis
must be distinguished from drivers of treatment resistance, metastasis, or recur-
rence in order to better understand the genetic changes behind cancer progres-
sion.
#1574 Computational approach for discovery of regulatory noncoding
variants in cancer. Yu Liu,1 Michael Edmonson,1 Xiaotu Ma,1 Michael Rusch,1
Yongjin Li,1 Benshang Li,2 Shuhong Shen,2 A. Thomas Look,3 Jinghui Zhang1.
1St. Jude Children’s Research Hospital, Memphis, TN; 2Shanghai Children’s Med-
ical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China;
3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Noncoding mutations in the cancer genome have historically been poorly
understood. Recent studies have shown however that mutations in inter-
genic regions may play an important role in cancer by introducing de novo
regulatory elements and thus cis-regulating target gene expression. While
mono-allelic expression of the dysregulated gene is an important signature
of regulatory noncoding mutations, recognition of this feature has not been
implemented by any methods evaluating noncoding mutations to date. To
perform genome-wide detection of noncoding mutations with a potential
regulatory function, we developed a novel computational approach imple-
menting this allelic specifıc expression signature (ASE) as a core component,
using WGS and RNAseq data as input. We fırst searched for genes showing
ASE across the tumor genome by comparing the minor allele frequency of
heterozygous markers between WGS and RNAseq data. We excluded genes
known to be in an imprinted locus, as well as sites matching a precomputed
set of 5,576,857 problematic polymorphismmarkers (estimated by analyzing
WGS data from 625 normal genomes). Next, the somatic mutations were
fıltered for regulatory candidates that could introduce a transcription factor
(TF) binding motif absent from the reference sequence. We included 614 TF
binding motifs from the HOCOMOCO database and performed motif anal-
ysis with the FIMO package. Finally, the somatic mutations were assigned to
dysregulated genes in the same topologically associating domains in human
defıned by public Hi-C data and prioritized by open chromatin state defıned
by DNaseI hypersensitivity regions (ENCODE project). We applied our ap-
proach to 22 T-ALL tumor samples collected at Shanghai Children’s Medical
Center in a pilot study consisting of 13 diagnosis and 9 relapse samples (9 of
these were trios). WGS was performed on both tumor and normal samples
and RNAseq was performed for the tumor sample only. We predicted 213
regulatory noncoding mutations (157 unique variants) in total from this
cohort, potentially targeting 119 genes. Among the dysregulated targets we
found TAL1 and LMO2, which are known TFs playing a key role in T-ALL.
TAL1 mutations were identifıed in a total of 6 tumors (3 trios). Besides the
known oncogenic insertion at 7kb upstream of TAL1 (1 trio), we also
discovered a novel mutation in the fırst intron of TAL1 (2 trios) that may
potentially drive ectopic TAL1 expression. Novel LMO2 mutations were
found in 6 tumors (3 trios) at 3 different sites. This approach also identifıed
novel targets such as GPSM1 and PTPRN2, shedding light on heretofore
unknown players in T-ALL targeted by noncoding mutations. By integrating
WGS and RNAseq data, our novel computational framework can identify
somatic noncoding mutations in cancer that may introduce de novo regula-
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tory elements, thus driving target gene expression. Wider application of this
approach will expand our understanding of the role of noncoding mutations
in the cancer genome.
ENDOCRINOLOGY: Prostate Cancer Biology and Therapy
#1575 Novel small molecule inhibitors of p300/CBP down-regulate AR
and c-Myc for the treatment of castrate resistant prostate cancer. Nigel
Brooks,1 Neil Pegg,1 Jenny Worthington,2 Barbara Young,3 Amy Prosser,3
Jordan Lane,3 David Taddei,3 Matthew Schiewer,4 Renee deLeeuw,4 Jennifer
McCann,4 Karen Knusden4. 1CellCentric Ltd, Cambridge, United Kingdom;
2Axis Bioservices, Coleraine, United Kingdom; 3Sygnature Discovery, Notting-
ham, United Kingdom; 4Sidney Kimmel Cancer Center, Thomas Jefferson
University, Philadelphia, PA.
Background: E1A binding protein (p300) and CREB binding protein
(CBP) are two closely related, paralogue histone acetyl transferase proteins
that act as transcriptional co-activators of a variety of cancer related genes.
We have developed potent, selective and orally active small molecule inhib-
itors of the bromodomain of p300/CBP and investigated their role in regu-
lating androgen receptor expression and function. We have also examined
their role in driving synthetic lethality in tumours. Loss of function muta-
tions in either p300 or CBP (including in signifıcant proportions of lung and
bladder tumours), can lead to a dependency on the corresponding paralogue
protein. Methods: Binding affınity to p300, CBP and BRD4 was measured in
a surface plasmon resonance (SPR) assay. Potency and functional activity
was demonstrated in a panel of prostate cells lines representing hormone
responsive (LNCaP), hormone independent (DU145, PC3) and castrate re-
sistant disease (22Rv1, C4-2, VCaP, LNCaP-AR) as well as wildtype (A549)
and CBP defıcient (H520, H1703, LK2) lung cancer cells. Combination ef-
fects of p300/CBP inhibitors with a PARP or CDK4/6 inhibitor were deter-
mined in LNCaP and C4-2 cells. Effects of p300/CBP inhibitors (and by
comparison, the BET inhibitor, JQ1), on AR, AR-V7 splice variant and c-
Myc protein, as well as c-Myc, KLK3 and TMPRSS2 gene expression, were
assessed in 22Rv1 cells in vitro. In vivo effects on biomarkers were measured
in a 22Rv1 xenograft model. Results: CCS1357, an in vitro probe compound,
binds to p300 and CBP with high affınity (Kd4nM) and selectivity
(Kd245nM; BRD4). It is a potent inhibitor of cell proliferation in castrate
resistant cell lines (IC50100nM in LnCaP-AR; 350nM in 22Rv1) with min-
imal effects in hormone independent lines. CCS1357 combined with palbociclib
(CDK4/6) or olaparib (PARP) inLNCaPorC4-2 cells, showed reduced cell viability
comparedwithanyof thesedrugsgivenalone. In22RV1cells,CCS1357signifıcantly
down-regulated AR-FL, AR-V7 and c-Myc protein by Western, an effect not seen
with JQ1 at equivalent proliferation IC50s. CCS1357 effects were reversed by the
proteasome inhibitor, MG132. CCS1357 also caused a profound inhibition of c-
Myc, KLK3 and TMPRSS2 genes measured by qPCR in 22Rv1 cells in vitro. A
preclinical candidate (CCS1477) given as a single oral dose (30mg/kg) inhibited
plasma PSA and tumourAR,AR-V7 and c-Myc in a 22Rv1 xenograftmodel. In the
lung cancer cell lines, we observeddifferential sensitivity toCCS1357;CBPdefıcient
lines were more sensitive (cell proliferation) compared with normal. Conclusions:
Taken together these data support the clinical testing of p300/CBP inhibition in
patients in two settings; fırstly, castrate resistant prostate cancer by down-regulating
of AR, AR-SV and c-MYC expression and function; and secondly in patients with
loss of functionmutations in p300 or CBP by driving synthetic lethality.
#1576 UGT2B17 promotes castration-resistant prostate cancer progres-
sion through enhancing ligand-independentAR signaling.Haolong Li,1 Ning
Xie,1 Ruiqi Chen,1 Mélanie Verreault,2 Ladan Fazli,1 Martin E. Gleave,1 Olivier
Barbier,2 Xuesen Dong1. 1University of British Columbia, Vancouver, British
Columbia, Canada; 2Laval University, Québec, Quebec, Canada.
Background: Castration resistant prostate cancer (CRPC) is characterized
by a shift of androgen receptor (AR) signaling from ligand-dependent to
ligand-independent. Defıning mechanisms that control AR signaling trans-
formation is important to develop therapies for disease control. UDP-glucu-
ronosyltransferase 2B17 (UGT2B17) is a key enzyme that maintains andro-
gen homeostasis by catabolizing AR agonists into inactive forms. Although
enhanced UGT2B17 expression by antiandrogens was reported in androgen-
independent prostate cancers, its role in regulating AR signaling transfor-
mation and CRPC progression remain unknown. Method and Results: We
fırst evaluated the UGT2B17 protein expression levels by immunohisto-
chemistry (IHC) on Vancouver Prostate Centre tissue microarrays.We show
that higher UGT2B17 protein expression in prostate tumors is associated
with higher Gleason score, metastasis and CRPC progression. The expres-
sion and activity of UGT2B17 are also higher in androgen-independent com-
pared to androgen-dependent cell lines. Interestingly, enzalutamide-resis-
tant MR49F cells expresses low UGT2B17 mRNA but strong protein
expression, suggesting that posttranslational mechanisms may enhance
UGT2B17 protein stability in these cells. We then constructed PCa cell lines
with gain-of-function UGT2B17 by lentivirus. Functional analyses indicate
that UGT2B17 stimulates cancer cell proliferation, invasion, and xenograft
progression to CRPC after prolonged androgen deprivation. To further de-
cipher the molecular mechanisms by which UGT2B17 enhance PCa cell
growth independent of androgen, we performed gene microarray using LN-
CaP(mock) and LNCaP(UGT2B17) cells cultured under the regular serum
condition or the prolonged androgen deprivation condition. Microarray
analyses reveal that UGT2B17 suppresses androgen-dependent AR tran-
scriptional activity, while enhancing androgen (ligand)-independent AR
transcriptional activity. The latter targets genes associated with cell mitosis.
These UGT2B17 actions in reprogramming androgen signaling are mainly
mediated by activating the c-Src kinase. We confırmed that, in CRPC tu-
mors, UGT2B17 expression is positively associated with c-Src activation.
Conclusion: These results indicate that UGT2B17 expedites CRPC progres-
sion by enhancing ligand-independent AR signaling that activates predom-
inantly cell mitosis in cancer cells.
#1577 GRK3 is a direct target of ADT-induced CREB1 activation and it
promotes neuroendocrine differentiation of prostate cancer cells. Dayong
Zheng,1 Mohit Hulsurkar,1 Meixiang Sang,1 Songlin Zhang,1 Jianming Xu,2
Martin Gleave,3 Michael Ittmann,2 Wenliang Li1. 1University of Texas Health
Science Center at Houston, Houston, TX; 2Baylor College of Medicine, Houston,
TX; 3University of British Columbia, Vancouver, British Columbia, Canada.
Treatment-related neuroendocrine prostate cancer (t-NEPC) is an aggressive
subtype of prostate cancer that is believed to arise through neuroendocrine
differentiation (NED) from prostate adenocarcinoma (PAC) upon castration
resistance to androgen deprivation treatment (ADT). t-NEPC is highly meta-
static with poor prognosis.With the recent introduction of potent ADTdrugs in
clinic, the incidence of t-NEPC is expected to increase dramatically. No effective
therapeutic is available for t-NEPC and its molecular mechanisms remain
poorly understood.We reported that GRK3 (G protein-coupled receptor kinase
3) promotes prostate cancer progression. We further demonstrated that the
ADT activates CREB1 (cAMP response element binding protein 1), which di-
rectly targets and induces GRK3. GRK3 expression is higher in t-NEPC than in
PAC cells andmousemodels, and it positively correlateswith the expression and
activity of CREB1 in human prostate cancers. Notably, overexpression of GRK3
in PAC cells increased the expression of NE markers. Conversely, silencing
GRK3 blocked CREB1-inducedNED in PAC cells, reversedNE phenotypes and
inhibited proliferation of t-NEPC cells in culture and in xenograft. Currently, we
are investigating the mechanisms underlying NEPC progression promoted by
theCREB1/GRK3 axis. Taken together, these results indicate thatGRK3 is a new
critical activator of NE phenotypes and mediator of CREB1 activation in pro-
moting NED of prostate cancer cells.
#1578 Distinct expression and biological functions of PMEPA1 isoforms
in prostate cancer. Shashwat Sharad, Hua Li, Allissa Dillman, Alagarsamy
Srinivasan, Albert Dobi, Shiv Srivastava. USU/Center for Prostate Disease Re-
search (CPDR), Rockville, MD.
Introduction and Objectives: The androgen receptor (AR) and TGF- dys-
functions contribute to prostate cancer (CaP) development and progression.
Our laboratory since the discovery of PMEPA1, has established PMEPA1/
NEDD4 and AR negative feedback loop and its role in AR regulation in prostate
cancer. PMEPA1 gene has also identifıed as a TGF- responsive gene and inhib-
its TGF- signaling via a negative feedback loop. Five isoforms are transcribed
from distinct promoters within the PMEPA1 locus. PMEPA1 isoforms were
shown to have variations at the N-terminus of the protein. Our previous study
has shown the differential correlations of 2 PMEPA isoforms (PMEPA1 and
STAG1) in context of AR expression in CaP. This study focuses on understand-
ing of the expression and biological functions of PMEPA1 isoforms in CaP.
Methods: RNA-Seq data from LNCaP and VCaP cells, and from The Cancer
Genome Atlas (TCGA) dataset, were used to evaluate the expression levels of
PMEPA1 isoforms. LNCaP cells were treated with R1881 (0, 0.1, 1.0 nM) and
DU-145 and PC-3 cells were treated with TGF- (0, 5 and 25 ng/ml) for 24
hours. PMEPA1 isoform specifıc plasmids and siRNAs were transfected into
LNCaP, DU-145 and PC-3 cells individually. Cell growth was analyzed by cell
counting andBrdU incorporation assay. The protein levels of PMEPA1 isoforms
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and AR were detected by immunoblotting, and the transcript levels were evalu-
ated by QRT-PCR. Results: Since the annotation of PMEPA1/TMEPA1 iso-
forms has been empirical in the literature, here we propose a new structure/
expression based nomenclature: PMEPA1 (reading frame of 252 amino acids
(aa)); PMEPA2 (344aa); PMEPA3 (287aa; STAG1); PMEPA4 (259aa); and
PMEPA5 (237aa). Expression of PMEPA1 and PMEPA2 was restricted to an-
drogen responsive prostate cancer cells in comparison to broader expression
pattern of other isoforms (PMEPA3-5). The expression of PMEPA1-2 was an-
drogen regulated, whereas expression of PMEPA 3-5 was regulated by TGF-.
Only PMEPA1 inhibited cell growth of LNCaP, DU-145 and PC-3 cells. In
contrast, PMEPA2-4 promoted cell growth of DU-145 and PC-3 cells. Of all the
isoforms only PMEPA1mediated AR protein degradation in CaP. Conclusions:
The PMEPA isforms appear to underscore distinct biological functions in the
context of androgen andTGF- signaling.Widely studied PMEPA1was specifıc
for AR degradation in prostate cancer cells and was consistent with previous
observations of association of AR upregulation with loss of PMEPA1 in prostate
cancer. The roles of PMEPA isoforms need to be better defıned in prostate
cancer and other cancers. Funding: This study was supported by CPDR,
USUHS, HU0001-10-2-0002 to DGM.
#1579 Bicalutamide-induced expression of T-type Ca2 channels in pros-
tate cancer cells undergoing neuroendocrine differentiation in vitro.Miguel
Martin-Caraballo, Megan Hall, Bryan Todd, Yoon Jung Kwon, Vu Nguyen,
Jennifer L. Hearne. University of Maryland Eastern Shore, Princess Anne, MD.
The growth of prostate cancer cells depends on the activation of androgen
receptors. Anti-androgen therapies that inhibit androgen synthesis or receptor
activation are effective in limiting tumor growth.However, prolonged treatment
with anti-androgen therapies result in the transition of prostate cancers into an
androgen refractory state. Neuroendocrine differentiation (NED) has been as-
sociated with the progression of prostate cancers to an androgen resistant phe-
notype. In this work we investigated the effect of the androgen receptor blocker
bicalutamide in promoting NED of LNCaP cells and whether it is accompanied
by increased T-type Ca2 channel expression. The ability of bicalutamide to
evoke morphological and biochemical changes associated with NED was as-
sessed by PCR, western blot and immuno-histochemical analysis. Changes in
the Cav3.2 T-typeCa2 channel subunit expressionwas studied using PCR anal-
ysis, western blot andwhole cell recordings. The role of T-type Ca2 channels in
promoting the differentiation of LNCaP cellswas assessed by a cell viability assay
and changes in cell morphology, specifıcally the development of neurite-like
processes. PCR analysis of bicalutamide-stimulated cells indicates no signifıcant
changes in Cav3.2 mRNA, yet results in Cav3.2 protein expression and func-
tional channels. Western blot and immuno-histochemical analysis of LNCaP
cells simulated with bicalutamide for 4-10 day reveals biochemical changes con-
sistentwithNED including the expression of tubulin IIIbeta andneuron-specifıc
enolase. Pharmacological inhibition of T-type Ca2 channel function with
nickel ions and NNC 33-0936 disrupts the morphological differentiation and
cell viability of LNCaP cells treated with bicalutamide. These results suggest that
bicalutamide treatment of LNCaP cells evokes signifıcant morphological and
biochemical changes associatedwithNED and results in increased expression of
T-type Ca2 channels, which can signifıcantly alter Ca2 homeostasis.
#1580 Combined neuroendocrine differentiation and androgen receptor
hyperactivity inMAP37 and CHD1 null prostate cancer. Leah C. Rider, Lind-
sey U. Rodrigues, Anis Karimpour-Fard, Lina Romero, Claire Gillette, James C.
Costello, ScottD. Cramer.Univ. of ColoradoAnschutzMedical Campus, Aurora,
CO.
We recently functionally validated a clinically aggressive subtype of prostate
cancer characterized by dual deletion of MAP3K7 and CHD1. This subtype
accounts for up to 25%of prostate cancer deaths. Androgen signaling is a critical
component of prostate tumorigenesis and disease progression, which is ex-
ploited in treatment of prostate cancer with androgen deprivation and anti-
androgen therapies. Neuroendocrine differentiation is thought to provide a se-
lective growth advantage of prostate cancer in androgen-depleted conditions
such as surgical or chemical castration. REST is a transcriptional repressor of
neuronal gene expression and has been implicated in neuroendocrine differen-
tiation of prostate cancer. The impact of combinedMAP3K7 and CHD1 loss on
androgen signaling and neuroendocrine differentiation has not been deter-
mined. Here, we demonstrate that dual loss of MAP3K7 and CHD1 simultane-
ously stimulates enhanced androgen signaling and enhanced neuronal differen-
tiation correlated with enhanced growth in both androgen-depleted and
androgen-replete conditions. These changes occur via increased androgen re-
ceptor chromatin binding, loss of CHD1 chromatin binding, loss of REST ex-
pression, and reduced chromatin binding by REST. Suppression of CHD1 and
MAP3K7 attenuates the antiproliferative activity of the anti-androgen Enzalut-
amide. Furthermore, we translate these fındings to clinical samples and show
that decreased expression of CHD1, MAP3K7, and REST is associated with
previous therapeutic intervention, castrate-resistant disease, and progression to
a neuroendocrine phenotype. Overall, patients with low expression of all three
have poorer disease-free survival. Together these data support the lineage plas-
ticity of prostate tumors with loss of CHD1 and MAP3K7 exhibiting both an-
drogen-dependent and -independent phenotypes leading to poor clinical out-
come, which poses challenges to conventional therapeutic approaches.
#1581 Androgen receptor action inprostate cancer partitions intodistinct
transcriptional codes that differ in clinical relevance. Sangeeta Kumari,1 Var-
adha Balaji Venkadakrishnan,1 Dhirodatta Senapati,1 Qiang Hu,2 Song Liu,2
HanneloreV.Heemers1. 1ClevelandClinic, Cleveland,OH; 2Roswell ParkCancer
Institute, Buffalo, NY.
With few exceptions the 30,000 prostate cancer (CaP) deaths annually in the
US are due to failure of androgen deprivation therapy (ADT). ADT prevents
ligand-activation of androgen receptor (AR). Despite remission, CaP progresses
while continuing to rely on AR. AR’s transcriptional output that controls CaP
behavior is an alternative therapeutic target, but its molecular regulation is
poorly understood. Here, we determined the androgen dependence of hundreds
of direct AR target genes on 18 coregulators that are relevant toCaPprogression,
and uncovered that the AR-dependent transcriptome breaks down in coregula-
tor-dependent gene sets. Pairwise comparison and unsupervised clustering
showed limited overlap between the gene subsignatures. Neither ChIP nor qRT-
PCR studies revealed differences in the kinetics of coregulator recruitment to
Androgen Response Elements (AREs) or of androgen regulation of different
gene sets. Rather, Cistrome analyses of AR binding sites demonstrated prefer-
ential enrichment in binding motifs for distinct transcription factors (TFs) be-
tween coregulator-dependent gene sets. Pathway and GSEA analyses of these
signatures indicated associationswith select biological processes and differential
enrichments between normal prostate and CaP, CaPs of different stages, and
CaP and bone marrowmicroenvironment. These results suggested that coregu-
latorsmayunite the action ofDNA-boundARandTF(s) to control select aspects
of androgen-dependent CaP cell biology. The presence and functionality of such
novel predicted AR transcriptional codes, namely AR-WDR77-p53 and AR-
STAT3-IRF1 with projected roles in CaP cell proliferation and stemness respec-
tively, was confırmed in Co-IP and gene expression profıling. As AR and p53 are
the major drivers of lethal CaP, the AR-WDR77-p53 code was explored further.
Mass spectrometry after WDR77 and p53 IP independently identifıed PGAM5,
a recently isolated serine/threonine protein phosphatase that regulates cell death
and unknown to be relevant to AR signaling or CaP biology, as part of the
AR-WDR77-p53 complex. Co-IP assays verifıed IP-mass spectrometry results
and ChIP studies confırmed recruitment of PGAM5 to WDR77-dependent
AREs. Expression profıling demonstrated signifıcant overlap in genes for which
androgen regulation was altered after silencing of WDR77, PGAM5 or p53.
Co-IP andChIP studies showed that androgen-dependent recruitment of p53 to
ARE-bound AR requires WDR77 and PGAM5. Western blotting and flow cy-
tometry analyses indicated that WDR77 and PGAM5 and their dependent AR
target genes control G1/S cell cycle progression, which was maintained in pres-
ence of clinically relevant gain-of-function p53 mutants. These novel insights
indicate that disrupting select protein-protein and protein-DNA interactions
may be a viable strategy to inhibit AR action that drives CaP lethal progression.
#1582 Therapeutic potential of combination therapy using a next gener-
ation antisense oligonucleotide targeting the androgen receptor and AKT
inhibitionwithAZD5363 ingenetically engineeredmousemodels of prostate
cancer.Marco A. De Velasco,1 Yurie Kura,1 Naomi Ando,1 Koichi Sugimoto,1
Kazuko Sakai,1 Barry R. Davies,2 Youngsoo Kim,3 A. Robert MacLeod,3 Masa-
hiro Nozawa,1 Kazuhiro Yoshimura,1 Kazuhiro Yoshikawa,4 Kazuto Nishio ,1
Hirotsugu Uemura 1. 1Kindai University Faculty of Medicine, Osaka-Sayama,
Japan; 2AstraZeneca, Macclesfıeld, United Kingdom; 3Ionis Pharmaceuticals,
Carlsbad, CA; 4Aichi Medical University, Nagakute, Japan.
Prostate cancer is highly dependent on androgen receptor (AR) and PI3K/
AKT signaling pathways for survival and disease progression. Preclinical evi-
dence suggests that combinatorial approaches targeting bothAR andPI3K/AKT
activity improves treatment effıcacy. However, sustained responses from tradi-
tional and next-generation anti-androgen therapies targetingAR remain elusive
in clinical practice due to inherent/acquired resistance resulting in lethal castra-
tion-resistant prostate cancer (CRPC).Mechanisms for continuedAR transcrip-
tional activitymay be ligand dependent or independent but still require AR gene
expression. Persistent AR gene expression is a key feature of CRPC. Thus, block-
ing AR gene expression by antisense oligonucleotides (ASO) is a logical ap-
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proach to CRPC. We previously showed that monotherapy with ISIS581088, a
generation 2.5 ASO targeting mouse AR, demonstrated strong antitumor activ-
ity in a transgenicmousemodel of PTEN-defıcient prostate cancer. In this study
we show the antitumor effects of combined therapy of ISIS581088 and
AZD5363, a potent AKT inhibitor and demonstrate the therapeutic benefıt of
combination therapy in a clinically relevant mouse model of CRPC. Sixteen-
week-oldmicewith PTEN-/- castration-naïve prostate tumorswere treatedwith
ISIS581088 and AZD5363 alone or in combination for four weeks. Tumor
growth inhibition rates were 41.2%, 20.2% and 54.4% for ISIS581088, AZD5363
and ISIS581088/AZD5363 treatment groups, respectively, P0.001. In a model
of mouse CRPC, 16-week-old mice with PTEN-/- castration-resistant prostate
tumors (eightweeks post castration) experienced reduced tumor burdenwith all
treatments but no enhancement was observed when the compounds were ad-
ministered in combination compared with monotherapy drug treatments. In a
randomized trial of advanced CRPC in PTEN/P53 double knockout mice, com-
bination therapy signifıcantly increased overall survival. Median survival were
18, 17 21, 22, and 38 days for control vehicle, control ASO, ISIS581088,
AZD5363 and ISIS581088/AZD5363 treatment groups, respectively, P0.041.
In conclusion, our data shows that combination therapy signifıcantly reduced
tumor burden in mice with castration-naïve tumors compared to those treated
with monotherapy. Notably, combination therapy did not produce an additive
effect in an early stage CRPC intervention model. Still, combination therapy
demonstrated a clear advantage in prolonging overall survival in a long-term
randomized mouse trial of PTEN/P53-defıcient CRPC. Thus, our data provides
preclinical evidence to support that next generation ASOs targeting AR in com-
bination with AKT inhibition is a potentially effective treatment approach for
CRPC.
#1583 Inhibition of proline isomerase Pin1 interrupts the function of the
androgen receptor N-terminal domain and suppresses androgen-indepen-
dent growthof prostate cancer cells. JackyK. Leung, Yusuke Imamura,Minoru
Kato, Nasrin R. Mawji, Marianne D. Sadar. British Columbia Cancer Agency,
Vancouver, British Columbia, Canada.
Patients with advanced prostate cancer continue to develop lethal castration-
resistant prostate cancer (CRPC) despite hormone therapy and maintaining
castrate levels of serum androgen. Most CRPC appears to be dependent on the
androgen receptor (AR), but instead of the C-terminal ligand-binding domain,
it is the N-terminal domain (NTD) harboring a powerful transactivation do-
main that drives AR transcriptional activity. This was supported by the discov-
ery of AR splice variants (ARv567es and V7) which are constitutively active, do
not encode a functional ligand-binding domain, and correlate with poor patient
outcome. The AR NTD is intrinsically disordered, but it contains several puta-
tive binding sites for Pin1, a proline isomerase specifıc for phosphorylated-Ser/
Thr-Pro motifs. Since the innate ability of the AR NTD to adopt multiple tran-
sient structures is important for transactivation of AR, we aimed to determine
whether Pin1 regulates motifs within the AR NTD. We tested several known
inhibitors of Pin1 in cell-based assays thatmeasure proliferation or transcription
mediated by AR. Our results demonstrated that inhibition of Pin1 interrupted
the function of the AR NTD. The Pin1 inhibitor juglone effectively and specifı-
cally blocked transcription mediated by AR induced by androgen, as well as
transactivation of the AR NTD in the presence of IL-6. We found that Pin1
predominantly interacted with a specifıc region of the AR NTD containing two
Pin1 binding sites, and by inhibiting Pin1 the interactions between endogenous
AR and STAT3 became attenuated. Furthermore, Pin1 inhibitors were more
effective than second-generation anti-androgens in blocking androgen-inde-
pendent proliferation of LNCaP95 cells driven by AR variants. Here we describe
that Pin1 is a critical factor for transcription mediated by AR, regardless of
ligand, by regulating the AR NTD. Understanding the molecular mechanisms
that may promote AR signaling in the absence of androgen will aid the develop-
ment of more effective therapies for CRPC.
#1584 Wnt/beta-catenin and Foxa2 axis activates AR signaling in castra-
tion resistant prostate cancer.ZacharyM. Connelly, ShuYang, Jiahe Li, Robert
Matusik, Xiuping Yu. LSUHSC Shreveport, Shreveport, LA.
Background: Prostate cancer (PCa) is the leading cancer among men in the
world. Androgen deprivation therapy is a common treatment to cease prostate
growth. However, androgen deprivation eventually fails and PCa relapses,
evolving into castration resistant prostate cancer (CRPCa). It has been estab-
lished that androgen receptor (AR) continues to be the central player in medi-
ating CRPCa. However, the mechanism by which the AR signaling remains
active is unclear.Wehave reported that activation ofWnt/beta-catenin signaling
pathway promotes castrate-resistant progression. Our study has also shown that
activation of the Wnt/beta-catenin pathway induces the expression of Foxa2, a
fork-head transcription factor that is expressed in embryonic prostate & ad-
vanced stage PCa. Here, we study the Wnt pathway and the role of Foxa2 in
retaining active AR signaling in advanced PCa in the absence of androgens.
TRAMPmice, SV40 T-antigen transgenic mouse models for PCa, were used. It
has been recognized that in this model, T-antigen, which is driven by androgen-
responsive probasin promoter, remains expressed following androgen ablation.
In this study, we identifıed a mechanism that sustains an active AR signaling in
CRPCa. Methods: To study whether the Wnt/beta-catenin pathway is active in
advanced stage PCa, we crossed the TRAMPmice withGFP-Wnt reportermice.
Some of the TRAMP/Wnt-reporter mice were castrated to study how androgen
deprivation affectsWnt/beta-Catenin signaling and promotes PCa progression.
Prostates were analyzed using IHC and IF staining. We also established a pros-
tate epithelial cell line that stably expresses Foxa2. Cell proliferation was exam-
ined with IncuCyte Zoom software. The expression of AR target genes was
assessed by using quantitative RT-PCR and Western blotting. ChIP was con-
ducted to assess the recruitment of transcriptional machinery to the promoters
of AR-regulated genes. Results: Utilizing the TRAMP/Wnt mouse model, we
show that Wnt/beta-Catenin signaling is active in advanced stage PCa. Addi-
tionally, our data showed that Foxa2, the downstream target of Wnt/beta-
Catenin signaling, drives the expression of androgen-responsive genes, regard-
less of androgendeprivation. Furthermore, cell proliferation assays revealed that
the expression of Foxa2 enabled an androgen-independent growth of prostatic
cells. Using thismodel system, we further explored themechanism that activates
the transcription of AR-responsive genes in the absence of androgens. Our data
indicated that Foxa2 is capable of recruiting H3k27Ac to AR-responsive pro-
moters. Conclusion: Together, these data indicate thatWnt signaling is activated
in advanced stage PCa, driving Foxa2 expression, and promoting AR signaling
to persist. This represents a novel mechanism that enables advanced PCa to
retain AR signaling pathway following androgen ablation. Targeting both Wnt
signaling and Foxa2 may pose as novel therapeutics for CRPCa.
#1585 Endostatin inhibits androgen-independent prostate cancer growth
by suppressing nuclear receptor-mediated oxidative stress. Joo Hyoung Lee,
MinsungKang, GurudattaNaik, JamesA.Mobley, Guru Sonpavde,W. Timothy
Garvey, Victor M. Darley-Usmar, Selvarangan Ponnazhagan.University of Ala-
bama at Birmingham, Birmingham, AL.
Androgen-deprivation therapy has been identifıed to induce oxidative stress
in prostate cancer (PCa), leading to re-activation of androgen receptor (AR)
signaling in a hormone-refractory manner. Thus, antioxidant therapies have
gained attention as adjuvants for castration-resistant PCa (CRPC). Here, we
report for the fırst time that human endostatin (ES) prevents androgen-inde-
pendent growth phenotype in PCa cells through its molecular targeting of AR
and glucocorticoid receptor (GR), and downstream pro-oxidant signaling. This
reversal following ES treatment signifıcantly decreased PCa cell proliferation
through downregulation of GR, and upregulation ofmanganese superoxide dis-
mutase and reduced glutathione levels. Proteome and biochemical analyses of
ES-treated PCa cells further indicated a signifıcant upregulation of enzymes in
major ROS scavenging machinery, including catalase, glutathione synthetase,
glutathione reductase, NADPH-cytochrome P450 reductase, biliverdin reduc-
tase and thioredoxin reductase, resulting in a concomitant reduction of intra-
cellular ROS. ES further augmented antioxidant system through upregulation of
glucose influx, pentose phosphate pathway (PPP) and NAD salvaging pathway.
This shift in cancer cell redox homeostasis by ES signifıcantly decreased the
effect of protumorigenic oxidative machinery on androgen-independent PCa
growth, suggesting that ES can suppressGR-inducedCRPCphenotype uponAR
antagonism, and dual targeting action of ES on AR and GR can be further
translated to PCa therapy.
#1586 Developing novel inhibitors of S100A4 for neuroendocrine (NE)
andmetastatic prostate cancer: systematic testing using relevantmodels and
drug development techniques. Mohammad Saleem,1 Arsheed A. Ganaie,1
Reihana Maqbool,1 Firdous A. Beigh,1 Syed Umbreen,1 Natalya G. Dulyani-
nova,2 Badrinath R. Konety3. 1Univ. of Minnesota Hormel Inst., Austin, MN;
2Albert Einstein College of Medicine of Yeshiva University, Bronx, NY; 3Univ. of
Minnesota, Minneapolis, MN.
S100A4, a calcium binding protein has been well studied as a marker of fıbro-
sis and metastasis. We recently showed that in addition of being a metastatic
marker, S100A4 is in fact an oncogene that plays an important role in the devel-
opment of prostate cancer (CaP) and is amenable of targeting for the treatment
of this lethal disease particularly neuroendocrine CaP (NE-CaP). Using a genet-
ically engineered transgenic mouse model of NE-CaP, we show that knocking
down of S100A4 signifıcantly inhibited growth of prostate tumorigenesis and
metastasis. Our noticeable fınding is that S100A4 is secreted by prostatic tumors,
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and extracellular/soluble S100A4 acts as a growth factor that has the ability to
confer aggressive potential to less aggressive or indolent tumor cells. We show
that serum-S100A4 level is highly elevated in human CaP patients with aggres-
sive disease regardless of their serum-PSA levels. We next asked if small mole-
cule inhibitors could be developed to inhibit the activity if intracellular as well as
extracellular S100A4. Using a highly robust Blue/Gene supercomputer-based in
silico method, we screened a library of 5000 molecules and based on their bind-
ing effıcacy to S100A4, identifıed potential inhibitors (SMI1 and SMI2).We next
tested if SMI1 and SMI2 bind to the S100A4 protein in biological solution. We
generated recombinant S100A4 protein and standardized an isothermal titra-
tion Calorimetry (ITC) assay for S100A4 binding. The ITC analysis (Kcal vs
time) shows that both SMI1 and SMI2 inhibitors signifıcantly bind to the
S100A4 protein nevertheless SMI2 exhibited higher binding affınity to S100A4
than SMI1. Next, we used Surface Plasmon Resonance (SPR) method (accurate
and sensitive technique) for detecting binding of inhibitors to S100A4. The SPR
data (sensogram) shows that SMI1 and SMI2 bind to the S100A4 protein. The
binding of S100A4 toMyosin IIA (MIIA) is known to disrupt the latter’s mono-
mer-polymer equilibrium. This phenomenon is captured in solution (in terms
of disassembly of MIIA fılaments and change in turbidity). Using disassembly/
or turbidity assays as an index of S100A4 activity (where recombinant S100A4
and MIIA are incubated/ inhibitors), we show that SMI1 and SMI2 inhibit
the activity of S100A4 protein. Next, we tested effıcacy of inhibitors in vitro and
show that SMI1 and SMI2 therapies inhibit the growth, proliferation, migration
and invasiveness of NE-CaP (TRAMPC2) and AI-CaP (DU145, PC3) cells. No-
tably, SMI1 and SMI2 therapies inhibited the growth-promoting effects of ex-
tracellular S100A4 and decreased activities of S100A4 downstream target pro-
teins (MMP9 and NFB). These data suggest that S100A4 inhibitors (SMI1 and
SMI2) exhibit high anti-metastatic effıcacy and are the potential candidates for
treating NE-CaP and metastatic AI-CaP. The validation of SMI1 and SMI2 un-
der in vivo models is underway in our laboratory.
#1587 Disruption of nuclear export with selinexor or KPT-8602 reduces
androgen receptor expression and leads to potent anti-tumor activity in pre-
clinical models of androgen-independent prostate cancer.Christian Argueta,
Boris Klebanov, Trinayan Kashyap, Hua Chang, Sharon Friedlander, Erkan Ba-
loglu, Margaret Lee, Humphrey Gardner, Sharon Shacham,William Senapedis.
Karyopharm Therapeutics, Newton, MA.
Metastatic castration resistant prostate cancer (mCRPC) is an advanced form
of prostate cancer (PC) associatedwith poor prognosis. Approximately 20 - 40%
of mCRPCs are androgen-independent and do not respond to treatment with
abiraterone or enzalutamide, drugs that suppress androgen synthesis or directly
target androgen ligand binding domains (LBD) respectively. Patients initially
responding to these drugs eventually relapse, highlighting the need for alterna-
tive therapies. Resistance is attributed to the emergence of constitutively active
AR splice variants lacking C-terminal LBDs such as AR variant 7. Although
ARv7 activity cannot be mitigated by current therapeutic approaches, it is
known that AR mRNA is exported from the nucleus by eIF4E and exportin-1
(XPO1). Selinexor and KPT-8602 are orally bioavailable SINE (Selective Inhib-
itor of Nuclear Export) compounds that specifıcally target XPO1. The purpose
of this study is to provide mechanistic evidence for using SINE compounds as
novel therapies for androgen-independentmCRPC.Methods: In vitro, selinexor
or KPT-8602 were tested on androgen-independent PC cell line 22Rv1. RNA
and protein were analyzed by qPCR and immunoblot. Cell viability was exam-
ined using the Celltiter-Glo assay. In vivo, immune defıcient SCID mice were
injected subcutaneously with 22Rv1 cells. Tumors were grown to 150 mm3
before treatment with selinexor (10 mg/kg qodx3) or KPT-8602 (15 mg/kg re-
duce to 10 mg/kg qdx5). Tumor growth and animal weights were monitored to
determine tumor growth inhibition (TGI) and tolerability to treatment. Tumors
were analyzed using immunohistochemistry (IHC). Results: We found that ex-
pression of AR, ARv7 and prostate specifıc antigen (PSA; transcriptionally reg-
ulated by AR) proteins are reduced following 24-hour treatment with SINE
compounds. Nuclear vs. cytoplasmic fractionation of RNA revealed that ARv7
and PSA mRNA localization was increased in the nucleus (4-fold and 3-fold,
respectively) and reduced in the cytoplasm (5-fold and 3-fold, respectively).
Moreover, KPT-8602 potently inhibited cell viability (IC50: 100 nM), while en-
zalutamide and abiraterone had no effect. Finally, mice bearing 22Rv1 xeno-
grafts, treated with selinexor or KPT-8602 exhibited a complete reduction in
tumor volume (95% and 94% TGI, respectively), which coincided with pro-
longed overall survival. IHC analysis showed a reduction of proliferation mark-
ers and a concomitant increase in cell death makers in selinexor and KPT-8602
treated tumors. Conclusion: SINE compounds show strong anti-tumor activity
in androgen-independent prostate cancer models in vitro and in vivo by reduc-
ing AR, ARv7, and PSA expression. These fındings highlight the promise of
SINE compounds as treatment options for androgen-independent mCRPCs re-
sistant to fırst line therapies.
#1588 Effects of the selective CYP17-lyase and androgen receptor (AR)
inhibitor, seviteronel, and the cyclin-dependent kinase (CDK) 4/6 inhibitor,
G1T38, on tumor growth in an AR-V7 castration-resistant prostate cancer
(CRPC) xenograft model. Suzanne E.Wardell,1 Alexander P. Yllanes,1 John D.
Norris,1 James P. Stice,1 Hannah White,2 Ronald A. Fleming,3 Jay C. Strum,2
William R. Moore,3 Donald P. McDonnell1. 1Duke University School of Medi-
cine, Durham, NC; 2G1 Therapeutics, Research Triangle Park, NC; 3Innocrin
Pharmaceuticals, Durham, NC.
Background: Castration-resistant prostate cancers that express the constitu-
tively active androgen receptor (AR) variant AR-V7 exhibit signifıcantly re-
duced progression-free and overall survival in response to the AR targeting
agents, enzalutamide (ENZ) and abiraterone. Inhibition of Phosphoinositide-3-
Kinase (PIK3CA) or CDK4/6 has been proposed as alternative therapies that
directly target the cell cycle pathway in these tumors. However, the combined
role of AR plus cell cycle inhibition in this treatment setting has not been estab-
lished. G1T38 is a potent, selective clinical stage CDK 4/6 inhibitor. Seviteronel
(SEVI) is a selective CYP17-lyase and AR inhibitor that blocks the growth of
CRPC tumors with clinically relevant ARmutations, including T878A and AR-
F876L. The activity of SEVI, ENZ and G1T38, alone or in combination, was
evaluated using the 22Rv1 (AR-V7) CRPC model in vitro and in vivo. Meth-
ods: Cellular proliferation (7 days) of 22Rv1 prostate cancer cells treated with
SEVI, ENZ, and G1T38 alone or in combination with SEVI or ENZA was as-
sessed by measuring DNA content. Orchiectomized male nu/nu mice bearing
22Rv1 were randomized to receive vehicle, SEVI (150mg/kg/day p.o.), ENZ (30
mg/kg/day p.o.), G1T38 (25-100 mg/kg/day p.o.), or SEVI or ENZ in combina-
tion with G1T38. A docetaxel (20 mg/kg weekly i.p.) group was included as a
standard of care comparison. Time to progression (X-fold increase in tumor
volume) and tumor volume changes were assessed over a 3-7-week dosing pe-
riod. Blood and tissues were collected for analysis of exposure and pharmaco-
dynamics markers of response. Results: SEVI and G1T38 alone or in combina-
tion, signifıcantly reduced the proliferation of 22Rv1 cells in vitro (p0.05).
Compared to vehicle, SEVI and G1T38 monotherapy signifıcantly inhibited
tumor growth and time to progression by 1.5 and 2.5 fold, respectively (p0.05);
the combination of SEVI and G1T38 further decreased tumor growth and re-
sulted in a 4-fold delay in progression (p0.001). In contrast, ENZ alone was
without effect on tumor growth and did not increase response to G1T38 as
compared to G1T38 alone. Conclusions: SEVI and G1T38 mono- or combina-
tion therapy signifıcantly decreased the growth of the AR-V7 22Rv1 CPRC
model in vitro and in vivo, an activity that distinguishes SEVI fromENZ. There-
fore, combining SEVI with a CDK4/6 inhibitor such as G1T38 may be an effec-
tive therapy for the treatment of CRPC that is resistant to current standards of
care.
#1589 Zinc inhibits androgen receptor expression to inhibit prostate can-
cer cell growth. Phuong Kim To, Young-Suk Cho, Se-Young Kwon, TaekWon
Kang, KyungKeunKim, Chaeyong Jung.ChonnamNational Univ.Med. School,
Hwasun-gun, Republic of Korea.
Background: Prostate gland contains high level of intracellular zinc which is
dramatically diminished during cancer development. Due to the obscure role of
zinc in this process, therapeutic application using zinc and its supplement is very
limited. This study aims to clarify the role(s) of zinc and its intervening mecha-
nism. Material and methods: Treated by zinc chloride (15-150 M), several
prostate cancer cell lines were applied to confocal microscopy for intracellular
traffıcking of exogenous zinc, in vitro proliferation assays for their growth, pros-
tate specifıc antigen (PSA)-based reporter-mediated transactivation, andWest-
ern blot for detection of androgen receptor (AR), PSA and ubiquitination. Fur-
ther in vivo studies were performed to demonstrate the effect of zinc (10-20
mg/kg) on xenograft cancer growth using syngeneic animals followed by tumor
analyses. Results: Zinc chloride suppressed androgen-dependent proliferation
of human prostate cancer cells and accordingly zinc chloride dramatically in-
hibited androgen-mediated transactivation and several androgen target protein
expressions, including PSA and p21. Further investigation showed that addition
of zinc chloride strikingly downregulatedARprotein levels after 4 hours up to 24
hours in both human LNCaP andmurine TRAMPC2 prostate cancer cell lines.
AR downregulation resulted from facilitated protein degradation instead of
transcriptional control. Further in vivo study was carried out using syngeneic
mice bearing C2 subcutaneous tumors. Peritoneal injection of zinc chloride
signifıcantly reduced tumor size. Analysis of these tumors revealed that there
were reduced expression of AR and increased cell death. Conclusions: Zinc has
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been shown to inhibit incumbent oncogenic NF-B pathway. These results also
suggest that intracellular zinc inhibits cell growth via downregulation of AR to
inhibit growth of prostate cancer. Considering that AR functions as a major
effector in prostate cancer development and progression into castration resis-
tant prostate cancer, loss of zincmay be a critical step for this devastating disease
and further studies can be performed to develop zinc-based cancer therapeutics.
#1590 High intranuclear mobility of AR-v7 reveals distinct mode of tran-
scriptional activity in prostate cancer with important therapeutic implica-
tions. Seaho Kim, Mohd Azrin Jamalruddin, Paraskevi Giannakakou. Weill
Cornell Medicine, New York, NY.
It is well established that androgen receptor (AR) signaling, is a key driver of
prostate cancer (PC) growth and metastatic progression. Therefore, androgen
deprivation therapy (ADT) is the fırst line of treatment for PC. However, most
patients develop castration resistant prostate cancer (CRPC). Interestingly, AR
signaling remains active in CRPC, due to the expression of transcriptionally
active AR splice variants (AR-Vs), which lack the ligand binding domain (LBD)
and constitutively translocate to the nucleus even in castrate conditions. AR-v7
is the most prevalent AR-V expressed in about 60% of CRPC tumors. AR-v7
expression was clinically correlated with poor prognosis of CRPC patients and
with resistance to next-generation AR signaling inhibitors, which are part of
standard clinical care. Therefore, inhibition of AR-v7 function is urgently
needed for the treatment of CRPC. Currently, there is no therapeutic modality
that can inhibit AR-v7 expression or activity. Mechanistically, AR-v7 transcrip-
tional targets largely overlap with those of AR-fl, with the exception of a few
AR-v7 unique targets. However, the exact mechanism by which transcription is
activated by AR-v7 is not known. In this study we sought to investigate the
mechanisms underlying the transcriptional activity of the ligand-independent
AR-v7 in comparison to liganded AR-fl. We used live cell imaging to monitor
the dynamics and intranuclear mobility of fluorescently-tagged AR-v7 or AR-fl.
Fluorescent recovery after photobleaching (FRAP) revealed that AR-v7 intranu-
clear mobility was signifıcantly faster than that of liganded AR-fl, with t1/2 3s
versus several minutes, respectively. To precisely map the spatial distribution
and chromatin-binding kinetics of AR-fl and AR-v7, we generated expression
plasmids with AR tagged with green-to-red mEos4 photo-convertible proteins.
Photoconversion of a discrete, subnuclear pool of AR-fl in the presence of its
ligand (R1881) followed by 1 hr of time-lapse imaging in 5 min intervals, re-
vealed absence of mobility indicating tight chromatin binding and active tran-
scription. In contrast, similar photoconversion experiment for AR-v7, revealed
immediate redistribution throughout the nucleus in less than 9 s, suggesting a
“hit-and-run” mode of interaction with DNA with uncertain transcriptional
output. QRT-PCR of endogenous target genes and ARE-mcherry reporter as-
says showed similar transcriptional activity of the two proteins.We are currently
investigating the relationship between rates of intranuclear mobility and tran-
scriptional activity and the mechanisms underlying the distinct mobility pat-
terns. These data suggest that AR-v7 has a distinct mode of interaction with
DNA and gene promoters, which may identify novel targetable pathways for its
inhibition in CRPC.
#1591 Inhibition of prostate tumor growth by an extract from themusca-
dine grape. Patricia E. Gallagher, E. Ann Tallant. Wake Forest School of Medi-
cine, Winston-Salem, NC.
Despite decades of advancements, cancer remains the second leading cause of
mortality in the United States with an estimated 1.7 million new cases and over
600,000 deaths predicted for 2016, indicating a clear need for more effective
chemotherapeutic and chemopreventive agents.While natural products derived
from plants have served as an abundant source of anticancer agents, it is pre-
dicted that less than 2 percent of the plant specieswithmedicinal value have been
investigated. Muscadine grape (Vitis rotundifolia) skin and/or seed extracts are
a popular nutraceutical supplement due to the high anti-oxidant, anti-inflam-
matory, and anti-proliferative effects of a distinct phytochemical composition of
polyphenols and proanthocyanidins. The current study examines the effects of a
proprietary muscadine grape extract formulation (MGE; Piedmont Research &
Development Corp.) on the proliferation of prostate cancer cells and tumors.
MGE inhibited the growth of humanLnCaPprostate cancer cells, in both a time-
and dose-dependent manner, as quantifıed using an IncuCyte Zoom Imaging
system. Cell growth was reduced by 36.8% after a 5-day treatment with 20
g/mL MGE compared to untreated cells (n  6, p  0.001). Athymic mice
(male, 15-20 g, 5-6weeks of age)were injected subcutaneously on the lower flank
with 1.6 x 106 LNCaP cells, to assess the effect of the MGE in vivo. When the
tumors reached 100mm3, themicewere randomized andMGEwas added to the
drinking water at a concentration of 0.2 g phenolics/mL (1.0 mg phenolics/
mouse/day for a 25 gmouse); controlmice drank untreatedwater. After 5weeks,
the mice were sacrifıced and the tumors were weighed. The volume of prostate
tumors growing in the flank of nude mice drinking water with MGE was mark-
edly reduced compared to the size of the tumors from control mice [252.6 	
61.73 mm3 (MGE) versus 765.2 	 101.8 mm3 (control); n6, p0.001). Fur-
ther, the weight of prostate tumors from mice drinking MGE was also signifı-
cantly decreased [0.96	 0.14 g (control) as compared to 0.41	 0.11 g (MGE)],
a reduction of 57% (p 0.05). Fivemicrons tumor sections were incubated with
an antibody to CD34 and tumor vessels were identifıed by positive immunore-
activity and morphology. MGE reduced the number of blood vessels/fıeld from
10.25	 0.9 to 7.10	 0.6 (p 0.05), suggesting that the extract inhibits angio-
genesis. Vascular endothelial growth factor (VEGF) and placental growth factor
(PLGF) were measured by qPCR, to determine the effect of the extract on an-
giogenic factors. MGE reduced VEGF mRNA from 1.02	 0.06 to 0.72	 0.07
relative units (p  0.05) and PLGF mRNA from 1.03 	 0.11 to 0.63 	 0.07
relative units (p  0.05), providing additional evidence of an anti-angiogenic
effect of the extract. Collectively, these results are the fırst to demonstrate that a
novel MGE formulation reduces prostate tumor growth in a mouse model, by
inhibiting angiogenesis, suggesting that MGEmay be an effective treatment for
prostate cancer.
#1592 Anti-cancer evaluation of various solvent extracts of blue honey-
suckle berry (Lonicera caerulea L.) against prostate cancer cells. SyedM. Ali,1
Alex Ourth,2 Chun-Tao Che,2 Mian-YingWang,1 Gnanasekar Munirathinam1.
1University of Illinois College of Medicine, Rockford, IL; 2University of Illinois at
Chicago, Chicago, IL.
Prostate cancer (PCa) is the second most common cancer among men in the
United Sates. It is estimated 1 in 6 men will be diagnosed with PCa and approx-
imately 180,890 new cases are predicted in 2016 alone. Standard treatments for
PCa include surgery, radiation, chemotherapy and hormonal therapy or a com-
bination of these treatments. However, factors like patient health, drug resis-
tance, specifıcity, and toxicity can result in poor disease prognosis. In order to
overcome these limitations and improve patient prognosis, there is an urgent
need to identify new anti-cancer agents withminimal side effects. Current stud-
ies are being focused on natural products and their components for alternative
therapeutics. Blue Honeysuckle (Lonicera caerule L.) a berry native to northeast
Asia, is known to be rich in Vitamin C and polyphenols such as anthocyanins,
flavonoids, and phenolic acids. Polyphenols are found to have several therapeu-
tic effects such as anti-inflammatory, antioxidant and antimicrobial properties.
Our present study used sequential solvent extracts of Blue Honeysuckle (BHS)
berry using Hexane, Ethyl Acetate, Methanol, and Water respectively. These
fractions were used to assess various therapeutic effects of BHS on DU 145,
PC-3, C4-2 and LNCaP PCa cell lines. The goal was to identify the most potent
BHS fraction that is effective against PCa using pre-clinical studies. MTT assays
were used to identify the anti-proliferative effects of various BHS fractions. The
above indicated PCa cells were treated with different doses (10-150 g/mL) of
BHS factions over various time periods (24, 48, 72 hr). Our data revealed that
Hexane extract (HE) exhibited the highest inhibition of cell viability in a time
and dose-dependentmanner.HE fraction showed to have an IC50 of 89.6g/mL
forDU145, 117.4g/mL for PC-3, 163.3g/mL for C4-2 and 140.84 for LNCaP
cells. Moreover, BHS HE fraction showed a decrease in migration capacity and
colony formation ability of PCa cells in vitro. Cellular senescence assay was
performed to assess -Galactosidase activity in PCa cells treated with BHS HE
extract. All the PCa cell lines treated with 100 g/mL of BHS HE showed in-
creased senescence. Western blotting was performed to identify the potential
anti-cancer mechanism of BHS against PCa using DU 145 and PC-3 cell lines.
Results from this study indicated that DU 145 and PC-3 cell lines after 24 hr
treatment with 100 g/mL of various BHS fractions especially BHS HE showed
an increase in apoptosis (Caspase 3,8,9 and PARP-1) and autophagy (LC3 A/B)
markers. Furthermore, cell cycle analysis of DU 145 and PC-3 cells treated with
BHS HE extract showed increased apoptotic cells. Further analysis of apoptotic
and autophagy pathwaysmodulated by BHS treatments are required to illustrate
its potential underlying anti-cancer mechanisms in PCa. In conclusion, results
from our study warrant further evaluation of BHS berry for potential PCa man-
agement.
IMMUNOLOGY: Cytokines: The First Modern Immunotherapies
#1593 Neutralization of IL-10 enhances antitumor effıcacy of dendritic
cell-targeting MIP-3-gp100 vaccine by way of type-I interferons in B16F10
mouse melanoma model. James Gordy, Kun Luo, Richard Markham. Johns
Hopkins School of Public Health, Baltimore, MD.
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The chemokine MIP-3 (CCL20) binds to CCR6 found on immature den-
dritic cells. Vaccines fusingMIP-3 to gp100 have been shown to be effective in
therapeutically alleviating melanoma in mouse models. Other studies have pro-
vided evidence that IL-10 neutralizing antibodies enhance immunological mel-
anoma therapies by modulating the tolerogenic tumor microenvironment.
Here, we report that neutralizing IL-10 enhances the therapeutic anti-melanoma
effıcacy of aMIP-3-gp100DNAvaccine. The current studies utilize the B16F10
syngeneic mouse melanomamodel system. TheMIP-3-gp100 DNA vaccine is
administered intramuscularly (i.m.) into the tibialis muscle, followed immedi-
ately by i.m. electroporation. The standard therapeutic protocol was the follow-
ing: challenge with lethal dose of B16F10 cells (5x104) on day 0; vaccinate with
50g vaccine plasmid on days 3, 10, and 17; and administer 150g of IL10
antibody intra-tumorally beginning on day 5, once every three days for up to six
doses. Tumor sizes, growth, and survival were all assessed. Treatment responses
were characterized by flow cytometric analysis of tumor infıltrate. Vaccine-spe-
cifıc T-cells were delineated by gp10025-33 stimulation followed by intracellular
cytokine staining for IFN- and assessment by flow cytometry. The mechanism
of IL-10 effıcacy was explored by RT-PCR and confırmed with a knockout
mouse model. With this therapeutic protocol, we demonstrate for the fırst time
that a therapy neutralizing IL-10 additively enhances the anti-tumor effıcacy of
a MIP-3-gp100 vaccine, leading to signifıcantly smaller tumors, slower grow-
ing tumors, and overall increases in mouse survival. Surprisingly, the additive
effects ofIL-10were not shown to be directlymediated by anyT-cell parameter
tested, including vaccine-specifıc tumor infıltrating lymphocytes (TILs), total
TILs of either CD4 or CD8 subset, regulatory T-cells, granzyme positive
T-cells, and others. We discovered, however, that IFN-4 transcripts in the
tumor were signifıcantly upregulated in mice given vaccine and IL-10 com-
pared to vaccine alone. Furthermore, infıltration into the tumor of plasmacytoid
dendritic cells, known to be professional IFN-producing cells, were enhanced
with the combination therapy. Amouse model with IFNR1 knocked out elim-
inated the protection provided by IL-10, demonstrating that the additional
therapeutic value of IL-10 is primarily mediated by type-I interferons. In con-
clusion, effıcient targeting of antigen to immature dendritic cells with a chemo-
kine fusion vaccine offers a potential alternative approach to the ex vivo den-
dritic cell antigen loading protocols currently undergoing clinical investigation.
Combining this approach with an IL-10 neutralizing antibody therapy that
modulates the tolerogenic tumor microenvironment offers promise as a novel
melanoma therapy.
#1594 Enhancement of the anti-tumor activity of CEA TCB via combina-
tion with checkpoint blockade by PD-L1 and interleukin-2 variant immuno-
cytokine. Marina Bacac, Sara Colombetti, Linda Fahrni, Tanja Fauti, Valeria
Nicolini, Johannes Sam, Petros Papastogiannidis,Marine LeClech, XavierMiot,
Inja Waldhauer, Karolin Rommel, Christian Gerdes, Christian Klein, Pablo
Umaña. Roche Innovation Center Zurich, Schlieren, Switzerland.
Cancer immunotherapy represents a promising therapeutic approach to ex-
tend the overall survival of cancer patients.However, severalmechanismswithin
the tumor microenvironment orchestrate the suppression of host immune re-
sponse requiring combination strategies to prolong the durability of effect.
Among suppressive pathways, up-regulation of PD-1 ligand (PD-L1) and its
interaction with PD-1 receptor plays a key role in suppression of T-cell activity,
a mechanism also called adaptive immune resistance. Therefore, approaches
able to inhibit the tumor immune suppressive mechanisms along with those
expanding the frequency of intra-tumor T-cells and enhancing/prolonging their
functionality are required. CEA TCB (RG7802, RO6958688) is a novel T cell
bispecifıc antibody targeting carcinoembryonic antigen (CEA) on tumor cells
and CD3 on T cells, currently being investigated as single agent and in combi-
nationwith atezolizumab in Phase 1/1b studies in patientswith advanced and/or
metastatic CEA-expressing tumors (NCT02324257; NCT02650713). CEA TCB
treatment leads to increased intra-tumoral T cell infıltration and T-cell activa-
tion along with up-regulation of PD-1/PD-L1 suppressive pathway. Here we
show that combination of CEA TCB with PD-L1 blocking antibody in vitro
enhances T cell activation as detected by increased CD3 signaling and secretion
of pro-inflammatory cytokines. Combination in vivo performed in both stem
cell humanized NOGmice (HSCmice engrafted withMKN45) and fully immu-
nocompetent human CEA transgenic C56BL/6 mice (hCEA Tg mice engrafted
with MC38-hCEA) demonstrated signifıcantly improved anti-tumor activity of
combination as compared to activity of single agents, yielding to increased num-
ber of tumor-free animals. Randomization of animals that progressed to CEA
TCBmonotherapy revealed that combination of CEATCBwith PD-L1 blocking
antibody is required to control tumor outgrowth, as tumors treated with corre-
spondingmonotherapy arms progressed to treatment. Effıcacy of CEATCBwas
also potentiated when administered in combination with a half-life-extended
IL-2 variant (untargeted (IgG-IL2v) or fıbroblast-activating protein-targeted
IL-2 variant (FAP-IL2v)), resulting in stronger tumor growth inhibition in
MKN45-bearing HSC mice or prolonged survival in PanCO2-hCEA-bearing
hCEA Tg C56BL/6 mice. Synergy likely reflects ability of IL2v to enhance anti-
tumor effıcacy by increasing number of effector T cells in tumors. In conclusion,
CEA TCB treatment leads to intra-tumoral T cell infıltration and T-cell activa-
tion. This is accompanied by up-regulation of PD-1/PD-L1 suppressive path-
way, which can be overcome by combination therapy with a PD-L1 inhibitor. In
vivo effıcacy of CEA TCB is further potentiated when administered in combi-
nationwith immunotherapies that increase the pool of available tumor-infıltrat-
ing effector cells.
#1595 IL15/IL15R heterodimeric Fc-fusions with extended half-lives.
Matthew J. Bernett, Christine Bonzon, Rumana Rashid, Rajat Varma, KendraN.
Avery, Irene W. Leung, Seung Y. Chu, Umesh S. Muchhal, Gregory L. Moore,
John R. Desjarlais. Xencor, Inc., Monrovia, CA.
IL15 and IL2 are similar cytokines that stimulate the proliferation and differ-
entiation of B cells, T cells, andNK cells. Both cytokines exert their cell signaling
function through binding to a trimeric complex consisting of two shared recep-
tors, the common gamma chain and IL2R, as well as an alpha chain receptor
unique to each cytokine: IL2R or IL15R. IL2R is highly expressed on Tregs,
and the therapeutic benefıt of IL2 for cancer treatment has been limited for this
reason. IL15 is produced by monocytes and dendritic cells and functions as a
stabilized heterodimeric complex with membrane-bound IL15R present on
the same cells. This IL15/IL15R complex is presented in trans to NK cells and
CD8 T cells expressing IL2R and the common gamma chain. It has been
shown that recombinant IL15/IL15R heterodimer is highly active. Currently
there are no approved versions of recombinant IL15 although several clinical
trials are ongoing. As potential drugs, cytokines suffer from a very fast clearance
that hinders favorable dosing. Consequently, a more druggable version of IL15
would consist of the IL15/IL15R complex coupled with slower clearance. We
created various IL15/IL15R heterodimeric Fc-fusions in an effort to facilitate
production, promote FcRn-mediated recycling of the complex, and thus pro-
long half-life. We engineered IL15/IL15R heterodimeric Fc-fusions by either
fusing IL15 to one side of a heterodimeric Fc-region, and the sushi domain of
IL15R to the other side, or by creating a single-chain IL15/IL15R that was
attached to one side of a heterodimeric Fc-region. These Fc-fusions were tuned
for optimal activity by engineering the linker regions between IL15/IL15R and
the Fc and/or by engineering substitutions on IL15 at the IL15/IL2R or IL15/
gamma chain interface. In vitro proliferation of T and NK cells in healthy
PBMCs was monitored by counting Ki67 cells after incubation with Fc-fu-
sions for 4 days. In vivo activity was evaluated using a mouse model in which
human PBMCs are engrafted into NSG mice (huPBMC-NSG) and measur-
ing the extent of T cell engraftment by flow cytometry as well as IFN. PKwas
evaluated in C57BL/6J mice. IL15/IL15R heterodimeric Fc-fusions were
successfully produced with favorable yields. The Fc-fusions enhanced pro-
liferation of T and NK cells in vitro. Treatment of huPBMC-NSG mice with
weekly doses of IL15/IL15R heterodimeric Fc-fusions promoted enhanced
T cell engraftment and elevated levels of IFN in a dose dependent manner.
Severe graft versus host disease was observed in treated mice. Little activity
was seen with a comparable weekly dose of recombinant IL15. PK in
C57BL/6J mice indicated half-lives of several days for the IL15/IL15R het-
erodimeric Fc-fusions, which are signifıcantly longer than the1 hr half-life
reported for IL15. Together, these data indicate that IL15/IL15R heterodi-
meric Fc-fusions demonstrate the high activity of IL15 with a more favorable
PK profıle.
#1596 Phase I trial of recombinant human Interleukin 15 (rhIL-15) ad-
ministered as continuous intravenous infusion (CIV) for 10 days (240 hours)
inpatientswith refractorymetastatic cancers.KevinC.Conlon, SigridDubois,
Chyi-chia Richard Lee, Thomas Fleisher, Jennifer I. Hsu, Thomas A. Wald-
mann. National Cancer Inst., Bethesda, MD.
Twenty-seven refractory metastatic cancer patients received continuous in-
travenous recombinant human Interleukin 15 (CIV rhIL-15) for 10 days (240
hours) in a phase 1 dose escalation trial. Six dose levels (0.125, 0.25, 0.5, 1, 2 and
4micrograms/kilogram/day [mcg/kg/day]) were assessed and 2mcg/kg was the
maximum tolerated dose Common adverse events included fevers, myalgias,
decreased albumin, anemia, decreased leukocytes, lymphocytes and platelets
and elevations of ALT, AST and bilirubin most often grade 1 or 2 in severity.
Serious adverse events were grade 5 (gr5) visceral ischemia, lymphocytic gastri-
tis (gr2), hospitalization for abdominal pain (gr2), papilledema (gr3), duodenal
hemorrhage (gr3), bronchial hemorrhage (gr3) and unexplained sudden death
(gr5) at home post-treatment in a patient who stopped treatment early for tox-
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icity and symptomatic disease progression. Patients treated at the higher doses
developed a striking end of treatment peripheral blood lymphocytosis showing
a 24X increase in absolute lymphocyte count, 10X increase in CD8 cells and 75X
increase in NK cell numbers. No patients developed anti-IL-15 antibodies.
Steady state serum IL-15 level was seen within the fırst 12 to 24 hours of therapy
and was maintained for several days. Dramatically lower IL-15 levels ( 8% of
earlyCmax)weremeasured during the last 2 days of treatment suggesting a large
reservoir of non-circulating IL-15 receptor positive cells. None of the patients
achieved a partial response, but 2 patients met the criteria for treatment beyond
cycle 2 (
 15% decrease in measurable disease). Evidence for tumor directed
immune effects included several patients who developed unilateral pleural effu-
sions in their disease involved hemithorax, complete regression of a cutaneous
chondrosarcoma metastasis and decreased CA19-9 (125.7 ¡ 47.3 U/mL) in a
patient with pancreatic cancer. Histologic analysis of pleural fluid from these
patients showed largely lymphocytes and other cells that were consistent with
the patients known cancers. Lymphocytic infıltration of the regressing cutane-
ous sarcoma metastasis was predominantly CD4 cells, with some CD8 cells and
a few NK cells. Immunohistochemical analyses of pre and on treatment tumor
biopsies obtained from several other patients are currently being performed to
better characterize the immunologic effects of this regimen. The results of this
trial indicate CIVrhIL-15 treatment generates considerable in vivo immune ac-
tivation and has important synergistic potential for combination therapy with
other Immunotherapeutics.
#1597 Inhibition of the novel therapeutic target pregnancy associated
plasma protein A (PAPP-A) in Ewing sarcoma enhances effıcacy of IGF1R
targeting in vivo. Sabine Heitzeneder,1 John F. Shern,2 Lee J. Helman,2 Javed
Khan,2 Crystal L. Mackall1. 1Stanford University, Palo Alto, CA; 2National Can-
cer Institute, Bethesda, MD.
Background: Despite intensive treatment regimens, Ewing sarcoma (EWS)
patients with metastatic or relapsed disease still face a 5-year overall survival of
less than 20%, indicating a clear need for novel targeted therapies. Utilizing
ribosomal depleted RNA sequencing of 122 EWS samples (49 cell lines and 73
tumor samples) and 96 normal samples of variable tissues, we previously re-
ported PAPP-A as one of the top 5 genes overexpressed in EWS ( than 4-fold)
compared to normal tissue. Notably, PAPP-A showed substantial expression in
tumors (median log2FPKM 3.933, n122) andminimal expression in normal
tissue (median log2FPKM -1.564, n96). Pregnancy Associated Plasma Pro-
teinA (PAPP-A) is a secreted zincmetalloproteinase, that anchors to cell surface
of heparan sulfate proteoglycans and enhances local IGF signaling. Through the
release of IGFs from IGFBP-4, IGFBP-2 and IGFBP-5, free, bioactive IGF is
being increased in close proximity to its receptors. In pregnancy PAPP-A is
highly expressed by placental trophoblasts and represents a key regulator of fetal
growth. The impact of IGF signaling in EWS is illustrated by themodest activity
of IGF-1R inhibition as a single agent treatment in clinical trials, an approach
that is limited by the rapid development of resistance.Methods: In an attempt to
investigate the role of PAPP-A in Ewing sarcoma, we used CRISPR/Cas9 tech-
nology to target the PAPP-A locus in EWS cell lines and generated PAPP-A
knockout clones (EW8, TC32) for further investigation in vitro and in vivo.
Additionally, we tested inhibition of PAPP-Aproteolytic function in a xenograft
NSG mouse model, as a single agent treatment as well as in conjunction with
IGF1R inhibition. Results: Knockout of PAPP-A in EWS cell lines utilizing
CRISPR/Cas9 technology completely abrogated PAPP-A secretion and metal-
loproteinase activity in single cell clones, resulting in signifıcantly increased
complexed IGFBP-4 and diminished bioactive IGF-1, together with decreased
cell growth in vitro. This phenotype could be rescued by recombinant, soluble
PAPP-A. In vivo experiments showed that treatment with a monoclonal
PAPP-A neutralizing antibody that inhibits the IGFBP-4 proteolytic activity of
PAPP-A delays tumor growth of xenografted EWS tumor cells (EW8) in NSG
mice. Furthermore, in conjunction with IGF1R inhibition (mAB h7C10),
PAPP-A neutralization signifıcantly decreased tumor growth and resulted in
prolonged survival of mice (p0.021). Conclusions: PAPP-A is a novel biolog-
ically relevant and highly tumor specifıc cell surface target in Ewing sarcoma.
Our data suggest that neutralization of PAPP-A is a new therapeutic option that
merits further evaluation for the treatment of Ewing’s Sarcoma.
#1598 Single agent NKTR-214, a biased IL2 pathway agonist, increases
immune cell infıltrates in brain tumors and prolongs survival in rodent (rat-
tus) glioblastoma (GBM). Lawrence Recht,1 Seema Nagpal,1 Taichang Jang,1
Milton Merchant,1 Irene Choi,2 Ute Hoch,2 Deborah Charych2. 1Stanford U
School of Medicine, Stanford, CA; 2Nektar Therapeutics, San Francisco, CA.
Background: Immunotherapy is an attractive option for brain tumor therapy
if a robust infıltrative T cell response can be elicited in the tumor. NKTR-214 is
a CD122-biased cytokine agonist conjugated with multiple releasable chains of
polyethylene glycol and designed to provide sustained signaling through the
heterodimeric IL-2 receptor pathway (IL-2R) to preferentially activate and
expand effectorCD8T andNKcells over Tregs. To assess the potential activity
of single agent NKTR-214 in GBM, we used an orthotopic rat glioblastoma
survival model. Methods:NKTR-214 was administered at 0.1 or 0.3 mg/kg q2w
iv to Sprague-Dawley rats starting 2 or 7 days (D2, D7) post (p)-implantation of
106 C6 glioma cells into the right striatum. The model requires euthanasia by
D14 due to tumor burden. Brain tumors were characterized by magnetic res-
onance (MR) and immunohistochemistry (IHC) for infıltration of CD4 and
CD8 T cells and for retention of PEG polymer in brain tumor. Results: Com-
pared to rats receiving vehicle (n  15), survival was signifıcantly prolonged
after NKTR-214 treatment (n  43, mean 17.2 vs. 10.0 days (P  0.001) with
15% of rats across all groups alive and tumor-free at Day 50 when the study was
terminated. Both doses were equally effective and well tolerated. Surprisingly,
treated rats bearing largeMR-detectableD7 tumors survived signifıcantly longer
compared to rats bearing microscopic D2 tumors (6/21 or30% versus 0/21 or
0% respectively at D50, mean 23.1 vs. 12 days, P 0.004). Concordantly, CD8
T cells in D7 tumors were signifıcantly increased after NKTR-214 therapy com-
pared to vehicle and D2 tumors, while CD4 remained low with no signifıcant
difference between groups. PEG polymer was detected in the tumor at least 72
hours p-injection. Conclusions: NKTR-214 is well tolerated, prolongs survival
and induces immunological activity in the brain when administered to rats har-
boring orthotopic GBM. While there was no signifıcant dose dependence, a
marked increase in survival was observed when larger D7 tumors were treated
withNKTR-214 compared tomicroscopicD2 tumors, associatedwith increased
intratumoral CD8T cells. Levels of CD4were unchanged, consistent with the
mechanism of CD-122 biased activation of the IL2 pathway. While requiring
further study, it is intriguing that the increased sensitivity of larger tumors also
corresponds to onset of angiogenesis and rapid tumor growth in this model.
NKTR-214 is currently being evaluated in an outpatient Phase 1 / 2 clinical trial
for the treatment of solid tumors. The results presented suggest a potential role
for NKTR-214 in the treatment of patients afflicted with GBM.
#1599 Antibody-based inhibition of CSF-1R as a component of combina-
tion immunotherapy in preclinicalmodels.David I. Bellovin, NebiyuWondy-
fraw, Barbara Sennino,QuinnWalker, Susan Johnson, Anita Levin, EmmaMas-
teller, Susannah D. Barbee, Robert Sikorski, Tom Brennan. Five Prime
Therapeutics, Inc., South San Francisco, CA.
The colony stimulating factor 1 receptor (CSF-1R) signaling pathway pro-
motes tumor progression via the recruitment, differentiation, and survival of
immuno-suppressive tumor-associated macrophages (TAMs). FivePrime has
developed cabiralizumab (FPA008), an IgG4 antibody against CSF-1R that
blocks the ability of both CSF-1 and IL-34 to bind and activate this receptor,
thereby modulating the immune response to tumorigenesis. In order to inves-
tigate the impact of CSF-1R signaling inhibition in preclinical models, we gen-
erated a surrogate antibody, cmFPA008, which targetsmouse CSF-1R and dem-
onstrates equivalent affınity and ligand-blocking ability as FPA008. Utilizing a
combination of flow cytometry and immunofluorescence analyses, we have
identifıed alterations in the tumor microenvironment that occur upon CSF-1R
inhibition, including signifıcant reduction of immunosuppressive TAMs and an
increase in tumor PD-L1 expression. Interestingly, we observe a transient in-
crease in CD8T cell number and activation upon TAMdepletion, followed by
a subsequent increase inMDSC populations that corresponds with reduction of
the CD8 T cell numbers. Moreover, we have used murine syngeneic tumor
models to examine the anti-tumor impact of CSF-1R inhibition in combination
with other immuno-oncology agents. Our results show that, when added to
PD-1/PD-L1 blockade, cmFPA008 can signifıcantly enhance anti-tumor effı-
cacy. We are currently exploring the effects of combining cmFPA008-induced
TAM depletion with additional immuno-oncology agents, including T cell ago-
nists. Our preclinical results demonstrate that inhibition of the CSF-1R pathway
can combine with various immuno-oncology agents with distinct mechanisms
of action. FivePrime has initiated a clinical trial in collaboration with Bristol-
Myers Squibb (BMS) to investigate the use of cabiralizumab in combination
with nivolumab (anti-PD-1, OPDIVO®) in six different tumor types.
#1600 Interleukin-8 (IL-8) in TGF- immunotherapy and chemothera-
pies. Larn Hwang,1 Kevin Ng,2 Osmond D’Cruz,2 Sanjive Qazi,2 Andrew
Schmidt,2 Vuong Trieu1. 1Oncotelic Inc, Agoura Hills, CA; 2Autotelic Inc, Costa
Mesa, CA.
Background: Increased expression of IL-8 and/or its receptors has been
characterized in cancer cells, endothelial cells, infıltrating neutrophils, and
tumor-associated macrophages, suggesting that IL-8 may function as a sig-
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nifıcant regulatory factor within the tumor microenvironment. OT-101 is a
phosphorothioate antisense oligodeoxynucleotide targeting transforming
growth factor-beta 2 (TGF-2). Herein, we examined the role of IL-8 in OT-101
treatment followed with chemotherapies during our Phase II trial in patients
with advanced pancreatic cancer (PAC). Methods: Time evolution of a panel of
31 cyto-/chemokine levels in plasma were tracked over 3 cycles of OT-101 ad-
ministration (140 mg/m2/day) for 12 PAC patients. Samples were acquired be-
fore onset ofOT-101 therapy and at 8 selected timepoints (Cycle 1 [Day 2 and 5],
Cycle 2 [Days 1, 2, and 5], Final Visit, Cycle 3 [Day 5]) during the therapy.
Samples were measured in duplicate and concentrations were expressed in pg/
mL. Standardized log10 transformed values calculated from the mean and stan-
dard deviation of each cyto-/chemokine in each patient was utilized in an AN-
COVAmodel to investigate the correlation with Overall Survival (OS). Results:
Clustering of correlation coeffıcients resulted in the identifıcation of three highly
correlated subsets of cyto-/chemokines (Cluster 1: EGF,MIP-1,MIP-1; Clus-
ter 2: FGF-2, IL-1RA, MIG, IP-10, IL-15, IFN-, IL-12A/IL-12; Cluster 3: HGF,
IL-2R, IL-6, IL-8). Protein-Protein Interaction networks constructed using
STRING10 algorithm identifıed a relationship between IL-8 and TGFR2 inhi-
bition. The ANCOVAmodel explained a signifıcant proportion of the observed
data for Cycle 1[Day 2] measurements of cyto-/chemokines (R2 0.3, F59,217
1.575, P 0.0103). Other time points did not exhibit a signifıcant model fıt or
signifıcant relationships in the interaction term. IL-8 expression showed signif-
icant association with OS (positive association, N12, T-value  2.92, P 
0.0039) at Cycle 1[Day 2] measurements (7% False Discovery Rate). Linear re-
gression of the increase in IL-8 levels during Cycle 1[Day 2] treatment with
OT-101 was related to an increase in OS outcome (R2 0.54). To further defıne
the appropriate chemoagent to combine with OT-101, we evaluated paclitaxel
(PTX), gemcitabine (GEM), and dacarbazine (DTIC) in animal model. Synergy
was observed with PTX and DTIC, but not with GEM. Both PTX and DTIC
induced IL-8 expression whereas, surprisingly, GEM reduced IL-8 expression.
Conclusion: IL-8 expression during early phase of OT-101 treatment cycle was
positively associated withOS across 12 patients. IL-8 is also induced by PTX and
DTICwhich synergizedwithOT-101. The data suggests that PAC andDTIC are
acting on the same target as our TGF-2 inhibitor; and potentially, the benefıcial
effect of these chemoagents is a result of chemoagent-induced immune/IL-8
response.
#1601 Anti-tumor effect of GAGomer-mediated intra-tumoral IL-2 ex-
pression following systemic administration. Genia Alpert,1 David Altreuter,2
Sunil Anamandla,2 Arlyssa Birt,2 Guy Cinamon,1 Keren Cohen Merimi,1 Orli
Even Or,1 Nir Gefen,1 Nadia Gurvich,2 Jeno Gyuris,2 Lorena Lerner,2 Adi
Mondshine,1 HongWang2. 1Quiet Therapeutics, Ness Ziona, Israel; 2Quiet Ther-
apeutics, Lexington, MA.
Cancer immunotherapies are revolutionizing cancer treatment. Unfortu-
nately, a large proportion of patients with solid tumors do not respond to
currently available immune-therapeutics. The lack of response is due to a
variety of mechanisms tumors adopt to avoid immune mediated clearance.
The multiplicity of immunosuppressive mechanisms operational in the tu-
mor microenvironment may not be overcome by single agents and require
interventions at multiple control points. However, systemic exposure to
combinations of immunoregulators may result in severe, dose limiting, acute
and chronic toxicities that might be prevented if the effect of these agents is
focused to the tumor microenvironment. We are engaged in the discovery of a
novel class of immuno-oncology drugs aimed at maximizing the effect of im-
munoregulatory molecules in the tumor microenvironment and minimizing
systemic adverse effects. These drugs incorporate plasmids, engineered to pro-
gram tumor cells to produce and secrete immune-regulatory proteins, within
hyaluronic acid (HA) coated lipid nanoparticles, called GAGomers, which spe-
cifıcally target tumor cells that overexpress activated HA receptors (GAG-
pDNA). GAG-pDNA based therapeutics promise highly potent but localized
activation of the immune system exclusively in the tumor microenvironment
following systemic administration, leading to the destruction of tumor cells by
activated immune cells without debilitating toxic side effects. To demonstrate
the feasibility of the GAG-pDNA approach we have incorporated a plasmid
directing the expression of murine IL-2 into GAGomers (GAG-pIL2) and as-
sessed the anti-tumor activity of the construct after systemic delivery into tumor
bearing mice. GAG-pIL2 administration resulted in statistically signifıcant in-
hibition of tumor growth,which correlatedwith elevated IL-2 levels in the tumor
and increased infıltration of T-cells into the tumor microenvironment. These
experiments demonstrate the feasibility of programming tumor cells using
GAG-pDNA to produce and secrete immunoregulatory molecules into the tu-
mor microenvironment and trigger robust anti-tumor immune responses.
#1602 Generation of anti-IL-17B antibodies neutralizing IL-17B-medi-
ated alterations of the immunemicroenvironment, promotion of tumor cell
initiating capacity and chemoresistance. Emilie Laprevotte,1 Aurélie Doc-
quier,1 Jeremy Bastid,1 Cécile Déjou,1 Marion Lapierre,1 Gilles Alberici,1 Ar-
mandBensussan,2 Jean-François Eliaou,3Nathalie Bonnefoy3. 1OREGABiotech,
Ecully, France; 2INSERM U976, PARIS, France; 3INSERM U1194, Montpellier,
France.
Interleukin 17B (IL-17B) is a pro-inflammatory cytokine that belongs to a
family encompassing 6 interleukins (IL-17A to F) and binds to the IL-17 recep-
tor B (IL-17RB). Recently, amplifıed IL-17B/IL-17RB signaling was found crit-
ical for breast and pancreatic tumorigenesis and elevated expression of IL-17RB
has been associated with the shortest survival rates in patients with breast or
pancreatic cancer. Using IL-17B knock-out (IL-17B KO) mice we demonstrate
here that melanoma, fıbrosarcoma and breast cancer cell tumorigenicity is
strongly impaired in immunocompetent IL-17B KO mice compared to WT
littermates, including a large number of tumor free mice. Reduced tumor inci-
dence in IL-17B KO mice is associated with alterations of the immune tumor
microenvironment especially within innate lymphocyte and myeloid sub-pop-
ulations. We further demonstrate that IL-17B is a key cytokine shaping the
tumor initiating cancer cell niche. Indeed, MDA-MB-468 human breast cancer
cells overexpressing IL-17B exhibit 10 times higher frequency of tumor initiat-
ing cells when xenografted at a serial limiting dilution in nude mice. Tumor
progression is, again, associated with alterations of NK cells within the tumor
microenvironment and with increased percentages of CD44hi/CD24lo tumor
cells, a phenotype associated with breast cancer stem cells (CSC). This is associ-
ated with resistance to conventional chemotherapeutic agents such as taxol, an
effect that is totally abrogated by disrupting IL-17B-IL-17RB signaling with a
neutralizing antibody. Altogether our results point out the key role of IL-17B in
regulating the immune microenvironment as well as cardinal features of CSC,
one of the alleged causes of resistance to therapy and tumor relapse. Thereby,
IL-17B and its receptor appear as potential therapeutic targets for cancer immu-
notherapy. Collectively, these data support the ongoing development of IL-17B
neutralizing antibodies.
#1603 NKTR-255 engages the IL-15 pathway driving CD8 T cell survival
andCD8memoryT cell proliferation.PeiwenKuo,MekhalaMaiti, PhiQuach,
Murali Addepalli, Arunasree Lanka, PoornachandraMathamsetti, Christie Fan-
ton, Ping Zhang, Peter Kirk, Takahiro Miyazaki, Jonathan Zalevsky. Nektar
Therapeutics, San Francisco, CA.
Background: IL-15, an immunostimulatory cytokine, plays an important role
in both the innate and adaptive immune system. Notably, this pleiotropic cyto-
kine is a key regulator of homeostasis and survival of CD8 and CD8 memory T
cells. Targeting the IL-15 pathway has therefore become a promising therapeutic
approach in oncology through the induction of long-term T cell activation and
durable memory responses. NKTR-255 is a polymer-engineered IL-15 that as a
single-agent reduces tumor burden in various tumormodels.Here, we show that
the anti-tumor effects of NKTR-255 can be attributed to its modulation of sur-
vival and proliferation of CD8 andmemoryCD8T cells.Methods: Immunophe-
notyping of CD8 T cell subpopulations was performed in naïve and tumor-
bearing Balb/c mice treated with NKTR-255. Cell surface staining of CD3, CD8,
CD44, CD62L and Sca-1 was conducted to identify effector (Tem), central
(Tcm) and stem (Tscm)memory T cells. Intracellular staining of Ki67 and Bcl-2
were also analyzed by flow cytometry. Human whole blood and PBMCs were
stimulated with IL-15 (0.0001-1000ng/ml) or NKTR-255 (0.001-10,000ng/ml).
At various time points pSTAT5 response in CD3, CD4, CD8 and NK (CD56
bright and dim) cells was monitored by flow cytometry. Results: In naive mice,
single dose NKTR-255 (dose range 0.06-1mg/kg) increased the proliferation of
Tem, Tcm and TscmCD8T cells in a dose-dependentmanner. Treatment at 0.3
and 1mg/kg dose levels increased proliferation at least 4 fold across the CD8
memory populations. The abundance of CD8 and CD8memory T cells was still
apparent 6 days post-treatment unlike single dose IL-15 which was ineffective.
In a CT-26 lung metastasis model, NKTR-255 reduced the number of lung
nodules in a dose-dependent manner. A 0.3mg/kg dose level increased Bcl-2
MFI 1.5 fold in CD8 T cells. Furthermore, administration of NKTR-255 at 0.3, 1
or 3mg/kg signifıcantly increased CD8 proliferation in a dose-dependent man-
ner in blood (1.7, 4.6 and 5.3 fold) and spleen (2.5, 5.7 and 6.9 fold) compared to
vehicle. The enhanced Bcl-2 expression and CD8 proliferation were accompa-
nied by elevated CD8 T cells in blood (1.5, 2.4, and 3.4 fold increase) and spleen
(1.3, 1.7 and 2.3 fold increase). Consistent with increased proliferation and in-
creased Bcl-2 levels observed in vivo, both IL-15 and NKTR-255 showed dose-
dependent induction of pSTAT5, a modulator of Bcl-2 expression, in CD4 and
CD8 T cells from human whole blood and PBMCs. Conclusions: NKTR-255
effectively engages the IL-15 pathway as evidenced by its strong induction of
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CD8 and memory CD8 T cell proliferation and promotion of survival. Com-
bined with sustained activity and potency in human blood and PBMCs, our
results support NKTR-255 as a novel tumor immunotherapeutic with great po-
tential.
#1604 NKTR-214 synergizes with radiotherapy to drive tumor regression.
Michael J. Mcnamara,1 Melissa Kasiewicz,1 Ian Hilgart-Martiszus,1 Ute Hoch,2
DeborahH.Charych,2WilliamL. Redmond1. 1Earle A. Chiles Research Institute,
Providence Portland Medical Ctr., Portland, OR; 2Nektar Therapeutics, San
Francisco, CA.
The purpose of this study was to investigate therapeutic and mechanistic
synergies between single-dose radiotherapy and systemic administration of
NKTR-214. NKTR-214 is a CD122-biased cytokine agonist conjugated with
multiple releasable chains of polyethylene glycol. NKTR-214 is designed to pro-
vide sustained signaling through the heterodimeric IL-2 receptor pathway (IL-
2R) to preferentially activate and expand effector CD8 T and NK cells over
Regulatory CD4 T cells. Preclinical models demonstrated NKTR-214 preferen-
tially expands effector CD8 T cells and NK cells within the tumor resulting in
marked tumor growth suppression as a single-agent and in combination with
checkpoint inhibitors. A phase I/II trial is in progress to evaluate NKTR-214
safety and effıcacy in an outpatient setting. Radiation therapy can induce anti-
gen-release and epitope spreading, while NKTR-214 can active and expand an-
tigen-specifıc effector populations. We hypothesized that the combination of
systemic NKTR-214 and local radiotherapy would generate better therapeutic
responses than either treatment alone. In this study, we evaluated the combina-
tion of systemic NKTR-214 treatment with single fraction high-dose radiother-
apy (20 Gy) inmultiple murinemodels.We used flow cytometry, multi-spectral
histology, and whole tumor mRNA profıling to investigate local, systemic and
potential abscopal immune responses. We used Nur77-GFP reporter mice to
enable detection of T cell receptor ligation in vivo and to evaluate the effects of
NKTR-214RT on tumor-reactive T cells. The results from these studies indi-
cate that the combination of NKTR-214 and radiotherapy is synergistic, provid-
ing signifıcantly better anti-tumor responses than either monotherapy. Consis-
tent with previous observations, NKTR-214 alone induces expression of a wide
range of activationmarkers expressed byCD4 andCD8T cells aswell asNK cells
in the blood, lymph nodes and tumor. The combination of radiotherapy and
NKTR-214 was found to have several unique effects including a signifıcant in-
crease (75%) in the absolute numbers of lymphocytes in the peripheral blood,
increased expression of activation markers (CD25, PD-1) by CD8 T cells in the
blood and tumor, and increased density of tumor-infıltrating NK cells. Evalua-
tion of tumor infıltrating lymphocytes (TIL) in Nur77-GFP reporter mice re-
vealed that the combination ofNKTR-214RT resulted in a higher frequency of
recently activated (Nur77-GFP) CD8 T cells in treated (irradiated) and absco-
pal (non-irradiated) tumors. Whole tumor mRNA profıling and multi-spectral
histology of these tumors is being assessed to identify key differences in the
tumor-microenvironment thatmay help to defıne the underlyingmechanism of
action. Taken together, these data provide evidence of synergy between localized
radiotherapy and systemic NKTR-214 treatment via an expansion of activated,
tumor-specifıc CD8 T cells.
#1605 Combined oral cytokine therapy effectively treats colon cancer in a
murine model. Neal Bhutiani, Qingsheng Li, Charles D. Anderson, Tao Gu,
Nejat K. Egilmez. University of Louisville, Louisville, KY.
Background: Regardless of its etiology, colorectal cancer development is inti-
mately associatedwith dysregulation of the intestinal immune system. Sustained
release, orally delivered IL-10 not only inhibits colon tumor growth but restores
T cell homeostasis both locoregionally and systemically. However, it does not
induce tumor regression. We aimed to combine orally delivered IL-12, a potent
immunostimulatory molecule with robust anti-tumor effect, with oral IL-10
therapy to induce tumor regression. Methods: 6 week old APCmin mice were
inoculated with enterotoxic Bacteroides fragilis (serotype 086) after fıve days of
intestinal flora depletion with antibiotics dissolved in drinking water. 7-10 days
after bacterial inoculation, mice were treated three times weekly with either 1)
blank polylactic acid microspheres for 3 weeks, 2) IL-10 containing micro-
spheres (0.5 microgram/dose) for 3 weeks, 3) IL-12 containing microspheres
(0.25 micrograms/dose) for 3 weeks, or 4) IL-10 containing microspheres for 1
week followed by a combination of IL-10 and IL-12 containingmicrospheres for
2 weeks. After euthanasia, colons were assessed for polyp counts and select
polyps were isolated for confocal microscopy analysis. Mesenteric lymph node
lymphocytes were isolated and analyzed using flow cytometry. Results: Mice
treated with oral IL-10 and IL-12 demonstrated a reduction in polyp number
compared to those mice treated with IL-10 alone, and both groups had fewer
polyps than mice treated with either IL-12 or blank microspheres. Addition of
IL-12 resulted in increased CD8 T cell numbers and IFN- production com-
pared to treatment with IL-10 alone. IL-10 retained its effect on CD4 T cells
when combining it with IL-12, resulting in a decrease in conventional regulatory
T cells (FoxP3 RORT -) as well as pathogenic regulatory T cells (FoxP3
RORT) and IL-17 producing CD4 T cells. Conclusions: The addition of
IL-12 to IL-10 therapy augments the therapeutic effect of oral cytokine treat-
ment on colon adenocarcinoma in the APCmin B. fragilis model. The effect ap-
pears additive and mediated by both IL-10’s effect on regulatory T cell popula-
tions and IL-12’s effect on CD8 T cells. Further studies in the setting of more
advanced disease, including liver metastases, will elucidate the therapeutic po-
tential of combination oral cytokine therapy with IL-10 and IL-12 for treatment
of colorectal cancer.
#1606 Targeting human T regulatory cells with novel Interleukin 2 alpha -
IL2 complex-specifıc RNA aptamer. Suresh Veeramani, Sue E. Blackwell,
William H. Thiel, Paloma H. Giangrande, George J. Weiner. University of
Iowa, Iowa city, IA.
Background: RNA aptamers are small RNAmolecules that bind antigens like
antibodies and are currently being explored as alternatives to antibodies for
diagnosis and therapy. A potential merit of aptamers is that they can be gener-
ated against native cellular antigens, such as those with unique post-transla-
tional modifıcations or receptor-ligand complexes, for which antibody genera-
tion can be diffıcult. Here, we report the use of a cell-based systematic
enrichment approach (SELEX) to develop a novel Treg-binding RNA aptamer
specifıc to IL2R-IL2 receptor-ligand complex. Methods and Results: A. Gen-
eration of Treg-binding aptamers: We designed a cell-based SELEX strategy to
generate RNAaptamers specifıc to humanT regulatory (Treg) cells. The starting
library consisted of random RNA aptamers with a structural diversity of1012.
Aptamers against common T cell antigens were pre-cleared using CD4CD25
Teff cells. Treg-binding aptamers were then positively selected using
CD4CD25Tregs from the samedonor.After amplifıcation of Treg binders by
RT-PCR, the whole selection was repeated eight times, each time with T cells
from a different donor. At the end, SELEX-enriched aptamer pools predomi-
nantly bound to Tregs, but not to Teff cells, which were then sequenced. The
most prevalent Treg-binder, Tr-1, showed 63,875-fold enrichment by the end of
SELEX (from 0.36 copies in the starting library to 22,995 copies in the eighth
round per million total reads). B. Tr-1 binds to IL2R- IL2 complex: We tested
if Tr-1 recognized human IL2R by measuring Tr-1 binding to recombinant
IL2R protein using RT-qPCR. Results indicated that Tr-1 bound to IL2R and
showed 3-fold higher binding to IL2R when IL2 was added indicating that
Tr-1 recognizes either the receptor-ligand complex or a conformational change
in IL2-bound IL2R. Binding of Tr-1 to IL2R did not signifıcantly alter its
affınity to IL2. C. Tr-1 inhibits Treg induction: Transformed B cells can induce
Treg development in the tumor microenvironment. Experimentally, this was
evaluated by quantifying Tregs generated from autologous CD4 T cells co-
cultured with Epstein-Barr virus-transformed B (EBV-B) cells. Addition of Tr-1
resulted in 30% reduction in EBV-B-induced Tregs (p0.017). Conclusion:
We used a Treg cell-based SELEX strategy to derive a novel Treg-binding RNA
aptamer (Tr-1) that preferentially binds to the IL2R-IL2 complex. Tr-1 re-
duced Treg induction by transformed B cells suggesting its potential as a thera-
peutic agent to reduce tumor-induced immunosuppression. Ongoing studies
are further exploring its use in Treg inhibition and in targeting receptor-ligand
complexes in cancer.While aptamers recognizing cellular receptors exist, to our
knowledge, this is the fırst report of an aptamer recognizing a receptor-ligand
complex. Our approach to generating aptamers against receptor-ligand com-
plexes could have huge scientifıc impact.
#1607 Durable effıcacy and anti-cancer immunity following intratumoral
administration ofmessenger RNAs encoding IL-36, IL-23 andOX40L. Josh
P. Frederick,1 Ailin Bai,1 Susannah Hewitt,1 Russ Karp,1 John Zielinski,1 Kana
Ichikawa,1 Ameya Apte,1 Dyane Bailey,1 Kristen Arnold,1 Sam Farlow,1 Darren
Potz,1 Bo Ying,1 Graham MacLean,1 Kerry Benenato,2 Maja Sedic,2 Steve M.
Kelsey1. 1Onkaido Therapeutics, Cambridge,MA; 2Moderna Therapeutics, Cam-
bridge, MA.
Immunologic responses to cancer involve complex interactions of cells within
the tumor microenvironment (TME). These interactions are mediated in part
through co-stimulatory and inhibitory transmembrane proteins, cytokines and
chemokines. Direct intratumoral (ITu) administration of messenger RNA re-
sults in synthesis of proteins that can prime and enhance an anti-cancer immune
response. Priming, expansion and migration of anti-cancer T-cell clones may
also result in a systemic or ‘abscopal’ response in distal lesions. There is mount-
ing preclinical evidence that OX40-OX40L signaling boosts anti-cancer immu-
nity via co-stimulatory activity on T-cells. We generated mRNA constructs en-
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coding OX40L with miR-122 binding sites that have been shown to suppress
protein translation in hepatocytes yet not within tumor cells. A single ITu injec-
tion of OX40L mRNA, formulated in a lipid nanoparticle, resulted in transfec-
tion of up to 25% of live tumor cells, predominantly cancer and myeloid cells.
OX40L protein persisted for 7 days after mRNA injection, and a resulting in-
crease in tumor T-cells was observed. Repeat dosing of OX40L mRNA induced
complete responses in a model that is sensitive to immune-meditated therapies,
such as anti-PD1/PD-L1 blockade, yet was ineffective in a related model that
might better represent an immunologically barren or immunosuppressive TME.
TheOX40L-resistant tumormodel was also resistant to anti-PD1 treatment and
was shown to contain fewer infıltrating immune cells. As this model may repre-
sent a subset of human cancers that do not respond well to checkpoint inhibi-
tors, it was used to test various mRNA constructs designed to cooperatively
harness components of both the innate and adaptive immune systems in igniting
a productive anti-cancer response. Both IL-36 and IL-23 have established roles
inmediating immune responses in humans and have been implicated in driving
various inflammatory diseases. IL-36 activates innate immune cells and pro-
motes Th1 responses, whereas IL-23 has been implicated in Th1/Th17 immu-
nity as well as in the modulation of antigen presenting cells. Repeated weekly
intratumoral co-administration of mRNAs encoding IL-23 and IL-36 resulted
in durable complete responses in both anti-PD1-sensitive and -resistant tumors
in a synergistic fashion. A further modest improvement in outcomes was ob-
served when the IL-23/36 mRNA doublet was co-administered with OX40L
mRNA. Further pharmacodynamic and mechanism of action studies with this
combination are underway. ITu injection of mRNA encoding combinations of
co-stimulatory proteins and cytokines represents a novel platform for cancer
immunotherapy, andmay be able to induce responses in patient tumors that are
resistant to checkpoint inhibition. The co-formulated combination of mRNAs
encoding human OX40L, IL-23 and IL-36 is planned to enter clinical trials in
2017.
#1608 CD122-selective IL-2/anti-IL-2 complexes reduce regulatory T cell
function and promote CD8 T cell polyfunctionality for durable ovarian
cancer immunotherapy. Justin M. Drerup, Sri Lakshmi Pandeswara, Aijie Liu,
CurtisA.Clark,Alvaro S. Padron,WanjiaoChen,VincentHurez, Tyler J. Curiel.
University of Texas Health Science Center at San Antonio, San Antonio, TX.
The IL-2 receptor (IL-2R) is an attractive target for cancer immunotherapy as
it controls both immune-suppressive regulatory T cells (Tregs) and anti-tumor
T cells. We tested depleting Tregs as immunotherapy using anti-CD25 (high-
affınity IL-2R subunit) antibodies (CD25) in ID8agg mouse ovarian cancer
(OC). CD25 reduced ascites and Treg numbers but failed to reduce tumor
burden, possibly because it depleted newly activated anti-tumor T cells in tu-
mor-draining lymph nodes. Thus, CD25 could be novel malignant ascites pal-
liation, but has limited stand-alone effıcacy.We then tested IL-2/anti-IL-2 com-
plexes (IL-2c) that selectively stimulatemedium-affınity (CD122/CD132) IL-2R
thought to expand anti-tumor T cells preferentially, but with little Treg effects.
In contrast to several single agents we tested that failed to treat ID8agg (e.g.,
CD25, PD-L1, IL-2 fusion toxin denileukin diftitox), IL-2c alone durably
reduced ID8agg tumor burden despite lowering the tumormicroenvironmental
CD8/Treg ratio. Thus, we hypothesized that IL-2c improved CD8 function,
reduced Treg function, or both. IL-2c increased polyfunctional IFN-TNF-
anti-tumor T cells as expected, an effect that persists weeks after drug clearance.
IL-2c also increased anti-tumor T cell CD25 expression that increased IL-2 sen-
sitivity and STAT5phosphorylation, a likelymechanism for increased polyfunc-
tionality. Unexpectedly, IL-2c reduced the Treg functional mediators CD25,
TIGIT and granzyme B, and reduced Treg suppressive function. Thus, favorable
Treg modifıcations are a novel IL-2c mechanism of action. Adding CD25 to
IL-2c to deplete Tregs further unexpectedly worsened IL-2c effıcacy in ID8agg
and reduced effector memory T cells and polyfunctional T cells in the tumor
microenvironment, suggesting a previously unappreciated role for CD25 in
IL-2c therapy. Similar data were seen in B16 melanoma, suggesting CD25
reduction of IL-2c effıcacy is not tumor or compartment-specifıc (ID8agg is
peritoneal and B16 is subcutaneous). PD-L1, an ineffective monotherapy in
ID8agg, combinedwith IL-2c to promote complete responses, suggesting poten-
tial for potent, novel combinatorial approaches. Our data suggest that antago-
nizing high affınity IL-2R (such as to deplete Tregs with CD25) has limited
cancer immunotherapy utility withoutmore specifıc Treg targeting. In contrast,
stimulating medium-affınity IL-2R with CD122-selective IL-2c has great trans-
lational promise by simultaneously improving benefıcial anti-tumor T cells and
reducing detrimental Treg function.
#1609 Oncolytic virotherapy for SCLC using immunocompetent mouse
models. Patrick Kellish, Daniil Shabashvili, Masmudur M. Rahman, Mary Re-
inhard, Grant McFadden, Frederic Kaye, Maria Zajac-Kaye. University of Flor-
ida, Gainesville, FL.
Background: Small cell lung cancer (SCLC) is an aggressive subtype of lung
cancer with few treatment advances over the past 3 decades and poor survival.
Locally targeted oncolytic virotherapy employs a viral vector that has selective
cytotoxicity for tumor cells and non-toxic for normal cells and tissues. The
therapeutic benefıt is proposed to arise from an initial viral cytotoxic phase
following by host immune responses. Myxoma Virus (MYXV) has been widely
tested in Australia to control rabbit populations with no toxicity to humans.
MYXV selectively infectsmouse and human tumors cells with no cytotoxicity to
normal tissues and is a promising oncolytic virotherapy agent that has not been
tested in human lung cancer or in clinical trials. Methods: To study MYXV
infection and viral replication in vitro, we utilized human and mouse SCLC cell
lines with MYXV engineered with fluorescent reporters. Using an optimized
conditional genetically engineeredmouse model (GEMM) (Ade-CREmediated
p53/Rb1/p130 null) we examined the effects of intrapulmonary MYXV treat-
ment on SCLC tumors at 5 and 30 days post-MYXV treatment. Survival analysis
was determined following intranasal MYXV 3 months post-Ade-CRE induc-
tion. We also tested intratumoral MYXV in patient derived xenografts (PDX)
and subcutaneous syngeneic allografts in immunocompetent mice. Results: We
optimized a conditional SCLC GEMM using limiting dilutions of intratracheal
Ade-CRE to reduce the SCLC foci to simulate human disease and generated
mouse SCLC lines from individual clones. We observed effıcient MYXV infec-
tion, late viral replication, and cytotoxicity in both human and mouse SCLC in
vitro. In contrast, we did not detect productive infection nor cytotoxicity in
non-tumor cells. Following intranasal MYXV instillation we observed MYXV
localized exclusivelywithin lungs at 3 days andno longer detected by 7 days’ post
treatment. TUNEL staining of SCLC lesions showed apoptosis and necrosis at 5
days within SCLC and the effect persisted with discrete foci of tumor necrosis 30
days’ post-treatment. There was no toxicity to any mouse tissues. SCLCGEMM
treated with intrapulmonary MYXV (n30) showed a modest but statistically
signifıcant prolongation of survival compared to PBS control mice (n30) (p
0.05). Direct intratumoral MYXV injections performed on PDX tumors in im-
munodefıcient mice showed effıcient infection and late viral replication in all
patient samples.We observed extensive tumor necrosis at 7 days, and persisting
virus at 10 days’ post treatment. Direct intratumoral MYXV injections per-
formed on allograft tumors in syngeneic immunocompetent mice showed ex-
tensive necrosis accompanied by immune cell infıltration into the tumor, and
the virus was undetectable 7 days’ post treatment. Conclusions: We show the
potential for MYXV as an oncolytic virotherapy for SCLC with enhanced cyto-
toxicity in immunocompetent mice suggesting a role for concurrent immune
checkpoint therapies.
#1610 Targeted cancer immunotherapy with engineered Salmonella ty-
phimurium secreting heterologous bacterial flagellin. Jung-JoonMin, Jin Hai
Zheng, Yeongjin Hong, Hyon E. Choy, Joon Haeng Rhee. Chonnam National
University Medical School, Gwangju, Republic of Korea.
Salmonella typhimurium is a facultative anaerobic bacteria and can selectively
grow in tumors following systemic administration. Different strategies have
been used to deliver payloads to tumor tissues using engineered Salmonellae.
We report a novel method of cancer immunotherapy using an attenuated S.
typhimurium strain engineered to secrete Vibrio vulnifıcus flagellin B (FlaB) in
tumor tissues.Previously, we developed an attenuated strain of S. typhimurium,
which is defective in ppGpp synthesis (ppGpp S. typhimurium), and mani-
fested signifıcantly increased LD50 by 100,000 to 1,000,000-fold. To generate an
inducible vector system for bacterial expression of the therapeutic gene, we
cloned the flaB gene into the pBAD plasmid vector in which the pelB leader
sequence was cloned upstream of flaB to guide extracellular secretion; gene
expression from the plasmid (pFlaB)was induced only in the presence of L-arab-
inose. To evaluate the antitumor activity of engineered S. typhimurium,
C57BL/6 mice transplanted with MC38 tumors were injected intravenously
(i.v.) with PBS, ppGpp S. typhimurium carrying an empty vector, or ppGpp
S. typhimurium carrying pFlaB (/ L-arabinose induction). To test whether
the FlaB-secreting ppGpp S. typhimurium has inhibitory effects on human
metastatic cancer, we next implanted HCT116-luc2 tumors into the intestinal
wall of BALB/c athymic nu-/nu- mice using a surgical orthotopic implantation
(SOI) procedure. Engineered FlaB-secreting Salmonellae signifıcantly sup-
pressed tumor growth and metastasis in mouse models and prolonged survival.
By using TLR5-negative colon cancer cell lines (MC38 and HCT116), we have
proved that the FlaB-mediated tumor suppression upon bacterial colonization
should be associated with TLR5-mediated host reactions in the tumormicroen-
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vironment. These therapeutic effects were completely abrogated in TLR4 and
MyD88 knockout mice, and partly in TLR5 knockout mice, strongly suggesting
that TLR4 signaling is a requisite for the FlaB-secreting bacteria-mediated tu-
mor suppression where TLR5 signaling augmented tumor suppressive host re-
actions. Tumor colonization by engineered Salmonellae appeared to induce the
infıltration of abundant immune cells such as monocytes/macrophages and
neutrophils via the TLR4 signaling. Subsequent secretion of FlaB from coloniz-
ing Salmonellae resulted in phenotypic and functional activation of intratu-
moral macrophages with M1 phenotypes and a reciprocal reduction in M2-like
suppressive activities. Taken together, these fındings provide evidence that non-
virulent tumor targeting bacteria liberating multiple TLR ligands can be used as
novel cancer immunotherapeutics.
#1611 Intravesical BCG induces CD4 T Cell expansion in an immune
competent model of bladder cancer. Max Kates, Thomas Nirschl, Nikolai
Sopko, Noah Hahn, DavidMcConkey, Alex Baras, Charles Drake, Trintiy Biva-
lacqua. Johns Hopkins Medical Institutions, Baltimore, MD.
Intravesical BCG Immunotherapy is the standard of care in treating non-muscle
invasivebladder cancer (NMIBC), yet itsmechanismofactionremains elusive.Both
innate andadaptive immune responseshavebeen implicated inBCGactivity.While
prior research has indirectly demonstrated the importance of T cells and shown a
rise inCD4Tcells inbladder tissueafterBCG,Tcell subpopulationshavenotbeen
fully characterized.We investigated the relationshipbetweeneffectorandregulatory
T cells in an immune competent, clinically relevant rodentmodel of bladder cancer.
Fischer 344 rats aged 7 weeks received 1.5mg/kg N-Nitroso-N-methylurea (MNU)
every other week for 6 weeks (4 doses). Bladder dysplasia began by week 8 and by
week 16 themajority of rats had a NMIBC phenotype. Beginning week 8 following
the fırst MNU dose, rats were intravesically administered 0.3ml of BCG (Tice),
cisplatin (1mg/ml), Mitomycin C (2mg/ml), MMC BCG, or saline (n10 for all
groups) weekly for 6 total doses. Animals were sacrifıced at week 16, and bladders
were processed for histopathology and digested into single cell suspensions for flow
cytometry.Whole transcriptomeexpressionprofılingwas thenperformedonsorted
CD4 and CD8 cells of post-BCG tumors vs untreated tumors to assess T cell differ-
entiation after BCG.Our data demonstrate that cancer progression in theMNU rat
model of bladder cancer is characterized by a decline in the CD8/FoxP3 ratio, con-
sistent with decreased adaptive immunity. By contrast, treatment with intravesical
BCG leads to a large, transient rise in theCD4Tcell population in theurothelium,
and is bothmore effective and immunogenic compared to intravesical chemother-
apy. Interestingly, whole transcriptome expression profıling of post-treatment in-
travesicalCD4 andCD8Tcells revealedminimal differences in gene expression
after BCG treatment. Together, our results suggest that while BCG induces T cell
recruitment to the bladder, the T cell phenotype does not markedly change, imply-
ing that combiningTcell activatingagentswithBCGmight improveclinical activity.
#1612 Production of CD3 cells using ferrofluids for cell isolation, acti-
vation, expansion and subsequent transfection for adoptive cell therapy.
Dustin W. Ritter, Todor R. Khristov, Paul A. Liberti. BioMagnetic Solutions,
State College, PA.
Thepurposeof the study is todemonstratewhethermagneticnanoparticles func-
tionalized with monoclonal antibodies in conjunction with solution-phase mono-
clonalantibodiescanbeused toactivateTcells forexpansion invitro.Theactivation,
expansion and transfection/transduction of immune cells—particularly T cells—
hasbecomeanareaof signifıcant interest basedonencouragingdatagenerated from
employing such geneticallymodifıed cells for cancer immunotherapies. The prom-
ise of soon being able to cure various types of cancers has resulted from years of
methodical experimentation in the fıelds of oncology, immunology, andgenetics, as
well as the development of a vast array of enabling technological advances. BioMag-
netic Solutions has developed colloidal magnetic nanoparticles—referred to as fer-
rofluids—which can be used to isolate a cell population through an immunomag-
netic separation. These ferrofluids comprise a crystalline core of magnetite (ca. 100
nm in diameter) coated with multilayers of clinical-grade human serum albumin
and further functionalized with a clinical-grade rat anti-mouse IgG1 monoclonal
antibody.These “common-capture ferrofluids” (ca. 130nmindiameter) are capable
of binding cells which have been labeled with a monoclonal mouse IgG1 antibody;
for example, CD3 cells can be readily isolated from a complex cell mixture by
labeling with a monoclonal mouse anti-human CD3 antibody, adding common-
capture ferrofluid, and subjecting the sample to amagnetic fıeld gradient. This tech-
nology can therefore be employed at the clinical scale to isolate T cells from an
apheresis product. In this study,we investigatedwhetherT cells isolated using com-
mon-capture ferrofluids could subsequently be activated and induced to expand in
vitro. Based on preliminary experiments showing that T cell-bound common-cap-
ture ferrofluid has excess antibody-binding capacity, we designed experiments to
test the hypothesis that solution-phase CD28 could be added to isolated T cells,
which would bind to both CD28 determinants on the cell surface as well as to the
cell-bound common-capture ferrofluid. Activation was quantifıed by measuring
CD25 expression after four days in culture and expansion was monitored over 15
days. Following an immunomagnetic separation of CD3 cells, magnetically iso-
lated cells were re-suspended in expansion medium (STEMCELL) supplemented
with 100 IU/mL IL-2 (Gibco) to a total concentration of 106 cells/mL and incubated
at 37 °C. The following day, 0.5g/mLmouse anti-humanCD28monoclonal anti-
body (Mabtech) was added, and thereafter, cells were periodically agitated and di-
luted to 106 cells/mLwith expansionmedia.After four days in culture, 88.4%of cells
expressed CD25, while a 311-fold expansion was observed after 15 days. In sum-
mary, we have demonstrated that common-capture ferrofluids can be used to acti-
vate T cells for expansion in vitro.
#1613 Genetically modifıed neuronal stem cells expressing IL-12 and
TNFSF14 attenuate highly metastatic mammary tumors in a mouse model.
Tej B. Shrestha,Dezhang Lu,MatthewT. Basel,Marla Pyle, StefanH. Bossmann,
Deryl L. Troyer. Kansas State University, Manhattan, KS.
Interleukin 12 (IL-12) is a heterodimeric cytokine encoded by two genes, p35
and p40. IL-12, also known as T cell-stimulating factor, induces proliferation of
T-lymphocytes and natural killer (NK) cells, while also demonstrating an anti-
angiogenic effect and inhibition of regulatory T cells. Similarly, LIGHT
(TNFSF14) is a transmembrane protein which acts as a costimulatory factor for
the activation lymphoid cells and stimulates the proliferation of T cells, leading
to increased apoptosis of tumor cells. Expression of IL-12 and LIGHT specifı-
cally in the tumor region could activate T cells and stimulate the immune system
to attenuate the tumor. Tumor homing neuronal stem cells C17.2 (NSC) were
genetically engineered to express the mouse-LIGHT gene and IL-12 using a
retrovirus. The expression of LIGHT and IL-12 genes in NSC was confırmed by
PCR, ELISA and Western blot. To test the antitumor effects of the engineered
cells, Balb/C mice bearing 4T1 mammary tumors were treated with NSC-
LIGHT, NSC-IL-12 and NSC-LIGHT/IL-12 cells intratumorally (I.T.) at day
nine. Repeated tumormeasurement over time showed attenuation ofmammary
tumor growth in the both NSC/IL-12 and NSC/LIGHT groups in comparison
with control groups PBS and NSC. Tumor growth was further reduced by treat-
ing the mice with NSC expressing both cytokines LIGHT and IL-12. Tumor
metastasis was also evaluated by removing the primary tumor surgically and
observing mice for any sign of metastatic burden. Treatment groups had less
metastatic tumor burden and survived longer than the control group. Therefore,
tumor homing NPC-LIGHT/IL-12 cells could be effective for the treatment of
highly metastatic mammary tumors.
#1614 Intratumoral delivery of a P2A-linked bicistronic IL-12 construct
leads to high intratumoral expression and systemic anti-tumor response.Da-
vid A. Canton, Christoph Burkart, Shawna A. Shirley, AnandaroopMukhopad-
hyay, Richard J. Connolly, Arya Bahrami, Jean S. Campbell, Robert H. Pierce.
OncoSec Medical, San Diego, CA.
The use of immunomodulatory cytokines has been shown effective in regress-
ing a wide range of tumors. However, systemic delivery of recombinant cyto-
kines can result in serious adverse effects, often life-threatening. DNA transfer
via electroporation (EP) is a safe and effective method of delivering cytokines to
target tissues. Intratumoral (IT) electroporation of Interleukin 12 (IL-12), a
potent immunomodulatory cytokine, is well tolerated with an acceptable safety
profıle and objective response rates of 34-40% and 33% in Phase II clinical trials
in advanced melanoma and Merkel cell carcinoma, respectively. We sought to
improve the systemic anti-tumor response of IT pIL-12-EP by improving IL-
12p70 expression and electroporation conditions, which were evaluated in vitro
and in vivo with a two-tumor syngeneic mouse model of melanoma. As func-
tional IL-12 p70 is a heterodimer, we compared different expression constructs
to achieve high levels of IL-12 protein expression. IL-12p70 protein expression
from a plasmid that incorporated a picornavirus-derived co-translational cleav-
age site (P2A) was higher than constructs with an internal ribosomal entry
sequence (IRES) or a fusion of the p35 and p40 subunits. In functional in vitro
assays, pIL-12(P2A) was superior to pIL-12(IRES) and the fusion protein. Using
the murine B16.F10 tumor model, we show that IT EP of pIL-12 (P2A) plasmid
regresses the treated lesions in a dose-dependent manner compared to control
treatments. Systemic effects of IT-expressed IL-12 was assessed by monitoring
generation of an antigen-specifıc CD8 T cell response and regression of B16.F10
contralateral (untreated) tumors following primary tumor electroporation. IT-
pIL12-EP treatment with the P2A-linked construct resulted in a signifıcant in-
crease in antigen-specifıc CD8 T cells, as well as enhanced contralateral tumor
growth inhibition suggesting the induction of strong systemic anti-tumor im-
mune response. * Contributed equally to this work.
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#1615 C-Reactive protein and radiotherapy-induced skin toxicity in
breast cancer. Jennifer J. Hu,1 Doug Case,2 Mark O. Lively,2 Eunkyung Lee,1
Cristiane Takita,1 James J. Urbanic,3 Glenn J. Lesser,4 Edward G. Shaw4. 1Univ.
of Miami Sylvester Comp. Cancer Ctr., Miami, FL; 2Wake Forest University
School of Medicine, Winston-Salem, NC; 3Univ of California San Diego, San
Diego, CA; 4Wake Forest Baptist Health, Winston-Salem, NC.
Background: Post-surgery adjuvant radiotherapy (RT) for breast cancer sig-
nifıcantly reduced the local recurrence rate. However, many patients develop
early adverse skin reactions (EASRs) that impact quality of life. Methods: In a
large prospective study of 1,000 breast cancer patients undergoing RT, we eval-
uated an inflammatory biomarker, C-reactive protein (CRP) in predicting RT-
induced EASRs. In each patient, we measured pre- and post-RT plasma CRP
levels using a highly-sensitive ELISA CRP assay. RT-induced EASRs were as-
sessed using the Oncology Nursing Society Skin Toxicity Criteria. Association
between EASRs and CRP were assessed using logistic regression models after
adjusting for potential confounders. Results: The study population includes 405
non-Hispanic White, 280 African Americans, 218 Hispanic Whites, 52 Asians,
and 45 others. RT-induced grade 3 and 4 skin toxicity at the end of RT were
observed in 42% and 15%patients, respectively. CRP levels differ signifıcantly by
race/ethnicity at baseline and at the end of RT. RT-induced grade 4 skin tox-
icity was signifıcantly associated with: obesity and pre-RT CRP  2mg/L
(OR3.27; 95%CI1.88, 5.68), obesity and post-RT CRP 2mg/L (OR4.42;
95%CI2.38, 8.23), or obesity and change of CRP  1mg/L (OR3.58;
95%CI2.00, 6.39). Conclusion: The current data validate our previous fındings
that the inflammatory biomarker CRP is associated with RT-induced EASRs,
particularly combined with obesity. Impact: Our current fındings support the
discovery and development of anti-inflammatory agents to protect normal tis-
sue fromRT-inducedEASRs and improve quality of life in breast cancer patients
undergoing RT.
#1616 S100A4 blockage alleviates agonistic anti-CD137 antibody induced
liver pathology without disruption of anti-tumor immunity. Jinhua Zhang,
Kun Song, Zhihai Qin. Institute of Biophysics, Chinese Academy of Science,
China.
Liver-related autoimmune toxicities triggered by anti-CD137 agonist anti-
bodies have greatly limited their use in clinic applications. Here we found that
anti-CD137 monoclonal antibody (mAb) treatment in mice induced the infıl-
tration of a large number of S100A4macrophages into the liver. Depletion of
these cells or defıciency of S100A4 decreased inflammatory cytokine profıles,
and drastically reduced the number of liver pathogenic CD8 T cells. Mecha-
nistically, soluble S100A4 directly activated the Akt pathway and specifıcally
prolonged CD8 T cell survival. Interestingly, one S100A4 neutralizing mono-
clonal antibody selectively alleviated liver abnormalities but did not affect the
anti-tumor immunity induced by anti-CD137 therapy. Thus, our study presents
a novel molecular link to the liver pathology induced by an immune stimulatory
antibody, and proposes that combinational immunotherapies targeting those
pathways could potentially elicit optimal anti-tumor immunity with minimal
side effects.
#1617 Mechanistic modeling of a new kinetically-controlled CD122 ago-
nist for cancer immunotherapy:NKTR-214 pharmacokinetics, pharmacody-
namics, and receptor pharmacology. SamiraKhalili, AleksandrsOdinecs,Deb-
orah H. Charych, Vidula Dixit, Peter Kirk, Thomas Chang, John Langowski,
Werner Rubas, Steve Doberstein, Jonathan Zalevsky, Michael A. Eldon, Ute
Hoch. Nektar Therapeutics, San Francisco, CA.
Introduction: NKTR-214 is a biologic prodrug currently in a Phase 1 / 2
clinical trial in patients with solid tumors, as a single agent and in combina-
tion with anti-PD1. It is a CD122-biased cytokine agonist conjugated with
multiple releasable chains of polyethylene glycol and designed to provide
sustained signaling through the heterodimeric IL-2 receptor pathway (IL-
2R) to preferentially activate and expand effector CD8 T and NK cells
over Tregs. Here we describe a mechanistic mathematical model that quan-
tifıes conjugated aldesleukin (IL-2) species that are generated from NKTR-
214, their sustained exposure, and biased receptor pharmacology in rodent
models. Methods: A mechanistic mathematical model, using ordinary dif-
ferential equations (ODE), was developed using Matlab® programming lan-
guage to describe the dynamics of NKTR-214 PEG release, clearance, distri-
bution, and receptor occupancy in vivo. The model was conditioned using
experimental data for in vitro binding of unconjugated IL-2 and active con-
jugated IL-2 derived from NKTR-214 to IL-2 receptors using surface plas-
mon resonance, in vitro PEG release data, and mouse pharmacokinetics
data. Simulations were performed to 1) quantify the concentration-time
profıles of the various conjugated IL-2 species derived from NKTR-214 and
contribution of each of them to the NKTR-214 mechanism of action, and 2)
compare occupancy at IL-2R and IL-2R receptors after administra-
tion of therapeutic doses of NKTR-214 and aldesleukin. Results: After
NKTR-214 administration, PEG chains are released slowly from the prodrug
and active conjugated IL-2 species gradually increase and reach maximum
concentrations about one day post-dose, followed by sustained exposure for
up to a week. Compared to an equivalent dose of aldesleukin, the active
conjugated IL-2 species derived from NKTR-214 achieve a 26-fold higher
area under the curve (AUC) of IL-2R occupancy, and a 0.34-fold lower
AUC of IL-2R occupancy. The signifıcant difference is due to the com-
bined effects of slow release of active conjugated IL-2 species from NKTR-
214 and their favorable binding kinetics towards IL-2R. Aldesleukin, even
when simulated at repeated daily doses or constant infusion, is incapable of
increasing the receptor occupancy at IL-2R without simultaneously in-
creasing the receptor occupancy at IL-2R in this model. Conclusions:
The mechanistic model demonstrated how NKTR-214’s intrinsic design en-
ables both biased receptor pharmacology and sustained exposure in vivo.
Such biased receptor binding could not be achieved by a sustained delivery of
aldesleukin.
#1618 Immune-modulating effect of bevacizumab in EGFRmutated lung
adenocarcinoma. Po-Hao Feng, Kang-Yun Lee. Shuang Ho Hospital, Taipei
Medical University, New Taipei City, Taiwan.
Background: Host immunity affect treatment effect of lung cancer. Pe-
ripheral blood S100A9 monocytic myeloid derived suppressor cells
(MDSCs) is a predictive factor for treatment response of chemotherapy and
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) of
lung adenocarcinoma patients. Bevacizumab have immune-modulating ef-
fect, including decreasing MDSCs, and improve treatment effect in combi-
nation with immunotherapy. However, the effect of immune modulation in
combination of bevacizumab and EGFR-TKI in EGFR mutated lung adeno-
carcinoma patients is not clear. Methods: Stage IV lung adenocarcinoma
harboring sensitive EGFR mutation patients receiving fırst line EGFR-TKI
or combination EGFR-TKI and bevacizumab were enrolled. The peripheral
blood mononuclear cell (PBMCs) were collected, and S100A9MDSCs per-
centage was calculated by flow cytometry from CD14S100A9 in PBMC.
Clinical data was collected. Results: Eight patients receiving EGFR-TKI and
bevacizumab, as combination group, and twenty patients received EGFR-
TKI alone, as control group, were enrolled. PBMC S100A9 MDSC de-
creased in combination group (decrease 39	18% from baseline), but not in
control group. Combination group had longer progress free survival (PFS)
comparing with control group. (Median PFS combination vs control group:
15.2 vs 9.9 months, Log Rank test, p0.05) Increased of peripheral blood
cytotoxic T cells also had trend in combination group but not in control
group. Conclusion: Besides the anti-angiogenesis effect, bevacizumab had
immune modulated effect, especially in decreasing circulating S100A9
MDSC in EGFRmutated lung adenocarcinoma patients. This might partially
explain the longer PFS in combination of EGFR-TKI of anti-angiogenesis
agent treatment.
#1619 Gemcitabine-generated ROS promotes neutrophil transmigration
and activation by synergistic CXCL8 production with PKC delta-activated
macrophages. Jinseon Jeong,1 Yong-Jae Kim,1 Kwang Hoon Yang,1 Sun Young
Yoon,2 Ki-Young Sohn,2Heung-JaeKim,2 Jae-UkChung,2Myung-HwanKim,3
Jae Wha Kim1. 1Korea Research Institute of Bioscience and Biotechnology, Dae-
jeon, Republic of Korea; 2Enzychem Lifesciences, Daejeon, Republic of Korea;
3Asan Medical Center, Seoul, Republic of Korea.
Chemotherapy-induced neutropenia (CIN) is a common side effect that
necessitate dose reductions during treatment of cancer patients. Preventing
CIN is critical in chemotherapy because a rapid decline of neutrophil counts
increase susceptibility to infection of cancer patients. In spite of its impor-
tance, the mechanism responsible for CIN still remains unclear. The purpose
of this study is to investigate the mechanism of CIN in an aspect of neutro-
phil activation by chemotaxis in in vivo and in vitro model systems. It is well
known that protein kinase C 	 (PKC	) is endogenously activated in immune
and cancer cells of tumor environments, and treatment of gemcitabine gen-
erates reactive oxygen species (ROS). Based on these phenomena, we hy-
pothesized that gemcitabine-generated ROS synergistically amplifıes PKC	
signaling and C-X-C Motif Chemokine Ligand 8 (CXCL8) production in
macrophages and neutrophil recruitment to the chemokine gradient follow-
ing cell death by activation. In breast tumor mouse model, we found that
intracellular PKC	 is activated in both the peritoneal cavity and the tumor
region. To investigate if neutrophils are transmigrated by gemcitabine treat-
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ment, blood and peritoneal leukocytes were analyzed at different times after
intraperitoneal administration of gemcitabine (50mg/kg). The number of
neutrophils signifıcantly decreased in the blood but increased in the perito-
neal cavity in the early phase (1-2h) after administration. However, both
blood and peritoneal neutrophil counts fell by almost the normal range in the
late-phase (15h). Similarly with the neutrophil migration, the level of mac-
rophage inflammatory protein 2 (MIP-2) was highest at 1h in the peritoneal
cavity. To check whether neutrophils elicit neutrophil extracellular trap
(NET) formation in response to gemcitabine treatment, we employed peri-
toneal neutrophils and determined that neutrophils produce NET in re-
sponse to gemcitabine as determined by immunofluorescence. To examine
the synergistic effects in in vitro systems, we induced mild PKC	 activation
using 0.1nM of phorbol 12-myristate 13-acetate (PMA) in humanmonocytic
THP-1 cells, and co-treatment of gemcitabine signifıcantly induced the in-
creased activity of PKC	 and the level of CXCL8 production compared to
their single treatments. The synergistic activation of PKC	 led to the increase
transcriptional activities, including AP-1, NF-B, and STAT3. In conclu-
sion, regulation of PKC	 activity is critical for preventing cancer patients
from CIN, and PKC	 regulators could be a potential therapeutic agent for
CIN.
#1620 Oral IL-10 suppresses colon carcinogenesis via elimination of
pathogenic CD4 T-cells and induction of antitumor CD8 T-cell activity.
TAO GU,1 Magdia DeJesus,2 Thomas P. Burris,3 Nejat K. Egilmez1. 1University
of Louisville, Louisville, KY; 2University at Albany School of Public Health, Al-
bany, NY; 3Saint Louis University, St. Louis, MO.
An oral sustained-release formulation of Interleukin-10 suppressed tumor
growth and enhanced survival in the APCmin/ / Bacteroides fragilis spontaneous
colon cancer model. Therapeutic benefıt was associated with a 5-fold reduction in
CD4RORγtFoxp3-IL-17 T-helper cell, CD4RORγtFoxp3IL-17
pathogenic T-regulatory cell (pgTreg) and CD4RORγt-Foxp3IL-17- conven-
tional T-regulatory cell (cTreg) numbers; and a concurrent enhancement of CD8
T-cell cytotoxicity in thecolonic laminapropria. Selective subsetdepletionandfunc-
tional blockade studies demonstrated that CD4RORγtIL-17 T-cell subsets
and CD4Foxp3 cTreg supported tumorigenesis/tumor progression whereas
CD8 cytotoxicT-lymphocytes suppressed tumorgrowth.These fındings establish
theutility of oral particulate IL-10 as apotential new therapeutic in themanagement
ofcoloncancerandshed lightonthecellularmechanismsthatunderlie its antitumor
activity.
#1621 Adoptively transferred B cells directly kill tumor cells via the
CXCR4/CXCL12 & perforin pathways. Leiming Xia,1 Yang Xia,1 Quanning
Chen,2 Yi Wang,3 Yangyi Bao,3 Steven K. Lundy Lundy,1 Fu Dai,3 Alfred E.
Chang,1 Qiao Li1. 1Univ. of Michigan, Ann Arbor, MI; 2Tongji Hospital of Tongji
University, Shanghai, China; 3The No.1 People’s Hospital of Hefei, Hefei, China.
Over the years, the role of B cells in the host immune response to malignancy
has been overshadowed by our focus on T cells. The role played by B cells in
cancer immunology is complex and controversial. The observationmade by our
lab that activated B cells alone can mediate tumor regression in the adoptive
immunotherapy of solid tumors is innovative (JI 2009; CCR 2011; JSO 2012; EJI
2015). One novel mechanism by which activated B cells mediate tumor regres-
sion is via direct tumor cell cytotoxicity in the absence of antibodies. We previ-
ously reported that antitumor B cells directly kill tumor cells via the Fas/FasL
pathway and are regulated by IL-10. In this study, we defıned additional mech-
anisms involved in B cell antitumor immunity. Administration of IL-2 signifı-
cantly augmented the therapeutic effıcacy of adoptively transferred tumor-
draining lymph node (TDLN) B cells which express IL-2R. Culture supernatant
of purifıed B splenocytes harvested from themice that received adoptive transfer
of 4T1 TDLN B cells plus IL-2 administration produced larger amounts of IgG
which bound to 4T1, resulting in 4T1 lysis. Furthermore, we detected CXCR4
expression on 4T1 TDLN B cells, and 4T1 tumor cells produced its ligand
CXCL12. Transwell experiments demonstrated the chemotraction of CXCR4-
expressing 4T1TDLNBcells towardsCXCL12-producing 4T1 cells. Blockade of
CXCR4 using a CXCR4-specifıc inhibitor, AMD3100, signifıcantly reduced the
killing of 4T1 tumor cells by 4T1 TDLN B cells. Blockade of FasL and CXCR4
concurrently inhibitedB cell-mediated direct killing of tumor cells in an additive
manner, indicating that both Fas/FasL and CXCL12/CXCR4 pathways are in-
volved in the direct killing of 4T1 cells by 4T1 TDLN B cells. TDLN B cells
produced perforin. Additional transwell experiments showed that effector B
cells could directly kill tumor cells in cell-cell contact via the Fas/FasL and
CXCR4/CXCL12 pathways as well as perforin, while without cell contact, per-
forin secreted by B cells led to tumor cell cytotoxicity. These fındings underscore
the diversity of function by which B cells can play an important role in the host
immune response to tumor, and clearly indicated that transferred effector B cells
can act independently of T cells in causing tumor destruction in adoptive im-
munotherapy.
#1622 The role of the CCL-2 on lymphopenia-induced myeloid derived
suppressor cells. Pasquale P. Innamarato, AmyWeber, Shari Pilon-Thomas.H.
Lee Moffıtt Cancer Center, Tampa, FL.
The induction of lymphopenia prompts the expansion of CD11bLy6ChiLy6G
monocytic MDSCs (M-MDSCs) and CD11bLy6CLy6G polymorphonuclear
MDSCs (PMN-MDSCs). Patients receiving adoptive cell therapy (ACT) require
nonmyeloablative chemotherapy to induce lymphopenia and support anti-tumor
immunity. However, the role of MDSCs in the setting of ACT is not fully under-
stood. As high levels of CCL-2 can bemeasured in lymphopenicmice, in this study
we investigate the role of CCL-2 in the expansion and function of lymphopenia-
inducedMDSCs usingCCR2KOmousemodels. Lymphopenia was induced inmel-
anoma-bearing C57BL/6 (WT) and CCR2KOmice by 600rad of total body irradia-
tion or combination therapy with cyclophosphamide and fludarabine. We fırst
evaluated the percentages of splenic MDSCs in WT and CCR2KO mice after the
induction of lymphopenia. At day 14, the expansion of totalMDSCswere similar in
WT(279%ofnormal) andCCR2KO (241%ofnormal).However, themeanpercent-
ages ofM-MDSCs (3.5%) andPMN-MDSCs (30.3%) inCCR2KOmicewere altered
compared to M-MDSCs (22.2%) and PMN-MDSCs (21.7%) in WT mice. In
addition, M-MDSCs in B16 tumors grown in CCR2KO mice were decreased
compared to intratumoral M-MDSCs in WT mice (p0.001). In contrast, the
percentages of M-MDSCs and PMN-MDSCs were unchanged in the bone mar-
row (BM). To investigate the suppressive capacity of lymphopenia-induced
MDSCs, OVA antigen-specifıc CD8 T cells were co-cultured with OVA pep-
tide in the presence of MDSCs purifıed from the spleens of CCR2KO and WT
mice. Both CCR2KO andWTMDSCs potently suppressed T cell proliferation as
measured by 3H thymidine incorporation. CCR2KO andWTMDSCs had signif-
icant arginase activity and production of nitrites. To investigate the effıcacy of
ACT, B16 tumor-bearing CCR2KO and WT mice were lymphodepleted and
gp100 antigen-specifıc Thy1.2CD8 T cells were adoptively transferred fol-
lowed by 3 days of IL-2 treatment.We found that donor T cell tumor infıltration
was similar and no difference in tumor growth was observed between CCR2KO
andWTmice. Collectively, these results suggest that the role of CCL-2 is impor-
tant for the egress of lymphopenia-inducedM-MDSCs from the BM, but has no
effect on the expansion or function of PMN-MDSCs in the setting of lymphope-
nia. These data suggest that factors besides CCL-2 play an important role in the
expansion and function of MDSCs after the induction of lymphopenia.
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#1623 Minute variation in murine ovarian cancer preclinical models sig-
nifıcantly impact immunotherapy results obtained for clinical trial. AJ Rob-
ert Mcgray, Kristen Starbuck, Samar Masoumi-Moghaddam, Ariel Francois,
Kunle Odunsi, Emese Zsiros. Roswell Park Cancer Institute, Buffalo, NY.
Cancer immunotherapies, particularly checkpoint inhibitors, have emerged
as highly promising approaches for treatment of a variety of solid tumors, in-
cluding recurrent ovarian cancer. While dramatic clinical benefıt is observed in
a subset of patients with ovarian cancer, the majority of ovarian cancer patients
do not respond to checkpoint inhibitors, thus combinatorial treatments are
sorely needed. Immune competent pre-clinical animal models are crucial to test
emerging treatment strategies and for the identifıcation of biomarkers to predict
response to therapy. As results from immune competent preclinical models are
often translated into clinical trials, we sought to investigate whether slight vari-
ability related to animal housing and/or breeding practices in the same strain
could impact experimental outcomes related to immunotherapy.We conducted
animal studies usingC57BL/6Jmice purchased from Jackson Laboratories (Cat#
000664) 2weeks prior to experimental use (Jax) and using the samemouse strain
purchased from Jackson Laboratories but bred within our institution for a pe-
riod of 6 months prior to use (Jax-R). Using the gold standard ID8 murine
metastatic intraperitoneal ovarian cancer model we tested the therapeutic effı-
cacy of anti-PD-1 monotherapy in both Jax and Jax-R animals. Aged-matched
female mice were housed under the same conditions for 2 weeks prior to tumor
inoculation and for the duration of study. Strikingly, we noted that while anti-
PD-1 monotherapy had absolutely no effect on tumor growth or survival of Jax
mice, the Jax-R animals showed dramatic tumor growth control and signifı-
cantly improved long term survival. Tumor progression and survival was
similar across sub-strains in untreated control animals, suggesting that the
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observed differences in treatment outcome following anti-PD-1 treatment
were not simply due to intrinsic differences between the animals. Response
to treatment was also associated with increased frequencies of circulating
CD4 and CD8 T cells in the Jax-R mice compared with the Jax animals.
Although major variations in age, animal strain and gut microbiome can
dramatically impact upon the effıcacy of checkpoint inhibitors, our fındings
demonstrate that even minute changes within sub-strains recently derived
from the same founder animals could result in signifıcantly different survival
and pre-clinical outcome. Thus, immunotherapy results obtained from im-
mune competent animal studies need to be interpreted with caution when
designing future immunotherapy trials.
#1624 NOTCH ligand-based therapeutics for immunomodulation in can-
cer and organ transplantation. Elena I. Tchekneva,1 Anneliese E. Antonucci,1
Irina Chekneva,2 Nicholas Long,1 Jason V. Evans,3 Anwari Akhter,1 David P.
Carbone,1 Thomas Magliery,1 Mikhail M. Dikov1. 1Ohio State University, Co-
lumbus, OH; 21stMoscow StateMedical University,Moscow, Russian Federation;
3West Virginia University, Morgantown, WV.
We demonstrated in human andmouse studies that tumor-inducedmodula-
tion of Notch ligand expression andNotch signaling in hematopoietic compart-
ment contributes to tumor immune escape. Down-regulation of delta-like li-
gands (DLL) leads to defects in T cell development and T helper (Th1) cell
differentiation with the prevalence of regulatory T cell (Treg) generation. To
determine the roles of Notch ligands in antigen-presenting dendritic cells in
regulation of antitumor immune responses we generated a set of lineage-specifıc
knock-out mice lacking one of the Notch ligands in CD11c dendritic cells
(DC).We are developing and testing a set of reagents for clinical application for
ligand-specifıc activation or inhibition ofNotch signaling to stimulate or inhibit,
respectively, various types of immune responses for applications in oncology
and immune diseases. Mice with DLL1 insuffıciency in DC demonstrated re-
markably accelerated growth of Lewis lung carcinoma (LLC) tumor, and re-
duced survival compared to wild type animals. This associated with impaired
anti-tumor immune responses indicated by the decreased tumor infıltration by
IFN-producing T cells. Jagged2 knockout did not cause any signifıcant altera-
tions. Notch ligand expression in antigen-presenting cells was identifıed as a
“checkpoint” regulating the type of immune response. Data reveal that expres-
sion of Notch ligands by antigen-presenting cells is an important immune re-
sponse specifying mechanism and that ligand-specifıc Notch signaling could be
a valuable therapeutic target. Reagents for the pharmacological modulation of
immune responses based on Notch ligand constructs is proposed. Our cell-
based study showed that pharmacological activation of Notch ligands required
multivalent receptor-ligand interaction, whereas soluble ligands acted as com-
petitive Notch inhibitors. We have generated reagents that comprise specifıc
domains of the DLL1 in multivalent or monovalent form. Therapeutic inhibi-
tion of Notch by monovalent DLL1-based reagent accelerated LLC tumor
growth and attenuated T cell-mediated anti-tumor immune response. In a heart
transplantation mouse model, monovalent DLL1 reagent signifıcantly pro-
longed allograft survival by inhibiting Th1 effector and memory T cell differen-
tiation. Multivalent forms of DLL1 effectively stimulated Notch signaling in T
cell cultures and enhanced IFN production, whereas monovalent reagent had
opposite effects. Pharmacological up-regulation of DLL1-mediated Notch sig-
naling with multivalent forms of ligand represents an effıcient strategy for the
enhancement of anti-tumor immunity and targeting multiple mechanisms of
tumor growth. Monovalent DLL1 forms could be utilized for therapeutic inhi-
bition of Th1 responses in autoimmune diseases and organ transplantation.
Reagents based on the mono- and multivalent forms of Notch ligands can be
effıciently utilized for therapeutic modulation of Notch signaling.
#1625 NGS reveals specimen characteristics have minimal impact on im-
mune gene expression signature. Jeffrey Conroy,1 Sean Glenn,1 Blake Bur-
gher,1 Sarabjot Pabla,1 Maochun Qin,1 Jon Andreas,1 Vincent Giamo,1 Marc
Ernstoff,2 Mary Nesline,1 Ji He,1 Mark Gardner,1 Carl Morrison1. 1OmniSeq,
LLC, NY; 2Roswell Park Cancer Institute, NY.
Background: Therapeutic antibodies targeting immune checkpoint mole-
cules have been approved by the FDA for the treatment of several types of cancer.
Currently, evaluation of the tumor checkpoint blockade is limited to FDA-ap-
proved IHC assays measuring PD-L1 ligand status which is subjective and not
analytically robust. As the number of antibodies targeting immune checkpoints
expands, assays that can evaluate additional biomarkers in tumor specimens are
needed to accurately predict patient response to these drugs. To address these
issues, a custom immune response NGS assay was developed to measure the
transcript level of 54 genes involving T-cell receptor signaling (TCRS) and tu-
mor infıltrating lymphocytes (TILs) in solid tumors of various characteristics
including heterogeneity, disease, biopsy type and age. As part of the study, we
evaluated the impact these variable have on the immune gene expression signa-
ture and their role as possible assay interferents.Methods: Studies were designed
to evaluate the analytical performance of a targeted RNA-seq assay for FFPE
samples fromNSCLC,melanoma, RCC,HNSCC, kidney andbladder cancer. To
assess degree of assay tolerance to thewide range of specimen characteristics that
are inherent in tumors, samples and mixed samples of various histopathologic
characteristics were included. PCA and unsupervised clustering was performed
on samples with checkpoint inhibition, TCRS and TILs genes to reveal sample
groups with three distinct immune signatures (low, indeterminate and high).
Further correlation and over-representation analysis was performed to deter-
mine impact of specimen characteristics on these three immune signatures.
Results: Immune signatures were maintained for the majority of characteristics
studied within a specifıed range. As expected, only TIL status was signifıcantly
associated with the high expression group. Other factors including architecture,
neoplastic content, percent necrosis, stroma quality/quantity, T-Path, PMR,
specimen type, tissue amount and specimen age were not over-represented in
any immune signature. Conclusion: Tumor samples harbor a mixture of poten-
tial assay interferents including variable benign, neoplastic and immune cells
populations with both naïve and reactive stroma contributing to a complex
tumormicroenvironment that is diffıcult to catalogue prior to testing.Our study
demonstrates that the immune signature present in the tumor microenviron-
ment is suffıciently strong to withstand a wide range of tumor heterogeneity,
thereby reducing the need of extensive tissuemacrodissection and the exclusion
of samples previously thought to be non-evaluable.
#1626 Technical variability in NGS immune gene expression and muta-
tion profıling has a nominal effect on tumor classifıcation. Sean Glenn,1 Jef-
frey Conroy,1 Blake Burgher,1 Sarabjot Pabla,1 Maochun Qin,1 Jon Andreas,1
Vincent Giamo,1 Marc Ernstoff,2 Mary Nesline,1 Ji He,1 Mark Gardner,1 Carl
Morrison1. 1OmniSeq, LLC, Buffalo, NY; 2Roswell Park Cancer Institute, Buffalo,
NY.
Background: A custom NGS cancer immune gene expression assay was de-
veloped which measures the transcript level of 350 genes involved in T-cell
receptor signaling (TCRS), tumor infıltrating lymphocyte (TILs) complement as
well as other key targets expected to predict the likelihood of patient response to
checkpoint inhibitors (CPI). In parallel to the gene expression assay, mutational
profıling was carried out using the 409 gene Comprehensive Cancer Panel
(ThermoFisher). As variability between runs is commonwhen performingNGS
assays a detailed comparison of specifıc technical variations were assessed for
their ability to effect gene expression and mutation profıles of clinical FFPE
samples. Methods: Studies were designed to characterize the analytical perfor-
mance of the immune responseNGS assay usingRNAandDNA froma subset of
300 FFPE tissues representing NSCLC, melanoma, renal cell carcinoma and
bladder cancer. As part of the study, we tested the impact of variability in RNA
andDNA input quantity at the library preparation step, sample batch size which
affects mapped reads/sample and depth of coverage, and linearity of expression
and sensitivity ofmutation profıling through serial dilutions of pico-molar (pM)
input of normalized library. PCAandunsupervised clusteringwas performedon
samples with checkpoint inhibition, TCRS and TILs genes as well as mutational
profıling to reveal sample groups with three distinct immune signatures (low,
indeterminate and high). Further correlation and over-representation analysis
was performed to determine impact of technical characteristics on these three
immune signatures. Results: Immune signatures including mutation profıles
and gene expression levels were maintained throughout variable RNA/DNA
input amounts at the library generation level as well as with diminution of pM
levels of library pooled at the sequencing step. Increase in the number ofmapped
reads and sequencing depth through decreasing the number of batched samples
per sequencing run also did not affect the gene expression and mutation profıle
signatures of the FFPE derived samples. Conclusion: The gene expression and
mutation profıles responsible for classifying FFPE samples using NGS are not
affected by variation normally introduced in the technical workflow commonly
associatedwith these platforms. The analytical assessment of input at the nucleic
acid, library, and sample size level has shown the plasticity available when using
amplicon based NGS technologies for classifying the immune gene expression
signature as well as mutational profıles of FFPE derived clinical tumor samples.
This flexibility increases the strength and utility of NGS-base gene expression
profıling and mutational analysis of tumor samples for both basic research and
clinical applications.
#1627 Enhancement of anti-cancer immunity by OMX, a novel oxygen
carrier immunotherapeutic that ameliorates the hypoxic tumor microenvi-
ronment. Kevin G. Leong, Yuqiong Pan, Jonathan A.Winger, Stephen P. Cary,
Natacha Le Moan, Ana Krtolica. Omniox, Inc., San Carlos, CA.
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Hypoxia is a hallmark of cancer and a driver of tumor progression and poor
patient outcomes. By generating an immunosuppressive tumor microenviron-
ment that limits cytotoxic T lymphocyte (CTL) infıltration and activation, hyp-
oxia limits the effectiveness of cancer immunotherapy and thus promotes tumor
cell evasion of the host immune response. Omniox has developed a fırst-in-class
anti-cancer immunotherapeutic, OMX, specifıcally designed to reverse tumor
hypoxia to enhance cancer immunotherapy effıcacy. In preclinical models, we
have demonstrated that OMX accumulates in rodent subcutaneous and ortho-
topic tumors, as well as spontaneous canine melanomas and brain tumors, re-
sulting in signifıcant tumor hypoxia reduction.Here, using multiple subcutane-
ous syngeneic mouse tumor models (MC38, CT26, 4T1), we assessed OMX
effects on intratumoral CTLs and immunosuppressive regulatory T cells (Treg),
as well as the anti-tumor potential of OMX as a single agent and in combination
with established immunotherapies. Using quantitative immunohistochemistry,
we confırmed reports that hypoxic tumor areas are devoid ofCTLs.Accordingly,
by flow cytometry we observed a negative correlation between tumor hypoxia
and CTL infıltration.While OMX single agent treatment did not affect the over-
all CD45-positive leukocyte population, Treg cells were selectively depleted and
the CTL:Treg ratio was substantially increased, suggesting that OMX induced a
shift towards immunosensitization. Consistent with this fınding, we observed
OMX single agent anti-tumor effıcacy in MC38 colon tumors. Impressively,
anti-tumor effects of OMX single agent were equivalent to that of a single treat-
ment of the checkpoint inhibitor anti-CTLA4. We next assessed whether OMX
would enhance the effıcacy of checkpoint inhibitors when used in combination.
In CT26 colon tumors, OMX exhibited combination anti-tumor activity with
anti-CTLA4, giving rise to faster cures and a greater number of complete and
durable responders compared to anti-CTLA4 alone. Of note, this enhanced
response was observed for both early-stage and late-stage CT26 tumors. In 4T1
breast tumors, known to be insensitive to checkpoint inhibitors, treatment of
early-stage (60 mm3) tumors with combination OMX and anti-PD1 resulted
in a 27% response rate, compared to a 0% response rate to anti-PD1 alone. Taken
together, our data suggest that OMX, by delivering oxygen to hypoxic tumor
areas, induces amicroenvironmental change from an immunosuppressive to an
immunopermissive state. Given that OMX is well-tolerated in both small and
large animals, and that its mechanism of action is upstream of numerous major
immunosuppressive pathways, OMX holds great clinical potential to synergize
withmultiple immunotherapeutic agents to enhance tumor control by restoring
anti-cancer immune responses in cancer patients.
#1628 Early events in metastatic spread: new approaches using targeted
therapeutics to disrupt formation of the pre-metastatic niche and develop-
ment of lung metastases. Khalid A. Mohamedali, Lawrence H. Cheung, Mi-
chael G. Rosenblum. UTMD Anderson Cancer Ctr., Houston, TX.
Solid tumors release soluble factors causing migration of a subset of normal
bone marrow derived cells (BMDCs) - primarily VEGFR-1 hematopoietic
progenitor cells and VEGFR-2 circulating endothelial progenitor cells - from
the bone marrow to organ sites. These normal BMDCs self-assemble into a
pre-metastatic niche- amicro-environment eventually hostingmigratory tumor
cells from the primary site. Disruption of this niche or selective targeting the
migratory tumor cells may inhibit metastatic spread. The signifıcance and spe-
cifıc characteristics of the BMDCs is still unclear. We have previously observed
migration of VEGFR-1 BMDCs to the lung and lymph nodes, and VEGFR-2
BMDCs to liver, lung and lymph nodes. Using GFP BMDC’s from genetically
engineeredmice, we characterized the role that recruitment of BMDCsmay play
in breast cancer metastasis. We assessed the BMDC recruitment profıle in le-
thally irradiated female nu/nu mice transplanted with GFP BMDCs from do-
nor mice, followed by orthotopic placement of MDA-MB-231/luc cells or in-
jected with MDA-MB-231/luc conditioned media for 30 days. Flow cytometry
results show a gradual increase in the recruitment of CD11bVEGFR-1 cells in
all the tissues examined from tumor-bearing mice. Recruitment of these cells to
the liver in mice treated only with MDA-MB-231/Luc conditioned media was
also apparent, but the increase was not as high as in livers of mice with the
orthotopically-placed tumors. Recruitment of CD11bVEGFR-2 BMDCswas
also observed but only in liver and lung. Interestingly, conditioned media
seemed to recruit this subset of cells more strongly to these two tissues than
signaling from orthotopic tumors. Spleen and lymph node showed minimal
recruitment of CD11bVEGFR-2 BMDCs.We have previously developed the
GrB/VEGF fusion construct- a novel pro-apoptotic fusion protein which spe-
cifıcally targets cells harboring VEGFR2 and have utilized this agent to specifı-
cally target BMDCs which are VEGFR2 . Our preliminary data indicate that
treatment with GrB/VEGF does not signifıcantly alter the recruitment of
VEGFR-1 orVEFGR-2 cells to lungs, when assessed twoweeks after the fınal
treatment. We observed increased recruitment of F4/80 macrophages to the
lung. On the other hand, CD11bGr-1- BMDCs were signifıcantly reduced
following GrB/VEGF treatment, although the F4/80 subpopulation carrying
this signature increased. Studies are ongoing to determine whether systemic
administration of this agent can disrupt the formation of the niche and the
eventual establishment ofmetastatic tumors. Understanding the role of BMDCs
inmetastatic spread and the formation of the pre-metastatic niche and their role
in the early development of metastasis will be critical in designing targeted ther-
apeutic approaches to inhibit the metastatic process. Research sponsored, in
part, by the Clayton Foundation for Research.
#1629 An integrated view of Notch signaling that regulates tissue renewal
in response to enteric infection. Badal C. Roy,1 Ishfaq Ahmed,1 Audrey Sea-
mons,2 Shrikant Anant,1 Lillian Maggio-Price,2 Seth Septer,3 Shahid Umar1.
1Kansas University Medical Center, Kansas City, KS; 2University of Washington,
Seattle, WA; 3Children’s Mercy Hospital, Kansas City, MO.
Background: Microbial dysbiosis and the associated gut inflammation unbal-
ances epithelial renewal, potentially leading to cancer which is increasingly be-
ing recognized as a stem cell disease. Notch signaling is active in multipotent
intestinal stem cells (ISCs); yet, how Notch signaling orchestrates communica-
tion between the gut microbes and ISC-dependent tissue renewal following a
pathogenic insult, is poorly understood. Aim: To investigate how Notch signal-
ing contributes towards ISC regeneration and pathogenesis of infection. Meth-
odology: Rag-1/mice andwild type littermateswere infectedwithCitrobacter
rodentium (CR; 108CFUs) and treated with Notch blocker Dibenzazepine
[(DBZ), ip at 10 mol/kg body weight]. Whole distal colon or purifıed crypts
were isolated for analyses. Fecal 16S rDNA analysis was performed. Transgenic
mice expressingMHC-II either in IEC (EpithTg) or in dendritic cells (CD11cTg)
were crossed to Rag2/ mice and received Helicobacter bilis (Hb) to induce
colitis. De-identifıed sections from control or Crohn’s Disease (CD) and Ulcer-
ative Colitis (UC) patients were stained for markers of ISCs and immune cells,
respectively. Results: Rag-1/mice but notWT littermates, exhibited dramatic
increases inDclk1 (Doublecortin-like kinase 1; an ISCmarker) expression in the
colonic crypts, measured via flow cytometry and IHC at 12-days post CR-infec-
tion that co-localized with Notch Intracellular Domain (NICD). CR-infected
mice when treated with DBZ for 10 days exhibited: i) signifıcant dysbiosis with
Proteobacteria dominating (48% compared to 27% after CR infection), ii) in-
creases in paracellular permeability concomitant with almost complete attenu-
ation ofDclk1 expression and, iii) exacerbation of inflammation/colitis. Intrigu-
ingly, Dclk1 immunoreactivity shifted towards the stroma wherein, Dclk1 co-
localized with NICD and with CD11c dendritic cells, CD11b;F4/80
macrophages andMHCII. Both EpithTg/Rag2/ andCD11cTg/Rag2/mice
when infected with Hb compared to uninfected mice, exhibited loss of crypt
Dclk1 and its co-localization with NICD that coincided with severity of colitis.
Sections prepared from the colons of Crohn’s Disease (CD) or Ulcerative Colitis
(UC) patients paralleled loss of crypt Dclk1 seen in mice while Dclk1 continued
to co-localize with NICD and with markers of immune cells within the stroma.
When CR infected and DBZ-treated Rag-1/ mice were given a cocktail of
antibiotics (500mg/l Vancomycin, 1g/l metronidazole and 0.2 g/l ciprofloxacin)
for 7 days, we observed increased survival and decreases in colon myeloperoxi-
dase activity that coincided with an elevated Dclk1 levels in the crypt. Conclu-
sions: 1. Bacterial dysbiosis following chronic Notch inhibition coupled with
loss of crypt Dclk1 impairs crypt regeneration. 2. Co-localization of stromal
Dclk1 with markers of immune cells and with MHCII, suggests a novel role for
Dclk1 in antigen presentation.
#1630 Modulation of the neuroblastoma microenvironment via poly-
amine blockade. Adriana D. Benavides, Annette Vu, Gabrielle M. Ferry, Mi-
chael D. Hogarty, Hamid Bassiri. Children’s Hospital of Philadelphia, Philadel-
phia, PA.
Despite improvements in therapy over the last few decades, neuroblastoma
(NB) still accounts for a considerable portion of childhood cancer-related mor-
talities and 5-year survival rates in patients with high-risk disease remains poor
(40-50%). Amplifıcation of MYCN and dysregulation in downstream Myc-re-
lated pathways result in NBs with high-risk features. Notably, MYCN-amplifıed
NBs have elevated polyamine (PA) levels, and the gate-keeper enzyme in the PA
synthesis pathway, ornithine decarboxylase (ODC1), is a direct target of Myc.
Yet, ODC1 activity can be irreversibly inhibited by the FDA-approved drug
difluoromethylornithine (DFMO), and exposure of NB cell lines in vitro to
DFMO reduces cellular growth. In a mouse model of MYCN-driven NB (TH-
MYCN/ transgenic mice), inhibition of PA synthesis with DFMO led to re-
ductions in NB burden and extension of survival that appeared more profound
than that predicted by the in vitro activity of the drug, suggesting that in addition
to tumor-intrinsic effects, DFMOmay have signifıcant effects on the NB tumor
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microenvironment (TME). We therefore sought to characterize the tumor mi-
croenvironment of NB in TH-MYCN/ mice in the presence or absence of
DFMO-mediated PA blockade. Tumors from DFMO treated and untreated
mice were dissected, mechanically and enzymatically dissociated, and the num-
ber and frequencies of variousTIL subsetswere assessed using an optimized flow
cytometry-based protocol. Our results indicate that DFMO reduces tumor
growth and results in distinct and reproducible alterations in the cellular com-
position of the NB TME, the most profound of which was a signifıcant increase
in the frequency of NK cells. Moreover, we found an increase in the percentage
of tumor cells expressing NK cell ligands. Concordantly, we also witnessed a
shift in the NK cell expression of activating and inhibitory receptors. These
fındings are consistent with the hypothesis that PA blockade induces distinct
TME changes that predispose to more effıcient immune control of NB
growth. To probe the contribution of NK cells to this process, we are now
testing whether antibody-mediated depletion of NK cells in DFMO-treated
TH-MYCN/ mice results in loss of the extension in survival afforded by
PA blockade. In parallel, we are also performing transcriptomic analysis on
tumor and NK cells sorted from DFMO-treated and untreated tumors, to
ascertain whether specifıc signaling pathways may be being altered by expo-
sure to DFMO. It is our hope that these studies will complement the data
being accrued from phase I/II clinical studies using DFMO in various ther-
apeutic strategies for NB, and will allow for an increased understanding of
how to more effectively combine PA blockade with other immunotherapies
for this disease.
#1631 Sequencing the circulating and infıltrating T-cell repertoire on the
Ion S5TM. Geoffrey Lowman,1 Elizabeth Linch,1 Lauren Miller,1 Denise Topa-
cio-Hall,1 Timothy Looney,2 Alex Pankov,2 Yongming Sun,2 Xinzhan Peng,1
Mark Andersen,1 Fiona Hyland,2 Ann Mongan1. 1ThermoFisher Scientifıc,
Carlsbad, CA; 2ThermoFisher Scientifıc, South San Francisco, CA.
T-cell repertoire (TCR) sequencing by next-generation sequencing (NGS) is a
valuable tool for building a deeper understanding of the adaptive immune sys-
tem. As immunotherapies, particularly T-cell dependent therapies, show in-
creasing potential in treating cancer, the ability to gain a detailed, unbiased view
of the TCR becomes imperative for biomarker discovery, immune response to
treatment, and study of tumor microenvironments. A key question the fıeld
seeks to understand is the relationship between circulating T-cells and infıltrat-
ing T-cells at the tumor site. Here, we present a novel approach for TCR se-
quencing using the Ion S5TM sequencer which leverages simplifıed library con-
struction workflows and offers a more complete characterization of the entire
V(D)J region of TCR. This method can leverage mRNA as input, minimizing
requirements in startingmaterials and focusing sequencing to productive TCR
arrangements. This approach targets the constant (C) and the FR1 regions,min-
imizing the potential for primer bias and greatly increasing the phylogenetic
information content compared to techniques that exclusively characterize the
CDR3 domain. Our results show that the observed circulating T-cell repertoire
size is approximately 2 orders of magnitude higher than the infıltrating T-cell
repertoire. Accordingly, while it is diffıcult to fully capture the complete reper-
toire of circulating T-cells due to its vast diversity, we show that it is possible to
reliably capture the complete infıltrating T-cell repertoire with as high as 10
samples on the Ion 530TM chip. Replicate sequencing runs of infıltrating T-cells
offers correlation of0.9, indicating that the results were reproducible, and the
samples were sequenced to appropriate depth. In summary, we believe that this
workflow will allow researchers to more routinely characterize the infıltrating
T-cell repertoire and offers the fıeld a better understanding of the impact of
repertoire diversity on tumor elimination.
#1632 Identifıcation and analysis of EGLN3 as tumor-associated peptide
in ccRCC.Anna Reustle,1MorenoDiMarco,2 Florian Büttner,1 StefanWinter,1
Daniel Kowalewski,2 Linus Backert,2 Steffen Rausch,3 Joerg Hennenlotter,3
Marcus Scharpf,4 Falko Fend,4 Arnulf Stenzl,3 Jens Bedke,3 Matthias Schwab,1
Elke Schaeffeler1. 1Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacol-
ogy andUniversity of Tuebingen, Stuttgart/Tuebingen, Germany; 2Department of
Immunology, University of Tuebingen, Tuebingen, Germany; 3Department of
Urology, University Hospital Tuebingen, Tuebingen, Germany; 4Institute of Pa-
thology and Neuropathology, University Hospital Tuebingen, Tuebingen, Ger-
many.
Introduction: Kidney cancer is the 12th most common cancer world-wide
with 338.000 newly diagnosed cases in 2012, according to the World Cancer
Research Fund International. With around 70-80%, clear cell renal cell carcino-
mas (ccRCC) make up the vast majority of kidney cancers. Advanced and met-
astatic ccRCCs are marked by poor survival rates despite the availability of tar-
geted therapies. Currently several immunotherapeutic approaches, including
checkpoint-blocking antibodies and dendritic cell vaccines are undergoing clin-
ical investigations. In this study we identifıed tumor-associated peptides which
could be used in cancer vaccines to improve treatment of patients with advanced
ccRCC. Methods: To identify suitable peptides for cancer vaccines we set up a
tissue collection of paired tumors and normal kidney tissues from 60 ccRCC
patients. From these tissues, HLA molecules were isolated by affınity chroma-
tography and bound peptides analyzed by mass spectrometry. HLA ligand pro-
fıles of tissues excised from various organ sites of non-ccRCCpatients were used
to complement the data. Based on these analyses, Egl nine homolog 3 (EGLN3)
was selected as a candidate for peptide vaccination and further investigated in
our own data cohort comprising the 60 ccRCC patients. Therefore, mRNA and
protein expression, as well as DNA methylation data were collected and corre-
lated with HLA ligandomics and clinical data. In addition, we integrated RNA-
Seq, DNA methylation, somatic mutation and clinical data from a ccRCC pa-
tient cohort from The Cancer Genome Atlas in our analyses. Finally, EGLN3
function was analyzed in 2D and 3D kidney carcinoma cell culture systems.
Results: 16 different peptides fromEGLN3were detected in 32 of the 60 analyzed
tumor samples, with the most frequent peptide found in tumors of 10 different
patients. Only two of the peptides were also detected in normal kidney or other
non-ccRCC tissues, rendering EGLN3 peptides promising candidates to be used
in ccRCC-directed vaccines. Most of our patients were HLA A*02:01 positive,
however using NetMHCpan (http://www.cbs.dtu.dk/services/NetMHCpan/)
only one of the peptides identifıed by HLA ligandomics was also predicted to be
a strong binder for that particular HLAmolecule. Expression of EGLN3mRNA
was not different in patients with and without HLA-presented peptides. Gener-
ally, EGLN3 mRNA expression was strongly induced in ccRCC tumors com-
pared to normal kidney (p10-6), whereas protein levels remained mainly un-
changed inmost patients. Functional investigations in different RCC cell culture
models indicated involvement of EGLN3 in regulation of apoptosis and cell
cycle progression. Conclusion: Advanced ccRCC is marked by poor survival
rates due to ineffective therapeutic options. Peptides from EGLN3, as well as
other ccRCC-exclusive peptides could represent activators of the immune sys-
tem to specifıcally fıght ccRCC tumors. The function and targetability of EGLN3
remains to be investigated.
#1633 Immunotherapy for malignant mesothelioma that combines a me-
sothelia-targeted immune-activating protein and CXCL12/CXCR4 block-
ade. Huabiao Chen, Binghao Li, Yang Zeng, Patrick Reeves, Qiuyan Liu, Ann
Sluder, Jeffrey Gelfand, Timothy Brauns, Mark Poznansky.Massachusetts Gen-
eral Hospital, Charlestown, MA.
Background and Purpose: There is a signifıcant unmet need for new treat-
ment strategies for malignant mesothelioma (MM). Despite relevant advances
in many cancer treatment areas, including improvements in diagnosis, staging,
and the clinical course of treated patients, MM remains a highly lethal disease.
The purpose of this study is to develop a combination immunotherapy forMM,
which involves a fusion protein to target and evoke a cellualr immune response
to mesothelin (MSLN) and the blockade of CXCL12/CXCR4 pathway to mobi-
lize cytotoxic effector cells into tumors. Experimental Procedures: The effıcacy
of the MSLN targeted immune activating fusion protein (scFv-MtbHsp70),
FDA-approved small molecule CXCR4 antagonist AMD3100 (plerixafor), and
the combinationwere evaluated in two syngeneic andorthotopicmurinemodels
of MM in immune competent C57BL/6 mice. Mice received 4 intraperitoneal
(i.p.) treatments from 7 days post i.p. injection of luciferase-expressing 40L and
AE17 cells. Tumor growth wasmonitored by in vivo imaging of luciferase activ-
ity with an IVIS Spectrum. Survival time was calculated as life span from the day
of tumor inoculation. In immunological studies, mice were sacrifıced 4 weeks
after tumor cell inoculation. Immune cells from spleens and tumorswere labeled
with antibodies against CD3, CD4, CD8, CD25 and Foxp3 antibodies, and ex-
amined by flow cytometry. Splenocytes were stimulated with MSLN and as-
sessed for intracellular IFN- production by flow cytometry. Results: In both
murinemesotheliomamodels, the fusion protein scFv-MtbHsp70 alone delayed
tumor growth and prolonged mouse survival, which was associated with in-
creased tumor infıltration by CD3CD8 T cells. Treatment enhanced the
cytotoxic function of tumor-specifıc CD3CD8 T cells by evoking dendritic
cell activation as well as antigen presentation and cross presentation. AMD3100
alone reduced the proportion ofCD4CD25Foxp3Treg cells in tumors and
decreased PD-1 expression on CD3CD8 T cells. The combination of the
fusion protein and AMD3100 further signifıcantly slowed tumor growth and
enhanced mouse survival while augmenting tumor-specifıc CD8 T-cell im-
mune responses and abrogating intratumoral immunosuppression.Conclusion:
Our fındings demonstrated for the fırst time the synergistic effect of combina-
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tion of MSLN-targeted immune-activating fusion protein scFv-MtbHsp70 and
AMD3100 in treatment ofMM inmice. This is a new therapeutic strategy which
may signifıcantly prolong survival of patients with this disease.
#1634 CDK4/6 inhibition directly enhances an anti-tumor immune re-
sponse in breast cancer. Molly J. DeCristo*,1 Shom Goel*,2 April C. Watt,2
Haley BrinJones,2 Jaclyn Sceneay,1 Ben Li,2 Jessalyn M. Ubellacker,1 Shaozhen
Xie,2 Susanne Ramm,3 Hye-Jung Kim,2 Sandra S. McAllister,1 Jean J. Zhao2.
1Brigham and Women’s Hospital, Boston, MA; 2Dana-Farber Cancer Institute,
Boston, MA; 3Harvard Medical School, Boston, MA.
The cyclin D:cyclin-dependent kinases 4 and 6 (CDK4/6) axis is one of the
most frequently dysregulated pathways in human cancers, and CDK4/6 inhibi-
tors have shown signifıcant activity against a number of solid tumors, including
breast cancer. Analogous to clinical experience, we found that the CDK4/6 in-
hibitor, abemaciclib, caused signifıcant tumor regression in the MMTV-rtTA/
tetO-HER2mouse model of luminal breast cancer. However, as CDK4/6 inhib-
itors are known to block tumor cell proliferation, but not directly induce tumor
cell apoptosis, as we confırmed in our study, the mechanisms by which CDK4/6
inhibition caused tumor regressionwere not clear. Notably, abemaciclib therapy
increased total CD3T cells in these tumors, while decreasing the immunosup-
pressive CD4 regulatory T cell population. Further investigation revealed that
CDK4/6 inhibition directly suppresses regulatory T cells by inhibiting their pro-
liferation without impacting natural regulatory T cell formation in the thymus,
the differentiation of inducible regulatory T cells, or regulatory T cell apoptosis.
We are currently exploring potential effects of CDK4/6 inhibition on regulatory
T cell function and lineage stability. Analysis of CD8 and CD4 T cells in
abemaciclib-treated tumors revealed amarked reduction in the expression of the
inhibitory immune checkpoint receptors PD-1, Tim-3, CTLA-4, and LAG3.
Specifıcally, the fraction of CD8 T cells expressing known markers of T cell
exhaustion (PD-1/Tim-3 double-positivity or high expression of PD-1) was de-
creased in abemaciclib-treated tumors. Importantly, antibody-mediated deple-
tion of CD8 T cells established that response of MMTV-rtTA/tetO-HER2
tumors to abemaciclib is dependent on CD8 T cells. Finally, given the ob-
served immunomodulatory effects of abemaciclib, we sought to determine if
abemaciclib treatment would sensitize MMTV-rtTA/tetO-HER2 tumors to im-
mune checkpoint blockade. Pretreatment with abemaciclib followed by combi-
nation abemaciclib and -PDL1 signifıcantly enhanced tumor regression com-
pared to abemaciclib or-PDL1 alone. Our studies reveal a novelmechanism by
which CDK4/6 inhibitors directly elicit an anti-tumor immune response. These
results provide strong rationale for further investigations into combining
CDK4/6 inhibitors with immune checkpoint blockade in breast cancer.
#1635 Multiplexed analysis of fıxed tumor tissues using imaging mass
cytometry. Franz Villarroel-Espindola,1 Daniel Carvajal-Hausdorf,1 Ila Datar,1
Amanda Esch,2 Narges Rashidi,2 Ala Nassar,1 Shelly Ren,1 Ruth R. Montgom-
ery,1 Roy S. Herbst,1 David L. Rimm,1 Kurt A. Schalper1. 1Yale University, New
Haven, CT; 2Fluidigm, San Francisco, CA.
Introduction: Comprehensive evaluation of the tumor microenvironment
with preservation of spatial context requires simultaneous in situ detection of
multiple targets. Current fluorescence-based methods can accommodate up to
5-6 distinct markers and can be applied to formalin fıxed, paraffın embedded
tissue (FFPE). Imaging mass cytometry uses metal-conjugated antibodies and
mass spectrometry to perform highly multiparametric, quantitative measure-
ment of protein targets within tissue sections providing unprecedented detail of
quantitative tissue labeling. To date, the IMC technology has not been widely
available and its performance has not yet been compared with other validated
methods. Methods: Using multiplexed quantitative immunofluorescence (QIF,
AQUA/Genoptix) and imaging mass cytometry (IMC, Fluidigm) we validated
and optimized metal-conjugated assays to detect HER2 (29D8-CST, 176Yb),
CD3 (DAKO, 170Er), Ki-67 (B56-BD biosciences, 168Er), Histone H3 (D1H2-
CST, 176Yb), pancytokeratin (C11-Biorad, 162Dy), Vimentin (RV202-BD
Pharmingen, 156Gd), LipoR (Fluidigm, 115In) and DNA/nuclei (DNA interca-
lator, Fluidigm, 191/193Ir). The markers were applied to FFPE samples from
tumor cell lines, human tonsil, lymph node; and breast and lung carcinomas
represented in tissuemicroarray format. Data was visualized usingMCD viewer
and ImageJ software and results from QIF and IMC were compared. Results:
Metal conjugation did not affect the performance of the primary antibodies
studied here. The staining patterns of the epithelial/tumor and stromal compart-
ments evaluated using the IMC platform and QIF were comparable. HER2 sig-
nal was higher in tumors and cell lines harboring HER2 amplifıcation by FISH/
IHC. The CD3 signal was higher in T-cell lymphoma cells and in the inter-
follicular areas of human tonsil and lymph nodes. Ki-67 signal was nuclear,
co-localized with Histone H3 and showed positivity in lymphoid germinal cen-
ters, cytokeratin-positive carcinoma cells andCD3 tumor infıltrating lympho-
cytes. Results obtained using the IMC at different time points in serial tissue
sectionswere comparable (P0.05). Conclusion:Quantitative and reproducible
measurement of immune and non-immune targets with spatial resolution using
the IMC platform is feasible in FFPE breast and lung carcinomas and the results
are comparable to multiplexed QIF. Expansion of the current panel to include
30 markers for immune cell phenotypes/function and tumor markers is on-
going.
#1636 Increased expression of programmed death-ligand 1 (PD-L1) on
infıltrating immune cells of hepatocellular carcinoma (HCC) tissues after
sorafenib treatment. Li-Chun Lu,1 Yi-Hsuan Lee,1 Chun-Jung Chang,2 Yu-
Yun Shao,1 Tsung-hao Liu,3 Ann-Lii Cheng,1 Chih-Hung Hsu1. 1National Tai-
wan Univ. Hospital, Taipei, Taiwan; 2National Taiwan University, Taipei, Tai-
wan; 3National Taiwan Univ. Hospital Hsin-chu Branch, Hsin-chu, Taiwan.
Background: PD-L1 expression in tumor microenvironment of HCC was
reported to associate with tumor aggressiveness and recurrence. The impact of
sorafenib treatment on PD-L1 expression on tumor cells (TC) or tumor-infıl-
trating immune cells (IC) of HCC has been unclear. Patients and Methods: We
reviewedpatientswithHCCwhohad received sorafenib for advanceddiseases at
National TaiwanUniversityHospital, Taipei, Taiwan. Patients with pairedHCC
tissues, obtained before and after sorafenib treatment, were included. Immuno-
histochemistry (IHC) assay with clone SP142 antibody (Spring Bioscience,
Pleasanton, CA, USA) was performed to analyze PD-L1 expression on TC and
IC in paired specimens obtained before and after sorafenib. PD-L1 expression
was scored as IHC 0, 1, 2, or 3 if1%,
1% but5%,
5% but10%, or
10%
of cells were PD-L1 positive, respectively. Further IHC assay was employed to
characterize the PD-L1-positive IC. Associations between the PD-L1 expression
and overall survival (OS) or duration of sorafenib treatment of the patients were
analyzed. Results: Twenty-three advanced HCC patients (Male: Female 20: 3,
median age of 64 years) with paired HCC tissues were included. All of the
post-sorafenib HCC tissues were obtained after disease progression. The me-
dian duration of sorafenib treatment was 4.3 months (range: 1.3 to 18.7). The
PD-L1 expression on IC was signifıcantly increased in post-sorafenib HCC tis-
sues, compared with tissues obtained before sorafenib (pre-sorafenib vs post-
sorafenib IHC 0/1/2/3: 10/5/5/3 vs 5/5/2/11, p0.046). However, the PD-L1
expression on TC was not signifıcantly different between pre- and post-
sorafenib tissues (IHC 0/1/2/3: 19/2/0/2 vs 14/5/0/4, p0.065). By using IHC
staining of CD68, CD66b, CD11b, and CD3 on the consecutive slides, we found
the PD-L1-expressing IC were mainly CD68-positive macrophages, but not
neutrophils or T lymphocytes. Neither the PD-L1 expression levels on IC of
pre-sorafenib or those of post-sorafenib tissues were associated with OS or du-
ration of sorafenib treatment. Conclusions: The PD-L1 expression on IC, espe-
cially on macrophages, in tumor microenvironment was signifıcantly increased
in post-sorafenib progression HCC tissues. Whether this increased PD-L1 ex-
pression contributes to treatment failure of sorafenib warrants further investi-
gation (This workwas supported by the grants ofNTUH105-M3232 andMOST
105-2314-B-002-180).
#1637 ICOS agonism induces potent immune activation and anti-tumor
response in non-clinical models. Sapna Yadavilli, Tianqian Zhang, Ashleigh
Hahn, Laura M. Seestaller-Wehr, Hong Shi, Yao-Bin Liu, M.Phillip DeYoung,
David J. Kilian, Meixia Bi, Michael P. Adam, Shu-Yun Zhang, Sabyasachi Bhat-
tacharya, Yuliya Katlinskaya, Christina Blackwell, Christopher B. Hopson, Ni-
ranjan Yanamandra, Roopa Srinivasan, Patrick A. Mayes, Axel Hoos. Glaxo-
smithkline, Collegeville, PA.
Inducible T-cell costimulator (ICOS) is a costimulatory receptor that is up-
regulated on activatedCD4 andCD8T cells and plays an important role in T cell
survival, differentiation, regulation of memory and regulatory T cell pools and
humoral responses. Preclinically, augmenting signaling through the ICOS path-
way has been reported to induce anti-tumor activity and enhance responses to
CTLA4 blockade. Here we present non-clinical data evaluating ICOS agonist
antibody activity in human andmousemodel systems using a different antibody
for each species. GSK3359609 is a novel, selective anti-human ICOS agonist.
GSK3359609 induces ICOS signaling through phosphorylation of intermediates
in the Pi3K pathway leading to lymphocyte activation, proliferation and pro-
inflammatory cytokine secretion in human PBMC in-vitro. A robust increase in
CD4 effector T cell proliferation and Granzyme B secreting CD8 T cells was
observed with GSK3359609 treatment in in-vitro assays utilizing PBMC from
healthy donors, cancer patients or tumor infıltrating lymphocytes (TIL).Modest
induction of regulatory T cell proliferation and IL-10 secretion were also ob-
served. Signifıcant increase in IFN (p0.05) and TNF secretionwas observed
in both primary PBMC and TIL based assays. Gene expression analysis of
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GSK3359609 treated human T cells confırmed changes in genes associated with
T and B cell activation. In mice, an ICOS surrogate antibody was utilized in
immune competent mouse tumor models. Tumor regressions were observed in
10-40% ofmice andwere associated with a robust increase in effectormemory T
cells in periphery as well as increases in T cell activation and proliferation in
lymphoid tissues and tumor. Robust increases in PD1, PD-L1 and PD-L2 gene
expression were observed in the tumors from ICOS antibody treatedmice along
with an increase in cytotoxic T cell signature and induction of an IFN gene
signature. Changes in regulatory T cell proliferation were also observed in the
blood and tumor ofmice treated with themouse ICOS agonist however changes
were consistently less in magnitude than corresponding functional changes in
cytotoxic CD8 and effector CD4 cells. We further explored treatment settings
where a combination therapymay condition the tumor immunemicroenviron-
ment to a more favorable context for ICOS agonist therapy. Treatment with an
anti-PD1 antibody resulted in strong upregulation of ICOS expression on tumor
infıltrating CD8, CD4 effector and regulatory T cells while decreasing ICOS
Tregs relative to CD8 and CD4 effectors in the tumor microenvironment. Syn-
ergistic anti-tumor activity was observed for the combination of PD-1 with
ICOS agonist antibodies in preclinical studies. These studies provide a strong
rationale for the ongoing FTIH Phase I study of GSK3359609 administered
alone and in combination with pembrolizumab to patients with selected ad-
vanced solid tumors.
#1638 Improved outcomes with drug-resistant immunotherapy in a hu-
man xenograft model of glioblastoma multiforme. Samantha B. Langford,1
Harold T. Spencer,2 Anindya Dasgupta,2 George Y. Gillespie,1 Kathryn Sutton,2
Larisa Pereboeva,1 Lawrence S. Lamb1. 1Univ. of Alabama at Birmingham, Bir-
mingham, AL; 2Emory University, Atlanta, GA.
INTRODUCTION: Conventional treatment strategies for high-grade glio-
mas have been uniformly dismal. We have previously shown that both primary
and Temozolomide (TMZ)-resistant glioblastoma (GBM) cell lines upregulate
stress-associated NKG2D ligands (NKG2DL) during the fırst several hours fol-
lowing exposure to TMZ, thereby creating an opportunity for NKG2DL-di-
rected cell therapy, particularly 	 T cells that directly recognize these stress-
associated antigens. Using a human/mouse patient-derived tumor xenograft
(PDTX) model, we combined TMZ chemotherapy and TMZ-resistant ex vivo
expanded/activated 	 T cells as Drug Resistant Immunotherapy (DRI). Drug
resistance in this example is conferred by O-6-methylguanine-DNA-methyl-
transferase (MGMT) gene transfer, thereby enabling cytotoxic lymphocyte
function in a chemotherapy-rich environment when the tumor is maximally
stressed. METHODS: A total of fıve GBM PDTX were examined, three parent
(X12P, X22P, X59P) and two TMZ-resistant (X12T, X22T). Tumor NKG2DL
expression and cytotoxicity of DRI were assessed using flow cytometry with
cultured human astrocytes as controls. Intracranial (IC) glioma xenografts were
established using either an unmodifıed (P) or a TMZ resistant clone (T) of
human GBM explants passaged exclusively in immunodefıcient mice. Tumor-
bearingmice received intraperitoneal 60mg/kg TMZ on days 6, 8,13, and 15 and
received IC injection of 1.5 x 106 DRI 4 hours following TMZ injection. Control
mice receivedDRI T cells alone, TMZ alone or no therapy. Survival was assessed
using Kaplan-Meier analysis. RESULTS: All xenografts were found to constitu-
tionally express NKG2DLwhich were upregulated upon exposure to TMZ. DRI
T cells were cytotoxic to all tumors in vitro, showing 65%-80% specifıc lysis at an
E:T ratio of 20:1 with no evidence of toxicity against cultured human astrocytes.
Median survival (MS) for all groups of untreated mice was approximately 25
days, and 	 T cell therapy alone did not improve survival in the absence of
TMZ. For the parent tumors, TMZ therapy signifıcantly improved MS over
untreated controls for both X12P and X59P (29 vs. 59 days and 20 vs 51 days
respectively, p0.0001) and eliminated tumors in X22P. DRI 	T cellsTMZ
signifıcantly increased median survival additionally over TMZ alone with 80%
of animals in both X12P and X59P surviving long-term (p0.0001 and 0.05
respectively).DRI hadno clear effect overTMZ forX22T (p0.46), however, for
X12T, DRI  TMZ signifıcantly increased median survival from 22 to 38 days
(72.7%) over TMZ alone (p 0.04). CONCLUSIONS: Combined TMZ chemo-
therapy and drug-resistancemodifıed	T cell therapy can produce a signifıcant
increase in time to progression and improvement inmedian and overall survival
for both primary andTMZ-resistantGBMusing a strategy is readily adaptable to
the clinical setting.
#1639 Combination of PD1 blockade and T cell costimulation by bispe-
cifıc antibodies promotes humanT cell activation and proliferation.Gregory
L. Moore, Michael Hedvat, Matthew J. Bernett, Rajat Varma, Suzanne Schub-
bert, Christine Bonzon, Kendra N. Avery, Rumana Rashid, Alex Nisthal, Liz
Bogaert, IreneW. Leung, Seung Y. Chu, Umesh S. Muchhal, John R. Desjarlais.
Xencor, Inc., Monrovia, CA.
Tumor infıltrating lymphocytes (TILs) express multiple checkpoint recep-
tors, in contrast to lymphocytes found in the periphery (Matsuzaki et al PNAS
2010, Fourcade et al Cancer Res 2012, Gros et al JCI 2014). Checkpoint blockade
has demonstrated increased clinical response rates relative to other treatment
options; however, many patients fail to achieve a response to checkpoint block-
ade. We sought to identify an additional therapeutic modality to stack with
checkpoint blockade that could increase patient response rate.We hypothesized
that engagement of T cell costimulatory receptors in combination with check-
point blockade could further increase T cell activation and proliferation. The
combination of checkpoint blockade with costimulation could be accomplished
using a bispecifıc antibody format, with the potential benefıts of reduced cost
and more selective targeting of TILs to improve safety. Antibodies binding to
immune checkpoint PD1 and a T cell costimulatory receptor were assembled in
a bispecifıc antibody platform with substitutions in the Fc domain to suppress
effector function. PD1 x costimulation (PD1 x costim) bispecifıc antibodieswere
evaluated in vitro by measuring antibody binding and de-repression of Staphy-
lococcal enterotoxin B (SEB) stimulated PBMCs. IL2 and IFN production was
measured by immunoassay. In vivo activity was evaluated using a mouse model
in which human PBMCs are engrafted into NSGmice (huPBMC-NSG) and the
extent of T cell engraftment is monitored by flow cytometry. We produced PD1
x costim bispecifıc antibodies that bound PD1 and a T cell costimulatory recep-
tor monovalently. The bispecifıcs bound to SEB-stimulated T cells more tightly
thanmonovalent controls, indicating that a single bispecifıc molecule was capa-
ble of avid simultaneous co-engagement of both PD1 and a costimulatory recep-
tor. The bispecifıcs enhanced IL2 and IFN production in an in vitro SEB stim-
ulation assay relative to control (p  0.001, n  19 donors). IL2 and IFN
production was superior to anti-PD1 or anti-costim antibodies alone (p 
0.001), indicating productive and synergistic combination of checkpoint block-
ade plus costimulation. Treatment of huPBMC-NSG mice with checkpoint
bispecifıcs promoted enhanced T cell engraftment relative to control. Engraft-
ment levels promoted by bispecifıcs were superior to those found for anti-PD1
treatment alone. For example, in one runof themodel, while anti-PD1 treatment
alone promoted a 2-fold increase in human CD45 cells, a PD1 x costim bispe-
cifıc antibody induced a 16-fold increase. Combination of checkpoint blockade
and costimulation with bispecifıc antibodies is feasible and promotes strong T
cell activation in vitro and in vivo. Compelling activity suggests clinical devel-
opment is warranted for the treatment of human malignancies.
#1640 A novel peptide-suppressing M2 polarized tumor-associated mac-
rophages enhances tumor response to chemotherapy. Anghesom A. Ghe-
bremedhin,1 Clayton Yates,1 Jesse Jaynes,1 George Martin,2 Henry Lopez,3
Charles Garvin2. 1Tuskegee Univ., Tuskegee, AL; 2Riptide Biosciences, Inc,
Vallejo, CA; 3Murigenics Inc, Vallejo, CA.
Introduction: Multiple reports have demonstrated that M2-polarized tumor
associated macrophages (TAMs) play a signifıcant role in promoting tumor
metastasis, survival and resistance to chemotherapy. Thus, limiting the pro-
tumorigenic activity of TAMs may hold great therapeutic promise. Objective:
To determine whether targeting the Cluster of Differentiation 206 (CD206)
receptor on TAMs with an engineered peptides having both CD206 specifıcity
and apoptotic activity, will limit the protumorigenic effects of TAMs and en-
hance cancer cells response to chemotherapy. Method: A class of engineered
peptides were designed to stimulate phagocytosis via theCD206 receptor, and to
initiate apopotic cell death once endocytosed. Primary cells were isolated from
C57BL/6J mice from Jackson Laboratory and were polarized to M1 and M2
phenotypes by treating with IL-4 (20ng/ml) and IFN- (10ng/ml) respectively
from R&D Biosciences for 24 hrs. CD206 targeting peptide was biotin-labeled
and utilized to treat M2-polarized cells. Precipitated proteins were analyzed by
mass spectrometry analysis, and informatics software. In vitro proliferation and
confırmation of apoptosis was assessed using Annexin/PI staining andWestern
blot analysis for Caspase 8 expression and activity. In xenograft models of triple
negative breast cancer (MDA-MB-231), mice were treated with CD206 peptide
and gemcitabine, singly or in combination Results: Mass spectrometry analysis
of gel bands from the biotin / streptavidin pull down assay confırmed CD206 as
a cell surface target. Bioinformatics analysis of the proteomics data from the pull
down assay further confırmed that apoptotic proteins were highly expressed in
theM2 populations than in theM1 populations. Treatment with CD206 peptide
produced a signifıcant decrease in cell proliferation only in M2 macrophages.
FACS analysis of Annexin/PI staining and Caspase 8 activity, demonstrated by
Western blot, showed that CD206 targeting peptide caused apoptosis specifı-
cally in M2 macrophages. In xenograft models of triple negative breast cancer
(MDA-MB-231) mice treated with peptide alone (10 mg/kg qD subcu), there
was a 39% reduction in tumor growth; gemcitabine@ 40mg/kg q4D produced a
68% reduction; however, peptide in combination with gemcitabine completely
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blocked tumor growth. Moreover, immunohistochemistry staining of treated
tumors showed a decrease in the expression of CD206 positiveM2macrophages
and CD45/CD25 positive Treg cells, and an increase in CD86 positive M1 mac-
rophages. These results were consistent with the in vitro results obtained. Dis-
cussion and Conclusion: These results suggest that a targeting CD206 peptide
engineered to promote apoptosis, enhances the tumor response to chemother-
apy by limiting the pro-tumorigenic activity of TAMs.
#1641 Dual antibody blockade of TIM3 and PD1 on NYESO1 redirected
human T cells leads to augmented control of lung cancer tumors. Edmund
Moon,1 Soyeon Kim,1 Shaun O’Brien,1 Naomi Saint Jean,1 Raluca Verona,2
Linda Snyder,2 Yangbing Zhao,1 Steven Albelda1. 1Univ. of Pennsylvania, Phil-
adelphia, PA; 2Janssen Research and Development, Springhouse, PA.
Background: Immunotherapy using checkpoint blockade has demonstrated
impressive, durable responses in select patients with solid malignancies. This is
especially true for the blockade of programmed death 1 (PD1). Currently, efforts
are focused on understanding non-response. One hypothesis is that multiple
inhibitory receptors (IRs) are upregulated on hypofunctional tumor-infıltrating
lymphocytes (TILs) and necessitates blocking multiple IRs to increase the re-
sponse rate. We describe data from a unique xenograft model of human lung
cancer where tumor-reactive human T cells become hypofunctional and up-
regulate multiple IRs including PD1 and TIM3 (T cell immunoglobulin and
mucin-domain containing-3). Combining a single IV dose of tumor-reactive T
cells with blockade of both PD1 andTIM3 led to greater control of tumor growth
than combining it with blockade of either alone. Materials/Methods: The A549
human lung cancer cell line was transduced to stably express the cancer-testis
antigen, NYESO1, expressed in the contact of HLA-A2 (A549-A2-ESO). 5x106
A549-A2-ESO cells were injected subcutaneously into the flanks NSG mice.
Activated T cells from healthy donors were lentivirally transduced with a TCR
targeting NYESO1 (Ly95). After two weeks when tumors were established and
measured150 mm3, the mice were randomly assigned to one of the following
treatments: 1) untreated, 2) non-transduced (NTD) T cells plus anti-PD1 and
anti-TIM3 Ab, 3) Ly95 T cells, 4) Ly95 T cells anti-PD1 Ab, 5) Ly95 T cells
anti-TIM3 Ab, 6) Ly95 T cells  anti-PD1 and anti-TIM3 Ab. T cells were
injected IV at a single dose of 10x106/mouse. Abs were injected intraperitonealy
(IP) at 10mg/kg every 5 days from the time of T cell injection. Tumor volumes
weremeasured serially. At the end, themice were sacrifıced and the tumors were
harvested, digested, and processed into single cell suspension. Flow cytometry
was performed to look at degree of TIL infıltration and expression of surface
markers. Ficoll gradient was used to isolate the T cells to conduct functional
analyses. Results/Conclusion: By twenty days post T cell injection, the tumors in
the Ly95 T cell group (3) were30% smaller than that of the untreated (1) and
the NTD T cellAb group (2). Anti-PD1 Ab augmented Ly95 T cell control of
tumor (4) (further decrease in size by30%) (4). Anti-TIM3Abhadno effect on
Ly95 T cell tumor control (5). Anti-PD1 plus anti-TIM3 Abs had the greatest
augmentation on Ly95 T cell control of tumor size (6) (greater than 50% reduc-
tion in tumor size compared Ly95 T cells alone) The greatest TIL infıltration and
ex-vivo TIL function were seen in tumors that received Ly95 T cell anti-PD1
and anti-TIM3 Abs. Flow cytometry analysis revealed dynamic, adaptive up-
regulation of one IRwhen another IRwas blocked. This explainedwhy augmen-
tation of Ly95 T cell control of tumor was greatest with combinatorial Ab block-
ade.
#1642 Evaluation of ENMD-2076 in combinationwith anti-PD1 in synge-
neic cancer models. Graham C. Fletcher,1 Reza Kiarash,1 Mark R. Bray,1
Amanda S. Hu,2 Ken K. Ren2. 1Campbell Institute, Univ. Health Network, To-
ronto, Ontario, Canada; 2CASI Pharmaceuticals, Rockville, MD.
ENMD-2076 is a clinical stage compoundwith potent activity towardsAurora
A and angiogenic kinases. ENMD-2076 has shown promising activity in multi-
ple Phase 1 clinical trials, as well as in a Phase 2 trial in advanced ovarian cancer.
ENMD-2076 is currently the subject of several ongoing Phase 2 clinical trials
including fıbrolamellar carcinoma, triple-negative breast cancer (TNBC), ad-
vanced/metastatic soft tissue sarcoma (STS), and advanced ovarian clear cell
carcinomas (OCCC). ENMD-2076 has been developed to date as a single agent,
however ENMD-2076 inhibits a spectrum of targets including Aurora A, FAK,
CSF1R, c-Kit, and KDR, that are potentially involved in immune evasionmech-
anisms. These kinases have been shown in published studies, when inhibited, to
enhance or augment the activity of immune checkpoint inhibitors such as anti-
PD1. A study was thereby conducted in syngeneic models to determine the
utility of ENMD-2076 combined with immune checkpoint inhibition as a ratio-
nal strategy for cancer therapy. The study evaluated the effıcacy of ENMD-2076
administered daily by oral gavage in the MC38 and CT26 colon cancer models,
alone and in combination with an anti-PD1 antibody. Xenografts were estab-
lished in the appropriatemouse strain (C57BL/6 andBALBc, respectively) by the
subcutaneous inoculation of MC38 or CT26 cells into the right flank of female
mice. Treatment was initiated 7 days following inoculation when tumor vol-
umes had reached amean volumeof approximately 85mm3.All treatmentswere
well tolerated, with no signifıcant body weight loss seen during either study.
While CT26 tumors were relatively refractory to single agent ENMD-2076, tu-
mor regression was observed in several MC38-bearing animals suggesting an
immune activating mechanism. In both models a trend was observed for an
augmentation of anti-tumor response in combination relative to single agent
ENMD-2076 and anti-PD1 alone. Further studies to evaluatemechanism and an
assessment of re-challenge experiments in animals exhibiting complete regres-
sion of tumors will be discussed. These studies support the further evaluation of
ENMD-2076 in combination with immune checkpoint inhibition as a strategy
for cancer therapy.
#1643 Cytotoxic T lymphocyte CD3, CD8, and immunoscore as prog-
nostic marker in patients after radical cystectomy. Jose J. Mansure, Alice Yu,
Shraddha Solanki, Ana B. Dias, Miguel M. Burnier, Fadi Brimo, Wassim Kas-
souf.McGill University Health Center, Montréal, Quebec, Canada.
Purpose: Prognosis after radical cystectomy for bladder cancer can be unpre-
dictable. There is increasing evidence that the presence of cytotoxic T lympho-
cytes correlates with survival. The Immunoscore, a new approach to classifıca-
tion of cancer using the number, type and distribution of immune cells, is an
independent predictor for survival in colon cancer.Our objectivewas to evaluate
the prognostic impact of lymphocyte distribution and the Immnoscore in blad-
der cancer. Methods: Cystectomy sections with core tumor (CT) involvement
and identifıable invasive margin (IM) were selected and stained for CD3 and
CD8 lymphocytes. Three non-contiguous areas of highest lymphocyte density
were selected from both CT and IM. The number of lymphocytes in each area
was used to calculate the Immunoscore based on previously defıned criteria.
Kaplan-Meier curves were used to determine differences between Disease-free
Survival (DFS) and Overall Survival (OS). Multivariate Cox proportional haz-
ards model was used to determine hazard ratios. Results: Total of 67 patients
who had cystectomy for invasive bladder cancer were included in the study.
High concentration of CD8 lymphocytes in the tumourmargin was associated
with better DFS (P0.005) and OS (P0.03). Similar results were found for
CD3 lymphocytes with regards to DFS (P0.05). A higher Immunoscore was
also associated with better DFS (P0.04). Onmultivariate analysis, CD8 in the
invasive margin was independently associated with better prognosis. Conclu-
sions: The host’s own immune system plays a valuable role in clinical outcome.
Our data suggests that a strong immune response in the tumor margin is inde-
pendently associated with better prognosis.
#1644 Combination of MT-3724 with sirolimus reduces anti-drug anti-
body response and prolongs drug exposure. Jack P. Higgins, Garrett L. Robin-
son, Sangeetha Rajagopalan, Brigitte Brieschke, Jensing Liu, Erin K. Willert.
Molecular Templates Inc., Austin, TX.
Molecular Templates is developing engineered toxin bodies (ETBs), potent
recombinant immunotoxins that combine the specifıcity of an antibody frag-
ment with the powerful direct cytotoxicity of the Shiga-like toxin A subunit.
ETBs can induce their own internalization, route through the cell in a predict-
able manner, enzymatically and irreversibly destroy ribosomes to shutdown
protein synthesis and induce apoptosis of tumor cells. Thismechanism of action
is distinct from that of other therapeutics, making ETBs an attractive treatment
for patients who have become resistant to chemotherapy and other treatment
modalities. MT-3724 is Molecular Templates’ fırst-generation ETB targeting
CD20, a surface receptor that is highly expressed on malignant B cells in hema-
tological malignancies. Pre-clinical and clinical studies have shown promising
results for non-Hodgkin’s lymphoma cell lines and patients; however anti-drug
antibodies are formed in experimental animals and patients after repeat dosing.
Sirolimus (rapamycin) is a macrolide compound approved to prevent organ
rejection and in LAM, and has been used in tolerization protocols with replace-
ment enzymes. In pre-clinical studies, we have co-administered sirolimus in
combinationwithMT-3724 in rodents aswell as in a non-humanprimatemodel
in order to reduce the anti-drug antibody response to MT-3724. These studies
demonstrated that the combination of sirolimus with MT-3724 decreased anti-
drug antibody response, prolonged serum exposure of MT-3724, and improved
B-cell depletion as compared to MT-3724 alone. Molecular Template’s ETB
technology has resulted in potent and targeted therapeutic agents that have a
unique mechanism of action in the fıeld of oncology. Our fırst-generation,
CD20-targeted therapeutic, MT-3724, has promising clinical results in the re-
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fractory setting for non-Hodgkin’s lymphoma. The combination of sirolimus
with MT-3724 is an attractive and feasible regimen which will be further ex-
plored in clinical studies.
#1645 CEACAM1-blockade for T-cell activation and antitumor T-cell re-
sponse. So-Young Eun. MOGAM Institute for Biomedical Research, YongIn,
Republic of Korea.
Immune checkpoint blockade became the most powerful way to control
cancer without causing tremendous side effects, since anti-PD-1 blocking
antibodies proved their superiority in clinical outcomes to those of tradi-
tional chemo- or targeted therapeutics. CEACAM1 (CCM1) is one of the
several immune checkpoint receptors expressed on T cells that mediate sup-
pression of inflammatory T cell response. CCM1 caught our attention for a
cancer immune-therapeutic target, because of its inhibitory role in TCR
proximal signaling complex. The anti-cancer therapeutic potential of
CCM1-blockade has already been studied in mouse models, and one of the
anti-human CCM1 antibody clones recently emerged in clinical Phase I
studies. CCM1-targeting antibody candidates were screened out of our in-
house synthetic libraries, among which a few of the clones stood out showing
their signifıcant blocking activities against CCM1-CCM1 homophilic inter-
action, enhancement of T cell activation, cytokine release, NFAT signaling,
and tumor lysis. One of the clones (C25) showed its strongest effıcacy equiv-
alent to that of a reference Ab in CCM1-dependent T cell activation, prolif-
xeration, and IL-2 release, in parental Jurkat cells as well as in CCM1-over-
expressing stable Jurkat cells. Moreover, C25 also enhanced tumor lysis by
CCM1 NK cells or CCM1 cytotoxic T cells in a CCM1-dependent man-
ner. In addition, C25 shows distinct characteristics in binding to CCM family
from those of a reference Ab. Thus, C25 is thought to have a strong thera-
peutic potential on CCM1 cancer.
#1646 Highly cytotoxic, completely human constructs targeting HER2
and containing the immuno-oncology payload granzyme B. Lawrence H.
Cheung,1 Yunli Zhao,2 KhalidA.Mohamedali,3 AnaAlvarez-Cienfuegos,3Wal-
terN.Hittelman,3MichaelG. Rosenblum3. 1MDAndersonCancerCenter,Hous-
ton, TX; 2Shenyang Pharmaceutical University, Shenyang, China; 3UT MD An-
derson Cancer Ctr., Houston, TX.
Recent immunotherapeutic approaches designed to augment T- and B-cell me-
diated killing of tumor cells has met with clinical success suggesting that immuno-
oncology (IO) approacheshave tremendouspotential for treatment in abroad spec-
trum of tumor types. After complex recognition of target cells by T and B cells,
delivery of the serine protease granzyme B (GrB) to tumor cells comprises the cyto-
toxic insult resulting in a well-characterized, multimodal apoptotic cascade. We
designed a recombinant fusion construct composed of a human anti-Her2 scFv
fused to active GrB for recognition and delivery of GrB to tumor cells simulating T
and B-cell therapy. The GrB-Fc-4D5 dimeric construct (mw 160 kDa) was gener-
ated and expressed in stably-transfected CHO-S cells at60 mg/L and purifıed to
homogeneity.Theenzymatic activityof the fusionconstructwas similar tocommer-
cially-available GrB and the affınity of the construct for purifıed Her2 extracellular
domain (ECD) was 0.328 nM, comparable to that of Herceptin (0.150 nM). The
GrB-Fc-4D5 construct was highly cytotoxic to Her2-positive cells such as SKBR3,
MCF7 andMDA-MB-231with IC50 values of 56, 99 and 27 nM respectively. Using
immunofluorescence, the fusion construct internalized rapidly into target (SKBR3
or SKOV3) cells within 1 h of exposure, rapidly delivering GrB to the cytoplasmic
compartment in a similar manner to that of immune T and B-cell targeting but
without the action of the transmembrane pore-forming agent perforin. Against a
large panel of various tumor types, GrB-Fc-4D5was highly cytotoxic to virtually all
cells regardless of natural expression levels of the nominal endogenous GrB inhibi-
tor PI-9. Contemporaneous studies with Kadcyla demonstrate similar levels of in
vitro activity against virtually all HER2-positive cells tested. GrB-Fc-4D5 demon-
strated activity against both log-phase and confluent tumor cells. In keepingwith its
relatively high molecular weight (160 kDa), the construct demonstrated a termi-
nal-phasehalf-lifeof13.6hrs. Invivoeffıcacy studiesarecurrentlyongoing inseveral
orthotopic xenograftmodels. Also ongoing are pre-IND toxicology, histopathology
and clinical chemistry studies. Research conducted, in part, by theClayton Founda-
tion for Research.
#1647 Characterization of MiXenoTM humanized mouse model for im-
muno-oncological therapy evaluation. Juan Zhang, Qian Shi, Lan Zhang.
CrownBio, Taicang, Jiangsu Province, China.
Backgrounds: Despite the unprecedented success of immune checkpoint anti-
body therapy in patients with various cancer types, lack of stable experimental im-
munotherapy models is still a big challenge in development of effective new im-
mune-therapeutics. Different strategies of humanized mouse model system,
includinghumanhematopoietic stemcell (HSC)orhumanPBMChumanization in
immune-defıcientmice, or chimericmodels harboringhuman immune checkpoint
targets in immune-competentmice have been reported. CrownBio has successfully
established a number of human PBMC-humanized xenograft models MiXenoTM
for in vivo IO therapy evaluation, which has been shown to be a rapid and simple
strategy of humanization. However, several outstanding questions, e.g. the optimal
PBMC injection route and cell number, the donor dependence of the effıcacy result
and impact of donor HLA type on the effıcacy, etc., need to be further addressed.
Results: PBMC number was titrated in one of ourMiXenoTMmodel HCC827, and
PBMCinjectionvia i.p. vs. i.v.was compared.Tumorgrowthcurve, graft versushost
disease (GVHD), and blood immunophenotyping were followed under different
settings. Furthermore, the antitumor activity of PD-1 antibody pembrolizumab in a
panel of PBMC donor context that bears diversifıed HLA types was precisely ana-
lyzed.We found that the effıcacywas highly donor dependent, and therewas lack of
correlation between effıcacy and donor/tumor HLAmatch. Conclusion: TheMiX-
enoTM model provides an alternative to the full stem cell reconstitution approach.
Better understandingon the characteristics of themodelmay allowa rationalmodel
selection and study design in the discovery IO therapeutics.
#1648 ImmunoGraft® platform for the evaluation of Immuno-Oncology
agents in PDX tumors models. David Cerna,1 Daniel Ciznadija,1 Bhavna
Verma,1 David Sidransky,2 Evgeny Izumchenko,2 Angela Davies,1 Maria Man-
cini1. 1ChampionsOncology, Baltimore,MD; 2JohnsHopkinsUniversity School of
Medicine, Baltimore, MD.
Recent breakthroughs in Immunotherapy have given new hope to treating
previously untreatable tumor types and provide a better tolerated alternative to
standard agents. There is an unmet need for a pre-clinical platform to test po-
tential immune-oncology therapeutics that would also provide a tool to examine
the mechanisms of response to better predict clinical outcomes. We have previ-
ously presented the Champions ImmunoGraft®, an innovative pre-clinical
model enabling immunotherapeutic agents to be evaluated for effıcacy in solid
tumors. This platform ismore reflective of the human tumormicroenvironment
(both immune and non-immune cell-based) and may be one of the most trans-
lationally-relevant models to date for screening therapies targeting the immune
system. However, optimization of humanization and PDX implantation proto-
cols that allow a broader reconstitution of cell linage andhigher engraftment rate
are necessary to further improve the pre-clinical evaluation of immune-oncol-
ogy therapeutics and enhance the value of this modality for patient’s benefıt. To
this end, immune-compromised NOG (PrkdcscidIl2rgtm1Sug) mice were recon-
stituted (humanized) with human CD34 cells using optimized procedure and
blood was collected at different time points post engraftment to check for the
major leukocyte linages. At ten weeks after humanization, mature human
CD45 cells comprised close to 50%of the leukocytes detected in the circulation
and secondary lymphoid tissues of the humanized animals. As a result of im-
proved methodology of the reconstitution protocol we have achieved an 85%
success rate of humanization with a shortened engraftment period utilizing
fewer CD34 cells that maintain humanization reconfırmed at 22 weeks post
reconstitution. Champions TumorGraft® database contains more than one-
thousand clinically relevant well-annotated PDX models. We have complied
data from extensive genetic and protein expression analyses to design applicable
ImmunoGraft® studies for testing of Immuno-Oncology agents. We have iden-
tifıed tumors expressing keymarkers thatmay predict response to immunother-
apy agents including PDL-1, CD40, IDO-1 and IDO-2 as well as tumors that
harbor a high mutational load. Here we present the effıcacy and clinically rele-
vant endpoints of two well-studied checkpoint inhibitors Ipilimumab and Pem-
brolizumab in this highly translational PDX platform.
#1649 In vivo CRISPR-Cas9 library screen for immune checkpoint regu-
lators. Sascha Karassek, Min Long, Xi Li, Zhengang Peng, Qunsheng Ji, Yong
Cang.WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China.
Therapeutic antibodies blocking immune checkpoints such as programmed
cell death protein 1 (PD1) have proven clinically benefıcial in multiple cancer
types. However, anti-PD1 drugs approved by FDA are neither effective in treat-
ing all cancer types nor in all patients in a responsive cancer type. Therefore,
understanding the mechanism underlying the effıcacy of immune checkpoint
blockade is critical for our rational design of synergistic treatment combina-
tions. Here we describe how we employ the latest CRISPR-Cas9 genome-wide
knockout screening strategies to identify targets in cancer cells or in T lympho-
cytes that control the sensitivity or resistance to anti-PD1 treatment. We con-
structed a sgRNA library targeting the functional domains of 116 mouse meth-
yltransferases and demethylases, which was infected into the mouse Cloudman
S91 melanoma cell line. Syngeneic mouse xenograft models derived from these
infected cells were treated with anti-mPD1monoclonal antibody, and the xeno-
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graft tumorswere harvest at different time points after antibody treatment.Deep
sequencing of the integrated sgRNA sequences in the tumors has identifıed
potential druggable targets to sensitize or antagonize the tumors resistance to
anti-mPD1 immunotherapy. Alternatively, we introduced the same library to
naïve T cells purifıed from the OT-1 transgenicmice. The T cell library was then
injected to B16-OVA melanoma syngeneic mouse models, followed by anti-
mPD1 treatment. Deep sequencing of the integrated sgRNA sequences in the
tumor-infıltratingT cells would allowus to uncover novel signalingmolecules in
the immune system that can potentially bemanipulated to enhance the anti-PD1
therapy. In summary, we provide in vivo knockout screen strategies that can be
applied to identify and validate combination therapies with immune checkpoint
antibodies.
#1650 Targeting CD47- SIRP interaction by novel peptide-based antag-
onists. Pottayil G. Sasikumar, Chennakrishnareddy Gundala, Nagaraj M.
Gowda, Sudarshan S. Naremaddepalli, Archana Bhumireddy, Rashmi Nair,
Wesley RoyBalasubramanian, Anirudha Lakshminarasimhan, Samiulla S. Dod-
heri, Kiran Aithal, Raghuveer K. Ramachandra, Girish Daginakatte, Murali Ra-
machandra. Aurigene Discovery Technologies Ltd., Bangalore, India.
Background: Cluster of differentiation (CD47) is a trans-membrane glycosy-
lated protein which is upregulated in several cancers. Increased expression of
CD47 on tumor cells is associatedwith immune evasion and cancer progression.
CD47 through its interaction with signal regulatory protein alpha (SIRP), a
cell-surface molecule onmacrophages inhibits phagocytosis of tumor cells. Dis-
rupting CD47-SIRP interactions by monoclonal antibodies targeting CD47
and recombinant SIRP proteins have been used as therapeutic strategies for
treating cancer. Our objective was to discover and develop peptide/peptidomi-
metic based CD47 antagonists for disrupting CD47-SIRP interactions. Meth-
ods: Through rational design based on crystal structure of CD47/SIRP inter-
acting interface, we designed peptides having potential to disrupt CD47-SIRP
interactions. FACS based cellular binding assay was developed to assess the
binding affınity of CD47 antagonists. SIRP protein labelled with fluorescent
dye was incubated with Jurkat T cells expressing high levels of CD47 in the
presence/absence of peptides. Binding affınity was measured by decrease in flu-
orescence. Functional activity of the peptides was evaluated in a FACS-based
phagocytosis assays, in which tumor cells were incubated with human/mouse
macrophages in the presence/absence of CD47 antagonists. Results: We identi-
fıed CD47 antagonists demonstrating disruption of CD47-SIRP interaction in
a cellular binding assay. These peptides signifıcantly inhibited phagocytosis of
different tumor cells by macrophages. The lead CD47 antagonist displaying
goodADMEproperties includingmoderate oral bioavailability was evaluated in
a B16F10 syngeneic mouse tumor model. The lead CD47 antagonist inhibited
primary tumor growth as well tumor metastasis to lungs. Biomarker character-
ization and effıcacy studies in additional tumor models are ongoing.
#1651 Targeting phosphatidylserine in combination with adoptive T cell
transfer eliminates advanced tumors without off-target toxicities in a mela-
noma preclinical model. Daniel Hirschhorn-Cymerman,1 Sara Sara Schad,1
Sadna Budhu,1 ZhongHong,1 Xia Yang,1 Hutchins T. Jeff,2 Bruce D. Freimark,2
Michael J. Gray,2 JeddWolchok,1 Taha Merghoub1. 1Memorial Sloan-Kettering
Cancer Center, New York, NY; 2Peregrine Pharmaceuticals, Tustin, CA.
A viable strategy to treat advanced cancers includes transferring of tumor-
specifıc T cells. T cells that recognize tumor antigens can be expanded and
reinvigorated ex-vivo. Furthermore, autologous T cells can be genetically mod-
ifıed to express anti-tumor T cell receptors or chimeric antigen receptors. Al-
though the potency and specifıcity of tumor-specifıc T cells can be manipulated
ex-vivo, once re-infused into patients, the T cells are subjected to immunosup-
pressive mechanisms established by the tumor. An important immune check-
point regulator within tumors is phosphatidylserine (PS). Innate immune cells
exposed to PS secrete suppressive cytokines and chemokines that can signifı-
cantly impair the function and activation of anti-tumor T cells. Therefore,
monoclonal antibodies that block PS activity can increase the anti-tumor po-
tency of transferred T cells to treat aggressive cancers. Here we show that a PS
targeting monoclonal antibody in combination with CD4 T cells that recog-
nize the melanoma antigen Trp1 can regress very advanced melanomas in all
treated mice. Combination of anti-Trp1 CD4 T cells with other immuno-
modulatory modalities such as anti-OX40 antibodies, can achieve equivalent
treatment rates but these are typically accompanied by severe immune related
adverse events. In contrast, in this setting, PS blockade did not show any off-
target toxicities. Flow cytometry analysis revealed lower levels of CD206 expres-
sion concomitant with higher activation markers in macrophages and neutro-
phils in tumors from anti-PS treated mice. These results suggest that
diminishing suppressive mechanisms locally in adoptive transfer protocols is a
highly desirable strategy that can eliminate tumors while minimizing related
adverse events.
#1652 Optogenetic immunoengineering to develop improved anti-cancer
immunotherapy. Lian He,1 Nhung Nguyen,1 Gang Han,2 Yun Huang,1 Yubin
Zhou1. 1TexasA&MUniversity,Houston, TX; 2University ofMassachusettsMed-
ical School, Worcester, MA.
The application of current channelrhodopsin-based optogenetic tools is lim-
ited by the lack of strict ion selectivity and the inability to extend the spectra
sensitivity into the near-infrared (NIR) tissue transmissible range.Herewe pres-
ent an NIR-stimulable optogenetic platform (termed “Opto-CRAC”) that selec-
tively and remotely controls Ca2 oscillations and Ca2-responsive gene ex-
pression to regulate the function of model cellular systems, as well as cells of the
immune system.When coupled to upconversion nanoparticles, the optogenetic
operation window is shifted from the visible range toNIRwavelengths to enable
wireless and remote photoactivation of Ca2-dependent signaling and optoge-
neticmodulation of immunoinflammatory responses. In amousemodel ofmel-
anoma by using ovalbumin as surrogate tumor antigen, Opto-CRAC has been
shown to act as a genetically-encoded “photoactivatable adjuvant” to improve
antigen-specifıc immune responses to specifıcally destruct tumor cells. In addi-
tion, we have extended similar engineering approaches to photomanipulate
membrane contact sites that play critical roles in controlling lipid metabolism
and calcium signaling in cancer cells. Our study represents a solid step forward
towards the goal of improving spatial and temporal control of anti-cancer ther-
apy through optogenetic immunoengineering.
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#1653 Modeling tumor immuno-dynamics to predict patient survival and
immunotherapy effıcacy.Nicholas K. Akers, Eric E. Schadt, Bojan Losic. Icahn
School of Medicine at Mount Sinai, New York, NY.
State of the art models of cancer survival are increasingly utilizing molecular
data that feature the number of non-synonymousmutations, or a network based
stratifıcation of mutations, as signifıcant predictors. It is widely hypothesized
that this association between mutations and survival is a result of neo-epitopes
that induce a robust anti-tumor immune response. Naively this implies that
patient neo-epitope burden should better predict survival than that ofmutations
alone, however this has generally been diffıcult to prove. Indeed, mutations and
predicted neo-epitopes explain roughly the same survival variance, likely due to
the intertwined diffıculties of neo-epitope prioritization and the often immuno-
suppressive tumormicroenvironment. Reasoning that integrating leading order
immune response with novel neo-epitope prioritization will lead to superior
performance, we built a statistical model to quantify the influence of tumor
immune-dynamics on patient survival. Neoepitopes (MHC-I/II) were predicted
from mutations and fıltered on a self-ligandome. The clonal structure of these
mutations and the distribution of resulting epitopes were assessed as predictive
features. Additionally, the existing response to epitopes was assayed by incorpo-
rating TCR and BCR sequence counts and entropy as a proxy for clonal tumor
infıltrating lymphocyte expansion. Leveraging the cancer genome atlas (TCGA)
for 9 major cancer types including bladder (BLCA), breast (BRCA), colorectal
(COAD/READ), glioblastoma (GBM), liver (LIHC), lung (NSCLC), melanoma
(SKCM), pancreatic (PAAD), and uterine (UCEC) cancer, we obtained omics
data for a total of 2,866 patients. Random forest based recursive feature
elimination was used to determine which features were most likely to be
predictive while overfıtting was controlled with k-fold cross validation. A
cox proportional hazard model of survival as a function of mutation burden
and functions of neoepitope and immune response predictors was con-
structed using the selected features. Our results confırm that neoepitope and
immune response based predictors for survival often signifıcantly outper-
form mutation burden alone and simultaneously suggest a quantitative clas-
sifıcation of immunotherapy effıcacy across cancer subtypes.
#1654 Development of subtype specifıc mouse models of bladder cancer.
Christof C. Smith* (contributed equally to this work),1 Ryoichi Saito* (contrib-
uted equally to this work),2 LisaM. Bixby,2 TakanobuUtsumi,2 Jordan Kardos,1
Shengjie Chai,1 Sara E.Wobker,1 Bhavani Krishnan,2 Jeffrey S. Damrauer,3 Jon-
athan S. Serody,2 David Darr,1 Benjamin G. Vincent† (contributed equally to
this work),2 William Y. Kim† (contributed equally to this work)2. 1UNC School
of Medicine, Chapel Hill, NC; 2Lineberger Comprehensive Cancer Center, Chapel
Hill, NC; 3Duke University, Durham, NC.
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Introduction: High-grade, muscle-invasive bladder cancer has recently been
shown to harbor intrinsic molecular subtypes with distinct biologic features.
Current murine models of bladder cancer, including the prominent carcinogen
induced model MB49, do not account for subtype specifıc characteristics, leav-
ing a gap in available tools for understanding subtype specifıc differences in
bladder cancer. We have developed and validated immunocompetent, subtype
specifıc models of bladder cancer, and we have used these models to assess
differential responses to immune checkpoint inhibition. Methods: Two distinct
models ofmurine bladder cancerwere developed in aC57BL/6 background. The
UPPL models were generated through Pten/Trp53 conditional knockout in
Uroplakin3a expressing cells. BBNmodels were generated through exposure of
wild-type C57BL/6 mice to the carcinogen N-Butyl-N-(4-hydmoxybutyl)nitro-
samine and subsequent generation of cell lines from spontaneous tumors.
RNAseq was performed on several BBN and UPPL tumors and cell lines, with
fındings validated with flow cytometry and T/B cell receptor (TCR/BCR) ampli-
con sequencing of tumor infıltrating lymphocytes (TILs). Results: BBN and
UPPLmodels reflected characteristics of human basal and luminal bladder can-
cers, respectively. BBN (basal) models demonstrated higher immune gene sig-
nature expression, with concordantly higher numbers of TILs compared to the
UPPL (luminal) model (p  0.0001). Two BBN and two UPPL models were
assessed for response to anti-PD-1 therapy in vivo as syngeneic tumors grown in
wild type C57BL/6 mice. One of the BBN lines (BBN963) demonstrated robust
control of tumor growth in some animals, including multiple complete re-
sponses (p 0.0003), but also tumors that progressed, leading us to characterize
BBN963 as a mixed response model. The marked response to PD-1 blockade in
BBN963 was associated with signifıcantly higher sharing of TCR CDR3 se-
quences among TILs compared to sequences of the other tumors (p 0.003). In
addition, analysis of BBN963 tumors by flow cytometry demonstrated naïve and
memory T cell phenotypes correlated with increased and decreased tumor sizes,
respectively. Closer examination of individual BBN963 tumor responses to
PD-1 blockade revealed distinct responder and non-responder infıltrating im-
mune cell phenotypes. Responders demonstrated a less diverse B cell repertoire
(p 0.0043) with increased BCRCDR3 sequence sharing (p 0.0001). Discus-
sion: We have developed two unique classes of murine bladder cancer lines,
UPPL andBBN,with gene expression andTIL profıles that closely correlate with
human luminal and basal bladder cancers, respectively. The BBN and UPPL
subtype specifıc models can serve as a tool for elucidating bladder cancer re-
sponses to immunotherapy. The mixed response of BBN963 tumors to PD-1
blockade should be an asset for assessing pathwaysmediating response to check-
point blockade as well as the value of combination therapy.
#1655 Organotypic 3D models to characterize the molecular require-
ments for NK and T-cell infıltration.Wolfgang Sommergruber,1 Annika Oss-
wald,1 Viola Hedrich,1 Marta Majewska,1 Helmut Dolznig2. 1Boehringer Ingel-
heim RCV, Vienna, Austria; 2Medical University of Vienna, Vienna, Austria.
Multiple studies have demonstrated that the presence of tumor infıltrating
lymphocytes is strongly correlated with increased survival. However, the level of
infıltration within a specifıc tumor entity and between various tumor types var-
ieswidely. Increasing the degree of lymphocyte infıltration in a tumor represents
an innovative drug concept. Organotypic 3Dmodels consisting of tumor spher-
oids, stromal fıbroblasts and Natural Killer (NK) or T-cells could represent
valuable models to appropriately model infıltration and establish novel thera-
peutic concepts in the area of immune-oncology. As a fırst step in the develop-
ment of a model for lymphocyte infıltration, the cytotoxicity and infıltration of
human NK cells in 3D tumor spheroids were analyzed. Different NK cell lines
and primary NK cells had a toxic effect on 3D tumor spheroids upon co-culture.
Cryosections of co-cultured tumor spheroids showed infıltrated NK cells inside
tumor spheroids. Infıltrated NK cells recovered from tumor spheroids were
characterized by flow cytometry. Results showed that a higher infıltration cor-
relateswith cytotoxicity on tumor spheroids and transcriptomes of infıltrated vs.
non infıltrated NK cells differ substantially. IL-12 stimulation increased the kill-
ing effect of NK cells on tumor spheroids, inducing higher expression of Perfo-
rin, IFN and GranzymeB levels. 3D tumor spheroids were embedded in a
Matrigel/Collagen mixture with fıbroblasts and the effect of compounds on NK
cell infıltration was monitored. It was demonstrated that not only IL-12 in-
creased NK cell infıltration, but also several compounds. Moreover, encapsu-
lated 3Dmodels with different cell types (tumor cells, fıbroblasts, NK or T-cells)
were established at a bioreactor scale to mimic the in vivo situation of complex
tumor tissues. We could demonstrate NK and T-cell infıltration into these en-
capsulated 3D tumor spheroids. These encapsulated model systems permit
long-term cultures to study the effect of compounds and/or NK or T-cells on
later stages of tumorigenesis. In conclusion, this study demonstrates that orga-
notypic 3D models are a valuable tool for the analysis of the molecular mecha-
nisms that regulate lymphocyte infıltration into tumors.
#1656 Comprehensive evaluation of human immune system reconstitu-
tion in NSGTM and NSGTM-SGM3 toward the development of a novel Onco-
HuTMxenograftmodel.Aaron J.Middlebrook,1 Eileen Snowden,2WarrenPor-
ter,2 Friedrich Hahn,2 Mitchell Ferguson,2 Brian Soper,3 James Keck,3 Joan
Malcolm,3 Shannon Dillmore,2 Smita Ghanekar,1 Rainer Blaesius2. 1BD Biosci-
ences, San Jose, CA; 2BD Technologies, Raleigh-Durham, NC; 3The Jackson Lab-
oratory, Bar Harbor, ME.
The recent successes of immunotherapeutic approaches to the treatment of
melanoma and the promise of similar treatments in a variety of other cancers
underscore the importance of the immune system in cancer. Indeed, effective
therapeutic design and evaluation require a comprehensive understanding of
the interplay between the immune compartment and the proliferating tumor
cells that comprise the tumor microenvironment. A humanized mouse strain
engrafted with cancerous tissue from a patient derived xenograft (PDX) tumor
provides researchers with a highly sophisticated tool, ideally suited to facilitate
the design of treatment strategies that prevent tumor evasion of immune cells
and that improve cytotoxic responses. Severely combined immunodefıcient
mice such as NOD scid gamma (NSGTM) and triple transgenic NSG mice ex-
pressing human cytokines KITLG, CSF2, and IL-3 (NSGTM-SGM3) are proven
hosts for the engraftment of human tumors and establishment of human im-
mune system components following hematopoietic stem cell (CD34) trans-
plantation. The endogenous expression of cytokines that support the develop-
ment of myeloid lineages and regulatory T cells potentially represents a
substantial improvement over standard NSG mice. Here we employ four 14-
color flow cytometry panels to perform a comprehensive and detailed analysis of
the entire immune system. The four panels are designed to fully characterize
specifıc branches of the immune system: 1) T cells 2) NK cells/dendritic cells/B
cells 3)myeloid lineages, and 4) immune checkpointmarkers. Blood, spleen, and
bone marrow tissue from both NSG and NSG-SGM3 mice were evaluated at 9,
16, 21, and 31 weeks of age using each of the four phenotyping panels. Our
results indicate that the triple transgenic NSG-SGM3mice exhibit a more com-
pletely humanized immune system compared to NSG mice, with specifıc im-
provements in the distribution of T-cell subsets and overall representation of the
myeloid lineage. NSGmice engrafted with allogeneic human tumors represent a
valuable preclinical testing platform for immuno-oncology.
#1657 Evaluating anti-tumor activity of the human anti-PD-1 antibody
pembrolizumab using humanized mouse models. Douglas E. Linn,1 Razvan
Cristescu,1 Kallol Ray,1 Shuli Zhang,2 Sripriya Dhandapani,2 Sarav Kaliyape-
rumal,2 Jennifer H. Yearley,2 Brian J. Long1. 1Merck & Co., Inc., Boston, MA;
2Merck & Co., Inc., Palo Alto, CA.
Targeting immune checkpoints has proven to be an effective strategy for
reactivating the immune system to elicit potent anti-tumor activity. For exam-
ple, the anti-PD-1 antibody pembrolizumab has shown robust and durable clin-
ical activity in numerous malignancies including melanoma and non-small cell
lung cancer. Unfortunately, a subset of patients do not benefıt from pembroli-
zumab treatment. Ongoing molecular analyses of patient samples are establish-
ing gene signatures which aim to more accurately predict which patients will
benefıt from immunotherapy. However, there are currently no preclinical in
vivo platforms that comprehensively translate these clinical fındings. Therefore,
we have explored the use of mice engineered with a human immune system to
examine the anti-tumor activity of pembrolizumab against a panel of human
tumor xenografts derived from both cultured cell lines as well as patient tissue.
Tumor models were selected based on parameters including PD-L1 expression
andmutational load in order to closelymimic responder patients in the ongoing
pembrolizumab clinical trials. Our data confırm that pembrolizumab can in-
duce signifıcant anti-tumor effıcacy in humanized mice inoculated with human
tumormodels derived fromboth cancer cell lines and patient tumors. In respon-
sivemodels, pembrolizumab caused signifıcant tumor growth inhibition and, in
some instances, tumor regressions. FACS analyses confırmed effective targeting
of PD-1 T cell populations. Anti-tumor effıcacy correlated with increased
effector T cell to regulatory T cell ratios as well as an elevated T cell infıltrate
presence. Nonresponsive models lacked robust immune infıltration detectable
by FACS or IHC, consistent with clinical data. Furthermore, presence of cyto-
lytic activity at baseline and T-cell inflamed environment were evaluated using
transcriptome analysis and subsequently linked to pembrolizumab response
and to somatic neoantigen burden of the tumors. Together these studies validate
the utility of humanized mice in the preclinical development of novel cancer
immunotherapies and may also be benefıcial in better defıning the patient re-
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sponder hypothesis and its prognostic value. Additionally, humanizedmicemay
help identify optimal combination treatment regimens to provide more mean-
ingful clinical benefıt to patients who do not respond to single-agent therapy
with pembrolizumab.
#1658 Establishment of CD137 humanized mouse model for effıcacy as-
sessment of agonistic anti-CD137 therapeutic antibodies. Davy Xuesong
Ouyang,1 GangChen,2 ZhenshengWang,1 Lei Zheng,1 Annie XiaoyuAn,1 Jean-
Pierre Wery,1 Jay Liu,2 Xin Dong,2 Henry Q. X. Li1. 1Crown Bioscience, Inc.,
Taicang, Jiangsu, China; 2Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing,
Jiangsu, China.
CD137 belongs to theTNF receptor super family, and its activation is essential
to the function of T cells and NK cells. Multiple agonistic CD137 antibodies are
currently being tested in humans with advanced cancer, which expected to be-
come an important new immuno-oncology therapeutics in clinic. It is important
to establish preclinical models for effıcacy assessment of investigational CD137
antibodies before entering clinic. Currently available animal models cannot
meet this need. Syngeneic mouse tumor models provide a useful platform for
testing surrogate immuno-oncology therapies, but cannot be used for testing
human therapeutic antibodies due to the species specifıcity; human immunity
reconstituted models, by human PBMC or hematopoietic stem cell inoculation
into immune defıcient mice, suffering from highly variable responses, are not
robust enough to provide a reliable system for effıcacy studies. Establishing
target humanized models by replacing mouse therapeutic target with human
counterpart while maintaining normal mouse immunity is a practical approach
to evaluate human therapeutic antibodies in vivo. Using CRISPR-Cas9 gene
editing, we have engineered humanCD137 knock-inmodel expressing chimeric
human/mouse CD137 composed of human extracellular and transmembrane
domains (Exon 4-7), with intact mouse signal peptide and intracellular domain.
FACS analysis of splenocytes derived from homozygous knock-in mice showed
that CD3/CD28 stimulated T cells only express chimeric CD137 reactive to
humanCD137 antibodies, but notmouseCD137; Yet the expression levels of the
chimeric CD137 in the knock-in mice are generally lower than endogenous
mouse protein in wild-type C57BL/6mice. At present, we are testing the effıcacy
of reference human CD137 agonistic antibodies by treating these homozygous
knock-in mice grafted with syngeneic MC38 tumor cells. Data will be presented
at the conference.
#1659 Immunological characterization of the Oncopig model and detec-
tion of cell-mediated immune responses to cancer.NanaH.Overgaard,1 Dan-
iel R. Principe,2 Jeanne T. Jakobsen,1 Laurie A. Rund,3 Paul J. Grippo,2 Gregers
Jungersen,1 Lawrence B. Schook3. 1Technical University of Denmark, Frederiks-
berg C, Denmark; 2University of Illinois, Chicago, IL; 3University of Illinois, Ur-
bana-Champaign, Urbana-Champaign, IL.
In recent years, immunotherapy has shown great breakthroughs; however,
the majority of preclinical studies has been based solely on rodent models and
tends to experience a troublesome translation to human patients often related to
the differences betweenmice and humans. Here, we utilized the Oncopigmodel
that, due to its similarity in the immunome, metabolism, and size between hu-
mans andpigs, can serve as a supplementary large animalmodel for translational
cancer research.With the establishment of the immunoscore as a new approach
for staging cancer patients, it has become evident that the immune status of the
tumor microenvironment has a crucial impact on the patient’s outcome and
response to therapies. For this reason, we set out to perform an immunological
characterization of Oncopig-derived tumors to elucidate the potential in using
this model for testing cancer immune therapeutic approaches. Following injec-
tion of Cre recombinase, the transgenic Oncopigs express KRASG12D and
TP53R167H, two mutations commonly found in human cancers, subsequently
resulting in tumor formation at the site of injection. The expression of these two
transgenes was confırmed using intracellular flow cytometry staining or immu-
nohistochemistry (IHC). Subcutaneous, intramuscular, and testicular tumors
all showed the presence of infıltrating CD3 cells, which were found both in the
periphery and in the core of the tumor as determined by IHC. With the estab-
lishment of a digestion protocol allowing isolation of the in vivo-generated tu-
mor cells, we confırmed the CD3 staining and found that the infıltrating T-cell
pool was comprised of both cytotoxic and regulatory cells as indicated by posi-
tive flow cytometry staining for the CD8 chain and FoxP3, respectively. In
order to investigate the immunogenicity of the tumor cells, we set up flow cy-
tometry detection of porcine TNF-, IFN-, and perforin in a PBMC-tumor cell
co-culture. Despite the production of various cytokines, actual tumor cell killing
is a desirable parameter to measure when evaluating both the immunogenicity
and response to therapy. Therefore, we developed, to our knowledge, the fırst
fluorescence-based in vitro porcine cytotoxicity assay and found a signifıcant
recognition and specifıc killing of autologous tumor cells in an effector-target
titration dependent manner. Taken together, our results show that the estab-
lished Oncopig tumors are infıltrated by T cells exhibiting an either cytotoxic or
regulatory phenotype, thus indicative of a tumormicroenvironmentmimicking
the complexity seen in human patients. Additionally, we were able to measure
cell-mediated immune responses to cancer in this novel, large animal model,
and both the cytokine production and tumor-specifıc killing hence underline
the potential in using theOncopig for future testing of immune therapies against
human cancer.
#1660 Humanization of patient derived xenograft (PDX) cancer model
mice with peripheral bloodmononuclear cells (PBMCs). Jens Henrik Norum,
Dag Josefsen, Gunnar Kvalheim, Olav Engebråten, Therese Sørlie, Gunhild M.
Mælandsmo. Oslo University Hospital, Norwegian Radium Hospital, Oslo, Nor-
way.
Immunocompetent transgenic mouse models have for decades served as
valuable tools to address the effect of oncogenes and tumor suppressors. Immu-
nodefıcient mice have been used to establish patient derived xenograft (PDX)
models harboring human tumors. These types ofmodels have beenused to study
cancer initiation and progression as well as preclinical evaluation of anticancer
drugs. One major limiting factor for both these model systems is the immune
system; the PDX models lack an immune system and the immune system in
immunocompetent mouse models display differences compared to the human
immune system. Thus, in cancer research there is a need for preclinical models
to study the influence of human immune cells on tumor progression and re-
sponse to cancer therapies. We have established and optimized protocols for
intravenous (IV) or intraperitoneal (IP) injections of isolated human PBMCs, to
generate humanizedmice harboring human immune cells. Our protocols do not
require irradiation or busulfan pretreatment of the animals. Flow cytometry
analyses showed that mainly T helper cells, CD4, and cytotoxic T cells, CD8,
were present in the humanized mice. Immunohistochemistry (IHC) analyses of
humanized PDX cancer model mice showed that human lymphocytes were
present in the tumor periphery and some very few cells within the tumor, in
addition to the human leukocytes in the liver and spleen. The growth rates of the
PDX tumors were not affected by the humanization. Our protocols require
minimal preparations of the animals and generate humanized PDX mice har-
boring human lymphocytes locating in close proximity of, as well as inside the
PDX tumors. The model systems are suitable for preclinical studies of human,
adaptive immune responses in tumor progression and cancer therapies.
#1661 Humanized mouse models for immune-oncology biotherapeutics:
Development, validation and applications. Gang Chen, Bin Cai, Feng Zhou,
Jerry Zhou, Jie Liu, Xin Dong. Nanjing Galaxy Biopharma, Nanjing, China.
With clinical success and FDA approval of Ipilimumab, Nivolumab, Pem-
brolizumab and Atezolizumab, developing biotherapeutics against immune
checkpoint targets, like CTLA-4, PD-1/PDL-1 and others, becomes hot pursuits
for big pharma and biotech. However, traditional syngeneic models with surro-
gate murine reagents or human immune cell re-constitution in immune defı-
cientmice are useful but not reliable and robust due to the species specifıcity and
highly variable responses. It is crucial to establish additional preclinical models
for effıcacy assessment of investigational immune-oncology antibodies before
entering clinic. Establishing human therapeutic target engineered mouse mod-
els by replacing mouse gene with human counterpart while maintaining intact
mouse immunity is a practical approach for in vivo studies. Applying CRISPR-
Cas9 and other gene editing techniques, we have engineered genetically a series
of single and double human immune-checkpoint genes, like PD-1/PDL-1,
CTLA-4, TIM3, CD137 and others, knock-in model expressing chimeric hu-
man/mouse targets composed of human extracellular domains, with intact
mouse signal peptide and intracellular domain. FACS analysis of immune cells
derived from homozygous knock-in mice showed that activated cells only ex-
press chimeric targets reactive to anti human target antibodies, but not mouse
gene specifıc antibodies. We have been testing the effıcacy of reference antibod-
ies by treating these homozygous knock-in mice inoculated with syngeneic mu-
rine tumor cells. Other applications, like target validation, combination therapy
and biomarker discovery, are also explored.
#1662 Development and validation of humanizedmicemodels implanted
with patient derived colorectal cancer xenografts.AnnaCapasso,1 Julie Lang,1
Todd M. Pitts,1 Sarah Lindsey Davis,1 Christopher Lieu,1 Scott Kopetz,2 Stacey
Bagby,1 Paul Francoeur,1 John J. Tentler,1 Jill Slansky,1 Roberta Pelanda,1 Gail
Eckhardt1. 1Univ. of Colorado Denver, Denver, CO; 2MD Anderson Cancer Cen-
ter, Houston, TX.
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Introduction: Agents that reverse T cell inhibitory signals have reinvigorated
the strategy of cancer immunotherapy and are leading to robust clinical re-
sponses. In colorectal cancer (CRC), objective responses to single-agent therapy
with anti-PD-1/PD-L1 antibodies have largely been restricted to the small pro-
portion of CRC patients with microsatellite unstable (MSI-high) disease. Al-
though there are additional subsets of advanced CRC patients that are respon-
sive to immune checkpoint inhibition in combination with tumor-targeted
agents, preclinical models have been hampered by their immune-compromised
status. In order to gain a better biological understanding of the context of im-
mune responses and facilitate preclinical evaluation of combination strategies
incorporating cancer immunotherapy, we developed a “hematopoietic” human-
ized mouse model utilizing patient-derived CRC xenografts with the intent of
leveraging this model for the development of rational combinations. Methods:
BRG.NODSirpalfa newborn pups were humanized through transplantation of
1x105 CD34 cells purifıed from umbilical cord blood. Mice were evaluated for
chimerism at 8 and 12 weeks. At 16 weeks, tumor tissue from established PDX
models was implanted on the right and left flanks of humanizedmice.When the
average tumor size reached a volume of150-300 mm3, themicewere random-
ized into vehicle or nivolumab (30 mg/kg twice weekly i.p.) treatment groups
according to %chimerism. Mice were monitored for signs of toxicity and tumor
size was evaluated twice weekly by caliper measurements (tumor volume
(length  width2)  0.52). At the end of the treatment, mice were euthanized
while sera, lymph nodes, spleen, bone marrow and tumors were collected for
immunological assessment. Results: As preliminary proof-of-concept, we suc-
cessfully established 3 humanized CRC PDX models and one breast cancer cell
line (MDA-MB-231). In one of the CRC (MSI-high) and in the breast model we
observed tumor growth inhibition in the treated groups vs control. We detected
differences in PD-1 expression among treated versus control mice, with lower
expression in the nivolumab-treated groups. We also observed an increased
number of TILs, CD8Tcells and greater numbers of T cells in the lymphnodes
of treated mice, suggesting T cell expansion. Mice were highly chimeric with
high TILs whereas responder tumors exhibited an increase of CD44 high IFN
T cells, high CD8% and a higher effector memory% (HLADR, CD45RO).
Conclusions: Humanized PDXmodels were successfully established and tumor
engraftment occurred in all humanizedmicewith nivolumab-treatedmice dem-
onstrating the development of lymph nodes that were populated by activated T
cells. These preliminary results demonstrate that human immunity and PD-1
expressing T cells exist in these models and provide the basis for planned im-
munotherapy combination studies.
#1663 Preclinical effıcacy model to promote immunotherapy develop-
ment for prostate cancer.Mari I. Suominen, Tiina Kähkönen, Yvonne Konkol,
Jenni Mäki-Jouppila, Jussi M. Halleen, Jenni Bernoulli. Pharmatest Services Ltd,
Turku, Finland.
Immunotherapy for prostate cancer has recently emerged as an attractive
treatment strategy. Yet, preclinical models where relationship between inflam-
mation, stroma, tumor cells and prostate cancer progression can be studied are
limited. GEMM models of prostate cancer are scarce and in xenograft models,
even when in humanized mice, the role of immune system in the initiation and
in progress of the malignancy cannot be studied. As the requirement to test
novel immunotherapies and especially combination treatments is increasing, a
preclinical model that takes into account tumor microenvironment and im-
mune systemwould be highly useful to promote development of novel therapies
to combat against prostate cancer. Aim of the present study was to reveal if there
is role between the immune system and development of prostate cancer, and
secondly, to validate a model to be utilized later in immunotherapy develop-
ment. Intact 10-12 weeks old male Noble rats were s.c. implanted with slow-
releasing estradiol and testosterone pellets for 6, 13 and 18 weeks. Daily release
for testosterone was 0.8 mg and for estradiol 0.08 mg. Control group animals
received placebo hormone pellets without hormones. Serum samples were col-
lected during the study to monitor hormone levels, and prostates were removed
and processed for histopathological evaluation at the end of the study. Hor-
monal treatment caused an increase in estradiol to testosterone ratio, and the
prostates were enlarged. Imbalance in hormone-milieu induced inflammation
in the prostate, followed by formation of prostatic intraepithelial neoplasia
(PIN)-like lesions and fınally adenocarcinomas in the periurethral region. In-
flammatory cells, mainly T-cells were noticed in the vicinity of PIN-like lesions.
During the progression of prostate cancer, inflammatory cells disappeared from
the adenocarcinoma sites. In the prostate, inflammation consisting of perivas-
cular, stromal and periglandular T-lymphocytes and intraluminal neutrophils
remained. Results of this study indicate signifıcance of hormonal milieu, espe-
cially estrogens and androgens, in the development of inflammation and pro-
gression of prostate cancer, with a key role for tumor microenvironment. Pres-
ence of lymphocytes in the proximity of PIN-like lesions during the early phases
of prostate cancer, and their disappearance later in the adenocarcinomas, indi-
cate interaction between innate and adaptive immune systemand cancer. There-
fore, this preclinical prostate cancer model that combines immune system and
cancer can be utilizedwhennew immunotherapies, combination treatments and
prevention possibilities against prostate cancer progression are developed.
#1664 Inhibition of 4T1mammary tumor growth in BALB/cmice by sub-
cutaneous and intraperitoneal injection of a 4T1 whole cell vaccine contain-
ing IL-2 and GM-CSF as adjuvants. Jonathan F. Head,1 Jeffrey T. Phillips,1
Xianpeng Jiang,1 Robert L. Elliott2. 1OncBioMune Pharmaceuticals, Baton
Rouge, LA; 2SAB Breast Foundation, Baton Rouge, LA.
Developing animal tumormodels for human cancer vaccines creates a tool to
investigate the mechanism of action, variations in formulation, dosing sched-
ules, and combinations with other forms of cancer therapy. In this study we
developed a mouse whole cell mammary cancer vaccine model with both sub-
cutaneous and intraperitoneal injection of the vaccine. The vaccine, containing
4T1 mouse mammary cancer cells (1,000,000 cells), IL-2 (0.2 g) and GM-CSF
(0.1 g) in a total volume of 150 l, was injected either subcutaneously into the
backs of BALB/c mice or intraperitoneally. There were six injections of the
vaccine (weeks 1, 2, 3, 7, 11, 15) and oneweek after the last injection 100,000 4T1
cells fromcell culture in a volumeof 100l were injected into the scapular region
of the mice. At 22 days post 4T1 tumor transplantation there was a 37% inhibi-
tion of the growth of the 4T1 tumor in the mice receiving the subcutaneous
injection of the vaccine and a 42% inhibition of the growth of the 4T1 tumor in
the mice receiving the intraperitoneal injection of the vaccine. The inhibition of
4T1 mammary tumor growth in this mouse model with subcutaneous injection
of a whole cell vaccine gives further support for the previously reported effıcacy
in a Phase 1/2 clinical trial of our therapeutic breast cancer vaccine containing
autologous and allogeneic breast cancer cells in the adjuvant setting. The inhi-
bition of 4T1 tumor growth with intraperitoneal injection suggests a delivery
method that may be applicable to ovarian cancer and cancer patients with ma-
lignant ascites.
#1665 MuScreenTM : A well-characterized syngeneic model platform for
rapid in vivo screening. Lan Zhang, Binchen Mao, Qian Shi. CrownBio, Tai-
cang, Jiangsu Province, China.
Background: Syngeneic tumor models, many shelved for decades, have been
revived as effective models for immunotherapy, accompanying the clinical suc-
cess of the immuno-checkpoint inhibitors (e.g. anti-CTLA4, anti-PD1, anti-
PD-L1 antibodies). In vitro cell-based screens that are frequently used in oncol-
ogy to quickly identify responsive cells and assess PD effects, often fail in
immuno-oncology, due to immunotherapeutics targeting the complex host im-
mune system. Alternatively, an in vivo screen with a panel of models addresses
many of these questions, e.g. PD and effıcacy, but may be cost prohibitive. Ma-
terial andmethods: Leveraging in-house detailed profıling data onour syngeneic
models, including effıcacy benchmarking with anti PD-1, PD-L1, CTLA-4, OX-
40, GITR , LAG3 and TIM3 antibodies, RNAseq data on tumor samples, and
FACS analysis on both baseline and post-treatment tumor samples, we created a
new in vivo screening tool for immune-oncology: MuScreen. MuScreen in-
cludes up to 20well-characterized syngeneicmodels in a 3month screening run.
Both PD and effıcacy may be determined in the run, allowing researchers to
make decisions based on results observed from a large dataset. To address the
cost issue, test agents from multiple clients are pooled together for each run
(sharing vehicle and other common groups) providing a signifıcant reduction in
the number of animals used and the associated costs. Results: CrownBio has
established the largest collection of syngeneic models with well-characterized
immunotherapy data. With the three MuScreen runs, we have generated new
data on common IO agents (e.g. aPD-1 antibody) and combinations treatments,
with FACS analysis, IHC, and effıcacy data. Based on these data, a bioinformatics
analyses were further explored to identify the makers/pathways that could be
correlated with the effıcacy or PD effect of the tested IO treatment. Conclusions:
MuScreen, the fırst in vivo screening tool for cancer immunotherapeutics, pro-
vides detailed response data on a panel of syngeneic models, and may help on
biomarker discovery in a cost and time effıcient manner.
#1666 Immune consequences of penfluridol treatment associated with
inhibition of glioblastoma tumor growth. Alok Ranjan, Nehal Gupta, Shara-
van Ramachandran, StephenWright, Sanjay Srivastava. Texas Tech Uni. Health
Science Center, Amarillo, TX.
Glioblastoma is the most common and lethal brain tumor associated with only
12%median survival rate of patients.Despite thedevelopment of advanced surgical,
radiation or use of combinations of anti-cancer drugs, treatment for glioblastoma
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patients is still a challenge. The major contributing factor in glioblastoma progres-
sion and resistive nature is its ability to evade the immune surveillance. Hence,
modulating the immunesysteminglioblastomatumorscouldbean important strat-
egy for anticancer therapeutics. Penfluridol, an antipsychotic drug has been shown
to have anti-cancer properties in our recently published studies. The present study
evaluates the immune response of penfluridol in glioblastoma tumors. Our results
demonstrated that penfluridol treatment signifıcantly suppressed glioblastoma tu-
mor growth. Our current results demonstrated about 72% suppression of myeloid
derived suppressor cells (MDSCs) with penfluridol treatment in mouse bearing
U87MG glioblastoma tumors. MDSCs are known to increase regulatory T cells
(Treg), which are immunosuppressive in nature and suppresses M1 macrophages
that are tumor suppressive in nature. Our results also showed suppression of regu-
latory T cells as well as elevation ofM1macrophages with penfluridol treatment by
58%and 57% respectively. Decrease inCCL4 aswell as IFNwith penfluridol treat-
ment was also observed indicating decrease in overall tumor inflammation. This is
the fırst report demonstrating immunemodulations by penfluridol treatment asso-
ciated with glioblastoma tumor growth suppression prompting further investiga-
tion to establishpenfluridol as a treatment option for glioblastomapatients. [Studies
supported in part by R01 grant CA129038, awarded by National Cancer Institute,
NIH].
#1667 Identifying intrinsic regulators of PD-L1 expression in cancer cells:
A genome-scale CRISPR knock-out approach. Jacqueline E. Mann, Megan L.
Ludwig, Rebecca C. Hoesli, Aditi Kulkarni, Simmy Patel, Judy Kafelghazal,
Alexey Nesvizhskii, J Chad Brenner. University of Michigan, Ann Arbor, MI.
Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most com-
mon cancer in theUnited States and affects 600,000 people each year worldwide.
With a fıve-year survival rate of only 50% and a recent rise in HPV-associated
HNSCCs, improved treatment protocols are urgently needed. Evidence of im-
munosuppression is often reported in HNSCC, making immunotherapy an at-
tractive strategy for the management of this disease. The immune checkpoint
inhibitor Pembrolizumab was recently approved for the treatment of metastatic
and recurrentHNSCC, but only 18%of initial participants in a trial of Pembroli-
zumab responded, and it remains diffıcult to predict patients likely to experience
benefıt. To increase the number of patients that respond to immune checkpoint
inhibition, we sought to identify targetable genetic factors modulating PD-L1, a
molecule that serves to dampen the anti-tumor immune response.We show that
several HNSCC models exhibit mild (2-4 fold) induction of PD-L1 expression
following treatment with interferon- (adaptive expression), and recent reports
suggest that common oncogenic pathways, including the EGFR and PI3K path-
ways,may provide a novel strategy to regulate PD-L1 expression. To this end, we
developed a high throughput screen to identify targetable pathways that may be
used to regulate PD-L1 expression in patients with specifıc genetic lesions. We
have employed a Genome-scale CRISPR Knock-Out (GeCKO) screening tech-
nique in HNSCC cell lines and selected for genetic knockouts exhibiting altered
PD-L1 expression. Stable knockout pools with representation of approximately
300 gRNAs per target gene (20,000 target genes in the library) were expanded
and serially sorted to create stable sub-populations with enhanced PD-L1 ex-
pression. These sub-populations were sequenced to identify gRNAs whose
knockout causes a change in PD-L1 expression (e.g. genes that repress or en-
hance PD-L1 expression). We expect that these large-scale screens, when per-
formed overmultipleHNSCC cell lines with diverse genetic lesions, will identify
patterns of targetable regulators that may ultimately be manipulated in combi-
nation with PD-1/PD-L1 inhibitors.
#1668 Comprehensive 10 color flow cytometry analysis of the neuroblas-
toma intratumoral immune response using the murine syngeneic neuro-2a
tumormodel.DavidD.Draper,Matt Thayer, AldenWong, Dan Saims, Scott C.
Wise.MI Bioresearch, Ann Arbor, MI.
Neuroblastoma is the most prevalent solid tumor in childhood and the
most common tumor in infants less than 1 year of age. In spite of aggressive
multi-modal therapeutic approaches, the 5-year survival rate in patients with
high-risk neuroblastoma remains poor at 50%. Recent advances have fo-
cused on harnessing the immune system to combat neuroblastoma. Anti-
bodies that abrogate the immune checkpoint signaling pathway such as anti-
CTLA-4 and anti-PD-L1 suppress neuroblastoma growth in certain mouse
models of disease. Furthermore, the dinutuximab antibody that targets gan-
glioside GD2 expressing cells has been demonstrated to trigger neuroblas-
toma regression using a mechanism that involves several immune subsets.
Although evidence suggest the host immune response can be exploited to
fıght neuroblastoma, the key immune subsets, their relative contribution,
and mechanism of action to suppress neuroblastoma growth have yet to be
fully characterized. To this end, we used flow cytometry to immunopheno-
type the intratumoral immune response in the neuro-2a model of neuroblas-
toma. This was accomplished by developing two 10-color panels to quantify
the proportions of various myeloid and T cell subsets respectively. Using the
myeloid panel, our results showed that total neuro-2a tumor immune cells
were predominantly myeloid lineage-derived (CD11b). A combination of
Ly-6G and Ly-6C antibodies demonstrated that myeloid-derived suppressor
cells (MDSCs) comprised the bulk of themyeloid cells and weremore heavily
skewed towards the granulocytic phenotype versus monocytic. An MDSC
exclusion gate and a combination of F4/80, MHC class II, and CD206 anti-
bodies enabled the analysis of tumor-associated macrophage subsets. Our
results revealed that neuro-2a tumors contained relatively few activated M1
macrophages, which are typically associated with anti-tumor responses, and
instead were dominated with a pro-tumor M2 macrophage response. The T
cell antibody panel revealed that CD4 T cells outnumbered CD8 T cells by
2-fold. Regulatory T cells (Tregs) in the CD4 T cell fraction were identifıed
by a combination of FoxP3 and CD25 antibodies. The frequency of Tregs
varied but represented 50% of total CD4 T cells. Finally, the activation
state of CD8 T cells was examined using Ki-67, CTLA-4, and PD-1 anti-
bodies. Analysis demonstrated that the majority of CD8 T cells in neuro-2a
tumors were actively proliferating based on the expression of Ki-67. How-
ever, most of the proliferating CD8 T cells also co-expressed PD-1 suggest-
ing a loss of anti-tumor functionality and an exhausted phenotype. This
study provides a comprehensive immune profıle of neuro-2a tumors and
supports a platform with which to test new single agent and combination
therapies designed to treat neuroblastoma.
#1669 Multiplex immunohistochemical staining of PD-L1, PD-1, CD3,
CD4, CD8, CD68, FoxP3, and Ki-67 and image analysis of tumor and inva-
sive margin in human FFPE NSCLC tissue. Lisa M. Dauffenbach, Gela C. Sia,
Jianping Zheng, Natalia Jun, Eric P. Olsen, Christopher A. Kerfoot.Mosaic Lab-
oratories, LLC, Lake Forest, CA.
Evaluating thedensity of immune cell subtypes and their relative spatial position-
ing in cancers has become an important tool in understanding response to immune
checkpoint inhibitors. The purpose of this study was to investigate protein expres-
sionof PD-L1, PD-1,CD3,CD4,CD8,CD68, FoxP3, andKi-67with fourmultiplex
immunohistochemical assays (Ki-67CD8, CD3CD4Ki-67, FoxP3PD-
1CD8, andCD68PD-L1CD3)usingDAB, red, and green chromogenswithin
formalin-fıxed, paraffın embedded non-small cell lung (NSCLC) tissues. The Ki-
67CD8multiplexwasdeveloped toevaluate thedensityof cytotoxicTcells and the
percentage that are proliferating. The CD3CD4Ki-67 multiplex characterizes
the frequency of CD4 T cells and evaluate proliferation in this subset. The
FoxP3PD-1CD8multiplex evaluates the regulatory T cell subset and evaluates
PD-1 expression. TheCD68PD-L1CD3multiplex characterizes PD-L1 expres-
siononmacrophagesandTcells.Celldensitieswereevaluated in thecenterof tumor
and invasive margin regions, and image analysis was performed to quantitate each
stain as a single agent and co-expression within eachmultiplex assay.
#1670 Identifıcation and characterization of novel mediators of tumor-
induced T-cell dysfunction. Geoffrey J. Markowitz,1 Mary Philip,2 Andrea
Schietinger,2 Vivek Mittal1. 1Weill Cornell Medicine, New York, NY; 2Memorial
Sloan Kettering Cancer Center, New York, NY.
Immunotherapies targeting T-cell functionality have been shown to have ef-
fıcacy in numerous cancers, including non-small cell lung cancer (NSCLC).
However, treatmentwith currently available therapeutics, such as anti-PD-1 and
anti-CTLA-4, induce responses only in a subset of patients. This raises the pos-
sibility that numerous other effectors of T-cell dysfunction remain to be eluci-
dated. To evaluate possible novel mediators of T-cell dysfunction, we isolated
CD8 T-cells from orthotopic KrasG12D/p53-/- murine lung adenocarcino-
mas (HKP-1) that exhibited either stable or progressive disease as a function of
tumor growth. RNAseq analysis revealed increased expression of several genes
including Tim3, PD-1, Lag3, 2B4, andCISH, and decreased expression of GzmB
and Eomes in CD8 T-cells isolated from progressive tumors indicative of a
dysfunctional state, as well as multiple novel genes not previously associated
with T-cell dysfunction. To explore the functional role of the novel candidate
genes, we have developed in vitro and in vivo assays leveraging Ova and GFP
overexpression in ourHKP-1 cell line (KP1-Ova-GFP).We have begun to target
these unique set of candidate genes in tumor-specifıc T-cells associated with
dysfunction through innovative RNAi/shRNA and adoptive transfer ap-
proaches to facilitate therapeutic reprogramming and enhanced T-cell-medi-
ated immunity in lung cancer. We expect to provide novel strategies for design-
ing rational immunotherapies targeting dysfunctional tumor-specifıc CD8
T-cells to generate durable anti-tumor immune responses for the treatment of
lung adenocarcinoma.
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#1671 Characterization of the immune landscape in stage II-III mela-
noma using qIF. Robyn Gartrell,1 Douglas Marks,1 Edward C. Stack,2 Yan Lu,1
Thomas D. Hart,1 Camille Gerard,3 Camden Esancy,4 Dan Tong Jia,1 Paul Ar-
menta,1 Daisuke Izaki,4 Danielle Davari,4 Ashley White-Stern,1 Zoe Blake,1 Yi-
chun Fu,1 Basil Horst,1 Yvonne Saenger1. 1Columbia University School of Med-
icine, New York, NY; 2PerkinElmer, Inc., Hopkinton, MA; 3Iuliu Hatieganu
University, Romania; 4Columbia University, New York, NY.
Background: The tumor microenvironment plays a crucial role in cancer
progression, often supporting immune evasion. This is of particular impor-
tance in melanoma, where immune checkpoint therapies have resulted in
signifıcant clinical benefıt, yet only in a subset of melanoma patients re-
spond. Precise biomarkers are urgently needed to characterize the tumor
immune micro-environment, both for prognostication and to predict the
benefıt of immuno-therapeutic intervention. HLA-DR on tumor cells and
Ki67 on cytotoxic (CD8) T cells have been proposed as biomarkers of
anti-PD1 activity. Quantitative immunofluorescence (qIF) allows for auto-
mated quantitation of phenotypes and spatial distributions of immune cell
populations within formalin fıxed paraffın embedded (FFPE) tissues. Meth-
ods: To characterize the tumor immune microenvironment, we screened
databases at the Herbert Irving Cancer Center (HICC) at Columbia Univer-
sity for early stage melanoma patients with documented clinical follow up.
We identifıed a preliminary population of 40 stage II-III melanoma patients
diagnosed between 2000 and 2012. Clinical follow up was available on 21
patients, 12 of whom were alive with no evidence of recurrence, 1 who died
of another malignancy, and 8 who died of melanoma. 19 patients had more
than 24 months of survival information available but no detailed clinical
information. 5m slides from either primary biopsy or subsequent wide
local excision procedure were stained using qIF for DAPI, CD3, CD8, CD68,
SOX10, HLA-DR and Ki67. Cell phenotypes within representative fıelds
selected by a trained dermatopathologist (BH), were visualized using multi-
spectral imaging, and analysis of spatial distribution of cells were analyzed
using inForm image analysis software (Perkin Elmer), and Spotfıre software
(TIBCO). Results: We were able to quantify and identify coordinates for
multiple immune cell subsets in melanoma tissues. In 21 patients with clin-
ical follow up, we found that higher densities of CD3CD8 T cells in
tumor and stroma trended towards correlation with non-recurrence. In ad-
dition, CD68HLA-DR- predicts poor prognosis (p0.05), whether in tu-
mor or stroma. Assessment of spatial distribution across all 40 tumors dem-
onstrated that CD3CD8 cells are closer to CD68 cells and Sox10
tumor cells when they express HLA-DR (p0.001). Conversely,
CD3CD8 cells are signifıcantly farther from tumor cells when they ex-
press Ki-67, (p0.001). Among patients with clinical follow up,
CD3CD8 cells were closer to CD68HLA-DR- cells in recurrent pa-
tients (p  0.05). Conclusion: Using qIF imaging and analysis we fınd that
density and spatial relationships of immune cell subsets correlates with re-
currence status. qIF may offer the potential for the development of prognos-
tic biomarkers in stage II/III melanoma.
#1672 Workflow automation and parallelization improves the isolation
and analysis of tumor-infıltrating immune subpopulations. Janina Brauner,
David Agorku, Anne Langhammer, Lukas Pohlig, Jan Drewes, Thomas Dino
Rockel, Oliver Schilling, Stephan Mehlhose, Wa’el Al Rawashdeh, Andreas Bo-
sio, Olaf Hardt.Miltenyi Biotec GmbH, Bergisch Gladbach, Germany.
Immunotherapy against cancer has proven clinical effıcacy and tremen-
dous potential in multiple tumor entities. Syngeneic mouse tumor models
represent the gold standard to analyze effects of immunotherapy due to their
fully competent immune-repertoire. However, the amount and composition
of tumor infıltrating leukocytes (TIL) is highly variable, complicating the
targeted analysis of subpopulations. In particular, small subpopulations can-
not be analyzed properly but may be lost in the background noise. When
working with large cohort sizes, even the immune-phenotyping of TIL by
flow cytometry is time consuming and data processing highly work intensive
making pre-enrichment methods for sample debulking attractive. We have
established an automated workflow combining tissue dissociation with TIL
specifıc isolation to improve and accelerate downstream analysis. Tumor
dissociation was automated using the gentleMACSTMOcto Dissociator and
optimized for epitope conservation to overcome bias in immune-phenotyp-
ing caused by dissociation with aggressive of impure enzymes. Next, isola-
tion of TIL was improved by developing a new CD45-specifıc enrichment
reagent for the magnetic cell sorting (MACS) based isolation directly from
dissociated tumor tissue. The whole workflow takes only about 90 min. To
validate this method on starting material showing variable frequencies of
TIL infıltration, we used syngeneic mouse tumors derived by injection three
independent tumor cell lines. Tumors derived from injection of B16.F10
melanoma showed TIL frequencies of 2-4%, CT26.WT colon carcinoma tu-
mors 15-21%, and 4T1 breast carcinoma tumors 32-37% among total viable
cells after dissociation. Using amanual separation system, TIL were enriched
to purities above 90% at yields above 70% for CT26.WT and 4T1 tumors, and
purities above 80% at high yields above 95% for B16.F10 tumors. To address
the need of parallelization and automation for sample processing in large
cohort sizes used in in vivo studies, a fully automated version of the Multi-
MACSTM Cell24 Separator was developed by integrating the instrument in a
liquid handling robotic platform. This new system, theMultiMACSTMX, can
process 24 cell separations in parallel with minimal hands-on time. When
compared to the manual system, equal purities were achieved whereas the
overall yield of target cells was increased from 70% to 90% as shown in the
case of CT26.WT tumors. Importantly, while the TIL enrichment signifı-
cantly reduced the time and reagent costs in immune subset analysis, the
composition of infıltrating immune cells was not affected, excluding the risk
of introducing a bias by this method. Taken together, we have developed an
automated workflow for the isolation of TIL from mouse tumors reducing
time and costs of downstream analysis while standardizing and enhancing
the detection and quantifıcation of immune cell subpopulations.
#1673 Mass spectrometric characterization of peptides associated with
molecules of the major histocompatibility complex. Michael Ford,1 Richard
Jones,1 David Allen,1 Ravi Amunugama,1 Paul Del Rizzo,2 Michael Pisano,2
James Mobley,2 Paul Domanski,2 Bill Ho,2 Daniel Bochar2. 1MS Bioworks, Ann
Arbor, MI; 2Cayman Chemical, Ann Arbor, MI.
The major histocompatibility complex (MHC) is a region of highly polymor-
phic genes encoding for glycoproteins (MHC molecules) that form part of the
cell-mediated branch of the acquired immune system. In the cytosol, cellular self
and foreign (non-self) proteins are constantly being degraded; it is the peptides
generated that are presented, non-covalently bound to MHCmolecules, on the
surface of cells for inspection by cytotoxic T-lymphocytes (CTLs). Non recog-
nition of the presented peptide ultimately leads to cell destruction. Characteriz-
ing the factors associated with Non recognition is an attractive proposition for
anyone interested in generating tools for targeted cell destruction. In the fıeld of
oncology the obvious application then is the targeted destruction of cancerous
cells. To enable the molecular level characterization of peptides associated with
molecules of the major histocompatibility complex requires a targeted protein
complex enrichment, an unbiased peptide elution and fınally a peptide analysis
method. Most frequently an immunoprecipitation is used to isolate the target
complex. The peptide elution is performed under conditions minimizing pro-
tein contamination and fınally peptide analysis is accomplished by mass spec-
trometry. Here we present a case study of our recent work optimizing and per-
forming a workflow for the analysis of peptides associated with Class I MHC
molecules. The goal of the assay optimization was to minimize the amount of
antibody required for the assay, to minimize the amount of biological material
needed from which the complex is isolated and to achieve the optimum sensi-
tivity towards the hitherto unknown target peptides.
#1674 Quantifying tumor-infıltrating leukocytes in hematoxylin stained
NSCLC tissue samples using morphometric features. Elliott Ergon, Allison S.
Harney, Nathan Martin, Will Paces, Famke Aeffner, Kristin Wilson, Janet Pat-
terson-Kane, Karen Ryall, Daniel G. Rudmann, Brooke Hirsch, Joseph Krueger.
Flagship Biosciences, Westminster, CO.
Quantifıcation of tumor-infıltrating lymphocytes (TILs) in non-small cell
lung cancers (NSCLC) is valuable for understanding patient prognosis and sur-
vival. TILs comprise a subset of tumor-infıltrating leukocytes that modulate
immune evasion and response to therapy. Understanding the composition of
TIL subsets, especially relative to the total tumor leukocyte population, may
provide additional context for understanding NSCLC pathogenesis and patient
response to treatment. However, availability of tissues and use of chromogenic
assays can limit the number of TIL and leukocyte subset markers assayed in a
tissue section. Therefore, this study evaluated the identifıcation of total leuko-
cyte component in NSCLC using morphometric parameters and routine TIL
marker monoplex immunohistochemistry (IHC) assays to further identify the
composition of TIL subsets. Computational Tissue Analysis (cTATM) tools were
used to determine the morphometric parameters which could identify immune
cells in the absence of biomarker stain. The morphometric features which char-
acterized immune infıltrates were used to quantify the total immune cell popu-
lation frequency in the tumor nests and surrounding stroma in hematoxylin-
stained tissues. The leukocyte population identifıed with morphometric
parameters was correlated with CD45 cell frequencies identifıed by cTA based
on biomarker staining inCD45-stained serial sections. Thismorphometric rule-
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set was then applied to CD3- and CD8-stained tissues to evaluate the frequency
of CD3 and CD8 TILs in the context of total infıltrating leukocytes. The
relative populations of CD3 and CD8 TILs were consistent with available
literature demonstrating that the morphometric ruleset could be utilized to en-
able evaluation of TIL sub-types relative to total leukocyte population without
the need for additional IHC stains. The approach could, therefore, provide an
added dimension of analysis for tissues stained by IHC for identifying the total
immune cell infıltrating component without requiring additional biomarker
staining.
#1675 Parallel genome and transcriptome-wide profıling of PD-L1 ex-
pressing tumor and infıltrating immune single cells in NSCLC. Stefano Ca-
sonato,1 Giulio Bassi,1 Chiara Bolognesi,1 Chiara Mangano,1 Valentina del Mo-
naco,1 Genny Buson,1 Claudio Forcato,1 Alberto Ferrarini,1 Farideh Bischoff,2
Gianni Medoro,1 Nicolò Menaresi,1 Francesca Fontana1. 1Menarini Silicon Bio-
systems SpA, Castel Maggiore, Bologna, Italy; 2Menarini Silicon Biosystems Inc,
San Diego, CA.
Introduction Targeting immune checkpoint has demonstrated contrasting
clinical response in non-small cell lung cancer (NSCLC) due to the lack of robust
biomarkers for patients stratifıcation. This is partially due to a poor understand-
ing of the role of the different cellular players (tumor, stromal, infıltrating im-
mune cells) within the tumormicroenvironment.Herewe present an innovative
workflow using the DEPArrayTM sorting system, to isolate different classes of
epithelial and hematopoietic viable single cells from fresh tissue biopsies for
integrated genome and transcriptome sequencing analysis. Methods Freshly
resectedNSCLC tissue was dissociatedmechanically and enzymatically down to
single cell suspension, and labelled with immunofluorescent antibodies target-
ing PD-L1 (28-8), EpCAM, CD8, CD45 along with Hoechst 33342 for nuclei
detection. Distinct pure single cells, along with pools of precise number of cells
were digitally isolated usingDEPArrayTM platformbased onmarker expression.
For each cell recovery, mRNAwas physically separated from genomicDNA and
then amplifıed using the Ampli1TMWTA Kit to generate a library of high qual-
ity, full-length double stranded cDNA. Amplifıed cDNA is used for NGS library
preparation and sequencing on Illumina® MiSeq System. In parallel, genomic
DNA is collected with magnetic beads and eluted directly into the reaction
mixture for whole genome amplifıcation by Ampli1TM WGA kit. The WGA
products were used to profıle genome-wide copy-number aberrations (CNA)
using Ampli1TM LowPass kit. Results As a fırst step, we identifıed two main cell
populations, the CD45 infıltrating hematopoietic cells and the EpCAM ep-
ithelial cells. The hematopoietic fraction was further investigated to evaluate the
presence of different subpopulations. Interestingly the PD-L1 population,
corresponding to immune suppressive hematopoietic cells, represented 47% of
the total CD45 fraction while CD8 cells corresponding to cytotoxic T cells
represented 9% of the total CD45. In the EpCAM population the PD-L1
fraction represented 29% of the cells. Single viable cells along with matching
pools of precise number of cells from each population were digitally isolated
with DEPArrayTM system for downstream analysis. Results of RNA-Seq and
genomic DNA copy-number aberrations profıling will be presented at the con-
ference. Conclusion We show here a new approach to isolate pure, single PD-
L1/ tumor and tumor infıltrating hematopoietic cells fromNSCLC tissue for
integrated genome and transcriptome sequencing. The direct comparison of
gene expression data to its corresponding genomic data in the same tumor cell,
along with the transcriptomic profıling of immune infıltrate and stroma, may
add a powerful tool to disentangle the tumor microenvironment biology. This
will potentially offer a novel tool to develop new biomarkers and identify ther-
apeutic leads.
#1676 EZH2 inhibitors in immunotherapy of melanoma. Peter Hersey,1
Stuart Gallagher,1 Jessamy Tiffen,1 Elena Shklovskaya,1 Stephen Wilson,2 Fa-
bian Filipp3. 1Univ. of Sydney, Sydney, Australia; 2University of California Mer-
ced, Merced, CA; 3University of California Merced, Merced, CA.
EZH2 contains the catalytic subunit of the PRC2 complex, which plays a role
in maintenance of stem cell- like state of cancer cells and in the progression of
melanoma. Our previous studies have shown that hyperactivation of EZH2 by
somatic mutations or copy number gain occurs in 20% of melanoma patients
and impacts overall survival. Elevated activity of EZH2 in cancer can be targeted
by small molecule drugs (e.g. GSK126) and is associated with sensitivity to ap-
optotic cell death. Transcriptomic profıling showed that several well-known
tumor suppressors such as BOK, NDRG1 and RASSF5 are down-regulated in
cells with abnormalities in EZH2, which can be reversed by inhibitor treatment.
By using our in vitro EZH2 drug targeting assay we validated genes associated
with immune recognition andMHCclass II antigen presentation such asHLAA
and B,DR and CD74 (HLA DR invariant chain). In addition, ChIP-Seq studies
identifıed adhesion molecules, chemokine ligands, and receptors involved in
traffıc of lymphocytes to tumors as well as the function ofNK cells. Treatment of
melanoma with EZH2 inhibitors showed increased killing by NK cells suggest-
ing that an immunosuppressive effect of EZH2 involving both innate and adap-
tive immunity. In a mouse model of subcutaneous B16 melanoma, a course of
daily treatment with an EZH2 inhibitor did not change tumour growth or im-
mune responses in immunosuffıcientmice but caused a transient 9-fold increase
in circulating Ly6G [granulocytic]myeloid-derived suppressor cells [MDSCs]
suggesting the effect of EZH2 modifıers on the myeloid compartment. In sum-
mary, patients with somatic activation of EZH2 may benefıt from treatment
combinations that include inhibitors of EZH2. Supported by NHMRC program
grant 633004, Sydney medical school foundation and Cancer Institute
NSW. F.V.F. is grateful for the support of grants CA154887 from the National
Institutes of Health, National Cancer Institute and CRCC CRN-17-427258.
#1677 Immuno-target selection of infıltrating immune cells and laser cap-
ture microdissection mediated transcriptional profıling. Ross Haggart,
Chaxiraxi Arzola-Donate, Elliott Harrison, Benjamin J. Reed, Saba Alzabin,
Gino Miele. Epistem Ltd., Manchester, United Kingdom.
Immune checkpoints defıne an evolving class of inhibitorymediators that are
expressed by tumour cells and infıltrating leucocytes to down-modulate the
effector immune response against tumour cells. Therefore, the most recent ef-
forts in cancer therapy centre on targeting immune-mediated mechanisms of
tumour evasion. The ability to assess gene expression profıles from isolated
populations of tumour-infıltrating lymphocytes (TILs) can assist in monitoring
checkpoint inhibitor therapy effıcacy and provide a better understanding of
clinical outcomes. Ideally, transcriptional profıles should be obtained from iso-
lated cell populations of interest, free from contaminating cell populations that
may create adverse background noise. Micro sampling by laser capture micro-
dissection is a powerful tool that allows for specifıc analysis from whole tissues,
particularly in a heterogeneous microenvironment such as in a tumour, where
less well represented target cells are dwarfed in abundance by tissue stroma and
other cell types.However,whilst the application is potentially powerful for target
discovery and mechanistic understanding, the process is notoriously diffıcult,
particularly in clinical specimens. We developed a methodology to successfully
overcome these challenges in analysing target cells, organelles or other tissue
subsets by transcriptional profıling following immunostain-mediated laser cap-
ture microscopy (LCM). Thorough optimisation of traditional immunohisto-
chemistry techniques enabled us to select target cell populations of interest from
tissue sectionswhilstminimising degradation ofmRNAandmiRNAallowingus
to perform genomic and pathway interrogation using microarray and/or RT-
qPCR analysis. Our technique allows multiple capture types per slide, sample
pooling when required, high capture throughput and capture image documen-
tation. Multiple target selection, to differentiate lymphocytes, can be performed
routinely using comparative serial sectioning. Here we exhibit simple staining
and immunostaining histology images using methods sympathetic to RNA in-
tegrity which allow for target selection by specifıc staining or targetmorphology,
and demonstrate comparative analysis of matched pairs of disease and healthy
sections of colon tumours. We used a Palm MicroBeam 4 LCM platform to
identify, cut and specifıcally capture CD8 tumour-infıltrating lymphocytes
from frozen embedded tissue. This approach enabled us to isolate discrete tar-
geted cell populations free from contaminating cell populations. Epistem’s Sin-
gle Cell RNA-AmpTM was then used to provide robust and linear amplifıcation
of RNA and enable comparative analysis in applications such as target discovery
and pharmacodynamics. The results indicated that transcriptional profıling was
technically robust with a good replicate correlation despite the limited input
obtained by micro-sampling.
#1678 A flow-based immunoprofıling strategy for interrogating system-
wide leukocyte composition in response to glioblastoma. Gregory J. Baker,1
P.S. Thiagarajan,1 Sucheendra K. Palaniappan,2 Stephanie H. Davis,1 Jodene K.
Moore,1 Peter K. Sorger1. 1Harvard Medical School, Boston, MA; 2Systems Biol-
ogy Institute, Tokyo, Japan.
Glioblastoma (GBM) is a deadly brain cancer that suppresses cellular immu-
nity through the production of anti-inflammatory cytokines/catabolites, expres-
sion of immune checkpoint molecules, and induction of tolerogenic immune
cell subsets. While preclinical models have shown each of these mechanisms to
negatively impact survival outcome, it remains unclear how these distinct pro-
cesses manifest themselves within the context of a coordinated immune system
andwhether additional immunosuppressivemechanisms exist. To address these
questions, we have developed an extensible in vivo screening platform to holis-
tically determine how GBM affects cellular immune organization. The method
allows for temporal assessment of leukocyte population dynamics in response to
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tumor progression. Leukocytes derived from lymphoid tissues of tumor-bearing
mice are isolated and immunolabeled with a 12-color optimized immunofluo-
rescence panel (OMIP) targeting several major leukocyte lineages. Single-cell
data is acquired by flow cytometry and is clustered in an unsupervised manner
based on cell-surface protein expression. A vector-based classifıcation system is
then used to map phenotypically distinct clusters onto known immune cell
lineages. The platform allows for the extraction of immune signatures whose
divergence from tumor-naïve standards may be quantifıed and statistically an-
alyzed; such signatures may also be correlated with response/resistance to ther-
apy. The approach has been validated on orthotopic GL261 glioma in syngeneic
C57BL6/J mice, yet it is readily amenable to the study of diverse model systems,
including de novo tumors driven by clinically-relevant oncogenes. Alternative
flow cytometry antibody panels may easily be substituted to probemore specifıc
immune cell subsets of interest. Systems biology approaches applied to the fıeld
of tumor-induced immunosuppression hold promise in identifying novel net-
work-level immune signatures, facilitating a better understanding of immuno-
therapeutic drug action, and driving next generation high-dimensional bio-
marker discovery.
#1679 BET inhibitors suppress PD-L1 expression in pancreatic stellate
cells. Kazumi Ebine, Brian T. DeCant, Katharine A. Collier, Thao N. Pham,
Krishan Kumar, Hidayatullah G.Munshi.Northwestern University, Chicago, IL.
Single agent treatmentwithT-cell checkpoint inhibitors has not been effective
in pancreatic ductal adenocarcinoma (PDAC) patients. The PDAC stroma,
which can account for asmuch as 80-90%of the tumormass, can act as a physical
and an immunologic barrier to T-cell-mediated therapies. Transgenic mouse
models have shown that ablation of pancreatic stellate cells (PSCs), key regula-
tors of fıbrosis in vivo, can sensitize PDAC tumors to immune checkpoint ther-
apies. Recently, inhibitors targeting bromodomains and extra-terminal (BET)
proteins, a number of which are currently being evaluated in clinical trials for
solid tumors, were shown to induce stellate cells to become quiescent and de-
crease collagen production. The BET family of proteins binds to acetylation
motifs present in histones and enables recruitment of transcription factors and
other chromatin regulators duringRNA transcription.Wehave found that PSCs
express signifıcantly increased PD-L1 levels compared to pancreatic cancer cell
lines. We show that BET inhibitors, and in particular specifıc knockdown of
BRD4protein, decrease basal and IFN--mediatedPD-L1 expression in primary
stellate cells. We also show that, in contrast to a recent report using cancer cells,
c-MYC does not mediate basal or IFN--mediated PD-L1 expression in stellate
cells. Instead, we show that the IFN--mediated PD-L1 expression is regulated
by IRF1, suggesting cross talk between BRD4 and IRF1 in the regulation of
PD-L1 expression. Ongoing in vivo experiments will evaluate the role of BET
inhibitors in the regulation of PD-L1 in mouse models of pancreatic cancer.
#1680 BPM31510, an anti-cancer agent selectively causes activation and
proliferation of T cells, demonstrating potential utility in an immune-oncol-
ogy setting. Maria-D Nastke, Nidhi Gaur, Louisa Dowal, Samantha Fowler,
Anne Diers, Stephane Gesta, Vivek K. Vishnudas, Niven R. Narain, Ranga-
prasad Sarangarajan. BERG, LLC, Framingham, MA.
BPM 31510, a clinical stage, nanodispersion of ubidecarenone has a unique
mechanism of action that effectuates an anti-Warburg switch in cancer cell
metabolism and activation of apoptosis. Given the observed central role of BPM
31510 in regulating mitochondrial function in cancer cells, it is of great interest
to investigate the ability of BPM 31510 to modulate immune cells and their
functionality. Therefore, the effects of BPM 31510 on peripheral blood mono-
nuclear cells (PBMCs) were investigated to elucidate the immuno-metabolic
mechanism of BPM31510. Healthy donor PBMCs activated with PHA or PWM
was used asmodel system, and the effect of BPM31510 on immune cells viability
was determined using flow cytometry. In addition, the effect of BPM31510 on
immune cell function was evaluated by measuring a panel cytokines released in
these cells, using a quantitative ELISA platform from Meso Scale Discovery.
Results: BPM 31510 has been shown in previous studies to effectively induce
apoptosis on a variety of cancer cell lines while sparing normal cells. Interest-
ingly, increasing concentrations of BPM31510 lead to an increased frequency of
viable CD3 cells. Further phenotypic analysis revealed that cytotoxic T cells
(CD8/CD3) and T helper cells (CD4/CD3), as well as NKT cells (CD56/
CD3) contributed to the observed increase in T cells frequency. On the other
hand, B cells (CD19), NK cells (CD56/CD3), and the monocytes (CD14)
showed a decrease in frequency, an effect reflected also by a reduction in viability
with increasing BPM 31510 concentrations. Cytokine analysis indicated that
effector cytokines IL-2, IFN-, and TNF- were secreted at signifıcantly higher
levels with increasing concentration of BPM31510. Interestingly, IL-10 level, an
immuno-regulatory cytokine, was strongly decreased in the supernatant of PB-
MCs treatedwithBPM31510. Taken together, we demonstrated that BPM31510
has a direct effect on immune cells and their functionality. Although BPM31510
induced apoptosis of cancer cells, our data indicate that it supports cell prolifer-
ation of T cells, and effector function of adaptive immune cells, likely by provid-
ing a higher energy supply for effector T cells. Subsequently, a higher activation
state of effector T cells may result in increased levels of cytotoxic effector mole-
cules (perforin, granzymes, Fas ligand) andmacrophage activating effectormol-
ecules (IFN-, IL-2, TNF-) which supports and attracts other immune cells like
NK cells to the tumor.
#1681 The antitumor effect of a soluble recombinant human thrombo-
modulin as growth suppression against gastrointestinal tumor in murine
peritonitismodel.EnAmada, Kazumasa Fukuda, Koshi Kumagai, Koichi Suda,
Hiroya Takeuchi, Yuko Kitagawa. Keio University School of Medicine, Tokyo,
Japan.
Introduction: Severe postoperative inflammatory response (PIR) with CARS
increases the risk of tumor recurrence after cancer surgery by Tregs suppressing
antitumor immunity. Also, cancer recruits Tregs into its tissue by secreting
CCL22 and TGF-beta that strengthen its survival. We established a model to
represent tumor dynamics undergo PIR by mice that are performed cecal liga-
tion and puncture (CLP) followed by subcutaneous injection of cancer cells into
the dorsum. In this model, we previously revealed signifıcant tumor growth and
increase number of Tregs both in tumor tissue and blood compared to the
normalmice. A soluble recombinant human thrombomodulin (rhTM) is devel-
oped as a treatment drug againstDIC. It has anti-inflammatory effect and several
reports showed that it prevents cancer metastasis. We hypothesized that rhTM
normalizes PIR and prevents cancer growth caused by inflammation. Method:
Ten-week-old C57BL/6 mice were divided in CLP/rhTM, CLP/normal saline
(NS), and control (simple laparotomy plus NS) groups. rhTM (3mg/kg/12hrs)
was injected subcutaneously for 7 consecutive days from the day before CLP.
CT26 cells (1104) were implanted 4 hours after CLP. Mice were sacrifıced 28
days after CLP. Then, the tumor tissue and blood were collected. To analyze
dynamics of Treg, peripheral blood leukocytes the tumor cells were isolated.
CD4, CD25 and Foxp3 were stained by fluorescent antibody and stained cells
underwent flow cytometric analysis. The quantity of Tregs is measured by the
rate of CD25/Foxp3 population in CD4 T cells. The level of CCL22 and
TGF-beta were measured both in serum and tumor tissue. The ELISA was used
for analyzing serum samples. And for tumor tissue, immunostaing by DAB was
performed and positively stained areas were calculated by image-editing soft-
ware. Results: CLP/NS groupmice exhibited signifıcant enhanced tumor growth
compared to controls (6.0	1.9 g vs. 3.5	1.6 g, p0.03), whileCLP/rhTMgroup
produced signifıcantly smaller tumors (2.2	1.1 g) than CLP/NS (p0.01). The
Tregs in the blood streamwas smaller inCLP/rhTMgroup compared toCLP/NS
group. Intratumoral Tregs showed signifıcant difference between CLP/rhTM
group and CLP/NS group (8.89	3.5 % vs. 24.1	15.0 %, p0.02). We found
signifıcant elevation of serum TGF-beta level by CLP (4.7	1.2 pg/ml vs.
15.4	7.0 pg/ml, p0.02) and relative reduction to 15.4	7.0 pg/ml by adminis-
tration of rhTM (p0.05). However, we did not recognize any change of serum
CCL22 level in this study. Intratumoral rate ofCCL22positive areas increased by
CLP (41% vs. 50%), while rhTM made it decreased to 43%. We found little
difference of TGF-beta positive areas among three groups in this study. Conclu-
sion: Acute inflammation induced by CLP enhances the growth of implanted
tumors, while administration of rhTM suppresses tumor growth by possibly
affecting dynamics Tregs via TGF-beta and CCL22.
#1681A Overcoming pd1 targeting antibody resistance using combina-
tion strategies. Jean-François Mirjolet, Maxime Ramelet, Damien France. On-
codesign S.A., Dijon Cedex, France.
PD-1 targeting antibodies (nivolumab, pembrolizumab) are now approved in
various tumor types either as second line treatment (locally advanced or meta-
static urothelial carcinoma, advanced renal cell carcinoma, recurrent or meta-
static head and neck squamous cell carcinoma, classical Hodgkin lymphoma) or
even as fırst line therapy (metastatic melanoma, metastatic non-small cell lung
cancer). Despite an increase in response rate as well as survival, there is still issue
with resistance to PD-1 targeting therapies. Selection biomarkers as well as re-
sponse biomarkers are still under intensive research. In addition, combination
strategies are needed to increase response rate and overcome resistance. Com-
bination strategies were therefore tested in one well characterized syngeneic
mouse model, i.e. EMT-6 breast carcinoma. The model is known to be highly
sensitive to CTLA-4 targeting antibody (optimum tumor to control ratio (T/C)
of 3%), amoderate responder to PD-1 targeting treatment (best T/C of 54%) and
a well immune infıltrated tumor. Antibodies targeting co-stimulatory receptor
such as OX40, GITR and 4-1BB as well as co-inhibitory receptor such as Tim3
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were combined to anti-PD-1 antibody. In all cases, combination arm produces
better therapeutic activity when compared to single treatment alone. Moreover,
both strategies, meaning combination of two antibodies targeting co-inhibitory
receptors (PD-1  Tim3) and combination targeting one co-inhibitory (i.e.
PD-1) and one co-stimulatory receptors (OX40, GITR or 4-1BB) worked. De-
tailed results will be presented including response rate, immune infıltrates and
cytokines profıles in order to rationally choose the best therapeutic treatment.
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#1682 Correlation of immune co-stimulatory molecule OX40 and out-
come in trastuzumab treated HER2-positive breast cancer patients in the
NCCTG-N9831. Saranya Chumsri,1 Daniel J. Serie,1 AfshinMashadi-Hossein,2
SarahWarren,2 AlvaroMoreno-Aspitia,1 GeraldoColon-Otero,1 Keith L. Knut-
son,1 Edith A. Perez,1 E. Aubrey Thompson1. 1Mayo Clinic Cancer Center, Jack-
sonville, FL; 2NanoString Technologies, Inc., Seattle, WA.
Background: Trastuzumab (H), a monoclonal antibody against HER2, has
revolutionized the treatment for HER2-positive breast cancer. Besides inhibit-
ing downstream signaling of HER2, several studies showed that H also exerts its
anti-tumor activity via immune-related mechanisms. While H is quite effective
in preventing recurrence, signifıcant numbers of patients still develop recur-
rence despite adjuvant H-based chemotherapy. In this study, we analyzed im-
mune-related genes thatwere associatedwith poor outcome inN9831.Methods:
NanoStringTM technology was used to quantify mRNA of immune-related
genes in baseline samples from 1,280 patients in N9831. In N9831, patients in
arm A were treated with chemotherapy alone (AC-T), arm B received chemo-
therapy followed by sequentialH (AC-T-H), and armC receivedH concurrently
with chemotherapy (AC-TH). Cox proportional hazard ratio (HR) was used to
determine the association of each immune-related gene with recurrence free
survival (RFS). Different immune subset signatures, including CD45, CD8, cy-
totoxic-cells, and T-cells were analyzed using algorithms developed by NanoS-
tring. Results: With the median follow up of 10.6 years, we identifıed a total 77
genes that were associated with improved outcome in arm C. Among these 77
genes, there were 20 tumor necrosis factor (TNF)-related genes. Of those, only
OX40 (TNFRSF4) and its ligand TNFSF4 have interaction p  0.10. Interest-
ingly, we found uneven distribution of OX40 expression in the N9831 speci-
mens. Approximately, 9.5% of HER2-positive breast cancer expressed OX40 at
distinctly low level. Low expression of OX40 was signifıcantly associated with
HR positivity (OX40 low 61% vs. OX40 high 51%, p 0.003) and larger tumor size
but not patients’ age, tumor grade, and lymph node status. Low expression of
OX40 was signifıcantly associated with low mTIL-CD45, CD8, cytotoxic-cells,
and T-cells immune signature scores. Tumors with low OX40 expression had
signifıcantly lower levels of CTLA4 (p 9.11e-71) and PD-L1 expressions (p
2.49e-92). Low expression of OX40 is associated with poorer outcome among
patients treated with H in both sequential (HR 0.88, 95% CI 0.79-0.98, p 0.022)
and concurrent arms (HR 0.86, 95%CI 0.76-0.98, p 0.027) but not in chemother-
apy only arm (HR 0.9, 95%CI 0.90-1.09, p 0.8). Similar fındings were observed
with its ligand TNFSF4 in armA (HR 1.02, 95%CI 0.92-1.15, p 0.68), arm B (HR
0.87, 95%CI 0.76-0.99, p 0.04), and arm C (HR 0.81, 95%CI 0.68-0.95, p 0.01).
Conclusion: Our study suggests that pre-existing expression of OX40 and its
ligand TNFSF4 are prognostic andmay also be predictive of adjuvant H benefıt.
Patients with distinctly low level of OX40 had poor outcome despite adjuvant
H-based adjuvant chemotherapy. Our study provides a rationale to further eval-
uate the strategy to increase immune activation to improve outcome in this
group of patients.
#1683 A novel adenosine A2A receptor antagonist optimized for high
potency in adenosine-rich tumor microenvironment boosts antitumor im-
munity. Erica Houthuys, Margreet Brouwer, Florence Nyawouame, Romain
Pirson, Reece Marillier, Theo Deregnaucourt, Joao Marchante, Jakub Swiercz,
Charlotte Moulin, Vanesa Bol, Gregory Driessens, Michel Detheux, Christophe
Quéva, Stefano Crosignani, Bruno Gomes. iTeos Therapeutics, Gosselies, Bel-
gium.
High levels of extracellular adenosine in the tumor microenvironment are
known to play a signifıcant role in tumor immune evasion and promote tumor
growth and metastasis. We defıned the receptor(s) required for mediating the
effect of adenosine on immune cells within the tumor microenvionment and
report the characterization of a novel Immuno-Oncology-dedicated adenosine
receptor 2A antagonist that functions in the high adenosine concentration
found in tumors. We fırst explored the expression of the four adenosine recep-
tors in primary human immune cells. A2A receptor was the main adenosine
receptor expressed by CD4 and CD8 T lymphocytes and monocytes, and the
only one inmature monocyte-derived dendritic cells and NK cells. A2B receptor
was poorly detected in T cells and monocytes, while A1 and A3 receptors were
never detected. Given these expression patterns, we further studied A2A func-
tions in primary human T lymphocytes and monocytes. Selective A2A agonists
such as CGS-21680 strongly suppressed cytokine production by activated pri-
mary human T lymphocytes, thus highlighting that A2A is the main effector
receptor of the sensing of adenosine in tumors. We further confırmed the ele-
vated extracellular adenosine level in the tumor microenvironment in several
mouse and human tumors. High adenosine levels correlated with strong tu-
moral expression of CD73, the enzyme that converts AMP to adenosine. Inter-
estingly, we showed that A2A receptor antagonists designed for Parkinson’s dis-
ease dramatically lost potency in a high adenosine environment ; our data
indicated that a 30-fold dose increase may be required for full target inhibition
within tumors. Therefore we developed a novel and potent A2A blocker with
sub-nanomolarKi and IC50 in a cAMPassay and amore than 100-fold selectivity
over other adenosine receptors. Our lead compound kept a high potency in an
adenosine-rich environment and restored cytokine production even in the pres-
ence of high concentrations of A2A agonists. iTeos inhibitor also effıciently re-
versed AMP-mediated T cell suppression. Furthermore, our compound rescued
A2A receptor agonist-induced decrease of TNF production by primary human
monocytes, and was able to potently increase CD8 T cell cytotoxicity in a cyto-
toxicity assay with CD8 T cells as effectors and cancer cells as targets. These
results suggest that iTeos newgeneration ofA2A receptor antagonist, designed to
keep a high potency in the adenosine-rich tumor microenvironment, may offer
a new therapeutic opportunity in Immuno-Oncology.
#1685 Effects of anti-ctla-4 and anti-pd-1 on memory T-cell differentia-
tion and resistance to tumor relapse. Stephen Mok, Colm R. Duffy, James P.
Allison.MD Anderson Cancer Center, Houston, TX.
The FDA has begun to expand the approved uses of immune checkpoint
blockade antibodies targeting CTLA-4 and PD-1. Blocking either checkpoint
relieves the negative regulation of T-cells resulting in signifıcant responses in
patients with cancer. Data has now begun to emerge regarding differences be-
tween these two therapies. While PD-1 therapy has a greater response rate
(30% vs. 11%) according to RECIST criteria, recent reports have suggested
responses to PD-1 may not be as durable as CTLA-4. 25% of patients who
initially responded to PD-1 have tumor relapse within 24 months. In contrast,
the 3-year survival rate of patients treated with CTLA-4 is at least25% sug-
gesting a durable response. Previous studies in bacterial or chronic LCMV in-
fectious models have shown that CTLA-4 can increase CD8memory T-cell
formation, whereas genetic ablation of PD-1 on T-cells often promotes the ter-
minally differentiated exhausted CD8 T-cell phenotype, while attenuating
memory T-cell formation. However, the mechanism which leads to relapse fol-
lowing PD-1 treatment in tumor models is not clear. The goal of this project is
to understand how immunotherapies shape memory T-cell formation and how
that relates to the mechanism of tumor relapse. To test whether CTLA-4 or
PD-1 can induce a better memory T-cell response, mice were vaccinated with
irradiated B16F10 murine melanoma cells and treated CTLA-4 or PD-1.
Mice were re-challenged with B16F10 80 days after vaccination. Although both
CTLA-4 and PD-1 improved tumor rejection compared with controls,
CTLA-4 treated mice exhibited superior tumor control compared to PD-1
(p0.0005) suggesting the memory T-cell response mediated by CTLA-4 is
more durable. In order to test whether this memory T-cell response is antigen-
specifıc, mice were re-challenged with unrelated MC38 or 3LL cancer cells. The
antibody treated groups did not show improved antitumor effect comparedwith
vaccine control (p0.5). To test whether the frequency of memory T-cells re-
cruited to the re-challenged tumor could affect memory T-cell response, anti-
gen-specifıc pmel-1 T-cells were infused to mice following vaccination with
CTLA-4 or PD-1. Our result suggested that there were more tumor-infıltrat-
ing pmel-1 T-cells in the CTLA-4 treated group compared to the PD-1
treated group (p0.05). In order to augment the durability ofPD-1 treatment,
PD-1 was combined with CTLA-4 following vaccination. The combined
treatment group has superior antitumor response compared to that with PD-1
(p0.000003) and overlapped with the CTLA-4 treated group (P0.05) dur-
ing re-challenge, indicating that the effect of the combined treatment is domi-
nated byCTLA-4. Collectively, our studies facilitate the design of combination
immunotherapy treatments that enhance both response rates and generation of
memory T-cells to prevent relapse.
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#1686 Epigenetic modulation of the tumor microenvironment enhances
vaccine induced T cell responses in a murine model of pancreatic cancer.
Brian Christmas,1 Blake Scott,1 Todd Armstrong,1 Nilofer Azad,2 Elizabeth
Jaffee1. 1Johns Hopkins University, Baltimore, MD; 2Johns Hopkins Sidney Kim-
mel Comp. Cancer Ctr., Baltimore, MD.
This project aims to test the hypothesis that epigenetic modulatory drugs
(EMD) and GVAX, a GM-CSF-secreting whole tumor cell vaccine, are capable
of altering the inflammatory environment of pancreatic ductal adenocarcinoma
(PDAC) and sensitizing it to checkpoint blocking agents. Recently the use of
antibody therapy targeting immune checkpoints, such asCTLA-4 andPD-1, has
become a major focus of cancer immunotherapy. In responsive patients, these
therapies have resulted in long-term control of chemotherapy-resistant disease.
The most compelling activity has been seen in the minority of patients with
immunogenic tumors where T cell infıltration naturally occurs. These benefıts
are not observed in non-immunogenic tumors, such as PDAC, with low expres-
sion of tumor-associated antigens (TAA) and a lack of intrinsic T cell infıltrates.
Therapies that can alter the tumormicroenvironment (TME) and allow infıltra-
tion of effector T cells, decrease immunosuppressive cells, and stimulate TAA
expression may convert non-immunogenic tumors into cancers sensitive to
checkpoint inhibitors. Recent work with EMDs has shown that they are capable
of altering the immunogenicity of the TMEby inducing the expression of cancer
testis antigens as well as increasing tumor cell expression of MHC class II and
decreasing Tregs in the TME. Additionally, GVAX has been shown to induce
tertiary lymphoid aggregates within the TME of patients with PDAC. We are
testing the hypothesis that treatment with EMDs and GVAX can sensitize the
inflammatory environment of PDAC to checkpoint blockade inhibition by eval-
uating changes in immune cell function within the TME via flow cytometry,
immunohistochemistry, and gene expression array. We are using a murine
model of hepatic metastases of pancreatic cancer which involves injecting syn-
geneic pancreatic tumor cells into the spleen followed by a hemisplenectomy,
resulting in the consistent formation of hepatic metastases that can be moni-
tored by ultrasound. We have evaluated entinostat, a histone deacetylase inhib-
itor, in combination with GVAX which induces T cell responses, and demon-
strated a signifıcant increase in survival when compared with either agent alone.
Flow cytometric analysis of the cells infıltrating the TME shows that the combi-
nation of entinostat and GVAX causes a signifıcant increase in CD4 T cell
infıltration as well as a shift from an M-MDSC dominant to a more G-MDSC
dominant myeloid population. Current studies aim to elucidate the functional-
ity of the MDSC population as well as identify potential changes in the T helper
cell subsets via flow cytometry. Additionally, future studies will evaluate changes
within checkpoint blockade pathways via flow cytometry and gene expression
array to identify pathways that require further modulation to enhance antitu-
mor responses.
#1687 Systemic immunological changes during fırst line chemotherapy in
patients with high-grade serous ovarian cancer. Fenne L. Komdeur, Florine A.
Eggink, Ninke Leffers, Hagma H. Workel, Kim L. Brunekreeft, Annechien Plat,
Marco de Bruyn, HansW. Nijman.University of Groningen, University Medical
Center Groningen, Groningen, Netherlands.
Ovarian cancer remains the most lethal gynecological malignancy and new
therapeutic strategies are urgently needed. High-grade serous ovarian cancer
(HGSC), in particular, is associated with a fıve-year survival of only 40%. A
promising new approach for treating HGSC is immunotherapy, which has re-
sulted in complete and durable responses, albeit in a minority of patients. One
potential approach for improving these response rates is by combining chemo-
and immunotherapy. Indeed, carboplatin/taxol chemotherapy was shown to
augment immune responses in cervical cancer patients by depleting circulating
myeloid suppressor cells. As patients with HGSC are treated in fırst line with
similar carboplatin/taxol chemotherapy, we explored the effects of chemother-
apy on systemic immunity in HGSC patients. Within this prospective observa-
tional study, 75 patients with suspected ovarian cancerwere included. Bloodwas
collected at three different time points during fırst line chemotherapy treatment,
namely: prior to chemotherapy, between the third and fourth cycle of chemo-
therapy and 4-6 weeks after the sixth cycle of chemotherapy. All patients re-
ceived 6 cycles of carboplatin/taxol chemotherapy and cytoreductive surgery
(either as primary debulking, or after 3 cycles of neo-adjuvant chemotherapy).
Peripheral blood mononuclear cells were isolated and analyzed for a total of 36
immune markers using 9 flow cytometry panels, in total analyzing 49 immune
cell subsets. Results were compared to an age-matched cohort consisting of
women surgically treated for a benign disease, and a cohort of healthy young
volunteers. 75 patients have been included so far fromwhich 22 were diagnosed
with benign disease, 3 were diagnosed with another malignancy, and 50 were
diagnosed with OC. Of the 50 OC patients, 18 were diagnosed with HGSC and
from 9 HGSC patients, multiple time points were available for analysis of che-
motherapy-dependent changes in the immune cell subsets. All patients devel-
oped leukopenia as a result of chemotherapeutic treatment. Age-related changes
in lymphocyte and myeloid cell subsets were observed in all HGSC patients and
patients with benign disease. Chemotherapy-dependent depletion of myeloid
cells was observed in a subset of patients. Depletion of myeloid subsets was
equally distributed among monocytes, macrophages and dendritic cells. No
HGSC- or chemotherapy-dependent changes in T cell subsets or migration and
activation markers were observed. Taken together, we observed no major sys-
temic changes in immune cell subsets during carboplatin/taxol chemotherapy
treatment, suggesting that combined chemo-immunotherapeutic strategies
could be feasible during fırst line treatment of HGSC.
#1688 HERA-CD40L: A novel hexavalent CD40 agonist with superior bi-
ological activity. Christian Merz, Jaromir Sykora, Meinolf Thiemann, Viola
Marschall, Karl H. Heinonen, Harald Fricke, Christian Gieffers, Oliver Hill.
Apogenix AG, Heidelberg, Germany.
Introduction: Targeted therapeutics for cancer treatment are mostly devel-
oped as antibodies, however, the natural signaling complexes of the members of
the TNF superfamily and their receptors consist of clusters of trimers. Conse-
quently, most of these bivalent agonistic antibodies depend on Fc receptor me-
diated crosslinking for biological activity. The HERA-Technology developed by
Apogenix generates hexavalent fusion proteins targeting the TNF-receptor su-
perfamily with high clustering capacity for the cognate receptor, which over-
comes this disadvantage of antibody-based drugs. Here we compared the effı-
cacy of different CD40 agonist formats, including the novel HERA-CD40L and
the functional consequences of differential receptor clustering. Materials &
Methods: Biological activity of CD40 agonists was compared using an engi-
neered reporter cell line and by flow cytometric analysis of CD40-induced IB
degradation in Ramos B cells. T lymphocytes andmonocytes were isolated from
buffy coats and expression of CD markers upon CD40 ligation was analysed by
multicolor flow cytometry (MC-FC). Secretion of cytokines in response toCD40
ligation was determined by ELISA. Monitoring of T cell-induced killing of tu-
mor cells in direct co-cultures employed a real-time cell analysis system (xCEL-
Ligence). Results: Direct comparison of bivalent CD40 antibodies with trivalent
CD40L and the hexavalent HERA-CD40L in two independent bioactivity assay
formats demonstrated that only the hexavalent agonist was fully active without
additional crosslinking. In contrast to HERA-CD40L, neither the bivalent ago-
nistic CD40 antibody nor the trivalent CD40L were able to upregulate expres-
sion of activation markers on B cells or to induce secretion of proinflammatory
cytokines such as IL-12 and TNF by PBMCs. In vitro generated M2-macro-
phages acquired anM1 phenotype and enhanced proliferation of naïve CD4T
cells in direct co-culture. Similarly, direct co-culture of CD4 T cells with
Ramos B cells in the presence of HERA-CD40L induced cytotoxic activity of
CD4 cells against tumor cells. The activating effect was dependent on cell-cell
contacts and was not observed in indirect co-cultures. Importantly, only the
hexavalent HERA-CD40L showed full biological activity without additional
crosslinking. Conclusion: The hexavalent CD40 agonist HERA-CD40L pro-
duced by Apogenix HERA-Technology platform triggers CD40 signaling on B
cells and cells of the monocytic lineage, leads to direct cytolytic activation and
proliferation of CD4T cells and shifts theM1/M2 balance towards proinflam-
matory conditions. Unlike bivalent CD40 antibodies or trivalent CD40L_ based
agonists, the hexavalent HERA-CD40L forms highly clustered signaling com-
plexes and thus exhibits superior biological activity over other agonistic formats
without the need for Fc receptor mediated crosslinking.
#1689 Dynamic monitoring of immune response and reagent effıcacy
through high throughput label-free impedance-based technology. Fabio
Cerignoli, Biao Xi, Garret Garret Guenther, Lincoln Muir, Leyna Zhao, Yama
Abassi. ACEA Biosciences Inc., San Diego, CA.
In vitro characterization of reagents effıcacy in the context of cancer immu-
notherapy is a necessary step before moving to more expensive animal models
and clinical studies. However, current in use in vitro assays like Chromium-51,
ATP-based luminescence or flow cytometry are either diffıcult to implement in
high throughput environment or are mainly based on end point methodologies
that are unable to capture the full dynamic of the immune response. Here we
present the adaptation of an impedance-based platform tomonitoring cytotoxic
activity of immune cells activated trough different means. Impedance technol-
ogy detects cell death and proliferation of adherent cells by measuring changes
in conductance of microelectrodes embedded in 96 and 384-wells cell culture
plates. We utilized adherent and B cell leukemia/lymphoma cell lines as well as
primary tumor cells as in vitro models for immunotherapy reagents evaluation.
We seeded the cells on electrodes coated 96-well plates and monitored cell ad-
CLINICAL RESEARCH: Adaptive Immunity to Cancer
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017432
hesion and proliferation for 24 hours. The following day effector cells were
added at multiple effector:target ratios in presence of BiTEs antibodies and/or
anti PD-1/PD-L1 antibodies. Impedance signal was monitored for up to seven
days. Control wells were set upwith effector cells only orwith target plus effector
cells but without antibodies. We adapted such adhesion-based technology to
monitor non-adherent B-leukemia/lymphoma cells, by developing a strategy
where the wells are coated with an anti-CD40 antibody. The coating allows
specifıc adhesion and retention of B cells and measurement of changes in im-
pedance that are proportional to cell number. Using increasing concentrations
of EpCAM/CD3BiTEwe demonstrated the suitability of such impedance-based
approach to quantitatively monitor the effıcacy of immune cells-mediated can-
cer cell killing both under different effector:target ratios and antibody concen-
trations. Combination treatments with checkpoint reduced timing and in-
creased amount of killed cancer cells. Similar results were also obtained with
engineered Car-T cells against CD19 or NK cell lines, we were able to demon-
strate specifıc killing of tumorB cells at very low effector:target ratios. The results
were also confırmed by flow cytometry. Overall, our results demonstrate the
value of such approach inmeasuring the cytotoxic response across the temporal
scale, an aspect that is otherwise very diffıcult to assess with more canonical end
point assays. Furthermore, the availability of 384-wells format and minimal
sample handling place the technology in an ideal spot for applications in large
reagent validation screening or personalizedmedicine, like therapeutic protocol
validation directly on patient samples.
#1690 Epitope-minigenes for optimal induction of the immune response
against tumor associated antigens and neoantigens. Silvio Bandini,1 Laura
Luberto,1 Fabio Palombo,1 Giuseppe Roscilli,1 Emanuele Marra,1 Gennaro Ci-
liberto,2 Luigi Aurisicchio1. 1Takis, Rome, Italy; 2Istituto Tumori Regina Elena,
Rome, Italy.
We have recently established aworkflow that allows the identifıcation of T cell
epitopes within Tumor Associated Antigens (TAAs) and the construction of
genetic cancer vaccine based on the use ofminigenes. The T-cell epitope in silico
prediction approach is based on three criteria: 1) binding toMHCClass I alleles;
2) uniqueness to the antigen of interest; 3) increased likelihood of natural pro-
cessing. The combination of in silico prediction and a biochemical binding/
stability assay resulted in an accurate identifıcation of novel TAA-derived
epitopes. Predicted T cell epitopes were connected by furin sensitive linkers and
linked to human tissue plasminogen activator (TPA) signal and E. Coli entero-
toxin B subunit, to construct an optimal minigene scaffold used as vaccine can-
didate. The present study was aimed at evaluating HER2/neu and hTERT (te-
lomerase) minigenes with the same technology platform. First of all, minigenes
delivered via Electro Gene Transfer (DNA-EGT) weremore immunogenic than
genetic vectors encoding the full-length protein or peptides injected subcutane-
ously and they were able to break immune tolerance in wild type and HLA-
A0201 transgenic mice. Moreover, this technology applied to epitopes selected
within Mutated Tumor Antigens results in strong immunogenicity and signifı-
cant antitumor effects in mouse models. In conclusion, we show that minigenes
delivered via DNA-EGT and based on predicted and/or experimentally identi-
fıed epitopes are powerful tools to induce immune responses and combat cancer.
Combination studies of minigenes with peptide vaccination, chemotherapy and
immune checkpoint blockade may defıne new therapeutic opportunities for
cancer patients.
#1691 USP7 inhibitors impair Foxp3Tregulatory cell function andpro-
mote antitumor immunity against solid tumors. Suresh Kumar, JianWu, Liq-
ingWang, FengWang, Ivan Sokirniy, HuiWang, David Sterner, Charles Grove,
Joseph Weinstock, Michael Mattern, Wayne Hancock. Progenra Inc, Malvern,
PA.
Tumor microenvironment (TME) plays critical role in suppressing the im-
mune system’s ability to recognize and destroy cancer cells. Although T cell
checkpoint blockers such as anti-PD1 antibodies unleash anti-tumor immune
response against a variety of tumors, the complex immunosuppressive tumor
milieu necessitates development of additional therapeutic agents to potentiate
active drugs and expand the realm of the revolutionary cancer immunotherapy.
The presence of highly immunosuppressive Foxp3 T-regulatory cells (Tregs)
in the TMEhas been correlatedwith poor prognosis. Thus, depletion of Tregs or
impairment of Treg function is considered an attractive therapeutic approach.
USP7, a deubiquitylase (DUB) implicated as a critical node in several cancer
signaling pathways has emerged as an essential factor in maintaining Treg
functions. Treg specifıc deletion of USP7 impairs Treg function leading to
lethal autoimmunity. Using the UbiProTM discovery platform, Progenra has
identifıed selective covalent USP7 inhibitors that were subjected to lead op-
timization and preclinical evaluation. Potent and selective candidate USP7
inhibitors have been shown to impair Treg functions ex vivo and in vivo as
well as exhibit powerful anti-tumor activity against syngeneic lung tumor
models in immunocompetent mice. Most importantly, Progenra’s USP7 in-
hibitors enhances the effıcacy of anti-PD1 antibody and cancer vaccines.
Along with the already established direct anti-tumor activities of USP7 in-
hibitors, these studies provide a strong rationale for combining USP7 inhib-
itors to suppress Treg functions and improve the effıcacy of currently ap-
proved cancer immunotherapy agents.
#1692 KRAS-mediated therapeutic resistance abrogates immunogenic
cell death in colorectal cancer cells. Yi-Jun Wang,1 Dongshi Chen,1 Jingshan
Tong,1 Jian Yu,1 Alberto Bardelli,2 Lin Zhang1. 1University of Pittsburgh Cancer
Institute, Pittsburgh, PA; 2University of Torino, Torino, Italy.
A hallmark of cancer is compromised immune surveillance, which is charac-
terized by failure of the immune system to recognize tumor-associated antigens
and specifıcally eliminate malignant cells. A number of studies showed the tu-
mor microenvironment in colorectal cancer (CRC) patients is highly immuno-
suppressive. Conventional chemotherapy and recent targeted therapy can re-
store anti-tumor immune response through induction of immunogenic cell
death (ICD) in tumor cells. However, themechanism and functional role of ICD
inCRC treatment remains vague. In this study, we found FOLFIRI (Leucovorin/
5-Fluorouracil/Irinotecan) combined with the anti-EGFR antibody cetuximab,
a commonly used regimen for CRC treatment, induces death of CRC cells with
characteristics of necroptosis, including ATP depletion, release of HMGB1, and
phosphorylation of RIP3 and MLKL. Cells subjected to the combination treat-
ment exhibited features of ICD including plasma membrane exposure of calre-
ticulin and phagocytosis by dendritic cells. We identifıed the BH3-only Bcl-2
family protein PUMA as a key mediator of necroptosis induced by the combi-
nation treatment in vitro and in vivo. Furthermore,we found thatCRCcellswith
acquired cetuximab resistance due to KRAS mutation or amplifıcation are defı-
cient in ICD. Collectively, our results suggest that oncogenic mutations cause
resistance of CRC cells to anticancer therapies in part by suppressing ICD.
#1693 T cell responses to peptide-epitopes can be boosted by immune
complexes of circulating anti-tetanus antibodies. Erika A. Fletcher,1 Wendy
van Maren,2 Robert Cordfunke,2 Jasper Dinkelaar,3 Ricardo Castelli,3 Jeroen
Codee,3 Gijs van de Marel,3 Cornelis J. Melief,2 Ferry Ossendorp,2 Jan Wouter
Drijfhout,2 Sara Mangsbo1. 1Uppsala University, Uppsala, Sweden; 2Leiden Uni-
versity Medical Center, Netherlands; 3Leiden University, Netherlands.
The ability of dendritic cells (DCs) to boost an antigen-specifıc immune re-
sponse is utilized in several cancer immunotherapy strategies including thera-
peutic vaccination using long peptides.Naked peptides are rapidly degraded and
oil-based delivery strategies trap immune cells to unwanted sites or have inap-
propriate adjuvant properties. To enhance the uptake of cancer or viral T cell
epitopes and subsequent activation ofDCswemake use of circulating antibodies
to mount cellular responses against tumor antigens of interest by conjugating a
B cell epitope to a T cell epitope. The conjugation of the two greatly improves
antigen uptake and concomitant activation of the same DC in contrast to naked
long peptides which are not conjugated. Our identifıed B cell epitope of choice is
derived from tetanus toxin and can be targeted by tetanus-specifıc antibodies
boosted by a standard tetanus toxoid vaccine.We have applied amodifıed chan-
dler loop model preserving intact cascade systems to characterize how the teta-
nus-peptide conjugated vaccine is targeted to human immune cells. The B cell-T
cell conjugate is taken up by human monocytes and blood DCs in an antibody-
dependent manner. Rather than FcRs, the internalization of the antigen ap-
pears to be partly mediated through the classical pathway of the complement
system. Tetanus-CMV conjugates, containing a T cell epitope from the pp65
protein of cytomegalovirus (CMV), strongly reactivates memory T cells when
analyzed in blood from donors with CMV-specifıc T cells. The CMV-specifıc T
cells rapidly produce IFN and TNF in response to the conjugate illustrating
that the uptake of the conjugate leads to activation of antigen-specifıc T cells.
Uptake as well as T cell activation occurs at low concentrations of the SLP
conjugate, superior to a conjugate lacking the tetanus-sequence as well as to
SLPs with or without additional adjuvant (LPS). Of importance, when the B and
T cell epitopes are separate entities but mixed, CMV-specifıc T cells are not
activated, illustrating the requirement of conjugating the two. Our data show
that we have a unique delivery system for peptide based vaccines that can aid
induction of human T cell responses, and may potentiate immune responses in
cancer patients.We are now actively working on a prostate cancer vaccine can-
didate using this novel loading/adjuvant technology.
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#1694 Systemic granulocyte-macrophage colony-stimulating factor (GM-
CSF) treatment increases T cell receptor diversity in localized andmetastatic
prostate cancer patients. David Y. Oh,1 Li Zhang,1 Jason Cham,1 Alan Pacio-
rek,1Mark Klinger,2 Malek Faham,2 Susan F. Slovin,3 Lawrence Fong1. 1Univer-
sity of Califonia, San Francisco, San Francisco, CA; 2Adaptive Biotechnologies,
South San Francisco, CA; 3Memorial Sloan Kettering Cancer Center, New York,
NY.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is frequently
utilized as an adjuvant in cancer immunotherapies, and has known effects as a
growth factor. However the extent to which GM-CSF modulates the adaptive
immune response, including possible effects on the antigenic repertoire, re-
mains unclear. We used next-generation sequencing of T cell receptor (TCR)
beta chain sequences amplifıed from total RNA from peripheral blood mono-
nuclear cells using consensus primers to assess changes in the circulating anti-
genic repertoire of prostate cancer patients treated with GM-CSF in multiple
clinical trials. Administration of systemic GM-CSF monotherapy to patients
with localized prostate cancer prior to planned radical prostatectomy
(NCT00305669) results in a signifıcant decline in clonality from the pre-treat-
ment timepoint to the 2-week timepoint on treatment, indicative of increased
early repertoire diversity (p0.039 byWilcoxon signed rank test). In a separate
clinical trial (NCT00064129), the combination of systemic GM-CSF (250 g/
m2/day on days 1-14 of each cycle) with ipilimumab in metastatic castrate-
resistant prostate cancer (mCRPC) patients also resulted in a signifıcant decline
in clonality from pre-treatment samples to the 2-week timepoint on treatment
(p0.002). In contrast, mCRPC patients who received ipilimumab alone in a
separate study (NCT00323882) did not experience a similar decline in clonality
after 3 weeks on treatment (p0.625). In addition, comparison of the dynamics
of specifıc clonotypes between the paired timepoints in the two mCRPC studies
demonstrates that while there is no signifıcant difference in the ratios of post-
treatment to pre-treatment clonality between studies, patients treated with the
combination of iplilimumab and GM-CSF show more repertoire change, with
lower Morisita’s distance for all clones found at either timepoint (p0.023),
smaller intraclass correlation coeffıcient (p0.028), and a smaller proportion of
clonotypes that remain unchanged (defıned by / 2-fold change for clones
found at both timepoints) (p0.002). These results indicate increased repertoire
turnover when GM-CSF is combined with checkpoint inhibition. Hence data
from both localized andmetastatic prostate cancer, and frommonotherapy and
combination therapy regimens, supports a role for GM-CSF in inducing early
diversifıcation of the TCR repertoire.
#1695 Exploiting thepancreatic cancermutome for immune interception.
Heather Kinkead,1 Eric Lutz,2 Thomas W. Dubensky,3 Elizabeth Jaffee1. 1Johns
Hopkins School ofMedicine, Baltimore,MD; 2WindMILTherapeutics, Baltimore,
MD; 3Aduro Biotech, Berkeley, CA.
This study aims to translate tumor-specifıc mutations identifıed by next-gen-
eration sequencing techniques into an effective anti-tumor vaccine for a classi-
cally non-immunogenic tumor, pancreatic ductal adenocarcinoma (PDA). Pan-
creatic ductal adenocarcinomas develop an average of 63 mutations during
tumorigenesis, collectively referred to as the “mutome.”Of these, approximately
45 are amino acid point mutations. These mutations are not present in normal
cells and provide a source of tumor-specifıc neoepitopes for targeted immuno-
therapy. Next-generation sequencing technologies allow for rapid identifıcation
of mutations present in patient tumors; however, methods for rapid identifıca-
tion of immunogenic neoepitopes which can be effectively targeted for tumor
clearance, and optimized vaccination strategies for targeting them, still need to
be developed. In this study, we are using a transplantable murine PDA model,
Panc02, to develop vaccination strategies for inducing neoepitope-specifıc T cell
antitumor responses, and to defıne parameters for selecting appropriate targets.
Exome sequencing identifıed 878 nonsynonymous mutations in the Panc02 cell
line. Three immunological epitope prediction servers identifıed 878 potentially
immunogenic peptides in the Panc02model, 29 of whichwere strong candidates
(scores50) and another 240 candidate epitopes within the limits of prediction
(scores1000). Panc02neoepitope peptide vaccinations inmice confırmed 14%
of the predicted epitopes to be immunogenic by IFN ELISPOT, which may
include both CD8 and CD4 T cell responses. Tumor transplant experiments
demonstrate that therapeutic vaccination against neoepitopes in combination
with a human STING-activating cyclic dinucleotide adjuvant is capable of in-
ducing a temporary regression of implanted tumors. After tumor escape and
regrowth, flow cytometry reveals a large population of infıltrating lymphocytes,
the majority of which are co-expressing the checkpoint molecules PD-1, Tim3,
and Lag3, indicating that treatment of vaccinated animals with checkpoint
blockade therapy may potentiate infıltrating lymphocytes and ultimately result
in permanent tumor regression. Thus, a broad and unbiased approach for
screening vaccine targets will allow for the evaluation of predictive algorithms
and ultimately the development of more effective vaccination approaches for
targeting the tumor mutome.
#1696 High-dose versus low-dose fractionated ionizing radiation to en-
hance antigen-specifıc antitumor immunity. Megan V. Morisada, Ellen C.
Moore, Jay A. Friedman, James W. Hodge, James B. Mitchell, Clint T. Allen.
National Institutes of Health, Bethesda, MD.
Ionizing radiation (IR) has variable effects on the solid tumor immune mi-
croenvironment. While many report additive or synergistic effects between IR
and immune activating therapies, most studies utilize single fractions or hypo-
fractionatedhigh-dose radiation of 8Gyor greater. For head andneck squamous
cell carcinoma (HNSCC), 30 or more low-dose fractions of 1.8-2Gy are utilized
as standard-of-care for the up-front treatment of early stage or advanced disease.
Preliminary experiments from our laboratory have demonstrated that 10 frac-
tions of 2Gy IR decreased the rate of rejection of T-cell inflamed syngeneic
carcinomas in wild-type B6 mice when combined with cyclic dinucleotide
(CDN) compared to CDN treatment alone (10% rejection rate with low-dose
fractionated IR plus CDN vs. 50% with CDN alone). Immune suppression fol-
lowing IR in mice is mediated by at least galectin-1. Further, HNSCC patients
treated with standard fractionated low-dose IR develop durable neutropenia.
Thus, we hypothesized that low-dose fractionated IR is immunosuppressive and
does not result in additive or synergistic effects when combined with cyclic
dinucleotide. To test this hypothesis, we performed a time-course analysis of
tumor immune infıltration and tumor-draining lymph node antigen-specifıc
T-lymphocyte activation in three syngeneic models of carcinoma with defıned
tumor rejection antigens (MOC1-p15E, B16-OVA and MC38-CEA) following
exposure to two different IR regimens of 8Gy x 2 fractions or 2Gy x 10 fractions.
Analysis of effector immune infıltration and antigen-specifıc activation pre-IR
and at 5, 10, and 20 days post-IR revealed consistent trends of profound immu-
nosuppression with the low-dose fractionated IR regimen (2Gy x 10) but pre-
served or enhanced immune activation with the high-dose hypofractionated
regimen (8Gy x 2). Galectin-1 levels will bemeasured fromwhole tumor lysates.
We plan to perform nano-string RNA array analysis on irradiated tissues to
serve as correlative immune analysis and also to validate this technology against
well-defıned immune read-outs for potential use in the clinical trial setting. We
also plan to combine both IR regimens with intra-lesional CDN (20 g x 3
injections) to determine if either IR regimen results in additive or synergistic
tumor control. Thiswork has profound implications for future pre-clinical stud-
ies and clinical trials combining IR and immune activating therapies, such as
CDN or checkpoint inhibitors.
#1697 Humanized immune-oncologymousemodels.Maria Stecklum, An-
nika Wulf-Goldenberg, Bernadette Brzezicha, Iduna Fichtner, Jens Hoffmann.
EPO GmbH, Berlin, Germany.
The recent clinical success of immune checkpoint modulators has stimulated
immune-oncology research leading to the identifıcation of new tumor immu-
nology targets. However both, target validation and drug development need
better preclinical immune oncology models. Translational research further ur-
gently needs suchmodels for identifıcation of clinically relevant biomarkers and
defıning rational combination strategies. Human patient-derived xenografts
(PDX) from different tumor indications transplanted on immunodefıcientmice
have demonstrated strong predictive power for many drug development pro-
grams in cancer research.However, one caveat of PDXmodels is, that thesemice
lack a functional immune system, which allows tumor engraftment in the xeno-
genic host. To overcome these constraints our aim is the development of PDX
models on mice with a functional human immune system. This strategy should
allow implementing the highly predictable PDX in a functional human immune
environment for better drug effıcacy and safety studies. We reconstituted a hu-
man immune system in mice by engrafting human hematopoietic stem cells in
immunodefıcient mice. We demonstrate the engraftment of a full set of human
immune cells, including T cells, B cells, NK cells, monocytes and dendritic cells
in these mice. Tumor expression of PD-L1 is currently evaluated as fırst bio-
marker for immunotherapy with the PD1 checkpoint inhibitors. We screened
our tumor cell lines and PDX models for PD-L1 expression to identify such a
correlation. PD-L1 positive and negative models were transplanted on human-
ized mice. Most of them showed no difference in tumor growth compared to
non-humanized mice ( fully immune resistant). However other PDX showed
a delayed growth on the humanized mice ( partly immune resistant), whereas
only one model did not grow at all ( immune sensitive), demonstrating a high
sensitivity to the innate immune response of this PDX. To evaluate the function
of the human immune cells and checkpoints, mice were treated with checkpoint
inhibitors ipilimumab and nivolumab. Checkpoint inhibitors alone or in com-
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bination led to a minor tumor growth delay and an increased number of acti-
vated T-cells in the blood and in the tumor. Our results from experiments with
n19 models revealed a fırst correlation: stronger tumor growth inhibition on
PD-L1 positive PDX and increased sensitivity of “partly immune resistant”
PDX. Furthermore wewere able to demonstrate, that treatment effects of check-
point inhibitors could be increased by combination with radiation. Summary:
Our humanized PDX models enable appropriate preclinical studies on tumor
immunebiology, evaluation of new immune therapies and combinations, aswell
as the identifıcation and validation of biomarkers for tumor immune therapy.
#1698 Immunoprevention of KRAS-driven lung adenocarcinoma by a
multi-peptide KRAS vaccine. Jing Pan,1 Qi Zhang,1 Shizuko Sei,2 Robert H.
Shoemaker,2 Ronald A. Lubet,2 Yian Wang,1 Ming You1. 1Medical College of
Wisconsin, Milwaukee, WI; 2National Cancer Institute, Bethesda, MD.
Lung cancer remains the leading cause of cancer death worldwide. Mutations
in KRAS are detected in up to 30% of lung cancer cases, about 80% of which
occur in codon 12, yet no effective therapies specifıcally targeting mutant KRAS
have been developed. Boosting the host immune response to cancer cells by
vaccinating against defıned tumor-associated antigens (TAAs) as a means of
treating established tumors or preventing the development of tumors in high
risk individuals such as current or former smokers is an area of intense research.
The present study evaluated both immunogenicity and anti-tumor effıcacy of a
newly formulated multipeptide (peptides 15-17 amino acids long) vaccine tar-
geting multiple epitopes of the KRAS molecule in a mouse model of KRAS-
driven lung tumor. Vaccination was performed in the prevention setting in a
transgenic mouse model, where mutated mouse Kras (G12D) is conditionally
over-expressed in the lungs of mice using a CCSP promoter. A multi-score
prediction algorithm was used to identify likely immunogenic epitopes in the
KRAS protein sequence. The identifıed peptides were synthesized and screened
in naïve mice for immunogenicity. The formulated vaccine contained the top
four peptides, which elicited the strongest immunologic response and showed
100% sequence homology between human andmouse. The multipeptide KRAS
vaccine was then tested in an inducible CCSP-TetO-KRASG12Dmouse model,
where the vaccines mixed with the Freund’s adjuvant or adjuvant alone were
administered prior to activating themutant KRAS protein. Our results show the
KRAS peptide vaccine exhibited striking effıcacy, reducing tumor number and
tumor burden by80% when compared with adjuvant alone. Splenocytes col-
lected from vaccinated animals at the end of the study showed a robust immu-
nologic response to the immunizing peptides. Furthermore, in vitro stimulation
of these splenocytes by the vaccine peptides resulted in the secretion of cytokines
indicative of Th1 (interferon gamma) and Th17 (IL17) responses but with min-
imal secretion of Th2 related cytokines e.g. IL3 and IL4. In the draining lymph
nodes from vaccinatedmice rejecting tumors, there was a substantial increase in
CD4 cells but a limited increase in CD8 cells. In summary, the multipeptide
KRAS vaccine was immunogenic and effıcacious in the primary prevention of
KRAS-induced lung cancer inmice, indicating that the approach can potentially
be used for the prevention of KRAS-driven cancers either alone or in combina-
tion with other modalities.
#1699 Impact of whole blood interferon gamma production for patient
selection in vaccination with autologous formalin-fıxed tumor vaccine.
Naoyuki Sakamoto,1 Takeshi Ishikawa,1 Tetsuya Okayama,1 Tomoyo Yasuda,1
Toshifumi Doi,1 Mari Tanigawa,2 Yuji Naito,1 Yoshito Itoh,1 Toshikazu Yo-
shikawa1. 1Kyoto Prefectural University of Medicine, KYOTO, Japan; 2Iseikai
Hyakumanben Clinic, KYOTO, Japan.
Introduction: Immune checkpoint blockade by anti-CTLA-4 antibody and
anti-PD-1 antibody led to clinical breakthrough for the treatment of patients
with solid tumors. Moreover, recent reports have shown that neoantigens are
important functional targets mediating response to immune checkpoint inhib-
itors. Therefore, sequential combination of personalized cancer vaccines and
immune checkpoint blockade has emerged as a potential therapeutic strategy.
However, existing drawbacks is that it is diffıcult to identify robust biomarkers
for patient selection in vaccination with cancer vaccine. In this study, we exam-
ined whether the development of delayed-type hypersensitivity (DTH) re-
sponse, measured after vaccination with autologous formalin-fıxed tumor vac-
cine (AFTV), correlates to parameters of immune function such as whole blood
cytokine levels and peripheral regulatory T cells (Treg) in patients with solid
tumors. Methods: Subjects comprised 52 patients with solid malignancy. AFTV
treatment consisted of 3 courses of vaccination performed at intervals of 2
weeks. DTH test was performed before and after vaccination. A positive DTH
response was defıned as a 
 10mm diameter erythema/induration. We evalu-
ated whole blood cytokine production after phytohemagglutinin (PHA) stimu-
lation using the bioplex array system.We also assessed the number of peripheral
Tregs as well as routine hematological and biochemical parameters. Results:
DTH positive patients and DTH negative patients did not differ with respect to
the number of peripheral Tregs, leukocytes, lymphocytes or granulocyte/lym-
phocyte ratio. Whole blood IFN- production levels after phytohemagglutinin
(PHA) stimulation at baseline inDTHpositive patientswere signifıcantly higher
than those in DTH negative patients (p0.0397). Conclusion: These data indi-
cate that whole blood IFN- production at baseline is likely to be useful to assess
immunologic competence in vaccinated patients with AFTV. Consequently,
clinical utility ofwhole blood IFN- production, as immunomonitoringmethod
for patient selection in vaccinationwith cancer vaccine, is required to investigate
in larger clinical studies in the future.
#1700 Radiation-induced vegf-targeted 4-1bb costimulation enhances
immune control of tumor growth. Brett Schrand,1 Bhavna Verma,1 Agata
Levay,1 Shradha Patel,1 Iris Castro,1 Ana Paula Benaduce,1 Randall Brenne-
man,1 Oliver Umland,1 Hideo Yagita,2 Eli Gilboa,1 Adrian Ishkanian1. 1Univer-
sity of Miami Miller School of Medicine, Miami, FL; 2Juntendo University School
of Medicine, Tokyo, Japan.
Radiotherapy (RT)-potentiated immunomodulation is an emerging fıeld in
solid tumor malignancies. RT induces peripheral antitumor immunity that can
lead to the reduction of distant, non-irradiated tumor lesions (abscopal re-
sponse). This has provided rationale for current early phase trials combining
existing checkpoint blockade and co-stimulatory mAbs with stereotactic RT.
Objective responses remain suboptimal with checkpoint blockade mono-
therapy, and dose limiting toxicity is widely observed with thesemodalities. We
hypothesize that targeting immunotherapy to the tumor using oligonucleotide
aptamers that bind to RT induced tumor stress products will signifıcantly en-
hance the therapeutic index. We used the aptamer platform to generate a bi-
specifıc construct containing a costimulatory aptamer ligand specifıc to murine
4-1BBwhichwas conjugated to an aptamer specifıc to products secreted into the
tumor stroma (VEGF or osteopontin). Tumor targeting, local control, abscopal
responses and toxicity were compared to unconjugated 4-1BB-VEGF con-
structs, or mAB based therapies, when used in combination with RT in murine
subcutaneous and autochthonous MCA tumor models. RT induced VEGF
upregulation was demonstrated in null/low VEGF secreting tumors that led to
preferential accumulation of VEGF-41BB aptamers in the irradiated
tumor.12Gy x1 elicited optimal tumor targeting of bi-specifıcVEGF-4-1BB con-
jugate. Signifıcant anti-tumor immune responses were observed in s.c. murine
tumor models. This conjugate showed dramatic reduction in systemic toxicity
compared to the equivalent gold standard 4-1BB mAb. RT-VEGF-4-1BB treat-
ment signifıcantly improved local control, overall survival and induced potent
abscopal responses compared to unconjugated and non-irradiated controls in
theBalb/c 4T1 andMCAmurine tumormodels. Furthermore, RT-VEGF-4-1BB
treatment showed similar anti-tumor effects as CTLA-4 mAB with signifıcantly
less systemic toxicity. This approach increased intra-tumoral CD4 and CD8
T cells, the CD8 to Treg ratio, and induced signifıcantlymore tumor cell death.
In conclusion, this strategy has been shown to induce potent anti-tumor im-
mune responses in relevant murine tumor models and signifıcantly improves
the therapeutic index over non-targeted mABs. Furthermore, radiotherapy can
expand the scope of tumor targeted immune modulation to virtually all solid
malignancies and induce potent abscopal responses. These results provide the
rationale for developing clinical grade bispecifıc aptamers for future testing.
#1701 The novel anti-CD205 antibody drug conjugate (ADC) MEN1309
shows strong antitumoral activity in diffuse largeB cell lymphoma (DLBCL).
Eugenio Gaudio,1 Chiara Tarantelli,1 Francesca Guidetti,1 Maurilio Ponzoni,1
Roberta Pittau Bordone,1 Alessio Fiascarelli,2 Andrea Rinaldi,1 Ivo Kwee,1 Afua
AdjeiwaaMensah,1 Anastasios Stathis,3 Davide Rossi,3 Georg Stussi,3 Emanuele
Zucca,3 Giuseppe Merlino,2 Mario Bigioni,2 Monica Binaschi,2 Francesco Ber-
toni1. 1Lymphoma and Genomics Research Program, IOR Institute of Oncology
Research, Bellinzona, Switzerland, Bellinzona, Switzerland; 2Menarini Ricerche
S.p.A., Pomezia, Italy, Pomezia, RM, Italy; 3Lymphoma and New Drugs Units,
IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, Bellin-
zona, Switzerland.
Background.Up to one third ofDLBCLpatients still succumb to their disease:
novel therapeutic approaches are needed. MEN1309 is a novel ADC consisting
of an anti-CD205 monoclonal antibody conjugated to the DM4 maytansine
derivative through a cleavable linker. Here, we assessed its anti-DLBCL antitu-
moral activity. Methods 24 DLBCL cell lines were exposed to MEN1309 and, as
control, to IgG-conjugated DM4 for 72h. Cell proliferation was measured with
MTT.Apoptosis activation, defıned by at least 1.5 fold increase in the caspase 3/7
signal respect to controls, was measured with the Promega ApoTox-Glo Triplex
Assay. Xenografts (15 x 106 cells/mouse, 200 L of PBS) were established s.c.
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into the left flanks of female NOD-SCID mice; i.v. treatments started with tu-
mors of 250-350 mm3 volume. Results. MEN1309 showed strong cytotoxic ac-
tivity in DLBCL (median IC50  300 pM; 95%CI, 200-771), while the IgG-
conjugated DM4 toxin was 100x less active (30 nM; 95%CI, 20-33). MEN1309
induced apoptosis in 17/24 (71%) DLBCL. No difference was seen based upon
DLBCL cell of origin, MYC or BCL2 translocations or TP53 status. MEN1309
activity was highly correlated with its target expression with an inverse correla-
tion between IC50 values and CD205 expression at flow cytometry or RT-PCR
(R  - 0.79, P  0.0001). No correlation was seen between CD205 expression
and IgG-conjugated DM4 activity. MEN1309 anti-tumor activity was in vivo
confırmed in a DLBCLmodel (OCI-Ly10) characterized by high CD205 expres-
sion. MEN1309 was administered at 3 different doses: 1.25, 2.5 and 5 mg/Kg
once / 3 weeks. Groups of control treated with IgG-DM4 (5 mg/Kg, every 3
weeks) were also used. MEN1309 5mg/Kg eradicated tumors in all mice with a
single dose, as also shown by highly signifıcant differences versus control mice
(D7, D21, D28; P 0.01). While all other groups had to be stopped by D35, the
MEN1309 5mg/Kg group skipped the second treatment at D21 because there
was no palpable tumor, and mice resulted cured even 2 months later (Kaplan-
Meier, survival analysis, P  0.0001). MEN1309 2.5 mg/Kg delayed tumor
growth versus control (D21, P 0.039). Much lower activity was observed with
MEN1309 1.25 mg/Kg (D7, P 0.012) and with IgG-DM4 (D21, P 0.049; D28, P
0.046). Conclusions. InDLBCLmodels, the novel ADCMEN1309 had strong in
vitro and in vivo anti-tumor activity, which is highly correlated with the expres-
sion of its target.
#1702 Multimeric anti-DR5 IgM antibody displays potent cytotoxicity in
vitro and promotes tumor regression in vivo. Beatrice Wang, Tasnim
Kothambalwala, Paul Hinton, Dean Ng, Avneesh Saini, Ramesh Baliga, Bruce
Keyt. IGM Biosciences, Inc., Mountain View, CA.
Death receptor 5 (DR5) is a member of the TNF receptor superfamily that
induces apoptosis upon receptor trimerization. It is expressed on many tumor
types and has therefore been an important target for developing antibody based
treatments of epithelial, solid tumors. However several agonistic Anti-DR5 IgG
antibodies that have demonstrated effıcacy in preclinical models have been un-
successful in clinical trials, likely due to insuffıcient receptor crosslinking by
bivalent IgGs. We have developed a multimeric anti-DR5 IgM antibody which
has strong avidity for the receptor. The IgM binds Colo205 cells and triggers
apoptosis, and is 1000-fold more potent than the respective IgG and 100-fold
more potent than crosslinked IgG in vitro. Anti-DR5 IgM displays strong in
vitro potency across a panel of tumor cell lines, including ones that are IgG-
resistant. Anti-DR5 IgM causes tumor regression and delays tumor growth in
various in vivo xenograftmodels includingColo205, HCT15 andMDA-MB231.
These results support the development of an human anti-DR5 IgM therapeutic
with the potential to treat solid tumors.
#1703 A novel tumor vaccine platform: direct conjugation of antigens to
the  glucan PAMP Imprime PGG enhances antigen presentation and T cell
priming. Kyle S. Michel, Ross B. Fulton, Steven M. Leonardo, Keith B. Gorden,
Jeremy R. Graff, Michael E. Danielson. Biothera Pharmaceuticals, Inc., Eagan,
MN.
Signifıcant clinical and pre-clinical research has shown that PAMPs- Patho-
gen Associated Molecular Patterns- can trigger an integrated anti-cancer im-
mune response involving both innate and adaptive immunity. Imprime PGG is
a soluble yeast -1,3/1,6 glucan currently in multiple phase 2 clinical studies in
combination with the immune checkpoint inhibitor (CPI), pembrolizumab.
Preclinical mechanistic research has shown that Imprime PGG can re-polarize
immunosuppressive myeloid cells in the tumor microenvironment and activate
antigen presenting cells to prime antigen-specifıc CD8 T cells thereby boosting
effector T cell function and expansion. Based on this ability to activate dendritic
cells and induce type I interferon, we sought to explore the use of Imprime as an
immune activating/antigen-directing scaffold onto which we could attach tu-
mor antigen to drive an antigen-specifıc T cell based immune response. Imprime
PGG has been safely administered intravenously to more than 400 human sub-
jects and thus represents a safe starting point for the development of a cancer
vaccine. Imprime’s 1,3/1,6 -glucan polymeric structure allows for the straight-
forward attachment of peptides and proteins via three different conjugation
routes. To explore this function we covalently linked the chicken ovalbumin
(OVA) protein to Imprime to generate a-glucan-protein conjugate (Imprime-
OVA). Using T cell receptor transgenic OT-I CD8 and OT-II CD4 T cells to
track responses toOVA,we treatedmice with Imprime-OVA intravenously and
examined the expansion and functional quality of the T cell response 7 days later
at the peak of expansion. Following Imprime-OVA treatment, both OVA-spe-
cifıc CD8 and CD4 T cells underwent vigorous expansion. OT-I CD8 T cells
upregulated the transcription factor Tbet, which is central to developing effector
functions, and were highly multifunctional in their ability to produce IFN-,
TNF- and IL-2. OT-I T cells responded similarly to vaccination with the min-
imal H-2Kb/OVA257-264 peptide covalently attached to Imprime. By compari-
son, vaccinationwith unconjugatedOVA (protein or peptide) and Imprimewas
much less effective in driving T cell expansion and differentiation. The CD8 T
cell response required Batf3-dependent cross-presenting DCs whereas the CD4
T cell response did not, and both CD4 and CD8 responses required the C-type
lectin receptor Dectin-1. These data show that an Imprime PGG-protein conju-
gate can effectively elicit the expansion and functional activation of cytotoxic T
cells and may have utility as a potential cancer vaccine platform. These data
provide evidence that Imprime PGG not only serves as a combination therapy
for CPIs, anti-angiogenics, and tumor targeting antibodies but may also be a
robust platform for multiple tumor vaccine strategies.
#1704 UPR signaling promotes T-cell dysfunction to prevent immune-
mediated cancer cell killing and immune checkpoint therapy resistance. Yis-
meilin R. FelizMosquea, David R. Soto Pantoja, AdamWilson, Pierre L. Triozzi,
Katherine L. Cook.Wake Forest University, Winston Salem, NC.
A critical point in cancer progression is evading recognition by the immune
system. Cancer cells accomplish this by stimulating immune checkpoint signals
on effector T-cells. In patients with advanced melanoma treated with immune
checkpoint inhibitors, 3-year survival increased by 20%. While immune check-
point therapies are the new fırst treatment option for advanced melanoma in
over a decade, their effıcacy is limited because resistance often develops. Under-
standing the molecular mechanisms of immune checkpoint inhibitor resistance
is critical to develop combinatorial drug therapy to potentiate therapeutic re-
sponsiveness. The unfolded protein response (UPR) is an endoplasmic reticu-
lum (ER) stress pathway activated when unfolded/misfolded proteins accumu-
late within the ER.Highly secretory cell types, such as T-cells, have larger ER cell
compartments and elevatedUPR components to deal with the increased protein
synthesis/folding required by these cell types. Therefore, these cell types may be
highly sensitive to ER stress. Our data demonstrates elevated UPR signaling
components as a driver of T-cell exhaustion/dysfunction. Using a previously
established T-cell exhaustion protocol, we stimulated naïve T-cells with anti-
bodies toCD3/CD28 for 5 days and co-cultured themwithMDA-MB-231 breast
cancer cells, Mun2b melanoma cell line, or CMI patient-derived melanoma cell
line. Exhausted T-cells displayed an increased PD-1 and PERK expression, sug-
gesting that UPR signaling is activated during T-cell exhaustion. Treatment of
naïve T-cells with DTT, a chemical agent that stimulates ER stress, also induced
PD-1 and PERK compared with vehicle-treated T-cells. Gene expression analy-
sis of T-cells indicate that co-culture with cancer cells, not CD3/CD28 activa-
tion, elevates T-cell UPR gene expression. Furthermore, induction of ER stress
through low-dose DTT treatment decreased cytotoxic T-cell mediated cancer
cell death, further supporting our hypothesis of ER stress inducing T-cell ex-
haustion. Inhibition of PERK by RNAi in TALL-104, a human cytotoxic T-cell
line, enhanced T-cell mediated cancer cell clearance when exposed to ER stress-
inducing agents, suggesting that PERK may represent a novel target to prevent
T-cell exhaustion or restore T-cell effector capabilities. PERK inhibition in the
patient-derivedmelanoma cells did not negatively affect T-cell-mediated killing,
suggesting that systemic PERK inhibition may be an effective therapeutic strat-
egy to enhance anti-tumor immune responses.Matched PBMC frommelanoma
patients before treatment or after ipilimumab therapy resistance indicated in-
creased UPR signaling components in PBMC samples from patients after ipili-
mumab resistance when compared with PBMC samples before therapy, sup-
porting a novel role UPR signaling in anti-CTLA4 therapy resistance.
#1705 Slide-based multi-parametric immunophenotyping of human
blood samples by cyclic immunofluorescence using theAccucyte-CyteFinder
system. Jia-Ren Lin,1 Lance U’Ren,2 Gregory J. Baker,1 Joshua J. Nordberg,2
Zoltan Maliga,1 Jackie L. Stilwell,2 Eric P. Kaldjian,2 Peter K. Sorger1. 1Harvard
Medical School, Boston, MA; 2Rarecyte, Inc, Seattle, WA.
Immunophenotyping is an approach to measuring the abundance and func-
tional state of immune cells as a means to understand mechanisms of homeo-
stasis, identify biomarkers of disease, and measure therapeutic and adverse re-
sponses to drugs such as immune checkpoint inhibitors. Such studies are
conventionally performed using flow cytometry together with combinations of
immunomarkers that allow for identifıcation of cell type, maturation state, and
activation status. Here we describe a method for profıling circulating human
leukocytes with highly-multiplexed immunofluorescence microscopy. The
method has distinct advantages over flow cytometry in that it has greater sensi-
tivity for detecting rare cell populations, allows for repeat analysis and long-term
storage of precious biological samples, and obviates the requirement for spectral
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deconvolution. Using an open-source multiplexed immunofluorescence proto-
col referred to as cyclic immunofluorescence (CycIF), and commercially avail-
able reagents and instruments (AccuCyte and CyteFinder; RareCyte Inc.), we
show that imaging can provide 16-plex, single-cell intensity data in addition to
information on cellular morphology. Analytic technologies borrowed from the
fıeld of mass cytometry, such as ViSNE and Phenograph, allow for downstream
phenotypic analysis and high-dimensional biomarker discovery. Current efforts
now aim to expand the number of validated immune targets and combine im-
aging with single-cell picking and sequencing technologies.
#1706 Neoantigen frequency as an independent prognostic factor in pa-
tientswith clear cell ovarian carcinoma (CCOC).HirokazuMatsushita,1 Kosei
Hasegawa,2 Katsutoshi Oda,1 Shogo Yamamoto,3 Akira Nishijima,1 Yuichi
Imai,2 Kayo Asada,1 Yuji Ikeda,2 Takahiro Karasaki,1 Keiichi Fujiwara,2 Hi-
royuki Aburatani,3 KazuhiroKakimi1. 1TheUniversity of TokyoHospital, Tokyo,
Japan; 2Saitama Medical University International Medical Center, Saitama, Ja-
pan; 3The University of Tokyo, Tokyo, Japan.
Aim: Neoantigens derived from tumor-specifıc somatic mutations are
thought to be targets for antitumor immune responses. It has been reported that
mutation/neoantigen burdens correlate with prognosis of certain cancers under
checkpoint blockade immunotherapy. In clear cell ovarian carcinoma (CCOC),
checkpoint inhibitors provided durable responses in a subset of patients. To test
whether the samemay apply in CCOC patients, who are not on immunomodu-
latory therapy, we investigated the number of mutations or neoantigens, and
immune signature of CCOC by integrated molecular analysis. Methods: We
performed exome sequencing and expression array for 74 CCOC patients. Can-
didate neoantigens derived frommutationswere identifıed byMHCclass I bind-
ing prediction algorism (NetMHCpan v 2.8). Immune signature was assessed by
gene ontology and gene set enrichment analyses for immune cell lineage or
molecule genes. We also analyzed their relationships with clinical outcomes.
Results: Neither number ofmissensemutations nor neoantigens correlatedwith
clinical outcomes in CCOC. However, we found neoantigen frequency defıned
here as the number of neoantigens per missense mutation correlated with clin-
ical outcomes. A cox multivariate regression analysis demonstrated that high
neoantigen frequency correlated with decreased progression free survival (PFS)
and was an independent prognostic factor (p0.032). Immune-related genes
including those related to effector memory CD8 T cell were dominantly ex-
pressed in tumors with low neoantigen frequency. This may suggest that CD8 T
cell-mediated immunity is constantly eliminating immunogenic subclones ex-
pressing neoantigens (immunoediting). In contrast, we observed increased ratio
of CTLA-4 and PD-1 to CD8A expression in tumors with high neoantigen fre-
quency. This may imply that restricted antitumor immunity by immunoinhibi-
tory mechanism result in the limited immunoediting and poor prognosis Con-
clusions: Neoantigen frequency underlying immunoediting in CCOC is an
independent prognostic factor for clinical outcome andmay become a potential
candidate biomarker for an immunomodulatory-based treatment.
#1707 Longitudinal and quantitative imaging of the localization, expan-
sion, and contraction of tumor targeted adoptively transferred T cells. Yog-
indra Vedvyas, Enda Shevlin, Marjan Zaman, Irene M. Min, Moonsoo M. Jin.
Weill Cornell Medicine, New York, NY.
Introduction: Current methodologies for monitoring adoptive cell transfer
(ACT) rely on soluble markers and T cell quantity in serum reflecting mixed
responses of T cell effıcacy or toxicity. Quantitative, longitudinal T cell visual-
ization can directly probe T cell distribution, expansion, and off-tumor localiza-
tion, and provide rational to predict therapy successes or failures. To enable
real-time PET imaging of adoptively transferred T cells in a manner directly
translatable to clinics, we utilized a genetic reporter, somatostatin receptor 2
(SSTR2) and a clinically approved radiotracer to quantitatively and longitudi-
nally visualize whole body T cell distribution and anti-tumor dynamics. SSTR2
imaging was also applied to chimeric antigen receptor (CAR) T cells in a setting
of solid cancer. Methods:We developed subcutaneous tumors with amixture of
SSTR2 positive and negative Jurkat T cells, ranging from 0 to 100%. From this
model and PET/CT imaging of SSTR2 radiotracer uptake, diagnostic perfor-
mance of our imaging technique was rigorously defıned. To apply SSTR2 imag-
ing to CART cells, a new lentivirus vector was designed to allow dual expression
of SSTR2 and CAR. Longitudinal PET/CT and luminescence imaging was per-
formed to concurrently measure the rate of tumor growth/killing and T cell
expansion and contraction. Blood was also collected to correlate serum cyto-
kines with T cell distribution at on- and off-tumor sites. Histology was per-
formed to confırm the validity of SSTR2 imaging of CART cells and relating it to
T cell activity. Results: Our T cell imaging technique was found to provide 1%
limit of detection (one T cell in one hundred neighboring cells or4x106 cell/
cm3 in solid tissues) with 95% specifıcity and 87% sensitivity. When applied to
CAR T cells in solid cancer, a biphasic T cell expansion and contraction was
observed in survivors where a temporal change of T cell density closely followed
the change in tumor burden with some time delay. In contrast, nonsurvivors
displayed unrelenting increases in tumor and T cell burden, indicating that
tumor growthwas outpacing T cell killing. Cytokine release syndrome indicated
by weight loss and elevated proinflammatory cytokines was also apparent in a
cohort of nonsurvivors. Conclusion:Our study is the fırst high quality and quan-
titative, longitudinal imaging of T cells, correlating T cell dynamism with ther-
apy and toxicity responses in subjects. Correlative changes in cytokines and T
cell density can be further developed for early prediction of the onset of cytokine
release syndrome as well as for screening adjuvant therapies to augment CAR T
cell effıcacy against solid cancer. Owing to the use of a human gene and FDA-
approved radiotracer, our imaging technique can be directly applicable to CAR
T cells and other T cell based therapy. We are currently preparing for a phase I
clinical study for real-time imaging CD19 CAR T cells in patients.
#1708 Effective and reversible control of anti-tumor activity in vivowith a
drug-regulated CAR T cell platform (DARIC). Wai-Hang Leung,1 Michael
Certo,2 Holly Horton,2 Joel Gay,1 Tracy VandenBerg,2 Jordan Jarjour,1 Alexan-
der Astrakhan1. 1bluebird bio, Seattle, WA; 2bluebird bio, Cambridge, MA.
Redirecting T cells against tumors by introducing antigen-specifıc chimeric
antigen receptors (CAR) has shown promising clinical results as a potential
treatment strategy for certain cancers. However, traditional CARs are constitu-
tively active, resulting in the persistent loss of all target cells (including off -tu-
mor, on-target activity against normal tissues that express the target antigen)
and enhanced potential of excessive T cell activation to drive cytokine release
syndrome.While “off switches” based on suicide cassettes or other depleting cell
approaches are in development, such systems by defınition result in the elimi-
nation of the therapeutic cells. Here we have developed a novel drug-regulated
CAR-based antigen targeting approach termed Dimerizing Agent Regulated
Immune-receptor Complex (DARIC) that aims to: i) minimize the long-term
toxicity of CAR T treatment; ii) allow the targeting of previously inaccessible
antigens; and iii) be amenable to multiplex antigen targeting. The DARIC plat-
form separates the antigen recognition and signaling functions of a CAR into
two distinct polypeptides that are further engineered to contain the FKPB12 and
FRB small-molecule regulated dimerization domains. In the absence of the
dimerizing drug (e.g. rapamycin or the non-immunosuppressive rapalog
AP21967) the DARIC system lacks signaling activity. However, the addition of
dimerizing agent drives the interaction of the two DARIC subunits, fully restor-
ing CAR function. Using CD19 as a model system, we show that treatment of
CD19-DARIC T cells with rapamycin or AP21967 results in equivalent cyto-
toxicity, cytokine production and proliferation compared to a standard CD19-
targeting CAR. Importantly, CD19-DARIC T cells were activated by picomolar
levels of rapamycin and exhibited a higher antigen sensitivity than standard
CD19-CAR T cells in vitro. In an aggressive CD19Nalm-6 xenograft tumor
mouse model, CD19-DARIC T cells did not exhibit anti-tumor activity in the
absence of dimerizing agent. However, CD19-DARIC treatedmice that received
either low-dose rapamycin or AP21967 showed an equivalent level of tumor
control compared to standard CD19-CAR treated animals. This activity was
dependent on the presence of the dimerizing drug, as cessation of drug treat-
ment resulted in the loss of CD19-DARIC T cell activity and the expansion of
Nalm-6 tumors cells in theDARICT cell treatedmice, consistent with the ability
to switch off CD19-DARICT cells in vivo by withdrawing drug. Taken together,
these results highlight the potential of the DARIC platform to facilitate the
regulation of CAR T cell function both in vitro and in vivo.
#1709 Targeting immune checkpoint therapy to the lung tumormicroen-
vironment. Allison S. Cohen,1 Michael L. Doligalski,1 Hong Zheng,1 Narges K.
Tafreshi,1Veronica Estrella,1NellaDelva,1 JonathanNguyen,1AmerBeg,1Mark
L. McLaughlin,2 David L. Morse1. 1H. Lee Moffıtt Cancer Center and Research
Institute, Tampa, FL; 2West Virginia University, Morgantown, WV.
Lung cancer is the leading cause of cancer deaths worldwide. Many lung
cancer patients are diagnosed with advanced disease. These patients have a low
5-year survival rate and limited treatment options. Novel therapies, which target
biomarkers that are overexpressed in lung cancer but have basal expression in
benign tissue, are desperately needed. The goal of this work was to develop a
targeted agent for immune checkpoint therapy of lung cancer. Recently, im-
mune checkpoint inhibitors have been approved for use in lung cancer and
many more are being tested in clinical trials. The current immune checkpoint
inhibitor agents are not tumor-targeted. Targeting the immune checkpoint in-
hibitor to tumor cell-surface markers should concentrate the conjugate in the
tumormicroenvironment and enhance the immune response in the tumorwhile
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reducing the systemic dosages needed, resulting in lower systemic toxicity. The
delta opioid receptor (DOR) is expressed in some lung cancers, but is not ex-
pressed or is expressed only at basal levels in normal tissues outside the brain.
We have previously synthesized fluorescently-labeled DOR-targeted imaging
agents based on a synthetic peptide antagonist (DORL). These targeted fluores-
cent agents have high affınity and selectivity for DOR, and exhibit good phar-
macokinetic (PK) and biodistribution (BD) profıles, i.e. specifıc tumor uptake
with rapid systemic clearance and no uptake in tissues of concern, e.g. brain.We
are now developing lung cancer-specifıc immunotherapy agents that target the
DOR by conjugating DORL to immunomodulatory molecules. In the current
work, we synthesized a fluorescently-labeled DOR targeting ligand and conju-
gated it to an anti-PD1 antibody (DORL-PD1). We synthesized immunoconju-
gates with several targeting ligand-to-antibody ratios (TARs). We engineered
murine lung cancer cells to constitutively express the DOR. By lanthanide time-
resolved fluorescence (LTRF) competitive binding assays, we have shown that
the agents have high avidity for the DOR in vitro with higher TARs resulting in
higher binding avidity. We characterized the uptake of DORL-PD1 in vitro
using live-cell fluorescence microscopy. Using syngeneic engraftment tumor
models in immunocompetent mice, we performed longitudinal fluorescence
imaging studies to determine the agent circulation time (PK), tumor selectivity
and tissue distribution (BD). Immune checkpoint effıcacy studies were per-
formed using the DOR negative mouse tumor models. In conclusion, we have
synthesized fluorescent DOR-targeted immune checkpoint therapy agents,
DORL-PD1; demonstrated avidity and selectivity for the DOR in vitro and in
vivo; and immune checkpoint therapy effıcacy in vivo. Future studies will eval-
uate the effıcacy of DORL-PD1 in immune competent mice bearing DOR posi-
tive tumors. These agents could be useful for increasing the effıcacy and reduc-
ing systemic toxicity of immune-checkpoint therapy of lung cancer.
#1710 Providing confıdence around computational tissue analysis using
heterogeneity assessments. Carsten Schnatwinkel,1 Daniel Rudmann,1 Famke
Aeffner,1 Jasmeet Bajwa,1 Natalie Hutnick,2 Michael Sharp,2 Gerry Chu,2 JD
Alvarez2. 1Flagship Biosciences Inc., Westminster, CO; 2Janssen R&D, Spring
House, PA.
Background: Though the techniques to interrogate the appearance of a bio-
marker in tissue sections have greatly advanced, there are limitations as to how
representative an analysis of a tissue section is compared to the entire diseased
tissue. Depending on the heterogeneous expression level of a biomarker, tissue
sampling can result in different interpretations of the biomarker’s appearance,
and hence could potentially lead to a false therapeutic intervention. Hypothesis:
Digital image analysis has demonstrated tremendous value in quantifyingmany
features related to biomarker distribution and expression in biological tissues.
The information can be collected for various indications and biomarkers and a
phenotypic signature can be established that describes a biomarker representa-
tion across indications. Moreover, the assessment of new samples can be com-
pared to the established phenotypic signature and a confıdence score applied in
support to the determined endpoint. Approach: For a proof of concept, 6 pros-
tate cancer samples were processed and a single section was collected after every
100microns. A total of 7 sections per sample were stained for the lymphocyte
marker CD3, and the number of positive target cells were determined in the
tumor and tumor microenvironment using tissue Image Analysis (tIATM). To
assess how indicative the evaluation of a single tissue section would be for the
entire tumor, the heterogeneity level was determined on the section level as well
as by randomgrid analysis on each individual section. Both criteria were utilized
to defıne an indication and biomarker specifıc confıdence interval and hetero-
geneity score. Conclusion: The combination of IHC and tIA is a powerful tool to
convert complex data into meaningful interpretations. tIA is also a capable tool
to catalogue valuable information about the biomarker’s expression pattern
across different disease stages and hence could be used to evaluate how repre-
sentative a single biomarker evaluation is in the grand scheme. Ultimately, we
demonstrated a technique that can be applied to any biomarker andwould assist
in guiding therapeutic decisions.
CLINICAL RESEARCH: Liquid Biopsies 1: Circulating Tumor
Cells
#1711 Detection of circulating tumor cells for use as prognostic, predic-
tive and pharmacodynamic biomarkers in neuroblastoma. Swathi Merugu,
Deborah Tweddle. Newcastle University, Newcastle, United Kingdom.
Introduction: Neuroblastoma (NB) is the commonest extracranial childhood
solid tumour. New treatments and a better understanding of drug resistance are
needed to improve survival. Circulating tumour cells (CTCs) may provide a
source of tumour cells for genetic biomarkers, give insights into tumour load
and serve as pharmacodynamic (PD) biomarkers for new treatments. In clinical
diagnostics, slide based FISH is used to detect MYCN amplifıcation in neuro-
blastoma tumours. As it is not possible to conduct slide based FISH on an entire
blood sample due to the infrequency of CTCs in peripheral blood (1 in 106
leucocytes), an alternative method FISH-IS (in suspension) was used in the
present study to detect MYCN gene amplifıcation using the Imagestream imag-
ing flow cytometer (ISx). Aims: 1) To detect CTCs from blood and disseminated
tumour cells (DTC) from bone marrow (BM) from NB patients using the (ISx)
2) To use these cells for genetic and PD biomarker studies for novel targeted
therapies.Methods: A panel of NB cell lines (n6) cloned into neuronal (N) and
substrate-adherent (S) types were used to determine expression of NB cell sur-
facemarkers (GD2 andNCAM)using the ISx.Western blotting and fluorescence
activated cell sorting (FACS) were used to validate NCAM and GD2 expression
respectively. 25 paired NB patient blood and BM samples were analysed for
CTCs and DTCs, 4 unpaired blood samples were analysed for CTCs and one
unpaired BM sample was for DTCs using the ISx to detect GD2 ve and
CD45-ve cells. Results: Using the ISx 80-90% of N-type cells immunostained
positive for GD2 compared to 0.8 -10% of S-type cells confırmed by FACS. CTCs
were detected in 21/29 patient samples andDTCs in 19/26 cases. The numbers of
CTCs ranged from 10-522/ml blood andDTCs from 57-35,515/ml of bonemar-
row. After validating FISH-IS protocol on ISx usingNGP and SHSY5Y cell lines,
4 NB patient DTC samples were analysed for MYCN amplifıcation. 2/4 cases
showed MYCN gene amplifıcation consistent with results obtained on the pri-
mary tumour. Conclusion: This the fırst study to show that DTCs and CTCs are
detectable in NB patient samples using the ISx. Future work will involve further
genetic characterisation and development of PD biomarkers for Phase I clinical
trials.
#1712 Detection of circulating tumor cells in stage IV non-small cell lung
cancer. StephanieN. Shishido,1 Lyudmila Bazhenova,2 Anders Carlsson,1 James
Hicks,1 Peter Kuhn1. 1University of Southern California, Los Angeles, CA; 2Uni-
versity of California, San Diego, La Jolla, CA.
Non-Small Cell Lung Cancer (NSCLC) is the most common cause of cancer
related deaths in bothmen andwomen. Some lung cancer patients have a unique
challenge of a tissue access due to tumor location or baseline lung disorders such
as emphysema and chronic obstructive pulmonary disease (COPD). Liquid bi-
opsy technologies can overcome tissue assess diffıculties. However, as of today
there are no commercially approved assays forCTCenumeration in lung cancer.
Multiple non-commercial assays exist and some show correlation of CTC enu-
meration and changes inCTC counts on therapywith prognosis and response to
therapy.Outside of absolute number ofCTC there is little published data regard-
ing prognostic signifıcance of CTC morphologic heterogeneity in late stage
NSCLC and its ability to predict treatment outcomes. Here we investigate CTC
counts in 81 patients with stage IV NSCLC using a fluid phase biopsy and high
defınition (HD) diagnostic pathology imaging of all nucleated cells. HD-CTCs
were detected in 51 (63%) patients at initiation of therapy with a median of 2.20
(range 0-509.20) and a mean of 26.21 HD-CTCs/mL (	15.64). There was no
correlation between the absolute number ofHD-CTCs at the time of initiation of
new therapy and patient outcomes. A subset of 25 patients was further analyzed
to determine the signifıcance of HD-CTC kinetics, which may follow three dis-
tinct patterns: an increase in HD-CTCs with therapy, unchanged HD-CTCs
numbers (stable), and a decline in HD-CTCs numbers. Patients that experi-
enced an increasing, stable, or decreasingHD-CTCprofıle had an overall change
of 118.40, 0.54, and 81.40 HD-CTCs/mL respectively during the fırst 3 months.
The overall survival (OS) for increasing profıles was 31.08 months (	13.08,
median 32.46, range 15.11-43.50), for stable profıles OS was 8.82 months
(	3.57, median 7.23, range 3.91-19.75), and for decreasing profıles it was 15.30
months (	6.39, median 14.06, range 3.81-28.06) months. CTCs are identifıable
in patients with stage IV NSCLC, but correlation of absolute HD-CTC counts
with disease progression was not statistically signifıcant. However, change in
CTC counts were predictive of OS in patients with metastatic lung cancer re-
ceiving chemotherapy.
#1713 Transferrin receptor 1 (TfR) as marker for circulating tumor cells
(CTCs) identifıcation in NSCLC.Giuseppe Galletti,1 Galatea Kallergi,2 Ashish
Saxena,1 Despoina Aggouraki,2 Christos Stournaras,2 Vassilis Georgoulias,2
Timothy E. McGraw,1 Nasser Altorki,1 Paraskevi Giannakakou1. 1Weill Cornell
Medical College, New York, NY; 2University of Crete, Greece.
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CTCs are used as a surrogate source of tumor material in solid tumors. Clin-
ical applications of CTCs as liquid biopsy comprise themonitoring ofmolecular
alterations during tumor progression and dynamic evaluation of molecular
markers of treatment response. The FDA-cleared method to isolate CTCs in
cancer patients (Cell Search) is based on positive selection of EpCAMexpressing
cells. However, this approach performs poorly in non-small cell lung cancer
(NSCLC) as it identifıes CTCs in only 7% of the subjects, failing to show any
prognostic relevance. Down-regulation/loss of epithelial markers to isolate (Ep-
CAM) and identify (cytokeratin, CK) CTCs could in part explain the low CTC
yield obtained in NSCLC with approaches based on epithelial markers expres-
sion. To overcome this challenge we used size-based CTC enrichment (ISET
fılters) from NSCLC patients’ peripheral blood. As a positive identifıer of CTCs
we used transferrin receptor 1 (TfR) which is a cell membrane-associated pro-
tein, that mediates intracellular iron uptake, and which is expressed at low levels
inmany normal tissues but over-expressed in cancer cells.We fırst analyzed TfR
protein expression by immunofluorescence in a panel ofNSCLC cell lines and in
healthy donor leukocytes.While all NSCLC cells lines analyzedwere positive for
TfR expression, none of the leukocyte expressed the receptor. Moreover, TfR
expression was detected also in EpCAM negative NSCLC cell lines. To deter-
mine the clinical applicability of this novel CTC identifıer, we determined TfR
expression in CTCs isolated from peripheral blood of 35 metastatic NSCLC
patients using the ISET fılter technology. The isolated CTCs were stained for
TfR, CK, CD45 and DAPI. For each patient, one additional ISET fılter was
stained with Giemsa for morphologic analysis by a pathologist. By using the
classic panel of CTC identifıers markers (CK/CD45-/DAPI), CTCs were
identifıed in 4/34 (11%) patients, while by using TfR as positive identifıer
(TfR/CD45-/DAPI)CTCswere identifıed in 31/35 (88%) subjects. Themor-
phologic review of Giemsa stained fılters confırmed the presence of tumor cells
in 28/34 (82%) samples [0-217 CTCs/sample]. Interestingly, patients with  6
TfR CTCs had a worse overall survival (OS) than patients with  6 TfR
CTCs [p0.048 Log Rank (Mantel-Cox)]. OS did not signifıcantly differ using
the same cutoff withCTCs defıned based onCKorGiemsa staining. Overall, our
data indicate that TfR is a promising biomarker for the detection of CTCs in
NSCLC CTCs, superior to CK or EpCAM. Our data also suggest that TfR may
potentially identify CTCs subpopulations with a signifıcant prognostic role in
NSCLC.We are currently isolating TfR CTCs from early stage and metastatic
NSCLC patients for further molecular characterization and determination of
clinical signifıcance.
#1714 TranslatingCTCs for clinical use:melanomapatient-derivedCTCs
evolution in xenografts. Monika Vishnoi,1 Haowen N. Liu,1 Debasish Boral,1
Wei Yin,1 Marc L. Sprouse,1 Jean P. Thiery,2 Isabella C. Glitza,3 Dario Mar-
chetti1. 1Houston Methodist Research Institute, Houston, TX; 2Cancer Science
Institute of Singapore, National University of Singapore, Singapore; 3The Univer-
sity of Texas MD Anderson Cancer Center, Houston, TX.
Circulating tumor cells (CTCs) are known to disseminate from primary/met-
astatic tumors, survive in the circulation, and develop competency to colonize
distant organs. Dissecting CTC heterogeneity is therefore crucial to provide
improve prognostic and diagnostic tools (concept of “liquid biopsy”). However,
the clinical signifıcance of CTCheterogeneity is still unknown.Wehypothesized
that melanoma patient blood-derived, lineage-negative cells (CD45-/CD34-/
CD73-/CD90-/CD105-) contain melanoma cell subpopulations (Melan A,
S100, CD146 and NG2 CTCs) that evolve in vivo and achieve metastatic
potency when reaching an organ-specifıc niche. We enriched Lin-negative cells
from peripheral blood of melanoma patients clinically diagnosed with or with-
out brain metastasis (MBM) by multi-parametric flow cytometry; and analyzed
CTC heterogeneity in xenografts by longitudinal capturing and interrogation at
the single-cell level (DEPArrayTM platform). First, we evaluated the presence of
melanoma CTC subpopulations in Lin-negative cells and developed Lin-nega-
tive murine xenograft models. Human-cell derived melanoma metastasis in
xenografts confırmed that CTCs require metastasis-potentiating factors present
in the Lin-negative population. Second, we performed multi-parametric flow
cytometry to isolate human-derivedHLA/Melan A/CTCs/DTCs popula-
tion frommurine blood and bonemarrow at T0, Tmid and Tend phases of metas-
tasis. We interrogated the differential levels of CTCs/DTCs in HLA/Melan
A cell population and established their neoplastic identity by genetic profıling
and the expression ofmelanomamarkers at single-cell level. Third, we dissected
longitudinal transcriptional signatures of CTCs vs DTCs in association with
MBM onset. We assessed the comprehensive EMT scores of CTCs and DTCs
transcriptomics and identifıed the pathways associated with CTC/DTCs dy-
namic functional states depending upon melanoma progression. Collectively,
this study provide important insights to identify novel EMT-related biomarkers
of MBM progression. Further elucidation of these CTC biomarkers and prop-
erties may provide novel therapeutic strategies that can be clinically useful in
melanoma patients which are yet to develop MBM.
#1715 EGFRmutational detection in ctDNA, Vortex-enriched CTCs and
comparison to tumor tissue in non-small-cell-lung-cancer (NSCLC) pa-
tients.Haiyan E. Liu,1 Meghah Vuppalapaty,1 Clementine A. Lemaire,1 Charles
Wilkerson,1 Steve C. Crouse,1 JonathanW. Goldman,2 Elodie Sollier-Christen1.
1Vortex Biosciences,Menlo Park, CA; 2DavidGeffen School ofMedicine at UCLA,
Los Angeles, CA.
Background: Lung cancer is the leading cause of cancer-related mortality
worldwide. Epidermal growth factor receptor (EGFR) tyrosine kinase inhib-
itor (TKI) therapies, based on the evaluation of EGFR mutation, have shown
dramatic clinical benefıts. EGFR mutation assays are mainly performed on
tumor biopsies, which carry risks and expense and are not always successful.
In order to identify the development of secondary EGFR mutations, which
cause resistance to 1st and 2nd generation TKI’s and an indication for therapy
with a 3rd generation drug, effective and non-invasive monitoring is needed.
Liquid biopsy biomarkers, such as circulating tumor cells (CTCs) and circu-
lating tumor DNA (ctDNA), allow such monitoring over the course of the
therapy. Interestingly, ctDNA or CTC analysis alone had less sensitivity vs.
combining both, with a genotyping of 70% and 80% for CTCs and ctDNA
respectively, but 100% when combined2. Vortex technology is a platform
enabling label-free capture of CTCs from blood samples and genomic assays
downstream3. The aim of this study is to demonstrate the sensitivity of a
combined CTC and ctDNA assay through Vortex using blood samples
spiked with molecularly-characterized lung cancer cell lines and then to
apply this technique to matched blood and tumor samples from NSCLC
patients. Method: Lung cancer cell lines with different EGFR mutations
(A549: wild type, H1975: L858R and T790M, HCC827: 19del) were
used to validate our CTC workflow. Blood samples and matched tumor
tissues were collected from NSCLC patients. Plasma was extracted fırst for
ctDNA assay. CTCs were isolated from the plasma-depleted-blood using
Vortex technology, immunostained (CK, Vimentin, CD45) and enumerated.
DNA from CTCs, plasma and matched tumor tissue was analyzed for EGFR
mutations 19del, L858R and T790M using the ctEGFR kit from EntroGen.
Results: Mutant DNA could be identifıed at a quantity as low as 0.5 ng (83
cells), with a sensitivity ranging from 0.1% to 2% for a total DNA varying
from 25ng (4 CTCs among 4000 WBCs) to 1ng (4 CTCs among 200
WBCs). We demonstrated the ability of Vortex technology to enrich CTCs
from metastatic NSCLC patients. Processing of plasma-depleted-blood
showed the same capture effıciency when compared to whole blood. This
makes possible the detection of EGFR mutations on CTC samples collected
by Vortex technology. 10 NSCLC patients are being enrolled in this study
and results will be presented at AACR. Conclusion: The ctEGFR mutation
assay performed well on both Vortex-enriched CTCs and ctDNA, enabling a
low cost approach to analyze EGFR mutation from a single blood tube. This
non-invasive EGFR mutation analysis will be potentially a useful tool for
monitoring treatment and medication guidance of NSCLC patients. 1. Cala-
buig-Fariñas et al. Transl Lung Cancer Res. 2016. 2. Sundaresan TK et al.
Clin Cancer Res. 2016. 3. Kidess-Sigal E et al. Oncotarget 2016.
#1716 GSTP1promotermethylation in in-vivo isolatedCTCs fromhigh-risk
prostate cancer patients.Athina N.Markou,1 Panagiotis Paraskevopoulos,1 Mari-
fıli Lazaridou,1 Shukun Chen,2 Thomas Kroneis,2 Monika Świerczewska,3 Joanna
Budna,3 Andra Kuske,4 TobiasM. Gorges,4Maciej Zabel,5 Peter Sedlmayr,2 Cathe-
rine Alix-Panabieres,6 Klaus Pantel,4 Evi Lianidou1. 1Univ. of Athens, Athens,
Greece; 2Institute forCell Biology,Histology andEmbryology,Graz, Austria; 3Poznan
University of Medical Sciences, Poznan´, Poland; 4University Medical Center Ham-
burg-Eppendorf, Hamburg, Germany; 5Poznan University of Medical Sciences, Po-
land; 6University Institute for Clinical Research (IURC), Laboratory of Rare Human
Circulating Cells, University Medical Centre of Montpellier Saint-Eloi Hospital,
EA2415, Montpellier, France.
Introduction:Glutathione S-transferase 1 (GSTP1) has been reported to func-
tion as tumor suppressor gene in various types of human cancers. GSTP1 inac-
tivation is associated with CpG island promoter hypermethylation in themajor-
ity of prostate cancers (PCs). The initiation of minimal residual disease (MRD)
and especially the detection of circulating tumor cells (CTCs) in patients’ pe-
ripheral blood represents a negative prognostic parameter for recurrence-free
survival. The aim of the present study was to assess the methylation status of the
GSTP1 gene in CTCs that were isolated, using the CellCollector® (GILUPI,
GmbH), a novel clinical device designed for the in vivo isolation of EpCAM-
positive CTCs. Patients and methods: In-vivo isolation of CTCs was performed
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by using CellCollector® from high-risk prostate cancer patients (n97) and 20
healthy volunteers. For all these patients, the Ab coated region of the CellCol-
lector® was washed in PBS , cut, and stored in Trizol reagent till analysis and
DNA was further prior to the analysis isolated DNA was modifıed by sodium
bisulfıte (SB) and subjected to a real time MSP assay specifıc for GSTP1 meth-
ylation. In all cases, peripheral blood was also collected and used for CTC anal-
ysis by Immunostaining and the CellSearch® system. Results: All DNA samples
were fırst checked for their quality. Based on the quality evaluation of all avail-
able DNA samples, only 63 DNAs were further qualifıed for analysis. GSTP1
promoter was foundmethylated in 12/63 (19%) the EpCAMpositive fraction of
in-vivo isolated CTCs. Moreover, in 5/12 (41.7%) patients for which GSTP1
promoter was found methylated, CTCs were also detected by the CellSearch®
and 7 /12 (58.3%) for which GSTP1 promoter was also found positive, CTCs
were also detected by the Immunostaining. Conclusion: GSTP1 promoter is
methylated in in-vivo isolated CTCs from high-risk prostate cancer patients.
GSTP1 promoter methylation in in-vivo isolated CTCs should be prospectively
validated as a novel tumor biomarker for prostate cancer patients in a large
cohort of patients. Acknowledgements: This research has been co-fınanced by
the European Union (European Regional Development Fund - ERDF) and
Greek national funds through the Operational Program ’’Competitiveness and
Entrepreneurship’’ of the National Strategic Reference Framework (NSRF) -
Research Funding Program: “ERA-NET on Translational Cancer Research
(TRANSCAN) Joint Transnational Call for Proposals 2011 (JTC 2011) on: “Val-
idation of biomarkers for personalised cancer medicine.
#1717 Orthogonal identifıcation of circulating tumor cells (CTCs) using
single cell low pass whole-genome sequencing (WGS) and copy-number al-
teration (CNA) analysis.Gareth Morrison,1 Valeria Sero,2 Yucheng Xu,1 Jacek
Pinski,1 Sue Ingles,1 David Quinn,1 Claudio Forcato,3 Genny Buson,3 Chiu-Ho
Webb,4 Kyle Horvath,4 Aditi Khurana,4 Gianni Medoro,3 Suman Verma,4 Mat-
thew Moore,4 Philip Cotter,4 Nicolò Manaresi,3 Farideh Bischoff,2 Amir Gold-
korn1. 1University of Southern California, Keck School of Medicine, Norris Com-
prehensive Cancer Center, LosAngeles, CA; 2Menarini Silicon Biosystems Inc, San
Diego, CA; 3Menarini Silicon Biosystems Spa, Bologna, Italy; 4Research DX, Ir-
vine, CA.
Introduction: Presence of circulating tumor cells has prognostic value inmul-
tiple malignancies, and molecular analysis of CTCs is currently ongoing in nu-
merous clinical trials. Most CTC enrichment methods rely on standard epithe-
lial and leukocytemarkers (CKCD45-), so recovered cells are assumed to be of
epithelial origin but never shown to be bona fıde tumor cells. Conversely, atyp-
ical cells lacking the characteristic marker profıle may not be analyzed, even
though they may represent important tumor subpopulations. Here we evaluate
a rapid, non-exhaustive, and cost-effective fırst-pass genomic analysis of indi-
vidual candidate CTCs. This approach allows effıcient upfront CNA-based con-
fırmation that a given cell is of tumor origin, while leaving abundant DNA for
deeper subsequent analysis in cells of interest.Methods:Whole peripheral blood
of metastatic prostate cancer patients was enriched for CTCs using the Cell-
Search® system (Janssen Diagnostics) under an IRB-approved protocol, and 5
samples with5 CTCs were selected for further study. Next, the DEPArrayTM
v2 system (Menarini Silicon Biosystems) was used to identify and isolate single
CTCs (CKCD45-DAPI) and paired white blood cells (WBCs; CK-
CD45DAPI) from the enriched samples. In addition, cells negative for both
cytokeratin andCD45 butwith characteristicmalignantmorphology (largewith
high nuclear-cytoplasmic ratio) were isolated. Recovered single cells were
whole-genome amplifıed with Ampli1TM WGA and quality controlled by Am-
pli1QC.Ampli1 LowPass kit was then used to prepareNGS libraries for absolute
CNA profıling by low-pass WGS. Results: Thirty-three single CTCs
(CKCD45-DAPI) and 30 WBCs (CK-CD45DAPI), as well as 47 puta-
tive CTCs with non-conventional phenotype (CK-CD45-DAPI) were iso-
lated. Single-cell WGA products with high Genome-Integrity Index (QC score

3) were prioritized for CNA analysis. Ampli1 LowPass data demonstrated
copy number gains/losses confırming tumor origin of the CK cells, while
WBCs showed a normal profıle. In addition, a portion of the cells having non-
conventional phenotype also demonstrated copy number alterations consistent
with tumor origin. Discussion: We demonstrate a WGA and low-pass WGS
approach on single CTCs sorted from enriched peripheral blood, which offers a
dual benefıt: i) it allows rapid, non-exhaustive upfront identifıcation of bona fıde
tumor cells for further study, and ii) it reveals genetic similarities and diversities
(vis a vis copy number alteration) across CTCs of classical as well as non-con-
ventional phenotypes, which may better represent clonal diversity. In a clinical
setting, this molecular approach may be more effective for reliably identifying
and characterizing heterogeneous CTCs, yielding profıles that more accurately
reflect disease evolution and inform treatment strategies.
#1718 RT-qPCR gene expression analysis of CTCs isolated through an
epitope-independent enrichment microfluidic device in patients with head
and neck squamous cell carcinoma. Martha Zavridou,1 Areti Strati,1 George
Koutsodontis,2 AmandaPsyrri,2 Evi Lianidou1. 1Univ. of Athens, Athens, Greece;
2Attikon University Hospital, Athens, Greece.
Background: Molecular characterization of circulating tumor cells (CTCs) is
very challenging since these cells are rare, and the amount of available sample for
their analysis is very limited. Moreover, CTC are highly heterogeneous and
enrichment technologies based on EpCAM expression present the risk of miss-
ing EpCAM-negative CTCs. The Parsortix system (ANGLE plc, UK), is a novel
microfluidic technology platform designed for marker-independent capture of
CTCs. In this studyweused for the fırst time theParsortix system to isolateCTCs
from patients with Head and Neck Squamous Cell carcinoma (HNSCC), and
proceeded to downstream molecular characterization through RT-qPCR gene
expression analysis. Methods: Peripheral blood samples (10 mL) from head and
neck squamous cell carcinoma (HNSCC) patients (n19) and healthy donors
used as a control group (n10) were used for the isolation of CTCs using the
Parsortix device. Enriched CTCs were harvested in Trizol reagent, followed by
extraction of total RNA and cDNA synthesis. RT-qPCR was performed in the
LightCycler (Roche) for the following gene targets: PD-L1, VIM, TWIST, EGFR,
and B2M (used as a reference gene). The expression levels of PD-L1, VIM,
TWIST and EGFRwere normalized using the 2Ct approach in respect to the
expression of B2M. Results: All samples analyzed were of excellent RNA quality
as this was evaluated by B2M expression. According to our results, PD-L1 over-
expressionwas detected in 5/19(26.3%) samples, VIMwas overexpressed in 3/19
(15.7%) and TWIST-1 in 1/19 (5.3%) sample, while EGFR expression was not
detected in any patient (0/19, 0%). These are preliminary results and these per-
centages may change, since the number of samples that we are analyzing is
continuously increasing. Conclusions: This preliminary study is showing for the
fırst time that RT-qPCR can be successfully used for themolecular characteriza-
tion of CTCs isolated by the label-free Parsortix microfluidic device in HNSCC.
Overexpression of individualized immunotherapy important biomarkers such
as PD-L1 inCTCs ofHNSCCpatients could be of signifıcant clinical importance
for the selection and follow up of these patients.
#1719 Dual-profıling of CTC and exosome from the cultured circulating
tumor cells using stimuli-responsive degaradable hydrogels. Yoon-Tae
Kang,1 Young JunKim,1 TaeHee Lee,2 Jae-Eul Shim,1 Young-HoCho1. 1KAIST,
Daejeon, Republic of Korea; 2Cell Bench Research Center(SEMCELL), Daejeon,
Republic of Korea.
Introduction: Liquid biopsy based on sub-micron or nanosized particles in
human body fluid have been received vast attention due to their non-invasive
characteristics and enablingmultiple check-up. Circulating tumor cells (CTCs),
as well as exosome are the most promising markers in liquid biopsy, however,
dual isolation and profıling have been hampered due to their size difference and
limited quantity for analysis. We proposed the novel and simple methods for
both isolation and study their similarity between them.Using the label-free CTC
fıltration device and anti-CD63 antibody-conjugated degradable hydrogel, the
CTCs and the CTCs-derived exosome are specifıcally isolated, and each samples
were followed by molecular study after recovery. This versatile platform facili-
tates the comprehensive study of two biomarkers with reflecting their inherent
characteristics, thus paving the way for revealing their roles in cancer progres-
sion and metastasis. Methods: In order to make stimuli-responsive degradable
hydrogel, poly (vinyl alcohol) and alginateweremixed under constant stirring at
85 °C. The mixture was poured into the mold and dried for 24 hours. Then, the
dried sheet was immersed into 100 mM calcium chloride solution to achieve
gelation through ionic interaction. Subsequently, the anti-CD63 antibody was
immobilized onto the prepared hydrogels via cross-linking. For the dual-profıl-
ing, the hydrogel and the fılters containing the captured breast cancer cells by
microfıltrationwere incubatedwith the exosome-depleted cell culturemedia for
6 hours. The captured cells were released from the device and the hydrogels were
degraded by adding EDTA. The cell and exosome lysate were prepared using
RIPAbuffer at 4 °C. The supernatantwas collected by centrifugation followed by
western-blot assay. Four different markers, including exosome-specifıc marker
(CD63), cancer-associated markers (EpCAM, vimentin), and a housekeeping
marker (-actin), were used. Results: All exosome and cell samples highly ex-
pressed the housekeeping marker. Especially, two exosome samples dissociated
from the hydrogel showed CD63 predominantly, which support the secretion of
exosome from the cancer cells. The samples from the released cancer cells from
the device did not express CD63 remarkably. To verify the phenotypical simi-
larity between cell and exosome, expressions of the epithelial marker (EpCAM)
and mesenchymal marker (vimentin) were examined. The exosome and cell
from MCF-7, epithelial cancer cell, showed higher expression of EpCAM then
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vimentin. On the contrary to this, the samples fromMDA-MB-231, mesenchy-
mal cell, showed higher vimentin expression then EpCAM.Discussion and con-
clusion: We showed that exosome follow the phenotypical characteristics of
mother-cells. This dual profıling would be helpful for in-depth study of cancer
with consideration of its heterogeneity and complexity.
#1720 Circulating tumor cell (CTC) enrichment and DNA mutation de-
tection by sequencing. Ruqin Kou,1 Eric Zhao,1 Conrad Leung,1 Priya Gogoi,2
Will Chow,2 Yixin Wang2. 1GENEWIZ, South Plainfıeld, NJ 08070, NJ; 2Celsee
Diagnostics, Plymouth, MI.
Molecular analysisof circulating tumorcells (CTCs) ishinderedby lowsensitivity
and high level of background leukocytes of currently available CTC enrichment
technologies. The Celsee PREP100 device captures CTCs with high sensitivity and
allows the captured CTCs to be retrieved for molecular analysis. To evaluate the
potential of utilizing PREP100 in CTC molecular analysis, we fırst prepared mock
samplesusing culturedprostate cancer cells PC3andLnCAPandanalyzed captured
cells by PCR amplicon sequencing. Using Celsee PREP100, we were able to recover
the average of 79% (ranging from 40% to 100%) of 110 - 1,100 PC3 cells and 60 -
1,500 LnCAP cells and detect p.K139fs*3 deletion in PC3 cells andT877Amutation
in LnCAP cells. In addition, we also spiked in the two cell lines into normal donor
blood samples and analyzed the captured cells by PCR amplicon sequencing. Pre-
liminary experiments showed that 40%of 250 spikedPC3cells and74%of 50 spiked
LnCAP cells were captured. Further, we were able to detect p.K139fs*3 deletion in
the retrieved 50 - 1,000 spiked PC3 cells. Our results illustrate that Celsee PREP100
system represents a promising technology for capturing and molecular character-
ization of CTCs.
#1721 Detection of CTCs in thoracic malignant tumors with ‘universal‘
CTC-chip. Kazue Yoneda, Taiji Kuwata, Yasuhiro Chikaishi, Kenichi Ko-
bayashi, Sakiko Yura, Hiroki Matsumiya, Masatoshi Kanayama, Akihiro Taira,
Yusuke Nabe, Shinji Shinohara, Masaru Takenaka, Soichi Oka, Ayako Hirai,
Yuko Tashima, Naoko Imanishi, Koji Kuroda, Fumihiro Tanaka. University of
Occupational and Environmental Health, Kitakyushu, Japan.
Background: Circulating tumor cells (CTCs) are tumor cells shed from pri-
mary tumor and circulate in the peripheral blood. CTCs, as a surrogate of distant
metastasis, can be potentially useful in diagnosis and monitoring therapeutic
effects in malignant tumors. Among a variety of systems for detection of CTCs,
the “Cellsearch” is the only approved system for clinical use. However, EpCAM-
negative tumor cells, such as those originating from non-epithelial cells and
those undergoing epithelial-mesenchymal transition (EMT) cannot be captured
with the “CellSearch” that is an EpCAM-based isolation system. Therefore, we
have developed a novel polymeric microfluidic device (“Universal” CTC-chip)
that can capture CTCswith or without EpCAMexpression (AACR 2015). In the
present study, we examined CTCs-detection performance of the CTC-chip in
patients with thoracic malignant tumors (lung cancer [LC] as an “EpCAM-
positive” tumor and malignant pleural mesothelioma [MPM] as an “EpCAM-
negative” tumor) in comparison with that of the CellSearch. Methods: Periph-
eral blood sampled from each patient was divided and subjected to quantitative
evaluation of CTCs with the CTC-chip as well as with the “CellSearch”. The
CTC-chip, coated with an anti-EpCAM antibody, was used to capture CTCs in
the blood samples (n19) from lung cancer patients. To capture CTCs in the
samples (n11) fromMPMpatients, theCTC-chipwas coatedwith an antibody
against podoplanin that is expressed on themesothelioma. After immuno-stain-
ing for cytokeratin and CD45 on the chip, a captured cell containing Hoechst-
positive nucleus and cytokeratin-positive/ CD45-negative cytoplasm was
judged as a CTC. The CTC-count for each sample was represented as the num-
ber per 7.5mL of the blood. Results: The median CTC-count detected with the
CTC-chip in LC was 50 (range, 0-270), which was signifıcantly higher than that
(the median CTC-count, 0; range, 0-47) with the CellSearch (p0.01). In the
peripheral blood sampled from MPM patients, CTC was detected in only one
patient using the CellSearch, but was detected in all 11 patients with the median
CTC-count of 144 (range 0-470). Conclusion: The “universal” CTC-chip
achievedhigher performance in detection ofCTCs of thoracicmalignant tumors
as compared with the CellSearch. The updated data will be presented at the
AACR annual meeting 2017.
#1722 Novel multiplex liquid biopsy detection of ALK and ROS1 rear-
rangements and intratumoral heterogeneity in lung cancer using circulating
tumor cells (CTCs) isolated from NSCLC patient bloods and TR-CytoTrap-
NanoTM technology. sangjun lee. Cytolumina, Los Angeles, CA.
Introduction: ALK and ROS1 rearrangements are common gene alterations
found in subsets of patients with NSCLC. Identifıcation of ALK and ROS1 rear-
rangement inNSCLC is critical for highly active targeted therapies aiming for these
two main tumorigenic drivers. Due to the similarity of tyrosine kinase domains
between ALK and ROS1, many ALK inhibitors are also functional in treatment of
ROS1 subtype NSCLC. For example, crizotinib, which is a standard therapy for
advancedALK-rearrangedNSCLCishighly effective inadvancedROS1-rearranged
genotype NSCLC patients. The mutational analysis of these genes requires serial
tumorbiopsying fromprimary lesions,which requires high risk clinical procedures.
Further, the current tissue-based diagnostics, such as fluorescence in situ hybridiza-
tion (FISH) and immunohistochemistry (IHC) are known to be challenging techni-
callywith limited sensitivity, subjective interpretationand inaccuracy inmonitoring
the current tumor status. The TR-CytoTrapNanoTM CTC technology is a blood-
based assay to utilize CTCs as a biosource for mRNA extraction to detect genetic
alteration or gene expression profıles including ALK and ROS1 gene rearrange-
ments. In this study, we determined the variant specifıc expression of ALK fusion
transcripts (EML4-ALK, KIF-ALK, and TGF-ALK) and ROS1 fusion transcripts
(EZR-ROS1, SDC4-ROS1, TPM3-ROS1, LRIG3-ROS1, GOPC-ROS1, CD74-
ROS1, and SLC34A2-ROS1) usingmultiplex digital droplet polymerase chain reac-
tion(ddPCR) technology. Method: The Peripheral Blood Mononuclear Cells iso-
lated from NSCLC patient bloods run through the TR-CytoTrapNanoTM
microfluidic system. The CTCs are enriched and captured on the chip surface con-
jugated with Anti-EpCAM targeting antibody, which specifıcally binds to CTCs of
epithelial origin. Following lysis step facilitate total RNArelease from trappedCTCs
and then puremRNAs are isolated using oligo-dT conjugatedmagnetic beads. The
mRNAs are used for following ALK and ROS1 specifıc reverse transcription reac-
tion to make cDNAs for either ALK or ROS1 fusion transcripts. The specifıc sub-
typing of ALK and ROS1 rearrangement are then validated using ddPCR. Results
and Conclusion:We tested several liquid biopsies from ALK and ROS1 rearrange-
ment positive patients and corresponding positive data to FISH assays using solid
tumor biopsies. Interestingly, some of the CTCs harboring ALK and ROS1 rear-
rangement has shownhigh intratumor heterogeneity in the subtypes of fusion part-
ners. we envision that our novel TR-CytoTrapNanoTM CTC ALK/ROS1 rear-
rangementAssay tomonitor treatment response and recurrence inNSCLCpatients
will be used to monitor treatment response and disease recurrence following treat-
ment with Tyrosine Kinase Inhibitors (TKIs).
#1723 Diagnostic leukapheresis results in a signifıcant increase in CTC
yield in metastatic breast and prostate cancer. Kiki C. Andree,1 Anouk Men-
tink,1 Joost F. Swennenhuis,1 LeonW. Terstappen,1 Nikolas H. Stoecklein,2 Rui
P. Neves,2 Rita Lampignano,2 Hans Neubauer,2 Tanja Fehm,2 Johannes C. Fi-
scher,2 Elisabetta Rossi,3 Mariangela Manicone,4 Umberto Basso,4 Piero Mar-
son,5 Rita Zamarchi,4 Yohann Loriot,6 Valérie Lapierre,6 Vincent Faugeroux,7
MarianneOulhen,6 Francoise Farace,7 GemmaFowler,8Mariane Sousa Fontes,9
Berni Ebbs,8 Maryou Lambros,8 Mateus Crespo,8 Penelope Flohr,8 Johann S. de
Bono9. 1University of Twente, Enschede, Netherlands; 2University Hospital of the
Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany; 3IOV-IRCCS and
University of Padova, Padova, Italy; 4IOV-IRCCS, Padova, Italy; 5University
Hospital of Padova, Padova, Italy; 6Gustave Roussy, Université Paris-Saclay,
Villejuif, France; 7Gustave Roussy, Villejuif, France; 8Institute of Cancer Re-
search, Sutton, UnitedKingdom; 9The Institute of Cancer Research andThe Royal
Marsden NHS Foundation Trust, Sutton, United Kingdom.
Introduction: Frequently the number ofCTC isolated in 7.5mLof blood is too
small to reliably determine tumor heterogeneity and to be representative as a
‘liquid biopsy’. In the EU FP7 program CTCTrap we aimed to validate and
optimize the recently introducedDiagnostic LeukApheresis (DLA; doi: 10.1073/
pnas.1313594110) approach to screen liters of blood and thereby substantially
increasing the number of CTC available for further characterization. Here we
present the results obtained from32metastatic cancer patients subjected toDLA
in the participating institutions. Methods Before the DLA procedure, whole
blood was drawn in a CellSave blood collection tube and a 7.5 ml aliquot was
processed with the ‘gold standard’ reference CellSearch® (Janssen Diagnostics,
USA). DLAs from metastatic cancer patients were performed for90 minutes
to obtain 40 mL of product containing4x109 mononuclear cells (MNC) rep-
resenting1 liter of blood. The obtained DLA samples were then divided, fıxed
with CellSave preservative, prepared and processed with each of the analysis
techniques as described in the Standard Operating Procedures developed for
DLA in the CTCTrap consortium (https://www.utwente.nl/tnw/mcbp/proto-
colsandtools/). Results: DLAs were obtained from 20metastatic prostate cancer
patients and 12 metastatic breast cancer patients at four different European
academicmedical institutions.Using a SOP for theDLAprocedure, similarDLA
products (MNC concentration: 64x106/mL, SD  38x106) could be generated
without any noticeable side effects. CTC in 7.5mL of blood ranged from 0 to 324
(mean 61,median 18). DLAprocessedwithCellSearch represented 7 to 212
mL of blood (mean 100, median 97), CTC ranged from 0 to 2913 (mean
330, median 105). Resulting in a signifıcant increase in CTC yield (p 0.004)
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ranging from0x to 40x (mean 13,median 9)when comparing 1mLofwhole
blood to 1mL of DLA. Filtration of 50x106 WBC of DLA, through 5um micro-
sieves yielded only 0 to 12 CTC (mean  2, median  0, n  16). Leukocyte
depletion of 18 mL of DLA followed by fıltration yielded 0 to 178 CTC (mean
37, median 4, n 22) not yielding a relative increase versus CellSearch DLA.
Leukocyte depletion followed by CellSearch yielded 271 to 1620 CTC (mean
792, median 484, n 3) also not yielding a relative increase versus CellSearch
DLA. In 7 patients 0 CTC were detected in 7.5mL of blood, in 4 out of these 7
patients CTC were detected in DLA. Conclusion: The yield of CTC can be sig-
nifıcantly increased by the use of DLA in patients with CTC detected in 7.5 mL
of blood. Technology to select CTC fromDLAswill need to be further improved
before one can make optimal use of the large processed blood volumes.
#1724 Genomic profıling of Vortex-enriched CTCs using whole genome
amplifıcation and multiplex PCR-based targeted next generation sequenc-
ing. Haiyan E. Liu,1 Melanie Triboulet,2 Amin Zia,3 Meghah Vuppalapaty,1
Evelyn Kidess-Sigal,4 John Coller,3 Vanita S. Natu,3 Vida Shokoohi,3 James
Che,1 Corinne Renier,1 Natalie Chan,2 Violet Hanft,2 Elodie Sollier-Christen,1
Stefanie S. Jeffrey2. 1Vortex Biosciences, Menlo Park, CA; 2Stanford University,
School of Medicine, Stanford, CA; 3Stanford University, Stanford, CA; 4Charite
University Hospital, Berlin, Germany.
Background: Genomic characterization of circulating tumor cells (CTCs)
provides insights into cancer genetic changes, and might be utilized for cancer
prognosis, diagnosis, as well as monitoring of therapeutic effıcacy. Targeted
Panel Next Generation Sequencing (NGS) enables analyzing CTC genetic vari-
ants of a focused gene panel at a relatively lower cost1. However, CTCs are rare,
often resulting in very limited DNA quantities available that require whole ge-
nome amplifıcation (WGA). In previous studies, we introduced theVortex tech-
nology, a platform enabling label-free enrichment of CTCs from blood samples
of colorectal cancer (CRC) patients and their use for genomic assays down-
stream2. In this study, we developed a simple and effıcient NGS workflow for
CTC samples collected by this technology. Method: An optimized workflow
using the Qiagen GeneRead DNAseq targeted panel and Illumina MiSeq NGS
was fırst verifıed onHCT116CRCcell line before being applied onpatientCTCs.
For patient blood samples, CTCs were collected with the Vortex technology,
immunostained (CK, Vimentin, CD45) and enumerated. Matched white blood
cell (WBC) DNA was included to subtract germline background. Fresh frozen
livermetastasis tissue was collected and analyzed using the sameNGSworkflow.
DNA from CTCs was extracted and amplifıed using Qiagen REPLI-g single cell
WGAkit.Mutation detection on theWGAamplifıedDNAwas performedusing
the GeneRead DNAseq CRC targeted panel of 38 genes and MiSeq sequencing.
The sequencing data were analyzed byQIAGENNGSData AnalysisWeb Portal
and Ingenuity Variant Analysis software. Results: The Vortex technology was
validated for the capture of CTCs from CRC patients. REPLI-g performed a
uniform, unbiased amplifıcation on fresh rare cells with a coverage of 97.7%,
which enabled further targeted panel NGS. Blood from 3 CRC patients (P1, P2,
P3) and 2 healthy donors (HD1,HD2)was processedwithVortex platform. Less
than 1 CTCs/mL blood were found in HD1 and HD2. P1 and P2 had 66 and 20
CTCs/ mL of blood respectively, with many vimentin positive CTC clusters. P3
had 2 CTCs/mL of blood. No somatic mutation was found in healthy donors.
Somatic variants were only detected in the CTCs from patient samples that were
not present in matched germlineWBCs. For P1, more mutations were found in
the CTCs than in the liver metastasis while it was the opposite for P2 and P3.
Conclusion: For each patient, variants in CTCs and germline WBCs were ana-
lyzed from one blood sample using an optimized targeted NGS workflow and
compared to liver mets. Our optimized workflow, using the Qiagen REPLIg and
GeneRead DNAseq Targeted Panel NGS enabled the detection of CTC muta-
tions for 38CRC-focused genes. The inclusion of a germlineWBC control in the
workflow allowed the detection of mutations from pooled CTC samples col-
lected using theVortex technology. Altmüller J, et al. (2014). Biol Chem. Kidess-
Sigal E, et al. (2016). Oncotarget.
#1725 Detection of ESR1 D538G mutation in circulating tumor cells
(CTCs) andpaired circulating tumorDNA (ctDNA) samples of breast cancer
patients. Eleni Tzanikou,1 Athina Markou,1 Eleni Politaki,2 Giorgos Koytsod-
ontis,3 Amanda Psyrri,3 Vassileios Georgoulias,2 Evi Lianidou1. 1University of
Athens, Athens, Greece; 2University of Crete, Heraklion, Greece; 3Attikon Univer-
sity Hospital, Athens, Greece.
AIMS: Molecular characterization of CTCs and ctDNA analysis holds prom-
ise as an extremely powerful tool for themolecular profıling of cancer patients in
real time. Estrogen receptor alpha (ER) is expressed in approximately 70% of
all breast cancers and endocrine therapy represents a major treatment modality
in ER-positive disease. Recently, somatic mutations in the ER gene (ESR1)
were linked to acquired resistance to endocrine therapies in breast cancer. In this
study, we analyzed the most frequent ERS1 mutation (D538G) in CTCs (DNA
samples isolated from CellSearch cartridges), corresponding ctDNA from early
and metastatic breast cancer patients and healthy donors. METHODS: We fırst
developed a highly sensitive and specifıc methodology for the detection of ESR1
D538G hotspot mutation, based on a combination of allele-specifıc PCR, asym-
metric rapid PCR and high resolution melting analysis. We analyzed DNAs
isolated from CTCs (CellSearch) and the corresponding ctDNA before and/or
after therapy in: a) 25 patients with ER operable breast cancer, b) 11 patients
with ERmetastatic breast cancer, c) 13 patientswith ER- early breast cancer, d)
5 patients with ER-metastatic breast cancer and e) 80 healthy female volunteers.
In all cases ctDNA (extracted from 2ml plasma) andDNA fromCTCswere fırst
examined for their DNA quality before analysis. RESULTS: The assay is highly
sensitive (analytical sensitivity: 0.05%) and specifıc (0/80 healthy donors). ERS1
D538G hotspot mutation was identifıed in ctDNA in 4/18 (22.2%) of ERme-
tastasis-verifıed and in 5/33 (15.2%) of ER early breast cancer. In CTCs, ERS1
D538Gmutation was identifıed in 6/18 (33.3%) of ERmetastasis-verifıed and
5/33 (15.2%) of ER early breast cancer. In ER-pos metastasis-verifıed breast
cancer, the concordance for D538G mutation between CTCs and ctDNA was
10/18 (55.6%), whereas the corresponding concordance for ER operable
breast cancer was 25/33 (75.8%). Moreover, ERS1 D538G hotspot mutation was
identifıed in ctDNA in 2/9 (22.2%) of ER- metastasis-verifıed breast cancer and
2/16 (12.5%) of ER- early breast cancer. ERS1 D538G hotspot mutation was
identifıed in CTCs in 3/16 (18.8%) of ER- operable breast cancer, whereas none
of ER- metastasis-verifıed breast cancer patients (0/9) were positive. In ER-
metastasis-verifıed breast cancer patients, the concordance between CTCs and
ctDNA for D538G mutation was 7/9(77.8%), whereas the corresponding con-
cordance for ER- early breast cancer was 15/16 (93.8%). CONCLUSIONS: We
developed and validated an ultrasensitive and highly specifıc methodology for
the detection of ERS1D538G hotspotmutation. Thismutation was detected not
only in the ER group, but also in the ER- group of breast cancer patients. We
will further evaluate our fındings in a large cohort of patients before and after
treatment, to evaluate response to endocrine therapies in breast cancer.
#1726 Evaluation of PD-L1/PD-1 on circulating tumor cells (CTCs) and
on primary tumor in advanced non-small cell lung cancer (NSCLC).Galaktea
Kallergi, Eleni Kyriaki Vetsika, Despoina Aggouraki, Eleni Lagoudaki, Anasta-
sios Koutsopoulos, Filippos Koinis, Panagiotis Katsarlinos, Maria Trypaki,
Christos Stournaras, Vassilis Georgoulias, Athanasios Kotsakis. University of
Crete, School of Medicine, Heraklion, Greece.
Introduction: Circulating tumour cells (CTCs) are responsible for the meta-
static dissemination of the tumor. They have been shown to express Pro-
grammed Death-Ligand1 (PD-L1) to escape from the immune system surveil-
lance through its ligation with the PD-1receptor on the surface of effector
immune cells. We investigated the expression of PD-1/PD-L1 on CTCs isolated
fromNSCLC patients treated with chemotherapy.Methods: CTCswere isolated
based on their size using the ISET platform from 30 stage IV chemo-naïve
NSCLC patients (before and after chemotherapy). CTCs were detected after
staining with Giemsa and immunofluorescence (IF). Double and triple staining
experiments with different combination of antibodies: [Cytokeratins(CK)/PD-
1/CD45 and CK/PD-L1/CD45] were performed and the samples were analyzed
with the ARIOL system. Results Giemsa staining showed that twenty-three
(77%) out of 30 and six (54.5%) out of 11 patients had detectable CTCs at
baseline and after the 3rd cycle of front-line chemotherapy. IF staining revealed
seventeen out of 30 (56.7%) patients positive for CTCs at baseline level and 8 out
of 11 (72.7%) samples after the 3rd cycle of treatment. PD-1 and PD-L1 expres-
sion was observed in 53% (9/17) and in 47% of the CTC-positive patients at
baseline; in addition, 13% (1/8) and 63% (5/8) patients had PD-1 and PD-L1,
respectively after the 3rd cycle. Among the total number of detected CTCs, 67%
were PD-1() at baseline and 25% after the 3rd cycle (p0.069). In addition,
26% and 80% were PD-L1() at baseline and after the 3rd cycle, respectively.
Patients with more than 3 PD-1 positive CTCs showed shorter PFS (p0.022).
Primary tissue from ten of the examined patients was also available. More than
5% of PD-L1 () tumor infıltrating lymphocytes (TILs) were observed in 20%
(2/10) of the patients. More than 5% PD-L1 positive cells in the primary tumor
were observed in 20%. However the two group of the patients were different. In
addition both patients with PD-L1 () TILs harvested CTCs with PD-1 expres-
sion and one of them had also PD-L1 positive CTCs. Conclusion: PD-1- and
PD-L1-positive CTCs could be detected before and during 1st line treatment in
metastatic NSCLC. This expression was related to patients’ prognosis, implying
that these molecules can be served as targets for metastasis restoration. Further-
more the expression of PD-1 on CTCs suggests a bilateral cross-talk between
tumor and immune cells.
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#1727 Circulating Tumor Cells (CTCs) in patients with extensive stage
small cell lung cancer and their association with clinical outcome. Chun
Zhang,1 Ryon Graf,2 Adam Jendrisak,2 Amanda K. Anderson,2 Priscilla On-
tiveros,2 Sarah Orr,2 Anne Chiang,3 David Spigel,4 Charles Rudin,5 Eric Hol-
mgren,1 Jakob Dupont,1 Gretchen Argast,1 Leonardo Faoro,1 Lei Zhou,1 John
Lewicki,1 Ann M. Kapoun1. 1OncoMed Inc., Redwood City, CA; 2Epic Sciences,
San Diego, CA; 3Yale School of Medicine, New Haven, CT; 4Sarah Cannon Re-
search Institute, Nashville, TN; 5Memorial Sloan Kettering Cancer Center, New
York, NY.
Background: The NOTCH pathway has been identifıed as a key therapeutic
pathway in SCLC. Tarextumab (TRXT, anti-Notch2/3, OMP-59R5) is a fully
human monoclonal antibody that targets the Notch2 and Notch3 receptors.
PINNACLE is a Phase 1b/2 trial of TRXT in combination with etoposide and
platinum therapy (EP) in patients with untreated extensive stage small cell lung
cancer (ES-SCLC). Baseline CTCs and post treatment changes in CTCs have
previously been shown to predict the response to chemotherapy in SCLC. CTCs
may also serve as pharmacodynamic biomarkers. Here we describe a study of
baseline and longitudinal CTCs in ES-SCLC patients from the PINNACLE
phase 1b trial (clinicaltrials.gov:NCT01859741). Materials and methods: CTCs,
CTC clusters, apoptotic CTCs and N-Cadherin CTCs were identifıed and
enumerated from patient blood samples using Epic Sciences CTC technology.
Baseline CTCs from 26 patients were correlated with clinical outcome: progres-
sion-free survival (PFS), overall survival (OS) and best overall response, as well
as metastatic status. A mixed effects model was used to investigate the post
treatment changes in CTCs among the dose groups. Association of CTCs with
PFS/OS and best overall response, including CTCs at each time point, as well as
temporal changes of CTC status, were studied. Multivariate analysis was per-
formed to identify CTC numbers in a subset of time points to correlate with
response to treatment. Results: CTCs were present in 81% of the patients (21/
26). CTC clusters and apoptotic CTCs were detected in 38% and 77% of the
patients, respectively. At baseline, CTC counts
 5/mL were signifıcantly asso-
ciated with poor OS (p0.04). There was a trend that the presence of CTC
clusters was associatedwithworseOS.With a cut-off of 3.4/mL, apoptotic CTCs
showed a trend in association with overall survival. CTC numbers in patients
with liver metastasis were signifıcantly higher than in patients without liver
metastasis. CTCs were also found to be correlated signifıcantly with the number
of metastatic sites. When measuring at Day 7 post dosing, CTC numbers were
signifıcantly decreased. Conclusions: Our fındings suggest that CTCs are fre-
quently detectable in patients and are a prognostic factor in ES-SCLC. CTCs
decrease with TRXT and platinum-based chemotherapy. Updated results will be
presented. CTCs will be further evaluated in the phase 2 portion of the PINNA-
CLE trial.
#1728 CTCs and CTM as prognostic factors in sarcoma patients. Alexcia
C. Braun, Celso A. Mello, Marcelo P. Corassa, Vanessa S. Alves, Emne A. Ab-
dallah, Ulisses R. Nicolau, Moˆnica Taiane de Macedo Diaz, Bianca de Ca´ssia
Troncarelli de Campos Parra Flores, Marcelo F. Fanelli, Patrizia Paternili-
Brecho´t, Ludmilla T. Chinen. AC Camargo Cancer Center, São Paulo, Brazil.
Background: Sarcomas represent 1%of all cancers in adults, 8% in adolescents
and young people, and 10% in children. Even though it is a rare cancer, it con-
tributes to a signifıcant loss of years of life in comparison with other types of
cancer (Amankwah, et al., 2013). The presence of isolated Circulating Tumor
Cells (CTCs) orCirculating TumorMicroemboli (CTM) in the blood of patients
with sarcoma may be early markers of tumor invasion, because it is known that
these cells circulate in the blood for months or years before the development of
metastases (Paterlini-Brechot and Benali, 2007; Klain, 2009; Rhim et al., 2012).
Objective: To isolate and quantify CTCs and CTM from sarcoma patients, eval-
uating their presence and correlation with progression free survival (PFS).
Methods: The blood (approximately 8mL) was prospectively collected from pa-
tientswith different types of high degree sarcoma. Bloodwas collected before the
beginning of chemotherapy. The samples were processed and fıltered on ISET
(Isolation by Size of Epithelial Tumor Cells, Rarecells, France) system for the
isolation and quantifıcation of CTCs and CTMs. Later, was performed immu-
nocytochemistry (ICC) with anti-CD45 antibody and counterstained with he-
matoxylin-eosyn for leucocytes population exclusion. The cutoff was estimated
using themaximumof the standardized log-rank statistic proposed by Lausen&
Schumacher (1992). Results: we analyzed 11 high degree sarcoma patients be-
fore the beginning of treatment (any treatment line). The median age was 53
years-old (18-77) and 54,5% were male. The median CTCs number was 2.0
CTCs/mL (1.0-11.0) at baseline. ByKaplan-Meier test, we observed that patients
with CTC number below the established cutoff (4.5 CTCs/mL) had better PFS
compared to those above the cutoff (7.4 vs. 1.0 months respectively; P 0.006).
Moreover, patientswithoutCTMhad also better PFS compared to those patients
with the presence of CTM (7.6 vs. 2.7 months respectively; P 0.13). Conclu-
sion: this is the fırst study to demonstrate, besides theCTC andCTMpresence in
sarcoma patients, its real prognostic value, even in a limited sample. Our next
step is to characterize these cells to better understand its capability to promote
tumor progression.
#1729 Detection of gene expression biomarkers from enrichedCTCprep-
arations.Bruce Seligmann,1MarilynMarron,2Milos Babic,1 Elliot Imler,1 Peter
Shepard,1 Pavani Chalasani,2 Alison Stopeck,3 Joanne Yeakley1. 1BioSpyder
Technologies, Inc., Tucson, AZ; 2University of Arizona, Tucson, AZ; 3Stony Brook
Cancer Center, Stony Brook, NY.
Circulating tumor cells (CTCs) offer an opportunity for non-invasive character-
ization ofmetastatic cancer, including the ability to follow subtype evolution, devel-
opmentof resistance, tissuehomingbiomarkers, andchanges incell signalingmech-
anisms required for metastasis and continued growth and survival of the tumor.
Analysis ofCTCs and translationof aCTCassay into a clinical test has beendiffıcult
due to issues of obtaining high purity, high yield preparations and/or isolating indi-
vidual CTCs. This is further compounded by the heterogeneity of CTCs, hurdles in
profıling theirmolecular signatures, anddiffıcultycorrelatingCTCnumber/subtype
to actionable therapy.Wepursued a detailed analysis of CTCgene expression using
whole transcriptome TempO-Seq targeted sequencing, a highly sensitive, direct ly-
sis, additiononlyassay.As thisassaydoesnot requirepurifıedCTCisolationorRNA
extraction, there is no risk of CTC nor RNA loss.We exploited the single cell sensi-
tivity of TempO-Seq to profıle enriched CTC preparations prepared by RosetteSep
gradient centrifugation, allowing us to characterize the phenotypes of CTCs within
a high background of normal blood cells. To handle this large and potentially over-
whelming backgroundwe developed and exploited a proprietarymethod of sample
normalization that increased the sensitivity and consistency of CTC gene signature
measurements. We demonstrated that the TempO-Seq assay could detect a single
MCF7 (EpCAM) Luminal-like cell in a background of 1,000MDAMB 231 (Ep-
CAM-)Basal-like cells (positive for anEndothelialMesenchymalTransition,EMT),
andviceversa.Next,wepreparedmixturesofdifferentproportionsof these cultured
cells spiked into normal blood, enriched the model “CTCs” using RosetteSep, and
profıled thebulkpreparation.Proportionaldiscriminationof cell-specifıc signatures
were obtained with as few as 40 spike-in cells. Finally, we profıled enriched CTC
preparations from the blood of patients with metastatic breast cancer. The results
demonstrated that the expression of HER2, ER, and EpCAM could bemeasured as
well as biomarkers of drug resistance, bone/brain homing, EMT, and all 50 Hall-
mark cell signaling pathways. TempO-Seq EpCAM gene level correlated with the
percent EpCAM cells measured by flow analysis while EMT signature levels cor-
related inversely. Patients with HER2- primary tumor and HER2CTCs could be
identifıed, as could patientswith elevated chemotherapy resistance pathways. These
data demonstrate that it is possible to profıle CTCphenotypes that are important in
metastases anduseful for selecting therapyusing a bulkCTCpreparation combined
with the sensitivity of the TempO-Seqwhole transcriptome assay. This suggests the
opportunity for the development of a predictive test using currently available puri-
fıcation platforms without need for expensive specialized equipment or separation
into single cells.
#1730 ESR1 methylation in circulating tumor cells, ctDNA and primary
tumors of breast cancer patients. Sophia Mastoraki,1 Areti Strati,1 Eleni Tzan-
ikou,1 Eleni Politaki,2 George Koutsodontis,3 Loukas Kaklamanis,4 Nikolaos
Malamos,1 Amanda Psyrri,3 Vassilis Georgoulias,2 Evi Lianidou1. 1University of
Athens, Athens, Greece; 2University of Crete, Herakleion, Greece; 3Attikon Uni-
versity Hospital, Athens, Greece; 4Onassis Cardiac Surgery Center, Athens,
Greece.
Background: Estrogen receptor (ER) is an important prognostic biomarker in
breast cancer. Epigenetic silencing of ESR1 could be of important clinical signif-
icance especially for its potential impact on endocrine treatment effıcacy. Liquid
biopsy provides real-time monitoring of tumor evolution and response to ther-
apy through analysis of CTCs and ctDNA. Our group has evaluated for the fırst
time epigenetic silencing of tumor andmetastasis suppressor genes in CTCs and
corresponding ctDNA. In this study, we evaluated for the fırst time ESR1 meth-
ylation in CTCs, paired ctDNA and primary tumors of breast cancer patients.
Methods: We developed and validated a highly sensitive and specifıc real-time
MSP assay for ESR1 methylation. We further applied the developed assay in
sodiumbisulfıte (SB) treatedDNA samples from: a) FFPEs from40 patientswith
operable breast cancer, 25 patients with metastasis, 30 mammoplasties and 15
fıbroadenomas, b) EpCAM immunomagnetically isolated CTCs fractions,
from 74 early breast cancer patients, 48 patients with metastasis and 30 healthy
donors, c) CellSearch® cartridges from 36 early breast cancer patients, 22 pa-
tients with metastasis, d) ctDNA isolated from plasma of matched samples and
54 healthy donors as a control group. Results: By using this highly specifıc and
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sensitive assay (sensitivity 0.1%) we detected methylation of ESR1 in: a) FFPEs:
16/40(40%) early breast cancer patients, 9/25(36%) patients with verifıedmetas-
tasis, 7/30(23.3%) mammoplasties and 5/15(33.3%) fıbroadenomas. A statisti-
cally signifıcant negative correlation was observed between ESR1 methylation
status and ER protein expression (56/65 samples, 86%, p0.001). b) In Ep-
CAM CTCs fraction samples: ESR1 was found methylated in 16/74(21.6%)
operable breast cancer patients, 10/48(20.8%) patients with metastasis, but only
in 1/30(3.3%) healthy donors. c) CTC CellSearch® cartridges: 3/13(23.1%) in
early breast cancer and 2/7(28.6%) in patients with metastasis. d) In ctDNA:
ESR1 methylation was observed in 3/36(8.3%) early breast cancer patients,
3/22(13.6%) patients with metastasis and 2/54(3.7%) samples in the control
group. ESR1 methylation status was highly correlated when paired DNA from
CellSearch® cartridges and corresponding ctDNA samples were compared;
36/36 (100%, p0.001) in early breast cancer and 21/22 (95.5%, p0.001) in
metastasis. Conclusions: ER expression and ESR1methylationwere found 100%
inversely correlated in primary tissues. The EpCAM CTC fraction of patients
with breast cancer was found methylated for ESR1. Interestingly, ESR1 methyl-
ation was detected exclusively in CTC samples as analyzed from CellSearch®
cartridges but in none of CTC- samples. In paired plasma samples, ESR1 meth-
ylation showed a high concordance (p0.001) with ESR1methylation in CTCs.
Additional studies are needed to further evaluate the clinical signifıcance of our
fındings.
#1731 Analysis of prostate cancer circulating tumor cells at the mRNA
andprotein level using amicrofluidic graphene oxide chip.MollyKozminsky,
Kathleen C. Day, Guadalupe Lorenzatti Hiles, Shamileh Fouladdel, Ebrahim
Azizi, Mark L. Day, Todd Morgan, Sunitha Nagrath. Univ. of Michigan, Ann
Arbor, MI.
While the relative fıve-year survival rate for men with localized prostate
cancer is nearly 100%, it plummets to 28% in the case of distant metastases.
This underscores the importance of investigating those cells able to spread
and form these metastases: circulating tumor cells (CTCs). Though rare and
surrounded by other blood cells, CTCs can be isolated using the sensitive
nanomaterial-based microfluidic technology the graphene oxide (GO) Chip.
Whole blood samples from 54 prostate cancer patients were obtained with
consent and processed on parallel chips for immunofluorescence and RNA
analysis. All of the samples were analyzed for CTC enumeration, where
captured cells were stained for cytokeratin 7/8 (CK), CD45, and DAPI. CTCs
were identifıed as DAPI/CK/CD45- cells. CTCs were detected in all of
the samples. Interestingly, 25 samples showed CTC clusters ranging from
2-10 CTCs per cluster. To explore the potential role of EGFR in metastatic
progression and CTC survival, a subset of samples was also assayed for EGFR
expression with 9/10 samples showing EGFR CTCs. RNA extracted from a
parallel device was reverse transcribed to cDNA. The cDNAwas analyzed via
qPCR for expression levels of 96 genes of interest, including housekeeping
genes; epithelial and mesenchymal genes; oncogenes and tumor suppressor
genes; prostate specifıc genes; extracellular matrix and inflammatory genes;
and others. The results show our ability to examine RNA from CTCs to
examine the role of relevant pathways in the cells in transit. With analysis
capabilities at both the RNA and protein levels, the GOChip is an example of
a clinically relevant microfluidic technology.
#1732 Accuracy of extrapolation of circulating tumor cell count from
small blood volumes: statistical estimation using the AccuCyte - CyteFinder
system. Jeffrey L.Werbin,1 PaulinaVarshavskaya,1ArturoB. Ramirez,1 Jackie L.
Stilwell,1Daniel E. Sabath,2 Ping-YuLiu,3 EricKaldjian1. 1RareCyte, Inc., Seattle,
WA; 2University ofWashington, Seattle, WA; 3Fred Hutch Cancer Research Cen-
ter, Seattle, WA.
Background: Baseline and post-treatment counts of circulating tumor
cells (CTCs) are prognostic of patient outcome in cancer. The FDA-cleared
CellSearch® system has defıned CTC count as the number of cells per 7.5 mL
of blood, with poor prognosis being 5 or more for breast and prostate can-
cers, and 3 or more for colon cancer. There are little reported data on
whether it is reasonable to extrapolate CTC counts from smaller blood vol-
umes, particularly when CTC count is low, given sampling variability. The
AccuCyte - CyteFinder system (RareCyte) collects 7.5 mL of blood for anal-
ysis, isolates the buffy coat and smears it onto 8 slides, which are then stained
with markers for CTCs that are identifıed by fluorescence microscopy. We
investigated the statistical accuracy of extrapolation of total CTC count from
fewer than 8 slides. Methods: 172 blood samples from various cancers were
processed to microscope slides, stained, and analyzed by CyteFinder. Counts
were made on a per slide basis, with total “true” CTC count being the sum of
all 8 slides. Samples with no CTCs were excluded. To extrapolate the total
CTC count from k slides, all possible combination of k slides were used to
estimate the total count of 8 slides. This was done for k  1-7 for all 172
samples and extrapolated counts were rounded to the nearest integer. The
proportion of times that extrapolated counts fell within a specifıed percent-
age of the true CTC count was calculated across the entire sample set, as well
as for 6 sub-categories defıned by true CTC count range. Results: The 6 CTC
count categories were: 1-4 (N39), 5-10 (N21), 11-25 (N21), 26-50
(N14), 51-100 (N24), more than 100 (N53). Cumulative proportions
within 5, 10, 25 and 50% of the true total CTC count were determined for the
entire sample set as well as by category. In the entire sample set, the propor-
tion of extrapolated counts that fell within 25% of the true count ranged from
0.448 (1 slide) to 0.723 (4 slides) to 0.951 (7 slides). Generally, the lower the
true total count, the lower the fraction of extrapolated counts that fell within
the specifıed percentage of the true count. For example, for true count 5-10,
the fraction that fell within 25% of the true count ranged from 0.208 (1 slide)
to 0.513 (4 slides) to 0.951 (7 slides). In contrast, for true count more than
100, the fraction that fell within 25% of the true count ranged from 0.751 (1
slide) to 0.968 (4 slides) to 1.000 (7 slides). Conclusions: In this sample set,
nearly three quarters of cases could be estimated within 25% of the true CTC
count by extrapolating from 4 AccuCyte slides. Estimating each slide to
represent 1 mL of processed whole blood, our analysis suggests that a 4
mL sample will have this level of accuracy relative to a CTC count from 7.5
mL. At low true CTC counts the accuracy of extrapolation decreases, indi-
cating that a larger volume of blood is required for this level of accuracy.
#1733 Automated identifıcation of circulating tumor cells by image anal-
ysis. Leonie L. Zeune,1 Guus vanDalum,2 François-Clément Bidard,3 Jean-Yves
Pierga,3 Tanja Fehm,2 Hans Neubauer,2 Brigitte Rack,4 Marianna Alunni-Fab-
broni,4 Mateus Crespo,5 Johann de Bono,5 Leon W.M.M. Terstappen,1 Chris-
toph Brune1. 1University of Twente, Enschede, Netherlands; 2Heinrich-Heine-
University of Duesseldorf, Duesseldorf, Germany; 3Institut Curie, Paris, France;
4Ludwig-Maximilians-University of Munich, Munich, Germany; 5The Royal
Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton,
United Kingdom.
In the fıeld of Circulating TumorCell (CTC) researchmany new technologies
are emerging to isolate CTCs. Some of them provide accompanying automated
image analysis tools that present possible CTCs to the user. Others need fully
manual image analysis. For all CTC isolation technologies the defınition of a
CTC based on the immuno-morphologic criteria is either customized to the
specifıc platform or subjective to the user causing high interreader differences –
a problem which may condemn many CTC-based clinical studies to failure.
Thus, an important issue that the fıeld is confronted with is the lack of a unifıed
and standardized defınition to classify a cellular object as a CTC. This problem is
addressed within the European FP7 consortium CTCTrap and the Innovative
Medicines Initiative (IMI) consortium CANCER-ID by the development of an
open-source image analysis toolbox for CTC identifıcation and enumeration.
This toolbox is baptized ACCEPT (Automated CTC Classifıcation, Enumera-
tion and Phenotyping) and can process images generated by various CTC isola-
tion technologies. Themain software components are theMarker Characteriza-
tion, the Full Detection and the Automatic Classifıcation. The Marker
Characterization tool aims at quantifying the antigens expressed by previously
selected CTCs. The Full Detection tool is based on advanced mathematical
methods to reliably detect all objects in the images, visualize the objects in scatter
plots and enable the user to classify the cell types by the use of gates or selection
of specifıc objects in the scatter plots or on the actual images. The Automatic
Classifıcation tool fırst detects all objects in the images followed by an automated
classifıcation approach that – as a result – presents found CTCs to the user. We
demonstrate the effectiveness of these tools on two different datasets. The
Marker Characterization tool was tested for Her2 expression on archived CTC
images isolated and classifıed by the CellSearch system from patients with met-
astatic breast cancer. Investigators from three different institutes were asked to
score these cells for Her2 positivity fırst on the images generated by the Cell-
Tracks Analyzer and afterwards using ACCEPT. We show that the improved
CTC visualization provided in ACCEPT, combined with several measurements
which we extract for each cell, can reduce the inter-user variability. The Full
Detection and Automatic Classifıcation tools of ACCEPT were tested on ar-
chived samples of patients with castration resistant prostate cancer processed
with the CellSearch system as well as on microsieves obtained after fıltration of
the blood discarded by theCellSearch system. Results were comparedwithman-
ually scored CTCs and showed the improvement of CTC classifıcation by the
availability of quantitative image analysis tools. TheOpen Source ACCEPT pro-
gram will be available on the MCBP website (http://www.tnw.utwente.nl/
mcbp).
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#1734 Absolute quantifıcation of circulating tumor cell RNAenables high
specifıcity detectionof hepatocellular carcinoma.MarkKalinich,1 IrunBhan,1
Tanya T. Kwan,1 David T. Miyamoto,1 Sarah Javaid,2 Joseph A. LiCausi,1 John
D. Milner,1 Xin Hong,1 Lipika Goyal,1 Srinjoy Sil,3 Melissa Choz,4 Ravi Kapur,5
Alona Muzikansky,1 Huidan Zhang,6 David A.Weitz,6 Lecia V. Sequist,1 David
P. Ryan,1 Raymond Chung,7 Andrew X. Zhu,1 Kurt J. Isselbacher,1 David T.
Ting,1 Mehmet Toner,5 Shyamala Maheswaran,1 Daniel A. Haber1. 1Massachu-
setts General Hospital Cancer Center, Charlestown, MA; 2Merck Research Labo-
ratories, Boston, MA; 3New York University School of Medicine, New York City,
NY; 4Boston College, Chestnut Hill, MA; 5Center for Bioengineering in Medicine,
Charlestown, MA; 6Harvard University, Cambridge, MA; 7Massachusetts Gen-
eral Hospital, Boston, MA.
Background: Although liver cancer has the second-highest mortality rate
among cancers internationally, accurate and scalable assays for the early
detection and longitudinal monitoring of hepatocellular carcinoma are lack-
ing. Circulating tumor cells are released from invasive cancers into the blood
stream, but the diffıculty inherent in isolating, identifying, and characteriz-
ing these ultra-rare cells has precluded their widespread implementation as a
biomarker. By combining a high-throughput microfluidic negative deple-
tion CTC isolation strategy with the absolute quantifıcation of lineage-spe-
cifıc RNAs, we report the highly specifıc detection of hepatocellular carci-
noma CTCs from patient blood draws. Methods: Blood draws from 48
hepatocellular carcinoma patients, 31 chronic liver disease patients, 25
healthy donors, and 44 patients with primary cancers other than hepatocel-
lular carcinoma were processed through the microfluidic device (CTC-
iChip). RNA was extracted, whole-transcriptome amplifıed, and quantifıed
using droplet digital PCR. Transcript counts were used to fıt a logistic re-
gression model to integrate distinct transcript levels into a single CTC-score.
The technical feasibility of utilizing RNA sequencing for identifıcation of
novel CTC transcripts of interest was also demonstrated with a liver cancer
cell line spike-in study. Results: 9 of the 16 untreated HCC patients were
successfully detected, while only 1/31 chronic liver disease patients were
incorrectly classifıed. HCC patients undergoing treatment showed a signif-
icant decrease in their CTC-score; only 9/32 patients actively receiving treat-
ment were positive. The CTC-score was not correlated with the HCC serum
biomarker alpha-fetoprotein, and combining these two orthogonal measures
led to estimated positive and negative predictive values of 80% and 86%,
respectively, in a high-risk cohort. RNAseq analysis of cell line spike-in data
revealed the potential of RNA sequencing for uncovering novel transcripts of
interest. Conclusion: Coupling microfluidic depletion with droplet digital
PCR allows for the highly specifıc detection of hepatocellular carcinoma. The
CTC-score generated from these data tracks with clinical intervention and is
orthogonal to the existing biomarker AFP; combining these two assays has
the potential to provide superior detection compared to either individual
approach.
#1735 Assessing circulating tumor cellswith ananotechnology-based cap-
ture system as a novel biomarker for treatment response and surveillance in
patients with oligometastatic solid tumors. Joseph M. Caster,1 Kyle Wang,2
Bhisham Chera,1 Sin-Jun Park,3 Seungpyo Hong,3 Andrew Z. Wang1. 1Univ.of
North Carolina, Durham, NC; 2Univ.of North Carolina, Chapel Hill, NC; 3Uni-
versity of Illinois at Chicago, Chicago, IL.
Purpose: To prospectively evaluate changes in circulating tumor cells
(CTCs) following defınitive treatment in patients with oligometastatic solid
tumors using a novel nanotechnology-based biomimetric platform. Experi-
ment Procedures: Patients with biopsy proven oligometastatic disease with
up to three lesions were eligible if all sites of disease were treated with defın-
itive therapy. Defınitive therapy could include fractionated 3D conformal
radiation, SBRT, IORT, surgical metastatectomy, and ablative procedures
including microwave ablation. Patients initially presenting with oligometa-
static disease were eligible if they had less than 3 lesions including the pri-
mary tumor. At least one lesion had to be treated with radiation. CTCs were
enumerated from whole blood using the Onco-Sense CTC capture system
which utilizes E-selectin and dendrimers functionalized with three cancer-
specifıc antibodies (aEpCAM, aHER-2, aEGFR). Whole blood was collected
from patients prior to starting treatment (baseline), mid-treatment, end of
treatment, within 12 weeks of fınishing treatment, and then every 3 months
in follow up. We then assessed changes in CTCs with treatment and looked
for associations between baseline CTCs, changes during treatment, and post-
treatment changes with clinical outcomes. Results: We have currently en-
rolled 24 patients. The majority of patients (20) had a single site of disease
treated with radiosurgery. Sites of metastasis include bone, lung, and lymph
nodes. Primary histologies include lung, breast, melanoma, prostate, RCC,
colorectal cancer, and SCC of the head and neck. CTCs were detected in
100% of patients at baseline and decreased with treatment from a mean of 45
CTCs/mL pretreatment (range 3-99) to 14 CTCs/mL post-treatment (range
3-59). Post-treatment CTCs are available for 14 patients with a median fol-
low up of 10.3 months. Ten of 14 patients remain clinically NED and post-
treatment CTCs are lower than baseline in 13/14 of these patients. There
have been 4 clinical failures and CTCs increased with or before radiographic
progression in all 4 patients. Three of the failures occurred at least 3 months
after initial complete responses to treatment and CTCs increased by a me-
dian 3.4-fold over post-treatment levels in these patients. One patient pro-
gressed before the fırst post-treatment follow up and CTCs increased from 7
to 22 CTCs/mL from baseline to post-treatment. Conclusions: We showed
here that we could enumerate CTCs in 100% of patients with oligometastatic
disease using a novel CTC capture system. CTCs decreased with treatment
and all clinical failures were preceded by signifıcant rises in CTCs. Our
preliminary data suggest that enumeration of CTCs by Onco-Sense may
provide a novel biomarker for assessing treatment response and/or post-
treatment surveillance for patients with oligometastatic solid tumors.
#1736 A novel RNA-based assay for the detection and monitoring of cir-
culating tumor cell signatures in breast cancer. Tanya T. Kwan,1 Aditya Bar-
dia,2 Tilak Sundaresan,1 Laura Spring,1 Mark Kalinich,1 David Miyamoto,1 Xin
Hong,1 Joseph LiCausi,1 Uyen Ho,1 Sarah Javaid,1 Erin Silva,1 Lecia Sequist,2
Shyamala Maheswaran,1 Daniel Haber1. 1Massachusetts General Hospital,
Charlestown, MA; 2Massachusetts General Hospital, Boston, MA.
Examination of circulating tumor cells (CTCs) holds the potential of of-
fering a real-time non-invasive window into tumor biology. Information
gleaned from CTC detection and characterization can be used for early can-
cer detection, choice of therapy decisions and long-term monitoring for
disease recurrence and the emergence of drug resistance mechanisms. How-
ever, technical diffıculties with CTC isolation and the inherent limitations of
imaging-based analysis have hindered the broad clinical use of CTCs as
biomarkers. To overcome these concerns, we have combined our unbiased
microfluidic CTC enrichment technology, the iChip, with a highly sensitive
and specifıc multi-gene RNA-based biomarker panel to develop an assay that
detects CTC signatures in patient blood samples in a high throughput and
quantitative fashion. This assay was applied to a cohort of breast cancer
patients, including women with both localized and metastatic disease. It
successfully identifıed CTC signal in 50-70% of metastatic and 20-40% of
localized pretreatment patient samples. Patient CTC scores, assigned based
on a multi-marker prediction algorithm, correlated with cancer stage and
grade, but not with hormone receptor status, suggesting the applicability of
the assay to a wide range of breast cancer subtypes. To determine if CTC
scoring was useful for disease monitoring, we performed monthly blood
collection from metastatic patients starting a new line of treatment. CTC
score as early as one month after initiation of therapy, but not at pretreat-
ment, was predictive of progression-free survival and treatment outcome,
suggesting that real-time kinetic changes in CTC signatures are more clini-
cally informative that one-time static evaluation of their presence in a given
sample. In addition, a subset of high-risk genes showed expression patterns
over the course of treatment that highly correlated with disease recurrence.
This observation indicates that a multi-marker panel can parse out dynamic
changes in cancer gene expression programs and provide a molecular insight
into treatment responses that are not achievable by assays built around one
or few markers. In conclusion, our novel RNA-based method of identifying
CTC signatures in liquid biopsies provides a sensitive platform for breast
cancer detection and monitoring that goes beyond CTC enumeration. It
offers a non-invasive quantitative molecular characterization of tumor gene
expression that can be used to guide informed clinical decisions in both
standard course of care and clinical trial settings.
#1737 ALK rearrangement analysis in circulating tumor cells of lung can-
cer patients. Min Kyung Jeon,1 Young Hun Kim,1 Eunjoo Hwang,1 Hye Seon
Lee,1 Ji-hyun Uh,1 Myoung Shin Kim,1 JooKyung Park,2 Byung Hee Jeon,1 Se-
Hoon Lee2. 1Cytogen Inc., Seoul, Republic of Korea; 2Samsung Medical Center,
Seoul, Republic of Korea.
The evaluation of ALK rearrangement in non-small-cell lung cancer
(NSCLC) is a signifıcant tool when considering chemotherapy. It is not al-
ways possible to perform a tumor biopsy in patients. We suggest isolation
and culturing of circulating tumor cells (CTCs) as an alternative tool to a
tumor biopsy for the diagnosis of ALK rearrangement. From 22 patients with
NSCLC harboring ALK rearrangement, blood samples were collected and
divided into two parts: one for immunofluorescence staining of CTCmarker
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and the other for culturing of CTCs. Both samples were processed by size-
based fıltration, and Cultured CTCs were analyzed for EML4-ALK translo-
cation by fluorescence in situ hybridization (FISH) using Vysis ALK break
apart FISH probe kit. CTC culturing was successful in 18 of 22 cases (81.8%).
Among 18 cases of successful CTC cultures, 13 cases showed ALK rearrange-
ment positivity (72.2%). Therefore, we suggest that the CTCs can be used as
an alternative method to tissue biopsy for diagnosing ALK rearrangement.
In addition, this method may have clinical applications including serial
blood sampling for the development of personalized cancer therapy based on
individual genomic information.
#1738 Platelet activation andheterotypic platelet leukocyte conjugate for-
mation in the blood of glioblastoma patients. Sascha Marx, Maximilian
Splittstöhser, Heiko Paland, Carolin Seifert, Madlen Juettner, Andreas Boehm,
Christoph A. Ritter, Sandra Bien-Moeller, Henry W. Schroeder, Bernhard
Rauch. University Medicine Greifswald, Greifswald, Germany.
Objective: Glioblastoma patients (GBM) suffer from an increased incidence
of cardiovascular events. Platelets are well known as main player of the primary
hemostasis, but have a broad range of additional functions. The formation of
heterotypic conjugates between platelets and leukocytes (PLC) represents a pro-
inflammatory surrogatemarker and is usually increased after platelet activation.
The aim of the present studywas to evaluate the platelet activation status and the
rate of circulating PLC inGBM.Methods: Blood samples were drawn of consec-
utive patients before surgery for a suspected glioblastoma. The formation of PLC
and several parameters of platelet activation were determined by flow cytometry
before and after stimulation with either ADP or the thrombin receptor-activat-
ing peptide (TRAP) in vitro: expression of P-Selectin, CD63, CD40L and fıbrin-
ogen-binding to the activated GPIIb/ IIIa. Blood samples from age and gender
matched healthy volunteers were used as controls. Statistical analysis was done
with the Mann-Whitney-Test. Results: Final analysis included 22 patients with
histopathological proven virgin glioblastoma (9f, 13m, mean age 67.5 years,
range from 55 to 86 years) and their respective controls. Basal platelet activation
and in vitro platelet reactivity was increased in GBM. The difference got signif-
icant in the basal expression of CD63 (2.8% versus 1.9%, p0.008), the Fibrin-
ogen-binding after ADP-stimulation (110.3 MFI versus 63.1 MFI, p0.04) and
the CD63 expression after TRAP-stimulation (38.4% versus 33.3%, p0.04).
Furthermore, a reduced number of circulating PLC and in vitro PLC formation
was seen in GBM without getting statistically signifıcant. Conclusions: In this
preliminary report, we show for the fırst time an increased level of platelet acti-
vation and agonist-induced platelet reactivity inGBM.Both could be a reflection
of the pro-thrombotic status in these patients. Interestingly, the formation of
PLC was not increased, but in tendency decreased. Whether this observation
potentially mirrors the intratumoral, anti-inflammatory microenviroment in
GBM remains unclear.
#1739 Analysis of EML4-ALK fusion transcripts in plasma andplatelets to
monitor response to crizotinib in EML4-ALK positive non-small cell lung
cancer patients (NSCLC). Cristina Aguado,1 Cristina Teixido,1 Ana Gimenez-
Capitan,1 Maria de los Llanos Gil,2 Sonia Rodriguez,1 Santiago Viteri,2 Niki
Karachaliou,3 Erika Aldeguer,1 Vicente Peg,1 Lidia Alonso,1 Miguel Angel Mo-
lina-Vila,1 Rafael Rosell2. 1Pangaea Oncology, Barcelona, Spain; 2Dr. Rosell On-
cology Institute, Barcelona, Spain; 3Hospital Sagrat Cor, Barcelona, Spain.
Background: Rearrangements in anaplastic lymphoma kinase (ALK) gene
can be detected in 5-7% of EGFR and KRAS wild-type advanced NSCLC
patients (p). Fluorescent in situ hybridization (FISH) and immunohisto-
chemistry (IHC) are currently used for screening but are unable to identify
the specifıc fusion partner and are unpractical to monitor clinical responses
due to diffıculty of obtaining rebiopsies. The RT-PCR technique has the
potential to overcome this pitfall and allow patient monitorization in blood.
Methods: A total of 405 formalin-fıxed paraffın-embedded (FFPE) samples
from advanced NSCLC were analyzed by ALK IHC (Ventana D5F3) and
FISH (Vysis). Positive patients were confırmed by RT-PCR and submitted to
Sanger in order to identify the variant. In a subset of 36 patients with EML4-
ALK-rearranged tumors who were treated with crizotinib, fusion transcripts
were analyzed by RT-PCR in mRNA purifıed from plasma and platelets and
correlated with clinical response. Results: ALK IHC was analyzed in 405
NSCLC patients and 37 tested positive (9.1%) whereas 25 (7.7%) were iden-
tify as translocated by FISH (n323). ALK fusion transcripts were analyzed
by RT-PCR and a new fusion variant of ALK was identifıed. A total of 36 p
benefıted from crizotinib treatment, including the p with the new variant.
Monitoring of EML4-ALK fusion transcripts in the plasma ad platelets of 35
ALK positive patients revealed a good correlation with clinical outcome to
crizotinib treatment, with the fusion transcripts becoming undetectable in p
with good clinical responses. Conclusions: Analysis of ALK fusion tran-
scripts in mRNA purifıed from plasma and platelets can have a value in
patients with no biopsy available and to monitor the course of the disease.
#1740 Phenotypic, genomic, and clinical associations of Circulating Tu-
mor Cells (CTCs) lacking epithelial biomarkers in metastatic Castration Re-
sistant Prostate Cancer (mCRPC). Ryon P. Graf,1 Yipeng Wang,1 Nicole
Schreiber,2 Brigit McLaughlin,2 Stephanie Greene,1 Angel Rodriguez,1 Adam
Jendrisak,1 Jerry Lee,1Mark Landers,1 RyanDittamore,1Howard I. Scher2. 1Epic
Sciences, Inc., San Diego, CA; 2Memorial Sloan Kettering Cancer Center, New
York, NY.
Background: Epithelial Plasticity (EP) is a proposed mechanism of im-
mune escape, resistance to programmed cell death, resistance to specifıc
drugs, and promotion of metastasis. EP has been extensively explored in
mathematical, cell biological, and animal models, which predict the presence
of these tumor cells in circulation. Most studies on CTCs in human subjects
are based on enrichment of cells expressing EpCAM prior to enumeration or
molecular interrogation, which precludes analysis of cells that might be EP.
The non-enrichment Epic Sciences platform was utilized to identify CTCs in
metastatic castration-resistant prostate cancer patient samples phenotypi-
cally consistent with EP: CTCs that do not express cytokeratins (CK), but do
express malignant or EP biomarkers: Androgen Receptor (AR), AR splice
variant 7 isoform (AR-V7) or N-cadherin. Phenotypic and genotypic analy-
ses of individual CTCs were performed to assess the malignant origin of CK-
CTCs and their prevalence associated with overall patient survival. Methods:
221 pre-therapy mCRPC blood samples were collected at Memorial Sloan-
Kettering Cancer Center and shipped to Epic Sciences. Patients represent a
diverse number of previous therapies and tumor burdens. All nucleated cells
were plated to glass slides and subjected to DAPI and immunofluorescent
(IF) staining of cytokeratin (CK), CD45 and another tumor marker (AR,
AR-V7, or N-cadherin), followed by CTC identifıcation by fluorescent scan-
ners and malignant morphology. All samples were stained for AR, with a
subset of samples stained for AR-V7 or N-Cadherin as well. Additionally, 83
AR()/CK() and 9 AR-V7()/CK() CTCs were analyzed for copy num-
ber variation (CNV) by low pass whole genome single CTC sequencing.
Abnormal genomes were identifıed by amplifıcations and deletions of known
oncogenes and tumor suppressors. Results: 3931 AR() CTCs were de-
tected, of which 2996 (76%) expressed CK and 935 (24%) did not. The
AR()/CK() CTCs had a lower median AR signal, less nucleoli, and more
nuclear speckles by digital pathology vs. CK() CTCs. AR()/CK() and
AR-V7()/CK() CTCs had gross genomic alterations consistent with ma-
lignant prostate origin (AR gain, PTEN loss, RB1 loss, 8q gain, 8p loss, etc),
often sharing the same genomic alterations with CK() CTCs in the same
patients, with some having unique CNV profıles Presence of AR()/CK()
CTCs was associated with worse overall survival (median 13.7 mo vs. 33.9
mo, p 0.0001) and remained additive and independent to treatment Line,
pre-therapy PSA, and therapy type in multivariate models. Conclusions:
Similar to CTCs expressing epithelial markers, CK() CTCs have gross
genomic aberrations consistent with metastatic prostate cancer and are a
negative prognostic factor associated with worse overall survival in both
iterative threshold and multivariable analyses.
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#1741 Whole-transcriptome characterisation of NRAS and BRAF mu-
tated primary melanomas associated with immune cell infıltration signa-
tures and differential survival benefıt. Joanna Pozniak, Jérémie Nsengimana,
Sathya Muralidhar, Jonathan Laye, D Timothy Bishop, Julia Newton-Bishop.
University of Leeds, Leeds, United Kingdom.
In 703 primary melanoma transcriptomes derived from formalin-fıxed tu-
mors removed from participants in the Leeds Melanoma Cohort, we used in
silico methodology described by Bindea et al.1 to develop immune cell signa-
tures. We showed these to be associated with survival2. There is some reported
evidence that patients with NRAS mutated melanoma have a better response to
checkpoint therapies3. Our aim was, therefore, to use the transcriptomic data to
ask if immune cell infıltration (evidenced by the presence of the immune cell
signature) differed between mutation subgroups. We saw that the survival ben-
efıt of the immune cell signature was strongest in wild-type (HR0.31,
P3x105), intermediate in BRAF mutated tumors (HR0.56, P0.008) but
absent in NRAS mutated tumors (HR1.09, P0.79). That is that even if the
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NRAS mutated tumors had a strong T cell signature that signature did not
correlatewith better survival. The results remained signifıcant after adjusting for
sex, tumor site, age at diagnosis, and AJCC stage. We observed no evidence of
increased numbers of regulatoryT cells (FOXP3), inNRASmutated tumors, nor
PDL1orPD1 expression. The only difference in checkpointmolecule expression
studied was a borderline lower expression of CTLA4 in the NRAS mutated
tumors (P0.09).Our data suggest that evenwhenT cells invadeNRASmutated
tumors some functional defıciency may be present in those tumors such that a
survival benefıt is not seen. Using genes signifıcantly differentially expressed
between NRAS and BRAFmutated tumor groups, we tested biological pathway
enrichment using Reactome FIViz plugin in Cytoscape. The most enriched
pathways in NRAS mutated melanomas were the PI3K (AKT3, NRAS) and
mitochondrial translation (CHCHD1, PTCD3). In the BRAF mutated the most
enriched were: direct P53 effectors (TGFA, IGFBP3), -catenin independent
WNT signaling (WNT5A) and MHC class I antigen processing (CYBA). A
number of pathways related to cell adhesion involving GRIN1 were also identi-
fıed. Others have reported that -catenin signaling inhibits transcription of the
chemokine CCL4 which reduces the traffıcking of CD141DC to melanomas
and therefore T cell infıltration4. We have evidence from the -catenin candi-
date transcriptomic analysis that primary melanomas without immune infıltra-
tion signatures have upregulated -catenin but the comparison between tran-
scriptomic patterns in NRAS and BRAF tumors did not suggest that -catenin
signaling was more active in NRAS mutated tumors. It may be that a different
immunosuppressive mechanism is more common in NRAS mutated tumors
than in others. References 1. Bindea et al. Immunity 39, 782-795 (2013) 2. New-
ton-Bishop et al. PCMR in press 3. Johnson et al. Cancer Immunol Res. 3,
288-295 (2015) 4. Spranger et al. Nature 523, 231-235 (2015).
#1742 Cancer cell-selective transcriptome analysis reveals new colorectal
cancermolecular subtypes with improved biological resolution and superior
predictive and prognostic performance. Claudio Isella,1 Sara E. Bellomo,1
Francesco Brundu,2 Francesco Galimi,3 Elisa Ficarra,2 Luigi Marchionni,4 Livio
Trusolino,1 Andrea Bertotti,1 Enzo Medico1. 1University of Torino, Candiolo
Cancer Institute, Candiolo, Italy; 2Politecnico di Torino, Torino, Italy; 3Candiolo
Cancer Institute, Candiolo, Italy; 4Sidney Kimmel Comprehensive Cancer Center,
Johns Hopkins University School of Medicine, Baltimore, MD.
Molecular classifıcation of colorectal cancer (CRC) based on gene expression
profıling of tumor samples is known to be heavily affected by transcripts of
stromal origin. As a consequence, current CRC transcriptional subtypes reflect
an admixture of cancer cell-intrinsic traits and tumor microenvironment fea-
tures.Whether selective analysis of the cancer cell transcriptome could improve
CRC subtyping, remains an open issue. In patient-derived xenografts (PDXs),
human transcripts only originate from cancer cells, because stromal transcripts
are of mouse origin. We therefore assessed cancer-cell intrinsic transcriptional
features of CRC by generating human-specifıc expression profıles of 515 PDXs
from 244 CRC patients, and performing unsupervised class discovery.We iden-
tifıed fıve “CRC intrinsic subtypes” (CRIS A-E) only partially overlapping with
the current ones, and robustly enriched for distinct molecular, functional and
phenotypic traits: (i) CRIS-A: mucinous, glycolytic, CIMP, and enriched for
microsatellite instability or mutations in KRAS; (ii) CRIS-B: marked TGF-
pathway activity, epithelial-mesenchymal transition and poor prognosis; (iii)
CRIS-C: MSS, elevated EGFR signaling and sensitivity to EGFR-targeted treat-
ments; (iv) CRIS-D: MSS, WNT activation, and IGF2 overexpression and am-
plifıcation; (v) CRIS-E:MSS, Paneth cell-like phenotype and higher frequency of
TP53mutation. CRIS subtypes successfully categorized independent sets of pri-
mary andmetastatic CRCs and cell lines, for a total of over 3000 samples profıled
by microarrays and RNAseq. The new subtypes displayed unprecedented pre-
dictive and prognostic performances, indipendent from knownmarkers includ-
ing stromal signatures, whose integration with CRIS further enhanced prognos-
tic signifıcance.
#1743 Comprehensive genomic characterization of a large cohort of plat-
inum-sensitive, high-grade serous ovarian cancer (HGSOC) FFPE speci-
mens. Brian C. Haynes,1 Marie E. Fahey,1 Darcy Myers,1 Diane Ilsley,1 Gary J.
Latham,1 Elizabeth B. Somers,2 Nicholas C. Nicolaides,2 Charles Schweizer,2
Daniel J. O’Shannessy2. 1Asuragen, Inc., Austin, TX; 2Morphotek, Inc., Exton,
PA.
Introduction: Ovarian cancer is a leading cause of cancer related death in
women. A comprehensive genomic characterization of platinum-sensitive tu-
mors is required to further refıne the defınition of molecular subtypes and iden-
tify targeted therapies for this patient population. To this endwehave performed
a large-scale genomic and transcriptomic characterization of 348 primary FFPE
tissues from a cohort of platinum-sensitive HGSOC patients collected from
multiple clinical sites. Methods: Macrodissection of FFPE resected tumor slides
or sectioned blocks was performed to enrich for tumor content. RNA and DNA
were each isolated from 2x 5m sections of FFPEmaterial. RNA expression and
gene fusions were profıled by whole transcriptome RNA-Seq. DNA variants
were analyzed by the AmpliSeqTM Cancer Hotspot Panel (Thermo Fisher). A
subset of tumor andmatched germline (PBL) specimens (N181) were assessed
for TP53mutations by theQuantideX®NGSTP53Assay (Asuragen, Inc.). CNV
analysis of FFPE tumor DNA was performed using the OncoScan® FFPE Assay
Kit (Affymetrix) and microsatellite instability was characterized by comparing
matched tumor and PBL specimens with capillary electrophoresis using the
Bethesda panel. Germline BRCA1/2 mutation status was determined by profıl-
ing PBL specimens with a custom AmpliSeqTM NGS panel. Results: The spec-
trum of DNA mutations and CNVs was consistent with other HGSOC cohorts
withmutations inTP53present in themajority of specimens (87% for specimens
with full exon coverage of TP53). Germline mutations in BRCA1 and BRCA2
were identifıed at 10.3% and 6.8% respectively. Analysis of recurrent whole
chromosomal arm gain and loss displayed a striking agreement with the TCGA
HGSOCcohort. Unsupervised analysis of the RNA-Seq expression data through
non-negative matrix factorization revealed 4 distinct transcriptional subtypes,
corresponding to the 4 established CLOVAR subtypes: differentiated, immuno-
reactive,mesenchymal and proliferative. Patients classifıed asmesenchymal had
the poorest prognosis. Further integrative analysis identifıed additional associ-
ations between the CLOVAR subtypes and other molecular indications. Con-
clusions: Through integrative genomic analyses on this challenging set of clini-
cal specimens we have reproduced and refıned the molecular subtypes of
platinum-sensitive HGSOC and highlighted alterations that may lead to im-
proved diagnostic and precision medicine strategies. In contrast to previous
large-scale molecular characterization efforts such as TCGAwhere fresh-frozen
tissues were collected under highly controlled settings, this study is based on
molecular profıling of FFPE tissues collected at dozens of clinical sites. Thus, our
study serves as a model for future molecular characterization efforts of FFPE
specimens collected in real-world clinical settings.
#1744 RNAseq identifıed immune signatures associatedwith adverse out-
come in high-risk neuroblastoma. Jun S. Wei,1 Shile Zhang,1 Igor Kuznetsov,2
Young K. Song,1 Shahab Asgharzadeh,3 Sivasish Sindiri,1 Xinyu Wen,1 Rajesh
Patidar,1 JaimeM. Guidry Auvil,1 Daniela S. Gerhard,1 Robert Seeger,3 JohnM.
Maris,4 Javed Khan1. 1National Cancer Institute, Bethesda, MD; 2University at
Albany, Bethesda, NY; 3The Children’s Hospital Los Angeles, Los Angeles, CA;
4The Children’s Hospital of Philadelphia, Philadelphia, PA.
Despite the success of multimodal therapies, the mortality and morbidity
remains substantial for patients with high-risk neuroblastoma (NBL). Se-
quencing of paired tumor/normal DNA of NBL has revealed a low somatic
mutation burden and few recurrent somatically-mutated genes. Here we
hypothesize that whole transcriptome sequencing (WTS) in patients with
high-risk NBL tumor will yield valuable insights into the biology of this
disease. We performed deep WTS of 150 NBLs (129 high-risk stage 3 and 4;
and 21 stage 4S tumors) of which majority of them had whole genome se-
quencing or whole exome sequencing of case-matched tumor/normal pairs
through the Therapeutically Applicable Research to Generate Effective
Treatments (TARGET) initiative. We identifıed correlations between gene
expression and clinical parameters of patients such as MYCN-amplifıcation
and survival to provide understandings of high-risk NBL biology. Consensus
clustering using gene expression profıles of tumors revealed 4 subgroups
with distinct survival probability (p0.01). Among them, the group with the
best outcome consisted of all stage 4S and 4S-like young patients; whereas
the worst survival group was made up mostly of high-risk patients with
MYCN-amplifıcation. In order to identify the gene expression patterns cor-
relating with outcome in the high-risk patients without MYCN-amplifıca-
tion, we further examined if any other known gene expression signatures can
further stratify these patients using Gene Set Enrichment Analysis (GSEA).
Among several molecular signatures, a previously reported 157-gene MYCN
activation signature was signifıcantly correlated with the poor outcome in
high-risk patients withoutMYCN-amplifıcation. Of note, we identifıed CD8,
cytolytic, and activated nature killer (NK) cell signatures that were signifı-
cantly associated with outcome in these patients. These fındings were vali-
dated in an independent dataset. Our data has an important clinical impli-
cation for a subset of high-risk neuroblastoma patients without MYCN-
amplifıcation that have an activated MYCN signature may benefıt from
immune-modulating agents such as immune check point inhibitors which
should be tested in context of clinical trials.
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#1745 Multifocal prostate cancer has high degree of genomic heterogene-
ity.Marthe Løvf,1 Sen Zhao,1 Ulrika Axcrona,2 Bjarne Johannesen,1 AndreasM.
Hoff,1 Anne Cathrine Bakken,1 Kristina Totland Carm,1 OlaMyklebost,3 Leon-
ardo A.Meza-Zepeda,1 Agnes K. Lie,4 Karol Axcrona,5 Ragnhild A. Lothe,1 Rolf
I. Skotheim1. 1Oslo University Hospital, Institute for Cancer Research, Oslo, Nor-
way; 2Oslo University Hospital, Department of Pathology, Oslo, Norway; 3Nor-
wegian Cancer Genomics Consortium, Oslo, Norway; 4Østfold Hospital Trust,
Department of Pathology, Fredrikstad, Norway; 5Akershus University Hospital,
Department of Urology, Lørenskog, Norway.
Prostate cancer is the most common cancer type among men in the West-
ern world. Most prostate cancers are multifocal with individual tumors har-
boring different aggressiveness. In recent genomics studies, the multifocal
nature of prostate cancer has been investigated only in small sample cohorts.
Here we have investigated the intra-organ mutational spectra of multiple
tumors from a large cohort of prostate cancer patients. From radical pros-
tatectomies performed between 2010 and 2012 at Oslo University Hospital,
43 prostatectomy specimens with multiple and clearly separated tumors
were identifıed based on histology. From each of these prostatectomy spec-
imens, DNA from frozen samples from 2-3 different tumor foci and corre-
sponding normal tissue samples were analyzed by high-coverage whole-
exome sequencing, adding up to a total of 159 samples. We identifıed 3093
somatic substitutions, insertions and deletions, with an average of 27 alter-
ations per tumor sample. Both known and novel signifıcantly mutated genes
were identifıed and their distribution among different tumor foci from the
same prostate was examined. Mutations in genes such as SPOP, MED12, and
FOXA1 have previously been identifıed in prostate cancer and were also
found to be frequently mutated in this cohort. However, the same mutations
were rarely found inmultiple tumor foci within the same prostate. In fact, for
13 out of the 43 examined patients there were no common mutations among
tumors from the same prostate. For 12 patients, we found only one overlap-
ping mutation among tumor foci. Whereas the overall list of mutated genes
(n  2101) overlap signifıcantly with the 594 genes of the Cancer Gene
Census (100/594; p9.6e-06), this was not the case for 142 genes with over-
lapping mutations among different tumor foci (2/594; p0.63). This indi-
cates that the overlapping mutations are not typical cancer driving genes. To
conclude, results from exome sequencing of multifocal prostate cancer show
a large degree of heterogeneity in genomic alterations between different
tumor foci within the same prostate. With very few common inter-foci mu-
tations, an implementation of genome-based personalized prostate cancer
medicine will require sampling of all tumor foci to tailor optimal treatment.
#1746 Rational molecular assessment and innovative drug selection
(RAIDs): Paving the way to personalizedmedicine in cervical cancer. Leanne
deKoning,1 BérengèreOuine,1 Aurélie Cartier,1 ElsM. Berns,2 Kirsten Ruigrok-
Ritstier,2 Corine Beaufort,2 Balazs Balint,3 Attila Kereszt,3 Gemma Kenter,4
Sanne Samuels,4 Ekaterina S. Jordanova,4 Emmanuelle Jeannot,1 Heiko von der
Leyen,5 Marina Popovic,6 Windy Luscap-Rondof,7 Vonick Sibut,7 Choumouss
Kamoun,7 Isabel Britto,7 Claudia Rincon,7 Philippe Hupé,8 Maud Kamal,1 Suzy
M. Scholl1. 1Institut Curie, Paris, France; 2Erasmus MC Cancer Institute, Rotter-
dam, Netherlands; 3SeqOmics, Moraholem, Hungary; 4Center for Gynecological
Oncology Amsterdam, NKI-AVL, Amsterdam, Netherlands; 5Hannover Clinical
Trial Center GmbH, Hannover, Germany; 6Institute of oncology of Vojvodina,
Vojvodina, Serbia; 7Institut Curie, INSERMU900, Paris, France; 8Institut Curie,
INSERM U900, Mines ParisTech, CNRS UMR 144, Paris, France.
Cervical cancer (CC) is the fourth most common cause of cancer deaths in
women worldwide, for which prognostic and predictive biomarkers are largely
lacking. RAIDs is a EU-funded project on cervical cancer that spans seven Eu-
ropean countries. The main objective of the RAIDs project is to use this tumor
type, which is easily accessible for repeated biopsies, to learn how to stratify
patients into targeted therapies. The project includes: 1) a cognitive cohort study
(BioRAIDs), one of the fırst prospective trials intended to defıne patient strati-
fıcation for targeted therapies, 2) a targeted clinical trial using an HPV directed
vaccine and 3) preclinical studies aiming at assessing new treatment strategies.
Molecular analysis on quality controlled tumor and sera samples from 400 pa-
tients include Next Generation Sequencing at SeqOmics (Hungary), PIK3CA
mutations detection in circulating tumor DNA at Erasmus MC (Netherlands),
Reverse Phase Protein array and HPV insertion sites analyses at Institut Curie
(France) and immune-microenvironment analyses at CGOA (Netherlands). In
addition, 20 CC cell lines have been profıled pharmacologically using a panel of
drugswhich potentially synergizewith “standard treatment”. The present poster
will mainly focus on the Reverse Phase Protein Array (RPPA) results of Bio-
RAIDs and how these relate to the genomic profıling and to patient outcome.
More than 150 cryopreserved baseline (before treatment) samples and 23 CC
cell lines have been screened by RPPA. From these, whole exome sequencing is
available for 92 patient samples. Stratifıcation of patients based on proteomics
and genomics has evidenced different subgroups (clusters) of patients display-
ing specifıc molecular characteristics. Genomics data and proteomics data both
demonstrate that these clusters differ notably in the pathways of oxidative phos-
phorylation, glycolysis and DNA repair. Patient response to treatment is as-
sessed by the presence or absence of residual tumor at six months after treat-
ment. The correlation of proteomics and genomics data with these clinical data
is ongoing and will identify putative predictive biomarkers. Correlation of pro-
tein data with response to drugs treatment in 20 CC cell lines has identifıed
several potential biomarkers, some of which again relate to (glucose) metabo-
lism. In conclusion, we here present new evidence for molecular subgroups of
cervical cancer that could benefıt from different treatment options. Notably, our
data suggest that the metabolism/glycolysis pathways are a major effector in CC
and constitute a potential therapeutic target in a subset of patients. This project
has received funding from the EuropeanUnion’s Seventh Program for research,
technological development and demonstration under grant agreement No
304810.
#1747 A microenvironment gene signature predicts poor outcome in pa-
tients with luminal breast cancers subjected to local-regional treatment.Ma-
ria Grazia Daidone, GiuseppeMerlino, PatriziaMiodini, Maurizio Callari, Vera
Cappelletti. Istituto Nazionale Tumori, Milan, Italy.
Gene expression studies, mainly addressed at the tumor cell compartment of
breast cancers (BC) contributed to unravel the molecular heterogeneity provid-
ing clinicianswith new and reliable tools for therapeutic planning.Despitemany
investigations have focused on genetic abnormalities initiating and driving tu-
morigenesis, there is now evidence that the cancer cell behavior depends not
only on intrinsic features, but also on the interactions with the microenviron-
ment. However, notwithstanding the interest in investigating tumor-stroma
cross-talks, the clinical relevance of subtype-specifıc molecular imprint of such
interactions is largely unexplored. As such, we attempted to clinically and bio-
logically validate the subtype-specifıc gene signatures derived from an in vitro
model recapitulating the interaction between BCs and activated stromal cells.
Gene expression signatures derived from luminal (T47D, MCF7, ZR75.1),
HER2 (SkBr3, BT474, MDA-MB-361) and basal-like (MDA-MD-468,
MDA-MB-231, BT20) cell lines treated by conditioned media from normal or
cancer-associated fıbroblasts (CAFs) showed common- and subtype-specifıc
pathways according toGSEA. In fact, interferon, IL-6, IL-12 and IL-23 signaling,
Toll Like Receptor pathway, pathways related to inflammation and metabolism
of carbohydrates were positively enriched in HER2 and luminal subtypes.
Complement cascade and Tumor Necrosis Factor pathways were positively en-
riched in basal and luminal tumors; no common pathway was observed in
HER2 and basal subtypes. The association between microenvironment signa-
tures specifıc for luminal, HER2 and basal BC cell lines and disease-free sur-
vival was evaluated in silico on published gene expression profıles (GEPs) from
2048 patients homogeneously treated. BCs were classifıed as microenviron-
ment-positive (ENVve, with GEP suggesting stroma activation), or negative
(ENV-ve) by correlating tumor’s GEPwith the respective subtype-specifıc sig-
nature. Patients with luminal ENVve tumors had 2.5-fold higher risk of
developing distant metastases (HR2.546; 95% Confıdence Interval, Cl: 1.751-
3.701, P9.84E-07), while ENV status did not affect or was only suggestive of
metastases in women with HER2-enriched (HR1.541; 95% Cl: 0.788-3.012,
P0.206) or basal tumors (HR1.894; 95%Cl: 0.938-3.824; P0.0747), respec-
tively. In luminal tumors, the ENV status maintained its prognostic role
(HR2.098; CI: 1.214-3.624; P0.00791) in multivariable analysis including
size, age and genomic grade index. Validity of our in vitro model was also sup-
ported by biological endpoints such as proliferation (MTT-assay) and migra-
tion/invasion (Transwell-assay). In vitro-derived gene signatures trace a sub-
type-specifıc interaction with CAFs and add independent information to
classical prognostic variables in women with luminal “microenvironment sen-
sitive” tumors.
#1748 Organ-specifıc epigenetic reprogramming of leukemia cells: Clues
to chemoresistance. Isabel Cunningham,1DianeHamele-Bena,1Audrey Papp,2
Yan Guo,3 Antony B. Holmes,1 Yu Shyr,3 Rory A. Fisher4. 1Columbia University
College of Physicians and Surgeons, New York, NY; 2Ohio State University, Co-
lumbus, OH; 3Vanderbilt University, Nashville, TN; 4University of Iowa Carver
College of Medicine, Iowa City, IA.
We previously reported our observation that tumors composed of leuke-
mic cells found in breast mimic solid breast cancers in gross and histologic
appearance (single-fıling of cells and distinctive keloid-like fıbrosis), inva-
siveness, metastatic pathway, and high mortality. They are resistant to anti-
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leukemia drugs; only 4% treated without excision lived 4 years but survivals
over 20 yrs resulted when tumor and its microenvironment were excised.
The incidence of occult leukemic tumors, still unknown as scans are not yet
routine, was estimated near 20% in 1970s autopsy studies. We hypothesized
there may be similarly altered genes in leukemic and epithelial breast tumors
directing clinical behavior and resistance that could provide targets for cu-
rative treatment. We performed RNA sequencing on 11 FFPE breast tumors
from annotated AML cases, all IHC-negative for hormones and E-cadherin,
compared to normal breast samples. Differential expression analysis identi-
fıed 3647 genes that were signifıcantly downregulated (adjusted p 0.05 and
log2 fold change  -2). Among the 100 genes downregulated 8-10 fold in
leukemic breast, FOXA1, CA12, CXCL14, SFRP1, SFRP4, DCN, LUM,
PHLDA1, NTN4, GABRP, TAGLN, AZGP1, and ARRDC3 have been asso-
ciated with poor prognosis in breast cancer, mainly triple-negative (TNBC)/
basal types. Compared to TNBC cases in the TCGA database, 851 genes were
similarly deregulated; signifıcantly enriched KEGG pathways include neu-
roactive ligand-receptor interaction, focal adhesion, ECM-receptor interac-
tion, and regulation of lipolysis in adipocytes. A role for altered stroma is
suggested as many of the similarly downregulated genes were reported in
dissected breast cancer stroma and silenced SFRP1 and CXCL14 were found
in keloid fıbroblasts. Silencing of SFRP1 and E-cadherin in AML marrows
was reported in 30-50% and each was correlated with poor survival. Reversal
of SFRP1 silencing has been achieved by epigenetic-modifying drugs in can-
cers and keloid fıbroblasts.We validated loss of SFRP1 and RGS6 in leukemic
breasts by RT-PCR. Loss of RGS6 in breast and other cancers promotes
doxorubicin resistance and DNMT1 upregulation leading to silencing of
tumor suppressor genes. These data open a new view of resistance of AML
cells to marrow-directed drugs through interaction with aberrant microen-
vironment. Solid tumors of epithelial and leukemic cells may share unrec-
ognized treatable targets. Adding drugs directed at tumor, including avail-
able epigenetic-modifying agents, to marrow-effective protocols, may fınally
decrease the persistently high rate of AML treatment failure.
#1749 Stability of copy-number profıles defınes two molecular subtypes
during urothelial carcinoma’s evolution. Bishoy M. Faltas,1 Davide Prandi,2
Scott T. Tagawa,1 David Nanus,1 Ana M. Molina,1 Himisha Beltran,1 Francesca
Demichelis,2 Mark A. Rubin1. 1Weill Cornell Medical College, New York, NY;
2University of Trento, Italy.
Background: Somatic copy-number alterations (SCNAs) are distinct mo-
lecular events occurring in muscle-invasive urothelial carcinoma (UC). De-
fıning the biologic role and the timing of SCNAs in UC’s evolution is critical
for understanding disease biology and for precision therapy. Methods: To
examine whether distinct SCNAs defıne specifıc subtypes of UC and charac-
terize the evolutionary dynamics of SCNA acquisition, we conducted whole-
exome sequencing (WES) of a discovery cohort of 44 advanced UC tumors
and matching germline samples, including 13 pairs of matched primary and
metastatic tumors prospectively collected before and after chemotherapy.
We queried WES data from 285 UCs from The Cancer Genome Atlas
(TCGA) as a validation cohort. We performed a novel in-depth allele-spe-
cifıc copy-number analysis in 2503 cancer genes using the CLONET compu-
tational framework, which accounts for tumor ploidy and cellularity to infer
the clonal hierarchy of SCNAs. Results: Analysis of SCNAs from tumor pairs
within each patient revealed punctuated evolution of SCNAs occurring early
in UC’s development followed by minor changes (clonal stasis) throughout
the tumor’s lifetime. Two distinct clusters of UCs with strikingly different
SCNA profıles in the discovery cohort emerged. Cluster A was defıned by
diploid copy number background and focal deletions in the 9p21 region
(CDKN2A, CDKN2B and MTAP). Cluster B was defıned by genome-wide
duplications and several enriched amplifıcations including 1q21.1 (SETDB1
andMLLT11), (P 0.0002) and 6p22.3 (E2F3), (P 0.001). TP53 mutations
(P  0.0001) were enriched in the cluster B, consistent with the role of
functional p53 as a “guardian of the genome” preventing chromosomal in-
stability. SCNAs clusters A and B were confırmed in the TCGA validation
cohort. Cluster A was enriched with tumors belonging to TCGA bladder
cancer cluster III (“basal/squamous-like”) (P  0.02). Conclusions: Using
novel allele-specifıc SCNAs analysis, we defıne two distinct clusters of UC
presenting a framework for understanding this aspect of UC’s biology. In
contrast to somatic mutations, SCNAs are clonally static during each tu-
mor’s evolution. This data has important implications for precision medi-
cine for UC.
#1750 Analysis of non-metastatic HCC patient tumors revealed the sig-
nifıcance of cell cycle regulation and tumor immunity in association with
overall survival and identifıed clinically relevant druggable targets. Pei-Zhen
Miao,1 Jeff Cheng,2 Kwame Okrah,3 Bonnie Liu,3 Charlie Sun,2 Grace Cao,2
Tony Guo,2 Shijing Fu,2 Marie-Claire Wagle,3 Elizabeth Blackwood,3 David
Shames,3 Garret Hampton,3 Lukas Amler,3 Astrid Kiermaier,4 Yevgeniya Frid-
lyand,3 Mark Lackner,3 Shih-Min Huang,3 Jian Zhou,1 Zhi Dai1. 1Liver Cancer
Institute, Zhongshan Hospital, Fudan University, Shanghai, China; 2Genentech,
Shanghai, China; 3Genentech, South SanFrancisco, CA; 4Genentech, Switzerland.
The lack of effıcacious therapies have hindered the progress in improving the
survival of HCC patients worldwide. As a disease that associates with the under-
lying liver injuries caused by various etiologies and remains asymptomatic dur-
ing most of its decades long progression, HCC presents challenges to accurately
depict its biological landscape and determine suitable therapeutic intervention.
An approach to tackle this issue is to defıne signifıcant biological variants that
impact patient survival in each disease stage, then attempt to chart paths of
potential therapies. To identify signifıcant biological determinants associated
with the overall survival (OS) of early stage, non-metastatic HCC patients, we
constructed focused Nanostring panels that are represented by 1,164 genes of
validated components and transcriptional outputs of multiple signaling path-
ways, cellular machineries, and tumor immunity. An unbiased analysis of pa-
tient survival and gene transcript levels revealed four distinct groups of genes
that are signifıcantly prognostic. The fırst two (Group 1 & 2) are associated with
poorer prognosis when expression is high (hazard ratio  2), whereas the re-
maining two (Group 3 & 4) correspond to signifıcantly better OS with elevated
transcript levels (hazard ratio0.5). Of note, Gene Set Enrichment Analyses
(GSEA) clearly indicated that while Group 2 was substantially enriched in genes
positively regulating cell cycle and cell division machinery, Group 4 was over-
represented by genes participating in the positive modulation and feedback
mechanisms of adaptive immune response, implicating the survival benefıt of
acquiring higher immunogenic tumor environment in early stageHCC. Search-
ing for druggable targets associated with poorer prognosis, we identifıed both
EZH2 andCHEK1 as candidates fromGroup 2. In vitro treatment of threeHCC
cell lines with EPZ-6438 (EZH2 inhibitor) or GDC-0425 (CHEK1 inhibitor)
resulted in signifıcant modulation of H3K27me3 or pCHEK1 levels (s345) re-
spectively. The growth of these cell lines was also dose-dependently suppressed
by each inhibitor in colony formation assays. Furthermore, the combination of
both inhibitors was able to achieve substantial cell growth inhibition at lower
concentrations, suggesting a combinatorial effect of targeting both EZH2 and
CHEK1 inHCCcell lines. Xenograft studies are ongoing to assess in vivo effıcacy
of this combination. In conclusion, utilizing well constructed Nanostring gene
panels, we identifıed signifıcant association of cell cycle machinery and adaptive
tumor immunity with HCC patient survival. Our fındings not only provided
potential rationale for expand testing of cancer immunotherapies to non-meta-
static, early stageHCC, but also revealed the potential utility of combiningEZH2
and CHEK1 inhibitors to treat HCC.
#1751 Systematic bias in genomic breast cancer classifıcation due to se-
lecting cases with high tumor percentage and good RNA quality. Esther H.
Lips, Antien L. Mooyaart, Maartje van Seijen, Lennart Mulder, Marlous Hoog-
straat, PetraM.Nederlof, LodewykF.Wessels, SjoerdRodenhuis,Gabe S. Sonke,
Jelle Wesseling. Netherlands Cancer Institute, Amsterdam, Netherlands.
Background Cancer classifıcation, prognostication, and prediction of treatment
sensitivity increasingly rely on DNA and RNA-based tests. This approach requires
suffıciently high tumor cell percentages to yield enough DNA or RNA for reliable
test results. As a consequence, samples of insuffıcient qualitymay drop out, e.g. due
to poor cellularity or high numbers of tumor infıltrating lymphocytes.We hypoth-
esized that requiring a high tumor cell percentage and high quality RNA causes
systemic bias when interpreting genomic test results in breast cancer, as specifıc
breast cancer subgroups may be over- or underrepresented. Patients and methods
For this analysis, we used pre-treatment frozen samples from patients included in
neoadjuvant chemotherapy trials at theNetherlands Cancer Institute between 2004
and 2012. Histological features and tumor cell percentage were reviewed and as-
sessed by a consultant breast pathologist. Gene expression profıling was done if the
tumor cell percentage exceeded 50% and RNA quantity (1 g) and quality (RIN
value
 6.5) were suffıcient. We compared patient and tumor characteristics be-
tween patients in whom gene expression profıling could be performed and those in
whom it could not be performed. In addition, we performed a systematic review on
gene expression profıling for breast cancer, to assess the percentage of sample drop-
out in published studies. Results Frozen biopsies were available from 658 patients
(79% of the total study population) and gene expression profıling could be per-
formed in 60% of the cases, a percentage comparable to what is reported in the
literature. Reasons for drop out were a low cellularity, poor quality and quantity of
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the RNA, or a too small biopsy for processing. These patients had more grade 3
tumors (43% versus 34%, p0.04) and were more node positive (76% versus 69%,
p0.03). Analysis of neoadjuvant chemotherapy response and survival in these
patients is ongoing andwill be presented at the AACRAnnualMeeting 2017. Con-
clusion Breast cancers for which gene expression data were successfully obtained
were associated with a higher grade and with lymph node metastasis. Such tumors
represent a more aggressive phenotype and have a relatively poor prognosis, com-
pared to thepatients forwhomgeneexpressiondata couldnotbemeasured.Asgene
expression arrays are now broadly used in a clinical context, it is important to ac-
knowledge this systematicbias, and tobecautious inapplyinggeneexpressionbased
tests on different patient populations than a test was developed on.
#1752 Immune-related gene signatures in colorectal liver metastases: Ex-
posing an opportunity for immune modulating therapy. Vigdis Nygaard,1
Vegar J. Dagenborg,1 Olga Østrup,2 Einar A. Rødland,2 Veronica Skarpeteig,2
Laxmi Silwal-Pandit,2 Krzysztof Grzyb,3 Audun E. Berstad,4 Åsmund A. Fret-
land,5 Gunhild M. Mælandsmo,1 Anne-Lise Børresen-Dale,2 Anne H. Ree,6
Bjørn Edwin,5 Kjersti Flatmark1. 1Dept. of Tumor Biology, Institute for Cancer
Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Nor-
way; 2Dept. of Cancer Genetics, Institute for Cancer Research, Oslo University
Hospital, The Norwegian Radium Hospital, Oslo, Norway; 3Dept. of Pathology,
Oslo University Hospital, Rikshospitalet, Oslo, Norway; 4Dept. of Radiology, Oslo
University Hospital, Norwegian Radium Hospital, Oslo, Norway; 5The Interven-
tion Centre, Oslo University Hospital, Rikshospitalet, Oslo, Norway; 6Dept. of
Oncology, Akershus University Hospital, Lørenskog, Oslo, Norway.
Colorectal cancer (CRC) is one of the most common cancers and one of the
leadingcausesof cancerdeath in theWesternworld.Upto50%ofpatientswithCRC
developmetastatic disease and the liver is themost common site. The recently iden-
tifıed consensus molecular subtypes (CMS1-4) based on analyses of primary CRC
haveprognostic and therapeutic implications, but it is unclearwhether thesemolec-
ular subtypes are valid formetastatic disease. In this study, characterisation of CRC
livermetastases (CLM)was performed atmultiplemolecular levels to identify char-
acteristics relevant tometastatic disease. Molecular stratifıcation of a defınedmeta-
staticCRCcohortmay yield results of clinical relevance andnovel treatment oppor-
tunities. Surgically resected CLM and tumor-adjacent liver tissue from 46 patients
were analysed for the presence of mutations (targeted deep sequencing), genome-
wide copynumber alterations (CNA), and transcriptionprofıled.Molecularprofıles
of CLM and tumor-adjacent liver tissues were analyzed and associations with clin-
icopathological features and outcome were investigated.We found oncogenic mu-
tations in all except one tumor. Both mutation and CNA profıles were similar to
profıles reported for primaryCRC.ACMS classifıer tool applied to gene expression
data, revealed the cohort to be highly enriched for CMS2. Unsupervised clustering
based on genes with highly variable expression identifıed a 55-gene cluster that
segregated the samples into two subgroups. The segregation pattern was replicated
inrelevantpubliclyavailabledata sets, but theclinical signifıcanceof thisobservation
is not evident. The 55 genes were associated with lipid metabolic and immune-
related functions, revealing a role of the tumor-host microenvironment. The en-
gagement of the immune system was further underlined by analyzing subgroups
defıned by neoadjuvant chemotherapy (NACT) administration, which revealed al-
tered expression of inflammatory mediators and immune regulatory genes. The
majority of treated patients had receivedOxaliplatin based chemotherapy. The uni-
form classifıcation of CLM by CMS may reflect the patient composition in our
cohort, but may also indicate that novel class discovery approaches need to be ex-
plored to uncover clinically useful molecular stratifıcation of CLM. Identifıed im-
mune-related gene expression signatures associatedwithmolecular and clinical fea-
tures underline the integration and importance of the immune interactome in
resectable CLM. Specifıcally, the transcriptomic snapshot of NACT exposed CLM
revealed altered genes associated with immunogenic cell death but also immune
suppression. These results point to rational exploration of immune-modulating
strategies in CLM in combination with NACT to increase effıcacy and broaden
treatment opportunities for this patient group.
#1753 Refıning breast cancer characterization through single-cell analysis
of ex vivo reprogrammed tumor and adjacent normal cells.Harikrishna Nak-
shatri, Manjushree Anjanappa, Angelo Cardoso, Lijun Cheng, Safa Mohamad,
Andrea Gunawan, Susan Rice, YanDong, Lang Li, Edward Srour. IndianaUniv.
School of Medicine, Indianapolis, IN.
Discovery of inter-individual functional variations in gene regulatory elements
and theobservation that tumor andnormal tissues of the sameorganare indifferent
differentiation states necessitate rethinking of gene expression based subclassifıca-
tion/characterization of tumors. To address this issue, we performed single cell
genomics of breast tumors and adjacent-normal cells propagated using epithelial
reprogramming growth conditions for a short duration. Epithelial cells analyzed
were either unselected for specifıc subpopulation or phenotypically defıned undif-
ferentiated ALDH/CD49f/EpCAM luminal progenitors present in the nor-
mal breast, which express both basal and luminal-enriched genes. Expression of 93
genes that included PAM50 intrinsic subtype classifıer and stemness-related genes
was analyzed in 420 tumor and 284 adjacent-normal cells. ALDH/CD49f/Ep-
CAM tumor andnormal cells clustereddifferently compared tounselected tumor
and normal cells. PAM50 genes-set analyses of ALDH/CD49f/EpCAM pop-
ulations effıciently identifıedmajor andminor clones of tumor cells with themajor
clone resembling clinical parameters of the tumor. Similarly, stemness-associated
gene set identifıed clones with divergent stemness pathway activation within the
same patient sample. This refıned technique distinguished genes truly deregulated
in cancer from genes that identify cellular precursors of tumors. Collectively, assays
presented here may enable precise identifıcation of genes deregulated in cancer,
early identifıcation of therapeutically-targetable minor population of tumor cells,
and eventually to refınement of precision therapeutics.
#1754 A new glycan biomarker for pancreatic cancer complements
CA19-9 and identifıes a distinct subpopulation of cancer cells. Daniel Bar-
nett,1 Ying Liu,1 Katie Partyka,1 Galen Hostetter,1 Herbert Zeh,2 Aatur D. Sin-
ghi,2 Ying Huang,3 Richard R. Drake,4 Randall E. Brand,2 Brian B. Haab1. 1Van
Andel Institute, Grand Rapids, MI; 2University of Pittsburgh Medical Center,
Pittsburgh, PA; 3FredHutchinson Cancer Research Center, Seattle,WA; 4Medical
University of South Carolina, Charleston, SC.
A major challenge in diagnosing and treating pancreatic cancer is the complex
diversity between and within tumors in cellular morphologies and behaviors. Mo-
lecularmarkers to detect and classify specifıc variants of cancer cells could facilitate
drug targeting of subtypes of cancer cells.We recently found that a glycan related to
theCA19-9 antigen is a strong serological biomarker and is elevated in theplasmaof
about half of the patients with low CA19-9. We hypothesized that the cancer cells
producingCA19-9 are adifferent subtype than thoseproducing thenewbiomarker,
referred to as sTRA. Using multimarker immunofluorescence on tissue microar-
rays, we found that sTRA was signifıcantly elevated (p  0.001) in tumor tissue
relative to adjacent pancreatic tissue in 3 separate TMAs covering 38 patients. The
sTRA and CA19-9 markers were present in 31/38 (82%) and 20/38 (53%) of the
tumors, respectively, with 17/38 (45%) displaying both and 3/38 (8%) displaying
neither. The morphologies of the cancer cells fell into distinct categories based on
glycan expression. Cells with dual staining of bothmarkers tended to be in well-to-
moderately differentiated ducts with good nuclear polarization and foamy cyto-
plasm,orwith flat and thin epithelium.Cellswithpredominantor exclusiveCA19-9
staining tended to be part of well-differentiated ducts with mucinous cytoplasm or
moderately-differentiated ducts with poor membrane integrity. In contrast, strong
sTRA staining was present in small clusters of cells or single cells with poor differ-
entiation and large vacuoles, or in small and invasive ducts. The phenotypes were
consistent in xenograftmodelsmadewith either cells lines or patient-derivedmate-
rial, as well as in 2D culture. Costaining with protein markers of differentiation
showed that the CA19-9-positive/sTRA-negative regions colocalized more with
MUC5AC, CK19, and E-cadherin relative to the sTRA-positive cells, indicating
ductal differentiation, and the sTRA-positive/CA19-9-negative regions were more
likely to colocalizewith beta-catenin than any othermarker, indicating potential for
anchorage-independent growth or altered cellular cohesion. The time-to-progres-
sion after surgerywas associatedwith the relative levels of the twomarkers, basedon
staining of tumors from 48 patients in an independent TMA. Patients with higher
dual-staining of CA19-9 and sTRA had statistically longer (p  0.01 by log-rank
test) time-to-progression, and patients with higher exclusive staining of either
marker relative to thedual staininghad shorter time-to-progression.Thus the sTRA
marker used in conjunction with CA19-9 could provide a basis for classifying and
targeting subtypes of cancer cells.
#1755 The fate of germline BRCA related mutations in breast tumor tis-
sues. Vassiliki Kotoula,1 Florentia Fostira Fostira,2 Kyriaki Papadopoulou,3
Paraskevi Apostolou,2 Eleftheria Tsolaki,4 Georgios Lazaridis,5 Kyriaki Man-
oussou,5 Flora Zagouri Zagouri,5 Dimitrios Pectasides,5 Ioannis Vlachos,4 Ioan-
nis Tikas,4 Sotiris Lakis,4 Irene Konstantopoulou,6 George Pentheroudakis,5
Helen Gogas,5 Pavlos Papakostas,5 Christos Christodoulou,5 Drakoulis Yan-
noukakos,6 George Fountzilas4. 1Aristotle Univ. School of Medicine, Thessalo-
niki, Greece; 2National Center for Scientifıc Research NCSR Demokritos, Athens,
Greece; 3Hellenic Foundation for Cancer Research, Athens, Greece; 4Hellenic
Foundation for Cancer Research, Greece; 5Hellenic Cooperative Oncology Group,
Greece; 6National Center for Scientifıc Research NCSR Demokritos, Greece.
Background - aim: Germline mutation carriers in BRCA1 and related genes
frequently develop triple-negative breast carcinomas (TNBC) that presumably
preserve the inherited mutation. Herein, we examined the clinicopathologic
features and prognostic impact of paired germline and tumor genotypes in this
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disease.Methods:We compared baseline germline and paraffın tumor genotype
data (next generation [NGS] and Sanger sequencing) from 194 patients with
operable TNBC who were treated with anthracyclines-taxanes based chemo-
therapy within adjuvant trials by our Group. Because tissue NGS did not target
BRCA-related genes, we additionally interrogated the presence of germlinemu-
tations in tumor and non-cancerous breast tissues, in carriers with available
tissue material (n33). We validated all NGS germline mutations with Sanger
sequencing and ensured matched germline/tumor identity with microsatellite
testing. Results: We identifıed 50 (26%) germline mutation carriers, 39 in
BRCA1, 4 in BRCA2 and the rest in RAD51C, BARD1, RAD50, NBN,MRE11A
and BRIP1. BRCA1 carriers were younger as compared to non-BRCA1 carriers
(median 42y.o. vs. 56y.o, respectively; p0.020), premenopausal (p0.014),
and had lower nodal status (p0.001). Somatic mutations were found in 136
tumors, TP53 in 113 (81%). The germline mutant allele was lost in 14/33 (42%)
tumor and matched normal tissues (mut-LOH). Loss affected 12 BRCA1muta-
tions, among them the common pathogenic p.Q1756fsX74 (c.5266dupC) and
p.G1738R (c.5212GA), and 2BRCA2mutations. In one such tumor, the germ-
line mutation was replaced by a somatic BRCA1 (p.Q1811X [c.5431CT]).
Tumors with mut-LOH were more often TP53 mutant as compared to those
with preserved germline mutations, which had mutations in other genes as well
(p0.034). Overall though, TP53 mutations were not associated with germline
status. Germline mutations and tumor TP53 mutations were not individually
associated with patient disease-free survival (DFS) but interacted with each oth-
er: in non-carriers, TP53 status did not affect outcome; in carriers, those with
mutant TP53 had unfavorable DFS compared to those with wild-type TP53
tumors (interaction p, multivariate analysis: 0.053). Conclusions: Germline
BRCA-related TNBC may be distinguished into two groups with potentially
different biological characteristics, those with preserved and lost inherited mu-
tation. The interaction between germline status and tumor TP53mutationsmay
have treatment implications and seems worthy pursuing in larger studies. Com-
bined germline/tumor genotype testing may be needed for TNBC patient clas-
sifıcation, especially in the context of clinical trials.
#1756 Genomic reclassifıcation of endometrial carcinoma predicts drug
response and facilitates refınement of current management based on PDX-
guided effıcacy outcomes. Chieh-Hsiang Yang,1 David K. Gaffney,2 Theresa L.
Werner,3 Elke A. Jarboe,4 Jason Gertz,5 Katherine E. Varley,5 Matthew Peter-
son,1 Margit M. Janat-Amsbury1. 1Department of OB/GYN, University of Utah,
Salt Lake City, UT; 2Department of Radiation Oncology, University of Utah, Salt
Lake City, UT; 3Department of Medicine, Division of Oncology, University of
Utah, Salt LakeCity, UT; 4Department of Pathology, University of Utah, Salt Lake
City, UT; 5Huntsman Cancer Institute, Salt Lake City, UT.
Endometrial cancer (EC) is the most common gynecological malignancy
amongAmericanwomen. Steadily increasing numbers of newly diagnosed cases
and deaths emphasize the necessity of improving current management strate-
gies. Rather than the commonly known two types of EC based on histological
classifıcation, the Cancer Genome Atlas (TCGA) Research Network recently
reported a reclassifıcation that categorizes EC into four subtypes based on
genomic characterization. Molecular similarities between these subtypes and
other cancers, including colorectal, ovarian, and breast cancers, were identifıed.
But to date, no prospective validation has delivered an improved understanding
onhow to translate these fındings to the clinic in the formof treatments adapting
genomic guidance. Objectives: To evaluate drug response according to TCGA
classifıcation using a panel of twenty-seven established endometrial cancer pa-
tient-derived xenografts (EC-PDXs). Methods: Twenty-seven EC-PDXs repre-
senting various stages of disease and histological subtypes were orthotopically
transplanted and propagated over multiple generations. Upon thorough char-
acterization including histology, metastatic status, and molecular features, EC-
PDXs were further categorized into the four TCGA molecular subtypes on the
basis of somatic copy number variations (CNV),microsatellite instability (MSI),
and POLE mutations. A PDX clinical trial (PCT) was performed to re-evaluate
current standard treatments in comparison to therapeutic agents adopted from
treatment regimens for other cancer types based on their molecular similarities.
Results: EC-PDXs established from patients with recurrent disease exhibited
minimal activity to fırst-line chemotherapeutic drugs, as expected, but remained
sensitive to other second-line drugs. None of the tested drugs exhibited suffı-
cient activity in POLE EC-PDXs. MSI EC-PDXs were found to be less sensitive
to platinum-based treatment and resistant to 5-FU as reported for MSI colorec-
tal cancer. CNV-high EC-PDXs were more sensitive to drugs adopted from
current ovarian and breast cancer treatment regimens. Conclusions: This is the
fırst study that demonstrates the utility of TCGA classifıcation for treatment
guidance based on a PCT. Patients with recurrent and persistent disease are in
desperate need of new therapeutic options. Our fındings open up the possibility
to utilize drugs which are currently used in the treatment of other cancers for the
treatment of EC based on molecular similarities. In addition, this is the fırst
study that successfully demonstrated the use ofmolecular classifıcation to enable
the prediction of drug response, and thus may facilitate the refınement of cur-
rent EC management in a more precise and personalized way.
#1757 Spectrum of BAP1 mutations identifıed in diverse cancer lineages.
ZoranGatalica, JoanneXiu, Jeffrey Swensen,WangjuhChen.Caris Life Sciences,
Phoenix, AZ.
Background: Germline mutations in the tumor suppressor gene, BAP1, a
deubiquitylase that regulates key cellular pathways, are associated with a
recently-described tumor predisposition syndrome characterized by early
onset benign melanocytic skin tumors, and a signifıcant risk of cancers that
include mesothelioma, cutaneous and uveal melanoma, renal cell carcinoma
(RCC) and cholangiocarcinoma. Somatic or germline BAP1 mutations have
been associated with an aggressive course and a poor prognosis in RCC and
cholangiocarcinoma and may render the cancer cells more sensitive to
HDAC inhibitors or Parp inhibitors. We investigated types and frequencies
of BAP1 mutations in a large cohort of diverse malignancies and their asso-
ciations with other molecular/genomic characteristics. Methods: A total of
9782 tumor samples from over 40 cancer types were molecularly profıled at
Caris Life Sciences by next generation sequencing (Illumina NextSeq plat-
form and Agilent SureSelect XT panel, 592 genes). Microsatellite instability
(MSI) was tested by PCR and fragment analysis (Promega MSI Analysis
System). Results: A pathogenic somatic or germline BAP1 mutation was
identifıed in 20 cancer types, with a total of 129 tumors with mutations found
(1.3% prevalence). As expected, BAP1 mutations were frequently seen in
uveal melanoma (50% or 24 in 48), malignant pleural mesothelioma (29% or
6 in 21), RCC (8% or 12 in 150), cholangiocarcinoma (6.6% or 13 in 196), and
cutaneous melanoma (2.2% or 7 in 319). In addition, pathogenic BAP1 mu-
tations were detected in carcinomas arising in parotid gland (10.3% or 3 in
29), anus (8.3% or 3 in 36), cervix (3.4% or 4 in 117), stomach (3.3%, or 6 in
180), head and neck (1 in 97 or 1%), lung (14 in 1590 or 0.9%), and breast
(0.8% or 7 in 887). A mutation was also noted in a meningioma (1 in 43) and
a uterine sarcoma (1 in 96). Variants of BAP1 (pathogenic, presumed patho-
genic, and variants of unknown signifıcance) were more often seen in MSI-
high tumors (compared to MSS) in both colorectal (12/61 vs. 18/1003) and
endometrial carcinomas (5 of 69 vs. 5 of 321; both p0.01). It was not
determined whether the BAP1mutations were somatic or germline in origin.
Conclusions: The study confırmed the presence of pathogenic BAP1 muta-
tions in carcinomas commonly associated with BAP1 germline and somatic
mutations. It also identifıed BAP1 mutations in additional cancer types (pa-
rotid gland, anal and cervical carcinomas), as well as its association with
MSI-H cancers (colon and endometrium). Evaluation of mutations in non-
cancerous tissues is underway to determine if these novel cancer associations
are related to germline predisposition.
#1758 A more mature immunophenotypic makeup of multiple myeloma
clone(s) at diagnosis correlates with a higher genomic instability. Marina
Martello,1 Rosalinda Termini,1 Barbara Santacroce,1 Enrica Borsi,2 Vincenza
Solli,1 Lucia Pantani,1 Elena Zamagni,1 Paola Tacchetti,1 Francesca Ulbar,1 Ga-
briella Chirumbolo,1 Mario Arpinati,1 Giovanni Martinelli,1 Michele Cavo,1
Carolina Terragna1. 1University of Bologna, Bologna, Italy; 2Fondazione Um-
berto Veronesi, Milano, Italy.
Intro:The sequenceof events underlying theprocess ofMultipleMyeloma (MM)
plasma cells (PC)differentiationhavenot yet fully elucidated, even if recent fındings
suggest that different cell subpopulations, with distinct phenotype, compose the
MMclone(s),whoseplasticity has emerged as a typical feature.Aim:To evaluate the
phenotypicplasticity andgenomicbackgroundofMMclone(s) atdiagnosis inorder
to stratify patients (pts) according to the PC differentiation stages and possibly cor-
relate with disease outcome. P&M Phenotypic characterization of both CD138/
CD38andCD19populationswascarriedouton44newlydiagnosedMM.Fresh
BM samples was analysed by 6color multiparametric flow citometry analysis, com-
bining CD138PE, CD38-PE-Cy7, CD20-APC, CD19-APC-Cy7, CD27-FITC,
CD45-FITC, CD28-APC, CD44-FITC, CD54-APC, CD81-PerCP-Cy5.5, CD56-
APC and SHH-PE, as a functional marker of Hedgehog pathway activation (Milte-
nyi Biotech). Cytoscan HD array were carried out in order to detect genomic copy
number alterations (CNAs). Results According to the CD19 and CD81 markers
co-expression, pts were stratifıed in 3 subgroups, recapitulating a progressive PC
maturation process: the most immature one, including pts with CD19/CD81
PC(11/4425%); the intermediateCD19-/CD81phenotypeone (19/4443%),
and the CD19-/CD81- PC one, whose clone wasmainly composed bymostmature
PCs. The two extreme subgroups were characterized by a differential expression of
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maturation markers: the more mature PCs displayed a higher expression of CD28
andCD44,whichusually characterized advanceddisease stages, aswell as a reduced
expression of CD20, CD27 and CD45, commonly associated to preceding PC dif-
ferentiation stages (p.05). Any differential expression of SHH pathway’s ligand
was observed.On the contrary, a higherHedgehog pathway activationwas detected
in the immature CD19 compartment of pts with immature plasma cells (median
SHH expression CD19/CD81 vs. CD19-/CD81-: 98,1% vs. 11,3%; p.05),
which probably highlighted a less quiescent immature reservoir pool. The CNAs
analysis showed thatmaturePCswere characterizedbyahigher genomic instability,
as compared to themore immature ones (totalCNA: 306.9 vs. 171.5, p 0.08; genome
changed: 36.96 vs. 13.55, p 0.01), including several alterations commonly associated
toworseprognosis (e.g. del17p). Finally, a higher frequencyof baseline clinical char-
acteristics associated to bad prognosis was observed in the more mature, as com-
pared to themore immature subgroups of pts (e.g. n. PET lesions, k/l ratio; p.05).
ConclusionMMclone(s) is amixture of different cell populations endowedwith an
inner phenotypic plasticity. Various PC differentiation stages were appreciable al-
ready at diagnosis andgenomic features associated tobadprognosis characterizepts
carryingmoremature clones. Acknowledgements: AIRC, Berlucchi, Prog. Bolondi,
FUV
#1759 Description ofmolecularmarker disparities andKRASmutational
spectrum of colorectal tumors from Puerto Rican Hispanics. Julyann Perez-
Mayoral,1 Camila Rivera-Lynch,1Marievelisse Soto-Salgado,2 Xavier Llor,3 Luis
Tous-Lopez,4 Marla Torres-Torres,4 Jose S. Reyes,4 Carlos Torres,5 Ajay Goel,6
Segundo Rodriguez-Quillichini,2 Marcia Cruz-Correa1. 1University of Puerto
Rico Comprehensive Cancer Center, San Juan, PR; 2University of Puerto Rico
Medical Sciences Campus, San Juan, PR; 3Yale University, NewHaven, CT; 4Ash-
ford PresbyterianHospital, San Juan, PR; 5Puerto Rico Cancer Registry, San Juan,
PR; 6Baylor Research Institute, Dallas, TX.
Colorectal cancer (CRC) causes 27% of all cancer deaths among Puerto Rican
Hispanics (PRH). Most CRC cases are due to sporadic genetic or epigenetic
events that lead to the development of the tumor. These events aggregate to
cause CRC carcinogenesis and involve genes that regulate cell growth and dif-
ferentiation. Improving understanding of themolecular events that lead to CRC
carcinogenesis has the potential to reduce CRC mortality by risk stratifying
individuals as well as developing prevention strategies. Currently, there are a set
of molecular markers that are used to characterize CRC tumors and inform
prognosis and treatment decisions. These markers include: microsatellite insta-
bility (MSI), CpG island methylation and mutational analysis of the KRAS and
BRAF oncogenes. The objective of this study was to characterize the molecular
markers present in the CRC tumors of PRH and understand the disparities
present at the molecular level in these tumors. The frequency of the MSI and
CIMP were evaluated in 488 CRC tumors from PRH. Mutations in the KRAS
gene and the BRAF V600E mutation were evaluated using SuperArray technol-
ogy. Additionally, information regarding sociodemographic and clinicopatho-
logic characteristics of the study population was obtained. Of the 488 evaluated
CRC tumors 1.6% (n2) showed MSI and 90.2% of the studied tumors had
CIMP low phenotype (n102). MSI-High tumors were more likely to be distal
tumors compared to MSS tumors (p0.02). The V600E mutation in the BRAF
gene were found in 9.17% (n11) of the studied tumors. KRASmutations were
found in 31.25% (n40) of tumors. The most common KRASmutations found
in the CRC tumors of PRH were: c.35GA (KRAS COSMIC521) (n12) and
c.38GA (n8) (KRAS COSMIC532). Furthermore, the traditional CRC car-
cinogenesis pathway was the predominant pathway observed for the develop-
ment of theCRC tumors of our study population. The following study highlights
a distinct molecular signature for the CRC tumors from PRH descent. The dis-
parities observed in the prevalence of the molecular markers (low MSI, CIMP
Lowandmainlywild-type forKRAS andBRAF) suggest that the drivers forCRC
in this population might differ from other populations. Additional studies are
required to fully elucidate the CRC carcinogenesis pathway in PRH.
#1760 High expression of CASZ1 is associated with poor prognosis in
ovarian cancer. Yuan-Jhe Chuang, Yu-Ling Liang, Yuh-Ling Chen, Tse-Ming
Hong, Keng-Fu Hsu. National Cheng Kung Univ. Hospital, Tainan, Taiwan.
Epithelial ovarian cancer (EOC) carries the highest mortality rate of all gyne-
cologic malignancies. This high mortality rate is attributed to the fact that most
cases of ovarian cancer are detected at late stages when metastases are already
present. We previously demonstrated that castor zinc fınger 1 (CASZ1) is up-
regulated in EOC cells and promotes EOC cells metastasis. However, the rela-
tionship between the ovarian cancer patient’s prognosis and CASZ1 expression
is not clear. In the present study, we examinedCASZ1 andCA125 expressions in
EOC using immunohistochemistry and correlated their expression levels with
patient survival. From January 2008 to January 2012, 144 EOC patients who
underwent staging or cytoreductive surgery at the National Cheng Kung Uni-
versity Hospital (NCKUH) were consecutively enrolled. Clinical and pathology
information, including age, stage, cell type, chemo-response, and survival, was
collected from medical charts. The staging met the criteria of the International
Federation of Gynecology and Obstetrics Classifıcation (FIGO). Histological
classifıcation was defıned according to the classifıcation standards of theWorld
Health Organization. The overall survival (OS) was calculated from the date of
diagnosis. Progression-free survival (PFS) was measured as the period from
surgery to the date of confırmed recurrence or disease progression or to the date
of the investigators’ last note of a disease-free status. CASZ1, CA125 expression
was evaluated by TissueFaxs microscopy system using an image analysis pro-
gram. Five fıelds of the tumor in each slide (corresponding to a mean of 10000
tumors cells per case) were photographed. Images were acquired from using
fluorescence-activated cell sorting (FACS)-like tissue cytometry. The percentage
of positive cells in each sample was further quantifıed using TissueQuest soft-
ware (TissueGnostics, Vienna, Austria). The CASZ1 was signifıcantly upregu-
lated in advanced EOC tissues, compared with early stage tumors. High CASZ1
expression levels were signifıcantly associated with worse EOC clinical charac-
teristics. By univariate survival analysis, high CASZ1 levels signifıcantly corre-
lated with decreased overall survival, progression-free survival. In addition, pa-
tients with both high expression with CASZ1 and CA125 carried the worst
prognosis. In conclusion, we demonstrate that high expression of CASZ1 levels
correlates with an aggressive EOCphenotype andmay contribute for poor prog-
nosis in EOC patient. Determination of CASZ1 could be clinically useful in
identifying high-risk EOC patients for a more aggressive adjuvant therapy.
#1761 A rapid and accurate nucleic acid amplifıcation and detection
method for KRAS mutation testing in colorectal cancer specimens. Yong
Shin, Choong Eun Jin, Seung-Seop Yeom, Seok-Byung Lim.University of Ulsan
College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Colorectal cancer (CRC) is one of the most common type of cancers both men
and women in worldwide. Fortunately, overall death rates of CRC have been de-
creasing for the last twodecadesdue to the improvementof screening test assays that
detect early-stagecancerandpre-cancerouspolyps.Nevertheless, themostcommon
treatment forCRCis surgery,because itmaycompletely eliminate thecancer region.
In case of the cancer with systemic metastasis, chemotherapy is required before or
after surgery for primary ormetastatic lesions. Among the regimens for the chemo-
therapy, both monoclonal antibodies (Cetuximab and Pantitumumab) against the
epidermal growth factor receptor have been shown to improve survival for only
patients with lack of RAS mutations. Thus, the KRAS gene mutations (codons 12
and13) inCRCpatientshavebeenextensively studiedasa strongnegativepredictive
biomarker to indicate whether a CRCpatient responds to the treatment. Therefore,
testing the KRASmutational status of tumor samples is becoming an essential tool
for managing patients with CRCs. Although amyriad of nucleic acid testing meth-
ods have been developed to analyze the mutation status in the key regions of the
KRAS gene of CRC, several obstacles still remain related to low sensitivity, time
consuming, and required large instruments including thermal cyclers. Here, we
present a novel nucleic acid amplifıcation and detection method for KRAS muta-
tions (G12D and G13D) testing that enable rapid and accurate detection. This
method is based on combination of isothermal DNA amplifıcation method and
bio-photonic silicon sensor that can be detected the mutations in a label-free and
real-timemanner. The proposedmethod candetect themutant cell present at 1% in
amixtureofwild typecells,whilebothPCRandsequencingcandetect themutations
in a sample containing approximately 30% of mutant cells. We used 60 tissue sam-
ples from CRC patients (22 samples with G12Dmutations, 23 samples with G13D
mutation, and 15 samples with nomutation) to compare the clinical utility of three
methods including PCR, Sanger sequencing and the proposed method. The pro-
posed method with both G12D and G13D showed a value of 100% and 100% for
sensitivity and specifıcity, respectively.One the other hand, the sensitivity and spec-
ifıcity of PCR (90.5% and 100%) and sequencing (95% and 100%) were lower than
that of the proposed method. Therefore, the proposed method was found to be a
rapid ( 30min), highly sensitive and specifıc method for KRASmutation testing.
We believe that this rapid and accurate method will enable proper treatment for
CRC patients.
#1762 Keratin 17 identifıes prognostic subtypes of pancreatic ductal ade-
nocarcinoma. Luisa F. Escobar-Hoyos,1 Cindy Leiton,2 Elizabeth Vanner,2 Lu-
cia Roa-Pena,2 Jinyu Li,2 Scott Powers,2 Ali Akalin,3 Jela Bandovic,2 Peter Bai-
ley,4 David Chang,4 Richard Moffıtt,5 Jen Jen Yeh,5 Andrew Biankin,4 Kenneth
Shroyer2. 1Memorial SloanKetteringCancer Center, NewYork,NY; 2StonyBrook
University, Stony Brook, NY; 3University of Massachusetts Memorial Medical
Center,Worcester,MA; 4WolfsonWohlCancer ResearchCentre, Glasgow,United
Kingdom; 5Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
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Recent RNA sequencing (RNASeq) studies fromBailey et al., 2016,Moffıtt et al.,
2015 and Collisson et al., 2011 reported that mRNA expression from bulk tumor
defınes molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) that are
highly correlated with patient survival. These studies independently identifıed Ker-
atin 17 (K17) mRNA overexpression as one of over 20 upregulated transcripts that
defıne the RNA signature of the most lethal PDACs. Studies in our lab determined
that neither K17 genemissensemutations nor copy-number alterations explain the
upregulation of K17 mRNA expression by malignant cells. In addition, we found
that K17 expression, measured at the protein level by immunohistochemistry or at
the level of mRNA by RNASeq, is suffıcient to stratify patients by short- vs long-
term survival at baseline after resection. These retrospective survival analyses were
performed in four independent patient cohorts using a uniform threshold to defıne
low- vs high-K17 patients (total n 558).High-K17 caseswere twice as likely to die
from this disease compared to stage-matched low-K17 cases (P values  0.05).
Furthermore, we determined that K17 expression is associated with outcome after
Gemcitabine treatment using the Bailey et al., 2016 patient cohort (n 94). This is
the fırst study to show that the expression of a single gene, K17, can accurately
subtypePDACat initial diagnosis. In conclusion,K17was identifıed as a robust and
independent, clinically relevant, prognostic and predictive biomarker to stratify
clinical outcome at the time of initial diagnosis and to potentially inform clinical
decisions regarding chemotherapeutic intervention.
#1763 A novel RNA in situ hybridization approach highly sensitive for
detection of Merkel cell polyomavirus. Lisha Wang,1 Paul W. Harms,1 Nalla-
sivam Palanisamy,2 Shannon Carskadon,2 Xuhong Cao,1 Javed Siddiqui,1 Rajiv
M. Patel,1 Sylvia Zelenka-Wang,1 Timothy M. Johnson,1 Alison Durham,1
Fengyun Su,1 Sudhanshu Shukla,1 Rohit Mehra,1 Arul M. Chinnaiyan1. 1Uni-
versity of Michigan, Ann Arbor, MI; 2Henry Ford Health System, Detroit, MI.
Background:Merkel cell carcinoma(MCC) isahighlyaggressiveneuroendocrine
tumorof the skin.Merkel cellpolyomavirus (MCPyV)playsanoncogenic role in the
majority of MCC tumors. Detection of MCPyV in MCC tumors has diagnostic
utility, and potentially prognostic and therapeutic implications. We investigated
whether RNAscope, a novel RNA in situ hybridization (ISH)method for detection
of RNA transcripts in tissues at the single-cell/single-molecule level, is useful for
MCPyV detection. Methods: We applied an RNAscope probe targetingMCPyV T
antigen transcripts on tissue microarrays (TMAs) and full tissue sections encom-
passing 91MCCtumors from75patients, 14 carcinomasof other types, andvarious
normal tissues. qPCR and immunohistochemistry (IHC) for MCPyV were per-
formed on 58 and 88 cases, respectively. qPCR was also performed on 18 cases of
normal skin toestablishbackground levelsofMCPyVinnon-tumor tissues.Results:
RNA-ISHdemonstrated thepresenceofMCPyVin46.2%(42/91)of cases.A totalof
58 samples had data from all the three detection modalities (qPCR, RNA-ISH and
IHC).RNA-ISHdemonstrated 100%concordancewith qPCRresults,whereas IHC
had a slightly lower concordance (96.6%). RNA-ISH demonstrated higher agree-
ment than IHCamongTMAcores fromthe samecase, andbetweenTMAcores and
matched full tissue sections.Of sampleswithbackground inflammatory cells, 5of 37
(15.6%) showed moderate nonspecifıc staining of lymphocytes by IHC, whereas
RNA-ISH lacked background. Conclusions: RNA-ISH is comparably sensitive to
qPCR for detection of MCPyV, and allows for correlation with tissue morphology.
Our fındings support RNA-ISH as a highly effective method forMCPyV detection
in tumors.
#1764 Accurate and reproducible detection of fusions and exon skipping
events inNSCLC-derived samples using a comprehensive, targetedRNA-Seq
system across multiple laboratories. Gary J. Latham,1 Richard Blidner,1 Brian
C. Haynes,1 Shobha Gokul,1 Maria L. Aguirre,2 Stephen Hyter,3 Ziyan Y. Pes-
setto,3 Maria Curtis,4 Dan Su,4 Tom Halsey,4 Victor Weigman,4 Patrick Hur-
ban,4 Andrew K. Godwin,5 Leon C. van Kempen2. 1Asuragen, Austin, TX; 2Jew-
ish General Hospital, Montreal, Quebec, Canada; 3University of Kansas Medical
Center, Kansas City, KS; 4Q2 Solutions, Morrisville, NC; 5University of Kansas
Cancer Center and University of Kansas Medical Center, Kansas City, KS.
Introduction:Reliableassessmentofcancer-associatedRNAmarkers in lungcan-
cer produced by gene-fusions or exon skipping events by next-generation sequenc-
ing requires integrated reagents, protocols, and interpretive software that can har-
monizeprocedures andensure consistent results across laboratories.Weevaluateda
comprehensive system for targetedRNA-Seq that includes reagents for nucleic acid
quantifıcation, library prep, run controls, and companion bioinformatics software.
The reproducibility of this system was evaluated in a multi-phase study design at 5
independent laboratories. Methods: Total nucleic acid (TNA) was isolated from
formalin-fıxed, paraffın-embedded (FFPE) residual non-small cell lung cancer
(NSCLC) tumor biopsies and cell-lines (RT-112, H596, HCC78). These TNA iso-
lateswereused toprepare a set of 30 test samples, including adilution series to assess
assay sensitivity.Anon-template control andkit positive controlwere also included.
The sample set was evaluated using the QuantideX® NGS RNA Lung Cancer Kit
RUO (Asuragen) and sequenced on theMiSeq® system (Illumina) at Asuragen and
4 independent laboratories. Analyses were conducted using QuantideX® NGS Re-
porterRUO(Asuragen), a software suite that includes a FASTQprocessing pipeline
and incorporates pre-analytical QC information into the fusion-caller algorithm
and reporting tool. Results: Laboratories were trained on the assay workflow and
companion bioinformatics software in less than two days followed by independent
library preparation and sequencing workflows. A total of 266 sample libraries were
evaluated frominputsdown to10ng.A single librarywas excluded fromsequenc-
ing due to a failed QC status. Specifıc targeted fusions (ALK, ROS1, FGFR3) and
splice variants (MET exon 14 skipping) were detected in 132 libraries and were
concordant at all sites. Designs to detect 3=/5= expression imbalances reported the
presence of gene fusions for ALK and ROS1 in a total of 96 libraries with one aber-
rant call and one missed call, which occurred in libraries flagged as “at risk” by the
interpretive software. Conclusions: The accuracy of this novel targeted NGS assay
for RNA fusions and splice variants in NSCLC was demonstrated in a multi-site
laboratory evaluation using clinically-relevant specimens and low inputs of TNA.
The ability of the panel to detect both common and rare gene fusion transcripts and
exon skipping events within an integratedwet- and dry-benchworkflow provides a
foundation for the reliable detection of oncogenic RNA fusions and aberrant splic-
ing events that can respond to current and emerging targeted therapies. This study
highlighted the ease of implementation and consistent performance that can be
achieved in different laboratories when the process from sample-to-report is highly
integrated.
#1765 Molecular and immunological characterization of non-small cell
lung cancer harboring cMET alterations. Maria Saigi,1 Carolina Pereira,1
Eva Pros,1 Elisabeth Brambilla,2 Ernest Nadal,3 Montse Sánchez-Céspedes1.
1IDIBELL, Barcelona, Spain; 2Centre Hospitalier Universitaire de Grenoble,
Grenoble, France; 3Catalan Institute of Oncology, Barcelona, Spain.
Purpose: To explore the correlation between the expression of immunological
biomarkers in a subset ofNSCLC tumors presenting cMET activation.Methods:
We retrospectively reviewed 200 tumor samples from a cohort of patients diag-
nosed with NSCLC in 3 different hospitals, from Spain and France. cMET acti-
vation was defıned by the presence of one or more of the following criteria: 1-
cMET mutations inducing exon 14 skipping (METex14), 2- cMET amplifıca-
tion, assessed by FISH3- cMEToverexpression, assessed by immunohistochem-
istry (IHC). METex14 mutations were determined by genomic sequencing and
RT-PCR. FISHwas interpreted according to Capuzzo scoring system, consider-
ing 5 or more gene copies as the mean value for positive amplifıcation. Concur-
rent genetic alterations in EGFR and ERBB2 tyrosine kinase receptors were also
determined. PD-L1 expression and density of tumoral infıltrating CD8 lym-
phocytes were assessed by IHC. Statistical correlation analysis was performed by
Chi-square and Fisher’s exact test. Results: METex14, cMET amplifıcation and
cMET overexpression were detected in 2%, 7.8% and 31% of tumors, respec-
tively.Histological subtypes included: 70% adenocarcinoma, 20% squamous cell
carcinoma, 8% large cell, 2% pulmonary sarcomatoid. Curiously, one of the
METex14 adenocarcinoma was concurrent with ERBB2 amplifıcation. Those
tumors harbouring METex14 or cMET amplifıcation were correlated with pos-
itivity for PD-L1 expression (p  0.02). However, this association was not ob-
served in cMET overexpressed tumors. Conclusions: We observed a direct cor-
relation between PD-L1 positivity and METex14 or cMET amplifıcation.
Functional analysis and a large cohort of tumors are required to better charac-
terize the potential role of cMETpathway in the regulation of PD-L1 expression.
#1766 Distinct pattern of alterations in tp53 mutated and wild type acute
myeloid leukemia (AML) patients.Anna Ferrari,1 Eugenio Fonzi,1 Maria Chi-
ara Fontana,1 Andrea Ghelli Luserna Di Rorà,1 Marco Manfrini,1 Antonella
Padella,1 Carmen Baldazzi,1 Cristina Papayannidis,1 Giovanni Marconi,1 Stefa-
nia Paolini,1 Viviana Guadagnuolo,2 Margherita Perricone,1 Valentina Robust-
elli,1 Enrica Imbrogno,1 Eugenia Franchini,1 ClaudiaVenturi,1 Elisa Zuffa,1Ma-
ria Chiara Abbenante,1 Giorgia Simonetti,1 Nicoletta Testoni,1 Emanuela
Ottaviani,1 Martinelli Giovanni1. 1Institute of Hematology, Bologna, Italy; 2Cell-
Ply srl, Bologna, Italy.
Background: Mutations in TP53 gene predict a poor prognosis in patients with
AML.The reportedTP53mutation rate inAMLis low(2.1%)bycontrastAMLwith
a complex karyotype (CK) is higher (69-78%) and have a poor outcome. Quite
common is to found paired TP53mutation together and a segmental 17p deletion.
Aims: To investigate the frequency, the types of mutations, the associated cytoge-
netic, the correlation with known molecular alterations and the prognostic role
TP53mutations inadultAMLpts.Moreoverwewould identifygenes/pathways that
aremainly affected in themutatedTP53groupcompared to thewtone.Patients and
Methods: 258 adult AML pts with miscellaneous cytogenetic abnormalities and
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normal karyotype were examined in our Institution for TP53mutations using sev-
eralmethods, includingSanger sequencing,NGSandHiSeq2000platformandwere
correlated with cytogenetic analysis. 124/258 samples were genotyped with SNP
arrays (Affymetrix, 3 250K, 43 SNP 6.0, 78 CytoScan HD). Copy Number Altera-
tions (CNAs) analyses were performed using Chromosome Analysis Suite (Af-
fymetrix) and Nexus Copy Number (BioDiscovery) software. Results: Mutation
analysisdetectedTP53mutationson39patientswith48different typesofmutations
(32 deleterious point mutations; 4 deletions); nine pts have 2mutations.We found
34/48 (70%) missense mutations, 5 mutations in the splice sites, 4 deletions ,2 in-
tronic and and 3 othersmutations. Themutation rate is of 15.1%.Mostly (28/39) of
the TP53 mutated pts (71.8%) had CK while only 11/39 (28.2%) mutated pts have
“no CK” (P0.0001). Alterations of TP53 were signifıcantly associated with poor
outcome (OS and EFS p0.0001). To take advantage of different methodological
characteristics, on TP53 locus, we matched two software and cytogenetic analysis
results.We identify 16mutated pts that were also deleted and one pt that presented
only adeletion.Therefore 50%ofmutatedpts present a concomitant deletion.OSof
TP53 mutated and deleted pts is statistically inferior respect to muted pts
(p0.0061). Comparing 32TP53mutated and 92TP53wt pts CNAs results that: a)
chromosomes signifıcantly alterated are 5q, 17p, 12p, 16q, 22q13.33 and 7q; b) over
900 genes are differentially involved (all in Loss); c) and that pathway categories
mainly enriched are Signal Transduction, Metabolism, Immune System, Trans-
membrane transport of small molecules, Gene expression, Cell Cycle. Conclusions:
Our data demonstrated that TP53mutations occur in 15.1% of AMLwith a higher
frequency in the subgroup of CK-AML (p0.0001). They predicted to be deleteri-
ous and signifıcantly correlated with worse prognosis especially if TP53 is both
mutated and also deleted. For these reasons, TP53 mutation/deletion screening
should be recommended. Different pattern of alterations inmutated andwt groups
have to be deeper investigated. ELN, AIL, AIRC, progetto Regione-Università
2010-12 (L. Bolondi), FP7 NGS-PTL project.
#1767 Analysis of biomarkers and anthracycline benefıt for hormone re-
ceptor-negative breast cancer: results from a randomized phase 2 neoadju-
vant study (KBOG 1101 Study). Takashi Ishikawa,1 Kazutaka Narui,2 Mari S.
Oba,2 Akimitsu Yamada,2 Kumiko Kida,2 Mikiko Tanabe,2 Yasushi Ichikawa3.
1Tokyo Medical University, Tokyo, Japan; 2Yokohama City University Medical
Center, Yokohama, Japan; 3Yokohama City University, Yokohama, Japan.
AIM: We compared 6 cycles of docetaxel and cyclophosphamide (TC6) with
3 cycles of 5-fluorouracil and epirubicin and cyclophosphamide followed by 3
cycles of docetaxel (FEC-D) as neoadjuvant chemotherapy for patients with
hormone receptor (HR)-negative breast cancer (BC) to identify biomarkers re-
quiring anthracycline treatment. Methods: In total, 103 patients with operable
HR-negative BC were administered TC6 or FEC-D. Triple-negative BC was
subdivided by CK5/6 and EGFR into basal- and non-basal BCs. The primary
endpoint was pathological complete response (pCR). Secondary endpoints were
safety, breast-conserving surgery ratio, disease-free survival, overall survival,
and predictive factors (Ki-67, P-53, ALDH1 and TOP2A by IHC and TOP2A by
FISH) for each regimen. Results: Of the 103 patients, 97 completed the study.
Overall pCR was higher for patients treated with FEC-D (36%) than for those
treated with TC6 (25.5%) (P0.265). FEC-D was signifıcantly superior to TC6
in basal BC (42.9% vs 13.6%; P0.033), while no differences in HER2 and non-
basal BCs. Aldehyde dehydrogenase 1 (ALDH1) positivity was inversely associ-
ated with pCR for both regimens, signifıcantly for FEC-D (FEC-D: p0.047,
TC6: p0.085). Patients who achieved pCR tended to have longer DFS (P 
0.287) and OS (P  0.069). Patients with basal and non-basal BC treated with
FEC-D had signifıcantly better DFS (P 0.016) and OS (P 0.034) than those
with TC6. Conclusion: We found TC6 was less effective than FEC-D for HR-
negative BC because it was not suffıcient to treat basal-BC. This suggests that
DNA damaging agents like anthracyclines are required for treating basal-BC.
Additionally, ALDH1 could be a marker for resistance to conventional chemo-
therapy.
#1768 A practical tool for probing protein glycosylation in clinical sam-
ples: Application to characterizing subtypes of MUC5AC glycosylation in
distinct subsets of pancreatic cancer patients. Peter Y. Hsueh. Van Andel In-
stitute, Grand Rapids, MI.
Glycans are critical to protein biology and are useful as disease biomark-
ers. Many studies of glycans rely on clinical specimens, but the low amount
of sample available for some specimens limits the experimental options. We
have a method to obtain information about protein glycosylation using a
minimal amount of protein, and we applied it to the study of biomarkers in
the blood plasma of pancreatic cancer patients. The method works by treat-
ing proteins that were captured by antibody microarrays (2.2 x 2.2 mm) with
exoglycosidases to successively expose underlying features, and then prob-
ing the native or exposed features using a panel of lectins or glycan-binding
antibodies. We use an algorithm to interpret the data and provide predic-
tions about the glycan motifs that are present in the sample. We applied the
method to the analysis of the glycosylation of a biomarker, MUC5AC, found
in the plasma of patients with pancreatic cancer. An O-linked glycan on
MUC5AC that is elevated in the plasma of about 75% of patient had mostly
2,3 linked sialic acid on type-1 N-acetyl-lactosamine (LacNAc), whereas
other glycans onMUC5AC had a 2,6 linkage of sialic acid on type-2 LacNAc.
Another glycan, fucosylated and sialylated/sulfated type-2 LacNAc, which is
elevated in distinct subset of patients, was on N-linked glycans, representing
an unusual fınding of N-linked glycans on mucins associated with cancer.
Further developments are enabling the testing for consistent structural fea-
tures associating with subtypes of cancer, which could improve our ability to
detect and target the subtypes. The on-chip glycan modifıcation and probing
(on-chip GMAP) method provides a platform for analyzing protein glyco-
sylation in clinical specimens and could facilitate the characterization and
discovery of glycan biomarkers.
#1769 The clinical outcome of stage I lung adenocarcinoma patients with
or without activating EGFR mutation. Yueh-Fu Fang. Chang Gung Memorial
Hospital, Taipei, Taiwan.
Purpose: Advanced stage lung adenocarcinoma patients with activating
EGFR mutation have better survival result after EGFR tyrosine kinase inhib-
itor developed. The prevalence of EGFR mutation is high in Asian lung
adenocarcinoma patients. The difference of clinical outcome of stage I lung
adenocarcinoma patients with or without activating EGFR mutation was
unclear. Our aim of study is to evaluate the clinical outcome between wild
and mutated stage I lung adenocarcinoma. Patients and Methods: We had
343 Stage I lung adenocarcinoma patients who received surgical resection
from January 2010 to April 2014. The preliminary data of EGFR mutation in
167 patients was done. Sanger method of direct PCR, scorpion & ARMS
method or ABI allele specifıc TagMan PCR were used to check the EGFR
mutation status of these patients’ samples. The selection of these methods
was depended on purity of tumor samples. Results: There were 93 stage IA
patients and 74 stage IB patients. Sixty-four (69%) patients had activating
EGFR mutations in stage IA patients, and fıfty (68%) patients had activating
EGFR mutations in stage IB patients. The survival of stage IA and IB were
similar in patients with or without EGFR mutations. The patients without
mutated EGFR had better progression free survival in IA and IB patients,
especially in the IB patients, although the signifıcance did not be reached in
small preliminary sample size. Conclusion: The survival was similar in stage
IA or IB lung adenocarcinoma with or without EGFR mutations. Patient
without EGFR mutation had better progression free survival although there
was no statistical signifıcance between patients with or without EGFR mu-
tations. We will collect more patients’ data for analysis.
#1770 The association between sarcopenia and cellular senescence of can-
cer associated fıbroblast in pancreatic cancer. Kensuke Yamamura, Yo-ichi
Yamashita, Yuki Kitano, Kota Arima, Takayoshi Kaida, Tatsunori Miyata,
Shigeki Nakagawa, Kosuke Mima, Katsunori Imai, Daisuke Hashimoto, Akira
Chikamoto, Hideo Baba. Graduate School of Medical Science, Kumamoto Uni-
versity, Kumamoto, Japan.
Background: Sarcopenia is a syndrome that is characterized by progressive
and generalized loss of skeletal muscle mass and strength. Several recent studies
have shown that sarcopenia has prognostic signifıcance for patients with malig-
nant disease, including cancers of the esophagus, colon, pancreas and liver. On
the other hand, cellular senescence is gaining increased attention from clinicians
and researchers, yet incompletely understood role in the development of malig-
nant disease. Previous studies reported that Caveolin-1 expression in cancer
associated fıbroblast is associated with cancer progression, and it is known in
recent years that caveolin-1 plays amajor role in controlling cellular senescence.
Therefore, we hypothesized that sarcopenia causes cellular senescence of cancer
associated fıbroblast (CAF). The aim of this study is to clarify the between sar-
copenia and cellular senescence of CAF through Caveolin-1 in pancreatic can-
cer. Methods: All consecutive patients with pancreatic cancer underwent cura-
tive resection between January 2004 and December 2014 were enrolled in this
retrospective study. Skeletal muscle and visceral fat amount at the third lumbar
vertebra (L3) in the inferior directionwere quantifıed using enhanced computed
tomography. The patients were divided into two groups, with and without sar-
copenia, based on Japan Society of Hepatology guidelines for sarcopenia. Next,
Caveolin-1 expression was analyzed by immunohistochemistry (IHC). More-
over, we investigated the relationship between sarcopenia and Caveolin-1 ex-
pression. Results: Forty-one (31.5%) of 130 patients were identifıed with sar-
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copenia. Kaplan-Meier analysis showed that patients with sarcopenia had a
signifıcantly worse cancer specifıc survival than patients without sarcopenia
(3-year-survival: 37.2% vs 50.4%, respectively, p 0.038). While, a high level of
Caveolin-1 expression was detected in 29.2% (38/130) of our samples. High
Caveolin-1 expression in CAF signifıcantly correlated with poor prognoses with
respect to overall survival (log-rank p 0.014) and disease-free survival (log-
rank p 0.0015). However, there was no relationship between sarcopenia and
IHC score of Caveolin-1 expression in CAF. Conclusion: The present result
suggested that sarcopenia and Caveolin-1 expression of CAF in patient with
pancreatic cancer is respectively associated with poor prognosis, but not associ-
ated each other. Now, we focus on Caveolin-1 expression of CAF, and establish
primary cultures of CAF from the pancreatic cancer tissues and examine its
function.
CLINICAL RESEARCH: Predictive Biomarkers 1
#1771 Phase 3 trial of adjuvant sunitinib in patients with high-risk renal
cell carcinoma: exploratory molecular analysis of tumor biomarkers. Daniel
J. George,1 Jean-Francois Martini,2 Yen-Hwa Chang,3 Michael Staehler,4 Jan
Breza,5 Jean-Jacques Patard,6 Robert J. Motzer,7 Ahmed Magheli,8 Bernard Es-
cudier,9 Giacomo Carteni,10 Paola Gerletti,11 Sherry Li,2 Michelle Casey,12 Bri-
gitte Laguerre,13 Hardev S. Pandha,14 Allan J. Pantuck,15 Anup Patel,16 Maria
Lechuga,11 Alain Ravaud17. 1Duke Cancer Center, NC; 2Pfızer Inc, CA; 3Taipei
Veterans General Hospital, Taiwan; 4Hospital of Munich, Germany; 5Slovak
Medical University, Slovakia; 6Bicêtre Hospital, France; 7Memorial Sloan Ketter-
ing Cancer Center, NY; 8Charité Universitaetsmedizin Berlin, Germany; 9Institut
Gustave Roussy, France; 10Azienda Ospedaliera di Rilievo Nazionale A.
Cardarelli, Italy; 11Pfızer, Italy; 12Pfızer Inc, PA; 13Centre Eugene Marquis,
France; 14University of Surrey, UnitedKingdom; 15Ronald ReaganUCLAMedical
Center, CA; 16Spire Roding Hospital, United Kingdom; 17Bordeaux University
Hospital, France.
Background: Adjuvant therapy with sunitinib (SU) compared with pla-
cebo (PBO) prolonged disease-free survival (DFS) in patients (pts) with
loco-regional high-risk renal cell carcinoma (HR0.76, 95% CI: 0.59-0.98;
P0.03; median[m] DFS, 6.8 vs 5.6 years). Here, we report the results of a
retrospective exploratory molecular biomarker analysis using nephrectomy
biospecimens from the S-TRAC trial. Materials and Methods: Formalin-
fıxed paraffın-embedded tumor tissue blocks from patients who provided
informed consent were used for immunohistochemistry (IHC) staining of
PD-L1, CD4, CD8, and CD68. Biomarker quantifıcation was done by auto-
mated image analysis of the regions of interest (ROI). The analysis algorithm
utilized an immunoscore approach applied to ROI, reflecting assessment of
both the center and invasive margin of tumors (for PD-L1 and CD8 stain-
ing). DFS was compared between biomarker stratum by  median vs 

median values of a particular IHC parameter using Kaplan-Meier (K-M)
analysis. Receiver Operating Characteristics (ROC) curves were generated to
further assess the potential clinical utility of biomarkers for which signifıcant
(P  0.05) results were obtained in K-M analysis. Results: In total, 191/615
(101, SU and 90, PBO) pts in the intent-to-treat population were included for
IHC analysis. Baseline characteristics were similar in the subpopulations
with and without IHC data. Shorter DFS was observed in the PBO group for
pts with PD-L1 vs PD-L1 tumors, although not statistically signifıcant
(HR1.75; 95% CI: 0.89-3.46; P0.103). In pts with PD-L1 tumors, DFS
was numerically longer for SU vs PBO (mDFS6.17 vs 2.67 years)
(HR0.58; 95% CI: 0.26-1.29; P0.175). In the SU group, pts with CD8
T-cell density 
 median (cutoff269.5 CD8 cells/mm2) had longer DFS
(mDFSnot reached [NR]; 95% CI: 6.83-NR) than pts with CD8 T-cell
densitymedian (mDFS3.47 years; 95% CI: 1.73-NR), and the difference
was statistically signifıcant (HR0.40, 95% CI: 0.20-0.81; P0.009), while
CD8

T-cell density showed no signifıcant difference in DFS for PBO pts
(HR0.80, 95% CI: 0.42-1.50; P0.484). The sensitivity and specifıcity for
CD8 T-cell density in predicting DFS were 0.604 and 0.658, respectively,
and the optimal cutoff was 222.22 cells/mm2 with an area under ROC curve
of 0.622. Conclusions: Increased density of CD8 T-cells in tumor tissue was
associated with longer DFS in SU-randomized pts but not PBO, suggesting
this may be predictive of treatment effect. Further validation in an indepen-
dent cohort is warranted. The prognostic value of PD-L1 expression in pri-
mary tumors from patients with high-risk non-metastatic RCC should be
further explored.
#1772 PIK3CA C2 domain deletions hyperactivate PI3K, generate onco-
gene dependence and are exquisitely sensitive to PI3K inhibitors. Sarah
Croessmann,1 Jonathan Sheehan,1 Gregory Sliwoski,1 Nalin Leelatian,1 Jie He,2
Rebecca Nagy,3 Justin M. Balko,1 Ingrid A. Mayer,1 Richard B. Lanman,3 Vin-
cent Miller,2 Lewis C. Cantley,4 Jonathan M. Irish,1 Jens Meiler,1 Carlos L.
Arteaga1. 1Vanderbilt University, Nashville, TN; 2Foundation Medicine, Cam-
bridge, MA; 3Guardant Health, Inc., Redwood, CA; 4Meyer Cancer Center of
Weill Cornell Medical College, New York, NY.
Background: A 63 year old postmenopausal woman with advanced ER
breast cancer resistant to endocrine therapy exhibited an exceptional response to
the PI3K inhibitor alpelisib (BYL719) and the aromatase inhibitor letrozole
(Mayer et al. Clin Cancer Res 2016). Targeted capture next generation sequence
(NGS) of DNA from a liver metastasis identifıed a P447_L455 deletion in the C2
domain of PIK3CA. About 80% of PIK3CA activating mutations are in ’hot
spots’ within the helical and kinase domains. C2 domain mutations make up
10% of all PIK3CAmutations in breast cancer (TCGA, FoundationMedicine)
and are frequently not reported by tumor andplasma cell-freeDNANGSpanels.
Deletions andmutations in this domain cluster in a region encompassing amino
acids 446-460 of PIK3CA.We investigated herein the functional role of PIK3CA
C2 domain mutations and their response to PI3K inhibitors. Methods: V5-
tagged lentiviral vectors encoding wild type, delP447-L455, and delH450-P458
were stably transduced intoMCF10A non-tumorigenic human breast epithelial
cells. Cell viability and acini formation in 3DMatrigel were examined in media
	 EGF or insulin or alpelisib. Markers of PI3K activation were examined by
immunoblot and phosphoflow analysis. The Rosetta software suite was used to
construct a structural model that would predict the change in stability of the
p85/p110 complex. Physical association of p85 and p110was determined by
precipitation with V5 antibodies and immunoblot analysis. Results: MCF10A
cells stably expressing V5-tagged PIK3CAdelP447-L455 and PIK3CAdelH450-P458
exhibited EGF- and insulin-independent growth and higher phosphorylation of
AKT, ERK and S6 when compared to parental MCF10A cells. In 3D Matrigel,
MCF10A cells with PIK3CA C2 domain deletions formed invasive acini with
increased protrusions, spindling, and bridging between acini. All these changes
were ablated upon the addition of 1 M of alpelisib whereas parental MCF10A
cells were unaffected by alpelisib. We hypothesized that delP447-L455 would
reduce the binding affınity of p110with the p85 regulatory subunit of PI3K. A
structural model of PIK3CAdelP447-L455 in the context of the regulatory complex
revealed specifıc favorable inter-residue contacts that would be lost as a result of
the deletion, predicting a signifıcant decrease in binding energy. Consistent with
this structural analysis, coimmunoprecipitation of p85 with V5 antibodies
showed reduced binding of the C2 domain deletionmutants with p85 compared
towild type p110. Conclusions: These data suggest that C2 domain deletions in
PIK3CA are activating mutations and generate oncogene dependence. As a re-
sult, tumors expressing these mutations are exquisitely sensitive to PI3K in-
hibitors. Thus, in addition to PIK3CA ’hot spot’ mutations, C2 domain muta-
tions should also be considered biomarkers of sensitivity to PI3K inhibitors.
#1773 A baseline IFNG gene expression signature correlates with clinical
outcomes in durvalumab-treated advancedNSCLC cancer patients. Brandon
W. Higgs, Chris A. Morehouse, Katie Streicher, Philp Z. Brohawn, Keith Steele,
Marlon Rebelatto, Fernanda Pilataxi, Carlos Bais, Li Shi, Xiaoping Jin, Joyce
Antal, Ashok Gupta, Koustubh Ranade.MedImmune, Gaithersburg, MD.
Durvalumab (D) is a human IgG1monoclonal antibody which inhibits PDL1
binding to PD-1 and CD80, restoring antitumor immunity. In D-treated (tx)
NSCLC patients (pts), we previously reported high baseline levels of tumoral
PD-L1 protein and IFN mRNA expression associated with improved ORRs,
PFS andOS.Here, a gene expression signature of baseline tumors associateswith
improved outcomes on D. CP1108/NCT01693562 was a nonrandomized phase
1/2 trial evaluating D in advanced previously tx NSCLC or other solid tumors.
By 29APR2016, 304 NSCLC pts received 10mg/kg Q2W of D12months with
median 18.8 months follow up. RNA sequencing of frozen biopsies was con-
ducted on 97NSCLC tumors of suffıcient quality withmatched IHC for tumoral
PD-L1 on 92 fresh or archival biopsies. Among 21 pre-identifıed immune-re-
lated genes,mRNAs for IFNG, LAG3,CXCL9, andPDL1 individually correlated
best with outcomes in NSCLC after adjustment for sex, age, prior therapy, his-
tology, ECOGand smoking. A signaturewas developed asmeanmRNA levels of
the four genes; signatures upper tertile were IFNG signature positive (IF-
NGS). Analysis was performed on NSCLC, then applied to 30 available
urothelial bladder cancer (UBC) biopsies. NSCLC with 
25% tumor cells
stained for PD-L1 at any intensity were PD-L1. 29 NSCLC had pre/post-
treatment tumors for mRNA analysis. KM and Cox PH models were used. IF-
NGS D-tx NSCLC pts had higher ORR, median PFS and OS compared to
PDL1, PDL1-, and IFNGS- pts (Table 1); IFNGS UBC D-tx pts also corre-
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lated with these outcomes. Following D treatment, IFNGS was induced in
NSCLC pts (FC2; p0.0046) regardless of clinical response. High levels of
pre-treatment IFNGS in NSCLC pts associated with greater benefıt from D. D
induces IFNGS within the tumor microenvironment. Observations from other
tumor types will be presented.
Table 1. Clinical outcomes by IFNGS or PD-L1 status
# Pts
(# events
[OS;PFS])
ORR %
(95% CI)
Median
OS months
(95% CI)
OS
adjusted
HRa; p
Median
PFS
months
(95% CI)
PFS
adjusted
HRa; p
NSCLC
IFNGS 32
(16;21)
37.5
(21.7,56.3)
24.6
(10.3,NA)
0.42;
0.0082
7.5
(3.6,NA)
0.32;
0.00028
IFNGS- 65
(40;51)
6.2
(2.0,15.8)
6.5
(4.8,15.7)
1.4
(1.4,2.6)
PDL1 TPS25% 38
(18;25)
28.9
(16.0,46.1)
20.5
(6.6,NA)
0.53;
0.0788
3.6
(1.7,14.6)
0.60;
0.0823
PDL1 TPS25% 54
(35;43)
7.4
(5.8,25.5)
9.1
(5.4,21.1)
1.5
(1.4,3.9)
NRNot Reached; NANot Applicable; aAdjusted for covariates. TPS tumor propor-
tion score Ventana SP263 assay
#1774 Progression-free survival curves suggest a dichotomous determi-
nant of PD-L1 inhibitor effıcacy. David J. Stewart,1 Dominick Bosse,2 Stepha-
nie Brule,1 Andrew G. Robinson,3 Michael Ong,1 John F. Hilton1. 1University of
Ottawa, Ottawa, Ontario, Canada; 2Harvard University, Boston, MA; 3Queen’s
University, Kingston, Ontario, Canada.
Background: PD-L1 expression varies across tumors but does not accurately
predict PD-L1 inhibitor effıcacy. Some negative tumors respond and some pos-
itive tumors fail. PD-L1 inhibitor progression-free survival (PFS) curve shape in
non-small cell lung cancer (NSCLC) suggests that a dichotomous (present vs
absent) factormight drive sensitivity rather than it being driven by a continuous
variable like PD-L1 expression. PFS curves may follow fırst order kinetics, with
a straight line if log % PFS is plotted vs time. If the population had 2 distinct
subgroups with differing rates of progression then one would expect an inflec-
tion point on the log-linear curve, and the curve would fıt a 2-phase decaymodel
in nonlinear regression analysis (NLRA). A more homogeneous population
would not fıt a 2-phase model. Methods: We used arohatgi.info/WebPlotDigi-
tizer/app/ to digitize published PFS curves, then GraphPad Prism5 for 2-phase
NLRA, with the constraints Y0100, plateau0. To generate standardized
2-phase curves, we utilized 1) unselectedNSCLCpatients treatedwith epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) where we ex-
pected a high proportion of curves to fıt a 2-phase model as only some patients
would have a sensitizingEGFRmutation; 2)NSCLCEGFRmutant andwild type
(WT) patients treated with EGFR TKIs, and patients treated with platinum-
based chemotherapy, taxanes or placebo/best supportive care (BSC), where we
expected a lower proportion of curves to fıt 2-phase models; 3) PD-L1 PFS
curves inNSCLCandother tumor types. Results:With EGFRTKIs in unselected
patients, 58 of 79 (73%) curves were fıt by 2-phase models, vs 5 of 37 (14%) with
EGFR TKIs in EGFR mutant patients (p0.0001), 13 of 27 (48%) in EGFRWT
patients (p0.02), 4 of 37 (11%)with platinum-based therapy (p0.0001), 15 of
47 (32%) with a taxane (p0.0001), and 6 of 22 (27%) with placebo/BSC
(p0.0001).With PD-L1 inhibitors inNSCLC, 30 of 32 (94%) curves fıt 2-phase
models (p0.0001 vs each of EGFR TKIs in EGFR mutants, EGFR WTs, plati-
numand taxane chemotherapy and placebo/BSC). In other tumor types, 27 of 32
(84%) PD-L1 curves fıt 2-phasemodels. Conclusions:Most PD-L1 inhibitor PFS
curves fıt a 2-phase model. This is similar to what we observed with EGFR TKIs
in unselected patients and different from EGFR TKIs in EGFR mutant andWT
patients, and from chemotherapy or placebo/BSC. This leads us to hypothesize
the existence of a dichotomous (present vs absent) factor such as a gene muta-
tion, deletion or silencing that sensitizes tumors to PD-1/PD-L1 inhibitors. If
found, such a dichotomous factor could prove to be a highly useful biomarker
that could permit accurate prediction of PD-1/PD-L1 inhibitor effıcacy. Since
PD-1/PD-L1 inhibitor effıcacy is higher in tumors with high PD-L1 expression,
any sensitizing dichotomous factor might also drive PD-L1 expression.
#1775 The interaction of PD-L1, TMB, and genomic alterations in
NSCLC. Michael E. Goldberg, Laurie M. Gay, David Fabrizio, Garrett M.
Frampton, Julia A. Elvin, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens,
Lee A. Albacker. Foundation Medicine, Inc., Cambridge, MA.
Introduction: In a cohort of non-small cell lung cancers (NSCLC), we identify
new potential biomarkers that may predict response to checkpoint inhibitors
through an analysis of genomics, PD-L1 protein expression, and tumormutational
burden (TMB).Motivation: In cancer therapy, anti-PD-1/PD-L1 checkpoint inhib-
itors provide long term responses in a subset of patients. The current biomarker,
PD-L1IHC, isonlypartially successful in identifying responders.TMB,ameasureof
the number of mutations in a tumor’s genome, is an emerging biomarker that can
predict response rates to checkpoint inhibition in addition to PD-L1 IHC. Higher
TMB is thought to confer a higher probability of expressing a neoantigen protein
recognizable by the immune system as non-self and therefore responding to check-
point inhibition.While TMB represents the likelihood that tumor cells express im-
mune-triggering neoantigens, PD-L1 expression represents one of many ways a
tumor can evade immune response. We investigated the patterns of PD-L1 IHC
staining and TMB in NSCLC. Methods: We tabulated PD-L1 IHC stain statuses,
TMB, and genomic alterations for 789 unique NSCLC tumor samples. Tumor cell
PD-L1 expression was measured by IHC and scored for distribution (0, 1-24%,
24% of cells) and intensity (0, 1, 2) as Negative, Low Positive, or High Positive.
Samples were tested with a comprehensive genomic profıling assay that identifıes
alterations in exons and select introns in405genes.TMBwas calculatedover 1.1Mb
by counting somatic, non-driver genomic alterations and scored as Low ( 6mut/
Mb),Medium(20,
6mut/Mb), orHigh (
20mut/Mb).Results: PD-L1 tumor
staining was signifıcantly correlated with TMB (P 3.52e-4), although the correla-
tion was not strong (Spearman’s rho 0.12). To better explain discordant TMB/
PD-L1,we ran Fisher’s exact tests to identify genes enriched for alterations inTMB-
High/PDL1-Negative or TMB-Low/PD-L1-High Positive samples. The TMB-
High/PD-L1-Negative subset preferentially harbored STK11 loss-of-function
alterations with an odds ratio of 3.65 (P  1.20e-3). The TMB-Low/PD-L1-High
Positive subset exhibited enrichment forBRAFalterationswith anodds ratio of 5.46
(P  1.71e-3). Conclusions: TMB-High tumors have high immunogenicity and
often rely onPD-L1 expression as ameans of immune evasion.Alterations inBRAF
and other genes enriched in TMB-Low/PDL1-High Positive samples may trigger
immune responsesmoderatedbyPD-L1 expression. Sampleswith these alterations,
although often TMB-Low, may nevertheless respond to checkpoint inhibitors. Al-
terations in STK11 and other genes enriched in TMB-High/PD-L1-Negative sam-
ples may be implicated as non-PD-L1-basedmechanisms for immune evasion. Al-
though furtherongoinganalysis is required,our studysuggests that thecombination
ofTMB, PD-L1 staining, and genomicsmayprovide the best prediction of response
to checkpoint inhibitors.
#1776 Impact of homologous recombination defıciency (HRD) biomark-
ers on outcomes in triple-negative breast cancer (TNBC) patients treated
with AC chemotherapy (SWOG S9313). Priyanka Sharma,1 William Barlow,2
AndrewK.Godwin,1HarshPathak,1Kamilla Isakova,1AnneR.Hartman,3Kris-
ten M. Timms,3 Hannah M. Linden,4 Debu Tripathy,5 Gabriel N. Hortobagyi,5
Daniel F. Hayes6. 1University of Kansas Medical Center, Westwood, KS; 2SWOG
Statistical Center/Cancer Research and Biostatistics (CRAB), Seattle, WA; 3Myr-
iad Genetics, Inc., Salt Lake City, UT; 4University of Washington/Seattle Cancer
Care Alliance, Seattle, WA; 5The University of Texas MD Anderson Cancer Cen-
ter, Houston, TX; 6University of Michigan, Ann Arbor, MI.
Introduction: There is a critical need to develop biomarkers of response and
resistance to adjuvant chemotherapy for TNBC. In preliminary studies, homol-
ogous recombination defıciency (HRD)-causing alterations have been reported
in TNBC patients. HRDmay impact response to standard chemotherapy as well
as investigational therapies, such as PARP inhibitors and platinum agents. We
report on the prognostic impact of two such markers in a large cohort of early
stage TNBCpatients whowere uniformly treatedwith adjuvant doxorubicin (A)
and cyclophosphamide (C). Aims: To investigate BRCA1 promotermethylation
(PM) and HRD score as prognostic markers in TNBC patients treated with
adjuvant AC on S9313. Methods: SWOG protocol S9313 accrued 3,125 women
with early stage breast cancer to two alternative dose schedules of AC with no
difference in outcomes between the two arms (J ClinOncol 2007).We identifıed
425 (14%) patients with centrally determined TNBC status for whom tissue was
available. BRCA1 PM (methylation specifıc PCR) andHRD score (composite of
loss of heterozygosity, telomeric allelic imbalance and large-scale state transi-
tions, Myriad Genetics Inc.) were performed on genomic DNA isolated from
pre-treatment FFPE breast tumor tissue. HRD was classifıed as positive if there
was either a deleterious tumor(t) BRCA1 or BRCA2 mutation and/or a pre-
defıned HRD score 42. The markers were tested for prognostic effect on DFS
and OS using a Cox regression model with adjustment for randomized treat-
ment assignment. Results: For 425 TNBC patients median age was 45 years
(range 22-74) and at a median follow up of 10.2 years there are 166 DFS and 129
OS events (5 year DFS and OS  74% and 82%, respectively; 10-year DFS and
OS  66% and 73%). BRCA1 PM was determined in 82% (348/425) and was
detected in 32% of patients. Presence of BRCA1 PM was suggestive of better
DFS, but not statistically signifıcant (HR0.74; 95% CI 0.50-1.08, p0.12).
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HRD results were determined in 91% (379/425) and 67% were HRD positive
(27% with tBRCA mutation and 40% tBRCA negative but HRD score 42).
HRD positive status was associated with a better DFS (HR  0.69; 95% CI
0.49-0.96 (p0.027)) and OS (HR 0.67; 95% CI 0.47-0.97 (p0.032)). High
HRD score (
42) in tBRCA negative patients (n274) was also associated with
better DFS (HR 0.62; 95% CI 0.42-0.92). tBRCA status (positive versus nega-
tive) did not impact DFS (p 0.78). Conclusions: Two thirds of TNBC patients
receiving adjuvant AC chemotherapy had tumor HRD positivity. HRD was as-
sociated with better DFS and OS, perhaps due to high responses to AC. HRD
status has the potential to be used as a selection criterion to identify TNBC
patients who receive signifıcant benefıt from anthracycline chemotherapy, and
may also be of value in selecting patients suitable for treatment with other DNA
damaging agents like platinum salts/PARP-inhibitors.
#1777 Development of apan-cancer 15 gene expression signature todetect
a subgroup driven by MAPK signalling. Laura A. Knight,1 Bethanie Price,1
AndrenaMcCavigan,1AyaEl-Helali,2 CharlieGourley,3Denis P.Harkin,4 Rich-
ard Kennedy,2 Nuala McCabe2. 1Almac Diagnostics Ltd, Craigavon, United
Kingdom; 2Queens University Belfast, Belfast, United Kingdom; 3Edinburgh Can-
cer Research Centre, United Kingdom; 4Almac Diagnostics Ltd, United Kingdom.
INTRODUCTION: Unsupervised hierarchical clustering of gene expression
data from 265 High Grade Serous Ovarian Cancer (HGSOC) patients identifıed
3 major molecular subgroups. One subgroup is driven by activation of the
MAPK pathway and is associated with poor prognosis and resistance to plati-
num chemotherapy. The MAPK pathway is currently being targeted by novel
therapeutics and hence an assay to detect activation of the pathway across can-
cers would be highly valuable as a clinical trial enrichment tool. Using internal
and publicly available gene expression datasets we have demonstrated that the
MAPK subgroup also exists in other cancer types and is associated with poor
prognosis. The aim of this study was to develop a gene expression signature to
predict the MAPK subgroup across multiple cancer types. METHODS: Evalua-
tion of gene expression data in a range of tumours (ovarian, colon, lung, mela-
noma and prostate) identifıed a common gene list (CGL) of 7802 genes showing
high variability and high expression across diseases. The CGL was input to
different machine learning algorithms developing signatures under 10x5-fold
cross-validation (CV), trained against theMAPKHGSOC subgroup. Filter-Fea-
ture-Selection removed 10% of genes under CV based upon ranked correlation
adjusted t-scores and the fınal model selected to satisfy a number of key criteria:
AUC for predicting the endpoint; associationwith survival (C-Index); and func-
tional relevance of signature content. RESULTS: A 15 gene signature was se-
lected, yielding an AUC0.87 [95% CI:0.84-0.89] with respect to the MAPK
subgroup. Thismodel has validated as a poor prognosticmarker in several other
cancer types (Colorectal, Relapse free survival: HR1.46 [95% CI:1.07-1.98];
Lung, Relapse free survival: HR2.18 [95% CI:1.33-3.56]; Prostate cancer, Bio-
chemical recurrence: HR 2.49 CI: 1.43-4.34), and is suppressed by MEK inhibi-
tion (p0.0023) and elevated by KRAS, NRAS andMEK1 overexpression in cell
line models (p0.0443, 0.0001and 0.0001). Additionally we have demon-
strated that the 15 gene signature strongly predicts response to the MEK inhib-
itors Trametinib and Selumetinib in established cell line models (p0.001) and
in primary cells isolated from breast and ovarian patients. CONCLUSION: A 15
gene signature has been developed from formalin fıxed paraffın embedded sam-
ples across multiple diseases to detect a molecular subgroup driven by MAPK
signalling. This assay predicts sensitivity toMEK inhibitors in pre-clinicalmodel
systems and in primary cells derived from patients. Further work aims to vali-
date the signature in clinical samples frompatients treatedwith aMEK inhibitor.
This assay may be helpful for clinical trial enrichment to select patients that are
likely to benefıt from MAPK targeted therapies.
#1778 A clinical genomic biomarker study of the CHK1 inhibitor prexas-
ertib in advanced head and neck squamous cancer and squamous cell carci-
noma of the anus. Ricardo Martinez,1 Sameera R. Wijayawardana,1 David
Hong,2 Johanna Bendell,3 Anna Maria Russell,4 Richard P. Beckmann,1 Aimee
Bence Lin1. 1Eli Lilly and Company, Indianapolis, IN; 2MD Anderson Cancer
Center, Dallas, TX; 3Tennessee Oncology, Nashville, TN; 4Eli Lilly and Company,
San Diego, CA.
CHK1 plays a critical role in DNA damage repair (DDR) pathways as well as
in coordinating DNA replication. Selective CHK1/CHK2 compounds are being
tested in clinical trials but predictive biomarkers of patient response are lacking.
A phase 1b expansion cohort study (I4D-MC-JTJA, NCT01115790) with the
CHK 1 inhibitor, prexasertib, included patients with advanced, metastatic head
and neck squamous cell carcinoma (HNSCC) or squamous cell carcinoma of the
anus (SCCA). To identify genomic biomarkers associated with single-agent
drug response, pre-treatment tissues (archived or biopsy) from 71 consented
patients (HNSCC47, SCCA24) were subjected to next-generation sequenc-
ing (NGS) using the FoundationOne gene panel. In this subset of patients, the
disease control rate (DCR) (Complete Response (CR) Partial Response (PR)
 Stable Disease (SD) based on RECIST Criteria (v 1.1)) was 60% (28/47) and
75% (18/24), respectively. We present here the observed genetic alterations cor-
responding to three pathways, Cell Cycle, DNA Damage Repair (DDR) and
PI3K. In addition, patients’ human papillomavirus (HPV) carrier status was
inferred fromDNA sequencing using HPV-specifıc capture probes. HPVwas
47% forHNSCC and 87% for SCCA.HPV and TP53mutations weremutually
exclusive across the two patient cohorts. In HNSCC patients with evaluable
progression-free survival (PFS) data, greater clinical effıcacy was observed in the
HPV cohort (median PFS: 4.5 vs 1.4 months, log-rank p 0.0008). Known or
likely loss-of-function (LOF) mutations in FBXW7 and PARK2, two genes im-
plicated in Cyclin E1 proteolysis, were noted in patients with favorable response
in both tumor types. Across bothHNSCC and SCCA cohorts, mutations and/or
germline variants in theDDRgenes BRCA1, BRCA2,MRE11A andATRbut not
in Fanconi (FANC) pathway genes, were found in patients with treatment ben-
efıt. Whereas PIK3CA mutations were infrequent in the HNSCC cohort, in
SCCA, mutations occurred in 5/8 (63%) patients with disease control vs 1/6
(17%)with PD.All 7 PI3KCAmutations observed inHPVHNSCC and SCCA
patients mapped to the helical domain suggestive of Apobec-induced mutagen-
esis as their source of origin. The enhanced clinical benefıt to prexasertib asso-
ciated with HPV in HNSCCmay reflect a prognostic effect. Alternatively, the
clinical biomarker fındings may support the hypothesis that oncogene-induced
replication stress (RS) (i.e. arising fromHPV E6/E7 and/or FBXW7 loss-depen-
dent Cyclin E1 dysregulation) in the context of attenuated DDR (i.e. BRCA1/2,
MRE11A mutations) may sensitize patients to prexasertib monotherapy.
#1779 Chronic NSAID use increases survival in PIK3CA-altered head and
neck squamous cell carcinoma.Matthew Louis Hedberg,1 Noah Peyser,2 Wil-
liam Gooding,1 Hua Li,2 Toni Brand,2 Victor Olivas,2 Trever Bivona,2 Simion
Choisea,1 Lin Wang,1 Jonas Johnson,1 Uma Duvvuri,1 Robert Ferris,1 Daniel
Johnson,2 Patrick Ha,2 Julie Bauman,3 Jennifer Grandis2. 1University of Pitts-
burgh School of Medicine, PA; 2University of California San Francisco, CA; 3Uni-
versity of Arizona Cancer Center, AZ.
Background: PIK3CA is the most commonly altered oncogene in head and
neck squamous cell carcinoma (HNSCC). Chronic non-steroidal anti-inflam-
matory (NSAID) use has been shown to reduce mortality in PIK3CA-mutated
colorectal cancer through an unknownmechanism. In this retrospective cohort
analysis, we evaluated the impact of NSAIDs on HNSCC survival, and sought a
biologically plausible explanation for the observed effect.Methods: ThePIK3CA
status of tumor tissue was determined by FISH and next generation sequencing
for 266HNSCCpatients treated at theUniversity of PittsburghCancer Institute.
Cox joint proportional hazards models were used to generate multivariate pro-
jections of disease-specifıc (DSS) and overall survival (OS). Prostaglandin E2
(PGE2) secretion and NSAID sensitivity were then assessed in HNSCC cell lines
with or without PIK3CAmutation. Results: Chronic NSAID use (
2 days/week
for
6 months) was associated with greater disease-specifıc (HR 0.24; 95% CI,
0.09 - 0.62; p 0.0032) and overall survival (HR 0.31; 95% CI, 0.14 - 0.69; p
0.0043) in patients whose tumors harbor PIK3CA mutation and/or amplifıca-
tion. Survival was unchanged by chronic NSAID use in patients with wild-type,
unamplifıed PIK3CA. Chronic NSAID users with PIK3CA-altered tumors had
an increase in estimated 5-year DSS from 25% to 72% and in OS from 45% to
78%. Benefıt was independent of age, stage, and human papillomavirus (HPV)
status; all of which were controlled for in the model. HNSCC cells with endog-
enous or engineered PIK3CAmutation secreted higher levels of PGE2 and were
more sensitive to growth inhibition byNSAID treatment. Conclusions: Chronic
NSAID use was associated with markedly improved survival in patients with
PIK3CA-alteredHNSCC, but not in thosewithwild-type, unamplifıed PIK3CA.
Preclinical studies implicate the PI3K-COX-PGE2 signaling axis as a potential
mediator of NSAID response. A prospective, randomized controlled trial of
NSAIDs in patients with PIK3CA-altered HNSCC is warranted.
#1780 Identifying preclinical predictive biomarkers to taselisib in breast
cancer cell lines. Heidi M. Savage, Heather M. Moore, Carol L. O’Brien, Wei
Zhou, Ciara Metcalfe, Mark R. Lackner, Timothy R. Wilson. Genentech, Inc.,
South San Francisco, CA.
The phosphoinositol-3-kinase (PI3K) signaling pathway is one of the most
frequently activated pathways in cancer, and controls critical cellular processes
such as proliferation, transcription and survival. Taselisib (GDC0032) is an
orally bioavailable, potent, and selective inhibitor of Class I PI3K alpha, delta,
and gamma isoforms, with 30fold less inhibition of the PI3K beta isoform rela-
tive to the PI3K alpha isoform. Previously published data demonstrated that
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taselisib has increased activity against PIK3CA mutant cancer cell lines (Ndu-
baku CO et al, J Med Chem, 2013). A panel of 50 breast cancer cell lines were
profıled for sensitivity to taselisib using viability assays and subsequently corre-
lated with PIK3CAmutations and expression of ER, PR, HER2 and PTEN. The
PIK3CA mutant cell lines displayed an average of 30-fold greater sensitivity in
IC50 compared to the PIK3CA wild-type cell lines. PTEN null cell lines were
largely refractory to taselisib.Within the PIK3CAwild-type cell lines, the HER2
amplifıed cells showed an average of 18-fold greater sensitivity in IC50 over the
HER2 wild-type cell lines. No differences in taselisib sensitivity were seen be-
tween the kinase, helical, or the C2 domain of the PIK3CA gene within the
PIK3CA mutant cell lines. In HER2 amplifıed PIK3CA wild-type cell lines, ta-
selisib did not fully suppress pAKT and pS6 signaling, however full suppression
was observed in combination with the HER2 inhibitor, lapatinib. Increased ap-
optosis was observed with the combination of taselisib and lapatinib in the
HER2 amplifıed, PIK3CA mutant cells, but not in HER2 amplifıed, PIK3CA
wild-type cells. In PIK3CA mutant luminal cell lines, taselisib induced ESR1
transcriptional activity, but not in PIK3CA wild-type luminal lines, as assessed
using PR, GREB1 and IGFBP4 gene expression. This induction was ER- and
estradiol-dependent, and was suppressed using the estrogen degrader, fulves-
trant. Lastly, as up to 40% of ER, second line PIK3CA mutant metastatic
tumors have been shown to harbor a mutation in the ESR1 gene (Spoerke JM et
al., Nat Commun, 2016), we assessed the crosstalk between the PI3K and ER
pathways in PIK3CA mutant MCF-7 cells that overexpress two ESR1 hotspot
mutations. These ESR1 mutant cell lines displayed increased ER transcriptional
activity, which was further activated by taselisib, an observation that was re-
versedwith fulvestrant co-treatment. These data suggest that the combination of
taselisib and an estrogen degrader can suppress crosstalk between PI3K and ER
in both an ESR1 mutant and wild-type background, and supports the ongoing
SANDPIPER study of taselisib in combination with fulvestrant in metastatic
ER, PIK3CA mutant cancers that have progressed following an aromatase
inhibitor therapy (NCT02340221).
#1781 EGFR amplifıcation-A candidate predictive biomarker of PARP
inhibitor Talazoparib sensitivity in gliomas. ShaofangWu,1 Feng Gao,1 Xiao-
long Li,1 Jie Ding,1 Siyuan Zheng,1 Emmanuel Martinez-Ledesma,1 Ningping
Feng,1 Erik Sulman,1 Roel Verhaak,2 John de Groot,1 Dimpy Koul,1W.K.Alfred
Yung1. 1MD Anderson, Houston, TX; 2Jackson Laboratory, Farmington, CT.
Poly (ADP-ribose) polymerases (PARP) are enzymes involved in DNA-dam-
age repair. Inhibition of PARP is a promising strategy for targeting cancers with
defective DNA-damage repair. Several PARP inhibitors are currently in trials in
the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian,
BRCA-mutated breast, and other cancers. Glioma Stem Cells (GSCs) exhibit
higher oxidative base damage, single-strand DNA breaks and genomic instabil-
ity and is reliant on single-strand break repair/base excision repair to tolerate
additional stress. PARP critical for maintaining genomic stability by regulating
a variety of DNAdamage repairmechanisms is constitutively activated inGSCs.
In this study, we show that talazoparib – a unique PARP inhibitor exhibits a
strong single agent activity to inhibit proliferation of GSCs in vitro and suppress
tumor progression in GSCs xenografts. Talazoparib cytotoxic activity was
through inhibiting PARylation and by trapping PARP-DNA complexes result-
ing in accumulation of DNA damage during replication and ultimately leading
to apoptosis. More importantly, we found EFGR amplifıcation, which occurs in
about 45% of GBM as a biomarker of response to PARPi. Gene expression and
RPPA data showed that GSCs with EGFR amplifıcation were associated with
increasedROS, basal expression ofDNA repair proteins andmoreDNAdamage
following talazoparib treatment, which may partially explain the sensitivity of
this group of GSCs to talazoparib. EGFR enzyme activity was important for
PARPi sensitivity since kinase dead mutant of EGFR or EGFR knock down cell
lines were resistant to PARPi as was also shown by decreased PARP/DNA com-
plex formation. Talazoparib showed strong inhibition of tumor growth in sub-
cutaneous gliomamodel and 20% increase in median survival in an intracranial
model with a 10% blood brain penetration of talazoparib. These data provide
mechanistic insights into the anti-cancer activity of PARP inhibitors withmech-
anistic rationale of PARP inhibition and potential EGFR amplifıcation as bio-
marker in the development for precision cancer.
#1782 Reactive oxygen species (ROS) and mitochondrial DNA (mtDNA)
damage in tumor hypoxia, poor radiotherapy response, and metastatic pro-
gression of rectal cancer. Paula A. Bousquet,1 Sebastian Meltzer,1 Linda Søn-
stevold,1 Ying Esbensen,1 Lars G. Lyckander,1 Svein Dueland,2 Kjersti Flat-
mark,2 Kathrine R. Redalen,1 Lars Eide,3 Anne H. Ree1. 1Akershus University
Hospital, Lørenskog, Norway; 2Oslo University Hospital, Oslo, Norway; 3Univer-
sity of Oslo, Oslo, Norway.
Background: Hypoxia is an important feature of the tumor microenviron-
ment and correlates with radiotherapy resistance and metastatic progres-
sion. Additionally, as the malignant phenotype promotes aerobic glycolysis
and contributes to the microenvironmental acidifıcation, an underlying
mechanism in radiation resistance and metastasis is likely linked to meta-
bolic changes caused by mitochondrial reprogramming. We hypothesized
that ROS and mtDNA damage might be indicators of poor therapy response
and dissemination of rectal cancer. Methods: Three colorectal cancer (CRC)
cell lines (HCT116, HT29, LoVo) were cultured under hypoxia (0.2% O2) or
normoxia (21% O2) for 24 hours. In a prospective rectal cancer trial, serum
was sampled from patients at the time of diagnosis. Levels of ROS were
determined by the ability to oxidize dihydrochlorofluoroscein into a fluores-
cent derivative. mtDNA damage was quantifıed by the ability of modifıcation
on template DNA to inhibit restriction enzyme cleavage. For the study pa-
tients, histologic tumor response to neoadjuvant radiotherapy was evaluated
according to standard ypTN staging and tumor regression grade (TRG) scor-
ing. Groups were compared using Student’s t-test. Survival differences were
assessed by the log-rank test. Results: Compared to normoxic conditions,
hypoxia signifıcantly reduced ROS levels in all CRC cell lines. Moreover, in
serum samples, ROS levels were lower for T4 cases than for patients with
T2-3 disease (p  0.037), and accordingly, low circulating ROS was associ-
ated with adverse metastasis-free survival (MFS; p  0.004) and overall
survival (p 0.001). Hypoxic HCT116 and HT29 cell lines, but not the LoVo
cells, showed signifıcantly higher mtDNA damage than under normoxia.
Given the indicated dependence of ROS and mtDNA damage to hypoxia, a
low ratio of ROS to mtDNA damage turned out to be a promising indicator
of hypoxic CRC cells. This ratio was lower in serum samples from patients
who obtained poor histologic tumor response to radiotherapy (ypT3-4 ver-
sus ypT0-2 and poor versus good TRG; p  0.044 for both). Accordingly, a
high ratio of circulating ROS to mtDNA damage was associated with longer
MFS (p 0.021). Conclusion: We showed that culturing of CRC cells under
hypoxia caused decrease in ROS levels but increase in mtDNA damage.
Interestingly, in serum samples from rectal cancer patients, low ROS levels
were associated with T4 disease, representing a bulky and often hypoxic
tumor, and thus adverse survival. Moreover, low ratio of ROS to mtDNA
damage was correlated with poor histologic tumor response to neoadjuvant
radiotherapy. These parameters may reflect an aggressive biological pheno-
type instigated by a hostile tumor microenvironment. The results are cur-
rently under validation in an independent patient cohort. Trial registration:
NCT00278694.
#1783 Early detection of thymidylate synthase resistance in non-small cell
lung cancer with FLT-PET imaging. Xiao Chen, Yizeng Yang, Sharyn Katz.
Hospital of the University of Pennsylvania, Philadelphia, PA.
Background: Inhibition of thymidylate synthase (TS) results in a transient
compensatory “flare” in thymidine salvage pathway activity which is mea-
sureable with 18F-thymidine (FLT) positron emission tomography (PET) at
2 hrs of exposure to therapy. Here we examine the predictive value of the
FLT-PET measured “flare” for NSCLC sensitivity to pemetrexed, a com-
monly used TS inhibitor, in a preclinical model. Experimental Design: Re-
sistance to pemetrexed therapy was induced in two sensitive human NSCLC
cell lines, H460 and H1299, by overexpressing TS. TS overexpression was
confırmed with RT-PCR and Western blotting and pemetrexed-resistance
confırmed with IC50 assays. The presence of a pemetrexed-induced DNA
salvage pathway “flare” was thenmeasured using 3H-thymidine in both pem-
etrexed-sensitive (H460 and H1299) and resistant (H460R and H1299R)
lines in vitro, as well as inherently resistant NSCLC cell lines CALU6, H522,
H650, H661, H820, H1838, and validated with FLT-PET in vivo using H460
and H460R xenografts. Results: Overexpression of TS induced resistance to
pemetrexed in the H460 and H1299 with IC50 for H460, H1299, H460R and
H1299R measured as 0.141 M, 0.656 M, 22.842 M, 213.120 M, respec-
tively. Signifıcant increases in DNA salvage pathway activity (“flare”) was
observed at 2hrs of therapy in the pemetrexed-sensitive H460 and H1299
lines but not the resistant H460R and H1299R, CALU6, H522, H650, H661,
H820, H1838 cell lines in vitro using 3H-thymidine assays. Similarly, FLT
“flare” was observed in the pemetrexed-sensitive H460 xenograft tumors but
not the pemetrexed-resistant H460R xenograft tumors with post-therapy
increases in measured FLTmax of 58% (STD 12.1) and 10.8% (STD 7.3)
respectively. Conclusions: FLT-PET imaging of TS inhibition may provide
an early indicator of NSCLC sensitivity to pemetrexed.
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#1784 Early feasibility and development of multiplexed, single-reaction
assays for ALK, ROS1 and RET novel ddPCR RNA fusions. Hestia Mellert,1
Kristin Alexander,1 Leisa Jackson,1 Galen Roda,1 Samantha Cooper,2 Dianna
Marr,2 Stephen J. Jones,2 Nia Charrington,2 Gary Pestano1. 1Biodesix, Inc., Boul-
der, CO; 2Bio-Rad, Inc., Pleasanton, CA.
We have previously described a targeted genomic Laboratory Developed Test
(LDT) that includes variant specifıc Droplet DigitalTM PCR (ddPCR) testing for
EGFR, KRAS and BRAF in plasma. This test supports the rapid delivery of
molecular diagnostic test results, with95%of tests results delivered in 72hours
of receipt in our Laboratory. This test then meets the key clinical need for the
delivery of results that can result in faster treatment decisions. Additionally, the
test may be of utility for those patients who need mutation results quickly or for
whom tissue may be unavailable or insuffıcient for molecular testing. This is
especially true for patients diagnosed with non-small cell lung cancer (NSCLC).
In this report we will update on new test concepts created using the recently
available design software engine for ddPCR assays. Specifıcally, we will describe
studies on the development of single-reaction,multiplexed assays for the respec-
tive detection of ROS1 (up to 11 variants), RET (up to 8 variants) and EML4-
ALK (v1 - v3). Design considerations, specifıcity and sensitivity, as well as re-
producibility and robustness studies for these complex assays will be reviewed.
Similar studies were conducted for the development of the commercially avail-
able test for the EML4-ALK fusion variants. EML4-ALK concordance studies
compared the fusions found in blood with known positives and negatives found
using FISH and PCR based methods (n24 evaluable matched pair samples).
Clinical sensitivity, specifıcity and concordance were 85%, 100% and 92% re-
spectively. In this study we also report on test performance of the ALK RNA
fusion test over 3 consecutive months of testing. Of note, we have delivered
greater than 95% of tests (n  272 samples) with an observed positive sample
frequency of 2%. The robust detection of rare variant, RNA fusions from plasma
within 72 hours represents a molecular testing option of value to patients with
NSCLC and their physicians.
#1785 Technical validation of novel 325RNApredictive biomarkers using
gene expression data generated byNanostring n-counter andAffymetrixmi-
croarray.MarciaV. Fournier,1 SaidAttiya,1 JoanChen,2 JohnObenauer,2 Anup
Madan,3 Patricia Smith3. 1BioarrayGenetics, Inc., Farmington, CT; 2Rancho Bio-
sciences, San Diego, CA; 3Covance Genomics Services, Redmond, WA.
Background: With new developments of oncology drug combinations and
targeted treatments, the ability to stratify categories of patient populations and
to develop companion diagnostics has become increasingly important. A panel
of 325 RNA-biomarkers was selected based on cancer-related biological pro-
cesses of healthy cells and gene expression changes over time during non-ma-
lignant epithelial cell organization. This ‘cancer in reverse‘ approach in combi-
nation with empirically derived algorithms resulted in a panel of biomarkers
having little overlap with 9 other widely-used commercial gene panels analyzed
to date (e.g., overlap with FoundationOne was 2% (lowest) and with On-
cotypeDX was 14% (highest)), providing a more in-depth and comprehensive
view of gene expression profıles and key cellular signaling pathways beyond
mutations in ‘driver-genes‘, and drug associations including chemotherapies,
immunotherapies, and targeted-therapies. Objective: In order to technically val-
idate an assay for the 325 RNA-biomarkers we compared gene expression pro-
fıles side-by-side using two technology platforms to address the reproducibility
of the assay. Methods and Results: We have mapped the 325 RNA transcripts
and 7 housekeeping genes in a custom NanoString n-Counter expression panel
to be compared to all potential probe sets in the Affymetrix Human Genome
U133 Plus 2.0 microarray. The experiments were conducted with 10 unique
biological formalin-fıxed paraffın-embedded (FFPE) breast tumor samples.
Each site extractedRNA from four sections of 10-microns thick FFPE tissue over
three different days by three different operators using an optimized standard
operating procedure and quality control criteria. Samples were analyzed using
mas5 in BioConductor and NanoStringNorm in R. Pearson correlation showed
reproducibility between sites for all 60 samples with r0.995 for Affymetrix and
r0.999 for NanoString. Correlation in multiple days and multiple users were
for Affymetrix r(0.962-0.999) and for NanoString r(0.982-0.991). The plat-
formswere compared using relative expression fold changes using linear regres-
sion (lm). Concordant genes were defıned to have gene expression levels within
/ 2 standard deviation (sd) of each other at 95% confıdence interval, or to
have greater than / 2 sd but have changes in the same direction in both
platforms. The discordant genes were defıned to have opposite direction of
changes. By this defınition, approximately 90% of the genes fell into the concor-
dant category. Conclusion: The 325 RNA-biomarkers showed reproducibility in
two technology platforms with high concordance. With fıve predictive tests
under development for breast (3), lung and pancreatic cancers future directions
include performing clinical validation studies and generate rationale for patient
selection in clinical trials using the technically validated assays.
#1786 Predictive value of LRP8,KPNA2 andGDF15 expression to anthra-
cycline/taxane based chemotherapy response in patients with locally ad-
vanced breast cancer. Hector Maldonado-Mtz,1 Alonso-Luna Oscar,2 Ali
Flores-Perez,2 Meneses-Garcia Abelardo,1 Erika B. Ruiz-Garcia,1 Cesar Lopez-
Camarillo,3HoracioAstudillo-de laVega4. 1INCan,Mexico, DF,Mexico; 2Nano-
pharmacia Diagnostica, Mexico, DF, Mexico; 3UACM, Mexico, DF, Mexico;
4IMSS, Mexico, DF, Mexico.
Background: Chemotherapy plays a major role in its treatment, though over-
treatment is frequent since its choice is based on clinicopathological prognostic
data. The identifıcation and validation of new predictive profıles or markers
continues to be relevant.New fındingsmay contribute to achieve better results in
this area, as well as to provide new targets of the pathways involved in chemore-
sistance. Karyopherin 2 (KPNA2), low density lipoprotein receptor-related
protein 8 (LRP8) and growth and differentiation factor 15 (GDF15), are three
candidate predictive biomarkers in breast cancer, previously identifıed on DNA
microarrays reports. Methods: Using tissue microarrays technology and immu-
nohistochemistry, we compared the expression of these three markers between
cases of breast cancer with response to chemotherapy (absence of recurrence),
and those with failure (with recurrence). All patients received chemotherapy
based on anthracyclines and taxanes. Potential confounding factors, as known
recurrence and progression risk factors, were controlled for during the compar-
ison. Results: 20 out of 63 patients had tumor recurrence. Potential confounding
factorswere similar among caseswith response and failure to chemotherapy. For
KPNA2 no differences were found between cases with response or failure. LRP8
showed higher expression in cases with failure to chemotherapy (mean 7.22 vs
14.01%, p 0.025). In Cox multivariable regression analysis, which included
potential confounding factors as covariates, only LRP8 remained as a signifıcant
predictive factor (HR1.28, p0.016).GDF15 showedno expression in our cases,
nor in an external set of cases. Conclusions:We demonstrated increased expres-
sion of LRP8 in breast cancer cases recurring after chemotherapy. KPNA2 and
GDF 15 showed no predictive value for chemotherapy response in our study.
LRP8 is a potential predictivemarkerworth of further investigation for its role in
chemoresistance as well as for its potential validation.
#1787 miR-150 as a predictor of hematopoietic reconstitution after my-
eloablation.MarshleenYadav, ArnabChakravarti, Naduparambil K. Jacob.The
Ohio State University, Columbus, OH.
The identifıcation of biomarkers that allow evaluation of myeloablation and
hematopoietic reconstitution time frame is important for tailoring the radiation
or chemo therapy in cancer patients. The fate of hematopoietic cells is regulated
at multiple stages by various genes and regulatory microRNAs. In this context,
miR-150 has been demonstrated as a major regulator of lymphoid lineage dif-
ferentiation and development. Our mouse model studies shows a novel role of
miR-150 in imparting radiation resistance. We observed a prolonged survival
benefıt in mice where both the copies of miR-150 genes are deleted in compar-
ison to that of wildtype mice in the same C57BL/6 background (p0.05). The
survival benefıt after total body irradiationwas found to be associatedwith lower
apoptosis and early reconstitution in hematopoietic stem cells (lin-
ckitsca1/) in bone marrow. Furthermore, the recovery kinetics at sub le-
thal dose (6Gy) showed that HSCs inmiR-150/mice recovers faster. Myeloid
(Mac1Gr1) and lymphoid (CD45CD19) lineage cells reconstitutes
within 14 days after radiation in KO mice compared to 21 days or more in WT
mice.We observed a statistically signifıcant upregulation inmyeloid cells in KO
mice which implicates an early recovery from radiation induced neutropenia
and hence more survivability. In addition, the enhanced bonemarrow reconsti-
tution was reflected in peripheral blood counts where a noticeable difference
(p0.05) in blood RBCs lymphocytes, monocytes, neutrophils, and basophiles
were noted when compared sub lethally irradiated KO with WT mice. Alto-
gether we demonstrate that the level ofmiR-150 regulates the bonemarrow cells
distribution and hence could be targeted for achieving accelerated hematopoi-
etic recovery after myeloablation. These fındings may be translated to human
cancer patients for therapy guiding based on miR-150 expression level. Besides
its use in prediction of reconstitution, miR-150 in the circulating system could
provide a direct readout of functional marrow and hence hematological acute
radiation syndrome (H-ARS).
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#1788 Extra cellular micro vesicle (EMV) miRNA signature as putative
predictive biomarker for targeted therapy in stage IV cutaneous malignant
melanoma. Hanna Erikssom, Fernanda Costa Svedman, Warangkana Loh-
charoenkal,Matteo Bottai, Suzanne Egyhazi Brage, Enikö Sonkoly, JohanHans-
son, Andor Pivarsci. Karolinska Institutet, Stockholm, Sweden.
Purpose: Although therapies targeting mitogen activated-protein kinase
(MAPK)pathway induce rapid responses and improved survival in patientswith
disseminated BRAFV600 mutant cutaneous malignant melanoma (CMM), re-
missions are often shortn and resistance emerge. There is a need to identify
biomarkers predicting durable responses. We aimed to correlate the expression
of extracellular micro vesicle (EMV) microRNAs in plasma samples from stage
IV CMM patients receiving MAPK inhibitors (MAPKis) with treatment out-
come. Patients and methods: EMV miRNAs signatures analyzed with micro
array from plasma samples collected before and during therapy with MAPKi
were correlated to response and progression-free survival (PFS) in 28 Stage IV
CMMpatients treated at the Dept of Oncology, Karolinska University Hospital,
Sweden. Clinical parameters.i.e. sex, age, lactate dehydrogenase (LDH) levels,
before and during treatment, were also included. Results: High LDH levels be-
fore treatment were signifıcantly correlated with a PFS (Hazard Ratio (HR) 
2.088; 95% CI  (1.032, 4.226); P  0.041). Increasing expression of EMV
MiR-let-7g-5p during treatment was signifıcantly correlated to a lower risk of
not responding to MAPKIs(Odds ratio  0.0004, 95% CI  0.000 -0.207, P 
0.0001). High levels of MiR-497-5p in plasmatic EMV during therapy were
associated with lower risk of progressing during therapy (HR 0.27, 95% CI
0.13-0.52, P  0.0001). Conclusions: Our results indicate that assessing the
miRNAs Mir-let-7g-5p and miR-497- in samples collecting before and during
treatment may have a potential as predictive markers of treatment response and
PFS in Stage IV CMM patients with MPAKis.
#1789 A gene expression-based nomogram predicts overall and progres-
sion free survival in PRRT-treated gastroenteropancreatic neuroendocrine
tumors.Mark Kidd,1 Lisa Bodei,2 Stefano Severi,3 Ignat Drozdov,1 Sylvia Nico-
lini,3 Giovanni Paganelli,3 IrvinM.Modlin4. 1Wren Laboratories, Branford, CT;
2Memorial Sloan Kettering Cancer Center, New York, NY; 3Istituto Scientifıco
Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy; 4Yale
University, New Haven, CT.
Background: Nomograms and grading/staging systems are fundamental in
guiding oncology disease management. Histological grading has effıcacy in the
management of gastroenteropancreatic neuroendocrine tumors (GEP-NET)
but tumor heterogeneity renders outcome unpredictable. Clinical parameters
alone have limited prognostic ability. A previously described NET nomogram
calculated risk for overall survival (OS). To augment accuracy, we developed a
circulatingNETmultigene expression blood test. TheNETest exhibits high level
metrics as a molecular prognostic for progression free survival (PFS). We eval-
uated whether combining clinical information with the NETest would provide
accurate prognostic information for PRRT treatment. Aim: Create a combined
clinical and gene expression nomogram to predict OS and PFS in PRRT-treated
GEP-NETs. Methods: 177Lu-based-PRRT-treated GEP-NETs (n57; median
age 65 yrs (31-83); 34M:23F; small bowel (47%), pancreas (35%), predominantly
G2: 65%) followed for amedian 15months (range 1-33). The clinical nomogram
comprised 10 variables (including: age, gender, grade, Ki67, stage symptoms,
liver metastases, somatostatin analog use, surgery extent, Chromogranin A
level) with a score range: 25-200. This data was interpolated with pre-therapy
NET transcript analysis results (range 0-100) into a hybrid molecular nomo-
gram (range: 25-300). Outcomes were OS and PFS (RECIST criteria). Receiver
operating characteristics (ROC), Kaplan-Meier survival and non-parametric
(Mann-Whitney) analyseswere performed. Results:MedianOSwas not reached
(8 deaths); mPFS was 19 months (20/57 disease progression). Neither grade nor
stage alone predicted a difference in OS or PFS. Clinical nomogram scores for
non-survivors was signifıcantly higher (139	20 vs. 87	6, p0.001) than survi-
vors. Pre-treatment NETest values were higher in non-survivors (56	10 vs.
36	3, p0.04). Integration of clinical and molecular nomogram scores into a
hybrid nomogram signifıcantly amplifıed the prognostic effıcacy. Non-survi-
vors had higher scores than survivors (189	14 vs. 113	9, p0.001). A cut-off
score of 130 exhibited an AUC for OS prediction of 0.84	0.05, (p0.002)
with a Hazard ratio (HR) of 8.7 (2.1-35.4, p0.002). A score of130 predicted
100% survival. PFS prediction using the hybrid nomogram cut off of 130 had an
AUC of 0.68	0.07, p0.02. The Gehan-Breslow-Wilcoxon test value was 7.2
(p0.008) demonstrating that high scores were prognostic of early progression
(treatment failure). The HR was 3.1 (1.2-7.4, p0.02) and the mPFS was 17
months vs. not reached. Conclusions: Hybrid molecular nomogram data de-
rived from a circulating gene expression signature combinedwith a clinical NET
nomogram accurately predicts OS in PRRT-treatedGEP-NETs. The nomogram
also predicted PFS particularly individuals with elevated transcript values who
will not respond to PRRT.
#1790 Evaluation of UCK2 protein expression as a potential predictive
biomarker of RX-3117. Young Bok B. Lee,1 Deog J. Kim,1 Christina George,1
Chang-ho Ahn,1 Julie Frank,1 Reza Mazhari,1 Lisa M. Dauffenbach,2 Eric P.
Olsen2. 1Rexahn Pharmaceuticals, Inc., Rockville, MD; 2Mosaic Laboratories,
Lake Forest, CA.
Background: A novel, orally bioavailable nucleoside analogue, RX-3117, is a
prodrug activated intracellularly by Uridine Cytidine Kinase 2 (UCK2) that is
thought to be expressed predominantly in tumor tissue. RX-3117 is currently
being evaluated in a Phase Ib/IIa multi-center, open-label clinical study in pa-
tients with advanced pancreatic and bladder cancer. In this study, we aimed to
determine the relation between UCK2 tissue protein expression and the effıcacy
of RX-3117 in mice xenograft models and also UCK2 protein expression in a
panel of human cancer tissues relative to normal tissue. Methods: The UCK2
protein expression in tumor tissues was analyzed by immunoblotting using
clone 22-1 rabbit monoclonal antibody. The validated procedure for the immu-
nohistochemistry (IHC) of UCK2 with clone 22-1 was performed in a panel of
human formalin-fıxed paraffın-embedded (FFPE) cancer and normal tissues.
Results: The immunoblotting protein level of UCK2 normalized to -actin and
corresponding tumor growth inhibition (oral RX-3117 dose of 500mg/kg,
TIWK) were 57 and 67% in MiaPaCa2, 30 and -5% in BxPC3, 199 and 92% in
Colo-205, 21 and 90% in Caki-1, 2 and 39% in A549, and 146 and 79% in H460,
respectively. This data indicates an anti-tumor effıcacy trend in a UCK2-depen-
dent manner. The IHC of UCK2 showed that positive staining of UCK2 in
cancer tissues was observed in 20/20 bladder cancer tissues (100% frequency),
19/20 CRC tissues (95% frequency), 18/20 NSCLC tissues (90% frequency), and
19/20 pancreatic cancer tissues (95% frequency). Average H-Scores of UCK2 in
cancer tissues vs. normal tissues were 104 vs. 9 in lung, 97 vs. 20 in bladder, 67 vs.
41 in pancreas and 39 vs. 21 in colon, respectively. Conclusions: The current data
showed a correlation trend between UCK2 protein expression level and degree
of antitumor activity of RX-3117 in xenograft models. It also supports a higher
UCK2 protein expression level in human cancer tissues compared to their nor-
mal tissues. This suggests that RX-3117 activity may be specifıc to tumor tissue,
and quantifıcation ofUCK2 expression in human cancer tissuesmay be useful as
a predictive biomarker to select patients for their sensitivity to RX-3117 in future
clinical studies.
#1791 Spatially positioned tumor infıltrating lymphocytes predict sur-
vival in metastatic HER2 positive breast cancer treated with trastuzumab.
Jussi Pekka Koivunen, Tiia Honkanen, Tiina Moilanen, Peeter Karihtala, Juha
Väyrynen, Markus Mäkinen. Oulu Univ. Hospital, Oulu, Finland.
Background: Disease outcomes of HER2 breast cancers have dramatically
changed after targeted therapies, such as trastuzumab, came to clinical practice
but predictive factors for trastuzumab sensitivity and resistance are frequently
unknown.Methods:Metastatic breast cancer patients (n48), whowere treated
with trastuzumab and had pre-treatment tumor samples available, were studied.
The tumors were immunostained for T-cell (CD3, CD8) and NK-cell (CD56)
markers and quantitative analysis of the immune cells was carried out using a
computer-assisted image analysis in different tumor locations. Results: High
number ofCD3 andCD8positive T-cells was associatedwith signifıcant survival
benefıt in the center of the tumor (CT) (p0.007, p0.001), but not in the
invasive region. NK-cell tumor infıltration was infrequent and they could not be
reliably analyzed. In a subgroup analyses, high density of CD8 CT cells was
associated with signifıcant survival benefıt in non-bone only disease, in TX-3,
and in ER tumors (p0.006, p0.003, p0.001).Moreover, highCD8CT cell
density was associated with good trastuzumab responses (p0.042). Conclu-
sion: High number of CD3 and CD8 positive tumor infıltrating lymphocytes in
the CT area is associated with survival benefıt in some patient groups with
HER2 breast cancer treated with trastuzumab. Furthermore, high number of
CD8 CT cells predicts benefıt from trastuzumab.
#1792 Immune system pathway activation for prediction of the response
to neoadjuvant chemotherapy in triple-negative breast cancer. Takeshi
Sawada,1 Riet Hilhorst,2 Savithri Rangarajan,2 Masayuki Yoshida,3 Kenji Ta-
mura,3 Rinie van Beuningen,2 Rob Ruijtenbeek,2 Hitoshi Tsuda,4 Fumiaki Koi-
zumi1. 1Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome
Hospital, Tokyo, Japan; 2PamGene International BV, ’s-Hertogenbosch, Nether-
lands; 3National Cancer Center Hospital, Tokyo, Japan; 4National Defense Med-
ical College, Saitama, Japan.
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Background: Triple-negative breast cancer patients (TNBCs) who receive
neoadjuvant chemotherapy (NAC) generally show a response to NAC, but
about 5% experience progressive disease (PD). AlthoughTNBCs that respond to
NAC have been well-studied, reports about TNBCs with PD during NAC are
absent.We aimed to compare kinase activity profıles of TNBCs of both groups to
identify a biological predictor of NAC non-responders. Methods: Tyrosine ki-
nase activity profıles of lysates of fresh frozen cancer tissues from NAC non-
responders and responders, the latter represented byTNBCswhodidnot receive
NAC, were determined with a peptide microarray system (Cancer Res. 2009;
69(14):5987-95). Tumor infıltrating lymphocytes (TILs) were counted in these
tissues. Results: Among 740 TNBCs, 20 NAC non-responders were identifıed.
For the 7 samples from PD confırmed patients and 10 TNBCs not receiving
NAC, no correlationwas observed betweenNAC response and age,menopausal
status, tumor size or axillary lymph node status. Kinase activity measurements
showed large differences in overall tyrosine kinase activity between responders
and non-responders. 35 peptides had signifıcantly (p 0.05) higher phosphor-
ylation in the responder group. Kinases that phosphorylate these peptides (up-
stream kinases) were identifıed from literature. Among others, the immune
related kinases Zap70, Syk and JAK2 were identifıed as upstream kinases. Path-
way analysis yielded evidence for increased activity in the responder group in
immune-related pathways and in pathways involved in development and signal
transduction. Responders had a signifıcantly higher (p  0.0053) TILs count.
Conclusion: Kinases related to the immune system are less activated in NAC
non-responders. The low TILs count in the non-responders confırmed that
activation of the immune system in non-responders is lower than in NAC re-
sponders. These data merit a further investigation of the use of kinase activity
profıling either alone or in combination with TIL scoring for the prediction of
the response to NAC in TNBC with a larger patient cohort.
#1793 Telomere length and mitochondrial DNA copy number variations
as predictors for survival in hepatocellular carcinoma patients treated with
sorafenib. Dong Yan. Beijing Chaoyang Hospital & UT MD Anderson Cancer
Ctr., China.
Background: The study aims to evaluate the potential predictive value of rel-
ative telomere length (RTL) and mitochondrial DNA (mtDNA) copy number
variations for survival in hepatocellular carcinoma (HCC) patients treated with
sorafenib. Methods: The study was conducted in 120 patients with pathologi-
cally or radiologically confırmed HCC who were treated with sorafenib as their
fırst-line or second-line monotherapy. RTL and mtDNA copy number in pe-
ripheral lymphocytes were measured using quantitative real-time polymerase
chain reaction (PCR)-based method. ANOVA and non-parametric tests were
applied to compare the RTL and mtDNA copy number between groups. Pro-
gression-free survival (PFS) and overall survival (OS) time was analyzed using
Kaplan Meier plot, log-rank test, and Cox proportional hazards regression
model. Results: A longer telomere was observed in patients with early stage
disease or normal bodyweight and inHispanics compared to their counterparts.
Patients with longer RTL compared to those with shorter RTL had signifıcantly
better PFS (6.90 vs 4.40 months, P0.048) and OS (16.53 vs 7.72 months,
P0.006). Cox regression analysis demonstrated that longer RTL was an inde-
pendent predictor for OS (hazard ratio [HR]0.47, 95% confıdence interval
[CI]0.29-0.76, P0.01) in all patients and for PFS in patients received
sorafenib (HR0.37, 95% CI0.15-0.94, P0.01) after adjusting for other clin-
ical predictors. RTL was positively correlated to mtDNA copy numbers
(r0.312, P0.001), but no signifıcant association of mtDNA copy numbers
and PFS or OS was observed. Conclusion: RTL, but not mtDNA copy number,
might be a potential predictor for OS and for response to sorafenib treatment in
HCC.
#1794 Lymphocyte apoptosis as a predictive biomarker for radiotherapy
de-intensifıcation in EBV-associated nasopharynx cancer.Kevin L.M. Chua,1
ShihabuddeenWaseemAhamed,1Ma Than Than Shwe,1 Li-lian Kwok,1 Joseph
T.S. Wee,1 Terence W.K. Tan,1 Prakash M. Hande,2 Kai Rothkamm,3 Melvin
L.K. Chua1. 1National Cancer Centre Singapore, Singapore, Singapore; 2National
University Singapore, Singapore, Singapore; 3University Medical Center Ham-
burg-Eppendorf, Hamburg, Germany.
Aims: Emerging evidence in viral-associated oro- and naso-pharynx cancers
supports the concept of radiotherapy (RT) dose de-intensifıcation in these radi-
osensitive tumours. This notion is particularly relevant in the background that a
majority of head and neck cancer patients develop severe late toxicities despite
modern precisionRT.A reasonable strategy could thus entail stratifying patients
at risk of late toxicities to dose de-intensifıcation. Here, we investigated the
utility of a lymphocyte apoptosis (RILA) assay to predict for late toxicities in
EBV-positive nasopharynx cancer patients. We also test if a multi-modal ap-
proach incorporating DNA damage induction and repair improves the predic-
tion of clinical radiosensitivity. Methods: Assays were assessed retrospectively
among survivors of a randomised controlled trial (NCC-0902), where patients
were assigned to weekly cisplatin-RT with or without neoadjuvant gemcitabine,
carboplatin, and paclitaxel. Late toxicities were assessed by CTCAE v.2 at the
following intervals - 2-mo year 1, 4-mo year 2, 6-mo years 3-5, and annually
thereafter; and considered severe if CTCAE v.2
Grade 2. RILA was based on a
fluorogenic inhibitor of caspases assay (48 h post-8Gy). DNAdamage induction
and repair were assessed by semi-automated scoring of ϒH2AX foci at 30 min
post-1Gy and 24hpost-4Gy, respectively. Results:Median follow-upof patients
was 5.7 (range 4.6-7.4) years. Clinical and treatment indices, including assigned
study arm andRTdosimetry to normal tissue structures, were balanced between
patients with andwithout late toxicities (p0.05).We observed a trend between
decreasingRILA scores and increased risks of late toxicities; odds ratio (OR) 1.27
(95% CI  0.92-1.72) for lowest quartile cut-off, corresponding to an AUC of
0.608 for prediction accuracy (p 0.049). Amulti-modal approach incorporat-
ing DNA damage induction and repair did not improve upon the predictive
accuracy of RILA for clinical radiosensitivity. Independently, DNA damage in-
duction and repair were not associated with risks of late toxicities; OR 1.03 (95%
CI  0.69-1.53, p  0.901) and 1.04 (95% CI  0.73-1.49, p  0.829), respec-
tively. Interestingly, onset of late toxicities was correlated to an improved dis-
ease-free survival in our cohort (5-y DFS 94.1% vs 73.3%, no late toxicity, p
0.003), which suggests a common mechanism underlying tumour and normal
tissue radiosensitivity in EBV-positive nasopharynx cancer. Conclusions:
Herein, we report on the potential utility of a RILA assay in stratifying for
patients at risk of late RT-induced toxicities. The clinical implication of this
assay is further exemplifıed by the observation of a superior survival in these
sensitive individuals, which supports the approach of selecting this subgroup for
treatment de-intensifıcation.
#1795 Hypermethylation status of PDX1 has potential of diagnostic and
predictive biomarker for risk stratifıcation in colorectal cancer patients.
Takashi Ichikawa, Yuji Toiyama, Yoshinaga Okugawa, Hiromi Yasuda, Hi-
royuki Fujikawa, Yoshiki Okita, Shigeyuki Yoshiyama, Junichiro Hiro, Minako
Kobayashi, Toshimitsu Araki, Masaki Ohi, Yasuhiro Inoue, Keiichi Uchida,
Yasuhiko Mohri, Masato Kusunoki. Mie University Graduate School of Medi-
cine, tsu,mie, Japan.
Background: Abnormal DNA methylation is an important epigenetic mech-
anism that has been strongly implicated in the pathogenesis and progression of
colorectal neoplasia. In contrast to other potential biomarker species such as
mRNAandprotein levels,measurement ofDNAmethylation has been shown to
be stable, reproducible and consistent between individuals. Based on these
standpoints, detecting aberrant methylation of cancer-related genes helps for
the development of diagnostic and prognostic biomarkers in colorectal cancer
(CRC). In this study, we comprehensively evaluatedwhole-genomemethylation
analysis using colorectal cancer tissues and normal colonic mucosa to discover
candidate CRC-specifıcDNAmethylation as potential diagnostic and predictive
biomarkers for risk stratifıcation in CRC patients. Patients and Method: The
study design included an initial discovery phases, and followed by a subsequent
clinical validation phase. In discovery phase, we performed whole-genome
methylation analysis using CRC tissues and normal colonic mucosae from total
fourteen patients to identify CRC-specifıc methylated CpG cites. Furthermore,
we evaluated methylation levels of candidate methylated CpG cites by quantita-
tive bisulfıte pyrosequencing using one hundred six colorectal specimens from
fıfty-three CRC patients to validate the fındings from discovery phase. Result: In
discovery phase, we successfully identifıed several candidates of CRC-specifıc
hypermethylated- and hypomethylated-CpG cites in CRC tissues compared
with normal colonic mucosa. Promoter lesion of PDX1 is one of candidate
methylated CpG cites in discovery phase, and we focus a specifıc CpG cite of
PDX1 promoter lesion as a target cite to progress in validation phase. We quan-
tifıed methylation status of PDX1 using 106 colonic tissues, and demonstrated
that PDX1 were signifıcantly hyper-methylated in CRC tissues compared with
normalmucosa (p0.0001,Wilcoxon rank correlation test). Receiver operating
characteristic (ROC) curves analysis revealed that methylation levels of PDX1
remarkably discriminated CRC tissues from normal colonic mucosa (AUC:0.9,
Sensitivity:85.4%, Specifıcity:91.5%). Interestingly, methylation levels of PDX1
tend to increase in stage-dependent manner, and hypermethylated status of
PDX1 was signifıcantly correlated with presence of distant metastasis in valida-
tion cohort. Conclusion: Assessment of the PDX1 methylation status could be
used as potential of diagnostic and predictive biomarker for risk stratifıcation in
CRC patients.
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#1796 A targeted RNA-seq assay to measure activating ERmutations and
ER/PR-associated gene expression predicts sensitivity to endocrine therapy
formetastatic breast cancer.RosannaLau,1 Lily Fu,1Michael Samuels,2 Rashmi
K. Murthy,1 Bruno Sinn,3 Jane Yu,1 Rebekah Gould,1 Jennifer Litton,1 Alda
Tam,1 StacyMoulder,1 Daniel Booser,1 Debu Tripathy,1 Vicente Valero,1 Fraser
Symmans1. 1M.D. Anderson Cancer Center, Houston, TX; 2RainDance Technol-
ogies, MA; 3Charité – Universitätsmedizin Berlin, Berlin, Germany.
Background: We developed SET4 as a targeted, droplet-based, next-genera-
tion RNA sequencing assay to measure both the SETER/PR index of gene expres-
sion and the percent of estrogen receptor (ER) transcripts with point mutation
in the ligand-binding domain (LBD) in metastatic biopsies of Stage IV breast
cancer. The SETER/PR index (31 genes) is a cumulative measure of gene expres-
sion for transcripts associated with ER and progesterone receptor (PR), exclud-
ing those with a direct role in proliferation. High SETER/PR could indicate in-
creased sensitivity to endocrine therapy, whereas LBD mutations indicate
resistance but might also induce high SETER/PR. Methods: Targeted needle bi-
opsies from a metastatic site were prospectively obtained from 82 patients with
HR/HER2- breast cancer at time of any progression event, and preserved in
RNAlater. Samples were prepared for targeted sequencing on a MiSeq by com-
bining purifıed total RNA with SET4 primers and RT-PCR master mix into
single molecule-formatted picodroplets using a RainDrop Source instrument,
followed by thermal cycling and sample indexing. Calculated SETER/PR index
and percent ER transcripts with LBD mutations were evaluated as continuous
variables and compared to progression-free and overall survival using Cox re-
gression analysis with log-rank test, if the next treatment after biopsy included
endocrine therapy. Results: The average read depth for the LBD of the ER tran-
script was 33,475X (range: 1230-180,889X), confıdently detecting mutation at
1% frequency. LBD mutations were identifıed in 17% (14/82) of metastases
(range of mutated transcripts 1%-98%). LBD mutations (10% of transcripts)
were only observed in metastases with higher SETER/PR (above the median). In
patients who next received endocrine therapy (n58), higher SETER/PR pre-
dicted longer progression-free (PFS) (HR0.37, p0.0004,  median PFS 9
months) and overall survival (OS) (HR0.49, p0.03). The predictions were
more pronounced in patients without LBDmutation (PFSHR0.32, p0.0001,
median PFS 13 months; OS HR0.42, p0.01). Currently, there are insuffı-
cient cases with LBD mutation for reliable survival analysis. Conclusion: The
SET4 assay measured the percent of ER transcripts with activating LBD muta-
tion (
1% prevalence) and also downstream ER/PR-related transcription. High
SETER/PR predicted longer PFS andOSwith endocrine therapy.While activating
LBDmutations may be associated with endocrine resistance of Stage IV cancer,
they were associated with high SETER/PR index. Consequently, metastatic can-
cers with high SETER/PR index and no LBD mutation in ER transcripts were
particularly sensitive to endocrine therapy. This single assay unraveled a possi-
ble interaction between genotype, phenotype, and treatment outcome; and is
currently being evaluated in a larger cohort of patients.
#1797 EGFR as a marker for head and neck squamous cell carcinoma-
derived small extracellular vesicles. Jenna A. Dombroski,1 Damaris Kuhnell,2
Susan Kasper,2 Scott M. Langevin2. 1University of Buffalo, Buffalo, NY; 2Univ. of
Cincinnati College of Medicine, Cincinnati, OH.
Head and neck cancer will account for an estimated 61,760 new cancer cases
and 13,190 cancer-related deaths in the United States in 2016, the majority of
which ( 90%) will be squamous cell carcinoma (HNSCC). The prognosis for
HNSCC is relatively poor, with an overall 5-year survival around 60%, and the
outlook worsens with increasing stage at diagnosis, which is problematic since
about two-thirds of patients present with advanced stage disease. This under-
scores the urgent need for discovery, development and translation of novel bio-
markers to facilitate early detection of HNSCC and bolster the chance for posi-
tive patient outcomes. Exosomes are nano-sized (40-150 nm) membrane-
encapsulated vesicles that may offer a new avenue for discovery and
development of novelHNSCCbiomarkers. However, they are released by essen-
tially all cells, both normal and malignant, into the extracellular space, resulting
in a noisy environment in biofluids from the perspective of biomarker measure-
ment. As such, a membrane-bound surface marker that allows for enrichment
for cancer-derived exosomes in patient samples would provide a clear benefıt.
Epidermal growth factor receptor (EGFR), which belongs to the ErbB/HER
family of receptor tyrosine kinases, localizes to the plasma membrane and is
over-expressed in as much as 90% of HNSCC tumors. Therefore, we hypothe-
sized that EGFR will be over-represented on membranes of HNSCC-derived
exosomes and thus may offer utility as a surface marker for detection and/or
enrichment. To test this, we cultured an HNSCC cell line that over-expresses
EGFR (FaDu), EGFR-defıcient SW620 colorectal adenocarcinoma cells, andpri-
mary human oral epithelial cells pooled from 3 healthy donors. Cells were cul-
tivated in supplier-recommendedmedia with 10% fetal bovine serum (FBS) that
was super-depleted of exosomes via 18 hour ultracentrifugation at 100,000g and
1% penicillin/streptomycin at 37°C with 5% CO2 in 150 cm2 flasks with 25mL
media. After reaching 80-90% confluence, media was harvested, and exosomes
were isolated and purifıed via differential ultracentrifugation. Exosome isolates
were whole-mounted on carbon grids, Immuno-Gold labeled with anti-EGFR,
and imaged on a JEOL JEM-1230 transmission electron microscope (Immuno-
EM); anti-nucleoporin 153 (NUP-153), which localizes to the nucleus, was used
as a negative control. Immuno-EM images indicate abundant EGFR expression
on exosomes secreted by FaDu HNSCC cells, but EGFR is not detectable on the
exosomes secreted by the oral epithelial cells from healthy donors. These results
indicate that EGFR may offer utility for enrichment for HNSCC-derived exo-
somes in human biofluid isolates using magnetic beads or flow cytometry.
#1798 Mortalin precursor as potential marker for chemoprevention with
SHetA2. Elangovan Thavathiru, Vishal Chandra, Rajani Rai, Doris Benbrook.
University of Oklahoma HSC, Oklahoma City, OK.
Introduction: The flexible heteroarotinoid (Flex-Het), SHetA2, is a novel an-
ticancer drug that induces both intrinsic and extrinsic apoptosis and autophagy
in cancer cells, but not in normal cells. Protein isolation / mass spectrometry
analysis using SHetA2-coupled polystyrene magnetic beads yielded three
SHetA2-binding proteins all belonging to HSPA family namely, HSPA9/morta-
lin, HSPA8/Hsc70 and HSPA5/BiP. Mortalin, in addition to its vital chaperon-
ing roles in other organelles of the cell, is essential for import and folding of
nuclear-encoded mitochondrial proteins. The precursor form of mortalin has a
46-amino acid N-terminal region that functions as a mitochondrial localization
sequence (MLS) and is cleaved by proteases after import into the mitochondrial
matrix. Hypothesis: SHetA2 binding to mortalin causes alterations that can be
measured to study mechanism and monitor drug effects in animal models and
clinical trials. Methods: Western blots of whole cell or subcellular protein ex-
tracts made from cultures of normal human fallopian tube secretory or mam-
mary epithelial cells, rat mammary tumors or human ovarian cancer cell lines
treated with SHetA2 or solvent were probed with an antibody that recognizes
total mortalin, a custom-made rabbit polyclonal antibody specifıc for the mor-
talin MLS (PA8238) or antibodies to loading control proteins. Immunocyto-
chemistry using these antibodies was performedwith an automated (Leica Bond
III) IHC work station on cells treated with SHetA2 or solvent. Results: Using a
commercial antibody against total mortalin, we observed a lower-mobility band
closely moving above the specifıc (mature) mortalin band inWestern blots. Our
mortalin MLS-specifıc antibody recognized only the lower-mobility band con-
fırming it as the precursor form of mortalin in the SHetA2-treated cell extracts.
Subcellular fractionation of the drug-treated cells revealed that the precursor
protein accumulated only in the cytoplasm and not in the mitochondria. Stain-
ing of whole cells with an antibody to total mortalin showed no effect of SHetA2
treatment on the punctate pattern of expression consistent with mitochondrial
localization. In contrast, staining with themortalinMLS-specifıc antibody dem-
onstrated that SHetA2 increased the intensity of the diffuse cytoplasmic staining
consistent with localization ofmortalin throughout the cytoplasm. These results
were consistently observed among the various cell types. Conclusions: SHetA2 is
the only known drug that blocks the translocation of the precursor mortalin to
mitochondria and its processing to mature protein. Such cytoplasmic accumu-
lation of the precursor form of mortalin can potentially serve as pharmacody-
namic endpoint to study SHetA2’s effect in laboratory experimental tumor
models as well as in human clinical trials. Funding: NCI PREVENT Task Order
HHSN26100002.
#1799 CRM1 expression in pancreatic adenocarcinoma correlates with
survivin expression and the proliferative activity.DavidM. Saulino, Pamela S.
Younes, JenniferM. Bailey,MamounYounes.University of TexasHealth Science
Center at Houston McGovern Medical School, Houston, TX.
Introduction: CRM1 is a nuclear export chaperone thatmediates the export of
proteins essential to growth regulation and tumor suppression. Its overexpres-
sion in tumors was found to be associated with poor prognosis. Selective inhib-
itors of nuclear export are in phase I and II clinical trials for several tumor types.
The expression of CRM1 in human pancreatic adenocarcinoma (PAC) and its
relation to survivin expression and tumor proliferative activity is largely un-
known. Experimental procedures: Sections of tissue microarray containing 77
formalin fıxed and paraffın embedded PACwere stained by immunohistochem-
istry (IHC) for CRM1, survivin, and Cyclin A. Expression levels of CRM1 and
survivin in tumor cells was determined using a quantitative digital image anal-
ysis solution (OTMIAS). The tumor proliferative activity was determined by
measuring the S-phase fraction (SPF) in sections stained for Cyclin A, also using
OTMIAS. Summary: Sixty-six of the 77 (86%) PAC showed at least some posi-
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tive staining for CRM1, and 11 (14%) were completely negative. The mean
CRM1 expression levels ranged from 0.3 to 53 units and the median from 0.3 to
45 units. There was signifıcant positive correlation between the mean and me-
dian expression levels of CRM1 in tumor cells with the mean and median levels
of survivin (p0.001). Moreover, there was positive correlation between the
mean and median CRM1 levels in tumor cells the SPF (p0.005). Conclusions:
CRM1 is expressed in a signifıcant proportion of PAC, and increased CRM1
expression correlates with increased survivin expression and increased prolifer-
ative activity, suggesting that selective inhibitors of nuclear export may be effec-
tive against PAC.
#1800 Noninvasive approach to assess metastatic lesion of advanced colo-
rectal cancer by denoised deep target sequencing. Jun-Kyu Kang,1 Hwang-
Phill Kim,1 Seul-Ki Cheon,1 Ye-Lim Park,1 Yoojoo Lim,2 Sae-Won Han,2 Tae-
You Kim2. 1Seoul National University, Seoul, Republic of Korea; 2Seoul National
University Hospital, Seoul, Republic of Korea.
The cell-free DNA (cfDNA) represents a minimally invasive and alternative
source of tumorDNA formolecular profıling.Despite next-generation sequenc-
ing (NGS) technique is qualifıed for genotyping cancer using cfDNA as a non-
invasive method, it has caused problems as sequencing error and reproducibil-
ity. cfDNA in plasma and gDNA of Peripheral Blood Mononuclear Cells
(PBMC) were isolated from each 54 advanced colorectal cancer patients. 39
available tumor tissues were isolated from same patients. Deep target-sequenc-
ing was performedwith paired-end library enriched exons of 10 genes which are
recurrently mutated in colorectal cancer. To reduce sequencing error, we de-
vised ’Denoising’ and calculated concordance of somatic variants between
cfDNA and tumor tissue sequencing data. In addition, correlation of concor-
dance data was analyzed with the clinical information. As a result, we selectively
could detect clinically important somatic alteration among low/high variant
allele frequency (0.31%79.42%). For somatic alteration of 10 genes, sensitivity,
specifıcity and accuracy were increased from 84.5%, 74.6% and 76.9% to 87.6%,
92.0% and 91.1% respectively after ‘Denoising’. On the other hand, patients with
high cfDNA concentration(50ng/ml) had higher somatic mutant fragments
and larger metastatic lesion in liver than patients who have low cfDNA concen-
tration. Our study showed that denoised deep target-sequencing is a suitable
method for cfDNA genotyping and provides insights into strategies for moni-
toring metastatic lesion of advanced colorectal cancer.
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#1801 Antiangiogenic agents targeting different angiogenic pathways
have opposite effects on tumor hypoxia in R-18 human melanoma xeno-
grafts. Jon-Vidar Gaustad, TrudeG. Simonsen, LiseMari K. Andersen, Einar K.
Rofstad. Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Background: Studies comparing the effect of antiangiogenic agents targeting
different angiogenic pathways are sparse. The purpose of this study was to com-
pare the effect of properdistatin and sunitinib treatment in a preclinicalmodel of
malignantmelanoma. Properdistatin is a small peptide derived from the throm-
bospondin-1 domain of the plasmaprotein properdin, and sunitinib is a tyrosine
kinase inhibitor targeting several receptors including the vascular endothelial
growth factor receptors. Methods: R-18 human melanoma xenografts growing
in dorsal window chambers were treated with properdistatin, sunitinib, or vehi-
cle. Parameters describing the morphology of tumor vasculature were assessed
fromhigh-resolution transillumination images, andBST (blood supply time; the
time needed for arterial blood to flow from the main supplying artery to down-
streammicrovessels) was assessed from fırst-pass imagingmovies recorded after
a bolus of fluorescence-labeled dextran had been administered intravenously.
Tumor hypoxia was assessed from immunohistochemical preparations of the
imaged tissue by using pimonidazole as a hypoxia marker. Results: Properdista-
tin treatment selectively removed small-diameter vessels and reduced BST,
whereas sunitinib treatment reduced the density of small- and large-diameter
vessel similarly and did not change BST. These observations imply that prop-
erdistatin treatment reduced geometric resistance to blood flow and improved
vascular function, whereas sunitinib treatment did not affect vascular function.
Accordingly, sunitinib-treated tumors showed higher hypoxic fractions than
properdistatin-treated tumors. Conclusions: Properdistatin and sunitinib both
inhibited angiogenesis, but had distinctly different effects on vascular morphol-
ogy, vascular function, and extent of hypoxia in R-18 human melanoma xeno-
grafts.
#1802 Apoptosis pathway-focused gene expression profıling of a novel
VEGFR2 inhibitor. Mohammad Algahtani,1 Khalid Alhazzani,1 Thiagarajan
Venkatesan,2 Appu Rathinavelu1. 1Nova Southeastern University, College of
Pharmacy, Davie, FL; 2Rumbaugh-Goodwin Institute for Cancer Research, Nova
Southeastern University, Davie, FL.
Sprouting of the new blood vessel (angiogenesis) is fundamental to tumor
growth, invasion, and metastatic dissemination. Vascular endothelial growth
factor (VEGF), an endothelial cell-specifıc mitogen, promotes cell survival via
opposing apoptosis.On the other hand, antagonizingVEGFpathway suppresses
endothelial cell overgrowth and promotes apoptotic signals leading to the re-
gression of the existing vasculature and prevents neovascularization of the tu-
mors. In this respect, a new chemical entity, code named as F16, that was devel-
oped in our institute can effectively stop VEGF-driven angiogenesis by
selectively blocking VEGFR2 and the downstream signals. Our previous studies
have revealed that human umbilical vein endothelial cells (HUVECs) undergo
apoptosis in response to F16 treatment. However, in the present study, ourmain
focus was on investigating the status of the signal mediators of the apoptotic
pathway after treating the HUVECs with F16. This was expected to outline the
intracellular sequence of events involved in triggering apoptosis following F16
treatment. For this purpose, we analyzed apoptosis pathway-focused gene ex-
pression inHUVECs using the human apoptosis RT2 profıler which contains 84
key genes involved in regulation of programmed cell death. Our experimental
results clearly identifıed up-regulated pro-apoptotic genes in response to F16
treatment which include tumor necrosis factor -8 and -10A (TNF-8 and TNF-
10A), tumor necrosis factor superfamilymember 9 (TNFRSF9), FAS cell surface
receptor (FAS), FAS ligand (FASLG), lymphotoxin alpha (LTA), caspase 5
(CASP5), and cytochrome c (CYCS).Moreover, a few anti-apoptotic genes were
also up-regulated which include B-cell lymphoma 2 related protein A1
(BCL2A1), caspase 14 (CASP14), Bcl2 associated athanogene 3 (BAG3), and
interleukin 10 (IL-10).However, anti-apoptotic genes such as Bcl-2, Bcl-2 like 10
(BCL2L10), baculoviral IAP repeat containing -3 and -6 (BIRC-3, and BIRC-6),
CASP8 and FADD like apoptosis regulator (CFLAR), and insulin like growth
factor 1 receptor (IGF1R) were found to be signifıcantly downregulated. Inter-
estingly, no changes were found in the expression of genes related to DNA
damage and repair pathways such as TP53, ABL1, CIDEA, and CIDEB. This
indicates that F16 may not provoke DNA damage-induced apoptosis instead, it
stimulates the intrinsic or the extrinsic pathway. In conclusion, the diverse gene
expressions impacting apoptosis related factors shows that F16 can induce apo-
ptosis via potentiation of TNF- and FAS- signaling. (This research was sup-
ported by the generous funds provided by the Royal Dames of Cancer Research
Inc., Ft. Lauderdale, Florida)
#1803 Combining anti-Ang-2/VEGF-A therapy with radio- and chemo-
therapy in glioma. Gergely Solecki,1 Matthias Osswald,1 Weber Daniel,1 Malte
Glock,1 Miriam Ratliff,1 Hans-Joachim Müller,2 Oliver Krieter,2 Yvonne Kie-
nast,2 Wolfgang Wick,1 Frank Winkler1. 1German Cancer Research Center
(DKFZ), Heidelberg, Germany; 2Roche Innovation Center, Munich, Germany.
Angiogenesis is a biological hallmark of malignant gliomas, but antian-
giogenic strategies especially targeting the VEGF axis did not show striking
antitumor activities in the majority of patients so far. Other pathways may be
more relevant in selected tumor entities or patients. Further, it remains
unresolved which antiangiogenic combination regimen with standard radio-
and/or chemotherapy is most effective. Therefore, we compared the thera-
peutic effects of anti-VEGF-A, anti-Ang-2, and bispecifıc anti-Ang-2/
VEGF-A antibodies, alone and in combination with radio- or temozolomide
(TMZ) chemotherapy in a malignant glioma model using multi-parameter
two-photon in vivo microscopy in mice. We demonstrate that anti-Ang-2/
VEGF-A leads to strongest vascular changes including vascular normaliza-
tion, both as monotherapy and when combined with chemotherapy. The
latter combination regimen was accompanied by most effective chemother-
apy-induced death of cancer cells independent of blood vessel proximity,
indicative of a better distribution of TMZ throughout the tumor. Further-
more, the combination of anti-Ang-2/VEGF-A plus TMZ consistently re-
sulted in decreased tumor cell motility, and decreased formation of resis-
tance-associated tumor microtubes (TMs), which fınally lead to best tumor
growth inhibition. Remarkably, all these parameters were just reverted when
radiotherapy was chosen as combination partner. In contrast, when anti-
VEGF-A was combined with radiotherapy, vascular normalization was high-
est, and TM length, nuclear motility and tumor growth were concordantly
reduced. In conclusion, while TMZ chemotherapy benefıts most from com-
bination with anti-Ang-2/VEGF-A, radiotherapy does from anti-VEGF-A.
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The fındings imply that unexpected, even divergent effects can occur when a
specifıc antiangiogenic therapy is added to chemo- or radiotherapy in gli-
oma, and that uninformed combination regimens should be avoided.
#1804 Identifıcation of novel NM23 inhibitors as potential anti-angio-
genic agents. Senny Nordmeier, Jon Evasovic, Suzann Duan, Ryan Wuebbles,
Dean J. Burkin, Iain L. Buxton. University of Nevada, Reno, NV.
Exogenous nucleoside diphosphate kinase (eNDPK or NM23) has been
shown to promote endothelial cell proliferation and migration and tumor-
mediated angiogenesis. This is facilitated by its transphosphorylase activity,
in which a gamma terminal phosphate group from a triphosphate nucleoside
is transferred to a diphosphate nucleoside, resulting in elevated ATP levels.
Increased levels of ATP in the tumor microenvironment can activate puri-
nergic receptors (P2Y1) on adjacent endothelial cells to promote angiogen-
esis, independent of VEGF stimulation. Triple negative human breast cancer
(MDA-MB-231) cells have been shown to elaborate exosomes that contain
NM23. These exosomes have implications in targeting specifıc tissues/cells
to promote angiogenesis and tumorigenesis. Our lab has shown that inhibi-
tion of eNDPK and the P2Y1 receptor reduces endothelial cell tubulogenesis
(Rumjahn, et al., 2007) and breast cancer metastasis (Yokdang, et al., 2015).
Therefore, targeted inhibition of eNDPK may have implications as a treat-
ment for early tumor-mediated angiogenesis. For this study, we utilized a
transphosphorylation activity assay to perform a drug screen on compounds
from the Prestwick chemical library. Recombinant NDPK-B was added to
FDA-approved drug compounds along with ADP and UTP substrates. Sub-
sequent ATP generation was detected with a luciferase luciferin reaction.
Decreased luminescence signal/inhibition of NDPK was compared to ellagic
acid control, a known inhibitor of NDPK. From our initial screen, we iden-
tifıed eight potential compounds that inhibited NDPK at comparable levels
to ellagic acid. These eight compounds were further examined to determine
the dose response curve. We found that Chicago Sky Blue 6B inhibited
NDPK at an IC50 value of 1.88M. The results from this study demonstrate
a drug screening method to discover alternative small molecule inhibitors
of NDPK as a potential treatment of angiogenesis and breast cancer metas-
tasis.
#1805 Antitumor activity of lenvatinib mesilate in human hepatocellular
carcinoma preclinical models. Masahiro Matsuki, Yuji Yamamoto, Taisuke
Hoshi, Takayuki Kimura, Yasuhiro Funahashi, Junji Matsui. Eisai Co., Ltd.,
Tsukuba-shi, Ibaraki, Japan.
Hepatocellular carcinoma (HCC) is a one of the leading causes of cancer death
worldwide; however systemic therapeutic option for unresectable HCC is lim-
ited. Liver carcinogenesis is a complex process and various pathways have been
found to be deregulated. Of those pathways, aberrant activation of fıbroblast
growth factor 19 (FGF19)/FGF receptor 4 (FGFR4) axis has been hypothesized
to participate in the development of HCC with poor prognosis. Lenvatinib me-
silate (lenvatinib) is an orally administeredmulti-targeted tyrosine kinase inhib-
itor (TKI) that selectively inhibits vascular endothelial growth factor receptors
(VEGFR)1-3, FGFR1-4, platelet-derived growth factor receptor (PDGFR),
RET, and KIT. In this study, we investigated the activities of lenvatinib against
human HCC cells with or without amplifıcation/overexpression of FGF19 gene
in vitro and in vivo. Lenvatinib inhibited in vitro proliferation of human HCC
cell lines Hep 3B2.1-7 and HuH-7 with IC50 values of 0.23 and 0.42 mol/L
(0.086 and 0.16mol/L as unbound IC50), respectively, whereas it did not show
potent antiproliferative activity against PLC/PRF/5 (IC50 10 mol/L). Both
Hep 3B2.1-7 and HuH-7 were reported to have an amplifıcation of FGF19 gene
and their cell growth was dependent on FGF19/FGFR4 axis. Sorafenib inhibited
in vitro proliferation of the 3 HCC cell lines with IC50 values of 2.2 - 5.3mol/L
(0.59 - 1.4 mol/L as estimated unbound IC50 based on previously reported
protein binding). Next, antitumor activity was evaluated in 2 human HCC cell
line (PLC/PRF/5 andHep 3B2.1-7) xenograftmodels. Lenvatinib treatments at 1
- 100 mg/kg resulted in tumor growth inhibition with a maximal antitumor
effect giving a minimum T/C value (minT/C) of 14% via its antiangiogenic
activity in the PLC/PRF/5model, and at 3 - 30mg/kg withminT/C of 31% in the
Hep 3B2.1-7 model. Sorafenib showed signifıcant antitumor effect at doses
30
mg/kg with minT/C of 30% in the PLC/PRF/5 model, and at 10 and 30 mg/kg
with minT/C of 47% in the Hep 3B2.1-7 model. Finally, we tested antitumor
activity in HCC patient-derived xenograft (PDX) model (LI0050), and PDX-
derived cell line (LIXC-012) xenograft model with FGF19 overexpression in
mice. Lenvatinib signifıcantly inhibited the tumor growth of LI0050 at 10 and 30
mg/kg with minT/C of 33%, and that of LIXC-012 at 3 - 30 mg/kg with minT/C
of 25%. Treatment with sorafenib at 30 mg/kg was intolerable in LI0050 model,
and sorafenib showed signifıcant antitumor activity at 30 mg/kg with T/C of
55%, but not 10 mg/kg in the LIXC-012 model. In conclusion, these results
indicate that lenvatinib has potent preclinical antitumor activity in humanHCC
xenograft models with or without amplifıcation/overexpression of FGF19. Fur-
thermore, the maximum antitumor effect of lenvatinib was greater than that of
sorafenib in this study. Direct effect of lenvatinib on proliferation of HCC cells
with an aberrant FGF signaling pathway in tumor warrants further investiga-
tion.
#1806 Endothelial cells activate the cancer stem cell-associated Nanogp8
pathway in colorectal cancer cells in a paracrine fashion. Rui Wang, Rajat
Bhattacharya, XiangcangYe,DelphineR. Boulbes, Fan Fan, LeeM. Ellis.UTMD
Anderson Cancer Ctr., Houston, TX.
INTRODUCTION: Median survival of patients with metastatic colorectal
cancer (mCRC) is 2.5 years and patients often become resistance to sys-
temic therapy within 1 year of the diagnosis of metastasis. There is accumu-
lating evidence for the existence of cancer stem cells (CSCs) in CRC, which
are now believed to mediate chemoresistance. The molecular mechanisms
that regulate the CSC phenotype in CRC have not been fully elucidated. We
have previously described that endothelial cells (ECs) from liver, the most
common site of metastases of CRC, secreted soluble Jagged-1 peptides to
activate Notch signaling and increase the CSC phenotype of CRC cells in a
paracrine fashion. In the current project, we sought to further elucidate the
paracrine roles of liver ECs and ECs from other organs in mediating specifıc
CSC-associated pathways in CRC cells. METHODS: Several EC lines from
liver, lung, colon mucosa and kidney were established and used to determine
if conditioned medium (CM) of ECs from distinct organs promotes the CSC
phenotype and chemoresistance in CRC cells. CRC cells were incubated with
either their own CM (control) or CM from ECs. The CSC phenotype was
determined by sphere formation assays. Chemoresistance was determined
by Western blotting for apoptotic markers and fluorescence-activated cell
sorting (FACS)-based Annexin V-PI double staining assay for apoptosis
after treating CRC cells with 5-fluorouracil (5-FU) either in control CM or
CM of ECs. The effects of EC CM on CSC-associated genes were determined
by unbiased qPCR array and validated by Western blotting. RESULTS: CM
from ECs from liver and other organs all signifıcantly increased sphere for-
mation in CRC cells. qPCR arrays and Western blotting showed that the
CSC-associated Nanog and Oct4 genes were increased by EC CM.Moreover,
CRC cells treated by liver EC CM became more resistant to 5-FU induced
apoptosis. Luciferase reporter assays suggested that the Nanog proteins in
CRC cells were encoded by the retrogene NANOGP8, and EC CM specifı-
cally induced the expression of NANOGP8 but not NANOG. The specifıc
induction of NANOGP8 in CRC cells were confırmed by AlwNI digestion, an
established technique to distinguish NANOG and NANOGP8 based on a
single nucleotide polymorphism (SNP) between two genes. In addition, Akt
was shown to mediate the induction of NANOGP8 in CRC cell, as the PI3K
inhibitor wortmannin blocked liver EC CM-induced NanogP8 expression
and blocked sphere formation in CRC cells. CONCLUSION: Our studies
demonstrated a paracrine role of ECs from several organs, including liver, in
regulating the CSC phenotype in CRC cells, via increasing NanogP8 expres-
sion. This study elucidated the importance of ECs in the microenvironment
in mediating the survival of metastatic CRC cells in the liver, and potentially
other organs.
#1807 Exosomal NM23 facilitates pro-angiogenic communication be-
tween triple-negative breast cancer cells and their vascular targets. Suzann
Duan, Senny Nordmeier, Iain L. Buxton. University of Nevada, Reno School of
Medicine, Reno, NV.
Functional interactions between primary tumor cells and their vascular tar-
gets orchestrate the formation of a metastatic milieu enriched with oxygen and
metabolic substrates. These interactions have been largely attributed to the ac-
tivation of VEGF receptor pathways through localized tumor-mediated release
of VEGF, in addition to indirect receptor phosphorylation. However, pro-an-
giogenic events are known to occur in the absence of VEGF and alternative
pathways resulting in dual activation of neovascularization and enhanced vas-
cular permeability are of growing interest. Our lab has previously shown that
triple-negative human breast cancer (MDA-MB-231) cells elaborate exosomes
carrying NM23, a nucleoside diphosphate kinase (eNDPK) that is suggested to
act as an upstreammediator of vasodilation and pro-angiogenic activity through
its action of elevating extracellularADP/ATP levels. To further elucidate the role
of eNDPK in breast cancer signaling andmetastasis, we show that 231-exosomes
induce a pro-angiogenic phenotype in both human umbilical vein and murine
pulmonary endothelial cells. Treatmentwith anNDPK-specifıc inhibitor and an
antagonist to the ADP/ATP-activated P2Y1 receptor results in amelioration of
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pro-angiogenic characteristics. Further, we report the development and appli-
cation of a novel murine implant model to demonstrate increased specifıcity of
231 exosome targeting to pulmonary endothelial cells over unrelated cell lines.
These results suggest the involvement of exosomes and eNDPK in pro-angio-
genic communication between metastatic breast cancer cells and their vascular
targets. Exosomes elaborated by these cells specifıcally target pulmonary endo-
thelium in vivo, mirroring the organotropic nature of breast cancer metastasis.
Implication of eNDPK in angiogenesis and metastasis may challenge current
and invasive treatment methods in favor of developing novel small molecule
inhibitors of eNDPK signaling. Lastly, eNDPK can be explored as a potential
biomarker for early detection of metastatic breast cancer as it uniquely appears
in the serum of patients with breast cancer and not in the serum of individuals
with unrelated pathologies.
#1808 Vascular endothelial growth factor receptor-2 (VEGFR-2)N-glyco-
sylationmodulates angiogenic signaling.KevinB.Chandler,DeborahR. Leon,
Rosana D. Meyer, Nader Rahimi, Catherine E. Costello. Boston Univ., Boston,
MA.
Angiogenesis, the formation of new blood vessels from pre-existing ves-
sels, is required for tumor growth and metastasis. Vascular endothelial
growth factor receptor-2 (VEGFR-2) is one of the most important receptor
tyrosine kinases (RTKs) among the VEGF receptor subfamily, and activation
of VEGFR-2 is essential for tumor angiogenesis. The extracellular domain of
VEGFR-2 contains seven immunoglobulin-like (Ig) domains, each with
multiple potential N-glycosylation sites. N-glycosylation is thought to play a
central role in receptor stability, ligand binding and traffıcking. However, to
date the occupancy and glycoform distributions at each of the potential
N-glycosylation sites and their putative role(s) in VEGFR-2 function remain
largely unknown. The objective of this study is to investigate the functional
importance of VEGFR-2 N-glycosylation in VEGFR-2 angiogenic signaling.
Porcine aortic endothelial (PAE) cells with ectopic expression of VEGFR-2
were treated with PNGase F to remove N-linked glycans or heat-denatured
PNGase F as a control. Following PNGase F treatment for 4 hours, cells were
treated with VEGF-A ligand for 0, 5, 10 or 30 minutes. VEGFR-2 phosphor-
ylation (activation) was measured via Western blot with an anti-pTyr-1054-
VEGFR-2 antibody. In addition, a polyclonal anti-VEGFR2 antibody was
used to immunoprecipitate untreated and PNGase F-treated VEGFR-2 from
PAE cell lysates. Evaluation of the N-glycosylation sites targeted by PNGase
F was carried out by gel electrophoresis, followed by protease digestion and
MS/MS analysis. MS/MS data were processed using Proteome Discoverer
1.4. To obtain site-specifıc glycosylation information we performed proteol-
ysis of VEGFR-2, glycopeptide enrichment via hydrophilic interaction liquid
chromatography (HILIC) and subsequent analysis of glycopeptides with an
Agilent 6550 Quadrupole Time-of-Flight (Q-TOF) MS using collision-in-
duced dissociation. We detected a dramatic increase in ligand-mediated ac-
tivation of VEGFR-2 after treatment with PNGase F, suggesting that certain
N-linked glycans may hinder ligand access to the VEGF binding site, or that
removal of N-linked glycans results in conformational changes that lead to
increased activation of the receptor by VEGF-A. To explore this observation
in greater detail, we have created a series of VEGFR-2 N-glycosylation site
mutants, and we are now using the mutants to determine which glycosyla-
tion sites are involved in the observed modulation of VEGFR-2 signaling.
#1809 PKM2 promotes tumor angiogenesis by regulating HIF-1alpha
through NF-kappaB activation. Ninel Azoitei,1 Alexander Becher,1 Konrad
Steinestel,2 Arefeh Rouhi,1 Kristina Diepold,1 Susanne Bobrovich,1 Thomas
Seufferlein1. 1University of Ulm, Ulm, Germany; 2University of Muenster, Muen-
ster, Germany.
Initially identifıed as a molecule that catalyzes the phosphorylation from
phosphoenolpyruvate to pyruvate in the fınal step of glycolysis, the M2 isoform
of pyruvate kinase (PKM2) was recently reported to have a central role in the
metabolic reprogramming of cancer cells as well as participating in the regula-
tion of apoptosis and proliferation. In this study, we have identifıed PKM2 as a
crucial molecule for progression of pancreatic cancer in which tumor microen-
vironment has been reported to be highly hypoxic. Our data show moderate to
strong PKM2 expression in all examined human pancreatic adenocarcinoma
samples. Depletion of PKM2 was associated with impaired proliferation and
augmented tumor cell death in vitro, while the in vivo tumor xenograft experi-
ments revealed a close association between impaired tumor growth and de-
creased blood vessel formation. Furthermore, abrogation of PKM2 prevented
hypoxia-mediated HIF-1alpha accumulation and HIF-1alpha promoter activ-
ity, which negatively impacted VEGF secretion by pancreatic cancer cells de-
prived of oxygen. Interestingly, PKM2 expression arrest was also mirrored by
impaired hypoxia-driven promoter activity of NF-kappaB which also drives the
transcription of VEGF. Ectopic expression of p65 restored VEGF transcription
after PKM2 ablation inferring that the kinase regulates VEGF via NF-kappaB/
p65 subunit. Altogether, our study suggests that in hypoxic pancreatic tumors
PKM2 interferes both with NF-kappaB/p65 and HIF-1alpha activation that ul-
timately triggers VEGF-A secretion and subsequent blood vessel formation.
#1810 Dysregulation of myristoylated alanine-rich C kinase substrate
(MARCKS): A novel therapeutic target in renal cell carcinoma. Ching-Hsien
Chen,1Wen-Hsin Chang,2 Eric Yu,1 Muhammad S. Arif,1 ReenWu,3 Robert H.
Weiss1. 1Division of Nephrology, Department of Internal Medicine, University of
California Davis, Davis, CA; 2Institute of Molecular Medicine, National Taiwan
University College of Medicine; Division of Nephrology, Department of Internal
Medicine, University of California Davis, Taiwan; 3Department of Internal Med-
icine, Division of Pulmonary and Critical CareMedicine and Center for Compar-
ative Respiratory Biology and Medicine, University of California Davis, Davis,
CA.
Targeted therapeutics, such as those abrogating hypoxia inducible factor
(HIF)/VEGF signaling, are initially effective against kidney cancer (or renal cell
carcinoma, RCC); however, drug resistance frequently occurs via subsequent
activation of alternative pathways. Through genome-scale integrated analysis of
theHIF-network,we identifıed themajor protein kinaseC substrateMARCKS
(myristoylated alanine-richC kinase substrate) as a potential targetmolecule for
kidney cancer. In a screen of nephrectomy samples from 56 patients with RCC,
we found that MARCKS expression and its phosphorylation are increased and
positively correlate with tumor grade. Genetic and pharmacologic suppression
of MARCKS in high grade RCC cell lines in vitro led to a decrease in cell prolif-
eration and migration. We further demonstrated that higher MARCKS expres-
sion promotes growth and angiogenesis in vivo in an RCC xenograft tumor.
MARCKS acted upstream of the AKT/mTOR pathway, activating HIF-target
genes, notably VEGF-A. Following knockdown of MARCKS in RCC cells, the
IC50 of the multi-kinase inhibitor regorafenib was reduced. Surprisingly, atten-
uation of MARCKS using the MPS peptide synergistically interacted with rego-
rafenib treatment and decreased survival of kidney cancer cells through inacti-
vation of AKT and mTOR. Our data suggest a major contribution of MARCKS
to kidney cancer growth and provide an alternative therapeutic strategy of im-
proving the effıcacy of multi-kinase inhibitors.
#1811 A PEAK1/GATA2 signaling axis controls VEGFR2 expression to
mediate angiogenesis. Richard L. Klemke. UCSDMoores Cancer Ctr., La Jolla,
CA.
Formation of new blood vessels (angiogenesis) is crucial for proper develop-
ment, but can also contribute to many diseases including cancer. Vascular en-
dothelial growth factor receptor 2 (VEGFR2) is a receptor tyrosine kinase that
mediates angiogenesis in developing vertebrates and is frequently upregulated
in many human cancers. However, the underlying mechanisms that regulate
VEGFR2 expression in normal and diseased cells are poorly understood. Here
we demonstrate that pseudopodium-enriched atypical kinase 1 (PEAK1) medi-
ates developmental and tumor-induced angiogenesis by modulating VEGFR2
expression and downstream signaling. Knockout of peak1 in zebrafısh using
TALEN technology (Transcription Activator-Like Effector Nucleases) or
knockdown by specifıc peak1 morpholinos (MO) induced severe pericardial
edema, blood-pooling defects, and inhibited formation of intersegmental (ISV)
and subintestinal vessels (SIV). In Peak1 knockout mice, neonatal retinal vessel
development was severely delayed, and the ex vivo angiogenic ability of adult
thoracic aorta was greatly reduced. Intravital time-lapse imaging of ISV forma-
tion in peak1 knockout zebrafısh revealed major defects in endothelial cell mi-
gration and proliferation. Similarly, PEAK1 knockdown or overexpression in
HUVECsmodulated endothelial cellmigration, proliferation, and vessel sprout-
ing in vitro. Biochemical studies and quantitative proteomic profıling of PEAK1
knockdown HUVECs revealed a dramatic loss of VEGFR2 mRNA and protein
expression, which attenuated downstream signaling to Akt and ERK, leading to
loss of VEGF-mediated vessel formation. PEAK1 specifıcally regulatedVEGFR2
levels and did not alter VEGFR1 expression, and reconstitution of PEAK1
knockdown cells with PEAK1 restoredVEGFR2mRNAand protein expression.
Mechanistic studies revealed that PEAK1 specifıcally regulates VEGFR2mRNA
transcription by modulating expression of the transcription factor GATA2. Re-
expression of GATA2 in PEAK1 depleted cells restored VEGFR2 mRNA and
protein expression as well as downstream signaling, indicating that GATA2 is a
necessary downstream component in this response. Also, introduction of gata2
mRNA into PEAK1 knockdown zebrafısh restored normal ISV formation and
vegfr2 mRNA expression in these animals. Finally, bioinformatics and interro-
gation of the TCGA RNAseq database revealed signifıcant Pearson’s correla-
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tions between PEAK1 and VEGFR2 expression in 17 of 32 different human
cancers. Collectively, our fındings indicate that PEAK1 regulates developmental
and tumor-induced angiogenesis by regulating GATA2-dependent VEGFR2
expression and its downstream signals.
#1812 In vitro and in vivo antiangiogenic activity of desacetylvinblastine
monohydrazide through inhibition of VEGFR2 and Axl pathways.Minfeng
Chen,1 Xueping Lei,1 Qiulin Nie,1 Jianyang Hu,1 Zhenjian Zhuo,1 Anita Yiu,2
Heru Chen,1 Nanhui Xu,1 Maohua Huang,1 Kaihe Ye,1 Liangliang Bai,1 Wencai
Ye,1 Dong-Mei Zhang1. 1College of Pharmacy, Guanghzou, China; 2School of Life
Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Background and Objective: Tumor angiogenesis process is regulated by mul-
tiple proangiogenic pathways, such as VEGFR2 and Axl. Inhibition of VEGF/
VEGFR2 signaling alone fails to block tumor neovascularization, and anti-
VEGF resistance is often associated with Axl. Hence, discovery of novel agents
that target multiple angiogenesis pathways is in demand. Here, we describe
desacetylvinblastine monohydrazide (DAVLBH), a derivative of vinblastine
(VLB) that exerts a more potent antiangiogenic effect than VLB in vitro and in
vivo by inhibiting VEGFR2 and Axl pathways. Methods: The antiangiogenic
effects of DAVLBH were studied in vitro (proliferation, migration, and tube
formation assays) and ex vivo (aortic ring assay). In vitro pericyte migration to
endothelial tubes was assessed using a three-dimensional co-culture assay. In
vivo assay was performed in HeLa xenograft model. Western blotting, immu-
nohistochemical and immunofluorescence assays were conducted to evaluate
the key proteins of the VEGF/VEGFR2 and Gas6/Axl pathways. Results: DAV-
LBH (1 nM) inhibited VEGF- and Gas6-induced angiogenesis in vitro. At 0.75
mol/kg, DAVLBH signifıcantly delayed tumor growth and reduced vascular
density in vivo, which was associated with the inactivation of VEGF/VEGFR2
and Gas6/Axl signalling pathways. DAVLBH blocked the compensatory up-
regulation of Axl in response to bevacizumab treatment in HUVECs. DAVLBH
also suppressed the recruitment of pericytes to well-established endothelial
tubes and reduced pericyte coverage in vivo, which was accompanied by inhibi-
tion of Axl. Conclusions: DAVLBH potently inhibited angiogenesis-mediated
tumor growth by blocking the activation of VEGF/VEGFR2 andGas6/Axl path-
ways. DAVLBH might serve as a promising antiangiogenic agent for cancer
therapy.
#1813 Bevacizumab potentiates the proteomic response to neoadjuvant
chemotherapy in breast cancer patients: Rppa exploration of consecutive tu-
mor samples in the NeoAva randomized phase II trial.MadsH. Haugen,1 Ole
Christian Lingjaerde,2 Marit Krohn,1 Wei Zhao,3 Evita M. Lindholm,1 Laxmi
Silwal-Pandit,1 Elin Borgen,4 Øystein Garred,4 Anne Fangberget,4 Marit M.
Holmen,4 Ellen Schlichting,4 Helle K. Skjerven,5 Steinar Lundgren,6 ErikWist,4
Bjørn Naume,4 Gunhild M. Maelandsmo,1 Yiling Lu,3 Anne-Lise Boerresen-
Dale,1 Gordon B.Mills,3 Olav Engebraaten1. 1Oslo University Hospital - Institute
for Cancer Research, Oslo, Norway; 2University of Oslo, Oslo, Norway; 3MD An-
derson Cancer Center, Houston, TX; 4Oslo University Hospital, Oslo, Norway;
5Vestre Viken Hospital, Drammen, Norway; 6St. Olav’s University Hospital,
Trondheim, Norway.
Antiangiogenic therapy using bevacizumab has proven effective for a number
of cancers; however, in breast cancer there is an unmet need to identify patients
that benefıt from such treatment. Sampling of tumor biopsies before and during
treatment, as well as at the time of surgery enables the assessment of response at
multiple molecular levels. At the proteomic level reverse phase protein analysis
(RPPA) support expression of numerous cancer associated proteins simultane-
ously, which can further be used to unravel molecular mechanisms associated
with clinical response to bevacizumab treatment. In this phase II clinical trial,
patients with HER2 negative primary tumors of 
25 mm were treated with
neoadjuvant chemotherapy (4 x FEC100  12 weeks of taxane-based therapy)
and randomized (1:1) to receive bevacizumab or not. Mammography, ultra-
sound and MR imaging were used for response evaluation, in addition to fınal
pathology assessment. Tumor responseswere evaluable in 132 patients; ofwhich
66 received bevacizumab. Ratio of the tumor size at fınal pathology assessment,
and at inclusion was calculated to obtain a continuous scale of response reflect-
ing the percentage of tumor shrinkage in response to therapy. Tumor biopsies
were removed before start of treatment, at week 12 at the start of taxane-based
tharapy and at the time of surgery. Lysates from each sample was analyzed on
reverse phase protein arrays (RPPA) for expression levels of 210 proteins of
which 54 were phospho-specifıc. The addition of bevacizumab to the chemo-
therapy do not alter proteomic response from week 0 to 25 to such extent that
this patient group cluster naturally together.While the proteomic response from
week 0 to 12 in both treatment arms had an overall similar profıle regarding up-
and down-regulated proteins, the combination treatment (FEC100  bevaci-
zumab) induced substantiallymore effect on the regulation of each protein. This
suggests that bevacizumab treatment have the capability to potentiate the effects
of the anthracyclin based chemotherapy from week 0 to 12. Conversely, from
week 12-25 (taxane-based therapy  bevacizumab) this effect was lost or even
reversed, possibly due to a de-vascularized and less accessible tumor. An excep-
tion to this observation was a few phospho-proteins that do seem to have sus-
tained stronger regulation over the whole treatment period. We are in the pro-
cess of analyzing in more detail the impact of phosphorylation and thus protein
activation states on treatment response. Deciphering molecular response and
activity regulation at the proteomic level is a promising approach andmay reveal
novel knowledge with potential important clinical relevance.
#1814 IL11 mediates tumor resistance to anti-VEGF therapy in lung can-
cer. Jie Li, Kun Xie, Shenglin Mei, Yuanjian Xu, Hua Gu, Dong Li, Kaiming
Chen, Fei Tao, Jiya Eerdeng, Jianmin Fang. Tongji University, Shanghai, China.
Anti-angiogenic therapy has been used for the treatment of a number of solid
tumors in clinic, however, survival benefıt is often limited due to development of
tumor resistance to the therapy. In previous studies, we developed a mouse
Lewis lung carcinoma (LLC) tumor model that is resistant to anti-VEGF ther-
apy. In this model, we identifıed that Interleukin 11 (IL11) was among the most
signifıcantly upregulated genes in the resistant tumors. In current study, we
demonstrated that IL11 was a pro-angiogenic factor and played a key role in the
development of resistance to anti-VEGF therapy in LLC tumor. IL11 could
effectively induceHUVECproliferation,migration and capillary tube formation
in vitro. It enhanced expression of MMP9 in endothelial cells. The conditioned
medium from the resistant LLC cell culture could induce HUVEC migration,
even VEGF was blocked, and this effect was attenuated by recombinant IL11
decoy receptor, an IL-11 inhibitor. Furthermore, combination therapy of anti-
VEGF agent and IL11 blockade exhibited enhanced anti-tumor activity in lung
cancer model. In addition, based on bioinformatics analysis on over 500 RNA-
seq data deposited to The Cancer Genome Atlas (TCGA), we found that IL11
was highly expressed in various tumor types in patients. Data showed that high
IL11 can predict a poor outcome in the lung cancer. The patients with the lower
IL11 expression have signifıcantly longer median survival time than those with
higher expression. These fındings support a role of IL11 signal as a compensa-
tory angiogenic pathway thatmight trigger tumor resistance to anti-VEGF treat-
ment. Therapeutically targeting IL11 could have a value in overcoming tumor
resistance to anti-VEGF therapy.
#1815 Extracellular vesicles derived from lung cancer cell may contribute
to the formation of malignant pleural effusion via activating Stat3/Tissue
factor/VEGF. Chien-Chung Lin, Wei-Lun Huang, Wu-Chou Su. National
Cheng Kung Univ. Hospital, Tainan, Taiwan.
Malignant pleural effusion (MPE) is a poor prognostic sign for patients with
non-small-cell lung cancer (NSCLC) and is noted around 15% at the time of
initial diagnosis and 50% in their later courses. Previously, we have shown that
IL-6/Stat3/tissue factor (TF)/VEGF pathway enhances lung cancer angiogene-
sis,metastasis and the generation ofMPE. In the current study,we demonstrated
that EVs derived from lung cancer cellsmay also contributeMPE formation.We
fırst used ultra-fıltration (UF)method aswell as the classical ultra-centrifugation
(UC)method to isolate EV from lung cancer cell line and demonstrated that the
EVs isolated byUFmethodwere characteristicwith exosomemarker inWestern
Blotting (Alix, CD63, and Tsg101), morphology at Transmission electron mi-
croscopy (TEM) and size in Nanosight system (30 to 150 nm). After labeling
these EVs with the green fluorescent dye Cellvue, EVs uptake in AS2 cell can be
imaged by the fluorescent microscopy. After the EV uptake of recipient cell, the
oncogenic signal such as Stat3 and AKT were activated with increasing phos-
phorylation atWestern blotting comparing to those adding serum freemedium.
Using the ELISAmethod, we found the cargos in these EVwere enriched in IL6.
We also found these cargo derived from EVs, containing high VEGF and TF,
induced more prominent extravasation than serum free medium did in Miles
assays. In clinical sample, we also isolated cancer cell fromMPEand the purity of
the cells was confırmed by immunofluorescent staining with specifıc TTF-1ex-
pression of lung adenocarcinoma. After short-term culture, EV fromMPE can-
cer cell have the characteristic of exosomemarker and inducedmore prominent
extravasation than serum free medium as EV from AS2 cell did. And we also
isolated EV direct fromMPE and pleural effusion from congestive heart failure
(CHF) patients. And we found EV derived fromMPE induced more prominent
extravasation than those derived from CHF in Miles assays. In conclusion, we
demonstrated the UF is clinical assessable method for isolating EV from body
fluid and EV derived from lung cancer cell and MPEmay contribute oncogenic
and angiogenic signal transmission accelerating the formation of MPE.
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#1816 Endogenous ADAMTS-13 regulates angiogenesis in cultured hu-
man endothelial cells.Huiyuan Tang,Manfai Lee, EunHoKim, Daniel Bishop,
George M. Rodgers. University of Utah, Salt Lake City, UT.
ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13, is a zinc-containing metalloprotease that cleaves von
Willebrand factor (vWf). Previous publications by our laboratory have shown
thatADAMTS-13may also be involved in angiogenesis; for example; addition of
exogenous ADAMTS-13 enhances endothelial cell (Lee et al. Microvascular Res
2012; 84:109) and glioblastoma cell (Lee et al. Blood 2013; 122:#2306) migration
and proliferation. For this study, we report the successful transient knockdown
of endogenous ADAMTS-13 in human umbilical vein endothelial cells
(HUVEC) via siRNA. 30pmols of ADAMTS-13 siRNA in a six-well plate inhib-
ited HUVEC ADAMTS-13 expression levels by 90% after 24hr incubation,
whereas control siRNA did not affect endogenous ADAMTS-13 levels. The
knockdown effect was decreased over time: 72hr after the initial knockdown,
ADAMTS-13 expression was reduced by only 50%. The effects of reduced en-
dogenous ADAMTS-13 on HUVEC angiogenesis functions were studied.
Transfection ofHUVECwith 10pmols of ADAMTS-13 siRNA in a 24-well plate
resulted in a 21% and 22% decrease in proliferation after 24hr and 48hr incuba-
tion, respectively. The effects of ADAMTS-13 knockdown on migration of
HUVECacross a scratchwoundwere also evaluated. 24hr after transfectionwith
control siRNA, there was robust cell migration across the scratch wound. This
dramatic migration did not occur with ADAMTS-13 knockdown cells. De-
creased expression of endogenous ADAMTS-13 also affected angiogenesis as
measured by endothelial cell tube formation using a Matrigel matrix method.
The tube lengths, sizes and junction numbers of the ADAMTS-13 knockdown
cells were all signifıcantly lower compared to control cells by about 40%.Activity
of the AKT pathway, one of the angiogenesis downstream signaling pathways
was down-regulated by ADAMTS-13 siRNA while ERK, a component of the
MAP kinase pathway was not affected upon knockdown of ADAMTS-13. These
data indicate that in cultured endothelial cells, one role of endogenous AD-
AMTS-13 is regulation of angiogenesis, mediated through the AKT signaling
pathway. Overall, our data suggest an additional model of endogenous AD-
AMTS-13 functionality, beyond that of cleaving von Willebrand factor.
#1817 Resistin induces angiogenesis and lymphangiogenesis in human
chondrosarcoma.Meng-Ju Chi, Chih-Yang Lin, Chih-Hsin Tang. China Med-
ical University, Taichung City, Taiwan.
Chondrosarcoma is a common kind of bone cancers, and it may develop
distant metastasis, followed by a signifıcant decline in overall survival. How-
ever, there are still no specifıc therapeutic methods for it today. For tumors to
metastasis, angiogenesis and lymphangiogenesis are both important in the
early processes. Therefore, inhibiting the development of angiogenesis and
lymphangiogenesis could be a method to decline tumor metastasis. Resistin
was discovered as an adipocyte-secreting adipokine, which may play a crit-
ical role in modulating cancer pathogenesis. In our lab, we previously found
that resistin appears to increase MMP-2 expression and then promotes me-
tastasis in human chondrosarcoma cells. Nevertheless, the role of resistin in
angiogenesis and lymphangiogenesis of human chondrosarcoma is still un-
known. To examine angiogenetic and lymphangiogenetic effects of resistin,
we used human endothelial progenitor cells (EPCs) and lymphatic endothe-
lial cells (LECs) to mimic capillary and lymphatic vessels formation. The
results indicated that resistin-treated chondrosarcoma cell lines promoted
EPCs VEGF-A-dependent as well as LECs VEGF-C-dependent tube forma-
tion and cell migration. Then we confırmed that treating cells with resistin
increased VEGF-A and VEGF-C expression in human chondrosarcoma cell
lines. Moreover, we found resistin-induced VEGF-A and VEGF-C expres-
sions are mediated by PI3K/AKT signaling and by the activation of c-Src
separately. In addition, resistin decreased the expression of miR-16-5p via
PI3K/AKT pathway, and so of miR-186 via c-Src. We also demonstrated that
miR-186 directly targeted on VEGF-C 3’ untranslated region, and regulated
the VEGF-C production. Besides, we found the expressions of resistin,
VEGF-A and VEGF-C was higher in human chondrosarcoma biopsy tissues
than those in normal cartilage. Taken together, resistin not only promotes
human chondrosarcoma angiogenesis through the activation of PI3K/AKT
signaling pathway and down-regulating miR-16-5p expression, but also pro-
motes human chondrosarcoma lymphangiogenesis through the activation of
c-Src and down-regulating miR-186. Consequently, resistin may represent a
potential novel molecular therapeutic target for human chondrosarcoma
therapeutic treatment.
#1818 Enhanced antitumor and anti-angiogenic effects of Apatinib com-
bined with chemotherapy in a zebrafıshmodel of non-small cell lung cancer.
Yi Xiang,1 Wenchao Zhang,1 Zhuanbin Wu,2 Zijun Qian,1 Jianping Zhou,1
Xiaofei Wang,1 Weiqin Wang,3 Ling Zhou,1 Jing Liu,1 Yun Feng,1 Min Zhou,1
Guochao Shi,1 Beili Gao1. 1Rui Jin Hospital, Shanghai Jiao Tong University,
School of Medicine, Shanghai, China; 2Shanghai Biomodel Organism Science &
Technology Development Co., Ltd, Shanghai, China; 3Tong Ren Hospital, Shang-
hai Jiao Tong University, School of Medicine, Shanghai, China.
Background: Apatinib is a highly selective VEGFR2 inhibitor, but its effects
on non-small cell lung cancer (NSCLC) has not been widely reported and
whether there is synergistic effect ofApatinib and conventional chemotherapeu-
tic drugs is also unclear. Methods: In vitro, MTT assay was used to evaluate the
combination effects of Apatinib and chemotherapy agents (Gemcitabine, Pacli-
taxel and Pemetrexed) against A549 (EGFR negative mutation cell line) lung
cancer cells. In vivo, we fırstly assessed the safety of Apatinib and chemotherapy
agent in zebrafısh model by observing organ developmental malformation and
zebrafısh embryos mortality induced by drug toxicity. The inhibition effect on
the development of blood vessel in zebrafısh was used to assess antiangiogenic
property of Apatinib. By means of microinjection, A549 cells stained with red
fluorescent cell tracer CM-Dil fluorescence were grafted into the yolk sac of
zebrafısh embryo. Then, zebrafısh were incubated with Apatinib, chemotherapy
agents or Apatinib combined chemotherapy agents, respectively. The tumor
xenografts volume was measured by estimating the relative fluorescence inten-
sity. Q-RTPCR was used to detect the expression of some genes associated with
angiogenesis in order to identify molecular mechanism of the combination ef-
fects of Apatinib and chemotherapy agent. Results: Apatinib had a direct inhib-
itory effect on A549 cells with the IC50 values ranging from 2.693 to 5.384mol.
Apatinib combined with Pemetrexed gave the most optimal anti-tumor effect
compared with Gemcitabine or Paclitaxel in vitro. In zebrafısh model, the LC50
value of Apatinib to zebrafısh embryos was only half it of Pemetrexed to ze-
brafısh embryos, suggesting that Apatinib is a low toxicity agent. In addition,
Apatinib strongly inhibits the process of angiogenesis but not the developed and
mature vasculature, suggesting that Apatinib can effectively inhibit tumor an-
giogenesis in lung cancer patient, which is aided in suppressing tumor growth.
As for antitumor effects, Apatinib or Pemetrexed, whatever alone or combina-
tion all signifıcantly inhibited tumor growth and the co-treatment of Apatinib
and Pemetrexed gave the most optimal anti-tumor effect, suggesting that the
combination of apatinib and Pemetrexed may be a promising alternative ther-
apy for lung cancer patients. Finally, the qRT-PCR showed that in addition to
synergistically inhibiting VEGFR2 gene expression, co-treatment of Apatinib
and Pemetrexed also synergistically inhibit Efnb2a, Robo4 and FGFR4 gene
expression. Conclusions: Apatinib combined with chemotherapies, especially
Pemetrexed, synergistically enhanced anti-tumor and anti-angiogenic effects in
zebrafısh model of NSCLCmainly through inhibiting VEGFR2, Efnb2a, Robo4
and FGFR4 pathways.
#1819 Reprogramming the tumor microenvironment by targeting endo-
thelial DNA repair. Cristina Espinosa-Diez, RaeAnna Wilson, Rebecca Ruhl,
Nathan Kanner, Namita Chatterjee, Clay Hudson, Sudarshan Anand. Oregon
Health & Science Univ., Portland, OR.
The tumor microenvironment (TME) plays a critical role in orchestrating
immune infıltration, tumor progression and response to therapeutics. There-
fore, strategies to manipulate the TME including cytokine gene therapy, anti-
bodies to reversemacrophage polarization etc are under active investigation.We
have identifıed an alternative approach to target the TME by disrupting DNA
repair in the tumor endothelial cells (ECs). We discovered a seven-microRNA
(miR) signature induced in ECs in in vitro and in vivo by oxidative stress and
DNA damage. The top miR candidate in this signature, miR-103 altered the
TMEby inducingDNAdamage in ECs, eliciting type I interferons, upregulating
immune costimulatory receptors and decreasing PD-L1 expressing tumor asso-
ciated macrophages and granulocytes. Moreover, miR-103 treatment had a
paracrine effect on the tumors and upregulated Fas andTRAIL receptors.Mech-
anistically, these functions of miR-103 were largely due to its downregulation of
the three prime exonuclease TREX1. Local, systemic or vascular targeted deliv-
ery of miR-103 decreased both angiogenesis and tumor burden in multiple
mouse tumor models. Complementary to the role of miR-103, two additional
miRs in the miR signature, miRs 494 and 99b each induced senescence in the
vasculature by downregulating theMre11a-Rad50-NBN (MRN) complex. Ecto-
pic expression of miRs 494 or 99b decreased telomerase activity, increase p21
levels with a concomitant decrease in pRb levels. Vascular targeted delivery of
miR-494 decreased angiogenesis in vivo whereas systemic delivery decreased
tumor growth. Interestingly, both miR mimics and the MRN knockdowns in-
duced the transcription of a number of senescence associated genes including
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CD44. Taken together these data suggest that miRs 494 and 99b targeting of the
MRN complex induces senescence. The MRN complex interacts with the ATM
kinase, histoneH2AXandTREX1 suggesting that themiRswe identifıed disrupt
critical nodes of a DNADamage Response (DDR) network. Our fındings reveal
a complex, miR mediated cross talk between EC DNA damage pathways, the
TME and tumor cells. These interactions can be exploited for designing thera-
pies that synergize with tumor cell killing to enhance host anti-tumor responses.
#1820 Synergistic lethality of mAbs with an EMT reversal agent, Nint-
edanib, in epithelial ovarian cancer. Jocelyn Teo,1 Heng Liang Tan,1 Ruby
Yun-Ju Huang,2 Andre Choo1. 1A*STAR, singapore, Singapore; 2Cancer Science
Institute, singapore, Singapore.
Epithelial-mesenchymal transition (EMT) has long been associated with can-
cer progression and metastasis. As a reversible process, it has the potential to be
a target for cancer therapy. However, this concept of reversing EMT has not yet
been widely explored in current treatment strategies. With the identifıcation of
Nintedanib as an EMT reversal agent, we aim to broaden the utility of this triple
angiokinase inhibitor by identifying agents that show synergistic lethality with
it, using monoclonal antibodies (mAbs) as a combinatory therapeutic. Nint-
edanib alone is not signifıcantly cytotoxic to cells, but it causes cell cycle arrest
and reverses EMT. By selecting for this sub-population of cells that are sensitive
to Nintedanib, their subsequent eradication can then be more intricately di-
rected. Since the anti-cancer application of EMT reversal agents are not fully
developed, it is vital to investigate mechanisms that sensitize cancer cells to
cytotoxic agents following EMT reversal.Our group has generated panels of
mAbs that are able to bind differentially to various breast and ovarian cancer cell
lines along the EMT spectrum. Some mAbs preferentially bind to Epithelial
lines, while some have stronger affınity to Mesenchymal lines. This implies that
mAbs have the ability to differentiate between epithelial andmesenchymal phe-
notypes, uncovering a new dimension to the capability of mAbs which have yet
to be explored.Using amesenchymal ovarian cancer cell line as a startingmodel,
Nintedanib-treated cells were screened with the mAbs and those showing a
2-fold increase in bindingwere shortlisted for further validation. Based on this
criteria, 26 mAbs were identifıed and further characterized in functional Anti-
body Drug Conjugate (ADC) assays with mAbs conjugated to a toxic drug,
Saporin (or Zap).Mabs successfully internalizing and killing the cancer cells will
then be further chosen for antigen characterization and in vivo functional stud-
ies. Ultimately, there is huge potential for mAbs to be discovered that shows
synergy with Nintedanib to enhance lethality to various types of cancer cells. A
novel clinical strategy, the application of EMT reversal in terms of utilising a
synthetic lethality-like approach allows better design of combinatory therapeu-
tics, increasing treatment effıcacy that might revolutionalise cancer treatment.
#1821 Sympathetic nerves regulate a metabolic switch promoting angio-
genesis through adrenergic signaling in prostate cancer. Ali Zahalka,1 Anna
Arnal-Estape,2 Maria Maryanovich,1 Fumio Nakahara,1 Cristian Cruz,1 Paul S.
Frenette1. 1Albert Einstein College of Medicine, Bronx, NY; 2Yale School of Med-
icine, New Haven, CT.
Nerves pattern the vasculature during development and regeneration. Recent
studies have shown that the sympathetic nervous system (SNS) is coopted to pro-
mote carcinogenesis, and that depletion of SNS -adrenergic receptors (ARs) in
the prostate stromal compartment inhibits tumor growth. As the vasculature is in
direct contact with the SNS, and regulates tumor glucose and oxygen delivery, we
aimed to identify the stromal populations thatmediate SNS signaling and themech-
anisms bywhich loss ofAR signaling inhibits prostate cancer progression. In vivo
xenograft tumor growth was measured in Adrb2/; Adrb3/mice using an or-
thotopic PC3-luciferase model. Prostate cancer progression in the transgenic au-
tochthonous HI-myc model was assessed after conditional Adrb2 deletion in stro-
malpopulationsby intercrossingAdrb2fl/fl line to stromalCre lines.Metabolismwas
measured ex vivo by flow quantifıcation of the lipophilic cationic dye TMREwhose
accumulation reflectsmitochondrialmembrane potential, and byNADHautofluo-
rescenceunderUVexcitation. Invitrooxidativephosphorylationandglycolytic flux
were measured in primary prostate endothelial cells (VeraVec) using the Seahorse
bioanalyzer and targeted gas chromatography-mass spectrometry (GC/MS). Dele-
tion of the SNSARneural receptors in themicroenvironment synergized to arrest
exponential tumorgrowth. Imaging the tumorvasculature revealedadefect invessel
branching, a phenotype also observed after chemical sympathectomy, suggesting
altered angiogenesis in the absence of AR stimulation. Histology revealed an in-
crease in vascular innervation and density during the transition from low to high
grade pre-neoplastic PIN. Conditional Adrb2 deletion (Adrb2cKO) in endothelial
cells (ECs), but not myeloid cells or pericytes, not only inhibited angiogenesis, but
also reduced disease progression throughout all histopathological cancer
stages. Transcriptome analysis of flow isolated Adrb2cKO ECs suggested an
increase in oxidative metabolism and upregulation of mitochondrial Coa6.
Ex vivo analysis of ECs revealed a metabolic switch during the low to high
grade PIN transition, and this switch was inhibited by Adrb2cKO. Further in
vitro characterization by Adrb2 knockdown revealed ametabolic shift in ECs
to oxidative phosphorylation, which was mediated by Coa6 upregulation. As
Coa6 cooperates with Cox10 in respiratory complex IV assembly, condi-
tional co-deletion of Adrb2 and Cox10 in the HI-myc mouse rescued aerobic
glycolysis, angiogenesis, and cancer progression. Our data thus demon-
strates that the SNS mediates a pro-angiogenic switch during the early stages
of prostate carcinogenesis. Moreover, we identifıed ECs as SNS stromal tar-
gets, and that abrogation of AR signaling inhibits the angio-metabolic
switch and delays prostate cancer progression, suggesting a novel therapeu-
tic target for prostate cancer treatment.
#1822 Antitumor activity of agents targeting the angiogenic factors an-
giopoietin-2 and thymidine phosphorylase inmousemodels of lung andpan-
creatic neuroendocrine cancer. Evelyn Aranda, Ziqiang Yuan, Steven K. Li-
butti, Edward L. Schwartz. Albert Einstein College of Medicine, Bronx, NY.
Angiogenesis is a critical component of the initiation, maintenance and
progression of tumors, and has been the target of extensive drug develop-
ment. In clinical practice there are several approved and investigational anti-
angiogenesis drugs, the majority of which primarily target the VEGF path-
way, however their long term effectiveness remains limited. In designing
new drug regimens, it is important to consider other known angiogenic
factors that likely contribute to the pro-angiogenic phenotype. We evaluated
two such factors: thymidine phosphorylase (TP) (aka platelet-derived endo-
thelial cell growth factor, PD-ECGF), an enzyme that can stimulate endothe-
lial cell migration, and angiopoietin 2 (Ang2), a member of the Ang/Tie2
signaling pathway. To target TP, we used a novel, highly specifıc, orally
available small molecule inhibitor, which we had previously designed,
named AEAC. To target Ang2, we used an Ang2 neutralizing peptibody,
L1-7[N] (provided by CTEP-NCI), which is a genetically engineered pep-
tide-Fc fusion protein that specifıcally binds Ang2. In a mouse NCI-H460
NSCLC sc xenograft model, AEAC and L1-7[N] produced 33% and 67%
reductions, respectively, in tumor growth, and the combination produced a
small, but statistically signifıcant further reduction, when compared to either
agent used alone. Tumor growth inhibition was paralleled by a reduction in
Ki-67 staining. L1-7[N] also produced a large infıltration of macrophages
(F4/80) into the tumors after treatment. We also tested the drug combina-
tion in amouse genetic model of pancreatic neuroendocrine tumors (PNET).
PNET are one the few human solid tumors that are clinically responsive to
angiogenesis inhibitors used alone. These mice have a conditional knockout
of the Men1 gene in the endocrine pancreatic cells (Pdx1-Cre;Men1 mice)
mimicking a primary genetic alteration seen in human disease. Men1 KO
PNET experiments were initiated when the mice were 10-11 months old, and
drug treatment was daily (5 days per week) for 3 weeks. To date, we have not
seen any antiangiogenic or antitumor effects of the drugs. Upon sacrifıce, the
mice were found to have extensive insulinomas, involving around 70% of the
entire pancreas. CD31() and F4/80() cells in the pancreas showed that
most of them concentrated inside the PNET, however there was no change
after the treatments. Studies are currently underway to determine if higher
doses and/or starting treatment at an earlier time would be more effıcacious.
#1823 Characterization of the anti-angiogenic properties of merestinib
(LY2801653), anoncokinase inhibitor.DianeM.Bodenmiller, JulieA. Stewart,
Glenn F. Evans, Victoria L. Peek, Jennifer R. Stephens, Xi Lin, Seema Iyer, Bev-
erly L. Falcon, Sudhakar Chintharlapalli, Sau-Chi Betty Yan, Anthony S. Fischl.
Eli Lilly and Company, Indianapolis, IN.
Merestinib (LY2801653) is an orally bioavailable smallmolecule inhibitor of sev-
eral oncokinases, includingMET, AXL, DDR1/2, MERTK, ROS1, Tie2 (aka TEK),
and MKNK1/2. Merestinib has been extensively characterized in a wide range of
preclinical tumor xenograft models and shown to potently inhibitMET driven and
non-MET driven tumor growth. In addition to its direct antitumor activity, meres-
tinib inhibits angiogenesis and induces a tumor vessel normalization phenotype in
xenograft tumors1.WhileMET signaling is important for angiogenesis, the effect of
merestinib on angiogenesis is likely not exclusively driven by MET inhibition. In
co-culture angiogenesis assays, merestinib inhibited VEGF-dependent and VEGF-
independent endothelial cell cord formation2,3 and sprouting4with potencies in the
low nM range (3-30 nM). In contrast, the MET-specifıc kinase inhibitor,
PF04217903, onlyweakly inhibited cord formation and endothelial sprouting. In an
established in vivo matrigel co-implant vasculogenesis model where VEGFR2 or
MET selective inhibition hadminimal effect, merestinib decreased vascular density
by 69%. In addition, while MET antibody emibetuzumab (human anti-MET anti-
TUMOR BIOLOGY: Angiogenesis and Vascular Biology 2
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017468
body) plus ramucirumab (human anti-VEGFR2 antibody) decreased vascular den-
sity by 64%, merestinib plus ramucirumab decreased it by 92%. In a mouse adeno-
virus-driven VEGF-A ear angiogenesis model5, treatment with DC101, a mouse
anti-VEGFR2 antibody, or merestinib inhibited angiogenesis; however the combi-
nation of DC101 and merestinib appeared to inhibit it even more. Finally, in the
MKN45 gastric tumor xenograft model, merestinib (T/C 4.8%) and DC101 (T/
C 15.3%) each signifıcantly inhibited tumor growth alone and the combination
resulted in 27.6% tumor regression andwas signifıcantly better than either single
agent alone. Together, these studies indicate that merestinib has greater effects
on angiogenesis than selectiveMET inhibition and its actions are not dependent
on VEGFR2. In addition, while in vitro studies show reductions in VEGFR2
phosphorylation with high concentration of merestinib, treatment with meres-
tinib did not inhibit VEGF dependent phosphorylation of VEGFR2 in mouse
lung tissue at clinically relevant exposures. These data suggest that the anti-
angiogenic activity of merestinib includes activities of other kinases targeted by
merestinib. These data provide rationale and support for the clinical evaluation
of combination of merestinib with ramucirumab (NCT02745769). 1-Yan et. al.
Invest NewDrugs. 2013;31:833-844, 2- Falcon et. al. J HematolOncol. 2013;6:31,
3- Falcon et. al. PLoSONE. 2014;9:e106901, 4- Nakatsu et. al. Methods Enzymol.
2008;433:65-82, 5- Nagy et. al. Methods Enzymol. 2008;444:43-64.
#1824 Endothelial mTORC2 defıciency inhibits tumor angiogenesis, tu-
mor progression andmetastasis in non-small cell lung cancer (NSCLC). Shan
Wang. Vanderbilt University Medical Center, Nashville, TN.
Vascular endothelial cells (ECs) are specialized components of the tumor
microenvironment that orchestrates tumor growth and invasion. They form
tumor-associated blood vessels (angiogenic) that supply nutrients and oxy-
gen, remove waste products, and also provide an entry site for tumorigenic
cells to spread to secondary sites in various organs. One of the major signal-
ing events in tumor vessels is PI3K/PDK-AKT-mTOR activation. mTOR is a
serine/threonine kinase that functions in two distinct complexes, mTORC1
and mTORC2,which regulate a diverse array of cellular processes including
cell growth, survival and metabolism. Although mTORC1, and to lesser
extent, mTORC2, has been broadly studied in cancers and diseases, little is
known regarding the relative contributions of mTORC1 versus mTORC2 in
tumor endothelium. Using mouse model of endothelium-specifıc Rictor (a
mTORC2 specifıc cofactor) gene targeting, we discovered that endothelial
Rictor deletion decreased tumor neovascularization, suppressed tumor
growth, and prevented metastasis in vivo. Direct co-culture of endothelial
cells and NSCLC tumor cells in vitro showed that knockdown of endothelial
Rictor inhibited tumor cell proliferation while Raptor (a mTORC1 specifıc
cofactor) depletion had a modest effect. However, loss of endothelial Rictor
or Raptor both markedly decreased tumor cell extravasation in response to
endothelial cells, and also inhibited tumor spheroid formation in a direct
co-culture system. Furthermore, a screen of phospho-kinase arrays revealed
that Raptor or Rictor depletion in endothelial cells decreased various phos-
phor-RTKs in tumor cells that were co-cultured with ECs, including mem-
bers of the Eph receptor family, Insulin receptor family and FGF receptor
family. Additionally, endothelial Rictor knockdown suppressed phosphory-
lation levels of nerve growth factor receptors TrkB and TrkC in tumor cells.
Collectively, these data suggest that endothelial mTORC1 andmTORC2 play
critical roles in regulating tumor progression through distinct signaling
pathways.
#1825 Angiopoietin-Tie-2 functional axis in colorectal cancer livermetas-
tasis (CRCLM) provides a new marker for stratifıcation and evaluation of
tumor progression. Nisreen S. Ibrahim. McGill University, Montreal, Quebec,
Canada.
Colorectal cancer (CRC) is the third leading cause of cancer in Canadians,
with liver metastases being the major cause of death from this disease. Tumors
induce angiogenesis, a phenomenon known as the ’angiogenic switch’, which is
an essential step in tumor progression whereby the balance of pro- and anti-
angiogenic factors are important for active angiogenesis. Clinical effıcacy of
targeted VEGF (anti-angiogenic) treatment has been validated as a cancer ther-
apy. Our group, together with others, has identifıed unique histological growth
patternsHGPs (desmoplastic, replacement and pushing) within livermetastases
that have different responses to anti-angiogenic therapy. The patients with Des-
moplastic HGP (DHGP) that received anti-angiogenic plus chemotherapy prior
to resection had a signifıcantly better pathologic response and survival than
patients with Replacement HGP (RHGP). The aim of this study was to explore
the role of Ang-1, Ang-2, Tie-2 and VEGF in the development and progression
of CRCLM tumors with distinct HGPs. Here, human CRCLM tumor samples
were analyzed by quantitative real-time PCR (Q-PCR) and immunohisto-
chemistry (IHC) staining. The Q-PCR results demonstrated that the expres-
sion of Ang-2 was lower in RHGP tumor samples compared with DHGP
tumor samples. This data was validated by IHC, were IHC scoring results
showed that the ratio of Ang-2: Ang-1 expression in DHGP tumors was
higher compared to RHGP tumors. VEGF and Tie2 proteins were expressed
in both tumor patterns. Thus vascular quiescence maintained by constitutive
Ang-1/Tie-2 signaling, found in RHGP tumors, prevails over destabilization
and pro-inflammatory Ang-2/Tie-2 signaling, which is higher in the DHGP
tumor samples. Since vascular remodelling is driven by Ang-2/Tie-2 in
DHGP, which is dependent on VEGF we would expect anti-angiogenic ther-
apy to be effective on DHGP. Furthermore, the RHGP had low levels of
Ang-2 and high levels of Ang-1, together with the presence of Tie-2, and then
one would predict that VEGF is not required for the growth of these tumors
and thus would not respond to anti-angiogenic therapy, as has been shown in
our patients’ cohort. Taken together, these data suggest that the Angiopoi-
etin/Tie-2 functional axis is an important player in CRCLM tumor progres-
sion and can be a potential target for CRCLM cancer therapy with stratifı-
cation of patients by HGPs.
#1826 Bioavailability, pharmacodynamics and safety profıle of a novel
anti-angiogenic compound JFD in pre-clinical models. Sivanesan Dhand-
ayuthapani, Thanigaivelan Kanagasabai, Khadija Cheema, Appu Rathinavelu.
Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern Univer-
sity, Fort Lauderdale, FL.
JFD, isoindole (1, 3-dioxo-2, 3-dihydro-1H-isoindol-4-yl)-amide, is a small
molecule that was developed using molecular modeling to specifıcally antago-
nize Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and associated
kinase activity, thereby producing anti-angiogenic and anti-cancer effects. Since
the original form of JFD is hydrophobic, it was recently modifıed into a water
soluble form (JFD-WS) to increase its water solubility and bioavailability. Ini-
tially, we investigated the in vitro pharmacodynamics effect of both JFD and
JFD-WS by utilizingMatrigel® tube formation assays, scratch and cell migration
assays followed by inhibition of VEGFR2 phosphorylation in human umbilical
vein endothelial cells (HUVECs). In vivo tumor growth inhibition of JFD and
JFD-WS was tested using GI-101A breast adenocarcinoma cells implanted
xenograft animals. Subsequently, the blood samples and the tumor proteins
were extracted from the control and experimental animals to measure the pro-
apoptotic signals and the levels of plasma biomarker such as MUC1 (mucin 1).
The safety profıle was established using Balb-cmice that were injected intraperi-
toneally (i.p) with JFD (6 mg/Kg body weight) and JFD-WS (100 mg/Kg body
weight) for 30 days. The pharmacokinetics (PK) of JFD including the plasma
concentration, excretion, elimination and distribution in the experimental ani-
mals were analyzed using a simple HPLC method. As expected, the JFD effec-
tively inhibited HUVECs migration, tube formation, and VEGFR2 phosphory-
lation. Moreover, both JFD and JFD-WS exhibited strong anti-tumorigenic
effects in xenograft implanted experimental animals that were evidenced by the
decreasing plasma levels ofMUC1. Thewestern blot analysis of apoptoticmark-
ers andDNA fragmentation analysis further confırmed the pro-apoptotic effects
of JFD as well as JFD-WS in our experimental system. Following i.p. injection,
there was a signifıcant distribution of JFD original into the liver, kidney, and
brain,which contained the highest concentration compared to other twoorgans.
When hematological, hepatic, renal and cardiac functionmarkerswere analyzed
in the experimental animals, that were treated with JFD-WS for four weeks, no
signifıcant alterations were found in the test group compared to the control
animals. Thus, whether used as a single agent or in combination with the other
anti-cancer drugs, JFD shows strong antitumor effects without producing severe
toxicities. The effıcient delivery of JFD original to the brain suggests that this
drug would be useful in treating solid tumors of the brain with pro-angiogenic
abilities. (This project was supported by the Community Foundation of Bro-
ward, Ft. Lauderdale, FL and The Royal Dames of Cancer Research Inc., Ft.
Lauderdale, FL).
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#1827 UsingDrosophila to study the role of metabolic enzyme mutations
in glioblastoma and leukemia. Julia Fabiano, Gabriela Chiaramida, MiraMag-
ner, Meghan O’Connor, Joseph Stallone, Nicholas DiDuca, Kathryn Neville,
Richard Tartarini, Marla Tipping. Providence College, Providence, RI.
Metabolic reprogramming is a common hallmark shared by nearly all prolif-
erating cancer cells, and thus has emerged as an exciting new direction in cancer
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research.Many signaling pathways have been implicated inmechanisms leading
to the shift of metabolic programs in tumors, but more recently a small number
of metabolic enzymes have also been identifıed in this process. Genes encoding
the metabolic enzymes Isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) were
found to be mutated in up to 70% of low-grade andmedium grade gliomas, and
in 15-20% of adult acute leukemia samples. These fındings were the fırst to link
the IDHgene to tumorigenesis. IDH1 and IDH2 function to irreversibly catalyze
the oxidative decarboxylation of isocitrate to -ketoglutarate (-KG). We are
studying how mutations in IDH affect the metabolism and cellular processes of
the cell. To this end, we have expressed IDH-R132H inDrosophila glial cells and
hemoctyes to learn more about the impact of neomorphic activity of IDH in
gliobastoma and chronic myeloid leukemia. We have verifıed that these cells
now produce 2-HG, as is known in human tumors harboring IDH mutations.
We have observed different cellular responses to IDH mutations in glia versus
hemoctyes and have begun to investigatewhy thismay be.Ultimately, the goal of
our research is to elucidate the mechanism(s) that cause IDH to contribute to
oncogenic activity in specifıc tissues, and use this knowledge to design tailored
therapeutics.
#1828 Are callipers obsolute? A novel 3D scanning technology tomeasure
subcutaneous tumor volume. Zena Wilson,1 Juan Delgado,2 Michael Davies,1
Rebecca Whiteley,1 Jennifer Hare,1 Amar Rahi,1 Stephen Marshall,1 Andrew
Smith,3 Stephen Atkinson,3 Jarno Ralli,3 Adeala Zabair,3 Adeala Zabair,3 Jane
Kendrew1. 1AstraZeneca Pharmaceuticals, Cheshire, United Kingdom; 2Glaxo
Medicines Research Council, Stevenage, United Kingdom; 3Fuel 3D, Chinnor,
United Kingdom.
Most preclinical oncology studies (xenograft, PDX, GEMMS) involve moni-
toring tumour growth rates, measuring them with callipers, and calculating the
volume. Volume is calculated from the width and the length to estimate a 3D
volume and is directly used to assess treatment effıcacy. Although this technique
is useful, it is unable to accurately assess non-uniformly shaped or very small
tumours and introduces a systematic bias by assuming that tumours present
with spheroid shape. Furthermore callipers do not inform of the tumour condi-
tion, which is dependent upon a visual estimation. Here we describe the devel-
opment and validation of a 3D scanner as an alternative method to callipers to
monitor tumour progression in rodents. The resulting 3D scanner solution
made up of hardware and software, has the potential to impact on the 3Rs
guiding principles underpinning the humane use of animals in oncology re-
search. The 3Rs benefıts identifıed are primarily through reduction of animals
via improved data accuracy allowing reduction in group sizes or the ability to
include irregularly shaped tumours to test. In addition the scanner system de-
scribed will make it possible to record tumour measurements in a rapid, min-
imally invasive, morphology-independent, and human-bias-free way, re-
moving interoperator variability. This photo-based technique captures
external symptoms of redness, paleness, ulceration of tumours, etc., which
could ultimately be used to detect early toxicities of compounds or deter-
mine scales of animal welfare. We describe the development and early vali-
dation of the scanner system within our laboratories. Using the 3D scanner
alongside tumour callipers to monitor tumour growth of Oncology tumour
studies we demonstrated that we can accurately measure tumour size param-
eters (length, width and volume) in multiple mouse strains and across a
range of tumour models. 3D scanning tumour data is comparable to tumour
measures generated from tumour callipers If successful the introduction of
this system to replace tumour callipers could have a large impact for groups
running oncology in-vivo tumour studies.
#1829 Evaluation of checkpoint inhibitors on tumour infıltrating im-
mune cells in theorthotopic andmetastatic tumourmicroenvironmentusing
bioluminescent syngeneic cell line models. Andrew McKenzie,1 Nektaria Pa-
padopoulou,1 Simon Jiang,1 Jane Wrigley,1 Sumanjeet Malhi,1 Jason King,1
Kelly Jones,1 Neil Williams,2 Rajendra Kumari1. 1Crown Bioscience UK, Lough-
borough, United Kingdom; 2KWS Biotest, Bristol, United Kingdom.
Background: Subcutaneous syngeneic models are widely used to evaluate the
impact of immunotherapy on tumor growth and tumor invading leucocytes
(TILs). However, the tumor microenvironment of orthotopic models is more
comparable to the patient as they form an organ-specifıc tumour, facilitate met-
astatic spread and, in the case of syngeneicmodels, support immune and stromal
component interactions. Bioluminescent imaging (BLI) enables non-invasive
longitudinal monitoring of orthotopic/metastatic tumor burden, allowing for
optimal randomisation, reduction of false positives and continuous feedback on
treatmentmid-study.Herewe describe the generation of several bioluminescent
variants of syngeneic cell lines and assess the impact of orthotopic growth on
response to immune checkpoint therapy. Methods: Bioluminescent variants of
syngeneic cell lines were established by lentiviral transduction for: 4T1/EMT6
(breast), B16-F10 (skin melanoma), H22 (liver) and Pan02 (Pancreas) murine
cancer cell lines. Subcutaneous growth ofwild-type and bioluminescent variants
was compared to assess any impact of luciferase expression on tumor growth,
inflammation and TILs. Orthotopic models were established for most cell lines,
and ametastaticmodel for B16-F10 was developed. BLI was carried out to assess
real-time tumor burden and at end stage (Spectrum CT; PerkinElmer). Re-
sponse to immune checkpoint therapy was evaluated and TIL infıltration was
assessed by FACs analysis and IHC. Results: No signifıcant differences in growth
profıles were exhibited when the bioluminescent variants of B16-F10 and Pan02
(subcutaneous) or EMT6 (mammary fat pad) were comparedwith the wild-type
equivalents. Bioluminescent 4T1 cells readily metastasised to the lungs from
both the orthotopic and subcutaneous sites and B16-F10 cells formed metasta-
ses. Response to immunotherapy, such as anti-CTLA-4, in the subcutaneous
setting between the bioluminescent and WT models was similar. Anti-CTLA-4
therapy resulted in a statistically signifıcant impact on orthotopic Pan02 tumor
growth (BLI) and fınal tumor weight; however, further characterization by IHC
and refınement of implantation conditions is required as the tumors exhibited
low basal TIL levels, poor stromal and blood capillary infıltration. Conclusions:
The growth and response to immunotherapy does not appear to be signifıcantly
impacted in the bioluminescent cell line models tested; as such they are a useful
tool for further assessing the impact of complex orthotopic, spontaneous and
experimental metastasis modelling in immunocompetent mice. However, the
orthotopic growth and TIL infıltration does vary between subcutaneous and
orthotopic/metastatic settings and requires characterisation and validation with
immunotherapeutics in order to understand the relevance and utilisation of
such models.
#1830 Targeted inhibition of EGFR and glutaminase induces metabolic
crisis in EGFRmutant lung cancer.MilicaMomcilovic,1 Sean T. Bailey,1 Jason
T. Lee,1Daniel Braas,1 ThomasG.Graeber,1MelissaWorks,2 Francesco Parlati,2
SusanDemo,2 TonyaC.Walser,1 StevenM.Dubinett,1 SamanSadeghi,1Heather
Christofk,1 David B. Shackelford1. 1UCLA, Los Angeles, CA; 2Calithera Biosci-
ences, CA.
Cancer cells exhibit increased use of nutrients including glucose and glu-
tamine to support the bioenergetic and biosynthetic demands of proliferation.
We tested CB-839, a small molecule inhibitor of glutaminase that impairs glu-
tamine utilization, in combination with erlotinib on EGFR mutant non- small
cell lung cancer (NSCLC) as a therapeutic strategy to simultaneously impair
cancer glucose and glutamine utilization and thereby suppress tumor growth.
Here we show that CB-839 synergizes with erlotinib to drive energetic stress and
activate the AMPK pathway in EGFR (del19) lung tumors. Tumor cells undergo
metabolic crisis and cell death resulting in rapid tumor regression in vivo in
mouse NSCLC xenografts. Consistently, positron emission tomography (PET)
imaging with 18F- fluoro-2-deoxyglucose (18F-FDG) and 11C-Glutamine
(11C-Gln) of xenografts indicated reduced glucose and glutamine uptake in
tumors following CB-839  erlotinib treatment. Therefore, PET imaging with
18F-FDG and 11C-Gln can be used to non-invasively monitor tumor metabolic
and therapeutic response to CB-839 and erlotinib combination therapy.
#1831 PET/CT imaging of interleukin-13 receptor alpha-2-targeted pep-
tide to glioblastoma after locoregional delivery. Anirudh Sattiraju,1 Ang
Xuan,2 Frankis Almaguel,1 DeniseHerpai,1WaldemarDebinski,1 AkivaMintz,1
Kiran Kumar Solingapuram Sai1. 1Wake Forest School of Medicine, Winston
Salem, NC; 2The People’s Hospital of Zhengzhou University, Zhengzhou, China.
Glioblastoma (GBM) is the most aggressive and common primary malignant
astrocytoma which is characterized by tumor heterogeneity, infıltrating mar-
gins. Radiotherapy, chemotherapy and experimental targeted therapies have
been ineffective at meaningfully increasing patient survival. One signifıcant
shortcoming of systemically delivered therapies is their inability to cross the
blood brain barrier (BBB) and access infıltrating tumor cells. Therefore, in this
work, we tested the potential of locoregionally targeting GBM via IL13R2,
which we discovered to be expressed on greater than 75% of GBMs. To accom-
plish this, we intracranially infused copper-64 (64Cu) radiolabeled IL13R2 spe-
cifıc peptide Pep-1L, previously developed by Pandya et al., into mice bearing
IL13R2 expressing orthotopic GBMs. Small animal micro PET/CT imaging
showed2-fold greater tumor specifıc localization and lower volume of distri-
bution of 64Cu-Pep-1L within brains of mice. Post-PET biodistribution study
showed greater retention of 64Cu-Pep-1L 4 hours (%ID/g 20.85	 0.65) and 24
hours (%ID/g 14.65	 0.30) post infusionwhen compared to similarly infused
64Cu radiolabeled scrambled control peptide 4 hours (%ID/g  10.73	 2.02)
and 24 hours (%ID/g  5.97	 1.47) post infusion. These results demonstrate
that Pep-1L effıciently targets IL13R2 expressing GBMs in vivo upon loco-
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regional delivery and can effectively deliver potential therapeutic agents toGBM
tumors while sparing normal brain. This work was supported by the American
Cancer Society Mentored Research Scholar grant # 124443-MRSG-13-121-01-
CDD (Mintz), 1R01CA179072-01A1 (Mintz), P30 CA012197 (Pasche),
R01CA07414519 (Debinski) and the Translational Imaging Program (TIP) of
the Wake Forest CTSA (UL1TR001420).
#1832 Bioluminescent pharmacokinetics of luciferin in preclinical brain
metastases of breast cancer models. Neal Shah, Chris E. Adkins, Afroz S. Mo-
hammad, Paul R. Lockman.West Virginia University, Morgantown, WV.
Background: Approximately 20% of breast cancer patients with disseminated
disease will develop brain metastases. Preclinical models of brain metastases of
breast cancer rely on ex-vivo histology to evaluate drug effıcacy. However, bio-
luminescence imaging allows more precise quantifıcation of tumor burden and
progression through counting photons per second without requiring animal
sacrifıce. This methodology has not readily been applied to hematogenously
derived brain metastases models given the heterogeneity of tumor burden and
growth. Herein we demonstrate repeatable methodology to quantify brain me-
tastases of breast cancer progression which is verifıed with histology. Methods:
Approximately 1.75 x 105 JIMT-1 (n3) and 231-BrLuc (n4) brain seeking
subclones were injected intracardially to produce metastatic brain lesions. Mice
were given 150 mg/kg of luciferin IP and luminescence was captured every
2-minutes for 60 minutes starting 24 hours after cell implantation. Radiance
(photons per second per square centimeter per steridian) was plotted to observe
peak luminescence. Imaging was repeated twice weekly to evaluate progression
until euthanasia. Results: Following intracardiac injection, both brain seeking
metastatic models produced a maximum luminescence signal between 14-20
minutes after luciferin injection. For all subsequent imaging, 5 minute imaging
between 15-20 minutes after luciferin injection was used. Longitudinally, both
tumor cell lines produce bioluminescence 24 hours after cell injection, which is
used to ensure tumor implantation and randomization. TheBLI signal decreases
to undetectable limits in both models between 3-7 days after cell implantation.
Re-emergence of signal occurs on day 14 for the JIMT-1 line and day 21 for
231-Br line. JIMT-1 bioluminescence on day 14 begins at 105 photons/sec/
cm2/sr and then over time signal increaseswith anslope of 5.6x105 until reach-
ing amaximumof 107 units on day 28. 231-Br bioluminescence on day 21 begins
at104 photons/sec/cm2/sr and then over time signal increases with an slope
of 1.1x106 until reaching a maximum of107 on day 53. Conclusion: To accu-
rately measure bioluminescence as a surrogate for tumor burden in hematog-
enously implanted metastases, the optimal circulation time is approximately 15
minutes with a 5 minute imaging period. Bioluminescence of the 231Br line
initially starts at a lower magnitude and later in time than the JIMT-1 line, but
slopes of both intracardiac models are similar and result in similar biolumines-
cent curves.
#1833 Imaging-guided brain tumor surgery strategy based on a triple-
modality MRI-PET-fluorescence imaging probe and imaging analysis. Hui
Meng,1 Yushen Jin,1 Shaowei Zhang,2 Shuai Zhang,3 XiboMa,1 Jie Tian1. 1Insti-
tute of Automation, Chinese Academy of Sciences, Beijing, China; 2Chinese PLA
General Hospital, Beijing, China; 3Shandong University, Jinan, China.
Precise brain tumor resection is valuable for increasing the 5-year survival
rate. However, the delineation of tumor margin is a major challenge. Trans-
ferrin modifıed nanoprobes had the property of passing the blood-brain
barrier (BBB). Here, we endeavored to use transferrin to fabricate a triple-
modality magnetic resonance imaging-PET-fluorescence imaging molecule
agent (MPF) which could improve diagnostic sensitivity and specifıcity of
the brain tumors in the imaging acquisition and analysis. The localization of
the tumor were determined by the MRI before surgery. Glucose metabolism
was derived from PET imaging which would be an important influence factor
for surgery strategy. Tumor margin was delineated using the quick segmen-
tation methods according to the fluorescence imaging after craniotomy
which could reduce residual tumor after resection. Finally, tissues were
sliced and stained with hematoxylin and eosin every 5 mm. The histology
results were processed into a whole image which can be used to evaluate the
accuracy of intraoperative tumor margin. This three modality imaging-
guided surgery strategy is a promising method which will probably achieve
its application in clinical trials in near future.
#1834 Constitutive Nedd9 null genotype promotes lung cancer aggres-
siveness. Alexander Deneka, Meghan Kopp, Anna S. Nikonova, Anna
Gaponova, Alexandra Nagele, Harvey Hensley, Erica Golemis. Fox Chase Can-
cer Center, Philadelphia, PA.
Non-small cell lung cancer (NSCLC) has a low survival rate, with metastasis
contributing to the vast majority of deaths. The NEDD9 (HEF1/Cas-L) protein
has been reported to be elevated in expression and to promote metastasis in a
large subset of lung cancers and in other malignancies. NEDD9 functions as a
scaffold for multiple critical effectors in integrin/FAK/SRC and receptor ty-
rosine kinase signaling cascades, as well as for themitotic kinase Aurora-A, with
overexpression thought to sustain signaling by these pro-oncogenic proteins.
Previous studies demonstrated depletion of NEDD9 by RNAi reduced the
growth and invasion of established lung cell lines and tumors, based on cell
culture and xenograft assays. We have now investigated the consequences of a
null genotype for Nedd9 from the earliest stages of tumor formation, crossing
Nedd9 null mice to a 129S/Sv-Krastm3Tyj/Trp53tm1Brn (KP) model in which Kras
mutation is induced specifıcally in lung tissue by inhalation of adenovirus bear-
ing the Cre gene. Unexpectedly, based on in vivo imaging, the Nedd9 null geno-
type signifıcantly accelerated tumor growth in KP mice. Pathological examina-
tion of tissues indicated Nedd9 null genotype also was associated with higher
invasive capacity in vivo, including direct invasion to the heart, as well as ele-
vated proliferation rate, decreased apoptotic activity, and changes in the expres-
sion of proteins such as vimentin, associated with mesenchymal status. Al-
though Nedd9 function has been implicated in immune cell activity, we found
minimal differences in tumor infıltration ofmyeloid cells ormacrophages based
onNedd9 genotype. Rather, use of Reverse Phase ProteinArray (RPPA) analysis
to characterize signaling in isolated tumors suggested tumor intrinsic changes in
glycolytic and proliferative signaling pathways, which were subsequently vali-
dated using direct functional assays. These results for the fırst time imply that
NSCLC tumor progression beyond early stages in the absence of Nedd9 requires
reprogramming of intrinsic tumor signaling to compensate for the absence of
this protein, emphasizing activities distinct from those associated with elevated
Nedd9 in late stage tumors.
#1835 Development of mammary hyperplasia, dysplasia, and invasive
ductal carcinoma in transgenicmice expressing the 8p11 amplicon oncogene
NSD3 (WHSC1L1). Alex C. Rutkovsky, Brittany Turner-Ivey, Ericka L. Smith,
Laura S. Spruill, Jamie N. Mills, Stephen P. Ethier. The Medical University of
South Carolina, Charleston, SC.
Amplifıcationwithin the 8p11-12 locus occurs in approximately 15%of breast
cancer (BC) and is associated with poor survival and distant recurrence. Over-
expression of many of the genes within the 8p11-12 region can confer a patho-
logical gain of function to breast cells. We and others have previously demon-
strated that NSD3 (WHSC1L1), a lysine methyltransferase, can act as a potent
transforming oncogene. Predictions by the GISTIC algorithm of the Human
Cancer Genome Atlas data suggest that NSD3 is a driving gene within 8p11-12
in multiple tumor types, including BC. We previously showed that NSD3 can
regulate the expression of influential genes, such as estrogen receptor alpha
(ESR1/ER). To further explore the role of NSD3 in promoting BC, we gener-
ated FVB/N transgenicmice with targeted overexpression of NSD3 in themam-
mary gland and compared them to matched non-transgenic wild-type (WT)
females. We observed that pups nursed by transgenic females were underdevel-
oped, regardless of genotype. Underdeveloped pups displayed delayed hair
growth and eye opening, and were half the weight of pups nursed by WT fe-
males. To investigate this phenotype, we characterized thoracic and inguinal
mammary glands from virgin, mid-pregnancy, lactating, and post-lactating
mice by whole mount and histological analysis. Mammary glands from virgin
transgenic females displayed increased branching and terminal bud formation.
Alveolar buds from mid-pregnant transgenic glands were more numerous and
densely packed. Glands from lactating transgenic females showed large areas in
which the alveoli failed to undergo functional differentiation, resulting in a
lactation defect. Mammary glands taken post-lactation exhibited areas of ductal
and alveolar hyperplasia. At 40 weeks of age, multiple transgenic mice had pal-
pable tumors which were excised at 1 cm3 size. Whole mount and histological
analysis of glands from tumor bearingmice commonly demonstrated hyperpla-
sia, dysplasia, and carcinoma in situ, contrary to age-matched WT glands. The
areas of ductal dysplasia and carcinoma in situ closely resembled several patterns
commonly observed in human breast cancer, including micropapillary, cribri-
form, and high grade areas of ductal carcinoma in situ. Mammary tumors were
analogous to infıltrating ductal carcinomas, many of which were high grade
tumors. In summary, overexpression of NSD3 in the mouse mammary gland
elicited drastic deformation, inhibited functional differentiation, and caused
tumor formation. Continued characterization of this mouse model, the onco-
genic role of NSD3, and other mechanistic studies are essential to improve pa-
tient outcome in 8p11-12 altered cancers.
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#1836 Patient-derived xenograft (PDX) models expressing HER2 reflect
clinical responses to targeted HER2 inhibition.Daniel Ciznadija,1 Amir Son-
nenblick,2 Jennifer Jaskowiak,1 Angela Davies,1 David Sidransky3. 1Champions
Oncology, Hackensack, NJ; 2Hadassah-Hebrew University Medical Center, Jersu-
laem, Israel; 3Johns Hopkins University School of Medicine, Baltimore, MD.
Background While HER2-directed agents are most often used for treating
breast cancer, there is increasing evidence that these therapiesmay be of value in
other solid tumors. Sequencing efforts and immunohistochemistry (IHC) have
identifıed mutations, amplifıcations, and overexpression of HER2 in ovarian,
HNSCC, NSCLC, and GI cancers. PDX models could permit evaluation of
HER2 response/resistance mechanisms to optimize therapeutic strategies. In
this pilot study, we evaluated the response of PDX models to HER2-targeted
therapies and correlated responses to clinical outcomes. Materials andMethods
PDXmodels were developed from a variety of patient solid tumors, evaluated by
IHC for HER2 expression and next-generation sequencing for genomic altera-
tions in HER2 (mutations, amplifıcations/deletions, and expression levels).
Models were screened against single agent HER2-directed therapies including
trastuzumab (n15), trastuzumab emtansine (n23), and lapatinib (n10).
Tumor regression (TR) values and RECIST criteria were determined and corre-
lated with known literature-based response rates (RR) as well as individual pa-
tient outcomes. Results 32 PDX models from 30 patients were interrogated
(primarily breast and colorectal). Twenty (63%)models have been sequenced to
date; 13 (65%) harbor amplifıcation at ERBB2 gene locus. Further, 56% (18/32)
have been evaluated by IHC forHER2 to date: 50%have 2HER2 staining, 17%
3 staining, and 33% 1/ staining. Based on PDX tumor growth, stable dis-
ease/regression was observed in 10% of models screened against lapatinib (CR/
PR0%), 50% screened against trastuzumab (CR/PR8%), and 67% tested
against trastuzumab emtansine (CR/PR14%). Only models with 2/3
HER2 staining showed regression with HER2-targeted treatment, with nearly
70% of 1/- HER2 models showing progressive disease. Finally, there were 4
correlations to patient clinical outcomes available, with 3/4 (75%) of the PDX
model responses mimicking those of the patient to the same treatment. Conclu-
sion and Future Directions Extensive sequencing of human cancers has demon-
strated HER2 amplifıcation or mutation in numerous solid tumors, suggesting
HER2-directed therapy could be applied more broadly in the clinic. Consistent
with clinical fındings, HER2 therapy responses depended upon the strength of
HER2 expression (based on IHC). Nevertheless, response rates in PDX models
varied depending onwhichHER2-targeted agentwas deployed, highlighting the
potential existence of differential mechanisms of de novo resistance/sensitivity.
Comprehensive sequencing and drug testing of these PDX models is planned
and could allow a deeper understanding of such mechanisms. In this context,
application of PDXmodels for translational modeling of HER2 drug responses,
particularly in the context of co-clinical trials, will continue to evolve.
#1837 High Ras activity promotes neoplasia in pancreatic ductal cells.
Kanchan Singh,1MelissaA. Pruski,1WasimA.Dar,1 Kishore Polireddy,1 John S.
Bynon,1 Mamoun Younes,1 Anirban Maitra,2 Craig D. Logsdon,2 Jennifer M.
Bailey1. 1University of TexasHealth ScienceCenter,Houston, TX; 2TheUniversity
of Texas MD Anderson Cancer Center, Houston, TX.
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malig-
nancy and is the third leading cause of cancer-related deaths in theUnited States.
Next generation sequencing efforts have revealedKRASmutations occur in over
99% of pancreatic ductal adenocarcinomas and are thought to be the initiating
mutation for pancreatic cancer. Despite the high prevalence of KRASmutations
in pancreatic cancer patients, murine models expressing endogenous levels of
mutant Kras in pancreatic cells do not develop PDAC.Anumber of publications
have revealed that acinar cells are more sensitive to early neoplastic lesion for-
mation in the presence of Kras mutations than ductal cells. In these models, a
second genetic hit (loss of tumor suppressor TP53, SMAD4 or CDKN) is
required for the development of invasive PDAC, including transforming
pancreatic ductal cells. Recent data has revealed a novel role for high levels of
Ras activity in acinar cells in the tranformation of this cell type to PDAC (Ji,
B., 2009). We hypothesized based on other preliminary data that high levels
of Ras activity would transform ductal cells. To test this hypothesis, we
studied the role of constitutively active high levels of Kras activity in acinar
and ductal cells by expressing an inducible KrasG12V allele in Ptf1a:Cre-
ERT2 (acinar cell specifıc) and Hnf1b:CreERT2 (ductal cell specifıc) mice.
Similar to previously published work, high levels of Ras activity in acinar
cells resulted in PDAC and a remarkably low survival time of 10 days after
mice were injected with tamoxifen. Mice with elevated Ras activity in ductal
cells needed to be euthanized two weeks after tamoxifen injection and man-
ifested a cancer cachexic phenotype. Histological analysis of these mice re-
vealed high grade oncocytic intraductal neoplasia and the phenotype ex-
tended throughout the pancreatobiliary ducts. Western blot analysis of
human PDAC and Cholangiocarcinoma tissue revealed similar levels of Ras
activity to our murine models, confırming human equivalent high Ras ex-
pression to both animal models. Oncocytic tumors are characterized by an
abundance of mitochondria. Thus, we are currently studying metabolic al-
terations and mitochondria accumulation in ductal and acinar cells express-
ing high Ras activity. Our goal is to determine howmitochondrial alterations
play a role in progression or inhibition of tumors in ductal vs acinar cells.
#1838 TGFalpha (an EGFR ligand) promotes growth of EGFR-mutant
lung tumors in airway regions but not in alveolar regions in a transgenic
mouse model. Koichi Tomoshige, Yutaka Maeda. Cincinnati Children’s Hospi-
tal Medical Center, Cincinnati, OH.
Although an exogenous EGF is dispensable for EGFRL858R-mediated
NIH3T3 cell transformation in vitro (Greulich et al., PLoS Med 2005), an
exogenous EGF promotes growth of H1650 and H1975 lung adenocarci-
noma cells that carry EGFR mutations in vitro (Sordella et al., Science 2004).
However, it is unknown whether an exogenous EGFR ligand plays a role in
growth of EGFR-mutant lung tumors in vivo. Here, using conditional trans-
genic mice expressing EGFRL858R or KRASG12D along with an exogenous
TGFalpha (an EGFR ligand) in lung epithelium, we sought to determine the
role of an EGFR ligand in EGFRL858R-lung tumors or wild type EGFR-lung
tumors (KRASG12D-lung tumors) in vivo. As previously reported, condi-
tional expression of TGFalpha (an EGFR ligand) in lung epithelium caused
pulmonary fıbrosis but not lung tumors (Korfhagen et al., J Clin Invest 1994;
Hardie et al., AJP-LCMP 2004), indicating that the expression of an exoge-
nous EGFR ligand is not suffıcient to induce lung tumors. Conditional ex-
pression of EGFRL858R or KRASG12D in lung epithelium caused lung tumors
as previously reported (Fisher et al., Genes Dev 2001; Politi et al., Gene Dev
2006). In our study using a new rtTA driver, Scgb1a1-rtTA line 2 (Perl et al.,
AJRCMB 2006), the majority of EGFRL858R-lung tumors occurred in alveolar
regions while KRASG12D-lung tumors occurred in both alveolar and airway
regions. Importantly, co-expression of EGFRL858R along with TGFalpha in
lung epithelium induced the growth of lung tumors in airway regions but not
in alveolar regions while the expression of EGFRL858R alone did not induce
lung tumors in airway regions. Co-expression of EGFRL858R along with TG-
Falpha also shortened survival of the mice compared to the expression of
either EGFRL858R or TGFalpha alone (median 32 days for EGFRL858R/TGFal-
pha vs 118 days for EGFRL858R alone or 248 days for TGFalpha alone). Co-
expression of KRASG12D with TGFalpha did not influence tumor location or
survival of the mice compared to the expression of either KRASG12D or
TGFalpha alone. Consistent with the mouse study, TGFalpha expression in
human EGFR-mutant lung cancer but not wild-type EGFR lung cancer was
associated with worse overall survival (median 44months for TGFalpha high
vs 75 months for TGFalpha low; p0.05) and recurrence free survival (me-
dian 21 months for TGFalpha high vs 61 months for TGFalpha low; p0.05).
Collectively, our results demonstrate that TGFalpha (an EGFR ligand) pro-
motes not only the growth of EGFRL858R-lung tumors but also influences the
regions where the EGFRL858R-lung tumors form.
#1839 TGFBR1*6A mouse model mimics human breast cancer devel-
opment and progression. Michael James Pennison, Minghui Wang, Hugo
Jimenez, Boris Pasche.Wake Forest Baptist Medical Center, Winston-Salem,
NC.
Transforming Growth Factor-ß (TGF-) is one of the most commonly
altered cellular signaling pathways in human cancer. Our group was the fırst
to discover TGFBR1*6A (*6A), a common hypomorphic variant of the type
I TGF-ß receptor (TGFBR1), which has been associated with increased risk
for breast cancer in multiple epidemiological studies. Functional analysis
also suggests that *6A is associated with decreased tumor suppressive TGF-
signaling in early tumor development and is involved with promoting tu-
morigenesis in advanced carcinomas. To better understand the functional
impact of *6A and constitutively reduced TGF-ß signaling on breast cancer
development and progression, we have recently developed a series of trans-
genic knock-in mouse model variants by replacing exon 1 of the mouse
Tgfbr1 sequence with human exon 1 sequences harboring both *6A and
wild-type (*9A) TGFBR1 variants and crossed them with MMTVneu mice.
We generated a total of 5 FVB double and/or triple transgenic mouse strains:
MMTVneu;9A/9A, MMTVneu;6A/6A, MMTVneu;9A/6A, MMTVneu;
*9A/-, and MMTVneu;6A/-. Following tumor development, measurements
were performed three times per week to determine tumor volume. All mice
were allowed to live up to 18 months (548 days) or until they died of natural
causes. Specimens were collected for later analysis of blood, tumors, normal
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mammary tissue, and were evaluated for lung metastases. Statistical compar-
isons performed using Student’s t-test. Only 34.4% of MMTVneu;9A/9A
mice (11/32) developed mammary tumors, while 80% of MMTVneu;6A/6A
mice (24/30; p0.0002) and 62.5% of MMTVneu;6A/- mice (19/32,
p0.046) developed tumors. The percentage of MMTVneu;9A/6A and
MMTVneu;*9A/- mice that developed tumors was higher than MMTVneu;
9A/9A mice (48.3% and 50%, respectively) but was not statistically signifı-
cant. Additionally, 66.7% of MMTVneu;6A/6A mice (20/30) developed 2 or
more tumors, while only 25% of MMTVneu;9A/9A mice (8/32) developed
multiple tumors (p0.0007). Our data suggests that we have developed
transgenic mouse strains that accurately mimic human breast cancer suscep-
tibility associated with *6A and constitutively decreased TGFBR1 expression
in humans, as evidenced by other studies. These mouse models may be a tool
to provide invaluable insight to better understand the role of TGFBR1 vari-
ants in the development and progression of breast cancer.
#1840 Whole-exome somatic mutation analysis of mouse cancer models
and implications for preclinical immunomodulatory drug development.
Bruno Zeitouni,1 Cordula Tschuch,1 Jason M. Davis,2 Anne-Lise Peille,1 Yana
Raeva,1Manuel Landesfeind,1 Sheri Barnes,2 Julia B. Schüler1. 1Oncotest GmbH,
Freiburg, Germany; 2Charles River Discovery, Morrisville, NC.
Experimental tumors raised in rodents represent an important preclinical
tool to develop innovative anticancer compounds before clinical testing.
Amongst others such models include solid tumors raised in syngeneic fully
immunocompetent hosts and tumors spontaneously growing in genetically
engineered mice (GEM) and derivate thereof. These model platforms have
gained additional value since the manipulation of the immune system to
fıght cancer has led to tangible benefıts for cancer patients. In the current
study, we analyzed somatic mutation profıles from whole-exome sequencing
(WES) data in a panel of 14 different mouse models covering 6 major cancer
types. 4 models were GEM-derived, all other lines were developed by injec-
tion of established cell lines into the corresponding mouse strain. In parallel,
these models were evaluated for their sensitivity towards checkpoint inhib-
itors (-CTLA-4, -PD-1 or -PDL-1) in mono- or combined therapy with
cytostatic and/or targeted agents.WES achieved an average-of-coverage of
165X in tumor models and normal DNA. A median mutation rate of 34
somatic mutations (m)/MB was detected, ranging from 7 m/MB (GEM de-
rived NSCLC model KP) to 328 m/MB (syngeneic NSCLC line Lewis Lung)
in exons. Mutation rates were markedly lower in GEM-derived models as in
syngeneic lines (median of 9 vs 43m/MB). This reflects very well the different
underlying carcinogenic mechanism of these two types of models. The cross-
comparison of tissue-transplants vs cell lines from GEM-derived model KP
revealed that 75% of the mutations found in the primary KP could also be
detected in the corresponding cell lines KP1 and KP4. Of note, the mutation
count increased 1.3- (KP4) and 2.9-fold (KP1) during cell line establishment.
Every model depicted a distinct profıle against modulators of the immune
system dividing the panel in responders and non-responders. In our hands
no signifıcant correlation could be determined between mutational load and
sensitivity towards checkpoint inhibition in vivo. This might be related to
the fact that the dataset was not broad enough and the number of models per
entity was too small, rendering the subtype analysis within the panel not
feasible. However, a strong tendency was observed when investigating the
colon lines Colon26, CT26 and MC38 showing best response to the combi-
nation of PD-1CTLA-4 inhibitors and in parallel the highest mutation
rates (52, 64 and 59 m/MB, respectively) compared to non-responders B16-
F10, CloudmanS91, 4T1 and KP1 (23 m/MB on average). Mouse models of
cancer are a relevant tool for preclinical studies specifıcally for immuno-
oncology. The molecular characterization of these models will help to opti-
mize their use in drug discovery. They will support the development of
innovative drugs and indentifıcation of biomarkers to classify the patient
cohort profıting the most from these new compounds.
#1841 Characterization of neuronal alterations in a new mouse model of
low grade glioma.Daniela Torres, AngelikiMela, Sohani Das Sharma, Nicholas
Hornstein, Peter Sims, Peter Canoll. Columbia University, New York, NY.
Diffusely infıltrating gliomas are themost common type of primary brain tumor
seen inadults. Patientswith lowgradeglioma (LGG)can survive formanyyears, but
often suffer from seizures and cognitive impairment, and these symptoms are asso-
ciatedwith an unfavorable prognosis. Glioma cells diffusely infıltrate cortical tissue,
where tumor cells aggregate around neuronal cell bodies, a growth pattern referred
to as perineuronal satellitosis, however the effects of tumor cells on neurons has not
beenwell defıned. To address this important issuewe generated amousemodel that
recapitulates the genetic and histological features of diffusely infıltrating LGG. In
ourmodel tumor growth is driven by PDGFAoverexpression and p53 deletion in a
RiboTag-Camk2a-Cre transgenic mouse. The RiboTag system allows for the isola-
tion and sequencing of ribosome-bound transcripts from Camk2a neurons to ob-
tain ameasure of transcription and translation. Our analysis in non-tumor bearing
brains identifıed neuron-specifıc genes that are highly regulated at the level of trans-
lation. mTOR signaling regulates cell growth, proliferation, and translation in re-
sponse to diverse stimuli. To characterize mTOR signaling in our model we used
immunohistochemical staining of pS6 as amarker ofmTORactivity and found that
neurons within the glioma infıltrated cortex have lower levels of pS6 staining com-
pared to neurons in the surrounding cortex. To further assess these results we are
using theRiboTagsystemto identify alterations inneuronal transcriptionand trans-
lation that occur in our model during glioma formation and in response to mTOR
targeted treatments. These studies will provide new insights into the neuronal alter-
ations contributing to seizures and cognitive impairment in glioma and enable the
identifıcation of potentialmolecular targets for novel therapies to treat the devastat-
ing consequences of cortical dysfunctions associated with glioma.
#1842 Breast cancer brainmetastasis (BCBM)model for determination of
therapeutic brain penetration. Emily A. Wyatt, Mark E. Davis. California In-
stitute of Technology, Pasadena, CA.
Purpose Brain metastases are presenting an increasing problem in the
clinic, and especially in treatment of patients with human epidermal growth
factor receptor-2 (HER2)-amplifıed breast cancer. Although extracranial
metastases respond well to HER2 inhibitors, human clinical data shows
brain metastases hide behind an intact blood-brain barrier (BBB) and are
largely untreatable. Many current preclinical models lack this barrier integ-
rity, limiting their utility in understanding delivery of drugs to the brain. We
present here the development of a new model suitable for evaluating thera-
peutic brain penetration in addition to effıcacy. Experimental procedures
Human HER2-amplifıed BT-474 breast cancer cells were inoculated intrave-
nously (tail vein) in female Rag2/;Il2rg/mice (2 million cells/mouse) to
induce multiorgan metastasis. Formation of metastatic brain lesions was
monitored by magnetic resonance imaging (MRI). For comparison, BT-474
cells were inoculated intracranially for direct brain tumor implantation
(50,000 cells/mouse). Response to a suite of HER2-targeted therapies known
not to appreciably cross an intact BBB (trastuzumab, lapatinib, etc.) was
monitored by MRI for both metastatic and implanted brain tumors. Mice
were sacrifıced following signs of prolonged distress or loss of 20% body
weight. Organs were collected for standard histological and immunohisto-
chemical analysis, as well as for CLARITY tissue clearing and large-scale 3D
macromolecule mapping. Results Intravenous inoculation of BT-474 cells
into Rag2/;Il2rg/mice consistently reproduced the full metastatic pro-
fıle seen in humans, with metastases in the lung, bone, liver, ovary, lymph,
and brain tissues. Brain metastases were detected in 90% of mice inocu-
lated intravenously. Histological analysis of metastatic brain tumors showed
different morphologies and invasive characteristics compared to those in-
tracranially implanted. Additional differences in vasculature between meta-
static and implanted brain tumors were identifıed by CLARITY. Impor-
tantly, HER2-targeted therapy markedly delayed progression of implanted
brain tumors, but failed to control metastatic brain tumor growth, recapit-
ulating the clinical situation. Conclusions These data, together with ongoing
efforts to further characterize therapeutic transport to these brain tumors,
suggest that intracranial inoculation disrupts the BBB and creates artifıcial
routes for therapeutics to reach implanted brain lesions, resulting in anom-
alous tumor response. In contrast, this new metastatic model reproduces the
discordant effects of HER2-targeted therapy in patients, and offers a plat-
form for studying the effıciency of therapeutic delivery across an intact BBB
as well as antitumor activity, both of which are critical to effective clinical
translation.
#1843 Intratumoral heterogeneity of renal cancer is related to differences
in drug response and development of therapy resistance. Michael Becker,1
Burkhard Jandrig,2 Susanne Flechsig,1 Reiner Zeisig,1 Daniel Schindele,2Martin
Schostak,2 Christian Schmees,3 AnnikaWulf-Goldenberg,1 Jörg Hennenlotter,4
Elke Schaeffeler,5 Matthias Schwab,5 Arnulf Stenzl,4 Jens Bedke,4 Jens Hoff-
mann1. 1EPO - Experimental Pharmacology and Oncology Berlin-Buch GmbH,
Berlin, Germany; 2UniversityMedical CenterMagdeburg, Magdeburg, Germany;
3NMI University Tuebingen, Tuebingen, Germany; 4University Hospital Tuebin-
gen, Tuebingen, Germany; 5Margarete Fischer-Bosch-Institut for Clinical Phar-
macology, Stuttgart, Germany.
Background: Patients with advanced renal cell cancer (RCC) have a poor
prognosis not least because of resistance towards standard drugs (SoC). Re-
cently, pronounced intratumoral heterogeneity (ITH) in RCC was shown. We
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were interested whether this ITH is a potential cause for treatment failure. We
developed a large panel of patient-derived xenograft (PDX) models from RCC,
including subsets of models from different regions of one individual tumor. The
PDXmodels were evaluated for response to SoC. To better understand correla-
tions between inter- and intratumoral heterogeneity and treatment response,
tumor models were panel sequenced and expression profıled. Methods: Speci-
mens from primary and metastatic RCCs were collected from consenting pa-
tients and transplanted into mice. Tumor engraftment was monitored for up to
4 months. Tumor sections were examined histopathologically to assess concor-
dance between patient tumor and model and were stained for RCC specifıc
markers (Pax2, Pax8, CD31, and RCC). Stable growing PDX were treated with
SoC (sunitinib, sorafenib, bevacizumab and everolimus). Global gene expres-
sion was analyzed in primary tumors and PDX models using microarrays (Af-
fymetrix). In addition, sequence variations (Illumina NGS cancer panel) and
MET and TERT gene copy numbers were analyzed in PDX models. Results: A
panel of 34 RCC PDXmodels was established frommore than 200 patient sam-
ples. Among these, 13modelswere derived fromdifferent tumor regions of three
advanced tumors. Original patient tumor and PDX showed a very similar and
characteristic RCC histopathology. Inter- and intratumoral heterogeneity was
preserved for several passages. We treated all PDXwith standard targeted drugs
and observed response rates comparable to results fromclinical trials.One out of
8 regions obtained fromone aggressiveRCCclearly differentiated in regard to its
response to bevacizumab and sunitinib. Genomic analysis revealed that this
region has differences in global gene expression and sequence variation pattern.
Besides a commonMETmutation an additional variation in theHRAS genewas
detected. In the whole PDX set we found 34 sequence variations in 20 genes, e.g.
ATM, MET, TP53 and VHL and copy number variations in the MET locus.
Conclusion:We have shown that PDX derived from distinct regions within one
individual tumor exhibit differences in targeted treatment response as well as in
genetic profıle. These differences and their correlation to their molecular heter-
ogeneity is subject of ongoing investigations to explain failure in treatment re-
sponse. The available panel of renal cancer PDX provides an excellent source for
translational research and for preclinical testing of new drug candidates.
#1844 Investigating the role of amphiregulin in breast cancer. Serena P.
Chiang, George S. Karagiannis, John S. Condeelis, Jeffrey E. Segall. Albert Ein-
stein College of Medicine, Bronx, NY.
Breast cancer is the most prevalent cancer in women worldwide and afflicts
more than 3.1 million women in the US alone. The epidermal growth factor
receptor (EGFR) is frequently overexpressed in breast cancer and is associated
with poor clinical outcome. Several therapies involving anti-EGFR agents have
been developed to target breast cancer. However, clinical trials have shown
mixed outcomes with these therapies. Amphiregulin (AREG) is a ligand for
EGFR that mediates estrogen-induced mammary ductal morphogenesis during
development. Expression of AREG is enriched in invasive breast carcinomas,
particularly ER-positive breast tumors. Studies have shown that AREG in-
creases the in vitro invasiveness of breast cancer cells. Furthermore, suppression
of AREG expression in transformed human breast epithelial cells reduces tumor
formation when injected in nude mice. These observations suggest that AREG
plays an important role in breast cancer development and progression. To in-
vestigate the role of AREG in breast cancer development and progression, we
utilized a spontaneous mammary tumor mouse model where oncogenesis is
driven by expression of the polyomamiddle T oncoprotein (PyMT) through the
mouse mammary tumor virus (MMTV) promoter. We have crossed AREG
knockout mice with the MMTV-PyMT mice to generate AREG KO mice that
spontaneously form mammary tumors. Tumors in AREG KO PyMT mice ini-
tially grow more quickly but eventually reach 2 cm in diameter at a relatively
time as compared to tumors formed in AREG WT PyMT mice. Histologically,
AREG KO tumors appear more differentiated and display a greater proportion
of tumor stroma. This prompted us to further hypothesize that AREGmay have
diverse effects in the tumoral or stromal compartment of developing tumors. To
individually assess the effects of AREG knockout in the tumor cells and the
stroma, we utilized a transplantationmodel inwhichwe prepared tumor chunks
from AREGWT and KO PyMT tumors and transplanted them into AREGWT
and KOmice. Through this model, we have found that AREG expression in the
tumor has a greater impact on tumor growth and progression than the tumor
stroma. Regardless of the AREG status of the recipient mice, AREG KO tumors
display a signifıcant growth impairment and reduced transplant effıciency. In
summary, these results demonstrate that AREG is important for mammary tu-
mor progression.
#1845 Mutant p53 promotes progression and metastasis of mouse oral
tumors induced by 4NQO, associated with specifıc immune infıltrates. Jin
Wang, Yuanyuan Zhang, BingbingWang, Adel K. El-Naggar, Jeffrey N. Myers,
Carlos Caulin. UTMD Anderson Cancer Center, Houston, TX.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most com-
mon malignancy worldwide. The vast majority of the human HNSCCs con-
tain p53 mutations, some of which acquire oncogenic gain-of-function
(GOF) activities. Previous mouse models in which either the p53R172H GOF
mutation or deletion of the p53 gene were co-activated with oncogenic K-ras
showed that p53R172H can predispose to oral tumor initiation, accelerate
tumor growth and promote progression to SCC. However, the impact of p53
gain- and loss-of-function (LOF) mutations in metastasis could not be as-
sessed because of the low rates of progression to SCC in that model. To
overcome this limitation, we used the tobacco-surrogate 4NQO to induce
oral lesions that may progress to advance carcinomas following stepwise
changes that resemble the gradual accumulation of histological and molec-
ular abnormalities observed during human oral cancer progression. To ex-
amine the role of p53 mutations during SCC malignant progression we ap-
plied 4NQO to mice in which the p53R172H mutation or homozygous
deletion of p53 were activated in oral epithelial cells. We observed that oral
tumors appeared faster in the presence of p53 mutations than in mice with
wtp53. No signifıcant difference was observed between the p53R172H muta-
tion and p53 deletion. However, survival was shorter in mice expressing
p53R172H than in mice with loss of p53. Notably, regional and distant metas-
tasis were only observed in mice with oral tumors expressing p53R172H.
Therefore, these mice are excellent tools for pre-clinical studies designed to
target early stages of tumor development or latest stages of progression and
metastasis. As immunotherapy is becoming adopted as part of the standard
treatment for head and neck cancer patients, we conducted a detailed char-
acterization of the immune infıltrates of the lesions that developed in these
mice in order to assess their immunogenicity. We observed a progressive
increase in T-cell infıltration from normal oral mucosa to oral premalignant
lesions (OPL) to SCC, in the presence or absence of p53mutations. Similarly,
the expression of immune checkpoint proteins, including PD1, PDL1 and
CTLA4 increased during oral tumor progression, regardless of the p53 sta-
tus. Interestingly, we observed a sharp increase in the presence of immune
infıltrates expressing the co-stimulatory OX40 in SCCs relative to premalig-
nant lesions, with different extent depending on the nature of the p53 mu-
tation. The signifıcance of these observations is currently being analyzed. In
summary, p53R172H promotes metastasis in oral tumors induced by 4NQO.
In addition, T-cell infıltration and activation of immune checkpoints during
oral tumor progression suggest that this is an excellent model to test immu-
notherapy-based strategies. Furthermore, our fındings suggest that OX40-
based therapies may be tailored to patients according to their p53 status.
#1846 Immunocompetent mouse allograft models for development of
therapies to target breast cancer metastasis therapies to target breast cancer
metastasis. Yu-an Yang,1 Howard Yang,1 Ying Hu,1 Peter Watson,2 Huaitian
Liu,1 Thomas R. Geiger,1 Miriam R. Anver,3 Diana Haines,3 Philip Martin,3
Maxwell P. Lee,1 Kent W. Hunter,1 Lalage M. Wakefıeld1. 1National Cancer
Institute, Bethesda, MD; 2British Columbia Cancer Agency, Victoria, British Co-
lumbia, Canada; 3Leidos Biomedical Research Inc., Frederick National Labora-
tory for Cancer Research, Frederick, MD.
Effective drug development to combat metastatic disease in breast cancer
would be aided by the availability of well-characterized preclinical animal mod-
els that (a) metastasize with high effıciency, (b) metastasize in a reasonable
time-frame, (c) have an intact immune system, and (d) capture some of the
heterogeneity of the human disease. To address these issues, we have assembled
a panel of twelve mouse mammary cancer cell lines that can metastasize effı-
ciently on implantation into syngeneic immunocompetent hosts. Genomic
characterization shows that more than half of the 30 most commonly mutated
genes in human breast cancer are represented within the panel. Transcriptomi-
cally, most of the models fall into the luminal A or B intrinsic molecular sub-
types, despite the predominance of an aggressive, poorly-differentiated or spin-
dled histopathology in all models. Patterns of immune cell infıltration,
proliferation rates, apoptosis and angiogenesis differed signifıcantly among
models. Inherent within-model variability of the metastatic phenotype man-
dates large cohort sizes for intervention studies but may also capture some rel-
evant non-genetic sources of variability. The varied molecular and phenotypic
characteristics of this expanded panel of models should aid in model selection
for development of anti-metastatic therapies in vivo, and serve as a useful plat-
form for predictive biomarker identifıcation.
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#1847 Evaluating the metastatic potential and the molecular heterogene-
ity of patient-derived orthotopic xenograft models of triple-negative breast
cancer. Vishnu C. Ramani,1 Rakhi Gupta,1 Gerald Quon,2 Melanie Triboulet,1
Corinne Renier,3 Cassandra Greene,4 Chad Sanada,4 Tracy Lu,4 Lukasz Sz-
pankowski,4 Naveen Ramalingam,4 Ameen A. Salahudeen,1 Sean de la O,1 Ran-
jani Rajapaksa,1 Shoshana Levy,1 Anne A. Leyrat,4 Jay A. West,4 Elodie Sollier-
Christen,3 Calvin J. Kuo,1 George W. Sledge,1 Stefanie S. Jeffrey1. 1Stanford
University, Stanford, CA; 2University of California, Davis, CA; 3Vortex Biosci-
ences, Inc., Menlo Park, CA; 4Fluidigm Corporation, South San Francisco, CA.
We report an in-depth characterization of patient-derived orthotopic xeno-
graft (PDOX) models of triple-negative breast cancer (TNBC) regarding their
molecular profıle at the single cell level, tumor heterogeneity, 3D organoid gen-
eration, and ability to generate circulating tumor cells (CTCs). A panel of seven
TNBC PDOX tumors were grown orthotopically in Nod scid gamma mice and
used in this study. Blood obtained via cardiac puncture from tumor bearing
animals was processed on the Vortex microfluidic platform, for label-free, size-
based enrichment of circulating tumor cells (CTCs). Enriched cell populations
were stained for human-specifıc cytokeratin (CK) and Vimentin (Vim), mouse-
specifıc CD45, andDAPI; CTCs were identifıed as cells that were CD45 negative
and positive for CK or Vim. Bulk tumor growing in the mammary fat pads was
dissociated to single cells and characterized using Fluidigm’s® PolarisTM plat-
form for single cell biological experimentation and cDNA generation within an
integrated fluidic circuit (IFC). From the cell suspension, Polaris identifıed sin-
gle cells that were then processed for mRNA-seq. The resulting cDNA libraries
were then multiplexed using Nextera XT® (Illumina®) and sequenced on Illu-
mina systems. Data generated from mRNA-seq was processed to correct for
confounding factors such as cell size, cell cycle and read depth and then analyzed
to screen for heterogeneity between different populations of cells. Tumors were
analyzed by flow cytometry for both tumor and immune cells and additionally
the single cell suspension was seeded into 3-D culture to generate organoids.
Finally, organs from tumor bearing animals were analyzed for metastases. With
the Vortex platform, we detected CTCs from a majority of our PDOX tumor-
bearing mice. The total number of CTCs varied over a wide range between
different PDOX tumors. There was a clear heterogeneity in CTCs in terms of CK
and Vim expression. In CTCs from one of the PDOX tumors, we detected a
small population of CTCs that were either CK orVim but themajor fraction
that was double positive (Vim CK). Probing the bulk tumor from different
PDOX models revealed heterogeneity in the levels and number of cells positive
for cell surface markers like EpCAM and a difference in the levels of infıltrating
myeloid cells (CD11b).mRNA-seq analyses of individual tumor cells from the
bulk tumor belonging to different PDOXmodelswill be described. Additionally,
lung andbrainmetastaseswere identifıed. 3Dorganoid cultures fromourPDOX
models were successfully grown and their gene expression profıles will be ana-
lyzed. In summary, PDOXmodels of TNBC will help advance our understand-
ing of the molecular basis of this deadly cancer.
#1848 Autocrine IGF1 signaling mediates the survival of pancreatic can-
cer cells following the ablation of oncogenes. Nirakar Rajbhandari. Univ. of
Nebraska Medical Ctr., Omaha, NE.
Pancreatic cancer is an extremely lethal disease, which is mostly associated
with the gain-of-functionmutation in KRAS gene. Due to a very high frequency
of activating mutations within the KRAS gene, mutant KRAS is considered a
rational therapeutic target in pancreatic cancer. In linewith the existing idea that
oncogenic KRAS is required for the maintenance of pancreatic cancer, we show
a complete macroscopic regression of both primary and orthotopically trans-
planted tumors in our ligand-regulatable (Doxycycline) mouse model of
KRASG12D-driven pancreatic cancer. This fınding indicate that the expression,
and provides a strong rationale for the development of KRAS targeted therapy
for the treatment of pancreatic cancer. However, in our current study, despite
the complete macroscopic regression of PDACs upon downregulation of onco-
genic KRAS, few cancer cells always survived and remained dormant for a pro-
tracted duration. These residual cancer cells were responsible for the rapid recur-
rence upon KRAS reactivation. Using a genome-wide gene expression (RNA-Seq)
analysis of in vivo-derived bulk and residual cancer cells followed by biochemical
analysis, we identifıed a signifıcant increase in autocrine IGF-1/AKT signaling in
residual cancer cells.We also identifıed IGF1 signaling as a common survivalmech-
anism of residual cancer cells in c-MYC-driven pancreatic tumor model. Pharma-
cological inhibition of IGF-1R signaling signifıcantly delayed the tumor recurrence
in both the tumor models, suggesting the crucial role of IGF-1R signaling in the
survival of cancer cells in the absence of oncogenic drivers. Our fındings from ani-
mal models were also validated in human pancreatic cancer cell lines harboring
KRAS mutations, by demonstrating a compensatory increase in IGF1 signaling in
response to a conditional knockdown of KRAS in vitro and in vivo. Collectively, all
our fındings frommousemodel andhumancancer cell studies strongly indicate that
residual cancer cells can survive in the absence of tumor driving oncogenes by up-
regulationof autocrine IGF1signaling loop.Thus, targetingoncogenicdrivers along
with IGF-1R signalingmight be an effective strategy for prevention of tumor recur-
rence in pancreatic cancer.
#1849 The role of leptin signaling in the promotion of obesity-associated
tumorigenesis and cancer stem cell characteristics in a transgenicmousemodel
of basal-like breast cancer. SubreenA.Khatib,1 LauraW.Bowers,1 Emily L. Rossi,1
Shannon B. McDonell,1 Claire G. Lineberger,1 David A. Cavazos,2 Linda A. de-
Graffenried,3 Stephen D. Hursting1. 1The University of North Carolina at Chapel
Hill, ChapelHill,NC; 2TheUniversity ofTexasHealth ScienceCenter at SanAntonio,
San Antonio, TX; 3The University of Texas at Austin, Austin, TX.
Background: Epidemiological studies have linked obesity to a greater risk of
breast cancer-specifıc mortality. This association may be mediated in part by en-
hanced cancer stem cell (CSC) enrichment, as CSCs are thought to be the primary
drivers of tumor initiation, growth, andmetastasis. We and others have have dem-
onstrated thatobesitypromotesCSCenrichment inpre-clinicalmodels of basal-like
breast cancer, butonlywhen leptin signaling ispresent.These fındings, coupledwith
evidence that elevated serum leptin and breast tumor leptin receptor expression are
linked to a worse breast cancer prognosis, suggest that leptin-induced CSC enrich-
ment may be a key contributor to obesity-associated breast cancer progression.
Methods: MMTV-Wnt-1 transgenic mice, which develop spontaneous basal-like
mammary tumors, were fed a control diet (10% kcal from fat) or a diet-induced
obesity regimen (DIO, 60% kcal from fat). Mice were euthanized when tumors
reached 1.5 cm in diameter. RNA sequencing was performed on 4 tumors/diet
group. Serum hormones and cytokines were measured via luminex-based assay.
ALDH activity, a putative CSCmarker, was quantifıed by an ALDHActivity Assay
Kit (abcam). Quantitative RT-PCR was used to determine expression of CSC-re-
lated genes, leptin, and the leptin receptor. Twomammary tumor cell lines isolated
from theMMTV-Wnt-1model (M-Wnt and E-Wnt cells) and humanMDA-MB-
231 were exposed in vitro to pooled serum fromDIO or control mice (2% concen-
tration), and cell viability, migration, invasion and expression of CSC related genes
were measured. Results: Tumor incidence and growth rate were greater in DIO
versus control mice. RNA sequencing revealed an upregulation in a CSC gene sig-
nature in tumors fromDIO versus controlmice. Signifıcant upregulation in several
of these genes, including aldh1a, oct4, twist1, twist2, and akt3, was confırmed by
qRT-PCR(P0.05).ALDHactivity in theDIO(relative tocontrol) tumorswasalso
signifıcantly increased (P 0.05). Serum levels andmammary tissue expression of
leptin and tumorexpressionof the leptin receptorwere signifıcantly elevated inDIO
versus control mice (P  0.05). Exposure to serum from DIO mice signifıcantly
increased (relative to control) M-Wnt, E-Wnt, and MDA-MB-231 cell viability,
migration, invasion, and expression of CSC-related genes in vitro (P 0.05). The
role of leptin signaling in these effects and in vitromeasures ofCSC enrichmentwill
be explored through additional in experiments. Conclusions: Obesity promotes
MMTV-Wnt-1 mammary tumor incidence and growth rate, possibly via CSC en-
richment. Preliminary fındings suggest increased leptin signalingmayunderlie obe-
sity-associated CSC enrichment andmay contribute to the breast cancer burden in
obese women.
#1850 Development of a NOTCH1 loss of function and PIK3CA mutant
transgenic model of HNSCC. Samantha N. Devenport, Nicole L. Michmerhui-
zen, Elizabeth Leonard, Brittany Jewell, Jacob Swanson, Sunny Wong, Thomas
E. Carey, J Chad Brenner. University of Michigan, Ann Arbor, MI.
Head and neck squamous cell carcinoma (HSNCC) is a debilitating disease
with a poor 5-year survival rate. The use of in vivomodels to study tumorigenesis
and to identify potential targeted therapies, especially those that work in com-
bination with immune checkpoint inhibitors, is essential in improving overall
patient care. However, the overall number of HNSCC transgenic models with
recurrent genetic lesions identifıed by the HNSCC TCGA project has been lim-
ited. For example, TCGA data has shown both Notch1 loss of function muta-
tions and PIK3CA activating mutations as some of the most common in
HNSCC, but bi-genic models of these lesions do not yet exist. Here, we have
designed a model which utilizes K14-CreERT to drive a bi-genic model with
Notch1flox and PIK3CAH1047R mutations in epithelial compartments. Charac-
terization of this line both in the context of spontaneous and carcinogen induced
tumor formation is a tool which can be utilized to better understand common
mutations in HNSCC. Immunohistochemistry confırms the overexpression of
PIK3CA in tamoxifen inducedmice. Furthermore, early characterization of this
model with chronic treatment of the smoking analogue 4-Nitroquinoline N-ox-
ide (4NQO) in drinking water shows tumor formation on the tongue and sur-
rounding head and neck regions in as little as 12-16 weeks. Hematoxylin and
Eosin staining confırmed the squamous tumor formation, while Ki67 staining
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showed enhancedproliferation of the transformed cells. In the future, thismodel
can be used to study tumor formation over time and in response to targeted
inhibitors and common therapies that are being advanced as companion diag-
nostic strategies for either NOTCH1 defıcient or PIK3CA aberrant HNSCC
tumors. Further detailed characterization of this model will allow for a deeper
understanding of the mechanisms which drive HNSCC and will translate to
improved patient care.
#1851 A murine model of von Hippel-Lindau associated retinal heman-
gioblastoma.HeruiWang, Qi Zhang, Lijin Dong, Liliana Guedez, Stanley Park,
Yujuan Wang, Shida Chen, Chun Gao, Wai T. Wong, Henry Wiley, Emily
Chew, Chi-Chao Chan, Zhengping Zhuang. NIH, Bethesda, MD.
Purpose: von Hippel-Lindau disease (VHL) is an autosomal dominant con-
dition that features a constellation of cysts or highly vascularized tumors due to
loss of heterozygosity (LOH) of theVHL gene, resulting in deregulated hypoxia-
induced factors (HIFs). Clinical manifestations of VHL include hemangioblas-
tomas in the central nervous system and retina. To date, no VHL animal model
has reproduced retinal capillary hemangioblastomas (RCH), the hallmark lesion
of ocular VHL. The RCHs may arise from arrested hemangioblast progenitor
cells, with VHL LOH in the tumor stroma. The stem cell leukemia (SCL) gene
encodes a basic helix-loop-helix (bHLH) transcription factor, a critical regulator
of hematopoiesis and vasculogenesis. We aim to generate a murine model of
VHL-associated RCH by conditionally inactivating Vhl in a hemangioblast pro-
genitor population with the angioblast-specifıc Cre line, (SCL) Cre-ERt2.Meth-
ods: We established a genetic mouse model in which the inducible Vhl gene is
specifıcally “knocked-out” in angioblast cells using the stem cell leukemia (SCL)
Cre-ERt2 transgenic mice. Two-week-old SCL-CreERt2;Vhl-F/F mice were ad-
ministrated tamoxifen (2mg/40g body weight) for 5 consecutive days to activate
the Cre recombinase that induces Vhl deletion in angioblast-derived cells. Fun-
doscopy was done monthly to detect retinal lesions. Fluorescein angiography
(FA) was performed on affectedmice. All retinas were analyzed by histology at 4
months of age. Genome typing of the Vhl conditional KO allele was conducted
in retinal lesions using microdissection, nest-PCR and Sanger sequencing. Re-
sults: About 64% (18/28) of the transgenic mice exhibited various retinal vascu-
lar defects following induction. Affected mice demonstrated retinal vascular
lesions that were variably associated with prominent vessels, anomalous capil-
lary networks, hemorrhage, exudates, and localized fıbrosis. FA revealed vascu-
lar leakage from the lesions. Histological analyses showed RCH-like lesions of
tortuous, dilated vessels surrounded by “tumorlet” cells, isolated foamy stromal
cells, and glia, classically found inRCH.Vhl LOHwas detected in the tumor-like
area as verifıed by sequencing. Conclusion: This is the fırst demonstration of
VHL-associated RCH in a transgenic mouse model. This model may be useful
for studying RCH pathogenesis, including HIF-dependent and HIF-indepen-
dent pathways, and for testing potential therapies.
#1853 Inhibition ofmTOR downregulates expression of DNA repair pro-
teins and is highly effıcient againstBRCA2-mutatedbreast cancerwhen com-
bined to PARP inhibition. Florence Coussy,1 Rania El Botty,1 Rana Hatem,1
Franck Assayag,1 Ahmed Dahmani,1 Marine Huppé,1 Sophie Chateau Joubert,2
Jean-Luc Servely,2 Virginie Bernard,1 Sophie Vacher,1 Berangere Ouine,1 Aure-
lie Cartier,1 Leanne De Koning,1 Paul Cottu,1 Ivan Bieche,1 Elisabetta Maran-
goni1. 1institut Curie, Paris, France; 2Ecole nationale veterinaire d’ Alfort,Maison
Alfort, France.
Purpose: DNA repair defıciencies and activation of PI3K/AKT/mTOR path-
way are common events in breast cancer. BRCA1/2 mutations have been asso-
ciatedwith sensitivity to PARP1 inhibitors (synthetic lethality), while alterations
in component of the PI3K/AKT/mTOR pathway might confer sensitivity to
PI3KCA and mTOR inhibitors. Here we explored the therapeutic benefıt of
combining a mTOR and a PARP inhibitor in BRCA2-mutated patient-derived
xenografts (PDX) with alterations in the PI3K/AKT/mTOR pathway. Experi-
mental design: the combination of the mTOR inhibitor everolimus and the
PARP inhibitor olaparib was tested in two BRCA2-mutated PDX established
from a luminal B tamoxifen-resistant and a basal-like breast cancers. Both car-
ried alterations in the PI3K/AKT/mTOR pathway: PIK3R1mutation and PTEN
loss for the luminal B PDX and PTEN loss for the basal-like PDX. To identify
putative crosstalk events betweenmTOR andDNA repair, a Reverse Phase Pro-
tein Array (RPPA) analysis of multiple signaling pathways and DNA repair
processes was performed on untreated and treated xenografts. Gene and protein
expression changes were confırmed by RT-PCR andWestern Blot analyses. The
capacity to repair DNA damage was measured by P-H2AX immunostaining.
Results: in both PDX, everolimus and olaparib showed marked anti-tumor ac-
tivity with a growth inhibition comprised between 78% and 86% in the mono-
therapy setting and 96% in the combination arm, where 100% of mice showed
tumor regressions. In the luminal B tumor this combination was more effıcient
than the combination of everolimus and endocrine therapies (fulvestrant or
tamoxifen). In both PDX, the fraction of P-H2AX (marker of unrepaired DNA
double-strand breaks) positive cells was increased after everolimus treatment,
suggesting a link between mTOR and DNA damage, and strongly increased in
the combination setting. RPPA analysis of tumors treated by everolimus alone
revealed amarked downregulation of different proteins involved inDNA repair,
including FANCD2, RAD50 and SUV39H1, a chromatin compactor factor es-
sential in homologous recombination. In the combination setting, expression of
these proteins was almost completely abolished, suggesting convergence of
PARP andmTOR in downregulation of DNA repair components. Conclusions:
our results suggest that combiningmTOR andDNA repair inhibitors could be a
successful strategy to treat a subset of breast cancer with BRCA2 mutation and
alterations in the PI3K/AKT/mTOR pathway. Further experiments withmTOR
and PARP inhibitors combinations are ongoing in sporadic breast cancer PDX
showing a BRCAness phenotype.
#1854 Generation and characterization of mouse model of Pmepa1 con-
ditional knockout in prostate epithelia. Hua Li, Shashwat Sharad, Talai Bar-
biev, Yingjie Song, Denise Young, Taduru Sreenath, Albert Dobi, Shiv Srivas-
tava. USU/Center for Prostate Disease Research (CPDR), Rockville, MD.
Introduction andObjectives: Prostate cancer (CaP) is themost commonnon-
skin malignancy diagnosed in American men and desfunctions of androgen
receptor (AR) plays an essential role in prostate tumorigenesis. PMEPA1 is an
androgen and TGF- -induced gene abundant in prostate, which was identifıed
to degrade AR protein via NEDD4 E3 ligase mediated pathway. Reduced or loss
of PMEPA1 expression, commonly detected in prostate tumors, led to increased
AR protein and activated AR signaling. PMEPA1 inhibited TGF- receptor 1
meditated signaling by a negative feedback loop. It was reported that loss of
PMEPA1 facilitates bone metastasis of CaP through blocking TGF- signaling.
To further investigating the biological function of PMEP1 gene in CaP tumori-
genesis, particularly via AR and TGF-, we generated Pmepa1 prostate condi-
tional knockout mouse model. Methods: C57BL/6 mice were utilized for gener-
ation of Pmepa1 conditional knockout model. Pmepa1 gene was conditionally
deleted inmouse prostate epitheliumbyARR2PB-Cre-Lox system.Malemice of
genotypes of wild-type, Pmepa1 flox/wild-type-ARR2PB-Cre, Pmepa1 flox/
flox-ARR2PB-Cre were euthanized at the age of 3 months for analysis. The
prostate tissue was collected for frozen and formalin fıxation for histology anal-
ysis, and other major organs including heart, lung, liver, spleen, bladder and
testis were also collected for control. The tissue were sectioned and stained with
Hematoxylin & Erosin (H&E). Total RNA and protein were harvested by ho-
mogenizing tissue. The protein levels of Pmepa1, Ar and Nkx3.1 were analyzed
by immunohistochemistry (IHC) and immunoblotting, and the transcript levels
of these genes were evaluated by in situ hybridization (ISH) and quantitative-
PCR (Q-PCR). Results: The expression of Pmepa1 proteinwas found to focus on
lateral lobe, consistent with Ar protein expression pattern. The data of Q-PCR
and ISH showed that transcript level of Pmepa1 was dramatically suppressed in
Pmepa1 flox/flox and flox/wild-typeARR2PB-Cremice. Compared towild-type
ones, Pmepa1 protein was shown signifıcantly decreased in heterozygous and
homozygous knockout mice by immunoblotting and IHC staining. And the
protein level of Ar was stronger in Pmepa1 conditional deleted mouse. There
was no dramatic morphology change in mouse prostate gland by H&E staining.
Conclusions: Conditional deletion of Pmepa1 gene in mouse prostate epithe-
lium led to enhanced Ar protein and activating Ar signaling. The effects of
Pmepa1 gene loss inmouse prostate gland on other signaling such as TGF- and
prostate tumorigenesis are needed to be further evaluated. Funding: This study
was supported by CPDR, USUHS, HU0001-10-2-0002 to DGM.
#1855 Developed operation method for patient-drived orthotopic xeno-
graft model of hepatocellular carcinoma.Hye Rim Byeon, YunSung Seo, Sun-
Young Kong, Seung Duk Lee. National Cancer Center, Goyang-si, Gyeonggi-do,
Republic of Korea.
Patient-drived xenograft(PDX) model is a biological organized platform and
a patient substitute. Recent studies use the ectopic model for hepatocellular
carcinoma(HCC) but thismodel don’t reflect likewise the tumor state of patient.
For exact prognosis, it is need to establish patient-derived orthotopic xenograft-
(PDOX) mouse model of hepatocellular carcinoma using direct injection tech-
nique. Additionally, secretion of growth factor from bone marrow stem cells is
promoted after partial hepatectomy. This mechanism is helpful to not only gen-
eral liver regeneration but also tumorigenesis. Based on former PDX research,
we develop the new protocol using direct injection technique. From January
2015 to June 2016, consent about getting tumor pieces to the patient of hepato-
cellular carcinoma. The pieces is stored in RPMI1640 and moved from opera-
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tion room to research room immediately. For PDOX and PDX to subcutaneous
model, 810weeks old NOD SCID and NSG male mouse is used. The tumor
pieces cutted to the cube size 1mm. For stop the bleeding, inferior vena cava is
blocked using Bulldog Clamp and the cube is directly injected median lobe to 3
places randomly. After clear the Bulldog Clamp, a left lobe is removed using tie
and weighted. After 3 months, the PDOX mouse is checked for cancer growth
using MRI or PET-CT. Successful PDOX or PDX to subcutaneous model is
sacrifıced and succeeded a generation to another Balb/C-nude male mouse
810weeks old. The rate of success of PDOX model and PDX to subcutaneous
model is about 10% respectively. Formed tumor is verifıed by H&E staining.
Based on protocol established, further study plan is required for improving on
the rate of success to establish PDOX model and clinical application.
TUMOR BIOLOGY: Imaging for Cancer Diagnosis and Image-
Guided Therapy
#1856 Dual-modality immunoPET/fluorescence imaging of prostate can-
cer utilizing 89Zr- or 124I-Cy5.5-anti-PSCA cys-minibody.Wen-Ting K. Tsai,
Kirstin A. Zettlitz, Richard Tavaré, Felix B. Salazar, Robert E. Reiter, Anna M.
Wu. University of California Los Angeles, Los Angeles, CA.
Prostate cancer patients can benefıt from non-invasive and more accurate
diagnosis, as well as improved visualization during surgery. ImmunoPET can
provide information on location and extent of the disease, while fluorescent
image-guided surgery can distinguish cancerous tissue during resection. Pros-
tate StemCell Antigen (PSCA) is upregulated in themajority of prostate cancers
and metastases and is therefore a promising target for imaging. Engineered
antibody fragments, such as the minibody, exhibit ideal imaging characteristics
due to fast blood clearance for high target-to-background images at short imag-
ing times post-injection. A dual-labeled minibody can reveal the whole-body
PSCA-expressing tumor burden by PET, followed by intraoperative visualiza-
tion of margins by fluorescence. The fully humanized anti-PSCAA11minibody
was engineered with a C-terminal cys-tag (A11 cMb) for site-specifıc labeling by
thiol-directed chemistry. In order to radiolabel with 89Zr, a metal chelator des-
ferrioxamine (DFO) was site-specifıcally conjugated to A11 cMb by maleimide
chemistry, while direct iodinationwas used to labelwith 124I. Singly labeled 89Zr-
and 124I-A11 cMb successfully imaged subcutaneous PSCA () and () 22Rv1
human prostate adenocarcinoma tumors in nude mice, resulting in positive-to-
negative tumor ratios of 2.5:1 and 8:1, respectively. Both 89Zr-A11 cMb and
124I-A11 cMb cleared from blood by 22 hours. As expected for the residualizing
radiometal, 89Zr-A11 cMb resulted in retention in the organs of clearance (liver
and kidneys). For dual-modality imaging, A11 cMb was site-specifıcally conju-
gated with Cy5.5-maleimide and radiolabeled with 124I. PET imaging with 124I-
Cy5.5-A11 cMb in the subcutaneous 22Rv1 tumor model resulted in a positive-
to-negative tumor ratio of 13:1. The PSCA () tumors were subsequently
visualized by fluorescence in situ and ex vivowith high contrast in comparison to
PSCA () tumors and tissues. In an orthotopic model, PSCA () 22Rv1 cells
were implanted in the prostate, and therefore 89Zr was used in order reduce
interfering signal from clearance to the bladder. A11 cMb was site-specifıcally
conjugated with Cy5.5 and randomly labeled with SCN-DFO, then radiolabeled
with 89Zr. 89Zr-Cy5.5-A11 cMb successfully imaged the prostate tumor, result-
ing in a 3:1 tumor-to-blood ratio. Fluorescence imaging clearly distinguished
prostate tumor from adjacent tissues including seminal vesicles. In conclusion, a
single injection of the dual-labeled A11 cMb can visualize tumor burden by
immunoPET and fluorescence imaging. This humanized probe has the potential
for clinical translation for primary andmetastatic prostate cancer detection and
surgical guidance that can ultimately enhance treatment success.
#1857 Early detection of pancreatic intraepithelial neoplasms (PanINs) in
transgenic mouse model by hyperpolarized 13C metabolic magnetic reso-
nance imaging. Prasanta Dutta, Yu Zhang, Michelle Zoltan, Marilina Mascaro,
Erick Riquelme, Jaehyuk Lee, Anirban Maitra, Florencia McAllister, Pratip
Bhattacharya. UTMD Anderson Cancer Ctr., Houston, TX.
Pancreatic cancer, one of themost lethal solid tumors, is an aggressive disease
that develops relatively symptom-free. Pre-invasive pancreatic intraepithelial
neoplasias (PanINs) have been identifıed as precursor lesions to pancreatic can-
cer. While there is growing evidence supporting PanIN’s genetic links to pan-
creatic cancer, there is no non-invasive method to detect them. There is an
unmet need of novel strategies for detection of pancreatic cancer at the earliest
stages, preferably at the stage of PanINs. Hyperpolarized magnetic resonance
imaging (HP-MRI) has shown potential for early detection of cancers andmon-
itoring therapeutic effıcacy. Here we have employed in-vivo 13C pyruvate met-
abolic imaging and ex-vivo nuclear magnetic resonance (1H-NMR) metabolo-
mics to identify and understand metabolic changes, to enable detection of early
PanINs and its progression to advanced PanINs and pancreatic cancer. Geneti-
cally engineered mouse (GEM) models with progression of PanIN lesions and
control animals, with no pancreatic lesions, were employed in this study. Hy-
perpolarization of pyruvate and in-vivo 13CMRS were performed using Hyper-
sense (Oxford Instruments) and 7T MRI scanner with a dual tuned 1H/13C
volume coil respectively. Tissue alanine and lactate concentrations were deter-
mined using a Bruker 500 MHz NMR spectrometer coupled with cryo-probe.
Histology and immunohistochemistry were performed on excised tissue sam-
ples. P48Cre mice were used as controls and P48Cre;LSLKrasG12D mice were
used for detection of early and advanced PanINs, which usually develop in these
mice between 12 and 20 months. The imaging experiments were performed at
the different stages of the disease. Progression of disease from tissue containing
predominantly low-grade PanINs to tissue with high-grade PanINs showed a
decreasing alanine/lactate concentration ratio. Real time in-vivo 13C MRS was
used to measure non-invasively changes of alanine and lactate metabolites with
disease progression and in control mice, following injection of hyperpolarized
pyruvate. The alanine-to-lactate (Ala/Lac) signal intensity ratio was found de-
creased as the disease progressed from low-grade PanINs to high-grade PanINs.
These results demonstrate that there are signifıcant alterations of alanine
transaminase (ALT) and lactate dehydrogenase (LDH) activities which favor the
transformation of aggressive pancreatic cancer from PanINs lesion. Our results
suggest that real-time conversion kinetic rate constants kPA(pyruvate-to-ala-
nine) and kPL(pyruvate-to-lactate) can be used asmetabolic imaging biomarkers
for assessing the early stage of pancreatic diseases. Findings from this highly
promising HP-MRI technique could be rapidly translated to the clinic for early
detection of pancreatic cancer in patients at high risk for developing the disease.
#1858 Theranostic nanoparticles for detection and treatment of pancre-
atic cancer.Phillip Chuong,Neal Bhutiani, Lacey R.McNally.Univ. of Louisville
Brown Cancer Ctr., Louisville, KY.
Background: Despite continued efforts to improve early detection and treat-
ment of pancreatic adenocarcinoma, the disease still carries a poor prognosis.
The combination ofmultispectral optoacoustic tomography (MSOT) and thera-
nostic nanoparticles offers a possible solution by providing tumor targeting
using fluorescent dyes and treatment through drug delivery. We describe a 40
nm colloidalmesoporous silica nanoparticle (CMS)with vermiformpores and a
chitosan coating and tagged with the V7 peptide to provide pH-specifıc dual
targeting to deliver a contrast agent in a tumor-specifıc fashion.Methods: CMSs
were synthesized using a modifıed Stober method, coated with chitosan, and
conjugated with a V7 peptide, resulting in a dual acidic pH targeting system.
Particle characterization was performed using transmission electron micros-
copy (TEM),UV-vis spectrophotometry, Zeta potential, and dynamic light scat-
tering. To determine acidic pH specifıcity of V7-CMS, Panc1 and S2VP10 cell
lines were incubated in cell culture medium at either pH 7.4 or 6.6 followed by
treatment with V7-CMS. Particle uptake was determined using near infrared
(NIR) fluorescence and tissue phantoms. Finally, for in vivo testing, the same
CMSNs were injected into mice bearing S2VP10 pancreatic tumors. MSOT im-
aging was performed 8 hours after CMS injection. Results: TEM images dem-
onstrated successful synthesis of approximately 40 nm V7-CMSs with vermi-
form pores. On NIR imaging, V7-CMS demonstrated acidic pH specifıcity in
both S2VP10 and Panc 1 cells at pH 6.6, with particle localization and signal
intensity 8-fold and 5-fold higher, respectively, than that observed at pH 7.4. In
tissue phantoms, increased pH specifıcity was also observed in both S2VP10 and
Panc 1 cells at pH 6.6. Particle location and signal intensity on MSOT was
20-fold and 4-fold higher, respectively, than that observed at pH 7.4. In the
murine orthotopic S2VP10 pancreatic tumor model, MSOT imaging 8 hours
after IV CMS injection demonstrated V7-CMS accumulation specifıcally within
pancreatic tumors. Conclusion: The acidic pH specifıc dual targeting system
using chitosan-coated and pHLIP V7-tagged CMSs results in tumor specifıcity.
Preferential binding and dye release was increased as much as 20-fold at pH 6.6
as compared to pH 7.4 in tissue phantoms. MSOT was able to detect tumor
specifıc accumulation ofV7-CMS in vivo. These small, pH specifıc particles hold
signifıcant promise for effectively identifying pancreatic tumors with high sen-
sitivity and specifıcity and for targeted drug delivery.
#1859 Hsp90 targeted near infrared molecular imaging to detect mam-
mografıcally occult invasive lobular breast cancer. Takuya Osada, Kensuke
Kaneko, Zachary Hartman, Amy Hobeika, Philip Hughes, Timothy Haystead,
Michael Morse, H. Kim Lyerly. Duke University, Durham, NC.
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Background: Early diagnosis of Invasive lobular carcinomas (ILCs) is clini-
cally challenging due to its histopathologic features making it diffıcult to detect
using mammography. Because of the diffuse infıltration of ILC cells into the
surrounding stroma, ILC is also associated with a higher incidence of positive
resection margins after breast-conserving surgery. Therefore, there is a signifı-
cant unmet need for improved imaging for early detection, clinical staging, and
possibly intraoperative imaging to assess surgicalmargins.We propose to detect
mammografıcally occult ILC by the in vivo detecting of malignant signaling
pathways activated in ILC.Heat shock protein 90 (Hsp90) comprises 1-3%of the
total cellular protein in most cells and acts as a molecular chaperone for more
than 200 reported client proteins. Recently, we developed a series of tethered
Hsp90 inhibitors that specifıcally target a tumor specifıc form of Hsp90 associ-
ated with poor outcomes. Using near infrared (nIR) probe-tethered Hsp90 in-
hibitors, we demonstrated that Hsp90 is actively re-internalized and can be used
to image murine and human breast cancer in vitro and in vivo. Methods and
Results: We tested the imaging effıcacy of the nIR-tethered Hsp90 inhibitor,
HS196, in ILC models in vitro and in vivo. An inactive structural analog HS199
was used as a control to monitor for non-specifıc (non-Hsp90 dependent) up-
take. Two ILC cell lines, MDA-MB-134 VI and SUM44-PE, and one patient-
derived ILC xenograft, HCI-013 EI, were tested. nIR signals of HS196 in vitro
and in vivo were detected by Odyssey (LI-COR) and Pearl Trilogy (LI-COR)/
SPYELITE imager (Novadaq), respectively.High uptake ofHS196was observed
in vitro by both cell lines ( 1 M), while the control HS199 resulted in weaker
nIR signals in these cells. In vivo imaging effıcacy of HS196 was tested using
HCI-013 EI xenograft in SCID-beige mice. After injection of 10 nmol com-
pounds via tail vein, quick and stronger accumulation and longer retention of
the HS196 in the ILC xenograft was observed, while HS199 showed signifıcantly
weaker accumulation and faster clearance (by 24 h after injection). Signifıcant
uptake of HS196 by HCI-013 EI tumors was confırmed by ex vivo imaging of
tumors 24 h after compound injection. Histological and flow cytometry analysis
of HCI-013 EI tumors showed strong nIR signals in tumor cells. Conclusions:
The non-radioactive, nIR imaging strategy, using a novel nIR-Hsp90 inhibitor
compound, HS196, was effective in the non-invasive imaging of ILC tumors.
This fınding suggests that newmolecular imaging techniques, not dependent on
micro calcifıcations or architectural distortion, may be a novel strategy to met
the need of ILC patients to detect, clinically stage and assess margins during
surgical resection. Ongoing pre-clinical models will be employed and fırst in
human testing of this approach in planned.
#1860 Ligand-conjugated superparamagnetic biosynthesized magnetite
nanoparticles for specifıc targeting via in vivo imaging of triple negative
breast cancer. John David Obayemi,1 Jingjie Hu,1 Vanessa Uzonwanne,1 Karen
Malatesta,1Winston Soboyejo2. 1PrincetonUniversity, Princeton, NJ; 2Worcester
Polytechnic Institute, Worcester, NJ.
This paper presents ligand-conjugated biosynthesized magnetite nanopar-
ticles (BMNPs) that serve asmolecularmagnetic resonance imaging (MRI) con-
trast agents for specifıc targeting of cell-surface receptors on triple negative
breast cancer cells. Superparamagnetic BMNPs were functionalized with Lu-
teinizing Hormone Releasing Hormone (LHRH), a molecular recognition units
(MRUs) that have been shown to have receptors that are overexpressed onMDA
MB 231 cells. Early and metastatic tumors from triple negative breast cancer
xenografts were targeted in vivo in a nude mouse model in the presence of both
ligand-conjugated and unconjugated superparamagnetic BMNPs. A combina-
tion of transmission electron microscopy (TEM), Atomic Force Microscopy
(AFM) and spectrophotometric analysis was used to investigate the specifıc ac-
cumulation of the functionalized superparamagnetic BMNPs tumor specifıc
sites. The results obtained compliment the in vitro experiment that showed
enhancement ofMRI contrast by ligand-conjugated BMNPs. At a concentration
of 20mg/kg of both nanoparticles, the ligand-conjugated BMNPs reveal spe-
cifıc attachment to tumor tissue as well as metastases in the lungs. However,
most of the unconjugated BMNPs were found to accumulate in the liver, spleen
and kidney which showed their non-specifıcity. The implications of the results
obtained is for the specifıc targeting and early detection of triple negative breast
cancer.
#1861 LHRH-conjugatedmagnetite nanoparticles for breast cancer detec-
tion and contrast enhancement in MRI. Jingjie Hu,1 John Obayemi,1 Karen
Malatesta,1 Derek Adler,2 Sean Wang,2 Edward Yurkow,2 Winston Soboyejo3.
1Princeton University, Princeton, NJ; 2Rutgers University, Piscataway, NJ;
3Worcester Polytechnic Institute, Worcester, MA.
Breast cancer is one of the most frequently occurring types of cancer in
women. Furthermore, at the time of initial diagnosis, some tumors may have
metastasized. There is, therefore, a critical need for novel procedures for the
early detection of breast tumors and their metasteses. One of the specifıc
targeting receptors for human breast cancer cells is Luteinizing Hormone
Releasing Hormone (LHRH). Approximately 52% of human breast cancers
express binding sties for LHRH. Within this context, LHRH-functionalized
nanoparticles have been considered for potential applications in cancer de-
tection and treatment. In this study, we present results of experimental and
theoretical studies of the entry of Luteinizing Hormone Releasing Hormone
(LHRH)-conjugated Magnetite Nanoparticles (MNPs) into MDA-MB-231
breast cancer cells. The internalization of LHRH-conjugated MNPs into
breast cells is studied using confocal fluorescence microscopy. The receptor-
mediated entry of nanoparticles into breast cancer cells is also elucidated
using a combination of thermodynamics and kinetics models. The trends in
predicted nanoparticle entry times and the size range of the engulfed nano-
particles are shown to be consistent with the experimental observations. The
specifıc interaction between LHRH receptors and LHRH can be used to
enhance the specifıc targeting of breast cancer cells. Furthermore, LHRH-
MNPs demonstrated specifıc enhancement for in-vivo signal in magnetic
resonance imaging (MRI) for breast tumor sites and their metastases in the
body. Lastly, nanoparticle concentration in different organs is presented to
show that the conjugated MNPs are accumulated mainly into the tumor sites
and their metastasis. While unconjugated MNPs are shown to accumulate in
the liver, kidney, spleen and heart. The current results show that LHRH-
conjugated magnetite nanoparticles have the potential for the specifıc tar-
geting and detection/treatment of breast cancer.
#1862 Direct observation of colorectal cancers using fıeld-emission scan-
ning electronmicroscopy with a thin polymer membrane, the NanoSuit.Hi-
rotoshi Kikuchi, Tomohiro Matsumoto, Takanori Hiraide, Yusuke Ozaki,
Amane Hirotsu, Tomohiro Murakami, Toshiki Kawabata, Yoshihiro Hira-
matsu, Kinji Kamiya, Takanori Sakaguchi, Yasuharu Takaku, Isao Ohta, Taka-
hiro Hariyama, Hiroyuki Konno. Hamamatsu Univ. School of Medicine,
Hamamatsu, Japan.
Background: Field-emission scanning electron microscopy (FE-SEM) en-
ables us to observe nano-sized objects with great depth of focus and high
resolution. However, the observation of biological samples including colo-
rectal tissues using an FE-SEM has been diffıcult because it requires to evac-
uate its inside to prevent electron scattering, therefore all organisms contain-
ing ca. 70% water are rapidly evaporated and consequently caused structural
disruption and collapse. To overcome the limitations of the conventional
SEM, equipment such as low-vacuum scanning electron microscopy and
environmental scanning electron microscope was developed. However, they
are not reliable enough to investigate living organisms or wet tissues with
high resolution level. We have recently reported that a simple surface mod-
ifıcation consisting of a thin extra layer, coined the term ‘NanoSuit®’, can
keep organisms alive in the high vacuum (103 to 107 Pa) of the SEM. We
now modifıed the technique and developed a new solution, which enables
FE-SEM observations of wet tissues. In this study, we utilized this technique
to observe real images of colorectal cancers and their adjacent normal mu-
cosae at high resolution. Materials and methods: Colorectal cancer tissues
and their adjacent normal mucosa were cut with a scalpel from specimens
surgically resected. All patients enrolled in this study provided written in-
formed consent. Observations were carried out with an FE-SEM (S-4800,
Hitachi or JEM-7100F, JEOL, Japan) at acceleration voltage of 1.0 kV. The
vacuum level of the observation chamber was 103 - 107 Pa. The newly
developed surface shield enhancer (SSE) solution was used to make Nano-
Suit® for wet tissue observation. To form the NanoSuit®, the specimens were
dipped for 1 min into the SSE solution and blotted briefly thereafter put on
dry fılter paper to remove excess solution. Specimens were then introduced
directly into an FE-SEM to form a NanoSuit® following irradiation of the
electron beam. Results: Fine structures of intestinal crypt and villi were
observed in normal colon mucosa using FE-SEM with a NanoSuit®, whereas
fıxed specimens prepared with conventional method showed obvious struc-
tural damage. Comparing with the region of normal colon mucosa, colorec-
tal cancer lesion had relatively amorphous surface, therefore the border be-
tween non-cancerous mucosa and cancer lesions in colon tissues are able to
be distinguished under high magnifıcation. In addition, fıber-like structure
was observed at the border between noncancerous mucosa and cancer le-
sions, suggesting an invasive front of colorectal cancer. Conclusions: We
successfully observed the real mucosal surfaces and cancer lesions of colo-
rectum with high resolution by an FE-SEM using a newly developed vacu-
um-proof suit, the “NanoSuit®”. This novel technique will enable us to in-
vestigate further physiopathology of GI tract including cancers.
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#1863 Non-invasive imaging of colitis using multispectral optoacoustic
tomography. Neal Bhutiani,1 William Grizzle,2 Susan Galandiuk,1 Dennis
Otali,2 Gerald Dryden,1 Nejat Egilmez,1 Lacey R. Mcnally1. 1Univ. of Louisville
Brown Cancer Ctr., Louisville, KY; 2UAB, Birmingham, AL.
Background: Currently, several non-invasive modalities, including MRI and
PET, are being investigated to identify early intestinal inflammation, longitudi-
nallymonitor disease status, or detect dysplastic changes in patientswith inflam-
matory bowel disease (IBD). Currently, multispectral optoacoustic tomography
(MSOT; often in combination with ultrasound) has been used to effectively
image tumor xenografts as well as several orthotopic tumor models, including
pancreatic adenocarcinoma, but not to specifıcally assess inflammatory or dys-
plastic changes in the bowel in murine models. Here, we assess the applicability
andutility of (MSOT) in evaluating the presence and severity of colitis.Methods:
Nine 6-7 week old C57B/6 mice underwent antibiotic depletion of gastrointes-
tinal flora before inoculation with enterotoxic Bacteroides fragilis to induce
colitis. Mice were then anesthetized, depilated, imaged from their superior tho-
rax to inferior pelvis using MSOT. Mice were evaluated prior to bacterial inoc-
ulation, 2 days after inoculation, and 7 days after inoculation. MSOT values for
oxygenated and deoxygenated hemoglobin were determined using MSOT im-
aging software and compared using linear regression. At each timepoint, three
mice underwent colonoscopy prior to euthanasia and colon processing for his-
tology. Results: Mice with bacterially-induced colitis demonstrated a temporal-
ly-associated increase in mesenteric and colonic vascularity, with an increase in
mean signal intensity of oxygenated hemoglobin (1.150 vs. 2.716 MSOT a.u.
compared to controls; p0.004) by MSOT two days after inoculation. These
fındings were signifıcantly more prominent 7 days after inoculation, with in-
creased mean signal intensity of oxygenated hemoglobin (1.150 vs. 2.716 vs.
3.422 MSOT a.u. for controls vs. 2 days post-ETBF vs. 7 days post-ETBF,
p0.0002) and the development of punctate vascular lesions on the colonic
surface. Compared to untreated controls, mice at 2 days and 7 days post ETBF
inoculation demonstrated an increased colitis score on colonoscopy (1.5 vs. 2.5
vs. 5.5), which correlated well with MSOT fındings of mean oxygenated hemo-
globin signal intensity (r0.82, p0.013). These fındings were also associated
with inflammatory changes observed on histologic analysis. Conclusions:
MSOT represents a non-invasive diagnostic modality that effectively identifıes
colitis in a murine model. With improvements in depth of tissue penetration,
MSOTmay hold potential as a sensitive, accurate, non-invasive imaging tool in
evaluation of both disease status and early detection of malignancy in patients
with IBD.
#1864 Feasibility of magnetic relaxometry for early ovarian cancer detec-
tion: preliminary evaluation of sensitivity and specifıcity in cell culture and
in mice. Kelsey Mathieu, Zhen Lu, Hailing Yang, Lan Pang, Adam Kulp, John
Hazle, Robert C. Bast. The University of Texas MD Anderson Cancer Center,
Houston, TX.
Introduction: Most ovarian cancers are diagnosed in a late, incurable stage,
which has prompted efforts towards earlier detection andmore effective screen-
ing strategies. To be considered effective, screeningmust provide suffıcient sen-
sitivity and specifıcity to impact patient mortality while minimizing false posi-
tives. Magnetic relaxometry (MRX), which detects binding of targeted iron
oxide nanoparticles (NPs) to cancer cells, offers the promise of improved sensi-
tivity and specifıcity over conventional early detectionmodalities. Methods:We
investigated the sensitivity and specifıcity of MRX by scanning ovarian cancer
cell samples containing 105, 106, and 107 cells incubated with a fıxed amount (57
g Fe3O4) of anti-HER2 antibody-conjugated, PEG-coated NPs or unconju-
gated, PEG-coated NPs (Senior Scientifıc LLC). To further evaluate specifıcity,
we used cell lines with both high and low expression ofHER2 (SKOV3 andHEY,
respectively). To assess MRX under in vivo conditions, we subcutaneously in-
jected 105, 106, and 107 anti-HER2NP-labeled SKOV3 cells into nudemice (n
9) and immediately performed MRX scanning. Prior to performing this study,
we verifıed successful antibody-NP conjugation through an ELISA assay, which
confırmed the presence of anti-HER2 antibody in NP pellets. Additionally, we
performed flow cytometry to confırm a high level of specifıc binding between
SKOV3 cells and anti-HER2-conjugatedNPs. Results: Our in vitro data revealed
strong linearity between cell number andMRX signal for both SKOV3 andHEY
cells incubated with anti-HER2 NPs (R2  0.99 and 1, respectively). Further-
more, there was little to no MRX signal for all cell samples incubated with
unconjugated, PEGNPs regardless of cell number. The highest MRX signal was
observedwhen 107 SKOV3 cells were incubatedwith anti-HER2NPs, whichwas
2.1	 0.3 and 15.7	 1.4 times higher than when 107 Hey cells were incubated
with anti-HER2 NPs or when 107 SKOV3 cells were incubated with unconju-
gated PEG NPs, respectively; signifıcantly higher MRX signals (relative to the
controls; p.01) were also noted for samples containing 106 SKOV3 cells incu-
bated with anti-HER2 NPs. When scanning live mice injected with 107 anti-
HER2NP-labeled SKOV3 cells, theMRX signal was signifıcantly higher than the
signal from the mice prior to the injection (p.001). Additionally, MRX signal
versus cell number in the injectedmice was highly correlated (r 0.99) with the
MRX data from the corresponding cell sample scans. Conclusion: MRX is suf-
fıciently sensitive to detect 1 million cells in culture or 10 million cells in mice
with a high level of specifıcity. Sensitivity may be improved by using nanopar-
ticles coated with antibodies against antigens that are overexpressed by a larger
fraction of ovarian cancers and will be the focus of future work.
#1865 Enhancing the in vivo detection of cancer by manipulating mag-
netic fıelds applied to tumor targeting superparamagnetic iron oxide nano-
particles.Todor Karaulanov, Erika C. Vreeland, AndrewGomez, Kayla E.Min-
ser, Caroline L. Weldon, William H. Anderson, Christopher Nettles, Giulio
Paciotti. Imagion Biosystems, Albuquerque, NM.
Superparamagnetic Relaxometry (SPMR) is combination technology for the
early detection of cancer. Conceptually, PEGylated superparamagnetic iron ox-
ide (Fe3O4) nanoparticles (NPs) coupled with a tumor targeting monoclonal
antibody are systemically administered and target solid tumors by both passive
(EPR) and active (receptor targeting) mechanisms. Once bound to the target
cells, the NPs are magnetized by a brief, low fıeld magnetic pulse to create mac-
roscopic magnetization. Once the fıeld is removed, the particle’s magnetization
decays and is measurable by superconducting quantum interference device
(SQUID) detectors. The pattern of decay, known as Néel relaxation, exhibits a
difference in latency specifıc to bound nanoparticles and differs from the
Brownian decay exhibited by free/unbound particles. As a proof of concept, we
developed PEGylated NPs that are covalently bound to an anti-Her-2 monoclo-
nal antibody. In vitro, the nanoconstruct exhibits specifıc binding to the Her-2
overexpressing BT-474 breast cancer cells, with little to no binding to Her-2
negative MCF-7cells. Similar patterns of selective targeting were observed in
vivo. To improve the specifıc detection of SPMR signals in tumors we developed
a novel system that selectively enhances the magnetic signal at tumor sites and
reduces the contribution of similar signals at off target sites such as the liver and
spleen. For these studies, we created phantoms of varying strength to mimic
tumor and non-specifıc signals.We observed that by creating non-homogenous
excitation magnetic fıeld patterns, we reduced the contribution of the non-spe-
cifıc signals by an order of magnitude, effectively increasing the signal to noise
ratio of the tumor signal. These results are clinically relevant and support the use
of SPMR in the detection of small tumors in cancer patients.
#1866 Ultrahigh resolution optical coherence microscopy for label-free
imaging of human cervical lesions ex vivo.Xianxu Zeng,1 Canyu Li,2 Xiaofang
Wang,1 Jason Jerwick,2 TaoXu,2 YuanNing,2 Linlin Zhang,1 YutaoMa,3 Xiaoan
Zhang,1 Chao Zhou2. 1Zhengzhou University, Zhengzhou, China; 2Lehigh Uni-
versity, Bethlehem, PA; 3Wuhan University, Wuhan, China.
Cervical cancer remains the fourth most common cause of cancer and the
fourth leading cause of cancer death in women worldwide. In contrast to the
decreasing prevalence in developed countries, incidence of cervical cancer
remains high in developing countries, such as China, India and Chile. Effec-
tive screening of cervical cancer is crucial for early diagnosis of the disease.
Ultrahigh resolution optical coherence microscopy (UHR OCM) is an
emerging label free imaging technique that can be used to obtain three di-
mensional (3D) “optical biopsy” of biological samples with cellular resolu-
tion up to 2 mm beneath the tissue surface. The goal of this study is to assess
the diagnostic value of UHR OCM for human cervical precancer and cancer
screening and identify characteristic features in UHR OCM images that
correlate with the gold standard histopathology. Six hundred and fıfty eight
(658) fresh cervical tissues from cervical biopsy, conization and panhyster-
ectomy were obtained from 254 consenting volunteers. Multiple 3D UHR
OCM images were obtained from each specimen before the sample was
processed for standard histopathology evaluation. Of the 658 samples im-
aged, 474 had normal cervix or benign lesions, 110 had low grade squamous
intraepithelial lesion (LSIL), 57 had high grade squamous intraepithelial
lesions (HSIL) and 17 had invasive cancer. UHR OCM images were com-
pared to histopathology slides obtained from the same specimens in order to
identify diagnostic image features. Distinctive patterns for squamous epithe-
lium, columnar epithelium, basement membrane, cervical inflammation and
erosion, koilocytic cells, low grade and high grade squamous intraepithelial
lesions and cervical cancer were clearly observed. Our results lay the foun-
dation for future non-invasive optical evaluation of cervical tissue in vivo.
This could lead to a less invasive and more effective screening strategy for
cervical cancer based on OCM guided biopsies.
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#1867 Near infrared fluorescent imaging of brain tumor with IR780 dye
incorporatedphospholipidnanoparticles. ShihongLi,1 Jennifer Johnson,1An-
derson Peck,1 QianXie2. 1VanAndel Research Institute, Grand Rapids,MI; 2East
Tennessee State University, Johnson City, TN.
Background: Near-IR fluorescence (NIRF) imaging is becoming a promising
approach in preclinical tumor detection and clinical image-guided oncological
surgery. While heptamethine cyanine dye IR780 has excellent tumor targeting
and imaging potential, its hydrophobic properties limit its clinical use. In this
study, we developed nanoparticle formulations to facilitate the use of IR780 for
fluorescent imaging of malignant brain tumor. Methods: Self-assembled IR780-
liposomes and IR780-phospholipid micelles were prepared and their NIRF
properties were characterized. The intracellular accumulation of IR780-nano-
particles in glioma cells were determined using confocalmicroscopy. The in vivo
brain tumor targeting and NIRF imaging capacity of IR780-nanoparticles were
evaluated using U87MG glioma ectopic and orthotopic xenograft models and a
spontaneous glioma mouse model driven by RAS/RTK activation. Results: The
loading of IR780 into liposomes or phospholipid micelles was effıcient. The
particle diameter of IR780-liposomes and IR780-phospholipid micelles were 95
nm and 26 nm, respectively. While stock solutions of each preparation were
maintained at ready-to-use condition, the IR780-phospholipid micelles were
more stable. In tissue culture cells, IR780-nanoparticles prepared by either
method accumulated inmitochondria, however, in animals the IR780-phospho-
lipid micelles showed enhanced intra-tumoral accumulation in U87MG ectopic
tumors. Moreover, IR780-phospholipid micelles also showed preferred intra-
cranial tumor accumulation and potent NIRF signal intensity in glioma ortho-
topicmodels at a real-time, non-invasivemanner. Conclusion: The IR780-phos-
pholipid micelles demonstrated tumor-specifıc NIRF imaging capacity in
glioma preclinical mouse models, providing great potential for clinical imaging
and image-guided surgery of brain tumors.
#1868 Molecular imaging of human esophageal cancer for early detection.
Xibo Ma, Hui Meng, Jie Tian. Institute of Automation, Chinese Academy of
Sciences, Beijing, China.
Esophageal cancer was the sixth common cancer for incidence and ranks
fourth for death rate in China, and squamous cell carcinoma is the main histo-
logical type. It is usually in an advanced stage at the time of diagnosis, resulting
in an overall 5-year survival rate of 15%. Early detection can lead to an im-
provement in patient outcomes but is limited by nonspecifıc contrast mecha-
nisms. As all we know, antibody and peptides establish a biological basis for
image contrast, which could achieve suffıcient target-to-background ratio for in
vivo detection. In this paper, anEGFRantibody (Cetuximab) conjugatedwith an
NIR dye (NIRDye800) was used for early detection of esophageal cancer. We
demonstrated our technology could identify esophageal cancer in small size (1
mm) and high-grade dysplasia from low-grade dysplasia. And 4.2-fold greater
fluorescence intensity for esophageal cancer compared with surrounding nor-
mal esophageal tissues. No toxicity was observed in our experiments. The result
indicated that this targeted, antibody-based imaging agents have great potential
in early detection of esophageal cancer and other epidermal cancer.
#1869 Improved image-guided surgical resection of glioblastoma with
[18F]fluoroethyltyrosine Cerenkov luminescence imaging. David Y. Lewis,1
RichardMair,1 Alan J. Wright,1 Kieren Allinson,2 Scott K. Lyons,1 Tom Booth,1
Robert Bielik,1 Dmitry Soloviev,1 Kevin M. Brindle1. 1University of Cambridge,
Cambridge, United Kingdom; 2Addenbrooke’s Hospital, Cambridge, United
Kingdom.
The ability of a surgeon to completely resect a tumor is directly related to
outcome in high- and low-grade gliomas. However current intraoperative nav-
igational tools are useful only in a subset of glioma patients and do not detect the
full extent of disease. We modelled orthotopic brain tumors by stereotactically
implanting human U87, rat F98 and C6 glioblastoma cells into the forebrains of
rats. We show here that a new hybrid PET-Cerenkov luminescence imaging
approach usingO(2-[18F]fluoroethyl)-L-tyrosine (FET) can accurately delineate
tumor margins pre- and intraoperatively. We demonstrate consistency in the
successful localisation and quantifıcation of tumor burden using PET and
Cerenkov luminescence imaging. TheCerenkov signal in individual tumors was
directly proportional to the signal detected in corresponding FET PET scans
(y  1.06x - 0.01; R2  0.98; p  0.0001) and subsequent autoradiography
indicated equivalence between modalities. Cerenkov luminescence was better
able to discriminate tumor from healthy brain tissue than the current ‘gold
standard’ for intraoperative mapping, 5-ALA (5aminolevulinic acid), indicated
by a greater area under the ROC curve in human xenograft (0.968 	 0.003 vs.
0.893 	 0.019; p  0.003) and syngeneic rat glioma models (0.970 	 0.010 vs.
0.774	 0.046; p 0.006). The quantitative accuracy of Cerenkov luminescence
enabled us to determine a threshold of 2.1 x 102 p1 sec1 cm2 sr1 MBq1 that
separated U87 human glioblastoma and normal brain tissue, more precisely
guiding tumor excision than 5-ALA. At the optimal threshold the specifıcity for
detecting syngeneic rat and human xenograft gliomas was better with FET
Cerenkov than 5ALA (91.1	 2.7 % vs. 67.2	 5.2 %; p 0.007 and 91.2	 1.0 %
vs. 82.9 	 1.8 %; p  0.005 respectively). We confırmed and extended these
fındings at higher spatial resolution on cryosections using FET autoradiography
and 5ALA confocal microscopy, with FET demonstrating higher specifıcity and
sensitivity for tumor detection than 5-ALA. FET PET-Cerenkov luminescence
imaging has the potential for guiding resections in a much broader range of
glioma patients than current approaches. Previous clinical experience with FET
offers a facile route for clinical translation of this technology.
#1870 Fluorescence-guided soft tissue sarcoma surgery using a cetux-
imab-imaging probe conjugate.Nicole K. Behnke, JasonM.Warram, Andrew
C. Prince. The University of Alabama at Birmingham, Birmingham, AL.
BACKGROUND: Soft tissue sarcomas (STS) are a heterogeneous group of
solid malignancies whose treatment includes margin-negative resection. Large
tumor size and anatomic constraints make margin assessment challenging. Flu-
orescence-guided surgical resection can help delineate intraoperative margins;
preclinical studies demonstrate improved oncologic outcomes in other malig-
nancies using cancer-specifıc imaging probes. Recent literature describes ca-
thepsin activated probes selective for STS, but no studies using disease-specifıc
chemotherapeutic agents conjugated to imaging probes. This novel strategy has
potential to decrease unnecessary healthy tissue resection and improve onco-
logic outcomes by reducing margin-positive resections. Epidermal growth fac-
tor receptor (EGFR) is overexpressed in multiple subtypes of STS and is a po-
tential target for fluorescence-guided surgery. Recent studies show fluorescently
labeled cetuximab, an FDA-approved, anti-EGFR antibody, to be safe and useful
formargin assessment in othermalignancies. Our aimwas to evaluate its poten-
tial for STS, examining tumor-targeting specifıcity of two drug-probe conju-
gates, and comparing them to the described cathepsin-activated probes. We
hypothesize the drug-probe conjugates would successfully target STS, with su-
perior tumor specifıcity. We also aimed to determine the smallest tumor detect-
able by our conjugate. METHODS: Athymic nude mice with subcutaneous
HT1080 fıbrosarcoma tumors were injected with one of fıve probes:
IRDye800CW fluorescent probe conjugated to either cetuximab (anti-EGFR) or
DC101 (anti-VEGFR2), IRDye800CW conjugated to an isotype control (IgG),
or a cathepsin-activated probe (IntegriSense 750 and Prosense 750). Fluores-
cence imaging was performed daily with open- and closed-fıeld systems. Tu-
mor-to-background ratios (TBR), signal washout times and normalized signal
averages were evaluated. On day 9, smallest resectable game evaluation was
performed to assess sensitivity for detecting residual post-resection tumor
RESULTS: At day 9 post-injection, the TBR of the cetuximab-IRDye800CW
group (11.1) was signifıcantly greater than Integrisense750 (6.88, p0.005), the
IgG-IRDye800CW control (4.44, p0.00005), Prosense750 (2.35, p0.00009),
and DC101-IRDye800CW (1.87, p0.00003). During in vivo imaging, cetux-
imab-IRDye800CW outperformed all other agents by several folds of contrast
enhancement. The smallest resectable game evaluation demonstrated 1mm3
fragment detection using the cetuximab-IRDye800CW probe. CONCLUSIONS:
This study demonstrates superiority of cetuximab-IRDye800CW for disease-spe-
cifıc imaging in a subcutaneous animalmodel of STS.Thenovel strategyof coupling
improved margin-negative surgical resection with established chemotherapy has
considerable translational signifıcance and is an avenue for exploration with other
drugs used to treat STS.
#1872 Fluorescence-guided surgery in the tumor microenvironment in a
syngeneic mousemodel of EL-4 lymphoma.Kosuke Hasegawa,1 Atsushi Suet-
sugu,1 Miki Nakamura,1 Takuro Matsumoto,1 Takahiro Kunisada,1 Masahito
Shimizu,1 Shigetoyo Saji,1 Hisataka Moriwaki,1 Michael Bouvet,2 Robert M.
Hoffman2. 1Gifu Univ. Graduate School of Medicine, Gifu, Japan; 2University of
California, San Diego, CA.
We report fluorescence-guided surgery (FGS) of the tumor microenviron-
ment of the EL-4-RFP lymphoma cells growing subcutaneously inC57/BL6GFP
transgenic mice. Using a portable hand-held Dino-Lite digital imaging system,
subcutaneous tumors were resected by FGS. The tumor surface contained both
RFP cancer cells and GFP stromal cells. The tumor microenvironment was
clearly visualized and resected with the Dino-Lite. Host stromal cells, including
adipocyte-like cells and blood vesselswith lymphocytes, were observed along the
tumor by confocal microscopy in addition to cancer cells by color-coded confo-
cal imaging. Stromal cells were within the tumor and that cancer cells also in-
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vaded the TME. Color-coded FGS, which distinguished cancer and stroma, sig-
nifıcantly prevented local recurrence, which bright-light surgery or single-color
FGS could not.
#1873 Intraoperative assessment of breast tumor margins using multi-
modal photoacoustic tomography (MarginPAT).KyleMcElyea,1 George San-
dusky,1 Rui Li,2 Lu Lan,2 Ji-Xin Cheng,2 Linda K. Han,3 Pu Wang4. 1Indiana
University School of Medicine, Indianapolis, IN; 2Purdue University,West Lafay-
ette, IN; 3Indiana University Health Simon Cancer Center, Indianapolis, IN; 4Vi-
bronix Inc., West Lafayette, IN.
Radical mastectomies are progressively becoming a surgery of the past.
Women today are increasingly opting for lumpectomies, a less invasive treat-
ment option. Clinical data has shown no difference in survival or clinical out-
comes between the two surgical groups in early stages of breast cancer. There is,
however, an undesired outcome yet to be adequately addressed. Lumpectomies
have, in some cases, failed to remove marginal malignant tumor cells left as a
product from surgery. Following surgery, tumor biopsies are analyzed for mar-
ginal tumor cells. Biopsies are cut in, fıxed, processed in a tissue processor,
embedded into a paraffın block, and stained with H&E. After processing, pres-
ence of marginal cancerous tissue is determined by a pathologist. This process
takes 3-5 days, ultimately requiring the patient to undergo reoperation if a pos-
itive margin is discovered. Presently, the reoperation rate is 20-30%. A device
capable of imaging removed tissue to determine remaining marginal tumor
during surgery would greatly reduce the reoperation rate. Multiple intraopera-
tive imaging tools existing or are emerging for breast tumormargin assessment.
Current devices fail to meet acceptable clinical specifıcations due to either long
procedure time (15 mins), or low sensitivity (70%), and low specifıcity
(68%). An unmet need exists in developing an intraoperative margin assess-
ment device that is rapid, sensitive, capable of measuring the entire tissue sur-
face, and images a depth of 2mm. The MarginPAT device presents a multi-
modal photoacoustic/ultrasound imaging system for rapid and highly sensitive
breast cancer margin assessment. After surgical removal of tumor, tissue is in-
serted, via cartridge, into MarginPAT for imaging. An automatic scan (3
mins) provides 3D images of the excised tissue, providing margin status. Such
immediate feedback allows the surgeon to re-operate immediately or allow the
patient to return home based on the marginal results from MarginPAT. Our
preliminary study on 40 patient samples, showed 93% sensitivity and 90% spec-
ifıcity in margin assessment by precise localization of adipose tissue using PA
imaging and further RF spectrum analysis of ultrasound signaling. Other than
the superior sensitivity and specifıcity, the unique features of MarginPAT in-
clude deep tissue sensing (3mm) and high surface scanning speed (20 cm2/per
min). These achieved specifıcations meet the needs of intraoperative margin
assessment, which are expected to surpass similar platforms. More importantly,
MarginPAT supports conventional ultrasound imaging, allowing for use in ul-
trasound-guided wire localization. These multimodality functions allow Mar-
ginPAT to be utilized inmultiple fıelds of breast cancer diseases, another advan-
tage over other platforms. In conclusion, current clinical results show through
both verifıcation and validation that MarginPAT competently performs in the
operating room.
#1874 First demonstration that hypoxia targeting with radiation im-
proves tumor control in a mammal tumor model. Howard J. Halpern, Boris
Epe;, MatthewC.Maggio,Martyna Krzykawska-Serda, GageH. Redler, Richard
C. Miller, Eugene D. Barth, Ralph R.Weichselbaum.University of Chicago, Chi-
cago, IL.
For over a century, resistance of radiation to living tissues has been associated
with hypoxia, a local lack of molecular oxygen, or low pO2. The focus of this
research has been to validate the hypothesis that has been assumed, but not
proven over the past century, that radiation treatment focused specifıcally on
hypoxic regions of tumors would improve tumor curability. This research used
Electron Paramagnetic Resonance (EPR) imaging to provide absolute pO2 im-
ages in volume elements or voxels of murine tumors with 1 torr pO2 resolution
and 0.7 mm spatial resolution in FSa fıbrosarcomas in the legs of C3Hmice.We
defıne hypoxic regions of tumors as those whose image subvolumes or voxels
have low pO2, voxels less than 10 torr. We have established EPR pO2 imaging as
a reliable locator of relevant radiobiologically relevant hypoxia. To determine if
pO2 based dose painting improves tumor cure, we implemented the
XRAD225Cx system to deliver gantry based x-ray treatments to mouse tumors
accurately registered with EPR pO2 images. All tumors were pretreated with a
dose of radiation that had been determined in separate experiments to cure 30%
of tumors, a TCD30. Conclusive failure to demonstrate a difference between
treating crude spherical volumes including  85% of hypoxic voxels with an
additional curative dose comparedwith treatmentwith shells of radiation avoid-
ing hypoxia (anti-boosts) proved tenets of radiation biology: a few surviving
hypoxic clonogens cause radiation treatment failure. In response, we imple-
mented rapid 3D printing Tungsten loaded, highly conformal plastic blocks to
compare treating 100% of hypoxic tumor voxels with hypoxia avoidance,
treating similar volumes of well oxygenated tumor. Only then did we observe
signifıcant (p0.01) tumor control differences between hypoxic boosts and an-
ti-boosts. This is the fırst validation of the curative effectiveness of focusing
hypoxia based dose painting in mammalian tumors.
#1875 [18F]HX4 shows potential as a predictive biomarker for the radio-
sensitizing capacities of metformin in a NSCLC xenograft model. Sven De
Bruycker,1 Christel Vangestel,2 Tim Van den Wyngaert,1 Steven Deleye,1 Do-
minique Vanderghinste,2 Steven Staelens,1 Sigrid Stroobants1. 1University of
Antwerp, Wilrijk, Belgium; 2Antwerp University Hospital, Edegem, Belgium.
Introduction Metformin (MET) may improve tumor oxygenation and thus
radiotherapy (RT) response. However, appropriate imaging biomarkers for pa-
tient stratifıcation, critically needed to be able to advance to clinical trials with
MET as a radiosensitizer, are still lacking. In this proof-of-concept (POC) study,
we fırst assessed the effect of acute MET administration on NSCLC xenograft
tumor hypoxia with PET using the novel hypoxia PET tracer [18F]HX4. Second,
we verifıed the influence of a single dose of MET prior to RT on treatment
outcome. Experimental procedures A549 tumor-bearing mice (n9; animals
were inoculated in both hind legs) underwent a [18F]HX4 PET/CT scan to de-
termine baseline tumor hypoxia. The next day, mice were administered 100
mg/kg MET IV. [18F]HX4 was administered IV 30 min. later, whereupon a
second PET/CT scan was performed to assess changes in tumor hypoxia. Two
days after this second scan, mice were randomized into three groups (n3/
group): a control group (1), a RT group (2), and a METRT group (3) with
comparable tumor volumes (259	103; 218	81 and 247	121 mm3, resp.). An-
imals were administered 0.9% saline (groups 1-2) or 100 mg/kg MET (group 3)
IV, followed by a single dose of 10 Gy 30min. after administration (groups 2-3).
Control animals of group 1 underwent shamRT.During the entire study, tumor
growth was monitored triweekly by caliper measurements. Calculation of the
relative tumor volumes (RTV) was initiated when tumors reached a mean base-
line volume of 100mm3with the formula RTVVtime x/Vbaseline. Tumor growth
inhibition (TGI) was calculated for each tumor in both treatment groups with
the formula TGI1-(RTVtreated/RTVcontrol). Results MET signifıcantly altered
A549 tumor hypoxia, as the mean [18F]HX4 tumor-to-blood ratio (TBR) was
reduced from 3.03	0.27 to 2.82	0.25 (p0.040) after MET administration.
The tempering influence of MET on tumor hypoxia improved RT response, as
fıfteen days after irradiation TGI was 63	7% in the METRT group as com-
pared to only 36	9% in the RT group, however signifıcancewas not reached. To
date, tumors are still beingmeasured triweekly and this will be continued until a
volume of 1500 mm3 is reached. Then, animals will be sacrifıced for histological
validations on tumor tissue to assess differences in a.o. proliferation and hyp-
oxia. Conclusions Using non-invasive imaging, we showed in A549 xenograft
tumors thatMET acts as a radiosensitizer possibly by decreasing tumor hypoxia.
Our results imply that [18F]HX4 PET imaging holds potential as a predictive
biomarker for the benefıcial effect ofMET in the treatment of NSCLC; however,
the small group sizes in this POC study did not allow us to draw sound conclu-
sions. These promising fındings will be validated in a larger follow-up study in
order to validate [18F]HX4 PET as a predictive biomarker for MET and RT
response.
#1875A Preclinical proof of concept for the fırst Nanocyclix TKI-PET
radiotracer targeting activated EGFR positive lung tumors. Philippe Genne,1
Cyril Berthet,1 Olivier Raguin,1 Sylvie Chalon,2 Xavier Tizon,1 Sophie Serriere,2
Peggy Provent,1 Marc Hillairet de Boisferon,1 Johnny Vercouillie,3 Céline
Mothes,4 Fabienne Gourand,5 Louisa Barre,5 Denis Guilloteau,2 Pétra Blom,1
Jan Hoflack1. 1Oncodesign S.A., Dijon Cedex, France; 2INSERM, Tours, France;
3INSERM/CERRP, Tours, France; 4Cyclopharma, Saint-Beauzire, France; 5CEA,
LDM-TEP, Caen, France.
Background: IMAkinib® program is an innovative approach, based on
Nanocyclix® chemistry technology, which aims to develop new Tyrosine
Kinase Inhibitors (TKIs) radiotracers used for Positron Emission Tomogra-
phy (PET). The epidermal growth factor receptor (EGFR) is an established
target for the treatment of advanced non-small cell lung cancer (NSCLC).
Gefıtinib (Iressa®), erlotinib (Tarceva®) and afatinib (Giotrif®), TKIs target-
ing EGFR have already been approved for treatment of advanced non-small
cell lung cancer (NSCLC). Unfortunately, the majority of patients develop a
resistance to the TKI, which is for most of them ( 50%) related to an
acquired T790M mutation of EGFR. TKI PET-imaging can provide a tool to
determine and predict the activity of EGFR and the responsiveness to EGFR
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TKI. Methods: New compound ODS2004436 was characterized in vitro for
its activity and metabolism. After radiolabeling with [18F], the compound
was evaluated in vivo in three clinically relevant lung cancer cell lines (NCI-
H441 – EGFR_wild-type (WT); NCI-H3255 - EGFR_L858R; NCI-H1975 –
EGFR_L858R/T790M) xenografted in nude rats. Results: The biochemical
and cellular profıles were comparable to gefıtinib on EGFR_WT and acti-
vated EGFR_L858Rmutant. The cellular activity was in the nanomolar range
(5	 2 nM) on NCI-H3255 and weak on NCI-H441 (42	 27 M) suggesting
that our compound might inhibit to a lesser extent non activatedWT-EGFR.
We observed a better biochemical inhibition (254 nM vs 1350 nM) and
cellular activity on NCI-H1975, the EGFR double mutant (4.8 	 0.7 M vs
18	 8.7 M) of ODS2004436 compared to gefıtinib. These data suggest that
our compound is suitable to bind in vivo activated EGFR. In vitro binding
experiments showed that [18F]-ODS2004436 specifıcally bound to patient
tumor samples expressing EGFR. The in vivo experiments in rats showed
that [18F]-ODS2004436 was rapidly cleared from the blood. Nevertheless the
tumor uptake is stable overtime (up to 180 min) with a mean tumor/muscle
ratio 4 in NCI-H3255 and 2 in NCI-H1975 at 90 min instead no specifıc
binding was observed in the WT tumor, NCI-H441. Moreover, we observed
a good correlation between the radiotracer uptake in the tumors and pEGFR
immunostaining, suggesting that [18F]-ODS2004436 is a good biomarker of
activated EGFR, regardless of the mutation. Conclusions: Based on this
study, we proved in vivo that [18F]-ODS2004436 binds selectively to acti-
vated EGFR, and is a good candidate to evaluate the EGFR activity in NLCSC
using PET imaging. Clinical evaluation of this novel radiotracer is ongoing
(fırst in-man phase 0/I clinical trial NCT02847377).
TUMOR BIOLOGY: Migration and Invasion 2
#1876 Cell cycle-dependent front polarized cell migration requires Au-
rora kinase A. Tony Lok Heng Chu, Lixin Zhou, Jennifer Won, Pooja Mohan,
OksanaNemirovsky, Abbas Fotovati, TorstenNielsen, Nelly Pante, Christopher
Maxwell. University of British Columbia, Richmond, British Columbia, Canada.
PROBLEM: Metastasis accounts for 90% of deaths from carcinomas. BACK-
GROUND: To initiate migration, epithelial cells must front-rear polarize and
reorganize the microtubule cytoskeleton directed toward the lamillipodia or
leading edge. During mitosis, centrosomematuration, duplication, spindle pole
assembly and chromosome segregation require Aurora kinase A (AURKA),
which is optimally active when complexed with TPX2. Accumulating evidences
identify non-mitotic functions for AURKA, such as cell migration and ciliary
reorganization.Overexpression ofAURKA leads to tumorigenesis in breast can-
cer. Mechanisms that activate non-mitotic AURKA and promote cell migration
as well as metastasis are yet to be uncovered. RESULTS: In a large breast cancer
tissue microarray (n 3,175), the abundance of phosphorylated RHAMM (a
substrate of AURKA) predicted overall and relapse-free survival in ER-negative,
basal-subtype, and triple negative breast tumors. We studied the AURKA-
TPX2-RHAMM signaling axis in mammary (MCF10A and nMUMG-FUCCI)
and HeLa cells. In scratch wound assays, migratory cells were found to have
front-polarized centrosomes, which correlated with G2 cell cycle phase, phos-
phorylated AURKA and elevatedmicrotubule nucleation at centrosomes. Small
molecule inhibition of Aurora kinase activity impaired centrosome polarity and
retarded the kinetics of cell migration. In parallel, silencing RHAMM altered
TPX2 location as indicated by immunofluorescence and immuno-EM, which
located TPX2 to the nuclear envelope and nuclear pore basket. Nuclear import
of recombinant TPX2 was attenuated in RHAMM silenced cells and nuclear
envelope accumulation was elevated. CONCLUSION: The AURKA-TPX2-
RHAMMaxis regulates centrosome polarity, microtubule nucleation and direc-
tional cellmigrationwhile phosphorylatedRHAMMpredicts survival in aggres-
sive forms of breast cancer.
#1877 Coordination of Rac1 and Cdc42 by centrosomal microtubules in
focal adhesion dynamics and directed cell migration. Jean-Cheng Kuo. Na-
tional Yang-Ming University, Taipei, Taiwan.
Cancer metastasis causes the increase of mortality in most cancer patients,
and abnormal cell migration contributes to this disease progression. To control
cell migration, the dynamical control of a protein complex within focal adhe-
sions has to be regulated appropriately. It is known that focal adhesions can be
regulated dynamically by microtubules. To examine the effects of centrosomal
microtubules and non-centrosomal microtubules in regulating focal adhesion
dynamics and directed cell migration, we fırst generated centrosome-defıcient
cells. We fınd that centrosomal microtubules and non-centrosomal microtu-
bules control focal adhesion dynamics throughmodulating focal adhesion com-
position, which dynamically control the activity of small GTPases Rac1 and
Cdc42. Defıciency of centrosomal microtubules signifıcantly disrupts the bal-
ance of Rac1 and Cdc42, thereby inhibiting directed cell migration. This study
reveals the effects of centrosome in focal adhesions, and indicates an important
role for Rac1 and Cdc42 activation that controls actin polymerization, cell po-
larization and directed cell migration.
#1878 PDZ-RhoGEF functions as a critical signaling effector for TROY.
Zonghui Ding,1 Alison Roos,1 Jean Kloss,1 Harshil Dhruv,2 Marc Symons,3
Nhan L. Tran,1 Joseph C. Loftus1. 1Mayo Clinic Arizona, Scottsdale, AZ; 2Trans-
lational Genomics Research Institute, Phoenix, AZ; 3The Feinstein Institute for
Medical Research at Northwell Health, Manhasset, NY.
GlioblastomaMultiforme (GBM) is themost common tumor of theCNSwith
a median survival of approximately 15 months. The highly aggressive invasion
of malignant cells into the surrounding normal brain tissue renders complete
surgical resection impossible, increases therapeutic resistance, and virtually as-
sures tumor recurrence. We have previously demonstrated that TROY
(TNFRSF19) has an important role in GBM invasion and resistance. TROY
expression is correlated with glial tumor grade and inversely correlated with
patient survival. Increased TROY expression stimulated cell migration/invasion
in vitro and in vivo and confers resistance to both ionizing radiation- and temo-
zolomide-induced apoptosis via activation of Akt and NF-B. These data indi-
cate that TROY stimulatedmigration/invasion is associatedwith signaling path-
ways that also increase survival and therapeutic resistance, however, the
mechanistic basis of this signaling remains unclear. To investigate the mecha-
nism by which TROY induces GBM cell invasion, we performed immunopre-
cipitation of the TROY receptor coupled with MALDI-TOF andMS/MS analy-
sis and identifıed PDZ-RhoGEF as a binding partner for TROY. We validated
the interaction of TROYwith PDZ-RhoGEF by immunoprecipitation andwest-
ern blotting, and demonstrated that PDZ-RhoGEF can exchange for both RhoA
and RhoC in glioma cells and is implicated in GBM cell invasion, proliferation,
and survival. In order to assess the specifıc role of PDZ-RhoGEF in TROY
signaling, we examined the effects of PDZ-RhoGEF on TROY-mediated activa-
tion ofNF-B.While overexpression of TROY alone strongly stimulatedNF-B
transcriptional activity in serum-free conditions, increased expression of PDZ-
RhoGEF alone had no effect on NF-B activity. Co-transfection of PDZ-Rho-
GEF with TROY synergistically promoted NF-B activation. Mutation of the
TRAF binding domain (TBD) in the cytoplasmic domain of TROY abolished its
capacity to activate NF-B, even in the presence of PDZ-RhoGEF, suggesting
that the TBD is important for TROY induced NF-B activation. Furthermore,
knockdown of PDZ-RhoGEF by shRNA attenuated NF-B activation in TROY
expressing cells, blocked TROY mediated invasion of primary GBM xenograft
cells and increased sensitivity to temozolomide. Collectively, these data indicate
that PDZ-RhoGEF plays an important role in TROY signaling and provides
insights into a potential node of vulnerability to limit GBM cell invasion and
decrease therapeutic resistance.
#1879 Transcriptional regulation of KAI1 by p73 in colorectal cancerme-
tastasis. Woo Kyun Bae,1 Kyung Hyun Yoo,2 Keunsoo Kang,3 Lothar Hen-
nighausen,4 Ik-JooChung1. 1CNUHH, Jeonnam, Republic of Korea; 2Sookmyung
Women’s University, Seoul, Republic of Korea; 3Dankook University, Choenan,
Republic of Korea; 4NIH, Bethesda, MD.
Background: p73 is a member of the p53 family transcription factors and
known tumor suppressor. However, its transcriptional activity is complex
owing to its multiple isoforms, and limited information is available regard-
ing the transcriptional and functional regulation of the p73 gene in colorectal
cancer. In this study, we examined the role of p73 in colorectal cancer.
Methods: We established a TAp73 overexpressing cell line using the Tet-on
inducible expression system and analyzed global RNA expression by RNA-
sequencing (RNA-seq). We studied the effects of TAp73 expression on the
migration, invasiveness, and EMT of colon cancer cells. We conducted ex-
periments in animals with liver metastasis of colorectal cancer. To investi-
gate the roles of p73 in colon cancer, we examined the samples from patients,
who had undergone surgical resection for colorectal cancer between 2009
and 2013. mRNA expression of TAp73 and KAI1 was analyzed in 108 colo-
rectal cancer specimen and adjacent non-cancerous tissues by real-time RT-
PCR. Results: RNA-seq showed the association between TAp73 and KAI1
expression. Migration and invasiveness of colon cancer cells were reduced by
TAp73 expression, but induced by KAI1 knockdown. TAp73 regulates KAI1
expression in colon cancer cell lines. TAp73-induced decrease in invasive-
ness and epithelial-mesenchymal transition (EMT) was abrogated by KAI1
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knockdown in TAp73 overexpressing cells. Migration ability of TAp73 over-
expressing cells was recovered by KAI1 knockdown. Hepatic metastases
were signifıcantly reduced in mice injected with TAp73 overexpressing cells
and increased in those injected with TAp73 overexpressing cells with KAI1
knockdown. mRNA expression of TAp73 and KAI1 was higher in colorectal
cancer tissues than in adjacent non-cancerous tissues. Signifıcant correlation
between TAp73 and KAI1 mRNA expression was detected in early stage
primary colorectal cancer, but not in the advanced stage. Conclusions: This
study suggests that p73 (TAp73) acts as a tumor suppressor in the progres-
sion of colorectal cancer and regulates the expression of KAI1, which is a key
target of p73 in colorectal cancer liver metastases.
#1880 Bulk lung cancer cell migration is more common than single cell
migration and regulated by different genes.Helmut H. Popper, Sylvia Eiden-
hammer.Medical Univ. of Graz, Graz, Austria.
Introduction: There are two different forms how tumor cells migrate: single
cell or small cell cluster movement as it is seen in small cell carcinoma, and
movement by large clusters of organized cells as seen most often in adenocarci-
nomaor squamous cell carcinoma. This lattermigration form is not understood.
Drosophila border cells formingwingsmigrate in large cell complexes similar to
what is seen in the carcinomas and the genes identifıed in these cells might
regulate the same process in carcinomas. Methods: 30 cases of pulmonary squa-
mous cell and adenocarcinomas were selected based on the identifıcation of
large tumor cell clusters visible within the stroma as well as in blood vessels.
Immunohistochemistry was done for receptor of activated C kinase (Rack1),
brinker (brk), mother against dpp (mad), and saxophone (sax), proteins shown
to be responsible for bulk cellmovement in drosophila development. In addition
immunohistochemistry was also done for Src-kinase, Twist, Snail, and TGF1
Tyrosine kinase substrate 5 (Tks5), E-cadherin, SARI (suppressor of AP-1), and
vimentin, all known to be associated with epithelial-to-mesenchymal transition
(EMT) and formation of invadopodia. Results and Conclusion: Most well dif-
ferentiated pulmonary carcinomas migrate in large cell clusters, for example
acinar adenocarcinomas form nicely structured acini deep within the stroma
and even within blood vessels. These carcinomas do not undergo classical EMT.
Proteins expressed by the four genes (Rack1, brk, mad, and sax) associated with
border cell movement in drosophila could also be identifıed in pulmonary car-
cinomas and might coordinate bulk cell movement. Other members of TGF-
beta signaling cascade were identifıed. Inhibition of Src by Rack1may be impor-
tant for border cell migration and cluster cohesion maintenance. Proteins
usually seen in single tumor cell migration, such as vimentin (a sign of EMT)
could not be proven in the tumor cell clusters. Findings of this study show that
similar mechanisms are working in pulmonary carcinomas and that bulk cell
migration is probably another way ofmetastasis. Further investigation using cell
culture system and genetically designed adenocarcinomas expressing these
genes should prove our fındings and contribute in understanding migration of
carcinoma bulk complexes.
#1881 STIM1 andOrai1 control non-Hodgkin lymphoma cellsmigration.
Simon Latour,1 Isabelle Mahouche,1 Floriane Cherrier,2 Jean-Philippe Merlio,2
Sandrine Poglio,2 Laurence Bresson Bepoldin1. 1INSERMU1218 ACTION, Bor-
deaux, France; 2INSERM UMR 1053 BaRITOn, Bordeaux, France.
Non-Hodgkin lymphoma is one of themost common cancer in United States
representing 4% of all cancer. Diffuse large B cell lymphoma (DLBCL) is the
most common and aggressive non-Hodgkin B lymphoma. One of the charac-
teristic features of this disease is the dissemination of the cancer cells, through
the lymphatic system in the secondary lymphoid organs and extranodal sites,
leading to the death of patients. Chemokines such as the Stromal Derived Factor
1 (SDF1) control the spread and the homing of the cancer cells. It is known that
SDF1 activates various signalling pathways involved in cell proliferation, tran-
scription or migration. Moreover, SDF1 induces an increase in intracellular
calcium concentration whose role is still unknown in B cells. Store-operated
Ca2 entry (SOCE) is a major Ca2 influx pathway in this type of cells. By
defınition, SOCE is activated by Ca2 release from the endoplasmic reticulum.
Two genes are responsible for SOCE activity: Stromal interaction molecule 1
(STIM1), an ER Ca2 sensor that detects store depletion and ORAI1, the pore-
forming subunit of Ca2 release-activated Ca2 (CRAC) channel. Several stud-
ies performed on adherent cells showed that Orai1/STIM1 proteins are involved
in cancer cell migration. However, the molecular mechanisms involved in cell
migration differ widely between adherent and non-adherent cells. We studied
the role of both actors of calcium entry : Orai1 and STIM1 in DLBCL pathology
and more precisely in basal and SDF1-induced of DLBCL cell migration. Using
Tissue MicroArrays approach we revealed that both Orai1 and STIM1 are un-
der-expressed in DLBCL tumoral tissue compared to normal lymphoid tissue.
Next, using calcium imaging experiments we confırmed that SDF-1 triggered
Ca2 responses in two DLBCL cell lines (SUDHL4 and HLY1) involving intra-
cellular Ca2 store mobilization and extracellular Ca2 influx. Based on these
observations, we investigated the role of Orai1 and STIM1 on SDF1-induced
Ca2 influx using pharmacological and RNA interference approaches. The in-
hibition of Orai1 by BTP2 as well as the under-expression of Orai1 or STIM1 by
shRNA, prevented Ca2 influx induced by SDF1 suggesting the involvement of
Orai1 and STIM1 in this process. Regarding this results , we studied the role of
Orai1 and STIM1 on DLBCL cell migration in vitro and in vivo. Our results
show that basal or SDF1-induced cell migration was signifıcantly inhibited by
underexpression of STIM1 or Orai1 in SUDHL4 and HLY1 cell lines. These
results suggest that STIM1 and Orai1 play a key role in the DLBCL cell migra-
tion. The identifıcation of STIM1 and Orai1 proteins as key players in the mi-
gration of DLBCL cells might provide new therapeutic targets for the treatment
of this pathology.
#1882 Tankyrase-binding protein TNKS1BP1 regulates cancer cell inva-
sion. Tomokazu Ohishi,1 Haruka Yoshida,1 Masamichi Katori,2 Toshiro
Migita,1 Yukiko Muramatsu,1 Mao Miyake,1 Yuichi Ishikawa,2 Akio Saiura,3
Shun-ichiro Iemura,4 Tohru Natsume,4 Hiroyuki Seimiya1. 1JFCR Cancer Che-
motherapy Center, Tokyo, Japan; 2JFCR Cancer Institute, Tokyo, Japan; 3JFCR
Cancer Institute Hospital, Tokyo, Japan; 4National Institutes of Advanced Indus-
trial Science and Technology, Tokyo, Japan.
Tankyrase, a member of poly(ADP-ribose) polymerase (PARP) family, cata-
lyzes addition of long PAR chains onto the acceptor proteins, such as TRF1, a
telomere-binding protein, and Axin, a repressor of Wnt/-catenin signaling.
Tankyrase-mediated PARylation of TRF1 and Axin represses the biological
functions of these proteins, leading to enhanced telomere elongation by telom-
erase and upregulation of Wnt/-catenin signaling, respectively. Thus,
tankyrase is a multifunctional protein that supports oncogenic properties of
cancer cells. Given that tankyrase has a large protein-protein interaction plat-
form called ANK repeat clusters, and is broadly distributed to various intracel-
lular loci, including telomeres, nucleoplasm, nuclear pore complexes, cyto-
plasm, Golgi, and spindle poles, this protein seems to have a yet unidentifıed
function. In the present study, we explored the function of a novel tankyrase-
binding protein called TNKS1BP1 and elucidated its contribution to regulating
cancer cell invasion. Since TNKS1BP1 co-localizes with the actin fılaments, we
fırst examined the effect of genetic manipulation of TNKS1BP1 expression on
cell invasion. We found that TNKS1BP1 depletion by small interfering RNAs
increased the invasive capacity of human fıbrosarcoma cells, whereas its over-
expression decreased the cell invasion. In TNKS1BP1-depleted cells, actin fıla-
ment dynamics, focal adhesion and lamellipodia ruffling were increased with
activation of the ROCK-LIMK-cofılin pathway, which promotes cell motility.
Importantly, tankyrase overexpression reproduced the phenotype of
TNKS1BP1-depleted cells and enhanced cell invasion in a PARP activity-depen-
dent manner. Under approval by Institutional Review Board of Japanese Foun-
dation for Cancer Research, we performed immunohistochemical analysis of
clinical pancreatic cancer. We found that TNKS1BP1 protein expression is de-
creased in invasive regions of the tumors. Taken together, these observations
suggest that the tankyrase-TNKS1BP1 axis constitutes a post-translationalmod-
ulator of cell invasion and its aberration promotes cancer malignancy.
#1883 Fibrillar 1D tumormicroenvironment is the key driver associating
high-speed tumor cell motility with nuclear shape in breast cancer. Ved P.
Sharma,1 James Williams,2 Edison Leung,1 Joseph Sanders,2 Robert Eddy,1
JamesCastracane,2 JohnCondeelis1. 1Albert Einstein College ofMedicine, Bronx,
NY; 2SUNY Polytechnic Institute, Albany, NY.
Unlike normal breast stroma, which contains curly collagen fıbrils, aligned
collagen fıbers oriented perpendicular to blood vessels are seen in both human
breast tumors and mouse models of breast cancer. These linear collagen fıbers
provide “highways” for tumor cells to migrate toward blood vessels in a direc-
tional migration mode known as tumor cell streaming. Streaming is character-
ized by tumor cell migration at high speed and directional persistence on 1D
collagen fıbers. Previous studies utilizing linear ECMsubstrates have shown that
tumor cells adopt elongated morphology and display increased speeds on linear
1D substrates compared to their 2Dmotility. However, the relationship between
1D geometry of ECM fıbers in breast tumor microenvironment and the under-
lying mechanotransduction mechanism regulating high-speed migration of tu-
mor cells is not well understood. Here, we analyzed in vivo ECM architecture by
SHG intravital imaging and found a narrow peak of fıber diameters falling in the
range 2-3 m. These fıbers were composed of collagen I and fıbronectin. Based
on these fındings, we developed a high fıdelity in vitro nanofıber system to study
the molecular mechanisms underlying tumor cell streaming migration. Breast
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carcinoma cells plated on 2 m ECM-coated fıbers showed enhanced motility
matching in vivo velocities averaging 1.2m/min.We varied 1D fıber diameter
(0.7-20m) and found that tumor cellsmove the fastest with highest persistence
on smaller fıberswithin a narrow range of diameters from0.7-3m.High tumor
cell speeds correlated with enhanced alignments of F-actin and focal adhesions
along the fıber axial dimension. Unexpectedly, we also observed nuclear defor-
mation during carcinoma cell migration on narrow fıbers in vitro, similar to
nuclear deformation observed in vivo. This was a surprising fınding because
nuclear deformation in vivo was assumed to be caused by squeezing through
ECMpores. Thus, we hypothesized that actomyosin forces not only regulate cell
motility parameters, but also nuclear deformation independently of ECM pore
size. To test this hypothesis, we disrupted the transmission of cytoskeletal forces
to the nucleus by knocking down LINC complex proteins - SUN1 and SUN2,
and found increased nuclear elongation and cell motility parameters, through
the upregulation of actin polymerization. These results indicate that in carci-
noma cells, F-actin associated forces are shared between the leading edge (to
maintain cell speed) and the nucleus (to dynamically regulate nuclear shape).
LINC complex disruption releases F-actin forces acting on the nucleus to the cell
front, leading to higher tumor cell motility speeds. In summary, our results
provide new insights into the interplay between actomyosin contractility and the
LINC complex in the regulation of nuclear shape and high-speed tumor cell
motility during carcinoma cell metastasis.
#1884 The breast cancer gene CCDC170 regulates the Golgi-associated
microtubule network and directional cell migration. Pengtao Jiang, Yueran
Li, Andrey Poleshko, Valentina Medvedeva, Natalia Baulina, Yongchao Zhang,
Yan Zhou, Carolyn M. Slater, Trinity Pellegrin, Jason Wasserman, Michael
Lindy, Mary Daly, Richard A. Katz, Xiaowei Chen. Fox Chase Cancer Ctr., Phil-
adelphia, PA.
Background: Breast cancer (BCa) is a genetically heterogeneous disease and
many genes contributing to BCa risk remain to be identifıed. Genome-Wide
Association Studies (GWAS) and subsequent fıne-mapping studies (50) have
strongly implicated genetic alterations at the CCDC170/C6ORF97-ESR1 locus
(6q25.1) as being associated with the risk of BCa. ESR1, encoding the estrogen
receptor, might be a more obvious candidate for influencing risk. Surprisingly,
our analysis using genome-wide differential allele-specifıc expression (DASE),
an indicator for BCa susceptibility, suggested that the genetic alterations of
CCDC170, but not ESR1, accounts for GWAS-associated BCa risk at this locus.
CCDC170 is a coiled-coiled domain-containing protein of poorly understood
function. BCa-specifıc truncation and missense mutations in CCDC170 also
have been detected, with the truncations being implicated in driving Luminal B
subtype BCa. Together these fındings demonstrate that the CCDC170 gene is
involved in BCa, but the underlyingmolecularmechanisms for its role in tumor-
igenesis are unknown. Experimental designs and results: By using the ap-
proaches of confocal microscopy and cell imaging analysis, here we report for
the fırst time that CCDC170 is associated with the Golgi apparatus and perinu-
clear microtubules (MTs), and support a role for CCDC170 in the Golgi-asso-
ciated microtubule network. We have shown that overexpression of CCDC170
triggersGolgi reorganization and stabilizesGolgi-associatedMTs, accompanied
by dramatically increased acetylation of -tubulin that is driven by the acetyl-
transferase ATAT1. The Golgi-associated MT network has been proposed to
regulate cell polarity and migration. In support of this concept, we have shown
that CRISPR knockout increases, and overexpression of CCDC170 decreases,
BCa directional cell migration in vitro. We also found that the BCa-specifıc
truncations result inmislocalization of CCDC170 and/or diminished stability of
Golgi-associated MTs. Lastly, we identifıed candidate CCDC170 functional
binding partners (e.g. MAP4) that are consistent with its localization and pro-
posed function. These partners may serve to mediate the acetylation and stabi-
lization of MTs. Conclusions: Taken together, our fındings demonstrate that
CCDC170 plays an essential role in Golgi-associated MT organization and sta-
bilization, and provide a mechanism for how perturbations in CCDC170 could
alter Golgi-mediated cell polarity, and thereby drive BCa and other abnormali-
ties. This work was partially supported by the Susan G. Komen for the Cure
(KG100274), NCI (CA186853), and Eileen Stein Jacoby Fund.
#1885 VEGFA/NRP1 signal contributes to fılopodia formation in breast
cancer cells. Marina Kiso, Sunao Tanaka, Masakazu Toi, Fumiaki Sato. Kyoto
Univ. Graduate School of Medicine, Kyoto, Japan.
Background and objective: Bevacizumab is an antibody of VEGF and sup-
presses tumor angiogenesis. Bevacizumab has exhibited some therapeutic effı-
cacy for metastatic breast cancer in combination with chemotherapy, but its
impact on overall survival has not been proved. VEGF is a multi-function mol-
ecule targeting cell members in tumor microenvironment. We aimed to reveal
VEGF-related molecular mechanisms on breast cancer cells itself. Methods and
Results: VEGF-expressing breast cancer cell line, MDA-MB-231 cells (231 cells)
were used. VEGFA of 231 cell was knocked out using Crisper-Cas9 system
(VEGFA-KO). VEGFA-KO 231 cells showed small and rounded morphology.
Migration assay demonstrated the impaired cell migration of VEGFA-KO 231
cells. Bevacizumab treatment did not induce this morphologic change and im-
paired migration. Exogenous VEGF addition to VEGF-KO 231 cells recovered
WT 231 cell like morphology and induced cell migration. Next, we generated
soluble neuropilin-1 (sNRP1) overexpressed 231 cells. sNRP1 traps VEGFA to
function as an antagonist. sNRP1-231 cells exhibited small and rounded mor-
phology and impaired cell migration similar to that of VEGFA-KO 231 cells.
Knock down of NRP1 by using siRNA in 231 cells also caused impaired cell
migration. We evaluated the cell morphology using scanning electron micro-
scope. It revealed diminished fılopodia formation in VEGF-KO 231 cells com-
pared to WT-231 cells. Exogenous rhVEGF addition to VEGF-KO 231 cells
recovered fılopodia formation. Filopodia is a fıngerlike protrusion that comes
out from the cell periphery by an actin polymerization. Filopodia is required for
cell development and functions such as cell migration. Our results indicate,
because of the absence of VEGF/NRP1 signaling, fılopodia formation is abro-
gated. As a result of diminished fılopodia formation, VEGFA-KO 231 cells
showed small and rounded shape and reduced migration. Bevacizumab and
NRP1 bind VEGFA at amino acid motifs from exon 3-4 and exon 7 of VEGFA,
respectively. Thus, our fındings suggested that VEGFA could play a role in
fılopodia formation via NRP1 for 231 cells, and that bevacizumab could not
block the VEGFA/NRP1 signal. Discussion NRP1 is a receptor of VEGF, Sema-
phorine and other growth factors, and expressed in variety of cancer cells. In-
tracellular portion ofNRP1 lacks kinase domain. Previous study showed that the
VEGF stimulated to form a complex between NRP1 and GIPC1/Syx/RhoA, and
promoted tumor cell proliferation independently from VEGFRs (Yoshida et al,
2015). However, the precise mechanisms regarding NRP1 signaling remain un-
known. In conclusion, inhibition of VEGFA/NRP1 signaling caused rounded
morphology with diminished fılopodia formation, which impaired cell migra-
tion of 231 cells. These fındings would provide profound insights regarding
molecular mechanisms in resistance to bevacizumab treatment.
#1886 mGluR1 drives invasion of proneural subtype of glioblastoma cells.
AlenaGladwin, Sen Peng, Jeff Kiefer, SeugchanKim,Michael Berens, Harshil D.
Dhruv. TGen (The Translational Genomics Research Institute), Phoenix, AZ.
Amajor cause for the therapeutic failure and subsequent morbidity andmor-
tality of glioblastoma (GBM) is the aggressive invasion of malignant cells into
the surrounding normal brain that effectively renders complete surgical resec-
tion impossible and virtually assures recurrent tumor growth. Multi-omic pro-
fıling of GBM led to their molecular sub-classifıcation into two distinct molec-
ular subtypes: proneural (PN) and mesenchymal (MES). However, very little is
known about shared or distinct invasion processes of cells in these genomically
different subtypes. UsingMicroarray gene expression profıles of microdissected
paired stationary core and invasive rim samples from 19 patients, we demon-
strated that invasive gene signature of MES subtypes differs from PN. Specifı-
cally, using three orthogonal but intersecting bioinformatic approaches, i.e. gene
set variation analysis, causal network analysis, and iRegulon analysis; we discov-
ered that genes differentially expressed between PN core and rim could, to a
meaningful degree, be accounted for based on their annotation as “regulated by
the transcription factor REST”. REST functions as a repressor of gene expres-
sion. Of the genes repressed by REST, mGluR1 (Metabotropic Glutamate Re-
ceptor 1) was signifıcantly overexpressed at the rim of PN glioma cells as com-
pared to the core. Finally, we also investigated the role of mGluR1 in glutamate
induced glioma cell migration; our results show that glutamate stimulates mi-
gration of proneural-like glioma cells (A172) as compare to non-proneural-like
glioma cell (T98G). mGluR1 activation by glutamate has shown to induce acti-
vation of Pyk2 and Src in astrocytes; knockout of mGluR1 is not embryonic
lethal. In summary, our data demonstrate that glutamate-induced glioma cell
migration of PN subtype of GBM is dependent on mGluR1 and thus raises the
prospect that therapeutic targeting of mGluR1 may be a novel approach to
controlling the invasion of this deadly disease.
#1887 Untethering heterochromatin: how loss of HP1a enhances cell in-
vasion by altering nuclear envelope integrity. Tracy K. Hale, Sarah Bond, Da-
vid Wheeler.Massey University, Palmerston North, New Zealand.
Malignant cell invasion is accompanied by complex changes in nuclear shape
and organisation. The onset of invasion correlates with the loss ofHP1a inmany
solid tumours including those of the thyroid, kidney, colon and breast, while in
cancer cell linesHP1a suppresses invasive potential. In normal cells HP1amain-
tains the condensation of transcriptionally silent heterochromatin and seques-
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ters it at the inner periphery of the nuclear envelope; an event critical for the
maintenance of nuclear stability and envelope rigidity. This role for HP1a leads
us to hypothesise that the un-tethering of heterochromatin from the nuclear
periphery that would occur after loss of HP1 causes a remodelling of nuclear
envelope that enhances cellular invasion. If true this would explain how the
nucleus, the largest and most rigid cellular organelles, becomes malleable
enough to squeeze through interstitial spaces in the surrounding tissue during
metastatic invasion. In support of this hypothesis we observed a 44% increase in
the invasive potential of the poorly invasive MCF7 breast cells when HP1a is
knocked down. Lamin A staining and electron microscopy also confırmed that
these HP1a knockdown cells had the expected alterations in nuclear morphol-
ogy and loss of heterochromatin at the nuclear periphery. Furthermore the loss
of HP1 was correlated with a decrease in the mechanical stability of the nuclei.
The signifıcant enrichment (p-val 6.7x108) of nuclear envelope proteins shown
by RNAseq analysis of transcripts that are differentially expressed in the MCF7
versus HP1a knock-down cells, suggests this loss of nuclear envelope integrity is
associated with alterations to its composition. The most striking change identi-
fıed in the nuclear envelope of cells lacking HP1a was the loss of two Nesprin1
isoforms. While reintroduction of HP1a in highly invasive MDA-MB-231 cells
shows the return of these isoforms to the nuclear envelope. As the Nesprin1
isoforms act as signalling scaffolds connecting to the cytoskeleton or reaching
into the nucleus, they represent a means of modulating nuclear malleability.
Together these fındings suggest that when loss of HP1a increases invasive po-
tential there is a corresponding disruption to the nuclear periphery that is a
weakness of these cells that could be exploited.
#1888 3D matrix confınement triggers vascular mimicry through a con-
servedmigratory and transcriptional response.DanielOrtiz, BrianTsui, Tyler
Goshia, Colleen Ricker, Hannah Carter, Stephanie I. Fraley. University of Cali-
fornia, San Diego, La Jolla, CA.
An initial step in solid tumormetastasis involves the migration of tumor cells
through extracellular matrix. Several cancer cell migration strategies exist in
vivo, and the local properties of collagen fıbers are implicated in modulating
migration behaviors. Yet, individual tumor cells also display heterogeneity in
their intrinsic ability to migrate and metastasize. It remains unclear to what
extent intrinsic and extrinsic heterogeneity contribute to the emergence of dis-
tinct migration phenotypes and whether certain migration phenotypes contrib-
ute more to metastasis than others. To study this, we generated 3D collagen
matrices of varying densities andmonitored single cancer cellmigration in these
matrices with time-lapse microscopy.We observed a collagen density threshold
at 2.5mg/ml, above which 86% of MDA-MB-231 breast cancer cells transition
from single mesenchymal migration to collective cell migration, with a 50%
increase in persistence after cell division. After seven days, these collectively
migrating cells created networks coated with basement membrane molecules
resembling a clinical phenotype known as vascular mimicry (VM).The remain-
ing 14% of cells migrated randomly and eventually formed spheroids. HT-1080
fıbrosarcoma cells also responded similarly, migrating persistently and forming
cellular networks.Nextwe sought to identify the physical feature of high-density
collagendrivingVM.Neither hypoxia ormatrix stiffnesswas suffıcient to induce
VM.However, PEG-inducedmatrix confınement triggeredVMnetwork forma-
tion. RNA sequencing revealed collectively migrating cells up-regulated a con-
served transcriptional program signifıcantly enriched for annotations of vascu-
lar development and motility regulation processes. This gene module predicted
survival in human tumor transcriptome datasets. Our results suggest that the
VM phenotype arises in a subpopulation of cells from a conserved transcrip-
tional and migratory response to confınement in 3D collagen.
#1889 Formation and merger of H69 and H69AR small cell lung cancer
(SCLC) tumor cell clusters (TCCs) in vitro. Nico O. Ruprecht,1 Martin Hun-
gerbuehler,1 Philipp Kellmann,2 Nathalie Harder,3 Günter Schmidt,3 Carlos
Wotzkow,2 Beat Haenni,2 Fabian Blank,2 Hendrik Von Tengg-Kobligk,1
Christof Granzow4. 1Inselspital, University Hospital Bern, Bern, Switzerland;
2University Bern, Bern, Switzerland; 3Defıniens AG, Munich, Germany; 4FLA-
COD GmbH, Heidelberg, Germany.
A novel manifestation of tumor cell invasiveness, termed mutual cellular perva-
sion (MCP),was observed in vitro. It involvedTCCs formedby SCLCcells. Suspen-
sionculturesofH69andH69ARcellsweregrown in flavin-freeRPMI1640medium
with 10% fetal bovine serum as the only source of flavins. Experiments and subcul-
tivations were performed under light with wavelengths above 520 nm. TCC mor-
phology was studied by confocal microscopy and transmission and scanning elec-
tronmicroscopy. Interactions of TCCswere followed by videomicroscopy in phase
contrast and fluorescence modes. Data were analyzed using the Defıniens software
suite. The interaction of H69AR TCCs with confluent monolayers of human um-
bilical vascular endothelial cells (HUVEC) was visualized. Freshly subcultivated,
singularized tumor cells rapidly formed aggregates. After two days, solid TCCs pre-
vailed whose surface cells were connected by desmosome-like junctions. Apoptosis
but not necrosis became obvious in central parts of clusters with diameters above
100 to 150 m. TCCs enlarged through both cell proliferation and serial cluster
mergers. In the course of TCCmerger, four stageswere distinguishable: (1) directed
cluster movement leading to contact of clusters, (2) formation of a near circular,
symmetric structure termed contact disc. It consists of planar surface areas towhich
bothTCCs involvedcontributeequally. (3)MergerofTCCstookplace in thecontact
disc, and was accompanied by active movement of adjacent cells. (4) Starting from
the merger zone, major surface areas of newly formed clusters were mutually per-
vaded by cells from both participating cell clusters. After numerous merger events,
only low numbers of TCCs reaching sizes of up to 2 to 3 mm were present at sub-
cultivation. No spontaneous bursting, shrinkage, degeneration, or decay of TCCs
has been observed. However, when TCCs of H69AR cells were confronted with
confluent layers of HUVEC, drastic changes occurred in both formations. First,
intense oscillatory cellular movements were triggered on TCC surfaces, preceding
the release of cell aggregateswhichmoved away fromTCCs to theHUVEC layer.At
the same time, HUVEC were disconnected from each other and started moving
either randomly or in an oscillatory fashion. Individual tumor cells attached to the
much larger HUVEC and spread on their surface, resulting in full covering which
secluded HUVEC from the medium. To our knowledge, neither formation nor
merger ofmalignantTCCs invitrohavebeendescribed so far.TCCmerger involves
mutual cellular penetration of the involvedTCC surfaces, i. e.MCP.Contrary to the
invasionof tumorcells intonon-tumor tissue,pervasiondoesnot lead todestruction
but results inTCCgrowth.However,key featuresof tumorcell invasion invivo, such
as chemotaxis, spreading and TCC formation as well as disruption of endothelial
layers, manifest under conditions in vitro, thus facilitating related experimental
studies.
#1890 PLEK2 contributes to lung cancer progression through upregula-
tion ofNDRG1 expression.Yi-PinHsieh, Hui-Chia Liu, Hao-YuHuang,Wan-
Jiun Tang, Tai-Lin Lee, Meng-Feng Tsai. Da-Yeh University, Changhua, Tai-
wan.
PLEK2 is one of the pleckstrin homology domain (PH domain) proteins.
Recently studies suggested that PLEK2 may play a critical role in T lymphocyte
migration through by PI3K/AKT dependent and independent pathways. How-
ever, the biological functions of PLEK2 in lung cancer is not clear. We detected
the expression of PLEK2 in various lung adenocarcinoma cell lines using quan-
titative RT-PCR methods. The results indicated that PLEK2 expression signifı-
cantly positive correctionwith cancer cellmigration and invasion ability. Forced
expression of PLEK2 in lung cancer cells exhibited markedly promoting in the
proliferation rate, anchorage independent growth, cell motility and invasion,
whereas knockdown of PLEK2 was found to suppress lung cancer cell progres-
sion. In addition, we also reported that PLEK2 expression induce lung cancer
cell epithelial-mesenchymal transition (EMT) phenomenon, and involve in che-
motherapeutic drug resistance through upregulation NDRG1 gene expression.
Overexpression of NDRG1 in PLEK2-knockdown cell line restored cancer cell
proliferation, migration, and invasion. These results will provide information
and help us to understand the roles of NDRG1 in lung cancer cells.
#1891 Annexin A2-binding S100 proteins promote proliferation and cell
cycle progression of EGFR positive cancer cells.Naoko Ogama, Ryuuichi Na-
gashima, Nobuyuki Tanaka.Miyagi Cancer Ctr. Research Inst., Natori, Japan.
(a) Aim: The purpose of this study is to clarify an unknown function of An-
nexin A2-binding S100A proteins in tumor growth, cell cycle progression and
invasion.AnnexinA2 is amembrane boundprotein originally identifıed as v-Src
substrate, and often found to be overexpressed in many types of cancers. As a
multicompartmental protein that orchestrates a spectrum of dynamic mem-
brane-related events, it is associated with actin cytoskeleton control, vesicle for-
mation and intercellular interaction. (b) Methods and Results: During our pro-
teomics analysis using solid tumor cell lines, we identifıed both Annexin A2 and
S100A proteins in cancer stem cell-rich population. We next examined S100A
proteins expression in several Head and Neck cancer PDX samples. Immuno-
histochemical data from in vivo specimens as well as western blots showed that
S100A expression abundance was well associated with poor prognosis. Annexin
A2 has been indicated to be involved in malignant phenotypes such as invasion
andmetastasis, and Annexin A2 and S100A form (S100-Annexin A2)x2 dimers,
we next examined roles of S100A proteins in cancer, by using shRNA-mediated
depletion experiments. (c) New Findings: Depletion of S100A from PDX-de-
rived cancer cells resulted in loss of both in vivo tumor formation and invasion.
Furthermore, cell cycle progression was inhibited by the depletion, suggesting
its potential role in proliferation controls. Similar to the mutant Ras-driven
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tumors, EGFR-overexpression increased S100A gene expresssion. (d) Conclu-
sion: These results strongly suggest that increases in S100A plays signifıcant
roles in cancer cell proliferation and invasion.
#1892 Smallmolecule NSC59984 prevents cancer cellmigration and inva-
sion. Shengliang Zhang, Jessica Wagner, Lanlan Zhou, Wafık S. El-Deiry. Fox
Chase Cancer Center, Philadelphia, PA.
Tumor metastasis is one of the main mechanisms leading to mortality of
cancer patients. Searching for new therapeutic strategies to prevent tumor me-
tastasis is one of the anti-tumor approaches in cancer therapy. Cell migration
and invasion are crucial initial steps in the complex process and progression of
tumormetastasis.Mutant p53 has been known as an important factor associated
to cancer cell migration. Therefore, targeting mutant p53 is a potential strategy
to avoid tumor metastatic spread. We previously reported an anti-tumor small
molecule, NSC59984 which degrades mutant p53 and restores p53 pathway via
activation of p73. Here we demonstrate that NSC59984 inhibits cancer cell mi-
gration and invasion. Treatment with NSC59984 partially attenuates cell migra-
tion in various cancer cells based on the scratch assay and Boyden chamber
assay. The effect of NSC59984 on cell migration is partially blocked by knock-
down of p73, a member of the p53 family, suggesting that restoration of p53
pathway signaling via p73 is required for NSC59984-inhibition of cell migration
in cancer cells. We found that NSC59984 induces ERK2-dependent p53 resto-
ration and mutant p53 degradation. To examine the role of ERK2 in the cell
migration, ERK2 signaling is blocked by U0126 treatment in cancer cells. The
effect of NSC59984 on cancer cell migration is partially inhibited by U0126
treatment, suggesting that NSC59984 inhibits cancer cell migration partially
dependent on ERK1/2 pathway signaling in cancer cells. In addition, the gelatin
degradation assay shows that NSC59984 inhibits cancer cell invasion. Consis-
tent to the in vitro assays, NSC59984 decreases tumor invasion of xenograft
tumors as compared to the xenograft tumors treatedwithDMSOas control. Our
results, taken together, suggest that NSC59984 not only suppresses tumor
growth, but also inhibits cancer cell migration and invasion. Our fındings pro-
vide the potential administration of p53-restoring compoundNSC59984 in can-
cer therapy by blocking tumor metastasis.
#1893 Alpha-tubulin acetyltransferase, MEC-17, regulates cancer cell
morphology andmigration through epithelial-mesenchymal transition sup-
pression and cell polarity disruption. Cheng-Che Lee,1 Chi-Yen Chang,2 Chi-
Min Lin,2 Jang-Yang Chang1. 1National Cheng Kung University, Tainan, Tai-
wan; 2National Health Research Institutes, Tainan, Taiwan.
Acetylation of -tubulin has characterized as a key process for microtubule
stabilization, and it can regulate cell spreading and modulate the dynamics of
focal adhesion.MEC-17, a newly identifıed alpha-tubulin-N-acetyltransferase 1,
serves as themajor-tubulin acetyltransferase to promote-tubulin acetylation
in vitro and in vivo. However, the physiological function of MEC-17 in cancer
cells and its effect on MT acetylation during cell morphogenesis and migration
has remained elusive. In the present study, our results showed that overexpres-
sion ofMEC-17 induced increment of cell focal adhesion area, suppressed pseu-
dopods formation in three-dimension collagen-embedded cultured environ-
ment and inhibited cancer cell migratory and invasive abilities. These changes
were further proved to be caused by epithelial-mensenchymal transition (EMT)
repression, cell polarity disruption caused by alteration of Golgi orientation and
cdc42 activity and the decrease in the phosphorylation of extracellular signal
regulatedkinase1/2 (Erk1/2). On the contrary, silencing of endogenousMEC-17
by specifıc shRNA accelerated the pseudopods formation and EMT process,
which lead to facilitating the cell migration. Taken together, these results dem-
onstrated that the important role of MEC-17 in the modulation of intrinsic
cellular morphogenesis and migratory and invasive functions through regula-
tion of EMT and polarization. (The studywas supported by the following grants:
MOST 103-2320-B-006-036-MY3 and MOST 105-2325-B-400-001 from the
Ministry of Science and Technology of Taiwan, ROC).
#1894 Gremlin-1 is an important regulator of invasiveness in malignant
mesothelioma.Miao Yin,1 Mira Tissari,1 Emmi I. Joensuu,1 Jenni Tamminen,1
Irene Ylivinkka,1 Mikko Rönty,2 Kaisa Lehti,1 Marko Hyytiäinen,1 Marjukka
Myllärniemi,3 Katri Koli1. 1University of Helsinki, Helsinki, Finland; 2HUSLAB,
Helsinki, Finland; 3Helsinki University Hospital, Helsinki, Finland.
The purpose of this study was to clarify the role of BMP inhibitor gremlin 1 in
invasion and migration in mesothelioma. Primary mesothelioma cells isolated
frompatient pleural fluid aswell asmesothelioma cell lines were used for in vitro
studies. Cells were transfectedwith siRNAs or transducedwith lentiviral expres-
sion vectors. Invasive growthwas analyzed in 3DMatrigel or collagen Imatrices.
mRNA expressions were analyzed using a commercial PCR array and quantita-
tive RT-PCR. Migration assays were performed using scratch wound assay or
transwell migration assay with fıbronectin or collagen coating. TGF- and BMP
signaling activity was measured with luciferase reporter assays. For in vivo
mouse xenograft experiment cells were additionally transduced to express a
luciferase marker. Subcutaneous cell injection with Matrigel matrix was per-
formed in the flank of nude mice. Malignant mesothelioma is an aggressive
cancer that develops from mesothelial cells, most often in the pleural lining of
the lung.We have previously shown that the BMP inhibitor protein gremlin 1 is
highly expressed inmesothelioma and induces amesenchymal and chemoresis-
tant phenotype in mesothelioma cells. Since mesothelioma tumors are locally
very invasive and has poor prognosis, we analyzed the role of gremlin 1 in
mesothelioma cell migration and invasive growth.We found thatmesothelioma
cells expressing gremlin 1 showed invasive sprouting when tumor cell spheroids
were imbedded into 3D collagen matrix. Silencing of gremlin 1 expression sig-
nifıcantly reduced invasive growth. In addition, cells overexpressing gremlin 1
gained more invasive phenotype. This was associated with increased mRNA
expression levels of Slug and matrix metalloproteinases (MMP) as well as re-
duced expression of E-cadherin. The cells were more migratory and exhibited
increased expression of certain integrins, especially the v subunit. Gremlin 1
induced invasive growth was dependent on MMP activity and associated with
increased TGF- activity. Intrapleural injection of mesothelioma cells overex-
pressing gremlin 1 isolated from a patient with epithelioid mesothelioma, pro-
duced tumors in 2/4 mice over 5 months after injection. Mice with cells trans-
duced with vector only did not develop tumors (0/4). When cells were injected
subcutaneously together with Matrigel gremlin 1 overexpressing tumors ap-
pearedmore slowly, but exhibited comparable luciferase signal 2.5 months after
injection. However, gremlin 1 tumors showedmore vascularization and in con-
trast to control tumors some also developed metastases (2/6 mice). As conclu-
sion, we identifıed gremlin 1 as an important regulator ofmesothelioma invasive
growth and chemoresistance. Blocking gremlin 1 function may overcome drug
resistance and reduce invasive behavior of mesothelioma.
#1895 A conserved E2F1-activated gene regulatory network encompass-
ing monocarboxylic acid transporter-1, its co-operating antisense lncRNA
SLC16A1-AS1 and their common downstream targetsmediates bladder can-
cer invasiveness. Berdien A. Jansen,1 Stella Logotheti,1 Dirk Heckl,2 Jan-Hen-
ning Klusmann,2 Dirk Kozcan,3 Laila Taher,4 Georg Fuellen,5 David Engel-
mann,1 Brigitte Pützer1. 1Institute of Experimental Gene Therapy and Cancer
Research, Rostock, Germany; 2Hannover Medical School, Hannover, Germany;
3Institute of Immunology, Rostock, Germany; 4University of Erlangen-Nürnberg,
Erlangen, Germany; 5Institute for Biostatistics and Informatics in Medicine and
Ageing Research, Rostock, Germany.
AIM: The therapeutic arsenal against muscle-invasive bladder cancer (BC) is
poor, leading to fatal outcomes and necessitating next-generation targeted ther-
apeutics. A causative event of BC progression is activation of the gene regulatory
networks (GRN) of the transcription factor E2F1. LncRNAs are emerging inte-
gral components of the E2F1-regulated GRNs, but their implication in BC pro-
gression is unknown. Our study focuses on lncRNAs that participate in E2F1-
activated GRNs underlying BC progression and the therapeutic exploitation
thereof. METHODS:We applied bioinformatics on BC patient cohorts to iden-
tify clinically relevant lncRNAs upregulated in invasive stages. Of those, the
E2F1-responsive lncRNAs were defıned by subjecting T24 clones inducibly
overexpressing E2F1 to HTA2.0 RNA arrays. Candidates in close proximity to
oncogenes/tumor-suppressors were further selected, based on an emerging
“guilt-by-association” rule of lncRNA biology. LncRNAs were qPCR-validated
and E2F1-transactivation was shown by ChIP and reporter assays. The
SLC16A1-AS1 lncRNAwas functionally characterized by CRISPR/Cas9 knock-
out in invasive BC cells, followed by migration/invasion/metabolic assays, tran-
scriptomics and mice in vivo experimentation. SLC16A1-AS1 homologues
across specieswere predicted by comparative genomics. RESULTS:Our pipeline
unveiled SLC16A1-AS1 lncRNA located nearby and antisense to SLC16A1 pro-
tein-coding gene. SLC16A1 synthesizes the membrane-bound Monocarboxylic
Acid Transporter-1 (MCT1), a key metabolic regulator that mediates lactate
uptake and glycolytic flux and favors BC invasiveness; while SLC16A1-AS1
function was unknown to date. SLC16A1 and SLC16A1-AS1 present a ‘head-to-
head’ gene arrangement, with a bidirectional E2F1-responsive promoter. This
‘operon-like’ gene cluster is conserved across mammals, implying functional
relevance of MCT1/E2F1/SLC16A1-AS1. In invasive BC cells, E2F1 transacti-
vates SLC16A1-AS1, which remains in the nucleus exerting gene regulatory
functions, as well as MCT1, which localizes in the cytoplasm to control lactate
flux. SLC16A1-AS1 induces EMT-independent invasiveness by regulating ex-
pression of downstream cell migration-related targets which are co-modulated
by MCT1. CONCLUSIONS: MCT1 and SLC16A1-AS1 constitute a composite,
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E2F1-responsive functional unit, co-operatively regulating common cell-migra-
tion related downstream targets. Their conserved gene arrangement, which en-
sures simultaneous transcription upon E2F1 upregulation, could facilitate co-
ordination between metabolism reprogramming and cell migration to establish
aggressive phenotypes. Combining SLC16A1-AS1 suppression with formulated
MCT1 inhibitors might provide a therapeutic basis against progressive BC.
#1896 Soluble lung-derived selectins promote breast cancer cell migra-
tion. Sami U. Khan,1 Jenny E. Chu,1 Ying Xia,2 Alison L. Allan1. 1Western Uni-
versity, London, Ontario, Canada; 2LondonHealth Sciences Centre, London, On-
tario, Canada.
Ninety percent of all breast cancer-related deaths are attributed tometastasis,
as current therapies are largely non-curative in themetastatic setting. One of the
most common sites of breast cancer metastasis is the lung. Previous work from
our lab has demonstrated that there are over 70 soluble factors produced by
murine lung tissue,many of which have been associatedwith cancer cell growth,
migration, invasion and metastasis. However, the relative contribution of each
individual factor in enhancing the metastatic behavior of breast cancer cells has
not been examined in detail. Three of the identifıed soluble lung-derived pro-
teins are E-, L- and P-selectin, and these were the focus of the current study. The
selectins are a family of glycoproteins with known physiological roles in vascu-
lar/immune cellmigration, and soluble selectins have been clinically observed to
be elevated in the sera of cancer patients. We hypothesized that soluble lung-
derived selectins enhance themetastatic behavior of breast cancer cells.We used
a 2Dex vivomodel of the soluble lungmicroenvironment, generated by isolating
conditioned media from dissociated healthy murine lung. E-, L- and P-selectin
were then individually immunodepleted from the lung-conditioned media
(lung-CM) and the subsequent functional effect on breast cancer cell migration
and proliferation was assessed using transwell migration and BrdU incorpora-
tion assays, respectively. MDA-MB-231 and SUM149PT human breast cancer
cells demonstrated signifıcantly enhanced cell migration toward lung-CM rela-
tive to basal media, and this migration was signifıcantly reduced when E-, L- or
P-selectin were depleted (p0.05). In contrast, although MDA-MB-231 and
SUM149PT human breast cancer cells demonstrated signifıcantly enhanced cell
proliferation in response to lung-CMrelative to basalmedia (p0.05), depletion
of soluble E-, L- or P-selectin from lung-CM had no influence on reducing
proliferation (p0.05). Ongoing studies are aimed at elucidating the pathways
through which soluble lung-derived selectins exert their pro-migratory func-
tion. If these results implicate a common receptor and downstream signalling
pathways for all three selectins, these ligand-receptor interactions may have
value as potential therapeutic targets for the prevention of pulmonarymetastasis
in breast cancer patients.
#1897 The role of nuclear deformation and rupture in breast cancer cell
migration. Alexandra L. McGregor, Joshua J. Elacqua, Emily S. Bell, Jan Lam-
merding. Cornell University, Ithaca, NY.
Invasion of tumor cells into the surrounding tissue is a critical step in the
metastatic cascade, which is responsible for the vast majority of cancer-related
deaths. Recent fındings have begun to demonstrate that the biophysical proper-
ties of the cell nucleus play a critical role in this process. During invasion, cancer
cells must often pass through interstitial spaces much smaller than the cell nu-
cleus. While the cell cytoplasm easily maneuvers through confıned spaces, the
deformability of the nucleus, which is the largest and stiffest organelle, ulti-
mately determines how effıciently a cell can pass through a tight space. Further-
more, as the nucleus deforms to move through a confıned space, it can exhibit
transient loss of nuclear envelope (NE) integrity, where the nuclear membranes
rupture and nuclear and cytoplasmic components interchange. We previously
showed that chromatin is exposed to the cell cytoplasm during NE rupture, and
cells can incurDNAdamage.While thiswork revealed that cancer cellmigration
requires nuclear deformation and can involve NE rupture, it is currently un-
knownwhether such events correlate withmetastatic potential.We used a panel
of human breast cancer cells lines, including claudin-low, basal-like, and lumen-
like cells. Cells were stably labeled with a green fluorescent protein fused to a
nuclear localization sequence (NLS-copGFP) to investigate whether some cell
lines were particularly well suited to migrate through tight spaces, and if any
were particularly prone to NE rupture. The cells were loaded into microfluidic
devices that were designed to mimic interstitial in vivo spacing and monitored
by time-lapsemicroscopy. Devices contained constrictions 5m tall and 1, 2, or
15 m wide. We found that claudin-low cell lines such as BT-549 migrated
through confıned spaces (12 m wide constrictions) signifıcantly faster and
more effıciently than basal-like HCC70 cancer cells. In contrast, the various cell
lines displayed similarmigration rates in the 15mwide constrictions, which do
not require nuclear deformation. Thus, the differences observed between the cell
lines reflect specifıc defects in migration through confıned spaces, and not gen-
eral migration defects. We are currently expanding our studies to a larger panel
of cancer cell lines and tomouse breast cancermodels. If confırmed, these results
could indicate that highly invasive cancer cells may benefıt from more deform-
able nuclei that facilitate movement through tight spaces encountered in the
tissue microenvironment.
#1898 MEG3 as a competing endogenous RNA binds with miR-27a to
promote PHLPP2 protein translation, and consequently impairs bladder
cancer invasion.ChaoHuang,1 Xin Liao,2 Jingxia Li,2 ChuanshuHuang2. 1New
York University School of Medicine and Wuhan Union Hospital, Tuxedo Park,
NY; 2New York University School of Medicine, Tuxedo Park, NY.
Muscle invasion and metastasis of bladder cancer dramatically decrease
survival rate, compared to 77% of 5 year survival rate of all bladder cancer,
metastasis bladder cancer is only 5%. This truth implies that one of the
therapeutic kernels of bladder cancer is to decrease, even block, its invasive-
ness. In the current study, we fınd thatMEG3 is signifıcantly downregulate in
human muscle-invasive bladder cancer tissues compared with non-muscle
invasive tissues. We also demonstrate the MEG3 strongly inhibits human
bladder cancer cell invasiveness by acting as a ceRNA. We fınd that MEG3
competes with PHLPP2 mRNA for miR-27a binding, which leads to a de-
creased miR-27a activity, and subsequently reducing the translation inhibi-
tion of miR-27a to PHLPP2. The upregulated PHLPP2 decreases the c-Jun
phosphorylation at Ser63/73, and in turn inhibits the c-Myc transcription
and its mediated invasiveness of the bladder cancer cells. This is the fırst
demonstration that MEG3 inhibits the invasiveness of human bladder can-
cer cells via negative regulation of c-Myc as a ceRNA. These fındings not only
provides a novel insight into understanding the mechanisms behind the
MEG3 inhibiting the cancer cell invasion, but also reveals a potential targets
for invasive bladder cancer prevention and therapy.
#1899 MKK4/JNK2 down-regulation inNSCLC suppresses tumor growth
and metastasis. Tamer Saad Kaoud,1 Nancy D. Ebelt,1 Lili Du,2 Sabrina Van
Ravenstein,3 Kenneth Y. Tsai,2 Kevin N. Dalby1. 1UT Austin College of Phar-
macy, Austin, TX; 2The University of Texas MD Anderson Cancer Center, Hous-
ton, TX; 3UT Austin, Austin, TX.
Mitogen-activated protein kinase kinase-4 (MKK4) has been reported to ei-
ther enhance or suppress oncogenesis. Evidences of its pro-oncogenic activities
in breast, pancreatic, lung and skin cancer have been reported. Although the
mechanism of its possible tumorigenic role is still unclear. Recent studies in
glioblastoma and lung carcinoma have suggested important roles for the consti-
tutive activation of its downstream substrate JNK2. JNKs require phosphoryla-
tion by both MKK4 andMKK7 to be fully activated. The JNK2 isoform shows a
unique propensity among the JNKs to autophosphorylate in vitro.Herewe show
that JNK2 autophosphorylation contributes to the proliferation and migration
of NSCLC cells under conditions of low serum through an MKK4-dependent
mechanism. This suggests a pro-oncogenic role of MKK4 in NSCLC through a
JNK2 autophosphorylation-dependent pathway. Evidence in several cell lines,
including mouse embryonic stem cells lacking MKK4 or MKK7 suggests that
autophosphorylation alone activates JNK2 weakly in cells. However, JNK2 au-
tophosphorylates on Thr-183, to create a pool of JNK2 primed for activation by
MKK4, which phosphorylates JNK2 on Tyr-185 to activate it. Under conditions
of low serum the down-regulation/overexpression of MKK4 or JNK2 but not
MKK7or JNK1 suppresses/promotes proliferation ofmultipleNSCLC cell lines,
through STAT3. Under the same conditions, A549 cell migration is inhibited
upon down regulation of either MKK4 or JNK2. Further supporting the notion
that active JNK2 results primarily from autophosphorylation of Thr-183, pan-
JNK ATP competitive inhibitors (JNK-IN-8 and SP600125) showed a dose-
dependent dephosphorylation of JNK2 in NSCLC cell lines and inhibited their
proliferation under conditions of low serum. Moreover, the downregulation of
MKK4 or inhibition of JNK2 autophosphorylation by SP600125 inhibited nu-
clear localization of JNK2 in A549 cells cultured in low serum. To further un-
derstand the pro-oncogenic role of MKK4 in the A549 cell line, we investigated
tumor growth and lung metastasis in A549 Xenografts in which either JNK2 or
MKK4 were stably knocked down. Either JNK2 or MKK4 down regulation
showed a similar suppression of tumor growth and lung metastasis if compared
to cells expressing an shRNA control. Sequencing of MKK4 in the A549 cells
revealed no genomic deletion or somatic mutations. Taken together, the data
suggest that MKK4may exhibit pro-oncogenic properties in NSCLC by activat-
ing Thr-183-autophosphorylated JNK2. Targeting this pathway may reduce or
block lung tumor progression and/or metastasis.
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#1900 Understanding the biological role of latexin in the normal andma-
lignant prostate. Robert I. Seed, Alberto J. Taurozzi, Giovanna Nappo, Holger
H. Erb, Anne Collins, Norman J. Maitland, Fiona Frame. University of York,
York, United Kingdom.
The retinoid-inducible protein Latexin (LXN) acts as a stem cell suppressor in
normal murine hematopoiesis, and in human tumors where it can influence
both tumor cell migration and invasion (Liang et al, Nature genetics 2007). We
have shown that LXN is silenced in the stem cell fraction of primary prostate
epithelial cells, and that expression increases as cells differentiate through the
prostate basal epithelial hierarchy towards mature luminal cells. Furthermore,
transient knockdown of LXN signifıcantly increased clonogenic potential and
promoted a more invasive phenotype in primary prostate epithelia (Oldridge et
al, Oncogenesis 2013). LXN may therefore be involved in the differentiation of
prostate epithelial cells, but could act as a tumor suppressor in Prostate Cancer
(CaP), in addition to other tumours. In genomedatabases LXN is described as an
inhibitor for Carboxypeptidase A4, but despite considerable molecular charac-
terisation, the mechanism of action has remained an enigma since perhaps par-
adoxically LXN appears to be able to function independently of its classical
CPA4 inhibitory role. To resolve this, we adopted an unbiased approach to
determine if targeted re-expression of LXNor its binding partners could provide
a viable novel drug target for the treatment of CaP. Our preliminary studies had
revealed that LXNwas an exclusively cytosolic protein in prostate epithelial cells.
However, subsequent live cell imaging of primary prostate epithelial cells over-
expressing YFP-LXN demonstrated for the fırst time that, whilst predominantly
cytosolic, LXN was also present within the cell nucleus. To characterise the
effects of LXN overexpression on gene transcription after LXN-expressing len-
tiviral transduction of primary prostate epithelial cells, we utilised Affymetrix
HTA2 gene arrays. Perhaps surprisingly, short-term overexpression of LXN did
not signifıcantly effect global gene transcription compared to controls (n4
PNS). Additionally, we used IP/MS to investigate the potential interacting
partners of LXN, using multiple approaches, including both overexpression of
HA-tagged andWTLXN, and endogenous LXNas bait. These approaches failed
to reveal any strong (and reproducible) intracellular protein interactors of LXN.
From these data, we hypothesised that LXNmay function as a secreted protein.
We found that LXN was present in not only the conditioned media of LXN
prostate epithelial cells, but also preliminary evidence that LXN is enriched in
extracellular exosomes. Therefore, LXN may perform its biological roles extra-
cellularly, or at the cell surface. Our current work is focusing on determining the
functional consequences of secreted LXN on prostate epithelia and to establish
potential protein: protein interactions of LXN in the extracellular space. Full
characterisation of LXN function considering its potent biological effects on
cancer cells will determine its suitability as a therapeutic in CaP and other can-
cers.
#1901 DNMT1 is involved in esophageal squamous cell carcinoma (ESCC)
and self-renewal ability of ESCC-cancer stem cells.Ying Teng, Xiying Yu, Hui
Yuan, Liping Guo, Wei Jiang, Shih-Hsin Lu. National Cancer Center/ Cancer
Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Col-
lege, Beijing, China.
DNAmethylation mediated by DNAmethyltransferase 1 (DNMT1) plays an
important role in carcinogenesis and self-renewal ability of cancer stem cells
(CSCs). However, the function of DNMT1 in esophageal squamous cell carci-
noma (ESCC) carcinogenesis, especially self-renewal ability of ESCC-CSCs re-
mains unclear. In this study, we found a high expression of DNMT1 in both side
population (SP) cells and sphere formation cells that represented as substitutes
for CSCs in KYSE150 and EC109 ESCC cell lines. In addition, the expression of
DNMT1was decreased during the differentiation from SP to None-SP (NSP) in
these ESCC cells. These results suggested that DNMT1 might have a role in
regulating self-renewal and/or differentiation of ESCC-CSCs. To further inves-
tigate DNMT1 in ESCC carcinogenesis and self-renewal ability of ESCC-CSCs,
we silenced the expression of DNMT1 in KYSE150 and EC109 ESCC cells using
lentivirus-mediated RNA interference (RNAi). Our results showed that ablation
of DNMT1 expression in KYSE150 and EC109 ESCC cells resulted in decreased
their CSCs by SP analysis and sphere formation assay. Meanwhile, ablation of
DNMT1 expression inhibited malignant phenotypes in KYSE150 and EC109
cells, including cell proliferation, colony formation, migration and drug resis-
tance abilities. Treatment of 5-aza-2=-deoxycytidine (5-aza-dC), aDNMT inhib-
itor that led to the degradation of DNMT1 protein by proteasome, revealed that
numbers of CSCs and the malignant phenotypes of KYSE150 and EC109 ESCC
cells were refrained signifıcantly, including a dramatic inhibition of self-renewal
ability of these ESCC-CSCs. Thus, our results indicated that DNMT1 was in-
volved in ESCC carcinogenesis, especially in the maintenance of ESCC-CSCs,
suggesting that DNMT1 could be a potential target for ESCC, especially ESCC-
CSCs, therapy.
#1902 Enrichment of putative cancer stem cells during anti-angiogenic
therapies promotes relapse formation in hepatocellular carcinoma. Darko
Castven,1 Carolin Czauderna,1 Diana Becker,1 Marcus A. Wörns,1 Snorri S.
Thorgeirsson,2 Peter Grimminger,1 Hauke Lang,1 Peter R. Galle,1 Jens U. Mar-
quardt1. 1University ofMainz,Mainz, Germany; 2CCR/NCI/NIH, Bethesda,MD.
Background and Aims: Activation of neo-angiogenic processes in hepatocel-
lular carcinoma (HCC) during disease progression is frequently associated with
poor clinical outcome. Consequently, inhibition of neo-angiogenesis is an effec-
tive treatment strategy for advanced HCC. However, development of chemore-
sistance is observed in themajority of patients. Compelling evidence suggest that
cancer stemcells (CSCs)may contribute to the acquisition of resistant properties
in many solid tumors, but their exact role in this process for HCC remains to be
defıned. Here, we evaluate the importance of CSCs in the development of resis-
tance and relapse formation after exposure to different anti-angiogenic thera-
pies in HCC and defıne the concomitant adaptive molecular changes. Methods:
Five HCC cell lines and one primary HCC isolate were exposed to sorafenib and
sunitinib for a total of 14 days. The treatment effects on CSCs were estimated by
sphere forming capacity in vitro as well as the side-population (SP) approach.
Expression levels of key oncogenic and CSC markers, such as EpCAM, CD133
and ABCG2 transporter, were assessed by qRT-PCR and flow cytometry. Fur-
thermore, whole transcriptome analyses were performed at different time
points. Results: Both treatment regimens effectively reduced oncogenic proper-
ties in all investigated HCC cells. However, sustained anti-proliferative effect
after treatments was observed in only one cell line. In three other hepatoma lines
an initial treatment effect was subsequently followed by rapid re-growth thereby
mimicking the responses observed in patients. Interestingly, two cell lines
showed differential response to applied drugs, showing anti-proliferative effects
to sorafenib, while relapse formation occurred after sunitinib treatments.While
anti-oncogenic effects in sensitive cell lines were associated with signifıcant re-
duction in sphere forming capacity, CSC marker EpCAM as well as SP cells,
resistant cell line showed a transient increased in CSC properties. Importantly,
acquired resistance to both drugs uniformly developed in the cell lines suggest-
ing that common molecular mechanisms might be operative. These adaptive
molecular changes involved signaling pathways known to be associated to cell
survival and proliferation (RAS, AKT, MYC), as well as angiogenesis (VEGFR,
PDGFR, HIF1a). Furthermore, the resistant cell lines showed compensatory
upregulation of key oncogenic molecules such as EGFR as well as multidrug
resistance ABC transporters. Conclusions: Our in vitro model recapitulates fea-
tures of drug resistance observed in human HCC patients. Resistance to anti-
angiogenic therapiesmight be fueled by transient expansion of CSCs. Therefore,
specifıc targeting of CSCs as well as pro-oncogenic compensatory signaling
pathways might be an effective therapeutic strategy to overcome resistance in
HCC.
#1903 Cancer stem cell vaccine signifıcantly reduces local tumor relapse
and prolongs survival in the adjuvant setting. Fei Liao,1 Yang yang Hu,1 Xin
Chen,1 Alfed E Chang,1 Robert E Hollingsworth,2 Elaine Hurt,2 John Owen,1
Jeffrey S Moyer,1 Mark E.P Prince,1 Joel Whitfıeld,1 Yuxin Chu,3 Qibin Song,3
Max SWicha,1 Qiao Li1. 1Univ. ofMichigan, Ann Arbor, MI; 2MedImmune INC,
MD; 3Renmin Hospital of Wuhan University, Wuhan, China.
Although surgical resection has been a standard treatment for solidmalignan-
cies, therapeutic effıcacy is limited by both local and distant recurrence. Effec-
tively preventing local tumor recurrence remains a signifıcant challenge. The
existence of micro metastasis at the time of tumor resection represents an even
greater therapeutic challenge, since 90% of tumor deaths are due to tumor me-
tastasis. There is increasing evidence that many cancers are driven and main-
tained by a subpopulation of cells that display stem cell properties. Cancer stem
cells (CSCs) can self-renew, mediate tumor growth and contribute to tumor
recurrence and metastasis. Targeting CSCs may thus increase the therapeutic
effıcacy of current cancer treatment.We previously described a strategy to target
CSCs using CSC-dendritic cell (DC) vaccination. However, the effıcacy of CSC
targeted therapeutics may be greatest when they are deployed in the adjuvant
setting. In this study, twomousemodels were utilized: SCC7 subcutaneous (s.c.)
tumors, and a D5 melanoma model. Established s.c. SCC7 tumors were surgi-
cally removed frommice followed by treatment using ALDHhigh SCC7CSC-DC
vaccine, which signifıcantly reduced local tumor relapse and prolonged animal
survival. This effect was signifıcantly augmented by simultaneous administra-
tion of anti-PD-L1 mAb. In the minimal disease setting of D5, ALDHhigh
CSC-DC vaccination signifıcantly inhibited tumor growth, reduced spontane-
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ous lung metastases resulting in increased survival. CCR10 and its ligands were
down-regulated on ALDHhigh D5 CSCs and in lung tissues respectively in ani-
mals subjected to ALDHhigh D5 CSC-DC vaccination. Down-regulation of
CCR10 by siRNA signifıcantly blocked tumor cell migration in vitro andmetas-
tasis in vivo. T cells harvested from ALDHhigh D5 CSC-DC vaccinated animals
selectively killed the ALDHhigh D5 CSCs. There was also evidence of humoral
immunological targeting of CSCs. As a result, CSC-DC vaccination signifıcantly
decreased the percentage of ALDHhigh cells in residual tumors. These data indi-
cate that, when used in an adjuvant setting, ALDHhigh CSC-DC vaccines effec-
tively inhibit local tumor recurrence, reduce spontaneous lung metastasis, and
prolong animal survival; comparedwith traditional DC vaccines and that simul-
taneous PD-L1 blockade can signifıcantly enhance this effect.
#1904 Novel 5-fluorouracil-thymoquinone hybrid kills colon cancer stem
cells. Benardina Ndreshkjana,1 Aysun Çapcı Karagöz,2 Volker Klein,2 Pithi
Chanvorachote,3 Julienne K. Muenzner,1 Kerstin Huebner,1 Chuanpit Ninson-
tia,3 Sara Steinmann,1 Abbas Agaimy,1 Maamoun Fatfat,4 Hala Gali-Muhtasib,4
Svetlana B. Tsogoeva,2 Regine Schneider-Stock1. 1University Hospital of
Friedrich-Alexander-UniversityErlangen-Nürnberg,Erlangen,Germany; 2Friedrich-
Alexander University of Erlangen-Nürnberg, Erlangen, Germany; 3Faculty of Phar-
maceutical Sciences, ChulalongkornUniversity, Bangkok, Thailand; 4AmericanUni-
versity of Beirut, Beirut, Lebanon.
Objectives: Recently, it has been shown that a subset population of cancer cells
in a tumor, the so-called cancer stem cells (CSCs), majorly contributes to
chemoresistance and the ability of a tumor to form recurrences and metastases.
Since the response to the standard chemotherapeutic drug 5-fluorouracil (5-FU)
in patients with colorectal cancer (CRC) leads only to an inadequate response,
we aimed to synthesize new hybrid molecules by combining 5-FU with the
plant-derived drug thymoquinone (TQ). Methods: The cytotoxic effect of hy-
brids, the single drugs and the combination was investigated by crystal violet
assays. HCT116, HT29 and 5-FU-resistant colorectal tumor cells were used to
assess the spheroid forming capability after treatment with different concentra-
tions of the hybrid and the single drugs by staining with the fluorescent stem cell
marker CDy1 and Hoechst 3324 after 21 days of incubation. Western Blot anal-
ysis for stem cell surface marker CD133 were performed to verify these results.
We have analyzed the anticancer effects of the single drugs TQ and 5-FU and the
most effective hybrid on deregulation of cancer signaling pathways utilizing the
NANOSTRING cancer pathway panel. In addition, we performed a single cell
cloning from spheroids to generate monoclonal cell lines with enriched CSC
populations. In vivo effects were studied in the chick chorioallantoic membrane
(CAM) assay and in mouse xenografts. Results: The 5FU-TQ hybrid has an
increased cytotoxic effect towards CRC cells when compared to single drug
treatments. The spheroid formation assay revealed the capability of the hy-
brid to reduce sphere number and size at fairly low concentrations (10, 20
M), however at 50 M there was a complete suppression of spheroid
growth. NANOSTRING analysis showed that gene expression of main com-
ponents of the PI3K/AKT signaling pathway was signifıcantly down-regu-
lated after treatment with all drugs but most prominently with the new
hybrid. After data processing we found that AKT3, IGF1, COL11A1, FGF10,
GNG7, EPO genes were downregulated in hybrid-treated cells, while
CDKN1A, BAX, JUN, MDM2, FAS were upregulated. This was verifıed via
Western Blotting for a panel of markers. Next, we investigated the effective-
ness of the hybrid to kill clones having an enriched CSC population. Indeed,
CD133 protein levels were signifıcantly decreased in hybrid-treated clones.
Histological analysis of in vivo CAM grafts showed that HCT116 control
cells developed a well vascularized tumor mass whereas HCT116 cells that
were treated with the hybrid showed no more vital tumor cells, but extended
areas of necrosis, calcifıcation, and desmoplasia. In vivo mouse xenografts
verifıed the potential of this hybrid as an antitumor agent reducing tumor
volume signifıcantly. Conclusion: Our fındings strongly suggest that the
newly synthesized 5-FU-TQ hybrid might become a promising anticancer
drug by directly targeting CSCs.
#1905 Possible cancer stem cells: Folate hydrolase-1 is expressed in a sub-
set of Oct4-positive melanoma cells. Marigdalia K. Ramirez-Fort,1 He Liu,2
Vicente Navarro,2 Barbara Meier,3 Mitch Levesque,4 Jonathan Moy,2 Jessica
Vissicchio,5 Emmanuel Contassot,3 Sae Kim,2 Talal Syed,1 Michael Zhang,1
Vincent Tem,1 Paul J. Christos,2 Scott T. Tagawa,2 Neil H. Bander,2 Christopher
S. Lange,1 Lars E. French3. 1State Univ. of New York, Brooklyn, NY; 2Weill Cor-
nell Medical College, New York, NY; 3University Hospital Zurich, Zurich, Swit-
zerland; 4University Hospital of Zurich, Zurich, Switzerland; 5Emory University,
GA.
Background: Folate hydrolase-1 (FOLH1; NAALADase; PSMA) is a type
II transmembrane protein that binds substrates with terminal glutamates.
The MXXXL motif on the cytoplasmic N-terminal domain of FOLH1 inter-
acts with clathrin and caveolin-1 to facilitate constitutive internalization
upon substrate binding. J591, an established monoclonal antibody (AB) to
FOLH1, is highly specifıc to and is effectively endocytosed after binding to
the extracellular domain of FOLH1; J591 is presently being developed in the
clinical trial setting, as a vehicle for AB-based brachytherapy in cancers that
express FOLH1. Physiological FOLH1 is expressed in cellular regions that
are protected by tight-junctions or the blood-brain-barrier, and are there-
fore not targeted by circulating J591. Functionally, FOLH1 is responsible for
cerebral glutamate production. In the oncological setting, FOLH1 is upregu-
lated throughout prostate cancer cellular membranes, and is luminally ex-
pressed by cancer neovessels. We have characterized neovascular FOLH1
expression in malignant melanoma (MM), a solid tumor of neural crest (NC)
origin. Comparative RTqPCR analysis of normal skin, primary (p), and met-
astatic (m)MM revealed respective 10.64 and 18.21 -fold increases in FOLH1
gene-expression in pMM (p0.0041) and mMM (p0.042) samples as com-
pared to normal skin. Immunohistochemistry of paraffın-embedded MM
tumors revealed FOLH1 protein expression in the neovasculature of 4/11
(36%) of pMM and 9/14 (64%) of mMM cases; we noted a subset of kerati-
nocytic and melanocytic FOLH1 positive cells. These results, and the known
functional role of glutamate production in a subset of NC-derived tissue,
suggest that MM cells may also express cellular FOLH1. Methods: Six (3
BRAF; 3 BRAF) MM cell lines were evaluated for cellular FOLH1 and
Oct4 expression with J591-based and anti-Oct4 AB immunofluorescence
(IF). Oct4 is a homeodomain binding protein encoded by POU5f1, widely
accepted as a stem cell marker. FOLH1 cell lines with permeablized and
non-permeablized membranes were incubated with J591. The effect of -ir-
radiation (0, 4.5, or 9 Gy) was also tested in FOLH1 cell lines with harvest-
ing 6 or 24 hours post-irradiation. Results: Ten to 40% of MM cells demon-
strated intracellular FOLH1 expression in 2 BRAF/6 MM cell lines, with a
predominant perinuclear and terminal dendritic distribution (e.g., axonal
morphology). IF co-labeling with J591 (cytoplasmic) and antibodies to Oct4
(nuclear) identifıed possible stemness of FOLH1 / Oct4 MM cells. RT-
PCR analysis of the irradiated cell lines demonstrated 2-fold increased
FOLH1 mRNA levels in 1/2 MM cell lines. Conclusions: Herein is the fırst
demonstration that MM cells express FOLH1. Given that FOLH1 glutamate
production is closely linked to NC-originating glial cells, it can be reasonably
postulated that this newly identifıed subset of FOLH1/Oct4 MM cells
could be NC precursors, or cancer stem cells, for MM. Further, radiation-
induced FOLH1 upregulation may increase the therapeutic ratio of AB-
based brachytherapy.
#1906 The role of immunogenic SPANX antigens in distinct cancer stem
cell subsets within triple negative breast cancers. Lauren Shahin, Elena
Cubedo, EbonyCoats, Jeff Boyd,DianaAzzam.Florida InternationalUniversity,
Miami, FL.
Breast cancer is the leading cause of death in women, primarily due to meta-
static disease rather than the primary tumor. Median survival with metastatic
breast cancer is 3 years, with no statistically signifıcant change in survival in over
20 years. Triple-negative breast cancer (TNBC) lacks estrogen and progesterone
receptor expression and ERBB2 amplifıcation and is the most lethal form of
breast cancer. It is resistant to endocrine therapy and chemo-resistance and
metastasis invariably emerge. Increasing evidence indicates that cancer stem
cells (CSCs) are chemo-resistant and initiate metastasis. We have previously
identifıed and characterized distinct subsets of CSCs within TNBC cell lines and
patient-derived tumors. Within the surface CD44 populations, CD24 expres-
sion defınes two subsets of CSCs: mesenchymal-like CD24neg and epithelial-like
CD24low. Epithelial-like CD24low cells are more aggressive than CD24neg
cells, with increased self-renewal, migration, invasion, tumor-initiation and
metastatic potential. In addition, CD24low cells are enriched following chemo-
and radiation therapies; greater than 80% of CD24neg cells die and the majority
of cells that survive are CD24low. Hence, therapies that selectively eliminate the
CD24low population in TNBC have the potential to be of enormous benefıt to
cancer patients. Therapeutic targeting of surface CD24 using antibodies have
not been successful due to the expression of CD24 on many different cell types
including B cells. Thus, there is a need formore selective strategies to target CSC
populations without affecting normal cells. Here, we show for the fırst time,
increased expression of a family of cancer/testis antigens (CTAs) namely
SPANX in the most aggressive CD24low CSC population. CTAs belong to a
class of testis-derived proteins which are only expressed in germ cells in themale
testis, and the expression of CTA genes is entirely silenced in the adult somatic
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tissues. Thus, SPANX may serve as a selective marker for targeting CSCs. In
addition, we demonstrate a functional role for SPANX in mediating CSC phe-
notype. Knockdown of SPANX decreased the percent of CD24low CSCs in
TNBCs. It also attenuated the proliferation, migration and invasion of
CD24
low
cells. Radiation treatment increased SPANX expression levels and en-
riched for CD24low cells. Loss of SPANX resulted in increased cell death of
CD24
low
cells after radiation treatment. Hence, we show that SPANX may be
promoters of the most aggressive CSC subset of TNBC. Since SPANX is highly
immunogenic, our data provide rationale for further testing of combined radi-
ation and immunotherapy approaches in the treatment of this deadly cancer. It
also supports the use of protective and therapeutic SPANX vaccines against the
most aggressive CSC subset in TNBC.
#1907 Identifıcation of a cancer stem cell-specifıc function for the histone
deacetylases HDAC1 and HDAC7 in breast and ovarian cancer. Abigail E.
Witt,1 Corrado Caslini,1 Chung-Wei Lee,2 Tong Ihn Lee,3 Diana J. Azzam,4 Bin
Wang,1 Fabio Petrocca,5 JamesGrosso,1Michelle Jones,1 EvanB. Cohick,2 Adri-
enne B. Gropper,3 Claes Wahlestedt,4 Andrea L. Richardson,2 Ramin Shiekhat-
tar,6 Richard A. Young,3 Tan A. Ince1. 1Sylvester Comprehensive Cancer Center,
Miller School of Medicine, University of Miami, Miami, FL; 2Brigham andWom-
en’s Hospital, HarvardMedical School, Boston,MA; 3TheWhitehead Institute for
Biomedical Research, Cambridge, MA; 4Center for Therapeutic Innovation, Uni-
versity of Miami Miller School of Medicine, Miami, FL; 5Boston Children’s Hos-
pital, HarvardMedical School, Boston,MA; 6University ofMiamiMiller School of
Medicine, Sylvester Comprehensive Cancer Center, Biomedical Research Build-
ing, Miami, FL.
Tumors are comprised of a highly heterogeneous population of cells, of which
only a small subset of stem-like cells possess the ability to regenerate tumors in
vivo. These cancer-stem-cells (CSCs) represent a signifıcant clinical challenge as
they are resistant to conventional cancer therapies and play essential roles in
metastasis and tumor relapse. Multiple signaling pathways involved in the reg-
ulation of CSCs have been identifıed. However, the regulation of CSCs is unlike
the reversible short-term changes in cellular phenotype induced by various ex-
tracellular factors, or the permanent changes induced bymutations. The hierar-
chical differentiation of CSCs to non-stem-tumor-cells (nsTCs) is long-lasting
over many cell generations but it is also reversible, that is more akin to tissue
differentiation, which suggests that epigenomic factors such as histone modifı-
cations may also be involved in the regulation of the CSC phenotype. Here, we
present evidence that specifıc histone deacetylases (HDACs) play essential roles
in the breast and ovarian CSC phenotype. HDACs are chromatin-modifying
enzymes that are involved in regulation of differentiation, autophagy, apoptosis,
migration, mitosis, and angiogenesis. Utilizing a novel breast CSC model com-
posed of isogenic BPLER (predominantly CSC) and HMLER (predominantly
nsTC) cell line pairs, along with conventional breast and ovarian cancer cell
lines, we discovered that among the 11 family members, HDAC1 and HDAC7
are specifıcally over-expressed in FACS-sorted breast CSCs when compared to
unsorted cells. Furthermore, we found that HDAC1 and HDAC7 are necessary
to maintain breast CSCs and that overexpression of HDAC7 is suffıcient to
augment the CSC phenotype. We also demonstrate that members of the benz-
amide class of HDAC inhibitors (HDACi) targeting HDAC1/2/3 enzymatic ac-
tivity, such asMS275 andMGCD0103, can be used to preferentially target breast
and ovarian CSCs andwe are now trying to elucidate themolecularmechanisms
behind theCSC-restricted downregulation ofHDAC7 and c-Myc transcript and
protein levels found in response to MS275 treatment. So far, limited clinical
studies have been completed with these HDACi, predominantly in Leukemia
and Lymphomas. Our results indicate that these drugs should be tested more
extensively in solid tumors. Furthermore, in standard trial designwith cytostatic
and cytotoxic drugs, the reduction in tumor size has been one of the main
metrics for monitoring patient response. Since the CSC-specifıc actions of
MS275 and MGCD0103 were previously unknown, CSC biomarkers were not
used in patient selection or formonitoring therapy response. Our results suggest
that biomarkers such as HDAC1 and HDAC7 are particularly compelling as a
supplement to tumor size measurements. Therefore, it would be feasible to use
HDAC7 immunohistochemistry to stratify patients in future clinical trials.
#1908 FGFR inhibitor, AZD4547, impedes the stemness of mammary ep-
ithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
Qingxia Zhao,1 Amanda B. Parris,1 ErinW. Howard,1 Ming Zhao,1 Ying Xing,2
Zhikun Ma,1 Xiaohe Yang1. 1North Carolina Central University, Kannapolis,
NC; 2Basic Medical College of Zhengzhou University, Henan, China.
The fıbroblast growth factor receptor (FGFR) family (FGFR1-4) of receptor
tyrosine kinases (RTKs) regulates signaling pathways involved in cell prolifera-
tion and differentiation. In particular, FGFR1 and FGFR2, which are found in
the terminal end buds of developing mammary ducts, play a role in mammary
development and glandular morphogenesis involving the regulation of mam-
mary stem cells (MaSCs) in mice. As such, a number of FGFR inhibitors are
being tested in preclinical studies and clinical trials for anti-tumor properties.
Nevertheless, reports on FGFR inhibitor-mediated breast cancer prevention are
sparse. In this study, we aimed to investigate the anti-cancer benefıts of
AZD4547, a small molecule inhibitor of FGFR1-3, on ErbB2-overexpressing
breast cancer models. We particularly focus on the effects of AZD4547 on
MaSCs and tumor-initiating cells (TICs) in the premalignant tissues ofMMTV-
ErbB2 transgenic mice. We fırst demonstrated the anti-proliferative effects of
AZD4547 (1-5 M) on human ErbB2-overexpressing breast cancer cell lines.
We further showed that AZD4547 confers potent inhibition of the stemness of
these breast cancer cells, as indicated by signifıcant depletion of ALDH cells
and impaired tumorsphere formation. To study the in vivo effects of AZD4547
on the stemness of mammary epithelial cells (MECs),MMTV-ErbB2 transgenic
mice were administered AZD4547 (2-6 mg/kg/day) for 10 weeks (weeks 8-18 of
age) during the ‘risk window’ for mammary tumor development. Histopatho-
logical analysis indicated that AZD4547 signifıcantly inhibited ductal branching
and MEC proliferation. To examine the effect of AZD4547 on MEC subpopu-
lations and tissue hierarchy dynamics in the premalignant mammary tissues of
this model, we performed flow cytometry analyses on the primary MECs using
CD24/CD49f and CD61/CD49f cell surface markers. The results showed that
AZD4547 treatment substantially reduced MaSC-derived luminal and myoepi-
thelial cell populations. AZD4547 also selectively suppressed the
CD61highCD49fhigh cell population, which is enriched with luminal progenitor
cells that give rise toTICs duringMMTV-ErbB2mammary tumor development.
Mammosphere and colony-forming cell (CFC) assays on primary MECs dem-
onstrated that the stemness of these cells was also blocked by AZD4547 prior to
malignant transformation. Consistently, AZD4547 inhibited the anchorage-in-
dependent growth of cells from spontaneous tumors. Moreover, we demon-
strated that AZD4547 downregulated multiple pathways, including the inacti-
vation of FGFR, EGFR, and Wnt/-catenin signaling. Collectively, the
morphogenic, MaSC/TIC, and signaling regulation associated with AZD4547
treatment provides critical evidence for AZD4547 as a breast cancer preventa-
tive and therapeutic agent, which ultimately reveals clues for more effective
eradication of refractory mammary tumors.
#1909 Non-alcoholic steatohepatitis promotes EpCAM positive cancer
stem cells mediated tumorigenesis in immunocompetent mouse model of
hepatocellular carcinoma. Harshul Pandit, Yan Li, Guozhen Cui, Suping Li,
Salina Li, Robert C. Martin. University of Louisville School of Medicine, Louis-
ville, KY.
Introduction: Non-alcoholic Steatohepatitis (NASH) is one of the major risk
factors for cirrhosis and its progression to Hepatocellular Carcinoma (HCC).
Cancer stem cells (CSCs) are sub-population of cells that bear stem-like prop-
erties, and are believed to contribute in tumor initiation and recurrence in tumor
microenvironment.Understanding role ofCSCs in tumorigenesiswas limited to
immunocompromised nude/SCIDmousemodels, and should be investigated in
immunocompetent mouse model(s) representing clinical conditions. In this
study, (1) we have investigated and confırmed CSCs properties in HCC cells
lines, and (2) investigated tumor initiation capability of EpCAM positive CSCs
in novel immunocompetent mouse model of HCC. Methods: In vitro CSC en-
richment was achieved by treating murine (Hepa1-6) and human (HepG2,
Hep3B) HCC cells in serum-free condition. To confırm CSCs, we analyzed CSC
biomarkers (EpCAM,CD90,CD44,CD133) using flow-cytometry and Immuno-
cytochemistry (ICC), and functional markers using Aldeflour assay and
Hoechst-33342 efflux. Drug resistance property of CSCs was studied using
Doxorubicin (anthracycline antibiotic) and Sorafenib (multikinase inhibitor) by
MTT assay. To study in vivo tumorigenesis, immunocompetent mouse model
was established using C57L/J mouse and copGFP expressing Hepa1-6 cells. Ca-
pability of EpCAM CSCs for tumor initiation was tested in 3 diet induced
groups, i.e. control (10% dietary fat), high-fat (60% dietary fat), andNASH (60%
dietary fat MCD diet with 0.1% methionine). 2 million FACS sorted Ep-
CAM/ or EpCAM-/- cells were orthotopically injected into left liver lob.
Tumor growth was monitored using high-frequency ultrasound and animals
were euthanized after 18 days. Histology and ICC analysis was performed to
confırm the tumors and fındings. Results: Spheroid formingHCC-CSCs showed
signifıcant higher EpCAM expression and signifıcant higher chemoresistance
compared with control HCC cells. Our in vivo fındings confırmed that EpCAM
CSCs required NASH microenvironment. In NASH group mice, EpCAM/
CSCs have shown signifıcant tumorigenesis compared with no tumors in Ep-
CAM-/- (n9, p0.005). Histology analysis of NASH liver tissue confırmed
lobular and portal inflammation, hepatocellular ballooning, and fıbrosis. Con-
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trol and high-fat diet group mice failed to develop tumors. Conclusions: We
have developed a novel mouse model to study CSCs to overcome confounding
limitations of immunocompromised mouse models for lacking functional im-
mune system components. Our fındings using immunocompetent mouse
model suggest that, in HCC, (1) EpCAM CSCs cannot initiate tumor by itself
within normal liver microenvironment in the presence of functional immune
components, (2) NASH microenvironment promotes EpCAM CSCs medi-
ated tumorigenesis while EpCAM-/- non-CSCs subset failed to develop tumor.
#1910 NF-kappaB classical versus alternative pathways support distinct
populations of ovarian cancer tumor-initiating cells. Carrie D. House, Chris-
tina M. Annunziata. National Cancer Institute, Bethesda, MD.
Ovarian cancer is the most lethal gynecological malignancy in the United
States with high morbidity and mortality due to recurrence and chemoresis-
tance. Our data suggest tumor-initiating cells (TICs) play an important role in
disease biology. We previously showed that a subset of ovarian cancer cells
depends onNF-kappaB signaling, and that expression of NF-kappaB proteins is
associated with poor survival. Given that NF-kappaB expression correlates with
a poor outcome in ovarian cancer, and NF-kappaB activity supports drug resis-
tance and tumorigenicity, we hypothesize that NF-kappaB supports a TIC pro-
gram responsible for ovarian cancer relapse. To investigate this pathway inTICs,
we designed a novel method to enrich for TICs from cell lines and patient
samples by culturing non-adherent, floating cells in stem cell conditions defıned
by low attachment flasks and serum free media. Preliminary data confırm that
these cells have higher stem cell marker expression, are chemoresistant, and are
more tumorigenic in nudemice compared to their adherent counterparts. These
TIC-enriched culture conditions enhance NF-kappaB expression and activity.
More specifıcally, alternative NF-kappaB signaling through the RelB transcrip-
tion factor supports TIC populations by regulating aldehyde dehydrogenase
(ALDH), an enzyme with high activity in TICs. Using an inducible shRNA
targeting RelBwe show that spheroid formation, ALDH expression and activity,
chemoresistance, and tumorigenesis in both subcutaneous and intrabursal
xenograft models, signifıcantly decreased in the absence of RelB. Interestingly,
loss of classical NF-kappaB signaling, through an shRNA targeting the RelA
transcription factor, was less effective in targeting TICs, but more effective at
targeting a proliferative subpopulation with high Ki67 staining. We conclude
that classical and alternative NF-kappaB signaling support ovarian tumor cells
with distinct phenotypes and the collaboration of these pathwaysmay be critical
for supporting tumor repopulation following chemotherapy. Current studies
will measure system level changes induced by these shRNAs, and identify a gene
signature specifıc to each NF-kappaB pathway in ovarian TICs. Clarifying the
nuances of NF-kappaB signaling in TICs will increase our understanding of
ovarian cancer recurrence and further focus therapeutic strategies to prevent
relapse.
#1911 R-SPONDIN3 antagonism sensitizes colorectal cancer to taxane
treatment. Marcus M. Fischer, V. Pete Yeung, Fiore Cattaruzza, Christopher
Murriel, James W. Evans, Gilbert O’Young, Alayne Brunner, Min Wang, Be-
linda Cancilla, Ann Kapoun, Timothy Hoey. OncoMed Pharmaceuticals, Inc.,
Santa Clara, CA.
Introduction: Colorectal cancer (CRC) is the third most common cancer
diagnosed in both men and women. Dysregulation of the WNT/-catenin
pathway is the most commonly mutated pathway in CRC. R-spondins
(RSPO), a family of secreted proteins, are enhancers of WNT signaling.
Previous preclinical studies have demonstrated that WNT inhibition results
in superior antitumor effıcacy in combination with taxanes. This superior
combinatorial activity with taxanes has been identifıed in lung, ovarian,
breast and pancreatic cancers. Taxanes have been found to be generally
ineffective in the clinical treatment of colorectal cancer. Analysis of the local
microenvironment, or stem cell niche, has identifıed stromal cells as an
abundant source of RSPO. In patient-derived tumor xenografts (PDX), the
murine stromal cells replace human stromal cells and provide the microen-
vironment that supports tumor cell growth. We have classifıed PDX tumors
as human RSPO3 high or low/negative using RNA sequencing and by ex-
pression studies. Inhibition of RSPO3 with OMP-131R10, a clinical stage
therapeutic antibody which binds to human and murine RSPO3, has dem-
onstrated effıcacy in human RSPO3 high, APCWT PDX. Purpose: Common
features in CRC are mutations in APC or -catenin which are present in
approximately 90% of cases. Tumors with RSPO3 genomic translocation
and/or overexpression of RSPO3 are generally APC WT and -cateninWT,
and thus RSPO overexpression represents an alternative mechanism to up-
regulate the Wnt pathway. Alternatively, RSPO3 may be secreted by murine
stromal cells, or by a rare population of tumor cells. In this study, we tested
OMP-131R10 in combination with taxane treatment in human RSPO3 low
CRC PDX models with APC or -catenin mutations and in a PDX model
with a RSPO3 translocation. Results: Anti-RSPO3 was highly effective in
combination with nab-paclitaxel in a CRC model with an RSPO3 transloca-
tion and RSPO3 overexpression. Furthermore, the combination of OMP-
131R10 and taxane treatment resulted in synergistic inhibition of tumor
growth in 8/10 PDX models with APC or  -catenin mutations and low
human tumor cell RSPO3 expression. Tumor regression or durable stable
disease was evident in 6/8 models. Responsive models contained either
heterozygous inactivating mutations in APC (6/8) or homozygous activating
mutations in -catenin (2/8). Combination of OMP-131R10 with paclitaxel
potentiated mitotic arrest, enhanced terminal differentiation and reduced
the tumorigenic cell frequency by 40 fold based on serial transplantation
studies. Conclusion: Anti-RSPO3 (OMP-131R10) was active in the majority
of CRC PDX models tested when combined with taxane treatment. These
CRC models harbored mutations in APC and -catenin. This data indicates
that RSPO3 inhibition is an effective means to target the mutated Wnt path-
way in CRC, and that antagonizing RSPO3 in combination with paclitaxel
may improve survival for CRC patients.
#1912 Actn4, a novel therapeutic target of dietary ellagic acid, promotes
breast cancer metastasis viamediating cancer stem cells.NengWang,1 Zhiyu
Wang,2 Xiaoming Xie3. 1Sun Yat-sen University Cancer Center; University of
Guangzhou Traditional Chinese Medicine, Guangzhu, China; 2University of
Guangzhou Traditional Chinese Medicine, Guangzhu, China; 3Sun Yat-sen Uni-
versity Cancer Center, Guangzhu, China.
Purpose: Pharmacology-based target identifıcation has become a novel
stratey leading to the discovery of novel pathological biomarkers. Ellagic acid
(EA), a dietary polyphenol compound, exhibits potent anticancer activities,
whereas the underlying mechanisms remain unclear. This study sought to de-
termine the role and regulation of ACTN4 expression in human breast cancer
metastasis and EA-based therapy. Experimental Design: The anti-metastasis
ability of EAwas validated byMMTV-PyMTmice and in vitro cellmodels. Drug
affıity responsive target stability (DARTS) was utilized to identify ACTN4 as the
direct target of EA in breast breast cancer stem cells (CSCs). The metastatic
regulatedmechanisms ofACTN4were assessed byCSC-related assays including
mammosphere formation, tumorigenic ability, reattachment differentiation
and signaling pathway analysis. The clinical signifıcance ofACTN4was based on
human tissue microarray analysis and TCGA database exploration. Results: EA
inhibited breast cancer growth and metastasis via directly targeting ACTN4 in
vitro and in vivo, accompanied with limited CSCs population. ACTN4 knock-
down resulted in blockage of malignant cell proliferation, colony formation and
ameliorated metastasis potency. ACTN4 positive CSCs exhibited higher ESA
proportion, increased mammosphere-formation ability, as well as enhanced in
vivo tumorigenesis ability. Increased ACTN4 expression was directly associated
with later cancer stage, increased incidence of metastasis, and poor overall sur-
vival period. Conclusions: ACTN4 plays an important role in breast CSCs-re-
lated metastasis and is a novel therapeutic target of EA treatment.
#1913 SOX9 regulates cancer stem-like cells in non-small cell lung cancer.
Maria Voronkova,1 Sudjit Luanpitpong,2 Heimo Riedel,1 Yon Rojanasakul1.
1West Virginia University, Morgantown, WV; 2Mahidol University, Bangkok,
Thailand.
Lung cancer is the leading cause of cancer death worldwide in both men and
women, every year killing more people than breast, prostate and colon cancers
combined. Drug/radiation resistance and tumor relapse contribute to low pa-
tient survival, which has largely been attributed to the acquisition of stem-like
cells (CSCs), or tumor initiating cells. Moreover, conventional therapies are not
effective against CSCs. This signifıes the need to identify mechanisms of CSC
regulationwhich could lead to the discovery ofCSC-specifıc drug targets and the
development of more effective drug therapies. An embryonic transcription fac-
tor SOX9has been implicated inCSC regulation in a number of cancer types, but
little is known about its role in non-small cell lung cancer (NSCLC). We dem-
onstrated that high SOX9 expression correlateswith poor survival in lung cancer
patients by analyzingTheCancerGenomeAtlas (TCGA) data.Wehypothesized
that SOX9 plays a key role in tumor progression and chemoresistance by up-
regulating CSCs in NSCLC. To test this hypothesis, SOX9 expression was stably
or transiently knocked down inNSCLC cells, and their effects onCSC formation
and biomarkers, and on drug resistance were investigated. Our results showed
that SOX9 knockdown decreased the number of tumor spheres in NSCLC cell
lines. Furthermore, SOX9 knockdown downregulated the expression and activ-
ity of stem cell marker ALDH1A1 as determined by Western blot and flow
cytometric assays. Consistent with this fınding, overexpression of SOX9 in non-
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cancer lung epithelial Beas-2B cells elevated tumor sphere formation, support-
ing the role of SOX9 in CSC regulation. Analysis of the soft agar colony forma-
tion assay further showed that SOX9 knockdown inhibited anchorage-
independent growth in NSCLC cells. More importantly, SOX9 knockdown
resulted in an increased sensitivity of the cells to a chemotherapeutic drug cis-
platin, whereas SOX9 overexpression decreased it. Together, our results indicate
an important role of SOX9 in the regulation of CSCs in NSCLC and suggest its
potential utility as a drug target for chemoresistant lung cancer.
#1914 GNS561 is a new quinoline derivative with high effıcacy on cancer
stem cells from colorectal liver metastasis and hepatocellular carcinoma.
Firas Bassissi,1 Elena Patricia Gifu,2 Sonia Brun,1 Jerome Courcambeck,1 An-
toine Beret,1 Jean Marc Pascussi,3 Julie Pannequin,3 Eric Raymond,1 Philippe
Halfon,1 Philippe Merle,4 Claude Caron de Fromentel2. 1Genoscience Pharma,
Marseille, France; 2CRCL, INSERM U1052 - CNRS 5286, Université Lyon1 -
Centre Léon Bérard, Lyon, France; 3Institut de Génomique Fonctionnelle (IGF),
Montpellier, France; 4CRCL, INSERM U1052 - CNRS 5286, Université Lyon1 -
Centre Léon Bérard, Hospices Civils de Lyon, Lyon, France.
Background: In spite of wide application of sorafenib for advanced hepato-
cellular carcinoma (HCC) treatment, and systemic chemotherapy cocktails (5-
fluorouracil, irinotecan, and oxaliplatin) for metastatic colorectal cancer, the
prognostic for both cancers remains poor. In recent years, highly tumorigenic
sub-populations of cancer cells named Cancer Stem Cells (CSCs) have been
claimed as responsible of some tumor recurrences. Indeed, CSCs are resistant to
chemotherapy, and they have the ability to regenerate all the tumor bulk with its
heterogeneous cell type populations. For this reason, new drugs with original
mechanism of action which target CSC properties would likely improve cancer
treatmentMaterial andmethods: Antitumor activity of GNS561 was tested on a
panel of cancer cell lines and primary tumors. GNS561 impact onCSCs subpop-
ulation in patient derived cells from colorectal hepatic metastatic tumors was
assessed by flow cytometry (ALDH activity). In HCC, the effect of this drug was
evaluated by sphere formation assay as readout to estimate CSC survival. Toler-
ance and plasma and liver pharmacokinetic were evaluated after single and
repeated dosing in mice and rats. In vivo GNS561 activity was tested in ortho-
topicmousemodel Results: GNS561 demonstratedmultiple cellular effects such
as inhibition of autophagy, induction of apoptosis and cell cycle modulation. It
showed antitumor activity against several human cancer cell lines. Furthermore,
GNS561 was effective against a panel of HCC tumors even from patients har-
boring sorafenib resistance. GNS561 showed nonetheless an original dose-re-
sponse cytotoxic activity against the whole tumor populations but also against a
subpopulation displaying high ALDH activity in three CRC patient-derived cell
lines established from fresh livermetastasis biopsies. Consequently, on the same
model this compound induced a striking decrease of sphere formation. In HCC
cell lines GNS561 was active on both whole populations (mean EC50 2M) and
subpopulations displaying CSC features (Epcam high). In addition, in the op-
posite of sorafenib, GNS561 decreases the HCC cell capacity to form spheroids.
Inmouse, GNS561was foundwell tolerated and highly selectively trapped in the
liver (exposure ratio liver/plasma about 170 animals). In HCC PDX mouse
model, tumor growth was signifıcantly reduced by GNS561 with a dose-re-
sponse manner, this tumor regression was associated with AFP level decreases
by 72%withGNS561 (p0.002) and 54%with sorafenib (p0.046) compared to
control Conclusions: GNS561 is a liver selective drugwhich offers great promise
for HCC and livermetastatic tumors treatment. By simultaneously targeting the
cancer stem cell subpopulation and tumor bulk, both cell heterogeneity, plastic-
ity and recurrences could be overcome at least in colorectal cancer and HCC.
GNS 561 is now aimed to further reach clinical development in patients in 2017.
#1915 Deconstructing cancer stem cells: IL-6, G-CSF and Activin-A as
mediators of stroma-orchestrated epithelial cells’ dedifferentiation.Carlos F.
Rodrigues,1 Eurico Serrano,2MarcoCunha,1Maria I. Patrício,3MarianaVal,4 João
Fonseca,1CéliaGomes,5AnteroAbrunhosa,6ArturPaiva,7FilomenaBotelho,2Lina
Carvalho,2 IsabelM.Carreira,4AlpoimCarmen1. 1Centre forNeursociences andCell
Biology, Coimbra, Portugal; 2Center for Research in Environment, Genetics and On-
cobiology (CIMAGO), Coimbra, Portugal; 3Nuffıeld Laboratory of Ophthalmology,
NDCN & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford,
UnitedKingdom; 4Cytogenetics andGenomics Laboratory, Faculty ofMedicine,Uni-
versity of Coimbra, Coimbra, Portugal; 5Institute for Biomedical Imaging and Life
Sciences, University of Coimbra, Coimbra, Portugal; 6Institute of Nuclear Sciences
Applied to Heath (ICNAS), Univers, Coimbra, Portugal; 7Centro Hospitalar Univer-
sitário de Coimbra (CHUC), Coimbra, Portugal.
Intercellular communication in cancer is a deceiving and extremely effıcient pro-
cess through which the corporal machinery is hijacked by a panoply of cellular and
molecular strategies turning the entire humanbody into an evolutionary arena. The
extensive crosstalk mediated by cytokines and chemokines overcome the ineffı-
ciency of the invasion-metastasis cascade, thus allowing the development of the
often-fatal metastatic disease. Cancer stem cells (CSCs) have recently been impli-
cated inmajor steps of the tumorigenic process, namely in tumor initiation, metas-
tasis formationand tumor relapse following therapy.Yet, despite their relevance, the
exact mechanisms underlying their formation are still unclear. After observing that
the malignant human bronchial epithelial RenG2 cells dedifferentiated following
culture in the subcutaneousmouse lumbar region, co-cultures of surgically isolated
mice lumbar stromal cells with RenG2 cells were established and the conditioned
media studied by multiplex and ELISA. Consequently, Interleukin-6 (IL-6), Gran-
ulocyte colony-stimulating factor (G-CSF) and Activin-A were identifıed as the
paracrine mediators of the intercellular communication process. Aiming to ascer-
tain the individual role of each cytokine in the dedifferentiationprocess, aswell as to
access the involvement of exosomes as transport vehicle, the same co-cultures were
reproduced in the presence of specifıc cytokine-communication blockers, either
individually or in combinations of up to three blockers, and exosome-mediated
communication inhibitors. Finally, exosomes were also collected from control co-
cultures and their cargo screened for the target cytokines. ELISA showed that the
threecytokineswerepresent inside fıbroblasts-secretedexosomes.Moreover,when-
ever exosomes’ release was blocked, dedifferentiation was abrogated, further prov-
ing the role of the aforementioned cytokines and of exosomes in the dedifferentia-
tion process. Additionally, the cytokine-blocking experiments revealed that only
IL-6 and Activin-A were endowed with the potential to orchestrate dedifferentia-
tion, as when at least one of these cytokines was present a stem cell population
developed insideRenG2cells. Finally,G-CSFappeared tobedecisive inmaintaining
the undifferentiated phenotype, as a larger pool of CSCswas attainedwhenever this
cytokine and either IL-6 or Activin-A were present. Altogether the attained results
implicated IL-6 and Activin-A in the formation of CSCs by dedifferentiation, and
G-CSFas apotent keeperof thededifferentiation status. Subsequent studies arenow
required toaccess theuseof these cytokinesas therapeutic targets so the tumorigenic
process may be abrogated in its initial steps, improving patients’ prognosis and
survival. Work sponsored by FEDER, POFC-COMPETE and the FCT grants
PTDC/BBB-BQB/2450/2012 and SFRH/BD/33884/2009.
#1916 Peptidylarginine deiminase IV (PADI4) is a novel tumor suppres-
sor that may contribute to regulation of breast cancer stem cell dynamics.
Nellie Moshkovich. NCI, Bethesda, MD.
Breast cancer is a global problem that accounts for almost a fourth of all
cancers in women. Despite the many therapeutic strategies currently in use,
treated patients often suffer from cancer relapse and metastasis due to the pres-
ence of a subpopulation of tumorigenic cells capable of self-renewal and termed
cancer stem cells (CSCs). To address the properties of this critical sub-popula-
tion, we utilized our recently-developed lentiviral CSC reporter carrying an
Oct4/Sox2 response element coupled to a green fluorescent protein (SORE6-
GFP) to detect and isolate theCSCpopulation in a low-gradeERhumanbreast
cancer model, MCF10Ca1h, by FACS. Whole transcriptome sequencing analy-
sis (RNA-seq) on the sorted cells identifıed Peptidylarginine deiminase IV
(PADI4) as differentially expressed between CSCs and non-CSCs. PADI4 was
recently shown to regulate citrullination of histone H1, displacing it from chro-
matin and resulting in global chromatin decondensation and pluripotency in-
duction in embryonic stem cells (Christophorou, et al., 2014, Nature 507:104).
Thus, we hypothesized that PADI4may also regulate the stemness phenotype in
breast cancer CSCs, likely through effects on chromatin structure. We showed
that PADI4 protein expression is higher in luminal breast cancer cell lines than
other subtypes, and we did shRNA knockdown (KD) of PADI4 in the luminal
MCF10Ca1h model. PADI4 KD increased tumorosphere formation and
clonogenicity indicating increased CSC population/activity. Additionally,
MCF10Ca1h cells treatedwith a PADI4 selective inhibitor showed an increase in
CSCs as assessed using the SORE6-GFP stem cell reporter. In vivo limiting
dilution studies demonstrate that PADI4 KD increased tumor incidence at low
cell inoculum, reflecting a statistically signifıcant 2-4 fold increase in CSCs upon
PADI4 KD. Our fındings suggest that PADI4 may function as a tumor suppres-
sor in luminal breast cancer. In support of this conclusion, deep deletions of
PADI4 locus are found in 1% of human breast cancers in the TCGA datasets.
Analysis of the effect of PADI4 KD on chromatin organization in the CSC and
non-CSC compartments is ongoing.
#1917 AXL inhibition in ovarian cancer stem-like cells increases chemo-
sensitivity. Jin-Young Kim, Hyewon Chung, So-Jin Shin, Eunyoung Ha, Chi-
Heum Cho. Keimyung University School of Medicine, Daegu, Republic of Korea.
Cancer stem-like cells (CSCs), a small population of cancer cells with regen-
erative potential, may lead to the initiation and progression of secondary tu-
mors. Long-term chemotherapeutic drug treatment can also result in the gen-
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eration of a drug resistant population of cancer stem cells. In this study we have
isolated CD44 and CD117 enriched ovarian cancer stem-like cells from pri-
mary cultured ascites cells removed from ascites fluid of naïve ovarian cancer
patients. AXL, a type I receptor tyrosine kinase family member, is found to be
over-expressed in ovarian cancer stem-like cells. Cell viability assays showed
that ovarian CSCs are chemo-resistant to concentration dependent paclitaxel
treatment. AXL was inhibited using a R428 and cell viability assays and apopto-
tic assays in the presence of paclitaxel were performed, which made the CSCs
chemo sensitive. Si-RNA based inhibition of AXL also displayed a similar pat-
tern of improving the sensitivity of the stem-like cells to the chemotherapeutic
drug. PI3-kinase/Akt signaling pathway has also been shown to be involved in
decreasing the cell viability during the inhibition of AXL. In conclusion, this
study establishes the role of AXL, a receptor tyrosine kinase, as one of the key
proteins influencing the chemo resistance in ovarian cancer stem-like cells.
#1918 Gene characterizationof lung-tumorspheres for their usage as an in
vitro screening platform for testing new therapeutic strategies. Alejandro
Herreros-Pomares,1 EsterMunera-Maravilla,1 Silvia Calabuig-Fariñas,2 Rut Lu-
cas,3 Rosa Farràs,4 Ana Blasco,5 Susana Torres,1 Jose Ferri,5 Ricardo Guijarro,6
Miguel Martorell,7 Eloísa Jantus-Lewintre,8 Camps Carlos9. 1Molecular Oncology
Laboratory, General University Hospital of Valencia Research Fundation, Valencia,
Spain; 2MolecularOncology Laboratory, General UniversityHospital of Valencia Re-
search Fundation; Department of Pathology. Universidad de Valencia., Valencia,
Spain; 3Department of Science History and Documentation. Universidad de Valen-
cia., Valencia, Spain; 4Department of Oncogenic signalling Laboratory. Centro de
Investigación Principe Felipe., Valencia, Spain; 5Department of Medical Oncology,
General University Hospital of Valencia, Valencia, Spain; 6Department of Thoracic
Surgery, General University Hospital of Valencia, Valencia, Spain; 7Department of
Pathology. Universidad de Valencia., Valencia, Spain; 8Molecular Oncology Labora-
tory, General University Hospital of Valencia Research Fundation; Department of
Biotechnology. Universidad Politécnica de Valencia., Valencia, Spain; 9Molecular
Oncology Laboratory, General University Hospital of Valencia Research Fundation.
Department ofMedicine.UniversidaddeValencia.Department ofMedicalOncology,
General University Hospital of Valencia, Valencia, Spain.
Background: Lung cancer features like treatment resistance or tumor relapse
have been linked to cancer stem cells (CSCs), a population of cells with self-
renewal properties, and the ability to grow forming tumorspheres in non-adher-
ent conditions. The aim of this study was to isolate and characterize tumors-
pheres from lung cancer cell lines and tumor tissue from resectable non-small
cell lung cancer (NSCLC) patients and to use them as an in vitro platform for
drug screening.Methods: This study was performed on cells from sevenNSCLC
tumor samples and fıve cell lines (H1650, H1993, H1395, A549 and PC9) grown
in monolayer and as spheroids. The expression of 60 genes, including CSC-
markers, pluripotency inducers, cell cycle regulators, invasion promoters and
components of Notch,Wnt and Hedgehog pathways was analyzed by RTqPCR.
Drugs commonly used in clinical guidelines (Cisplatin, Paclitaxel, Gefıtinib,
Erlotinib, Afatinib, Pemetrexed andVinorelbine) and specifıc inhibitors ofWnt
and Hedgehog pathways (Iwp2, Xav939, LDE225 and Vismodegib and Saly-
nomicin) were tested in triplicates at 4 different concentrations. Cell viability
was measured after 48h and 72h usingMTS Assay, normalized to the respective
mock-treated control cells and presented as percentage of control. Statistical
analyses were considered signifıcant at p0.05. Results: Lung tumorspheres had
signifıcant increased expression of CSC-related genes EPCAM1, CD44,
CCND1, KLF4 and CDKN1A, compared to their paired-adherent cells. Like-
wise, epithelial to mesenquimal transition (EMT) inducer SNAI1 and integrin
ITGA6 were overexpressed in spheroids too. Regarding stemness pathway,
Notch pathway ligands JAG1 andDLL4 and receptors NOTCH1,NOTCH2 and
NOTCH3 showed higher expression in lungspheres. In Wnt pathway, higher
expression levels of WNT3, CTNNB1 and GSK3B were found in tumorspheres.
No signifıcant differences were found for the rest of genes. Drug screening
showed classical anticancer drugs, such as Cisplatin, Vinorelbine or Pem-
etrexed, had mild cytotoxic effects on lungspheres, obtaining signifıcant differ-
ences with the adherent-cultured cells. In contrast, the stemness pathways in-
hibitors IWP2, XAV939, Salinomycin andVismodegib showed higher cytotoxic
effects on spheroids than in cells grown in monolayers. Conclusions: Lung-
tumorspheres derived from cancer cell lines and primary tumor tissues show
increased levels of CSC markers and components of Notch and Wnt signaling
pathways compared to the cells grown in adherence. Spheroids showed resis-
tance to classical anticancer drugs, and a greater response to inhibitors from
Notch, Wnt and Hedgehog pathways, strengthening its possible use as a short-
term culture platform for a simple, and cost-effective screening to investigate
novel therapeutic approaches. Supported by grants RD12/0036/0025 from
RTICC-FEDER, PI12-02838/PI15-00753 from ISCIII and SEOM/2012.
#1919 Twist1 modulates paclitaxel-induced cancer stem cell enrichment
in triple-negative breast cancer.AiminYang, XiaoyuanHe, BradleyA. Schulte,
Steven L. Carroll, Stephen P. Ethier, Gavin Y.Wang.Medical University of South
Carolina, Charleston, SC.
Triple-negative breast cancer (TNBC), themost aggressive subtype of breast can-
cers, is highly refractory to chemotherapyandhas ahigh incidenceofmetastasis and
tumor relapse. Targeted therapies for TNBC do not exist because this subtype lacks
druggablehormonereceptors andHER2amplifıcationoroverexpression.Although
Taxane-based chemotherapy is a standard of care for TNBC treatment, paclitaxel
(Taxol)-induced cancer stemcell (CSC) enrichment presents a signifıcant challenge
to the success of breast cancer treatment. Thus, there is a critical need to understand
the mechanisms by which chemotherapy induces CSC enrichment in residual tu-
mors following anticancer therapies. Here we report that Taxol-induced enrich-
ment for CSCs correlates well with a marked upregulation of Twist1 expression in
humanTNBCcells.KnockdownofTwist1 inhibits theclonogeniccapacityofTNBC
cells in vitro and TNBC tumorigenesis in vivo. Mammosphere formation assays
indicate that silencing of Twist1 greatly diminishes the tumor sphere-forming po-
tential of breastCSCs. Furthermore, limiteddilutionassays and stemcell xenotrans-
plantation reveal that knockdown of Twist1 expression decreases the frequency of
CSCsby 72-fold inhumanTNBCcells.More importantly,we show that silencingof
Twist1 blocks Taxol-induced CSC enrichment in residual tumor cells that have
survived drug treatment. Together, these results demonstrate a previously unrecog-
nized role for Twist1 in mediating Taxol-induced CSC enrichment in residual tu-
mors of human TNBC and suggest that targeted inhibition of the Twist1 signaling
pathwaymay represent a novel therapeutic strategy to tackle therapy-induced CSC
enrichment in breast cancer treatment.
#1920 Prostaglandin E2 accumulation enhances the expansion of
ALDH1-positive cells and Kras-driven tumorigenesis in the pancreas. Kota
Arima,1 Takatsugu Ishimoto,1 Masaki Ohmuraya,2 Keisuke Miyake,1 Tsugio
Eto,1 Hirohisa Okabe,1 Yuki Kitano,1 Kensuke Yamamura,1 Takayoshi Kaida,1
Katsunori Imai,1 Daisuke Hashimoto,1 Akira Chikamoto,1 Hideo Baba1. 1Grad-
uate School of Medical Sciences, Kumamoto University, Kumamoto, Japan;
2Hyogo College of Medicine, Nishinomiya, Japan.
Background:Chronic inflammation is known tobe a risk factor of carcinogenesis
and tumor development, and it was demonstrated that oral aspirin intake reduced
cancer-relateddeath includingpancreatic ductal adenocarcinoma (PDAC) through
inhibiting prostaglandin synthases. On the other hand, cancer stem cells (CSCs)
refer to a subset of tumor cells that have self-renewal ability and generate plenty of
non-CSC cells that comprise a tumor. Prostaglandin E2 (PGE2) and inhibition of
15-PGDH, which is an enzyme degrading PGE2, promoted hematopoietic and tis-
sue stem cell fraction, however, little is known about the role of PGE2 accumulation
for CSC fraction. A number of CSCmarker candidates have been explored to date,
and Aldehyde dehydrogenase 1 (ALDH1) was identifıed as one of CSCmarkers in
PDAC. The aim of this study is to elucidate the functional role of PGE2 in ALDH1
positiveCSC fraction during tumor development in pancreas.Methods: The clono-
genic growth potential of ALDH1-positive PDAC cells was assessed in vitro by
growth assays and sphere formation assays. We next investigated the expression of
ALDH1 and self-renewal related genes in PDAC cell lines with PGE2 or 15-PGDH
inhibitor treatment.We further conducted functional experiments using siALDH1
in PDACprogression. Furthermore, we examined the effect of PGE2 for pancreatic
tumorigenesis using Kras-driven genetic mouse model treated with 15-PGDH in-
hibitor. Finally,ALDH1andKi67 expressionwas examinedby immunohistochem-
istry in 121 primary surgical specimens of PDAC and analyzed a relationship with
clinicopathological factors and clinical outcomes. Results: The number of ALDH1-
positive cells was signifıcantly increased by PGE2 treatment, and PGE2 promoted
growth and sphere formation potential in PDAC cells. In addition, 15-PGDH in-
hibitor induced PGE2 accumulation and gave rise to ALDH1-positive cells harbor-
ing high proliferating potential in PDAC cells. The growth and sphere formation
potential were inhibited by silencing ALDH1 expression in PDAC cells. We next
found that the expression of Nanog and Oct-4 genes was regulated by PGE2-
ALDH1 signaling. Furthermore, 15-PGDH inhibitor induced ALDH1 expression
andpromotedPanINformation inKras-drivengeneticmousemodel.Finally, ahigh
level of ALDH1 expression was signifıcantly associated with large tumor size and
high Ki67expression, and poor prognosis in PDAC patients. Conclusion: Current
fındings suggested that PGE2 positively regulated ALDH1 expression, and the
growth and sphere formation potential were promoted by regulating self-renewal
related genes expression, resulting in poor prognosis of PDAC patients. Inhibiting
PGE2-ALDH1 signaling could lead to the suppression of tumor growth in PDAC
patients.
#1921 Stem-like clusters ofCD44 circulating tumor cells seedmetastases
in breast cancer. Xia Liu, Wenjing Chen, Rokana Taftaf, Huiping Liu. Case
Western Reserve Univ., Cleveland, OH.
TUMOR BIOLOGY: Normal and Neoplastic Stem Cells
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 493
Background: Circulating tumor cells (CTCs) are cells shed from primary
tumor and circulate in the peripheral blood. They are considered the seeds of
metastasis. Compared to single CTCs, clusters of multiple CTCs possess 50
times higher metastatic capacity in mouse breast cancer models. However,
the mechanisms underlying the metastatic promotion effect of CTC clusters
are unclear. In addition, whether clustered CTCs have cancer stem cell (CSC)
properties and what stem cell markers they express have not been deter-
mined. Methods: Immunohistochemistry (IHC) was used to detect CTCs in
vascular structures, and the stem cell markers in single and clustered CTCs.
Lung metastases were either monitored by bioluminescence imaging (BLI)
or visualized by fluorescence microscopy. Stem cell properties were exam-
ined by mammosphere assays in vitro and tumorigenic assays in vivo. Clus-
tering assay was performed by culturing cells in Poly-HEMA coated plates
(for cell lines) or collagen-coated plates (for primary cells derived from
patient-derived breast tumor xenografts, PDXs), and then monitored by
IncuCyte live cell dynamic imaging. Results: CD44 enriched circulating
tumor cell (CTC) clusters were found in the lung/liver vascular structures in
vivo in both metastatic breast cancer patients and PDXs that develop spon-
taneous lungmetastases. Comparing to single CD44 cells, clustered CD44
cells formed more mammospheres, increased tumorigenic potential, and
promoted lung colonization. Combining siRNA-mediated knockdown and
CRISPR/Cas-based knockdout, we found that CD44 is required for breast
tumor cell cluster formation and lung colonization upon tail vein seeding.
During cluster formation, EGFRwas activated, which improved both stemness and
survival of clustered CTCs. Anti-EGFR antibody mimicked CD44 knockdown to
inhibit cluster formation of PDX-derived tumor cells. Administration of EGFR in-
hibitor Erlotinib effıciently inhibited CD44 cells-mediated spontaneous metasta-
ses to the lungs without affecting primary tumor growth. Conclusions: Our data
provide new insights into the cellular andmolecularmechanisms of stem-like clus-
teredCD44 cells-seededmetastasis, and implicate that targetingCD44CTCclus-
ters by inhibition of EGFR activity could be a new therapeutic strategy to treat
metastatic breast cancer.
#1922 S-SHIP promoter expression identifıes a putative cancer stem cell
population in C3(1)/Tag murine mammary tumors. Lu Tian,1 Chann Laga-
dec,2 Eric Adriaenssens,2 Emmanuel Bouchaert,3 Hélène Bauderlique-Le Roy,4
Xuefen LeBourhis,2 Roland P. Bourette1. 1CNRSUMR 8161 - Institut de Biologie
de Lille - SPES team, Lille, France; 2Cell Plasticity and Cancer - Inserm U908 -
Université Lille 1, Lille, France; 3Plateforme des modèles animaux du SIRIC ON-
COLille, Oncovet Clinical Research, Lille, France; 4BioImaging Center Lille Nord
de France - Institut Pasteur de Lille, Lille, France.
Breast cancer is the most common cancer in women worldwide. The iso-
lation and characterization of breast cancer stem cells (CSC) are crucial for
understanding cancer biology and revealing potential therapeutic targets.
One of the major issues in the study of CSC is the lack of reliable markers. A
transgenic mouse model (Tg 11.5kb–GFP) was generated using the 11.5kb
s-SHIP (stem-SH2-containing 5=-Inositol Phosphatase) promoter that spe-
cifıcally expressed enhanced green fluorescent protein (GFP) in embryonic
and various tissue stem cells. In the mammary gland, previous experiments
showed that GFP labels puberty cap cells and pregnancy basal alveolar bud
cells, and it has been demonstrated that these mammary GFP cells are
activated tissue stem cells. In order to determine if s-SHIP promoter expres-
sion could also mark mammary cancer stem cells, we generated a bi-trans-
genic mouse model by crossing Tg 11.5kb-GFP mice with Tg C3(1)/Tag
mice. Tg C3(1)/Tag mice express SV40 T antigen under the regulatory con-
trol of the rat prostatic steroid binding protein C3(1) gene. In female mice,
the transgene is expressed primarily in the mammary gland. Mice develop
mammary hyperplasia by 3 months of age with subsequent development of
mammary adenocarcinoma by 6 months of age. Here we show the presence
of a rare population of GFP cells in mammary tumors of female bi-trans-
genic mice by using immunohistochemical and flow cytometry analysis. The
GFPmammary cancer cells are also CD24/CD49f/CD29. As compared
to GFP cells, GFP cells exhibit both a higher tumor sphere-forming po-
tential, and a higher tumorigenicity when transplanted into SCID and FVB
recipient mice. Moreover, upon subsequent transplantation, the GFP cells
generated heterogeneous tumors that displayed properties similar to the
primary tumor. Currently, we are conducting transcriptomic analysis of
these GFP and GFP cells in order to reveal differentially expressed genes.
Altogether, these results suggest that s-SHIP promoter expression may be a
new marker of mammary CSC that enables their identifıcation and isolation
via a single consistent parameter. Furthermore, our bi-transgenic C3(1)/Tag
x 11.5kb-GFP mice provide a novel model for study of mammary cancer
stem cells and investigation of potential therapeutic targets for breast cancer.
#1923 Paired isolation and expansion of CSC and CTC from primary
small cell lung cancer patient tissue and blood using the 3DKUBE bioreactor
platform.Melissa Millard,1 Alina Lotstein,1 Lillia Holmes,1 David Schammel,2
Ki Chung,3 Jeff Edenfıeld,3 Hal E. Crosswell,1 Tessa DesRochers1. 1KIYATEC,
Inc., Greenville, SC; 2PathologyConsultants, Greenville, SC; 3GHS,Greenville, SC.
Surgical resection is rarely an option for small cell lung cancer (SCLC) pa-
tients as themajority present with extensive disease at diagnosis. This scarcity of
patient samples suitable for research presents a signifıcant road block for the
development of SCLC targeted-therapeutics. To address the problem of tissue
scarcity, we have developed a method for the isolation and expansion of cancer
stem cells (CSC) and circulating tumor cells (CTC) from primary tissues and
blood of SCLC patients using the 3DKUBETM perfusion microbioreactor. We
have established a label-free, combined chemical and functional selection
method for the isolation of CSCs from SCLC samples, solid tumor as well as
blood, that does not rely upon the bias imposed bymarker-based selection. Cells
enriched in this manner were further purifıed and expanded under optimized
conditions (growth factors, ECM, scaffolding and oxygen tension) within the
3DKUBETM perfusion microbioreactor. These isolated and expanded CSCs
have maintained resistance to cisplatin and etoposide, stabilized the expression
of traditional CSC markers, and been validated in vitro through serial spheroid
formation assays. These CSCs are currently being characterized and compared
to parental tissue through correlative genomic and phenomic analysis and vali-
dated through in vivo tumorigenesis models. These cells will be utilized to gen-
erate 3D microtumors to accurately predict SCLC drug response in vitro, a
determination that is not accurately performed in conventional 2D cell culture
and is inhibited by both cost and time in patient-derived xenografts (PDX).
#1924 Caveolin-1 inhibits mammary carcinogenesis via suppressing c-
myc-induced metabolism reprogramming in breast cancer stem cells. Zhiyu
Wang,1 Neng Wang,2 Shengqi Wang,1 Yifeng Zheng1. 1Guangzhou Univ. Of
Chinese Medicine, Guangzhou, China; 2Sun Yat Sen University, Guangzhou,
China.
Purpose: Caveolin-1(CAV1), a membrane constituent protein, exhibits tu-
mor suppressor activities in multiple malignancies, whereas the underlying
mechanisms remain unclear. The current study aimed to determine the signifı-
cance ofCAV-1 in regulating cancermetabolism and its relation to breast cancer
stem cells (CSCs). Experimental Design: The anti-carcinogenic function of
CAV1 was evaluated by in vitro cell model, CAV1 knockout mice and MMTV-
PyMT spontaneous breast cancer xenografts. Glycolysis activity and mitochon-
drial metabolism were assessed by immunoblotting, oxygen consumption and
mitotacker staining analysis. Mammosphere formation, tumorigenic ability, re-
attachment differentiation and signaling pathway analysis were applied to study
the regulation effects of CAV1onbreast CSCs. The clinical signifıcance ofCAV1
was also analyzed by human tissuemicroarray. Results: In bothmammary trans-
formed cells and spontaneous breast cancer xenografts, CAV1 is found signifı-
cantly downregulated and positively correlated to increased glycolysis activity
and impaired mitochondrial metabolism. Cav1 knockout results in increased
ductal hyperplasia, associating with increased stem cell population and glycoly-
sis metabolism. Breast CSCs exhibits glycolytic phenotype and decreased CAV1
expression compared to normal mammary stem cells, and CAV1 overexpres-
sion signifıcantly limits CSCs’ self-renewal via inhibiting c-myc induced glyco-
lysis. Clinical investigation suggests that high CAV1 expression is revealed with
better overall survival and decreased CSCs population. Conclusions: CAV1 loss
facilitates mammary carcinogenesis via enhancing glycolytic activity in breast
CSCs, and CAV1 based therapymight become a novel strategy for breast cancer
prevention.
#1925 Modeling physiologic microenvironments in three-dimensional
microtumors facilitates brain tumor initiating cell maintenance.Ashley Gil-
bert,1 KieraWalker,2AnhTran,2 YanceyGillespie,2 Raj Singh,1Anita B.Hjelme-
land2. 1Vivo Biosciences, Birmingham, AL; 2Univ. of Alabama at Birmingham,
Birmingham, AL.
Development of effective novel anti-tumor treatments will require improved
in vitro models that incorporate physiologic microenvironments and maintain
intratumoral heterogeneity including tumor initiating cells. Brain tumor initi-
ating cells (BTIC) are a target for cancer therapy because they are highly tumor-
igenic and contribute to tumor angiogenesis, invasion, and therapeutic resis-
tance. Current leading studies rely on BTIC isolation from patient-derived
xenografts followed by propagation as neurospheres. As this process is expen-
sive and time-consuming, we determined whether three-dimensional microtu-
mors were an alternative in vitro method for modeling tumor growth via BITC
maintenance and/or enrichment. Brain tumor cells were grown as neurospheres
or asmicrotumors produced using a human-derived biomatrixHuBiogelTM and
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maintained with physiologically relevant microenvironments. Percentages of
BITCs were determined based on cell surface marker expression (CD133), label
retention (carboxyfluorescein succinimidyl ester; CFSE), and tumorsphere for-
mation capacity. Our data demonstrate that expansion of brain tumor cells as
hypoxic and nutrient restricted microtumors signifıcantly increased the per-
centage of both CD133 and CFSE cells. We further demonstrate that BTIC-
marker positive cells isolated from microtumors maintain neurosphere forma-
tion capacity in the in vitro limiting dilution assay and tumorigenic potential in
vivo. These data demonstrate that microtumors can be a useful three-dimen-
sional biological model for the study of BTIC maintenance and targeting.
#1926 The effect of Beta-Catenin upon the tumor molecular biology and
growth inHNSCC: role of cancer stem cells.AustinMaas, Anirban Chatterjee,
Lisa Sudmeier, Kwang Nickel, Randall J. Kimple. Univ. of Wisconsin-Madison,
Madison, WI.
Overview: Head and neck squamous cell carcinomas (HNSCC) are the sixth
most prevalent type of malignancy worldwide. Recent reports have demon-
strated that nearly every tumor contain a small subpopulation of cells called
cancer stem-like cells (CSCs), which are responsible for tumor maintenance,
metastasis relapse and therapeutic resistance. Recent studies demonstrate that
even established HNSCC cell lines contain a defınite sub-population of CSC
providing us with the opportunity to discerning their roles in progression, treat-
ment, and relapse of the disease. Background:Wehave previously demonstrated
that a defınite subpopulation of CSCs exists in most HNSCC cell lines. Signifı-
cant differences were seen between the HPV and HPV- subtypes, confırmed
by analyses of stem-ness genes and EMT markers. In vivo tumor xenograft
formation has established the heightened tumorigenicity of CSCs. We investi-
gated the molecular and functional roles of Beta-catenin in HNSCC CSCs by
shRNAknock down and then subjecting the knocked down (KD) cells to various
molecular analysis and in-vivo tumor formations in nude mice. We have also
identifıed SOX2 as a down-stream effector gene that could exert the tumor
promoting effects of Beta-catenin. The promoter region of the Sox2 gene was
found to contain several putative Beta-catenin binding sites.Methods&Results:
After identifying CSCs by in-vitro Sphere Forming (SFA) capabilities and mo-
lecular gene signatures, we have knocked down both Beta-catenin and Sox2 in
both HPV and HPV- HNSCC cell lines (UMSCC47 and UMSCC6). SFA with
the Beta-catenin KD-cells depicts a 50% decrease in sphere formation ability.
Molecular analyses show lower expression of stemness genes: Sox2 ( 3 fold)
and Oct4 ( 2 fold); metastatic genes: N-cadherin ( 2.5 fold), Vimentin ( 3
fold), Twist ( 4 fold), Snail ( 2.5 fold), Slug ( 2.5 fold) andHif-1alpha ( 1.5
fold). Two tissue microarrays (TMA) were stained for Oct4, Sox2, and CD44
gene expression by multiplex RNA in situ hybridization. Nearly all tumor cells
expressed high levels of CD44. Cells high in both Oct4 and Sox2 were quantifıed
within duplicate cores and correlated with local control (TMA-1) and radiation
response (TMA-2). Conclusions: Initial molecular analyses depicted that upon
loss of Beta-catenin, the crucial stem-ness genes are negatively affected and the
loss of stem-ness is also reinforced by decreased sphere formations. Both the
metastatic and hypoxic gene signatures are markedly altered. We expect similar
outcomes with the in-vivo tumor formations in nude mice.
#1927 The signifıcance of calreticulin in pancreatic cancer: a molecule
highly expressed in pancreatic cancer stem-like cells. Satoshi Matsukuma,1
Kiyoshi Yoshimura,2 Atsunori Oga,1 Moeko Inoue,2 Takuya Fujimtoto,1 Atsuo
Kuramasu,1 Masanori Fuse,2 Ryouichi Tsunedomi,1 Hidetoshi Eguchi,3 Hiroto
Matsui,1 Shinsuke Kanekiyo,1 Yukio Tokumitsu,1 Shinobu Tomochika,1Michi-
hisa Iida,1 Yoshihiro Tokuhisa,1 Kazuhiko Sakamoto,1 Nobuaki Suzuki,1 To-
moko Furuya-Kondo,1 Hiroshi Itoh,1 Shigeru Takeda,1 Shigeru Yamamoto,1
Shigefumi Yoshino,4 Shoichi Hazama,5 Tomio Ueno,1 Hiroaki Nagano1.
1YamaguchiUniversityGraduate School ofMedicine,Ube, Japan; 2National Can-
cer Center of Japan, Tokyo, Japan; 3Osaka University Graduate School of Medi-
cine, Suita, Japan; 4Yamaguchi University Hospital, Ube, Japan; 5Yamaguchi
University School of Medicine, Ube, Japan.
Cancer stem-like cells (CSLCs) in solid tumors are thought to be resistant to
conventional chemotherapy ormolecular targeting therapy and to contribute to
cancer recurrence andmetastasis. In this study,we aimed to identify a biomarker
of pancreatic CSLCs (P-CSLCs). P-CSLC-enriched population was generated
from pancreatic cancer cell lines using our previously reported method and its
protein expression profıle was compared with that of parental cells by two-
dimensional electrophoresis and tandem mass spectrometry. The results indi-
cated that a chaperone protein calreticulin (CRT) was signifıcantly upregulated
in P-CSLCs compared to parental cells. Flow cytometry analysis demonstrated
that CRT was mostly localized to the surface of P-CSLCs and did not correlate
with the levels of CD44v9, another P-CSLC biomarker. Furthermore, the side
population in CRThigh/CD44v9low population is much higher than that in
CRTlow/CD44v9high population. CRT expression was also assessed by immuno-
histochemistry in pancreatic cancer tissues (n  80) obtained after radical re-
section and was found to be associated with patients’ clinicopathological fea-
tures and disease outcomes in the Cox’s proportional hazard regression model.
Multivariate analysis identifıed CRT as an independent prognostic factor for
pancreatic cancer patients, along with age and post-operative therapy. Our re-
sults suggest that CRT can serve as a biomarker of P-CSLCs and a prognostic
factor associated with poorer survival of pancreatic cancer patients. This novel
biomarker can be useful for detecting P-CSLCs independently, which had been
detectable bymultiple surfacemarkers like CD24, CD44 and ESA.Wewill pres-
ent CSLCs properties of CRThigh population in P-CSLCs.
#1928 The lung microenvironment promotes stem-like phenotype and
behavior of breast cancer cells.Ashkan Sadri, Alison L. Allan.Western Univer-
sity, London, Ontario, Canada.
Ninety percent of breast cancer-related mortalities result from metastasis, a
processwhereby the primary tumour disseminates and targets distant secondary
organs. We have previously demonstrated that stem-like breast cancer cells ex-
pressing high levels of aldehyde dehydrogenase (ALDH) and CD44 are critical
for metastasis. These ALDHhiCD44 cells preferentially migrate and/or metas-
tasize to the lung and bone microenvironments, where secondary tumours can
severely impede organ function. However, the specifıc role of the lung and bone
marrow (BM) microenvironments in supporting and/or promoting metastasis
of ALDHhiCD44 cells remains poorly understood, and this is the purpose of
the current study. Using a 2D ex vivo model, lung and bone marrow (BM)
conditioned media (CM) enriched in tissue-specifıc soluble proteins were gen-
erated from murine tissues and utilized in cell culture to assess their ability to
influence the stem-like phenotype and behavior ofMDA-MB-468 human breast
cancer cells. Exposure to lung-CM promoted the generation of a viable, non-
adherent (“floating”) breast cancer cell subpopulation that was not observed in
response to BM-CM or basal media (p0.05). Phenotypic analysis by flow cy-
tometry and gene expression analysis by RT-qPCR revealed notable differences
in ALDH/CD44 phenotype in whole cell populations, adherent subpopulations,
and/or non-adherent subpopulations in response to 72 hour exposure to
lung-CM relative to basal media. In particular, the non-adherent breast cancer
cell subpopulation generated in response to lung-CM demonstrated increased
CD44 and ALDH1A3 gene expression and decreased ALDH1A1 gene expres-
sion relative to the adherent subpopulation (p0.05). No signifıcant phenotypic
or gene expression differences were observed in MDA-MB-468 breast cancer
cells in response to BM-CM. Taken together with our previous studies, these
fındings suggest that while both the lung and bone microenvironments support
breast cancer cells with a pre-existing ALDHhiCD44 phenotype, the lung mi-
croenvironment may additionally help to even further promote stem-like phe-
notype and behavior in the secondarymetastatic site. Ongoing studies are aimed
at elucidating the mechanisms by which aggressive ALDHhiCD44 breast can-
cer cells interact with and/or are influenced by the lungmicroenvironment dur-
ing metastatic progression.
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#1929 A novel orthotopic mouse model in sarcomas. Silvia Garcia Mon-
clús, Juan Huertas Martínez, Laura Lagares Tena, Santiago Rello Varona, Olga
Almacellas Rabaiget, David HerreroMartin, Roser López Alemany, OscarMar-
tinez Tirado. IDIBELL, Hospitalet de Llobregat, Spain.
Pediatric sarcomas are a heterogeneous group of bone and soft tissue malig-
nancies affecting children and young adults. One of the most important prog-
nostic factors of those diseases is the presence of metastasis at diagnosis. In that
context, we have developed a novel orthotopicmodel which consists in injecting
Ewing Sarcoma (ES) or Rhabdomyosarcoma (RMS) tumor cells at the gastroc-
nemiusmuscle ofmice and extracting the tumor at a of 10mmx 13mmvolume.
After surgery, animals maintain a complete functional extremity and can live
until lung metastasis detection (about 60 days post-injection). Moreover, we
have validated the suitability of the model with an Ewing Sarcoma EphA2-low
expression cell line. Epha2 is a tyrosine kinase receptor that has been found
overexpressed in a wide variety of tumors and correlated with malignant phe-
notype. In this studywe report that EphA2 receptor is phosphorylated at S897 in
a panel of ES cell lines, which is related to the oncogenic properties of the recep-
tor. Stable silencing of EphA2 in two different ES cell lines resulted in a decrease
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in the clonogenic, proliferation, migration and invasion capacity in vitro.More-
over, we performed an experimental metastasis assay, injecting tumor cells
through the tail vain of mice and observed a reduction in the lung metastasis
incidence in EphA2 silenced cells. We then used this new orthotopic metastasis
model to validate the impairment in the invasion capacity of EphA2 silenced
cells and confırm the decrease in lung metastasis incidence, indicating an onco-
genic role for EphA2 in ES. This novel orthotopic metastasis model is a valuable
tool both for the study of spontaneous metastasis and also for evaluating thera-
peutic index in the onset of metastasis, which can also be applied to the study of
other pedriatric sarcomas.
#1930 Evaluating the effect of PARP inhibitors in combination with nic-
otinamide phosphoribosyltransferase inhibitors inEwing sarcoma. JoshuaT.
Baumgart,1 Christine Heske,1 Mindy I. Davis,2 Kelli Wilson,2 Xiaoha Zhang,2
Rajarshi Guha,2 Marc Ferrer,2 Arnulfo Mendoza,1 Craig J. Thomas,2 Lee J. Hel-
man1. 1National Cancer Institute, Bethesda,MD; 2National Center for Advancing
Translational Sciences, Rockville, MD.
Previous research has shown that Ewing sarcoma cells are sensitive to PARP
inhibition, but in vivo studies and early phase clinical trials have failed to dem-
onstrate meaningful responses to PARP inhibitors when used as single agents.
For this reason, studies combining PARP inhibitors with other agents to en-
hance their effects in Ewing sarcoma are of particular interest. PARP, an enzyme
involved inDNAdamage repair, relies onNAD to function. In tumor cells,NAD
production occurs primarily through the salvage pathway, in which nicotin-
amide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme.Hence,
the combination of PARP andNAMPT inhibitionwould be expected to enhance
the activity of PARP inhibition through depletion of cellular NAD. The aim of
this study was to assess the synergistic potential of PARP inhibition in combi-
nation with NAMPT inhibition in Ewing sarcoma cell lines and xenograft mod-
els. Synergistic drug combinations in Ewing sarcoma cells were initially identi-
fıed using a high-throughput matrix drug screen. In vitro activity was further
assessed using proliferation assays of multiple Ewing sarcoma cell lines treated
with the PARP inhibitor niraparib and the NAMPT inhibitor GNE-618. In vitro
measurement of PAR activity was performed to further understand the mecha-
nism of action of the combination. For in vivo studies, female SCID-biege mice
were orthotopically injected with Ewing sarcoma cells and randomized into
treatment groups of vehicle, niraparib,GNE-618, or the combination. The initial
screen revealed synergy betweenNAMPT inhibitors and PARP inhibitors using
multiple combinations of different agents in each drug class. In vitro assays of
the combination of niraparib with GNE-618 confırmed the results of the screen.
Assays measuring PAR activity yielded results supporting the hypothesis that
dual inhibition of NAMPT and PARP depletes PARP more than PARP inhibi-
tors alone. In vivo studies with short term (5 day) dosing showed no activity of
single agent nirapirib and only temporary disease stabilization with single agent
GNE-618. However, mice treated with the combination underwent tumor re-
gressions resulting in prolonged survival. When treatments were extended to 2
cycles (5 days each), the effect persisted for longer. Mice tolerated the agents
well, with no signs of toxicity. Preclinical data suggest that PARP inhibition in
combination with NAMPT inhibition may be a promising therapeutic strategy
for Ewing sarcoma patients.
#1931 The fırst circulating tumor cell detection technique from frozen
PBMCs. Heming Li,1 Izhar Singh Batth,1 Xueqing Xia,1 Frank J. Hsu,2 Neeta
Somaiah,1 Keila Enitt Torres,1 RuoyuWang,3 Shulin Li1. 1MDAnderson Cancer
Center, Houston, TX; 2Immune Design, South San Francisco, CA; 3Zhongshan
Affıliated Hospital of Dalian University, Dalian, China.
Circulating tumor cells (CTCs) enter the vasculature or lymphatic system
after shedding from the primary tumor. CTCs may serve as “seed” cells for
tumor metastasis. The utility of CTCs in clinical application is not fully investi-
gated, partly due to the necessity for fresh blood samples and the lack of CTC
specifıc antibody. Of note, there is no CTC detection tool for pediatric tumors.
To overcome these drawbacks, we developed a protocol for CTC capture from
frozen peripheral blood mononuclear cells (PBMCs) based on the cell-surface
vimentin (CSV) antibody 84-1. CSV is a uniquemarker compared to others such
as EpCAM because it is only specifıc to tumor cells and has been demonstrated
to be a viable target for isolation and enumeration of CTCs across tumor types.
In this study,we report the fırst CTC isolation technology from frozenPBMCsof
osteosarcoma patients using the CSV antibody 84-1. The CTCs captured using
this new protocol were validated by single cell gene sequencing analysis and
mesenchymalmarker-SMA staining.Moreover, spiking analysis was also per-
formed to ensure the specifıcity and sensitivity of this unique CTC capture
analysis. Linear regression analysis yielded a positive correlation between the
number of detected sarcoma cells and the number of sarcoma cells spiked in
both fresh and frozen PBMCs. In summary, our results demonstrate for the fırst
time, a technology to specifıcally detect and isolate mesenchymal origin CTCs
from frozen PBMCs. This technology can be easily expanded to other types of
cancers including pediatric tumors because the antibody used is universal and
CTC specifıc. Such a technology will boost the feasibility and utility of CTC-
based diagnosis and therapeutic treatment monitoring in a centralized labora-
tory.
#1932 Mutations in ATRX increase genetic instability and sensitivity to
PARP inhibitors in paediatric glioblastoma cells. Janat Fazal-Salom, Mara
Vinci,DianaCarvalho,HelenPemberton, Stephen J. Pettitt, Christopher J. Lord,
Alan Mackay, Lynn Bjerke, Chris Jones. Institute of Cancer Research, London,
United Kingdom.
Paediatric glioblastomas (pGBM) are amongst the most common causes of
cancer-related deaths in children, and are defıned by highly recurrentmutations
in H3 histones. Mutations affecting the chromatin remodeling protein ATRX
have been reported in 30% of pGBM cases, and are strongly associated with the
alternative lengthening of telomeres (ALT) phenotype, but their precise inter-
action with histone mutations and their role in tumorigenesis remain unclear.
We collected sequence data from 262 published and 64 unpublished cases of
pGBM and identifıed somatic ATRXmutations in 54/326 (17%) of cases. ATRX
mutations aremainly loss of functionmutations, with themajority of frameshift
mutations (37/54, 68,5%) found upstream of the helicase domain resulting in
truncation of themain functional domain of ATRX.Missensemutations (16/54,
29,6%) reside almost exclusively in the helicase domain (11/54, 20,4%), whereas
nonsensemutations are a less common event (7/54, 13%) but present in both the
helicase (4/7, 57,1%) and ADD domains (3/7, 42,9%). ATRX mutations com-
monly co-segregate with H3.3 G34 (16/54) and TP53 (42/54) mutations, and
defıne a subgroup of patients with a longer overall survival (16 months median
overall survival in mutant ATRX cases versus 11 months in wild-type ATRX
cases, COXPH p 0.079), though with a greater number of somatic mutations
(MWU p 0.023) and copy number alterations (MWU p 0.0011) than wild-
type cases. We screened a series of 21 primary patient-derived pGBM cell cul-
tures for histone and ATRX mutation status in addition to ATRX protein ex-
pression and ALT, and subjected the panel to a high-throughput in vitro cell
viability screen of400 chemotherapeutics and small molecules. We identifıed
a specifıc genetic dependency for ATRX mutation and sensitivity to distinct
PARP inhibitor chemotypes, including olaparib and rucaparib (PARP catalytic
inhibitors), and talazoparib (PARP trapper inhibitor). These datawere validated
using CRISPR-Cas9-engineered ATRX knockout, targeting either the ADD or
helicase domain, in SF188 pGBM cells. Gene editing was confırmed by IonTor-
rent sequencing and Western blot. ATRX mutant clones were also more sensi-
tive to drugs targeting DNA damage response pathways such as bleomycin and
sapacitabine. Gene expression analysis of ATRX mutant pGBM samples con-
fırmed an intact homologous recombination pathway and overexpression of
PARP1, suggesting an underlying mechanism distinct from that observed in
BRCA-mutant breast and ovarian cancers. Ongoing work is aimed at unravel-
ling the specifıc pathways involved, and evaluating the utility of PARP inhibition
in orthotopic pGBM xenografts in vivo. These data suggest a synthetic lethality
for PARP inhibitors in ATRX-defıcient pGBM cells, and may represent a novel
therapeutic strategy for these highly aggressive tumours in children.
#1933 Discovery of fırst-in-class small molecule CD99 inhibitors for tar-
geted therapy of Ewing sarcoma.Haydar Celik,1 Marika Sciandra,2 Bess Flash-
ner,1 Elif Gelmez,1 Neslihan Kayraklıoğlu,1 David V. Allegakoen,1 Jeff R. Petro,1
Erin J. Conn,1 Sarah Hour,1 Jenny Han,1 Lalehan Oktay,1 Purushottam B. Ti-
wari,1 Mutlu Hayran,3Maria CristinaManara,2 Jeffrey A. Toretsky,1 Katia Scot-
landi,2 Aykut Uren1. 1Georgetown University Medical Center, Washington, DC;
2Rizzoli Orthopaedic Institute, Bologna, Italy; 3Hacettepe University, Ankara,
Turkey.
Ewing sarcoma (ES) is an aggressive bone and soft tissue malignancy that
affects predominantly children and adolescents with a high propensity to me-
tastasize and poor prognosis. CD99 is a transmembrane cell surface protein that
is highly expressed on ES cells, and routinely used as a marker for histological
diagnosis of ES. We screened small molecule libraries for their binding to re-
combinant CD99 protein and subsequent selective inhibition of ES cell growth.
We identifıed two structurally similar FDA-approved nucleoside analogues, clo-
farabine and cladribine that selectively inhibited the growth of ES cells in a panel
of 14 ES vs. 28 non-ES cell lines. A signifıcant negative correlation was found in
human cell lines between CD99 expression and IC50 values for clofarabine and
cladribine. Both drugs inhibited CD99 dimerization and its interaction with
downstream signaling components cyclophilinA and PKA-RII as well as led to
reduced ROCK2 protein expression and migration in ES cells. A membrane-
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impermeable analog of clofarabine showed similar cytotoxicity in ES cells, sug-
gesting that it can function through inhibiting CD99 alone without any effect on
DNA metabolism. Clofarabine and cladribine led to a signifıcant increase in
hypodiploid DNA content of ES cells, which was diminished by suppression of
CD99 expression. Both drugs drastically inhibited anchorage-independent
growth of ES cells, but clofarabinewasmore effective in inhibitingES xenografts.
Finally, the screening of a set of chemotherapy drugs revealed a synergy for the
combination of anti-CD99 drugs and dasatinib in ES cells, which may translate
into increased survival and reduced toxicity. Overall, our fındings suggest that
clofarabine is a good candidate for early phase clinical trials in children with ES.
#1934 Retinoic acid and DFMO induce differentiation and inhibit tumor
formation in neuroblastoma. Austin Voydanoff,1 Ping Zhao,2 Abhinav Nagu-
lapally,2 Jeff Bond,2 Giselle L. Sholler2. 1Michigan State University, Grand Rap-
ids, MI; 2Helen DeVos Children’s Hospital, Grand Rapids, MI.
Background: A key component of high risk neuroblastoma (NB) therapy in-
volves cis-retinoic acid (RA) for differentiation of minimal residual disease.
DFMO induces differentiation and inhibition of tumor formation through the
targeting of cancer stem cell (CSC) pathways via reversal of the Lin28/Let7 axis.
Preventatitve DFMO therapy is currently in a phase II clinical trial at the end of
therapy and in a Pilot study in combination with RA and ch14:18 antibody. We
hypothesize that the combination of cis-RA and DFMO will induce greater
differentiation, inhibition of tumor formation, and reduction of cell prolifera-
tion of NB. Methods: NB cell lines SMSKCNR, BE2C and CHLA90 were incu-
bated in 96 well plates for 24 and 48 hours with low doses of DFMO (2.5 and 5
mM), RA (5 and 10 M), and the four combinations of dosages. A Calcein AM
Cell Viability Assay and BrdU Cell Proliferation Assay Kit were used to deter-
mine cell viability and cell proliferation, respectively. Western blot analysis was
used to measure protein levels of CSC and differentiation markers. A neuro-
sphere assay was used to assess inhibition of CSCs and tumor formation within
wells. Cells were plated 2 cells/well in 96 well plates, drugged with single agents,
cominbation, or DMSO and the percentage of wells per plate that formed neu-
rospheres was determined after 1 and 2 weeks. IncuCyte ZOOM Live-Cell Im-
aging system was used for kinetic monitoring of neurite length to assess differ-
entiation of NB cells. Results: Low dose RA and DFMO combination treatment
(2.5-5mMDFMO and 5-10 MRA) resulted in decreased cell viability as dem-
onstrated through calceinAM.DFMOandRA combination treatments reduced
cell viability by 60-71%, 75-78%, and 83-91%, in Be2C, CHLA90, and SMSR
cells, respectively. BrdU incorporation demonstrated a reduction in cell prolif-
eration at 48 hours of was 69-70.%, 60.2-64.5%, 62.7-71.1% in Be2c, CHLA90,
and SMSR, respectively. Western blot analysis showed that DFMO, RA, and
their combination reduced the CSC and increased the differentiationmarkers at
48 hours compared to control. The combination treatment also decreased tumor
formation; the relative reduction inneurosphere formation at 2weekswas 34.5%
with 2.5 mM DFMO, 48% with 5 M RA, and 73.2% with combination treat-
ment. Lastly, differentiationwas shown by neurite length increased by a factor of
1.4-1.6 and 5, in SMSRandBE2C cells, respectivelywith combination treatment.
Conclusion: This study indicates that the combination retinoic acid and DFMO
effectively cause a decrease in cell viability with a reduction in cell proliferation.
Further, the combination results in differentiation ofNB cells aswell as targeting
of CSC pathways and inhibition of tumor formation. Preventative DFMO ther-
apy has been initiatied with RA in a pilot study for the treatment of high-risk
neuroblastoma patients.
#1935 Molecular characterization of orthotopic patient-derived xeno-
graft models of pediatric brain tumors. Sebastian Brabetz,1 Susanne N. Gröb-
ner,1 Huriye Seker-Cin,1 Florian Selt,2 Till Milde,2 David T. Jones,1 Madison T.
Wise,3 Jessica M. Rusert,4 Kyle Pedro,3 Andy Strand,3 Olaf Witt,2 Sarah E.
Leary,3 Xiao-Nan Li,5 Robert J. Wechsler-Reya,4 James M. Olson,3 Stefan M.
Pfıster,2 Marcel Kool1. 1German Cancer Research Center (DKFZ) and German
Cancer Consortium (DKTK), Heidelberg, Germany; 2German Cancer Research
Center (DKFZ), German Cancer Consortium (DKTK), Center for Individualized
Pediatric Oncology (ZIPO) and Pediatric Brain Tumors, Department of Pediatric
Oncology, University Hospital and National Center for Tumor Diseases (NCT),
Heidelberg, Germany; 3Fred Hutchinson Cancer Research Center and Seattle
Children’s Hospital, Seattle, WA; 4Sanford Burnham Prebys Medical Discovery
Institute, Heidelberg, CA; 5Baylor College of Medicine, Houston, TX.
[Introduction: Solid tumors of the nervous system are the most common child-
hood cancers after leukemias. Even thoughwemight be able to curemore andmore
patients, survivors still severely suffer long-term from the intensive treatments.
Therefore, new treatment strategies are urgently needed. Orthotopic patient-de-
rived xenograft (PDX)models are an excellent platform for biomarker and preclin-
ical drug development. However, the rarity of pediatric brain tumors and the mul-
titude of different sub entities hinder the generation of large collection of PDX
modelsof specifıc entitieswithin single institutions. Inorder togenerateanoverview
aboutexistingPDXmodels in thecommunity,westartedcollectingestablishedPDX
models from various centers all over the world and performed extensive molecular
characterization to precisely determine the distinct molecular subgroup and con-
stellation of genetic alterations for each PDXmodel, and thus identify its targetable
oncogenic drivers.Material andMethods: PDXmodels were established andmain-
tained by dissociating tumor material into a single cell suspension and then ortho-
topically injecting it into thebrainof immunodefıcientanimals.AllPDXmodelsand
matching primary tumors (if available) have been analyzed by whole-exome and
low-coverage whole-genome sequencing, as well as DNA methylation and gene
expression profıling at the German Cancer Research Center (DKFZ). Results and
Discussion: Thus far, we have collected and characterized 70 establishedPDXmod-
els from 6 ATRTs, 8 ependymomas, 16 high-grade gliomas, 38 medulloblastomas,
and 2 CNS-PNETs. PDX models always retain their molecular subtype and in the
vast majority of cases also the mutations and copy number alterations when com-
pared to their primary tumors. Only in rare cases do we observe additional aberra-
tions,whichmost likely representoutgrowthsof subclones fromtheprimary tumor.
Analysis of our entire cohort identifıed anoverrepresentationof themost aggressive
tumor subtypes, but also subtypes which have not been available for preclinical
testing before due to lack of genetically engineered mouse models or suitable cell
lines, such as Group 4 medulloblastoma. Based on our current analysis, the PDX
models within the community are not yet covering the entire heterogeneity within
the patient population. As a follow up, we aim to make these models and data
accessible in a user-friendly manner so that the community can use them for pre-
clinical research. Conclusion: PDXmodels of pediatric brain tumors are very rare.
Ourmolecular characterizationallows researchers all over theworld to fınd the right
models for their specifıc scientifıc question. Therefore, this work will provide an
unprecedented resource to study tumor biology and pave the way for improving
treatment strategies for children withmalignant brain tumors.
#1936 Epigenetic challenges in derivation of the fırst cell-based model of
Beckwith-Wiedemann Syndrome. Stella K. Hur,1 Joanne L. Thorvaldsen,1 Suhee
Chang,1 Carolyn Lye,1 Alice Yu,2 Monserrat C. Anguera,3 Marisa S. Bartolomei,1
JenniferM.Kalish2. 1Perelman School ofMedicine at theUniversity of Pennsylvania,
Philadelphia, PA; 2Children’s Hospital of Philadelphia, Philadelphia, PA; 3University
of Pennsylvania School of VeterinaryMedicine, Philadelphia, PA.
Beckwith-Wiedemann Syndrome (BWS) is a cancer predisposition syndrome
that affects at least 1 in 10,500 children. Up to 25% of children with BWS develop
tumors, primarily Wilms tumor and hepatoblastoma. BWS is due to genetic or
epigenetic changes that affect imprinted loci on chromosome 11 and these same
changes are also found in other types of cancer. There are no cell-based models of
BWS andmostmousemodels do not recapitulate the tumor phenotype. To under-
stand more about the mechanisms leading to tumor formation in BWS, we devel-
oped the fırst human cell-based model of BWS. Human induced pluripotent stem
cell (iPSC)models are commonly used to study disease mechanisms in tissue types
that are not normally accessible for study. In the case of BWS, we plan to use such
models to study how the genetic and epigenetic changes in BWS lead to tumor
formation in hepatic and renal cells. Using skin fıbroblasts from four BWSpatients,
we derived the fırst iPSCmodels of BWS. Prior to iPSCderivation,we characterized
different tissues available from these four patients, and demonstrated geneticmosa-
icism in different tissue types, including blood, skin, and pancreas. During the der-
ivation process, we demonstrated that both normal and BWS iPSC lines could be
derived from the same patient fıbroblast sample and the number of clones of each
type from each sample approximated the initial level of mosaicism in the original
sample. For each patient, these lines are isogenic except for the BWS critical region.
The BWS and isogenic normal iPSCs were characterized for pluripotency markers
and demonstrated to have normal karyotypes. Following this analysis, BWS and
isogenic normal lines were characterized extensively for DNA methylation at spe-
cifıc imprinted loci in both early passage and extended culture.Methylation analysis
wasperformedbybothpyrosequencingandCOBRAassays.Methylationwasmain-
tained at some imprinted loci but not at others in extended culture. Importantly,
relatively stable methylation levels were observed at the BWS critical imprinted
regions (H19/IGF2 and KvDMR), regardless of methods of reprogramming, indi-
cating a relatively stable state of DNAmethylation in this region. Additionally, nor-
malmethylationwas seenat the SNRPNlocus. In contrast, another imprinted locus,
IG/MEG3, displayed abnormal hypermethylation in iPSCs. These data indicate that
reprogramming and extended culture of iPSCs can affect stability of DNAmethyl-
ation at certain imprinted loci. Therefore caution should be used in interpreting
studies using iPSCs as these aberrant methylation states at imprinted loci can affect
the downstream functionality of iPSC models. BWS iPSCs and isogenic controls
with normal methylation will be used for further study of the mechanism of tumor
formation in BWS.
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#1937 Evolution of neuroblastoma patient-derived orthotopic xenografts
through space and time. Noémie Braekeveldt,1 Susanne Fransson,2 Kristoffer
von Stedingk,3 Ingrid Öra,3 Rosa Noguera,4 Tommy Martinsson,2 David Gis-
selsson Nord,5 Sven Påhlman,1 Daniel Bexell1. 1Translational Cancer Research,
Lund University, Lund, Sweden; 2Department of Clinical Genetics, Sahlgrenska
UniversityHospital, Gothenburg, Sweden; 3Department of Paediatrics, LundUni-
versity, Lund, Sweden; 4Department of Pathology, Medical School, University of
Valencia, Valenica, Spain; 5Department of Clinical Genetics, Lund University,
Lund, Sweden.
Background: Recently, we established orthotopic neuroblastoma patient-derived
xenografts (PDXs)whichmaintain thephenotypic, genomic, andstromalhallmarks
of patient tumors. Here we examined how PDXs evolve following years of in vivo
growth. Materials and Methods: We established up to eight in vivo generations of
neuroblastoma orthotopic PDXs through serial passaging in NSG mice. RNA se-
quencing, exome sequencing and SNP array analysis were used to analyze patient
tumors and PDXs from different in vivo generations. Results: Using SNP analysis,
we found mostly a remarkable genomic stability at chromosomal level between
patient tumors, early and late PDX generations. RNA-seq revealed that patient tu-
mors expressed higher levels of genes involved in immune responses and ECM
metabolism compared to PDXs. Different PDX samples clustered correctly into
their respective tumor type. PDXs from all early generations did not separate from
PDXsfromlategenerations.Thus, geneexpression levels are surprisinglyoftenquite
stable despite years of in vivo growth. To shed light on neuroblastoma intratumor
heterogeneity, we implanted 10 different tumor fragments from a single patient
tumor into mice. We classifıed the 10 mice into three groups based on the time
periods required for tumor growth. RNA-seq showed that each of these groups had
a distinct gene expression profıle andpathways involved in neuroblastomaprogres-
sion have been identifıed. Conclusions: Neuroblastoma orthotopic PDXs are often
very stable at chromosomal and gene expression levels despite years of in vivo
growth. We utilized multiple PDXs to show functional intratumor heterogeneity
coupled to distinct gene expression profıle.
#1938 Exportin-1 (XPO1) is a novel therapeutic biomarker for patients
with neuroblastoma. Basia Galinski,1 Marcus Luxemburg,1 Michelle Ewart,2
Yosef Landesman,3 Daniel Weiser1. 1Albert Einstein College of Medicine, Bronx,
NY; 2Montefıore Medical Center, Bronx, NY; 3Karyopharm Therapeutics, New-
ton, MA.
Background: Half of patients with high-risk neuroblastoma succumb to disease,
yet these patients with inferior outcome cannot be identifıed at diagnosis despite
contemporary risk stratifıcation that integrates MYCN copy number status, tumor
histology, and patient age. We have shown that overexpression of Exportin-1
(XPO1) is associated with poor survival in neuroblastoma, affırmingwhat has been
identifıed across a range ofmalignancies. Selinexor (KPT-330, KaryopharmThera-
peutics), an XPO1 inhibitor in early phase clinical trials, inhibits the nuclear to
cytoplasmic translocation of tumor suppressor and growth regulatory proteins im-
plicated in oncogenesis. We hypothesized that protein expression level of XPO1 in
neuroblastoma cell lines predict the effective response of treatment with selinexor.
Methods:We used a panel of early passage patient derived neuroblastoma cell lines
including IMR5,NLF,KELLY,NB-EBC1, andSKNSHthat are representative of the
spectrum and genetic diversity of human disease. Cell lines were treated with vary-
ing concentrations of selinexor. RNA and whole cell protein extract as well as nu-
clear and cytoplasmic fractionatedproteinwas obtained fromuntreated and treated
conditions. Treated and untreated cells were also pelleted, and, along with patient
tumor samples, formalin-fıxed and paraffın-embedded formicroscopic and immu-
nohistochemical (IHC) evaluation. Results: Compared to noncancerous cell lines,
neuroblastoma cell lines have high protein andmRNA expression of XPO1; higher
expression correlates with greater sensitivity to selinexor. Selinexor treatment re-
ducedXPO1 protein and increased XPO1mRNA expression, and it lead to nuclear
retention of XPO1 cargo such as p53 and survivin. Comparison of microscopic
features andprotein staining intensity of patient sampleswith knownXPO1expres-
sion is ongoing.Conclusions: This studyprovides rationale forXPO1protein abun-
dance as a potential biomarker of therapeutic response to the drug selinexor. By
usingpatientderivedneuroblastomacell lines,weareable toevaluate theresponseof
selinexor and XPO1 expression in the context of this enigmatic disease. These data
suggest that initial drug response to selinexor can be predicted early in the course of
disease andmore investigation of the high expression ofXPO1 seen in patientswith
poor outcome will provide strategies for combinatorial treatment approaches.
#1939 Loss of MST/Hippo signaling promotes tumorigenesis in a geneti-
cally engineered mouse model of fusion-positive alveolar rhabdomyosar-
coma.KristianneOristian, Lisa E. Crose, Rex Bentley,NinaKuprasertkul, David
G. Kirsch, Corinne Linardic. Duke University, Durham, NC.
While improvement in survival for pediatric cancer patients over the last 40 years
has been encouraging, certain cancer types evade cure. One such example is fusion-
positive alveolar rhabdomyosarcoma (aRMS), a pediatric soft tissue sarcoma of
mesenchymal origin with skeletal muscle features and a 5-year survival rate of
50%. A hallmark of this aggressive malignancy is the t{2;13} translocation fusion
gene PAX3-FOXO1 (PF). Primary cell-basedmodeling experiments in our labora-
tory and others have shown that PF is necessary but not suffıcient for aRMS tumor-
igenesis, indicating additionalmolecular alterations are required to initiate and sus-
tain tumor growth. Previously we showed that PF-positive aRMS tumorigenesis
relies on alterations inHippopathway signaling, including upregulation of theYAP
transcriptional co-activator, and downregulation of the MST/Hippo kinase, which
occurs when the scaffold protein RASSF4 (itself a PF transcriptional target) binds
and inhibitsMST1/Hippo.We hypothesized that ablatingMST/Hippo signaling in
anexistinggenetically engineeredmousemodel (GEMM)ofaRMSwouldaccelerate
tumorigenesis and provide insight into the role of this pathway in aRMS. To assess
the role of MST/Hippo signaling in aRMS, MST1/2-floxed (Stk3F/F;Stk4F/F) mice
were crossed with an established MSTWT aRMS GEMM driven by conditional ex-
pression of Pax3-Foxo1 from the endogenous Pax3 locus and conditional loss of
Cdkn2a in Myf6-expressing cells. Statistical analysis revealed that compared to
MSTWT aRMS control animals, MSTNull have signifıcantly accelerated tumorigen-
esis (median survival 112 vs. 224 days, p 0.0001) and increased tumor penetrance
(76% vs. 27%). MSTNull animals developed tumors disproportionately in the head
andneckas compared to control, and incurredmultiple tumorsper animal.Tumors
were analyzed via immunohistochemistry for MyoD and myogenin, markers of
RMS, as well asMyf5, an earlymarker ofmyogenesis. Tumors in both cohorts were
for positive for aRMSmarkers. Tumor-derived cell lines were used for in vitro cell-
based assays and molecular interrogation. We have identifıed the MST/Hippo sig-
naling axis as an important tumor suppressormechanism in aRMS.The rapid onset
and increased penetrance of tumorigenesis in this GEMMprovides a powerful tool
for interrogating aRMS biology and screening novel therapeutics.
#1940 Prenatal stress increases malignancy of neuroblastoma tumors in
TH-MYCN animal model. Sung Hyeok Hong, Larissa Wietlisbach, Susana
Galli, AkankshaMahajan, Shiya Zhu, Jason Tilan, Yichien Lee, Olga Rodriguez,
Chris Albanese, JoannaKitlinska.GeorgetownUniversityMedical Center,Wash-
ington, DC.
Neuroblastoma (NB) is a pediatric malignancy arising due to defects in sympa-
thetic neuron differentiation.NB is a heterogeneous disease, with phenotypes rang-
ing fromspontaneously regressing tohighly aggressive, incurable tumors. This clin-
ical variability cannot be explained solely by genetic aberrations. Even in families
with hereditaryNB the penetrance of the disease is incomplete and the same genetic
mutation often results in tumorswith phenotypes varying fromdifferentiating gan-
glioneuromas to undifferentiated, highly aggressiveNBs. Thus, other, perhaps non-
genetic factors can contribute to thedisease development andmodify its phenotype.
Strikingly, the two factors promoting de-differentiation ofNB cells and theirmalig-
nant phenotype, hypoxia and glucocorticoids, are elevated in the fetus during ma-
ternal stress, suggesting a role for prenatal stress in NB tumorigenesis. Previously,
usingTH-MYCNmice as amodel of aggressiveNB,wehave shown that an increase
inmaternal corticosterone levelsduringpregnancyattainedby insertingslowrelease
pellets resulted in increased tumor frequency in TH-MYCN offspring. The goal of
the current studywas to determine the effect of prenatal stress onNBmetastasis. To
this end, pregnant mice carrying TH-MYCN hemizygous offspring were subjected
to chronic stress at embryonic days 10-17, the time of sympathetic neuroblast pro-
liferation and differentiation. Two established stress paradigmswere used - chronic
unpredictable stress, in which mice were subjected daily to various stressors, and
chronic cold stress comprising of daily 30min exposure to cold. The phenotypes of
the disease and its dissemination were compared between offspring of control and
stressedmothers.Theoffspring frombothprenatally stressedgroupspresentedwith
moremalignant disease, asmanifested by the presence of advanced lungmetastases
disseminating from small primary tumors (200mm3). This phenotype was asso-
ciated with increased mortality in prenatally-stressed TH-MYCN offspring
(p0.01). In contrast, no advanced lung metastases and no disease-related deaths
were observed in TH-MYCN offspring of control mothers despite the presence of
largeprimary tumors (1,000mm3).Althoughnotcommon, lungmetastasesoccur
preferentially in NB patients with MYCN amplifıcation and are associated with
signifıcantly worse prognosis, as compared to patients with metastatic disease, but
no pulmonary involvement (14 vs 43% 3-year event-free survival, respectively).
Thus, the profound pulmonary dissemination observed in prenatally-stressed TH-
MYCNmicemimics one of themostmalignantNBphenotypes observed inhuman
disease.Altogether, our data implicatematernal stress during pregnancy as a poten-
tial environmental factormodifying theeffectsofgeneticaberrationsandpromoting
malignant phenotype of NB.
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#1941 Cell surface vimentin is a novel marker for CTC detection in neu-
roblastoma. Izhar S. Batth,1 Heming Li,1 Giselle Saulnier Sholler,2 Shulin Li1.
1UT MD Anderson Cancer Center, Houston, TX; 2Helen DeVos Children’s Hos-
pital, Grand Rapids, MI.
Among children in the United States, brain cancers now account for most
number of cancer-related deaths. Neuroblastomas (NB) and sarcomas account
for 13% of all childhood cancers in the United States. Despite signifıcant prog-
ress yielding increased 5-year survival, 1250 deaths are expected this year from
childhood cancers and cancer incidence has been steadily increasing. One of the
key contributors to cancer mortality is tumor metastasis. It is generally believed
that CTCs are shed into the circulation from primary tumors and contain
unique driver mutations enabling their aggressive phenotype. However, detec-
tion of CTCs from NB is diffıcult as there is no direct method. Our lab has
developed a monoclonal antibody targeting vimentin on the cells’ surface. Cell
surface vimentin (CSV) is only observed in tumor cells; it remains intracellular
in normal cells. We have published data demonstrating the superior specifıcity
and sensitivity of our approach in breast, colon, and prostate cancer. Here, we
report direct CTC detection in NB using our CSV mAb. As part of our collab-
orative effort analyzing NB blood samples from a multicenter Phase II trial, we
present novel discoveries regarding treatment of NB with difluoromethylorni-
thine (DFMO) and its effects on CTC release into the circulation in patients
under remission. Among our observations, approximately 1/3 patients have
lowornoCTCswhile1/4with highnumbers ofCTCare responding toDFMO
treatment. Remaining patients show oscillating CTC numbers. Further, treat-
ment with DFMO showed a statistically signifıcant decline in CTCs after the
beginning of therapy. Ongoing work including whole genome analysis can pos-
sibly reveal new insight into CTCs’ entering the circulation. These data demon-
strate that our CTC capture using CSV is a novel and unique approach for
detection in NB.
#1942 The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor,
OT-82, exhibits in vitro and in vivo effıcacy against patient-derived xenograft
models of high-risk acute lymphoblastic leukemia. Kathryn Evans,1 Tara
Pritchard,1 Michelle J. Henderson,1 Klaartje Somers,1 Mawar Karsa,1 Leanna
Cheung,1 Raymond Yung,1 StephenW. Erickson,2 Lioubov Korotchkina,3 Olga
Chernova,3 Andrei Gudkov,4 Malcolm A. Smith,2 Richard B. Lock1. 1Children’s
Cancer Institute, Sydney, Australia; 2National Cancer Institute,MD; 3Oncotartis,
Inc., Buffalo, NY; 4Roswell Park Cancer Institute, Buffalo, NY.
Cancer cells are highly dependent on nicotinamide phosphoribosyltrans-
ferase (NAMPT) for the biosynthesis of nicotinamide adenine dinucleotide
(NAD). Besides its role in energy metabolism, NAMPT influences the activ-
ity of NAD-dependent enzymes, including poly (ADP-ribose) polymerase-1
(PARP-1) and sirtuins, and thereby regulates cellular survival and stress re-
sponse. Disruption of NAD synthesis through NAMPT inhibition represents a
potential therapeutic strategy for treating cancer. The aim of this study was to
evaluate the effıcacy of the novel NAMPT inhibitor OT-82, initially isolated for
its selective toxicity against a panel of adult leukemia cell lines, in a diverse panel
of leukemia cell lines in vitro and pediatric acute lymphoblastic leukemia (ALL)
patient-derived xenografts (PDXs) in vivo, and to identify potential biomarkers
predictive of OT-82 response. OT-82 demonstrated low nanomolar IC50 values
(0.9 – 3.4 nM) in 3ALL and 3 acutemyeloid leukemia cell lines as determined by
resazurin reduction assays. In vivo effıcacy of OT-82 (40 mg/kg x 3 days x 3
weeks, p.o.) was evaluated as a single agent against pediatric ALL PDXs, includ-
ing B-cell precursor ALL (n 3), Philadelphia chromosome (Ph) positive ALL
(n 2), Ph-like ALL (n 2), T-cell ALL (n 3), and early T-cell precursor ALL
(n 3) in immune defıcient (NSG)mice. Response to treatment was assessed by
time to event or stringent objective response criteria modeled after the clinical
setting. OT-82 was well tolerated, signifıcantly increased event-free survival
(EFS) relative to control mice in 11/13 ALL PDXs, and elicited objective re-
sponses in 11/13 (85%) PDXs [3 Partial Responses, 4 Complete Responses (CRs)
and 4 Maintained CRs (MCRs)]. Analysis of basal protein expression revealed
elevated levels of poly (ADP-ribosyl)ated (PARylated) PARP-1 in 4/5 respond-
ers versus 0/2 non-responders. In vitro studies examining various chemothera-
peutic agents used for childhood leukemia showed synergy between cytarabine
(AraC) and OT-82 in an ALL cell line. In an OT-82 sensitive Mixed Lineage
Leukemia (MLL) PDX, treatment with AraC (25 mg/kg x 5 days x 2 weeks, i.p.)
and OT-82 (40 mg/kg x 3 days x 2 weeks, p.o.) signifıcantly increased EFS com-
pared to OT-82 (P0.0001) or AraC (P0.0001) alone. Moreover, the OT-82/
AraC combination elicited an MCR compared to OT-82 (CR) and AraC (Pro-
gressive Disease) alone. The results herein demonstrate signifıcant activity of
OT-82 against leukemia cell lines and a range of pediatric ALL subtypes in vivo,
and the potential for PARylated PARP-1 expression as a biomarker for predict-
ing OT-82 response. Moreover, the enhanced activity of OT-82 in combination
with AraC over single agent therapy further suggests NAMPT inhibition as
an attractive strategy for treating high-risk pediatric ALL. Supported by
U01CA199000 from the NCI.
#1943 High-throughput chemical screening identifıes Focal AdhesionKi-
nase and Aurora Kinase B inhibition as a synergistic treatment combination
in Ewing sarcoma.BrianCrompton,1 SarahWang,1 ElizabethHwang,1 Rajarshi
Guha,2MatthewBoxer,2 CrystalMcKnight,2Min Shen,2NicoleMelong,3 Chan-
sey Veinotte,3 Amy Conway,1 Jason Berman,3 Matthew Hall,2 Mindy Davis,2
Kimberly Stegmaier1. 1Dana-Farber/Boston Children’s Cancer and Blood Disor-
der’s Center, Boston,MA; 2National Center for Advancing Translational Sciences,
Bathesda, MD; 3Dalhousie University, Halifax, Nova Scotia, Canada.
Ewing sarcoma is the secondmost commonbonemalignancyof childhood.Cur-
rent treatment employs chemotherapy, surgery, and radiation. Although this ap-
proach cures approximately 70% of patients with localized disease, treatments are
largely ineffective for patients with metastases or relapse. Furthermore, these treat-
ments are associated with an alarming rate of long-term toxicities. New treatment
combinations are necessary to improve cures and lower toxicities for these patients.
Werecently foundthatEwingsarcoma isdependenton focal adhesionkinase (FAK)
for cell viability and tumor proliferation. In order to identify candidate treatment
combinations for Ewing sarcoma, we performed a screen of 1912 compounds to
identify those with synergistic anti-Ewing activity when combined with FAK inhi-
bition. The A673 Ewing cell line was treated with PF-562271, a FAK-specifıc inhib-
itor, in combination with compounds from the Mechanism Interrogation PlatE
(MIPE) 4.0 library. Cell viabilitywasmeasured after 48 hours of treatment.Multiple
computational metrics were utilized to identify and rank all compound combina-
tions for synergistic impairment of cell viability. Multiple Aurora kinase inhibitors
scored as synergistic with FAK inhibition in this screen. Aurora kinases are impor-
tant in the regulation ofmitosis and are highly expressed in Ewing sarcoma tumors
and cell lines. We found that Aurora kinase B inhibitors were synergistic across a
larger rangeof concentrations thanAurorakinaseAinhibitorswhencombinedwith
FAK inhibition in multiple Ewing cell lines. We found that AZD-1152, an Aurora
kinase B-selective inhibitor, and PF-562271 when used in combination induced
apoptosis in Ewing cells at concentrations that had minimal effect on cell survival
when either drug was used alone.We also found that the combination signifıcantly
impaired tumor proliferation in zebrafısh xenograft models of Ewing sarcoma and
prolonged survival inmurine xenografts compared to either single-agent treatment
alone. Interestingly, treatment with AZD-1152 alone also signifıcantly impaired tu-
morproliferation andprolonged survival compared to vehicle treatment in amouse
xenograft model of Ewing sarcoma. Our data demonstrate that FAK and Aurora
kinase B inhibition synergistically impair Ewing sarcoma cell viability in vitro and
signifıcantly inhibit tumor proliferation in vivo. With multiple FAK and Aurora
kinase inhibitors in early phase trials for adult malignancies, these results have the
potential to be translated into clinical trials for patients with Ewing sarcoma. Previ-
ous studies have also suggested a dependency of Ewing sarcoma on Aurora kinase
activity;ourdata further supportsa role forAurorakinaseB inhibitorsas therapeutic
candidates in this disease.
#1944 Tazemetostat displays synergistic antiproliferative activity with
backbone therapies in preclinical models of AT/RT and MRT. Christine R.
Klaus, Jeffrey A. Keats, Jesse J. Smith, Richard Chesworth, Robert A. Copeland,
Scott Ribich, Alejandra Raimondi. Epizyme, Inc., Cambridge, MA.
Malignant Rhabdoid Tumors (MRT) and Atypical Teratoid Rhabdoid Tu-
mors (AT/RT) are typically pediatric cancers which are rare and aggressive with
extremely high unmet medical need. At a molecular level MRT and AT/RT
tumors are almost universally characterized by loss of the INI1 protein (also
known as SNF5 or SMARCB1), a component of the Switch Sucrose Non-fer-
mentable (SWI/SNF) multimeric chromatin modifying complex. In many cell
types, the SWI/SNF complex and the PRC2 complex have an antagonistic rela-
tionship in the regulation of tumor suppressor genes, cell cycle checkpoints,
hedgehog and myc pathway genes, among others [Wilson et al, Cancer Cell.
2010 Oct 19;18(4):316-28.]. This explicated the possibility of a novel treatment
modality for these tumors, based on inhibition of EZH2 - the catalytic subunit of
PRC2. Tazemetostat (EPZ-6438) is a potent and orally bioavailable small mole-
cule inhibitor of EZH2 currently in phase 2 clinical trials in adult patients with
non-Hodgkin lymphoma, INI1-negative tumors and mesothelioma. Depen-
dency of INI1-negative tumors on EZH2 catalytic activity was demonstrated in
preclinical models of MRT, where robust tumor regressions were induced with
tazemetostat treatment [Knutson et al, Proc Natl Acad Sci USA. 2013 May
7;110(19):7922-7]. Consistent with this, tazemetostat demonstrated activity in
relapsed or refractory patients with INI1-negative tumors enrolled in the adult
phase 1 clinical trial. In addition, a phase 1 dose escalation study in pediatric
patients with INI1-negative solid tumors is currently ongoing. Backbone thera-
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pies for MRT and AT/RT are comprised of cytotoxic chemotherapy which may
or may not be administered in the context of stem cell transplant, in addition to
surgical resection and radiation therapy. In support of combination clinical
scenarios including EZH2 inhibition in this setting, we sought to explore the
antiproliferative effects of combining tazemetostat with current small molecule
treatment therapies in cell line models of AT/RT and MRT. Synergistic activity
was observed when tazometostat was combined with individual components of
chemotherapeutic regimens and targeted therapies such as vincristine, doxoru-
bicin, alisertib and HDAC inhibitors.Further, we investigated the effects of ion-
izing radiation together with tazemetostat treatment. Application of X-ray irra-
diation concomitantly or after tazemetostat treatment, induced robust
antiproliferative activity and reduction in clonogenic potential of both AT/RT
cell lines tested.Taken together these results suggest that pharmacological inhi-
bition of EZH2 enhances the activity of backbone therapy and may have an
advantage overmonotherapy in INI1-negative cancers supporting the therapeu-
tic potential of combination regimens that include tazemetostat in these tumors.
#1945 PPM1D/Wip1, promising new target in childhood cancers neuro-
blastoma andmedulloblastoma. JelenaMilosevic,1 Nina Eissler,1 Diana Treis,1
Malin Wicktröm,1 Susanne Fransson,2 Baldur Sveinbjornsson,3 Ninib Baryawno,1
Subazini Kosalai,2 Chandrasekhar Kanduri,2 Kazuyasu Sakaguchi,4 Tommy Mar-
tinsson,2 John Inge Johnsen,1 Per Kogner1. 1Karolinska Institutet, Stockholm, Swe-
den; 2University of Gothenburg, Gothenburg, Sweden; 3University of Tromsö,
Tromsö, Norway; 4Hokkaido University, Sapporo, Japan.
Background: The most common cytogenetic lesions in the embryonal neural
tumors medulloblastoma (MB) and neuroblastoma (NB) affect chromosome 17,
with 17q or isochromosome 17q, in approximately one-third of MB with these
aberrations being a signifıcant indicator of poor clinical outcome. Similarly, in NB
gainof 17q is themost powerful genetic predictor of adverse clinical outcome. 17q
correlates with poor survival in our population-based material where we found
aberrations of chromosome 17 in 85%of primary neuroblastomas, specifıcally, gain
of PPM1D/Wip1 at 17q23.Wip1 is a serine/threonine phosphatase encoded by the
gene PPM1D, described as a gatekeeper in theMdm2-p53 regulatory loop involved
in genetic stability, inflammation and a potential oncogene contributing to carcino-
genesis. Methods: Comparative genomic hybridization (CGH), immunostaining,
mRNA arrays, qPCR, exome- and RNA-sequencing was used to examine PPM1D/
Wip1 in neuroblastoma and medulloblastoma. Genetic and pharmacological inhi-
bition was used to analyze the function of Wip1 in preclinical neuroblastoma and
medulloblastomamodels. Results: CGH-array analysis detected PPM1D/Wip1 ex-
tra copies in all tumors and cell lines containing 17q-gain. Expression arrays and
immunostaining showedhighexpressionofWip1 inneuroblastomacorresponding
to poor survival. RNA sequencing confırmed PPM1D-gain and revealed truncated
isoformswith oncogenic potential. Exome-sequencing detected amutation leading
to constitutive PPM1D/Wip1 activation in an aggressive metastatic infant neuro-
blastoma.Wip1 knockdown experiments showed signifıcant decrease of cell viabil-
ity, proliferation and colony formation aswell as substantial increase ofDNA-dam-
age response in neuroblastoma and medulloblastoma cells. Tumor neuroblastoma
xenograft development was signifıcantly delayed showing median tumor develop-
ment (0.10 mL) to be more than doubled (median 15 days, vs. 33 days, p0.001)
afterWip1 downregulation compared to scrambled controls. A novelWip1 inhibi-
tor was highly potent in cytotoxic/cytostatic effect in neuroblastoma and medullo-
blastoma cell lines. Furthermore, thisWip1 inhibitor signifıcantly inhibited growth
of established human neuroblastomas and medulloblastomas in nude mice after
treatment (P0.01). Conclusions: Our results show that PPM1D/Wip1 is onco-
genic in neuroblastoma andmedulloblastoma development.We propose three dif-
ferent ways on how PPM1D/Wip1 is activated: due to chromosomal gain, alterna-
tive RNA-isoforms and/or DNA-mutation. PPM1D/Wip1 provides a novel
therapeutic target in neuroblastoma andmedulloblastoma.
#1946 Synergistic effects of theXPO1 inhibitor selinexorwith proteasome
inhibitors in pediatric high-grade glioma and diffuse intrinsic pontine gli-
oma. John DeSisto,1 Patrick Flannery,1 Trinayan Kashyap,2 Rakeb Lemma,1
Shelby Mestnik,3 Andrew Kung,4 Rajeev Vibhakar,1 Yosef Landesman,2 Adam
Green1. 1University of ColoradoAnschutzMedical Campus, Aurora, CO; 2Karyo-
pharm Therapeutics Inc., Newton, MA; 3Rocky Vista University College of Osteo-
pathic Medicine, Parker, CO; 4Memorial Sloan Kettering Cancer Center, New
York, NY.
Background: Pediatric high-grade gliomas (HGG) and diffuse intrinsic pon-
tine gliomas (DIPG) account for the majority of pediatric brain tumor deaths
and respond poorly to chemotherapy. Selinexor, a nuclear export inhibitor, is
effective against HGG andDIPG in in vitro and in vivomodels, but resistance to
treatment develops. We previously identifıed the NF-B pathway as a likely
mediator of selinexor’s activity in these tumors. NF-B transcriptional activity is
regulated by an inhibitor, IKB-, whose levels are in turn regulated by ubiquiti-
nation and proteasomal degradation. IKB- is a client of exportin-1 (XPO1); its
nuclear levels are increased by selinexor treatment, leading to inhibition of NF-
B. We subsequently identifıed proteasome inhibitors as potentially synergistic
with selinexor in HGG and DIPG through a screen of all FDA-approved che-
motherapy agents. Proteasome inhibition has also been shown to synergize with
selinexor treatment in multiple myeloma and osteosarcoma. Methods: We
treated HGG cell lines (BT245 and GBM1) and DIPG cell lines (DIPG4, DIPG7
and SF7761) for fıve days with selinexor in combination with each of three
proteasome inhibitors, bortezomib, carfılzomib and marizomib, and assayed
cell viability at the conclusion of treatment. In each experiment, cells were
treated with selinexor, a proteasome inhibitor, and a combination of the two
drugs at several constant ratios. IC50 values were computed for each drug acting
alone, and the combination index (CI) of the two drugs acting together was
computed using the Chou-Talalay method. We also treated SF7761 cells with a
combination of radiation (8Gy), selinexor, and a proteasome inhibitor. Results:
The proteasome inhibitors had widely varying IC50 values in the cell lines
treated, ranging from 1nM to 5M.TheCI for the combination of selinexor and
each proteasome inhibitor was consistently less than 1 (indicating a synergistic
relationship) in the cell lines tested. We found that radiation and proteasome
inhibition had an antagonistic relationship (CI1), radiation and selinexor a
synergistic relationship (CI1), and the combination of all three was mixed,
with some combinations being synergistic and others antagonistic. Conclusions:
Selinexor and proteasome inhibitors showpromise as a combination therapy for
HGG and DIPG.We are conducting in vivo experiments to further explore this
combination for subsequent clinical trial use.
#1947 Combination of Vincristine and Clotam induces antiproliferative
response in medulloblastoma cells. Shruti V. Patil,1 Don Eslin,2 Robert Sut-
phin,2 Umesh T. Sankpal,1 Yazmin Hernandez,1 Areeba Hafeez,1 W. Paul Bow-
man,1 Riyaz Basha1. 1University of North Texas Health Science Center, Fort
Worth, TX; 2Arnold Palmer Hospital for Children, Orlando, FL.
Medulloblastoma (MB) is themost commonpediatricmalignant brain tumor
and usually originates in the cerebellum. These tumors have the propensity to
disseminate throughout the central nervous system and are often diffıcult to
treat. Chemotherapy is widely accepted as part of the multimodality treatment
approach forMB. However, it is associated with debilitating toxicity and poten-
tial long term disabilities. Vincristine is a commonly used chemotherapeutic
agent forMB treatment. This drug is known to induce some toxic effects includ-
ing peripheral neuropathy. The aim of this study was to test a combination
treatment involving Vincristine and an anti-cancer non-steroidal anti-inflam-
matory drug, Clotam (Tolfenamic acid) against MB cell lines. Previously, we
showed that Clotam inhibited MB cell proliferation and tumor growth in mice
by targeting the transcription factor, Specifıcity protein1 (Sp1) and an inhibitor
of apoptosis protein, BIRC5 (baculoviral inhibitor of apoptosis repeat-contain-
ing 5). The overexpression of BIRC5 is associated with aggressiveness and poor
prognosis in several cancers. MB cells, DAOY and D283 cells were treated with
vehicle (dimethyl sulfoxide) or low dose of Vincristine (DAOY: 2ng/ml; D283:
1ng/ml) or Clotam (DAOY&D283: 10g/ml) or combination of Vincristine
Clotam and the cell viability was measured at 1 and 2 days post-treatment using
Cell-TiterGlo kit. Flow cytometry was employed to analyze apoptotic cells using
Annexin-V staining and cell cycle phase distribution using propidium iodide
staining. The activation of apoptotic pathways was further investigated by as-
sessing the levels of effector caspases with CaspaseGlo kit and the expression of
apoptotic markers [cleaved Poly (ADP-ribose) polymerase (c-PARP), B-cell
lymphoma 2, and BIRC5] by Western blot analysis. The expression of key pro-
teins associated with cell cycle (Cyclin A, B, D, CDK4/6, and p21) was also
determined byWestern blot analysis. When compared to individual agents, the
combination of Clotam and Vincristine increased MB cell growth inhibition
which is accompanied by an induction of apoptoticmarkers and themodulation
of (Cyclin A, B, D and CDK4/6: down-regulation; p21: up-regulation) proteins
associated with cell cycle phase distribution. These results suggest that Vincris-
tine and Clotam combination treatment is effective for inducing anti-prolifera-
tive effect inMB cells. The experiments to evaluate the effect of this combination
in animal model for MB are currently under study.
#1948 Tumor-specifıc copy number alterations uncover therapeutic op-
portunities in osteosarcoma. Leanne C. Sayles,1 Marcus Breese,2 Amanda L.
Koehne,2 Stanley Leung,1 Aviv Spillinger,1 Alex Lee,1 Avanthi Shah,1 Krystal
Straessler,2 Sheri Spunt,2 Neyssa Marina,2 Damon Jacobson,3 Raffı S. Avedian,2
David G. Mohler,2 Steven DuBois,4 Douglas S. Hawkins,3 E. Alejandro Sweet-
Cordero1. 1UCSF, San Francisco, CA; 2Stanford, Stanford, CA; 3University of
Washington, Seattle, WA; 4Dana-Farber Cancer Institute, Boston, MA.
TUMOR BIOLOGY: Pediatric Cancer 1: Biomarkers, Preclinical Models, and New Targets
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017500
Osteosarcoma (OS) is a highly malignant cancer for which no targeted ther-
apies are currently available. Current treatment modalities are limited to inten-
sive, highly toxic chemotherapy and surgical resection. OS is characterized by
wide spread copy number alterations and structural rearrangements. In con-
trast, no recurrent pointmutations in protein-coding genes have been identifıed,
suggesting that copy number alterations (CNAs) are key oncogenic drivers in
this disease. However, as copy number alterations are highly heterogeneous, it is
likely that each tumor has a distinct set of oncogenic drivers, making a unifıed
treatment approach diffıcult to defıne. To identify candidate patient-specifıc
drivers, we used a simple heuristic based on degree of amplifıcation (as assessed
byWhole Genome Sequencing) and changes in gene expression (as assessed by
RNA sequencing). Using patient-derived tumor xenografts (PDTXs), we as-
sessed if individualOS tumors respond to targeted therapy selected based on this
approach. We rank-ordered CNAs in 9 PDTXs by the amplitude of the copy
number gain and identifıed 5 pathways for targeted therapy including CCNE1,
MYC, CDK4, PTEN/AKT and AURKB. Next, we prioritized drug choices to
those that are in clinical trials and that are readily available and identifıed 5 drug
matches for 9 PDTXs. We used the CDK2 inhibitor Dinaciclib for CCNE1 am-
plifıcation and observed TGI of 85.5% and 67.8% for 2 different CCNE1 ampli-
fıed PDTXs tested. CDK9 inhibitor AT7519 was used to treat 2 different MYC
amplifıed PDTXs resulting in TGI of 104% and 83.9%. CDK4 amplifıed PDTXs
were treated with CDK4/6 inhibitor, Palbociclib, resulting in TGI of 82.7%.
AKT1 inhibitor MK-2206 was used to treat either AKT1 gains or PTEN loss
resulting in TGI of 65.6% and 60.8% respectively. AURKB inhibitor AZD-1152
for AURKB amplifıed PDTXs in combination with cisplatin resulting in TGI
85.8%. These results support the hypothesis that specifıc genes within CNA
regions serve as oncogenic drivers and that these represent therapeutic oppor-
tunities in OS. Our studies provide a roadmap for personalized genome-in-
formed therapy of osteosarcoma, a cancer in which no new therapies have been
identifıed in over 30 years.
#1949 Salvage pathway enzymeHPRT as amolecularmarker for Burkitt’s
Lymphoma. Michelle H. Townsend, John Ellis Lattin, Michael D. Anderson,
Abigail Felsted, Edwin Velazquez, Evita Weagel, Richard Robison, Kim L.
O’Neill. Brigham Young University, Provo, UT.
The aim of this study is to investigate the potential of Hypoxanthine phos-
phoribosyltransferase (HPRT) as a surface biomarker and target for future im-
munotherapies in Burkitt’s B-cell Lymphoma. B-cell malignancies are the most
common type of childhood cancer. Development of immunotherapies could
improve current treatment. HPRT is a cytosolic transferase involved in nucleo-
tide production via the purine salvage pathway. Altered expression of TK1, a
salvage pathway enzyme, is an indicator of prognosis and diagnosis in multiple
cancer types due to active proliferation of cells and the resulting elevated nucle-
otide demand. It has previously been reported that some salvage pathway en-
zymes are found on the surface of Burkitt’s Lymphoma cells. HPRT presence on
the surface of this B-cell lymphoma subtype could provide a target for adoptive
cell transfer and other immunotherapies. The potential surface presentation of
HPRTwas assessed using flow cytometry, scanning electronmicroscopy (SEM),
and cytoplasmic staining on both healthy lymphocytes andBurkitt’s Lymphoma
cells (Raji). Flow cytometry experiments withHPRT antibodies and fluorescent-
labeled secondary antibodies show that Raji cells exhibit an 81.4% (p-
value.0001) positive fluorescence shift when compared to IgG controls (1.5%).
Healthy lymphocytes had a fluorescence shift of 2.38% (p-value.9787). The pres-
ence of HPRT on the surface of both Raji cells and healthy lymphocytes was
further confırmed using gold-labeled antibodies. Utilizing a scanning electron
microscope, the presence of the protein on the surface was evaluated and quan-
tifıed via increases in gold weight percentage of the sample. When treated with
antibodies against HPRT, there was a signifıcant increase in gold binding along
with an increase in gold weight percentage. These results suggest a direct rela-
tionship between HPRT and the surface of Burkitt’s lymphoma cells, indicating
HPRT as a potential target for future immunotherapeutic treatment in Burkitt’s
B-cell lymphoma pediatric patients.
#1950 Introducing c-Myc into transformed human mesenchymal stem
cells and osteoblasts to recapitulate the osteosarcoma phenotype. Sajida Pip-
erdi (Thein),1 Wendong Zhang,1 Daria Ivenitsky,1 Yidan Zhang,1 Yunjia
Zhang,1 David S. Geller,2 Bang Hoang,2 Rui Yang,2 Jonathan B. Gill,1 Michael
Roth,1 Richard Gorlick1. 1Albert Einstein College ofMedicine and The Children’s
Hospital at Montefıore, Bronx, NY; 2Montefıore Medical Center, Bronx, NY.
Osteosarcoma (OS) is themost common primarymalignant bone tumor in chil-
dren and young adults. It remains unclear at what point in the pathway of differen-
tiationbetweenhumanmesenchymal stemcells (hMSCs) andosteoblasts (OBs),OS
originates. Since high grade OS frequently demonstrates histologic variability, as
well as the potential for multi-lineage differentiation, some consider the
hMSC as the cell of origin in OS, whereas others believe the osteoblast to be
the most likely cell of origin. Identifying the primary cell of origin is crucial
in understanding the molecular pathogenesis of OS. To address the potential
for hMSCs or OBs to transform into OS, we have performed insertional
mutagenesis in hMSCs and OBs with defıned genetic elements which have
the potential to lead to tumorigenesis and whose pathways have been altered
in OS patient specimens. Serial introduction of the viral constructs hTERT
(T), SV40Tag (S), and H-RAS (R), led to spindle cell tumor formation in
mice. However, MSC-TSR tumors did not form osteoid, whereas OB-TSR
tumors showed only scant production of osteoid. Also the addition of
-catenin to MSC-TS cells failed to lead to tumor formation in mice. Based
on these fındings, MSC-TS and OB-TS cell lines may be ideal platforms for
further analysis of the impact of the genetic transformation of hMSCs and
OBs into OS. c-Myc has been shown to be overexpressed in OS cells and
hence has been suggested as an oncogene. It has been also suggested as a
novel target of RUNX2 through rescue from the apoptosis. MSC-TS and
OB-TS cells were transformed with a retrovirus containing human c-Myc.
Drug resistant colonies were picked up 21 days after selection to obtain
stably transformed cell lines. Quantitative PCR and western blots were car-
ried out to detect both gene and protein expression patterns in transformed
cell lines, respectively. Furthermore, in order to determine the expression
pattern of c-Myc in OS, quantitative PCR and western blots were also per-
formed on human osteosarcoma primary samples, xenografts and cell lines.
All functional assays outlined below will be performed to determine the
tumorigenic properties of transformed cell lines. Six out of seven (86%)
osteosarcoma primary samples showed a signifıcantly greater c-Myc gene
expression level compared to the positive control cell lines. Selection of
stably transformed clones and comparison between cell lines and character-
izations are underway. Further ongoing characterization includes: soft agar
assays, in-vivo tumorigenic assays, histological examination for osteoid pro-
duction and other OS specifıc immunohistochemical markers, proliferation,
invasion and migration, and differentiation assays. It is our hope that this
study will highlight the model that closely recapitulates the human osteosar-
coma phenotype by forming a malignant spindle cell tumor that produces
aberrant osteoid, and has the potential for multi-lineage differentiation.
#1951 ROR activation opposes MYCN signaling and restores the circa-
dian clock in neuroblastoma. Myrthala Moreno-Smith,1 Ling Tao,1 Ronald
Bernardi,1 Kathleen De Preter,2 Mario Capasso,3 Sanjeev Vasudevan,1 JasonM.
Shohet,1 Eveline Barbieri1. 1Baylor College of Medicine, Houston, TX; 2Ghent
University, Houston, Belgium; 3University of Napoli, Italy.
Background. MYCN activation is a hallmark of advanced tumor stage in
neuroblastoma (NB), characterizing high-risk patients prone to resistant dis-
ease. MYCN is also a potent regulator of metabolic reprogramming that favors
NB adaptation to its microenvironment. The retinoic acid receptor-related or-
phan receptor (ROR) is a key regulator of cell metabolism, immunity, as well
as the circadian rhythm. Importantly, ROR activates the transcriptio of
BMAL1, a master circadian transcription factor frequently deregulated in hu-
man cancers. Moreover, synthetic ligands ROR agonists (i.e. SR1078) have
been recently optimized with great therapeutic potential. Methods.Multivariate
logistic regression analysis identifıed low levels of ROR as independent predic-
tors of EFS and OS survival in large NB patients’ cohorts (n890 patients).
MYCN inducible over-expression and knock-down NB lines were generated
and Q-PCR assays used to assess MYCN-mediated disruption of central com-
ponents of the clock machinery. Growth-suppressive and pro-apoptotic effects
of genetic ROR over-expression andROR activation (via SR1078)were tested
in a panel of MYCN-amplifıed and non-amplifıed lines, as well as in MYCN-
inducible MYCN-3 cells (Tet-ON). MYCN-amplifıed xenografts were used to
test in vivo therapeutic response to SR1078. Results. Ectopic MYCN expression
upregulates the circadian repressor REV-ERB and suppresses the circadian
activator ROR and the central clock BMAL1. In contrast, MYCN silencing
effectively restores their expression levels. Interestingly, the expression of the
main regulators of the clock machinery (ROR, REV-ERB, and BMAL1) are
also profoundly altered in MYCN-amplifıed NB patient samples. Specifıcally,
ROR and BMAL1 are uniformly repressed in MYCN-amplifıed NB and their
reduced levels independently correlate with poor survival in large patients’ co-
horts (n890 patients total, p0.0001). Importantly, re-activation of ROR
(via SR1078) strongly suppresses MYCN transcription and restores BMAL1
levels, inhibiting cell survival. Moreover, SR1078 reduces cell viability and in-
duces apoptotic cell death to a higher extent in MYCN-amplifıed compared to
MYCN-non amplifıed lines. Lastly, both SR1078 treatment and inducible ROR
over-expression signifıcantly (p0.020) inhibit tumor growth in MYCN NB
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xenografts. Together, our data suggest that ROR loss promotes MYCN-in-
duced disruption of molecular clock, contributing to NB tumorigenesis. Resto-
ration of ROR opposes theseMYCN functions, representing an effective strat-
egy for MYCN-amplifıed NB.
#1952 Epigeneticmodifıers outperform chemotherapy in prolonging sur-
vival in patient-derived xenograft models of Down syndrome AML. Sonali P.
Barwe, E A. Kolb, Anilkumar Gopalakrishnapillai. Nemours/A. I. duPont Hos-
pital for Children, Wilmington, DE.
Children with Down syndrome (DS) are at a 500-fold increased risk for de-
veloping acute myeloid leukemia (AML) before they reach fıve years of age.
DS-AML blasts have somatic mutations in the gene encoding the essential he-
matopoietic transcription factor GATA-1 resulting in hypersensitivity to che-
motherapeutic drugs such as cytarabine and daunorubicin. However, therapy-
induced toxicity results in greater morbidity and remains a major barrier in
attaining higher survival rate. Thus, alternate therapy approaches to minimize
toxicity and increase effıcacy are needed. Trisomy 21 and GATA-1mutations in
DS-AML are known to alter the epigenetic landscape in multiple ways. There-
fore, we evaluated the effıcacy of epigenetic drugs in comparison to chemother-
apy in two patient-derived xenograft (PDX) models of DS-AML.We developed
two distinct PDX models by successfully engraftment and serial passage of pri-
mary DS-AML cells in NSG-B2m mice. Both PDX lines possessed GATA-1
mutation resulting in the expression of a truncated form of GATA-1. NTPL-60
had a nonsense mutation generating a premature stop codon after the initiation
codon, while NTPL-386 had a 136 bp deletion in exon 2 resulting in the loss of
the initiation codon. The mouse passaged cells were intravenously injected into
6-8 week old NSG-B2mmice. Once disease establishment was confırmed based
on the presence of human cells in mouse peripheral blood, fıve mice per group
were treated with vehicle or DNAmethylation inhibitor azacitidine and histone
deacetylase inhibitor panobinostat either singularly or in combination at a pre-
viously determined maximally tolerated dose of 2.5 mg/Kg each. NTPL-386
xenografted mice treated with azacitidine or panobinostat survived 29 and 21
days longer than the vehicle-treated mice respectively, while the mice treated
with the combination survived the longest (35 days). Similarly, azacitidine and
panobinostat extended the survival of mice transplanted with NTPL-60 by 48
and 31 days respectively compared to the vehicle-treated mice. NTPL-60 mice
treated with the epigenetic drug combination are alive at 57 days. Thus, we
observed that the azacitidine-panobinostat combination showed statistically
signifıcant (p  0.0001) differences in leukemic burden and mouse survival
compared to treatments with either drug alone in bothNTPL-386 andNTPL-60
PDX models. We also tested the effıcacy of epigenetic therapy followed by che-
motherapy. The inclusion of epigenetic therapy before chemotherapy prolonged
survival by 39 days compared to vehicle-treated mice. Taken together, our data
indicate that epigenetic therapy may be of benefıt for the treatment of children
with DS-AML.
#1953 Accelerating prediction of pediatric and rare cancer vulnerabilities
using next-generation cancer models. Yuen-Yi Tseng,1 Andrew Hong,1 Paula
Keskula,1 Shubhroz Gill,1 Jaime Cheah,2 Grigoriy Kryukov,1 Aviad Tsherniak,1
Francisca Vazquez,1 Glenn Cowley,1 Sahar Alkhairy,1 Coyin Oh,1 Anson Peng,1
Rebecca Deasy,1 Abeer Sayeed,1 Peter Ronning,1 Samuel Ng,3 Steven Corsello,1
Corrie Painter,1 David Sandak,4 Levi Garraway,3 Mark Rubin,5 Calvin Kuo,6
Sidharth Puram,7 DavidWeinstock,3 Adam Bass,3 Nikhil Wagle,3 Keith Ligon,3
Katherine Janeway,3 David Root,1 Stuart Schreiber,1 Paul Clemons,1 Aly
Shamji,1 Aly Shamji,1 William Hahn,3 Todd Golub,1 Jesse Boehm1. 1The Broad
Institute ofMIT andHarvard, Cambridge,MA; 2Massachusetts Institute of Tech-
nology, Cambridge,MA; 3Dana-Farber Cancer Institute, Boston,MA; 4Rare Can-
cer Research Fundation, Durham, NC; 5Weill CornellMedical College, NewYork,
NY; 6Stanford University, Palo Alto, CA; 7Massachusetts General Hospital, Bos-
ton, MA.
Ongoing pre-clinical efforts aim to deploy genome-scale CRISPR/Cas9 tech-
nology and large collections of small molecules to catalog maps of cancer vul-
nerabilities at scale. However, such efforts in pediatric and rare cancers have
lagged behind comparable efforts in more common cancer types due to the
dearth of cell models. Here, we present an update from our “Cancer Cell Line
Factory” project on efforts to overcome key laboratory and biologistics chal-
lenges precluding progress in pediatric and rare cancers. This effort, now in it’s
3rd year, represents an industry scale pipeline aiming to generate, characterize
and share novel cancer models of many tumor types with the scientifıc commu-
nity. Overall, we have processed 1153 samples from 818 patients across over 16
cancer types through this pipelinewith a 28% success rate overall, including over
350 patient samples from rare and pediatric cancers. To optimize conditions for
each tumor type,we have systematically compared publishedmethods including
(1) next-generation 2-dimension, (2) organoid and (3) standard approaches and
have captured all information with a data management system that should en-
hance the ability to predict optimal ex vivo propagation conditions for future
samples. Among the successful cell models verifıed already as part of this effort,
we have generated a series of over 30 unique pediatric and rare cancer models,
many of which represent the fırst of their kind. We screened these and other
models against a library of highly annotated 440 small molecules that were
previously tested against 860 existing cancer cell lines. Our results suggest that
dependency data generated with novel next-generation cell cultures is poten-
tially backwards-compatible with existing small molecule dependency datasets.
Furthermore, we tested the novel Broad Institute Drug Repurposing library
consisting of 4100 approved therapeutics, or those under investigation for any
disease, against the fırst cell line models of several of these rare next generation
models including angioimmunoblastic T-cell lymphoma and renal medullary
carcinoma, leading to several novel drug repurposing hypotheses for rare can-
cers. Given these proof-of-concept studies, in partnership with the Rare Cancer
Research Foundation, we launched an onlinematchmaking platform to connect
patients with rare cancers to available research studies, facilitate online consent
and provide biologistics support to enable fresh tissue donation to support can-
cer model generation from any clinical site in the United States. We will present
results from this novel direct-to-patient approach to facilitate the generation of
even larger numbers of next generationmodels from rare and pediatric cancers,
propelling the generation of pre-clinical dependency maps of these tumors for
the scientifıc community.
#1954 Metabolic serum signatures as potential prognostic biomarkers for
neuroblastoma patients.Richa Jain, KirandeepGill, LeonQingliang Li, Amrita
K. Cheema, Joanna B. Kitlinska. Georgetown Univ., Washington, DC.
Neuroblastoma (NB) is a pediatricmalignancy with phenotypes varying from
spontaneously regressing to metastatic tumors. Thus, disease stratifıcation and
the subsequent treatment decision is of utmost importance for NB patients. The
methods, which are currently available for prognosis, require complex genetic
analyses and access to the tumor tissue. Thus, there is a need for new prognostic
and predictive markers that reflect the NB biology and rely on simple tests and
easily accessible material. Serum metabolite profıles reflect a combination of
factors released by the tumors and the general metabolic state of the patients.
Thus, identifying the differences in metabolites between patients with various
tumor phenotypes and responses to treatment may lead to discovery of biolog-
ically relevant prognostic biomarkers. The goal of our study was to determine
blood-based metabolic signatures characteristic for patients with low and high-
risk NB and identify potential biomarkers of high-risk disease. Plasma samples
from NB patients at different stages of the disease were obtained from the Chil-
dren’s Oncology Group. Initially, 50 samples were analyzed by Ultra Perfor-
mance Liquid Chromatography (UPLC) in conjunction with electrospray-
quadrupole-time of flight mass spectrometry (ESI-Q-TOF). A set of 26
independent plasma samples was then used for validation study. Statistically
signifıcant differences in metabolic profıles were observed between serum from
patients with low and high risk disease, various stages of the disease (stage 1-2 vs
stage 3 and/or stage 4), as well as undifferentiated vs. differentiating tumors. For
all comparisons, the metabolic signatures consisting of metabolites signifıcantly
different between the groups exhibited high test sensitivity and specifıcity (the
area under the ROC curves 0.92-1). Metabolites that were dysregulated in high
risk NBs included those involved in energy and choline metabolism, as well as
amino acid and lipid biosynthesis. Of particular interest was a signifıcant in-
crease in serum levels of oxoglutaric acid observed in patients with high-risk
disease (p0.01) and metastatic tumors (p0.001). As oxoglutaric acid is a key
metabolite of the tricarboxylic acid (TCA) cycle that is involved in regulation of
the balance between glutamine and glucosemetabolism, aswell as lipid synthesis
and hypoxia response, these data warrant further investigations into the biolog-
ical role of these pathways in biology of high risk NB. In summary, using a
metabolomics approach we were able to delineate blood based biomarkers that
could potentially be used for patient stratifıcation following large scale valida-
tion studies.
#1955 Targeting ribonucleotide reductase (RNR) in Ewing sarcoma. Kelli
Goss, Stacia Koppenhafer, Kathryn Harmoney, David Gordon. University of
Iowa, Iowa City, IA.
Ewing sarcoma is a highly aggressive bone and soft tissue cancer that is caused
by the EWS-FLI1 fusion protein. The EWS-FLI1 oncoprotein functions, in part,
as an aberrant transcription factor and is required for tumor growth and sur-
vival. In order to identify downstream targets of EWS-FLI1, we used human
embryonic stem cells that express inducible EWS-FLI1 to model the initiation
and development of Ewing sarcoma in a genetically defıned system. We then
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used this model system and a gene expression based approach to identify that
Ewing sarcoma cells are uniquely vulnerable to inhibitors of ribonucleotide
reductase (RNR), which impair DNA replication by blocking the synthesis of
deoxyribonucleotides. Here we report that the treatment of Ewing sarcoma cells
with gemcitabine, an irreversible inhibitor of the RRM1 subunit of RNR, results
in impaired DNA replication, cell cycle arrest, and apoptosis in Ewing sarcoma
cells. Additionally, we have found that the effect of gemcitabine on the viability
of Ewing sarcoma cells is sustained even after removal of the drug from the cell
culture medium. Moreover, ataxia telangiectasia and rad3-related protein
(ATR) and checkpoint kinase 1 (CHK1) inhibitors increase the toxicity of gem-
citabine in Ewing sarcoma cells by blocking the adaptive response to impaired
DNA replication. Currently, ongoing work is focused on the in vivo testing of
gemcitabine, alone and in combination with CHK1 and ATR inhibitors, as a
novel therapeutic approach for the treatment of Ewing sarcoma.
#1956 ABCE1 regulates the translational profıle of neuroblastoma to
drive tumor progression. Jixuan Gao,1 Klaartje Somers,1 Katherine M. Han-
nan,2 Jamie I. Fletcher,1 Bing Liu,1 Ross D. Hannan,2 Richard B. Pearson,3 Mi-
chelle Haber,1 Murray D. Norris,1 Michelle J. Henderson1. 1Children’s Cancer
Institute, Randwick, Australia; 2The Australian National University, Canberra
City, Australia; 3Peter MacCallum Cancer Centre, East Melbourne, Australia.
Neuroblastoma is the most common extracranial solid tumor in children. A
key driver of high-risk neuroblastoma is the MYCN transcription factor which
fuels neuroblastoma progression by enhancing metabolic processes including
protein translation (1). ABCE1, a member of the ATP-binding cassette (ABC)
superfamily of transporters, is a translation factor directly up-regulated by
MYCN (2). It is thought to dissociate the 80S ribosome into free 40S and 60S
subunits so they can re-initiate translation and provide the protein building
blocks required for rapid cell growth andmigration (3).HighABCE1 expression
is associated with poor clinical outcome in neuroblastoma patients (2). There-
fore, we hypothesized that ABCE1 suppressionmay inhibit the aggressiveness of
neuroblastoma by disabling protein synthesis. To test this, we suppressed
ABCE1 using siRNAs in MYCN-amplifıed neuroblastoma cell lines, SK-N-
BE(2) and CHP-134, which resulted in severely impaired cell migration
(P0.001) and proliferation (P0.005). In mice xenografted with SK-N-BE(2)
cells, ABCE1 suppression delayed tumor growth (P0.001) and metastasis
(P0.001). Mechanistically, when polyribosome analysis was used to monitor
the impact of ABCE1 expression on protein translation in SK-N-BE(2) cells, loss
of ABCE1 reduced the proportion of actively translating ribosomes (P0.001),
leading to lower global protein synthesis (P0.018). This is the fırst report of
ABCE1 acting as pro-tumorigenic factor in neuroblastoma. Our data imply that
targeting the translational machinery through ABCE1 may be an effective ther-
apeutic approach for the treatment of MYC-driven cancers. 1. Boon, K., Caron,
H. N., van Asperen, R., Valentijn, L., Hermus, M. C., van Sluis, P., Roobeek, I.,
Weis, I., Voûte, P.A., Schwab, M. & Versteeg, R. (2001) EMBO J. 20, 1383-1393.
2. Porro, A., Haber,M., Diolaiti, D., Iraci, N., Henderson,M., Gherardi, S., Valli,
E., Munoz, M.A., Xue, C., Flemming, C., Schwab, M., Wong, J.H., Marshall,
G.M., Della Valle, G., Norris,M.D.&Perini, G. (2010) J. Biol. Chem. 285, 19532-
19543. 3. Pisarev, A.V., Skabkin, M.A., Pisareva, V.P., Skabkina, O.V., Rakoton-
drafara, A.M., Hentze, M.W., Hellen C.U. & Pestova, T.V. (2010). Mol. Cell, 37,
196-210.
#1957 Molecular pathogenesis and drug synergism in a zebrafıshmodel of
high risk neuroblastoma. Shuning He,1 Marc R. Mansour,2 MarkW. Zimmer-
man,1 Hillary M. Layden,1 A. Thomas Look1. 1Dana-Farber Cancer Institute,
Boston, MA; 2University College London, London, United Kingdom.
We have developed a transgenic zebrafısh model that overexpresses MYCN
and harbors loss-of-function mutations of the nf1 tumor suppressor. In this
model, loss of nf1 leads to aberrant activation of RAS-MAPK signaling, promot-
ing both increased tumor cell survival and rapid tumor cell proliferation. These
neuroblastomas are very aggressive in that almost all of the fısh develop neuro-
blastoma by 3 weeks of age. Three-week old juvenile fısh are very small, making
it feasible to test the effectiveness of many drugs and drug combinations in vivo
for activity against the primary tumors.We demonstrate these advantages of the
model by showing marked synergistic anti-tumor effects of a MEK inhibitor
(trametinib) and a retinoid (isotretinoin) in vivo at several different dosage
combinations by in vivo isobologram analysis. Thus, inhibition of RAS-MAPK
signaling can signifıcantly improve the treatment of this very aggressive form of
neuroblastoma when it is combined with the inhibition of other key pathways.
Because of the very high penetrance and rapid onset of neuroblastoma in our
nf1-defıcient, MYCN-transgenic zebrafısh model, it is one of the only model
systems in which extensive analysis of the synergistic activity of two or more
drugs can be evaluated in primary tumors in vivo. This capability is especially
valuable given that mutations causing RAS-MAPK pathway hyperactivation
have been shown to arise frequently at the time of relapse of childhood neuro-
blastomas, indicating the need to eliminate these mutated tumor cells as a com-
ponent of the primary treatment.
TUMOR BIOLOGY: Regulation and Imaging of Tumor Metastasis
#1958 Opposing roles of Smad2 and Smad3 in the regulation of growth
and invasion of TNBC through TMEPAI. Prajjal K. Singha, Srilakshmi Pan-
deswara,Manjeri A. Venkatachalam, Pothana Saikumar.UTHealth Science Ctr.
at San Antonio, San Antonio, TX.
The dependency of triple negative breast cancers (TNBC) onTGF- signaling
activity for their growth and metastasis is well documented. Breast tumors de-
velop resistance to TGF--induced growth inhibition, which helps in tumor
progression. Additionally, TGF- is enriched in the tumor microenvironment
and is a key inducer of epithelial to mesenchymal transition (EMT) in breast
cancer. In an effort to understand the mechanisms by which TGF- induces
breast tumorigenesis, we sought to identify the relative individual contributions
of Smad2 and Smad3 in mediating cancer cell growth andmetastasis by TGF-.
Screening of several TNBC cell lines showed increased Smad3/Smad2 expres-
sion ratio compared to normalmammary epithelial cells, which suggested breast
cancer cells may escape TGF-mediated cell cycle arrest by altering their rela-
tive expressions of Smad3 and Smad2. Since overexpression of R-Smadsmaynot
always accurately reflect the functional status of the endogenous molecules, we
individually knocked down each R-Smad and tested its effect on pro-oncogenic
behavior of TGF-. Although Smad2 defıciency has no effect on breast cancer
cell behavior, Smad3 defıciency reduced growth and invasion capacity of breast
cancer cells. Interestingly, while Smad3 defıciency was associated with reduced
TMEPAI/PMEPA1 and EMT gene expressions and increased expression of cell
cycle inhibitors, Smad2defıciency had opposite effect on these regulators.More-
over, the decreased growth, invasion and associated gene expressions were
largely reversed by overexpressing TMEPAI in Smad3 knockdown cells, sug-
gesting that Smad3-TMEPAI axis may be involved in subverting growth sup-
pressive effects of TGF- into growth promotion. Compared to control and
Smad2 defıcient cells, Smad3 defıcient cells had markedly elevated PTEN pro-
tein levels and suppressedAkt phosphorylation both under basal conditions and
TGF- stimulation.We identifıed that Smad3 but not Smad2 plays an important
role in stimulating TMEPAI expression, growth and EMT in triple negative
breast cancer cells by promoting TGF- dependent non-canonical signaling by
decreasing the cellular content of PTEN and p27 in a TMEPAI dependent man-
ner. Taken together, the results demonstrate a novel role for Smad3 in cancer
transformation and cancer progression through TMEPAI. Current therapeutic
strategies are aiming at antagonizing the whole TGF- signaling thereby com-
pletely blocking both Smad2 and Smad3 signaling pathways. Selective targeting
of TGF--Smad3-TMEPAI axis may bemore benefıcial in triple negative breast
cancer therapy and prevention.
#1959 MTA1 promotes tumor progression and bone metastasis in pros-
tate cancer via positive regulation of MUC1 and CTSB. Avinash Kumar,1
Swati Dhar,2 Gisella Campanelli,1 Nasir A. Butt,2 Christian R. Gomez,2 JasonM.
Schallheim,2 Anait S. Levenson1. 1Long Island University, Brooklyn, NY; 2Uni-
versity of Mississippi Medical Center, Jackson, MS.
About 80% of the time that prostate cancer cells metastasize, they spread to
the bones. Metastasis involves activation of invasive programs through genetic
and epigenetic alterations, including changes in expression of chromatin re-
modeler proteins.We have previously identifıedmetastasis-associated protein 1
(MTA1), a chromatin remodeler, as a component of vicious cycle of bone me-
tastasis and confırmed signifıcantly higher expression of MTA1 in bone meta-
static samples from patients. In an attempt to dissect molecular mechanisms of
MTA1 action, we performed integrative analysis of our bone metastasis signa-
ture data alongwithMTA1ChIP-Seq data, which revealedmucin 1 (MUC1) and
cathepsin B (CTSB) as strong potential candidates responsible forMTA1-driven
invasiveness.Here, we show that loss of function studies with MTA1 in PC3M
cells exhibit reduced expression forMUC1 andCTSB.We also demonstrate that
depletion of MTA1 in PC3M aggressive prostate cancer cellsdoes not affect cell
proliferation but leads to decrease in colony forming ability, invasive and mi-
gratory property of these cells.When PC3M cells silenced forMTA1 and tagged
with luciferase are used to generate subcutaneous or intracardiac xenografts, it
leads to reduced tumor progression or decreasedmetastasis to bone, respectively
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as evident by bioluminescent measurements and histology of tumors. Ongoing
experiments aim to validate the role of MUC1 and CTSB inMTA1-driven inva-
siveness and metastasis in prostate cancer.
#1960 Upregulation of MCP-1 regulates invasiveness in triple negative
breast cancer. Pranabananda Dutta, Kimberly Paico, Inez Yuwanita, Yanyuan
Wu, Marianna Sarkissyan, Jaydutt Vadgama. Charles R. Drew University, Los
Angeles, CA.
Background: Triple negative breast cancer (TNBC) poses a critical problem
for targeted therapy due to lack of signifıcant expression of estrogen, progester-
one receptor or Her2/neu oncogene. Hence, it is imperative to identify novel
therapeutic strategies to target TNBC. Our study is aimed to examine whether
Monocyte Chemoattractant Protein -1 (MCP-1) is a specifıc marker for TNBC
metastasis. Experimental Design: We employed ELISA to determine secreted
MCP-1 in cell conditioned media, as well as Real-time PCR to determine the
status of MCP-1 in TNBC cell lines. Boyden chamber assay was used to deter-
mine the effect of recombinant MCP-1 on cellular metastasis. Cellular prolifer-
ation wasmeasured withMTT assay. Immunofluorescence staining was utilized
for protein of interest in breast cancer cells. MCP-1 knockdown was performed
using lentiviral vector with shRNA targeting MCP-1 coding regions. Results:
Our data show that the key inflammatory chemokine MCP-1 is upregulated in
TNBC cell lines both transcriptionally as well as in terms of secretion compared
to ER-positive cell line, MCF-7. MCP-1 stimulation inMDA-MB231 andMCF-
7cells does not affect cellular proliferation. However, MCP-1 enhances meta-
static properties of MDA-MB-231 cells along with BT-549 cells. Inhibiting
Chemokine receptor 2/4 (CCR2/4), cognate receptor for MCP-1, with small
molecule antagonists negatively affects invasiveness in MDA-MB-231 cells as
evidenced by Boyden chamber assay. Knocking down MCP-1 by shRNA de-
creases cell invasion inTNBCcell line, BT-549 alongwith downregulation of key
epithelial to mesenchymal transition markers, N-cadherin and Vimentin.
MCP-1 induced cell invasion in TNBC may involve activation of p44/p42
MAPK Thr202/Tyr204. Conclusion: Our study suggests that highMCP-1 levels
in TNBC is driving up metastasis potential in cells. Thus MCP-1 and its medi-
ated pathways could be potential therapeutic targets for the treatment of TNBC.
#1961 Downregulation of proteasome activity promotes epithelial-mes-
enchymal transition. Daniel A. Garcia, Asoka Banno, Eric D. Van Baarsel,
Patrick J. Metz, Christella E. Widjaja, Stephanie H. Kim, Jack D. Bui, Jing Yang,
John T. Chang. UCSD, La Jolla, CA.
The epithelial-mesenchymal transition (EMT) is a developmental program
that is aberrantly activated in cancer cells, producing an invasive phenotype that
can lead tometastases. Inducers of EMT are largely known and have beenwidely
studied. However, the mechanisms that regulate the link between extracellular
stimuli and EMT phenotypes remain poorly understood. Preliminary evidence
fromour laboratory suggests that downregulation of proteasome activitymay be
responsible, in part, for driving EMT. Using immortalized human mammary
epithelial (HMLE) cells as a model, we show that (1) EMT is associated with
decreased proteasome activity and increased polyubiquitinated substrates, (2)
pharmacologic inhibition of proteasome activity leads to increased EMT phe-
notypes and functionality, and (3) pharmacologic inhibition of proteasome ac-
tivity leads to increased EMT via stabilization of the TGF- signaling pathway.
Together, these data suggest that proteasome activity may be an unappreciated
regulator of EMT.
#1962 Regulation of invasion by lysine demethylase 5B in non-small cell
lung cancer cells. Elizabeth L. Zoeller, Jessica Konen, Joshua Bell, Emily Sum-
merbell, Jeanne Kowalski, AdamMarcus, Paula Vertino. Emory Univ., Decatur,
GA.
Histonemodifying enzymes are often dysregulated during carcinogenesis and
are major contributors to the development of oncogenic features, including
proliferation, drug resistance, and metastasis. Given these roles, histone modi-
fıers are promising new targets for oncological therapeutics. One of the enzyme
families at the center of this area of research is the lysine demethylase family
KDM5, for which several inhibitors are in development. KDM5A and KDM5B
are frequently overexpressed or mutated in human non-small cell lung cancer
(NSCLC). In overexpression studies, KDM5B promotes invasion andmigration
of NSCLC cells, whereas invasion andmigration of NSCLC cells were decreased
following knockdown of KDM5B. Furthermore, in patients with NSCLC,
KDM5B is expressed at higher levels in brainmetastasis sites when compared to
both normal tissues and primary tumors. These fındings suggest a role for
KDM5B in lung cancer and metastatic spread. However, the precise role of
KDM5 family members in lung cancer invasion and metastasis is not known.
Recently, we discovered that KDM5B is differentially expressed in cell subtypes
within a 3D model of NSCLC collective cell invasion. In this model isolated
single cells at the forefront of invasive branches (leader cells) express more 2-4
fold more KDM5B protein than the cells following (follower cells), while
KDM5A and KDM5C are evenly expressed across both cell types. KDM5B
mRNA expression is similar across cell types suggesting that the differential
protein expression is mediated at the posttranscriptional level. Interestingly,
global H3K4me3 levels are decreased in leader cells as compared to follower
cells, supporting the idea that the lysine demethylases targeting this residuemay
be expressed at higher levels in leader cells. Collectively, these data suggest that
KDM5B could be contributing to initiation of invasion at the primary site and
thus, promoting metastasis. Given the rising prominence of therapeutic inhibi-
tors of KDM5 familymembers, a better understanding howKDM5B contributes
to cell invasion may lead to a new approach to the prevention of metastasis.
#1964 Identifıcation of a novel molecule target for the detection, predic-
tion, and treatment of peritonealmetastasis of gastric cancer.MitsuroKanda,
Haruyoshi Tanaka, Dai Shimizu, Daisuke Kobayashi, Chie Tanaka, Hideki
Takami, Masamichi Hayashi, Naoki Iwata, Yukiko Niwa, Suguru Yamada, Tsu-
tomu Fujii, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka
Fujiwara, Yasuhiro Kodera.NagoyaUniv. Graduate School ofMedicine, Nagoya,
Japan.
Background: Advanced gastric cancer (GC) frequently recurs because of un-
detected micrometastases even when disease is localized and patients undergo
curative resection.Moreover, peritonealmetastasis is fatal.We aimed to develop
novel diagnostic and therapeutic targets specifıc for peritoneal metastasis of GC
to improvemanagement.Methods:We conducted ametastatic pathway-specifıc
transcriptome analysis to identify candidate biomarkers comprising 340 pa-
tients allocated to discovery and validation sets (1:2) to evaluate the diagnostic
and predictive value. The mRNA and protein levels in primary GC tissues were
compared with patients’ clinical characteristics and survival. The effects of
siRNA-mediated knockdown on phenotype and fluorouracil sensitivity of GC
cells were evaluated in vitro, and the therapeutic effects of siRNAs were evalu-
ated using a mouse xenograft model. Results: Synaptotagmin VIII (SYT8) was
identifıed as a candidate biomarker specifıc to peritoneal metastasis. SYT8 levels
were elevated in the validation set comprising patients with peritoneal recur-
rence or metastasis. High SYT8 levels were signifıcantly and specifıcally associ-
ated with peritoneal metastasis, and served as an independent prognostic
marker for peritoneal recurrence-free survival of patients with stage II/III GC.
The survival difference between high and low SYT8 levels was associated with
patientswho received adjuvant chemotherapy. Inhibition of SYT8 expression by
GC cells correlated with decreased invasion, migration, and fluorouracil resis-
tance. Intraperitoneal administration of SYT8-siRNA inhibited the growth of
peritoneal nodules and prolonged survival of mice engrafted with GC cells.
Conclusions: SYT8 expression represents a promising diagnostic and predictive
biomarker for peritoneal metastasis of GC.
#1965 A novel biocompatible fluorescent nanoparticle enables enhanced
live cell tagging and tracking of cancer cells. Nick Asbrock,1 Vi Chu,1 Kevin
Su,1 Ben Zhong Tang,2 Bin Liu3. 1MilliporeSigma, Temecula, CA; 2The Hong
KongUniversity of Science&Technology, ClearWater Bay, Kowloon,HongKong,
China; 3National University of Singapore, Temecula, CA.
Metastasis is the leading cause of cancer mortality. Metastasis is a multi-step
process which includes local tumor cell invasion, cell migration into the vascu-
lature, exit of cells from the circulation and colonization at the distal tissue sites.
Long-term noninvasive cell tracking by fluorescent probes is of great impor-
tance to life science and biomedical engineering. Current methods used to fluo-
rescently tag cancer cells have been limited by short signal duration, high back-
ground auto-fluorescence or lengthy cell line generation using GFP. We have
developed a biocompatible fluorescent nanoparticle which relies on Aggrega-
tion Induced Emission (AIE) technology that are highly resistant to fluorescent
signal quenching. These particles enable highly effıcient live cell fluorescent
taggingwhile retaining fluorescent signal for up to 10 days in vitro and 21 days in
vivo. These nanoparticles will open new avenues in the development of fluores-
cent probes for following biological processes such as carcinogenesis.
#1966 Cell-surface major vault protein is a novel marker for circulating
tumor cells with nonepithelial phenotypes in hepatocellular carcinoma.
HyunMin Lee,1 JaeWon Joh,2Won Tae Kim,1Min KyuKim,1 Se Ri Seo,1 Hong
Seo Choi,1 Hee Jin Chang,3 Young Joo Jang,4 Dae Shick Kim,2 Chun Jeih Ryu1.
1Sejong University, Seoul, Republic of Korea; 2Sungkyunkwan University, Seoul,
Republic of Korea; 3National Cancer Center, Goyang, Republic of Korea; 4Dank-
ook University, Cheonan, Republic of Korea.
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Hepatocellular carcinoma (HCC) is currently is the fıfth most common ma-
lignancy worldwide and the poor because of frequent metastasis and resistance
to chemotherapy. Circulating tumor cells (CTCs) in blood have attracted atten-
tion as potential seeds for metastasis and an important indicator of treatment
outcome. However, the biological properties of CTCs are largely unknown due
to rarity and lack of CTC-specifıc surfacemarkers.Major vault protein (MVP) is
upregulated during malignant progression and drug resistance development in
various cancer cells, although it is ubiquitously expressed in many normal tis-
sues. Here, we found for the fırst time that MVPwas expressed on the surface of
various cancer cells including HCC cell lines, althoughMVP has been known as
a cytoplasmic and nuclear protein. To investigate the role of cell-surface MVP
(csMVP) on HCC cell lines, MVP expression was knocked down in Huh7 cells
by small interfering RNA. MVP knockdown decreased cell growth and in-
creased apoptotic cell death. When Huh7 cells were treated with a polyclonal
anti-MVP antibody (-MVP) recognizing csMVP, Huh7 cell proliferation was
decreased without apoptotic cell death. Cell sorting revealed that csMVP-posi-
tive Huh7 cells showed a higher proliferation and survival rate than csMVP-
negative Huh7 cells under the stress of low density seeding. Huh7 cells treated
with -MVP also inhibited cell invasion andmigration in vitro. Thus, csMVP is
positively associated with HCC cell proliferation, survival, invasion and migra-
tion. Analysis of signaling molecules showed that MVP knockdown caused a
signifıcant decrease in the levels of phosphorylation of FAK, ERK,AKTand S6K.
MVP knockdown also increased E-cadherin but decreased vimentin, indicating
that MVP promotes the process of epithelial-to-mesenchymal transition. To
further analyze the role of csMVP during HCC metastasis, blood samples from
62 HCC patients and 10 healthy volunteers were stained with csMVP, EpCAM,
HSA, EGFR, CK, and/or vimentin antibodies after the depletion of red blood
cells and CD45-positive cells. csMVP-positive CTCs were detected in approxi-
mately 85.5% ( 0.46CTCs/ml) of patients, and the cell countmeasured inml of
blood ranged between 0.48 and 37.8. Double staining showed that almost all
csMVP-positive cells were panCK-negative while approximately one fıfth of
csMVP-positive CTCs was HSA-positive. Triple staining further showed that
among csMVP-positive cells, EpCAMVimentin, EpCAMVimentin, Ep-
CAMVimentin and EpCAMVimentin cells were approximately 0, 0, 49
and 51%, respectively, suggesting that a half of csMVP-positive cells are EMT-
phenotypic cells and the rest of them are both EpCAM- and vimentin-negative
cells. The results suggest that csMVP is a novel marker on CTCs in patients with
HCCs, where it is expressed predominantly on EMT phenotypic and EpCAM
vimentin intermediate CTCs.
#1967 A novel 40kDa CPE-	N isoform promotes proliferation and inva-
sion in pancreatic cancer cells. XuYu Yang, Cong Ling, Hong Lou, Loh Yoke
Peng. National Institutes of Health, Bethesda, MD.
Carboxypeptidase E (CPE) is a prohormone processing exopeptidase that
cleaves C-terminal basic residues frompeptide hormones liberated endoproteo-
lytically from prohormones. It is a 476- amino acid protein with a signal peptide
in its N-terminus and is mainly expressed in neuropeptide-rich areas of brain
and endocrine tissues. As amultifunctional protein, CPE plays many non-enzy-
matic roles such as prohormone sorting, vesicle transport, and secretion in ad-
dition to its carboxypeptidase activity. Moreover, high expression of CPE is
found in metastatic tumor tissues, including liver cancer, renal clear cell carci-
noma, colorectal cancer, cervical cancer andmelanoma, suggesting CPEmay be
involved in tumor metastasis and progression. In this study, a novel CPE splice
isoform mRNA was identifıed by Northern blotting, which is 1.83kb in size.
RACE assay and sequence analysis confırmed existence of this CPE isoform
mRNA, which partially lacks a N-terminus region, and has a shorter 3=-UTR
compared to WT-CPE mRNA, by removal of 188 nucleotides within the fırst
exon and 589 nucleotides out of the 3=-UTR, respectively. Bioinformatics anal-
ysis revealed that this CPE isoform mRNA has a shortened ORF, which starts
coding from the 3rd ATG relative to wild-type (WT) CPEmRNA and encodes a
40kDa CPE-N protein with the N-terminus truncated. Western blot analysis
showed that 40kD CPE-N is expressed in multiple cancer cell lines and tumor
tissues. In Panc-1pancreatic cancer cells, knockdown of endogenous CPE(s)
inhibited cell growth and invasion; in contrast, ectopic expression of 40kD CPE
isoform signifıcantly promoted proliferation, colony formation, invasion and
migration, whereas overexpression of WT-CPE had only a small effect. These
results suggest that the 40kD CPE-N isoform plays a role in cell growth and
metastasis.
#1968 A novel mechanism of metastasis: Extracellular ATP promotes in-
vasion andmetastasis independent of purinergic receptor signaling.Yanyang
Cao, Xuan Wang, Xiaozhuo Chen. Ohio Univ., Athens, OH.
Cancer is one of the top deadliest diseases in the US and worldwide. Metas-
tasis, the dissemination of cancer cells from the primary tumors to distant or-
gans, is responsible for 90% of solid tumor-related deaths. Tumor invasion and
metastasis is a multistep process in which loss of cell-cell adhesion, increased
proteolysis, and cell motility has been shown to be critical steps. Extracellular
ATP is potentially a very important factor involved in tumor invasion and me-
tastasis because both cell detachment and migration require energy, which is
known to be mainly provided by ATP. Recent studies have indicated that the
extracellular microenvironment of tumors contains much higher concentra-
tions of ATP than normal tissues of the same cell origins. Our recent studies
demonstrated that extracellular ATP is taken up by cancer cells through mac-
ropinocytosis and other endocytosis and promotes cancer cell growth, survival,
and drug resistance (1-3). Based on all these, we hypothesized that extracellular
ATP (eATP) plays critical roles in the regulation of tumor cell detachment,
motility, invasion and tumor metastasis initiation. It was previously shown that
ATP-induced purinergic receptor (PR) signaling is involved in metastasis. Our
hypothesis is different in that eATP also mediates invasion andmetastasis inde-
pendent of PR signaling. Various bioassays were used in human non-small cell
lung cancer (NSCLC) A549 cells to test our hypothesis. Our results show that
eATP treatment led to a substantially increased number of floating cancer cells,
and these cells were viable and formed clones in a clonogenic assay. This indi-
cates that eATP induces cancer cell detachment. Moreover, treatment of eATP
also induces cell migration in cell wounding and Transwell migration assays. In
vitro invasion assay showed that eATP induced a dose-and time-dependent
increase in the invasive capacities of the A549 cells. Western blot analysis indi-
cates that eATP treatment reduced the expression of cell-cell adhesionmolecule
E-cadherin. PR inhibitors only slightly attenuated these effects. All these suggest
novel ATP mechanisms independent of the PR signaling that are unreported
before and imply novel targets for inhibiting/preventing metastasis. References
1. Qian et al. Cancer Letters 351; 242-251 (2014). 2. Chen, Qian, and Wu. Free
Radical Biol Med 79; 253-263 (2015) 3. Qian et al. Mol Cancer Res 14(11);
1087-1096 (2016).
#1969 PKC-induced Twist1 phosphorylation is a novel regulator of
Twist1 stabilization.RoslynTedja,1 Ayesha B.Alvero,1 CarlosCardenas,1Mary
Pitruzzello,1 Gang Yin,2 Yang Yang-Hartwich,1 Cai Roberts,1 Carlotta Glackin,3
Gil G.Mor1. 1YaleUniversity School ofMedicine, NewHaven, CT; 2Central South
University, Hunan, China; 3City of Hope Medical Center, Duarte, CA.
Background: Epithelial - mesenchymal transition (EMT) is a pre-requisite for
cancer metastasis. Twist-1 is a transcription factor with a central role in the
process of EMT and thereforemetastasis formation. Using ovarian cancermod-
els, our group has previously shown that although the stationary epithelial phe-
notype express Twist1 mRNA, this phenotype is enforced by mechanisms that
constitutively ubiquitinates and degrades the Twist1 protein. The objective of
this study is to identify molecular mechanisms that promote Twist1 protein
stabilization and therefore confer a mesenchymal andmobile phenotype. Mate-
rials and methods: Novel phosphorylation sites on Twist1 protein, which are
adjacent to ubiquitination sites, were identifıed using NetPhosK and Ubpred.
Further analysis demonstrates that most of these sites contain the consensus
sequence for PKC. Constitutively active PKC (PKCcat) was ectopically ex-
pressed in HEK293T cells and patient-derived epithelial ovarian cancer cell
lines. Protein expression and phosphorylation status were determined using
western blot analysis using either whole cell lysates or cellular fractions. Protein-
protein interactionwas determinedby immunoprecipiation. The specifıc Twist1
domain required for PKC interaction was determined by co-transfection with
Twist1 deletion mutants. Results: Ectopic expression of PKCc at in HEK293T
cells and ovarian cancer cells resulted in increased levels of Twist1 protein com-
pared to empty vector control. In ovarian cancer cells, PKCcat-induced upregu-
lation of Twist1 protein is not associated with an increase in Twist1 mRNA but
instead is associated with Twist1 phosphorylation, decreased ubiquitination,
and enhanced stabilization.We identify the twist box (WR) domain of Twist1 as
a pre-requisite for PKC binding and PKCcat-induced Twist1 stabilization.
Moreover, we identify TGF1 as a potent activator of endogenous PKC in
epithelial ovarian cancer cells. TGF1 (1 ng/ml) is able to: promote the activa-
tion and membranal translocation of PKC; increase Twist1 protein levels; and
induce spheroid formation and EMT in epithelial ovarian cancer cells. Interest-
ingly, TGF1 had no effect on Twist1 mRNA suggesting that this mechanism is
independent of the classical TGF-Smad pathway. Conclusions: We demon-
strate for the fırst time a novel TGF-PKC signaling pathway that specifı-
cally targets Twist1 protein for phosphorylation and stabilization resulting
in EMT. This mechanism is independent of the classical TGF-Smad path-
way that controls EMT via transcriptional regulation. Since TGF is a pleio-
tropic cytokine that can affect multiple cell types, the identifıcation of PKC
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as a novel target in ovarian cancer cells may aid in the development of better
therapeutic modalities that can prevent EMT and curtail metastasis forma-
tion.
#1970 Glucose-regulated protein 94 is the novel progression biomarker in
esophageal squamous cell carcinoma.Yu-Jia Chang,1 Chien-YuHuang2. 1Tai-
peiMedical Univ., Taipei, Taiwan; 2Department of Surgery, Shuang HoHospital,
Taipei Medical University, Taipei, Taiwan.
Background: Esophageal cancer is a worldwide health problem with a very
poor prognosis as most patients present very late when the disease is advanced
and diffıcult to cure. It is urgent to fıgure out a diagnostic and therapeutic strat-
egy. Glucose-regulated protein 94 (GRP94) has been found highly correlation
with cancer progression. However, the role of GRP94 in the progression and
metastasis of esophageal squamous cell carcinoma (ESCC) is still unclear.
Methods: We investigated the GRP94 expression level of ESCC cells and gener-
ated GRP94-KD cells by shRNA technique. The proliferation assay, migration,
invasion assay were performed. The tissue array was performed to see the cor-
relation of GRP94 and clinical outcome on ESCC. Mitochondrial bioenergetics
were assessed using a Seahorse XF24 flux analyzer. The Transmission Electron
microscopy was applied to see the structure of mitochondria. Results:We found
that ESCC specimen that expressed higher GRP94 showed the lower overall
survival in tissue array results. The ESCC cells expressed high level of GRP94.
Silencing GRP94 reduced the proliferation, migratory and invasion activity.
Transmission Electron microscopy revealed the impaired mitochondrial in
GRP94-KD cells. GRP94-KD cells also displayed reduced basal respiration,
spare of respiratory capacity and ATP production. GRP94-KD caused the accu-
mulation of oxidative damage. Inmolecularmechanism,we found that silencing
GRP94 may cause a decrease COX2 expression and alter EMT expression pat-
tern. Conclusion: We found that silencing GRP94 in ESCC cells suppressed
cancer growth and metastasis ability through COX-2 and EMT molecules ex-
pression. In addition, GRP94 may mediate the functional mitochondria in
ESCC. GRP94may be a new target to develop the therapeutic strategy for ESCC.
#1971 ITGBL1 is a novel epithelial mesenchymal transition-associated
prognostic biomarker in colorectal cancer. Takatoshi Matsuyama,1 Toshiaki
Ishikawa,2 Naoki Takahashi,3 Yasuhide Yamada,3 Masamichi Yasuno,2 Tat-
suyuki Kawano,2 Hiroyuki Uetake,2 Ajay Goel1. 1Baylor Scott &White Research
Institute andCharles A SammonsCancerCenter, Dallas, TX; 2TokyoMedical and
Dental University, Tokyo, Japan; 3National Cancer Center Hospital, Tokyo, Ja-
pan.
Purpose: Colorectal cancer (CRC) ranks as the third leading cancer world-
wide, and its incidence continues to rise gradually, highlighting the need to
stratify the risk of recurrence after curative surgery. Recently, several genes have
been identifıed which appear to associate with metastasis, as they mediate epi-
thelial-to-mesenchymal transition (EMT) in cancer. This study aimed to iden-
tify novel EMT and cancer recurrence-associated biomarkers through system-
atic and comprehensive discovery and validated strategy in multiple,
independent CRC cohorts. Experimental Design: Two independent gene ex-
pression microarray datasets (n 173 and n 307 respectively) were used to
identify novel metastasis-recurrence biomarkers for CRC. Following carefully
selection and prioritization of biomarkers, we selected a candidate gene and
validated its performance as a recurrence marker in a large testing cohort
(n566), and two independent clinical validation cohorts (n201, n475, re-
spectively). To confırm the protein expression of ITGBL1 in cancer, immuno-
histochemistry (IHC) was performed in paired 33 primary CRCs and adjacent
normal mucosa, as well as a subset of liver and lung metastases tissues. In addi-
tion, we usedGene Set EnrichmentAnalysis (GSEA) to determine the functional
role of ITGBL1 in CRC. Results: During the discovery step, gene expression
profıles from differentially expressed genes between recurrence positive and
negative primary CRCs, as well as evaluation of the metastatic sites compared
with primary CRC, identifıed ITGBL1 as a most promising candidate bio-
marker. High expression of ITGBL1 associated with poor overall survival (OS)
in stage I-IV patients and worse disease-free survival (DFS) in stage I-III pa-
tients. Subgroup validation of these results in two large and independent patient
cohorts confırmed these fındings and demonstrated that high ITGBL1 expres-
sion correlated with shorter DFS in stage II and III CRC patients. In addition,
high ITGBL1 expression emerged as an independent prognostic factor for DFS
in stage II and III patients. IHC analysis revealed that both early stage CRCs and
adjacent normal colonic mucosa displayed low ITGBL1 expression, while IT-
GBL1 expression gradually increased from tumor surface to the invasive front in
late stage cancer, indicating that ITGBL1 may facilitate EMT process and pro-
mote a more aggressive phenotype in CRC. Conclusions: High expression of
ITGBL1 in primary tumors was associated with tumor recurrence in CRC pa-
tients after curative surgery. Collectively, we have identifıed ITGBL1 as a novel
EMT-associated biomarker which could be used for risk stratifıcation for met-
astatic potential in CRC.
#1972 Identifıcation of novel candidate driver genes of colorectal cancer
on chromosome 7p. Yuta Kouyama,1 Yushi Ogawa,2 Takaaki Masuda,1 Yuki-
hiro Yoshikawa,1 Miwa Noda,1 Hiroaki Wakiyama,1 Kuniaki Sato,1 Sho Nam-
bara,1 Qingjiang Hu,1 Shinya Kidogami,1 Tomoko Saito,1 Shotaro Sakimura,1
Naoki Hayashi,1 Yohsuke Kuroda,1 Shuhei Ito,1 Hidetoshi Eguchi,1 Koshi Mi-
mori1. 1Kyushu University Beppu Hospital, Japan, Japan; 2Showa University
Northern Yokohama Hospital, Japan, Japan.
Background: Colorectal cancer (CRC) is one of the most prevalent types of
cancer. The highmortality rate of CRC is a serious problem. Hence it is urgently
necessary to identify novel molecular target to improve the mortality rate. Am-
plifıcation of chromosome 7p is frequent in CRC, and it has been considered to
harbor driver genes that promote tumorigenesis or tumor progression by the
gain of function. The aim of this study is to identify novel candidate driver genes
on chromosome 7p and to clarify the clinical signifıcance of their expression in
CRC.Material andMethods: 1.We selected the candidate genes that satisfıed the
following criteria using CRC data from The Cancer Genome Atlas (TCGA). 1)
TheDNA copy number andmRNA expression is positively correlatedwith each
other, 2) overexpressed in the tumor tissues compared to the normal tissues. 2.
The mRNA expression of the candidate genes was measured in 108 surgically-
resected CRC tissues and the paired normal tissues in our hospital by quantita-
tive RT-PCR. The differences of mRNA expression between CRC tissues and
normal tissues were analyzed by Mann Whitney U-test. 3. Survival analysis
betweenhigh and low expression groupof the candidate geneswas performedby
Kaplan-Meier method. Correlation between the mRNA expression of the can-
didate genes and the clinicopathological factors were analyzed by Fisher’s exact
test. 4. We performed Gene Set Enrichment Analysis (GSEA) in CRC data from
TCGA to clarify the correlation between the candidate genes and gene sets that
are associated with tumorigenesis or tumor progression. Results: DEAD Box
Helicase56 (DDX56), ATP-dependent RNAhelicases involved in several aspects
of RNA metabolism including mRNA splicing and transport, transcription,
translation and remodeling of ribonucleoprotein complexes, was satisfıed with
the criteria. The expression of DDX56 was signifıcantly higher in CRC tissues
than in normal colon tissues (p0.005), and it correlated with lymphatic inva-
sion (p0.02), and distant metastasis (p0.03). The high DDX56 expression
group had a signifıcantly poorer prognosis than the low expression group
(p0.03). On multivariate analysis, high DDX56 expression was an indepen-
dent prognostic factor affecting OS (p0.013) with hazard ratios (95% CI) of
2.32 (1.20-4.48) among clinicopathological factors. GSEA showed that DDX56
expression was positively correlated withmitotic cell cycle progression and spli-
ceosome. Conclusions:We identifıedDDX56 as a promising driver gene of CRC
on chromosome7p.DDX56 expressionwas positively associatedwith lymphatic
invasion and distantmetastasis, andwas an independent poor prognostic factor.
Furthermore, DDX56 may be involved in tumor progression through stimulat-
ing cell-cycle. DDX56 could be a therapeutic target as well as a poor prognostic
biomarker in CRC.
#1973 Novel relationships of expression of methylxanthine alkaloid re-
ceptor genes and risk of breast carcinoma recurrence. Seth B. Sereff, Michael
W. Daniels, James L. Wittliff. University of Louisville, Louisville, KY.
Consumption of methylxanthine alkaloids such as caffeine, theophylline and
theobromine may induce breast pain. Caffeine appears to induce its biological
activities by antagonizing adenosine receptors, which have been implicated in
breast cancer cell behavior in vitro.Our goal is to evaluate expression of genes for
methylxanthine receptors andmetabolizing enzymes for assessing risk of breast
cancer recurrence. Procedures: De-identifıed primary cancers previously col-
lected, stored and analyzed under stringent conditions were employed to amass
an IRB-approved, de-identifıed comprehensive Database. Patient-related prop-
erties (e.g., nodal status, clinical outcome) and results from estrogen (ER) and
progestin receptor (PR) analyses and gene expression assays guided selection.
To decode clinical utility of gene expression profıles, Laser Capture Microdis-
section (PixCell IIeTM Arcturus/Thermo Fisher) was used previously to non-
destructively collect carcinoma cells. RNA was extracted, amplifıed and ana-
lyzed by microarray ( 22,000 genes). Results: Gene expression levels of 8
methylxanthine receptors, 8 metabolizing enzymes and various phosphodies-
terases were retrieved from microarray results of 247 breast biopsies. Univari-
able Cox regressions and Kaplan Meier plots were determined for each candi-
date gene with R software. Kaplan-Meier plots of PDE4A, CYP2A6 or CYP2E
individually indicated lower expression was related to decreased progression
free (PFS) and overall survival (OS) while PDE1A over-expression predicted
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decreased PFS and OS. ADORA2B and RYR1 over-expression was associated
with lower OS. Gene expression was examined with ER or PR status without
regard to clinical outcome. Breast cancers that were ER exhibited lower
ADORA1, ADORA2B andRYR1 expression and elevated expression of PDE4A,
CYP2A6 and CYP2E. PR carcinomas also exhibited decreased expression of
ADORA2B and RYR1 expression. However, over-expression of ADORA3,
PDE4A, CYP2C8 and CYP2E was observed in PR cancers. Analysis of vari-
ance (ANOVA) of carcinomas according to ER/PR status indicated ADORA2B
expression was elevated in ER- cancers regardless of PR status. ANOVA also
showed PDE4A was over expressed in ER carcinomas regardless of PR status.
LASSO analysis revealed CYP2E, PDE1A and PDE4A expression taken jointly
predicted PFS which was validated externally (Breast Cancer Meta-base) with
SurvExpress. Conclusions: Collectively, results suggest expression of genes in-
volved in methylxanthine action and metabolism may be used to predict breast
cancer behavior. Signifıcantly, we identifıed gene expression signatures in single
cell types that were highly associated with clinical outcome suggesting promise
for development of novel prognostic tests for breast carcinoma management
and design of new therapeutics.
#1974 Novel function of PCNA in mammary tumor development and
distantmetastasis through tyrosine phosphorylation.Yuan-LiangWang,1 La-
nie Chang,2 Susan E. Waltz,3 Shao-Chun Wang1. 1China Medical University &
Hospital, Taichung City, Taiwan; 2ChinaMedical University Hospital, Taichung
City, Taiwan; 3University of Cincinnati, Cincinnati, OH.
Breast cancer is the most common cancer besides skin cancer and is the
second leading cause of cancer-related death in women in the US. Despite in-
tensive study, metastasis and tumor dormancy continue to be major hurdles to
eradicate this disease. PCNA forms a homotrimer ring encircling the DNAdou-
ble helix and acts as a sliding platform indispensable for DNA replication, dam-
age repair, and chromatin remodeling. While a positive role of PCNA in is
conceivable, how PCNA functions in tumor progression remains elusive due to
the embryonic lethal phenotype in PCNA-defıcient mice. We have shown that
PCNA is regulated by phosphorylation at tyrosine 211 (Y211) meditated
throughmultiple growth factor-stimulated signaling pathways. Y211 phosphor-
ylation enhances chromatin-bound PCNA to promote cell proliferation and is
frequently detected in multiple human cancers including breast cancer. To fur-
ther dissect its biological functions, we have generated the PCNA211F/211F
“knock-in” mice in which Y211 is replaced with a structurally similar but non-
phosphorylatable amino acid phenylalanine (F). Comparing to wild-type mice,
PCNA211F/211F mice have signifıcantly reduced mammary tumor formation
upon induction by the carcinogen DMBA. To understand its biological role in
oncogene-induced mammary tumorigenesis, the PCNA211F/211F mice were
crossed with the MMTV-PyMT mice in which mammary gland expression of
the oncogene polyoma virus middle T antigen (PyMT) is driven by the mouse
mammary tumor virus (MMTV) enhancer/promoter. PCNA211F/211F;MMTV-
PyMT mice have statistically signifıcant but only moderate decrease in mam-
mary tumor development. However, their lung metastasis is dramatically ab-
lated compared to PCNAWT/WT;MMTV-PyMTmice harboring primary tumors
of similar size. These results suggest that pY211-PCNAhas an essential function
not only in tumorigenesis but more importantly in progression to distant me-
tastasis. Consistently, mammary tumors derived from PCNAWT/WT;MMTV-
PyMT mice exhibits more pronounced stromal activity than tumors of
PCNA211F/211F;MMTV-PyMTmice. The suppression of metastasis and stromal
activity in PCNA211F/211F;MMTV-PyMTmice is associated with reduced num-
ber of tumor-initiating cells (TICs) as determined by in vitro and in vivo analy-
ses. Further study using syngeneic orthotopic model of transplanting murine
cancer cells into the mammary glands of PCNAWT/WT and PCNA211F/211F mice
unveils an unexpected function of pY211-PCNA in the stromal compartment on
tumor development. Thus, our study reveals a novel tumor-promoting function
of PCNA in both parenchymal and stromal compartments besides its traditional
role in cell proliferation. Given our prior fındings that the signaling pathways
leading to Y211 phosphorylation can also be inhibited by FDA-approved drugs,
our results suggest that pY211-PCNA may be a new druggable mechanism to
target tumor metastasis.
#1975 FAM83B:Anovel regulator of cell plasticity inbreast cancer.Court-
ney A. Bartel, Damian J. Junk, Mark W. Jackson. Case Western Reserve Univer-
sity, Cleveland, OH.
Epithelial to mesenchymal transition (EMT) is an important process in both
metastasis and cancer stem cell (CSC) enrichment. Recent studies suggest that
instead of simply transitioning from one cell state to another, cancer cells exist
along a continuum of epithelial and mesenchymal cell states. Identifying novel
regulators of tumor cell plasticity will be critical to fully understand this contin-
uum and to target metastasis and CSC phenotypes in the future. FAM83B is a
novel oncogene identifıed by the Jackson Laboratory in a forward genetic screen
for drivers of Human Mammary Epithelial Cell (HMEC) transformation. Pre-
vious work showed that FAM83B expression is elevated in triple negative breast
cancers and that FAM83B also activates key cell signaling pathways (EGFR,
MAPK, and PI3K) in breast cancers. Here, we implicate FAM83B as a novel
regulator of epithelial-mesenchymal plasticity using a HMEC transformation
model. Transformation of primary HMEC by expressing shp16, shp53, c-Myc,
and RAS results in the generation of two distinct transformed cell populations.
One population retains epithelial characteristics, while an emergent population
spontaneously acquires a mesenchymal morphology and a CD24LOCD44HI
(CSC) cell surface marker profıle. Moreover, isolation of epithelial,
CD24HICD44LO cells (non-CSC) and exposure to Oncostatin M (OSM), an
EMT-inducing cytokine, can also generate cells with a mesenchymal/CSC phe-
notype. Interestingly, FAM83B expression was signifıcantly elevated in the epi-
thelial/non-CSC population compared to the mesenchymal/CSC population.
Moreover, treatment of purifıed epithelial/non-CSC cells with OSM resulted in
decreased FAM83B expression levels, indicating FAM83B expression is sup-
pressed as the cells move through EMT. FAM83B expression also correlated
with an epithelial phenotype in a panel of breast cancer cell lines. shRNA-medi-
ated knock-down of FAM83B from epithelial/non-CSC resulted in increased
spontaneous EMT, concomitant with elevated expression of the mesenchymal
marker Vimentin and master EMT transcription factor Zeb1. Following treat-
ment with OSM, sh83B cells maintain prolonged, elevated p-Stat3 and p-ERK
signaling, known contributors to the mesenchymal/CSC phenotype. Con-
versely, OSM-induced EMT was blunted in epithelial/non-CSC expressing ex-
ogenous FAM83B. Thus, FAM83B expression is a determinant in maintaining
an epithelial phenotype, while suppression of FAM83B is important during
EMT. Future work will seek to defıne novel FAM83B-mediated signaling path-
ways important for regulating cellular plasticity.
#1976 Dried blood imaging and immunoassay: Spot formation, particle
migration, and tumor cell detection. Quanxu Shen,1 Bin Hong2. 1The Fifth
Central Hospital of Tianjin, Tianjin, China; 2TeloVISION LLC, West Lafayette,
IN.
Blood droplet, when dried, forms a structured sedimentation pattern with
central flat, corona ring and peripheral rim. This pattern can be fıne-tuned with
the blood formula. Surfactant is critical to promote the gelation process, elimi-
nate the fılm cracking and delamination, and hence, suppress the coffee-ring
effect. Additionally, surfactant restrains the shrinkage of the dried fılm.Without
surfactant, the contraction was 100150m for 20L of blood; decreased with
surfactant added; fully stopped at 10% of concentration. Drying at room tem-
perature with surfactant formed a flat disc-shaped deposit, while at 37°C, volca-
nic protuberance was developed. The size of the protuberance depended on the
concentration of the surfactant primarily, and the anticoagulant type, evapora-
tion velocity, and blood volume. To monitor the dynamic desiccation process,
video recording of the evaporating drop was employed. It revealed a quick dis-
location of the leukocyte-resembling beads to the outer region of the blood spot,
reportedly at velocity of 10m/sec. The use of 1 and 10m sized beads further
demonstrated layered convective flow below the surface. Beads migrated out-
ward primarily before gelation, inward slightly during solidifıcation, and ulti-
mately settled down across the spot. The movement of beads was found in the
range of a few hundredmicrons tomillimeters before and after desiccation for a
50L drop. Notably, plasma proteins and saline have influenced the bead distri-
bution more than the surfactant. After plasma removal and mixing with surfac-
tant, the majority of beads were dragged to the periphery, compared with many
beads for no plasma and surfactant, some for whole blood with surfactant, and
none for whole blood without surfactant. For a thick blood fılm, detection of
embedded cells and beads can be diffıcult. Experiments showed that beam of
longer wavelength, 532nm, was capable of visualizing all fluorescent cells and
beads. Dried blood spot (DBS) assay has been widely used for newborn meta-
bolic testing and DNA analysis. To detect rare tumor cells in DBS, the dried
patternwas optimized to eliminate the artifacts, stabilize the cells, and enrich the
targeted cell. DBS assay holds greater potential for cancer detection when the
medical resource is limited.
#1977 Tracking cancer colonization in xenografts using ultrasensitive ac-
celerator mass spectrometry methods.Nicholas R. Hum, Kelly A. Martin, Mi-
chael Malfatti, Kurt Haack, Bruce A. Buchholz, Gabriela G. Loots. Lawrence
Livermore National Laboratory, Livermore, CA.
Background: The inability to effectively treatmetastases is themain reason for
the limited progress in reducing the rates of cancer morbidity and mortality.
One major drawback is the lack of quantitative assays for assessing the size and
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tissue prevalence of tumors in newly diagnosed individuals. Current methods
for quantifying tumor burden are mainly qualitative and include measuring the
gross weight of the affected organ, counting tumors on the surface of the organ,
or evaluating a small sample of the organ using histologic sections. These meth-
ods are crudemeasures of tumor burden and size distribution, and in the case of
histology, they are time consuming, diffıcult to process an adequate sample size
and non-quantitative. Methods: Animal models of metastasis have been useful
in identifying genes that regulate susceptibility to the development and progres-
sion of metastasis and have helped to highlight potential novel targets for drug
development. In particular several small animal imaging technologies including
magnetic resonance imaging, high frequency ultrasound, and optical imaging
have been recently applied to this task. Each of these methods may be useful for
specifıc research projects, based on their unique combination of resolution, im-
age acquisition time, animal throughput, and cost-effectiveness, yet none of
these modalities adequately address the need for rapid quantifıcation of tumors
across the entire organism, nor do they assess therapeutic effectiveness in erad-
icating cancer in xenograft models. We have developed an Accelerator Mass
Spectrometry (AMS)-based high precision quantitativemethod for assessing the
metastatic potential of primary tumors isolated from newly diagnosed patients.
Results: OurAMS-basedmethodology to studymetastasis uses xenograft cancer
cells labeled with 14C-labeled thymidine that are delivered intravenously into
NSG mice and allowed to develop metastatic cancer over the course of up to 10
weeks. At the end of the experiment, all vital organs are collected; the DNA is
isolated and is examined byAMS for the presence of 14C-signal. The labelingwas
optimized to achieve suffıcient signal such that a tumor derived froma single cell
could be detected by AMS, in secondary tumors, in vivo, independent of histo-
logical data. Conclusions: Using this approach we have determined that tissue
colonization by tumor cells is a very rare event, where most metastatic tumors
are initiated by less than 10 cells delivered into NSGmice. Further optimization
of these techniques will allow us to explore the metastatic potential of primary
tumors, isolated from biopsies and expanded in Avatar mice. This study was
supported in part byNIHP41MI03483 andwas conducted under the auspices of
the USDOE by LLNL (DE-AC52-07NA27344). IM number: LLNL-678306.
#1978 Identifıcation of the metastatic cell populations in a spontaneous
mouse model of melanoma. Xiaoshuang Li, Raul Torres, Lidia Kos. Florida
International University, Miami, FL.
Melanoma is the deadliest form of skin cancer due to its high propensity to
metastasize and resistance to current therapies. We have created a spontaneous
mouse model of metastatic melanoma (Dct-Grm1/K5-Edn3) where metastasis
to the lungs is 80% penetrant. The primary tumors of thesemice present cellular
heterogeneity with cells at varying levels of differentiation. Themain goal of this
study is to determine the metastatic potential of the primary tumor resident
Tyrosinase positive cells and evaluate the dynamic pattern of gene expression as
those cells move from the primary tumors to the sites of metastasis. To accom-
plish this aimwe crossed theDct-Grm1/K5-Edn3mice toCreERT2/ROSAmT/mG
mice to indelibly label Tyrosinase cell populations within the primary tumor by
topical application of 4-hydroxytamoxifen at the tumor site. In vivo lineage
tracing and characterization of those labeled cells was performed in the meta-
static lesions. We found that Tyrosinase positive cells enter the circulation be-
fore the appearance of any noticeable tumor or nevus and establish close inter-
actions with the vasculature as single cells. Metastatic cells in close association
with the inner wall of the vasculature lose pigmentation and do not express
melanocytic markers. Interestingly, those intravascular cells mimic endothelial
cell properties with the expression of platelet endothelial cell adhesionmolecule
(PECAM-1, also known as CD31). In the lung tissue, the primary tumor derived
Tyrosinase positive cells or their progeny can survive and establish successful
metastases with pigmentation. This in vivo lineage tracing system in mouse will
be a powerful model to evaluate and help us understand the etiology and patho-
genesis of melanomametastasis. Further characterization of those more aggres-
sive cells in melanoma will allow for the development of new prognostic tests
and novel therapeutic strategies to eliminate metastasis.
#1979 Cell lines that genomically resemble high-grade serous ovarian car-
cinomas display differences in growth and invasive capacities in an ortho-
metastatic nude mouse model. Sarah S. Alghamdi, Alicia A. Goyeneche, Zu-
hua Gao, Carlos M. Telleria.McGill University, Montreal, Quebec, Canada.
Ovarian cancer (OC) is a complex disease that can be divided into various
histopathological subtypes. High-grade serous OC (HGSOC) is the most abun-
dant histotype, accounting for up to 70% of all OC cases. Whereas the majority
of patients are diagnosed when the disease is already disseminated in the peri-
toneal cavity, orthometastatic mouse models of peritoneal OC—needed to per-
form preclinical studies—are not well developed. The human OC cell lines
mostly studied for in vivo tumor development in immunosuppressedmice have
been implanted subcutaneously, not intra-abdominally, thus not reflecting the
tumor niche this disease actually encounters when advanced. Furthermore,
most studies utilize cells which do not have the genetic fıdelity of HGSOC. Thus,
we set up a study to track the development of intra-abdominal disease induced
by 3 human OC cells lines with the genetic fıdelity of HGSOC: OVCAR-4,
OVSAHO, and PEO14. The 3 cell lines showed abundant expression of
ARID1A, PAX8 and mutant p53, with varied levels of expression of CA125 and
WT1. We contrasted among them, the time needed for the disease to develop,
the tissues being targeted, and the histopathological abnormalities detected.We
found that the elapsed time for the disease to develop for the 3 lines ranged
between 4 to 11 months. This result stands in stark contrast with the less than 3
months it takes for the disease to evolve in the peritoneal cavity when injecting
cells of unlikelyHGSOCgenomic fıdelity, such as SKOV-3, IGROV-1, orA2780.
Within the cell lines with HGSOC genotype we found commonalities and dif-
ferences in terms of their in vivo behavior. Among the commonalities, all cells
homed to the omental-spleen-pancreatic area, the liver base, themesentery, and
the diaphragm. Among the differences, PEO14 cells developed into sizable
masses not invading the parenchyma of the abdominal organs. OVSAHO cells
developed discretemasses closely surrounding the organs, whileOVCAR-4 cells
displayed full invasiveness into the parenchyma of several abdominal organs in
addition to developing micro-metastases within the lung stroma. Whereas
OVCAR-4 cells caused accumulation of large volume bloody ascites carrying
abundant multicellular structures (MCS), OVSAHO and PEO14 cells led to the
formation of low volume bloody ascites carrying scarceMCS. These phenotypic
heterogeneities were further reflected in the different end-of-wellness endpoints
criteria reached, which were: the increase in the abdominal circumference
caused by the accumulation of ascites in animals carrying OVCAR-4 cells, the
size of the solid abdominal masses in animals carrying PEO14 cells, and the
dramaticweight loss in animals carryingOVSAHOcells. In conclusion,we show
that, despite having similar genetic fıdelities, HGSOC cell lines are heteroge-
neous in terms of their phenotypic behavior when ortometastatically implanted
in nude mice.
#1980 Fusion of cancer and stromal cells imaged by color-coded imaging
ofmetasasis.MikiNakamura,1Atsushi Suetsugu,1KousukeHasegawa,1 Takuro
Matsumoto,1HitomiAoki,1 TakahiroKunisada,1Masahito Shimizu,1 Shigetoyo
Saji,1 HisatakaMoriwaki,1 Robert M. Hoffman2. 1Gifu Univ. Graduate School of
Medicine, Gifu, Japan; 2AntiCancer,Inc., San Diego, CA.
We report here imaging of stroma during the metastatic process. RFP-EL4
lymphoma cells were injected subcutaneously in C57/BL6 GFP transgenicmice.
Subcutaneous tumors were resected and immediately transplanted to the ab-
dominal cavity of BALB/c nude mice. Metastases to the liver, perigastric lymph
node, ascites, bone marrow and as well as the primary tumor were imaged.
Metastases expressed GFP at low magnifıcation. At higher magnifıcation, yel-
low-remaining cancer cells resulting from fusion of GFP stromal cells and RFP
cancer cells were observed. Metastasis contained fusion of caner and stromal
cells which may be a feature of metastasis.
#1981 Tissue-engineered bone for longitudinal intravital microscopy of
solid tumor growth and therapy response. Eleonora Dondossola,1 Stephanie
Alexander,1 Boris Holzapfel,2 Christopher J. Logothetis,1 Dietmar W. Hutm-
acher,2 Peter Friedl1. 1UT MD Anderson Cancer Ctr., Houston, TX; 2Institute of
Health and Biomedical Innovation, Queensland University of Technology, Bris-
bane, Australia.
Bonemetastases are the initial site of progression and account formany of the
complications experienced by men with metastatic prostate cancer (PCa), in-
cluding therapy resistance. Besides cell intrinsic mechanisms, the interaction
between PCa cells and the bone microenvironment critically contributes to le-
sion expansion and drug sensitivity. We here developed a mouse model amena-
ble to intravital multiphoton microscopy (iMPM) to longitudinally study PCa-
stromal cell interactions and therapy response in a partially humanized
neobone, established in the dermis of the mouse. Tissue engineered bone con-
structs, TEBCs, were generated by functionalizing polymeric polycaprolactone
scaffolds with human mesenchymal stem cells (hMSCs) differentiated to osteo-
blasts followed by cell-derived calcifıcation of the inter-scaffold space. 30 days
after implantation of functionalized scaffolds under the skin of the mouse, bone
and bone marrow maturation resulted in a 30mm3 cavity surrounded by opti-
cally transparent cortical bone of 50-60mthickness, asmonitored bymicroCT
and iMPM. Intra-bone tumor growth and osteolysis dynamics caused by human
fluorescent PCa cells (PC3) were three-dimensionally reconstructed by multi-
parameter detection through a body window, including collagen and bone ma-
trix (SHG), calcifıed bone (fluorescent bisphosphonates), osteoclasts (cathepsin
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K), bone surface (THG), blood vessels and stromal phagocytes (fluorescent dex-
tran), and PC3 cells (nuclear H2B/eGFP, cytoplasmatic DsRed2). As a proof of
concept, the effıcacy to halt bone remodeling during bisphosphonate therapy
was detected, revealing the composition and kinetics of the bone-tumor inter-
face. Combining engineered neobone with an optical window is suited to detail
the 3D organization and dynamics of cancer lesions in bone and providesmech-
anistic insight and effıcacy predictions for therapy response. Thus, this strategy
will be implied to dissect the therapeutic effect of radium 223, a radioisotope
with bone seeking properties, and the fırst agent that improves the duration and
quality of life of advanced metastatic PCa patients. By using this model we will
test the hypothesis that 223Ra alters stromal niches, structurally and molecu-
larly, in a manner that accounts for the clinical observations in establishedmac-
roscopic lesions.
#1982 -arrestin 2 mediates tumor growth and metastasis in renal cell
carcinoma cells. Jude Masannat, Yushan Zhang, Hamsa Purayil, Yehia Daaka.
University of Florida, Gainesville, FL.
Renal Cell Carcinoma (RCC) is one of the most lethal urological cancers
worldwide, with incidence and mortality rates increasing in the past two de-
cades. The disease does not present early clinical symptoms and is commonly
diagnosed at the metastatic stage, leaving the 5-year survival rate at 10-20%.
For a wide array of neoplasms, many key molecular determinants involved in
mediating the process of tumor cell growth, invasion, and colonization at a
secondary site (i.e. metastasis) have been reported. However, few molecular
predictors have been identifıed for RCC, rendering the mechanism(s) underly-
ing RCCmetastases poorly understood. This results in the lack of effective treat-
ment for patients with advanced RCC. G protein-coupled receptors (GPCRs)
and their effectors, such as the arrestin proteins, have been implicated in tumor
growth, metastasis, and angiogenesis. Arrestin proteins are well known for their
function in the desensitization and traffıcking of GPCRs, but have also been
implicated in unique signaling pathways to regulate fundamental cellular func-
tions, including cell cycle progression, cell migration, and survival. Further-
more, arrestin involvement has been identifıed in a number of breast, colorectal,
lung, and hematological malignancies. However, the role of arrestin proteins in
RCC is yet to be determined. Our preliminary data show that -arrestin 2
(arr2) protein levels correlate with growth and metastatic potential in several
RCC cell lines, including ACHN and SN12C. We hypothesize that arr2 regu-
lates RCC tumor progression, specifıcally through involvement in proliferation,
invasion, and metastatic processes. To test our hypothesis, we used genetic-
based loss of function approaches such as interfering RNA and CRISPR/Cas9.
arr2 knockdown results indicated a role in RCC malignancy as it signifıcantly
reduces the migration and invasion of RCC cell lines in vitro. arr2 knockout
(KO) impaired 3D spheroid formation of these cells and inducedmorphological
changes compared to control cells as observed under confocal microscopy im-
aging. Moreover, epithelial marker E-cadherin expression levels were elevated
whilemesenchymalmarkers twist1, twist2 and vimentin levelswere decreased in
the arr2 KO cells compared to control, indicating a mesenchymal to epithelial
transition. In vivo data support our hypothesis that arr2 plays a critical role in
tumor growth and metastasis. Our data suggests a role for arr2 in RCCmalig-
nancy and present a possible target in development of therapies for patients with
advanced RCC.
#1983 CD117 expression and activation induce prostate cancer metasta-
sis. Koran Harris,1 Lihong Shi,1 Taylor Peak,1 Stephanie Sanders,1 Aleksander
Skardal,2 Bethany Kerr1. 1Wake Forest University School of Medicine, Winston
Salem, NC; 2Wake Forest Institute for Regenerative Medicine, Winston Salem,
NC.
Tyrosine kinase receptors have been shown to drive prostate cancer progres-
sion andmetastasis. In particular CD117/c-kit expression is upregulated during
tumor progressionwith the highest levels being expressed in bonemetastases. In
addition, the numbers of circulatingCD117 cells was higher in advanced pros-
tate cancer patients. The presence of these cells in patients’ circulation after
radical prostatectomywas also associated with biochemical recurrence. Further,
the expression of CD117 can be upregulated on prostate cancer cells after re-
peated culturing in the bone microenvironment. These data indicated that
CD117 expression and activation may be associated with bone metastasis. To
test this, LNCaP-C4-2 cells were sorted into CD117 and negative cell popula-
tions. Proliferation, matrigel invasion, and gene expression were compared in
the two cell populations in the presence and absence of the ligand stem cell factor
(SCF) or CD117 and Akt inhibitors. To track cells during coculture and compe-
tition experiments, sorted cells were infected to express mCherry (CD117) or
ZsGreen (negative). Using these cells, competition was tracked using an In-
cuCyte ZOOM live cell imager for in vitro studies and an IVIS imager for in vivo
xenograft studies. To better visualize transendothelial migration, a 3Dmicroflu-
idic metastasis-on-a-chip was developed to track tumor cell migration through
the ECM and across an endothelial cell layer. Here, we examine the activation of
CD117 in prostate cancer cell progression andmigration. CD117 expressionwas
associated with increased proliferation, beta1 integrin expression, and EMT
marker expression. Interestingly, treatment with the CD117 ligand stem cell
factor (SCF) reduced proliferation but further enhanced invasion indicating that
CD117 activation may drive metastasis. CD117 activation stimulated Akt ex-
pression and drove the cancer stem cell phenotype as demonstrated by increased
Oct4 and Sox2 expression. CD117 expression was associated with increased
expression of cancer progression and EMT signaling pathways. Using live cell
imaging, competition between CD117 and negative cells was visualized in
proliferation, scratch healing, invasion, trans-endothelial migration, and sphere
formation. Xenograftmodels also demonstrated competition in vivo. Sectioning
of tumors demonstrated the localization and composition of co-injected cells. In
vivo fluorescent imagingwas used to examine tumor initiation capabilities of the
two cell populations. Using 3Dmicrofluidics, we have modeled the competition
between CD117 and negative cell populations during transendothelial migra-
tion. CD117 expression on prostate cancer cells drives a more aggressive cell
phenotype and may be involved in metastasis. Further, CD117 cells represent
a possible cancer stem cell population.
#1984 CtBP1 and metabolic syndrome induce breast cancer progression
and lung metastasis. Paula Lucía Farré, Georgina Scalise, Nicolás Guillermo
Dalton, Rocío Belén Duca, Karen Daniela Graña, Cintia Massillo, Juliana Por-
retti, Adriana De Siervi, Paola De Luca. Instituto de Biología y Medicina Exper-
imental - CONICET, Buenos Aires, Argentina.
Breast cancer (BrCa) is one of the most important public health problems in
the entire world.Metabolic syndrome (MeS) increases the incidence and aggres-
siveness of BrCa. C-terminal binding protein 1 (CtBP1) is a co-repressor of
tumor suppressor genes that is activated by low NAD/NADH ratio. Recently,
we generated a MeS-like experimental mice model by chronically feeding ani-
mals with high fat diet (HFD) and we found that CtBP1 and MeS modulated
breast carcinogenesis and tumor growth. We also showed that CtBP1 and MeS
decreased BrCa cell adhesion, a crucial event in the beginning of metastasis.
Considering metastasis is still the main cause of death, and around 30 % of
womenwith BrCa diagnosed at early stages will progress tometastatic stage, it is
crucial to understand the impact of non-inherited factors and the mechanism
underlying this process. The aimof this workwas to exploreCtBP1 andMeS role
in BrCa cell migration and metastasis. By wound healing assay, we found that
CtBP1 increased cell migration of MDA-MB-231 and 4T1 BrCa cells. To study
CtBP1 andMeS effect in tumor progression, MeS nude mice induced by chron-
ically feeding animalswithHFD; and control diet fed animals, were injectedwith
CtBP1-depleted expression or -control MDA-MB-231 cells. Six weeks post-in-
jection primary tumors were surgically removed. After two weeks, mice were
sacrifıced and the presence of metastasis in lung, liver and ascites was analyzed
by histology and/or quantifıed by RT-qPCR using specifıc primers for human
GAPDH. Consistently with the onset of metastasis, MeS increased the number
of mice that developed neoplastic ascites (20% in MeS vs. 50% in control) with
presence of tumor cells (TC) detected by RT-qPCR. In addition, histological
analysis andRT-qPCRquantitation revealed thatCtBP1hyperactivation byMeS
signifıcantly increased BrCa lung metastasis. Interestingly, human Vimentin
mRNA was induced in TC from ascites compared to primary TC; while it was
diminished in lung, suggesting the crucial role of EMT/MET processes in me-
tastasis. Finally, we analyzed expression of cell adhesion and EMT-related genes
in primary tumor tissue byRT-qPCR.We found thatCtBP1 andMeSmodulated
cell adhesion and EMT expression genes: Vimentin, Slug, ITGB4, ITGB6,
Col17A, FABP4 and PRSS2. Altogether, these results suggest a key role for MeS
and CtBP1 inducing BrCa EMT and metastasis.
#1985 Tbk1 loss in pancreatic cancer leads to changes in epithelial plastic-
ity.Victoria Haley Burton, Rolf A. Brekken, Melissa Gross, Alberto Bremauntz.
UT Southwestern Medical Ctr., Dallas, TX.
Effective therapies are needed to enhance the long-term survival of patients
with pancreatic ductal adenocarcinoma (PDA), which is the fourth leading
cause of cancer-related deaths in the United States and eighth worldwide. Initial
stages of PDA are commonly characterized by an activatingmutation in K-RAS,
yet direct inhibition of K-RAS through pharmacological means remains a chal-
lenge. Higher levels of TANKBinding Kinase 1 (TBK1)mRNA, a critical down-
stream effector of mutant active K-RAS in lung cancer, are associated with
poorer overall survival in a cohort of human PDA patients.We hypothesize that
TBK1 is also an effective mediator of K-RAS driven pancreatic cancer. Here we
report that TBK1 is expressed and more active in human PDA cell lines relative
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to immortalized pancreatic epithelial lines (HPNE) and fıbroblasts. We found
that human PDA cell lines are sensitive to a small molecule inhibitor of TBK1 in
the low micromolar range. Further mice engineered to express a mutant kinase
dead form of TBK1 (Tbk1/) are viable and fertile yet display smaller tumors at
early time points in a genetically engineeredmousemodel of PDA. Interestingly,
tumors from Tbk1/: PDA mice are more epithelial in gene expression and
show signifıcantly less collagen deposition compared to Tbk1/: PDA tumors.
Additionally, cell lines isolated from Tbk1/: PDA tumors are more epithelial
in morphology and less migratory and invasive relative to Tbk1/: PDA cell
lines. Current work is focused on delineating the functional contribution of
TBK1 to tumor cell motility in vivo as well as mechanistic understanding of the
epithelial phenotype in Tbk1/: PDA tumors. These results will further our
understanding ofRas signaling in pancreatic cancer and are critical for exploring
a new avenue of targeted therapy.
TUMOR BIOLOGY: Tumor Microenvironment 2
#1986 Determining the signaling pathway of epithelial-IKK deletion-
mediated symbiotic bacterial and fungal infection in carcinogenesis. Na-
Young Song, JamiWillette-Brown, Feng Zhu, Yinling Hu.NCI-Frederick, Fred-
erick, MD.
Bacteria and fungi, two major components of the microbiota, generally share
niches anddevelop both antagonistic and symbiotic relationships, regulating the
pathological impacts on the host. The epithelium is where the bacterial-fungal
interaction occurs most abundantly, but the relationship between the epithe-
lium, bacteria, and fungi on the pathogenesis, particularly tumorigenesis, is
poorly understood. IKK is one of the crucial factors regulating the homeostasis
of squamous epithelial tissues. Recently, our lab has established a mouse model
that develops esophageal squamous cell carcinomas associated with IKK re-
duction, inflammation and chronic fungal infection. Cladosporium cladospori-
oides was a major type of fungi identifıed in this mouse model. Because IKK
deletion in the keratinocytes causes impaired skin barrier, we hypothesized that
loss of epithelial IKKmay control fungal colonization through regulating the
barrier integrity and inflammation. We generated IKKf/f mice with inducible
K15.Cre (IKKf/f/K15.Cre) specifıcally expressed in keratinocytes in hair folli-
cles which is considered as skin stem cells. After deleting IKK in K15 cells in
oral mucosa and skin, IKKf/f/K15.Cre mice were orally inoculated with Cla-
dosporium cladosporioides. We found that epithelial IKK deletion increased
bacterial colonization in oral mucosa and skin. Moreover, Cladosporium infec-
tion further promoted bacterial and fungal colonization in oral cavity and de-
velopment of skin tumors. Taken together, our data suggest that loss of epithelial
IKK induces the bacterial-fungal symbiosis in oral mucosa, promoting skin
tumors. This study will shed light on the importance of the epithelial-bacterial-
fungal interaction in the pathogenesis, proposing epithelial IKK as a novel
regulator of the bacterial-fungal interaction.
#1987 Inhibition of collagen receptor discoidin domain receptor-1
(DDR1) reduces gastric cancer cell motility and metastasis. Ryo Yuge,1 Ya-
suhiko Kitadai,2 Hidehiko Takigawa,1 Shinji Tanaka,1 Kazuaki Chayama,1 Wa-
taru Yasui1. 1Hiroshima Univ., Hiroshima, Japan; 2Hiroshima Prefectual Univ.,
Hiroshima, Japan.
Accumulating evidences suggest that a unique set of receptor tyrosine kinases,
known as discoidin domain receptors (DDRs), play a role in cancer progression
by interaction with their surrounding collagen matrix. Although abnormal ex-
pression of DDRs is reported in some human cancers, little is known about the
expression and function of DDRs in gastric cancer progression. In this study, we
investigated expression and the role of DDR1 in the tumor progression of hu-
man gastric cancer. The expression and distribution of DDR1 was analyzed by
immunohistochemistry in 127 human gastric cancer cases, and the expression
level of DDR1 in 7 human gastric cancer cell lines was analyzed by RT-PCR and
western blotting. Proliferation, migration, invasion, and tube formation assays
were conducted inDDR1 silenced gastric cancer cells. The effect ofDDR1 on the
tumor growth and metastasis were examined in orthotopically implanted nude
mice model and a model of liver metastasis. DDR1 was expressed in human
gastric cancer cell lines, and expression of DDR1 in human gastric tumor was
associated with poor prognosis. Among 7 gastric cancer cell lines, MKN74 ex-
pressed DDR1 at highest level. DDR1-silenced MKN74 cells showed unaltered
proliferation activity. In contrast, migration, invasion, and tube formation were
signifıcantly reduced. When examined in an orthotopic nude mouse model,
DDR1-silenced implanted tumor signifıcantly decreased angiogenesis and lym-
phangiogensesis, thereby leading to reduction of lymph node metastasis and
liver metastasis. We showed that treatment of DDR1 inhibitor also inhibited
lymph node metastasis in an orthotopic nude mouse model These results sug-
gest that DDR1 is involved in GC tumor progression and metastasis. DDR1
could be not only an independent prognostic classifıer, but also a promising
therapeutic target in patients with GC.
#1988 Exosome-mediated ovarian cancer tumorigenesis mediated by
miR1246/Rb/Cav1 axis. Pinar Kanlikilicer, Recep Bayraktar, Mohammed
Rashed, Burcu Aslan, George A. Calin, Anil K. Sood, Gabriel Lopez-Berestein.
MD Anderson Cancer Center, Houston, TX.
Exosomes are secreted frommany cell types and play an important role in the
tumor microenvironment. The most impressive breakthrough in exosomes re-
search was that they contain the genetic material of the host cell. However,
whether cancer cells use their exosomes to transfer their oncogenic material to
recipient cells, or to get rid of their tumor suppressor material is not well under-
stood. We previously identifıed that miR-1246 was hundreds of folds higher
expressed in six different ovarian cancer exosomes compared to their originat-
ing cells. Here, we showed that miR-1246 co-localized in the exosomes in ovar-
ian cancer cells. miR-1246 act as an oncogenic miRNA and the levels were
elevated in ovarian cancer patients compared to health donors.We also demon-
strated that miR-1246 inhibitor treatment in combination with paclitaxel was
signifıcantly inhibited tumor burden in SKOV3-ip1 orthotopic ovarian cancer
model. Our results suggest that miR-1246 inhibited RB tumor suppressor pro-
tein and regulate Cav-1 and platelet-derived growth factor receptor beta precur-
sor signaling in ovarian cancer. In addition InhibitingmiR-1246 led a signifıcant
decrease in exosome release. Together, our fındings provide strong evidence that
oncogenicmiR-1246 canbe targeted as a potential novel therapeutic approach in
the treatment of ovarian cancer.
#1989 Characterization and integration of mantle cell lymphoma mi-
croenvironments are determinant for the development of rational targeted
therapies. David Chiron,1 Celine Bellanger,1 Antonin Papin,1 Benoit Tessou-
lin,1 Christelle Dousset,1 Sophie Maiga,1 Philippe Moreau,2 Cyrille Touzeau,2
Steven Le Gouill,2 Martine Amiot,1 Catherine Pellat-deceunynck1. 1CRCNA,
INSERM, CNRS, Université de Nantes, Nantes, France; 2Service d’Hématologie
Clinique, Unité d’Investigation Clinique, CHU, Nantes, France.
Mantle cell lymphoma (MCL) accumulates in lymph nodes (LN) and dissem-
inates early on in extranodal tissues. Recent effort has been invested on the
identifıcation of intrinsicMCL abnormalities but little attention has been paid to
the importance of the surrounding cells and soluble factors in this pathology.
Further investigations that integrate the key role of the microenvironments are
nowneeded to overcome drug resistance in this incurablemalignancy. Despite a
signifıcant level of the proliferation index Ki67 in LN, we did not detect any
proliferating peripheral blood (PB) MCL cells, suggesting a major role of the
tumor ecosystem. To determine whether stromal (hMSC) or lymphoid-like
(CD40L) interactions could support survival and proliferation, primary circu-
lating MCL cells were cocultured ex vivo. In all the 21 samples tested, CD40L,
but not hMSC, induced cell-cycle progression that was amplifıed by a MCL-
specifıc cytokine cocktail (Ck). To determine the microenvironment dependent
molecular modulations, RNA-seq in MCL cells from PB or cocultured was per-
formed (n8) and comparedwith genes expressed inMCLcells fromLNandPB
(Geo, PB n77, LNn107).More than 65% of genes induced by “CD40LCk”
were also upregulated in the LN. Our model recapitulated molecular signatures
that are characteristic of MCL i.e., cell cycle, BCR, NFkB, NIK and survival,
confırming the relevance of the coculture. We further studied the coculture-
induced regulation of the genes belonging to the survival signature. The major
regulation was an increase in expression of Bcl-xL protein associated with a
striking downregulation of Bcl2 and Bim. Using the functional BH3-profıling
assay, we demonstrated that, whereas PBMCL cells were dependent on Bcl2 for
survival, Bcl-xL upregulation was responsible for loss of mitochondrial priming
and drug resistance. Consequently, whereas clinically available Bcl2 BH3-mi-
metic effıciently triggered apoptosis in PBMCL, cells protected by the microen-
vironment were resistant. We then hypothesized that targeting BclxL could in-
crease treatment effıcacy. By integration of microenvironment modulations
using our coculture model, we developed effıcient targeted strategies (i.e.: BTK
inhibitor, Type II anti-CD20), which counteract BclxL overexpression and over-
come drug resistance in primary cells ex vivo. This strategy should target cells
protected into their niches and our ongoing OAsIs Trial (NTC#02558816) will
rapidly determine in vivo effıcacy in MCL. In summary, we reported here the
development of a relevant model that provides new insights into the microen-
vironment-dependent regulation of proliferation and Bcl-2 family expression.
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Our increased understanding of intrinsic abnormalities and the integration of
extrinsic signaling offer new opportunities to design mechanism-based strate-
gies to overcome drug resistance in MCL and other B cell malignancies.
#1990 Single cell co-expression profıles of immunotherapy targets in the
tumor microenvironment of NSCLC samples. Jeffrey Kim, Nan Su, Xiao-Jun
Ma, Emily Park. Advanced Cell Diagnostics, Newark, CA.
Cancer immunotherapies have made great strides in recent years, yet identi-
fying key molecules in the tumor microenvironment is necessary to develop
improved approaches to achieve more durable responses in a greater number of
patients. Obstacles such as adaptive resistance to individual checkpoint marker
blockade, such as PD1 and CTLA4, have led researchers down the path of pur-
suingmultiple immune targets thatmay be upregulated on the same lymphocyte
as a consequence ofmono-antibody therapies.While several clinical trials taking
a combinatorial approach are currently in progress, including targetingmultiple
checkpoint markers, it is clear that these new strategies may rely on the pre-
existing immune system, regardless of being treatment naïve or previously
treated. The challenge now is to identify the relevant biomarkers and to stratify
patients to provide the most appropriate treatment. As a proof of concept, here
we evaluate single cell co-expression profıles of key therapeutic targets in ar-
chived tissues of non-small cell lung cancer (NSCLC) samples using the RNAs-
cope® Duplex Assay, an advanced in situ hybridization platform that allows for
the visualization of single cell gene expression ofmRNA targets directly in tissue.
In our investigation of 60 archived formalin-fıxed paraffın embedded NSCLC
tissues, co-expression profıles of PD1 or PD-L1 coupled with another therapeu-
tic target (IDO1, LAG3, 4-1BB, GITR, and TIM3) were assessed, bringing to
light substantial variations in the tumormicroenvironment between tissue sam-
ples. These marked differences of co-expressed targets on tumor infıltrating
lymphocytes were scrutinized through quantitative image analysis to further
reveal both the diversity and degree of individuality between tissue samples.
Quantitativelymeasuring the expression ofmultiple targets in single cells within
intact tissues exposed the distinct milieu of targetable therapeutic molecules,
leading to the potential identifıcation of responsive tumors which could help
guide in stratifying patients for different combinatorial approaches.
#1991 Enhanced role of the extracellular matrix in ovarian cancer recur-
rence. Zhiqing Huang, Brad Foster, Carole Grenier, Gregory Sfakianos, Regina
Whitaker, Andrew Berchuck, Susan K. Murphy. Duke Univ. Medical Ctr., Dur-
ham, NC.
Purpose:Despite improvements in care and advancements in the understand-
ing of ovarian cancer (OC) pathobiology and genetic alterations, the survival
rate is disappointingly low when compared to that of other types of cancer. One
factor contributing to the poor survival rate is the development of chemothera-
peutic resistance and a high rate of recurrent tumor growth in the months and
years following primary OC treatment. Our objective was to identify potential
new therapeutic targets for prevention of recurrence through examination of
changes in gene regulation that occur in recurrent versus matched primary
tumors. Procedures: We used 16 primary-recurrent tumor pairs from patients
with stage III/IV serous epithelial OC from the Duke Gynecologic Oncology
Tissue Bank. Illumina Infınium HumanMethylation450 BeadChips and Af-
fymetrix Human Genome U133A arrays were used to quantify methylation and
gene expression, respectively. Expression and methylation of POSTN and
COL11A1 were analyzed using an independent OC dataset comprising 38
women with3 years survival and 26 women with7 years survival, 3 normal
ovarian surface epithelium (OSE) and 2 fallopian tube fımbriae epithelium
(FTFE) samples. siRNA knockdown of POSTN and COL11A1 in OC cells was
followed by expression and proliferation assays. Results: Paired student t tests
showed a 2-fold difference for 13 of the 1,569 signifıcantly differentially ex-
pressed genes, seven with increased expression in recurrent OC (POSTN,
COL11A1, MMP1, MMP13, TNC, ASPN, and EPYC), and six with decreased
expression (GATA6, PEG3, SST, MAOB, TSPAN8, and C7). Interestingly, all
seven up-regulated genes are involved in extracellular matrix (ECM) functions,
an important component of the tumor microenvironment. With an indepen-
dent OC microarray dataset, we found elevated COL11A1 mRNA in OCs as
compared to OSE and FTFE tissues (p0.05). There are inverse correlations
between COL11A1 expression and methylation at fıve promoter CG sites (R-
0.58 to -0.65, p0.05). Immunohistochemistry showed higher expression of
POSTN and COL11A1 in recurrent OC. Knockdown of POSTN and COL11A1
in OC cell lines led to signifıcantly reduced proliferation (p0.05). Conclusion:
Our fındings indicate that the genes involved in extracellular matrix function
that contribute to the composition and regulation of the tumor microenviron-
ment play critical roles in OC recurrence, andmay offer new therapeutic oppor-
tunities.
#1992 Changes in gene expression of stromal and epithelial cells during
prostate cancer progression. Milos Babic,1 Elliot Imler,1 Peter Shepard,1
Joanne Yeakley,1 Raymond Nagle,2 Bruce Seligmann1. 1BioSpyder Technologies,
Inc., Carlsbad, CA; 2University of Arizona, Tucson, AZ.
Prostatic intraepithelial neoplasia (PIN) is a histologic abnormality which
arises within the secretory epithelium of prostate glands, without disrupting
the layer of basal cells which separates the epithelium from the surrounding
stroma. PINs are generally considered to be a step towards development of
prostatic adenocarcinoma (PCA). Molecular steps in the transition from
normal glands to PIN to PCA are poorly understood, in part due to the
diffıculty of accessing and characterizing individual PINs without contami-
nation from surrounding tissue. Furthermore, stromal cells surrounding
pre-cancerous glands may play an active role in cancer development and
progression, but are diffıcult to profıle. We utilized the ultra-sensitive and
quantitative TempO-Seq gene expression assay of the whole transcriptome
to profıle microdisections of stromal vs. epithelial cells in archival prostatec-
tomy FFPE tissue. TempO-Seq is highly insensitive to RNA degradation
(measurements of intact RNA RIN9.1 to degraded RNA RIN3.0 corre-
late with R20.97) and does not require RNA extraction, allowing measure-
ment of both soluble and insoluble cross-linked RNA. This allowed depar-
affınization and H&E staining of prostate sections prior to the assay, so that
morphology was clearly visible and subsections could be readily extracted
and profıled. Microdissections were performed on individual 5 m FFPE
sections of prostatectomies from patients with Gleason sum scores of 6,
containing PIN alongside PCA. We removed an 300 m diameter region
of stroma surrounding individual normal, PIN, and PCA glands, followed by
targeted dissection of the gland epithelium itself which was lysed and assayed
separately. Stroma and epithelial samples from 3 adjacent sections of the
same glands were pooled together (adding up to 0.005 mm3 tissue/repli-
cate), and then profıled. We compared the whole transcriptome expression
profıle of stroma vs. epithelium at every stage of progression. Our results
indicate that stroma and epithelium undergo separate and distinct changes
in gene expression patterns throughout the development of PCA, most no-
tably in genes involved in cell-cell signaling. Specifıcally, we found that
changes in cAMP signaling in stromal cells accompanied the shift from
normal glands to PIN. Furthermore, changes in androgen signaling path-
ways were present in stromal cells as well as in epithelium during the tran-
sition from PIN to invasive carcinoma. These results shed light on the mo-
lecular progression to PCA and demonstrate the feasibility of profıling gene
expression at the level of tissue microstructure to elucidate changes within
the tissue microenvironment. Since archival FFPE can be used, studies of
progression can be carried out and the fındings translated to diagnosis and
prognosis as well as to the investigation of new therapeutic approaches.
#1993 Acidic tumor microenvironment stimulation of GPR4 alters cyto-
skeletal dynamics and migration of vascular endothelial cells. Elizabeth A.
Krewson, Li V. Yang, Lixue Dong. East Carolina University, Greenville, NC.
The acidic tumormicroenvironment results fromaberrant vasculature, insuf-
fıcient oxygen delivery and aerobic glycolysis of cancer cells. As cancer pro-
gresses, the acidic microenvironment can lead to structural changes of endothe-
lial cells (ECs) resulting in increased vascular permeability which may increase
metastasis. Extracellular acidifıcation can activate cellular signaling molecules,
including G-protein coupled receptor 4 (GPR4), which is prominently ex-
pressed in ECs. We have previously reported that acidic activation of GPR4
induces the transcription of several pro-inflammatory and ER-stress related
genes in ECs. The purpose of the study is to identify the functional response of
acidosis-induced GPR4 activity using Human Umbilical Vein Endothelial Cells
(HUVECs) as a model system. The expression of GPR4 was overexpressed
(HUVEC/GPR4) or knocked down (GPR4 shRNA) using several genetic con-
structs. HUVECs were treated withmedia buffered to pH 6.4 or to physiological
pH 7.4. Permeability of a HUVEC cell monolayer was assessed by quantifying
gap formation as one indicator. Cell migration was assessed through wound-
healing assays. Cytoskeletal dynamics were also investigated using Rhodamine
Phalloidin to investigate actin stress fıber formation and immunocytochemistry
to investigate focal adhesion dynamics. Our results showed acidic pH induced
GPR4 activation changed the cytoskeletal phenotype, decreased cellular migra-
tion, and proliferation inHUVECs compared to the physiological pH treatment.
There was also a further increase in gap area of a HUVEC/GPR4monolayer and
formation of actin stress fıbers in response to acidic conditions. Additionally,
altering expression of phosphorylated paxillin and focal adhesion kinase were
observedunder acidosis/GPR4mediated stress. In conclusion, the proton sensor
GPR4 induces cytoskeletal variations, reduces cellular migration, and prolifera-
tion in response to an acidic tumor microenvironment.
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#1994 Defıning peritumoral and tumoral stromal gene signatures associ-
ated with response to neoadjuvant chemotherapy in breast cancer. Celine
Pourreyron,1 Violet Warwick,1 Patsy Whelehan,1 Philip Coates,2 Lee Jordan,1
Colin Purdie,1 Sarah Vinnicombe,1 Alastair Thompson,3 Andrew Evans,1 Fran-
ces Fuller-Pace1. 1University of Dundee, Dundee, United Kingdom; 2Regional
Centre for Molecular Oncology, Brno, Czech Republic; 3MD Anderson Cancer
Center, Houston, TX.
Neoadjuvant chemotherapy (NACT) is used in breast cancer to decrease tu-
mor and lymph node burden and the extent of surgery. However, response is
variable and prediction poor. Stromal cells are involved in breast cancer pro-
gression and drug resistance although very little is known about the mecha-
nisms. Our research aims to characterize breast cancer-associated fıbroblasts
(CAFs) and peritumoral fıbroblasts (PTFs) that predict response to NACT and
could be used to influence treatment choices. Pre-NACT core biopsies from
cancer-associated and peritumoral tissues were collected under ultrasound
guidance. To date, mRNAs from early passage (passage 5) fıbroblasts isolated
from cores of 23 matched pairs (CAFs and PTFs) (8 triple-negative (TNBC), 7
ERHer2 and 8ERHer2- tumors) and an additional 8 PT samples (4TNBC,
1 ERHer2 and 3 ERHer2-) have been analysed by whole-genome expres-
sion array (Illumina beadchip HT12v4). Data were analysed with Partek® Ge-
nome SuiteTM 6.6 and Pathway softwares (Partek Inc., St. Louis, MO, USA).
Differentially expressed genes (DEGs) were identifıed (t-test, p-value  0.05,
fold-change (FC)
 1.3) between CAFs and PTFs and between NACT respond-
ers (Residual Cancer Burden (RCB) 0/1) and non-responders (RCB 2/3). No
signifıcant difference betweenCAFs and PTFs was seen by principal component
analysis and t-test. PTFs showed similar mRNA levels of major myofıbroblast
markers (e.g. FAP, ASMA) with only FSP1 being lower in PTFs compared to
CAFs (FC  -1.4, p-value  0.023), suggesting that PTFs, like CAFs, are acti-
vatedmyofıbroblasts.We then tried to identify a gene signature inCAFs or PTFs
that could predict response to NACT. Comparing RCB 0/1 vs RCB 2/3 resulted
in very few DEGs due to cancer subtype variation in both CAFs and PTFs.
Similar to other studies, only 2/19 patients in our cohort with ER tumours
achieved RCB 0/1, preventing analysis of these samples. However, 45% (5/11)
TNBC responded to NACT and we identifıed 566 DEGs between RCB 0/1 and
RCB 2/3 CAFs, with changes in metabolism, Pi3K/AKT pathway, proteoglycan
synthesis or ECM-receptor interaction. For PTFs, 186 DEGs were identifıed,
with changes in Wnt signalling and ECM-receptor pathways. Microarray data
from our uniquely large sample set of 23 pairs of CAFs and PTFs from breast
cancer patients suggest that PTFs have a similar gene expression profıle to CAFs.
Although others have demonstrated that CAF phenotype is breast cancer sub-
type dependent, we are the fırst to show similar observations in PTFs. Finally, we
identifıed gene signatures from both CAFs and PTFs that relate to NACT re-
sponse in TNBC.We are currently in the process of confırming the most highly
dysregulated genes by qPCR and/or immunohistochemistry analysis.
#1995 The omentum promotes ovarian cancer cell survival by increasing
cell cycle duration and chemoresistance. Carlos Cardenas, Ayesha B. Alvero,
Mary Pitruzzello, Roslyn Tedja, Gil G. Mor. Yale University School of Medicine,
New Haven, CT.
Background: Ovarian cancer is the most lethal of all gynecologic cancers. It is
characterized by the presence of carcinomatosis at time of presentation and
chemoresistant micrometastatic seedings at the time of recurrence. The omen-
tum, an adipocyte-rich organ, is a frequent site of ovarian cancer metastasis in
patients and the most common site of post-chemotherapy residual disease in
animal models. Whereas previous studies have shown how the adipocyte mi-
croenvironment can induce metabolic re-programming in cancer cells, it is not
clear if it can regulate pathways that affect chemoresponse. The objective of this
study is to determine the effect of the adipocytemicroenvironment on pathways
that control cell cycle and apoptosis. Methods: In vitro: Patient-derived epithe-
lial ovarian cancer cell lines were cultured in the presence of absence of omen-
tum conditioned-media. Cell growthwas determined bymeasuring culture con-
fluence using IncucyteTM. Protein expression was determined by western blot
analysis, and flow cytometry. In vivo: Human ovarian cancer xenografts were
established intra-peritoneally in nude mice. Tumor implants from adipocyte-
rich organs such as the omentum, pelvic fat, andmesentery and tumor implants
from non-adipocyte-rich organs such as liver, ovaries, and GI tract were col-
lected and analyzed independently. Results: Compared to cells cultured in
growth media, epithelial ovarian cancer cells cultured in omentumCM demon-
strated a more fıbroblastic morphology characterized by elongated shape and
bipolarity, signifıcantly slower growth kinetics (p  0.0001) accompanied by
upregulation of the cell cycle inhibitor, p27, and enhanced secretion of the pro-
angiogenic factor, VEGF. More importantly, these cells express higher levels of
the anti-apoptotic proteins Bclxl and Mcl-1. Consequently, ovarian cancer cells
in growth media treated with Carboplatin had a IC50 of 14.5 g/ml. In contrast,
cells cultured in omentum CM demonstrated enhanced resistance to carbopla-
tin with IC50 of 50 g/ml. Analysis of tumor implants in vivo showed similar
results as observed in vitro. Thus, tumor implants isolated from adipocyte-rich
organs express higher levels of p27, Bclxl, and Mcl-1. Conclusion: We demon-
strate in this study that the adipocytemicroenvironment inducesmajor changes
in the phenotype of ovarian cancer cells characterized bymorphological changes
chemoresistance and growth rate. These fındings highlight the importance of
the adipocyte microenvironment in the progression of ovarian cancer. Further
studies that can identify specifıc therapeutic targets in the adipocyte-educated
chemoresistant ovarian cancer cells may aid in the development of novel thera-
pies and improve patient survival.
#1996 CXCL12 drives selective expansion ofAKT-induced quiescent, pre-
neoplastic breast cells. Zahra S. Masoud,1 Lisa Kim,1 Kelsey J. Weigel,2 Mat-
thewM. Champion,2 Zachary T. Schafer,2 Cheuk Leung1. 1University of Minne-
sota, Minneapolis, MN; 2University of Notre Dame, Notre Dame, IN.
A critical stage of premalignant development in breast tumorigenesis is the
emergence of preneoplastic cells that carry key oncogenic drivers yet remain
quiescent. Preneoplastic cells maintain a state of quiescence, but may be trig-
gered to proliferate through largely unknown factors. Expansion of these cells is
key to driving clonal evolution, which is evident in early lesions and tissue fıelds
surrounding tumors. Although preneoplastic development is determinant to
successful evolution and formation of tumor growth, the cellular mechanisms
controlling preneoplastic development is unclear. Our limited mechanistic un-
derstanding of quiescent, preneoplastic cell outgrowth highlights a major
knowledge gap in the early control of tumor development. Advancements in
detecting molecular changes in precancerous lesions have provided opportuni-
ties for devising early intervention strategies. Aberrant AKT activation has
emerged as a founding oncogenic alteration in preneoplastic cells.Whilemolec-
ular changes predispose these cells to develop tumors and presumably favors
their selection during early tumor development, how these alterations contrib-
ute to the cellular control of quiescent preneoplastic cells remains unknown. A
major barrier to studying quiescent preneoplastic cells is the lack of physiolog-
ically relevant experimentalmodels. Here, we utilized a novel quiescent, preneo-
plastic cell model that reconstructs the molecular and cellular contexts of pre-
neoplastic breast tissue. We combined a three-dimensional (3D) organotypic
cell culture on reconstituted basement membrane with cells that can be induced
to activate defıned oncogenic pathways. Using this model, we investigated the
contribution of aberrant AKT activation in preneoplastic breast tumor develop-
ment. We found that aberrant AKT signaling in quiescent, preneoplastic mam-
mary cells does not stimulate cells to proliferate under normal conditions, but
confers cell sensitivity to stroma-derived CXCL12 through upregulating the
receptor CXCR4. Using heterotypic co-culture to recapitulate a tumor-promot-
ing environment and quantitative proteomic analysis, we found that stromal-
derived chemokine CXCL12 selectively promotes expansion of preneoplastic
cells with hyperactivated AKT signaling. Mechanistically, we showed that AKT
signaling induces the expression of the chemokine’s receptor, CXCR4, which
confers the selective sensitivity to CXCL12. This CXCL12-CXCR4 axis serves as
an alternate mitogenic signal through PKA and ERK to drive the downregula-
tion of CDKN1C and promote cell proliferation in AKT-induced preneoplastic
cells. Our studies uncovered a distinct role of AKT signaling in promoting pre-
neoplastic development. Furthermore, our studies suggest a model of preneo-
plastic clonal expansion where oncogene signaling confers quiescent preneo-
plastic cell sensitivity to alternate mitogenic stimuli in a permissive tissue
microenvironment.
#1997 Charting the DNA methylation landscape of prostate cancer asso-
ciated fıbroblasts. Mitchell G. Lawrence,1 Ruth Pidsley,2 Elena Zotenko,2
Birunthi Niranjan,1 Aaron Statham,2 Jenny Song,2 Nicola Armstrong,2 John
Pedersen,3Mark Frydenberg,1 Renea Taylor,1 Clare Stirzaker,2 Gail Risbridger,1
Susan Clark2. 1Monash University, Melbourne, Australia; 2Garvan Institute of
Medical Research, Sydney, Australia; 3TissuPath Pathology, Melbourne, Austra-
lia.
Most studies of the genome and epigenome landscape of tumors focus on the
aberrations in epithelial cancer cells. However, the growth and progression of
solid tumors involves dynamic cross-talk between cancer epithelium and the
surrounding microenvironment, including cancer-associated fıbroblasts
(CAFs). The molecular landscape of these cells is still poorly understood, so it is
important to defıne the epigenetic features that underpin the functional differ-
ences between CAFs and non-malignant prostate fıbroblasts (NPFs) and influ-
ence cancer progression. Therefore, we used whole-genome bisulphite sequenc-
ing to chart the epigenome landscape of CAFs at single base resolution. Our data
TUMOR BIOLOGY: Tumor Microenvironment 2
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017512
revealed that NPFs and CAFs from localized prostate cancer have remarkably
different epigenome profıles characterized by locus-specifıc rather than global
changes in DNA methylation. CAFs exhibited more than 7500 differentially
methylated regions compared to NPFs. In contrast, no recurrent genomic aber-
rations were detected in CAFs, emphasising the importance of epigenome
changes in reinforcing their pro-tumorigenic phenotype. Many differentially
methylated regions occurred at known regulatory loci and were associated with
differentially expressed genes measured using RNAseq. The methylation and
gene expression changes were highly consistent across patients when validated
using an independent cohort of patient-matched NPFs and CAFs. Remarkably,
a subset of differentially methylated regions in CAFs is shared with prostate
cancer epithelial cells, revealing the new concept of tumour-specifıc epigenome
modifıcations in the tumour and its microenvironment. Collectively, these data
demonstrate that CAFs are defıned by an enduring epigenetic signature that
comprises a distinct set of locus-specifıcDNAmethylation alterations in cancer-
related regulatory loci. The distinct methylome of CAFs provides a novel epige-
netic hallmark of the cancer microenvironment and promises new biomarkers
to improve interpretation of diagnostic samples.
#1998 Transcriptome analysis of hypoxic head and neck cancer cells un-
covers intron retention in EIF2B5 as a mechanism to reduce protein synthe-
sis. Lauren K. Brady,1 Hejia Wang,1 Caleb Radens,1 Milan Radovich,2 Amit
Maity,1 Cristina Ivan,3Mircea Ivan,2 Yoseph Barash,1 Constantinos Koumenis1.
1University of Pennsylvania, Philadelphia, PA; 2IndianaUniversity, Indianapolis,
IN; 3University of Texas, MD Anderson Cancer Center, Houston, TX.
Hypoxia is a key feature of solid tumors that contributes to resistance to
therapy and reduced overall survival. Cellular adaptation to the hypoxic tumor
microenvironment involves attenuation of energy-consuming processes such as
macromolecular synthesis. We have identifıed RNA processing as another ma-
jor processwhich is globally downregulated under hypoxic stress. By sequencing
RNA of normoxic and hypoxic head and neck cancer cells, we observed wide-
spread repression of genes that regulate RNA splicing and processing. As a
result, we observed over 1,000 changes in relative mRNA isoform expression,
including a signifıcant increase in hypoxia-induced intron retention in nearly
100 genes. Genes observed to undergo intron retention in hypoxia included
major regulators of RNA processing and protein synthesis, such as the transla-
tion initiation factor EIF2B5. Surprisingly, hypoxia-induced intron retention in
EIF2B5 creates a premature termination codon, which results in a truncated
protein isoform of eIF2B. We provide evidence that this isoform acts in oppo-
sition to the full-length protein to inhibit translation under stringent hypoxic
conditions.Moreover, this intron is expressed in solid cancers known to contain
hypoxic fractions and is overexpressed in head and neck cancer in a stage-
dependent manner compared to normal tissue. To investigate how this intron is
retained, we are examining the role of hypoxia-mediated changes in phosphor-
ylation of the C-terminal domain (CTD) of RNA polymerase II. Our data sug-
gest that increased phosphorylation of the CTD may lead to transcriptional
pausing and subsequent retention of intron 12 in EIF2B5. Furthermore, distinct
sequence features at this locus, such as a weak splice site at the intron12:exon13
junction, may explain how this intron is selectively retained in hypoxic cells.
These results implicate mRNA splicing as a key mechanism to induce alternate
transcripts and subsequent protein isoforms under hypoxia that influence cel-
lular adaptation to stress.
#1999 Cofactor Paragon: a novel tool to analyze the tumormicroenviron-
ment using RNAseq. Ryan Bloom, Raman Talwar, Jeff Hiken, Jon Armstrong.
Cofactor Genomics, St. Louis, MO.
The impact of cancer immunotherapy on clinical cancer care is growing rap-
idly. However, there are several mechanisms by which a tumor can avoid recog-
nition and/or elimination by the immune system. Immune recognition, activa-
tion, and infıltration are each required for effective clearance of a tumor by the
immune system. Impairment of any one of these mechanisms requires a differ-
ent therapeutic strategy or combination of strategies to signifıcantly address.
The development of new multi-modal biomarker technologies that have the
ability to provide insight into each of these factors in a cost-effective manner is
essential to effectively guide treatment choice for patients and to discover new
therapeutic targets. We have developed Paragon, which is an RNA sequencing
based panel that utilizes novel informatics technologies to provide a compre-
hensive picture of a tumor’s transcriptomic and immune micro-environment.
There are three distinct outputs of Paragon: measurement of the expression
levels of ten immune checkpoint genes, quantifıcation of the total mutational
burden of the tumor, and the levels of infıltration of 24 different immune cell
subtypes within the tumor microenvironment. These outputs collectively in-
form the various mechanisms that tumors use to evade recognition and clear-
ance by the immune system.We show that Cofactor Paragon accurately reports
on gene expression, mutational burden and infıltrating leukocytes compared to
gold standardmethods from just 20 ng of FFPE tumor RNA.We further analyze
the data to show the correlation between mutational burden and infıltrating
CD4 and CD8 T-cell levels. Finally, we show how Paragon can identify
expression of genes involved in inhibitory tumormetabolism that correlate with
resistance to PD-1 blockade therapy. These results position Cofactor Paragon as
a novel tool that can help identify ideal therapeutic strategies in immuno-oncol-
ogy.
#2000 Targeted characterization of tumor heterogeneity through RNA-
Seq analysis of phenotypically defıned subpopulations.Warren Porter, Eileen
Snowden, Friedrich Hahn, Mitchell Ferguson, Frances Tong, Shannon Dill-
more, Rainer Blaesius. BD Technologies, RTP, NC.
Cancer progression and metastases have been linked to the complex hetero-
geneity found within many solid tumors. In order to understand the complexi-
ties within solid tumors there is a need for in-depth characterization of the
tumor and the surroundingmicroenvironment, including the identifıcation and
measurement of the subpopulations found within the diseased tissue. Here we
describe a method to interrogate the heterogeneity within patient derived xeno-
graft (PDX) derived solid tumors through tissue dissociation, single cell flow
sorting, and expression analysis of the resulting subpopulations. Cell sorting
enables the identifıcation and capture of phenotypically defıned subpopulations
within the tumor microenvironment for additional downstream analysis.
Whole transcriptome RNA-Seq was performed on samples collected through-
out the workflow to characterize the expression changes in cells during the
different steps of the process. Expression differences were measured before and
after tissue dissociation, before and after incubation, and before and after cell
sorting. Expression differences were also measured between phenotypically de-
fıned subpopulations sorted by the CD133 and CD49f surface markers. Several
signifıcant differentially expressed gene combinations between samples were
observed. These differences involved unique pathway characteristics between
the different subpopulations sorted based on expression of CD133 and CD49f
markers. In contrast, changes induced by the workflow process alone were re-
stricted to a small andwell-defıned gene subset of immediate early genes (IEGs).
Within the workflow, these changes were restricted to the tumor dissociation
step and no changes were detected after incubating and/or cell sorting the dis-
sociated cells. Our results indicate that solid tumor dissociation followed by flow
cytometric analysis and sorting enables the interrogation of phenotypically de-
fıned subpopulations found within solid tumors. Since workflow induced
changes are minimal and defıned, these methods reveal biological differences
between subpopulations within and between cancers. Differential expression of
numerous surfacemarker genes were identifıed by ourmethod allowing discov-
ery of other candidate surfacemarkers thatmay extend the subpopulation struc-
ture. Once verifıed these additional surface markers could serve to elucidate the
dynamic changes cancer tissue undergoes during progression as well as in re-
sponse to selective pressures such as drug therapy.
#2001 Preclinical investigation of a 15 gene hypoxia profıle in different
prostate cancer cell lines. Thomas R. Wittenborn,1 Brita S. Sorensen,1 Morten
Busk,1 Mathilde B. Thomsen,2 Steffen Nielsen,1 Michael R. Horsman1. 1Aarhus
University Hospital, Aarhus C, Denmark; 2Aarhus University Hospital, Aarhus
N, Denmark.
Purpose: Hypoxia is known to reduce the response to radiotherapy and
has been found to be a common feature in prostate cancer. Identifying pa-
tients with hypoxic tumors will allow us to select those patients that require
specifıc hypoxic modifıers. Previously our department has developed a gene
profıle consisting of 15 genes, which demonstrated prognostic and predictive
impact for hypoxic modifıcation in head and neck squamous cell carcinomas
(HNSCC). In the current study we investigated the 15 gene profıle in vitro in
different prostate cancer cell lines, and subsequently in vivo in the PC3
xenograft model. Methods: For the in vitro experiments the prostate cancer
cell lines investigated were PC-3, LNCaP and DU-145. Cell lines were cul-
tured under normoxic (21% O2) or varying hypoxic conditions (0%, 0.5%,
1.0%, 2.0%, and 5.0% O2) for 24 hours, totRNA was extracted and gene
expression levels measured by qPCR. Individual reference genes were se-
lected (PSMC4, TBP, NDFIP1) and applied in the normalization of the rel-
ative expression levels, together with the reference genes previously used in
the HNSCC study. For in vivo experiments, the PC3 cell line was inoculated
on the flank of female NMRI nu/nu mice. Two hypoxia-sensitive tracers
(18F-FAZA and Pimonidazole) were administered in order to determine
hypoxic and non-hypoxic regions on excised tumor sections. These regions
were isolated by laser-assisted microdissection, after which totRNA was ex-
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tracted and gene expression levels measured by qPCR. Results: In the in vitro
experiments, all three prostate cancer cell lines had 14 of the 15 genes in-
duced by hypoxia, when comparing the anoxic cells (0% O2) to the normox-
ic.cells (21% O2). The only discrepancy was ALDOA, which was not upregu-
lated in the hypoxic cells. In the PC3 and DU-145 cell lines genes were
investigated at additional hypoxic levels (0.5%, 1.0%, 2.0%, and 5.0% O2),
giving a more intricate expression of the 15 genes. In vivo experiments are
still ongoing but preliminary results show a hypoxia induced upregulation in
10 out of the 15 genes, of which 4 were signifıcantly upregulated (ADM,
ANKRD37, FAM162A, and LOX). Conclusion: We investigated the 15 gene
hypoxic profıle in different prostate cancer cell lines, both in vitro and in
vivo. A hypoxia dependent induction of genes was observed in both types of
experiments, however with a differential gene expression with regard to
hypoxia level. From the performed experiments, and looking only at oxygen
dependency, it appears that the gene profıle could be suitable for prostate
cancers as well as HNSCC. Funding sources: Danish Cancer Society ; The
Danish Council for Independent Research: Medical Sciences ; EC FP7 proj-
ect METOXIA (project no. 222741) ; CIRRO: The Lundbeck Foundation
Center for Interventional Research in Radiation Oncology and The Danish
Council for Strategic Research.
#2002 Disrupting immunosuppressive tumor microenvironment via
stealthy nanobombs to enhance T-cell anticancer effıcacy. Hongwei Chen,
Hayley J. Paholak, Xin Luan, Joseph P. Burnett, Nicholas O. Stevers, Kanokwan
Sansanaphongpricha, Duxin Sun. University of Michigan, Ann Arbor, MI.
Despite the fact that the immunosuppressive tumor microenvironment
(ISTME) has long been recognized as a major hurdle that signifıcantly limits
the anticancer effıcacy of various therapeutic strategies, including T-cell-
based immunotherapy, there is currently no effective way to address this
challenge. In this work, we prove that sequential photothermal therapy
(PTT), mediated with stealthy laser-triggerable nanobombs composed of
iron oxide nanoparticles (IONPs) following systemic delivery, can remove
both pre-resident and also newly triggered immunosuppressor cells in es-
tablished tumors to enhance the effıcacy of T-cell anticancer therapy. Using
flow cytometry to study various T-cell populations in tumor tissues 48 h post
PTT in a 4T1mouse model, our data suggest that IONP-mediated PTT could
signifıcantly reduce the CD4FoxP3 regulatory T-cell population. Our
data also suggest that CD8 cytotoxic T-cell populations in PTT-treated
tumor tissues return to those of non-treated tumors, and are believed to be
newly activated at the tumor site or recruited from periphery blood following
PTT. Our data further suggest that PTT twice spaced by a 24 h interval has
the best anticancer effıcacy, compared to PTT once or three times at 24 h
increments. This enhanced anticancer effect from the sequential IONP-me-
diated PTT (twice) is believed to be due to an enhanced ability to eliminate
triggered immunosuppressor cells that respond faster than cytotoxic CD8
T-cells. Furthermore, our Luminex analysis of chemokine serum concentra-
tions indicates that IONP-mediated PTT can decrease suppressor-cell-at-
tractive protein secretion, such as G-CSF. In addition, our immunohisto-
chemistry data from tumor tissue staining indicate that IONP-mediated PTT
down-regulates tumor cell PD-L1 expression to disrupt tumor-cell-medi-
ated immunosuppression. The capability of IONP-mediated PTT to disrupt
ISTME can signifıcantly enhance T-cell anticancer effıcacy toward both
treated established tumors and distal tumor cells. When combining IONP-
mediated PTT with anti-CTLA-4 therapy to block CD8 T-cell inhibition,
our data suggest that combination treatment signifıcantly inhibits tumor
growth (p  0.01), while control treatments, including the antibody alone,
IONP-mediated PTT alone, and mock treatment, fail to do so. Our data
further show that in a metastasis-mimic model, mice (6/6) that had primary
tumors treated with PTT/anti-CTLA-4 reject pre-inoculated cancer cells at a
distal site. Our data also show that the majority of the PTT/anti-CTLA-4
treatment-cured mice can reject subcutaneously (8/12) or tail-vein injected
4T1 cancer cells (9/9), indicating memory T-cell immune surveillance. In
conclusion, this study provides a nanotechnology-based novel strategy to
effectively disrupt not only pre-existing but also treatment-induced ISTME
to boost T-cell-based cancer immunotherapy.
#2003 Antibody against TIGIT (T cell immunoreceptor with Ig and ITIM
domains) induces anti-tumor immune response andgenerates long-term im-
mune memory. Angie Inkyung Park, Minu Srivastava, Erin Mayes, Hyun-Bae
Jie, Rui Yun, Christopher Murriel, Ming-hong Xie, Andrew Lam, May Ji,
Fumiko Axelrod, JorgeMonteon, John Lewicki, TimHoey, Austin Gurney.On-
coMed Pharmaceuticals, Inc., Redwood City, CA.
T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a co-inhib-
itory molecule containing an immunoreceptor tyrosine-based inhibition
motif (ITIM) within its cytoplasmic tail, and is highly expressed on regula-
tory T cells and activated CD4 T, CD8 T, and NK cells. TIGIT competes
with CD226, which contains an immunoreceptor tyrosine-based activation
motif (ITAM) within its cytoplasmic tail for ligands poliovirus receptor
(PVR) and poliovirus receptor-related 2 (PVRL2), with higher affınity to
PVR. The ligands are expressed on the surface of antigen presenting cells and
at high levels on most tumors. Therefore, when TIGIT is present, the ligands
preferentially engage TIGIT rather than CD226, leading to cell suppression.
We have generated antibodies against TIGIT that blocks ligand binding and
inhibits TIGIT signaling. The clinical candidate, OMP-313M32 binds hu-
man TIGIT but not rodent and non-human primate TIGIT. Therefore, a
surrogate antibody was generated for pre-clinical assessments in mice. An-
tibody 313R12 is an anti-mouse TIGIT antibody that can block mouse PVR
ligand binding and inhibit TIGIT signaling in amanner similar to the clinical
candidate OMP-313M32. 313R12 inhibited the growth of syngeneic colon
and kidney tumors in immune competent mice. In some cases, anti-TIGIT
antibody 313R12 caused complete tumor regression and a potent anti-tumor
immune memory response as demonstrated by the lack of tumor growth
upon re-challenge of mice that remained tumor-free after prior anti-TIGIT
treatment. Mechanistically, anti-TIGIT antibody 313R12 was shown to in-
duce a Th1 response and increase cytotoxic T lymphocyte (CTL) activity. By
in vivo depletion of T cell populations, we have shown that CD8 T cell
depletion completely abrogated the anti-TIGIT therapeutic effect, whereas
CD4 T cell depletion led to partial reversal of effıcacy of anti-TIGIT. There-
fore, both CD4 and CD8 T cells are critical for anti-TIGIT-mediated
immune responses. Using mice reconstituted with human hematopoietic
stem cells, we also demonstrated that the clinical candidate OMP-313M32
inhibits patient-derived melanoma tumor growth. Taken together, these
data demonstrate that anti-TIGIT therapy suppresses tumor growth and
generates long-term immunological memory against multiple tumors.
#2004 Epigenetic targetingofCD276 expression inmedullolbastoma.Ma-
heedhara R. Guda,1 Jose R. Castellanos,1 Collin M. Labak,1 Ramadevi Sanam,2
David J. Daniels,3 Sarah E. Martin,1 Julian J. Lin,1 Andrew J. Tsung,1 Kiran K.
Velpula,1 SwapnaAsuthkar1. 1University of Illinois College ofMedicine at Peoria,
Peoria, IL; 2GVK Biosciences, Hyderabad, India; 3Mayo Clinic, Rochester, MN.
Medulloblastoma (MB) is the most common malignant brain tumor in chil-
dren and accounts for 20% of pediatric CNS tumors. Following surgery and
treatment with chemotherapy and radiation, MBs recur in a signifıcant propor-
tion of patients. Moreover, survivors experience comorbidities related to the
tumor and/or its treatment. New insights into MB tumor pathogenesis are
needed for improving the survivorship and outcome of MB. Epigenetic silenc-
ing, including histone modifıcation and DNA methylation, is an important tu-
morigenic mechanism in MB. However, its role in cancer immunopathology is
poorly understood. Using datamining and immunohistochemistry analysis, we
show that B7-H3 (CD276), an important immune checkpointmember of the B7
and CD28 families, is highly upregulated in all four molecular subtypes of MB
compared to normal tissue. Based on the clinical success of inhibitory immune
checkpoint blockades (CTLA-4, PD-1, and PD-L1), CD276 appears to be a
promising therapeutic target for cancer immunotherapy. Moreover, we ob-
served that increased expression of CD276 correlates signifıcantly with the ex-
pression of Enhancer of Zeste Homologue 2 (EZH2), a histone H3-methylating
(H3K27me3) catalytic subunit in the human MB specimens. We hypothesize
that combined targeting of CD276 and EZH2may have greater impact on tumor
progression and immune cell response in MB. Simultaneously, we performed
LC/MS analysis to identify novel interaction partners of CD276 in MB tumor.
These fındings taken together suggest that CD276 is strongly associated with
several epigenetic markers, indicating a strong relationship between cancer im-
mune evasion and epigenetic mechanisms.
#2005 Synergistic effect of phenyl alpha-galactosylceramide C34 and che-
motherapy on 4T1-tumor bearingmousemodel. Jung-TungHung, Jen-Chien
Wu, Tsai-HsienHung, Jing-RongHuang, John Yu, Alice L. Yu. Institute of Stem
Cell & Translational Cancer Research, Taoyuan City, Taiwan.
Invariant natural killer T (iNKT) cells represent a unique subpopulation of
innate immune cells which have immune modulatory effects on many immune
effector cells such as CD4 T cells and CD8 T cells. Alpha-galactosylceramide
(a-GalCer) is a well-known iNKT-stimulating glycolipid. Using a-GalCer as a
template, we have generated amore potent a-GalCer analogC34,which contains
two aromatic rings at the acyl chain and demonstrated its anti-cancer effect on
tumor bearingmicemodel. It has been reported that NKT cells killed cancer cell
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lines treated with chemotherapy agents through TRAIL- and FasL-mediated
pathways. In this study, we evaluated the anti-cancer effects of chemotherapy
andC34 on tumor-bearingmousemodel. First, BALB/cmice bearing 4T1 breast
cancer were injected with various dose of chemotherapy agents weekly x 5 and
the sub-optimal dose of docetaxel and doxorubicin was determined to be 0.5
mg/Kg. Similarly, sub-optimal dose of cisplatin and docetaxel in TC1 lung can-
cer-bearing C57BL/6 mice was determined to be 1 mg/Kg and 2 mg/Kg, respec-
tively. In both tumormodels, the suboptimal dose of C34 was found to be 0.1 ug
per mouse. The treatment schedules of combination of chemotherapy and C34
were examined by administration of C34 at the same day (0D), three days (-3D)
and one day (-1D) before chemotherapy and one day (1D) after chemother-
apy. We observed a survival benefıt in mice injected with C34 one day after
docetaxel treatment in 4T1-bearing mice as compared to those treated with the
other schedules. Moreover, the survival of mice was signifıcantly prolonged
when C34 was injected three days after cisplatin treatment in TC1-bearing mice
(median survival: 46 days for cisplatin and 55 days for cisplatinC34, log-rank
test p  0.041). In the 4T1 tumor microenvironment, we found the number
of CD3CD8 T cells was signifıcantly greater in mice treated with
docetaxelC34 (23,536 / 901.4) than those treated with docetaxel only
(2,270/ 1,536, t-test P 0.0001). In addition, the number of PD1 CD8 T
cells was slightly higher, but did not reach statistical signifıcance (t-test p 0.3),
in mice treated with docetaxelC34 (23.3 / 8.5) than in mice treated with
docetaxel only (14.6/ 10.1). In short, we have established an optimal treat-
ment schedule for the combination of C34 and chemotherapy that showed syn-
ergistic anti-tumor effıcacy. We also demonstrated that C34 could increase the
number of CD8 T cells in the tumor microenvironment in mice receiving
chemotherapy. These results indicate that combination of C34 and chemother-
apy administered with an optimal treatment schedule might have synergistic
therapeutic effıcacy for patients with lung cancer and breast cancer.
#2006 AMX-513 polyamine depletion therapy inhibits tumor growth and
reverses immunosuppression in cancers including MYC-driven neuroblas-
toma and pancreatic cancer. Mark R. Burns,1 Kathy Fosnaugh,2 Michael G.
Palfreyman,1 Laura Gamble,3 Jayne Murray,3 Sophie Allan,3 Georgina Eden,3
Sara Sarraf,3 Murray Norris,3 David Ziegler,3 Michelle Haber3. 1Aminex Ther-
peutics, Inc., Kirkland, WA; 2Aminex Therpeutics, Inc., Kenmore, WA; 3Chil-
dren’s Cancer Institute Australia, Sydney, Australia.
Tumorigenesis is associated with increased polyamine levels and involves the
induction of ornithine decarboxylase (ODC), the initial rate-limiting enzyme in
polyamine biosynthesis, and increased uptake of polyamines from the blood and
diet. Aswell as contributing to proliferation, polyamines are reported to exert an
immunosuppressive effect. Amplifıcation of the MYC/MYCN oncogenes has
been shown to directly induce ODC activity and inhibition of this enzyme by
-difluoromethylornithine (DFMO) markedly delays tumor development.
Aminex Therapeutics is developing a polyamine depletion approach targeting
both biosynthesis and transport of polyamineswithAMX-513, a combination of
the approved ODC inhibitor, DFMO, together with AMXT 1501, an alkylated
polyamine mimetic which blocks polyamine uptake. In the syngeneic
CT26.CL25 mouse model of colorectal cancer, AMX-513, dosed daily for four
weeks, reduced tumor growth  75% compared to vehicle-treated control in
immunocompetent Balb/C mice. There was no effect in athymic nude mice
indicating that tumor growth inhibition by AMX-513 is T-cell-dependent. In
the induced transgenic K6/ODC squamous tumor mouse model, stable regres-
sion was sustained 10 weeks after treatment ended and was accompanied by
tumor infıltrate increases in IFNγ and in CD3 and CD8 T-cells. Tumor
infıltrates from AMX-513-treated KPC pancreatic cancer transgenic mice with
tumor regressions showed 90% reductions in myeloid-derived suppressor
cells (MDSCs; CD11b Gr-1) but no changes in mature myeloid cells
(CD11Gr-1neg) by FACS analysis. AMX-513 treatment did not impact the
percentage or number of CD4CD25FoxP3 Tregs, but did signifıcantly
increase the percentage of activated CD8 T cells in tumors. Neuroblastoma is
an aggressive childhood cancer frequently associated with MYCN and ODC
deregulation. In neuroblastoma cell lines, theAMX-513 combinationwas highly
synergistic (CI0.5). Prophylactic treatment of neuroblastoma-prone TH-
MYCN transgenic mice with AMX-513 signifıcantly extended survival com-
pared to either agent alone (median survival time  81.0	11.8 days versus
DFMO alone  57.1	7.1 days; P0.0001). Treatment of mice with small pal-
pable tumors with AMX-513 in combination with cyclophosphamide/topote-
can signifıcantly improved survival compared with either AMX-513 or cyclo/
topo alone (5/9 long term survivors compared to 0/10 and 0/9 for cyclo/topo and
AMT-513, respectively; P0.001 in each case). Polyamine levels were signifı-
cantly decreased in mice undergoing AMX-513 treatment compared to DFMO
or AMXT 1501 alone. In conclusion, AMX-513 treatment alone or in combina-
tion with other cancer therapies results in signifıcant tumor growth reduction in
multiple cancer models and demonstrates novel immunotherapeutic potential.
Clinical evaluation of AMX-513 is planned in 2017.
#2007 MHC class I polypeptide related sequence A (MICA) in context of
aggressive prostate cancer.Marcelo J. Sakiyama, Ingrid Espinoza, Amit Reddy,
Jack R. Lewin, Xinchun Zhou, Xu Zhang, Jesus Monico, Charles R. Pound,
Christian R. Gomez. Univ. of Mississippi Medical Center, Jackson, MS.
Prostate cancer (PCa) is the second most common cancer in American
men, with higher incidence and death rates in African Americanmen (AAM)
relative to Caucasian American men (CAM). MHC class I polypeptide-re-
lated sequence A (MICA) is a protein expressed in the membrane of tumor
cells that binds to the NKG2D receptors in NK cells and subtypes of CD8T
cells, activating its cytotoxic effects. Aggressive tumors cleave MICA from
the membrane, release the soluble form (sMICA) into the plasma and down-
regulate the NKG2D receptor from the immune cells. Reports in PCa show
loss of MICA expression from the cell surface is associated to a more aggres-
sive phenotype. Likewise, increased levels of sMICA were linked to patients
with Gleason score (GS) greater than 7. We hypothesized that conditions
related to tumor aggressiveness in the microenvironment, would modify the
levels of MICA in PCa. We also speculated that, when compared to CAM,
MICA would be differentially expressed in tumors from AAM. To access the
different expression of MICA in AAM and CAM PCa patients we stained a
TMA containing 41 CAM and 44 AAM tumor cores for MICA expression.
Our results showed that CAM PCa tumor cores had higher proportion of
high expression of MICA than the AAM (38% vs 7% respectively, p0.008).
Moreover, the association between race and MICA expression was more
profound with GS greater than 7 (p0.001). Next, we explored the effect of
hypoxia, a condition known to be associated with tumor aggressiveness, on
MICA surface expression.We stained our TMA for hypoxia-inducible factor
1-alpha (HIF1-), the master regulator of cellular and developmental re-
sponse to hypoxia. Similar to MICA expression, HIF1-  expression was
observed in tumor cores compared to normal tissue cores (43% vs 17%
respectively, p0.021). In CAM there was a positive correlation between
MICA and HIF1- immunostaining (rs 0.50, p 0.004), while in AAM
correlation was weak (rs 0.32, p 0.081). FACS analysis on C4-2B cells
revealed that 1% O2 (hypoxia) reduced MICA expression by 24.1%, relative
to 20% O2 (normoxia). Likewise, incubation of PCa cells in the presence of
100M cobalt chloride, a compound that mimics hypoxia by inducing HIF-
1/3 , reduced MICA by 16.7%, relative to control conditions. Altogether,
our results indicate that expression of MICA is modifıed by disease aggres-
siveness and hypoxic conditions. Experiments to validate our results in mi-
norities are currently in progress. Of equal interest is the progress of exper-
iments focused on elucidation of the mechanistic involvement of tumor
microenvironment on MICA-mediated tumorigenesis and immunoevasion.
Funding acknowledgements: PCRP W81XWH-14-1-0151 (CRG), UMMC
Department of Pathology (CRG), CAPES (MJS).
#2008 Intestinal microbiota may dynamically facilitate the anti-PD-L1
immunotherapy. Jia Xue,1 Zhun Wang,1 Sheng Guo,1 Jie Cai,1 Davy Ouyang,1
Bin Cai,2 Gang Chen,2 Jie Liu,2 Xin Dong,2 Henry Li1. 1Crown Bioscience, Inc.,
Beijing, China; 2Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing, China.
Cancer immunotherapies, e.g. the antibody against programmeddeath ligand
1 (PD-L1), a checkpoint inhibitor, have witnessed great successes in treating
certain cancers in recent years. Recent data have also demonstrated that gut
microbiota are important modulators on anticancer immunotherapy1,2. Heter-
ogeneity in patient outcome seems to suggest complex communications be-
tween microbiota and host antitumor immunity. To this end, we tested an en-
gineered chimericMC38mouse cell line, hPDL1-MC38-HuCELLTM via human
PD-L1 knock-in procedure, where MC38 CRC syngeneic cell is derived from
C57BL/6. After treatment of PD-L1 antibodies (cD7A8 and BMS PD-L1 of dif-
ferent dose regimens), we observed signifıcantly different drug responses among
themice from three different Chinese rodent suppliers: the mice fromVendor 1
showed no tumor progression after treatment with a variety of doses while no
favorable response was observed in mice from Vendor 2 and Vendor 3. To
deeply study the gut microbiota of these mice, we performed 16S ribosomal
RNA sequencing on untreated mice from three groups (5 replicates for each).
Global diversity analysis by Quantitative Insights Into Microbial Ecology (QI-
IME) tool revealed a clear separation in the three sources of mice: the mi-
crobiota composition of Vendor 2 and Vendor 1 are relatively closer to each
other whereas the Vendor 3 mice are different, suggesting that the main
difference seen between Vendor 1/2 and 3 in the original composition of gut
microbiota is not the key impact for the observed anti-PD-L1 effıcacy, and
TUMOR BIOLOGY: Tumor Microenvironment 2
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 515
there should be other complex dynamics impacted anti-PD-L1 treatment,
which remains unknown. Moreover, a group of 27 taxa were identifıed with
signifıcant difference in abundance (Kruskal-Wallis test, p-value  0.05)
across the groups, such as Bacteroidaceae, Lachnospiraceae, and Rumino-
coccaceae, which confırmed the previous data1. In conclusion, intestinal
microbiota dynamically facilitate anti-PD-L1 effıcacy and reversely anti-
PD-L1 treatment could influence reconstruction of gut microbiota. Refer-
ences 1. Sivan A, et al. Commensal Bifıdobacterium promotes antitumor
immunity and facilitates anti-PD-L1 effıcacy. Science 2015;350(6264):
1084-9. 2. Vétizou M, et al., Anticancer immunotherapy by CTLA-4 block-
ade relies on the gut microbiota. Science 2015;350(6264):1079-84. 3. Capo-
raso JG, et al., QIIME allows analysis of high-throughput community
sequencing data. Nat Methods. 2010;7(5):335-6.
#2009 CC-90002 (anti-CD47 antibody) in vivo anti-tumor activity is asso-
ciated with an increase in M1-polarized macrophages. Bing Zheng,1 Piu
Wong,1 WenQing Yang,2 Rama Narla,2 Michael Burgess,1 Laure Escoubet,2
Heather Raymon,2 Kandasamy Hariharan,2 John Boylan,2 Kristen Hege,1 Vic-
toria Sung1. 1Celgene Corporation, San Francisco, CA; 2Celgene Corporation, San
Diego, CA.
CD47, also known as integrin-associated protein, is over-expressed in
several tumor types, including AML, NHL, breast cancer and multiple my-
eloma. Elevated expression of CD47 on the cell surface protects tumors from
phagocytosis by macrophages through binding to signal regulatory protein
alpha (SIRP) on the surface of macrophages. The CD47-SIRP interaction
triggers events that culminate in the inhibition of the phagocytic process.
Macrophages are one of the immune cell types frequently found in the tumor
microenvironment and exist as a heterogeneous population that includes
both M1 and M2 macrophages. While the spectrum of macrophage sub-
populations are likely quite diverse, traditionally, it is thought that M1 mac-
rophages are pro-inflammatory, enhancing immune responses against tu-
mor cells, while M2 macrophages are pro-tumor, since they express a wide
array of anti-inflammatory molecules, cytokines and growth factors that
promote tumor growth, angiogenesis and an immunosuppressive microen-
vironment. We evaluated CC-90002 effıcacy in the RPMI-8226 multiple my-
eloma and MDA-MB-231 breast cancer xenograft models and enumerated
mouse M1/M2-like macrophage populations within in the tumor before and
after C-90002 treatment. In both RPMI-8226 andMDA-MB-231models, M2
macrophages were the primary resident macrophage. Our studies show that
when mice bearing RPMI-8226 multiple myeloma xenografts were treated
with CC-90002 (a humanized anti-CD47 antibody), tumor regression was
preceded by infıltration of macrophages into the xenograft. In the MDA-
MB-231 breast cancer model, resident macrophages appeared to mediate the
CC-90002 anti-tumor effıcacy in vivo without additional macrophage traf-
fıcking. Interestingly, in both models, M1 macrophages appear to mediate
CC-90002 effıcacy regardless of whether macrophages infıltrate the tumor or
are tumor-resident. In the MDA-MB-231 breast cancer model where CC-
90002 did not induce infıltration, it is possible that resident tumor macro-
phages were re-educated to an M1 phenotype. In in vitro experiments using
human monocyte-derived macrophages, both M1 and M2 macrophages are
able to promote phagocytosis and additionally, we observed that CC-90002
selectively inhibited migration of M2 macrophages toward tumor cell con-
ditioned media. This would presumably shift the overall balance of tumor-
associated macrophages toward the M1 phenotype and suggests that inhib-
iting CD47 can both promote tumor phagocytosis and skew tumor
macrophage subpopulations toward an anti-tumor phenotype. CC-90002 is
currently being tested in two ongoing Phase I clinical studies in subjects with
advanced solid and hematologic cancers (NCT02367196, NCT02641002).
#2010 BTK inhibitor BGB-3111 demonstrates anti-tumor activity in solid
tumormodels.NanHu, Jiye Zhang,MinHe, Shuo Zhang, Yong Liu, LaiWang.
BeiGene Bio, Ltd., Beijing, China.
Background: BGB-3111 is a novel, irreversible, second generation BTK inhib-
itor with better selectivity profıle and DMPK property compared to ibrutinib. It
has demonstrated promising anti-tumor activities in patients with advanced B
cell malignancies. Given BTK is expressed in all hematopoietic lineages except
for T lymphocytes, it is reasonable to explore the immune modulatory effect of
BGB-3111. In this study, we sought to investigate the anti-tumor activity of
BGB-3111 in solid tumor models. Methods: Cell viability was assessed with Cell
Titer Glo® assay and half maximal inhibitory concentrations (IC50) were esti-
mated. In vivo activity was assessed in subcutaneous mouse xenograft models.
Treatments were administered by oral gavage and individual body weight and
tumor volume was recorded twice weekly. Results In vitro studies showed that
MDA-MB-436 cells are insensitive to BGB-3111, which do not expresse BTK. In
both human breast cancer MDA-MB-436 and human A431 epidermoid carci-
noma subcutaneous xenograft models, the tumor cells were co-injected with
peripheral blood mononuclear cells (PBMCs) of healthy donors. In MDA-MB-
436model, BGB-3111 (15mg/kg, BID) single agent signifıcantly induced tumor
growth inhibition (TGI) of 55%, whereas showed no anti-tumor effect if no
PBMCs co-injected. Furthermore, co-treatment of BGB-3111 (15 mg/kg, BID)
and anti-PD-1 antibody BGB-A317 (10 mg/kg, QW) demonstrated enhanced
therapeutic effect in A431 allogeneic model. Interestingly, in BCLU200 and
BCLU054 NSCLC primary tumor xenograft models (without PBMC co-injec-
tion), BGB-3111 (15 mg/kg, BID) also demonstrated signifıcant anti-tumor ac-
tivity. Conclusions: In summary, BGB-3111 showed interesting activity in solid
tumormodels, suggesting BTK inhibitormight have potential to be used beyond
hematology malignancies..
#2012 UVB-induced ULBP1 upregulation in melanocytes depends on
HMGB1-mediated activation of NF-B and IRF3. Zhaohui Wu, Wei Wang.
Univ. of Tennessee Health Science Ctr., Memphis, TN.
Anti-tumor immune surveillance mediated by innate immunity cells such
as NK cells plays a critical role in eliminating “damaged” cells at precancer-
ous stage and preventing cancer progression. As a key epidemiological factor
associated with melanoma, solar UV radiation also elicit immunosurveil-
lance by upregulating ligands for NK cell activating receptor NKG2D. Nev-
ertheless, how UVR upregulates NKG2DL in melanocytes is not completely
understood. We found UVB exposure induced secretion of damage-associ-
ated molecular patterns molecule HMGB1 from skin cells. HMGB1 activates
transcription factors NF-B and IRF3 in melanocytes which synergistically
enhances NKG2D ligand ULBP1 transcription. Moreover, RAGE is essential
for HMGB1-induced activation of NF-B and IRF3, which serves as the
HMGB1 receptor and mediates activation of TBK1. Consistently, HMGB1
defıcient melanoma cells are less susceptible to NK cells mediated cytotox-
icity. Our study provides a mechanistic link between environmental UV
radiation and antitumor immunosurveillance induced in melanocytes,
which may play a critical role in the early stages of melanomagenesis.
#2013 IncreasedMMPs activity inMDM2overexpressing cancer cell lines.
Ali Alaseem, Thiagarajan Venkatesan, Thanigaivelan Kanagasabai, Khalid Al-
hazzani, SaadAlobid, PriyaDondapati, AppuRathinavelu.Rumbaugh-Goodwin
Institute for Cancer Research-Nova Southeastern Univ., Davie, FL.
The matrix metalloprotenases (MMPs) are a family of zinc-dependent endo-
peptidase and have proteolysis activity which found to impact several physio-
logical and pathophysiological conditions including cancer. In cancer, over 20
types of MMPs promote invasion, angiogenesis, metastasis, and proliferation.
For instance, MMP-9 is involved in many processes such as wound healing,
tissue remodeling and regulation of inflammation. So far, several studies have
also shown that MMP-9 is associated with poor clinical outcome. MMP-9 can
facilitate angiogenesis and metastasis by releasing cytokines, pro-angiogenic
and pro-metastatic factors. Conversely, the tissue inhibitor of metalloprotei-
nases (TIMP-1) is a well-known negative regulator of MMPs which can also
modulate other biological functions independent of MMPs regulation. TIMP-1
dysregulation has been shown to impact ECM integrity and potentiate meta-
static ability also. Similarly, MDM2 (Murine Double Minute) has been recog-
nized as an important multi-domain protooncogene which is overexpressed in
many types of cancer and is associated with poor prognosis in different tumor
types including sarcomas and carcinomas. Previously, our group reported that
MDM2 overexpression is regulating MMP-9/TIMP-1 axis in LNCaP and
LNCaP-MST (MDM2 transfected) prostate cancer cells. In order to further an-
alyze the status of MMP in MDM2 overexpressing cancers the fluorescence
activity assay and the zymography assay were used for measuring the activity of
MMPs including MMP-9. Immunoblotting analysis were also used to correlate
the expression levels ofMDM2,MMP-9, and TIMP-1 inMDM2 overexpressing
cell lines with and without Nutlin-3 (20 uM) treatment. Our results indicated
that MMP activity is elevated by 97.3 % in LNCaP-MST cells compared to
LNCaP. This may be possibly due to the near knockdown levels of TIMP-1 that
was observed in LNCaP-MST cells. However, the Nutlin 3 treatment was able to
decrease the MMP-9 levels and activity only marginally, without elevating
TIMP-1 levels. This suggests that, in addition to MDM2, the PTEN loss in LN-
CaP-MST cells may also play a role in regulating the levels of TIMP-1 and
consequently the activity ofMMP-9. Furthermore, in order to verify our original
speculation, we analyzed the levels of TIMP-1 in SJSA1 and GI-101A cell lines,
which are known to overexpress MDM2 and impart aggressive metastatic abil-
ities. Interestingly, the levels of TIMP-1 were found to be elevated in both SJSA1
and GI-101A cell lines compared to LNCaP-MST cells. This fınding indicates
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that TIMP-1may paly dual role depending on cancer types and the gene expres-
sion status in the tumormicroenvironment. Further studies are required to fully
delineate the interplay betweenMDM2andpro-metastaticmechanisms, includ-
ing the expression of TIMP-1 and MMP-9. (The fınancial support from the
Royal Dames of Cancer Research Inc., Ft. Lauderdale is gratefully acknowl-
edged).
#2014 Genitourinary cancer-derived cells produce microenvironment
proteinases that regulate proteinase activated receptors (PARs) to drive on-
cogenic signaling. Stacy G. Gibson,1 Koichiro Mihara,1 Andries Zijlstra,2 Mat-
thew E. Hyndman,1 Morley D. Hollenberg1. 1University of Calgary, Calgary,
Alberta, Canada; 2Vanderbilt University, Nashville, TN.
Background: Thrombin-triggered activation of proteinase-activated re-
ceptor-1 (PAR1) is recognized as a key stimulus for driving epithelial malig-
nancies (IUBMB life.63:397, 2011; PMID:21557443). However, the enzymes
for regulating PAR1 in the tumour microenvironment are not known. Hy-
pothesis: We hypothesize that prostate (PC) and urinary bladder cancer
(UBC) cells can regulate microenvironment signaling to drive cancer pro-
gression via the secretion of proteinases that cleave/regulate proteinase-ac-
tivated receptors (PARs). Aims: 1.) Visualize the cleavage status of N- and
C-terminally-dual-labelled PARs in receptor-transfected UBC- and PC-de-
rived cells. 2.) Measure PAR cleavage by UBC and PC-secreted proteinases.
3.) Identify the UBC & PC-derived proteinases that cleave/regulate PAR
function. Methods: The cleavage status of dual-labeled PARs (N-terminus-
mCherry/C-terminus-YFP) expressed in PC & UBC cells was determined by
confocal image analysis as already described (JBC 288:32979, 2013; PMID:
26957205). Intact receptors look ‘yellow’ and cleaved receptors look ’green’.
The cleavage of PARs in UBC and PC cells was studied for dual-tagged-PAR-
expressing UBC and PC cells exposed or not to cell-derived culture super-
natants, enzyme agonists for PAR1 and 2 (thrombin and trypsin, respec-
tively), and proteinase inhibitors (e.g. for MMPs and other enzymes). The
impact of CRISPR-mediated elimination of MMPs from PC3 cells on PAR1
cleavage status was also monitored. Results: UBC- and PC-produced en-
zymes can cleave PAR1 as effıciently as thrombin, an established PAR1 ag-
onist. None of the UBC cell lines produce proteinases that cleave PAR2.
Inhibition of MMP activity partially prevents PAR1 cleavage by UBC cells
and completely prevents PAR1 cleavage in PC3-PC cells. Conclusions: We
conclude that UBC and PC cells secrete PAR-regulating proteinases that can
directly regulate PAR1 in the tumour microenvironment so as to drive can-
cer progression. Funding: Alberta Innovates CRIO Grant, Prostate Cancer
Canada Discovery Grant, Motorcycle Ride for Dad, Johnson & Johnson Al-
berta Health Partnership and CIHR
#2015 Mesenchymal stemcell correlates oral leukoplakiamalignant trans-
formation through regulate T cell response. Yichen Chen, Bailin He, Da Ma,
Jingjing Song, Xi Wang, Bin Cheng, Zhi Wang. Sun Yat-sen University, Guang-
zhou, China.
Introduction: Leukoplakia is one of the most common clinically presented
oral potential malignant disorders (OPMD). Detailed understanding of leuko-
plakia-associated molecular or cellular changes would help us better undertand
about the progress of leukoplakia malignant transformation. In this study, we
examined the potential involvement of MSC in this very progress, and demon-
strated lesion resident MSCs may favour leukoplakia malignant transformation
through its strong immunoregulation onT cell.Methods: Eighteen six-week-old
female Sprague-Dawley rats (180-220g) were given 0.05g/L 4NQO in drinking
water for 22 weeks for development of lesions. Lesions classfıed by histological
HE stainnig. MSCs were obtained from single cell suspesion of lesions, and
cultured with splenocyte to study its immunoregulate ability. Results: 1. MSC-
like cells are enriched in carcinogen induced leukoplakia and cancers. Represen-
tative results showing the lesions on tongue of rats. And relative proportion of
MSC phenotype marker (CD29, CD31-, CD45-, CD90) in oral lesions
(OMSC) were counted by flow cytometry. 2. Leukoplakia-derived MSC (L-
OMSC), cancer-derivedMSC (C-OMSC), and the normalmucosa-derivedMSC
(N-OMSC) share the similar stemness properties. 3. Cancer lesion have less
infıltrating T cells (quantifıed by IHC and FCMof CD3 ). Cancer-derivedMSCs
suppress T cell proliferation, but not promote T cell apoptosis and inhibit T cell
migration to the lesions. 4. Higher number of lesion derived MSCs associates
with higher celluar proliferation in the lesions. Summary: Our study demon-
stratedMSCs couldmigrate to pre-malignant leukoplakia lesions prior to tumor
establishment. Further, MSCs play an important role in leukoplakia malignant
transformation induced by chemicals, which via its strong immunomodulatory
activities.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Cell
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#2016 Novel dual cIAP1/XIAP antagonist ASTX660 activity in preclinical
models of human papillomavirus() and (
) head and neck squamous cell
carcinoma. Roy Xiao, Yi An, Adeeb Derakhshan, Zhong Chen, Nicole C.
Schmitt, Carter Van Waes. National Institutes of Health, Bethesda, MD.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most com-
mon cancer with a fıve-year survival of50%. HNSCC are linked to human
papillomavirus (HPV) or tobacco carcinogenesis (HPV-). The Cancer Ge-
nome Atlas recently analyzed 279 HNSCC, revealing that 30% overexpress
FADD (Fas-Associated Death Domain), with or without BIRC2/3 genes en-
coding cellular Inhibitor of Apoptosis Proteins 1/2 (cIAP1/2), which are
critical components of the Tumor Necrosis Factor (TNF) Receptor signaling
pathways that determine cell death or survival. The frequency of such mu-
tations provides a window for potential therapeutics, as IAP antagonists
have been shown to switch cancer cell TNF signaling from being pro-
survival to pro-apoptotic. We recently showed that birinapant, a second
mitochondrial activator of caspases (SMAC) mimetic that promotes IAP
degradation, sensitizes HNSCC to cell death by TNF and eradicates tumors
in combination with radiation in HPV- HNSCC models overexpressing
FADD/BIRC2. ASTX660 (developed by Astex Pharmaceuticals) is a
novel dual cIAP1/XIAP antagonist currently in clinical trials for treating
advanced solid tumors and lymphomas. The objective of the present study is
to determine the therapeutic effects of ASTX660 in HPV/ HNSCC pre-
clinical models. ASTX660 at nanomolar concentrations was found to po-
tently inhibit cell proliferation (measured using XTT assays) and induce
apoptosis (Annexin/7-AAD flow cytometry), and displayed combinatorial
activity with TNF, TRAIL, or cisplatin in multiple human HPV/ HN-
SCC cell lines. Western blotting showed near complete degradation of cIAP1
expression at nanomolar concentrations in human HNSCC cell lines. Flow
cytometry revealed that ASTX660 in combination with either TNF or cis-
platin reduced MHC-I expression and increased PD-L1 expression, suggest-
ing that potential synergistic effıcacy could be observed in combination with
immune checkpoint inhibitors. Our results demonstrate that ASTX660 is a
potential therapeutic agent for both HPV/ HNSCC. Experiments evalu-
ating the anti-tumor effects of ASTX660 as a monotherapy and in combina-
tion with radiation, cisplatin, and anti-PD-1 therapies are ongoing, using
both human HNSCC xenograft and syngeneic mouse oral cancer (MOC)
models. Supported by NIDCD intramural projects (ZIA-DC-000016, 73
and 74).
#2017 The role of ceramide in the dual cytotoxic and metabolic stimula-
tive effects of sigma-2 receptors. Cheri Z. Liu, Ellen Sukharevsky, Wayne D.
Bowen. Brown University, Providence, RI.
Sigma-2 receptors are highly overexpressed in cancer cells compared to
normal cells, as well as in proliferative versus quiescent cells. Sigma-2 recep-
tors have been of interest as an antineoplastic target, as sigma-2 agonists
cause cell death via a variety of pathways. Recently, a new class of sigma-2
agonists has been discovered, with ligands such as CM764, that do not induce
cell death but that affect cellular metabolism, as shown by increased MTT
reduction, increased ATP level, and HIF-1 stabilization. Previously, our lab
has shown that treatment of breast tumor cells with sigma-2 receptor ago-
nists CB-184 and BD737 caused dose dependent increases in ceramide and
simultaneous decreases in sphingomyelin, suggesting that sigma-2 receptors
modulate the sphingolipid pathway. The ceramide pathway has been shown
to play both prosurvival and pro-apoptotic roles in cancer cells. Here, we
examine the role of ceramide in sigma-2 receptor mediated pathways in
human SK-N-SH neuroblastoma cells. A 24 h treatment of SK-N-SH neuro-
blastoma cells with 20 M exogenous C6-ceramide caused less than 20% cell
death. Interestingly, this compared to over 50% cell death in MCF-7 breast
adenocarcinoma cells and PANC-1 pancreatic cancer cells, indicating a dif-
ferential role of ceramide in cell death pathways across cell lines. SK-N-SH
cells were treated with 10 M of either CM572, a classic sigma-2 agonist that
causes cell death, or CM764, a sigma-2 agonist that stimulates metabolism.
Fumonisin B1 is a potent inhibitor of ceramide synthase. Treatment of cells
with fumonisin B1 (10 M) did not signifıcantly alter CM572-induced cyto-
toxicity. Conversely, treatment with fumonisin B1 did signifıcantly inhibit
the MTT reduction caused by CM764. Taken together, these results suggest
that ceramide formation may play more of a role in the metabolic stimulative
effect of sigma-2 receptors, as opposed to the cytotoxic effect. Decreased
levels of ceramide have been shown to increase cellular resistance to apopto-
sis. Therefore, it has been of interest to increase intracellular ceramide levels
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in drug resistant cancer cells in order to sensitize the resistant cells to che-
motherapeutics. Multidrug resistance (MDR) in cancer cells is often attrib-
uted to the overexpression of particular ABC transporters that effectively
pump drugs out of the cells. One such protein is the multidrug resistance-
associated protein 1 (MRP1). It has been shown that increased expression of
drug efflux pumps also decreases cell sensitivity to ceramide. Treatment with
CM572 caused a dose-dependent decrease in MRP1 protein levels, while
treatment with CM764 had little effect on MRP1. We will examine how this
modulation of MRP1 affects sensitivity to C6-ceramide. We will also exam-
ine whether combination of C6-ceramide with sigma-2 receptor ligands aug-
ments the cytotoxic and/or metabolic stimulative effects of sigma-2 recep-
tors.
#2018 Synergistic interactions between PLK1 and HDAC inhibitors in
non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed
throughmultiple mechanisms. Tri Nguyen,1 Rebecca Parker,1 Elisa Hawkins,1
Victor Yazbeck,1 Akhil Kolluri,1 Maciej Kmieciak,2 Mohamed Rahmani,1 Ste-
ven Grant3. 1Department of InternalMedicine, Virginia Commonwealth Univer-
sity andMassey Cancer Center, Richmond, VA; 2Massey Cancer Center, Virginia
Commonwealth University, Richmond, VA; 3Department of Internal Medicine,
Biochemistry, Pharmacology, Virginia Commonwealth University and Massey
Cancer Center, Richmond, VA.
The mitotic kinase polo-like kinase 1 (PLK1) is over-expressed in neoplastic
cells, including non-Hodgkin’s lymphoma (NHL) cells, but not in normal cells,
prompting development of PLK1 inhibitors e.g., volasertib (Boehringer-Ingel-
heim). PLK1 plays key roles in cell cycle progression, mitosis, cytokinesis, cen-
triole duplication, and the DNA damage response (DDR). Notably, volasertib
demonstrated preliminary signs of activity in NHL patients in a phase I trial.
HDAC inhibitors (HDACIs) modify chromatin structure and gene expression,
but also induce multiple mitotic abnormalities including mitotic slippage and
DNA damage checkpoint disruption. Given these complementarymechanisms,
we sought to examine volasertib interactions with the pan-HDACI belinostat
(Spectrum Pharmaceuticals) in diffuse large B-cell lymphoma (DLBCL) and
mantle cell lymphoma (MCL) cells in vitro and in vivo. Exposure ofDLBCL cells
to extremely low (e.g., 5-30 nM), minimally toxic concentrations of volasertib
and low (e.g., 100-400 nM), marginally toxic belinostat concentrations for 48 hr
synergistically increased apoptosis in SU-DHL16, SU-DHL4, SU-DHL8 (GC
subtype), HBL-1, U2932 (ABC-subtype), and OCI-LY18, Carnaval (double hit)
DLBCL cells. Similar interactions occurred in primary lymphoma cells, Granta-
519 and Rec-1 (MCL), SU-DHL4/BR and SU-DHL16/BR (bortezomib-resistant
cells exhibiting up-regulation of the proteasome sub-unit PSMB5 and bort-
ezomib binding site mutation (Ala49Val). In contrast, identical regimens were
minimally toxic to normal hematopoietic progenitors. Volasertib/belinostat in-
duced massive M-phase arrest, p-histone H3 up-regulation, a marked increase
in mitotic errors, and pronounced M-phase cell death associated with striking
DNA damage (H2A.X formation). Belinostat diminished c-Myc mRNA and
protein in DLBCL cells, an effect signifıcantly enhanced by volasertib. Notably,
PLK1 knock-down in DLBCL cells signifıcantly increased belinostat-induced
M-phase accumulation, phospho-histone H3 accumulation, H2AX genera-
tion, and apoptosis. Analogously, c-Myc knock-down increased DNA damage
and apoptosis in response to volasertib, arguing that c-Myc down-regulation
plays a functional role in lethality. Volasertib/belinostat co-administration dra-
matically reduced tumor growth in an ABC-DLBCL flank model (U2932) and
signifıcantly increased survival (56.2 vs 39.7 days; p 0.001) without weight loss
or other toxicities. The regimen also enhanced survival and reduced tumor cell
bone marrow engraftment in a systemic double-hit lymphoma model (OCI-
Ly18). Together, these fındings indicate that PLK1/HDAC inhibition warrants
attention as a therapeutic strategy inNHL.Accordingly, based on these fındings,
a phase I volasertib/belinostat trial in patients with aggressive NHL is planned
(NCT02875002).
#2019 Synergistic anticancer activity of the RAD51 inhibitor IBR2 with
inhibitors of receptor tyrosine kinases andmicrotubule protein. Peter J. Fer-
guson,1 Mark D. Vincent,2 James Koropatnick1. 1Lawson Health Research Insti-
tute, London, Ontario, Canada; 2London Regional Cancer Program, London,
Ontario, Canada.
Although cancer cell genetic instability contributes to characteristics thatme-
diate tumorigenicity, it also contributes to the selective toxicity that some che-
motherapy drugs have for cancer cells. This ‘synthetic lethality’ (Nature 434:913,
’05) can be enhanced by agents that inhibit DNA repair (Mol Onc 8:1429, ‘14;
Proc AACR 57:3718, ’16). To exploit this potential ‘Achilles heel’, we tested the
ability of a small molecule inhibitor of RAD51 to potentiate the cytotoxicity of
established chemotherapy drugs. 2-(benzylsulfonyl)-1-(1H-indol-3-yl)-1,2-di-
hydroisoquinoline (IBR2)was obtained fromDrs. J-WZhu andW-HLee (Univ.
California - Irvine). IBR2 inhibits RAD51-mediated double-strand DNA break
repair, but also enhances induction of apoptosis by the ABL inhibitor imatinib
against K562 cells (EMBOMol Med 5:353,’13). There is potential value of such
synergistic interaction among other tumor types and with other drugs. IBR2-
drug combinations were therefore examined across a spectrum of cancer cell
lines from various tissues (AML, CML, carcinoma of breast, colon, stomach,
lung, and head) representing a range of oncogenic drivers (ABL, c-kit, Raf, Ras,
ER, mutant p53). Cells were exposed to IBR2 simultaneously with inhibitors of
various tyrosine kinase receptors, DNA-damaging agents, or inhibitors of mi-
crotubule function. Cells were cultured in 96-well plates, exposed to drugs alone
and in combination, and cell density determined by viability staining (alamar-
Blue or neutral red) 4 days later. Inhibition of proliferation by drug combina-
tions was normalized to that of IBR2 alone. Depending on the drug sensitivity of
the cell line, IBR2, at concentrations that inhibited proliferation between 0% and
75% as a single agent, enhanced toxicity of imatinib by up to 80%. IBR2 also
greatly enhanced antiproliferative activity of regorafenib (targets RAF, kit, oth-
ers), EGFR inhibitors erlotinib, gefıtinib, afatinib and osimertinib, and micro-
tubule inhibitor vincristine (VCR). However, IBR2 was antagonistic with VP-
16, cisplatin, irinotecan, melphalan, and olaparib. To determine a possible
mechanism of the observed synergy, the interaction between IBR2 and imatinib
or VCR was compared with that between verapamil, a P-glycoprotein inhibitor,
and the latter 2 drugs. The VCR-resistant head and neck cell line HN-5a/V15e
was not cross-resistant to imatinib, but IBR2 enhanced imatinib toxicity in this
cell line, its HN-5a parent, andHT-29 by up to 60%,much better than verapamil
(up to 40% at similar concentrations, P0.05). IBR2 enhanced VCR toxicity in
these 3 lines to degree similar to verapamil, decreasing the IC50 by up to 90%.
IBR2 appears to enhance drug toxicities via mechanisms other than just inhibi-
tion of RAD51 and may potentially interfere with microtubule function. The
results indicate that this agent may be useful as a clinical adjuvant to numerous
cytotoxic drugs.
#2020 Synergistic induction of apoptosis of combined mesupron and au-
ranofın treatment in humanbreast cancer cells. Joo-Eun Lee, Yeo-JungKwon,
Kyung-Soo Oh, Young-Jin Chun. Chung-Ang Univ. College of Pharmacy, Seoul,
Republic of Korea.
Urokinase-type plasminogen activator (uPA) system may play a crucial role
in cancer cell invasion and metastasis. uPA has been validated as a predictive or
prognostic biomarker protein and considered as a therapeutic target in human
breast cancer. Mesupron is a uPA inhibitor blocking uPA enzymatic activity to
reduce tumor cell invasion, migration and cell growth. Auranofın has been
known as an antirheumatic drug and a thioredoxin reductase inhibitor and
recently its anticancer activity in ovarian and breast cancers has also been iden-
tifıed. To study whether cotreatment with mesupron and auranofın shows a
signifıcant anticancer activity, the synergistic induction of apoptosis of mesu-
pron with auranofın was determined. Auranofın or mesupron alone inhibited
cancer cell growth in MCF-7 cells with IC50 of 0.25 Mor 25 M, respectively.
Flow cytometric analysis also showed an increased apoptosis. When cells were
treated with mesupron (0.125 M) in combination with auranofın (10 M), we
found a signifıcant induction of apoptosis although the cytotoxic effects of me-
supron or auranofın alone at those concentrations were not quite strong. Inter-
estingly, combined mesupron and auranofın treatment signifıcantly suppressed
mitochondrial antiapoptotic proteins includingBcl-2 andBcl-xL.We also found
the increase of caspase-3 and PARP cleavages. The combination index (CI) also
indicated the synergistic induction of apoptosis by auranofın and mesupron.
Taken together, these data suggest that the use of mesupron and auranofın in
combination can be valuable to achieve higher anticancer activity.
#2021 Ablation of caspase-7 promotes solar-simulated light-induced
mouse skin carcinogenesis through upregulation of keratin-17. Mee-Hyun
Lee,1 Do Young Lim,2 Sung Young Lee,2 Jung Hyun Shim,3 Xuejiao Liu,1 Ran
Zhao,1HaiHuang,1 G.Timothy Bowden,4 Young-Joon Surh,5 Yong-YeonCho,6
Ann M. Bode,2 Zigang Dong2. 1China-US (Henan) Hormel Cancer Institute,
Zhengzhou, China; 2The Hormel Institute, Austin, MN; 3Department of Phar-
macy, College of Pharmacy and Natural Medicine Research Institute, Mokpo
National University, Mokpo, Republic of Korea; 4University of Arizona Cancer
Center, Tucson, AZ; 5Department of MolecularMedicine and Biopharmaceutical
Sciences, Graduate School of Convergence Science and Technology, College of
Pharmacy, Seoul National University, Seoul, Republic of Korea; 6College of Phar-
macy, The Catholic University of Korea, Bucheon, Republic of Korea.
Solar UV irradiation is an environmental carcinogen that causes skin cancer.
Caspase-7 is expressed at reduced levels inmany cancers. The present study was
designed to examine the role of caspase-7 in solar-simulated light (SSL)-induced
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skin cancerr and to elucidate its underlying molecular mechanisms. Our study
revealed thatmicewith genetic ablation of caspase-7 are signifıcantly susceptible
to SSL-induced skin carcinogenesis. Epidermal hyperplasia, tumor volume and
tumor numbers were increased in caspase-7 knockout (KO) mice compared
with SKH1 wild-type mice irradiated with SSL. The expression of cell prolifera-
tion biomarkers, such as survivin and Ki-67, was elevated in SSL-irradiated skin
of caspase-7 KO mice compared with those observed in SSL-exposed wild-type
SKH1mouse skin.Moreover, SSL-induced apoptosis was abolished in skin from
caspase-7 KO mice. 2-DE gel electrophoresis, followed by matrix-assisted laser
desorption/ionization-time-of-flight analysis of skin tissue lysates from SSL-
irradiated SKH1 wild-type and caspase-7 KO mice revealed an aberrant induc-
tion of keratin-17 in caspase-7 KOmice. Immunohistochemical analysis of skin
tumors also showed an increase of keratin-17 expression in caspase-7 KO mice
compared with SKH1wild-typemice. Furthermore the expression of keratin-17
was also elevated in SSL-irradiated caspase-7 KO keratinocytes as well as in
human basal cell carcinomas. The in vitro caspase activity assay showed kera-
tin-17 as a substrate of caspase-7, but not caspase-3. Overall, our study suggests
that genetic loss of caspase-7 promotes SSL-induced skin carcinogenesis by
blocking caspase-7-mediated cleavage of keratin-17.
#2022 Hsp90 inhibitor (NVP-AUY922) enhances anti-cancer effect of
Bcl-2 inhibitor (ABT-737) in small cell lung cancer.Hannah Yang, Kang-Seo
Park, Junyoung Choi, Sang-We Kim Kim, Dae Ho Lee. Asan Medical Center,
Seoul, Republic of Korea.
Background: Bcl-2 family is a group of apoptosis regulators that plays an
anti-apoptotic role for cell survival and is known to contribute to induce che-
motherapy resistance in small cell lung cancer (SCLC). ABT-737 is an anti-
cancer drug that induces apoptosis by selectively blocking the activities of Bcl-2
and Bcl-xL, but not Mcl-1. Consequently, the effıcacy of ABT-737 is largely
restricted in the presence of Mcl-1. Heat-shock-protein 90 (Hsp90) is highly
expressed in most tumors and Hsp90 inhibitors induce the proteasomal degra-
dation of Hsp90 client proteins. In addition, Hsp90 inhibitor can reduce Mcl-1
expression, a down-stream of Akt and Erk pathway. Furthermore, Hsp90 inhib-
itor inhibits activities of NF-B by degradation of IKK. Thus, we show that
downregulation of Mcl-1 and NF-B by Hsp90 inhibitor can lead to synergistic
pro-apoptotic effects with ABT-737. Materials and methods: The proliferative
activity, apoptotic activities, and expression of apoptotic proteins were assessed
in SCLC cell lines after treatment with ABT-737, NVP-AUY922, or both drugs.
The synergy effects of ABT-737 and NVP-AUY922 were analyzed by cell viabil-
ities with different concentrations in SCLC cell lines, and the combination index
values were 1. In addition, the synergy effects of the drugs were showed with
xenograft model with human SLCL cell line in vivo. Results: Here, we show that
NVP-AUY922, an Hsp90 inhibitor, can potentiate the pro-apoptotic effects of
ABT-737 not only by reducing the levels of Akt but also by inhibiting pNF-B,
both of which are proteins regulating apoptosis signaling. Western blot analysis
revealed that proteins associated with apoptosis such as PARP, Caspase 3 and 7
were more upregulated in SCLC cells exposed to the drug combination than in
cells exposed to NVP-AUY922 or ABT-737 alone. In addition, Annexin V &
dead cell assay showed dual inhibition of the Hsp90 and Bcl-2 signaling path-
ways more increased apoptotic cells and dead cells in SCLC. In our result, ABT-
737 induced apoptosis by blocking Bcl-2 activation, and NVP-AUY922 blocked
the levels ofHsp90 client proteins, Akt and pErk, ultimately leading to decreased
level of Mcl-1. In addition, NVP-AUY922 induced degradation of IKK, and
increased IB- inhibited activation ofNF-B. And this combination treatment
showed higher BIM and BID expression, pro-apoptotic proteins, than single
treatment. Furthermore, synergy effects of combination were verifıed in xeno-
graft model with human SCLC cell line. Conclusions: Consequently, NVP-
AUY922 synergizes with ABT-737 to induce apoptosis by reducing activities of
Mcl-1 and NF-B in SCLC. This study suggests that adopting an appropriate
combination of drugs can lead to better outcomes compared with monotherapy
in SCLC.
#2023 Artemisinins enhanced the antileukemic effıcacy of BCL2 inhibi-
tors. Blake S. Moses,1 Jennifer M. Fox,1 Xiaochun Chen,1 Jeffrey W. Tyner,2
Gary H. Posner,3 Patrick Bailey,1 Curt I. Civin1. 1University of Maryland Balti-
more, Baltimore, MD; 2Oregon Health and Science University, Portland, OR;
3Johns Hopkins Univesity, Baltimore, MD.
More effective, less toxic treatments are needed to improve longevity and
quality of life for patients with acute leukemias. Artesunate (AS), the current
WHO-recommended drug for severe malaria, is a semi-synthetic derivative of
the natural compound Artemisinin. AS has broad antineoplastic activity in
vitro, and is well tolerated, inexpensive, and can be parenterally or orally admin-
istered in humans. Both AS and amore potent synthetic derivative, artemisinin-
derived trioxane diphenylphosphate dimer 838 (ART-838), substantially inhib-
ited acute leukemia growth in vivo and in vitro, at doses where normal CD34
hematopoietic stem-progenitor cell clonogenicity was essentially unaffected.
Moreover, AS and ART-838 synergized with several current antileukemic drugs
(Fox et al, Oncotarget, 2015). To identify additional potential antileukemic drug
combinations, we screened for the growth inhibitory effects of AS and ART-838
against 3 acute leukemia cell lines co-treated with a panel of 122 antileukemic
compounds (mainly emerging antineoplastic drugs). Both AS and ART-838
showed synergistic or additive growth inhibition with several compounds. Two
BCL2 protein family inhibitors demonstrated among the highest levels of syn-
ergy. One of these, ABT-199 (venetoclax), was recently approved by the FDA for
the treatment of chronic lymphocytic leukemia (CLL) and received break-
through designation for acute myeloid leukemia (AML). Therefore, we decided
to further investigate the combination ofABT-199withASorART-838. Synergy
between AS (or ART-838) and ABT-199 was confırmed across several acute
leukemia cell lines with varying sensitivities to each drug. Both leukemia cell
proliferation and survival were affected synergistically by exposure to the com-
bination of AS (or ART-838) plus ABT-199. Utilizing in vivo imaging, we as-
sessed changes in growth kinetics of tail vein-injected acute leukemia cell lines
and primary patient-derived samples constitutively expressing luciferase in
mice treated with AS, ABT-199, or the combination. The combination of AS
plus ABT-199 had the greatest antileukemic effect. Based on these data, we
propose that Artemisinins plus BCL2 inhibitors comprise an antileukemic drug
pair with high potential for incorporation into acute leukemia therapeutic reg-
imens.
#2024 Reactivating apoptosis in BFL-1/A1 driven cancer with cysteine-
reactive stapled peptide inhibitors. Rachel M. Guerra, Annissa J. Huhn, Ed-
ward P. Harvey, Gregory H. Bird, Loren D. Walensky. Dana Farber Cancer
Institute, Boston, MA.
BFL-1/A1 is a BCL-2 family protein implicated in the progression and
chemoresistance of melanoma, lymphoma, and other cancers, yet it remains
undrugged. Anti-apoptotic BCL-2 family proteins block cell death by trapping
the critical -helical BH3 domains of pro-apoptotic members in a surface
groove. Cancer cells hijack this survival mechanism by overexpressing a spec-
trumof anti-apoptoticmembers,mounting formidable apoptotic blockades that
resist chemotherapeutic treatment. Drugging the BH3-binding pockets of anti-
apoptotic proteins has become a highest-priority goal, fueled by the clinical
success of venetoclax, a selective BCL-2 inhibitor, in reactivating apoptosis in
BCL-2-dependent cancers. A natural juxtaposition of two unique cysteines at
the binding interface of the NOXA BH3 helix and BFL-1/A1 pocket informed
the development of stapled BH3 peptides bearing acrylamide warheads to irre-
versibly inhibit BFL-1/A1 by covalent targeting. Here, we describe the develop-
ment and application of cysteine-reactive stapled peptides that, compared to
their non-covalent analogs, trigger rapid mitochondrial cytochrome c release,
caspase 3/7 activation, and apoptosis induction of BFL-1/A1driven cancers such
as melanoma. Mechanism of action studies demonstrated the exquisite BFL-
1/A1 selectivity and mitochondrial localization of the in situ covalent reaction.
Given the frequent proximity of native cysteines to regulatory binding surfaces,
covalent stapled peptide inhibitors provide a new therapeutic strategy for tar-
geting oncogenic protein interactions.
#2025 A distinct role of RhoB in simvastatin-induced cytotoxicity in
breast cancer cells. Serena Seah, Tingting Wang, Soo Chin Lee. National Uni-
versity of Singapore, Singapore, Singapore.
Purpose Statins, a class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, are initially developed as cholesterol-lowering drugs
by inhibiting the mevalonate pathway. They have recently gained attention for
their potential anticancer properties, but the mechanisms of their anticancer
effects remain elusive. This study aims to investigate the antiproliferative effects
of statins in breast cancer cell lines. Methods We screened a panel of breast
cancer cell lines (Estrogen receptor positive (ER): CAMA1, MCF7, T47D,
ZR-75-1 and Hcc1428; triple negative (TNBC): MDA MB231, MDA MB468,
BT549, Hs578T and Hcc1806) and assessed the sensitivity of these cells to sim-
vastatin in relation to their hormone receptor status using cell proliferation
assay. Next, to elucidate the mechanisms underlying simvastatin sensitivity, we
evaluated the (i) expression of key enzymes in the mevalonate pathway using
qPCR and western blot analysis and (ii) the role of sterol biosynthesis metabo-
lites by exogenously adding these compounds and testing their effects on simv-
astatin-induced cytotoxicity. Finally, we performed functional assays following
siRNA knockout to identify the key small GTPase involved. Results We found
TNBC cell lines to be more susceptible to simvastatin compared to ER cell
lines (mean IC50 of 7.98M [95%CI 2.75-13.22] versus 41.74M [95%CI 6.71-
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76.78]). Simvastatin treatment induced robust apoptosis in TNBC but not the
ER cells. Therewas no signifıcant difference inmRNAexpression ofHMGCR,
HMGCS, MVK, MVD, IDI1 enzymes involved in the mevalonate pathway be-
tween TNBC and ER breast cancer cell lines. Supplementation with gera-
nylgeranyl pyrophosphate but not farnesyl pyrophosphate, inhibited simvasta-
tin-mediated cell death, suggesting the involvement of geranylgeranylated
proteins such as Rho family of GTPases. Here, we identifıed RhoB to be a key
player in simvastatin-mediated cytotoxicity. RhoB showed a signifıcant increase
in transcript and protein levels in response to simvastatin treatment in the
TNBC cells. Interestingly, the increase in protein expression was not associated
with an increase in its prenylation as the accumulation of RhoB was observed
only in the cytosolic fraction. Finally, silencing RhoB was able to abrogate the
cytotoxic effects mediated by simvastatin in TNBC cells. Conclusions Taken
together, our data reveals a critical role of RhoB in the anticancer activity of
simvastatin, which appears to be exclusive to TNBC cells suggesting that HMG-
CoA reductase inhibitors may provide new therapeutic strategies for TNBC
treatment.
#2026 CHK1 inhibition synergizes with cisplatin to promote mitotic cell
death via activation of caspase 2 and downregulation of E2F1 in small cell
lung cancer. Wei-Hsun Hsu,1 Xiaoliang Zhao,1 In-Gyu Kim,1 Guanhua Rao,1
Justine McCutcheon,1 Shuo-Tse Hsu,1 Afshin Dowlati,2 Yu-Wen Zhang,1 Gi-
useppe Giaccone1. 1Georgetown Univ. Medical Ctr., Washington, DC; 2Case
Western Reserve University, Cleveland, OH.
Platinum-based chemotherapy remains the standard treatment for patients
with small cell lung cancer (SCLC), one of the deadliest cancers, but the benefıt
of such therapy is often hampered by rapid emergence of drug resistance. Thus
far, there is no targeted therapy available for SCLC, mainly due to the lack of
targetable oncogenic driver alterations; nevertheless, over 90% of SCLC tumors
harbor inactivating mutations in tumor suppressor p53, an important check-
point regulator for the control of cell cycle progression in the event of DNA
damage. SCLC cells with p53-defıciency heavily rely on the checkpoint kinase 1
(CHK1), a key checkpoint regulator, to prevent the progression of cell cycle
through G2/M in the presence of damaged DNA. Using CHK1 inhibitors and
siRNA knockdown approaches, we explored the potential therapeutic benefıt of
CHK1 inhibition in SCLC models in combination with cisplatin, a DNA dam-
aging agent. We demonstrated that CHK1 inhibition was able to release G2/M
cell cycle arrest induced by cisplatin, and synergized with cisplatin to induce
mitotic cell death especially in the p53-defıcient SCLC cell lines. CHK1 inhibi-
tion activated caspase 2 and downregulated the expression of E2F1 transcription
factor in these cells. We showed that activation of caspase 2 was required for the
mitotic cell death induced by the combination of cisplatin andCHK1 inhibition.
Interestingly, the upregulation of E2F1 induced by CHK1 inhibition was medi-
ated in part by caspase 2, and E2F1 played a role in the DNAdamage checkpoint
control as knockdown of E2F1 enhanced cytotoxicity induced by cisplatin or
CHK1 inhibitor inGLC4 cells. However, ectopic overexpression of E2F1 also led
to increase of phospho-histoneH3,H2AX and cleaved PARP, and signifıcantly
enhanced cisplatin cytotoxicity, indicating that proper dosage of E2F1 is critical
forDNAdamage checkpoint response. These data provide amechanistic insight
of CHK1-mediated DNA damage checkpoint control and the anticancer effect
of CHK1 inhibition against SCLC. In tumor samples derived from SCLC pa-
tients treatedwith platinumbased chemotherapy, we found that high expression
of CHK1 and E2F1 signifıcantly correlated with poorer overall survival, further
suggesting a link between CHK1 and E2F1 and potentially collaborative roles of
these two factors in DNA damage checkpoint response. Moreover, we showed
that CHK1 inhibition resensitized cisplatin-resistant cells to cisplatin treatment
and induced mitotic cell death via caspase activation in these cells. These data
indicate that CHK1 inhibitionmay enhance the benefıt of cisplatin treatment for
SCLC and overcome cisplatin resistance. We are presently confırming the in
vitro results of CHK1 inhibition in combination with cisplatin treatment in
xenograft tumor models in athymic nude mice.
#2027 Preclinical evaluation of AMG 176, a novel, potent and selective
Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer
models. Sean R. Caenepeel, Brian Belmontes, Jan Sun, Angela Coxon, Gordon
Moody, Paul E. Hughes. Amgen Inc., Thousand Oaks, CA.
Evasion of apoptosis represents an essential hallmark in the progression of
many cancers. The Bcl-2 family of proteins plays a central role in regulating the
apoptotic process. Targeting pro-survival Bcl-2 family members likeMcl-1 with
small molecule inhibitors represents a viable therapeutic approach for the treat-
ment of cancer. This study evaluated the in vitro and in vivo activity of AMG
176, a potent and selective Mcl-1 inhibitor currently in Phase I clinical develop-
ment. AMG 176 binds with high affınity and selectivity to the BH3-binding
groove of Mcl-1. In a cell based split-luciferase complementation assay, AMG
176 disrupted the interaction between Mcl-1 and Bak, leading to downstream
activation of the intrinsic apoptosis pathway as measured by increased caspase
activity and subsequent effects on viability. Oral administration of AMG 176 to
mice bearing OPM-2 multiple myeloma xenografts resulted in a dose-depen-
dent increase in activated Bakwith a clear PK/PD relationship. Dosing regimens
(20-60 mg/kg PO, QD) evaluating discontinuous and continuous administra-
tion of AMG 176 in established OPM2 xenografts demonstrated robust tumor
growth inhibition with complete tumor regression at an elevated dose. Effıcacy
in this model was achieved at doses in agreement with those eliciting induction
of apoptotic markers. Treatment of tumor cell lines with Compound A, a close
structural analog of AMG 176, revealed a dose- and time-dependent increase in
Mcl-1 protein levels that was reversible upon compound washout. Subsequent
experiments performed with cycloheximide suggested that elevations in Mcl-1
protein levels were due to an increase in Mcl-1 protein half-life, likely driven by
the compounds ability to disrupt proteasome-mediated degradation. Com-
poundAwas also used to characterize the kinetics of activating apoptosis. These
studies revealed a rapid induction of apoptosis and loss of viability in Mcl-1
dependent multiple myeloma and AML cell lines. In cell lines highly dependent
onMcl-1, treatment with CompoundA for as little as two hours was suffıcient to
achieve complete cell killing. Cell line profıling studies (200 lines) revealed
robust effects on cell viability in a subset of solid tumor cell lines and cell lines of
hematological origin, includingmultiple myeloma, acute myeloid leukemia and
non-Hodgkin lymphoma. Subsequent association analysis with molecular pro-
fıling endpoints identifıed an inverse correlation betweenBCLxL expression and
sensitivity to Mcl-1 inhibition. Combination screens with Compound A re-
vealedmultiple highly synergistic combinations including compounds targeting
the MAPK pathway, standard of care chemotherapeutics and agents targeting
additional pro-survival members of the BCL-2 family. In conclusion, AMG 176
is a potent and selective Mcl-1 inhibitor, with signifıcant in vitro and in vivo
activity in Mcl-1 dependent cancer models.
#2028 PDE3A modulation for cancer therapy. Xiaoyun Wu,1 Timothy
Lewis,1 Luc de Waal,2 Galen Gao,1 Jian Zhang,1 Monica Schenone,1 Colin Gar-
vie,1 Brett Diamond,3 Selena Lorrey,1 Andrew Cherniack,1 Steven Corsello,4
Alex Burgin,1 ToddGolub,1 Stuart Schreiber,1MatthewMeyerson,4HeidiGreu-
lich1. 1Broad Institute, Cambridge,MA; 2C4Therapeutics, Cambridge,MA; 3Uni-
versity of Connecticut, Cambridge, MA; 4Dana-Farber Cancer Institute, Boston,
MA.
In a differential cytotoxicity screen,we identifıed a novel smallmoleculemod-
ulator of phosphodiesterase 3A (PDE3A) that kills cancer cells expressing ele-
vated levels of PDE3A and SLFN12 (deWaal, Nat Chem Biol, 2016). Treatment
with this cell-selective cytotoxic small molecule, DNMDP, induces complex for-
mation between PDE3A and SLFN12, resulting in apoptosis. Inhibition of
PDE3A enzymatic activity is not suffıcient for cancer cell killing, and expression
of both PDE3A and SLFN12 are required. Although themechanism of signaling
to the apoptosis machinery remains unclear, we examined more closely the role
of the PDE3A-SLFN12 complex in cancer cell killingmediated by DNMDP.We
found that cancer cell lines made resistant to DNMDP by persistent exposure
downregulated SLFN12 expression and that re-expression of SLFN12 was suffı-
cient to restore sensitivity. Furthermore, ectopic expression of PDE3A and
SLFN12 are suffıcient to sensitize cancer cells to DNMDP. These data under-
score the tight correlation of PDE3A-SLFN12 complex formation and cancer
cell killing mediated by DNMDP.
#2028A Glutamine deprivation-elicited sensitization of multiple my-
eloma to venetoclax is associated with electron transport chain inhibition.
Richa Bajpai, Changyong Wei, Mala Shanmugam. Winship Cancer Institute,
Emory University, Atlanta, GA.
Cancer cells exhibit altered glucose and glutaminemetabolism to sustain sur-
vival and proliferation. Altered nutrient utilization also contributes to the devel-
opment of resistance to apoptosis via regulation of pro and anti-apoptotic BCL-2
family members. We previously reported that glutamine deprivation enhanced
binding of BIM to BCL-2 thereby sensitizing myeloma cell lines and patient
samples to Venetoclax (ABT-199). In this study we investigated the metabolites
regulated by glutamine withdrawal that contribute to enhanced BIM-BCL-2
association and ABT-199 sensitivity. Metabolite profıling and isotope tracing
flux analyses of glutamine deprived myeloma cell lines revealed specifıc reduc-
tion of TCA cycle metabolites including succinate, that were not maintained by
glucose present in the medium. Cellular bioenergetics end points i.e. OCR and
ATP were also suppressed upon glutamine withdrawal correlating with a sup-
pression of the TCA cycle and oxidative phosphorylation. Supplementation of
cell permeant dimethyl--ketoglutarate (DMK), a TCAcyclemetabolite derived
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from glutaminolysis, to glutamine deprived cells reversed sensitivity to ABT-
199. This ability ofDMK to reverseABT-199 sensitization in glutamine deprived
cells was associated with a replenishment of TCA cycle intermediates without
restoration of ATP levels. Therefore, we sought to further interrogate the TCA
cycle and electron transport chain (ETC) in facilitating glutamine withdrawal-
associated ABT-199 sensitization. TCA cycle metabolites are linked to mito-
chondrial respiration through ETC complexes. Inhibition of ETC complexes I,
II, III or V in myeloma cell lines enforced similar effects as glutamine depriva-
tion and sensitized cells to ABT-199. Among all fıve complexes, complex II is
more explicitly linked with the TCA cycle through succinate dehydrogenase
(SDH). SDH facilitates the oxidation of succinate to fumarate in the TCA cycle
through its subunit SDHA, and transfers the released electrons to ubiquinone
via its SDHB, C and D subunits supporting the ETC activity of complex II.
Competitive inhibition of succinate dehydrogenase by 3-nitro propionic acid
(3NPA) induced BIM expression and sensitized myeloma cells to ABT-199,
similar to that detected upon glutamine deprivation. Our observations thus
narrow down a role for ETC inhibition in facilitating ABT-199 sensitivity and
underscore the importance of further interrogation of ways to metabolically
perturb and sensitize cancer cells to the highly potent BH3 mimetic ABT-199.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Combination Therapy 2
#2029 Precision therapeutic combinations are synergistic against triple
negative breast cancer using compensatory pathways. Jeffrey P. Solzak,1 Brad
Hancock,1 Robin Paul,1 Patrick Kiel,2 Todd Skaar,1 Bryan Schneider,1 Milan
Radovich1. 1Indiana Univ. School of Medicine, Indianapolis, IN; 2IU Health,
Indianapolis, IN.
Introduction: Triple negative breast cancer (TNBC) accounts for 15% of all
breast cancer cases in theUnited States, and despite its lower incidence, contrib-
utes to a disproportionately higher rate of morbidity andmortality compared to
other breast cancer subtypes.NoFDA-approved targeted therapies are currently
available. It has been hypothesized that drug combinations could potentially be
chosen based on a tumor harboring two or more druggable genomic mutations.
However, previously published data has noted that single agent treatment can
change the genomic landscape andmay be responsible for the lack of synergy of
dual genomic drug targeting. Herein we show that targeting a compensatory
pathway after treatment with a genomically-directed agent, results in synergistic
combinations and can outperform choosing two drugs a priori based on
genomic mutations. Methods: Nine TNBC cell lines were chosen based on the
presence of two or more clinically actionable genomics targets. Drug combina-
tions based on targeting two genomic mutations were chosen using DNA-seq
data from CCLE and a board consisting of oncologists and researchers. Com-
pensatory therapies were found using RNA-seq data from untreated versus sin-
gle-agent treated TNBC cell lines. The merged transcript RPKMs were trans-
formed and analyzed for differential expression. Statistically signifıcant genes
were imported into Ingenuity Pathway Analysis (IPA) to identify therapeutics
based on compensatory targets using the Causal Network Analysis and Up-
stream Regulator functions. Cell viability was assessed via Celltiter-Fluor. Syn-
ergy of the combinations was calculated using the Chou-Talalay method. Re-
sults: Using two-drug combinations based on genomic mutations alone in all
nine cell lines resulted only in additive or antagonistic responses. However,
using RNA-seq data of each cell line treated with one genomically-directed
agent, IPA analysis identifıed several compensatory targets that were upregu-
lated or activated. Treating each cell line in combination with one genomically-
directed agent plus one compensatory agent resulted in a striking increase in
synergy. To understand why targeting compensatory pathways was superior to
targeting two genomicmutations, we re-evaluated the RNA-seq data. This anal-
ysis revealed that treatment with the fırst genomically-directed agent, in many
cases, resulted in down-regulation or inactivation of the second genomic-target.
This may explain the lack of synergy when targeting cells with two drugs based
only on genomic mutations. Conclusion: Targeting TNBC cell lines based on
drug combinations informed by compensatory pathways results in signifıcant
synergy and is superior to choosing drug combinations based on genomic alter-
ations alone.
#2030 Fisetin, a dietary flavonoid for the prevention and treatment of
PIK3CA-mutant colorectal cancer.Naghma Khan, Farah Jajeh, Devon Miller,
Rachel Van Doorn, Richard B. Halberg, Hasan Mukhtar. Univ. of Wisconsin-
Madison, Madison, WI.
Colorectal cancer (CRC) is one of the most frequent and deadliest cancers
worldwide with patients often diagnosed in advanced stages of the disease. Ap-
proximately 15-20% of advanced colorectal cancers harbor activatingmutations
in PIK3CA, which has been identifıed as an important oncogene in multiple
cancers. Therefore, modeling the effects of this type of mutation in themamma-
lian colon is signifıcant. Fisetin is a naturally occurring flavonoid in strawberry,
apple, persimmon, grape, onion and cucumber. 5-Fluorouracil (5-FU) is the
most used chemotherapeutic agent in CRC; however, it has serious side-effects.
Therefore, augmentation of the 5-FU therapeutic effect could lead to lower ef-
fective doses and subsequently fewer side effects. We conducted in-vitro and
in-vivo studies to determine the effect of fısetin, 5-FU and their combination on
PI3K/AKT/mTOR signaling in PIK3CA-mutant colon cancer cells (HCT116
and HT-29), PIK3CA wild-type colon cancer cells (SW480), and newly devel-
oped mouse models. We found that there was more pronounced decrease in
cell-viability and number of colonies in PIK3CA-mutant colon cancer cells than
PIK3CA wild-type colon cancer cells. Apoptotic genes and proteins are prom-
ising targets for cancer treatment as they provide several theoretical basis to
influence pathways causing greater tumor cell death.We observed an increase in
the protein expression of Bax and decrease in Bcl2 on treatment with combina-
tion of fısetin and 5-FU than either agent alone. The full size PARP (116 KD)
protein was also cleaved to yield an 85 KD fragment after treatment of cells with
fısetin, 5-FU and their combination. Apoptotic effects of fısetin and 5-FU com-
bination were also confırmed by flow cytometry in PIK3CA-mutant colon can-
cer cells. The PI3K/AKT pathway is frequently activated in CRC leading to
tumorigenesis and the resistance to chemotherapy. Treatment of PIK3CA-mu-
tant colon cancer cells with fısetin and 5-FU caused decrease in the expression of
(i) PI3K (p85 and p110), (ii) phosphorylation of Akt (Ser473 and Thr308), (iii),
phosphorylation of mTOR, its target proteins, and constituents of mTOR sig-
naling complex. Treatment with fısetin and 5-FU also led to an increase in the
phosphorylation ofAMPK. Next, we performed studies to investigate the effect
of the treatment of combination of fısetin and 5-FU on colorectal tumorigenesis
in FC13K1ApcMin/mice. These animals form tumors in the distal small intes-
tine and colon that have lost APC activity and express constitutively active PI3K
as often occurs in humans. Interestingly, the effect of fısetin was much stronger
than that of 5-FU and comparable to the fısetin and 5-FU combination. Both
fısetin only and combination treatment groups had signifıcantly lower incidence
relative to the control group. We suggest that fısetin could be used as a preven-
tive agent as well as an adjuvant with 5-FU for the treatment of PIK3CA-mutant
CRC.
#2031 Antitumoral synergy of iron chelators and chemotherapies in tri-
ple-negative breast cancer cell lines and patient-derived xenograft. Sandrine
Tury,1 Sophie Vacher,1 Véronique Becette,2 Franck Assayag,1 Sophie Chateau-
Joubert,3 Jean-Luc Servely,3 Elisabetta Marangoni,1 Ivan Bièche,1 Céline Cal-
lens1. 1Institut Curie, Paris, France; 2Institut Curie, Hôpital René Huguenin,
Saint Cloud, France; 3National Veterinary School of Alfort, Maison-Alfort,
France.
Introduction: Tumor cells present an iron metabolic disorder with high pro-
liferation rate, increased iron storage (ferritin and Labile Iron Pool - LIP) and
high sensibility to iron deprivation, which could be a therapeutic target. Anti-
cancer effect of iron chelators deferoxamine (DFO) and deferasirox (DFX) has
been revealed in several types of cancers. In breast cancer (BC), the development
of new therapeutic approaches is urgently needed for triple negative (TN) sub-
typewhich presents poor prognosis and lacks targeting therapy.We investigated
the therapeutic potential of iron chelators combined with chemotherapeutic
agents in TNBC cell lines and patient-derived xenografts (PDX). Methods: An-
ticancer effects of iron chelators combined with chemotherapeutic agents
(doxorubicin, cisplatin or carboplatin) were evaluated in vitro in 4 TNBC cell
lines by MTT assay, annexin V/PI staining and assessment of caspase 3/7 activ-
ity. Assessment of LIP, transferrin receptor 1 (TfR1) expression level, Reactive
Oxygen Species (ROS) production andmitochondrialmembrane potential vari-
ations were performed by flow cytometry, and ELISA assay for ferritin level. The
activity of DFX alone or combined with doxorubicin/cyclophosphamide (AC)
was tested in theHBCx-10TNBCPDX selected because of its relapse toAC. Iron
homeostasis, hypoxia and PI3K pathway were analyzed by immunohistochem-
istry (IHC) and Western-blot in both cell lines and PDX tumors. In DFX/
AC treated and untreated tumors, induction of apoptosis was performed by
TUNEL assay and a transcriptome analysis is ongoing. Results: Iron chelators
acted in synergy effect with three chemotherapies in all cell lines which were
tested to inhibit cell proliferation and induce apoptosis. Chelators increased
cytotoxicity until 60% compared to chemotherapies alone. In all cell lines, ch-
elators treatment increasedTfR1 expression level anddecreased LIP and ferritin.
Furthermore, down-regulation of PI3K pathway, hypoxia, mitochondrial mem-
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brane potential, and the production increasing of ROS were observed. In
HBCx-10 PDX, a trend for antitumoral activity of DFX alone was observed
(p0.09) at the end of the experiment (day 81). A signifıcant difference of Rel-
ative Tumor Volume (RTV) was observed since day 18 between the AC group
and the DFXAC group (tumor growth inhibition: 37 to 61%, tumor growth
delay: 10 to 14 days, 0.005p0.04). Same as the observing in vitro, modula-
tions of PI3K pathway and hypoxia are involved in this antitumoral synergy.
Except neutropenia (due to chemotherapy), no other hematologic toxicity was
observed in both AC and DFXAC groups. Conclusions: Iron chelators may
increase the effectiveness of conventional chemotherapies forTNBC treatments.
This antitumoral synergy involves PI3K pathway downregulation, ROS produc-
tion and decrease mitochondrial membrane potential.
#2032 Combination of epigenetic regulation via LSD1 inhibitionwith sig-
nal transduction inhibitors signifıcantly enhances anti-tumor activity in
models of hematologicmalignancies. SangHyun Lee,Matthew Stubbs, Ashish
Juvekar, Melody Diamond, Antony Chadderton, Robert Collins, Xiaoming
Wen, Holly Koblish, Chunhong He, Liangxing Wu, Richard Wynn, Andrew
Combs, Chu-Biao Xue, Wenqing Yao, Gregory Hollis, Reid Huber, Peggy
Scherle, Bruce Ruggeri. Incyte Corporation, Wilmington, DE.
Combinatorial therapeutic strategies have achieved improved response rates
and durability of responses in severalmalignancies either by selectively targeting
distinct and non-overlapping oncogenic signaling pathways (e.g. PARP and
phosphoinositide 3-kinase (PI3K) inhibition in subsets of breast and ovarian
cancers), or alternatively, inhibiting distinct nodal points of regulation in com-
mon oncogenic signaling pathways (e.g BRaf and MEK inhibition in subsets of
melanoma). Recent data suggest that deregulated epigenetic modifıcations may
be just as signifıcant as genetic mutations in driving cancer development and
growth by inhibition of tumor suppressor activity and activation of oncogenic
pathways. We therefore hypothesized that an epigenetic regulator could poten-
tiate the effıcacy of a protein kinase inhibitor to result in robust tumor growth
inhibition. We previously reported that the potent and selective LSD1 inhibitor
INCB059872 potently inhibited tumor growth in multiple tumor xenograft
models of AML and SCLC as a single agent and in a combination with standard
of care of agents. In this study, we explored the anti-tumor effect of combining
INCB059872 and various signal transduction pathway inhibitors, including the
PIMkinase inhibitor INCB053914, the JAK1/2 inhibitor ruxolitinib, or the PI3K
delta-selective inhibitor INCB050465 in models of human hematologic malig-
nancies. Each of these therapeutic combinations signifıcantly inhibited tumor
growth in theMolm-16 humanAML xenograft model.Mechanistic studies sug-
gested that MYC expression levels were downregulated by these combinations
both in vitro and in vivo. Treatment with INCB059872 alone or in combination
with signal transduction kinase inhibitors signifıcantly downregulated cytokines
levels, particularly IL-10, sCD40L, and MCP-1 in Molm-16 tumors. These data
suggest that the combination of an LSD1 inhibitor and signal transduction in-
hibitor can co-regulate key tumor intrinsic and extrinsic pathways involved in
paracrine or autocrine signaling in AML. In addition to the improved effıcacy
observed in AML models, the combination of INCB059872 with the PI3Kdelta
inhibitor INCB050465 enhanced tumor growth inhibition in the Will-2 xeno-
graft model (GCB subtype, double hit lymphoma), whereas the activity of these
single agents were modest in this particular subtype of lymphoma. Additional
mechanistic studies are ongoing to further understand the molecular bases of
these observations. Taken together, these data suggest that targeting distinct
epigenetic andoncogenic signaling pathwaysmaypotentiate anti-tumor effıcacy
and overcome intrinsic resistance mechanisms in specifıc hematologic malig-
nancies.
#2033 Testing the combined effects of low dose olaparib plus ibrutinib on
MCL cytotoxicity. Adam D. Curtis, Todd A. Hoffert, Sheila S. Rajan, Jens Ru-
eter, Lindsay S. Shopland. Eastern Maine Medical Center, Brewer, ME.
Mantle cell lymphoma (MCL) presents a therapeutic challenge, with frequent
relapses after therapy due to high levels of DNA damage and disease evolution.
One currently approved MCL therapeutic, ibrutinib, is a tissue-specifıc agent
with relatively few adverse effects. However, ibrutinib is administered at high
dose for MCL and provides only a short progression-free survival time. To
potentially improve ibrutinib therapy for MCL, we tested the effects of combin-
ing ibrutinib with the DNA damage response inhibitor, olaparib, on MCL cells
in vitro.We confırmed that ibrutinibmonotherapy is cytotoxic toMCL cell lines
only at high doses ( 25 M). In contrast, single-agent olaparib treatment is
cytotoxic at lower concentrations (10 M). Importantly, the addition of low
dose olaparib to ibrutinib has an additive cytotoxic effect. Notably, the effects of
ibrutinib alone and in combination are dependent on cell medium composition.
Our fındings support clinical testing of ibrutinib plus olaparib therapy to reduce
MCL cell burden initially and to potentially slow MCL cell evolution in the
longer term. Our data also suggest the possibility for more effective ibrutinib-
based therapy via manipulation of the MCL cell niche.
#2034 LSD1 inhibition alone and in combination with chemotherapy in
Ewing sarcoma cell lines. Darcy Welch, Elliot Kahen, Christopher L. Cubitt,
Damon R. Reed.Moffıtt Cancer Center, Tampa, FL.
Background: Ewing Sarcoma (ES) is the second most common primary bone
cancer affecting children and young adults. Despite advances in treatment that
have led to survival rates of approximately 73% for localized disease, outcomes
for patients with metastatic or recurrent ES remain poor. A distinguishing fea-
ture of ES is the presence of the EWS/FLI1 fusion in 85% of cases. The fusion has
been shown to alter expression of a number of oncogenic genes. Mechanistic
studies have demonstrated that the NuRD co-repressor complex interacts with
EWS/FLI1. The associated protein LSD-1 contributes to the repressive function
by histone modifıcations. While reversible LSD1 inhibitors demonstrate single
agent activity, in preclinical models, a system to evaluate combinations may be
needed for optimizing effect in clinical trials. Methods: Here, we seek to confırm
promising single drug activity and evaluate combination therapies using active
chemotherapies currently utilized in ES care (4-HC, etoposide, SN-38, vincris-
tine and doxorubicin) along with the LSD1 Inhibitors SP2509 and SP2577 and
romidepsin, an HDAC inhibitor. We evaluated these combinations in high-
throughput screening platforms and well-established cell line models for ES
(A-673, TC-32, RD-ES, TC-71). Taking into consideration past lessons learned
from in vitro experiments, we designed stringent screening conditions that as-
sess the candidate compounds and combinations at clinically-relevant concen-
trations and exposure times thatmimic the in vivo pharmacokinetics in an effort
to maximize the translational potential of these results to the clinical setting. All
combinations of agents were studied in two-drug combinations to evaluate for
synergy in addition to effıcacy. Results: IC50 for SP2509 was found to be in the
submicromolar range across cell lines with SP2577 being more potent. A-673
andTC-71were 5-10 fold less sensitive thanRD-ES andTC-32.Agents currently
utilized in clinic were universally active at clinically achievable concentrations
and exposure times. Combinations showed additivity frequently and demon-
strated promising activity that can be used to inform further decision making
once LSD1 inhibition toxicities are better known. These fındings suggest poten-
tially promising opportunities for developing combination clinical trials tomax-
imize development of LSD1 inhibitors.
#2035 MGMT inhibition leads to CDK4/6 inhibition and enhances palbo-
ciclib and abemaciclib activity in breast cancer.George C. Bobustuc, Amin B.
Kassam, Richard A. Rovin, Deborah L. Donohoe, Maxwell Albiero, Tarun Jella,
Olivia Fukui, Cameron Piron, Santhi D. Konduri.Aurora Health Care, Milwau-
kee, WI.
Background:MGMT(O6methylguanineDNAmethyltransferase), aDNArepair
protein leading to chemotherapy resistance, increasingly studied for its cell cycle
regulatory functions, also known to control ER expression and function, is overex-
pressed inamajorityof cancers, includingbreast cancer.MGMTinhibitionhasbeen
reported to restore ER function and sensitivity to hormonal therapy in tamoxifen
resistant breast cancer. CDK4/6 is a cell cycle regulator targeted by a new class of
drugs in the treatment of breast cancer in patients who had progressed during prior
endocrine therapy.We investigated apotential correlative role betweenMGMTand
CDK4/6 expression/activity. In this therapeutic context MGMT inhibition would
have the dual role of increasing/restoring effect of endocrine therapy and facilitate
activity of CDK4/6 inhibitors (Palbociclib and Abemaciclib). Methods: We have
tested the effect of Antabuse (disulfıram, DSF), as anMGMT inhibitor, at nontoxic
doses, on the expression of CDK4/6, or in combination with Palbociclib (PB) or
Abemaciclib (LY2835219 - LY) onERbreast cancer cells. Results:DSF at very low
doses (achievable in human serum with standard DSF clinical dosing) decreases
ER breast cancer cell growth (MCF7, T47DandZR75) in a dose-dependentman-
ner. DSF further sensitizes breast cancer cells to PB or/and LY and signifıcantly
inhibits breast cancer growth without causing unwanted side effects on the normal
breast epithelial cells.Dose effect and isobologramstudies confırm synergistic activ-
ity of DSF LY and moderate synergism for DSF PB. DSF, alone or in combi-
nationwithPB (DSF	PB) and/orLY (DSF	LY), signifıcantly inhibits expression
of MGMT, CDK4/6, ER and aldehyde dehydrogenase activity - all involved in
breast cancer cell cycle proliferation and tumorigenesis. Furthermore, PB and LY
dosedependentlydecreasedMGMTandCDK4expression inbreast cancercells and
signifıcantly accumulatedbreast cancer cells inG1phase of the cell cycle.DSF, alone
or in combination with PB (DSF	 PB) and/or LY (DSF	 LY) caused signifıcant
apoptosis in breast cancer cells. DSF inhibited colony formation which was further
enhanced by addition of PB/LY (DSF	 PB/LY). Similarly, DSF alone or in combi-
nationwith PB (DSF	PB) and/or LY (DSF	LY) decreased themetastatic poten-
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tial of breast cancer cells. Conclusions: Our fındings suggest that DSF as anMGMT
inhibitor signifıcantly enhances the antitumor effect of CDK4/6 inhibitors (PB or
LY) in ER breast cancer.
#2036 In vitro and in vivo effect of carmustine and selenite combination
on EGFR signaling in androgen-independent prostate cancer.Vijayalakshmi
Thamilselvan, Mani Menon, Sivagnanam Thamilselvan. Vattikuti Urology In-
stitute, Henry Ford Health System, Detroit, MI.
Introduction: Despite the use of androgen deprivation therapy, the majority
of prostate cancer patients will progress to castration resistant disease within 2-3
years, driven by aberrant androgen receptor activation. We have previously
shown that combination of carmustine and selenite effectively induces apoptosis
by completely reducing AR and AR-variants in AR-dependent castration resis-
tant prostate cancer cells both in vitro and in vivo. Although studies have dem-
onstrated that AR signaling is a central mechanism of castration resistant pros-
tate cancer progression, the cell growth mediated by AR-independent signaling
is also operative. EGFR signaling has been implicated in the survival, invasion,
and metastasis of prostate cancer cells in an AR-independent manner. There-
fore, in this study, we testedwhether the combination of carmustine and selenite
could inhibit EGFR signaling, induce apoptosis, and inhibit growth of AR-inde-
pendent prostate cancer cells in an in vitro cell culture and in vivo xenograft
models. Methods: AR negative PC-3 prostate cancer cell line was used to study
the effect of carmustine and selenite alone or in combination onEGFR signaling.
Cell viability, proliferation, and apoptosis in the presence or absence of EGF
(50ng/ml) were determined. Dose and time dependent effect of EGF on the
activation of EGFR was studied. The carmustine and/or selenite effect on EGF
stimulated phospho-EGFR, and its downstream signaling pathways, such as
AKT and MAPK, were studied in comparison with inhibitors of EGFR
(AG1478) or PI3 kinase (LY294002) or MAPK (PD98059). The in vivo effect of
carmustine and selenite was examined on PC-3 tumor growth in athymic nude
mice. Results: Combination of carmustine and selenite treatment in the presence
of EGF markedly suppressed cell viability and proliferation of PC-3 cells. EGF
exposure increased phospho-EGFR (Tyr845, Tyr992, Tyr1068, and Tyr1045),
pAkt (Ser473), and pERK1/2 (Thr204/Tyr202) protein expression levels in PC-3
cells in a dose and time dependent manner. The combination treatment exhib-
ited a strong inhibitory effect on EGF stimulated EGFR, Akt, and ERK1/2 phos-
phorylation. Combination treatment was able to induce apoptosis even in the
presence of EGF. Consistent with in vitro results, combination treatment for
3 weeks reduced PC-3 xenograft tumors in nude mice by 88% without any
toxicity. Whereas individual agent treatment showed only partial effect both
in vitro and in vivo. Conclusions: Our pre-clinical data demonstrate that the
combination treatment of carmustine and selenite substantially inhibits
EGFR signaling, induces apoptosis, and reduces tumor growth of AR-inde-
pendent prostate cancer cells in vitro and in vivo. Our novel fındings suggest
that the combination of carmustine and selenite is an effective therapeutic
agent for successful treatment, survival, and improved quality of life for
patients with prostate cancer.
#2037 Oral nitroxoline in combination with intravesical bacille calmette-
guerin (BCG) shows synergistic antitumor effıcacy in mouse bladder cancer
orthotopic xenograft. Qiang Li,1 Kevin Pan,1 Xiezhao Li,2 Naijin Xu,3 Peng
Huang3. 1Asieris Pharmaceuticals Co., Ltd, Shanghai, China; 2ZhujiangHospital,
Southern Medical University, Guangzhou, Guangdong Province, China; 3Okayama
University, Okayama, Japan.
Nitroxoline, an antibiotic used to treat urinary tract infection, had previously
been identifıed as a MetAP2 inhibitor and found to show antitumor effıcacy in
mouse models of human breast cancer xenograft and bladder cancer orthotopic
xenograft [1]. Our purpose in this study was to evaluate the feasibility of com-
bining oral nitroxoline with intravesical BCG, the fırst-line therapy for interme-
diate- and high-risk non-muscle invasive bladder cancer (NMIBC), in mouse
bladder cancer orthotopic xenograft. The luciferase-expressing murine bladder
cancer cell lineMBT-2-Luc cells was transurethrally implanted in the bladder of
syngeneic female C3H/He mice. The animals were randomly divided into
groups and treated with phosphate-buffered saline (PBS), oral nitroxoline, in-
travesical BCG alone, and a combination as described in methods. The IVIS
spectrum images analyses of luciferin-stained tumor at 21 days after inoculation
revealed that combining oral nitroxoline with intravesical BCG showed syner-
gistically enhanced antitumor effıcacy and prolonged long-term survival, impli-
cating the potential of combining bladder cancer treatment using oral nitroxo-
line with intravesical BCG in the clinical setting. The mechanism behind this
observation is currently under investigated.
#2038 Reactive oxygen species-mediated synergism of fenretinide and ro-
midepsin in preclinical models of T-cell lymphoid malignancies. Monish
Ram Makena, Balakrishna Koneru, Min H. Kang, C. Patrick Reynolds. Texas
Tech Univ. Health Science Ctr., Lubbock, TX.
Introduction: T-cell lymphoid malignancies (TCLMs) are in need of novel
and more effective therapies. Romidepsin is a histone deacetylase (HDAC) in-
hibitor that achieved FDA registration as 2nd line therapy for peripheral and
cutaneous T-cell lymphomas. The cytotoxic retinoid fenretinide achieved dura-
ble complete responses against T-cell lymphomas in early-phase clinical trials
andT-cell lymphomapatientswho failed prior romidepsin treatment responded
to fenretinide. Fenretinide is currently being evaluated in a Phase IIa clinical trial
for relapsed/refractory PTCL patients (NCT02495415).We investigated the po-
tential for using these two agents in combination in TCLMs. Methods and Re-
sults: Using the DIMSCAN assay, we demonstrated cytotoxic synergy between
romidepsin and fenretinide in fıfteen TCLM cell lines at clinically-achievable
concentrations that lacked cytotoxicity for non-malignant cells (fıbroblasts and
blood mononuclear cells). In vivo, romidepsin  fenretinide  ketoconazole
(enhances fenretinide exposures by inhibiting fenretinide metabolism) showed
greater activity in subcutaneous (COG-LL-317m and TX-LY-183x PDX) and
disseminated (COG-LL-317m Luc expressing the luciferase gene) TCLM xeno-
graft models than single agent romidepsin or fenretinide ketoconazole. Fen-
retinide  romidepsin caused a reactive oxygen species (ROS, measured by
DCFDA dye)-dependent increase in pro-apoptotic proteins (Bim, tBid, Bax and
Bad), apoptosis (via TUNEL assay), and inhibition ofHDAC enzymatic activity,
which achieved a synergistic increase in histone acetylation. The synergistic
cytotoxicity, apoptosis, and histone acetylation of fenretinide romidepsinwas
abrogated by antioxidants (vitamins C or E). Romidepsin  fenretinide acti-
vated p38 and JNK via ROS, and shRNA knockdown of p38 and JNK1 signifı-
cantly decreased the synergistic cytotoxicity and apoptosis. Romidepsin fen-
retinide also showed synergistic cytotoxicity for B-lymphoid malignancy cell
lines, but did not increase ROS, acetylation of histones, activation of p38 JNK,
or cytotoxicity in fıbroblasts and blood mononuclear cells. Conclusion: Ro-
midepsin  fenretinide achieved synergistic activity in preclinical models of
TCLMs, but not in non-malignant cells, via a novel molecular mechanism.
These data support conducting clinical trials of romidepsin  fenretinide in
relapsed and refractory TCLMs.
#2039 The use of self nano-emulsifying drug delivery systems to improve
bioavailability of combination therapy and overcome erlotinib resistance in
non-small cell lung cancer. Ebony Nottingham, Vasanth Sekar, Arindam
Mondal, Mandip Sachdeva. Florida Agricultural and Mechanical University,
Tallahassee, FL.
Background: Erlotinib, an EGFR selective reversible inhibitor, improved re-
sponse of patients diagnosedwith non-small cell lung cancer (NSCLC)with 70%
of patients showing signifıcant tumor regression upon treatment. Unfortunate-
ly,most patients eventually relapse due to development of resistance. Our re-
search goal is to quantify the effects of combination treatment of erlotinib with a
glycyrrhetinic acid analogs and to improve the oral bioavailability of this treat-
ment using self nano-emulsifying drug delivery systems. Methods: NSCLC cell
lines HCC827, HCC827 (4M erlotinib resistant), HCC827 Cl4 (second site
EGFR mutated), HCC827BEAS2B, and H1975 (4Merlotinib resistant)
were treated in combination with CDODA-Me, CF3CDODA-Me and Erlo-
tinib. The cell viability assays were performed and combination index (CI)
values were calculated by isobolographic analysis. Self nano-emulsifying
drug delivery systems (SNEDDs) were formulated and characterized through
in vitro and in vivo studies. Results: CF3CDODA and improved effıcacy for
erlotinib in all cell lines with IC50 values of 6.0M, 7.8M, 4.6M and
4.2	1.56M for HCC827(RESISTANT), H1975(RESISTANT), HCC827CL4
and HCC827 respectively compared to IC50values of erlotinib alone (25M,
21M, 23M, and 8M). This was superior when compared to IC50 values of
CDODA-Me combination treatment (6.66M, 7.32M, 12.06M, and 5.45M
respectively). Combination treatment showed strong synergismwith a constant
concentration of 0.5MCF3CDODA and CI values of 0.461, 0.548, 0.389, 0.550
for HCC827 4M, H1975M, HCC827CL4, and HCC827 respectively and an-
tagonism in HCC827BEAS2B (1.508) cells. This is comparable to the synergism
observed at a minimum concentration of 2M CDODA-Me with CI values of
0.337, 0.67, 0.64, and 0.657 respectively and antagonism CI of 1.175 for
HCC827BEAS2B. CF3CDODA Combination therapy showed a 2.5-fold de-
crease in colony formation in resistant cells making them comparable to wild
type. This was comparable to CDODA-Me combination treatment with a 1.46-
fold decrease in colony formation. Both combination treatments showed little
effect onHCC827BEAS2B.Western Blot analysis showed decreaseMET expres-
sion and decreased apoptosis inhibiting markers BCL2 and Survivin. SNEDD
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formulations increased maximum drug plasma concentrations for Erlotinib
(281ng/ml to 442ng/ml) and circulating time as well (12hrs - 21hrs). Conclu-
sions: Based on the results of these studies, CDODA-Me and CF3CDODA have
shown to overcome erlotinib resistance in non-small cell lung cancer and when
combining these treatments with the use of SNEDDS, they have shown to be a
promising treatment regimen.
#2040 Superior therapeutic effıcacy of nanoparticle albumin-bound pac-
litaxel over cremophor-bound paclitaxel in experimental esophageal adeno-
carcinoma. Md Sazzad Hassan, Niranjan Awasthi, Roderich E. Schwarz, Mar-
garet A. Schwarz, Urs von Holzen. Indiana University School of Medicine-South
Bend, South Bend, IN.
Introduction: Esophageal adenocarcinoma (EAC) has become the dominant
type of esophageal cancer in United States. EAC is the fastest growing cancer in
thewesternworld and the overall 5 year survival rate of EAC is below 20 percent.
Most patients with EAC present with locally advanced or widespreadmetastatic
disease, where current treatment is largely ineffective. Prognosis for EAC pa-
tients remains poor even with combination therapies due to high resistance to
chemotherapy. Therefore, new therapeutic approaches are urgently needed.
Paclitaxel (PTX) has been used in combination with carboplatin (CP) as a stan-
dard combination therapy for advanced EAC. PTX required emulsifıcation with
solvents to allow intravenous administration which has resulted in hypersensi-
tivity reactions and potentially dramatic side effects in patients. Nanoparticle
albumin-bound (nab) PTX is an albumin-stabilized, cremophor-free and water
soluble nanoparticle formulation of PTX. Nab-PTX is a novel microtubule-
inhibitory cytotoxic agent and the potential role of nab-PTX has not been tested
yet in experimental EAC. Methods: We explored the antiproliferative and anti-
tumor effıcacy with survival advantage following CP, PTX and nab-PTX as
monotherapy and in combinations in in-vitro, and in murine subcutaneous
xenograft and peritoneal metastatic survival models of human EAC. Results:
Nab-PTX inhibited in-vitro cell proliferationwith signifıcantly lower IC50 (0.25
MinOE19 and 49 nM inOE33) than that of PTX (0.74MinOE19 and 98 nM
in OE33) and CP (5.21 M in OE19 and 1.05 M in OE33) in OE19 and OE33
EAC cell lines. Nab-PTX treatment resulted in signifıcantly higher antitumour
effıcacy and survival benefıt compared with PTX or CP treatment. After two-
week nab-PTX, PTX, CP, nab-PTXCP or PTXCP treatments, the average
in-vivo local tumor growth inhibition rate was 73, 60, 35, 81 and 68 percent
respectively (p0.025). Nab-PTX treatment increased expression of the mitotic-
spindle associated phospho-stathmin, decreased expression of proliferative
marker Ki-67 and enhanced apoptosis as confırmed by increased expression of
cleaved-PARP and cleaved caspase-3. There was an increase in median animal
survival after nab-PTX treatment (65 days) compared to controls (46 days,
p0.0023), PTX (57 days, p0.0034) or to CP therapy (53 days, p0.0034).
Conclusion: In conclusion, the present study demonstrates that nab-PTX had
stronger antiproliferative and antitumor activity in experimental EAC than the
current standard chemotherapeutic agents. This strong antitumor activity sup-
ports the rationale for clinical evaluation of nab-PTX as promisingmicrotubule-
inhibitory agent in EAC.
#2041 High-throughput chemical screening for sensitization of bladder
cancer to gemcitabine and cisplatin chemotherapy. Yuki Kita, Takashi Ko-
bayashi, Ryouichi Saito, Toshinari Yamasaki, Takahiro Inoue, Osamu Ogawa.
Kyoto University, Kyoto, Japan.
Introduction and Objectives: Gemcitabine and cisplatin chemotherapy (GC)
is the current standard regimen for locally advanced and metastatic bladder
cancer (BC). Despite a relatively high initial response rate, some cases do not
regress (intrinsic resistance) and the remaining cases often show regrowth after
initial shrinkage (acquired resistance). To identify novel therapeutic agents for
overcoming these resistances, we applied a high-throughput screening of chem-
icals administered in combination with GC. Methods As a high-throughput
screening, 2100 compounds were administered alone or in combination with
GC to human BC cell lines (J82, UMUC-3). Cell viability was determined after
3-day incubation and chemicals that enhanced inhibitory effect of GC were
screened. The in vivo effect of disulfıram (DSF) was studied in UMUC-3 cell
xenografts, and western blot, immunofluorescence, induced coupled plasma
spectrometry and measurement of reactive oxygen species (ROS) were done in
vitro for mechanistic exploration. Results: The initial screening identifıed 26
compounds and further validation narrowed them into the most synergistic
agent DSF, an FDA-approved drug for alcoholism. Combination index assay
showed synergistic effects of DSF with cisplatin but not with gemcitabine in J82,
UMUC-3, T24, HT1197 and HT1376 cells. Co-administration of DSF signifı-
cantly increased DNA-platinum adducts by regulating cisplatin efflux trans-
porter ATP7A and enhanced apoptosis by GC treatment in UMUC-3 cells, with
signifıcant increase of ROS production. Use of DSF in combination with GC
(GCD) signifıcantly inhibited tumor growth of UMUC-3 subcutaneous xeno-
graft on athymic mice (by 39% compared with GC alone, p 0.02). GCD regi-
menwas as tolerable as GC and no signifıcant differences were observed in body
weight of treatedmice between the two regimens. Conclusions: Repositioning of
DSF to a chemotherapy sensitizer is a promising treatment strategy, which can
be translated rapidly in the future.
#2042 Nano-tetraiodothyroacetic acid (NDAT) potentiates gefıtinib-in-
duced antiproliferation in colorectal cancer cells by inhibiting EGFR sialyla-
tion and PI3K activation. Yu-Tang Chin,1 Chi-Yu Lin,1 Chun A. Changou,1
JacquelineWhang-Peng,1 Paul J. Davis,2Hung-YunLin1. 1TaipeiMedical Univ.,
Taipei, Taiwan; 2Albany Medical College, Albany, NY.
The resistance of gefıtinib has been revealed to complicate cancer therapy.
Tetraiodothyroacetic acid (tetrac) and its nanoparticulate derivative (NDAT,
nano-tetrac) have been proved in vitro and in vivo xenograft demonstrating
anti-proliferative and anti-angiogenetic activities. It also indicates that they po-
tentiate anti-cancer agent-induced anti-proliferation in cancer cells. In this
study, we investigated the effects of NDAT on gefıtinib-induced anti-cancer
activities in human colorectal cancer cells. Gefıtinib inhibited cell proliferation
at concentration 1 M in K-ras wild type HT29 cell and NDAT enhanced the
anti-proliferation-induced gefıtinib signifıcantly. Meanwhile, both inhibited
proliferative and metastatic genes expression in HT29 cells. On the other hand,
10 M gefıtinib inhibited cell proliferation in K-ras mutant HCT116 cell which
was further enhanced by NDAT. Different from results in HT-29 cells, only
NDAT inhibited proliferative and metastatic genes expression signifıcantly and
enhanced the effect of gefıtinib in HCT116 cells. ST6Gal-1 catalyzes sialylation
of EGFR and induces gefıtinib-resistant in colorectal cancers. In addition,
NDAT did reduced not only ST6Gal-1 gene expression, but also its protein
production. However, the inhibition of ST6Gal-1 expression may not be suffı-
cient to induced anti-proliferation in colorectal cancer cells. PI3K inhibitor,
LY294002, was able to potentiate the gefıtinib-induced anti-proliferation in
HCT116 cells suggesting that constitutive activation of PI3Kmay play a key role
on gefıtinib-resistance in HCT116 cells. In summary, NDAT potentiated ge-
fıtinib-induced anti-proliferation via inhibiting the activity of ST6Gal-1 and
PI3K activation in gefıtinib-resistant colorectal cancer cells.
#2043 Entinostat in combination with Cladribine synergistically induces
apoptosis inmultiplemyeloma cells. BolunWang, Hui Lyu, Bolin Liu.Univer-
sity of Colorado Anschutz Medical Campus, Aurora, CO.
Cladribine (2-CDA) is a well-known purine nucleoside analog against lym-
phoproliferative disorders. Entinostat, a selective class I histone deacetylase
(HDAC) inhibitor, exerts anti-tumor activity in various cancers, includingmul-
tiple myeloma (MM). We sought to determine whether cladribine and entinos-
tat may exhibit synergistic anti-proliferative/anti-survival effects on MM cells.
Here we showed that, in cell growth MTS assays, either cladribine or entinostat
alone inhibited cell proliferation in a dose-dependent manner. The combina-
tions of cladribine and entinostat signifıcantly induced growth inhibition inMM
cells tested. The combination index (CI) curves showed a synergistic effect be-
tween cladribine and entinostat. An apoptotic-ELISA and western blot analyses
of caspase-3 and PARP revealed that entinostat in combination with cladribine
exhibited a much more potent activity than either agent alone to promote the
MM cells undergoing apoptosis in a dose and time-dependent manner. Collec-
tively, our data suggest that combinations of entinostat and cladribine possess
synergistic anti-proliferative/anti-survival activity in MM cells. Regimens con-
sisting of entinostat and cladribine may represent novel therapeutic strategies
against MM.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Drug
Resistance: Other Topics
#2044 Development of stable and brain-penetrating disulfıram nanopar-
ticles, characterization and effıcacy in glioma cell culture andxenograftmod-
els. Hanumantha Rao Madala,1 Surendra R. Punganuru,1 Francis Ali-Osman,2
Kalkunte S. Srivenugopal1. 1Texas TechUniv.Health Sciences Ctr., Amarillo, TX;
2Duke University, Durham, NC.
Blood brain-barrier entry, tumor heterogeneity, need to eliminate the tumor-
igenic stem cells and inhibit the DNA repair protein MGMT are all essential
considerations in glioma treatment. Previously, we showed that alcohol aversion
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drug disulfıram (DSF) shares all these properties [Carcinogenesis 35, 692, 2014;
Oncotarget 4,502, 2013]. DSF was shown to inhibit the MGMT activity in the
sameway asALDHby conjugatingwith the active-site cysteine 145 and sensitize
brain tumors to alkylating agents. Although DSF exerts signifıcant anticancer
effects in vitro, the drug undergoes rapid decomposition and metabolism. To
overcome this problem, we engineered DSF nanoparticles by encapsulating the
drug in PEG: PLGA polymer by solvent evaporation method. The formulation
was optimized for various process formulation variables. The optimized nano-
formulation (NP) ranged from 70-80 nm in particle size as confırmed using
dynamic light scattering and transition electron microscopy. Drug loading, en-
capsulation effıciency, in vitro releasewere also optimal and the particles showed
excellent BBB permeability in vitro. The time course of internalization of parti-
cles using a cyanine dye (HITC-1) showed a lysosomal accumulation followed
bymitochondria. Live animal imaging after IV injections of HITC-labeledDSF-
NPs revealed a selective accumulation in the brain and subcutaneous tumors.
Further, the cytotoxicity elicited by DSFNPs against SF188, DAOY, UW18,
UW28 andT98G brain tumor cells was extended and greater than obtainedwith
the free drug. When combined with DSF-NPs, temozolomide showed an 8-10-
fold increased cytotoxicity against glioma cell lines. The DSFNPs also induced
signifıcant degradation ofMGMTand other redox-sensitive proteins such as the
NF-B, MDR1 and GSTP1 in a concentration-dependent manner in glioma
cells. ROS induction by the encapsulated drug was confırmed throughDCF-DA
and DHE staining of live cells; co-staining these cells with the mitochondrial
membrane potential markers DiOC6 and DHE confırmed the altered integrity.
GSTP1 inhibition and ROS induction by DSFNPs led to an activation of JNK/
MAPK pathway, culminating in autophagy and apoptosis as verifıed by western
blotting, FACS and immunofluorescence of appropriate markers. Finally, the
antitumor effıcacy of DSFNPs was tested in intracranial glioblastoma developed
in nude mice by injecting luciferase-expressing SF-188 GBM cells. A superior
tumor regression was evident in DSFNP-administered animals compared with
the free drug after IVIS bioluminescence and histochemical staining of brain
tissue. Collectively, our efforts provide strong evidence that DSF nanoparticles
can cross the BBB and offer a sustained drug supply to eliminate CNS cancers.
Further refınement of DSFNPs by incorporating brain targeting strategies is
underway (supported by CPRIT grants RP130266 & RP170207 to KSS).
#2045 Exploring the potential of cellular thermal shift assay (CETSA) to
study drug resistance during cancer therapy. Lekshmy KunjammaUsha Sree-
kumar, Yan Ting Lim, Saranya Veerappan, Par Nordlund.Nanyang Technolog-
ical University, Singapore, Singapore.
The aim of this project is to understand the variousmechanisms contributing
to drug resistance development in cancer therapy. The effıcacy of therapeutics is
dependent on a drug binding to its target. We have developed a method that
allows for the fırst time to directly evaluate drug binding to target proteins in
cells and tissue samples the cellular thermal shift assay (CETSA) (MartinezMo-
lina et al. Science, 341:84). CETSA is based on the biophysical principle of li-
gand-induced thermal stabilization of target proteins. By monitoring the drug
occupancy in the target protein, CETSA can be used to study processes of drug
transport and metabolism in cancer cells. We have used CETSA to study the
acquired drug resistance of, antifolate and fluropyrimidine drugs in pairs of
parental and resistant cell lines. CETSA shifts and isothermal dose response
fıngerprint (ITDRF) were used to study the relative drug target engagement in
these cells. Quantitative mass spectrometry was used to monitor differences in
protein expression levels across the cell lines. Based on the CETSA measure-
ments, resistant cells clearly showed a higher drug dose threshold as compared
to the parent cell lines, typically requiring 8-50 times higher dose to establish
similar target engagement. Several potential mechanism for drug resistant
emerged - we, for example, observed up-regulation of thymidylate synthase and
down regulation of reduced folate carrier (RFC) protein associated with antifo-
late transport, in some resistant cell lines. The data supports that CETSA is a
potential valuable tool to dissect various mechanisms those contribute to resis-
tant development in cancer cells.
#2046 Investigation of MDR1 in ovarian cancer using biodynamic imag-
ing. Gayatri Narayanan,1 David D. Nolte,1 Daniela Matei,2 Ran An,3 John J.
Turek1. 1Purdue University, West Lafayette, IN; 2Northwestern University, Chi-
cago, IL; 3Animated Dynamics, Inc, Indianapolis, IN.
Multidrug resistance is one of the main causes of ineffective treatment of
ovarian cancer. Almost 80%of advanced cases have recurringmalignancies after
treatment, even after initial responsiveness to the usual platinum-based chemo-
therapeutics. One of the manymechanisms for resistance is the transmembrane
drug efflux pumpp-glycoprotein, encoded by the geneMDR1. It has been shown
that overexpression of this protein in ovarian cancer is associated with poor
chemotherapeutic response and multidrug resistance due to low intracellular
accumulation of the drug. Its wide substrate specifıcity allows it to pump out
several common drugs such as vincristine, paclitaxel, doxorubicin, and etopo-
side. Biodynamic imaging (BDI) is a low-coherence form of digital holography
that provides deep 3D functional information on intratumor subcellular motil-
ity and provides spectral signatures related to drug mode of action and for
mitosis, apoptosis, and necrosis. BDI is currently being used in clinical trials to
identify drug resistance in patient tumor biopsies. It was hypothesized that ovar-
ian cancer spheroids with varying degrees of platinum resistance and p-glyco-
protein would have identifıable p-glycoprotein signatures that could serve as a
spectral biomarker for drug resistance. Ovarian cancer tumor spheroids from
the A2780 and SKOV3 cell lines were cultured with varying degrees of cisplatin
to select for increasing platinum resistance and p-glycoprotein as detected by
immunofluorescence and western blot analysis. Cells were grown as 3D spher-
oids and treated with anticancer drugs that are known p-glycoprotein substrates
such as doxorubicin and paclitaxel. Treatments were used in combination with
and without p-glycoprotein inhibitors such as verapamil and zosuquidar. For
BDI, background spectral data was collected for 3 hrs and then for 9 hrs after
drug treatment. Parallel experiments were done in 2D cultured cells in 96-well
plates and cell viability was assessed with the XTT assay. A suppression of aver-
age intracellular motion in the low-frequency range (0.01 Hz) was observed
when 20Mverapamilwas used in combinationwith 10Mpaclitaxel inA2780
cells. This result may be due to the microtubule stabilizing effect of paclitaxel.
SKOV3 spheroids were treated with verapamil plus 10 Mdoxorubicin. Doxo-
rubicin treated spheroids have increased high (10Hz) and low (0.01Hz) spectral
signatures indicative of apoptosis. Addition of MDR1 modulators resulted in
frequency changes associated with a greater apoptotic response in SKOV3
spheroids. Modulation of p-glycoprotein alters the spectral response to drugs in
a manner associated with the drug mode of action. A specifıc MDR1 spectral
signature was not observed in these experiments but experiments with MDR1
silenced spheroids are underway to identify a possible signature.
#2047 The muscarinic receptor antagonist, benztropine, blocks the ex-
pansion of a temozolomide resistant subpopulation of glioma cells. Damian
A. Almiron Bonnin, Joseph M. Howard, Alison L. Young, Mark A. Israel, Mat-
thew C. Havrda. Geisel School of Medicine at Dartmouth, Lebanon, NH.
Virtually all malignant gliomas become drug-resistant and recur after initial
treatment, recurrent tumors are fatal within two-years, and no therapies exist
that cure gliomas. The recognition that subpopulations of primitive cells with an
oligodendrocyte precursor-like (OPC-like) phenotype capable of resisting stan-
dard therapy and contributing to recurrence, frames the question of whether
adjuvant therapies designed tomodify or eliminateOPC-like cells could slow the
progression of glioma. Agents that force the differentiation of treatment-resis-
tant OPC-like glioma cells, a phenomenon that requires cessation of prolifera-
tion, are compelling candidates for targeting OPC-like GSCs. Recently, it was
observed that OPC proliferation was driven by activation of theM1,M3 andM4
muscarinic receptors. In another report, a large-scale drug screen designed to
seek drugs to induce OPC differentiation in the context of multiple sclerosis
identifıed a muscarinic receptor antagonist, benztropine (a.k.a. Cogentin), as a
promoter of OPC differentiation and cell cycle exit. We have conducted studies
in glioma cell lines supporting a role for benztropine in suppressing the devel-
opment of drug-resistance to the standard glioma chemo-therapeutic temozo-
lomide (TMZ). Upon treatment with TMZ, we identifıed the emergence of an
OPC-like subpopulation of glioma cells identifıable by the co-expression of
CD44, CD15 and PDGFRa. Treatment with pre-inhibitory doses of benztropine
signifıcantly reduced the TMZ IC50 in all glioma lines examined in association
with blocking emergence of the CD44/CD15/PDGFR-positive subpopulation.
Ongoing studies are designed to determine the tumor initiating potential of the
CD44/CD15/PDGFR-positive subpopulation and whether benztropine will
suppress the development of TMZ resistance in animal models of glioma.
#2048 Saturated fatty acids in cell membrane phospholipids play an im-
portant role in chemoresistance in colorectal cancer.Takanori Hiraide, Taka-
nori Sakaguchi, Satoru Furuhashi, TomohiroMatsumoto, Yusuke Ozaki, Ryota
Kiuchi, Makoto Takeda, Yasushi Shibasaki, Yoshifumi Morita, Hirotoshi Kiku-
chi, Megumi Baba, Mitsutoshi Setou, Hiroyuki Konno. Hamamatsu University
School of Medicine, Shizuoka, Japan.
[Background and Aim] Resistance to chemotherapy represents the major
obstacle to survival in patients with chemoresistant colorectal cancer. Various
factors, such as drug efflux, autocrine survival signaling, and alterations in DNA
damage repair mechanisms, can contribute to chemoresistance; however, the
actual underlyingmechanism is yet to be elucidated. The aimof this studywas to
elucidate themechanismbehind anticancer drug resistance based on lipidomics.
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[Materials andMethods] 1) Spheroids were derived from three colorectal cancer
patient-derived xenograft models (A, B, and C) that were incubated with che-
motherapeutic agents, such as 5-fluorouracil (5-FU). We analyzed the response
rate of spheroids under 5-FU treatment. Global lipid analysis was performed on
5-FU resistance spheroids (A) and sensitive spheroids (C) using a Q Exactive
LC-MS/MSmass spectrometer, and lipid identifıcationwas performed using the
Lipid Search software. 2) We tried to identify genes that were responsible for
changes in phospholipid profıles in the cell membrane. 3) To determine phos-
pholipid profıle changes in the cell membrane that occur in colon cancer cell
lines (HCT116, SW480) during anticancer drug resistance, the genes responsi-
ble for such resistance were knocked down using siRNA. [Results and discus-
sion] 1) Response to 5-FU was different in individual spheroids. Global lipid
analysis and chemosensitivity assay revealed that phospholipids of 5-FU resis-
tant spheroids were rich in saturated fatty acids (SFAs), while those of the 5-FU
sensitive spheroids were rich in monounsaturated fatty acids (MUFAs). 2) The
enzyme stearoyl-CoA desaturase (SCD) converts SFAs to MUFAs in the phos-
pholipids. Based on these fındings we hypothesized that decreased SCD expres-
sion is possibly associated with chemoresistance. 3) Cell lines with SCD knock
down demonstrated increased SFA containing phospholipids and chemoresis-
tance towards 5-FU. Viable cells after the administration of the anti-cancer
agent confırmed that the expression of CD44 was upregulated. Therefore,
changes in the phospholipid composition of cell membranes regulate 5-FU re-
sistance in colon cancer. [Conclusions] Identifıcation and analysis of the role of
membrane lipids has become possible using high-sensitivity and high-resolu-
tion mass spectrometers and the relevant software, such as Lipid Search.
Changes of phospholipid composition regulates chemoresistance. In future, in-
vestigation of the pathophysiology of membrane lipids in cancer may help to
reveal novel strategies for cancer therapy.
#2049 The role of epigenetic mark profıle, cell cycle alteration and DNA
repair in resistance of glioblastoma cells to photodynamic therapy. Somayeh
Shahmoradi Ghahe,1 Karolina Kopania,1 Agata Ciuba,1 Marek Foksinski,2
Ryszard Olin´ski,2 Barbara Tudek3. 1Institute of Genetics and Biotechnology, Fac-
ulty of Biology, University of Warsaw, Warsaw, Poland; 2Department of Clinical
Biochemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz,
Poland; 3Institute of Biochemistry and Biophysics, Polish Academy of Sciences,
Warsaw, Poland & Institute of Genetics and Biotechnology, Faculty of Biology
University of Warsaw, Warsaw, Poland.
Glioblastoma is the most aggressive primary brain tumor. Treatment regi-
mens for glioblastoma tumors, such as surgery, radiotherapy, and chemother-
apy, are very invasive and can only prolong the median patient life to several
months. It was shown that 5-aminolevulinic acid (5-ALA)-based photodynamic
therapy (PDT) is a promising and less aggressive adjuvant modality for diagno-
sis and treatment of glioblastoma. Limiting point of PDT outcome is appearing
of cells with intrinsic or acquired PDT resistance that fınally results in repopu-
lating the tumor and short-term survival of glioma patients. Therefore, our
study was designed to determine therapy resistance markers in PDT resistant
glioblastoma cell line. Potential markers subsequently can be used for sensitiza-
tion of glioblastoma to PDT. Glioblastoma (U-87) cell line resistant to PDT
(U-87R) was isolated from parental, sensitive line (U-87P) by applying several
cycles of ALA-PDT, and further growing of surviving cells. U-87R cells subse-
quently were characterized from different aspects such as epigenetic markers,
cell cycle events, oxidative stress and DNA repair capacity. Assessment of nu-
cleotide modifıcations and epigenetic marks in PDT resistant glioblastoma and
its parental cell line showed signifıcant higher level of two epigenetic marks
including 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) in
U-87R compare to U-87P, before and after PDT. Doubling time of U-87R cells
was considerably longer than that of U-87P. Cell cycle analysis showed longer
G1 phase in U-87R cells compare to U-87P. Moreover, accumulation in G2
phase following PDTwas observed earlier in resistant cells than in parental line.
That suggests the role of early activation of DNA damage response in resistant
cells. Resistant glioblastoma cells were then sensitized to PDT by applying in-
hibitor of one of the main kinases of DNA damage response, ATM kinase. In
comparison with parental cells, U-87R cells also showed higher activity of some
DNA base excision repair (BER) enzymes including glycosylases and AP-endo-
nuclease1 (APE1). Studies of the whole protein profıle of PDT resistant and
parental cells demonstrated that the level of superoxide dismutase (SOD) was
considerably higher in U-87R than in U-87P. That data was then confırmed by
detecting lower oxidative stress inU-87R followingPDT. PDT resistant glioblas-
toma cells as a model of resistant cells in glioblastoma tumor population dem-
onstrated the signifıcant role of epigenetic mark profıle, cell cycle alteration,
higher DNA repair capacity, and antioxidant defense in conferring resistance to
photodynamic therapy. This workwas supported by the PolishNational Science
Centre (NCN) grants: DEC-2012/07/B/NZ1/00008, UMO-2014/15/B/NZ5/
01444, UMO-2014/13/N/NZ3/00863.
#2050 Polyploid tumor cells: a chemoresistant cell type in triple-negative
breast cancer.Rekha Gyanchandani, Adrian Lee.University of Pittsburgh, Pitts-
burgh, PA.
Background: Triple-negative breast cancers (TNBC) are associated with an
extremely poor prognosis due to their aggressive behavior and rapid resistance
to chemotherapy. Chemotherapy may select for resistant subclones and lead to
tumor recurrence. Although, DNA aneuploidy has been a long known prognos-
tic biomarker in breast cancer, the biological role of aneuploid or polyploid
cancer cells in tumorigenesis and chemoresistance is largely undefıned. Polyp-
loid cells arise due to repeated rounds of DNA duplication in the absence of
mitosis. Chemotherapeutic DNA-damaging agents or mitotic inhibitors can
also induce formation of polyploid cells and subsequent senescence. However,
recent reports indicate that polyploid cells represent a viable and proliferating
subpopulation within a tumor that may escape chemotherapy and contribute to
tumor recurrence. Methods: In this study, we examined the prevalence and
functional signifıcance of polyploidy occurring de novo or induced by chemo-
therapy in TNBC cell lines. DNA ploidy was analyzed in Hoechst 33342 stained
cells using FACS. Cells with greater than 4N DNA content were defıned as
polyploid. Live-cell imaging was done to observe cell division patters in polyp-
loid cells using IncuCyte Zoom. Cell proliferation was assessed in the absence
and presence of chemotherapy drugs with distinct modes of action (docetaxel
and paclitaxel: mitotic inhibitors, cisplatin: DNA cross-linking agent, and eto-
poside or VP16: topoisomerase inhibitor). RNAseq was performed to compare
gene expression profıles between treatment-naive diploid and polyploid cells.
Results: Hoechst 33342 staining determined the prevalence of polyploid cells in
HCC1395(6.7%) andHCC1937 (5.8%) cells lines. Live-cell imaging in polyploid
cells showed formation of mitotic structures suggesting multi-polar cell divi-
sion. Cell proliferation assay revealed that polyploid cells grow slower than dip-
loid cells and show reduced sensitivity to all four chemotherapy drugs. Do-
cetaxel treatment resulted in induction of polyploidy and drug-induced
senescence in parental TNBC cells. Drug-induced polyploid cells were resistant
to subsequent docetaxel treatment. Time-lapse imaging showed budding of
small daughter cells from polyploid senescent cells. Majority of senescent cells
died, some cells survived and regenerated the diploid and polyploid subpopula-
tions similar to those present in parental cells. RNAseq identifıed differentially
expressed genes involved in G1-S and G2-M checkpoint pathways (BRCA1/2,
RAD51), cell proliferation (Aurora kinase A/B) and apoptosis (BIM, BIRC3).
Conclusions: Above fındings indicate that there are molecular and functional
differences between diploid and polyploid cells that are both naturally occurring
or induced by chemotherapy. In our future studies, we will examine combina-
torial approaches to overcome polyploidy-associated chemoresistance.
#2051 LSTRA cell line as amodel for large granular lymphocytic leukemia
in drug screening. Fu-Shin Chueh,1 Fu-Yu Chueh,2 Chao-Lan Yu2. 1Asia Uni-
versity, Taichung City, Taiwan; 2Chang Gung University, Taoyuan City, Taiwan.
Large granular lymphocytic (LGL) leukemia is a rare form of leukemia that is
caused by the increase in cytotoxic T-lymphocytes or natural killer (NK) cells. A
subcategory of T-LGL leukemia that co-expresses T andNK cell surfacemarkers
is very aggressive and has a very poor prognosis. Current treatment of aggressive
T-LGL is based on non-specifıc immunosuppressive therapy. Lack of model cell
lines contributes to slow progress in designing targeted therapy and clinical
trials. Our recent studies demonstrate that the mouse T-leukemic cell line
LSTRA reproduces some important characteristics of aggressive T-LGL leuke-
mia. This is the fırst report of a cell line model mimicking the deadly human
leukemia and has great potentials for drug screening in treating T-LGL leuke-
mia. Bortezomib is one of the drugs that show promising results in treating LGL
leukemia patients in clinical trials. Bortezomib is the fırst FDA-approved revers-
ible proteasome inhibitor in treating multiple myeloma and mantle cell lym-
phoma patients. One of the major concerns in using single-agent bortezomib is
that patients develop resistance during the course of treatment and cancers
relapse. Therefore, it is important to developnovel strategies in overcoming LGL
leukemic cells’ resistance to bortezomib and its derivatives. In our current
study, we showed that bortezomib inhibited cell proliferation and induced
apoptosis in LSTRA leukemic cells. Partial reversion after 48-72 hr of bort-
ezomib treatment suggested development of resistance to bortezomib. We
further established bortezomib-resistant LSTRA cells that tolerated signifı-
cantly higher levels of bortezomib. Both carfılzomib (FDA-approved second
generation irreversible proteasome inhibitor) and MLN 4924 (proteasome
pathway upstream inhibitor) failed to overcome bortezomib resistance. Only
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luteolin, a common flavonoid found in plants, can effectively overcome bort-
ezomib resistance. Metabolic reprogramming has been linked to drug resis-
tance in cancer cells. Indeed, We found that bortezomib-resistant LSTRA
cells had smaller cell size as well as reduced rate of glucose uptake, lactate
secretion, and mitochondrial respiration. These results suggest that reduced
mitochondrial activity may be an important molecular marker for LSTRA
cell’s resistance to bortezomib. All together, we identifıed luteolin as a po-
tential small molecule in overcoming LGL leukemia’s resistance to protea-
some inhibitor therapy. Altered mitochondrial activity and cell metabolism
in bortezomib-resistant cells provide additional targets in developing novel
combined chemotherapy for cancer patients.
#2052 Chemotherapy sensitivity, cytokine IL-8 level, and genetic expres-
sion mRNA IL-8 in gastric cancer treatment response prediction. Sirikan
Limpakan (Yamada). Chiang Mai Univ. Faculty of Medicine, Chiang Mai, Thai-
land.
Aims: To determine chemotherapy sensitivity in primary gastric cancer cell
isolated fromThai gastric cancer patients against anticancer drugs. To search for
the correlation of interleukin-6 and interleukin-8 levels in primary gastric can-
cer cell culture in comparison with tissue mRNA IL-8 gene expression and drug
response or resistance. Method: The control background of corpus normal epi-
thelial and gastric adenocarcinoma biopsy tissues were treated for primary cell
culture with single cell isolation technique. The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay was performed to ex vivo exam-
ine the chemotherapy sensitivity to three anticancer drug, cisplatin, oxaliplatin,
5-Fluorouracil , and Irinotecan. Biopsy tissues from tumor site were collected
before chemotherapy treatment in 63 patient who received neo-adjuvant che-
motherapy by FOLFOX IV regimen due to advance stage III and IV in both
resectable and un-resectable cases. The IL-8 mRNA gene expression was re-
ported by relative quantitation real time RT-PCR. ELISA technique was per-
formed to investigate the cytokine level from primary cultures taken from 41
gastric cancer patients who undergone biopsy from Maharaj Nakorn Chiang
Mai Hospital during year 2014 to 2016. The clinical data base was parallel col-
lected and analysed in correlation with clinical response and ex-vivo response.
Results: Each patient has different sensitivity pattern to the standard anticancer
drugs. There are no signifıcantly direct correlations or difference between cyto-
kine IL-8 levels or mRNA IL-8 expression, and the chemotherapy sensitivity to
the actual drugs that are being used for treatment of gastric adenocarcinoma in
individual patients. However, the chemotherapy resistance to all drugs in pri-
mary gastric cancer cell culture has trend to increase after the third cycle of
chemotherapy treatment when compared to prior cell treatment with fluctua-
tion of cytokine level. Different cytotoxic drug gives the same response result for
chemrsensitivity test in this population. The author observed the down regula-
tion of tissue mRNA IL-8 expression and cytokine level in the good responders.
Conclusion: The results provide an additional basis of information for primary
chemotherapy selection in the individualised treatment for advance gastric ad-
enocarcinoma patients. Therefore, the author suggest to select the less toxicity
cytotoxic drug for being primary chemotherapy of choice. Cytokine gene level
and mRNA IL-8 gene expression show individually signifıcantly change after
chemotherapy treatment in good responder. This resultmay lead us to fınd some
new targeted therapy or additional treatment for its suppression.
#2053 Mechanisms of resistance to palbociclib and aromatase inhibitors
in hormone receptor positive breast cancer. Armina A. Kazi,1 Antony Sare,1
Saranya Chumsri,2 Angela Brodie3. 1Loyola University MD, Baltimore, MD;
2Mayo Clinic, Jacksonville, FL; 3University of Maryland, Baltmore, Baltimore,
MD.
Estrogen receptor-positive (HR) breast cancer is themost common form of
breast cancer that is accountable for the majority of breast cancer mortality.
Currently, the cyclin dependent kinase inhibitor palbociclib in combination
with endocrine therapy represents the new standard fırst and second line ther-
apy for patients with metastatic HR breast cancer. While palbociclib has been
shown to signifıcantly improved progression free survival in combination with
aromatase inhibitor (AI) and fulvestrant, resistance will inevitably occur in pa-
tients with metastatic breast cancer. However, the mechanisms of resistance to
the combination of palbociclib andAI remain largely unknown. It is also unclear
whether resistance mechanisms would be the same if palbociclib was given as
fırst line treatment in combination with letrozole vs. if palbociclib was given as
second line treatment after letrozole resistance had already occurred. To address
this, previously well established and well characterizied letrozole-sensitive
MCF7Ca cells and letrozole-resistant LTLTCa cells were subjected to continu-
ous, long term treatment with increasing doses of letrozole and palbociclib until
resistance to both drugs was achieved (MCF7Caletpalb and LTLTCapalb, re-
spectively). Preliminary MTT cell viability assays indicate palbociclib IC50s of
750 nM in MCF7Ca and LTLTCa cells vs. 21 uM in palbociclib and letrozole-
resistant cells. First line and second line palbociclib resistance correlated with
changes inmorphology, protein expression, and cancer stem cell characteristics.
Under phase contrastmicroscopy, fırst line and second line palbociclib-resistant
MCF7Ca and LTLTCa cells were larger in size, more irregular in shape, and
tended not to grow in epithelial cell-like groups compared to palbociclib-sensi-
tive MCF7Ca and letrozole cells, with second-line palbociclib resistant cells ex-
hibiting these characteristics the most. Western blot showed that ER protein
expression in ER/HER2- MCF7Ca cells decreased with fırst line palbociclib
and letrozole resistance, and that both ER and HER2 protein expression were
decreased with second line palbociclib resistance in ERlow/HER2 LTLTCa
cells. Lastly, mammosphere assays demonstrated increasing percentage of can-
cer stem cells with letrozole resistance alone (4 per 1000 cells platedMCF7Ca vs.
58 per 1000 planted LTLTCa) and with palbociclib and palbociclib resistance
(317 per 1000 cells platedMCF7Ca and 202 per 1000 cells plated LTLTCa cells).
Overall, these results indicate that 1) resistance to palbociclib, whether as fırst
line or second line treatment has signifıcant effects on breast cancer cells that
may be relevant to patient diagnosis and treatment.
#2054 Cerivastatin overcomes the acquired resistance to crizotinib in
EML4-ALK positive non-small cell lung cancer by controlling YAP activa-
tion.Miran Yun,1 Hun Mi Choi,2 Kyoung Ho Pyo,2 Byoung Chul Cho2. 1Jeuk,
Seoul, Republic of Korea; 2Yonsei University College of Medicine, Seoul, Republic
of Korea.
Crizotinib is highly effective in patients with non-small cell lung cancer
(NSCLC) harboring the echinoderm microtubule-associated protein-like 4
(EML4)-anaplastic lymphoma kinase (ALK) fusion. However, its effıcacy has
been limited by the development of acquired resistance, and the mechanisms of
such resistance remain largely unknown.Herein, we investigated a possible can-
didate for circumventing the acquired resistance to crizotinib. We established a
model of acquired resistance to crizotinib (H3122-CR) by exposingEML4-ALK-
positiveH3122 lung cancer cells to increasing doses of crizotinib, and performed
MTT screening using a library of FDA (Food and Drug Administration)-ap-
proved drugs composed of a collection of 640 clinically used compounds. Our
MTT screening identifıed that cerivastatin, a drug targeting 3-hydroxy-3-meth-
ylglutaryl-CoA (HMG-CoA) reductase, signifıcantly inhibited the cell growth in
H3122-CR cells, which was completely restored by addition of geranylgeranyl
pyrophosphate (GGPP), a keymetabolite ofmevalonate pathway.We also found
that yes-associated protein (YAP), amajor effector of theHippo tumor suppres-
sor pathway, was robustly accumulated in nucleus with a concomitant decre-
ment of YAP phosphorylation in H3122-CR cells compared to parental cells.
Importantly, inhibition of geranylgeranylation (GGylation) by GGTI-298 or
cerivastatinmarkedly increased YAPphosphorylation, led to cytoplasmic trans-
location of YAP, and subsequently induced YAP inactivation. Moreover, the
enrichment of EGFR signaling pathway and cell cycle signature including tran-
scriptional targets of YAP was enhanced in H3122-CR cells, whose induction
contributed YAP-mediated resistance to crizotinib. Inhibition of YAP function
with siRNA or verteporfın as a YAP inhibitor greatly abrogated cell growth of
H3122-CR cells by modulating cell cycle regulators and EGFR activation. Fi-
nally, we confırmed up-regulation of nuclear YAP expression in crizotinib-ac-
quired resistant patient derived tumor xenograft (PDTX) models established
from EML4-ALK positive NSCLC patients. Collectively, our fındings defıne the
GGylation-mediated YAP transcriptional activation as a new mechanism of
resistance to crizotinib, providing a rationale for further exploring statins as a
possible anticancer agent to overcome the acquired resistance to crizotinib in
EML4-ALK positive NSCLC cells.
#2055 Therapeutic resistance toBETbromodomain inhibition inprostate
cancer. Carl G. Engelke, Rohit Malik, Steven Kregel, Irfan A. Asangani, Kari
Wilder-Romans, Xia Jiang, Xuhong Cao, Corey Speers, Arul M. Chinnaiyan.
University of Michigan, Ann Arbor, MI.
Prostate cancer is themost common cancer amongmen and a leading cause of
cancer-related death in North America. Current therapies include radical pros-
tatectomy and radiotherapy for localized disease, and androgen deprivation
therapy (i.e. surgical or medical castration) for metastatic disease. Recently, we
described the use of inhibitors of bromodomain and extraterminal (BET) pro-
teins for the treatment of castration-resistant prostate cancer (CRPC), which
have since undergone investigation in clinical trials. In anticipation of patients
refractory to treatment with BET inhibitors, we explored the development of
resistance to a clinical-grade BET inhibitor in four cell line models—VCaP,
LNCaP, LNCaP-AR, and 22Rv1—by serially passaging cells in increasing con-
centrations of drug with matched controls in DMSO. All resistance models
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displayed several-fold increased IC50 values relative to control in in vitro cell
viability assays. Additionally, we have modeled resistance to BET inhibition in
vivo by serially passaging cell line- and patient-derived xenografts in animals
treatedwith BET inhibition. Interrogating thesemodels through traditionalmo-
lecular techniques and next-generation sequencing, we discovered several puta-
tive mechanisms of resistance to BET inhibition that we are currently validating
in our laboratory.
#2056 MYC and HIF-2alpha mediates resistance to Epidermal Growth
Factor Receptor (EGFR) antagonism in oral squamous carcinoma cells. Su-
kanya Gayan,1 Reza Bayat-Mokhtari,1 Bidisha Pal,1 Anupam Sarma,2 Joyeeta
Talkudar,3 Sorra Sandhya,3 Rashmi Bhuyan,1 Seema Bhuyan,3 Jaishree Gar-
hyan,1 Debabrat Baishya,4 Amal Kataki,2 Rakesh Bhatnagar,5 Herman Yeger,6
Bikul Das1. 1Forsyth Institute, Cambridge, MA; 2B. Borooah Cancer Institue,
Guwahati, India; 3KaviKrishna Laboratory, Guwahati Biotech Park, IIT, Guwa-
hati, India; 4Gauhati University, Guwahati, India; 5Jawaharlal NehruUniversity,
New Delhi, India; 6Hospital for Sick Children, Toronto, Ontario, Canada.
Background: Oral squamous cell carcinoma (OSCC) is a devastating dis-
ease. Recent fındings suggest that the EGFR antagonist including erlotinib
may induce tumor regression alone or in combination with chemo/radia-
tion. Our preliminary clinical study conducted at KaviKrishna laboratory
indicates that many poor patients are taking the highly expensive drug Er-
lotinib, and or equivalent EGFR antagonists. However, oral cancer lesions
are often hypoxic, and the hypoxia-induced cellular mechanisms might con-
tribute to drug resistance. Here, we investigated, whether resistance to EGFR
antagonists may involve MYC and HIF-2alpha, two transcription factors
upregulated during hypoxia by using established oral cancer cell lines. We
have also obtained primary oral cancer cells from patients living in the Ka-
mrup district of Assam, where KaviKrishna laboratory is located. We intend
to evaluate the drug sensitivity of these oral cancer cells towards EGFR
antagonists. Method: We used SSC-25 and SCC-9 cell lines, as well patient
derived primary oral cancer cells (n5) for the study. Immunomagnetic
sorting was performed to obtain ABCG2 population. The self-renewal was
studied using in vitro clonogenic and in vivo serial transplantation assay in
NOD/SCID mice. Results: First, we identifıed a rare ABCG2 expressing,
highly tumorigenic cell population in SSC-25, and SCC-9 having cancer stem
cell (CSC) like characteristics. Second, we found that the ABCG2 cells
exhibited sensitivity to PD158780 (10 uM; 62% inhibition within 48 hours),
and AG1478 (10 uM; 56% inhibition within 48 hours), two small molecular
inhibitors of EGFR tyrosine kinase. These small molecular inhibitors signif-
icantly inhibited the clonogenic capacity of the ABCG2 cells. Next, we
found that ABCG2 cells also showed sensitivity to Erlotinib in the in vitro
clonogenic assay. Third, the ABCG2 cells, when exposed to hypoxia
(0.1% O2, 24 hours), exhibited enhanced expression and transcriptional
activity of MYC, and HIF-2alpha. The post-hypoxia ABCG2 cells exhib-
ited complete resistance to PD158780, AG1478 and Erlotinib treatment,
which could be reversed by siRNA silencing of MYC and or HIF-2alpha.
ChIP assay revealed that HIF-2alpha directly binds to MYC in ABCG2
cells. We found similar results in ABCG2 cells obtained from primary oral
cancer samples (n4). Importantly, ABCG2 cells directly isolated from
patients exhibited hypoxic phenotype, including the high expression of HIF-
1alpha, and HIF-2alpha, as well as resistance to erlotinib. Furthermore, er-
lotinib enhanced the stemness of ABCG2 cells by activation of the MYC/
HIF-2alpha self-renewal pathway (1). Conclusion: These data indicate that
MYC andHIF-2alpha co-operate tomediate intrinsic resistance of oral squa-
mous cancer cells to EGFR antagonist in the hypoxia microenvironment. (1).
Bhuyan et al. Cancer Research, volume 76 (14), abstract 935; 2016.
#2057 Evaluation of anti-tumor effıcacy of EC1456 in low-passage and
pre-treated patient-derived xenograft models of triple-negative breast can-
cer. Yingjuan Lu,1 Nikki L. Parker,1 Haiyan Chu,1 Michael R. Pugh,1 Satish I.
Rao,1 Patrick J. Klein,1 Michael F. Ritchie,2 Lonnie D. Myer,2 Jennifer Jas-
kowiak,2 Christopher P. Leamon1. 1Endocyte, West Lafayette, IN; 2Champions
Oncology, Baltimore, MD.
Triple negative breast cancer (TNBC) patients are insensitive to hormonal or
anti-HER2 therapy and have a higher recurrence rate among all breast cancer
subtypes. There is a lack of common therapeutic targets in TNBC due to its six
distinctmolecular characteristics. Recently,50% of TNBC cases were found to
express the folate receptor alpha (FR) on tumor cells. FR is a GPI-anchored
membrane glycoprotein capable of bringing folate-targeted small-molecule
drug conjugates (SMDCs) inside the cell. EC1456 is a folic acid-tubulysin B
hydrazide (TubBH) SMDC that specifıcally binds to the membrane FR and is
internalized by endocytosis. While encapsulated within the early endosome,
EC1456 releases TubBH into the cytosol where it inhibits the polymerization of
tubulin into microtubules, thus blocking spindle formation to arrest cells in
metaphasewhich ultimately induces apoptosis. EC1456 is currently under Phase
1 clinical investigation in patients with common solid tumors [IND# 118,859].
The purpose of this study is to evaluate EC1456 activity in Champions Tumor-
GraftTM TNBC patient-derived xenograft (PDX) models to help guide our drug
development strategies. These PDX models were derived from patients who
were treated with multiple lines of standard-of-care agents. A total of six low-
passage, FR-positive TNBC models were tested against two different treatment
regimens of EC1456 (once or twice a week for 2 weeks only). Plasma and tumor
drug concentrations were quantifıed by LC-MS/MS using satellite study ani-
mals. The tumor-bearing animals were monitored for up to 60 days to assess
both short-term (i.e. % TGI) and long-term (%PR, CR, TFS) anti-tumor re-
sponses. Using a stringent effıcacy criteria (
60% CR/TFS), 3 of the 6 TNBC
models were found highly sensitive to EC1456 and 3 were found resistant. To
identify potential gene signatures of EC1456 response, bioinformatics analysis
was performed using existing RNA-seq data and compared across a broad panel
of TumorGraftTM TNBC models, regardless of FR expression status. Specifıc
biomarkers of interest were further analyzed by qRT-PCR using control tumors
from the current study. Together, our analysis revealed potential resistance
mechanisms associated with microtubule dynamics as well as a cancer cell’s
ability to undergo apoptosis.
#2058 Co-treatment ofNVP-BSK805 highly sensitizes drug-resistant can-
cer cells by increasing P-gp inhibition. Yu Jin Park, Ji Hyun Cheon, Ji Yeon
Son, Sung Pil Yoon, Hyung Sik Kim. School of Pharmacy, Sungkyunkwan Uni-
versity, Suwon, Republic of Korea.
The high expression of P-glycoprotein (P-gp) is consistently observed inmul-
tidrug resistance (MDR) cancer cells. The purpose of our study is to identify
conditions that could increase the sensitivity of P-gp-overexpressing drug-resis-
tant KBV20C cancer cell line. We have used the commercially available epige-
netic library, which includes 128 compounds. Using the cellular viability test, we
also identifıed that NVP-BSK805 is highly sensitized to KBV20C-resistant cells
and vincristine treatment. However, NVP-BSK805-induced sensitization was
not observed in vincristine-treated sensitive KB parent cells, suggesting that the
effects are specifıc to resistant cancer cells. Using FACS analysis, western-blot,
and Annexin V staining, we identifıed that NVP-BSK805 sensitized vincristine-
treated KBV20C cells arrest via apoptosis and G2 arrest. Furthermore, sensiti-
zation potency of NVP-BSK805 in combination with vincristine was measured
in KBV20C cells when comparing with P-gp inhibitor verapamil or another
Jak2 inhibitor CEP-33779. We further investigated the mechanisms of NVP-
BSK805 against sensitization of vincristine-treated KBV20C cells. The sen-
sitization mechanism of NVP-BSK805 was mainly dependent on the inhibi-
tion of P-gp. In addition, ATPase activity was also conducted to identify its
potential role in NVP-BSK805 for P-gp inhibition. Both NVP-BSK805 and
CEP-33779 showed high binding affınity docking scores of -9.1 and -7.4,
respectively, against the ABCB1 receptor protein. Collectively, inhibition of
P-gp by NVP-BSK805 can increase the vincristine-sensitivity inMDR cancer
cells through increased apoptosis and G2 arrest. Our fındings indicate that
Jak2 inhibitor may be a promising target in the treatment of patients resis-
tant to anti-mitotic drug.
#2059 Co-treatment of XL019, a selective Jak2 inhibitor, highly sensitizes
drug-resistant cancer cells by increasing P-gp inhibition. Ji Hyun Cheon, Yu
Jin Park, Ji Yeon Son, Sung Pil Yoon, Hyung Sik Kim. School of Pharmacy,
Sungkyunkwan University, Suwon, Republic of Korea.
1 Co-treatment of XL019, a selective Jak2 inhibitor, highly sensitizes drug-
resistant cancer cells by increasing P-gp inhibition Ji Hyun Cheon1, Yu Jin Park,
Ji Yeon Son, Sung Pil Yoon, and Hyung Sik Kim Lab of molecular of toxicology,
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea A high
expression of P-glycoprotein (P-gp) is consistently observed in multidrug resis-
tance (MDR) cancer cells. The purpose of our study was to identify conditions
that would increase the sensitivity of P-gp-overexpressing drug-resistant
KBV20C cancer cell line. We used commercially available epigenetic library,
which includes 128 compounds. Using cellular viability test, we identifıed that
XL019 highly sensitized KBV20C-resistant cells to vincristine treatment. How-
ever, XL019-induced sensitization was not observed in vincristine-treated sen-
sitive KB parent cells, suggesting that these effects are specifıc to resistant cancer
cells. Using FACS analysis, western-blot, and annexin V staining, we identifıed
that XL109 sensitized vincristine-treated KBV20C cells via apoptosis and G2
arrest. Furthermore, sensitization potency of XL109 in combination with vin-
cristine was measured in KBV20C cells when comparing with P-gp inhibitor
verapamil or another Jak2 inhibitor CEP-33779. We further investigated the
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Drug Resistance: Other Topics
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017528
mechanisms of XL109 against sensitization of vincristine-treated KBV20C cells.
The sensitizationmechanism of XL109 wasmainly depends on the inhibition of
P-gp. In addition, ATPase activity was also conducted to identify as potential
role of XL019 in P-gp inhibition. In the docking modeling, XL019 and CEP-
33779 showed high binding affınity docking score against ABCB1 receptor pro-
tein by -10.590 and -9.104, respectively. Collectively, inhibition of P-gp by
XL109 can increase the vincristine-sensitivity in MDR cancer cells through in-
creased apoptosis andG2 arrest.Our fındings indicate that Jak2 inhibitormay be
a promising target in the treatment of patients resistant to anti-mitotic drug.
#2060 Characterizing acquired resistance to palbociclib in breast cancer.
Smruthi Vijayaraghavan, Iman Doostan, Jason P.W. Carey, Khandan Keyo-
marsi. UTMD Anderson Cancer Center, Houston, TX.
The CDK4/6 inhibitor palbociclib is currently being used in combination
with endocrine therapy to treat advanced ER positive breast cancer patients.
While this treatment has shown great promise in the clinic, about 25% of the
patients do not respond, and almost all patients eventually acquire resistance to
palbociclib treatment. Hence, understanding the mechanism(s) of acquired re-
sistance to CDK4/6 inhibition is crucial to devise alternate treatment strategies.
To interrogate this, we developed MCF7 and T47D resistant cells by treating
themwith increasing doses of palbociclib over a 6-month period. After confırm-
ing that these cells were resistant to palbociclib, we performed genome-wide
expression analysis via RNA-seq, in comparison with the parental (sensitive)
cells. RNA- seq analysis revealed 2888 differentially expressed genes (p0.05) in
the resistant cells when compared to parental. Further, gene set enrichment
analysis (GSEA) revealed enrichment of immune pathways (interferon alpha
and gamma response, immune response) and pathways known to regulate EMT
and cancer stem cells (IL-6/Stat3, IL-2/STAT-5, Notch, Wnt) in the resistant
cells. Additionally, GSEA analysis revealed downregulation of G2/M check-
point, estrogen response and DNA repair pathways (double strand break re-
pair). Thus, this data suggests that combined targeting of two or more pathways
that are altered in the resistant cells can provide a novel therapeutic strategy to
combat CDK4/6 inhibitor resistance.
#2061 Non-covalent EGFRT790M targeting TKIs inhibit AZD9291 resis-
tant EGFRC797Smutants. Jacqulyne P. Robichaux,MoniqueNilsson, JohnV.
Heymach. UTMD Anderson Cancer Center, Houston, TX.
Approximately 10-15% of non-small-cell lung cancers (NSCLC) have epider-
mal growth factor receptor (EGFR) mutations resulting in increased sensitivity
to 1st generation tyrosine kinase inhibitors (TKIs) such as gefıtinib and erlotinib.
For common mutations in EGFR, treatment with 1st generation TKIs results in
approximately 70% overall response rate, increased progression free survival,
and increased quality of life compared to chemotherapy alone. However, resis-
tance to 1st generation TKIs typically develops within12months, and approx-
imately 55%of patients acquire a secondarymutation in EGFRExon 20, T790M.
To overcome resistance, 2nd and 3rd generation covalently binding TKIs target-
ing T790M mutations have been developed. Recent studies show that approxi-
mately 40% of acquired resistance to 2nd and 3rd generation TKIs can also occur
via a third acquired EGFR mutation at the site of covalent binding, C797S. To
date, there are no standard approved targeted therapies for treating EGFRC797S
mutant NSCLC. Moreover, with proposed increased use of covalent inhibitors
in the fırst line setting, C797Smutations are expected to becomemore prevalent
and new strategies to overcome therapeutic resistance will be required. To this
end, we have generated stable Ba/F3 and HCC827 NSCLC cell lines expressing
C797S mutant EGF receptors with common mutations in EGFR including,
L858R/T790M/C797S, and Ex19del/T790M/C797S. EGFR mutant cell lines ex-
pressing C797S were screened against 1st, 2nd, and 3rd generation EGFR TKIs
and cell viability was determined using Cell Titer Glo. Triple mutant cell lines
containing T790M andC797Smutations were not sensitive to any 1st, 2nd, or 3rd
generation inhibitors with IC50 values of 10M, 7.0M, and 7.6M, respec-
tively. However Ba/F3 and HCC827 cell lines transfected with EGFR triple mu-
tants were inhibited by non-covalent inhibitors: CUDC-101, an EGFR, HER2
and HDAC inhibitor, and PKC412, a FLT3 inhibitor. In triple mutant Ba/F3
cells, CUDC-101 and PKC412 had IC50 values of 470nMand 250nM in Ex19del/
T790M/C797S EGFR mutants, respectively, and IC50 values of 690nM and
270nM in L858R/T790M/C797S EGFRmutants. In HCC827 cells, PKC412 had
IC50 values of 610nM and 520nM in L858R/T790M/C797S and Ex19del/
T790M/C797S triple mutants, respectively. In addition, western blot analysis of
triple mutant Ba/F3 cells showed decreased phosphorylation of EGFR in pres-
ence of 50nM PKC412 and 500nM of CUDC-101. Moreover, PKC412 partially
decreased p-EGFR expression at 50nM in HCC827 triple mutant cell lines. In
conclusion, unlike other EGFRTKIs, the non-covalent EGFR inhibitors CUDC-
101 and PKC412 inhibit both T790M and C797S EGFRmutants at low concen-
trations. Currently, we are establishing additional osimertinib resistant
HCC827, H1975, PC9 and H4006 cell lines for further in vitro and in vivo
studies.
#2062 Inhibition of STAT3 overcomes gemcitabine resistance in pancre-
atic cancer cells. Chi-Wei Chen, Ruiqin Wu, Yunxiao Meng, Wenge Zhu. The
George Washington University, Washington DC, DC.
Gemcitabine is used as the fırst line treatment of pancreatic ductal adenocar-
cinoma (PDAC), however, either innate or acquired resistance to gemcitabine
limit its therapeutic effıcacy. In this study, severalDNAdamage agents including
DNA repair inhibitors, and kinase inhibitors were examined for suppression of
cell growth of gemcitabine resistant cells. The results show that most of these
compounds are cross-resistant to gemcitabine-resistant pancreatic cells. By us-
ing STRINGprotein network database, we found that STAT3 signaling pathway
plays a connectional role to link targeted proteins we tested. Interestingly, gem-
citabine-resistant pancreatic cells have higher level of phosphor-STAT3
(pSTAT3) and are more sensitive to STAT3 inhibitor, S3I-201. Furthermore,
combined S3I-201 with gemcitabine synergically suppresses the growth of both
cell lines in vitro. We also confırmed the therapeutic effıcacy of combined treat-
ments using xenografted model. Taken together, inhibition of STAT3 over-
comes gemcitabine resistance in pancreatic cancer cells. This studymay provide
us with a new approach to treat pancreatic cancer as well as gemcitabine resis-
tance of pancreatic cancer.
#2063 The farnesyltransferase inhibitor tipifarnib causes dramatic tumor
regression and increases survival in murine HrasG12V driven aggressive thy-
roid cancers: Consequent adaptive and acquired resistance mechanisms in-
formcombination treatmentswith improved responses.BrianR.Untch,Van-
essa Dos Anjos,Maria ERGarcia-Rendueles, Jeff A. Knauf, Alan L. Ho, James A.
Fagin.MSKCC, New York, NY.
Of the three RAS oncoproteins, only HRAS is delocalized and functionally
inactivated by farnesyltransferase inhibition (FTI), an approach that has yet to
be exploited clinically. We treated a murine model of poorly differentiated and
anaplastic thyroid cancer (Tpo-cre/HrasG12V/p53flox/flox; Hras;p53) with the FTI
tipifarnib, and observed sustained tumor regression and increased survival;
however, tumors eventually recurred. Following HRAS delocalization by tipi-
farnib in vitro, ERK phosphorylation was only inhibited transiently in HRAS-
mutant cell lines, which was associated with increased GTP loading of wild-type
RASproteins in the setting ofRTK ligand stimulation. This adaptive reactivation
of RAS-MAPK signaling was abrogated by selective RTK (i.e. EGFR, FGFR)
inhibitors, or by MEK inhibitors. Importantly, tipifarnib combined with the
MEK inhibitor AZD6244 led to improved responses inHras;p53mouse tumors,
whereas combination with the EGFR/FGFR inhibitors erlotinib and ponatinib
did not, suggesting heterogeneity of upstream inputs. In order to identify ac-
quired resistance mechanisms, tumor-bearing Hras;p53 mice were treated with
tipifarnib until resistance developed (6 months). Whole exome sequencing of
resistant tumors identifıed a truncating NF1 mutation and an activating muta-
tion in GNAS at high allelic frequency. Upon NF1 knockdown in the human
HRAS- mutant cell line C643, tipifarnib failed to inhibit pERK in vitro and
caused resistance to tipifarnib in xenografts. By contrast, activating GNAS mu-
tations transduced into Hras;p53 mouse tumor cell lines produced tipifarnib-
resistant xenografts that activated the GNAS-cAMP-CREB pathway and dem-
onstrated signs of redifferentiation. These data show that pharmacological
targeting of RAS in a genetically accurate,mousemodel of a RAS-driven virulent
cancer leads to objective major responses and improved survival. We identifıed
adaptive and acquired resistance mechanisms, and show that combined treat-
mentwith selectiveMEK inhibitors are benefıcial. These data should also inform
a currently enrolling clinical trial of tipifarnib for HRAS-mutant malignancies.
#2064 Tumor cells treated with a PBD-based antibody-drug conjugate
targeting 5T4 develop acquired resistance due to 5T4 down-regulation and
response to alternate therapeutics. Shenlan Mao,1 Andrew Garcia,1 Tracy
Chen,1 Raghothama Chaerkady,1 Allison Marreno,1 Helen Zhong,1 Dorin
Toader,1 Nazzareno Dimasi,1 Maureen Kennedy,1 Philip Howard,2 Changshou
Gao,1 Herren Wu,1 Ronald Herbst,1 David Tice,1 Jay Harper1. 1MedImmune,
Gaithersburg, MD; 2MedImmune, London, United Kingdom.
Resistance to antibody-drug conjugates (ADC) has been observed in both
preclinicalmodels and in the clinic. It has been previously reported that anADC
targeting CD33 with a DNA cross-linking pyrrolobenzodiazepine (PBD) dimer
was active inmodels of multidrug-resistant (MDR)AML, suggesting that PBDs,
delivered as part of a molecular-targeted cancer therapy may be effective in
MDR settings. However it could still be possible to develop resistance to PBD-
conjugated ADCs though other mechanisms that remain unknown. Studies
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were conducted to determine if tumor cells have innate resistance to PBDs or an
anti-5T4 ADC delivering PBDwarhead. It was found that both the ADC and its
PBDwarhead, SG3199, completely eradicatedMDA-MB-361 breast cancer cells
and NCI-N87 gastric cancer cells in culture, suggesting a lack of intrinsic resis-
tance in these cell lines. The potential emergence of acquired resistance was
investigated by culturing MDA-MB-361 cells in gradually-increasing concen-
trations of either the ADC or SG3199 for over a year and the variants resistant to
either the ADC (361-ADCr) or the PBD warhead (361-PBDr) were established
as determined by decreased sensitivity in cytotoxicity assays. Transcriptional
profıling characterization of these two cell models demonstrated that neither of
them had signifıcant upregulation of P-glycoprotein (P-gp) or other drug efflux
transporter genes. Signifıcant 5T4 antigen down-regulation was observed in the
361-ADCr cells but not the 361-PBDr cells and these cells also remained sensi-
tive to alternate treatments including ADCs targeting a different surface antigen
with the same PBD warhead, suggesting that down-regulation of target was
likely the main driver of resistance in 361-ADCr cells. Further transcriptional
profıling analyses conducted on 361-PBDr cells suggest amulti-factorial process
may be needed to develop resistance to PBDwarheads as differential expression
of genes associated with DNA damage and repair, drug metabolism and cell
cycle was observed. Similar gene expression profıles were observed in both cul-
tured cells and in tumors derived from these cells. Studies to validate these
differentially expressed genes, including proteomic and phosphoproteomic pro-
fıling are currently being conducted. Collectively these data could identify how
resistance to ADCs conjugatedwith PBDpayloadsmay develop in the clinic and
more importantly, provide insight into developing strategies to overcome such
resistance.
#2065 Targeting the crosstalk betweenMET andNotch signaling inRhab-
domyosarcoma. Rossella Rota,1 Cristina Cossetti,1 Silvia Pomella,1 Alberto
Gualtieri,1 Elena Carcarino,1 Carola Ponzetto,2 Riccardo Taulli,3 Lucio Miele,4
Franco Locatelli1. 1Ospedale Pediatrico Bambino Gesù, Roma, Italy; 2Univerisity
of Turin, Turin, Italy; 3University of Turin, Turin, Italy; 4Louisiana Research
Cancer Center, New Orleans, LA.
Rhabdomyosarcoma (RMS) in a pediatric soft tissue sarcoma expressing
myogenic markers. RMS includes two histological subtypes, embryonal and al-
veolar, which differ clinically and molecularly. The majority of alveolar RMS
expresses fusion oncoproteins such as PAX3/7-FOXO1. Fusion positive (FP)
RMSare at high risk showing a dismal prognosiswhile fusionnegative (FN) ones
have a better outcome. The MET protooncogene is a target gene of PAX3-
FOXO1 and is overexpressed in FP RMS. However, it is upregulated/overacti-
vated in FN RMS as well. It concurs to disease pathogenesis and is a potential
target of therapy. We have shown that MET is down-regulated by the myomiR
clustermiR-1/206 that promotesmyogenic-like differentiation and inhibits pro-
liferation of RMS cells. Notch signaling is also deregulated in RMS and inhibi-
tion of either Notch1 in FN or Notch3 in both subtypes leads to tumor growth
blockade. Some preliminary data from our lab indicate that the expression of
miR-1/206 is induced in Notch3-silenced RMS cells. Therefore, we sought to
investigate the crosstalk between MET and Notch signaling in RMS. We de-
tected a down-regulation of MET transcript and protein in Notch3 knocked
down RMS cells. In turn, MET silencing reduced Notch1 and Notch3 activation
together with the levels of Notch ligands, JAG1 and DLL1. In line with this,
forced expression of an activated form of MET (Tpr) resulted in Notch1 over-
activation and up-regulation in FN RMS cells. Notably, a FN cell line treated for
long time (more than 6 months) with growing doses of EMD, a clinically rele-
vant MET inhibitor, showed resistance to treatment, over-activation of MET,
i.e., hyperphosphorylation, and Notch1 signaling hyperactivation. These pre-
liminary results suggest that MET and Notch signaling could crosstalk in RMS
and that their co-targeting could be used to overcome drug resistance to single
agent therapy. To this end, combination treatments of MET inhibitors with
clinically relevant gamma-secretase inhibitors are in course. The work is sup-
ported by Associazione Italiana Ricerca sul Cancro project IG15312 to RR.
#2066 Delivery of 2‘F-PS2 PTGER3 siRNA-DOPC enhances anti-tumoral
activity in cisplatin resistant ovarian cancermodel. Emine Bayraktar, Cristian
Rodriguez-Aguayo, Zahid Siddik, Gabriel Lopez-Berestein.MDAnderson Can-
cer Center, Houston, TX.
RNAi-based therapeutics approaches holds a big promise for clinical transla-
tion. However, siRNAs are very weak and highly susceptible to degradation by
nucleases. Nanoparticle delivery systems and chemical modifıcations of small
interfering RNA (siRNA) can enhance effıcient intracellular delivery and resis-
tance to degradation for various siRNAs resulting in an increase in their clinical
therapeutic potential. Here, we hypothesized that DOPC nanoparticles incor-
porated with a chemically fluoro phosphorodithioate (2‘F-PS2) modifıed-PT-
GER3 siRNA will enhance the stability, prolong the silencing effect in vitro and
increase the anti-tumoral effect when is combined with cisplatin in vivo. We
screened 51 different chemically modifıed PTGER3-siRNAs which have 2=-F-
PS2 or 2=-O-methyl modifıcation on selectively protected nuclease-sensitive
sites. We determined PTGER3 gene expression after siRNA-2=-F-PS2 or 2=-O-
methylmodifıedmediated silencing, stability, time-response silencing effect and
the therapeutic effect in xenograft OC in vivo model. We demonstrated that
siRNA-2=-F-PS2 prolong the stability for more than 24 hours and enhance the
silencing for more than 96 hours. Moreover, we found that PTGER3-silencing
effect can control the expression of CFTRmultidrug resistant pump by regulat-
ing ERK-ELK1-ETS1-CFTR axis, resulting in an increase of the cisplatin uptake,
decreased the tumor-associated angiogenesis and tumor growth in xenograft
OC in vivomodel. SiRNA-PTGER3-2=-F-PS2modifıcation increase the stability
and time-response silencing effect, leading to a synergistic anti-tumor in com-
bination with cisplatin in ovarian cancer models.
#2067 Tumor-infıltrating PMN-MDSCs mediate sorafenib resistance in
hepatocellular carcinoma through immune suppression.Chun-Jung Chang,1
Li-Chun Lu,1 Cher-wei Liang,2 Chih-Hung Hsu,1 Ann-Lii Cheng1. 1Graduate
Institutes of Oncology, College of Medicine, National Taiwan University, Taipei,
Taiwan; 2Department and Graduate Institute of Pathology, National Taiwan
University Hospital, Taipei, Taiwan.
Background]: The mechanisms underlying the inherent or acquired resis-
tance to sorafenib in advanced hepatocellular carcinoma (HCC) are not fully
understood. We studied the role of myeloid-derived suppressor cells (MDSCs),
a subset of bone marrow cells with immune-suppressive and proangiogenic
activities, in sorafenib-treated mice and patients. Materials and Methods: An
orthotopicmouse liver cancermodel was established by implanting BNL cells to
BALB/cByJNarl mice. Liver tumor-bearing mice were treated with sorafenib (5
mg/kg/d) for 1 week or 3 weeks from the day 8 after tumor cells implantation.
For combination therapy, mice were treated sorafenib and anti-IL-6 Ab or its
isotype control Ab (500g/every 3 days starting fromday 4 for 4 doses). Tumor-
infıltrating leukocytes (TILs) and leukocytes of other tissues including liver,
spleen, peripheral blood, and bone marrow were isolated, and characterized by
flow cytometry analysis. Morphological characteristics of MDSCs were deter-
mined by cytospin and Liu staining. Pro-inflammatory cytokines were detected
by ELISA or mouse inflammatory cytokines beads array (BD). Paired HCC
tissues from advanced HCC patients treated with sorafenib (before and post-
sorafenib progression tissues) were evaluated for the expression of CD11b,
CD15, and CD66b in TILs by immunohistochemistry. Results: In mice treated
with sorafenib, the CD11bGr1Ly6GMDSCs were signifıcantly increased in
liver tumors, but not in others tissues. Morphologically, these MDSCs were
segmented nuclear PMN type cells. The analysis of TILs revealed that the per-
centage of total immune effectors (CD4 or CD8 IFN--expressing T cells)
versus total immune suppressors (IL-10 or TGF -expressing CD4 T cell,
FOXP3-expressing CD4 T cells) was lower in the tumors of sorafenib-treated
mice than those of the vehicle-treated mice. The T cell proliferation capability
was also signifıcantly decreased in TILs of sorafenib-treated mice versus TILs of
vehicle-treatedmice.Multiple inflammatory cytokines includingVEGF,G-CSF,
MCP-1, and IL-6were signifıcantly increased inmouse liver tumors treatedwith
sorafenib. When combined with sorafenib, anti-IL-6 antibody alleviated the
early tumor-infıltration of Ly6GMDSCs, restored the proliferative activity of
TILs, decreased the levels of pro-inflammatory factors in tumors, and sup-
pressed the liver tumor growth synergistically. In 6 paired human HCC tissues,
we found that 3 exhibited higher proportion of CD11b, CD15, or CD66b cells
in post-sorafenib progression tissues than their pre-sorafenib treatment tissues.
Conclusions: Our data indicate that tumor-infıltrating PMN type MDSCs and
associated immunosuppression may be an important mechanism impeding the
therapeutic effıcacy of sorafenib in HCC. (This works was supported by MOST
105-2314-B-002-180).
#2068 Development of a rational triple combination therapy for castra-
tion-resistant prostate cancer. Yuanyuan Qiao, Todd M. Morgan, Arul M.
Chinnaiyan. University of Michigan, Ann Arbor, MI.
Background: The androgen receptor (AR) signaling pathway drives prostate
cancer development and progression, making it a major target for drug devel-
opment. However, resistance to AR targeted therapies invariably develops and
eventually leads to an aggressive, castrate-resistant prostate cancer (CRPC). Al-
though CRPC often remains dependent on AR signaling, anti-androgen thera-
pies can lead to the development of AR independent disease and metastatic
CRPC. Understanding the molecular basis of this transition and resistance to
current anti-androgen therapy will provide important insight and reveal novel
therapeutic strategies for both AR-positive and -negative disease pathways.
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Methods and Results: We analyzed in silico data of AR (signaling)-positive or
-negative human CRPC tissue samples and discovered that MET expression is
specifıcally increased only in AR-negative CRPC samples. When AR-positive
CRPC models are subjected to AR signaling inhibition (by the AR antagonist
enzalutamide or androgen deprivation), MET is increased and susceptible to
activation by its ligand HGF. Therefore, we postulate that dual targeting of AR
andMET signaling pathwaysmay be a better approach to prevent and overcome
resistance-related disease progression. Our preliminary AR ChIP-seq data sug-
gested thatMET transcription is not affected byARdirectly rather,METprotein
is modulated by AR signaling at the post-translational level. Therefore, we hy-
pothesize that a combination therapy of a proteasome inhibitor andMET inhib-
itor may have potential therapeutic benefıt for some CRPC patients. By using in
vitro and in vivo models of AR-dependent CRPC, we have showed that combi-
nation of the dual MET/VEGFR2 inhibitor cabozantinib and enzalutamide
treatment is more effıcacious than either inhibitor alone. In addition, Bort-
ezomib, an FDA-approved proteasome inhibitor, showed signifıcant synergistic
effect when paired with cabozantinib in our preliminary data using in vitro and
in vivo CRPC models. In vitro results suggest that triple combination of anti-
androgen, MET inhibitor and proteasome inhibitor therapies will maximize
inhibition in CRPC. Conclusion: MET is a compensatory survival pathway in
ARCRPCupon anti-androgen therapy. The rational for triple combination of
anti-androgen, MET inhibitor and proteasome inhibitor therapies is a feasible
approach to maximize inhibition in CRPC while minimizing development of
drug resistance to any single agent.
#2069 Overcoming drug resistance by targeting melanoma dedifferentia-
tion through information-theoretic analysis and single cell proteomics.Yap-
eng SU,1 Wei Wei,2 Lidia Robert,2 Jennifer Tsoi,2 Min Xue,1 Jungwoo Kim,1
ThomasGraeber,2 Raphael Levine,2 Antoni Ribas,2 JamesHeath1. 1Caltech, Pas-
adena, CA; 2UCLA, Los Angeles, CA.
Despite impressive initial response of BRAF targeted therapy in mestastic
melanoma patients, acquired drug resistance, often times derived from tumor
heterogeneity, always limit its clinical outcome. A dedifferentiation process
named melanocyte to neural crest transition (MNT) has shown to be critical in
the early stage resistance development. The dedifferentiation could induce a
whole cell state change resulting a drug tolerant state of melanoma cells, which
will lead to initial drug resistance. Mathematic modeling indicates the nature of
the transition as results of both stochastic phenotypic transition andnon-genetic
drug selection, which indicates and further proved that the whole cell state
transition should be reversible during drug removal. Information theoretic anal-
ysis reduced the dimensional of thousands of gene expression level changes as
results of only two unbalanced processes onto a cellular steady state. Reversible
transition trajectory defıned through two processes indicates it to resemble a
critical transition in physical systems. Refıned single cell proteomic analysis of
those proteins that associate with major unbalanced processes identify the crit-
ical points of the transition as early as day6, which cannot be resolved from bulk
proteomic measurement. By co-targeting the drivers at the critical points in
combination with original brafı targeted drug successfully arrested the transi-
tion and induced a sustained tumor growth inhibition in multiple patient-de-
rived melanoma cell lines. This study provides us a noval methodology of min-
ing whole transcriptomic transition with information theoretic analysis to
reduce the dimensionality and then using single cell proteomic analysis for re-
fıning critical points anddriver proteinswhich eventually rationalized a effective
combination therapy to stop the drug resistance development early on.
#2070 HMGB1 governs p53 to autophagic degradation via its nucleus-to-
cytoplasm transport. Qiaojun He, Peihua Luo, Xiaochun Yang, Qinjie Weng,
Ling Ding, Bo Yang. Zhejiang Univ. College of Pharmaceutical Sci., Hangzhou,
China.
P53 is under exquisitely fıne regulation and acts as a transcription factor that
regulates the expression of thousands of genes that control apoptosis, necroptosis,
ferrotosis, cell cycle arrest, senescence, metabolism and fertility. Regulation of p53
turnover is essential not only for the response to chemotherapeutic drugs or radia-
tion in cancer cell but also to keep p53 activity under control in a normal cell.
Moreover,.p53 is found to be overactivated in various diseases including idiopathic
pulmonary fıbrosis (IPF), alcoholic liver disease (ALD) andnon-alcoholic fatty liver
disease (NAFLD). Promoting hyperactivated-p53 degradation can combat these
diseases. However, the strategies that based on known proteasome-dependent deg-
radation only can stabilize the expression level of p53 such as nutlins (inhibit the
interaction betweenmdm2 and tumor suppressor p53). Autophagy-lysosomal deg-
radation is the other pathway for controlling cellular protein stability. More and
more researches have established that numerous proteins can be degraded through
both proteasome and autophagy-lysosome pathways. However, very little is known
todateaboutp53 turnover throughautophagy-lysosomepathway.Herewediscover
that the activation of p53 autophagic degradation during an oral small molecule
receptor tyrosine kinase inhibitor sunitinib in p53 wt cancer cells and normal cells.
Mechanistically, the nucleus-to-cytoplasm shift is essential for the autophagic deg-
radation of p53 induced by sunitinib, however, does not require p53 nuclear export
signals. Indeed, p53 degradation is achieved by the nucleus-to-cytoplasm transport
of its nuclear binding target HMGB1, shifting the distribution of p53 from the nu-
cleus to the cytoplasm. Then cytoplasmic p53 directly interacts with the autophagy
cargo receptor p62 to promote degradation. Importantly, inhibition of HMGB1
sensitizes cancer cell to sunitinib. Taken together, our study identifıed an alternative
p53protein turnovermechanisminducedby sunitinib, thusnotonly elucidating the
underlyingmechanisms that limit sunitinibeffıcacy incancer therapybut alsoopen-
ing an avenue for expanding the clinical indications of sunitinib.
#2071 Sub-clonal heterogeneity and risk of treatment failure in Philadel-
phia-positive leukemias. Michael W. Schmitt,1 Justin R. Pritchard,2 Lan
Beppu,3 J. Graeme Hodgson,2 Victor M. Rivera,2 Lawrence A. Loeb,1 Jerald P.
Radich3. 1University ofWashington, Seattle,WA; 2ARIADPharmaceuticals, Inc.,
Cambridge, MA; 3Fred Hutchinson Cancer Research Center, Seattle, WA.
Molecularly targeted therapies have been exceptionally successful in the treat-
ment of some malignancies, most notably chronic myeloid leukemia (CML).
However in other cancers, e.g. Philadelphia-positive acute lymphoblastic leuke-
mia (Ph ALL), drug resistance is a frequent occurrence. Resistance mutations
may pre-exist as a consequence of intra-tumor heterogeneity; thus the extent of
heterogeneity may determine the likelihood of treatment failure. Intra-tumor
heterogeneity is challenging to quantitate, as heterogeneousmutations are likely
to occur below the background error rate of conventional approaches for muta-
tiondetection. Toovercome this limitation and explore the relationship between
intra-tumor heterogeneity and drug resistance in Ph leukemias, we utilized
single-molecule Duplex Sequencing (DS) of the ABL1 gene. DS eliminates se-
quencing errors by independently tagging the two strands of individual DNA
molecules; truemutations are present at the same position in both strands, while
PCR and sequencing errors are only present in one strand. DS has an error rate
below 0.00001%, and thus enables quantitation of heterogeneous mutations
with unprecedented resolution. We fınd that CP-CML, a disease that is often
well controlled with targeted therapy, has an extremely low burden of intra-
tumor heterogeneity at the time of diagnosis, with a sub-clonalmutation burden
similar to that of normal individuals. Simulations which take into account the
low cancer stemcell fraction ofCP-CMLand the sub-clonalmutation burdenwe
measured reveal that only a minority of CP-CML patients will harbor pre-exist-
ing drug resistance, which may explain the unusual success of targeted therapy
in this setting. Next, we studied patients with advanced Ph leukemias (refrac-
tory BP-CML and Ph ALL), which have a high rate of treatment failure and
poor outcomes.We fınd that patients with BP-CML and PhALL have a signif-
icant elevation in sub-clonal heterogeneity relative to those with CP-CML. We
demonstrate that the higher extent of intra-tumor heterogeneity correlates with
a signifıcantly higher rate of drug resistance mutations and compound resis-
tance (i.e. two concurrent resistance mutations) in patients. Unlike CP-CML,
pre-existing mutations conferring resistance to targeted therapy are nearly cer-
tain in refractory BP-CML and Ph ALL as a consequence of the load of intra-
tumor heterogeneity and high cancer stem cell fraction.We support this concept
by three distinct approaches: (i) detection of pre-existing sub-clones that drive
treatment failure; (ii) modeling the growth kinetics of resistant clones; and (iii)
extrapolation of the mutation burden measured by DS. Our results suggest that
intra-tumor heterogeneity influences the likelihood of resistance to molecularly
targeted therapy. Quantitation of sub-clonal mutation load may be broadly ap-
plicable in other malignancies for predicting the likelihood of response to tar-
geted therapy and monitoring disease progression.
#2072 Combination of CDODA-Me, a glycyrrhetinic acid derivative, and
Erlotinib overcomes chemo-resistance inNSCLCPDXspheroids and3Dbio-
printed cells. ArindamMondal,1 Aragaw Gebeyehu,1 Ebony Nottingham,1 Ar-
vind Bagde,1 Subramanian Ramakrishnan,2 Arun K. Rishi,3 Mandip Singh1.
1FloridaA&MUniversity, Tallahassee, FL; 2Florida StateUniversity, Tallahassee,
FL; 3Wayne State University, Detroit, MI.
Patient-derived Xenografts (PDXs) are considered as relevant preclinical
model for anticancer drug development due to original recapitulation of patient
genetic profıle, gene expression patterns and tissue histology. In this study, we
investigated combination effıcacy of CDODA-Me (Methyl 2-cyano-3,11-dioxo-
18-olean-1,12-dien-30-oate) and TKI inhibitor Erlotinib (ERL) against Lung
NSCLCPDX spheroids and 3Dbio-printed PDX cells. NSCLCPDX cells (EGFR
T790M mutants) were obtained from Dr. Rishi’s Laboratory. PDX spheroids
were grown in DMEM/ F12 media supplemented with L-glutamine, B27 sup-
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plement, recombinant human epidermal growth factor (EGF) and recombinant
human basic fıbroblast growth factor (bFGF). Spheroids were treated with
CDODA-Me, ERL alone and in combination. Cell viability was measured by
MTT assay. Western blot analysis was used to study the modulation of Bcl-xL,
MDR1 andABCG2 in treated PDX spheroids. For 3D bio-printing of PDX cells,
hydrogels were prepared by partial cross-linking of sodium alginate (4.5% w/v)
and gelatin (1%w/v)mixturewith 40mMCaCl2 solution. PDXCells weremixed
with partially cross-linked hydrogel and printed with Inkredible 3D bio-printer
(CELLINK, Sweden). Bio-printed scaffolds were fully cross-linked by 160 mM
CaCl2 solution and then incubated overnight with cell culture media. The scaf-
folds were treated with CDODA-Me and ERL alone and in combination. After
48 h cell viabilities were determined by live/dead assay using fluorescence mi-
croscopy. MTT assay showed that approximately 65% and 74% viability was
observed at 10MERL and 2.5MCDODA-Me respectively. Decreased spher-
oid cell viability was observed in ERL and CDODA-Me combination treatment.
Ourwestern blot studies showeddown-regulation of Bcl-xL,MDR1 andABCG2
in combination group. Further, 81.04 	 5.65, 78.65 	 3.98 and 74.35 	 4.24
percent viable PDX cells were observed in the bio-printed scaffolds after 48, 72
and 96 h respectively. Higher percentage of dead cells (52.62	 1.66) were found
in the combination group than CDODA-Me (28.39	 1.60) and ERL (29.62	
4.91) alone. In conclusion, CDODA-Me in combination with ERL was found to
be effective against human lung PDX spheroids and bio-printed PDX cells by
decreasing the cell viability and overcoming drug resistance. Partially cross-
linked sodium alginate-gelatin hydrogel enhances the possibility of PDX cell
bio-printing with high cell survival rate. CDODA-Me can be considered as an
effective neo-adjuvant to improve ERL effıcacy in human NSCLC.
#2073 A systematic investigation of the effect of scheduling of targeted
combination therapies on response anddynamics of relapse in triple negative
breast cancer cells.Gauri A. Patwardhan, VikramB.Wali, Lajos Pusztai, Chris-
tos Hatzis. Yale University, New Haven, CT.
Cancer treatment typically involves administration of combination of tar-
geted therapies, but initial response is often followed by disease relapse. The
effıcacy of a treatment regimen depends on the complex interplay between
cancer growth dynamics, drug specifıcity and kinetics, treatment dose and its
scheduling. In standard high-throughput drug screening assays, cells are
treated with a single drug cocktail bolus and cell viability is assessed after 2-3
days, thus not considering treatment interactions and long-term effects. Re-
cently we have reported a promising synergistic combination of crizotinib
(ALK/MET inhibitor) and ABT-263 (BCL2/BCL-XL inhibitor) against triple
negative breast cancer cells. To understand the effect of the sequence and
combination doses of crizotnib and ABT-263, we designed a comprehensive
experimental plan that involved a total of 567 treatment regimens by varying
treatment duration with the fırst drug (1, 2, or 3 days), followed by drug
withdrawal and recovery period (2, 5 or 10 days) and then by a second cycle
of treatment and recovery periods over a 26-day period. Cell viability was
assessed by the CellTiter-Glo luminescence assay. Interestingly, ABT-263
alone induced higher cytotoxicity than an equivalent dose of crizotinib, but
the remaining viable cells recovered much faster after ABT-263 withdrawal
than cells after crizotinib withdrawal. Furthermore, cells exposed to higher
doses of ABT-263 eventually become less sensitive to crizotinib. Among
sequential regimens, crizotinib followed by ABT-263 was signifıcantly more
effective than ABT-263 followed by crizotinib, and combinations that in-
cluded lower doses of ABT-263 were most effective. Taken together, our
results show a signifıcant interaction between the two targeted therapies, and
suggest that it may be possible to select treatment scheduling that can delay
drug resistance and tumor relapse in vivo.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Growth
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#2074 Targeting SHP-1 mediated VEGF signaling to block the migration
of human triple negative breast cancer. Jung-Chen Su,1 Ai-Chung Mar,2
Chun-Yu Liu,3 Kuen-Feng Chen,4 Chung-Wai Shiau5. 1National Yang-Ming
University Faculty of pharmacy, Taipei, Taiwan; 2Institute of Biomedical Sci-
ences, Academia Sinica, Taipei 11521, Taiwan, Taipei, Taiwan; 3Division of He-
matology and Oncology, Department of Medicine, Taipei Veterans General Hos-
pital, Taipei, Taiwan, Taipei, Taiwan; 4Department of Medical Research,
National TaiwanUniversityHospital, Taipei, Taiwan, Taipei, Taiwan; 5National
Yang-Ming University, Taipei, Taiwan.
Patients with triple-negative breast cancer (TNBC) had an increased like-
lihood of distant recurrence and death, as compared with those with non-
TNBC subtype. Regorafenib is a multi-receptor tyrosine kinase (RTK) inhib-
itor targeting oncogenesis and has been approved for metastatic colorectal
cancer and advanced gastrointestinal stromal tumor. Recently, scientists
have suggested that regorafenib also acts as a SHP-1 phosphatase agonist. In
this study, we aimed to investigate the role of regorafenib in suppressing
metastasis of TNBC cells through targeting the SHP-1/p-STAT3/VEGF-A
axis. We fırst observed a signifıcant correlation between migration ability
and SHP-1/p-STAT3/VEGF-A expression in several human TNBC cell lines.
Importantly, we also demonstrated that VEGF-A expression is correlated
with worse disease-free and distant metastasis-free survival in clinical TNBC
patients. Furthermore, we showed that regorafenib could inhibit the migra-
tion of human TNBC cells, which was related to downregulation of p-STAT3
and VEGF-A. To exclude the role of RTK inhibition in regorafenib-induced
anti-metastasis, we synthesized a regorafenib derivative, SC-78, that had
minimal effect on VEGFR2 and PDGFR kinase inhibition, while having
more potent effects on SHP-1 activation. SC-78 demonstrated superior in
vitro and in vivo anti-migration to regorafenib. This study indicated that the
SHP-1/p-STAT3/VEGF-A axis is a potential therapeutic target for meta-
static TNBC, and SC-78 may be a promising lead compound for suppressing
metastasis of TNBC. (Grant supported byMOST 104-2628-B-075-001-MY3,
MOST 105-2325-B-010-007, 105F026.)
#2076 Targeting the FGFR pathway in androgen receptor negative castra-
tion resistant prostate cancer.ColmMorrissey,1 EvaCorey,1 Lisha Brown,1 Ilsa
Coleman,2 Holly Nguyen,1 Michael Schweizer,1 Peter Nelson2. 1Univ. of Wash-
ington, Seattle, WA; 2Fred Hutchinson Cancer Research Center, Seattle, WA.
Metastatic castration-resistant prostate cancer (CRPC) has a poor prognosis
and remains a signifıcant therapeutic challenge. The continued importance of
androgen receptor (AR) signaling as a growth and survival pathway in most
advanced prostate cancer (PC) has prompted the development of therapeutics
directed toward further suppressing AR ligands or the AR itself. However, total
androgen blockade can give rise to AR-negative PC and currently there are no
effective therapies for AR-negative PC. We have developed two novel patient-
derived xenograft (PDX)models from a liver metastasis and a ribmetastasis of a
patientwithCRPC: LuCaP 173.1 (Neuroendocrine;NE) andLuCaP 173.2 (Dou-
ble negative: DN (AR-negative andNE-negative)). Using RNA-Seqwe observed
that both of these lines express high levels of fıbroblast growth factors (FGF’s)
and downstream effectors. We hypothesized that FGF signaling promotes sur-
vival and proliferation of NEPC and DNPC. To determine if blocking the FGFR
survival pathway can attenuate the growth of NEPC/DNPC tumors, to charac-
terize the molecular response and resistance to FGF signaling inhibition, and to
support further evaluation in the clinic, we treated both PDX models with the
FGFR inhibitor CH5183284. CH5183284 signifıcantly reduced LuCaP 173.2 tu-
mor volume (TV) (p0.0001). The reduction in TV in CH5183284-treated an-
imals bearing LuCaP 173.1 tumors was not as signifıcant. To address this differ-
ence, we analyzed FGFR1 expression at the transcript and protein levels.
Analysis of the FGFRs in the LuCaP 173.1 PDXmodel revealed a loss of FGFR1
expression. FGFR2 and FGFR3 transcripts were expressed at similar levels in
both PDXs. The loss of FGFR1 expression may explain the low effıcacy of
CH5183284 in the LuCaP 173.1 PDX model. We are currently assessing the
molecular pathways impacted byFGFR inhibition andmechanisms of resistance
to treatment in these studies. We have demonstrated that FGFR inhibition at-
tenuated tumor growth in FGFhigh AR-negative PC. We intend to target the
FGFR survival pathway in additional NE and DNPC PDXmodels to investigate
tumor heterogeneity in response to therapy and identify mechanisms of resis-
tance. These studies will provide translational evidence that FGFR inhibitors
could represent a new therapy for CRPC patients with AR-negative PC.
#2077 SelectiveMETkinase inhibition inMET-dependent gliomamodels.
Corina van den Heuvel,1 Anna Navis,1 Houshang Amiri,1 Kiek Verrijp,1 Arend
Heerschap,1 Karen Rex,2 Isabelle Dussault,2 Sean Caenepeel,2 Angela Coxon,2
Pieter Wesseling,1 William Leenders1. 1Radboudumc, Nijmegen, Netherlands;
2Amgen Inc., CA.
Background - Grade IV diffuse gliomas (glioblastomas) are notoriously
diffıcult to treat. Many studies aim at targeting tumor-specifıc aberrations,
such as mutations in genes encoding oncogenic receptor tyrosine kinases
(RTKs). Of high interest as a tumor target in diffuse glioma is the RTKMET,
which is amplifıed in a signifıcant proportion of glioblastomas, and a number
of MET inhibitors have been developed. However, most RTK inhibitors
available in the clinic today, including those inhibiting MET, are not entirely
selective and inhibit additional kinases at the doses used. They therefore may
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induce potentially undesired off-target effects, such as blood-brain barrier
normalization in the case of concomitant VEGFR2 inhibition. Methods –
We studied the effects of the novel, selective MET-kinase inhibitor (Com-
pound A) and the combined VEGFR2/RET/MET inhibitor cabozantinib on
MET activation and proliferation in theMET-amplifıed E98 astrocytoma cell
line in vitro, using western blot analysis and MTT proliferation assays. Ef-
fects of compound A were also studied in mice carrying orthotopic xeno-
grafts of the same E98 cell line. Survival was monitored and effects of MET
inhibition were investigated by immunohistochemistry using phospho-spe-
cifıc antibodies. Results – E98 cells were highly sensitive to treatment with
Compound A in vitro (IC509.4 nM). Furthermore, Compound A effec-
tively inhibited phosphorylation of MET in orthotopic E98 xenografts. In
contrast, we have previously shown that after treatment with cabozantinib in
the same model the high levels of phosphorylated MET were maintained.
While treatment with Compound A signifıcantly prolonged the survival of
E98-xenograft bearing mice, tumors still developed and showed extensive
AKT phosphorylation in the absence of MET phopshorylation, suggesting in
vivo therapy resistance mechanisms. Interestingly, resistance to Compound
A was not seen in vitro in an E98 cell line derived from Compound A-resis-
tant tumor xenografts. Conclusions – Compound A is a promising, highly
selective MET kinase inhibitor with activity against gliomas with constitu-
tive MET signaling. Selective MET kinase inhibitors may be more suited for
treatment of glioma than combined VEGFR2/MET inhibitors, as the latter
may induce vessel normalization resulting in poor tumor penetration. Sim-
ilar to clinical experience, E98 tumor-bearing mice ultimately develop resis-
tance to TKIs. Combination therapies targeting both MET and potential
resistance pathways may be required to allow long-term tumor treatment.
#2078 CK-101 (RX518), a mutant-selective inhibitor of EGFR that over-
comes T790M-mediated resistance in NSCLC. Xiangping Qian,1 Yong-Liang
Zhu,1 Edward Cullen,2 Robert M. Niecestro,2 James F. Oliviero2. 1NeuPharma,
Inc., Foster City, CA; 2Checkpoint Therapeutics, Inc., New York, NY.
Patients with non-small cell lung cancer (NSCLC) with activating epidermal
growth factor receptor (EGFR) mutations initially respond to small molecule
inhibitors of the EGFR tyrosine kinase such as gefıtinib and erlotinib. However,
secondary mutations in the kinase domain lead to acquired resistance to these
inhibitors and limited clinical effıcacy, with the EGFR T790M mutation being
the most common mechanism of acquired resistance in more than half the
patients that experience disease progression. CK-101 (also known as RX518) is a
novel, irreversible, orally administered EGFR kinase inhibitor that specifıcally
targets the mutant forms of EGFR, including T790M, while exhibiting minimal
activity toward the wild-type (WT) EGFR. WT EGFR inhibition is believed to
drive the commonly observed side effects of skin rash and diarrhea. The 50%
inhibitory concentrations (IC50s) of CK-101 and 2 reference compounds, afa-
tinib and AZD-9291, were determined in cell proliferation assays in human
cancer cell lines in vitro after incubation for 72 hours. Xenograft studies were
conducted in BALB/c nude mice or SCID/Beige mice using once daily oral
administration of CK-101 or afatinib for 14 or 21 days. CK-101 selectively in-
hibited cell proliferation of cell lines expressing both the activating (e.g.
HCC827, IC50 0.015 M) and resistance mutations (NCI-H1975, IC50
0.005 M), but was much less potent at inhibiting proliferation of cell lines
expressing theWT form of the receptor (e.g. A431, IC500.5 M; i.e., CK-101
was over 100 fold less potent against A431 than against NCI-H1975). Single
agent CK-101 signifıcantly inhibited tumor growth in EGFR-mutated NSCLC
tumor xenograftmodels, with no activity in aWTEGFR tumor xenograftmodel.
In a xenograft study of PC-9 cells (exon 19 deletion) in SCID/Beige mice, CK-
101 inhibited tumor growth by up to 90% (p 0.001). In a xenograft study of
NCI-H1975 cells (L858R/T790Mdoublemutant) in BALB/c nudemice, CK-101
inhibited tumor growth by up to 95% (p0.001). The pre-clinical fındings from
this work strongly supported the clinical development of CK-101, and a fırst-in-
human study of CK-101 was initiated in September 2016.
#2079 Osimertinib, an irreversiblemutant selective EGFR tyrosine kinase
inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion
mutant-EGFR.Nicolas Floc’h, SusanAshton,AmbraBianco,NicolaColclough,
Darren AE Cross, Maria Emanuela Cuomo, M. Raymond V. Finlay, Matthew J
Martin, Ludovic Menard, Darren McKerrecher, Daniel J O’Neill, Jonathan P
Orme, Anna D Staniszewska, Richard AWard, James W T Yates. AstraZeneca,
Cambridge, United Kingdom.
EGFR exon 20 insertion (Ex20Ins) mutations represent a combination of
in-frame insertions and/or duplications that account for 4-10% of all EGFR
mutants in non-small cell lung cancer (NSCLC). To date, more than one
hundred different Ex20Ins mutations have been identifıed. With the notable
exception of the rare A763_Y764insFQEA insertion (1%), EGFR Ex20Ins
mutations are clinically unresponsive to early generation EGFR inhibitors,
the standard of care for NSCLC patients with EGFR Ex20Ins mutations is
chemotherapy. Therefore, a signifıcant unmet need remains requiring the
development of an EGFR TKI agent that can more effectively target NSCLC
with EGFR Ex20Ins mutations. Osimertinib is a newly developed EGFR TKI
approved for the treatment of advanced NSCLC with EGFR T790M tumors.
This work describes the potential of osimertinib and AZ5104, a circulating
metabolite of osimertinib, in Ex20Ins tumours. Using CRISPR-Cas 9 ge-
nome editing technology, we engineered cellular disease relevant models
carrying the most prevalent Ex20Ins mutations, namely Ex20Ins
D770_N771InsSVD (22%) or Ex20Ins V769_D770InsASV (17%). Using these
models, we show that osimertinib and AZ5104 inhibit signalling pathways and
cellular growth of Ex20Ins CRISPR-Cas9 engineered cell lines in vitro. This
translates into sustained tumor growth inhibition in vivo in both the Ex20Ins
SVD (65%, p0.001 & 95%, p0.001 respectively at day 14) and Ex20Ins ASV
(82%, p0.001 & 95%, p0.001 respectively at day 14) xenograft models when
compared to the control group. Importantly in vivo osimertinib was dosed at
exposures consistent with the 80 mg osimertinib clinical dose. Moreover, a dual
EGFR blockade strategy combining osimertinib or AZ5104 with cetuximab (an
EGFR antibody) improved the anti tumor effect further. We also describe the
anti-tumor activity of osimertinib and AZ5104 using a series of patient derived
xenograft models harbouring the rarer Ex20Ins H773-V774insNPH andM766-
A767insASV mutations. In addition, we performed pharmacodynamic studies
to explore the relationship between effıcacy and target/pathway modulation.
These studies establish a clear relationship between depth and duration of phos-
pho-EGFR inhibition and anti tumor effıcacy. Interestingly, we observed that
downstream signallingmolecules displayed amore transient inhibition than the
phospho EGFR signal. Two patients from the AURA Phase 2 osimertinib trials
with plasma positive Ex20Ins (concurrent with Ex19del and T790M) had dura-
ble PFS responses of 6.4 and 13.9 months, supporting the premise that
osimertinib has the potential to be clinically benefıcial in tumors harboring
Ex20Ins. The work presented herein demonstrates that osimertinib has the po-
tential to improve upon the current treatment options for NSCLC patients
whose tumors harbour an Ex20Ins mutation, and warrants its further clinical
investigation.
#2080 Polycomb-mediated disruption of an AR-feedback loop drives cas-
tration-resistant prostate cancer.Ka-Wing Fong,1 JonathanZhao,1 JungKim,1
Shangze Li,1 Angela Yang,1 Bing Song,1 Laure Rittié,2MingHu,3 Ximing Yang,1
Bernard Perbal,4 Jindan Yu1. 1Northwestern Univ., Chicago, IL; 2University of
Michigan Medical School, Ann Arbor, MI; 3New York University School of Med-
icine, New York, NY; 4Université Côte d’Azur, CNRS, GREDEG., GREDEG,
France.
Androgen receptor (AR) is an androgen-stimulated transcription factor that
critically promotes prostate cancer development and progression. In addition to
its conventional role in transcriptional activation, AR also acts as a transcrip-
tional repressor to directly inhibit target gene expression. Through meta-analy-
sis of androgen-regulated expression microarray data, we nominated CCN3/
NOV, a CCN family protein, as one of the top AR-repressed genes in prostate
cancer, implicating that CCN3 may play a tumor suppressive role in prostate
cancer development. Therefore, we sought to investigate the molecular func-
tions of CCN3 and its roles in prostate cancer progression especially in castra-
tion-resistant prostate cancer (CRPC). We fırst showed that CCN3 protein
physically interacts with AR. The CCN3 interaction domain was mapped in the
N-terminal domain of AR which is also present in constitutively active AR vari-
ants. Using immunofluorescencemicroscopy aswell as subcellular fractionation
technique, we demonstrated that CCN3 sequesters AR or AR variants into the
cytoplasm to inhibit AR nuclear translocation, which in turn suppresses AR
chromatin targeting and transcriptional activation.However, this negative feed-
back loop between AR and AR-repressed gene CCN3is disrupted in CRPC
through CCN3 persistent epigenetic silencing by the Polycomb group protein
EZH2, rendering AR transcriptional activation and CRPC progression. Taking
advantage of this repressivemechanism, we restored CCN3 inCRPC cell model,
either through ectopic overexpression or treatment with EZH2 inhibitor, which
results in strong suppression of CRPC cell proliferation and anchorage-inde-
pendent cell growth. Consistently, application of EZH2 inhibitor remarkably
reduced tumor size in a castratedmicemodel. Taken together, our data highlight
CCN3 as a novel regulator of AR signaling and support the promise of EZH2-
targeting agents in treating CRPC.
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#2081 Robust activity of BLU-285, a potent and highly selective inhibitor
of mutant KIT and PDGFR, in patient-derived xenograft (PDX) models of
gastrointestinal stromal tumor (GIST). Yemarshet K. Gebreyohannes,1 Ag-
nieszkaWozniak,1Madelina-Elena Zhai,1 JasmienWellens,1 JasmienCornillie,1
Erica Evans,2 Alexandra K Gardino,2 Christoph Lengauer,2 Maria Debiec-Ry-
chter,3 Raf Sciot,4 Patrick Schöffski1. 1Laboratory of Experimental Oncology,
Department of Oncology, KU Leuven, and Department of General Medical On-
cology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium;
2Blueprint Medicines Corporation, Cambridge, MA; 3Department of Human Ge-
netics, KU Leuven and University Hospitals Leuven, Leuven, Belgium; 4Depart-
ment of Pathology, KU Leuven and University Hospitals Leuven, Leuven, Bel-
gium.
Objective: Patients with advanced and treatment-resistant GIST are
treated with tyrosine kinase inhibitors (TKI) such as imatinib (IMA),
sunitinib (SUN) or regorafenib (REG). Resistance to these TKI is mainly
caused by the emergence of on-target secondary KIT mutations in exons 13
and 17. We tested the activity of BLU-285 (Blueprint Medicines), a potent
and highly selective inhibitor of mutant KIT and PDGFR, in three PDX
models of primary and refractory GIST that respond differently to the ap-
proved TKI used in the treatment of GIST. Methods: NMRI nu/nu mice
(n93) were transplanted bilaterally with human xenografts UZLX-GIST3
(KIT: exon 11 p.W557_V559delinsF; IMA-sensitive), GIST2B (KIT: exon
9 p.A502_Y503dup, IMA dose-dependent sensitive) and GIST9 (KIT: exon
11 p.P577del; W557LfsX5; exon 17 D820G; IMA and SUN-resistant). We
performed the following experimental comparisons: BLU-285 (10, 30 and
100 mg/kg/qd) vs. control and IMA (50 mg/kg/bid) [GIST3]; BLU-285 (10,
30 and 60 mg/kg/qd) vs. control and IMA (50 and 100 mg/kg/bid or SUN 40
mg/kg/qd) [GIST2B]; and BLU-285 (10 and 30 mg/kg/qd) vs. control, IMA
(50 mg/kg/bid) or REG (30 mg/kg/qd) [GIST9]. Animals were dosed orally
for 16 days. Activity was assessed by tumor volume measurement, histopa-
thology and Western blotting of the KIT signaling pathway (WB). Mann
Whitney U test was used for statistical analysis. A p value0.05 was consid-
ered signifıcant. Results: In all models, BLU-285 resulted in a dose dependent
reduction of tumor volume, signifıcant inhibition of proliferation (p 0.005
compared to the control in all models, at all doses tested), and inhibition of
KIT signaling as assessed by WB. In two models, BLU-285 led to a higher
histologic response (graded as described previously by Antonescu et al.
2005), a signifıcant increase of apoptosis (p 0.005 compared to the control
in both models, at all doses tested), and a pronounced decrease in MAPK
phosphorylation as compared to the control. The activity of BLU-285 was
similar (GIST3) or better (GIST2B and GIST9) than a standard dose of IMA.
In the IMA-resistant model (GIST9), the anti-tumor effects of BLU-285 were
signifıcantly better those seen with either IMA or REG. BLU-285 was well
tolerated at all administered doses. Conclusions: BLU-285, an investiga-
tional agent, has signifıcant anti-tumor effects in GIST PDX models charac-
terized by different KITmutations and variable sensitivity to established TKI
therapies. These data support the therapeutic rationale for the ongoing Phase
I clinical trial being conducted by Blueprint Medicines (NCT02508532) and
provide further evidence that BLU-285 has the potential to be an important
treatment option for patients with PDGFR or KIT-driven GIST.
#2082 NMS-E668, a potent and selective RET kinase inhibitor character-
ized by specifıcity towards VEGFR2 and high antitumor effıcacy against
RET-drivenmodels. Elena Ardini, Patrizia Banfı, Nilla Avanzi, Marina Ciomei,
Paolo Polucci, Alessandra Cirla, Antonella Ermoli, Ilaria Motto, Elena Casale,
Giulia Canevari, Cinzia Cristiani, Sonia Troiani, Federico Riccardi Sirtori, Na-
dia Amboldi, Dario Ballinari, Francesco Caprera, Eduard Felder, Arturo Gal-
vani, Daniele Donati, Antonella Isacchi, Maria Menichincheri. Nerviano Medi-
cal Sciences, Nerviano, Italy.
RET, a receptor tyrosine kinase (RTK) expressed mainly in neural crest-de-
rived tissues, plays a role in cell growth and differentiation and its physiological
activation depends upon binding to theGDNF family. Genetic aberrations lead-
ing to constitutive RET activation are well-established as oncogenic events. Ac-
tivating point mutations of RET, for example, are present in ca. 70% of medul-
lary thyroid carcinoma patients including all hereditary cases, while RET gene
rearrangements resulting in production of activated RET fusion proteins occur
in approximately 10% of sporadic papillary thyroid carcinomas. More recently,
recurring RET gene rearrangements have also been found in 1-2 % of lung
adenocarcinomas and subsets of other solid tumors including colorectal and
salivary gland carcinomas. Thus RET kinase represents an actionable therapeu-
tic target in multiple clinical settings with high medical need. Consequently
several small-molecule inhibitors targeting this kinase have been explored in
clinical settings. A common feature of most advanced agents is their lack of
selectivity and in particular their potent cross-reactivity against VEGFR2, an
RTK whose inhibition is associated with serious, dose-limiting cardiovascular
toxicity. Indeed, the high homology between the two kinases renders identifıca-
tion of ATP competitive compounds that selectively inhibit RET over VEGFR2
a highly challenging task.Herewe describe the preclinical activity ofNMS-E668,
a potent and selective ATP-competitive RET inhibitor characterized by favor-
able activity, selectivity and ADME profıles. Biochemically, NMS-E668 has an
excellent selectivity profıle against a panel of 50 kinases, notably including
10-fold selectivity over VEGFR2. Selectivity of NMS-E668 for RET vs.
VEGFR2was confırmed inNIH-3T3 cells engineered to express activated forms
of these kinases. NMS-E668 potently (IC50 circa 50 nM) and selectively inhib-
ited proliferation of RET-dependent tumor cells, including TTmedullary carci-
noma cells harboring a RETC634W activating point mutation and LC2/ad lung
carcinoma cells bearing the oncogenic fusion protein CCDC6-RET. NMS-E668
also potently inhibited IL3-independent growth of Ba/F3 cells expressing
KIF5B-RET, the RET rearrangement that is most commonly found in lung ad-
enocarcinomas. Cellular mechanism studies confırmed that NMS-E668 inhibits
RET autophosphorylation and downstream signaling at doses consistent with
antiproliferative activity. Tested in vivo against KIF5B-RET-driven Ba/F3 tu-
mors, NMS-E668 displayed 90% tumor growth inhibition accompanied by
target modulation following oral administration at 10 and 20 mg/kg, with pro-
longed tumor regressions observed at the higher dose. ThusNMS-E668, a potent
and VEGFR2-sparing RET inhibitor is an innovative and highly promising can-
didate for further development.
#2083 Development of novel targeted adjuvant therapy for triple negative
breast cancer.Nidhi Bansal,1 Eduardo Farias,1 Veronica Gonzalez,2 Garry No-
lan,2 Samuel Waxman1. 1Icahn School of Medicine at Mount Sinai, Manhattan,
NY; 2Stanford University School of Medicine, Stanford, CA.
There is an unmet clinical need for targeted adjuvant therapy in Triple Neg-
ative Breast Cancer (TNBC) to overcome its poor prognosis, short disease-free
interval and metastatic dissemination. We previously reported that blocking
interactions between the PAH2 domain of chromatin regulator Sin3 and Sin3
interaction domain (SID) containing proteins like PF1 andTGIF1 by SIDdecoys
(peptides and small molecule, C16) decreased the cancer stem cell population,
invasion, EMT, and metastases. This, programmed upregulation of retinoid
signaling that sensitized TNBC cells to AM80, a novel clinically available RAR-
specifıc agonist. Here we report preclinical investigations on effects of SID
decoys and AM80 treatments on cellular heterogeneity, primary tumors,
metastatic dissemination, minimum residual disease (MRD) and host mi-
croenvironment. Using CyTOF2, wemade single cell measurements of markers
of differentiation, proliferation and stemness in CSC-enriched 4T1 tumors-
pheres. Treatment with SID peptide decreased cell populations expressing
nanog, sox2, vimentin and -catenin with increase in H2AX. Addition of
AM80 in combination with C16, resulted in populations with increased expres-
sion of differentiation marker CD24 with decrease in vimentin, -catenin and
Ki-67. To interrogate the neo-adjuvant effects of C16-AM80 treatments, pri-
mary 4T1 tumors in Balb/c mice were treated with C16 and AM80 alone or in
combination. Compared to DMSO,40 % decrease in tumor weight, 60% de-
crease in ALDH activity and 60% decrease in lung metastasis was seen in mice
treatedwithC16-AM80 combination. In post-surgical adjuvant settings, in both
4T1 and MMTV-myc xenografts, we observed 100% disease-free survival and
absence of macrometastasis in mice receiving minimally toxic adjuvant therapy
with the C16-AM80 combination for 90 days. However, MRD was found con-
sisting of a small number of single CK8 cells which failed to form colonies
when recovered from the bone marrow and selectively cultured in vitro. Upon
stopping the treatments, 20-40% animals developedmacrometastaseswithin the
fırst three months. To test the influence of C16-AM80 to condition the host
microenvironment to prevent macrometastases mice received only pretreat-
ment with C16 and AM80 followed by 4T1 cells injected in the tail vein. The
percentage of parenchyma occupied bymetastatic nodules were: DMSO 50%;
AM80  25%; C16 10% and C16-AM  10%; the mitotic features were
greatly reduce from 0-5 in DMSO to 0-1 per 400x/fıeld in the C16-AM80 com-
bination. The predominant effects were observed with C16 treatment, which
was enhanced to a small degree in combination with AM80. These results sug-
gest that C16 can potentially induce changes in the host microenvironment to
prevent the colonization and metastatic growth of cancer cells in TNBC. Alto-
gether, our preclinical studies merit expansion of a pre-clinical program for
development of C16-AM80 combination as a targeted adjuvant therapy to treat
TNBC.
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#2084 Conformational activation and allosteric inhibition of SHP2 in
RTK-driven cancers. Michael G. Acker,1 Ying-Nan P. Chen,1 Matthew J. La-
Marche,1 Ho Man Chan,1 Peter Fekkes,1 Jorge Garcia-Fortanet,1 Jonathan R.
LaRochelle,2 Brandon Antonakos,1 Christine Hiu-Tung Chen,1 Zhuoliang
Chen,1 Vesselina G. Cooke,1 Jason R. Dobson,1 Zhan Deng,1 Fei Feng,1 Brant
Firestone,1Michelle Fodor,1 Cary Fridrich,1 Hui Gao,1 Huai-XiangHao,1 Jaison
Jacob,1 Samuel Ho,1 Kathy Hsiao,1 Zhao B. Kang,1 Rajesh Karki,1 Mitsunori
Kato,1 Jay Larrow,1 Laura R. La Bonte,1 Gang Liu,1 Shumei Liu,1 Dyuti Majum-
dar,1Matthew J.Meyer,1MarkPalermo,1MinyingPu,1 EdmundPrice,1 Subarna
Shakya,1 Michael D. Shultz,1 Kavitha Venkatesan,1 Ping Wang,1 Markus War-
muth,1 Sarah Williams,1 Guizhi Yang,1 Jing Yuan,1 Ji-Hu Zhang,1 Ping Zhu,1
Stephen C. Blacklow,2 Timothy Ramsey,1 Nicholas J. Keen,1William R. Sellers,1
Travis Stams,1 Pascal D. Fortin1. 1Novartis Institutes for BioMedical Research,
Cambridge, MA; 2Dana-Farber Cancer Institute, Boston, MA.
The non-receptor protein tyrosine phosphatase (PTP) SHP2 is an important
component of RTK signaling in response to growth factor stimulus and sits just
upstream of the RAS-MAPK signaling cascade. The fırst oncogenic phosphatase
to be identifıed, SHP2 is dysregulated in multiple human diseases including the
developmental disorders Noonan and Leopard syndromes, as well as leukemia,
lung cancer and neuroblastomawhere aberrant activity of SHP2 leads to uncon-
trolled MAPK signaling. Cancer-associated activating mutations in SHP2 im-
part an “auto-on” state of the enzyme, boosting basal activity by shifting the
equilibrium away from the auto-inhibited state. Reduction of SHP2 activity
through genetic knockdown suppresses tumor growth, validating SHP2 as a
target for cancer therapy. SHP099, a recently reported potent and selective allo-
steric inhibitor of SHP2, stabilizes the auto-inhibited form of SHP2 through
interactions with the N-terminal SH2 and C-terminal PTP domains of the pro-
tein. SHP099 suppresses MAPK signaling in RTK amplifıed cancers resulting in
suppressed proliferation in vitro and inhibition of tumor growth in mouse tu-
mor xenograft models. Together, these data demonstrate the therapeutic poten-
tial of SHP2 inhibition in the treatment of cancer and other RAS/MAPK-linked
diseases.
#2085 Development of a novel targeted therapy for malignant mesotheli-
oma carcinoma by a midkine inhibitor. Takuya Fukazawa,1 Yuitaka Maeda,2
Tomoki Yamatsuji,1 Munenori Takaoka,1 Masakazu Yoshida,1 Naomasa
Ishida,1 Miki Iwai,1 Etsuko Yokota,1 Takuro Yukawa,1 Minoru Haisa,1 Noriko
Miyake,1 Tomoko Ikeda,1 Nagio Takigawa,1 Jeffery Whitsett,2 Yoshio Nao-
moto1. 1KawasakiMedical School, Okayama, Japan; 2Cincinnati Children’s Hos-
pital Medical Center, Cincinnati, OH.
Malignant pleural mesothelioma is an aggressive tumor of mesenchymal
origin and is increasing worldwide as a result of widespread exposure to
asbestos. The median survival of patients with mesothelioma from time of
diagnosis ranges between 1 and 2 years. Themortality is expected to increase,
at least until 2020, which is mainly due to the long latency (30-50 years) of the
disease. Despite considerable advances in the understanding of its pathogen-
esis and etiology, malignant mesothelioma remains largely unresponsive to
standard modalities of cancer therapy. Thus, there is an urgent need for new
therapeutic options for mesothelioma.Midkine (MDK) is a heparin-binding
growth factor that is highly expressed in many malignant tumors, including
lung cancers. We have previously reported that a MDK inhibitor, iMDK,
suppresses non-small cell lung cancer expressing MDK without harming
normal cells. Importantly, iMDK inhibits the PI3 kinase / Akt pathway and
induces apoptosis in MDK expressing non-small cell lung cancer cells. In the
present study, we have investigated the antitumor effect of iMDK against
malignant mesothelioma both in vitro and in vivo. 48 hours after treatment,
iMDK dose-dependently inhibited cell growth of MDK expressing malig-
nant mesothelioma cells. iMDK also suppressed colony formation of MSTO-
211H mesothelioma cells. TUNEL positive cells were signifıcantly increased
in MSTO-211H cells 48 hours after iMDK treatment in a dose-dependent
manner, confırming the induction of apoptosis in mesothelioma cells by
iMDK. Combination treatment of iMDK and Bcl-2 inhibitor ABT-263 is
more effective than each drug alone in MSTO-211H mesothelioma cells.
Moreover, systemic administration of iMDK signifıcantly inhibited tumor
growth in a mesothelioma xenograft tumor in vivo. Inhibition of MDK with
iMDK provides a potential therapeutic approach for the treatment of malig-
nant mesothelioma that is driven by MDK.
#2086 Dominant role of receptor tyrosine kinase in the activation of
MAPK signaling in BRAF non-V600mutant cancers.Hiromichi Ebi, Hiroshi
Kotani, Hidenori Kitai, Yuta Adachi, Seiji Yano. Kanazawa Univ. Cancer Re-
search Inst., Kanazawa, Japan.
BRAFmutations are found in8%of all cancers. In addition to the common-
est mutation in kinase domain at the V600, a wide range of other missense
mutations (non-V600) have been reported. Non-V600 mutant BRAF protein
was also shown to enhance MAPK signaling, suggesting the effectiveness of
MEK inhibitors. However, the existence of feedback mechanism in MAPK sin-
gling and the roles of receptor tyrosine kinases (RTKs) in these cells are not fully
understood. To interrogate this, BRAF non-V600 cell lines with intermediate/
impaired kinase activity were treated withMEK inhibitor. RTKs involved in the
upregulation of P-MEK followingMEK inhibition in BRAF non-V600Emutant
cell lines were determined by phosphor-RTK arrays. The effect of combinatorial
inhibition of RTKs and MEK in BRAF non-V600 cancer was assessed in vitro
and in vivo. By analyzing drug screen data, we fırst found cells with BRAF
non-V600E mutation were less sensitive to MEK inhibition compared with
BRAF V600E mutant cell lines and almost comparable to RAS/RAF wild-type
cell lines. MEK inhibition did not induce P-MEK suppression and it resulted in
signifıcant upregulation of p-MEK compared to BRAF V600Emutant cell lines.
Phospho-RTK arrays in the presence or absence of trametinib displayed basal
phosphorylation of RTKs including EGFR, MET, and IGF1R, although the
phosphorylation level was not consistently changed following MEK inhibition.
Among these RTKs, treatment with the EGFR inhibitor erlotinib led to more
complete suppression of P-ERK upon trametinib treatment. Furthermore, we
found that erlotinib monotherapy downregulated P-ERK in BRAF non-V600
mutant cell lines in contrast that inhibition of RTKs had no effect on MAPK
signaling in BRAF V600 mutant cells. While erlotinib treatment led to MAPK
inhibition both in intermediate active and impaired kinase active BRAFmutant
cells, p-MEK and p-ERKweremore strongly suppressed in impaired type BRAF
non-V600mutant cells. The combination of EGFR inhibitor andMEK inhibitor
suppressed cell growth and achieved tumor shrinkage in mice xenograft. These
results suggest that RTKs, especially EGFR, are dominantly involved in the reg-
ulation of MAPK signaling in BRAF non-V600 cancer cells.
#2087 Pan-HER inhibitor, varlitinib, disrupts HER/ERK signaling and
causes apoptosis in triple-negative breast cancer cells. Chun-Yu Liu,1 Tzu-
Ting Huang,1 Chun-Teng Huang,2 Hsiu-Ping Yang,1 Ling-Ming Tseng,1
Chung-Wai Shiau,3 Kuen-Feng Chen4. 1Taipei Veterans General Hospital, Tai-
pei, Taiwan; 2Yang-Ming Branch of Taipei City Hospital, Taipei, Taiwan; 3Na-
tional Yang-Ming University, Taipei, Taiwan; 4National TaiwanUniversity Hos-
pital, Taipei, Taiwan.
Background: Triple-negative breast cancer (TNBC), characterized by aggres-
sive behavior and poor prognosis, represents an important clinical challenge
because there is no well-established target therapy. Therefore, the identifıcation
and validation of a targeted therapy for TNBC is an urgent need. Molecular
profıling studies have shown some TNBC tumors harboring aberrant epidermal
growth factor receptor (EGFR) or human epidermal growth factor receptor
(HER) signaling, suggesting therapeutic potential with EGFR inhibitors.
Varlitinib (ASLAN001) is a small molecule reversible pan-HER inhibitor of
EGFR (HER1), HER2 andHER4. To-date, varlitinib has been extensively inves-
tigated in several tumor types, includingHER2 positivemetastatic breast cancer.
TNBC is known to demonstrate expression of EGFR. Since varlitinib also targets
EGFR signaling, we hypothesized that it may also have antitumor effıcacy in
TNBC. Methods: MDA-MB-231 andMDA-MB-468 TNBC cell lines were used
for in vitro studies. Cell viability was examined byMTT assay. Apoptotic effects
were examined by flow cytometry and Western blot. Signal transduction path-
ways in cells were assessed by Western blot. Results: We fırst examined the
protein expression of EGFR in a panel of TNBC cell lines. We identifıed MDA-
MB-468 and MDA-MB-231 as EGFR-expressing cell lines. We found that
varlitinib signifıcantly inhibited cell viability and induced cell apoptosis in
MDA-MB-468 cells but not in MDA-MB-231 cells. MDA-MB-231 cells carry
the KRASG13Dmutation that drives downstream ERK signaling.We therefore
examined the downstream signaling proteins of EGFR, including PI3K/Akt and
MAPK/ERK signaling. Results showed that the protein levels of p-MEK and
p-ERK were decreased in varlitinib-sensitive MDA-MB-468 cell lines, but there
was no signifıcant change in these phospho-proteins in varlitinib-resistant
MDA-MB-231 cells. Furthermore, we found that ERK inhibition resensitized
varlitinib-resistant cells to varlitinib-induced cell death. In addition, ectopic
expression of ERK reduced the varlitinib-induced apoptosis on varlitinib-sensi-
tive MDA-MB-468 cells. In addition, MDA-MB-468 cells are known to harbor
p53-R273H gain-of-function mutation that may activate EGFR-signaling,
whether the mutation is associated with varlitinib sensitivity needs further in-
vestigation. Conclusions: In this study, we identifıed TNBC as another tumor
type that may be sensitive to varlitinib’s antitumor activity through the inhibi-
tion of HER/MAPK signaling and subsequent increase in apoptotic activity.
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#2088 Theactivity of theFGFRselective inhibitorDebio 1347 is correlated
with high mRNA expression. Franck Brichory,1 Anna Pokorska-Bocci,1 Paolo
Nuciforo,2 Stefania Rigotti,1 Nathalie Lembrez,1 Grégoire Vuagniaux,1 Corinne
Moulon,1 Anne Vaslin1. 1Debiopharm International SA, Lausanne, Switzerland;
2Vall d’Hebron Institute of Oncology, Barcelona, Spain.
Dysregulation of the fıbroblast growth factor receptor (FGFR) signaling path-
way due to receptor overexpression, gene amplifıcation, point mutations or
fusions/chromosomal translocations is associated with cancer development and
progression. Debio 1347 (CH5183284) is an oral selective FGFR inhibitor
(FGFR1, 2 and 3) currently in clinical development. The aim of this study was to
investigate Debio 1347 activity in patient derived xenograft (PDX) mouse mod-
els harboring diverse FGFR alterations in multiple indications. The trial was
conducted in 66 PDX models of diverse histotypes selected according to their
FGFR1, 2 and 3 alteration status. Debio 1347 was administered orally once daily
at 40 up to 80mg/kg for 10 to 22 consecutive days (N3/group). Tumor volume
was compared to the vehicle control group and measured by caliper twice
weekly. Treatment response was determined by relative treatment-to-control
ratios (T/C) of which a responding model was defıned as /C 0. PDX
tumors were collected at the end of the treatment period and extensively char-
acterized using FISH, nCounter Gene Expression and immunohistochemistry
(IHC). Effect on downstreamDual Specifıcity Phosphatase 6 (DUSP6) signaling
was also investigated by qPCR and RNA in situ hybridization (ISH). Debio 1347
induced tumor regression in 33% of PDX models that exhibited a gene copy
number gain and/or the presence of a FGFR fusion gene and/or an FGFR mu-
tation. In addition, Debio 1347 treatment led to tumor regression in 29% of
models that did not harbor any FGFR genetic alteration. In contrast, all models
that responded to Debio 1347 were shown to display a high expression level
(mRNA) of at least one FGFR gene. These fındings suggest that high expression
of at least one FGFRmight be a better predictor of sensitivity toDebio 1347 than
genetic alteration. Furthermore, response to Debio 1347 was associated with a
decrease in DUSP6 mRNA levels, suggesting that it could be a reliable pharma-
codynamic biomarker in clinical trials. These results provide new mechanistic
insights into the predictive sensitivity to Debio 1347 and will help refıne patient
selection for FGFR-targeted therapy.
#2089 Evaluation of fruquintinib, a potent and selective oral VEGFR in-
hibitor, in combination with targeted therapies or immune checkpoint in-
hibitors in preclinical tumor models. Yongxin Ren, Qiaoling Sun, Jingwen
Long, Shiming Fan, Renxiang Tang, Wei Zhang, Xuelei Ge, Jianxing Tang, Lin-
fangWang, Dongxia Shi, Hongbo Chen,Min Cheng,WeiguoQing,Weiguo Su.
Hutchison MediPharma Ltd., Shanghai, China.
The development of therapies targeting tumor angiogenesis, tumor driver gene
alterations and tumor immune evasion hasmade tremendous advancement in im-
proving overall survival. However, effıcacy may be limited and resistance often de-
velops rapidly when targeting a single axis of tumorigenesis. Therefore, it is worth-
while to explore rational combinationof therapies basedon tumor-specifıc features.
Fruquintinib is a potent and selective oral VEGFR inhibitor currently in Phase III
clinical trials for non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC).
We report here the evaluation of anti-tumor effect of fruquintinib in preclinical
animal tumor models in combination with therapies targeting tumor driver gene
alterations such as EGFR and c-MET or with immune checkpoints. In NSCLC
xenograft models with EGFR activation such as activatingmutations, gene amplifı-
cation or protein overexpression, fruquintinib plus an EGFR tyrosine kinase inhib-
itor such as gefıtinib or theliatinib (HMPL-309) was found to be more effıcacious
than either monotherapy. For instance, in PC-9 subcutaneous tumor model carry-
ingEGFRexon19deletion, single agent treatmentwith fruquintinib at 2mg/kg and
gefıtinib at 5 mg/kg produced the tumor growth inhibition (TGI) of 58% and 63%,
respectively, while the combination treatment resulted in a TGI of 100% and tumor
regression was observed in 11 of 16 mice treated with combinational therapy. In
multiplexenograftmodelsderived fromlungcanceror renal cell cancerwithc-MET
activation (amplifıcation or over-expression), addition of fruquintinib to a c-MET
inhibitor savolitinib (AZD6094,HMPL-504) also improved the tumor growth inhi-
bition substantially. At the endof the effıcacy studies, CD31 andphosphorylation of
EGFR, c-MET, AKT and ERK were analyzed with immunohistochemistry and
western blotting method in tumor tissues. The results suggested that the enhanced
anti-tumor effect in combination therapy could be attributed to the simultaneous
blockade of cell signaling in tumor cells (EGFRor c-MET) andVEGFR suppression
in the tumor microenvironment. Up-regulation of the immune inhibitory check-
points induced by VEGF is one of the important mechanisms for tumor cells to
escape immune surveillance. In a syngeneic murine tumor model, co-administra-
tion of fruquintinib and anti-PD-L1 antibody was found to provide improved anti-
tumor effect compared to fruquintinib or anti-PD-L1 single agent alone. Studies to
understand the mechanism responsible for the combination effect are under way.
All combinationswith fruquintinibdescribedabovewerewell tolerated.Theeffıcacy
observed in thesemodels suggested that simultaneous blockade of tumor angiogen-
esis and tumor cell signaling or immune evasion may be a promising approach in
improving treatment outcomes.
#2090 Targeting estrogen receptor negative breast cancer cells using dia-
rylthiourea analogs of SHetA2.Hongye Zou,1 Emily Ginn,1 SabahM. Francis,2
Shengquan Liu,2 Maggie Louie1. 1Dominican University of California, San Ra-
fael, CA; 2Touro University of California, Vallejo, CA.
Breast cancer is one of the most common cancers that occur in women in the
United States. Depending on the expression of estrogen receptor  (ER), breast
cancer can be classifıed as ER-positive or negative. ER-negative (ER-) breast cancers
areoftenmoreaggressiveandhavepoorerprognosis comparedwith theER-positive
(ER) subtype. Consequently, there is a great need to develop more targeted ther-
apeutic options for ER- breast cancer. One such compound is SHetA2, a flexible
heteroarotinoid (flex-hets) that has been shown to inhibit growthofmultiple cancer
types includingbreast cancer.However, the clinical utility of SHetA2 is limitedby its
high lipophilicity (LogP). The goal of this study is to screen eleven 2nd generation
analogs of SHetA2with lowerLogPvalues—SL1-22, 24, 27, 29, 30, 32, 36, 37, 38, 39,
and 40— on different breast cancer cell lines to identify potential lead compounds
that show the highest anti-growth activities against ER- breast cancer cells and fur-
ther delineate the mechanism by which these compounds affect breast cancer cell
growth. Results from this study demonstrate that SL1-38 [1-(3-chloro-4-methyl-
phenyl)-3-(4-nitrophenyl)thiourea] and SL1-39 [1-(4-chloro-3-methylphenyl)-3-
(4-nitrophenyl)thiourea], inhibit ER-negative breast cancer cells (MDA-MB-231,
MDA-MB-453 and MDA-MB-468) effectively at micromolar concentrations. In
order to understand the mechanisms of action, we evaluated the effects of SL1-38
and39on the expressionof key cell cycle regulators.Our results show that these two
analogs down-regulate the expression of cyclin A, cyclin B, cyclin D1, cyclin E and
cdk2 and block S-phase progression. Taken together, these preliminary results sug-
gest that SL1-38 and 39may be further developed as anti-cancer agents for treating
ER-negative breast cancer.
#2091 PRN1371, an irreversible, covalent inhibitor of FGFR1-4 exhibits
sustained pathway inhibition in cancer cell lines. Eleni Venetsanakos, Yan
Xing, Natalie Loewenstein, J. Michael Bradshaw, Dane Karr, Jacob LaStant,
PhilipNunn, Jin Shu, Abha Bommireddi, JensOliver Funk, DavidM.Goldstein,
Stefani Wolff, Ken A. Brameld, Steven G. Gourlay. Principia Biopharma, South
San Francisco, CA.
Introduction:Multiple human cancers harbor alterations in FGFRs that drive
tumor growth, including mutations, translocations and amplifıcations.
PRN1371 is an irreversible, covalent FGFR1-4 inhibitor that exhibits highly
selective and sustained inhibition of FGFR which extends well beyond circulat-
ing drug concentrations in preclinical models. The duration of inhibition of the
FGFR signaling pathway is dependent on protein turnover of FGFR, whichmay
vary depending on the type of FGFR alteration. Thus, we set out to investigate
whether the duration of target inhibition differs across cancer cell lines of vari-
ous lineages harboring different FGFR alterations, including fusions and muta-
tions. Furthermore, as FGFR inhibitors exhibit hyperphosphatemia via on-tar-
get pharmacology, we also investigated the duration of target inhibition in
primary renal epithelial cells which arewild-type for FGFR.Materials andMeth-
ods: Cancer cell lines from several lineages harboring different FGFR alterations
were treated with increasing concentrations of PRN1371 in vitro for 1 hour,
before washing out the compound. Cells were harvested at various time-points
post-washout, protein lysates were generated and assessed formodulation of the
downstream signaling pathway by western blot analysis. Results: Dose-depen-
dent inhibition of phospho-ERK was observed in the cancer cell lines tested in
response to compound treatment for 1 hour in vitro. Dose dependent partial or
full rebound of phospho-ERK back to baseline levels were detected in cancer cell
lines after a prolonged period post-washout. In contrast, full rebound of phos-
pho-ERK was observed at 1 hour post washout in response to a non-covalent
inhibitor. Studies are on-going to assess duration of pathway inhibition in the
primary renal proximal epithelial cells. Conclusions: PRN1371 is a potent,
highly selective irreversible inhibitor exhibiting sustained inhibition of FGFR
signaling across cancer cell lines harboring different FGFR alterations. The du-
ration of inhibition of the downstream signaling was comparable across cancer
cell lines harboring different FGFR alterations, includingmutations, fusions and
amplifıcation of FGFR and was prolonged when compared to a non-covalent
inhibitor. A Phase 1 clinical trial of PRN1371 for the treatment of solid tumors
harboring FGFR alterations is ongoing (NCT02608125).
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#2092 A potent and selective RET inhibitor with effıcacy in RET-driven
mouse models of medullary thyroid carcinoma and lung adenocarcinoma.
Mandy Watson,1 Helen Small,1 Ben Acton,1 Habiba Begum,1 Samantha
Hitchin,1 Allan Jordan,1 Paul Kelly,1 Rebecca Newton,1 Ian Waddell,1 Gina
Paris,2 DonaldOgilvie1. 1Cancer Research UKManchester Institute,Manchester,
United Kingdom; 2Champions Oncology Inc., Baltimore, MD.
Background: The aim of this CRUK-MIDrugDiscovery project is to deliver a
RET-selective inhibitor for the treatment of cancers with RET activating muta-
tions, which include 1-2% of lung adenocarcinomas andmedullary thyroid can-
cers (MTC). Recent data supports the hypothesis that the effıcacy of vandetanib
and cabozantinib, clinically approved multi-kinase inhibitors, is limited by tox-
icities associated with potent activity against KDR. Therefore, a RET-selective
inhibitor would represent a best-in-class agent for the treatment of these can-
cers. Methods: We have established a robust screening cascade to develop a
potent, selective RET inhibitor and developed several in vivomodels to evaluate
compound PKPD and antitumor effıcacy. Tumor growth inhibition and PKPD
studies were carried out in BaF3mouse allograft models overexpressing KIF5B-
RET or RETV804M and other disease relevant models, including an MTC xeno-
graft (MZ-CRC-1), a KIF5B-RET lung cancer patient derived xenograft (PDX)
model (CTG-0838, Champions Oncology) and a lung cancer control xenograft
(Calu-6). Results: Two orally bioavailable compounds displaying nanomolar
RET potency and10 fold selectivity over KDR in cellular assays were selected
from the lead series and further evaluated in our in vivo PD and effıcacymodels.
Both compounds demonstrated effıcacy in the BaF3 KIF5B-RET driven model
(71% and 103% tumor growth inhibition (TGI), respectively), accompanied by
reduced levels of pRET in the tumor tissue. Following further lead optimisation;
a compound displaying an improved DMPK profıle and additional nanomolar
potency versus the gatekeeper mutation (RETV804M) was identifıed and acceler-
ated through our DMPK/in vivo cascade. We consider this additional activity
versus RETV804M benefıcial since mutations at the gatekeeper residue in other
tyrosine kinases (e.g. EGFR) have been shown to mediate acquired drug resis-
tance in the clinic. This compound demonstrated signifıcant TGI of 58% and
82% respectively in the BaF3 KIF5B-RET and BaF3 RETV804M allograft models.
Moreover, tumor growth in the lung cancer PDX model was strongly inhibited
(95% TGI) and tumor regression induced in the MTC xenograft model (109%
TGI). As expected, this potent and selective RET inhibitor was not active in the
Calu-6 model, which is sensitive to KDR inhibition, whereas vandetanib, a po-
tent KDR inhibitor, signifıcantly inhibited tumor growth (84%TGI). Additional
in vitro and in vivo DMPK analyses further support the nomination of this
compound as a preclinical candidate. Conclusions: The identifıcation of selec-
tive RET inhibitors with signifıcant in vivo activity and minimal toxicity may
overcome the limitations of the currently available clinical compounds.Wehave
made considerable progress towards this goal and showhere the compelling data
supporting our nomination of a preclinical development compound.
#2093 HEC73543 is a novel potent, selective Flt3 receptor tyrosine kinase
(RTK) Inhibitor for the treatment of refractory acute myeloid leukemia
(AML). Cliff Cheng. HEC Pharm Group, Dongguan, China.
Background: Adults acute myeloid leukemia (AML) account for 30% of
leukemia and 40% of leukemia-related deaths. FLT3 is a receptor tyrosine
kinase that is normally expressed on immature hematopoietic cells and func-
tions in the development of both stem cells and the immune system. FLT3 is the
most frequently mutated gene in AML, with an estimated 30 % of AML patients
harboring FLT3 mutations. FLT3-ITD is a commonmutation in AML and cor-
relates with a poor prognosis and higher risk of relapse of AML patients. Meth-
ods and Results: HEC73543 is a potent, orally bioavailable small molecule ty-
rosine kinase inhibitor (TKI) against FLT3 which have been implicated in acute
myeloid leukemia (AML) pathogenesis. In cell-based assays, HEC73543 showed
IC50s  1.5 and 1.4 nM against MV-4-11 and MOLM-13 cells in proliferation
(both cell lines are FLT3-ITD). Induction of apoptosis following treatment of
FLT3-ITD leukemic MV-4-11 cells for 48 h was assayed by flow cytometry. In
MV-4-11 cells, a concentration of 10 nM HEC73543 induced 64.8% of the cells
to undergo apoptosis and had a dose dependent increase. When single dosed
orally (4.5mg/kg) to MV-4-11 tumor-bearing nude mice, HEC73543 potently
inhibited the phosphorylation of FLT3 and its downstream signaling kinases
STAT5, AKT and ERK1/2 for up to 8 hours in tumor tissues. The antitumor
activity of HEC73543 was evaluated using an FLT3-ITD subcutaneous tumor
xenograft model (MV-4-11 and MOLM-13) in athymic mice. Groups of 8 tu-
mor-bearing mice were treated with vehicle alone or with HEC73543 adminis-
tered orally at 0.5, 1.5, or 4.5mg/kg/day. The compound was well tolerated and
no signifıcant body weight loss or lethality was observed. The antitumor activity
of HEC73543 was dose dependent. At the 1.5 mg/kg/day dose level all animals
had a complete regression (CR) in MV-4-11 model, and the CR induced by
4.5mg/kg/day in MOLM-13 model. HEC73543 can signifıcant prolong mice
survival time at 1 mg/kg/day dose level inMOLM-13 systemic xenograft model.
We have studied cytotoxic interactions of HEC73543 with conventional antile-
ukemic agents cytarabine using two leukemia cell lines carrying FLT3-ITD
(MOLM-13, MV-4-11) The combination of HEC73543 with cytarabine pro-
duced additive effects in MV-4-11 and MOLM-13 cell lines. HEC73543 dis-
played excellent oral bioavailability and desirable drug exposures in mice, rats,
dogs and monkeys. Conclusions: Together, HEC73543 exhibits potent target
inhibition and effıcacy in FLT3-ITD models suggests that this compound may
have a therapeutic benefıt for patients with FLT3-ITD leukemia.
#2094 Dual inhibition of FLT3 and Src pathways by ON150030, a type 1
inhibitor, as a novel strategy for relapsed and refractory AML therapy. Helya
Ghaffari,M.V.RamanaReddy, StephenC.Cosenza,RodrigoVasquesdelCarpio, E.
Premkumar Reddy. Icahn School of Medicine at Mount Sinai, New York City, NY.
Approximately one third of patients suffering from Acute Myeloid Leukemia
harbor a FLT3 Internal tandemduplicationmutation (FLT3-ITD).Whenmutated,
this receptor tyrosine kinase increases the activity of pathways for proliferation and
blocks apoptosis. Quizartinib is a 2nd generation FLT3 inhibitor that inhibits FLT3-
ITD in AML, but has a median duration response of 12.1 weeks. Studies revealed a
secondarymutation inFLT3at theaspartateofcodon835(D835X) is responsible for
relapse. TheD835 substitution renders FLT3 constitutively active. Type 2 inhibitors
like Quizartinib bind to FLT3 in its inactive state and fail to inhibit FLT3-ITD har-
boring aD835mutation.Here, we tested the utility ofON150030, developed by our
group, as a novel therapeutic agent to treat AML. Structural studies suggest
ON150030 binds to the active formof FLT3 (Type 1 inhibitor) somutations such as
D835X do not affect the inhibitory activity of the compound. In vitro kinase assays
demonstrate that ON150030 potently inhibits Wildtype and FLT3-D835Y forms,
while Quizartinib fails to inhibit FLT3-D835Y. Additionally, ON150030 demon-
strated time and temperature dependent inhibition of FLT3, suggesting that the
compound is an irreversible inhibitor of FLT3. Biological studies reveal that
ON150030 specifıcally inhibits thegrowthofMV4-11cellsharboring theFLT3-ITD
mutation (GI50: 10nM).Western blot analysis demonstrates thatMAPKandPI3K/
AKT pathways in these cells are inhibited with increasing dose of ON150030. The
JAKindependentphosphorylationofSTAT5seen in thecontextofFLT3-ITDisalso
reduced in response to ON150030. Future goals are to introduce FLT3 and its vari-
ous mutant isoforms into the mouse myeloid cells (32Dcl3) and examine how it
affects proliferation and differentiation, and then compare the effects of ON150030
and Quizartinib. In addition to strongly inhibiting FLT3, ON150030 inhibits SRC,
which was shown to induce resistance to targeted therapies in several leukemias
including AML.We will introduce SRC into the 32D-FLT3-ITD cell lines sensitive
toON150030andtestwhether thesecells retain their sensitivity to thedrug.Next,we
will perform cytotoxicity and biochemical assays on patient-derived primary AML
cells using ON150030. Mouse xenograft models will be used to determine if
ON150030 synergizes with standard chemotherapy agents and inhibits cancer pro-
gression in vivo. At the conclusion of this project, we hope to demonstrate that
ON150030 can be used in combination therapies in all AML patients harboring a
FLT3mutation, and result in sustained remission of disease.
#2095 E7090, a novel and selective FGFR inhibitor, for the treatment of
cholangiocarcinoma cells harboring FGFR2-fusion genes. Saori W. Miyano,1
Yasuhito Arai,2 Junji Matsui,1 Tatsuhiro Shibata3. 1Eisai Co., Ltd, Tsukuba-shi,
Ibaraki, Japan; 2Division of Cancer Genomics, National Cancer Center Research
Institute, Tokyo, Japan; 3Laboratory of Molecular Medicine, Human Genome
Center, The Institute of Medical Science, The University of Tokyo, Division of
Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Genetic abnormalities (gene fusion, mutation and amplifıcation) of fıbroblast
growth factor receptor (FGFR) family members are known to cause constitutive
activation of their signaling pathways, which play an important role in prolifer-
ation, survival and migration of cancer cells, as well as tumor angiogenesis.
Several recent studies have identifıed that FGFR2 gene fusions were found in
about 10% of intrahepatic cholangiocarcinoma and acted as oncogenes. E7090,
an orally available FGFR1, 2 and 3 inhibitor, whose chemical-structure and basic
kinase inhibitory profıle have been disclosed at AACR2015, is currently under a
fırst-in-human study (NCT02275910). The antitumor activity of E7090 against
NIH3T3 and human cholangiocarcinoma cells harboring FGFR2-fusion genes
was investigated. NIH3T3 cells stably infected of fıve FGFR2-fusion genes
(FGFR2-AHCYL1, FGFR2-BICC1 type1, FGFR2-BICC1 type2, FGFR2-TX-
LNA, or FGFR2-KCTD1), all of which were discovered in human intrahepatic
cholangiocarcinoma patients, were successfully established and exhibited an-
chorage-independent cell growth in soft agar assay. E7090 revealed an inhibitory
activity on soft agar colony formation of these cells with IC50 values of 0.9 to 17.3
nmol/L in a dose dependent manner. E7090 also reduced activation of down-
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stream pathways of FGFR signaling (MAPK and STAT3) in these cells. Subcu-
taneous transplantation of FGFR2-BICC1 type2, FGFR2-TXLNA, or FGFR2-
KCTD1 expressing cells into immune-defıcient mice produced tumor growth,
and then oral administration of E7090 at 12.5, 25 and 50 mg/kg showed signif-
icant tumor growth inhibition. Finally, antitumor activity of E7090 was exam-
ined in a patient derived xenograft (PDX)model of human cholangiocarcinoma
harboring FGFR2-BICC1 fusion gene. E7090 also showed dose-dependent an-
titumor activity and more than 50% of tumor regression was achieved at a dose
of 50 mg/kg. In conclusion, E7090 showed potent antitumor activity against
FGFR2-fusion genes found in intrahepatic cholangiocarcinoma both in vitro
and in vivo models, suggesting that E7090 may provide therapeutic opportuni-
ties for cholangiocarcinoma harboring FGFR2-fusion genes.
#2096 Bozitinib, a highly selective inhibitor of cMet, demonstrates robust
activity in gastric, lung, hepatic andpancreatic in vivomodels. Joe Shih,1 Boyu
Zhong,1 Hepeng Shi,2 David Xue,2 Gavin S. Choy,3 Sanjeev Redkar3. 1Crown
Bioscience, Taicang City, Jiangsu Province, China; 2Beijing Pearl Biotechnology
Limited Liability Co., Chaoyang District, Beijing, China; 3CBT Pharmaceuticals,
Inc, Santa Clara, CA.
Background: cMET is a receptor tyrosine kinase that is located on the cell
surface and is activated by the binding of its ligand, hepatocyte growth factor
(HGF). In cancer cells, MET can be aberrantly active and cause abnormal sig-
naling, which leads to tumor growth, angiogenesis, andmetastasis. In vitro stud-
ies have demonstrated that bozitinib (CBT-101, PLB-1001) is a highly selective
and specifıc inhibitor (8 nM) of tumor cell proliferation. Methods: In-vivo
PD studies of gastric (MKN45), lung (LUM858, LU1901, LU2503), hepatic
(LIM0612, LIM0801), and pancreatic (KP4) were evaluated. These models cov-
ered both the HGF-dependent and HGF-independent mechanisms. Among
these models, LUM858, LU1901, LU2503, LIM0612 and LIM0801 are PDX
models. In particular, in the LU1901 model, bozitinib (BT) was compared to
capmatinib (INC280). Groups included: BT at 1, 3 and 10 mg/kg QD21 and
INC280 at 1, 3, and 10 mg/kg QD21 and 10 mg/kg BID21 via IG, CDDP 5
mg/kg, Q7D3 as a positive control via IP and the vehicle control (QD21 via
IG). Each group (n8 mice) and the tumor volume was evaluated on D21.
Results: In MKN45, LU2503, LIM0612 and LIM0801, the effect of BT seemed
superior than that of crizotinib; in LUM858, its effect was higher than that of
erlotinib; in LU1901, its effect was higher than that of crizotinib and INC280. In
the LU1901 model, the strongest activity was observed at BT 10 mg/kg with a
T/C ratio of 2%, compared to an equi-dose of INC280 (T/C of 22%). All doses of
BT and INC280 were well tolerated; no mouse experienced weight loss. In
MKN45 model, BT showed a PK/PD correlation and dose-dependence. BT in-
hibited the phosphorylation of c-Met protein; the rate of target inhibition ex-
ceeded 90% at7mg/kg. The plasma concentration for BT decreased over time
with a signifıcant decrease 16h after its administration, conferring at least 16h of
phosphorylation inhibition of the c-Met protein. Conclusions: In conclusion,
BT was well-tolerated, with no animal death nor major weight loss. The in vivo
experiments demonstrated that BT is a viable candidate with effective anti-
tumor activities. BT is currently under evaluation in cMet dysregulated NSCLC
(NCT02896231) with additional trials planned.
#2097 A novel J-series prostamide induces ER stress-mediated apoptosis
and upregulates ER oxidoreductase 1 alpha (ERO1) in human colon cancer
cells.HussamM. Albassam, Daniel A. Ladin, Rukiyah VanDross. East Carolina
University, Greenville, NC.
Colon cancer is the third most common cancer and the third leading cause of
cancer-related death in the United States. The endoplasmic reticulum (ER) is a
cellular organelle responsible for protein synthesis and oxidative folding. ER stress
occurswhen theprotein folding loadexceeds theprotein foldingcapacity.Lowlevels
of ER stress promote survival while excessive ER stress causes cell death. An impor-
tant regulator of the cytotoxic ER stress pathway is the transcription factor, C/EBP
homologous protein 10 (CHOP10). It has been shown that CHOP10 regulates the
transcription of ER oxidoreductase 1 (ERO1). ERO1 promotes ER luminal ox-
idation and under conditions of excessive ER stress releases H2O2 into the cyto-
plasm, resulting in oxidative stress-mediated apoptosis. Previous studies from our
laboratory showed that15deoxy,12,14 prostamide J2 (15dPMJ2) inducedERstress-
mediated apoptosis, leading to a reduction in cell viability in tumorigenic keratino-
cytes andmelanocytes. In addition, 15d PMJ2-induced ER stress-apoptosis was de-
creased in the presence of ER stress inhibitors, 4-phenylbuterate (PBA) and
salubrinal. However, the specifıc pathway involved in 15d PMJ2-induced ER stress-
apoptosis have not been identifıed. In this study, we hypothesize that 15d PMJ2
causesERstress-mediatedapoptosis incolon tumorcellsbyactivatingCHOP10and
its downstream transcriptional target, ERO1. To examine the anti-proliferative
effect of 15d PMJ2, tumorigenic colon cells (HCT116) and non-tumorigenic colon
cells (FHC) were treated with different concentrations of 15d PMJ2 or 10M thap-
sigargin (TG) for 24 hours and cytotoxicity wasmeasured by lactate dehydrogenase
(LDH) assay. A signifıcant increase in cell death was observed in HCT116 cells
treated with 5M15d PMJ2 and this cytotoxic effect was 3-fold greater in HCT116
compared to FHC cells. Apoptotic measurements showed a signifıcant increase in
caspase 3/7 activity and annexin-V positivity following 15d PMJ2 treatment. The
expression of CHOP10 was signifıcantly enhanced in the 15d PMJ2-treated group.
In addition, 15dPMJ2-induced apoptosiswas decreased in the presence of ER stress
inhibitors, PBA and salubrinal, suggesting that ER stress is essential for 15d PMJ2-
induced apoptosis. Western blot analysis revealed an increase in ERO1 protein
expression following 15d PMJ2 treatment. Apoptosis measurements showed a sig-
nifıcant inhibition in 15d PMJ2-mediated apoptosis in the presence of ERO1 in-
hibitor, EN460, suggesting that ERO1 is important for 15dPMJ2-induced apopto-
sis. These fındings suggest that 15d PMJ2-induced apoptosis is mediated via the ER
stress pathway. CHOP10 and its transcriptional target, ERO1, play a potential role
in 15d PMJ2-induced ER stress-apoptosis, suggesting that 15d PMJ2 could be a
potential anti-neoplastic agent with a uniquemechanism for colon cancer.
#2098 NVP-FGF401,a fırst-in-classhighlyselectiveandpotentFGFR4inhib-
itor for the treatment of HCC. Diana Graus Porta,1 Andreas Weiss,1 Robin A.
Fairhurst,1 Markus Wartmann,1 Christelle Stamm,1 Flavia Reimann,1 Alexandra
Buhles,1 Jaqueline Kinyamu-Akunda,2 Dario Sterker,1 Masato Murakami,1 You-
zhen Wang,3 Jeffrey Engelman,3 Francesco Hofmann,1 William R. Sellers3. 1No-
vartis, Basel, Switzerland; 2Novartis, East Hanover, NJ; 3Novartis, Cambridge, MA.
Hepatocellular carcinoma (HCC) is the seventhmost common cancer world-
wide and the third leading cause of cancer-related death. Sorafenib is the only
targeted agent to show a marginal improvement in overall survival (OS) for
patients with advancedHCC. Recent data have implicated aberrant activation of
the FGF19-FGFR4/KLB axis as the driver of certain forms of HCC, making this
pathway a novel therapeutic target in this disease. The fırst evidence for this is
the fınding that aberrant expression of FGF19, as a consequence of gene ampli-
fıcation and other not yet known mechanisms, occurs in subsets of HCC’s and
HCC cell lines leading to constitutive FGFR4 activation. In this setting, condi-
tional knock downof FGF19, as well as its receptors FGFR4 andKLB, suppresses
proliferation of HCC cell lines, supporting the notion that FGF19 activates
FGFR4 in an autocrine fashion. Secondly, in transgenic mouse models, FGF19
produced by non-tumor cells at an ectopic site (skeletal muscle) acts in a para-
crine fashion on the liver hepatocytes leading to liver dysplasia and HCC. In
these mice, tumorigenesis is abolished in an FGFR4 null background, as well as
upon treatmentwith anti-FGF19 and anti-FGFR4 blocking antibodies. Thus, we
anticipate that targeted therapies aimed at blocking the FGFR4 pathway might
be effıcacious in subsets of HCC’s. We have identifıed and developed NVP-
FGF401, a fırst in class, highly selective and potent FGFR4 inhibitor that is
currently in PhI/II clinical testing. NVP-FGF401 binds in a reversible covalent
manner to the FGFR4 kinase domain and it inhibits FGFR4 with an IC50 of 1.1
nM. In biochemical assays, it shows at least 1,000 fold selectivity against of panel
of 65 kinases and in a kinome wide scan, consisting of 456 kinases, FGFR4 was
the only target of NVP-FGF401. In xenograft animal models in vivo, NVP-
FGF401 showed a consistent pharmacokinetic / pharmacodynamic (PK/PD)
relationshipwith phospho-FGFR4 over total FGFR4 (p/tFGFR4) levels in tumor
robustly inhibited in a dose dependent manner. The data support a lowest ob-
served trough concentration (Ctrough) driven PD/effıcacy relationship. The
anti-tumor activity was confırmed across several xenograft animal models, as
well as in patient-derived tumor xenografts (PDX) established in mice. The
excellent drug-like properties of NVP-FGF401 drove us to test its effıcacy in
HCC patients in a PhI/II study, being the fırst selective FGFR4 inhibitor to ever
enter into clinical trials (NCT02325739).
#2099 In vitro characterization of the effect of nazartinib against non-
small cell lung cancer activating clinically relevant EGFR mutants. Keita
Masuzawa, Hiroyuki Yasuda, Toshiyuki Hirano, Shigenari Nukaga, Hanako
Hasegawa, Junko Hamamoto, Katsuhiko Naoki, Kenzo Soejima, Tomoko Bet-
suyaku. Keio University, School of Medicine, Shinjuku-ku, Tokyo, Japan.
Purpose: Multiple EGFR-TKIs are available and under development to treat
patients with lung cancer harboring EGFR mutations. Nazartinib is one of the
3rd generation EGFR-TKIs targeting EGFR T790M as well as common muta-
tions such as L858R and exon 19 deletions. Today, there is no clear guideline
regarding which EGFR-TKIs should be used for which mutations. The purpose
of this study is to clarifywhich EGFR-TKIs including nazartinib are best for each
EGFRmutation, especially exon 20 insertionmutations using in vitromodeling.
Experimental design: We evaluated drug sensitivity and downstream signaling
of human lung cancer cell lines (PC9, H3255, H1975, PC9ER, BID007) and
Ba/F3 cells harboringmultiple types of EGFRmutations for 1st- (erlotinib), 2nd-
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(afatinib) and 3rd- (osimertinib and nazartinib) generation EGFR-TKIs byMTS
assay andwestern blotting. An in vitromodel ofmutation specifıcity was created
by calculating the ratio of IC50 values between mutated and wild type EGFRs.
Results: Themodel of mutation specifıcity identifıed a wide therapeutic window
of each EGFR-TKIs for exon 19 deletions and L858R. On the other hand,
osimertinib and nazartinib have wide therapeutic window for T790M positive
mutations in human cell lines andBa/F3 cells. In human cell lines andBa/F3 cells
harboring exon 19 deletions or L858R, afatinib dramatically inhibited the phos-
phorylation of EGFR, AKT, and ERK. Afatinib and 3rd generation EGFR-TKIs,
osimertinib and nazartinib, effectively inhibited the phosphorylation of EGFR,
AKT, and ERK in T790M positive cells. For EGFR exon 20 insertion mutations,
althogh afatinib, osimertinib and nazartinib effectively inhibited the phosphor-
ylation of EGFR, AKT, and ERK in several exon 20 insertion mutations,
osimertinib and nazartinib were potent and presented a wide therapeutic win-
dow. Conclusion: Nazartinib as well as osimertinib has wide therapeutic win-
dows for exon 19 deletions, L858R, T790M and some exon 20 insertions.
#2100 Selective inhibition of FGFR4 by INCB062079 is effıcacious in
models of FGF19- and FGFR4-dependent cancers. Phillip C.C. Liu, Liang Lu,
Kevin Bowman, Matthew C. Stubbs, Liangxing Wu, Darlise DiMatteo, Sindy
Condon, Ronald Klabe, Ding-Quan Qian, Xiaoming Wen, Paul Collier, Karen
Gallagher, Michael Hansbury, Xin He, Bruce Ruggeri, Yan-ou Yang, Maryanne
Covington, Timothy C. Burn, Sharon Diamond-Fosbenner, Richard Wynn,
Reid Huber, Wenqing Yao, Swamy Yeleswaram, Peggy Scherle, Gregory Hollis.
Incyte, Wilmington, DE.
Aberrant signaling through Fibroblast Growth Factor Receptors (FGFR) has
been reported in multiple types of human cancers. FGFR4 signaling contributes to
the development and progression of subsets of cancer: in approximately 10 percent
of hepatocellular carcinoma (HCC), genetic amplifıcation of FGF19, encoding an
endocrine FGF ligand that activates FGFR4-KLB receptors, has been reported. In
models with this alteration, FGF19-FGFR4 signaling is oncogenic and antagonism
of the FGF19-FGFR4 axis has been shown to be effıcacious suggesting that selective
targeting of FGFR4may be an effective strategy for malignancies with FGFR4 acti-
vation. We describe the preclinical characterization of INCB062079 a potent and
selective inhibitor of the FGFR4 kinase. In biochemical assays INCB062079 inhib-
ited FGFR4 with low nM potency and exhibited at least 250-fold selectivity against
otherFGFRkinases andgreater than800-fold selectivity against a largekinasepanel.
This selectivity derives from the ability of INCB062079 to bind irreversibly to
Cys552, a residuewithin theactive siteofFGFR4 that isnon-conservedamongother
FGFR receptors. Covalent binding of INCB062079 to Cys552 was demonstrated
using a LC/MS/MS-based proteomic analysis that confırmed specifıcity for the tar-
get Cys. In assays using HCC cells with autocrine production of FGF19,
INCB062079 inhibited the autophosphorylation of FGFR4 and blocked signal
transduction by FGFR4 to downstreammarkers of pathway activation. Cancer cell
lines that have amplifıcation and expression of FGF19 are uniquely sensitive to
growth inhibition by INCB062079 (EC50 less than 200 nM) compared with HCC
cell lines or normal cells without FGF19-FGFR4 dependence (EC50  5000 nM)
confırming selectivity for FGFR4. In vivo, oral administration of INCB062079 in-
hibited the growth and induced signifıcant regressions of subcutaneous xenograft
tumors dependent upon FGFR4 activity at doses that were well-tolerated (10-30
mg/kg BID) and did not result in a signifıcant increase in serum phosphate levels
which is observed with FGFR1/2/3 inhibition. Suppression of tumor growth corre-
latedwithpharmacodynamic inhibitionofFGFR4 signaling.Collectively, thesepre-
clinical studiesdemonstrate that INCB062079potentlyandselectively inhibitsmod-
els of FGF19-FGFR4-dependent cancers in vitro and in vivo, supporting clinical
evaluation in patients harboring oncogenic FGFR4 activation.
#2101 Ormeloxifene suppresses the growth of prostate tumor via inhibi-
tion of -catenin induced AR signaling. Aditya Ganju, Bilal Bin Hafeez, Mo-
hammed Sikander, Vivek Kumar Kashyap, Murali Mohan Yallapu, Subhash C.
Chauhan, Meena Jaggi. Univ. of Tennessee Health Science Ctr., Memphis, TN.
Background: Prostate cancer (PrCa) fırst manifests as an androgen-dependent
disease and can be treated with androgen-deprivation therapy. Despite the initial
success of androgen ablation therapy, resistance to anti-androgen therapy displays
by progression to hormone refractory (androgen-independent) advanced stage
PrCawhich is primary cause of patient’s death.Main underlying cause for the onset
of hormone refractory cancer is ligand independent activation of AR signaling in
PrCa cells. It has been shown that-catenin acts as a non-androgen activator of AR
which enhancesAR transactivation inPrCa cells. Thus, identifıcationof agentswith
excellent pharmacokinetics and pharmacodynamics parameters that can inhibit li-
gand independent activation of AR signaling might be highly useful for the treat-
ment of advanced stage PrCa. Herein, we identifıed a synthetic molecule, ormelox-
ifene (ORM), which effıciently represses -catenin mediated ligand independent
activation of AR signaling, thus, inhibits growth and metastatic features of PrCa
cells.Methods:Androgen-refractorybutARpositivePrCacell (C4-2)wasusedasan
invitro and invivomodel systems.Effect ofORMonARandPSAprotein levelswas
determined byWestern blot analysis. Effect ofORM treatmentwas analyzed onAR
andPSAluciferaseactivitiesby transiently transfecting theC4-2cellsbyARandPSA
luciferase plasmids. Renilla construct was used as an internal control. C4-2 cells
nuclear and cytoplasmic lysates were prepared usingActiveMotif kit. Immunopre-
cipitation analysiswas performed todetermine ifORMinhibits physical interaction
of -catenin with AR. Therapeutic effıcacy of ORMwas evaluated in cell lines and
PrCaxenograftmousemodels. Results:ORMdose-dependently (10, 15 and20M)
inhibited the protein levels of AR and its downstream target protein PSA.ORM (10
and20M) treatment also inhibitedAR transactivation as determinedbydecreased
promoter activities of AR and its target gene PSA. ORM (10 and 20M) treatment
inhibited protein levels of nuclear -catenin and physical interaction of -catenin
with AR in PrCa cells. ORM administration dose- dependently (intra-peritoneal;
100 and/or 500g/mouse; thrice/week) signifıcantly (P0.01) inhibited growth of
C4-2 cells derived xenograft tumors in athymic nude mice. ORM treatment signif-
icantly (P0.01) inhibited the expressions of nuclearARand-catenin expressions
in xenograft tumor tissues. These ORM treated mice did not show any apparent
toxicity in our study. Conclusion: Our study demonstrates that ORM is a potent
inhibitor of-catenin-mediated activation of AR signaling. Based on its safety pro-
fıle, ORMmight be an ideal candidate for repurposing to treat advanced stage PrCa
alone or in combination with other therapies.
#2102 ONC201 targets AR andAR-V7 signaling pathways, reduces PSA and
synergizes with everolimus in castration resistant prostate cancer. Avital Lev,
Amriti R. Lulla, David T. Dicker, Wafık S. El-Deiry. Fox Chase Cancer Ctr., Phila-
delphia, PA.
Androgen receptor (AR) signaling plays a key role in prostate cancer progres-
sion; thus Androgen Deprivation Therapy (ADT) is a mainstay therapy for
patients with advanced prostate cancer. However, in most cases the tumor be-
comes androgen-independent and resistant to ADT with patients ultimately
progressing tometastatic castration resistant prostate cancer (mCRPC). Consti-
tutively activated AR splice variants (AR-Vs) have emerged as major mediators
of resistance to AR-targeted therapy and progression of mCRPC, representing
an important therapeutic target for mCRPC. Out of at least 15 AR-Vs described
thus far, AR-V7 is the most abundant in prostate cancer and its expression
correlates with ADT resistance. ONC201 is the foundingmember of the imipri-
done class of small molecules that induces apoptosis in a variety of tumor types
tested. It is currently in Phase I/II clinical trials for advanced solid tumors and
hematological malignancies, including mCRPC with encouraging activity ob-
served in patients in early clinical testing (Stein et al., ASCO, 2016).We demon-
strate here that ONC201 treatment induces apoptosis in both castration-resis-
tant and –sensitive human prostate cancer cell lines. Furthermore, an in-vitro
synergistic effect is observed with ONC201 and FDA approved drugs for pros-
tate cancer such as enzalutamide, docetaxel and everolimus.Mechanistically, we
found that ONC201 inhibits both AR and AR-V7 signaling pathways. Analysis
of AR cell lines stimulated with DHT showed a signifıcant decrease in both
RNAand protein levels of AR, AR-V7, PSA and other AR-target genes following
ONC201 treatment. Ongoing experiments are aimed at better understanding
the molecular and cellular mechanisms that enable ONC201 to inhibit the AR
signaling pathway. In-vivo studies with AR-negative hormone refractory pros-
tate cancer xenografts demonstrate single agent ONC201 anti-tumor effıcacy.
Ongoing studies are further evaluating the in-vivo effıcacy ofONC201 as a single
agent or in combinationwith enzalutamide and everolimus usingmousemodels
of both castration-resistant and -sensitive prostate cancer. These preclinical re-
sults indicate that ONC201 is well suited to address mCRPC, including tumors
that harbor AR-V7, as a single agent that may be combined synergistically with
enzalutamide or everolimus.With these observations we envision further devel-
opment a combination of ONC201 plus everolimus in CRPC with or without
enzalutamide resistance.
#2103 NVP-FGF401: Cellular and in vivo profıle of a novel highly potent
and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB
tumors. Andreas Weiss,1 Diana Graus Porta,1 Flavia Reimann,1 Alexandra
Buhles,1 Christelle Stamm,1 RobinA. Fairhurst,1 Jacqueline Kinyamu-Akunda,2
Dario Sterker,1 Masato Murakami,1 Markus Wartmann,1 Youzhen Wang,3 Jef-
freyA. Engelman,3 FrancescoHofmann,1WiliamR. Sellers3. 1Novartis Institutes
for BioMedical Research, Basel, Switzerland; 2Novartis Institutes for BioMedical
Research, East Hanover, NJ; 3Novartis Institutes for BioMedical Research, Cam-
bridge, MA.
Hepatocellular carcinoma (HCC) is the most common primary malignancy
of the liver and a deadly disease. Treatment options are limited and prognosis
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generally is poor. Aberrant signaling through the fıbroblast growth factor 19
(FGF19) - fıbroblast growth factor receptor 4 (FGFR4) axis has been implicated
in the development of HCC, and recently FGF19 has been determined as a
specifıc driver gene amplifıcation in a subset of liver tumors and cancer cell lines.
Here, we describe the cellular and in vivo profıle of NVP-FGF401, a highly
potent and selective, fırst in class, reversible-covalent small-molecule inhibitor
of the kinase activity of FGFR4. NVP-FGF401 is exquisitely selective for FGFR4
versus other FGFR family members and all other kinases. We show that among
the FGF19-amplifıed liver cancer cells in the cancer cell line encyclopedia
(CCLE), only those with concomitant expression of-klotho (KLB), a co-recep-
tor for FGF19 that facilitates its binding to FGFR4, are sensitive to NVP-
FGF401. NVP-FGF401 has good oral PK properties and shows an excellent in
vivo PK/PD relationship. NVP-FGF401 has remarkable anti-tumor activity in
mice bearing HCC tumor xenografts and PDX models that are positive for
FGF19, FGFR4 and KLB. NVP-FGF401 is the fırst FGFR4 inhibitor to enter
clinical trials, and a PhI/II study is currently ongoing in HCC and other types of
solid tumors.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Mechanism of Drug Action
#2104 In vitro drug effects on cancer cell morphology and functional state
revealed bymultiparameter imagingmass cytometry.OlgaOrnatsky, Alexan-
dre Bouzekri, Bedilu Allo, Jessica Watson. Fluidigm Canada, Markham, On-
tario, Canada.
Results of in vitro drug testing are correlated with clinical response to chemo-
therapy: Accuracy to predict clinical drug resistance was found to be as high as
90%. The benefıt of using in vitro models lies in the ability to probe cellular
response in a controlled closed system, where effects of drug concentrations,
treatment duration, drug efflux kinetics and multidrug combinations can be
assessed by a variety of cell biology techniques. Cisplatin is a widely used che-
motherapy drug that targets genomicDNAof the cells, forming both interstrand
and intrastrand cross-links that lead to cell death. One limitation of its clinical
use is in predicting the development of resistance and severe side effects in
patients. Mechanisms of resistance such as reduced drug accumulation, in-
creased detoxifıcation through cisplatin binding to cellular thiols, reducedDNA
platination, and increased DNA repair have been reported, however (tamoxifen
enhancement of cisplatin). In vitro models of different cancer types (SKOV3,
HeLa, A431, MCF-7) were used to study the effects of cisplatin on cell morphol-
ogy and phenotypic and functional characteristics with a large panel of metal-
tagged antibodies and Imaging Mass Cytometry (IMC) at the single-cell level
(1). Proteins involved in DNA damage repair (H2AX, PP2A, pHistone H3),
apoptosis (CD98, caspase-3, cleaved PARP), cell proliferation (cyclin B1, Ki-67),
metastasis (vimentin, -catenin, VEGF, CD63, CD9), substrate adhesion
(CD29, CD49e, CD49b, CD51, CD54, CD47, CD61), organelle morphology
(CD107a,Mito, histoneH3), and signaling pathways (STAT3, pERK1/2, pS6), as
well as surface receptors (EGFR, HER2, BRCA,MUC1, CD44, EpCAM, CD142,
CD59, beta-catenin) and structural markers (CK5, CK8/18, -actin, -tubulin),
were identifıed simultaneously in each individual cell with specifıc metal-con-
jugated antibodies. S-phase cells were visualized by detection of 127I in 5-iodo-
2=-deoxyuridine (IdU) added to culture media. Presence of cisplatin in cell nu-
clei and cytoplasm was registered by IMC of platinum stable isotopes.
Combination therapy of cisplatin and paclitaxel is a standard chemotherapeutic
regimen to treat recurrent or metastatic cervical cancer. Cell lines from various
tumors may develop resistance to cisplatin. Reduced cisplatin uptake has been
observed in cervical cancer cells with cisplatin resistance. The cisplatin-resistant
HeLa cells and A431 (A431/Pt) cells show 50% and 77% reduction in cisplatin
uptake, respectively, compared with the parental cell lines. Human ovarian can-
cers (in vitro model SKOV3), for which cisplatin is a mainstay of treatment,
develop drug resistance and pose an important clinical challenge. (1) Chang, Q
et al. Nature Scientifıc Reports 6 (2016): 36641.
#2105 Evaluation of antitumor properties ofmetformin over humanmul-
tidrug-resistant chronic myeloid leukemia cells. Ligia P. Oliveira, Débora L.
Renó, Rodrigo S. Curvello, Luana P. Lima, Ana Carolina S. Galvão. UFABC,
Santo André, Brazil.
Besides the progress in the knowledge of cancer biology, the rates ofmortality
due to this disease are still considerably elevated. Therefore, application of new
drugs in antitumor therapies has been constantly studied. However, any of them
have achieved a considerable success so far. In this work we evaluated the ability
of metformin, a traditional hypoglycemic prescribed to treatment of type II
diabetes along decades, over programmed cell death and modulation of meta-
static potential in multidrug resistant (MDR) humanmyeloid chronic leukemia
cells (Lucena), through MTT reduction test, flow cytometry, western blotting
and gelatin zymography. Metformin was able to reduce the cell viability in a
concentration and time-dependent manner, but was not able to induce Lucena
cells to apoptosis or necrosis, though activation of the apoptotic machinery.
Indeed, it was not observed activation of caspase 3, in contrast to an expressive
activation of PARP. Interestingly, proteins associated to autophagy were over-
expressed by Lucena cells, and an arrest of cell cycle was observed after exposi-
tion to the drug. Finally, it was verifıed that metformin was able to modulate
activity of MMP2 and MMP9, enzymes associated to the metastatic process.
Taken together these results suggest that the hypoglycemic is able to acts over the
fırst steps of cancers in more aggressive stages. Finally, inhibition of MMPs
indicates a promissory action of metformin for the treatment of metastatic dis-
ease.
#2106 In-depth profıling of the energy depletion-mediated cancer cyto-
toxicity by passively delivered zinc complexes via PARP1 activation. Jinhyuk
F. Chung,1 Tae Jung Park,2 Yoko Norihisa3. 1Xylonix Pte Ltd, Singapore, Singa-
pore; 2Chung-Ang University, Seoul, Republic of Korea; 3Cheongshim Interna-
tional Medical Center, Gyeonggi-do, Republic of Korea.
Dysfunctional apoptotic function from impaired p53 tumor suppressor activ-
ity leads to poorer prognosis in cancer patients by compromising drug sensitiv-
ity and promoting drug resistance development. Programmed necrosis follow-
ing energy crisis is a theoretically proposed cytotoxic mechanism for
circumventing this problem. Herein we demonstrate that a biodegradable zinc
complex is capable of triggering the programmed necrosis via activation of
PARP1/PARG/MPTP, which consistently resulted in p53-independent broad
spectrum cytotoxicity in vitro across all 20 cancer cell lines tested including
many with reported drug resistance phenotypes. Additionally, we investigated
its possible interaction with agents that influence p53 for possible antagonism/
synergism. Supporting in vivo evidence in both animal models and clinical case
studies involving terminal chemo-resistant gastric cancer patients upon oral
administration (30 mg Zn/day) are presented. These results implicate macro-
molecular biodegradable zinc complexes as promising antitumor agents of sim-
ple compositions for overcoming the current hurdles in clinics, and warrant
further clinical investigations. We plan to advance the studies through non-
invasive smart devices reporting real-time blood glucose, blood pressure, mi-
croperfusion, and other hemodynamic parameters.
#2107 Tetra-arsenic hexoxide induces G2/M cell cycle arrest, apoptosis,
and autophagy via p38 MAPK- and AKT-mediated pathways in SW620 hu-
man colon cancer cells. Won Sup Lee,1 Jeong Won Yun,1 Min Jeong Kim,1
Arulkumar Nagappan,1 Jing Nan Lu,1 Seong-Hwan Chang,2 Jae-Hoon Jeong,3
GonSup Kim,1 Jin-Myung Jung,1 Soon Chan Hong1. 1Gyeongsang National
Univ. Hospital, Jinju, Republic of Korea; 2Konkuk University School of Medicine,
Seoul, Republic of Korea; 3Korea Institute of Radiological and Medical Sciences,
Seoul, Republic of Korea.
Tetraarsenic hexoxide (As4O6) has been used in Korean folk remedy for the
treatment of cancer since the late 1980’s. Evidence suggests that As4O6 show
anti-cancer effects, whosemechanisms are different from those forAs2O3.How-
ever, the detailed anticancermechanism is still unclear.Here,we investigated the
anticancer effects of As4O6 on SW620 human colon cancer cells. As4O6 induced
cell death in a dose-dependent manner. Flow cytometry analysis revealed that
As4O6 increased the sub-G1 (apoptotic cell population) and G2/M phase popu-
lation in a dose-dependent manner. Further, nuclear condensation and cleaved
nuclei were also observed upon staining with Hoechst 33342 in As4O6-treated
SW620 cells. Western blot revealed that As4O6 signifıcantly down-regulated the
cyclin B1, cdc 2, pro-caspases -3, -8 and -9, and up-regulated p21 and cleavage of
PARP in SW620 cells. In addition, As4O6 increased the expression of death
receptor 5 (DR5), suppressed Bcl-2 andXIAP family proteins, and promoted the
conversion of LC3-I to LC3-II in a Beclin-1 independent manner. Interestingly,
As4O6 dephosphorylated Akt and JNK and phosphorylated p38MAPK, and the
cell death was inhibited by p38 MAPK inhibitor; whereas Akt inhibitor aug-
mented the As4O6 induced cell death, suggesting p38 MAPK and AKT were
associatedwithAs4O6-induced cell death. Taken together, these fındings suggest
that As4O6 induced G2/M arrest, apoptosis and autophagic cell death at least in
part through p38 MAPK and AKT pathways in SW620 human colon cancer
cells. This study may explain the anecdotal anticancer effects showing central
necrosis with dormant status of cancers when treated by As4O6 as folk remedy.
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#2108 Imatinib-induced downregulation of Skp2 inhibits cell growth in
human squamous cell carcinoma. Hyo Jin Jeong. Institute of Life science and
Biotechnology, Daegu, Republic of Korea.
It is apparent that Skp2(S-phase kinase associated protein) plays a crucial role
in tumorigenesis of various human cancers. Imatinib, inhibitor of BCR-ABL
tyrosine kinase, KIT and PDGF receptor, has been approved for the treatment
and investigation of chronic myeloid leukemia, gastrointestinal stromal tumors
and additional various solid tumors. But An area of skin cancer has not been yet
investigated. The aimof this studywas to explore the role of the Skp2 in Imatinib
antitumor effect on human skin cancer. To explore Imatinib effect on growth of
A431 cells (squamous cell carcinoma / skin cancer) we conducted CCK8 assay
and Flow cytometry. Western blot assay was performed for determining the
functions and molecular mechanism of Imatinib in A431 cells. we found that
Imatinib signifıcantly inhibited cell growth and induced cell cycle arrest at
G0/G1 phase. Furthermore, we observed that depletion of Skp2 triggered cell
cycle arrest and colony formation inhibition by Imatinib. Mechanistically we
identifıed that Imatinib markedly downregulated Skp2 protein expression and
subsequently upregulated p21 expression via increased protein stability. In con-
clusion, Imatinib exerts its antitumor activity via inhibition of Skp2 - p21 axis
and these fındings suggest that targeting Skp2 by Imatinib could be promising
therapeutic approach for Squamous cell carcinoma therapy.
#2109 Transcriptional analysis of human leukemia cells treated with the
experimental anticancer drug laromustine. Amanda J. Loya,1 Dylan J. Cin-
cotta,1 Abdel Elkahloun,2 David Bodine,2 Kevin P. Rice1. 1Colby College,Water-
ville, ME; 2National Human Genome Research Institute, Bethesda, MD.
Laromustine is an experimental anticancer prodrug that demonstrated signif-
icant activity against acute myeloid leukemia in human clinical trials. Upon
base-catalyzed activation, laromustine yields two reactive, electrophilic species
in situ: 90CE, which can chloroethylate the O6 position of guanine in DNA
causing lethal interstrand crosslinks, andmethyl isocyanate, which can carbam-
oylate biochemically relevant nucleophiles, such as cysteine sulfhydryl groups.
Previous in vitro and ex vivo investigations into laromustine’s molecular mech-
anism of action reveal several biochemical consequences of methyl isocyanate,
many of which may explain either the acute cytotoxicity of the drug’s carbam-
oylating activity or the observed synergism with the cytotoxicity of guanine O6
chloroethylation. The combined activities of the electrophilic subspecies of la-
romustine are believed to induce apoptosis in leukemia cells. Presented herein
are extensive flow cytometry experiments using FITC-AnnexinV and pro-
pidium iodide suggesting a dose-dependent cytotoxicity that includes apopto-
tosis. So as to gain a more complete understanding of the drug’s toxicity, an
investigation into how laromustine modulates gene transcription in HL60 cells
is also carried out and reported here. Total mRNA was harvested from cultured
HL60 cells treated with sub-lethal doses of laromustine or analogs lacking either
carbamoylating or chloroethylating activity. These samples were subjected to
GeneChip analyses against control mRNA. More than 4,000 genes were signif-
icantly dysregulated upon the cells’ exposure to laromustine. The analog of
laromustine possessing only carbamoylating activity caused the dysregulation of
nearly 3,000 genes, the vastmajority of whichwere also dysregulated in response
to laromustine. 90CE, which lacks carbamoylating activity but retains chloro-
ethylating activity, understood to be principally responsible for therapeutic cy-
totoxicity, demonstrated very little effect on gene transcription in HL60 cells.
Preliminary analysis of gene pathways affected by laromustine suggests that
among the altered pathways, those associated with cancer progression, the G1/S
checkpoint, and hematological disorders are particularly stressed. The carbam-
oylating activity of laromustine is responsible for most of these effects. Identify-
ing genetic pathways disrupted by this potentially useful drug may inform clin-
ical strategies or identify potential targets for co-therapeutic agents.
#2110 Anti-invasive and antimetastatic actions of omega-3 polyunsatu-
rated fatty acids in glioblastoma cells. Soyeon Kim,1 Soyeon Shin,2 Soyeon
Jeong,1 Seung-Hyeon Han,3 Yoon-Seon Yoo,3 Prashanta Silwal,3 Young-Joo
Jeon,3 Jun-Young Heo,4 Gi-Ryang Kweon,4 Seung-Kiel Park,5 Jong-Il Park,5
Kyu Lim6. 1Dept. of Biochemistry, Infection Signaling Network Research Center,
Chungnam National University, Daejeon, Republic of Korea; 2Dept. of Biochem-
istry, Cancer Research Institute, Chungnam National University, Daejeon, Re-
public of Korea; 3Dept. of Biochemistry, Dept. of Medical Science, School of Med-
icine, Chungnam National University, Daejeon, Republic of Korea; 4Dept. of
Biochemistry, Dept. of Medical Science, School of Medicine, Infection Signaling
Network Research Center, Chungnam National University, Daejeon, Republic of
Korea; 5Dept. of Biochemistry, Chungnam National University, Daejeon, Repub-
lic of Korea; 6Dept. of Biochemistry, Dept. of Medical Science, School of Medicine,
Cancer Research Institute, Infection Signaling Network Research Center, Chung-
nam National University, Daejeon, Republic of Korea.
Glioblastoma (GBM) is themost aggressive and deadliest brainmalignancy in
adults. Despite of surgical techniques, radiotherapy and chemotherapy, GBM
has remained an invariably lethal tumor with a median survival less than 15
months. Although the anticancermechanisms of omega-3 polyunsaturated fatty
acids (3-PUFAs) have been reported in several cancers, it is still unclear in
brain cancer. Here, our data show the anti-invasive and anti-metastatic effects of
3-PUFAs in GBM. Invasiveness using transwell chamber was inhibited by
docosahexaenoic acid (DHA) treatment in D54MG and GL261 cells. In zymog-
raphy, MMP-2 activity was suppressed by DHA in a dose dependent manner.
MMP-2 promoter activity was also decreased. DHA inhibited both p-STAT3
and -catenin levels that contribute to invasion by stimulating pro-invasion
factors such as MMP-2. Additionally, fat-1 (3-desaturease) stable D54MG cell
was established and the effect of the high level of 3-PUFAs was investigated
endogenously. The invasiveness were signifıcantly inhibited in the fat-1 stable
cells compared to control cell. Moreover, themetastasis in vivo was signifıcantly
reducedwhenGL261mouse glioma cells were injected through tail vein into the
fat-1 transgenic mice. In immunohistochemistry, intensity of p-STAT-3 and
-catenin were signifıcantly weak in metastatic lung tumor from Fat-1 mice
compared to wild type mice. These results indicate that anti-invasive and
anti-metastatic actions of 3-PUFA may be correlated with inhibition of
MMP-2 through decrease of STAT3 and -catenin in GBM cells. Thus, these
fındings provide important preclinical evidence and molecular insight for
utilization of -3 PUFAs for the chemoprevention and treatment of human
GBM. [This work was supported by the National Research Foundation of
Korea (NRF) grant funded by the Korea government (MEST) (2007-
0054932, NRF-2015R1D1A1A01056887) and by the framework of interna-
tional cooperation program managed by National Research Foundation of
Korea (2015K2A2A6002008)].
#2111 Ciclopirox inhibits tumor cell motility by suppressing protein ex-
pression of small GTPases and phosphorylation of paxillin. Shile Huang, Tao
Shen. Louisiana State Univ. Health Sciences Ctr., Shreveport, LA.
Ciclopirox olamine (CPX), an off-patent antifungal drug, is used for the treat-
ment of superfıcial mycoses. Recent studies have demonstrated that CPX also
possesses potent anticancer activity by inhibiting cell proliferation and inducing
cell death in tumor cells. However, it is unknown whether CPX inhibits cell
motility. In the present study, we found that CPX potently inhibited cell motility
in a concentration-dependent manner in rhabdomyosarcoma (Rh30 and RD)
cells, which was independent of the reduction of cell viability. As small GTPases
(RhoA, Cdc42, and Rac1) and focal adhesion proteins (paxillin) play critical
roles in the regulation of cell motility, we further studied whether CPX affects
these proteins. Our Western blot analysis revealed that CPX did inhibit cellular
protein expression of RhoA, Cdc42 and Rac1. However, by RT-PCR analysis,
CPX did not alter the mRNA levels of the small GTPases. As microRNAs
(miRNAs) can regulate protein expression at transcriptional andpost-transcrip-
tional levels, we investigated the effect ofCPXon the expression ofmiRNAs.Our
miRNA PCR array revealed that treatment with 10 M of CPX for 24 hours
upregulated the expression of 27miRNAs by 2.04-6.10 fold, and downregulated
the expression of 7 miRNAs by 2.00-7.89 fold in Rh30 cells. Further research is
ongoing to identify whether these up/downregulated miRNAs are linked to the
reduced expression of small GTPases and potentiallymore proteins. In addition,
we found that CPX inhibited the phosphorylation of paxillin, despite no effect
on the total cellular protein expression. The results suggest that CPX inhibits
tumor cell motility at least by suppressing the protein expression of small GT-
Pases and the phosphorylation of paxillin. Supported by the Feist-Weiller Can-
cer Center, LSU Health Sciences Center, Shreveport, LA.
#2112 FoxO3a activation by HDAC class IIa inhibition induces cell cycle
arrest in pancreatic cancer cells. Makoto Usami, Shohei Kikuchi, Kohichi
Takada, Yusuke Sugama, Yohei Arihara, NaotakaHayasaka,HajimeNakamura,
Yuki Ikeda, Yusuke Kamihara, Masahiro Hirakawa, Makoto Yoshida, Masayo-
shi Kobune, Koji Miyanishi, Junji Kato. Sapporo Medical University, School of
Medicine, Sapporo City, Japan.
Pancreatic cancer is highly chemo-resistant associated with oncogenic muta-
tions such as KRAS and/or p53. The effect of conventional chemotherapy is not
suffıcient and new target and strategy is urgently needed. The forkhead box
(Fox) proteins aremultidirectional transcriptional factors strongly implicated in
malignancies. Although Fox O (FoxO) protein, and particularly FoxO3a, works
as negative regulator of cell proliferation by repressing cyclin proteins and in-
ducing cell cycle inhibitors such as p21Waf1/Cip1, its expression is consistently
suppressed by several oncogenic pathways including phosphatidylinositol-3 ki-
nase (PI3K) / AKT pathway, constitutively activated in pancreatic cancer. Thus,
upregulating FoxO3a activity could be a promising target of pancreatic cancer
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treatment without impact of underlying oncogenicmutations. Class IIa Histone
deacetylase (HDAC) is a subgroup of HDAC. Though HDAC inhibitors
(HDACi) have been extensively investigated as a cancer target, its action mech-
anism is considered due to histone modifıcation by class I. Biological signifı-
cance of class IIa HDACs which have minimal histone deacetylation activity
have not been elucidated yet. Recent studies show class IIa HDACs act as a
transcriptional regulator including FoxO3a. In this study, we investigate the
biologic impact of HDAC class IIa inhibition on FoxO3a and anti-tumor effect
against pancreatic cancer cell line using selective class IIa HDACi TMP269.
TMP269 treatment showed increased FoxO3a expression in a dose dependent
manner with immunoblotting and modest cell growth inhibition effect at 57.5
Mof IC50 dose for 48-hour treatment against AsPC-1 inMTT.G1/S arrest was
observed with cell cycle assay. Upregulated p21Waf1/Cip1 and downregulated
CDK2 and 4/6 and cyclin D1 and D2 expressions were further observed, consis-
tent with inducing G1/S arrest and transcriptionally activated FoxO3a. Impor-
tantly, upregulated p21Waf1/Cip1 was observed in AsPC-1 p53 null cell line, sug-
gesting independent with p53 pathway. These fındings suggest upregulated
FoxO3a induced by HDAC class IIa inhibition activated its transcription and
resulted in cell growth inhibition. Because PI3K/AKT leads FoxO3a to the ubiq-
uitylation-mediated proteasome degradation, we examined irreversible protea-
some inhibitor carfılzomib (CFZ) combined with TMP269, aiming synergistic
FoxO3a upregulating. As expected, FoxO3a expression was further increased in
TMP269 combined with CFZ compared with TMP269 or CFZ alone. Following
the activated FoxO3a, p21Waf1/Cip1 expression was upregulated and cell growth
inhibitionwas dramatically enhanced. In conclusion, HDAC class IIa inhibition
modifıed FoxO3a transcriptional activation and upregulating FoxO3 by dual
inhibition of HDAC class IIa and proteasome is promising target against pan-
creas cancer.
#2113 Mechanism of action of pixantrone in non-Hodgkin’s lymphoma
cells. Serina Ng, Ruben Muñoz, Daniel Von Hoff, Haiyong Han. Translational
Genomics Research Institute, Phoenix, AZ.
Background: Pixantrone (PIX), an anthracenedione analog, has shownprom-
ising results with reduced cardiotoxicity as compared to structurally similar
mitoxantrone and doxorubicin (DOX) in early phase clinical trials in patients
with non-Hodgkin’s lymphoma (NHL). The exactmechanisms of action onhow
PIX induce cell death by targeting DNA replication through intercalating DNA
and/or inhibiting Topoisomerase II has not been clearly illustrated. Methods: A
short-term cell proliferation assay (3 days treatment) and a long-term clono-
genic assay (cells were treated with the drugs for 24 hours and then allowed to
grow into colonies for 10-14 days) were used to assess and compare the effects of
PIX and DOX on cell growth in three NHL cell lines, OCI-Ly8, Z138, and Raji.
Immunofluorescent assays using H2AX antibodies, and DAPI staining were
used to examine the effect of PIX and DOX on the formation of double-strand
breaks and micronuclei. Results: In the short-term cell proliferation assay, PIX
was not as potent as DOX (IC50 values ranging from 22 nM to 2737 nM for PIX
and 2.8 nM to 67 nM forDOX). The two drugs were signifıcantlymore potent in
the long-termclonogenic assaywith IC50 values in lownanomolar range (5.1 nM
to 82.8 nM) and the difference between PIX and DOX was much smaller. Cells
treated with PIX displayed less increases in DNA double-strand breaks com-
pared to those of DOX as quantifıed by the number of H2AX positive foci
formed in the cells. Furthermore, PIX treatment signifıcantly increased the for-
mation of micronuclei in a drug concentration and time dependent manner.
Conclusions: The fındings from the current study indicate that PIX induces
DNAdamages that impair the chromosomal segregation but donot signifıcantly
trigger double-strand breakage checkpoint response.Overall, our results suggest
that PIXmay exert its antitumor activity via mechanisms that are different from
those of DOX.
#2114 Targeting invasive and drug-resistant PDAC with photodynamic
therapy. Gwendolyn Cramer, Seyedehrojin Jafari, Hamid El-Hamidi, Dustin
Jones, Jonathan Celli. University of Massachusetts Boston, Boston, MA.
Pancreatic ductal adenocarcinoma (PDAC) is associated with an extensive
desmoplastic reaction and a characteristic extracellularmatrix (ECM)-rich stro-
malmicroenvironmentwhich is amajor determinant of disease progression and
therapeutic response. Using 3D cell culture models of PDAC, we recently
showed that an invasion-promoting ECM composition leads to differential re-
sponse to chemotherapy agents and photodynamic therapy (PDT), in which
cytotoxic response is triggered by light activation of a photosensitizing agent. In
particular, ECM-infıltrating populations with characteristic mesenchymal phe-
notype display a marked increase in sensitivity to PDT (using the photosensi-
tizer verteporfın), while the same cells exhibit increased chemoresistance. Here,
motivated by these fındings we systematically disentangle influences associated
with the physical and biochemical properties of ECM as regulators of PDAC
growth behavior and treatment response. In 3D tumor spheroids transplanted
into invasion-promoting type 1 collagen gels, we use riboflavin-mediated pho-
tocrosslinking as a tool to regulate ECM stiffness (independent of its concentra-
tion), combined with high-content imaging to co-register invasive progression
and differential response to chemotherapy and PDT. Increased extent of photo-
crosslinking correlates with increased collagen stiffness as confırmed by bulk
oscillatory rheology, and is associated with a decrease in the invasive velocity
(migration speed directed away from the primary transplanted spheroid) of
ECM-infıltrating PDAC cells. Preliminary comparisons of PDT and oxaliplatin
chemotherapy in low and high collagen crosslinking conditions show that PDT
is signifıcantly more effective than oxaliplatin in ECM-invading populations
regardless of collagen stiffness. We also compare oxaliplatin chemotherapy and
PDT before and after PDAC invasion into Matrigel ECM, and fınd that PDT
effıcacy is only enhanced after extensive invasion into the surrounding matrix.
These results support the effıcacy of PDT in targeting locally invasive PDAC
while stressing the importance of elucidating how both biochemical and bio-
physical ECM interactions regulate therapeutic susceptibilities.
#2115 Therapeutic potential of fıngolimod against prostate cancer cells is
partly attributed to interrupting the cross talk between estrogen and sphin-
golipid metabolisms. Rasha M. Allam,1 Ahmed M. Al-Abd,1 Alaa Khedr,2 Ola
A. Sharaf,1 Salwa M. Nofal,1 Amani E. Khalifa,3 Hisham A. Mosli,4 Ashraf B.
Abdel-Naim3. 1National Research Centre of Egypt, Giza, Egypt; 2King Abdulaziz
University, Jeddah, Saudi Arabia; 3Faculty of Pharmacy, Ain Shams University,
Cairo, Egypt; 4Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi
Arabia.
Sphingolipids influence tumor microenvironment in different malignancies.
Estrogen and estrogen metabolites are involved in prostate cancer. Fingolimod
is Sphingokinase-1 (SphK1) inhibitor which possesses anticancer properties in
various tumor types. The aim of the current study is to investigate the interfer-
ence of Fingolimod with the cross talk between sphingolipid and estrogen me-
tabolisms within prostate cancer cells as a novel therapeutic strategy. The design
is based on determining the mutual influence between estrogen metabolism/
signaling and sphingolipidmetabolismwithin prostate cancer cells. Cytotoxicity
using SRB-U assay; cell cycle analysis using DNA cytometry and intracellular
caspase-3 concentration were assessed. Estrogen metabolites and estrogen me-
tabolizing enzymes were determined using LC/MS and RT-PCR, respectively.
Estrogen receptor (ER and ER) expression and their downstream signaling
(CXCR4 and Cyclin-D1, respectively) were measured using immunocytochem-
ical staining and RT-PCR, respectively. Fingolimod showed antiproliferative/
cytotoxic effects against different prostate cancer cells (LNCaP, DU145 and
PC3) with IC50 ranging from 3.0	0.3 to 6.8	1.7 M. Fingolimod induced sig-
nifıcant decrease in estradiol, estrone, 4-hydroxyestradiol and 16-hydroxye-
strone concentrations with reciprocal increase in 2-methoxyestrone and 2-me-
thoxyestradiol concentrations. This was mirrored by signifıcant down
expression for the enzymes, aromatese, CYP1A1 and CYP1B1 and over expres-
sion for the enzyme COMT. Additionally, Fingolimod suppressed the expres-
sion of ER and ER within prostate cancer cells as well as their downstream
signaling (CXCR4 and Cyclin-D1, respectively). Reciprocally, it was found that
estradiol and catechol estrogens induce the expression of SphK1whilemethoxy-
lated catechol estrogen suppresses its expression. Our results give compelling
evidence that Fingolimod has therapeutic potential by modulating the estro-
genic micromilieu and interrupting its cross talk with sphingolipid metabolism
in prostate cancer cells.
#2116 Combining the power of different profıling approaches to better
understand the activity of kinase inhibitor drugs. Alastair J. King,1 Jesse J.
Parry,1 Samantha C. Burkart,1 Lee R. Cavedine,1 AlyssaM. Cracchiolo,1 Brogan
A. Epkins,1 Steven M. Garner,1 Timothy J. Sindelar,1 Charles R. Wageman,1
Stephen P. Davies,2 Andrew Plater,2 AnnaM.Woodward,2 UshaWarrior1. 1Eu-
rofıns Panlabs Inc., St. Charles, MO; 2Eurofıns Pharma Discovery Services UK,
Ltd., Dundee, United Kingdom.
Profıling of inhibitors for eventual therapeutic use is an essential part of drug
discovery and development. Evaluating the in vitro potency of kinase inhibitors
in a wide panel of enzyme assays is critical, not only to guiding SAR knowledge
for improving drug design, but also for assessing selectivity, which has long-
reaching consequences for both biological activity and safety. Evaluation of the
same inhibitors in cellular models yields information on the activity of these
inhibitors in amore physiologically relevant environment.However,while some
selective kinase inhibitors showpredictably selective profıles in cell proliferation
assays, others do not. Thus, the biological context in which a kinase inhibitor
functions, and the signaling networks influenced by inhibition of both the de-
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sired target andoff-target activities, help to defıne how that inhibitorwill work in
a cellular setting and, ultimately, in a therapeutic application. We demonstrate
the power of profıling several well-known kinase inhibitors in complementary
panel assays, to predict behavior that has implications for clinical activity. The in
vitro profıles of selective (trametinib, vemurafenib) and less selective (dasatinib,
sorafenib) kinase inhibitors are shown and compared. With careful evaluation
of their in vitro enzyme activity profıles in Eurofıns’ KinaseProfılerTM panel,
cellular response profıles in OncoPanelTM, and predictive biomarker identifıca-
tion by univariate genomic analysis, a fuller picture of these inhibitors’ biological
activity can be generated, and may be applied to predicting the therapeutic
potential of such inhibitors. While, in some cases, clinical response is seen as
expected, this kind of comprehensive analysis opens up the possibility for ex-
panding clinical utility of an asset by potential repurposing for other indications.
Collectively, this demonstrates not only the need to understand an inhibitor’s
fundamental activity(ies) at its designated target(s), but also the importance of
considering cellular context, when assessing itsmaximumpotential clinical util-
ity.
#2117 TRAIL-induced apoptosis in TRAIL-resistant breast carcinoma.
Jasmine M. Manouchehri, Michael Kalafatis. Cleveland State University, Cleve-
land, OH.
Recombinant human tumor necrosis factor-related apoptosis-inducing li-
gand (rhTRAIL), the optimized form of the endogenous death ligand TRAIL,
shows therapeutic potential for cancer due to its ability to induce apoptosis in
cancer cells independent of p53, while exhibiting minimal toxicity to normal
cells. Despite this, a majority of breast cancers display resistance to rhTRAIL
treatment due to up-regulation of pro-apoptotic proteins, down-regulation of
anti-apoptotic proteins, and/or up-regulation of death receptors (DR) 4 and 5.
To overcome rhTRAIL resistance, natural compounds have been investigated as
sensitizing agents. This study considered the application of the naturally occur-
ring flavonol Quercetin (Q). Q has been shown to have the ability to up-regulate
DR5 and down-regulate anti-apoptotic proteins in cancer cells, and thereby,
makingQ a favorable choice to be employed as a sensitizing agent. The intention
of this study was to ascertain the capacity of Q to sensitize rhTRAIL-resistant
triple negative breast cancer BT-20 cells and hormone-dependent breast cancer
MCF-7 cells to rhTRAIL-induced apoptosis and elucidate the underlyingmech-
anism for Q’s sensitization. Q demonstrated the ability to intensify rhTRAIL’s
pro-apoptotic effects in the breast cancer BT-20 andMCF-7 cell lines as detected
through Annexin V/PI assays followed by FACS analysis. In comparison to
single agent treatments, the cotreatment of Q and rhTRAIL enhanced the in-
duction of the extrinsic pathway of apoptosis as marked by PARP cleavage (a
hallmark of apoptosis), activation of caspase 8, and activation of the executioner
caspases 3 and 7. The mechanism for Q’s augmentation in breast cancer was
determined to be through the down-regulation of c-FLIPL (caspase 8 inhibitor)
in a dose-dependent manner. Furthermore, Q promoted the ubiquitination of
c-FLIPL facilitating the proteasome-mediated degradation of c-FLIPL in breast
cancer. An additional mechanism for Q’s sensitization was displayed in breast
cancer BT-20 cells. Q up-regulated DR5 membrane and protein expression in
breast cancer BT-20 cells in a dose-dependent manner. RT-PCR analysis re-
vealed that Q’s influence onDR5 expression occurred at the transcriptional level
in those breast cancer cells. Thus, these data suggest that the cotreatment of Q
and rhTRAIL possesses the therapeutic potential to be an effective anti-breast
carcinoma regimen.
#2118 The food additive agent potassium bromate prevents growth and
aggressive phenotypes by targeting multiple molecular signatures in breast
cancer cells. Priyanka Ghosh, Gargi Maity, Snigdha Banerjee, Sushanta Baner-
jee. VAMedical Center, Kansas City, MO.
Potassium bromate (KBrO3) is by-product of ozone that has found multi-
functional purpose in modern society. It is used as disinfectant in drinking
water, a bleaching agent to improve flour, a component of cold-wave hair lotion
and an ingredient in the production of fısh paste and fermented beverages.
Potassium bromide has also been used in America for bread-baking as a safe
food additive since 1914. Despite the commercial value of this chemical, some
studies suggest that KBrO3 could be a carcinogen. During the bread-baking
process, Potassium bromate is normally converted into a stable and inert com-
pound, potassium bromide (KBr). However, due to incomplete reduction, the
residual KBrO3 remains in the bread, which eventually acts as a potential car-
cinogen to humans. Interestingly, our studies, in breast cancer cells, found con-
trasting results. We found that KBrO3 delays growth of ER- positive luminal
type breast cancer cells and triple-negative breast cancer cells (TNBC) via induc-
ing apoptosis in a dose-dependent manner. KBrO3-induced apoptosis is medi-
ated via targeting BCL-2/Bax and Caspase-3 signaling pathway. Moreover, ag-
gressive phenotypes such as migration, invasion and sphere-forming ability of
breast cancer cells are signifıcantly impaired by KBrO3-treatment via targeting
multiplemolecular signatures in breast cancer cells. The growth inhibition effect
of KBrO3 is also documented in a tumor xenograft model. Collectively, our
fındings provide a rationale for the basic and pre-clinical evaluation of the role of
KBrO3 in breast cancer progression and therapy.
#2119 Acetylated secretory APE1/Ref-1 induces apoptotic cell death in
orthotopic xenografts of triple-negative breast cancer.YuRan Lee,1 Hee Kyo-
ung Joo,1 Eun Ok Lee,1 Myoung Soo Park,2 Byeong Hwa Jeon,1 Sunga Choi1.
1ChungnamNational Univ. College of Med., Daejeon, Republic of Korea; 2Chun-
gnam National University Hospital, Daejeon, Republic of Korea.
The anticancer properties of acetylated secretory apurinic/apyrimidinic
endonuclease-1 (Ape1/Ref-1) was suggested in triple-negative breast cancer
(TNBC) cells; Posttranslational modifıcation, hyperacetylation in MDA-
MB-231 cells caused extracellular secretion of acetylated-APE1/Ref-1 (Ac-
APE1/Ref-1) and initiated apoptotic cell death by auto-, paracrine binding to
the receptor for advanced glycation end products (RAGE). In the present
study, we observed potential therapeutic effıcacy of Ac-APE1/Ref-1 in pre-
clinical orthotopic models of TNBC in response to hyperacetylation. The
extracellular Ac-APE1/Ref-1 was confırmed by proximity ligation assay in
hyperacetylated tumor tissue, showing direct binding of Ac-APE1/Ref-1 and
RAGE. Treatment of orthotopic TNBC xenografts with acetylating agents
induced a strong growth inhibition in the tumor development as observed in
computed tomography: it caused an increase of RAGE expression and acti-
vation of caspase-3 and PARP. The tumors also exhibited markedly higher
count of apoptotic bodies and reduced proliferation index and neovascular-
ization compared with control tumors. However, the Ac-APE1/Ref-1-stim-
ulated apoptotic cell death was remarkably retarded in RAGE-knockout tu-
mor even in hyperacetylation compared with RAGE-overexpressed one. The
functional role of secreted Ac-APE1/Ref-1 in hyperacetylated TNBC was
confırmed in vivo, demonstrating its relevance to the anticancer agent. Our
fındings suggest that Ac-APE1/Ref-1 protein possesses potent chemothera-
peutic effıcacy against TNBC, resistant to standard chemotherapeutic
agents, warranting further evaluation as an anticancer agent.
#2120 Distinct molecular effects of chemotherapeutic agents on choline
phospholipid metabolism of triple-negative breast cancer cells. Menglin
Cheng, ZaverM. Bhujwalla, KristineGlunde. JohnsHopkins University School of
Medicine, Baltimore, MD.
The magnetic resonance spectroscopy (MRS)-detected total choline (tCho)
signal is a promising non-invasive surrogate marker able to predict chemother-
apy response in breast cancer patients early on. However, the molecular mech-
anisms bywhich common chemotherapeutic drugs affect the tCho signal, which
consists of glycerophosphocholine (GPC), phosphocholine (PC), and free cho-
line (Cho), are mostly unknown. Here we have employed some widely used
cancer chemotherapeutic drugs such as doxorubicin, paclitaxel, and vinorelbine
to treat triple-negative human MDA-MB-231 breast cancer cells to elucidate
their molecular effects on choline phospholipid metabolism. High-resolution
(HR) 1H MRS of water-soluble cell extracts was employed to detect changes in
cellular choline metabolite profıles, and quantitative RT-PCR (qRT-PCR) to
assess the corresponding changes in the expression levels of choline-metaboliz-
ing enzymes. After 48 hours of doxorubicin treatment, the GPC levels in MDA-
MB-231 cells signifıcantly increased, while PC level decreased, and the tCho
concentration remained unchanged. Vinorelbine treatment displayed a compa-
rable effect to doxorubicin, but the GPC increase and PC decrease occurred to a
lesser extent. Paclitaxel treatment caused an increased GPC level along with an
unaltered PC level, leading to a slightly increased tCho level. In all these cases,
the PC/GPC ratio decreased from 3.5 in the control to about 2.0 in paclitaxel- or
vinorelbine-treated samples, to about 1.0 in doxorubicin-treated samples. qRT-
PCR-detected mRNA expression levels showed that GDPD6 and Chk were
downregulated by doxorubicin. GDPD5, GDPD6, and Chk genes displayed a
reduced mRNA expression level following vinorelbine treatment, while no sig-
nifıcant change in these three genes was detected after paclitaxel treatment. For
comparison, the known GDPD6 inhibitor dipyridamole signifıcantly increased
cellular GPC levels, but, as expected, did not affect GDPD6 mRNA expression
levels as it acts as an enzyme inhibitor. Our study demonstrates that choline
containing metabolites change differently depending on the type of drug used
for breast cancer treatment. However, all tested chemotherapeutic treatments
resulted in metabolic alteration away from the ‘cholinic phenotype’, which was
caused in some cases by decreases in expression of Chk, GDPD6, and GDPD5
following drug treatment. The cholinemetabolite concentrations ofGPCand/or
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PC and/or the PC/GPC ratio may serve as non-invasive surrogate makers of
therapeutic response in triple-negative breast cancer patients undergoing che-
motherapy.
#2121 Deguelin-derivative, L80 suppresses tumor growth and metastasis
via inhibition of STAT3 activation in triple-negative breast cancer. Tae-Min
Cho, Eunhye Oh, Daeil Sung, Yoon-Jae Kim, Ji Young Kim, Jeewoo Lee, Jae
Hong Seo. Korea University, Seoul, Republic of Korea.
Triple-negative breast cancer TNBC is associated with aggressive metastasis
and poor clinical outcomes due to a lack of effective treatment options. There-
fore, new drugs that effectively target both cancer cell proliferation and metas-
tasis are needed to improve clinical outcomes. The 90-kDamolecular chaperone
heat-shock protein, HSP90 has been implicated in cancer progression and me-
tastasis bymodulating the stabilization andmaturation of many oncogenic pro-
teins. Our objective was to investigate the mechanism of action of C-terminal
HSP90 inhibitor, deguelin-derivative L80 onTNBCproliferation andmetastasis
in vitro and in vivo. L80 induced apoptosis and suppression of cell viability in
TNBC cell lines via inhibition of Akt activation with concomitant nuclear accu-
mulation of p27. L80 treatment also caused a marked suppression of cell migra-
tion and invasion. These responses were associated with inhibition of STAT3
phosphorylation (Tyr705) as evidenced by downregulation of STAT3 down-
stream target genes including cyclin D1 and survivin. The syngeneic orthotopic
mouse model with 4T1 cells, L80 administration resulted in signifıcant reduc-
tion in tumor growth together with decreased number of Ki-67-positive cells
and downregulation of phospho-STAT3. Double-label immunofluorescence
analysis showed that individuals receiving L80 exhibited a marked reduction in
co-localization and expression of HIF-1 and HSP90 compared to their control
groups in vivo. Finally, we observed that L80 administration signifıcantly sup-
pressed lung metastasis, as determined by in vivo bioluminescent imaging sys-
tem. Our fındings suggest that L80may be potentially effective for the treatment
for metastatic TNBC patients.
#2122 Pharmacologic interconversion of EMT to MET for prostate can-
cer. Zheng Cao,1 Shahriar Koochekpour,2 Stephen E. Strup,1 Natasha Kypri-
anou1. 1University of Kentucky Medical Center, Lexington, KY; 2Roswell Park
Cancer Institute, Buffalo, NY.
Introduction and objection: Dysregulation of transforming growth factor-
(TGF-) and insulin-like growth factor (IGF) axis has been linked to reactive
stroma dynamics in the tumor microenvironment during prostate cancer pro-
gression. IGFBP3 induction is initiated by stroma remodeling and represents a
potential therapeutic target for advanced prostate cancer. A lead quinazoline-
based Doxazosin® derivative, DZ-50, generated in our laboratory (US Patent #
8377948), inhibits prostate tumor growth via inducing anoikis and disrupting
focal adhesions. Molecular profıling revealed that the process of epithelial-mes-
enchymal-transition (EMT) is targeted by DZ-50. In this study, we investigated
the effect of DZ-50 on EMT landscape, EMT to mesenchymal-epithelial-transi-
tion (MET) conversion, and invasive properties of prostate cancer cells. Meth-
ods: Human prostate cancer cells LNCaP, LNCaP overexpressing TGF- type II
receptor (TRII), and cancer associated fıbroblasts (CAFs) derived fromhuman
prostate cancer specimens, were used. The antitumor effect of DZ-50 against
prostate cancer epithelial cells andCAFswas evaluated using cell viability assays.
Effect of the drug on EMT key regulators (including IGFBP3) was determined
using RT-PCR and Western blot analysis. Drug-induced phenotypic conver-
sions of EMTwere evaluated by confocalmicroscopy. Impact of TGF- from the
stroma microenvironment or exogenous cytokine, on prostate tumor cell mi-
gration and invasion, was assessed in co-cultures with CAFs. The functional
contribution of IGFBP3 to EMT-MET interconversion in response to DZ-50
was assessed using siRNA approaches. Results: DZ-50 induced cell death in
prostate cancer epithelial cells andCAFs, in a concentration-dependentmanner.
DZ-50 downregulated IGFBP3 mRNA and protein expression and promoted
EMT-MET conversion in both LNCaP and LNCaPTRII cells. IGFBP3 knock-
down in LNCaPTRII cells led to E-cadherin upregulation andMET induction,
implicating IGFBP3 as a potential target of DZ-50 to reverse EMT to MET.
Moreover exposure to TGF- reversed DZ-50-induced MET by upregulating
IGFBP3 in LNCaPTRII cells. Co-cultures of LNCaPTRII with CAFs pro-
moted prostate cancer cell invasion via TGF- and IGFBP3, an effect that was
inhibited by the drug. Conclusions: Treatment of prostate cancer cells with the
novel agent DZ-50 inhibits cell migration and invasion and causes reversal of
EMT to MET by regulating IGFBP3. This study integrates IGFBP3 as new sig-
naling effector driving the antitumor action of DZ-50 via targeting the EMT-
MET phenotypic landscape in the prostate tumor microenvironment. Ongoing
work in pre-clinical models will establish the therapeutic value of this novel
compound in advanced metastatic prostate cancer.
#2123 Inhibition of AURKA induces Raf1-independent activation of
MAPK pathway in breast cancer cells. Malgorzata Gil,1 Archana Chi-
dambaram,1 Thaer Khoury,1 Kazuaki Takabe,1 Igor Puzanov,1 Irwin Gelman,1
AntonioD’Assoro,2MateuszOpyrchal1. 1Roswell Park Cancer Institute, Buffalo,
NY; 2Mayo Clinic College of Medicine, Rochester, MN.
Background: Aurora A (AURKA) is a mitotic kinase responsible for centro-
some segregation and mitotic spindle formation. In normal cells, expression of
AURKA is highly regulated and is predominantly restricted to G2/M phases of
the cell cycle. Unlike healthy cells, cancer cells overexpress AURKA through all
phases of the cell cycle resulting in the acquisition of alternate non-mitotic
functions. Little is known about cellular functions regulated by AURKA and its
interaction with other signaling molecules. Here, we report a novel interaction
betweenAURKA and themitogen-activated protein kinase (MAPK) pathway in
wild type BRAF breast cancer cells as well as demonstrate an additive cytotoxic
effect of AURKA- and MEK1/2-specifıc inhibitors against estrogen positive
(ER) and triple negative (ER, PR, HER2) breast cancer cells. Results: We
show that treatment of ER HER2 MCF-7, ER HER2 SKBR3 and ER
HER2 BT549 cells with AURKA specifıc inhibitors alisertib, MK8745 and Au-
rora A Inhibitor I resulted in over 2-fold increase in the levels of both pMEK1/2
and pERK1/2 compared to the untreated controls. The activation of the MAPK
pathwaywas rapidwith changes seenwithin 5min after treatment withAURKA
inhibitors and was sustained for at least 48 hours. No differences in phosphor-
ylation of MEK1/2 or ERK1/2 were observed in BRAFG464V triple negative
MDA-MB-231 cells. Treatment with AURKA inhibitors resulted in downregu-
lation of pAURKA and a signifıcant increase in levels of total AURKA protein.
The pull-down assaywithRas-binding domain coated agarose beads followedby
western blot analysis with anti-pan-RAS Ab revealed no changes in active GTP-
bound RAS in alisertib-treated MCF-7 cells compared to the untreated control.
Consistently, no signifıcant changes were observed in RAS-inducible phosphor-
ylation of RAF1 activation site at Ser338 as demonstrated bywestern blot. Treat-
ment with the pan RAF inhibitor TAK-632 did not diminish alisertib-induced
pERK and pMEK1/2. Alternatively, treatment with the MEK1/2 specifıc inhib-
itor PD0325901 completely abrogated alisertib-induced phosphorylation of
MEK1/2 and ERK1/2. Furthermore, combined treatment of alisertib and
PD0325901 in vitro revealed signifıcant additive cytotoxic effect in MCF-7 and
BT549 cells when compared to either agent used alone (p 0.008 and p0.011;
p0.04 and p0.028). Conclusions: Our data suggests that AURKA is a RAF1-
independent negative regulator of MAPK activity in breast cancer cells. The
in-depth analysis of the AURKA-MEK1/2 interaction is currently under inves-
tigation. The results reveal a promising new strategy for the treatment of wild
type BRAF, TNBC patients using a combination of AURKA andMEK1/2 inhib-
itors.
#2124 Differentiation of myeloid and multiple myeloma cell lines by in-
ecalcitol involves a marked decrease in CD44 and CD49d cell surface label-
ing. Susan Benjamin, Cecile Planquette, Remi Delansorne. Hybrigenics, Paris,
France.
Inecalcitol is a vitamin D receptor (VDR) agonist characterized by a high
antiproliferative activity on various cancer cell lines (Okamoto et al., 2012;Ma et
al., 2013) and a low calcemic potential as demonstrated by the high maximal
tolerated oral daily dose of 4 mg in human patients (Medioni et al., 2014). On
myeloid cells, inhibition of proliferation by vitaminDderivatives is paralleled by
induction of differentiation into a monocyte/macrophage phenotype, mostly
described as gain of functions (increase in lysozyme activity, phagocytosis and
cell motility; Abe et al., 1981) and of the cell surface CD11b and CD14 biomark-
ers. The stimulation of the secretion of cathelicidin, a natural human antimicro-
bial peptide, is another specifıc activity of vitaminD and its derivatives (Wang et
al., 2004). During a screening of 48 CD biomarkers on 4 human myeloid cell
lines (HL-60,U-937,MOLM-13 andTHP1) and 4 humanmultiplemyeloma cell
lines (MM.1R,MM.1S, L-363 andRPMI-8226) treated for 72 hours at 10 nM,we
recently discovered that inecalcitol reproducibly induces CD38 expression
(Benjamin et al., 2016), another gain of function.We now report the decrease in
CD44 and CD49d cell surface labeling in all 8 cell lines (except CD44 in L-363
cells). This loss of functions reached -60% to -70% inMOLM-13 andHL-60 cells.
We have then determined the EC50 (mean	 SEM; n 3 or 4) of inecalcitol for
several differentiation parameters on HL-60 cells. The most sensitive gains or
loss of functions were the secretion of cathelicidin (0.2	 0.1 nM), the induction
of CD38 (0.3	 0.1 nM) and the decrease in CD44 (0.8	 0.4 nM). Inhibition of
proliferation (1.9	 0.8 nM) was exactly parallel to induction of CD11b (1.8	
0.8 nM). Decrease in CD49d (6.6 	 1.1 nM) and increase in CD14 (8.0 	 0.5
nM) occurred as fınal markers of differentiation by inecalcitol. CD44 is the
receptor for hyaluronic acid; it is found on the surface of acutemyeloid leukemia
stem cells and suspected to favor the spread and relapse of the disease. CD49d is
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the integrin 4-subunit involved in the interactions of tumor cells with their
microenvironment resulting in their “hiding” and survival. Therefore, decreas-
ing both CD44 and CD49d represents newly identifıed potential benefıcial pro-
differentiation effects of inecalcitol.
#2125 Flavokawain A, a kava chalcone, inhibits growth and invasion of
human osteosarcoma cells by targeting Skp2. Yidan Zhang,1 Wendong
Zhang,1 Nikolas Zaphiros,1 Xiuquan Du,1 Pratistha Koirala,1 Michael Roth,1
Jonathan Gill,1 Sajida Piperdi,1 David Geller,1 Rui Yang,1 Jinghang Zhang,2
Richard Gorlick,1 Xiaolin Zi,3 Tao Ji,4 Bang H. Hoang1. 1Montefıore Medical
Center, Albert EinsteinCollege ofMedicine, Bronx,NY; 2Albert EinsteinCollege of
Medicine, Bronx, NY; 3University of California, Irvine Medical Center, Orange,
CA; 4Peking University People’s Hospital, Beijing, China.
Purpose: Osteosarcoma (OS) is the most common primary bone malignancy
with a high propensity for local invasion and distant metastasis. Flavokawain A
(FKA), amajor chalcone fromkava extract, has been reported to have antitumor
effects on multiple cancer cell lines. The consumption of kava-containing bev-
erage has been associatedwith a low cancer incidence. In a previous report, mice
treated with high-dose FKA did not demonstrate any signifıcant major organ
toxicity. However, the effıcacy and anticancer mechanisms of FKA in OS is still
to be elucidated. Experimental Design: OS cell lines were treated with increasing
dosage of FKA and tested for cell motility, proliferation, and invasion by MTT
assay and Matrigel invasion assay. Cell cycle analysis was performed using flow
cytometry. We examined Skp2 expression in several OS cell lines using western
blot and in patient tissue array by immunostaining. Kaplan-meier analysis and
log rank test were used to compare overall survival. Both Skp2-dependent cell
cycle progression and Skp2-related RhoA expression were also examined after
FKA treatment. The effects of FKA on lung metastasis were evaluated after
orthotopic injection of OS cells into the tibia. Results: We show that FKA inhib-
its the growth and motility of multiple OS cell lines in vitro. Flow cytometry
analysis confırms cellular apoptosis and arrest in G2/M phase after FKA treat-
ment, whereas cellular invasion is also inhibited in a dose-dependent manner.
Skp2 is expressed in several OS cell lines and is associated with a poor prognosis
in OS patients. Skp2 levels in OS cell lines decreased after FKA treatment. The
expression of cell cycle regulators including p21 and p27, which are downstream
of Skp2, was upregulated. Moreover, Skp2-related RhoA expression is inhibited
by FKA and confırmed at protein level. Conclusions: Taken together, the evi-
dence suggests FKA exerts anti-invasive effects in association with Skp2-depen-
dent cell cycle progression and Skp2-related RhoA expression. Since Skp2 is a
negative prognostic factor forOS patients, FKA should be investigated further as
an anti-Skp2 therapeutic strategy for OS.
#2126 CA102N, a conjugate of hyaluronic acid (ha) andNimuselide deriv-
ative (H-Nim) interferes with PI3K/Akt/mTOR signaling pathway in colo-
rectal cancer (CRC) cells and inhibits tumor growth in vivo. Eskouhie H.
Tchaparian, Louis Lin. Holy Stone Healthcare Co., Ltd., Taipei, Taiwan.
Aberrant PI3K/Akt/mTOR signaling pathway is common in several human
cancers, including CRC. The pathway regulates many major cellular processes
and promotes tumorigenesis and inhibition of apoptosis. Targeting the PI3K/
Akt/mTOR network could be important in resistance mechanisms in cancer.
CA102N, is a conjugate of Hyaluronic Acid (HA) and H-Nim, a nimuselide
(COX-2 inhibitor) derivative, currently under investigation for preclinical de-
velopment in CRC. Studies have suggested that the anti-proliferative effects of
COX-2 inhibitors could be attributed to modulation of the PI3K/AKT signaling
pathway; therefore, in this study we aimed to examine the overall molecular
mechanism of the antitumor activity of CA102N and evaluate its impact on the
PI3K pathway proteins. Cell based studies indicated that in addition to cell cycle
arrest; the antitumor activity of CA102N is also related to apoptosis. Adminis-
tration of CA102N to nudemice bearing establishedHT29 subcutaneous tumor
xenografts caused signifıcant tumor growth inhibition with no signs of systemic
toxicity. Immunohistochemical analyses of xenograft tumors demonstrated in-
hibition of VEGF and CD31, suggesting a role for CA102N in angiogenesis.
Disruption of angiogenesis and apoptosis was correlated with a decrease in
VEGF and the antiapoptotic protein BCL-2. Suppression of PI3K downstream
signaling was a key observation in HT29 cells in vitro and in xenograft tumors
treated with CA102N. As compared to untreated vehicle control, a signifıcant
decrease in phosphorylation of AKT, mTOR, p70S6K, PRAS40, 4EBP1 and
FOXO1 was detected byWestern blot analyses. The reduction observed may be
caused by both specifıc protein dephosphorylation/deactivation and by ubiqui-
tin-mediated proteasomal degradation of pathway proteins. These results sug-
gest that the antitumor activity of CA102N may be at least partly related to the
modulation of the PI3K/Akt pathway proteins. CA102N represents a promising
anticancer agent with minimal toxicity, the insights provided into the mecha-
nisms of its anticancer activitymay be the basis for advancing this candidate into
clinic.
#2127 p53-independentNoxa inductionby cisplatin is regulatedbyATF3/
ATF4 in HNSCC cells. Kanika Sharma,1 Thien-Trang Vu,1 Mitra Naseri,1 Wa-
taruNakajima,2 Kevin Zhan,1 Hisashi Harada1. 1VCUMassey Cancer Ctr., Rich-
mond, VA; 2Nippon Medical School, Tokyo, Japan.
Head and neck cancer is the sixth leading cancer worldwide and head and
neck squamous cell carcinoma (HNSCC) accounts for more than 90% of inci-
dent cases. The long-term prognosis of patients with advanced HNSCC has
shown little improvement over the last three decades. Induction chemotherapy
with platinum-based compounds, taxanes, and 5-fluorouracil is benefıcial for
head andneck cancer patients, but the prolonged use of chemotherapeutic drugs
is limited by their toxicity and by the development of resistance. Tumor cell
death induced by both conventional and targeted chemotherapy is often medi-
ated by the BCL-2 family-dependent mitochondrial apoptotic pathway. How-
ever, initiators of this apoptotic pathway, such as p53, are frequently mutated or
deleted in HNSCC rendering it refractory to treatment. To counter such resis-
tance, direct therapeutic targeting of the BCL-2 family is conceptually appealing.
We have investigated the cytotoxic effects of a DNA damaging agent, cisplatin
that is used for a standard therapy for locally advanced HNSCC. Cisplatin pro-
duces anticancer effects mainly by generating DNA lesions and activating DNA
damage response followed by inducing BCL-2 family-dependent mitochondrial
apoptosis. Cisplatin induces the expression of a pro-apoptotic BH3-only pro-
tein, Noxa that binds to the pro-survival BCL-2 family protein, MCL-1 to inac-
tivate its function and induces cell death. To examine the contribution of Noxa
in cisplatin-induced apoptosis, shRNA for Noxa was introduced in p53-null
HNSCC cells, since p53 is mutated or deleted in more than 50% of HNSCC.We
found that the up-regulation of Noxa is critical for cisplatin-induced apoptosis
in p53-independent HNSCC cells. This Noxa induction is regulated at the tran-
scriptional level. Thus, we examined the regulation of the Noxa promoter with a
series of luciferase reporter assays. We found that the CRE (cAMP responsive
element located at -66-59 from the transcription start site) on the promoter
plays a critical role in Noxa induction. The CRE is known to be regulated by
ATF/CREB transcription factors. Downregulation of ATF3 orATF4 by shRNAs
clearly reducedNoxa induction. Furthermore, the binding of these transcription
factors to the CRE on the Noxa promoter was increased by cisplatin treatment,
determined by chromatin-immunoprecipitation assays. In conclusion, ATF3
and ATF4 are important regulators for cisplatin-induced Noxa in a p53-inde-
pendent pathway. The results suggest thatmodulation of the signaling pathways
that activate ATF3/ATF4 could be an alternative approach to induce Noxa fol-
lowed by apoptosis in HNSCC.
#2128 PDGFR beta signaling is required for hypoxia induced mitophagy
in glioblastoma survival. Jinkyu Jung, Mark R. Gilbert, Deric M. Park. NCI,
NIH, Bethesda, MD.
BACKGROUND: Platelet-derived growth factor (PDGF) signaling plays a
key role in gliomagenesis. Glioblastomas express all PDGF ligands and both cell
membrane receptors, PDGFR and PDGFR, that are involved in pro-survival
autocrine andparacrine loops.Our previouswork demonstrated that expression
of PDGFR is enriched in hypoxic glioblastoma tumor tissues. Also, induction
of mitophagy is a well-known critical coping response to tissue hypoxia. We
therefore investigated the role of PDGFR signaling cascade in regulating hy-
poxia-induced mitophagy of glioblastoma. METHODS: Protein detection was
performed by immunoblotting and immunofluorescence to determine changes
in levels of target proteins upon RNA interference, treatment with PDGFR
inhibitor, and ectopic gene transfection. MitoSox assay was used to measure
mitochondrial reactive oxygen species (ROS). Tumor growth assays were per-
formed in vitro and in vivo using subcutaneous tumor implantation model.
RESULTS: PDGFR signaling was essential for induction of hypoxia-mediated
mitophagy in glioblastoma cells. Nix, a hypoxic responsive protein and regulator
of mitophagy, was necessary for PDGFR-mediated glioblastoma survival. In-
hibition of PDGFR signaling pathway killed glioblastoma cells by suppressing
mitophagy and leading to subsequent elevation of mitochondrial ROS. Further-
more, interference of mitophagic response by blocking PDGFR signaling en-
hanced cell death even in chemotherapy-resistant tumor cells. CONCLUSION:
This work suggests a potential mechanism by which PDGFR inhibition could
kill glioblastoma cells through suppression of NIX-mediated mitophagy. Ma-
nipulation of NIX and PDGFR pathwaymay provide novel therapeutic oppor-
tunities in chemoresistant tumor models.
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#2129 Assessing the effıcacy of targetingmitochondrial respiration in de-
laying lung tumor growth by using subcutaneous xenografts in mouse mod-
els. Sarada Preeta Kalainayakan, PoorvaGhosh, SanchareekaDey, Li Zhang.UT
Dallas, Richardson, TX.
Previously, studies have focusedmainly on the precept that tumors depend on
glycolysis for energy and growth (theWarburg effect) and that themitochondria
are dysfunctional in cancer cells. However, there is mounting evidence that
some cancer cells exhibit elevated mitochondrial respiration. Recent studies in
our lab have demonstrated that Non-Small Cell Lung Cancer (NSCLC) cells
exhibit intensifıedmitochondrial respiration and oxygen consumption.We fur-
ther demonstrated that targeting increased mitochondrial respiration by a ther-
apeutic agent effectively hampers proliferation of Non-Small cell lung cancer
(NSCLC) cells in vitro. The purpose of the study is to determine to what extent
mitochondrial respiration is affected by the therapeutic agent in vivo. In order to
achieve this goal, NSCLC cells were transduced with lentiviral particles carrying
luciferase sequence. NSCLC cells expressing luciferase cells were implanted on
the right flank of 4-6 weeks old female NOD/SCIDmice to generate subcutane-
ous xenografts. The therapeutic agent was administered intravenously. Tumor
implantation and growth were monitored by bioluminescence imaging (BLI)
using Perkin Elmer’s IVIS Lumina III Imager. On sacrifıcing the mice, the tu-
mors were harvested, formalin fıxed and paraffın embedded for Immunohisto-
chemistry (IHC). Our BLI data suggest that there is a considerable reduction in
radiance (total flux in photons per second) in the group ofmice that were treated
with therapeutic agent in comparison to control. Further, there is a signifıcant
reduction in tumor volume in mice that received treatment. Our IHC data sug-
gest that there is a reduction in expression of a vital enzyme involved in heme
synthesis and hemoproteins involved inmitochondrial respiration.Our BLI and
IHC data suggest that the therapeutic agent affects mitochondrial respiration by
affecting mitochondrial complexes in vivo. Additional experiments to corrobo-
rate the results are underway.
#2130 Antitumor activity of marin natural product derived Psammaplin
A analogs in human lung cancer cells. Woong sub Byun, Yoonho Shin, Sang
Kook Lee, Hyeung-geun Park, Suckchang Hong. College of pharmacy, seoul na-
tional university, Seoul, Republic of Korea.
Natural products are important sources for bioactive molecules, which
have been developed to treat various human health-related symptoms. In our
continuos efforts to search for anticancer agents from natural sources, Psam-
maplin A (PsA), isolated from marine natural products, was found to be a
potential candidate in the growth inhibition of cancer cells. PsA, a unique
symmetrical bromotyrosine contained in a number of marine sponges of the
order Verongida, has exhibited a variety of bioactivities including antimi-
crobial activity, cytotoxicity against the leukemia cell line, and inhibitory
activity of DNA gyrase and DNA topoisomerase. PsA is also known to be a
potent inhibitor of DNA methyltransferase and histone deacetylase with
growth-inhibitory activity of cancer cells. However, its underlying mecha-
nism of action and the structure-activity relationship (SAR) with PsA ana-
logs have not been elucidated yet. In the present study, twenty-eight syn-
thetic analogs of PsA were newly synthesized and examined the potential of
cytotoxicities against cancer cells. A SAR study revealed that the presence of
free oxime and disulfıde functional groups was responsible for high cytotox-
icity. Furthermore, the bromotyrosine component in PsA was relatively tol-
erable and hydrophobic aromatic groups preserved the cytotoxicity. The
aromatic groups were dependent on their size and spatial geometry. Among
them, a -naphthyl derivative of PsA showed a potential cytotoxicity and
was comparable to that of PsA. The compound also exhibited a potential
antitumor activity in a nude mouse xenograft model. These fındings indi-
cated that free oxime and disulfıde linker in the chemical structure play an
important role for cytotoxicity and PsA analogs might be provided as poten-
tial antitumor agents. This work was supported by the National Reseach
Foundation of Korea (NRF) Grant funded by the Korean Government
(MEST) (NRF-2016M3A9B6903499) and also supported by a National Re-
search Foundation of Korea (NRF) grant funded by the Korean Government
(MEST) (No.2009-0083533).
#2131 Tanshinone IIA can decrease growth factor receptors expression
and dural-block both Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR path-
ways to inhibit human breast cancer BT-20 cells. Chin Cheng Su. Changhua
Christian Hospital, Changhua City, Taiwan.
Background: Tanshinone IIA (Tan-IIA, C19H18O3) with anti-inflamma-
tory activities and antioxidant properties, is one of the diterpine quinones
extracted from Salviae miltiorrhizae radix (Danshen). Tan-IIA can inhibit
many human cancer cell lines through different molecular mechanisms. The
phosphoinositide-3-kinase (PI3K)/AKT/ mammalian target of rapamycin
(mTOR) and RAS/RAF/MEK/ERK pathways are two of the most frequently
dysregulated kinase cascades in human cancer. Transmembrane tyrosine
kinase has been strongly implicated in the proliferation, survival, and me-
tastasis of human tumors. Both pathways represent important signal trans-
duction mechanisms that facilitate the proliferation and survival of cancers
driven by growth factor receptors, such as vascular endothelial growth factor
receptor (VEGFR), insulin-like growth factor-I receptor (IGF-IR), or epider-
mal growth factor receptor (EGFR). Targeting both the Ras/Raf/MEK/ERK
and Ras/PI3K/Akt/mTOR Pathways for suppressing inhibitor resistant cells
is necessary because the individual downstream components of these signal-
ing cascades either through epigenetic modifıcation or somatic mutation are
also known to be frequently altered in cancer, thus contributing to resistance
to anticancer therapies and tumorigenesis. Material and methods: In the
present study, the human breast cancer BT-20 cells were treated with Tan-
IIA in vitro. The cytotoxicity of Tan-IIA was evaluated by MTT assay. The
effects of Tan-IIA on the protein expressions of EGFR, IGF-IR, VEGFR,
PI3K, AKT, mTOR, Ras, Raf, MEK and ERK and -actin in the BT-20 cells
were examined by western blot analysis. Results: The results showed that
Tan-IIA can induce the proliferation inhibition with time and dose depen-
dent and inhibit the activity of the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/
mTOR pathways. In addition, it was showed that Tan-IIA treatment inhib-
ited the protein expression levels of EGFR, VEGFR and IGF-IR signifıcantly.
Conclusions: These fındings indicated that one of the molecular mechanisms
for Tan-IIA to inhibit BT-20 cells maybe through inhibiting the protein
expression levels of EGFR, VEGFR, IGF-IR and both Ras/Raf/MEK/ERK and
Ras/PI3K/Akt/mTOR pathways. The use of Tan-IIA for breast cancer may
become a feasible novel therapy option. Further studies are warranted to
elucidate its mechanisms fully.
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#2132 Novel therapeutic approach through systemic depletion of
L-cyst(e)ine with engineered cyst(e)inase enzyme for suppression of pros-
tate tumor growth. Achinto Saha, Shira L. Cramer, Sabin Kshattry, Stefano
Tiziani, Everett Stone, George Georgiou, John DiGiovanni. University of
Texas at Austin, Austin, TX.
Prostate cancer (PCa) is the most common non-skin neoplasm and second
leading cause of cancer death in men in the USA. The major drawbacks of PCa
treatment is the development of resistance to androgen ablation therapy. Due to
abnormal growth and genetic alterations, cancer cells experience higher oxida-
tive stress from reactive oxygen species (ROS) than the normal cells. The L-cys-
teine (Cys) containing tripeptide, glutathione (GSH) is the major intracellular
antioxidant and is essential for the survival and proliferation of cancer cells.
Under conditions of elevated ROS, endogenous Cys production is insuffıcient
for GSH synthesis. This necessitates uptake of Cys that is predominantly in its
disulfıde form, L-cystine (CSSC), via the xCT() transporter. Cys is a non-
essential amino acid in animals; therefore, eliminating Cys and CSSC uptake
should selectively impact tumors that display increased ROS production, with-
out causing an adverse effect on normal physiology. However, inhibition of
xCT() alone is insuffıcient because free Cys is still imported via other trans-
porters. A superior approach is the elimination of Cys and CSSC through the
action of an enzyme that converts these amino acids into non-toxic products.
Based on the idea that enzyme mediated systemic depletion of the serum Cys/
CSSC pool would constitute a powerful and completely novel therapeutic ap-
proach, we developed a genetically engineered and pharmacologically opti-
mized human enzyme called cyst(e)inase. We show that administration of
cyst(e)inasemediates sustained depletion of the extracellularCys andCSSCpool
inmice. Treatmentwith this enzyme selectively causes cell cycle arrest and death
in cancer cells due to depletion of intracellular GSH and ensuing elevated ROS;
yet no apparent toxicities in mice even after months of continuous treatment.
Cyst(e)inase suppressed the growth of prostate carcinoma allografts and re-
duced tumor growth in PCa xenografts. Mechanistically, cyst(e)inase treatment
increased AMPK phosphorylation, reduced mTORC1 activity, formation of
LC3 II as well as modulation of several cell cycle proteins including p27, c-Myc,
CDK2, CDK4, pRB, E2F4 and cyclins A, D1 and E1. Further studies showed
cyst(e)inase produced synergistic effects with aGSH synthesis inhibitor, buthio-
nine sulfoximine and the natural compound, curcumin for cell growth inhibi-
tion and ROS production in vitro. Cyst(e)inase also showed synergistic tumor
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growth inhibition with curcumin in a xenograft model of human castrate resis-
tant PCa cells. Collectively, enzyme-mediated depletion of serumCys and CSSC
pool suppresses the growth of prostate tumors, and is very well tolerated. These
results suggest that cyst(e)inase represents a potentially safe and effective ther-
apeuticmodality as a single agent or in combination for the treatment of prostate
and possibly other cancers.
#2133 Pre-clinical studies of EC2629, a highly potent FR targeted DNA
crosslinking agent. Joseph A. Reddy, Melissa Nelson, Christina Dircksen, The-
resa Johnson, Marilynn Vetzel, Spencer Hahn, Longwu Qi, Iontcho Vlahov,
Christopher Leamon. Endocyte, Inc., West Lafayette, IN.
Folate receptor (FR) targeted small molecule drug conjugates (SMDCs) have
shown promising results in early stage clinical trials with vintafolide and
EC1456. In our effort to develop FR targeted SMDCs with varying mechanisms
of action, we have now built EC2629, a folate conjugate of a DNA crosslinking
agent based on a novel DNA-alkylating moiety. This agent was found to be
extremely potent with an in vitro IC50  100 x lower than any other folate
SMDC we have created to date. Treatment of nude mice bearing FR positive
human xenografts led to cures in 100% of the mice at very low doses (300
nmol/kg) using a convenient once a week schedule. The observed activity was
not accompanied by any noticeable weight loss (up to 20 weeks post end of
dosing) or major organ tissue degeneration. Complete responses were also ob-
served in other FR-positive drug resistant (paclitaxel and cisplatin) models.
When evaluated against FR-positive PDX models of ovarian, endometrial and
triple negative breast (TNBC) cancers, EC2629 showed signifıcantly greater an-
ti-tumor activity than EC1456 or standard of care (SOC) treatments. Taken
together, these studies demonstrated that EC2629 with a distinct DNA reacting
mechanism has signifıcant anti-tumor growth activity in numerous models,
including those which were drug resistant, thus lending support to our planned
clinical development of this novel FR-targeted agent.
#2134 Use of methionine gamma-lyase-loaded erythrocytes to induce effec-
tivemethioninedepletion in cancer therapy.FabienGay,1KarineAguera,1Karine
Senechal,1 Philip Lorenzi,2 Alexander Scheer,1 Françoise Horand,1 Vanessa
Bourgeaux1. 1ERYTECH Pharma, Lyon, France; 2MD Anderson Cancer Center,
Houston, TX.
Methionine (Met) dependence is a cancer-specifıc metabolic defect that has
emerged as a target during the last two decades. The use of methionine gamma-
lyase (MGL; EC number 4.4.1.11), a bacterial Met-catabolizing enzyme, is a
promising strategy for treatment ofMet-dependent cancers. However, one chal-
lenge is thatMGL has a very short half-life (2 hours), resulting in a short-term
Met depletion in vivo. Additionally, its cofactor, pyridoxal 5=-phosphate (PLP)
is rapidly eliminated from plasma (Yang et al., 2004). PEGylation extends the
MGLhalf-life inmice to up to 38 hours.Nevertheless, frequent injections are still
necessary formaintaining an effectiveMet depletion over time (Sun et al., 2003).
In addition, the low bioavailability of PLP remains a major hurdle due to both
scavenging by plasma proteins and very short half-life ( 15 minutes) in the
blood stream (Zempleni, 1995). Studies showed that pyridoxine (PN), a vitamin
B6 vitamer, can easily cross red blood cells (RBCs) membrane to be rapidly
converted to PLP via an enzymatic reactions cascade (Anderson et al., 1971).
Considering those particular characteristics of RBCs, we propose that RBC-
encapsulated MGL (ERY-MET) will protect the enzyme from degradation/im-
mune reactions and therefore overcome the pharmacodynamic limitations for
its use in the treatment of Met-dependent cancers. Pharmacokinetics, pharma-
codynamics, and safety parameters of MGL-loaded RBCs were evaluated in
healthy mice. In parallel, the role of RBC in PLP biosynthesis from exogenous
uptake of PN was investigated in vivo. Finally, we investigated the antitumoral
effect of repeated injections of MGL-loaded RBCs combined with daily intra-
gastric administration of PN in two subcutaneous xenografted mouse models
for human gastric and glioblastoma tumors. The MGL half-life increased
from  24 hours to  10 days when encapsulated in RBC, with no toxicity
reported after one injection of ERY-MET. Following intragastric administration
(3.2 mg/kg), PN was rapidly (15 minutes) converted into PLP within the RBC,
resulting in an increase of MGL activity (holoenzyme). Combining a weekly
single intravenous injection of ERY-MET for 5 days, in associationwith daily PN
supplementation by gavage led to a sustained Met depletion in plasma and
induced a 85% inhibition of tumor growth 45 days following implantation of
glioblastoma cells. In the gastric mouse model, tumor growth was inhibited by
72% at the same time point (45 days).This study clearly demonstrated that en-
capsulation of MGL in erythrocytes both strongly improved the half-life and
contributed to provide active cofactor. In parallel, repeated injections of ERY-
MET were effective against tumor growth in mouse models. Thus, due to the
RBC intrinsic characteristics, ERY-MET represents a new promising treatment
against a broad scope of cancers that rely on Met metabolism.
#2135 Selectivity and specifıcity of engineered T cells expressing KITE-
585, a chimeric antigen receptor targeting B-cell maturation antigen
(BCMA).Gregor B. Adams, Jun Feng, AtefehGhogha, ArmenMardiros, Ruben
Rodriguez, Tassja J. Spindler, JedWiltzius, Tony Polverino.Kite Pharma, Santa
Monica, CA.
Background: Immunotherapy has provided treatment options for cancers
that are otherwise refractory to standard approaches. One such technique is to
use adoptive transfer of engineered autologous T cells expressing a chimeric
antigen receptor (CAR) directed against a tumor antigen. The effıcacy of CART
cells directed against hematologicalmalignancies, particularly CD19-expressing
B cell leukemia and lymphomas, has been demonstrated in multiple clinical
studies. The success of this approach has prompted development of CAR T cells
directed to different tumor antigens for other tumor types. To ensure the selec-
tivity and specifıcity of the CAR T cells against their intended target, screening
methods need to be employed. Multiple myeloma is an incurable malignancy of
plasma cells. B-cell maturation antigen (BCMA), also known as tumor necrosis
factor superfamily member 17 (TNFRSF17) is nearly ubiquitously expressed on
multiple myeloma cells, plasma cells and subsets of mature B cells. Methods: In
order to screen for the specifıcity of novel CAR T cells directed against BCMA,
we utilized a cell microarray platform developed by Retrogenix. In this screen,
approximately 4500 humanplasmamembrane proteins (representing up to 75%
of the humanplasmamembrane proteome) are individually expressed in human
HEK293 cells. Fluorescently labeledCARTcells, which showed cytolytic activity
againstMMcell lines expressing BCMA, were applied to the cell microarray and
specifıc binding of the CAR T cells to target cells was determined. Results: Pri-
mary hits were sequenced to confırm identity and secondary specifıcity screens
were performed on the identifıed hits. Specifıc binding of bothmock transduced
and BCMA CAR transduced T cells were confırmed for different plasma mem-
brane proteins expressed from the HEK293 cells. These included known T cell
interactors, such as ICOSLG,CD244 andCD86, where binding is proposed to be
independent of CAR expression. Subtracting the hits of the mock transduced T
cells from the BCMA CAR T cells demonstrated specifıc binding of the CAR T
cells to BCMA. Utilizing the fully human IgGs directed against BCMA from
which the single-chain variable fragments (scFvs) of the CARs were derived, we
further confırmed specifıc binding to BCMA in additional secondary screens.
Additionally, a lack of off-target binding of the fully human IgGs to normal
tissue was demonstrated in a tissue cross reactivity screen. Conclusions: These
studies highlight the tractability of this cell microarray approach for determin-
ing the specifıcity of novel CAR constructs expressed in T cell. Demonstrating
the selectivity and specifıcity of anti-BMCA CAR T cells further supports the
progression of KITE-585 towards Phase 1 clinical studies in MM patients.
#2136 Inhibiting cancer growth by targeting the TNFR2 oncogene with
TNFR2 antagonistic antibodies.Heather Torrey, John Butterworth, Toshiyuki
Mera, Yoshiaki Okubo, Limei Wang, Danielle Baum, Audrey Defusco, Sara
Plager, SarahWarden,DanielHuang, EvaVanamee, Rosemary Foster, Denise L.
Faustman. Massachusetts General Hospital & Harvard Medical, Charlestown,
MA.
Background: Although antibody targeting of the HER2 oncogene represents
an outstanding clinical treatment and a success story showing direct cancer
killing with antibodies, many oncogenes are intracellular and are not expressed
broadly, whether on a single or multiple tumor types. The recently discovered
TNFR2 oncogene is broadly expressed on many human tumors. Colon cancer
cells, multiple myeloma cells, renal cell carcinoma cells, Hodgkin’s lymphoma
cells, ovarian cancer epithelial cells and cutaneous non-Hodgkin’s lymphoma
cells can aberrantly express the TNFR2 receptor as an oncogene for growth. For
non-cutaneous T cell lymphomas, the genetic basis of the TNFR2 deregulation
has recently been tied to constitutive overexpression of TNFR2 from frequent
gene duplications or cytoplasmic TNFR2 mutations that confer constitutive
agonism, i.e. tumor expansion. These features make TNFR2 an advantageous
molecular target for direct tumor targeting. Methods: We designedmonoclonal
antibodies to target the TNFR2 oncogene and directly kill human tumor cells.
TNFR2-directed antibodies were screened for their ability to induce the death of
rapidly growing tumor cells, such as ovarian cancer cells (i.e., OVCAR3). Re-
sults: Novel dominant anti-TNFR2 antibody candidates (TNFR2 antagonistic
antibodies) did not require Fc binding for activity, expressed dominance over
TNF-mediated agonism, and hampered intracellular NF-KB activation and
phosphorylation obligatory for TNFR2 signaling and cell growth of tumor cells.
Even low doses of TNFR2 antagonists rapidly and directly killed TNFR2 onco-
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gene-expressing ovarian cancer cells. Examination of the structural biology of
these dominant TNFR2 antagonist antibodies uncovered a unique and stabiliz-
ing TNFR2 receptor formation, anti-parallel dimeric TNFR2, which inhibits
intracellular signaling, cannot bind TNF, cannot be cleaved to create soluble
TNFR2 and is exponentially more active on the dividing cells of cancer. Conclu-
sions: TNFR2 is a unique and broadly expressed human oncogene that can
potentially be targeted to directly stop the growth of cancer cells (including
ovarian cancer cells) by antibody-induced cell death. The creation of dominant
TNFR2 antagonism provides a unique, non-signaling complex that has impli-
cations for the therapeutic targeting of TNF superfamily receptors, especially
TNFR2.
#2137 JAK2 as a novel therapeutic target in anaplastic thyroid cancer.
Nicole C. Pinto,1 Kara Ruicci,1 Stephenie Prokopec,2 Karlee Searle,1 Matthew
Lowerison,1 John Yoo,1 Kevin Fung,1 Danielle MacNeil,1 Hon S. Leong,1 Ales-
sandro Datti,3 Paul C. Boutros,2 JohnW. Barrett,1 Anthony C. Nichols1. 1West-
ernUniversity, London,Ontario, Canada; 2Ontario Institute for Cancer Research,
Toronto, Ontario, Canada; 3Lunenfeld-Tanenbaum Research Institute, Toronto,
Ontario, Canada.
Introduction: Thyroid carcinoma is the most common endocrine malig-
nancy. Anaplastic thyroid cancer (ATC) is rare (1.3%) and represents arguably
themost lethal humanmalignancy with 1-year survival rates of only 10%. There
are currently no effective treatments for themajority of patients, highlighting an
urgent need for novel therapeutics tomanage this disease. Objective: To validate
the functional importance of JAK2 as a therapeutic target in ATC. Methods: In
this study, we have used siRNA knockdown to interrogate the JAK2 signaling
pathway as a therapeutic target in ATC. We investigated the mechanism of
action and cell death, and assayed formigration and invasion, in vitro. The chick
chorioallantoic membrane (CAM) model was also utilized for drug testing,
whereby 1x106 Cal62 ATC cells were on-planted to the chick embryo mem-
brane. Two days post on-plant, CAM models were treated with the vehicle
(DMSO) or lestaurtinib to measure outcomes including tumor volume and vas-
cularity. Results: We identifıed the JAK2 inhibitor lestaurtinib as an inhibitory
agent controlling cell line proliferation at submicromolar mean inhibitory con-
centrations. Immunoblotting revealed the inhibition of phosphorylation of the
downstream signaling molecule STAT5 in a dose-dependent manner. Treat-
ment of Cal62 cells resulted in a decrease in cell migration using the scratch-
wound assay. The anti-proliferative effective of lestaurtinib did not cause apo-
ptosis, autophagy or cell senescence. CAM models treated with a 4 uM dose of
lestaurtinib showed a signifıcant decrease in both tumor volume and vascularity.
Conclusions: Lestaurtinib was found to provide potent control of ATC cell pro-
liferation and migration, and was also found to decrease tumor growth and
vascularity in a CAMmodel. Knockout studies are underway to confırm that the
anticancer effect of this drug is indeed mediated through JAK2 signaling. If
validated, JAK2 represents a novel therapeutic target for the treatment of aggres-
sive thyroid cancers.
#2138 Tumor treatment fıelds downregulate the BRCA1/FA pathway
genes leading to reduced DNA repair capacity, the inhibition of mitophagy
and enhanced cell death. Narasimha Kumar Karanam, Lianghao Ding, Brock
Sishc, Debabrata Saha, Michael D. Story.UT SouthwesternMedical Center, Dal-
las, TX.
The application of new physical cancer treatment modality utilizing alternat-
ing electric fıelds termed tumor treatment fıelds (TTFields) has revolutionized
the treatment of recurrent andnewly diagnosed glioblastoma. This non-invasive
exposure to low-intensity, intermediate frequency, alternating electric fıelds to
the region of the tumor has resulted in a signifıcant increase in overall survival
when compared to standard therapy with very minimal side effects. Clinical
trials are recruiting or ongoing at additional tumor sites including lung, pancre-
atic, and ovarian cancer. The primary mechanism of TTField cell killing is
thought to be the disruption of mitosis; however, other potential mechanisms
are under investigation. Using a panel of fıve NSCLC cell lines we found that
TTFields treatment alone inhibits cell proliferation, and decreases survival,
though the degree of inhibition varies between cell lines. To understand the
molecularmechanisms underlying the biological effects of TTField exposure we
studied temporal gene expression changes in the NSCLC cell lines after TTField
treatment. We observed that most differentially expressed genes are part of cell
cycle and proliferation pathways which is in agreement with earlier fındings.
Interestingly we found that the expression of BRCA1DNA damage repair path-
way geneswere signifıcantly downregulated (P 0.05) uponTTField treatment.
We confırmed the downregulation of BRCA1/FA pathway proteins by western
blot. When examining the nuclear role of the BRCA1/FA pathway genes we
found that TTField treatment slowed the repair of ionizing radiation-induced
DNA damage compared to radiation alone which is evident by an increased
number ofDNAdouble strand break repair foci at any given time.Moreover, we
found that TTField treatment increased the incidence of chromatid aberrations.
We also examined the newly identifıed BRCA1/FA pathway genes cytosolic role
inmitophagy where we observed alterations inmitophagy related gene (PINK1,
OSCP1, ATP5 and DAPIT) expression and confırmed the same at the protein
level by western blot. We hypothesized that TTFields disrupt the clearance of
damagedmitochondria due to the downregulation of BRCA1/FA pathway play-
ers, causing an imbalance in oxygen metabolism leading to the production of
high levels of radical oxygen species (ROS) and as a result, cell death. Using
CellROX dye we found that TTField treatment did result in increased ROS
production suggesting a newmechanism of action for TTField exposure. Novel
chemotherapy agents, particularly PARP inhibitors, in combination with DNA
damaging agents like radiation and TTFields may be advantageous through the
conditional vulnerability of down-regulated BRCA1.
#2139 The effects of cyclodipeptide on the transport of doxorubicin and
its cytotoxicity on tumor cell. Ikumi Sugiyama, Yasuyuki Sadzuka. Iwate Med-
ical Univ. School of Pharmacy, Shiwa-Gun, Japan.
Purpose: Chemotherapy using antitumor agents plays an important role in clin-
ical cancer therapy.Amongthe treatments involvingantitumoragents, theenhance-
ment of antitumor activity was observed by combined chemotherapy. We have
shownpreviously that some amino acids included theanine, taurine and anserine et
al. as food components, increased doxorubicin (DOX) induced antitumor effect in
vitro and in vivo. These effects by combined amino acids have depended on the
increased DOX concentration in the tumor cells. Furthermore, these suppressions
of DOX efflux by theanine and taurine were caused by the inhibitions of glutamate
transporter and taurine transporter, respectively. The effect of anserine on DOX
influxmight connectwithdipeptide transporter.Thus, other aminoacidandunique
peptidesmayact toDOXtransport. In this study, the effects of cyclodipeptideon the
transport of DOX and its cytotoxicity on tumor cell were clarifıed.Methods: Cyclo-
leucine-proline (cyclo-Leu-Pro), cyclo-phenylalanine-proline (cyclo-Phe-Pro) and
cyclo-glycine-proline (cyclo-Gly-Pro) as cyclodipeptide was used in this study. In
transportofDOX,DOXinfluxor effluxwasdeterminedwithcombinedcyclodipep-
tide inM5076 ovarian sarcoma cells or P388 leukemia cells. DOX concentration in
tumor cell wasmeasured using spectrofluorometer (Ex. 470 nm, Em. 580 nm). The
cytotoxic study of DOX with combined cyclodipeptide was performed using
WST-8. Results and Discussion: Cyclo-Phe-Pro and cyclo-Gly-Pro did not affect
DOX influx and efflux inM5076 ovarian sarcoma cells and P388 leukemia cells. By
combined cyclo-Leu-Pro, DOX influx into both M5076 ovarian sarcoma cells and
P388 leukemia cells changed, compared to that of DOX only group. Into M5076
ovarian sarcoma, cyclo-Leu-Pro had strong effect in increased DOX influx in par-
ticular.And cyclo-Leu-Pro showed a tendency to suppressDOXefflux fromM5076
ovarian sarcoma. In this studies of influx and efflux, concentrationof cyclo-Leu-Pro
existed optimum amount for increased DOX concentration in tumor cells. It is
expected that cyclo-Leu-Pro induces the increment of DOX concentration in the
tumor in vivo. DOX had the cytotoxic effects on M5076 ovarian sarcoma cells or
P388 leukemia cells in culture. The combined cyclo-Leu-Pro with DOX increased
cytotoxic effect, compared to that in the DOX alone group. In conclusion, cyclo-
Leu-Prohas increased effect onDOX influx and inhibited effect onDOXefflux, and
DOX induced cytotoxicity. It is expected that the combined cyclo-Leu-Pro will im-
prove cancer chemotherapy byDOX.Moreover, cyclo-Leu-Promay be help to pre-
vent adverse effect since it will be able to decrease DOX dose.
#2140 Understanding molecular mechanisms underlying heme function
in non-small cell lung cancer cells. Sagar Sohoni, Chantal Vidal, Li Zhang.
University of Texas at Dallas, Richardson, TX.
Heme is a centralmolecule formitochondrial respiration and for all processes
involved in oxygen utilization.Heme serves as a prosthetic group or as a cofactor
for a number of oxidative phosphorylation enzymes and other oxygen-utilizing
hemoproteins. Heme directly regulates the synthesis, translocation and assem-
bly of these enzyme complexes. Most, if not all, human cells can synthesize and
uptake heme from the circulation. A number of epidemiological studies have
shown that high heme intake is associated with increased risk of cancer, includ-
ing lung cancer. To assess the status of hememetabolism in lung cancer cells, we
performed a series of experiments in non-small-cell lung cancer (NSCLC) cell
lines such as HCC4017, H1299, A549, H2009, H1395, H460 and Calu-3. We
then compared results with an immortalized normal lung cell line, HBEC30KT
and observed signifıcant increase in rates of heme synthesis and heme uptake in
NSCLC cells compared to HBEC30KT. Previous studies carried out in our lab
showed intensifıed mitochondrial respiration and increased levels of heme and
hemoproteins in NSCLCs. We examined the effect of heme depletion on mito-
chondrial biogenesis and function. We observed that mitochondrial functions
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such as ATP production, NAD/NADH ratios and ROS production are also af-
fected by heme depletion. Proteins involved in mitochondrial biogenesis are
signifıcantly affected when cells are grown in heme depleted medium. Studies
are currently underway to check how heme depletion affects the interactions of
various transcription factors involved inmitochondrial biogenesis and function.
#2141 Development of a novelmiR-129mimic with enhanced therapeutic
potential for treatment of resistant colorectal cancer.AndrewT. Fesler,1 Ning
Wu,1 Hua Liu,2 Jingfang Ju1. 1Stony Brook University, Sound Beach, NY; 2Stony
Brook University, Stony Brook, NY.
Treatment of advanced stage colorectal cancer remains a clinical challenge
associated with resistance to fluoropyrimidine based chemotherapy. There is an
urgent need to discover and develop new strategies to enhance treatment effı-
cacy in order to improve outcomes for these patients. Non-coding microRNAs
(miRNAs) have important functions as oncogenes or tumor suppressor genes in
the regulation of cancer development and progression. Recently, miRNAs have
emerged as potential therapeutic options. We have previously identifıed miR-
129 as a tumor suppressor miRNA and potential therapeutic candidate in colo-
rectal cancer. The expression of miR-129 is progressively lost in colorectal can-
cer patients and is an important regulator of apoptosis through the targeting of
genes such as BCL-2. miR-129 was also found to enhance 5-flurouracil (5-FU)
cytotoxicity in vitro and in vivo. To further developing miR-129 based novel
therapeutics in colorectal cancer, we have designed a modifıed version of miR-
129 to enhance stability and effıcacy. The miR-129 mimic is signifıcantly more
potent in inhibiting proliferation of a panel of colon cancer cell lines than the
native miR-129 precursor, with 79% reduction by miR-129 mimic compared to
38% for native precursor. ThemiR-129mimic induces profound cell cycle arrest
at the G1/S checkpoint. The G1/S ratio increased 3.8 fold compared to control
when cells were transfectedwithmiR-129mimic.We also demonstrated that the
miR-129 mimic retains its target specifıcity to BCL-2, TS and E2F3. The thera-
peutic potential of miR-129 mimic was demonstrated in vivo mouse colon tu-
mor models as a potent inhibitor of tumor growth and metastasis. As a result,
miR-129 mimic has a great potential to be further developed as a novel thera-
peutic drug for treatment of advanced colorectal cancer.
#2142 Role of TRAIL signaling through the development of carcinogen-
induced colorectal cancer. Yumin Oh,1 Seulki Lee,1 Kang Choon Lee2. 1Johns
Hopkins School ofMedicine, Baltimore,MD; 2SungkyunkwanUniversity, Suwon,
Republic of Korea.
TNF-related apoptosis-inducing ligand (TRAIL/APO-2L) is a death ligand that
can induce apoptosis by its cognate death receptors (DRs). Due to its unique ability
to selectively induce DR-mediated apoptosis in cancer cells while showing no ap-
parent toxicity to normal cells, the rhTRAIL has been actively studied for cancer
therapy.Clinical studies of TRAIL revealed a broad tolerability in humans but failed
to demonstrate a robust therapeutic benefıt in oncology. The main factors respon-
sible for the disappointing results of TRAIL used in cancer patients are 1) its short
half-life (less than 30 min in humans) and 2) heterogeneous primary cancers are
generallyTRAIL-resistant.Toovercome the short half and lowpotencyofTRAIL in
vivo, we have developed an engineered PEGylatedTRAIL (TRAILPEG). PEGylation
is a gold standard to extend the half-life of protein drugs and a highly effıcient
commercial strategy. While investigating the improved therapeutic potential of
TRAILPEG incolitis-associatedcancer (CAC),wevalidated thatTRAILPEGcaname-
liorate an inflammatory bowel disease (IBD), the high risk for CRC. Therapeutic
effıcacy of systemically administered long-acting TRAIL was validated in vivo in
IBD and CAC animal models showing an anti-inflammatory and anti-cancer ef-
fects. Dimethylhydrazinemetabolite azoxymethane (AOM) used to induceCAC in
A/Jmice, while a chronic inflammationmodel of colitis/IBDwas inducedwithDSS
without the AOM.Most of the mice administered with AOM/DSS developed ade-
nocarcinomaonthedistalpartof thecolon,but thenumberof adenocarcinomasper
colon was signifıcantly lower in the TRAILPEG treated mice than in the vehicle-
treated groups. The shortening of the colon length, a measurable characteristic of
colitis severity was more recovered in mice treated with TRAILPEG compared to
disease control. The TRAILPEG treatment signifıcantly decreased the number of
large neoplasms in total tumor and led to an over 3040% reduction in the total
tumors. Inaddition, the symptomsof rectalbleeding in theAOM/DSSmicewas rare
to detect. The elevated MPO activity was signifıcantly suppressed by TRAILPEG
treatment. In parallel, we found that TRAILPEG treatment resulted in the activation
of Caspase-8 and decrease of phosph-STAT3 suggesting the dual roles of TRAIL
signaling for apoptosis and anti-inflammation bywestern blotting. ThemRNA lev-
els of inflammatory cytokines including of IL-6, IL-17, MCP-1, ICAM-1, and
TNF-were recovered by TRAILPEG in theAOM/DSSmodel. Our studies demon-
strated that TRAILPEG could effectively treat IBD and CAC in AOM/DSS mice
model. Themechanisms involved in this effect of TRAILPEG on IBDandCACwere
associated with an increase of cell death, as well as, intervention inflammatory re-
sponses.
#2143 Occupational exposure to automobile exhaust fumes: Genotoxic-
ity, clastogenicity and cell growth assessment inE. coliPQ37 andAllium cepa
models. Solomon Eduviere Owumi, Michael A. Gbadegesin, Nkemdilim Anya-
oku, Oyeronke A. Odunola. University of Ibadan, Ibadan, Nigeria.
Epidemiological studies have established links between occupational expo-
sures to automobile exhaust fumes (AEF) and lung cancer, the propensity for
systemic toxic responses. Street hawking and begging between automobiles, on
various highways in Nigeria is on the increase. This occupational hazard is
further worsen by dire economic recession in Nigeria, and growing population
with limited prospect of improving their economic situation. Ages of vulnerable
population ranges: 4 to 60yrs, exposure to AEF and susceptibility to health haz-
ardmaybe age related.We examined the effect of AEF exposure on E. coli PQ37
deoxyribonucleic acid (DNA)damage, cell growth and chromosomal aberration
in Allium cepa. The effective concentration of AEF was determined as EC50:
0.43mg/ml from A. cepa root length growth against AEF concentrations. Fur-
thermore, A. cepa exposed to AEF at EC50 (0.43mg/ml), EC25 (0.108mg/ml) and
EC10 (0.043mg/ml) for 12, 24 and 48hrs mitotic index and chromosomal aber-
ration were evaluated at various endpoints. Chromosomal abnormalities were
observed in dividing cells and decreases inA. cepa cell growth occurred dose and
time dependently. Exposure of E. coli to AEF (EC100, EC50, EC25, EC10) resulted
in DNA damage (SOS inducing potency (SOSIP) with increasing concentration
of AEF and compared to the positive control 4- nitroquinolone oxide (4-NQO).
Decreases in the SOSIP (at EC200) indicate a threshold beyondwhich E. coli SOS
response genemay have been extensively damaged to produce a response. Taken
together we conclude that constituents of AEF are genotoxic in E. coli, induce
chromosomal aberration and increases cell growth in A.cepa. We speculate on
the possibilities of toxic health outcomes including carcinogenesis in humans
persistently exposed to AEF fumes either occupationally or by any other means
as observed in both street hawkers and beggars in Nigeria.
#2144 Anovelmethod for high-throughput discovery of neo-antigens and
corresponding T-cell receptors. Songming Peng,1 Jesse Zaretsky,2 Michael T.
Bethune,1 Alice Hsu,1 David Baltimore,1 Antoni Ribas,2 James Heath1. 1Califor-
nia Institute of Technology, Pasadena, CA; 2UCLA, Los Angeles, CA.
Immunotherapies that boost the ability of endogenous T cells to destroy can-
cer cells have demonstrated therapeutic effıcacy in several humanmalignancies.
Cytotoxic T cells actively recognize peptide antigens, which are displayed on
major histocompatibility complexes (MHCs) on the surface of the malignant
cells, to play a central role in cancer immunotherapy. However, effıcient meth-
ods for identifying the tumor antigens and the correspondingT cell receptors are
still limited. We report here a DNA-barcode nanoparticle and microfluidics-
based method to sort and enumerate neoantigen-specifıc T cells, at an unprec-
edented level of sensitivity. The method also permits the matching of a single
neoantigen to a specifıc CD8 T cell with the TCR a/b gene sequence. The
resultant information informs an immunotherapy regimen that is specifıc for
that patient, which can be used to custom-design effective ACT therapies.
#2145 Regulation of YAP1 during hypoxia and its novel role in vascular
mimicry and angiogenesis. Namrata Bora Singhal, Srikumar Chellappan. H.
Lee Moffıtt Cancer Center and Research Institute, Tampa, FL.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mor-
tality. As in other solid tumors, angiogenesis is necessary for the growth and pro-
gression of NSCLC. Vascular mimicry is a phenomenon in which non-endothelial
tumor cells form angiogenic vascular structures. We have shown in the past that
NSCLCcancer stem-like cells (CSCs) have unique ability to undergo vascularmim-
icry. Thepresent study shows that transcriptional co-activatorYAP1, the oncogenic
component of the Hippo pathway, enables the NSCLC CSCs to form angiogenic
tubule-like structures in matrigel. Inhibition of YAP1 or depletion of YAP1 sup-
pressed vascular mimicry of CSCs as well as angiogenic tubule formation by
HUVECs inmatrigel as well as in a fıbrin gel bead assay (FIBA) assay. The NSCLC
CSCswere found to have highermRNAexpression ofVEGF receptor II (KDR) and
Angiopoietin-2 (AngPT-2)anddepletionofYAP1reduced theexpressionofVEGF,
KDR and AngPT-2 mRNA; these promoters were induced by YAP1 in transient
transfection assays, suggesting a possible molecular mechanism by which YAP1
regulates angiogenesis. Hypoxia is a strong inducer of tumor angiogenesis, cancer
progression and metastasis. Our experiments showed that NSCLC cells grown in
hypoxic conditions or treated with hypoxia mimetic DMOG have higher YAP1
mRNA and protein expression. However, such a change was not observed in the
expression of YAP1orthologue, TAZ, nor in the canonicalHippo pathway proteins
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like LATS1&2, Mst1&2, Sav or Mob. We identifıed a novel regulation of YAP1 by
prolyl hydroxylase PHD2, which is mainly known to regulate HIF1. PHD2 was
found tohydroxylateproline residue(s) inYAP1 ina regionbetweenaa284 toaa289
as seen by mutational analysis. YAP1 was found to directly bind to PHD2 and
depletion of PHD2 or treatment with DMOG which is an inhibitor of prolyl hy-
droxylases, elevatedYAP1protein levels in thenucleus. Further,YAP1was found to
associate with HIF1 as detected by co-immunoprecipitation experiments and
could enhance HIF1-mediated induction of the VEGF promoter. Proximity liga-
tion assays performed on TMA showed enhanced YAP1 and HIF1 interaction in
lung tumor tissues compared to normal cells. Our data suggest a novel regulation of
YAP1 in hypoxic environment that supports angiogenesis and tumor growth.
#2146 Expression of SLC22A23 gene in laryngeal carcinoma. Nur Buyru,
Seda Ekizoglu, Emin Karaman, Turgut Ulutin. Istanbul University, Istanbul,
Turkey.
Laryngeal squamous cell carcinoma (LSCC) accounts for approximately 30-
40% of head and neck cancers. Although tobacco and alcohol consumption are
considered the major risk factors for LSCC, various genetic and epigenetic fac-
tors have also been associated with LSCC development and progression. Since
early detection and diagnosis of LSCC can greatly increase the chance of a suc-
cessful treatment and survival, several studies have addressed the identifıcation
of target genes involved in LSCCpathogenesis. In this studywe aimed to identify
differentially expressed genes involved in the pathogenesis of LSCC using the
Genefıshing technique. As a result of this investigation we identifıed the
SLC22A23 gene as one of the differentially expressed gene. Solute carriers (SLC)
comprise the largest family of membrane transport proteins withmore than 300
members which have been divided into 52 families. Themain functions of these
proteins is to transfer a wide range of substrates such as amino acids, lipids,
inorganic ions, peptides, saccharides, metal ions, proteins, xenobiotics and
drugs. It is well known that cancer cells need extra metabolic requirements
during rapid cell cycles. One of the known functions of the SLC proteins is to
facilitate the uptake of nutrients and removal of metabolites. SLC22A23 (solute
carrier family 22, member 23) belongs to the SLC family of organic ion trans-
porters that are responsible for the uptake or excretion of many compounds
including drugs, toxins and endogenous metabolites in a variety of tissues.
SLC22A23 is expressed in various tissues but no substrates or functions have yet
been identifıed for SLC22A23. Altough the exact function is unknown, single-
nucleotide polymorphisms which are located in the SLC22A23 gene have been
associated with inflammatory bowel disease, endometriosis-related infertility
and the clearance of antipsychotic drugs. On the other hand, SLC22A23 was
identifıed as a prognostic gene to predict the recurrence of triple-negative breast
cancer. In this study, to confırm the GeneFishing assay data, we investigated
expression of the SLC22A23 gene in laryngeal tissue samples obtained from 83
patients by quantitative RT-PCR.We detected statistically signifıcant upregula-
tion of the SLC22A23 mRNA in laryngeal tumor tissues (55.4%) (p0.001).
However, no signifıcant correlation was found between SLC22A23 expression
and clinicopathological parameters including age, sex, stage, histological grade
and smoking (p0.05). To understand the association between the SNPs in
SLC22A23 and LSCC we also investigated the frequency of different genetic
variants (rs4959235, rs6923667, rs9503518). 77.2% of patients were homozygote
for the rs9503518-AA genotype and %52.2 of these patients had increased
SLC22A23 expression (p0.046). Our results indicate that there is a clear need
for further studies investigating the SLC22A23 gene to identify its exact function
and way of action in LSCC.
#2147 IDH1mutation-inspired-ketoglutaric acidmimics for epigenetic
therapy of higher grade gliomas. Hanumantha Rao Madala, Surendra Reddy
Punganuru, Kalkunte S. Srivenugopal. Texas Tech Univ. Health Sciences Ctr.,
Amarillo, TX.
Mutations at the active site of isocitrate dehydrogenase 1 gene (IDH1; R132H)
occur at a high frequency (70%) early in the oncogenesis of lower grade ma-
lignant gliomas, and result in a dramatic accumulation of the oncometabolite
D-2 hydroxyglutarate ( D-2HG), that effectively replaces the normal metabolite
-ketoglutarate (-KG) in cell physiology. Surprisingly, IDH1 mutations be-
stow superior therapeutic responses to alkylating agents and better patient sur-
vival. D-2HG, effectively competes with -KG and potently inhibits various
dioxygenase reactions, including the TET1, TET2 DNA -demethylases and his-
tone demethylases (5m-cytosine to 5-OH cytosine, H3-K-meX to H3-K-meX-1)
thereby, re-shaping and reprogramming the epigenetic landscape, and conse-
quent transcriptional silencing; the DNA repair protein O6-methlguanine DNA
methyltransferase (MGMT), which confers drug resistance is one major target
for such repression.As a novel and innovative strategy of turning the tide against
GBMs by exploiting the mechanistic aspects of the oncometabolite, we hypoth-
esized that D-2HG and-KG derivatives that can replace the natural metabolite
in epigenomic dioxygenase reactions will serve as potent anti-glioma drugs ei-
ther by themselves or in combination with the alkylating agents. To this end, we
fırst synthesized a D-2HG diethyl ester to enhance its cellular uptake and tested
its effects on four human brain tumor cell lines (DAOY, T98G, SF188 and
UW18). This compound, at 5-10mMand 24 h treatments, moderately inhibited
the DNA repair activity of MGMT, increased temozolomide cytotoxicity by 1.5
to 3-fold, and induced histone H3-methylations as determined by western blot
analyses. To increase the potency and design better compounds mimicking the
oncometabolite and validate its impact on epigenesis, we synthesized a 2,4-
dimethyleneglutaric acid (DMG), a -KG mimic with methylene groups in-
serted at the C2 and C4 positions. The hydrophobic DMG ester, by itself, was
cytotoxic with IC50 values up to 500Magainst brain tumor cell lines, however,
when combined at 100 Mwith TMZ resulted in a great synergistic cell killing
(generally-9 fold, but 28-fold withUW-18GBM cells). 0.25mMDMG inhibited
the cellularMGMTactivity by80%, induced degradation of TET1 protein and
highly increased the methylation levels of histones (H1K25me1, me2 and
H2BK25me2). Currently, experiments to determine the BBB-penetrance of
DMG, its ability to induce genomic andMGMT-specifıcmethylations in glioma
cells and GBM regression in intracranial xenograft models developed in nude
mice are underway. Collectively, these data reveal that acute treatments of-KG
analogs can alter the cellular epigeneticmakeup in amanner ascribed toD-2HG,
and open up the much-needed novel and exciting avenues of oncometabolite
therapy for brain tumors (supported by CPRIT grants RP130266&RP170207 to
KSS).
#2148 Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and con-
tributes to its anti-cancer effects. Wen Zhang, Kin Yip Tam. University of
Macau, Macau, China.
In cancer cells, the metabolic features are signifıcantly different from those of
normal ones, which are hallmarks of several malignancies. Recent studies
brought atypical cellular metabolism, such as aerobic glycolysis or theWarburg
effect, into the scientifıc limelight. Pyruvate dehydrogenase kinase 1 (PDK1), a
key enzyme in the pathway of glucosemetabolism, could inactivate the pyruvate
dehydrogenase (PDH) by phosphorylating it and preserving the substrates py-
ruvate, lactate and alanine for gluconeogenesis. Overexpression of PDK1 could
block the oxidative decarboxylation of pyruvate to satisfy high oxygen demand
in cancer cells, while inhibition of PDK1 could upregulate the activity of PDH
and rectify the balance between the demand and supply of oxygen, which could
lead to cancer cell death. Thus, inhibitors targeting PDK1might be a promising
strategy for cancer treatment by acting on glycolytic tumors while showingmin-
imal side effects on the oxidative healthy organs. Phenyl butyrate (PB) has been
proved to decrease PDH phosphorylation level and increase PDH activity by
inhibiting PDK1 in fıbroblast cells, PDHdefıciency zebrafısh andwild typemice.
PB has also shown effıcacy in many cancers and so far, all of its anti-tumor
activity has been attributed to the histone deacetylase (HDAC) inhibitor mode
of action. As PDK1/PDH controls the critical switch between oxidative phos-
phorylation and glycolysis in cancer cells, PDK1 is a key target in tumor metab-
olism for anti-cancer treatment. We hypothesize that the therapeutic effects of
PB in cancersmight depend on suppressing PDKs and promoting PDH activity,
in addition to its proposed role as HDAC inhibitor. We showed that PB directly
inhibited the kinase activity of PDK1 in a purifıed system. In several different
cancer cell lines, PB reduced the phosphorylation level of PDH, increased the
mitochondrial respiration, decreased glycolysis in cytoplasm, reversed mito-
chondrial hyperpolarization, activated some proteins in apoptotic signalling
pathway and then induced the apoptosis of cells. In summary, this is the fırst
study indicated that PB could exert its anti-cancer effects through inhibiting
PDK1, altering the mitochondrial bioenergetics and inducing apoptosis.
#2149 Unusual expression ofHPRTon the surface of the colorectal cancer
cell lines HT29 and SW620. Evita G. Weagel, Michelle H. Townsend, Michael
D. Anderson, Edwin J. Velazquez, K Scott Weber, Richard A. Robison, Kim L.
O’Neill. Brigham Young Univ., Provo, UT.
Colorectal cancer is one of the most common cancers in the world, affecting
nearly 1.2 million people in the United States alone. The aim of this study is to
investigate the salvage pathway enzyme HPRT as a possible biomarker in two
colorectal cancer cell lines: HT29 and SW620. HPRT is a transferase in the
purine salvage pathway that functions primarily by catalyzing the conversion of
hypoxanthine to inosinemonophosphate and guanine to guanosinemonophos-
phate. Because of its role in proliferation and cell cycle regulation, we hypothe-
sized an increase in HPRT expression within cancer cells, which could poten-
tially lead to presentation on the surface of the cell. HPRT surface localization
was assessed utilizing confocal microscopy, flow cytometry, and scanning elec-
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tron microscopy. These techniques allowed us to visualize HPRT on the plasma
membrane and quantify expression. There was statistically signifıcant expres-
sion of HPRT on the surface of both HT29 and SW620 cells with a 28% and 58%
fluorescent shift in the population, respectively. Confocal microscopy images
revealed overlap between cells stained with a membrane dye and anti-HPRT
FITC antibody, which indicates a direct relationship between HPRT and the
plasma membrane of SW620 cells. To visualize the location of HPRT on the
plasma membrane, anti-HPRT antibodies were labelled with gold and protein
presence was quantifıed using an electronmicroscope, whichmeasured the gold
elemental weight percentage of each sample. When exposed to anti-HPRT an-
tibody, the gold weight percentage of the samples signifıcantly increased with
12.4% gold in SW620 cells and 11.2% gold in HT29 cells, indicating signifıcant
HPRT surface presence. The observed localization ofHPRT to the plasmamem-
brane was variable between the two different cancer cell lines. SW620 cells,
which are faster growing and more aggressive, had signifıcantly higher HPRT
presentation that HT29 cells. These data collectively suggest that HPRTmay be
a possible biomarker target for the identifıcation and possible treatment of colo-
rectal cancer cells.
#2149A CRISPR/Cas9 mutagenesis invalidates a genetic target of clinical
trials in cancer. Ann Lin, Christopher Giuliano, Nicole Sayles, Joan Smith,
Jason Sheltzer. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
TheMaternal Embryonic Leucine Zipper KinaseMELKhas been described as
a genetic dependency in several cancer types, most notably in the highly-aggres-
sive basal subtype of breast cancer; MELK inhibition through the use of both
RNAi and small-molecule approaches appears to block the growth of cancer
types with such dependency. Based on these results, the MELK inhibitor
OTS167 is currently being tested as a novel chemotherapy agent in multiple
clinical trials. Here, however, we report thatmutagenizingMELKwith CRISPR/
Cas9 has no effect on the fıtness of basal breast cancer cell lines or cell lines from
other cancer types. Through seven guide RNAs targeting the kinase and kinase-
associated domains ofMELK,we demonstrate thatmutagenesis ofMELKcauses
no defect in proliferative ability or anchorage independent growth in these can-
cer types. Additionally, cells with mutagenized MELK remain sensitive to
OTS167, suggesting that this drug blocks proliferation through an off-target
mechanism. Finally, the patient tumor gene expression data that initially iden-
tifıedMELKas being signifıcantly upregulated in patientswith poor survival was
reexamined. As MELK is thought to play a role in mitosis, we compared MELK
expression to a set of well-known cell proliferationmarkers and show signifıcant
correlations of MELK with the proliferation genes; this suggests a role of MELK
in representing the mitotic activity of a tumor, rather than possessing a trans-
formative role in itself. In total, our results undermine the rationale for a series of
current clinical trials based on MELK inhibition and provide an experimental
approach for the use of CRISPR/Cas9 in preclinical target validation that can be
broadly applied.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Targeting p53, Apoptosis, and the Cell Cycle
#2150 Oncogenic role of GAEC1 and its potential modulation with p53 in
pathogenesis of colon cancer. Riajul Wahab, Farhadul Islam, Vinod Gopalan,
Alfred King-Yin Lam. Griffıth University, Southport, Gold Coast, Australia.
Introduction: GAEC1 (Gene amplifıed in esophageal cancer 1), is fre-
quently amplifıed and overexpressed in colon cancer tissues. In the present
study, we aimed to unveil the oncogenic potential of GAEC1 in carcinogen-
esis of colon cancer by studying the underlying cellular functions and mo-
lecular interactions by in vitro and in vivo experiments. Method: Transient
overexpression of GAEC1 with pcDNA3.1-GAEC1 and silencing with
GAEC1-siRNA was performed and several downstream assays were done
such as migration, clonogenic and apoptotic assay. Analysis of cell kinetics
was done using flow cytometry and cell counting kit-8 was used for cell
proliferation assay. Immunofluorescence and Western blot assay were used
to determine the expression of different target proteins. Co-immunoprecipi-
tation was used to confırm the protein-protein interaction. For xenotrans-
plantation the severely combined immunodefıcient (SCID) mice (4 groups, 6
in each group) were injected subcutaneously with GAEC1 shRNA and con-
trol shRNA transfected (stable) SW480 and SW48 colon cancer cells. Result:
The overexpression of GAEC1 increased cell proliferation, migration, re-
duced apoptosis in colon cancer cells. Also, these cells showed cell cycle
arrest at the synthetic phase, activation of Bcl-2, K-ras, pAKT proteins as well
as inhibition of p53, PUMA, p21 and BAX proteins. Conversely, knockdown
of GAEC1 reduced cell proliferation, migration, decreased the phosphory-
lation of AKT, and induced apoptosis, G2/M phase arrest and cleavage of
poly (ADP-ribose) polymerase (PARP). Co-immunoprecipitation revealed
GAEC1’s interaction with p53. In addition ectopic over expression and si-
lencing of GAEC1 lead to reciprocal effects of p53 protein expression. More-
over, knockdown of GAEC1 reduced the nuclear translocation of murine
double minute 2 protein (mdm2) indicating that GAEC1 is responsible for
the degradation of p53 through the direct interaction between mdm2-p53 in
nucleus. Furthermore, our in vivo data demonstrate that the loss of GAEC1
inhibits the tumor formation in xenograft model. Conclusion: Collectively
our study demonstrates that GAEC1 exhibits the oncogenic role in colon
cancer by reducing expression of p53 through protein-protein interaction
which leads to the inhibition of PUMA, p21, BAX, and activation of Bcl-2,
K-ras and pAKT protein expression.
#2151 Inhibition of WIP1/PPM1D phosphatase by GSK2830371 po-
tentiates the growth inhibitory and cytotoxic activity of MDM2 antago-
nists (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells.
Chiao-EnWu,1 Arman Esfandiari,1 Yi-Hsuan Ho,1 Colin Shepherd,1 Ahmed
Khairallah Mahdi,1 Erhan Aptullahoglu,1 John Wen-Cheng Chang,2 Penny
Lovat,3 John Lunec1. 1Northern Institute for Cancer Research, School of Med-
icine, Newcastle University, United Kingdom; 2Division of Hematology-On-
cology, Department of Internal Medicine, Chang Gung Memorial Hospital at
Linkou, Chang Gung University College of Medicine, Taoyuan, Taoyuan, Tai-
wan; 3Dermatological Sciences, Institute of Cellular Medicine, Newcastle Uni-
versity, United Kingdom.
Cutaneous melanoma is the most serious skin malignancy. The current
study aimed to investigate the WIP1 inhibitor GSK2830371 and MDM2-p53
antagonists (nutlin-3, RG7388 and HDM201) alone and in combination
treatment in cutaneous melanoma cell lines and explored the mechanistic
basis of these responses in relation to the genotype and induced gene expres-
sion profıle of the cells. A panel of three p53WT (A375, WM35, C8161) and
three p53MUT (WM164, WM35-R5R1, CHL-1) melanoma cell lines were
used. GSK2830371 (10 M) alone had no growth-inhibitory or cytotoxic
effects on the cells, measured by sulforhodamine B (SRB) and clonogenic
assays. In combination treatment GSK2830371 signifıcantly potentiated the
growth-inhibitory and clonogenic cell killing effects of MDM2 inhibitors in
p53WT but not p53MUT melanoma cells, indicating the potentiation worked
in a p53-dependent manner (Table). Western blotting demonstrated
GSK2830371 increased p53 stabilization through Ser15 phosphorylation and
consequent Lys382 acetylation when it was combined with MDM2 inhibi-
tors. These changes were ATM-mediated, shown by reversal with the ATM
inhibitor (KU55933). Furthermore, GSK2830371 was demonstrated to slow
down p53 degradation when de-novo protein synthesis was inhibited by
cycloheximide. In qRT-PCR, nutlin-3 or RG7388 induced p53 transcrip-
tional target genes (CDKN1A, MDM2, BAX, FAS, PUMA, TNFBSF10B,
TP53INP1) and GSK2830371 enhanced the induction in p53WT but not
p53MUT cells. In conclusion, GSK2830371, aWIP1 inhibitor, at doses with no
growth-inhibitory activity alone, potentiated the growth-inhibitory and cy-
totoxic activity of MDM2 inhibitors, by increasing phosphorylation, acety-
lation, and stabilization of p53 in cutaneous melanoma cells in a functional
p53-dependent manner. Further studies in vivo are warranted to investigate
the effıcacy of this combination treatment.
GI50 by sulforhodamine B (SRB) and LC50 by clonogenic assays in p53WT
melanoma cells
Cell lines
GI50
(Mean  SEM) A375 WM35 C8161
GSK2830371      
Nutlin-3 (M) 5.1 0.6 1.5 0.4 8.3 1.5 5.3 1.4 1.7 0.3 1.0 0.5
p value 0.012 0.010 0.049
RG7388 (nM) 228 39 62 2 377 58 169 57 46 0 15 5
p value 0.025 0.028 0.009
HDM201 (nM) 167 25 41 9 165 98 77 59 81 11 49 10
p value 0.0046 0.1048  0.001
LC50 (Mean
SEM)
A375 WM35 C8161
GSK2830371      
Nutlin-3 (M) 2.0 0.9 0.8 0.5 0.5 0.1 0.4 0.1 0.9 0.2 0.4 0.1
p value 0.040 0.0714 0.003
RG7388 (nM) 166 95 54 37 186 78 68 23 50 22 21 10
p value 0.006 0.070 0.026
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GI50 by sulforhodamine B (SRB) and LC50 by clonogenic assays in p53WT
melanoma cells
Cell lines
GI50
(Mean  SEM) A375 WM35 C8161
HDM201 (nM) 198 70 15 4 11 3 8 3 139 85 19 5
p value 0.001 0.1062 0.010
#2152 Protein phosphatase Mg2 and Mn2 dependent 1F promotes
smoking-induced breast cancer by inactivating phosphorylated p53-induced
signals. Li-Ching Chen. Taipei Medical University, Taipei City, Taiwan.
Previously we demonstrated that the activation of 9-nicotinic acetylcholine
receptor (9-nAchR) signaling by smoking promotes breast cancer formation.
To investigate the downstream signaling molecules involved in 9-nAChR-
induced breast tumorigenesis, we used real-timepolymerase chain reactions and
Western blotting to assess expression of protein phosphatase Mg2/Mn2 de-
pendent 1F (PPM1F), a Ser/Thr protein phosphatase, in human breast cancer
samples (n167). Additionally, stable PPM1F-knockdown and overexpressing
cell lines were established to evaluate the function of PPM1F. The phosphatase
activity of PPM1F in nicotine-treated cells was assessed through Western blot-
ting, confocal microscopy, and fluorescence resonance energy transfer. Higher
levels of PPM1F were detected in the breast cancer tissues of heavy smokers
(n7, 12.8-fold) greater than of non-smokers (n 28, 6.3-fold) (**p0.01). In
vitro, nicotine induced PPM1F expression, whereas 9-nAChR knockdown re-
duced the protein expression of PPM1F. A series of biochemical experiments
using nicotine-treated cells suggested that the dephosphorylation of p53 (Ser-
20) and BAX (Ser-184) by PPM1F is a critical posttranslational modifıcation, as
observed in breast cancer patients who were heavy smokers. These observations
indicate that PPM1F may be a mediator downstream of 9-nAChR that acti-
vates smoking-induced carcinogenic signals. Thus, PPM1F expression could be
used for prognostic diagnosis or inhibited for cancer prevention and therapy.
#2153 Elephant p53 (EP53) expression induces apoptosis of human cancer
cells. Lisa M. Abegglen,1 Lauren N. Donovan,1 Genevieve Couldwell,1 Rosann
Robinson,1 CristhianToruno,1MorGoldeder,2 Aleah F. Caulin,3 Katrin P.Guil-
len,1 Bryan E. Welm,1 Carlo C. Maley,4 Avi Schroeder,2 Joshua D. Schiffman1.
1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 2Technion -
Israel Institute of Technology, Haifa, Israel; 3Driver, San Franscisco, CA; 4Biode-
sign Institute and School of Life Sciences, Arizona State University, Tempe, AZ.
The goal of our study was to determine if elephant TP53 (EP53) proteins
contributing to increased apoptosis and possible cancer resistance in elephants
could translate into human cancer cells as a future effective cancer treatment.
We previously reported that elephants have a lower than expected rate of cancer,
20 copies of TP53 (1 ancestral gene with introns [EP53-anc] and 19 retrogenes
[EP53-retro1-19]), and increased p53-mediated apoptosis induced by DNA
damage in elephant cells compared to human cells (Abegglen JAMA 2015). For
the current study, we expressed various EP53 proteins in human cancer cells
with different p53 status, including osteosarcoma (U2-OS, Saos-2), glioblastoma
(T98G), and breast cancer (MCF7). Western blot analysis confırmed EP53 ex-
pression. We compared apoptosis in the human cancer cells transfected/trans-
duced with negative control vectors vs. epitope or protein-tagged EP53 exposed
to doxorubicin (to induce DNA damage). Apoptosis was measured by cell via-
bility, caspase activity, Propidium Iodide/Annexin V staining, and fluorescence
microscopy. We observed a signifıcant increase in caspase activity (normalized
to cell viability) of U2-OS and T98G cells expressing EP53 compared to negative
control treated cells as shown in Table 1, and apoptosis with p21 restoration in
Saos-2. InU2-OS, which overexpressMDM2, EP53wasmore effective at induc-
ing apoptosis compared to human TP53. Taken together, we found that EP53-
anc restored p53-mediated apoptosis and EP53-anc / EP53-retro9 enhanced
p53-mediated apoptosis. These data suggest for the fırst time that EP53 func-
tions in human cancer cells to promote cell death. Ongoing efforts are exploring
the EP53 mechanism of action that leads to increased apoptosis, including ex-
pression of EP53 in additional cancer types (lung, melanoma, colon, prostate,
and others) with a variety of genetic backgrounds to characterize its functional
context. These results support the further exploration of EP53-based cancer
therapeutics.
Table 1: Increase in apoptosis with EP53 expression relative to EP53 empty vector
control cells
Cell Type
TP53
Status
EP53-
anc
EP53-
retro9 Construct
Assay
Results
No
Treatment
(fold difference) P-value
1uM
doxorubicin
(fold difference) P-value
U-2 OS
(osteosarcoma)
WT Apoptosis Apoptosis myc-
EP53-
retro9
Increasein
caspase
relative
tocontrol
1.73 0.0091 1.79 1.7x10^-5
eGFP-
EP53-
retro9
Increase
in
caspase
relative
tocontrol
1.68 6.7x10^-5 2.59 0.0041
eGFP-
EP53-
retro9
Percent
decrease
inGFP
positive
cells
23%
percent
decrease
4.8x10^-5 - -
dyk-
EP53-
anc
Increase
incaspase
relativeto
control
14.22 5.4x10^-7 3.31 1.0x10^-5
dyk-
huTP53
Increase
incaspase
relative
tocontrol
10.9 1.2x10^-7 2.47 5.8x10^-5
MCF7
(breast
cancer)
WT - Apoptosis eGFP-
EP53-
retro9
Cell
deathby
Propidium
Iodide
staining
0.15%
GFP/
surface
area
0.011 - -
T98G
(glioblastoma)
Null Apoptosis No
Apoptosis
dyk-
EP53-
anc
Increase
incaspase
relative
tocontrol
3.07 7.9x10^-9 1.55 2.6x10^-5
myc-
EP53-
anc
Increase
incaspase
relative
tocontrol
3.46 0.00015 1.52 6.8x10^-5
dyk-
huTP53
Increase
incaspase
relative
tocontrol
2.82 1.2x10^-5 1.8 8.6x10^-5
#2154 P53 pathway restoring compound P306 inhibits colorectal cancer
growth. Xiaobing Tian, Shengliang Zhang, Amriti Lulla, wafık S. El-Deiry. Fox
Chase Cancer Ctr., Philadelphia, PA.
We recently reported that P01 is a potent p53 pathway-restoring small mole-
cule that acts through increasing levels of TAp73. Further, it also interferes with
the p73-mutant p53 protein-protein interaction and by downregulation of
Np73 (Tian, Zhang and El-Deiry, abstract# 3830, AACR 2016). P01 is a mem-
ber of the natural products that have been shown to have potent anti-cancer
activity against tumors withmutated p53. Based on the structure of the pharma-
cophore of compound P01, we designed and synthesized new analogs based on
published structure-activity relationship and organic synthesis papers. The
newly synthesized analogs were potent in reducing both short-term and long-
term proliferation in a broad panel of mutant p53 cell lines such as HT29,
SW480,DLD-1,MDA-MB-231andH1975with EC50s in the range of 0.16Mto
0.26 M. We are currently evaluating the anti-cancer effects of three analogs
P301, P304 and P306, of which only two of these analogs induce TAp73 as
assayed by western blot.We are currently characterizing the analog P306, which
is themost potent compound among them. P306 engages the apoptosis pathway
by upregulation of pro-apoptotic proteins like PUMA, DR5, and BIM and
downregulation of anti-apoptotic markers such as Mcl-1 in a time-and dose-
dependent manner in colorectal cancer cell lines. P306 treatment also down-
regulates both mRNA and protein level of MET and EGFR in HT29 cells that
overexpressMETandEGFR receptors.We are currently investigating themech-
anisms of induction of both PUMA and DR5 in mutant p53 cells and determin-
ingwhether either gene is necessary for the apoptotic effects of P306 in colorectal
cancer cells. Our preliminary data indicates that upregulation of DR5 is through
the ATF4/CHOP pathway post-P306 treatment. It has been reported that Puma
is a target gene of ATF4, CHOP and p73, however, we found that none of them
is responsible for P306-induced upregulation of PUMA in p53 mutated DLD1,
SW480 or HCT116 p53-null cell lines. Thus, our ongoing in vitro studies are
focused on further understanding the mechanism of action of P306 in mutant
p53 cells and potentially exploring combinations with FDA-approved therapies.
We are also in the process of conducting, fırst-in animal studies of P306 as single
agent or in combination with chemotherapy or targeted therapy.
#2155 Small molecule NSC59984 suppresses cancer cell growth under
hypoxia. Shengliang Zhang, Lanlan Zhou, Wafık S. El-Deiry. Fox Chase Cancer
Center, Philadelphia, PA.
Hypoxia is one of the main features of solid tumors, contributes to drug
resistance and is associated with poor prognosis.We have reported that a small-
molecule NSC59984 restores p53 signaling and degrades mutant p53 protein in
cancer cells. We fınd that NSC59984-mediated p53 signaling restoration and
mutant p53 degradation is signifıcantly blocked byNAC, an inhibitor of reactive
oxygen species (ROS), while, further enhanced by BSO, a chemical compound
increasingROS in cells. These results suggest that ROS is a factor required for the
effect of NSC59984 on cancer cells. Cellular ROS is produced by hypoxia in solid
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Targeting p53, Apoptosis, and the Cell Cycle
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017552
tumors. We investigated the effect of NSC59984 on p53 pathway and cell death
in p53mutant colorectal cancer (CRC) cells cultured under hypoxia. NSC59984
increases p53 signaling in p53 mutant cancer cells under hypoxia, as it does
under normoxia. The effect of NSC59984 under hypoxia is blocked by NAC.
Moreover, NSC59984 decreases cancer cell viability in a dose-dependent man-
ner under hypoxia similar to normoxia. Our results suggest that NSC59984
inhibits cancer cell growth under hypoxia. Hypoxia has been known to increase
cancer stem cells in tumors, which is one of the reasons causing drug resistance.
We then evaluate the effect of NSC59984 on the stem cell growth. NSC59984
signifıcantly reduces colonosphere formation of SW480, DLD-1 andHT29 cells.
CRC stem cellmarkers such as CD44 andALDHare decreased in colonospheres
upon NSC59984 treatment, suggesting that NSC59984 inhibits stem cell self-
renewal or/and growth. Our results provide the rationale for administration of
NSC59984 in solid tumors with or without hypoxia and in combination treat-
ment with ROS activators.
#2156 NSC59984 induces mutant p53 degradation via activating ERK2
pathway-MDM2 axis. Shengliang Zhang, Lanlan Zhou, David Dicker, Wafık S.
El-Deiry. Fox Chase Cancer Center, Philadelphia, PA.
Mutant p53 protein is highly expressed in most cancer cells due to its protein
stabilization. Mutant p53 loses wild-type p53 function but gains new oncogenic
functions in driving tumor growth and drug resistance. Depletion ofmutant p53
is an attractive strategy for cancer therapy. We reported a small-molecule
NSC59984destabilizesmutant p53 protein via protein degradation (Zhang et al.,
Cancer Research, 2015). In this study, we demonstrate that the ERK2 pathway
plays a specifıc role in NSC59984-induced mutant p53 degradation via MDM2-
mediated ubiquitination.We observe a sustained-phosphorylation of ERK1/2 in
cancer cells treated with NSC59984. ERK1/2 pathway is negatively regulated by
MKP-1. We fınd that MKP-1 activity is partially inhibited by NSC59984 in a
dose dependent manner in vitro. These results suggest that NSC5998 sustains
ERK1/2 phosphorylation partially via disruption of the feedback-loop between
MKP-1 and ERK2 pathway. Knockdown of ERK2 rescues mutant p53 from
NSC59984-mediated degradation, and inhibits NSC59984-restoration of p53
signaling in mutant p53-expressing cells. On the contrary, the effect of
NSC59984 on the mutant p53 is not inhibited by the blockage of JNK and P38,
two pathways negatively regulated by MKP-1. These results suggest that the
ERK2 phosphorylation is specifıcally required for NSC59984-mediated mutant
p53 degradation. We further fınd that NSC59984 induces ERK2-dependent
MDM2 phosphorylation. The effect of NSC59984 onMDM2 phosphoryation is
partially inhibited by the blockage of ERK2 signaling (via U0126 treatment or
Knockdown of ERK2), not by the attenuation of the JNKpathway. Furthermore,
NSC59984-mediated mutant p53 protein degradation is inhibited by MDM2
knockdown, and enhanced by MDM2 overexpression in cancer cells.
NSC59984-increased ubiquitination of mutant p53 is attenuated by U0126. Our
results suggest that the ERK2 signaling pathway-MDM2 axis is a major deter-
minant of NSC59984-mediated mutant p53 degradation. We further demon-
strate that NSC59984 induces cell death via apoptosis, and NSC59984-induced
cell death is mainly rescued by inhibition of the ERK2 pathway in p53 mutant
cancer cells. Taken together, our results suggest that phosphorylated-ERK2 is an
important factor required for NSC59984-mediated mutant p53 degradation
which may further contribute to NSC59984-induced cell death in cancer cells.
#2157 P73 isoforms regulate cellular survival and response to treatment in
diffuse large B-cell lymphoma.HeshamM. Hassan,1 Michelle L. Varney,2 Pa-
mela A. Althof,2 Gabriel C. Caponetti,3 Kai Fu,2 Dennis D. Weisenburger,4
Rakesh K. Singh,2 Bhavana J. Dave2. 1Assiut University, Egypt; 2Univ. of Ne-
braskaMedical Ctr., Omaha, NE; 3Univ. of Pennsylvania, Philadelphia, PA; 4City
of Hope, Duarte, CA.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of
non-Hodgkin’s lymphoma (NHL) and is curable in more than 60% of the cases.
Despite long-term remission achieved with current therapies, relapse occurs in
almost one-third of the cases. Rearrangements of chromosome locus 1p36 with
ensuing deletion or disruption of TP73, one of the most distally located putative
tumor suppressor genes, is frequent in many NHL subtypes, including DLBCL,
and confers inferior prognosis. Recent reports in normal B-cells and lymphoma
animal models suggest an important role of p73 in B-cell lymphomas; however,
the biological signifıcance of p73 isoforms in DLBCL is not clear. TP73 is a
member of theTP53 family that shares structural homology andhence is capable
of transactivating p53 target genes. We investigated the relationship between
rearrangements of chromosome locus 1p36 and p73 expression and examined
whether differential expression of p73 isoforms (TAp73 and Np73) correlate
with proliferation and apoptosis inDLBCL.Weutilizedmolecular techniques in
conjunction with fluorescence in situ hybridization (FISH) in untreated histo-
logically confırmed DLBCL patient specimens. In our data set, the 1p36 chro-
mosomal locuswas disrupted (mainly heterozygous deletion) in 35%of the cases
and was signifıcantly associated with Np73 expression. Subsequent immuno-
histochemical analysis showed a signifıcant positive correlation between TAp73
and cleaved caspase-3 expression and between Np73 and Ki-67 expression.
Additionally, we observed a negative correlation between TAp73 and the anti-
apoptotic molecules Bcl-2 and Bcl-6. We then performed in vitro studies in
DLBCL cells and modulated the expression of TAp73 andNp73 using expres-
sion vectors and siRNA. TAp73-transfected cells were more susceptible to se-
rum deprivation and doxorubicin treatment, conversely theNp73-transfected
cells were more resistant to serum deprivation and doxorubicin treatment com-
pared to control cells. Thus, rearrangements of 1p36 consequently deregulates
p73 isoform expression in DLBCL. Our data emphasizes the importance of
delineating the functional aspect of genetic alterations and underscores the sig-
nifıcant role of p73 isoforms in DLBCL pathogenesis and treatment.
#2158 Targeted intracellular disruption of oncogenic p53/HDM2 and
p53/HDMX complexes underlies the therapeutic activity of a stapled peptide
drug. Loren D. Walensky, Franziska Wachter, Ann Morgan, Marina Godes,
Gregory Bird. Dana-Farber Cancer Inst., Boston, MA.
The fırst anti-cancer stapled peptide drug has now been advanced to clinical
testing in relapsed human cancers that retain the expression of wild-type p53. A
commonmechanism for cancer cell suppression of wild-type p53 is overexpres-
sion of the negative regulators HDM2 and HDMX, which neutralize p53
through protein interaction. SelectiveHDM2 inhibitormolecules can effectively
reactivate p53 in certain cancers, but the co-expression of HDMX can cause
resistance, highlighting the need for dual HDM2/HDMX targeting. We previ-
ously developed stapled peptides modeled after the p53 transactivation domain
to harness the natural propensity of this alpha-helical motif to engage both
targets with high affınity and selectivity. Here, we demonstrate that ALRN-7041,
a next-generation, clinical-grade stapled peptide, achieves time-dependent cel-
lular uptake and nuclear localization without membrane perturbation, dose-
dependently dissociates p53/HDM2 and p53/HDMX complexes as assessed by
real-time protein interactionmonitoring in live cells, and impairs the viability of
cancer cells bearing wild-type p53 by inducing a surge in p53 protein level.
Applying an unbiased statistical approach to determine which biophysical pa-
rameters dictate the cellular uptake of stapled peptides, we elucidated the design
features of ALRN-7041 that confer intracellular access, providing a roadmap for
generating cell-permeable stapled peptides with on mechanism cellular activity
for clinical translation.We fınd that cancer cells exhibiting a signature ofHDM2,
HDMX, and wild-type p53 co-expression are strikingly susceptible to ALRN-
7041, highlighting the therapeutic potential of dual HDM2/HDMX inhibition
by a cell-penetrant stapled peptide in human cancer.
#2159 A specifıc 17-beta-hydroxywithanolide (LG-02) sensitizes cancer
cells to apoptosis in response to TRAIL and TLR3 ligands. Poonam Tewary,1
Alan D. Brooks,1 Ya-ming Xu,2 Kithsiri E.MWijeratne,2 Leslie A. Gunatilaka,2
Thomas J. Sayers1. 1Leidos Biomedical Research Inc, Frederick, MD; 2The Uni-
versity of Arizona, Tucson, AZ, AZ.
Recent studies have demonstrated a role of toll-like receptor 3 (TLR3) signal-
ing for the initiation of apoptosis in some malignant cells. We have previously
shown that, withanolide E (WE), a 17-hydroxywithanolide (17-BHW) natural
product derived from the medicinal plant Physalis peruviana was capable of
sensitizing tumor cells to tumor necrosis factor-related apoptosis-inducing li-
gand (TRAIL)-mediated apoptosis by reducing cellular levels of the anti-apo-
ptotic protein cFLIP. Animal studies also revealed that WE sensitized human
renal carcinoma cells to apoptosis at concentrations that did not promote apo-
ptosis in normal cells. Thus we further screened a library of 30 natural and
semi-synthetic 17-BHWs for their ability to promote death ligand-mediated
cancer cell death. Among the 30 compounds tested, LG-02 (physachenolide C)
was found to be 4-5 fold more potent thanWE in sensitizing some human renal
carcinoma and melanoma cells to apoptotic cell death in response not only to
TRAIL but also to the synthetic polynucleotide poly (I:C), which is known to
mimic anti-viral responses by activating TLR3 signaling. To date there are no
withanolides known to have this dual apoptosis sensitizing activity. LG-02 and
Poly (I:C) treatment resulted in increased activation of caspase-8, and apoptosis
was blocked by the pan caspase inhibitor zVAD-FMK. Poly (I:C)-driven apo-
ptosis signaling was dependent on endosomal acidifıcation, but independent
of IRF 3 and Interferon / signaling. Molecular studies suggested a role for
changes in the anti-apoptotic proteins cFLIP, IAPs, and Livin on apoptosis
signaling in LG-02 treated cells. Loss of cIAP activity is reported to promote
spontaneous formation of an intracellular death-inducing protein platform
the ripoptosome, that can activate either apoptosis or necroptosis. Immuno-
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precipitation of either the TRAIL death-inducing signaling complex (DISC) or
the Poly (I:C) ripoptosome, demonstrated enhanced levels of FADD and RIP1
and decreased levels of cFLIP in thesemacromolecular apoptosis signaling com-
plexes in LG-02 treated cells. Intratumor administration of LG-02 and Poly (I:C)
in a xenograft M14 melanoma model provided therapeutic benefıt leading to
complete tumor regression in 90 % of the mice as compared to control mice.
Further studies with active 17-BHWs could lead to the identifıcation of more
potent analogues, and novel and common therapeutic targets involved in apo-
ptosis signaling in response to both TNF death receptor family members as well
as TLR3 ligands.Funded by FNLCR Contract HHSN261200800001E
#2160 Novel sulfonamide derivative inhibits JAK2-STAT3 signaling and
induces ROS-mediated apoptosis in colorectal cancer cells. Rehan Ahmad,
Mansoor-Ali Vaali-Mohammed, Omar Al-Obeed, Maha Abdulla. King Saud
Univ. College of Medicine, Riyadh, Saudi Arabia.
Colorectal cancer is a major worldwide health problem owing to its high
prevalence and mortality rate. Developments in screening, prevention, bio-
marker, personalized therapies and chemotherapy have improved detection and
treatment. However, despite these advances many patients with advanced met-
astatic tumors will still succumb to the disease. New anti-cancer agents are
needed for treating advance stage colorectal cancer as most of the deaths occur
due to cancer metastasis. A recently developed novel sulphonamide derivative,
4-((2-(4-(Dimethylamino)phenyl)quinazolin-4-yl)amino)benzenesulfonamide
(3d) has shown to have potent antitumor effect; however themechanism under-
lying the antitumor effect remains unknown. Our study revealed that 3d treat-
ment signifıcantly reduced the viability of human colorectal cancer cells HT-29
and SW620. This is further evidenced by the induction of p53 and Bax, release of
cytochrome c, activation of caspase-9, caspase-7 and caspase-3 and cleavage of
PARP in 3d treated cells. This compoundwas found to have signifıcant effect on
the inhibition of anti-apoptotic proteins, Bcl2, BclxL and XIAP. The results
further demonstrate that 3d inhibited JAK2-STAT3 pathway by decreasing the
constitutive and IL-6-induced phosphorylation of JAK2 and STAT3. 3d further
decreased JAK2- STAT3 target genes like Cyclin D1 and Survivin. Furthermore
3d treatment induced the generation of reactive oxygen species (ROS) in human
colorectal cancer cells. Confırming our observation,NAC signifıcantly inhibited
ROS production, induction of apoptosis, cytochrome c release and PARP cleav-
age. Additionally, treatment with 3d resulted in decreased glutathione (GSH)
levels. The results further demonstrate that 3d inhibited cell migration by mod-
ulating EMTmarkers and inhibiting TGF-induced phosphorylation of Smad2
and Samd3. Collectively these fındings indicate that 3d inhibited JAK2-STAT3
signaling; induced apoptosis via generation of reactive oxygen species and inhi-
bition of cell migration by altering EMT markers and TGF-Smad pathway.
#2161 Pharmacological downregulation of BFL-1 by the BET bromodo-
main inhibitor CPI203 overcomes ABT-199 resistance in MYC/BCL2
double hit lymphoma.Anna Esteve-Arenys,1 JuanGarcia-Valero,1 DavidGon-
zalez,1 Aránzazu Chamorro-Jorganes,1 Vanina Rodriguez,1 IvanDlouhy,2 Itziar
Salaverria,1 Elias Campo,2 Dolors Colomer,2 Antonio Martinez,2 Grzegorz
Rymkiewicz,3 Patricia Pérez-Galán,1 Armando Lopez-Guillermo,2 Gaël Roué1.
1IDIBAPS, Barcelona, Spain; 2Hospital Clinic, Barcelona, Spain; 3The Maria Sk-
lodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw,
Poland.
Double-hit lymphoma (DHL) is a rare subtype of B-cell lymphoma charac-
terized by MYC and either BCL2 or BCL6 chromosomal rearrangements. DHL
cases may have different morphology and are included in the updated 2016
WHO classifıcation as a new category of high grade B-cell lymphoma with rear-
rangements. DHL patients usually undergo a rapidly progressing clinical course
and are poorly responsive to standard chemo-immunotherapy. As a conse-
quence, the prognosis of this entity is particularly poor with a median overall
survival of approximately one year. ABT-199 (venetoclax) is a potent and selec-
tive small-molecule antagonist of BCL-2 recently approved for the treatment of
some lymphoid malignancies. In this study, we demonstrate that single-agent
ABT-199 effıciently displaces pro-apoptotic BAX from BCL-2 complexes but
fails to maintain a signifıcant antitumor activity over time in most MYC/
BCL2 DHL cell lines and primary cultures, as well as in a xenograft mouse
model of DHL. We further identify the accumulation of the BCL2-like protein,
BFL-1, to be a major mechanism involved in acquired resistance to ABT-199.
We show this phenomenon to be manageable by the BET bromodomain inhib-
itor CPI203, since gene expression profıling identifıes BCL2A1 as one of the top
apoptosis-related gene modulated by the compound. Upon CPI203 treatment,
simultaneous downregulation of MYC and BFL-1 at both mRNA and protein
levels further overcomes resistance to ABT-199 both in vitro and in vivo, allow-
ing DHL cultures and tumor xenografts to undergo synergistic caspase-medi-
ated apoptosis. Together, these fındings highlight the relevance of BFL-1 in
DHL-associated drug resistance and support the combined use of BCL-2 antag-
onist and BET inhibitor as a promising therapeutic strategy in patients with
aggressive DHL.
#2162 MEK signaling marks resistance to synthetic lethality induced by
PI3K/Akt and BCL-XL inhibition in PTEN-mutant cancers. Raghav Joshi,
Wenying Ren, Paul Mathew.Molecular Oncology Research Institute, Tufts Med-
ical Ctr., Boston, MA.
Background: Loss of PTEN represents one of the most common disruptions
of tumor suppressor activity in the progression of human neoplasia. There are
no established precision medicine approaches defıned in PTEN-defıcient neo-
plasmswhich include prostate, breast, glioblastoma (GBM) and uterine cancers.
In PTEN-mutant prostate cancer cells, the PI3K/Akt pathway collaborates with
BCL-XL specifıcally, to regulate the apoptotic threshold (Ren, MCR 2016).
Whereas single agent PI3K/Akt inhibitors are ineffective in inducing cell death,
combined inhibition of PI3K/Akt and BCL-XL in PTEN-mutant prostate cancer
cells results in synergistic apoptosis suggesting a novel therapeutic strategy with
translational potential in this important subset of disease. Hypothesis: We hy-
pothesized that synthetic lethality following combinatorial PI3K/BCL-XL inhi-
bition is conserved across the range of PTEN-mutant cancers. Methods: PTEN-
mutant cell lines (ATCC), validated for PTEN-loss and p-Akt expression, were
assessed in apoptosis (cleaved Parp) and cell-viability assays following com-
bined PI3K (Buparlisib, SelleckChem) and BCL-XL (A-1331852, AbbVie) inhi-
bition (1Meach, 24h). SinceMEKsignaling has been associatedwith resistance
to PI3K pathway inhibition, p-Erk was profıled as a candidate marker of resis-
tance. The contribution of MEK signaling to the apoptotic threshold in p-Erk
expressing PTEN-mutant cells was testedwith pharmacologicalMEK inhibition
(Trametinib, SelleckChem; 1,3,5 M 48h) in combination. Results:
MEK signaling and PI3K/BCL-XL inhibition in PTEN-mutant cancers
Source
Cell
line PTEN p-Akt p-Erk
Synergistic
Apoptosis
with
PI3K/BCL-XL
inhibition
Loss of
cell
viability
p-Erk
suppression
with MEK
inhibition
Apoptosis
with
concomitant
MEK
inhibition
Prostate PC3 Absent Present Absent Yes Yes N/A N/A
Prostate LNCaP Absent Present Absent Yes Yes N/A N/A
Prostate C4-2B Absent Present Absent Yes Yes N/A N/A
Breast ZR-75-1 Absent Present Weak Yes Yes N/A N/A
Uterine SK-UT-1 Absent Present Present No No Yes Yes
GBM A-172 Absent Present Present No No Yes No
Cervix C33-A Absent Present Present No No  
Conclusions: Synthetic lethality in PTEN-mutant tumor cells with PI3K/
BCL-XL inhibition was confıned to tumor cells without active MEK signaling.
MEK inhibition inconsistently overcomes resistance to therapy suggesting het-
erogeneity of survival pathways in p-erk expressing PTEN-defıcient tumors.
These data have implications for precision medicine approaches in PTEN-defı-
cient tumors as absence of p-Erk expression may predict for a responsive phe-
notype.
#2163 Combined targeting of MEK and MCL-1 induces apoptosis and
tumor regression of KRAS mutant NSCLC. Aaron N. Hata,1 Faria M. Sid-
diqui,1MariaGomez-Caraballo,1 Samantha J. Bilton,1DariaTimonina,1Varuna
Nangia,1 Angela Coxon,2 Sean Caenepeel,2 Paul Hughes2. 1Massachusetts Gen-
eral Hospital, Charlestown, MA; 2Amgen, Inc, Thousand Oaks, CA.
There are currently no effective targeted therapeutic strategies for KRASmu-
tant non-small cell lung cancer (NSCLC). Single agent MEK inhibitors have
demonstrated showed disappointing clinical activity, partly due to inability to
induce a robust apoptotic response. Combining MEK inhibitors with BCL-XL/
BCL-2 inhibitors may be effective for a subset of KRAS mutant cancers that are
dependent on BCL-XL for survival, however this combination is unlikely to be
an effective strategy for cancers dependent onMCL-1.We investigated the effect
of combining theMEK inhibitor trametinibwith a novelMCL-1 inhibitor (com-
poundA), which possesses potent and selective anti-MCL-1 activity in vitro and
in vivo, onKRASmutant cancers. In contrast to colorectal cancermodels, which
are largely sensitive to combinedMEKBCL-XL inhibition, a subset of cell line
andpatient-derivedmouse xenograft (PDX)KRASmutantNSCLCmodelswere
signifıcantly more sensitive to MEKMCL-1 inhibition compared to MEK
BCL-XL. To model potential clinical strategies, we tested intermittent dosing
regimens and unexpectedly discovered a method strategy for dramatically sen-
sitizing KRAS mutant NSCLC cells to the MEKMCL-1 combination. These
studies provide rationale for the clinical evaluation of combinedMEKMCL-1
inhibitors for KRAS mutant NSCLC.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Targeting p53, Apoptosis, and the Cell Cycle
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017554
#2164 BLID is a novel drug-inducible apoptotic molecule: Identifıcation
of an integrative mechanism of chemosensitivity in breast cancer cells. Si-
varamakrishna Yadavalli, Rong Hu, Antonina Rait, Xin Li, Esther Chang, Rob-
ert Clarke, Usha Kasid. Georgetown Lombardi Comp. Cancer Ctr., Washington,
DC.
The triple-negative breast cancer (TNBC) is an aggressive form of breast
cancer frequently seen in African American women and BRCA1 mutation car-
riers. The TNBC tumors often relapse with distant metastases following stan-
dard chemotherapy. It is now evident that discoveries of new mechanisms and
approaches that explain and target breast cancer biology are urgently needed for
durable intervention of metastatic disease. Earlier, we have demonstrated that
BLID, BH-3 Like motif containing Inducer of cell Death, is a strong prognostic
factor in invasive breast cancer. Frequent lack of BLID has been associated with
TNBC, African American ethnicity and younger women. Signifıcant correla-
tions exist between BLID negative breast cancer and declines in overall survival,
local relapse-free survival and distant metastasis-free survival. Recently, BLID
has been shown to inhibit breast cancer cell growth andmetastasis. The purpose
of this study was to investigate the role of BLID in response of breast cancer cells
to chemotherapeutic drugs. In the dose response and time course studies, BLID
mRNAexpressionwas found to be induced by chemotherapeutic drugs. Expres-
sion of BLID cDNA nanocomplex (scLBLID) resulted in signifıcant increase in
chemosensitivity in SKBr3 and MDA-MB-231 cells, and a comparison of BLID
with p53 showed that the chemosensitization effect of BLID was signifıcantly
greater than that of p53. Consistently, BLID knockdown led to reversal of drug-
induced cytotoxicity. In the ChIP-PCR and ChIP-qPCR assays, drug treatment
of breast cancer cells resulted in an increased binding of pro-apoptotic transcrip-
tion factor FOXO3a to the BLID promoter, and the reversal of drug-induced
BLID reporter activity was seen in presence of FOXO3a siRNA. Furthermore,
siRNA silencing of FOXO3a was found to be associated with decrease in endog-
enousBLIDmRNAexpression. Remarkably, we found that expression of central
tumor suppressor microRNA miR34a also resulted in increased BLID mRNA
expression and drug toxicity in breast cancer cells. Because lack of BLID expres-
sion has been associated with poor prognosis in breast cancer patients, we rea-
soned that the silencing of BLID may reveal as yet unknown changes in gene
expression thatmay drive breast cancer cell proliferation and therapy resistance.
In this context, themRNA array profıling studies showed that BLID knockdown
inMDA-MB-231 cells was associated with increased expression of the oncogen-
ic/anti-apoptotic molecules CYP1B1, BIRC3 and CSF1, and decreased expres-
sion of the anti-oncogenic/apoptotic molecules AKAP12, DFNA5 and
CHRDL1. Our data suggest that chemotherapeutic drugs induce BLID expres-
sion via activation of FOXO3a, and the BLID signaling axis downstream of
FOXO3a andmiR34a is a novel integrativemechanismof breast cancer response
to chemotherapy. SY and RH are equal contributors in this study.
#2165 Deletion of survivin sensitize human hepatocellular carcinoma
cells to low dose of doxorubicin and induce apoptosis. Joseph George,
Nobuhiko Hayashi, Takashi Saito, Kazuaki Ozaki, Nobuyuki Toshikuni, Mut-
sumi Tsuchishima, Mikihiro Tsutsumi. Kanazawa Medical University, Uchi-
nada, Japan.
Background and Aims: Hepatocellular carcinoma (HCC) is one of the most
common cancers in the world and patients with advanced HCC face a dismal
prognosis due to lack of effective therapy. Survivin, a member of the family of
inhibitor of apoptosis proteins, is highly upregulated in HCC as well as in ex-
perimentally induced intrahepatic tumors. Doxorubicin, the only known che-
motherapeutic agent for HCC, is cardiotoxic in addition to several well known
side effects. Methods: Survivin gene deletion was established in HepG2, Hep3B,
and PLC/PRF/5 human HCC cells using CRISPR/Cas9 system. All the three
HCC cells in culture were treated with doxorubicin at various concentrations
before and after survivin gene knockout upto 72 hr. TUNEL assay and FACS
analysis were performed to demonstrate the induction of apoptosis after doxo-
rubicin treatment. Western blotting was carried out for cleaved fragments of
caspase-9 and caspase-3 as well as major apoptotic executioner molecules. Re-
sults: Cell viability studies depicted around 20% cell death at 24 h, 50% at 48 h,
and 80%at 72 h after treatmentwith doxorubicin at 1M(fınal concentration in
the media). Among the three cell lines studied, Hep3B cells were more suscep-
tible to doxorubicin compared toHepG2 and PLC/PRF/5 cells. After deletion of
survivin gene, the dosage of doxorubicin could reduce to fıve fold (200 nM, fınal
concentration in the media) with the same cytotoxic effect before the knockout
of survivin gene. HCC cells treated with reduced doses of doxorubicin depicted
induction of apoptosis that was proved with TUNEL assay and FACS analysis as
wells as increased levels of cleaved caspases and major apoptotic executioner
molecules. Conclusions: Our studies demonstrated that blocking of survivin
moleculewith effectivemethodswould be a successful approach to treat primary
hepatic tumors with low and safe doses of doxorubicin and other anticancer
agents.
#2166 Arsenic trioxide targets BCL6 oncoprotein for degradation in
BCL6-dependent diffuse large B-cell lymphoma. Lok Man Yue, David Hau
Wing Chau, Wenying Piao, (Eric) Wai Choi Tse, Yok Lam Kwong. The Univer-
sity of Hong Kong, Hong Kong, Hong Kong.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-
Hodgkin lymphoma throughout the world. B-cell lymphoma 6 (BCL6) overex-
pression is frequently observed inDLBCL. Several recent studies have supported
that BCL6 is a critical pathogenic oncoprotein in DLBCL. BCL6 represses vari-
ous downstream genes, including ATR, TP53 and CDKN1A, thereby impairing
DNA repair leading to derangement of cellular proliferation. Most importantly,
a specifıc small molecule inhibitor targeting BCL6 successfully suppressed
growth of BCL6-dependent DLBCL cell lines and primary human DLBCL cells,
further suggesting that BCL6 plays an important pathogenetic role. Arsenic
trioxide (As2O3) has been reported to target various oncogenic proteins, includ-
ing PML-RARA in acute promyelocytic leukemia, cyclin D1 in mantle cell lym-
phoma, NPMc in acute myeloid leukemia and NPM-ALK in anaplastic large
cell lymphoma, for degradation through ubiquitin-proteasome pathway. In this
study, we investigated the effects of As2O3 on BCL6 inDLBCL. As2O3was found
to inhibit cell proliferation and induce cell death via apoptosis in DLBCL cells.
More interestingly, BCL6-dependent DLBCL cells were found to show higher
sensitivity towards As2O3-induced cytotoxicity. BCL6was found to be degraded
by As2O3 at posttranslational level through the ubiquitin-proteasome pathway.
Such degradation led to an upregulation of several downstream targets of BCL6,
including PRDM1, CD44 andCD69.Moreover, As2O3 synergizedwith cisplatin
to inhibit cell proliferation and enhance apoptosis in BCL6-dependent DLBCL
cell lines. Concomitant treatmentwithAs2O3 and cisplatin further enhanced the
phosphorylation of Chk1 and H2AX in these cells. In conclusion, our data
suggest that As2O3 is a potential therapeutic agent for the treatment of BCL6-
dependentDLBCL.On top of that, new combination therapies can be developed
to expand the therapeutic spectrum of As2O3 to other neoplasms.
#2167 Preclinical validation of an Omomyc cell-penetrating peptide as a
viable anti-Myc therapy. Marie-eve Beaulieu,1 Toni Jauset,2 Daniel Massó-
Vallés,2 Peter Rahl,3 Sandra Martinez-Martin,2 Loika Maltais,4 Mariano F. Zac-
arias-Fluck,2 Silvia Casacuberta,1 Erika Serrano del Pozo,2 Christopher Fiore,3
Laia Foradada,1 Matthew Guenther,3 Eduardo Romero Sanz,5 Marta Oteo
Vives,5 Cynthia Tremblay,4MartinMontagne,4Miguel ÁngelMorcilloAlonso,5
Jonathan R. Whitfıeld,2 Pierre Lavigne,4 Laura Soucek2. 1Peptomyc S.L., Barce-
lona, Spain; 2Vall d’Hebron Inst. of Oncology (VHIO), Barcelona, Spain; 3Syros
Pharmaceuticals, Cabridge, MA; 4University of Sherbrooke, Quebec, Canada;
5Centre de Investigaciones Energeticas, Medioambientes y Tecnologicas (CI-
EMAT), Madrid, Spain.
Deregulation of theMYConcoprotein promotes tumorigenesis inmost, if not
all, cancers and is often associated with poor prognosis. However, targeting
MYC has long been considered impossible based on the assumption that it
would cause catastrophic side effects in normal tissues. Despite this general
preconceived notion, we showed thatMYC inhibition exerts extraordinary ther-
apeutic impact in various geneticmousemodels of cancer, and causes onlymild,
well-tolerated and reversible side effects. For these studies we employed the
systemic and conditional expression of a dominant negative of MYC, called
Omomyc, which we designed and validated, and that can inhibit MYC transac-
tivation function both in vitro and in vivo. To date, Omomyc has only been
considered a proof of principle, with any potential clinical application limited to
gene therapy. Here we actually show that the 11 kDa Omomyc polypeptide
spontaneously transduces into cancer cells, demonstrating unexpected cell-pen-
etrating ability. Once inside the nuclei, the polypeptide effectively blocks MYC
binding to its target DNA sites, interfering withMYC transcriptional regulation
and halting cell proliferation. Moreover, intranasal (i.n.) administration of the
Omomyc polypeptide in mice results in its rapid and persistent distribution to
lungs, as well as to other organs (i.e. intestine, liver, kidneys and brain). Impor-
tantly, i.n. treatment of mice bearing either Non-Small-Cell-Lung-Cancer
(NSCLC) or glioblastoma (GBM) with the Omomyc cell-penetrating peptide
(OmomycCPP) signifıcantly reduces tumor burden compared to their control
counterparts. Notably, tumor regression is accompanied by signifıcant repro-
gramming of the tumor microenvironment and tumor immune response. In
summary, our data indicate that this novel generation of polypeptides represents
a new opportunity to potentially inhibit MYC pharmacologically in a variety of
malignant diseases.
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#2168 Nucleic acid clamp-mediated recognition and transcriptionalmod-
ulation of MYC oncogenes through the stabilization of G-quadruplexes.
Taisen Hao, Tracy A. Brooks. University of Mississippi, University, MS.
G-quadruplexes (G4s) tend to cluster around biologically important re-
gions such as promoters of DNA, 5=-UTR of mRNA and telomeres. Modu-
lating the stability of G4 as in these regulatory sequences is an emerging
approach for cancer treatment. MYC proto-oncogene is overexpressed in
over 80% of tumor types, contributing to deregulated cancer cell prolifera-
tion. Silencing MYC expression has been demonstrated to be an effective
approach to inhibit tumor growth. Among all the silencing strategies, stabi-
lizing MYC promoter G4 that serves as an on-off switch for the transcription
of MYC has been explored by the targeting of small molecules. However, the
binding specifıcity of small molecule retarded the drug development process.
Exploring novel MYC G4-targeting strategies is necessary to potentiate the
pharmacological specifıcity of MYC G4 modulation. Here, we adopted a
nucleic acid clamp based approach to recognize and stabilize the physiolog-
ically predominant MYC G4. Previously, a clamp (clamp A) was been dem-
onstrated to recognize the physiologically relevant MYC G4 with high spec-
ifıcity and to downregulate MYC promoter activity. In the current research,
we modifıed and optimized this clamp to allow for flexibility with labeling
andmonitoring techniques. The original 18 Å polyethylene glycol phosphate
linker connecting the 5= and 3= regions of clamp A were substituted with
thymine bases of varying lengths; 5 thymines were found to be optimal. The
binding specifıcity and MYC G4 recognizing ability of this optimized clamp
A T5 were confırmed by EMSA and ECD; the G4 stabilizing ability of clamp
A T5 was demonstrated by DMS footprinting. The cytotoxicity of clamp A
T5 was examined by MTS assay on HEK-293 and MCF-7 cells. The intracel-
lular localization of clamp A T5 is being determined microscopically with a
6-FAM-labeled clamp A T5 after being transfected into and incubated with
HEK-293 and MCF-7 cells for 48 hr. Nuclear localization is being examined
by co-staining with DAPI, and MYC promoter localization is being deter-
mined by clustering with a MYC FISH probe. The modifıcation of the clamp
is both cost-effective, and enables the detailed study of intracellular func-
tions. This clamp has potential as both a diagnostic tool to inform the use of
MYC G4-targeted small molecules, and as a nanotherapeutic.
#2169 Pharmacological modulation of CXCL12-CXCR4 intracellular
traffıcking potentiates the in vitro and in vivo activity of the BET bromodo-
main inhibitor CPI203 in diffuse large B-cell lymphoma. Clara Recasens-
Zorzo,1 Teresa Cardesa-Salzmann,2 Laia Ros-Blanco,3 Anna Esteve-Arenys,1
Guillem Clot,1 Martina Guerrero-Hernández,1 Alejandra Valera,2 Alejandra
Moros,1 Gonzalo Gutierrez,4 Isolda Casanova,5 Ramón Mangues,5 Alejandra
Sanjuan,6 Pablo Menéndez,6 Vanina Rodriguez,1 Antonio Martínez,2 Pedro
Jares,2 Dolors Colomer,2 Jordi Teixidó,3 José Ignacio Borrell,3 Elias Campo,2
Armando López-Guillermo,4 Luís Colomo,7 Patricia Pérez-Galán,1 Gaël Roué1.
1Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona,
Spain; 2Hospital Clínic, Barcelona, Spain; 3Institut Químic de Sarrià, Universitat
Ramón Llull, Barcelona, Spain; 4Hospital Clinic, Barcelona, Spain; 5Institut
d’Investigacions Biomèdiques-Sant Pau (IIB-Sant Pau), Barcelona, Spain; 6Josep
Carreras Leukemia Research Institute, University of Barcelona, Barcelona, Spain;
7Hospital del Mar, Barcelona, Spain.
Constitutive activation of CXCR4, a chemokine receptor commonly overex-
pressed in cancer, is associated with tumor progression, invasion, and chemo-
therapy resistance. Although theCXCR4pathway has recently been suggested as
an adverse prognostic marker in diffuse large B-cell lymphoma (DLBCL), its
biological relevance remains underexplored as the evolution of the malignant
clone has been traditionally thought to rely mainly onmicroenvironment-inde-
pendent factors, including MYC. To evaluate a possible interplay between
CXCR4 and MYC signaling in DLBCL we have analyzed the expression of
CXCR4 and its ligand CXCL12 in tissue biopsies of a homogeneous cohort of 86
patients with de novo DLBCL, and correlated it with clinico-pathological char-
acteristics and gene expression profıling. We found that co-expression of
CXCL12 andCXCR4was associatedwith an inferior overall survival when com-
pared to the sole expression of CXCR4 (p0.017). An ELISA-based array cov-
ering 175 human cytokines further showed that tissue levels of CXCL12 best
correlated with high microvessel density (p0.02) pointing out a role for both
CXCR4 and CXCL12 in DLBCL tumor aggressiveness. In support of the estab-
lished role of nuclear CXCR4 on tumor metastasis, abundant nuclear CXCR4
was detected in DLBCL primary tumors and cell lines compared to normal
tonsils. This feature was signifıcantly associated with the migratory potential of
the tumor cells, thus suggesting CXCR4 as a potential therapeutic target to
hamper lymphoma cell dissemination. In silico and in vitro screening of a
CXCR4 inhibitor (CXCR4i) library further identifıed the tetra-amine IQS-01.01
as a potent inhibitor of CXCR4 nuclear translocation. IQS-01.01 prevented
CXCL12-mediated chemotaxis and triggered apoptosis in a panel of 14 DLBCL
cell lines and primary cells, with improved pharmacological properties than the
standardCXCR4i, AMD3100.Mechanistically, IQS-01.01-mediated blockage of
CXCR4 signaling was associated with downregulation of p-AKT, p-ERK1/2 and
MYC. The combined use of IQS-01.01 with the BET bromodomain inhibitor
CPI203 exerted a synergistic cytotoxic effect in DLBCL cell lines in vitro (mean
combination index: 0.6	0.2). In a xenotransplant model of DLBCL the IQS-
01.01/CPI203 combination decreased tumor burden (p0.004) through pre-
vention of CXCR4 nuclear import and MYC downregulation, resulting in a
synergistic apoptosis induction. Our results point out an emerging role of nu-
clear CXCR4 in the pathogenesis of DLBCL and support the simultaneous tar-
geting of CXCR4 and BET bromodomain as a promising, rationale-based strat-
egy for DLBCL.
#2170 Rb1 suppresses prostate cancer metastasis and lineage plasticity
underlying castration resistance. Sheng-Yu Ku,1 Spencer Rosario,1 Yanqing
Wang,1 PingMu,2 Mukund Seshadri,1 Zachary Goodrich,1 Maxwell Goodrich,1
Eduardo Cortez Gomez,1 Jianmin Wang,1 Bo Xu,1 Charles L. Sawyers,2 Leigh
Ellis,1 David G. Goodrich1. 1Roswell Park Cancer Institute, Buffalo, NY; 2Memo-
rial Sloan Kettering Cancer Center, New York, NY.
Androgen deprivation therapy (ADT) is an effective treatment for metastatic
prostate cancer (mPCa), but patients eventually relapse with ADT resistant disease.
Well-characterizedmechanismsofADTresistance includeARamplifıcation, intra-
tumoral androgen synthesis, AR splice variants, and growth receptor bypass. All of
these mechanisms function to maintain suffıcient AR signaling for tumor growth
andsurvival. ImprovedADTlikeabirateroneacetate (AA)andenzalutamide (Enza)
weredevelopedtocombat suchresistancemechanismsassociatedwithalterations in
androgen receptor or androgen metabolism. While AA and Enza extend survival,
clinical benefıts are short-lived.Anew formof resistance is increasingly appreciated
in patients relapsing fromAAorEnza, histologic transformation of prostate adeno-
carcinoma (PADC) to neuroendocrine prostate cancer (NEPC) variants. NEPC is
lethal and the survival time is less than a year as effective targeted therapy is unavail-
able. NEPC typically exhibits reduced AR expression, increased expression of neu-
roendocrinemarkers, and visceral metastasis in the absence of rising PSA. Of note,
NEPC possesses the similar genome rearrangements with adjacent PADC cells, in-
dicating they share clonal origin. Thus, NEPCmay arise by histologic transforma-
tion of PADC.Underlyingmechanisms of histologic transformation are not under-
stood and experimental models are limited, hindering development of effective
remedies. RB1 loss is common inNEPC, but rare in PADC; genetic profıling shows
humanNEPCexhibit elevated levelsof several epigeneticmodifıers.Wehypothesize
that transdifferentiation from PADC to NEPC in the context of RB1 loss is due to
epigenetic alterations and can be reversed or blocked by epigenetic targeted thera-
pies.We established several genetically engineeredmousemodels (GEMMs) to test
the role of Rb1, and we fınd Rb1 loss causes metastatic progression of PADC initi-
ated by Pten defıciency. This Rb1/Pten defıcient (DKO) PADC exhibits expression
markers for bothPADCandNEPCas seen inhumanpatients. Yet, these tumors are
sensitive toADTbut relapsewith lowARexpressionandacquiredTrp53mutations.
RNA profıling demonstrates the phenotype of DKO tumors is similar to human
NEPC. Both human and mouse NEPC is accompanied by increased expression of
epigenetic reprogramming factors like Sox2 and Ezh2. Clinically relevant Ezh2 in-
hibitorsGSK126 andEPZ6438 can restoreEnza sensitivity by reversingneuroendo-
crine transformation. This fınding has been genetically validated using short-hair-
pinRNA(shRNA) invitro.These resultsuncovergeneticmutationsdrivingprostate
cancer lineage plasticity and suggest an epigenetic approach for extending the clin-
ical benefıts of ADT.
#2171 Multi-CDK inhibition effıciently suppresses AR function and cell
growth in prostate cancer. BrianW. Simons, Maria Ybanez, Emmanuel S. An-
tonarakis, Jun Luo, Barry D. Nelkin. Johns Hopkins Univ. School of Medicine,
Baltimore, MD.
Metastatic castration resistant prostate cancer (CRPC) continues to result in over
26,000 deaths per year in the United States. For 70 years, therapy for advanced
prostate cancer has relied on AR-directed therapies. Unfortunately, even with the
second generation androgen deprivation compounds, treated cancers commonly
progress to castration resistance and lethality. This progression to castration resis-
tance remains the central therapeutic roadblock for advanced prostate cancer. Im-
portantly, in the vastmajority of CRPC cases, the tumor still depends onAR signal-
ing, but this signaling becomes androgen independent. The most common
mechanisms, includingmutation, protein truncation, andalternative splicing, affect
the C-terminal domain, suggesting that antagonism of AR function via the N-ter-
minal domain may be a promising target for CRPC therapy. Several groups have
shown that CDKs 1, 5 and 9 activate AR by phosphorylation of the N-terminal
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domain. Here, we show that the multi-CDK inhibitor roniciclib (BAY1000394)
inhibits activationofAR in apanel of prostate cancer cell lines, including several cell
lines which exhibit androgen-independent AR signaling via AR-V7 alternative
splicing. In vivo, roniciclib inhibited growth of prostate cancer xenografts. SinceAR
inhibition in prostate cancer has been shown to induce compensatory PI3K signal-
ing, we also treated xenografts with a combination of roniciclib and the PI3K inhib-
itor copanlisib (BAY 80-6946). This combination was especially effective, and was
well tolerated by the mice. Our results suggest that a combination of a multi-CDK
inhibitor and a PI3K inhibitor may be promising for CRPC therapy.
#2172 ON 123300, an orally administered novel CDK4/6 ARK5 inhib-
itor, exhibits potent antitumor activity in vivo: comparative studies with Pal-
bociclib. Shraddha Patel,1 Priya Pancholi,1 Tanvi Visal,1 Amruta Samant,1 Dh-
vanir Kansara,1 V J. Rajadhyaksha,2 Benjamin S. Hoffman,2 Manoj Maniar,2
Vikas Sehdev1. 1Long Island Univ., Brooklyn, NY; 2Onconova Therapeutics Inc.,
Newtown, PA.
Background: The overexpression of cyclin-dependent kinases 4/6 (CDK4/6)
is known to cause cell cycle dysregulation in certain cancer types, making these
cell cycle kinases attractive targets for pharmacological inhibition. The effective-
ness of fırst-generation non-selective cyclin-dependent kinases, such as rosco-
vitine and flavopiridol, was hampered by toxicities, leading to the development
of second-generation compounds like IBRANCE®/Palbociclib that specifıcally
inhibit CDK4 and 6. ON 123300 is a third-generation potent CDK4/6 inhibitor
that also inhibits ARK5 with low nanomolar potency and has the potential to
improve upon second-generation compounds. Previous studies have demon-
strated the inhibitory effect of single-agent ON 123300 in various pre-clinical
cancer models of MM and leukemia. In this study, we investigated the compar-
ative therapeutic potential of ON 123300 as an oral anticancer agent and a
second-generation inhibitor, Palbociclib, in xenografted Rbve mouse models.
Methods: MDA-MB-435S xenografted mice were treated once a day for 21 days
with ON 123300 (125mg/kg) or Palbociclib (125mg/kg). Tumor volumes were
measured and peripheral blood was gathered to evaluate the effects on hemato-
logical parameters. Separately, Western blot analyses were performed to deter-
mine the effect ofCDK4/6 inhibition onp-Rb following intra-tumoral treatment
with ON 123300 (2.5M) or Palbociclib (2.5M). Results: ON 123300 and Pal-
bociclib reduced tumor growthwith an equivalentmagnitude during the 21-day
treatment period, suggesting that the two compounds were equally effective in
this model. Both compounds decreased RBC and platelet counts, however Pal-
bociclib had a more prominent and statistically signifıcant (P0.05) inhibitory
effect on neutrophil counts when compared to ON 123300 (30.70 	 3.55 vs.
45.10	 2.04). Western blot analysis of tumor tissues demonstrated equivalent
effects on p-Rb for both compounds. Conclusions: Xenograft data indicates that
a third-generationCDK4/6 inhibitor, ON123300, is as effective as Palbociclib in
an Rbve xenograft model. Moreover, this study also suggests that ON 123300
may have the added advantage of reduced neutropenia compared to Palbociclib.
Prior preclinical data suggest that ON 123300 may be effıcacious in Rb-ve tu-
mors, where second-generation compounds have diminished single-agent ac-
tivity, and our ongoing studies are aimed at further characterizing the in vivo
activity of ON 123300 in this setting.
#2173 TargetingCDK1andMEK/ERKovercomemutantBRAF-mediated
apoptosis resistance in human colorectal cancer cells. Hisato Kawakami,
Shengbing Huang, Frank A. Sinicrope.Mayo Clinic, Rochester, MN.
BRAFV600E mutation occurs in 10% of human colorectal cancers (CRC)
where it is associated with treatment resistance and poor prognosis. Data from
TCGA and a clinical trial cohort identifıed a distinct subset of BRAF mutant
colon cancers with deregulation of the cell cycle and overexpression of CDK1
(Barras D, et al, Clin Cancer Res. 2016). We tested the hypothesis that CDK1
inhibition can enhance apoptosis in BRAFV600E CRC cells. Since BRAF mutant
cells show p-ERK activation, combined inhibition of CDK1 andMEK/ERK was
evaluated. Using isogenic colon cancer cells, BRAFmutant alleles were shown to
confer resistance to the CDK1 inhibitor, R0-3306, in a gene dose-dependent
manner that was associated with reduced cleavage of caspase-3 and downstream
PARP, and decreased pH2AX (DNA fragmentation marker). Ectopic
BRAFV600E or constitutively active MEK mutant also conferred resistance to
R0-3306. CDK1 siRNA was shown to increase cobimetinib-induced apoptosis,
including annexin V labeling, and increased pH2AX. Furthermore, ERK siRNA
or cobimetinib treatment attenuated CDK1 protein expression and increased
R0-3306-induced pH2Ax. Moreover, treatment with R0-3306 plus cobimetinib
signifıcantly enhanced a caspase-dependent apoptosis and markedly reduced
colony formation vs either drug alone in two CRC cell lines. Caspase-3 cleavage
by R0-3306  cobimetinib was dependent upon caspase-8. Mechanistically,
CDK1 inhibition byR0-3306 suppressed the phosphorylation of procaspase-8 at
Ser-387 shown by R0-3306 withdrawal which restored p-C8-S387 coincident
with expression of the mitotic marker, pH3S10. In conclusion, inhibition of
CDK1 can signifıcantly augment apoptosis induction by MEK/ERK inhibition
in BRAFV600E CRC cells, suggesting a novel therapeutic strategy to overcome
mutant BRAF-mediated resistance.
Apoptosis induction by CDK1 inhibitor (R0-3306)MEK/ERK
inhibitor cobimetinib
Treatment Treatment Treatement Treatment
CRC cell lines DMSO R0-3306 (5 M) cobimetinib (5 M) combination
Annexin V (%) RKO 13.43	 1.41 32.55	 2.93 15.04	 0.26 52.72	 3.16
Annexin V (%) HT-29 11.22	 1.84 42.44	 2.70 25.29	 0.16 65.62	 4.11
#2174 Inhibition of CDK8 kinase with SEL120-34A allows for a personal-
ized approach in AML. Tomasz Rzymski,1 Michal Mikula,2 Eliza Zylkiewicz,1
Agnieszka Dreas,1 Katarzyna Wiklik,1 Aniela Golas,1 Katarzyna Wojcik,1
Magdalena Masiejczyk,1 Iga Dudzicz,1 Katarzyna Kucwaj,1 Malgorzata Statkie-
wicz,2 Krzysztof Goryca,2 Aleksandra Grochowska,2 Aleksandra Cabaj,2 Jerzy
Ostrowski,2 Urszula Kukliniska,2 Krzysztof Brzozka1. 1Selvita S.A., Krakow, Po-
land; 2Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.
Inhibition of oncogenic transcriptional programs is recognized to be a prom-
ising therapeutic strategy. SEL120-34A is a novel inhibitor of Cyclin- dependent
kinase 8 (CDK8), which regulates transcription by associatingwith theMediator
complex. SEL120-34A interacts with the ATP binding site of CDK8 in type I
inhibitor fashion and forms several types of interactions, including halogen
bonds with the protein’s hinge region and hydrophobic complementarities
within its front pocket. Although the compound was only modestly active in
solid tumor cell lines, it repressed phosphorylation of STAT5 Ser726 and could
differentially inhibit viability of AML and ALL cell lines in vitro and in vivo,
along with other type I CDK8 inhibitors. Transcriptomic analysis identifıed
major transcriptional programs altered in responder cell lines, which strongly
indicated that apart from repression of survival pathways, CDK8 inhibitors
could induce differentiation in cell lines with leukemia stem cells characteristics.
Further studies on a large panels of responder and non-responder cell lines
identifıed robust biomarkerswhich could be usedwith high confıdence for strat-
ifıcation and personalized approach in CDK8-dependent AML cases. Favorable
pharmacokinetics, confırmed safety and in vivo effıcacy in leukemia models
provide the rationale for further clinical development of SEL120-34A.
#2175 Vietnamese medicinal plant compounds show potent anti-pancre-
atic cancer activity in vitro. Danielle Bond,1 Phuong Thien Thuong,2 Do Thi
Ha,2 Nguyen Minh Khoi,2 Judith Weidenhofer,1 Christopher J. Scarlett1. 1The
University Of Newcastle, Ourimbah, Australia; 2National Institute of Medicinal
Materials, Viet Nam.
BACKGROUND: Pancreatic cancer is a devastating disease with a dismal
survival rate of less than 7%. This is due to its late diagnosis and aggressive,
metastatic disease. Currently treatment typically consists of surgery and/or
treatment with gemcitabine; gemcitabine/nab-paclitaxel or FOLFIRINOX - all
chemotherapeutic agents that have natural product-derived components that
only prolong survival by 5-6 months at best. As traditional Vietnamese medic-
inal plants have been used to treat a number of diseases for several thousands of
years, there is great potential to investigate their importance as sources of novel
therapeutic agents for pancreatic cancer. METHODS: Pancreatic cancer cell
lines (BxPC3, MiaPaCa2 and CFPAC1) and the normal pancreatic ductal epi-
thelial (HPDE) cell line were treated with pure compounds isolated from the
Vietnamese plants Croton tonkinensis and Salacia cochinchinensis and the ef-
fects on cell viability (CCK-8 assay) and apoptosis (caspase-3/-7 activation as-
say) were assessed to determine their anti-cancer capacity. RESULTS: Treat-
ment of pancreatic cancer cell lines with Pristimerin (from Salacia
cochinchinensis) and CT1 (from Croton tonkinensis) resulted in signifıcant
dose-dependent growth inhibition. Pancreatic cancer cell lines showed signifı-
cantly greater sensitivity to Pristimerin treatment after 24 and 72hrs, with a 1.7
– 2.3 fold lower IC50 value in MiaPaCa2 pancreatic cancer cells compared to
normal HPDE cells, respectively (24hrs: 48 vs. 111nM; 72hrs: 63.85 vs. 111nM).
Signifıcant cytotoxicity was also seen in other pancreatic cancer cell lines
(BxPC3 103 - 210nM; CFPAC1 77nM). Treatment with CT1 also resulted in
signifıcant dose-dependent cytotoxicity with an IC50 value that was 1.5 – 1.8 fold
lower in MiaPaCa2 cells compared to normal HPDE cells, respectively (24hrs:
116 vs. 177nM; 72hrs: 46.5 vs. 84.5nM). Treatment of BxPC3 and CFPAC1 cells
with CT1 also led to signifıcant cytotoxicity with IC50 values of 300nM and 170nM,
respectively. Moreover, treatment with Pristimerin and CT1 at concentrations of
625nM and 1M induced caspase-dependent apoptosis of MiaPaCa2 and HPDE
cells after 22hrs of treatment. CONCLUSIONS: Pure compounds fromVietnamese
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medicinal plants show signifıcant pancreatic cancer growth inhibition and induce
apoptosis in vitro at concentrations that have minimal effect on normal pancreatic
cells and therefore show promise as novel anti-pancreatic cancer therapies.
#2176 Thymoquinone synergizes the anticancer properties of cisplatin
against head and neck squamous cell carcinoma and protects normal oral
epithelial cells.Abdulwahab Noorwali,1 Omar Aloafı,1 Safıa Al-Attas,1 Fatheya
Zahran,1AhmedM.Al-Abd2. 1KingAbdulazizUniversity, Jeddah, SaudiArabia;
2National Research Centre of Egypt, Giza, Egypt.
Cisplatin (CDDP) is potent anticancer agent different tumors such as head
and neck cancers. Thymoquinone is natural compound drawing attention as
chemotherapeutic and chemomodulator. Herein, we studied the chemomodu-
latory effect of thymoquinone to CDDP against squamous cell carcinoma cells.
CDDP killed head and neck squamous cell carcinoma cells (UMSCC-14C) with
IC50’s of 5.2	0.2, 2.6	0.2 and 1.6	0.1 M after treatment for 24h, 48 h and
72 h, respectively. On the other hand, IC50’s of CDDP against normal oral epi-
thelial cells were 36.4	1.1, 16.3	0.6 and 6.7	1.1 M after exposure for 24h,
48 h and 72 h, respectively. Thymoquinone alone exerted considerable cytotox-
icity against UMSCC-14C cells with IC50’s of 9.0	0.2, 6.9	0.1 and 5.0	0.2M
after treatment for 24h, 48 h and 72 h, respectively. While signifıcantly weaker
killing effect was noticed for thymoquinone against normal oral epithelial cells
(OEC) with IC50’s of 41.1	0.5, 36.6	1.1and 26.3	1.2M after exposure for
24h, 48 h and 72 h, respectively. Equitoxic combination of thymoquinone and
CDDP showed synergistic interaction against UMSCC-14C cells (Combination
index of 0.58) and antagonistic interaction against OEC cells (Combination
index of 1.12). Using annexin-V/PI staining, it was found that thymoquinone
alone (5 M) increased apoptotic cell fraction in UMSCC-14C cells, as early as
after only 6 hours, from 1.7	0.1% to 24.4	0.6% compared to 2.7	0.04 apopto-
sis induced by CDDP (5 M). Combination of CDDP with thymoquinone fur-
ther increased total apoptosis inUMSCC-14C to 32.9	1.5% after 6 h. prolonged
exposure of UMSCC-14C to thymoquinone (5 M) alone for 24 h resulted in
96.7	1.6% total apoptosis which was increased after combination with CDDP
to 99.3	1.2% in UMSCC-14C cells. In contrast to UMSCC-14C cells, thymo-
quinone did not induce any signifıcant apoptosis in OEC and even decreased
apoptosis induced by CDDP alone from 4.5	0.3% to 3.4	0.2% after combina-
tion for 24 h. Using western blot analysis, neither thymoquinone nor CDDP
managed to increase the expression level of p53 apoptotic protein; while com-
bination of CDDPwith thymoquinone signifıcantly increased p53 expression by
4.5 folds. On the other hand, both CDDP and thymoquinone decreased the
expression level of the anti-apoptotic protein Bcl-2 to be 60% and 20%of control
level, respectively. Combination of both agents further abolished the level of
Bcl-2 to be 10% of control level. Caspase-9 expression was similarly induced by
2 folds and 4.5 folds after treatment with CDDP and thymoquinone, respec-
tively. Combination of CDDP and thymoquinone further induced the level of
caspase-9 to be 6 folds original basal expression level. None of these fınding
could be detected in normal OEC cell line. In conclusion, thymoquinone syner-
gize the anticancer properties of CDDP against squamous cell carcinoma cells
and protects from its damaging effect against normal epithelial cells.
#2177 The olive biophenol oleuropein selectively induces apoptosis in
pancreatic cancer cells in vitro. Chloe D. Goldsmith,1 Helen Jankowski,1 Dan-
ielle Bond,1 Judith Weidenhofer,1 Costas Stathopoulos,2 Paul Roach,1 Christo-
pher Scarlett1. 1The University of Newcastle, Ourimbah, Australia; 2University of
Abertay, Dundee, United Kingdom.
Pancreatic cancer is a devastating disease with a 5-year survival rate of less
than 5%. Resistance to conventional treatment options and toxicity of current
chemotherapy agents (gemcitabine) makes pancreatic cancer a target for the
development of novel therapeutic agents. Oleuropein is the most abundant bio-
phenol found in olive products; it has anti-atherogenic and anti-inflammatory
properties as well as activity against cancers of the breast, colon and prostate.
However, there has yet to be any investigation into the effects of oleuropein on
pancreatic cancer cells. Consequently, this study aimed to assess the anti-pan-
creatic cancer activity of oleuropein in vitro. Two cell lines were investigated; a
pancreatic cancer cell line (MiaPaCa-2) and a normal pancreas cell line (HPDE).
The viability of cells after treatment with 0-200M oleuropein was assessed
using the Dojindo CCK-8 viability assay and compared to gemcitabine. The
induction of apoptosis was measured by way of caspase 3/7 activation, using a
MUSE flow cell analyser, and expression of Bcl-2, Bax and Bac using Western
blot. Cell cycle analysis was conducted using the MUSE flow cell analyser. RNA
expression was assessed using Affymetrix GeneChip® Whole Transcript (WT)
expression arrays. The IC50 values for oleuropein against MiaPaCa-2 cells
was148M. However, importantly, oleuropein did not decrease the viability of
HPDE cells within the treatment range. In comparision, 20nM of gemcitabine
did not show selectivity; it reduced the viability ofMiaPaCa-2 cells to 21% and of
HPDE cells to 2%. An increase in the expression of caspase 3/7 was seen in
MiaPaCa-2 cells when treated with oleuropein but it had no effect on the HPDE
cells. Furthermore, when treated with oleuropein, an increase in the expression
of genes involved in the NRF-2 (oxidative stress) pathway was observed in Mi-
aPaCa-2 cells, an effect not observed in HPDE cells. Conclusion Oleuropein
selectively induced apoptosis in the pancreatic cancer cells (MiaPaCa-2), ap-
pearing non-toxic to normal pancreas cells (HPDE)within the treatment ranges;
this is signifıcant, since gemcitabine was comparatively more toxic to HPDE
cells. Furthermore, the link between oleuropein and the NRF-2 pathway in Mi-
aPaCa-2 cells justifıes further study into themechanisms of action of oleuropein
and its potential as a novel therapeutic approach for pancreatic cancer.
#2178 Growth inhibition of the crude extracts of Musa basjoo in human
colon carcinoma cells. Harutoshi Matsumoto,1 Saeko Ando,1 Katsumi Fuka-
machi,1 Mitsuru Futakuchi,1 Kazunori Kimura,2 Naoki Yoshimi,3 Masumi Su-
zui1. 1Department of Molecular Toxicology, Nagoya City University Graduate
School of Medical Sciences and Medical School, Nagoya, Japan; 2Department of
Clinical Pharmacy, Nagoya City University Graduate School of Medical Sciences
and Medical School, Nagoya, Japan; 3Department of Pathology and Oncology,
Graduate School of Medicine and Faculty of Medicine, University of the Ryukyus,
Okinawa, Japan.
Musa basjoo (MB) is a tropical evergreen tree growing mainly in subtropical
or tropical countries. MB has been used globally as a folk medicine such as
antipyretic, diuretic, and hemostatic drugs for centuries but evidence-based bi-
ological activities and molecular mechanism of action of MB are unknown.
Therefore, in the current study we examined whether the crude extracts of MB
exert anticancer activity in HT29 and HCT116 human colon carcinoma cell
lines. Dried leaves of MB samples were extracted with acetone or methanol.
Crude extracts of MB were then dissolved in dimethylsulfoxide (DMSO) and
used for the following experiments. Growth inhibition was determined by col-
ony orMTT assays in these cell lines. Cells were treated with increasing concen-
trations (12.5 to 200g/mL in colony assays, 25 to 400g/mL inMTT assays) of
acetone/methanol extracts of MB in DMEM/5%FBS. Untreated control cells
were treated with DMSO alone. Crude extracts of MB inhibited the growth of
cells with IC50 values of 118g/mL (acetone extract, HT29), 75g/mL (acetone
extract, HCT116),200 g/mL (methanol extract, HT29), 141 g/mL (metha-
nol extract, HCT116) in colony assays, and with IC50 values of 137 g/mL (ac-
etone extract, HT29), 73 g/mL (acetone extract, HCT116), 240 g/mL (meth-
anol extract, HT29), 248 g/mL (methanol extract, HCT116) in MTT assays.
Acetone extract was used in the flowcytometry and western blot analyses be-
cause it showed stronger growth inhibition than methanol extract in both cell
lines. Flowcytometry analysis indicated that when HT29 and HCT116 cells
were treated with 100 g/mL acetone extract of MB for 96h, the percentage
of cells in G1 increased by 5.4% and this was associated with a concomitant
decrease of cells in the S and G2-M phases of the cell cycle. Acetone extract of
MB did not cause subG1 fraction in either HT29 or HCT116 cell lines. The
results indicate that acetone extract of MB causes carcinoma cells to arrest in
the G1 phase. We then performed western blot analysis to determine
whether treatment of carcinoma cells with acetone extract of MB alters cel-
lular levels of the G1 cell cycle control proteins cyclin D1, cdk4 and the cell
cycle inhibitor protein p21CIP1. When HT29 and HCT116 cells were treated
with 50 and 100 g/mL acetone extract of MB for 96h, there was a marked
decrease in the levels of expression of the cyclin D1 and cdk4 proteins and a
marked increase in the levels of expression of the p21CIP1 protein. Thus, a
decrease in cyclin D1 may cooperate with the induction of p21CIP1 to arrest
cells in G1 and thereby further contribute to MB-induced growth inhibition.
Taken together, the crude extracts of MB contain active component(s) that
exert growth inhibition of human colon carcinoma cells. The current study is
the fırst systematic examination of the anticancer activity of MB and may
provide a novel approach to the chemoprevention and/or chemotherapy of
human colon carcinoma.
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#2179 Targeted delivery of nanoparticulate cytochrome c into GL261 gli-
oma cells through the proton-coupled folate transporter. Yuriy Kucher-
yavykh,1 Jescelica Ortiz-Rivera,1 Michael Inyushin,1 Luis Cubano,1 Moraima
Morales-Cruz,2 Alejandra Cruz-Montañez,2 Kai Griebenow,2 Lilia Kucher-
yavykh1. 1Universidad Central del Caribe, Bayamon, PR; 2University Of Puerto
Rico, Rio Piedras, PR.
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In this study we identifıed the proton-coupled folate transporter (PCFT) as a
route for targeted delivery of drugs to glioma cells. Using the techniques of
confocal imaging, western blotting, and siRNA knockdown against the PCFT
(encoded by the SLC46A1 gene), we demonstrated that Gl261 glioma cells, but
not primary cultured astrocytes, express the PCFT, which provides selective
internalization of folic acid (FA)-conjugated cytochrome c-containing nanopar-
ticles (FA-Cyt c NPs), followed by glioma cell death. FA-Cyt c NPs, used at a
concentration of 100 g/ml, had no cytotoxic effects in astrocytes but caused
40% death in GL261 cells. Whole-cell patch clamp recording revealed FA-in-
duced membrane currents, with maximum activity at pH 6.0, which is specifıc
for the PCFT. Currents were reduced by siRNA PCFT knockdown in a similar
manner as by application of FA-Cyt c NPs, indicating that the PCFT is a major
carrier of FA and a route for internalization of FA-conjugated NPs in GL261
cells. We conclude that the PCFT provides a mechanism for targeted delivery of
FA-conjugated nanodrugs to glioma cells with high specifıcity for GL261 cells,
effectively causing apoptosis in these cells, and provides a starting point for the
development of effıcient methods for treating gliomas. The research was
supported by NIH grants SC2GM102040, SC2GM095410, G12MD007583,
R25GM110513, and US Department of Education Grant P031S130068.
#2180 Triphenylmethanol conjugates of leuprorelin asanti-cancer prod-
rugs.Yousef Ahmadibeni, KalehKarim,WilliamBoadi.Tennessee State Univer-
sity, Nashville, TN.
Leuprorelin (LEP) is a synthetic analogue of gonadotropin-releasing hor-
mone (GnRH), fırst was approved by the FDA for treatment of advanced pros-
tate cancer and endometriosis in 1985. The initial effect of administration LEP is
to stimulate the pituitary secretion of FSH and LH. After a prolonged stimula-
tion (constant concentration of LEP in the blood) pituitary becomes insensitive
to the action of GnRH. This reduces the level of gonadotropin in the blood,
resulting in decreased levels of sex hormones to postcastration or menopausal
levels. In addition to the usual side effects of this agonist analogs of LH-RH,
other reported adverse effects include transient hypertension, drymouth, exces-
sive salivation, paraesthesia and increased dysuria. Improving the biological
activity of LEP by increasing the cellular uptake and retention is a remedy to this
end. In this study, a prodrug strategy has been introduced to optimize the hy-
drophobicity of LEP by using an appropriate hydrophobic linker attached to
tris(4-methoxyphenyl)methanol (TPM) derivatives with the expectation to
improve the cellular uptake. In this regard, several LEP conjugates of TPM
derivatives with optimized hydrophobicity were synthesized by the reaction
of methoxy benzenes (e.g. anisole, 2-fluoroanisole, 2-methylanisole 1,2-di-
methoxybenzene or methyl 2-methoxybenzoate and 1,3,5-trioxane, followed by
the conjugation with LEP and dodecanedioic acid in the presence of HBTU/
DIPEA/DIC in moderate yields. Comparative antiproliferative assays between
TPM-LEP conjugates and the corresponding non-covalent physical mixtures of
the TPM derivatives and LEP were performed against human Caucasian pros-
tate adenocarcinoma (PC3), human breast cancer cell line (BT549) and mouse
pre-adipocytes (3T3-L1) cells and indicated moderare to high inhibition of the
cell proliferation at a concentration of 5-100 M after 24-72 h of incubation.
These data suggest that TPM-LEP derivatives with optimized hydrophobicity
can be used to improve the biological activity of LEP.
#2181 Antibody-conjugated nanoparticles for targetingmetastatic triple-
negative breast cancer. Vidhi Khanna, Stephen Kalscheuer, Ameya Kirtane,
Jayanth Panyam. University of Minnesota, Minneapolis, MN.
Early detection and the availability of new treatments have improved the
survival rates of patients presenting with local or regional breast cancer to as
high as 99% and 85%, respectively. On the contrary, patients with metastatic
disease have a dismal 5-year survival rate of 17%. Thus, there is an urgent need
for treatment strategies directed towards metastasis. Our lab has developed an-
tibodies (Clone 6 and AM6) capable of recognizing tumor cells that have under-
gone epithelial-to-mesenchymal transition (EMT), a key step in the generation
of circulating tumor cells and metastasis. The goal of the current study was to
determine whether we use these antibodies as targeting ligands for directing
anticancer drug-loaded polymeric nanoparticles to metastatic triple negative
breast cancer cells as a novel therapeutic option. Polymeric PLGA nanoparticles
loaded with paclitaxel, a chemotherapeutic agent, were functionalized with the
antibodies using thiol-maleimide chemistry. We optimized the conjugation re-
action in order to achieve maximal cell uptake of nanoparticles without com-
promising antibody binding. In vitro studies were carried out in an MDA-MB-
231 derivative cell line with enhanced lung metastatic potential as well as a
melanoma metastatic cell line M12. Clone 6 nanoparticles and AM6 nanopar-
ticles showed signifıcant improvement in cellular uptake as well as retention. A
competition experiment confırmed target-mediated uptake of nanoparticles.
Cytotoxicity studies showed improved cell kill using Clone 6 nanoparticles and
AM6 nanoparticles. Based on these promising in vitro results, we are currently
carrying out in vivo studies inmice. The development of a targeted drug delivery
system for the treatment of metastatic triple negative breast cancer can signifı-
cantly enhance the survival rate for patients who often have a life-expectancy of
less than one year.
#2183 Targeted delivery of hyaluronic acid-labeled chitosan nanopar-
ticles against CD44 overexpressed endothelial cell for tumor angiogenesis
therapy. Gahee Kim, Heedong Han. Konkuk University, Seoul, Republic of Ko-
rea.
Objective: RNA interference (RNAi)-based approaches hold great potential
for cancer therapy. Here, we developed siRNA-incorporated chitosan nanopar-
ticles coated with hyaluronic acid (HA-CH-NP/siRNA) to target CD44 receptor
on the surface of tumor endothelial cells Methods: Size and zeta potential of
HA-CH-NP were measured by light scattering with a particle size analyzer and
Zeta Plus.Morphology ofHA-CH-NPwas observed by atomic forcemicroscopy
(AFM). HA-based selective binding of HA-CH-NP on the CD44 positive cells
was assessed by flow cytometry and immunohistochemistry (IHC) analysis.
Therapeutic effıcacy was examined in orthotopic mouse models of ovarian car-
cinoma. PLXDC1 mRNA was quantifıed using real-time reverse transcription-
polymerase chain reaction (RT-PCR). Additionally, biological effect on angio-
genesis (MCD), cell proliferation (Ki67), and apoptosis (TUNEL) in the tumor
tissue were examined by IHC analysis. Results: HA-CH-NP/siRNA was 185 	
10nm in size and zeta potential was 26.4mV, respectively. The loading effıciency
of siRNA into HA-CH-NP/siRNAwas up to 60%.We confırmed selective bind-
ing effıciency of HA-CH-NP/siRNA with CD44 tumor endothelial cells was
increased 2.1-fold compared to CH-NP/siRNA. PLXDC1 silencing using HA-
CH-NP/siRNA signifıcantly inhibited tumor growth in A2780 tumor growth in
A2780 tumor-bearing mice compared to control (p 0.0001), and mRNA ex-
pression of PLXDC1 was signifıcantly decreased in HA-CH-NP/siRNA treated
group. In addition, treatment with HA-CH-NP/siRNA resulted in signifıcant
inhibition of cell proliferation (p 0.05), microvessel density ( p 0.05), and
increased cell apoptosis (p  0.05). Conclusion: This study demonstrated that
HA-CH-NP/siRNA was a novel and highly selective delivery system for siRNA
with potential for broad applications for tumor angiogenesis therapy.
#2184 Development and testing of nanoformulation of a vascular disrupt-
ing agent in rat glioma with MRI monitoring. Meser M. Ali, Sunalee Jaya-
sundara, James R. Ewing. Henry Ford Hospital, Detroit, MI.
Anti-angiogenesis therapy VEGF-VEGF receptors (VEGFRs) axis alone or in
combination with other therapeutic agents have demonstrated mixed results,
with the majority of reports indicating that glioblastoma multiform (GBM) de-
veloped resistance against anti-angiogenesis therapy as well as small molecular
receptor tyrosine kinase inhibitors. This result is perhaps not unexpected, be-
cause angiogenesis is obviously complex, involving dozen of different growth
factors that trigger a cascade of subsequent events. Even if a drug effectively
blocks one angiogenic growth factor, such as VEGF, blood vessels may still
develop via activating alternative pathways. Yet without a suffıcient blood sup-
ply, cancerous tumors can’t grow larger than the head of a pin and are unlikely to
become lethal. Therefore, tumor vascularization is a critical process that deter-
mines tumor growth, progression and metastasis. Thus, tumor vasculature has
become an emerging target for new chemotherapeutic drugs Vascular disrupt-
ing agents (VDAs) for example, combretastatin (CA4), represent a new class of
chemotherapeutic agent that targets the newly formed vasculature in solid tu-
mors. Preclinical and early phase trials have demonstrated the promising ther-
apeutic benefıts of CA4. Nevertheless, the clinical translation of CA4 has been
signifıcantly hampered due to its poor systemic bioavailability and the non-
specifıc distribution of CA4 throughout the body when administered intra-
venously. Thus, it is reasonable to explore novel formulations of CA4 that
overcome the limitations mentioned above. To improve bioavailability com-
bretastatin phosphate (CA4-P) has been synthesized. But, CA4-P showed
short blood half life. We have engineered dendrimer-based nano-sized CA4
conjugate which demonstrates high water solubility. Preliminary intrave-
nous (i.v.) delivery of nano-combretastatin in an orthotropic glioma model
demonstrated a necrosis at the core of the tumor leaving a rim of viable
tissue. The MRI-determined tissue parameters Ktrans, blood flow (CBF),
DWI, ADCmap, distribution volume and tumor size indicated the effective-
ness of nano-combretastatin treatment.
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#2185 Cross-disciplinary optimization of nano-drug delivery to ovarian
carcinoma and glioma cells. Rupin Singh,1 Rana Falahat,2 Eva Williams,2 Jo-
seph O. Johnson,3 Norma Alcantar,2 Aleksandra Karolak,3 Katarzyna Rejniak,3
Marzenna Wiranowska1. 1University of South Florida Morsani College of Medi-
cine, Tampa, FL; 2University of South Florida College of Engineering, Tampa, FL;
3H. Lee Moffıtt Cancer Center and Research Institute, Tampa, FL.
This study reports on the quantitative analysis of the diffusion and localiza-
tion of a targeted drug delivery system (DDS) consisting of fluorescent labeled
0.01 Mpaclitaxel-BODIPY 564/570 encapsulated in non-ionic surfactant ves-
icles embedded in a thermosensitive cross-linked chitosan hydrogel. This is a
multi-tiered DDS that allows for enhanced stability, sustained and controlled
delivery of embedded drugs to tumor sites, and reduced toxicity. We showed
that cancer cells of epithelial origin, such as human ovarian epithelial carcinoma
OV2008 and highlymigratorymouse gliomaG-26, overexpressMUC1, amucin
surface antigen, which effectively enhances the specifıc targeting capacity of
chitosan. Utilizing this DDS we found that OV2008 carcinoma cells had 2
times higher fluorescence intensity level than normal ovarian epithelial IMCC3
cells with a statistical signifıcance at 5 min and 24 h incubation times suggesting
that this DDS had a higher affınity for tumor cells. Therefore, we hypothesized
that there is a difference in PTX diffusion towards epithelial origin tumor cells
when compared to normal cells in both distance/location and time. Diffusion
and localization of fluorescent labeled PTXwas evaluated in vitro using confocal
microscopy. The fluorescence intensity captured on the images was quantifıed
with ImageJ software in OV2008 carcinoma cells and compared to IMCC3 nor-
mal cells at time intervals 5 min, 1 h, 24 h, 48 h, and 72 h. The fluorescence
intensity image datawas analyzed inmultiple radial line segments separated into
three different zones of 24 m each to represent multiple diffusion distances.
Our results showed that fluorescence intensity levels in the zones around the
IMCC3 normal cells at 5 min and 1 h were signifıcantly higher (p0.05) than
around OV2008 carcinoma cells correlating reciprocally with our fınding of
intracellular fluorescence intensity in these two cell lines. Therefore, the data
evaluating fluorescence levels in the radial zones outside the cells indicated that
the migrating DDS-PTX had already been taken up by the tumor cells. Further-
more, the normal cells which showed signifıcantly lower intracellular levels of
fluorescence had higher levels of fluorescence in the measured radial zones out-
side the cells. This PTX-BODIPY 564/570 diffusion data from in vitro studies is
currently being used for computational modeling in the in vivo intracerebral
model of G-26 glioma. It will be integrated with mathematical model simula-
tions that describe the pharmacokinetic and pharmacodynamic (PK/PD) prop-
erties of this drug delivery system for the evaluation of its effıcacy and to opti-
mize drug delivery in vivo. Computational modelling is being done in Matlab
using the treatment scenario of the post-surgical late-stage glioma. The simula-
tion studies will be used to determine optimal drug concentrations, chitosan
density, and localization.
#2186 Peptide-cleavable maytansinoid (ADCs) induce high bystander
killing leading to improved anti-tumor activity in vivo.Wayne C. Widdison,
Juliet A. Costoplus, Jose F. Ponte, Leanne Lanieri, Yulius Setiady, Ling Dong,
Anna Skaletskaya, RuiWu,QifengQiu, YelenaKovtun, Ravi V. Chari. Immuno-
Gen Inc., Waltham, MD.
Antibodies targeting surface antigens on cancer cells typically have progres-
sively lower access to tumor cells that are further removed from blood vessels.
Also, the antibody will not bind to cells in the tumor mass that do not express
antigen, including stromal cells of the tumor, many of which reportedly aid in
the survival or metastasis of cancer cells. ADCs can bind to antigen positive
cancer cells, after which they are internalized and catabolized to release one or
more cytotoxic metabolite(s) that can kill the targeted cell. Metabolites that are
membrane permeable may also diffuse into and kill neighboring cells, often
called bystander cells, that would normally be less accessible. The goal of this
work was to design ADCs that would have increased bystander activity, which
could result in greater killing of cancer cells and stromal cells in the tumor
environment. We have prepared a new type of peptide-cleavable immolative
ADC (PCI-ADC) that effıciently releases membrane permeable cytotoxic may-
tansinoid metabolites upon cleavage of the peptide linker, followed by immola-
tion. Several PCI-ADCs were prepared that release metabolites having different
degrees of hydrophobicity. As the hydrophobicity of the metabolite increased,
the PCI-ADCs’ bystander activity also increased. The lead PCI-ADC generally
displayed a similar degree of in vitro cytotoxicity as maytansinoid ADCs that
utilize disulfıde linkers, however the PCI-ADC induced signifıcantly more by-
stander killing. In mice bearing large tumor xenografts (250 mm3) or tumor
xenografts that express the target antigen heterogeneously, PCI-ADCs were
found to bemore effıcacious thanmaytansinoid ADCs that use disulfıde linkers,
as well as our recently reported peptide-para-anilino maytansinoid ADCs. The
nature of the amino acid residues in the peptide linker of the PCI-ADCwas also
altered so that the tolerability of the ADCs in mice could be increased without
impeding effıcacy. In conclusion, we have developed a promising new type of
maytansinoid ADC, one that provides a high degree of bystander killing, im-
proved activity in homogeneous and heterogeneous tumor models in vivo, and
has a different mechanism of metabolite release than current maytansinoid
based ADCs.
#2187 Apro-nanodrugwith intratumoral reconstitution and intracellular
delivery beyond therapy-resistance molecular pumps. Rong Xu,1 Mauro Fer-
rari,2 Haifa Shen2. 1Department of Pharmacology, School of Basic Medicine,
TongjiMedical College, HuazhongUniversity of Science andTechnology,Wuhan,
China; 2Department of Nanomedicine, Houston Methodist Research Institute,
Houston, TX.
Tumor metastases to distant organs pose a serious challenge to cancer treat-
ment. The metastatic tumor lesions are less accessible to cancer drugs and the
malignant cells often quickly develop therapy resistance. To address both bio-
logical and drug transport concerns in cancer treatment, we have developed a
novel composite pro-nanodrug to provide sustained intra-tumoral assembly of
nanotherapeutics, and tested its anti-cancer effıcacy in murine models of breast
cancer metastases to the lung and liver. Specifıcally, large payloads of polymeric
doxorubicin (pDox) pro-drug were packaged as single molecules into a porous
silicon microparticles that can be enriched in tumor tissue in the forms of vas-
cular and cellular depots. Once inside the tumor, the pDox molecules self-as-
semble into nanoparticles that are released into the tissue where they are effec-
tively internalized by tumor cells. The nanoparticulate prodrug is transported
through the vesicular system, and doxorubicin is cleaved from the polymer and
released in the immediate proximity of the nucleus beyond the reach of the drug
efflux pumps. In vivo effıcacy studies demonstrated that the pro-nanodrug was
effective in treating metastatic tumors with or without expression of the multi-
drug resistant genes.
#2188 Targeted delivery of pro-apoptotic peptide using ELP-based carrier
for effective cancer therapy in various cancer model. Sarangthem Vijaya,
Rang-Woon Park. Kyungpook National University, School of Medicine, Daegu,
Republic of Korea.
Therapeutic peptides classifıed as biopharmaceuticals have gained attention
as a new generation of cancer therapeutics with enhanced effıciency and dimin-
ished toxicity. They often fail to have suffıcient effects due to their unsatisfactory
pharmacokinetic profıles, which include poor bioavailability, low stability, short
half-life, and poor penetration across the biological membrane. Elastin-like
polypeptide (ELP)-based drug delivery has been utilized for various applications
including cancer therapies formany years. Genetic incorporation of internaliza-
tion ligands and cell targeting peptides alongwith ELPpolymer enhanced tumor
accumulation and retention time as well as stability and activities of the drug
conjugates. Herein, we described a unique delivery system comprised of genet-
ically engineered ELP incorporated withmultiple copies of IL-4 receptor target-
ing peptide (AP1) periodically and proapoptotic peptide (KLAKLAK)2 referred
to as AP1-ELP-KLAK. It triggered thermal responsive self-assembly into a
nanoparticle-like structure at physiological body temperature and stabilized its
helical conformation, which is critical for its membrane disrupting activities.
Increased IL-4 receptor specifıc cellular internalization was associated with the
enhanced cytotoxic effect of (KLAKLAK)2 peptide. Additionally, multivalent
presentation of targeting ligands by AP1-ELP-KLAK signifıcantly enhanced in-
tratumoral localization and prolonged the retention time compared to ELP-
KLAK, non-targeted control. Systemic administration of AP1-ELP-KLAK sig-
nifıcantly inhibited tumor growth by provoking cell apoptosis in MDA-MB231
breast cancer and B16F10 melanoma tumor xenograft models without any spe-
cifıc organ toxicity. Thus, our newly designed AP1-ELP-KLAK polymer nano-
particle is a promising candidate for effective cancer therapy and due to the
simple preparative procedures of ELPs, this platform can be used as a good
carrier for tumor-specifıc delivery of other therapeutics.
#2189 Adhesion and entry of gold nanoparticles into breast cancer cells:
Nanoparticles for localized drug delivery/hyperthermia. Vanessa O. Uzon-
wanne,1 John David Obayemi,1 Jingjie Hu,1 Karen Malatesta,1 Nicolas Anuku,2
Winston Soboyejo3. 1Princeton University, Princeton, NJ; 2Bronx Community
College, Bronx, NY; 3Worcester Polytechnic Institute, Worcester, MA.
The specifıc targeting of breast cancer cells is important for the early detection
and treatment of cancer cells /tumor tissue, hence the drive for the development
of nanoparticles. This paper presents results of an atomic force microscopy
study on the adhesion between triple negative breast cancer cells (MDA-MB-231
and MDA-MB-468) and biosynthesized gold nanoparticles (GNP) conjugated
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with luteinizing hormone releasing hormone (LHRH) which is known to target
LHRH receptors that are over-expressed on the surfaces of breast cancer cells. It
also estimates time scales for Gold nanoparticle entry into cells by means of an
analytical model. The adhesion forces between the LHRH-conjugated gold
nanoparticles and the breast cancer cells are found to be about 4-5 times greater
than those between normal breast cells and LHRH-conjugated gold nanopar-
ticles. The increase in the adhesion of LHRH to breast cancer cells is shown to be
associated with an increase in the LHRH receptor density, which is revealed
using confocal microscopy. The implications of the results are discussed for
localized treatment of breast cancer.
#2190 Theranostical nanoscale metal-organic frameworks-mediated
rapid multiplexed microRNA detection and highly therapeutic effıcacy in
living oral cancer cells. Pei Yu,1 Zehang Zhuang,1 Guihua Qiu,2 Haolin Chen,1
Yuying Zhao,1 Jinxiang Chen,2 Xiqiang Liu1. 1Guanghua School of Stomatology,
Hospital of Stomatology, Sun Yat-sen University, Guangzhou, China; 2College of
Pharmacology, Southern Medical University, Guangzhou, China.
Oral cancer represents the sixthmost frequent cancer in the world, character-
ized by high poor prognosis and low survival rate due to local relapse and me-
tastasis. MicroRNAs (miRNAs) have been discovered as diagnostic biomarkers
and therapeutic targets for oral cancer. However, one of the major challenges of
miRNAs-based theranostical approach is to achieve effıcient and safe delivery.
Thus, a reliable sensing strategy that can detect miRNAs expression levels in
living cancer cells is urgently needed. Herein, a novel sensing platform based on
nanoscale metal-organic framework (NMOF) conjugated with the fluoro-
phores-labeled single-stranded DNA probe (p-DNA) was fabricated tomonitor
and inhibit multiplexed miRNAs expression in living oral cancer cells. The flow
cytometry and confocal laser scanning microscopy (CLSM) were carried out to
evaluate the expression levels of miRNAs in oral cancer cells. The miRNA inhi-
bition effıciency was examined by RT-PCR. The effects of the complexes on
tumor cell invasion and migration were assessed by transwell assay and wound
healing. The flow cytometry, colony formation assay and CCK8 were used to
assess cell apoptosis and proliferation. The results showed that NMOF works as
fluorescence quencher of the labeled p-DNA. In presence of the target miRNA
(including miR-7, miR-21, and miR-155), p-DNA was able to rapidly hybridize
and release from the NMOF leading to the recovery of fluorescence in living
cells, which can be detected in real-time. Moreover, RT-PCR results demon-
strated that the multiplexed miRNAs could be effectively downregulated after
treatment of p-DNA@NMOF, resulting in the simultaneous suppression of oral
cancer cell proliferation, anti-apoptosis, migration and invasion in vitro. In
summary, our study suggests that p-DNA@NMOF possess great potential for
combining early diagnosis and gene therapy of oral cancer.
#2191 Multiple imaging reporter labeled acid-degradable dextran nano-
polymer as a COX-2 siRNA carrier for COX-2 specifıc downregulation. Zhi-
hang Chen, Balaji Krishnamachary, Marie-France Penet, Zaver M. Bhujwalla.
Johns Hopkins University, SOM, Baltimore, MD.
Cyclooxygenase-2 (COX-2) as a target has attracted interest for multiple de-
generative diseases and cancers. COX-2 siRNA provides specifıc and effective
down-regulation of COX-2. However, because artifıcial cationic polymers can
induce proinflammatory signals that increase COX-2 expression, there are few if
any reports about the use of artifıcial cationic polymers as siRNA carrier to
downregulate COX-2 in cancer cells. Here we developed a method to effıciently
synthesize a multiple imaging reporter labeled biodegradable dextran to use as
an effıcient cationic polymer carrier for COX-2 siRNAdelivery. Amine function
groups were conjugated to the dextran platform through acetal bonds. Acetal
bonds were broken at acidic conditions that occur in cancer and endocytosis
compartments. Rhodamine was labeled to the amine groups to detect degrada-
tion and removal of these groups from the cell, while the dextran scaffold was
labeled with Cy5.5. The rapid cleavage and release of amine groups minimized
the proinflammatory side effects of the positively charged amine groups.Colo-
rimetric assay of Cy5.5 and rhodamine in different pH buffer indicated that the
amine group was cleaved at pH 5.5 buffer but was stable in pH 7.4 buffer. Fluo-
rescence imaging showed that the dextran siRNA nanoplex entered the cells
through endocytosis that provided acidic conditions for the breaking of the
amine group. For the fırst time, the intracellular breaking of acetal bonds was
clearly visualized by multiple imaging reporters. Because the rapid cleavage and
release of amine groups minimized the proinflammatory side-effects, quantita-
tive reverse transcription polymerase chain reaction (qRT-PCR) assay indicated
that this dextran COX-2 siRNA nanoplex could downregulate COX-2 expres-
sion effıciently. Prostaglandin E2 level decreased signifıcantly with COX-2
siRNA/dextran treatment. In vivo imaging demonstrated that the COX-2
siRNA/dextran nanoplex accumulated in MDA-MB-231 tumors. QRT-PCR
and western blot assays of COX-2 levels in tumor tissue demonstrated that this
nanoplex signifıcantly downregulated COX-2 expression in vivo effıciently and
within 24h. This dextran nanopolymer can be used as a safe, reproducible, and
biocompatible siRNA carrier to effectively reduce COX-2 expression in cancer
cells and tumors.
#2192 DFP-10825 IP delivery provides a new effective treatment option to
peritoneal-disseminated cancers.Cheng Jin,1 Kenzo Iizuka,1 Kokoro Eshima,1
Masakazu Fukushima,1 Tatsuhiro Ishida,2 Cheng-LongHuang,3HiromiWada,3
Kiyoshi Eshima1. 1Delta-Fly Pharma, Inc., Tokushima, Japan; 2Tokushima Univer-
sity, Tokushima, Japan; 3Kyoto University, Kyoto, Japan.
Objective: Peritoneal disseminated ovarian and pancreatic cancers are the
most diffıcult to be treated with conventional cytotoxic or molecular targeted
drugs. The treatment option is very limited although an intraperitoneal (IP)
paclitaxel has been available and shown to improve a prognosis in patients.
Therefore, it is urgent to develop a new IP chemotherapeutic drug regulating the
fast DNA synthesis in peritoneal disseminated tumors originated commonly
from the ovary, pancreas and stomach. We have developed a unique RNAi
molecule consisting of shRNA (55-mer) against TS and a cationic liposome
(DFP-10825) and tested its anti-tumor activity and PK profıle in peritoneal
disseminated ascetic tumor models. Methods: We developed luciferase gene-
transfected ovarian cancer (SKOV3-luc) and pancreatic cancer (PANC-1-luc)
models inmice.After IP injection of 5x106 cells,DFP-10825 containing 20gTS
shRNA (20 mg/mouse) was administered in an IP route (q3d x 4) to the tumor-
bearingmice. In combination therapy, paclitaxel (10mg/kg) was also IP admin-
istered to SKOV3-luc model to which the treatment was performed in the same
schedule. The anti-tumor effect was assessed by measuring luciferase activity
and tumor volume. Furthermore, the TS expression level in both ascetic tumor
cells and solid tumors was measured by conventional RT-PCR. For PK study
with DFP-10825 (especially TS shRNA), total RNAs were isolated at various
time points from ascetic tumor cells and disseminated SKOV3-luc solid tumor
models treatedwithDFP-10825 andTS shRNA levels were determined by Stem-
loop RT-PCR. Results: IP DFP-10825 delivery signifıcantly suppressed the
growth of ascetic SKOV3-luc and PANC-1-luc tumor cells and extended the
survival time of these tumor-bearingmice compared with that of control group.
Combination with the IP paclitaxel augmented the effıcacy of DFP-10825. After
the IP administration, TS shRNA levels derived fromDFP-10825 in ascetic fluid
were maintained at nM range (0.7 - 4.3-nM) across 24 hours but not detected
(below 5 pM) in the plasma, suggesting that TS shRNA be relatively stable in the
peritoneal cavity to be able to exert its anti-tumor activity but not in blood. Also,
TS expression (TS mRNA) in ascetic tumor cells was signifıcantly suppressed,
supporting the notion that the anti-tumor activity and host survival benefıt by
DFP-10825 in tumor-bearing mice are through MOA to knock down the TS
level in tumors specifıcally. Conclusion: IP administration of newly developed
DFP-10825, the TS shRNA conjugated with cationic liposome is localized stably
in the peritoneal cavity and provides a new effective treatment option to the
intractable peritoneal disseminated ovarian and pancreatic cancers without any
systemic adverse events.
#2193 Structural modifıcation of the chemotherapeutic anandamide: De-
signing anti-cancer agents and investigating their COX-2 metabolic prod-
ucts. Andrew Morris,1 Eman Soliman,2 Rukiyah Van Dross,1 Colin Burns1.
1East Carolina University, Greenville, NC; 2Faculty of Pharmacy, Zagazig Uni-
versity, Zagazig, Egypt.
Many epithelial cancers have been shown to overexpress the enzyme cyclo-
oxygenase-2 (COX-2), an enzyme responsible for metabolizing anandamide
(AEA) to prostamides. AEA has demonstrated cytotoxicity in COX-2 overex-
pressing cancers via its metabolism to novel J-series prostamides, namely 15d-
PMJ2. Fatty acid amide hydrolase (FAAH) degrades AEA into arachidonic acid
and ethanolamine (EA), limiting the cytotoxic capability of AEA. Cell lines with
high FAAHexpression have demonstrated resistance toAEA. By understanding
the metabolic characteristics of FAAH, we can design AEA analogs which cir-
cumvent FAAH breakdown. To examine the effects of altering polarity, steric
bulk, and functional groups on AEA-mediated cytotoxicity, we investigated
known AEA derivatives which possess these properties. Arvanil, Arachidonoyl
Diethanolamine (ADA), Arachidonoyl Serinol (AS), and R1-methanandamide
(m-AEA) add steric bulk to the molecule via aromatic rings, extra EA arms and
additional alcohol/methyl functional groups respectively. Arachidonoyl glycine
(NAGly) substitutes the terminal EA alcohol with a carboxylic acid increasing
polarity. Arachidonoyl-2=-chloroethylamine (AC) substitutes the terminal EA
alcohol with a highly soluble chlorine. Furthermore, it is known that Arvanil,
ADA, AS, and m-AEA resist degradation of the molecule by FAAH and NAGly
is a known substrate of COX-2. Therefore our goal was to determine which
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structural modifıcations improve AEA-mediated cytotoxicity. To determine
this, JWF2 tumorigenic keratinocytes were exposed to differing concentrations
of the AEA analogs for 24 hours and cell viability was measured by conducting
MTS assays. Arvanil demonstrated a 90% reduction in cell viability, NAGly
demonstrated a 70% reduction in cell viability, and m-AEA demonstrated a
100% reduction in cell viability at 20M, the optimal dosage of AEA. Due to the
fact that ADA, AS, and AC did not show a signifıcant reduction in cell viability
thesemoleculeswere not further examined.MTS assayswere conducted in other
epithelial cancer cell lines with varying expressions of COX-2 and FAAH. Each
cell linewas exposed to varying concentrations of eitherNAGly, Arvanil, or both
for 24 hours. NAGly demonstrated a 40% reduction in cell viability in HT-29
colon cancer cells (low COX-2, high FAAH). Arvanil demonstrated a 60% re-
duction in A431 tumorigenic keratinocytes. NAGly demonstrated a 60% reduc-
tion in cell viability and Arvanil demonstrated a 100% reduction in cell viability
in patient-derived primary melanoma. These fındings suggest that modulation
and substitute to the core structure of AEAwill result in decreased susceptibility
to FAAH degradation and enhanced antineoplastic activity.
#2194 Synergistic cytotoxicity of targeted liposomes containing doxoru-
bicin andC6-ceramide against nucleolin-overexpressing ovarian cancer cells
is supported by the downregulation of the Akt pathway. Ana Filipa Cruz,1
Nuno André Fonseca,2 Susana F. Sampaio,2 VeraMoura,3 Ramiro D. Almeida,2
Sérgio Simões,1 João Nuno Moreira1. 1CNC - Center for Neuroscience and Cell
Biology; FFUC - Faculty of Pharmacy; University of Coimbra, Coimbra, Portugal;
2CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coim-
bra, Portugal; 3TREAT U, SA, Coimbra, Portugal.
The acknowledgment that cancer stem cells (CSC) may originate from non-
stem cancer cells, interconverting through an EMT-mediated process has
turned these distinct cell subpopulations into two relevant therapeutic targets.
Moreover, the PI3K/AKT/mTOR pathway is essential to CSC proliferation and
survival and it is often over activated in ovarian cancer. One of the strategies to
target these different tumor cell populations, relies on the combination of con-
ventional chemotherapeutic drugs (as tumor debulking agents, targeting non-
stem cancer cells) with sphingolipids targeting CSC (at the level of PI3K/Akt/
mTOR). Nucleolin overexpression has been demonstrated on the surface of
both breast CSC and non-stem breast cancer cells (Fonseca NA, Biomaterials
2015) and endothelial cells from tumor blood vessels. The pH-sensitive lipid-
based nanoparticle, functionalized with the nucleolin-binding F3 peptide, was
recently modifıed to encapsulate a synergistic combination of a sphingolipid
(C6-ceramide) and doxorubicin (DXR). Following the promising results in
breast cancer, the aim of this work was to assess the therapeutic potential of this
strategy against nucleolin-overexpressing ovarian cancer cell lines, as well as the
underlying mechanism of action at the molecular level. A 12.9-fold increase of
association of fluorescently-labelled F3 peptide-targeted liposomes ([F3]L), rel-
ative to the non-targeted counterparts, into (bulk) ovarian cancer cell lines
(SKOV-3, OVCAR-3 and TOV-112D) was observed by flow cytometry. Impor-
tantly, a similar pattern of association by putative CSC enriched population
(CD44high/EpCAMhigh) was also observed. These results corroborated the
marked increase of cytotoxicity (assessed by the resazurin reduction viability
assay) enabled by the targeted drug combinations, relative to [F3]L containing
only DXR. In fact, the targeted drug combination enabled a 90% death of
SKOV-3 cancer cells, following an 8 h incubation, a level of cell killing not
achieved by the counterpart containing only DXR. Against the OVCAR-3 and
TOV-112D cell lines, the IC90 of the targeted drug combination, following 1 h of
incubation, was 2-fold lower than the one resulting from the incubation with
[F3]L containing only DXR. In addition, the effect of nucleolin-mediated intra-
cellular delivery of C6-ceramide at the p-Akt protein levels was further discrim-
inated by western blot analysis in SKOV-3 cells. The observed 3.2-fold down-
regulation of p-Akt levels supported the C6-ceramide-mediated improved
cytotoxicity of the drug combination. Overall, these results pointed out the en-
hanced effıcacy of targeted synergistic drug combinations against ovarian can-
cer, due to the capability to target nucleolin-overexpressing cancer cells and
further inhibit the Akt pathway.
#2195 Combined strategy based on pre-activated analogs of oxazaphos-
phorines for increased therapeutic index and immunemodulation. Julia De-
lahousse,1,7 Charles Skarbek,1 Valentine Gauthier,1 M. Desbois,2 Emilie Roger,3
C. Pioche-Durieu,4 M. Rivard,5 D. Desmaële,6 T. Martens,5 E. Le Cam,4 Jean-
Pierre Benoit,3 P. Couvreur,6 Nathalie Chaput-Gras,2 Angelo Paci1,1,7,8. 1UMR
CNRS 8203, Gustave Roussy, Villejuif, France; 2INSERM/CNRS-UMS3655, Ville-
juif, France; 3INSERM-U1066, Angers, France; 4UMR 8126, CNRS, Gustave
Roussy, Villejuif, France; 5ICMPE, UMR 7182, CNRS, Thiais, France; 6UMR
8612, CNRS, Chatenay-Malabry, France; 7Gustave Roussy, Villejuif, France;
8Universite Paris-Sud, Chatenay-Malabry, France.
Oxazaphosphorines (Oxaza) represented by cyclophosphamide (CPA) and
ifosfamide (IFO) are still the corner stone of several polychemotherapy proto-
cols as they are widely indicated in the treatment of numerous cancer from soft
tissue sarcomas to lymphomas and immune-related diseases. However, Oxaza
are prodrugs requiring cytochrome (CYP) P450 bioactivation responsible of
limiting adverse effects. In the case of IFO, bioactivation leads to a low release of
4-OH-IFO (10%), which generates the active nitrogenmustard displaying DNA
cross-links. Associated toxicities of IFO due to acrolein, (urotoxicity) and to
chloroacetaldehyde (neuro and nephrotoxicity) have been described. Thus, in-
creasing IFO therapeutic index could be of major interest. To circumvent these
toxicities, our team has designed new pre-activated IFO analogs to avoid CYP
bioactivation (Skarbek et al J Med Chem 2015). Among these analogues some
have the ability to self-assemble as nanoassemblies (NAs), the others can be
encapsulated within nano-lipid capsules (NLCs). These new drug delivery sys-
tems (DDS) can take advantage of passive targeting, as stealthiness of these
DDS can be provided by PEGylation by using Cholesterol-polyethylene gly-
col or the use of surfactant. These DDS can also be functionalized by appro-
priate monoclonal antibodies leading to multi stage DDS with active target-
ing properties. Regarding CPA, it has been shown and described in literature
that low doses of CPA enhance the immunity by promoting differentiation of
CD4 cell toward Th1. As IFO is isomeric form of CPA, it was assumed that
IFO could also have such properties. Studies on immunocompetent
MCA205 mouse model, an immunogenic fıbrosarcoma mouse model, dem-
onstrate a dose-dependent immunomodulation of IFO towards a modula-
tion of the secretion of IFNy, IL-17A and IL-6 cytokines. The ongoing ex-
periments on mouse model depleted in CD4 T cells and CD8 T cells show
the antitumor effıcacy of IFO 150mg/kg on these immune cells in tumor
regression. Both strategies could lead to the design of nano-immuno-conju-
gates (NICs) which could benefıt of the immunomodulatory effects of X-
Oxaza combined to their antiproliferative properties targeted through im-
mune checkpoint antibodies. These new functionalized DDS may provide a
useful strategy to give specifıcity to active drugs used for many years in
clinical practice. Both DDS could be grafted with mAbs which could lead to
a new family of DDS aiming to combine antiproliferative and immuno-
modulatory properties for a dual antitumoral action.
#2196 SDF-1/CXCR4 axis-mediated tumor-tropism of monocyte mem-
brane-coated nanoparticles.Yi-NanLi, Chien-WenChang, Chi-ShiunChiang.
National Tsing Hua University, Hsinchu City, Taiwan.
Tumor-associated macrophages are one of the most abundant infıltrating
cells in solid tumors. These cells are originated from the bone marrow and
circulating in peripheral blood. Through the specifıc chemoattractant released
by the tumor cells or stromal cells, bone marrow-derived monocytes (BMDMs)
are able to accumulate at the tumor site by their corresponding receptors. In this
study, we utilized the characteristics of tumor-tropism of BMDMs on a nano-
particle-based drug delivery system. We hypothesized that the cellular mem-
brane of BMDMs can provide nanoparticle protection from the mononuclear
phagocyte system and the chemokine receptor on the membrane can enhance
the tumor-tropism of the nanoparticles. To prove the hypothesis, the cellular
membrane was extracted from BMDMs and then coated on the drug-loaded
nanoparticles.We also found that the expression of chemokine receptor CXCR4
on the bone BMDMs can be induced following the stimulation of tumor condi-
tioned medium. The tumor targeting effect of the monocyte membrane-coated
nanoparticles is diminished against SDF-1 knockdown tumor cells. These re-
sults indicate that the SDF-1/CXCR4 axis is contributed to the tumor-tropismof
the monocyte membrane-coated nanoparticles toward astrocytoma cell line,
ALTS1C1, and this effect can be boosted by the stimulation of tumor condi-
tioned medium. In conclusion, we established a nanoparticle-based drug deliv-
ery platform against brain tumor with the cellular membrane coating technol-
ogy andmaximized the effect of tumor-targeting by tumor conditionedmedium
stimulation.
#2197 Characterization of immunoliposomes as delivery vehicles for the
Rac inhibitor Ehop-016 in HER2 type breast cancer. Michael J. Rivera-Rob-
les,1 Pablo E. Vivas-Mejia,2 Linette Castillo-Pichardo,3 Cornelis Vlaar,4 Eliud
Hernández,4 SuranganieDharmawardhane5. 1University of Puerto Rico School of
Medicine, San Juan, PR; 2University of Puerto Rico, San Juan, PR; 3Universidad
Central del Caribe, Bayamon, PR; 4University of Puerto Rico School of Pharmacy,
San Juan, PR; 5Surangani Dharmawardhane, San Juan, PR.
Due to the critical need for improved therapeutics against advanced Stage IV
breast cancer, we developed and pre-clinically validated the small molecule
Ehop-016 as a potential anti-metastatic drug. Ehop-016 is a small molecule
inhibitor of the interaction Rac with the guanine nucleotide exchange factor
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(GEF)Vav2, which consequently decreases invasive actin structures and cellular
migration. In a human epidermal growth factor receptor 2 (HER2) type breast
cancer model in nude mice, Ehop-016 inhibits mammary tumor growth, angio-
genesis, and metastasis. Moreover, Ehop-016 reduces HER2 cancer cell vi-
ability and migration, individually or in combination with anti HER2 or EGFR
directed therapeutics. By inhibiting the key signaling intermediate Rac, Ehop-
016 has the potential to block signaling downstreamofHER2 andEGFRs, aswell
as signaling via the myriad of receptors that activate Rac, and inhibit cancer
progression. Our new results demonstrate that Ehop-016 inhibits both cancer
cells and leukocytes in the tumor microenvironment, as well as cytokine levels
(IL-6) in mouse plasma. Even though these characteristics are desirable in anti-
cancer agents, systemic therapy with Ehop-016 may adversely affect normal
immune system function. Therefore, a strategy was developed for the targeted
delivery of Ehop-016 into mammary tumors, using nanoliposomes containing
the current breast cancer therapeutic, Trastuzumab, a monoclonal antibody
directed at the HER2. We tested various nanoliposome formulations as tar-
geted delivery systems for Ehop-016. First, the encapsulation effıciency of
Ehop-016 loaded liposomes was tested using different drug loadingmethods.
To obtain HER2 targeted liposomes, we prepared Trastuzumab-lipid conju-
gates and incorporated them into the Ehop-016 containing liposomes. The
binding, internalization and selectivity of our HER2 targeted delivery system
was verifıed in human metastatic breast cancer cell lines, by using fluores-
cence microscopy to assess the co-staining of the lipid bilayer and Trastu-
zumab. In order to evaluate the effectiveness and selectivity of the immuno-
liposomes in delivering Ehop-016 and inhibiting Rac activity, pull-down
assays were performed to detect active Rac-GTP in cells treated with Ehop-
016 alone or Trastuzumab-conjugated liposomes with Ehop-016. Results
show that the Trastuzumab-conjugated liposomes are more selective at
binding to HER2 breast cancer cells and inhibiting Rac, than treatment
with Ehop-016 alone. In summary, our novel delivery system containing
Ehop-016 and Trastuzumab has been shown to be effective in breast cancer
cells, and needs to be validated in animal models of metastatic breast cancer.
The development of this targeted delivery system has implications, not only
in the fıeld of breast cancer therapeutics, but may be adapted for the treat-
ment of other diseases, and used to overcome the side effects of current
treatments.
#2198 Cancer cellmembrane coated biomimetic nanoparticles: Synthesis,
characterization, and functionality. Jiefu Jin, Di Chang, Samit Chatterjee,
Balaji Krishnamachary, Yelena Mironchik, Sridhar Nimmagadda, Zaver M.
Bhujwalla. Johns Hopkins Univ. School of Medicine, Baltimore, MD.
Introduction: Biomimetic nanoparticles (NPs) combining synthetic and bio-
logical materials have flexibility and functionality for drug delivery and immu-
nomodulation.1 Red blood cell (RBC)membranes coated poly(lactic-co-glycolic
acid) (PLGA) NPs that mimic RBCs and act as nanosponges for toxins were
recently described.2-3Here, we coated cancer cellmembranes onto PLGANPs in
a “right-side” out manner, to translocate membrane anchored proteins onto
NPs. Cancer cell membrane coated PLGA NPs hold promise for disrupting
cancer cell-stromal cell interactions, and for priming the immune system in
cancer immunotherapy. Method: Plasma membrane fractions (MFs) of U87
(low CXCR4) and U87-CXCR4 (high CXCR4) cells were isolated upon homog-
enization, and sucrose density gradient centrifugation. MFs and PLGA NPs
were mixed and physically extruded through a porous membrane to obtain
MF-coated PLGA NPs. MFs were probed with antibodies against cell fraction
markers, andCXCR4.MFs-coatedNPs,MFs and PLGANPswere characterized
on size, morphology, and zeta-potential. The orientation ofMFs andMF-coated
NPs was investigated by confocal microscopy and flow cytometry. Transwell
migration assays were performed to investigate the migration of cancer cells
towards human mammary fıbroblasts (HMFs). Immune-competent Balb/c
mice were immunized with IR700-labeled MFs or MF-coated NPs via subcuta-
neous injection through hock and imaged in vivo and ex vivo by near-infrared
(NIR) fluorescence. Immune responses to MFs or MF-coated NPs were exam-
ined on activating CD4 and CD8 T lymphocytes in lymph nodes and spleens
by flow cytometry. Results: Plasmamembrane purity was confırmed fromwest-
ern blot analysis that showed the signifıcant enrichment of Na/K-ATPase,
negligible amount of GPR78 or GAPDH inMFs. PLGANPs, U87-CXCR4MFs
andU87-CXCR4MFs-coatedNPs had average diameters of 50 nm, 200 nm, and
70 nm, respectively. Z-average diameters and zeta-potential of PLGANPs, U87-
CXCR4MFs, and U87-CXCR4MFs-coated NPs were 79.8 nm, 336 nm and 168
nm, and -34.3 mV, -24.9 mV and -25.0 mV, respectively. Confocal fluorescence
microscopy and flow cytometry detected intense PE fluorescence and higher
CXCR4 inU87-CXCR4MFs andU87-CXCR4MFs-coatedNPs thanU87 coun-
terparts, confırming a “right-side” out orientation. When U87 or U87-CXCR4
MFs were added to HMFs in the transwell assay, fewer cancer cells migrated
towards HMFs, identifying the unique ability of MFs in disrupting HMF-
cancer cell interactions. U87-CXCR4 MFs and MF-coated NPs were ob-
served in the popliteal lymph nodes, and triggered the induction of CD8 T
lymphocytes, identifying a role for MF-coated NPs in providing cancer cell
membranes to antigen presenting cells to induce a tumor-specifıc immune
response. References: 1. Fang, R. et al. Small 2015; 2. Hu, C. et al. PNAS 2011;
3. Hu, C. et al. Nat. Nanotechnol. 2013. Supported by NIH R21 CA198243
and P50 CA103175.
#2199 Magnetoelectric nanoparticles for high-specifıcity treatment of
cancer. Sakhrat Khizroev,1 Abhi Nagesetti,1 Tiffanie S. Stewart,2 Emmanuel
Stimphil,1 Alexa Rodzinski,1 Rakesh Guduru,1 Ping Liang3. 1Florida Interna-
tional University, Miami, FL; 2University of Notre Dame, Notre Dame, IN; 3Cel-
lular Nanomed, Weston, FL.
Introduction:Delivering adrug specifıcally into the tumor cell past itsmembrane
and then releasing the drug into the tumor cells without affecting the normal cells
remains a formidable challenge. Unlike any other nanoparticles, magnetoelectric
nanoparticles (MENs) display a non-zero magnetoelectric (ME) effect and thus
presentauniquecapability touseexternalmagnetic fıelds tocontrol intrinsic electric
fıelds associated with cell membranes and the interaction betweenMENs and ther-
apeutic loads. Because cancer and normal cells of the same type have different elec-
tric properties,MENs is used for high-specifıcity targeted delivery. An a.c.magnetic
fıeld is used to trigger drug release off the nanoparticles. Brief Methods: 30-nm
CoFe2O4-BaTiO3 core shellMENs, with amagnetization of 1 emu/g, a coercivity of
300 Oe, and a ME coeffıcient of 10-100 mV cm1 Oe1 were prepared with a co-
precipitationprocess.MENswerecoatedwith fluorescein isothiocyanate tomonitor
their intra-cellular transport through a high-contrast confocal microscopy. Three
cancer cell lines including Skov-3 (Ovarian adenocarcinoma), U87-MG (Glioblas-
toma), andMCF-7A (Breast adenocarcinoma), and two normal cell lines including
brain endothelial cells (Brain EC) and ovarian cells HOMECwere cultured at 37°C.
The transport of MENs loaded with drugs, peptides, and RNAs through the cell
membranes and the consequent release of the load under different d.c. and a.c.
magnetic fıelds were studied through confocal microscopy and photoabsorption
spectroscopy, respectively. Trypan-blue viability count was used to assess cell
growth inhibitionunder different study conditions.Atomic forcemicroscopyof the
cellmembraneswas conducted tounderstand the interactionbetween thenanopar-
ticles and the cells. Summary of new data: Comparison of MENs with purely mag-
netic iron oxide nanoparticles showed that the penetration through the cancer cell
membrane could be achieved onlywithMENs. It took d.c. fıelds of 100Oe and over
1000 Oe to nanoelectroporate the membranes of SKOV-3 and HOMEC cell lines,
respectively.Ana.c.magnetic fıeldwitha strengthof50Oeandanear-d.c. frequency
of 100 Hz was suffıcient to enable release of a therapeutic load off MENs. All the
cancer cell lines under study showedmembrane penetration threshold d.c. fıelds at
least a factor of ten smaller compared to their normal counterparts. Conclusion:
MENs displayed unique capabilities for externally controlled high-specifıcity tar-
geted anticancer drugdelivery and release ondemandvia application of d.c. and a.c.
magnetic fıelds, respectively. Because MENs rely on a physical mechanism rather
than antibody-mediated delivery, they can be used for high specifıcity delivery and
high-effıcacy controlled release of a broad range of therapeutic loads including
drugs, peptides, and RNAs to treat many different cancers.
#2200 Dual carfılzomib and doxorubicin carrying nanoparticles for syn-
ergistic effıcacy in multiple myeloma. Basar Bilgicer, Tanyel Kiziltepe, David
Omstead. University of Notre Dame, Notre Dame, IN.
We describe the synthesis and analysis of dual carfılzomib and doxorubicin
loaded nanoparticles in their ability to deliver both drugs to multiple myeloma tu-
mor cells at their optimal synergistic ratio. First, to identify the optimal synergistic
ratio, variousmolar ratios of carfılzomib to doxorubicinwere screened againstmul-
tiple myeloma cell lines using the Chou-Talalay method. Both therapeutic agents
were then incorporated into liposomes at the identifıed optimal synergistic ratio of
1:1 to achieve dual drug loaded nanoparticles with a narrow size distribution of
100 nm and with high reproducibility. Our results established that the dual drug
loaded nanoparticles exhibited synergy in vitro andweremore effıcacious in inhib-
iting tumor growth in vivo than a combination of free drugs, while at the same time
reducing systemic toxicity. In conclusion, this study achieved the preclinical evalu-
ation of dual drug loaded liposomes containing carfılzomib and doxorubicin for
enhanced therapeutic effıcacy to improve patient outcome inmultiple myeloma.
#2201 Downregulation ofNF-kBbynanoconjugates to overcomedrug resis-
tance in ovarian tumors.Ajit P. Zambre,1 Sarjukumar Panchal,1 AlyssaWorland,1
Sarah Chapman,2 Matthew Leevy,2 Anandhi Upendran,1 Raghuraman Kannan1.
1Univ. of Missouri, Columbia, MO; 2University of Notre Dame, Notre Dame, IN.
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Ovarian cancer is the fıfth leading cause of cancer deaths in women. Globally,
around 140k women die from ovarian cancer per year. Recurrence can lead to de-
velopment of resistance to fırst line agents such as platinum analogs, taxanes, and
doxorubicin. Several studies have shown that decrease of NF-B expression will
inhibit P-glycoprotein maturation and thereby overcome drug resistance. In this
context, it is well known that Disulfıram (DSF), a FDA approved drug for anti-
alcoholism, have been identifıed as moderate inhibitor of NF-B activity. It is also
shown that DSF possess mild anti-cancer effects via increased permeability of the
outer membrane of mitochondria resulting in leakage of proteins, such as cyto-
chrome C, generation of ROS that simulates the ROS-MAPK pathway leading to
apoptosis, and inhibition of P-glycoprotein. As suchDSF is not a strong therapeutic
agent; however, in combinationwith copper it showed excellent therapeutic benefıt.
This effect ismainly attributed tometabolitediethyldithio-carbamate -aproteasome
inhibitor that was produced upon complexation of DSF with copper. However,
delivery ofDSF-Cu complexwas not successful in clinical setting.We hypothesized
gold nanoparticles can serve as potential delivery vehicle to selectively transfer Cu-
DSF to turmorwithout toxicity. Indeed, cellular studies in drug sensitive (OVCAR)
andAdriamycin resistant p-glycoprotein expressing (NCI-ADR/RES) ovarian can-
cer cells indicated that the gold nanoconjugate exhibit signifıcant cytotoxicity and
the IC-50 values was decreased 2.5 fold times compared to the Cu-DSF complex.
NF-Bexpressionwasdecreasedby two folds compared tonativeCu-DSFcomplex.
Detailed cellular and mechanistic studies along with the evaluation of [Au(DSF-
Cu)NP] in humanmulti-drug resistant (NCI-ADR/RES) mouse xenografts will be
presented.
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#2202 FABP5 in urinary extracellular vesicles is a potential biomarker of
high Gleason score prostate cancer. Kazutoshi Fujita,1 Hideaki Kume,2 Kyo-
suke Matsuzaki,1 Atsunari Kawashima,1 Takeshi Ujike,1 Akira Nagahara,1 Mo-
tohide Uemura,1 Yasushi Miyagawa,1 Takeshi Tomonaga,3 Norio Nonomura1.
1Osaka Univ. Graduate School of Medicine, Osaka, Japan; 2Laboratory of Pro-
teome Research, National Institute of Biomedical Innovation, Health and Nutri-
tion, Ibaraki, Japan; 3National Institute of Biomedical Innovation, Health and
Nutrition, Ibaraki, Japan.
Urine collected after prostate massage is a promising source of new biomark-
ers of prostate cancer, and was reported to contain extracellular vesicles (EVs)
that are secreted from prostate cancer cells. EVs are microvesicles secreted from
various cell types. EVs contain microRNAs, proteins, and mRNAs and play a
role in intercellular communications via the mechanisms of exocytosis and en-
docytosis. We aimed to discover a new biomarker for high Gleason score (GS)
prostate cancer (PCa) in urinary EVs via quantitative proteomics. Material and
methods: Urine samples after massage were collected from 18 patients before
prostate needle biopsy. Six patients had negative biopsy outcomes, 6 had Glea-
son score 6 prostate cancer (GS6), and 6 hadGleason score 8 to 9 prostate cancer
(GS8-9). Urinary EVs were isolated from urine with ultracentrifuge. Protein
extracted fromEVswere labeledwith 4-plex iTRAQand liquid chromatography
tandem mass spectrometry (LC-MS/MS) was used for proteome analysis. The
candidate proteins were quantitated in the independent set by selected reaction
monitoring/multiple reactionmonitoring analysis (SRM/MRM). Results: Seven
proteins increased in patients with PCa compared to those with negative biopsy
(ratio 2.0, p-value 0.05). Thirteen proteins were chosen for further analysis
and verifıed in 29 independent urine samples (negative [n 11], PCa [n 18])
using selected reactionmonitoring/multiple reactionmonitoring. Among these
candidate markers, fatty acid binding protein 5 (FABP5) was higher in the can-
cer group than in the negative group (p-value  0.009) and was signifıcantly
associated with GS (p-value for trend  0.011). Conclusions: We applied the
proteomic analysis to discover biomarkers in EVs in urine collected after pros-
tate massage. FABP5 in urinary EVs could be a potential biomarker of high GS
prostate cancer. Additional large-scale studies are warranted to confırm this
fınding.
#2203 A SRM/MRM based targeted proteomics strategy for absolute
quantifıcation of potential biomarkers of TKI sensitivity in EGFR mutated
lung adenocarcinoma. Shivangi Awasthi,1 XuZhang,1 TapanMaity,1 Benjamin
L. Oyler,2 David R. Goodlett,3 Udayan Guha1. 1Thoracic & Gastrointestinal On-
cology Branch, Center for Cancer Research, NCI, Bethesda, MD; 2Institute of
Marine and Environmental Technology, University of Maryland Center for Envi-
ronmental Science, Baltimore,MD; 3School of Pharmacy,University ofMaryland,
Baltimore, MD.
Lung cancer remains the leading cause of cancer-related deaths worldwide.
Epidermal growth factor receptor(EGFR) is the primary driver oncogene in
10-30% lung adenocarcinoma. Kinase domain mutations in EGFR (L858R and
E746-A750 deletion) provide sensitivity to EGFR-specifıc tyrosine kinase inhib-
itors (TKIs). Despite good tumor inhibitory effects, after approximately a year,
patients acquire resistance to EGFR TKIs. We have carried out a stable isotope
labeling with amino acids in cell culture (SILAC)-based quantitative mass spec-
trometry (MS) on a Thermo Orbitrap Elite to identify and characterize the
dynamics of tyrosine phosphorylation upon TKI treatment of human lung ad-
enocarcinoma cell lines. The degree of inhibition of phosphorylation of several
phospho-sites correlated with the extent of TKI-sensitivity. Several kinases and
adaptor proteins that were signifıcantly differentially phosphorylated include
AHNAK-Y160, -Y715, STAT5A-Y694, DAPP1-Y139, ERRFI1-Y394, NEDD9-
Y164, NF1-Y2579, INNPL1-Y1135, suggesting that these are a subset of poten-
tial biomarkers of TKI response. To corroborate our results, the next logical step
is to carry out clinical validation of these phospho-sites in human lung adeno-
carcinoma patients, however no absolute quantifıcation assay is currently avail-
able for these tyrosine phosphorylated peptides in human samples. The MS
method most often used to complement shotgun methods is selected/multiple
reaction monitoring (SRM/MRM) because of its high sensitivity, speed and
dynamic range. We have performed SRM/MRM-MS using a nano-flow high
performance liquid chromatography instrument coupled to a nano-electro-
spray ionization source attached to a Triple Quadrupole MS (Agilent 6495).
In this method, digested proteins are chromatographically separated and
ionized. The resulting precursor ions are m/z fıltered in the fırst quadru-
pole(Q1) and collision induced dissociation is carried out in Q2 and the
resultant product ions are m/z fıltered in Q3. Each precursor-product pair is
termed as a transition. For absolute quantifıcation, heavy isotope labelled
versions of the target peptides are spiked in biological samples to build a
calibration curve. For the robust assay development, we have carried out the
initial empirical refınement process using the heavy labelled versions of the
target peptides, including selection of optimal transitions, normalizing re-
tention times of peptides, running peptide stability assays and digestion time
course experiments. We are currently validating these assays in human lung
adenocarcinoma cell lines with known EGFR mutations with or without
treatment with 1st and 3rd generation EGFR TKIs. The overall goal of these
targeted studies is to develop absolute quantitation assays to precisely and
accurately quantify these potential biomarkers in clinical samples.
#2204 A proteomic landscape of diffuse-type gastric cancer. Sai Ge,1 Xia
Xia,2 Chen Ding,3 Bei Zhen,2 Quan Zhou,2 Jinwen Feng,4 Jiajia Yuan,1 Rui
Chen,5 Yumei Li,5 Zhongqi Ge,5 Jiafu Ji,1 Lianhai Zhang,1 Jiayuan Wang,1
ZhongwuLi,1 Yumei Lai,1 YingHu,1 Yanyan Li,1 Yilin Li,1 JingGao,1 LinChen,6
Jianming Xu,7 Chunchao Zhang,5 Sung Yun Jung,5 Mingwei Liu,2 Lei Song,2
Wanlin Liu,2 Gaigai Guo,2 Tongqing Gong,2 Yin Huang,2 Yang Qiu,2 Tieliu
Shi,4WeiminZhu,2 YiWang,5 FuchuHe,2 Lin Shen,1 JunQin,2CNHPP. 1Peking
University Cancer Hospital & Institute, Beijing, China; 2National Center for Pro-
tein Sciences (The PHOENIX center), Beijing, China; 3Fudan University, Shang-
hai, China; 4East China Normal University, Shanghai, China; 5Baylor College of
Medicine, Houston, TX; 6General Hospital of Chinese People’s Liberation Army,
Beijing, China; 7Affıliated Hospital of Academy of Military Medical Sciences,
Beijing, China.
Gastric cancer is a heterogeneous disease characterized by poor clinical out-
comes and limited targeted treatment options.Among them, diffuse-type gastric
cancer (DGC) is the subtype with worst prognosis. Here we describe the fırst
proteomic landscape of DGC. We carried out proteome profıling and targeted
exome DNA sequencing of 84 DGC samples. We analyzed the 1,008 (168 x 6)
raw fıles together for uniformed quality control and protein identifıcation with
1% global protein false discovery rate (FDR), which resulted in the identifıcation
of 11,340 gene products (GPs). A SAM (signifıcance analysis of microarray)
analysis identifıed 1,641 proteins as differentially expressed between T (tumor)
and N (nearby) with statistical signifıcance (FDR q value0.01 by SAM and
differential expression ratio0.5/ -0.5), including 1,211 up-regulated and 430
down-regulated GPs. Gene Ontology annotation indicated that tumor pro-
teomes were signifıcantly enriched in cell cycle, DNA replication, checkpoint,
E2F, WNT, p53 signaling, epithelial mesenchymal transition (EMT), and in-
flammation/cytokine-receptor interaction pathways, and the proteomes of the
nearby tissues are enriched in metabolism pathways, such as fatty acid metabo-
lism, oxidative phosphorylation, and amino acid metabolism. Notably, many
gastric makers (ANXA10, VSIG1, CLDN18, CTSE, TFF2, MUC5AC and
MUC6) and signature proteins for stomach functions, including digestion, ab-
sorption, secretion, and stomach acid generation (PGC, GIF, GAST, and
ATP4A), were lost in tumors. Based on proteome profıling alone, DGC can be
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subtyped into 3 major classes (PX1-3) that exhibit distinct proteome features
and correlate with distinct clinical outcomes (Gehan-Breslow-Wilcoxon P 
0.024). PX1 exhibits proteome stability and the best overall survival; PX2 exhib-
its dysregulation in DNA replication and cell cycle, and is most sensitive to
chemotherapy; PX3 features hyper-activated immune response and is not re-
sponsive to chemotherapy.We identifıed seven-marker proteins that can stratify
DGC patients into these three subtypes, opening a door for proteome subtyping
in clinical application and intervention. Furthermore, we nominated drug target
candidates taking into consideration both the altered DGC proteome and asso-
ciation data with patients’ overall survival. This study revealed the altered sig-
naling pathways in DGC and demonstrated the advantage of proteomic ap-
proach in molecular subtyping of cancer.
#2205 Identifıcation of potential biomarker related to EGFRmutation by
functional proteome profıling in primary non-small cell lung cancer. Yuan-
Ling Hsu, Szu-Hua Pan. National Taiwan Univ., Taipei, Taiwan.
Non-small-cell lung cancer (NSCLC) accounts for approximately 85%of lung
cancers which the leading cause of cancer-related death worldwide. Recently,
epidermal growth factor receptor (EGFR) activating mutations have been
proved relevant to NSCLC and let treatment of EGFR tyrosine kinase inhibitors
(EGFR-TKIs) become an alternative therapy for NSCLC patients. Despite excel-
lent clinical response to EGFR-TKIs, the intrinsic and acquired resistance to
EGFR-TKI created challenges in clinical practice. Although severalmechanisms
may contribute to solve EGFRTKIs resistance, there still have 20% to 30% of
these patients that how the resistance developed remain unclear. Studies indi-
cated that the increment of membrane efflux may be associated with drug resis-
tance. In this study, we use differential membrane proteomic analysis to identify
potential biomarkers for therapeutics of EGFR-TIKs resistance in NSCLC pa-
tients.Several primary NSCLC cell lines with different EGFR status were be
isolated by our laboratory. Identifıcation of modulators on membrane of pri-
mary cancer cells with different EGFR status was analyzed by membrane pro-
teomic assay using LC-MS/MS. The expression patterns of EGFRmutation cells
would comparewith that of wild type groups and the potential candidates would
be selected by cross the results of interactome profıles of EGFR mutation cell
lines. The expression patterns and functional role of these candidates were be
examined in NSCLC cells by several molecular, cellular and biochemical analy-
sis; and demonstrated the clinical relevance of these specifıc targets with EGFR
mutation. The expressions of 100 modulators up-regulated in EGFR mutation
cells compared with that of wild type group. After cross reacted with the 474
interaction proteins of mutated EGFR, 8 proteins were selected as potential
candidates that related to EGFR-TKI resistance, especially the expression of a
protein we called SHX in EGFR mutation cells. We demonstrated the real ex-
pression levels of SHX in different lung cancer cells, and performed network
analysis of SHX and EGFR in translational level.The analysis of differential
membrane proteomic found several novelbiomarkers and potential regulation
mechanisms that related to the development of EGFR-TKIs resistance in
NSCLC. These identifıcation may provide us new direction for exploiting ther-
apeutic strategy for NSCLC treatment in the future.
#2206 Proteome phenotype of stage III metastatic melanoma and re-
sponse toMEK inhibition.Christoph Krisp,1 Robert Parker,1 Dana Pascovici,1
James Wilmott,2 John F. Thompson,2 Graham J. Mann,2 Richard A. Scolyer,2
Nicholas K. Hayward,3 Mark P. Molloy1. 1Macquarie University, Sydney, Aus-
tralia; 2University of Sydney, Sydney, Australia; 3QIMRBerghofer, Brisbane, Aus-
tralia.
Introduction: Melanoma accounts for 5% of all skin cancers, yet is the most
common cause of skin cancer-related deaths, and is the commonest lethal ma-
lignancy in young people (40yrs). Patients with BRAF mutant melanoma
show survival benefıt from MAPK pathway inhibition, although response rates
vary. We conducted proteomic screening using mass spectrometry to detect
cellular processes that might predict response to MEK inhibition more effec-
tively than genotyping alone. Methods: Protein extracts from early passages of
ten AJCC Stage III local lymph nodemetastatic melanoma cell lines with known
MAPKmutational status (BRAFmut,NRASmut,MAPKwt,)were used. Further,
32 fresh frozen NRASmut or BRAFmut AJCC Stage IIIC metastatic melanoma
(lymph node metastases) specimens were obtained from patients with varying
survival. Lysed cells and tissue were digested with trypsin and analysed by LC-
MS/MS using a TripleTOF 5600/6600 mass spectrometer. Data-independent
acquisition (or SWATH-MS) was used to match multiplexed MS/MS spectra
against a spectral ion library enabling relative protein quantifıcation. Cell line
viability in the presence of 2M AZD6244 (MEKi) was determined using a
PrestoBlue assay. Results: The SWATH-MS approach enabled quantifıcation of
2500 proteins across all 10 cell lines. Principal component analysis clearly
segregated melanomas based on in vitro sensitivity to MEK inhibition, whereas
genotype alone did not. In total, we show 57 proteins whose abundances corre-
late (r²0.75) with response to MEKi, revealing roles in cell pigmentation bio-
synthesis, lipid metabolism, adherence and inter-cell communication. Survival
analysis demonstrated that patients whose cell lines were responsive to MEKi
had lower mortality than patients whose cells were resistant to MEKi (survival
7.5 years MEKi sensitive versus 1.7 years MEKi resistant, p0.01). Across
the 32 tumour samples, 2000 proteins were quantifıable. The proteome phe-
notype associated withMEK inhibition observed in patient cell lines was a dom-
inant signal in fresh frozen stage IIImetastaticmelanoma specimens, suggesting
these patients may have profıted from MAPK pathway inhibition had these
drugs been available. In this patient cohort neither the genotype nor proteome
phenotype correlated with survival. Conclusion: Proteomic profıling by mass
spectrometry demonstrated a MEK inhibition phenotype in early passage cell
lines and fresh frozen melanoma metastases which may provide utility for se-
lecting patients to treat with MEK drugs.
#2207 HSP90 inhibition leads to a differential proteomics profıle in non
small cell lung cancer cell lines.AngelaMarrugal,1 Irene Ferrer,1MariaDolores
Pastor,2 Alvaro Quintanal,1 Antonio Lucena-Cacace,2 Amancio Carnero,2 Luis
Paz-Ares,1 Sonia Molina-Pinelo1. 1CNIO, Madrid, Spain; 2IBIS, Sevilla, Spain.
Background: The cancer chaperone, Heat Shock Protein 90 (HSP90), is
known for its ability to regulate the stability of different oncogenic proteins.
Thus, its overexpression has been related to unfavorable prognosis in some types
of tumors. EGFR and EML4-ALK, two of the most important drivers in non-
small cell lung cancer (NSCLC), are HSP90 clients and extremely depend on it.
As a consequence, this chaperone is especially important in NSCLC hence
HSP90 inhibition shows a lot of possibilities to future treatments in this tumor
type. Nevertheless, to obtain a successful clinical development, will be essential
supporting evidence of inhibitory effıcacy in several molecularly defıned sub-
groups ofNSCLC.Methods:NSCLCcell lines carrying different genemutations,
whose direct (HCC827: EGFRmutated andH3122: EML4-ALK rearrangement)
and indirect (A549: KRASmutated) relationshipwithHSP90 has been reported,
were used. In these cell lines, alongwithH1781 (EGFR,KRAS,ALKwild type) as
control, the activity of the chaperone studied was interrupted. To this end, phar-
macological inhibition of HSP90 was achieved through geldanamycin and res-
orcinol derivates. First, western blotting was carried out to confırm the effect of
this inhibition. Later, to identify a proteomic profıle associated with HSP90
inhibition, two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of
selected cell lines were performed. Results: The expression of the oncogenic
HSP90 client proteins studied was decreased by the inhibitors in the NSCLC cell
lines. The oncoproteins drivers EGFR and EML4-ALK showed a strong depen-
dence on HSP90 observed through a high sensitivity of the cell lines HCC827
and H3122 to the inhibition. Therefore, these cell lines were selected with the
purpose of identify a proteomic signature linked to HSP90 inhibition by 2D-
PAGE. The untreated EGFR positive cell line presented 104 protein spots sig-
nifıcantly up-regulated, whereas 80 spots were down-regulated compared to
inhibited cell line. Meanwhile, the cell line harboring the EML4-ALK transloca-
tion showed 16 spots up-regulated and 5 down-regulated in the untreated versus
inhibited cell line. In additionHSP70 overexpression, compared to unprocessed
cell lines, was detected after treatments. This feedback, previously reported,
confırmed HSP90 inhibition in the two cell lines studied. Conclusions: The
evidence of treatment response, in the cell lines studied, was showed through
oncogenic client proteins reduction as well as HSP70 induction. The proteomic
profıles identifıed, of HSP90 inhibited and untreated tumor cells, revealed sev-
eral deregulated pathways involved in the tumorigenesis.
#2208 Peptide-mediated ‘miniprep’ isolation of extracellular vesicles is
suitable for high-throughput proteomics; method evaluation and applica-
tion in colon cancer. Meike De Wit,1 Jaco Knol,2 Inge de Reus,2 Tim Tim
Schelfhorst,2 Logan Bishop-Currey,2 Nicole van Grieken,2 Sander Piersma,2
ThangV. Pham,2 Remond J. Fijneman,1 Gerrit A.Meijer,1 HenkVerheul,2 Con-
nie R. Jimenez2. 1Netherlands Cancer Institute, Amsterdam, Netherlands; 2VU
University Medical Center, Amsterdam, Netherlands.
Objective: Extracellular vesicles (EVs) are cell-secreted membrane vesicles
enclosed by a lipid bilayer derived from endosomes or from the plasma mem-
brane. Since they are released into body fluids, and their cargo includes tissue-
specifıc and disease-related molecules, EVs represent a rich source for disease
biomarkers. However, standard ultracentrifugation methods for EV isolation
(UC-EV) are laborious, time-consuming, and require high inputs. Method: A
recently described isolationmethod,which can be performed at small ‘miniprep’
scale, utilizes specifıc Heat Shock Protein (HSP)-binding peptides to aggregate
HSP-decorated EVs (Ghosh et al. (2014), PLoS ONE 9:e110443). The authors
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showed comparable results for their method (abbreviated HSP-EV here) and
UC-EV, but a detailed proteomic comparison was lacking. Therefore, we com-
pared both methods using label-free proteomics of replicate EV isolations from
HT-29 cancer cell-conditioned medium. Subsequently we applied this tech-
nique on secretomes of fresh human colorectal cancer (CRC) (n17) and colon
adenoma (n4) tissue as well as patient-matched normal colon tissue. Results:
Despite a 30-fold different input scale (UC-EV: 60 ml versus HSP-EV: 2 ml),
both methods yielded comparable numbers of identifıed proteins (3115 versus
3085), with reproducible identifıcations (72.5% versus 75.5%) and spectral
count-based quantifıcation (average CV 31% versus 27%). EVs obtained by ei-
ther method contained established EV markers and proteins linked to vesicle-
related gene ontologies. In the EV fraction of the tissue secretomes 6390 proteins
were identifıed, of which 471 proteins were signifıcantly 5-fold more present in
CRC samples than in normal tissue EVs. Gene ontology analysis revealed en-
richment of nuclear proteins involved in DNA damage response, chromosome
organization and RNA processing in the CRC EVs. Conclusions: The HSP-EV
method provides an advantageous, simple and rapid approach for EV isolation
from small amounts of biological samples, enabling high-throughput analysis in
a biomarker discovery setting.
#2209 Characterization of FABP5 antibodies in prostate.Dennis A.Otali,1
Denise K. Oelschlager,1 James Kearns,2 SandraM. Gaston,2William E. Grizzle1.
1Univ. of Alabama at Birmingham, Birmingham, AL; 2Tufts Medical Center,
Boston, MA.
FABP5, a member of a family of small proteins (15 kDa) that transport
lipids, is emerging as an important biomarker because it is differentially ex-
pressed in prostate cancers (PrCa) compared to uninvolved prostate glands and
lipids are important to the progression of prostate cancer. This study was to
select an antibody (Ab) for use in immunostaining (IHC) FABP5 in formalin
fıxed paraffın embedded (FFPE) tissue and also an Ab for use in Western blot-
ting (WB).Amousemonoclonal antibody (mAb) cloneA9 to FABP5 fromSanta
Cruz (SC) Biotechnology, Inc. and a rabbit polyclonal antibody (pAb) to FABP5
from Abcam (AB) (cat. # ab37267) were tested. Six prostate cell lines (PC3,
DU145, 22Rv1, MDA PCa 2b, LNCaP, and normal primary prostate epithelial
cells (NH Pri Pro) were used to study protein and mRNA levels of FABP5.
Protein expression of FABP5was determined byWB of whole cell lysates as well
as cytoplasmic and nuclear lysates. GAPDH, a “housekeeping” gene expressed at
similar levels in most types of cells, was used as a loading control for WB. Cells
from the six prostate cells lines also were embedded in HistoGel, processed to
FFPE and immunostained. The prostate cells were transfected with FABP5
siRNA forWB with aliquots of the transfected prostate cells processed to FFPE.
qrtPCR was performed to measure mRNA levels. The expression of whole cell
lysates on WB probed with the AB pAb to FABP5 was NH Pri Pro  PC3 
DU145  22Rv1  MDA PCa 2b  LNCaP compared to NH-Pri Pro 
PC3DU145 22Rv1 when probed with the SCmAb.WB of the cytoplasmic
fractions from each cell line has a similar pattern. In HistoGel sections immu-
nostained with AB pAb, the FABP5 cytoplasmic expression was PC3 
DU145  22Rv1  MDA PCa 2b  NH Pri Pro  LNCaP. These levels of
expression among the cell lines followed a similar trend in evaluation of immu-
nostaining of cell membranes, nuclear, and the perinuclear area. In HistoGel
sections immunostained with SC mAb, the FABP5 expression was PC3 
DU145 with weak signals in 22Rv1MDA PCa 2bNH Pri Pro LNCaP.
A recombinant blocking peptide (RBP) to FABP5 strongly inhibited the immu-
nostaining with the antibodies to FABP5 in FFPE sections from archival radical
prostatectomy specimens. This RBP is the same sequence as the peptide used to
produce the AB antibody. No RBP to FABP5 was available from SC. Incubation
with the RBP strongly inhibited the extent of immunostaining with FABP5 SC
mAb. Similarly, immunostaining of the 6 cell lines with the AB pAb following
incubationwith RBP strongly inhibited staining. In analysis ofmRNA levels, the
expression of FABP5 was PC3  22Rv1   DU145  MDA PCa 2b 
LNCaP. We demonstrated by siRNA and the use of a RBP that both these anti-
bodies are specifıc and sensitive for detecting FABP5 by immunostaining but the
ABAb ismore useful forWB.These results are presentedwith the IHCof FABP5
in normal and uninvolved prostate glands in PrCa.
#2210 Scavenging for lethal prostate cancer biomarkers in FFPE tissue.
Håkon Ramberg,1 Peder R. Braadland,2 Maria E. Stensland,3 Mehrdad Rakaee,4
Ståle Nygård,3 Olov Øgren,1 Viktor Berge,1 Aud Svindland,2 Elin Richardsson,5
Gustavo A. de Souza,3 Sigve Andersen,5 Kristin A. Taskén2. 1Oslo University
Hospital, Oslo, Norway; 2Oslo University Hospital and University of Oslo, Oslo,
Norway; 3University of Oslo, Oslo, Norway; 4University of Tromsø, Tromsø, Nor-
way; 5University Hospital of North Norway and University of Tromsø, Tromsø,
Norway.
The aim of this study was to identify protein biomarkers that can be used to
stratify indolent and aggressive prostate cancer using formalin-fıxed paraffın-
embedded tissue (FFPE) from radical prostatectomy specimens. The protein
expression profıles of benign and malign samples from 23 patients, who had
either died of prostate cancer or were alive 10 years after diagnosis, were deter-
mined using an Easy nLC1000 Nano-LC system connected to a quadrupole-
Orbitrap (Q Exactive) mass spectrometer equipped with a nanoelectrospray ion
source. The generated MS raw fıles were submitted to MaxQuant software for
protein identifıcation. Differential expression of LFQ-normalized intensities
was tested by Cox proportional hazards modeling and LASSO (least absolute
shrinkage and selection operator) regression analysis within the R software en-
vironment. The label freeOrbitrap analysis identifıed 3523unique proteins from
the FFPE tissue samples. LASSO of protein expression profıles of indolent and
aggressive prostate cancer tissue samples identifıed ten proteins which could
stratify the groups. Seven of the proteins were signifıcantly correlated with time
to prostate cancer specifıc mortality in Cox proportional hazards modeling (p-
value  0.05). The selected proteins were found to be linked to NFkappaB
signaling, cell structure, translation and metabolic pathways. Finally, proteins
capable of distinguishing benign frommalignant prostate tissue were identifıed
by LASSO, and 22 of these were signifıcantly different between the groups (Bon-
ferroni-adjusted p-value  0.05). Selected candidate biomarkers are currently
being validated by immunohistochemical analyses of 535 radical prostatectomy
specimens from two independent Norwegian cohorts with long follow-up time.
#2211 Characterization of monoclonal antibodies specifıc for HPV-posi-
tive head and neck cancer.Hsuan-Chen Liu,1 Falguni Parikh,1 Thomas Kraus,2
Thomas Moran,2 Andrew Sikora1. 1Baylor College of Medicine, Houston, TX;
2Icahn School of Medicine at Mount Sinai, New York, NY.
HPV-driven head and neck squamous cell carcinoma (HNSCC) are among
the fastest growing cancers. Although, HPV-HNSCC patients have an overall
favorable prognosis, a signifıcant number of patients relapse post-treatment,
and currently there is no specifıc therapeutic approach targeting the unique
biology of HPV-driven HNSCC. Our ongoing efforts to target HPV-HNSCC
focus on the identifıcation of cell surface antigens that are upregulated by HPV
infection. We have developed an ‘antigen-agnostic‘ approach for generating
HPV-HNSCC-targeting monoclonal antibodies for cancer diagnosis and treat-
ment that does not rely on prior identifıcation of target antigens.We usedHPV-
HNSCC membrane fractions to immunize recipient mice and generated HPV-
specifıc hybridomas. We then screened fıve thousand hybridoma colonies by
flow cytometry to test the specifıcity of binding toHPV-positive cancer cell lines
(2HNSCC and 2 Cervical Cancer) and HPV-negative cancer cell lines (4
HNSCC and 1 CC). After primary screening, we narrowed down to forty-four
clones; among these hybridoma clones, 6D8 and 6B3 bound preferentially to
HPV-positive cancer cell lines. The binding targets of 6D8 and 6B3 were iden-
tifıed by immunoprecipitation andmass spectrometry; their targets are integrin
alpha6 (ITGA6) and tissue factor (F3) respectively. Future work will validate the
biological function of these mAbs in in vitro and in vivo models, and continue
identifying more binding target of mAbs. We propose mAbs specifıcally target-
ing membrane-expressed antigens on HPV-related cancer cells as a potential
approach for early diagnosis and targeted therapy.
#2212 Protein engineering of the decapping enzymeNudT16 enhances its
ability to hydrolyze protein-conjugated ADP-ribose for post-translational
site identifıcation via mass spectrometry. Puchong Thirawatananond, Robert
L. McPherson, Jasmine K. Malhi, Anthony K. Leung, Sandra B. Gabelli. Johns
Hopkins University, Baltimore, MD.
During nonhomologous end joining of DNA follow double-stranded breaks,
one common signaling response is the adenosine diphosphate ribosylation
(ADP-ribosylation) of recruiter scaffold proteins. ADP-ribosylation is a post-
translational modifıcation (PTM) that occurs on aspartate, glutamate, lysine,
arginine and cysteine on proteins and is mediated chiefly by polyadenosine
ribose polymerases (PARP). Using NAD as its substrate, PARP transfers an
ADP-ribose onto another protein, releasing a nicotinamide ring in the process;
this modifıcation presents as a mono-ADP-ribosylation (MARylation) or poly-
ADP-ribosylation (PARylation).While site identifıcation ofMARylated protein
can be achieved through tandemMS/MS and searching for peptideswhose spec-
tra have been shifted by 541.0611 Da, a similar approach for PARylated protein
is confounded by the variable length and branching of its PTM. To this end,
ADP-ribosylated protein is normally incubated with a snake venom phospho-
diesterase (SVP) to leave a standardized phosphoribose tag of 212.0086 Da. It
has been shown that a recombinantly-expressed Nudix protein NudT16 pro-
vides a cost-effective alternative to SVP to process ADP-ribosylated protein.
NudT16 in the cell normally decaps small nucleolar RNA. Our studies here
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sought to utilize the x-ray crystallographic structure of NudT16 in complex with
ADP-ribose in guiding rational design mutations to enhance binding of our
desired ADP-ribose substrate and to widen the hydrolase’s active site to better
accommodate a protein-conjugated ADP-ribose. Mutants have demonstrated
improved catalytic effıciency forADP-ribose hydrolysis. Radiolabeled immuno-
assays of PARylated protein concur with these kinetic experiments by showing a
reduction of radiolabeled PARP. Rational design of a ADP-ribose-hydrolyzing
NudT16 with comparable catalytic effıciency to SVP eases lead discovery of
biological mechanisms that are mediated through ADP-ribosylation such as
DNA repair.
#2213 Aberrant glycoprotein expression in recurrent and non-recurrent
prostate cancer tissue. Sarah M. Totten, Cheylene Tanimoto, Abel Bermudez,
Amy Hembree, James D. Brooks, Sharon J. Pitteri. Stanford University School of
Medicine, Palo Alto, CA.
The primary aim of this study is to identify and quantify aberrancies in gly-
cosylation patterns and glycoprotein levels expressed in high grade prostate
cancer tissue from men with and without recurrence following radical prosta-
tectomy usingmulti-dimensional chromatography and tandemmass spectrom-
etry techniques. Glycosylation is a common and highly complex posttransla-
tionalmodifıcation, and is linked to protein function. Elucidating specifıc glycan
structures is key to understanding the underlying role glycosylation plays in
regulating cellular activity, including tumorigenesis, invasion, and metastasis.
Aberrant glycosylation is an emerging hallmark of various cancers, demonstrat-
ing that alterations in glycosylation disrupt cellular behavior in key pathways.
Furthermore, comprehensive glycan characterization can lead to more effective
biomarkers with increased clinical utility for distinguishing indolent disease
from cancers that aremore likely to becomemetastatic, recur and/or pose higher
risk. In this study, glycoproteomic analysis was performed on prostate cancer
tissue and matched normal prostate tissue from ten men with high grade pros-
tate cancer (Gleason 7/8) - fıve of which experienced recurrence. Proteins were
extracted from tissue lysates, denatured, reduced and alkylated. Isotopic labels
for quantitation were incorporated during alkylation - normal and cancer tissue
was labeled with 12C and 13C acrylamide respectively. Paired normal/cancer
tissues were combined. Glycosylated proteins from each pair were separated by
multi-lectin chromatography designed to capture sialylated, core-fucosylated,
and highly branched complex glycans, fractionating the complex mixture into
four discrete fractions containing specifıc glycoforms. LC-MS/MS was used to
analyze the tryptic digest from each fraction for protein identifıcation and quan-
titation. This experimental design reveals differences between the glycosylation pat-
terns and protein levels of cancerous and normal tissue in ten men, but also allows
for the comparison between those with recurrent cancers. The glycosylation pat-
terns across hundreds of prostate tissue proteins were systematically screened, en-
abling the detection and relative quantitation of specifıc glycoforms of proteins that
may be dysregulated in prostate cancer. Preliminary results reveal the identifıcation
of 6,202 unique proteins, and quantitation of 2,894 proteins, most of which con-
tained sialylated glycoforms. In all patients (regardless of treatment outcome), sev-
eral hundred proteins had elevated total protein levels in the 13C-labeled cancer
tissue compared to the 12C-labeled normal tissue proteins, such as TACSTD2 and
LPP, while other proteins demonstrated upregulation only among certain glyco-
forms. Other glycoproteins were up-regulated in cancer only in recurrent patients,
including CPNE1, TXND5, and CASC4.
#2214 Adaptive dynamic artifıcial polyligand targeting (ADAPT): a
method to identify exosomal proteins from a prostate cancer cell line.Tassilo
Hornung, Stephen Logie, Aniket S. Bondre, VarunMaher, Melissa N. Richards,
Jelena Zarkovic, Teresa T. Tinder, Heather A. O’Neill,Mark R.Miglarese, David
B. Spetzler. Caris Life Sciences, Phoenix, AZ.
In the recent years it was demonstrated that a multitude of body fluids con-
tains substantial amounts of exosomes, extracellular vesicles with sizes ranging
between 40 and 100 nm. Those vesicles have protein profıles characteristic of
their cells of origin. It was shown that exosomes play a role in cell-to-cell com-
munication making them attractive targets to identify early disease stage bio-
markers. Cancer heterogeneity is known for a long time to be an important
clinical determinant of patient outcome. We developed the highly multiplexed
ADAPTplatform to capture systems-based biological signatures thatmay reflect
the molecular heterogeneity of various cancer types and help to improve diag-
nosis of the disease. Exosomes from two prostate cancer cell lines, VCaP and
LNCaP, were used to train ssDNA libraries to discriminate them. A highly di-
verse library of 1012 oligonucleotides (ODNs) was subjected to fıve rounds of
positive and negative selection against exosomes from VCaP and LNCaP pros-
tate cancer cell lines. Individual ODNs that bound preferably to exosomes from
VCaP cells were identifıed byNGS, resynthesized and binding of co-precipitated
ODNs toVCaP exosomeswas verifıed by qPCR. LC-MS/MSwas used to identify
binding partners of ODNs bound to VCaP exosomes. Several of those binding
partners (CHMP1b/2a/4b, VPS28, Syntenin-1) were found to be part of the
ESCRTmachinery, which participates in exosomes biogenesis. It was found that
those proteins are overexpressed in human cancers. In addition, we identifıed
the chemokine I-TAC, which is overexpressed in blood and tissue of men with
advanced prostate adenocarcinomas. Finally, we found hnRNP-1, a cancer as-
sociated splicing factor, and the cold shock proteins RNPL and A18 hnRNP.
Knock-down of these cold shock proteins has been shown to enhance chemo-
therapeutic cell killing of prostate cells. ADAPT is an unbiased profıling plat-
form that identifıes cancer associated proteins expressed on exosomes. This
platform can be deployed against multiple cancer types and offers broad poten-
tial applications in biomarker discovery.
#2215 Detection of novel markers of transitional cell carcinoma of the
ovary, the TCC-like variant of high grade serous carcinoma, using proteom-
ics and immunohistochemistry. Basile Tessier-Cloutier,1 Jamie Magrill,2 Ste-
fan Kommoss,3 Blake C. Gilks,1 David G. Huntsman,2 Dawn R. Cochrane,2
Aline Talhouk,2 Robert Soslow,4Gregg B.Morin,2 Chris J. Hughes,2 AnthonyN.
Karnezis,2 Christine Chow,1 Angela S. Cheng,1 Andreas du Bois,5 Jacobus Pfıs-
terer,6 Friedrich Kommoss1. 1Vancouver General Hospital, Vancouver, British
Columbia, Canada; 2BC Cancer Agency, Vancouver, British Columbia, Canada;
3Tübingen University Hospital, Tübingen, Germany; 4Memorial Sloan Kettering
Cancer Center, New York, NY; 5Kliniken EssenMitte, Vancouver, Germany; 6Gy-
necologic Oncology Center, Kiel, Germany.
Background: The current WHO classifıcation does not separate transitional
carcinoma of the ovary (TCCO) from conventional high grade serous carci-
noma of the ovary (HGSC). TCCO has a better prognosis, possibly due to better
chemosensitivity or less infıltrative growth pattern. The available immunohis-
tochemical (IHC)markers donot differentiate between the two subtypes. There-
fore, we sought to compare the proteomic profıles of conventional HGSC and
TCCO to identify surrogate biomarkers of good prognosis from TCCO that
could identify conventional HGSC tumors with a better prognosis. Design: Full
proteome analysis of 12 cases of TCCO and 12 cases of HGSC was performed
using SP3-clinical proteomics, run on an ThermoFisher Orbitrap Fusion. For
validation, tissue microarrays of TCCO (n89) and HGSC (n237) were im-
munostained with antibodies against proteins found to be enriched in TCCO.
All cases and immunostains were scored by a gynecologic pathologist. Univari-
ate analysis was performed comparing IHC expression in TCCO vs. HGSC.
Results: We identifıed 1220 proteins that were signifıcantly enriched in TCCO
over HGSC. Claudin 4 and Ubiquitin carboxyl-terminal esterase L1 (UCHL1)
were selected as potentialmarkers of TCCO-like biology (p0.0017, 0.0322). By
IHC, Claudin 4 (95% confıdence interval (CI) 0.171, 0.430) andUCHL1 (95%CI
0.291, 0.550) showed a signifıcantly higher expression in TCCO as compared to
HGSC (see table).
% of tumors with high immunoreactivity scores
Claudin 4 UCHL1
Pure TCCO 34/59 (58%) 26/59 (44%)
Mixed TCCO-HGSC, TCCO
component
14/29 (48%) 8/29 (28%)
Mixed TCCO-HGSC,
HGSC component
19/28 (68%) 6/28 (21%)
Conventional HGSC 33/235 (14%) 32/237 (14%)
Legend: Mixed TCCO: TCCO with minor component of conventional HGSC
Conclusion: Proteomic analysis showed differing protein profıles for TCCOand
HGSC. By IHC, Claudin 4 and UCHL1 were identifıed as potential markers for
TCC-like differentiation of high-grade serous carcinomas. Further studies will
focus on the prognostic signifıcance of these and othermarkers in larger cohorts
of HGSC. This study presents a novel approach at identifying potential diagnos-
tic and prognostic biomarkers as well as therapeutic targets.
#2216 A novelMRM-basedmass spectrometry assay to quantify HMGB1.
Dawn Zhaohui Chen, Weston R. Spivia, Yang Gao, Jennifer Van Eyk, Shreya
Kanodia. Cedars-Sinai Medical Center, Los Angeles, CA.
Background:Highmobility groupbox1 (HMGB1) is a versatile proteinwithdual
roles. Within the cell, this highly conserved chromosomal protein functions as a
DNA chaperone. Outside of the cell, it functions as the prototypical damage-asso-
ciated molecular pattern. There is signifıcant evidence that HMGB1 dysfunction
contributes to cancer development, particularly in mesothelioma, where its role in
carcinogenesis is better defıned. Goal: To develop a mass spectrometry based im-
mune-multiple reactionmonitoring (iMRM) assay to quantifyHMGB1 and its dis-
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ease-associated post-translationally modifıed forms. Methods: Mesothelioma cell
lines (Ren,Phi andPP-Mill) knownto secreteHMGB1wereused.Concentratedcell
line supernatants, anti-HMGB1 antibody-loaded magnetic beads were incubated
overnight. Beads were extensively washed and theHMGB1 released from the beads
was enzymatically digested prior to targeted MRM mass spectrometry. Known
quantity of N15 labeled synthetic peptides were spiked in to be used as internal
standards toassess the total proteinconcentrationsaswell as theacetylatedmodifıed
peptides that encompass the Lys residue. To ensure tight reproducibility during
sample processing, we developed an automated workflow from enrichment to di-
gestionwith%coeffıcientof varianceof less than20%.Results:TwomultiplexMRM
assays were developed forHMGB1: 1) total HMGB1 protein assay based on trypsin
digested peptides and 2) Acetylated HMGB1 assay based on Endoproteinase GluC
(Staphylococcus aureus Protease V8) digestion to obtain the peptides containing
hyper-acetylated Lysine residues, which are not located within a suitable tryptic
peptide. Four signifıcant milestones were accomplished. i) We optimized the
HMGB1 liquid chromatography and mass spectrometry performance through the
utilization of signature synthesized peptides representing the common amino acid
sequence and potential acetylated regions. The calibration curves for both peptides
based on the ratio of light and heavy isotopic labeled internal standards were
achieved. LLOD and LLOQ and the inter and intra-day variability of the iMRM
assay have been achieved. ii) A robust immuno-capture protocol was established.
The fınal protocol included isolation of HMGB1 using a capture antibody followed
by protein release, denaturation, reduction, alkylation and digestion. To date, we
have optimized the conditions for HMGB1 attachment to antibody, antibody cou-
pling tomagnetic beads, thewash and elution steps. iii) The protocol was applied to
quantify HMGB1 inmesothelioma cell lines. HMGB1wasmeasured in cytoplasm,
nucleus and supernatant from the cell lines. iv) Finally, the assay was adapted to
workonhumanplasma samples.Conclusion:We successfully developed the iMRM
workflow for quantifıcation of total HMGB1 and acetylated HMGB1 based on the
measurement of the target signature peptides in HMGB1.
#2217 Detection of circulating immune biomarkers of cervical disease
using proteome arrays. Radwa Ewaisha, Ian Meshay, Jack Resnik, Tirinder
Bharaj, Karen S. Anderson. Arizona State University, Tempe, AZ.
Introduction: More than 260,000 women die of cervical cancer every year.
Screening methods have reduced the incidence of cervical cancer in high-income
countries, but detection continues to lag in low and middle income countries
(LMICs). IgGantibody(Ab) immunity toearly (E)HPVantigens (Ags)arepotential
biomarkers of disease progression. Since HPV16 accounts for only50% of inva-
sive cervical cancers,wedevelopedproteinmicroarrays expressing theproteomesof
12 HPV types to detect host IgG Abs to a broad spectrum of viral Ags to detect
pre-invasive and invasive cervical disease. Methods: We developed custom HPV
protein microarrays displaying the proteomes of two low-risk HPV types (HPV6
and11) and tenoncogenichigh-riskHPVtypes (HPV16, 18, 31, 33, 35, 39, 45, 51, 52
and 58). Arrays were probed with serum samples obtained fromwomenwith inva-
sive cervical cancer (ICC; n80), no or low-grade cervical disease (CIN 0/I; n60),
and high-grade cervical dysplasia (CIN II/III; n60). To identify positive serologic
responses, arrays were scanned and the signal intensity of each protein spot was
quantifıedandnormalized.Visual examinationofdiffusedsignal (ring)aroundeach
spotwas performed and theAb response to each proteinwas scored on a scale from
0to5.Results:Toverifyarrayqualityandreproducibility,weconfırmedhighprotein
expression levels for 98% (96/98) of the antigens printed and high correlation (R

0.90) of protein expression signals between different randomly selected arrays.
Epitope expression was confırmed using four commercial monoclonal Abs raised
againstHPV16Ags.HostAbs toat leastoneearlyantigen(E1,E2,E4,E6,orE7)were
detected in the sera of 31.2% and 43.3% of ICC andCINII/III patients, respectively,
comparedwith11.7%ofwomenwithCIN0/I. 73.1%ofCINII/III casesdetectedhad
Abs only to non-HPV16 Ags. Abs to E1, E2, E4, E6, and E7 Ags were detected in
3.8%, 7.7%, 54%, 19%, and31%ofCINII/III versus 16%, 16%, 32%, 32%, and40%of
ICC cases that were positive. The immunodominant Ags in women with CINII/III
and ICCwereE4 (54%) andE7 (40%), respectively. These results are consistentwith
the difference in tissue expression levels of these proteins in these twodisease stages.
This emphasizes the importance of broadening the scope of serological detection to
include non-HPV16 proteomes. Conclusions: This study demonstrates that Abs
against high risk HPV16 and non-HPV16 serotypes are potential biomarkers for
both the diagnosis of cervical cancer and the differentiation betweenhigh grade and
low-grade pre-invasive cervical lesions. These results suggest that serology is a po-
tentialminimally invasive tool for early detection of cervical cancer. High-through-
put immunoprofıling of HPV-associated cancers and pre-invasive lesions may be
informative for understanding thediversity of host immunity andviral progression.
#2218 Quantitative multiplex analysis of immune checkpoint protein ex-
pression in circulation and in the tumor microenvironment.Wen-Rong Lie,
Jehangir Mistry.MilliporeSigma, St. Charles, MO.
Immune checkpoint inhibitors have been proven to be an effective method in
improving antitumor immune response. Many immune checkpoint proteins are
expressed as soluble forms in circulation and in the tumor and tumor microenvi-
ronment.Herewe report the development of bead-based Luminexmultiplex assays
for the quantitative profıling of co-inhibitory and co-stimulating immune check-
point proteins CTLA-4, PD-1, TIM-3, LAG-3, HVEM. GITRL, BTLA, CD27,
CD28,CD40,GITR,PD-L1,B7-1/CD80,B7-2/CD86, and ICOS. Inorder to explore
the use of soluble immune checkpoint proteins as putative cancer biomarkers, we
used these multiplex assays to measure checkpoint protein levels in serum samples
from breast cancer patients, colon cancer patients, and a corresponding set of nor-
mal serum samples. Analysis of the soluble checkpoint protein signatures generated
from thismultiplex approach revealed a signifıcantly elevated level of solubleTIM-3
protein in the breast cancer serum samples and in the colon cancer serum samples
compared to the healthy serum controls (p0.001). In addition, we analyzed the
immune checkpoint protein expression profıles in lysates of tumor and adjacent
normal tissues from 3 patients with metastatic breast cancer and 2 patients with
colorectal cancer.Differential expressionofmultiple checkpoint proteins, including
BTLA,CD27,TIM-3,HVEM,CD40,GITR,LAG3,CTLA-4,B7-1,PD-L1, or ICOS,
weredetected in thesematched lysates, indicating the roles andcomplexityof check-
point proteins in tumor microenvironment. In summary, our results demonstrate
that the multiplex assays we developed are useful research tools for the simultane-
ously quantitation of immune checkpoint proteins, as well as its potential applica-
tion in cancer biomarker discovery and translational research in cancer immuno-
therapy.
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#2219 Cancer prevention using a novel fatty acid synthase inhibitor.Neil
L. Spector,1 TimHaystead,1 Sumin Zhao,1 Yazan Alwarawrah,1 David Alcorta,1
William Kim,2 Jose R. Roques,2 Michael Trinkler,2 David B. Darr2. 1Duke Uni-
versity Medical Center, Durham, NC; 2UNC-Chapel Hill, Chapel Hill, NC.
Tumor growth and survival is dependent upon de novo fatty acid synthesis
regulated via preferential upregulation of fatty acid synthase (FASN) in tumor
cells. Here a novel FASN inhibitor that has shown antitumor activity in estab-
lished tumor models (Alwarawrah Y et al., 2016), now shows promise blocking
oncogene-induced cell transformation and signifıcantly delaying time to tumor
development in a prevention study using a GEMM of triple negative breast
cancer. Non-malignant, immortalized MCF10A human breast epithelial cells
were infected with lentivirus encoding for the highly oncogenic 110 kDa trun-
cated form of HER2, herein referred to as p110, under a doxycycline inducible
promoter. Lentivirus containing a sham insert served as a control. Forty-eight
hours after lentiviral infection, p110 was induced by dox and cells treated with
FASN (2 and 4 M) or vehicle alone for 21 days, and then assessed for cell
growth and evidence of senescence. TheC3TAgGEMMmodel of triple negative
breast cancer was used to study FASN in the prevention setting. The mice
(FVB/N background) express C(3)SV40 T-antigen resulting in the inactivation
of p53 and Rb. Eighteen mice were randomized to receive FASN treatment
(15mg/kg/ 5 days per week) or control (non-treatment [NT]). The mice were
randomized and started treatment at 6 weeks of age, and continued until tumors
reached an average size of 87.5mm3. Allmiceweremonitored (5 times/week) for
weight loss and time to tumor development. Expression of p110 led to the trans-
formation of MCF10A cells, as evidenced by the formation of plaques in cell
culture. Treatment with FASN blocked transformation in p110 expressing
MCF10A cells and instead induced growth arrest, expression of senescence as-
sociated -gal, and morphologic appearance consistent with cell senescence.
Analysis of viable p110 expressing MCF10A cells that were maintained in the
continuous presence of FASN for 60 days led to the identifıcation of a potential
mechanism of therapeutic resistance. In the C3TAg in vivo prevention study,
FASN resulted in a signifıcant prolongation in time to tumor development (Log-
rank (Mantel-Cox); p 0.0056). The median days of tumor onset between the
NT and treated groups were 111 and 145 with a range of 84-130 and 85-163,
respectively. No gross toxicity or weight loss was observed in FASN treated
animals. A novel small molecule FASN inhibitor blocked oncogenic cell trans-
formation and induced a state of senescence. Moreover, FASN signifıcantly de-
layed the onset of mammary tumors in a GEMM model of aggressive triple
negative breast cancer. Identifıcation of a mechanism(s) enabling tumor cells to
survive long termFASN inhibitionwill provide rationale combination strategies
to induce permanent senescence or apoptosis, and improve the effıcacy of FASN
inhibitors as preventative agents.
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#2220 Repurposing statins for preventionof triple-negative breast cancer.
Anjana Bhardwaj,1 Harpreet Singh,1 Kimal Rajapakshe,2 Cristian Coarfa,2 Isa-
belle Bedrosian1. 1UTMDAndersonCancer Ctr., Houston, TX; 2Baylor College of
Medicine, Houston, TX.
Introduction: Although triple negative breast cancer (TNBC) accounts for
15% of the 250,000 annual cases of breast cancer, its more aggressive nature,
coupled with lack of targeted therapy, results in a disproportionate rate of mor-
tality in women with this disease underscoring the critical need for prevention-
based approaches.We hypothesized that identifyingmiRNA-mRNA functional
pairs and their driver pathway(s) deregulated during preneoplastic progression
would provide themost informative insights into themolecular drivers of TNBC
carcinogenesis. Methods: We performed next generation RNA sequencing of
TNBC likeMCF10Abasedmodel system and focused on detailing themolecular
changes preceding the development of in situ carcinoma (DCIS). We used ki67,
MTT and colony formation assays to study the growth inhibitory effect of
miRNA and pathway targeting. To identify direct gene targets of a miRNA, we
cloned the 3=untranslated region containing miRNA-binding sites from its pre-
dicted gene targets in a luciferase reporter vector, and studied the effect of
miRNA overexpression on the repression of luciferase reporter activity. Results:
In-silico analyses of small RNA seq data showed loss ofmiRNA-140-3p as one of
the top deregulated miRNA relevant to preneoplastic transition fromMCF10A
parental toMCF 10AT1 preneoplastic cell line. Staining of breast tissue samples
also confırmed loss of miRNA-140-3p in tumors compared to normal breast
epithelial cells, suggesting a tumor suppressive role. To investigate the func-
tional role of miRNA-140 during TNBC development, we ectopically expressed
miRNA-140 inMCF10.AT1 andMCF10.DCIS cells. Interestingly, these studies
revealed miRNA-140 replacement to preferentially inhibit colonizing ability
and cell proliferation of preneoplastic MCF10.AT1 cells in contrast to a much
weaker cell inhibitory effects in DCIS cells. Next, we identifıed the functional
gene target/s of miRNA-140-3p by integromics studies involving next-genera-
tion RNA-seq on the MCF10A model employing bioinformatics pipeline,
SigTerms. These analyses identifıedHMGCRandHMGCS1 as top 2 gene targets
of miRNA-140-3p that map in cholesterol biosynthesis pathway. Consistently,
we foundmiRNA-140-3p to directly bind in 3=UTR of HMGCR, HMGCS1 and
repress their expression as shown by luciferase assays. miRNA-140 binding of
these gene targets is also functionally relevant as inhibition of HMGCR activity
by an FDA approved statin inhibitor, fluvastatin, preferentially inhibited the cell
proliferation and colonizing ability of preneoplastic MCF10AT1 cells. Further
studies focused on testing the potential of fluvastatin to prevent progression of
breast atypia cells in mouse xenografts are underway. Conclusions: Our results
suggest miRNA-140 and its downstream functional cholesterol biosynthesis
pathway targeting, especially by FDA approved Fluvastatin, may be a novel
strategy for targeted prevention of TNBC.
#2221 Honokiol stimulates immune reactivity in UV-irradiated skin
through DNA demethylation-dependent functional activation of dendritic
cells inmice. Santosh K. Katiyar, Tripti Singh, Harish C. Pal, Ram Prasad.Univ.
of Alabama at Birmingham, Birmingham, AL.
Solar ultraviolet radiation (UVR), and in particular UVB spectrum (290-320
nm), are considered as a complete carcinogen for cutaneous malignancies. The
over-exposure ofUVR suppresses the development of allergic contact hypersen-
sitivity (CHS) response in both laboratory animals as well as in humans. CHS
response is considered to be a prototypic T-cell mediated immune response.
UVR-induced suppression of immune sensitivity has been implicated in skin
cancer risk. Therefore, the treatment options which can inhibit UVB-induced
suppression of immune sensitivity may be useful in the management of skin
cancers, including both melanoma and non-melanoma. Previously, we have
shown that topical treatment of honokiol inhibits UVB induced immune sup-
pression, which was associated with the reduction in UVB-induced inflamma-
tory mediators in the mouse skin. Here, we have further determined the under-
lying mechanism of action of honokiol on UVR-induced immunosuppression
including its effect on epigenetic regulators and their relationship with immune
sensitivity in mouse skin. Topical treatment of C3H/HeN mice with honokiol
(0.5 and 1.0 mg/cm2 skin area) in hydrophilic-cream based topical formulation
signifıcantly inhibits UVB-induced suppression of CHS response (P0.01-
0.005), which was associated with reduced levels of DNAmethylation as well as
Dnmt activity in the mouse skin compared with non-honokiol-treated and
UVB-exposed control mice. To characterize the cell population responsible for
the honokiol mediated inhibition of UVB-induced immunosuppression, we
used an adoptive transfer approach. DNA-methylated (most of cells) dendritic
cells (DCs), isolated from the draining lymph nodes of donormice that had been
UVB-exposed and sensitized to 2,4,-dinitrofluorobenzene (DNFB) with and
without honokiol (0.5 and 1.0 mg/cm2 skin area) treatment, were transferred
into naïve recipient mice. The CHS response of the recipient mice to DNFB was
then measured. Honokiol treatment of UVB-exposed donor mice relieved this
suppression of the CHS response in naïve mice, while the recipient mice, ob-
tained DNA-methylated DCs from UVB-exposed donor mice that were not
treated with honokiol, showed signifıcant suppression in the CHS response. The
restoration of CHS response in mice receiving DCs from honokiol treated, UV-
exposed donor mice was also associated with enhanced secretion of Th1-type
cytokines compared with the Th1-type cytokines from the DCs obtained from
non-honokiol-treated and UVB-exposed donor mice. These data suggest that
honokiol mediated inhibition of UVB induced suppression of CHS response is
associated with functional activation of dendritic cells and that is dependent on
DNA demethylation in DCs.
#2222 Sildenafıl suppresses inflammation-driven colorectal cancer in
mice. Bianca N. Islam,1 Sarah K. Sharman,1 Yali Hou,1 Allison Bridges,1 Ravin-
dra Kolhe,2 JImena Trillo-Tinoco,1 Nagendra Singh,1 Sangmi Kim,1 Subbara-
miah Sridhar,2 Frankin G. Berger,3 Darren D. Browning1. 1Augusta University,
Georgia Cancer Center, Augusta, GA; 2Augusta University, Medical College of
Georgia, Augusta, GA; 3University of South Carolina, Columbia, SC.
Intestinal cyclic guanosine monophosphate (cGMP) signaling regulates epi-
thelial homeostasis, and has been implicated in the suppression of colitis and
colorectal cancer (CRC). In this study, we investigated the cGMP-specifıc phos-
phodiesterase-5 (PDE5) inhibitor sildenafıl to prevent tumorigenesis in the
azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colo-
rectal cancermodel. Treatment ofmice with sildenafıl activated cGMP signaling
in the colon mucosa and protected against DSS-induced barrier dysfunction. In
mice treated with AOM/DSS, oral administration of sildenafıl throughout the
disease course reduced polyp multiplicity by 50% compared to untreated con-
trols. Polyps formed in sildenafıl-treated mice showed less proliferation and
were more differentiated compared to polyps from untreated mice, but apopto-
sis was unaffected. Polyps in sildenafıl-treatedmice were also less inflamed; they
exhibited reduced myeloid-cell infıltration, and reduced expression of iNOS,
IFN and IL-6 compared to untreated controls. Most of the protection was
observed when sildenafıl was added during the initiation stage of carcinogenesis
(40% reduction in multiplicity), whereas administration of sildenafıl later dur-
ing the promotion stages did not affect polyp number. While later treatment
with sildenafıl did not affect multiplicity, it did have a similar effect on polyp
phenotype, including increased mucus production, reduced proliferation and
inflammation. In summary, our results demonstrate that oral administration of
sildenafıl suppresses inflammation and polyp formation in mice treated with
AOM/DSS. This suggests that PDE5 inhibitors could have therapeutic value for
the prevention of CRC in inflammatory bowel disease patients.
#2223 Rapamycin suppresses ErbB2-overexpressing mammary tumors
through selective inhibition of luminal progenitor cells and tumor-initiating
cells. Qingxia Zhao,1 Amanda B. Parris,1 Erin W. Howard,1 Ming Zhao,1
Zhiying Guo,1 Ying Xing,2 ZhikunMa,1 Xiaohe Yang1. 1North Carolina Central
University, Kannapolis, NC; 2Basic Medical College of Zhengzhou University,
Henan, China.
Rapamycin is a potent inhibitor of themTOR pathway and has demonstrated
anti-cancer properties in various cancer models. Although rapamycin was re-
ported to inhibit mammary carcinogenesis at multiple stages, including initia-
tion, invasion, and metastasis, the underlying mechanisms remain unclear,
especially in individual breast cancer subtypes. Specifıcally, ErbB2/Her2 am-
plifıcation occurs in approximately 25%of invasive human breast cancers, and is
characterized by Akt-mTOR pathway deregulation. Recent reports also suggest
that cancer stem cells (CSCs) play a critical role in tumor development and
metastasis. Therefore, we investigated the effıcacy of rapamycin in the preven-
tion of mammary tumor development in MMTV-ErbB2 transgenic mice by
focusing on its effects on CSCs/tumor-initiating cells (TICs). In this study,
MMTV-ErbB2 mice were inoculated with syngeneic 78617 cells, which are de-
rived fromMMTV-ErbB2mammary tumors, followed by rapamycin treatment
(1.5 mg/kg/day) for 12 days. We found that rapamycin elicited strong anti-
tumorigenic effects on the syngeneic tumors, as indicated by substantially re-
duced tumor volume andweight. To determine the effect of rapamycin onmam-
mary epithelial cells (MECs) in premalignant tissues, MMTV-ErbB2 mice were
treated with low-dose rapamycin (1 mg/kg/day) between weeks 10 and 20 of
age. Rapamycin signifıcantly inhibited mammary morphogenesis at 20
weeks of age as compared to the control mice. As such, the branching den-
sity, ductal elongation, and proliferative index of the mammary glands from
the rapamycin-treated mice were markedly decreased. Flow cytometric anal-
ysis of primary MECs demonstrated that rapamycin selectively inhibited the
CD61highCD49fhigh subpopulation, which are enriched with luminal progenitor
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cells and TICs. 3D culture of FACS-sorted MEC subpopulations indicated that
CD61
high
CD49fhigh cells are the major subpopulation that gives rise to 3D
colonies. We further demonstrated that rapamycin signifıcantly suppressed
colony-forming cell (CFC) number and primary/secondary sphere forma-
tion of primary MECs and spontaneous MMTV-ErbB2 tumor cells, indicat-
ing rapamycin-induced inhibition of mammary progenitor cells and CSC self-
renewal, respectively. Furthermore, molecular analysis of MECs demonstrated
that rapamycin inhibited signaling associated with ER, ErbB2, and mTOR. In
particular, rapamycin strikingly inhibited Wnt/-catenin and TGF/Smad3
signaling. Taken together, our results demonstrate that rapamycin-mediated
prevention of MMTV-ErbB2 mammary tumor development involves selective
targeting of mammary progenitor cells and potential TICs in the premalignant
mammary tissues through regulation of MEC stemness and multiple signaling
pathways, which contributes to its potent anti-tumor effects on ErbB2-overex-
pressing breast cancer.
#2224 Increased 15-lipoxygenase-1 activity limits tumor development in
the azoxymethane mouse model of colon cancer: impact of omega-3-acid
ethyl esters.Xiangsheng Zuo, Jennifer K. Colby, Fuyao Liu, ShenGao, LingWu,
Jonathan C. Jaoude, Micheline J. Moussalli, Lin Tan, Peiying Yang, Imad
Shureiqi. University of Texas M.D. Anderson Cancer Center, Houston, TX.
Pro-inflammatory signaling has been shown to promote colorectal tumori-
genesis and is a target for the development of effective chemopreventive ap-
proaches. The specialized pro-resolving lipid mediators (SPMs, e.g. resolvins),
bioactivemetabolites of eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), actively terminate inflammation and have been proposed to possibly
contribute to the anti-tumorigenic effects of DHA and EPA. The enzyme 15-
lipoxygenase-1 (ALOX15) is a key biosynthetic enzyme in generation of re-
solvins. However, 15-LOX-1 expression is commonly lost during human CRC
tumorigenesis starting in premalignant stages via transcriptional mechanisms
independent of substrate availability. The impact of ALOX15 on DHA and
EPA’s effects on tumorigenesis remain unknown. Mice with intestinal epitheli-
um-specifıc expression of human ALOX15 (15-LOX-1-gut mice) and wild-type
FVB controls were injected with azoxymethane (AOM, 7.5mg/kg) once weekly
for 6w and followed for 20w. Mice were fed diet with 1% omega-3-acid ethyl
esters (O3AEE, a pharmaceutical grade fısh oil preparation of EPA and DHA
ethyl esters) or control diet starting 3w before initiation with AOM. Colonic
tumors developed in 10 of the 13 (77%) wild type (WT) mice fed control diet, 5
of the 10 (50%)WTmice fed O3AEE diet, 5 of the 12 (42%) 15-LOX-1-gut mice
fed control diet, and 3 of the 10 (30%) 15-LOX-1-gutmice fed control diet. Lipid
mediator levels were measured by liquid chromatography/ tandem mass spec-
trometry (LC-MS/MS). The SPMs resolvin E1 and D2 (RvE1, RvD2) as well as
the pathway intermediates 18-HEPE and 17-HDHEwere increased inALOX15-
gutmice onO3AEE (see Table; data are shown as ng/mg protein;mean	 SEM).
Our results demonstrate that ALOX15 activity is important to DHA and EPA
formation of resolvins and inhibition of colonic tumorigenesis. Supported by
grants CPRIT RP150195 and NIH RO1 R01CA195686.
SPMs in O3AEE or control diet fed mice
WT Control diet WT O3AEE diet
15-LOX-1-gut
Control diet
15-LOX-1-gut
O3AEE diet
18-HEPE 0 0.46 0.5 0 0.82 0.31
17-HDHE 0.21 0.09 0.2 0.7 4.2 0.41 13.35 3.1
RvE1 0 0 0 1.98 0.77
RvD2 0 0.024 0.024 0.17 0.022 0.3 0.077
#2225 Green tea polyphenols suppress tumor growth and invasion by tar-
getingmatrixmetalloproteinases, RECK and TIMP-3, in amousemodel im-
planted with prostate tumors. Eswar Shankar, Natarajan Bhaskaran, Rajnee
Kanwal, Sanjay Gupta. Case Western Reserve University, Cleveland, OH.
Green tea polyphenols (GTP) and its major constituent, epigallocatechin-3-
gallate (EGCG) reactivate epigenetically silenced genes in cancer cells that re-
duces invasiveness and migration capabilities; however, the mechanisms
whereby these effects occur are not well understood. RECK, a novel tumor sup-
pressor and the tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) genes
negatively regulates matrix metalloproteinases (MMPs) and inhibits tumor in-
vasion, angiogenesis and metastasis. In the present study, we demonstrate that
GTP mediate epigenetic induction of RECK and TIMP-3 thereby playing a key
role in suppressing invasiveness and gelatinolytic activity of MMP-2 and
MMP-9 in vivo in an orthotopic implantation model of human prostate cancer.
Athymic nude mice were implanted with human prostate cancer LNCaP tumor
in the ventral prostate for 2 weeks and later treated DNA methyltransferase
inhibitor, 5-aza-2=-deoxycytidine (AZA), histone deacetylase inhibitor, tricho-
statin A (TSA) and histone methyltransferase inhibitor, 3-Deazaneplanocin A
(DZNep) individually at 0.1 mg/kg body weight intraperitoneally at alternate
days/week; and combination of AZATSA and DZNepTSA at similar doses
and times; whereas GTP was provided peroral by gavage at 7.5 and 15.0 mg/kg
body weight freshly prepared in 100l PBS. Treatment of mice with GTP re-
sulted inmarked decrease in tumor growth and its local invasion in dose depen-
dent manner, compared to treatment with epigenetic inhibitors and their com-
bination after 8 weeks of intervention. GTP treatment signifıcantly reduced
serum levels of MMP-2, MMP-9 and VEGF, compared to treatment with epige-
netic inhibitors alone. Combination of AZATSA exhibited similar effect
which was equivalent to the lower dose of GTP treatment. Furthermore, GTP
treatment signifıcantly reduced EZH2 and H3K27me3 and class I HDAC pro-
tein levels in tumors. GTP partially reversed the hypermethylation status of
RECK and TIMP3 gene and signifıcantly enhanced their protein expression in
the tumor tissue. Inhibition of VEGF, MMP-2 and MMP-9 levels were also
noted after GTP treatment in tumor tissue in dose-dependent manner. Our
fındings suggest that induction of RECK and TIMP-3 are key epigenetic events
modulated by GTP that results in suppression of matrix degradation and angio-
genesis to delay prostate cancer invasion and its subsequent progression.
#2226 Sildenafıl suppresses tumorigenesis in ApcMin/ mouse model.
Sarah K. Sharman,1 Bianca N. Islam,1 Yali Hou,1 Allison Bridges,1 Nagendra
Singh,1 Subbaramiah Sridhar,2 Frankin G. Berger,3 Darren D. Browning1. 1Au-
gusta University, Georgia Cancer Center, Augusta, GA; 2Augusta University,
Medical College of Georgia, Augusta, GA; 3University of South Carolina, Colum-
bia, SC.
The cGMP signaling pathway regulates homeostasis in the colon epithelium
and has been implicated in the suppression of colorectal cancer. Exisulind is a
weak phosphodiesterase-5 (PDE5) inhibitor that was previously shown to re-
duce polyp formation in familial adenomatous polyposis (FAP) patients. De-
spite this validation of PDE5 as a therapeutic target, the failure of Exisulind due
to toxicity halted further trials of cGMP elevating agents. The present study
tested the effect of the PDE5 inhibitor sildenafıl, and the receptor guanylyl-
cyclase C (GCC) agonist linaclotide on tumorigenesis in the ApcMin/ mouse
model of colon cancer. Administration of either sildenafıl or linaclotide to both
wild type and ApcMin/ mice caused dramatic effects on homeostasis that in-
cluded reduced proliferation and increased goblet cell differentiation. With
treatment beginning at 4 weeks, sildenafıl and linaclotide caused a 50% and 67%
(respectively) reduction in the number of polyps per mouse. Furthermore, the
polyps in sildenafıl and linaclotide treated animals exhibited a reduced prolifer-
ative index and increased mucus density compared to polyps from untreated
mice. The mean polyp size was not changed by treatment with either drug. In
support of a tumor-suppressive role for cGMP signaling in the intestine, the
ApcMin/mice showed reduced levels of endogenous GCC agonists in the intes-
tinalmucosa compared towild type animals. This suggests that part of the tumor
preventative effects observed here could be due to compensation for this defıcit
by augmenting cGMP signaling with PDE5 inhibitors or GCC agonists. While
the tumor suppressive mechanism is not fully understood, the results presented
here demonstrate in a preclinical model, that increasing intestinal cGMP levels
by targeting PDE5 orGCCmay be a viable chemoprevention strategy for human
FAP patients.
#2227 Fgf2 from visceral adipose tissue stimulates neoplastic transforma-
tion of nonmalignant epithelial cells.Debrup Chakraborty, Vanessa Benham,
Elena Y. Demireva, Blair Bullard, Jamie J. Bernard. Michigan State University,
East Lansing, MI.
Background: Adiposity plays a crucial role in the pathogenesis and prognosis
of different types of cancers. Epidemiological evidence suggests visceral adipose
tissue (VAT) and high-fat diets (HFD) are associated with increased cancer risk
however the mechanism is not understood. The aim of this study was to explore
the factors inVAT that stimulate neoplastic transformation.Methods:Wemod-
eled visceral adiposity-stimulated neoplastic transformation using our novel ex
vivo systemofVAT-conditionmedium stimulated epithelial cell transformation
(measured by growth in soft agar) and our in vivo murine lipectomy model of
ultraviolet light B (UVB)-induced, VAT promoted skin tumor formation.
FgfR1(-/-) stable cells were generated by using CRISPR-Cas9 technology and
were used to investigate the role of fıbroblast growth factor-2 (FGF2) andFGFR1
dependent signaling in neoplastic transformation, both in vitro and in vivo.
Results: Only the VAT of obese mice fed a HFD [not VAT from low-fat diet
(LFD) fed mice] stimulated neoplastic transformation of skin epithelial cells.
Furthermore, human VAT stimulated both skin and mammary epithelial cell
transformation. The differences in VAT activity between LFD and HFD fed
mice and human donors were associated with the levels of FGF2. Circulating
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levels of FGF2 were associated with non-melanoma tumor formation in vivo.
Human andmouseVAT failed to stimulate transformation in FgfR1(-/-) cells and
do not form tumors when injected in Nude mice in vivo. Conclusion: Collec-
tively, our data show FGF2 released fromVAT and its interactionwith FGFR1 is
a novel and potential direct path of VAT-enhanced tumorigenesis. Blocking the
FGFR1 induced signaling in VAT of abdominally obese individuals may be an
important cancer prevention strategy as well as an adjuvant therapy for improv-
ing outcomes following cancer diagnosis.
#2228 Altering rictorwith diosmetin reduces tumor progression in ortho-
topic prostate cancer model. Rebecca Pakradooni, Ahmad Khalifa, Riddhi
Patel, Sanjeev Shukla. Case Western Reserve Univ., Cleveland, OH.
Rapamycin insensitive companion of mTOR (Rictor) is an essential subunit
ofmTOR complex 2,maintains the integrity of the complex and functions as full
activator of Akt. Rictor has been implicated to be involved in growth and pro-
gression of malignancies. Reports suggested that overexpression of Rictor in
prostate cancer tissues, which may have potential role in prostate cancer pro-
gression.We demonstrated silencing Rictor in PC-3 cells decreased p- Akt (Ser-
473) expression; conversely p-Akt (Thr-308) and p-PKC (Ser-657) expression
was increasing. Additionally to observe themolecular mechanism of Rictor reg-
ulation, we took HAP1 cells (derived frommale chronic myelogenous leukemia
(CML) cell lineKBM-7)were edited and silenced byCRISPR/Cas9with 2 and 10
base pair Rictor in a coding exon 5. HAP1 haploid human cell line contains a
single copy of all chromosomes except for a heterozygous 30-megabase frag-
ment of Chromosome 15; these cells are instrumental for genetic screening, as
gene inactivation is greatly facilitated by the absence of a second gene copy. In
these cells we observed p-Akt (Ser-473) expression was signifıcantly less with
more pronounced in 10 base pair than 2 base pair. Further to determine poten-
tial role of diosmetin (5, 7-Trihydroxy-4=-methoxyflavone; a natural flavonoid
present in citrus plant, has anti-mutagenic properties) on Rictor silenced 2 base
pair and 10 base pairHAP1 cells, we treated these cells in concentration response
fashion, and observed decrease in p-Akt (Ser-473) expression than control cells.
Next, we determine invivo potential of Rictor silencing, we used luciferase tag
PC-3 cells silencedwith Rictor gene orthotopically implanted in ventral prostate
of mice. After 8 weeks of Rictor silenced cells implanted mice, we observed less
luciferase activity in prostate and occasional metastasis than control luciferase
PC-3 cells. Moreover, diosmetin fed mice in dose dependent fashion (20 and
50g/animal/day) represented decrease in tumor luciferase activity with re-
duced tumor volume and no metastasis than control mice. We observed
metastasis only in control and rapamycin (8 mg/kg body weight intraperito-
neally every alternate day) treated mice in spine, lung and kidney. Taken
together, our studies demonstrate that diosmetin fed animals resulted in
growth inhibition and induction of apoptosis by altering Rictor signaling
cascade. We are demonstrating that diosmetin modulates molecular targets
viz., Rictor and Akt to alter cellular events and elicit anticancer effects in
prostate cancer cells.
#2229 Prevention by tolfenamic acid and characterization of the molecu-
lar targets in Pirc and FAP colorectal adenomas. Furkan U. Ertem,1Wenqian
Zhang,2 Kyle Chang,3Wan-MohaizaDashwood,2 Praveen Rajendran,2 Deqiang
Sun,2 Ala Abudayyeh,3 Maen Abdulrahim,4 Eduardo Vilar,3 Roderick H. Dash-
wood2. 1University of Pittsburg Medical Center, Pittsburg, PA; 2Texas A&M
Univ. Health Science Ctr., Houston, TX; 3University of TexasMDAnderson Can-
cer Center, Houston, TX; 4Duke University Medical Center, Durham, NC.
A critical need exists in sporadic and high-risk colorectal cancer patients
for endoscopic screening combined with safe and effective preventive agents.
To prioritize molecular targets for prevention studies in vivo, RNA-seq anal-
yses were conducted on colorectal adenomas from familial adenomatous
polyposis (FAP) patients, and from the Apc-mutant polyposis in rat colon
(Pirc) model. Using a new murine endoscopic polypectomy methodology
(F.U. Ertem et al., Gastrointest Endosc 2016;83:1272-6), we evaluated agents
that might substitute for the current standard of care, Sulindac, and identi-
fıed tolfenamic acid (TA) as a promising candidate for further investigation.
At clinically-relevant doses in the Pirc model, TA suppressed tumorigenesis
signifıcantly both in the small intestine and in the colon. Inhibition by TA of
colonic crypt cell proliferation, and the concomitant activation of apoptosis,
coincided with reduced expression in target tissues of -catenin, cyclin D1,
Survivin and matrix metalloproteinase 7. Based on the oncogene candidates
defıned by RNA-seq analysis, endoscopic tracking revealed the time-course
of tumor suppression by TA, and the temporal changes in S100a9, Nppb,
Aldh1a3 and Mmp7, highlighting their value as potential early biomarkers
for prevention in the clinical setting. As an “old drug” repurposed from
migraine, TA appears to offer an exciting new therapeutic avenue in FAP and
other high-risk colorectal cancer patient populations. This work was sup-
ported in part by NIH grants CA090890, CA122959, ES00210, ES023512, the
John S. Dunn Foundation, and a Chancellor’s Research Initiative. 1
#2230 Luteolin selectively inhibits EZH2 and blocks H3K27 methylation
in prostate cancer cells.RajneeKanwal,1 XiaopingYang,2 Eswar Shankar,1 San-
jay Gupta1. 1Case Western Reserve Univ., Cleveland, OH; 2VA Medical Center,
Cleveland, OH.
The histone methyltransferase enhancer of zeste homolog 2 (EZH2) is the
catalytic subunit of the polycomb repressive complex (PRC2) and is involved
in chromatin remodeling and gene silencing through its methylation of hi-
stone H3 on lysine 27 (H3K27). Specifıcally, trimethylation of H3K27 is
associated with gene silencing and plays critical role in cancer initiation and
progression. Therefore, blocking EZH2 catalytic activity may present a valid
preventive and/or therapeutic strategy for the treatment of cancers with
EZH2 overexpression including prostate cancer. Our multistep approach of
molecular modeling and direct binding has led to the identifıcation of plant
flavone luteolin (3=, 4=, 5, 7-tetrahydroxyflavone) as a specifıc inhibitor of
EZH2 with preferential blocking of its catalytic site. Here we report luteolin,
in micro molar range, inhibits EZH2 catalytic activity, demonstrates anti-
proliferative and anti-invasive activities in functional cell based assays.
Treatment of human prostate cancer DU145 and 22Rv1 cells, which possess
high constitutive EZH2 expression, with 5-20 M luteolin signifıcantly in-
hibits EZH2 and SUZ12 protein expression in dose and time dependent
manner, although luteolin treatment did not affect protein expression of
EED and RbAp46/48 protein, other members of PRC2 complex. Treatment
of both cell lines with luteolin also reduced H3K27me3 and H3K27me2
protein and its enzymatic activity in dose and time dependent manner with-
out affecting total H3 protein. In addition, luteolin was also effective in
suppressing in vitro methylation performed using recombinant PCR2 com-
plex. These events led to increase in the expression of downstream tumor
suppressor genes including E-cadherin, SLIT2 and TIMP3, respectively. In-
terestingly, treatment of cells with proteasome inhibitor, MG132 together
with luteolin did not prevent EZH2 degradation indicating that proteasomal
degradation might not contribute to EZH2 inhibition. Taken together, our
study suggest that luteolin acts on the catalytic binding site of EZH2 to
exhibit downregulation of histone H3methylation and could be developed as
a potential promising agent for the prevention and/or treatment of various
human cancers including prostate cancer with EZH2 overexpression.
#2231 15-Keto prostaglandin E2 inhibits STAT3 signaling inH-Ras trans-
formedmammary epithelial cells.Eun-Ji Lee,1 Young-IlHahn,1 Su-JungKim,1
Young-Joon Surh,1 Hye-Kyung Na2. 1Seoul National University, Seoul, Republic
of Korea; 2Sungshin Women’s University, Seoul, Republic of Korea.
Prostaglandin E2 (PGE2) is a potent lipid mediator that plays a key role in
inflammation and carcinogenesis. The intracellular level of PGE2 is regulated
by NAD-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
This enzyme catalyzes the oxidation of the 15(S)-hydroxyl group of PGE2 to
generate 15-keto PGE2. Down-regulation of 15-PGDH was observed in var-
ious malignancies and overexpression of 15-PGDH has been known to sup-
press the carcinogenic processes. However, mechanisms underlying anti-
carcinogenic effects and tumor suppressive functions of 15-keto PGE2 are
poorly understood in various cancer. H-Ras transformed mammary epithe-
lial MCF10A-ras cells show enhanced expression of cyclooxygenase-2 and
activation of signal transducer and activator of transcription 3 (STAT3) and
down-regulation of 15-PGDH compared to normal mammary epithelial
MCF10A cells. STAT 3 plays a key role in growth of cancer cells as well as
inflammation-associated carcinogenesis. This prompted us to investigate the
effect of 15-keto PGE2 on STAT3 activation in MCF10A-ras cells. 15-Keto
PGE2 suppressed the phosphorylation of STAT3 in MCF10A-ras cells in
concentration- and time-dependent manners as determined byWestern blot
and immunocytochemical analyses. 15-Keto PGE2 also inhibited the
dimerization of STAT3 which led to suppression of nuclear translocation
and transcriptional activity of STAT3 as determined by Western blot analy-
sis and the luciferase assay, respectively. 15-keto PGE2 suppressed the ex-
pression of cyclin D1. In addition, 15-keto PGE2 inhibited the growth of
MCF10A-ras cells as determined by anchorage-independent growth and col-
ony forming assays. However, a non-electrophilic analogue 13,14-dihydro-
15-keto PGE2 which lacks the ,-unsaturated carbonyl moiety failed to
inhibit the phosphorylation, dimerization, and nuclear translocation of
STAT3. Moreover, 13,14-dihydro-15-keto PGE2 did not affect the growth of
MCF10A ras cells. These fındings suggest that the ,-unsaturated carbonyl
moiety of 15-keto PGE2 is essential for its suppression of STAT3 signaling.
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STAT3 has several cysteine residues in its activation sites. We observed that
reducing agents N-acetyl-L-cysteine and dithiothreitol abrogated the sup-
pressive effect of 15-keto PGE2 on STAT3 phosphorylation, suggesting that
the involvement of the thiol modifıcation. Biotinylated 15-keto PGE2 cova-
lently bound to STAT3 as determined by immunoprecipitation with STAT3
followed by immunoblotted with streptavidin. Molecular docking analysis
predicted Cys251 and Cys259 residues of STAT3 as putative binding sites of
15-keto PGE2. In conclusion, 15-keto PGE2 inhibits STAT3 signaling
through cysteine thiol modifıcation, thereby suppressing MCF10A-ras cell
growth and proliferation. Thus, tumor suppressor function of 15-PGDH is
attributable, at least in part, to inactivation of oncogenic STAT3 signaling by
its catalytic product 15-keto PGE2.
#2232 Dietary flavonoids, CYP1A1 genetic variants, and the risk of colo-
rectal cancer. Jeongseon Kim, Young Ae Cho, Jeonghee Lee, Jae HwanOh, Dae
Kyung Sohn, Hee Jin Chang.National Cancer Ctr. Korea, Goyang-si, Republic of
Korea.
The role of dietary flavonoid intake in colorectal carcinogenesis might differ
according to flavonoid subclasses and individual genetic variants related to car-
cinogen metabolism. Therefore, we examined whether greater habitual dietary
intake of flavonoid subclasses was associated with a lower risk of colorectal
cancer and whether CYP1A1 genetic variants altered this association. A semi-
quantitative food frequency questionnaire was used to assess the dietary intake
of six flavonoid subclasses (flavonols, flavonones, flavanones, flavan-3-ols, an-
thocyanidins, and isoflavones) in 923 patients with colorectal cancer and 1,846
controls; furthermore, CYP1A1 genetic variants (rs4646903 and rs1048943)
were genotyped. A logistic regression was used to investigate dietary flavonoid
intake, CYP1A1 genetic variants, and their interaction in relation to colorectal
cancer risk. Among the subclasses of flavonoids, flavonols (OR [95% CI] 0.10
[0.06, 0.16], highest vs. lowest quartile) and flavan-3-ols (OR [95% CI]  0.54
[0.41, 0.71], highest vs. lowest quartile) were signifıcantly associated with colo-
rectal cancer risk after adjusting for confounders. Homozygous variants of
CYP1A1 rs4646903 showed a protective effect on the risk of rectal cancer (OR
[95% CI]  0.60 [0.37, 0.96], CC vs. TT/TC). Carriers of the CC homozygous
variant with high flavonol intake showed a greater decrease in colorectal cancer
risk comparedwith T allele carriers with low flavonol intake (P for interaction
0.02), particularly regarding rectal cancer (P for interaction 0.005). In conclu-
sion, the effect of dietary flavonoid intake on colorectal cancer risk differs by
flavonoid subclasses and CYP1A1 genetic variants.
#2233 The fatty acid amide hydrolase inhibitor URB937 ameliorates radi-
ation-induced lung injury in amousemodel.Rui Li, JianxinXue, You Lu.West
China Hospital, West China School of Clinical Medicine, Chengdu, China.
Radiation-induced lung injury (RILI) is a common and potentially serious
complication from radiotherapy to the thoracic region. In the current study, we
examined the potential protective effects of URB937, an inhibitor of fatty acid
amide hydrolase in a mouse model of RILI. Here we challenged male C57BL/6
mice with irradiation (16Gy to the thoracic region), and then injected intraperi-
tonealy either URB937 (1mg/kg) or vehicle three times a week for 30 days. Mice
were sacrifıced at either the end of treatment or120 days from irradiation to
evaluate the extent of RILI and mice survival. Potential effects of URB937 on
irradiation induced tumor growth inhibition were also evaluated. We found
URB937 increased endocannabinoids in the lungs, attenuated the extent of RILI,
prolonged the survival,inhibited mice developed pathological alterations of
pneumonitis and lung fıbrosis. Irradiation-induced increases of proinflamma-
tory and profıbrotic cytokines were decreased, including interleukin-1, inter-
leukin-6, tumor necrosis factor-, transforming growth factor-1 in plasma and
lung tissue. Moreover, malondialdehyde in plasma and inflammation cells in
bronchoalveolar lavage fluid were lower in mice treated with irradiation plus
URB937. URB937 did not affect tumor growth inhibition caused by irradiation.
These results suggested that inhibiting fatty acid amide hydrolase through
URB937 could ameliorate the RILI, without affecting the effıcacy of irradiation
on tumor control.
#2234 Efatutazonereducesmammosphere formation inBrca1WT/fl11/Cre/p53/

and Brca1fl11/fl11/Cre/p53/
 mice. Sahar J. Alothman, Shan Chao, Weisheng Wang,
PriscillaA. Furth.GeorgetownUniversity,Washington,DC.
Introduction: Efatutazone, a PPAR gamma agonist, may affect tumor growth
through the induction of terminal cell differentiation. Thus, we hypothesize that
efatutazone could affect progenitor cell number. Here, we evaluate progenitor cell
number by measuring mammospheres, which is considered one way to measure
potential progenitor cells. Methods: Two month old Brca1WT/fl11/Cre/p53/
(n  14) and Brca1fl11/fl11/Cre/p53/ (n  10) C57Bl/6 mice were randomly
placed on either control or treated with efatutazone through the diet (30-mg/kg
concentration, F3028, rodent diet, grain-based, 1/2-in pellets; Bio-Serv, French-
town, NJ) with necropsy at four months and isolation of primary mammary
epithelial cells from thoracic glands for studies of mammosphere formation
using SCIVAX 96-well low adhesion nanoculture plates (Organogenix, Inc.,
Japan) using EpiCult-B Mouse Media (Stem Cell Technology, Inc., Vancouver,
Canada) with 0,1,5, and 10% fetal bovine serum (FBS) added. Thoracic mam-
mary gland tissue was frozen at -20°C followed by isolation of RNA and evalu-
ation of PPAR gamma pathway gene expression by real-time RT-PCR using
TaqMan® Array Mouse Lipid Regulated Genes (Thermo Fisher Scientifıc, Inc.,
WalthamMA). One inguinal gland was fıxed for mammary gland whole mount
and the other inguinal gland was formalin-fıxed and paraffın-embedded for
histology. Results: SCIVAX nanoculture plates showed reproducible increases
in mammosphere numbers with increasing FBS concentrations (p 0.05 one-
way, Kruskal-Wallis). A signifıcant increase in sphere number was seen in
Brca1fl11/fl11/Cre/p53/ compared to Brca1WT/fl11/Cre/p53/ mice (p0.05 one-
way, Kruskall Wallis). Efatutazone treatment signifıcantly decreased sphere
numbers in Brca1WT/fl11/Cre/p53/ and in Brca1fl11/fl11/Cre/p53/mice (p0.05
one-way, Kruskall Wallis). Expression of PPAR gamma pathway genes were
increased at the RNA level with statistically signifıcant increases in Acadvl, Tnf,
Alox5 (p0.05) and Il1B, Srebf2, Hmgcs1, Hmgcr (p0.01) genes (BootsRatio,
http://rht.iconcologia.net/stats/br/several.html) in mice on efatutazone as com-
pared to control diet. Discussion: SCIVAX nanoculture plates can be used to
quantitatively evaluate and comparemammosphere numbers between different
genotypes and treatment groups. The higher numbers of mammospheres found
with loss of both Brca1 copies as compared to one copy is consistent with pre-
viously published literature. The decrease in mammosphere numbers with efat-
utazone treatment could be secondary to its differentiating impact onmammary
epithelial cells. Conclusion:While efatutazone statistically signifıcantly reduced
mammosphere numbers, the absolute reduction was less the 25%.
#2235 Preventive effects of the sodium glucose cotransporter 2 inhibitor
tofogliflozin on liver tumorigenesis in obese and diabetic mice. Yohei Shi-
rakami, Koki Obara, Masaya Ohnishi, Takayasu Ideta, Hiroyasu Sakai, Takuji
Tanaka, Masahito Shimizu, Mitsuru Seishima. Gifu Univ. Graduate School of
Medicine, Gifu, Japan.
Obesity, diabetes mellitus, and their related metabolic abnormalities are as-
sociated with increased risk of hepatocellular carcinoma (HCC). Sodium glu-
cose cotransporter (SGLT)-2 inhibitors, recently approved anti-diabetic agents,
are expected to ameliorate the abnormalities associated with metabolic syn-
drome including non-alcoholic fatty liver disease (NAFLD). In this study, we
investigated the effects of the SGLT2 inhibitor tofogliflozin on the development
ofNAFLD-related liver tumorigenesis inC57BL/KsJ-Leprdb/Leprdb (db/db)
obese and diabetic mice. The direct effects of tofogliflozin on human HCC cell
proliferation were also evaluated. Male db/db mice were administered diethyl-
nitrosamine-containing water for two weeks and were treated with tofogliflozin
throughout the experiment. Tofogliflozin was kindly provided by Kowa Co.,
Ltd. and the chemical structurewill be disclosed at the time of presentation at the
meeting. In mice treated with tofogliflozin, the development of hepatic pre-
neoplastic lesions was markedly suppressed, and hepatic steatosis and inflam-
mation signifıcantly reduced, as evaluated using the NAFLD activity score, in
comparison to those in the control mice. Serum levels of glucose and free fatty
acid andmRNA expression levels of pro-inflammatorymarkers in the liver were
reduced by tofogliflozin treatment. Conversely, the proliferation of SGLT2 pro-
tein-expressingHCCcellswas not inhibited by this agent. These fındings suggest
that tofogliflozin suppressed the early phase of obesity- and NAFLD-related
liver carcinogenesis by attenuating chronic inflammation and steatosis in the
liver, while the agent had no signifıcant direct effect on the proliferation of HCC
cells. Therefore, SGLT2 inhibitors may have a chemopreventive effect on obesity-
related HCC.
#2236 High-throughput screen for chemopreventative agents that influ-
ence adipose-tissue driven epithelial neoplastic transformation. Vanessa
Benham, Debrup Chakraborty, Blair Bullard, Thomas S. Dexheimer, Jamie J.
Bernard.Michigan State University, East Lansing, MI.
Epidemiological studies have established a link between excess adiposity and
cancer risk. Our previous data demonstrate that adipose tissue stimulates the
transformation (steps a cell undergoes to become malignant) of both skin and
mammary epithelial cells asmeasured by anchorage-independent growth in soft
agar. Therefore, agents that influence growth in soft agar may be used therapeu-
tically for skin and breast cancer prevention. However, soft agar in a 24-well
format is unsuitable for high-throughput screens. Our objective was to develop
a high-throughput assay to evaluate chemopreventative agents that influence
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adipose-tissue driven epithelial neoplastic transformation.We demonstrate that
growth in low attachment conditions in a 384-well plate format is strongly cor-
related with growth in soft agar. We utilized this methodology and discovered
the ability of several compounds to inhibit adipose tissue-stimulated transfor-
mation. These compounds will be used in vivo in our models of adipose tissue-
or HFD-promoted tumor formation.
#2237 Novel selenium-containing aspirin molecule AS-10 suppresses an-
drogen receptor signaling and induces apoptosis of LNCap prostate cancer
cells. Deepkamal N. Karelia, Sangyub Kim, Srinivasa Ramisetti, Cheng Jiang,
Shantu Amin, Arun K. Sharma, Junxuan Lu. Penn State College of Medicine,
Hershey, PA.
Aspirin as the best known low cost Non-Steroidal Anti-inflammatory drug
(NSAID) has been associated with lowering risk of colorectal cancer, in addition
to its cardiovascular health benefıt at low dose (baby Aspirin) and over-the-
counter pain medication. Through an innovative research program aiming at
enhancing the bioactivities of NSAIDs by incorporation of selenium, we have
discovered AS-10 as a novel Aspirin-selenium compound with promising anti-
cancer drug-like properties in terms of potency enhancement (at least 3 orders of
magnitude compared to Aspirin), selective cytotoxicity against cancer cells in-
cludingmajority of NCI-60 panel, while sparing normalmoue embryonic fıbro-
blasts in cell culture screening assays. Preliminary toxicology study in mice had
shown a wide safety margin. Extensive structure-activity relationship investiga-
tion suggested a novel structural basis, instead of releasable selenium, that ac-
counted for the striking potency. To investigate the potential chemopreventive
attributes of AS-10 against prostate carcinogenesis, we selected LNCaP cells
(wild type p53, functional androgen receptor, AR) to examine the growth sup-
pression and apoptosis responses in cell culture. The rationale for choosing
LNCaP cell line as target cells rests in the fact that precancerous prostatic lesions
that are the intended targets of chemoprevention as well as early stage prostate
cancer retain wild type p53 and they are critically dependent onAR signaling for
survival. Our results show that cell viability (MTT) test detected a potent growth
inhibition of LNCaP cells in a time and concentration dependent manner, with
an EC50 in range of 1.7 to 2.5Mrange comparedwithAspirin in themillimolar
range. Western blot analysis of AS-10 treated LNCaP cells showed decreased
protein level of AR and its best known downstream target prostate specifıc an-
tigen (PSA) in a concentration-dependent manner. In addition, AS-10 treat-
ment led to increased Annexin V staining, caspase 3/7 activity, and PARP cleav-
age, all indicators of caspase-mediated apoptosis. Furthermore,AS-10 treatment
increased the expression of p53-DNA damage response (DDR) proteins such as
p21 (canonical target of p53) and p-H2A.X (a marker for DNA strand breaks).
Given that our earlier work with pancreatic cancer cells has indicated a rapid
induction of reactive oxygen species (ROS) by AS-10 exposure, we hypothesize
that ROS generation may be involved in LNCaP cells to trigger the DDR and
apoptosis responses. In summary, our fındings suggest AS-10 as a potential
chemopreventive agent for prostate carcinogenesis.
#2238 Novel sylibin analogues target ovarian cancer EMT-Wnt/-catenin
resistance pathways. Haneen A. Amawi,1 Noor Hussein,1 Aubry Fetcenkoa,1
Rawan Alnafısah,1 Karthikeyan Chandrabose,2 Elangovan Manivannan,3 Piy-
ush Trivedi,2 Amit K. Tiwari1. 1Univ. of Toledo, Toledo, OH; 2Rajiv Gandhi
Proudyogiki Vishwavidyalaya, Bhopal, India; 3Devi Ahilya Vishwavidyalaya, In-
dore, India.
Ovarian cancer (OC) is one of most lethal malignancies in woman reproduc-
tive tract. TheOCdiagnosed in advanced stage (III-IV) patients is highly aggres-
sive and relapses back in over 80% patient after initial response to chemother-
apy. Currently used chemotherapies are limited due to signifıcant adverse/toxic
effects, a narrow therapeutic index, and development of multidrug resistance
mediated by the epithelial-to-mesenchymal transition (EMT) and cancer cell
membrane efflux transporters. It is presumed that an ideal anti-OCdrug that has
diverse mechanisms, would inhibit several key cell-survival signaling and resis-
tance pathways when combined with conventional chemotherapy (paclitaxel
and cisplatin). Silybin, a polyphenolic flavonoid, has previously shown to inhibit
metastasis by inhibition of EMT pathways and bypass other drug resistance
factors i.e. efflux transporters in ovarian cancer both in vitro and in vivo. How-
ever, clinical use of silybin is limited due to their poor absorption and low
bioavailability and poor potency. To overcome this, we designed and synthe-
sized 11 silybin derivatives using molecular modeling, computer aided drug
design, structure activity relationship, natural product lead optimization and
ring disjunction approaches. In our preliminary fındings, we found the lead
molecule (15k) to have a cytotoxicity (IC50&lt1M) with potency more than
200-fold compared to silybin (IC50150M). The 15k was found to be around
10-fold selective in OC cells (OV2008, A2780) compared to normal ovarian
cells. Additionally, compared to other cancer cells belonging to prostate, breast,
lung, 15k was (3-6)-fold selective in OC cells (OV2008, A2780). The 15k pro-
duced synergistic activity and potentiated the cytotoxic effects of platinum (cis-
platin), anthracyclines (doxorubicin) and taxane (paclitaxel) anticancer agents.
While 15k also reversed the drug resistance mediated by ABC-efflux transport-
ers to paclitaxel and doxorubicin. Mechanistically, the cytotoxic effect of lead
compound 15k, as determined by using molecular biology assays, was found to
be due to inhibition of apoptosis, tubulin inhibition, and inhibition of stemness
pathways (Wnt--catenin-EMT). The 15khad signifıcant anti-metastatic effects
as shown by their inhibition of migration and invasion potential on OC cells. In
silico fındings suggest that pharmacokinetic [PK] profıles of these compounds
are favorable compared to silybin. Further in vivo PK/pharmacodynamic stud-
ies are underway to establish the clinical use of lead molecule in advanced me-
tastasized, drug resistant OC patients.
#2239 Establishment of lung cancer CTCs competent for lungmetastasis.
Zujun Que,1 Bin Luo,2 Qihui Shi,3 Jianhui Tian2. 1Shanghai Institute of Tradi-
tional ChineseMedicine, Institute of TCMOncology, Shanghai, China; 2Longhua
Hospital, ShanghaiUniversity of Traditional ChineseMedicine, National Clinical
Research Centre for Traditional Chinese Medicine and Oncology, Shanghai, Chi-
na; 3Systematic Biomedical Research Center of Shanghai Jiao Tong University,
Shanghai, China.
Circulating tumor cells (CTCs) have been implicated as a population of cells
that may seed metastasis, which led to the 90% of dead in cancer patients.
Though the detection technologies has been developing swiftly, how to culture
the cells successfully and established a permanent cell line are the bottleneck in
the research of metastasis mechanism. Here, we report, for the fırst time, the
establishment of permanent cell line from CTCs of one Non-small cell lung
cancer patient and identifying the biological characterization. The cell line des-
ignated CTC-0430 has been cultured for more than one and half years, and the
cells have been characterized at the genome, proliferation, drug resistance, the
expression of surface marker, cytokine secretion level and the characterization
of tumor formation in vivo by immunohistochemisty and immunofluorescence.
This thorough analysis showed that CTC-0430 cells display a stable phenotype
characterized by an intermediate epithelial/mesenchymal phenotype, stem-cell
like properties and the drug sensitivity test indicating stronger drug resistance
compared to A549 and 95-D. When compare with A549 and 95-D cells, CTC-
0430 cells high expression of ICAM-1 and ICAM-3, low expression of CX3CL1
and CXCL1. Functional studies showed that CTC-0430 cells induced rapidly in
vivo tumors after subcutaneous transplantation in immunodefıcient mice, and
the lungmetastasiswere found after sixmonths later. Besides, threemonths after
we injected the cells into the caudal vein ofNOD/SCIDmice, the lungmetastasis
were formed. And then themetastasis lung tissuewere used tomake IHC and IF,
which indicated that the biological characterizations of this cell line are different
fromA549. The establishment stable cell line of lung cancerCTCs can provide in
vivo research platform for the intervention study of postoperative metastasis of
lung cancer.
#2240 “Smart” selenium compound ISC-4 inhibits androgen receptor sig-
naling and induces ROS- and p53-dependent apoptosis in LNCaP prostate
cancer cells. Wei Wu, Kartick Pramanik, Cheng Jiang, Shantu Amin, Arun K.
Sharma, Junxuan Lu. Penn State University College of Medicine, Hershey, PA.
“Smart” selenium compound phenylbutyl isoselenocyanate (ISC-4) was de-
veloped by substituting sulfur in cancer chemopreventive compound phenylbu-
tyl isothiocyanate (PBITC) with selenium, resulting in increased anti-cancer
activity in several melanoma and colon cancer cell lines. The in vivo anticancer
benefıcial effects of ISC-4 have been reported in both melanoma and colon
cancer mouse models as well. To explore the potential chemopreventive attri-
butes of ISC-4 against prostate carcinogenesis, we selected LNCaP cells (with
wild type p53 and functional androgen receptor (AR) signaling) to examine the
growth suppression and apoptosis responses in cell culture and interrogated
signaling mechanisms through pharmacological and siRNA knockdown ap-
proaches. Results show that when compared with PBITC, ISC-4 was more po-
tent at suppressing cell growth and inducing apoptotic cell death in LNCaP cells.
ISC-4 induced caspase-mediated apoptosis (as evidenced by cleavage of PARP)
in dose- and time-dependent manners in association with decreased AR and its
best known target prostate specifıc antigen (PSA) protein abundance and up-
regulation of p53-DNA damage response (DDR) protein expression levels: p53,
its canonical target p21, and p-H2AX that marks DNA double-strand break
sites. Similar to the rapid induction of reactive oxygen species (ROS) by isothio-
cyanates, ISC-4 exposure resulted in increased dihydroethidium-detectable
ROS in a concentration-dependent manner. Preincubation with the ROS scav-
enger N-Acetyl-L-cysteine (NAC, 10 M to 2 mM), markedly reduced ISC-4-
PREVENTION RESEARCH: Molecular Targets and Cancer Prevention
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 573
induced cell death and attenuated p53, p21 and p-H2AX. Moreover, siRNA
knockdown of p53 did not suppress ROS production, but decreased ISC-4-
induced Annexin V-positive apoptosis, PARP cleavage and the DDR proteins.
Taken together, these data suggest that ISC-4 inhibits LNCaP cell growth and
survival with concomitant suppression of AR signaling and induction of ROS-
p53-DDRmediated apoptosis. Given the pivotal signifıcance of AR signaling in
prostate epithelial survival, cancer genesis and progression, and the preservation
of wild type p53 in precancerous lesions and early stage prostate cancer, our
fındings suggest attractive chemopreventive potential of ISC-4 against prostate
carcinogenesis.
#2241 Diosmetin induces apoptosis in humanprostate carcinoma cells via
the Rictor pathway invitro and inhibits tumor growth in vivo. Riddhi Patel,
Rebecca Pakradooni, Ahmad Khalifa, Natarajan Bhaskaran, Sanjeev Shukla.
Case Western Reserve Univ., Cleveland, OH.
Cell growth is a fundamental biological process, where mTOR (mammalian
target of rapamycin) pathway has its role, regulates cell growth by coordinating
energy and nutrient signals with growth factor. mTOR protein kinase have two
different complexes; complex-I contains major component raptor; a target of
rapamycin and complex II; insensitive to rapamycin, has major component
rictor. Rictor is important as it phosphorylates Ser-473 of Akt/PKB, which is
essential for full Akt/PKB activation. Reports suggested that overexpression of
mTOR in prostate cancer tissues, which may have potential role in prostate
cancer progression. The known mTOR inhibitor rapamycin is not specifıc for
mTOR-II complex, as it doesn’t inhibit main component Rictor. We need to
have effective chemo-preventive agents, which can modulate Rictor signaling
cascade to inhibit prostate cancer. Diosmetin (5, 7-Trihydroxy-4=-methoxyfla-
vone), a natural flavonoid present in citrus plant, has anti-mutagenic and anti-
allergic properties. Earlier we demonstrated growth factors Insulin-like growth
factor-1 and cytokine (IL-6) induces Rictor expression, and phosphorylated Akt
at Ser-473. Using diosmetin in concentration dependent fashion (5-40M) to
LNCaP and PC-3 cells down regulated phosphorylation of Rictor (Thr1135),
Akt (Ser-473) andPKC (Ser-657) expressions. This resulted in downregulation
of survival molecules; Survivin and X-linked inhibitor of apoptosis protein,
which induced apoptosis and inhibited cells growth. Luciferase tag PC-3 cells
orthotopic implant in ventral prostate of nude mice represented signifıcant de-
crease in tumor volume of diosmetin (20 and 50g/animal/day) fed mice com-
pared to control mice. Similarly bioluminescence imaging of orthotopically im-
planted mice represented decreased tumor luciferase activity after diosmetin
feeding than control mice. Moreover, diosmetin feeding to tumor bearing nude
mice reduced the phosphorylation of Rictor, (Thr1135), Akt (Ser-473) and
PKC (Ser-657) expressions and induced apoptotic events to inhibit tumor
growth signifıcantly. Based on results we may suggest diosmetin can be devel-
oped as an anticancer agent for prostate cancer.
#2242 Vitamin E -tocotrienol inhibits NF-B activation by up-regulat-
ing A20 in macrophages and suppresses colitis-promoted colon tumorigen-
esis in mice. Chao Yang, Qing Jiang. Purdue University, West Lafayette, IN.
Nuclear factor-B (NF-B) plays a key role in inflammatory responses and
cancer development. Inhibition of NF-B has been shown to attenuate inflam-
mation and cancer progression. 	-Tocotrienol (	TE) is a natural vitamin E form
rich in annatto seeds and has been shown to inhibit NF-B in pancreatic cells.
However, potential effect of 	TE on NF-B activation in immune cells and the
underlying mechanism have not been investigated. In the present study, we
found that 	TE inhibited TNF- induced activation of NF-B, as indicated by
diminished phosphorylation and degradation of IB in the cytosol, and phos-
phorylation of p65 in the nucleus. Furthermore, 	TE potently inhibited TNF--
induced phosphorylation of TAK1, a key upstreamkinase that is required for the
activation of NF-B. Interestingly, 	TE signifıcantly increased the expression of
A20 and CYLD, both of which are negative regulators of NF-B. Knockout of
A20 partially diminished 	TE’s anti-NF-B effect, supporting the notion that
induction of A20 plays a key role in 	TE’s anti-NF-B effect. To translate mech-
anistic fındings to a whole body environment, we further investigated the effec-
tiveness of 	TE and its metabolite, 	TE-13=-COOH, against azoxymethane
(AOM) induced and colitis-promoted colon tumorigenesis in male BALB/c
mice. We found that 	TE-rich mixed tocotrienols (	TE /γTE 8/1, at 0.035%
diet) inhibited colon tumorigenesis, as indicated by 36% reduction of multiplic-
ity of large adenomatous polyps (2mm(2), P0.07) and decreased tumor sur-
face area by 31% (P0.05). 	TE-13=-COOH (at 0.04% diet) signifıcantly sup-
pressed multiplicity of total polyps by 25% (P0.06) and large polyps by 54%
(P0.01). Our study demonstrates that 	TE has potent anti-NF-B activity and
this vitamin E form and its metabolite suppress colitis-promoted colon tumor-
igenesis in mice.
#2243 Elucidating the mechanism of action of molecular iodine on breast
cancer cells. Zack Xu, Xin Chen, Noymi Yam, kin Chan, Usha Nagavarapu.
Biopharm X, Menlo Park, CA.
Each year, over 1.7 million women are diagnosed with breast cancer world-
wide and about 35% of these diagnosed are expected to die from the disease. A
signifıcant barrier to improving treatment of breast cancer lies in our incomplete
understanding of breast cancer initiation and metastasis. Regular use of molec-
ular iodine has been shown to reduce the sensitivity of breast cells to the prolif-
erative effects of estrogen, resulting in normalization of breast tissue.The aim of
the current study was to evaluate the mechanisms of molecular iodine on two
common breast cancer sub-types using well-established breast cancer cell lines.
In order to study Luminal A and triple-negative breast cancer in vitro, MCF7
(cells from a luminal A subtype) andMDA-MB231 (cells from a triple-negative
subtype), were treated with molecular iodine at various concentrations to mea-
sure proliferation and cell death. This was subsequently followed by gene ex-
pression analysis of key important molecular markers, which are primarily re-
sponsible for cell growth and apoptosis. Primary human mammary epithelial
cells derived from healthy female donor were used as an internal control. Data
from this study indicated that molecular iodine had potent inhibitory effects on
cell growth and showed a dramatic increase in cell death in both breast cancer
cell lines. Gene expression analysis using quantitative RT-PCR further con-
fırmed that cell cycle genes controlling G1-S phase transition were largely up-
regulated. Changes were not seen in Cyclin B expression levels, which further
suggest that cells were arrested before entry into cell division. BCL-2, PPAR-
and PPAR- were also up-regulated along with down-regulation of Caspase 3,
suggesting molecular iodine induced cell death through activation of a caspase-
independent apoptosis pathway. Interestingly, mesenchymal-epithelial transi-
tion (MET) occurrence was noticed upon molecular iodine treatment as indi-
cated by sharp increase of GATA3 and E-Cadherin and signifıcant down-
regulation of Vimentin in invasive MDA-MB231 cells. Our current study
enables us to understand amolecular mechanism controlling tumor cell growth
anddemonstrates potent cellular effects ofmolecular iodine onbreast cancer cell
lines. These results also demonstrate promising effects of molecular iodine for
regulation of breast cancer EMT differentiation, which is required for tumor
initiation and metastasis. Further studies are underway to determine possible
effects of molecular iodine in these breast cancer subtypes using in vitro 3D
models.
#2244 Pharmacological TLR4 antagonism using topical resatorvid blocks
solar UV-induced skin tumorigenesis in SKH-1 mice. Sally E. Dickinson,1
Karen Blohm-Mangone,2 Nichole B. Burkett,2 Shekha Tahsin,2 Paul B.Myrdal,1
Kelly L. Karlage,1 Jaroslav Janda,2 Kathylynn Saboda,2 Denise J. Roe,1 Zigang
Dong,3 Ann M. Bode,3 Emanuel F. Petricoin,4 Valerie S. Calvert,4 Clara Curiel-
Lewandrowski,1 David S. Alberts,1 Georg T. Wondrak1. 1University of Arizona,
Tucson, AZ; 2University of Arizona Cancer Center, Tucson, AZ; 3University of
Minnesota, Austin, MN; 4George Mason University, Manassas, VA.
An urgent need exists for the development of more effıcacious molecular
strategies targeting non-melanoma skin cancer (NMSC), the most common
malignancy worldwide. Inflammatory signaling downstream of Toll-like re-
ceptor 4 (TLR4) is a causative factor in several forms of tumorigenesis, yet its
role in solar UV-induced skin carcinogenesis remains undefıned. In our
recently published work based upon immunohistochemical (IHC) analysis
of NMSC tissuemicroarrays and proteomic analysis of reverse-phase protein
microarrays (RPPA) from banked human tissue, we observed increased
TLR4 expression in association with tumorigenic progression from normal
skin to actinic keratosis and cutaneous squamous cell carcinoma. In immor-
talized keratinocytes expressing luciferase reporter constructs, resatorvid
potently inhibits UV-induced AP-1 and NF-B signaling, associated with
downregulation of inflammatory mediators (IL-6, IL-8, IL-10) and MAP
Kinase phosphorylation. In a subsequent acute exposure model in SKH-1
mice, topical resatorvid effıciently antagonized UV-induced stress signaling
while potentiating UV-induced epidermal apoptosis. In the current report,
we show for the fırst time that pharmacological inhibition of TLR4 using the
specifıc antagonist resatorvid (TAK-242) blocks UV-induced tumorigenesis
in SKH-1 mice. After assessing photostability, effıcient cutaneous delivery,
and skin residence time of topical resatorvid, we then tested the feasibility of
TLR4-directed inhibition of UV-induced tumorigenesis. To this end, SKH-1
mice were split into three groups (n  20). Each group was exposed to
solar-simulated UV (three times a week; 15 weeks duration), followed by
another 10 weeks in the absence of UV exposure (sacrifıce at week 25). The
control group received topical vehicle (acetone) on their backs 1 hour prior
to UV exposure (three times a week until sacrifıce). The “Prevention” group
received topical resatorvid following an analogous dosing regimen. The “In-
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tervention” group received vehicle 1hr prior to each UV treatment but
switched to topical resatorvid three times a week only after UV was termi-
nated. In the Prevention model, topical treatment with resatorvid signifı-
cantly inhibited both tumor area (66% reduction, p  0.0052) and tumor
multiplicity (32% reduction, p 0.0329; cross sectional Kruskal-Wallis test).
In the Intervention model, a marked inhibition of both measures of tumor
yield was observed, yet they did not reach statistical signifıcance. Likewise,
suppression of UV-induced TLR4-driven signaling was also confırmed in
murine skin harvested at week 14 (prior to tumor onset), as assessed by IHC
and RPPA analysis. Taken together, these data generated using resatorvid in
a murine photocarcinogenesis model suggest that pharmacological TLR4
antagonism may represent a novel molecular strategy for topical prevention
of solar UV-induced NMSC.
#2245 Evaluationof new rexinoids for lung cancer.DiZhang,1Ana S. Leal,1
SarahE.Carapellucci,1 KaylaZydeck,1NicoleChaaban,1Michael B. Sporn,2Carl
E.Wagner,3 KarenT. Liby1. 1Michigan StateUniversity, East Lansing,MI; 2Dart-
mouth Medical School, Hanover, NH; 3Arizona State University, Phoenix, AZ.
Lung cancer remains the leading cause of cancer deaths around the world.
It is estimated that there will be over 150,000 deaths in the United States
alone from this disease every year.With no signifıcant improvement in 5 year
survival rates over the past 30 years, effective prevention or early interven-
tion is a promising approach to reduce the high mortality of lung cancer.
Rexinoids are selective ligands for retinoid X receptors (RXR), which regu-
late the expression of a wide variety of genes. As transcription factors, rexi-
noids play important roles in proliferation, differentiation, and apoptosis,
which are highly relevant in cancer. Bexarotene is the only synthetic rexinoid
that has been approved by the FDA and is used for the treatment of refractory
cutaneous T-cell lymphoma. It has also been tested in various clinical trials
for lung cancer and breast cancer. However, Bexarotene is not potent or
selective enough for RXRs, causing limited effıcacy and unacceptable toxic-
ities. Therefore, we synthesized a series of new rexinoids and screened them
for their ability to inhibit nitric oxide (NO) production in RAW264.7 mac-
rophage-like cells stimulated with LPS. Several of these compounds inhib-
ited NO production at nanomolar concentrations. Based on this screening
and other in vitro assays, two new rexinoids were chosen for in vivo testing.
Female A/J mice were injected i.p. with vinyl carbamate (16 mg/kg). One
week later, the mice were fed control diet or rexinoids in diet (40-80 mg/kg
diet) for 16 weeks. Tumor number, size and histopathology were then eval-
uated. All of the rexinoids reduced the number and size of the lung tumors.
However, Bexarotene only reduced the average number of tumors by 8-17%,
while a new pyrimidine-analog of Bexarotene—henceforth, pyrimidine-
Bexarotene—reduced the number of tumors by 24-28%. The average tumor
burden on lung sections was also reduced by pyrimidine-Bexarotene by 59%
compared to the controls (from 0.47	 0.19 mm3 in the control group to 0.19
	 0.05 mm3 in the treated group). In contrast, average tumor burden was
0.35 	 0.08 mm3 in the group treated with Bexarotene, a reduction of 26%.
Notably, the percentage of high grade tumors (both histological and nuclear
characteristics) were signifıcantly (p0.05) higher in the mice fed Bexaro-
tene (63%) than in the control group (38%), while the percentage of high
grade tumors was only 34% in the pyrimidine-Bexarotene group. Since a
major side effect of rexinoids is an elevation in triglyceride levels, we mea-
sured total triclycerides in both liver and plasma. Pyrimidine-Bexarotene
reduced triclyceride levels in the liver (7.17 ug/kg tissue) compared to Bex-
arotene (8.23 ug/kg tissue) and plasma (3.6mg/ml vs. 4.8mg/ml, respectively;
p0.05). These studies suggest that new rexinoids can be synthesized that
are superior to Bexarotene for prevention of lung cancer. Additional synthe-
sis and testing of new rexinoids will be performed to further enhance the
potency and selectivity of this promising class of drugs.
#2246 Anti-proliferative activities of lipid fractionof extract fromthe skin
of the catfıshArius Bilineatus, Valenciennes. Peiying Yang,1 Jibin Ding,1 Yong
Pan,1 Yan Jiang,1 Mohammad Afzal,2 Bincy M. Paul,2 Sosamma O. George,3
Jassim M. Al-Hassan2. 1UT MD Anderson Cancer Ctr., Houston, TX; 2Kuwait
University, Safat, Kuwait; 3CMS College, Kottayam, Kerala, India.
The catfısh (Arius bilineatus, Val.) secretes a gelatinous substance composed
of biochemically active lipids and proteins from its skin upon stress or injury.
Preparations from the skin have previously been shown to affect blood clotting
and accelerates healing of non-healing diabetic foot ulcers in man. We have
reported previously fısh skin preparation (CSP) derived from the skin of the
Catfısh and it’s lipid fraction exerted anti-inflammatory activity in the in vitro
cells and in vivo animal models. Here anti-proliferative effect of a lipid fraction
of fısh skin preparation (CSP-L) derived from the skin of the catfısh and its
plausible mechanism were investigated in human hepatocellular carcinoma
(HCC) Hep3B and human pancreatic cancer Panc-1 cells. Cells were treated
with CSP-L (0 to 100 g/ml) for 72 hrs and cell proliferation was measured by
the MTT assay. The results showed much stronger inhibition by CSP-L in
Panc-1 cells than that of Hep3B cells with IC50 of 5.5	 1.4g/ml and 19.5	 7.7
g/ml, respectively. Cell cycle analysis with PI staining suggested that CSP-L
(25 - 100g/ml) led toG1 phase arrest inHep3B cells whereas S phase arrest was
observed in Panc-1 cells, suggesting the differential molecular mechanisms re-
sponsible for CSP-L induced cell growth suppression inHep3B and Panc-1 cells.
The alteration of cell cycle was concentration dependent. Additionally, CSP-L
concentration dependently suppressed the invasion of Hep3B and Panc-1 cells.
The molecular mechanism associated with CSP-L’s anti-proliferative effect was
examined by Western blotting in both Hep3B and Panc-1 cells. Intriguingly,
CSP-L (50 and 100 g/ml) notably decreased protein levels of cyclin D, Stat3,
pRB and pERk in Hep3 B cells in a concentration dependent manner. In con-
trast, only pRB and pERK protein expression were reduced in CSP-L treated
Panc-1 cells. These again suggest that CSP-L inhibited the proliferation of
Hep3B and Panc-1 cells by different molecular mechanisms. Collectively, our
preliminary data suggest that CSP-L has a great potential to be developed as an
anticancer or preventive agent for both HCC or pancreatic cancer and warrants
further investigation. This study was support by a grant from Kuwait Founda-
tion for the Advancement of Science No. KFAS 2013-120701A-D, and Kuwait
University Research Grant No. SL03/14.
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#2247 Associations between total T-lymphocytes and colorectal cancer
survival in a prospective cohort study of older women. Anna E. Prizment,1
Robert A. Vierkant,2 Thomas C. Smyrk,2 Lori S. Tillmans,2 Heather H. Nelson,1
Charles F. Lynch,3 Stephen N. Thibodeau,2 Timothy R. Church,1 James R. Cer-
han,2 Kristin E. Anderson,1 Paul J. Limburg2. 1University of Minnesota, Minne-
apolis, MN; 2Mayo Clinic, Rochester, MN; 3University of Iowa, IA.
Background: The increased number of T-lymphocytes residing in the tumors
of colorectal cancer (CRC) patients is consistently shown to predict better sur-
vival of CRC patients independent of stage. In addition to tumor itself, T-lym-
phocytes also infıltrate normal tissues adjacent to tumors; however, little is
known about how the inter-individual T-cell variability in tumor-adjacent tis-
sues affects CRC prognosis. Our goal was to characterize total T-cells in colo-
rectal tumor and tumor-adjacent tissues and study their associations with all-
cause and CRC-specifıc survival in the Iowa Women’s Health Study. Methods:
We constructed tissue microarrays and quantifıed CD3 antibody staining
(Clone F.7.238; Dako), an established marker for total T-cells, in paraffın-em-
bedded tissue samples from 463 women diagnosed with incident CRC from
1986-2002 (mean age at diagnosis was 74 years). Up to 3 tumor and 3 tumor-
adjacent cores were immunostained for each person. An experienced patholo-
gist quantifıed CD3 T cells in each area using 4 categories: non-detected, mild
(1-10 cells per 0.28 mm2); moderate (11-29 cells per 0.28 mm2); and strong
infıltration (
30 cells per 0.28mm2). The obtained scores were averaged over all
quantifıed cores for each person. Cox regressionwas used to estimate the hazard
ratio (HR) and 95% CI for all-cause and CRCmortality in relation to (1) tumor
score; (2) tumor-adjacent score; and (3) the ratio of tumor to tumor-adjacent
score, hereafter called Score ratio. All scores were categorized in quartiles. The
fınal model adjusted for age at diagnosis, SEER stage, tumor grade, body mass
and smoking history. Results: During follow-up for amaximumof 25 years, 67%
of participants diagnosed with CRC died (30% died from CRC). There was a
weak but signifıcant correlation betweenCD3 tumor and tumor-adjacent scores
(Spearman coeffıcient: r0.15, p0.02). CD3 tumor score was inversely associ-
ated with stage and was higher in those with proximal colon cancer, and for
MSI-high, CIMP-high and BRAF-mutated tumors. The HRs (95%CI) for the
highest versus lowest category of CD3 tumor score were 0.61 (0.44-0.84) (p-
trend0.003) for all-causemortality and 0.27 (0.15-0.48) (p-trend0.0001) for
CRC-specifıc mortality. The tumor-adjacent score was not associated with any
characteristics or death. The associations between the Score ratio and all-cause
and CRC survival mirrored those for the tumor score but were weaker. TheHRs
(95%CI) for the highest versus lowest quartile of the Score ratio were 0.70 (0.45-
1.09) (p-trend0.09) for all-cause and 0.45 (0.23-0.87) (p-trend0.003) for
CRC-specifıc mortality. Conclusions. Based on data from prospectively identi-
fıed CRC cases in the IWHS cohort, colorectal tumor T-cell infıltration is asso-
ciated with improved survival. Further investigation is needed to determine the
T-cell subtypes that are most predictive of CRC survival outcomes.
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#2248 Common TDP1 polymorphisms in relation to survival among
small cell lung cancer patients in a multicenter study from the International
Lung Cancer Consortium. Pawadee Lohavanichbutr,1 Lori C. Sakoda,2 Chris-
topher I. Amos,3 SusanneM. Arnold,4 David C. Christiani,5 Michael P. Davies,6
John K. Field,6 Eric B. Haura,7 Rayjean J. Hung,8 Takashi Kohno,9 Maria Teresa
Landi,10 Geoffrey Liu,11 Yi Liu,12 Michael W. Marcus,6 Grainne M. O’Kane,11
Matthew B. Schabath,7 Kouya Shiraishi,9 Stacey A. Slone,4 Adonina Tardón,13
Ping Yang,12 Kazushi Yoshida,9 Ruyang Zhang,5 Xuchen Zong,8 Noel S.
Weiss,14 Chu Chen1. 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2Kaiser Permanente, Oakland, CA; 3Geisel School of Medicine at Dartmouth,
Lebanon, NH; 4University of Kentucky Markey Cancer Center, Lexington, KY;
5Harvard School of Public Health, Boston, MA; 6University of Liverpool, Liver-
pool, United Kingdom; 7Moffıtt Cancer Center, Tampa, FL; 8Lunenfeld-Tanen-
baum Research Institute, Sinai Health System, Toronto, Ontario, Canada; 9Na-
tional Cancer Research Institute, Tokyo, Japan; 10National Cancer Institute,
Bethesda, MD; 11Princess Margaret Cancer Centre, Toronto, Ontario, Canada;
12Mayo Clinic, Rochester, MN; 13University of Oviedo, Spain; 14University of
Washington, Seattle, WA.
Introduction:DNA topoisomerase inhibitors (e.g. etoposide, irinotecan, teni-
poside, topotecan) are commonly used for treating small cell lung cancer
(SCLC). Tyrosyl-DNAphosphodiesterase (TDP1) plays a role in repairingDNA
damage caused byDNA topoisomerase inhibitors and it is believed to be respon-
sible for resistance to this class of drugs. The purpose of this study was to deter-
mine whether common TDP1 polymorphisms are associated with overall sur-
vival among SCLC patients. Method: Two common TDP1 SNPs (rs942190 and
rs2401863, r2(European)0.63 and r2(East Asian)0.26) were analyzed in 898 pa-
tients from 10 studies in the International Lung Cancer Consortium, conducted
in the U.S., Canada, Japan, Italy, Spain and the United Kingdom. Genotype data
were obtained from either the OncoArray Consortium or other existing ge-
nome-wide association studies. Cox proportional hazard regression models
with robust standard error were used to evaluate genotype associations for over-
all survival at 36 months post-diagnosis, adjusting for age, sex, race and tumor
stage. Results: Patients homozygous for the minor allele (GG) of TDP1 SNP
rs942190 were associated with poorer survival compared to those carrying both
major alleles (AA), with a hazard ratio (HR) of 1.36 (95% confıdence interval
(CI): 1.07-1.72, p-value0.01), but there was no association with survival for
patients with the heterozygous genotype (HR1.02, 95% CI: 0.83-1.27,
p-value0.83). For rs2401863, patients carrying bothminor alleles (CC) tended
to have better survival than patients carrying AA alleles, but this was within the
limits of chance given no signifıcant association (HR0.79, 95% CI: 0.61-1.02,
p-value0.07). In addition, multi-tissue expression quantitative trait loci
(eQTL) analyses from the Genotype-Tissue Expression Project indicated a po-
tential effect of rs942190 on lung tissue, with higher TDP1 gene expression for
the GG than AG or AA genotypes. Conclusion: We found that among SCLC
patients the TDP1 rs942190 GG genotype was associated with poor overall sur-
vival. Further study could determine if this genotype can serve as a predictive
marker for the treatment effıcacy of DNA topoisomerase inhibitors in SCLC.
#2249 Integrated multi-level omics-based biomarker models for ovarian
cancer survival. Alan Fu,1 Shen-Chih Chang,1 Aileen Baecker,1 Helena R.
Chang,2 Zuo-Feng Zhang1. 1UCLA Fielding School of Public Health, Los Angeles,
CA; 2David Geffen School of Medicine at UCLA, Los Angeles, CA.
Background:Although a number of prognostic biomarkers for ovarian cancer
have been proposed, the pool of clinically useful biomarkers remains small.
While the predictive power of individual biomarkersmay be weak, the advent of
more affordable high-throughput technologies and readily available “omics”
level data point toward the possibility of high performance biomarker panels. In
this study, we used tumor-based somatic mutation, mRNA andmiRNA expres-
sion, and DNA methylation data from The Cancer Genome Atlas (TCGA) to
construct integrated biomarker models for overall and progression-free sur-
vival. Methods: The somatic mutations, mRNA expression, and DNA methyl-
ation of 451 candidate genes, as well as the expression of the miRNAs targeting
them, were individually analyzed for association with overall and progression-
free survival in 488 TCGA serous cystadenocarcinoma patients of predomi-
nantly Caucasian descent. Following correction for multiple comparisons, mo-
lecular variations associated with survival were combined to construct
integrated cross-validated prediction models for overall and progression-free
survival. The discriminative power of thesemodels was then evaluated for 1-, 3-,
and 5-year overall and progression-free survival using ROC analysis. Results:
Our cross-validated integrated molecular models were demonstrated to predict
5-year overall survival in the total patient pool with a ROC AUC of 0.801 and
5-year overall and progression-free survival in Caucasian patients with ROC
AUCs of 0.866 and 0.809, respectively. Conclusions: Our fındings suggest the
potential utility of our multi-omics-based biomarker models in helping to in-
form clinical decisions following ovarian cancer diagnosis. Although extensive
efforts were made to maximize the predictive potential of our models, further
retrospective and prospective validation efforts are necessary before their clini-
cal utility can be accurately assessed.
#2250 Systemic inflammation and sarcopenia predict colorectal cancer
survival. Elizabeth M. (Cespedes) Feliciano,1 Candyce H. Kroenke,1 Jeffrey
Meyerhardt,2 Carla M. Prado,3 Patrick T. Bradshaw,4 Marilyn Kwan,1 Jingjie
Xiao,3 Stacey Alexeef,1 Erin K.Weltzien,1 Adriemme L. Castillo,1 Bette J. Caan1.
1Kaiser Permanente Division of Research, Oakland, CA; 2Dana Farber Cancer
Institute, MA; 3University of Alberta, Edmonton, Alberta, Canada; 4University of
California, Berkeley, CA.
Importance: A higher neutrophil-to-lymphocyte ratio (NLR, indicating sys-
temic inflammation), and sarcopenia (reduced skeletal muscle mass) predict
morbidity/mortality in a variety of cancers, but no prior research examines
associations of pre-diagnostic NLR with at-diagnosis sarcopenia, nor whether
NLR and sarcopenia combined identify early-stage patients with poor prognosis
in colorectal cancer (CRC).Objective: To evaluate the association between pre-
diagnosis NLR and at-diagnosis sarcopenia and of their combination with CRC
survival, controlling for age, ethnicity, sex, body mass index, stage, and cancer
site. Design, Setting, and Participants: This observational cohort with prospec-
tively-collected data included 2470 patients diagnosed with stage I-III CRC at
Kaiser Permanente from 2006-2011 with computed tomography (CT) scans
from clinical care (mean days pre-diagnosis6). Exposures: Systemic inflam-
mation measured via average NLR in the 24 months pre-diagnosis (mean
count3 measures, mean months pre-diagnosis7). The reference value was
NLR below 3, indicating low/no inflammation. Main Outcomes and Measures:
Sarcopenia, defıned by published cutoffs for skeletal muscle index (CT muscle
area in cm2 at the third lumbar vertebra divided by squared height in m2; below
52-cm2/m2 and 38-cm2/m2 for normal/overweight men and women, respec-
tively, and below 54-cm2/m2 and 47-cm2/m2 for obese men and women, re-
spectively), and incident death (overall or CRC-related). Results: Average age
was 63 years; half of patients were female. NLR above 3 and sarcopenia were
common (46% and 44%, respectively). Over a median of 6 years, we observed
656 deaths, 357 from CRC. Elevated NLR was associated with sarcopenia in a
dose-response manner (compared to NLR below 3, Odds Ratio [OR]1.35;
95%CI:1.10-1.67 for NLR 3-5; OR1.47; 95%CI:1.16-1.85 for NLR above 5).
NLR above 3 and sarcopenia were also independently associated with survival
(Hazard Ratio [HR]1.65; 95%CI:1.45-1.98 for overall death and HR1.29;
95%CI:1.09-1.53 for CRC death); patients with both sarcopenia and NLR above
3 (versus neither), had double the risk of death overall (HR2.53; 95%CI:1.87-
3.41) and from CRC (HR2.19; 95%CI:1.74-2.75). Conclusions and Relevance:
Host inflammatory/immune response shortly prior to diagnosis predicts mus-
cularity at diagnosis. Low muscle combined with systemic inflammation pre-
dicts worse CRC prognosis regardless of stage. A better understanding of the
crosstalk between inflammatory/immune responses and the onset of changes in
skeletalmusclemay open new therapeutic avenues to improve cancer outcomes.
#2251 Tumor tissue gene expression in association with survival of triple-
negative breast cancer. ShuyangWang,1 Qiuyin Cai,1 Hui Cai,1 Pingping Bao,2
Jie Wu,1 Fei Ye,1 Wei Zheng,1 Ying Zheng,2 Xiao-Ou Shu1. 1Vanderbilt Univer-
sity School of Medicine, Nashville, TN; 2Shanghai Municipal Center for Disease
Control and Prevention, Shanghai, China.
Triple-negative breast cancer (TNBC) is an aggressive type of cancer with
limited treatment options. Previous studies have shown that gene expression
profıles were associated with TNBC prognosis. Information on specifıc genes
that are predictive of TNBC outcome is limited. Using data and samples from a
cohort of 469TNBCcases fromShanghai Breast Cancer Survival Study (SBCSS),
we systematically evaluated expressions of 302 genes in tumor tissue with sur-
vival of TNBC. Genes included in the study are PAM50 genes, genes encoding
drug metabolizing enzymes and, genes implicated in TNBC biology and pro-
gression based on literature reviews. Gene expression levels were measured in
total RNA isolated from formalin-fıxed paraffın-embedded breast cancer tissues
using the NanoString nCounter assay. Cox regression was applied to evaluate
disease-free survival (DFS) and overall survival (OS) in association with gene
expression. Analysis was adjusted for known predictors of TNBC outcome, in-
cluding age, disease stage, basal like subtype and DUSP4 gene expression. Dur-
ing a median follow-up of 5.3 years (range: 0.7-8.9 years), 100 deaths and 92
recurrences/breast cancer deaths were documented. Expression levels of 17
genes were signifıcantly associated with OS, and 15 genes with DFS (P0.05).
The top 5 most signifıcant genes are EOMES (Hazard Ratio, HR  0.88; 95%
Confıdence Interval, 95%CI: 0.82-0.96), GZMK (HR 0.91, 95%CI: 0.85-0.97),
EPIDEMIOLOGY: Biomarkers of Risk and Prognosis
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017576
TUBB3 (HR  1.12, 95% CI: 1.03-1.21), SIT1 (HR  0.90, 95% CI: 0.83-0.98)
and ZNF224 (HR  0.89, 95% CI: 0.81-0.97) for OS, and TUBB3 (HR  1.14,
95% CI: 1.05-1.24), KRT14 (HR 1.08, 95% CI: 1.02-1.14), BAG1 (HR 1.19,
95% CI: 1.05-1.35), CD44 (HR 0.73, 95% CI: 0.58-0.92) and EOMES (HR
0.89, 95% CI: 0.82-0.97) for DFS. Study is on-going to replicate the fındings of
this study.
#2252 Microbial profıling of the head and neck tumormicroenvironment
as a biomarker of clinical response to chemoradiation. Christine M. Pierce
Campbell,1 Bo-Young Hong,2 Maria F. Gomez,1 Blake M. Hanson,2 Erica So-
dergren,2 Sybil T. Sha,3 Jeffery S. Russell,1 George M.Weinstock2. 1Moffıtt Can-
cer Center, Tampa, FL; 2The Jackson Laboratory for Genomic Medicine, Farm-
ington, CT; 3Cornell University, Ithaca, NY.
PURPOSE: Despite advances in cancer treatment, patients with advanced
head and neck cancer (HNC) have amedian overall survival of1 year and 30%
cure rate. Evidence suggests thatmicrobiotamaymodulate the response to ther-
apy through a crosstalk with cancer cells, immune cells, and inflammatory me-
diators. This study was conducted to profıle the tumor microbiome of HNC
patients to determine whether bacteria and fungi in the tumor microenviron-
ment are associated with the clinical response to chemoradiation. METHODS:
Fresh frozen tumor tissues from 30 newly diagnosed, treatment-naïve patients
who received chemoradiation at Moffıtt Cancer Center for squamous cell HNC
were evaluated. Genomic DNA was extracted from 25mg of tissue. The V1-V3
hypervariable region of the bacterial 16S rRNA gene and fungal internal tran-
scribed spacer (ITS) 1 region were sequenced using a PCR amplicon-mediated
workflow on the IlluminaMiSeq. 16S sequences were clustered into operational
taxonomic units and taxonomic identifıcation was determined using the RDP
database and ITS sequences were classifıed using an in house reference database.
Patients’ charts were reviewed to ascertain clinical response 3, 6 and 12 months
after treatment cessation. Response was dichotomized as complete (no evidence
of disease) and incomplete (partial response, stable disease, and progressive
disease). RESULTS: At the time of tumor collection, patients ranged in age from
20-79 years, and were predominantly men (83%) and current smokers (40%).
The most common anatomic site was the oral cavity (70%) followed by the
larynx (20%) and oropharynx (10%), andmost were diagnosed at stage 4 (87%).
Three, 6 and 12months after treatment cessation, 4 (14%), 9 (36%), and 10 (40%)
patients had an incomplete response to therapy, respectively. Bacterial sequenc-
ing was successful in 29 (97%) samples and fungal in 15 (50%). Clustering anal-
yses of bacterial abundance profıles suggested that 4 types of communities
existed, each dominated by Fusobacterium, Prevotella, Streptococcus, or
Treponema. HNC patients with incomplete clinical responses (3, 6, or 12
months after treatment) were more likely to have treatment-naïve tumors dom-
inated by Fusobacterium (cluster 1; 56%) than any other genus, whereas patients
with complete clinical responses were more likely to have treatment-naïve tu-
mors dominated by Prevotella (cluster 2; 40%) than any other genus.None of the
patients with incomplete responseswere dominated by Streptococcus (cluster 3)
or Treponema (cluster 4). Fungal ITS profıling revealed that the tumor micro-
biome was largely dominated by the fungi Malassezia. CONCLUSIONS: The
current study demonstrates that intratumoral bacterial profıles dominated by
Prevotella may serve as a biomarker of improved prognosis, while profıles dom-
inated by Fusobacteriummay indicate a poor prognosis following chemoradia-
tion in HNC patients.
#2253 5 Gene prognostic signature for dedifferentiated liposarcomas.
DeannaNg,Nicholas Shannon, JohnnyOng,Melissa Teo.National Cancer Cen-
tre Singapore, Singapore, Singapore.
Introduction: Liposarcomas, despite being rare consist of a number of
entities spanning low to high grade sarcomas. De-differentiated liposarcoma
(DDLS) is associated with increased frequency of recurrence and lower over-
all survival. We aimed to identify gene expression changes associated with
OS in DDLS. Secondary aims was to postulate a mechanism for DDLS. Meth-
ods: We analysed data from gene expression omnibus (GEO, ID 
GSE30929) to identify genes associated with DDLS (n39). A signature
representing genes overexpressed in DDLS was then applied to an indepen-
dent dataset, utilising data from The Cancer Genome Atlas (TCGA, n58
DDLS) to segregate samples based on gene expression and groupings com-
pared for survival. Results: A 5 gene signature was generated consisting of
genes with increased expression in DDLS and its relation to OS. The signa-
ture was signifıcantly enriched for genes involved in lipid metabolism
(AQP7, PRKAR2B, FABP4 p0.01) and genes involved in the cell cycle and
cell proliferation (FBN2, CEBPA p0.01). Segregation of DDLS in the
TCGA cohort on the basis of median gene signature score gave a signifıcant
difference in overall survival. High score (stronger DDLS signature) was
associated with a lower median survival(33.5 vs 76.4 months, p 0.027), and
poorer 2 year (63.4% vs 89.2%) and 5 year survival (20.6% vs 71.1%). The
survival difference remained signifıcant when applied to retroperitoneal
DDLS only (n51, median survival 34.5 vs 54.2 months, p  0.034) and
poorer 2 year survival (. A postulated mechanism is that DDLS have gained
defıciency in AQP7, PRKAR2B and FABP4 leading to fatty acid and glycerol
accumulation in cells, increasing cancer cell replication. CEBPA inhibits
CDK4 and a defıciency of CEBPA in DDLS leads to up regulation of CDK4,
increasing cell proliferation. An upregulation of FBN2 in DDLS up regulates
TGF-1, increasing cell proliferation. Conclusion: Gene expression changes
associated with dedifferentiated liposarcomas include changes in cell cycle
checkpoint regulation. The signature is associated with poorer overall sur-
vival in DDLS and can be used to prognosticate patients.
#2254 Reactive oxygen speciesmodulator 1 (Romo1) predicts unfavorable
prognosis in colorectal cancer patients.Min Jee Jo, Hong JunKim, Suk-Young
Lee, Dae-Hee Lee, Sang Cheul Oh. Korea University Guro Hospital, Seoul, Re-
public of Korea.
Reactive oxygen species modulator 1 (Romo1) is a novel protein that has
been reported to be crucial for cancer cell proliferation and invasion. How-
ever, its clinical implications in colorectal cancer (CRC) patients are not
well-known. For the fırst time, we investigated the association between
Romo1 and the clinical outcomes of CRC patients. We examined Romo1
expression in resected tumor tissues immunohistochemically and assessed it
with histological scores. We conducted survival analyses for patients who
had curative resection (n190) in accordance with clinical parameters in-
cluding level of Romo1 expression, and we examined the association be-
tween Romo1 expression and cell invasion using Matrigel invasion assay in
CRC cell lines. We observed signifıcantly longer mean disease-free survival
(DFS) in the low Romo1 group compared with the high Romo1 group (161 vs
127.6 months, p0.035), and the median overall survival (OS) of the low
Romo1 group was signifıcantly longer than that of the high Romo1 group
(196.9 vs 171.3 months, p0.036). Cell invasiveness decreased in the Romo1
knockdown CRC cells in contrast to the controlled cells. Romo1 overexpres-
sion in tumor tissue was associated with a high lymph node ratio (LNR)
between the metastatic and examined lymph nodes (p0.025). Romo1 over-
expression in tumor tissue was signifıcantly associated with survival in cu-
ratively resected CRC patients, suggesting Romo1 expression as a potential
adverse prognostic marker. Increased Romo1 expression was found to be
associated with high LNR. Cancer invasiveness appeared to be a key reason
for the poor survival related to highly expressed Romo1.
#2255 SMAD4 loss is associated with poor prognosis in Middle Eastern
colorectal cancer. Maqbool Ahmed, Abdul K. Siraj, Tariq Masoodi, Rong Bu,
Fouad Al-Dayel, Khawla S. Al-Kuraya. King Faisal Specialist Hospital & Res.
Ctr., Riyadh, Saudi Arabia.
Background: Colorectal cancer (CRC) is major cause of morbidity and
mortality in cancer patients worldwide and it ranks as the most common
cancer in males and the third most common among females in Saudi Arabia.
Alteration in TGF- pathway has been reported in many cancers. So In
search for new molecular targets we analyzed the role of SMAD4, critical
TGF- pathway mediator, in Saudi colorectal cancers Methods: 426 CRC
cases were analyzed for SMAD4 mutations by targeted capture sequencing
and protein expression status by immunohistochemistry in a tissue microar-
ray format. Results were analyzed for association with any clinico-patholog-
ical parameters and for prognostic signifıcance. Results: SMAD4 mutations
were detected in 11.9 %( 50/418) cases of Saudi colorectal cancers. CRC with
SMAD4 mutations were signifıcantly associated with NRAS mutations
(p0.0481). SMAD4 complete loss of expression by immunohistochemistry
was seen in 12.8% (52/404) cases and this loss was associated with young age
(p0.0236) and inversely with MSI-high tumors (p0.0005). SMAD4 ex-
pression loss by immunohistochemistry and mutation were signifıcantly as-
sociated with each other (p0.0028). In the multivariate analysis using the
Cox proportional hazard model SMAD4 expression loss was an independent
marker of poor prognosis (p0.0119) Conclusion: SMAD4 alteration was
found to be associated with a poor overall survival in the Saudi colorectal
cancer patients. With the advent of targeted anticancer therapy, this study
confırms the fındings of other investigators and highlights a potential target
which can be exploited to improve the survival of CRC patients in the King-
dom of Saudi Arabia.
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#2256 Semaphorin 3C has a possibility of a new prognostic marker in
colorectal cancer. Shingo Kawano,1 Kota Amemiya,1 Yuki Tsuchiya,1 Toshiaki
Hagiwara,1 HirokazuMatsuzawa,1 YurikaMakino,1 ShunsukeMotegi,1 Ryoichi
Tsukamoto,1 Ryosuke Ichikawa,1 Kazumasa Kure,1 Kumpei Honjo,1 Hisashi
Ro,1 Shingo Ito,1 Yu Okazawa,1 Rina Takahashi,1 Kosuke Mizukoshi,1 Masaya
Kawai,1 ShinyaMunakata,1 Koichiro Niwa,1 Shun Ishiyama,1 Kiichi Sugimoto,1
Hirohiko Kamiyama,1 Hiromitsu Komiyama,1 Makoto Takahashi,1 Yutaka Ko-
jima,1 Michitoshi Goto,1 Atsushi Okuzawa,1 Yuichi Tomiki,1 Kazuhiro Saka-
moto,1Motohiro Kojima,2 Atsushi Ochiai2. 1Juntendo University, Tokyo, Japan;
2National Cancer Center Hospital East, Chiba, Japan.
Background:Generally, Semaphorins are secretary or transmembrane-bound
molecules that act as axon guidance cues in the nervous system. Recent research
showed increased expression of semaphorin 3C correlates with cancers that
possess higher invasive and metastatic characteristics. For example, in breast
cancer, inhibition of semaphorin 3C reduces adhesion and invasion. The aim of
this study was to evaluate a possibility that semaphorin 3C might be a new
prognostic marker in colorectal cancer. Material and methods: We used two
cohorts. Cohort 1 was the 192 patients with colorectal cancer resected surgically
between 2009 and 2010.We usedGSE 14333 dataset as Cohort 2 which included
226 patients with the colorectal cancer. In each cohorts, we divided the patients
in to the two groups i.e., high or low semaphorin 3C expression group using
receiver operating characteristic (ROC) curve based on the information of the
recurrence of colorectal cancer. Disease-free-survival (DFS) rates were calcu-
lated using Kaplan-Meier methods. Differences between curves were evaluated
with the log-rank test. Results: In the cohort 1, the DFS in the patients with
higher expressionwasworse than that in the patientswith lower expression (P
0.0467). Semaphorin 3C has two probes (203788_s_at and 203789_s_at) in
GSE14333. In the cohort 2, using each two probe of semaphorin 3C, the DFS in
the patients with higher expression was worse than that of those patients with
lower expression (P  0.0015 and P  0.0003). Conclusions: This study sug-
gested that Semaphorin 3C might be a new prognostic marker in colorectal
cancer.
#2257 Pre-diagnostic sex hormone levels and breast cancer survival in the
Nurses’ Health Study. Kevin H. Kensler,1 A. Heather Eliassen,2 Bernard A.
Rosner,2 Susan E. Hankinson,3 Myles Brown,4 Rulla M. Tamimi2. 1Harvard
T. H. Chan School of Public Health, Boston, MA; 2Brigham andWomen’s Hospi-
tal, Boston,MA; 3University ofMassachusetts School of Public Health andHealth
Sciences, Amherst, MA; 4Dana-Farber Cancer Institute, Boston, MA.
Background The role of estrogens has been well established in the develop-
ment and progression of breast cancers, while an independent function of an-
drogens remains to be fully elucidated. There is consistent evidence that in-
creased levels of circulating sex steroid hormones predict subsequent breast
cancer risk. However, few studies to date have evaluated circulating sex hor-
mone levels in relation to breast cancer prognosis and the limited available
evidence suggests that higher estrogen and androgen levels are associated with
worse prognosis. Identifying the distinct roles of estrogens and androgens and
their hormone receptor signaling pathways in breast cancers may inform novel
approaches to breast cancer prevention and treatment. Methods We evaluated
the association betweenpre-diagnostic circulating sex hormones andbreast can-
cer survival among 683 breast cancer cases from theNurses’Health Study (NHS)
cohort. The NHS began in 1976 with the enrollment of U.S. registered nurses
between the ages of 30 and 55. The women in this analysis provided a blood
sample in 1989-1990,were postmenopausal andnot usingmenopausal hormone
therapy at the time of blood draw, and were diagnosed with invasive breast
cancer between 1990 and 2010. Levels of estradiol, estrone, estrone sulfate, tes-
tosterone, androstenedione, DHEA, DHEAS, and SHBG were measured in
plasma. The association between hormone levels and survival was assessed
through construction of Kaplan-Meier survival curves and through use of Cox
proportional hazards models to estimate hazard ratios and 95% confıdence in-
tervals adjusted for patient, tumor, and treatment covariates. Results Over fol-
low-up through 2014, a total of 219 deaths occurred, including 57 breast cancer
deaths. For each hormone, we found no association with breast cancer survival
by the log-rank test. Upon adjustment for patient, tumor, and treatment cova-
riates, we observed non-signifıcant 47% increases in breast cancer mortality per
unit increase in log estradiol (HR1.47, 95% CI 0.94-2.31) and estrone sulfate
(HR1.47, 95% CI 0.97-2.24). Log testosterone was not associated with breast
cancer survival (HR0.84, 95% CI 0.46-1.53) and the fındings were null for the
other hormones. These fındings were robust when evaluating overall survival
and when stratifying by tumor estrogen receptor expression. Conclusions We
observed no signifıcant associations between pre-diagnostic sex hormone levels
and breast cancer survival among postmenopausal women. This is the fırst anal-
ysis to evaluate pre-diagnostic hormone levels in relation to survival. Though
limited by sample size, it improves upon past analyses of post-diagnostic hor-
mone levels by reducing the possibility of the tumor affecting hormone levels
and by better accounting for tumor and treatment characteristics. The fındings
should be replicated in a larger population to further assess the prognostic value
of circulating sex hormones in breast cancer survival.
#2258 Genome-wide association studies of breast cancer prognosis.Mar-
janka K. Schmidt,1 Qi Guo,2 Thilo Dörk,3 Diana Eccles,4 Renske Keeman,1
Jacques Simard,5 PeterKraft,6Douglas F. Easton,2 PaulD. Pharoah,2 on behalf of
the Breast Cancer Association Consortium2. 1Netherlands Cancer Institute, Am-
sterdam, Netherlands; 2University of Cambridge, Cambridge, United Kingdom;
3Hannover Medical School, Hannover, Germany; 4University of Southampton,
Southampton, United Kingdom; 5Laval University, Québec City, Quebec, Can-
ada; 6Harvard School of Public Health, Boston, MA.
Introduction: The prognosis and response to treatment in womenwith breast
cancer varies considerably after taking into account clinic-pathological vari-
ables. Other factors such as host genotype are also likely to be important. We
therefore investigated the role of germline genetic variation on survival after
breast cancer using data from the Breast Cancer Association Consortium. Ma-
terials and methods: We included data from ten projects in which breast cancer
case cohorts were genotyped using arrays providing genome-wide coverage of
common variants. The majority of samples was genotyped using the Illumina
custom iCOGS orOncoArray chips. Data were imputed using the 1000Genome
phase 3 as a reference panel using a two-stage procedure. We assessed the asso-
ciation between genotype and 10-year breast cancer specifıc survival for each
SNP using Cox proportional hazards regression adjusted for principle compo-
nents and stratifıed by country. Genotype data from 87,877 breast cancer cases,
63,170 ER-positive and 20,297 ER-negative, with 6,511 known breast cancer
deaths were included in the analyses. Results: Preliminary analyses shows that in
all invasive cases, ER-positive andER-negative disease 123, 110, and 212 variants
respectively, were associated with breast cancer-specifıc mortality at P5x10-5.
A single variant, rs1295683, was associated with higher mortality at genome-
wide signifıcance in all patients: HR1.16 (95%CI:1.10-1.22); P2.8x10-8 (risk
allele frequency: 0.12). We identifıed four variants to be associated with mortal-
ity in ER-negative disease at P5x10-8. The strongest association was for
rs145963877: HR1.32 (95%CI:1.20-1.46); P2.3x10-8. No variant reached ge-
nome-wide signifıcance for ER-positive disease; themost signifıcant variant was
chr7:41400313 with an HR1.17 (95%CI:1.10-1.24); P1.8x10-7. In addition,
using OncoArray data, we provided independent validation of higher mortality
of CHEK2 c.1100delC carriers compared with non-carriers (HR1.56 (95%CI:
1.22-2.01)), previously reported inWeischer et al JCO 2012. Using iCOGS data,
we evaluated the association between mortality and the polygenic risk score
(PRS) based on 77 known breast cancer susceptibility SNPs. A higher PRS
was signifıcantly associated with lower breast cancer-specifıc mortality:
HR0.87(95%CI:0.81-0.93) (per unit of PRS) with a similar association in ER-
negative and ER-positive disease. The association was attenuated after adjusting
for tumor grade. Conclusion: We have identifıed a novel set of germline genetic
variants that are associated with breast cancer prognosis. The effect sizes are
small for each of the variants and unlikely to be of immediate clinical relevance.
However, understanding of the biology that underlies the associationsmay iden-
tify novel pathways and targets for therapy. Being at higher risk of breast cancer,
as defıned by the breast cancer susceptibility PRS, is not associated with an
adverse prognosis.
#2259 Evaluation of polymorphisms in myeloid-associated genes and gli-
oma survival.Daniel I. Jacobs,1 Yanhong Liu,1 KonradGabrusiewicz,2 Spiridon
Tsavachidis,1 E. Susan Amirian,1 Georgina N. Armstrong,1 Renke Zhou,1 Jun
Wei,2 Cristina Ivan,2 George Calin,2 Michael Scheurer,1 Anna Dahlin,3 Terri
Rice,4 Paige M. Bracci,4 Helen M. Hansen,4 John K. Wiencke,4 Margaret R.
Wrensch,4 Beatrice Melin,3 Amy B. Heimberger,2 Melissa L. Bondy1. 1Baylor
College of Medicine, Houston, TX; 2University of Texas MD Anderson Cancer
Center, Houston, TX; 3Umeå University, Umeå, Sweden; 4University of Califor-
nia, San Francisco, San Francisco, CA.
BACKGROUND: Gliomas are highly infıltrated by immune cells including
microglia, macrophages, andmyeloid-derived suppressor cells (collectively, gli-
oma-associatedmyeloid cells). These cells have been shown to be induced by the
tumor to be immune-suppressive and tumor-supportive, and are a negative
prognosticator for survival in mouse models. Here, we examine whether inher-
ited variants in genes important to the function of glioma-associated myeloid
cells are associated with survival following low-grade glioma diagnosis. METH-
ODS: Subjects for this study were 484 patients with WHO grade II or grade III
glioma treated at The University of Texas MD Anderson Cancer Center in
Houston, Texas between 1992 and 2008 and followed up for survival through
EPIDEMIOLOGY: Biomarkers of Risk and Prognosis
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017578
August, 2016.We selected 100 genes for analysis including transcription factors,
cytokines and chemokines, receptors, enzymes, and other genes central to the
function of glioma-associated myeloid cells. Genotyping was originally per-
formed using the Illumina Human 610-Quad Bead Chip platform and 2,040
tagging SNPs as determined by Haploview Tagger software were selected for
analysis with minor allele frequency (AF)
 1%. Associations between selected
SNPs and survival were evaluated by Cox regression analysis under an additive
allelic model adjusting for age, sex, extent of surgery (biopsy only/partial resec-
tion/gross total resection), radiotherapy (yes/no), and chemotherapy (yes/no).
Models were examined to ensure that proportional hazards assumptions were
not violated. RESULTS: Median survival among low-grade glioma patients was
6.7 years. Age at diagnosis, extent of surgery, and having received radiotherapy
or chemotherapy were each signifıcantly associated with survival. Five SNPs
were associated with survival at a signifıcance level of p0.001, and two re-
mained signifıcantly associated with low-grade glioma survival after adjustment
for multiple comparisons (FDR-adjusted p-value (q)0.10). These results indi-
cated inferior survival for carriers of the C allele (AF1.4%) at rs147960238 in
CD163 (HR5.47, 95%CI: 2.49-11.99, p2.23x105, q0.046) and for carriers
of the G allele (AF3.8%) at rs17138945 in MET (HR2.27, 95% CI: 1.52-3.38,
p5.61x105, q0.057). These SNPs are located in the 10th and 2nd introns of
CD163 and MET, respectively. CONCLUSIONS: Here we provide preliminary
evidence of an association between polymorphisms in two genes related to gli-
oma-associatedmyeloid cell function and low-grade glioma survival. CD163 is a
receptor that is highly expressed on macrophages and may play a role in mac-
rophage-mediated anti-inflammatory responses, while MET is a receptor ty-
rosine kinase and well-studied proto-oncogene that is also involved in the ex-
pansion of myeloid-derived suppressor cell populations. Further investigation
of these associations is warranted, and validation of these fındings is planned in
an independent population.
#2260 Haplotypes of chromosome 17q21.31 affect liver metastasis by
small intestinal neuroendocrine tumors. Shinta Kobayashi,1 Edaise da Silva,2
Tanupriya Contractor,3 Laura Tang,2 Chris R. Harris3. 1Institute for Advanced
Study, Princeton, NJ; 2Memorial Sloan Kettering Cancer Center, New York, NY;
3Raymond and Beverly Sackler Foundation, New Brunswick, NJ.
Neuroendocrine tumors are the most common tumors of the small intestine.
Very little is known about genetic changes that cause SI-NETs, which have a very
low frequency of mutations. SI-NETs are highly metastatic to the liver, and
patients with liver metastases have a fıve year survival rate of less than 50%.
Caucasian patients are more likely to develop metastasis than patients of other
races. We have studied a 900 kB inversion at chromosome 17q21.31, which is
common to Caucasians but rare in other races. Within a collection of 117 Cau-
casian patients with ileal carcinoids, patients with the inversion haplotype were
signifıcantly less likely to have liver metastasis. A second Caucasian-specifıc
haplotype in this region, beta2, was also tested for potential association with
metastasis of ileal carcinoids. Unlike the inversion haplotype, beta2 associates
with increased metastasis of ileal carcinoids. We suspect that the fact that the
metastasis-promoting beta2 haplotype is more common among Caucasians
than the metastasis-suppressing inversion haplotype (44% incidence vs. 33%
incidence) is probably why Caucasians wind up with a higher frequency of
metastasis than races that carry neither beta2 nor the inversion.
#2261 Synergistic effect and VEGF/HSP70-hom haplotype analysis: Rela-
tionship to prostate cancer risk and clinical outcome. Sana Sfar,1 Hamadi
Saad,2 Faouzi Mosbah,3 Lotfı Chouchane1. 1Faculty of Medicine, Monastir, Tu-
nisia; 2EPS Fattouma Bourguiba, Monastir, Tunisia; 3EPS Sahloul, Sousse, Tuni-
sia.
Prostate cancer (PCa) is a complex disorder resulting from the combined
effects of multiple environmental and genetic factors. Our previous single-locus
analysis showed that VEGF and HSP70-hom polymorphisms were signifıcantly
associated with PCa susceptibility and prognosis. Both genes encoding these
proteins were located on chromosome 6p21, and combining the neighboring
single nucleotide polymorphisms (SNPs) into haplotypes may increase the as-
sociation with the disease. Three tagging polymorphisms, the HSP70-hom 2437
T/C, the VEGF-1154 G/A, and the VEGF-634 G/C SNPs were genotyped in 101
cases and 80 controls. For the combined analysis of VEGF and HSP70-hom, we
found a positive gradient in the odds ratios (ORs) related to the number of
high-risk genotypes with a 3.53-fold increase of prostate carcinoma risk (OR
3.53; p 0.015). Furthermore, the TAG and CAG haplotypes at positions
HSP70-hom, VEGF-1154 and VEGF -634 exhibited a two-fold (OR 0.46; p
0.014) and a seven-fold (OR 0.14; p 0.00005) reduction in PCa risk, respec-
tively. Regarding PCa prognosis, the TAG haplotype had a negative association
with the aggressive phenotype as defıned by the histopathological grade (OR
0.28; p 0.006). Our fındings confırm the role of at-risk haplotype across the
HSP70-hom/VEGF gene cluster in determining susceptibility to PCa.
#2262 Correlation between number and sites of metastases and differen-
tial pretreated EBV DNA load profıles and their effects on outcomes in pa-
tients with metastatic nasopharyngeal carcinoma. Cheng-Lung Hsu, Hung-
MingWang, Tung-Liang Lin, Yung-Chia Kuo.Chang GungMemorial Hospital,
Taipei, Taiwan.
Differential overall survival of different organ site metastases in nasopharyngeal
carcinoma (NPC) had been reported but the underlying mechanism was unclear.
We try to fınd out the possible mechanism from plasma and tumor tissuemarkers.
Total 178 patients of metastatic NPC were enrolled. Their pre-treatment plasma
EBVDNA concentrations and cytokines and tissue macrophage, proliferation and
apoptosis markers were determined. The overall patient response rate after treat-
ment was 51.7% andmedian overall survival (OS) was 19months. Single organ site
metastasis had better outcome than multiple organs involved (median OS: 26
months vs. 16 months) with statistical signifıcance. Among single organ site in-
volved,pure lungmetastasishad longer survival thanboneor liver involved (median
OS: 50 months vs. 21 months vs. 18 months) with P0.001. Pretreatment plasma
EBVDNAconcentrations were lower in patients with lungmetastasis than bone or
livermetastasis in singleorgan involvedgroup.PlasmaIP-10andMCP-1expression
level correlated with the differential single organ site metastasis OS and EBVDNA
load. Liver metastatic tissue had higher macrophage infıltration density and higher
proliferation index than lung metastatic group. In single organ site metastasis of
NPC, lung involved patients had better outcome than bone or livermetastasis. Low
pretreatment plasma EBV DNA load, cytokines expression such as IP-10 and
MCP-1, tissue macrophage infıltration, and proliferation index may contribute
these results.
#2263 Neonatal hormone levels and risk of testicular germ cell tumors
(TGCT). Libby Morimoto,1 David Zava,2 Katherine McGlynn,3 Frank Stanc-
zyk,4 JosephWiemels,5 Xiaomei Ma,6 CatherineMetayer1. 1UC Berkeley, Berke-
ley, CA; 2ZRT Laboratory, Beaverton, OR; 3National Cancer Institute, Bethesda,
MD; 4University of Southern California, Los Angeles, CA; 5UCSF, San Francisco,
CA; 6Yale University, New Haven, CT.
Testiculargermcell tumors (TGCT)are themost commonlyoccurringcancers in
adolescent and young adult males in the U.S. Steroid sex hormones play a central
role in the development of the testis. As proposed by the testicular dysgenesis syn-
dromehypothesis, theorigins ofTGCTare likely tobe inuteroor early in life, and to
be a manifestation of disturbed prenatal testis development. However, no studies
have provided direct, empirical evidence to date. Using an innovative linkage be-
tween the California birth records and cancer registry data, we conducted a popu-
lation-based case-control study of neonatal hormones levels and risk of TGCT di-
agnosed at 0-19 year of age.We obtained archived neonatal dried blood spot (DBS)
specimens from 370 TGCT cases (276 adolescent and young adults [AYA] aged
15-19 yrs at diagnosis; 94 0-4 yrs at diagnosis), and 344 age- and race/ethnicity-
matched controls, born between 1982 and 2009. Liquid chromatography with tan-
demmass spectrometry was used to measure a panel of 17 sex steroids, glucocorti-
coids, and mineralcorticoids; 12 were present at detectable levels in the newborn
DBS samples, including estrone (E1), estradiol (E2), estriol (E3), testosterone (T),
dehydroepiandrosterone (DHEA), and androstenedione (A4). Logistic regression
was used to estimate odds ratios (OR) and 95% confıdence intervals (CI), adjusting
for matching factors and age (in hours) of child at blood spot collection. A4, a
precursor for T and E1, was positively associated with TGCT (OR: 1.71, 95% CI:
1.09-2.69). Analyses stratifıed by age group showed that this associationwas limited
toAYA, andwas of strongermagnitude in this group (OR: 2.33, 95%CI: 1.37-3.97).
A similar, though weaker, trend was observed for T (ORoverall: 1.37, 95% CI: 0.86-
2.19; ORAYA: 1.73. 95% CI: 1.00-3.00). There was no signifıcant association of the
other measured hormones with risk. In the fırst case-control study of TGCT with
directmeasures of neonatal hormone levels, we found that higher levels of T andA4
wereassociatedwith increased riskofTCGT,particularly amongmalesdiagnosedat
15-19years of age.These results oppose thedominant theory inTGCTetiology, that
TGCT is related to androgen insuffıciency in utero, and provides an important link
in the etiologic pathway of this increasingly common cancer.
#2264 Telomere biology genemethylation and cancer risk.Brian T. Joyce,1
Yang Li,1 Yinan Zheng,1 Lei Liu,1 Hushan Yang,2 Chad Achenbach,1 Pantel
Vokonas,3 Joel Schwartz,4 Andrea Baccarelli,5 Lifang Hou1. 1Northwestern Uni-
versity, Chicago, IL; 2Thomas Jefferson University, Philadelphia, PA; 3VA Boston
Healthcare System, Boston, MA; 4Harvard University, Boston, MA; 5Columbia
University, New York, NY.
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Background: Telomeres maintain genomic stability and regulate cellular
senescence. Numerous studies have examined blood telomere length (BTL)
and cancer risk, including our own which previously identifıed a dynamic
relationship between BTL and cancer risk over time: Relative to subjects who
remained cancer-free, those who later developed cancer experienced accel-
erated telomere shortening until 3-4 years prior to cancer diagnosis/censor-
ing, at which point BTL in the incident cancer group stabilized. Other studies
have suggested that cancer cells are able to hijack telomere maintenance
mechanisms (e.g., telomerase) in order to circumvent the Hayflick limit,
which will otherwise induce senescence and limit cancer cells’ ability to
multiply. As DNAmethylation dysregulation is a known epigenetic hallmark
of cancer, our objective was to understand whether DNA methylation of
telomere biology genes is associated with cancer risk and BTL. Methods: We
studied 915 blood measurements from 491 subjects in the Normative Aging
Study taken between 1999 and 2013, who were cancer free in 1999 and
randomly selected for whole-epigenome DNA methylation profıling using
the Illumina 450K BeadChip array. Among these subjects, 125 cases devel-
oped cancer and 366 controls remained cancer free for our entire follow up
(median 10.1 years). Our analysis focused on 2,731 CpG sites on 142 genes
related to telomere length maintenance. We used linear models to identify
CpGs differentially methylated by cancer status at the fırst blood draw only,
followed bymixedmodels using our full data to determine the fınal CpG sites
of interest for Cox models of cancer risk, and another set of mixed models to
compare trajectories over time of methylation in cancer patients vs. controls.
Finally an additional mixed model explored the temporal relationship be-
tween methylation measured at the fırst visit and BTL measured at the sec-
ond visit. Results: Our screening identifıed 167 CpG sites, 10 of which were
associated with time-dependent cancer risk at FDR 0.05. Methylation of
one CpG on each of CDC73, NSMCE2, and RPA1 was associated with de-
creased cancer risk. Methylation of one CpG on each of DCLRE1C, DDB1,
H2AFY, HNRNPA2B1, and TEP1, as well as two CpGs on TERF2, was asso-
ciated with increased cancer risk. DNAmethylation trajectory at three CpGs
was signifıcantly different across cancer status (cg20772347 on DDB1,
cg23157637 on TEP1, and cg04818274 on TERF2). One CpG on NSMCE2
and one on TERF2 were associated with BTL in cancer-free subjects, while
another CpG on TERF2 was associated with BTL in subjects who later de-
veloped cancer. Conclusion: These fındings suggest that methylation
changes in telomere maintenance genes may be a mechanism by which can-
cer cells alter telomere length, thus undermining genomic stability and pro-
tecting cancer cells from senescence. Future studies should confırm these
fındings, and explore these CpG sites and genes as potential early detection
biomarkers and therapeutic targets.
#2265 HPV16 serostatus and risk of oropharyngeal carcinoma.Kristina R.
Dahlstrom,1 Karen S. Anderson,2 Matthew S. Field,2 Diego Chowell,2 Guojun
Li,1 Erich M. Sturgis1. 1UT MD Anderson Cancer Ctr., Houston, TX; 2Arizona
State University, Tempe, AZ.
Background:Thecurrent epidemicofhumanpapillomavirus (HPV)-relatedoro-
pharyngeal cancer (OPC) urgently demands a screening strategy for this disease.
Antibodies to HPV type 16 (HPV16) early (E) antigens have been detected in pa-
tients with HPV16-related OPC, and are potential biomarkers of HPV-relatedma-
lignancies.Thegoal of this studywas to evaluate thediagnostic accuracyof apanel of
antibodies to HPV16 E antigens. Methods: This was a case-control study that in-
cluded 378 patientswithOPC, 153 patientswith non-oropharyngeal head andneck
cancer, and 782 healthy control subjects. All patients had newly diagnosed, previ-
ouslyuntreateddiseaseandwerematchedwithcontrolsbyageandsex.TumorHPV
statuswasdeterminedbyp16 immunohistochemistry. IgGantibodies to theHPV16
antigens E1, E4, E5, E6, E7, and the N-terminal and C-terminal fragments of E2
(NE2, CE2) were quantifıed using a custommultiplexed bead array assay. A binary
logistic regression classifıer based on the combined relative light units of all E anti-
gens on ELISA was pre-defıned and applied to the dataset. Odds ratios (OR) with
95% confıdence intervals (CI) were calculated using logistic regression analysis. Re-
sults: Of the 378 patients with OPC, 348 had p16-positive OPC. Using the single
cutoff values, the frequency of seropositivity for the individual antigens vs. controls
wasE1 (74%vs7%);CE2(68%vs1%);E6 (42%vs1%); andE7(64%vs1%)(Table1).
Positivity for the binary classifıer was associated with an OR of 453 (95% CI, 199-
1030) for p16-positiveOPC,with a sensitivity of 83%and a specifıcity of 99% (Table
1).Conclusions:HPV-specifıc IgGantibodies tomultiple early antigens aredetected
at the time of diagnosis of HPV-related OPC. A multiparametric algorithm im-
proves the specifıcity of detection of cases over single antibodies and are potential
biomarkers for HPV-associated malignancies that may be advantageous for risk
stratifıcation in future screening trials.
Table 1. A blinded study ofHPV16 serology of patients with p16-positive OPC (n348)
and controls (n782)
Controls p16OPC
N (%) N (%) OR (95%CI)a Sensitivity Specifıcity PPV NPV AUC
E1 52 (6.7) 256 (73.6) 43 (28-67) 74 93 83 89 .84
NE2 14 (1.8) 128 (36.8) 43 (20-90) 37 98 90 78 .68
CE2 7 (0.9) 235 (67.5) 290 (114-741) 68 99 97 87 .83
E4 14 (1.8) 110 (31.6) 27 (13-54) 32 98 89 76 .65
E5 48 (6.1) 37 (10.6) 2 (1-4) 11 94 44 70 .52
E6 9 (1.2) 146 (42.0) 80 (34-187) 42 99 94 79 .70
E7 11 (1.4) 224 (64.4) 106 (54-208) 64 99 95 86 .82
Classifıer 8 (1.0) 288 (82.8) 453 (199-1030) 83 99 97 93 .91
aAdjusted for sex, smoking, and alcohol status (never vs. former vs. current).
OR: odds ratio; CI: confıdence interval; PPV: Positive Predictive Value; NPV: Negative
Predictive Value; AUC: Area Under the Curve.
#2266 A prospective study of serum metabolites and glioma risk. Jiaqi
Huang,1 Stephanie J. Weinstein,1 Cari M. Kitahara,2 Edward Karoly,3 Joshua N.
Sampson,1 Demetrius Albanes1. 1NIH, Bethesda, MD; 2NIH, bethesda, MD;
3Metabolon, Inc., Morrisville, NC.
Malignant glioma is one of the most devastating adult malignancies. Although
there exists an urgent need for actionable leads regarding its prevention and early
detection, the etiology of glioma remains largely unknown. We conducted a pro-
spective serummetabolomic analysis of glioma based on 64 cases and individually
matched controls selected fromAlpha-Tocopherol, Beta-Carotene Cancer Preven-
tion (ATBC) Study. Median time from collection of baseline fasting serum to diag-
nosis of glioma was nine years (interdecile range 3-20 years). We used ultra-high
performance LC/MS which identifıed 730 known metabolites for analysis. Condi-
tional logistic regression models examined odds ratios (ORs) and 95% confıdence
intervals for one-standard deviation differences inmetabolite signals on a log-scale.
Forty-three serummetabolites were associated with glioma at P0.05. 2-Oxoargi-
nine, cysteine, alpha-ketoglutarate, chenodeoxycholate and argininate yielded the
strongest metabolite signals and were inversely associated overall risk of glioma
(0.0065P0.0083).Three serumacylcarnitines (0.016P0.046), andsevenxan-
thine (i.e., caffeine) metabolites (0.017P0.042) were higher in cases than con-
trols.Findingsweremostly similar inhigh-gradegliomacases, althoughproportion-
ally more metabolites showed positive risk associations such as N-acetylglutamate,
ribonate, and 5-methyluridine (0.04P0.02). Notably, xanthine compounds ap-
peared unrelated to high-grade glioma. Prominent metabolite signals for inverse
associations were the bile acids glycocholenate sulfate and 3-hydroxy-5-cholenoic
acid, xenobiotic methyl-4-hydroxybenzoate sulfate, sex steroid 5alpha-pregnan-
3beta,20beta-diolmonosulfate, and cofactor/vitaminoxalate.We foundweaker risk
associations for lower-gradeglioma, ofwhichnoneachieved signifıcance atP0.05.
Themetabolic sub-pathwayanalysis revealedassociations forprimarybile acid,urea
cycle/arginineandproline, tocopherol, glycolysis/gluconeogenesis/pyruvatemetab-
olites with overall glioma risk (0.005P0.048); ascorbate and aldarate pathways
were associatedwithhigh-grade glioma (P0.02),whereas glycolysis/gluconeogen-
esis/pyruvate, eicosanoid and glutamate pathways were found to be associated with
lower-grade disease (0.01P0.04). These associations did not, however, reach the
stringent Bonferroni signifıcance threshold for correction ofmultiple comparisons.
Inconclusion,we identifıedaserummetabolomicprofıleofglioma,years inadvance
of clinical diagnoses, characterized by altered molecular signals in the arginine/
proline, antioxidant, bile acid, and glycolytic pathways. The observed patterns pro-
vide potential new leads regarding the molecular basis relevant to etiologic or sub-
clinical biomarkers for glioma. The fındings require reexamination in larger and
more diverse populations, including through glioma consortia.
#2267 A prospective assessment for telomere length in relation to risk of
cancer in the Singapore Chinese Health Study. Jian-Min Yuan,1 Renwei Wang,1
KennethBeckman,2Aizhen Jin,3Woon-PuayKoh4. 1Univ. ofPittsburgh,Pittsburgh,
PA; 2Univ. of Minnesota, Minneapolis, MN; 3Health Promotion Board, Singapore,
Singapore; 4Duke-NUSMedical School, Singapore, Singapore.
Background: Telomeres are crucial in themaintenance of chromosome integrity
and genomic stability. A critically short telomere length can trigger cell to enter
replicative senescencewitharesultof celldeath; alternatively, cells continue todivide
if death does not occur, which results in genomic instability and chromosomal ab-
normality. A series of epidemiological studies have examined the association be-
tween telomere length and the risk of cancers, but the fındings remain conflicting.
Methods: Among 63,257 participants of the Singapore Chinese Health Study, a
population-based prospective cohort of Chinesemen andwomen aged 45-74 years
recruited from 1993 through 1998, 28,219 provided baseline blood samples. We
usedquantitativepolymerase chain reaction (PCR)method toquantify relative telo-
mere length determined by the ratio of telomere repeat copy number (T) to single-
copy gene for albumin (S) (i.e., TSR) on all subjects. The present analysis included
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24,847 subjectswith validTSRvalues after excluding sampleswith insuffıcientDNA
(n1,908)and/orpatientswithprevalentcanceratbaselineblooddraw(n1,464).
As of December 31, 2015, 3,778 participants developed cancer, including 722 colo-
rectal cancer, 599 lung cancer, and 412 breast cancer. Cox models were used to
estimate hazard ratio (HR) and 95% confıdence interval (CI) of developing any
cancer and these selected specifıc cancer types for different quintiles ofTSR.Results:
Womenhada5.7%higherTSRvalue thanmen (P0.0001).Age, level of education,
number of cigarettes/day, years of smoking, and pack-years of smoking were all
inversely associated with TSR (P0.0001). High TSR was associated, in a dose-
dependentmanner,with signifıcantly increased risk of total cancer andbreast, colo-
rectal and lung cancer. Compared with the lowest quintile, the HRs (95% CIs) of
total cancer for the 2nd, 3rd, and 4th, and 5th quintile of TSR were 1.03 (0.89, 1.20),
1.08 (0.93-1.26), 1.15 (0.98-1.34), and1.36 (1.16-1.58), respectively, after adjustment
for age, sex, education and smoking (Ptrend0.001). The corresponding HRs (95%
CIs) were 1.21 (0.72-2.03), 1.59 (0.97-2.60), 1.59 (1.04-2.75) and 1.62 (0.99-2.66) for
breast cancer (Ptrend0.023); 1.44 (1.03-2.00), 1.10 (0.76-1.59), 1.32 (0.92-1.90) and
1.88 (1.32-2.66) for colorectal cancer (Ptrend0.004); and 1.41 (0.98-2.05), 1.37
(0.93-2.02), 1.31 (0.86-1.99) and 1.88 (1.26-2.81) for lung cancer (Ptrend0.010).
Conclusions: This prospective cohort study demonstrates that longer telomere
length is associated with signifıcantly increased risk of total and major cancers in a
general population. These results suggest a complex role of telomere in the develop-
ment of cancer.
#2268 Serum insulin and glucose, indices of insulin resistance, and risk of
lung cancer. Ilona Argirion,1 Stephanie J. Weinstein,2 Satu Männistö,3 Dem-
etrius Albanes,2 Alison M. Mondul1. 1University of Michigan, Ann Arbor, MI;
2National Cancer Institute, Bethesda, MD; 3National Institute for Health and
Welfare, Helsinki, Finland.
Background: Although insulin is crucial in human growth and development, it
also harbors antiapoptotic properties and acts as a growth factor by stimulating
mitosis through the Akt pathway, which could lead to tumor growth and promo-
tion. Insulinhasbeenpositively associatedwith several cancer sites, butno studies to
date have examined fasting serum insulin concentrations and risk of lung cancer.
Methods:TheAlpha-Tocopherol, Beta-CaroteneCancerPrevention (ATBC)Study
was a randomized, double-blind intervention trial conducted among 29,133 male
smokers in southwest Finland. Participants were randomly assigned to one of four
groups in a 2x2 factorial design (-tocopherol alone,-carotene alone, both supple-
ments,orplacebo). 196 lungcancercasesand395subcohortmemberswere sampled
from the larger cohort. Fasting serum collected at enrollment (5-12 years prior to
diagnosis)was analyzed for insulinusing adouble-antibody immunochemilumino-
metric assay, and for glucose using a hexokinase assay. Cox proportional hazards
models were used to estimate the hazard ratio (HR) and 95% confıdence intervals
(CI) of lung cancer risk by quartiles of insulin, glucose, and surrogate indices of
insulin resistance (insulin:glucosemolar ratio andhomeostasismodel assessmentof
insulin resistance [HOMA-IR]).Multivariablemodels adjusted for age, BMI, family
history of lung cancer, and pack-years of smoking. Results: Insulin was positively
associatedwith riskof lungcancer (Q4vs.Q1HR:2.10, 95%CI: 1.12, 3.94).Asimilar
association was seen with HOMA-IR (Q4 vs. Q1 HR: 1.83, 95% CI: 0.99, 3.38). We
observed no statistically signifıcant associations with glucose or the insulin:glucose
molar ratio (P-trend0.55 and P-trend  0.27, respectively). Insulin and
HOMA-IR were associated with lung cancer risk regardless of stage, although the
fındings were stronger for the lower stage cancers (Q4 vs. Q1 insulin, stage I-II
HR2.85, 95% CI: 1.14, 7.15, P-trend0.01; stage III-IV HR0.94, 95% CI: 0.93 -
4.06, P-trend0.23; HOMA-IR stage I-II HR2.25, 95% CI 0.89-5.69,
P-trend0.02, stage III-IVHR1.78, 95%CI0.87 -3.61,P-trend0.34). Findings
were similar across histologic subtypes of lung cancer. Conclusion: Higher fasting
seruminsulin and insulin resistance appear tobeassociatedwithan increased riskof
lung cancer. In addition, elevated insulin concentrations may be more strongly as-
sociated with lower stage lung malignancies, suggesting a role for insulin in stimu-
lating the growth of early pulmonary cancers.
#2269 Circulating lipids and breast cancer subtypes in a Spanish popula-
tion. Manuela Gago-Dominguez,1 Manuel Calaza,2 Victor Muñoz-Garzon,3
Maria Elena Martinez,4 Jose Esteban Castelao5. 1Galician Foundation of
Genomic Medicine, Servicio Galego de Saude (SERGAS), Instituto de Investi-
gación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain; 2University
Santiago Compostela. Galician Foundation of Genomic Medicine, Instituto de
Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain; 3Ra-
diotherapy Department, Instituto de Investigación Galicia Sur CHUVI, Servicio
Galego de Saude (SERGAS), Vigo, Spain; 4Department of Family Medicine and
Public Health, Moores Cancer Center, University of California San Diego, San
Diego, CA; 5Oncology and Genetics Unit. Instituto Investigacion Biomedica Gali-
cia Sur, CHUVI, Servicio Galego de Saude (SERGAS), Vigo, Spain.
Background:Althoughseveral studieshave lookedat thecirculating lipids-overall
breast cancer relationship, no prior investigation has examined this relationship
according to the fourmajor subtypes of breast cancer. Materials andMethods: The
BREOGAN (BREast OncologyGAlicia Network) study is a population-based case-
control study conducted in Galicia, Spain between 1997 and 2014, including 1,766
women diagnosed with invasive breast cancer and 1,205 population- and age-
matched controls. Data on demographics, breast cancer risk factors, and clinico-
pathological characteristicswere collected.Three-hundredeighty-fıve cases and412
controls had data on fasting blood lipids (total cholesterol, LDL, HDL and triglyc-
erides)beforedateofdiagnosis forcases, and timeof interviewforcontrols, andwere
included in the present study.We examined the blood lipids-breast cancer relation-
ship overall and according to the four major breast cancer subtypes [hormone-
receptor-positive, HER2-negative (luminal A); hormone-receptor-positive, HER2-
positive (luminal B); hormone-receptor-negative, HER2-negative (TNBC); and
hormone-receptor-negative, HER2-positive (HER2 overexpressing)] as well as
grade and morphology in Spanish women. Results: The mean plasma triglyceride
levels for breast cancer cases overall and controls were 118.8 (74-142) and 100.7
(68-121) mg/dL, respectively (p  0.001). Regarding breast cancer subtypes, the
mean levels for luminal A breast cancer caseswere 123.5 (80-153)mg/dL compared
to100.7 (68-121)mg/dL forcontrols (p0.001).Theriskof luminalAbreast cancer
signifıcantly increased with increasing circulating levels of triglycerides (OR for the
highestversus the lowest category3.29,95%CI1.66-6.49,p for trend0.0001).
No associations were detected for any other circulating lipid (total cholesterol, LDL
orHDL) or any other breast cancer subtype.Nodifferenceswere detected by histol-
ogy (ductal versus lobular) or grade (I, II or III). Results will also be presented on a
Mendelian randomization analysis to evaluate associations between circulating tri-
glyceride levels and breast cancer risk using individual-level data from BREOGAN
cancer cases and controls genotyped on OncoArray. Variants with genome-wide
signifıcantassociationswith lipid traitswillbeused toconstructpolygenic riskscores
for analyses of triglycerides in relation to breast cancer risk. Conclusions. To our
knowledge, this is the fırst study examining the association between circulating lip-
ids and breast cancer according to the fourmajor breast cancer subtypes. Our fınd-
ings indicate that breast cancer risk increased with increasing triglyceride level
among postmenopausal luminal A breast cancer. No differences were detected by
histology or grade.
#2270 C-reactive protein and ovarian cancer risk: preliminary results
from the Ovarian Cancer Cohort Consortium (OC3). Elizabeth M. Poole,1
BrittonTrabert,2 RenéeT. Fortner,3NicolasWentzensen,2 Shelley S. Tworoger1.
1Brigham &Women’s Hospital, Boston, MA; 2National Cancer Institute, Wash-
ington, DC; 3German Cancer Research Center, Germany.
Background: C-reactive protein (CRP), a general marker of inflammation has
been consistently associatedwith increased ovarian cancer risk.However, few stud-
ies have had the ability to evaluate differences in association by ovarian tumor sub-
type. Methods: We pooled existing data on CRP and ovarian cancer risk among
nested case-control studies conducted within 6 studies participating in the Ovarian
Cancer Cohort Consortium (OC3): CLUEII, EPIC, NHS, NHSII, NYUWHS, and
PLCO.Cohort-specifıc tertilesandquartileswereanalyzedusingconditional logistic
regression, as were common cutpoints at1mg/L, 1-10mg/L and
10mg/L and
OddsRatios (OR)and95%confıdence intervals (CI)were calculatedusing random-
effects meta-analysis. We also evaluated differences in the association between se-
rous and non-serous cancers. Results: There was no signifıcant association between
the top vs. bottom tertile (OR: 1.10; 95%CI: 0.91-1.32) or the top vs. bottomquartile
(OR: 1.10; 95% CI: 0.89-1.36). However, there was a strong, positive association
between very high CRP (
10mg/L vs.1 mg/L: OR: 1.96; 95% CI: 1.36-2.84). As-
sociations of very high (
10 mg/L vs. 1 mg/L) did not differ by histologic type:
serousOR: 1.63; 95%CI: 1.11-2.43; endometrioidOR: 1.78; 95%CI: 0.63-5.00; mu-
cinousOR: 10.43; 95%CI: 1.27-85.86; clear cell OR: 2.30; 95%CI: 0.39-13.34). Con-
clusion: Our results confırm the consistent observation of a positive association
between very high CRP levels and ovarian cancer risk. Pooled analyses accounting
for potential confounders are ongoing.
#2271 DNMT1 expression is peripheral mononuclear cells is associated
with increased breast cancer risk. Lissette Delgado-Cruzata,1 Xinran Ma,2
Yuyan Liao,2 Maya Kappil,2 Regina M. Santella,2 Mary Beth Terry2. 1John Jay
College, City University of New York, New York, NY; 2Mailman School of Public
Health, Columbia University, New York, NY.
Loss of global DNA methylation in peripheral tissue has been identifıed as a
biomarker of breast cancer susceptibility in several studies. DNAmethyl-trans-
ferases or DNMTs are the enzymes in charge of catalyzing the addition of the
methyl group to the DNA molecule. Of the different DNMTs described in hu-
mans, only DNMT1 has been found to be in charge of adding methyl groups to
the newly synthesized DNA strand. Therefore, compromised levels of this en-
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zyme might lead to a loss of global DNA methylation and concomitantly an
increase in breast cancer risk. However, to date no study has examined the
association between peripheral levels of DNMT1 and breast cancer. To investi-
gate this relation, we conducted a case-control study including sisters in theNew
York site of the Breast Cancer Family Registry. We extracted mRNA from pe-
ripheral mononuclear cells (PMNC) in 196 sister sets, a total of 479 female
participants, and assayed DNMT1 gene expression levels using Taqman expres-
sion assays. The results were analyzed using generalized estimating equations
(GEE).We found that there were no large differences between themean levels of
DNMT1 expression levels of womenwith breast cancer and controls; mean level
in cases was 0.46	 0.71 versus 0.63	 1.42 in controls (p0.10). When exam-
ining expression levels as a continuous variable, there also were no associations
in GEE regression models adjusting for age at blood drawn and smoking status
Odds Ratio (OR) 1.17 (95% confıdence interval (CI) 0.97 - 1.40 per one unit
increase in expression levels), p0.11). However, when results were analyzed by
categorizing DNMT1 expression in tertiles, lower DNMT1 expression (
0.17%)was associatedwith statistically signifıcantly higher odds of breast cancer
(OR 1.47 (95%CI 1.02 - 2.10), p0.04). If replicated in other studies, these
fındings suggest that low DNMT1 expression in PBMC has the potential to be
used as a biomarker of breast cancer risk in women at high risk of the disease.
#2272 A prospective study of urinary prostaglandin E2 metabolite, Heli-
cobacter pylori antibodies, and gastric cancer risk. Tianyi Wang,1 Hui Cai,2
Wei Zheng,2 Angelika Michel,3 Michael Pawlita,3 Ginger Milne,4 Yong-Bing
Xiang,5 Yu-Tang Gao,5 Hong-Lan Li,5 Nathaniel Rothman,6 Qing Lan,6
Xiao-Ou Shu,2 Meira Epplein2. 1Peking University Health Science Center, Bei-
jing, China; 2Division of Epidemiology, Department of Medicine, Vanderbilt Ep-
idemiology Center and Ingram Cancer Center, Vanderbilt University Medical
Center, Nashville, TN; 3Division of Molecular Diagnostics of Oncogenic Infec-
tions, Research Program in Infection, Inflammation, and Cancer, GermanCancer
Research Center (DFKZ), Heidelberg, Germany; 4Division of Clinical Pharmacol-
ogy, Department of Medicine, Vanderbilt University Medical Center, Nashville,
TN; 5Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China;
6Division of Cancer Epidemiology and Genetics, Occupational and Environmen-
tal Epidemiology Branch, National Cancer Institute, National Institutes of
Health, Rockville, MD.
Background. Previous studies suggest that a stable end-product of prostaglan-
din E2, the urinary metabolite PGE-M, is excreted in the urine and can be used
as an index of systemic prostaglandin E2 (PGE2) production. In the present
study we investigate the PGE-M, Helicobacter pylori (H. pylori), and gastric
cancer association. Methods. The present analysis included 359 prospectively
ascertained gastric cancer cases and 700 individuallymatched controls from two
population-based prospective cohort studies, the Shanghai Women’s Health
Study and Shanghai Men’s Health Study. Urinary PGE-M was measured by a
liquid chromatography/tandem mass spectrometric method. Sero-positivity to
15 H. pylori recombinantly expressed fusion proteins was detected by H. pylori
multiplex serology. Results. Adjusting for H. pylori, increasing PGE-M was as-
sociated with higher risk of gastric cancer (Quartile 4 vs. 1, OR1.76, 95% CI:
1.17-2.66, Ptrend0.004). This association remained after excluding those diag-
nosed within two years from sample collection (OR1.73, 95% CI: 1.12-2.65,
Ptrend0.007). However it was no longer present among individuals with 10 or
more years of follow-up (2-4.9 years, OR3.15, 95% CI: 1.11-8.91; 5-9.9 years,
OR2.23, 95% CI: 1.22-4.06; 
10 years, OR0.73, 95% CI: 0.31-1.70). The
association of PGE-M with gastric cancer risk was not modifıed by H. pylori
status, but added predictive ability beyond H. pylori; compared to H. pylori-
negative individuals with below-median PGE-M levels, H. pylori-positive indi-
viduals with above-median PGE-M levels had a 5-fold increase in the odds ratio
of gastric cancer (OR5.08, 95% CI: 2.47-10.43). Conclusion. In China, higher
PGE-M levelsmay indicate an increased risk of gastric cancer independent of the
risk conferred by H. pylori infection status, particularly for cancers diagnosed
within 10 years of sample collection.
#2273 Serum choline,methionine, betaine, dimethylglycine, and trimeth-
ylamine-N-oxide in relation to pancreatic cancer risk in two nested case-
control studies in Asian populations. Joyce Huang,1 Lesley Butler,1 Øivind
Midttun,2 Renwei Wang,3 Aizhen Jin,4 Yu-Tang Gao,5 Per Ueland,6 Woon-
Puay Koh,7 Jian-Min Yuan1. 1University of Pittsburgh, Pittsburgh, PA; 2Bevital
A/S, Bergen, Norway; 3University of Pittsburgh Cancer Institute, Pittsburgh, PA;
4National Registry of Diseases Offıce, Health Promotion Board, Singapore, Singa-
pore; 5Department of Epidemiology, Shanghai Cancer Institute/Shanghai Jiao-
tong University, Shanghai, China; 6Department of Clinical Science, University of
Bergen; Laboratory of Clinical Biochemistry,HaukelandUniversityHospital, Ber-
gen, Norway; 7Duke-NUS Medical School, and Saw Swee Hock School of Public
Health, National University of Singapore, Singapore, Singapore.
Background: Choline, methionine, and betaine are methyl group donors as-
sociated with DNAmethylation. Diets defıcient in choline andmethionine have
been shown to promote pancreatic carcinogenesis in experimental animals. We
have previously reported an inverse association between dietary intake of cho-
line and pancreatic cancer risk in a prospective cohort of Singapore Chinese. In
the present study biomarkers of dietary choline and other methyl donor nutri-
ents were evaluated in relation to pancreatic cancer risk. Method: Two case-
control studies were nested within the Shanghai Cohort Study (129 cases and
258 matched controls) and the Singapore Chinese Health Study (58 cases and
104matched controls). Concentrations of choline,methionine, betaine, dimeth-
ylglycine (DMG), and trimethylamine-N-oxide (TMAO)weremeasured by LC-
MS/MS in pre-diagnostic serum samples. Odds ratios (ORs) and 95% confı-
dence intervals (CIs) were calculated using conditional logistic regression
method with adjustment for potential confounders. Results: Choline, methio-
nine, and betaine were moderately associated with each other (spearman corre-
lation coeffıcient: 0.28 0.43). In the pooled analysis, serum choline, betaine,
and methionine were inversely associated with risk of pancreatic cancer, while
TMAO, an oxidative metabolite of choline produced by gut microbiota, was
positively associated with risk of pancreatic cancer. Compared with the lowest
quartile, ORs (95%CIs) of pancreatic cancer for the highest quartiles of choline,
methionine, betaine, and TMAO were 0.37 (0.17-0.80), 0.39 (0.22-0.69), 0.49
(0.28-0.85), and 1.60 (0.94-2.74), respectively (all Ps for trend 0.05). DMGwas
not associated with pancreatic cancer risk. Conclusion: The novel inverse asso-
ciations of serumcholine,methionine, and betainewith risk of pancreatic cancer
support the notion that methyl groups related to DNA methylation may mod-
ulate the risk of pancreatic cancer development. The positive association be-
tween TMAO and pancreatic cancer risk suggested gut microbiota may play an
important role in pancreatic carcinogenesis.
#2274 Extreme telomere length was associated with gastric adenocarci-
noma risk: The Singapore Chinese Health Study. Zhensheng Wang,1 Woon-
Puay Koh,2 Aizhen Jin,3 Renwei Wang,4 Jian-Min Yuan4. 1Univ. of Pittsburgh,
Pittsburgh, PA; 2National University of Singapore, Singapore City, Singapore;
3National Registry of Diseases Offıce, Singapore City, Singapore; 4University of
Pittsburgh Cancer Institute, Pittsburgh, PA.
Background: Evidence regarding extreme telomere length and increased gas-
tric cancer risk has been limited in retrospective case-control study settingwhich
was potentially subjected to selection bias and reverse causality.We conducted a
prospective analysis in an Eastern Asian population to examine the hypothesis
that extreme telomere length is associated with increased risk of gastric adeno-
carcinoma. Methods: Among 63,257 participants of the Singapore Chinese
Health Study, a population-based prospective cohort of Chinese men and
women aged 45-74 years recruited between 1993 and 1998, 28,219 provided
baseline blood samples. We used quantitative polymerase chain reaction (PCR)
method to quantify relative telomere length determined by the ratio of telomere
repeat copy number (T) to single-copy gene for albumin (S) (i.e., TSR) on all
subjects. The present analysis included 24,846 subjects with valid TSR values
after excluding samples with insuffıcient DNA (n 1,908) and/or patients with
prevalent cancer at baseline blood draw (n 1,465). As of December 31, 2014,
191 study participants who were free of cancer developed gastric adenocarci-
noma. The information on demographic and lifestyle characteristics was col-
lected using structured questionnaires at baseline and two follow-up interviews.
Cox proportional hazard regression method was used to estimate hazard ratio
(HR) and the corresponding 95% confıdence interval (CI) of developing gastric
adenocarcinoma for different levels of decile TSR. Restricted cubic spline (RCS)
analysis was applied to examine the nonlinear relationship between TSR level
and gastric adenocarcinoma risk. Results: The RCS analysis revealed aU-shaped
relationship between TSR and gastric adenocarcinoma risk (p-value for non-
linear association0.009). Compared with the 4th decile, HR (95% CI) for the
lowest and highest deciles of TSR 2.27 (1.17-4.40) and 1.98 (0.95-4.13), respec-
tively after adjusting for age, sex, education, interview year, dialect group and
smoking status. Conclusions: This was the fırst prospective analysis of TSR and
risk of developing gastric adenocarcinoma in a general population. The study
demonstrates both extreme short and long telomere length to be associated with
signifıcantly increased risk of gastric adenocarcinoma. These results suggest a
complex relationship between telomere length and gastric cancer risk.
#2275 Serum retinol and risk of overall and site-specifıc cancer in the
Alpha Tocopherol, Beta-Carotene Cancer Prevention Study. Manila Hada,1
Alison Mondul,1 Stephanie Weinstein,2 Demetrius Albanes2. 1University of
Michigan, Ann Arbor, MI; 2National Cancer Institute, Bethesda, MD.
Retinol, one of the most biologically active forms of vitamin A, influences
many biologic pathways potentially related to cancer. However, results of obser-
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vational studies of serum retinol and cancer risk have been mixed. We prospec-
tively examined serum retinol and risk of overall and site-specifıc cancer in the
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, a ran-
domized, double-blind, placebo controlled trial of -tocopherol (AT) and
-carotene (BC) supplementation conducted in male smokers in southwestern
Finland. At enrollment, overnight fasting blood samples were collected and
stored at -70°C protected from light. Serum retinol concentration wasmeasured
for all 29,133 participants using reverse-phase high performance liquid chroma-
tography. 10,798 cancer cases occurred through 12/31/2012. Cox proportional
hazardsmodels were used to estimate the prospective association between quin-
tiles of baseline serum retinol and overall and site-specifıc cancer incidence.
Known or hypothesized risk factors for cancer were included in the multivari-
able model (AT and BC supplementation group, cigarettes smoked/day, years
smoked, age, BMI, alcohol intake, and serumAT, BC, and cholesterol). Stratifıed
analyses for all subgroups of the covariates (by category or by medians for con-
tinuous variables) and follow-up time to diagnosis (10 vs. 
10 y) were also
performed for overall cancer and for the cancers for which an association with
serum retinol was observed. After adjustment for age, higher serum retinol was
associated with a lower risk of overall cancer (Q5 vs. Q1: HR0.93,
95%CI0.88-0.99, p-trend 0.04). This fınding was attenuated and no longer
statistically signifıcant after multivariable adjustment (MV-adj) (Q5 vs. Q1:
MV-adj HR 0.97, 95% CI  0.91-1.03, p-trend  0.43). Higher retinol con-
centrations were associated with increased risk of prostate cancer (Q5 vs. Q1:
MV-adjHR1.28, 95%CI 1.13-1.45, p-trend 0.0001) and lower risk of both
lung and liver cancers (Q5 vs. Q1: liver MV-adj HR  0.70, 95%CI  0.50-
0.99,p-trend  0.03; lung MV-adj HR  0.80, 95%CI  0.72-0.88, p-trend 
0.0001). No associations with other cancers were observed. The inverse associ-
ation between retinol and lung cancer was signifıcantly modifıed by serum BC
with a stronger association among men with higher serum BC (p for interac-
tion  0.018). No other statistically signifıcant interactions were observed. In
this large prospective study, higher serum retinol was associated with increased
risk of prostate cancer and lower risk of lung and liver cancers. Understanding
the biological mechanisms that underlie these associations may provide insight
into retinol’s role in cancer prevention.
#2276 Effect modifıcation by isoflavones on the association between salt
intake and gastric cancer risk: A case-cohort study within the Korean multi-
center cancer cohort. Jieun Jang, Yunji Hwang, Choonghyun Ahn, Kwang-Pil
Ko, Aesun Shin, Keun-Young Yoo, Sue K. Park. Seoul National University Col-
lege of Medicine, Seoul, Republic of Korea.
Backgrounds: Attenuation by genistein, an isoflavone abundant in soy-
bean, of gastric carcinogenesis induced by sodium chloride was reported in
an animal study. Up to date, role of isoflavone as an effect modifıer on the
association between salt intake and gastric cancer risk is not clearly estab-
lished. Methods: We randomly selected 640 subcohort subjects without can-
cer history at enrollment from the Korean multi-center cancer cohort par-
ticipants. Ninety-nine gastric cancer cases were identifıed from the inside
(N8) and the outside (N91) of the subcohort after the 12.2 years of
median follow-up time. To estimate individual’s salt intake, we measured
24-hour urinary sodium excretion from spot urine using the Tanaka’s equa-
tion. Three isoflavone plasma concentrations (Genistein, daidzein, and
equol) of 167 subjects among case-cohort subjects had been measured using
time-resolved fluoroimmunoassay. Cubic spline curve for gastric cancer risk
according to urinary sodium level was used to defıne optimal cut-off points
of urinary sodium excretion concentration.Weighted Cox proportional haz-
ard regression was used to calculate hazard ratios (HRs) and their 95% con-
fıdence intervals (CIs). Stratifıed analysis by isoflavone level was conducted
to assess effect modifıcation by isoflavone on the association between salt
intake and gastric cancer. Results: Gastric cancer risk in the high salt intake
group (urinary sodium excretion
6,000mg/day) was signifıcantly increased
(HR, 1.69; 95% CI, 0.99-2.90) compared to the reference group (urinary
sodium excretion 4500-5,999mg/day). Magnitudes of gastric cancer risk by
high salt intake were more strengthened in the group with low plasma iso-
flavone concentrations (One or no genistein, diadzein or equol levels over
the median concentrations) (HR, 6.92; 95% CI, 1.80-26.56). Contrary to the
low isoflavone group, no signifıcant differences in gastric cancer risk accord-
ing to salt intake levels were found in the group with high isoflavone con-
centration. Conclusions: High salt intake is associated with gastric cancer
risk, but this association can be attenuated by high concentration of isofla-
vones.We suggest that suffıcient intake of soybean products, the rich sources
of isoflavone, may give protection against gastric cancer in the population
with high salt intake.
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#2277 Adherence to cancer prevention guidelines and risk of cancer
among older white and black adults in the Health ABC Study. Audrey Y.
Jung,1 Christina Gu,1 Iva Milijkovic,2 Susan Rubin,3 Suzanne Satterfıeld,4 Ste-
phen B. Kritschevsky,5 Heidi Klepin,5 Anne B. Newman,2 Jane Cauley,2 Hilsa
Ayonayon,3 Tamara B. Harris,6 Rachel A. Murphy1. 1University of British Co-
lumbia, Vancouver, British Columbia, Canada; 2University of Pittsburgh, Pitts-
burgh, PA; 3University of California at San Francisco, San Francisco, CA; 4Uni-
versity of Tennessee Health Science Center, Memphis, TN; 5Wake Forest School of
Medicine, Winston-Salem, NC; 6National Institute on Aging, Bethesda, MD.
Background: About one-third of cancers can be prevented by healthy life-
style behaviors. The American Cancer Society (ACS) have guidelines for
reducing the risk of cancer by maintaining a healthy body weight, being
physically active, eating well and limiting alcohol. Few studies have exam-
ined adherence to cancer preventive behavior and subsequent cancer risk in
older populations that are inclusive of men, women and minorities. Meth-
ods: We evaluated adherence to ACS cancer prevention guidelines and sub-
sequent risk of all incident cancer in the Health, Aging and Body Composi-
tion Study. The population included 2,124 white and black men and women
aged 71-80 years who were initially free of cancer at baseline (1998-1999).
Adherence to ACS guidelines was scored from 0 (lowest adherence) to 8
(greatest adherence). Maintenance of healthy body weight was determined
from body mass index at ages 25 and 50 (recalled at baseline) and measured
height and weight at baseline. Physical activity and alcohol intake were as-
sessed by questionnaire. Diet was assessed by food frequency questionnaire
(servings of fruits and vegetables, the ratio of whole grains to refıned grains
and intake of red meat and processed meats). Incident cancer (all types
except non-melanoma skin cancer) was confırmed from pathology reports
when available, or medical records and death certifıcates. Risk of cancer was
determined with cox regression adjusted for gender, age and study site.
Participants with the lowest adherence to ACS guidelines were the referent.
Results: The lowest adherence category (scores 0-2) had 297 participants
(14% of all participants), 1,316 (62%) were in the moderate adherence cate-
gory (scores 3-5), and 511 (24%) were in the highest adherence category
(scores 6-8). Adherence was lower among men (P0.001), black (P0.001)
and older participants (P0.01). After a median follow-up of 12.5 years, 517
people developed incident cancer. Participants with moderate adherence
had a 23% lower risk of cancer [HR0.77, 95% CI0.60-0.97]. Participants
with the greatest adherence had a 26% lower risk of cancer [HR0.74, 95%
CI0.56-0.98]. Conclusions: Only 1 in 4 older adults closely followed
healthy lifestyle behaviors outlined by the ACS for cancer prevention.
Greater adherence to recommendations was associated with lower likelihood
of total cancer in older white and black adults. Public health efforts to in-
crease preventive lifestyle behaviors may be particularly needed among men,
black and older individuals.
#2278 Risk factors by molecular subtypes of breast cancer: a pooled anal-
ysis of nine cohorts.Mia M. Gaudet,1 Gretchen Gierach,2 Brian Carter,1 Juhua
Luo,3 RogerMilne,4 ElisabeteWeiderpass,5 GrahamGiles,4WendyChen,6 Rulla
Tamimi,6 Heather Eliassen,6 Diane Feskanich,6 Alicja Wolk,7 Hans-Olov
Adami,8 Karen Margolis,9 Susan Gapstur,1 Montserrat Garcia-Closas,2 Louise
Brinton2. 1American Cancer Society, Atlanta, GA; 2National Cancer Institute,
Rockville, MD; 3Indiana University, IN; 4Cancer Council Victori, Australia;
5Karolinska Institutet, Sweden; 6Brigham and Women’s Hospital and Harvard
Medical School, Boston, MA; 7Karolinska Institute, Sweden; 8Dana Farber/Har-
vard Cancer Center, MA; 9HealthPartners, Minneapolis, MN.
Etiological differences between molecular subtypes of breast cancer, de-
fıned by estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2), have been examined in previous
studies but results are inconsistent, most likely due to small numbers of rarer
subtypes. In a recent systematic review of these studies, only six of the pos-
sible 44 associations had consistent fındings, primarily with the most com-
mon luminal A subtype (ER or PR/HER2-). To provide larger numbers
from prospective studies for these associations, we utilized a harmonized
dataset of nine cohort studies (Cancer Prevention Study-II Nutrition Co-
hort, Melbourne Cancer Cohort Study, the National Cancer Institute-Amer-
ican Association of Retired Persons cohort study, Nurses’ Health Study,
Nurses’ Health Study-2, Prostate, Lung, Colorectal, and Ovarian Cancer
Screening cohort, Swedish Mammographic Cohort, Swedish Women’s Life-
style and Health Study, andWomen’s Health Initiative) that had case data on
ER, PR, and HER2 from medical records or state tumor registry records.
Multivariate, joint Cox proportional hazard regression models were used to
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calculate hazard ratios (HR) and 95% confıdence intervals (CI), and to com-
pare associations across subtypes. Among 616,109 study participants, 11,861
invasive breast cancer cases were diagnosed, including 8,777 luminal A,
1,388 luminal B (ER or PR/ HER2), 532 HER2-enhancing (ER-/PR-/
HER2), and 1,164 triple negative (ER-/PR-/HER2-) subtypes. The mean
age at baseline of the study participants was 54.8 (SD12.2) years for cases
and 54.2 (SD14.4) years for controls, and the majority self-described as
white. We found that the associations of race, benign breast disease, parity,
number of live births, age at fırst birth, age at menopause, alcohol consump-
tion, and smoking initiation relative to fırst birth were statistically-signifı-
cantly different for at least one of the molecular subtypes compared to the
associations for the ER or PR/HER2- subtype (p-value for tumor homo-
geneity0.05). For example, women who drank 
2 drinks/ day were at
increased risk of the luminal A-like (HR1.44, 95% CI 1.28 - 1.63) and
luminal B-like subtypes (HR1.33, 95% CI 0.97 - 1.81), but not HER2-
enhancing (HR0.92, 95% CI 0.52 - 1.62) or triple negative subtypes
(HR0.89, 95% CI 0.61 - 1.30; p-value for homogeneity  0.001). Younger
age at menarche, fırst degree family history of breast cancer, ever use of oral
contraceptives, ever use of menopausal hormones, higher education, and
postmenopausal body mass index were positively associated with all molec-
ular subtypes. Our results highlight the importance of consideringmolecular
subtype when evaluating breast cancer associations by risk factors, and pro-
vide precise estimates of association for the development of molecular sub-
type-specifıc risk prediction models.
#2279 Burden of colorectal cancer attributable to lifestyle-related risk fac-
tors: a pooled study of seven Australian cohorts. Claire M. Vajdic,1 Maria
Arriaga,1 Peter Hull,1 Karen Canfell,2 RobertMacInnis,3 Emily Banks,4 Graham
Giles,3 Paul Mitchell,5 Robert Cumming,5 Barbara-Ann Adelstein,1 Julie Byles,6
Dianna J.Magliano,7 Jonathan Shaw,7AnneTaylor,8KayPrice,9VasantHirani,5
Maarit A. Laaksonen1. 1University of New SouthWales, Sydney, Australia; 2Can-
cer Council New SouthWales, Sydney, Australia; 3Cancer Council Victoria, Mel-
bourne, Australia; 4Australian National University, Canberra, Australia; 5Uni-
versity of Sydney, Sydney, Australia; 6University of Newcastle, Newcastle,
Australia; 7Baker IDI Heart and Diabetes Institute, Melbourne, Australia; 8Uni-
versity of Adelaide, Adelaide, Australia; 9University of South Australia, Adelaide,
Australia.
Aim: To quantify the burden of colorectal cancer in Australia avoidable by
modifıcations to established lifestyle-related risk factors: smoking, excess body
weight, excessive red and processed meat consumption, excessive alcohol con-
sumption and physical inactivity.Methods: Data on exposure to lifestyle-related
risk factors from seven Australian cohort studies (N  367,772) were harmo-
nized and pooled. The cohorts were linked to the Australian Cancer Database
and National Death Index to identify incident cancers and deaths. The strength
of the exposure-cancer and exposure-death associations were estimated using a
proportional hazards model, adjusting for age, sex and the other lifestyle expo-
sures. Age- and sex-specifıc exposure prevalence was estimated from the Aus-
tralian National Health Survey (NHS) 2011-2012 or from the latest 45 and Up
cohort study when not available in the NHS. These estimates were then com-
bined to calculate the Population Attributable Fractions (PAFs), i.e. fractions of
cancer attributable to the lifestyle-related risk factors, and their 95% confıdence
intervals (CIs) using an advanced method accounting for competing risk of
death. Results: During the fırst 10-years follow-up, 3,498 incident colorectal
cancers and 20,135 deaths were ascertained as fırst events. Current or former
smoking explained 9% (CI 5-13%), BMI
 25 kg/m2 9% (CI 4-14%), red or
processedmeat consumption 3 ormore times/week 6% (CI 3-8%), and drink-
ing more than 2 alcoholic drinks/day 4% (CI  2-6%) of the colorectal cancer
burden. PAF results for physical inactivity were not signifıcant. The contribu-
tion of each factor was more pronounced in men than in women, with most of
the burden attributable to excess weight in men (PAF 15%, CI 7-22%) and
smoking in women (PAF  7%, CI  3-12%). Jointly the four signifıcant life-
style-related risk factors were responsible for 25% (CI  19-30%) of the colo-
rectal cancer burden, 33% (CI  25-40%) in men and 15% (CI 7-23%) in
women. Given the projected Australian incidence rates, this translates to 49,000
avoidable colorectal cancer cases, 35,000 in men and 14,000 in women, over the
next 10 years. Conclusions: These fırst Australian and international colorectal
cancer PAF estimates based on cohort studies and accounting for competing risk
of death show that several modifıable risk factors contribute to the burden of
colorectal cancer and their ranking differs by sex. Further analyses may identify
subpopulations that would benefıt from targeted intervention activities. Due to
the high incidence of colorectal cancer, these PAF estimates translate into a
signifıcant number of avoidable cases.
#2280 Burden of lung cancer in Australia avoidable bymodifıcations to
lifestyle-related risk factors. Maarit A. Laaksonen,1 Maria Arriaga,1 Peter
Hull,1 Karen Canfell,2 Robert MacInnis,3 Emily Banks,4 Graham Giles,3 Paul
Mitchell,5 Robert Cumming,5 Barbara-Ann Adelstein,1 Julie Byles,6 Dianna
J. Magliano,7 Jonathan Shaw,7 Anne Taylor,8 Kay Price,9 Vasant Hirani,5
Claire M. Vajdic1. 1University of New South Wales, Sydney, Australia; 2Can-
cer Council New South Wales, Sydney, Australia; 3Cancer Council Victoria,
Melbourne, Australia; 4Australian National University, Canberra, Australia;
5University of Sydney, Sydney, Australia; 6University of Newcastle, Newcastle,
Australia; 7Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
8University of Adelaide, Adelaide, Australia; 9University of South Australia,
Adelaide, Australia.
Aim:The cancer burden avoidable through risk factormodifıcation canbe quan-
tifıed using the Population Attributable Fraction (PAF) which combines estimates
of theprevalenceof the risk factor exposure in thepopulationand the strengthof the
exposure-cancer association. PAF for risk factors causally related to cancer is most
accurately estimated from cohort studies, using analytical approaches that account
for death as a competing risk. We provide the fırst such estimates of the lifestyle-
related avoidable lung cancer burden. Methods: Seven contemporary Australian
cohort studies (N  367,772), with comprehensive data on exposure to lifestyle-
related risk factors, were linked to the Australian Cancer Database and National
Death Index to identify lung cancers and deaths from any cause. The risk factors
were harmonised across the studies and the data pooled. The strength of the expo-
sure-cancer and exposure-death associations were estimated using a proportional
hazards model, adjusting for age, sex and the other lifestyle exposures. Age- and
sex-specifıc exposureprevalencewasestimated fromtheAustralianNationalHealth
Survey 2011-2012. These estimates were then combined to calculate the PAFs and
their 95%confıdence intervals (CI) using a newly developedmethod accounting for
competing risk of death. Results: During the fırst 10-years follow-up, 2,030 incident
lung cancers and 20,348 deaths were ascertained as fırst events. Smoking, physical
inactivity and insuffıcient fruit intake were statistically signifıcantly associated with
both lung cancer incidence anddeath.Most of the lung cancer burden (PAF73%,
CI 69-76%)was attributable to current or past smoking,with 31% (CI 27-35%)
of the burden attributable to current smokers. Physical activity below Australian
recommendations ( 150 minutes of moderate or 75 minutes of vigorous exercise
per week) explained 14% (CI 6-22%) and fruit intake below Australian recom-
mendations ( 2 daily serves) explained 6% (CI 0-12%) of the lung cancer bur-
den. Each risk factor contributed more to the lung cancer burden in men than in
women. Overall, 78% (CI 74-81%) of the lung cancer burden was attributable to
current or past smoking, physical inactivity and insuffıcient fruit intake. The com-
bined contribution ofmodifıable risk factors (i.e. excluding past smoking) was 44%
(CI  37-50%). Based on projected Australian cancer incidence rates, this would
translate to59,000avoidable lungcancers in thenext 10years.Conclusions:Accord-
ing to these joint PAF estimates, the current lung cancer burden in Australia could
be reduced by up to half in 10 years by quitting smoking and increasing physical
activity and fruit intake to the recommended levels. As the combined effect of risk
factors is rarely additive, knowing both individual and joint effects of risk factors on
cancer burden is essential in planning cancer interventions and public health poli-
cies and predicting their potential impact.
#2281 Environmental tobacco smoke exposure and breast cancer risk in
theNorwegianwomenand cancer study cohort. IngerT.Gram,Tonje Braaten,
Eiliv Lund, Idlir Licaj. UiT The Arctic University of Norway, Tromsø, Norway.
Background: Today, themajority ofmiddle-agedwomen inNorway are ever (i.e.
either former or current) smokers, who started to smoke in their teens. Many of
those who never have smoked themselves were exposed to environmental tobacco
smoke (ETS) as children. The purpose of the study,was to examine the effect of ETS
in childhood on breast cancer risk in the NorwegianWomen and Cancer Study, a
nationally representative prospective cohort study. Material andMethods: We fol-
lowed 121 662 women, that were aged 34-70 years at enrolment, who completed a
baseline questionnaire between 1991 and 2007, through linkages to national regis-
tries throughDecember 2014. Questionnaire data included information on lifestyle
factors, including lifetime history of smoking. We used Cox proportional hazards
models to estimate hazard ratios (HRs) and 95% confıdence intervals (CIs) while
adjusting for relevant confounders and stratifıed by birth cohort. We included the
following variables in the fınal multivariate models; age at enrolment, years of edu-
cation (lt 10, 10-12, 13-16, 17), age at menarche (lt 13,13-14, 15), ever oral
contraceptives use (yes, no), a variable including nulliparous and a combination of
total numberof births, (1, 2, 3) andof age at fırst childbirth (age lt 20, 20-24, 25-29,
30) for a total of 13 categories, family history of breast cancer in the mother (yes,
no), body mass index (calculated from current height and weight (lt 20, 20-24.9,
25-29.9, 30) kg/m2, ,menopausal status (yes, no), postmenopausal hormone ther-
apy use (never, former, current) and average alcohol consumption, based on the
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content of pure alcohol in different sorts of beverages and portion sizes, as grams of
alcohol per day (0, 0.1-1.40, 4.1-10,10)). Women who reported to be teetotalers
and those answering ‘seldom or never’ had their alcohol consumption set to 0. Re-
sults: During a mean follow-up of 15 years, 4501 women developed invasive breast
cancer confırmed by histology. Altogether, 23.7% of the women reported to be ex-
posed toETSduring childhood.Thewomenreported that the active smoker in7.7%
was the father, in 0.66 % the mother, in 3.57% both parents, and in 11.8 % the
information about the active smoker was missing. Compared with never smokers,
the multivariable adjusted HR estimate for ETS during childhood where the father
was the smokerwas statistically signifıcantly increasedwith 23% (HR1.23; 95%CI
1.07-1.42). The corresponding fıgures for those being exposed toETSby themother
was aHR of 1.22 (95%CI 0.88-1.69), for those being exposed by both parents was a
HR of 1.06 (95% CI 0.88-1.26) and for those with no information about the active
smoker theHRwas 1.03 (95%CI 0.89-1.20). In conclusion, we found that exposure
to environmental tobacco smokeduring childhoodwas associatedwith ahigher risk
of breast cancer for women who reported that the father was the active smoker.
#2282 Smoking and alcohol and the risk of myelodysplastic syndrome:
The JPHC study. Tomotaka Ugai,1 Keitaro Matsuo,1 Norie Sawada,2 Motoki
Iwasaki,2 Taiki Yamaji,2 Taichi Shimazu,2 Shizuka Sasazuki,2 Manami Inoue,2
Yoshinobu Kanda,3 Shoichiro Tsugane2. 1Aichi Cancer Center Research Insti-
tute, Nagoya, Japan; 2National Cancer Center, Tokyo, Japan; 3aitama Medical
Center, Jichi Medical University, Omiya, Japan.
Background. Myelodysplastic syndromes (MDS) are a heterogeneous group of
clonal disorders of hematopoietic stem cells that are characterized by ineffective
hematopoiesis, multilineage dysplasia, peripheral cytopenias, and susceptibility to
leukemic transformation.Evenwithoutprogression to leukemia, there is substantial
morbidity and mortality. Therefore, a better understanding of the etiology of this
disease can lead to a signifıcant reduction in the incidence and the mortality as a
consequence, but it remains largely unknown. Smoking and alcohol are important
modifıable risk factors for human cancers. However, only a few epidemiological
studies have investigated their associationwith the risk ofMDS.Here, we evaluated
the association of smoking and alcohol consumption and the risk of MDS in a
large-scale population-based cohort study in Japan. Methods. We included 95,950
Japanese subjects (45,451menand50,059women; age40-69years at baseline)of the
Japan Public Health Center-based Prospective Study who completed a question-
naire about their smoking and alcohol habits. During 18.3 years of follow-up, we
identifıed70MDScases (50menand20women).Wecalculatedhazardratios (HRs)
and their 95% confıdence intervals (95% CI) using the Cox proportional hazards
model to describe the relative risk ofMDS associatedwith the smoking categories at
baseline (never smokers, former smokers, current smokers, ever smokers of 30
and
30 pack-years) and the drinking categories at baseline (non-drinkers, occa-
sional drinkers, and regular drinkers of 1-299 or 
300 g/week of ethanol) after
adjustment for potential confounders. Results. Smoking was marginally associated
withan increasedriskofMDSamongmen,withaHRforcurrent smokers relative to
never smokers of 2.11 (95% CI: 0.91-4.89). This risk increase was also observed in
ever smokerswithmore than 30pack-years compared tonever smokers (HR2.22,
0.95-5.19). A linear increase in HR with increasing pack-years was also seen, albeit
without statistical signifıcance (p-trend0.083). In contrast, alcohol consumption
was associated with a dose-dependent decrease in the risk of MDS among men
(nondrinkers: reference, occasional drinkers: HR0.48, 0.16-1.43; 0-299 g/week:
HR0.37, 0.19-0.74; 
300 g/week: HR0.45, 0.20-0.99, p for trend0.008). All
types of alcohol beverages (sake, distilled spirit and beer) consistently showed a
protective effect. We also explored a possible interaction between smoking and al-
cohol consumption, but no obvious interaction was observed. Conclusions. This
study showed that alcohol has a signifıcant protective effect on the risk of MDS
among Japanese men. In addition, this study also provides evidence that smoking
increases the risk ofMDS amongAsian population, as it does amongWestern pop-
ulations. Previous fındings on the association between alcohol and the risk ofMDS
have been inconsistent, and further investigation across multiple populations is
needed.
#2283 Population-level relevance of lifestyle-related risk factors for pan-
creatic cancer in Australia. Maria E. Arriaga,1 Maarit A. Laaksonen,1 Karen
Canfell,2 Robert MacInnis,3 Emily Banks,4 Graham Giles,3 Paul Mitchell,5 Rob-
ert Cumming,5 Barbra-Ann Adelstein,1 Julie Byles,6 Dianna J. Magliano,7 Jona-
than Shaw,7 Anne Taylor,8 Kay Price,9 Vasant Hirani,5 Claire M. Vajdic1. 1Uni-
versity of New South Wales (UNSW), Sydney, Australia; 2Cancer Council,
Sydney, NSW, Australia; 3Cancer Council, Melbourne, Victoria, Australia; 4Aus-
tralian National University, Canberra, Australia; 5University of Sydney, Sydney,
Australia; 6University of Newcastle, Newcastle, Australia; 7Baker IDI Heart and
Diabetes Institute, Melbourne, Victoria, Australia; 8University of Adelaide, Ade-
laide, South Australia, Australia; 9University of South Australia, Adelaide, South
Australia, Australia.
Aim: To estimate the proportion of exocrine pancreatic cancers in Australia
that can be attributed to the established risk factors, smoking and excess body
weight, and the suggested risk factors, excessive alcohol consumption and ex-
cessive red and processed meat consumption. Methods: The proportion of pan-
creatic cancers attributable to lifestyle-related risk factors was quantifıed using
the Population Attributable Fraction (PAF) which combines estimates of the
strength of the exposure-cancer association and the exposure prevalence in the
population. The study population included seven Australian cohort studies
(N367,772) with comprehensive data on exposure to lifestyle-related risk fac-
tors and long-term follow-up. Pancreatic cancer incidence and all-cause mor-
tality were identifıed through linkage with the Australian Cancer Database and
National Death Index, respectively. A proportional hazards model was used to
estimate the strength of exposure-cancer and exposure-death associations ad-
justing for age, sex and other lifestyle exposures. The age- and sex-specifıc ex-
posure prevalence was calculated from the Australian National Health Survey
(NHS) 2011-2012 except for red and processed meat consumption which was
not available and was calculated from the latest 45 and Up study. A newly de-
veloped method that takes into account the competing risk of death was used to
produce PAF estimates and their 95% confıdence intervals (CIs). Results: Dur-
ing the fırst 10-years follow-up to incidence of pancreatic cancer, death or end of
follow-up, there were 21,541 deaths and 613 incident exocrine pancreatic can-
cers. 10% (CI 1-17%) of pancreatic cancers in Australia could be attributed to
current or past smoking. Current smoking explained 8% (CI 4-13%) of pan-
creatic cancers. Using cancer incidence projections estimated by the Australian
Institute of Health and Welfare, a PAF of 8% translates to 2,700 potentially
preventable pancreatic cancers over the next 10 years. The PAF results for excess
bodyweight (
 25 kg/m2), excessive alcohol consumption ( 2 drinks/day) and
excessive red and processed meat consumption (
 4 times/week) were not sta-
tistically signifıcant. Conclusion: According to the fırst pancreatic cancer PAF
results from cohort studies, and accounting for competing risk of death, smok-
ing control could reduce the number of pancreatic cancers by one tenth. Further
PAF studies should include confıdence intervals for the estimates to allow an
evaluation of their signifıcance.
#2284 Effects of smoking on breast tumor pathology. Nicholas Costan-
tino,1 Craig D. Shriver,2 Rachel E. Ellsworth3. 1Chan Soon-Shiong Institute of
Molecular Medicine at Windber, Windber, PA; 2Murtha Cancer Center,
Bethesda, MD; 3Murtha Cancer Center, Windber, PA.
Background: Although smoking is not a well-established breast cancer
risk factor, proximity of lungs to the breasts and fındings that tobacco smoke
constituents serve as mammary carcinogens in animal models suggests that
smoking may alter the breast microenvironment and affect breast tumori-
genesis. To determine how smoking influences tumor pathogenesis, the re-
lationships between smoking and pathological characteristics and outcome
were evaluated in 1,707 women with invasive breast cancer. Methods: Pa-
tients enrolled in the Clinical Breast Care Project 2001-2013 fılled out a
questionnaire that included answers to current smoking status, current and
previous pack use/day, number of years smoked, and length since last
smoked. Patients were classifıed as never, former or current smokers. Pack
years was calculated as years smoked x pack use/day. Logistic regression was
performed to determine whether smoking was associated with any charac-
teristics. Signifıcance was defıned as P0.05. Results: 55.7% of women never
smoked, 31.5% were former smokers and 12.8% were current smokers. The
average number or pack years was 14.5 in former smokers and 25.5 in current
smokers. Current smoking status was associated with lymph node metastasis
(OR 1.44; 95% CI 1.03-2.01), positive HER2 status (OR 1.54, 95% CI 1.04-
2.25), larger tumor size (OR 1.55; 95% CI 1.14-2.11) and higher tumor stage
(OR 1.54, 95% CI 1.16-2.04) when compared to never smokers. Former
smokers were less likely to be diagnosed with later stage tumors (OR 0.77,
95% CI 0.62-0.96) compared to never smokers. No signifıcant associations
were detected when pack years were considered as a continuous variable;
when categorized as 0, 20, 20-34 or 35 pack years, 35 pack years was
associated with positive HER2 status (OR 1.80, 95% CI 1.06-3.03) and tu-
mors of the ERHER2 subtype (OR 1.99, 95% CI 1.07-3.7). Overall sur-
vival was signifıcantly lower for former and current smokers compared to
never smokers (P0.014); however, breast cancer specifıc survival did not
differ signifıcantly between groups (P0.226). Conclusions: Current smok-
ers are at increased risk for having larger and later stage tumors with positive
lymph node and HER2 status. Tumor size, stage and lymph node status are
temporal factors, thus suggest that current smokers may have delayed diag-
nosis compared to never and former smokers. In contrast, HER2 status re-
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flects a biological phenomenon and the risk of HER2 positivity increases with
pack years, suggesting that carcinogens found in tobacco smoke may pro-
mote overexpression of HER2.
#2285 Menopausal hormone therapy (MHT) use and breast cancer risk by
receptor subtypes: results from the New South Wales Cancer Lifestyle and
EvAluation of Risk (CLEAR) study.Usha G. Salagame,1 Emily Banks,2 Dianne
O’Connell,3 Sam Egger,3 Karen Canfell3. 1Cancer Council NSW, NSW 2011,
Australia; 2AustralianNationalUniversity, AustralianCapital Territory, Austra-
lia; 3Cancer Council NSW, Woolloomoolloo, NSW 2011, Australia.
Background: Prior observational studies have identifıed an elevated breast
cancer risk associated with current MHT use for ER (Estrogen Receptor
positive), and for ER / PR (Estrogen and Progesterone Receptor positive)
breast cancers than for ER- and ER-/PR- subtypes respectively. We have
previously reported, from a large case-control study for all cancer types (the
NSWCLEAR study) that current MHT use was associated with a doubling of
the odds of breast cancer. Here, we describe further analyses investigating
the MHT-breast cancer association for the breast cancer tumor receptor
subtypes defıned by ER expression, by ER and PR expression and by the joint
expression of ER, PR, and HER-2 (Human Epidermal growth factor Recep-
tor-2). Methods: Analyses were carried out for a subset of registry-verifıed
CLEAR breast cancer cases with hormone receptor status data (n410) and
CLEAR (cancer-free) controls recruited over the same period (n324). We
used a multinomial logistic regression model to estimate Odds Ratios (ORs)
adjusted for other breast cancer risk factors and 95% Confıdence Intervals
(CI) for current and past MHT use in subgroups defıned by tumor receptor
subtypes. Never users comprised the reference group. Findings: In a multi-
nomial model, current MHT use was associated with an elevated risk of ER
breast cancer (aOR 2.04, 95%CI: 1.28 -3.24). When breast cancers were
categorised by ER and PR status, current use was associated with an elevated
risk of developing ERPR breast cancer (aOR 2.29, 1.41-3.72). Current
MHT use was associated with the surrogate luminal A breast cancer charac-
terized by ER/PR/HER2- phenotype (aOR 2.30, 1.42-3.73). None of
the other subtypes of breast cancer (ER/PR/HER2, ER-/PR-/HER2,
and ER-/PR-/HER2-) were signifıcantly associated with current MHT use. A
signifıcant difference in the odds of developing breast cancer for current
MHT users was detected between the surrogate luminal A and luminal B
(ER/PR/HER2) subtypes only (aOR 0.28, 0.09-0.88, p0.029). None
of the other groups were signifıcantly differently associated with MHT use,
although this may be due to lack of power. Past MHT use was not associated
with an increased risk of breast cancer for any breast cancer subtype. Con-
clusion: The fındings from this contemporary Australian study are consis-
tent with fındings from other studies that current, but not past, use of MHT
is associated with increased risk of breast cancer, with higher risks reported
for ER, ER and PR and ER/PR/HER2- (surrogate luminal A) sub-
types. Our fındings are consistent with the hypothesis that breast cancers
induced by MHT may occur through receptor-mediated mechanisms.
#2286 Atopic allergic conditions and risk of pancreatic cancer: the Multi-
ethnic Cohort. Brian Z. Huang,1 Loic Le Marchand,2 Christopher A. Haiman,3
Kristine Monroe,3 Lynne Wilkens,2 Zuo-Feng Zhang,1 Veronica Wendy
Setiawan3. 1UCLA School of Public Health, Los Angeles, CA; 2University of Ha-
waii Cancer Center, Honolulu, HI; 3University of Southern California, Los Ange-
les, CA.
Background: Previous studies, mostly case-control studies, have suggested
that atopic allergic conditions (AACs) are associated with a decreased risk of
pancreatic cancer. Scarce data, however, are available fromprospective, USmul-
tiethnic populations. In this largest prospective study to date, we investigated the
association between AACs (asthma, hay fever, or allergy) and risk of developing
pancreatic cancer in the US Multiethnic Cohort Study (MEC). Methods: AACs
were assessed via a baseline questionnaire when participants joined the MEC in
1993-1996. Hazard ratios (HRs) and 95% confıdence intervals (CIs) for pancre-
atic cancer incidence by AACs status were calculated using Cox regression,
adjusting for age, sex, race/ethnicity, education, smoking status, family history
of pancreatic cancer, body mass index, diabetes, and alcohol intake. Results:
During an average of 16.2-year follow-up, 1,455 incident cases of pancreatic
cancer were identifıed among 187,226 white, African-American, Native Hawai-
ian, Japanese-American, and Latinomen andwomen.AACswere not associated
with pancreatic cancer incidence (HR1.00; 95% CI: 0.88, 1.12). The null asso-
ciation was observed inmen andwomen and across racial/ethnic groups, smok-
ing status, BMI groups, diabetes status, and family history of pancreatic cancer.
Conclusions: Based on these results, AACs is unlikely to be associated with risk
of pancreatic cancer.
#2287 Number of risky lifestyle behaviors and breast cancer subtypes in
a large nested case-control study from Norway. Merete Ellingjord-Dale,1
Linda Vos,1 Steinar Tretli,1 Solveig Hofvind,1 Anette Hjartåker,2 Hege
Russnes,3 Isabel dos-Santos-Silva,4 Giske Ursin1. 1Cancer Registry of Nor-
way, Oslo, Norway; 2University of Oslo, Oslo, Norway; 3Oslo University Hos-
pital, Oslo, Norway; 4London School of Hygiene and Tropical Medicine, Lon-
don, United Kingdom.
Background: Alcohol, smoking, physical inactivity, high body mass index
(BMI) and menopausal hormone therapy have been shown to be associated
with increased risk of breast cancer. However, it is unclear how these risk
factors combined influence overall breast cancer risk, and whether they are
associated with only certain subtypes. Methods: We conducted a case-con-
trol study nested within a cohort of 457,036 women who participated in the
Norwegian Breast Cancer Screening Program (NBCSP) in 2006-2014, and
who completed a questionnaire at baseline screening. In all, 4 686 breast
cancer cases with information on risk factors and hormone receptor status
(i.e. estrogen receptor (ER), progesterone receptor (PR) and human epider-
mal growth factor 2 (HER2) occurred during the follow-up. The following
surrogate defınitions of breast cancer subtypes were used: ERPRHER2-
(‘luminal A-like‘), ERPR-HER2- (‘luminal B-like, HER2 negative‘), ER
PR/PR-HER2 (‘luminal B-like, HER2 positive’), ER-PR-HER2 (‘HER2
positive’) and ER-PR-HER2- (‘triple negative’). We defıned risky lifestyle
behaviors as ever smoking, weekly consumption of more than 2 glasses of
alcoholic beverage, less than 3 hours leisure time physical activity per week,
ever use of menopausal hormone (estrogen or estrogen and progesterone)
therapy and BMI (kg/cm²) 25. We used conditional logistic regression to
estimate odds ratios (ORs), with 95% confıdence intervals (CIs), adjusted for
age, education, age at menarche, number of pregnancies and menopausal
status. Results: Number of risky lifestyle behaviors was associated with an
increased risk of breast cancer overall (p-trend0.0001). Compared to
women with no risky lifestyle behaviors, women with 1 (OR1.28, 95% CI
0.87-1.88), 2 (OR1.63, 95% CI 1.13-2.36), 3 (OR1.85, 95% CI 1.28-2.68),
4 (OR2.27, 95% CI 1.56-3.29) and 5 (OR2.38, 95% CI 1.58-3.59) risky
lifestyle behaviors had increased risk of the luminal A-like subtype (p-trend
0.0001). However, number of risky lifestyle behaviors was not associated
with an increased risk of the triple negative subtype (p-trend0.27). Con-
clusions: This study showed that number of risky lifestyle behaviors was
positively associated with a marked increased risk for luminal A-like breast
cancer. These fındings suggest that healthy lifestyle choices may play an
important role in the prevention of the commonest form of this cancer.
#2288 Effects of tobacco smoking and alcohol consumption on risks of
CYP1B1 polymorphisms for prostate cancer. Taku Kato, Yutaka Hashimoto,
Shigekatsu Maekawa, Marisa Shiina, Mitsuho Imai-Sumida, Pritha Dasgupta,
Priyanka Kulkarni, Soichiro Yamamura, Shahana Majid, Sharanjot Saini,
Varahram Sharryari, Guoren Deng, Rajvir Dahiya, Yuichiro Tanaka.University
of California San Francisco and Veterans Affairs Medical Center San Francisco,
San Francisco, CA.
Cytochrome P450 1B1 (CYP1B1) converts xenobiotics to carcinogens and
polymorphic variants have been shown to increase activity levels. Lifestyle
choices such as tobacco smoking and alcohol consumption are known to
enhance the carcinogenesis process and in this study, how these factors may
interact with CYP1B1 polymorphisms and affect prostate cancer risk was
assessed. Blood genomic DNA from a Caucasian population consisting of
405 healthy men and 400 prostate cancer patients were obtained. Of these,
507 were current or former smokers and 407 were alcohol drinkers. Eight
polymorphic sites of the promoter region of CYP1B1 (rs2551188 G to A,
rs2567206 G to A, rs2567207 A to G, rs162556 A to G, rs10175368 C to T,
rs163090 T to A, rs162330 T to G, and rs162331 A to G) were analyzed in
samples using Taqman genotyping assays and real-time PCR. Lifestyle fac-
tors and its influence on CYP1B1 polymorphisms toward cancer risks were
also evaluated. Overall, both alcohol (P0.006) and smoker (P0.069) sta-
tus were associated with prostate cancer. CYP1B1 variants were also risks for
cancer at rs2551188 (P0.043), rs2567206 (P0.008), and rs10175368
(P0.001). Evaluation of linkage disequilibrium show rs2551188, rs2567206,
rs2567207, and rs10175368 to be linked and interestingly, the G-G-A-C haplotype
(wildtype at respective sites) was signifıcantly reduced in cancer (P0.0282).When
classifıed by lifestyle factors, no associations for CYP1B1 variants were found for
cancer among non-smokers with rs10175368 (P0.051) being a risk among non-
drinkers. On the other hand, variants at both rs2567206 and rs10175368 showed
increased cancer risk among smokers (P0.032 and 0.002, respectively) as well as
drinkers (P0.044 and 0.019, respectively). No genotyping differences were ob-
served when analyzing cancers by pathological grades. These results demonstrate
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smoker and alcoholic drinker status tomodify the risks of CYP1B1 polymorphisms
for prostate cancer and this is of importance in understanding their role in the
pathogenesis of this disease.
#2289 -carotene supplementation and lung cancer risk in the ATBC
Study: the role of tar and nicotine. Pooja Middha,1 Stephanie J. Weinstein,2
Satu Männistö,3 Demetrius Albanes,2 Alison M. Mondul1. 1University of
Michigan School of Public Health, Ann Arbor, MI; 2National Cancer Institute,
Bethesda, MD; 3National Institute for Health and Welfare, Helsinki, Finland.
Background: Globally, lung cancer is the most common cancer and the lead-
ing cause of cancer death. Early observational studies reported a protective as-
sociation between intake of -carotene rich vegetables and lung cancer risk,
which led to interest in -carotene supplementation as a potential chemopre-
ventive strategy, particularly in high-risk populations such as cigarette smokers.
A large randomized controlled trial, theAlpha-Tocopherol, Beta-CaroteneCan-
cer Prevention (ATBC) Study, demonstrated that -carotene supplementation
increased lung cancer incidence by 18% in smokers, and led to an 8% excess in
overall mortality. It is also well-documented that cigarettes with higher (versus
lower) tar and nicotine content are associated with a higher risk of lung cancer.
To our knowledge, however, no studies have examined whether the increased
risk associated with -carotene supplementation in smokers varies by cigarette
tar or nicotine content. Methods: The ATBC Study was a randomized, double-
blind vitamin supplementation trial conducted among 29,133 male smokers in
southwest Finland. Participantswere randomly assigned to one of four groups in
a 2x2 factorial design (-tocopherol alone, -carotene alone, both supplements,
or placebo). A detailed smoking history was collected at baseline, including
brands of cigarettes smoked (for which machine measured tar and nicotine
content was available). Cox proportional hazards models were used to estimate
the hazard ratio (HR) and 95% confıdence intervals (CI) of lung cancer risk by
trial-carotene assignment stratifıed by a priori categories of cigarette tar (ultra-
light 7 mg, light 8-14 mg, medium/regular 15-20 mg, high/non-fıltered/self-
made20 mg) and nicotine content (ventilated fıltered0.8 g, unventilated
fıltered 0.8-1.3 g, non-fıltered 1.3 g). Statistical interaction was estimated
using the likelihood ratio test. Results: The -carotene supplemented arm had a
statistically signifıcantly higher risk of developing lung cancer in all categories of
tar content [yes vs. no -carotene supplementation - ultra-light: HR1.31 95%
CI0.91-1.89; non-fıltered: HR1.22 95% CI0.91-1.64; p-interaction0.91].
Similarly, there was no apparent interaction with cigarette nicotine content [yes
vs. no -carotene supplementation - ventilated cigarettes: HR1.23, 95%
CI0.98-1.54; non-fıltered cigarettes: HR1.22, 95% CI0.91-1.64; p-interac-
tion0.83]. Conclusion: These fındings indicate that supplementation with
-carotene increases lung cancer incidence in smokers regardless of the tar or
nicotine content of cigarettes smoked.Our data suggest that all smokers, regard-
less of the type of cigarette smoked, should continue to avoid -carotene sup-
plementation.
#2290 Perceived stressfulness of life events impacts breast cancer risk.
Avital Fischer, Argios Ziogas, Hoda Anton-Culver. UCI, Irvine, CA.
Background: Breast cancer is the most prevalent malignancy and the sec-
ond most common cause of cancer mortality among women. Approximately
60% of variability in breast cancer risk remains unexplained. It is imperative
to perform further research focusing on identifying preventable risk factors
for breast cancer. The relationship between psychological stress and breast
cancer risk is unclear. Psychological stress arises when environmental de-
mands are appraised as going beyond one’s coping abilities. Higher per-
ceived stress has been linked to increased cortisol levels and HPA perturba-
tions. The purpose of this study is to understand the relationship between
stressfulness appraisal of salient life events and breast cancer risk. Methods:
A case-control design was used and included 664 female cases identifıed
through the Cancer Surveillance Program of Orange County, CA and 203
female population-based controls. Participants completed a risk factor ques-
tionnaire that included a life event section. Participants were asked to deter-
mine if events occurred and if they were considered to be signifıcantly stress-
ful or not. Multivariate unconditional logistic regression was used to
calculate ORs while adjusting for known breast cancer covariates. Results:
Cumulative adverse life events perceived as stressful were associated with
increased breast cancer risk in a dose response fashion (OR1.63, 95%
CI1.00-2.66, Ptrend0.045). Conversely, cumulative adverse life events not
reported as stressful did not have a signifıcant impact on breast cancer risk
(OR2.04, 95% CI0.77-5.43). History of personal illness was directly re-
lated to increased breast cancer risk, when perceived as stressful (OR2.84,
95% CI1.96-4.11) or non-stressful (OR3.47, 95% CI1.34-8.94). Inter-
estingly, abortion and relocation were observed to have a protective effect on
breast cancer risk only when reported as being stressful (OR0.54, 95%
CI0.32-0.92; OR0.63, 95% CI0.43-0.93 respectively). Conclusions:
This study broadens our understanding of the relationship between major
life events and breast cancer risk and underscores the importance of stress-
fulness appraisal. Our results indicate the importance of incorporating as-
sessments of perceived stressfulness in future epidemiological investigations
focusing on the assessment of life events and breast cancer risk.
#2292 Lung function and lung cancer risk: a Mendelian randomization
study of UK Biobank cohort and the International Lung Cancer Consor-
tium. Linda Kachuri,1 Mattias Johansson,2 Paul Brennan,2 Phillip Haycock,3
Geoffrey Liu,4 Maria Teresa Landi,5 David C. Christiani,6 Neil E. Caporaso,5
Xifeng Wu,7 Melinda C. Aldrich,8 Demetrius Albanes,5 Adonina Tardón,9
Gad Rennert,10 Chu Chen,11 Gary E. Goodman,11 Jennifer A. Doherty,12
Heike Bickeböller,13 Dawn Teare,14 Lambertus A. Kiemeney,15 Stig E.
Bojesen,16 John K. Field,17 Aage Haugen,18 Stephen Lam,19 Loic Le March-
and,20 Matthew B. Schabath,21 Angeline S. Andrew,12 Jonas Manjer,22 Philip
Lazarus,23 Susanne M. Arnold,24 Valérie Gaborieau,2 Richard Martin,3 Car-
oline Relton,3 George Davey Smith,3 Christopher I. Amos,12 James D. Mc-
Kay,2 Rayjean J. Hung1. 1Lunenfeld-Tanenbaum Research Institute, Sinai
Health System, Toronto, Ontario, Canada; 2International Agency for Re-
search on Cancer, Lyon, France; 3University of Bristol, Bristol, United King-
dom; 4Princess Margaret Hospital, Ontario Cancer Institute, Toronto, On-
tario, Canada; 5National Cancer Institute, MD; 6Harvard T.H. Chan School
Of Public Health, MA; 7University of Texas MD Anderson Cancer Center,
Houston, TX; 8Vanderbilt University Medical Center, TN; 9University of
Oviedo, University Institute of Oncology, Oviedo, Spain; 10Technion Faculty
of Medicine and Carmel Medical Center, Israel; 11Fred Hutchinson Cancer
Research Center, WA; 12Geisel School of Medicine, Dartmouth College, NH;
13University Medical Centre Göttingen, Göttingen, Germany; 14School of
Health and Related Research, University of Sheffıeld, Sheffıeld, United King-
dom; 15Radboud University Medical Centre, Nijmegen, Netherlands; 16Herlev
and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark;
17University of Liverpool, Liverpool, United Kingdom; 18National Institute of
Occupational Health, Oslo, Norway; 19BC Cancer Agency, Vancouver, British
Columbia, Canada; 20University of Hawaii Cancer Center, HI; 21Moffıtt Can-
cer Center, FL; 22Skåne University Hospital, Lund University, Lund, Sweden;
23College of Pharmacy, Washington State University, WA; 24Markey Cancer
Center, University of Kentucky, KY.
Background: Impaired lung function (LF) is strongly associated with in-
creased lung cancer risk. However, since airflow obstruction is a diagnostic
criterion for obstructive lung disease, and a consequence of tobacco smok-
ing, isolating the causal relationship between LF and lung cancer has re-
mained a challenge. Methods: We investigated 3 standardized (mean0,
standard deviation1) LF metrics: forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), and FEV1/FVC. To evaluate the causal
relevance of LF in lung cancer etiology we conducted: i) survival analyses in
the UK Biobank cohort (UKB); and ii) Mendelian Randomization (MR)
analyses using genetic instrumental variables (IVs) developed in UKB and
tested using individual-level data from the OncoArray, a genome-wide array
with in-depth coverage for common cancers. Results: 702 incident lung can-
cers were diagnosed in 484,194 UKB participants during follow-up. Cox
regression was used to estimate hazard ratios (HR) and 95% confıdence
intervals (CI), adjusted for age, sex, smoking status, socioeconomic status,
and assessment center. Adjustment for other smoking metrics yielded sim-
ilar results. Lung cancer risk increased per 1 unit decrease in FEV1
(HR1.80, 95% CI: 1.64-1.98, p3.31034), FVC (HR1.45, 1.30-1.60,
p2.31012), and FEV1/FVC (HR1.39, 1.33-1.46, p1.31038). This pattern
wasobserved for adenocarcinoma (n300): FEV1 (HR1.77, p6.01012), FVC
(HR1.48, p1.4105), FEV1/FVC (HR1.34, p8.31011); and squamous
cell carcinoma (n166): FEV1 (HR1.97, p9.91010), FVC (HR1.60,
p1.0104), FEV1/FVC (HR1.38, p5.9108). Next, a genome-wide asso-
ciation study of 67,708 UKB participants and 12.6 million variants was carried
out to develop genetic IVs for LF. Results were fıltered to retain independent
variants (R20.2) associated with each LF phenotype (p5108). The follow-
ing IVs were developed: FEV1 (n28 variants, 0.72% of variation explained),
FVC (n44, 1.08%), and FEV1/FVC (n45, 1.85%). Odds ratios (OR) for each
IV and lung cancer were estimated for 18,686 cases 15,190 controls (80%
European ancestry) from 23 studies. Effect estimates were combined using
maximum-likelihood MR models to estimate causal ORs. MR results indi-
cate that genetic scores associated with improved airflow are unrelated to
lung cancer risk: FEV1 (OR1.00, 95% CI: 0.96-1.03, p0.86), FVC
(OR1.00, 0.97-1.03, p0.93) and FEV1/FVC (OR1.00, 0.91-1.10,
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p0.95). The null association observed for the genetic determinants of
FEV1, FVC and FEV1/FVC was not modifıed by tumor histology or smoking
status. Conclusions: LF is a robust predictor of lung cancer risk, however, our
fındings do not support the existence of causal pathways that are indepen-
dent of obstructive lung disease or smoking. This apparent lack of a causal
relationship should be interpreted with caution since pleiotropic effects of
LF loci cannot be ruled out.
#2293 Oligomenorrhea, polycystic ovary syndrome, and risk of ovarian
cancer histotypes, evidence from the Ovarian Cancer Association Consor-
tium. Holly R. Harris,1 Susan Jordan,2 Harvey Risch,3 Mary Anne Rossing,1
Marc T. Goodman,4 FrancesmaryModugno,5 SusanneKrüger Kjær,6 JoellenM.
Schildkraut,7 Elisa V. Bandera,8 Nicolas Wentzensen,9 Catherine Phelan,10
Hoda Anton-Culver,11 Anna H. Wu,12 Kathryn L. Terry13. 1Fred Hutchinson
Cancer Research Ctr., Seattle, WA; 2QIMR Berghofer Medical Research Institute,
Herston, Australia; 3Yale School of Public Health, NewHaven, CT; 4Cedars-Sinai
Medical Center, Los Angeles, CA; 5University of Pittsburgh School of Medicine,
Pittsburgh, PA; 6Danish Cancer Society Research Center, Copenhagen, Denmark;
7The University of Virginia, Charlottesville, VA; 8Rutgers Cancer Institute of New
Jersey, New Brunswick, NJ; 9National Cancer Institute, Bethesda, MD; 10Moffıtt
Cancer Center, Tampa, FL; 11University of California Irvine, Irvine, CA; 12Uni-
versity of Southern California Norris Comprehensive Cancer Center, Los Angeles,
CA; 13Brigham and Women’s Hospital, Boston, MA.
Background: Oligomenorrhea, defıned as infrequent or irregular periods has
been shown to be associated with epithelial ovarian cancer risk in some but not
all studies. Polycystic ovary syndrome (PCOS), which is characterized by oli-
gomenorrhea and abnormal hormone levels including hyperandrogenism, hy-
perinsulinemia, and gonadotropin imbalance, has been suggested to increase
ovarian cancer risk. However, these associations have been rarely examined by
histologic subtype. We sought to examine these associations among 14 studies
participating in the Ovarian Cancer Association Consortium. Methods: Partic-
ipants included 16,594 patients with invasive (n13,719) or borderline
(n2,875) ovarian cancers and 17,718 controls who had answered questions
regarding menstrual cycle irregularity, menstrual cycle length, and/or PCOS.
Study specifıc odds ratios (ORs; 95%confıdence intervals [95%CI]), adjusted for
ovarian cancer risk factors, were calculated and then combined using a random-
effects meta-analysis. Pooled histologic subtype specifıc ORs (95% CI) were
calculated using polytomous logistic regression. Results: Women reporting
menstrual cycle length35 days had decreased risk of invasive ovarian cancer
compared to women reporting cycle length35 days (OR0.70; 95%CI0.58-
0.84). Decreased risk of invasive ovarian cancer was also observed among
women who reported irregular menstrual cycles compared to women with reg-
ular cycles (OR0.83; 95% CI0.76-0.89). No signifıcant association was ob-
served between self-reported PCOS and invasive ovarian cancer risk (OR0.87;
95% CI0.65-1.15). For menstrual cycle length 35 days, decreased risk was
observed for all invasive histotypes: low grade serous (OR0.48; 95% CI0.25-
0.92), high grade serous (OR0.62; 95% CI0.48-0.80), mucinous (OR0.38;
95% CI0.19-0.76), endometrioid (OR0.75; 95% CI0.54-1.06), and clear
cell (OR0.70; 95% CI0.43-1.13) but not for serous borderline tumors
(OR1.18; 95% CI0.87-1.59) (pheterogeneity0.006). An increased risk of se-
rous borderline disease was observed among women reporting irregular cycles
(OR1.34; 95% CI1.16-1.55) (pheterogeneity0.0001). No statistically signifı-
cant differences by histologic subtype were observed for self-reported PCOS.
Conclusion: In this large consortium analysis we observed a decreased risk of
most invasive epithelial ovarian cancer histotypes among women reporting lon-
ger or irregular menstrual cycles. In contrast, such cycles were associated with
increased risk of the serous borderline tumors.
#2294 Atypical nevi and risk of incident skin cancer inUSmen: a prospec-
tive study. WEN-QING LI,1 Eunyoung Cho,1 Alisa Goldstein,2 Yen-Tsung
Huang,1MartinWeinstock,1AbrarQureshi1. 1BrownUniversity, Providence, RI;
2National Cancer Institute, Bethesda, MD.
Background and Aims: Atypical nevi (AN) are a strong risk factor as well as a
precursor of melanoma. However, most previous studies on the associations
between atypical nevi (AN) and the risk of melanoma have been conducted in
retrospective case-control settings and the few available prospective studies have
been based on small sample sizes. Further, few studies have examined the asso-
ciations between AN and risk of keratinocyte carcinomas (formerly called non-
melanoma skin cancer). We prospectively examined the risk of incident mela-
noma, squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)
associated with AN. Methods: In the Health Professionals Follow-up Study,
information on AN was collected by self-report. Only those confırmed cases of
AN by a supplementary questionnaire, the Atypical Nevus Screening Question-
naire (ANQ), were included in the analyses. Diagnosis of skin cancers was re-
ported biennially and information on melanoma and SCC was pathologically
confırmed. A total of 50193 men were included in our study, with 1239 con-
fırmed cases of AN with information on diagnosis year. Cases of AN that were
not confırmed or did not respond to the ANQwere excluded from the analyses.
Time-dependent Cox-regression analyses were conducted for the associations
betweenANand risk of incidentmelanoma, SCC, andBCCrespectively. Results:
We identifıed 545melanoma cases, 1721 SCCcases, and 13498BCCcases during
the follow-up (1986-2012). A history of AN was signifıcantly associated with
increased risk of incident melanoma (hazard ratio [HR]3.50, 95% confıdence
interval [CI]: 2.13-5.76) overall and at different body sites (head and neck, trunk,
or limbs). The risk ofmelanomawas particularly augmentedwith the increasing
number of AN that were surgically removed (HR1.26, 95% CI: 1.16-1.37 per
AN) and for cases of AN with tissue re-excision from the nevus removal sites
(HR4.59, 95% CI: 1.70-12.41). A history of AN was also signifıcantly associ-
ated with increased risk of BCC (HR1.84, 95% CI: 1.60-2.10) and was only
associated with risk of SCC at the trunk sites (HR3.09, 95% CI: 1.24-7.72).
Conclusions: A history of AN signifıcantly increased the risk of subsequent
melanoma in a prospective study ofmen. A history of ANmay also be associated
with increased risk of BCCoverall and trunk SCC,which requires further studies
to replicate.
#2295 Association between metformin use and the risk of colorectal ade-
nomas: A systematic review and meta-analysis. Sheetal Hardikar,1 Jessica S.
Li,2 Qianchuan He,1 Jonathan Kocarnik,1 Edward J. Boyko,2 Polly A. New-
comb1. 1Fred Hutchinson Cancer Research Center, Seattle, WA; 2University of
Washington, Seattle, WA.
Metformin, the most commonly prescribed drug in type-2 diabetes, has been
evaluated for its potential cancer chemopreventive role. While evidence from
meta-analyses suggests a reduced risk for colorectal cancer in association with
metformin use, recent European studies have reported no association between
metformin and colorectal cancer risk. For precursors to colorectal cancers such
as colorectal adenomas, however, literature evaluating their relationship with
metformin use is sparse.We performed a systematic review andmeta-analysis of
available studies to quantitatively assess the association of metformin use with
risk of colorectal adenomas. In accordance with PRISMA guidelines and using
relevant MeSH terms, we searched the PubMed, EMBASE, andWeb of Science
databases through September 30, 2016 to identify full-text articles investigating
the risk for colorectal adenomas associated with the use of metformin. Overall
risk ratios (RR) and 95% confıdence intervals (CI) for colorectal adenomas were
calculated using a fıxed-effects model. Heterogeneity between studies was eval-
uated using theCochrane’sQ- test and the I2- statistic. Potential publication bias
was assessed by constructing a funnel plot. Sub-group analyses were performed
to examine whether the association with metformin use differed by country/
region. Of the 609 articles identifıed through searching the three databases, 6
studies were eligible for our meta-analysis (1 randomized trial, 2 case-control,
and 3 cohort studies; 4 Asian studies and 2 US-based studies) and contributed a
total of 9613 patients. The meta-analysis suggested that the risk for colorectal
adenomas was signifıcantly lower among metformin users as compared to
non-users [overall RR (95% CI): 0.69 (0.62-0.77), test for overall effect Z
18.52, P-value 0.0001]. This protective risk applied both for studies
within the US and Asian regions [pooled RRs (95% CI): 0.72 (0.64-0.81) and
0.62 (0.47-0.76), respectively]. There was no heterogeneity observed between
studies (Q-test p 0.09, I2-statistic 47.3%) and no evidence of any publica-
tion bias on funnel plot visualization. This meta-analysis indicates that the
use of metformin is signifıcantly associated with a lower risk of colorectal
adenomas. As metformin is an affordable and well-tolerated drug, it has the
potential to be an effective agent for polyp chemoprevention. Further long-
term randomized controlled trials are needed to confırm the anti-neoplastic
effects of metformin in reducing the risk of colorectal polyps, and eventually
colorectal cancer, in the general population.
#2296 Metformin reduces colon cancer risk in patients with type 2 diabe-
tes: a retrospective cohort analysis.Chin-Hsiao Tseng.National Taiwan Univ.
College of Medicine, Taipei, Taiwan.
Background: The effect of metformin on colon cancer is rarely investigated in
Asian populations. Methods: This is a retrospective cohort study. Patients with
newly diagnosed type 2 diabetes during 1999-2005were recruited fromTaiwan’s
National Health Insurance. A 1:1 propensity score matched-pair sample of
16314 ever users and 16314 never users of metformin were followed until De-
cember 31, 2011. Cox regression incorporated with the inverse probability of
treatment weighting using propensity score was used to estimate hazard ratios.
Results: The incidence of colon cancer was 272.04 and 392.44 per 100,000 per-
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son-years, respectively, in ever and never users. The overall hazard ratio (0.691,
95% confıdence interval: 0.578-0.826) suggested a signifıcantly lower risk in
metformin users. While compared to never users, the hazard ratio (95% confı-
dence interval) for the fırst (20.00 months), second (20.00-45.20 months) and
third (45.20 months) tertile of cumulative duration of metformin therapy was
1.455 (1.165-1.816), 0.683 (0.526-0.885) and 0.224 (0.152-0.331), respectively.
The protective effect ofmetformin on colon cancer was not affected by the use of
aspirin and statin or the infection of Helicobacter pylori in additional analyses.
Conclusions: Metformin reduces colon cancer risk in patients with type 2 dia-
betes. The protective effect is more remarkable when the cumulative duration is
more than 20 months.
#2297 Household stove improvement and risk of chronic obstructive pul-
monary disease in Xuanwei, China: a cohort study. Jinming Zhang,1 Bryan A.
Bassig,1 Roel Vermeulen,2 Wei Jie Seow,1 Jason Y.Y. Wong,1 Wei Hu,1 Bofu
Ning,3 George S. Downward,2 HormuzdA. Katki,1 Bu-Tian Ji,1 Nathaniel Roth-
man,1 Robert S. Chapman,4 Qing Lan1. 1National Cancer Insitute, Rockville,
MD; 2Utrecht University, Utrecht, Netherlands; 3Xuanwei Center of Disease Con-
trol, Xuanwei, China; 4Chulalongkorn University, Bangkok, Thailand.
Background: In Xuanwei County, China, chronic obstructive pulmonary dis-
ease (COPD) rates are over twice the national average. Patients with COPDhave
higher risks of both lung cancer and poor treatment outcomes after lung cancer
diagnosis. In a prior retrospective cohort study (1976-1992), household stove
improvement was found to be associated with decreased COPD incidence
among lifetime smoky (bituminous) coal users. However, whether the protec-
tive effects persist over time is unclear. Our objective was to evaluate the associ-
ations between risk of COPD, and vented and portable stove use with extended
follow-up (1976-2011). Methods: The study population comprised 22,833 resi-
dents who were born between 1917 and 1951 and lived in Xuanwei as of January
1, 1976. Participants were followed retrospectively from 1976 to 1992, and then
followed prospectively through 2011. We conducted two surveys in 1992 and
2011. During each survey, we collected comprehensive information on house-
hold stove type, fuel use, family size and number of rooms in each residence
during the lifetime, smoking, education, age started cooking food and time spent
indoor from each subject. Participants were also asked to report any medically
diagnosed chronic bronchitis or emphysema, age and place of diagnosis, which
we combined into a single category of COPD. COPD cases diagnosed before
January 1, 1976 were excluded. Sex-specifıc time-dependent Cox regression
models were used to estimate the hazard ratio (HR) of stove improvement for
COPD incidence among lifetime smoky coal users. Results: The analysis was
restricted to lifetime smoky coal users. A signifıcant reduction in COPD inci-
dence was found after change to vented stoves (Men’s model: HR0.66, 95%
confıdence interval(CI): 0.59-0.75; Women’s model: HR0.63, 95% CI: 0.55-
0.72) and portable stoves (Men’s model: HR0.77, 95%CI: 0.67-0.88;Women’s
model: HR0.63, 95% CI: 0.54-0.74). There was a downward trend of COPD
incidence over time after change to vented stove or portable stove (p-
trend0.01). Similar fındings were noted in bothmen and women. Conclusion:
Consistent with prior research, our fındings suggest that household stove im-
provement was associated with a substantially decreased risk of COPD, a strong
risk factor for lung cancer. Domestic smoky coal use and unvented coal com-
bustion are important risk factors for COPD. Our fındings support the need for
replacing smoky coal with less carcinogenic fuels in areas where domestic coal
use is common for cooking and heating, especially in the developing countries.
#2298 Antibiotic use and breast cancer risk: results from the Sister Study.
Sandra L. Deming-Halverson,1 M. Elizabeth Hodgson,1 Aimee D’Aloisio,1 Da-
vid Shore,2 Dale Sandler3. 1Social & Scientifıc Systems, Inc., Durham, NC; 2Wes-
tat, Durham, NC; 3NIEHS, Durham, NC.
Background: Regular antibiotic use is hypothesized to influence breast cancer
risk by a number of mechanisms including disruption of intestinal microflora
which plays a role in the conversion of food-based phytochemicals into bioactive
substances suggested to be protective against cancer, and by influences on the
immune system and inflammatory response. Previous results have beenmixed,
and given the sparse and conflicting data in epidemiologic literature, we ana-
lyzed the association between regular antibiotic use and breast cancer risk, over-
all and by different classes of antibiotics. Methods: Regular antibiotic use, as
characterized by class type and number, duration, and indication for use, was
evaluated for its association with breast cancer risk among participants of the
NIEHS Sister Study, a prospective cohort of 50,884 US women aged 35-74 with-
out breast cancer who have had a sister diagnosed with breast cancer. Results:
5,312 (10.4%) of women in the Sister Study reported ever having regular antibi-
otic use (at least 3 times per week for 3months in a row or longer) with amedian
duration of 1.50 years (0.25 – 53.8). 34%of regular uses reported use greater than
2 years. Skin conditions including acne and rosacea were the most common
indications for use (6.02%). The hazard ratio (HR) was 1.10 (0.99-1.27) for ever
regular antibiotic use and 1.40 (1.16-1.69) for greater than 2 years of regular use.
Results are suggestive of an increased risk among regular users who have only
ever used one class rather than more than one class of antibiotics. Adjusted
hazard ratios were 1.40 (0.99-1.99) for tetracyclines only, 1.45 (0.95-2.20) for
penicillins only, 1.42 (0.94-2.15) for macrolides alone. However, there does not
appear to be an association between ever regular use of more than one class of
antibiotics and breast cancer. Furthermore, there was no association between
indications for ever regular use and breast cancer risk, among all women report-
ing regular use of antibiotics, regardless of class. Conclusion: Overall, there is a
suggestion that ever regular use of a single class of antibiotics, but not use of
more than one class, may be associated with increased breast cancer risk. How-
ever, given that most individuals reported only a single episode of regular anti-
biotic use for a duration of less than 2 years; further exploration is warranted to
rule out effects of underlying indication for use or explore other possible class
specifıc-confounders.
#2299 Toxic metals in private well water and bladder and kidney cancer
incidence inNorthCarolina.Deepika Shrestha,1 SelinCronkrite,1Alison Sand-
ers,2 Rebecca Fry,3 Katie M. Applebaum1. 1George Washington University,
Milken Institute School of Public Health,Washington, DC; 2Icahn School of Med-
icine at Mount Sinai, New York, NY; 3University of North Carolina, Gillings
School of Global Public Health, Chapel Hill, NC.
Introduction: There are a limited number of studies conducted in the US that
have related metals in well water with kidney and bladder cancer. We investi-
gated levels of arsenic (As), cadmium (Cd), manganese (Mn), and lead (Pb) in
private well water and the association with incidence of bladder and kidney
cancer in 100 counties in North Carolina, a state that has among the highest
proportion of well water consumers in the country. Methods: Between 1998-
2010, privatewells across 100NCcountieswere analyzed for levels ofAs, Cd,Mn
and Pb (n63,836, n22,915, n70,675 and n65,535 measurements, respec-
tively) and geocoded. Bladder and kidney cancer incidence for each county
between 1990 and 2011 were obtained from the North Carolina Department of
Health and Human Services. County-level data on potential confounders were
obtained from US Census Bureau data (2010) and the Behavioral risk factor
surveillance study (2003, 2005). For each county, the mean concentration of
each metal and the incidence rate of kidney and bladder cancer were calculated
separately. Using counties as the unit of analysis, we used Poisson regression to
estimate incidence rate ratios (IRRs) and 95% confıdence intervals (CIs) be-
tween mean concentration of the four metals and kidney and bladder cancer
incidence, adjusting for age, gender, race, education, physical activity, smoking,
diabetes, hypertension and residential well water supply. County mean metal
levels were analyzed in tertiles. Counties with less than 10 cases or fewer than 10
well measurements for any metal were excluded from the analysis. Results:
Ninety-eight counties were included in the fınal analysis. In the fully adjusted
model, elevated IRRs for kidney cancer were observed in counties with the high-
est tertile of As (3rd tertile: 0.99-11.44 ppb, IRR1.05 (95% CI 1.00, 1.11)).
Similarly, elevated IRRs for kidney cancer were observed for both the 2nd and 3rd
tertiles of Cd (3rd tertile 0.61-2.98 ppb: IRR1.05 (95% CI 1.00, 1.10)) and the
2nd tertile of Pb (3.88-5.05 ppb, IRR1.05 (95%CI 1.00, 1.10)). A dose response
was observed for kidney cancer incidence and Mn (2nd tertile: 37.33-51.74 pbb;
IRR1.06 (95% CI 1.02, 1.11); 3rd tertile: 52.95-146.60 ppb: IRR1.13 (95% CI
1.08, 1.19)). For bladder cancer, no relationship was observed with As but IRRs
were elevated for the other metals including potential dose-response trend with
Cd andMn (Pb 2nd tertile 3.88-5.05 ppb: IRR1.03 (95% CI 1.00, 1.07); Cd 3rd
tertile 0.61-2.98 ppb: IRR1.10 (95%CI 1.06, 1.15); Mn 3rd tertile 52.95-146.60
ppb: IRR1.12 (95% CI 1.08, 1.16)). Conclusion: In North Carolina, counties
with higher mean private well metal levels had elevated kidney and bladder
cancer incidence rates. The conclusions are limited by the ecological approach,
but the consistency of the associations suggests that the influence of metals in
private well water in North Carolina on health outcome deserves additional
investigation.
#2300 Pesticides and primary liver cancer: A systematic review andmeta-
analysis. Hamdi Abdi, Jennifer Lee, Gary Ellison, Gabriel Lai, Tram Lam. Na-
tional Cancer Institute, Rockville, MD.
Background: Primary liver cancer is the sixth most occurring cancer world-
wide and the second most common cause of cancer mortality. Hepatocellular
carcinoma (HCC) is the most prevalent histologic type of liver cancer, with
well-established risk factors (e.g., chronic infections with hepatitis B virus or
hepatitis C virus, and alcohol-related liver disease). Exposure to pesticides may
also contribute to the etiology of liver cancer. The use of pesticides has increased
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signifıcantly in both developed and developing countries within the last few
decades. The association between pesticides and liver cancer is unclear. We
conducted a systematic review and meta-analysis to investigate the relationship
between exposure to pesticides (e.g.; organophosphates, organochlorines, car-
bamates, dichlorodiphenyltrichloroethane, dichlorodiphenyldichloroethylene,
agent orange) and liver cancer incidence and mortality. Methods: We searched
PubMed and EMBASE databases using a combination of medical subject head-
ing terms and key words for articles published before June 2016. Articles were
identifıed as relevant if they were original studies andmet the following criteria:
1) primary liver cancer was an identifıed outcome for risk or mortality, 2) pes-
ticides were themain exposure of interest, 3) exposure to pesticides was assessed
histologically (e.g.; blood serum) or through questionnaires, and 4) the estimates
for the association between liver cancer risk/mortality and pesticide exposure
were reported. Titles and abstracts meeting search criteria were reviewed and
relevant full-text articles were read and analyzed independently by two research-
ers. We calculated the summary estimates [Odd Ratios (ORs) or Relative Risks
(RR)] and 95% confıdence intervals (CIs) using random-effects models. All
analyses were conducted using STATA 14.0. Results: Of 1644 articles reviewed,
a total of 34 observational studies were identifıed as relevant and 20 were in-
cluded in themeta-analysis for liver cancer risk (5 case-controls and 15 cohorts).
All of the identifıed studies investigated HCC as the outcome; none investigated
other types of liver cancer. The results showed that pesticide exposure was asso-
ciated with a 73% increased risk of HCC (RRsummary:1.73, 95% CI 1.40-2.13;
I285.9%, P0.001). Stratifıed analyses by study design showed similar re-
sults (case-control: 1.69, 95% CI 1.31-2.18; cohorts: 1.47, 95% CI 1.25-1.72).
Furthermore, in analysis stratifıed by sex and type of pesticide similar elevated
risks were observed. Analysis of articles that reported on liver cancer mortality
(n7) showed an excess in mortality from HCC for individuals exposed to
pesticides. Conclusion: The existing epidemiological data supports the hypoth-
esis that exposure to pesticides is associated with a signifıcant increased risk of
HCC and death from liver cancer.
#2301 Genital use of talc and risk of ovarian cancer:Ameta-analysis.Paolo
Boffetta,1 Wera Berge2. 1Mt. Sinai Icahn School of Medicine, New York, NY;
2University of Dresden, Dresden, Germany.
Some epidemiological studies suggest an association between genital use of
talc powders and increased risk of ovarian cancer, but the evidence is not con-
sistent.We performed ameta-analysis of epidemiologic studies to formally eval-
uate this suspected association. A systematic search was conducted in Medline,
Embase and Scopus, leading to the identifıcation of 24 case-control studies and
3 cohort studies, including 302,705 women with ovarian cancer. In the meta-
analysis, we used a random-effect model to calculate summary estimates of the
association between genital use of talc and occurrence of ovarian cancer. We
assessed potential sources of between-study heterogeneity and presence of pub-
lication bias. The summary relative risk (RR) for ever use of genital talc and
ovarian cancer was 1.22 (95% confıdence interval [CI] 1.13-1.30). The RR for
case-control studies was 1.26 (95%CI 1.17-1.35) and for cohort studies was 1.02
(95% CI 0.85-1.20, p heterogeneity0.007). Serous carcinoma was the only histo-
logic type for which an association was detected (RR 1.24; 95% CI 1.15-1.34).
There was no trend in RR with either duration or frequency of genital talc use.
This meta-analysis resulted in a weak but statistically signifıcant association
between genital use of talc and ovarian cancer, which appears to be limited to
serous carcinoma. The heterogeneity of results by study design and the lack of a
trend for duration and frequency of use, however, detract from a causal inter-
pretation of this association.
#2302 Differences in risk factor-colorectal adenoma associations accord-
ing to non-steroidal anti-inflammatory drug use. Sobia Mujtaba, Roberd M.
Bostick. Emory University, Atlanta, GA.
Multiple observational studies and large, randomized controlled trials indi-
cate that non-steroidal anti-inflammatory drugs (NSAIDs) strongly reduce risk
for colorectal neoplasms. The strengths of these fındings suggest that NSAIDs
may somask various risk factor-colorectal neoplasm associations, that theymay
be undetectable among NSAID users. Temporal changes and between-popula-
tion differences in regular NSAID use prevalence may account for some of the
inconsistencies in reported fındings for risk factor-colorectal neoplasm associ-
ations. We investigated whether associations of known colorectal cancer risk
factors with colorectal adenoma differed by non-aspirin NSAID use using
pooled data from3 colonoscopy-based case-control studies of incident, sporadic
colorectal adenoma conducted in Minnesota, North Carolina, and South Caro-
lina between 1991 and 2002. Participants (n789 cases, 2,035 polyp-free con-
trols) provided risk factor data prior to colonoscopy. Themultivariable-adjusted
odds ratios (OR) (95% confıdence intervals [CI]) for those in the highest relative
to the lowest quartiles of exposure, by regular non-aspirin NSAID non-use/use,
respectively, were 1.57 (CI 0.96, 2.55) vs. 1.22 (CI 0.40, 3.70) for total fat, 1.37 (CI
0.86, 2.18) vs. 0.78 (CI 0.26, 2.35) for saturated fat, 0.92 (CI 0.67, 1.26) vs. 1.31 (CI
0.62, 2.76) for total calcium, 0.88 (CI 0.64, 1.22) vs. 1.38 (CI 0.65, 2.93) for total
fruits and vegetables, 1.05 (CI 0.73, 1.50) vs. 0.73 (CI 0.33, 1.62) for red and
processed meats, and 0.84 (CI 0.65, 1.10) vs. 0.97 (CI 0.54,1.75) for physical
activity. For current smokers relative to never smokers, the ORs (CIs) among
regular non-NSAID users/non-users were 2.88 (CI 2.20, 3.77) vs. 1.64 (CI 0.85,
3.17), respectively, and for those who were obese relative to those who were
normal weight, they were 1.65 (CI 1.27, 2.16) vs. 1.20 (CI 0.70, 2.04). The asso-
ciations of age, height, and intakes of alcohol, dietary fıber, and total folate with
adenoma did not substantially differ according to NSAID use. These fındings
suggest that regular non-aspirin NSAID use may mask, beyond simple con-
founding, associations of various risk factors with colorectal adenoma, suggest-
ing that differential proportions of regular NSAID users between study popula-
tions may explain some inconsistencies in reported risk factor-colorectal
neoplasm associations, and support routinely assessing such associations strat-
ifıed by regular non-aspirin NSAID use.
#2303 Entacapone and prostate cancer in patients with Parkinson’s dis-
ease: A large Veterans Health Administration study. Jacqueline M. Major,1
Francesca Cunningham,2 Diane Dong,2 Kunthel By,3 Kwan Hur,2 David C.
Shih,1 Simone P. Pinheiro,1 Gerald D. Podskalny,4 David J. Graham1. 1US Food
and Drug Administration/CDER/OSE, Silver Spring, MD; 2US Department of
VeteransAffairs, Hines, IL; 3US Food andDrugAdministration/CDER/OB, Silver
Spring,MD; 4US Food andDrugAdministration/CDER/OND, Silver Spring,MD.
Background:An increased risk of prostate cancerwas observed in Parkinson’s
disease (PD) patients treated with entacapone during a pre-approval random-
ized clinical trial. Objective: To investigate a potential association between en-
tacapone use and prostate cancer in an ambulatory setting.Methods: Using data
from the Department of Veterans Affairs (VA) healthcare system, new-user
cohorts were created of PD patients treated with add-on entacapone or add-on
dopamine agonist/monoamine oxidase B inhibitors between January 2000 and
December 2014. Patients were followed on-treatment for occurrence of prostate
cancer, identifıed via VA cancer registry linkage. Cox proportional hazards re-
gressionwith time-dependent exposurewas used to calculate hazard ratios (HR)
and 95%confıdence intervals (CI). Confoundingwas controlled by using inverse
probability treatment weighting calculated from propensity scores. Results:
Mean follow-up timewas 3.1 and 4.0 years in the entacapone and control cohort,
respectively. There were 17,666 subjects meeting study criteria (mean age, 74
(SD 8.6) years); the group treated with entacapone comprised 5,257 subjects.
Twenty-three prostate cancers occurred in the entacapone cohort and 97 in the
control cohort. The overall incidence of prostate cancerwas 1.8 per 1000 person-
years of risk. There was no difference in risk of prostate cancer between the
cohorts for increased duration of entacapone intake (adjusted HR: 1.08; 95%
confıdence interval: 0.46-2.51 for cumulative exposure of
2 years). Time since
starting drug therapy and cumulative dose (mg) were also examined. Conclu-
sion: In this cohort of PD patients, extended duration of entacapone use was not
associated with an increased incidence of prostate cancer.
#2304 Environmental pollutants and breast cancer: 2006-2016 epidemio-
logical studies designed to evaluate biological hypotheses provide evidence of
risk for certain pesticides, organic solvents, and products of combustion.
Kathryn M. Rodgers, Julia O. Udesky, Ruthann A. Rudel, Julia G. Brody. Silent
Spring Institute, Newton, MA.
Common environmental chemicals have plausible links to breast cancer be-
cause they are mammary gland carcinogens in animal studies or are known to
activate relevant hormonal pathways or enhance susceptibility of the mammary
gland to carcinogenesis. An institute ofMedicine report prioritized human stud-
ies of these exposures. Yet the long latency and multifactorial etiology of breast
cancermake evaluation of these chemicals in humans challenging, adding to the
importance of study designs that are well-suited to capture hypothesized breast-
cancer mechanisms. With this in mind, we updated Brody et al’s 2007 review in
Cancer to evaluate the strength of the epidemiologic evidence for several classes
of chemicalswithwidespread exposure.We conducted a systematic search of the
PubMed database for articles published in 2006-2016 using 147 terms and the
inclusion/exclusion criteria defıned in Brody et al’s 2007 review. We critically
reviewed articles identifıed by our search, including whether study designs were
suited to the biological evidence. We identifıed 158 new articles since 2006. In
the past 10 years, the strength of evidence for an association between breast
cancer and banned but persistent endocrine disrupting chemicals polychlori-
nated biphenyls (PCBs) and organochlorine pesticides has increased, based on a
unique 50-year cohort study that captured exposure during potentially critical
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windows for breast development (in utero, adolescence, pregnancy) and at the
time when the chemicals were still in use. Studies that considered early life
exposure to organic solvents and/or exposure of long duration also added to
evidence for an association with breast cancer. Solvents are used in dry cleaning,
electronics manufacturing, leather and fur processing, and metal, auto, textile,
and somemilitary work. Other important reports included theU.S. Agricultural
Health Study, which provided the fırst evidence of an association between or-
ganophosphate pesticides and breast cancer. Analyses from the Long Island
Breast Cancer Study Project showed higher risk associated with polycyclic aro-
matic hydrocarbons (PAHs, products of combustion) in women with certain
genetic variations. Consumer product chemicals, includingBPA, phthalates, per
fluorinated compounds, and hair dyes were evaluated in a few studies with
inconsistent results;many of these studies had seriousmethodologic limitations.
Animal and mechanistic evidence suggest that timing could be crucial to carci-
nogenic actions ofmany environmental chemicals, however we found thatmost
epidemiologic studies in the past 10 years did not evaluate a specifıc timeframeof
exposure prior to diagnosis. Those that did enhanced our understanding of
relevant windows for biological activity of certain classes of chemicals.
#2305 Residential airborne heavy metal concentrations and breast cancer
characteristics. Jacob K. Kresovich, Serap Erdal, Maria Argos, Hua Yun Chen,
Peter H. Gann, Garth H. Rauscher. University of Illinois-Chicago, Chicago, IL.
Background: Ambient airmetal concentrations have recently been implicated
in the etiology of breast cancer. Previous studies have shown airborne concen-
trations of arsenic and cadmium are associated with the development of estro-
gen receptor-negative tumors. This study aims to replicate these fındings and
examine the role of other toxic and essential heavymetals.Methods: Participants
were women who were diagnosed with breast cancer in Chicago between 2005
and 2008. We examined estrogen and progesterone receptor-negative (ER-/
PR-) and high-grade tumors as markers of aggressive breast cancer, and esti-
mated 15-year markers of exposure of 11 heavy metals. Exposures were calcu-
lated using census tract-level airborne concentrations from the National-scale
Air Toxics Assessment and participants’ residential histories. We adjusted all
models for socioeconomic status and reproductive factors. Results: We found
that prevalent ER-/PR- tumors were associated with increased residential expo-
sure to airborne concentrations of antimony (Q4 vsQ1:OR 1.81; 95%CI: 0.95,
3.44; Ptrend 0.04), cobalt (Q4 vs Q1: OR 2.37; 95% CI: 1.26, 4.45; Ptrend 
0.01), manganese (Q4 vs Q1: OR 2.55; 95% CI: 1.24, 5.24; Ptrend 0.04), and
selenium (Q4 vs Q1: OR 1.85; 95% CI: 1.03, 3.29; Ptrend 0.05), and also
identifıed marginally signifıcant trends for arsenic (Ptrend 0.06), chromium
(Ptrend 0.08), lead (Ptrend 0.08), and mercury (Ptrend 0.07). We did not
identify any overall associations with high-grade tumors, however when strati-
fying by menopausal status we found that antimony (Q4 vs Q1: OR 6.97, 95%
CI: 1.61-30.19) and arsenic (Q4 vs Q1: OR 6.97, 95% CI: 1.61-30.19) were
associated with prevalent high-grade tumors in premenopausal women only.
Discussion: This study found further support for a role of airborne arsenic con-
centrations, and novel evidence implicating other airborne estrogen-pathway
disruptingmetal concentrations, in the development of aggressive breast cancer
subtypes. Additionally, this is the fırst study to implicate heavymetal exposure in
the etiology of high-grade tumors. These results suggest that long-term, low-
dose exposures to certain heavy metals play a role in the etiology of aggressive
breast cancer characteristics. Airborne exposures have the ability to affect large
populations and fındings from this and similar studies have large public health
implications.
#2306 Sleepdurationand riskof fatal prostate cancer inCPS-I andCPS-II.
Susan M. Gapstur, Victoria L. Stevens, Brian D. Carter, Ying Wang, Eric J.
Jacobs. American Cancer Society, Atlanta, GA.
There is growing evidence that factors associated with circadian rhythm dis-
ruption may be associated with prostate cancer risk. In a previous analysis fo-
cusing on shift-work in theCancer Prevention Study (CPS)-II that included only
employed men, we observed an association between short sleep duration and
higher risk of prostate cancer death that was limited to the fırst eight years of
follow-up of the cohort. To corroborate and expand on these results, we exam-
ined the association between sleep duration and death from prostate cancer in a
combined analysis ofmen inCPS-II andmen enrolled in an earlier cohort study,
CPS-I, regardless of employment status. After excluding men with uninterpre-
table sleep information, prevalent cancer and prevalent prostate disease at base-
line, the analysis included 407,649men fromCPS-I followed from 1950 through
1972, and 416,040 men from CPS-II followed from 1982 through 2012. During
follow-up, 1,546 men in CPS-I and 8,704 men in CPS-II died of prostate cancer.
Cox proportional hazards regression was used to estimate multivariable-ad-
justed relative risks (RR) and 95% confıdence intervals (CI) and estimates were
meta-analyzed using a fıxed-effects model because the design and population of
CPS-I and CPS-II were similar. Among men aged 65 years and younger, short
sleep duration was associated with higher risk of death from prostate cancer
during the fırst eight years of follow-up; compared to 7 hours/night, the RRs
(95%CIs) for 3-5, and 6 hours/night were 1.61 (1.10-2.37), and 1.25 (0.99-1.58),
respectively. Among men older than age 65 years, the corresponding RRs (95%
CIs) were 0.97 (0.68, 1.38), and 1.02 (0.82, 1.27), respectively. There was no
association between sleep duration and fatal prostate cancer during later follow-
up. These fındings support evidence that factors related to circadian rhythms
may increase fatal prostate cancer risk. The observed association between short
sleep duration and higher risk of fatal prostate cancer only during the fırst
8-years of follow-up suggests that short sleep duration could affect later stages of
prostate carcinogenesis. Reasons for lack of an association in older men are
unclear but may include the marked decline in nocturnal melatonin levels with
age, which could reduce the relative biologic impact of melatonin inhibition by
sleep-deprivation.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Apoptosis and Other Regulated Cell Death in Cancer
#2307 The p53/p21 complex is a functional unit that regulates cancer cell
invasion and apoptosis by targeting Bcl-2 family proteins. Eun Mi Kim,
Hong-Duck Um. Korea Inst. of Radiological & Medical Sci., Seoul, Republic of
Korea.
Although well known as a transcription factor, the p53 tumor suppressor also
exists in the cytoplasm (including themitochondria) of normal and cancer cells.
Moreover, nuclear p53 is translocated to themitochondria upon apoptotic stim-
ulation of cells. The cytoplasmic/mitochondrial p53 can bind pro-survival Bcl-2
family proteins (e.g., Bcl-2, Bcl-XL, and Bcl-w), liberating Bax therefrom. Bax
then exerts its pro-apoptotic or anti-invasive function depending on experimen-
tal conditions. Given the ability of p53 to interact with p21, we investigated the
possible involvement of p21 in these functions. Here, we show that whereas p53
can bind to Bcl-w alone, it requires p21 to liberate Bax fromBcl-w and suppress/
promote cell invasion/death, respectively. p21 consistently binds Bcl-w, forming
a p53/p21/Bcl-w complex. Only this trifold complex, but not any of the pairings,
facilitates the release of Bax from Bcl-w. Accordingly, a p53 derivative incapable
of binding p21 fails tomediate radiotherapy-induced tumor retardation and cell
death in mice. We further show that Bcl-2 and Bcl-XL also serves as a target of
p53/p21 cooperative action.Overall, our fındings indicate that the p53/p21 com-
plex rather than p53 itself regulates cell invasion and death by targeting Bcl-2
proteins. We propose that the p53/p21 complex is a functional unit that acts on
multiple types of cellular components, providing a new foundation for under-
standing the tumor-suppressing functions of p53 and p21.
#2308 Sigma-2 receptor ligands induce apoptosis and inhibit prolifera-
tion in breast cancer cell line mda-mb-231. Gladys Asong, Felix Amissah,
Olufısayo Salako, Rosemary Poku, ElizabethNtantie, AugustineNkembo,Naza-
rius Lamango, Seth Ablordeppey. Florida A&M University, Tallahassee, FL.
Introduction: Despite the reduction in mortality from breast cancer achieved
in the last 30 years due to more effective targeted therapies, the survival rate for
patients with triple negative breast cancer (TNBC) is poor and has virtually
plateaued. Due to the absence of estrogen, progesterone, and human epidermal
growth factor receptors 2, no targeted treatment options are currently available
for TNBC. Moreover, the current standard systemic treatments are known to
cause tremendous side effects. Thus, there is an urgent need to identify novel
strategies for treating TNBC. Several reports have revealed that sigma-2 recep-
tors are over-expressed in all solid tumors includingTNBC,making it a plausible
biomarker to explore for TNBC treatment. In this study, we investigated the
effects of novel sigma-2 receptor ligands (XYZ-XI-14 and XYZ-VII-69) synthe-
sized in our lab on the viability and survival of the TNBC,MDA-MB-231.Meth-
ods:MDA-MB-231 cells were treated for 48 hwithXYZ-XI-14 andXYZ-VII-69,
cell viability and proliferation were assessed using resazurin cell titre assay and
cell count methods respectively. The effects of the ligands on spheroids forma-
tion, cell cycle, and mode of cell death were also investigated. Results: XYZ-
XI-14 and XYZ-VII-69 decreased cell viability of MDA-MB-231 cells in a con-
centration-dependent manner. The EC50 for XYZ-XI-14 and XYZ-VII-69 were
12 and 13 M respectively; and at 5 M, the ligands inhibited cell proliferation,
induced apoptosis, and arrested MDA-MB-231 cells at the G0/G1 phase of cell
cycle. Additionally, concentrations of the ligand as low as 1 M prevented the
formation of spheroids as evidenced by the lack of compact spheroids, and
EPIDEMIOLOGY: Tobacco, Alcohol, and Other Risk Factors
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 591
caused the disintegration of preformed spheroids. Conclusion: This study indi-
cates that targeting sigma-2 receptors with novel sigma-2 ligands (XYZ-XII-14
and XYZ-VII-69) effectively inhibits TNBC cancer cell growth by inducing ap-
optosis and cell cycle arrest, thus presenting a unique and effective pathway for
treating TNBC. Additionally, the sigma-2 receptor ligands (XYZ-XI-14 and
XYZ-VII-69) have the potential to halt tumor growth and prevent tumor re-
lapse, as seen in our 3D culture assays. Thus, the sigma-2 receptor has the po-
tential to be a valuable target for the development of novel agents for the treat-
ment of TNBC.
#2309 Acetylation of survivin represses transactivation of STAT3 to in-
duce sodium butyrate-induced apoptosis in human mucoepidermoid carci-
noma cell lines. Sung-Dae Cho. Seoul National University, School of Dentistry,
Seoul, Republic of Korea.
Sodiumbutyrate (NaBu) is one of histone deacetylase inhibitors andpossesses
anticancer activity. Here, the aim of this study is to determine the molecular
mechanism by which NaBu controls apoptosis in MC3 and YD15 human mu-
coepidermoid carcinoma (MEC) cell lines. NaBu caused growth inhibition and
induced apoptosis in both cell lines accompanied by the acetylation of histone
proteins H2A and H3. NaBu clearly increased survivin and cleaved caspase 3
evidenced by human apoptosis array and it regulated survivin molecule at a
post-transcriptional level. NaBu caused nuclear translocation of survivin pro-
tein and increased survivin acetylation in both cell lines. In addition, STAT3 and
survivin were co-localized in nucleus by NaBu resulting in the decrease in the
expression level of Bcl-XL mRNA which is one of STAT3 downstream mole-
cules. In addition, NaBu induced caspase-dependent apoptosis in human MEC
cells. Taken together, these results suggest that NaBu is a potent apoptosis in-
ducer in humanMEC cell lines through survivin-STAT3 signaling cascades and
these fındings provide the basis of its clinical application for the treatment of
humanMEC. This abstract is supported by SNU Invitation Program for Distin-
guished Scholar and the Basic Science Research Program through the National
Research Foundation of Korea (NRF) funded by the Ministry of Education
(2014R1A12055874)
#2310 Molecular dynamics simulation of permeation pathway of cyto-
chrome C through Bax pore. Mingzhen Zhang,1 Jie Zheng,1 Ruth Nussinov,2
Buyong Ma2. 1University of Akron, Akron, OH; 2Leidos Biomedical Research,
NCI-Frederick, Frederick, MD.
How cytochrome C is released from the mitochondria to the cytosol via Bax
oligomeric pores, a process which is required for apoptosis, is still a mystery.
Based on the residue-residue distances detected experimentally for Bax and its
homologous protein (Bak), we recently computationally solve the fırst atomic
model for Bax oligomeric pores at the membranes. Next, we investigate the
mechanism at the microsecond time- and nanometer space- scale using coarse-
grained replica exchange and all-atom MD simulations. Our free energy land-
scape depicts a low barrier for the permeation of cytochrome C into the Bax
C-terminal mouth, with the pathway proceeding to the inner cavity and exiting
via the N-terminal mouth. Release is guided by organized charged/hydrophilic
surfaces. The hydrophilicity and negative charge of the pore surface gradually
increase along the release pathway from the pore entry to the exit opening.
Rather than inert passing of cytochromeC through a rigid pore, the flexible pore
may selectively aid the cytochrome C passage. The energy barrier is under 4
kcal/mol. Thus, once the Bax pore is formed in the membrane, the release of
cytochrome C may be readily achieved through energy fluctuations. Collec-
tively, our work provides mechanistic insight and atomic detail into the release
of cytochrome C through Bax oligomeric pores.
#2311 A peptide derived from a photosynthetic cupredoxin protein, au-
racyanin, induces a p53-independent apoptosis in cancer cells. Samer A. Naf-
fouje, Tohru Yamada, Tapas K. Das Gupta. University of Illinois at Chicago,
Chicago, IL.
Cupredoxins are a family of low-molecular weight, water soluble, copper-
containing redox proteins involved mainly in the electron transfer chain in
prokaryotes. Azurin is a member of the cupredoxin family secreted by Pseu-
domonas aeruginosa, of which a 28-amino acid sequence (p28) was identifıed to
acquire the capability of preferential entry into cancer cells of various histogen-
esis. Upon entry, it exerts a cytostatic effect in these cancer cells via a p53-
mediated pathway. Our aim was to study whether the other members of the
cupredoxin family possess a similar function to that of azurin in the eukaryotic
cancer cells. Based on structural and sequence analyses, helical regions of aura-
cyanin A& Bwere shown to resemble p28 closely. Thus, we studied the biologic
function of two 28-amino-acid peptides derived from auracyanin A (aurA; pI
4.5, MW 2.6 kD), and auracyanin B (aurB; pI 3.4, MW 2.7 kD). Cancer growth
and MTT assays demonstrated that aurB, but not aurA, induced cytotoxicity in
various cancer cell lines in a dose-dependent (range 0.1uM-100uM) and time-
dependent (72 hours) pattern, including p53-null (prostate cancer PC-3) and
dn-p53 (breast cancer MDD-2 and ovarian cancer SKOV-3) in which p28 did
not demonstrate a signifıcant growth inhibition. Annexin-V assays showed a
dose-dependent apoptosis in prostate cancer cell lines of various p53 statuses
(wt-p53 LNCaP, mut-p53 DU-145, p53-null PC-3) following treatment with
aurB at 5-50uM for 48 hours, whereas p28 did not demonstrate an apoptotic
activity in p53-null cell lines, suggesting an aurB-induced apoptosis via a p53-
indepdnent pathway. In contrast, aurAdidnot appear to induce apoptosis in any
of the above cell lines. Induction of apoptosis wasmediated through depolariza-
tion of the mitochondrial membrane and caspase cascade activation in cancer
cells. Moreover, fluorescence microscopy demonstrated that aurB, unlike p28,
does not acquire a similar pattern of preferential entry into cancer cells. This
proposes that aurB acquires the potential as an anticancer cell penetrating pep-
tide, and differs from p28 in its mode of entry and p53-mediated action. Our
studies pertaining to azurin and auracyanin, suggest that cupredoxins, as a fam-
ily of prokaryotic metalloproteins, could represent a fountainhead of numerous
derived peptides that hold promise as novel and effıcient antineoplastic agents
against various cancer cell lines.
#2312 Feasibility study of a fractionation method in the treatment of tu-
mor treating fıelds. Yunhui Jo,1 Jiwon Sung,1 Hyo Sook Song,1 Eun Ho Kim,2
Myonggeun Yoon1. 1Korea University, Seoul, Republic of Korea; 2Korea Institute
of Radiological and Medical Sciences, Seoul, Republic of Korea.
Tumor treating fıelds (TTFs) treatment has been reported to have great po-
tential to treat various cancers. Inspired by a similarity between TTFs and radio-
therapy in electromagnetic property, TTFs using a fractionated treatment
scheme originally designed for radiotherapy were applied to cancer (Human
glioblastoma,U373) and normal cells (intestinal epithelial, IEC-6) for three days
with durations of 3, 6, 9, or 24 hours/day. As the treatment time of TTFs in-
creases from 3 to 24 hours/day, the relative cancer cell growth rates in both cell
lines were reduced. While the difference in cancer cell growth rate compared to
control was25% (decreased from 100% to75%) for the treatment time of 6
hours/day, the growth rates of cells treated for additional 6 hours (i.e., 12 hours/
day) and additional 18 hours (i.e., 24 hours/day) differed only 5% and 8%
from that of cells treated for 6 hours/day, respectively. Our results suggested that
the dependence on treatment time in cancer cell inhibition is weakened dis-
tinctly at treatment times over 6 hours/day. For normal cells, the relative growth
rates corresponding to the treatment time of TTFs was not decreased much for
the treatment time of 3, 6, 12 hours/day revealing 93.3%, 90.0%, 89.3% of cell
growth rates compared to control, respectively, but it suddenly reduced to
73% for 24 hours/day of treatment. The experimental results indicated that the
effects of TTFs on growth rates of cancer cells are higher than the effects of TTFs
on growth rates of normal cells for treatment times of 3-12 hours/day, but the
difference became minimal for treatment times of 24 hours/day. Our results
suggest that the fractionated scheme in the treatment of tumor treating fıelds
may reduce treatment time while maintaining effıcacy, suggesting that this
method can increase patients’ quality of life.
#2313 Promoting caspase-8-dependent apoptosis signalingusing17-beta-
hydroxywithanolides. Alan D. Brooks,1 Ya-ming Xu,2 E. M. Kithsiri Wijer-
atne,2 Curtis J. Henrich,1 Poonam Tewary,1 Leslie Gunatilaka,2 Thomas J. Say-
ers1. 1Frederick National Laboratory for Cancer Research, Frederick, MD; 2The
University of Arizona, Tucson, AZ.
We have previously reported that withanolide E (WE), a steroidal lactone
from Physalis peruviana, was highly active in sensitizing various human carci-
noma cell lines to TRAIL-mediated apoptosis. Therefore, over 100 natural and
semi-synthetic withanolides were evaluated for their ability to promote caspase-
8-dependent cancer cell death. Our studies identifıed several withanolides that
were 4-8 fold more potent thanWE in sensitizing the renal carcinoma cells and
melanoma cells to caspase-8-dependent apoptosis in response to either TRAIL
or the TLR3 ligand poly (I:C). All active withanolides were 17-beta-hydroxy-
withanolides (17-BHW). The highly active 17-BHWs were more effıcient than
withanolide E at reducing cellular levels of both cFLIPL and cFLIPS and enhanc-
ing caspase-8 activation. Furthermore, immunoprecipitation of the TRAIL
death-inducing signaling complex (DISC), or the related ripoptosome, demon-
strated enhanced levels of both FADD and RIP1 in these macromolecular apo-
ptosis signaling complexes following treatment with active 17-BHWs. The 17-
BHWs used in this work were obtained by the application of an effıcientmethod
of plant biomass production involving our innovative and patented soil-less
aeroponic cultivation of P. crassifolia and P. peruviana and by chemical modi-
fıcation of natural withanolides produced by these plants. Preliminary structure
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activity relationship (SAR) studies suggested that the enonemoiety in ringAwas
essential for activity. In addition, acetoxylation at C-18, an alpha orientation of
the side-chain lactone group and the double bond at C-24(25) of the lactone
ring played important roles in determining the activity of 17-BHWs as apo-
ptosis sensitizers. This suggests that the 17-BHW scaffold is amenable to
optimization by a medicinal chemistry approach, which could lead to the
identifıcation of highly active natural product-based sensitizers of cancer
cells to caspase-8-dependent apoptosis. The cellular molecular target(s) of
active 17-BHWs are currently under further investigation. Funded by FN-
LCR Contract HHSN261200800001E.
#2314 Novel BH3 mimetic based therapeutic strategies for the treatment
of breast cancer. Zachary Kratche, MacKenzie Adams, RobertWilson, Stephen
Ethier, Stephen Guest.Medical Univ. of South Carolina, Charleston, SC.
Bcl-2 homology domain 3 (BH3) mimetics are a new class of targeted anti-
cancer compounds that function by inducing cancer cell apoptosis. Testing in a
variety of pre-clinical tumormodels has shown that BH3mimetics are capable of
inducing remarkable tumor regressions. Recently, a clinical trial of the BH3
mimetic venetoclax in Chronic Lymphocytic Leukemia (CLL) resulted in an
impressive response rate of 80% leading to FDA approval. Using unbiased
genomic and functional genomic approaches, we identifıed gene amplifıcation
of the BCL2L1 gene, which encodes the anti-apoptotic protein BCL-XL, as a
novel driver event in breast cancer. We identifıed focal amplifıcation of the
BCL2L1 gene in the SUM-185 breast cancer cell line and a genome-wide RNAi-
based screen identifıed BCL2L1 as one of the top genes necessary for viability of
this cell line (ranked 5th out of 15,256 genes). Treatment of SUM-185 cells with
navitoclax showed that these cells are intrinsically sensitive to this drug (IC50
100nM). This sensitivity was 1-2 logs greater than what was observed for breast
cancer cell lines that do not harbor BCL2L1 gene amplifıcation. To expand the
relevance of these fındings beyond the SUM-185 cell line, we used the cancer cell
line encyclopedia (CCLE) database to identify an additional breast cancer cell
line, HCC38, that also harbors a focal BCL2L1 gene amplifıcation. Treatment of
HCC38 cells with navitoclax revealed a high level of sensitivity that was equiva-
lent to that of SUM-185 cells. These fındings demonstrated that a subset of breast
cancers that harbor BCL2L1 gene amplifıcation are highly sensitive to a BH3
mimetic that targets BCL2L1 suggesting that BH3 mimetics could be used as a
single agent to effectively treat these breast cancers.We also examined the effec-
tiveness of BH3mimetics when used as part of a combination therapy approach.
In addition to a focal amplifıcation of the BCL2L1 gene, the SUM-185 breast
cancer cell line also harbors a focal amplifıcation of the fıbroblast growth factor
receptor 3 (FGFR3) gene as well as an activating mutation in the phosphatidyl-
inositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene.
Treatment of SUM-185 cells with low doses of navitoclax, a FGFR inhibitor, or
a PIK3CA inhibitor had little effect on colony forming effıciency. At these same
low doses, combined treatment with navitoclax and the FGFR inhibitor or the
PIK3CA inhibitor resulted in a strikingly synergistic effect with near complete
loss of colony forming ability (less than 10% of controls). We further showed
that this loss of clonogenicity was the result of a rapid induction of apoptosis by
the combination therapies. These results suggest that combining BH3mimetics
with inhibitors of PIK3CAor FGFR is a promising novel therapeutic strategy for
a subset of breast cancer patients.
#2315 Overcoming treatment resistance in cisplatin-resistant ovarian car-
cinoma cells by tissue-specifıc miRNAs. Michael Kleemann,1 Jeremias Bere-
uther,1 Simon Fischer,2 KimMarquart,1 SimonHänle,1 KristianUnger,3 Verena
Jendrossek,4 Christian U. Riedel,5 René Handrick,1 Kerstin Otte1. 1University of
Applied Sciences Biberach, Biberach, Germany; 2Boehringer Ingelheim, Biberach,
Germany; 3Helmholtz Zentrum München, München, Germany; 4University of
Essen, Essen, Germany; 5University of Ulm, Ulm, Germany.
Ovarian cancer is a common human cancer with a poor outcome and a high
risk of death. Due to resistances to current standard therapies (carboplatin and
paclitaxel for 3 to 6 cycles) additional therapeutic approaches are required and
novel specifıc biomarkers for ovarian cancer patients are necessary.MicroRNAs
(miRNA) are conserved, small noncoding RNAs regulating gene expression by
binding to their target mRNA which have been shown to regulate biological
processes including apoptosis. Apoptosis is a conserved, irreversible process
that allows cells to undergo a highly regulated form of cell death. However, the
fınal role of miRNAs in apoptotic signaling has not yet been fully determined.
Modulating the expression of key molecular components of the cell death ma-
chinery is an attractive strategy for cancer therapy overcoming chemo drug
resistance. To extend the pool of potential miRNA as anticancer agents and
biomarkers, we transferred a high content miRNA screening for pro-apoptotic
miRNAs to human cancer cell lines. Based on the high recovery rate of apoptosis
inducing miRNAs in SKOV3 cells analyses were extended to multiple ovarian
carcinoma cell lines with different genetic background. After transfection of
miR-1912-5p the apoptosis rate increased strongly in cisplatin-resistant cells. In
combination treatment with carboplatin the apoptotic effect increased after
transfection ofmiR-1912-5p in the cisplatin-resistant A2780 cells. Furthermore,
miR-1912-5p, miR-147b and miR-3073a showed signifıcant apoptosis induc-
tion in the various ovarian cancer cell lines alone and in combined therapy with
carboplatin. Western Blot analysis revealed an enhanced expression of the pro-
apoptotic proteins Bak1 and Bax and a decrease inBcl2 and Bcl-xL. We charac-
terized the miRNAs in regard to their endogenous expression and detected an
enhanced expression after apoptosis induction by chemotherapeutic drugs. Fi-
nally, analysis of The Cancer Genome Atlas data showed an influence on the
median survival of ovarian cancer patients ( 69 years). Our data indicate a
potential benefıt of tissue specifıc pro-apoptotic miRNAs in regard to cisplatin-
resistant cells. Furthermore the study identifıed novel pro-apoptotic miRNAs
with their potential use as novel therapeutic entities or prognostic biomarkers
for ovarian cancer.
#2316 Elevated H-Ras suppresses death receptor-mediated apoptosis in
cancer cells. Su-Ryun Kim. FDA, SIlver Spring, MD.
TNF-related apoptosis inducing ligand (TRAIL) induces apoptosis through
its death receptors (DRs) 4 and/or 5 expressed on the surface of target cells.
Despite its selectivity in killing cancer cells over most normal cells, recombinant
human TRAIL or its receptor agonists (monoclonal antibodies against DR4 or
DR5) encountered resistance in many tumor cells while the underlying mecha-
nisms remain partially understood.Here, we show that wild-typeH-RasGTPase
is systemically upregulated in TRAIL-resistant cells compared to TRAIL-sensi-
tive cells. The elevatedH-Ras expression correlatedwith a defıciency ofDR4 and
DR5 on plasmamembrane in TRAIL-resistant cell lines. Notably, knockdownof
H-Ras in TRAIL-resistant cells successfully restored the surface expression of
DR4 and DR5, thereby sensitizing the cells to TRAIL-induced apoptosis. Con-
sistently, ectopic expression of H-Ras in TRAIL-sensitive cells reduced surface
DR4 andDR5whichwas associatedwith a loss of TRAIL sensitivity. By contrast,
the status of K-Ras or its mutations was not casually linked to TRAIL receptor
expression or TRAIL sensitivity across the panel of cancer cell lines tested. These
data suggest that H-Ras may play a distinct role to negatively regulate TRAIL
receptors and apoptosis. The upregulated H-Ras could be a predictor of tumor
resistance to DR-targeted agents and a potential therapeutic target for combina-
tional therapy to achieve better treatment outcomes.
#2317 Prostanoid EP4 receptor induces cleavage of HSP90 via ROS gen-
eration in human colon cancer cells. In Gyeong Chae, Mi-hee Yu, Kyung-Soo
Chun. Keimyung Univ., Daegu, Republic of Korea.
Prostaglandin E2 (PGE2) has been reported to play critical roles in cell fate
decision by interacting with four types of G protein-coupled membrane recep-
tors such as EP1, EP2, EP3 and EP4. We previously reported that EP4 stimula-
tion by treatment with its agonist CAY10598 induced apoptosis via reactive
oxygen species (ROS) formation in colon cancerHCT116 cells.Moreover, treat-
ment with CAY10598 diminished the phosphorylation of JAK2 and induced
degradation of this oncoprotein, leading to the attenuation of STAT3 activation
in HCT116 cells. In the present study, we attempted to delineate the molecular
mechanisms underlying the degradation of JAK2 by activation of EP4. HSP90, a
member of the heat shock protein family, is amolecular chaperone that supports
stability of client proteins, such as, EGFR,MET,Akt and JAK2.HSP90-mediated
stabilization/activation of these client proteins contributes to the acquisition of
cancer cell hallmarks, including proliferation, survival, angiogenesis and inva-
sion. It has been recently reported that the chaperoning function of HSP90 may
be disrupted by post-translational modifıcation induced by oxidative stress.
Treatment of human colon cancer HCT116 cells with CAY10598 down-regu-
lated expression of HSP90 client proteins in a concentration- and time-depen-
dent manner and the down-regulation was restored by pretreatment with ROS
scavenger N-acetyl cysteine (NAC) or proteasome inhibitor MG132. However,
cotreatment with cycloheximide, protein synthesis inhibitor, accelerated the
CAY10598-induced degradation of HSP90 client proteins. These data suggest
that CAY10598-induced HSP90 client protein degradation may be caused by
ROS generation. In renal carcinoma Caki cells, CAY10598 also down-regulated
expression of HSP90 client proteins, suggesting that EP4 stimulation may regu-
late HSP90 activity in colon cancer cells as well as renal cancer cells. We found
that HSP90 was cleaved to 40 or 55 kDa, while HSP90 cleaved to 25 kDa by
CAY10598 treatment and the cleavage of HSP90 and  was blocked by NAC
treatment. Furthermore, EP4 inhibition by treatment with antagonist
GW627368x attenuated not only degradation of HSP90 client proteins but also
cleavage of HSP90 in CAY105998-treated HCT116 cells. In conclusions, EP4
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agonist CAY10598 induces degradation of HSP90 client proteins via ROS-de-
pendent HSP90 cleavage, leading to apoptosis in HCT116 cells. This is a novel
mechanism by which EP4 activation induces apoptosis of cancer cells that in-
volved inhibiting HSP90 function.
#2318 Cyclopamine sensitizes endoplasmic reticulum stress-mediated in-
crease of death receptor 5 and survivin degradation in trail-resistant gastric
cancer cells. Yoo Jin Na, Dae-Hee Lee, Jung Lim Kim, Bo Ram Kim, Seong Hye
Park,Min Jee Jo, YoonA Jeong, Sang Cheul Oh.Korea University, Seoul, Repub-
lic of Korea.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has
been known as one of the most effective cancer treatment owing to its selective
killing effect of cancer but not normal cells. However it has been reported that
several gastric cancer cells showed resistance to TRAIL because of scarcity of
death receptor 5 (DR5) expressed on the cell surface. In this study, we elucidated
cyclopamine sensitizes to TRAIL-induced apoptosis by elevating the expression
level of DR5 in gastric cancer cells. Interestingly, survivin hampers existence of
DR5 protein under normal condition. Cyclopamine decreases expression level
of survivin. It is a reason for cyclopamine to act as a TRAIL sensitizer. Mecha-
nistically, cyclopamine induces endoplasmic reticulum (ER) stress by Reactive
Oxygen species (ROS), and CHOP, which as a last protein of ER stress pathway
regulates stability of survivin protein by proteasome degradation. Taken to-
gether, our results indicate that cyclopamine can be used for the purpose of
combination therapy in TRAIL-resistant gastric cancer cells.
#2319 Defıciency of protease-activated receptor 2 signaling sensitizes
EGFR-TKI-induced apoptosis in colorectal cancer. Weiwei Li, Yiming Ma,
Longmei He, Hongying Wang. State Key Laboratory of Molecular Oncology,
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences
and Peking Union Medical College, Beijing, China.
Colorectal carcinoma (CRC) patients show resistance to EGFR-TKI (epider-
mal growth factor receptor -tyrosine kinase inhibitor) treatment. Protease-acti-
vated receptor 2 (PAR2) has been shown to transactivate EGFR. We aim to
investigate whether PAR2 sensitizes EGFR-TKI-induced apoptosis in CRC.
Firstly, inhibition of PAR2with shRNAorENMD-1068 (a selective antagonist of
PAR2) signifıcantly sensitized EGFR-TKI (gefıtinib or AG1478)-induced apo-
ptosis, which was measured with Annexin V/ PI staining and activation of
caspase-3 in different CRC cell lines. In xenograft tumor model, gefıtinib treat-
ment dramatically reduced the tumor volume inHT-29-shPAR2 comparedwith
HT-29-vector. Mechanism study showed that PAR2 knockdown signifıcantly
reduced bcl-xL expression at both mRNA and protein level. Consistently, acti-
vation of PAR2 upregulated bcl-xL. Furthermore, inhibition of protein phospha-
tase (PP) with okadaic acid signifıcantly downregulated bcl-xL. Moreover,
knockdown of PP1 with siRNA blocked PAR2-induced accumulation of bcl-xL.
In summary, our fındings suggest that inhibition of PAR2 sensitizes EGFR-TKI-
induced apoptosis via downregulation of bcl-xL in colorectal cancer. Consider-
ing the extensive expression of PAR2 and PAR2-activating proteases in colon, it
strongly indicates that inhibition of PAR2 may be a potential avenue to over-
come EGFR-TKI resistance in patients with CRC.
#2320 CucurbitacinD induces cell cycle arrest and apoptosis by inhibiting
STAT3 and NF-B signaling in doxorubicin-resistant human breast carci-
noma (MCF7/ADR) cells. Jin Mo Ku, Se Hyang Hong, Myeong-Sun Kim, Hyo
In Kim, Soo-Yeon Kang, Kangwook Lee, Yu-Jeong Choi, Chunhoo Cheon, CH-
ING WEN HUANG, Youme Ko, Yui Sasaki, Sohyeon Kang, Ji Hye Kim, Hye
Sook Seo, Tai Young Kim, Yong Cheol Shin, Seong-Gyu Ko.Kyung Hee Univer-
sity, Seoul, Republic of Korea.
Objective: We examined whether cucurbitacin D affects doxorubicin resis-
tance of MCF7/ADR breast cancer cells. Methods: Cell viability was measured
by MTT assay. Levels of p-STAT3, p-NF-B, IB, and caspases were measured
by western blot analysis. Nuclear staining of Stat3 and NF-B was measured by
immunocytochemistry. STAT3 andNF-B transcriptional activity was detected
by STAT3 andNF-B luciferase reporter gene assays. Analysis of cell cycle arrest
was performed by flow cytometry. Induction of apoptosis by cucurbitacinDwas
measured by annexin VFITC/PI assay. Results: More than 90% of MCF7/ADR
cells lived upon treatment with doxorubicin for 24 h. However, upon treatment
with cucurbitacin D, cell death was more than 60%. Co-administration of cu-
curbitacin D and doxorubicin induced apoptosis, G2/M cell cycle arrest, and
inhibited upregulated Stat3 by doxorubicin on MCF7/ADR cells. Additionally,
cucurbitacin D led to an increase in the IB level in the cytosol and a decrease
in the p-NF-B level in the nucleus. Finally, cucurbitacin D inhibited transloca-
tion of Stat3 and NF-B and decreased transcriptional activity in the nucleus.
Conclusion: Cucurbitacin D decreases cell proliferation and induces apoptosis
by inhibiting Stat3 and NF-B signaling in doxorubicin-resistant breast cancer
cells. Cucurbitacin D could be used as a useful compound to treat Adriamycin-
resistant patients.
#2321 Reactive oxygen species dictate the apoptotic response of mela-
noma cells to TH588. jiayu wang, Jin Lei, Xu Guang yan, Simonne Sherwin,
Margaret Farrelly, Yuan Yuan Zhang, Fen Liu, Chun YanWang, Su Tang Guo,
Hamed Yari, Ting La, Jennifer McFarlane, Fu Xi Lei, Hessam Tabatabaee, Jie
Zhong chen, Amanda Croft, chen chen Jiang, Xu Dong Zhang. life sciences
building, Newcastle, Australia.
Cancer cells commonly contain elevated levels of reactive oxygen species
(ROS) resulting from oncogenic stimulation. On one hand, ROS promote
cancer cell survival, proliferation, andmetastasis. On the other, high levels of
ROS suppress tumour growth through inhibition of proliferation and induc-
tion of apoptosis and senescence via damage to DNA. Incorporation of oxi-
dized dNTPs such as 8-oxo-deoxy-guanine (8-oxo-dGTP) and 2-OH-deoxy-
adenosine (2-OH-dATP) into genomic DNA plays an important role in
apoptosis induced by ROS. Human MutT homolog 1(MTH1) is an enzyme
that sanitizes oxidized dNTP pools through converting 8-oxo-dGTP and
2-OH-dATP intomonophosphates, thus preventing their incorporation into
genomic DNA. Inhibition of MTH1 by small molecule inhibitors has been
suggested to be a promising approach in cancer treatment. However, we have
found that while silencing of MTH1 does not affect survival of melanoma
cell, TH588, one of the fırst-in-class MTH1 inhibitors, kills melanoma cells
through apoptosis independently of its inhibitory effect on MTH1. Induc-
tion of apoptosis by TH588 was not alleviated by MTH1 overexpression or
introduction of the bacterial homologue of MTH1 that has 8-oxodGTPase
activity but cannot be inhibited by TH588, indicating that MTH1 inhibition
is not the cause of TH588-induced killing of melanoma cells. Although
knockdown of MTH1 did not impinge on the viability of melanoma cells, it
rendered melanoma cells sensitive to apoptosis induced by the oxidative
stress inducer elesclomol. Of note, treatment with elesclomol also enhanced
TH588-induced apoptosis, whereas a ROS scavenger or an antioxidant at-
tenuated apoptosis triggered by TH588. Indeed, the sensitivity of melanoma
cells to TH588 was correlated with endogenous levels of ROS. Collectively,
these results suggest that: 1) TH588-induced apoptosis of melanoma cells is
not associated with its inhibitory effect onMTH1; 2) TH588 remains a prom-
ising candidate for the treatment of melanoma; 3) MTH1 inhibition in com-
bination with oxidative stress inducers may be a useful approach in mela-
noma treatment; and 4) the endogenous levels of ROS are a potential
biomarker for prediction of the response of melanomas to TH588 andMTH1
inhibition in combination with oxidative stress inducers.
#2322 Antitumor activity of spicatoside A, a steroidal saponin, via induc-
tion of switch from autophagy to apoptotic cell death.WonKyungKim, Yuna
Pyee, Hyen Joo Park, Ji-YoungHong, Sang Kook Lee. Seoul National University,
Seoul, Republic of Korea.
The antitumor activity of spicatoside A (SA), a steroidal saponin isolated
from the tuber of Liriope platyphylla (Liliaceae), and its underlying mecha-
nisms were investigated in HCT116 human colorectal cancer cells. SA in-
duced autophagy and apoptotic cell death and inhibited tumor growth in a
nude mouse xenograft model implanted with HCT116 cells. Treatment with
SA for 24 h enhanced the formation of acidic vesicular organelles in the
cytoplasm, indicating the induction of the onset of autophagy. This event
was associated with the regulation of autophagic markers including micro-
tubule-associated protein 1 light chain 3 (LC3)-II, p62, beclin 1, lysosomal-
associatedmembrane protein 1, and cathepsin D by inhibiting the PI3K/Akt/
mTOR signaling pathway, regulating mitogen-activated protein kinase
signaling, and increasing p53 levels. However, a prolonged exposure to SA
resulted in apoptosis characterized by the accumulation of a sub-G1 cell
population and an annexin V/propidium iodide-positive cell population.
Apoptosis induced by SA was associated with the regulation of apoptotic
proteins including Bcl-2, Bax, and Bid, the release of cytochrome c into the
cytosol, and the accumulation of cleaved poly ADP-ribose polymerase
(PARP). Further study revealed that cleavage of beclin 1 by caspase-8 plays a
critical role in the SA-mediated switch from autophagy to apoptosis. Taken
together, these fındings highlight the signifıcance of SA in the modulation of
crosstalk between autophagy and apoptosis, as well as the potential use of SA
as a novel candidate in the treatment of human colorectal cancer cells. Ac-
knowledgement: This work was supported by a National Research Founda-
tion of Korea (NRF) grant funded by the Korean Government (MEST) (No.
2009-0083533).
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#2323 The inhibitory role of Kaempferol-3-O-rutinoside induced AMPK
activation on the growth of human breast cancer cell lines. Chea Ha Kim.
Hallym UNIV., Chuncheon, Republic of Korea.
Solidago virga-aurea, herbaceous perennial plant of the familyAsteraceae, has
astringent, diuretic, and antiseptic assets. In our current study, we found that
kaempferol-3-O-rutinoside (KR) from Solidago virga-aurea extract prompted
cellular apoptosis in breast cancer cells. The present study was conducted to
investigate its effects on MCF-7 cells with respect to the induction of inhibitory
effect on cell viability againstMDA-MB-231 andMCF-7 breast cancer cell lines.
In addition, apoptotic protein, especially Bim, was also increased in KR treated
MDA-MB-231 andMCF-7 cell line.However, an anti-apoptotic protein, Bcl-xL,
was not changed by KR. To fınd out positive regulator of Bim expression, FOXO
(forkhead-box transcription factor, group O) 3a and AMPK (5= AMP-activated
protein kinase) protein expressions were examined in KR treated cells. Immu-
noblot analysis showed dramatically increased expressions of FOXO3a and
AMPK in KR treated MDA-MB-231 and MCF-7 cells. In addition, cell cycle
analysis indicated that G0/G1 arrest was intensely increased in KR treated
MDA-MB-231 andMCF-7 cells.Moreover, phospho-AMPK (pT172) andphos-
pho-FOXO3a (S472) expression were also increased in KR treated MDA-MB-
231 and MCF-7 cells. Our results suggest that KR induces apoptosis by AMPK-
FOXO3a mediated Bim expression. The mechanisms of KR mediated AMPK
and FOXO3a regulation is not fully elucidated yet, but further studies about
these molecular mechanisms between two proteins will give some ideas for can-
cer therapies for certain breast cancer patients.
#2324 The role of SERCApump in cell death and autophagy. Paula Szalai,1
Morten Luhr,1 Frank Sætre,1 Søren B. Christensen,2 Jesper V. Møller,3 Poul
Nissen,3 Nikolai Engedal1. 1University of Oslo, Oslo, Norway; 2University of Co-
penhagen, Kopenhagen, Denmark; 3University of Aarhus, Aarhus, Denmark.
The purpose of the study is to elucidate structural and molecular determi-
nants of SERCA inhibition by Thapsigargin (Tg) and related analogs for their
effects on intracellular calciumhomeostasis, ER stress, cell death and autophagy.
Tg specifıcally binds and blocks the sarco/endoplasmic reticulumCa2ATPase
(SERCA), which pumps Ca2 from the cytosol to the ER. Sustained SERCA
inhibition leads to calcium depletion from the ER causing ER stress and ulti-
mately cell death. Recently we showed that Tg-induced calcium perturbation
potently blocks autophagy (1). Tg is an attractive potential anti-tumor drug
because it effectively kills both slow and fast proliferating cancer cells. However,
since Tg is toxic also to normal cells, it must be targeted towards the cancer cells.
Replacing a side chain with a linker connecting the Tg core to a peptide prevents
Tg from entering cells. Two different linker-peptide sequences have been intro-
duced in clinically tested Tg prodrugs; one is cleaved by PSA, secreted by pros-
tate cancer cells, and the other is cleaved by PSMA, which is secreted by neovas-
cular tissues of a broad range of tumors. The Tg analogs unmasked by the
cleavage are able to enter cells and exert their toxic effects. Interestingly, how-
ever, in vitro experiments indicate that Tg analogs have different potencies and
cellular effects depending on the terminal amino acid residue (2). Exploringwhy
this is the case may lead not only to better Tg prodrug formulations, but also to
a deeper understanding of the biological functions of SERCA pump activity.We
compare a broad panel of Tg analogs in various cell types for their biological
effects. Methods used so far are western blotting, real-time RT-PCR, live-cell
imaging, flow cytometry, and assays that measure autophagic sequestration and
degradation activity. Our unpublished data indicate the ER-stress sensors
PERK, ATF4, CHOP, and IRE1 but not XBP1 and ATF6 to be involved in cell
death signaling in LNCaPprostate cancer cells.Moreover, Tg-induced cell death
required death receptor 5 and caspase-8. All Tg analogs tested displayed exactly
the same molecular requirements for induction of cell death, although some
required 5 to 10 times higher doses than Tg to evoke the same strength of death
signal. Like Tg (1) the analogs inhibited autophagy before the closure of phago-
phores, but at higher doses and/or with slower kinetics. These results indicate
that thapsigargin and its analogs evoke similar anti-autophagic and death sig-
naling pathways. Further investigations are aimed at exploring the causes for
differential potencies, and includemeasurements of cytosolic and compartmen-
talized calcium, as well as solving crystal structures of selected analog:SERCA
complexes complemented with biophysical studies of analog:SERCA interac-
tions. References 1. N. Engedal et al., Autophagy 9, 1475 (2013). 2. C. Dubois et
al., Febs j 280, 5430 (2013).
#2325 Destruction of circulating tumor cells by fluid shear stresses gener-
ated in a microfluidic system. Sagar Regmi,1 Afu Fu,1 Sierin Lim,1 Kathy Qian
Luo2. 1Nanyang Technological University, Singapore, Singapore; 2University of
Macau, Taipa, Macau, China, Macao.
Circulating tumor cells (CTCs) are mainly responsible for the cause of cancer
metastasis. Although most CTCs can be destroyed by the bloodstream, some of
them can still manage to withstand hemodynamic shear stress in blood stream.
To study the effects of fluidic micro-environment on CTCs, we designed a mi-
crofluidic system that can produce various levels of shear stress which can be
generated in human artery under resting or exercise condition. We also gener-
ated three human breast cancer cell lines with increased ability to form lung
metastases in nude mice (i.e. 213-M1A231-M1231-C3). All three cell lines
can produce a fluorescence resonance energy transfer (FRET)-based sensor
which can reveal apoptosis in real-time by changing its color from green to blue.
Besides these, we also investigated the effects of shear stress onmultiple types of
cancer cells including lung cancer (A549), ovarian cancer (2008), breast cancer
(UACC-893) and leukemia (K562). For all the cell lines, except the non-attached
K562 cells, cells were cultured on petri-dishes, detached by trypsinization and
re-suspended in a normal culturemedium to a cell density of 2x105 cells/ml.One
milliliter of this cell suspensionswas circulated in ourmicrofluidic systemunder
the shear stresses of 15, 30, 45 and 60 dyne/cm2 for 2-18 h. The effects of shear
stress on morphology and viability of CTCs were determined by FRET imaging
microscopy and MTT assay. And the impact of shear stress on causing necrosis
in CTCs were examined by propidium iodide (PI) staining and LDH assay. Our
fındings are summarized below: 1)High shear stress (SS60, 4 h) ismore potent to
destroy CTCs than low shear stress (SS15, 4 h). 2) High shear stress can destroy
most of the CTCs via necrosis. 3) This high level of shear stress is theoretically
achievable via physical exercise. 4) Highly metastatic 231-M1A cells are more
resistant to high shear stress compared to less metastatic 231-C3 cells. 5) Leuke-
mia K562 cells representing the white blood cells showed stronger resistance to
high shear stress compared to the cancer cells tested in this study.We think these
fındings can help people to understand howmetastatic CTCs resist shear force-
induced cell death which are useful for designing more effective therapies
against metastatic CTCs. Additionally, the fınding that high shear stress is more
effective to kill CTCsmay inspire cancer patients to consider exercise as a way to
increase their hemodynamic shear stress, consequently destroy CTCs and pre-
vent cancer metastasis.
#2326 A high-throughput screen identifıed cancer selective small mole-
cules that kill independent of mitochondrial apoptosis. Catriona M. Dowl-
ing,1 Micheal Hemann,2 James Bradner,3 Anthony Letai,4 Triona Ni Chong-
haile1. 1Royal College of Surgeons, Dublin, Ireland; 2Koch Institute for Integrative
Cancer Research at MIT, Massachusetts Institute of Technology, MA; 3Dana-
Farber Cancer Institute, HarvardMedical School, Department of Medical Oncol-
ogy, MA; 4Dana-Farber Cancer Institute, Boston, MA.
Triple negative breast cancer (TNBC) lacks expression of oestrogen receptor
(ER), progesterone receptor (PR) and human epidermal growth factor 2
(HER2). Importantly, there have been fewer advances in the treatment of TNBC
with the mainstay of treatment being cytotoxic chemotherapy. All too often
though tumor responds poorly to chemotherapy, or relapse and resistance fol-
low an initial response. We previously found in a range of hematological and
solid tumors that chemoresistant cancers are far from the mitochondrial apo-
ptotic threshold. To identify novel therapeutics for the treatment of chemore-
sistant breast cancer, we performed a high-throughput screen to identify small
molecules that are cancer selective but can kill independent of themitochondrial
pathway of apoptosis. To perform this screenwe usedTNBC lineMDA-MB-231
in which the pro-death proteins BAX/BAK were knocked down. BAX/BAK are
essential for mitochondrial apoptosis. To enrich for compounds that were not
non-specifıcally toxic, we simultaneously counter-screened against the non-
transformed breast epithelial cell line MCF10a. We screened a total of 30,000
compounds in duplicate across the two cell lines. There was a hit rate of 0.3% in
the screen and 85 compounds were retested in the validation cherry pick screen.
From the cherry pick screen 18 compounds were further validated with low-
throughput assessment formitochondrial independent killing and selectivity for
cancer cells. To identify themechanism of action of the lead compound we used
a genetic approach to generate an RNAi signature for the compound. This sig-
nature enables classifıcation of the compound into known or novel class of
compounds. The lead compound signature was most like that of histone
deacetylase inhibitors (HDAC). Using an in vitro HDAC inhibitor screen, we
identifıed that the compound selectively inhibited HDAC6. Importantly, we
validated that the lead compound caused an increase in acetylated tubulin in
cells, a target of HDAC6. In conclusion, we have identifıed a novel HDAC6
specifıc inhibitor that selectively kills cancer cells independent of mitochondrial
apoptosis.
#2327 Apoptosis ofmelanoma inducedbynon-thermal atmospheric pres-
sure bio-compatible plasma activated media. Ihn Han, Ying Li, Eun Ha Choi.
Kwangwoon University, Seoul, Republic of Korea.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Apoptosis and Other Regulated Cell Death in Cancer
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 595
Melanoma is the most dangerous type of skin cancer, which mostly related
with the exposure of ultraviolet (UV), and especially happened to those who
have low skin pigment levels. Epidemiological studies showed Europeans and
NorthAmericans have a high incidence ofmelanoma, while it is less common in
Asia and Africa. Therefore, the new and more effective methods to treat mela-
noma are still necessarily needed. Non-thermal atmospheric pressure bio-com-
patible plasma (NBP) is defıned as a partially ionized gas with electrically
charged particle, which has been reported have cytotoxicity on various cancer
cells induce DNA damage and apoptosis other than normal cells. Reactive oxy-
gen and/or nitrogen species (RONS) were proved to play the most important
role during this process, by inducing oxidative stress and depolarization of mi-
tochondria membrane potential with the consequence of various cancer cells
apoptosis. The plasma activatedmedia (PAM), which themedia treated directly
by NBP with different time, containing mostly long-live secondary species such
as hydrogen peroxide (H2O2) which have been confırmed anti-microorganism
and cytotoxic activity. Researches already investigated that PAMalso effective in
cancer therapy via inducing apoptosis. However, the underlying molecular
mechanisms of apoptosis are remaining elusive. The purpose of this studywas to
evaluate the potential of PAM as an effective tool to induce apoptosis in mela-
noma cells. Our results showed that PAM has a killing effect to melanoma cells
in a time-dependent manner, for 3minutes treatment could induce almost 40%
cells entry death, after treated by 5 minutes more than 60%, and 10 minutes
treatment reduced the cell viability to approximately 30%. Annexin-V/PI stain-
ing demonstrated that PAM kills these cells via apoptosis pathway. We also
found that with a manner of treatment time PAM signifıcantly increased the
concentration of intracellular NO andH2O2, reflecting an influx of extracellular
RONS may result in melanoma cells apoptosis. Besides, western blot assay
showed that P53 and caspase 3 increased after PAM treatment. Taken together,
PAM is effective to induce the apoptosis in melanoma cells in vitro, further in
vivo experiments will be performed to investigate the functional effects in the
animals.
#2328 Race specifıc hyper-activation of CCR9-mediated survival signals
and its impact on effıcacy of docetaxel in prostate cancer.Neeraj Kapur,1Hina
Mir,1Guru Sonpavde,2 Shailesh Singh1. 1Morehouse School ofMedicine, Atlanta,
GA; 2UAB Comprehensive Cancer Center, Birmingham, AL.
Current approaches to treat and manage prostate cancer (PCa) have failed to
reduce racial disparity primarily due to undefıned molecular mechanism. We
have shown higher expression of chemokine receptor-9 in PCa cells and CCR9
expression was higher in PCa cells (MDA-PCa-2b) derived fromAfrican Amer-
ican (AA) patient compared to PCa cells derived formEuropeanAmerican (EA)
patients (LNCaP and PC3). Using antibody microarray we observed hyper acti-
vation of survival molecules and down-regulation of apoptotic molecules in AA
PCa cells compared to EA PCa cell lines, following CCL25 stimulation. Com-
parative heatmap analysis showed signifıcant increase (2-3 fold) in phosphor-
ylation of pro-survival proteins in AA cells compared to EA cells treated with
CCL25, which was further confırmed by western blot analysis. Furthermore,
CCL25 treated PCa cells showed decreased expression of pro-apoptotic proteins
(Bim, Bid, Bak), which was signifıcantly abrogated by CCR9 shRNA. This effect
was more pronounced in AA cells compared to EA cells. Effıcacy of docetaxel
(DTX) was higher after CCR9 blockade in presence of CCL25 compared to cells
treated with CCL25 without blocking CCR9. Improvement in effıcacy of DTX
was due to inhibition of cell survival and activation of pro-apoptotic signals
following CCR9 blockade. These observations suggest potential involvement of
CCR9 mediated molecular pathways in disparity associated with outcome of
PCa.
#2329 TMEM33 induces apoptosis via UPR signaling and autophagy in
breast cancer cells. Rong Hu, Xiyuan Zhang, Leena Hilakivi-Clarke, Usha
Kasid, Robert Clarke.Georgetown Lombardi Comp. Cancer Center,Washington,
DC.
TMEM33 is a novel transmembrane protein that resides in the endoplasmic
reticulum (EnR). It has been shown to activate the PERK and IRE1 branches of
the unfolded protein response (UPR). However, the underlying mechanism of
action of this EnR resident protein TMEM33 and the cellular functions that it
regulates remain largely unknown. In this study, we show that overexpression of
TMEM33 induces robust cell death in breast cancer cells. Inhibition of the
PERK/eIF2alpha pathway with eIF2alpha inhibitor ISRIB blocks the TMEM33
induced cell death. TMEM33 overexpression strongly activates UPR associated
pro-death JNK-p53 signaling. We also observed a signifıcant inhibition of the
downstream survivin, which blocks cell death activation by binding to caspases
and inhibiting their activation. We further show that the blockage of JNK acti-
vation with either an inhibitor or overexpression of survivin, protects cells
against TMEM33 induced apoptosis. In addition, we show that TMEM33 over-
expression induces autophagy in breast cancer cells. Inhibition of autophagy
with using either the inhibitor chloroquine or knockdown of the Atg5 gene,
further sensitizes breast cancer cells to the effects of TMEM33 overexpression.
Cell death induced by TMEM33 is also decreased by overexpression of the au-
tophagy gene Beclin 1. The fındings in this study demonstrate that the novel EnR
resident protein TMEM33 induces cell death by activating IRE1-JNK-p53-
survivin signaling in breast cancer cells. Concurrently, autophagy is also acti-
vated by TMEM33, and functions as a pro-survival mechanism. Cell fate reflects
the balance between the pro-death and pro-survival activities as regulated by
TMEM33.
#2330 BI5: a novel SMAC mimetic that triggers tumor cell death and
potentiatesPD-1mediated cancer therapy.MarkusReschke,MariaAntonietta
Impagnatiello, Ulrich Reiser, Dirk Scharn, Walter Spevak, Alexander
Savchenko, Andreas Wernitznig, Martina Sykora, Rebecca Langlois, Elisabeth
Zier, Daniel Zach, Sabine Kallenda, Pilar Garin-Chesa, Jens Quant, Mark Pear-
son, Darryl McConnell, Norbert Kraut, Juergen Moll. Boehringer Ingelheim,
Vienna, Austria.
Background: Inhibitors of apoptosis proteins (IAPs) regulate cellular apopto-
sis by interfering with the proteolytic activities of caspases. IAP inhibitors
(SMAC mimetics) have been developed to restore the defective apoptosis that
characterizesmany tumour cells. Emerging evidence demonstrates that IAPs are
critical components of immune-modulatory pathways that control innate and
adaptive immunity. Accordingly, SMAC mimetics hold the promise of both
inducing tumour cell killing and stimulating the immune system to recognize
and eliminate dying tumour cells. Here we show that BI5 primes immune com-
ponents and synergises with PD-1 checkpoint inhibitors to promote eradication
of syngeneic tumors. Methods: Here we report the effıcacy and modulation of
the immune response by a potent and selective SMAC mimetic, BI5. We char-
acterised the effect of BI5 on tumor growth inhibition as a single agent and in
combination with an anti-PD-1 antibody in syngeneic mouse tumor models. A
detailed 17-colour multi-color flow cytometry analysis was used to investigate
the mechanisms by which the SMACmimetic interacts with anti-PD-1 therapy
in vivo. Results: Treatment of the syngeneic mouse tumor models MBT-2 and
EMT-6 with the SMAC mimetic in combination with an anti-PD-1 antibody
results in remarkable tumor regressions in vivo. Importantly, the combined
effect of the SMACmimetic and anti-PD-1 on tumor growth was dependent on
the adaptive immune system in vivo.Mechanistic studies show that degradation
of IAP triggers tumor cell death, which leads to a potent activation of dendritic
cells in the draining lymph nodes and a subsequent influx of T andNK cells into
the tumor microenvironment. Interestingly, in the presence of the SMAC mi-
metic alone, an induction of PD-1 expression on tumor-infıltrating CD8 T
cells was observed, which in turn resulted in the exhaustion of these cells and
tumor outgrowth. In the presence of the anti-PD-1 antibody, T cells are reacti-
vated leading to potent and long term tumor eradication. Conclusion:We show
that our SMACmimetic leads to a potent induction of immunogenic cell death
and sets up a “virtuous cycle” by potentiating dendritic cell and T cell mediated
immune responses that further promote induction of cell death. These effects
are potentiated by checkpoint inhibitors, leading to long term tumor control.
Tumours with minimal T-cell infıltration are poorly responsive to PD-1 mono-
therapy. These studies indicate that SMAC mimetics, such as BI5, represent
promising and tolerated combination partners for checkpoint inhibitors in pa-
tients that lack a strong immune inflammatory signature.
#2331 FAM3B/PANDER inhibits cell death and increases tumor growth
bymodulating the expression of Bcl-2 and Bcl-XL cell survival genes. Izabela
Caldeira,1 Paula Maciel-Silva,1 Flavia Ramos Siqueira,1 Anna Carla Goldberg,2
Viviane Abreu Nunes,1 Jose Ernesto Belizario,1 Humberto Miguel Garay-Mal-
partida1. 1University of Sao Paulo, São Paulo, Brazil; 2Hospital Israelita Albert
Einstein, São Paulo, Brazil.
FAM3B/PANDER is a novel cytokine-like protein that induces apoptosis in
insulin-secreting beta-cells. Since in silico data revealed that FAM3B can be
expressed by prostate and breast tumors, we evaluated the putative role of this
cytokine in prostate and breast tumor progression. The FAM3B expression was
compared by quantitative PCR in LnCAP, PC-3 and DU145 prostate tumor cell
lines andMCF-7, ZR-75 andMDA-MB-231 breast tumor cell lines. After treat-
ment with either recombinant FAM3B protein or secreted FAM3B obtained
from conditionedmedia (CM) derived fromFAM3B-overexpressing 293T cells,
the cell death and viability of DU145 and MDA-MB-231 cell lines were evalu-
ated. DU145 andMDA-MB-231 cells overexpressing FAM3B protein were pro-
duced by lentiviral-mediated transduction of full-length FAM3B cDNA. Cell
viability and apoptosis were analyzed in DU145-FAM3B and MDA-231-
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FAM3B cells after treatment with several cell death inducers. Anchorage-inde-
pendent growth and scratch wound assays were used to evaluate in vitro tumor-
igenicity and cell migration, respectively. In vivo tumorigenicity and
invasiveness were evaluated by tumor xenograft growth in nude mice. We ob-
served that FAM3B was highly expressed by hormone responsive cells (LnCAP
and MCF-7) and low expressed in unresponsive hormone cells (PC-3, DU145
and MDA-MB-231). Cell viability and survival of DU145 and MDA-MB-231
cells increased after exogenous treatment with recombinant FAM3B protein or
CM containing FAM3B-secreted protein. Overexpression of FAM3B in DU145
andMDA-MB-231 cells promoted an inhibition of apoptosis triggered by TNF-
alpha, staurosporine and serum-deprived conditions. Cell death inhibition was
accompanied by increased gene expression of the anti-apoptotic Bcl-2 and
Bcl-xL genes, and by slight decrease in expression of pro-apoptotic gene Bax and
diminished caspases-3, -8 and -9 proteolytic activities. When compared to con-
trol, cells overexpressing FAM3B displayed a decreased anchorage independent
growth and increased motility in vitro, as well as an increased tumor growth in
xenografted nudemice. The immunohistochemistry analysis from tumor xeno-
grafts revealed similar anti-apoptotic phenotype displayed by FAM3B-overex-
pressing tumor cells. Taken together, by activating pro-survival mechanisms,
FAM3B overexpression contribute to increased cell death resistance and tumor
growth in nude mice, highlighting a putative role for this cytokine in prostate
and breast cancer progression.
#2332 Integral modulation of nuclear factor-kappa B activation by
C/EBP and the endoplasmic reticulum stress sensor PERK to mediate es-
trogen-induced apoptosis in estrogen-deprived breast cancer cells.Ping Fan,1
Amit K. Tyagi,1 Fadeke A. Agboke,2 Niranjana Pokharel,1 V. Craig Jordan1.
1University of Texas MD Anderson Cancer Center, Houston, TX; 2Georgetown
University, Washington, DC.
Stress responses are critical for estrogen (E2) to induce apoptosis in E2-de-
prived breast cancer cells. Nuclear factor-kappa B (NF-B) is well known as a
therapeutic target to prevent stress responses in chronic inflammatory diseases
including cancer. However, whether E2 activates NF-B to participate in stress-
associated apoptosis in E2-deprived breast cancer cells is unclear. We demon-
strated that E2 differentially modulates NF-B activity in E2-deprived breast
cancer cells according to the treatment time. Because E2 initially has signifıcant
potential to down modulate the NF-B activation, it completely suppresses the
tumor necrosis factor alpha (TNF)-induced NF-B activation. We found that
E2 preferentially and constantly enhances the expression of transcription factor
CCAAT/enhancer binding protein beta (C/EBP) which is responsible for sup-
pression of NF-B activation by E2 in MCF-7:5C cells. The mTOR signaling
pathway promotes repression of NF-B by C/EBP which is confırmed by the
evidence that inhibition of mTOR is synergistic with E2 to upregulate NF-B-
dependent genes, such as TNF. Interestingly, NF-B p65 activity is upregu-
lated when E2-treatment is administered for 48 hours, leading to induction of
TNF. Blocking the nuclear translocation of NF-B completely prevents E2
from induction of TNF and apoptosis. Importantly, protein kinase RNA-like
endoplasmic reticulum kinase (PERK), a stress sensor of unfolded protein re-
sponse, is activated by E2 and plays an essential role in increasing NF-B p65
DNA binding through the activation of STAT3, independently of canonical
IB signal pathway. Thus, inhibition of PERKkinase activity completely blocks
nuclear activation of NF-B andNF-B-dependent induction of TNF, thereby
preventing E2-induced apoptosis. All of these fındings illustrate a crucial role for
the novel PERK/NF-B/TNF axis in E2-induced apoptosis which is integrally
modulated by the stress responsive transcription factor C/EBP and endoplas-
mic reticulum stress. This study provides an important rationale for exercising
caution in clinical trials when considering targeting PERK or NF-B following
the development of acquired resistance to aromatase inhibitors whereas mTOR
may be a target to enhance the therapeutic effects of E2 in antihormone resistant
breast cancer.
#2333 Modulation of Bax and mTOR for cancer therapeutics. Rui Li,1
Chunyong Ding,2 Jun Zhang,1 Maohua Xie,1 Dongkyoo Park,1 Ye Ding,3 Guo
Chen,1Guojing Zhang,1MelissaGilbert-Ross,1Wei Zhou,1 AdamMarcus,1 Shi-
Yong Sun,1 Zhuo Chen,1 Gabriel Sica,1 Suresh Ramalingam,1 Andrew Magis,4
Haian Fu,1 FadloKhuri,1Walter Curran,1 TaofeekOwonikoko,1Dong Shin,1 Jia
Zhou,2 Xingming Deng1. 1Emory Univ., Atlanta, GA; 2University of Texas Med-
ical Branch, Galveston, TX; 3University of Texas Medical Branch, Atlanta, TX;
4Institute for Systems Biology, Seattle, WA.
Pharmacologic manipulation of the serine (S)184 phosphorylation site of Bax
protein to functionally regulate its proapoptotic activity is an attractive antican-
cer strategy. We recently identifıed three small molecule Bax agonists. SMBA1
was selected as the lead compound based on its chemical structure and its drug-
like properties, from which a more effective analog, CYD-2-11, was generated.
CYD-2-11 targets the structural pocket around S184 in the C-terminal tail of
Bax, directly activating its proapoptotic activity via 6A7 conformational change
and formation of Bax homo-oligomers in mitochondrial membranes. CYD-
2-11 suppresses tumor growth in SCLC, NSCLC and patient-derived lung can-
cer xenografts as well as the genetically engineered mutant KRAS-driven lung
cancer model with no signifıcant normal tissue toxicity. Inhibition of mTOR by
RAD001 enhances S184Bax phosphorylation in lung cancer cell lines and tumor
tissues from lung cancer patients treated with RAD001, which inactivates the
propaoptotic function of Bax, contributing to rapalog-resistance. Combined
CYD-2-11 and RAD001 treatment not only displays strong synergistic activity
against lung cancer but also overcomes rapalog-resistance in vitro and in vivo.
Therefore, a mechanism-driven combination of Bax agonist and mTOR inhib-
itor represents a highly attractive therapeutic strategy to improve lung cancer
patient outcomes.
#2334 Examining the contribution of autophagy to TRAIL resistance in
an in vitro model of circulating breast cancer cells. Julianne D. Twomey,
Baolin Zhang. Food and Drug Administration, Silver Spring, MD.
Circulating tumor cells (CTCs) are cancer cells which dissociate from the
primary tumor and circulate within the peripheral blood, initiatingmetastasis at
a distant location. CTCs present a “non-invasive, liquid biopsy”, making them
attractive targets for the development of cancer biomarkers and therapies. In
order to formmetastases, these cells must undergo a phenotypic shift acquiring
the ability to survive anoikis within the blood stream and evade immune sur-
veillance involving death events mediated by death receptors (DRs) expressed
on the surface of cancer cells. Under physiological conditions, these DRs can be
activated by circulating cytokines such as TNF, Fas ligand, and TNF-related
apoptosis inducing ligand (TRAIL), triggering cell death. In vitro studies have
demonstrated that environmental stress caused by non-adherent suspension
culture conditions, similar to circulation, will increase autophagy in cancer cell
lines aiding anoikis survival. Our lab has previously identifıed a link between
increased autophagic rates and decreased DR surface expression. Based on this
we were interested in determining whether increased autophagy due to non-
adherent conditions caused breast cancer cell lines to decrease death receptor
expression, evading immune surveillance and resisting death-ligand induced
apoptosis. To this end, breast cancer cell (BCC) lineswere cultured inmonolayer
or a non-adherent suspension condition for 7 days. Following 7 days of culture,
death receptor expression and autophagy initiationweremeasured using immu-
noblot and flow cytometry microscopy. BCCs were treated with TRAIL and
analyzed over 24 hours for apoptosis and caspase activation. We found that the
BCC lines decreased total and surface expression of DR5 and total expression of
TNFR1 over the 7 days of suspension condition. The reduced expression of DR5
in suspension cultured BCCs resulted in a delayed response to TRAILmediated
apoptosis, with delayed caspase activation and PARP cleavage compared to
monolayer cultured parental cells. Under suspension condition, autophagy was
initiated by increased LC3-II/ LC3-I turnover and p62 degradation. This initia-
tion of autophagy is potentially due to increased expression of themitochondrial
related proteins BNIP3 and BNIP3L, which have been implicated in anoikis
survival. This work warrants additional studies investigating the therapeutic
potential of targeting CTCs within the blood to limit metastatic spread and
disease progression in breast cancer. Our fındings suggest the potential to sen-
sitize CTCs to anoikis and circulating death ligands through autophagy inhibi-
tion.
#2335 Targeting the DNA repair as well as survival functions of MCL-1
enhances cancer cell killing. Abid Mattoo,1 J Milburn Milburn Jessup,1 Tej K.
Pandita2. 1Inova Schar Cancer Institute, Falls Church, VA; 2The Houston Meth-
odist Research Institute, Houston, TX.
MCL-1 is a a pro-survival BCL2 protein family member which is over-ex-
pressed in drug resistant cancer cells. Our purpose was to assess whetherMCL-1
increases genomic instability along with its anti-apoptotic function in cancer
cells. Depletion ofMCL-1 by treating human small cell lung cancer (SCLC) lines
with immunotoxin sensitizes these cells to increased killing by BH3 mimetic -
Navitoclax (ABT-263) both in vitro and in mice xenograft models. These SCLC
cell lines are resistant to both single agent Immunotoxin or ABT-263. In addi-
tion, inhibition of NANOG or NANOGP8 by lentivrus delivered shRNA de-
pletes MCL-1 in human colorectal cancer cells and sensitizes these cells to in-
creased cell killing by venetaclox (ABT-199). This increased killing depended on
loss ofMCL-1, was caspase-dependent and reversed by re-expression ofMCL-1.
Depletion of MCL-1 in cancer cells , increases cell sensitivity to ionizing radia-
tion (IR) induced death, which was reversed by expression of MCL-1. In re-
sponse to IR, MCL-1 depleted cells showed reduced survival even at radiation
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doses less than 6Gy, however an increase in caspases 3/7 activity was observed at
6 Gy and above, suggesting that apoptosis is activated only when MCL-1 de-
pleted cells are irradiated with higher IR doses. In order to explain the decreased
survival post- irradiation the genomic instability andDNArepair pathwayswere
analyzed in MCL-1 depleted cells. Post-irradiation MCL-1 depleted cells exhib-
ited increased genomic instability as measured by increase in chromosome ab-
errations at different phases of the cell cycle. The increase in aberrations were
signifıcantly higher in G2 and S- phases of the cell cycle suggesting defect in
Homologous recombination repair pathway (HR). Moreover, the MCL-1 de-
pleted cells show decreased gamma-H2AX foci at earlier time points (30 and 90
minutes) post-irradiation indicating defect in DNA Damage response (DDR)
and higher residual foci at 360 minutes, indicating defective DNA repair. These
observations were further confırmed by decreased phosphorylation of ATR sug-
gesting defect inDNADamage response and higher levels of residual 53BP1 and
RIF1 foci inMCL-1 depleted cells , confırmingDNADSB repair by homologous
recombination (HR) was compromised. Consistent with this model, MCL-1
depleted cells exhibited a reduced frequency of IR-induced MRE11, BRCA1,
RPAandRad51 foci formation, decreasedDNAend resection anddecreasedHR
repair in the DR-GFP DSB repair model. Similarly, after Hydoxyurea (HU)
induction of stalled replication forks in MCL-1 depleted cells there was a de-
creased ability to subsequently restart DNA synthesis, which is normally depen-
dent uponHRmediated resolution of collapsed forks. In summary,MCL-1 is an
important therapeutic target in cancer cells and its depletion increases cell kill-
ing by either increase in apoptosis or suppression of HR and increased replica-
tion stress.
#2336 Novel regulatory mechanisms for Bcl2-related Ovarian Killer
(BOK) expression in breast cancer. Benjamin Chidi Onyeagucha,1 Panneer-
doss Subbarayalu,1 Subapriya Rajamanickam,1 Nourhan Abdelfattah,1 Santosh
Timilsina,1 RosaM.Guzman,2 Carla Zeballos,1 Vijay Eedunuri,1 Sanjay Bansal,1
Hima Bansal,1 Tabrez A. Mohammad,1 Yidong Chen,1 Manjeet K. Rao1. 1Uni-
versity of Texas Health Science Center San Antonio, San Antonio, TX; 2St Mary
Unversity, San Antonio, TX.
Deregulation of apoptosis is central to cancer progression and a major obsta-
cle to effective treatment. The Bcl-2 gene family members play important roles
in the regulation of apoptosis and are frequently altered in cancers. One such
member is Bcl-2-relatedOvarianKiller (BOK), which is a pro-apoptotic protein.
Despite its critical role in apoptosis, the regulation of BOK expression is poorly
understood in cancers. Here, we discovered that miR-296-5p, regulates BOK
expression by binding to its 3=UTR in breast cancers. Furthermore, we show that
depletion of BOK by either miR-296-5p or siRNA against BOK protected breast
cancer cells from undergoing paclitaxel-induced apoptosis. Interestingly, miR-
296-5p also regulates the expression ofMcl-1, which is an anti-apoptotic protein
and is highly expressed in breast cancers. Our results reveal thatMcl-1 is impor-
tant for suppression of BOK function as ectopic BOK expression inducedMcl-1,
while silencing of BOK resulted in reducedMcl-1 levels in breast cancer cells. In
addition, we show that specifıc silencing ofMcl-1 reduced the long-term growth
of breast cancer cells, whereas BOK inhibition didn’t have any effect on the
growth of breast cancer cells. Surprisingly, silencing of both Mcl-1 and BOK
rescued the effect ofMcl-1 silencing on breast cancer cell growth, suggesting that
BOK is important for attenuating cell growth in the absence of Mcl-1, and also
showing a tight feedback regulatory loop between BOK and Mcl-1 in breast
cancer cells. Furthermore, we demonstrated that BOK protein level is regulated
post-translationally by GSK3 and to some extent GSK3 as GSK3 inhibitor
(CHIR99021) or silencing of GSK3 signifıcantly increased BOK protein levels in
breast cancer cells. Notably, we found that Mcl-1 interacts with GSK3/ and
silencing of Mcl-1 using siRNA signifıcantly attenuated endogenous GSK3/
levels in breast cancer cells. Taken together, our results suggest that fıne tuning
(either post-transcriptionally by miR-296-5p or post-translationally by GSK3)
of the levels of pro-apoptotic protein BOK and anti-apoptotic protein Mcl-1
decide the fate of cancer cells to either undergo Apoptosis or proliferation.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: CDKs
and CDK Inhibitors
#2337 miR-6883 and family miRNAs induce G1-arrest in colon cancer
cells by targeting CDK4/6. Amriti R. Lulla, Margret B. Einarson, Yan Zhou,
Michael Slifker, David T. Dicker, Wafık S. El-Deiry. Fox Chase Cancer Ctr.,
Philadelphia, PA.
Dysregulation of the CDK4/6-Rb pathway is a hallmark of various tumor
types. Cancer cells subvert different cell cycle checkpoints to continue un-
checked growth and proliferation. Some common mechanisms of overcoming
cell cycle checkpoints involve loss of tumor-suppressor proteins such as p16
INK4A or Retinoblastoma (Rb). Alternately, cancer cells can also increase ex-
pression of oncogenes like cyclin D1, other CDKs by gene amplifıcation or gene
translocation. Thus, targeting different oncogenes in the cell cycle pathway,
particularly CDKs has been considered an important therapeutic strategy.
Events of overexpression of cell cycle oncogenes and suppression of tumor sup-
pressors are mutually exclusive and tumor-type specifıc. In colorectal cancer
(CRC), it has been shown that there is overexpression ofCDK4/6.We conducted
TCGA analysis of 50 matched tumor and normal CRC tumors, and validated
that CDK4 and CDK6 are signifıcantly overexpressed in patient tumor samples
by RNA-seq (p 1.55 e09 and p 4.439 e05). Thus, ongoing clinical trials for
CRC patients with advanced disease are currently evaluating the effıcacy of
CDK4/6 inhibitors as single agents and in combination with chemotherapy
(JClinOncol 33, 2015 ,suppl 3; abstr 626; Zhang 2016).We evaluated the effıcacy
of miRNAs targeting CDK4/6 as novel therapeutics in CRC. We performed in
silico analysis using TargetScan to identify miRNAs that can target the 3=UTR
regions of CDK4/6.We have identifıed a novel family ofmiRNAs (based on seed
sequence similarity) that can potently target CDK4/6mRNAand thereby reduce
both the RNA and protein levels of CDK4/6 in cancer cells. Of the fourmiRNAs
in the family, we chose to characterize miR-6883-5p and miR-149* in a panel of
CRC, melanoma and pancreatic cancer cell lines. Our preliminary TCGA anal-
ysis in 11 matched T/N samples shows miR-149* expression is signifıcantly lost
(p 0.0049) in CRC samples and this further positively correlates with the stage
of the tumor. Ongoing in vitro studies using miRNA mimics in CRC cell lines
indicate that both miR-6883-5p and miR-149* have anti-proliferative effects as
assayed by CellTiterGlo (CTG) and MTT. Further, both miRNAs induce G1-
arrest as a consequence of downregulation of CDK4 and CDK6 in all cell lines
and we also observe induction of apoptosis in a subset of CRC cell lines. Knock-
down of CDK4 and CDK6 mimics the phenotypes observed with restoring ex-
pression of both miR-6883 and miR-149* in CRC cell lines. Combination of
miR-6883 with FDA-approved drugs Irinotecan and 5-FU showed strong syn-
ergy and led to apoptosis as assayed by CTG and PARP cleavage. Our ongoing
work is further looking into the mechanisms of synergy and identifying addi-
tional target genes in CRC cell lines. Thus, our novel miRNA based strategy to
target CDK4 has potential to translate as both a single agent/combinatorial ther-
apy and to identify biomarkers of response, which is critical for understanding
the clinical results seen with CDK inhibitors.
#2338 CDK4/6 and autophagy inhibitors synergize to induce senescence
in cancers with an intact G1/S checkpoint. Smruthi Vijayaraghavan,1 Cansu
Karakas,1 Xian Chen,1 Iman Doostan,1 Akshara S. Raghavendra,1 Min Yi,1 Ravi
Amaravadi,2 Kelly Hunt,1 Debu Tripathy,1 Khandan Keyomarsi1. 1UT MD An-
derson Cancer Center, Houston, TX; 2U Penn School of Medicine, PA.
Deregulation of the cell cycle machinery is a hallmark of most cancers. The
crucial role of the CDK4/6-CyclinD pathway in tumorigenesis has led to the
successful development and FDA approval (palbociclib) of CDK4/6 inhibitors
for the treatment of advanced estrogen receptor positive breast cancer. How-
ever, two major clinical challenges remain: i) lack of a reliable biomarker to
predict treatment response and ii) adverse events leading to interruption or
discontinuation of treatment which possibly thus curtailing therapeutic benefıt.
We found that treatment of ER breast cancer cell lines with the CDK4/6 in-
hibitor palbociclib resulted in a dose-dependent sustained growth inhibition
and senescence. Interestingly, breast cancer cells activate autophagy in response
to palbociclib, a stress response process that promotes cancer cell survival. Ge-
netic ablation of crucial autophagic genes or pharmacological inhibition of au-
tophagy increases the sensitivity of ER breast cancer cells to palbociclib and
the other CDK4/6 inhibitors, ribociclib and abemaciclib. This was confırmed in
vivo, where the combination of palbociclib and autophagy inhibitor, hydroxy-
chloroquine (HCQ) resulted in a signifıcantly improved and a sustained tumor
shrinkage. To identify biomarkers that predict response to CDK4/6 inhibition,
we examined the G1 checkpoint proteins and found that knockdown of Rb or
overexpression of the oncogenic low molecular weight isoforms of Cyclin-E
(LMW-E) mediates resistance to palbociclib and its combination with au-
tophagy inhibitor. More signifıcantly, immunohistochemically staining of pre-
treatment biopsies from palbociclib treated patients strengthened the correla-
tion between palbociclib effıcacy and an intact G1/S checkpoint (Rbve/
LMWE-ve), resulting in a signifıcantly longer progression free survival com-
pared to the other patient groups; thus solidifying Rb and LMW-E as reliable
prognostic biomarkers for palbociclib treatment. Finally, we examined the bio-
marker driven synergy between CDK4/6 and autophagy inhibition in several
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other cancer cell lines. Several solid tumors (ovarian, lung, pancreatic, colon,
prostate) and triple negative breast cancer (TNBC) cell lines exhibited a syner-
gistic response to palbociclib/HCQ combination treatment dependent upon an
intact G1/S transition (Rb/LMWE-). This was also verifıed in a TNBC patient
derived xenograft (PDX) model. Thus, this study addresses the aforementioned
limitations and provides a novel and promising biomarker-driven combination
therapeutic strategy to treat breast and other solid tumors. We predict that this
combination of CDK4/6 and autophagy inhibitors would be more benefıcial
than standard dose palbociclib in patients, allowing us to lower the dose, mini-
mize palbociclibmediated toxicities and potentially improve overall patient sur-
vival - a goal that has not yet been met with currently approved treatment com-
binations.
#2339 Downregulation of cell cycle genes in HNSCC by erufosine. Shariq
S. Ansari,1 Ashwini K. Sharma,1 Michael Zepp,1 Frank Bergmann,2 Rainer
König,3 Martin R. Berger1. 1The German Cancer Research Center (DKFZ),
Heidelberg, Germany; 2University Clinic Heidelberg, Heidelberg, Germany;
3Leibniz Institute for Natural Products Research and Infection Biology, Jena, Ger-
many.
Head and neck cancer ranks amongst the sixthmost prevalent cancers world-
wide and oral squamous cell carcinomas (OSCC) constitute 90% thereof. Eru-
fosine is an ether-lipid-derived synthetic compound belonging to alkylphospho-
cholines (APCs), which has been shown to inhibit the proliferation of OSCC
cells. It simultaneously induces apoptosis and autophagy by modulating the
Akt-mTOR signaling pathway, however, its exact mechanism of action is not
fully understood. Here, we describe the activity of erufosine on the expression of
cell cycle related genes inOSCC cells. The anti-proliferative effect of erufosine in
cells of two humanOSCC cell lines, HN-5 and SCC-61, was determined byMTT
assay after 24h, 48h and 72h exposure. Based on these results, HN-5 cells were
exposed to erufosine at concentrations corresponding to IC25, IC50 and IC75
concentrations, and then their mRNA was isolated and analyzed by Illumina
Chip array. Gene expressionmodulation was confırmed qRT-PCR andWestern
blot. Gene set enrichment analysis was performed to identify core KEGG (Kyoto
Encyclopedia of Genes and Genomes) pathways and GO (Gene Ontology)
terms. In addition, erufosine’s effect on cell cycle distribution and colony for-
mation was determined as well as its antineoplastic effect on respective xeno-
grafts in nude mice. As shown from TCGA data, cell cycle deregulation in
HNSCC ranks amongst the top three out of 24 different types of cancers. In line
with this, the median expression of cell cycle genes was higher than that of other
geneswithinHNSCC.We also looked at themedian gene expression of all CDKs
and cyclins in 519 HNSCC patient samples from TCGA and found that the
expression levels were higher than the global gene expression. This was in agree-
ment with IHC staining of CCND1 in tumors from 30 South East AsianHNSCC
patients. Furthermore, increased CCND1 and CDK6 expression levels from
TCGA data had negative implication on patient survival. In our experimental
results erufosine caused a dose dependent growth inhibition of OSCC cell lines
and negative enrichment of genes related to the cell cycle process. Our microar-
ray fındings revealed that cyclins and CDKs were downregulated in a dose de-
pendentmanner in response to erufosine exposure. These fındings were verifıed
at both, mRNA and protein levels. Erufosine not only caused a massive G2M
block but also inhibition of colony formation thus preparing the OSCC cells to
undergo apoptosis. We are the fırst to show that erufosine inhibited tumor
growth in vivo in a HNSCC xenograft model and caused downregulation of
cyclinD1, CDK4 and CDK6 in lesions of the animals. These fındings collectively
show the potential of erufosine to be used as a cell cycle inhibitor in HNSCC
progression and support the future evaluation of erufosine as a therapeutic ap-
proach in cancer treatment alone, or in combination.
#2340 Thymidine kinase activity as a response marker for CDK 4/6 inhi-
bition.Geoffrey Shapiro,1 Magnus Neumuller,2 Sara Lööf,3 Smaranda Bacanu,3
Takahiro Seki,4 John Hilton,1 Khan Do,1 Nicole Chau,1 Leena Gandhi,1 Joseph
W. Gibson,1 Robert Distel,1 Pawel Niekrasz,2 Edward M. Suh,2 Mattias
Bergqvist2. 1Dana-Farber Cancer Institute, Boston, MA; 2Biovica International
AB, Uppsala, Sweden; 3Karolinska University Hospital, Stockholm, Sweden;
4Karolinska Institute, Stockholm, Sweden.
Selective CDK4/6 inhibition is now part of standard treatment for HR
breast cancer. There is a pressing need for a practical biomarker that can provide
early indication of the biologic activity of these agents and correlate with clinical
outcome. Expression of thymidine kinase (TK) occurs in actively proliferating
cells, is E2F-dependent and is downregulated after CDK4/6 inhibitor-mediated
G1 arrest. Here, we have investigated TK activity (TKA) as a pharmacodynamic
marker for CDK4/6 inhibition in both preclinical and clinical contexts and dem-
onstrate the potential of this assay as CDK4/6 inhibitors are further developed.
TKA in response to the CDK 4/6 inhibitor palbociclib (palbo) was studied in cell
culture, mouse models and samples from clinical studies. TKA was determined
by the DiviTum Assay (Biovica, Sweden). In culture, the intracellular TKA and
TK release in response to palbo were determined by analysis of cellular extracts
and tissue culture media. In vivo, mice bearing human xenografts were treated
with vehicle or palbo to determine effects on TKA in serum and in tumor ex-
tracts. Finally, serum TKA (s-TKA) was assayed in patient samples procured
before and after palbo treatment in a Phase 1 study of palbo and the MEK
inhibitor PD0325901 (NCT02022982). Palbo was administered on 3/4 (21 of
every 28 days) or 4/4-week (continuous) schedules. In K562 cells, intracellular
TKA levels exhibited a clear dose response to palbo. Reductions in TKA were
seen at lower drug concentrations than those affecting cell viability. Similar
results were observed in MCF-7 xenografts, where lower TKA in serum and
tumor was observed after palbo treatment, whereas in E0771 xenografts, no
change in TKA was observed. Clinically, serum samples were obtained before
and at various time points after palbo exposure in 20 cancer patients. One pa-
tient, who discontinued study treatment at the end of cycle 1, demonstrated an
increase in s-TKA. In contrast, for the other 19 patients, there was a marked
decrease in s-TKA at day 21. Pre-treatment s-TKA values were higher than
C1D21 (paired t-test, p.0001). In 11 patients therewas a reduction in s-TKA to
below the assay detection limit. Five patients exhibited a reduction in s-TKA
within the working range, with mean residual activity at day 21 of 32%. In the 6
patients receiving continuous palbo, s-TKA remained low after day 21. Of the 14
patients on the 3/4-week schedule, 9 exhibited an increasing level of s-TKA
between day 21 and day 1 of cycle 2, consistent with reversible effects of palbo on
cell cycle progression after cessation of exposure. These data suggest that s-TKA
reflects MOA response to the selective CDK4/6 inhibitor palbo. The DiviTum
assay may provide a practical, non-invasive tool for monitoring the effects of
CDK4/6 inhibitors in both preclinicalmodels and patients.We plan inclusion of
the assay into additional studies to determine whether the assay can predict
clinical outcome or portend development of resistance.
#2341 In situ labelling identifıes a novel landscape of nuclear CDK2 sub-
strates. Bruce E. Clurman, Yong Chi. Fred Hutchinson Cancer Research Ctr.,
Seattle, WA.
Cellular signal transduction pathways rely heavily on protein kinase-medi-
ated phosphorylation events. Comprehensive identifıcation of the physiologic
targets of protein kinases is key to understanding their functions and elucidating
cellular signalling pathways. Various direct and indirect approaches, combined
with advancedmass spectrometry technologies, havemade it possible to identify
many candidate targets of a given kinase, but have also yielded many false-
positive identifıcations, largely due to technical limitations. Identifying direct
and physiological kinase targets thus remains a diffıcult task. We developed a
mass spectrometry-based in situ approach that utilizes substrate thiophospho-
rylation and ATP analog-sensitive CDK2 (AS-CDK2) to identify over one hun-
dred potential cyclin-dependent kinase 2 (CDK2) substrate in intact nuclei.
More than one-third of these candidates are known CDK substrates, indicating
signifıcant enrichment for physiologic CDK2 substrates, and we also we identi-
fıed and validated newCDK2 substrates. Importantly, many of these newCDK2
substrates are chromatin-associated proteins with roles in histonemodifıcation,
DNA replication, and DNA repair, which likely reflects our use of AS-CDK2
within its normal nuclear context, and regulated by endogenous cyclins. These
methods should be broadly applicable to the study of other kinaseswith complex
substrate networks.
#2342 TNFAIP8 promotes prostate cancer cell survival by modulating
autophagy. Suresh Niture,1 Malathi Ramalinga,2 Habib Kedir,3 Deepak Ku-
mar1. 1North Carolina Central University, Durham,NC; 2University of District of
Columbia,Washington, DC; 3North Carolina Central University and UDC, Dur-
ham, NC.
TNF- inducible protein (TNFAIP8) is an antiapoptotic protein with roles in
tumor cell growth and survival. Mechanisms of cell survival by TNFAIP8 re-
mains elusive. In the current study, we investigated the role and molecular
mechanism related to TNFAIP8 in the modulation of cell/cycle, autophagy and
drug resistance/cell survival in prostate cancer cells. Microarray data from PC3
prostate cancer cells ectopically expressing TNFAIP8 demonstratedmodulation
of cell cycle related genes such as CDKs, CDCs and PCNA. Immunoblotting
data from overexpression of TNFAIP8 in PC3 cells shows upregulation of cell
cycle proteins cyclin A, cyclin B1, Myt1 and Chk1. However, no change in cell
cycle was found. Phosphorylation of Histone-S10, CDC2-Tyr15 and Wee1-
S642] was also observed. Autophagy plays an important role in tumor cell sur-
vival. We evaluated the effects of TNFAIP8 in modulating autophagy. Overex-
pression of TNFAIP8 leads to induction of autophagy. TNFAIP8 positively
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modulates the expression/stabilization of autophagymarkers and effectors such
as LC3 I/II, Beclin1, 4EBP1, oncogene p62 and SIRT1. Knockdown of
TNFAIP8 inhibits autophagy induced by nutrient starvation in PC3 prostate
andMCF7 breast cancer cells.We also evaluated cell growth and survival in PC3
cells. We demonstrate that TNFAIP8 promotes cell growth and proliferation in
PC3, LNCaP and C4-2 prostate cancer cells. Furthermore, we have found that
TNFAIP8 increase resistance against anticancer drugs docetaxel and doxorubi-
cin. These data collectively suggest that by the creation of cellular autophagy
events TNFAIP8 promotes cell survival and drug resistance in prostate cancer
cells.
#2343 The novel potential of palbociclib (CDK4/6 inhibitor) in the treat-
ment of triple-negative breast cancer. Shinichiro Kashiwagi, Yuka Asano,Wa-
taru Goto, Koji Takada, Tsutomu Takashima, Tamami Morisaki, Satoru Noda,
NaoyoshiOnoda, KoseiHirakawa,MasaichiOhira.OsakaCityUniversity Grad-
uate School of Medicine, Osaka, Japan.
Background: The effectiveness of palbociclib (CDK4/6 inhibitor) for estrogen
receptor positive breast cancer has been demonstrated by large-scale clinical
studies, with the drug garnering attention as a key drug for breast cancer sub-
types with endocrine sensitivity in the future. According to PALOMA-3 trial,
palbociclib has been demonstrated to contribute to the extension of progres-
sion-free survival in patients with advanced hormone receptor-positive and
HER2-negative metastatic breast cancer after endocrine therapy. On the other
hand, in the case of triple-negative breast cancer (TNBC), luminal AR (LAR)
related to androgen signaling is believed to have endocrine activity. Previous
clinical data revealed that palbociclib shows high sensitivity in luminal breast
cancer cell lines with endocrine activity, with effectiveness also expected in LAR.
In this study, we created TNBC cell lines that forcibly express AR and examined
the effectiveness of palbociclib for TNBC. Materials and Methods: MCF-7 and
T-47D were used as luminal breast cancer cell lines, while MDA-MB-231 and
BT-549 were used as TNBC cell lines. In addition, we created TNBC cell lines
that forcibly express AR, called AR-MDA-MB-231, by the transfection of
pEGFP-C1-AR Plasmid Vector using Lipofectamine® 3000 Reagent. We con-
fırmed the expression of AR by qRT-PCR as well asWestern blotting and exam-
ined the impact of palbociclib on proliferation as well as apoptosis of breast
cancer cell lines. Results: AR was found to have been expressed only in luminal
breast cancer cell lines but not TNBC cell lines. It was confırmed that AR was
expressed in AR-MDA-MB-231 which are stable cell lines with the properties of
LAR. In a CCK assay, palbociclib showed high sensitivity in AR-MDA-MB-231
as in luminal breast cancer cell lines. Furthermore, in an apoptosis assay using
FACS and cell cycle assay, apoptosis was induced in AR-MDA-MB-231 and cell
cycle arrest at the G1S check point was confırmed. Conclusion: palbociclib
(CDK4/6 inhibitor) showed effectiveness for TNBC cell lines that compulsively
express AR, suggesting it may be one treatment option for TNBC in the future.
#2344 Beyond RB1: the pocket protein p130 mediates the effects of
CDK4/6 inhibition in RB1-defıcient urothelial carcinoma. Bishoy M. Faltas,
Ethan Shelkey, Rebecca Meyer, Nathan Young, Mark A. Rubin. Weill Cornell
Medical College, New York, NY.
Introduction: Urothelial carcinoma is characterized by a high incidence of
molecular alterations in the CDKN2A-RB-E2F axis. Loss of the cyclin-depen-
dent kinase inhibitor p16 encoded by CDKN2A or amplifıcation of CDK4/6 is
associated with sensitivity to CDK4/6 inhibitors in various cancers. Functional
RB1 is believed to be canonically required for mediating the effects of CDK4/6
inhibition in this setting. However, muscle-invasive urothelial carcinomas har-
bor RB mutations and copy-number losses in 21% of patients. To extend the
activity spectrum of CDK4/6 inhibitors to these RB1-defıcient cancers, we in-
vestigated the role of pocket protein p130 encoded by the Retinoblastoma-Like 2
(RBL2) gene, in mediating the downstream effects of CDK4/6 inhibition. Meth-
ods: CRISPR-Cas9 was used for CDKN2A knockout in the 5637-urothelial can-
cer cell line with an RB-mutant background and in TCCSUP cell line with wild-
type RB. CDKN2A cells were subsequently treated with CDK4/6 inhibitor
palbociclib. Levels of RB1, phospho-RB1 (at serine 807/ serine 811), p130 and
phospho-p130 (specifıcally, the CDK4/6-dependent serine-672 phosphoryla-
tion) proteins were quantifıed using SDS-PAGE. Cell-cycle phase analysis was
performed using flow cytometricmeasurement of BrdU andPI staining. Results:
CRISPR-induced disruption of CDKN2Awas validated using genomic PCR and
targeted Miseq sequencing. p16 protein knockdown was validated using SDS-
PAGE. CRISPR-induced CDKN2A knockdown resulted in increased cell pro-
liferation and faster G1/S transition even in the absence of functional RB in the
5637-urothelial cancer cell line. A signifıcant increase in the levels of phospho-
p130 was observed after p16 knockdown without changes in the levels of un-
phosphorylated p130. TCCSUP cell line with functional RB demonstrated a
similar increase in proliferation, faster G1/S transition and an increase in phos-
pho-p130. Palbociclib was effective in reversing these changes in all the tested
cell lines. Conclusions: the pocket protein p130 plays an important role in me-
diating downstream effects of CDK4/6 inhibition in urothelial cancer cell lines
with both wild-type and more importantly, defıcient RB. CDK4/6-dependent
phosphorylation of p130 can effectively compensate for the functional loss of RB
activating E2F family of transcription factors that control G1/S checkpoint.
These fındings potentially explain the lack of correlation between RB and re-
sponse to CDK4/6 inhibitors in clinical trials. These results provide amechanis-
tic rationale for extending clinical trials of CDK4/6 inhibitors to patients with
RB1-defıcient tumors.
#2345 CDK4 inhibition enhances anti-melanoma effects of BRAF/MEK
inhibition. Yanping Zhang, Eddy C. Hsueh. Saint Louis Univ., St. Louis, MO.
Introduction: Targeted therapy against BRAF-mutatedmelanoma has shown
clinical effıcacy. However, resistance to therapy often occurs. CDK4 (INK4)-
retinoblastoma (RB) pathway controls cell cycle progression by regulating the
G1-S checkpoint. Defect in the p16INK4A: cyclingD-CDK4/6: RB pathway is also
detected in melanoma. We study the effect of combining CDK4-RB pathway
inhibition with BRAF/MEK inhibition as a possible strategy to overcome resis-
tance to therapy. Methods: Three BRAF wild-type and three BRAF-mutated
melanoma cell lines were selected. CDK4/6 inhibitor (PD0332991; PD), BRAF
inhibitor (PLX4032; PLX), MEK inhibitor (AZD6244; AZD), and PI3K/AKT
inhibitor (XL765; XL) were used alone or in combination. Cell proliferation
assay was performed using Cell Titer Blue assay. Cell migration assay was per-
formed by artifıcial wounding of melanoma cell monolayer and observing mi-
gration of cells into the wound up to 48 hours. Western blotting was performed
for expression of pERK/ERK, pRB/RB, Cyclin D1, CDK4, and GAPDH. Data
were presented as means 	 SD for triplicate experiments. For comparison be-
tween groups, the student’s t test was used and p0.05 was considered to be
statically signifıcant. Results: Variable inhibition of cell proliferation andmigra-
tion was observed in a dose- and time-dependent fashion. Enhanced inhibition
of melanoma proliferation and migration was observed with PDAZD and
PDPLX combination compared with single agent AZD or PLX. Differential
enhancement was observed in BRAF wild-type cell lines with PDAZD and in
BRAFmutated cell lines with PDPLX combination.Minimal change in tumor
proliferation and migration inhibition was noted with PDXL combination
compared with PD or PLX alone. No correlation was observed between expres-
sion of CDK4 and cyclin D1 and sensitivity to singe agent or the combination.
Inhibition of phosphorylated RB1 and ERK expression was observed with expo-
sure to single agent PD, PLX, XL, AZD. Enhancement of pRB1 and pERK inhi-
bition was noted with PDPLX and PDAZD combination but not PDXL.
Conclusion: CDK4 inhibition can enhance anti-proliferation and migration ef-
fects of BRAF/ MEK inhibition in melanoma cells. The mechanism is via aug-
mented down-regulation of pRB expression.
#2346 Preclinical selectivity profıle of the CDK4/6 inhibitor ribociclib
(LEE011) compared with that of palbociclib and abemaciclib. Ralph Tiedt,1
Scott Delach,2 Steven Kovats,2 Thomas Horn,2 Michael Acker,2 Barbara Sch-
acher Engstler,1 Giordano Caponigro2. 1Novartis, Basel, Switzerland; 2Novartis,
Cambridge, MA.
A hallmark of cancer is unchecked cell division. Retinoblastoma protein (Rb)
is a human tumor suppressor that guards a cell’s entry into S phase by binding
E2F transcription factors and keeping them inactive. Many growth-promoting
stimuli increase expression of D-type cyclins, which bind to and activate cyclin-
dependent kinases 4 and 6 (CDK4/6). The cyclin D–bound CDK4/6 holoen-
zymes phosphorylate Rb, resulting in release of E2F, which in turn activates
genes required for S phase entry and DNA replication. Numerous oncogenic
aberrations converge at the CDK4/6–Rb pathway, providing a strong rationale
for developing CDK4/6 inhibitors as cancer therapeutics. Ribociclib (LEE011) is
a selective CDK4/6 inhibitor that has received FDA breakthrough therapy and
priority review designations for treatment of hormone receptor–positive breast
cancer in combination with letrozole and is being tested in additional clinical
trials. Here we describe the preclinical selectivity profıle of ribociclib in bio-
chemical and cellular assays. Ribociclib inhibits both CDK4–cyclin D1 and
CDK6–cyclin D3 kinase activity with nanomolar IC50s in biochemical assays.
To comprehensively address the selectivity of ribociclib in direct comparison
with 2 other clinical CDK4/6 inhibitors, palbociclib and abemaciclib, we made
use of the KINOMEscan assay consisting of 450 kinase active site–directed
competition-binding assays. We adjusted the test concentrations in the kinase-
selectivity panel per the binding constants for CDK4 and CDK6 to account for
the higher potency of abemaciclib. Data showed that both ribociclib and palbo-
ciclib have high selectivity for CDK4 (CDK6 was not covered in the panel), with
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very few distinct additional binding events detected. In contrast, abemaciclib is
a much more promiscuous kinase inhibitor. Next, we sought to determine the
relative potencies of the 3 inhibitors against CDK4 vs CDK6 in cellular assays.
When testing different routinely used readouts of cellular viability, we found
that assays that measured metabolic activity (eg, CTG) tended to underestimate
the effects of CDK4/6 inhibition; thus, assays that either directly or indirectly
assessed cell number were used instead. We fırst identifıed cancer cell lines
primarily dependent on either CDK4 or CDK6 as judged by combined RNA
expression analysis and shRNA or CRISPR-based functional assays. When de-
termining IC50s of the 3 CDK4/6 inhibitors in these cell lines, we found that
ribociclib and abemaciclib demonstrated greater activity in CDK4-dependent
cells vs CDK6-dependent cells, whereas palbociclib was similarly active in both
cell types. The high degree of CDK4 selectivity of ribociclib suggests that off-
target kinase inhibition is an unlikely complication in patients. Moreover, the
apparent preference for CDK4 over CDK6 could be an advantage in certain
cancer types that are primarily dependent on CDK4.
#2347 MicroRNAmediated CDK4/6 inhibitor resistance via extracellular
signaling. Liam Cornell, Geoffrey I. Shapiro. Dana Farber Cancer Institute,
Boston, MA.
Multiple potent and highly selective inhibitors of the cell cycle kinases - CDK4
and CDK6 are in development. One such inhibitor, palbociclib, was recently
approved for use in combination with letrozole for the treatment of estrogen
receptor positive (ER) breast cancer. Cyclin D-dependent kinase activity is a
driving factor for ER breast carcinogenesis, irrespective of CCND1 amplifıca-
tion, making CDK4/6 inhibition a promising approach for this breast cancer
subset. However, as with all cancer treatments, resistance will be a major issue
limiting the effıcacy of this approach. To date, mechanisms of palbociclib resis-
tance have not been extensively investigated. Through interrogation of the gen-
eratedCDK4/6 inhibition resistant cells we discovered overexpression of CDK6,
specifıcally, mediates resistance. CDK6 depletion reversed resistance and over-
expression caused resistance, whereas the same was not true when CDK4 or D
cyclin protein levels were manipulated. Interestingly, when generating and an-
alyzing resistant cell populations, we observed a “bystander effect”, by which
resistance was transmissible between cells. The “resistant bystander” cells dis-
play all characteristics of the drug exposure induced resistant cells, however
became resistant in just 48 hours as oppose to 14 weeks. Analysis of conditioned
medium revealed that the transmission of resistance is dependent on exosomes,
but not protein or DNA. We identifıed a specifıc miRNA, present in the exo-
somes of resistant cells, by microarray which caused resistance when excreted.
Additionally, overexpression and inhibition of the miRNA confırmed that it is
responsible for causing resistance. miRNA overexpressing cells exhibited the
same phenotype as drug induced resistant cells, and furthermore, could cause
resistance in neighboring cell populations by exosome mediated signaling. Us-
ing Biotin labelled miRNA-mRNA pulldown followed by RNA-seq, we identi-
fıed the TGF pathway as the miRNA target. Downregulation of the TGF
caused a decrease in the CDK inhibitors, p15 and p21, resulting in an increased
CDK6 protein level and palbociclib resistance. We subsequently confırmed
these data in patient samples by comparing before treatment and post relapse
biopsies. These fındings highlight a novel mechanism of conferred drug resis-
tance as well as new insights into acquired CDK4/6 inhibitor resistance.
#2348 Targeting the p27kip1/cdk4/cdk2/Rb axis in breast cancer using a
peptidomimetic of Brk’s SH3 domain. Stacy W. Blain,1 Jason Quinones,1 Pri-
yank Patel,1 Vladislav Tsiperson,1 Susan Gottesman,1 Jonathan Somma,1 Yun
Wu2. 1State University of New York, Downstate Medical Center, Brooklyn, NY;
2State University of New York, University of Buffalo, Buffalo, NY.
Purpose: Cyclin D-cdk4 (DK4) has been a highly sought after therapeutic
target because it drives cancer proliferation in a majority of human tumors. We
have explored the clinical utility of a recently discoveredmechanism of cell cycle
control exerted on DK4 by p27Kip1 and its activator, the Breast tumor Related
Kinase (Brk), in predicting responsiveness to therapy and as a new target for
treatment. Although known as a DK4 assembly factor and cdk2 inhibitor, p27
also acts as a DK4 ON/OFF “switch.” Tyrosine (Y) phosphorylation of p27 (pY)
by Brk gatekeeps both ATP binding and CAK phosphorylation of cdk4’s T loop,
essential forDK4 activation. This function is restricted to cdk4: p27’s association
with cdk2, whether Y phosphorylated or not, appears to be inhibitory. However,
in vivo Y phosphorylated p27 is a target for cdk2-dependent ubiquitin-mediated
degradation, reducing p27’s association with cdk2, indirectly activating this
complex. We showed that blocking p27 pY inactivates cdk4 directly AND cdk2
indirectly, and thus represents a novel way to block cancer cell proliferation. pY
also serves as a predictive biomarker of cdk4 activity and tumor response.Meth-
ods: We used a small peptide, ALT, which contains a portion of Brk’s SH3
domain. ALT binds to p27, blocks Brk’s association and ability to phosphorylate
p27, inhibiting cdk4 and increasing p27’s ability to inhibit cdk2. We engineered
a lipid-based nanoparticle delivery vehicle (NP-ALT), permitting us to test ALT
as a fırst generation therapeutic in breast cancer cell lines that were both respon-
sive and non-responsive to cdk4i therapy. ALTwas also used with Palbociclib to
determine if combination therapy reduced drug resistance.We developed a dual
IHCassay for p27 andpY,whichweused to analyze paraffın-embedded, archival
human tumor samples, to determine whether we could pinpoint patients who
would have responded to cdk4 inhibition therapy. Results: NP-ALT blocks pY,
cdk4 and cdk2 activity, and proliferation in both Palbociclib sensitive and resis-
tant cell lines. As a dual therapy, ALT treatment synergized with Palbociclib to
arrest cells for 30 days, increased senescence, and in animal models caused
tumor regression instead of just slowing tumor growth as seen with Palbociclib
alone. Analysis of human cancer, obtained from archival sources, demonstrated
that pY is never detected in quiescent benignmammary tissue, but is detected in
about half of the advanced ER/PR/Her2- tumors analyzed, and using explant
culture techniques, we were able to stratify pY with Palbociclib response. Con-
clusion: Use of an Brk SH3 based peptide (NP-ALT) has proven effective in
blocking p27 pY, inhibiting both cdk2 and cdk4, inducing senescence and in-
creased durability. pY levels correlate with Palbociclib sensitivity in low, mod-
erate and non-responders, suggesting that this may be a biomarker highlighting
responsiveness to cdk4i therapy.
#2349 Sensitivity and resistance to cell cycle and IGF-1R inhibitors in
rhabdomyosarcoma. Justin Montoya, DavidW. Lee, Eiman Aleem. Institute of
Molecular Medicine at Phoenix Children’s Hospital, Phoenix, AZ.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in chil-
dren and young adults. The fıve-year survival rate for RMS has hardly improved
over the last three decades despite intensive and toxic chemotherapy, radiother-
apy with surgery. Therefore, novel treatment approaches are required to change
these outcomes. RMS has two major subtypes, embryonal RMS (ERMS) and
alveolar RMS (ARMS). ARMS, the more aggressive subtype, is characterized by
translocations that fuse two transcription factor-encoding genes; creating novel
PAX3/PAX7-FOXO1 fusion proteins. The PAX3-FOXO1 is highly expressed in
the G2 phase of the cell cycle, allowing the cell to divide following a sustained
checkpoint arrest despite DNA damage induced by chemotherapy, suggesting
that PAX3-FOXO1 may enhance the survival of tumor cells in response to che-
motherapy. Many cell cycle regulators are altered in RMS, including CDK2,
CDK4 andp53. Furthermore, RMS cells are highly dependent on the insulin-like
growth factor -1 receptor (IGF-1R) signaling, however, IGF-1R targeting was
not successful in the clinic. Therefore, targeting key cell cycle regulators individ-
ually or in combination with IGF-1R inhibition may expand the available ther-
apeutic options for RMS. Purpose: The goal of the present study was to investi-
gate the cytotoxicity of 15 small molecule inhibitors targeting the IGF-1R and
cell cycle regulators in RMS cell lines and to determine potential mechanisms of
drug sensitivity or resistance.Methods and Results: Seven RMS cell lines includ-
ing ERMS and ARMS were studied. The IC50 values were determined for the
following targeting compounds: linsitinib, BMS-754807 and picropodophyllin
(PPP) (IGF-1R), riobociclib and palbociclib (CDK4/6), dinaciclib and flavopiri-
dol (pan CDK inhibitors), BS-181HCL (CDK7), MK-1775 (WEE-1), MK-8776
(CHK1), alisertib (AURKA) and volasertib (PLK1). The most potent com-
pounds with IC50 10 nM were dinaciclib and volasertib. The ARMS cell lines
were resistant to alisertib in comparison to the ERMS cell lines. Most cell lines
were sensitive to flavopiridol, MK-1775, BMS-754807 and PPP with IC50 100
nM, and relatively resistant to BS-181 HCL, linsitinib, R0-3306 and MK-8776
with IC50 (1-70M). Palbociclib and BMS-754807 showed a synergistic effect in
some RMS cell lines. Ongoing studies are focusing on determining the mecha-
nisms of interaction of these two compounds through studying cell cycle, apo-
ptosis, and mRNA and protein expression of key regulators in the IGF-1R and
RB pathways. Conclusion: These data demonstrate that dinaciclib, volasertib,
flavopiridol, MK-1775, BMS-754807 and PPP are highly cytotoxic in RMS cell
lines. The CDK4/6 inhibitor palbociclib may sensitize selected RMS cell lines to
IGF-1R inhibitors. Targeting selected cell cycle regulators individually, or in
combination with IGF-1R inhibitors may thus provide an effıcacious treatment
approach to be further validated in RMS patients with poor outcome.
#2350 In vivo E2F reporting on effıcacious dosing schedules of MEK plus
CDK4/6 inhibition inmelanoma. Jessica Teh,1 NedaNikbakht,1 Timothy Pur-
win,1 Inna Chervoneva,1 Prem Patel,1 Michael Davies,2 Andrew Aplin1.
1Thomas Jefferson University, Philadelphia, PA; 2MD Anderson University of
Texas Houston, Houston, TX.
Pharmacological targeting of cyclin dependent kinases 4 and 6 (CDK4/6)
could represent a viable therapeutic option in combination with BRAF and/or
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MEK inhibitors in different genetic subsets of melanoma. Indeed, continuous
and concurrent dosing of MEK inhibitor (MEKi) plus a CDK4/6 inhibitor
(CDK4/6i) leads tomelanoma regressions in in vivomodels and delays the onset
of MEKi resistance. Current scheduling in breast cancer patients for the CDK4/
6i, palbociclib, is intermittent due to adverse effects resulting in neutropenia. It
is unclear what the most effıcacious schedules are of palbociclib plus a MEKi.
Utilizing an E2F reporter system, we sought to analyze the effıcacy of different
CDK4/6i plusMEKi schedules in a quantitative and temporalmanner. Intermit-
tent dosing (3 weeks on/1 week off) of both CDK4/6i and MEKi combination
therapy resulted in tolerant tumors and rapid reactivation of E2F activity during
drug holiday. Continuous MEKi with intermittent CDK4/6i led to more com-
plete responses as compared to continuous CDK4/6i with intermittent MEKi.
Weight loss of mice was also evident in the continuous CDK4/6i plus intermit-
tentMEKi arm suggesting adverse events related to continuous CDK inhibition.
Importantly, functional proteomic analysis revealed distinct mechanisms of ac-
quired resistance/drug tolerance that arose from the three scheduling arms.
Here, we report that upregulation of S6 phosphorylation is associated with ac-
quired resistance toMEK plus CDK4/6 inhibition and can be overcome with an
mTOR inhibitor. Taken together, in vivo reporting allows for quantitative mea-
surement of pathway activity associated with inhibitor resistance and can be
utilized to optimize combination schedules to improve the therapeutic index in
patients.
#2351 The novel potential of palbociclib (CDK4/6 inhibitor) in the treat-
ment of triple-negative breast cancer.YukaAsano, Shinichiro Kashiwagi,Wa-
taru Goto, Katsuyuki Takahashi, Tsutomu Takashima, Satoru Noda, Naoyoshi
Onoda, Shuhei Tomita, Kosei Hirakawa, Masaichi Ohira.Osaka City University
Graduate School of Medicine, Osaka, Japan.
Background: The effectiveness of palbociclib (CDK4/6 inhibitor) for estrogen
receptor positive breast cancer has been demonstrated by large-scale clinical
studies, with the drug garnering attention as a key drug for breast cancer sub-
types with endocrine sensitivity in the future. According to PALOMA-3 trial,
palbociclib has been demonstrated to contribute to the extension of progres-
sion-free survival in patients with advanced hormone receptor-positive and
HER2-negative metastatic breast cancer after endocrine therapy. On the other
hand, in the case of triple-negative breast cancer (TNBC), luminal AR (LAR)
related to androgen signaling is believed to have endocrine activity. Previous
clinical data revealed that palbociclib shows high sensitivity in luminal breast
cancer cell lines with endocrine activity, with effectiveness also expected in LAR.
In this study, we created TNBC cell lines that forcibly express AR and examined
the effectiveness of palbociclib for TNBC. Materials and Methods: MCF-7 and
T-47D were used as luminal breast cancer cell lines, while MDA-MB-231 and
BT-549 were used as TNBC cell lines. In addition, we created TNBC cell lines
that forcibly express AR, called AR-MDA-MB-231, by the transfection of
pEGFP-C1-AR Plasmid Vector using Lipofectamine® 3000 Reagent. We con-
fırmed the expression of AR by qRT-PCR as well asWestern blotting and exam-
ined the impact of palbociclib on proliferation as well as apoptosis of breast
cancer cell lines. Results: AR was found to have been expressed only in luminal
breast cancer cell lines but not TNBC cell lines. It was confırmed that AR was
expressed in AR-MDA-MB-231 which are stable cell lines with the properties of
LAR. In a CCK assay, palbociclib showed high sensitivity in AR-MDA-MB-231
as in luminal breast cancer cell lines. Furthermore, in an apoptosis assay using
FACS and cell cycle assay, apoptosis was induced in AR-MDA-MB-231 and cell
cycle arrest at the G1S check point was confırmed. Conclusion: palbociclib
(CDK4/6 inhibitor) showed effectiveness for TNBC cell lines that compulsively
express AR, suggesting it may be one treatment option for TNBC in the future.
#2352 Effect of inhibition of cell cycle versus transcription cyclin-depen-
dent kinases (CDKs) in ovarian cancer cells. Rosaria Chilà, Nicolò Panini,
Eugenio Erba, Giovanna Damia, Massimo Broggini. IRCCS - Istituto di Ricerche
Farmacologiche Mario Negri, Milan, Italy.
Background: Cell cycle is regulated by cyclin-dependent kinases (CDKs) ac-
tivity, whose deregulation can lead to uncontrolled proliferation and cancer.
Other CDKs are engaged in the regulation of transcription and post-transcrip-
tional mRNA processing through the phosphorylation of the C-terminal do-
main of RNA polymerase II, such as CDK9 and CDK12. Inhibitors of cell cycle
CDKs have been developed as anticancer agents and some of them are under
clinical validation (e.g. palbociclib). While recent data would suggest that inhi-
bition of CDK9 is feasible and has antitumor effect, the data on the therapeutic
role of CDK12 inhibition are very scanty. Methods: Ovarian cancer cell lines
were maintained in RPMI medium supplemented with 5% glutamine and 10%
FBS. Cells were treatedwith different drug concentrations and after 72 hours cell
survival was evaluated byMTS assay (Promega). IC50 values were calculated by
interpolation method. Cell cycle analysis and apoptosis were performed with
standard flow cytometric methods. A2780 and SKOV3 ovarian cancer cell lines
knocked out for CDK12 were generated with CRISPR/CAS9 genome editing
tool. Results. The cytotoxicity of palbociclib (a CDK4/6 inhibitor) and
LDC000067 (a CDK9 inhibitor) was tested in a panel of ovarian cancer cell lines
(A2780, SKOV3, OVCAR3, OVCAR5, OVCAR8, OVCA432, OVCA433,
IGROV1, EFO27). Sensitivity of cells was similar for palbociclib and
LDC000067, ranging from 10 to 33 and from 8 to 60 M, respectively. A pref-
erential G1 block was observed with palbociclib, while LDC000067 caused a
S-G2block.Ahigher induction of apoptosiswas observed after LDC000067 than
after palbociclib treatment in both A2780 and SKOV3. The palbociclib-induced
G1 block was associated with decreased Rb phosphorylation, while no modula-
tion of the Ser2 in the carboxyterminal domain of RNA polymerase II was ob-
served after LDC000067 treatment. We generated CDK12 knocked out cells
transfecting CRISPR/CAS9 engineered plasmid in both A2780 and SKOV3
ovarian cancer lines. The biological and pharmacological characterization of
these clones is under study. Conclusions: Palbociclib and LDC000067 showed a
dose dependent cytotoxic effect in the panel of ovarian cancer cell lines tested
and were active in the M range. Preliminary data of treatment induced cell
cycle perturbation and apoptosis suggest that the two drugs behave in a different
manner and have distinct molecular effects on cells.
#2353 CDKI-15, a novel and highly selective CDK4/6 inhibitor: discovery,
in vitro and in vivo anticancer effıcacy. Solomon Tadesse, Laychiluh Bantie,
Khamis Tomusange, Saiful Islam, Muhammed H. Rahaman, Benjamin Noll,
Frankie Lam, Mingfeng Yu, Shudong Wang. University of South Australia, Ad-
elaide, Australia.
Cyclin D dependent kinases CDK4 andCDK6 are crucial regulators of the G1
to S phase transition of the cell cycle. The facts that myriad cancer types show
aberrance in INK4-CDK4/6-cyclin D-Rb-E2F pathway, and the rapidly emerg-
ing positive clinical data of pharmacological inhibitors have validated CDK4/6
as anticancer drug targets. As the fırst commercialized CDK inhibitor, palboci-
clib in combination with letrozole or fulvestrant has received regulatory ap-
proval for the treatment of breast cancer. This represents an important scientifıc
advance in the fıeld.However, the limited structural diversity and undesired side
effects due to broader kinase interactions of existing inhibitors mean that the
hunt for new and highly selective CDK4/6 inhibitor drug candidates continues.
Using our advanced medicinal chemistry, targeted biochemical and cell-based
assays, and animal pharmacology, we synthesized and evaluated a novel series of
inhibitors. Many compounds were highly potent and selective against CDK4/6,
& exhibited low nanomolar potency against a range of human cancer cell lines.
Notably, inhibition of CDK4D1 by compoundCDKI-15 (Ki 4 nM)was over 3
orders of magnitude greater than CDK1B, CDK2A, CDK7H and CDK9T1. In-
terrogation of a panel of 369 protein kinases revealed CDKI-15 to be highly
selective for CDK4/6 with only 3 other kinases inhibited potently. CDKI-15
reduced the level of Rb phosphorylation and induced G1 cell cycle arrest, con-
fırming cellular inhibition of CDK4/6 in cancer cells. Moreover, CDKI-15 pos-
sesses superior pharmacokinetic profıle with oral bioavailability of 100% in
mice. Treatment of nude BALB/c mice bearing human MV4-11 acute myeloid
leukemia cells with CDKI-15 at daily dose of 100 mg/kg by oral administration
resulted in a robust inhibition of tumor growth compared to vehicle treated animals
(T/C 30%, p 0.00001). Strikingly, CDKI-15 caused a complete and sustained
tumor regression inone-thirdof the animals.Nodetectable toxicitywas observed in
the animals during andpost treatment. Taken together, our data provide a rationale
for CDKI-15 to be developed towards clinic for cancer therapy.
#2354 Identifıcation of CDK1 as an aspirin and salicylic acid binding pro-
tein: a potential role in chemoprevention. Jayarama B. Gunaje,1 D.Ramesh
Kumar,2 Siddharth Kesharwani,1 Eduardo Callegari,3 Hemachand Tummala,1
Rakesh Dachineni1. 1South Dakota State Univ. College of Pharmacy, Brookings,
SD; 2University of Kentucky, Lexington, KY; 3University of South Dakota, Ver-
million, SD.
Data emerging from the past 10 years have consolidated the rationale for
investigating the use of aspirin for chemoprevention; however, the mechanisms
leading to its anti-cancer effects are still being elucidated. We hypothesized that
aspirin’s ability to exert chemopreventive effects may involve altering the levels
and activity of cell cycle regulatory proteins. In the present study, using HT-29
colon cancer cells and other cancer cells, we demonstrated that both aspirin and
its primary metabolite, salicylic acid, downregulated the protein and mRNA
levels of cyclin B1 and cyclin dependent kinase-1 (CDK1). Lactacystin, a 26S
proteosomal inhibitor, prevented aspirin and salicylic acid mediated degrada-
tion of cyclin B1, but not CDK1. Decrease in protein levels of cyclin B1/CDK1
was correlated with a corresponding decrease in CDK1 kinase activity. Molecu-
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lar docking studies showed that aspirin and salicylic acid independently can
dock on CDK1 through interactions with Leucine 83. Incubation of recombi-
nant CDK1 with aspirin resulted in acetylation at lysine residues, this was also
observed in cell culture experiments. Pre-incubation of CDK1with salicylic acid
dose dependently prevented aspirin’s ability to acetylate CDK1 in purifıed prep-
arations confırming the data obtained from molecular docking studies. Our
results show that CDK1 is a salicylic acid binding protein (SABP) and the che-
mopreventive actions of aspirinmay involvemodulation of levels and activity of
cyclin B1 and CDK1.
#2355 Palbociclib enhances the antitumor activity of taxanes by abrogat-
ing cell cycle checkpoints and alleviating hypoxia in squamous cell lung can-
cer. JoanCao,1 ZhouZhu,1HuiWang,1 TimNichols,1 Edward Rosfjord,2 Chris-
tine Hopf,2 Erik Upeslacis,2 Paul Rejto,1 Scott Weinrich,1 Todd Vanarsdale,1
James Hardwick,1 Ping Wei1. 1Pfızer, Inc., San Diego, CA; 2Pfızer, Inc., Pearl
River, NY.
Lung cancer remains one of the leading causes of cancer-related mortality.
Squamous cell lung cancer (SqCLC) is the second most common subtype of
non-small cell lung cancer (NSCLC) and is responsible for100,000 deaths in
the US and EU. Most SqCLC patients receive chemotherapy as 1st line treat-
ments and have a high un-met medical need for new therapies. Therapeutic
approaches that enhance the effıcacy of chemotherapy would therefore improve
clinical outcomes for this patient population. CDK inhibitors comprise a class of
drugs that target the dysregulated cell cycle in malignant cells. Treatment of
tumor cells with the CDK4/6 inhibitor palbociclib inhibits tumor growth by
decreasing retinoblastoma (RB) protein phosphorylation and inducing cell cycle
arrest at the G1/S phase transition. Based on promising clinical trial results,
palbociclib in combination with letrozole was granted accelerated approval by
the US FDA for the treatment of postmenopausal women with ER-positive,
HER2-negative advanced breast cancer. Like hormone receptor positive breast
cancer patients, the vast majority of SqCLC patients harbor wild type RB and
thusmay also benefıt frompalbociclib treatment. Previously, we reported robust
cytotoxicity and antitumor effects of palbociclib plus taxanes, including nano-
particle albumin-bound paclitaxel (Nab-PTX) or docetaxel (DTX), in several
preclinical models of SqCLC. In the present study, we extended our effıcacy
studies of this combination to additional RB SqCLCmodels with diverse mo-
lecular genetic backgrounds. In search of mechanisms of action underlying the
observed combinatorial effects, we identifıed several novel mechanisms, includ-
ing cell cycle checkpoint abrogation as well as reduction of hypoxia-inducible
factor 1 alpha (HIF-1). Decrease inHIF-1 protein led to strongmodulation of
downstream genes involved in angiogenesis, resulting in reduced blood vessel
size in tumor vasculature. Our results suggest that palbociclib enhances the
antitumor activity of taxanes by abrogating cell cycle checkpoints and alleviating
hypoxia in SqCLC.
#2356 Functional characterization ofCDKN1A loss in bladder cancer and
effects on cisplatin sensitivity. Philip H. Abbosh, Rahmat K. Sikder, Wafık S.
El-Deiry. Fox Chase Cancer Ctr., Philadelphia, PA.
Introduction: Muscle-invasive bladder cancer (MIBC) is most optimally
treated with cisplatin-containing combination chemotherapy, and if clinically
localized, bladder removal. With recent discoveries delineating aberrant driver
genes involved inMIBC, it is now possible to personalize treatment approaches.
Development of a therapeutic rationale for personalized therapies which is
based on mutational landscape or other characteristic of each tumor may pro-
spectively identify patients prone to chemoresponse, thusmaximizing therapeu-
tic index. Inactivating mutations in CDKN1A, the gene encoding cyclin depen-
dent kinase inhibitor p21, occur in about 14% ofMIBCs, with amajority of these
truncating the peptide.We hypothesized that after DNA-damaging events, cells
defıcient in p21 would be unable to halt the cell cycle to repair the damage, and
subsequently proceed down an apoptotic pathway, potentially serving as a ther-
apeutic vulnerability. Methods: RT4 and SW780 cell lines were chosen for study
based on chemoresistance to cisplatin and WT status of CDKN1A and TP53.
Cell-cycle arrest and apoptotic pathways were evaluated withWestern blot after
treatmentwith IC50 doses. CRISPR sgRNAswere generated to introduce frame-
shifts 5= to the regions encoding the cyclin binding domain (CDI), within the
CDI, and 5= to the PCNA binding domains. Knock-outs were confırmed by
immunoblot. MTT was used to assess cipslatin response. Results: p53 increased
in both cell lines 24 hours after a 3h pulse of cisplatin exposure. However, p53
peaked at 24 hours and then diminished in RT4 but continued to rise in SW780.
p21 was basally expressed in both cell lines, decreased at 24 hours, then increas-
ing at 72 hours. In RT4, peak Rb phosphorylation (pRb) occurred at 24 hours,
indicating cell cycle arrest, and gradually decreased at 72 hours. In SW780 pRb
remained unchanged during the course of the treatment. In RT4, PARP cleavage
was observed at 24 hours and increased at 48 hours indicating apoptosis. RT4
cells harbored extensiveDNAdamage as indicated by persistent phosphorylated
H2AX. In contrast a smaller fraction of SW780 cells underwent PARP cleavage
at 48 and 72 hours and there was less phosphorylated H2AX. Single cell
CDKN1A knockout clones were generated and confırmed by immunoblotting.
sgRNAs targeting amino acids 12 and 59 completely abolished p21 detection,
and an sgRNA targeting amino acid 109 generated a truncated peptide, confırm-
ing p21’s apparent stability. CDKN1Adisruption at any of the three sites did not
reverse chemorensitance to cisplatin in either cell line. Conclusion: Cisplatin
resistant cell lines use a combination of arrest and repair to survive an apoptotic
insult. Although p21 loss did not reverse cisplatin resistance, it may impact
sensitivity to other agents. Othermechanisms of chemo- and radio-sensitization
are being explored.
#2357 CDK4/6 inhibition in early stage triple negative breast cancer.Wil-
liam B. Kietzman, Virginie Ory, Fransisco Saenz, Ghada Sharif, Anton Well-
stein, Anna T. Riegel. Georgetown University, Washington, DC.
Palbociclib (PD), a CDK4/6 inhibitor, has recently been approved for use in
advanced ER positive breast cancer, demonstrating signifıcant benefıt in com-
bination with endocrine therapies. Ductal carcinoma in situ (DCIS) is an inob-
ligate precursor to invasive ductal carcinoma with anywhere from 14-53% of
cases progressing. Progression is unpredictable and driven by poorly under-
stood mechanisms. In this study, we assess the effıcacy of PD in the context of
this early stage disease using a triple negative DCIS model(MCF10DCIS), not
only in inhibiting cell cycle but also in hindering the progression from in situ to
invasive lesion. We demonstrate similar effıcacy of PD in 2D on MCF10DCIS
and immortalmammary epithelial cells (MCF10As) in preventing proliferation,
inhibiting phosphorylation of RB and stopping cell cycle progression. Yet in 3D,
MCF10DCIS cells form smaller, more organized spheres in the presence of drug
while MCF10As appear unaffected, highlighting potential disease selectivity in
vivo. Interestingly, when a cDNA array is performed on MCF10DCIS cells
grown in 3D/ PD, the most regulated genes are not well characterized cell
cycle genes as one might predict based on previously published data and 2D
response to treatment, suggesting alternative CDK4/6 targets may be responsi-
ble for the phenotype observed in 3D. We also demonstrate in a nude mouse
xenograft model of MCF10DCIS that PD is able to signifıcantly reduce overall
tumor burden while simultaneously delaying the progression of lesions to inva-
sive disease. Though the growth of PD treatedMCF10DCIS lesions is delayedwe
demonstrate that proliferation is unaffected in vivo by the presence of the drug,
based on equivalent Ki67 signal within the lesions. This reiterates the possibility
that in 3D and in vivo contexts PD targets mechanisms outside of cell cycle
regulation in order to slow tumor growth and delay invasive transition. We
believe that investigation into alternative targets of CDK4/6 altered by PD in 3D
and in vivomayprovide insights on importantmechanisms ofDCISprogression
in DCIS models and human patients.
#2358 Impact of MDM2 inhibition on cell cycle regulation through Au-
rora Kinase B - CDK1 axis in prostate cancer cells. Thanigaivelan Kanaga-
sabai,1 Khalid Alhazzani,2 Thiagarajan Venkatesan,1 Sivanesan Dhandayutha-
pani,1 Ali Alaseem,2 Appu Rathinavelu1. 1Rumbaugh Goodwin Institute for
Cancer Research, Nova Southeastern University, Fort Lauderdale, FL; 2College of
Pharmacy, Nova Southeastern University, Fort Lauderdale, FL.
Cyclin-dependent kinases (CDKs) are critical regulators of cell cycle progres-
sion and therefore overexpression of CDKs contributes to the proliferation of
cancer cells. A variety of genetic and epigenetic events cause over activity of the
CDKs in human cancers, and their inhibition can lead to cell cycle arrest and
apoptosis. In malignant cells, both elevated expression of CDKs and their mod-
ulators including cyclins, and loss of expression of CDK inhibitors result in
deregulated CDK activity, providing a selective growth advantage for cancer
progression. In this respect, the multifunctional mouse double minute 2 ho-
molog (MDM2) oncoprotein has been gaining a signifıcant amount of attention
towards better understanding the cell cycle regulatory mechanisms. It is well
established that MDM2 gene amplifıcation can occur in diverse human malig-
nancies including prostate cancer. Also, MDM2 oncoprotein has been shown to
exert both p53-dependent and p53-independent roles in oncogenesis. It has
beenwell established in several laboratories, including ours, that overexpression
ofMDM2, can eventually lead to the inactivation of cell cycle control and loss of
apoptotic ability in many tumors. However, the mechanisms underlying the
regulation of CDK1 by MDM2 in cancer cells have not been fully identifıed.
Therefore, the main objective of our study was to understand the impact of
MDM2 overexpression on CDK1 that regulates cell cycle progression and apo-
ptosis. Our preliminary data from human cell cycle PCR array experiments
revealed the expression profıle of genes that are involved in different phases of
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cell cycle regulation in LNCaP-MST cells with and without nutlin-3 treatment.
Our study clearly demonstrated a signifıcant increase in the expression level of
Aurora Kinase B (AURKB), CDC25C andCDK1 inMDM2 transfected LNCaP-
MST cells as compared with non-transfected LNCaP cells. However, after treat-
ing the cells with 20 M of MDM2 specifıc inhibitor nutlin-3, for 24 h, the
expression levels of the above mentioned proteins were signifıcantly altered
when compared to untreated controls. In addition, inhibition of MDM2 with
nutlin-3 leads to increased expression of pro-apoptotic proteins p53, p21, and
Bax. Our results offer signifıcant evidence towards the effectiveness of MDM2
inhibition in causing cell cycle arrest via blocking the transmission of signals
through AURKB-CDK1 axis and inducing apoptosis in cancer cells. It is clearly
evident from our data thatMDM2 overexpression probably is the primary cause
for CDK1 up-regulation in the LNCaP-MST cells, which might have occurred
possibly through activation of AURKB. However, further studies in this direc-
tion should shed more light on the intracellular mechanisms involved in the
regulation of CDK1 in MDM2 positive cancers. (This project was supported by
The Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida).
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#2359 Inhibition of the ATR kinase enhances therapeutic effıcacy of cis-
platin in ATM low uterine carcinosarcoma cells. Emily R. Penick,1 Paulette
Mhawech-Fauceglia,2 Nicholas Bateman,1 Kelly Conrads,1 Tracy Litzi,1 Chun-
qiao Tian,1 Chad A. Hamilton,1 Kathleen Darcy,1 George Maxwell,3 Thomas
Conrads3. 1Gynecologic Cancer Center of Excellence, Murtha Cancer Center,
Walter Reed National Military Medical Center, Department of Obstetrics and
Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD;
2University of Southern California, Los Angeles, CA; 3Inova Schar Cancer Insti-
tute, Inova Center for Personalized Health, Annandale, VA.
Objective: Uterine carcinosarcoma (UCS) is an aggressive malignancy, mak-
ing up less than 5% of uterine cancers. Pharmacologic inhibition of ATR kinase
synergistically enhances the ability of cisplatin to kill carcinoma cells of many
solid tumor types and is further enhanced in ATM low carcinoma cells. It is
unknown whether ATR inhibition (ATRi) offers a therapeutic opportunity in
UCS. The goal of this study was to evaluate ATM expression in UCS tumors and
determine the response of an ATM low UCSmodel to ATRi cisplatin combi-
nation. Methods: ATM expression was evaluated in full tissue sections from 74
UCS tumors by immunohistochemistry (IHC) with an ATM specifıc monoclo-
nal antibody (clone Y170, Abcam), and was categorized as negative vs any pos-
itive staining in the carcinomatous (C) vs sarcomatous (S) components. In vitro
models of UCS: SK-UT-1, SK-UT-1B, KLE, and RL95-2 cell lines were treated
with an ATRi (AZD6738), cisplatin, and ATRi  cisplatin. ATM low models
were generated in RL95-2 cells using short hairpin RNA (shRNA) lentivirus
targeting ATM and a non-target control. Cells were subjected to cisplatin and
ATRi dose response analyses. Results: Negative IHC expression of ATMprotein
was observed in 24% of the C vs 31% of the S components of the 74 UCS cases
(Table 1). ATRi increased the sensitivity of uterine carcinosarcoma cell line
models to cisplatin. Western blot confırmed a 57% knockdown in ATM in
RL95-2 cells infectedwith shRNA forATMand treatment withATRicisplatin
therapy showed20% increase in cell death in ATM low vs control cells lines,
p0.02. Conclusions: IHC analyses of UCS tumors showed an average of27%
of tumors have loss ofATM inCand S components. Preliminary evidence shows
thatATRi increases the sensitivity ofUCS cellmodels to cisplatin therapy, which
is further increased in ATM low uterine carcinoma cells. These fındings suggest
a novel therapeutic opportunity for ATRi  cisplatin therapy in UCS patients
with low ATM expressing tumors.
Immunohistochemistry-based quantifıcation of ATM expression in uterine
carcinosarcoma tumors
ATM Uterine Carcinosarcoma
Intensity Carcinomatous component Sarcomatous component
0-1 31 (41.9%) 33 (44.6%)
0 18 (24.3%) 23 (31.1%)
1 13 (17.6%) 10 (13.5%)
2-3 43 (58.1%) 41 (55.4%)
2 11 (14.9%) 10 (13.5%)
3 32 (43.2%) 31 (41.9%)
TOTAL 74 74
#2360 Regulation of theMAPKphosphataseMKP-1 by the E3 ligaseGP78
in cancer cells. Dhonghyo Kho, Gen Sheng Wu. Wayne State Univ. School of
Medicine, Detroit, MI.
Mitogen-activated protein kinase (MAPK) phosphatase 1 (DUSP1/MKP-1) is
a member of the threonine-tyrosine dual-specifıcity phosphatase family that is
endogenous inhibitor for extracellular signal-regulated protein kinases (ERKs),
p38 MAPKs, and JNKs signaling. MKP-1 plays a key role in determining the
magnitude and duration of MAPK activation in response to extracellular stim-
uli. In human cancers, abnormal expression of DUSP1 is associated with tumor
development, chemoresistance and prognosis. However, the mechanism by
whichMKP-1 is regulated is not fully understood. Here, we show that GP78, an
E3 ligase, plays an important role in regulation of MKP-1 protein levels. Specif-
ically, we found thatMKP-1 interacts with GP78 both in vitro and in vivo. Their
interaction occurs between the N-terminal, Rhodanese domain of MKP-1 and
C-terminal E3 ligase domain of GP78. We also found that K230, 280, and 289
residues on MKP-1 are responsible for its ubiquitination. Importantly, this in-
teraction causes MKP-1 ubiquitination and subsequent degradation. Further-
more, we showed by overexpression and knockdown studies that GP78 down-
regulates the level of MKP-1 protein in cancer cells. Therefore, we identify a
novel mechanism by which GP78 controls MKP-1 protein levels and suggest
that this regulatory mechanism may play an important in cancer.
#2361 Pim kinase inhibition alters mRNA splicing in AML cell lines.
Tejashree A. Joglekar, Xiang Li, Charles J. Bieberich. University of Maryland,
Baltimore County, Baltimore, MD.
Oncogenic kinase activity is a common feature of nearly all cancers and ki-
nases aremajor targets for therapeutic intervention. Pimkinases are deregulated
in hematopoietic cancers including Acute Myeloid Leukemia (AML), as well as
prostate cancer. While cancer cells can become dependent on Pim activity to
sustain proliferation, in normal adult tissues, Pim kinase activity appears to be
dispensable. These features make Pim kinases an attractive target for cancer
therapy, however, their physiological roles have not been fully characterized.
Using the reverse in-gel kinase assay (RIKA),we identifıed a battery of novel Pim
substrates that are involved inmRNA splicing regulation.We hypothesized that
Pim family kinases regulatemRNAsplicing throughphosphorylation of splicing
factors.Microarray analysis revealedmore than 10,000 splicing changes in AML
cells treated with the highly selective small molecule Pim kinase inhibitor
AZD1208. Using RT-PCR analysis, multiple AZD1208-induced splicing
changes were validated. To discern the mechanisms whereby Pim kinases regu-
late splicing, we determined whether Pim inhibition alters phosphorylation of
serine/arginine-rich (SR) proteins. Inhibition of serine arginine protein kinase
(SRPK) activity using a small molecular inhibitor (SRPIN340) reduced SR pro-
tein phosphorylation, whereas Pim kinase inhibition did not, suggesting that
Pim kinases regulate splicing through an SRPK independent pathway. Compar-
ison of splicing changes in AZD1208 and SRPIN340 treated AML cells demon-
strated distinct patterns, providing further evidence of SRPK-independent splic-
ing regulation by Pimkinases. Biomarkers of kinase inhibitor effıcacy are critical
components of clinical trials. These data suggest that changes inmRNA splicing
may serve as a biomarker for assessing patient responsiveness to Pim inhibition
therapy.
#2362 Mechanistic insights into phosphoinositide 3-kinase . Sweta Ma-
heshwari. Johns Hopkins University School of Medicine, Baltimore, MD.
Phosphoinositide 3-kinases (PI3Ks) are at the center of mTOR pathway that
plays key roles in regulating cell survival, proliferation, protein synthesis and
vesicle traffıcking. Dysregulation of the mTOR pathway has been implicated in
various diseases such as cancer, diabetes, arthritis, inflammation and respiratory
illnesses. PI3Ks have dual kinase specifıcity with a lipid kinase activity that phos-
phorylates the 3=-hydroxyl of phosphoinositides, and a protein kinase activity
including auto-phosphorylation. In this study, we explored the roles of residues
of the catalytic domain and regulatory subunit of human PI3K in the lipid and
protein phosphorylation. We used site-directed mutagenesis and kinetic assays
to precisely map the molecular basis of substrate recognition and catalysis in
PI3K. Kinetic analysis of K776, located in the P-loop of PI3K, reveals that a
lysine at this position is essential for the recognition of the lipid and ATP sub-
strates. This same residue plays an important role in the auto-phosphorylation
of the enzyme. Replacement of histidine residues–H936 andH917 in the activa-
tion and catalytic loops respectively with alanine residues results in a dramatic
change in the kinetics of PI3K. While H936A inactivates the lipid kinase activ-
ity without affecting auto-phosphorylation, H917A abolishes both the lipid and
protein kinase activities of PI3K. On the basis of kinetic and structural analysis,
we proposed possible mechanistic roles of these critical residues in catalysis.
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#2363 Targeting Src-family kinases to combat acquired inhibitor resis-
tance in FLT3-ITD AML. Ravi K. Patel, Mark Weir, Sabine Hellwig, Heather
Dorman, Thomas E. Smithgall. University of Pittsburgh, Pittsburgh, PA.
Activating internal tandem duplication (ITD) mutations in the FMS-like re-
ceptor tyrosine kinase 3 (Flt3) are found in approximately 30% of acute myeloid
leukemia (AML) patients. Flt3-ITD expression is associated with aggressive,
chemotherapy-resistant disease and decreased overall survival. Multiple selec-
tive Flt3 kinase inhibitors have been developed as targeted therapy for Flt3-
ITD AML. However, the clinical utility of these kinase inhibitors has been
limited by the rapid recurrence of drug-resistant disease that often results from
Flt3 kinase domain mutations that prevent inhibitor action. Recent studies re-
vealed that multiple non-receptor tyrosine kinases are over-expressed in AML,
including the myeloid Src-family kinases Hck, Lyn and Fgr, and may cooperate
with Flt3 to drive disease. These observations suggest that kinase inhibitors with
specifıcity profıles targeting Flt3 and these AML-associated cytoplasmic kinases
may be less prone to acquired resistance. In the present study, we determined the
contributions of Hck and Fgr kinase activities to Flt3-ITD AML cell growth
using a chemical genetics approach. While RNAi-mediated knockdown of each
of these kinases reduces proliferation and increases apoptosis in primary AML
cells, the impact of pharmacologic inhibition of their kinase activities on AML
cell growth is not known. Because no selective Hck or Fgr inhibitors exist, we
developed kinase domain mutants that desensitize each kinase to the broad-
spectrum SRC-family kinase inhibitor, A-419259. Examination of a previous
crystal structure of Hck with A-419259 bound to the active site suggested a role
for the ‘gatekeeper’ residue in compoundbinding. Substitution of the gatekeeper
threonine of Hck and Fgr with methionine conferred 3-fold resistance to
A-419259 in vitro without diminishing kinase activity. When expressed in hu-
man TF-1 myeloid cells transformed with Flt3-ITD, these inhibitor-resistant
Hck and Fgr mutants conferred resistance to growth inhibition by A-419259 to
a similar extent, while expression of the corresponding wild-type kinases was
without effect. The sensitivity of the TF-1/Flt3-ITD cell lines to A-419259 cor-
related with inhibition of mutant Hck and Fgr kinase activity in the cells. Our
fındings suggest that suppression of AML cell growth by A-419259 is due in part
to inhibition of Hck and Fgr, and identify these AML-associated kinases as
therapeutic targets. Ongoing studies are addressing the role of Hck and Fgr as
inhibitor targets in Flt3-ITD AML cell lines and patient samples as well as the
propensity of A-419259 and other multi-targeted inhibitors of AML-associated
kinases for acquired drug resistance.
#2364 Src-like adaptor protein 2 negatively regulates FLT3 and KIT
downstream signaling. Sausan A. Moharram, Lars Rönnstrand, Julhash U.
Kazi. Lund University, Lund, Sweden.
Type III receptor tyrosine kinases (RTKs) including FLT3 and KIT play a
major role in cell differentiation, proliferation, and survival of hematopoietic
stem cells. FLT3-ITD and KIT-D816V mutations are the most common onco-
genic mutations in FLT3 and KIT found in hematological cancers. These muta-
tions lead to constitutive activation of proliferative and survival signals. Ty-
rosine kinase inhibitors (TKIs) in combination with chemotherapy display
promising results in a clinical setting, but patients develop resistant disease after
short-term treatment,. Hence, proteins that regulate the activity of RTKs can be
alternative targets for patients carrying thesemutations. Activation of FLT3 and
KIT results in phosphorylation on several tyrosine residues that recruit SH2
domain-containing signaling proteins. In this study we identifıed Src-like adap-
tor protein 2 (SLAP2) as a potent FLT3 and KIT interacting protein. The inter-
action requires an intact SH2 domain of SLAP2 aswell as phosphorylation of the
receptor. Overexpression of SLAP2 in murine proB Ba/F3 cells inhibited onco-
genic FLT3-ITD-mediated cell proliferation and colony formation. SLAP2 dis-
played a similar inhibitory potential in cells expressing KIT-D816V. SLAP2
partially blocked phosphorylation of several FLT3 and KIT downstream signal-
ing proteins such as AKT, ERK and p38. Moreover, SLAP2 expression inhibited
FLT3-ITD-mediated STAT5 phosphorylation and KIT-D816V-mediated
STAT3 phosphorylation. SLAP2 expression signifıcantly accelerated ubiquiti-
nation-mediated degradation of FLT3 and KIT. Collectively, these data suggest
that SLAP2 negatively regulates FLT3 and KIT signaling and therefore, modu-
lation of SLAP2 expression levels may become a potential target for anticancer
therapy.
#2365 Dual inhibition of the PI3k/Akt and MEK5/ERK5 pathways in ta-
moxifen resistant breast cancer. Thomas D. Wright, Mahmud Hasan, Paula
Witt-Enderby, Jane Cavanaugh. Duquesne Univ. School of Pharmacy, Pitts-
burgh, PA.
Approximately 70% of breast cancers are considered estrogen receptor
alpha (ER) and/or progesterone receptor (PR) positive, and their growth is
primarily driven by the hormone estrogen. Initially these cancers are respon-
sive to endocrine therapies such as tamoxifen. However, over time patients
become resistant to conventional endocrine therapy and treatment becomes
more diffıcult. Tamoxifen resistance occurs due to several mechanisms: loss
of ER expression, gain of function mutations, pharmacological tolerance,
alterations of co-activators, and ligand independent activation of ER by var-
ious kinase cascades. Aberrations in the Phosphoinositide-3-kinase (PI3K)
and Mitogen Activated Protein Kinase (MAPK) pathways have been linked
to increased breast cancer proliferation and survival. It has been proposed
that these survival characteristics are enhanced through compensatory sig-
naling and crosstalk mechanisms. The crosstalk between PI3K/Akt and
MEK1/2/ERK1/2 has been characterized in several systems. However, new
evidence suggests that MEK5/ERK5, a member of the MAPK family, is a key
component in the proliferation and survival of therapy resistant cancers.
MEK5/ERK5 has been shown to promote ER alpha driven transcription in
ER breast cancers and actin reorganization and metastasis in ER- breast
cancers. Furthermore, MEK5/ERK5 promotes hormone independent tu-
morigenesis in breast cancer. Our lab has previously investigated these path-
ways in hormone independent breast cancers, TNBC (triple negative breast
cancer). Our previous results indicate that combinations of PI3k/Akt and
MEK5/ERK5 blockade are promising because they inhibit both the pro-
proliferative and pro-metastatic pathways in TNBC. Additionally, PI3k/Akt
and MEK5/ERK5 inhibition was shown synergistically reduce viability in a
diverse panel of cell lines (TNBC, ER, and Triple Positive). Based on these
initial results we hypothesize that PI3k/Akt and MEK5/ERK5 inhibition de-
creases viability via a hormone independent mechanism: perhaps by reduc-
ing the cytosolic sequestration of Bad. In this study we investigate the utility
PI3k/Akt andMEK5/ERK5 inhibition in aMCF-7 TamR cell line. The goal of
our study is to elucidate the roles of PI3k/Akt/mTOR and MEK5/ERK5 in
endocrine resistant breast cancer and broaden the scope of a dual inhibition
strategy.
#2366 Targeting PI3 pathway in ibrutinib resistant diffuse large B-cell
lymphoma. Neeraj Jain,1 Lalit Sehgal,1 Stephen Joseph Shuttleworth,2 Felipe
Samaniego1. 1UT MD Anderson Cancer Ctr., Houston, TX; 2Karus, Abingdon,
United Kingdom.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of
non-Hodgkin lymphoma (NHL) and approximately 30% of patients with
DLBCL develop relapsed/refractory disease that becomes a major cause of
mortality and morbidity. The Bruton kinase (BTK) inhibitor ibrutinib suc-
cessfully blocks B-cell receptor signaling and shows clinical benefıt in leuke-
mia and lymphomas, including mantle cell lymphoma (MCL) and DLBCL.
Ibrutinib elicits overall desirable response rate with relapsed/refractory
MCL and ABC DLBCL. However, in spite of these encouraging results, re-
sponses are variable and generally incomplete, acquired resistance is com-
mon, and recurrence and persistence of lymphoma is a problem. We under-
took a study of factors underlying acquired ibrutinib resistance (IR) in
initially ibrutinib-sensitive DLBCL cell lines. In this study, IR DLBCL cell
lines were generated by continuous culturing of parental (PT) cell lines in
increasing concentrations of ibrutinib. Once established, IR cell lines were
removed from ibrutinib, expanded, and cultured under the same conditions
as the PT cell lines for further experiments. Of 5 ABC DLBCL cell lines
tested, two (OCI-LY3, U2932) were initially resistant to ibrutinib
(IC5010M).Three (TMD8, OCI-LY10, HBL1) were sensitive (IC50  10
nM). In comparison to PT versions of these cell lines, IR cells did not form
clumps in suspension cultures, displayed irregular cell morphology, showed
elevated colony formation ability inmethylcellulose matrix, and had a higher
proliferation rate.Western blots and gene expression profıle analysis showed
increased expression by IR cell lines of inhibitors of apoptosis (IAP) family
members, survivin, cIAP2, and oncogenic BCL2 and BCL6. The DNA dam-
age repair pathway was found to be elevated with enhanced expression of
CHK1 kinase. IR cell lines had reduced BTK expression without acquiring
mutations, and downstream enhanced PI3K-Akt signaling. Analysis of PI3K
isoforms revealed up-regulation of PI3K and PI3Kwith decreased expres-
sion of PI3K	 and PTEN (PI3K negative regulator). Given the enhanced
PI3K isoform expression with IR, we treated IR cell lines with the PI3K/	
isoform-targeting drug KA2237 and observed reduced metabolic activity
(survival) of PT cell lines and further reduction of surviving IR cell lines. In
conclusion, this study highlights how changes in a regulator (PTEN) and
mediator (p110) of PI3K/AKT signaling have important roles in the devel-
opment of ibrutinib resistance in DLBCL. Treatment with KA2237 may pro-
vide a better outcome for ibrutinib-resistant DLBCL.
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#2367 Identifıcation of ALK alternative transcription initiation in BRAF-
negativemetastaticmelanomapatients. ShanZhong,1 Christine Lovly,2 Chris-
tine Malboeuf,1 Kristina Brennan,1 Douglas Johnson,2 Kelsie Riemensch-
neider,2 Catherine Meador,2 Emily White,1 Geoff A. Otto,1 Doron Lipson,1
Philip Stephens,1 Vincent Miller,1 Jeffrey Ross,1 Jie He1. 1Foundation Medicine,
Inc, Cambridge, MA; 2Vanderbilt University, Nashville, TN.
Background: Genomic alterations in the ALK tyrosine kinase, such as copy
number gains, point mutations, and ALK gene fusions, have been described in a
broad spectrumofmalignancies. Recently a novelmechanism of ALK activation
inmelanomawas discovered inwhichALK transcriptionwas initiated from a de
novo alternative transcription initiation (ATI) site in ALK intron 19 (ALK-ATI)
[1]. In this study, we usedwhole transcriptome sequencing (WTS) to interrogate
a cohort of clinical melanoma specimens in order to identify those that express
ALK-ATI. Method: RNA-seq libraries of 33 BRAF-negative clinical metastatic
melanoma specimens were prepared using the KAPA Stranded RNA-Seq Kit
with RiboErase with 200ng RNA as input and sequenced on Illumina HiSeq
4000 at 2x75bp. The specimenswere sequenced to an average of 69.4m total read
pairs with 11.3mon-target distinct read pairs. Sequencing reads weremapped to
the human genome and transcriptome, gene- and exon-level expressions were
quantifıed. An algorithm to identify the ALK-ATI was developed based on as-
sessing 1) transcription of intron 19 putative ATI region, 2) ALK relative RNA
expression and 3) ALK 5= to 3= differential expression. In addition, immunohis-
tochemistry (IHC) staining for ALK (using D5F3 antibody) was done on 10 of
the 33 samples with adequate tumor material. Results: High coverage (median
30x) of intron 19 ATI region and high ALK relative expression (log ratio  2)
were observed in 4 of the 33 specimens tested, in which the ATI site is consistent
with what had been reported in [1]. Among the 4 potential ALK-ATI positive
cases, 3 have shown signifıcant 3= to 5= overexpression of ALK. IHC staining
were performed on the 4 putative ALK-ATI positive cases and 6 putative nega-
tive cases, and has confırmed ALK-ATI calls detected byWTS assay. Two of the
ALK IHC positive cases harbor the highest ALK expression, and the other two
ALK-ATI likely cases are ALK IHC weak positive. ALK-ATI occurred in cuta-
neous, mucosal, and unknown primary melanoma, and co-occurred with other
driver mutations (NRAS, NF1, KIT). None of the above specimens had ALK
rearrangements detected from DNAseq (by FoundationOne) or WTS. Conclu-
sions: Our fındings confırmed previously reported ALK activation through
ALK-ATI in an independent melanoma cohort, and provided direct evidence
that such events can be detected using whole transcriptome sequencing and
align with IHC results in clinical FFPE tumor specimens. This confırmation
together with future functional validation and clinical evidence may provide
new therapeutic opportunities for BRAF-negative metastatic melanoma pa-
tients. 1.Wiesner, T. et al. Alternative transcription initiation leads to expression
of a novel ALK isoform in cancer. Nature 526, 453-457 (2015).
#2368 Differential role of Pik3caH1047R and Pten
/
mutations in thyroid
cancer development. Michela Ranieri, Antonio Di Cristofano. Albert Einstein
College of Medicine, Bronx, NY.
Anaplastic thyroid cancer (ATC) is one of the most lethal malignancies, with
a median survival of less than 6 months from time of diagnosis. Molecular
changes that characterize ATC involvemost often p53 loss or inactivation (up to
80%), activation of the PI3K cascade through PTEN loss (12%) and PIK3CA
activating mutations (20%) or gene amplifıcation (30-60%), RAS family mem-
bers activation (6-50%), and BRAF activation (25-50%). Studies performed in
endometrial and breast cancer suggest that although PI3K activating mutations
andPTEN loss of function both enhance PI3K signaling, thesemutations are not
equivalent. We have tested whether Pik3caH1047R and Pten/ mutations have
the same impact on thyroid cancer development and if these two mutations
differ in their ability to cooperate with additional genetic alterations, such as p53
deletion and the KrasG12D activating mutation. We have generated a series of
mouse models and cell lines carrying thyroid-restricted p53/, KrasG12D,
Pten/, andPik3caH1047R alleles. Analysis of single and compoundmutants has
revealed important and striking differences between Pten and PI3K abilities to
control the PI3K signaling pathway. Tumor development analysis in Pten/
and Pik3caH1047R mice has revealed that Pik3ca activation is less potent in in-
ducing thyroid hyperplasia and subsequent transformation than Pten loss, even
though the two mutations appear to have similar ability to induce AKT activa-
tion. This differential activity correlates with lower levels of PIP3 found in the
thyroids of Pik3caH1047R mice, compared to that of Pten/ mice. We also ob-
served that while Pten loss synergizes with Trp53 loss to induce anaplastic thy-
roid cancer, activation of Pik3ca leads to the development of a smaller and well
differentiated tumors. On the other hand, Pten loss and Pik3ca activation are
equivalent in inducing poorly differentiated tumors in the presence of a Kras
activating mutation. However, KrasG12D, Pik3caH1047R cell lines are more sensi-
tive to PI3K,MEK and combined PI3K/MEK inhibition thanKrasG12D, Pten/
cell lines. Accordingly, tumors developing in mice carrying the KrasG12D,
Pik3caH1047R alleles are more sensitive than KrasG12D, Pten/ mice to a dual
PI3K/mTor inhibitor as well as a MEK inhibitor. All together these results sug-
gest that Pten loss has a stronger impact than Pik3ca activation to thyroid cancer
development and resistance to small molecule inhibitors.
#2369 Transcription activators that regulate PKC-zι expression and are
downstream targets of PKC-zι. Andre H. Apostolatos, Wishrawana S. Ratnay-
ake, Tracess Smalley, Anisul Islam, Mildred Acevedo-Duncan. University of
South Florida, Tampa, FL.
Protein Kinase C-iota (PKC-zι) is an anti-apoptotic oncogene over-expressed
in multiple cancers including prostate, ovarian, and glioma. PKC-zι is part of a
cycle that helps cancer cell avoid senescence by releasing the transcription factor
NFkB and promoting apoptotic resistance. PKC-zι is activated externally by fac-
tors like loss of PTEN (Paget 2012). However, while under the effect PKC-zι
specifıc inhibitors, expression levels decreased, suggesting PKC-zι plays a role in
regulating its own expression. A previous study showed the ELK1 transcription
factor to be a regulator of PKC-zι (Gustafson 2003). Other transcription factors
including Jun, ISGF3, PAX3, EGR1, and FOXO1 bind on or near the promoter
sequence of the gene and their role in PKC-zι regulation was analyzed. Each
transcription factor was systematically silenced with its own siRNA. Western
Blotting revealed expression of PKC-zι in the transcription factor silenced cells
determining which transcription factors are key players in regulation of PKC-zι.
qPCR and microarray were performed to analyze the transcriptome of treated
cells tomatch protein levelswithmRNA levels. Targets both up anddownstream
of PKC-zι were analyzed to fınd the pathway that PKC-zι uses to help regulate
itself.
#2370 Depletion of p21-activated kinase 4, PAK4, inhibits cellular prolif-
eration, motility and clonogenicity in oral squamous cell carcinoma. Felicia
F. Chung,1 Si-Hoey Tan,1 Vijay J. Raja,2 Pei Yuen Ng,3 Ian C. Paterson,4 Chye
Ling Tan,5 Chee-Onn Leong1. 1International Medical University, Kuala Lum-
pur, Malaysia; 2Weill Cornell Medical College, New York, NY; 3The National
University of Malaysia, Kuala Lumpur, Malaysia; 4University of Malaya, Kuala
Lumpur, Malaysia; 5Agency for Science, Technology and Research (A*STAR),
Singapore, Singapore.
Oral squamous cell carcinoma (OSCC) accounts for 90% of all malignancies
in the oral cavity, and is often associated with low survival and poor prognosis.
While considerable progress in OSCC treatment has been made, options for
targeted therapy remain limited. Thus, it is imperative that new druggable tar-
gets are identifıed and characterized. p21-activated kinase 4 (PAK4) is amember
of the PAK family of serine/threonine kinases, which are known modulators of
a diverse range of oncogenic pathways including cell proliferation, escape from
apoptosis, and anchorage-independent growth. Previous reports have indicated
that PAK4 is overexpressed in a subset of invasive OSCC, and is highly associ-
atedwith poor prognosis. However, the specifıc role of PAK4 inOSCChas yet to
be elucidated. Here, we show that RNAi-mediated depletion of PAK4 conferred
reduced clonogenicity, cell motility, and cell proliferation inOSCC cell lines in a
cell line-dependent manner. Global proteomic profıling of PAK4-depleted
H103 and H357 cells was conducted to identify the molecules and signaling
pathways responsive to PAK4 depletion. In addition to reported targets of PAK4
such as CFL1, ACTB, and TUBB6, we observed that p16INK4a, pre-mRNA splic-
ing factors (SRSF2, SRSF5, SRSF6, SLU7), and proteasome activator subunits
(PSME1-4) were dysregulated as a result of PAK4 depletion. These results indi-
cate that PAK4 plays a role in promoting OSCC progression by regulating mul-
tiple signaling pathways. Of note, there have yet to be any reports describing
interactions between PAK4 signaling andmRNA splicing or proteasome activa-
tion. Further investigation is thus warranted to further delineate the potential
role of PAK4 in regulating these targets.
#2371 Oncogenic transformation of FLT3-ITD is partially dependent on
tyrosine 842 in the activation loop. Julhash U. Kazi, Lars Rönnstrand. Lund
University, Lund, Sweden.
Acute myeloid leukemia (AML) is a heterogeneous disease of the blood.
About 30 % of AML patients carry an oncogenic mutant of the type III receptor
tyrosine kinase FLT3. Among the various mutations in FLT3, the internal tan-
dem duplication (ITD) mutations in the juxtamembrane domain are the most
common type of mutation, while point mutations in the kinase domain also
occur. Although oncogenic FLT3 mutants are constitutively active, the wild-
type receptor needs its ligand (FLT3 ligand, FL) for activation. Ligand binding to
the receptor induces dimerization, auto-phosphorylation, and activation of the
receptor. Tyrosine phosphorylation sites on FLT3 constitute docking sites for
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Cell Growth Signaling Pathways 5
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017606
interacting proteins that transduce pro-survival and proliferative signals. The
so-called activation loop tyrosine residue (in FLT3, Y842) is well conserved in all
receptor tyrosine kinases and long been known essential for the activity of some
but not all receptor tyrosine kinases. Recently we have shown that activation
loop tyrosine residue in KIT is not essential for its activation but plays an im-
portant role in receptor stabilization and downstream signaling. However, so far
the role of FLT3 activation loop tyrosine residue remains unknown. We gener-
ated 32D cell lines carrying a Y-to-F mutant (Y842F) of FLT3 in either the
wild-type or ITD background to study the role of this tyrosine residue.We show
that the Y842 residue is not necessary for FLT3 activation or stability but is
required for oncogenic transformation. We observed that Y842F mutation re-
sults in reduced cell viability, proliferation and in vitro colony formation in
semi-solid medium. In addition, cells expressing the Y842F mutant in FLT3-
ITD background display a signifıcant reduction in tumor volume and weight in
a xenograft model in nude mice. Gene set enrichment analysis (GESA) shows
thatmutation of Y842 causes suppression of anti-apoptotic genes. Furthermore,
we demonstrated that phosphorylated Y842 is one of the binding sites of the
protein tyrosine phosphataseSHP2, which is required for activation of signaling
through the RAS/ERKpathway. Taken together, our data suggest that activation
loop tyrosine residue in FLT3 plays an important role in the cellular transfor-
mation which is regulated by RAS/ERK signaling.
#2372 Xkr5 negatively regulatesKIT/D816V signaling. Jianmin Sun,1 Tine
Thingholm,2 Tianfeng Li,3 Julhash U. Kazi,2 Hui Zhao,3 Lars Rönnstrand2.
1NingxiaMedical University, Yinchuan, China; 2LundUniversity, Lund, Sweden;
3the Chinese University of Hong Kong, Hong Kong, Hong Kong.
D816V is the most often occurred mutation of type III receptor tyrosine
kinase KIT in mastocytosis and CBF-AML. In attempting to identify specifıc
downstream signaling pathways of KIT/D816V, we found that KIT/D816V but
not wild-type KIT can bind to Xkr5 that was not studied previously. In addition
to the association with KIT/D816V, Xkr5 is phosphorylated at Tyr 369, Tyr487
and Tyr 543 by KIT/D816V, and the phosphorylation is mediated by only mu-
tations of Asp 816 in KIT but not by other KIT mutations that occurred in
gastrointestinal stromal tumors and melanoma. Furthermore, the tyrosine
phosphorylation of Xkr5 is not dependent on Src family kinases that play a
crucial role in the activation of wild-type KIT. In KIT/D816V expressing mast
cells, phosphorylation of Xkr5 inhibits KIT/D816V downstream signaling mol-
ecules Akt, Erk and p38. As a consequence, cell proliferation and colony forma-
tion are inhibited by the tyrosine phosphorylation of Xkr5 as well, indicating
that Xkr5 is a negative regulator of KIT/D816V signaling.
#2373 Analysis of the distinct activities of the C1a and C1b domains of
protein kinase C theta. Agnes Czikora,1 Satyabrata Pany,2 Youngki You,2
Amandeep Saini,1 Noemi Kedei,1 Nancy E. Lewin,1 Adelle Abramovitz,1 Joydip
Das,2 Peter M. Blumberg1. 1National Cancer Institute, LCBG, Bethesda, MD;
2Department of Pharmacological and Pharmaceutical Sciences, Houston, TX.
PKC isozymes, themajor receptors for tumor-promoting phorbol esters, play
a central role in cellular signal transduction downstream of the second messen-
ger diacylglycerol. The PKC isozyme has been extensively studied particularly
in the context of hematopoiesis and immunity, where is required for the devel-
opment and maturation of specifıc T cell subsets. PKC also plays a role in
Notch-driven T cell leukemia and in a subset of gastrointestinal stromal tumors,
melanoma and breast cancers. TheC1 domains represent the regulatorymotif in
the PKCs responsible for their recognition of diacylglycerol / phorbol esters.
PKC is unique among the conventional and novel PKC isoforms in that one of
the two C1 domains of PKC, the C1a domain, has been reported to show little
or no affınity for diacylglycerol or phorbol ester, unlike the C1b domain. Like-
wise, the PKC C1b domain has been reported to play the predominant role in
the membrane translocation and activation process of PKC. We observed that
the C1a domain in fact has appreciable binding activity for [3H]phorbol 12,13-
dibutyrate (PDBu), with a Kd of 254 nM, albeit much less than that of the C1b
domain, 1.58 nM. Replacing individually in the C1a domain ten of the amino
acid residues that differed between the C1a and C1b domains, using the corre-
sponding residue from the C1b domain, we found that only the P9K replace-
ment restored [3H]phorbol 12,13-dibutyrate binding activity to theC1a domain,
yielding a Kd of 3.60 nM, close to that of the C1b domain. Strikingly, the recip-
rocal replacement in the C1b domain of K9P still preserved appreciable binding
affınity, 11.7 nM.We conclude that other features in the C1a domain contribute
to the extent to which the P9 residue negatively influences binding. We further
explored the role of the C1 domains of PKC on translocation using confocal
microscopywith a variety of full length constructs inwhich theC1domainswere
manipulated. Consistent with the binding studies, we showed that the C1b do-
main was the main contributor to translocation, that the full length PKC with
the C1b K9P retained response, albeit more weakly, and that deletion of the C1a
domain or its replacement with a second C1b domain enhanced the transloca-
tion to the plasmamembrane. Exploitation of the structural differences between
theC1domains inPKC and those of other PKC isoforms, both at the level of the
direct ligand interactions and the more complicated interplay between C1 do-
main, ligand, and phospholipid bilayer, may help to afford specifıc ligands for
this member of the PKC family.
#2374 Mixed-Lineage Kinase 3 signals through the FRA1-MMP1 axis to
drive triple-negative breast cancer invasion and transendothelial migration.
Chotirat Rattanasinchai, Brandon Llewellyn, Susan E. Conrad, Kathleen A.
Gallo.Michigan State Univ., East Lansing, MI.
Mixed-lineage kinase 3 (MLK3), a mitogen-activated kinase kinase kinase
(MAP3K), contributes to metastasis of triple-negative breast cancer (TNBC), in
part through its regulation of paxillin phosphorylation and focal adhesion turn-
over. However the signaling mechanisms through whichMLK3 promotes inva-
sion and metastasis are not fully understood. We found that in non-metastatic,
estrogen receptor positive (ER) breast cancer cells, inducedMLK3 expression
robustly upregulates the oncogenic transcription factor, FOS-related antigen-1
(FRA-1), as well as matrix metalloproteinases (MMPs), MMP-1 and MMP-9.
MLK3-induced MMP-1 induction is abrogated by FRA-1 silencing, demon-
strating that MLK3 signals through FRA-1 to control MMP-1. In complemen-
tary experiments performed in metastatic TNBC models, high levels of FRA-1
are signifıcantly reduced upon gene silencing of MLK3 or by MLK3 disruption
using the CRISPR/Cas9n approach. Furthermore, bothMMP-1 andMMP-9 are
decreased upon ablation of MLK3 or MLK inhibitor treatment. Reduced endo-
thelial permeability and transendothelial migration is observed in experiments
with MLK3-depleted TNBC cells compared with parental counterparts. In ad-
dition, MLK inhibitor treatment or MLK3 depletion renders TNBC cells defec-
tive in Matrigel invasion. Furthermore, circulating tumor cells (CTCs) derived
from aTNBC-bearingmouse which show an intermediate epithelial-mesenchy-
mal phenotype display increased levels ofMLK3, FRA-1, andMMP-1 compared
with parental cells, supporting a role for the MLK3-FRA-1-MMP-1 signaling
axis in tumor cell invasion and vascular intravasation.Consistentwith the role of
MMP-1 in multiple steps of metastasis, high levels of MMP-1 in breast cancer
patient tumor samples are associated with increased distant metastases and
poorer overall survival, particularly in TNBC. Our results demonstrating the
requirement for MLK3 in controlling the FRA-1/MMP-1 axis suggest that
MLK3 is a potentially effective therapeutic target for TNBC.
#2375 Functional role of the tumor suppressor protein phosphatase,
PP2A-B55, in breast cancer. Nikita Panicker,1 Abdul Mannan,1 Lauren F.
Watt,1 Ben Copeland,1 Matt D. Dun,1 Simon King,2 Megan Clarke,3 Kathryn
Skelding,1 Severine Roselli,1 NicoleM. Verrills1. 1Univ. of Newcastle, Callaghan,
Australia; 2Pathology North, New Lambton, Australia; 3Hunter Cancer Research
Alliance, New Lambton, Australia.
Breast cancer is the most common cancer in women and a leading cause of
death. Dysregulation of cellular signalling pathways controlling proliferation,
survival andmigration, such as the PI3K/Akt and Ras/MAPK pathways, are key
features of breast cancer. Protein phosphatase 2A (PP2A) negatively regulates
many components of these pathways. PP2A is a family of trimeric serine/thre-
onine phosphatases, each consisting of a structural, a catalytic and a regulatory
subunit of which there aremultiple isoforms. The addition of specifıc regulatory
subunits provides subcellular targeting and substrate specifıcity to the enzyme.
While PP2A is generally considered a tumor suppressor, a specifıc role for indi-
vidual PP2A subunits in breast cancer has not been described. To address this,
we fırst examined PP2A subunit expression in human breast tumors. Immuno-
histochemical analysis revealed signifıcantly lower expression of the structural
subunit, PP2A-A, and regulatory subunits PP2A-B55 and PP2A-B56, in pri-
mary tumors and metastases, compared to adjacent normal mammary tissue.
We further found an association of low PP2A-B55 with aggressive breast can-
cer subtypes, and with worse disease-free and overall survival. Functionally,
shRNA-mediated knockdownof PP2A-B55 in normalmammary epithelial 3D
cultures induced a tumorigenic phenotype, characterised by increased prolifer-
ation and enlarged multi-lobular acini. In contrast, overexpression of PP2A-
B55 in breast cancer cells inhibited proliferation. Thus PP2A inactivation, in
particular loss of B55, is functionally important in breast tumorigenesis. PP2A-
B55 complexes play an important role in DNA damage repair, and we found
B55 knockdown impaired DNA damage repair. Thus low PP2A-B55 may
contribute to genomic instability. To examine the functional role of PP2A-B55
in vivo, we have generated the fırst PP2A-B55 (Ppp2r2a) knockout mouse.
Constitutive knockout of Ppp2r2a is embryonic lethal, with embryos dying dur-
ing late development, post 14.5 days p.c. Heterozygous Pppr2ra mice
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(Ppp2r2a/) are viable, despite expressing only10% of PP2A-B55 protein
levels compared toWTmice. Interestingly, Ppp2r2a/mice have signifıcantly
reduced branching in the developing mammary gland, similar to that observed
in mice with mammary-specifıc loss of the breast tumor susceptibility gene,
Brca1. Analysis of breast tumor formation in these mice, either alone or when
crossed with MMTV-Neu animals, is underway. Finally, we show that pharma-
cological activation of PP2A, using FTY720, or the non-phosphorylatable ana-
logue, AAL(S), inhibits tumor growth andmetastases in an orthotopic xenograft
model of aggressive, triple negative breast cancer (MDA-MB-231). Together this
work demonstrates the importance of PP2A as a tumor suppressor in breast
cancer, and suggests that targeting PP2A is a potential therapeutic strategy for
poor outcome patients.
#2376 Novel insights into the regulation of ERK3’s kinase activity and its
ability to promote cancer cell invasiveness. Lobna Elkhadragy, Hadel Alsaran,
Weiwen Long.Wright State University, Dayton, OH.
In comparison with the well-studied conventional MAPKs, such as extracel-
lular signal-regulated kinase (ERK)1/2, much less is known about the regulation
and downstream targets of ERK3, an atypical MAPK. Whereas dual phosphor-
ylation of the TXY activation motif in ERK1/2 is critical for their activation, it is
unclear if phosphorylation of the single phospho-acceptor site (S189) in the SEG
activationmotif of ERK3 is critical for its kinase activity or function. In addition,
little is known about the functions of the structurally distinct elongated C-ter-
minus extension of ERK3. Recent studies have revealed important roles for
ERK3 in promoting cancer progression.Of note, our previous study showed that
ERK3 increases cancer cell invasiveness by phosphorylating the oncogenic pro-
tein steroid receptor co-activator 3 (SRC-3) and upregulating SRC-3-mediated
matrix metalloproteinase gene expression. Here we aimed to elucidate the im-
portance of the phospho-site S189 and the C-terminus in regulating ERK3 ki-
nase activity and its functions in cancer cells. By performing in vitro kinase
assays, we found that as compared to the wild type (WT) ERK3 protein, ERK3-
S189A has remarkably reduced kinase activity towards auto-phosphorylation
and phosphorylating SRC-3. In line with the critical role of S189 in ERK3 kinase
activity, mutation of S189 to alanine greatly reduced ERK3’s activity in promot-
ing the migration and invasion of lung cancer cells. To study the regulatory role
of the C-terminus in ERK3 kinase activity, we expressed and purifıed the N-ter-
minal ERK3 (aa 1-340) that retains the kinase domain but has deletion of the
C-terminus. While it showed higher auto-phosphorylation ability than the full
length ERK3 protein, ERK3 (aa 1-340) had greatly decreased ability to phos-
phorylate SRC-3. Interestingly, ERK3-S189A (aa 1-340) exhibited kinase activity
equivalent to that of ERK3 (aa 1-340). These results suggest that on one hand, the
C-terminusmay play an auto-inhibitory role onERK3 kinase activation through
intramolecular interaction and that the phospho-S189 is required for relieving
this auto-inhibition; on the other hand, C-terminus plays a critical role for ERK3
to recruit substrates, such as SRC-3. In agreement with its inability to phosphor-
ylate SRC-3, ERK3 (aa 1-340) had decreased ability to stimulate migration and
invasion of lung cancer cells as compared to full length ERK3. Taken together,
our study unravels the importance of ERK3 S189 residue as well as the C-termi-
nus for the intramolecular regulation of ERK3 kinase activity and invasiveness-
promoting ability in cancer cells.
#2377 The AML linked Src family kinase Fgr is uncoupled from SH2 and
SH3 domain regulation and drives oncogenic transformation. Kexin Shen,1
Heather R. Dorman,1 Haibin Shi,1 Ravi K. Patel,1 Jamie A. Moroco,2 John R.
Engen,2 Thomas E. Smithgall1. 1Univ. of Pittsburgh School of Medicine, Pitts-
burgh, PA; 2Northeastern University, Boston, MA.
Fgr is a member of the Src family of non-receptor protein-tyrosine kinases,
which are over-expressed and constitutively active in many human cancers. Fgr
expression is restricted tomyeloid hematopoietic cells and strongly upregulated
in a subset of primary human AML bone marrow samples, suggesting that Fgr
kinase activity may contribute to AML pathogenesis. To investigate the onco-
genic potential of Fgr, we expressed the wild-type kinase in Rat-2 fıbroblasts and
scored transformation in soft-agar colony-forming assays. Remarkably, Fgr ex-
pression resulted in strong transforming activity, suggesting that over-expres-
sion of the kinase is suffıcient to overcome regulatory control by its SH2 and SH3
domains. To test this idea, we mutated the negative regulatory tail tyrosine of
Fgr. Phosphorylation of the homologous tyrosines in c-Src, Hck and other Src-
familymembers by the regulatory kinaseCsk causes intramolecular engagement
of the SH2 domain to suppress kinase activity. Substitution of the Fgr tail ty-
rosine with phenylalanine did not further enhance the transforming or kinase
activity of Fgr in Rat-2 cells, suggesting that its kinase domain is uncoupled from
regulation by its non-catalytic SH3-SH2 region. To explore the regulatorymech-
anism further, we expressed near-full-length Fgr in insect cells, purifıed it to
homogeneity, and confırmed that it was singly phosphorylated on its negative
regulatory tail (and not the activation loop). Hydrogen-deuterium exchange
mass spectrometry demonstrated that the SH3 and SH2 domains are protected
from deuterium uptake as observed previously for recombinant, downregulated
Hck, suggesting that they are packed against the back of the kinase domain. We
then tested recombinant Fgr for sensitivity to activation in vitro using peptide
ligands for the SH3 and SH2 domains, as well as a peptide that engages both
domains simultaneously. Fgr kinase activity was unaffected by these peptides,
providing further evidence that the kinase domain is not allosterically coupled to
SH3 and SH2 control. In contrast, Hck and c-Src were both stimulated by these
peptides, consistent with a domain displacement mechanism of activation de-
scribed previously. Control experiments using surface plasmon resonance spec-
troscopy confırmed that the SH3 and SH2 domains of both Hck and Fgr bind to
each of the peptide ligandswith similar kinetics and affınity. Taken together, our
data show that Fgr is a unique Src familymember in that its kinase domain is not
subject to regulatory domain control despite evidence for intramolecular inter-
actions with the SH3 and SH2 domains. As a consequence, simple over-expres-
sion of Fgr is suffıcient to induce transformation of rodent fıbroblasts, unlike
Hck or other Src family members. By extension, over-expression of Fgr may
contribute toAMLdevelopment and selective targeting of its kinase activitymay
be of therapeutic benefıt.
#2378 A kinome analysis of the molecular pharmacodynamics of PT-112
in a human cancer cell line.Diego Tosi,1 Esther Perez-Gracia,1 Philippe Pour-
quier,1 Tyler D. Ames,2 Richard A. Wing,2 José Jimeno,2 Céline Gongora1. 1In-
stitut de Recherche en Cancérologie de Montpellier, Montpellier, France; 2Phos-
platin Therapeutics, New York, NY.
Background: To better understand the mechanism of action of PT-112, we
investigated the effects of PT-112 on kinase activity within HCT116 human
colorectal cancer cells. PT-112 is a pyrophosphate-conjugated platinum (Pt)
containing new chemical entity under clinical development in the US and Tai-
wan. Designed to reduce certain toxicities associated with Pt agents and drug
resistance fromDNA-repair pathway activity, PT-112 differs in signifıcant ways
from traditional Pt therapies. PT-112 results in potent anti-proliferation effects
with lower Pt accumulation inwhole cell andDNAextracts.Upregulation of p16
and p21 and, consistently, inhibition of the cell cycle at theG1/S phase transition
is observed with PT-112 use, a fınding not commonly associated with Pt agents.
Further, sensitivity to PT-112 is not signifıcantly affected by the functionality of
DNA repair pathways. Finally, the induction of immunogenic cell death by
PT-112 has been indicated via release of HMGB1, cell surface localization of
calreticulin, and suppression of STAT3. Methods: A broad analysis of the phos-
phorylation pattern of kinase targets was achieved by utilizing the Tyrosine
Kinase and Serine / Threonine Kinase PamChip® Arrays, each spotted with 144
peptides harboring kinase phosphorylation sites. Data were collected after 1, 6,
and 24hr of exposure to 10 M PT-112, a concentration achievable in human
patient plasma at sub-toxic doses, and the degree of phosphorylation of these
peptide targets wasmeasured by the PamStation®. Results: A set of kinase targets
was identifıed as differentially phosphorylated relative to untreated control sam-
ples. In total, 4/15/30 targets were more phosphorylated than controls at the
1/6/24hr time points, respectively, while 1/0/10 targets were less phosphory-
lated. Several of these targets connect to key cancer relevant pathways, including
anti-angiogenesis (VGFR1), apoptosis (BAD), cell cycle regulation (CDC2, Rb,
RBL2), cell growth (EGFR, MK07, RBL2), and cancer immunology (STAT4,
CSF1R). Conclusions: A narrow set of initial effects on kinase activity from
PT-112 exposure, which broaden over time, was observed. While we cannot
discriminate direct from indirect effects, these data are consistent with PT-112
having mechanistic targets independent of nuclear DNA. Several observations
were consistent with fındings from previous experiments (e.g. evidence of im-
pacts on apoptotic, cell cycle, and immunological pathways), while others were
novel (e.g. impact on VGFR1, EGFR,MK07). In conclusion, PT-112 at pharma-
cologically achievable concentrations leads to a unique pattern of kinase disrup-
tion in vitro. Further work will be conducted to validate these fındings, identify
the driver kinases, and connect these observations into a coherent network of
kinases and targets affected by PT-112 treatment, and to understand the clinical
impact of the unique pharmacodynamic profıle of PT-112.
#2379 Nuclear lemur tyrosine kinase-2 regulates RNA polymerase II de-
pendent transcription in prostate cancer. Kalpit Shah,1 Justin Foley,2 Michael
L. Nickerson,1 Michael Dean,1 Neil Bradbury2. 1National Cancer Institute,
Bethesda, MD; 2Rosalind Franklin University of Medicine & Sciences, North Chi-
cago, IL.
The Androgen Receptor (AR), a DNA-binding transcription factor plays a
key role in the development and maintenance of prostate epithelia by modulat-
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ing expression of growth-promoting genes. AR has been proposed to regulate
gene expression by enhancing the effıciency of RNA polymerase II (RNAPII)
dependent transcription elongation. Dysregulation of this AR-dependent tran-
scriptional activity has been implicated not only in prostate cancer but also
androgen-independent prostate cancer. Recently, we showed that protein ex-
pression of Lemur Tyrosine Kianse-2 (LMTK2), a serine-threonine kinase is
downregulated in prostate cancer. Importantly, our study ascribed a novel role
for LMTK2, as a negative regulator of AR-dependent transcriptional activity in
prostate epithelial cells. However, themechanism throughwhich LMTK2 is able
to regulate AR remains to be determined.Here, we show that LMTK2 is not only
present in cytoplasmic fraction but also, within the nucleus of mammalian cells
where it co-localizes with AR, newly transcribed mRNA and with RNA poly-
merase II (RNAPII). Interestingly, our data reveals that LMTK2 colocalizes with
elongating RNAPII, phosphorylated on serine 2 of the carboxyl-terminal do-
main. This presents an interesting possibility that LMTK2 might be able to
regulate transcription of AR-dependent genes by interactingwith the elongating
RNAPII and transcription & epigenetic factors. As such, our study potentially
identifıes LMTK2 as an important player regulating the AR-RNAPII mediated
transcription machinery in mammalian cells.
#2380 Insertionmutations in the tyrosine kinase domain of FLT3 display
a higher oncogenic potential than the D835Ymutation in acute myeloid leu-
kemia.AlissaMarhäll,1 Thomas Fischer,2 FlorianHeidel,3 JulhashU.Kazi,1 Lars
Rönnstrand1. 1Translational Cancer Research, Lund University, Lund, Sweden;
2Otto-von-Guericke University Medical Center, Magdeburg, Germany; 3Univer-
sity Hospital Jena, Jena, Germany.
Acute myeloid leukemia (AML) remains the most common form of acute
leukemia among adults and accounts for a large number of deaths. Mutation in
FMS-like tyrosine kinase 3 (FLT3) is one of the most prevalent factor in this
heterogeneous disease. The major mutations in FLT3 can be categories as inter-
nal tandem duplications (ITD) and point mutations. Recent studies suggest that
ITDs are subdivided in to two groups depending on their location: the jux-
tamembrane domain (ITD-JM) and the tyrosine kinase domain (ITD-TDK).
Although, ITD-JM has been characterized well the ITD-TKD has not yet been
studied well due to its recent discovery. For this reason, we compared ITD
mutations in TKD and JM, as well as the most frequently occurring point mu-
tation located in the TKD, D835Y. The purpose of this study was to understand
whether it is the mutation’s nature or location that plays the driving role in
leukemogenesis. We used a cytokine-dependent mouse pro-B cell line, BaF3, to
overexpress different FLT3 mutants. We fırst examined the colony formation
capacity in semisolid cytokine- and serum-free medium. The assay resulted in
indistinguishable number and size of colonies for both ITD-JM and ITD-TKD,
while D835Y-TKD transfected cells failed to form colonies suggesting that the
ITD-TKDmutations have stronger transforming potential than other TKDmu-
tations. In addition to colony formation assays, cell proliferation and survival
was signifıcantly higher in ITD-TKD expressing cells compared to cells express-
ing D835Y-TKD. Finally, we showed that phosphorylation of STAT5 and AKT
is increased in ITD-TKD, while other FLT3 downstream signaling remained
unaffected. All together, our data suggest that ITD-TKD displays higher onco-
genic potential than other TKD mutants.
#2381 The effect of ERK5 inhibition in clear cell renal cell carcinoma.
Hidenori Kanno, Sei Naito, Osamu Ichiyanagi, Norihiko Tsuchiya. Yamagata
University, Yamagata City, Japan.
Introduction: Clear-cell renal cell carcinoma (ccRCC) is the most prevalent
kidney cancer and is characterized by von Hippel-Lindau tumor suppressor
gene (VHL) mutation. VHL protein acts in a ubiquitin ligase complex, mediat-
ing the proteasomal degradation of ubiquitinized proteins, including hypoxia-
inducible factor (HIF). Therefore, HIF accumulates in VHL-defective cell lines.
A recent study revealed that extracellular signal-regulated kinase 5 (ERK5) is
degraded through the ubiquitin-proteasome system, in a process mediated by
VHL andHIF.Our objectives were to examine the effects of ERK5 in ccRCC and
to investigate ERK5 as a potential therapeutic target. Methods ERK5 expression
was investigated in surgically resected ccRCC specimens using immunohisto-
chemistry. To confırm that ERK5 is degraded by the VHL pathway, ERK5 levels
were examined bywestern blotting inCaki-1VHLwildtype renal cell carcinoma
(RCC) cells and in A498 and A704 VHL-mutant RCC cells with or without the
MG132 proteasome inhibitor. Furthermore, VHL-mutant cell lines were exam-
ined, with or without siRNA and XMD8-92-mediated ERK5 inhibition, to in-
vestigate the role of ERK5 in RCC cells using flow cytometry, MTS assays, and
western blotting. Results In surgical specimens, RCC cells showed higher levels
of ERK5 expression than did normal cells. In addition, MG132 enhanced ERK5
expression in wildtype cell lines, but not in VHL-mutant cell lines. Therefore,
ERK5 degradation involves the VHL pathway. Furthermore, ERK5 inhibition
resulted in increase of the sub-G1 population as observed by flow cytometry and
cleaved RARP expression as seen by western blotting, indicating an increase in
apoptotic cells. ERK5 inhibition also suppressed cell viability and downregu-
lated p16 and Bcl-2 expression. Conclusion Our results show that ERK5 inhibi-
tion contributes to the downregulation of anti-apoptotic and cell cycle proteins
and suggest that ERK5 is a promising therapeutic target for ccRCC.
#2382 RACK1 regulates PKA activity to drive tumorigenesis in colon can-
cer. Sheri L. Hayes, Catríona M. Dowling, John C. Coffey, Patrick A. Kiely.
University of Limerick, Limerick, Ireland.
RACK1 (Receptor for Activated C Kinases) is a scaffolding protein with 7
WD repeats that interacts with the Insulin-like Growth Factor I receptor
(IGF-IR), integrins, and other signalling proteins. RACK1 functions as a
scaffolding protein and regulator of many key biological processes and it is
highly expressed in most tissue. We recently reported that RACK1 is essen-
tial for IGF-I-mediated regulation of PP2A activity and AGAP2 activity at
focal adhesions. Downstream of IGF-1R signaling in cancer cells, the scaf-
folding properties of RACK1 are altered providing distinct migratory advan-
tages to the cell and suggesting that RACK1 is an important regulator of
IGF-I signalling in cancer progression. It is important to further characterise
the role of RACK1 in cancer and to delineate the molecular mechanisms by
which it regulates key signalling pathways. We have identifıed Protein Ki-
nase A (PKA) as RACK1 interacting protein. PKA is a complex, multicom-
ponent enzyme which is a fundamental protein that functions in cell sur-
vival, proliferation, and cytoskeletal remodelling among others. Our
hypothesis is that RACK1 regulates the PKA axis in cancer cells leading to
Akt and MAP Kinase activation downstream of IGF-1R signalling. We have
demonstrated that RACK1 is required to mediate PKA activity in colon
cancer cells. Although we show that PKA expression is not altered in colon
cancer tissue, we believe that PKA activity is altered signifıcantly in the
disease state. Using PKA inhibitors, we have shown that PKA regulates IGF-
I-mediated MAP Kinase activation in colon cancer cell lines. In conclusion,
this research project will help elucidate the role of PKA in colon cancer.
Inhibiting or promoting specifıc protein interactions with RACK1 will pro-
vide very novel therapeutic opportunities and anti-cancer drug targets.
#2383 Nicotinamide N-methyltransferase inhibits Protein Phosphatase
2A activity by promoting Y307 phosphorylation. John R. Jacob, Arnab
Chakravarti, Kamalakannan Palanichamy.Ohio State Univ. College of Medicine
and Comprehensive Cancer Center, Columbus, OH.
Recent evidence indicates that suppression of protein phosphatase 2A
(PP2A) activity plays an essential role in malignant transformation and can-
cer cell maintenance. Despite the importance of PP2A as a tumor suppressor
in cancer, the mechanisms by which other enzymes regulate PP2A remain
largely unknown. We recently identifıed Nicotinamide N-methyltransferase
(NNMT) as a novel regulator of PP2A activity in glioblastoma (GBM).
NNMT is a cytosolic N-methyl transferase which utilizes methyl groups
from S-Adenosyl methionine (SAM), forming the by-product S-Adenosyl
Homocysteine (SAH). PP2A becomes activated following the trimer forma-
tion of the three PP2A subunits, which requires the methylation of the cat-
alytic subunit of PP2A (PP2AC) at L309.In cancer, NNMThas been reported
to decrease the cellular methylation potential (SAM:SAH) and correspond
with decreased PP2A activity. It was hypothesized that the decrease in meth-
ylation potential accounts for the decrease in PP2A activity by kinetically
disfavoring the methylation of PP2A C. Interestingly, when we overex-
pressed NNMT in GBM cell lines and used LC-MS/MS (LC-MS Quadrupole
Time-of-Flight and LC-MS Triple Quad) to monitor the methylation poten-
tial, we discovered that overexpression of NNMT increased methylation
potential, however, still lead to a decrease in PP2A activity. As a result, we
hypothesized that NNMT suppresses PP2A activity in a methylation-inde-
pendent manner. In an effort to identify an alternative mechanism by which
NNMT decreases PP2A activity, we found that NNMT expression was re-
quired for the phosphorylation of PP2A C at residue T307, which inhibits
PP2A trimer formation and activation. Further, we found that NNMT ex-
pression leads to the constitutive activation of the PP2A target serine/thre-
onine kinases (STKs): Akt, MAPK, and SAPK/JNK. NNMT silencing re-
sulted in the deactivation of these STKs and radiation-induced cellular stress
was not suffıcient to rescue their activation. This suggests that NNMT-in-
duced PP2A suppression is essential for the activation of these kinases. Over-
all, this study demonstrates a novel mechanism independent of methylation
by which NNMT represses the activity of tumor suppressor PP2A.
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#2384 Aberrant expression of PDZbinding kinasemodulates humanpan-
creatic cancer cell invasion.Charles Hinzman,1 Jose Trevino,2 Partha P. Baner-
jee1. 1Georgetown Univ. Medical Ctr., Washington, DC; 2University of Florida
Medical Center, Gainesville, FL.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of
cancer-related deaths and projected to be the second leading cause of cancer
deaths by 2030. Incidence to mortality ratio for PDAC is almost one suggesting
its aggressive phenotype. The poor survival rate of PDAC patients is due to
metastasis to distant organs, and therefore, recent focus has been aimed towards
the identifıcation of molecular targets that drives metastatic disease. We are
investigating an under-studied kinase, PDZ-domain binding kinase (PBK) as a
target for pancreatic cancer (PanCa) therapy. PBK is a dual-specifıcity serine/
threonine kinase involved in mitosis and invasive behavior of cancer cells. It is
expressed physiologically in testis, but aberrant expression results in an aggres-
sive phenotype in a variety of cancers. Our results demonstrate that PBK expres-
sion varies across a panel of human PanCa cell lines, and directly correlates with
their invasive ability. Similarly, a panel of patient-derived primary PanCa shows
higher PBK levels associated with aggressive behavior and invasion. To assure
specifıcity of PBK to this invasive phenotype, we measured the effect of PBK
overexpression or knockdown on the PanCa lines’ invasive ability. Overexpres-
sion of PBK in low PBK expressing cells increased PanCa invasion 10-fold,
while PBK knockdown reduced invasive ability5-fold. Immunohistochemical
analyses of resected human PanCa specimens revealed that PBK is present in the
majority of human PanCa tissue samples tested but not in the adjacent normal
pancreatic tissue. Interestingly, aberrant PBK localization was found in even
early stages of PanCa development and was sustained throughout its progres-
sion. In search of molecular effectors of invasion regulated by the PBK, we
examined various genes/proteins that are involved in cancer cell invasion and
metastasis. RelB a well-known metastatic inducer in various cancers was found
to be a major payer in PanCa and regulated by PBK. These data indicate a novel
molecular pathway of PBK where its presence plays a role in invasion of human
PanCa cells. Therefore, the role of PBK in promoting cancer cell invasion, com-
bined with its general lack of expression in normal cells, nominates PBK as a
potentially important therapeutic target for pancreatic cancer.
#2385 Systematic characterization of kinase inhibitors reveals heteroge-
neity in responses by class and cell line. Caitlin E. Mills,1 Marc Hafner,1 Dejan
Juric,2 Peter K. Sorger1. 1Harvard Medical School, Boston, MA; 2Massachusetts
General Hospital, Boston, MA.
Several publications have addressed concerns surrounding drug response
screens by pointing out sources of variability and by presenting recommenda-
tions for better experimentalmethods andmore robust analytical approaches. In
the presented profıling effort, we integrated the latest advances in drug response
measurement and focused on data diversity and quality rather than on breadth.
We selected 32 breast cancer cell lines with a strong bias towards triple negative
lines as well as 4 cell lines established from relevant patient-derived xenografts.
We evaluated a panel of clinically relevant kinase inhibitors using amicroscopy-
based drug response assay to measure drug potency, and to quantify drug effı-
cacy in terms of growth inhibition (GRmetrics) and cell death. The use of theGR
metrics to quantify drug sensitivity enabled us to identify and study differences
between cytostatic and cytotoxic responses. This systematic dose response da-
taset is complemented bymeasurements of baseline mRNA expression levels by
RNAseq and endogenous protein levels by shotgunmass spectrometry across all
cell lines. The completeness and controlled conditions under which these data
sets were collected provide confıdence in their integration. The baseline RNA
and protein expression levels were used to build predictors of themeasured drug
responseswith the goal of identifying the biological processes responsible for the
differences in sensitivity across drugs and cell lines. Differences in the pheno-
typic responses of cell lines to kinase inhibitors with the same nominal targets
have been investigated, and associated with variable inhibitor polypharmacol-
ogy.
#2386 HDAC6 regulates ERK1’s kinase activity via deacetylation.
Jheng-Yu Wu,1 Xiaohong Zhang2. 1Univ. of South Florida College of Medicine,
Tampa, FL; 2Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Extracellular signal-regulated kinases 1/2 (ERK1/2) are important kinases
regulating cell proliferation and cell migration, and have been established as
therapeutic targets for cancer treatment. Previously, we found that ERK1 phos-
phorylates histone deacetylase 6 (HDAC6), a class IIb HDAC, to regulate its
enzymatic activity. HDAC6 plays an important role in several types of cancers.
HDAC6 governs cancer cells’ migration by cooperating with cytoskeleton pro-
teins and their associated proteins, and HDAC6 is arising as a determinant for
cisplatin-resistance in non-small cell lung cancer (NSCLC) and ovarian cancer.
Here, we have shown that HDAC6 manipulates ERK1’s kinase activity via
deacetylation. We demonstrated that both ERK1 and ERK2 interact with
HDAC6 physically via GST pull-down assays. To examine whether ERK1/2 are
acetylated, we transfected GST-ERK1 or GST-ERK2 into HEK293T cells, and
treated the cellswith a pan-HDAC inhibitor, TrichostatinA.We showed that the
level of acetylated GST-ERK1/2 increased in a dose- and time-dependent man-
ner. Furthermore, when GST-ERK1 or GST-ERK2-expressed cells were treated
with an HDAC6-specifıc inhibitor, ACY-1215, the level of acetylated GST-
ERK1/2 increased. These results suggest that HDAC6 is a deacetylase for
ERK1/2. In addition, we determined that acetyltransferases CBP and p300 acet-
ylate ERK1/2.We found a novel acetylation site located in ERK1N-terminus by
mass-spectrometry analysis. We then mutated this lysine (K) site with either
Glutamic acid (Q) or Arginine (R) to mimic the acetylation or deacetylation
status, and performed kinase assays using ELK1 as a substrate. The acetylation
mimicking mutant exhibits a decreased kinase activity toward ELK1, while the
deacetylation mimicking mutant exhibits a similar level of kinase activity as the
wild-type ERK1 does, suggesting that acetylation/deacetylation alters ERK1 en-
zymatic activities. Therefore, HDAC6 may regulate ERK1’s kinase activity via
deacetylation of this site. Furthermore, we have shown that HDAC6 is overex-
pressed in lung cancer tissue samples and plays an important role in chemo-
sensitivity in lung cancer.We predict that inhibition of theHDAC6-ERK1 path-
way may provide clinical benefıt for lung cancer patients.
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#2387 Overexpression of NSUN2 by DNA hypomethylation is associated
with metastatic progression in human breast cancer. Jie Yi,1 Yu Chen,1 Ran
Gao,1 Zhuo Yang,1 Jinhua Wang,2 Yingchun Xu1. 1Peking Union Medical Col-
lege, Beijing, China; 2Chinese Academy of Medical Science and Peking Union
Medical College, Beijing, China.
NSUN2 is a RNA methyltransferase that has been shown to be implicated in
development of human cancer. However, the functional role of NSUN2, mech-
anism of NSUN2 overexpression and its association with clinicopathologic fea-
tures in breast cancer remain unclear. To investigate alterations in the expres-
sion and functional role of NSUN2 in breast cancer, NSUN2 expression was
assessed in breast cancer cells and tissues obtained from cancers at different
American Joint Committee on Cancer (AJCC) stages, and its functions were
investigated using breast cancer cells. NSUN2 expression was shown to be sig-
nifıcantly higher in breast cancer cells and tissues than in normal breast epithe-
lial cells and tissues, at both mRNA and protein levels. Overexpression of
NSUN2 was shown to promote cell proliferation, migration, and invasion while
NSUN2 knockdown inhibited these processes in vitro and in vivo. NSUN2 ex-
pression level was associated with the methylation level of its promoter. Our
results demonstrated that the overall expression of NSUN2 signifıcantly corre-
latedwith clinical stage (P0.027), tumor classifıcation (P0.012), pathological
differentiation (P0.023), as well as with the expression levels of estrogen re-
ceptor (P0.001), progesterone receptor (P0.001), and Ki-67 (P0.001). Our
fındings provide a unique insight into the roles and effects of NSUN2 overex-
pression in breast cancer cells, and highlight the necessity of the investigation of
novel therapeutic targets, such as NSUN2, for the improvement of breast cancer
treatments.
#2388 Low grade gliomas exhibit distinct patterns of epigenetic aging
associatedwithprognosticmolecular subtype.Peter Liao, Jill Barnholtz-Sloan.
Case Western Reserve University, Cleveland, OH.
Background: Low grade gliomas make up a signifıcant proportion of malig-
nant brain tumors and possess a high degree of heterogeneity, highlighting a
need for clinically useful markers for prognosis and further biologic investiga-
tion.We used an existing model of biological age based upon DNAmethylation
to characterize epigenetic age in low grade gliomas (LGG) according to existing
molecular classifıcations and assessed the prognostic utility of epigenetic age.
Methods: We analyzed the full TCGA LGG cohort consisting of 516 patients;
216 grade 2 and 241 grade 3 tumors. Age at diagnosis ranged from 14-87 years
with median age 43. We calculated “DNAmethylation age” (DNAm age) based
upon 353 CpG probes according to the epigenetic clock developed by Steve
Horvath, and calculated age acceleration according to the DNAm age of tumor
tissue relative to reported chronological age of patient at diagnosis. DNAm age
was assessed for prognostic value using Cox proportional hazards regression.
Age acceleration differences were assessed across LGG molecular classifıcation
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methods using the Wilcoxon Ranked Sum test. Results: DNAm age remained
highly correlated with chronological age in LGG tumor tissue (cor0.58,
p0.001), with an average age acceleration of 33.5y. DNAm age was weakly
positively correlated with mutational burden (cor0.12, p0.01). Higher
DNAm age was positively associated with survival independent of chronologic
age and Karnofsky Performance Score (p0.003), but not when IDHmutation
status was included into the Cox proportional hazards model. Further investi-
gation showed that DNAm age acceleration was associated with IDH mutation
status and was signifıcantly increased in IDH-mutant compared to IDH-wt tu-
mors (95% CI 18.6-28.8y) as well as MGMT-promoter methylated versus un-
methylated cases (95%CI 18.1- 28.9y). No signifıcant DNAm changes were
observed across histological subtype or grade. Conclusions: Although the regu-
lation of DNAm age in cancers remains poorly understood, signifıcant associa-
tion of DNAmage accelerationwith prognostically usefulmolecular subtypes in
LGGs underscores biological differences that cannot be discerned in LGGs
based upon histological classifıcation. This association suggests that LGGs may
provide an avenue for investigating DNAm age, molecular subtype, and their
relation to tumor behavior and clinical prognosis.
#2389 LINE-1 tumor hypomethylation is associated with shorter recur-
rence-free survival in localized clear-cell renal cell carcinoma. Gabriel G.
Malouf, Roger Mouawad, Frederick Allanic, Eva Compérat, Morgan Roupret,
David Khayat, Jean-Philippe Spano. Salpetriere Hospital, Paris, France.
Background: Cancer cells are characterized by alterations of DNA methyl-
ation patterns involving global DNA hypomethylation and site-specifıc CpG
island promoter hypermethylation. Global DNA hypomethylation is thought to
play a role in genetic instability and tumor aggressiveness. Long interspersed
nucleotide element-1 (L1/LINE-1) repetitive elements represent 40% of the ge-
nome and their methylation is a good indicator of the global DNAmethylation
level. Although LINE-1methylation has been previously shown to be associated
with prognosis of patients with cancer, the value of LINE-1 methylation in pre-
dicting recurrence of patients with localized clear-cell renal cell carcinomas re-
mains unknown.Material andMethods:We quantifıed the LINE-1methylation
using bisulfıte pyrosequencing in cohort of 200 patients with resected clear-cell
renal cell carcinomas (AJCC stage I-III). LINE-1methylation of adjacent normal
kidney was also assessed in 128 cases. Threshold of tumor LINE-1 hypomethy-
lation was defıned as LINE-1 methylation in normal samples minus three stan-
dard deviation. Results: Median methylation of tumor samples was 59.01% ver-
sus 61.61% for normal adjacent kidney samples (p105). LINE-1 methylation
level of normal adjacent kidney was associated with tumor size (Spearman
R0.21, P0.02) but not with age (p0.24) or Leibovitch score (p0.05). Tu-
mor LINE-1 hypomethylation was observed in 20 samples (n10%). Strikingly,
those were enriched for tumors occurring in female (60% versus 27.7%)
(p0.005); of note, no association was found between LINE-1 tumor hypom-
ethylation and tumor grade (p0.31), stage (p1), age (p0.24) and Leibovitch
score (p0.82). In multivariate analysis, only Leibovitch score and LINE-1 hy-
pomethylation were independently associated with poor recurrence-free sur-
vival. Conclusion: LINE-1 hypomethylation is associated with shorter recur-
rence-free survival in patients with resected clear-cell renal cell carcinomas,
suggesting the possibility of using it as predictive biomarker of recurrence.
#2390 Clinical validation of an epigenetic fıeld of susceptibility to detect
signifıcant prostate cancer from 2 non-tumor biopsies. Bing Yang,1 Johna-
thon McCormick,1 Adam Schultz,1 Glen Leverson,1 Geoffrey Sonn,2 Cristina
Magi-Galluzi,3 Eric A. Klein,3 Michael Fumo,4 David F. Jarrard5. 1Univ. of Wis-
consin-Madison, Madison, WI; 2Stanford University, Palo Alto, CA; 3Glickman
Urological and Kidney Institute, Cleveland, OH; 4Rockford Urological Associates,
LTD, Rockford,WI; 5Univ. ofWisconsin-Madison Carbone Cancer Center, Mad-
ison, WI.
Background: An epigenetic fıeld of cancer susceptibility exists for prostate
cancer that gives rise to multifocal disease in the peripheral zone. In a previous
studies (Neoplasia 2013, J Urol 2014) we identifıed using methylation arrays
over 50 altered regions in normal prostate tissue of men with prostate cancer. In
the current multicenter study, a validation was performed to determine the
predictive strength of this approach. Methods: We evaluated 2 archived, cancer
negative prostate biopsy core tissue from 129 subjects from 4 urological centers.
All negative cases (controls) underwent 2 or more repeat negative biopsies
within 24 mo with a central review of all histopathology. Cancer cases were
negative biopsies selected frompatientswhoultimatelywent prostate removal to
confırm a fınal grade Gleason Score 7. Biopsies were analyzed using pyrose-
quencing for DNA methylation changes at multiple CpGs surrounding the
genes EVX1, CAV1, PLA2G16, FGF1, SPAG4 and NCR2. Analyses used multi-
plex logistic regression modeling with backward elimination. Results: Patients
diagnosed with GS7 cancer (77) and the control group (52) were similarly
matched except for PSA (7 vs 5.8; p0.03) and prostate size (46 vs 36; p0.02).
We observed robust methylation differences for all genes (p0.05) (Table). A
multiplex regression model for biomarker performance incorporating a gene
combination of EVX1, NCR2, PLAG2 and SPAG4 discriminated non-tumor
from tumor-associated tissues (AUC 0.744, p0.0001). A multiplex model in-
corporating 3 genes (EVX1, PLA2G16, NCR2) and clinical information (PSA,
age) identifıed patients with GS7 prostate cancers (AUC 0.808, p0.001).
Conclusions: A widespread epigenetic fıeld defect can be used to detect GS7
prostate cancers in patients with histologically negative biopsies. This assay is
sensitive in requiring only 2 biopsies and detects alterations in nontumor cells at
distance from the cancer. This has the potential to decrease the need for repeat
prostate biopsies, a procedure associated with cost and complications. Support:
UW Ignitor; Gen X foundation.
#2391 Integrated analysis ofmethylation and expression profıle of telom-
ere-related genes in breast cancer patients. Jianfu Heng,1 Xinwu Guo,2 Lili
Tang,3 FanZhang,1 LiminPeng,2MingChen,2XipengLuo,2XunxunXu,2 Shou-
manWang,3 Jun Wang1. 1Central South University, Changsha, China; 2Sanway
Gene Technology Inc., Changsha, China; 3Xiangya Hospital, Central South Uni-
versity, Changsha, China.
Telomeres at the ends of chromosomes are critical in maintaining the integ-
rity and stability of the genome. Aberrant telomere or telomerase dysfunction
participates in tumorgenesis. A majority of human cancers exhibit critically
aberrant telomere length, suggesting that tumors can arise from genetically in-
stable cells with dysfunctional telomeres. Many genes are involved in the com-
plex regulatory mechanisms of telomere length and telomerase activity. In ad-
dition, the methylation and expression pattern for most of telomere related
genes in breast cancer are still unknown. Using microfluidic-PCR based target
enrichment and next-generation bisulfıte sequencing technology, we explored
the promoter methylation profıle of 29 telomere-related genes in 184 breast
cancer patients with paired tumor and matched normal tissues. The average
methylation level was signifıcantly higher in tumor (8.13%) than that inmatched
normal tissues (7.08%) (P  4.30E-21). Four genes showed signifıcant hyper-
methylation in the breast tumor tissues. All of these 4 genes are annotated with
potential TFBSs in the promoter regions. In subtype analysis, RAD51D showed
signifıcant methylation difference among four subtypes. In analysis of the asso-
ciation between methylation and clinicopathologic characteristics, TERC
showed signifıcant difference between ER/ER tumors. The expression profıle
of the 4 signifıcant hyper-methylated genes was explored in the same cohort
using qPCRmethod. All of them showed signifıcantly lower expression in breast
tumor tissues compared with the matched normal tissues. Two genes showed
signifıcant and negative cis correlation between methylation and gene expres-
sion. These results were also validated in the TCGA database. The 4 genes panel
showed a good performance in predicting breast cancer with ROC analysis. In
summary, our results revealed themethylation pattern of telomere related genes
in breast cancer and illustrated the epigenetic regulatory mechanism on expres-
sion of aberrant methylated genes. Our study provides a novel panel of telomere
related genes which may be a valuable diagnostic biomarker for breast cancer
prediction.
#2392 A multiplex histone H3 PTM assay for epigenetic biomarker dis-
covery in tissue biopsy and archived clinical samples. Mary Anne Jelinek,
Melissa Ritland, AJ Westergren. Active Motif, Inc., Carlsbad, CA.
Dysregulation of epigenetic mechanisms is known to play an important role
in the development and progression of cancer. One such mechanism is mani-
fested as altered levels of histonemodifıcations involved in regulating gene tran-
scription. N-terminal histone tails can have a variety of modifıcations, such as
phosphorylation, methylation and acetylation at specifıc amino acid residues
which are conserved throughout eukaryotes and function by altering chromatin
structure and creating binding sites for chromatin readers, writers or erasers.
Numerous studies have reported aberrant global levels of several histoneH3 and
H4 post-translational modifıcations (PTMs) in a wide range of solid tumor
types. These changes have been shown to be predictive of clinical outcome,
raising the possibility that histone modifıcations have potential as epigenetic
biomarkers. Clinical samples have immense potential for biomarker identifıca-
tion since they are often accompanied with valuable information pertaining to
patient history, treatment courses and disease outcome. The preferred method
for clinical sample preservation is formalin-fıxation followed by paraffın embed-
ding (FFPE).While extraction and downstream analysis of DNA andRNA from
FFPE samples is now routine, proteomic studies of FFPE samples is hampered
by extensive protein cross-linking generated by formalin fıxation. Analysis of
histone PTMs in patient archival samples is limited to low-throughput immu-
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nohistochemical staining, and is not an ideal approach for mining large sample
cohorts for biomarker identifıcation. Western blot or ELISA methods, which
have large sample requirements, are simply not an option for FFPE samples.We
have developed a multiplex bead-based ELISA assay which enables simultane-
ous interrogation of thirteen histone H3 PTMs. The assay is performed in 96-
well plates and is ideally suited for profıling histone modifıcation levels in lim-
iting or small samples. We will present the application of this technology in a
variety of sample types including frozen tissue, formaldehyde-cross linked cells
and tissues, and in small molecule inhibitor screens with as few as 2,000 cells per
well. The ability to simultaneous detect up to thirteen histoneH3PTMsprovides
a unique feature that enables determination of for on-target and off-target ef-
fects within the same sample.
#2393 Decreased expression of 5-hydroxymethylcytosine is associated
with grade of malignancy in lung cancer. Yoshiaki Tominaga,1 Ken-ichi Ito,1
Jun Nakayama2. 1Division of Breast, Endocrine and Respiratory Surgery, Depart-
ment of Surgery(II), Shinshu University School of Medicine, Matsumoto, Japan;
2Department of Molecular Pathology, Shinshu University Graduate School of
Medicine, Matsumoto, Japan.
Purpose: The ten-eleven translocation (TET) proteins are critical regulators
in epigenetic modifıcation. It is well known that TET proteins catalyze the oxi-
dation of 5-methylcytosine (5-mC) to generate 5-hydroxymethylcytosine (5-
hmC), and 5-hmC levels reflect diverse functions of TET proteins. It has been
reported that the expression of 5-hmC in cancer tissues is decreased compared
with that in normal tissues in several organs. However, 5-hmC expression in
lung cancer has not been fully analyzed. To examine whether or not 5-hmCwas
associated with phenotypes or progression of lung cancer, we evaluated 5-hmC
expression in a variety of histological types of lung cancers. Materials andmeth-
ods: The expression of 5-hmC was analyzed by immunohistochemistry in 109
paired specimens of lung cancer and adjacent normal tissues obtained from the
patients underwent operation at Shinshu University Hospital. Eighty-nine ade-
nocarcinomas, 17 squamous cell carcinomas, two large cell carcinomas, and one
small cell carcinoma were analyzed in the study. Results: 5-hmC expression in
female was signifıcantly lower than that in male, and was lower in smokers than
non-smokers. 5-hmC expression was positive in 34.1	22.0% of lung cancer
tissues and 69.4	18.8% of normal tissues. The expression of 5-hmC was signif-
icantly decreased in the lung cancer tissues compared with that in the adjacent
normal tissues (p0.001). With regard to the histological types, the positive
ratios of 5-hmC expression were 36.0	21.7% in adenocarcinoma, 24.0	20.3%
in squamous cell carcinoma, 8.0	7.3% in large cell carcinoma, and 13.0% in
small cell carcinoma. Thus, the frequency of positive expression of 5-hmC was
decreased in accordancewith the increase of grade ofmalignancy of lung cancer,
and a negative correlation between 5-hmC expression and the grade of malig-
nancy of lung cancer was observed. On the other hand, no difference of the
expression of 5-mC was observed between lung cancer tissues and normal tis-
sues. Conclusions: Our results indicate a possibility that 5-hmC may be related
to carcinogenesis and progression or differentiation of lung cancer.
#2394 Subpopulation of infıltrating lymphocyte andMGMTmethylation
in brain tumor prognosis. Carlos Castaneda, Miluska Castillo, Carolina Bel-
mar-Lopez, Sandro Casavilca, Luis Angel Bernabe, Tatiana Vidaurre. Instituto
Nacional de Enfermedades Neoplasicas, Lima, Peru.
Background: Clinicopathological features including MGMT methylation
have been correlated to prognosis in Glioblastoma (GBM). Tumor infıltrating
lymphocytes (TILs) are predictive of clinical outcome in different malignancies.
We evaluated association between clinicopathological features including
MGMT methylation and IHC infıltrating immune cell subpopulations in 43
resected GBM cases who came from 2008 to 2013. Methods: A prospective
evaluation of TIL (CD3, CD4, CD8 and CD20) and macrophages (CD68 and
CD163) through H&E was performed by a pathologist and evaluated Immune
cell subpopulations was evaluated through scanning, and software analysis
(BX63 Olympus and TissueMorph-Visionpharm) with pathologist support.
MGMT evaluation was prospectively performed by bisulphyte PCR test in par-
affın samples. Results:Median agewas 47.9 y,men (51.2%), Karnofsky scale 90%
(62.8%), median tumor size of 5.1 cm, and partial/ complete tumor resection
(22/21). MethylationMGMT test was performed in 31 cases and 17 showed un-
methylated, 4 partial methylated and 10 methylated. TILs evaluation by HE
showed low- intensity (29 cases), middle- intensity (1) and high- intensity level
(9). Pattern of distribution was focal (9 cases), multi- focal (13) and diffuse (17).
Median CD3, CD4, CD8, CD20, CD68 and CD163 were 1.6%, 0.032%, 1.6%,
0.03%, 9.1% and 2.2% (regarding total cells), respectively. Higher CD163 level
was associated to male (p0.03) and larger size (p0.05). Higher levels of CD8
was associated to larger size (p0.05). Higher CD8 and CD20 was associated to
unmethylatedMGMT (p0.041 and 0.013). Median follow- up was 14 months.
Only total resection (p0.05) andMGMTmethylation (p0.05) was associated
to outcome. Lymphocyte infıltration (H&E) was not associated to outcome:
Lymphocyte intensity (p0.703), distribution (p0.61). Longer OS was associ-
ated to lower CD4 levels (p0.01). Conclusion: Tumor Infıltrating immune cell
are not common in GBM, CD8 and CD20 was associated to unmethylation, and
CD4 and MGMTmethylation were associated to prognosis.
#2395 Differentiation of carcinoma ex pleomorphic adenoma from pleo-
morphic adenoma by TERT promoter hypermethylation and elevated TERT
mRNA expression. Seungjae Lee,1 Sumit Borah,1 Kurt Patton,2 Armita Bah-
rami1. 1St. Jude Children’s Research Hospital, Memphis, TN; 2Trumbull Labora-
tories, Memphis, TN.
The purpose of this studywas to determinewhether i) genetic or ii) epigenetic
aberrations of the TERT promoter, iii) elevated TERTmRNA level or iv) abnor-
mal p53 expression pattern effectively distinguishes cases of carcinoma ex pleo-
morphic adenoma (CA ex PA) frompleomorphic adenoma (PA). PA is themost
common salivary gland tumor which in rare cases progresses into an epithelial
malignancy, termed CA ex PA. Fusion genes involving PLAG1, or less com-
monly HMGA2, are common in both PA and CA ex PA and are thought to be
early genetic drivers in their development. Although the key molecular events
which occur during malignant transformation of PA are still unknown, some
genetic and epigenetic changes proposed to play a role include amplifıcation of
PLAG1, HMGA2, MYC, ERBB2, or chromosome 12q and aberrant promoter
hypermethylation of RASSF1, especially in combination with promoter hyper-
methylation of p16, TERT andWT1. The importance of TERT promoter hyper-
methylation formalignant transformation in PAmay be underappreciated since
hypermethylation of that region most critical for malignancy in several cancers,
termed the upstreamof transcriptional start site (UTSS), has not previously been
assayed in PA or CA ex PA. Point mutations or genomic rearrangement in the
TERTpromoter and elevatedTERTmRNA levels are also characteristic ofmany
cancers.We used a panel of 10 PA and 6 CA ex PA clinical samples to determine
whether these alterations of TERT, or aberrant expression of TERT mRNA or
p53 protein, could effectively distinguish CA ex PA from PA. UTSS hypermeth-
ylation in each sample was determined by treatment of genomic DNA with
sodium bisulfıte followed by MassARRAY and Sanger sequencing. Mutation
and arrangement of TERT were screened for by Sanger sequencing and fluores-
cence in situ hybridization, respectively. p53 expression pattern was visualized
by immunohistochemistry and TERT mRNA levels were measured by RT-
qPCR. Mutation or rearrangements of the TERT promoter were not observed.
However, all 6 CA ex PA samples harbored hypermethylated TERT promoter
and had much higher TERT mRNA levels than the PA samples. Two of these
samples also had aberrant p53 expression patterns, suggesting the presence of a
TP53 missense mutation. None of the PA samples had aberrant p53 expression
patterns, although 2 had hypermethylated TERT promoter and elevated TERT
mRNA levels as comparedwith the other PA samples. The signifıcance of this for
long term outcome in these patients was unclear. Overall, these results suggest
that TERT is commonly upregulated in CA ex PA and that this upregulation is
oftenmediated through hypermethylation of the TERT promoter UTSS. Future
large scale studies are warranted to determine the usefulness of TERT promoter
hypermethylation for differentiating benign PA from CA ex PA, or the PAs at
risk of malignant transformation.
#2396 Methylation of subtelomeric repeat D4Z4 in peripheral blood leu-
kocytes is associatedwithbiochemical recurrence in localizedprostate cancer
patients.YuyanHan, Jeri Kim,XifengWu, JianGu.UTMDAnderson,Houston,
TX.
Background: Global DNAmethylationmay affect chromosome structure and
genomic stability and is involved in carcinogenesis. In this study, we aimed to
investigate whether methylation of pericentromeric repeat (NBL2) and subtelo-
meric repeat (D4Z4) in peripheral blood leukocytes was associated with the
aggressiveness of prostate cancer (PCa). Methods: We measured the methyl-
ation status of different CpG sites of NBL2 and D4Z4 in 900 PCa patients via
pyrosequencing after bisulfıte treatment. We then used multivariate logistic re-
gression to estimate the odds ratio (ORs) and 95% confıdence intervals (CIs) for
analyzing the association of NBL2 and D4Z4 methylation with the aggressive-
ness of PCa at diagnosis. We then analyzed the association of CpG sites with the
risk of biochemical recurrence (BCR) in patients receiving radical prostatec-
tomy or radiotherapy using a multivariate Cox proportional hazards model
adjusting for age, BMI, smoking status, pack year, D’Amico risk groups, and
treatments. In addition, we used the Kaplan-Meier survival function and log-
rank tests to assess BCR-free survival associated with these markers. Results:
There was no signifıcant differences in the methylation level of NBL2 and D4Z4
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between clinically defıned aggressive and non-aggressive PCa at diagnosis.
However, the methylation of subtelomeric region D4Z4 was associated with
BCR, while the methylation of NBL2 was not associated with BCR. In tertile
analysis, we found that patients with higher methylation of D4Z4 exhibited an
increased risk of BCR in localized patients receiving defınitive therapy. Because
of the relatively low rate of BCR among patients, we combined the highest and
second tertiles to increase statistical power. Patients in the second and third
(highest) tertiles had an increased risk of BCR (HR1.74, 95%CI, 1.14-2.65; p
0.0096) compared to patients in the lowest tertile after adjustment of age, BMI,
smoking status, pack year, D’Amico risk groups, and treatments. We assayed 4
CpG sites in this region. In detailed analysis of eachCpG site, the associationwas
mostly attributable to the methylation of the 2nd methylation site of D4Z4
(HR1.80, 95% CI, 1.19 - 2.72). Conclusion: These data suggest that methyl-
ation in the subtelomeric regionD4Z4may be able to predict worse prognosis of
localized PCa patients.
#2397 Epigenetic silencing in clear renal cell carcinoma:KEAP1 promoter
hypermethylation. Federico Pio Fabrizio,1 Manuela Costantini,2 Massimiliano
Copetti,1 Anna Maria la Torre,1 Angelo Sparaneo,1 Andrea Fontana,1 Maria
Luana Poeta,3 Michele Gallucci,2 Steno Sentinelli,2 Paolo Graziano,1 Paola Par-
ente,1 Vincenzo Pompeo,2 Laura De Salvo,2 Giuseppe Simone,2 Rocco Papalia,2
Francesco Picardo,4 Teresa Balsamo,1 Gerardo Paolo Flammia,5 Domenico
Trombetta,1 Angela Pantalone,4 Klaas Kok,6 Paranita Ferronika,6 Lucia Anna
Muscarella,1 Vito Michele Fazio1. 1IRCCS Casa Sollievo Della Sofferenza, San
Giovanni Rotondo, Italy; 2Regina Elena National Cancer Institute, Rome, Italy;
3University of Bari, Bari, Italy; 4University Campus Bio-Medico, Rome, Italy;
5Campus Bio-Medico University Hospital, Rome, Italy; 6University Medical Cen-
ter Groningen, Groningen, Netherlands.
The Keap1/Nrf2 pathway is a master regulator of the cellular redox state
through the induction of several antioxidant defense genes implicated in che-
motherapeutic drugs resistance of tumor cells. An increasing body of evidence
supports a key role for Keap1/Nrf2 pathway in kidney diseases and renal cell
carcinoma, but data concerning the molecular basis and the clinical effect of its
deregulation remain incomplete. Here we performed a comprehensive genetic
and epigenetic analysis of the KEAP1 gene in 37 tumor/normal paired tissues of
clear cell Renal Carcinoma (ccRCCs). Promoter methylation analysis was per-
formed by using a quantitative methylation specifıc PCR assay in real time,
whereas mutation scanning was performed on FFPE tissues by direct sanger
sequencing of the exons 4-7 codifying for theDGRdomain of theKeap1 protein.
A tumor-specifıc DNA methylation of the KEAP1 gene promoter region was
found in 18 out of 37 ccRCCs (48,6%) and a direct effects on the modulation of
Keap1mRNA levels was confırmed by in vitro 5-azacytidine treatment on three
different ccRCCs cell lines. Analysis of an independent TGCA data set corrob-
orate the epigenetic fındings and reveals a signifıcant correlation inmultivariate
analysis of epigenetic KEAP1 silencing with Overall Survival in ccRCCs. Our
results further suggest that epigenetic deregulation of the Nrf2/Keap1 system
could play a pivotal role in the cancerogenesis of ccRCCs. In addition identifying
patients with KEAP1 epigenetic abnormalities may contribute to disease pro-
gression prediction and response to therapy in ccRCC affected patients.
#2398 Molecular analysis of histone methyltransferases SUV420H1 and
SUV420H2 and their potential as prognostic markers in head and neck can-
cer.Doralina do Amaral Rabello Ramos, Beatriz Itai Haupt Ribeiro, Tércia Ma-
riaMendes Lousa de Castro, VívianD’Afonseca da Silva Ferreira, GustavoHen-
rique Soares Takano, ElizaCarla BarrosoDuarte, FabianaPiraniCarneiro, Fábio
Pittella Silva. University of Brasilia, Brasilia, Brazil.
The incidence of head and neck cancer as well as its mortality rates continues to
increase, evidencing the need for diagnostic and prognostic markers that can im-
proveclinicalmanagementof thesepatients.HistoneMethyltransferases (HMT)are
responsible for the methylation of histone tails, a mechanism important for the
regulation of gene transcription, cell differentiation and proliferation. Although al-
terations on these enzymes have been associated with many types of cancer, their
relationship with head and neck carcinogenesis is not yet understood. SUV420H1
and SUV420H2 are members of the SUV family of HMTs that contain the con-
served SETdomain, which catalyzes the addition ofmethyl groups to specifıc lysine
residues, leading to chromatin compaction and gene repression. In the present
study, we investigated the tissue expression profıle of SUV420H1 and SUV420H2
using immunohistochemistry in 10 formalin-fıxed paraffın-embedded human oral
cancer samples andadjacentnon-tumor tissues.Wealso investigated the alterations
of SUV420H1 and SUV420H2genes in head andneck cancerwith in silico analyses
from public databases. Immunohistochemistry revealed moderate to strong
SUV420H1 and SUV420H2 expression in the majority of oral cancer cells, mainly
with cytoplasmic staining in the invading tumor cells. In silico analyses using data
from 530 head and neck squamous cell carcinoma samples (The Cancer Genome
Atlas - TCGA, via cBioPortal) revealed that amplifıcation is the most frequent ge-
netic alteration in SUV420H1. Considering all known lysine methyltransferases,
SUV420H1 was among the top three with the highest frequency of amplifıcation.
ForSUV420H2, the frequency foramplifıcationanddeletionalterationswas similar.
Thegene expression level of thesemethyltransferaseswas also analyzed. SUV420H1
showed a high expression of mRNA in head and neck cancer samples, with amod-
erate correlation (R: 0.588) between genetic copy number alteration and mRNA
level. SUV420H2 did not show signifıcant altered expression. In addition,
SUV420H1mRNAoverexpressionwasassociatedwithdecreasedoverall survival in
head and neck cancer patients (p: 0.0233). Since these enzymes are important in
chromatin compaction and gene transcription repression, an increase in their ex-
pression level, as detected in this study, could lead to changes inhistonemethylation
pattern, resulting in aberrant silencingof genes essential tomaintainnormal cellular
function, such as tumor suppressor genes. Taken together, our data indicates a pos-
sible role of SUV420H1 in head and neck carcinogenesis, with the potential to be
used as a prognostic marker for the disease.
#2399 Metabolic and epigenetic targets in multiple myeloma therapy.
LaureManeix, Fu-Yuan Shih, Polina Iakova, Joanne I. Hsu, Andre Catic. Baylor
College of Medicine, Houston, TX.
The dynamic interaction of transcription factors (TFs) with promoters and en-
hancers allows cells to continuously adjust gene expression.Whereas the composi-
tion and binding of TFs at genomic sites is the focus of awidespread research effort,
relatively little is known about how these complexes are being removed.We previ-
ously devised amethod to detect genomic locations that are associatedwith nuclear
protein turnover mediated by the ubiquitin-proteasome system (UPS). Multiple
myeloma, the second most common hematopoietic malignancy, has become a
model disease for drugs that interfere with the UPS through either blocking or
facilitating protein elimination. The proteasome inhibitorVelcade, for instance, has
become fırst-line treatment inmyeloma. Yet, our knowledge of howmyeloma cells
are killed by this drug is incomplete. Our research is focused on defıning how pro-
teolysis regulates transcriptional dynamics in this disease andhow this impactsVel-
cade sensitivity. Following proteasome inhibition, we are utilizing next generation
sequencing to identify sites of nuclear protein turnover and evaluate epigenetic
changes. Our aim is to identify TFs and epigenetic marks that may qualify as more
specifıc targets for treatment compared to blunt proteasome inhibition. Our fınd-
ings reveal that certain TFs, including metabolic and cell growth regulators, are
particularly sensitive to Velcade. Among these transcriptional regulators, the co-
repressor NCoR1 plays a key role in controlling cell metabolism by adjustingmito-
chondrial gene expression. We are currently validating the mechanism of NCoR1
degradation, with a particular emphasis on the new role of its E3-ubiquitin ligase
Seven in absentia 2 (Siah2) in mitochondrial regulation, to better understand how
this degradation pathway impacts myeloma proliferation andmetabolism. This re-
searchprojectwill contribute toourunderstandingof epigenetic and transcriptional
dynamics in multiple myeloma. With the focus on gene programs that are contin-
uously adapting or changing, we seek to unlock new attractive targets formolecular
therapy.
#2400 Identifıcation of histone modifying enzymes associated with ta-
moxifen resistance in MCF7 breast cancer cells. Min-Ho Lee, Mi-Ock Lee.
Seoul National Univ. College of Pharmacy, Seoul, Republic of Korea.
Tamoxifen is widely used to treat estrogen receptor-alpha positive breast can-
cer. However, resistance to tamoxifen often prevent the success of endocrine
therapy. Epigenetic change in tumors are associated with cancer development
and progression. Although altered histone modifıcation has been implicated in
tumorigenesis, their role in endocrine resistance was little known. To identifıed
tamoxifen-resistance associated histone methylation modifying enzyme, we ex-
amined the global histone H3 methylation patterns in tamoxifen-resistance
MCF7 breast cancer cells. Our results show that, the levels ofmethylated histone
H3 lysine 4 (H3K4) and histone H3 lysine 9 (H3K9) was upregulated in tamox-
ifen resistance MCF7 breast cancer cells. Next, we analysis expression levels of
H3K4 and H3K9methylation modifying enzyme in tamoxifen resistance breast
cancer cells. qRT-PCR results show that H3K4methyltransferases (KMT2A and
KMT2C) is upregulated in tamoxifen resistance breast cancer cells. Moreover,
we observed that si-RNAmediated knockdownofKMT2Cwasmore susceptible
to tamoxifen-induced growth inhibition. Finally, Analyses of publicly available
patient data sets indicated that KMT2A andKMT2C levels are higher in patients
after endocrine therapy failure (recurrence), compared to those of responders
(non-recurrence). Our study indicates that elevated levels of KMT2A and
KMT2C in the tamoxifen-resistance breast cancers may contributed tamoxifen
resistance.
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#2401 Connecting oxidative DNA damage to epigenetic alterations dur-
ing inflammation-driven tumorigenesis. Ashley Maiuri, Ning Ding, Heather
M. O’Hagan. Indiana University, Bloomington, IN.
Inflammation contributes to the development of a diverse array of diseases,
including cancer. At sites of chronic inflammation epithelial cells are exposed to
high levels of reactive oxygen species and undergo cancer-associated DNA
methylation changes, suggesting that inflammation initiates epigenetic altera-
tions. Cancer cells are globally DNAhypomethylated, but have aberrant gains in
promoter DNA methylation that transcriptionally silence tumor suppressor
genes (TSGs), linkingDNAmethylation directly to tumorigenesis.However, the
mechanisms of targeting and initiation for these stable disease-specifıc epige-
netic marks are unknown. We have linked inflammation and oxidative DNA
damage to acute changes in the interaction of epigenetic silencing proteins with
each other and the chromatin. Recently, we demonstrated that the mismatch
repair (MMR) protein heterodimer MSH2-MSH6 participates in the oxidative
damage-induced recruitment of DNA methyltransferase 1 (DNMT1) to chro-
matin and provided evidence that the role of DNMT1 at sites of oxidative dam-
age is to reduce transcription. To connect these fındings to epigenetic changes in
tumors we use a model of inflammation-driven tumorigenesis where we infect
micewith the human commensal bacterium enterotoxigenic Bacteriodes fragilis
(ETBF). ETBF infection causes colon inflammation that drives tumorigenesis in
Multiple intestinal neoplasia (Min)mice. The central hypothesis for this work is
that oxidative damage at sites of inflammation causes acute genome-wide
changes in the binding of epigenetic silencing proteins that result in the perma-
nent epigenetic silencing of genes in tumors that form at the sites of exposure.
Using genome-wide DNA methylation techniques we identifıed TSGs with in-
creased promoter DNA methylation and decreased expression in tumors from
ETBF infected Min mice as compared to normal tissue. In Min mice lacking
expression of Msh2 in their intestinal epithelium (Msh2lox/loxVCMin) there is a
loss of the inflammation-induced change in binding of epigenetic proteins that
occurs in Min mice even though the cytokine response to infection is normal.
Because they lack functional MMR, ETBF infection of Msh2lox/loxVCMin mice
causes an increase in colon tumor number and these tumors are positive for
microsatellite instability, unlike tumors from ETBF infected Min mice. Impor-
tantly, DNA hypo- and hypermethylation changes in tumors from Msh2lox/
loxVCMin ETBF infected mice are reduced both globally and at promoter CpG
islands of candidate TSGs as compared to tumors fromMinETBF infectedmice.
Altogether, this work suggests a novel mechanism by which oxidative damage
induces acute epigenetic changes through the interaction ofDNMT1withMMR
proteins and that this acute change drives DNA methylation alterations during
tumorigenesis.
#2403 Anovelmechanism for regulation of breast cancermetastasis.Ken-
neth Jiao, Yin Peng, Lizhong Wang, Runhua Liu. University of Alabama at Bir-
mingham, Birmingham, AL.
Ourmajor goal is to determine the role of Chromodomain-helicase-DNA-bind-
ing protein 7 during breast cancer (BC) metastasis. This protein is an ATP-depen-
dent nucleosome remodeling factor and is critical for embryonic development in
both animal models and human patients. Our most recent studies provide direct
evidence suggesting its novel role in repressing BC metastasis. We found that this
protein, butnot themRNA, is highly expressed in a low-metastatic breast cancer cell
line (Mcf-7), while its expression is much reduced in metastatic cell lines (MDA-
MB-468 andMDA-MB-231). Furthermore, this protein is predominantly localized
in the cytoplasm of 468 and 231 cells, in contrast to its nuclear localization inMcf-7
cells. In thecytoplasmof468and231cells, thisprotein is colocalizedwitha lysosome
marker, suggesting that in high metastatic BC cells, this protein is exported to the
cytoplasm tobedegraded in lysosomes. Blocking the activity of lysosomes increased
expression of this protein in high metastatic BC cell lines. This result suggests a
mechanismaccounting for the reduced expression of this protein in highmetastatic
BC cell lines. To further support the potential clinic relevance of our results, this
protein is localized in the nucleus of almost all duct epithelial cells in normal breast
tissues; however, in a large portion of epithelial cells of breast tumors, this protein is
localized in the cytoplasm. Through reporter and mutagenesis analysis, we identi-
fıed the nuclear exporting signal (NES) sequence responsible for exporting this pro-
tein into cytoplasm. In the next set of experiments, we attempted to determine the
function of this gene in BCmetastasis.We found that knocking down expression of
this gene in 468 cell signifıcantly increased their migration and invasion. We next
applied the CRISPR genome editing technique to mutate the critical amino acids
within the NES region in the endogenous gene locus and found that the amount of
protein in the nucleus is signifıcantly increased compared to wild type cells. Migra-
tion/invasion of these cells was also dramatically decreased. At the molecular level,
we found that forced expression of this protein in nucleus reduced expression of
epithelial markers and increased expression of epithelial-mesenchymal-transition
markers. We are now applying ChIP-Seq and RNA-Seq approaches to determine
direct regulatory network of this protein in 231 cells. We will further test whether
thisproteinacts throughmodulating the epigenetic statusof the enhancers/promot-
ers to regulate expression of its target genes to repress BCmetastasis. In summary,
our data collectively suggest that Chromodomain-helicase-DNA-binding protein 7
is a novel epigenetic regulator to repress BC metastasis. To the best of our knowl-
edge, our study represents the fırst to address the activity of this protein in BC.
#2404 Paternal intake of an obesity-inducing diet before conceptionmod-
ulates the risk of pancreatic cancer in offspring in a mouse model. Raquel
Santana Da Cruz, Johan Clarke, Ali Baird, Hong Cao, Carlos Benitez, M. Idalia
Cruz, Sonia De Assis. Georgetown University Medical Center, Washington, DC.
Pancreatic cancer is amostlyuntreatablemalignancy,with5-year survival ratesof
about 5%. Life-style and dietary factors have been associatedwith pancreatic cancer
risk. Particularly, the consumption of high-fat diets and obesity (and underlying
metabolic dysfunction) have been linked to increased susceptibility to this cancer.
Recent studies have shown that the paternal diet and life-style can have a signifıcant
influence on offspring’s health via epigenetic information transmitted in the germ-
line. Paternal overweight before conception has been shown to increase offspring’s
susceptibility of developing metabolic diseases and some types of cancer. Here, we
evaluated the effects of paternal overweight in the susceptibility of pancreatic cancer
in offspringusing theP48Cre/ /KrasG120/mousemodel of pancreatic cancer. LSL-
KrasG120/ and P48Cre/ male mice were fed either an obesity-inducing (OID) or
control (CO) diet for 8 weeks from weaning to sexual maturity. After this period,
OID-fed andCO-fedmalemicewere housed togetherwith 7week-old femalemice,
with free access to CO diet, for 3 days. Pregnant dams were kept on the CO diet
duringpregnancy andafter givingbirth. Pupswereweaned frommothers at 21days
of age, fed a standard chowdiet for the extent of the study andweighedweekly. The
offspring of CO or OID fathers were used to study body weight, metabolic param-
eters and pancreatic cancer development. Fathers fed an OID gained signifıcantly
more weight (CO 15.7	1.0g; OID 19.7	1.3g, p0.02) and had higher leptin levels
(p0.04), compare to CO group fathers. Body weight analyses of OID and CO
offspring, showed gender-specifıc effects. While the OID female offspring had
higher weight at birth (p0.005) and at weaning (p0.02), compare to CO group,
no signifıcant differences were observed between the CO and OIDmale offspring.
Those gender-specifıc differences were also observed inmetabolic parameters such
GTTwith theOIDmale, but not female, offspring showing impaired glucose toler-
ance (p0.0004) compared to CO. While the monitoring period is still ongoing,
8-week old OID offspring present gender-specifıc differences in susceptibility to
pancreatic cancer: Males OID offspring have higher number/area (481	25;
2.6	0.3) of pancreatic intraepithelial neoplasia (PanIn), compared toCO (359	61;
2.0	0.5). On the other hand, femaleOIDoffspring have similar levels of PanIn, but
havehigher incidenceofPDACscompare toCO. In conclusion, anancestral history
of overweight through the paternal lineage may be associated with an increased
susceptibility topancreatic cancerdevelopment in adulthood.Themechanismsme-
diating this effect remain to be elucidated.
#2405 The 8p11 amplicon oncogenes ASH2L and NSD3 alter the epig-
enomic landscape and provide the foundation for novel application of epige-
netic therapy in luminal B breast cancers. Jamie N. Mills, Stephen P. Ethier.
Medical University of South Carolina, Charleston, SC.
The 8p11-p12 genomic region is amplifıed in 15% of breast cancers and is asso-
ciatedwithpoorerprognosis, especially in the luminalB (ER) subtype.This region
harbors several oncogenes, three of which are epigenetic modifıers of chromatin:
NSD3(WHSC1L1)andASH2L,whicharehistonemethyltransferases, andKAT6A,
a histone acetyltransferase. NSD3 preferentially di-methylates histone 3 lysine 36
(H3K36me2) in gene bodies to facilitate elongation, and ASH2L primarily tri-
methylates histone 3 lysine 4 (H3K4me3) in promoter regions, which is also associ-
ated with active transcription. Previous work in the amplicon-bearing cell line
SUM-44 implicated NSD3 in growth, survival, and overexpression and estrogen-
independent activation of the estrogen receptor. Current work is focused on eluci-
dating the mechanism behind these transforming features and exploring the epig-
enomic interactions of 8p11 oncogenes. Chromatin immunoprecipitation andhigh
throughput sequencing (ChIP-seq) using an NSD3 antibody confırmed the pres-
ence of this factor in the gene bodyof ESR1, aswell as several other important genes.
As NSD3 lacks the ability to bind chromatin directly, it relies on adaptor proteins
such as BRD4, a member of the BET bromodomain family that binds acetylated
histones such as those generated by KAT6A. Indeed, we have shown that BRD4
binds NSD3 in SUM-44 cells. Similar to our previous fındings with NSD3, knock-
down of BRD4 and ASH2L reduced cell proliferation and clonogenic potential. To
examine the influence of ASH2L on histone methylation in gene promotors, we
performed ChIP-seq using an H3K4me3 antibody. The data showed a dramatic
decrease in thenumberofpeakscalled followingknockdownofASH2Landpeaks in
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the NSD3 promotor disappeared. This fınding solidifıes the connection between
these oncogenes and their cooperative regulation of the epigenome, and therefore
the transcriptome, in this cell line, explaining the effects ofNSD3on cell growth and
behavior.Amplifıcationandoverexpressionofoncogenes in the8p11 region ismost
prevalent in ER breast cancer, treated clinicallywith endocrine therapies. Patients
with poor response to these therapies have few alternatives and often succumb to
their disease. This study and continued investigation of 8p11 amplicon oncogenes
opens an important new treatment opportunity for these patients: epigenetic ther-
apy. Previous work identifying these patients as candidates for novel anti-estrogen
SERD compounds suggests that combination therapy with a BET bromodomain
inhibitor could havemajor therapeutic benefıt in a patient group currently without
treatment options, thereby improving patient outcomes by a novel mechanism in
luminal B breast cancer.
#2406 LSD1 promotes castration-resistant prostate cancer cell survival
independently of the androgen receptor and of histone demethylation.
Archana Sehrawat,1 Lina Gao,1 Junior Tayou,1 Armand Bankhead,1 Laura M.
Heiser,1 Carly J. King,1 Yuliang Wang,1 Jacob Schwartzman,1 Joshua Urrutia,1
Daniel J. Coleman,1 Sheila Weinmann,2 Bhaskar V. Kallakury,3 Deborah L.
Berry,3 ReinaHaque,4 StephenK.VanDen Eeden,5 TomaszM. Beer,1 GeorgeV.
Thomas,1 ShannonMcWeeney,1 Joshi J. Alumkal1. 1OHSUKnight Cancer Insti-
tute, Portland, OR; 2Kaiser Permanente NW, Portland, OR; 3GeorgetownUniver-
sity Medical Center, Washington, DC; 4Southern California Kaiser Permanente
Medical Group, Pasadena, CA; 5Kaiser Permanente Northern California, Oak-
land, CA.
Background: Androgen deprivation therapy (ADT) or interference with an-
drogen receptor (AR) function is the principal treatment for advanced prostate
cancer. However, progression is universal, and therapies following the emer-
gence of castration resistance do not offer durable control of the disease. Lysine
specifıc demethylase 1 (LSD1) is a histone demethylase and a key regulator of
gene expression in cancer. Prior work demonstrates that LSD1 may act as a
cofactor of the AR in androgen-dependent prostate cancer cells. In this report,
we describe a distinct role of LSD1 as a driver of proliferation and survival of
castration-resistant prostate cancer (CRPC) cells independently of the AR and
independently of histone demethylation. Methods: We used gain and loss of
function studies to determine the importance of LSD1 for survival of prostate
cancer cells. To identify transcriptional networks that contribute to cell survival,
we suppressed LSD1 with RNAi and measured gene expression changes with
microarrays. To determine the importance of histone demethylation in regula-
tion of these gene networks, we suppressed LSD1 and measured levels of LSD1
canonical histone substrates (H3K4me2 and H3K9me2) genome-wide with
chromatin immunoprecipitation-sequencing. Results: Cell viability assays dem-
onstrated that LSD1 is important for proliferation and survival of CRPC cells
independently of the AR. Microarray studies demonstrated that LSD1 activates
androgen-independent genes that comprise cell cycle and embryonic stem cell
maintenance gene sets that are enriched in lethal human tumors. Importantly,
our global epigenomic studies after LSD1 suppression demonstrated that LSD1
activates these gene sets independently of demethylation of its canonical histone
substrates. Conclusions: Our results demonstrate that LSD1 promotes CRPC
cell survival independently of the AR and suggest that LSD1 regulates key path-
ways in CRPC through demethylation of non-histone substrates or via a scaffold
function—mechanisms we are currently investigating. In summary, LSD1 con-
tributes to CRPC cell survival through non-canonical mechanisms and repre-
sents an attractive therapeutic target in lethal prostate cancer.
#2407 Inhibition of gene expression during non-alcoholic steatohepatitis
(NASH)-related hepatocarcinogenesis is mediated by histone H4 lysine 16
deacetylation. Kostiantyn Dreval,1 Aline de Conti,1 Orish Ebere Orisakwe,2
Frederick A. Beland,1 Igor P. Pogribny1. 1FDA-National Center for Toxicological
Research, Jefferson, AR; 2University of Port Harcourt, Rivers State, Nigeria.
Hepatocellular carcinoma (HCC) is one of the most aggressive human can-
cers and the incidence is steadily increasing worldwide. The molecular mecha-
nisms leading to the development of HCC consist of genetic and epigenetic
aberrations, including changes in global and gene-specifıc DNA methylation
and altered expression of several classes of non-coding RNAs.While changes in
DNA methylation and microRNA expression during the development of HCC
are well-studied, the role of aberrant post-translational histone modifıcations
remains unexplored. Using a mouse Stelic Animal Model (STAM) of NASH-
associated liver carcinogenesis, we have investigated alterations in hepatic his-
tone modifıcations at steatotic (6 weeks), fıbrotic (12 weeks), and full-fledged
HCC (20 weeks) stages of the HCC development. NASH-related liver carcino-
genesis was characterized by a progressive decrease in the levels of histone H4
lysine 20 trimethylation (H4K20me3) and histone H4 lysine 16 acetylation
(H4K16ac), with the greatest decrease occurring in full-fledged tumors. Mech-
anistically, the deacetylation of H4K16ac was associated with nuclear protein 1
(Nupr1)-mediated inhibition of histone lysine acetyltransferase KAT8. In addi-
tion to a global loss of hepatic H4K16ac, there was a signifıcant decrease of
gene-specifıc H4K16ac, as indicated by a reduced level of H4K16ac in 16 out
of 25 critical cancer-related genes. More importantly, the changes in the
extent of gene-specifıc H4K16 deacetylation were positively correlated with
the level of gene transcription (r  0.965, p  0.01). These results indicate that a
reduction of global and gene-specifıc ofH4K16ac is a key pathophysiologicalmech-
anism contributing to the development of NAFLD-derived HCC.
#2408 Epigenomic characterization of MSC from myeloid malignancies.
Manuel Rodríguez-Paredes,1 Stefanie Geyh,2 Mahshid Gazorpak,1 Julian
Gutekunst,1 Felix Bormann,1 Rainer Haas,2 Thomas Schröder,2 Frank Lyko1.
1German Cancer Research Center, Heidelberg, Germany; 2University of Düssel-
dorf Medical Faculty, Düsseldorf, Germany.
Ineffective hematopoiesis is a hallmark of myeloid malignancies such as My-
elodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML). Our pre-
vious research has shown that mesenchymal stromal cells (MSC), one of the
main cellular regulatory components of the bonemarrowniche and essential for
the differentiation of new blood cells fromHematopoietic StemCells (HSC), are
molecularly and functionally impaired inMDS and AML patients. More specif-
ically, these cells display reduced proliferative and differentiation capacities, an
increased cellular senescence, or the altered expression of key hematopoietic
factors, defects that can provide an explanation for the cytopenia associatedwith
these diseases. But most interestingly, we have also discovered that MDS- and
AML-derived MSC present aberrant methylomes. Our data, based on 450k
DNAmethylation microarrays, show that these abnormalities are shared by the
MSC from both malignancies and affect key transcription factors like TBX15,
PITX2 or HOXB6, formerly linked to differentiation and development. This
results can account for some of the defects observed in the disease-related MSC
and represent an important paradigm for cancer-induced epigenetic changes in
normal cells. Aiming to further explore the importance of this epigenetic dereg-
ulation, we performed RNAseq experiments usingMSC from healthy donors as
well as from MDS and AML patients. This approach not only suggests a pro-
found impact of the epigenetic aberrancies on gene expression, but also allowed
us to identify TGF as the soluble factor that, released by the malignant cells in
the bone marrow, appears to trigger the above-mentioned defects in the MDS-
andAML-derivedMSC. Indeed, our results show that, when treatedwith TGF,
healthy MSC undergo the deregulation of TBX15, PITX2 or HOXB6 and de-
velop some of the observed aberrant phenotypes. Conversely, the treatment of
MDS- and AML-derivedMSC with a TGF antagonist like SD208 can abrogate
these effects. Finally, our preliminary DNAmethylation data reveal a very sim-
ilar deregulation in the methylome of MSC from Multiple Myeloma (MM) pa-
tients, strongly suggesting that the same scenario could also be common to other
hematological malignancies from the lymphoid branch.
#2409 Loss of L1TD1 suppresses Notch1 induced LINE1methylation and
genomic stability.Chia-ChenChiu,1Wei-ChenHuang,1 Kuan-Der Lee,2 Chih-
Cheng Chen,2 Chia-Chen Hsu,2 Mei-Ling Kang,1 Yu-Wei Leu,1 Shu-Huei
Hsiao1. 1National Chung Cheng Univ., Chiayi County, Taiwan; 2Chang Gung
Memorial Hospital, Chiayi County, Taiwan.
The silencing of endogenous retrotransposon like LINE1 is critical for the
maintenance of genomic stability and the LINE-1 type transposase domain con-
taining 1 (L1TD1) gene possesses the repeated, putative LINE-1 RNA-binding
domains and was hypothesized to regulate the activity of LINE-1 through DNA
methylation. To verify if L1TD1 is responsible for LINE-1 silencing and the
maintenance of somatic genome stability, CRSPR/Cas9 system was used to
knockout (KO) L1TD1 locus in gastric, colon and breast cancer cells so as in the
mesenchymal stem cells (MSCs). We observed that L1TD1 KO blocked the
entrance of SUV39H1, histone methyl transferase, into cell nuclear which sup-
pressed the tri-methylation of histone 3 at lysine 9 (H3k9me3) and LINE-1
methylation. A global demethylation and reduced HP1 recruitment were also
observed. The global distribution of CTCFbinding loci was also distorted aswell
as the bivalent histonemarks. Further, L1TD1KOdistorted normal distribution
of RassF1A expression, cytoskeleton conformation and therefore cell stiffness.
The MSC-to-neuron differentiation was also blocked by the KO. Further, we
found that overexpressed Notch-1 increased DNA methylation within LINE1
promoter, and this increase was attenuated by L1TD1 KO. Therefore, we con-
clude that the external signals like Notch1 affect L1NE1 methylation and ge-
nome stability through possible LINE1 interacting L1TD1. Since L1TD1 hyper-
methylation was observed in colon (n100), gastric (n19) and breast (n79)
cancers, L1TD1 abnormality is then a candidate for cancer biomarker. (Sup-
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ported by: MOST-105-2320-B-194-004, MOST-105-2314-B-182A-134, MOST
Taiwan and CMRPG6F0092, Chang Gung Memorial Hospital, Chia-Yi, Tai-
wan)
#2410 Toward mutation analysis of regulatory elements: Epigenetic pro-
fıling of primary breast tumors. Samah El Ghamrasni, Paul Guilhamon, Rene
Quevedo, Cindy Yang,Mathieu Lupien, Trevor Pugh. PrincessMargaret Cancer
Centre, University Health Network, Toronto, Ontario, Canada.
Non-coding mutations found in regulatory elements can function as driver
mutations in breast cancer by changing the binding affınity of transcription
factors for DNA, thereby resulting in direct change of expression of genes that
promote cancer development. Identifying such additional driver mutations can
reveal the molecular mechanisms favorable to breast cancer development and
progression, as well as reveal new biomarkers to better tailor personalized/pre-
cision cancer medicine. In this study we have collected 20 primary luminal
breast tumors and optimized experimental workflow to dissociate solid tumors
and map open chromatin using ATAC-seq. In our initial experiments using
ATAC-seq profıling of bulk tumor tissues, we were able to call an average of
15x103 peaks. Subsequently, flow cytometry analysis showed the presence of
15-25% of immune cells in our primary tumors. Therefore, we have optimized a
workflow to eliminate immune cells and focus mainly on epithelial tumor cells.
Primary breast tumors were digested using collagenase and further dissociated
with dispase. Cells were sorted into two populations (mammary epithelial and
immune cells) using anti-CD45, anti-CD49f and anti-EpCAM antibodies.
Sortedmammary epithelial cellswere thenused forATAC- andRNA-seq library
preparation as well as for generation of patient derived organoids. Our new
workflow resulted in an increased number of called peaks (40x103 vs 15x103), as
well as a signifıcant increase in the percentage of unique peaks compared to bulk
sequencing (45% vs 15%). By refıning our workflow to enrich for tumour con-
tent, wewill continue our ongoing effort to profıle these open chromatin regions
and contextualize the mutations within in a large cohort of luminal breast can-
cers using targeted sequencing. These data will be compared with large-scale
whole genome data generated by our group and made publicly available by
others.
#2411 The role ofA-to-IRNAediting inhuman cancer.HanLiang.UTMD
Anderson Cancer Ctr., Houston, TX.
Recent studies show that A-to-I RNA editing introduces a large number of
specifıc nucleotide changes in cancer transcriptomes. Using the genomic/tran-
scriptomic data from The Cancer Genome Atlas, we systematically character-
ized the landscape of RNA editing in a variety of cancer types and revealedmany
sites with clinically relevant patterns. We further integrated proteomic data
from the Clinical Proteomic Tumor Analysis Consortium and found that mu-
tations andRNAediting introduced similar numbers of amino acids changes per
tumor sample in breast and ovarian cancers. The amino acid changes engen-
dered by these RNA editing eventsmay signifıcantly alter protein stability. Some
of the identifıed RNA editing events show critical consequent changes driving
tumor growth and altering therapeutic activity. We also identifıed the RNA
editing hotspots in miRNAs across cancer types, and some of RNA editing
events modify the miRNA target genes. They could function as potential thera-
peutic targets and therapeutics.Our study suggests a large contribution ofA-to-I
RNA editing to protein diversity and gene regulation, and highlights its transla-
tional potential as both biomarkers and therapeutic targets.
#2412 Monitoring small molecules and macromolecules methyltrans-
ferase activities using homogenous luminescent assay. Said A. Goueli, Kevin
Hsiao. Promega Corp., Madison, WI.
It is well recognized that methylation/demethylation of not only DNA, RNA,
Proteins but alsomethylation of small molecules playmajor roles inmodulation
of the epigenome, transcriptome, neurotransmitter uptake and metabolic regu-
lation. Recent biochemicval and biological data suggest that the activity of these
enzymes and their expression level are under very strict regulation and any
abnormal alteration in either one or both results in awide varieties of pathogenic
conditions such as cancer, inflammation, and neurodegenerative diseases. In
addition to chromatin modulation, altered methylation of DNA and more re-
centlymRNAhave been recognized to regulate the transcriptome and the rate of
message translation and stability. Furthermore, methylation of small molecules
such as catechols and nicotinamide play critical roles in neurotransmitters up-
take and function, and metabolic regulation, respectively. Thus, pharmacologi-
cal modulation of these enzymes by small molecules will be benefıcial in devel-
oping novel therapeutics formultiple unmetmedical needs. Towards this goal of
searching for activators/inhibitors of these enzymes for the development of next
generation of drugs, screening assays for these modulators are urgently needed.
To address these unmet needs, we have developed a novel assay that monitors
the activities of these enzymes and their modulation by small molecules. The
assay is bioluminescent based, HTS formatted and highly sensitive. A unique
feature of this assay is its universality since it is based on monitoring the forma-
tion of the universal product S-adenosylhomocysteine (SAH), i.e., capable of
detecting changes in activity of a broad range of methyltransferases such as
DNA, RNA, protein, and small molecules. In addition, the assay has been vali-
dated for all classes of protein methyltransferases (Lysine and Arginine), and
with different types of substrates (small peptides, large proteins, or even nucleo-
somes). This enables determining the specifıcity of these enzymes and their
substrate requirements. The assay has high signal to background, low C.V.,
robust (Z’ value 0.7), and has been validated using various plate densities such
as 96-, 384, and 1536-well plates. A strong feature of this assay is its utility with
broad range of substrates concentrations or the composition of the substrates
(short vs. long peptides), thus enabling the generation of kinetic data and deter-
mining themechanism of action of various modulators of methyltransferases of
interest.
#2413 SIRT1 regulatesMxd1 throughoutmelanoma progression. Fabiana
M. Meliso,1 Danilo Micali,1 Camila T. Silva,1 Thais S. Sabedot,2 Simon G. Co-
etzee,2 Adrian Koch,3 Fabian B. Fahlbusch,3 Houtan Noushmehr,2 Regine Sch-
neider-Stock,3 Miriam G. Jasiulionis1. 1Universidade Federal de São Paulo, São
Paulo, Brazil; 2Universidade de São Paulo, Ribeirão Preto, Brazil; 3Friedrich-
Alexander University, Erlangen, Germany.
In amurinemelanomamodel of malignant transformation promoted by sus-
tained stress, increased levels of reactive oxygen species were found to result in
DNAdamage andwere related tomassive epigenetic alterations. Since the chro-
matinmodifıer Sirtuin-1 (SIRT1) is a protein attracted to double-strandedDNA
break (DSB) sites and can recruit other components of the epigeneticmachinery,
we aimed to defıne the role of SIRT1 in melanomagenesis through our mela-
noma model. The DNA damage marker, H2AX was found increased in mela-
nocytes after 24 hours of deadhesion, accompanied by increased SIRT1 expres-
sion and decreased levels of its target, H4K16ac. Moreover, SIRT1 started to be
associated toDNMT3B during the stress condition, and this complex wasmain-
tained along malignant progression. Mxd1 was identifıed by ChIP-seq among
the DNA sequences differentially associated with SIRT1 during deadhesion and
was shown to be a common target of both, SIRT1 and DNMT3B. In addition,
Mxd1was founddown-regulated frompre-malignantmelanocytes tometastatic
melanoma cells. Treatment with DNMT inhibitor 5AzaCdR reversed the Mxd1
expression. Sirt1 stable silencing increased Mxd1 mRNA expression and led to
up-regulation ofMYC targets, such asCdkn1a, Bcl2 andPsen2, the upregulation
of which is associated with human melanoma aggressiveness and poor progno-
sis. We demonstrated a novel role of the stress responsive protein SIRT1 in
malignant transformation of melanocytes associated with deadhesion. Mxd1
was identifıed as a new SIRT1 target gene. SIRT1 promoted Mxd1 silencing,
which led to increased activity of MYC oncogene contributing to melanoma
progression.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
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#2414 Fibromodulin expression in human prostate cancer tissue: Impli-
cations for prostate cancer progression. Estebana Ines Benedetti Padron,1 An-
gelo De Marzo,2 Javier Baena Del Valle,2 Jan Geliebter,3 Niradiz Reyes1. 1Uni-
versidad de Cartagena, Cartagena, Colombia; 2Johns Hopkins University,
Baltimore, MD; 3New York Medical College, Valhalla, NY.
Background: Fibromodulin is a small leucine-rich proteoglycan important for
extracellular matrix organization and essential for tissue repair in multiple or-
gans. Recently, differential expression of fıbromodulin has been shown in hu-
man prostate cancer cell lines with different cancer phenotypes and in human
prostate cancer tissue compared to normal/benign tissue. Methods: The protein
expression level of fıbromodulin was analyzed by immunohistochemistry using
a prostate tissue microarray (TMA), constructed from archival radical prosta-
tectomy and trans-urethral prostatectomy tissue specimens, from patients with
localized prostate cancer (PCa). Stained sections from the donor blocks were
evaluated, and a representative area from PCa, high grade prostatic intraepithe-
lial neoplasia (HGPIN), proliferative inflammatory atrophy (PIA), and benign
prostate tissue (BPT) was included into the TMA. Staining for each lesion was
scored, usingH-score, bymicroscopic assessment of the percentage of epithelial
cells with positive staining. H-score values were compared between groups by
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ANOVA test, and p 0.05 was considered statistically signifıcant. The Ethical
Review Board of the academic institution approved this study. Results: Fibro-
modulin expression at protein level was evaluated in 378 cores representing PCa
(143 cores), HGPIN (58), PIA (102), and BPT (78). Mean fıbromodulin expres-
sion in cores with PCa, HGPIN, and PIA was signifıcantly higher than mean of
fıbromodulin expression in normal glands (p0.0001). There was a higher
mean staining score in PCa (156, 95%CI:144–167), compared toHGPIN (131.4,
95% CI:109-153), PIA (128, 95% CI:117-138), and BPT (33.3, 95% CI:27-38).
Thus, fıbromodulin expression increased across the PCa progression model.
Conclusions: The expression pattern of fıbromodulin showed a signifıcant in-
crease from benign prostate tissue through pre-cancerous lesions to PCa. These
fındings suggest that this proteoglycanmaybe involved in the process of prostate
cancer progression, with low levels in pre-cancerous lesions and higher levels in
cancer tissue. Additional studies are required to determine the biological role
and potential clinical implications of fıbromodulin in prostate cancer.
#2415 Genome-wide alterations in gene expression of prostate cancer
(PC) cells surviving neo-adjuvant androgen deprivation therapy. Anna C.
Ferrari,1 Hatem Sabaawy,1 Mark Stein,1 David Foran,1 Ying Chen,1 Srinivasan
Yegnasubramanian2. 1Rutgers Cancer Institute of New Jersey, New Brunswick,
NJ; 2Johns Hopkins University Sidney Kimmel Cancer Center, Baltimore, MD.
Background: Although androgen deprivation therapy initially decreases PC
tumor burden, resistance to further androgen receptor (AR)-directed treat-
ments or chemotherapy is inevitable once CRPC is established. We postulated
that the stress of ADT triggers widespread alterations in expression that renders
a metastable physiologic state conditioned by epigenetic changes that might be
initially reversible by targeting non-androgen pathways. We conducted a pilot
study to explore genome-wide expression alterations in PC foci surviving 3
months ADT (eADT). Methods: mRNA from 7 frozen microdissected PC foci
and normal counterparts (NC) were processed for RNA-seq. RNA-seq changes
in eADT specimens were compared fırst with NC and the untreated PC in the
TCGAPRAD (TCGA) database to castrate resistant (mCRPC) specimens in the
dbGAP study phs000915.v1.p1database. The rawdata (fastq fıles)was quantifıed
using kallisto, normalized by TMM using R package edgeR, batch effects cor-
rected using R package SVA. Analysis of differential gene expression by R pack-
age sleuth. Pathway and gene set by GSEA, GAGE/pathview packages for Gene
Ontology (GO) and KEGG. Results: TMPRSS2-ERG, 5/7. Highest DEG in
eADT vs. TCGA vs mCRPC were non-coding RNA’s. Among 17431 differen-
tially regulated paths; GSEA of eADT vs TCGA or mCRPC: 341 (1.95%) and
1366 (7.84%) up- vs 46 (0.26%) and 59 (0.34%) down-regulated. KEGG paths,
eADT vs. TCGAormCRPC, 11 and 53 up vs. 2 and 3 down- respectively. Highly
down- path in eADT vs TCGA (log q1017) was ribosomal vs. cell cycle and
DNA replication in mCRPC. Six paths signifıcantly up- in eADT vs TCGA or
mCRPC:Wnt, adherence junction, steroid biosynthesis, unsaturated fatty acids,
citrate cycle, ErbB.Calcium,MAPK, insulin,GnRHandHedgehogwere also up-
in eADT vsmCRPC. AR full-length wasmarginally higher in eADT than TCGA
and lower than mCRPC, no differences in gene targets. Conclusions: This pilot
data shows that ADT triggers a wide range of gene expression alterations that
support PC cell survival andmay be vulnerable to therapeutic targeting in addi-
tion to the androgen pathway. Validation of these fındings is planned in a larger
set of samples from the same bank.
#2416 Transcriptome and cluster analysis of infant acute lymphoblastic
leukemia cases with and without MLL (KMT2A) rearrangement. Byunggil
Yoo,1 Midhat S. Farooqi,1 Rumen Kostadinov,2 Neil Miller,1 Jeff Johnston,1
Emily Farrow,1 Shannon Kelley,2 Margaret Gibson,1 Patrick Brown,2 Erin
Guest1. 1Children’sMercyHospital andClinics, KansasCity,MO; 2JohnsHopkins
University, Baltimore, MD.
Background: Infant acute lymphoblastic leukemia (ALL) is a high-risk cancer
with poor survival due to treatment failure and relapse. The majority of infant
ALL cases possess an MLL (KMT2A) translocation (MLL-R), where MLL joins
with AF4 (AFF1), ENL (MLLT1), or another partner gene to create a novel
fusion gene. A subset of infant ALL cases do not involve anMLL rearrangement
(non-MLL-R). Gene expression profıling delineates MLL-R from non-MLL-R
cases. Here, we describe transcriptome profıling and cluster analysis of MLL-R
and non-MLL-R cases and compare between partner genes. Methods: We per-
formed RNA sequencing (RNA-seq) on diagnostic blood or bone marrow sam-
ples from 40 infants with ALL. Cohort A included 16 patients with MLL-R ALL
known to have relapsed; cohort B, 10 patients with MLL-R ALL not known to
have relapsed; and cohort C, 14 patients with non-MLL-R ALL whom to date
have also not relapsed. RNA-seq was performed to an average of 8.8Gb and
analyzed using Bowtie2, RSEM, and limma-voom. Multiple different groups of
cases (e.g. cohortA versus B)were compared for differential gene expression; the
resulting genes were ranked by adjusted P value with a signifıcance cutoff of 0.01
and further evaluated for pathway analysiswith Ingenuity software.Hierarchical
clustering of samples was conducted using distance measures computed from
normalized gene expression. Results: Transcriptome analysis of MLL-R versus
non-MLL-R cases found 2,334 differentially expressed genes. Ingenuity pathway
analysis of these genes showed enrichment in specifıc gene sets, such as those
involved in PTEN, EGF, and NF-B signaling. Ingenuity predicted increased
PTEN signaling and diminished EGF and NF-B signaling in MLL-R cases
relative to non-MLL-R cases. Transcriptome analysis of relapsed versus non-
relapsed MLL-R cases found no differentially expressed genes meeting signifı-
cance criteria, while analysis of MLL fusion partners identifıed 46 differentially
expressed genes including BMI1 and MYC. Cluster analysis demonstrated a
distinct grouping of non-MLL-R cases relative to MLL-R cases. Additionally,
MLL-R samples sub-clustered according to their MLL fusion gene partners.
However, no difference in clustering was appreciated betweenMLL-R cases that
later went on to relapse versus those that did not. Conclusions: Our fındings
show that MLL-R infant ALL has a distinct gene expression signature at diag-
nosis that correlates with the type of MLL translocation present. This is impor-
tant because it suggests treatment strategies could be tailored to theMLLpartner
gene. Risk of relapse inMLL-R cases could not be predicted by this signature due
to a paucity of differentially expressed genes between relapsed and non-relapsed
groups at diagnosis. Similar to prior profıling studies, we fınd that non-MLL-R
cases independently cluster together and have a gene expression signature dis-
tinct fromMLL-R cases.
#2417 Large scale integrated transcriptomic and epigenetic profıling de-
fınes the molecular hallmarks of HGSOC and disease origins. Kate Lawren-
son,1 Marcos Abraao,2 Felipe Segato,2 Janet M. Lee,1 Simon Coetzee,1 Ji-Heui
Seo,3 Matthew L. Freedman,3 Dennis Hazelett,1 Simon Gayther,1 Houtan
Noushmehr4. 1Cedars-Sinai Medical Center, Los Angeles, CA; 2Ribeirão Preto
Medical School, Sao Paulo, Brazil; 3Dana-Faber Cancer Center, Boston, MA;
4Henry Ford Hospital, Detroit, MI.
High-grade serous ovarian cancers (HGSOCs) are themost common subtype
of epithelial ovarian cancer. Pathways driving HGSOC development are poorly
understood, and the cellular origins are debated in the literature. Previously,
ovarian surface epithelial cells (OSECs) were thought to be cellular precursors of
HGSOC, but there is now strong evidence that at least half of all HGSOCs arise
from fallopian tube secretory epithelial cells (FTSECs). We took a large-scale
integrated transcriptomic-epigenomic profıling approach to defıning the mo-
lecular hallmarks of HGSOC and to explore the disease cell-of-origin. RNA
sequencing was performed on 121 OSEC cultures and 84 FTSEC cultures and
integrated with 394 HGSOC transcriptomes profıled by TCGA. We identifıed
around 100 genes that differentiateOSECs and FTSECs, and pathway analysis of
this gene list identifıed ovarian cancer genes as highly enriched (p2.2x108),
with ZEB1 and estrogen the most signifıcant predicted upstream regulators
(P3.7x107). We integrated gene expression data with clinical metadata to
identify associations between gene expression signatures and clinical variables
and found that in patients diagnosed with ovarian cancer, OSEC and FTSEC
profıles converged, suggestive of a fıeld cancerization phenotype occurring in
the normalOSECs on the unaffected ovary contralateral to a clinically diagnosed
ovarian carcinoma. Transcriptomic signatures for OSECs, FTSECs and HGSOCs
were then merged with superenhancers defıned by performing chromatin im-
munoprecipitation data for acetylated H3K27 profıled in primary HGSOC tis-
sue specimens. We detected many more superenhancer-target gene relation-
ships in the normal cells than in the tumor cells, suggesting superenhancer
fıngerprints defıne the cell of origin rather than determining upregulation of
oncogenes driving cancer. To explore this further we determined the similarities
of HGSOCs to OSEC and FTSEC using a machine learning model. Using a
pre-defıned gene signature of OSECs and FTSECs, our model (high specifıcity
and sensitivity; 95% CI 0.77-1, p-value6.15) was applied to HGSOCs and
we observed that the majority of HGSOCs were classifıed as FTSEC-like. Inter-
estingly, the mesenchymal subtypes were enriched as FTSEC-like. Moreover, a
subset of HGSOCs were characterized as OSEC-like, and these tumors were
associated with poorer outcomes. Our data describe molecular subgroups
withinHGSOCprecursor tissues aswell as defıning the transcriptional networks
that defıne HGSOC precursor tissues, drive HGSOC development; furthermore
we describe the interplay between the epigenetic landscape and the transcrip-
tome in these cell types. In closing, these large-scale integrative analyses support
a predominantly FTSEC origin for HGSOCs, but reinforce conclusions that
OSECs cannot be excluded as origins of HGSOC, and may represent a subset of
tumors with a different biology.
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#2418 Characterization of the PAX8 regulatory network in epithelial
ovarian cancer. Rosario I. Corona,1 Emily Adler,2 Janet M. Lee,1 Norma Rodri-
guez-Malave,1 Paulette Mhawech-Fauceglia,2 Heidi Sowter,3 Dennis J. Ha-
zelett,1 Kate Lawrenson,1 Simon A. Gather1. 1Cedars-Sinai Medical Center, Los
Angeles, CA; 2University of Southern California/Keck School of Medicine, Los
Angeles, CA; 3University of Derby, Derby, United Kingdom.
PAX8 is a lineage-restricted transcription factor expressed in a large propor-
tion of epithelial ovarian cancers (EOCs). PAX8 is commonly upregulated in
EOCs relative to precursor tissues, suggesting it functions as an oncogene. How-
ever, the biological role of PAX8 during cancer initiation and development is
poorly understood, and the genome-wide transcriptional targets have yet to be
comprehensively catalogued. Using stable models of PAX8 knockdown in
HEYA8 and IGROV1 EOC cell lines we show that PAX8 knockdown reduces
cell proliferation in vitro and tumor growth in vivo. To understand how PAX8
regulates neoplastic phenotypes in cancer cells we performed RNA expression
profıling by microarray in HEYA8 and IGROV1 before and after PAX8 knock-
down. We also performed chromatin immunoprecipitation followed by next
generation sequencing (ChIP-seq) for PAX8 and a marker of active chromatin
(H3K27ac) in both cell lines. De novo motif discovery in the ChIP-seq profıles
identifıed a PAX-like binding motif and several potential PAX8 cofactors in
IGROV1 that are not enriched in HEYA8. These cofactors include members of
the TEAD and Sp/KLF families of transcription factors. We divided the genes
from our differential expression (DE) analysis in PAX8 knockdown into three
non-overlapping categories: (a) direct regulatory targets (RTs), i.e. DE genes
with PAX8 binding sites in their promoter regions; (b) putative enhancer RTs,
where DE genes and PAX8 binding sites reside within the same topological
association domain (TAD) defıned from embryonic stem cells; and (c) indirect
RTs. Our fındings reveal that PAX8 can function as either an activator or a
repressor, and that PAX8 regulates a very different set of genes in each cell line,
as only a small fraction RTs (50) is shared between HEYA8 and IGROV1.
Nonetheless, independent pathway enrichment analysis reveals four pathways
downstream of PAX8 that are common to both cell lines: DNA replication,
cellular response to lipopolysaccharides, TNFA signaling via NFKB and ana-
tomical structure morphogenesis. Individually, we discovered enrichment for
G2M checkpoint and EMT signaling in HEYA8, and tissue morphogenesis and
mesenchymal cell development in IGROV1. Collectively, our results suggest
that PAX8 regulates cell proliferation and cancer promoting processes via highly
tissue-specifıc regulation of common oncogenic pathways.
#2419 Genome-wide profıling of PAK4DNA-binding sites and transcrip-
tome reveals its potential transcriptional control on DNA repair-related
genes in ovarian cancer cells. Ivy Tsz-LoWong,1OscarGee-WanWong,1 Yim-
ing Qin,1 Junwen Wang,2 Annie Nga-Yin Cheung1. 1The University of Hong
Kong, Hong Kong; 2Mayo Clinic Arizona, Scottsdale, AZ.
Oncogenic role of p21-activated protein 4 (PAK4) in relation to cell growth
andmigration through various signalling cascades has beenwell studied inmul-
tiple cancer types. Such role might be contributed largely by cytoplasmic PAK4
as most of the known PAK4 signalling events occur in the cytoplasm. However,
recent studies have demonstrated that PAK4 is capable of shuttling between
nucleus and cytoplasm. The precise function of nuclear PAK4 (nPAK4) remains
substantially unexplored. We have previously shown that PAK4 can act as a
transcription factor. Herein, we aim to identify nPAK4-regulated genes by de-
lineating the PAK4-binding landscape in ovarian cancer genome and mapping
the PAK4 transcriptome in ovarian cancer cells. PAK4-enriched genomic re-
gions were identifıed by chromatin immunoprecipitationwith a PAK4 antibody
followed by next-generation sequencing (ChIP-seq) in OVCAR3 cells. PAK4
transcriptome datawas generated using RNA extracted fromSKOV3 cells stably
expressing PAK4 in the Affymetrix GeneChIP® Human Transcriptome Array
2.0 system. Gene lists generated from both ChIP-seq and microarray dataset
were subjected to pathway enrichment analysis by Partek® PathwayTM. Among
the 20 most signifıcantly enriched pathways from microarray studies, several
pathways in which PAK4 has no known reported function by far have been
identifıed. Notably, DNA repair pathways that are known to influence drug
chemosensitivity in ovarian cancer, such as the nucleotide excision repair
(p0.008), homologous recombination (p0.012), mismatch repair (p0.018)
and DNA replication (p0.018) pathways were signifıcantly enriched. In con-
cordance with the fındings, the nucleotide excision repair pathway was also
signifıcantly enriched (p0.006) in the gene list derived from promoter-re-
stricted PAK4 binding sites in the ovarian cancer genome. Among the many
candidates that were deregulated by PAK4, cyclin-dependent kinase 7 (CDK7),
a core component in the CAK subcomplex crucial to nucleotide excision repair
pathway, was further validated. The transcription start site (TSS) of cyclin-de-
pendent kinase 7 (CDK7) was bound by PAK4. CDK7 mRNA expression was
upregulated upon PAK4 overexpression. Quantitative-PCR showed downregu-
lated CDK7 mRNA expression upon siRNA-mediated knockdown of PAK4 in
OVCAR3 and TUOS3. This study points to the possible role of PAK4 in regu-
lating gene transcription as PAK4 is mapped to several core promoter/TSS re-
gions in the ovarian cancer genome. Our fındings also shed light into the poten-
tial role of PAK4 in regulating drug chemosensitivity via its transcriptional
control on genes implicated in DNA repair pathways. We postulate CDK7 as a
direct transcriptional target of PAK4 and thereby contributes to chemoresis-
tance in ovarian cancer cells.
#2420 Integrative analyses of gene expression, DNA methylation, geno-
type and copy number alterations characterize X-chromosome inactivation
in ovarian cancer. Stacey J. Winham,1 Nicholas B. Larson,1 Sebastian M. Ar-
masu,1 Zachary C. Fogarty,1 Melissa C. Larson,1 Kimberly R. Kalli,1 Kate Law-
renson,2 Simon Gayther,2 Brooke L. Fridley,3 Ellen L. Goode1. 1Mayo Clinic,
Rochester, MN; 2Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Medical Center, Los Angeles, CA; 3University of Kansas Medical Center, Kansas
City, KS.
Introduction: In females, X-chromosome inactivation (XCI) epigenetically
silences transcription of one copy of the X chromosome.Which chromosome is
silenced is randomly selected, and is tissue- and cell-specifıc. While some genes
are known to escape XCI under normal conditions, aberrant XCI patterns are
thought to occur in female-specifıc cancers, although the role of XCI in ovarian
tumorigenesis and progression is largely unknown. The process of XCI is com-
plex, and integration of gene expression, DNA methylation, and copy number
data can inform the XCI status of individual genes and chromosome-wide XCI
patterns for individual patients. Methods: We evaluated gene- and chromo-
some-level patterns of XCI by integrating RNA sequence, copy number altera-
tion, genotype, and DNA methylation data to study XCI escape patterns in
tumor samples from 99 ovarian cancer patients. We measured allele-specifıc
expression (ASE) for 397 X-linked genes to identify the active alleles for each
tumor. Combining ASE data with knowledge of copy number status, we used a
Bayesian beta-binomial mixturemodel to estimate which genes escaped XCI for
each patient, and validated our fındings using DNAmethylation data. To assess
global XCI patterns, we performed cluster analyses on the ASE andmethylation
data, after adjusting for loss of heterozygosity. We examined the relationship
between the clusters and clinical factors, including overall survival and time to
recurrence. Results: DNA promoter methylation demonstrated inverse regional
correlations with ASE. Cluster analyses using ASE and methylation data dem-
onstrated evidence of two tumor clusters, representing normal XCI and global
XCI dysregulation. The dysregulated XCI cluster (N52) was associated with
lower X-inactive specifıc transcript expression as expected (p0.01). Patients
with XCI dysregulated tumors were higher grade, stage, serous histology and
were sub-optimally debulked (p0.05). These patients also had shorter overall
survival time (HR1.87, p0.02) and time to recurrence (HR2.34, p0.01),
although associations were attenuated after covariate adjustment. In 45 tumor
samples with suffıcient data, we observed escape patterns largely consistent with
previous reports of multiple tissue types. When comparing tumor to normal
ovarian tissue, eight genes (CXorf23, CXorf36, BRWD3, ELF4, SLITRK4, GA-
BRE, CLCN4, SH3BGRL) showed putative escape in the tumor and two genes
(RBBP7, OFD1) showed discrepant tumor inactivation. Conclusions: We iden-
tifıed discrepant gene-level XCI tumor classifıcations compared to normal tissue
and identifıed a group of patients with chromosome-wide XCI dysregulation
associated with worse clinical prognosis. This provides evidence of the role of
XCI in ovarian cancer and highlights the need to integrate multiple genomic
data types to study XCI.
#2421 The role of p53mutational status and SOX9 suppression in chemo-
therapy response of ovarian cancer. Noelle L. Cutter, Matthew Lucito, Ryan
Frank, Kimberly Doyle.Molloy College, Rockville Centre, NY.
Ovarian cancers are highly heterogeneous where platinum based chemother-
apy which induces DNA crosslinking resulting in apoptosis of the cell is the
preferred treatment. However, many patients are intrinsically resistant or
quickly develop resistance. The Sox factors are a large family of transcription
factors that play important roles in tumor development and progression in a
variety of human malignancies and diverse developmental processes, but their
impact in clinical tumorigenesis is still unclear. An analysis of genomic changes
in ovarian cancer has provided the most comprehensive and integrated view of
cancer genes for any cancer type to date. Ovarian serous adenocarcinoma tu-
mors from 500 patients were examined by The Cancer Genome Atlas (TCGA)
Research Network and analyses are reported in a recent issue of Nature. This
evidence suggests that epigenetic deregulation, such as methylation, may be a
key factor in the onset and maintenance of chemoresistance. Previous microar-
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ray analysis results in our lab correctly identifıed a subset of about 300 genes that
when methylated altered the chemoresistance of the ovarian epithelium cells in
culture. Of the genes identifıed in the analysis we further set out to characterize
oncogenes and tumor suppressor genes that interact with the guardian of the
genome, TP53, to determine if we could elucidate the mechanism by which it
increased resistance. Using several in-vitro assays, we determined that the loss of
p53 in conjunction with SOX9 decreased the level of apoptosis in response to
carboplatin. Furthermore, in cells with mutated p53/SOX9 show an increase in
tumorigenesis. Regulation of several pathways with p53 mutations in ovarian
cancer might represent a therapy response prediction and could be a future
therapeutic target for ovarian cancer. In addition, the crosstalk between p53/
SOX9 and epigenetic regulators may present a valid treatment option for in-
creasing carboplatin sensitivity in resistant patients.
#2422 Simultaneous detection of activating somatic DNAmutations and
expressed fusion transcripts from lung tumor FFPE samples. A. McGarry
Houghton,1 GavinMeredith,2 Julia Kargl,1 Jill McKay-Fleisch,2 P.Martin Ross,2
Anisha Kharkia,2 AfshinMashadi-Hossein,2 Dae Kim,2 Joseph Beechem2. 1Fred
Hutchinson Cancer Research Center, Seattle, WA; 2NanoString Technologies,
Inc., Seattle, WA.
Worldwide, lung cancer is the most commonly diagnosed form of cancer with a
survival rate among the lowest. Combined, somatic mutations (in the form of
SNVs and InDels) and gene fusions, account for the majority of interpretable and
actionable genomic alterations. Importantly, this typically requires the analysis of
DNA and RNA from limited amounts of FFPE-preserved specimens. Currently,
these analyses typically require complex samplepre-processing for assayonseparate
platforms or separate complex library preparationmethods for assessment by high
throughput sequencing. To provide a unifıed and simpler alternative, NanoString’s
molecular barcoding technologyhas beenmodularized to permit simultaneous dig-
ital measurement of cancer-relevant targets that span these two analyte classes.
Novel ‘SNV= probes enable sensitive and specifıc identifıcation of DNA mutant
allele sequences down to a level of detection of 5% from 5 ng of FFPE-extracted
genomic DNA. Fusion transcripts are detected with 5=/3= imbalance probes and
toehold-mediated junction probes. This dual analyteworkflow requires just a single
5-10 micron section of FFPE tissue and provides to sample-to-answer results with
approximately 5minutes of hands-on time per sample after nucleic acid extraction.
Todemonstrateutility, 37 lung cancer sampleswere assayed simultaneouslywith an
SNV panel that targets 100 solid tumor somatic mutations and a lung cancer
fusion gene panel that provides general evidence of ALK, RET, and ROS1 gene
fusion events along with specifıc detection of 35 unique fusion transcripts that cor-
respond to known break-points. In this particular cohort, 16 samples were positive
for activating KRAS SNVs (one of which was also positive for an activating STK11
variant), 3 were positive for activating EGFRmutations including two SNVs and an
18-base InDel and one was positive for an activating KIF5B16:RET12 fusion tran-
script. Positivemutation calls obtainedwith the SNVpanel couldonly be confırmed
bywhole-exome sequencing (average depth of 100X) for 13 of 20 variants detected;
however, ultra-deep (average depth of 4400X) targeted sequencing revealed that the
7 additional panel-detected mutations were, in fact, present. Measured against the
sequencing datasets, the SNV panel provided 100% sensitivity, specifıcity, accuracy
andprecision for all variants present at 5%or greater allele frequency.TheKIF5B16:
RET12 fusion event was also confırmed by sequencing. Combined, these results
show that these two important classes of activating mutations can be readily and
effıciently assayed together on a NanoString nCounter® system (for research use
only).
#2423 Bronchial airway gene expression signatures in mouse lung squa-
mous cell carcinoma and their modulation by cancer chemopreventive
agents. Donghai Xiong,1 Jing Pan,1 Qi Zhang,1 Eva Szabo,2 Mark S. Miller,3
Ronald A. Lubet,3 Ming You,1 YianWang1. 1Medical College of Wisconsin, Mil-
waukee, WI; 2National Cancer Institute, Bethesda, MD; 3Division of Cancer Pre-
vention, National Cancer Institute, Bethesda, MD.
Due to exposure to environmental toxicants, a “fıeld cancerization” effect
occurs in the lung resulting in the development of a fıeld of initiated but mor-
phologically normal appearing cells in the damaged epithelium of bronchial
airways with dysregulated gene expression patterns. Using a mouse model of
lung squamous cell carcinoma (SCC), we performed transcriptome sequencing
(RNA-Seq) to profıle bronchial airway gene expression and found activation of
the PI3k and Myc signaling networks in cytologically normal bronchial airway
epithelial cells of mice with preneopastic lung SCC lesions, which was reversed
by treatment with the PI3K Inhibitor XL-147 and pioglitazone, respectively.
Activated MYC signaling was also present in premalignant and tumor tissues
from human lung SCC patients. In addition, we identifıed a key microRNA,
mmu-miR-449c-5p, whose suppression signifıcantly up-regulated Myc expres-
sion in the normal bronchial airway epithelial cells of mice with early stage SCC
lesions.We developed a novel bronchial genomic classifıer inmice and validated
it in humans. In the classifıer, Ppbp (pro-platelet basic protein) was overex-
pressed 115 fold in the bronchial airways of mice with preneoplastic lung SCC
lesions. This is the fırst report that demonstrates Ppbp as a novel biomarker in
the bronchial airway for lung cancer diagnosis.
#2424 The in-parallel whole-genome ChIP-Seq analysis of primary tis-
sues, patient derived xenografts, and cancer cell lines fromHPV-relativeHN-
SCC samples. Dylan Z. Kelley,1 Emily L. Flam,1 Hildegard A. Wulf,1 Theresa
Guo,1 Evgeny Izumchenko,1 DzovA. Singman,1 Ludmila V.Danilova,1 ElenaD.
Stavrovskaya,2 Michael Considine,1 Justin A. Bishop,1 William H. Westra,1
Zubair Khan,1 Wayne M. Koch,1 David Sidransky,1 Sarah Wheelan,1 Joseph A.
Califano,3 Alexander V. Favorov,1 Elana J. Fertig,1 Daria A. Gaykalova1. 1Johns
Hopkins Univ., Baltimore, MD; 2Moscow State University, Moscow, Russian Fed-
eration; 3Univ. of California, San Diego, La Jolla, CA.
This project develops a novel experimental technique to perform ChIP-Seq
(chromatin immunoprecipitation with massively parallel DNA sequencing) analy-
sis of chromatin structure in primary tumor tissues from high risk HPV-related
head and neck squamous cell carcinomas (HPV HNSCC). Recent data suggest
that chromatin structure is the central regulator and predictor of cancer-specifıc
expression andmutagenesis landscape of diseased cells. Genome-wide gene expres-
sion dysregulation in many tumors, including HPV HNSCC, are incompletely
described by current knowledge. Methods for study of chromatin structure in pri-
mary tumor tissue are needed to better understand the role global epigenetic
changesmayplay in these tumors.However, ChIP-Seq,which is the state-of-the-art
method of elucidating chromatin structure, until now, has not been reliably per-
formed on anyHNSCC samples. Because chromatin structure is disrupted at room
temperature, ChIP-Seq is especially complicated for primary patient tissues, which
are primarily obtained as surgical waste after pathology review. Snap freezing of
leftover waste surgical tissues and further tissue thawing for the analysis decreases
chromatin structure integrity necessary for highly sensitiveChIP-Seqmethodology,
especially for tumor samples with chromatin structure deformed during carcino-
genesis. To improve the chromatin structure integrity in tumor sample we added a
xenografting step andminimized the exposureof cancer tissue to roomtemperature
conditions aftermouse surgery.We alsominimized patient non-cancer tissue pres-
ervation at ambient temperature after patient surgery. We successfully performed
ChIP-Seq for H3K4me3, H3K9me3, andH3K9ac on frozen uvulopalatopharyngo-
plasty (UPPP) primary tissues, frozen patient derived xenograft tissues, and freshly-
cultured head and neck squamous cell carcinoma cell lines, revealing comparable
success rates between tissue type and sample preservation techniques. ChIP-Seq
techniqueswereperformedandcrossvalidatedusing triedandtrueqRT-PCRmeth-
ods to demonstrate data reproducibility. The biological relevance of the ChIP-Seq
data was confırmed throughmassive RNA-Seq analysis of 47HPVHNSCC sam-
ples and 25 non-cancer controls. Analysis revealed that most H3K9ac and
H3K9me3enrichment is similar inprimary tissues, regardlessofdisease status.Only
small portion of them showed differential histone enrichment, which correlated
with differential expression of corresponding genes. On the other hand, H3K4me3
showed strong tissue specifıcity andwere found differentially enriched especially in
tumor samples. The proposed experimental pipeline demonstrates high reproduc-
ibility between biological replicates, diversity of tissuemodels, and low dependence
of ChIP-Seq analysis on tissue preservation techniques.
#2425 Delving into molecular phenomena of methylation, polyadenyla-
tion andmutation suggests their importance in regulating gene expression in
GBSCC. Richa Singh,1 Esita Chattopadhyay,1 Roshni Roy,2 Bidyut Roy1. 1In-
dian Statistical Institute, Kolkata, India; 2Baylor Scott and White Health, TX.
Background: Gingivo-buccal squamous cell carcinoma (GBSCC) is one of the
most prevalent types of oral cancers in India. Althoughwhole exome studies in oral
cancer have reported somaticmutational driver genes, studies onmethylation,mu-
tations and alternative polyadenylation (APA) to identify differentially expressed
transcripts and exons, respectively, are rare. The aim of our study is to investigate
possible causes of expression deregulation due to methylation, APA or mutations.
Methods: Whole transcriptome data was generated from 12 tumor-normal paired
GBSCC tissues andanalyzed for differential gene expression, differential exonusage
and predicting APA site.Whole exome sequencing was performedwith same sam-
ple set and the data was analyzed to identify somatic mutations. Reduced represen-
tation of bisulphate sequencing (RRBS) was also done for some of these samples to
inquire about the methylation status of deregulated genes. Results: A total of 465
genes were found to have differential exon usage in tumor leading to expression of
different isoforms and change in overall gene expression. About 194 genes were
predicted to utilize alternate polyadenylation site in tumors. Amongst these, 11
genes including ERBB3, CDC25B and LTBP4were shown to have differential exon
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usage in tumor with altered gene expression hinting upon the influence of polyad-
enylation in expression change. From the exome sequencing study, 180 SNVs and
11 indel somaticmutations per sample were observed. Apart from other non-silent
exonicmutations at TP53, CASP8, DIS3 andDLG1, splice site mutations were also
found in37and4genesdue topoint and indelmutations respectively.Genes suchas
TPM3, NBN, CXCL12 along with others showed differential exon usage and were
found to harbor somaticmutations andAPA site. This suggests for coupled regula-
tion by APA andmutation in altering expression of those genes. Apart from this, a
subset of deregulated genes (n54) were observed to have differential methylation
in tumors. Expression change of TAP1, SLN, ELN etc. corroborated with their
methylation status suggesting the influence ofmethylation in regulating expression
of these genes. Conclusion: Differential exon usage suggested different transcript
formation leading to overall change in gene expression in tumor. Upon excavating
into the regulatory causes, a subset of genes showed change in methylation pattern
while few others showed change in APA site with/without somatic mutation effect.
These molecular phenomena explain how different mechanisms are involved in
expression deregulation of genes observed in GBSCC which would help in further
functional research for cure of the disease.
#2426 Oncopig soft-tissue sarcomas recapitulate key transcriptional fea-
tures of human sarcomas.KyleM. Schachtschneider,1 Yingkai Liu,2 SuviMake-
lainen,3 Ole Madsen,3 Laurie A. Rund,2 Martien A. Groenen,3 Regina M.
Schwind,1 RonC. Gaba,1 Schook B. Lawrence2. 1University of Illinois at Chicago,
Chicago, IL; 2University of Illinois, Urbana, IL; 3Wageningen University, Wage-
ningen, Netherlands.
Human soft-tissue sarcomas (STS) are rare, aggressive mesenchymal tumors
with a late stage 5-year survival rate (50-60%) that has for decades remained
unchanged. Research into STS treatment is hampered by the limited human STS
cell line availability and the large number of STS subtypes. Therefore, there is a
need to develop STS cell lines and animal models representative of diverse hu-
man STS subtypes. Pigs represent ideal human disease models due to their sim-
ilar size, anatomy, metabolism, genetics, and epigenetics compared to humans.
In this regard, porcine cancer models provide the opportunity to produce STS
cell lines and in vivo tumors similar to those clinically observed in humans. The
Oncopig encodes Cre recombinase inducible porcine transgenes encoding
KRASG12D and TP53R167H, allowing the Oncopig to model a number of human
sarcomas in an inducible and temporal manner. However, comparative analysis
is required to determine to what extend the Oncopig STSmodel mimics human
STS on a molecular level. The purpose of this study was to identify similarities
between Oncopig and human STS transcriptional profıles to validate the Onco-
pig model as a viable model for human STS. Towards this end, Oncopig fıbro-
blasts were isolated from ear notches of 4 Oncopigs and cultured in vitro. Fol-
lowing confırmation of their mesenchymal origin (positive vimentin
immunostaining), Oncopig fıbroblasts were transformed via Cre recombinase
exposure, resulting in the formation of Oncopig STS cell lines. Oncopig STS
tumors were produced in vivo through intramuscular injection of adenovirus
encoding Cre in 2 Oncopigs (2 sites/Oncopig), resulting in the formation of 4
tumors detectable by 10 days post injection. The mesenchymal origin of the
resulting tumorswas confırmed throughhistological characterization.Genome-
wide expression of Oncopig STS cell lines and tumors was profıled via RNA-seq.
Reproducible Oncopig STS cell line and tumor expression profıles were ob-
served, and Oncopig STS cell lines also displayed high temporal reproducibility.
Differential expression analysis was performed by comparing Oncopig STS cell
lines and tumors to untransformed fıbroblasts and skeletal muscle, respectively.
A total of 3,360 and 7,652 differentially expressed genes were identifıed in the
Oncopig STS cell lines and tumors, respectively. Commonly identifıed altera-
tions in human STS gene expression and pathway regulation were identifıed in
Oncopig STS, including altered TP53 signaling, activation ofWnt signaling, and
evidence of epigenetic reprogramming. Furthermore, master regulators of On-
copig STS gene expression were identifıed, including FOSL1, which was previ-
ously identifıed as a potential therapeutic target for human STS. These results
demonstrate the Oncopig STS model’s ability to mimic human STS on a tran-
scriptomic level, making the Oncopig a valuable resource for sarcoma research
and cell line development.
#2427 Alterations in gene expression after exposure ofMDA-MB-231 cells
to isobutylparaben. Christine Strelchuk,1 Holly Jones Taggart2. 1University of
Toronto, Toronto, Ontario, Canada; 2University of Ontario Institute of Technol-
ogy, Oshawa, Ontario, Canada.
Parabens are a group of chemical compounds extensively used as preserva-
tives in consumer products such as cosmetics, pharmaceuticals and processed
food. Parabens have been shown to have endocrine disrupting properties, to
accumulate in breast tissue and to increase the proliferation of hormone recep-
tor positive breast cancer cell lines through competitive binding to the estrogen
receptor. Studies have shown that isobutylparaben has the highest binding af-
fınity for the aryl hydrocarbon receptor (AhR), reported to bind environmental
toxins. This study examined the alterations in gene expression correlated to
exposure of the hormone receptor negative breast cancer cell lineMDA-MB-231
to isobutylparaben over a 72 hour time frame. Exposure of the cells to concen-
trations of isobutylparabens commonly found in consumer products alters the
genetic expression profıle of the cells. In our study, detectable expression levels
of AhRmRNA decreased, while cytochrome P450 (CYP1A1) and receptor acti-
vator of NFB ligand (RANKL) mRNA levels increased, as analyzed by qPCR.
The downregulation of AhR and altered expression levels of invasion related
genes is suggestive of an increasedmetastatic phenotypewith exposure to isobu-
tylparaben.
#2428 The cytidine deaminase APOBEC3B is a regulator of gene expres-
sion in breast cancer. Manikandan Periyasamy. Imperial College London, Du
Cane Road, London, United Kingdom.
The APOBEC3B (A3B) cytidine deaminase gene has been implicated driving
the mutational landscape in breast and other cancer types. We have discovered
that A3B is a co-activator of estrogen receptor (ER)mediated gene expression in
breast cancer. Mechanistic studies established that A3B regulates gene expres-
sion by promoting C-to-U deamination at ER binding regions. We show that
these C-to-U changes lead to the generation of DNA strand breaks through
activation of base excision repair (BER) and to repair by non-homologous end-
joining (NHEJ) pathways. We have performed RNA-seq and A3B ChIP-seq, in
multiple ER and ER breast cancer cell lines. Remarkably, these studies dem-
onstrate that A3B regulates the expression of many genes in inflammatory and
interferon signaling pathways, in addition to the regulation of ER target genes.
These fındings, together with other data to be presented, provide a clear role for
A3B in transcription regulation. These fındings also raise the possibility that
transcription factor mediated recruitment of A3B to DNAmay facilitate acqui-
sition of A3B driven cancer mutations.
#2429 Generation of a transcriptome of oncogenic mutant p53 in triple-
negative breast cancer. Rebecca E. Steele, Simon S. McDade, Paul B. Mullan.
Queen’s University Belfast, Belfast, United Kingdom.
The purpose of this study was to generate a transcriptional profıle specifıc
for mutant p53 in triple-negative breast cancer (TNBC), representing poten-
tial novel therapeutic targets. The highly heterogeneous TNBC tumor sub-
group is established as having a poor clinical outcome. There are currently
no targeted therapies for women with TNBC; consequently, there is an un-
met clinical need to identify targetable pathways. Approximately 75% of
these tumors are known to harbour a mutation in Tp53 (mutp53). Chroma-
tin Immunoprecipitation Sequencing (ChIP-Seq) for mutp53 and ETS-1 (a
knownmutp53 interactor) was carried out using the D0-1 (sc-126) and sc-20
antibodies respectively, in the MDA-MB-468 TNBC cell line. The aim of
these ChIP-seq experiments was to identify sites bound by endogenous
R273H mutp53 and ETS-1 and to confırm that target genes were co-regu-
lated. We identifıed 282 novel mutp53 specifıc genomic binding sites and 37
mutant p53 and ETS1 shared binding sites. In-house data analysis and peak
calling generated a list of potential transcriptionally co-regulated genes ad-
jacent to these genomic sites. PDGF, TRIB3, BTRC, TNFSF18 & PI3 were
successfully validated as being transcriptionally regulated by R273Hmutp53
and not wild-type p53 (as shown by MCF7 ChIP-seq comparisons). A num-
ber of these genes are known to be aberrantly expressed in TNBC patient
tumors and harbor interesting immune biology, providing potential oppor-
tunities for novel therapeutic strategies. In addition, DNA damaging chemo-
therapy-resistant MDA-MB-468 derivatives express elevated levels of
mutp53 protein and altered expression of our validated transcriptional tar-
gets, suggesting that they may also have roles in promoting resistance to
current chemotherapy treatments, downstream of mutp53. In conclusion,
we have identifıed a cohort of ‘mutp53 specifıc’ transcriptional targets which
may have roles in modulating immune responses to TNBCs, driving resis-
tance to current chemotherapies and could provide opportunities for the
development of novel treatments for TNBCs.
#2430 The expression of BCL6 and ZEB family transcription factors and
their correlation in breast cancers.MinZhao, LinAng, Li Zheng, JinWang, Jin
Huang, Hongguang Hu, Qiang Zou. the Second People’s Hospital of Hefei, Hefei,
China.
The proto-oncogene B-cell lymphoma 6 (BCL6) is an evolutionarily con-
served zinc fınger protein and a potent transcriptional repressor. It is also the
master regulator of B-lymphocyte development. Emerging evidence indicates
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that BCL6may play an important role in breast cancer progression. In this study,
we investigated the expression of BCL6 and tis correlationwith the expression of
epithelial-mesenchymal transition (EMT)-associated transcription factors zinc
fınger E-box-binding homeobox 1 (ZEB1) and ZEB2 in invasive breast cancers.
The mRNA and protein expression of BCL6, ZEB1 and ZEB2 were examined
using in situ hybridization and immunohistochemistry, respectively, in 228
breast cancer patients and 80 patients with breast benign diseases. The associa-
tion of BCL6, ZEB1 and ZEB2 expression with clinicopathological parameters
and patient survival were analyzed.We found that the expression of BCL6, ZEB1
and ZEB2 protein and mRNA were signifıcantly higher in breast cancer tissues
than in breast benign disease tissues (P0.05). The expression levels of BCL6,
ZEB1 and ZEB2 were all positively correlated with the tumor size, lymph node
metastasis and higher tumor stages (P0.05). Furthermore, patients with BCL6,
ZEB1 and ZEB2 protein-positive primary tumors were associated with a signif-
icant lower overall survival (OS) rate (P0.001, 0.002 and 0.001, respectively)
and post-operative relapse-free survival (RFS) rate (P0.002, 0.001 and 0.003
for the expression of BCL6, ZEB1 and ZEB2, respectively). The mRNA expres-
sion of ZEB1 and ZEB2 were positively correlated with BCL6mRNA expression
(rs0.326, P0.001; and rs0.382, P0.001, respectively); the protein expres-
sion of ZEB1 and ZEB2 were also positively correlated with BCL6 protein ex-
pression (rs0.449, P0.001; and rs0.669, P0.001, respectively). These re-
sults indicate that BCL6, ZEB1 and ZEB2 may be as potential biomarkers for
predicting invasion, metastasis and prognosis of breast cancer and that BCL6
may be a regulator of ZEB family transcription factors (ZEB1 and ZEB2).
#2431 Single cell gene expression profıling in breast cancer cells with the
Her2/neu gene knockout by CRISPR-Cas9. Xiaoyang Wang,1 Chip Lomas,1
Michael A. Tycon,1 Craig Betts,2 Suzanne Weaver2. 1BD Biosciences, San Jose,
CA; 2BD Genomics, Menlo Park, CA.
The Her2/neu gene is amplifıed and overexpressed in 15%-30% of breast
cancers. The overexpression of this oncogene is strongly correlated with de-
creased survival, increased cancer relapse, and poor prognosis. Although ther-
apy has been successfully developed to target this oncogene, a better understand-
ing of this oncogene will provide further insight for breast cancer biology and
future drug development. In recent years, theCRISPR-Cas9 systemhas emerged
as an effıcient method for genetic engineering, enabling targeted gene knockout
with minimal off-target effects. In this study, we employed a plasmid-based
CRISPR-Cas9 system to knock out the Her2/neu gene in breast cancer cells.
Puromycin selected, GFP-positive (two indicators of the incorporation of the
CRISPR-Cas9 system), Her2-negative individual cells were index-sorted using a
BDFACSMelodyTM system into individual wells of a 96-well BDTMPrecise plate
with sample barcoding and molecular indexing. A whole transcriptome ampli-
fıcation (WTA) assay was performed to obtain a gene expression profıle for each
of the Her2/neu knockout cells. Her2 gene knockout was performed on two cell
lines: T47D, a ductal carcinoma-derived breast cancer cell line with no Her2
amplifıcation that shows low to intermediate Her2/neu expression; and SKBR3,
an adenocarcinoma-derived breast cancer cell line known for Her2/neu gene
amplifıcation and overexpression. For comparison, WTA assays were also car-
ried out on parental cells without gene editing. Comparison of the gene expres-
sion profıles reveals downstream changes in gene expression correlated to the
Her2 knockout. The profıling of gene expression in Her2/neu CRISPR-Cas9
knockout cells on a single cell level promises to provide insight into the mecha-
nisms in these aggressive cancers that could help future drug discovery. For
Research Use Only. Not for use in diagnostic or therapeutic procedures. 23-
19341-00.
#2432 GPER1 expression is modulation by D-glucose concentration in
estrogen-responsive cancer and tumor cells. Yan Zheng, Kevin D. Houston.
New Mexico State Univ. - Las Cruces, Las Cruces, NM.
G protein-coupled estrogen receptor 1 (GPER1, aka GPR30), is a 7-transmem-
brane receptor thatmediates rapid cell signaling events stimulated by 17-estradiol
(E2) in cancer and tumor cells. In breast cancer cells, GPER1mediates E2-induced
CTGF-dependent cell migration and cyclin E expression resulting in cell cycle pro-
gression.GPER1hasalsobeenshowntomediate antiproliferative cell signaling such
as p53-dependent inhibition of cell cycle progression in breast cancer cells treated
with the GPER1-specifıc agonist G1 and the inhibition of IGF-1R signaling in ta-
moxifen-treated breast cancer cells. In addition to E2, both natural and synthetic
compounds have been shown to activate GPER1 in breast cancer cells. GPER1 has
alsobeenshownto regulate cell signaling incells that lackER. For example,GPER1
is antiproliferative in triple-negative breast cancer cells. While the importance of
GPER1 in themodulation of E2-responsive tumor and cancer cells as been demon-
strated, there is very little informationregarding the regulationofGPER1expression
in these cell types. The work presented here is aimed at determining the molecular
mechanisms that regulate GPER1 expression. To determine if GPER1 expression is
sensitive to D-glucose concentration in breast cancer cells, MCF-7 and T47D hu-
man breast cancer cells were cultured in media containing increasing concentra-
tions of D-glucose and GPER1 expression was measured using real-time PCR and
immunoblot. Data from these experiments showed that GPER1 expression was
signifıcantly increased inbreast cancercells cultured inmediacontaining lowD-glu-
cose concentrations (0 and 2.5mM) and signifıcantly reduced in media containing
high D-glucose (25 mM). Since low D-glucose concentration is known to activate
the energy-sensing AMP kinase (AMPK), the observed GPER1 induction in low
D-glucose conditions was determined after pretreatment with the AMPK inhibitor
compound C. GPER1 expression was inhibited in both MCF-7 and T47D breast
cancer cells cultured in low D-glucose media when pretreated with compound C.
Additionally, theAMPKactivatormetformin inducedGPER1expression inMCF-7
andT47Dbreast cancer cells cultured in highD-glucose (25mM) conditions. These
data suggest thatAMPKmediatesGPER1 expression in cells cultured in lowD-glu-
cose. The D-glucose sensitivity of GPER1 expression was also determined in the
Eker rat-derived uterine leiomyoma cells (ELT-3 and ELT-6) which are character-
ized by hyperactive AMPK. In both ELT-3 and ELT-6 cells, GPER1 expression was
not sensitive to D-glucose concentration nor was the activation state of AMPK
sensitive to D-glucose concentrations. However, the inhibition of AMPK by com-
pound C in both ELT-3 and ELT-6 cells resulted in decreased GPER1 expression.
These fındings reveal a previously unknown mechanism that regulates GPER1 ex-
pression in E2-responsive tumor and cancer cells.
#2433 Altering nuclear size impacts cancer cell characteristics in mela-
noma cell lines. Lidija D. Vukovic,1 Bradley A. Stohr,2 Dan L. Levy1. 1University
of Wyoming, Laramie, WY; 2University of California, San Francisco, CA.
Nuclear size is altered in cancer cells, a change used by pathologists to distinguish
cancer fromnormal cells. Previous studies inXenopus identifıed two nuclear trans-
port proteins, importin andNTF2, as regulators of nuclear size. In general, impor-
tin  and NTF2 levels positively and negatively affect nuclear size, respectively.
Increased importin  expression is used as a biomarker in non-small cell lung car-
cinoma and breast cancer and correlates with increased nuclear size. We identifıed
decreased NTF2 protein expression as a potential biomarker in melanoma, consis-
tentwithNTF2 levels negatively regulating nuclear size. Following up on this result,
our current studies focus on manipulating nuclear size in melanoma cells to assess
the impact on cancer cell characteristics, including proliferation rate,migration po-
tential, andapoptosis. First,wemeasurednuclear size andNTF2expression levels in
different stagemelanoma cell lines. Compared to a normal melanocyte cell line, we
consistently observed larger nuclei and lower NTF2 protein levels in all melanoma
cell lines examined.Next,weperformed transient transfections inHeLa,MRC5, and
melanoma cell lines, demonstrating that ectopic NTF2 expression leads to reduced
nuclear size.Themostdramatic effectswereobserved inprimarymelanomacell line
WM3211 where higher NTF2 expression caused a 40% reduction in nuclear cross-
sectional area. To obtain more precise control over NTF2 expression levels, we
generated a stably transfected metastatic melanoma cell line (WM983B) in which
NTF2 expression can be titrated by varying the concentration of doxycycline in the
growth media. Higher doxycycline levels lead to increased NTF2 expression and
smaller nuclei. In particular, 20 ng/ml doxycycline induced a 10% reduction in nu-
clear cross-sectional area. In awoundhealing assay, doxycycline-treated cells exhib-
ited a 40% reduction in cellmotility compared to non-treated cells or the parent cell
line treated with doxycycline. Furthermore, the doxycycline-treated cells exhibited
an increased rate of apoptosis.We propose that reduced nuclear size in the doxycy-
cline-treated cells causes changes in chromatin organization and gene expression,
thus giving rise to observed effects on cellmigration and apoptosis. To test this idea,
we are currently performing a global transcriptomics analysis of our cell lines to
identifygeneswhoseexpression isalteredbynuclear size.Using this information,we
will use DNA FISH to map the intranuclear position of differentially-expressed
genes as a functionofnuclear size.Also invivoexperiments areongoing inwhichwe
have subcutaneously injected NTF2-inducible melanoma cells into NSG mice in
order to examine tumor formation andmetastatic capacity of cells with differently-
sizednuclei.Regarding that inmostcancercellsnuclear size is enlarged,understand-
ing the causes and effects of these changes can help us to better understand cancer
biology.
#2434 LEF1 negatively regulates differentiation of HCC by activation of
Notch signaling pathway. Shuo FANG,1 Lei LI,2 MIng LIU,3 Janice Tsang,4
Xinyuan GUAN5. 1The university of Hong Kong, Hong Kong, China; 2Sun Yat-
Sen University Cancer Center, Guangzhou, China; 3Guangzhou Medical Univer-
sity, Guangzhou, China; 4The university of Hong Kong, Queen Mary Hospital,
Hong Kong, China; 5The University of Hong Kong, Department of Clinical On-
cology, Hong Kong, China.
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Lymphoid enhancer binding factor-1 (LEF1), an essential regulatory pro-
tein, plays a crucial role on self-renewal and differentiation properties of
several cancers, contributing to tumor malignancy degree and prognosis.
However, its molecular mechanisms to promote tumor differentiation still
keep unknown, especially in hepatocellular carcinoma (HCC). In this study,
by analyzing the transcriptome datasets and our qPCR result of clinical HCC
samples, we found that LEF is frequently overexpressed in HCCs and signif-
icantly associated with HCC differentiation (p0.015). In addition, func-
tional study showed that LEF1 could enhance the cell proliferation, matrigel
invasion, transwell migration, as well as self-renewal abilities both in vivo
and in vitro experiments. We also demonstrated LEF1 is closely related to
Notch intracellular domain (NICD), and revealed several putative sites as the
targets for LEF1 activating Notch signaling pathway. LEF1 could induce the
Notch signaling via transcriptionally up-regulate Notch expression through
direct DNA binding. The expressions of several downstream members in
Notch signaling pathway including Notch1 and Notch2 were subsequently
increased. Moreover, LEF1 could down-regulate various differentiation
markers and over-express tumor stemness related genes. Together, LEF1 is a
novel oncogene that show a crucial role in the tumorigenesis and progression
of HCC via activating Notch signaling pathway and inhibiting the differen-
tiation and stemness of HCC, resulting in poor pathologic differentiation
and leads to high degree of malignant. All the fındings suggest a novel treat-
ment possibility and a new target for liver stem cell eradication. LEF1 could
be investigated for clinical early diagnosis and prognosis prediction of HCC
patients and improving the development of new therapy against HCC.
#2435 Smoothened a new perspective for uterine leiomyoma treatment.
Natalia Garcia,1 Laura Gonzalez Anjos,2 Giovana De Nardo Maffazioli,1 Nilo
Bozzini,2 Edmund Chada Baracat,2 Katia Candido Carvalho2. 1Univ. of São
Paulo Faculty ofMedicine,Mogi das Cruzes, Brazil; 2Univ. of São Paulo Faculty of
Medicine, São Paulo, Brazil.
Background: Uterine leiomyomas (LM) are the most common gynecologic
tumors occurring in women of reproductive age. Patients may present clinical
complications such as bleeding, pain and infertility. Additionally, some re-
searchers believe that a leiomyosarcoma can arise from a degenerated LM. Effı-
cient treatments for LM are still limited. Identifıcation of gene markers can help
to elucidate these tumors pathogenesis and to reveal molecules that can be used
as therapeutic targets. Objective: To assess gene and miRNAs expression, and
DNA methylation profıles of genes related to the Sonic Hedgehog (SHH) sig-
naling pathway in uterine leiomyoma samples in order to look for potential
therapeutic targets.Methods: 80 samples of LMand 20myometrium (MM)were
obtained in the Department of Obstetrics and Gynecology at HCFMUSP/Sao
Paulo - Brazil. Expression profıle of 106 genes and 84miRNAs sequences related
to SHH regulation, and the percentage of methylation in the promoter region of
the SHH, PTCH1, SMO, SUFU, GLI and GLI3 genes were performed by quan-
titative Real Time PCR. Results: Among 106 genes evaluated, 16 showed hyper-
and 11 showed hypoexpression in LM samples, compared to MM. Only
SMOOTHENED (SMO) was found hyperegulated in LM. miRNAs analysis
showed 16 sequences with different regulation profıles between LM and MM.
None of them is involved in the regulation of SMO expression. DNA methyl-
ation profıle showed a higher percentage of methylation in LM samples, but this
difference did not exceed 2% of methylation for the PTCH1, SMO, GLI1 and
GLI3 genes. Conclusion: Our results suggest an activation of SHH pathway in
LMs by hyperexpression of SMO. These results are very interesting because
there are SMO specifıc drugs approved by FDA for other tumors types.
#2436 Non canonical activation of Sonic Hedgehog pathway in uterine
leiomyosarcoma.Natalia Garcia, Bianca C. Oliveira, Kelly P. Ferreira, Edmund
C. Baracat, Katia C. Carvalho.Univ. of São Paulo Faculty ofMedicine, São Paulo,
Brazil.
Background: Uterine leiomyoma (ULM) and leiomyosarcoma (ULMS) are
smooth muscle tumors with distinct clinical and biological behavior. They can
be a cause of infertility and even death. Little is known about the factors that can
to influence these tumors behavior and biology. Sonic Hedgehog (SHH) path-
way components were previously implicated in the ULMS malignancy risk;
however its activationmechanism is unknown. In this study, we investigated the
gene expression profıle of Sonic Hedgehog Signaling and pathway upstream
genes in myometrium (MM), ULM and LMS cell lines. Methods: Total RNA
obtained from cell lines were submitted to cDNA synthesis and quantitative real
time PCR (qRT-PCR), using 7500 System (Life Technologies, USA). Gene ex-
pression of SHH, PTCH1, SMO, SUFU, GLI 1-3, CCND1, BCL-2 and BMP4
were assessed. Results: Gene expression data showed an upregulation of SMO,
SUFU, GLI1, BCL-2 and BMP4 in LMS cells when compared to MM. GLI1
(RQ11) and BCL-2 (RQ20) genes had higher expression. In the other side,
SHH, PTCH1, GLI2 and GLI3 showed upregulation in MM cells. Conclusion:
Our results showed that the Sonic hedgehog pathway is activated in LMS cells
but by SHH independent form (non-canonical pathway). This could be ex-
plained by the downexpression of SHH ligand and the PTCH1 receptor, and by
the upexpression of SMO,GLI1 andpathway target genes as BCL-2 andBMP4 in
uterine LMS cells compared to LM andMM. These results suggest a new thera-
peutic perspective for LMS by target drugs to inhibit SMO and GLI1 molecules.
#2437 Overexpression of MYL5 promotes cervical cancer cell metastasis
through SLUG andHIF-1 signaling. Lan Zhang. Sun Yat-senUniversity Can-
cer Center, Guangzhou, China.
Myosin light chains (MLC) serve important regulatory functions in a wide
range of cellular and physiological processes. Previous research found thatMLC
are also chromatin-associated nuclear proteins which regulate gene transcrip-
tion. In this study, we show that theMLCmembermyosin regulatory light chain
5 (MYL5) controls metastasis in cervical cancer. We uncover this role of MYL5
through clinical cervical cancer samples and various in vitro and in vivo models
of metastasis. MYL5 promotes metastasis by enhancing the transcription of
SLUG and hypoxia inducible factor-1 (HIF-1). Moreover, we reveal a bidi-
rectional regulation between MYL5 and HIF-1. HIF-1 specifıcally binds to
the MYL5 promoter region, and hypoxia leads to increased levels of MYL5 in
cervical cancers. Overexpression of MYL5 sustained HIF-1 expression in nor-
moxic condition. Clinical data confırmed a positive correlation between MYL5
and HIF-1. In summary, our observations suggest a potential application of
MYL5 in prognosis prediction and cancer treatment.
#2438 Analysis of IL-13 signaling through IL-13R2 in human brain tu-
mor specimens in situ. Rukmini Bhardwaj, Akiko Suzuki, Pamela Leland,
Bharat H. Joshi, Raj K. Puri. FDA-CBER, Silver Spring, MD.
Previously, we have demonstrated that IL-13 receptor alpha2 (IL-13R2),
a high affınity receptor for Th2 cytokine IL-13, is overexpressed in most
glioblastoma multiforme (GBM) cell lines and approximately 78% of the
patient-derived samples. We have also demonstrated that IL-13R2 can be
targeted by a number of immunotherapeutic agents including chimeric an-
tigen receptor modifıed T (CAR-T) cells, targeted lentivirus and adenovirus
vectors, and a chimeric fusion immunotoxin consisting of IL-13 and trun-
cated Pseudomonas exotoxin (IL-13-PE). However, the signal transduction
initiated by IL-13 in GBM tumor is not known to occur through the
IL13R2, which has a high affınity for IL-13. We have recently observed that
IL-13 can signal through IL-13R2 by activating AP-1 transcription factors
in human brain tumor cell lines. In this study, we have examined IL-13R2
expression in human brain tumor and normal brain specimens, and the
subsequent signaling through the AP-1 pathway in situ. Using six human
glioblastoma and three astrocytoma specimens, we evaluated the expression
of AP-1 transcription factors by immunohistochemistry (IHC) and com-
pared the extent of immunostaining and percent positive fıelds with three
normal brain specimens. Six GBM specimens examined showed high degree
of immunostaining for c-Fos, c-Jun, Jun D and Fra-1 (AP-1 family of tran-
scription factors) and a high percentage of positive fıelds. These specimens
also showed strong immunostaining for IL-13R2 (4) in 70% fıelds
(P0.001 compared to normal brain). Three astrocytoma specimens showed
staining for IL-13R2 (2 and 32% fıelds, P0.01 compared to normal
brain), but the extent of staining was lower compared to GBM. Similar to
IL-13R2 expression, the extent of staining and percentage of positive fıelds
for AP-1 transcription factors were highly statistically signifıcant between
tumors and normal brain (P0.001 for GBM compared to normal brain and
P0.01 for astrocytoma compared to normal brain). The extent of immu-
nostaining in GBM was highest for c-Fos (4, 78% fıelds) followed by c-Jun
(3, 57% fıelds), Fra-1 (2, 70% fıelds) and Jun-D (2, 28% fıelds). Jun-B
expression was the lowest among the AP-1 transcription factors (1, 7%
fıelds) in GBM specimens. Astrocytoma specimens showed lesser extent of
immunostaining for AP-1 members compared to GBM; c-Fos showed 2
staining and 42% positive fıelds followed by c-Jun (2, 12% fıelds), Fra-1
(2, 48% fıelds) and Jun-D (1, 18% fıelds). Jun-B staining intensity was
1 in only 6% fıelds. Normal brain specimens showed no immunostaining
for AP-1 family members. Our results generally corroborate with data ob-
tained from GBM cell lines and confırm that IL-13 can signal in IL-13R2
positive GBM tumors in-situ through the AP-1 pathway, thus indicating that
this pathway may be an important target for therapeutic intervention of
GBM in addition to targeting IL-13R2.
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#2439 Establishment of six human colorectal cancer cell lines: identifıca-
tion of genes that have metastatic potential. Soon-Chan Kim, Chang-Won
Hong, Sang-Geun Jang, Seung-Yong Jeong, Jae-Gahb Park, Ja-Lok Ku. Seoul
National University, Medical Campus, Seoul, Republic of Korea.
A number of genes have been studied in accordance with theirmetastatic poten-
tial. Nevertheless, widely usedmetastatic colorectal cancer cell lines such as SW-620
or IS3 only show the influence of metastatic genes within limited mutational land-
scape. Here, three pairs of primary CRC (SNU-2335A, SNU-2335D, SNU-2404A,
SNU-2404B, SNU-2414A, andSNU-2414B) andcorrespondingmetastasis cell lines
were established and analyzed by whole exome sequencing and microarray. Three
pairs of primary CRC (SNU-2335A, SNU-2404A, and SNU-2414A) and corre-
sponding matched metastasis cell lines (SNU-2335D, SNU-2404B, and SNU-
2414B)wereanalyzed forgeneexpressionbymicroarrayandwhole exomesequenc-
ing. Selected target genes frommicroarraywere analyzed again by real-time PCR in
order to confırm themRNAexpression level in the pairedCRC cell lines. The genes
selected for examination were calponin 3, acidic (CNN3); sorbin and SH3 domain
containing 1(SORBS1); epithelial stromal interaction 1 (EPSTI1); bone marrow
stromal cell antigen 2(BST2); kelch-like 5 (KLHL5); trypsinogen C (TRY6); and
synaptotagmin-like 5 (SYTL5).We calculated the intersectionof all threemetastatic
CRC cell lines. Five genes (BST2, SORBS1, CNN3, EPSTI1, and KLHL5) were up-
regulated in metastatic cell lines compared to primary cell lines. Two genes (TRY6
and SYTL5) were down-regulated in metastatic cell lines compared to primary cell
lines. Then, we ranked 15 genes that were up-regulated and 15 genes that were
down-regulated in omentalmetastasis regardless of the 2-folds threshold. Of the 30
genes thatwere differently expressed, we selected three genes (CNN3, SORBS1, and
TRY6) that showed thehighest fold changes andare found in2-fold changeanalysis.
We identifıed 7 genes that were differently expressed in metastatic CRC cell lines
compared to primary CRC cell lines. These genes may serve as diagnostic markers
and therapeutic targets for patients withmetastatic CRC.
#2440 Cross-tissue interactome analyses unravel novel oncogenic roles of
SOX2. Thorsten Schaefer,1 Silvia Candido,1 Hui Wang,1 Thomas Bock,2 Alex-
ander Schmidt,2 Claudia Lengerke1. 1University of Basel and University Hospital
Basel, Basel, Switzerland; 2Biozentrum, University of Basel, Basel, Switzerland.
First recognized for its signifıcance in early embryogenesis, SOX2 (sex deter-
mining regionY box 2)more recently receivedmajor attention as a (i) transcrip-
tional master regulator of stemness driving the re-programming of terminally
differentiated somatic cells back into a pluripotent stem cell state and (ii) pow-
erful oncogene of the cancer stem cell (CSC) compartment.We and others have
shown that SOX2 expression relies on canonical PI3K/AKT signaling involving
direct physical contact and phospho-modifıcation by AKT. Interestingly, we
observed that these interactions are highly tissue specifıc which prompted us to
perform a systematic proteomic analysis of co-factors regulating SOX2 biology.
The SOX2 interactome was analyzed in human breast carcinoma and glioblas-
toma cell lines by co-immunoprecipitation (co-IP) and HPLC/MS revealing
900 individual and70 conserved proteinaceous co-factors, thus underscor-
ing a hitherto underestimated scaffolding function of SOX2. As expected, a
major proportion of binding partners cluster in functional categories implicated
inDNAbinding and/or nucleotidemodifıcation (e.g. helicases, transferases, and
ligases). However, a near equal share of SOX2 associated factors fall into func-
tional classes formally unrelated to transcription modulation such as cell adhe-
sion, cytoskeletal organization, or metabolic adaptation. Using SOX2 knock-
down and overexpression cells generated by lentiviral technology, we confırm
co-regulation of SOX2 with selected binding partners. Moreover, we observe
co-depletion of SOX2 and protein co-factors in cells of stalled AKT activity, and
amolecular restoration of both upon proteasomal inhibition.We conclude that,
besides its known signifıcance in DNA activity control, the SOX2 protein en-
gages in various interactions seemingly unrelated to transcription modulation.
These newly discovered interactions are likely to synergize with canonical SOX2
functions (i.e. the induction and maintenance of stemness), but involve regula-
tion at post-translational level and of extra-nuclear components. Our efforts
thus add an exciting new facet to SOX2 biology and eventually, may open new
therapeutic avenues for targeted anti-CSC therapy.
#2441 NanoString 3DBiologyTM technology: simultaneous digital count-
ing of DNA, RNA and protein.Chris Lausted,1 Yong Zhou,1 Jinho Lee,2 Chris-
topherVellano,2 KarinaA. Eterovic,2 Ping Song,2 Lin-ya Tang,2Gloria Fawcett,2
Tae-BeomKim,2 KenChen,2 GaryGeiss,3 GavinMeredith,3 QianMei,3 Gokhan
Demirkan,3 DwayneDunaway,3 Dae Kim,3 P.Martin Ross,3 ElizabethManrao,3
Nathan Elliott,3 SarahWarren,3 Christina Bailey,3 Chung-Ying Huang,3 Joseph
Beechem,3 Gordon Mills,2 Leroy Hood1. 1Institute for Systems Biology, Seattle,
WA; 2MD Anderson Cancer Center, Houston, TX; 3Nanostring Technologies,
Inc., Seattle, WA.
Introduction: Development of improved cancer diagnostics and therapeutics re-
quires detailed understanding of the genomic, transcriptomic, and proteomic pro-
fıles in the tumormicroenvironment.Current technologies can excel atmeasuring a
single analyte, but it remains challenging to simultaneously collect high-throughput
DNA, RNA, and protein data from small samples.We have developed an approach
thatusesoptical barcodes to simultaneouslyprofıleDNA,RNA,andprotein fromas
little as 5ng DNA, 25ng RNA, and 250ng protein or just 2 5m FFPE slides, and
simplifıes data analysis by generating digital counts for each analyte. Methods: The
approach uses paired capture and reporter oligonucleotide probes and optical bar-
codes to enumerate up to 800 targets. The platformwas initially developed tomea-
sure RNA, and we have adapted it to measure DNA single nucleotide variants
(SNVs), proteins, and phospho-proteins. SNVs are detected by direct hybridization
of sequencediscriminatingprobes to thewild-type andmutant sequence of interest.
Proteins are detected via binding of oligonucleotide-conjugated antibodies. Results:
Combinations of DNA, RNA, and protein in biological and experimental contexts.
SNV probes are able to detect variant alleles down to 5% abundance within a wild
type population and can discriminate variants within mutation hotspots. It was
96% accurate at identifying variants from samples displaying a range of allele
frequencies and DNA integrity when benchmarked against next-generation se-
quencing. Protein detection has been developed for cell surface, cytosolic, and nu-
clear proteins, as well as phospho-proteins. It was validated against flow cytometry,
western blot, and mass spectrometry using cell lines with ectopic target expression
and primary cells. To demonstrate concurrent measurement of DNA, RNA, and
protein froma single system,BRAFWTorBRAFV600E cell lineswere treatedwith the
BRAFV600E inhibitor vemurafenib and theMEKinhibitor trametinib.Wemeasured
the allele usage at the BRAFV600 locus, as well as BRAFV600E dependent changes in
mRNA expression, protein expression and protein phosphorylation in a single ex-
periment. Conclusions: 3D Biology has several advantages over other analytical ap-
proaches. Direct, single-molecule digital counting allows detection over a broad
dynamic range with high reproducibility, often over 98% concordance between
technical replicates. The simultaneous interrogation of DNA, RNA, and protein
maximizes the amount of data obtained from precious samples and minimizes in-
strumentation demands by leveraging a single detection platform. The 3D Biology
approach allows holistic, digital analysis of biological samples with high specifıcity
and precision. This technology is currently available for research use, but may also
have clinical application in the future.
#2442 Simplifıed sequencing of full-length isoforms in cancer on the
PacBio Sequel System. Meredith Ashby, Ting Hon, Elizabeth Tseng, Aparna
Vedula, Tyson A. Clark. Pacifıc Biosciences, Menlo Park, CA.
Tremendous flexibility is maintained in the human proteome via alternative
splicing, and cancer genomesoften subvert this flexibility topromote survival. Iden-
tifıcation and annotation of cancer-specifıc mRNA isoforms is critical to under-
standing how mutations in the genome affect the biology of cancer cells. While
microarrays and other NGS-based methods have become useful for studying tran-
scriptomes, these technologies yield short, fragmented transcripts that remain a
challenge for accurate, complete reconstruction of splice variants. In cancer pro-
teomics studies, the identifıcation of biomarkers from mass spectroscopy data is
often limitedby incompletegene isoformexpression information tosupportprotein
to transcript mapping. The Iso-SeqTM protocol developed at PacBio offers the only
solution for direct sequencing of full-length, single-molecule cDNA sequences
needed to discover biomarkers for early detection and cancer stratifıcation, to fully
characterize gene fusion events, and to elucidate drug resistance mechanisms.
Knowledgeof the complete isoformrepertoire is also key for accurate quantifıcation
of isoform abundance. As most transcripts range from 1 - 10 kb, fully intact RNA
molecules can be sequenced using SMRT® Sequencing without requiring fragmen-
tation or post-sequencing assembly. However, some cancer research applications
have presented a challenge for the Iso-Seq protocol, due to the combination of
limited sample input and the need to deeply sequence heterogenous samples. Here
wereport theoptimizationof the Iso-Seq librarypreparationprotocol for thePacBio
Sequel platform and its application to cancer cell lines and tumor samples. We
demonstrate how loading enhancements on the higher-throughput Sequel instru-
ment have decreased the need for size fractionation steps, reducing sample input
requirements while simultaneously simplifying the sample preparation workflow
and increasing the number of full-length transcripts per SMRT Cell. The results
highlight the potential for broader application of the Iso-Seqmethod tomore com-
prehensively characterize alternative splicing in cancer.
#2443 Massively parallel single-cell RNA-Seq identifıes diverse subpopu-
lations displaying EMTand stem-like features.Billy Lau, JiaminChen,Hanlee
P. Ji. Stanford School of Medicine, Stanford, CA.
Single-cell transcriptome analysis enables a new paradigm for studying complex
systems in cancer. As opposed to bulk sequencing, which averages genomic signals
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across thousands or millions of cells and obscures the presence of rare subtypes,
single cell sequencing enables the interrogation of individual cells. In cancer, intra-
tumoral heterogeneity is observed at both genomic and epigenomic levels, and its
analysis enables the discovery of new actionable targets and treatment modalities
tailored to individual subpopulations. As an example, many cancer cell lines and
those derived from patients contain subpopulations marked by distinct patterns of
surfacemarkers such asCD44, and are linked to drug resistant and tumor initiating
phenotypes. A complete characterization of such cellular populations ideally re-
quiresmarker-free sampling, followed by clustering into distinct subgroups. In this
study, we demonstrate the signifıcant advantages of such an approach; we utilize a
high-throughput single-cell RNA-Seq method to characterize the transcriptomic
profıles of cellular populations. We performed single-cell RNA-Seq on thou-
sands of cells in the matched SW480 (primary) and SW620 (metastatic)
colorectal cell lines using a microfluidic droplet barcoding technology that
enables the tracking of single cells during library preparation. By focusing on
genes with high inter-cell variability, we discovered a small subpopulation of
cells that displayed a distinct gene expression signature from the major sub-
population. Differential gene expression analysis of this subpopulation
yielded genes virtually all enriched in the epithelial-to-mesenchymal transi-
tion (EMT) pathway. These cells showed signifıcant increases in canonical
mesenchymal marker genes such as VIM, CD44, and SOX9. Gene expression
profıles of these subpopulations also correlated with established EMT signa-
tures. Remarkably, this subpopulation did not display mutual exclusivity in
gene expression with the epithelial marker EPCAM, which possibly indicates
an intermediate mesenchymal phenotype. We also observed in the major
population cluster a small subset of cells totaling less than 1% of the popu-
lation that were signifıcantly enriched for LGR5 expression, a common stem-
like marker in colorectal cancer. Overall, we demonstrate the use of single-
cell RNA-Seq to discover and characterize a diversity of cellular states that
would otherwise be impossible from bulk analysis.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Genomic Landscape of Lymphoma, Leukemia, and Lung, Bladder,
and Other Cancers
#2444 Recurrent mutations and clinical outcomes in patients with follic-
ular lymphoma. Kilannin Krysiak,1 Cody Ramirez,1 Felicia Gomez,1 Christo-
pher A. Miller,1 Robert S. Fulton,1 Friederike Kreisel,1 Amanda F. Cashen,1
Nancy L. Bartlett,1 Ana Ruano,2 Eric D. Hsi,2 Malachi Griffıth,1 Obi L. Griffıth,1
Todd A. Fehniger1. 1Washington University in Saint Louis, Saint Louis, MO;
2Cleveland Clinic, Cleveland, OH.
Follicular lymphoma (FL), the most common indolent non-Hodgkin lym-
phoma (NHL), is associated with a highly heterogeneous clinical course. The
genetic landscape of FL is less understood than other B-cell NHLs such as
chronic lymphocytic leukemia and diffuse large B-cell lymphoma. With ongo-
ing clinical trials using therapies targeting B cell receptor signaling (e.g., ibruti-
nib) in FL, recurrent mutations could impact the interpretation of these trial
outcomes and the identifıcation of specifıc patient subpopulations that have
increased or decreased clinical benefıt. To identify novel recurrent mutations in
FL, we designed a large custom capture lymphoma-related gene panel (WUSM-
LP) and queried 113 predominantly treatment-naïve FL samples. To design the
WUSM-LP reagent (NimbleGen), we targeted the coding regions of 1716 genes
identifıed in exome sequencing data from a cohort of 24 patients (28 samples)
with FL combined with genes recurrently mutated in B-cell non-Hodgkin lym-
phoma in the literature (KrysiakK et al., Blood, 2016). Previously, we applied the
WUSM-LP to the discovery cohort and an additional 81, primarily treatment-
naïve, FL samples. Using mutations identifıed in these 105 individuals, we iden-
tifıed 39 signifıcantly mutated genes (SMGs). These included well-characterized
genes in FL (e.g., KMT2D, EZH2, TNFRSF14), and identifıed novel mutations
(BTK, HVCN1, and others) thereby expanding the repertoire of mutations af-
fecting genes in the BCR signaling pathway, SWI/SNF complex and histone
family. Including novel BTKmutations, we identifıed 23 (22%) individuals har-
boring mutations that likely up-regulate signaling downstream of BTK, poten-
tially affecting response rates to BTK-targeting therapies at the point of FL di-
agnosis. We also focused on the subset FL patients (N59) that were sequenced
within 1 year of front-line therapy in order to identify clinical associations be-
tween recurrentmutations and clinical outcomes, comparingmutation status of
SMGs to progression-free survival (PFS) rates. Improved PFS was observed in
patients harboring HVCN1mutations (p0.05) in the treated cohort. CREBBP
mutations were associated with signifıcantly reduced PFS (p0.05). Since our
initial analysis, we have completed sequencing of an additional 174 FL samples
with clinical data available. Confırming our earlier observations with an inde-
pendent cohort, we observed 9 TNFAIP3 truncating, 18 CARD11 coiled-coil
domain, 4 BCL10 truncating and 8 BTK mutations in these samples. These
mutations affect 18.4% of FL patients in this cohort, are likely to up-regulate
NFkappaB signaling and may impact ibrutinib sensitivity. With the additional
power of 8 HVCN1 and 110 CREBBP mutations we have identifıed, we will
evaluate the previously identifıed associations. The analyses of recurrent muta-
tions and clinical correlations in this combined cohort of nearly 300 FL patients
are ongoing and will be presented.
#2445 Integrative genetic analysis identifıes therapeutic relevance of cell
of origin-specifıc genetic alterations in diffuse large B-cell lymphoma.
Daisuke Ennishi,1 Ali Bashashati,2 Saeed Saberi,2 AnjaMottok,1 BarbaraMeiss-
ner,1 Merrill Boyle,1 Susana Ben-Neriah,1 Robert Kridel,1 Kerry J. Savage,1 Lau-
rie H. Sehn,1 JosephM. Connors,1 Ryan D.Morin,3 Marco A.Marra,3 Sohrab P.
Shah,2 Christian Steidl,1 DavidW. Scott,1 RandyD.Gascoyne1. 1Centre for Lym-
phoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia,
Canada; 2Molecular Oncology, British Columbia Cancer Agency, Vancouver,
British Columbia, Canada; 3Genome Science Centre, British Columbia Cancer
Agency, Vancouver, British Columbia, Canada.
Introduction:Diffuse large B-cell lymphoma (DLBCL) comprises twodistinct
cell-of-origin (COO) subtypes: the germinal center B-cell-like (GCB) and the
activated B-cell-like (ABC) subtypes. Several sequencing studies have informed
on DLBCL biology and identifıed numerous candidate genes implicated in
pathogenesis.However, comprehensive analysis of recurrent genetic alterations,
and related prognostic signifıcance according to COO subtypes has not yet been
performed. To understand the molecular distinctions and their therapeutic rel-
evance specifıc to COO subtype in DLBCL, we performed a comprehensive
genetic analysis on a population registry-based cohort of 347 patients with de
novo DLBCL uniformly treated with R-CHOP. Methods: Tissue biopsies from
347 patients were analyzed using deep amplicon sequencing of 58 genes, Af-
fymetrix SNP 6.0 arrays, and RNAseq. Immunohistochemical staining was per-
formed on tissue microarrays. COO subtype was assigned by Lymph2Cx assay.
Results:We detected COO-specifıcmutations, copy number alterations (CNAs)
and gene fusions. Furthermore, integrative analysis showed COO-specifıc trans
gene expression effects onCNAs, demonstrating that CNAs inGCB-DLBCL are
tightly linked to the deregulation of networks associated with PI3K-AKT signal-
ing. We also identifıed the signifıcant prognostic impact of recurrent genetic
alterations within each COO subtype, including deletions of MIR15a/16-1 and
TP53 and NFATC1 gain in ABC-DLBCL, TP53 and CREBBP mutations,
PRAME deletions and MYC gain in GCB-DLBCL. In addition, deletions of
PTEN and INPP4B, which are negative regulators of PI3K-AKT signaling, were
individually associated with poor outcome in GCB-DLBCL (p0.01 and
p0.045, respectively). Furthermore, patients whose tumors harbored both ge-
netic alterations had an even worse prognosis (p0.004), suggesting the clinical
importance of PI3K-AKT signaling in GCB-DLBCL. Based on these genetic
data, we found that the PI3K-AKT signaling pathway was more commonly
altered in GCB-DLBCL than in ABC-DLBCL (64% vs 23%, p0.0001). We also
confırmed frequent genetic alterations involved in the BCR-NFB signaling
pathway inABC-DLBCL (80%),while this pathwaywas less frequently altered in
GCB-DLBCL (54%; p0.0001). In addition, epigenetic modifıcation and im-
mune recognition pathwaysweremore commonly altered inGCB-DLBCL com-
pared to ABC-DLBCL (70% vs 44%; p0.0001, 71% vs 56%; p0.015, respec-
tively). Finally, we demonstrated that the majority of DLBCL cases are altered
for at least two of the four pathwaysmentioned above (86% of ABC-DLBCL and
87% GCB-DLBCL). Conclusion: we describe the landscape of common genetic
aberrations in a population-based uniformly-treated DLBCL cohort, broadly
representative of patients treated with curative intent, providing the genetic
foundation for implementing precision medicine in this disease.
#2446 Integrated analysis of somatic mutations in subcutaneous pannic-
ulitis-like T-cell lymphoma bywhole-exome and -transcriptome sequencing.
Hyojin Song,1 Youngil Koh,2 Daeyoon Kim,1 Hongseok Yun,3 Choong-Hyun
Sun,3 Hogune Im,3 Dong-Yeop Shin,2 Sung-Soo Yoon2. 1Seoul National Univer-
sity College of Medicine, Seoul, Republic of Korea; 2Seoul National University
Hospital, Seoul, Republic of Korea; 3Samsung SDS, Seoul, Republic of Korea.
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rarely differ-
entiated form of non-Hodgkin lymphoma. This uncommon disease is triggered
by preferential lymphoma infıltration into subcutaneous adipose tissue, and
nodule formation in the fatty tissue. Consequently, the early stage symptoms of
SPTCL is found as multiple subcutaneous nodules beneath the skin. Due to the
low incidence rate and indolent progression of the disease, the genetic altera-
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tions associated with SPTCL still remains poorly characterized. Genetic profıl-
ing of SPTCL by integrated whole-exome and -transcriptome sequencing will
augment the comprehensive characterization of somatic mutations in SPTCL.
To investigate the genetic alterations associatedwith the incidence of SPTCL,we
performed whole-exome sequencing of both biopsy sample collected from the
patient’s left shoulder lesion, and matched saliva sample to 200X and 100X read
depth of coverage, respectively. Whole-transcriptome sequencing of the tumor
sample was also performed for expression level analysis; gene fusions are also
explored by TopHat-fusion-post. Somatic mutations were precisely detected by
our internally developed somatic variant caller, which is an adjusted version of
VarScan2 with additional fılters based on thresholds of p-value and odds ratio.
Overall, we discovered a total of 158 somatic variants: 139 SNVs and 19 indels,
by using somatic variant detection algorithm of our own. By applying the addi-
tional fılters to these variants, two genes were remarkably identifıed: SQSTM1
and BAGE3. SQSTM1 (sequestosome 1), also known as ubiquitin-binding pro-
tein p62, encodes proteins that regulate ubiquitination, autophagy, and activa-
tion of NFkB1. Through cBioPortal database search, SQSTM1 found to be
highly amplifıed across the various cancer types, such as neuroendocrine pros-
tate cancer (NEPC), kidney renal clear cell carcinoma (RCC), and pancreatic
cancer. On the other hand, BAGE3, B melanoma antigen 3, was reported as a
candidate gene encoding tumor antigens. Gene fusions were identifıed by com-
paring the number of spanning reads and mate pairs, and fusion of NOL7 and
RANBP9 on chromosome 6 showed the highest fusion score of 604.45. Com-
prehensive characterization of the initiation, progression, and relapse of subcu-
taneous panniculitis-likeT-cell lymphoma is yet thoroughly understood.Hence,
establishing the genetic basis and profıling the genomic landscape of SPTCLwill
broaden our understanding of SPTCL, and enhance the therapeutic effective-
ness in the pre-diagnosis and treatment of the disease, as well as targeted gene
therapies. Furthermore, to strengthen the statistical power of the somatic muta-
tion analysis, we are planning to expand the cohort and conduct functional
validation study of selected genes by using secured paraffın blocks of SPTCL
patients.
#2447 Themutational landscape of chemo-refractory Burkitt lymphoma.
Claudia M. Wever,1 Maryse Lemaire,1 Donald C. Vinh,1 Josée Hébert,2 Yasser
Riazalhosseini,1 Ryan Morin,3 Nathalie A. Johnson1. 1McGill University, Mon-
treal, Quebec, Canada; 2Université de Montréal, Montreal, Quebec, Canada; 3Si-
mon Fraser University, British Columbia, Canada.
Background: Burkitt Lymphoma (BL) is characterized by rapid cellular pro-
liferation driven by the canonical IG-MYC translocation. BL can evade apopto-
sis by silencing the tumor suppressor TP53 or by mutating MYC. Other muta-
tions contribute to the pathogenesis of BL, including TCF3 or ID3, which
stimulate PI3K/MAPK/MTOR signaling, or mutations in CCND3, which accel-
erate cell cycle progression.While BL is curable in 90%of patients, the prognosis
for relapsed BL is dismal. The mutational landscape of relapsed BL (rBL) is not
well characterized because it is rarely re-biopsied at the time of relapse. Two
youngmen at our institution experienced a BL relapse within 3 months of com-
pleting intensive chemotherapy. We hypothesized that mutations implicated in
therapeutic resistance would be enriched in the tumor cells taken at the time of
relapse. Our aim was to identify these mutations and develop cell lines from
these patients to study these tumours inmore detail.Methods: Both patients had
whole exome sequencing (WES) performed on tumor cells obtained at the time
of diagnosis (T1) and relapse (T2), using unaffected peripheral blood to exclude
germline variants. The novel cell lines (CL) derived fromT2were also sequenced
and karyotyped. Results: The total number of coding mutations in patient 509
was: T1 78, T2 84 and CL 63, and in patient 533: T1 43, T2 66 and
CL 70. All samples had multiple missense mutations (5 to 7) in MYC and had
evidence of clonal heterogeneity. Patient 509 had a TP53 (R248) mutation that
was clearly selected for during chemotherapy, where the variant allele fraction
(VAF) increased from 2% at T1 to 93% at T2. 19 genes had acquired missense
mutations at T2 including: CD14, GSTM3, BCR and ELMO3. The following
genomic rearrangements were observed in the 509CL by karyotype:-Y, t(8;
14)(q24.21;q32),der(10)t(10;22)(p1?3;q11.2),t(13;17)(q3?2;q11.2), del(17)(p11.2)
and -22. Patient 533 had multiple frameshift mutations that occurred in all three
samples (T1, T2 and CL), including in CCND3, BAX, ARID1A, ARID1B, DDX5,
DETD1B, TSFM, SP3 andTFAP4. T2 and theCLhad additional acquiredmissense
or nonsensemutations in ZFP36L2, CCL7, FAM13C and IKBKB. The 533CLhad 3
dominant clones by karytope, The rearrangements observed were: del(2)(p21p23),
t(8;14)(q24.21;q32), t(1;12)(q12;q24) and 7. The frameshift mutations in
ZFP36L2 andBAXwere homozygous in the 533CL.Conclusions:Multiple genes
are implicated in the pathogenesis of chemotherapy-resistant BL,many ofwhich
had not been appreciated in studies focused on sequencing de novo BL (e.g.
BAX,ARID1A). To our knowledge, these are the fırst BL cell lines that have been
well-characterized with respect to the serial acquisition of mutations after expo-
sure to chemotherapy andwith knowledge of germline variants. These are useful
resources to study oncogene cooperation, clonal evolution, chromatin remod-
elling (ARID1A), RNA processing (DDX5, ZFP36L2) and apoptosis (P53 and
BAX null) in BL.
#2448 Deep exome sequencing reveals recurrent somatic mutations in
Hodgkin’s lymphoma. Felicia Gomez, Kilannin Krysiak, Cody Ramirez, Nancy
Bartlett, Amanda Cashen, Friederike Kreisel, Eric Duncavage, Malachi Griffıth,
Todd Fehniger, Obi Griffıth.Washington University, St. Louis, MO.
High-throughput sequencing provides insights into cancer pathogenesis. The
application of genomics technologies to cancers characterized by rare cell pop-
ulations is a challenge. DNA extracted from bulk tumor samples is a mixture of
malignant and non-malignant cells. This is a problem in cancers defıned by rare
cell populations because it complicates the task of identifying true somatic mu-
tations. Hodgkin lymphoma (HL) exemplifıes this challenge. The pathologic
hallmark of HL is Hodgkin-Reed-Sternberg (HRS) cells. HRS cells have a low
abundancewithin an affected lymphnode (1-30%of tumormicroenvironment).
Because HRS cells are rare, a limited number of studies have described charac-
teristic genomic events. These studies have examinedHL cell lines, and, recently,
a small number of flow-sorted HRS-cells (Reichel et. al. 2015).We hypothesized
that recurrent somatic mutations can be identifıed in HRS cells using bulk HL
biopsies and ultra deep exome sequencing. The Illumina HiSeq X,which can
generate 1.6 Tb of sequence data per run, is a applicable tool for the discovery
of somatic mutations in HL. Frozen tumor (lymph node)/normal (skin) pairs
from 31 patients with HL were examined. Three KAPA libraries were con-
structed per sample. The libraries were pooled, size selected, and captured using
an IDT xGen capture reagent. The pools were sequenced across eight lanes of a
HiSeq X. A total of 7.04 x 1012 bases were sequenced across all samples with an
average of 1.10 x 1011 bases per sample. The mean depth of coverage achieved
across all samples was 783.4x (425.9x - 1091.9x). Given the low abundance of
HRS cells we anticipatedmost somatic sites would have a VAF of 1% -5%. Given
the level of coverage we anticipate that most somatic variants will have5 reads
of support. Instrument data were processed using the McDonnell Genome In-
stitute somatic variant calling pipeline that includes 5 SNV callers and 3 indel
callers. We used these steps to fılter variants: min. 50x coverage, max. 5000x
coverage, min. 1% tumor VAF, max. 5%, normal VAF, and min. 5 variant reads
in the tumor.Herewe report preliminary data onmutations in fıve pilot samples.
The remaining 26 will be presented at the meeting. We confırmed 7 previously
identifıed recurrent mutations in HL (Reichel et al. 2015). Within our pilot data
13 recurrently mutated genes were found. Themost interesting of our recurrent
genes is TNFAIP3, which was the second most frequently mutated gene in
Reichel et al. 2015. These data suggest that ultra deep sequencing of tumor
samples containing rare HRS cells can identify recurrent somatic mutations.
Thus, ultra deep exome sequencingmay be a useful discovery tool for rare tumor
populations, and will improve our understanding of HL.
#2449 Transcriptome and whole-genome sequencing analysis of a novel
murinemodel of chronic lymphocytic leukemia.LiliWang,1 Jing Sun,1Amaro
Taylor-Weiner,2 Jaegil Kim,2 Zachary J. Cartun,1 Angela N. Brooks,3 Donna
Neuberg,1 Mark D. Fleming,4 Benjamin L. Ebert,4 Gad Getz,2 Ruben Carrasco,1
Catherine J. Wu1. 1Dana-Farber Cancer Institute, Boston, MA; 2Broad Institute,
Cambridge, MA; 3University of California, Santa Cruz, CA; 4Boston Children’s
Hospital, Boston, MA.
Large-scale cancer sequencing of primary chronic lymphocytic leukemia
(CLL) has identifıed SF3B1, an RNA splicing factor, as one of the most fre-
quently mutated CLL genes. SF3B1 mutations localize to a hotspot (50% at
K700E site) and highly co-occur withmutations in ATMor deletion of chromo-
some 11q (minimally deleted region contains ATM). How this splicing factor
mutation alone or in cooperation with ATM deletion contributes to CLL re-
mains elusive. Genetically engineered mice are powerful tools in understanding
genetic lesions and cancer phenotypes.We therefore generated amouse line that
conditionally expresses heterozygous Sf3b1-K700E mutation. We modeled the
effects of the combined alterations by crossing mice with conditional knockout
of Atm and mice with Sf3b1-K700E. By breeding these mice with homozygous
CD19-Cre transgenicmice, we achievedB cell-restricted expression of heterozy-
gous Sf3b1 mutation and Atm deletion. B cell co-expression of these two muta-
tions in vivo led to clonal expansion of CD19CD5 B cells in blood, marrow
and spleen in aged mice (18 to 24-month old) at low penetrance. No leukemia
cells were found in the Sf3b1-K700E mice (up to 24-month old). The CLL cells
from the doublemutantmice could be engrafted in both immunocompetent and
immunodefıcient mice, with detectable disease within 2-4 weeks following
transfer, thus making this mouse line amenable to drug discovery and biologic
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investigations. To investigate how Sf3b1 mutation and Atm deletion synergisti-
cally contribute to CLL, we asked if there are RNA andDNA level changes in the
doublemutantmice with CLL. First, we performed transcriptome sequencing of
splenic B cell RNA collected from age-matched mice that either express wild-
type, singly mutant alleles of Sf3b1 or Atm, or doubly mutant alleles with or
without CLL-like disease. Using the tool JuncBASE, we classifıed and quantifıed
splice variants associated with the different genetic alterations. Consistent with
prior fındings in human CLL, we observed that splice variants in Sf3b1-mutant
mice alone were highly enriched at 3= splice sites. Sf3b1 and Atm doublymutant
B cells displayed a splicing pattern similar to that in Sf3b1 singly mutant cells.
Moreover, we identifıed unique CLL splice variants in genes (Setdb2, Phf11c)
previously shown to be associated with CLL. Next, we examined the muta-
tion rate in DNA derived from splenic B cells collected from mice with a
singly mutated allele of Sf3b1 or Atm, or with doubly mutated alleles with
and without CLL-like disease through comparison against matched germline
DNA from kidney by whole-genome sequencing. We have observed that
co-expression of Sf3b1 mutation and deletion of Atm results in a higher
mutation rate compared to singlymutant cells. Our analysis has revealed that
altered RNA splicing and genomic instability all contribute to CLL leukemo-
genesis. We will further dissect how the two lesions contribute to CLL func-
tionally using this model.
#2450 Mutational profıling of MLL-PTD acute myeloid leukemia. Ling-
wen Ding,1 Qiaoyang Sun,1 Kar-Tong Tan,1 Wenwen Chien,1 Anand Maya-
konda,1 Dechen Lin,1 Xinyi Loh,1 Jinfen Xiao,1 Manja Meggendorfer,2 Tamara
Alpermann,2 Manoj Garg,1 Su-Lin Lim,1 Vikas Madan,1 Norimichi Hattori,1
Yasunobu Nagata,3 Satoru Miyano,4 Allen Yeoh Eng Juh,1 Hsin-An Hou,5
Yan-Yi Jiang,1 Yan-Yi Jiang,1 Sumiko Takao,1 Li-Zhen Liu,1 Siew-Zhuan Tan,1
Siew-Zhuan Tan,1 Michael Lill,6 Mutsumi Hayashi,7 Akitoshi Kinoshita,7
Hagop M. Kantarjian,8 Steven M. Kornblau,8 Seishi Ogawa,3 Torsten Hafer-
lach,2 Henry Yang,1 H. Phillip Koeffler1. 1Cancer Science Institute of Singapore,
Singapore, Singapore; 2MLL Munich Leukemia Laboratory, Munich, Germany;
3Department of Pathology and Tumor Biology, Kyoto, Japan; 4The University of
Tokyo, Tokyo, Japan; 5National Taiwan University Hospital, Taiwan, Taiwan;
6Cedars-Sinai Medical Center, Los Angeles, CA; 7Keio University School of Med-
icine, Tokyo, Japan; 8MD Anderson Cancer Center, Houston, TX.
In this study, we performed whole-exome and targeted sequencing on 85
MLL-PTD AML patients. These AMLs have oncogenic tandem duplication of
the MLL gene. At least one well-known oncogenic driver mutation was identi-
fıed in over 90%of theMLL-PTDpatients. In linewith earlier sequencing studies
of otherAML subtypes and the TCGA-AML-sequencing project, DNMT3Awas
the most often mutated epigenetic regulator (25%); IDH1/2 hotspot mutations
were identifıed in 31% of patients. TET family was the third most prominently
mutated epigenetic regulator (TET1 (5%), TET2 (16.3%). Mutations of epige-
netic regulators also occurred in polycomb-associated proteins (EZH2, ASXL
family members), chromatin remodelers (ARID2, ARID1A), genes associated
with histone acetylation (CREBBP, EP300, KAT6A, KAT6B) and histone meth-
ylation (MLL2, MLL3). Proliferation-related pathway was extensively mutated,
with 54 of 80 MLL-PTD patients (67.5%) carrying at least one mutation of
proliferative genes. Specifıcally, FLT3 mutations were found in 46% of patient
samples. Notably, some FLT3-ITD patients had more than one type of internal
tandem duplication (ITD) insertion, probably reflecting existence of multiple
subclones in these leukemias. We found highly prevalent mutations of cohesin
genes: STAG2 (16%), SMC1A (6%), SMC3 (1%), RAD21 (1%) and CTCF (6%).
Cohesin pathway is more frequently mutated in MLL-PTD patients (26%) than
the AML samples from either TCGA (13%) or a meta-analysis of 1000 AML
(9.1%). Remarkably, an extremely high proportion of themutations had a strong
tendency to disrupt the coding sequence in STAG2, emphasizing their crucial
tumor-suppressor role in this AML subtype (16% inMLL-PTD vs 3% in TCGA-
AML. RNA processing pathway was also strikingly altered in MLL-PTD pa-
tients. Themost prominently mutated genes within this category were the splic-
ing factors. They included U2AF1 (13%, S34F/Y), SRSF2 (3%), SF3A1 (5%),
ZRSR2 (3%), DHX15 (1%) andCWC22 (1%).Multiplemutations co-occur with
MLL-PTD which are usually acquired in a sequential manner. A potential or-
dering for acquisition of many mutations include IDH2/DNMT3A/U2AF1/
TET2¡MLL-PTD¡RAS-receptor tyrosine kinase based on the following rea-
sons: #1, real-time-PCR showed that MLL-PTD was absent in remission while
mutations of IDH2, DNMT3A, TET2 and U2AF1 were still retained with a high
VAF. This suggests that MLL-PTD was acquired after mutations of IDH2,
DNMT3A, TET2 and U2AF1; #2, MLL-PTD is highly stable during disease
progression as compared with mutations of the RAS-RTK. On the other hand,
RAS-RTK mutations frequently exist as subclonal mutations and tend to be
unstable during disease progression. These observations support a notion that
MLL-PTD was acquired prior to RAS-RTK. Taken together, MLL-PTD is ac-
quired after those remission-persisting, initiating mutations (IDH2, DNMT3A,
TET2 and U2AF1), but prior to lesions of the proliferation-related drivers.
#2451 Genomic wide microarray analysis identifıes novel copy number
alterations in adult acute myeloid leukemia.Maria Chiara Fontana, Giovanni
Marconi, Cristina Papayannidis, Eugenio Fonzi, Giorgia Simonetti, Antonella
Padella, Anna Ferrari, Emanuela Ottaviani, Silvia Lo Monaco, Stefania Paolini,
Simona Soverini, Giovanni Martinelli. Department of Experimental, Diagnostic
and Specialty Medicine. University of Bologna, Bologna, Italy.
Introduction: Novel array-based technique as SNP microarray can detect
losses or gains of chromosomic material, which could be predictive of response
and can help defıne therapeutic strategies. The aim of this study is to improve
conventional cytogenetic analysis and identify new genetic alterations relevant
to leukemogenesis, by a SNP array-based genotyping approach. Materials and
Methods: We performed SNP 6.0 or Cytoscan HD (Affymetrix) in 235 Acute
Myeloid Leukemia (AML) patients at diagnosis. Seventy-eight/235 samples
were also performed byWhole Exome Sequencing,WES (HiSeq,Illumina). SNP
Array data were analyzed by Nexus Copy Number v8.0 (BioDiscovery) and R
Core Team. Results: CopyNumber Alterations (CNAs) were scattered across all
chromosomes and all pts showed CNA events. SNP array analysis showed that
several genes were preferentially deleted, including MRPS5 (14.8%), PHF6
(9.3%), SCAPER (7.2%), CASK (5.9%), WNK (4.6%), STAG2 (4.2%), LRRK1
(3.4%), PALB2 (3.4%), while the genes preferentially amplifıed were RABL2B
(16.1%), NF2 (10.2%), NBPF9 (7.6%), JAK2 (6.8%), RB1, NF1 and KMT2A
(4.2%), PTEN (3.4%), TP73 and SMAD2 (2.5%). Single-copy losses and dele-
tions were enriched (p.001) for genes mapping into the following path-
ways: aberrant PD-1 signaling, loss of function of SMAD4 in cancer and
SMAD4 MH2 Domain mutants in cancer. The functional pathways signifı-
cantly (p.001) deregulated in our cohort with single copy gain and ho-
mozygous amplifıcation were: regulation of transcription and nucleic acid,
negative regulation of metabolic processes, constitutive signaling by aber-
rant PI3K in cancer and PI3K/AKT network. Finally, in order to defıne driver
alterations, we correlate deletions and losses with mutational data. Interest-
ingly, we found losses which are also targeted by mutations (BRCA2,
LRRK1). Moreover, some deleted genes, as CASK, CDK6 and MAPT, were
involved in pathways affected by genomic mutations (CASK deletion and
MPP6 mutation, CDK6 deletion and PPM1D mutation, MAPT deletion and
SPAG5 mutation). Conclusion: We have identifıed new CNAs and pathways
involving novel potential leukemia-related genes. Our results suggest that
the comparison between SNP and WES data could provide important fınd-
ings on prognosis of AML patients. Minimal deleted regions of genes impli-
cated in deregulated pathways deserve further investigation in order to iden-
tify new candidate genes which could be relevant AML biomarkers.
Acknowledgements: ELN,AIL,AIRC,progetto Regione-Università 2010-12
(L. Bolondi),FP7 NGS-PTL project,HARMONY.
#2452 Detailed genomic characterization of CNL/aCML/MPN-U/CMML
reveals disease subgroups that may benefıt from rationally-designed combi-
nation therapies. Haijiao Zhang,1 Beth Wilmot,1 Daniel Bottomly,1 Libbey
White,1 Erik Segerdell,1 Shannon K. McWeeney,1 Vishesh Khanna,1 Angela
Rofelty,1 SophieMeans,1 Brian Junio,1 Samantha Savage,1 Emily Stevens,2 Kim-
Hien Dao,1 Julia E. Maxson,1 Jeffrey W. Tyner1. 1Oregon Health & Science Uni-
versity Knight Cancer Institute, Portland, OR; 2FredHutchinson Cancer Research
Center, Seattle, WA.
Purpose: Chronic neutrophilic leukemia (CNL), chronic myelomonocytic
leukemia (CMML), atypical chronic myeloid leukemia (aCML), and unclas-
sifıed myeloproliferative neoplasms (MPN-U) are a group of heterogeneous
disorders belonging to rare entities of myeloproliferative or myelodysplas-
tic/myeloproliferative (MDS/MPN) syndromes. Due to lack of specifıc mo-
lecular markers and the limited understanding of pathogenesis, the treat-
ment of these diseases remains empirical, resulting in poor outcomes.
Recently, recurrent mutations in ASXL1, TET2, SRSF2 and cell signaling
genes have been identifıed in these diseases. In this study we aim to analyze
the co-occurrence patterns of these gene mutations, as well as the association
of different mutations with disease subtypes and treatment outcomes. Meth-
ods and results: We performed whole exome sequence and RNA-Seq on
primary patient samples. Consistent with previous studies, high frequencies
of ASXL1, SRSF2, TET2, SETBP1 and signaling pathway mutations were
observed; whereas mutations of MPL, CEBPa, IDH1/2, and TP53 were rare.
Further variant allelic frequency analysis demonstrated that mutations of the
chromatin modifıers, epigenetic markers and splicing factors are mostly
present in the major clones indicating early acquisition of these mutations.
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In addition, ASXL1/2, splicing factor and signaling pathway mutations co-
occur in around 45% of all patients with these mutations, indicating that they
drive these diseases in a cooperative manner. RNA-seq analysis demon-
strated two major gene expression clusters with high levels of either RAS or
JAK-STAT signaling alterations respectively, indicating a potential need for
distinct therapeutic targeting of specifıc subgroups of these diseases. In ad-
dition, we observed that 17% of patients have more than one signaling path-
way mutation, possibly in distinct subclones, providing rationale for drug
combination treatment. Furthermore, we observed that mutations related to
RAS signaling pathway are prevalent in CMML; CSF3R and JAK2 mutations
are enriched in CNL; whereas, RAS and JAK-STAT pathway double muta-
tions aremore frequent in aCML. Similar incidence of ASXL1, splicing factor
and epidemics mutations are observed across all these diseases. Conclusions:
CNL/aCML/MPN-U/CMML is a group of heterogeneous diseases associated
with chromatin modifıer, epigenetic, splicing factor and signaling pathway
mutations in concomitant manner. We propose future studies of rational
drug combinations with agents, targeting epigenetic and splicing factors,
together with the appropriate signaling pathway inhibitors. Our study rep-
resents a large-scale comprehensive genomic analysis of these diseases,
which reveals novel insight into patterns of mutation co-occurrence which
could translate into new treatment paradigms for these diffıcult to treat
hematologic malignancies.
#2453 Chromatin remodeling genes are frequently somatically altered in
cervical carcinomas. Akinyemi Ojesina, Aishwarya Sundaresan, Vinodh Srini-
vasasainagendra, Hemant Tiwari, Warner Huh. University of Alabama at Bir-
mingham, Birmingham, AL.
Introduction: Cervical cancer is responsible for 15% of all deaths due to
cancer in women worldwide. There is a need to identify somatic mutations
driving this cancer in order to facilitate development of novel therapeutic
strategies. Experimental procedures: We analyzed whole exome sequencing
data from 430 cervical carcinomas. The data were derived from a combina-
tion of our previously published work (Ojesina et al. Nature 2014; Chung et
al, Int J Cancer 2015), and publicly available data generated by the Cancer
Genome Atlas (TCGA). The Mutect2.0 and MutSig2CV algorithms were
used to identify somatic mutations and signifıcantly mutated genes (SMGs)
respectively. Copy number alterations were analyzed using the GISTIC al-
gorithm. Findings: Based on MutSig2CV false discovery rate threshold of
0.1, we identifıed MLL3 (19%) and MLL2 (13%) as novel signifıcantly mu-
tated genes (SMGs) in cervical cancer. In addition, other chromatin modi-
fying genes including EP300 (12%) and ARID1A (7%) were confırmed as
SMGs. Further investigation of genes that did not meet the threshold re-
vealed that 228 of 430 (53%) of cervical tumors harbored at least one somatic
mutation in a chromatin modifying gene. These include genes in the my-
eloid/lymphoid or mixed-lineage leukemia (MLL) family (28%), lysine (K)-
specifıc demethylase (KDM) family (23%), AT rich interactive domain
(ARID) family (13%), SWI/SNF related, matrix associated, actin dependent
regulator of chromatin (SMARC) family (8%) and histone cluster 1 (HIST1)
family (4%). Conclusions: We have demonstrated that a majority of cervical
cancers harbor somatic mutations in chromatin remodeling genes. This
novel fınding was facilitated by the larger sample size derived from combin-
ing multiple datasets, and may have diagnostic and therapeutic implications
in cervical cancer.
#2454 Genetic landscape of glioma reveals defective neuroactive ligand
receptor interaction pathway as a poor prognosticator in glioblastoma pa-
tients. Jagriti Pal,1 Vikas Patil,1 Anupam Kumar,2 Kavneet Kaur,2 Chitra
Sarkar,2 Kumaravel Somasundaram1. 1Indian Institute of Science, Bangalore,
India; 2All India Institute of Medical Science, New Delhi, India.
Glioblastoma (GBM; grade IV), is highly proliferative, infıltrative and
treatment refractory. Hence, understanding the complete genetic alteration
profıle of GBMwould help us in identifying molecules or pathways that have
strong implications in GBM pathogenesis, thus opening up avenues for tar-
geted therapy. Recent large scale studies suggest that three pathways - recep-
tor-tyrosine kinase, TP53 and RB, are signifıcantly altered in GBM. How-
ever, even with the tremendous increase in our understanding of the tumor,
advancement in therapeutics is minimal and the median survival still re-
mains at 15 months. Hence, we need to elucidate novel altered molecules and
pathways in GBM progression such that more effective therapeutic options
can be explored. Here, we have carried out whole exome sequencing of grade
II, grade III and GBM samples which revealed the mutation spectrum of
glioma from our patient set. Further, we performed integrative analysis of
mutated genes from our patient cohort as well as TCGA cohort (The Cancer
Genome Atlas) to fınd out mutated pathways that predict survival in GBM
patients. The most signifıcant pathway - neuroactive ligand-receptor inter-
action pathway was explored further. Patients with mutations in one or more
genes of this pathway had poor survival. The pathway comprises of G-pro-
tein coupled receptors, ion channels and ligands which functions in modu-
lation of neural plasticity, memory processes, behavior etc. Of the enriched
genes belonging to this pathway, Calcitonin Receptor (CALCR), which was
highest mutated in GBM (2.75%), was taken up for further investigation.
CALCR was found to be downregulated in GBM andmutation or downregu-
lation of the gene was found to predict poor survival in patients. Functional
studies through cell-line based experiments revealed CALCR is a tumor
suppressor in GBM. The peptide hormone calcitonin (CT), a high affınity
CALCR ligand, inhibited proliferation, migration and anchorage-indepen-
dent growth of glioma cells expressing CALCR with a concomitant decrease
in the phosphorylation levels of ERK, AKT and JNK signaling molecules.
However, CT failed to do these functions in CALCR silenced glioma cells.
Exogenous overexpression of CALCR in glioma cells expressing low levels of
the receptor was found to inhibit proliferation, migration and anchorage
independent growth and this effect was further augmented when CT was
added. Further, introduction of tumor-derived mutations in CALCR led to
the abrogation of its tumor suppressor function. Studies are ongoing to
demonstrate the tumor suppressive nature of CALCR using in vitro astrocyte
transformation and intracranial orthotopic mouse glioma model. Thus, our
study fınds CT-CALCR signaling axis is an important tumor suppressor
pathway in glioma development and underscores the importance of using
CT as a novel therapeutic molecule for GBM treatment.
#2455 Human glioblastoma arises from the distant subventricular zone
normal appearing but harboring tumor-initiating mutations. Joo Ho Lee,1
Jeong Eun Lee,2 Jee Ye Kahng,1 Junseong Park,3 Seon Jin Yoon,3 Se Hoon Kim,3
Jong Hee Chang,3 Seok-Gu Kang,3 Jeong Ho Lee1. 1Korea Advanced Institute of
Science and Technology, Daejeon, Republic of Korea; 2Chungnam National Uni-
versity Hospital, Daejeon, Republic of Korea; 3Severance Hospital, Yonsei Univer-
sity College of Medicine, Seoul, Republic of Korea.
Glioblastomamultiforme (GBM) is the most devastating and incurable brain
tumor. Although the identifıcation of cells with tumor initiating mutations or
their location can provide the fundamental basis for understanding disease pro-
gression, the origin of GBM remains controversial due to the lack of direct
evidence in humanGBMpatients. Here, we performed ultra-deep sequencing of
triple-matched tissues of i) radiologically and pathologically normal subven-
tricular zone (SVZ), which is distant from tumor, ii) GBM tumor, and iii) blood
(or normal cortical tissues) from patients with GBM (IDH-wildtype), compared
to those with other type of brain tumors such as GBM (IDH-mutant), meningi-
oma, oligodendrgolioma, metastatic brain tumor, and GBM (IDH-wildtype)
with SVZ-invasion. Surprisingly, we found that in 55.5% of IDH-WT GBM
patients (5 of 9), normal appearing and distant SVZ already contained the low
level of GBMmutations such as TP53, EGFR, RB1, PDGRF or TERT variations
observed in thematched tumor. Single cell sequencing of GBM tumors and laser
capturemicrodissection analysis of the SVZ show thatmutations are enriched in
the astrocyte ribbon area, which clonally evolved from the SVZ to the distant
GBM tumor. Furthermore, using CRISPR-Cas9 system in the postnatal mouse
brain, we showed that neural stem cells with TP53, PTEN, EGFR mutations
migrated away from the mutated SVZ site and then formed the high grade
malignant glioma in the distant cortical region. Taken together, this study pro-
vides the direct evidence that human glioblastoma arises from the distant SVZ
that is normal-appearing but harboring tumor-initiating mutations.
#2456 Distinct genomic landscape of upper urinary tract urothelial carci-
noma. Yoichi Fujii,1 Yusuke Sato,2 Hiromichi Suzuki,1 Tetsuichi Yoshizato,1
Yusuke Shiozawa,2 Kenichi Yoshida,1 Yuichi Shiraishi,3 Kenichi Chiba,3Hiroko
Tanaka,3 Tohru Nakagawa,2 Haruki Kume,2 Hiroaki Nishimatsu,4 Toshikazu
Okaneya,5 Masashi Sanada,6 Hideki Makishima,1 Satoru Miyano,3 Yukio
Homma,2 Seishi Ogawa1. 1Graduate School of Medicine Kyoto University, Kyo-
toshi, Japan; 2The University of Tokyo Hospital, Bunkyoku, Japan; 3Institute of
Medical Science, The University of Tokyo, Minatoku, Japan; 4The Fraternity Me-
morial Hospital, Sumidaku, Japan; 5Toranomon Hospital, Minatoku, Japan;
6Clinical Research Center, Nagoya Medical Center, Nagoya, Japan.
Backgrounds: Upper urinary tract urothelial carcinoma (UTUC) is relatively
rare, accounting for 5-10% of urothelial malignancies with frequent multifocal
development. To clarify distinct characteristics of UTUC, we comprehensively
investigated the genetic alterations of this disease.Materials &methods: Surgical
specimens of UTUC and matched normal samples were obtained from 99 pa-
tients with various stages who underwent nephroureterectomy, and subjected to
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whole exome and RNA sequencing. We compared our results in UTUC with
datasets previously reported in bladder urothelial carcinoma (BUC). Mutations
in apparently normal urothelial epithelia in 5 cases were also interrogated. Re-
sults: Genetic alterations were most frequently observed in TERT promoter
(51% of cases), followed by KMT2D (48%), FGFR3 (44%), CDKN2A (42%),
TP53 (31%), and RAS pathway (HRAS/KRAS/NRAS, 21%). More than 95% of
cases harbored either TP53/MDM2, FGFR3, or RAS pathway mutations in an
almost mutually exclusive manner, based on which UTUCs are classifıed into 3
distinct subgroupswith uniquemolecular and clinical features; FGFR3-mutated
tumors showed a signifıcantly better postoperative overall survival than those
with TP53/MDM2 (p0.001) and RAS pathway (p0.010) lesions. KMT2D
mutationswere common in patients with TP53,MDM2, and FGFR3 alterations,
but rare in those with RAS pathway alterations. Mutation patterns were com-
pared between different urothelial cancers with regard to their location. Despite
common genes affected, their mutation frequencies were substantially different;
KMT2D mutations were more frequent in UTUC, while RB1 alterations were
more prevalent in BUC. In addition, KMT2Dmutations were signifıcantlymore
common in UTUCs in the ureter than those in renal pelvis (85% vs. 35%,
p0.0001). UTUC showed 4 predominant mutation signatures; age-related,
APOBEC, Transcriptional coupled repair (TCR), and mismatch repair (MMR)
associated ones. Among these, TCR andMMR signatures were more specifıc to
UTUC, although the latter is only detected in 4 hypermutated cases with biallelic
MMR-gene defıciencies. In the analysis of normal ureter tissues (N25 from 5
patients), driver mutations were identifıed in 6 samples from 2 patients. In one
case, tumor and normal samples shared 10-42 mutations, indicating that the
cancer evolved within a background of clonal precancerous proliferation in
apparently normal epithelia. By contrast, in the other case, none of the muta-
tionswere shared between tumors and normal epithelia, suggesting the presence
of a fıeld effect on urothelial carcinogenesis. Conclusions: UTUC tumors are
classifıed into 3 molecularly and clinically distinct subtypes based on the status
of mutations in TP53/MDM2, FGFR3, and RAS pathway. Depending on their
location, urothlial cancers have different genetic backgrounds, where a fıeld
effect unique to urothelial epitheliamight contribute tomultifocal occurrence of
UTUC.
#2457 Investigating the functional signifıcance of novel, recurrent non-
coding mutations of TBC1D12 in bladder cancer. Angela S. Li, Jason A. Reu-
ter, Can Cenik, Michael P. Synder. Stanford University School of Medicine, Stan-
ford, CA.
Somatic noncodingmutations remainwidely unexplored despite examples of
critical importance such as driver mutations in the promoter of the TERT gene.
We recently identifıed novel somatic mutations in the regulatory Kozak se-
quence (just upstream of the translation start site) of TBC1D12 in 15% of
bladder cancer patients, making it one of the most frequently mutated noncod-
ing regions in any cancer (Araya et. al 2016). TBC1D12 was not previously
implicated in cancer, and little is currently known about its function. It is a
member of the TBC1 superfamily, suggesting a role in intracellular traffıcking as
a RAB-specifıc GTPase-activating protein (GAP). To investigate the functional
implications of TBC1D12 mutations in bladder cancer, we undertook a com-
bined computational and experimental approach. We analyzed clinical corre-
lates, identifıed downstream effector candidates, and assessed the impact of
these mutations on gene expression. To determine the clinical relevance of the
TBC1D12 mutation, we did correlation and survival analyses of clinical data of
bladder cancer patients fromTCGA.We found that TBC1D12mutations confer
slightly worse survival but were not linked to other clinical correlates. To iden-
tify potential downstream effectors, we used reverse phase protein array (RPPA)
data from127 patients to search for proteins that were differentially expressed or
phosphorylated between patients with or without TBC1D12 mutations. We
found differential expression of GSK3 and differential phosphorylation of
p90RSK and c-Jun, suggesting three potential downstream effector candidates.
Hierarchical clustering of RPPA data for these three proteins revealed 4 sub-
groups with distinctmolecular phenotypes. Furthermore,most of the TBC1D12
mutants were clustered within one molecular subtype. To experimentally test
these downstream effector candidates and identify new ones, we modulated the
levels of TBC1D12 in bladder cancer cell line Ku-19-19 using overexpression
plasmids or siRNAs. After validating that these transfections were effective in
changing TBC1D12 expression, we performed RNA-Seq experiments. Results
from this study are expected to be presented at the meeting. In summary, these
studies suggest that the novel and recurrent noncoding mutations in TBC1D12
may affect patient survival and alter the expression or post-translational modi-
fıcation of downstream targets. Potentialmolecularmechanisms associatedwith
the presence of TBC1D12 mutations will be discussed, and a series of follow-up
studies are underway. These studies also demonstrate that applying both com-
putational and experimental approaches can help develop and test evidence-
based hypotheses, contributing to an understanding of the clinical and func-
tional impact of TBC1D12.
#2458 Spatial genomic heterogeneity of multifocal bladder cancer. Rachel
Goldberg, Maria Del Carmen Rodriguez, Leslie Cope, Aline C. Tregnago, Evg-
eny Izumchenko, George J. Netto, David Sidransky, Mohammad O. Hoque.
Johns Hopkins University, Baltimore, MD.
Urothelial cancer (UC) is a well-known multifocal disease with frequent
recurrences. The clonal origin of spatially separated UC foci is controversial.
Here we propose to elucidate the multifocal UC genome by next generation
sequencing (NGS) and thereby identify novel clonal heterogeneity among
the lesions of a single bladder. Until now, all experiments aimed at under-
standing the molecular heterogeneity were generated mostly by candidate
gene approach and older technologies. There is a lack of comprehensive
molecular information in these multifocal lesions partly due to inadequate
sample size for comprehensive molecular studies. Identifıcation of muta-
tional status at the gene level in different multifocal lesions will allow us to
identify markers for prognostic classifıcation, and predictive classifıcation of
response to UC therapies, as well as identify potential therapeutic targets. To
understand the molecular heterogeneity among the lesions of a single blad-
der, we used The Ion AmpliSeqTM Comprehensive Cancer Panel (CCP)
(ThermoFisher). The Ion AmpliSeqTM CCP was designed to target all exons
of 409 key tumor suppressor genes (TSGs) and oncogenes most frequently
cited and mutated in cancer. We tested 41 lesions from 16 cystectomized
bladders. Among these lesions, we performed an initial analysis of a total of
21 lesions and 8 germ line controls from 8 patients. We further technically
validated selected mutational events found by NGS by a complementary
approach, namely droplet digital PCR (ddPCR). We then compared the in-
tra- and inter-tumoral mutation profıles. Two separate lesions were used for
analysis in 3 patients and 3 lesions were taken from each of the remaining 5
patients. Our initial analysis showed mutational heterogeneity among the
lesions of most of the samples. Briefly, two of the patients had one clone
found at all sites, while the rest of the patients showed more variation
amongst their lesions. For instance, ARID2, TRRAP, PDGFB, and FBXW7
were mutated in two out of three lesions in one of the patients, indicating
hotspot for heterogeneous mutational events. Three mutational events were
confırmed by ddPCR, denoting the accuracy of our NGS data analysis. Our
analysis demonstrates that targeted next generation sequencing is a sensitive
and reliable method for interrogating the molecular landscape of bladder
cancer, and indicates that both clonal and spontaneous events can account
for multifocal bladder cancer. Our data suggests that sequencing of multiple
lesions from an individual patient is necessary to accurately elucidate the
mutation profıle and tailor appropriate targeted treatment. Further analysis
in an extended number of samples is necessary to fully understand the mo-
lecular heterogeneity at the mutational level in urothelial cancer.
#2460 Copy number alterations in NOTCH2 and PTP4A3 are associated
with prognosis and support novel therapeutic strategies for malignant pleu-
ral mesothelioma. Leticia G. Leon,1 Maria Gemelli,2 Paolo A. Zucali,2 Christos
Zoumadakis,3 Elisa Giovannetti1. 1University of Pisa, Pisa, Italy; 2Humanitas
Clinical and Research Center, Rozzano, Italy; 3University of La Laguna, La La-
guna, Spain.
Malignant pleural mesothelioma(MPM) is an aggressive cancer, which inci-
dence has constantly increased over the past two decades and is expected to peak
in 2020. The overall prognosis is poor, andpredictive biomarkers of drug activity
are missing. Given the heterogeneous and complex nature of MPM, it is likely
that genomic aberrations changing the expression of several genes, might affect
therapeutic response. Therefore, the aim of the present study was to identify
genes whose copy number alterationsmight predict theMPMprognosis. Recur-
rent copy number alterations of genes were analyzed by high-resolution whole-
genome sequencing in DNA obtained from a “discovery cohort” of 26 resected
MPM patients treated with pemetrexed-based chemotherapy (8 with progres-
sive disease, vs. 10 with stable disease and 8 with partial response). Prognostic
markers identifıed by Copy Number Variation analysis with Nexus, Control-
FREEC and ReadDepth software were validated by PCR gene copy number and
gene expression analyses both in the “discovery” and in two “validation” cohorts
of pemetrexed-treated and untreated patients (N45 and 40). The role of
emerging genes was evaluated through siRNA and pharmacological studies us-
ing proliferation, migration and apoptosis assays in MPM cells. As reported
previously we observed copy number loss of CDKN2A (15.4%) and BAP1
(7.7%). Interestingly, copy number gain of NOTCH2 was observed in 50% of
samples of the patients who underwent progression, whereas losses of PTP4A3
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were associated with clinical benefıt (SDPR). The prognostic relevance of
NOTCH2 was confırmed by PCR analysis. NOTCH-2 silencing reduced MPM
cell migration and enhanced apoptosis induction by pemetrexed, while a
PTP4A3 inhibitor overcame pemetrexed resistance in MPM cells characterized
by high NOTCH2 and PTP4A3 expression. These results support the role of
NOTCH2as a novel prognostic/predictive biomarker forMPM, prompting pro-
spective randomized trials for its validation. Moreover, preclinical data suggest
that NOTCH2 and PTP4A3 are oncogenes suitable for effective therapeutic
targeting in pemetrexed-resistant MPM cells.
#2461 Molecular classifıcation and clinical characterization of a large
uterine leiomyomapatient cohort.NettaMäkinen,1Hanna-RiikkaHeinonen,1
Annukka Pasanen,2 Jaana Tolvanen,1 Simona Bramante,1 Miika Mehine,1 Jari
Sjöberg,3 Oskari Heikinheimo,3 Ralf Bützow,2 Lauri A. Aaltonen1. 1Genome-
Scale Biology Research Program and Department of Medical and Clinical Genet-
ics, University of Helsinki, Helsinki, Finland; 2Department of Pathology and Lab-
oratory of Helsinki University Hospital (HUSLAB), Helsinki University Hospital,
University of Helsinki, Helsinki, Finland; 3Department of Obstetrics andGynecol-
ogy, Helsinki University Hospital, Helsinki, Finland.
Uterine leiomyomas (ULs), benign smooth muscle tumors, represent one of
the most common neoplasms in women with an estimated prevalence varying
from 20% to over 70% during the reproductive years. Approximately every
fourth woman with ULs has clinically relevant lesions, which cause morbidity
and thus require treatment. Still today, hysterectomy is the primary treatment
option for ULs worldwide, and remarkably, their annual societal costs exceed
those of colon and breast cancer combined. Our previous fındings, derived from
the use of high-throughput technologies, suggest that there are at least three
distinct molecular UL subclasses, each displaying a characteristic genetic driver
aberration and unique global gene expression profıle: MED12 (mediator com-
plex subunit 12) mutation-positive, HMGA2 (high mobility group AT-hook
2)-overexpressing, and FH (fumarate hydratase)-defıcient ULs. The aim of this
study is to examine the molecular subclasses, their respective proportions, and
clinical characteristics in a large UL patient cohort. The study material consists
of 1026 ULs and corresponding normal myometrium tissue from 322 patients,
who had ultrasound-diagnosed ULs and underwent hysterectomy in Helsinki
University Hospital, Finland between October 2013 and June 2016. From each
uterus, we harvested all feasible ULs 
1 cm in diameter and a piece of the
corresponding normal myometrium tissue. The location of the collected sam-
ples in the uterus, their size, and any observed special characteristics were care-
fully documented at the time of sample removal. In addition, comprehensive
clinical information of the patients was obtained from medical and pathology
reports, as well as from a questionnaire, and the histopathology of all lesions
were characterized according to the WHO 2014 criteria. All collected ULs have
been systematically screened for MED12 mutations by Sanger sequencing.
Overexpression of HMGA2 typically arises from a chromosomal translocation,
and deletions at FH locus suggest the presence of potential biallelic FH inacti-
vation. Therefore, HMGA2-overexpressing and FH-defıcient ULs have tenta-
tively been identifıed using a high-density customizable Infınium® Human-
Core-24BeadChipwith over 305,000markers. Currently, the data analyses are
ongoing. Suffıcient numbers of well-documented high-quality samples are a
prerequisite for successful research. We hypothesize that ULs can emerge
through several distinct molecular mechanisms that contribute to different bi-
ological and clinicopathological features and response to treatment. Their mo-
lecular classifıcation and further characterization will lead to increased knowl-
edge on UL genesis as well as improved management of the disease.
#2462 Whole-exome sequencing reveals genetic variants in ERC1 and
KCNG4 in complete hydatidiformmoles fromChineseHanwomen.YanYu,1
Bingjian Lu,1 Weiguo Lu,1 Xinyu Wang,1 Pengyuan Liu,2 Yan Lu,2 Xiaodong
Cheng,1 Xing Xie1. 1Women’s Hospital School of Medicine Zhejiang UNIV.,
Hangzhou, China; 2Institute for TranslationalMedicine School of Medicine, Zhe-
jiang University, Hangzhou, China.
Complete hydatidiform mole (CHM) is an uncommon pregnancy-related
diseasewith an invasive potential. The genetic background of the sporadic CHM
has not been addressed previously despite the possible mechanisms of maternal
genetic variants to the development of this disease with biparental origin. We
performed the whole-exome sequencing analysis on 51 CHM patients and 47
normal healthy women, then the second screening of the probable mutations by
mass spectrometry in 199CHMpatients and 400normal healthywomen. Finally
the candidate genetic polymorphisms were validated by direct Sanger sequenc-
ing in 247 cases and 599 controls with another 205 new controls. We eventually
found that two SNPs c.G48C(p.Q16H) in ERC1 and c.G1114A(p.G372S) in
KCNG4, were associated with an increased risk for CHM (p0.05). These ge-
netic variants will facilitate our understanding on the pathogenesis of CHM and
related tumors as well as the oogenesis and embryonic implantation. They will
provide benefıcial information for the pregnant women both in physiology and
psychology. Further multiple-disciplinary collaborations should be encouraged
to clarify the accurate pathogenesis of CHM.
#2463 Tumor profıling of separated carcinomatous and sarcomatous
components from uterine carcinosarcoma biopsies provides insights into
their development.Yihua Liu,1 ZacharyWeber,2 F.Anthony SanLucas,3Aditya
Deshpande,4 Raed Sulaiman,5 Mary Fagerness,5 Natasha Flier,5 Joseph Sulai-
man,5 Christel M. Davis,2 Jerry Fowler,3 Gareth E. Davies,2 David Starks,5 Luis
Rojas-Espaillat,5 Paul Scheet,3 Erik A. Ehli2. 1Graduate School of Biomedical
Science, University of Texas at Houston Health Science Center, Houston, TX;
2Avera Institute for Human Genetics, Sioux Falls, SD; 3University of Texas MD
Anderson Cancer Center, Houston, TX; 4Weill Cornell Graduate School of Med-
ical Sciences, New York, NY; 5Avera Cancer Institute, Sioux Falls, SD.
Uterine carcinosarcoma (UCS) is a rare and aggressive form of uterine
cancer. It is bi-phasic, exhibiting histological features of both malignant
epithelial (carcinomatous) and mesenchymal (sarcomatous) elements. Stud-
ies have indicated that UCS arises from sarcomatous differentiation of high-
grade carcinoma while others have suggested a bi-clonal nature. Given these
differences, we sought to separate the carcinoma and sarcoma elements of
UCS to try to understand their molecular differences and gain further in-
sights into how these tumors develop. We macrodissected carcinomatous,
sarcomatous, and normal cells from formalin fıxed paraffın embedded
(FFPE) uterine samples of 10 UCS patients. DNA and RNAwere isolated and
extracted using the Qiagen AllPrep DNA/RNA FFPE kit. Whole-genome
SNP microarrays and deep sequencing of 26 cancer genes was performed,
using the Illumina Infınium OmniExpressExome array and the TruSight
Tumor panel respectively. Illumina HiSeq mRNA sequencing was also per-
formed to quantify gene expression. The genomic allelic imbalance (AI)
profıling, called from the SNP data by hapLOH, showed that sarcoma sam-
ples were more aberrant than their carcinoma counterparts (abstract 131,
AACR 2016). From the targeted sequencing, the Illumina Amplicon-DS So-
matic Variant Caller was employed to call somatic mutations. Mutations
were identifıed in TP53 in both the sarcoma and carcinoma samples of all 10
patients. Frequently mutated genes included APC, EGFR, MET and MSH6
which were found in 60-80% of the patients. Genes mutated in less than 50%
of the patients included PTEN, KRAS, KIT, FBXW7, PIK3CA, FGFR2, and
CTNNB1. Current results showed no association of a mutated gene to either
the sarcoma or carcinoma component of UCS. RSEM, STAR and EBSeq were
applied to the RNA-seq data for gene expression quantifıcation. Approxi-
mately 2500 genes were identifıed as being differentially expressed (DE)
between normal and carcinoma samples. Just over 4000 genes were identifıed
as being DE between normal and sarcoma samples. 75% of the DE genes in
the carcinoma were also identifıed in the sarcoma. Using DAVID functional
annotation tool, we characterized these gene sets with KEGG pathways. De-
regulated pathways identifıed in both carcinoma and sarcoma include: cell
cycle, transcriptional regulation, Ras and p53 signaling. Some additional
pathways are putatively associated with sarcoma only, including MAPK and
PI3K-Akt signaling. We report here the differences between sarcoma and
carcinoma components of UCS from multiple molecular perspectives. From
the genomic AI and DE analysis, the carcinoma aberrations appear to be
mostly a subset of the sarcoma tumor profıles, where sarcoma samples ap-
pear to be more highly aberrant compared to the carcinoma samples. One
possible inference from this is that the sarcoma originated and evolved from
the carcinoma cells.
#2464 Papillary renal cell carcinoma, proposal of a new classifıcation sys-
tem based on integrated molecular, histological and clinical analysis. Rola
Saleeb,1 Mina Farag,1 Fadi Brimo,2 Fabio Rotondo,1 Pamela Plant,1 George
Yousef1. 1Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, On-
tario, Canada; 2McGill University Health Center, Montreal, Quebec, Canada.
Background: Papillary Renal Cell Carcinoma (PRCC) is divided into his-
tological subtypes 1 and 2. Type 2 is known to have worse clinical behavior.
A number of PRCC cases ( 50%), fail to meet all reported morphological
criteria for either type, hence are best characterized as PRCC not otherwise
specifıed (NOS). There are yet no reliable markers to resolve the PRCC NOS
category. That in turn reflects the clinical dilemma of how to manage these
patients. Experimental Design: PRCC patient cohort of 115 cases was se-
lected for the study. Cases were subtyped histologically into PRCC types 1, 2
and NOS. Potentially distinguishing markers ABCC2, CA9, SAll4, and BCL2
selected from our previous genomic analysis, were assessed by immunohis-
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tochemistry (IHC). A total of 24 cases were further selected for molecular
analysis using miRNA expression and copy number variation (CNV). Uni-
variate andmultivariate survival analysis were performed using Log rank test
and cox proportionate hazards. Results: Markers ABCC2, CA9 exhibited
distinct staining patterns between the two classic PRCC subtypes; and suc-
cessfully classifıed many of the PRCC NOS (45%) cases. Moreover, immu-
nomarkers revealed a third distinct subtype of PRCC (35% of the PRCC
cohort). Molecular testing using miRNA expression and CNV analysis con-
fırmed the presence of three distinct molecular signatures corresponding to
the 3 subtypes. On univariate analysis DFS was signifıcantly enhanced in the
type1 versus 2& 3 (p value 0.047). PRCC subtyping retained signifıcance on
multivariate analysis (p value 0.025, HR:6, 95% CI 1.25 to 32.2). Conclusion:
We propose a new classifıcation system of PRCC integrating morphological,
immunophenotypical, and molecular analysis. Our classifıcation reveals a
3rd PRCC subtype that was not previously described. This subtype has over-
lappingmorphology of with PRCC types 1 and 2, hence would be subtyped as
PRCC NOS in the current classifıcation. Molecularly PRCC type 3 has a
distinct signature and clinically it behaves similar to PRCC type 2. The new
classifıcation stratifıes PRCC patients into clinically relevant subgroups and
has signifıcant future implications on the management of PRCC.
#2466 Identifying confıdently measured genes in single pediatric cancer
patient samples using RNA sequencing. Holly Beale,1 Du Linh Lam,1 John
Vivian,1 Yulia Newton,1 Avanthi Tayi Shah,2 Isabel Bjork,1 Ted Goldstein,1 An-
gela N. Brooks,1 Josh Stuart,1 Sofıe Salama,1 E. Alejandro Sweet-Cordero,2 Da-
vid Haussler1,1 Olena Morozova1. 1UCSC Genomics Institute, Santa Cruz, CA;
2Stanford University, Stanford, CA.
In the UC Santa Cruz Treehouse Childhood Cancer Initiative (tree-
housegenomics.soe.ucsc.edu), we are exploring the utility of using RNA-Seq
analysis of tumor samples from children to identify potential novel therapeutic
options for each individual. Within a single RNA-Seq data set, the gene expres-
sion measurements are not equally accurate. The identifıcation of activated,
druggable pathways requires accurate gene-level expressionmeasurements. We
receive samples from a variety of clinical and research settings, and the quantity
and complexity of the available input material and the depth of sequencing
differ. These factors inspired us to develop a tool that will allow us to identify
accurate measurements in most RNA-Seq samples we receive. First, we charac-
terized the relationship between depth of sequencing and the accuracy of the
gene expression measurement. We analyzed subsets of reads in samples with
more than 50 million Uniquely Mapped, Exonic, Non-duplicate (UMEND)
reads. UMEND reads typically constitute over 80% of the reads in a high quality
experiment with suffıcient starting material. We compared gene expression
across the subsets of reads to calculate howmanyUMEND reads are required to
produce consistent measurements. We found that, on average, genes expressed
at 1-5 TPM in our data require 30 million reads to be accurately measured. For
this calculation, we defıne accuracy as the condition in which 75% of genes are
measured to within 25% of the true value. Secondly, we use these known rela-
tionships to identify genes that have been accurately measured in our tumor
RNA-Seq samples. For a sample with 15 million UMEND reads, we fınd that
genes expressed above 5 TPM can be accurately measured and are retained. In
the fırst twelve samples analyzed, samples with more than 10 million UMEND
reads retained at least 46% of the genes expressed above zero. We exclude as
references those samples with fewer than 10 million UMEND reads due to the
marked gene loss after thresholding for this group. Using accurately measured
genes allows us to more confıdently assess similarity to other samples, identify
enriched pathways, and confırm the expression of drug targets and related mol-
ecules under consideration. For example, we reconsidered the CDK4 inhibitor
Palbociclib in one patient because the expression of RB1, downstream effector
required for Palbociclib-mediated tumor cell death, was under our accuracy
threshold. Accuracy thresholds can also be used in experiment planning. Accu-
racy thresholding allows us to better assess the value of anRNA-Seq data set and,
if necessary, identify the subset of genes whose expression can be confıdently
considered in a clinical setting. Our experience points to the importance of
careful quality control in this process.
#2467 Mutation analysis using next-generation sequencing in histologi-
cally heterogeneous of primary lung cancers.Hayato Koba, HideharuKimura,
Kazuo Kasahara. Kanazawa University Hospital, Kanazawa, Japan.
Rare cases of primary lung cancer are known to have different histological
types. Recently, small cell carcinoma was reported to be developed in adenocar-
cinoma patients with epidermal growth factor receptor (EGFR) mutations after
EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. The purposes of this
study are to evaluate mutational status in two different histological types sepa-
rately, and to further understand the molecular pathogenesis. Twelve tumor
samples from 6 patients were collected in our institution. 4 patients had primary
adenocarcinoma and small cell carcinoma transformed after EGFR-TKI. One
patient had primary adenocarcinoma and squamous cell carcinoma trans-
formed after EGFR-TKI. The other one patient had carcinosarcoma in a surgi-
cally resected tumor. Two samples per patient were collected from histologically
different areas within a resected tumor or the 2 distinct metastatic sites. DNA
was extracted from formalin-fıxed, paraffın-embedded tumor tissues.Next-gen-
eration sequencings in the 12 samples were performed on 160 cancer-related
genes using GeneReadTM DNAseq Targeted Panels V2 Human comprehensive
Cancer Panel (QIAGEN). In a carcinosarcoma case with deletional mutation in
EGFR gene, a total 504 in adenocarcinoma and 595 in sarcoma variants in 160
genes were detected with high confıdence. The gene of identical alterations, as
truncal alterations, were EGFR, CBLB, TP53 andMEN1 and the number of that
as an unique alteration corresponding to each histology is 25 for adenocarci-
noma and 85 for sarcoma.We show relations between the histological types and
the genomic alterations, identical alterations and unique alterations, in each
patient. Furthermore, we raise essential factors for the histological transforma-
tion.
#2468 Gene aberrations for precision medicine against lung adenocarci-
noma. Motonobu Saito,1 Koji Kono,2 Takashi Kohno1. 1National Cancer Ctr.
Japan, Tokyo, Japan; 2Fukushima Medical University, Japan.
Lung adenocarcinoma (LADC) is often triggered by an aberration in a
driver oncogene. LADC harboring EGFR mutation and ALK fusion can be
treated with anti-cancer drugs that target the aberrant gene products. These
molecularly targeted drugs showed signifıcant positive effectiveness for the
LADC patients with EGFRmutations and ALK fusions. Additional oncogene
aberrations, including RET, ROS1, and NRG1 fusions, skipping of exon 14 of
MET, and mutations in BRAF, HER2, NF1, and MEK1, were recently added
to the list of such “druggable” driver oncogene aberrations, and their re-
sponses to targeted therapies are currently being evaluated in several clinical
trials. On the other hand, about 30% and 50% of LADCs in patients in Japan
and Europe/USA, respectively, lack the driver oncogene aberrations listed
above. Therefore, novel therapeutic strategies, such as those that exploit the
vulnerabilities of cancer cells with non-oncogene aberrations, are urgently
required. In this presentation, we show gene mutation profıles according to
driver oncogenes and summarize the frequencies of those aberrations. We
also compare driver aberrations between Japan and USA according to smok-
ing status and sex. This will provide the current status of research on preci-
sion medicine against LADC and enumerates the research priorities for the
near future.
#2469 The B-cell lymphoma specifıc aptamer C10.36 binds a ribonucleo-
protein complex on the cell surface of cancer cells. Sonal S. Tonapi, Janet E.
Duncan, Matthew Rosenow, Melissa Richards, Teresa L. Tinder, Heather A.
O’Neill, Mark R. Miglarese, David Spetzler, Michael Famulok, Günter Mayer.
Caris Life Sciences, Phoenix, AZ.
Aptamers have recently gained prominence for their diagnostic and thera-
peutic potential. The DNA aptamer C10.36 forms a G-quadruplex and has been
shown to bind the Ramos Burkitt’s lymphoma cell line. However, its binding
partner on the cell surface remains unknown. Here we report on the identifıca-
tion of the molecular target of C10.36, which suggests its application in the
therapy of B-cell lymphoma and leukaemia. Aptamer-affınity purifıcation, fol-
lowed by LC-MS/MS revealed unique proteins pulled down with C10.36 associ-
ated with Ramos cells but not Jurkat, a T-cell lymphocyte cell line. The majority
of the identifıed target molecules were found to be associated within ribonucle-
oprotein complexes, of which the abundant and consistent ones belong to the
nucleolin complex including nucleolin (NCL) itself and its interacting partners,
i.e. nucleophosmin (NPM1), heterogeneous nuclear ribonucleoprotein (HN-
RNP) family members such as HNRNP C1C2 and U, rRNA 2=-O-methyltrans-
ferase fıbrillarin (FBL), actin (ACTB), nucleolar RNA helicase 2 (DDX21), and
proline- and glutamine-rich splicing factors (SFPQ). All proteins identifıed in
the above ribonucleoprotein complex are aberrantly expressed on the surface of
several disparate cancer cell types andhave been shown to play an oncogenic role
in cancer. Another G-rich anti-NCL aptamer, AS1411, has been shown to in-
duce cell death in100 cancer cell lines. Therefore, we tested the effect ofC10.36
on viability of Ramos and other non-Hodgkin B-cell lymphoma (NHL) cancer
cell lines. Our results indicate that C10.36 treatment causes specifıc cell death of
certain lymphoma cell lines such as Ramos but not Jurkat cells. The present
study identifıes C10.36 as a novel anti-B cell lymphoma aptamer and under-
scores its potential for the development of a new targeted therapy to treat B-cell
lymphomas.
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MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Homologous Recombination and DNADouble-Strand Break
Repair
#2470 Compromised BRCA1-PALB2 interaction is associatedwith breast
cancer risk. Tzeh Keong Foo,1 Marc Tischkowitz,2 Srilatha Simhadri,1 Talia
Boshari,3 Kathleen A. Burke,4 Samuel H. Berman,4 Nadia Zayed,3 Yuan Chun
Ding,5 Susan L. Neuhausen,5 Britta Weigelt,4 Jorge S. Reis-Filho,4 William D.
Foulkes,3 Bing Xia1. 1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;
2University of Cambridge, Cambridge, United Kingdom; 3Jewish General Hospi-
tal, McGill University, Montreal, Quebec, Canada; 4Memorial Sloan Kettering
Cancer Center, New York, NY; 5Beckman Research Institute at the City of Hope,
Duarte, CA.
The major breast cancer suppressor proteins BRCA1 and BRCA2 play essen-
tial roles in homologous recombination (HR)-mediated DNA repair, which is
thought to be critical for tumor suppression. The two BRCA proteins are phys-
ically and functionally linked by a third tumor suppressor, PALB2 (partner and
localizer of BRCA2), in the HR pathway. Heterozygous PALB2 mutation carri-
ers have increased risk of breast, ovarian and pancreatic cancer. While truncat-
ing mutations in BRCA genes are generally pathogenic, interpretations of mis-
sense variants remains a challenge. To date, patient-derived missense variants
that disrupt PALB2 binding have been identifıed in BRCA1 and BRCA2; how-
ever, there has not been suffıcient evidence to establish their pathogenicity in
humans. Variants in PALB2 that disrupt either its BRCA1 or BRCA2 binding
have not been reported. Here, we report on the identifıcation of a novel PALB2
variant, c.104TC [p.L35P], that segregated in a family with a strong history of
breast cancer. Functional analyses showed that L35P abrogates the PALB2-
BRCA1 interaction, resulting in impaired HR and sensitivity to platinum salts
and PARP inhibitors. Whole-exome sequencing of breast tumor from a
c.104TC carrier revealed a somatic, truncatingmutation in the second allele of
PALB2, with the tumor displays hallmark genomic features of tumors with
BRCA mutations and HR defects. Using a combination of traditional clinical
genetics, tumor whole-exome sequencing and in-depth functional analyses, we
have provided direct evidence to cement the pathogenicity of L35P. Parallel
analyses of other germline variants in the PALB2 N-terminal BRCA1-binding
domain also identifıed multiple variants that affect HR function to varying de-
grees, suggesting their possible contribution to cancer development. Our fınd-
ings establish p.L35P as the fırst pathogenic missense mutation in PALB2 iden-
tifıed to date and directly demonstrate the requirement of the PALB2-BRCA1
interaction for breast cancer suppression.
#2471 Role of PALB2-BRCA1 interaction in tumor suppression.Amar H.
Mahdi, YanYing Huo, Bing Xia. CINJ, New Brunswick, NJ.
Homologous recombination (HR) is the only error-free pathway for the re-
pair of DNA double strand breaks (DSBs). BRCA1 and BRCA2, the two major
breast cancer suppressor proteins, play essential roles in HR-mediated repair of
DSBs by promoting the recruitment of RAD51, the recombination enzyme, to
DNA damage sites for the initiation of HR. PALB2 (partner and localizer of
BRCA2) plays a key role in this pathway by acting as a chromatin adaptor for
BRCA2 and a linker between BRCA1 and BRCA2. Like BRCA1 and BRCA2,
PALB2 is a tumor suppressor gene itself. Germline, heterozygous mutations in
the gene increase the risk of breast, ovarian and pancreatic cancers. However, its
mechanism is not fully understood. To investigate the in vivo role of the PALB2-
BRCA1 interaction, we previously generated a Palb2 knockin mouse strain
which contains amutation that disrupts BRCA1binding. Thismousemodel also
allows us to bypass the embryonic lethality of the Palb2 KO mice. In this study,
we hypothesized that the direct communication between the two proteins is
critical for proper DNAdamage repair and response in vivo and for suppression
of tumorigenesis. Indeed, both immunohistochemistry (IHC) and immunoflu-
orescence (IF) demonstrated that different tissues of the mutant mice have
higher levels of endogenous DSBs (H2AX foci) and slower DSB repair kinetics
after ionizing radiation (IR). Yet, mutant cells were more resistant to cell death.
When aged under normal conditions, mutant mice showed increased tumor
incidence in multiple tissues, particularly in the liver. When challenged by IR,
mutant mice quickly developed thymic lymphoma and later in other tissues
including liver and ovary, etc. Interestingly, when crossed with Trp53 mutant
mice, the resulting Palb2m/m;Trp53/ mice showed greatly accelerated de-
velopment of thymic lymphoma and osteosarcoma, which are typically associ-
ated with Trp53 but not Palb2 mutations. Exome sequencing revealed focal
deletion of thewild-type allele of Trp53 in themajority of the tumors, suggesting
that disruption of BRCA1-PALB2/BRCA2 axis promotes regional genomic de-
letions that may lead to loss of other tumor suppressors such as p53. Our results
underscore the importance of the BRCA1-PALB2/BRCA2 pathway for tumor
suppression and suggest a potentially novel mechanism for BRCA1/PALB2-
mediated tumor suppression, which is by preventing Trp53/TP53 loss of
heterozygosity (LOH), which allows for tumor development.
#2472 Defıning the role of the XAB2 complex during homologous recom-
bination. David O. Onyango, Jeremy Stark. City of Hope, Duarte, CA.
Several factors associated with RNA processing are important for homol-
ogous recombination (HR), but the mechanistic links between these pro-
cesses remain poorly understood. To this end, we have examined the func-
tion of the tetratricopeptide repeat factor XAB2 in HR, since this factor has
a conserved function in RNA processing. We have found that XAB2 is im-
portant for chromosomal double strand break (DSB) repair via two pathways
of HR that require end resection as an intermediate step, end resection of
camptothecin (Cpt) induced DNA damage, and RAD51 recruitment to ion-
izing radiation induced foci (IRIF). Furthermore, XAB2 mediates CtIP hy-
perphosphorylation induced by Cpt and BRCA1 IRIF, as well as histone
acetylation events linked to HR profıciency. The capacity for XAB2 to pro-
mote HR correlates with its ability to form a complex with ISY1 and PRP19,
which show a similar influence as XAB2 on HR. Our recent efforts include
examining other members of the XAB2 complex, as well as the transcription
unit aberrations caused by loss of this complex, which may contribute to the
defects in HR.
#2473 Breast cancer whole genomes link homologous recombination de-
fıciency (HRD)with therapeutic outcomes.Eric Y. Zhao,1 Yaoqing Shen,1 Erin
Pleasance,1 Katayoon Kasaian,1 Martin R. Jones,1 Carolyn Ch’ng,1 Caralyn Re-
isle,1 Peter Eirew,2 Karen Mungall,1 Nina Thiessen,1 Yussanne Ma,1 Alexandra
Fok,1 Andrew J. Mungall,1 Yongjun Zhao,1 Richard Moore,1 Diego Villa,2 Ta-
mara Shenkier,2 Caroline Lohrisch,2 Stephen Chia,2 Stephen Yip,3 Karen
Gelmon,2 Howard Lim,2 Sophie Sun,2 Kasmintan A. Schrader,2 Sean Young,3
Aly Karsan,1 RobynRoscoe,1 Janessa Laskin,2MarcoA.Marra,1 Steven J. Jones1.
1Canada’sMichael SmithGenome Sciences Centre, Vancouver, British Columbia,
Canada; 2British Columbia Cancer Agency, Vancouver, British Columbia, Can-
ada; 3The University of British Columbia, Vancouver, British Columbia, Canada.
Background: Homologous recombination defıciency (HRD) is common in
cancer - germline BRCA1 & BRCA2 mutations account for 5-10% of breast
cancers and confer 85% lifetime risk. HRD cancers exhibit genomic instability
and sensitivity to platinum-based therapy and PARP inhibitors. While not all
causes ofHRDare known, recent sequencing efforts have revealed genome-wide
somaticmutation signatures that characterize theHRDgenomic instability phe-
notype, also known as “BRCA-ness”. This provides a promising new assay to
predict sensitivity to platinum-based therapy. Here, we integrate two whole-
genome sequencing metrics to assess their association with therapeutic out-
comes in a breast cancer cohort. Methods: Whole-genome sequencing of 47
breast cancer tumors (100x coverage) and matched normals (60x) was per-
formed on an Illumina HiSeq. Alignment, assembly, SNV calling, and loss of
heterozygosity (LOH) detection were performed with BWA, ABySS, Strelka,
and APOLLOH respectively. SNV signatures were deciphered by non-negative
matrix factorization withMonte Carlo resampling. AnHRD score comprised of
LOH, telomeric allelic imbalance (TAI), and large scale transition (LST) counts
was computed. Clinical endpoints were obtained by retrospective review of
treatment and imaging reports. Analysis is ongoing in an independent valida-
tion cohort of 62 sequenced cases. Results: The HRD-linked SNV signature was
signifıcantly associated with radiographic clinical response (CR) to platinum-
based therapy (p0.015). Logistic regression demonstrated a 59% improved
odds of CR to platinum-based therapy per 1000 somatic SNVs attributed to
HRD (odds ratio 1.16-2.50). Tumors carried up to 10,246 such SNVs and all
patients with CR were among the top quartile. The LOH-TAI-LST score was
correlated with SNV signature (r0.6, p7106) and associated with CR
(p0.025). Notably, elevated HRD signatures associated with CR were identi-
fıed in tumors with wild-type BRCA1/BRCA2 or variants of unknown signifı-
cance. Tumors with above median HRD signatures were associated with a 69-
day longer time to treatment failure and an 18% daily decreased probability of
treatment failure per 1000 HRD-attributed SNVs (hazard ratio 0.71-0.95, p 
0.007). Discussion:We found that HRDmutation signatures are associated with
clinical response and longer time to treatment failure with platinum-based ther-
apy.While similar benefıts were observed in patients with somatic bi-allelic loss
of BRCA1/BRCA2, such cases are less common (8% of our cohort) compared to
those with elevated HRD signature. Thus, mutation signature methods may
identify patients who stand to benefıt from platinum-based therapy missed by
BRCA screening alone.
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#2474 The mechanistic role of polyamines in DNA double-strand break
repair.Chih-Ying Lee,1 Guan-Chin Su,1Min-YuKo,1Wen-YenHuang,2 Geen-
Dong Chang,1 Sung-Jan Lin,2 Peter Chi1. 1Institute of Biochemical Sciences, Na-
tional Taiwan University, Taipei, Taiwan; 2Institute of Biomedical Engineering,
National Taiwan University, Taipei, Taiwan.
Polyamines are essential organic cations for cell growth, proliferation and
tissue remodeling. The rate-limiting step in the biosynthesis of polyamines is
catalyzed by ornithine decarboxylase (ODC). The activity of ODC and the level
of intracellular polyamines signifıcantly increase inmany cancers, indicating the
critical role of polyamines in tumorigenesis. Depletion of polyamines sensitizes
cells to DNA damage agents that lead to DNA double-strand breaks (DSBs),
suggesting that endogenous polyaminesmay participate in DNA repair process.
However, the mechanistic role of polyamines in DSB repair remains largely
unknown. Here, we wish to ascertain the role of polyamines in DSBs repair
pathway and to delineate the underlyingmechanism by combining biochemical
analyses, cell-based and animal approaches. Our cell-based experiments dem-
onstrated that polyamines indeed participate in DNA double-strand break re-
pair. Specifıcally, the level of intracellular polyamines regulates homologous
recombination (HR) repair pathway rather than non-homologous end joining
(NHEJ). Furthermore, our in vitro reconstitution system and functional analy-
ses demonstrated that polyamines signifıcantly enhanceRAD51-mediatedDNA
strand exchange reaction. Importantly, we reveal that the stimulatory effect of
polyamines by RAD51 stems from the enhancement of duplex DNA captures in
the DNA exchange reaction. Finally, the physiological role of polyamines in
DSBs repair was examined by using mouse hair follicle as a model system. The
animalmodel clearly highlights the signifıcant contribution of polyamines to the
DNA repair in vivo. Our fındings thus furnish valuable insight into the mecha-
nistic basis of polyamines in DNA repair.
#2475 In vitro and in vivo assessment of the mechanism of action of the
PARP inhibitor rucaparib. Liliane Robillard, Minh Nguyen, Thomas C. Hard-
ing, Andrew D. Simmons. Clovis Oncology, Inc., Boulder, CO.
Background: Rucaparib (CO-338) is an oral small molecule inhibitor of poly
(ADP-ribose) polymerase (PARP) that is being developed for patients with
BRCA1 and BRCA2mutated and homologous recombination defıcient ovarian
cancer (Swisher et al., 2016; Lancet Oncol. Epub). The mechanism of action
(MOA) of rucaparib was characterized in the studies reported here. Methods:
Enzymatic and cellular reporter assay profıling were performed by BPS Biosci-
ences. Rucaparib potency was assessed using 6-day cell viability assays (CellTi-
ter-Glo). In vivo PK/PD and effıcacy studies in the MDA-MB-436 (BRCA1
mutant) and the HBCx-17 (BRCA2 mutant) TNBC models were performed at
Crown Biosciences and XenTech, respectively. Results: In biochemical assays
rucaparib inhibited PARP-1, PARP-2 and PARP-3, with IC50 values of 0.8, 0.5,
and 28 nM, respectively. Rucaparib weakly inhibited PARP5a (tankyrase
1[TNKS1]) and PARP5b (tankyrase 2[TNKS2]) with an IC50 of 796 and 486 nM;
however rucaparib did not inhibit TNKS1/2 in a cellular reporter assay evaluat-
ing Wnt pathway signaling (IC50 10 M). Rucaparib cytotoxicity was evalu-
ated in the BRCA1 mutant (UWB1.289) and wild-type (UWB1.289BRCA1)
isogenic pair, and a panel (n26) of breast and ovarian cancer cell lines. The
UWB1.289 cell line was more sensitive to rucaparib (IC50  375 nM) than
the UWB1.289BRCA1 cell line (IC50  5430 nM). Rucaparib also decreased
the cell viability of several BRCA1 andBRCA2mutant ovarian and breast cancer
cell lines. Mechanistic analyses in the UWB1.289 cell line demonstrated a dose
dependent decrease in poly (ADP) ribosylation (PAR; IC50  2.8 nM), and an
increase in DNA damage and apoptosis. Taken together, these results are con-
sistent with the concept of synthetic lethality, where simultaneous inhibition of
multiple DNA repair pathways results in irreparable DNA damage and cell
death. In vivo PK/PD and effıcacy studies assessed the MOA and activity of
rucaparib in theMDA-MD-436 (BRCA1mutant) xenograft model. In a PK/PD
study, dose dependent inhibition of PAR was observed in the tumors of mice
treated with 15, 50 and 150 mg/kg BID rucaparib, resulting in statistically sig-
nifıcant (p 0.05) inhibition of 45%, 86% and 96%, respectively. An inverse and
dose dependent correlation between PAR and rucaparib levels in the plasma and
tumor was observed, and the levels of rucaparib in the tumor were consistently
higher ( 2-fold) than the levels of rucaparib measured in plasma. Dose depen-
dent and statistically signifıcant tumor growth inhibition was observed in both
subcutaneous and orthotopic xenograft studies evaluating the anti-tumor activ-
ity of rucaparib in the MDA-MB-436 model. Rucaparib also demonstrated po-
tent activity in the BRCA2 mutant HBCx-17 patient-derived xenograft model.
Conclusion: These results demonstrate that rucaparib is a potent and selective
inhibitor of PARP1, PARP-2, and PARP-3 with in vitro and in vivo activity in
BRCA1/2 defıcient tumors.
#2476 Preclinical assessment of the PARP inhibitor rucaparib in homol-
ogous recombination defıcient prostate cancer models. Minh Nguyen, An-
drew D. Simmons, Thomas C. Harding. Clovis Oncology, Inc., Boulder, CO.
Rucaparib (CO-338) is an oral small molecule inhibitor of the poly(ADP-
ribose) polymerase (PARP) enzymes PARP-1, PARP-2 andPARP-3 that is being
developed for cancer patients with evidence of homologous recombination
(HR) defıciency, including BRCA1 and BRCA2 mutations. PARP inhibitors
have demonstrated clinical activity in BRCA1, BRCA2, and ATMmutant pros-
tate cancer patients (Mateo et al. N Engl J Med. 2015;373:1697-708); however,
limited preclinical validation of PARP inhibitors in prostate cancer has been
reported to date, since no BRCAmutant norHRdefıcient prostate cell lines have
been identifıed. In this study, we modelled the functional inactivation of DNA
repair genes using siRNAandCRISPR/Cas9, and examined the impact onPARP
inhibition, in the DU145 and PC-3 prostate cancer cell lines. These cell lines
were chosen based on transfection effıciency, lack of obvious genetic defects in
DNA repair pathways, and baseline insensitivity to rucaparib (IC50 10M).A
panel of 26 DNA repair genes were individually knocked down by siRNA, and
changes to rucaparib potency were examined in a 7-day cell viability assay. The
knockdown of BRCA1 or BRCA2 increased rucaparib cytotoxicity in both pros-
tate cell lines. For example, the IC50 of rucaparib in DU145 and PC-3 cells with
reduced BRCA2 levels was 275 and 297 nM, representing a 36- and 37-fold
increase in rucaparib sensitivity, respectively. In addition to BRCA1 and
BRCA2, the knockdown of several other genes including BARD1, CDK12,
FANCA, PALB2, RAD51, RAD51C, RAD51D, and RAD54L increased rucapa-
rib effıcacy 
 2-fold in at least 1 cell line examined. To further investigate HR
defıciency in prostate cancer, BRCA2 was knocked out in the human 22Rv1
prostate cancer cell line using CRISPR/Cas9. Clone 1-50 displayed biallelic
BRCA2 inactivation due to the introduction of a deleterious premature stop
codon, and immunoblot analysis verifıed lack of the full-length BRCA2 protein.
The IC50 of rucaparib in the parental and clone 1-50 cells was 9,504 and 287 nM,
respectively, demonstrating a 33-fold increase in rucaparib cytotoxicity in this
BRCA2 defıcient model. Androgen receptor (AR) signaling and proliferation
were also examined in clone 1-50. In contrast to published reports (Schiewer et
al. Cancer Discov. 2012;2:1134-49), no impact of PARP inhibition on dihy-
drotestosterone (DHT) induced gene expression was observed in the parental
22Rv1 and BRCA2 defıcient clone 1-50 cell lines. In vivo model development
and effıcacy studies with the 22Rv1 and clone 1-50 cell lines are ongoing. Taken
together, these fındings support the hypothesis that defıciencies in BRCA1 and
BRCA2, as well as additional HR genes, may sensitize prostate cancer cells to
rucaparib. A phase 2 study investigating rucaparib in patients with metastatic
castration-resistant prostate cancer and HR gene defıciency (TRITON2) is on-
going (NCT02952534).
#2477 Genomic instability in BRCA1-defıcient cells is a result of the anti-
recombinogenic activity of BLM helicase. Dharm S. Patel, Sarah M. Misenko,
Samuel F. Bunting. Rutgers University, Piscataway, NJ.
Mutations in BRCA1 are responsible for approximately 5% of cases of breast
cancer, and there are few treatment options that substantially alter the probabil-
ity of disease onset in individuals with BRCA1mutations. BRCA1-defıcient cells
exhibit increased genomic instability following DNA damaging treatments due
to a defect in the homologous recombination (HR) DNA repair pathway. Pres-
ently, Olaparib, a PARP inhibitor, is approved as a targeted monotherapy for
germline BRCA1 mutated advanced ovarian cancers. As use of this treatment
has expanded, data suggests that patients exhibit a further relapse and resistance
to PARP inhibitors via mechanisms that include the development of secondary
BRCA1 reversion mutations, enhanced drug efflux relating to P-glycoprotein,
andmutations in otherDNA repair proteins that restoreHR.Here, we show that
the RECQ helicase, BLM, mediates the genomic instability observed in BRCA1-
defıcient cells by a mechanism that depends in part on its anti-recombinogenic
activity. We have generated conditional knockout mice with single and com-
bined defıciencies in BRCA1, BLM, and 53BP1 in the B lymphocyte cell popu-
lation. Ablation of BLM in BRCA1-defıcient cells allows the HR repair pathway
to be restored, leading to a partial rescue of the genomic instability that is present
in BRCA1-defıcient cells. The stable accumulation of RAD51, a marker for HR,
at DNA double-strand break sites is inhibited by BLM in BRCA1-defıcient B
cells. However, DNA end resection is not impacted by single or co-deletion of
BRCA1 and BLM. Furthermore, cells co-defıcient in BRCA1 and BLM display
limited sensitivity to PARP inhibition. The rescue in HR and PARPi sensitivity
phenotypes following deletion of BLM is only present in hypomorphic
BRCA1
11/11
cells and not the RING domain defıcient BRCA12/2. These re-
sults demonstrate that the anti-recombinogenic activity of BLM is of potentially
great signifıcance for regulating the balance of HR versus other error-prone
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repair pathways. Mutation of BLM in BRCA1-defıcient tumors is therefore a
potential pathway leading to resistance to PARPi and other DNA damaging
agents.
#2478 PARP trapping by PARP inhibitors have distinct effects onHR and
ALT NHEJ DSB repair, potentially impacting its therapeutic effıcacy in
breast cancers. Bryan M. Pelkey. University of MD, Baltimore, Baltimore, MD.
PARP inhibitors (PARPi) have exhibited clinical success in inherited breast
cancers with mutations in homologous recombination (HR) DNA double
strand break (DSB) repair genes BRCA 1/2 by synthetic lethality. Novel PARPi
have been shown to function not only by catalytic inhibition of PARP 1/2 activ-
ity, but also by “trapping” of PARP to sites of DNA damage. Trapping of PARP
is a response generated by PARPi that is independent of the inhibition of PARP’s
catalytic activity, and leads to lethal unrepairedDSBs during replication. Impor-
tantly, PARP trapping ability of PARPi correlates with its cytotoxic effect. In this
study, we investigated whether PARP trapping has distinct effects on regulation
of DNA DSB repair in breast cancer cells. Major DSB repair pathways in
mammalian cells include HR and non-homologous end joining (c-NHEJ).
Alternative NHEJ (ALT-NHEJ) is a recently discovered and highly error-
prone pathway which requires DNA resection like HR, and utilizes PARP1.
Our hypothesis is that PARP1 catalytic inhibition vs ‘trapping’ leads to dis-
tinct outcomes on DSB repair, highlighting inhibitor effıcacy. To test our
hypothesis, we utilized MCF10A (non-tumorigenic), MDA-MB-231
(TNBC/BRCA), and SUM149PT (TNBC/BRCA-) breast cancer cell lines
with stably integrated GFP-reporter plasmids designed to assess interchromo-
somal activities of the specifıc DSB repair pathways. For our analysis, we used
varying concentrations of Talazoparib (MDV3800), which is a potent PARP
trapping agent when used in combination with DNA damaging agents such as
methyl methanesulfonate (MMS). First, we determined optimal conditions to
induce PARP trapping in cells without leading to signifıcant toxicity. As ob-
served by others, combination treatments with of MMS/MDV3800 led to a sig-
nifıcant increase in PARP trapping relative to treatments with individual drugs.
Studies were also performed with a potent inhibitor of coenzyme NAD (Da-
porinad/FK866) that blocks poly-ADP ribosylation activity in combination of
MMS. We observed signifıcant PARP trapping with FK866/MMS combination
treatment, indicating that PARP depletion under the conditions of DNA dam-
age also leads to potent PARP trapping. Next, we investigated the effects of these
inhibitors onDSB repair. Surprisingly, combinationMDV3800/MMS lead to an
overall decrease in HR and increase in ALT NHEJ activity. These results were
observed in both our BRCA/ lines. Similar results are observed between the
repair activities when using FK866/MMS treatments. Overall, our results sug-
gest that PARP inhibitors with potent PARP trapping activity increases ALT
NHEJ, whichmay potentially compensate for lack of HR. Studies are ongoing to
determine whether targeting ALTNHEJmay increase cytotoxicity in these cells.
#2479 A functionally null RAD51Dmissense mutation is strongly associ-
ated with ovarian carcinoma. Barbara Rivera. McGill University, Montreal,
Quebec, Canada.
Background and goal: RAD51D is a key player in DNA repair by homologous
recombination (HR) and carriers of truncating RAD51D mutations have an
increased risk for ovarian cancer (OC). However, the contribution of non-trun-
cating RAD51Dvariants to cancer predisposition remains uncertain.We sought
to fully characterize the previously described missense RAD51D variant
c.620CT;p.S207L in order to elucidate its role inOC.Methods: A clinical panel
screening was used to identify the RAD51D variant c.620CT;p.S207L in two
FrenchCanadian (FC) kindred affected with familial HighGrade Serous Cancer
(HGSC) of the ovary or endometrium. High resolution melting, TaqMan geno-
typing and Sanger sequencing were used to genotype the p.S207L variant in a
series of unselected cases of HGSC of the ovary and endometrium, breast, pan-
creas and colorectal cancer and healthy controls, all of a FCorigin.Whole exome
sequencing (WES) was performed to study the genetic signature characterizing
RAD51D associated tumors. RAD51 foci formation and CRISPR-Cas9-stimu-
lated and HR-mediated gene targeting assays were used to assess HR activity of
RAD51D-S207L mutated CHO cells. HR activity in RAD51D-S207L mutated
human cells was tested by a DR-GFP assay. The effect of RAD51D p.S207L on
RAD51D-XRCC2 interactions was analyzed by co-immunoprecipitation and
quantifıed in-vivo in a single cell colocalization assay. Sensitivity to PARP inhib-
itors (PARPi) was evaluated in a cell survival assay. Results: Using deep sequenc-
ing and case-control genotyping studies, we showed that the missense RAD51D
variant c.620CT;p.S207L is over-represented in the French Canadian popula-
tion affected by HGSC of the ovary (3.8% cases vs 0.002% controls; p 0.0001).
The frequency of the p.S207L variant did not differ from that of controls in
breast, endometrial, pancreas and colorectal adenocarcinomas. A commonhap-
lotype shared by all the carriers suggested a founder origin for c.620CT;
p.S207L mutation. WES analysis of RAD51D tumor profıles revealed the pres-
ence of signature 3 which is known to be associated with HR defects.
Functionally, we show that this mutation impairs HR by disrupting the
RAD51D-XRCC2 interaction and confers PARP-inhibitor sensitivity to CHO
cells. Conclusions: This work identifıes RAD51D p.S207L as the fırst bona fıde
pathogenicmissense susceptibility allele forHGSCof the ovary and supports the
use of targeted PARPi therapies in OC patients carrying missense RAD51D
mutations.
#2480 Suppression of homology-dependentDNAdouble-strand break re-
pair induces PARP inhibitor sensitivity in VHL-defıcient human renal cell
carcinoma. Susan E. Scanlon, Parker L. Sulkowski, Peter M. Glazer. Yale School
of Medicine, New Haven, CT.
The von Hippel-Lindau (VHL) tumor suppressor gene is inactivated in the
vast majority of human clear cell renal carcinomas. The pathogenesis of VHL
loss is currently best understood to occur through stabilization of the hypoxia-
inducible factors, activation of hypoxia-induced signaling pathways, and tran-
scriptional reprogramming towards a pro-angiogenic and pro-growth state.
However, hypoxia also drives other pro-tumorigenic processes, including the
development of genomic instability via down-regulation of DNA repair gene
expression. Here, we fınd that DNA repair genes involved in double-strand
break repair by homologous recombination (HR) and inmismatch repair, which
are down-regulated by hypoxic stress, are decreased inVHL-defıcient renal can-
cer cells relative to wild type VHL-complemented cells. Non-homologous end
joining (NHEJ) genes are not decreased in VHL-defıcient cells, demonstrating
specifıcity of the down-regulation and similarity to hypoxia. Functionally, this
repression of HR genes is associated with impaired DNA double-strand break
repair in VHL-defıcient cells, as determined by the persistence of ionizing radi-
ation-induced DNA double-strand breaks and reduced activity in a homology-
dependent plasmid reactivation assay. Furthermore, VHL defıciency conferred
increased sensitivity to the DNA crosslinking agent mitomycin C and PARP
inhibitors, analogous to the synthetic lethality observed between hypoxia and
these chemotherapeutic agents. Finally, we discovered a correlation between
VHL inactivation and reduced HR, but not NHEJ, gene expression in a large
panel of human renal carcinoma samples. Together, our data elucidate a novel
connection between VHL-defıcient renal carcinoma and hypoxia-induced
down-regulation of DNA repair, and identify potential opportunities for target-
ing DNA repair defects in human renal cell carcinoma.
#2481 RAD51 andAICDAdefıne a new synthetic lethal interaction that is
targetable in multiple tumor types. Kevin D. Mills,1 Marly I. Roche,1 Amber
Cyr,1 TylerMaclay,1Muneer G. Hasham,2 Kristin Lamont,2 Jane Branca,2 Fran-
cesca Cavallo,3 Francesca Cavallo,3Maria Jasin,3 Alvin Stern,4 Youngho Kwon,5
Weixing Zhao,5 Patrick Sung5. 1Cyteir Therapeutics, Inc, Cambridge, MA; 2The
Jackson Laboratory, Bar Harbor, ME; 3Memorial Sloan-Kettering Cancer Center,
New York, NY; 4Cepter BioPartners, Hoboken, NJ; 5Yale University School of
Medicine, New Haven, CT.
Antigen stimulated B-cells transiently express Activation Induced Cytidine
Deaminase (AID) which initiates point mutations and DNA double strand
breaks (DSB) in immunoglobulin genes to promote B-cell maturation. How-
ever, AID is capable of broadly damaging the B-cell genome. We have shown
that AID-induced DSBs require the homologous recombination factor RAD51
for their repair. Using genetic approaches, we discovered that reducedHR func-
tion is cytotoxic to AID-expressing B-cells. We subsequently demonstrated the
feasibility of small molecule inhibition of RAD51 to sensitize AID-overexpress-
ing tumor cells. Here we build on those observations, fınding that AID-RAD51
synthetic lethality occurs viamitotic catastrophe, involving themTOR pathway.
We have now developed potent and selective RAD51 modulatory small mole-
cules that preferentially kill AID-expressing tumor cells. Usingmousemodels of
lymphoma and leukemia we provide in vivo effıcacy data demonstrating the
potential therapeutic feasibility of RAD51 modulation. These studies provide
evidence for a novel “synthetic lethal” approach for treating AID-expressing
malignancies, via the induction of mitotic catastrophe.
#2482 Inhibition of RAD51 with a cell penetrating antibody, 3E10. Peter
M. Glazer, Audrey Turchick. Yale University, New Haven, CT.
Many human malignancies arise in the setting of defective DNA repair path-
ways, leading to genetic instability, carcinogenesis and tumor progression.
However, DNA repair defıciency can provide for a therapeutic window that can
be exploited with targeted agents. One such anti-cancer agent is 3E10, a unique
cell penetrating, anti-DNA autoantibody. 3E10 by itself is considered non-toxic
to normal cells but has been shown to have deleterious effects on cells withDNA
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repair defıciencies. Specifıcally, 3E10 has been shown to reduce the effıciency of
homologous recombination (HR). This has been attributed to its ability to pref-
erentially binding to ssDNA tails, thereby inhibiting Rad51 mediated strand
exchange. Prior work has shown that treatment with 3E10 alone can selectively
kill cells with geneticmutations that lead to abnormal DNA repair. For example,
3E10has been shown to be synthetically lethal inBRCA2defıcient human cancer
cells. Additionally, 3E10 sensitizes cells to radiation and other DNA damaging
therapies. The goal of this project is to characterize the specifıc mechanism by
which 3E10 inhibits DNA repair pathways. Previously, themechanism bywhich
3E10 inhibits HR was attributed to 3E10’s DNA binding ability. Through the
biochemical evaluation of 3E10 variants, new evidence now suggests that 3E10
inhibits HR independently of 3E10’s ability to bind DNA. We have found that
this HR inhibition is a result of a physical interaction between 3E10 and Rad51.
Biochemical analysis revealed that 3E10 binds to the N-terminal domain of
Rad51, the domain that plays a role in Rad51 homo-oligomerization and fıla-
ment formation. This 3E10-Rad51 interaction impairs Rad51’s ability to localize
to the nucleus and form repair foci. Taken together, this data suggests that 3E10
inhibitsHRby physically interactingwithRad51.Overall, 3E10 holds promise as
a novel therapeutic agent for certain subsets of cancer.
#2483 Molecular mechanisms of dianhydrogalactitol (VAL-083) in over-
coming chemoresistance in glioblastoma. Beibei Zhai,1 Anna Gobielewska,2
Anne Steino,3 Jeffrey A. Bacha,3 Dennis M. Brown,4 Simone Niclou,2 Mads
Daugaard1. 1University of British Columbia, Vancouver, British Columbia, Can-
ada; 2Luxembourg Institute ofHealth, Luxembourg, Luxembourg; 3DelMar Phar-
maceuticals, Inc., Vancouver, British Columbia, Canada; 4DelMar Pharmaceuti-
cals, Inc., Menlo Park, CA.
Standard treatments for glioblastoma (GBM) include surgery, radiation and
chemotherapy with temozolomide (TMZ). Nearly all tumors recur and 5-year
survival is less than 3%, largely due to chemoresistance. Evidence shows that
cancer cells utilize DNA damage repair pathways to overcome cytotoxic effects
of chemotherapy. GBM tumors expressing O6-methylguanine-DNA-methyl-
transferase (MGMT) display intrinsic chemoresistance to TMZ and nitro-
soureas, while a defıcient DNA mismatch repair system (MMR) confers
chemoresistance to TMZ and platinum agents. Alterations in p53, particularly
gain-of-function mutations, are correlated with increased MGMT-expression
and poor prognoses in GBM. Second line anti-angiogenic treatment with bev-
acizumab has not improved overall survival and has been shown to induce in-
tratumor hypoxia and increased chemoresistance. VAL-083 is a bi-functional
alkylating agent that readily crosses the blood-brain barrier, accumulates in
brain tumor tissue and has demonstrated activity against GBM in prior NCI-
sponsored clinical trials. VAL-083 induces interstrand cross-links at guanine-N7
causingDNAdouble-strand breaks and cancer cell death. VAL-083 is equiactive
against GBM cancer stem cells (CSCs) and non-CSCs independent of MGMT
and p53 status, in vitro. We recently showed that VAL-083 leads to irreversible
S/G2-phase cell cycle arrest, proposing synergy with S-phase specifıc chemo-
therapeutics, including topoisomerase and PARP inhibitors. VAL-083 further
showed persistent activation of the homologous recombination (HR) DNA re-
pair pathway and its potencywas increasedwhenHRwas impaired, demonstrat-
ing that VAL-083-induced lesions are repaired via HR suggesting increased
VAL-083 potency in HR-impaired tumors. Further, hypoxic cancer cells are
known to downregulate their HR pathway, proposing increased VAL-083 po-
tency in hypoxic tumors. Bevacizumab treatment increases hypoxia in tumor
cells, presumably impairing HR, proposing VAL-083 as a treatment option in
HR-defıcient or hypoxic cancers following, or as part of a combination treat-
ment with, bevacizumab. Here, VAL-083 cytotoxicity and DNA damage re-
sponse was evaluated by crystal violet assays, western blot and flow cytometry.
VAL-083’s ability to overcomeMMR-related chemoresistance was investigated
using lentiviralMLH1 andMSH2 vectors inHCT116 and LoVo cancer cells.We
report synergy between VAL-083 and etoposide or camptothecin in A549 and
PC3 cancer cell lines. We also investigated the potency of VAL-083 in GBM
under hypoxia either in vitro or in vivo as part of a combination treatment with
bevacizumab. Our results demonstrate a distinct anti-cancer mechanism for
VAL-083, resulting in the ability to overcome resistance to TMZ and nitro-
soureas, increased activity in cancers with impaired HR and synergy with eto-
poside or camptothecin.
#2485 Development and validation of Predi-HRD liquid biopsy test for
PARP inhibitor clinical trials. Zhixin Zhao, Toni Wiegers, Tak Cheung, Pan
Du, Shidong Jia. Predicine, Inc, CA.
Response to DNA-damaging agents, such as platinum and recently emerged
PARP inhibitors, is associated with homologous recombination defıciency
(HRD) pathway. In fact, as reported by multiple clinical trials, patients with
advanced breast, prostate, and ovarian cancers who have harmful mutations in
BRCA1 and BRCA2 have demonstrated a great benefıt from treatment of PARP
inhibitors including olaparib, niraparib, and talazoparib. Current companion
diagnostic assays that mainly examine germline defects from blood or somatic
alterations from tumor tissues have shown several practical challenges: germline
test does not capture somatic alterations of a tumor, initial biopsies froma tumor
may not reflect the current status of the tumor’s genetic profıle over time, and
tissue biopsy may be of insuffıcient quantity or unavailable/unobtainable for
downstream molecular profıling. Here we introduce the Predi-HRD blood test,
a non-invasive, next-generation sequencing (NGS)-based multiplex assay that
enables real-time monitoring of temporal change of tumor heterogeneity and
highly sensitive detection of defects in HR genes including BRCA1, BRCA2,
ATM, CHEK2, among others. Technical validation was performed to evaluate
assay sensitivity, specifıcity and accuracy using reference samples with known
genetic profıling and further validated on a variety of orthogonal platforms such
as digital PCR, allele-specifıc PCR and Sanger sequencing. Mutation prevalence
of HR genes was examined in clinical plasma samples from patients with ad-
vanced ovarian cancer after systemic chemotherapy. The successful develop-
ment of Predi-HRD liquid biopsy test offers an effıcient solution to stratify and
monitor cancer patients whomay benefıt fromHRD-targeted therapeutics such
as PARP inhibitors.
#2486 Tumor hypoxia induces DNA repair vulnerabilities through con-
textual loss of heterozygosity.OsmanMahamud,1 Melvin Chua,2 Winnie Lo,2
Gaetano Zafarana,3 Robert Bristow2. 1University of Toronto, Toronto, Ontario,
Canada; 2Princess Margaret Cancer Centre, Toronto, Ontario, Canada; 3Univer-
sity Health Network, Toronto, Ontario, Canada.
Introduction: Intratumoural hypoxia leads to decreased expression in DNA
damage response (DDR) and repair pathways. Given the ‘two-hit’ model for loss
of gene function, we hypothesize that hypoxia-mediated down-regulation of
gene expression and function, coupledwith an already inactive allele contributes
to an exploitable contextual ‘loss-of-heterozygosity’ phenotype. Method: To in-
terrogate this relationship, isogenic DLD-1 cells heterozygous and homozygous
null for BRCA2, were placed under normoxic (21%) or hypoxic (0.2%) condi-
tions for 72 hours. Hypoxia-mediated changes in DDR response and DNA re-
pair were evaluated by cell proliferation, cell cycle analysis, western blots, qPCR,
immunofluorescence, clonogenic assays and functional repair assays. Results:
No differences in proliferation and cell survival were observed between oxic and
hypoxic cells (72 hours - 0.2% O2). Under chronic hypoxic conditions, con-
fırmed by the up-regulation of VEGF andHIF1a,mRNAand protein expression
of key homologous recombination (HR) genes (BRCA1, BRCA2, RAD51) were
down-regulated. Functionally, BRCA2/ null cells proved unable to recruit
Rad51 foci and were profoundly sensitivity to PARP inhibition. Conversely,
heterozygote BRCA2/ cells retained the ability to recruit Rad51 foci under
both oxic and hypoxic conditions. However, exposure to chronic hypoxia re-
sulted in a reduction of foci formation. Chronically hypoxic BRCA2/ cells
exhibited a 30-40% increase in sensitivity to PARP inhibition compared to their
oxic counterparts. Preliminary data shows a similar synthetically lethal relation-
ship in genetic (BRCA2/) and tumor microenvironment induced (BRCA2/)
HR defıcient cells, when challenged with DNA damage response (DDR) kinase
inhibitors ATRi and DNAPKi. Conclusions: Herein, we demonstrate a novel
mechanism of contextual ‘loss-of heterozygosity’, which marries the tumour
microenvironment and innate genetic alterations. The resultant increased sen-
sitivity to DDR kinase inhibitors and PARPi highlights the therapeutic signifı-
cance of this phenomenon.
#2487 Functional characterization of the BRCA2 variant, K3326X.
Srilatha R. Simhadri, Sonia C. Dolfı, Atul Kulkarni, Bing Xia, Shridar Ganesan,
Kim M. Hirshfıeld. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
Individuals with germline mutations in the breast cancer susceptibility gene,
BRCA2, have an approximate 70% risk of developing breast cancer, a 30% risk of
developing ovarian cancer, a 20-fold increased risk of developing prostate can-
cer, and a 10-fold risk of developing pancreatic cancer during their lifetime. Loss
of function germline mutations in BRCA2 affect its role in the homologous
recombination (HR) DNA repair pathway leading to signifıcant genomic insta-
bility. In addition to deleterious truncatingmutations, several sequence variants,
collectively called Variants of Unknown Signifıcance (VUS), have been identi-
fıed and are distributed along its length. One such variant is rs11571833, a non-
sensemutation in the last exon (c.9976AT,K3326X), resulting in the loss of the
C-terminal 93 amino acid residues in BRCA2. This truncated variant has been
previously described as a polymorphism that does not increase susceptibility to
breast and ovarian cancers, and as a neutral unclassifıed variant non-deleterious
to its function. However, recent studies identifıed K3326X to be enriched in
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breast cancer cases and to increase the risk for lung, pancreatic, ovarian, and
upper aero-digestive tract cancers. Preliminary data, obtained from the Rutgers
Cancer Institute of New Jersey breast cancer case-control study, identifıed
K3326X enrichment in 1.25% of cases compared to 0.7% of controls. Several of
the carriers had second primaries and displayed a trend toward increased num-
ber of family members diagnosed with colon cancer. Notably, K3326X was also
identifıed in 1.38% (11 of 796) of our histologically-diverse cohort of genomi-
cally-profıled tumors that included cancers of the breast, ovarian/fallopian tube,
lung, vulvar, cancer of unknown primary, and one breast cancer case having
prolonged response to platinum-based therapy. Thus, K3326X may represent a
functional loss of wild type BRCA2 function, as we observe concomitant loss of
heterozygosity at this locus. In a preliminary study, we evaluated the K3326X
variant, in vitro, in a functional DR-GFP-based reporter assay measuring HR.
Our data reveal the BRCA2 K3326X variant to be impaired in the HR pathway
indicating a loss of wild-type protein function.Wewill also evaluate cell viability
of the K3326X variant in the presence of DNA damaging drugs like cisplatin,
poly-ADP ribose polymerase inhibitors and mitomycin C. Future studies will
also incorporate a retrospective evaluation of tumor specimens that have under-
gone comprehensive genomic profıling. These data would indicate that BRCA2
K3326X represents a functional hypomorphic variant that may have implica-
tions in therapeutic approaches and cancer risk evaluations across a spectrum of
tumor types.
#2488 Tumor necrosis factor-alpha signaling determines cytotoxicity in-
duced by BRCA2 defıciency. Anne M. Heijink, Francien G. Talens, Anouk
Baars, Marcel A. van Vugt. University Medical Center Groningen, Groningen,
Netherlands.
Introduction Breast cancer 2, early onset (BRCA2) is involved in DNA-dam-
age repair via homologous recombination (HR). Defective HR leads to severe
genomic instability and homozygous deletion of BRCA2 is therefore deleterious
for survival of normal cells. In apparent contrast, inherited heterozygous muta-
tions in BRCA2 increase the risk to develop cancer, which goes along with
somatic loss of the wild type allele. So paradoxically, BRCA2 loss is lethal in
normal cells, but can be tolerated in cancer cells. It is currently unclear how
tumor cells can survive without BRCA2. To address this question, we performed
a genome-wide functional genetic screen and identify Tumor Necrosis Factor-
alpha (TNF) signaling, via TNF receptor 1 (TNF-R1) and Src-associated-sub-
strate-during-mitosis-of-68kDa (Sam68), as an important determinant of cell
death induction upon BRCA2 inactivation. Material & Methods A genetic
screen was performed in human near-haploid KMB-7 cells. Two monoclonal
KMB-7 lines were engineered to express independent doxycycline-inducible
BRCA2 short hairpin RNAs (shRNAs). Cells were randomlymutagenized using
retrovirus carrying a strong splice-acceptor, resulting in gene knock-outs. Deep
sequencing of surviving colonies revealed gene mutations that prevented sh-
BRCA2-mediated cell death. Validation of TNF-R1 and Sam68 was done by
shRNAs inmultiple breast- and leukemic cell lines. Cell viabilitywas determined
by MTT and clonogenic assays. Competition assays with vectors expressing
shRNA including IRES-driven mCherry were analyzed with flow cytometry.
Biochemical analyses were assessed by western blotting and ELISA. Immuno-
precipitation with FLAG-tagged TNF was performed to study TNF-R1 com-
plex formation. Results From our genetic screens, loss-of-function mutations
involved in TNF signaling were found to signifıcantly rescue cell death in
BRCA2-depleted cells. To validate these fındings, BRCA2was stably depleted in
a panel of cancer cell lines, which decreased viability. Subsequent co-depletion of
TNF-R1 or Sam68 rescued survival. Notably, BRCA2 depletion resulted in the
production of TNF. In line with this fınding, the majority of tested cancer cell
lines were found to be sensitive to recombinant TNF upon BRCA2 depletion.
This phenomenon was not restricted to BRCA2 inactivation, since depletion of
related DNA repair genes (BRCA1, FANCD2) or hydroxyurea-induced replica-
tion stress also sensitized cells to recombinant TNF. Mechanistically, BRCA2
depletion was induced to observe differential complex formation of TNF-R1
with downstream effector proteins upon TNF activation. ConclusionOur data
reveal that down-regulation of TNF-R1 or its downstream signaling component
Sam68 rescued cytotoxicity upon BRCA2 inactivation. These fındings and
mechanistic follow-up experiments describe a novel mechanism by which auto-
crine TNF signaling, induced by loss of BRCA2, limits tumor cell viability.
#2489 Mre11-CDK2 interaction during the DNA double-strand break re-
sponse. Mary J. Morgan, Todd A. Festerling, Jeffrey Buis, David O. Ferguson.
University of Michigan, Ann Arbor, MI.
TheMRN(Mre11/Rad50/NBS1) complex is agroupofhighly conservedproteins
central to the detection and repair of DNA double-strand breaks (DSBs). Inherited
defıciencies inDNADSBsignaling result ina spectrumofdisorders featuringcancer
predisposition, neurodegeneration, and immunodefıciency. MRN directly binds
DNA DSB ends and facilitates activation of ataxia-telangiectasia mutated (ATM)
kinase, which initiates cellular responses including DNA repair, cell cycle check-
points, and in some circumstances, apoptosis. Cellular responses to DNA DSBs
require rapid communication between DNA repair complexes and the cell cycle
machinery, butmuch about this relationship remains unclear. Our lab recently dis-
covered an interaction between Mre11 and Cyclin-dependent kinase 2 (CDK2), a
key component of the cell cycle machinery (Buis et al., NSMB, 2012). CDK2, when
bound to its regulatory partner CyclinA, promotes cell cycle progression through S
phase.Wedemonstrated that theMre11-CDK2/CyclinAinteraction is important in
regulating the capacity for DNA repair by homologous recombination in normally
dividing cells. Current work is focused on understanding the role of this interaction
duringDNAdamage responses.Wehypothesize thatMre11 interactionwithCDK2
is a component of a molecular switch between the normal cell cycle and the DNA
damage response. To test our hypothesis, we take advantage of murine alleles of
Mre11previously generated in the lab.Weperformed immunoprecipitation studies
to investigate the protein-protein interaction in the presence of DNA damage. We
alsoutilizedkinase inhibitors to investigate the roleofapicalkinases inregulating the
interaction. Finally, we are currently optimizing in vitro kinase assays to further
understand a relationship between Mre11 and CDK2 enzymatic activity.Unpub-
lished fındings reveal that the Mre11-CDK2/Cyclin A interaction is altered upon
DNA damage, a process which appears to be important for cell cycle checkpoint
regulation. In conclusion, we demonstrate that the Mre11-CDK2 interaction plays
important roles both in normally dividing cells and in the DNA damage response.
Taken together, our data suggests that Mre11 may act to bridge the gap between
DNA repair complexes and the cell cycle machinery.
#2490 Rad51 suppresses innate immune response by blocking MRE11-
mediated degradation of newly replicated genome. Kalayarasan Srinivasan,
Souparno Bhattacharya, Salim Abdisalaam, Shibani Mukherjee, Asaithamby
Aroumougame. UT Southwestern Medical Ctr., Dallas, TX.
Purpose of the study: Eukaryotic cells accrue DNA damage as a result of
endogenousmetabolic activities such as DNA replication, recombination errors
or environmental exposures such as ionizing radiation, ultra-violet light and
chemical mutagens. Unrepaired DNA damage leads to tumorigenesis. Rad51 is
a multifunctional protein that plays a central role in DNA replication and ho-
mologous recombination repair. It is known that defects in Rad51 function can
cause cancer. The goal of this study is to identify a novel role for Rad51 outside
of its known functions in DSB repair and replication fork processing. Methods:
Since Rad51 knockout is lethal to cells, we generated an inducible system in
which we can down-regulate Rad51 expression in HT1080 cells after Doxycy-
cline treatment. To determine the effect of Rad51-knockdown in global gene
expression pattern, we carried out unbiasedmicroarray gene expression analysis
and after induction of DNA damage and replication stress by radiation. ssDNA
and dsDNA in the cytosolic fractions were quantifıed using Quant-iT OliGreen
and PicoGreen Assay Kits. For cytoplasmic BrdU detection, exponentially
grown cells were labeled with BrdU for 18-20 h and then immunostained with
anti-BrdU antibody. Additionally, we measured the expression and post-trans-
lational modifıcation of proteins involved in innate immune signaling by west-
ern blotting. We also employed DNA fıber assay to determine the role of Rad51
in replication fork processing. Results: We found that defects in Rad51 lead to
the accumulation of self-DNA in the cytoplasm, triggering a STING-mediated
innate immune response after replication stress and DNA damage. Mechanisti-
cally, the unprotected newly replicated genome in the absence of Rad51 is de-
graded by the exonuclease activity of Mre11, and the fragmented nascent DNA
accumulates in the cytosol, initiating an innate immune response. Our data
revealed that in addition to playing roles in homologous recombination-medi-
ated DNA double-strand break repair and replication fork processing, Rad51 is
also implicated in the suppression of innate immunity. Conclusion: Rad51 plays
a novel role in immunity outside its known functions in DSB repair and repli-
cation fork processing. We discovered that the lack of Rad51 leads to the up-
regulation of innate immune response pathway genes upon DNA damage and
replication induced by irradiation. We found that in the absence of Rad51 the
newly replicated genome is degraded by the exonuclease activity of Mre11. We
also showed that these degraded nascent DNA fragments are exported to the
cytoplasm, triggering innate immune response signaling. Our study reveals a
previously unidentifıed role for Rad51 in triggering an innate immune response,
and places Rad51 at the hub of new interconnections between DNA replication,
DNA repair, and immunity. Funding: This work was supported by NIH
R01AG053341 grants.
#2491 Beclin1 promotes DNA double-strand breaks repair. Fei Xu,1 Lili
Yan,1 Jianrong Wang,1 Jinming Yang2. 1Soochow University, China, Suzhou,
China; 2Penn State Univ., PA.
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Beclin1 is a well-established core mammalian autophagy protein that has
been presumed to suppress oncogenesis via an autophagy-mediated mecha-
nism. Since its discovery, studies have also shown that Beclin1 interacts with
an increasing number of cofactors. However, the tumor suppressive roles of
Beclin1 remain a major research focus, and the exact mechanism by which
Beclin1 acts as a tumor suppressor has remained largely obscure. Our con-
focal analysis showed that in embryonic and neonatal mice, Beclin1 is pri-
marily located in the cytoplasm in hepatocytes, with a very small portion
located in the nucleus. When the mice were 15d, roughly half of the total
Beclin1 was located in the nucleus. Thereafter, Beclin1 progressively redis-
tributed from cytoplasma to nucleus within a few weeks after birth. This
pattern, was similarly sustained not only in hepatocytes but also in other
tissues. And we found both 0-50 and 254-278 residues are required for Be-
clin1 nuclear localization. Furthermore, loss of Beclin1 resulted in reduced
DNA damage repair. We found that the beclin1/ cells showed a marked
increased -H2AX foci that are considered as a biomarker of DNA DSBs.
Moreover, beclin1/ cells showed approximately about 60-fold and 30-fold
reductions in DSB repair by NHEJ and HR pathways. A series of key DSBs
repair proteins were signifıcantly reduced in beclin1/ cells. Interestingly,
Beclin1 regulates DSB repair independent of autophagy. Autophagic flux was
maintained in the beclin1/ cells. Perhaps an alternative autophagy may be
activated when beclin1 is deleted as ULK1 was upregulated. We further
found that Beclin1 promotes DSB repair via a direct interaction with DNA
topoisomerase II (Top2b). Pull down results showed that Top2b is one of
themajor Beclin1-interacting proteins in the nucleus. And we found that this
interaction was intensifıed after exposure to IR. Top2b and Beclin 1 were
found to be colocalized to the DSB sites, after exposure to IR. Strikingly,
depletion of Top2b by gene silencing completely prohibited Beclin1 local-
ized to the DNA break sites. We constructed a beclin1-/- cell line using
CRISPR/Cas9 system. The spot counts of protein foci were measured by
imaging flow cytometry after exposure to 6Gy IR. HR and NHEJ reporter
assays were used to detect the activity of DSBs repair pathways. We pulled
down nuclear proteins with ectopically expressed Flag-tagged Beclin1. The
identities of the Beclin1-interacting proteins were determined using mass
spectrometry. Our work establishes that Beclin1 plays an autophagy-inde-
pendent role in maintaining genomic integrity by promoting DNA damage
repair. The fınding challenge the long-standing paradigm of the mechanisms
that are involved in the autophagy-mediated tumor suppressive role of Be-
clin1. This fınding suggests that whenmanipulating cytoplasmic Beclin1 that
is involved in the autophagy pathway in order to explore targeted tumor
therapies, the non-autophagy cytoprotective role of Beclin 1 in the nucleus
should also be considered.
#2492 DNA polymerase beta participates in DNA end-joining. Sreerupa
Ray, Michelle DeVeaux, Gregory Breuer, Ranjit Bindra, Daniel Zelterman,
Joann Sweasy. Yale University, New Haven, CT.
DNA double strand breaks (DSBs) are one of the most deleterious lesions.
If left unrepaired, DSBs lead to genomic instability and carcinogenesis. The
cells combat DSBs by two classical pathways that include homologous re-
combination (HR) which requires the sister chromatid for sequence homol-
ogy, and non-homologous end-joining (NHEJ), wherein the two DNA ends
are re-joined. Recently a back-up NHEJ pathway has been reported and is
referred non-canonical NHEJ which has been given many names, such as
alternative NHEJ or microhomology-mediated end joining (MMEJ). The
enzymatic mechanisms of non-canonical NHEJ are not well defıned. NHEJ
requires processing enzymes including nucleases and polymerases, although
the roles of these enzymes in the pathway are poorly understood. Recent
studies have implicated a role for DNA polymerase theta (Pol ), an A-family
polymerase is essential for non-canonical NHEJ pathway. Emerging evi-
dence indicates X-family polymerases, mammalian DNA polymerases
lambda () and mu () and yeast Pol 4 promote DNA end-joining. Our
laboratory has recently provided evidence for a role for DNA polymerase
beta (Pol ), another X-family polymerase, in V(D)J recombination, a pro-
cess that requires end-joining. Here, using a recently developed fluorescence
based assay that monitors non-canonical NHEJ andHR, we provide evidence
that Pol  plays a role in the non-canonical NHEJ process. DNA sequencing
at the break point junctions revealed Pol -depleted cells have fewer small
deletions than control cells, but signifıcantly greater numbers of insertions
and large deletions. We further demonstrate that Pol -depleted cells have
increased sensitivity to DNA damaging agents that induce double-strand
breaks and that there is persistent accumulation of DSBs in these cells. In
combination, our results suggest that Pol  is critical for double-strand break
repair.
#2493 Identifıcation of the mutant p53-PARP-MCM chromatin axis as a
triple negative breast cancer replication stress target. Wei-Gang Qiu,1 Alla
Polotskaia,2 GuXiao,2 LiaDi,2 Yuhan Zhao,3WenweiHu,3 John Philip,4 Ronald
Hendrickson,4 Jill Bargonetti1. 1City Univ. of New York at Hunter College and
The Graduate Center, New York, NY; 2City Univ. of New York at Hunter College,
New York, NY; 3Rutgers Cancer Institute of New Jersey, Rutgers, NJ; 4Memorial
Sloan-Kettering Cancer Center, New York, NY.
Approximately 15% of all breast cancer is triple-negative and of these
about 80% are found to have mutations in the gene for the tumor suppressor
p53 (TP53). Many TP53 mutations encode gain-of-function oncogenic mu-
tant p53 (GOF mtp53) protein. We used inducible knockdown of endoge-
nous GOF mtp53 in MDA-MB-468 cells in conjunction with stable isotope
labeling with amino acids in cell culture (SILAC) and subcellular fraction-
ation. We sequenced over 70,000 total peptides for chromatin and cytoplas-
mic reciprocal data sets and were able to identify 3,010 unique cytoplasmic
fraction proteins and 3,403 unique chromatin fraction proteins. We found
that the heterohexomeric minichromosome maintenance (MCM) complex
(MCM 2-7) along with PARP are high mtp53-chromatin associated path-
ways. When we depleted R273H mtp53 we found a large reduction of the
amount of MCM complex and PARP proteins on the chromatin. Further-
more a direct mtp53-MCM2 interaction was detected. Overexpressed
mtp53, but not wild type p53, showed a protein-protein interaction with
MCM2 and MCM4. We treated cells with the PARP inhibitor talazoparib
and the alkylating agent temozolomide and detected synergistic activation of
apoptosis only in the presence of functional MCM2-7 and mtp53. The
mtp53-PARP-MCM axis has potential use as a therapeutic and diagnostic
target.
#2494 ATR inhibitor AZD6738 asmonotherapy and in combination with
olaparib or chemotherapy: defıning pre-clinical dose-schedules and effıcacy
modelling. Alan Y. Lau,1 James Yates,1 Zena Wilson,2 Lucy A. Young,1 Adina
M. Hughes,1 Alienor Berges,1 Amy Cheung,1 Rajesh Odedra,2 Elaine Brown,2
Mark J. O’Connor,1 Simon Hollingsworth1. 1AstraZeneca, Cambridge, United
Kingdom; 2AstraZeneca, Macclesfıeld, United Kingdom.
Introduction: AZD6738 is a potent and selective oral inhibitor of the
ataxia telangiectasia and rad3 related (ATR) protein kinase. ATR has a key
role in the DNA replication stress response (RSR) pathway of DNA repairby
facilitating the recovery and repair of potentially cytotoxic persistent, stalled
DNA replication forks. Inhibition of ATR leads to the inability to resolve
replication associated damage and the accumulation of DNA strand breaks,
which if remains unrepaired leads to cell death. AZD6738 is currently in
Phase I/II clinical trials being evaluated as a monotherapy and in combina-
tion with novel agents olaparib / Lynparza (PARP DNA damage response
inhibitor), durvalumab (PD-L1 immune checkpoint inhibitor) and DNA-
damaging agents such as carboplatin and ionising radiation. Critical in help-
ing to guide the clinical usage of AZD6738 and maximise patient benefıt,
pre-clinical studies were performed to determine optimal doses and sched-
ules as monotherapy and in combination with olaparib and carboplatin.
Experimental procedures: Human cancer cell lines, xenograft and patient-
derived explant (PDX) models of non-small cell lung cancer (NSCLC), head
& neck squamous cell carcinoma (HNSCC), and triple-negative breast can-
cer (TNBC) were tested comparing once daily versus twice daily dosing, the
number of consecutive days dosing (3 days/week, 5 days/week, continuous)
and co-dosing versus sequential or intermittent dosing with AZD6738 alone
or in combination with olaparib or carboplatin. Themagnitude and duration
of anti-tumour responses were then compared with AZD6738 mouse phar-
macokinetic (PK), pharmacodynamic (PD) and in vitro target (IC) / growth
inhibition (GI) profıles. Results: A mathematical model was derived which
adequately described the AZD6738 PK/PD-effıcacy relationship. This mod-
elling confırms that duration of cover (time) above cellular ATR target inhi-
bition thresholds (IC90 pCHK1 / GI90) per day, rather than Cmax or exposures
per se, is the major determinant of anti-tumour responses. As monotherapy,
in sensitive ATM-defıcient models, it is necessary to inhibit ATR continu-
ously to give tumour stabilisation, which can be achieved through repeat
daily of AZD6738 over several weeks. Co-dosing AZD6738 in combination
with olaparib or carboplatin gives best effıcacy compared to sequential dos-
ing and PK cover over the fırst 48-72 hours is necessary to give tumour
regressions. The models predict that extending the duration of ATR cover,
achieved through repeat daily dosing, further increases effıcacy. These pre-
clinical dose-schedules were compared to human free plasma AZD6738 PK
data and predicted effıcacious exposures found to be clinically achievable.
Conclusions: Together these data further support the clinical evaluation of
AZD6738 and suggest optimal dosing schedules for ATR inhibitors.
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Metabolomics and Metabolic Regulation
#2495 The metabolic secretome of cachexia inducing pancreatic ductal
adenocarcinoma. Santosh K. Bharti,1 Paul T. Winnard,1 Louis Dore-Savard,2
YelenaMironchik,1Marie-France Penet,1 ZaverM. Bhujwalla1. 1The JohnsHop-
kins University School of Medicine, Baltimore, MD; 2McGill University Health
Center, Montreal, Quebec, Canada.
Cachexia is an underexplored and yet devastating consequence of cancer that
is the cause of 20% of all cancer related deaths1. Cachexia inducing tumors cause
a ‘wasting away’ of the body. The condition is associated with poor treatment
outcome2, fatigue, and extremely poor quality of life2,3. Because of the multi-
factorial characteristics of this condition, it has been diffıcult to understand the
mechanisms driving the impact of the tumor on body organs and the sequence
of events that leads to this lethal condition. Here we have used 1H MRS to
characterize themetabolic profıle of tumor interstitial fluid (TIF) obtained from
noncachexia (Panc1) and cachexia inducing (Pa04C) tumors to further under-
stand the impact of the deranged metabolism of cachexia-inducing tumors on
the tumor metabolic secretome. The human pancreatic cancer cell line, Panc1,
was obtained from ATCC. The human pancreatic cancer cell line, Pa04C, was
provided by Dr. Maitra4. Six to 8 week old male SCID mice were inoculated in
both the right and left flank with cancer cells (5106, Panc1N2, Pa04CN2).
We created a collection chamber to collect TIF. The chamber was implanted
togetherwith small tumor pieces harvested from the subcutaneous flank tumors,
into the subcutaneous flank space of SCID mice (Panc1 N8 and Pa04C N6)
until the tumor encompassed the chamber (4-5 weeks). The tumor was then
removed and the tumor tissue and TIF were collected. To obtain control TIF, an
empty chamber was implanted in the subcutaneous flank space of healthy mice.
Dual phase solvent extraction was performed on tumor tissue. The water phase
was separated, freeze dried, reconstituted in D2O PBS for spectral acquisition.
All 1H MR spectra were acquired on an Avance III 750 MHz (17.6T) Bruker
NMR spectrometer equipped with a 5 mm broad band inverse (BBI) probe.
Spectral acquisition, processing and quantifıcation were performed using TOP-
SPIN 2.1 software. Notable differences between Pa04C compared to Panc1 TIF
or normal interstitial fluid were a signifıcant decrease of polyunsaturated fatty
acids (PUFA) and lipids, and formate, pyruvate, glutamine, and glucose. Lactate,
glutamate, succinate, glycine and acetone signifıcantly increased in Pa04C TIF
compared to Panc1 TIF or normal interstitial fluid. These differences in TIF
cannot be explained solely by the differences in the tumormetabolic profıle. Our
data provide new insights into changes in the metabolic secretome with induc-
tion of cachexia that may shed new light on the cachexia cascade, and identify
metabolic strategies to reverse the syndrome. References: (1) Argiles, J. M., et al.
Nature reviews. Cancer 2014, 14, 754-762. (2) Ozola Zalite, I., et al. Pancreatol-
ogy 2015, 15, 19-24. (3) Fearon, K. C., et al. HPB (Oxford) 2010, 12, 323-324. (4)
Penet, M. F., et al. Clinical Cancer Research 2015, 21, 386-395. Acknowledg-
ment: This workwas supported byNIHR01CA193365,NIHP50CA013175 and
NIH P30CA06973.
#2496 Targeting brain tumor stem cells by interfering with choline me-
tabolism: Evidence for an EMT-choline oncometabolic network. Katharina
Koch,1 Rudolf Hartmann,2 Abigail K. Suwala,1 Dayana Herrera Rios,1 Ulf D.
Kahlert,1 Jaroslaw Maciaczyk1. 1University Hospital Duesseldorf, Duesseldorf,
Germany; 2Forschungszentrum Juelich, Juelich, Germany.
Glioblastoma (GBM) is the most lethal primary malignant brain tumor with a
median survival of less than two years. High levels of therapy resistance, strong
cellular invasiveness and rapid cell growthdemandaggressivemultimodal therapies
involving resection as well as radio-chemotherapy. Recent evidence has pointed to
the existence of brain tumor stem cells (BTSCs), a subpopulation of human brain
tumors which is thought to be responsible for tumor dissemination, relapse and
chemo resistance. BTSCs have been associatedwith the expression ofmesenchymal
features as a result of epithelial-mesenchymal transition (EMT). Using high resolu-
tion proton nuclearmagnetic resonance spectroscopy (1HNMR)we compared the
intracellular metabolic composition of GBM cells after induction vs. inhibition of
EMT aswell as under stem cell or differentiated conditions.We identifıed that both
EMT and enrichment for stemness induces the cholinic phenotype which is char-
acterizedbyhigh intracellular levelsofphosphocholineand total cholinederivatives.
Furthermore, interference with choline metabolism by targeting choline kinase al-
pha (CHK) reversed EMT in GBM cells as we observed reduced invasiveness,
clonogenicity, and expression of EMT associated genes. Taken together, interfering
with choline metabolism is a powerful strategy to suppress EMT and thus target
BTSCs. Moreover, the newly identifıed BTSC-oncometabolic network could be
used to non-invasively monitor the invasive properties of glioblastomas and the
success of anti-BTSC therapy.
#2497 Differential requirement of amino acids on cell survival of ovarian
cancer cells.Akiko Furusawa,1 Jun Inoue,1 Hitoshi Tsuda,2 NaoyukiMiyasaka,1
Johji Inazawa1. 1Tokyo Medical and Dental University, Tokyo, Japan; 2National
Defense Medical College Hospital, Tokorozawa, Japan.
Amino acids (AAs) are traditionally classifıed into nutritionally essential
AAs (EAAs) or nonessential AAs (NEAAs) for animals and humans. Recent
studies have demonstrated that not only EAAs but also NEAAs play impor-
tant roles on energy metabolisms in cancer cells. However, which AAs are
indispensable for human cancer cell survival has not been fully elucidated.
The purposes of this study were 1) to determine the indispensable AAs for
ovarian cancer (OVC) cells and 2) to investigate the relationship between the
AAs synthetase and cancer cell survival. Firstly, OVC cell lines were cultured
with different medium in which each AA was depleted and cancer cell sur-
vival was examined. Among 17 OVC cell lines, EAAs were required in 12 cell
lines, whereas others did not require EAAs for cell survival. Interestingly,
cancer cell lines which required EAA also required at least one NEAAs,
including arginine, cystine, glutamine, serine and tyrosine. Although extra-
cellular glutamine has been known to be a critical factor for cancer cell
survival and growth, 3 OVC cell lines did not require extracellular glu-
tamine. Hence, we next examined glutamine synthetase (GS) gene, which is
a critical enzyme for production of endogenous glutamine from glutamate.
In OVC cell lines which did not require extracellular glutamine, GS expres-
sion level was positively correlated with cell survival rate under glutamine-
depleted condition. Furthermore, we found that the expression of GS protein
was negative in 38 of 645 primary OV tumors (5.9 %). Taken together, these
results suggest that GS-down-regulated OVC cells require extracellular glu-
tamine for their survival. Therefore, uptake inhibition of extracellular glu-
tamine or reduction of extracellular glutamine level may be a novel thera-
peutic strategy for patients with ovarian cancer with “GS down-regulation”,
as well as development of an AA-based precision medicine of OVC.
#2498 Amine and lipid metabolites are enriched in advanced prostate
cancer. Lorelei A. Mucci,1 Ericka Ebot,1 Clary Clish,2 SarahMarkt,1 Renea Tay-
lor,3 Matthew Watt,3 Philip Kantoff,4 Edward Giovanucci,1 Matthew VAnder
Heiden,5 Kathryn Wilson1. 1Harvard School of Public Health, Boston, MA;
2Broad Institute of MIT/Harvard, Cambridge, MA; 3Monash University, Austra-
lia; 4Memorial Sloan Kettering Cancer Center, NY; 5Masachusetts Institute of
Technology, Cambridge, MA.
Background: Obesity is an established risk factor for advanced prostate can-
cer. We performed whole body metabolomics profıling in pre-diagnostic blood
specimens to identify metabolites associated with risk of advanced prostate can-
cer, and assess the extent to which obesity modifıes this association. Methods:
Our study was nested within the prospective USHealth Professionals Follow-up
Study during the study period 1993 and 2014.We selected 212 advancedprostate
cancer (
 stage T3b, distant metastasis or cancer death during follow-up) pa-
tients and 212matched controls for whom pre-diagnostic bloods were collected
with a median 5.5 years prior to diagnosis. Metabolomics profıling was per-
formed at the Broad Institute using liquid chromatography-tandemmass spec-
trometry to assay 295 known metabolites. We estimated odds ratios and 95%
confıdence intervals usingmultivariable conditional logistic regression to exam-
ine associations of individual metabolites and cancer risk. We also performed
pathway analyses using a method adapted from gene set enrichment analysis to
identify metabolite classes associated with advanced prostate cancer. Results:
We identifıed 29 circulating metabolites in pre-diagnostic bloods that were sig-
nifıcantly associated with advanced prostate cancer risk. These metabolites in-
cluded carnitines and phospholipids, diacylglycerols (DAG) and triacylglycerols
(TAG). Using pathway analyses, we found metabolites in DAG and TAG path-
ways were highly signifıcantly (FDR108) enriched in men with advanced
prostate cancer. 166 of the 295 metabolites were signifıcantly (p0.001) associ-
ated with obesity. When we stratifıed by a man’s obesity status, we observed
unique metabolomics profıles associated with advanced prostate cancer. Circu-
lating amines (including carnitines) were associated with advanced prostate
cancer in overweight men while lipid metabolites (including DAGs and TAGs)
were associated with advanced cancer in the healthy weight men. Conclusion:
Altered levels of TAGandDAGmetabolites in prediagnostic bloods are strongly
associated with an increased risk of advanced prostate cancer, independent of
obesity. The fınding that circulating lipids were specifıcally associated with ad-
vanced prostate cancer in healthy weight patients suggests there are men with
normal body mass index but who are metabolically obese. The specifıc lipid
metabolite classes enriched in advanced prostate cancer support the hypothesis
that obesity acts through dysregulation of liver fatty acidmetabolism rather than
through metabolic actions of the adipose tissue itself.
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#2499 Arginine deprivation-induced autophagy renders ASS1-defıcient
sarcomas dependent on serine metabolism. Jeff Kremer, Bethany Prudner,
Brian Van Tine.Washington University in St Louis, St. Louis, MO.
Objective: Argininosuccinate Synthetase 1 (ASS1) is silenced in 90% of
sarcomas. Upon arginine starvation, ASS1 () sarcoma cells undergo au-
tophagy and growth arrest, but not cell death. In order to identify potential
synthetic lethal targets arising from the arginine deprivation, mass spectros-
copy was performed to determine the metabolic alterations caused by short
and long term arginine deprivation resulting from treatment with pegylated
arginine deiminase (ADI-PEG20). With recent studies showing the impor-
tance of serine biology in cancer, as well as recent generation of a small
molecule inhibitor to the rate limiting enzyme in serine biosynthesis, this
newly identifıed synthetic lethality proves to be an exploitable therapeutic
option for ASS1 defıcient sarcomas. Methods: The SKLMS1 cell line was
cultured in normal culture conditions, as well as with ADI-PEG20 for three
days and subjected to metabolite extraction and capillary electrophoresis
mass spectrometry (CE-MS). Similarly, additional samples were cultured for
2 days, with or without ADI-PEG20, and subsequently treated with UC13
labeled glucose for an additional 24 hours before being subjected to metab-
olite extraction. CE-MS was performed on the samples to determine the
abundance of 54 metabolites, and all respective isotopomers. Cell death was
measured by propidium iodide fluorescent activated cell sorting after inhi-
bition of serine metabolism by the small molecule inhibitor of PHGDH
(CBR-5884) with and without ADI-PEG20. Results: Upon treatment with
ADI-PEG20, the stable isotope labeled glucose derived component of a vast
majority of metabolites decreased signifıcantly. The pathway with the largest
increase in metabolic flux was serine biosynthesis, including subsequent
conversion into glycine, rendering LTAT lines signifıcantly more susceptible
to antifolate metabolites. Signifıcant changes in the enzyme responsible for
the rate limiting step of serine biosynthesis, phosphoglycerate dehydroge-
nase (PHGDH) were observed upon short term arginine deprivation, with
further upregulation observed upon long term treatment. Cell death levels
were signifıcantly higher in samples when inhibition of PHGDH was paired
with ADI-PEG20 treatment, with LTAT lines having even further suscepti-
bility to cell death induction upon PHGDH inhibition than short term ADI-
PEG20 treated samples. Conclusion: By determining the alterations in the
fate of glucose in the SKLMS1 cell line upon short and long term treatment
with ADI-PEG20, we were able to illustrate an increase in the level of serine
biosynthesis. Inhibition of this escape pathway by inhibition of PHGDH
induced cell death. LTAT lines were the most sensitive to treatment with the
PHGDH inhibitor as well as the commonly used antifolate metabolite, meth-
otrexate.
#2500 Urinarymetabolites are diagnostic biomarkers of liver cancer.Ma-
jda Haznadar,1 Kristopher W. Krausz,1 Christopher M. Diehl,1 Elise D. Bow-
man,1 Anuradha S. Budhu,1 Jittiporn Chaisaingmongkol,2 Siritida Rabib-
hadana,2Marshonna Forgues,1 TakahiroOike,1Mathuros Ruchirawat,2 Frank J.
Gonzalez,1 Xin W. Wang,1 Curtis C. Harris1. 1National Cancer Institute,
Bethesda, MD; 2Chulabhorn Research Institute, Bangkok, Thailand.
Liver cancer is third leading cause of cancer-related deaths worldwide. A
tremendous burden of this disease is evident in that there is an estimated rise in
liver cancer incidence from 39,239 in 2016 to 95,374 by 2020. This bleak statistic
serves as a motivation to search for early diagnosis biomarkers, especially con-
sidering that the 5-year relative survival rate for people with localized disease is
30.5%, and for regional stage is only 10.7%. Hepatocellular Carcinoma (HCC)
is the most common primary malignant tumor of the liver, and is considered to
be the third leading cause of all cancer-related deaths and fıfth common cancer
worldwide. Hepatitis virus B and C infections, fatty and alcoholic liver disease
are established risk factors for developing HCC. Cholangiocarcinoma (CCA) is
the second most common primary hepatic malignancy. Liver fluke, a chronic
parasitic disease of the bile ducts, is a risk factor for developing CCA; otherwise
not enough is known about the etiology of this form of liver cancer. We initially
conducted a pilot study in the NCI-MD cohort comprising 98 HCC cases, 101
high risk subjects and 95 controls, to evaluate whether previously identifıed
urinary metabolite biomarkers of lung cancer were also predictive of liver can-
cer, given preliminary evidence that they were universally elevated in several
cancer types. Thus, we leveraged ultraperformance liquid chromatography cou-
pled to tandemmass-spectrometry (UPLC-MS/MS) for quantitation of creatine
riboside, N-acetylneuraminic acid, cortisol sulfate, and a lipid molecule desig-
nated as 561. This study resulted in fındings that all four aforementioned
metabolites are signifıcantly increased in HCC cases compared to both, popula-
tion controls and, more importantly, high risk subjects. We next evaluated
whether our previously described fındings from the NCI-MD liver case-control
study validate in the TIGER-LC cohort (n370 cases, 471 high risk subjects, 251
controls), where CCA is highly prevalent. We confırmed that indeed the four
metabolites were signifıcantly increased in HCC cases compared to both, con-
trols andhigh risk subjects inTIGER-LC.Most importantly, we also showed that
these metabolites are also deregulated in CCA, as their levels are signifıcantly
elevated in CCA cases when compared to both, controls and high risk subjects.
Furthermore, we showed in the Receiver Operating Characteristic (ROC) anal-
ysis a robust ability of the four-metabolite profıle to classify both, HCC
(AUC0.75) and CCA (AUC0.81) compared to high risk subjects. Addition-
ally, the four-metabolite profıle performed better in classifying CCA than a
clinically utilized CCA tumor marker, CA19-9, and their combination led to a
signifıcantly improved classifıer (AUC0.88, P9.4E-7). Currently, we are in-
vestigating a number of pesticides and herbicides used in the areas of Thailand
from where TIGER-LC subjects were recruited, to investigate whether these
putative carcinogens participate in the etiology of CCA.
#2501 Assessing metabolic activity of patient-derived models of non-
small cell lung cancer using stable isotope resolved metabolomics (SIRM).
Connor J. Kinslow,1 Jinlian Tan,2 Yihua Cai,2 Jun Yan,2 Richard M. Higashi,3
AndrewN. Lane,3 TeresaW. Fan3. 1Columbia University College of Physicians &
Surgeons, NEW YORK, NY; 2University of Louisville, Louisville, KY; 3University
of Kentucky, Lexington, KY.
Stable Isotope-Resolved Metabolomics (SIRM) has been a useful tool in in-
terrogating metabolic reprogramming in cancer. We have recently published
several protocols using SIRM in patient-derived models of non-small cell lung
cancer (NSCLC)1. In this case study, we compared central metabolic activity in
three different model systems, all derived from the same patient. Slices from the
human tumor (Warburg slices 2,3), slices from an NSG mouse bearing the hu-
man tumor 4, and the patient-derived cell culture were incubated in [U-13C]-
glucose or [U-13C,15N]-glutamine for 24 hours. Samples were then harvested
and analyzed by gas-chromatography-mass spectrometry and NMR. All three
models displayed similar levels of fractional enrichment after 24 hours, making
metabolic comparison possible, despite their very different 3D architectures.
Glucose metabolism in particular, showed consistent labeling patterns of me-
tabolites in glycolysis and the Krebs cycle. Glutaminemetabolism, however, was
distinct in the cell culture, with a pattern that indicated upregulation of anaple-
rotic glutaminolysis. Activation of glutaminolysis may be an important trans-
formative step in the establishment of a viable cell culture. We are also in the
process of validating the present fınding by comparing multiple patient-derived
models of NSCLC and tracking the evolution of their metabolic activity. 1 Lane,
A. N., Higashi, R. M. & Fan, T. W.-M. Preclinical models for interrogating drug
action in human cancers using Stable Isotope Resolved Metabolomics (SIRM)
Metabolomics 12, 1-15 (2016). 2 Fan, T. W.-M. et al. Distinctly perturbed met-
abolic networks underlie differential tumor tissue damages induced by immune
modulator-glucan in a two-case ex vivo non-small cell lung cancer study. CSH
Molec. Case Studies J. 2, a00083, (2016). 3 Fan, T.W.-M., Lane, A. N. &Higashi,
R. M. Stable Isotope Resolved Metabolomics Studies in ex vivo Tissue Slices.
Bio-protocol 6, e1730 (2016). 4 Lane, A. N., Yan, J. & Fan, T. W.-M. 13C Tracer
Studies of Metabolism in Mouse Tumor Xenografts. Bio-protocol 5, e1650
(2015).
#2502 Liquid diet introduction of tracers into mice for stable isotope-
resolved metabolomics (SIRM) investigations. Ramon C. Sun, Marc O. War-
moes, Ye Yang, Pan Deng, Qiushi Sun, Andrew N. Lane, Richard M. Higashi,
Teresa W-M Fan. University of Kentucky, Lexington, KY.
Tracer-based mapping of metabolic networks in vivo is a powerful approach
for revealing metabolic reprogramming in human cancer. However, current in
vivo labeling techniques for model animals face important challenges including
insuffıcient depth of pathway coverage (e.g. inability to detect labeled nucleo-
tides, proteins, and lipids) and stress-related artifacts. Here, we report stress-free
administration of 13C6-glucose via liquid diet into mice. 13C enrichment was
observed in metabolites of glycolysis, the Krebs cycle, the pentose phosphate
pathway, nucleobases, UDP-sugars, as well as macromolecules glycogen, lipids,
and proteins from major organs in NSG mice. We have applied the liquid diet
method to map the glucose metabolic networks in NSCLC tumors in a patient-
derived xenograft (PDX) model. We observed a high enrichment in the metab-
olites of glycolysis, Krebs cycle, and PPP as well as de novo synthesized nucleo-
tides and amino acids by IC-UHR-FTMS analysis. Lung PDX displayed
unexpectedmetabolic complexity, such as the use of pyruvate to fuel anaplerosis
as well as gluconeogenesis. We also found high 13C enrichment in both tumor
and plasma glutamine, which implies that glutamine in the PDX tumors largely
came fromotherorgans via theblood rather thanbeing synthesized in situ.Ourdata
showed that liquid diet is an effective and noninvasive means for comprehensive
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analysis of glucose-associated metabolic networks in human tumor xenografts,
which can also be extended to SIRM studies with other fuel sources. Acknowledge-
ments: This work was supported in part by grants: 1R01ES022191-01 (to TWMF
and RMH), 1P01CA163223-01A1 (to ANL and TWMF), and 1U24DK097215-
01A1 (to RMH, TWMF, andANL) R.C. Sunwas supported by a T32 training grant
toM. Vore (5T32ES007266-25)
#2503 Metabolomics identifıes a caveolin-1-associated plasma glycosph-
ingolipid and sphingomyelin signature that differentiates aggressive from
indolent prostate cancer in an active surveillance cohort. Johannes Fahrmann,
Jody Vykoukal, Spyridon Basourakos, Jianxiang Wang, Jennifer Dennison, Eu-
niceMurage, Jeri Kim,TimothyC.Thompson, SamirHanash.UTMDAnderson
Cancer Center, Houston, TX.
Purpose: To identify a plasma signature that can distinguish aggressive from
indolent prostate cancer in patients on active surveillance based on metabolo-
mics profıling. Introduction: The slow growth rate and low likelihood of disease
progression in low-risk prostate cancer patients have led to the widely imple-
mented active surveillance (AS) strategy. Given tumor heterogeneity, a clinical
challenge is how to expand the pool of patients eligible for AS safely. Conse-
quently, additional markers able to identify patients at increased risk of disease
progression are needed. We previously identifıed plasma caveolin-1 (CAV1) as
predictive of aggressive prostate cancer in an AS cohort. Complementary in
vitro and in vivo studies demonstrated that CAV1 mediates major reprogram-
ming of lipidmetabolism, collectively suggesting that dysregulated lipid biogen-
esis may be associated with aggressive prostate cancer. Experimental Proce-
dures: An integrated approach was utilized which included multi-assay
untargeted metabolomics to characterize alterations in the metabolome and
lipidome of conditionedmedia from prostate cancer cell lines following overex-
pression of CAV1 (LNCaP) or CAV1 siRNA knockdown (PC3M). In parallel,
sera from PBCrePTENloxp/loxp;PBCav-1 and PBCrePTENloxp/loxp;PBCav-1
micewere collected formetabolomics analysis to furtherdelineate signatures related
to CAV1-associated aggressive prostate cancer. We further conducted untar-
geted metabolomic analysis on plasma samples (n16 per group) prospectively
collected from patients with early stage prostate cancer undergoing AS who
exhibited early progression (defıned as upgrading of Gleason score (GS) and/or
increased tumor volume on surveillance biopsy within 18 months after start of
AS) or indolent disease (did not progress for a minimum of 5 years after start of
AS). Patients were matched with respect to age, clinical stage, prostate-specifıc
antigen, and GS on baseline biopsy at start of AS. We evaluated plasma samples
collected at baseline (start of AS) and after 12 months. Results: Analysis of
conditioned media identifıed a metabolomics signature with major alterations
in lipid composition highlighted by CAV1-mediated elevations in lipid-raft as-
sociated sphingomyelins and glycosphingolipids. This signaturewas observed in
patients who had early progression but not in patients with indolent disease.
Importantly, this signature was observed at baseline and at least 18months prior
to disease progression on surveillance biopsy. Conclusions:We have identifıed a
plasma-derived lipid signature that differentiates aggressive versus indolent
prostate cancer in an active surveillance cohort. Our fındings highlight the po-
tential utility of altered lipid profıles as additional risk markers for aggressive
prostate cancer.
#2504 Melatonin decreases plasma arginine, its precursors and acylcar-
nitines in breast cancer xenograft model at specifıc time point during circa-
dian rhythm. Debora Zuccari,1 Rubens Paula Junior,1 Nathália Martins Sone-
hara,1 Roger Chammas,2 Florence Raynaud3. 1Faculdade de Medicina de São
José do Rio Preto - FAMERP, São José do Rio Preto, Brazil; 2Instituto doCâncer do
Estado de São Paulo - ICESP, São Paulo, Brazil; 3The Institute of Cancer Research,
Sutton, London, United Kingdom.
The circadian rhythm regulates the whole metabolism modulating the concen-
tration of various circulating substances through the clear and dark variation. Mel-
atonin is themainmediator of this flow and breast tumors development is linked to
imbalance of this rhythm. This hormone has several anti-cancer effects extensively
proved by our group. Currentlymetabolomics analysis have been used in cancer to
provide a comprehensive profıle of the metabolic changes. Important tumor fea-
tures are regulated by amino acids likewise fatty acids metabolism. Therefore the
comprehension of specifıcmetabolic pathwaysmodulated bymelatonin is essencial
to verify its useful as adjuvant treatment. The aim of this study was to evaluate the
metabolic profıle in breast cancer xenograft model treated with melatonin and ac-
cording the circadiancycle.Wereused160 femaleBalb/cnudeathimicmicedivided
into fourgroups:Tumor /Melatonin,Tumor /Vehicle,Non-tumor /Melatoninand
Non-tumor / Vehicle. The tumor-bearing animals were developed by implantation
of 3x106 triplenegativehumanbreast cancer cells (MDA-MB-231) in themammary
fat pad. All the animals received 100 ul of solution by intraperitoneal injection (IP)
for fıve days a week during 21 days. The treated groups received 40mg/kg of mela-
tonina. Blood sample were collected every 3 hours during 24 hours (eight time
points) and the plasma was extracted for analysis by liquid chromatography-mass
spectrometry (LC-MS) using the Absolute IDQ p180 Kit (BioCrates). Orthogonal
Partial Least Squares (OPLS) analysis showed evident separation of the animals
metabolic profıle not only because the circadian cycle, but also because themelato-
nin treatment.We founda signifıcant increasing inarginineandprecursors concen-
tration in blood of the tumor-bearing animals specifıcaly at 6am and 9am. Beside
these data we also found alterations in the acylcarnitines levels. The concentrations
of medium and long-chain acylcarnitines increased signifıcantly at 3pm. Tumor-
bearing animals which have been treated with melatonin showed reduced levels of
these amino acids and acylcarnitines in blood achieving the same levels of non-
tumour bearing animals. In summary ourt work reveals a strong relationship be-
tween the metabolic profıle and the entire circadian variation as well as the exoge-
nous melatonin can regulates the metabolism. This pre-clinical trial so far
unpublished has shown an increase of arginine, its precursors and acylcarnitines at
specifıc time points in the plasma of breast tumor-bearing animals. The treatment
with melatonin is capable to deacrese the concentration of these amino acids and
acylcarnitines achievning basal levels. Our results corroborate the literature which
characterizes these metabolites as biomarkers for cancer and increasingly allow the
use of melatonin as an adjuvant therapy for breast cancer.
#2505 High-resolution MRS characterization of malignant ascites in two
models of ovarian cancer. Santosh Bharti,1 Flonne Wildes,1 Chien-Fu Hung,2
TC Wu,2 Zaver Bhujwalla,1 Marie-France Penet1. 1JHU ICMIC Program, Divi-
sion of Cancer Imaging Research, Department of Radiology, Johns Hopkins Univ.
School of Medicine, Baltimore, MD; 2Department of Pathology, Johns Hopkins
Univ. School of Medicine, Baltimore, MD.
Build-up ofmalignant ascites occurs inmore than one third of ovarian cancer
patients and signifıcantly contributes to poor quality of life and mortality. Ad-
vances in understandingmalignant ascites formation and fınding new therapeu-
tic options are urgently needed. High-resolution 1HMRS has been described as
extremely useful in detecting endogenous metabolites to diagnose cancer, by
providing a detailed overviewofmetabolic pathways in a singlemeasurement. In
the present study, we are using two ovarian cancer cell lines, the murine ID8-
VEGF-Defb29 cell line and the human OVCAR3 cell line. Implanted orthoto-
pically, these two ovarian cancer models are characterized by different profıle of
ascites formation. Themouse cell line ID8-VEGF-Defb29 induces large volumes
of ascites, often more than 10 mL, while the human OVCAR3 cell line induces
ascites less frequently and at smaller volumes, usually less than 0.2 mL. We
applied high-resolution 1HMRS to compare the metabolic composition of both
ascitic fluids. To better understand the differences observed, we characterized
the metabolism of these ovarian cancer cells in culture by analyzing cell lysates
and conditioned culture media with 1H MRS to advance our understanding of
cancer cell metabolic reprogramming in malignant ascites formation and the
role of the tumormicroenvironment in ascites formation and composition. The
two tumor models used in this study induced different ascitic profıles. While
OVCAR3 tumor bearing mice developed small viscous volume of ascites, ID8-
VEGF-Defb29 induced higher volumes. ID8-VEGF-Defb29 ascitic fluids were
characterized by higher levels of glutamine, glucose, poly-unsaturated fatty acids
and pyruvate compared to the OVCAR3 fluids, while all the other metabolites,
including glutamate, lactate, myo-inositol, choline and acetate, were lower. To
determine if the differences observed in the ascitic fluids were only due to a
different metabolism of the cancer cells, we investigated their metabolism in
vitro.We analyzed themetabolites present in the conditioned cell culturemedia,
and in the cells, and observed differences in OVCAR3 and ID8-VEGF-Defb29
cellsmetabolism in vitro, without replicating the differences observed in vitro. A
Venn diagram of the different metabolites present in the cells, media and ascites
showed differences in the metabolites present in those 3 compartments, and
highlighted the ones in common. Beta-hydroxybutyrate, lipids, maleic and ci-
trate were found in both ascites, and not in the cells or media. Ascites MRS
derived biomarkers could help in ovarian cancer diagnosis, and enhance our
understanding of the biochemical and metabolic changes associated with ovar-
ian cancer, and with ascites formation. Supported by Tina’s Wish Foundation,
NIH P50CA013175 and P30CA06973.
#2506 Untargeted and targeted multiplatform metabolomic and lipido-
mic approaches for monitoring biological effects in serum from total body
irradiated humans.Evagelia C. Laiakis,1 Evan L. Pannkuk,1 SiddheshwarChau-
the,1 Yi-Wen Wang,1 Ming Lian,2 Tytus D. Mak,3 Christopher A. Barker,2 Gi-
useppe Astarita,1 Albert J. Fornace1. 1Georgetown University, Washington, DC;
2Memorial Sloan Kettering Cancer Center, New York, NY; 3National Institute of
Standards and Technology, Gaithersburg, MD.
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Investigation of responses to radiation therapy or exposure to radiation in an
intentional or accidental manner have identifıed signifıcant biomarkers for bio-
dosimetry and monitoring of individuals in urine through metabolomics (1).
We extend the investigation in serum by combining targeted and untargeted
methodologies with a multiplatform approach. Serum was collected from pa-
tients exposed to total body irradiation (TBI) prior to hematopoietic stem cell
transplantation at Memorial Sloan Kettering Cancer Center. The underlying
diseases (chronic myelogenous leukemia, acute lymphocytic leukemia, acute
myeloid leukemia, non-Hodgkin lymphoma, or myelodysplastic syndrome)
were in remission and the cohort included both males and females. Serum was
collected prior to irradiation, at 3-8 h after a single dose of 1.25 Gy, and at 24h
after three fractions of 1.25 Gy each. Untargeted metabolomic and lipidomic
approaches with liquid chromatography (LC) mass spectrometry (MS) and gas
chromatography (GC) MS demonstrated signifıcant perturbations at the later
time point and higher total dose. Alterations in circulating levels were observed
in lipids from monoacylglycerol, triacylglycerol, phosphatidylcholine, phos-
phatidylglycerol, phosphatidylserine, and phosphatidic acid lipid classes. Fatty
acids were some of the most dysregulated lipids, with increased levels linked to
pro-inflammatory processes. To further investigate the presence of low abun-
dance pro-inflammatory metabolites, we utilized a targeted and highly quanti-
tative approach measuring downstream molecules from fatty acids, such as
thromboxanes, prostaglandins, and leukotrienes that can act as signaling mole-
cules and mediators of systemic inflammation. Results identifıed a rapid re-
sponse within the fırst 3-8 hours primarily mediated through the enzymatic
action of lipoxygenase (LOX) and cytochrome P450 (CYP450), although some
dissipated at the later timepoint. Less signifıcant alterationswere observed in the
anti-inflammatory pathway, although the fatty acid precursor -linolenic acid
remained elevated in both time points. Finally, as observed in our previous
published study of a similar cohort (1), sex-dependent differences were analyzed
and unlike the urinary results, females appeared to be more responsive to radi-
ation effects as measured in serum with lipidomics and metabolomics. No sex
differences were observedwith the targeted approach. The ability to identify and
quantify small molecules in blood following radiation exposure can therefore be
utilized to not onlymonitor systemic effects of radiotherapy but also to generate
signatures that can be utilized to identify accidentally exposed individuals that
may require medical intervention. 1. Laiakis EC et al. Radiat Res 2014; 181:
350-361.
#2507 Using 1H NMRmetabolomics to study breast cancer and endothe-
lial cell metabolic interactions. Suehelay Acevedo-Acevedo, Sean P. Palecek.
University of Wisconsin-Madison, Madison, WI.
Breast cancer is the secondmost commonly diagnosed cancer among women
worldwide. Patient death is typically caused by metastasis development rather
than the primary tumor.Metastasis in breast cancer has been shown to occur via
blood and lymphatic vessels. Research shows that breast cancer cells ‘educate’
lymphatic and blood endothelial cells to support tumor growth by stimulating
growth factor secretion; specifıcally VEGF, PDGF-BB and EGF secretion. In
addition, cell metabolism is altered during malignant transformation. Cancer
cells have increased energy and macromolecule biosynthesis requirements to
sustain rapid proliferation. Increased angiogenesis observed in tumors points to
a need for an increased nutrient supply. However, it remains unclear how tumor
endothelial cell metabolism is altered and how metabolism regulates tumor an-
giogenesis. Therefore, this study aims to use 1HNMRmetabolomics to identify
breast cancer-endothelial cell metabolic interactions in a high-throughputman-
ner. Firstly, we studied if in vitro co-culture with breast cancer altered endothe-
lial cell metabolism. We identifıed distinct metabolic profıles for HUVECs
grown inmonoculture or co-culture with three different breast cancer cell lines.
Metabolism of HUVECs co-cultured with MCF7 and SKBR3 breast cancer cell
lines was signifıcantly altered compared to mono-culture control. The most
impacted metabolic pathways by co-culture were amino acid metabolism, en-
ergy metabolism and lipid biosynthesis pathways. Culturing HUVECs with
MDA-MB-231 triple negative breast cancer cells did not have a signifıcant im-
pact on HUVEC metabolism, however. Together, these results indicate that
culturingHUVECs with certain breast cancer lines causes signifıcant changes in
endothelial metabolism. Alterations in endothelial cell metabolism in response
to breast cancer co-culture can further our understanding of tumor-vascular
interactions andmay lead to identifıcation ofmetabolic biomarkers or therapeu-
tic targets that can disrupt tumor angiogenesis.
#2508 Profıling the metabolic effects of AGI-5198 treatment on IDH1-
mutated gliomas. Victor Ruiz Rodado, Adrian Lita, Tyrone Dowdy, Mark R.
Gilbert, Mioara Larion. National Institutes of Health, Bethesda, MD.
Background: AGI-5198 (a specifıc IDH1mut inhibitor) inhibits the formation
of D-2-hydroxyglutarate (D-2HG) typically produced in millimolar quantities
by the R132H mutation of isocitrate dehydrogenase I (IDH1). AGI-5198 was
found to delay growth, to promote differentiation in cells and to decrease tumor
volume in IDH1-mutant (IDH1mut) mice xenographs, and as a result, has been
advanced to clinical trials in humans with IDH1mut glioblastomas. However, no
metabolic study of this drug has been reported to date. Here, we investigated the
metabolic changes induced by AGI-5198 treatment in order to determine if the
drug restores the normal metabolic status once D-2HG concentration is de-
creased. Methods: We treated glioma cells carrying an IDH1 mutation with 10
M AGI-5198 for 72 h. Metabolic changes were explored using an untargeted
metabolomics approach. Cell viability analysis verifıed that the concentration of
drug does not lead to signifıcant cell death. NMR andMS-linked metabolomics
together with in vivo cell imaging using RAMAN were used. Principal compo-
nent analysis was employed to explore the differences in the metabolic profıles
comparing treated and untreated glioma cells. Results and Conclusions: We
confırmed that AGI5198 treatment reducedD-2HG levels in the cell lines inves-
tigated, validating previous reports. Moreover, we observed a decrease in phos-
pholipid levels upon AGI-5198 treatment, which suggests a decreased prolifer-
ative potential for these cells; of particular importance for clinical application.
Our preliminary analysis also suggests that metabolites involved in one carbon
metabolism are altered upon AGI-5198 treatment. This pathway provides the
methyl group for the DNAmethylation by DNAmethylases producing a hyper-
methylated phenotype. Our fındings suggest that combining the AGI-5198
treatment with a DNA methylase inhibitor may improve outcomes in IDH1-
mutated gliomas.
#2509 High-resolution 1H<MRS>human plasma profıling of pancreatic
ductal adenocarcinoma. Santosh K. Bharti, Michael Goggins, Zaver M. Bhu-
jwalla. The Johns Hopkins University School of Medicine, Baltimore, MD.
Early detection of pancreatic ductal carcinoma (PDAC) is critically important
because by the time PDAC is detected almost 80% of patients are surgically
unresectable1. While imaging with CT, MRI and ultrasound is making signifı-
cant inroads in PDAC detection, the costs associated with imaging impose a
barrier for routine screening. Plasma based detection of PDACwould provide a
relatively inexpensive and easy method for routine screening for the purpose of
early detection. Metabolic profıling of plasma samples using high resolution 1H
MRS provides an opportunity to assist in the detection of PDAC. Here we char-
acterized the plasma metabolome of normal subjects, subjects with benign pan-
creatic disease, and subjects with PDAC to evaluate the ability of 1H MRS to
identify metabolic changes in plasma associated with PDAC. Plasma from pa-
tients with PDAC (n4), patients with benign pancreatic disease (n2) and
from healthy control subjects (n4) were included in this study. Final diagnosis
was established by histopathological evaluation of surgical specimens. Three
hundred micro liter of D2O phosphate buffer saline (NaCl 0.9% in 90% D2O)
was mixed with 300 L of plasma and transferred to 5 mm NMR tubes. High-
resolution 1H MRS was performed on an Avance 750 MHz Bruker MR spec-
trometer. The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence with water
suppression [PRESET-90°-(d-180-d)n-Aq] was performed to remove short T2
components arising due to the presence of macromolecules2. The metabolites
were identifıed and quantifıed from 1HMRS spectra from the three groups. Even
with a small sample size clear differences were identifıed in metabolites such as
lactate, pyruvate, -hydroxybutyrate, acetate and acetoacetate in plasma from
PDAC subjects compared to normal subjects. The increase of lactate and pyru-
vate detected in plasma may reflect altered glucose metabolism occurring in
PDAC.-hydroxybutyrate, acetate and acetoacetate are involved in ketone body
synthesis and may reflect altered ketone body metabolism occurring in PDAC.
In a recent study, higher levels of ketone bodies and lactate were detected in the
serum of rats with 7,12-dimethylben(a)anthracen (DMBA)-induced pancreatic
intraepithelial neoplasia (PanIN) compared to plasma. Interestingly, with pro-
gression to PDAC several of these metabolites decreased3. Our data support
further investigation of 1HMRS of human plasma to detect PDAC in combina-
tion with techniques such as circulating tumor cell phenotyping References: (1)
Kotteas, E., et al. J Cancer Res Clin Oncol 2016, 142, 1795-1805. (2) Van, Q. N.,
et al. Biochem Biophys Res Commun 2003, 301, 952-959. (3) Lin, X., et al. Mol
Biosyst 2016, 12, 2883-2892. This work was supported by NIH R01 CA193365.
#2510 Interrogating liver metabolic stress due to cancer-induced ca-
chexia. SantoshK. Bharti,1 Paul T.Winnard,1 YelenaMironchik,1 AnirbanMai-
tra,2 Zaver M. Bhujwalla1. 1The Johns Hopkins University School of Medicine,
Baltimore, MD; 2The Uuniversity of Texas MD Anderson Cancer Center, Dallas,
TX.
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Cancer-induced cachexia accounts for approximately 20% of all cancer
deaths1. In pancreatic cancer, the syndrome affects nearly 80% of patients2,3.
Cachectic patients experience a wide range of symptoms affecting the function
of several organs such as muscle, liver, brain, and heart, that decrease quality of
life and worsen prognosis. A major characteristic of cachexia is the accelerated
skeletal muscle and fat storage wasting causing nutrient mobilization both di-
rectly as lipid and amino acids, and indirectly as glucose derived from the ex-
ploitation of liver gluconeogenesis that reaches the tumor through the blood-
stream4. Patients with cachexia develop a wide range of metabolic stress from
increased proteins and fat tissue burning resulting in increased energy expendi-
ture. Here, for the fırst time, we have performed high-resolution quantitative 1H
magnetic resonance spectroscopy (MRS) of liver tissue obtained from normal,
noncachectic and cachectic mice bearing PDAC that are cachectic (Pa04C) and
noncachectic (Panc1). A signifıcant reduction in liver weight and signifıcant
changes in 1H MRS derived metabolite profıles were detected with cachexia.
Human pancreatic cancer cell lines, Panc1 and Pa04C, were used for the study.
Six to 8 week old male severe combined immunodefıcient mice were inoculated
in the right flank with cancer cells (5106) and in the right hind leg muscle with
reporter myoblasts (2106) to monitor the development of cachexia in mice5.
Live animal optical imaging was done using a Xenogen IVIS® Spectrum
(PerkinElmer) optical scanner. Dual phase solvent extraction was performed on
liver tissue to extract water solublemetabolites. All 1HMR spectrawere acquired
on anAvance 750MHz Bruker NMR spectrometer.We found, for the fırst time,
that the liver in Pa04C tumor bearing mice underwent a profound weight loss;
although Panc1 tumor bearing mice showed some liver weight loss this was not
as profound as observed with Pa04C tumors. Signifıcant decreases in lactate,
glucose and glutathione were observed in cachectic mouse liver compared to
noncachectic mouse liver, and the liver from healthy control mice. The signifı-
cant decrease of these metabolites in cachectic livers may reflect increased utili-
zation of glucose, lactate and glutathione by the tumor or other organs during
the cachexia cascade4. These results provide new insights into changes in liver
metabolism during cachexia, and support investigating metabolic strategies
such as supplementing glutathione or glucose to reduce cachexia associated
morbidity. References: (1) Argiles, J. M., et al. Nature reviews. Cancer 2014, 14,
754-762. (2) Fearon, K. C., et al. HPB (Oxford) 2010, 12, 323-324. (3) Ozola
Zalite, I., et al. Pancreatology 2015, 15, 19-24. (4) Porporato, P. E. Oncogenesis
2016, 5, e200. (5)Winnard, P. T., et al. Cancer Research 2015. Acknowledgment:
This work was supported by NIH R01 CA193365. We thank Dr. Marie-France
Penet for useful discussions.
#2511 The role of lipids metabolism in bladder cancer. Gang Wang, Rui
Cao, Qiangqiang Ge, Yu Xiao, Xinghuan Wang. Zhongnan Hospital of Wuhan
Univesity, Wuhan, China.
Bladder cancer (BCa) is one of the most common malignancy of the urinary
tract. Many risk factors for BCa has been demonstrated, including aging, smok-
ing, exposure to chemicals, dietary total cholesterol intake, dietary fatty acids
intake, etc. In order to investigate the role of lipidsmetabolism in bladder cancer,
we collected several human BCa tissues and normal bladder tissues to generate
an affected pathway network by microarray analysis, and it revealed that glyc-
erolipid metabolism, fatty acid degradation and fatty acid biosynthesis have a
close correlation with bladder cancer. Therefore, Simvastatin, one of the 3-hy-
droxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, have
been well-known regarding its effects on rate-limiting step in cholesterol syn-
thesis, was used to treat with BCa cells. We observed that simvastatin could
reduce BCa cell proliferation, induce cell cycle arrest at G0/G1 phase and inhibit
cell metastasis. Then, the potential alterations of lipids metabolism in bladder
cancer cells after simvastatin treatment was investigate by lipidomics analysis.
These foundings demonstrate that lipids metabolism plays important role in
bladder cancer and some lipids or related enzymes may be the novel targets for
bladder cancer treatment.
#2513 Multi-omics-based approach to colorectal cancer metabolism. Ki-
yotoshi Satoh, Tomoyoshi Soga. Institute for Advanced Biosciences, Keio Univer-
sity, Tsuruoka, Japan.
Cancer cells exhibit manymetabolic alterations to acquire energy and cellular
components required for their proliferation and thus, cancer specifıc metabolic
pathways are attractive targets for cancer therapy. However, the regulation
mechanisms underlying metabolic reprogramming are poorly understood.
Here, we performed multi-omics-based analyses of paired normal and tumor
tissues from patients with colorectal cancer (CRC) to understand the regulation
mechanisms of metabolism in colorectal cancer. First, we carried out capillary
electrophoresis time-of-flight mass spectrometry (CE-TOFMS)-based metabo-
lomeprofıling of tumor andnormal tissue obtained from275 patientswithCRC.
S-adenosylmethionine (SAM), a principal methyl group donor produced by
one-carbon metabolism, was the most increased metabolite in tumor tissue.
Glucose was the second most decreased metabolite in tumor tissue, whereas
lactate was accumulated, indicating activation of glycolysis, commonly known
as theWarburg effect. Every amino acid except glutamine, the starting metabo-
lite in glutaminolysis, was signifıcantly accumulated in tumor tissue. Interest-
ingly, most of the changes in metabolite levels were occurred in the adenoma
stage. In addition, next-generation and Sanger sequencing analyses of genomic
DNA obtained from tumor tissue revealed that metabolic alterations occurred
independently of mutations in oncogenes and tumor suppressor genes, such as
KRAS, APC, and TP53. Furthermore, DNA microarray analysis of paired nor-
mal and tumor tissues fromCRC patients demonstrated that expression profıles
of many metabolic genes were also altered at the adenoma stage. Most of genes
regulating purine/pyrimidine synthesis, one-carbon metabolism and fatty acid
synthesis were highly expressed, whereas those in fatty acid oxidation were
down-regulated in tumor tissue. We will discuss the raised questions, which
molecules contribute to the regulation of metabolic reprogramming of colorec-
tal cancer metabolism.
#2514 Tetra-O-methyl nordihydroguaiaretic acid (M4N) broadly sup-
presses cancer metabolism and synergistically induces strong anticancer ac-
tivity in combination with etoposide, rapamycin and UCN-01. Kotohiko
Kimura, Ru Chih C. Huang. Johns Hopkins Univ., Baltimore, MD.
The ability of Tetra-O-methyl nordihydroguaiaretic acid (M4N) to induce
rapid cell death in combination with Etoposide, Rapamycin, or UCN-01 was
examined in LNCaP cells, both in cell culture and animal experiments. Mice
treated with M4N drug combinations with either Etoposide or Rapamycin
showed no evidence of tumor and had a 100% survival rate 100 days after tumor
implantation. By comparison all other vehicles or single drug treatedmice failed
to survive longer than 30 days after implantation. This synergistic improvement
of anticancer effect was also confırmed in more than 20 cancer cell lines. In
LNCaP cells, M4N was found to reduce cellular ATP content, and suppress
NDUFS1 expression while inducing hyperpolarization of mitochondrial mem-
brane potential. M4N-treated cells lacked autophagy with reduced expression of
BNIP3 and ATG5. To understand the mechanisms of this anticancer activity of
M4N, the effect of this drug on three cancer cell lines (LNCaP, AsPC-1, and L428
cells) was further examined via transcriptome and metabolomics analyses.
Metabolomic results showed that there were reductions of 26metabolites essen-
tial for energy generation and/or production of cellular components in common
with these three cell lines following 8 hours of M4N treatment. For instance,
among the amino acids, the content of aspartate, a key metabolite in electron
transport system in themitochondria, was specifıcally suppressed byM4N.Deep
RNA sequencing analysis demonstrated that there were sixteen genes whose
expressions were found to be modulated following 6 hours of M4N treatment
similarly in these three cell lines. Six out of these 16 genes were functionally
related to the 26 metabolites described above. One of these up-regulated genes
encodes for CHAC1, a key enzyme affecting the stress pathways through its
degradation of glutathione. In fact M4Nwas found to suppress glutathione con-
tent and induce reactive oxygen species production. The data overall indicate
that M4N has profound specifıc negative impacts on a wide range of cancer
metabolisms supporting the use of M4N combination for cancer treatments.
#2515 Understanding metabolic dysfunction in retinoblastoma develop-
ment. Nilanjan Guha,1 Carolina Livi,2 Vishnu Suresh Babu,3 Lisa Winer,2
Deepak SA,1 Syed Lateef,1 Seetaraman Gundimeda,1 Arunkumar Padmanab-
han,1 Brian Dranka,2 Arkasubhra Ghosh3. 1Agilent Technologies, Bangalore, In-
dia; 2Agilent Technologies, Santa Clara, CA; 3Narayana Nethralaya, India.
Metabolic dysfunction or reprogramming is the underlying cause of many
diseases including cancer. In this study, we looked into the transcriptomic and
metabolomic profıle of retinoblastoma (Rb), a pediatric eye cancer, from tumor
and normal tissue, aqueous humor, vitreous humor and tear. The samples were
collected from enucleated eyes of 9 subjects and 2 deceased controls, whose
cause of death is not due to any eye related disease. The study was corroborated
with cell line models of retinoblastoma, used for metabolic phenotyping. Com-
bined pathway analysis of transcriptomics data from subject tissue samples and
retinoblastoma cell line WERI-Rb-1 revealed a signifıcant overlap in the differ-
entially regulated genes belonging to both glycolysis and OXPHOS pathways.
The results were correlated with Rb1 overexpressed and its respective control
also. To better understand the implications of these two major pathways in the
progression of retinoblastoma, metabolic study using Seahorse analyzer enables
measurement of extracellular flux (oxygen consumption rate and extracellular
acidifıcation rate) to provide insight into mitochondrial function and glycolytic
activity. Using a pharmacological approach, the contribution of glucose, glu-
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tamine and fatty acid oxidation pathways can be assessed. Overall the study
demonstrates the value of using a multi-omics approach with functional meta-
bolic profıling to understand the extent of metabolic dysfunction in retinoblas-
toma and also to identify implications of various biological pathways in Rb.
#2516 Pokemon functions as ametabolic oncoprotein integrating glucose
& lipid metabolism in hepatocellular carcinoma. Yibao Jin,1 Shangfu Li,2 De-
liang Cao,3 Dan Gao,2 Hongxia Liu,2 Feng Liu,2 Tiejie Wang,1 Yuyang Jiang4.
1Shenzhen Institute for Drug Control, Shenzhen, China; 2The State Key Labora-
tory Breeding Base-ShenzhenKey Laboratory of Chemical Biology, TsinghuaUni-
versity, Shenzhen, China; 3Southern Illinois University School of Medicine,
Springfıeld, IL; 4Department of Pharmacology and Pharmaceutical Sciences,
School of Medicine, Tsinghua University, Shenzhen, China.
Pokemon (also known as FBI-1 or LRF) is a proto-oncogene encoded by
ZBTB7A gene. It functions as a transcription factor, playing important roles in
embryonic development, cell differentiation and neoplasia. Pokemon is abnor-
mally expressed in hepatocellular carcinoma (HCC) and may contribute to the
metabolic homeostasis of HCC cells, but the mechanism of action remains to be
fully understood. This study demonstrated that Pokemon may integrate glyco-
lysis and lipid metabolism in hepatocellular carcinogenesis. Our data showed
that Pokemon was upregulated in HCC cell lines and clinical samples. Ectopic
expression of Pokemon stimulatedHCC cell growth and proliferation in culture
and tumorigenesis in nude mice. Lipid metabolomic analysis by LC/MS exhib-
ited that in HCC cells lipogenesis was positively correlated with Pokemon ex-
pression levels, and targeted expression of Pokemon in HCC cells promoted the
flux of radiolabeled glucose to lipids, including membrane phospholipids,
through the aerobic glycolysis-acetyl-CoAmetabolic stream. Mechanistic stud-
ies revealed that Pokemon stimulated glycolysis through activation of PKA and
its mediated Raf/c-Myc pathway. In the tested HCC cells, Pokemon activated
fatty acid synthase (FASN) and suppressed AMPK, an inhibitor of acetyl-CoA
carboxylase  (ACC-), stimulating fatty acid and lipid synthesis. Together our
results suggest that Pokemon correlates glycolysis and lipid synthesis and thus
promotes lipogenesis and hepatocellular tumorigenesis.
#2517 Prognostic biomarkers of PDAC - a cross-validation study. Hung-
JenWu,1 Smrithi S.Menon,1 KeithUnger,2Massimo S. Fiandaca,3 Yassi Fallah,1
Mark Mapstone,3 Howard J. Federoff,3 Amrita K. Cheema1. 1Georgetown Uni-
versity, Washington, DC; 2Med-Star Georgetown University Hospital, Washing-
ton, DC; 3UCI, Irvine, CA.
Introduction: Pancreatic ductal adenocarcinoma (PDAC) represents 90% of
pancreatic neoplasms and the fourth leading cause of cancer death in theUnited
States. Recently, several research groups have focused on conducting metabolo-
mics based clinical investigations to identifymetabolitemarkers of PDAC. Since
a central biomarker repository for PA is lacking, however, it remains challenging
to delineate the total number of metabolites reported, and importantly, which
bio-signatures overlap between the disparate studies. Approach: We performed
an extensive literature search to delineate PDAC case-control studies reporting
dysregulated metabolite biomarkers for PDAC utilizing three main sources:
PubMed, EDRN and GDOC. We refıned our search to 36 publications that
reported blood based metabolomics/lipidomic biomarkers. Data from these
studies was compiled based on up/down-regulation of specifıc metabolites in
PDAC, study sample size, and other clinical determinants. The fınal list con-
sisted of 12 metabolites (including amino acids, fatty acids and small organic
acids), that were reported by two ormore research groups as being dysregulated
in PDAC. Of note, these 36 disparate studies were carried out using different
methodologies, analyzed on diverse analytical platforms, and utilized different
statistical and bioinformatics methodologies. Resultant common features,
therefore, were deemed signifıcant as candidate biomarkers for cross-validation.
Next, we used stable isotope dilution multiple-reaction monitoring mass spec-
trometry (SID-MRM-MS) for targeted quantitation of these 12 metabolite
markers in plasma samples obtained from patients that were diagnosed with
PDACand compared the same profıles tomatched normal controls. Results:We
delineated of a sub-set of the original 12 metabolites that showed concordance
with those reported in the literature. Statistical analyses to determine the sensi-
tivity and specifıcity of the resultant panel, and any influence provided by age,
gender, and type 2 diabetes, on the predictive performance of the biomarker
panel are ongoing. These data will be presented at the AACR meeting. Conclu-
sion: Developing a specifıc and sensitive panel of blood-derived biomarkers
offers a practical approach towards screening and allows increasing overall sur-
vival rates for PDAC with early diagnosis. Such disease-specifıc bio-signatures
allow identifıcation of molecular targets for therapeutic development; improve
early treatment strategies and thereby clinical outcomes. Creating a compen-
dium of existing biomarker data and performing cross-validation studies repre-
sent the fırst steps for developing clinical assays for the diagnosis and prognosis
determination of PDAC. The integration of data generated from multiple ana-
lytic platforms and diverse subject cohorts is likely to help identify robust bio-
signatures that would then be ready for large scale validation studies. Supported
by American Cancer Society
#2518 Accumulation of a liver- and microbiome-derived metabolite in
human breast tumors is associated with patient survival.Wei Tang,1 Tiffany
Dorsey,1 Vasanta Putluri,2 Nagireddy Putluri,2 Stefan Ambs1. 1NCI-CCR,
Bethesda, MD; 2Baylor College of Medicine, Houston, TX.
Breast cancer is the most common cancer in women in the United States.
Gene expression profıling studies of breast tumors led to the discovery of disease
subtypes with different biologies. These studies also described novel biomarkers
for therapy response and disease survival. However, it remains a challenge to
defıne breast cancer biology solely based on gene expression. Recently, metabo-
lomics emerged as a new discovery tool with the promise of identifying prog-
nostic biomarkers and targetable metabolic dependencies of cancer cells. We
previously measured the abundance of 536 metabolites in 67 breast tumor and
their tumor adjacent noncancerous tissue by untargeted mass spectrometry. In
the current study, we explored the prognostic power of the metabolome and
conducted an integrated analysis comprising of themetabolome, transcriptome,
and proteome to explore the association of metabolites with cell systems, tumor
biology, and disease outcome. We built a predictive model based on multivari-
able Cox proportional hazards using the L1 penalized log partial likelihood
(LASSO) method after pre-selecting prognostic metabolites following cross-
validation with 1000 iterations. The median C-index was 0.73, indicating a cer-
tain robustness of metabolites as classifıers of breast cancer outcome. The mod-
els identifıed fıve metabolites including a bile acid-related metabolite,
glycochenodeoxycholate (GCDC), as the most frequently selected features and
outcomemarkers among thesemetabolites. An increasedGCDC tumor content
was associated with improved patient survival.We corroborated the presence of
GCDC and three other bile acids in the human breast tissues using absolute
measurements and confırmed their occurrence in breast tumors. Because addi-
tional large-scale transcriptome and proteome data were available for the same
tissue samples, we further characterized the tumors based on their GCDC abun-
dance, which showed that cell cycle-related pathways were enriched for differ-
ently expressed genes and tumors with a high GCDC content tended to have a
low cell proliferation score, indicating that accumulation of GCDC leads to
growth inhibition.We also conducted a correlation analysis for the relationship
betweenGCDC abundance with othermetabolites and identifıed 51metabolites
that were signifıcantly correlated with GCDC. In this analysis, metabolite abun-
dance in the sterol/steroid pathway associated most strongly with the GCDC
tissue content. Lastly, we evaluated the effect of bile acids on breast cancer cell
lines. The data showed a strong reduction of cancer cell proliferation under bile
acid treatment, consistent with the tumor data, and distinct changes in gene
expression. In conclusion,we propose that integratedmetabolomics canprovide
powerful prognostic information with GCDC being a novel prognostic marker
in breast cancer because accumulation of GCDC reduces cancer cell prolifera-
tion.
#2519 Analysis of gene expression patterns and metabolomics correlated
to obesity, diabetes, and outcomes in patients with epithelial ovarian cancer.
AllisonM.Montgomery,1 Angelina I. Londono,1 Eric R. Craig,1 Cindy Tawfık,1
Haller J. Smith,1 Charles A. Leath,1 Ashwini A. Katre,1 Sara J. Cooper,2 Rebecca
C. Arend1. 1University of Alabama at Birmingham, Birmingham, AL; 2Hudson-
Alpha Institute for Biotechnology, Huntsville, AL.
Objective: Diabetes and obesity have been associated with a poor prognosis in
ovarian cancer (OVCA); the exact mechanism has yet to be determined. Data
suggests that obesity diminishes normal immunological response and better
prognoses in non-obese patients may be attributable to an intact immune re-
sponse. The objective of this study was to analyze the correlation between gene
expression pattern/metabolomics and obesity/diabetes in OVCA patients..
Methods: Following IRB approval, UAB patients with suspected OVCA under-
going surgerywere consented. Tissuewas collected during cytoreduction and 35
samples were analyzed using RNAseq technology andmass spectrometry-based
metabolomics. DESeq2 was used for RNAseq analysis to identify gene expres-
sion differences between diabetics and non-diabetics stratifıed by BMI: obese
(BMI
30) and non-obese (BMI30). Gene set enrichment analysis was con-
ducted to determinewhether there was an over-representation of immune path-
ways among altered genes. Profıles were normalized in the analysis of the me-
tabolite profıles using ChromaTOF. Results: 76 genes (p-value 0.05) were
differentially expressed in the tumor samples from patients with BMI 
30 to
those30. These genes were highly enriched for immune-related genes, includ-
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ing 34 immunoglobulin genes, and complement activation. The list of identifıed
genes also included 3HLA genes (HLA-G(down),HLA-H(up) andHLA-DMA-
(down). Furthermore, when analyzing tumor from diabetics (n7), there were
18 genes differentially expressed compared to controls. These genes are not
statistically enriched for any functional class. Additionally, genes associatedwith
response to platinum-based therapy, differentiating patients with BMI
30 v.
30 were analyzed. No genes met genome-wide signifıcance; however, there
were 14 genes with a genome-wide p-value0.1. When diabetes status as a
covariate was controlled for, this number was reduced to 9. Conclusion: By
evaluating the transcriptomic profıles generated through RNAseq analysis, a
signifıcant number of differences in RNA expression were identifıed in compar-
ing obese to non-obese OVCA patients. Due to the small sample size, no genes
were identied as being associated with the presence or absence of diabetes.
#2520 Differential metabolite requirements in breast cancer cells corre-
late with ER/PR status and doubling time. Vijesh J. Bhute, Kylie R. Knutson,
Yan Ma, Sean P. Palecek. University of Wisconsin-Madison, Madison, WI.
Metabolism in cancer cells is signifıcantly altered as compared to their normal
counterparts. Metabolic rewiring can assist cancer cells to meet their require-
ments for uncontrolled proliferation and survival. In addition to their role in
protein synthesis and energy generation, metabolites also act as signaling mol-
ecules, antioxidants and perform osmoregulatory functions. Differences in ge-
netic makeup and phenotype of cells can lead to differences in these metabolic
needs. A detailed analysis of metabolic signatures of different cancer cells can
therefore prove useful in understanding metabolic interactions with the pheno-
type in cancer cells. This study aims at identifying these metabolic differences
among distinct breast cancer cell lines and gaining mechanistic insights into
possible reasons for differential abundance of metabolites. We used nuclear
magnetic resonance (NMR) spectroscopy to quantify intracellular metabolites
in fıve breast cancer cell lines having distinct genetic and phenotypic composi-
tion.We show that the intracellular abundance of essential amino acids depends
on cell type and medium composition. We also show that myo-inositol abun-
dance was signifıcantly higher in ER-/PR- than ER/PR breast cancer cells
due to increased expression of inositol-3-phosphate synthase 1 expression.
Myo-inositol is an osmolyte and also a precursor of inositol phosphates which
participate in PI3K and calcium signaling pathways. Although the reason ER-/
PR- cells contain greater concentrations of myo-inositol than ER/PR cells is
not yet known, increased myo-inositol abundance could potentially serve as a
marker of ER-/PR- breast cancer cells. We also observed signifıcant changes in
phospholipid metabolism, specifıcally, glycerophosohocholine (GPC) concen-
tration correlated with doubling time. We also found that reducing serum con-
centration in the growth medium reduced the growth rate of MCF7 cells, which
led to increased GPC abundance in the cells. GPC is also an intracellular os-
molyte and is a degradation product of phosphatidylcholine (PtdCho). Phos-
pholipid metabolism has been shown to be signifıcantly altered in breast cancer
cells and has been used as prognostic marker in breast cancer cells. A positive
correlation of doubling time with GPC irrespective of ER/PR status may prove
useful in deciding therapeutic options. Our results highlight the differences in
metabolic requirements in different breast cancer cell lines and suggest potential
for gainingmechanistic understanding of these differences usingmetabolomics.
#2521 Inhibition of metabolic reprogramming by zerumbone alters the
tumorigenic potential of hepatocellular cancer. Nissar A. Wani, Bo Zhang,
Kun-yu Teng, Juan Barajas, Kalpana Ghoshal, Rafael Brüschweiler, Samson T.
Jacob. Ohio State Univ., Columbus, OH.
Incidenceofhepatocellular carcinoma(HCC) that represents90%ofall casesof
primary liver cancer is on the rise worldwide. Sorafenib, the only approved targeted
therapy, prolongsmedian survival only by3months. Thus, new therapeutic strat-
egies are urgently needed. In this study, we investigated therapeutic potential of
zerumbone, a sesquiterpene fromanedible ginger, againstHCC.Zerumbone inhib-
ited proliferation and clonogenic survival of HCC cells by blocking glycolysis and
pentose phosphate pathway, arresting cells atG2/Mphase of cell cycle and inducing
apoptosis. To uncover the underlyingmolecular mechanisms of its action onHCC
cells, we employed several unbiased approaches. First, phosphokinase array showed
signifıcant inhibition PI3K/AKT/mTOR and STAT3 signaling in zerumbone-
treated HCC cells. Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway
Analysis (IPA) of the microarray data revealed that zerumbone-deregulated genes
showed positive correlationwith PI3/AKT/mTOR and STAT3 pathways and those
involved in metabolism, apoptosis and cell cycle. Notably, the alteration in expres-
sionofgenes regulatedbyPI3/AKT/mTORorSTAT3pathwaysanddownregulated
by zerumbone in HCCs is associated with poor patient survival. These results im-
plicate that treatmentwith this dietary sesquiterpenemight lead to a better outcome
in HCC patients. Indeed, zerumbone treatment signifıcantly inhibited growth and
lung metastasis of orthotopic HCC xenografts in NSG mice. These fındings reveal
novel therapeutic strategies targeting cancer metabolism. Collectively, these obser-
vations underscore the therapeutic potential of zerumbone in HCC.
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#2522 MiRNA-652 induces neuroendocrine-like differentiation in LN-
CaP prostate cancer cells through decreased PP2A function. Tania Benatar,
Yutaka Amemiya, Christopher J. Wallis, Linda Sugar, Christopher Sherman,
Robert Nam, Arun K. Seth. Sunnybrook Research Institute, Toronto, Ontario,
Canada.
Background: MicroRNA (miRNA) dysregulation has been shown to contrib-
ute to prostate cancer progression. Recently, we identifıed a panel of fıve miR-
NAs associated with prostate cancer recurrence and metastasis using next gen-
eration miRNA sequencing. Here, we examine the clinical implications of
dysregulation of miR-652 and its biological mechanism. Methods: Using a co-
hort of 585 patients treated with radical prostatectomy, we examined the prog-
nostic signifıcance ofmiR-652 using the KaplanMeiermethod andCox propor-
tional hazardmodels.We examinedmiR-652 expression in prostate cancer cells
and created cell lines that overexpressed miR-652 for functional assays. Finally,
we examined pathways through which miR-652 may function using prediction
algorithms, and confırmed by Western blotting, IHC and luciferase reporter
assays. Results: Patients overexpressing miR-652 had signifıcantly increased
rates of biochemical recurrence (p0.0001). In multivariable models adjusting
for known clinical prognostic factors, patients with high miR-652 expression
had an increased risk of biochemical recurrence (HR 1.47, 95% CI 1.09-1.98).
Overexpression of miR-652 in PC3 and LNCaP cells resulted in increased
growth, migration and invasion. Prostate cancer cell xenografts overexpressing
miR-652 had increased tumorigenicity andmetastases. Using themiRNA target
prediction program miRanda, we identifıed the B” regulatory subunit,
PPP2R3A, of the tumor suppressor PP2A as a potential target of miR-652. PC3
and LNCaP cells transfected with miR-652 mimic dowregulated the PR72 iso-
form of PPP2R3A. Mutation of the miR-652 binding site in the PPP2R3A gene
negated this effect. Western blotting demonstrated that mir-652 induced
PPR2R3A inhibition induced epithelial-mesenchymal transition (EMT) in PC3
cells. ProlongedmiR-652 expression in LNCaP cells induced a neurite-likemor-
phology, suggesting neurodocrine-like differentiation (NED). Western blotting
of LNCaP cells after prolonged miR-652 exposure, resulted in increased phos-
pho-AKT and phospho--catenin (phosphorylated at Serine 552), reduced AR
expression, and upregulation of the NED marker, neuron specifıc enolase
(NSE), consistent with NED. Expression of NED markers, chromogranin A,
NSE, and synaptophysin were also observed in a xenografted tumor derived
from LNCaP-652 overexpressing cells. Conclusion: These observations suggest
that increased levels of miR-652 found in prostate cancer may contribute to
tumor progression by promoting NED, tumor cell survival and cell migration/
invasion through decreased PP2A function which may provide an opportunity
for novel therapy in prostate cancer.
#2523 Key cluster for prostate cancer diagnosis and therapy; miR-888
cluster. Tsuyoshi Hasegawa, Aurora Kerscher. Eastern VirginiaMedical School,
Norfolk, VA.
Prostate cancer (PCa) is the 2nd leading cause of cancer death amongmen in the
U.S. No accurate biomarkers exist and therapeutic options are limited for advanced
PCa.MicroRNAs (miRNAs), small non-coding RNAs, act as negative regulators of
gene expression.MiRNAshave recently emerged as promising therapeutic tools for
cancers. It is poorly understood how they function to promote cancer progression.
We found miR-888 was involved with PCa progression. miR-888 belongs to a
genomic cluster on human chromosome Xq27.3, linked to hereditary PCa. I hy-
pothesized additionalmembers of this cluster (miR-892c, -890, -892a, -892b, -891b,
-891a) function to promote PCa progression. Our lab profıled miR-888 cluster ex-
pression in paired syngenic human PCa cell lines (RWPE1&WPE1-NB26, LNCaP
& C4-2, PC3-N & PC3-ML) differing in metastatic status and androgen response.
Wenoted that themiR-888clusterwaspreferentially elevated inmetastaticPC3-ML
and under-expressed in non-aggressive PC3-N cells. I examined miR-888 cluster
function in vitro and found that forced expression (via miRNAmimics) of certain
miR-888 clustermembers, notablymiR-888 andmiR-891a, promoted cell prolifer-
ation, colony formation, migration and invasion in PC3-N cells. Conversely, other
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clustermembers inhibited these activities. Experimentswithhormone sensitiveLN-
CaP cells showed similar results in these assays. PC3-ML transfected with miRNA
inhibitors exhibited reciprocal effects. In mouse xenograft studies, I used lentiviral
vectors to individually overexpress miR-888 and miR-891a in PC3-N cells and in-
jected them subcutaneously into flanks of NOD/SCIDmice. The miRNAs acceler-
ated tumor formationand increased tumor size compared tocontrols.miR-888may
promote tumorigenesis by suppressing the tumor suppressorsTIMP2andSMAD4,
which our lab validated as miR-888 targets using luciferase reporter assays. I con-
fırmed by western blot that xenograft tumors overexpressing miR-888 had de-
creased protein levels for these targets. Studies reveal miRNAs exist in exosomes,
small membrane bound vesicles involved in cell-to-cell communication. I postu-
lated that aggressive tumors secrete exosomeswith themiR-888 cluster as cargo and
promote PCa progression. Indeed, I noted that miR-888 cluster expression is ele-
vated in exosomes isolated from aggressive PC3-ML compared to PC3-N cells as
well as in EPS urine exosomes from high-grade PCa patients versus those with
low-grade disease. My work indicates miR-888 and miR-891a are novel oncogenic
factors in the prostate and may use exosomes to exert their effects. This is the fırst
report to explore the functional role of the miR-888 cluster in any tissue and may
lead to promising clinical strategies for PCa.
#2524 MiR-124 suppresses p62 and p65/NFkB to regulate autophagy, in-
flammation and cell death inKRASmutantmesenchymalNSCLC cells.Anita
K. Mehta,1 Kevin Hua,1 William Whipple,1 Mihn-Thuy Nguyen,1 Rushika M.
Perera,2 Johanns Haybaeck,3 Joanne Weidhass,4 Jeffrey Settleman,5 Anurag
Singh1. 1Boston University School of Medicine, Boston, MA; 2University of Cali-
fornia at San Francisco, San Francisco, CA; 3Medical University of Graz, Graz,
Austria; 4University of California at Los Angeles School of Medicine, Los Angeles,
CA; 5Calico Life Sciences, South San Francisco, CA.
Background KRAS mutant non-small cell lung cancers (NSCLC) are molec-
ularly and histologically diverse. Epithelial-like cells aremore KRAS dependent,
whereas mesenchymal-like cells are less KRAS dependent. These two subtypes
are designated KE (epithelial) and KM (mesenchymal), respectively. A KE ver-
sus KM subtype transcriptional signature reveals specifıc modes of KRAS de-
pendent survival signaling in the KE subtype. This KRAS dependency signature
is signifıcantly enriched with predicted microRNA (miRNA) target genes of
miR-205 and miR-34b/c. MiRNAs can function as tumor suppressors by coor-
dinately regulating multiple oncogenic signaling pathways. The role of deregu-
lated miRNA function in mediating the survival of KM versus KE NSCLC cells
has not been investigated to date. Methods Differential miRNA expression in
KRASmutant cell lines was determined using Taqman low-density qPCR arrays
(TLDA). Functional miRNA reconstitution experiments of downregulated
miRNAs were performed in a panel of KM cell lines. Effects on apoptosis and
autophagy were performed by Western blotting, immunofluorescence and live
cell microscopy and caspase assays. The molecular targets of miR-124 were
computationally identifıed by TargetScan or miRWalk and experimentally ver-
ifıed using 3’UTR luciferase-based assays. Functional rescue of miRNA-depen-
dent cell viability defects was determined by ectopic predicted target gene ex-
pression. Results Comparison of KE to KM cells yielded a KE-KM miRNA
subtype classifıer/signature. This signature revealed a number of silenced or
suppressed miRNAs in KM cell lines, including members of the miR-200
family. MiR-200 and miR-205 reconstitution in KM cells modulated epithe-
lial plasticity by Zeb1 protein suppression and increased E-cadherin levels.
Reconstitution of miR-124, miR-625 and miR-518-3p in KM cells caused
pronounced loss of cell viability. Furthermore, miR-124 caused autolyso-
some maturation defects. We identifıed SQSTM1/p62, TRAF6 and RELA/
p65 as key predicted targets of miR-124. MiR-124 reconstitution in KM cells
caused decreased p62, TRAF6 and p65 protein levels. The effect of miR-124
on p62 expression was verifıed using a Luciferase-p62-3’UTR reporter con-
struct. Overexpression of p62 in KM cells rescued the cell viability defects
caused by miR-124. Conclusion These studies implicate miR-124 as a con-
text-dependent tumor suppressor miRNA in KM subtype cells. MiR-124
directly suppresses expression of SQSTM1/p62 to promote defects in autoly-
sosome maturation. In parallel, miR-124 suppresses RELA/ p65 and in some
cases, TRAF6, to alter expression levels of several cytokines. Thus, miR-124
coordinately regulates autophagy and inflammation to disrupt the fınely-
tuned balance between pro and anti-inflammatory signals, resulting in cyto-
toxic effects in a specifıc subtype of mesenchymal-like KRASmutant NSCLC
cells.
#2525 Targetingmyeloma cell-derived runx2 bymiRNAs suppressesmul-
tiple myeloma growth and progression. Pramod S. Gowda, Mohammad Q.
Hassan, TimothyN. Trotter, Yang Yang.University of Alabama at Birmingham,
Birmingham, AL.
In Multiple myeloma (MM), abnormal plasma cells accumulate in the bone
marrow and spread to newbone sites.However, themechanisms underlying this
spread ofMM cells remain unclear. Runx2 is a bone specifıc transcription factor
upregulated in various human tumors, including MM. Our studies have previ-
ously demonstrated that Runx2 is a major driver ofMMprogression in bone. In
the present study, our goal was to identify miRNAs targeting Runx2 to reduce
tumor growth and dissemination of MM to new bone sites and asses their ther-
apeutic potential. Expression analysis of a panel of miRNA’s regulating Runx2
revealed an inverse relationship between Runx2 expression and two miRNAs:
miR-342 and miR-363. miRNA expression analysis using the Gene Expression
Omnibus database showed that miR-342 and miR-363 are highly expressed in
plasma cells of normal donors (n 3), while Runx2 is detected at very low levels.
In contrast, MM cells of patients with newly diagnosed (n23) and relapsed
MM (n17) expressed very little miR-342 and miR-363 but showed high levels
of Runx2 expression. Reconstituting CAGhumanMMcells with syntheticmiR-
342, miR-363 or miR-342miR-363 in combination reduced the expression of
Runx2 and the metastasis-promoting Runx2 target genes RANKL, DKK1 and
DMP1. Tumor cell viability and migration were also decreased compared to
control in vitro. We then transfected miR-342, miR-363 or miR-342miR-363
in mouse 5TGM1 MM cells expressing high levels of Runx2 and tested bone-
homing and growth in syngenic C57Bl/KaLwRij mice by intravenous injection.
Mouse serawere collected atweek 2 and 4 after tumor cell injection and the levels
of IgG2b, a marker of 5TGM1 cells, were measured by ELISA. The results
showed signifıcantly decreased IgG2b levels in mice bearing miR-342 or miR-
363 transfected tumors compared to mice bearing control miR-scramble tu-
mors. Additionally, miR-342miR-363 co-transfection produced a synergistic
effect on reducing tumor growth. Mechanistic studies demonstrated that miR-
342 and miR-363 induced Runx2 suppression, results in inhibition of Runx2-
downstream signaling pathways Akt/-catenin/survivin, which are required for
MM tumor progression. In conclusion, we have identifıed two novel miRNAs,
miR-342 and miR-363, that negatively regulate Runx2 expression in MM cells.
We further demonstrated that enhanced expression of miR-342 or miR-363 in
MMcells inhibitsMMgrowth in vivo. Thus,miR-342 andmiR-363 are potential
novel markers of MMprognosis and can be developed as new therapeutic drugs
for MM treatment.
#2526 MicroRNA expression signature of patients with tyrosine kinase
inhibitors failure:miR-10a-5p inhibits cancer cell aggressiveness in renal cell
carcinoma. Takayuki Arai,1 Atsushi Okato,1 Akira Kurozumi,1 Mayuko Kato,1
Yusuke Goto,1 Keiichi Koshizuka,1 Satoko Kojima,2 Yukio Naya,2 Tomohiko
Ichikawa,1 Naohiko Seki1. 1Graduate School of Medicine, Chiba University,
Chiba, Japan; 2Teikyo University Chiba Medical Center, Ichihara, Japan.
Renal cell carcinoma (RCC) is a disease in which cells undergo oncogenic
transformation in the kidney tubules. The fıve-year survival rate of advanced
stage RCC is poor (5-10%) due to recurrence or distant metastasis. Recently,
anti-angiogenic multi-tyrosine kinase inhibitors (TKIs) have been developed
and have been used as fırst and second line treatments for RCC. However, these
treatments extend progression-free survival only slightly, and relapse and me-
tastasis eventually develop inmost patients. Themolecular mechanisms of RCC
recurrence, metastasis and drug resistance are not yet fully understood. There-
fore, analysis of the molecular mechanisms underlying RCC development and
progression and studies of novel oncogenic pathways based on current genome-
based approaches could signifıcantly improve diagnosis, therapy, and preven-
tion of the disease. miRNAs (miRNAs) are small noncoding RNAs that function
to fıne tune the expression of protein coding/noncoding RNAs by repressing
translation or cleaving RNA transcripts in a sequence-depending manner. The
unique characteristic function of miRNAs is to regulate RNA transcripts in
human cells. Therefore, dysregulated expression of miRNAs can disrupt tightly
regulated RNA networks in cancer cells. In this study, we constructed a miRNA
expression signature to identify pathways activated by TKI treatment using au-
topsy specimens from patients with RCC. We have sequentially identifıed tu-
mor-suppressive miRNA and its regulated RCC pathways based on the signa-
ture. The aim of this study was to investigate the functional signifıcance of
miR-10a-5p and to identify the molecular targets and pathways mediated by
miR-10a-5p inRCCcells. The expression levels ofmiR-10a-5pwere signifıcantly
reduced in RCC clinical specimens and RCC cell lines compared with non-
cancerous kidney tissues (P  0.001). TCGA data showed that the overall sur-
vival of low miR-10a-5p expression group was signifıcantly shorter than that of
high expression group (P  0.00408). Restoration of miR-10a-5p signifıcantly
inhibited cancer cell migration and invasion in RCC cell lines (P  0.0001).
Spindle and kinetochore associated complex subunit 1 (SKA1) was identifıed as
a direct target gene ofmiR-10a-5p by genome-wide gene expression analysis and
in silico analysis. Overexpression of SKA1 was observed in RCC clinical speci-
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mens. Moreover, the overall survival of high SKA1 expression group was signif-
icantly shorter than that of low expression group by TCGA analysis (P 1.44E-
07). Tumor-suppressive miR-10a-5p was identifıed by using miRNA signature
of patients with TKI failure. Overexpression of SKA1might be involved in RCC
aggressiveness, metastasis and drug resistance. Elucidation of tumor-suppres-
sive miRNAs regulated molecular pathways and targets could provide new in-
formation on potential therapeutic strategies in the disease.
#2527 The role ofmiR-601 in prostate cancer progression. Jessica L. Flem-
ing, EricaH. Bell, KathrynAndrews, Arnab Chakravarti.TheOhio State Univer-
sity, Columbus, OH.
Prostate cancer (PCa) is the second most common cancer among men
worldwide. In order to advance treatment options for these men, it is crucial
to understand the molecular underpinnings behind this cancer. Previously,
our group identifıed miR-601 as a biomarker of signifıcance in PCa. Few
studies to date have functionally validated molecular biomarkers and cur-
rently little is known about the function of miR-601 in PCa. Based on our
previous publication, we hypothesized that miR-601 plays a role in PCa
progression and radiation response. To test this hypothesis, miR-601 was
over-expressed and knocked down in DU145 and PC3 cell lines and assays
were performed evaluating cell proliferation, colony formation, apoptosis,
and cell cycle progression. Additionally, to provide more information re-
garding miR-601-associated pathways, we identifıed putative gene targets of
miR-601 using in silico prediction programs, microrna.org and TargetScan.
org and evaluated top gene targets in vitro. To date, our data suggest that
miR-601 may be playing a role as a tumor suppressor. Over-expression of
miR-601 in cell lines resulted in a signifıcant reduction in cell viability. This
was confırmed both by MTS as well as colony formation assays. We looked
into the mechanism behind the reduction in cell viability by testing the effect
of miR-601 on apoptosis and cell cycle progression. We found that cells
over-expressing miR-601 had slightly higher levels of apoptosis, however
miR-601 did not induce a substantial effect on cell cycle progression. Addi-
tionally, we found that miR-601 enhances radiosensitization in DU145 and
PC-3 cell lines. Similar results have been observed in breast cancer 1 as well as
in a large miRNA screen performed in the LNCaP cell line2. Two putative
gene targets of miR-601 were identifıed and investigated in vitro, SIRT1, a
histone deacetylase known to be both an oncogene and tumor suppressor,
and BCL2L2, an anti-apoptotic gene known to be an oncogene. SIRT1 and
BCL2L2 had strong scores on both online prediction programs as likely
targets of miR-601. Our in vitro results confırmed this. We saw reduced
mRNA and protein expression of these targets in cells over-expressing miR-
601. Our data thus far suggest that miR-601 is acting as a tumor suppressor
in PCa. Targeted therapies for miR-601 and/or its targets may be promising
in the treatment of PCa, however additional work is needed to validate this.
Future work will focus on the role of miR-601 in cell migration and invasion
as well on identifying the direct molecular mechanism(s) by which miR-601
is reducing cell viability and conveying radiation sensitivity. Funding:
R01CA108633 (To AC), 1RC2CA148190 (To AC) U10CA180850-01 (To
AC), 1R01CA169368 (To AC) from the NCI, Brain Tumor Funders Collab-
orative Grant (To AC), OSUCCC Award (To AC). 1. Hu JY et al. (2016)
Biomedicine and Pharmacotherapy. 79: 247-53 2. Hatano K. et al. (2015)
Nucleic Acids Research. 43: 4075-86
#2528 miR-452 inhibitsmigration and invasion of prostate cancer cells by
targetingE3ubiquitin ligase-1 (WWP1). SatokoKojima,1YusukeGoto,2Akira
Kurozumi,2 Mayuko Kato,2 Atsushi Okato,2 Takayuki Arai,2 Tomohiko
Ichikawa,2 Yukio Naya,1 Naohiko Seki2. 1Teikyo University Chiba Medical Cen-
ter, Ichihara, Japan; 2Chiba University Graduate School of Medicine, Chiba, Ja-
pan.
Introduction: Most prostate cancer (PCa) patients initially respond to andro-
gen-deprivation therapy (ADT), but eventually acquire resistance to ADT and
progress to castration-resistant prostate cancer (CRPC), resulting in metastasis
causing PCa death. We have developed the microRNA (miRNA) expression
signature of PCa using clinical specimens and determined the target genes of the
tumor suppressive miRNAs, whose expressions are signifıcantly decreased in
PCa specimens. Based on the signature, our previous study revealed that miR-
224 functions as a tumor suppressor, especially contributes to cancer cell metas-
tasis directly targeting miR-224-TPD52 signaling. In human genome, miR-452
is located nearby tumor-suppressive miR-224, forming clustered miRNAs on
chromosomeXq28 region. The aimof the studywas to investigate the functional
signifıcance of miR-452 and to identify novel miR-452-mediated cancer path-
ways and responsible genes in PCa cells.Material andmethods: Clinical prostate
specimenswere obtained frompatients admitted to the TeikyoUniversity Chiba
Medical Center from 2008 to 2013. Ninety-two patients with elevated PSA levels
underwent transrectal prostate needle biopsy, and three patients who died of
CRPC underwent autopsies. PCa tissues (n54), noncancerous prostate tissues
(non-PCa, n36), were used for analysis of expression levels of miRNAs. Func-
tional studies of differentially expressed miRNAs were analyzed using PC3 and
DU145 cells. The influence on CRPC-free survival of expression levels of
miRNA was estimated using the Kaplan-Meier methods. In silico database and
genome-wide gene expression analyses were performed to identify molecular
targets regulated by the miRNAs. Results: (The miRNA expression signature of
PCa specimens showed that the cluster miRNAs miR-224 was signifıcantly
downregulated, suggesting that thismiRNAmay act as tumor suppressor.) Clin-
ical data using advanced PCa showed that low expression of miR-452 predicted
a short duration of progression to CRPC. Restoration of miR-452 in PC3 and
DU145 cells revealed signifıcant inhibition of cancer cell migration and inva-
sion. WW domain-containing E3 ubiquitin protein ligase-1 (WWP1) was con-
fırmed as a direct target of miR-452 by in vitro transfection of miR-452 and
Luciferase assay. Knockdown of the expression of WWP1 using siRNA showed
inhibiting cell migration and invasion in PC3 and DU145 cells. Immunohisto-
chemistry showed overexpressedWWP1 in advanced PCa. Conclusions: Loss of
the tumor suppressive miR-452 enhanced migration and invasion in PCa cells.
Regulation of the miR-452-WWP1 axis contributed to PCa cell migration and
invasion, and elucidation of downstream signaling of this axis will provide new
insights into the mechanisms of (progression to CRPC) metastasis of PCa.
#2529 TTF-1/NKX2-1 induced miR-532-5p targets KRAS and MKL2 on-
cogenes and causes apoptosis in lung adenocarcinoma cells. Sebastian Gries-
ing,1 Taisuke Kajino,1 Mei Chee Tai,1 Zhuoran Liu,1 Masahiro Nakatochi,2 Mo-
toshi Suzuki,1 Takashi Takahashi1. 1Nagoya University Graduate School of
Medicine, Nagoya, Japan; 2Nagoya University Hospital, Nagoya, Japan.
Our group and others have previously identifıed TTF-1/NKX2-1 as a lineage
survival oncogene in lung adenocarcinoma. Subsequent studies revealed double-
edged sword characteristics of TTF-1 in the development of lung adenocarcinoma.
TTF-1 elicits lineage-survival signaling by inducing transcriptional targets such as
ROR1, while TTF-1 also inhibits tumor progression by decreasing cell motility
through direct activation of genes such as MYBPH. It is thus clear that a more
comprehensive picture of this still enigmatic lineage-survival oncogene needs to be
elucidated. Whereas most of the previous studies on TTF-1 have focused on its
regulation of protein-coding genes, very little is known about regulation ofmicroR-
NAs by TTF-1. In the present study, we combined in vivo patient data with in vitro
data from lung adenocarcinoma cell lines, aiming at identifyingmiRNAs,which are
transcriptionally regulated by TTF-1. Our integrative approach identifıed miR-
532-5p as a microRNA regulated by TTF-1. Expression of miR-532-5p decreased,
when cell lines with a high endogenous level of TTF-1were transfectedwith siRNA
against TTF-1, while it was increased by overexpression of exogenous TTF-1 in
TTF-1-negative cell lines. ByChIP and luciferase assays, TTF-1was found to induce
miR-532-5p expression through its binding to the MIR532 promoter region, iden-
tifyingmiR-532-5p as a direct target of TTF-1.We next employedmicroarray anal-
ysis and target prediction using TARGETSCAN to search for potential targets of
miR-532-5p.We consequently identifıed KRAS andMKL2 as candidates and con-
fırmed this by qRT-PCR, Western blot and luciferase analyses. Overexpression of
miR-532-5p induced apoptosis and inhibited colony formation in lung adenocarci-
noma cell lines, while depletion of MKL2 phenocopied the effects of miR-532-5p
introduction, similarly exhibiting occurrence of marked apoptosis. In addition,
miR-532-5p signifıcantly decreased tumor formations in vivo in amouse xenograft
model. Itwas also of note thatmiR-532-5p inhibited lung adenocarcinoma cell lines
regardless of the presence or absence of KRAS mutations. In summary, we have
found that TTF-1 transactivates miR-532-5p, which potently induces apoptosis in
lung adenocarcinoma cells. MiR-532-5p directly targetsMKL2, which we have also
uncovered to be crucially involved in lung adenocarcinoma survival. In addition,
whileprevious reportshave shownthatTTF-1 inhibitsKRAS-driven tumorigenesis,
this study identifıesKRASasa targetofmiR-532-5p,providing theirpotentialmech-
anistic link.Ourresults thus shed lightonhowTTF-1playsa tumor-suppressive role
in theprocessof lungcarcinogenesis,whichmightultimately lead todevelopmentof
a novel therapeutic strategy for this devastating disease.
#2530 Validation andpathway analysis of ametastasis-specifıcmicroRNA
signature in primary colon cancer. Robert R. Coebergh van den Braak, Anieta
S. Sieuwerts, Zarina S. Lalmahomed, Marcel Smid, Vanja de Weerd, Michelle
van der Vlugt - Daane, Anne van Galen, Shanshan Xiang, Katharina Biermann,
John A. Foekens, JohnW.Martens, Jan N. IJzermans. Erasmus University Med-
ical Center, Rotterdam, Netherlands.
Introduction: In lymphnode negative (LNN) colon cancer 20%of the patients
develops disease recurrence. Identifıcation of these patients is needed. Micro-
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RNAs (MiRNAs), a group of short non-coding RNAs, can function as tumor
suppressors or oncogenes. Hur et al recently found 6 differentially expressed
MiRNAs when comparing primary colorectal cancer and matched liver metas-
tasis (MiR-320, MiR-221, MiR-30b, MiR-10b, MiR-885-5p, Let-7i). The expres-
sion of 2MiRNAswas signifıcantly correlatedwith distantmetastasis (lowLet-7i
expression and high MiR-10b) in primary colorectal cancers. When split at the
median and combined into a signature (Let-7i high andMiR-10b low [n22] vs.
Let-7i low and/or MiR-10b high[n122]), the fırst group showed 100% metas-
tasis free survival (MFS).We assessed the prognostic value of theseMiRNAs and
the signature in a clinically well-defıned cohort of primary colon cancers. Meth-
ods: Expression of the 6 MiRNAs were measured using RT-qPCR in a cohort of
232 colon cancer patients (n155 untreated LNN and n77 adjuvant treated
lymphnode positive [LNP] patients) selected from theMATCH-cohort. Expres-
sion levels were related to microsatellite instability (MSI), and MFS, hepatic
metastasis free (HFS) and overall survival (OS). Results: MiR-221, Mir-30b,
Mir-10b and MiR-885-5p levels were signifıcantly associated with MSI. In uni-
variate Cox regression analysis, MiR-30b was signifıcantly associated with MFS
(HR1.23 p0.004), and MiR-30b and Let-7i were associated with HFS
(HR2.52 p0.005 and HR0.40 p0.001, respectively) in the total group. In
the LNN group results were similar for MiR-30b (MFS HR2.07 p0.008 and
HFSHR2.94 p0.005) and Let-7i (HFSHR0.28 p0.001), but did not reach
signifıcance in the LNP group. These associations remained signifıcant when
correcting for MSI. Pathway analysis for MiR-30b and Let-7i with the GSEA
hallmark gene sets between the 50 samples with the highest and 50 samples
with lowest expression revealed a signifıcantly higher expression of the TGF-
beta pathway in the MiR-30b high group, and a signifıcantly higher expres-
sion of the EMT pathway in the Let-7i high group. MiR-30b and Let-7i
expression was split at the median level and combined into two groups
(’Let-7i high and MiR-30b low’ vs. ‘Let-7i low and/or MiR-30b high’). The
‘Let-7i high and MiR-30b low’ group in the total group (n74) had a signif-
icantly better 5-yr HFS (100% vs 87.4% p0.002), and had a signifıcantly
better 5-yr MFS (91.7% vs 78% p0.036) and HFS (100% vs 87.8% p0.01)
in the LNN group (n52). Conclusion: in our cohort and more specifıcally
the LNN group, we confırmed Let-7i and identifıed MiR-30b as a prognostic
factor for MFS and HFS. We did not confırm the prognostic value of Mir-
10b. The combination of Let-7i and MiR-30b identifıed a group with a 100%
HFS. Pathway analysis showed higher expression of the TGF-beta pathway in
the MiR-30b high group, and higher expression of the EMT pathway in the
Let-7i high group.
#2531 Regulation of androgen signaling axis and tumor suppressive func-
tion of miR-149-5p in prostate cancer. Savita Singh,1 Jey Sabith Ebron,1 Eswar
Shankar,2 SanjayGupta,2 Daniel Lindner,3 Girish Shukla1. 1Cleveland State Uni-
versity, Cleveland, OH; 2CaseWestern Reserve University & University Hospitals
Case Medical Center, Cleveland, OH; 3Taussig Cancer Center, Learner Research
Institute, Cleveland, OH.
Prostate cancer growth and proliferation depends on androgen signalingme-
diated by transactivation of Androgen Receptor (AR). Androgen ablation re-
mains the mainstay therapy for treatment of the disease. However, despite an-
drogen ablation, the disease relapses to more aggressive form known as
castration-resistant prostate cancer (CRPC). Androgen Signaling Inhibitor such
asAbirateroneAcetate andEnzalutamide are themost effective treatmentmeth-
ods currently being used to treat CRPC.However,more than one-third of CRPC
patients develop resistance to these treatments, mostly due to the gain of func-
tion in the AR protein and increase in intratumoral dihydrotestosterone (DHT)
synthesis. Intratumoral DHT synthesis from steroid precursors in tumors is
augmented by up-regulation of enzymes of cholestrogenesis and steroidogene-
sis, such as HMG-CoA reductase, SCARB1, and 17HSD respectively. Tumor-
specifıc downregulation of microRNAs which regulate the AR and steroid bio-
synthesis has been implicated in tumor growth and resistance to therapeutics in
CRPC. We are focusing on tumor suppressive role of miR-149-5p in PCa. We
discovered that miR-149-5p expression was signifıcantly lower in prostate can-
cer tissues compared to normal tissues. The mechanistic investigation revealed
that miR-149-5p downregulates wild type and alternatively spliced variant of
AR. It also down regulates the expression of SCARB1, HMGCS and HMG-CoA
reductase, the proteins known to facilitate intratumoral DHT synthesis. Ectopic
expression of miR-149-5p negatively regulated the expression of prostate-spe-
cifıc antigen, a downstream target of androgen signaling and it also inhibited
invasion and proliferation of CRPC cells. Our fındings indicate a signifıcant role
of miR-149-5p in regulating androgen signaling and possibly DHT synthesis in
CRPC. This provides a strong rationale for further investigating the signifıcance
of miR-149-5p for generation of new therapeutic for CRPC.
#2532 High expression of MiR-432-3p is associated with the chemoresis-
tance by NRF2 stabilization via directly targeting KEAP1. Burak Akdemir,1
Jun Inoue,1 Tatsuyuki Kawano,2 Johji Inazawa1. 1Department of Molecular Cy-
togenetics, Tokyo Medical and Dental University, Tokyo, Japan; 2Department of
Esophageal and General Surgery, Tokyo Medical and Dental University, Tokyo,
Japan.
NF-E2-related factor 2 (NRF2) is a master transcriptional regulator that inte-
grates cellular stress responses and is negatively regulated by Kelch-like ECH-
associated protein 1 (KEAP1) at the post-translational level. In human cancers,
aberrantly stabilized NRF2, either by mutation of NRF2 or KEAP1, plays a vital
role in chemoresistance through the activation of target genes, suggesting that
targeted inhibition of NRF2 is a potential therapy for NRF2-stabilized tumors.
MicroRNAs (miRNA) are endogenous small noncoding RNAs that can nega-
tively regulate gene expression by interfering with the translation or stability of
target transcripts. Previously, we identifıedmiRNAs negatively regulatingNRF2
pathway via directly targeting NRF2 itself by a reporter-coupled miRNA library
screening and demonstrated the potential of miRNA-based therapy against
NRF2-stabilized tumors in esophageal squamous cell carcinoma (ESCC) (Mol.
Cancer Res 2014, Cancer Res 2015). In the present study, we further identifıed
miR-432-3p as a miRNA positively regulating NRF2 pathway. MiR-432-3p
could directly targeted KEAP1 via binding to its seed sequence within the cord-
ing region. Overexpression of miR-432-3p resulted in enhanced resistance to
cisplatin via activation of NRF2 in ESCC cell lines. Furthermore, miR-432-3p
was overexpressed in 55 of 84 primary ESCC tumors, compared with that of
corresponding non-cancerous esophageal mucosa (65.5%). Importantly, we
showed the negative correlation between the expression level of KEAP1 and
miR-432-3p in primary ESCC tumors. Taken together, these fındings suggest
that the high expression of miR-432-3p may contribute to the chemoresistance
by NRF2 stabilization via down-regulation of KEAP1 expression in ESCC.
#2533 Sox2 promotes cell proliferation of esophageal squamous cell car-
cinoma through themiR-17-92 cluster, PTEN, AKT, mTORC1 pathway.Kei
Terasaki. Kyoto Prefectural University of Medicine, Kyoto, Japan.
SOX2, amember of the SOX family of transcription factors, play an important
role of differentiation and morphogenesis of the esophagus. We previously re-
vealed that SOX2 is the target of gene amplifıcation at 3q26 in esophageal squa-
mous cell carcinoma (ESCC) (Cancer Genet Cytogenet. 2010), and that SOX2
promotes ESCC cell proliferation in vitro and in vivo through the activation of
the AKT/mTORC1 signaling pathway (Cancer Sci. 2013). However, the mech-
anisms by which SOX2 promotes AKT/mTORC1 signaling remain unknown. It
is known that PTEN is a negative regulator of AKT and the PTENgene is a target
of the miR-17-92 cluster. In the present study, we showed that SOX2 up-regu-
lated the expression of miR-17-92 cluster and repressed PTEN expression using
RNA interference (RNAi)-mediated knockdown of SOX2 and enforced expres-
sion of SOX2. In summary, SOX2 promotes cell proliferation of ESCC through
the miR-17-92 cluster /PTEN/AKT/mTORC1 pathway.
#2534 miRNA expression as potential biomarker for synovial sarcoma.
Laura Pazzaglia, Serena Pollino, Mattia Vitale, Amalia Conti, Piero Picci, Maria
Serena Benassi. Istituto Ortopedico Rizzoli, Bologna, Italy.
Synovial sarcoma (SS) is a rare tumor, with dismal survival when metastatic.
SS contains a characteristic translocation (X;18)(p11;q11), representing the fu-
sion of SYT on chromosome 18 with either SSX1, SSX2, or rarely SSX4 on
chromosome X The resulting fusion genes appear to be mutually exclusive and
concordant in primary and metastatic tumours. New prognostic and predictive
factors are needed. Chemokine receptor 4 (CXCR4) is a seven-transmembrane
G protein-coupled chemokine receptor and it is the chemokine receptor most
commonly expressed in tumour cells, involved in cell migration and invasion, as
well as angiogenesis.microRNAs (miRNAs) are involved in post-transcriptional
gene expression regulation and control important physiological processes like
development, cell differentiation and cell signaling. Altered expression of
miRNAs is strongly correlated with the malignant phenotype and there is data
reporting a strong association between microRNA expression, patient age and
STS prognosis. By three different databases (miRBase, TargetScan , miRanda)
and by literature data we identifıed twomiRNA regulators of CXCR4,miR-133b
and miR-494. The expression of these miRNAs was evaluated by RT-PCR in 42
SS primary samples stored at Rizzoli biobank. 20 tissues from non oncologic
patients were used as control. Our results showed a signifıcant lower expression
of miR-133b and miR-494 (respectively p0.0005 and p0.001) when com-
pared to non tumor tissue. In vitro study on SW982 cell line with miR-133b
precursor show a CXCR4 downregulation and a decrease of cell proliferation.
Our preliminary data confırmed a miR-133b and miR-494 downregulation in
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SS. Correlation with clinical data, with CXCR4 expression and in vitro studies
also with miR-494 in several SS cell lines are on-going to better investigate their
role as potential prognostic and therapeutic markers.
#2535 MicroRNA-518c-5ppromotes themetastasis of oral cancer.Makoto
Kinouchi, Daisuke Uchida, Nobuyuki Kuribayashi, Yuske Komiyama, Shuji
Tsuchida, Hitoshi Kawamata. Dokkyo University School of Medicine, Tochigi,
Japan.
We have demonstrated that CXCR4 system is involved in the metastatic pro-
cess of oral cancer. Recently, we identifıed the miR-518c-5p as a downstream
target of the CXCR4 system. In this study, we examined the function of miR-
518c-5p on the metastasis of oral cancer. We transfected miR-518c expression
vector into oral cancer cells, B88 and CAL27, and isolated stable transfectants,
B88-518c andCAL27-518c, respectively. The growth andmigration of both cells
were signifıcantly enhanced in compared with those of mock cells. LNA-based
miR-518c-5p inhibitor signifıcantly impaired the enhanced cell growth and mi-
gration of these cells, indicating that these phenomena were dependent on the
expression of miR-518c-5p, not on that of miR-518c-3p. Next, we examined the
function of miR-518c-5p in vivo. miR-518c or mock transfectants were inocu-
lated into themassetermuscle or the blood vessels of nudemice. Tumor volume,
lymph nodes metastasis, and lung metastasis were signifıcantly increased in the
mice inoculated with miR-518c transfectants. Furthermore, we examined the
mRNA expression induced by miR-518c-5p using B88 cells and B88-518c cells
by cDNAmicroarray analysis. Consequently, some of the genes involved in the
cell growth andmetastasis were upregulated in the B88-518c cells. These results
indicate thatCXCR4 system regulates themetastases of oral cancer via induction
of miR-518c-5p.
#2536 miR-187-5p and miR-219a-1-3p: potential biomarkers associated
with chemotherapeutic response and prognosis in ovarian cancer. Chia-Yen
Huang,1 Hsien-Da Huang2. 1Cathay General Hospital, Taipei, Taiwan; 2Na-
tional Chiao Tung University, Hsinchu, Taiwan.
Background: Epithelial ovarian cancer (EOC) is the fıfth-most common cause
of female cancer death and is associated with high recurrence and mortality
despite recent advancements in therapeutic strategies. Chemoresistance re-
mains themain cause of treatment failure in EOCpatients. The aim of this study
is to identify specifıcmiRNAmarkers closely associatedwith the chemoresponse
in EOC patients. Methods:We analyzed 374 serous ovarian cancer patients who
receiving combination chemotherapy from The Cancer Genome Atlas (TCGA)
and identifıed the most signifıcantly altered miRNAs between different groups
patients of chemotherapy response. We then used Kaplan-Meier and log-rank
methods to analyze the relationship between these miRNAs and progression-
free and overall survival in TCGA (n 460) and Bagnoli (n 130) datasets. In
vitro study for response to chemotherapy agents were performed in human
ovarian cancer cell lines and their transfectants. The biological relevance of
putative miRNA targets was also analyzed using bioinformatics. Results: MiR-
187-5p and miR-219a-1-3p were associated with better response to chemother-
apy and longer progression-free and overall survival in two independent epithe-
lial ovarian cancer patient cohorts (all p 0.05). These two miRNAs also
sensitized ovarian cancer cells to chemotherapy, thus recapitulating the clinical
observation. Conclusions: This study showed that miR-187-5p and miR-219a-
1-3p could be useful biomarker for prediction of chemotherapy response and
survival in serous ovarian cancers. MiR-187-5p and miR-219a-1-3p may be
potential molecules in the treatment of EOC for sensitizing cancer cells to che-
motherapy.
#2537 MicroRNA targeting anti-apoptotic and G2/M pathways as thera-
peutic targets for castration resistant prostate cancer. Pheruza Tarapore,1
Sarah To,2 Bin Ouyang,1 Yuet-Kin Leung,1 Ana Cheong,1 Shuk-mei Ho1. 1Uni-
versity of Cincinnati, Cincinnati, OH; 2Hudson Institute of Medical Research,
Melbourne, Australia.
Prostate cancer (PC) is one of the most common cancers in men. Unfortu-
nately, limited treatment options currently exist for those who have developed
advanced castration-resistant PC (CRPC). G-1 is a GPER1/GPR30 agonist, and
a promising candidate forCRPC therapy.G-1 is effective in halting the growth of
CR tumors but not those grown in intact hosts. These fındings suggest GPER1 is
a therapeutic target for CRPC.We found thatG-1, through activation ofGPER1,
inhibited growth of CRPC cells via cell-cycle arrest at the G2-M phase, probably
leading tomitotic catastrophy.However, the exactmode of action ofG-1was not
known. To better understand the pathways involved in G-1 action, we con-
ducted a genome-wide mRNA-seq and miRNA-seq study on G-1 treated xeno-
grafts.We identifıed a panel of novelG-1-associated tumor suppressivemiRNAs
and genes. Moreover, Ingenuity Pathway Analysis revealed that the G-1 differ-
entially regulated genes are involved in “Cellular Growth and Proliferation”,
“endocrine function” and “Cancer” pathways. We validated the expression of
the key miRNA (miR-34c, miR-10b, miR-138 and miR218) and genes in G-1
treated castration resistant xenografts and cell lines (C4-2 and 22Rv1). Further-
more, we have shown the tumor suppressor function of these miRNA in cell
survival, migration, and invasion. The predicted target genes were next exam-
ined for decreased expression by qRT-PCR.We confırmed decreased expression
of some of the downstream targets, which consist of genes involved in cell cycle
regulation (CCNA and CCND, CDK1, CDK4, PLK1), cell survival (Bcl2, Sur-
vivin), cell migration/F-actin formation (LASP, PCDH7, ITGA9, ROBO1,
SLIT1) and G2/M checkpoint (CDK1, PLK1, BCL-2 Survivin). Thus these miR-
NAs - miR-34c, miR-10b, miR-138 and miR218 - are ideal candidates for ther-
apy of CRPC.
#2538 MiR-638 promotes autophagy andmalignant phenotypes of cancer
cells via directly suppressing DACT3.Ming Yang. Shandong Cancer Hospital
and Institute, Jinan, China.
Dyregulation of autophagy is implicated in human cancers and the mecha-
nism details remains largely unclear. Herein we report the regulatory role of
miR-638 in autophagy of esophageal squamous cell carcinoma (ESCC) and
breast cancer cells.We found thatmiR-638 overexpression promotes starvation-
and rapamycin-induced autophagy. In ESCC and breast cancer cells, miR-638
acts as an oncogene andpromote cell proliferation,migration, aswell as invasion
in vitro and in vivo. In accordance with this, we observed signifıcantly higher
miR-638 expression in ESCC and breast cancer tissues compared to normal
tissues. To further elucidate regulatory mechanisms of miR-638 in autophagy,
we performed a computational nomination of its target genes through intersect-
ing the results of multiple prediction algorithms. DACT3, a key regulator of
Wnt/-catenin signaling, was predicted to be regulated by miR-638 by all pro-
grams and confırmed by experimental results. Depletion of DACT3 pheno-
copied effects of miR-638 overexpression, demonstrating its importance in au-
tophagy. These results elucidate that the miR-638-DACT3 axis might be an
important molecular pathway in controlling and autophagy and tumorigenesis.
Our data in clinical tissue samples highlight miR-638 and DACT3 with histo-
logical marker for cancer detection and potentially therapeutic implications.
#2539 MiR-96-5p functions as anoncogenicmiRNAby inhibiting apopto-
sis in hepatocellular carcinoma. Naoto Iwai, Kohichiroh Yasui, Akira Tomie,
Kei Teasaki, Tomoko Kitaichi, Osamu Dohi, Yasuyuki Gen, Yoshito Ito. Kyoto
Prefectural University of Medicine, Kyoto, Japan.
Hepatocellular carcinoma (HCC) is one of the most aggressive cancers with
high mortality worldwide. MicroRNAs (miRNAs) are small non-coding RNAs
that have been used as cancer-related biomarkers and expected to be therapeutic
agents. We performed genome-wide miRNA expression profıling of paired
HCC tumors and non-tumorous liver tissues from patients with primary HCCs
using the miRNA microarray (Agilent). We found that miR-96-5p was most
signifıcantly up-regulated in HCC tumors compared to non-tumor tissues. Al-
though miR-96-5p is suggested to be an oncogenic miRNA, the function of
miR-96-5p remains largely unknown.We identifıed the caspase-9 gene (CASP9)
as a novel target of miR-96-5p, in addition to the forkhead box O1 gene
(FOXO1) which is the known target of it. Caspase-9 protein is thought to play a
central role in apoptosis and to be a tumor suppressor. Overexpression of miR-
96-5p decreased caspase-9 protein expression and resulted in resistance to apo-
ptosis induced by doxorubicin and UV in HCC cells. Our results suggested that
miR-96-5p functions as an oncogenic miRNA by inhibiting apoptosis through
decreasing caspase-9 expression in HCC.
#2540 miR-196b as a potential biomarker for human esophageal cancer.
Xiaohui Tan,1 Tao Chen,2 Robert Siegel,1 Sidney Fu1. 1George Washington
Univ., Washington, DC; 2Chengdu Military General Hospital, Chengdu, China.
Esophageal cancer is the sixth most common cause of cancer related death.
Although multiple genetic and epigenetic alterations have been detected in
esophageal cancer, molecular markers for early diagnosis and prediction of
prognosis or treatment responses are quite limited. microRNA (miRNA) is a
class of small-regulatory non-coding RNA, acting as either a tumor suppressor
or oncogene by regulating gene expression through pairing with complemen-
tary seed of the targeted messenger RNAs (mRNA). A number of miRNA ex-
pression profıling studies have been conducted in esophageal. In our current
study, we analyzed the most recent studies on miRNAs expression profıles in
esophageal cancer. Consistently dysregulated miRNAs have been identifıed in
esophageal cancer, including upregulation of miR-196b, miR-135a, and down-
regulation ofmiR-141,miR-200a-5p,miR-200b-3p,miR-27b,miR-210.We fırst
assessed expression of miRNAs in esophageal cancer cell lines and primary
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esophageal cancer tissues by real-time reverse transcriptase-polymerase chain
reaction (qRT-PCR). Signifıcantly overexpressedmiR-196bwas observed in hu-
man esophageal squamous cell carcinoma KYSE-70 and KYSE-180 compared
with normal esophageal squamous cell line, HET-1A. Furthermore, overexpres-
sion of miR-196b was detected in 12 out of 14 (86%) cancer tissues compared to
the matched normal tissues. Forced expression of miR-196b promotes the pro-
liferation and invasion in esophageal cancer cell lines. TargetScanS and mi-
Randa were used to identify the target genes of miR-196b. A list of targets genes
were predicted, including GATA6, ARHGAP28, EPS15 and EPHA7. Forced
expression of miR-196b resulted in signifıcant downregulated EPS15 and
EPHA7 expression in esophageal cancer cell lines. Our present work suggested
that miR-196b acts as an oncomiR by regulating EPS15 and EPHA7. Therefore,
miR-196b could be used as a biomarker for esophageal cancer.
#2541 Two miR-34 loci, miR-34a and miR-34b/c, have differential anti-
cancer effects in lung adenocarcinomas. Jeong Seon Kim, Young-Ho Ahn.
Ewha Womans University College of Medicine, Seoul, Republic of Korea.
Three miR-34 family members (miR-34a, miR-34b, and miR-34c) are clus-
tered on two different chromosomal loci, miR-34a and miR-34b/c, and have
identical seed-sequences predicted to target the same set of genes; however,
miR-34a andmiR-34c have different sets of negatively correlated genes inTCGA
data of human lung adenocarcinomas. Therefore, we hypothesized that miR-34
family members, which are tumor suppressive miRNAs, might have differential
effects on lung tumorigenesis. To prove this, we overexpressed each miR-34
cluster, miR-34a and miR-34b/c, in murine lung cancer cells. miR-34b/c en-
hanced cancer cell attachment and suppressed cell growth and invasion com-
pared withmiR-34a. In a syngeneicmousemodel, bothmiR-34a andmiR-34b/c
blocked lung metastasis; whereas, miR-34b/c suppressed tumor growth more
than miR-34a. miR-34b/c also decreased mesenchymal markers (Cdh2 and
Fn1), and increased epithelial markers (Inadl, Crb3, Ocln, and Dsp) and miR-
200 family members better than miR-34a, implying that miR-34b and miR-34c
partially inhibit EMT. Furthermore,miR-34b andmiR-34c are better prognostic
markers than miR-34a in human lung adenocarcinoma patients. Collectively,
we suggest that miR-34b and miR-34c are more effective tumor suppressors
than miR-34a.
#2542 MSI2 binds LncRNAs and promotes self-renewal and oncogenesis
through MYC expression. Hifzur Siddique, Padmani Narayan, Vasu Punj,
Douglas E. Feldman, Keigo Machida. University of Southern California Keck
School of Medicine, Los Angeles, CA.
Backgrounds and Aims: RNA-binding protein MSI2 is elevated in several
cancers and is linked to poor prognosis. Here, we sought to elucidate the role of
MSI2 in regulating the expression of proto-oncogenes or tumor suppressor
genes in hepatocellular carcinoma (HCC). Methods: We performed RIP-seq
using anti-MSI2 antibody in tumor-initiating stem-like cells (TICs) and subse-
quent validation by qPCR analysis. Results: Among the MSI2-bound RNAs,
MYC mRNA and long noncoding RNA (LncRNA) miR22 host gene
(MIR22HG) and MARAT1 were identifıed by RIP-qPCR analysis. MSI2-
MARAT1 binding dereppresses polycomb reppressor to recruit E2F1 in MYC
promoter regions. It is known that the 5’-untranslated region of MYC contains
an internal ribosome entry sequence (IRES) which allows IRES-dependent
translation initiation along with canonical cap-dependent mechanisms. Our
data show thatMSI2 acts as an IRES trans-acting factors forMYCmRNA trans-
lation.MSI2 does not have any effect on the steady state level ofMYCmRNAbut
signifıcantly increases MYC protein levels, indicating that MSI2 regulates MYC
at the post-transcriptional level. Further, we observed that MSI2 reduced the
level of mature miR22 derived from MIR22HG processing. We showed that
miR22 suppresses the expression of MYC thorough a 3’-UTR dependent pro-
cess. Overexpression of MSI2 promotes TIC self-renewal and tumor initiation
property in xenograft tumormousemodels, whereas silencingMSI2 reduces this
occurrence. Conclusion: we demonstrate that MSI2 promotes liver tumorigen-
esis by maintenance of MYC expression through dereppression of polycomb
repressor and an IRES-dependent translation mechanism and possibly by inhi-
bition of miR22 processing. Thus, MSI2 may be a useful prognostic factor for
HCC and MSI2 targeted therapy and thus may be benefıcial in the treatment of
HCC patients.
#2543 The novel long non-coding RNA TALNEC2, regulates tumor cell
growth and the stemness and radiation response of glioma stem cells. Wei
Jiang,1 Shlomit Brodie,2 Simona Cazacu,1 Cunli Xiang,1 Laila Poisson,1 Steve
Kalkanis,1 Doron Ginsberg,2 Chaya Brodie1. 1Henry Ford Hospital, Detroit, MI;
2Bar-Ilan University, Ramat Gan, Israel.
Despite advances in novel therapeutic approaches for the treatment of glio-
blastoma (GBM), the median survival of 12-14 months has not changed signif-
icantly. Therefore, there is an imperative need to identifymolecularmechanisms
that play a role in patient survival. Here, we analyzed the expression and func-
tions of a novel lncRNA, TALNEC2 that was identifıed using RNA seq of E2F1-
regulated lncRNAs. TALNEC2 was localized to the cytosol and its expression
was E2F1-regulated and cell-cycle dependent. TALNEC2 was highly expressed
in GBM with poor prognosis, in GBM specimens derived from short-term sur-
vivors and in glioma cells and glioma stem cells (GSCs). Silencing of TALNEC2
inhibited cell proliferation and arrested the cells in theG1ßphase of the cell cycle
in various cancer cell lines. In addition, silencing of TALNEC2 decreased the
self-renewal and mesenchymal transformation of GSCs, increased sensitivity of
these cells to radiation and prolonged survival of mice bearing GSC-derived
xenografts. Using miRNA array analysis, we identifıed specifıc miRNAs that
were altered in the silenced cells that were associatedwith cell-cycle progression,
proliferation and mesenchymal transformation. Two of the downregulated
miRNAs, miR-21 and miR-191, mediated some of TALNEC2 effects on the
stemness and mesenchymal transformation of GSCs. In conclusion, we identi-
fıed a novel E2F1-regulated lncRNA that is highly expressed in GBM and in
tumors from patients of short-term survival. The expression of TALNEC2 is
associatedwith the increased tumorigenic potential of GSCs and their resistance
to radiation. We conclude that TALNEC2 is an attractive therapeutic target for
the treatment of GBM.
#2544 The lncRNA Meg3 acts as an epigenetic determinant of oncogenic
signaling inmultiple endocrineneoplasia type 1. Sucharitha Iyer, SunitaAgar-
wal. National Institutes of Health, Bethesda, MD.
Loss of tumor suppressors and gain of oncogenic properties is a hallmark of
cancer.But thepathways leading to tumor formationarepoorlyunderstood.Agood
example is the multiple endocrine neoplasia type 1 (MEN1) syndrome, in which
patients inherit germline mutations in theMEN1 gene, predisposing to tissue-spe-
cifıc loss of the encoded tumor suppressor protein menin. Consequently, tumors
develop inmultiple endocrine organs - the pituitary, the parathyroids, and the duo-
deno-pancreatic tissues, including pancreatic neuroendocrine tumors (PNETs). In-
sulinomas are the most common type of functioning PNETs that also occur in
MEN1 patients. We investigated the molecular pathways associated with insulino-
mas. We previously showed that menin loss downregulated Maternally Expressed
Gene 3 (MEG3), a long non-coding RNA (LncRNA), by eliciting promoter hyper-
methylation along with the loss of Histone H3 lysine 4 trimethylation (H3K4me3).
Gene expression microarray analyses and RT-PCR, of mouse insulinoma MIN6
cells stably transfectedwithMeg3, showed a 5-fold decrease in the proto-oncogenic
signaling receptor c-Met, suggestinga tumor suppressor function forMeg3.Wealso
found MEG3 downregulation with concurrent upregulation of c-MET in PNETs.
However, the molecular underpinnings of MEG3 governed c-MET repression re-
main elusive. To identify the mechanisms by which MEG3 inhibits oncogenic c-
MET signaling to suppress tumorigenesis, we examined the effect of various Meg3
isoforms, exploredMeg3 associationwith the epigenetic regulatorymachinery, and
RNA-DNA triplex formation. We provide direct evidence for the fırst time that
ectopically expressed Meg3 isoforms could attenuate the highly abundant c-Met
transcript in MIN6 insulinoma cells. Meg3 also interacted with components of the
epigeneticmachinery, such as the PolycombRepressive Complex 2 (PRC2) protein
conglomerate, to regulate c-Met RNA expression. Additionally, analyses of triplex
forming oligos (TFOs) in MIN6 cells revealed that triple helix formation between
Meg3 and dsDNA could potentially disrupt c-Met transcription. Combined, these
dataoffermechanistic insight into thedysregulationof c-METrepression inPNETs,
and support the conclusion that MEG3 acts as an important determinant of onco-
genic signaling in MEN1-associated endocrine tumor cells (insulinoma). These
fındings warrant further investigation into the tumorigenic pathways that may re-
sult from the loss of tumor suppressorMEG3 and gain of oncogenic c-MET signal-
ing in otherMEN1-associated endocrine tumors.
#2545 Upregulated lncRNA-HNGA1, a target ofmiR-378a, contributes to
aerobic glycolysis of head and neck squamous cell carcinoma through in-
creasing levels of the C-C chemokine receptor type 7 (CCR7).YunWang. Sun
Yat-sen University, Guangzhou, China.
Introduction: Long non-coding RNAs (lncRNAs) have been regarded as
key regulators in aerobic glycolysis of human cancer. However, the role and
function of lncRNAs in Head andNeck Squamous Cell Carcinoma (HNSCC)
aerobic glycolysis remain unclear. Here, we report a novel lncRNA, HNGA1,
which could promote HNSCC aerobic glycolysis and malignancy by com-
peting for miR-378a binding to regulate CCR7. Materials and methods: Mi-
croarrays were performed to explore the lncRNA/miRNA profıles in tissues
samples. qRT-PCR and functional analysis were used to confırm the expres-
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sion and role of lncRNA/miRNA. Bioinformatics approach and luciferase
assay were used to verify the miRNA target gene and the interation between
lncRNA andmiRNA. Nude mouse model was utilized to observe the effect of
lncRNA/miRNA in vivo. Tissue array was performed to explore the associ-
ation between lncRNA and postoperative survival. Results: 1. LncRNA HN-
SCC glycolysis-associated 1 (HNGA1) was up-regulated in tumor tissues,
while miR-378a was down-regulated signifıcantly. These observations were
confırmed in 60 pairs of HNSCC tissues/non-tumor tissues samples and 7
cohorts of HNSCC cell lines. 2. Silencing of HNGA1 inhibited HNSCC cells
proliferation and glycolysis, while overexpression of HNGA1 had the oppo-
site effect. 3. Ectopic expression of miR-378a repressed HNSCC cells prolif-
eration and glycolysis, whereas miR-378a inhibition resulted in the opposite
effect. MiR-378a could repress the CCR7 expression by binding to the 3’-
UTR region of CCR7 directly. 4. There was an inverse correlation between
HNGA1 and miR-378a in HNSCC specimens. Moreover, miR-378a sup-
pressedHNGA1’s expression and function by directly binding to HNGA1. In
addition, HNGA1 could reverse the inhibitory effect of miR-378a on HN-
SCC cells, which might act as an endogenous ‘sponge’ by competing for
miR-378a binding to regulate CCR7. 5. The xenograft mouse model unveiled
the suppressive effects of miR-378a on HNSCC tumor growth and glycolysis,
while HNGA1 could accelerate this process. 6. The clinicopathological fınd-
ings suggested that the up-regulation of HNGA1 in HNSCC patients was
associated with the poorly differentiated degree and more metastasis. More-
over, the results of tissue array showed that HNGA1 was correlated with
postoperative survival. Conclusion: Taken together, our data highlights the
pivotal role of HNGA1 in HNSCC aerobic glycolysis. More importantly, we
elucidate a novel lncRNA-miRNA-mRNA regulatory network that is
HNGA1-miR-378a-CCR7 axis in HNSCC malignancy and progression.
#2546 The long noncoding RNA SChLAP1 inhibits the SWI/SNF com-
plex, revealing a therapeutic opportunity in prostate cancer. Julia Dan-
court,1 Anirban Sahu,2 John R. Prensner,2 Benjamin Chandler,2 Qi Cao,2
Nithin Edara,2 Udit Singhal,2 Matthew K. Lyer,2 Rohit Malik,2 Xuhong Cao,2
Saravana M. Dhanasekaran,2 Yashar S. Niknafs,2 Shuang Zhao,2 Corey
Speers,2 Arul M. Chinnaiyan,2 Felix Y. Feng1. 1University of California San
Francisco, San Francisco, CA; 2University of Michigan, Ann Arbor, MI.
Background: Recently, we identifıed the long noncoding RNA SChLAP1
that is expressed highly in 20-30% of prostate cancers and signifıcantly as-
sociates with metastatic and lethal disease. SChLAP1 enhances cell invasive-
ness in part by interacting with and abrogating genome-wide binding of the
tumor-suppressive SWI/SNF complex. Approximately 20% of all cancers
harbor a mutation in SWI/SNF, and several recent studies have identifıed
therapeutic opportunities arising from SWI/SNF inactivation. We hereby
investigate the relationship between SChLAP1 and SWI/SNF and its poten-
tial therapeutic implications. Methods: In silico data mining was used to
correlate the SWI/SNF complex mutation frequency with SChLAP1 expres-
sion in prostate cancer samples. A systematic tiling deletion approach was
then used to map important domains on the SChLAP1 gene. In vitro migra-
tion and invasion assays as well as cell proliferation assays were used to
quantify phenotypes associated with over-expression of SChLAP1 or its de-
letionmutants. Moreover, CHIP was used to study the influence of SChLAP1
on the genomic binding of SWI/SNF. Results: In prostate cancer samples,
SWI/SNF mutations correlate with low SChLAP1 expression while high
SChLAP1 expression may represent a mutation-independent modality of
SWI/SNF inhibition. We identify a 250 nucleotide region necessary for
SChLAP1 to bind to SWI/SNF and to confer invasiveness to a prostate epi-
thelial cell line. Further studies suggest that SChLAP1 inhibition is selective
for the BRG1-containing SWI/SNF sub-complex, inferring potential
genomic specifıcity. Moreover, we show that SChLAP1 over-expression is
associated with enhanced sensitivity to BRM knockdown, in accordance
with the BRG1/BRM synthetic lethality previously described in BRG1-defı-
cient cancers. Conclusions: Our fındings indicate that SChLAP1-mediated
SWI/SNF inhibition may function similarly to SWI/SNF mutation, exposing
similar therapeutic opportunities.
#2547 Discovery and characterization of late-stage breast cancer estrogen
receptor alpha 1bound longnon-codingRNAs. JessicaMonique Silva-Fisher,1
AbdallahM. Eteleeb,1 TorstenNielsen,2 CharlesM. Perou,3 Jorge S. Reis-Filho,4
Mathew J. Ellis,5 Elaine R. Mardis,6 Christopher A. Maher1. 1Washington Uni-
versity School ofMedicine, St. Louis,MO; 2Vancouver Hospital &Health Sciences
Centre, British Columbia, Canada; 3Univeristy of North Carolina, NC; 4Memo-
rial Sloan Kettering, NY; 5Baylor College ofMedicine, TX; 6Nationwide Childrens
Hospital, OH.
Breast cancer (BC) is the second most common newly diagnosed cancer and
the second leading cause of cancer death among women in the United States.
Despite the proven benefıts of adjuvant endocrine therapy in women with hor-
mone receptor positive BC, relapses still occur even after initial treatment with
endocrine therapy for 5 years, referred to as late-stage relapse. Long non-coding
RNAs (lncRNAs) have been shown to be dysregulated in breast cancer. Recent
studies have also shown lncRNAs to function by interfacing with corresponding
RNA binding proteins to play critical regulatory roles of diverse cellular pro-
cesses. Therefore, we hypothesize that lncRNAsmay interact with ER to regulate
genes promoting late-stage relapse. To address this, we aimed to identify ln-
cRNAs bound to the estrogen receptor alpha 1 protein (ESR1) that promote
late-stage relapse breast cancer.We fırst used transcriptome sequencing to iden-
tify altered expression levels of lncRNAs between 72 primary tumors and 24
late-stage relapse breast cancer patients. We detected 1192 altered lncRNAs
when comparing the metastatic to the primary samples (FDR 0.05). Next, to
identify ESR1 bound lncRNAs associated with late-stage BC, we conducted
RNA Immunoprecipitation Sequencing of all transcripts bound to ESR1 as com-
pared to an IgG control in the ER T47D cell line. We identifıed 217 lncRNAs
bound to ESR1 of which 50 were up-regulated in late-stage BC, termed Late-
Stage Relapse BC ESR1-bound lncRNAs (LASERs). Next, we focused on char-
acterizing the most up-regulated differentially expressed lncRNA, LASER1.We
found that LASER1 has increased expression in ER breast cancer cell lines.
Further, elevated expression of LASER1 was also detected in MCF7 long-term
estrogen deprived cells lines that have amplifıed ER, suggesting an ER depen-
dent mechanism. Preliminary functional studies indicate LASER1 to promote
proliferation and invasion in BC cell lines. Ongoing studies will decipher how
LASERs interact with ESR1 to promote late-stage relapse. Overall, this is the fırst
study to discover ESR1 bound lncRNAs that may be contributing to late-stage
relapse in BC patients.
#2548 Oncogenic function and molecular mechanism of H19 noncoding
RNA in colorectal cancer.Hui Ling,1 Masahisa Ohtsuka,1 Cristina Ivan,1 Mar-
tin Pichler,1 Meng Chen,1 Ondrej Slaby,2 Ajay Goel,3 Milan Radovich,4 George
Calin1. 1MDAnderson Cancer Center, Houston, TX; 2Masaryk University, Czech
Republic; 3Baylor University Medical Center, TX; 4Indiana University School of
Medicine, TX.
The clinical signifıcance of long noncoding RNAs (lncRNAs) in colorectal
cancer (CRC) remains largely unknown. We analyzed a large panel of cancer-
associated lncRNAs in 483 TCGACRC cases, and identifıed that H19 correlates
most signifıcantly with overall survival and disease-free survival, independent of
stage and other clinical parameters. We validated the TCGA fındings with two
additional CRC cohorts. As one of the “oldest” lncRNAs, diverse activities of
H19 including interaction with epigenetic regulators, regulation of microRNAs
as competing endogenous RNA (ceRNA), and production of miR-675 as a pri-
mary transcript have been reported. However, an unbiased study to clarify the
essential mechanisms of H19 is lacking. To decipher the functional involvement
of H19 in CRC, we used an integrative approach combining unbiased microar-
ray analysis, experimental validation, and bioinformatic analysis of clinical data.
With such approach,we revealed not only previously reportedmechanisms such
as let-7 and MYC regulation by H19, but also several novel mechanisms that
have not been appreciated before. We discovered a mechanism of H19 on reg-
ulating RB-E2F signaling and accordingly controlling cell cycle progression.We
also identifıed for the fırst time that H19 regulates CDK8, an oncogenic driver in
CRC pathogenesis, and consequently affects -catenin activity (Firestein et al.,
Nature, 2008). We further identifıed an interaction of H19 with macroH2A, a
histone variant reported to repress CDK8 transcription (Kapoor et al., Nature,
2010). Importantly, expression correlation analysis with clinical samples
strongly supported the above-identifıed mechanisms. Combined analysis of
H19 with its targets showed strong independent prediction power for CRC sur-
vival. These data indicate the clinical relevance of Rb-E2F and CDK8/-catenin
signaling in mediating H19’s oncogenic activity in CRC.
#2549 A long non-coding RNA regulates the androgen receptor and me-
diates prostate cancer progression. Sethuramasundaram Pitchiaya, Rohit
Malik, Marcin Cieslik, Yajia Zhang, Xia Jiang, Arul M. Chinnaiyan. Univ. of
Michigan Comp. Cancer Ctr., Ann Arbor, MI.
The pervasive expression of long non-codingRNAs (lncRNAs) and their roles in
a plethora of cellular processes has revolutionized our understanding of functional
genetic elements. Emerging evidence suggest that lncRNAs are promising cancer
biomarkers and dysregulation of lncRNAs results in attenuated or accelerated on-
cogenic phenotypes. In support of these fındings, recent reports from the Chinnai-
yan labsuggest that lncRNAscanpotentiallydriveandactas independentpredictors
of aggressive prostate cancer (PCa). Central to PCa progression is the androgen
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: MicroRNAs and Other Noncoding RNAs as Tumor Suppressors or Oncogenes 1
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 649
receptor (AR), a nuclear hormone receptor, and the dysregulated transcriptionpro-
gram it mediates. Consequently, androgen deprivation therapy (ADT) supple-
mentedwithanti-androgens is the initial standard-of-care in treatingadvancedPCa.
Yet, the disease often manifests as a lethal, hormone-refractory castration-resistant
prostate cancer (CRPC) after initial ADT and this phenomenon is linked to the
resumption of AR activity. Therefore, we sought to identify novel and therapeuti-
callyactionable targetsofARthat candetect theonsetofPCaor stratifyPCavariants.
To this end, our lab recently characterized the transcriptional landscape of cancer
and discovered 50,000 novel transcripts, a signifıcant fraction of which were tis-
sue- and cancer-specifıc lncRNAs. Using this updated transcriptome as a reference
and performing RNA-seq on PCa cells stimulated with dihydrotestosterone (an
androgen), we identifıed Androgen Receptor regulated lncRNA-1 (ARlnc1) as an
important PCa-specifıc, AR-regulated lncRNA that reciprocally regulates AR. By
employing single-molecule fluorescence in situ hybridization (smFISH), we fınd
that ARlnc1 and AR transcripts colocalize within the nucleus of PCa cells and that
ARlnc1 promotes transcription of AR. Moreover, we found that ARlnc1 interacts
with anti-apoptotic, stress-granule related proteins and regulates PCa cell prolifer-
ation in vitro and in mouse xenografts. We have additionally found that anti-sense
oligonucleotides (ASOs) that target this lncRNAcan reduce tumor growth in xeno-
graftmodels.Taken together,ourdata suggests thatARlnc1andARreciprocallyand
positively modulate each other to promote PCa progression and that ARlnc1 may
serve as an enhancer RNA that regulates AR transcription. Our data suggests that
ARlnc1 can be therapeutically targeted to orthogonally modulate the AR signaling
axis for PCa treatment.
#2550 Anti-MALAT1 synthetic oligonucleotides target the proteasome
and exert anti-multiple myeloma activity. Maria Angelica Stamato,1 Nicola
Amodio,1 Eugenio Morelli,1 Giada Juli,1 Martina Manzoni,2 Maria Eugenia
GalloCantafıo,1 Lavinia Biamonte,1 Elisa Taiana,2 AnnamariaGullà,1 Emanuela
Altomare,1 Francesca Scionti,1 Daniele Caracciolo,1 Cirino Botta,1Maria Cucè,1
Mariamena Arbitrio,1 Maria Teresa Di Martino,1 Marco Rossi,1 Antonino
Neri,2 PierosandroTagliaferri,1 PierfrancescoTassone1. 1UniversityMagnaGre-
cia of Catanzaro, Catanzaro, Italy; 2Universita’ Degli Studi di Milano, Milano,
Italy.
Dysregulation of non-coding RNAs features prominently in the biology of
multiplemyeloma (MM). However, if short non-coding RNAs have been exten-
sively studied in this malignancy, the role of long non-coding RNAs remains to
be elucidated. A custom annotation pipeline of microarray data investigating
lncRNA expression in plasma cells from 20 MGUS, 33 smoldering MM, 170
MM, 36 plasma cell leukemia patients, and 9 healthy donors, indicates overex-
pression of the lncRNAMALAT1 during MM progression. On this fınding, we
sought to investigate the functional signifıcance of MALAT1 expression inMM
by the use of 16-mer LNA-gapmeR synthetic oligonucleotides, that trigger spe-
cifıc RNAse H-dependent degradation of MALAT1. Transfected or gymnotic
(naked) anti-MALAT1 gapmeRs decreased MM patients (n3) and cell lines
growth (n7), triggering ER stress and apoptosis, while spared healthy periph-
eral bloodmononuclear cells.Microarray gene profıling indicates thatMALAT1
depletion was associated with modulation of various gene sets, and specifıcally
had a negative impact on genes encoding for 20S proteasome subunits, such as
PSM2/4/5 and 7, whose overexpression is linked to proteasome impairment in
cancer cells. Down-modulation of PSMs after anti-MALAT1 gapmeRs expo-
sure was confırmed at protein level and was associated to reduced trypsine,
chymotrypsine and caspase-like proteasomal activities and to the accumulation
of poly-ubiquitylated species. Consistently, anti-MALAT1 gapmeRs enhanced
the in vitro anti-MM activity of the proteasome inhibitor bortezomib in bort-
ezomib-sensitive and resistant MM cells. In vivo, i.p. administration of naked
anti-MALAT1 gapmeRs (10 and 25mg/kg) inhibited the growth of bortezomib-
resistant MM xenografts, with no evidence of organ toxicity. Mechanistically,
anti-MALAT1-induced PSMs down-modulation could be ascribed to the in-
hibition of the transcription factors NRF1-2, which act as positive regulators of
PSMSs transcription. On the other hand, siRNA or pharmacologic inhibition
of NRF1 by all-trans retinoic acid decreased promoter activity and expression of
MALAT1, indicating the occurrence of a feedback loop involvingMALAT1 and
NRF1. Collectively, our data indicate that MALAT1-targeting represents a
promising strategy to dampen aberrant proteasome activity in MM cells, and
provide the preclinical rationale to use oligonucleotide therapeutics as anti-
MALAT1 gapmeRs for MM treatment.
#2551 LongnoncodingRNAHOXA11antisensepromotes tumor progres-
sion via the Notch pathway in serous ovarian cancer.Hee Jung Kim,1 GaWon
Yim,2Kyung Jin Eoh,1 LeeKyungKim,1 Jung-YunLee,1 Eun JiNam,1 SangWun
Kim,1 Young Tae Kim1. 1Institute of Women’s Life Medical Science, Yonsei Uni-
versity College of Medicine, Seoul, Republic of Korea; 2Department of Obstetrics
and Gynecology, National Medical Center, Seoul, Republic of Korea.
The biological function of long noncoding RNAs (lncRNAs) is only partially
understood. We investigated the expression of the novel HOXA11 antisense
(HOXA11as) lncRNA and its oncogenic role in serous ovarian cancer (SOC).
HOXA11as expression was examined in 129 serous ovarian cancer tissue sam-
ples by real time RT-PCR. Clinicopathologic factors and patient survival were
compared between high (N 27) and low HOXA11as expression group (N
102). To investigate the role of HOXA11as in cell proliferation, invasion, and
migration, HOXA11as expression in ovarian cancer cells was knocked down
using RNA interference. HOXA11as expression in cancer tissue was 77-fold
higher than that of noncancerous tissue (P 0.05). Higher HOXA11as expres-
sion signifıcantly correlated with histologic grade (P 0.017) and preoperative
CA125 (P 0.048). HOXA11as overexpression in SOC cells led to increased cell
proliferation, invasion, and migration. In addition, HOXA11as was associated
with the expression of genes that involve in cell proliferation, invasion, and
migration. Moreover, Knockdown of HOXA11as decreased the expression of
vascular endothelial growth factor, matrix metalloproteinase-9 and epithelial-
mesenchymal transition (EMT), which are important for cell motility and me-
tastasis.Mechanistic investigation revealed thatNotch1,Hes1 andp300 proteins
could be inhibited by HOXA11as depletion. In multivariate analysis,
HOXA11as was a prognostic factor of progressive disease and mortality (HR
1.730, 2.170 and P  0.043, 0.033, respectively). Progression-free and overall
survival were signifıcantly shorter in patients with high HOXA11as expression.
These fındings highlight the clinical signifıcance of HOXA11as in predicting the
prognosis of SOC patients and suggest its potential in promoting tumor aggres-
siveness by regulation of the Notch signaling pathway and EMT-related mech-
anisms.
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#2552 MDM2 induces cell fusion in breast cancer and osteosarcoma. Da-
vid J. Olivos, Mikhail Chtcherbinine, Eric R.Wolf, CiaránMcAtarsney, Lindsey
D. Mayo. Indiana University School of Medicine, Indianapolis, IN.
Cell fusion is a physiological process utilized by a variety of biological
systems during fertilization, embryogenesis, and cellular differentiation and
morphogenesis. During the malignant transformation of breast and bone
tissues, normal and malignant cells become fused to form hybrid structures.
These enhanced phenotypes acquire genetic characteristics which support
initiation, progression, and oncogenesis. In breast cancer and osteosarcoma
cell lines, cell fusion generates chromosomal instability, aneuploidy, and
DNA damage while maintaining the characteristics of enhanced migration,
invasion, and chemoresistance. We have found that mouse double minute 2
(Mdm2) signifıcantly induces cell fusion and the generation of large multi-
nucleated cells in MDA468, MDA231, MDA157, T47D breast cancer and
MG63 osteosarcoma cell lines under normoxia when compared to silenced
Mdm2 controls (P0.0005). Interestingly, silencing mutant p53 in the
MDA468 cell line resulted in signifıcantly higher fusion events (P0.0004)
suggesting mutant p53 may play a regulatory role in reducing Mdm2-asso-
ciated cell fusion. Silenced Mdm2 MDA231 cells showed a three-fold in-
crease under hypoxia whereas MG63 cells showed similar levels of cell fusion
events as in normoxic conditions suggesting cell specifıc dependency to en-
vironmental stimulus. The variation in proportions of cell fusion among
each cell type suggests this phenomenon is dependent on Mdm2 expression
and cell type. CD133MDA468 cells have increased fractions of polyploidal
cell events suggesting stemness may influence the polyploidal giant cancer
cell (PGCC) dynamics. The mechanism by which cell fusion occurs in breast
and osteosarcoma is poorly understood. Collectively these data suggest the
interplay of Mdm2, p53, and stemness in supporting the formation of fused
polypoidal cells and may serve as relevant targets for cancer therapy.
#2553 High-density array-CGHwith targetedNGSunmaskmultiple non-
contiguousminutedeletions on chromosome3p21 inmesothelioma.Michele
Carbone,1 Yoshie Yoshikawa,2 Mitsuru Emi,2 Tomoko Hashimoto-Tamaoki,2
Masaki Ohmuraya,2 Ayuko Sato,2 Tohru Tsujimura,2 Seiki Hasegawa,2 Takashi
Nakano,2Masaki Nasu,1 Sandra Pastorino,1 Agata Szymiczek,1 Angela Bononi,1
Harvey I. Pass,3 Haining Yang1. 1Univ. of Hawaii Cancer Ctr., Honolulu, HI;
2Hyogo College ofMedicine, Hyogo, Japan; 3New York University, New York, NY.
We used a custom-made comparative genomic hybridization-array (aCGH;
average probe interval 254 bp) to screen 33 malignant mesothelioma (MM)
biopsies for somatic copy number loss throughout the 3p21 region (10.7 Mb)
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that harbors 251 genes, including BRCA1-associated protein 1 (BAP1), themost
commonly mutated gene in MM. We identifıed frequent minute biallelic dele-
tions (3Kb) in 46/251 genes: fourwere cancer associated genes: SETD2 (7/33),
BAP1 (8/33), PBRM1 (3/33) and SMARCC1 (2/33). These four genes were fur-
ther investigated by targeted Next Generation Sequencing (tNGS), which re-
vealed sequence-level mutations causing biallelic inactivation. Combined high-
density aCGH and tNGS revealed biallelic gene inactivation in SETD2 (9/33,
27%), BAP1 (16/33, 48%), PBRM1 (5/33, 15%) and SMARCC1 (2/33, 6%). The
incidence of genetic alterations detected is much higher than reported in the
literature because minute deletions are not detected by NGS or commercial
aCGH. Many of these minute deletions were not contiguous but rather they
alternated with segments showing oscillating copy number changes along the
3p21 region. Functional assays revealed that SETD2, PBRM1 and SMARCC1 act
as tumor suppressor in MM. In summary, we found that in MM: 1) multiple
minute simultaneous biallelic deletions are frequent in chromosome 3p21,
where they occur as distinct events involving multiple genes; 2) in addition to
BAP1,mutations of SETD2, PBRM1 and SMARCC1 are frequent inMM; 3) our
results suggest that high-density aCGH combined with tNGS provide a more
precise estimate of the frequency and types of genes inactivated in human can-
cer, than approaches based exclusively on NGS strategy.
#2554 PRR14, a novel regulator of Ras signaling pathway. Mei Yang,1
Meijun Long,2 Xiaoliu Shi,1 Zhi-Min Yuan,3 Hang Su4. 1The Second Xiangya
Hospital of Central South University, Changsha, China; 2The Third Affıliated
Hospital of Sun Yat-sen University, Guangzhou, China; 3Harvard T.H. Chan
School of Public Health, Boston, MA; 4The University of Texas Health Science
Center at San Antonio, San Antonio, TX.
PRR14, a component of nuclear lamina, has recently been identifıed as a novel
oncogene in lung cancer. Frequently upregulated in lung cancers, PRR14 pro-
motes tumorigenesis through activating the PI3-kinase/Akt/mTOR signal path-
way. The regulatory effect is mediated by direct interaction with GRB2, a dock-
ing protein upstream of both PI3K and Ras. Indeed, PRR14 is commonly
elevated in many cancer types including lung cancer and breast cancer, but our
understanding of the underlying molecular mechanism is still very elusive.
Given the complicated interplay between PI3K and Ras signal pathways and
their importance in carcinogenesis and optimal treatment, we further explored
the effect of PRR14 on Ras activation. We used MCF10A human mammary
epithelial cells and its K-RasV12-induced cancerous counterparts to establish
isogenic cell lines that express different levels of PRR14. Colony formation and
growth curvesweremonitored simultaneously.Western blot andRas pull-down
activation assay were employed to examine protein level and Ras activity. Cell
fractionation was performed to detect protein location. We found that the ex-
pression level of PRR14 positively correlated with both Ras protein level and its
activity, resulting in consequent changes in cell proliferation and colony forma-
tion. Remarkably, elevated PRR14 promoted translocation of Ras from cyto-
plasm into the cell nucleus and its stabilization. In conclusion, PRR14 seques-
ters, stabilizes and activates Ras in cell nuclei. When upregulated, PRR14
promotes tumorigenesis, andRas signaling pathway presents one of the complex
underlying mechanisms.
#2555 ZC3H8 associates with PML bodies and influences aggressive tu-
mor cell behavior. John A. Schmidt, Emily Duffner, Gerard Walker, Keith G.
Danielson, Janice E. Knepper. Villanova Univ., Villanova, PA.
The ZC3H8 gene encodes a protein with three zinc fınger motifs in the C-ter-
minal region, suggesting a role as an RNA binding protein, but whose specifıc
function remains unclear. ZC3H8 protein localizes to both PML bodies and
Cajal bodies within the nucleus, as confocal microscopy demonstrates colocal-
ization of ZC3H8with both PML and coilin proteins. ZC3H8 has a casein kinase
2 phosphorylation site in the N-terminal region, and treatment with a casein
kinase 2 inhibitor causes the numerous PML bodies and their associated ZC3H8
to coalesce to a few larger bodies. Removal of the inhibitor restores PML bodies
to their original state. We constructed a mutant of ZC3H8 that removed the
predicted CK2 phosphorylation site by replacing the serine with an alanine
residue. Cells transfectedwith thismutant had reduced numbers of PMLbodies,
similar to cells treated with the CK2 inhibitor. In contrast, a mutant constructed
with a glutamic acid in place of the phosphorylatable serine was predicted to
behave as a constitutive mutant. This mutant did not exhibit differences from
wild type localization. These experiments suggest that ZC3H8 integrity is key to
maintenance of PML bodies. Other studies have identifıed ZC3H8 as a compo-
nent of the LEC (little elongation complex), andwe found that another identifıed
component, ICE2 (Narg) also localizes to PML bodies. The ZC3H8 gene is over-
expressed in a number of human andmouse breast cancer cell lines, and elevated
mRNA levels are associated with a poorer prognosis for women with breast
cancer. We have used RNA silencing to decrease levels of expression in two
independentmousemammary tumor cell lines. Cells with lower ZC3H8 expres-
sion have dramatic phenotypic changes, showing decreased rates of prolifera-
tion, slower migration in wound healing assays, formation of fewer and smaller
colonies in soft agar assays, and decreased ability to invade through a basement
membrane in transwell assays. Further, ZC3H8-depleted cells have decreased
rates of growth as spheroids and decreased growth in vivo in syngeneicmice.We
developed an inducible vector driving expression of ZC3H8. Upon treatment
with the inducer, doxycycline, cells assume a more aggressive phenotype. We
introduced a synonymous mutant of ZC3H8 unable to be silenced by the RNAi
into the knockdown cells, and rescued the aggressive phenotype of the original
tumor cells. Overexpression of ZC3H8 in non-tumorigenic COMMA-D cells
leads to a less pronounced, but opposite, increase in proliferation, motility, and
invasion. We have engineered the synonymous ZC3H8 with disrupted zinc fın-
ger motifs, and preliminary results suggest that disruption of the fırst zinc fınger
is not suffıcient to cause loss of the aggressive phenotype. We suggest that
ZC3H8 is an oncogene with substantial effects on the cancer cell phenotype.
These effects are hypothesized to be associated with ZC3H8 function in PML
bodies.
#2556 Loss of progesterone receptor through epigenetic regulation is as-
sociatedwith poor prognosis inmultiple solid tumors.Yiyang Li, Tamar Kav-
lashvili, Cheng Huang, Yuping Zhang, Xiangbing Meng, Kristina Thiel, Kim-
berly Leslie, Shujie Yang. Univ. of Iowa, Iowa City, IA.
Introduction: As a tumor suppressor in the endometrium, progesterone and
its synthesized analogue progestin have a long history as a treatment for endo-
metrial cancer. Loss of progesterone receptor (PR) in endometrial cancer leads
to therapeutic failure, and our group has identifıed several mechanisms under-
lying PR loss, most notably epigenetic silencing of PR transcription. Recently, a
Finnish group demonstrated that progestin therapy in premenopausal women is
associated with a lower incidence of not only endometrial cancer, but also ovar-
ian, pancreatic and lung cancers. This unexpected protective function of proges-
tin in organs outside of the reproductive system led us to hypothesize that tumor
progression effects in endometrial, ovarian, pancreatic and lung cancer is occurs
due to the loss of progesterone’s protective effects. Methods and results: Sup-
porting a potential protective role of progesterone, we discovered that PR is
downregulated in multiple tumors, including breast, endometrial, ovarian, cer-
vical, pancreatic and lung cancers, and loss of PR was consistently associated
with a poor prognosis based on analysis of theOncomine database. Similarly, PR
expression was low in multiple ovarian, pancreatic and lung cancer cells. Mech-
anistic studies revealed that PR downregulation wasmediated by the polycomb-
repressor complex and DNA methylation, though the precise mechanism dif-
fered among cell lines and cancer types. Treatment with epigenetic modulators,
which are FDA-approved for multiple myeloma, restored functional PR expres-
sion at both the mRNA and protein level and promoted marked cell death
through induction of apoptosis.. Moreover, overexpression of PR or treatment
with epigenetic modulators in combination with progesterone enhanced this
effect, indicating a key protective role for progesterone signaling through PR.
Conclusion: These data suggest loss of PR may be a general theme for tumori-
genesis or disease progression in multiple tumor types beyond the classically
studied endometrial cancer. In addition, the epigenetic mechanisms contribut-
ing to PR downregulation in endometrial tumors were recapitulated in other
tumor types, including ovarian, pancreatic and lung tumors. These studies col-
lectively set the stage for use of progestin therapy in combinationwith epigenetic
modulators, a concept we term “molecularly enhanced progestin therapy,” as a
novel therapeutic approach for many cancers. This combinatorial strategy has
the power to revitalize the use of epigenetic modulators, which have proved
disappointing in solid tumors, as an approach to resensitize cancer cells to a
tumor suppressor.
#2557 Role of microRNAs in breast cancer. Hesham Abbas El-Mahdy,1
Ossama Abdelmotaal Mansour,1 Mohamed Mohamed Badr,1 Reham Aly
Elshimy2. 1Faculty of pharmacy, Cairo, Egypt; 2National Cancer Institute, Cairo,
Egypt.
Background: Breast cancer (BC) is one of themost common cancer in women
around the world and the second leading cause of deathworldwide.MicroRNAs
(miRNAs) expression participates in breast cancer. Objectives: The purpose of
this study is to investigate the expression of miR-133a and miR-155 in breast
cancer serum and study their correlation with tumor suppressor protein (p53),
carcinoembryonic antigen (CEA) and cancer antigen-15.3 (CA-15.3) concen-
trations in serum of breast cancer patients and also study their correlations with
clinicopathological features. Material and methods: In this study the expression
of miR-133a andmiR-155 in serumwere measured using quantitative real-time
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polymerase chain reaction (qRT-PCR), P53 concentration was measured by
enzyme-linked immunosorbent assays (ELISA), CEA and CA-15.3 concentra-
tion were measured using ARCHITECT immunoassay in women with breast
cancer (n60) and controls (n 80). Results: In this study miRNA-155 was
signifıcantly overexpressed (P0.001) while miR-133a had signifıcant down
expression (P0.001) in the serum of breast cancer patients compared to con-
trol serum. P53 had no signifıcant correlations with any of the studiedmiRNAs.
Carcinoembryonic antigen and CA-15.3 have signifıcant higher concentration
in the serum of breast cancer patients compared to control serum. A signifıcant
association was observed between miR-133a with tumor grade (P0.05) and
miR-155 with lymph node involvement (P0.05). A signifıcant correlation be-
tweenmiR-155 andCEA (P0.05). No correlations betweenmiR-133a and P53,
CEA, CA-15.3. By using receiver operating characteristic (ROC) curve, the two
miRNAs showed higher sensitivity, specifıcity, positive predictive value and
negative predictive value than routinemarkers.OurConclusion: ThesemiRNAs
have a signifıcant signature in the pathogenesis of breast cancer and can be used
as non-invasive potential biomarkers for breast cancer detection.
#2558 MYC-dependent transformation model of triple-negative breast
cancer in vivo. Corey Lourenco, Manpreet Kalkat, Dharmesh Dingar, Jason De
Melo, Rosemary Yu, Linda Penn. Princess Margaret Cancer Centre, Toronto,
Ontario, Canada.
Recent comprehensive breast cancer studies examining mutations and genomic
alterations have determined that deregulation ofMYCand the PI3Kpathway occur
frequently during breast cancer progression and may be useful targets for therapy.
Asa result, therehavebeen largeefforts todevelopPI3K,AKTandmTORinhibitors
(PAMinhibitors) for clinical use, however clinical trial datademonstrates thatmany
patients treatedwith PAM inhibitors develop resistant disease. An alternative strat-
egy would be to targetMyc, though a lack of effective and specifıc inhibitors makes
this diffıcult. To identify the core vulnerabilities in these cancerswe developed an in
vivo xenograft model of triple-negative breast cancer driven by deregulated PI3K
signaling andMYC.We hypothesize that determining how these pathways co-op-
erate to transform normal human breast cells into breast carcinomas will reveal a
tumor progression signature and highlight new therapeutic opportunities. We de-
veloped our model using the spontaneously immortalized, basal, triple-negative
MCF10A cell line. By expressing the hotspot PIK3caH1047R protein alone in
MCF10A cells (MCF10.H) in addition to MYC (MCF10.HM), we can model nor-
mal/earlybreast cancerand invasiveductal carcinomarespectively.This is the fırst in
vivo humanmodel of breast cancer dependent onMYC for transformation.When
injected into female NOD-SCID mice, MCF10A.H cells form organized acinar
ducts embedded in extracellularmatrix.MCF10A.Hducts formwith hollow lumen
and a single layer of myoepithelial cells, recapitulating normal human breast
histology. Alternatively, MCF10A.HM cells grow as high-grade carcinomas
indicative of invasive disease. MCF10A.H benign growths andMCF10A.HM
tumors remain basal-like and triple-negative by immunohistochemistry.
Importantly, MCF10A.HM tumors are sensitive toMYC repression and therefore
may be a suitablemodel to evaluate direct and indirect anti-MYC therapies.Having
relevant human xenograft samples representing both normal and IDC tissue, we
performedRNA-seq to identify aMYC-signature driving breast cancer transforma-
tion. Our current work will involve targeting the resulting MYC-driven pathways
identifıed by RNA-seq to therapeutically targetMYC in breast cancer.
#2559 FoxF1 is a potential oncogene in prostate cancer. Carolin Boss-
mann,1 Constanze Merz,1 Yuri Tolkach,1 Jessica Carlsson,2 Sven Perner,3 Ove
Andrén,2 Glen Kristiansen,1 Michael Nowak1. 1University Hospital Bonn, Bonn,
Germany; 2University Hospital of Örebro, Örebro, Sweden; 3University Medical
Center Schleswig-Holstein, Lübeck, Germany.
Background: FoxF1 belongs to the family of forkhead box transcription fac-
tors. Many forkhead box proteins are linked to cancer development and pro-
gression. However, the regulation and exact function of FoxF1 remains unclear.
The aim of this study was to elucidate how the transcriptional activity of FoxF1
is controlled and to assess the role of FoxF1 within prostate cancer. Design: For
assessment of FoxF1 functions tumor cell lines were stably transfected with wild
type FoxF1 or mutant FoxF1 constructs lacking putative phosphorylation sites.
Protein expression and localization of FoxF1 were analyzed by immunprecipi-
tation andWestern Blot. Using tissuemicroarrays of prostate cancer cohorts we
analyzed the protein expression and intracellular localization of FoxF1 in tu-
mors compared to benign tissue. Results: Primary tumors anddistantmetastases
exhibited a signifıcantly higher FoxF1 expression compared to benign prostate
tissue. In tumors and metastases nuclear localized FoxF1 was more abundant
compared to benign tissue. Transfection of tumor cell lines with FoxF1 followed
by immunprecipitation and Western Blot showed that nuclear FoxF1 but not
cytoplasmic FoxF1 is phosphorylated in tyrosine residues, conceivably tyrosine-
39, as suggested by literature data. We further transfected tumor cell lines with
different amino acid exchange mutants of putative phosphorylation sites and
analyzed the transcription of the known FoxF1 target gene Pecam-1, revealing a
complex pattern of regulation, dependent on the site of phosphorylation. Over-
expression of FoxF1 in tumor cell lines resulted in epithelial-mesenchymal tran-
sition, as observed by loss of E-cadherin expression, gain of Vimentin expres-
sion, the up-regulation of Snail and Twist and changes to a spindle-like
morphology. Furthermore, overexpression of FoxF1 led to anchorage-indepen-
dent growth in soft agar as well as increased migration rates in vitro without
affecting the proliferation rate. Transfection of tumor cell lines with FoxF1 fol-
lowed by immunprecipitation andWestern Blot showed that nuclear FoxF1 but
not cytoplasmic FoxF1 is phosphorylated in tyrosine residues, conceivably ty-
rosine-39, as suggested by literature data.We further transfected tumor cell lines
with different amino acid exchange mutants of putative phosphorylation sites
and analyzed the transcription of the known FoxF1 target gene Pecam-1, reveal-
ing a complex pattern of regulation. Conclusion: In summary, our results point
to a role of FoxF1 as a potential oncogene in prostate cancer whose nuclear
localization and activity is regulated by phosphorylation.
#2560 Identifıcation and characterization of EWS-FLI1 binding partners
in Ewing sarcoma cell lines. Matthew L. Rotondi, Peter J. Houghton. Greehey
Children’s Cancer Research Institute, San Antonio, TX.
Ewing sarcoma (ES) is characterized by a reciprocal translocation t(11;22) that
results in a fusion of the EWSR1 and FLI1 genes (EWS-FLI). The objective of this
study is to identify protein binding partners of the purportedly undruggable chime-
ric transcription factorEWS-FLI1 to serve as alternative pharmacological targets for
potential ES-selective drug therapies. The literature identifıes the orphan nuclear
receptorDAX1 (encoded byNR0B1) as a binding partner of EWS-FLI1 the expres-
sion of which is restricted outside ES, thereby providing a target for a potential ES
selective drug. Yeast two-hybrid (Y2H) screening using EWS-FLI1 as the bait was
employed to identifyotherpotential targets.The importanceof thebindingpartners
identifıed by the Y2H screen was initially assessed by a series of proliferation assays
involving the ES cell lines EW8, ES7 and ES6 aswell as rhabdomyosarcoma cell line
Rh30 (Non-Ewing control). Prior tomeasuring proliferation, cells were transfected
a siRNA designed to target the putative binding partner of EWS-FLI1. These cells
were thengrownalongside cells transfectedwith a control siRNAover aperiodof 96
hr. The change in cell confluence in the wells was measured by a live-cell real-time
measurement (Incucyte).GeneknockdownwasconfırmedbyRT-PCRandwestern
blot analysis. The proliferation assays showed that the knockdown of DAX1 pro-
duces a notable reduction in cell proliferation compared to siRNA control prolifer-
ation in all three of the Ewing cell lines (10% to 25%). No signifıcant DAX1 siRNA
based inhibition of cell proliferation was detected in the Rh30 non-Ewing control
cell line. Three of the proteins identifıed by the Y2H screen showed signifıcant re-
ductions in ES cell proliferation. Methyl-CpG-Binding Domain Protein 1 (MBD1)
knockdown caused the proliferation of the ES cell lines to level off at 60% to 80%
within 2 to 4 days. Proliferation of MBD1 siRNA and control siRNA transfected
Rh30 cells was similar for the full 4 days of the assay. Mannosidase--class 2B-
member 2 (MAN2B2) knockdown caused the proliferation of the ES and Rh30 cell
lines to level off at 25% to 65%within 1 to 2 days.Mixed-Lineage Leukemia Protein
3 (MLL3) knockdown caused the proliferation of the EW8andES7 cell lines to level
off at 52% and 70% respectively.MLL3 knockdowndid not inhibit the proliferation
of Rh30 cells when compared to siRNA control cells. In contrast, ES6 cell prolifera-
tion was also not inhibited by MLL3 knockdown when compared to their siRNA
control cells. The knockdownsofDAX1,MLL3 andMBD1 suggest that theseEWS-
FLI1 binding partners would likely provide potential targets for ES drug develop-
ment. The effect of knocking downY2H-identifıed EWS-FLI interactors on colony
formation, migration and tumorigenicity is ongoing.
#2561 Wip1 constrains p53 activity during embryogenesis to permit nor-
mal neuronal development. Sharlyn J.Mazur, YantenewGete, Aamir Akbarali,
Charles Halsey, R Mark Simpson, Ettore Appella. National Cancer Institute,
Bethesda, MD.
The oncoproteins MDM2 and Wip1 (PPM1D) each negatively regulate tu-
mor suppressor p53 activity and overexpression of either promotes tumorigen-
esis. Both MDM2 and PPM1D genes are characteristically induced by p53 fol-
lowing exposure to DNA damage and both negatively regulate p53, but by
differentmechanisms. Inmice, homozygous deletion ofMdm2 is embryonically
lethal (E5.5-E6.5) resulting from excess p53-dependent apoptosis, whereas
Ppm1d/ embryos exhibit partial mid-gestation lethality. To investigate the
role of p53 in the partial lethality of Ppm1d/ embryos, we generated an en-
dogenous Ppm1d promoter -galactosidase reporter allele, Ppm1d3(LacZ), and
a new Ppm1d knockout allele, Ppm1d3.We also generated Trp53/Ppm1d3/3
double knockout embryos and mice. From Ppm1d/3 Ppm1d/3 crosses, ap-
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proximately 40% of Ppm1d3/3 embryos die between E10.5 and E12.5 and an ad-
ditional 40% die shortly after birth, leading to the survival of only approximately
20%of Ppm1d3/3 pups to adulthood. Sections of Ppm1d/3(LacZ) embryos show
dispersed LacZ staining activity with regions of higher activity, especially in specifıc
regionsofdevelopingneuronal tissues.Thedevelopingneural tissuesofPpm1d3/3
embryos are characterized by distorted cellular architecture, cell dropout, and dark,
pyknotic nuclei. Although the frequency of apoptotic cells was nearly three-fold
higher inPpm1d3/3 comparedwithPpm1d/ embryos (p 0.005), thenumber
ofapoptotic cellswere less than1%,even in theknockout. Interestingly, thenumbers
ofpHH3positivecells (Mphase) inventricularandsub-ventricular regionsofneural
tissue were reduced in E10.5 (p  0.01) and sharply reduced in E11.5 (p  0.05)
Ppm1d3/3 embryos compared with Ppm1d/ embryos. Intriguingly, the num-
bers of -H2AX foci per cell observed in Ppm1d3/3 sections were approximately
three-fold higher than in Ppm1d/ sections (p 0.002). The specifıc phenotypes
of excess mid-gestation embryonic lethality, excess neuronal apoptosis, and de-
fıcient ventricular and sub-ventricular pHH3 cell numbers, but not excess in
-H2AX foci numbers, were rescued by loss of p53 in Trp53/Ppm1d3/3
embryos. These results support a specifıc function of Wip1 in regulating p53
activity to ensure normal development of the brain and spinal cord during em-
bryogenesis.
#2562 Stromal antigen 1 (SA1) as a potential pro-neoplastic factor in non-
small-cell lung cancer (NSCLC). Michelle Zhang, Mart Dela Cruz, Navneet
Momi, Sanjib Chowdhury, Hemant Roy, Adam Lerner. Boston Medical Center,
Boston, MA.
Introduction: SA1, encoded by the STAG1 gene, is a subunit of the higher-
order chromatin remodeler cohesin. SA1 defıciency has been implicated as a
driver of aneuploidy and tumorigenesis (Remeseiro et al, EMBO J 2012). Fur-
thermore, our lab has recently shown that SA1 functions as a tumor suppressor
protein in early colon cancer (Wali et al, Cancer Prev Res 2016). The aim of this
project was to investigate the role of SA1 in NSCLC. Combining data from The
Cancer Genome Atlas (TCGA), human lung tissue, and in vitro gene knock-
down, we have surprisingly identifıed SA1 as a potential pro-neoplastic factor in
NSCLC. Methods: Data was extracted from TCGA and plotted to characterize
STAG1 gene alteration in NSCLC. Immunohistochemistry (IHC) was per-
formed on human lung tissue microarray assay (TMA) to assess SA1 protein
expression. Transient knockdowns were performed on A549 human lung ade-
nocarcinoma cells using STAG1 siRNA (Dharmacon) with an incubation time
of 48 hours. Following this, quantitative real-time polymerase chain reaction
(qPCR, Life Technologies) andWST-1 cell proliferation assays (Promega) were
performed as per protocol. Results: STAG1 alterations occur in about 3%of lung
adenocarcinoma and 17%of lung squamous cell carcinoma.Of these alterations,
themajority were amplifıcations. Furthermore, although not reaching statistical
signifıcance, there was a trend towards decreased survival with STAG1 altera-
tion in adenocarcinoma patients (11.6 months vs. 46 months). IHC demon-
strated a 1.7-fold increase in SA1 protein expression in NSCLCwhen compared
with non-malignant lung tissue (p0.001). Transfected A549 cells showed a
78% decrease in SA1 RNA expression (qPCR, p0.0002) and a 50% decrease in
cell proliferation (WST-1, p0.0001). Proliferating cell nuclear antigen
(PCNA), amarker of cell proliferation, was also decreased by 37% in transfected
cells (p0.001). Conclusions: Using TCGA data, we found that STAG1 altera-
tion occurs with some frequency in NSCLC and that many of these alterations
are amplifıcations of the gene. Furthermore, there is a trend towards decreased
survival with a STAG1 gene alteration. Our IHC data shows robust over-expres-
sion of SA1 in NSCLC when compared with non-malignant lung tissue. Our
qPCR data showed a profound decrease in SA1 mRNA expression following
transfection; accordingly, our WST-1 proliferation data suggests that knock-
down of the STAG1 gene signifıcantly decreases proliferation of A549 lung ad-
enocarcinoma cells. Decreased PCNA confırms a true anti-proliferative effect,
rather than a pro-apoptotic effect. This novel data suggests a link between SA1
and NSCLC, of which there are no prior published accounts. Even more com-
pelling is the implication that in NSCLC, SA1may be pro-neoplastic rather than
anti-neoplastic, which introduces a new potential target for future gene therapy.
#2563 LSD1 maintains differentiation and survival of mammary luminal
cells and suppresses invasion of luminal breast cancer cells via GATA3. Xin
Hu,1 Dongxi Xiang,2 Luwei Tao,2 Ying Xie,2 Yue Jin,1 Yidi Guo,1 Luca Pinello,3
Guo-Cheng Yuan,3 Zhe Li2. 1Jilin University, Changchun, China; 2Brigham &
Women’s Hospital, Boston, MA; 3Dana-Farber Cancer Institute, Boston, MA.
LSD1 (also known as KDM1A) is a histone demethylase that has been shown
to play both oncogenic and tumor suppressor roles in breast cancer. However,
the exact context under which it functions as a tumor suppressor or oncoprotein
remains largely elusive. To address this, we characterized its role in normal
mammary epithelial cells (MECs) and found MEC-specifıc ablation of Lsd1
largely phenocopied that of Gata3, which encodes amaster regulatory transcrip-
tion factor for luminalMECs. In the luminal lineage, LSD1-loss led to reduction
in both mature ductal and alveolar luminal subpopulations. In human luminal
breast cancer cells, we found LSD1 interacts with GATA3 and their common
target genes are highly related to breast cancer. In particular, we found LSD1
might be recruited by GATA3 to the GATA3 promoter region, to positively
regulate GATA3 expression via demethylation of H3K9me2. Knockdown of
LSD1 led to increased invasion of luminal breast cancer cells, in part via down-
regulation of GATA3 and multiple cell junction genes (e.g., CDH1, VCL, CT-
NNA1), as well as upregulation of mammary stem/progenitor cell genes (e.g.,
ELF5, ITGB1). However, LSD1 knockdown also led to reduced proliferation of
luminal breast cancer cells, in part via downregulation of RBBP4 (encoding a
Histone-binding protein) and upregulation of CDKN1A (encoding p21). Col-
lectively, our data suggest that LSD1 is required for maintaining luminal MEC
differentiation and survival and for suppressing luminal breast cancer cell inva-
sion, in part via GATA3. As inhibitors of LSD1 are currently under clinical trials
(e.g., in leukemia), our data suggest that although treatment of luminal breast
cancer by the LSD1 inhibitor may lead to reduced tumor cell proliferation (and
thus tumor shrinkage), the treatment may also lead to increased invasion of
surviving breast cancer cells. Thus, our study is expected to have important
implications for developing better epigenetic therapy in an individualized, con-
text-dependent fashion.
#2565 VCP/p97 segregase-mediated regulation of chromatin-bound
PTEN stability. Jinshan He, Gulzar Wani, Qianzheng Zhu, Altaf A Wani. The
Ohio State University, Columbus, OH.
Phosphatase and Tensin homolog (PTEN) tumor suppressor protein is asso-
ciated with many human cancers. PTEN has been shown to accumulate in the
nucleus and control DNA repair in response to genotoxic stress. PTEN down-
regulation impairs the capacity of global genomic nucleotide excision repair by
suppressing the early DNA damage sensor, Xeroderma pigmentosum C (XPC),
protein. Our recent work has demonstrated that the Valosin-containing protein
(VCP)/p97 segregase participates in proteolytic processing of XPC and Cock-
ayne syndrome B (CSB) proteins. Here, we show that (i) VCP/p97 segregase, in
conjunction with its adaptor proteins, specifıcally extracts PTEN from damaged
chromatin for targeted proteasomal degradation, (ii) inhibition of VCP/p97
activity induces the accumulation of PTEN on chromatin, and (iii) VCP/p97
physically interacts with PTEN.Depletion of VCP/p97, in p97-knockout cells or
siRNA-mediated ablation in normal cells, affects the stability of PTEN in re-
sponse to cellular UV irradiation. Results show that compromising the protea-
some and VCP/p97 functions causes the accumulation of PTEN accompanied
by an increase of UBXD7, proteasomal RPN2 and Sug1 within the chromatin
compartment. To our knowledge, this is the fırst report to reveal that VCP/p97
segregase extracts tumor suppressor PTEN from damaged chromatin. (This
work was supported by NIH grants ES002388 and ES012991 to AAW).
#2566 Positive cross-regulatory loop links ZBTB7A to estrogen receptor
alpha expression in breast cancer. Mary Ellen Molloy, Monika Lewinska,
ThanhThaoNguyen, Zhi-Min Yuan.Harvard THChan School of Public Health,
Boston, MA.
In breast development and tumorigenesis the biological functions of estrogen
are mediated by estrogen receptor alpha (ER). Approximately 70% of breast
cancers are classifıed as ER positive and are therefore candidates to receive
various forms of endocrine therapy.Denovo or acquired resistance to endocrine
therapies limits their clinical effectiveness. Identifıcation of novel targets is crit-
ical to combat disease progression.Our lab has recently discovered that ZBTB7A
suppresses glycolysis by transcriptionally repressing key genes within the glyco-
lytic pathway in various cancer types (Liu, X.S., et al. 2014). Currently, ZBTB7A
is proposed to be an oncogene in breast cancer (Zu, X., et al. 2011), however its
function in ER positive breast cancers has yet to be fully addressed. Using
publically available datasets, we found that in luminal breast cancers relapse free
survival was improved for patients whose tumors expressed high levels of
ZBTB7A.Gene expression analysis of TCGAdatasets revealed that ZBTB7Aand
ER are highly correlated in human breast tumors prompting us to evaluate
their potential cross regulation. ERmRNAandprotein levelswere signifıcantly
decreased upon ZBTB7A silencing both in MCF-7 and T47D breast cancer cell
lines. Upon estradiol stimulation, ZBTB7A silencing reduced ER target gene
expression and estrogen response element driven luciferase reporter activity.
Additionally, silencing of ZBTB7A inhibited estradiol-induced proliferation
and decreased sensitivity to tamoxifen in MCF-7 and T47D cells. These data
suggest that ZBTB7Amay be required to mediate the pro-proliferative signal of
estradiol through its regulation of ER expression in breast cancer cell lines. To
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evaluate the potential regulation of ER on ZBTB7A, ER was silenced and
ZBTB7AmRNAand protein expressionwere determined. ER silencing had no
effect on ZBTB7A mRNA levels, but led to decreased ZBTB7A protein expres-
sion. These effects on ZBTB7A protein expression were attenuated by the pres-
ence of the proteasomal inhibitor MG132. Together, these data suggest a model
in which ZBTB7A promotes ER expression at the transcript level while ER
stabilizes ZBTB7A post-transcriptionally conferring a positive feedback loop
and sensitivity to estradiol and endocrine therapies. ZBTB7Amay contribute to
the transcriptional program maintaining a hormone and endocrine therapy re-
sponsive phenotype in breast cancer.
#2567 CYP24A1-induced vitaminD insuffıciency promotes breast cancer
growth.MakotoOsanai, Akira Takasawa, Kumi Takasawa,MasakiMurata, No-
rimasa Sawada. Sapporo Medical Univ., Sapporo, Japan.
Vitamin D plays a critical role in the maintenance of tissue homeostasis by
regulating the expression of genes affecting cell proliferation, differentiation,
and apoptosis. The vitamin D 24-hydroxylase CYP24A1 functions in vitamin D
target tissues to degrade the hormonal form of vitamin D. Existing knowledge
regarding dysregulated CYP24A1 expression supports its candidacy as a puta-
tive oncogene. In our presentation, we demonstrate that the suppression of
constitutive CYP24A1 expression by CYP24A1-specidic shRNA conferred tar-
get cells with increased susceptibility to apoptosis and consequently inhibited
anchorage-independent growth in breast carcinoma cells. In addition, suppres-
sion of vitamin D metabolism following knockdown of CYP24A1 signifıcantly
reduced tumor growth in vivo. Since these data provide substantial evidence for
a pro-survival and stimulatory oncogenic effect of CYP24A1 in breast carci-
noma cells, we will discuss the potential feasibility of CYP24A1-inhibitory can-
cer therapies.
#2568 Mutant p53 regulates HSP70 expression and nuclear localization.
Kishore Polireddy, Kanchan Singh, Melissa Pruski, Wasim Dar, John S. Bynon,
Jennifer M. Bailey. University of Texas Health Science Center, Houston, TX.
Pancreatic cancer is the 3rd leading cause of cancer related deaths in the US
with a median survival of less than one year. No effective therapies or early
detection tests are available for these patients. Scientists have been studying
cellular origins of pancreatic cancer to aid in the development of novel treat-
ments and biomarkers. Several studies have demonstrated that acinar cells have
a high propensity to undergo acinar to ductal metaplasia and form precursor
lesions of pancreatic ductal adenocarcinoma. We have recently shown that si-
multaneous expression of Kras and mutant TP53 can generate invasive ductal
adenocarcinoma from ductal cells. We hypothesized specifıc mutations in TP53
have different mechanisms of transforming ductal cells. In order to understand
the role of mutant TP53 in transforming pancreatic ductal cells into invasive
ductal adenocarcinoma, we used a lentiviral system to express mutant
TP53R175H and TP53R273H, two of the most frequently mutated TP53 alleles in
pancreatic cancer patients, in immortalized pancreatic ductal epithelial cells
carrying a Kras mutation (HPNE-KrasG12D). Trypan blue dye exclusion assay
and Spheroid formation assays were used to study cellular proliferation and
cancer stem cell (CSC) populations. Mutant TP53 over expression enhanced
CSCpopulationswithout altering cellular proliferation inHPNE-KrasG12D cells.
Reverse phase protein array (RPPA) was carried out to detect gene expression
changes in HPNE-KrasG12D cells upon mutant TP53 over expression. RPPA
assay results suggested that TP53R175H uniquely induced HSP70 expression in
HPNE-KrasG12D cells, as cells expressing either vector control or TP53R273H
failed to do so. HSP70 expression was further validated by transiently overex-
pressing TP53R175H and TP53R273H. Surprisingly, TP53R175H specifıcally pro-
moted nuclear localization of HSP70 without altering the expression of a re-
cently identifıed HSP70 nuclear transporter, Hikeshi. Future studies will
determine 1) whether HSP70 is required for p53-mediated stemness in HPNE-
KrasG12D cells and 2) the function of nuclear HSP70. In summary, over expres-
sion of mutant p53 enhanced cancer stem cell properties of HPNE-KrasG12D
cells, through upregulation HSP70. The exact mechanism behind HSP70 nu-
clear localization and increased cancer stem cell properties is being more rigor-
ously explored.
#2569 BCL6 promotes glioma and serves as a novel therapeutic target.
Liang Xu,1 Ye CHEN,1 Marina Dutra-Clarke,2 Anand Mayakonda,1 Masaharu
Hazawa,1 Steve E. Savinoff,2 NganDoan,3 JonathanW. Said,3WilliamH.Yong,3
Henry Yang,1 Ling-Wen Ding,1 Yan-Yi Jiang,1 JeffreyW. Tyner,4 Jianhong Ch-
ing,5 Jean-Paul Kovalik,5 Markus Müschen,6 Joshua J. Breunig,3 De-Chen Lin,1
Phillip Koeffler1. 1National University of Singapore, Singapore, Singapore; 2Ce-
dars-Sinai Medical Center, UCLA, Los Angeles, CA; 3UCLA, Los Angeles, CA;
4Oregon Health & Science University, OR; 5Duke-NUS GraduateMedical School,
Singapore, Singapore; 6University of California San Francisco, CA.
ZBTB transcription factors orchestrate gene transcription during tissue de-
velopment. However, their roles in glioblastoma multiforme (GBM) remain
unexplored. Here, through a functional screening of ZBTB genes, we identify
that BCL6 is required for GBM cell proliferation and is overexpressed in GBM
samples. Using a somatic transgenicmousemodel, Bcl6 confers the proliferative
and invasive stimuli to glioma cells in vivo. Moreover, we discover AXL as a
novel downstream target of BCL6. Through AXL, BCL6 enhances both MEK-
ERK and S6K-RPS6 axes. Pharmacological inhibition of BCL6 activity effec-
tively blocksGBMgrowth and inhibitsAXL expression. Together, these fındings
uncover a novel glioma-promoting role of BCL6, and provide the rationale of
targeting BCL6 as a potential therapeutic approach.
#2570 Induction of mild oxidative stress as a strategy for reactivation of
mutant p53 proteins: KSS72, a small molecule derived from ethacrynic acid
restores the biological functions of R248W/Q mutant. Surendra R. Punga-
nuru, Hanumantha Rao Madala, Kalkunte S. Srivenugopal. Texas Tech Univ.
Health Sciences Ctr., Amarillo, TX.
p53 gene mutations in 50% of human cancers drive the emergence of onco-
genic genomes and confer resistance to anticancer drugs& apoptosis. Therefore,
a pharmacological reactivation of p53 mutant proteins to their wild-type forms
has emerged as an intense research area. We have shown that induction of
oxidative protein modifıcations primarily underlie the mechanistic conversion
of mutant to wt or wt-like p53 forms (Eur JMedchem 107:233, 2016; Int J Oncol
48:1426, 2016). R248W/Q DNA contact mutations in the p53 core are highly
frequent and cause functional inactivation. No small molecules reactivating this
p53mutation are available. Here, we describe the design and synthesis of a small
molecule KSS72 using a cell-based screening and its potency in reactivating the
R248 p53 mutants. KSS72 is a non-diuretic hydrophobic analog [1-(2,3-di-
chloro-4-methoxyphenyl)-2-methylenebutan-1-one] of ethacrynic acid (Ede-
crin) obtained by removing the carboxylate side chain. KSS-72 retained the
ability to bind with GSH, inhibit GSTs and induce marked redox-imbalance in
tumor cells. KSS72 displayed preferential cytotoxicity (3-4 foldmore cell killing)
against cancer cells expressing the allele specifıc R248Wmutation (MiaPaca-2)
in comparison with the wt p53 or p53-null cancer cell lines. Further, we devel-
oped isogenic cell lines expressing the R248W and R248Q mutants in the p53-
nullH1299 lung cancer cells and evaluated their sensitivity towardsKSS72; these
models again verifıed the greater drug effıcacy. To prove the hypothesis the
higher effıcacy of KSS72 stems from the reactivation of mutant p53, the confor-
mation-specifıc antibodies (Pab1620 for wt and Pab420 for mutant) were em-
ployed. Immunoprecipitation and immunostaining using confocal microscopy
showed that KSS72 treatment of R248W or R248Q p53-cells results in a marked
reciprocal loss of mutant protein and gradual increase of wt-like protein. EMSA
revealed a time-dependent restoration of DNA-binding of the mutant p53,
which was accompanied by a distinct upregulation of pro-apoptotic signaling
pathwaysmediated by PUMA,Bax, p21cip1 andMDM2proteins. A strongG2/M
arrest and signifıcant apoptosis were observed. Other data showed that KSS72
restores the wt structure and function by covalently binding the p53R248 pro-
tein. Pharmacokinetics showed that KSS72 has excellent oral bioavailability with
a half-life of 3.5 h. InMiaPaca-2 xenografts developed in nude mice, there was a
marked tumor growth suppression with KSS72 as a single drug. In conclusion,
KSS72 is an attractive lead compound for further development because p53
reactivation occurred without discernible organ toxicities after oral doses and a
wide therapeutic window. The redox-sensitive cysteines involved in the p53
reactivation are being identifıed by mass spectrometry (supported by CPRIT
grants RP130266 & RP170207 to KSS).
#2571 DBC1, a novel CBP-interacting protein, promotes p53 stability by
regulating CBP-dependent p53 polyubiquitination. Oluwatoyin E. Akande,1
Priyadarshan K. Damle,1 Nicholas E. Sherman,2 Steven R. Grossman1. 1Virginia
Commonwealth University, Richmond, VA; 2University of Virginia, Charlottes-
ville, VA.
The acetyltransferase CBP, in conjunction with the E3 ubiquitin ligase en-
zyme, Mdm2, maintains physiologic levels of the tumor suppressor protein p53
in the absence of cellular stress, via a cytoplasmic, but not nuclear, p53-directed
E4 polyubiquitin activity. CBP also possesses cytoplasmic, but not nuclear, E3
ubiquitin ligase, autoubiquitination activity. To understand the mechanism by
which the ubiquitin ligase activities of CBP are compartmentalized in the cell, we
have employedMultidimensional Protein Identifıcation Technology (MudPIT)
to identify cytoplasmic and nuclear CBP interacting proteins. MudPIT analysis
revealed that Cell Cycle and Apoptosis Regulator protein (CCAR2), also known
as Deleted in Breast Cancer 1 protein (DBC1), is a novel CBP- interacting pro-
tein in both the nucleus and cytoplasm. The N-terminus of DBC1 bound to
multiple CBP domains, including the putative E3/E4 domain of CBP located at
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the N-terminus. Interaction between DBC1 and CBP suppressed the in vitro E3
autoubiquitination activity of CBP. Functional studies demonstrated that DBC1
directly regulates the cellular compartmentalization of CBPE3 and p53-directed
E4 ubiquitin ligase activities. Knockdown of DBC1 in U2OS cells stimulated
normally absent nuclear p53 polyubiquitination, and also caused a decrease in
p53-dependent and p53-independent apoptosis, rescued by CBP/DBC1 double
knockdown. Further, over-expression of DBC1 rescued the increase in nuclear
p53 polyubiquitination and decrease in p53 half-life observed in DBC1 depleted
cells. Together, these results identify DBC1 as a novel binding partner of CBP
and a critical regulator of CBP ubiquitin ligase activities. Based on our data that
DBC1 loss inactivates p53 function through destabilization, we queried the
TCGA database for co-occurrence of DBC1 loss with maintenance of wild-type
p53 status which showed that 33% of breast, 40% of lung, and 96% of prostate
cancer cases with DBC1 alterations maintained wild-type p53 status. Therefore,
by restoring DBC1 function, this work could lead to reactivation of p53 tumor
suppressor activity in tumors with DBC1 alterations maintaining wild-type p53
status.
#2572 The novel long non-coding RNA PANCR is an intracellular p53
activator. Yu Cao. Southern illinois University, Springfıeld, IL.
Longnon-codingRNAs (LncRNAs) function as oncogenes or tumor suppres-
sors in development and progression of cancer. Chromosome 16q22.1 region is
frequently deleted in breast cancer, which may contribute to breast carcinogen-
esis by inactivation of tumor suppressor genes. This study characterized a new
LncRNA tumor suppressor, named p53 activating non-coding RNA (PANCR),
located in this Chromosome 16q22.1 region. This PANCR LncRNA consists of
1.5kb in length.Our data showed that PANCR was downregulated in breast
cancer cell lines and tissues. In the breast cancer cell lines, PANCR expression
appeared reversely correlated with cell malignancy, and in breast cancer tissues,
PANCR was downregulated over 2 times in 31(62.0%) of 50 cases when com-
pared to adjacent normal breast tissues. In breast cancer cellsMCF7 and immor-
talized human mammary epithelial cells MCF10A, ectopic expression of
PANCR inducedmarked apoptosis, suppressing cell proliferation in culture and
tumor growth in xenografts, but in contrast, shRNA-mediated silencing of
PANCR promoted cell growth and proliferation. Mechanistic approaches re-
vealed that in bothMCF7 andMCF10A cell, PANCR activated p53 and upregu-
lated pro-apoptotic proteins bid and bim and cell cycle inhibitors p21waf/cip1 and
p27Kip1. We further explored the mechanism of action that PANCR activates
p53, and our results fromRNA immunoprecipitation (RIP), RNApulldown and
immunoprecipitation (Co-IP) demonstrated that the PANCR can bind to p53,
dissociate p53-MDM2 complex and thus activate p53.Together our data suggest
that the novel LncRNA PANCR located in the deleted Chromosome 16q22.1
region is an intracellular p53activator, functioning as a tumor suppressor by
activating p53-mediated apoptosis.
#2573 TP73’s regulation and expression in human cancer cell lines. Zhix-
ing Yao, David R. Yao, William Yu, Hassan Brim, Hassan Ashktorab, Zaki A.
Sherif. Howard Univ., Washington, DC.
TP73 is the homologue of themaster tumor suppressor TP53. It is involved in
cellular responses to stress and development. The TP73 gene encodes two dif-
ferent proteins, TAp73 and Np73 and maps to a region on chromosome 1p36
that is frequently deleted in neuroblastoma and other tumors, and thought to
contain multiple tumor suppressor genes. However, the analysis of p73-knock-
out mice yielded conflicting results with respect to tumor suppression. World-
wide efforts in sequencing the TP73 gene in patient tumor samples have not
provided evidence for genetic alterations as a common cause of p73 inactivation
in human cancer. The role of TP73 in tumorigenesis has remained elusive to
date. In this study, we isolated two stem cell lines from normal young and old
human liver tissues and determined TP73 expression in human breast cancer
cell lines (MCF7&MDA321), humanhepatocellular carcinoma (HCC) cell lines
(HepG2, SNU398, SNU449 & SNU475), neuroblastoma cell lines (IMR32 &
SK-N-SH), normal liver stem cell, non-cancerous Li-Fraumeni Syndrome (LFS)
skin fıbroblasts cells and normal skin fıbroblasts. Results show that TAp73 only
expresses in cancer cell lines. Moreover, when HepG2 and MDA231 were
treated with paclitaxel, a cytoskeletal drug that targets tubulin, TAp73 expres-
sion was drastically down-regulated in HepG2 cells and abrogated in MDA231
cells at 1 to 5 mol/L concentrations. Furthermore, ChIP assay results demon-
strated that TP53 andCTCF (a chromosomal networking proteinCCCTCbind-
ing factor) bind to TP73 promoter and regulate TP73 expression. Our observa-
tion may prove signifıcant for the development of future therapeutic and
diagnostic applications. *These authors contributed equally to this work.
#2574 ThePICT-1 is required forUSP7 to effectively stabilize p53protein,
and codon 389 polymorphism is a risk factor for ovarian cancer. Masafumi
Yoshimoto, Aoi Tokuda, Yuji Yaginuma. Kumamoto Univ. Graduate School of
Health Sci., Kumamoto, Japan.
The ovarian cancers causes the deaths of more than 100,000 women per year
worldwide, and it is a complex disease, with multiple both histological subtypes
and molecular characteristics recognized; therefore, overall survival rates have
improved little in the last 30 years. We have to precisely identify genetic and
molecular events which could serve as markers for early diagnosis or targets for
new therapeutics for ovarian cancers. The PICT-1 (also named GLTSCR2), one
of the nucleolar proteins, has several tumor suppressor functions, such as the
stabilization of PTEN and p53. Some studies reported that the loss of or low
PICT-1 expression is the common alteration in many cancers, such as brain,
skin, lung, esophageal, prostate, kidney, breast, and cervix, but its association
with ovarian carcinogenesis has been unknown. Therefore, we investigated its
alteration, regulation mechanism, and the effect for p53 stabilization in ovarian
cancer. We found that polymorphism on codon 389 (rs184994) was a statisti-
cally signifıcant association with the risk of ovarian cancers. Furthermore, ecto-
pic expression of PICT-1 was required for USP7 to effectively stabilize p53 pro-
tein. Because PICT-1 was reported to bind both p53 andMDM2 that enabled to
form USP7-p53-MDM2 complex, we investigated whether PICT-1 was regu-
lated by USP7-p53-MDM2 complex. Our results suggested that this complex
was the important regulator for PICT-1. In the investigation of the role of
PICT-1 that played in the ovarian carcinogenesis using immunohistochemical
stainig, we found that PICT-1 protein levels decreased in ovarian cancer tissues
compared to normal ovary, and there was a positive correlation between PICT-1
and USP7 protein expression. Our fındings suggested that PICT-1 involved in
exactly p53 regulation along with MDM2 and USP7, and PICT-1 should be
considered as a potential target for therapeutic human cancers.
#2575 Concurrent mutation of CDKN2A and TP53 loci in primary kera-
tinocytes. Bin Li, Edmund A.Mroz, JamesW. Rocco. The Ohio State University
Comprehensive Cancer Center, Columbus, OH.
Concurrent inactivation of the p16Ink4a and p53 tumor suppressors, often
throughmutation of CDKN2A and TP53, is frequent in early development of head
and neck squamous cell carcinoma (HNSCC) and other cancers. The role of this
early combined inactivation, and the oncogenic drivers that subsequently lead to
tumor development, are poorly defıned. To characterize the precancerous role of
concurrently mutated CDKN2A and TP53, we combined a number of recent ad-
vances to disrupt both loci in primary cells. First, we grew primary keratinocytes in
medium conditioned by irradiated J2-3T3 cells and containing an inhibitor of
ROCK kinases, conditions that greatly extend their normally limited proliferative
potential. Second, we transfected primary keratinocytes with plasmid vectors ex-
pressing both Cas9 and sets of guide RNAs targeting specifıc regions of CDKN2A
andTP53.We targeted either or both of the p14Arf and p16Ink4a protein products
of CDKN2A for knockout (KO), together with either TP53 KO or a TP53 point
mutation (R248Q protein product), two major categories of genetic alterations of
p53 in HNSCC. Third, we evaluated use of nutlin-3, an inhibitor of p53-MDM2
interaction, to try to select against cells that still contained wild-type p53. We as-
sessedKOeffıciencybyPCRof genomicDNA; theTP53pointmutation introduced
a SauA3i site into TP53. Two weeks of nutlin-3 treatment led to a 3 fold increase in
p53KOeffıciencyversusuntreatedcells (50%versus14%).p16Ink4aKOeffıciencies
were enhanced2 to 14 fold after nutlin-3 treatment, dependingon the specifıcCas9/
guide-RNAconstructs used. In cells transfected toproducep53R248Q, 14%ofPCR
products amplifying the mutated region after nutlin-3 exposure showed Sau3Ai
digestion, whereas no Sau3Ai digestion was detected in untreated cells. This result
suggests that up to 14%of nutlin-3 treated keratinocytes had integrated themutated
donor oligo sequence. We similarly enrich for mutated keratinocytes having
p14Arf-specifıc or combined CDKN2A KO along with TP53 KO or mutation.
Combined transfection to generate concurrent CDKN2A and TP53mutations un-
der conditions that allow extendedproliferation in culture, followedby selection for
successful TP53mutation with nutlin-3, will facilitate identifıcation of keratinocyte
clones with bi-allelic knockout genotypes. This panel of keratinocytes with concur-
rent CDKN2A and TP53 mutations will help delineate the roles of these genes in
early cancer development and will allow screening for the oncogenic drivers re-
quired for tumor development andmetastasis, with emphasis on discoveringmore
effective and specifıc druggable targets for improving treatment.
#2576 Benzyl isothiocyanate potentiates p53 signaling and antitumor ef-
fects against breast cancer through activation of p53-LKB1 and p73-LKB1
axes. Arumugam Nagalingam,1 Bei Xie,1 Panjamurthy Kuppusamy,2 Nethaji
Muniraj,1 Peter Langford,1 Balázs Győrffy,3 Neeraj Saxena,2 Dipali Sharma1.
1Johns Hopkins University, Baltimore, MD; 2University of Maryland, Baltimore,
MD; 3Hungarian Academy of Sciences, Hungary.
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Functional reactivation of p53 pathway, although arduous, can potentially
provide a broad-based strategy for cancer therapy owing to frequent p53 inac-
tivation in human cancer. Using a phosphoprotein-screening array, we found
that Benzyl Isothiocynate, (BITC) increases p53 phosphorylation in breast can-
cer cells and reveal an important role of ERK and PRAS40/MDM2 in BITC-
mediated p53 activation. We show that BITC rescues and activates p53-signal-
ing network and inhibits growth of p53-mutant cells. Mechanistically, BITC
induces p73 expression in p53-mutant cells, disrupts the interaction of p73 and
mutant-p53, thereby releasing p73 from sequestration and allowing it to be
transcriptionally active. Furthermore, BITC-induced p53 and p73 axes converge
on tumor-suppressor LKB1 which is transcriptionally upregulated by p53 and
p73 in p53-wild-type and p53-mutant cells respectively; and in a feed-forward
mechanism, LKB1 tethers with p53 and p73 to get recruited to p53-responsive
promoters. Analyses of BITC-treated xenografts using LKB1-null cells corrob-
orate in vitro mechanistic fındings and establish LKB1 as the key node whereby
BITC potentiates as well as rescues p53-pathway in p53-wild-type as well as
p53-mutant cells. These data provide fırst in vitro and in vivo evidence of the
integral role of previously unrecognized crosstalk between BITC, p53/LKB1 and
p73/LKB1 axes in breast tumor growth-inhibition.
#2577 Expression of P53/PTEN/c-Myc in peripheral blood leukocytes
from patients with breast cancer and its clinical signifıcance. Guangcheng
Huang,1 Qiang Ma,2 Jiang Zou,1 Ru Sun,1 Lihua Yao,1 Lei Xu,1 Dongsheng
Wang,2 Xiaolan Guo2. 1North Sichuan Medical College, Nanchong, China; 2Af-
fıliated Hospital of North Sichuan Medical College, Nanchong, China.
Breast cancer remains the most frequently diagnosed malignancy and
leading cause of cancer deaths in women worldwide. Current data showed
that the morbidity of breast cancer has been rising shifting with younger age
in the last decades, therefore early detection is urgently needed to improve
the management of breast cancer as what has been working on many other
malignancies. Dysfunction of tumor suppressor gene and/or oncogene
might play vital roles in tumorigenesis and cancer progression, such as P53,
PTEN and c-Myc. In this study we aim to detect the expression of P53/
PTEN/c-Myc mRNA in peripheral blood leukocytes from patients with
breast cancer and benign breast diseases, and investigate its correlation with
the clinicopathologic characteristics, further to explore the potential clinical
application signifıcance. In this study, fluorescent quantitation Real-time
Polymerase Chain Reaction (FQ-RT-PCR) was employed to detect the ex-
pression of P53/PTEN/c-Myc mRNA in peripheral blood leukocytes from
304 cases, including 105 patients with breast cancer, 107 cases of benign
breast diseases and 92 healthy women as control. 2CT was used to calcu-
late the relative quantitative gene expression and Mann-whitney U test was
carried to distinguish the differences among the independent cohorts. The
results showed that P53 and PTENmRNAwere signifıcantly reduced in both
breast cancer group and benign breast diseases group, respectively(P0.01),
moreover, the P53 mRNA in benign breast diseases was even lower than that
in breast cancer(P0.01). However, c-Myc didn’t show any obvious differ-
ence among the three groups. Further investigation the genes expression
with clinicopathologic characteristics, we found that PTEN in patients with
breast cancer was correlated with lymph nodes metastasis and clinical stage
as well. Among those breast cancer patients without lymph node metastasis,
the level of PTENmRNA in peripheral blood leukocytes was obviously lower
than that in patients with metastatic lymph node positive (P0.05), on the
other hand, breast cancer patients with ductal carcinoma in situ and earlier
stages(0III) showed lower PTEN mRNA than those in later or advanced
stages (IIIIV) (P0.01). Above results indicated that P53 and PTEN
mRNA in peripheral blood leukocytes displayed apparent difference among
patients with breast cancer, benign breast diseases and healthy control, and
dysregulation of P53/PTEN was found in patients with benign breast dis-
eases, even more obvious than that in breast cancer patients. Moreover,
down-regulation of PTEN might predict and/or display the early events of
breast cancer carcinogenesis and lymph nodes metastasis. Our fındings sug-
gest that detection of tumor related genes in peripheral blood leukocytes
would serve as a unique potential approach in early and noninvasive diag-
nosis of tumors, also would be very promising in clinical applications as well.
#2578 Investigating the role of mutant p53 in esophageal squamous cell
carcinoma. Ashley Lento,1 Apple Long,1 Veronique Giroux,1 Qiaosi Tang,1
Morgan Sammons,1 Andres Klein-Szanto,2 Shelly Berger,1 Anil Rustgi1. 1The
University of Pennsylvania, Philadelphia, PA; 2Fox Chase Cancer Center, Phila-
delphia, PA.
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive cancer
characterized by a high rate of metastasis, limited therapeutic options, and a
poor prognosis. However, there is limited information regarding the molecular
mechanisms underlying the metastatic properties of ESCC. p53 is one of the
most commonly mutated genes in ESCC, and our group has shown that esoph-
ageal cells lines expressing a mutation in human p53 shows signs of malignancy
and increased invasion in 3D organotypic culture. A mouse model of mutant
p53 (R172H) in ESCC is lacking in the fıeld. To elucidate the role of mutant p53
in ESCCwe developed a novelmousemodel utilizing a genetic and carcinogenic
approach. L2cre;p53/ and p53R172H/mice were generated and treated with
4NQO in their drinking water for 16 weeks, which resulted in the development
of ESCC. Compared to wildtype mice, p53R172H/- mice and p53/mice exhib-
ited a decreased tumor latency time, increased tumor frequency and a more
severe tumor diagnosis. However, p53R172H/mice and p53/mice displayed
similar tumorigenic properties. RNA-seq was performed on cell lines estab-
lished from wildtype and p53 mouse models and reveled different gene expres-
sion profıles between wildtype, p53R172H/, and p53/ cells. p53R172H/ cells
displayed an increase inmesenchymal and decrease in epithelial marker expres-
sion, supporting the idea that they are undergoing EMT. In addition, several
endocytic recycling related genes, including Rab11-fıp1, Rab25, and Myo5b
were downregulated inmutant and null p53 compared to wildtype cells. Further
examination of the differing genetic profıles in our mouse models can provide
novel insight into the role of mutant p53 in ESCC tumorigenesis and lead to the
identifıcation of new therapeutic targets.
#2579 Identifying pathways that regulate the turnover of gain-of-function
p53mutant proteins in ovarian cancer cells.Achuth Padmanabhan,1 Nicholes
Candelaria,1 Kwong-Kwok Wong,2 Bryan C. Nikolai,1 David Lonard,1 Bert W.
O’Malley,1 JoAnne S. Richards1. 1Baylor College ofMedicine, Houston, TX; 2MD
Anderson Cancer Center, Houston, TX.
Ovarian cancer is the fıfth leading cause for cancer-associated deaths among
women in the US. High-grade serous ovarian carcinoma is the most common
histological subtype and is characterized by frequent (90%) mutations in the
TP53 (p53) gene. Gain-of-function (GOF) p53 mutant proteins form highly
stable aggregates that accumulate in ovarian cancer cells and have been shown to
have oncogenic activity. Increasing evidence indicates the stabilization of GOF
p53mutants to be important for tumor progression and drug resistance. There-
fore, selective degradation of the GOF p53mutant proteins is a highly attractive
therapeutic strategy to specifıcally target ovarian cancer cells. We identifıed that
a small molecule named MCB-613, originally discovered as a stimulator of ste-
roid receptor coactivator-3 (SRC-3), causes rapid degradation of the usually
stable p53R175H conformational mutant aggregates leading to catastrophic cell
death in human ovarian cancer cell lines. Our results indicate this effect is inde-
pendent of SRC-3 mediated gene expression, but rather by post-translational
modifıcation of p53 mutant protein. Upon MCB-613 treatment, the p53R175H
mutant is rapidly exported from the nucleus, ubiquitinated and degraded
through a lysosomal pathway. Interestingly, in contrast to its effect on the
p53R175H mutant, MCB-613 causes a slight stabilization of wild type (WT) p53
but had less of an effect on the turnover of other frequently observed p53 mu-
tants (R248Q and R273H) in human ovarian cancer cell lines. MCB-613 also
causes a rapid decrease in MDM2 protein but not mRNA. Further, the effect of
MCB-613 on p53R175H is phenocopied bymultiple deubiquitinase (DUB) inhib-
itors, confırming the role of ubiquitination in the selective turnover of p53R175H
mutant aggregates. Taken together, these results show that different pathways
regulate the turnover ofWT p53 and the specifıc GOF p53mutant proteins. We
are currently investigating the precise mechanism by which MCB-613 and the
different DUB inhibitors induce selective turnover of p53R175H mutant protein.
We anticipate the proposed work to signifıcantly advance our understanding of
pathways important in ovarian cancer progression and pave way for the devel-
opment of new targeted therapies for ovarian cancer patients with specifıc p53
mutations. This work is funded by NIH-CA-181808, NIH-HD-07857 andNIH-
HD-076596.
#2580 Ceramide-rubusoside nano-micelles restores p53-mediated tumor
suppression in p53R248Wmutant ovarian cancer cells. sachinK. khiste,1 Zhi-
jun Liu,2 Yong-Yu Liu1. 1University of Louisiana at Monroe, Monroe, LA; 2Lou-
isiana State University, Monroe, LA.
Ceramide (Cer), a sphingolipid metabolite, has crucial functions in anti-pro-
liferation, cell differentiation and apoptosis. Cellular Cer levels highly correlates
to therapeutic effıcacy of anticancer drugs, however, the hydrophobicity Cer has
limits to develop it as a therapeutic agent. Here, we report that Cer-rubusoside
(Cer-RUB) nanomicelles enhanced Cer bioavailability and restored p53-medi-
ated tumor suppression. These nanomicelles signifıcantly increased the levels of
NBD-C6-Cer by more than 50-fold in serum, 40-fold in tumor and 70-fold in
lung of tumor-bearingmice (1mg/kg, i.p., 24 hr), respectively. Cer-RUB (3M)
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signifıcantly increased OVCAR-3 (p53 R248W) cell sensitivity to cisplatin, and
the IC50 values decreased by 3-fold, even though these valueswere no signifıcant
changes in A2780 (wt p53) cells. Furthermore, Cer-RUB treatments (1 mg/kg,
i.p. every 3 days for 24 days) signifıcantly increased cisplatin effıcacy in tumor
growth-arrest in OVCAR-3 tumor-mice, and the tumor volumes reduced by
52% (1653 vs. 805 mm3) in combination with cisplatin, compared to cisplatin
alone.We found that ovarian cancer stem cells (CD44/CD133) decreased by
10-fold (0.85 vs. 0.08% of total cells) inOVCAR-3 tumors treated with Cer-RUB
combined with cisplatin, as compared to cisplatin alone, respectively. Western
blotting showed that Cer-RUB treatments selectively increased the expression
levels of phosphorylated p53 (Ser15), BAX and p21 in OVCAR-3 cancer cells
and tumors, respectively. These studies indicates that the gain-of-function
(GOF) of p53 R248W leads OVCAR-3 cell resistance to cisplatin and tumor
growth. Cer-RUB can restore p53 and eliminates the GOF of p53 R248W in
cancers.
#2581 VGLL4 suppresses the human breast cancer progression through
the inhibition of YAP oncogenic function. Jianmin Zhang. Roswell Park Can-
cer Inst., Buffalo, NY.
VGLL4 is a Vestigial-like (VGLL) protein that is deregulated in various types
of cancer. However, the functions of VGLL4 in breast cancer remain largely
unknown. Here, we demonstrate that VGLL4 expression positively correlates
with survival for breast cancer patients. The overexpression of VGLL4 in breast
cancer cells reduced cell proliferation, colony formation, cell migration and
invasion in vitro and inhibited tumor growth in vivo. We found that the 2nd
TEAD-interacting domain (TDU2) of VGLL4 is involved in interactions be-
tween VGLL4 and the transcription factor TEAD and that the deletion of this
domain completely abolished the phenotype induced by VGLL4 overexpres-
sion. Interestingly, RNAseq analysis indicated that VGLL4 overexpression not
only inhibits YAP targets but also activates the TGF- and Notch signaling
pathways. Our study provides evidence of the tumor-suppressive effects of
VGLL4 on breast cancer progression and suggests that VGLL4 and its TDU2
domainmay become promising and effıcient therapeutic targets for delaying the
development of breast cancer and improving patient survival.
BIOINFORMATICS AND SYSTEMS BIOLOGY: Computational
Tools and Databases
#2582 KIRnome: KIR genotyping for whole genome/exome sequencing
data.Daeyoon Kim,1 Sung-Soo Yoon,1 Youngil Koh,1 Su Yeon Lee,2 Hongseok
Yun,2 SunghoonCho,3Hyung-LaeKim4. 1SeoulNationalUniv. Cancer Research
Inst., Seoul, Republic of Korea; 2Development Group, Healthcare Analytics Team,
Samsung SDS, Seoul, Republic of Korea; 3Functional Genome Institute, PDXen
Biosystems Inc, Seoul, Republic of Korea; 4Department of Biochemistry, Ewha
Womens University College of Medicine, Seoul, Republic of Korea.
In this study, we tried to develop valid KIR calling algorithm fromWES/WGS
data. As a consequence, here we suggest KIRnome (KIR typing for whole ge-
nome and exome sequencing) which is a KIR typing method for applying se-
quencing data such asWES/WGS. A total of 71 sequencing data (18WES and 53
WGS data, respectively) and matched experimentally validated KIR genotype
data are used to train and validate. Before developing this method, two types of
allele references (genomic and coding, here after called gSeq and cSeq) are con-
structed by allele sequence of IPD/KIR. KIRnome consists of two part, fırst part
is calculating normalized depth (here after called depth) of 16 KIR genes and
considering allele reference length and second is estimating KIR type based on
depth. In general, we get higher normalized depth when using genomic refer-
ences for WGS data and using coding references for WES data. This coincides
with scheme KIRnome and the characteristics of WGS andWES data. Given 71
samples of 3 data sets, we evaluated KIR genotyping performance of KIRnome
per each KIR gene. For all 16 KIR genes, KIRnome shows98.5% accuracy.
When KIRnome performance was tested only in 13WES samples, the accuracy
slightly drops to 94%. We assume this is attributable to relatively small number
of the samples. In conclusion, we developed a novel and unique method named
KIRnome for KIR typing fromNGS data. KIRnome could determine KIR geno-
type accurately from WES and WGS data respectively. We expect KIRnome
would facilitate revealation of immunogenetic facts in various disease. More-
over, future generation of KIR specifıc NGS data and improved reference se-
quence information of KIR would enable KIRnome to type KIR at allele level in
a near future.
#2583 A model for capturing and integrating complex molecular altera-
tions related to clinically relevant effıcacy evidence. Cara M. Statz, Sara E.
Patterson, Taofei Yin, Susan M. Mockus. The Jackson Laboratory for Genomic
Medicine, Farmington, CT.
The ability to capture data relevant to different types of oncology-related
variations, including single nucleotide variations, deletions, insertions, copy
number variations, and fusions in a single system is crucial to a comprehensive
understanding of cancer biology. However, collectively linking these varied
types of molecular alterations to capture their compound impact to clinically
relevant effıcacy evidence within a database can prove challenging. Thus, we
have built the JAX Clinical Knowledgebase (JAX-CKB), a flexible relational da-
tabase that allows curation of complex molecular profıles and provides the abil-
ity to associate these profıles with documented effıcacy evidence, thereby pro-
viding a more detailed overview of therapeutic relevance. To demonstrate the
utility of creating complex molecular signatures in relation to effıcacy evidence,
the JAX-CKB was queried to fırst determine the overall degree of effıcacy evi-
dence content related to complex profıles. Additionally, two specifıc types of
complex molecular profıles were queried, which included EML4-ALK plus a
missensemutation(s) and BRAFV600E plus any type ofmolecular alteration(s).
Within the JAX-CKB, there are 1,383 unique effıcacy evidence lines linked to
complex molecular profıles. The complex molecular profıles consisting of
EML4-ALK and one or more additional missense mutations were associated
with 174 unique effıcacy evidence lines. Of the 174 lines, 69 were annotated with
a resistant response type, while 68were annotatedwith a sensitive response type.
The combination of BRAF V600E with one or more molecular alterations was
linked to 229 unique effıcacy evidence lines. The majority of the lines, 118, were
specifıc to a resistant response type and 83 were associated with sensitivity.
Comprehensive genomic profıling of cancer patient samples can often reveal
complexmolecular signatures. The JAX-CKB is an inclusive knowledgebase that
allows one to interpret these complex signatures and rapidly identify appropri-
ate targeted therapies, which could be critical in a clinical setting.
#2584 TheUCSCXena system for cancer genomics data visualization and
interpretation.MaryGoldman, BrianCraft, JingchunZhu, DavidHaussler.UC
Santa Cruz, Santa Cruz, CA.
TheUCSCXena platform (http://xena.ucsc.edu/) allows biologists and bioin-
formaticians to securely analyze and visualize their private functional genomics
data in the context of public genomic and clinical data sets. The Xena platform
consists of a set of federated data hubs and the Xena browser, which integrates
across hubs, providing one location to analyze and visualize all data. Our ex-
panding public XenaDataHubs currently hosts 1400data sets frommore than
35 cancer types, as well as Pan-Cancer data sets. Our public data hubs serve
seminal cancer genomics and functional genomics data set to the scientifıc com-
munity, including the latest TCGA, TARGET, ICGC, and GTEx data sets. We
support most data types including somatic and germline SNPs, INDELs, large
structural variants, CNV, gene-, transcript-, exon- protein-,miRNA-expression,
DNA methylation, phenotypes, clinical data, subtype classifıcations and
genomic biomarkers. Additionally, investigators’ own functional genomics data
can be hosted on private hubs running on their laptop or behind the fırewall.
Data is integrated on the UCSC Xena Browser, allowing biologists to view and
interpretation of their genomic data in the context of a large collection of cancer
genomics data sets such as TCGA. The lightweight Xena data hubs are straight-
forward to install on Windows, Mac and Linux operating systems and loading
data is easy using either our application or command line interface. This system
of the browser and hubs helps researchers combine new or preliminary results
from their laptops or internal servers, or even data from a new paper, securely
with vetted data from the public sphere. Visualizations and analyses include
dynamic Kaplan-Meier survival analysis to assess survival stratifıcation by any
information in addition to our visual spreadsheet, scatter plots and bar graphs.
We seek feedback at our poster on new visualizations and functionalities.
#2585 viGEN: An open source bioinformatics pipeline for viral RNA de-
tection and quantifıcation in human tumor samples.Krithika Bhuvaneshwar,
Lei Song, Yuriy Gusev. Georgetown University, Washington, DC.
We present a novel pipeline for viral RNA detection and quantifıcation in
human RNA-seq data. Our pipeline has been tested on the TCGA liver cancer
cohort, can not only detect the presence of a viral species, but also provide gene
level read counts for individual viral species and extract viral-variants. Introduc-
tion Approximately 20% of human cancer types are associated with viral infec-
tion that is routinely detected in blood samples. However the extent and biolog-
ical signifıcance of viral presence/infection in actual tumor samples is generally
unknown but could be measured using existing Human RNA-seq data from
tumor samples.We have developed a bioinformatics pipeline viGEN combining
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existing and novel RNAseq tools that allows for detection and quantifıcation of
viral RNA in human RNAseq data. Methods The pipeline includes 4 major
modules: The fırst module allows to align and fılter out human RNA sequences;
secondmodule maps and count (remaining un-aligned) reads against reference
genomes of all known and sequenced human viruses; the third module calcu-
lates quantitate read counts at the individual viral genes level thus allowing for
downstreamdifferential expression analysis of viral genes between experimental
and controls groups. The fourth module calls variants in these viruses. To the
best of our knowledge there are no publicly available pipelines or packages that
would provide this type of complete analysis in one package. Customized solu-
tions have been reported in the literature however were notmade public. Results
We used this pipeline to examine viruses present in RNA-seq data from 75 liver
cancer patients in the TCGA data collection. Our pipeline allows conducting
quantitative analysis at the gene level for visualization and detection of statisti-
cally signifıcant differentially expressed viral genes between groups of patients
known to be infected with both HBV and various subtypes of HCV. Once the
viral genomes are detected at the genome level, we examine the differences
between “Dead” and “Alive” samples at the viral-transcript level, and at the
viral-variant level. Conclusion Our results show that it is possible to detect viral
sequences fromwhole-transcriptome (RNA-seq) data in humans.We were able
to not only quantify them at a viral-gene/CDS level, but also extract variants
from the 75-sample dataset from TCGA. The results presented here are in cor-
respondencewith published literature and are a proof of concept of our pipeline.
This pipeline can be used on cancer and non-cancer human RNA-seq or other
NGS data to provide additional insights into the biological signifıcance of viral
infection in complex diseases, tumorigeneses and cancer immunology.
#2586 CellMinerCDB: Enabling cross-database exploration of molecular
pharmacology data and response determinant discovery in cancer cell lines.
Vinodh N. Rajapakse,1 Augustin Luna,2 Chris Sander,2 William C. Reinhold,1
Yves Pommier1. 1National Cancer Institute, Bethesda, MD; 2Dana-Farber Can-
cer Institute, Boston, MA.
Cancer cell line panels are widely used for evaluating drug response across
diverse tissue types. A growing set of molecular profıling data complements
measurements of chemosensitivity, providing novel avenues for response deter-
minant discovery and clinical translation. Accessing and inter-relating data
fromdifferent sources is essential for evaluating such determinants, but remains
challenging. To enable wider access to cell line pharmacogenomic data, we have
developed CellMinerCDB (CellMiner Cross-Database, discover.nci.nih.gov/
cellminercdb), a web application integrating data from several widely studied
cancer cell line panels, including the NCI-60 (NIH), GDSC (Sanger/MGH), and
CCLE/CTRP (Broad). All together, our database spans over 1300 distinct cell
lines, 400 clinically relevant cancer drugs, 20,000 experimental compounds, and
molecular profıling data, such as gene/protein expression, DNA copy, methyl-
ation, and mutational status. Cell line and tested drug overlaps allow cross-
database validation of genomic anddrug data, andCellMinerCDB simplifıes this
by transparently matching differently named entities between sources. Data ex-
ploration can be additionally restricted to particular tissue types, with individual
cell lines annotated to the OncoTree ontology for consistent treatment across
sources. A range of analysis tools support interactive data exploration, from 2D
plots of drug response andmolecular profıling features to exhaustive correlation
analyses and multivariate predictive models. We illustrate the power and utility
of CellMinerCDBwith examples of response determinant discovery and predic-
tive modeling for Top1 and PARP inhibitors. Beginning with established indi-
vidual determinants, such as SLFN11 mRNA expression, we show how both
unbiased and biological knowledge network-based feature selection methods
enable iterative refınement of a multivariate genomic signature of drug re-
sponse. ForTop 1 inhibitors, additional predictive features include expression of
chromatin remodeling factors and genes modulating apoptosis capacity, while
complementary PARP inhibitor response determinants include PARP1 and
drug efflux pump expression. Pathway and process-based gene annotations al-
low biological interpretation of response predictive features. CellMinerCDB
also includes ongoing algorithmic work to improve the construction of multi-
variate predictive models using constraints from biological networks. These
approaches bridge a limiting gap in existing methods, which either ignore bio-
logical knowledge altogether or are limited to exploration within known path-
ways and processes.
#2587 VCF2CNA: a tool for effıciently detecting copy number alteration
using VCF genotype data. Daniel K. Putnam, Xiaotu Ma, Stephen V. Rice, Yu
Liu, Jinghui Zhang, XiangChen. St. Jude Children’s ResearchHospital,Memphis,
TN.
Whole genome sequencing (WGS) is increasingly used in both research and
clinical settings. The Variant Call Format (VCF) specifıcation is a widely ad-
opted fıle format for genetic variation data exchange partially due to its smaller
fıle size compared to rawWGSBAMs. Each variant in a typical VCF fıle contains
its chromosome position, reference/alternative alleles and corresponding allele
counts. This makes it possible to identify copy number alterations (CNAs). To
this end, we developed VCF2CNA (http://vcf2cna.stjude.org), a web interface
tool for CNA analysis from VCF fıles. A user of VCF2CNA, uploads a VCF fıle
via the providedweb interface. The entire analysis runs remotelywith an average
run time of 23 minutes. Results are emailed to the user as either a downloadable
link or fıle attachments. VCF2CNA also accepts input in the Mutation Annota-
tion Format (MAF) and the variant fıle format produced by the Bambino pro-
gram. We analyzed 22 TCGA glioblastoma tumor/normal pairs by Illumina
technology to evaluate VCF2CNA’s performance. It achieved high consistency
(average F1-score: 0.952	 0.082) with CONSERTING, a tool that incorporated
read-depth and SV data from raw BAMs for CNA detection. A segment-by-
segment comparison between results from CONSERTING and VCF2CNA in-
dicated that the latter was less sensitive to focal CNAs. This is expected because
there is less information in the VCF input than in raw BAMs. Further analysis
using samples with a “fractured genome” pattern revealed that VCF2CNA was
more robust to library artifacts and produced relatively clean CNA profıles (on
average 76.2-fold reduction compared to the number of segments reported by
CONSERTING). Finally, we analyzed 137 pediatric neuroblastoma samples
from the TARGET project, sequenced by Complete Genomics, Inc. (CGI) tech-
nology. MYCN amplifıcation has been clinically validated in 33 samples.
VCF2CNA identifıed high amplitude MYCN gains in 32 samples and the re-
maining sample carried a low-level broad gain covering MYCN. For compari-
son, CGI’s HMM-based method reported MYCN gains in only 15 out of the 33
samples. VCF2CNA further identifıed two additional MYCN amplifıcations
among the remaining samples. Collectively, our analysis suggests that
VCF2CNA is a platform-independent, effıcient, robust and accurate tool for
general WGS-based CNA analysis. It further complements CONSERTING,
which produces more accurate result in focal CNAs at the cost of signifıcantly
higher computational burden.
#2588 GenePattern Notebook: an environment for reproducible cancer
research. Michael M. Reich,1 Thorin T. Tabor,1 Ted Liefeld,1 Barbara Hill,2
Helga Thorvaldsdottir,2 Jill P. Mesirov1. 1University of California, San Diego, La
Jolla, CA; 2Broad Institute, Cambridge, MA.
As the availability of genetic and genomic data and analysis tools from large-
scale cancer initiatives continues to increase, the need has become more urgent
for a software environment that supports the entire “idea to dissemination” cycle
of an integrative cancer genomics analysis. Such a systemwould need to provide
access to a large number of analysis tools without the need for programming, be
suffıciently flexible to accommodate the practices of non-programming biolo-
gists as well as experienced bioinformaticians, and would provide a way for
researchers to encapsulate their work into a single “executable document” in-
cluding not only the analytical workflow but also the associated descriptive text,
graphics, and supporting research. To address these needs, we have developed
GenePattern Notebook, based on the GenePattern environment for integrative
genomics and the Jupyter Notebook system. GenePattern Notebook unites the
phases of in silico research – experiment design, collaborative analysis, and
publication – into a single interface. GenePattern Notebook presents a familiar
lab-notebook format that allows researchers to build a record of their work by
creating “cells” containing text, graphics, or executable analyses. Researchers
add, delete, and modify cells as the research evolves, supporting the initial re-
search phases of prototyping and collaborative analysis. When an analysis is
ready for publication, the same document that was used in the design and anal-
ysis phases becomes a research narrative that interleaves text, graphics, data, and
executable analyses, serving as the complete, reproducible, in silico methods
section for a publication. GenePattern Notebook features are designed to make
it easy for nonprogramming users to create and adapt notebooks. We have
developed new cell types that allow users to choose analyses, specify input pa-
rameters and datasets, navigate results, send result fıles to new analyses, and
create richly formatted text, all without the need for programming. We have
released a freely available onlineGenePatternNotebookworkspace, http://note-
book.genepattern.org, where researchers can develop and publish notebook
documents. We have provided a collection of template notebooks that walk
users through various machine learning analyses, and are collaborating with
cancer research laboratories to create integrative cancer genomics notebooks as
well. Notebook topics in development include characterization of intratumoral
heterogeneity from single cell RNA-Seq data, effective clinical interpretation of
comprehensive genomic profıling from whole exome sequencing of a patient’s
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tumor and germ line samples, and identifıcation of master regulators/transcrip-
tion factors associated with the downstream transcriptional effects associated
with the activation of an oncogene.
#2589 Identifying cancer susceptibility variants and genes using whole
exome and genome sequencing: a literature review.Melissa Rotunno,1 Mindy
Clyne,1 Tram Lam,1 Leah Mechanic,1 Danielle Daee,1 Stefanie Nelson,1 Eliza-
beth Gillanders,1 Alisa Goldstein2. 1NCI-DCCPS, Rockville, MD; 2NCI-DCEG,
Rockville, MD.
The application ofNextGeneration Sequencing (NGS) technologies in cancer
research enabled the discovery of novel somatic mutations at an unprecedented
speed through effıcient high-throughput profıling of DNA variation in tumor
samples. In contrast, the identifıcation through NGS studies of germline varia-
tion associated with cancer has been more diffıcult and with limited consensus
around best practices for study design and analytical techniques.We performed
a review of the 2005-2016 PubMed English literature for genome-wide germline
sequencing studies that were aimed at identifying new cancer susceptibility
genes or variants.We extracted and summarized the experimental and analytical
designs, methods and tools implemented in the selected literature together with
their degree of success and limitations in identifying cancer susceptibility vari-
ants. About 80 in-scope publicationswere identifıed and examined in depth. The
most studied cancer types were colorectal, breast, blood and lung and were
investigated predominantly via whole exome sequencing (primarily using Illu-
minaHiSeq) in familial cases of Caucasian ethnicity. Only 10 studies usedwhole
genome sequencing and 15 adopted a case control study design. A large fraction
of the familial studies was limited to 1 or 2 families and sequenced 2 or less cases
per family. Reporting of key data quality information (e.g., human sequence
coverage) was inconsistent throughout the publications. While the methods for
sequence alignment and variant calling converged towards those implemented
in established bioinformatic tools (e.g., BWA, GATK), there were no standard
approaches for fıltering or prioritizing of variants. Most studies included some
degree of technical validation, often restricted to the top few variants or genes.
About 60%of the studies included replication in an independent group of cancer
patients and 55% functionally validated their fındings to some extent. Our work
provides valuable data and insights to inform future sequencing studies of can-
cer genetic susceptibility, and points to the need for improving standardization
and completeness in reporting of quality control metrics, study design rationale
and interpretation of fındings.
#2590 Analysis of APOBEC3A and APOBEC3B mutational signatures
using next-generation sequencing data from cancer cell lines. Suleyman
Vural, Julia Krushkal, Richard Simon.National Cancer Institute, Rockville, MD.
The APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypep-
tide-like) gene family of cytidine deaminases includes evolutionarily conserved
genes that play important roles in DNA repair andmRNA editing. Activity of at
least two APOBEC family members, APOBEC3A and APOBEC3B, can lead to
kataegis, a mutagenic process in cancer cells that generates clusters of closely
spaced, single strand specifıc C-T DNA substitutions. APOBEC mutagenesis
has a characteristic signature, most commonly represented by the 5’-Tp(C-
T)pW-3’ sequence motif, with additional substitutions also reported. This
hypermutation signature and high mRNA expression of APOBEC3A and
APOBEC3B have been associatedwith several cancer types.Most previous stud-
ies of APOBEC signatures have examined tumor sequence data from clinical
samples, for which limited or no information about drug response was available.
We investigated the presence of themutational signature andmRNAexpression
patterns of the APOBEC3A and APOBEC3B genes in extensively characterized
cell lines, in order to identify those cell lines that carry mutations generated by
kataegis, with the aim of establishing associations between the APOBEC muta-
tional signature, individual cancer types, and the patterns of sensitivity to anti-
tumor agents. For this purpose, we analyzed whole exome sequencing (WES)
data and mRNA expression of the APOBEC3A and APOBEC3B genes in two
resources with extensive drug response data: the NCI-60 cell line panel, which
includes 59 human cancer cell lines representing 9 cancer types and drug re-
sponse information for thousands of anticancer agents, and theCancer Cell Line
Encyclopedia (CCLE), which provides WES, whole genome, and RNA-seq se-
quence information on hundreds of cancer cell lines and drug response data to
over 200 agents. We analyzed WES data of 325 CCLE cell lines and 59 NCI-60
cell lines, with variants identifıed using GATK pipeline and Varscan2 software.
The variants in each cell linewere fıltered to remove commonpolymorphisms in
dbSNP and 1000 Genome Project databases. We searched the discovered vari-
ants for the presence of APOBEC signatures, 5’-Tp(C-AGT)pN-3’, 5’-Tp(C-
AGT)pD-3’, and 5’-Tp(C-AGT)pW-3’ in closely spaced (1000 and 10,000
bp) windows that appeared on the same DNA strand. We will discuss the use of
optimal fılters for detecting APOBECmutational signatures andwill present the
analyses of associations between APOBEC signatures, mutational load of the
tumor cell lines, APOBEC gene expression, and chemosensitivity to treatment.
These results contribute to additional characterization of available cell lines by
providing information about specifıc mutational signatures in different catego-
ries of cancer. Our fındings may assist with identifying antitumor agents that
would be appropriate for treatment of cancer cells with specifıc signature pat-
terns generated by APOBEC mutagenesis.
#2591 A guide to fıltering TARGET Complete Genomics germline vari-
ants. James P. Evans,1 Rajesh Patidar,2 Zalman Vaksman,1 Sivasish Sindiri,2
Douglas R. Stewart,2 Javed Khan,2 Jun S. Wei,2 Sharon J. Diskin1. 1Children’s
Hospital of Philadelphia, Philadelphia, PA; 2National Cancer Institute, Bethesda,
MD.
With the public release of TARGET’s pediatric cancer data, researchers
are eager to investigate and integrate variants from both tumor and germline
sequencing data, but caution should be used when interpreting TARGET
variant calls from Complete Genomics data, as they unlike the Illumina
based calls for which most of our databases and tools are customized. Here,
we use germline samples from 55 neuroblastoma cases with both whole
genome Complete Genomics variants and whole exome Illumina variants
from GATK, Pindel, Platypus, and bam2mpg to investigate differences be-
tween germline variant calls from Complete Genomics and Illumina plat-
forms. Our study of160,000 single nucleotide polymorphisms (SNPS) and
19,000 insertions or deletions (indels) reveals that while SNP sets largely
agree between Complete Genomics and Illumina, Complete Genomics data
have many indels not present in Illumina calls, making it diffıcult to screen
Complete Genomics indels against popular Illumina based variant databases
like those provided by the Exome Aggregation Consortium and the National
Heart, Lung, and Blood Institute Exome Sequencing Project. Further prob-
ing of Complete Genomics indels uncovered inconsistent indel formatting
resulting a loss of recurrent variants, andmiscalculated read depths in earlier
versions of the Complete Genomics platform. To solve these issues andmake
Complete Genomics variant calls comparable to Illumina calls, we introduce
a Snakemake pipeline that reformats Complete Genomics variant fıles and
creates variant features for use in decision tree or random forest classifıers
trained to recognize Complete Genomics variants that will be present in
Illumina variant call sets. We determine that the most important features for
locating Complete Genomics variants likely to be found in Illumina germline
variant call sets are the presence of reads from both directions, average
variant allele fraction across the cohort, a variant call in the matched tumor,
the variant fraction of reads, and read depth. Using ten fold cross validation
with our decision tree, we obtain95% recall and98% precision for SNPs,
and90% recall and85% precision for indels. We advocate the use of our
pipeline and fıltering scheme for making Complete Genomics variant calls
comparable to Illumina based calls.
#2593 Accelerating pediatric brain tumor research through team science
solutions.AmandaChristini,1 Angela J.Waanders,2 Joost B.Wagenaar,1 Alex S.
Felmeister,2Mariarita Santi,2 Nitin R.Wadhwani,3 Jennifer L.Mason,2Mateusz
P. Koptyra,2 Jena V. Lilly,2 Jeffrey W. Pennington,2 Rishi R. Lulla,3 Adam C.
Resnick2. 1Blackfynn, Incorporated, Philadelphia, PA; 2TheChildren’sHospital of
Philadelphia, Philadelphia, PA; 3Ann & Robert H. Lurie Children’s Hospital of
Chicago, Chicago, IL.
Introduction: The Children’s Brain Tumor Tissue Consortium (CBTTC), an
international repository of genomic and phenotypic data, has partnered with
Blackfynn, Inc., to create a cloud-based data management platform to facilitate
team-science across disciplines. Background: The CBTTC through the CHOP
Department of Biomedical and Health Informatics (DBHi) has developed a
network of informatics and data applications for researchers across the globe to
work together and perform real-time analyses on existing clinical, phenotypic,
and genomic data. Historically, rare disease datasets are siloed, locked in pro-
prietary formats, segregated by data types, and hidden from the view of experts
in the fıeld. This has been a signifıcant barrier to fınding effective therapeutics for
children with pediatric brain tumors. Blackfynn was founded by a group of
multidisciplinary experts in neuroscience, neurology, medicine, software devel-
opment, engineering, computer science and business with the goal to empower
researchers to cure neurologic disease and provide solutions to these challenges.
Description of Methods: The CBTTC and Blackfynn teamed up to provide a
cloud-based, team-focused data management and analytics platform. The plat-
form provides a commercial grade, scalable approach to upload, view, and inte-
grate digital pathology images with relevant subject data such as MRIs, pathol-
ogy reports and genomic information. Stakeholders can search integrated data
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without requiring users to change their current workflow or conform to im-
posed data standards. This platform is a simple, intuitive, end-to-end software
platform for teams of scientists and pathologists to review, annotate and discuss
cases, enabling rapid diagnostic consensus, quality control, and empowered dis-
covery. Summary ofUnpublishedResults: TheCBTTC/Blackfynn data platform
enabled CBTTC members to engage in a cross-institutional collaboration to
reach consensus on digital pathology data in ways that were previously not
possible. We demonstrated that this solution removes existing barriers to col-
laborative efforts and provides a rich analytic and discovery platform bridging
imaging with genomics and other data formats. The platform provides a new
model for the scientifıc community to facilitate translation towards improved
treatments for children diagnosed with brain tumors. Discussion and Future
Direction: This pilot project will be scaled to other CBTTC sites for centralized
review of pathology images to enable the research community to collaborative
on specifıc projects. Thenext phase of platformdevelopmentwill include further
integration CBTTC platforms fully integrating genomics data, and side-by-side
viewing and analyses of MRI, pathology and clincal data to facilitate specifıc
project work around large and complex research data types in a cloud environ-
ment.
#2594 Optimizing the replication of cancer genomics workflows: case
studies. Jerry Fowler,1 F. Anthony San Lucas,1 Smruthy Sivakumar,1 Aditya
Deshpande,2 HumamKadara,3 Paul A. Scheet1. 1UTMDAnderson Cancer Cen-
ter, Houston, TX; 2Weill Cornell Graduate School of Medical Sciences, New York
City, NY; 3American University of Beirut, Houston, TX.
Reproducing results is amajor issue in cancer biology, whose “work bench” is
dynamic and complex, with frequently updated algorithms and software. The
better to manage our work in this environment we have developed SyQADA, a
System for Quality-Assured Data Analysis – a workflow automation system
designed to simplify common sequential analysis processes on the same or dif-
ferent data. SyQADA manages many of the details of procedural bookkeeping
involved in bioinformatics workflows: What samples are we using? Where are
the raw data? Were all the samples processed? Did every job complete satisfac-
torily? Is there asmuch output as expected?Where are the input fıles for the next
step? How long does a typical job take to run? Which program versions did we
use? Canwe easily compare these results with the output of a different version of
a program, or with different input data? Using SyQADA, we have found our-
selves better able to reproduce resultswhile at the same time reducing the human
effort required to manage our upstream data analyses. Here, we briefly describe
how our lung cancer studies have benefıtted from the use of SyQADA. To un-
derstand the effect of different variant callers for Ion Torrent deep sequencing
data in a lung cancer genomics study, we created awork protocol that allowed us
to compare the different sets of variants called on 34 distinct somatic DNA
samples from 4 patients. This complex processing framework involved running
multiple variant callers, annotating variants, fıltering germline variants using
quality control metrics, and collating results across samples and callers. With
SyQADA,wewere able to re-run individual processes changing parameterswith
trivial changes to our confıguration, yielding improved output.We then applied
that unmodifıed protocol to the 500 samples from 48 individuals in our study,
and rapidly produced data fromwhichwe could performbiological analysis.We
then applied the protocol to a study of pre-malignant lesions in 25 lung cancer
patients. In both studies, our workflow allowed us to generate comparable re-
sults in a matter of hours rather than days. SyQADA has been used by individ-
uals with backgrounds ranging from expert programmer to Unix novice, to
perform and repeat dozens of diverse analytical workflows. Projects to which
SyQADA has been applied include allelic imbalance studies of TCGA samples
for cancers of the breast, pancreas, lung, and colon, processing roughly 6000
samples through a dozen steps. A zipfıle containing the SyQADA executable
source code, documentation, tutorial examples, and workflows used in our lab
will be available.
#2595 Enabling petabyte-scale cancer genomics with the NCI Cancer
Cloud Pilots. Gaurav Kaushik, Yilong Li, Erik Lehnert, Zeynep Onder, Devin
Locke, Brandi N. Davis-Dusenbery, Deniz Kural. Seven Bridges, Cambridge,
MA.
The advent of next generation sequencing has accelerated the generation of
genomic data and created a need for methodologies to organize, share, and
analyze large volumes of data. To date, petabytes ofmulti-dimensional informa-
tion from thousands of patients have been collected. Access and analysis of this
information becomes increasingly challenging as the amount of data grows. This
diffıculty is exemplifıed when we consider data generated by the efforts of The
Cancer Genomics Atlas (TCGA) network, which encompasses more than 2.5
petabytes.Historically, downloading the complete TCGA repository can require
several weeks with a highly optimized network connection and access to large
institutional compute clusters to perform integrated analysis, which is out of
reach for many researchers. The Cancer Cloud Pilot project seeks to directly
address these challenges by co-localizing data with the computational resources
to analyze it where researchers can access it securely and easily. The project was
born out of the recognition that conducting biological research is increasingly
computationally-intensive and new approaches are required to support effective
data discovery, storage, computation, and collaboration. Funded by the Na-
tional Cancer Institute, the Cancer Genomics Cloud (CGC) enables researchers
to leverage the power of cloud computing to gain actionable insights about
cancer biology and human genetics from massive public datasets including
TCGA and the Cancer Cell Line Encyclopedia on the CGC. Our approach to
create a cancer cloud platform includes collaborative tools, security permissions,
data harmonization, and making the data easier to query through the use of
metadata curation, resource description frameworks, and visual tools. Addition-
ally, we implemented the CommonWorkflow Language, an emerging standard
for describing computational workflows, to support computational reproduc-
ibility. To date, more than 1200 researchers have accessed and analyzed TCGA
and analyzedmore than 50000 samples on the CGC since its launch in February
2016. In addition to themotivation, inception, and development of the CGC, we
will present a case study on the application of unsupervised learningmethods to
identify individual cell types within tumors using RNA Sequencing data from
TCGA cohorts. We will demonstrate how these computationally-intensive
methods are benefıted by the cloud and how researchers can apply open pipe-
lines to interrogate cancer subtypes andmixed cell populations fromTCGAdata
on their own data.
#2596 MediSapiens Explorer Technology Platform - Integrated Solution
for big biomedical data. Henrik Edgren, MediSapiens bioinformatics and de-
velopment teams.MediSapiens Ltd, Helsinki, Finland.
During recent years, the increasing throughput and decreasing cost of tech-
nologies for genomic, transcriptomic, proteomic and other high throughput
profıling of samples has enabled collection of very rich data sets on large sample
cohorts. As methods have been developed to analyze e.g. large human germline
sequencing studies, it has simultaneously become clear that the potential of the
data can be fully and effectively leveraged only if technical solutions are devel-
oped to curate, store, harmonize and jointly use these omics data sets together
with clinical and phenotypic data on the samples. In the fıeld of modern data-
driven research, heterogeneous data is increasingly available throughmany dis-
persed resources, and in many cases, data from public sources is combined with
proprietary data for analysis. Thus, it is not only important to have effective
solutions for data storing and data management, but for data curation and data
analysis and visualization. Data curation ensures that data from various sources
are harmonized, standardized and cross-comparable. Powerful data analytics
and visualization is pivotal in transforming data into information, new insights
and added value. To address these problems, MediSapiens has developed the
ExplorerTM Technology Platform solution, based on its extensive experience in
both industrial software development and academic biomedical research. The
ExplorerTM Technology Platform has been designed for all of the three major
parts of the data research workflow: For curating data, storing and managing
data, and analyzing and visualizing data. This web browser based, integrated
solution provides functionalities to import, curate, ontology map and store rich
clinical data, as well as very large data sets of gene expression, copy number,
mutation and other profıling data for both bulk and single-cell analyses (e.g.
single-cell RNA-seq), and perform various analyses and visualization on the
data. Existing software components in the ExplorerTMTechnology Platform can
quickly and effıciently be used to construct custom UI tools to query, analyze
and interpret data according to individual customer needs. Further, the platform
provides APIs which enable retrieval of data for integration with other systems,
or development of custom analyses using e.g. R. Here, we will illustrate the
application of Explorer Technology Platform concept to solve a variety of prob-
lems in preclinical cancer research and personalized medicine, starting from
effıcient automated curation of clinical data through to integration of clinical
and multi-omics data.
#2597 Celecoxib fıxed dose combinations - patient level data analyses.
Sanjive Qazi,1 Lynne Murphy,2 AnshumaMehta,2 WenWang,2 Mihir Munsif,2
Zachary Yim,2 Vuong Trieu2. 1Autotelic Inc, Costa Mesa, CA; 2Marina Biotech,
Agoura Hills, CA.
Background:Celecoxib is a highly effective anti-inflammatory drug.However, its
use is associated with adverse events including edema and hypertension (HTN).
High dose celecoxib has been shown to be effective against familial adenomatous
polyposis (FAP).However, it was discontinued because of safety concerns. Herewe
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examined the impact of celecoxib intake on HTN and edema. The concomitant
intake of celecoxib and one of the antihypertensives (AH) was also evaluated as
means to suppress the sideeffectsof celecoxib.Methods:This is a retrospective study
that uses twopatient level data (PLD) sources: (1) anonymousPLDfromSymphony
from Jan 2012 to Dec 2014 (3 years), and (2) Pinnacle registry data fromAmerican
College of Cardiology (ACC) over the same time period with detailed clinical data
such as blood pressure (BP) readings, peripheral edema flags, etc. In Symphony
dataset there are162million (M)uniquepatients, 4.3Mpatientsoncelecoxib, 16.3M
patientswith osteoarthritis (OA)(15.4MonlyOA) ,and 2.3Mpatientswith rheuma-
toid arthritis (RA) (1.4MonlyRA). InACCdataset, there are 1.58Muniquepatients
with BP readings, 870K patients with edema flag. Results: There was no impact of
celecoxib consumed on the change in BP readings. Therewere asmany increases as
decreases, regardless of the amount of celecoxib consumed between BP readings. A
breakdown by baseline BP readings did not reveal any trends. Concomitant use of
AHwith celecoxib did not impact BP. Onset of edemawas not correlatedwith total
dose of celecoxib. Less than 10% of the observations indicated a change in edema
status. However, unlike BP, increasing % of edema was observed for increment in
doses and days of treatment with celecoxib plus any other drug combination, sug-
gesting drug induced edema. Edemawas baselinedwith concomitant consumption
of angiotensin receptor blocker (ARB) or angiotensin converting enzyme (ACE) or
hydrochlorothiazide. It was further aggravated by non-thiazide diuretics andmini-
mally impacted by calcium channel blocker. Conclusion: Previous analysis has
shown that dose increment of celecoxib to more than 200mg/day did not improve
treatment effıcacy, but signifıcantly increased the edema rate but not BP in OA
patients.Hereweconfırmedourmeta-analysisusingPLDdata.CelecoxibwithARB
exhibited the lowest incidence of edema andwith non-thiazide diuretics the highest
incidence (Odds ratio3.34 (95%CI2.85-3.94), p0.0001).ARBwith celecoxib
displayed a signifıcant reduction in edema incidence compared to celecoxib alone
(Odds ratio 0.626 (95% CI 0.539-0.724), p0.0001). The celecoxib-ARB and
celecoxib-ACE FDCs are being investigated further as therapy for FAP and more
broadly for colorectal cancers.
#2598 Paradigm to ensure curation transparency and consistency of a
cancer genomic database - the JAX Clinical Knowledgebase (CKB). Taofei
Yin, Sara E. Patterson, CaraM. Statz, Anuradha Lakshminarayana, Daniel Dur-
kin, SusanM.Mockus. The Jackson Laboratory for GenomicMedicine, Farming-
ton, CT.
In the era of personalized medicine, comprehensive cancer genomic data-
bases represent critical tools for interpreting gene variants and their relevant
therapies. As the number of cancer genomic databases grow, it is challenging for
users to compare and assess the data integrity and validity of such databases. The
lack of disclosure of curation processes makes it diffıcult to cross reference dif-
ferent databases. The JAX Clinical Knowledgebase (CKB) is a comprehensive
relational database providing evidence-based information on gene variants, tar-
geted therapies, effıcacy evidence, and clinical trials. At the Jackson Laboratory
for Genomic Medicine, we have developed a curation paradigm to ensure cura-
tion transparency and consistency of the JAX-CKB. First, to ensure standard-
ization of nomenclature, we have integrated standard nomenclature and ontol-
ogies, including HGNC approved nomenclatures for genes, HGVS guidelines
for variants, and the Disease Ontology for indications/tumor types. Second, we
implemented decision matrices to maintain uniformity of our evaluation of
scientifıc and clinical data. For example, evaluation of the effect of gene variants
on protein function is solely based on changes in the intrinsic activity of the
protein instead of downstream pathway activation or the effects on pathogene-
sis; the response type of gene variants to therapies are classifıed based on the
evidence of targeting specifıcity; and the effıcacy evidence are further classifıed
as actionable, diagnostic, prognostic, risk factor, emerging, or not active cen-
tered on the response type and the strength of the evidence. Third, to provide
convenient evaluation of the clinical relevance of effıcacy data, we further devel-
oped a tier ranking system based on emerging consensus guidelines, which takes
response type, evidence type, and approval status into consideration. Finally, all
decision matrices are clearly outlined on the JAX-CKB open access website for
users’ reference. In summary, we have curated a highly structured and seman-
tically consistent cancer genomic database following a set of specifıc curation
guidelines. As a result, JAX-CKB open access has become a valuable resource for
both the clinical and research communities, and is utilized by numerous inde-
pendent groups for variant interpretation.
#2599 COSMIC Cancer Gene Census: expert descriptions across genes in
oncogenesis. Zbyslaw Sondka, Sally Bamford, Charlotte G. Cole, Elisabeth
Dawson, Laura Ponting, Raymund Stefancsik, Sari A. Ward, John Tate, Peter J.
Campbell, Simon A. Forbes. Wellcome Trust Sanger Institute, Cambridge,
United Kingdom.
The Cancer Gene Census is an ongoing effort to catalogue genes for which
somatic mutations have been causally implicated in cancer. The Census com-
prisesmanually curated summaries of themost relevant information for cancer-
driving genes and their somatic mutations and brings together the expertise of a
dedicated curation team, cancer scientists and the comprehensive resources of
the COSMIC database. Current research focuses on characterising the partici-
pation of 609 census genes in hallmarks of cancer and identifıcation of addi-
tional genes involved in these biological traits primarily via altered expression,
CNA or epigenetic changes. New overviews of cancer gene function focused on
hallmarks of cancer pull togethermanually curated information on the function
of proteins coded by cancer genes and summarises the data in simple graphical
form. It presents a condensed overview of most relevant facts with quick access
to the literature source, aiming to provide summary characteristics of a cancer
gene, rather than a full monography, to avoid information overload. This func-
tional characterisation enables the creation of lists of genes of interest focused on
the particular role they play in the development of cancer, as well as aiming to
identify the cellular functions affected by mutations in particular tumours, and
help to choose right targets for targeted therapy or synthetic lethality experi-
ments. The Census is available from the COSMIC website for online use or
download at: http://cancer.sanger.ac.uk/census.
#2600 Analysis of drug resistance mechanisms and strategies for over-
coming resistance in cancer therapy using a curated clinical knowledgebase.
Sara E. Patterson, Cara M. Statz, Taofei Yin, Susan M. Mockus. The Jackson
Laboratory for Genomic Medicine, Farmington, CT.
Emergence of resistance to targeted therapies is a critical problem in cancer
therapy, andunderstanding both themechanisms of resistance and strategies for
overcoming resistance are crucial to effective treatment of cancer patients. The
JAXClinical Knowledgebase (JAX-CKB), which incorporates data on therapeu-
tic effıcacy in the context of molecular alterations, enables rapid analysis of
known therapy resistance mechanisms and current data surrounding strategies
for overcoming resistance, both in the preclinical and clinical setting. Using the
JAX-CKB, we have identifıed over 1250 lines of evidence corresponding to ther-
apy resistance across tumor types. Of those lines, 147 correspond to therapy
resistance in lung cancer. The JAX-CKB contains 22 variants in ALK associated
with ALK therapy resistance.Within ALK fusion-positive lung cancer, evidence
lines corresponding to ALK inhibitor resistance are associated primarily with
complex molecular profıles containing secondary ALK mutations, and mecha-
nisms for overcoming resistance in this setting were associated with use of novel
agents. Within EGFRmutation positive lung cancer, lines associated with resis-
tance to EGFR inhibitor therapy included copy number alterations, primary
resistance mutations, secondary resistance mutations, and expression level
changes. Strategies for overcoming resistance in these settings include novel
agents and/or various combination therapies. The JAX-CKB provides a unique
global view into current data on resistance to targeted therapies in oncology,
which may enable more rapid assessment of effective therapy options and ex-
pose opportunities for additional research into strategies for overcoming resis-
tance.
#2601 COSMIC-3D: exploring cancer mutations in three dimensions for
drug design and discovery.Harry C. Jubb,1 Harpreet Saini,2 Marcel Verdonk,2
Simon Forbes1. 1Wellcome Trust Sanger Institute, Hinxton, Cambridge, United
Kingdom; 2Astex Pharmaceuticals, Cambridge, United Kingdom.
Explosions in the availability of cancer genomic data and protein structure
data give us the potential to explore cancer molecular biology at an unprece-
dented scale, and in atomic detail. We present COSMIC-3D, which combines
COSMIC, the most comprehensive cancer mutation database available (http://
cancer.sanger.ac.uk), with the wealth of publicly available 3D protein structure
data, to create a resource with which the protein-structural nature of cancer can
be probed. COSMIC-3D will help us understand which cancer mutations drive
the progression of cancers, by identifying which are in functional sites that have
an effect ondriving cell growth andproliferation, andwhere they are clustered in
protein structures across the proteome, for specifıc cancer types. Through un-
derstanding the effects of cancer mutations on known and predicted drug bind-
ing sites, we aim to predict potential new drug targets in cancers, and improve
the specifıcity and effıcacy of new or existing drugs, by using protein structure
with cancermutation data to guidemutation-specifıc drug design. COSMIC-3D
is available as a web interface at http://cancer.sanger.ac.uk/cosmic3d, and en-
ables interactive exploration of the cancer mutome in a 3D peptide environ-
ment, showing all forms of exonic point mutation. Individual mutant locations
can be highlighted as molecular surfaces, while recurrence across nonsynony-
mous substitutions is visualized as 3D heat-maps. Cancer mutations can also be
visualised in combination with precalculated small-molecule “druggable” bind-
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ing sites, providing a powerful visual approach for development of hypotheses
across structural, functional, and drug-resistance impacts of cancer variants.
COSMIC-3D shows, for example, the steric occlusion of the binding site of
ATP-competitive small-molecule inhibitors in the EGFR kinase domain by the
mutation of L858 to arginine; these kinds of insights can be applied to novel
cancer targets for any protein-structuralmutation of interest. The human cancer
structural proteome comprising COSMIC-3D extends to nearly 8,500 human
genes; 1/3rd of genes in COSMIC. Over 30,000 human protein structures are
available across these genes, to which over 345,000 cancer mutations are
mapped. From structure based druggability prediction, over 6,500 proteins in
COSMIC are predicted to have small-molecule druggable binding sites, making
COSMIC-3D a powerful and exciting resource for the exploration and guidance
of drug design and discovery in oncology.
#2602 The ICGC data portal and its underlying open source software ar-
chitecture. Junjun Zhang, Bob Tiernay, Dusan Andric, Phuong-My Do, Sid
Joshi, Vitalii Slobodianyk, Chang Wang, Shane Wilson, Andy Yang, Vincent
Ferretti. Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
The goal of the International Cancer Genome Consortium (ICGC) is to ana-
lyze the cancer genomes of at least 500 tumour samples with matched controls
from 50 different cancer types and subtypes, building a comprehensive cata-
logue of somatic abnormalities for the benefıt of the research community. The
amount of data ICGC members will generate is close to that of 50,000 human
genome projects and, to date, has received commitments for 107 projects to
study more than 27,000 tumor genomes. The ICGC Data Coordination Center
(DCC) is responsible for collecting, curating, aggregating, and disseminating the
data generated by the consortium’s member projects. Given the size and the
complexity of the ICGC data, these tasks represent signifıcant scientifıc and
technological challenges that require a performant, robust software infrastruc-
ture. Key to this infrastructure is the ability to scale as data grows. Using state-
of-the-art Big Data, bioinformatics and cloud computing technologies, we de-
veloped a suite ofweb-based applications andmicroservices that enablemember
projects to fırst submit their data and validate their submissions according to the
rules defıned in the submission specifıcation. Following validation, the data is
processed, annotated and loaded into the data portal using a modular Extract-
Transform-Load (ETL) pipeline. Submission, ETL and portal systems are built
using scalable and distributed technologies such as Hadoop, Spark, MongoDB
and ElasticSearch. Spark is used to validate, join, index, and harmonize annota-
tions on submitted variants while ElasticSearch powers our variant query en-
gine, API and portal displays. Here we present the ICGC Data Portal and de-
scribe both the current features and capabilities accessible to users alongwith the
architecture of the underlying infrastructure. The portal provides scientists with
powerful and unique tools for exploring and visualizing the millions of variants
and annotations available. These include sophisticated, faceted search capabili-
ties making data exploration extremely fast and easy, a suite of interactive
Javascript components for in-depth analysis and visualization of specifıc
genomic features, embedded genome and pathway browsers, synthetic cohorts
comparisons and a streaming data download service. The portal integrates a
large variety of annotations such as variant consequences and frequencies, func-
tional impact factors and druggability. The portal also offers cloud-based tools
for searching a catalog of raw ICGC data fıles stored in worldwide repositories
and compute clouds. All source code is open to the community under theGPLv3
license.
#2603 A patient driven cancer database to collect information, analyze
data, and predict outcomes. LoriMarx-Rubiner,1 AnneMarie Ciccarella,2 Vin-
cent An,3 Jared Bass,3 Will Berman,3 Jackson Berry,3 Chloe Chan,3 Christopher
Han,3 Louis Harboe,3 Joshua Lurie,3 Sara Ma,3 Parker Malachowsky,3 Naylee
Nagda,3 Simon Schneider,4 E. Bircan Çopur,4 Jorge J. Nieva,5 Jan Liphardt,6
Peter Kuhn,7 Jeremy M. Mason7. 1Independent Research Advocate and Meta-
static Breast Cancer Patient, Los Angeles, CA; 2Independent Research Advocate
and Breast Cancer Patient, Glen Head, NY; 3University of Southern California,
Iovine and Young Academy, Los Angeles, CA; 4Zyncd Ltd, Munich, Germany;
5Norris Comprehensive Cancer Center, Los Angeles, CA; 6Stanford University,
CA; 7University of Southern California, Los Angeles, CA.
It is widely held thatmajor breakthroughs in cancer treatmentwill result from
properly amassing, analyzing and utilizing existing and emerging “big data.” To
date there is no single vehicle that integrates the data available, and of those
being developed, none that put patient needs and outcomes as primary foci.
CancerBase was released as part of the CancerMoonshot launch in June 2016. It
is a global, real-time data collection tool designed by and for patients. Patients
were recruited through social media to share their information, including but
not limited to, demographic details, personal cancer data, and history of treat-
ment. Combining open text boxes and drop down preselected response boxes
allow for the capture of information in a way that patients understand. In addi-
tion to cancer data, Facebook comments demonstrated immediate engagement
with the tool and captured the organic community of patients who eagerly
shared their stories with others. Personal interviews and a communal Twitter
chat have recorded the interests and priorities from patients who were not nec-
essarily familiar with CancerBase. In addition to medical data, general informa-
tion and questions CancerBase participants wanted to add to the system have
been collected. Incorporation of patient-driven deliverables is unique in the
space of big data and cancer in that other tools, both existing and still in devel-
opment, are geared toward the needs of researchers, payors, policy-makers and
clinicians. CancerBase is unique in that it adapts to growth. Patient feedback
drives improvements via ongoing communication between developers, PIs and
participants. Wherever possible, participant recommendations and questions
are rapidly incorporated into the website design. The remaining patient recom-
mendations are cataloged and will be incorporated in the forthcoming releases
of CancerBase. The initial launch of CancerBase demonstrated patient willing-
ness to share personal, anonymized data and to recruit others. Patients were
eager to engage and manipulate the limited data collected in the fırst release.
Moving forward, patient priorities include: How do my treatment decisions
compare with others and what can I learn from those who have come beforeme;
What is the likelihood that I will have a recurrence; and, in the case of metastatic
patients, how long might I have between progressions, to which organ(s) is
progressionmost likely, andwhat aremy likely survival outcomes. CancerBase is
a database tool that resonates with the patient community and is driven by
patient needs and interests. As the tool becomes increasingly robust it will grow
to support the decision-making needs of clinicians and guide the investigations
of researchers. The relaunch ofCancerBase in Spring 2017will address emerging
patient concerns, integrate collected data, and utilize existing forecasting data-
bases to add value to patients.
#2604 The Georgetown Database of Cancer (G-DOC): A web-based data
sharing platform for precision medicine. Krithika Bhuvaneshwar, Anas Bel-
ouali, Shruti Rao, Adil Alaoui, Yuriy Gusev, Robert Clarke, Louis M. Weiner,
Subha Madhavan. Georgetown University, Washington, DC.
Introduction An overarching goal of biomedical research is to improve the
use and dissemination of rapidly growing biomedical datasets to support preci-
sion medicine. Individualized molecular profıling and the identifıcation of pre-
dictive biomarkers can powerfully inform the choice of therapies for cancer
patients. However, both require integration of extensivemolecular, clinical, and
pharmacological data, often from disparate and diverse sources. The George-
townDatabase of Cancer (G-DOC) was designed and engineered to be a unique
multi-omics data analysis platform to enable translational research and preci-
sion medicine. Methods G-DOC is home to 61 datasets that contain data from
over 10,000 patients across 14 diseases (10 cancers and 4 non-cancers). 1700
researchers from over 48 different countries worldwide currently use the plat-
form. The data and tools in the G-DOC system have enabled over 40 research
publications. G-DOC has the largest public collection of brain cancer patients
from NCI Rembrandt dataset (671 patients).G-DOC integrates clinical, tran-
scriptomic, metabolomic, microRNA, next generation sequencing (NGS) data,
and MRI medical images with systems-level analysis tools into a single, user-
friendly platform. The “Variant Search” feature in G-DOC currently enables
exploratory analysis ofmutations based on genes, chromosomes, and functional
location. A researcher can use this feature to 1) identify clinically actionable
mutations in their dataset 2) identify pathways that may be affected by these
mutations, and 3) identify novel mutations in their dataset and explore their
potential impact on protein function. Results and ConclusionWe are currently
working on developing features to support the import, integration, search, and
retrieval of CLIA/CAP-certifıed cancermolecular diagnostic (molDx) data. This
will enhance G-DOC’s interoperability with clinical and patient molecular pro-
fıling data that may be already stored in other databases. Our vision is to con-
tinuously improve and expand G-DOCwith the long-term vision of supporting
integration of informatics techniques into everyday research and practice.
#2605 Improving data quality in oncology immunotherapy clinical re-
search by big data analytics and data visualization. Chengsen Xue, Joanne
Cuomo, Walter Meyers, Thomas W. Mc Closkey. ICON Laboratory Services,
Farmingdale, NY.
Flow cytometric assessment of cellular and intracellular biomarkers facilitates
the development of new classes of cancer immunotherapy therapeutics. This
powerful tool has multiple applications including 1) detecting PD1, PDL-1 and
caspase-3 for apoptosis, 2) isolating, defıning, and quantifying dendritic cells
and their intracellular cytokine profıle, 3) immunophenotyping subpopulations
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of B, T, NK, regulatory T, and helper T cells, and, 4) using tetramer analysis to
detect and monitor the frequency of antigen-specifıc cytotoxic T lymphocytes
(CTL).However, lack of knowledge of normal distributions and standard ranges
for the esoteric reportables generated by flow cytometry is one of the most
challenging problems in this promising fıeld. Here we describe a newmethod to
improve data quality in clinical research by big data analytics and data visual-
ization. Each data point was tagged. By applying a simple statistical analysis, a
self-defıned range allowed all of the outlier numbers to be identifıed. By repeat-
ing this process, clear patterns emerged, and all questionable data points were
marked. In addition, the system can differentiate biodiversity in subjects from a
more homogenous population,which can be exploited further for the purpose of
personal and precisionmedicine. Other benefıts of the new system are to predict
the outcome of the clinical study and to generate new clues in the understanding
of the underlying biological mechanisms. Big data analytics and data visualiza-
tion show unparalleled advantages in oncology studies through simultaneously
monitoring unlimited data points related to surface and intracellular biomark-
ers. It opens a new avenue in cost saving for long, time-consuming clinical trials
by using all available data to detect a status change of the immune system.With
the improvement of data quality, big data analytics has become an essential tool
and an integrated part of cancer immunotherapy and the development of cancer
vaccines.
#2606 Accelerating clinical research using cloud technology. Arun Apte,1
Shonali Paul,1 Aditi Gade,1 Carolyn Compton2. 1CloudLIMS.com, Wilmington,
DE; 2Arizona State University, AZ.
Introduction: Existing protocols for clinical trials are typically slow and error-
prone due to lack of informatics tools for sharing and accessing clinical data in real
time. There is an increasing pressure on clinical trial laboratories to change the way
clinical research is performed so as to minimize costs and speed up R&D, which in
turnwill produce better and faster outcomes. Cloud-based technologies are emerg-
ing as one of the most viable options for streamlining the heavily regulated clinical
research processes. Description: Cloud-based software tools such as laboratory in-
formation management systems (LIMS) are much more capable than traditional
paper-based or desktop tools for accelerating a clinical trial life cycle. Cloud-based
LIMS enhance collaboration between sponsors and investigators, enabling more
timely and accurate sharing of information with pharmaceutical companies. Sum-
mary: Many sponsors are now adopting cloud-based LIMS for conducting clinical
trials. The onus is on service providers to keep pace with the demands of the indus-
try, comply with the regulatory framework and at the same time deliver value to
CROs and testing labs by reducing costs and maintaining effıciency. Conclusion:
CloudLIMS.com has developed a cloud based software called CloudLIMS Lite for
managing clinical research workflows to provide a cost effective solution to the
clinical research industry. Being on the cloud, CloudLIMS Lite facilitates users to
access and sharedata in real time, acrossmultiple laboratories indifferent geograph-
ical locations and adhere to the regulatory framework. This in turn improves their
operational effıciency. CloudLIMS Lite uses 256-bit AES encryption SSL protocol,
thereby enabling secure data transmission. CloudLIMS Lite deploys a separate da-
tabase layer for eachof its customersmaking it impossible for any thirdparty toview
or access data.
#2607 The cBioPortal for Cancer Genomics: an open source platform for
accessing and interpreting complex cancer genomics data in the era of preci-
sion medicine. Jianjiong Gao,1 Ersin Ciftci,2 Pichai Raman,3 Pieter Lukasse,4
IstemiBahceci,5AdamAbeshouse,1Hsiao-WeiChen,1 InodeBruijn,1 Benjamin
Gross,1 ZacharyHeins,1 RitikaKundra,1 Aaron Lisman,1AngelicaOchoa,1 Rob-
ert Sheridan,1 Onur Sumer,1 Yichao Sun,1 Jiaojiao Wang,1 Manda Wilson,1
Hongxin Zhang,1 James Xu,1 Andy Dufılie,2 Priti Kumari,2 James Lindsay,2
Anthony Cros,2 Karthik Kalletla,3 Fedde Schaeffer,4 Sander Tan,4 Sjoerd van
Hagen,4 Jorge Reis-Filho,1 Kees van Bochove,4 Ugur Dogrusoz,5 Trevor Pugh,6
Adam Resnick,3 Chris Sander,2 Ethan Cerami,2 Nikolaus Schultz1. 1Memorial
Sloan Kettering Cancer Center, New York, NY; 2Dana-Farber Cancer Institute,
Boston, MA; 3Children’s Hospital of Philadelphia, Philadelphia, PA; 4The Hyve,
Netherlands; 5Bilkent University, Turkey; 6Princess Margaret Cancer Centre, To-
ronto, Ontario, Canada.
The cBioPortal for Cancer Genomics is an open-access portal (http://cbioportal.
org) that enables interactive, exploratory analysis of large-scale cancer genomics
data. It integrates genomicandclinical data, andprovides a suiteof visualizationand
analysis options, including cohort and patient-level visualization, mutation visual-
ization, survival analysis, enrichment analysis, andnetwork analysis. Theuser inter-
face is user-friendly, responsive, andmakes genomic data easily accessible to trans-
lational scientists, biologists, and clinicians. The cBioPortal is a fully open source
platform. All code is available on GitHub (https://github.com/cBioPortal/) under
GNUAfferoGPL license.Thecodebase ismaintainedbymultiplegroups, including
Memorial SloanKetteringCancerCenter,Dana-FarberCancer Institute,Children’s
Hospital of Philadelphia, PrincessMargaret Cancer Centre, andTheHyve, an open
source bioinformatics company based in the Netherlands. More than 30 academic
centers as well asmultiple pharmaceutical and biotech companiesmaintain private
instances of the cBioPortal. This includes the recently launched cBioPortal instance
at the NCIGenomic Data Commons (https://cbioportal.gdc.nci.nih.gov/), and two
large cBioPortal instances hosting genomic and clinical data at MSK and DFCI,
supporting theMSK-IMPACT andDFCI Profıle projects, two of the largest clinical
sequencing efforts in the world. Our multi-institutional software team has acceler-
ated theprogressof evolving the core architectural technologies anddevelopingnew
features to keep pace with the rapidly advancing fıelds of cancer genomics and
precisioncancermedicine. For example,wehave integratedmulti-platformgenom-
ics data with extensive clinical data including patient demographics, treatment his-
tory, and survival data.Wehave alsodeveloped apatient-centric view that visualizes
both clinical and genomic data with annotation fromOncoKB knowledge base. In
the next few years, the development team will focus on the following areas: (1)
Implementing major architectural changes to ensure future scalability and
performance. (2) New features to support precision medicine, including (i)
improved integration of knowledge base annotation, (ii) enhanced visualiza-
tion of patient timeline, drug response, and tumor evolution, (iii) new pa-
tient similarity metrics, (iv) improved support for immunogenomics and
immunotherapy, and (v) new visualization and analysis features for under-
standing response to therapy. (3) New analysis and target discovery features
for large cohorts, including (i) supporting user-defıned virtual cohort by
selecting samples from multiple studies, and (ii) comparison of genomic or
clinical characteristics of two or more selected cohorts. (4) Expanding com-
munity outreach, user support and training, and documentation.
#2608 Global integration of knowledgebases for clinical interpretation of
cancer variants.Obi L. Griffıth,1 Malachi Griffıth,1 David Tamborero,2 Alex H.
Wagner,1 Kilannin Krysiak,1 Catherine Del Vecchio Fitz,3 Debyani Chakra-
varty,4 Ethan Cerami,3 Olivier Elemento,5 Nikolaus Schultz,4 AdamMargolin,6
Nuria Lopez-Bigas2. 1Washington University School of Medicine, Saint Louis,
MO; 2Institute for Research in Biomedicine, Barcelona, Spain; 3Dana-Farber
Cancer Institute, Boston, MA; 4Memorial Sloan Kettering Cancer Center, New
York, NY; 5Weill Cornell Medical College, New York, NY; 6Oregon Health &
Science University, Portland, OR.
Theparadigmofprecisionmedicine envisions a future inwhichacancerpatient’s
molecular information can be interpreted in the context of accumulated knowledge
to inform diagnosis, prognosis and treatment options most likely to benefıt that
individual patient. Accordingly, many groups have created knowledgebases to an-
notate cancer genomic mutations associated with evidence of pathogenicity or rel-
evant treatment options. However, in real-life practice, clinicians and researchers
are unable to utilize the accumulated knowledge derived from such efforts. Integra-
tion of the available knowledge is currently infeasible because each group (often
redundantly) curates their own knowledgebase without adherence to any interop-
erability standards. Therefore, there is a clear need to standardize and coordinate
clinical-genomics curation efforts, and create a public community resource able to
query the aggregated information. To this end we have formed the Variant Inter-
pretation forCancerConsortium(VICC)aspartof theGlobalAlliance forGenomic
Health (GA4GH) to bring together the leading institutions that are independently
developing comprehensive cancer variant interpretation databases. VICC partici-
pants share a desire to coordinate efforts and thus enhance the value of each inde-
pendent effort. Each participant has agreed to: (1) sharing at least a minimal set of
required data elements for cancer variant interpretations; (2) Protecting patient pri-
vacy by focusing on only clinical interpretations of variants derived from published
fındings, not individual patient/variant-level observations, thus avoiding the possi-
bility of linking variants to individuals; (3) Sharing all or a signifıcant proportion of
interpretations accumulatedby their ongoing curation efforts; (4)Releasing content
under a permissive license (free and non-exclusive for research use); (5) Releasing
software in public repositories with open source licenses; (6)Making data available
through publicly accessible and documented APIs and as cross-knowlegebase bulk
downloads; and (7) Using, the existing schemas, APIs and demonstration imple-
mentations developed by GA4GH. To date a large number of academic and com-
mercial groupshave agreed toparticipate including those atWashingtonUniversity
(CIViC), MSKCC (OncoKB), Weill Cornell (PMKB), Oregon Health and Science
University, Dana-Farber, Institute for Research in Biomedicine, Illumina Inc, and
others.Additional participants arewelcome (http://ga4gh.org/#/vicc).Wewill pres-
ent progress by the VICC to create a federated query service able to interrogate
associations between cancer gene alterations and clinical actions, for each cancer
disease setting, basedon evidence amassed fromall participating institutionsworld-
wide.
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#2609 Columbia University’s Center for Cancer Systems Therapeutics
(CaST) 2017 Scholars Program:A synergistic partnershipwith students from
Brooklyn College, CUNY. Rahimah Ahmad,1 Tasnim Azad,1 Carlos Barreto,1
Kamrun Begum,1 Mahlaqa Butt,1 Daniel Gruffat,1 Aulon Jerliu,1 Jonathan
Kwiat,1 Mikaela Murph,1 Katherine A. Rivera Gómez,1 Barry Honig,2 Andrea
Califano,2 Shaneen Singh,1 Diana Murray2. 1CUNY Brooklyn College, Brooklyn,
NY; 2Columbia University, New York, NY.
The Cancer Systems Therapeutics (CaST) Outreach helps foster community
building throughout the NCI Cancer Systems Biology Consortium (CSBC). The
overallmission of theCaSTOutreachCore is to advance progress in cancer systems
biologyby tapping intoandmakingconnectionsacross research talent at all stagesof
educational and professional attainment. A unique component is our partnership
with motivated undergraduate, post-baccalaureate, and graduate students from
BrooklynCollegeof theCityUniversity ofNewYork (CUNY).These students com-
prise the fırst cohort of theCaSTScholarsProgramandare immersed in the cutting-
edge biological and biomedical science underlying Cancer Systems Biology. In sub-
sequent years, CaSTOutreach will partner with students from other CUNY Senior
Colleges while continuing interactions with our Brooklyn College Scholars. This
integrative approachwill create a network of CaST Scholars throughout the CUNY
system. Because Systems Biology is highly interdisciplinary, participants in the pro-
gram can come from many backgrounds, including biology, computer science,
physics, chemistry, genomics, engineering, and other fıelds. The program has no
fıxed curriculum and each of nine Brooklyn College students has developed an
individualizedCSBC educational plan tailored to their interests. TheCaST Scholars
Programopportunities include 1) tuition-free attendance at amaster’s level Systems
Biology course taught by a CaST investigator and offered through Columbia Uni-
versity’s School of Professional Studies; 2) supported attendance at the AACR an-
nualmeeting; 3)monthly informal discussionmeetings with CaST investigators; 4)
weekly formal tutorials in the design and applications of CaST computational algo-
rithms; 5) research internships with CaST investigators; 6) participation in a wide-
range of Center activities; 7) a scholarship to support participation; and 8) ongoing
mentorship fromCaST investigators. This poster provides summaries of the collab-
orative, synergistic experiences and achievements of each Scholar and of the group
as a whole. The CaST Scholars Program offers a unique opportunity for early-stage
scientists to learn how Systems Biology is transforming cancer research and preci-
sion medicine at Columbia University Medical Center. Regardless of their chosen
professional path, CaST Scholars will obtain a solid foundation in themethods and
potential of Cancer Systems Biology.
#2610 A database for evaluating methylation biomarkers in bladder can-
cer. Meaghan M. Kennedy, Garrett M. Dancik. Eastern Connecticut State Uni-
versity, CT.
Bladder cancer is the fourth-most common cancer in men, one of the most ex-
pensive types of cancer to treat, and recurs frequently.While the genomic pathways
associatedwith high-grade,muscle invasive (MI) tumors and low-grade, non-mus-
cle invasive (NMI) tumors are well-established, recent studies have also found that
MI and NMI tumors have unique methylation patterns, and that methylation may
play a role in the development of early-stage bladder cancer. Interestingly, bladder
cancer patients have frequent mutations in chromatin remodeling genes that alter
knownhistonemarkersofDNAmethylation. Sincemethylationmarks arepharma-
cologically reversible, the identifıcation of methylation biomarkers is a promising
avenue for therapeutic treatment. Indeed, several candidate prognosticmethylation
biomarkers have been identifıed, but await prospective evaluation. The Bladder
Cancer Biomarker Evaluation Tool (BC-BET) is a web-based resource for rapidly
evaluating biomarkers in publicly available genomic datasets. Initially developed for
gene expression biomarkers, BC-BET includes 1451 patients across 13 cohorts, and
40 bladder cancer cell lines, with gene expression profıles. In this work, we describe
the addition of methylation data to BC-BET, so that candidate methylation bio-
markers can be rapidly evaluated across multiple patient cohorts. BC-BET now
containsmethylation profıles from four patient cohorts (250 patients) and includes
the available bladder cancer data from theGeneExpressionOmnibus andTheCan-
cerGenomeAtlas. In ‘evaluation‘mode, auser selects ageneof interest, andBC-BET
evaluates whether the selected gene is differentially methylated between tumor vs.
normal samples,NMIvs.MI tumors, and low- vs. high-grade tumors.Alternatively,
the “biomarker discovery” mode allows a user to identify all differentially methyl-
atedgenesat adesired falsediscovery rate (FDR). Inbothcases, graphical summaries
of the results are displayed and statistical results can be downloaded to an Excel
spreadsheet.ThemethylationmoduleofBC-BETis implementedusingshiny, aweb
application framework for R for developing interactive web pages. The addition of
methylationdata toBC-BETmakes it a valuable resource for evaluatingmethylation
biomarkers in bladder cancer. BC-BET is available from the following link: https://
gdancik.github.io/bioinformatics/BCBET
#2611 A crowdsourcing-based clinical trial information curation and
searching system. Pengfei Yu, Qingxuan Song, Yang Han, Guanghui Hu. Ad-
mera Health, South Plainfıeld, NJ.
Targeted cancer therapies based on actionablemutations identifıed are the future
of cancer treatment. Besides those approved by the Food andDrugAdministration
(FDA) for different types of cancers, many other target therapy drugs are in devel-
opment under different phases of clinical trials. Access to information about these
clinical trials is important to health care professionals and patients. Public clinical
trials database (www.clinicaltrials.gov) provides a very comprehensive resource for
clinicians and researches to search for relevant clinical trials basedondifferent kinds
of searching criteria. However, due to the complexity of wording and phasing upon
submission, some of the searching results returned by native search engine did not
perfectly match the search criteria. Many undesired results are presented with false
positives and false negatives when users are searching for clinical trials targeting
specifıc actionablemutations. To tackle this problem,we developed a crowd-sourc-
ing based clinical trial curation and searching system on top of the information
extracted from public database.We divide the information extracted from clinical-
trials.gov into three different levels: standard, easy-to-clean and unstructured.With
the crowdsourcing approach, our online system can harness the brainpower of bio-
logical scientists to translate the most unstructured information such as cancer
types, genemutations into standard format that is easy to be queried. In the search-
ingphase,we combine the aspects of actionablemutation, cancer type, location, and
clinical trial phase to select the bestmatches between patient conditions and clinical
trials in our curated database. With the same searching criteria, our system can
providemore relevant clinical trials comparedwith those provided by clinicaltrials-
.gov. The curation system is currently open to reviewers with eligibility check. The
search engine is publicly available at: https://agis.admerahealth.com/AGIS/ClinTri-
als/.
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#2612 Anti-Tigit induces T cell mediated anti-tumor immune response
and combines with immune checkpoint inhibitors to enhance strong and
long term anti-tumor immunity. Minu K. Srivastava, Rui Yun, Erin Mayes,
Janice Yu, Hyun-Bae Jie, Fumiko Axelrod, Ming-Hong Xie, Jorge Monteon,
Andrew Lam, May Ji, Yuwang Liu, John Lewicki, Tim Hoey, Austin Gurney,
Angie Inkyung Park. OncoMed Pharmaceuticals, Inc., Redwood City, CA.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) has been recently
described as an inhibitory receptor which blocks CD8 T cell-mediated anti-tumor
immune responses.Wehave generated an anti-mouseTIGIT antibody (313R12) to
evaluate drug effıcacy andmechanismof action in pre-clinical tumormodels. Anti-
TIGIT as a single agent promoted an anti-tumor immune response in multiple
syngeneic mouse tumor models. Anti-TIGIT enhanced tumor specifıc T cell re-
sponses, particularly of the Th1 type and reduced Th2 type responses and also in-
creased the function of cytotoxic T cells. Furthermore, anti-TIGIT displayed com-
bination activity with immune checkpoint inhibitors anti-PD1 and anti-PDL1 in
inhibiting tumor growth, promoting complete tumor rejection and signifıcantly
increasingmouse survival in themurineCT26coloncarcinomamodel as compared
to controls and single agents alone. Mice “cured” with anti-TIGIT/anti-PDL1 or
anti-TIGIT/anti-PD1 combination treatments did not form tumors upon subse-
quent re-challenges with increasing number of CT26 tumor cells, suggesting the
existence of immunologic memory. IL2 and tumor-specifıc IFN- production by
splenic T cells were increased in mice who responded to combination treatment
compared to controls. Additionally, both effector and memory CD8 T cell fre-
quencies were increased within the total CD8 T cell population in responding
mice.We also demonstrated a systemic increase in tumor-specifıc CD8T cells after
anti-TIGIT/anti-PDL1 combination treatment compared to controls. Therefore,
these results suggest that co-targeting of TIGIT and PD1 or PDL1may be an effec-
tive and durable cancer therapy by increasing T cell-mediated anti-tumor immune
responses and promoting long-term immunological memory.
#2613 Combination agonist and antagonist antibody therapy enhances
vaccine induced T cell responses in non-immunogenic cancers.Hayley S.Ma,
Evanthia Roussos Torres, Brian Christmas, Blake Scott, Tara Robinson, Todd
Armstrong, Elizabeth Jaffee. Johns Hopkins University School of Medicine, Bal-
timore, MD.
Immune tolerance by multiple mechanisms is a major obstacle in the imple-
mentation of successful immunotherapy. T regulatory cells (Tregs) andmyeloid
derived suppressor cells (MDSCs) suppress the immune response, and the pres-
ence of extensive stromal networks within the tumormicroenvironment (TME)
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can prevent T cell infıltration in many tumor types. Furthermore, tumor anti-
gen-specifıc T cell tolerance limits the effıcacy of therapeutic cancer vaccines.
CD40 is expressed on antigen presenting cells, and CD40 signaling is critical to
the decision of whether cytotoxic T lymphocytes become primed or tolerized.
Administration ofmonoclonal CD40 agonistic antibody (Ab) has been shown to
promote CD8 activation in vivo, and likely alters the myeloid component of the
TME. Our study asks the question of whether combining a T cell inducing
vaccine and PD-1 inhibition with CD40 agonistic Ab can induce T cell priming
and tumor infıltrating lymphocyte (TIL) activation in non-immunogenic solid
malignancies. We utilized an orthotopic transplant model in which HER2/neu-
expressing breast tumor cells were implanted into the mammary fat pad of
syngeneic neu-Nmice to assess the effects of drug combinations on intratumoral
immune responses. Tumor-bearing mice were treated with a granulocyte mac-
rophage colony-stimulation factor secreting vaccine (GVAX)  anti-PD-1 Ab
alone or in combination with CD40 agonistic Ab, and monitored for tumor
clearance and survival. A separate cohort of mice were analyzed by IHC and
multi-color flow cytometry to assess T cell infıltration and activation, myeloid
maturation, andMDSCs after one week of treatment.We demonstrated delayed
tumor progression and increasedmedian survival inmice treatedwithGVAX
anti-PD-1 Ab  CD40 Ab relative to CD40 Ab alone, although endogenous T
cell infıltration remained low across treatment groups.However, adoptive trans-
fer of neu-specifıc TCR transgenic cells revealed 100% tumor clearance in the
combination-treated mice, along with signifıcant T cell infıltration and activa-
tion as measured by IFN, Granzyme B and TNF-secreting CD8 T cells. In
contrast, only 20%ofmice treatedwithGVAX anti-PD-1Abwere able to clear
tumor, and none of the mice receiving vehicle or CD40 Ab alone had long-term
survival. Trends were also observed in monocytic and dendritic cell infıltration
andmaturation in the tumors of combination-treatedmice, andwarrant further
investigation. In conclusion, GVAX, anti-PD-1 Ab and CD40 agonist Ab have
potential synergy in modulating anti-tumor immunity in breast cancer. These
results support further studiesmore broadly in non-immunogenic solid tumors.
#2614 Decrease of benefıt from immune checkpoint inhibitors in women
withnon-small cell lung cancer. JosephA.Pinto,1 LuisA.Mas,1Carlos S.Vallejos,1
Jhajaira Araujo,1 Leny Bravo,2 Alfredo Aguilar,1 Zaida Morante,1 Denisse Bretel,1
Henry L. Gomez,1 Christian Rolfo3. 1Oncosalud, Lima, Peru; 2Universidad Privada
San Juan Bautista, Lima, Peru; 3Antwerp University, Lima, Peru.
Introduction: In a previous work we found differences in immune gene sets
enrichment in NSCLC between genders, regardless their smoking status, where
women had higher expression of gene sets associated with immune processes.
Based in this fact, we hypothesize fewer benefıts from immune checkpoint in-
hibitors in women patients compared than men patients. Objectives: Evaluate
the benefıt (in terms of progression-free survival) of women patients from im-
mune checkpoint inhibitors nivolumab and pembrolizumab in published ran-
domized phase III trials.Methods:We evaluated bymeta-analysis four random-
ized phase III studies, two of prembrolizumab (Herbst et al., 2015 andReck et al.,
2016) and two of nivolumab (Borghaei et al., 2015 and Brahmer et al., 2015).We
analyzed TCGA data for lung adenocarcinoma to evaluate differences in the
expression of PDCD1, CD274 genes (encoding for PD-1 and PD-L1, respec-
tively). Results: For all studies, it was observed an overallHR0.79 (CI95%:0.71-
0.87;P0.00001), although was observed a signifıcant heterogeneity between
studies (P0.002). In male patients, was observed an overall HR0.71 (CI95%:
0.62-0.80;P0.00001) with signifıcant heterogeneity between studies
(P0.002). For female patients, there was not seen a clear benefıt from niv-
olumab or pembrolizumab (overall HR0.97, CI95%:0.82-1.14;P0.67). There
was not heterogeneity between the cohorts (P0.45). Therewere not differences
in the expression of PDCD1 andCD274 genes according to gender in the TCGA
data (P0.371 and 0.144, respectively). Conclusion: Although there are not
differences between genders in the expression of PDCD1 and CD274 genes ,
such as is previously described for expression for PD-1 and PDL-1 proteins, in
ourmeta-analysis we shown that womenhavemodest benefıt from anti immune
checkpoint inhibitors. Blockade of PD1 and PD-L1 is a promising therapy in
lung cancer; however, a better stratifıcation of patients should be done.
Meta-analysis of four phase III randomized studies
Study
All patients
Weight
Hazard
Ratio IV,
Fixed,
95% CI
Men
Weight
Hazard
Ratio IV,
Fixed,
95% CI
Women
Weight
IV,
Fixed,
95% CI
Reck et al.,
2016
10.6% 0.50
[0.37, 0.68]
10.4% 0.39
[0.26, 0.581]
8.0% 0.71
[0.40, 1.26
Brahmer
et al.,
2015
13.7% 0.63
[0.48, 0.82
17.8% 0.63
[0.46, 0.86]
11.2% 0.75
[0.46, 1.22]
Meta-analysis of four phase III randomized studies
Study
All patients
Weight
Hazard
Ratio IV,
Fixed,
95% CI
Men
Weight
Hazard
Ratio IV,
Fixed,
95% CI
Women
Weight
IV,
Fixed,
95% CI
Borghaei
et al.,
2015
30.3% 0.91
[0.76, 1.09
26.6% 0.81
[0.63, 1.04]
37.8% 1.02
[0.78, 1.33]
Herbst
et al.,
2015
45.4 0.85
[0.73, 0.98]
45.2% 0.78
[0.64, 0.95]
43.0% 1.04
[0.81, 1.33]
Total
(95%
Cl)
100.0% 0.79
[0.71, 0.87]
100.0% 0.71
[0.62, 0.80
100.0% 0.97
[0.82, 1.14]
Heterogeneity:
Chi214.73,df3
(P0.002);
I2 80%
Test for
overall
effect: Z
4.73
(P0.00001)
Heterogeneity:
Chi211.12,
df3
(P0.01);
I273%
Test for
overall
effect:
Z 5.28
(P0.00001)
Heterogeneity:
Ch22.67,
df3
(P
0.45);
I20%
Test for
overall
effect:
Z 0.42
(P
0.67)
#2615 Preclinical evaluation and mechanistic characterization of M7824
(MSB0011359C), a novel bifunctional fusion protein targeting the PD-L1
and TGF pathways. Yan Lan, Dong Zhang, Chunxiao Xu, Bo Marelli, Jin Qi,
Huakui Qi, Guozhong Qin, Xiaomei Xu, Hong Wang, Aroop Sircar, Beatrice
Brunkhorst, Eric Austin, Laszlo Radvanyi, Kin-Ming Lo. EMD Serono Research
and Development Institute, Inc., Billerica, MA.
Dual targeting of the programmed death ligand 1 (PD-L1) and transforming
growth factor  (TGF) pathways, 2 key mediators of tumor immune evasion,
may provide synergistic antitumor activity. The novel bifunctional fusion pro-
teinM7824 (MSB0011359C) is a fully human IgG1monoclonal antibody against
PD-L1, fused via a glycine-serine linker at the CH3-C terminus to the extracel-
lular domain of human TGF receptor II, which functions as a TGF “trap.”
Thus, M7824 is designed to exert independent and complementary anti-immu-
nosuppressive functions by simultaneously blocking the PD-L1 andTGF path-
ways. The purpose of this study was to evaluateM7824 preclinically. M7824 was
effıcacious in multiple syngeneic tumor models (EMT-6, MC38, PANC02, 4T1,
CT26, and GL261). In orthotopic EMT-6 and intramuscular MC38 models,
M7824 showed superior additive antitumor effects compared to anti-PD-L1
antibody or TGF trap monotherapy. M7824 also inhibited spontaneous me-
tastases in EMT-6 and 4T1models. Furthermore, M7824 extended survival and
conferred long-term protective antitumor immunity, as demonstrated by pro-
tection of cured mice against tumor cell rechallenge. Mechanistically, the dual
anti-immunosuppressive activity of M7824 in the MC38 model resulted in
unique activation of both the adaptive and innate immune systems, including
increased tumor infıltration, proliferation, and cytotoxicity of CD8 T cells;
increased prevalence of splenic tumor antigen-specifıc CD8 T cells; increased
CD8 TEM infıltration and CD8 TEM/naïve ratio; increased tumor-infıltrated
natural killer (NK) cells; increased ratio of M1/M2macrophages; and decreased
infıltration of tumor-associated neutrophils and myeloid-derived suppressor
cells. Similar immunophenotypic changes were observed in the EMT-6 model.
Activation of both the adaptive and innate immune systems contributed to the
antitumor activity of M7824 in the MC38 model, as depletion of CD8 T cells
and NK cells led to a substantial decrease inM7824-mediated tumor regression;
CD4 T cells and antibody-dependent cellular cytotoxicity, however, appeared
dispensable. Toxicologic evaluation in cynomolgus monkeys indicated M7824
was well tolerated, with only minor hematologic effects observed. Although
M7824 is a bifunctionalmolecule, its antitumor activity can be further improved
by combination with standard-of-care therapies: in the MC38 model, combin-
ing M7824 with radiotherapy or chemotherapy resulted in more effective inhi-
bition of tumor growth and an increased frequency of tumor antigen-specifıc
IFN--producing CD8 T cells vs either monotherapy. Collectively, our pre-
clinical data suggest thatM7824 elicits potent and synergistic antitumor activity
via the simultaneous blockade of the PD-L1 and TGF pathways. Phase 1 clin-
ical trials with M7824 are under way in patients with solid tumors.
#2616 Upregulation of program death ligand 1 expression after a single
cycle of chemotherapy is associated with inferior survival in patients with
local advanced esophageal squamous cell carcinoma treated with preopera-
tive chemoradiotherapy. Ta-Chen Huang,1 Cher-Wei Liang,1 Chia-Chi Lin,1
Ya-Jhen Chen,2 Kuan-Ling Lin,1 Ann-Lii Cheng,1 Chin-Hung Hsu1. 1National
Taiwan University Hospital, Taipei, Taiwan; 2National Taiwan University, Tai-
pei, Taiwan.
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Introduction: Previous studies have demonstrated that the expression of pro-
gramdeath-ligand 1 (PD-L1), a ligand of an immune checkpoint, on cancer cells
or on immune cells may have prognostic signifıcance in multiple cancer types
including esophageal squamous cell carcinoma (ESCC). We evaluated the ex-
pression of PD-L1 and its dynamic changes following one cycle of chemotherapy
before standard preoperative chemoradiotherapy (CRT) in a cohort of locally
advanced ESCC patients. Patients and Methods: A cohort of 66 patients of lo-
cally advanced ESCC have been enrolled to a phase II clinical trial of a single-
cycle chemotherapy (a combination of weekly paclitaxel, cisplatin and 24 hour
infusional 5-fluorouracil, 2 week on plus one week off, followed by paclitaxel/
cisplatin (TP) -based preoperative CRT and radical surgery. Paired tumor tis-
sues from endoscopic biopsy before and after the single-cycle chemotherapy
were available in 21 patients. Immunohistochemical stain for PD-L1 expression
was performed using the Clone SP142 antibody (Spring Bioscience, Pleasanton,
CA, USA). The expression of PD-L1 was scored as previously reported. Tumor
cells were scored according to percentage of positively-stained cells: TC3
50%,
TC2
5% and 50%, TC1
1% and 5%, and TC01%; Immune cells:
IC3
10%, IC2
5% and10%, IC1
1% and5%, and IC01%. Results: In 21
baseline ESCC tissues, 7 of 19 (37%) exhibited positive PD-L1 expression on
tumor cells, and 10 of 21 (48%) exhibited positive expression on immune cells.
In 21 ESCC tissues obtained a median of 18 days after initiating chemotherapy,
9 of 18 (50%) and 15 of 21 (71%) demonstrated positive PD-L1 expression on
tumor cells and immune cells, respectively. The expression of PD-L1 was signif-
icantly increased in post-chemotherapy ESCC tissues compared with baseline
tissues (p0.010); and the increased PD-L1 expression between paired tissues
was signifıcant on immune cells (p0.0056) but did not reach statistical signif-
icance on tumor cells (p0.11). The positive PD-L1 expression in baseline ESCC
tissues was correlated with better survival (HR: 0.37, p0.023). Besides, patients
with more increase of PD-L1 expression after chemotherapy had signifıcantly
worse survival than those with less (median survival: 19.4 vs 71.20 months, HR:
4.07, p0.0089). Conclusion: PD-L1 expression of ESCC can be up-regulated by
chemotherapy. The up-regulation of PD-L1 is associated with poor outcome for
locally advanced ESCC patients. (The study was supported by the grant NTUH
104-M2891 and the grant MOST 105-2314-B-002-186-MY3).
#2617 Inducing neoantigens in therapeutic and prophylactic cancer im-
munotherapy. Greta Garrido Hidalgo, Agata Levay, Alexey Berezhnoy, Brett
Schrand, Eli Gilboa. University of Miami, Miami, FL.
Correlation between clonal neoantigen burden (neoantigens generated early
in tumorigenesis and therefore represented at high frequency in all tumor le-
sions) and responsiveness to checkpoint blockade has underscored the relevance
of neoantigens in promoting tumor immunogenicity. Yet, the most of patients
do not express, or express lownumbers of, clonal neoantigens, and consequently
will be less likely to benefıt from checkpoint blockade. We describe strategies to
generate de novo neoantigens in the patient’ disseminated tumors and show that
in mouse tumor models they potentiate checkpoint blockade. We previously
showed that tumor inhibition of the Nonsense-mediated mRNA decay (NMD)
results in the neoantigens’ induction and reduces tumor growth (Pastor et al.,
2010). We now demonstrate that tumor-targeted NMD inhibition potentiates
PD-1 blockade. A general concern and potential limitation of this approach is
that a signifıcant proportion of the induced neoepitopes come from mutated
products and hence will not be shared by all tumor lesions. To that end, we are
exploring alternative strategies by targeting key components of antigen presen-
tation pathways, specifıcally the TAP transporter, ERAAPpeptidase, and Invari-
ant chain. Studies show that downregulation of these products, not only reduces
the canonical antigenic presentation but also upregulates alternative pathways
that present new, otherwise silent or subdominant, epitopes. Since such epitopes
are not generated by random events they are more likely to represent clonal
neoepitopes. We are developing approaches to inhibit the aforementioned me-
diators using corresponding siRNAs targeted to tumor cells by conjugation to a
nucleolin-binding aptamer. Nucleolin, a nucleolar product, is translocated to
the surface themajority of tumors and thereby serves as a broad target to deliver
therapeutic cargo to the disseminated tumors.We show that nucleolin aptamer-
targeted downregulation of TAP, ERAAP or Invariant chain inhibits tumor
growth and potentiates PD-1 blockade. Recent studies suggest that tumor neo-
antigen-specifıc T cells are dysfunctional due to constant antigenic exposure.
Transiently expressed siRNA inhibition-induced neoantigens are not expected
to be defective. Ongoing studies explore the combinatorial use of neoantigen
induction methods with others immune potentiating strategies. Prophylactic
cancer vaccination obviates the limitations of therapeutic vaccination. A major
barrier for developing this modality is the choice of antigens that will appear in
the future cancer. The ability to induce tumor neoantigens can serve the basis for
developing a new approach to prophylactic, though not preventative, cancer
vaccination whereby neoantigens are induced in the healthy individual (at risk
for cancer), and if or when a cancer develops induce the same antigens in the
patient’ tumor by the methods described above. Preliminary studies in mice
show that the approach has merit.
#2618 Agonist antibodies targeting OX40 and GITR enhance the activity
of the IDO1-selective inhibitor epacadostat in preclinical models. Holly K.
Koblish,1 BrendanHorton,2MichaelHansbury,1 Sybil O’Connor,1 Kerri Lasky,1
Christina Stevens,1 Thomas Condamine,1 Leslie Hall,1 Liang-Chuan Wang,1
Yue Zhang,1HoracioNastri,1 GregoryHollis,1 ReidHuber,1 ThomasGajewski,2
Peggy Scherle1. 1Incyte Corporation, Wilmington, DE; 2University of Chicago,
Chicago, IL.
The majority of immunotherapeutic agents developed thus far either at-
tempt to stimulate a more productive anti-tumor immune response or to
inhibit key proteins in the immunosuppressive tumor milieu. PD-1/PD-L1
axis blockade, CTLA-4 blockade and IDO1 inhibition are examples of the
latter approach and have been utilized to reverse the suppressive tumor
microenvironment, resulting in clinical benefıt for cancer patients. Recent
clinical and preclinical data have also demonstrated that combining these
approaches results in enhanced therapeutic benefıt. Notably, the IDO1-se-
lective inhibitor epacadostat has been shown to increase the effıcacy of two
checkpoint inhibitors, the anti-CTLA-4 antibody ipilimumab and the anti-
PD-1 antibody pembrolizumab, in patients with melanoma. Because both
checkpoint receptors and IDO1 serve as negative regulators of the immune
response, we also explored the ability of IDO1 inhibition to combine with
agents that directly activate T cells through costimulatory receptors of the
tumor necrosis factor receptor (TNFR) superfamily. Rodent active surrogate
agonist antibodies to 4-1BB, OX40 and GITR were tested with epacadostat in
multiple preclinical models. In the B16-SIY melanoma model that does not
express IDO1 in tumor cells, both epacadostat and anti-OX40 had little
effect, but the combination resulted in enhanced effıcacy. This was associ-
ated with increased infıltrates of CD8 T cells and decreased numbers of
FoxP3 TILs. Increased numbers of SIY-reactive T cells were found in both
the tumor and the TDLN post-therapy. In contrast, epacadostat did not
provide any enhancement to the activity seen with 4-1BB. Clear combinato-
rial effects were seen with anti-GITR and epacadostat in the more inflamed,
IDO1-expressing PAN02 pancreatic cancer model. These data suggest that
IDO1 inhibition can be effective in combination with agents that agonize T
cell costimulatory receptors as well as with agents that block coinhibitory
receptors.
#2619 Combinationof ECP1014 and anti-PD-L1 reduces tumor growth in
the CT26 murine colon carcinoma model of a cold tumor. Bobby W.
Sandage,1 John J. Talley,1 Eduardo J. Martinez,2 Maryland R. Franklin,3 Mary
Anne Meade,3 Dan Saims,3 Matt Thayer,3 Scott Wise,3 David Draper,3 Wilber
Leopold3. 1Euclises Pharmaceuticals, Inc., St. Louis, MO; 2Rgenix, Philadelphia,
PA; 3MI Bioresearch, Ann Arbor, MI.
Objective: The objective of this study was to evaluate the effect of ECP1014, a
new selective COX2 inhibitor, in combination with a PDL1 inhibitor on tumor
growth in a CT26 murine colon carcinoma model. Colon cancer has been de-
scribed as a “cold tumor” and antiPDL1monotherapy has shown limited or no
benefıt. In addition, many colon cancer cell lines produce high levels of PGE2,
which may in turn dampen the immune system. The hypothesis was that com-
bining ECP1014, which we have shown potently decreases PGE2 in CT26, with
a checkpoint inhibitor would increase immune response to the tumor, turning it
“hot” and producing superior tumor control versus either agent alone.Methods:
Balb/C mice were implanted with CT26 cells and randomly assigned to 7 treat-
ment groups; vehicle (G1), 10mg/kg rat IgG2b control (G2), 10mg/kg antiPDL1
(G3), 10mg/kg ECP1014 (G4), 10mg/kg ECP101410mg/kg rat IgG2b (G5),
10mg/kg ECP101410mg/kg antiPDL1 (G6), 1mg/kg ECP101410mg/kg
antiPDL1(G7). ECP1014was given daily by oral gavage; rat IgG2b and antiPDL1
(clone 10F.9G2) were administered IP. Treatment was started on day 3 post
implant and mice were followed for 16 days. Tumor measurements were taken
every 2 to 3 days, and a nonparametric approachwas taken to assess the pairwise
differences among groups using day 16 tumor volumes. In addition, a responder
analysis was used. Tumor infıltrating lymphocytes (TIL) were also assessed by
flow cytometry on day 16. Results: All animals developed tumors. G4 to 7 dem-
onstrated statistically signifıcantly (p0.05) slowing of tumor growth when
compared to vehicle (G1). In particular, G7 produced an 87% suppression of
tumor growth compared to vehicle. Three animals in G7 showed regression of
tumor growth and one additional animal had no detectable growth until day 16.
G6 produced 65% suppression of tumor growth compared to G1. G2 to 5 pro-
duced 30, 54, 73 and 50% suppression of tumor growth respectively when com-
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pared toG1. G7 had the highest number of responders 75% vs. 62.5% for G6 and
G4, with all other groups having 25% responders. TIL analysis from G4, G6
and G7 also displayed the highest levels of CD8 Tcells (6.3%, 6.8%, and 6.7%
respectively, versus 3.8% for antiPDL1 and 2.5% for vehicle groups). Summary:
ECP1014 alone was superior to antiPDL1 in slowing tumor growth. However,
the combination of ECP1014antiPDL1showed the greatest tumor response
and growth suppression and markedly increased CD8 Tcells infıltrating into
the tumor vs. single agent anti-PDL1 treatment.
#2620 Selecting the right chemotherapy partner for checkpoint inhibi-
tors: an in vivo comparison of different drugs and dosages. Stefania Orec-
chioni, Giovanna Talarico, Valentina Labanca, Patrizia Mancuso, Francesco
Bertolini. European Inst. of Oncology, Milan, Italy.
Anti-PD-1 and anti-PD-L1 monoclonal antibodies (checkpoint inhibitors,
CIs) have shown a remarkable clinical activity in a variety of types of solid
cancers and hematological malignancies. However, complete and/or long-last-
ing clinical responses have been observed only in a minority of patients. The
clinical response to CIs depends on a complex balance between tumor-associ-
ated and circulating CD3CD4 and CD3CD8 T, regulatory, B, NK and
myeloid/suppressor cell subsets. We have used immunocompetent mice to
generate orthotopic models of breast cancer (BC, injecting 4T1 triple nega-
tive murine cells) and of non-Hodgkin’s lymphoma (NHL, injecting A20
murine malignant B cells). In these models and in cancer-free mice we stud-
ied by 10-color flow cytometry the effect of different doses of 3 widely-used,
orally-active chemotherapy drugs (cyclophosphamide, CTX; capecitabine,
5FU; and vinorelbine, VNR) over a variety of immune cell subsets including
CD3CD4 and CD3CD8 T cells, CD56 NKs, CD19 B cells,
CD3CD4CD25CD127low/neg Tregs, GR1-CD11bCD11cmonocytes,
SSClowCD11bGR1 total Myeloid-Derived Suppressor Cells (t-MDSC, mono-
cytic and polymorphonuclear), SSChighCD11bGR1 granulocytes and
CD11cCD11b-GR1- antigen-presenting cells (APCs). Chemotherapy drugswere
given alone or in combination with murine anti-PD-1 or anti PD-L1 monoclonal
antibodies (Bioxcell clones J43 and 10F.9G2, respectively). For every type of
chemotherapy drugs, we selected 3 dosages representative of clinical low-dose
metronomic (LDM), medium (M), or maximum tolerable (MT) dosages. Mice
were treated for 3 weeks, blood cell subsets were measured weekly. CTX and
5FU, at M and MT dosages, reduced signifıcantly the number of T, B, and NK
cells and of t-MDSC. CTX, but not 5FU, reduced Tregs and APCs. 5FU, but not
CTX, reduced t-MDSC. At variance, VNR at LDM, M and MT doses did not
reduce T, NK and t-MDSC. At M and MT doses, VNR reduced Tregs, B and
SSChighCD11bGR1 granulocytes. Considering these data, we designed pre-
clinical protocols in both BC and NHLmodels associating CTX, 5FU and VNR
with CIs. Cumulative and unbearable toxicities were observed in mice treated
with 2 or more chemotherapy drugs at MT doses plus CIs. In both models,
anti-PD-L1 plusM or LDM combinatory doses of CTX and VNRwere the most
effective therapies for reducing local andmetastatic neoplastic growth. Our data
indicate that chemotherapy drugs have relevant effects on immune cell subsets
involved in the anti-neoplastic activity of CIs, and that the type and the dosage of
chemotherapy are crucial to obtain synergy with CIs. Further studies are ongo-
ing to fınd the right chemotherapy/CI balance to a) maintain an adequate T,
APC and NK cell activity, b) reduce Tregs and myeloid suppressors, c) avoid
toxicity, and d) target cancer cells.
#2621 Microsatellite instability is a potential biomarker for immune
checkpoint inhibitor in endometrial cancer. Hitomi Yamashita, Kentaro Na-
kayama,Noriyoshi Ishikawa, ToshikoMinamoto, Tomoka Ishibashi, Kohei Na-
kamura, Kaori Sanuki, Ruriko Ono, Masako Ishikawa, Takeshi Isobe, Satoru
Kyo. Shimane University Faculty of Medicine, Izumo city, Japan.
[Introduction] In recent years, tumor cells have immune escape mechanism
and immune checkpoint inhibitor therapy (anti PD-1/ PD-L1 antibody) has
shown benefıt in various cancers. Somatic mutations have the potential to en-
code “non-self” immunogenic antigens and lymphocytes infıltrate tumor cells in
Microsatellite-instable (MSI) endometrial cancers. Therefore, immune check-
point inhibitor therapymight be effective inMSI endometrial cancers. [Method]
Mismatch repair protein (MLH1, PMS2,MSH2, andMSH6), tumor-infıltrating
lymphocytes (CD8), and PD-1/PD-L1 expression were assessed by immunohis-
tochemistry in 60 patients with endometrial cancer.We examined whetherMSI
status have enhanced immune microenvironment and become the therapeutic
effect predictor of PD-1/PD-L1 immunotherapy in endometrial cancer. [Re-
sults] Loss of mismatch repair protein (MSI group) was identifıed in 8 (13.3 %)
of 60 patients with endometrial cancer. Expression of tumor-infıltrating lym-
phocytes (CD8) and PD-L1/PD-1 were signifıcantly higher in MSI group com-
pared to MSS group (p0.001, p0.044 and p0.013). [Conclusion] These
results suggested that immune checkpoint inhibitor (anti PD-1/PD-L1 anti-
body) is effective in endometrial cancers with MSI. MSI testing is likely to be a
biomarker for PD-1/PD-L1 immunotherapy in endometrial cancer.
#2622 Two new TLR9 agonists for cancer immunotherapy: Combination
with checkpoint inhibitors. Kerstin Kapp,1 Barbara Volz,1 Detlef Oswald,1
Burghardt Wittig,2 Manuel Schmidt1. 1MOLOGEN AG, Berlin, Germany;
2Foundation Institute Molecular Biology and Bioinformatics, Freie Universitaet
Berlin, Berlin, Germany.
Introduction: TLR9 agonists are developed as anti-cancer therapies based on
their broad activation of the innate and adaptive immune system. Single-
stranded oligodeoxynucleotides (ODN) containing non-methylated CG-motifs
activate TLR9. Previously, chemical modifıcation was used to prevent their deg-
radation by exonucleases. To avoid the off-target effects observed with chemical
modifıcations, new TLR9 agonists containing only natural DNAwere stabilized
by structural components. The dSLIM® family of TLR9 agonists is protected
from exonucleolytic degradation by its covalently-closed dumbbell-shaped
structure. It contains an immunomodulatory sequence with CG-motifs in its
loops. The linear single-stranded EnanDIM® family of TLR9 agonists utilizes
L-deoxyribonucleotides (natural enantiomers of D-deoxyribonucleotides) at
their 3’-ends to prevent degradation. Since themode-of-action of TLR9 agonists
starts upstream of the targets of checkpoint inhibitors anti-PD-1/anti-PD-L1 a
combinatory approach may support synergistic immune activation and thus
enhanced anti-tumor effects. Methods: The impact of dSLIM2006 and En-
anDIM-1 on T cell responses was analyzed employing an in vitro assay using
human peripheral blood mononuclear cells (PBMC). PBMC were treated with
peptides selected from HLA class I-restricted T-cell epitopes of recall-antigens
(CMV, EBV, FluCEF), TLR9 agonists and anti-PD-1 as checkpoint inhibitor.
In addition, in vivo studies were used to investigate the anti-tumor effect of
dSLIM2006 and EnanDIM-1 in combination with anti-PD-1 in a syngeneic
murine CT26 tumor model. Results: The IFN-gamma secretion of human
PBMC after stimulation of CEF peptides was roughly 5-fold increased by
EnanDIM-1 and dSLIM2006, whereas treatment with anti-PD-1 resulted
barely in a two-fold increase. The combination of the TLR9 agonists and
anti-PD-1 further enforced IFN-gamma secretion by about 7-fold. In the
murine colon cancer model CT26 the subcutaneous injection of EnanDIM-1
or intraperitoneal injection of anti-PD-1 had a moderate effect on the tumor
growth when used in monotherapy (28.3% or 57.0% tumor growth inhibi-
tion, TGI). Notably, a combination of EnanDIM-1 and anti-PD-1 further
reduced tumor growth (74.7% TGI). Intratumoral injection of dSLIM2006 in
combination with intraperitoneal injection of anti-PD-1 reduced tumor
growth (54.2% TGI) whereas the single components had more limited effects
(dSLIM2006: 18.7%, anti-PD-1: no inhibition). Combined treatment with
TLR9 agonists and anti-PD-1 prolonged survival of the mice in comparison
to single treatments. Conclusions: The TLR9 agonists and immune surveil-
lance reactivators (ISR) EnanDIM-1 and dSLIM2006 enhance T cell re-
sponses and anti-tumor effects of the anti-PD-1 checkpoint inhibitor. These
data show their promising potential not only for monotherapeutic but also
combinatory approaches.
#2623 Identifıcation of neo-antigens driving melanoma response to im-
mune checkpoint blockers via in vivo screening. Chi-Ping Day,1 Eva Perez-
Guijarro,1 Rajaa ElMeskini,2 ZoeWeaverOhler,2Maxwell Lee,1 HowardYang,1
Suman Vodnala,1 Shyam Sharan,3 Glenn Merlino1. 1National Cancer Institute,
NIH, Bethesda, MD; 2Frederick National Laboratory for Cancer Research, Fred-
erick, MD; 3National Cancer Institute, NIH, Frederick, MD.
Immune checkpoint blockers (ICBs) have rendered unprecedented, durable
responses in metastatic melanoma, but the heterogeneous response among pa-
tients continues to be the major obstacle for their therapeutic development. It is
generally hypothesized that neoantigens derived from mutated genes are in-
volved in tumor response to ICBs, since the latter is correlated witt mutational
loads of tumors. However, direct experimental evidence showing that threshold
quantity or specifıc properties of neoantigens drive ICB response are mostly
lacking. To identify and characterize neoantigens implicated in ICB response,
we have generated two UV-induced melanoma models based on the BrafV600E/
Pten-knockout (Braf/PKO) and Hgf-transgenic (Hgf-tg) mouse, which dis-
played intrinsic resistance and high sensitivity to an anti-CTLA-4 antibody,
respectively. Exome sequencing identifıed 216 and 291 non-synonymousmuta-
tions in the Braf/PKO and UV-Hgf melanoma cell lines, respectively. By RNA
sequencing, 74 (34%) and 121 (42%) of these mutated genes were found to be
expressed in eachmodel, respectively, and there were no overlappingmutations
between them. The mutations found in the “sensitive” UV-Hgf melanoma were
analyzed in silico for their binding affınity to MHC-I and/or MHC-II, thus
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characterizing putative neoantigens. A “neo-epitope” library was generated by
cloning the DNA sequences flanking non-synonymousmutations in frame with
the eGFP gene in a lentiviral vector. We further showed that such eGFP-fused
epitopes can be presented by the cells to induce specifıc T cell responses. The
library will be transduced into the “resistant” Braf/PKO melanoma, which will
be treated with anti-CTLA-4 inmice to identify the neoantigens required for the
response. To prevent immunity against eGFP expressed by tumors, the library-
transducedmelanoma cells will be transplanted into the eGFP-tolerant “glowing
head mice”. The results will be used to determine if one, or more, of our candi-
date neo-epitopes can induce a response to anti-CTLA-4.We will also analyze if
the response to this ICB is an epitope-specifıc reaction or require multiple
epitopes, which will help to identify resistance mechanisms. We anticipate that
our results will provide insight into the role of neoantigens in ICB response.
Moreover, our models will serve as a platform to study the specifıc contribution
and predictive value of neoantigens for melanoma response to immunotherapy,
which could help improve therapeutic strategies involving ICBs.
#2624 An FKBP5-based immunophenotype for assessment of the immu-
nosuppression status and possible prediction of immunotherapy response in
melanoma patients. Simona Romano,1 Ester Simeone,2 Anna D’Angelillo,1
Paolo D’Arrigo,1 Mario Capasso,1 Vito Alessandro Lasorsa,1 Martina Tufano,1
Anna Rea,1Michele Russo,1 Nicola Zambrano,1 Paolo AntonioAscierto,3Maria
Fiammetta Romano1. 1Univ. of Naples Federico II, Napoli, Italy; 2National Can-
cer Institute “G Pascale”, Napoli, Italy; 3National Cancer Institute, Napoli, Italy.
Background and aim: FKBP51 is an immunophilin encoded by FKBP5 gene
on chromosome 6. It is a protein resident in lymphocytes and involved in im-
mune response. Recently, our group demonstrated that the inhibitory check-
point PD-L1/PD1 promoted the alternative splicing of FKBP5 gene, resulting in
increased expression of its variant 4, in PBMCofmelanoma patients. The aim of
this study was to address whether such a molecular signature could help in
identifying an immune profıle associated with increased probability of immu-
notherapy response. Experimental Design: The splicing FKBP51 isoform or
FKBP51s was measured in peripheral blood T lymphocytes subsets (CD3/CD4,
CD3/CD8, CD25 and PD-L1) and CD14 monocytes from a cohort of 118 pa-
tients and 77 age- and sex-matched healthy controls, by flow cytometry. Blood
samples were collected before patients underwent ipilimumab treatment. Fur-
thermore, in 64 out of 118 patients, expression of FKBP51s was also assessed in
regulatory T cells. Results: Physiologically, each PBMC subset analyzed con-
tained a fraction of an FKBP51spos component, which resulted expanded in
melanoma patients. We also measured an increase in CD3/CD8 and PD-L1
lymphocytes in patients. CD4 T lymphocytes showed the FKBP51sneg fraction
signifıcantly impaired, whichmight reflect the condition of impaired T cell help.
Treg count was increased, in accordance with previous studies. The count of
FKBP51sposTregs defıned a subgroup of nonresponder patients to ipilimumab,
by 92.6%. A 2D hierarchical partitioning of data from FKBP51s-immunophe-
notype (heatmap) revealed 3 main clusters: C1 (33 pts, 51,5%), C2 (14 pts, 22%)
and C3 (17 pts, 26,5%). FKBP51spos Treg subset appeared globally increased in
all clusters. In C1, values of effector T cells and monocytes were not different
from normal donors. C2 showed a signifıcant increase of FKBP51spos PD-L1
monocytes and a signifıcant probability of not responding (Chi-square5.46;
p0.019). This fınding is consistent with the hypothesis that response to ipili-
mumab is prevented by accessory cells exerting a negative immune regulatory
control. C3 showed a signifıcant increase of FKBP51s in overall lymphocyte
subsets analyzed. Patients in this cluster showed reduced overall survival. This
fınding suggests that a prevalence of activation (CD25) and co-inhibitory (PD-
L1) markers together with the expansion of FKBP51spos effector T cells might
reflect a condition of chronic lymphocyte stimulation in some advanced mela-
noma patients, contributing to T cell-exhaustion. Conclusions: FKBP51s-based
immunophenotype of melanoma patients revealed several profıles virtually re-
lated to a negative immune regulatory control and highlights an impairment of
a Treg subset endowedwith increased suppressive potential. Such FKBP51sTreg
subset is likely to be associated with immunotherapy response (Chi-
square9.916, p0.002).
#2625 Clinicopathological features of programmed cell death ligand 1
(PD-L1) expression in resected non-small cell lung cancers. Yoshihito
Ohhara,1 Ichiro Kinoshita,1 Utano Tomaru,1 Kanako C. Hatanaka,2 YutakaHa-
tanaka,2 Rio Honma,1 Satoshi Takeuchi,1 Yasushi Shimizu,1 Kichizo Kaga,1 Yo-
shihiro Matsuno,2 Hirotoshi Dosaka-Akita1. 1Hokkaido University Graduate
School of Medicine, Sapporo, Japan; 2Hokkaido University Hospital, Sapporo,
Japan.
Background: Antibodies against programmed death 1 (PD-1) and pro-
grammed death ligand 1 (PD-L1) have recently demonstrated a survival benefıt
in several types of cancer, including melanoma and non-small cell lung cancer
(NSCLC). PD-L1 expression has provided a predictive biomarker for anti-PD-
1/PD-L1 therapy. However, the relationship between PD-L1 expression and
clinical and clinicopathological characteristics remains unclear in NSCLCs. The
aim of this study was to investigate the relevance of PD-L1 expression to clinical
and clinicopathological factors in resected NSCLCs. Materials and Methods:
PD-L1 expressionwas evaluated in 154 surgically resectedNSCLC specimens by
immunohistochemistry (IHC) using the SP142 antibody. Before the IHC of
clinical samples, we performed a concordance study of Western blot analysis
and IHC in 17 lung cancer cell lines. We evaluated the relationship between
PD-L1 expression and clinical and clinicopathological factors by univariate and
multivariate analyses. Survival curves were estimated by the Kaplan-Meier
methods, and differences in survival distributions were evaluated by the log-
rank test. Results: PD-L1 expressionwas well concordantly observed inWestern
blot analysis and IHC in the lung cancer cell lines analyzed. PD-L1 expression
was observed in 51 of 154 (33%) surgically resected NSCLCs. PD-L1 expression
was signifıcantly correlated with male, heavy smoking history, squamous cell
carcinoma, andmoderate/poor differentiation of tumors by univariate analysis.
In multivariate analysis, tumor differentiation had a strong relationship with
PD-L1 expression (odds ratio: 6.32, 95%CI: 1.70-23.49, P 0.006). The survival
was not statistically different between patients with high and low PD-L1 expres-
sion (5-year survival rate: 44.1% versus 58.1%, P 0.22). PD-L1 expression was
not an independent prognostic factor in univariate and multivariate analyses.
Conclusion: PD-L1 expression was strongly associated with tumor differentia-
tion in resected NSCLCs. PD-L1 expression was not a prognostic factor in this
cohort of resected NSCLCs.
#2626 Expression of human poliovirus receptor, an immune checkpoint
biomarker in lung cancer. Camilla Koczara,1 Hui Yu,1 Kim Ellison,1 Christo-
pher Rivard,1 Leslie Rozeboom,1 Daniel Chan,1 Kenichi Suda,1 Kristine
Brovsky,1 Rafal Dziadziuszko,2 Fred Hirsch1. 1University of Colorado Anschutz
Medical Campus, Aurora, CO; 2Medical University of Gdansk, Gdansk, Poland.
Background: Recently, immune therapy has shown notable effıcacy in mela-
noma, non-small-cell lung cancer (NSCLC), among others, indicating that the
targeting of immune checkpoints may be a promising treatment for malignant
tumors. The human Poliovirus Receptor (CD155), an immune checkpoint, has
been found to be overexpressed on the membranes of various tumor cells in-
cluding colorectal and ovarian carcinoma. Examining PVR’s expression in
NSCLC could shine light on PVR’s potential role and its possible correlation to
the prognosis and outcomes for NSCLC patients. Material and Methods: Gene
expression data for lung cancer cell lines and tumor tissues was derived from the
Cancer Cell Line Encyclopedia (CCLE [www.broadinstitute.org/ccle]) and the
TCGA database (www.cbioportal.org), respectively. Immunohistochemistry
(IHC) was performed on a Ventana Benchmark XT platform using an anti-PVR
antibody (Cell Signaling #D3G7H at a 1:100 dilution). IHC staining was evalu-
ated for a NSCLC Cell Line Tissue MicroArray (TMA) and a NSCLC patient
cohort TMA. The H-score system was used to generate a semi-quantitative
score, ranging from 0 to 300, that evaluates the intensity and prevalence of the
staining on tumor cells. Patient data was analysed to uncover correlations be-
tween outcome and PVR expression in the NSCLC TMA cohort. Western blot
analysis was performed to confırm antibody specifıcity and PVR expression
levels in three NSCLC cell lines. Results: Analysis of mRNA expression data
fromCCLE and TCGAdatabases identifıed that PVR is highly expressed in lung
cancer. Three lung cancer cell lines were chosen based onmRNA expression for
this study: NCI-H211 (high), NCI-H1650 (moderate) and NCI-H187 (nega-
tive). Cell line data revealed that PVR demonstrated higher expression levels in
lung cancer than other immune checkpoints, such as PD-L1, PD-L2, and Gal-9
among others. In addition, PVR expression was not correlated with other neg-
ative immune checkpoints including PD-L1 and Gal-9. Western blot analysis
confırmed that the Cell Signaling antibody was specifıc to the PVR protein in
NSCLC cell lines. IHC staining of NSCLC cell lines revealed that non-squamous
NSCLC cell lines express higher levels of PVR than do squamous cell cell lines
(p0.0001, Fisher test). The prevalence of PVR in theNSCLCpatient cohortwas
68% (68/100) using a H-score cutoff of
 7. Analysis revealed a lower positivity
of 61.7% (37/60) in squamous carcinoma as compared to 77.5% (31/40) in non-
squamous NSCLC. Analysis of the patient outcome data demonstrated that
higher levels of PVR protein expression is correlated with poorer outcomes in
patients with both squamous lung cancer and adenocarcinoma. Conclusions:
PVR protein expression could potentially serve as a new immune checkpoint
biomarker in lung cancer. This study demonstrates that high PVR protein levels
predict poorer outcomes in lung cancer patients; suggesting that PVRmay be an
important target for future immune therapy.
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#2627 A study of dynamic changes in PD-L1 expression in KRASmutant
adenocarcinoma of the lung exposed to signal transduction inhibitors.Anna
R. Minchom,1 Parames Thavasu,1 Zai Ahmad,1 Adam Stewart,1 Alexandros
Georgiou,1 Mary ER O’Brien,2 Sanjay Popat,3 Jaishree Bhosle,2 Timothy A.
Yap,1 Johann de Bono,1 Udai Banerji1. 1Institute of Cancer Research, Sutton,
United Kingdom; 2Royal Marsden Hospital, Sutton, United Kingdom; 3Royal
Marsden Hospital, Chelsea, United Kingdom.
Aim:MEK andAKT inhibitors inhibit signaling down steamofKRAS and are
being evaluated as single agents or in combination with other anticancer drugs
for the treatment ofKRASmutant adenocarcinomaof the lung (adeno-NSCLC).
We investigated whether increased PD-L1 expression with functional T cell
inhibitory consequences were a common mechanism of resistance to these
drugs in this setting. Material andMethods: A panel of 10 KRASmutant adeno-
NSCLC cell lines were studied. Cells were exposed to GI50 concentrations of a
MEK (trametinib) and AKT (AZD5363) inhibitor for 6hrs, 24hrs and 3 weeks.
PD-L1 expression on cell lines was studied by immunofluorescence. Immuno-
fluorescence at various time points were expressed as a ratio of values in drug
treated cells compared to untreated control. Functional consequences of PD-L1
expression were studied using a T cell cancer cell line (Jurkat) transfected with a
luciferase reporter where co-culture of cancer cells expressing PD-L1 led to
reduction in luminescence. Luminescence at various time points were expressed
as ratio of luminescence values of drug treated cells compared to untreated
controls. Results: Following characterization of expression of PD-L1 in 10KRAS
mutant adeno-NSCLCcell lines, 5 cell lineswith the highest expression of PD-L1
was chosen for functional assays (H441, H2291, H23, H2030 and A549). When
exposed to trametinib for 3 weeks, 3/5 cell lines (H23, H2030 and A549) showed
an statistically signifıcant increase in expression of PD-L1 (range 1.1-2.4) how-
ever signifıcant reduction of luciferase activity was only observed in H23 and
H2030, 0.93 and 0.75, p 0.018 and p0.01 respectively. When exposed to
AZD5363 for 3 weeks, 3/5 cell lines (H441, H23 and H2030) showed a statisti-
cally signifıcant increase in PD-L1 expression (range 1.3-1.9) however signifı-
cant reduction in luciferase reduction was seen in only H441 and H23, 0.86 and
0.76, p 0.03 and p 0.04 respectively. Conclusion: Chronic exposure of KRAS
mutant cell lines to MEK and AKT inhibitors cause minor increases in PD-L1
expression but this does not result in functional inhibition of T cells in all in-
stances. Consequently, a functional increase in PD-L1 expression is unlikely to
be a common mechanism of resistance to MEK and AKT inhibitors in KRAS
mutant adeno-NSCLC.
#2628 BGB-A425: a humanized anti-humanTim-3 antibody that exhibits
strong immune cell activation. Tong Zhang, Liu Xue, Jing Zhang, Qi Liu, Jie
Ma, Yi Zhang, Yingdi Shi, Hongjia Hou, Hao Peng, Ning Liu, Yilu Zhang,
Xiaomin Song, Yucheng Li, Jing Song, Lai Wang, Min Wei, Kang Li. BeiGene,
Beijing, China.
Background: Tim-3 (T-cell immunoglobin andmucin-domian containing-3)
is a “checkpoint” inhibitory receptor, which is primarily expressed in activated
or “exhausted” T cells, NK cells, macrophages and DCs. Engagement of Tim-3
receptor by its ligand phosphatidylserine (PtdSer) or galectin-9 leads to activa-
tion of negative regulatory signaling inT-cells, promoting functional exhaustion
of tumor-infıltrating T-lymphocytes. BGB-A425 is a novel humanized IgG1
(variant) anti-Tim-3 antibody under preclinical development. The immuno-
modulatory activity of BGB-A425 was evaluated both in vitro and in vivo. Ma-
terials and methods: BGB-A425 was generated through hybridoma fusion, hu-
manized by CDR grafting and structural simulation. The Fc region (IgG1) of
BGB-A425 was engineered to remove Fc gamma receptor (FcR) binding. The
binding affınity and specifıcity were studied by ELISA, FACS and SPR (Biacore).
The immunomodulatory functions of BGB-A425 were evaluated using primary
immune cells as well as cell lines. Results: BGB-A425 binds to the extracellular
domain of human Tim-3 with high affınity (KD 0.36 nM) and specifıcity. In a
competition assay, BGB-A425 effıciently blocks the interactions between Tim-3
and PtdSer. In vitro, BGB-A425 signifıcantly enhances IFN- production of
primary T cells and NK-mediated cytotoxicity against tumor cells. In a MLR
assay, BGB-A425 augmentsT-cell response to allogeneic antigens either alone or
in combinationwith an anti-PD-1 antibodyBGB-A317. Besides blockingTim-3,
BGB-A425 can also induce the internalization of Tim-3 receptor on cell surface.
In vivo, BGB-A425 in combination with BGB-A317 inhibits tumor growth in a
mouse xenograft cancer model. Conclusions: BGB-A425 demonstrates potent
activity to stimulate immune cell function both in vitro and in vivo, supporting
its clinical development for the treatment of human cancers.
#2629 The synergy between BXCL701, a DPP inhibitor, and immune
checkpoint inhibitors discovered using AI and Big Data analytics. Luca Ras-
telli, Snigdha Gupta, Akhil Dahiya, Zeenia Jagga, Krishnan Nandabalan, Sana-
tan Upmanyu. BioXcel, Branford, CT.
Using the proprietary Big Data PharmGPS® Discovery platform, BioXcel has
created a comprehensive relationship map between immune-evasion and im-
mune-activation pathways, comprising interacting genes and all overlapping
pharmacological agents and tumors. This map was used to identify clinically
validated compounds that would act synergistically in combination with im-
mune-checkpoint inhibitors (ICI) by remodelling the tumormicro-enviroment
and transforming cold, non-inflamed tumors into hot immune-sensitive tu-
mors. One of the several compounds thus identifıed is BXCL701, previously
known as Talabostat/PT-100, a DPP inhibitor that by inducing a wide panel of
cytokines and chemokines stimulates both the innate and acquired immune
system. BXCL701 has a dual immuno-oncology relatedMOA.Via the Fibroblast
Activator Protein (FAP) target, it inhibits the activation of immuno-suppressive
fıbroblasts and through an angiogenic related effect, it increases immune cell
extravasation into the tumor tissue. Via the DPP8/9 targets, it depresses the
immuno-suppressive activity of MDSCs by inducing a granulocytic differentia-
tion while it stimulates the priming, migration and cytotoxicity of T-cells and
NK cells and the formation of memory T-cells. The hypothesis that BXCL701
immune-mediated MOA would complement the action of ICIs was validated
in-vivo in the syngeneic MC38 mouse model of colon adenocarcinoma. Co-
administration of BXCL701 combined with anti-PD1 showed a synergistic in-
hibition of tumor growth as well as synergistic up-regulation of immuno-stim-
ulatory cytokines, IL-2, IL12 andGM-CSF. The effects of the combination on the
immune-phenotyping of the circulating and tumor infıltrated immune cells will
also be presented. The fındings support BXCL701 ability to transform the im-
mune-suppressive tumourmicroenvironment to an immuno-permissivemilieu
sensitive to immune-checkpoint inhibitors. Further supporting the therapeutic
potential of BXCL701, an analysis of genomic alterations in FAP, DPP8 and
DPP9 across a wide range of tumors singled out castration-resistant prostate
cancer with a high level of DPP9 amplifıcation (14%) and overexpression of
DPP8 in 50% of the patients which could make this patient population uniquely
sensitive to the combination as shown by in-vitro and in-vivo experiments. This
study provides further evidence of the capability of Big data analytics to generate
in-silico hypothesis of synergistic combination effects that can be converted in
validated therapeutic opportunities to benefıt patients non- responsive to ICI
therapy.
#2630 MEN1309, a novel antibody drug conjugate (ADC) targeting Ly75
antigen, induces complete responses in several xenografts of solid tumors.
Mario Bigioni,1 Giuseppe Merlino,1 Cristina Bernadó Morales,2 Rossana Bu-
gianesi,1 Attilio Crea,1 Rosanna Manno,3 Joaquin Arribas,2 Rachel Dusek,4
Nickolas Attanasio,4 KeithWilson,4 Christian Rohlff,5Monica Binaschi1. 1Men-
arini Ricerche S.p.A., Pomezia (RM), Italy; 2Vall D’Hebron, Institute of Oncology,
Barcelona, Spain; 3Research Toxicology Center, Pomezia (RM), Italy; 4Oxford
BioTherapeutics, Inc., San Jose, CA, USA, San Jose, CA; 5Oxford BioTherapeutics,
Ltd., Abingdon, UK, Abingdon, United Kingdom.
The cell surface antigen Lymphocyte antigen 75 (LY75, CD205, DEC-205) is
over-expressed in several tumor histotypes. It is a type I C-type lectin recep-
tor (CLR), normally expressed on various APC subsets, characterized by a
cytoplasmic domain containing protein motifs crucial for endocytosis and
internalization upon ligation. These features make the antigen ideal to be
exploited as a target for a novel ADC. MEN1309 is a humanized IgG1 anti-
body directed against the cell surface antigen Ly75, conjugated through a
cleavable linker to a potent maytansinoid microtubule disruptor, DM4. In
this study, we evaluated the in vitro and in vivo (xenografts and PDX) effı-
cacy of MEN1309 in different tumor histotypes. A PK/PD relationship was
also investigated in tumor-bearing mice. IHC demonstrated high prevalence
of Ly75 in human pancreatic, triple negative breast, and bladder cancers, as
well as in diffuse large B-cell lymphoma. In vitro experiments showed that
cytotoxic activity of MEN1309 was in nM/sub nM range against several
lymphoma, pancreatic, bladder and triple-negative breast cancer (TNBC)
cell lines. Moreover, MEN1309 exhibited high cell-killing ability against cells
having either strong as well as low to moderate antigen expression. In vivo,
MEN1309 at 2.5-5 mg/kg (schedule varying from single dose, q7dx3, or
q21dx3) showed an impressive antitumor activity, resulting in complete and
long lasting responses in most of the xenograft models representing lym-
phoma, TNBC, bladder and pancreatic cancers, expressing the antigen at
high but also at low levels. No treatment related toxicity in terms of change of
body weight and death events were detected. Moreover, the administration
of (i) isotype control-DM4, (ii) the non-conjugate antibody IgG1 and (iii)
the free toxin DM4 (at a dosage corresponding to the equimolar concentra-
tion linked at 10 mg/kg ADC) showed little to no therapeutic effıcacy on
tumor growth. In TNBC patient-derived xenograft (PDX) model (coming
from a heavily pre-treated patient and expressing high level of the antigen
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Ly75), MEN1309 (5 mg/kg q21dx3) showed a complete tumor regression.
Finally, in the pancreatic adenocarcinoma xenograft model HPAFII, the
pharmacokinetics profıle in serum of MEN1309 at 5 mg/kg was character-
ized and it was qualitatively correlated, using immunofluorescence, with the
occurrence of phosphorylation of Serine 10 of H3 Histone in cancer cells, as
a pharmacodynamic (PD) marker of DM4 activity on microtubules. Initial
ADC exposure was noteworthy and was followed by a relatively fast decline.
In parallel with the decay of the serum ADC concentrations there was a
progressive increase in the number of positive cells showing the PD marker
for mitotic arrest. Overall, our data suggest that MEN1309 is a selective and
potent novel antitumoral ADC and it deserves to enter into aPhase I study for
a variety of Ly75 positive tumor histotypes.
#2631 Enhanced anti-tumor effects by a combination approach of inter-
feron- producing recombinant Bifıdobacterium and anti-mPD-1 antibody
in syngeneic mouse model. Yuji Seki,1 Koichiro Shioya,1 Satoshi Kobayashi,1
Yuko Shimatani,1 Minoru Fujimori,2 Shun’ichiro Taniguchi3. 1Anaeropharma
Science, Inc., Matsumoto, Japan; 2Department of Breast Surgery, Tokyo Medical
University Ibaraki Medical Center, Ibaraki, Japan; 3Department of Comprehen-
sive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Cancer immunotherapies like antibodies targeting immune checkpoint
molecules have resulted in an extraordinary success in cancer treatment.
Still, large fraction of cancer patients doesn’t respond to the antibody immu-
notherapy and lots of patients are suffered from immune-related adverse
events (irAEs) which sometimes cause discontinuation of the treatment. The
above problems highlight the needs in the cancer immunotherapy for at-
tempting various approaches like synergistic combination therapy to mini-
mize adverse events and enhance effıcacy. Interferon- is a cytokine having
antitumor activity and has been developed as an anticancer drug in multiple
cancer indications but failed due to its limited effıcacy and severe adverse
events. In several publications, IFN- has been clarifıed to induce PD-L1
expression in tumors [1,2]. Upreguration of PD-L1 renders tumor resistance
to cytotoxic T cell and it may cause the limited effıcacy of IFN- therapy. Our
preliminary experiments suggested that an intratumoral injection of purifıed
IFN- and following addition with anti-murine PD-1 antibody showed sig-
nifıcant tumor suppression, implying a combination effects of regional
IFN- and immune checkpoint blockers. Here in the present report, in an
aim of decreasing adverse events, we have created recombinant Bifıdobacte-
rium, which is a non-pathogenic anaerobic bacterium to secrete IFN- spe-
cifıcally inside solid tumor, and then demonstrated the combination of
IFN- producing Bifıdobacterium and anti-murine PD-1 antibody signifı-
cantly suppress tumor growth whereas each single treatment moderately
contributes to tumor suppression in a CT26 bearing syngeneic mouse model.
In addition, ELISA assay indicated that there are substantial IFN- detected
in tumor tissue but none of them are detectable in blood on the Day 4 of
treatment. All in together, combination treatment with IFN- producing
Bifıdobacterium and anti-murine PD-1 antibody offers a promising anti-
tumor approach. Reference: 1. Abiko K., Br J Cancer, 2015 Apr 28;112(9):
1501-9. IFN- from lymphocytes induces PD-L1 expression and promotes
progression of ovarian cancer. 2. Mimura K., Cancer Sci., 2014 Oct;105(10):
1236-44. Inhibition of mitogen-activated protein kinase pathway can induce
upregulation of human leukocyte antigen class I without PD-L1-upregula-
tion in contrast to interferon- treatment.
#2632 4SC-202 induces inflamed tumor microenvironment, strongly en-
hances tumor infıltration with cytotoxic T cells and primes tumors for anti-
PD1/PD-L1 therapy.TanjaWulff, Kerstin Kronthaler, Sabine Schrepfer, Ulrike
Parnitzke, Anne Catherine Bretz, Roland Baumgartner, Svetlana Hamm. 4SC,
Martinsried, Germany.
Various HDAC inhibitors were described as benefıcially affecting anti-
tumoral immune response. Although different HDAC inhibitors were inves-
tigated in syngeneic tumor models, the mode of anti-tumoral action is not
yet fully understood. Here, we analyzed the anti-tumoral mode-of-action
(MOA) of 4SC-202, an orally available clinical stage epigenetic small mole-
cule inhibitor specifıcally targeting histone deacetylases HDAC class I as well
as the lysine-specifıc demethylase LSD1. To ensure that the conclusions
would be relevant for the clinical situation we used a clinically equivalent
dose and schedule. Anti-tumoral effıcacy and the impact of 4SC-202 alone or
in combination with an anti-PD-L1 antibody on the tumor microenviron-
ment were analyzed in the syngeneic colorectal CT26model in immunocom-
petent BALB/c or in nude/irradiated BALB/cmice. A broad spectrumHDAC
inhibitor was used for comparison. Transcriptome analysis was performed
by RNA-Seq, and the composition of immune cell subpopulations in the
tumor was determined by flow cytometry. 4SC-202 treatment at clinically
relevant dosage regimen signifıcantly inhibited growth of CT26 tumors. A
competent immune system was apparently necessary for the anti-tumoral
effect of 4SC-202 since its tumor-reducing effect was lost in immunocom-
promised mice. 4SC-202 treatment led to an increase of MHC class II mol-
ecules and enhanced expression of inflammatory markers like IFN- and
various chemokines in the tumors. Detailed analysis of the tumor microen-
vironment revealed that 4SC-202 strongly increased the number of tumori-
cidal cytotoxic T cells (CTL). In contrast, a broad-spectrumHDAC inhibitor
tested in the same model demonstrated anti-tumoral effıcacy but did not
affect the number of CTLs in tumors demonstrating that HDAC inhibitors
employ different MOAs for their anti-tumoral response and that the effect
on CTLs is not attributed to HDAC inhibition in general. Since the T cell
abundance is pre-requisite for the effıcacy of PD1/PD-L1 blockade, we tested
the combination of clinically relevant dosage regiment of 4SC-202 with an
anti-PD-L1 antibody. The combined treatment was more effıcacious than
monotherapies and resulted in signifıcantly longer survival. 4SC-202 already
demonstrated a favorable safety profıle in a phase I clinical trial with relapsed
or refractory hematological malignancies with two objective responses (1
CR, 1 PR) and disease stabilizations in several patients. 4SC-202’s immune
priming capacity offers further options for clinical development of 4SC-202
in combination with various cancer immunotherapy approaches.
#2633 Identifıcation of novel T cell co-inhibitory and co-stimulatory re-
ceptors from screening a comprehensive library of extracellular proteins.
Arthur Brace, Nathan Sallee, Justin Chou, Lindsay Garrenton, Diana Chen,
Ryan Liang, Greg Kemper, David Yang, Marina Jaquez, Janine Powers, Mikayel
Mkrtichyan, Thomas Brennan, Luis Borges. Five Prime Therapeutics, South San
Francisco, CA.
Antibody blockade of immune checkpoint regulators such as PD-1 and
CTLA-4 has been shown to be an effective cancer treatment strategy; however, a
large percentage of patients still do not respond to existing therapies. Discovery
of additional immune checkpoints and co-stimulatory receptors and develop-
ment of antibody therapeutics against them are likely critical to address this
unmet patient need. We generated a comprehensive library of essentially all
human extracellular proteins and have used this library to screen for new agents
that modulate the function of various immune cell subsets both in vitro and in
vivo. Using primary T effector and regulatory T cells, we have identifıed new
targets that modulate the activities of these T cell populations in vitro and are
currently evaluating these proteins as possible targets for cancer immunother-
apy. In addition, we have expressed a subset of the library in three different
models of tumor-bearing mice and have identifıed several proteins that modu-
late anti-tumor immunity in vivo. Several of the proteins identifıed in these
screens have activity across multiple primary cell and in vivo tumor model
screens and we are rapidly evaluating them as possible targets for novel im-
muno-oncology therapeutics. Taken together, we believe that we have devel-
oped robust in vitro and in vivo platforms that will allow us to discover novel
cancer immuno-therapeutics that will help address the needs of cancer patients
that fail to respond to current immunomodulatory therapies.
#2634 EVT801: Standalone cancer immunotherapy in VEGFR3 tumors
and combination with immune checkpoint therapies in VEGFR3
 tumors.
Michael Esquerré,1 Pierre Fons,1Gaëlle Badet,1 PaulineBarron,1 JérémyKagan,1
AntoineAlam,2 JérômeMeneyrol,1 Isabelle Blanc,2 Roselyne Broussy,1 Florence
Gaujarengues,1 Joanna Lisztwan,1 Michael Paillasse,1 Mark Whittaker,1 Fran-
çoise Bono1. 1EVOTEC, Toulouse, France; 2Sanofı, Lyon, France.
In collaboration with Sanofı, we previously showed that inhibition of the
VEGFR3 pathway by SAR131675 leads to reduction of tumor growth by acting
on the tumor microenvironment. We have identifıed a new drug candidate,
EVT801, and evaluated its activity on tumor models expressing VEGFR3. For
proof-of-concept, we transfected the mouse BNL hepatoma cell line with
VEGFR3. EVT801 displayed a strong therapeutic activity by acting on both
VEGFR3 tumor cells and on the Tumor Microenvironment (TME). By deci-
phering the mechanism of action of the compounds we showed that EVT801
strongly decreased tumor-associated immunosuppression by decreasing
MDSCs (Myeloid Derived Suppressor cells) and CD4 regulatory T cells and by
increasing macrophages with a M1 phenotype inside the tumor. As a conse-
quence the T-cell:MDSC ratioswere increased in the TMEand also in peripheral
blood. In addition to its immunomodulatory properties, EVT801 decreased an-
giogenesis without increasing hypoxia. We have evaluated EVT801 therapeutic
activity in syngeneic tumor mouse models which are not expressing VEGFR3
such as 4T1 mammary carcinoma and CT26 colon carcinoma models. As ex-
pected, we observed an intermediate therapeutic activity of the compound on
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both tumor models. Positive modulation of the TME was equivalent to what we
observed with the VEGFR3 tumor model. With this unique mechanism of
action of EVT801 on the TME, we evaluated its ability to increase therapeutic
activity of standard Immune Checkpoint Therapies (ICT) such as anti-CTLA-4
and anti-PD-1 mAbs. Strong additive therapeutic activities were observed with
EVT801 in combination with these ICT as illustrated by the development of
long-term tumor-specifıc memory CD8 T cell responses. Toxicological data
show that EVT801 has a favorable pharmacological profıle consistent with its
entry into pre-clinical development. Taken together, these results indicate that
EVT801 represents an innovative drug for cancer Immunotherapy which pro-
vide a favorable microenvironment to promote tumor regression. In addition,
EVT801 may improve the frequency of response to ICT.
#2635 Baselinemyeloid-derived suppressor cell and eosinophil cell counts
predict clinical effıcacy in patients with non-small cell lung cancer (NSCLC)
treated with nivolumab in second line. Patrizia Mancuso, Antonio Passaro,
Valentina Labanca, Sara Gandini, Gianluca Spitaleri, Elena Guerini, Massimo
Barberis, Cristina Noberasco, Ester del Signore, Alessia Pochesci, Chiara Cata-
nia, Filippo DeMarinis, Francesco Bertolini. European Inst. of Oncology, Milan,
Italy.
The anti-PD-1monoclonal antibody nivolumab is clinically active in a variety
of tumor types including squamous (sq) and non-squamous (non-sq)NSCLC in
second-line, where randomized phase III trials have shown a survival benefıt.
However, no predictive/prognostic or dynamic biomarkers have been found so
far to correlate with clinical benefıt in patients treated with anti-PD-1 antibod-
ies. The aim of the present study is to investigate the potential role of baseline
peripheral blood cell counts in relation to survival and response rate in NSCLC
patients treated with nivolumab in a second-line setting. From July toMay 2016
we evaluated 45 patients with Sq (n 10) and non-Sq (n 35) NSCLC, previ-
ously treated with fırst-line platinum-based chemotherapy, who received niv-
olumab 3 mg/kg IV on day 1 of each 2 week treatment cycle. Clinical character-
istics (T-Stage, lymph nodes involvement, M-Stage) were assessed. Total
numbers of white blood cells, myeloid-derived suppressor cells (MDSCs, in-
cluding both monocytic [Mo-MDSC]) and polymorphonuclear [PMN-MDSC]
types), regulatory T cells (T-regs), and serum lactate dehydrogenase (LDH)were
assessed. Endpoints were correlations with objective response rate (RR), pro-
gression-free survival (PFS, categorized as  3 or  3 months) and overall
survival (OS). Tumor response was assessed using RECIST criteria, version 1.1,
at week 9 and every 6 weeks thereafter until disease progression. Statistical in-
vestigations were based on univariate analyses by the Wilcoxon rank test. The
median PFS of the overall study population was 3 months. Data about PMN-
MDSCs (identifıed by flow cytometry as Lin-CD15CD14-CD11bHLA-
DRlow/-), Mo-MDSCs (Lin-CD14-CD11bHLA-DRlow/-) and absolute eosino-
phil count (AEC) were available in 37/45 patients (82% of treated patients).
Baseline absolute numbers of PMN-MDSCs,Mo-MDSCs andAECwere greater
in patients with a good prognosis (PFS 3 months) and a better RR. In partic-
ular, among patients with shorter PFS and lower RR, the median numbers of
PMN-MDSCs, Mo-MDSCs and AEC were signifıcantly lower than those de-
tected in patients with longer PFS (4 vs 13 cell/l, p0.01; 4 vs 21 cell/l,
p0.06; 55 vs 155 cell/l; p0.02, respectively). Our data suggest that a baseline
blood signature characterized by low levels of PMN-MDSCs, Mo-MDSCs and
AEC is associated with a poor clinical outcome (median PFS of 3 months and
low RR) in 67.6% of patients treated with nivolumab. In contrast, patients with
high levels of these three biomarkers showed a median PFS signifıcantly longer
than 3 months and a higher RR. The OS analysis is ongoing, and further studies
have been planned to understandwhether this signature has a biomarker poten-
tial also in chemotherapy-naïve, fırst line NSCLC patients.
#2636 Targeted therapies to ERBB receptors downregulate expression of
PD-L1: implications in combination therapies. Christopher A. Hamm,1
Sumin Zhao,2 Cesar A. Santa-Maria,3 Massimo Cristofanilli,3 Neil L. Spector,2
Sarah Bacus1. 1American Molecular Laboratories, Vernon Hills, IL; 2Duke Uni-
versity Medical Center, Durham, NC; 3Northwestern University Feinberg School
of Medicine, Chicago, IL.
Background: Inflammatory breast cancer (IBC) is the most aggressive and
lethal form of primary breast cancer. Inflammatory signaling pathways are ac-
tive in IBC, but the function of the immune response remains elusive. ErbB
receptors play a role in IBC. ERBB2 is amplifıed in 50% of IBCs, and ERBB3 is
also mutated in IBC. Currently, Lapatinib, a dual ErbB inhibitor, is used in IBC
patients with ERBB2 amplifıcation. Although immune cell inflammatory signal-
ing may promote IBC tumor growth and metastasis, the presence of cytotoxic
tumor-associated lymphocytes has also been associated with a more favorable
breast cancer prognosis. The contradictory nature of the immune data high-
lights the need to elucidate the relationship between the immune response
and subsequent treatments. Given the active IBC immune component and
the recent clinical benefıt of immune checkpoint inhibitors in cancer treat-
ment, IBC’s may represent a clinically unique breast cancer population that
may benefıt from immunomodulating agents. Interestingly, Myc is a down-
stream effector of ErbB signaling, and Myc is thought to regulate the expres-
sion of immune checkpoint proteins CD47 and PD-L1. The presence of
PD-L1-positive IBC immune infıltrate suggests that IBC’s may benefıt from
therapies that disrupt PD-L1 signaling together with ErbB inhibitors.
METHODS: IHC was used to examine immune checkpoint signaling and
characterize the tumor-immune infıltrate. Tumor tissues were also charac-
terized using an RNA-seq panel that examined the expression of 377 im-
mune-related genes. Cell lines (BT474, SKR3, AU565, and SUM225) were
treated with Lapatinib and Neratinib to examine the relationship between
growth factor receptors and downstream immune signaling pathways. RE-
SULTS: RNA-seq revealed the expression of specifıc immunosuppressive
signaling pathways in tumors. Treatment of breast cancer cells with ErbB
inhibitors resulted in a decrease in the levels of PD-L1. Treatment with
Lapatinib and Neratinib diminished PD-L1 in all cell lines. Levels of Phos-
pho-Stat3 decreased in BT474 and Sum225 but not in SKBR3 and AU565,
implying that PD-L1 is regulated by another mechanism (ERK-MYC). CON-
CLUSION: Our results provide mechanistic insight into ErbB receptor acti-
vation and the expression of downstream signaling molecules (Stat3, Myc,
PD-L1, and others). In addition, our unique RNA-seq immune signature
reveals the expression of several genes that may serve as biomarkers of in-
hibitory immune signaling pathways. Our laboratory is currently examining
the correlation between PD-L1 expression and the activation of ErbB2 in
model systems and clinical trials using ErbB inhibitors in combination with
PD-L1 inhibitors. Our immune panel gene signature may serve as a useful
diagnostic test that, in conjunction with traditional ErbB testing, can identify
patients that will benefıt from combination therapy of an ErbB inhibitor and
an immune checkpoint inhibitor.
#2637 Anti-tumor activity of cisplatin is enhanced by PD-1 blockade in
preclinical models of head and neck squamous cell carcinoma. Linda Tran,1
Clint T. Allen,2 So-Jin Park,1 Roy Xiao,1 Carter VanWaes,1 Nicole C. Schmitt2.
1NIDCD, Bethesda, MD; 2Johns Hopkins University and NIDCD, Bethesda, MD.
Rationale: Cisplatin, which remains the most commonly used systemic drug
for head and neck squamous cell carcinoma (HNSCC), reduces numbers of
circulating immune cells. However, recent studies suggest that cisplatin may
enhance some aspects of anti-tumor immunity in the tumormicroenvironment.
We previously found that cisplatin increases expression of major histocompat-
ibility (MHC) class I and programmed death ligand 1 (PD-L1) in HNSCC cell
lines in vitro. Methods: In the current study, we investigated other components
of the antigen processing machinery (APM) by flow cytometry following treat-
ment with cisplatin. Using the syngeneic mouse oral cancer 1 (MOC1)model of
HNSCC, we then investigated the effects of cisplatin and anti-PD-1 antibody,
alone or in combination, on tumor growth and survival. Results: Using three
different HNSCC cell lines, we found that levels of the APM components LMP2,
ERp57 and calreticulin increased in all cell lines treated with cisplatin, whereas
TAP1/2 increased dramatically only in one cisplatin-treated cell line with wild-
type TP53 (UMSCC-74A). In MOC1 tumor-bearing mice, tumor growth was
partially delayed by treatment with cisplatin and anti-PD-1 antibody alone and
substantially delayed when these agents were given in combination, with resul-
tant increased survival. Comparison of different treatment schedules suggested
that concurrent administration is more effective than giving cisplatin one day
prior to anti-PD-1 or giving anti-PD-1 one day prior to cisplatin. Conclusions:
Despite upregulating PD-L1 on tumor cells and decreasing levels of circulating
immune cells, cisplatin may enhance some aspects of anti-tumor immunity in
the tumor microenvironment. While no mice were cured with concurrent cis-
platin and anti-PD-1 antibody, tumor growth was substantially delayed. These
results suggest a rationale for combining cisplatin and anti-PD-1 monoclonal
antibodies, perhaps with radiation or other therapies, in additional preclinical
studies and clinical trials of HNSCC. Supported by NIDCD intramural project
ZIA-DC-DC000090.
#2638 Clinical characteristics and PD-L1 expression of pulmonary sarco-
matoid carcinoma. Sung Yong Lee, Jae Kyeom Shim, Jee Youn Oh, Kyung
HoonMin,GyuYoungHur, Jae Jeong Shim,KyungHoKang, BongKyung Shin,
Young Seok Lee. Korea University Guro Hospital, Seoul, Republic of Korea.
Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differ-
entiated non-small cell lung cancer (NSCLC) containing a component of
spindle cell or giant cell. Because the prevalence of PSC is very rare, there is
IMMUNOLOGY: Checkpoints 2: Small-Molecule Inhibitors
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 671
insuffıcient data about clinical feature, therapeutic strategy and prognosis.
Method:We reviewed the medical records of 26 patients diagnosed with PSC
from January 2009 to June 2015, and analyzed the clincopathological char-
acteristics, treatment modality and their outcome, and risk factors of overall
survival (OS). Programmed death ligand 1 (PD-L1) expression was tested in
13 patients by using archival tissues (PD-L1 IHC 22C3 pharmDx assay).
Results: The median age of PSC patients was 69.5 years. 23 patients were
male. 25 patients were current or former heavy smokers. Pleomorphic car-
cinoma was the most common subtype, and epidermal growth receptor mu-
tation (EGFR) was positive in 2 of 11 patients who were tested. Among 13
patients tested for programmed death ligand 1 (PD-L1), eight showed PD-L1
high expression (tumor proportion score, TPS 
 50%). Four patients
showed low expression (1%  TPS  49%), and one patient showed no
expression (TPS 1%). The median OS of all patients was 286 days. Age and
the time from symptom onset to diagnosis were signifıcantly associated with
OS. PD-L1 expression showed the trend of positive prognostic value onOS in
univariate analysis but was insignifıcant in multivariate analysis. 12 patients
were treated with chemotherapy: 9 with platinum-based doublet therapy, 2
with tyrosine kinase inhibitor and 1 with docetaxel. 7 patients showed partial
response or stable disease. The median OS and progression free survival of
patients receiving chemotherapy were 260 days and 85 days, respectively.
Conclusions: It has poor prognosis compared with ordinary NSCLC. How-
ever, PSC patients showed comparatively fair response to chemotherapy and
generally showed higher PD-L1 expression. Active treatment with cytotoxic
chemotherapy, EGFR TKIs or immune checkpoint inhibitors are necessary
to achieve a better results of PSC management.
#2639 Development of small molecule selective inhibitors of GCN2 as an
immunotherapy aimed at preventing immune escape of tumor cells.Michał
Gałe˛zowski, Kamil Sitarz, ElizaMajewska, Stefan Chmielewski, KingaMichalik,
Magdalena Masiejczyk, Agnieszka Adamus, Arkadiusz Białas, Joanna Fogt,
Marcin Bien´, Mateusz Świrski, Maciej Mikulski, Julian Zachmann, Krzysztof
Brzózka. Selvita S.A., Kraków, Poland.
GCN2 is a protein kinase capable of sensing amino acid (AA) shortage. It gets
activated by binding of unloaded tRNAs and subsequently phosphorylates
translation initiation factor 2 alpha (eIF2) eventually leading to induction of
ATF4-mediated integrated stress response (ISR). Elevated catabolism of one of
the essential amino acids - tryptophan (Trp), driven by overexpression of critical
enzymes in Trp metabolism - IDO and TDO, leads to immunosuppressive mi-
croenvironment in many types of cancer. GCN2 is a key effector signaling com-
ponent for IDO/TDO and is considered as a metabolic checkpoint of highly
Trp-dependent T-cells. GCN2 activation through accumulation of unloaded
tRNAs leads to inhibition of CD8 effector T-cells and increase in generation
and activation of regulatory T-cells. According to these fındings, selective inhi-
bition of GCN2may be an effective strategy for targeting Trp-dependent immu-
nosurveillance of tumor cells. In this study, we report the results for a series of
novel smallmoleculeGCN2kinase inhibitors that have beendeveloped at Selvita
and, to our best knowledge, are themost potentGCN2 inhibitors reported so far.
Newly synthesized compounds exert low nanomolar potency for GCN2, good
selectivity as well as ADME profıles. Profound assessment of the compounds
potency and effıcacy using a selection of in vitro activity/binding assays will be
presented.
#2640 Small-molecule inhibitors of CD73, CD39 and A2aR: Three anti-
cancer targets in the ATP/adenosine signaling pathway. Ulrike Schindler,
Joanne B. Tan, Matt Walters, Annette Becker, Fangfang Yin, Ada Chen, Yu
Chen,WanHsin Lim, Steve Young,Manmohan Leleti, Jay Powers, Juan C. Jaen.
Arcus Biosciences Inc., Hayward, CA.
INTRODUCTION: In the tumor micro-environment (TME) Adenosine
(ADO) dampens the immune response towards cancer cells by inhibiting the
cytotoxic activity of effector cells and promoting the proliferation of immuno-
suppressive cells. Extracellular ADO is generated by the two ecto-nucleotidases
CD39 (ATP¡AMP) and CD73 (AMP¡ADO). In immune cells ADO signals
primarily through the G-protein coupled receptor A2aR. Inhibition of ADO
generation and signaling have been shown to be promising therapeutic ap-
proaches for the treatment of cancer. METHODS: Potent and highly selective
small molecule inhibitors for A2aR, CD73 and CD39 have been designed and
synthesized by the Medicinal Chemistry Department at Arcus Biosciences. En-
zymatic assays: CD39 and CD73 activity was assayed by quantitating hydrolysis
of ATP or AMP, respectively. Inorganic phosphate was detected using a colori-
metric (malachite green) protocol. ADO receptor assays: The potency of A2aR
antagonists and selectivity towards related receptors was determined by mea-
suring cAMP elevation in stably-expressing CHO cells following NECA (ADO
mimic) stimulation. CD8 T cell assays: Activation, proliferation and effector
function of CD8 T cells were quantifıed following compound treatment in the
presence and absence of ATP. Mixed Lymphocyte Reaction (MLR): Cytokine
levels were determined in an MLR assay after compound treatment in the pres-
ence and absence of ATP. Tumor models: CT26 and B16F10 syngeneic tumor
models were used to assess the therapeutic effect of the inhibitors. RESULTS:
Potent and highly selective small molecules have been generated to block either
ADOgeneration orADOsignaling. The therapeutic potential of thesemolecules
was assessed in CD8 T cell assays, MLR assays and in various tumor models.
CD73 inhibition blocked the conversion of AMP to ADO. CD39 inhibition
blocked the conversion of ATP to AMP and A2aR inhibition abolished the in-
creases in intracellular cAMP following ADO stimulation. The compounds are
highly selective relative to related enzymes/receptors, as well as a large panel of
unrelated targets. Inhibition of any one of the three targets robustly reversed
adenosine-mediated inhibition of proliferation, CD25 expression, and IFN-
and granzyme B production by human CD8 T-cells. Robust inhibition of tu-
mor growth in combination with anti-PD1 antibody was observed for several of
these compounds. CONCLUSIONS: Highly potent and selective inhibitors of
each of the 3 molecular targets involved in the ATP/adenosine pathway have
been identifıed. Their ability to interfere with the extracellular generation of
ADO and the immune-suppressive effects of ADO, as well as their effects on
experimental tumor biology, have been demonstrated in various in vitro and in
vivo models.
#2641 AZD4635 A2A receptor occupancy in cynomolgus monkey using
PET and its application to an oncology clinical development program. Peter
Johnström,1 Pablo Morentin Gutierrez,2 Katarina Varnäs,3 Magnus Schou,1
Akihiro Takano,3 Lorraine Jones,4 Ganesh Mugundu,5 Patricia McCoon,5 Paul
Lyne,5 Jeffrey Infante,6 Gerald Falchook,6 Manish Patel,6 Janet Karlix,6 Melinda
Merchant,5 James Clarke,2 Alan Cross,5 Nicholas Seneca,1 Lars Farde,1 Miles
Congreve,7 Jon S. Mason,7 Fiona H. Marshall7. 1AstraZeneca, Stockholm, Swe-
den; 2AstraZeneca, Cambridge, United Kingdom; 3Karolinska Institutet, Stock-
holm, Sweden; 4AstraZeneca, Macclesfıeld, United Kingdom; 5AstraZeneca,
Waltham, MA; 6Sarah Cannon, Nashville, TN; 7Heptares, Welwyn Garden City,
United Kingdom.
Introduction: AZD4635 is an A2A receptor antagonist currently being tested
asmonotherapy and in combinationwith durvalumab in patientswith advanced
solid cancers. High adenosine levels found in tumors are immune suppressive
and therefore AZD4635 could potentiate immune checkpoint inhibitors such as
durvalumab (anti-PDL1). Predictions of A2A receptor engagement in patients at
different doses and at different time points may enable better interpretation of
clinical biomarker data measuring effects on immune modulation. A quantita-
tive assessment of the receptor occupancy in the brain of non-human primates
was conducted for AZD4635 with PET imaging and the resulting PK/PDmodel
was applied to predict occupancy in humans in tumors.Methods: PETmeasure-
ments of A2AR occupancy in brain was performed using the radioligand
[18F]MNI-444 in three anesthetized cynomologus monkeys. PET data acquisi-
tion was performed for 120 min following IV-administration of [18F]MNI-444
at baseline and following pretreatment of AZD4635. Sampling for AZD4635
plasma exposure determinationwas performed.As part of PK/PDanalysis of the
occupancy data, a novel modifıcation of the non Invasive-LOGAN data analysis
of the PET data was performed to obtain a time course of occupancy for each
dose. A bio-phase PK/PD mathematical model was then used to describe the
relationship of occupancy with circulating concentrations of AZD4635. In par-
allel, a PKmodel for AZD4635 in humanswas developed using data from cohort
1 (Clinical trial NCT02740985) after 125 mg and used for PK predictions for
alternative doses of AZD4635 in the clinic. Results: A clear Exposure-Effect
relationship was observed for AZD4635-driven A2AR occupancy in cyno brain
when dosed 30 min prior to PET measurement. The PK/PD analysis of cyno
PET-determined receptor occupancy provided anOcc50 that is in linewith the in
vitro potency for the compound under physiological concentrations of adeno-
sine in the brain. The resulting PK/PD model has then been applied to predict
the level of occupancy in human tumours at other clinically relevant doses.
Different simulations were done varying the amount of endogenous adenosine
levels. Conclusions: AZD4635 was shown to occupy A2AR in cyno brain in an
exposure dependent manner. The resulting PK/PDmodel built using this data-
set was used to run simulations of expected tumor receptor occupancy in man
and aid clinical dose selection for AZD4635. Sensitivity analysis has shown that
prediction of humanoccupancy in the tumour is highly dependent on adenosine
concentrations in the tumour. Simulations with tumor adenosine concentra-
tions of 1 M indicate that AZD4635 is predicted to provide 90% receptor
occupancy over the whole dosing interval at a clinically relevant dose.
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IMMUNOLOGY: Immune Response to Hematopoietic Tumors:
New Development in Tumor Immunology
#2642 Preclinical effıcacy of daratumumab in acute lymphoblastic leuke-
mia. Karen Lee Bride,1 Tiffaney Vincent,1 Soo-Yeon L. Im,1 Tori Fuller,1 The-
resa Ryan,1 DavidM. Barrett,1 Shannon L.Maude,1Mignon L. Loh,2Michelle L.
Hermiston,2 Stephan A. Grupp,1 Brent L. Wood,3 David T. Teachey1. 1CHOP,
Philadelphia, PA; 2UCSF Medical Center - Mission Bay, San Francisco, CA;
3Seattle Children’s Hospital, Seattle, WA.
Targeted immunotherapy has become critical for the successful treatment of
many forms of cancer, particularly therapeutic antibodies with cytotoxic abili-
ties.No safe and effective immunotherapies have beendeveloped forT-cell acute
lymphoblastic leukemia (T-ALL). CD38 is a transmembrane glycoprotein found
on the cell surface of activated T cells, terminally differentiated B cells, but
relatively low levels on normal lymphoid and myeloid cells. Daratumumab
(dara) (Darzalex, Janssen Biotech, Inc.) is a human IgG1monoclonal antibody
that binds to a unique CD38 epitope and was recently FDA approved for the
treatment of refractorymultiple myeloma. In order to ensure CD38 is a relevant
target in T-ALL and surface expression does not change with chemotherapy, we
evaluated CD38 expression by flow cytometry (FACS) from 21 patients with
T-ALL (10 early T-cell precursor (ETP) and 11 non-ETP) at diagnosis and after
one month of induction chemotherapy. All of the samples had detectable CD38
expression which did not change signifıcantly after induction (mean CD38MFI
at diagnosis vs end-induction: 3.27 log vs 3.19 (S.I.; p  0.25). Therefore we
hypothesized that targetingCD38with darawould be effective against T-ALL. In
order to test this hypothesis, we xenografted primary ALL blasts from 15 differ-
ent patients, including 7 with ETP-ALL and 8 with non-ETP T-ALL. Mice were
randomized to dara (200 g /mouse intraperitoneally (IP) weekly) vs control
(isotype control at 200 g/mouse IP weekly; 5 mice per arm for each sample)
after they developed1% peripheral blood (pb) blasts by FACS. Disease burden
was assessed by FACS enumeration of pb blasts weekly and splenic blasts at
sacrifıce. We demonstrate striking effıcacy of dara monotherapy in 6 of 7 ETP-
ALL samples with reduction of pb and splenic blasts. Mice treated with high
disease burden from 5 of the 8 non-ETP samples were moribund immediately
after dara injection, possibly from aggregates of antibody bound to tumor cells
leading to pulmonary embolism or tumor lysis, and were therefore inevaluable.
We have since repeated the experiments for 3 of the samples, treating the mice
after injection but before detectable engraftment of peripheral blasts. Dara was
effective in all 3 samples. Experiments are ongoing for the other 2 samples.
Overall, we have found Dara was effective in 4 of 6 evaluable non-ETP T-ALL
samples. In summary, we found dara is a highly effective novel monotherapy for
T-ALL in preclinical models. Based on these results, we are developing an early
phase trial for children and young adults with relapsed/refractory T-ALL.
#2643 Thymic precursor cells generate acute myeloid leukemia in NP23-
NHD13 double transgenic mice. Subhadip Kundu,1 Eun Sil Park,2 Yang Jo
Chung,3 Trevor Stephen Barlowe,4 Peter D. Aplan3. 1NIH/NCI, Rockville, MD;
2Gyeong-Sang Natl Univ. Hosp., Jinju, 660-702, Republic of Korea; 3NIH/NCI/
CCR, Bethesda, MD; 4Darthmouth Geisel School of Medicine, Hanover, NH.
Oncogenic fusion genes have been identifıed in a large number of hemato-
logic malignancies. We previously generated mice that expressed either a
NUP98-PHF23 (NP23) or NUP98-HOXD13 (NHD13) fusion in the hemato-
poietic compartment. Both NP23 and NHD13 mice develop a wide variety of
leukemias, includingmyeloid, erythroid, megakaryocytic and lymphoid, at 9-14
months of age. NP23-NHD13 double transgenic mice were generated by inter-
breedingNP23 andNHD13mice. Surprisingly, 100%of theNP23-NHD13 dou-
ble transgenic mice showed rapid onset of acute myeloid leukemia (AML)
within 3 months. The leukemias were characterized by extraordinarily high
WBC and replacement of the thymus with Mac1/Gr1myeloblasts; the per-
cent of malignant myeloid cells in the thymus was often higher than the bone
marrow (BM). It led to the intriguing hypothesis that the AML generated in
NP23-NHD13mice arose in the thymus, as opposed to the BM.We transplanted
unfractionated cells from the thymus of a NP23-NHD13 mouse, invaded by
Mac1/Gr1AML cells or residual CD4-/CD8- double negative (DN) thymo-
cytes into sub-lethally irradiated recipients. All mice (transplanted with either
unfractionated leukemic cells or DN cells from same leukemic mouse) devel-
oped Mac1/Gr1 AML within 26 days, indicating that the AML was aggres-
sive and transplantable, and could be transmitted by DN thymocytes. The ob-
servation that theAMLwas transmitted by theDN thymocytes orMac1/Gr1
AML suggested that the DN thymocytes may be the cell of origin for this AML.
To rule out the possibility that the leukemia in this experiment was transmitted
by rare, contaminant Mac1/Gr1 cells, we repeated the experiment, twice,
using DN thymocytes from 4-5 wk old mice with no signs of leukemia. DN
thymocytes again transmitted aMac1/Gr1AML.We further fractioned DN
thymocytes into DN1, DN2, DN3 and DN4 populations; the recipients of DN1
and DN2 populations developed a Mac1/Gr1 AML, but DN3 and DN4
recipientswere healthywith no signs of engraftment in the peripheral blood.DN
thymocytes from non-leukemic NP23-NHD13 mice were cultured on an OP9
stromal layer, which has been shown to support myeloid differentiation in vitro.
DN thymocytes from non-leukemic NP23-NHD13 mice cultured on a OP9
stromal layer showed a markedly enhanced ability to differentiate into Mac1/
Gr1 myeloid lineage cells compared to WT (56% vs 1.4 % at day 10). The
NP23-NHD13 cells lost expression of Mac1 and Gr1 after 26 days; with immu-
nophenotype now CD4, CD8, CD25-, CD44, Thy-1.2 and cKit, consis-
tent with a self-renewing DN1 thymocyte. These cells were transplanted; all
recipients were anemic, and demonstrated engraftment of NP23-NHD13 my-
eloid cells as well as a less prominent (7.85%-38.5%) population of CD71/
Ter119 erythroid cells in the BM and spleen. Taken together, these results
indicate that NP23-NHD13 thymic progenitors are potently leukemogenic, and
retain myeloid and erythroid differentiation potential.
#2644 SY-1425,aselectiveRARagonist, induceshigh levelsofCD38expres-
sion in RARA-high AML tumors creating a susceptibility to anti-CD38 thera-
peutic antibody treatment. Kathryn Austgen, Michael R. McKeown, Darren
Smith, Emily Lee, Chris Fiore,MatthewL. Eaton,Christian Fritz, Tracey Lodie, Eric
Olson. Syros Pharmaceuticals, Cambridge, MA.
CD38 is a cell surface protein expressed primarily on white blood cells and
considered a marker of differentiation initiation. CD38 is involved in the im-
mune systemby engaging cross-talkwithT andB cells aswell as activation ofNK
cells. In multiple myeloma (MM), a subset of tumor cells have high CD38 ex-
pression (CD38hi), which has led to the development of effective anti-CD38
therapeutic antibodies, such as daratumumab (DARA). Thus, cancer cells that
express CD38 can be selectively targeted for elimination by the immune system
using these therapeutic antibodies. In multiple myeloma, DARA is most effec-
tive in patients whose tumor cells are CD38hi. In contrast, CD38 expression in
AML tumors is generally observed to be negative (CD38neg) or dim (CD38dim),
and DARA has not shown activity in preclinical AML models. We previously
reported that SY-1425, a clinical stage RAR agonist with improved pharmaco-
kinetics, potency, and selectivity over pan-retinoic acid agonists, induces differ-
entiation in non-APL AML cell lines and primary patient samples with a RARA
super-enhancer associated biomarker (RARA-high). Since CD38 was found to
be among the most differentially expressed genes in response to SY-1425, we
hypothesized that SY-1425 mediated CD38 induction to levels comparable to
MM may sensitize RARA-high AML cells to anti-CD38 therapy. We demon-
strate that SY-1425 treatment of four RARA-high AML cell lines and four
RARA-high primary AML patient PBMCs induces the CD38hi phenotype, as
measured by flow cytometry, similar to that found in the DARA sensitive MM
cells. In contrast, we see no induction in RARA-low cell lines. We then demon-
strated the activity of the SY-1425 andDARA combination in an ex vivo NK cell
co-culture assay. Two RARA-high AML cell lines treated with SY-1425 and
DARAwere co-cultured with NK cells andmonitored for both antibody depen-
dent cell-mediated cytotoxicity (ADCC) and NK cell activation by interferon
gamma production. The combination of SY-1425 and DARA led to a six-fold
increase in tumor cell death relative to the single agent controls, and 5-10 fold
increases in NK cell activation is observed only in the SY-1425 and DARA
combination treatment of RARA-high AML cell lines. Neither single agent,
when administered alone, resulted in ADCC. Furthermore, a RARA-low AML
cell line does not respond in the ADCC assay following the combination treat-
ment due to the lack of CD38 induction in this SY-1425 insensitive line. In
summary, we have identifıed a novel and rational combination treatment ap-
proach for a subset of patients with RARA-high AML. By inducing the expres-
sion of CD38, SY-1425 in combination with DARA elicits tumor cell death and
NK cell activation. Based on these fındings, a phase 2 clinical studywith SY-1425
in combination with an anti-CD38 antibody is planned in AML using an RARA
biomarker patient selection strategy.
#2645 Development of a fırst in class APRIL fully blocking antibody
BION-1301 for the treatment ofmultiplemyeloma. JohnDulos,1 LilianDries-
sen,1Marc Snippert,1Marco Guadagnoli,1 Astrid Bertens,1 David Lutje Hulsik,1
Tai Yu Tzu,2 Kenneth Anderson,3 Jan Paul Medema,4 Kate Cameron,4 Hans
Eenennaam,1 Andrea Elsas1. 1Aduro Biotech Europe, Oss, Netherlands; 2Jerome
Lipper Multiple Myeloma Center, Harvard Medical School, Boston, MA; 3LeBow
Institute forMyelomaTherapeutics and Jerome LipperMultipleMyelomaCenter,
Dana Farber Cancer Institute, Harvard Medical School, Oss, MA; 4University of
Amsterdam, Amsterdam, Netherlands.
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APRIL, or tumor necrosis factor super family member 13 (TNFSF13), is a
ligand for the receptors B-cell maturation antigen (BCMA) and transmem-
brane activator calcium modulator and cyclophilin ligand (CAML) interac-
tor (TACI). APRIL serum levels are enhanced in patients diagnosed with
multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and colorec-
tal carcinoma and are correlated with poor prognosis. As a paracrine factor
produced by osteoclasts, macrophages and other cells in the bone marrow
niche, APRIL binds to BCMA to drive proliferation and survival of human
Multiple Myeloma (MM) cells and induces resistance to several standard of
care agents. Using a mouse anti-human APRIL blocking antibody 01A1 orig-
inally discovered using Aduro’s B-Select platform, we demonstrated that
osteoclast-induced MM cell in vitro proliferation and survival is dependent
on APRIL. In these co-cultures, cytolytic activity of lenalidomide and bort-
ezomib is signifıcantly enhanced by 01A in a dose-dependent fashion2. Im-
portantly, APRIL drives and 01A inhibits expression of an immunosuppres-
sive gene set including the immune checkpoint programmed death ligand-1
(PD-L1), interleukin-10, vascular endothelial growth factor, and transform-
ing growth factor beta. The human APRIL antagonist antibody 01A was
humanized and designated BION-1301. The antibody binds an epitope over-
lapping the BCMA and TACI binding sites potently and fully blocks BCMA
and TACI binding (IC50 1 nM). Biophysical and functional experiments
indicated that BION-1301 recapitulated all characteristics of 01A. In vivo,
BION-1301 was shown to suppress T cell-independent B cell responses to
NP-Ficoll. Furthermore, APRIL blockade demonstrated single agent anti-
multiple myeloma activity in a humanized SCID model2 confırming its ac-
tivity in vivo, and potentially indicating that BION-1301 is active targeting
multiple myeloma cells in a tumor-protective bone marrow microenviron-
ment. To our knowledge, BION-1301 is a fırst-in-class humanized APRIL
antagonist demonstrated in to inhibit multiple myeloma survival, drug re-
sistance and an immune suppressive phenotype preclinical. These data sug-
gest a rationale to develop BION-1301 as a single agent, and in combination
with lenalidomide, bortezomib, or possibly checkpoint inhibitors such as
anti-PD-1. BION-1301 is expected to enter Phase 1 in 2017. 1) Guadagnoli at
al. Blood. 2011 Jun 23;117(25):6856-65. 2) Yu-Tzu et al. Blood. 2016 Jun
23;127(25):3225-36.
#2646 Intratumoral delivery of TTI-621 (SIRPFc), a CD47-blocking im-
munotherapeutic, inhibits tumor growth and prolongs animal survival in a
subcutaneous B cell lymphoma model. Gloria H. Lin, Marilyse Charbonneau,
Vien Chai, Alison M. O’Connor, Bolette Bossen, Hui Chen, Mark Wong, Na-
tasja N. Viller, Emma Linderoth, Lisa D. Johnson, Xinli Pang, Jeffery Winston,
Penka S. Petrova, Robert A. Uger. Trillium Therapeutics Inc., Mississauga, On-
tario, Canada.
Tumor cells often evademacrophage-mediated destruction by increasing cell
surface expression of CD47, which delivers an anti-phagocytic (“do-not-eat”)
signal by binding the inhibitory signal-regulatory protein (SIRP) receptor on
macrophages. We have previously shown that blockade of the CD47-SIRP
pathway using TTI-621, a soluble SIRP-IgG1 Fc fusion protein, triggers mac-
rophage phagocytosis of tumor cells in vitro as well as inhibits tumor growth in
vivo when delivered systemically. In the current study, the effıcacy of intratu-
moral delivery of TTI-621 was evaluated in a subcutaneous diffuse large B-cell
lymphoma (Toledo) xenograft model. Tumor bearing mice were randomized
into treatment groups when tumor volumes reached approximately 120 mm3.
Weekly intratumoral administration of TTI-621 at 10, 1 and 0.1 mg/kg dose
levels resulted in statistically signifıcant decreases in tumor growth and im-
proved survival relative to vehicle control treatment. Notably, at day 50 post-
tumor implantation 100% survival was achieved at the highest dose level (vs. 0%
survival with vehicle control treatment).Moreover, weekly intratumoral admin-
istration of TTI-621 was effıcacious even at a high tumor load setting in which
the pre-dose volumes were approximately 300 mm3. Flow cytometry analysis of
the dissociated tumor samples demonstrated no signifıcant change in the num-
bers of M1 and M2 tumor-associated macrophages (TAMs) following intratu-
moral administration of TTI-621. Nevertheless, TTI-621 dramatically increased
the phagocytosis of Toledo cells by bothM1 andM2TAMs to a similar extent ex
vivo, suggesting that TTI-621 is effıcacious in increasing the phagocytosis of
tumor cells by a heterogeneous population of TAMs. Collectively, these results
demonstrate that TTI-621 is effıcacious when delivered intratumorally and can
increase the phagocytosis of tumor cells by both M1 andM2 TAM populations.
These data support the evaluation of intratumoral administration of TTI-621 in
cancer patients, and a Phase I study of intratumorally delivered TTI-621 in
patients with percutaneously accessible solid tumors and mycosis fungoides is
ongoing (NCT02890368).
#2647 TGF- type I receptor inhibitor (TEW-7197) diminishes myeloma
progression by multiple immunomodulatory mechanisms in combination
with ixazomib. Byung-Gyu Kim,1 Olga Sergeeva,1 George Luo,1 Sung Hee
Choi,1 Zhenghong Lee,1 Seong-Jin Kim,2 John Letterio,1 Ehsan Malek1. 1Case
Western Reserve University, Cleveland, OH; 2Seoul National University, Republic
of Korea.
Background: Multiple myeloma (MM) is an incurable cancer of plasma cells.
MM thrives in the bonemarrow tumormicroenvironment (TME)where several
factors sustain MM growth and viability. TGF- is a multi-functional cytokine
elaborated by MM cells and by cells in the bone marrow (BM) TME. TGF-
stimulates MM progression through promotion of catabolic bone remodeling,
IL-6 secretion and Th17 T cell development, which act in concert to induce
osteolytic bone disease, immune suppression andmyeloma progression. There-
fore, we evaluated the anti-MM therapeutic potential of a small molecule inhib-
itor of the TGF- type I receptor kinase (TRI), TEW-7197, in combination
with the proteasome inhibitor, ixazomib. Currently, TEW-7197 is being evalu-
ated in phase I clinical trials in patients with solid tumors, and exposure to this
agent is associated with an acceptable tolerability profıle. Methods: The preclin-
ical immunocompetent 5T33MMmodel (C57BL/KaLwRij) was used to charac-
terize the role of TGF- signaling in the BM TME. Mice bearing 5T33MM cells
expressing luciferase were treated with TEW-7197, ixazomib and the combina-
tion of TEW-7197 plus ixazomib daily for 3 weeks, and evaluated for MM
growth by bioluminescence imaging (BLI). Cellular and molecular assays were
performed in human RPMI8226 and U266 as well as murine 5T33MM cells via
apoptosis, real-time PCR andWestern blotting. Immunological assayswere per-
formed via immunohistochemistry and FACS analyses. Peripheral bloodmono-
clonal protein concentration, M-spike, was measured by ELISA. Results: TEW-
7197 attenuated the growth and viability of human and murine MM cells by
inducing apoptosis and it inhibited TGF--induced activation of Smad2/3 in
MM cells in vitro. In our 5T33MM preclinical model, oral administeration of
TEW-7197 as single agent inhibitedMMprogression asmeasured by peripheral
blood monoclonal protein concentration and BLI before and after treatment.
TEW-7197 also induced a decrease in mortality and an increase in body
weight of mice bearingMM. TEW-7197 alone or combination with ixazomib
also attenuated TGF- activation of Smad2/3, reduced the expansion of
CD11bGr-1 myeloid derived suppressor cells (MDSCs) in BM TME, and
diminished the population of Foxp3 regulatory T cells (Treg) in the spleen.
Combination therapy of TEW-7197 plus ixazomib prolonged survival and ex-
hibited a synergistic anti-tumor effect when compared to either TEW-7197 or
ixazomib alone by signifıcant a reduction in both theM-spike and BLI. Conclu-
sion: Our data demonstrate that the smallmolecule inhibitor of the TRI, TEW-
7197, effectively modulate the MM TME and is associated with a potent anti-
myeloma effect in an immunocompetent murine model of MM. These data
provide a rationale for clinical evaluation of the combination therapy of ix-
azomib and TEW-7197 as a potential therapeutic strategy to improve outcomes
in patients with MM.
#2648 CD47antibody-induced engulfment of humanT-cell leukemia cells
by bonemarrow-derivedmacrophages.Gillian Lovell,1 Clare Szybut,1 Kalpana
Patel,1 Hinnah Campwala,1 Nicola Bevan,1 Dan Appledorn,2 Tim James Dale,1
Derek John Trezise1. 1Essen BioScience Ltd, Welwyn Garden City, United King-
dom; 2Essen BioScience Inc, Ann Arbor, MI.
CD47 is a trans-membrane “don’t-eat-me” signaling protein that enables tu-
mor cells to evade clearance by neighboring phagocytes. Blocking CD47 allows
phagocytes to identify and clear tumor cells and is a promising new approach for
cancer immunotherapy. In this study, we characterized anti-CD47 antibody-
mediated engulfment of living tumor cells (CCRF-CEM) by mouse bone-mar-
row derived macrophages (BMDMs) or immortalized mouse macrophages
(J774A.1). Phagocytosis was quantifıed using a pH-sensitive cell-labeling fluo-
rescent probe, pHrodo, and automated kinetic live-cell analysis (IncuCyte).
CCRF-CEM cells were fırst labeled using pHrodo (250ng ml1 for 1h), washed
and then treated with antibody for 1 h. Target cells were then added to BMDMs
or J774A.1 that had been seeded overnight on 96-well plates. Phase- and fluo-
rescence images were captured and quantifıed every 15min. Anti-CD47 anti-
body (B6H12.2, 0.04-5g ml1), but not IgG-control, produced time- and con-
centration-dependent engulfment of CCRF-CEMs by BMDMs (30’-4h), as
evidenced by an increase in intracellular fluorescence as the label accumulates in
the acidic phagosome. After 4h the red fluorescence area was increased by 25-
fold (1975	 391m2 vs 80	 41m2). From close inspection of the time-lapse
images cellular engulfment could be clearly observed, coincident with the ap-
pearance of the fluorescent signal. Similar observations weremade with J774A.1
as the effector cell. Interestingly, the rate and degree of engulfment appeared
effector cell-dependent. Themechanism of engulfment was not via induction of
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target cell apoptosis since anti-CD47 did not induce PS externalization (An-
nexin V) or activate caspase 3/7. Anti-CD47 had no direct effect on CCRF-CEM
proliferation for the fırst 4 h but upon longer exposures (8 h) cell growth was
attenuated. Our experimental fındings substantiate the known pro-phagocytic
effects of anti-CD47 antibodies, and provide a model system and method for
quantitative functional analysis andmechanistic insight of CD47modulators as
cancer therapeutics.
#2649 Fc-effector function activity of the CXCR4 IgG1 antibody PF-
06747143: a novel clinical candidate for the treatment of hematologic malig-
nancies. Flavia Pernasetti, Shu-Hui Liu, Gu Yin, Bernadette Pascual, Zheng-
ming Yan, Max Hallin, Rolla Yafawi, Cathy Zhang, Connie Fang, Wenlian
Wang, Justine Lam,Mary E. Spilker, Eileen Blasi, Brett Simmons, Nanni Huser,
Wei-Hsien Ho, Kevin Lindquist, Thomas-Toan Tran, Jyothirmayee Kudara-
valli, Jing-Tyan Ma, Gretchen Jimenez, Ishita Barman, Colleen Brown, Sher-
man-Michael Chin, Maria Costa, David Shelton, Tod Smeal, Valeria R. Fantin.
Pfızer, CA.
The chemokine receptor CXCR4 triggers signaling pathways that control cell
migration to tissues where its ligand, CXCL12, is highly expressed, including the
bone marrow (BM). In hematologic cancers, CXCR4 expression is associated
with poor prognosis. CXCR4-driven homing of malignant cells to the BM pro-
tective niche is a key mechanism of chemotherapy resistance. PF-06747143 is a
novel humanized IgG1 therapeutic antibody that binds to CXCR4 and inhibits
CXCL12-driven pathways. Human IgG1 antibodies can induce strong cytotox-
icity mediated by the antibody Fc-region, including antibody-dependent cell-
mediated cytotoxicity (ADCC) and complement-driven cytotoxicity, while hu-
man IgG4 antibodies show minimal or no Fc-driven cytotoxicity. Here we
generated an IgG4 version of PF-06747143 (m15-IgG4), which has similar bind-
ing to CXCR4 as the IgG1 antibody.We then characterized the role of Fc-driven
cytotoxic function, comparing both antibodies in effıcacy and safety studies. In
an ADCC assay, PF-06747143 showed strong cytotoxicity of non-Hodgkin’s
lymphoma (NHL) and acute myeloid leukemia (AML), while m15-IgG4 had no
signifıcant cytotoxicity. In a NHL mouse tumor model, the IgG1 CXCR4 anti-
body resulted in superior tumor growth inhibition, with 50% of mice exhibiting
complete tumor regressions, compared to the m15-IgG4 antibody, which had
limited activity, with no tumor regressions (p0.01). The two antibodies had
comparable exposure, suggesting that the difference in effıcacy is due to the IgG1
antibody Fc-driven cytotoxic function. Furthermore, CXCR4 inhibition was
previously shown to induce leukocyte mobilization from the BM; however, pro-
longed cell mobilizationmay lead to safety related issues, including hyperleuko-
cytosis. In a study in non-human primates, we show that the IgG1 CXCR4
antibody elicited short leukocyte mobilization, lasting 16-24 hrs, while m15-
IgG4 induced prolonged cell mobilization, lasting 4 days. Since both antibod-
ies had comparable exposures, the different mobilization duration is likely due
to the ability of the IgG1 CXCR4 antibody to reduce the number of mobilized
cells via Fc-driven cytotoxic function. Finally, CXCR4 has been shown to play a
key role in chemotherapy resistance. In a chemo-resistant PDX AML mouse
model, in which the standard of care agents daunorubicin and cytarabine had
limited activity, resulting in 30% of tumor cells remaining in the BM post-
treatment, we show that combination of PF-06747143 with these chemo agents
led to synergistic activity, with tumor burden reduced to 0.3% tumor cells in the
BM. In conclusion, PF-06747143 attributes offer potential effıcacy- and safety-
related advantages over other CXCR4 antagonists currently in development,
which do not have Fc-driven cytotoxic activity. PF-06747143 is now being eval-
uated in a Phase 1 clinical trial in relapsed and refractory AML (NCTID
02954653).
#2650 Radioimmunotherapy for acute myeloid leukemia targeting hu-
man aspartyl (asparaginyl) -hydroxylase. Michael S. Lebowitz,1 Ekaterina
Revskaya,2 Kanam Malhotra,1 Amir Shahlaee,3 Steven Fuller,1 Maria R. Baer,4
Noa G. Holtzman,4 Ashkan Emadi,4 Ekaterina Dadachova,5 Hossein A. Ghan-
bari1. 1Panacea Pharmaceuticals, Inc., Gaithersburg, MD; 2Albert Einstein Col-
lege ofMedicine, Bronx, NY; 3Institute for Asthma andAllergy P.C., Chevy Chase,
MD; 4University of Maryland School of Medicine, Baltimore, MD; 5University of
Saskatchewan, Saskatoon, Saskatchewan, Canada.
Treatment options for acute myeloid leukemia (AML) are limited and have
modest impact on 5-year survival rates in patients60 years of age (35-40%)
and on median survival of older patients ( 1 year). The incidence of AML has
been rising, with an anticipated 19,950 new cases in 2016. Thus, the need for
novel, more effıcacious and better tolerated therapy for AML is urgent. Human
aspartyl (asparaginyl) -hydroxylase (HAAH) is an embryonic/developmental
protein, which is down-regulated in normal cells after birth but overexpressed
on the surface of many malignant cells, where it has been demonstrated to be
suffıcient to induce cancer cell proliferation, motility and invasiveness. We hy-
pothesized that HAAH is selectively overexpressed on leukemia cells and thus
targeting it with a fully human monoclonal antibody (mAb) conjugated to the
short half-life-emitter 213Bi could provide a novel radioimmunotherapy (RIT)
treatment optionwith a reasonable therapeutic index.Using immunocytochem-
istry and flow cytometry with anti-HAAHmousemAbs as well as a fully human
mAb, PAN-622, we investigated the expression of HAAH on a variety of cyto-
genetically- and mutationally heterogeneous leukemia cell lines, including
MV4-11,MOLM-14,HL-60, KG1, Kasumi-1, K562, J45.1, andCCRF-CEM, as
well as on normal human leukocytes. PAN-622 was further modifıed with
DTPA-maleimide to allow chelation of radionuclides, specifıcally 213Bi, to the
antibody. The 213Bi-DTPA-PAN-622 was then employed in killing assays to
measure selective dose-dependent killing of leukemic cells. HAAH was highly
expressed, as detected by flow cytometry, on all tested leukemia cell lines with
KG1 and HL-60 demonstrating the highest levels of expression amongst the
AML lines. Binding was observed by both PAN-622 and the modifıed DTPA-
PAN-622 conjugate. Interestingly, expression of HAAH was not detected on
CD45

normal human leukocytes, including in subpopulations of monocytes
(CD14), B-cells (CD19), T-cells (CD3) or hematopoietic stem cells
(CD34). To determine whether PAN-622 could selectively target leukemia
cells in a background of normal human blood, flow cytometrywas performed on
leukemia cells spiked into whole blood. Only leukemia cells were stained with
thePAN-622 antibody as indicated by simultaneous staining for surfacemarkers
specifıc to the various leukocyte subpopulations. Selective killing of leukemia
cell lines was demonstrated following incubation with 213Bi-DTPA-PAN-622
which induced dose dependent specifıc killing over a 6.7-670 pM concentration
range. No killing was detected when using 213Bi conjugated to an isotype-
matched control antibody at a similar specifıc activity and dose range. Thus,
HAAH is a novel oncogenic target expressed on leukemia cells, which can be
selectively targeted for RIT via the fully-human PAN-622 mAb. Experiments
targeting primary leukemia cells in patient-derived bone marrow aspirates are
ongoing.
#2651 A novel CD19 targeting antibody-drug conjugate, huB4-DGN462,
shows promising in vitro and in vivo activity in CD19-positive lymphoma
models. Eugenio Gaudio,1 Chiara Tarantelli,1 Alberto J. Arribas,1 Roberta Pit-
tau Bordone,2 Andrea Rinaldi,1 Georg Stussi,2 Emanuele Zucca,2 Davide Rossi,1
Anastasios Stathis,2 Min Li,3 Alan Wilhem,3 Kate Lai,3 Qifeng Qiu,3 Stuart
Hicks,3 Callum Sloss,3 Francesco Bertoni1. 1Institute of Oncology Research - IOR,
Bellinzona, Switzerland; 2Oncology Institute of Southern Switzerland - IOSI, Bell-
inzona, Switzerland; 3Immunogen Inc., Waltham, MA.
Background. CD19 is a cell surface membrane protein expressed in most
mature and immature B cell neoplasms, making it a promising target for anti-
body-drug conjugate (ADC) therapy for B cell malignancies. Here we describe
the preclinical activity of a novel CD19-targeting ADC, based on the potent
indolinobenzodiazepine DNA-alkylating payload DGN462. Methods. The hu-
manized anti-CD19 antibody, huB4, was conjugated to DGN462 via a cleavable
disulfıde linker, sulfo-SPDB. In vitro activity of the huB4-DGN462 ADC or the
unconjugated DGN462 toxin was evaluated in 54 lymphoma cell lines [27 dif-
fuse large B cell lymphomas (DLBCL); 10 mantle cell lymphomas; 6 marginal
zone lymphomas; 5 anaplastic large T-cell lymphomas; 6 others]. Cell prolifer-
ation/viability after 72h of exposure was measured using a MTT assay. Apopto-
sis activation was defıned by at least 1.5-fold increase in caspase 3/7 signal acti-
vation in respect to controls using the Promega ApoTox-Glo Triplex Assay.
Gene expression profıling (GEP) was performed with the Illumina Hu-
manHT-12 Expression BeadChips on untreated cell lines followed by GSEA
(NES 2 , P0.05, FDR0.25) and limma t-test (FC 1.2 ; P0.05; top 200 up
and top 200 down). In vivo effıcacy of huB4-DGN462 was evaluated in CD19-
expressing xenograft tumor models. Results. huB4-DGN462 was cytotoxic
against a broad panel of 48 B cell lymphoma cell lines (median IC50 100 pM;
95%CI, 38-214). The cytotoxic activity was not limited by P53, BCL2, MYC or
CDKN2A status, or associated with DLBCL cell of origin. Consistent with over-
all lower CD19 expression, huB4-DGN462 was signifıcantly (p-value0.007)
less active in eight T cell-derived lymphomas (median IC50 of 1.75 nM (95%CI,
0.5-5.75)) than in B cell lymphomas. huB4-DGN462 induced caspase 3/7 acti-
vation in 48/54 cell lines (89%) consistent with an apoptotic mechanism of
action. huB4-DGN462 demonstrated compelling anti-tumor activity after a sin-
gle intravenous dose in two diffuse large B-cell lymphoma cell line xenograft
models: DoHH2 (a subcutaneousmodel) and Farage (a disseminatedmodel). In
the DoHH2 model, huB4-DGN462 resulted in a signifıcant, dose-dependent
tumor growth delay and survival benefıt at 1.7 mg Ab/kg compared to a non-
targeted control DGN462 ADC. In the disseminated Farage model, a signifıcant
dose-dependent increase in survival was observed in mice treated with as low as
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0.17 mg Ab/kg of huB4-DGN462. At 1.7 mg Ab/kg, the life span was increased
400% compared to untreated mice. Conclusions. The novel ADC huB4-
DGN462 presented strong preclinical anti-lymphoma activity, which provides
evidence for further study.
#2652 Favorable outcome of primary mediastinal large B-cell lymphoma
treated by Dose Adjusted EPOCH-Rituximab regimen. Fatiha Grifı, Soraya
Bougherira. University of Annaba, Annaba, Algeria.
Background: Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) is a
unique type of B-cell lymphoma probably arising from a putative thymic me-
dulla B-cell. One to 2% of NHL, 7% of all diffuse large B-cell lymphomas
(DLBCL), occurring more often in young females. Often presents with superior
vena cava syndrome and airway compromise. Treatment is with chemotherapy
combined with Rituximab, followed by involved fıeld radiation therapy to me-
diastinum. PMLBCL has better outcome than others DLBCL. We aimed to de-
velop amore dose-dense/intense regimens that improves the rate of curewith an
attempt to avoid mediastinal radiation. Patients and methods: A prospective
study was conducted in our department from January to December 2015, in 6
patients with untreated primary mediastinal B-cell lymphoma. An infusional
dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine,
prednisone, and rituximab (DA-EPOCH-R) has been administred according to
the protocol Day 1 : Rituximab 375mg/m2 IVDay 1-4 : Etoposide 50mg/m2 IV,
Doxorubicin 10mg/m2 ANDVincristine 0.4mg/m2Day 5 : Cyclophosphamide
750 mg/m2 Days 1-5 : Prednisone 60 mg/m2 PO BID. Administer G-CSF 5
mcg/kg SQonday 6 until ANCexceeds nadirCycleswere repeated every 3weeks
for a toal of 6 cycles Results: The median age of the patients was 32 years, the
male to female ratio : 2:4. Systemic symptomsmainly fever andweight loss, were
present in all cases; increased LDH levels were also observed in 50% of cases.
Majority of the patients (83%) presented with stage I/II disease, bulkymass with
a median tumor diameter 15 cm. Most had features of local extension like
pleuro-pericardial effusion. Absence of infradiaphragmatic lymphnodes and no
bonemarrow involvement at presentation. All patients required biopsy from the
mediastinal mass by image guided core biopsy. The patients were treated by
RDA-EPOCH, they received 4 to 6 courses, without involved fıeld radiotherapy
(only one patient underwent radiotherapy for residual mass). No late morbidity
or cardiac toxic effects were found in any patients. After 24months of follow-up,
one patient still received treatment and was not evaluable. 5 patients achieved
complete remission andwere disease-free at the last visit. Conclusion: PMBCL is
a specifıc lymphoma entity seen in the youngwith good survival. It has a distinct
clinical behavior and prognosis, and therefore require a different therapeutic
approach. TheR/DA-EPOCHregimenneed to be confırmed in further prospec-
tive study for a large cohort.
#2653 The anti-myelomaactivity ofTTI-621 (SIRPFc), aCD47-blocking
immunotherapeutic, is enhanced when combined with a proteasome inhibi-
tor. Emma Linderoth, Simone Helke, Vivian Lee, Tapfuma Mutukura, Mark
Wong, Gloria H. Lin, Lisa D. Johnson, Xinli Pang, Jeff Winston, Penka S.
Petrova, Robert A. Uger, Natasja N. Viller. Trillium Therapeutics Inc., Missis-
sauga, Ontario, Canada.
CD47 is transmembrane glycoprotein that delivers an anti-phagocytic (“do
not eat”) signal by binding to its receptor, signal-regulatory protein  (SIRP),
on the surface of macrophages. Many tumors, including multiple myeloma
(MM), express high levels of CD47 as a means to exploit the CD47-SIRP path-
way and escape macrophage-mediated immune surveillance. TTI-621
(SIRPFc) is a soluble recombinant fusion protein consisting of the CD47-
binding domain of human SIRP linked to the Fc region of human IgG1. It is
designed to promote anti-tumor responses by blocking the CD47 “do not eat”
signal and engaging activating Fc receptors on macrophages. We have previ-
ously shown that TTI-621 enhances phagocytosis of malignant cells in vitro and
exhibits anti-tumor activity in acute myeloid leukemia and B lymphoma xeno-
graft models. In this study we investigated the anti-myeloma activity of TTI-621
as both a single agent and in combination with bortezomib or carfılzomib, two
proteasome inhibitors that are approved for use in MM patients. The ability of
TTI-621 to trigger macrophage phagocytosis of MM cells was assessed using a
flow cytometry-based phagocytosis assay. Blockade of CD47 using TTI-621 ef-
fectively triggered macrophage-mediated phagocytosis of MM cells, and this
anti-tumor effect was signifıcantly enhanced by pre-treatment of MM cells with
bortezomib or carfılzomib. In order to understand the molecular mechanism
behind this enhanced phagocytic effect, we performed immunophenotyping of
the tumor cells and observed an upregulation of pro-phagocytic “eat” signals on
the tumor cell surface that potentially augment the phagocytic response. To
investigate whether CD47 blockade in the context of proteasome inhibition
translates to enhanced anti-tumor activity in vivo, we employed aMMxenograft
model. NOD.SCID mice were subcutaneously engrafted with human MM cells
followed by treatment with TTI-621, in the absence or presence of concurrent
administration of a proteasome inhibitor. As monotherapies, both TTI-621 and
the proteasome inhibitor reduced tumor burden relative to vehicle controls.
Moreover, the combination of CD47 blockade and proteasome inhibition re-
sulted in a greater reduction in tumor growth as compared to the two drugs
alone. In conclusion, these data demonstrate that TTI-621 exhibits anti-my-
eloma activity that is further enhanced by combination with bortezomib or
carfılzomib. TTI-621 monotherapy is currently being evaluated in a Phase 1b
study in patients with MM and other hematological malignancies
(NCT02663518). These data provide a rationale to evaluate a combination study
of TTI-621 and a proteasome inhibitor in MM patients.
#2654 Resveratrol and piceatannol synergistically induce PDL1 expres-
sion. Justin P. Lucas,1 Joseph M. Wu,2 TzeChen Hsieh,2 Zbigniew Darzynkie-
wicz,2 Halina Dorota Halicka-Ambroziak2. 1Pfızer/New York Medical College,
Pearl River, NY; 2New York Medical College, Valhalla, NY.
The interaction of programmed cell death-1 (PD-1) and its ligand programed
cell death-1 ligand (PD-L1) is amajor focus of recent immune oncology therapy
efforts. The expression of PD-1 onT lymphocytes and its subsequent interaction
with PD-L1, either from antigen presenting or tumor cells, will result in apop-
tosis-dependent inactivation of the T lymphocytes. This interaction plays an
integral role in tumor immunology, specifıcally augmenting immune evasion.
Relatively little is known about the regulation of PD-L1 in either the tumor or
normal environment. We investigated the ability of natural dietary compounds
to induce PD-L1 expression on normal epithelial cells and various cancer cell
lines. These molecules have been evolutionary selected to control inflammation
and cancer cell transformation and progression, understanding their mecha-
nism of action could be important to understanding how this system works.
Using flow cytometry and immunohistochemistry, we focused our studies on
resveratrol and its metabolite piceatannol, key phytochemicals extracted from
grapes, after an initial screen of various natural products. Experimental data
showed that both compounds can individually up-regulate the expression of
PD-L1 on tumor cell lines and normal epithelial cells, by an IFN--independent
mechanism. PD-L1 induction by both of these compounds was higher in tumor
than in normal epithelium, suggesting greater signifıcance in tumor regulation
than inflammation. Additionally, the combination of resveratrol and piceatan-
nol acted synergistically, leading to a signifıcantly greater induction of PD-L1
expression across multiple tumor indications. Understanding whether resvera-
trol and piceatannol use a common signaling pathway to induce PD-L1 expres-
sion in tumor cells, was critical to understand the synergistic induction ob-
served. Studies utilizing specifıc inhibition of IKK phosphorylation were
accompanied by a signifıcant reduction in the ability to induce PD-L1 expres-
sion on tumor cells, either as single agents or in combination. These results are
consistent with the hypothesis that induction of PD-L1 by resveratrol or picea-
tannol, or their combination involves molecular determinants down-stream of
NF-kB signaling.
#2655 Drug resistant B-cell tumors eliminated by novel therapeutic anti-
bodies in vivo. Hong Qin,1 Guowei Wei,1 Ippei Sakamaki,2 Zhenyuan Dong,1
Wesley A. Cheng,1 Diane L. Smith,1 Feng Wen,3 Han Sun,1 Soung-chul Cha,4
Sattva S. Neelapu,4 Larry W. Kwak1. 1City of Hope, Duarte, CA; 2University of
Fukui, Awara, Japan; 3Sichuan University, China; 4University of Texas MD An-
derson Cancer Center, Houston, TX.
B-cell malignancies have been successfully targeted in the clinic by thera-
pies such as anti-CD20 antibody rituximab or Bruton’s tyrosine kinase in-
hibitor ibrutinib. However, leukemias and lymphomas remain incurable due
to primary or acquired resistance, ultimately leaving patients without an
effective treatment option. We sought to circumvent this drug resistance by
pursuing an alternative target known as B cell activating factor receptor
(BAFF-R). Despite past limited success, BAFF-R remains a prime target for
B-cell lymphoma and leukemia therapeutic antibody development due to its
key role in B-cell proliferation and development.We report the development
of two novel monoclonal antibodies (mAbs) against human (h) BAFF-R. The
mAbs were generated by immunizing mice with (h)BAFF-R-expressing
mouse fıbroblast cells presenting a natively folded, cell-surface immunogen.
The two mAbs presented unique complementarity determining regions that
specifıcally bound (h)BAFF-R-expressing mouse fıbroblast cells but not the
parental counterpart. Furthermore, the antibodies were specifıc to B-cell
containing organs such as tonsil and spleen, by immunohistochemical stain-
ing and without detectable reactivity in heart, lung, brain, liver, and kidney
tissues. To tailor the antibodies for clinical application, a human IgG1 Fc
capable of eliciting an immune response was substituted, creating chimeric
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versions. We showed that both chimeric mAbs bound with high affınity to
human B-cell lymphoma cell lines including JeKo-1 (mantle cell lymphoma;
MCL), SU-DHL-6 (diffuse large B cell lymphoma; DLBCL), Raji (Burkitt
lymphoma), and RL (follicular lymphoma). The chimeric antibodies also
elicited antibody-dependent cell-mediated cytotoxicity (ADCC) with pri-
mary human natural killer (NK) cells in vitro against these tumor lines as
well as primary lymphoma samples (n5) from patients who progressed
after rituximab exposure. Most notably, the antibodies demonstrated effı-
cacy in two in vivo drug resistant lymphoma models we developed, a ritux-
imab-resistant CD20 genomic knockout variant of JeKo-1 and the naturally
ibrutinib-resistant Z-138. Using these lymphomas lines for xenogeneic tu-
mor models in NOD scid gamma (NSG) mice, we found our antibodies
signifıcantly inhibited tumor growth, conferring long-term and tumor free
survival on the mice. Our in vitro and in vivo results robustly demonstrate
the high specifıcity and signifıcant anti-tumor effects of our anti-BAFF-R
antibodies against a broad variety of B-cell malignancies, especially against
cases of rituximab and ibrutinib resistance. This successful development of
novel anti-BAFF-R therapeutic antibodies warrants support for further
translational development for clinical use in light of current resistance cases.
#2656 Polatuzumab vedotin signifıcantly enhances in vitro cell death and
overall survival against CD79b Burkitt lymphoma (BL)/primarymediasti-
nal large B-cell lymphoma (PMBL)NSG xenograftmice.Aradhana A. Tiwari,
Janet Ayello, ChristeenAzmy, Carmella van deVen,Mitchell S. Cairo.NewYork
Medical College, Valhalla, NY.
Background: Mature B-NHL, including Burkitt lymphoma and primary me-
diastinal large B cell lymphoma express CD79b and have an excellent progno-
sis with chemo-immunotherapy (Cairo et al Blood, 2007, Gerrard/Cairo et al.
Blood, 2013). However, a subset of patients with relapsed/refractory mature
B-NHL has chemoimmunotherapy resistant disease a dismal prognosis ( 10%
5 years, EFS) (Cairo et al. JCO, 2012). The antibody drug conjugates (Polatu-
zumab Vedotin, PV) has demonstrated signifıcant preclinical activity against
indolent CD79bNHL (Polson et al. Can. Res. 2009). More recently PV has
been safe and well tolerated in adult with CD79b refractory CLL (Palanca-Wes-
sels et al. Lancet Oncol, 2014) but its preclinical activity against mature B-NHL
(BL/PMBL) is unknown. Objective: To determine the effıcacy of the PV against
CD79b PMBL and rituximab (RTX) sensitive/resistant BL tumor cell lines
in-vitro and in-vivo. Design/Methods: Raji/Raji4RH (BL, provided byM. Barth,
Roswell Park Cancer Institute) andKarpas1106P andMedB-1(PMBL) were cul-
tured in 10-20% RPMI. Tumor cells were incubated with hu anti-CD79b-vc-
MMAE, and/or anti-CD79b,MMAEor huIgG1 (generously supplied byGenen-
tech Inc.) for 24 hrs. Cell death was evaluated by staining with annexin V/7AAD
and analyzed by flow cytometry, n3. Six to 8 week old female NSG (NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ), were divided into 5 groups: PBS only (control),
isotype control (IgG), PV (5mg/kg), anti-CD79bmAb (5mg/kg) andMMAE (5
mg/kg). Mice were xenografted with intravenous injections of Luc Raji/
Raji4RH and Karpas1106P cells as we have previously demonstrated (Awasthi/
Cairo et al, BJH, 2015). Mice were treated twice a week for 6 weeks. Tumor
burden was monitored by IVIS spectrum system. Results: Anti-CD79b-vc-
MMAE compared to anti-CD79b Ab or IgG1 Ab alone (10g/ml, 24hrs), sig-
nifıcantly enhanced cell death in Raji, 47.2	1.3% vs 29.1	6.0% vs. 28.2	4.3%,
(p0.0008 and p0.00006), Raji4RH, 29.8	9.1% vs 25.4	3.9% vs. 18.0	8.2%
(pNS and p0.03), Karpas1106P, 46.8	5.3% vs 33.8	3.5% vs. 26.2	0.4%
(p0.02 and 0.006) and MedB-1, 47.4	2.2% vs 27.6	2.4% vs. 23.9	1.7%
(p0.002 and 0.0001), respectively. Further, median survival time in mice re-
ceiving 5 mg/kg of PV was signifıcantly increased when compared to mice re-
ceiving 5 mg/kg of anti-CD79b Ab or isotype control in Raji, Raji4RH and
Karpas1106P (35.5 vs.17 vs. 19.5 days, p0.0001, 0.0003, 50 vs. 18 vs. 18.5 days
and 150 vs 89 vs 64 days, p0.03 ,0.003, respectively) Conclusions: Our prelim-
inary data indicates that PV signifıcantly enhances cell death in RTX sensitive/
resistant BL andPMBLcompared toCD79bAbor isotype control. Furthermore,
PV signifıcantly increased survival in BL and PMBL NSG xenografts.
#2657 PD-L1 blockade enhances T cell cytotoxicity against primarymedias-
tinal B cell lymphoma. Tishi Shah, Wen Luo, Aradhana Awasthi, Janet Ayello,
Jessica Hochberg, Mitchell Cairo.New YorkMedical College, Valhalla, NY.
Background: PrimaryMediastinal B cell Lymphoma (PMBL) represents 2-4% of
Non-Hodgkin Lymphomas (NHL) in adolescents and young adults (AYA) (Ger-
rard/Cairo et al., Blood, 2013). Disease progression, relapse and long-term toxicity
remain a concern for patients treated on current chemo-immunotherapy and me-
diastinal radiotherapy. Alternative therapeutic regimens are urgently needed, espe-
cially in patientswithout an early response to therapy. ProgrammedDeath 1 (PD-1)
is a negative co-stimulatory receptor critical for suppression of T-cell activation,
with binding of PD-1 and ProgrammedDeath Ligand 1 (PD-L1) resulting in T cell
exhaustion (Postow/Wolchok et al., J ClinOncol, 2015). Gain in 9p associated with
amplifıcationof PD-L1has been reported inup to 60%ofPMBL specimens, leading
to overexpression of PD-L1 and potential immune cell evasion of PMBL (Rosen-
wald/Staudt et al., J Exp Med, 2003; Twa/Steidl et al., Blood, 2014). Blockade of
PD-1/PD-L1 interaction, therefore, constitute a potentially promising alternative
for treatment of resistant PMBL.Objective: In the current study,we sought to inves-
tigate whether PD-L1 blockade enhances T cell responses in PD-L1 expressing
PMBL.Methods: PD-L1expressiononKarpas 1106pPMBL treatedwithorwithout
IFNwas investigatedbywesternblotting and flowcytometry analyses. T cellswere
isolated fromhuman PBMC followed by activation and expansion using anti-CD2,
anti-CD3 and anti-CD28 Biotinylated MACSiBead particles. T cell activation was
confırmed by CD25 and CD69 expression using flow cytometry. Activated T cells
were incubatedwithorwithout anti-PD-L1 (Clone6E11,Genentech) at a dose of 10
ug/ml together withKarpas 1106p cells treatedwith orwithout IFN. Cell prolifer-
ationwas assessedwithMTS assays after incubation for 24 hours. Results:Wedem-
onstrated that Karpas 1106p cells express a low level of PD-L1. However, following
IFN  treatment (48 hours) there was a signifıcant increase in PD-L1 expression.
Anti-PD-L1 had no signifıcant effect on T cell mediated inhibition of cell prolifera-
tion in Karpas 1106p cells with low PD-L1 expression. However, anti-PD-L1 and T
cell treatment signifıcantly inhibitedcell proliferation in IFN treatedKarpas1106p
cells when compared to T cell treatment alone (32	18% vs. 3	3% at E:T5:1,
p0.048). Conclusion: PD-L1 blockade enhances T cell cytotoxicity against PMBL,
which is dependent on PD-L1 expression level on PMBL cells. Future in-vivo NSG
xenograft studies are ongoing.
#2659 MT-4019: a de-immunized engineered toxin body targeting CD38
for multiple myeloma. Garrett L. Robinson, Sangeetha Rajagopalan, Brigitte
Brieschke, Jane Neill, Jennifer Erdman, Rodney Flores, Jensing Liu, Jack P. Hig-
gins, Erin K. Willert.Molecular Templates Inc., Austin, TX.
Molecular Templates is developing engineered toxin bodies (ETBs), po-
tent recombinant immunotoxins that combine the specifıcity of an antibody
fragment with the powerful direct cytotoxicity of the Shiga-like toxin A
subunit (SLTA). ETBs can induce their own internalization, route through
the cell in a predictable manner, enzymatically and irreversibly destroy ri-
bosomes to shutdown protein synthesis and induce apoptosis of tumor cells.
This mechanism of action is distinct from that of other therapeutics, making
ETBs an attractive treatment for patients who have become resistant to che-
motherapy and other treatments. Safety and effıcacy in refractory non-
Hodgkin’s lymphoma patients has been observed in a phase I study with
Molecular Template’s fırst-generation CD20-targeting compound, MT-
3724. CD38 is a surface receptor that is highly expressed on malignant
plasma cells. CD38 is a clinically validated target of monoclonal antibodies
for treatment of multiple myeloma and is known to persist after failure of
antibody treatment. MT-4019 is a CD38-targeted next-generation ETB, uti-
lizing a modifıed SLTA. The SLTA subunit of the next-generation ETB scaf-
fold has been modifıed through proprietary genetic engineering to system-
atically and comprehensively reduce B cell and CD4T cell epitopes, as well
as to dampen the innate response by decreasing binding to TLR-4. This
de-immunized next-generation scaffold retains the potency and specifıcity
of an ETB containing an unmodifıed SLTA. Pre-clinical studies in rodents
and non-human primate models have demonstrated the tolerability of MT-
4019, along with a decreased anti-drug antibody response. Additionally, in
the non-human primate model, MT-4019 showed reduced neutrophil and
monocyte activation as compared to an ETB with an unmodifıed SLTA sub-
unit, indicating that SLTA modifıcation also exhibits a diminished innate
immune response. Molecular Template’s ETB technology has resulted in
potent, targeted therapeutic agents that have a unique mechanism of action
in the fıeld of oncology. MT-3724, a fırst-generation CD20-targeted ETB, has
shown promising clinical results in the refractory setting for non-Hodgkin’s
lymphoma. The next-generation scaffold, as exemplifıed in the CD38-tar-
geted MT-4019, retains potent and specifıc direct cell kill activities, and
additionally reduces the innate and adaptive immune response to the ther-
apeutic. MT-4019 is a promising lead and is under further development to
enable clinical studies in multiple myeloma.
#2660 PD-1 blockade in combination with zoledronic acid to enhance the
antitumor effıcacy in the breast cancer mouse model. Yuan Li,1 Yang Du,2
Ting Sun,1 Huadan Xue,3 Jie Tian,2 Zhengyu Jin3. 1Peking Union Medical Col-
lege, Peking Union Medical College Hospital, Chinese Academy of Medical Sci-
ences, Beijing, China; 2Key Laboratory ofMolecular Imaging of Chinese Academy
of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, China;
3Peking Union Medical College Hospital, Beijing, China.
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Purpose: Blockade of PD-1 receptor may provide proof of concepts for the
activity of an immune-modulation approach for the treatment of a breast
cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis,
invasion, and adhesion of tumor cells. The aim of this study was to investi-
gate the potential of antibody treatment towards the T-cell checkpoint in-
hibitor PD-1 alone or in combination with ZA in BC mouse model. Experi-
mental Design: The 4T1-Luc mouse mammary tumor model was used in this
study. The anti-tumor effıcacy of anti-PD-1 antibody alone or in combina-
tion with ZA was monitored by measuring tumor volume and biolumines-
cence imaging (BLI). At the end of study, the tumor immunohistochemistry
was performed to confırm the in vivo observation and flow cytometry was
used to determine the immune cell population in tumors. The survival rate
was also calculated to evaluate the treatment effıcacy. Results: The results
showed that mice treated with the combination therapy exhibited the best
antitumor response compared to untreated controls or single therapy. Fur-
thermore, Combination therapy inhibited tumor regrowth as determined by
BLI imaging, and thus signifıcantly improved the median overall survival
compared to other groups. Conclusions: Our study provides evidence for
enhanced clinical BC treatment benefıt from targeting co-signal molecules
by combining PD-1 blockade with ZA treatment.
#2661 A broad approach for the selection of therapeutic mAbs to TNFR-
superfamilymembers for use in combinationwith an anti-PD-1mAb.Cheng
Chen, XiaoniuMiao, Yao Yan, Liang Tang, Bingliang Chen, Junjian Liu, Xiaolin
Liu, Michael Yu, Andy Tsun. Innovent Biologics Co. Ltd., Suzhou, China.
The rise of therapeutic antibodies directed towards T cell checkpoint inhibi-
tors has paved the way to a novel and exciting frontier of cancer treatments.
Spearheaded by anti-CTLA-4 and PD-1/PD-L1 inhibitors, many investigators
have strived to uncover combinatory therapies that could synergize with
CTLA-4 and PD-1 inhibitors to improve the overall survival of cancer patients.
The TNFR-superfamily has been seen as an ideal combinatory target in provid-
ing co-stimulatory T cell signals in sync with the unleashing of T cells from their
CTLA-4 and PD-1 brakes. The ideal outcome of these combinations is the in-
duction of T cell memory and effector function towards tumour cells. Current
clinical-stage agents against TNFR-superfamily targets include conventional or
Fc-engineered therapeutic antibodies andmultimeric ligands that aim to cluster
and activate targets such as OX40, 4-1BB, GITR, and CD27. For OX40 and
GITR, wildtype IgG1 variants offer target cell depletion of OX40/GITR-high
expressing Treg cells, and also provide agonism through FcgR-mediated cross-
linking. We have taken a broad approach of screening IgG1, IgG2, Fc-engi-
neered and tetravalent antibodies to select for potent therapeutic antibody can-
didates to TNFR-superfamily targets, and conducted humanized mouse studies
as a screen for candidate potency.
#2662 Statins modulate MMP-9 and beta catenin in epithelial cells. Na-
deem Fazal, Walid Al-Ghoul. Chicago State University, Chicago, IL.
The effect of statins (Simvastatins) mediated mechanisms that affect inflam-
matory or non-inflammatory pathways causing formation and progression of
cancer need to be investigated. Currently, suffıcient data are lacking to support
the use of statins for the prevention of cancer and further research is clearly
warranted. We studied these antineoplastic mechanisms in rodent inflamma-
tory model, which might be instrumental in drug discovery research for the
development of future cancer therapeutics. MMP9 is a member of the family of
zinc-containing endopeptidases, which degrade various components of the ex-
tracellular matrix, thereby regulating matrix remodeling. Since matrix remod-
eling plays an important role during growth and progression of cancer and
considering the fact that, tumor cells switch to aerobic glycolysis as its major
energy source, this study was designed to analyze the effect of Statins onMMP9
and epithelial cell integrity at gastrointestinal gut barrier.Weused an established
model of thermal injury (TI) to study the effects of simvastatins. We found that
the percentage of stained MMP-9 in the control tissue and TISMV tissue was
lower than the percentage in thermal injury tissue (P0.05). Moreover, fluores-
cent stained sections of intestinal epithelial from control, thermal injury and
thermal injurySMV. -catenin determination was performed with fluores-
cence microscope. -catenin levels were signifıcantly (p0.05) decreased in
thermal injury tissue, which was reversed by statins. Our studies conclude that
statins have anti-neoplastic effects and affect metallopeptidases, -catenin and
e-cadherins.
#2663 Characterization of the pharmacodynamic immune response to a
novel immunotherapeutic agent, ALKS 4230, in mice and non-human pri-
mates. Jared E. Lopes, Heather C. Losey, Reginald L. Dean, Heather L. Flick,
Michael R. Huff, Rosemarie A. Moroso, Lei Sun, Juan C. Alvarez.Alkermes, Inc,
Waltham, MA.
ALKS 4230 is a selective agonist of the intermediate-affınity IL-2 receptor
(IL-2R). A phase 1 study is ongoing to evaluate the safety and tolerability of
ALKS 4230 in the treatment of patients with refractory solid tumors. The selec-
tivity of ALKS 4230 is achieved through the stable fusion of circularly permuted
IL-2 to the extracellular portion of the IL-2R chain, CD25. The resulting fusion
protein is sterically prevented from binding to the high-affınity IL-2R complex,
comprised of IL-2R, IL-2R, and common gamma chain, expressed preferen-
tially on CD4 FOXP3 regulatory T cells (CD4Tregs) yet retains full ability to
signal through the intermediate-affınity IL-2R complex, comprised of IL-2R
and common gamma chain, expressed on memory CD8 T cells and NK cells.
Repeated dosing of ALKS 4230 drives the signifıcant expansion of various CD8
T cell and NK cell populations without activation and minimal expansion of
CD4 Tregs in mice and non-human primates (NHP). The kinetics of the im-
munological responses in mice and NHP demonstrate that the pharmacody-
namic effects persist beyond systemic exposure ofALKS 4230.Data demonstrat-
ing the effects of ALKS 4230 on tumor-infıltrating lymphocyte populations in
syngeneic tumor models will also be presented.
#2665 Green tea catechin, EGCG, enhances antitumor immunity by
down-regulation of PD-L1 expression in non-small human lung cancer cell
lines.Anchalee Rawangkan,1 Keisuke Iida,1 Ryo Sakai,1 Hirota Fujiki,2 Masami
Suganuma1. 1SaitamaUniversity, Saitama, Japan; 2SagaUniversity, Saga, Japan.
()-Epigallocatechin gallate (EGCG) is now widely accepted as a non-toxic,
effective cancer preventive compound. EGCG also acts as a synergist with anti-
cancer drugs for cancer treatment. Considering the wide benefıcial effects of
EGCG, we think EGCG might have antitumor immunity. Programmed death-
ligand 1 (PD-L1) expression on tumor cells is involved in PD-L1/PD-1 pathway.
PD-L1 protein levels varied among 6 non-small human lung cancer cell lines
(NSCLCs): LC-AI and Lu99 cell lines showed the highest PD-L1 expression,
A549 and H322 cell lines were medium, and H1703 and H1299 were very low,
independent on cancer cell lines. Since PD-L1 expression is induced by various
cytokines and growth factors, we studied the effects of IFN- and EGF on cell-
surface PD-L1 level using flow cytometry, and its gene expression using RT-
PCR. Treatment with IFN- dose-dependently stimulated PD-L1 expression in
both A549 and H1299 cells, and not effective on Lu99 cells, whereas treatment
with EGF stimulated PD-L1 in Lu99 cells only. Pretreatment with EGCG for 3 h,
dose-dependently inhibited INF--induced PD-L1 gene expression and protein
level on cell-surface in both A549 andH1299. It is important to note that EGCG
also inhibited phosphorylation of STAT1. In addition, EGCG inhibited EGF-
induced PD-L1 gene expression and protein level in Lu99 cells via inhibition of
phosphorylation of Akt. In order to study the effects of EGCG in between rodent
carcinogenesis experiment and antitumor immunity, green tea extract (GTE)
was given to NNK-induced lung tumors in A/J mice, which showed signifıcant
reduction of PD-L1 protein level, determined by immunohistochemical analysis
using anti-PD-L1 antibody. Furthermore, the group treated with NNK GTE
signifıcantly showed reduced number of tumors per mouse from 3.2 to 2.2, and
decreased tumor size. Treatment with Wortmannin, a PI3K inhibitor, as a con-
trol, did not inhibit PD-L1 expression in A549 and H1299 cells. The results
strongly suggest that EGCG enhances antitumor immunity via inhibition of
PD-L1 expression in cancer cells, resulting in signifıcant cancer preventive ac-
tivity.
#2666 Using “omics” to select immunotherapy and conventional therapy
combinations. Sarit Schwartz,1 Robert Heaton,1 Yuan Tian,1 Zack Sanborn,2
Shankar Sellappan,1 Kerry Scott,1 Fabiola Cecchi,1 Steve Benz,2 Todd Hem-
brough1. 1NantOmics, Rockville, MD; 2NantOmics, Santa Cruz, CA.
Background: As only a subset of patients respond to immunotherapies, ther-
apeutic biomarkers are needed to predict which patients will benefıt and which
should be spared from potentially toxic treatment. Proteins expressed by tumor
cells and by the immune microenvironment may predict response to immune
checkpoint inhibitors. In non-inflamed tumors, chemotherapy and targeted
therapy may stimulate an immune response thereby affecting the relationship
between tumor and immune system. Combinations of immunotherapies and
conventional therapies are the subject of ongoing clinical trials. We hypothe-
sized that genomic and proteomic evaluation ofmultiple immune biomarkers in
tumor tissue and in lymphocytes would identify a signature that could (a) dif-
ferentiate between responders and non-responders to checkpoint inhibitors and
(b) identify candidates for combination therapy. Methods: A pathologist
marked areas of tumor and tumor-associated lymphocytes on archived tissue
sections (N2) of non-small cell lung cancer (NSCLC) and melanoma. The
marked areas were microdissected and solubilized to tryptic peptides. In each
liquefıed tumor sample, 110 protein biomarkers, including 60 immunomarkers
were quantifıed with a mass spectrometry-based proteomic assay. The genomic
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material was analyzed by whole genome sequencing (WGS) and RNA-seq. Re-
sults: Tumor and lymphocytes expressed several immunomarker proteins (eg,
PDL1, IDO1, B7H3, B7-2, STAT1, GBP1). The melanoma patient’s tumor and
lymphocytes expressed protein markers for response to immunotherapy (PDL1
and IDO1), and the tumor had high mutational burden as identifıed by WGS.
Furthermore, biomarker analysis suggested sensitivity to BRAF inhibitors and
resistance to platinumand taxane. TheNSCLCpatient’s tumor and lymphocytes
expressed IDO1 protein, but genomic analysis suggested a non-inflamed tumor.
Based on expression levels of ERCC1 and hENT1, one possible regimen for this
patient is platinum plus gemcitabine followed by immunotherapy. In one pa-
tient, comparison of protein expression in tumor-associated lymphocytes versus
distal lymphocytes (1mm frommarked tumor areas) showed variation 10%
for 11 proteins and 30% for 14 proteins. Conclusions: Both lymphocytes and
tumor expressed immunoproteins that may be used to select patients for ap-
proved immunotherapies or clinical trials. Proteomic and genomic profıling
also characterized biomarkers that inform selection of targeted therapies and
chemotherapies. Ongoing clinical trials of immunotherapy and combination
therapies could benefıt from precise, quantitative molecular stratifıcation of pa-
tients. Protein level cutoffs that correlatewith response to immunotherapy are in
development.
#2667 In vitro properties and pre-clinical activity of PF-06801591, a high-
affınity engineered anti-human PD-1. Sawsan Youssef,1 Yasmina Abdiche,2
HoangKim Nguyen,1 Joyce Chou,1 Sherman Michael Chin,1 Cris Kamper-
schroer,1 Patricia A. Schneider,1 Eugenia Kraynov,1 Heike I. Krupka,1 Arvind
Rajpal,3 John Lin1. 1Pfızer Inc., South San Francisco, CA; 2WasatchMicrofluidics,
Salt Lake City, UT; 3BMS, Redwood City, CA.
Monoclonal-antibody-based therapies targeting the immune checkpoint re-
ceptors have become the new standard of care in many cancers. Antibodies that
specifıcally target programmed death receptor-1 (PD-1) or its cognate ligand,
programmed death receptor ligand-1 (PD-L1), alone or in combination, have
yielded clinical benefıts and durable responses in patient subsets with various
cancers (including metastatic melanoma, NSCLC, RCC, urothelial cancer, cHL
and others). Here we report on the biophysical characteristics and non-clinical
antagonistic activities of PF-06801591. PF-06801591 is a humanized anti-PD-1
antibody of human IgG4 isotype, that binds selectively and with similar potency
to human and cynomolgusmonkeyPD-1 receptor (EC5050 pM) andblocks its
interaction with its cognate ligands PD-L1 and PD-L2 (IC50  1 nM) with no
detectable Fc effector function. The interaction of PF-06801591 to PD-1 rescues
T cell suppression and exhaustion that translates intoNFAT activation, IL-2 and
IFN-gamma secretion and T cell proliferation both in vitro cultures and in vivo
using an acute xeno GvHD model with human PBMC transfer. Binding of PF-
068001591 to human and cynomolgus PD-1 is characterized by the formation of
a very stable complex (T1/2 2 h) as measured by SPR at 37 C, resulting in high
affınity (KD20 pM) asmeasured in solution byKinExAat 23C. In addition,we
explored therapeutic potential of anti-PD-1 in combination with other immu-
notherapy agents using surrogate antibodies in non-clinical tumor models. The
data presented here support future development of PF-06801591 as a single
agent or in combination with other immunotherapies.
#2668 Effıcacy study of immuno-checkpoint antibodies in humanized
CDX and PDX models. Feifei Zhang, Yang Yang, Hongkui Chen, Lijun Jia,
KedongOuyang,DanyiWen, TaipingChen.LIDEBiotech Ltd, Shanghai, China.
Immune therapeutic intervention has been accepted widely for many hema-
topoietic malignancies and solid malignancies in past several years. Preclinical
animalmodels with reconstitution of immune cells and target-expressing tumor
cells were urgently needed for prove of concept studies demonstrating stimula-
tory immune system activation. Here we describe two established models of
humanPBMCco-transplantation of CDX andPDX. The study designwas based
on co-inoculation of human PBMC and PD-L1 expressing cell in NOGmice for
reconstitution of immuno-checkpoint blockage. A therapeutic anti-PD1 anti-
body was applied for immune system activation and tumor growth inhibition
measurement. After drugs were administrated i.p. for three weeks, 95 % TGI for
A375 CDX model were observed. At the termination of the effıcacy study at 28
days post therapeutic intervention, tumors of vehicle (tumor only, PMBC only),
PD1 Ab treated groups were collected for immunostaining of CD45. Infıltrating
T-cell with CD45 label was found within the tumors when co-inoculated with
humanPBMC. PBMChumanized PDXmodels of ovarian cancerwas implanted
into mice which reconstituted with human PBMC for therapeutic intervention.
Results showed that 85% TGI for PBMC humanized ovarian PDX models was
observed. In conclusion, the models established here are feasible for immuno-
therapeutic evaluation and further additional immune therapeutic test articles
can be explored with similar approaches.
#2669 Antitumor activity of the CMP-001 (TLR9 agonist) alone or com-
bined with immune modulators in syngeneic tumor models. Francis Bichat,1
Sylvie Maubant,1 Jean-François Mirjolet,1 Philippe Slos,1 Arthur M. Krieg,2
Aaron Morris2. 1Oncodesign S.A., Dijon, France; 2Checkmate Pharmaceuticals,
Cambridge, MA.
Targeted blockade of checkpoint inhibitors such as CTLA-4 or PD-1 with
antagonist monoclonal antibodies (mAbs) has shown impressive and durable
clinical responses in patients with advanced cancer. An alternative strategy to
boost anti-tumor immunity is to promote T cell activation through co-stimula-
tory receptors such as OX40 and 4-1BB. OX40 is of particular interest as treat-
ment with an activating anti-OX40 mAb augments T cell differentiation and
cytolytic function leading to enhanced anti-tumor immunity. However, each of
these agents benefıts only a subset of patients, highlighting the critical need for
more effective combinatorial therapeutic strategies. Toll-like receptor 9 (TLR9)
agonist CpG oligodeoxynucleotides (ODN) are candidates to promote an anti-
tumor immune response. CMP-001, a CpG-A ODN formulated within a virus-
like particle, is designed to activate TLR9 (the receptor for CpG-A) in tumor-
associated plasmacytoid dendritic cells (pDC) within the tumor or tumor-
draining lymph nodes. Resting or immature pDC promote tumor growth, but
when activated by CpG-A, the resulting mature pDC promote a robust anti-
tumor immune response. Activation of pDC causes secretion of very large quan-
tities of type I interferons, increased expression of costimulatorymolecules, and
recruitment and activation of other DC subsets to enhance tumor antigen pre-
sentation to T cells, culminating in the generation of effective anti-tumor T cell
responses. The preclinical effıcacy of intratumorally administered CMP-001
alone or in combinationwith an intraperitoneally administered PD-1 antagonist
and/or an OX40 agonist was examined and assessed in a variety of syngeneic
tumormodels: CT-26 colon tumormodel,MBT-2 bladder tumormodel, RenCa
kidney tumor model, 4T1 breast tumor model and LLC-1 lung tumor model.
Tumors were implanted into left and right flanks while only one tumor was
injected with CMP-001. In addition to body weight and overall survival, tumor
volume was monitored on both flanks to assess direct and abscopal/systemic
anti-tumor activity. Some discrepancies were observed between evaluated syn-
geneic tumor models with non-responders (LLC-1, 4T1) and responders (CT-
26, MBT-2, RenCa). The most effıcacious results were registered in the CT-26
model. Each therapeutic yielded weak activity as a single agent, which improved
when combined with another treatment modality. The best therapeutic effıcacy
was obtained with the combination of all three agents resulting in cures of both
treated and untreated CT-26 tumors in 40% of the mice. The median survival
timewas increased for these animals compared to those treatedwith only vehicle
or one or two immune modulators (50 vs 18 vs 21 or 23-28 days, respectively).
Similar resultswere generated in theMBT-2model (and to a less extent inRenCa
model) though no complete response was recorded. These data support the
clinical investigation of these combinations in cancer patients.
#2670 Combination of anti-HER2ADCXMT-1522 and checkpoint inhib-
itor pembrolizumab for treatment of NSCLC in preclinical models. Natalya
Bodyak, Marina Protopopova, Qingxiu Zhang, Alex Yurkovetskiy, Mao Yin,
LiuLiangQin, Laura L. Poling, RebeccaMosher, Donald A. Bergstrom, Timothy
B. Lowinger.Mersana Therapeutics, Inc., Cambridge, MA.
The combination of antibody-drug conjugates (ADCs) and immunomodula-
tory cancer therapies is emerging as a powerful strategy for cancer treatment.
Tumor-targeted delivery of a cytotoxic payload capable of inducing immuno-
genic cell death (ICD) can trigger both an innate and an adaptive immune
response, whereby increased recruitment of effector T-cells to the tumor and
formation of tumor specifıc immunological memory can result in a durable
treatment response. The ADC XMT-1522 consists of a novel human IgG1 anti-
HER2 monoclonal antibody and a novel, auristatin-based cytotoxic payload
(Auristatin F-hydroxypropylamide, AF-HPA). An average DAR of 12 AF-HPA
molecules is achieved via a biodegradable polymer conjugation platform. We
have characterized the ability of both the free payload AF-HPA and the ADC
XMT-1522 to induce ICD in vitro in multiple cell lines (NCI-N87, HT-29,
SKBR3), as measured by the cell surface expression of the ICD marker calreti-
culin (CRT) bymicroscopy and flow cytometry (FACS). CRT, usually contained
in the lumen of the endoplasmic reticulum, translocated to the cell surface
within a few hours after treatment with AF-HPA or XMT-1522. XMT-1522 as a
single agent induced signifıcant tumor regressions in two patient-derived xeno-
graft (PDX) models of HER2-espressing non-small cell lung cancer (NSCLC) at
a dose of 3 mg/kg weekly for 3 doses. The combination of XMT-1522 in combi-
nation with the checkpoint inhibitor pembrolizumab was tested in one of these
patient-derived HER2-expressing PDX models in a mouse with a humanized
immune system. Expression of huPD-L1 in the tumor was confırmed by FACS
and immunohistochemistry (IHC). Lymphocyte sub-populations were quanti-
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fıed in whole blood and in tumor by FACS and IHC. XMT-1522 treatment alone
induced tumor growth delay after 3 weekly doses of 1mg/kg. Pembrolizumab as
a single agent administered every 5 days for 6 doses (q5dx6) at a dose of 2.5
mg/kg led to less tumor growth delay than XMT-1522 treatment. The combina-
tion of these two treatment regimens resulted in a better response than either of
the two monotherapies. These data provide a rationale for XMT-1522 to be
tested clinically as a single agent in HER2-expressing NSCLC, as well as a ratio-
nale for combination of XMT-1522 and immunomodulatory therapies in
NSCLC.
#2671 Antitumor activity of NKTR-214 in combination with pmel-1 ACT
in an aggressive murine melanoma model. Giulia Parisi,1 Justin Saco,1 Siwen
Hu-Lieskovan,1 Ruixue Zhang,1 Paige Krystofınski,1 Cristina Puig Saus,1 Deb-
orah H. Charych,2 Antoni Ribas1. 1UCLA, Los Angeles, CA; 2Nektar Therapeu-
tics, San Francisco, CA.
The adoptive cell transfer (ACT) of genetically engineered T cells expressing
cancer-specifıc T-cell receptors (TCR) has been shown to induce effective anti-
tumor response. However, tumors frequently relapse after an initial response.
Another strategy towards stimulating the immune system is the use of high-dose
interleukin-2 (IL-2) to target the IL-2 receptor (IL2R), leading to immune cell
expansion. However, clinically approved IL-2 expands both tumor-killing
CD8 effector T cells (CD8T) as well as regulatory T cells (Tregs) through
binding the IL-2R and IL-2R complexes, respectively. Tregs in the tumor
lead to immune suppression, which hampers the antitumoral response. NKTR-
214 is a CD122-biased cytokine agonist conjugated with multiple releasable
chains of polyethylene glycol and designed to provide sustained signaling
through the heterodimeric IL-2 receptor pathway (IL-2R) to preferentially
activate and expand effector CD8 T and NK cells over Tregs. We used the
pmel-1 ACT/B16 melanoma tumor model to test the anti-tumor activity of
NKTR-214 and evaluate its effects on tumor-specifıc TCR transgenic T cells. On
Day 0 (D0) C57BL/6 mice were implanted with B16-F10 mouse melanoma cells
and lymphodepleted with 500 cGy on D6. On D7, mice were treated with either
the combination of ACT (T lymphocytes activated in vitro with 1g/ml gp100)
plus NKTR-214 (0.8mg/kg, q9dx3, i.v.) or with C57/B6 T cells plus PBS (vehicle
control). The tumors of the vehicle control mice (n12) rapidly grew to the
1500mm3 endpoint in 12 days post-treatment, versus 35 days for theNKTR-214
group (n12) with only 1 out of 12 mice reaching endpoint. Bioluminescence
imaging was used to visualize the in vivo distribution and tumor-homing of
antigen-specifıc T cells. Interestingly, the reporter T cells were retained in the
spleen until D7 and could be seenmigrating to the tumor at D9 reaching peak of
bioluminescence at day 12, a delayed time point compared to the 5 days usually
observed in mice treated with standard IL-2. The signal persisted in the NKTR-
214  ACT group until D20 versus D7 in the vehicle-control animals. These
data suggest that NKTR-214  ACT is well tolerated and provides a robust
anti-tumor response in the aggressive B16F10 model. Treatment with NKTR-
214ACT robustlymobilizes T cells into the tumorwhere they durably persist.
The robust and long-lasting effect of NKTR214 supports its potential use in
combination with cell-based therapeutics.
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#2672 Response to anti-PD-1 based therapy in metastatic melanoma pa-
tients is associatedwith thediversity and compositionof the gutmicrobiome.
Vancheswaran Gopalakrishnan,1 Christine Spencer,1 Alexandre Reuben,1 Peter
Prieto,1DiegoVicente,1 TatianaV.Karpinets,1 CourtneyW.Hudgens,1Diane S.
Hutchinson,2Michael Tetzlaff,1 Alexander Lazar,1Michael A.Davies,1 Jeffrey E.
Gershenwald,1 Robert Jenq,1 PatrickHwu,1 Padmanee Sharma,1 JamesAllison,1
Andrew Futreal,1 Nadim Ajami,2 Joseph Petrosino,2 Carrie Daniel-Mac-
Dougall,1 Jennifer A. Wargo1. 1UT MD Anderson Cancer Center, Houston, TX;
2Baylor College of Medicine, Houston, TX.
Background: Melanoma therapy has benefıtted greatly from immune check-
point blockade, although responses are variable and not always durable. There is
a growing appreciation of the role of themicrobiome in cancer-related outcomes
and recent evidence in murine models suggests that modulation of the gut mi-
crobiome may enhance responses to immune checkpoint blockade in mela-
noma.However this has not been investigated in patients. Here, we demonstrate
that differential bacterial “signatures” exist in the gutmicrobiome of responders
(R) and non-responders (NR) to anti-PD-1 therapy, and that insights gained
could be used to derive actionable strategies to enhance responses.Methods:We
collected buccal (n105) and stool (n53) samples from a cohort of anti-PD-1
treatedmetastaticmelanoma patients (n110). Patients were classifıed as either
R or NR based on RECIST criteria, and 16S rDNA, and whole-genome shotgun
sequencing was performed to characterize the diversity, composition and func-
tional capabilities of the microbiomes. Immune profıling (via 7-marker IHC
panel of CD3, CD8, PD-1, PD-L1, Granzyme B, RORT and FoxP3) and cyto-
kine analyses were also performed on available tumors and serum samples at
baseline. Results: In these studies, we observed signifıcant differences in the
diversity and composition of the gutmicrobiome in R versus NR to PD-1 block-
ade at baseline, but no clear differences in buccal microbiomes. Specifıcally, R
had a signifıcantly higher alpha diversity compared to NR (p0.017), and the
Ruminococcaceae family of the Clostridiales order was enriched in R whereas
Prevotellaceae family of the Bacteroidales order was enriched in NR. Immune
profıling demonstrated signifıcantly increased immune infıltrates in baseline
tumor samples of R, with a positive correlation between CD8, CD3, PD-1 and
FoxP3 T-cell density and abundance of specifıc bacteria enriched in R (e.g.
Faecalibacterium). Low diversity was also associated with elevated levels of
chronic inflammation markers in the serum at baseline. Lastly, we saw differen-
tially abundant metabolic pathways in the gut microbiomes of R (pyrimidine
nucleotide biosynthesis, fatty acid biosynthesis, shikimate pathway) vs NR (Tri-
carboxylic acid cycle, assimilatory sulphate and nitrate reduction, tryptophan
biosynthesis). Conclusion: Differences exist in the diversity and composition of
the gutmicrobiome in R vsNR to anti-PD-1 therapy and thesemicrobiota could
bridge the gap between host metabolism and anti-tumor immunity. These re-
sults have far-reaching implications and suggest that modifıcations to the gut
microbiome could potentially enhance therapeutic responses to immune check-
point blockade.
#2673 Divergent therapeutic responses to CD40L blockade or CD40 acti-
vation in Ras-driven skin cancers determined by origin of tumor initiating
cell. Adam B. Glick,1 Jacob T. Bailey,1 Andrew Gunderson,2 Kyle Breech,1 Mi-
chael Podolsky1. 1Pennsylvania State University, University Park, PA; 2Earle A.
Chiles Research Institute, Portland, OR.
Heterogeneity in tumor immune responses is a poorly understood yet critical
parameter for successful immunotherapy. We used doxycycline-inducible epi-
dermal squamous cancer models driven by oncogenic Ras to test whether the
origin of the tumor-initiating cell influenced the tumor immune response.
Threshold doxycycline induced expression of H-RasG12V in either the basal/
stem cell layer with a Keratin14-rtTA transgene (K14Ras), or committed pro-
genitor/suprabasal cells with an Involucrin-tTA transgene (InvRas), caused dis-
tinct immune responses despite similar levels of Ras, tumor latency, and tumor
numbers. End stage K14Ras tumors had an immunosuppressed microenviron-
ment with abundant Tregs and Bregs which evolved from an initially Th1 dom-
inant environment in the earliest detectable lesions. In contrast InvRas tumors
had a Th2 pro-inflammatory microenvironment, with signifıcantly fewer Tregs
or Bregs at any time point. This difference in immune microenvironment be-
tween the tumor models was also found in hyperplastic skin after 5 days of
maximal Ras expression, indicating that it was not simply a property of the end
stage tumor. Surprisingly, adaptive immunity had opposite roles in tumor de-
velopment. InvRasRag1/ mice developed fewer and smaller tumors that
regressed while K14RasRag1/ mice developed more tumors with shorter
latency than Rag1/ controls. In bothmodels adoptive transfer and depletion
studies showed that cooperation between B and CD4 T cells drove the opposing
tumor responses, lymphocyte polarization, and tumor immune phenotype. Co-
culture of tumor-conditioned but not splenic B cells from eachmodel with naive
CD4 T cells showed that direct contact and CD40-CD40L ligation was required
for opposite polarization towards either a Th2 or Treg phenotype. Importantly,
we found that anti-CD40LmAb caused regression of preexisting InvRas tumors
but enhanced growth of K14Ras tumors. In contrast, CD40 agonist mAb en-
hanced growth of preexisting InvRas tumors, and suppressed growth of K14Ras
tumors. Thus in an in vivo setting the type of tumor immunemicroenvironment
and opposing role of CD40-CD40L in tumor development generates distinct
responses to therapeutic antibodies. Together these data show that the position
of a tumor initiating cell within the stem cell hierarchy in a stratifıed squamous
epithelia has important consequences for the type of tumor immune microen-
vironment and response to checkpoint therapy.
#2674 Fusobacterium nucleatum subspecies animalis influences pro-in-
flammatory cytokine expression andmonocyte activation in human colorec-
tal tumors. Xiangcang Ye,1 Rui Wang,1 Rajat Bhattacharya,1 Delphine R. Boul-
bes,1 Fan Fan,1 Ling Xia,1 Adoni Harish,1 Nadim J. Ajami,2 Matthew C.Wong,2
Daniel P. Smith,2 Joseph F. Petrosino,2 Susan Venable,2 Wei Qiao,1 Veera
Baladandayuthapani,1 Dipen Maru,1 Lee M. Ellis1. 1UT MD Anderson Cancer
Ctr., Houston, TX; 2Baylor College of Medicine, Houston, TX.
IMMUNOLOGY: Immune Response to Hematopoietic Tumors: New Development in Tumor Immunology
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017680
Chronic infection and associated inflammation have long been suspected to
promote human carcinogenesis. Recently, certain gut bacteria, including some
in the Fusobacterium genus, have been implicated in playing a role in human
colorectal cancer (CRC) development. However, the Fusobacterium species and
subspecies involved and their oncogenic mechanisms remain to be determined.
We sought to identify the specifıc Fusobacterium spp. and ssp. in clinical CRC
specimens by targeted sequencing of Fusobacterium 16S ribosomal RNA gene.
Five Fusobacterium spp. were identifıed in clinical CRC specimens. Additional
analyses confırmed that Fusobacterium nucleatum ssp. animalis was the most
prevalent F. nucleatum subspecies in human CRCs.We also assessed inflamma-
tory cytokines in CRC specimens using immunoassays and found that expres-
sion of the cytokines interleukin-17A and tumor necrosis factor-alpha was
markedly increased but interleukin-21 decreased in the colorectal tumors. Fur-
thermore, the chemokine (C-C motif) ligand 20 was differentially expressed in
colorectal tumors at all stages. In in vitro co-culture assays, F. nucleatum ssp.
animalis induced CCL20 expression in CRC cells and monocytes. It also stimu-
lated the monocyte/macrophage activation and migration. Our observations
suggested that infection with F. nucleatum ssp. animalis in colorectal tissue
could induce inflammatory response and promote CRC development. Further
studies are warranted to determine if F. nucleatum ssp. animalis could be a novel
target for CRC prevention and treatment.
#2675 MMP9modulates ROS levels andDNA repair pathway tomaintain
genomic stability in colitis associated cancer. Lewins Walter, Adani Pujada,
Brandon Canup, Hamed Laroui, Pallavi Garg.Georgia State University, Atlanta,
GA.
Introduction: Chronic inflammation predisposes tissues to oncogenic, and in
the colon this condition is termed as colitis associated cancer (CAC). CAC is the
inflammation-dysplasia-carcinoma pathway which is signifıcantly different
compared to the adenoma-carcinoma pathway of sporadic colon cancer (CRC).
In CAC, chronic inflammation causes accumulation of reactive oxygen species
(ROS) resulting in DNA damage that nurtures tumor microenvironment and
accelerates cancer cell growth. Gut microbiota is important in regulating ROS
levels, andDNA repair pathways are critical in restoring the genomic instability.
Matrix Metalloproteinases (MMPs) are a family of zinc dependent endopepti-
dases which mediate inflammation, tissue remodeling, and tumorigenesis.
MMP9 is the most unique MMP because it is undetectable in healthy tissue but
highly upregulated during inflammation and cancer.We have previously shown
that MMP9 plays a protective role in CAC which is opposite to its conventional
role of mediator in acute inflammation and cancer. Aim: In this study, we ex-
amined that if MMP9 acts as a tumor suppressor by modulating gut microbiota
andmismatch repair (MMR) genes to reinstate genomic stability in CAC.Meth-
ods: We used C57/B6 transgenic MMP9 mice which can express MMP9 under
villin promoter (TgM9) and their wild type (WT) littermates. CACwas induced
by azoxymethane (AOM) and dextran sodium sulfate (DSS, inflammation in-
ducer) to assess the microbiota population. As a proof of principal model, we
used MMP9 small interfering RNA (siRNA) encoded within nanoparticles and
gavaged WT mice to inhibit MMP9 in colonic epithelium. Results: QPCR data
showed that mRNA levels of total microbiota population were more among
TgM9 mice compared to WTs in CAC. QPCR analysis also indicated increased
mRNA levels for the phylum Bacteroidetes sp., Akkermansia muciniphila but
decreased mRNA levels for the phylum Firmicutes sp. TgM9 mice had lower
levels of ROS compared to WTs in CAC. WB data showed decrease in protein
expressions of H2AX and MDC1 while an increase in protein expressions of
MLH1 and pCNA compared to WTs in CAC. WT mice treated with MMP9
siRNA loaded nanoparticles showedworsenedCACcondition compared toWT
mice given scrambled siRNA loaded nanoparticles as reflected by signifıcant
bodyweight loss and higher clinical score. We also observed that WT mice
treated with MMP9 siRNA loaded nanoparticles showed increase in protein
expression of H2AX while decrease in MLH1 protein levels compared to con-
trol group. Conclusion: Our study has two clinically relevant outcomes that
MMP9 expression in CAC: i) promotes the benefıcial microbiota population
and controls the ROS production, ii) restores the DNA damage via activation of
the MMR pathway. This implies the contradiction of the use of targeted MMP9
inhibitors in CAC treatment therapies by showing that MMP9 expression may
be a natural way to suppress CAC.
#2676 Role of the RON kinase in the regulation of the antitumor immune
response in pancreatic cancer. Alex Cazes, Michele L. Babicky, Jeffery Chake-
dis, Divya Sood, Dawn Jaquish, Andrew M. Lowy. University of California San
Diego, La Jolla, CA.
RON is a cell-surface receptor for the macrophage-stimulating protein ex-
pressed in tissue-residentmacrophages and overexpressed inmultiple epithelial
neoplasms including pancreatic cancer. Our laboratory recently found that
RON serves to mediate pancreatic duct carcinogenesis initiated by KRAS. We
demonstrated that RON overexpression in the pancreas results in more rapid
local and metastatic progression ultimately associated with decreased survival.
We also discovered profound changes in the immunophenotype within the tu-
mor microenvironment associated with RON expression. We notably estab-
lished that RON expression drives the polarization of tumor-associated macro-
phages into an alternative, pro-tumorigenic state. We hypothesize that these
unique activities help to shape the immunosuppressive milieu of the pancreatic
cancer microenvironment and that RON directed therapy has the potential to
serve as a novel immunomodulatory strategy in this disease. The aim of this
work is to defıne how RON signaling contributes to shaping the pancreatic
cancer microenvironment. In order to further interrogate the role of RON dur-
ing pancreatic carcinogenesis, we bred kinase-dead RON mice (KD) to Pdx1-
cre/LSL-KRASG12D mice. We observed a signifıcant delay in the onset of pan-
creatic neoplasia and a signifıcant decrease in tumor weight. The absence of
functional RON kinase markedly reduced traffıcking of CD11b cells to the
pancreas and immunophenotyping in tumors showed a clear reduction of alter-
natively polarized macrophages when compared to RON overexpression or
KRASmutation alone. Because RON is expressed in both epithelial and stromal
cell populations, we further sought to dissect the relevance of RON function to
tumor growth within these cellular compartments. We performed orthotopic
injections of organoïd-3D cells derived from tumors of KPC mice (LSL-
KrasG12D/; LSL-Trp53R172H/; Pdx-1-Cre). These cells were injected in wild
type (WT) or RON KD mice. Preliminary results show that tumor growth is
impaired in KD mice, suggesting that RON activity in the host microenvi-
ronment influence tumor growth. In order to identify all immune popula-
tions regulated by RON, we will conduct an exhaustive immunophenotyping
of murine pancreatic tumors. A transcriptomic analysis will then be con-
ducted on selected cell populations to better defıne the molecular mecha-
nisms associated with the RON regulation. Finally, given the effect of RON
signaling onmacrophage polarization, we will also dissect the effects of RON
signaling from bone marrow derived myeloid cells versus resident tissue
macrophages. Preliminary results and future experiments will signifıcantly
narrow the gap in our understanding of how RON signaling contributes to
shaping the pancreatic cancer chimera and therefore how RON-directed
therapies could be most successfully utilized to the benefıt of those afflicted
with this most deadly disease.
#2677 Role of CLEC4D in inflammation-driven liver carcinogenesis.
Elena Riboldi,1 Luca Di Tommaso,2 Nausicaa Clemente,3 Chiara Raggi,2 Elisa
Forti,2 Simone Merlin,3 Fabio Pasqualini,2 Antonia Follenzi,3 Antonio Sica1.
1Università del Piemonte Orientale, Dept. of Pharmaceutical Sciences, Novara,
Italy; 2Humanitas Clinical and Research Center, Rozzano, Italy; 3Università del
Piemonte Orientale, Dept. of Medical Sciences, Novara, Italy.
Hepatocellular carcinoma (HCC) accounts for approximately 90% of all
primary liver tumors and is the secondmost deadly cancer in the world. HCC
commonly arises in a chronically damaged liver that contains large amounts
of inflammation and fıbrosis. Indeed, interactions among hepatocytes, stro-
mal, and inflammatory cells create a complex microenvironment permissive
to tumor development. Myeloid cells are crucial players in cancer-related
inflammation. From transcriptional profıling of liver myeloid cells, we iden-
tifıed the gene encoding for the C-type lectin receptor CLEC4D as one of the
genes upregulated during the inflammatory response that precedes cancer
development in a spontaneous model of murine HCC.We hypothesized that
CLEC4D may be involved in the molecular mechanisms that drive HCC
pathogenesis. We used the murine model of diethylnitrosamine (DEN)-in-
duced liver carcinogenesis and evaluated tumor growth in genetically mod-
ifıed mice lacking CLEC4D (CLEC4D KO mice), as compared to C57BL/6
wild type (WT) mice. We observed that tumor burden (number of tumors
per mouse and tumor dimensions) was reduced in CLEC4D KO mice com-
pared to WT mice. Gene expression analysis of tumor lesions showed that
the tumor microenvironment of CLEC4D KO mice was less inflammatory.
CLEC4D expression was then evaluated in surgical specimens and tissue
microarrays from HCV HCC patients. CLEC4D-positive inflammatory
cells (macrophages and granulocytes) were present both in the peritumor
and in the tumor areas. The percentage of intratumor CLEC4D-positive cells
inversely correlated with the degree of the lesion: CLEC4D expression was
higher in dysplastic nodules compared to high grade HCCs. Our results
indicate that the CLEC4D-dependent pathway contributes to the initiation
and the progression of HCC. By targeting CLEC4D, we could modulate
immune responses and provide an environment less favorable to tumor
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growth. An intervention at this level could represent a chemopreventive
strategy to arrest the development of HCC in a cirrhotic liver.This work has
been supported by Fondazione Cariplo, grant n° 2014-0962.
#2678 Novel host-pathogen interactions of Helicobacter pylori and their
implications to gastric cancer.EmineGuvenMaiorov, RuthNussinov, Chung-
Jung Tsai. National Cancer Institute, Leidos Biomed. Research, Inc., Frederick,
MD.
About 20% of the cancer incidences worldwide have been estimated to be
associated with infections. There is a strong correlation of some pathogens
with various cancer types. Although presence of commensal microbiome
helps chemotherapy to be more effective, pathogenic microbiota increases
the cancer risk. Invading pathogens interact with the host mainly through
proteins. To subvert host defense, pathogens hijack host pathways by mim-
icking the binding surfaces (interfaces) of host proteins. This similarity in
interfaces permits the pathogenic protein to compete with host proteins to
bind to a target protein, alter the physiological signaling and cause persistent
infections as well as cancer. Detection of host-pathogen interactions (HPIs)
and mapping the re-wired HPI network - along with its structural details - is
critical for in-depth understanding of the underlying pathogenesis mecha-
nisms of infections and pathogen-triggered cancers, and developing effıcient
therapeutics. Here, we developed a novel computational approach to identify
novel HPIs by employing “interface mimicry”, We applied this approach to
Helicobacter pylori, dominant species in gastric microbiome that greatly
increases the gastric cancer risk in order to understand how they modulate
host immunity and lead to tumorigenesis. We found that its proteins inter-
fere with the functioning of host apoptosis pathway, cytokine and chemo-
kine pathways, and also cell-cell adhesions. Our results shed light on the
molecular mechanisms of resistance to apoptosis, immune evasion and loss
of cell junctions that are seen in Helicobacter pylori-infected host cells. In
conclusion, HPIs can help us unravel which human pathways are targeted by
the pathogenic proteins and how they contribute to pathogenesis of infec-
tions and pathogen-triggered cancer. With a better grasp on immunomodu-
latory strategies of pathogens, we can develop better therapies against them.
#2679 A promoting role for the epithelial MyD88/IRAK4/NF-B signal-
ing in K-ras mutant lung tumorigenesis. Susana Castro,1 Soudabeh Daliri,1
Maria Miguelina De La Garza,1 Amber M. Cumpian,1 Misha Umer,1 Diana Del
Bosque,2 Sabah Akbani,2 Scott E. Evans,1 Seyed Javad Moghaddam1. 1The Uni-
versity of Texas MDAnderson Cancer Center, Houston, TX; 2University of Hous-
ton, Houston, TX.
K-ras mutation is the most common oncogenic alterations associated with
lung cancer development. Unfortunately, all attempts to develop therapies di-
rectly targeting K-ras have been failed thus far, clearly stating the need for new
strategies targeting downstream effectors and/or cooperating pathways of K-ras
to overcome lung cancer displaying such a molecular profıle. Using a condi-
tional K-ras mutated lung cancer mouse model, CC-LR (CCSPcre/LSL-
K-rasG12D) we previously showed that K-ras mutated lung tumorigenesis is as-
sociated with lung inflammation due to activation of NF-B pathway and in-
creased expression of its downstream targets in the lung. Here we have shown
that lack of NF-B activity in the airway epithelium by selectively targeting
IKK, which is required for NF-kB activation, signifıcantly reduces lung tumor
burden (3.4-fold) and changes the inflammatory cells andmediators in the bron-
choalveolar lavage fluid (BALF) of CC-LRmice. Immunohistochemically stain-
ing of lung tissues with specifıc markers, Ki-67 and CD-31, demonstrated sig-
nifıcantly lower tumor cell proliferation and angiogenesis in CC-LR mice with
lack of epithelial NF-kB activity. To further dissect the role of NF-B pathway in
this process, CC-LR mice were crossed with MyD88f/f mice to develop a mouse
with lack of MyD88 (an adaptor protein upstream to IKK) in the airway epi-
thelial cells (CC-LR/MyD88/ mice). As we had hypothesized, the resulting
tumor numbers in the lungs were signifıcantly lower (1.9-fold) in CC-LR mice
with lack of MyD88 in the airway epithelial cells compared to control CC-LR
mice. Tumor reduction in CC-LR-MyD88/ mice was also associated with
decreased tumor cell proliferation and angiogenesis compared to controlCC-LR
mice. Surprisingly, unlike to lack of epithelial NF-B activity, absence ofMyD88
in the airway epitheliumdid not change the BALF inflammatory cell component
of CC-LR mice. We then targeted another upstream signaling molecule to NF-
B, IRAK4, which is down stream ofMyD88 by crossing CC-LRmice to IRAK4
knock out mice. Similar to lack of MyD88, we found a signifıcant reduction in
lung tumor number (1.8-fold) with no changes in BALF inflammatory cell com-
ponent inCC-LRmicewith lack of IRAK4 compared to the control CC-LRmice.
Taken these together, we conclude that there is an essential role for MyD88/
IRAK4/NF-B pathway activation in promotion of K-ras mutant lung cancer.
#2680 A novel pro-tumorigenic role for IDO1 in inflammatory neovascu-
larization. Arpita Mondal,1 Erika Sutanto-Ward,1 James B. DuHadaway,1 Ar-
turo Bravo-Nuevo,2 Sunil Thomas,1 George C. Prendergast,1 Alexander J.
Muller1. 1Lankenau Inst. forMedical Research,Wynnewood, PA; 2ArtDemTher-
apeutics, Holmes, PA.
Small molecule inhibitors of the tryptophan catabolizing enzyme IDO1 (in-
doleamine 2,3-dioxygenase 1) have shown early promise in clinical trials as
immuno-oncology agents. While the tolerogenic activity of IDO1 has been well
established, we have recently identifıed an additional role for IDO1 in support-
ing neovascularization at the regulatory interface between the inflammatory
cytokines IFN (interferon) and IL6 (interleukin 6). IFN is a primary inducer
of IDO1, but is also a key mediator of immune-based tumor suppression, which
studies have associated with its anti-angiogenic activity. Conversely, genetic
studies in mice have clearly established the tumor-promoting role of IDO1,
suggesting that itmay act in a negative feedback capacity. Targeted disruption of
the Ido1 gene in mice resulted in enhanced resistance to lung tumor andmetas-
tasis development. This corresponded with attenuated induction of the pro-
angiogenic cytokine IL6, which, when provided through ectopic expression, was
able to restore pulmonary metastasis susceptibility to Ido1/mice. These ini-
tial fındings led us to hypothesize that IDO1might contribute to cancer promo-
tion by countering the anti-neovascular effect of IFN, possibly through IDO1-
potentiated elevation of IL6. Testing this hypothesis inmousemodels of oxygen-
induced retinopathy and pulmonary metastasis, we determined that loss of
IDO1 did indeed result in reduced neovascularization in conjunction with im-
paired metastasis outgrowth, effects that were completely reversed by the con-
current elimination of IFN. Loss of IL6 was likewise associated with IFN-
dependent reductions in neovascularization and impaired metastasis
outgrowth, as predicted. Having established a novel role for IDO1 in inflamma-
tory neovascularization, current investigations are focused on the underlying
molecular and cellular mechanisms involved. At the molecular level, one of the
consequences of tryptophan catabolism by IDO1 can be to trigger the ISR (in-
tegrated stress response) through activation of the GCN2/CHOP pathway that
has previously been linked to the downstream induction of IL6. Thus far, data
collected in both the oxygen-induced retinopathy and pulmonary metastasis
models are consistent with the ISR being the relevant downstream signaling
pathway from IDO1 in this biological context. At the cellular level, we have
detected the incorporation of non-endothelial, IDO1-positive cells into the ves-
sels that comprise the neovascular tufts, implicating IDO1 in the process of
vasculogenesis. These insights into this unrecognized aspect of IDO1biology are
likely to have important ramifıcations for IDO1 inhibitor development, not only
in cancer where clinical trials are currently ongoing, but in other disease indica-
tions involving neovascularization as well.
#2681 Oralmicro biome enhances stemness in oral cancer cells by activat-
ing Toll like receptor signaling. Joyeeta Talukdar,1 Rashmi Bhuyan,2 Bidisha
Pal,2 Sorra Sandhya,1 Hong Li,2 Seema Bhuyan,1 Sukanya Garhyan,1 Debabrat
Baishya,3 Anupam Sarma,4 Jyotirmoy Phukan,1 Amal Kataki,4 Bikul Das2.
1KaviKrishna Laboratory, Guwahati Biotech Park, IIT, Guwahati, India;
2Forsyth Institute, Cambridge, MA; 3Gauhati University, Guwahati, India;
4B Borooah Cancer Institue, Guwahati, India.
Background: The resistance and progression of cancers after chemotherapy to
invasive andmetastatic stages accounts for the overwhelmingmajority of cancer
deaths. Recent studies suggest, microbiomes can induce a cascade of host events
to either support or inhibit tumor growth. Specially, in oral cancer, chemother-
apy treatment may alter the oral microbial flora, which may favor or inhibit
tumor growth.Hence, it is importantl to develop novel experimental approaches
to study the role of oral microbial flora in oral cancer stemness (self-renewal and
undifferntiated state of cancer stem cells). Importantly, patients in developing
area, including Assam, where KaviKrishna laboratory is located, may have dis-
tinct oral microbial flora that could favor oral cancer growth. Hence, it is impor-
tant to include patients from developing countries for such studies. Our previ-
ous research showed that chemotherapy ehances stemenss in many cancer cell
types, including oral squamous cell carcinoma cell line SSC-25. The stemness
switch is characterized by enhanced expression of stemness associated genes
including Nanog, Lin28A/B, Oct-4, MYC, HIF-2alpha and inflammation asso-
ciated genes includingToll like receptor (TLR) 2/4.Herewe investigated the role
of oral microbiomes in the TLR mediated stemness switch of oral cancer cells.
Methods: SCC-25 oral cancer cell line was treated with bacterial product li-
popoly saccharide (LPS), and the stemness switch evaluated by isolation of
ABCG2 cells and expression of stemness associated genes by these cells. Ca-
pacity of interaction of tumor stromal cells with mesenchymal stem cells was
also evaluated. Additionally, we obtained sputum from oral cancer subjects un-
dergoing chemotherapy. The patients were from the Kamrup district of Assam,
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where KaviKrishna laboratory is located. The sputum was processed and then
added to the culture medium of SCC-25 cells. These post-sputum treated
SCC-25 cells were subjected to phenotypic stemness switch analysis. Results:We
found, LPS and sputum treatment led to the enhanced stemness of ABCG2
cells, including the high expression of TLR2/4, MYC, Nanog, Sox-2, and HIF-
2alpha. Importantly, sputum derived from oral cancer subjects under remission
showed inhibitory activity on ABCG2 cell self-renewal. In contrast, sputum
obtained from oral cancer subjects with relapse showed enhanced stemness of
ABCG2 cells, and also increased tumorigenic potential. The post-sputum
treated ABCG2 cells exhibited high expression of TLR2/4 and associated in-
crease ofHIF-2alpha andMYC transcriptional activity. The sputum treatedwith
broad spectrum antibiotic ciprofloxacin did not enhance the stemness and
TLR2/4 signaling of SCC-25 cells. Conclusion: These results indicate that oral
microbiomes may differentially influence the stemness of oral cancer cells. We
also conclude that live bacteria present in the sputum may be required to en-
hance stemness in a TLR2/4 dependent manner.
#2682 IL-6/STAT3 activation in hepatocytes drives the formation of a
pro-metastatic niche in the liver during pancreatic tumorigenesis. JaeW. Lee,
Paige M. Porrett, Chad A. Komar, Whitney L. Gladney, Gregory L. Beatty.Uni-
versity of Pennsylvania, Philadelphia, PA.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth-leading cause of
cancer-related deaths in the United States with metastasis to the liver as the
major cause of mortality. While the propensity of PDAC to spread to the liver
may reflect mechanical trapping of tumor cells that enter the portal circulation,
primary tumor cells have also been suggested to secrete factors that may pro-
mote recruitment of myeloid cells to establish a pro-metastatic niche. In this
study, we used the LSL-KrasG12D/;LSL-Trp53R127H/;Pdx-1-Cre (KPC)mouse
model of PDAC to investigate the impact of PDAC development on the forma-
tion of a pro-metastatic niche in the liver. We found that KPC mice (compared
to age- and gender-matched control mice) demonstrated an increased suscepti-
bility to tumor seeding in the liver even prior to development of invasive PDAC.
Examination of the liver ofKPCmice revealed diffuse activation of Signal Trans-
ducer and Activator of Transcription 3 (STAT3) signaling, particularly in hepa-
tocytes. Although hepatocytes are recognized as important regulators of inflam-
mation, their role in establishing a pro-metastatic niche is unknown. To defıne
changes in the liver associated with development of a pro-metastatic niche, we
performed QuantSeq analysis on RNA isolated from the liver of KPC versus
control PCmice. Our results showed increased transcriptional levels of myeloid
chemoattractants, particularly serum amyloid A proteins that are predomi-
nantly produced by hepatocytes. Consistent with this fınding, we observed an
accumulation of F4/80 and Ly6G myeloid cells in the liver of KPC mice by
immunofluorescencemicroscopy.We next determined the role of tumor cells in
driving cellular activation seen in the liver by establishing intraperitoneal and
orthotopicmodels of PDAC. Using thesemodels, we found that implantation of
pancreatic tumor cells induced STAT3 activation in hepatocytes and stimulated
F4/80 and Ly6Gmyeloid cell recruitment to the liver. To determine whether
cellular activation in the liver was associated with systemic release of soluble
factors, we performed parabiotic joining of tumor-implanted mice and control
wild typemice, andwe found evidence of STAT3 activation andmyeloid recruit-
ment to the liver in parabiotic pairs. As interleukin-6 (IL-6) is a key inflamma-
tory cytokine that can activate STAT3 signaling, we hypothesized a role for IL-6
directed STAT3 activation in hepatocytes for development of a pro-metastatic
niche in the liver. Consistent with this hypothesis, we found that IL-6 receptor
blocking antibodies administered after tumor implantation reduced STAT3 ac-
tivation in hepatocytes and decreased transcriptional levels of hepatocyte-de-
rived chemoattractants. Together, our fındings support a role for IL-6/STAT3
signaling in hepatocytes in driving a pro-metastatic niche in the liver during
PDAC development.
#2683 The gastrointestinal microbiome and its composition are critical
for antitumor effıcacy of immune checkpoint inhibition by anti-PD-L1.Ben-
jamin G. Cuiffo, Caitlin S. Parello, Chelsea Ritchie, Katie Pedrick, Alexandra
Kury, Catarina Costa, Brett VanDam, Jonathan Jung, GregoryD. Lyng, Stephen
T. Sonis. Biomodels, Watertown, MA.
The intestinal microbiome has become increasingly appreciated as a signifı-
cant mediator of systemic antitumor immunity/response in both naïve and
treatment contexts. In naïve contexts, an intact intestinal microbiome has been
demonstrated to enhance tumorigenesis, and its composition to mediate pri-
mary tumor growth kinetics. In the context of cancer treatment, antibiotic de-
pletion of the intestinal microbiota has been reported to inhibit the effıcacy of
cyclophosphamide and that of the immune checkpoint inhibitor CTLA4.
Compositional modulation of the intestinal microbiota has been found to be
suffıcient to enhance the antitumor effıcacy of PD-L1. Here, we assessed the
relative importance of the intestinalmicrobiota inmediatingPD-L1 antitumor
effıcacy in a B16.F10.SIY murine model of melanoma, by performing parallel
effıcacy studies in C57BL/6 germ-free (Taconic) or specifıc pathogen free (Tac-
onic or Jackson)mice.We observed thatPD-L1 treatment provided signifıcant
antitumor effıcacy of in Taconic mice carrying an intact microbiome; however,
this effıcacy was abolished in germ-free Taconic mice. Furthermore, we ob-
served that tumors of Jackson mice carrying an intact but compositionally dif-
ferent microbiome did not respond to PD-L1 treatment. Phenotyping of local
tumor and systemic immune responses, as well as characterization of the intes-
tinal microbiome in responder vs nonresponder animals provided mechanistic
insights. Taken together, these observations suggest that rational modulation of
the microbiome may enhance response to immune checkpoint inhibition, and
indicate that the gastrointestinalmicrobiome and its composition are critical for
the antitumor effıcacy of PD-L1.
#2684 Multiplex immunofluorescence profıling of tumor infıltrating im-
mune subsets in HNSCC biopsies provides a powerful tool when combined
with patient outcome data. Matt Levin, Mark Lingen, David Schwartz, Helen
Snyder. Cell IDx, San Diego, CA.
Head and neck squamous cell carcinoma (HNSCC) is one of the growing
number of tumors for which an anti-tumor immune response is implicated
to play a role in the course of the disease. Profıling of the tumor microenvi-
ronment including specifıc infıltrating lymphocyte subsets, antigen present-
ing cells, expression of regulatory molecules on both tumor and immune
cells and spatial relationships between cells could lead to predictive signa-
tures for responsiveness to both conventional and immunemodulatory ther-
apies. While flow cytometry results in multi-parametric analysis of immune
populations within the tumor, their context i.e. the spatial relationship of
these cells to tumor and to other immune cells, is lost. In this current study
we use Cell IDx’s novel UltraPlex technology, which is based on a simple
two-step, autostainer compatible protocol using hapten labeled primary an-
tibody cocktails followed by fluor labeled anti-hapten secondary cocktails to
simultaneously detect 4 cellular markers on the same cell in tumor biopsies.
Image registration of serial sections increases multiplexing to 12-16markers.
This technology, which allows generation of full immune subset profıling,
quantitative marker expression and relative cellular localization, was applied
to a HNSCC tumor microarray as a test system. Data are presented showing
the potential of this technology for correlation of tumor “immune signature”
with patient outcome.
#2685 Modulating tumor microenvironments through inflammasome
and IL-1 pathways. Beichu Guo, Jinyu Zhang, Shun-Jun Fu.Medical University
of South Carolina (MUSC), Charleston, SC.
Chronic Inflammation has been shown to play important roles at all stages of
tumor development including initiation, growth, invasion and metastasis. The
inflammasome is an important innate immune pathway critical for the produc-
tion of active IL-1, a potent inflammatory cytokine. While extensive evidence
indicates that inflammasomes are involved in infections and autoimmune dis-
eases, the role of inflammasomes in tumor development remains controversial.
To dissect the roles of the inflammasome and IL-1 pathway in tumor develop-
ment, we utilized the MMTV-PyMT transgenic model, which develops mam-
mary gland tumors with a high incidence of lung metastasis. Our results have
demonstrated that inflammasome and IL-1 play a critical role in promoting
tumor growth andmetastasis. We found that tumor growth was associated with
inflammasome activation and elevated levels of IL-1 in tumor microenviron-
ments in mouse mammary tumor models and in human breast cancer tissues.
Mice defıcient for inflammasome components or IL-1R signaling exhibit signif-
icantly reduced lung metastasis. Our data also show that inflammasome activa-
tion led to the accumulation of myeloid cells, such as such as myeloid-derived
suppressor cells (MDSCs) and tumor-associatedmacrophages (TAMs) in tumor
microenvironments. Furthermore, blocking IL-1R signaling with IL-1R antag-
onist (IL-Ra) or anti-IL-1R antibody inhibited tumor growth and metastasis.
Our results suggest that targeting the tumormicroenvironment through inflam-
masome and IL-1 blockade may provide a novel approach for the treatment of
breast cancer.
#2686 Dual inhibition of BCR and TLR signaling has therapeutic poten-
tial in chronic lymphocytic leukemia. Eman L. Dadashian, Sarah Herman,
Adrian Wiestner. NIH/NHLBI, Bethesda, MD.
Introduction: The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is
clinically active in lymphoproliferative diseases driven by B-cell receptor
(BCR) and Toll-like receptor (TLR) signaling, including chronic lympho-
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cytic leukemia (CLL) and Waldenstrom macroglobulinemia (WM), respec-
tively. However, deep remissions are uncommon and resistance to single
agent has been described. The hallmark of WM is an activating mutation in
MYD88 in the TLR signaling pathway. While mutations in MYD88 are un-
common in CLL, our previous study identifıed gene signatures indicative of
active BCR and TLR signaling in CLL cells residing in lymphoid tissues
(Herishanu, Blood 2011). Further, TLR9 activating CpG oligonucleotides
induce proliferation and extend CLL cell survival in vitro. These observa-
tions suggest that BCR and TLR signalingmay cooperate to activate CLL cells
in the tissue microenvironment. Here, we tested the hypothesis that target-
ing both BCR and TLR signaling could improve therapy for CLL. Methods:
CLL PBMCs were treated with ibrutinib and/or an IRAK1/4 inhibitor (Cal-
biochem) for 1h and then stimulated with soluble IgM, CpG, or both. We
quantifıed changes in phosphorylation of BTK, PLC2 and ERK (BCR path-
way) and STAT3 and STAT1, as well as total IRAK1 (TLR pathway). Results:
As expected, ibrutinib inhibited phosphorylation of BTK, PLC2 and ERK
(P.05) and decreased the survival of CLL cells stimulated with IgM
(P.001). CpG stimulated TLR signaling degrades IRAK1 and the stimulates
cytokine secretion that can, in autocrine fashion, activate STAT phopspho-
rylation. The IRAK1/4 inhibitor effectively inhibited TLR signaling resulting
in stabilization of IRAK1 (P.002), decreased phosphorylation of STAT1/3
(P.04) and decreased viability compared to CpG stimulated but not IRAK
inhibitor treated cells. Ibrutinib had no effect on CpG-induced IRAK1 deg-
radation, but was comparable to IRAK1/4 inhibition in reducing STAT
phosphorylation, suggesting that inhibition of BTK can antagonize down-
stream effects of TLR activation but not upstream IRAK dependent steps. In
contrast, IRAK1/4 inhibition had no effect on IgM-induced BCR activa-
tion. Next we evaluated the effect of dual BCR and TLR activation, modelling
co-operative activation of both pathways in the tumor microenvironment.
Under these in vitro conditions, ibrutinib prevented BCR activation and
partial TLR activation, while IRAK1/4 affected only the TLR pathway. When
ibrutinib and the IRAK1/4 inhibitor were combined, activation of both BCR
and TLR signaling was prevented resulting in a signifıcant reduction in CLL
cell viability (P.01) compared to co-activation of both pathways. Conclu-
sion: While ibrutinib partially inhibited TLR signaling, an IRAK1/4 inhibi-
tor was required for full inhibition of the pathway. The combination of BTK
and IRAK1/4 inhibition for the treatment of lymphoproliferative diseases
warrants further investigation.
#2687 Toll like receptors mediated inflammatory signals mediate promo-
tion of K-ras mutant lung cancer by chronic obstructive pulmonary disease.
Nasim Khosravi,1 Nelly Torres-Garza,2 Soudabeh Daliri,1 Maria Miguelina De
La Garza,1 Amber Cumpian,1 Evelyn Beltran,1 Misha Umer,1 Diana Del
Bosque,1 Saba Akbani,1 Scott Evans,1 Seyed Javad Moghaddam1. 1UT MD An-
derson Cancer Ctr., Houston, TX; 2Tecnológico deMonterrey School of Medicine,
Monterrey, Mexico.
Lung cancer is the leading cause of cancer death worldwide, and cigarette
smoking is its main cause. However, smoker with chronic obstructive pul-
monary disorder (COPD), an inflammatory disease of the lung, have an
increased risk of lung cancer (3 to 10 fold) compared to smokers without
COPD. Importantly, lung inflammation persists and lung function contin-
ues to deteriorate as does the increased risk of lung cancer even after cessa-
tion of cigarette smoking among former smokers. These facts suggest a
strong link between COPD-related airway inflammation and lung cancer
promotion, however, the precise mechanistic link is not known. We have
previously developed a COPD-like mouse model of airway inflammation
through repeated aerosol challenge to a lysate of nontypeable (i.e., unencap-
sulated) Haemophilus influenzae (NTHi). NTHi is the most common colo-
nizing bacteria in the lower respiratory tract of patients with COPD and
could be a potential cause of perpetuating and promoting airway injury and
inflammation in these patients. We then showed that this type of airway
inflammation promotes lung cancer in a K-ras mutant mouse model of lung
cancer (CC-LR), which was associated with the activation of MyD88/NF-B
pathway and increased expression of its downstream targets in the lung. We
have further shown that lack of NF-kB or MyD88 (an adaptor protein up-
stream to NF-B) in the airway epithelium of CC-LR mice changes the
bronchoalveolar lavage fluid cellular component of CC-LRmice and inhibits
the promoting effect of COPD-like airway inflammation on lung tumorigen-
sis. Upstream to MyD88 and NF-B and downstream to bacterial stimuli is
the toll-like receptors family (TLRs), which play critical role in the innate
immune response. Among TLRs, TLR-2, TLR4, and TLR9 play critical roles
in mediating inflammatory responses in lung and are required for primary
epithelial response to inflammatory stimuli and activation of MyD88/NF-B
pathway in the airway epithelium. Accordingly, we further hypothesized that
TLR-2, 4, and 9 mediate promoting effect of inflammtion on lung tumori-
genesis in an MyD88/NF-kB dependent manner. Therefore, CC-LR mice
were separately crossed to TLR-2, TLR-4 and TLR-9 knock out mice in order
to test this hypothesis. We found that genetic ablation of these TLRs in
CC-LR mice, causes signifıcant reduction in lung surface tumor numbers
compared to age and sex matched control CC-LR mice in the presence of
COPD-like airway inflammation. This tumor reduction was associated with
signifıcant reduction in the numbers of inflammatory cells in bronchoalveo-
lar lavage fluid of mice with lack of these TLRs. Taken these together, we
conclude that promoting effect of COPD on lung cancer is mediated through
TLR2, 4, 9-mediated activation of epithelial MyD88/NF-B pathway.
#2688 Multiplex IHC detection of immune checkpoint receptors in the
tumor microenvironment. Jennifer E. Ziello, Sarah R. Klein, Emily Alonzo,
Herbert Haack. Cell Signaling Technology, Inc, Danvers, MA.
As immune checkpoint blockade has been shown to partially reverse the ex-
hausted T cell phenotype and consequently lead to a decrease in tumor burden,
there is a need for an understanding of this T cell type. Using recently developed,
highly validated antibodies, we have developed a fluorescent multiplex, TSA-
based assay in order to examine the interaction of PD-L1 with PD-1-expressing
exhausted T cells in various tumor types. Here, we construct a seven-color mul-
tiplex panel in order to simultaneously visualize cytokeratin (the tumor mask),
DAPI (nuclear counterstain), CD8 (cytotoxic T cell marker), the exhausted T
cell markers PD-1, Tim-3 and Lag-3, and the ligand for PD-1, PD-L1. This
technique not only enabled the concurrent detection of these markers, but also
provided high-resolution visualization of interactions betweenPD-1-expressing
CD8 T cells and PD-L1-expressing CD68 macrophages in the tumor mi-
croenvironment. The seven-plex panel was applied to FFPE tumor microarrays
(TMAs) consisting of breast, lung and ovarian tumor tissue and each core was
subsequently analyzed for the distribution, co-localization, frequency and prox-
imity of these targets in relation to one another. While we often visualized co-
expression of Lag-3 and PD-1 on T cells, Tim-3 was frequently observed on
PD-L1 macrophages in several tumor types. This data provides valuable in-
sight into the co-expression profıles of these markers in multiple tumor types
and has implications for the use of combination therapies that aim to target both
the innate and adaptive immune systems.
#2689 The protumorigenic, proinflammatory effects of obesity are re-
versed by weight loss via bariatric surgery, but not a low-fat diet. Laura W.
Bowers,1 Emily L. Rossi,1 Subreen A. Khatib,1 Steven Doerstling,1 Alfor Lewis,2
Randy J. Seeley,2 Stephen D. Hursting1. 1Univ. of North Carolina, Chapel Hill,
NC; 2Univ. of Michigan, Ann Arbor, MI.
Background: Obesity negatively impacts basal-like breast cancer (BLBC)
prognosis, but the reversibility of these pro-cancer effects via weight loss re-
mains unclear. However, there is consistent evidence suggesting that weight loss
via bariatric surgery reduces breast cancer risk. This may be related to the re-
ductions inmetabolic perturbations and inflammation that follow bariatric sur-
gery, effects that could be mediated by epigenetic reprogramming and/or
changes in the gut microbiome. Purpose: We previously demonstrated that
mammary tumor growth and inflammation remain elevated in formerly obese
mice, in concordance with aberrant methylation of inflammation-related genes.
Here we aim to determine the differential effects of surgical versus non-surgical
weight loss on inflammation,DNAmethylation, the gutmicrobiome, and tumor
burden in a mouse model of BLBC. Methods: Mice were fed a low fat control
(n25) or high fat diet-induced obesity (DIO, n75) regimen for 15 weeks to
model chronic obesity. DIO mice were then randomized to remain on DIO
(Obese) or receive either a surgical (sleeve gastrectomy) or dietary (low fat con-
trol diet) weight loss intervention, resulting in formerly obese (FOb)-Surg or
FOb-Diet mice, respectively. The Control mice were maintained on the low fat
diet throughout study. Four weeks after weight stabilization in the FObmice, all
mice were orthotopically injected with E0771 mammary tumor cells, which
model BLBC. Stool samples were collected at baseline and prior to tumor cell
injection. Results: The average weight and percent body fat of the FOb-Surg and
FOb-Diet mice were equivalent to Control and signifıcantly lower than Obese
mice at study endpoint. Average tumor weight in FOb-Surg mice was statisti-
cally equivalent to Control mice, but tumor weight in FOb-Diet mice was sig-
nifıcantly greater than Control mice and statistically equivalent to Obese mice.
Furthermore, FOb-Surgmice had signifıcantly lower serum tumor necrosis fac-
tor alpha, mammary gland interleukin-6 expression, and tumor-infıltrating adi-
pocyte area in comparison to FOb-Diet. To further defıne the effects of surgical
versus non-surgical weight loss, characterization of the gutmicrobiota as well as
global mammary tissue gene expression and DNAmethylation via paired RNA
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sequencing and reduced representation bisulfıde sequencing is in progress.
Conclusions: Our results suggest that the strong anti-cancer benefıts seen with
bariatric surgery may be related to a signifıcant reduction in systemic and local
inflammation, which did not occur with non-surgical weight loss. Identifıcation
of the mechanisms mediating the protective effects of bariatric surgery against
breast cancer could help identify new targets and strategies for breaking the
obesity-cancer link.
#2690 MK2pathway blockade inhibits inflammatory cytokine production
and colorectal cancer growth and invasion. Anita L. Ray, Amanda S. Peretti,
Wade Johnson, Gregory Gan, Ellen J. Beswick. The Univ. of New Mexico, Albu-
querque, NM.
Introduction: Colorectal cancer is the third most common malignancy diag-
nosed for both men and women in the United States of America. High levels of
inflammatory cytokines in colorectal tumors cause increased growth and inva-
sion and carry a higher risk of metastasis. Identifying new targets to control
inflammation is important for developing improved treatment approaches. Mi-
togen-activated protein kinase-activated protein kinase 2 (MK2) is a regulator of
pro-inflammatory cytokines that may promote colorectal tumor progression.
MK2 signaling is known to induce IL-1, IL-6, and TNF- production. These
pro-inflammatory cytokines are associated with CRC development, invasion,
and metastasis. We hypothesized that the MK2 pathway could be an important
component of CRC growth, invasion and tumor regrowth. Methods: To inves-
tigate this pathway, CT26 CRC cells were examined. Cells were flank-injected
into Balb/c mice with and without MK2 inhibitor treatment. At day 19 after
tumor injection, tumors were harvested andmeasured using calipers. Cytokines
were quantitated by multiplex bead array in organ culture supernatants and in
supernatants from tumor cells plated in fıbronectin coated wells. In culture,
tumor cell invasion was measured in scratch wound assays containing matrigel.
Results: Treating CT26 cells with MK2 inhibitors markedly reduced tumor
growth in mice by a mean of 60% compared to vehicle control treated cells.
Inflammatory cytokines were also dramatically decreased with MK2 inhibition
compared to controls by up to 80%. Cytokines affected included both known
MK2 downstream cytokines (IL-1, IL-6, and TNF-) and also chemokines such
as MIP-1 and MCP-1 in both supernatants from cultured tumor cells and in
organ culture supernatants. MK2 inhibition also decreased invasion of tumor
cells in a cytokine dependentmanner. Conclusions: TheMK2 pathway regulates
production of multiple pro-inflammatory cytokines in colorectal tumors, in-
cluding several previously unreported chemokines. Inhibition of this pathway
markedly decreases tumor growth and invasion. Thus,MK2may be a promising
tumor target to prevent colorectal cancer progression.
#2691 Cigarette smoke induced upregulation of endothelin axis in the
initiation of pancreatic cancer. Suprit Gupta, Satyanarayana Rachagani, Sushil
Kumar, Surinder Kumar Batra, Maneesh Jain. University of Nebraska Medical
Center, Omaha, NE.
Background: Cigarette smoke is an established risk factor for pancreatic duc-
tal adenocarcinoma (PDAC). Smoke induced inflammation accelerates the pro-
gression of PDAC in presence of constitutively active K-Rasmutation. Endothe-
lin (ET) axis comprising of endothelin converting enzymes (ECE-1, ECE-2, and
ECE-3), endothelin isoforms (ET-1, ET-2 and ET-3) and two receptors A
(ETAR) and B (ETBR), is linked to pathobiology of pancreatitis and its compo-
nents exhibit aberrant overexpression in PDAC. However, the expression of
ET-axis in the oncogene-associated early Pancreatic Intraepithelial neoplastic
(PanINs) lesions following exposure to cigarette smoke is unknown. We hy-
pothesize that smoke induced alterations in the ET axis facilitate acinar to ductal
metaplasia (ADM) in presence of oncogenic K-Ras. Thus, we characterized the
impact of cigarette smoke exposure on ET axis components in the pancreas of
mice harboring mutant K-Ras. Methods: Expression of ECE-1, ET-1, ETAR and
ETBR was analyzed by IHC and RT-PCR fırst in the murine model of preneo-
plastic lesions [KC model: (Pdx1-Cre, KrasG12D)). To determine the changes in
ET axis after smoke exposure, wild type (WT) and KC mutant mice were ex-
posed to cigarette smoke for 20 weeks and expression was analyzed in the pan-
creas. The impact of smoking on ET-axis was also studied onmurine acinar and
tumor cell lines derived from KC mice (UN-KC6141) and KPC (Pdx1-Cre,
p53 (R172H) KrasG12D) mice (UN-KPC-961) by western blot and RT-PCR analy-
sis. Results: In contrast to the normal ducts, the expression of ECE-1, ET-1,
ETAR and ETBR was upregulated in the early PaNIN lesions (20-30 weeks). In
the advanced lesions (50 weeks), signifıcant overexpression of all fourmolecules
was noticeable in the tumor cells and stromal compartment. Smoke exposure
resulted in signifıcant increase in the transcripts of ET-1, ETAR and ETBR (p
values  0.04, 0.03 and 0.01 respectively) in the KC mice while the increase in
WTmice was not signifıcant. The changes in the expression were also corrobo-
rated by tissue IHC. Expression of ET axis components was predominantly seen
in the islet cells in WT mice, while low immunoreactivity was observed in the
acinar compartment. Smoke exposure of KC mice resulted in accelerated pro-
gression of PanIN lesions along with concomitant increase in the expression of
ET axis components both in the ductal and stromal cells. In vitro exposure of
cigarette smoke extract (CSE) to UN-KC6141 and UN-KPC-961 cells for 24
hours elicited a dose dependent upregulation of ECE 1 and ET-1. Conclusions:
In presence of mutated KrasG12D, smoking-mediated inflammatory insult pro-
motes PanIN progression and tumorigenesis. The sustained increase and acti-
vation of ET axis with increasing dysplasia in the ductal compartment during
this progression in KCmice and its further upregulation following smoke expo-
sure suggests its possible role in promoting inflammation-associated pancreatic
tumor progression.
#2692 Inflammatory patterns exhibited by African American colon tu-
mor-derived cell lines. Jenny E. Paredes Sanchez,1 Ping Ji,2 Maria Munoz-
Sagastibelza,1 Laura Martello-Rooney,1 Jennie Williams2. 1SUNY Downstate
Medical Ctr., Brooklyn, NY; 2Stony Brook University, Stony Brook, NY.
Despite progress in closing the gap, health disparities still persist among Af-
rican American (AA) colon cancer patients both in incidence and death rates.
Previous studies fromour group reported that colon tumors fromAAsdisplayed
hypermethylation of DNA regions in inflammatory genes such as NELL1,
GDF1, ARHGEF4, and ITGA4 when compared to Caucasian Americans (CA).
To assess potential differences in the inflammatory response, we utilized twoAA
colon cancer cell lines generated in our laboratory and compared them with the
commercially available CAs colon cancer cell lines, Caco-2 and HT-29. Recent
experiments by our group with the anti-inflammatory drugs Ibuprofen, Sulin-
dac and Aspirin, showed signifıcantly higher IC50 values in proliferation assays
for AA cell lines compared to CA cell lines. Therefore, we evaluated the anti-
inflammatory effects of these drugs by determining secretion of inflammatory
cytokines and MAPKs activation in response to the pro-inflammatory cytokine
TNF-alpha. The same parameters were tested for the anti-inflammatory cyto-
kine IL-10. As hypothesized, our results in theCA cell lines demonstrated down-
regulation of MAPKs activation in response to TNF-alpha after pre-treatment
with Ibuprofen. On the contrary, Ibuprofen concentrations as high as the IC50
values for the CA cell lines were not able to induce down-regulation of MAPKs
in the AA cell lines. Interestingly, IL-10 treatment was more effective in the AA
compared to the CA cell lines, suggesting that the main anti-inflammatory cy-
tokine of the colon will be more effective in controlling inflammation in AA
colon tumors. Further studies are needed to elucidate the major differences in
inflammatory responses between AA and CA colon cancer cell lines and their
potential role in CRC health disparities. As it has been documented that AA
colon cancer patients are less responsive to the chemotherapeutics Fluorouracil
and Capecitabine, in future studies we will evaluate the effect of these therapeu-
tic agents on AA and CA cell lines in terms of inflammation, cell viability, apo-
ptosis and invasion.
#2693 Inflammatory signalling in the colon tumour microenvironment
enhances stromal cell mediated suppression of anti-tumour immune re-
sponses. Grace O’Malley, Kevin Lynch, Serika Naicker, Paul Lohan, Athina
Rigalou, Thomas Ritter, Laurence J. Egan, Aideen E. Ryan. National University
of Ireland, Galway, Galway, Ireland.
The colon tumour microenvironment (TME) comprises many cell types in-
cluding endothelial cells, stromal cells and immune cells. Recent evidence sug-
gests that high tumour stromal cell density correlates with a poor prognosis for
colon cancer patients. The majority of these stromal cells are of mesenchymal
origin (MSCs) and are known contributors to tumour angiogenesis and inva-
siveness. Little is known about the role of their immunosuppressive potential in
the colon TME.We investigated themolecular regulation of the induced immu-
nosuppressive, tumour-promoting phenotype of tumour-associatedMSCs, and
the effect of inflammation on this process. Balb/c bone marrow derived MSCs
were treated with conditioned medium from untreated CT26 tumour cells
(MSCTCM) or TNF- treated CT26 cells (MSCTNF-TCM). Cell surface analysis of
MSCs after 72h revealed an increased expression of TCR ligands MHC-I,
MHC-II and PD-L1 compared to MSCControl. This was further potentiated by
TNF- induced tumour cell inflammation.MSCTCM co-culturedwith syngeneic
activated T cells displayed an enhanced ability to suppress CD8 T cell prolif-
eration, which was further potentiated by inflammatory activation of CT26
(MSCTNF-TCM). This effect was dependent on induced PD-L1 expression on
MSCs as PD-1 blockade restored CD8 T cell proliferation, activation and
granzyme B secretion. In an immunocompetent Balb/c syngeneic model, we
assessed tumour growth and anti-tumour immune responses following sub-
cutaneous injection of CT26 cells alone or co-injection with MSCControl/
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MSCTNF-TCM. Co-injection of MSCControl signifıcantly promoted tumour
growth, and this was further potentiated by the co-injection of MSCTNF-TCM.
This effect was associated with signifıcantly reduced tumour infıltration of CD8
GranzymeB secretingT cells.We showed that this stromal cellmediated tumour
promotion could be reversed by administration of a PD-1 blocking antibody, via
restoration of granzyme B secreting CD8 T cells. We show for the fırst time
that stromal cells in the inflammatory TME directly modulate anti-tumour im-
mune responses via PD-L1. This data could lead to better stratifıcation of pa-
tients for immunotherapeutic regimens resulting in more targeted and durable
responses to overcome stromal mediated tumour immunosuppression in colon
cancer.
#2694 Target obesity-associated inflammation to decrease murine basal-
like mammary tumor burden. Emily L. Rossi,1 Subreen A. Khatib,1 Laura W.
Bowers,1 Steven S. Doerstling,1 Andrew J. Dannenberg,2 Stephen D. Hursting1.
1Univ. of North Carolina at Chapel Hill, Chapel Hill, NC; 2Weill Cornell Medical
College, New York, NY.
Background: Adipose tissue dysregulation, a hallmark of obesity, contributes
to a chronic state of low-grade inflammation that promotes cancer growth
through multiple signaling pathways. We previously showed that inflammation
and basal-like breast cancer (BLBC) growth are increased in chronically obese
mice and persist following weight normalization. Purpose: We tested the hy-
pothesis that targeting inflammation in obese mice by treating them with the
nonsteroidal anti-inflammatory drug (NSAID) Sulindac would offset the pro-
cancer effects of obesity in amousemodel of BLBC.Methods:Mice were admin-
istered a control diet (10 kcal % fat; n34) or diet-induced obesity regimen
(DIO, 60 kcal % fat; n34). After 15 weeks on control or DIO diets, mice were
randomized to either receive Sulindac supplementation at 160 ppm in the diet
(n17/diet) or no supplementation (n17/diet). Twelve weeks later, all mice
were orthopically injected with E0771 cells, a model of basal-like breast cancer.
Five mice/group were killed at a 4-week interim time-point after injection, and
their tissue collected and stored. The remaining 12 mice/group continued in a
survival study; these mice were killed when tumor size reached 1.2 cm in diam-
eter in any direction. Results: Sulindac supplementation in DIO mice signifı-
cantly reduced serum insulin and leptin to levels statistically equivalent to con-
trol mice, but had no effect on body weight, body fat percentage, or ex vivo
visceral white adipose weight. Sulindac supplementation in DIO mice (but not
control) signifıcantly reduced mean tumor volume in the interim tumor study
and signifıcantly increased tumor latency in the survival study. Analysis of H&E
stained tumor demonstrated that DIO mice had signifıcantly increased adi-
pocytes infıltrating into the tumor (relative to control), but Sulindac supplemen-
tation inDIOmice decreased adipocyte infıltration to levels observed in control.
Conclusions: Sulindac supplementation signifıcantly reduced insulin and leptin
in DIO mice, and increased tumor latency in DIO mice, but had no effects on
body weight or fat depots, suggesting that Sulindac offsets some of the pro-
tumorigeneic effects of obesity rather than targeting obesity directly. Prelimi-
nary analyses of inflammatory surrogates, including circulating cytokines and
prostaglandins, mammary gland crown-like structures and cyclooxygenase-2
levels, suggests Sulindac’s effects in obese mice are mediated through its eico-
sanoid-depressing effects.
#2695 Role of tumor generated acidity in immune stromal interactions
during prostate carcinogenesis. Asmaa El-Kenawi, Jasreman Dhillon, Arig
Ibrahim-Hashim, Dominique Abrahams, Shari Pilon-Thomas, Brian Ruffell,
Robert Gatenby, Robert Gillies.Moffıtt Cancer Ctr., Tampa, FL.
Insuffıciency in tumor perfusion and high rate glycolysis combine to reduce
the pH of tumor microenvironment. In a TRAMPmodel of prostate cancer, we
had shown that carcinogenesis is associated with increasing acidifıcation of the
microenvironment and that neutralization of this acidity can prevent cancer
emergence or metastases. Carcinogenesis in the TRAMP model is also associ-
ated with increased fıbrosis and immune cells infıltration. We thus sought to
determine if fıbrosis drives immune infıltration in early tumorigenesis or vice-
versa; andwhether this dynamics is affected by tumor acidity. To investigate this,
we harvested prostates from TRAMP mice or their matching non-transgenic
controls at different time points and stained serial prostate tissue sections with
F4/80 (macrophages), SMA (cancer-associated fıbroblasts, CAFs), andMasson’s
Trichome (collagen).Quantitative image analysis reveals that increase in fıbrosis
occur prior to macrophage infıltration and that both events preceded tumor
development. However, the relative amount of collagen fıbers was unchanged
across all time points. Notably, neither fıbrosis nor macrophage infıltration oc-
curred in mice treated with buffer, suggesting an involvement of acidity in this
immune stromal interactions. Interestingly, macrophages isolated from latter
time points in the untreated group as well as macrophages co-cultured with
prostate tumor cells at acidic pH, possessed anM2-like phenotype by expressing
immunosuppressive genes (e.g. Arginase 1, Arg1) and a range of scavenging
receptors (e.g. mannose receptor, Cd206), as well as releasing more angiogenic
factors (e.g. VEGF and MMPs). Similar results were recapitulated when M2
macrophages were stimulated at acidic pH by showing enhanced Cd206 and
Arg1 expression. On the functional level, macrophages activated at acidic pH
had a higher ability to uptake fluorescently labelled ovalbumin and collagen, as
examples of mannosylated ligands that prevail the fıbrotic microenvironment.
In summary, these results suggest that tumor acidity may promote fıbrosis, with
subsequent macrophage infıltration and phenotypic switching, leading to in-
creased collagen turnover. It is suspected that this extracellular matrix remod-
eling may be permissive for tumor progression.
#2696 PD-1 antibody treatment induces gutmicrobiota changes in CT-26
colon cancer syngeneic model. Jian Ding, Binchen Mao, Qian Shi. CrownBio,
Taicang, Jiangsu Province, China.
The gut microbiota plays an important role in shaping systemic immune
response. One novel frontier in cancer research is investigating how the gut
microbiota change immune response and influence the effıcacy of anticancer
immunotherapy drugs; this has been reported in CTLA4 and PD-L1 antibody
treatment, both in laboratory and clinical settings. One recent study reported
that composition of patient‘s gutmicrobes appears to be a determining factor for
immunotherapy, at least in melanoma patients. These fındings shed light on the
potential use of gut microbial as a biomarker for responders in cancer immuno-
therapy and even as a novel treatment. Here, we evaluated the gut microbiota
profıling upon PD-1 antibody (RMP1-14) treatment in CT-26 colon cancer
syngeneic mouse model. Fresh feces were collected at different time points be-
fore and after treatment, snap frozen and sent for 16s RNA sequencing for
microbiome profıling. Our results identifıed top 25 abundant taxa in genus level
in CT-26 feces. Signifıcant abundance changes were observed in several genera
after PD-1 antibody treatment, especially in Akkermansia. These fındings indi-
cate that immunotherapy like PD-1 antibody can induce the profıle changes of
gut microbiota in CT-26 model. Furthermore, we also investigated the correla-
tion of gutmicrobiomewith immune-microenvironment and the effıcacy upon
IO therapy, as well as the possibility to utilize microbiota profıling as a quality
control step that may help to explain the variability observed inmany syngeneic
studies.
#2697 A role for the membrane type-1 matrix metalloproteinase in the
transcriptional regulation of carcinogen-induced inflammasome compo-
nents. Samuel Sheehy, BorhaneAnnabi.Université duQuébec àMontréal,Mon-
tréal, Quebec, Canada.
BACKGROUND: Signal transducing functions driven by the cytoplasmic do-
main of membrane type-1 matrix metalloproteinase (MT1-MMP) are believed
to regulatemany inflammation-mediated cancer cell functions includingmigra-
tion, proliferation, and survival. Besides the upregulation of the inflammation
biomarker cyclooxygenase (COX)-2 expression, MT1-MMP’s role in relaying
the signals triggered from pro-inflammatory cues remain poorly understood.
METHODS: Here, we treated HT1080 fıbrosarcoma cells with phorbol-12-my-
ristate-13-acetate (PMA), a well-known carcinogen and inducer of COX-2 and
of MT1-MMP. In order to assess the global transcriptional regulatory role that
MT1-MMP may exert on inflammation biomarkers, we combined gene array
screens to transiant MT1-MMP gene silencing strategy. RESULTS : We found
that MT1-MMP expression exerted both stimulatory and repressive transcrip-
tional control of several inflammasome-related biomarkers such as IL-1B, IL-6,
IL-12A, and IL-33, as well as of transcription factors such as EGR1, ELK1, and
ETS1/2 in PMA-treated cells. Among the signal transducing pathways explored,
silencing of MT1-MMP prevented PMA from phosphorylating Erk, IB, and
p105 KF-B intermediates. We also highlight a signaling axis linking MT1-
MMP to MMP-9 transcriptional regulation. CONCLUSIONS: Altogether, our
data evidence an important involvement of MT1-MMP in the transcriptional
regulation of inflammatory biomarkers consolidating its contribution in signal
transducing functions, in addition to its classical hydrolytic activity.
#2698 IL-17A alone or in combination with IL-4/IFN- induces Duox2/
DuoxA2 expression and reactive oxygen production in human colon and
pancreatic cancer cells. James H. Doroshow,1 Yongzhong Wu,2 Jiamo Lu,2
Smitha Antony,1 JenniferMeitzler,2 Agnes Juhasz,2 Guojian Jiang,2 Iris Dahan,1
Mariam Konate,1 Krishnendu Roy1. 1NCI-DCTD, Bethesda, MD; 2NCI-DTP,
Bethesda, MD.
NADPH oxidase (NOX)-derived reactive oxygen species (ROS) contribute
signifıcantly to inflammation-associated carcinogenesis. Expression of dual ox-
idase 2 (Duox2), one of sevenmembers of the NOX gene family, is up-regulated
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in inflammatory bowel disease, chronic pancreatitis, and in many human ma-
lignancies including carcinomas of the colon, pancreas, prostate, lung, and
breast. Previously, we demonstrated that Stat1 and/or NF-kB play a critical role
in modulating the enhanced expression of Duox2, and its cognate maturation
factor DuoxA2, by the pro-inflammatory mediators IFN- and lipopolysaccha-
ride in human pancreatic cancer cells. This cytokine-mediated increase in
Duox2 expression was responsible for a signifıcant increase in tumor cell H2O2
production, DNA damage, and HIF-1 and VEGFA upregulation in pancreatic
cancer cell lines. Using the T84 human colon cancer line, and BxPC-3, AsPC-1,
and HTB134 pancreatic cancer cell lines, we now report that the pro-inflamma-
tory cytokine IL-17A, pivotal in the adaptive immune response against various
pathogens, and in the promotion of colon and pancreatic cancer progression,
strongly induces Duox2/DuoxA2 mRNA and protein expression (alone or in
combination with IL-4 or IFN-). In BxPC-3 cells, IL-17A enhances the expres-
sion of Duox2/DuoxA2 in a time- and concentration-dependentmanner, which
leads to a signifıcant increase in the generation of extracellular H2O2. When
IL-17A is combined with IL-4 in either T-84 or AsPc-1 lines, Duox2-mediated
ROS formation is suffıcient to produce a DNA damage response, indicated by
the strong induction of H2AX expression; moreover, in AsPc-1 cells, Duox2-
specifıc siRNA signifıcantly attenuated cytokine-induced ROS production and
H2AX phosphorylation. IL-17A in combination with IL-4 also signifıcantly
increases Stat3 phosphorylation and promotes proliferation in AsPC-1 cells.
Ongoing cellular experiments are focused on whether the cytokine-mediated
upregulation of Duox2/DuoxA2 is responsible for Stat3 activation and cell
growth promotion in the K-ras mutated AsPC-1 cells. Bio-informatic analysis
with the TCGA data set, as well as RT-PCR using surgically-resected human
colon cancer samples compared to adjacent, uninvolved colonic epithelium re-
vealed that Duox2 was signifıcantly upregulated in human colon cancers. These
studies, in concert with our previous data demonstrating high-level Duox pro-
tein expression in pancreatitis, pancreatic intra-epithelial neoplasia (PanIN),
and frank pancreatic cancer, strongly suggest that ROS, produced as a conse-
quence of cytokine-related Duox2 up-regulation, may be associated with the
development of inflammation-related gastrointestinal malignancies.
#2699 NFATc2 in non-small cell lung cancer mediates inhibition of pe-
ripheral bloodmononuclear cell proliferation. IanK. Lam, Zhi-Jie Xiao,Vicky
P. Tin, Fang Ping Huang, Maria P. Wong. The University of Hong Kong, Hong
Kong, Hong Kong.
Lung cancer is the leading cause of cancer death worldwide. While genetic
mutations that provide growth advantages to cancer cells are fundamental to
malignant transformation, ability to evade the immune system is also crucial in
tumorigenesis. We have previously shown that human lung cancers with high
expression of nuclear factor of activated T cells, cytoplasmic 2, (NFATc2) are
associated with reduced recurrence-free and overall survival. NFATc2 is ex-
pressed inmost immune cells and has been extensively studied in immune cells.
However, its function in cancer development is not completely understood. In
this study, the role of NFATc2 in lung cancer on immune escape is explored.
Lung cancer cell lines with high NFATc2 expression were co-cultured with pe-
ripheral bloodmononuclear cells (PBMC) and a signifıcant inhibition of PBMC
proliferation was observed compared to PBMC only control. However, the in-
hibitory effect of PBMC proliferation was reversed in co-culture with NFATc2
knockdown cancer cells. When cancer cells and PBMC were separated by a
membrane using Transwell inserts, the anti-proliferative effect on PBMC was
not observed suggesting that cell-cell contact was required for the NFATc2-
mediated inhibition. Moreover, interleukin-2 (IL-2) was produced by PBMC
irrespective of the presence or absence of lung cancer cells. These results showed
that the inhibition of proliferation was independent of the activation of PBMC.
Taken together, we have shown NFATc2 in lung cancer plays a role in immune
modulation by inhibiting PBMC proliferation and this could be a novel mech-
anism of immune evasion in lung cancer.
#2700 Intestinal Vitamin D receptor defıciency increases susceptibility
for theDSS-induced colon disease. Jung-HwanKim,1 Satoshi Yamaori,2 Frank
J. Gonzalez2. 1Gyeongsang National University, Jinju, Republic of Korea; 2Na-
tional Cancer Institute, Bethesda, MD.
To investigate the function of the intestinal Vdr gene in inflammatory bowel
disease (IBD), in conjunction with the discovery of possible metabolic markers
for IBD using intestine-specifıc Vdr knockout mice. VdrIEpC mice were gener-
ated, phenotyped and treated with a time-course of 3% dextran sulfate sodium
(DSS) to induce colitis. Colitis was diagnosed by evaluating clinical symptoms
and intestinal histopathology. Gene expression analysis was carried out. In ad-
dition, metabolic markers of IBD were explored by metabolomics. VdrIEpC
mice showed abnormal body size, colon structures and feces color. Calcium,
collagen, and intestinal proliferation-related gene expressionwere all decreased,
and serum alkaline phosphatase was highly increased. In the acute model which
was treated with 3%DSS for six days, VdrIEpCmice showed a high score of IBD
symptoms; enlarged mucosal layer and damagedmuscularis layer. In the recov-
ery experiment model, where mice were treated with 3% DSS for four days and
water for three days, VdrIEpC mice showed a high score of IBD symptoms;
severe damage of mucosal layer and increased expression of genes encoding
proinflammatory cytokines. Feces metabolomics revealed decreased concentra-
tions of taurine, taurocholic acid, taurodeoxycholic acid and cholic acid in Vdr
IEpC mice. In conclusion, disruption of the intestinal Vdr gene showed pheno-
typical changes. These factors combined may exacerbate IBD. Taken together,
the results suggest that VDR may play an important role in IBD.
#2700A Impact of radiation and EGFR inhibitor treatment on the expres-
sion of immune susceptibility markers in human head and neck squamous
cell carcinoma. Lauryn R. Werner, Lindsey K. Werner, Joseph G. Kern, Shyh-
min Huang, Jasdeep Kler, Clinton Heinze, Zachary S. Morris, Paul M. Harari.
Univ. of Wisconsin-Madison, Madison, WI.
Treatment with radiation (RT) and/or molecular targeted therapies may en-
hance tumor susceptibility to immune response. We previously demonstrated a
cooperative interaction between RT and various immunotherapies in vivo. We
subsequently demonstrated that there are delayed, transcriptionally-mediated
effects of RT on the expression of tumor markers of immune susceptibility in
murine and human melanoma. To expand these fındings and explore applica-
tions in other tumor types, we investigated the effects of RT on immune suscep-
tibility markers in human head and neck squamous cell carcinoma (HNSCC)
cell lines. In addition, we examined whether treatment with the anti-EGFR
monoclonal antibody cetuximab could further enhance these effects. We used
quantitative polymerase chain reaction (qPCR) tomeasure RT-induced changes
in gene expression of a variety of immune susceptibility markers over time in
HSCCC cell lines. We observed a time-dependent increase in the expression of
specifıc death receptors (Fas, DR5), as well as T cell co-stimulatory/co-repressor
ligands (PD-L1, CD40). The timing of these changes correlated with tumor
susceptibility to ADCC immune response in vivo. Western blots confırmed
RT-induced changes in protein expression of selected markers consistent with
the observed changes in gene expression. To assess the effect of cetuximab on the
expression of immune susceptibility markers, we performed western blots and
qPCR to measure the effect of treatment with radiation, cetuximab, or combi-
nation treatment on protein and gene expression of immune susceptibility
markers in HNSCC cells. We found that cetuximab treatment enhanced RT-
induced changes in gene expression of several markers in both SCC6 and SCC1
cells, including MHC I-A, CD40, and OX40-L. Similar enhancement of RT-
induced changes in protein expression was confırmed via western blotting. To
validate that the effects of combination treatment were specifıc to EGFR inhibi-
tion, we examined the effects of RT on gene and protein expression of selected
markers in cells in which EGFR had been transiently knocked down via siRNA
transfection. Similar enhancement of RT-induced changes was observed with
EGFR-knockdown and treatment with cetuximab. This study highlights the
impact that treatment with RT and/ormolecular targeted therapiesmay have on
tumor cell immunogenicity and suggests opportunities to enhance anti-tumor
response by combining immunotherapeutic agents with RT or RT and EGFR
inhibitors. These fındings suggest opportunities to further optimize clinical
treatment regimens by combining RT,molecular targeted therapies, and immu-
notherapies in the treatment of patients with HNSCC.
CLINICAL RESEARCH: Clinical Molecular Genetics and
Laboratory Correlates
#2701 Large-scale ex vivo generation of human neutrophils from cord
blood CD34 cells. Zhenwang Jie,1 Yu Zhang,1 Chen Wang,2 Bin Shen,1 Xin
Guan,1 Zhihua Ren,1 XinxinDing,3WeiDai,4 Yongping Jiang1. 1Biopharmaceu-
tical R&DCenter, Peking UnionMedical College of TsinghuaUniversity, Suzhou,
China; 2Biopharmagen corp., Suzhou, China; 3College of Nanoscale Science and
Engineering, SUNYPolytechnic Institute, Albany, NY; 4EnvironmentalMedicine,
NYU Langone Medical Center, Tuxedo, NY.
Ex vivo expansion of hematopoietic stem cell and subsequent differentia-
tion into mature neutrophils remains a challenge. Here, we have developed a
three-stage culture system to produce effıciently functional neutrophils de-
rived from cord blood CD34 cells. A procedure of ex vivo expansion and
differentiation in a large-scale was developed in a modifıed IMDM basal
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medium supplemented with transferrin, insulin, fetal bovine serum, and
some other nutrients with selected cytokine combination that contained
stem cell factor (SCF), Flt-3 ligand (FL), granulocyte-colony stimulating
factor(G-CSF), granulocyte macrophage colony-stimulating factor(GM-
CSF) and thrombopoietin (TPO) in stage I (days 06); SCF, FL, G-CSF,
interleukin 3 (IL-3), and GM-CSF in stage II (days 69); SCF, FL, and G-CSF
in stage III (days 918), respectively. Enriched CD34 cells were fırstly
cultured and expanded in 25-T flasks. After 6 day-culture, the cells were
transferred to a 2-L bottle with 500 ml of medium in the bottle-turning
device system. During the differentiation process, neutrophil marker CD66b
was evaluated by flow cytometry. Ex vivo generated neutrophils or medium
only were incubated with E.coli overnight for its bacteria killing assay, and
then the E.coli colony-forming units were counted separately. Matured neu-
trophils or vehicle were transplanted into NOD/SCIDmice intravenously for
chemotactic activity in vivo. The cells that accumulated in the pouch with
chemoattractant were collected and subjected to flow cytometric analysis for
human CD66b antigen. The ex vivo generated neutrophils/progenitors were
then injected into sub-lethal irradiated NOD/SCID mice to monitor the
viability and maturation in vivo. After the three-stage culture, proliferation
fold of total cell reached 30013 	 286.5 with 60.2% 	 2.4% for CD66b
neutrophils. The calculated yield of matured neutrophils from each CD34
cell was ranged from 1.8 104 to 1.87 104 for 18-day culture. There was no
E.coli colony formed after incubation with neutrophils in bacteria killing
assay, indicating that the generated neutrophils was functional. For in vivo
chemotaxis assay, the neutrophils collected from 18-day culture were in-
jected into mice and detected at 1.08%	0.16% for human CD66b cells and
no any CD66b cell observed for negative control group. In addition, the
CD66b cells were extended for 4 days from a 15-day cultured neutrophil
group in mouse peripheral blood (PB), while only for 2 days from a freshly
isolated human PB neutrophils post injection, indicating that the ex vivo
generated neutrophils/progenitors could further matured in vivo. Taken to-
gether, we have established a pilot-scale culture system to produce functional
human neutrophils ex vivo. Considering that one neutrophil transfusion
unit (100ml) contains 21010 cells, the CD34 cells from one CB unit (80
ml) would generate 1.61011 neutrophils, which are equivalent to 8 unit
doses of neutrophils in the clinical application.
#2702 Mutations of SPOP, FOXA1 and IDH1 are associated with prostate
cancermetastasis and biochemical outcomes. JinluMa,1 Suxia Han,1 Xin Sui,1
Wenyan Lu,2 Yonghe Li,2 Bo Xu2. 1The First Hospital, Xi’an Jiaotong University,
Xi’an, China; 2Southern Research Inst., Birmingham, AL.
Recent genomic studies have shed light on cataloging genomic alterations
in prostate cancer. Mechanistic studies allow the use of this information to
subclassify the heterogeneous prostate tumors for optimized treatment plan-
ning. Speckle-Type POZ Protein (SPOP), Forkhead Box Protein A1
(FOXA1) and Isocitrate Dehydrogenase 1 (IDH1) are among the genes that
show frequent point mutations in primary prostate cancers. However, the
clinical signifıcance of these gene mutations in cancer patients is less clear.
To determine the whether SPOP, FOXA1 and IDH1mutations are associated
with clinical outcomes in prostate cancer, we pyro-sequenced the three genes
in prostate cancer patients and evaluated the clinical and prognostic signif-
icance. 198 patients from the fırst hospital of Xi’An Jiaotong University
(China) were analyzed. All patients were newly diagnosed with prostate
cancer from January 2010 to December 2015. No patient was lost to follow-
up. The average follow-up time after the primary diagnosis was 27 months.
The Fisher’s exact tests were used to compare categorical data. The risk of
metastasis among patients with SPOP, FOXA1 and IDH1 mutations was
evaluated using univariate and multivariate logistic regression models. The
prognostic signifıcance of clinical and gene mutations was determined using
multivariate Cox regression analysis. SPOP mutations were found in 16 pa-
tients (8.1%), with all of the mutations clustered in the substrate-binding
MATH domain. FOXA1 mutationswere found in nine patients (4.5%), and
were clustered in the Forkhead domain. IDH1 mutations were detected in
three patients (1.5%). Mutation frequencies of SPOP, FOXA1 and IDH1
were associated with prostate-specifıc antigen (PSA), a biochemical marker
of prostate tumor presence/risk which is decided by Gleason Score, T stage
and PSA level, along with prostate cancer PSA failure andmetastasis. Among
patients with SPOP mutation, 56.3% showed metastasis at the time of diag-
nosis of primary cancer, compared to only 11.5% of patients with wild-type
SPOP. Similarly, the probabilities of FOXA1 and IDH1 mutations with me-
tastasis were approximately 44.4% and 66.7% versus 13.8% and 14.4%, re-
spectively, comparing to their wild-type counterparts. The metastasis risk
for patients with SPOP mutation was 1.27 times of the SPOP wild-type
patients (P  0.003). We also found that patients with SPOP (P  0.0001)
and FOXA1 (P 0.0403) mutations showed higher risk of PSA failure com-
pared with wild-type. The PSA failure risk for patients with SPOP mutation
was 35.49 times of the SPOP wild-type patients. In contrast, IDH1 mutation
was not associated with PSA failure (P 0.054). Multivariate analyses dem-
onstrate that SPOP mutation is an independent factor that is associated with
prostate cancer metastasis and PSA failure recurrence. These fındings un-
derscore the clinical signifıcance for profıling SPOP, FOXA1 and IDH1.
#2703 Extraskeletal myxoid chondrosarcoma: a clinicopathologic and
molecular study reveals novel genetic aberrations by targeted next-genera-
tion sequencing. Marcel Trautmann,1 Magdalene Cyra,1 Ilka Isfort,1 Inga
Grünewald,1 Konrad Steinestel,1 Sebastian Huss,1 Reinhard Büttner,2 Eva
Wardelmann,1 Wolfgang Hartmann1. 1University Hospital Münster, Gerhard-
Domagk-Institute of Pathology, Münster, Germany; 2University Hospital Co-
logne, Institute of Pathology, Cologne, Germany.
Background: Extraskeletal myxoid chondrosarcomas (EMCs) are rare mes-
enchymal neoplasms comprising approx. 3% of all soft tissue tumors. EMCs
arisemainly from the deep soft tissues of the extremities, accompaniedwith high
rates of recurrence and metastases. The molecular hallmarks of EMCs are vari-
ous cytogenetic NR4A3 rearrangements, generating chimeric -NR4A3 proteins.
The most common reciprocal translocation t(9;22)(q22;q12), results in a fusion
of the EWS RNAbinding protein 1 gene (EWSR1) to the nuclear receptor sub-
family 4, groupA,member 3 gene (NR4A3orTEC; approximately 75%of cases).
Further cytogenetic t(9;17)(q22;q11) rearrangements involve TAF15RNApoly-
merase II, TATA box binding protein (TBP)associated factor (TAF15; approx-
imately 15% of cases). The less frequent reciprocal translocations t(9;15)(q22;
q21) and t(9;3)(q22;q12), result in transcription factor 12 (TCF12)NR4A3 and
TRKfused gene (TFG)-NR4A3 fusion proteins. Although the oncogenic
-NR4A3 fusion transcripts seem to have a crucial role in EMC tumorigenesis
and progression, the specifıc biological function and the mechanism of action
remain to be defıned. Methods: We characterized the cytogenetic rearrange-
ments of 25 comprehensive EMC tumors byRT-PCR and/or fluorescence in situ
hybridization (FISH). Next generation sequencing (NGS) was performed (Illu-
minaMiSeq platform) to reveal additional genetic alterations besides the known
chromosomal translocation. Therefore, a comprehensive cancer panel was de-
signed, comprising 27 cancer-related genes known to be frequently mutated
across variousmalignancies. Results: Overall, fusion transcripts were detected in
22 of 25 samples (88%). Sixteen were positive for the EWSR1-NR4A3 and six for
the TAF15-NR4A3 fusion gene. The t(9;15) and t(9;3) translocations, resulting
in TCF12NR4A3 and TFG-NR4A3 fusion proteins were not identifıed in any
EMC case. In Addition, several known oncogenic mutations were detected
which have not been previously reported in EMC. Conclusions: The combina-
tion of RT-PCR and FISHon paraffın-embedded tissue is a sensitive and specifıc
method for the molecular detection of the pathogenic translocations to be ap-
plied in the differential diagnosis of extraskeletalmyxoid chondrosarcomas.Our
results emphasize that cytogenetic NR4A3 rearrangements are the initiating
events in the pathogenesis of EMC. Furthermore, our results indicate the occur-
rence of additional genetic aberrations providing a rational base for novel tar-
geted therapeutic approaches.
#2704 Pathogenicmutations and variants of unknown signifıcance (VUS)
in cancerpredispositiongenes are associatedwithover 10%ofpediatric rhab-
domyosarcoma: a report from the Children’s Oncology Group. Erin L.
Young,1 LukeMaese,1 RosannRobinson,1 Lance Pflieger,1 BarryMoore,1 Shawn
Rynearson,1 Trent Fowler,1 Sean V. Tavtigian,1 Mark Yandell,1 Clinton C. Ma-
son,1 Douglas S. Hawkins,2 Philip J. Lupo,3 Joshua D. Schiffman1. 1University of
Utah, Salt Lake City, UT; 2University of Washington, Fred Hutchinson Cancer
Research Center, Seattle, WA; 3Baylor College of Medicine, Houston, TX.
Approximately 5% of rhabdomyosarcoma (RMS) cases are due to known
cancer predisposition syndromes (e.g., Li-Fraumeni syndrome, Neurofıbroma-
tosis-1), but these estimates have not been confırmed in large-scale studies.
Furthermore, no recommended germline testing protocols exist for RMS. We
tested the hypothesis that germline mutation burden is greater than previously
reported and present several new predisposition genes as potential drivers of
pediatric RMS.We sequenced 59 cancer susceptibility genes in 213 childrenwith
RMS enrolled on one clinical trial (COG ARST0531), unselected for family
history of cancer. Validation was performed with Sanger sequencing. Our anal-
ysis included determining the incidence of pathogenic variants in known RMS
predisposition genes, followed by other cancer predisposition genes on our
panel but not previously associated with RMS. In our cohort, 3.9% of unselected
RMS cases harbor a pathogenic variant in a known predisposition gene (Table
1). Using VAAST, we next identifıed the top 10 genes possibly associated with
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RMS. Variants of uncertain signifıcance (VUS) were restricted to rare variants
(0.1%) with severe CADD and Polyphen2 scores, which added 16 additional
patients (7.4%). To distinguish incidental fındings from true correlations, we
compared our allele frequencies to those in the GnomAD database (126,216
exome sequences and 15,136 whole-genome sequences). Including both patho-
genic mutations and rare VUS, 10.8% of RMS cases carry a variant with poten-
tially important clinical implications, suggesting that newly diagnosed RMS
would benefıt frommultigene genetic testing. Future directions include linkage
to clinical data such as family history, age at diagnosis, tumor stage/location/
histology, and clinical outcome, as well as expanding both the RMS and control
cohorts.
Table 1. List of genes with numbers of carriers identifıed in 213
rhabdomyosarcoma cases
Gene Carriers %
% of
carriers
in GnomAD SIR 95% CI Pvalue
Truncating Variants and Known Pathogenic Missense
ATM 0 0.42% - - -
BAP1 0 0.87% 0.05% - - -
BRCA2 2 0.87% 0.85% 1.01 (0.12-3.66) 1.1736
DICER1 1 0.43% 0.06% 7.75 (0.20-43.19) 0.2421
MSH2 1 0.43% 0.15% 2.93 (0.07-16.30) 0.5790
NF1 2 0.87% 0.88% 0.98 (0.12-3.54) 1.2088
PMS2 0 0.87% 0.18% - - -
PTCH1 0 0.15% - - -
TP53 3 1.30% 0.13% 10.10 (2.08-29.51) 0.0070
WT1 0 1.30% 0.02% - - -
Total 9 3.90% 3.42% 1.14 (0.52-2.16) 0.7882
Combined Analysis of Pathogenic Variants plus Variants of
Uncertain Signifıcance (VUS)
ATM 2 0.87% 0.78% 1.11 (0.13-4.02) 1.0734
BAP1 2 0.87% 0.22% 3.89 (0.47-14.05) 0.1891
BRCA2 2 0.87% 1.52% 0.57 (0.07-2.06) 1.7286
DICER1 7 3.03% 0.86% 3.52 (1.41-7.24) 0.0089
MSH2 1 0.43% 0.78% 0.56 (0.01-3.10) 1.6690
NF1 2 0.87% 1.70% 0.51 (0.06-1.84) 1.8062
PMS2 1 0.43% 0.64% 0.68 (0.02-3.78) 1.5425
PTCH1 3 1.30% 0.86% 1.52 (0.31-4.43) 0.6348
TP53 4 1.73% 0.25% 6.93 (1.89-17.76) 0.0058
WT1 1 0.43% 0.31% 1.40 (0.04-7.81) 1.0197
Total 25 10.82% 9.94% 1.09 (0.70-1.61) 0.7232
#2706 KRT16 germline mutation associated with familial syndrome of
tylosis with esophageal cancer (TOC). Erin L. Young,1 Lance Pflieger,1 Luke
Maese,1 Trent Fowler,1 Kinley Garfıeld,2 N. Jewel Samadder,1 Bella Johnson,1
Clinton C. Mason,1 Barry Moore,1 Shawn Ryanearson,1 Mark Yandell,1 Wendy
Kohlmann,2 Joshua D. Schiffman1. 1University of Utah, Salt Lake City, UT;
2Huntsman Cancer Institute, Salt Lake City, UT.
Tylosis (palmoplantar keratoderma) with esophageal cancer (TOC) also
known as Howel-Evans syndrome has been associated with pathogenic muta-
tions in RHBDF2. A potential TOC family was referred for clinical evaluation at
the Family Cancer Assessment Clinic (FCAC) at Huntsman Cancer Institute,
Salt Lake City, Utah.Multiple relatives of the proband had hyperkeratosis on the
areas of skin associated with pressure and friction, especially the feet, as well as
oral leukoplakia. The proband’s father, paternal aunt, paternal grandfather, and
paternal great grandfather had been diagnosed with esophageal cancer. Clinical
testing was unable to identify a germline mutation in RHBDFR2 that explained
the observed phenotype and inheritance pattern. As part of Heritage 1K Project
(University of Utah), Pediatric & Adult Cancer Section, we performed whole
genome sequencing (WGS) on 5 family members, 4 that were affected with the
hyperkeratosis, and 1 unaffected family member, to identify other potential
genetic causes for the observed TOC phenotype. We prioritized variants via
VAAST (Variant Annotation, Analysis and Search Tool). Reducing our genes of
interest to those involved in palmoplantar keratoderma with PHEVOR (Pheno-
type Driven Variant Ontological Re-ranking Tool), we identifıed a pathogenic
mutation: KRT16 c.379CT p.Arg127Cys. This mutation is reported in a large
palmoplantar keratoderma family (without esophageal cancer) and is listed as
pathogenic in Clinvar (www.ncbi.nlm.nih.gov/clinvar). KRT16 c.379CT
p.Arg127Cys was present in each of the affected family members, but not in the
unaffected relative. Our analysis is the fırst of its kind to suggest carriers of
pathogenic variants in KRT16 are at-risk for esophageal cancer, andmay benefıt
from esophageal surveillance. Additionally, patients presenting with a family
history of esophageal cancer should be considered for germline testing for
KRT16 mutations along with RHBDF2 mutations.
#2707 Targeted RNA sequencing reveals thus far unknown diagnostically
relevant fusion partners confırming its diagnostic potential. Niroshan Na-
darajah, ManjaMeggendorfer, Torsten Haferlach,Wolfgang Kern, Claudia Ha-
ferlach.Munich Leukemia Laboratory, Munich, Germany.
Introduction: The genomic landscape of hematological malignancies has been
resolved mainly based on whole exome and whole genome sequencing, primarily
targeting gene mutations. In addition to mutations, gene fusions have also been
identifıed as therapeutic targets, impressively shown e.g. for BCR-ABL1 andETV6-
PDGFRB. Even though fluorescence in situ hybridization (FISH) is the current gold
standard in fusiondetection, it is by concept limited to the selectedgenes it is applied
to. In contrast, targeted RNA sequencing is a valuable hypothesis-free approach to
discover all possible fusion junctions in a single reaction. Aim: Explore the value of
targeted RNA sequencing in a routine diagnostic work up. Patients and Methods:
We sequenced 134 cases in parallel to our routine diagnostics workflow using chro-
mosome banding analysis (CBA), FISH and real-time quantitative (RQ-PCR). Tar-
getedRNAsequencingwas performedon theNextSeq 500 using theTruSight RNA
Fusion panel (Illumina, San Diego, CA) consisting of 7690 probes covering 507
genes known tobe involved in gene fusions.Analysiswas performedwith theRNA-
SeqAlignmentAppv1.2.0 (BaseSpace SequenceHub)using Star forAlignment and
Manta for gene fusion calling with default parameters (Illumina, San Diego, CA).
Results: In 127 of 134 (95%) cases the results of FISH, subsequently confırmedwith
RT-PCRwere also picked up by RNA Seq. This included diagnostically highly rele-
vant fusions like BCR-ABL1 (n8), KMT2A rearrangements (n7), PML-RARA
(n4), and ETV6 and NPM1 rearrangements. In addition to the confırmation of
orthogonal results, we were able to identify novel rare gene fusions, which we sub-
sequently confırmedbyRQ-PCR.This included immediately targetable fusions like
TNIP1-PDGFRB and ETV6-EFL1, ETV6-FOXO1, IRF2PB1-RARA, RARA-
SAE1). Conclusion: 1) In the vast majority of instances targeted RNA sequencing
confırmed results obtained by FISH/RT-PCR and in addition discovered new rare
gene fusions 2)Targetable genetic aberrationswere identifıed,whichwere not iden-
tifıable by chromosome banding analysis but would now lead to more individual-
ized treatment. 3) Thus, targetedRNA sequencingmay be a valuable tool in routine
diagnostics and for patients with rearrangements unresolved by standard tech-
niques, also paving the way to precision medicine in a considerable number of
patients.
#2708 A custom gene expression panel for consensus molecular subtype
classifıcationof archival primary andmetastatic colorectal cancers.Ling-Yuh
Huw, Robert Piskol, Felipe de Sosa e Melo, Doris Kim, Xueping Qu, Hartmut
Koeppen, Mark Lackner, Garret Hampton, Omar Kabbarah, Rachel Tam. Ge-
nentech, Inc., South San Francisco, CA.
Stratifıcation of Colorectal Cancer (CRC) into actionable molecular subtypes
has tremendous clinical value. Recently, a consolidated classifıer identifıed four
molecularly distinct CRC subtypes (CMS1-4) that were associated with unique
biology and clinical outcomes based on global transcriptional analysis of frozen
tissues. Here, we developed and applied a novel CRC panel that is ideally suited
for transcriptional classifıcation of archival clinical samples. Findings from in
silico analysis demonstrated that the 800 genes on our panel could accurately
classify CRC samples from external public datasets into the correct CMS sub-
types. We applied our panel in the analysis of a novel cohort of 312 formalin-
fıxed paraffın-embedded (FFPE) tissues from 205 patients, and were able to
detect all 4 CMS subtypes in primary CRCs and in metastases. When we exam-
ined the CMS subtypes of primary tumors and matched metastases from 50
patients we found 70% of cases to be concordant, as were key biologies, such as
WNT/MYC pathway activation in CMS2 and EMT features in tumors of the
CMS4 subtypes. This was confırmed by in situ hybridization (ISH) using the
markers ASCL2 for CMS2 and SPARC for CMS4, respectively. Discordance in
the CMS subtypes between primary tumors and matched metastases were ob-
served in 30%of cases andmay reflect tumor heterogeneity.Our fındings suggest
that our CRC-focused panel many have clinical utility for CMS classifıcation of
FFPE samples, and point to potential risks of using CMS subtypes of primary
tumors to inform clinical decision-making at the metastatic stage in a subset of
patients.
#2709 Evaluation of CD37 expression and binding of AGS67E, an anti-
body-drug conjugate (ADC) against CD37, on white blood cells (WBCs) col-
lected from phase I non-Hodgkin lymphoma (NHL) patients. Sher Karki,1
Hector Avina,1 Jacqueline Lackey,1 Ahmed Sawas,2 Kerry J. Savage,3 Raymond
Perez,4 Ranjana Advani,5 Jasmine Zain,6 Owen A. O’Connor,2 Sara Gulesse-
rian,1 Hui Zhao,1 Peng Yang,1 Karen Morrison,1 Leonard Reyno,1 Fernando
Donate1. 1Agensys Inc., an affıliate of Astellas Pharma, Santa Monica, CA; 2Co-
lumbia University Medical Center, New York, NY; 3British Columbia Cancer
Center, British Columbia, Canada; 4University of Kansas, Kansas City, KS; 5Stan-
ford University, Stanford, CA; 6City of Hope, Duarte, CA.
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AGS67E is an antibody drug conjugate (ADC) against CD37 conjugated to
monomethyl auristatin E (MMAE). CD37 is expressed on normal WBCs, but is
also highly expressed in NHL, CLL and AML (Pereira et al., 2015). A phase I
study is currently evaluating the safety, PK and anti-cancer activity of AGS67E
with orwithout growth factor (GF) in subjectswith relapsed/refractoryNHL. To
assess CD37 expression on WBCs, binding of AGS67E, and potential pharma-
codynamic effects, samples from subjects were collected at pre-dose, D2, D8,
and D15 and analyzed by flow cytometry. CD37 expression on subject tumor
samples was also evaluated by immunohistochemistry (IHC). Our results dem-
onstrated that CD37 was highly expressed in tumor samples and that AGS67E
binds toWBCs causing down-regulation of CD37, achieving saturation of bind-
ing at 24 hours post-treatment (earliest timemeasured) at or above 0.9mg/kg. A
dose-dependent decrease in the number of all cell types examined was observed
with a nadir occurring at D8, with partial or full recovery at D15, except for
neutrophils. NK and T cell counts appeared to be least impacted while neutro-
phils were most affected. B cell counts were extremely low pre-dose for some
patients, presumably from prior therapies. In patients treated at 0.9 mg/kg and
higherwithoutGF, recovery of neutrophils was delayed beyondD15. At doses of
1.2 mg/kg and higher, use of GF resulted in a signifıcant recovery of neutrophils
by D15. The extent of cell count decreases did not correlate to the proportion of
cells expressing CD37. For example, decreases in NK cells, monocytes, and, in
some cases, T cells, were much greater than the proportion of cells expressing
CD37. Furthermore, matureWBCs are unlikely to be affected by AGS67E. This
raises the possibility that the main effect of AGS67E may be on rapidly growing
precursor cells and that cells with low, or no, CD37 expressionmay be impacted
by the membrane permeable MMAE through a by-stander effect. The effect of
AGS67E on neutrophils was investigated in an in vitro assay where hemato-
poietic stem cells were differentiated into neutrophils. Using this method, we
showed that when AGS67C antibody was conjugated to a non-cleavable,
membrane impermeable auristatin (mcMMAF) less cytotoxicity to differen-
tiating neutrophils was observed compared to AGS67E. Previously, we have
shown that neutrophils secrete proteases that can liberate MMAE from
ADCs (Zhao et al, 2016). These results suggest that AGS67E contributes to
neutropenia through a by-stander effect, in addition to the CD37-mediated
internalization of the ADC. In conclusion, the results showed that AGS67E
bound to its target CD37, modulated its expression, achieved saturation of
binding at doses at or above 0.9 mg/kg, and reversibly depleted WBCs, with
the exception of neutrophils for which GF administration appeared to sig-
nifıcantly improve recovery rate.
#2710 Molecular and clinical characteristics of IGHV4-34 expressing clas-
sic and variant HCL. Evgeny Arons, Katherine Potocka, Maryalice Stetler-
Stevenson, Hong Zhou, Mark Raffeld, Mark Sokolsky, Sarah Davies, Robert J.
Kreitman. National Cancer Inst., Bethesda, MD.
Classic hairy cell leukemia (HCLc) is a B-cell malignancy with distinctive
immunophenotype, typically expressing CD20, CD22, CD25, CD11c,
CD103, CD123, annexin A1, tartrate-resistant acid phosphatase (TRAP),
and BRAF V600E mutation. Purine analog therapy is highly effective with
complete remission rates of approximately 85% in fırst line. HCL variant
(HCLv) is recognized as a distinct entity, lacking CD25 and usually lacking
annexin A1, tartrate-resistant acid phosphatase expression, CD123, and also
lacks the BRAF V600E mutation. Patients respond poorly to purine analogs,
with partial response in less than 50% and relatively poor overall survival
from diagnosis. HCLc expressing B-cell receptor (BCR) with the IGHV4-34
immunoglobulin rearrangement has a poor prognosis like HCLv, whether
immunophenotypically consistent with HCLv or HCLc, and also lacks BRAF
V600E. We previously reported a series of 17 patients expressing IGHV4-34,
immunophenotypically resembling HCLc in 7 and HCLv in 10 cases. Using
routine deep sequencing of patient samples for immunoglobulin rearrange-
ments, we have been able to accumulate 42 IGHV4-34 expressing cases in-
cluding 23 classic HCL and 19 HCLv. Six (26%) of 23 HCLc vs 12 (63%) of 19
HCLv were truly unmutated, with VH gene germline identity (GI) 100%.
Eleven (48%) of 23 HCLc and 7 (37%) of 19 HCLv were borderline-mutated
(97GI100), and 6 (26%) of 23 HCLc were signifıcantly mutated (97GI).
There was no signifıcant difference between the 5 groups with respect to
either IGHD or IGHJ genes usage, or CDR3 length. However, we found a
signifıcant restriction of IGHD genes between 12 HCLv truly unmutated and
6 HCLc truly unmutated cases, in that there was no overlap of any IGHD
genes between these 2 groups (p0.0001). Of 28 cases test for BRAF V600E,
only 5 were positive, all HCLc with GI 93.18-97.49%. The 23 BRAF wild-type
(WT) cases included one with only one with GI93.64%, but GI was98.7%
for the remaining 22 cases (p0.0001). Of the 23 BRAFWT cases, 9 patients
died of disease, 9 have active disease, and only 2 are in remission. Patients
commonly had highly aggressive courses, with infıltration of HCLc/HCLv
into spinal cord and cranial nerves, cardiac muscle, lungs, and cervical
lymph nodes. Complete remission was achieved only through either recom-
binant immunotoxin therapy of combination purine analog and rituximab,
but not by purine analogs alone. Additional clinical and genetic studies are
ongoing to better characterize this poor-prognosis syndrome and determine
if therapy can be optimized.
#2711 Whole exome sequencing analyses of colorectal cancers associated
with liver metastasis. Yanlei Ma,1WenhaoWeng,2 Yongzhi Yang,1 QingWei,3
Sanjun Cai1. 1Fudan University Shanghai Cancer Center, Shanghai, China;
2Tongji University, Shanghai, China; 3Shanghai Tenth People’s Hospital, Shang-
hai, China.
Purpose: Liver metastasis is one of the major causes of death in colorectal
cancer (CRC) patients. But the process is still unknown. Here, we analyzed
genetic differences between primary tumors associated with liver metastasis
and those without liver metastasis and predicted clinical signifıcance. Exper-
imental design: Eight primary tumors associated with liver metastasis and
twelve without liver metastasis of CRC were analyzed by whole-exome se-
quencing. The functional characterisation for the role of metastatic-related
genes was investigated through in vitro migration and invasion assays. For
clinical relevance, TMAs were used for immunohistochemistry assay. Re-
sults: The mutation spectrum was similar to that of previous studies. TP53,
APC and KRAS were the three most frequently mutated genes, with no
signifıcant difference of mutation frequency between primary tumors from
patients with liver metastasis and those from other patients. Notably, four
recurrently mutated genes (FBXW7, EDIL3, KCNK9 and PCDHGA7) were
identifıed exclusively in the tumors associated with liver metastasis. Further-
more, in vitro analyses showed that EDIL3 and KCNK9 overexpression re-
sulted in enhanced cell migration and invasion, while CRISPR-mediated
deletion of FBXW7 and PCDHGA7 exhibited enhanced migratory and in-
vasive properties as well. For clinical relevance, highly expressed EDIL3 and
KCNK9 was signifıcantly associated with liver metastasis, whereas the ex-
pression of FBXW7 and PCDHGA7 negatively correlated with it in our
cohorts. Pathway enrichment analysis also indicated a role for cell adhesion
signaling in liver metastasis of CRC patients. Conclusion: Our study identi-
fıed candidate genes, which might response to the initiation of metastasis,
exclusively mutated in tumors associated with liver metastasis. These fınd-
ings also provided potential therapeutic targets for personalized treatment.
#2712 Relationship between CLDN18-ARHGAP fusion gene and clinico-
pathological features of gastric cancer in young adult. Izuma Nakayama, Eiji
Shinozaki, Seiji Sakata, Noriko Yamamoto, Satoko Baba, Kensei Yamaguchi,
Shunji Takahashi, Kengo Takeuchi, TetsuoNoda. Japanese Foundation for Can-
cer Research, Tokyo, Japan.
Introduction: Gastric cancer (GC) in young adults comprises a small part of
this disease population having the distinctive clinicopathological features, such
as diffusive tumor growth and peritoneal dissemination. Genetic alterations
underlying these features and the development of cancer in early ages remain
unclear. Comprehensive molecular analyses by TCGA have suggested 4 molec-
ular subtyping of GC and revealed enrichment of CLDN18-ARHGAP fusion
gene inGenomically stable (GS) type whichmainly included diffuse type. In this
study, we examined the relationship between CLDN18-ARHGAP and clinico-
pathological features of GC affecting young adults. Method: Patients (pts) diag-
nosed at the age younger than 40 years-old were defıned as the GC in young
adults, and underwent surgery at our institute between Jan 2006 and Dec 2015
were enrolled to this study. Tissue microarrays were prepared from formalin-
fıxed and paraffın-embedded surgical specimen. DNAprobes for CLDN18, AR-
HGAP-26 and -6were created using bacterial artifıcial chromosomes and fusion
genes were detected by a FISH method. Results: Out of 155 surgical specimens
available for analysis, we found CLDN18-ARHGAP fusion gene in 21 pts
(13.5%). Among these, 19 cases were CLDN18-ARHGAP26 fusion and the oth-
ers were CLDN18-ARHGAP6. Cancers with CLDN18-ARHGAP fusion genes
were all diagnosed as diffuse type and includedmore large-sized,multiple lymph
node metastases and advanced stages tumors (table 1). The proportion of de-
tected fusion genes in this study was almost equivalent to that of GS type in
TCGA cohort. Analysis of variations of breakpoint is planned to confırm by
RT-PCR and sequencing. Additionally, we are going to study the association of
CLDN18-ARHGAP with RHOA or CDH-1. Conclusion: CLDN18-ARHGAP
fusion gene might account for the characteristic of a part of diffuse type GC.
Further comprehensivemolecular analysis comparing to general GCpopulation
is warranted.
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Patient demographics
positive (n21) negative (n134) p-value
Age 0.646
30 / 30-39 2/19 9/125
Sex 0.482
man/woman 8/13 65/69
Tumor location 0.507
Upper/Middle/Lower 4/10/7 43/53/38
Tumor size (mm) 75.6 64.7 0.117
80/80 9/12 34/100
Borrmann 0.648
Type 2/3/4/others 0/8/3/10 10/38/20/62
Lauren NS
intestinal/diffuse/mixed 0/21/0 5/124/5
T (TNM) 0.479
T1/T2/T3/T4 6/1/4/10 50/18/18/48
N (TNM) 0.044
N1/N2/N3 6/2/2/11 71/12/20/31
Stage (TNM) 0.032
I/2/3/4 7/1/5/8 57/28/31/18
#2713 The mutational landscape of recurrent and nonrecurrent human
papillomavirus-associated head and neck squamous cell carcinoma. Richard
A. Harbison,1 Mark Kubik,2 Eric Q. Konnick,1 Seok-Geun Lee,3 Michael Kao,1
Michael Mason,4 Thomas Yu,4 Chang Xu,3 Daniel Faden,2 Colin C. Pritchard,1
Cristina P. Rodriguez,1 Chu Chen,3 Justin Guinney,4 Umamaheswar Duvvuri,2
Eduardo Mendez1. 1University of Washington, Seattle, WA; 2University of Pitts-
burgh, Pittsburgh, PA; 3Fred Hutchinson Cancer Research Center, Seattle, WA;
4Sage Bionetworks, Seattle, WA.
Background: Despite the better prognosis for human papillomavirus
(HPV)-associated head and neck squamous cell carcinoma (HNSCC) com-
pared to HPV-negative HNSCC, 10% to 25% of HPV-associated cases recur
within 3 years of completing therapy. We sought to compare the mutational
profıles of primary tumors among recurrent and non-recurrent HPV-asso-
ciated HNSCC. We hypothesized that the mutational profıle of primary tu-
mors from recurrent cases resembles that of HPV-negative HNSCC. Meth-
ods: Sequencing was performed on DNA extracted from the primary tumors
of p16-positive recurrent and non-recurrent HNSCC cases utilizing a high-
coverage (500X), CLIA-certifıed, 262 multiplexed gene sequencing panel
(i.e., UW OncoPlex). Primary tumors from 11 recurrent and 13 non-recur-
rent cases were included in our sample. Mutational differences between the
primary tumors of recurrent and non-recurrent tumors were evaluated. Re-
sults: 88% of patients were male with a mean (standard deviation; SD) age of
60.3 (11) years. Among the recurrent cases, 100% arose from the oropharynx.
Among the non-recurrent cases, 77% arose from the oropharynx with the
remainder originating from the oral cavity, nasal cavity, and larynx. 83% of
patients presented with stage III or higher disease, and the median survival
time was 21 months and 19 months among the recurrent and non-recurrent
cases, respectively. The mean (SD) number of somatic nucleotide variants
per tumor among the recurrent cases was 16.4 (12.2) compared to 4.3 (1.5)
among non-recurrent cases (p  0.05). The ratio of nonsynonymous to
synonymous variants among primary tumors of recurrent cases was 2 vs 5
among the non-recurrent cases (p  0.224). Among primary tumors of re-
current cases, 17% of variants included indels, splice site, and nonsense
mutations vs 14% of variants among the non-recurrent cases. The mean (SD)
number of tumor suppressor mutations per tumor was 1.2 (1.3) among re-
current cases vs 1.0 (1.0) among non-recurrent cases (p  0.81). Interest-
ingly, the mean (SD) number of mutations in DNA damage response (DDR)
genes among the primary tumors of recurrent cases was 2.7 (2.4) compared
to 0.7 (1.2) mutations per tumor among non-recurrent cases (p  0.07).
Conclusion: We observed a greater mutational burden among the primary
tumors of recurrent HPV-associated HNSCC compared to non-recurrent
HNSCC. Moreover, among the primary tumors of recurrent cases, there
were more mutations in DNA damage response genes coupled and relatively
fewer deleterious mutations compared to non-recurrent cases. Dysregula-
tion of DDR genes may select for advantageous mutations via genomic in-
stability. Alternatively, gain of function of DDR genes may promote treat-
ment resistance. Future work aims to further characterize mutational
differences between the primary tumors of HPV-associated recurrent and
non-recurrent HNSCC and evaluate mechanisms promoting treatment re-
sistance.
#2714 Analytical validation of clinical whole genome and transcriptome
sequencing of patient derived tumors: clinical application of whole genome
sequencing for reporting targetable variants in cancer.KazimierzO.Wrzeszc-
zynski,1 Avinash Abhyankar,1 Vanessa Felice,1 Esra Dikoglu,1 Lukasz Kozon,1
Nicolas Robine,1 Anne-Katrin Emde,1 Olca Basturk,2 Umesh K. Bhanot,2 Alex
Kentsis,2 Mahesh Mansukhani,3 Govind Bhagat,3 Vaidehi Jobanputra1. 1New
York Genome Center, New York, NY; 2Memorial Sloan Kettering Cancer Center,
New York, NY; 3Columbia University Medical Center, New York, NY.
Next Generation DNA Sequencing (NGS) technologies are currently be-
ing applied in the clinical setting for the treatment of disease. The goal is to
use high-throughput sequencing to identify specifıc variants within each
tumor and recommend personalized treatment approaches or clinical trials
tailored to the individual’s disease and genomic profıle. These assays are
comprised of either predefıned sequencing panels, where a handpicked set of
clinically signifıcant genes are examined within each patient, or are cancer
type specifıc targeted sequencing protocols or whole exome platforms cov-
ering only the coding region of the patient’s genome. Whole genome se-
quencing allows hypothesis-free interrogation of both coding and non-cod-
ing regions of the genome revealing more potential therapeutic options than
examining a small set of genes or genomic loci. The protocol eliminates
sequence capture related bias observed in whole exome or panel sequencing.
The New York Genome Center therefore has performed analytical validation
of whole genome and transcriptome sequencing (WGTS) of patient derived
tumors and matched normals for the purposes of clinical testing and have
devised a clinical reporting strategy of signifıcant driver and therapeutic
associated mutations. Many clinical NGS guidelines are directed toward
targeted panel or exome sequencing validation. Here, we expanded on New
York State’s Department of Health NGS guidelines developing them into
novel standards applicable to WGTS for the purposes of clinical test valida-
tion. We fırst sequenced a virtual tumor at very high coverage (300x) and
downsampled to determine the optimum depth of sequencing necessary for
high confıdence somatic variant calling across the entire genome. We then
validated whole genome sequencing laboratory protocols for DNA and RNA
sequencing on a total of 50 specimens derived from fresh frozen (FF) and
formalin-fıxed paraffın-embedded (FFPE) tumor samples. We performed a
series of experiments to assess the accuracy and reliability of the results based
on our laboratory and bioinformatics protocols. We performed our valida-
tion on the 50 tumor normal pairs, a subset of which had known genomic
profıles. Comparisons were also made for variant calling concordance and
reproducibility between matched FF and FFPE tumors. Here, we present our
validation results and clinical WGTS standards for depth of sequencing,
reproducibility, sensitivity, and present limit of detection analysis for SNV
calling, copy number identifıcation and structural variants. RNA sequencing
is performed to call fusion or exon skipping events and to confırm the DNA
variants. The New York Genome Center WGTS clinical assay is intended to
provide a more comprehensive patient variant discovery approach suitable
for directed oncological therapeutic applications.
#2715 Precision-designed, rapid and low-cost singlemolecule detectionof
mutations from circulating tumor DNA. Christina M. Wood-Bouwens,1
Christine Handy,2 Billy Lau,2 Hanlee Ji1. 1Stanford University, Stanford, CA;
2Stanford Genome Technology Center, Stanford, CA.
Detecting and quantifying mutations from circulating tumor DNA (ctDNA)
is a new approach for longitudinally monitoring cancer patients throughout the
course of treatment.However, general limitations to the clinical utility of ctDNA
include sample concentration, overall assay cost, and result turnaround time.
We have developed a novel molecular assay that utilize single color digital drop-
let PCR (ddPCR) to both genotype and quantify the number of tumor derived
DNA molecules in a given sample. Our assay routinely detects as few as three
mutant DNAmolecules per a reaction volume, can be tested effıciently for fewer
than ten dollars per reaction, and generates useable mutation information
within four hours. Additionally, the assay can be rapidly confıgured to detect
different mutations specifıcally identifıed in any cancer patient. To demonstrate
the single molecule sensitivity and specifıcity for clinically relevant hotspot mu-
tations, we have validated the assay using multiple input sources including high
quality cell line DNA, formalin-fıxed paraffın embedded tissue (FFPET) DNA,
and ctDNA. Our ddPCR assay utilizes a novel primer design that is not rely on
fluorescent probes. The overall simplicity of assay design enables one to detect
nearly any coding mutation; practically, this means that any cancer or DNA
sample can be tested effıciently.We have created customized precisionmutation
assays for two individual cancer patients. After extracting ctDNA from500L of
plasma we prepare a controlled mixed wild type and mutant standard curves
which contain between 150-3 detectable mutant molecules of interest per reac-
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tion. We then assay the patient ctDNA sample in parallel to the controlled
standard curve and generate clustering confıdence intervals. We have designed
precision mutation assays targeting KRAS A146V, AKT1 E17K, and TP53
R175H for Patient A as well as KRAS G12V and PIK3CAH1047R for Patient B.
The results of our single-color precisionmutation quantifıcation assays support
the original mutation fındings from the primary tumors. In one case, from 1L
of un-amplifıed ctDNA equivalent to less than 0.5ng of DNA, we identifıed 4
mutantmolecules per ddPCR reaction volume.We have verifıed the presence of
hotspotmutations fromun-amplifıed patient derived ctDNA and quantifıed the
number of mutant molecules present in each ctDNA sample. This assay has
many features that make it amenable to automation. We are currently develop-
ing amassively high throughput process to design assays for tens of thousands of
mutations in a matter of weeks. Overall this is an extremely low cost, highly
sensitive and scalable diagnostic technology. We anticipate that this technology
will be a valuable tool for rapidly monitoring ctDNA longitudinally in cancer
patients.
#2716 Amulti-parameter assay for the detection of raremalignant cells in
classicalHodgkin lymphoma.LanceU’Ren,1DavidWu,2 JonathanR. Fromm,2
Jackie Stilwell,1 Eric Kaldjian1. 1RareCyte Inc., Seattle,WA; 2University ofWash-
ington, Seattle, WA.
Background: Classical Hodgkin Lymphoma (CHL) ranks among the most
frequently occurring lymphomas and is marked by Hodgkin and Reed-
Sternberg (HRS) cells, frequently multi-nucleated neoplastic cells that are
derived from germinal center B cells. The genetic alterations involved in the
pathogenesis of this lymphoma have been diffıcult to study because HRS cells
are rare and are surrounded by robust, non-neoplastic infıltrate, therefore
they frequently represent less than 0.1% of cells within involved lymph
nodes. Consequently, methods that isolate these rare cells are required to
understand pathobiology of this lymphoma. We used the AccuCyte® -
CyteFinder® system (RareCyte) to develop a method for detection and iso-
lation of HRS cells. Methods: A 6-parameter immunofluorescence assay was
designed to identify HRS cells that included HRS markers (CD40, CD30,
CD15), CD3, combined CD20/CD14 and a cell membrane permeability vi-
ability dye. The assay was tested using the KMH2 Hodgkin lymphoma cell
line spiked into PBMC and transferred to well slides for imaging by
CyteFinder. This instrument utilizes 6-color scanning microscopy coupled
with predefıned algorithms to identify rare cell populations. The assay was
then applied to a frozen fıne needle aspirate (FNA) sample taken from the
lymph node of a patient with histologically confırmed CHL. The FNA sample
was thawed, prepared into a suspension, stained and analyzed as above. Cells
identifıed with HRS phenotype were individually retrieved using the inte-
grated CytePicker module. PCR of framework regions of the immunoglob-
ulin heavy chain gene (IGH) was performed on single HRS cells (Invivo-
Scribe) to assess clonality. Results: Of 200 KMH2 cells spiked into blood,
the assay identifıed 180 cells (90%) with the correct HRS phenotype. HRS
phenotype cells were identifıed in the patient lymph node FNA sample. Two
individual cells analyzed by IGH framework region PCR demonstrated iden-
tical size PCR products, indicating clonality of the B cell receptor rearrange-
ment. Conclusion: A multi-parameter assay was successfully developed for
identifying rare HRS cells with the CyteFinder system. Cells with HRS phe-
notype in a lymph node FNA sample were demonstrated to have clonal IGH
rearrangements, demonstrating that actual HRS cells were identifıed. This
methodmay be a useful tool for the diagnosis of CHL by identifıcation of rare
HRS cells from FNA specimens, as well as to investigate the molecular
genomics of CHL.
#2717 Identifıcation of three distinct molecular subtypes in meningioma
samples using microarrays for copy-number variants. Josef Srovnal,1 Vladi-
mir Balik,2 Magdalena Houdova Megova,3 Jiri Ehrmann,3 Miroslav Vaverka,2
Lumir Hrabalek,2 Radek Trojanec,3 Katerina Staffova,3 Jana Vrbkova,3 Marian
Hajduch3. 1Palacky University, Olomouc, Czech Republic; 2University Hospital
Olomouc, Olomouc, Czech Republic; 3Palacky University, Faculty of Medicine
and Dentistry, Olomouc, Czech Republic.
Background: Meningioma represents one of the most common intracranial
tumors. They are generally thought to progress from low to high-grade lesions.
However, the molecular mechanisms underlying their pathogenesis remain still
uncertain. Identifıcation of meningioma molecular subgroups may have signif-
icant potential to improve clinical management, through molecular disease risk
stratifıcation strategies and the identifıcation of patients who could benefıt from
targeted molecular therapeutics. Methods and patients: Formalin-fıxed paraffın
embedded tumor samples were obtained from 45 meningioma patients and 5
healthy controls (dura mater). Comprehensive clinical-pathological data were
mined. There were 15 males and 30 females; median age was 54 years, range
28 - 99 years. Total DNA was purifıed from FFPE samples after pathological
verifıcationusing proteinaseK treatment followedbyQIAmpDNAFFPETissue
Kit (Qiagen). Microarray analysis was performed using the OncoScan FFPE
Assay Kit (Affymetrix), raw data were obtained using Chromosome Analysis
Suite (Affymetrix) in default manner. The data were analyzed using “R” soft-
ware, version 3.2.3. Results: Our results confırm that chromosome 22 deletion
and del(1p) are the most common (55%, resp. 47% of cases) deletions inmenin-
gioma.We revealed chromosomal gains not as rare as was published previously
while the dup(3q) was present in 31% of cases. Three meningioma molecular
patterns were identifıed based on CNV profıling - normal-like profıle, deletion
profıle and complex profıle. Deletion profıle was characterized by loss of 1p and
monosomy of chromosomes 6, 10, 14, 18 and 22. The complex profıles com-
bined gains (3q, 8q, chromosomes 12, 15 and 20) and losses (1p, chromosomes
13, 21 and 22). The primary tumor samples of patients with meningioma recur-
rence (20 patients) had different CNV profıle in comparison with patients with-
out recurrence (25 patients). Recurrent tumors had statistically signifıcant
higher frequencies of losses on chromosomes 1, 9, 10, 11, 13 and 21 and gains on
chromosomes 12, 19 and 20. Moreover, we analyzed CNV profıles of paired
tumor samples of 15 recurrent meningioma patients (primary tumor and recur-
rent tumor in each patient). After extraction, it was found, that the most com-
mon alteration in recurrent tumors is chromosome 7q31 and 1p36 gains and
chromosome 15q21 losses. Conclusion: We have identifıed three distinct me-
ningiomamolecular patterns - normal-like profıle, deletion profıle and complex
profıle. Chromosome 22 deletion, del(1p) and dup(3q) are the most common
CNV (55%, 47%, resp. 31% of cases) in meningioma. Potential CNV changes in
recurrent meningioma were identifıed. However, it will require further valida-
tion using FISH. Acknowledgment: This work was fınancially supported by
Ministry of Health of the Czech Republic, grant nr. 15-29021A, IGA UP LF
2016_010 and NPU LO1304.
#2718 Molecular Tumor Board treatment predictions on rare EGFR exon
20mutations.Anthonie J. van derWekken,1MatthewR. Groves,2 Arja ter Elst,1
Nils A. ‘t Hart,1 Lucie B. Hijmering-Kappelle,1 Thijo J. Hiltermann,1 Anke van
den Berg,1 Wim Timens,1 Ed Schuuring,1 Harry J. Groen1. 1University of Gro-
ningen, University Medical Center Groningen, Groningen, Netherlands; 2Univer-
sity of Groningen, Groningen, Netherlands.
Purpose: To evaluate treatment response following theMultidisciplinaryMo-
lecular Tumor Board (MTB) decisions which focused on EGFR exon 20 muta-
tions in lung adenocarcinoma. Methods: Molecular studies were routinely per-
formed using the Ion Torrent sequencing platform for histologically or
cytologically diagnosed lung adenocarcinoma. SinceOctober 2014 patients with
rare (prevalence1%) or combinations of rare mutations were discussed at the
MTB of the University Medical Center Groningen. More common, known sen-
sitive EGFR, BRAF V600E, as well as KRAS, and PIK3CA mutations were ex-
cluded. To predict the best therapy for a subset of patients with EGFR exon 20
insertion mutations the literature is reviewed and molecular models were built
using SWISS-MODEL, is used to predict protein tertiary structure (https://
swissmodel.expasy.org/interactive/wcurbt/models/). Summary of data: Over a
period of 2 years 1389 samples were tested. A total of 170 (12.2%) raremutations
were detected in lung cancer. Among these raremutationswe observed 16EGFR
exon 20 insertions and other mutations like e.g: p.T790M, p.D761N,
p.D770delinsGY, p.S768_D770dup, p.V769_D770insSFL, p.N771_H773dup,
p.T790S. Using an in silico modeling of protein responses with TKI were pre-
dicted to be likely in EGFR T790Mmutations and p.S768_V769delinsIL, but
not in p. D770delinsGY, p.S768_D770dup, p.V769_D770insSFL, and
p.N771_H773dup mutations. Eight patients with an exon 20 mutation were
treated with an EGFR TKI. One patient (p.D761N) had a partial response on
erlotinib 300mg daily. On afatinib monotherapy 2 out of 3 pts had stable
disease (PFS 3-11 months). On afatinib/cetuximab treatment 1 out of 2 pts
(p.D770delinsGY) had a partial response and the other patient had stable
disease (p.S768_D770dup) (PFS 11 and 4 months, resp.). Two evaluable
patients were treated with osimertinib: the fırst patient initially progressed
on afatinib (p.V769_D770insSFL). The protein model predicted no re-
sponse, since we predicted hindrance of osimertinib. The model predicted
no response on osimertinib in the second patient as well, and during treat-
ment a stable disease for 4 months was observed (p.N771_H773dup). This
molecular information from the weekly MTBmeeting was delivered within 2
weeks to the treating physician. Feedback on treatment outcome helped to
further improve treatment predictions. Conclusion: The Molecular Tumor
Board is an effective multidisciplinary team to discuss rare mutations. Our
pilot data show that the evaluation of the use and effectiveness of a theoret-
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ical model concerning protein structures is not possible yet, however, did
provide a clear insight in protein structures in a mutated EGFR receptor
supporting decision making of treatment options.
#2719 Accelerated BRAFmutation analysis using a fully automated PCR
platform improves the management of patients with metastatic melanoma :
MELFAST trial.AlexandreHarlé, Delphine Serre, Julia Salleron,MarieHusson,
Agnès Leroux, Lionnel Geoffrois, Jean-Louis Merlin. Institut de Cancérologie de
Lorraine, Vandoeuvre Les Nancy, France.
Background: Molecular diagnosis has become a standard of care in many
cancers and BRAF mutations analysis in FFPE tumor specimens is needed to
initiate personalized therapy using BRAF tyrosine kinase inhibitor (vemu-
rafenib, dabrafenib) in BRAF-mutatedmetastaticmelanoma.AcceleratedBRAF
mutation analysis is achievable using CE-IVD fully automated (FA) PCR-based
platform (Idylla, Biocartis) and enables the determination of BRAF mutational
status in less than 2 hours including sample preparation and proved suitable for
routine molecular diagnosis of metastatic melanoma (Harlé et al. PloS ONE
11(4); e0153576). Patients and methods: MELFAST trial is an observational
monocentric study aiming at evaluating the clinical impact of reducing BRAF
status determination delay in patients with metastatic melanoma. 40 patients
(pts) were included inMELFAST trial, 31 pts were included retrospectively with
BRAFmutation analysis being performed according to standard operating pro-
cedures (SOP) using conventional PCR, 10 pts were included prospectively with
BRAFmutation analysis being performedusing FA-PCR.Results: Among the 40
pts included, 3 pts were excluded because of violation of inclusion criteria. 37 pts
that were analyzed (29 pts with retrospective inclusion and 8 pts with prospec-
tive inclusion). BRAFmutational status was not known at the time of treatment
decision in 11/29 (38%) pts included retrospectively and in all the pts included
prospectively. Using FA-PCR enables to provide BRAFmutational status within
the same day for most of the samples and the reporting delay was signifıcantly
reduced using FA-PCR as compared to SOP (0 vs 7 days, p0.001) and the delay
of initiation of anti-BRAF therapy was subsequently reduced (16 vs 26 days,
p0.035). This reduced delay was found to be consistent with that observed
when BRAFmutational status had been anticipated and was already available at
the time of treatment line decision (20 days, p0.798). Conclusion: As com-
pared to conventional SOP, using FA-PCR accelerates BRAF mutation analysis
reporting and signifıcantly reduces the delay before initiation of personalized
therapy in pts with metastatic melanoma. This warrants the investigation of the
impact on the patients outcome i.e. progression free and overall survival.
#2720 Association between fıve common polymorphisms of plasminogen
activator inhibitor-1 gene and colorectal cancer risk in Korean population.
Jisu Oh. CHAMedical Center, CHA University, Seongnam, Republic of Korea.
Background: The plasminogen activator inhibitor-1 (PAI-1) is expressed in
many cancer cell types and allows the modulation of cancer growth, invasion,
and angiogenesis. The present study investigated the association between fıve
polymorphisms in PAI-1 gene and colorectal cancer (CRC) risk. Material and
Methods: Genotyping of fıve PAI-1 polymorphisms (844GA [rs2227631],
675 4G/5G [rs1799889], 43GA [rs6092], 9785GA [rs2227694], and
11053TG [rs7242]) was assessed by polymerase chain reaction-restriction
fragment length polymorphism assay in 459 CRC cases and 416 controls. Re-
sults: The increased risk of CRC was found for the PAI-1-675 5G/5G polymor-
phism compared with 4G/4G (AOR1.556; 95% CI, 1.012 to 2.391, p0.044).
In contrast, for the PAI-1 11053 polymorphism, we found a reduced risk of
CRC for GG genotype (AOR0.620; 95% CI, 0.413 to 0.932, p0.022) than TT
genotype, aswell as for recessive carriers (TTTGvs.GG,AOR 0.662; 95%CI,
0.469 to 0.933, p0.019). For patients with age 61 years (AOR 1.942; 95%
CI, 1.247 to 3.024, p0.003), without HTN (AOR 1.694; 95% CI, 1.093 to
2.627, p0.019), without DM (AOR 1.464; 95% CI, 1.051 to 2.039, p0.024),
with folate
 3.8ng/mL (AOR 1.449; 95% CI, 1.030 to 2.039, p0.033), with
homocysteine 13.2umol/L (AOR 1.630; 95% CI, 1.163 to 2.285, p0.005),
PAI-I -675 5G/5G genotype was shown increased risk of CRC. For patients with
age  61 years (AOR0.563 ; 95% CI, 0.333 to 0.950, p0.031), with HTN
(AOR0.618 ; 95%CI, 0.382 to 1.001, p0.05), withoutDM(AOR0.633 ; 95%
CI, 0.425 to 0.942, p0.024), with folate 
 3.8ng/mL (AOR0.669 ; 95% CI,
0.448 to 0.999, p0.049), with BMI
 25 (AOR0.420 ; 95% CI, 0.192 to 0.920,
p0.03), however, PAI-1 11053 TGGG genotype was related to protective
effect about CRC. Inmultivariate Cox proportional analysis, compared with the
43 GG genotype,43 AA genotype was associated with poor OS (HR8.551;
95% CI, 1.833 to 39.89; p0.006) and RFS (HR12.71; 95% CI, 1.330 to 121.3;
p0.027).Moreover, OS (HR9.330; 95%CI, 2.043 to 42.61, p0.004) andRFS
(HR11.97; 95% CI, 1.433 to 100; p0.022) were shown in recessive genotype
(GGGA vs. AA). Conclusion: Our results support the relationship between
CRC susceptibility and PAI-1 gene polymorphisms. Our study suggests that the
-675 5G/5G genotype is associated with an increasing CRC development but
11053 GG genotype is vice versa. Additionally, we found evidence that the
43 AA genotypemay be related to unfavorable CRC prognosis. This is the fırst
study to identify an association between fıve PAI-1 polymorphisms and CRC
incidence in the world. Further research into the association between fıbrinoly-
sis and cancer could lead to the discovery of novel drug targets for cancer pre-
vention or treatment.
#2721 Prospective whole exome and whole transcriptome sequencing of
hematologic cancers for biomarker-driven treatment : Preliminary results of
a randomized pragmatic clinical trial. Sanga Kim,1 Ryul Kim,1 Youngil Koh,1
Choong Hyun Sun,2 Hogune Im,2 Hong Seok Yun,2 Dong-Yeop Shin,1 Inho
Kim,1 Sung-soo Yoon1. 1Seoul national university, Seoul, Republic of Korea;
2Samsung SDS, Republic of Korea.
Introduction: Biomarker-driven early clinical trials of molecularly targeted
agents have reported improvement of the response rate in variousmalignancies.
In this pragmatic clinical trial, we aimed to assess whether biomarker-driven
treatment strategy could improve outcomes of incurable hematologic cancer
patients. Methods: This is an open-label, randomized, pragmatic trial in adult
patients with hematologic cancer. Patients with any kind of hematologic cancer
refractory to standard-of-care are eligible. We randomly assigned these patients
to receive a matched molecularly targeted agent (experimental group) or treat-
ment at physician’s choice (control group). Randomizations are determined by
central block randomization in 2:1 ratio. Clinicians and patients are not masked
to allocation. Whole exome and whole transcriptome sequencing (WES/WTS)
are applied for detecting all classes of genomic alterations: single nucleotide
variation (SNV), insertions and deletions (INDEL), copy number alterations,
Fms-Related Tyrosine Kinase 3 (FLT3) internal tandem duplication (ITD),
Mixed-lineage leukemia partial tandem duplication and gene rearrangements.
The primary endpoint is response rate in the intention-to-treat population. Re-
sults: Twenty-three patientswithmedian age of 53 years andmale to female ratio
of 11:12 were enrolled betweenDecember 2015 andOctober 2016; 15 patients in
experimental group, 8 patients in control group. Actionable mutations were
identifıed in four patients in experimental arm. A 78-year-old female with acute
myelogenous leukemia (AML) had FLT3 ITDat exon 14, whichwas identifıed as
a long insertion mutation in SNV/INDEL calling. She received ASP2215 (FLT3
inhibitor), and showed a dramatic reduction in blast counts of peripheral blood.
A 75-year-old female with myelodysplastic syndrome had TSC1P39A mutation.
Because mTOR exists in downstream signaling pathway of TSC1, everolimus
was administered and regression of disease activity, reflected by reduction of
C-reactive protein level, was observed.NOTCH2c.17= andKITD815Vmutation
were identifıed in two patient; 69-year-old female with multiple myeloma and
42-year-old male with AML, respectively. Among 8 patients in control arm,
seven patients received cytotoxic chemotherapy. One undergone another com-
prehensive genomic profıling called FoundationOneHeme, however no action-
able mutations was identifıed. Conclusions: Among patients with incurable he-
matologicmalignancy, actionablemutations could be identifıed in one fourth of
patients for whom WES/WTS were performed. They showed favorable initial
response to molecularly targeted agents. This randomized pragmatic clinical
trial is currently ongoing(NCT02758080).
#2722 Next generation targeted sequencing reveals four unknown muta-
tions in the Mexican population with Gorlin syndrome. Fragoso Veronica,1
Natalia Espinosa,2 Julieta Dominguez,1 Felipe Vaca-Paniagua,1 Luis A. Her-
rera,1 Rosa M. Alvarez1. 1Instituto Nacional de Cancerología, Mexico City, Mex-
ico; 2Centro Dermatológico Pascua, Mexico City, Mexico.
Aim: Nevoid Basal Cell Carcinoma Syndrome (NBCCS), an autosomal dom-
inant disorder, is characterized by the presence of a variety of developmental
anomalies, and predisposition to multiple basal cell carcinomas (BCCs), and
other neoplasias. NBCCSmainly results fromgerminalmutations in the PTCH1
gene, that encodes a transmembrane glycoprotein, component of the hedgehog
signalling pathway. The incidence of NBCCS in general population is estimated
at 1 in 150000. Data related to NBCCS inMexican patients is reduced to clinical
case reports, without molecular testing. Therefore, we conducted next-genera-
tion sequencing (NGS) of PTCH1, in 9 Mexican patients with diagnosis of NB-
CCS. Material and methods: NGS of PTCH1 was performed, in the context of a
hereditary cancer gene panel. The PTCH1 regions with insuffıcient coverage
(30 read depth), were complemented by Sanger sequencing, to ensure 100%
coverage of the gene. In-silico analysis was perfomed for missenses mutations.
The identifıed pathogenic mutations were verifıed by capillary sequencing. Re-
sults: Targeted analysis of PTCH1 gene, looking for deletions, insertions, splice-
site alterations, nonsense and missense mutations, was done. Four PTCH1
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mutations (4/9) were identifıed: a deletion (c.1044delG); one insertion
(c.631dupA); a non-sense mutation (c.3406GT), and a missense mutation
(c.1488CA). None of the mutations had been previously reported. Conclu-
sions : NGS of PTCH1 gene in 9 Mexican patients with clinical criteria for
NBCCS allowed the identifıcation of four novel pathogenic mutations (44%
frequency). This is the fırst molecular overview of PTCH1 in NBCCS patients of
our population. The perspectives of the current study lie in themolecular testing
of other genes involved in NBCCS (PTCH2, SUFU), and other mechanisms
(whole gene deletion), as well as the review of possible phenotype-genotype
correlations.
#2723 MET exon 14 skipping mutations in advanced non-small cell lung
cancer (NSCLC) are not associated with MET amplifıcation and overexpres-
sion.AnaGimenez-Capitan,1 Cristina Teixidó,1 CristinaAguado,1 Sonia Rodrí-
guez,1 Jordi Bertran-Alamillo,1 Josep Castellví,1 Zaira Yeste,1 Ana Pérez,1 Rafael
Rosell,2 Miguel Angel Molina-Vila1. 1Pangaea Oncology, Barcelona, Spain; 2In-
stitut Català d’ Oncologia, Badalona, Spain.
Background: Activating alterations of the mesenchymal epithelial transition
(MET) oncogene inNSCLC are potentially actionable with targetedMET inhib-
itors.MET exon 14 skippingmutations have been described in 3%of patients (p)
in NSCLC,.Fluorescent in situ hybridization (FISH) and immunohistochemis-
try (IHC) are currently used for detecting MET amplifıcation and overexpres-
sion, respectively, but are not useful to detect MET splicing variants. On the
other hand, the reverse transcription-polymerase chain reaction (RT-PCR)
technique has the potential to detect this actionable alteration. Methods: We
designed and validated a custom set of 5´and 3´ primers to detect theMET exon
14 splicing variant by RT-PCR. RNA isolation from FFPE samples was per-
formed with Roche High Pure FFPET RNA isolation kit and M-MLV Reverse
Transcriptase enzyme was used in the RT-PCR. A panel of cell lines was initially
employed to assess the performance of the technique. Subsequently, a total of
232 formalin-fıxed paraffın-embedded (FFPE) samples from advanced NSCLC
patients were analyzed. Of them, 15 were positive by RT-PCR (n209) for the
MET exon 14 variant. The bands corresponding to the splicing variant were
submitted to Sanger sequencing. Results were comparedwith FISH (ZytoVision
Dual Color probeZ-2087-200) and IHC (VentanaCONFIRManti-Total c-MET
(SP44)). Results: A total of 232 EGFR-wt advanced NSCLC p were analyzed by
IHC and 42 (18.1%) were considered as positive (cut-off 3
 50%). Regarding
FISH,MET amplifıcation was detected in 13 out of 58 p (22.4%) evaluable while
the MET exon 14 skipping variant was detected in 15 (7.2%) out of 209 p.
Unexpectedly, only three (21.4%) of the positive MET exon 14 skipping p by
RT-PCRwere positive for IHC. Finally, of the 15MET exon 14 positive p, 5 were
evaluable for FISH and none of them were positive for MET amplifıcation.
Conclusion: In our cohort of 232 EGFR-wt, advanced NSCLC p, the MET exon
14 skipping mutation had an incidence of 7.2% No correlation was found be-
tween the presence of the MET exon 14 variant by RT-PCR and MET overex-
pression or amplifıcation. Detection of MET exon 14 alterations poses a chal-
lenge for diagnostic testing.
#2724 Brush biopsy miRNA based OSCC detection and diagnosis.Guy R.
Adami,1 Joel L. Schwartz,1 Yalu Zhou,1 Jessica L. Tang,1 Michael Markiewicz,1
Gina D. Jefferson,1 Joel Epstein,2 Antonia Kolokythas3. 1Univ. of Illinois at Chi-
cago, Chicago, IL; 2Cedars-Sinai Medical Center, Los Angeles, CA; 3University of
Rochester Medical Center, Chicago, IL.
RNA based diagnosis and prognosis of squamous cell carcinoma has been
slow to come to the clinic. Improvements in RNAmeasurement, statistical eval-
uation, and sample preservation still have not made these methods accurate
enough to allow truly independent external validation. We propose that in the
case of squamous cell carcinoma of the oral cavity that a chief source of variabil-
ity is sample dissection which leads to variable amounts of stromamixed in with
tumor epithelium. We have used brush biopsy of suspicious lesions to charac-
terizemiRNAexpression inOSCC epithelium.Weused it to show an 11miRNA
signature for OSCC that can differentiate OSCC in both smokers and never
smokers from normal tissue. We will report on efforts to optimize this classifıer
to distinguish OSCC from benign oral lesions such as lichen planus and leuko-
plakia that can be mistaken for OSCC.We also provide evidence that body fluid
samples show similar changes in RNAswithOSCC that are seen in brush biopsy
samples -suggesting much of the RNA is coming from the same source tumor
epithelium. Finally, using a variation of mirPath designed to eliminate false
positive, we have identifıed the neurotrophin signaling pathway as disregulated
in most OSCC epithelium, and for the fırst time highlight the miRNAs that may
control this pathway in OSCC, miR-486-5p, miR-7-5p, miR-146-5p, miR-101-
3p, miR-18b-5p, miR-10b-5p, miR-21-5p, miR-20b-5p, miR-126-3p and miR-
31-5p.
#2725 Circulating CD9-GFAP-survivin exosomes during active specifıc
immunotherapy, a potential biomarker for glioma.Michael J. Ciesielski, Phil-
lip Galbo, Sheila Figel, Laura Wiltsie, Cheryl Frank, Jingxin Qiu, Robert A.
Fenstermaker. Roswell Park Cancer Inst., Buffalo, NY.
Background: We evaluated circulating exosomes isolated from the serum
of malignant glioma patients enrolled in a completed phase I clinical trial of
an anti-survivin vaccine (SurVaxM). Exosomes are microvesicular bodies
with potential mechanisms for cell-cell communication. Identifying circu-
lating exosomes from cancer patients as potential indicators of disease status
and response to therapy is of interest. The inhibitor of apoptosis protein
(IAP) survivin (SVN) promotes cancer cell proliferation and resistance to
chemotherapy. Survivin is expressed in many cancer types including malig-
nant gliomas and is a potential target for active immunotherapy. In the above
mentioned clinical trial, fıve patients experienced early tumor progression
with a mean of 2.8 months (1.9-5.4 months) from study entry, while three
patients had either late (20.5-22.5 months) or no tumor progression (no
evident disease at 48 months in one patient). Methods: To determine
whether changes in CD9/GFAP/SVN exosomes correlated with dis-
ease progression, patient serum was evaluated prior to treatment (study
entry), 8-10 weeks after initial vaccination, and at the time of MRI-defıned
tumor progression. By employing ImageStream flow cytometry technology
we were able to analyze multiple markers on individual exosomes, identify-
ing highly specifıc populations of survivin exosomes which co-expressed
the brain/tumor marker protein GFAP. The combination of these markers
made it possible to differentiate patient exosomes from those of healthy
individuals. Results: The levels of CD9/GFAP, CD9/SVN, and
CD9/GFAP/SVN (SVN) exosomes were signifıcantly increased in
patients. Serum from three patients who experienced the longest progres-
sion-free intervals, showed 98-99% decreases in SVN exosomes after treat-
ment with SurVaxM, and maintained similarly low exosome levels over sev-
eral months. Five early progressing patients experienced a detectable
persistence of, or increase in SVN exosomes at 9 weeks following initial
vaccination. One patient had rising SVN exosomes detectable 16 weeks
prior to the discovery of tumor progression by brain MRI scan. One patient
with no tumor progression sustained a 99% reduction in serum SVN exo-
somes which was sustained over 48 months. Conclusion: This study dem-
onstrates that increased numbers of CD9/GFAP/SVN specifıc exo-
somes appear to be associated with early tumor progression in recurrent
malignant glioma patients. Larger studies are needed to determine whether
the correlation between SVN exosome levels and disease progression is
specifıc to SurVaxM treatment, and whether rises in SVN exosomes levels
are predictive of generalized glioma progression. Our study suggests that
levels of circulating SVN exosomes may be altered during anti-survivin
immunotherapy and could serve as a potential biomarker for clinical trials
and tumor monitoring.
#2726 Guidance by molecular selection improves the outcome of early
phase treatment for gynecological (GYN) cancers. Rowan E. Miller,1 Michael
John Devlin,1 Nicholas Brown,1 Kin Woo,1 Tami Grunewald,2 Arran Speirs,1
Miriam Mitchison,2 Michelle Lockley,2 Mary McCormack,2 Jonathan Leder-
mann,2 Martin Forster,1 Tim Meyer,1 Rebecca Kristeleit1. 1NIHR Clinical Re-
search Facility, University College London Hospitals, London, United Kingdom;
2University College London Hospitals, London, United Kingdom.
Background: Patients (pts) with advanced gynecological (GYN) cancers have
limited therapeutic options and the prognosis is poor. Early phase trials may be
a suitable option for pts with good performance status. Increasingly, molecular
characterisation guides pt selection for early phase trials. We sought to deter-
mine the outcome of GYN pts treated in a phase 1 unit and examined the role of
molecular selection to inform therapeutic decision making. Methods: Medical
records of all pts with a GYN malignancy treated within an early phase trial
between 2010 and 2016 were reviewed. Data comprising patient and tumor
characteristics, prior treatment, trial therapy and outcome were analysed. Re-
sults: 81 pts with a median age of 60 years (range 20-75) with a diagnosis of
ovarian (OC, 54), endometrial (EC, 15) or cervical/vulval (CC, 12) cancer were
identifıed. The median number of prior therapies for advanced disease was 3
(OC) and 2 (EC and CC) (overall range 1-6). 9 pts (11%) entered a second and 1
pt a third phase 1 study on disease progression. Next Generation Sequencing
(NGS) using a targeted panel was performed in 32 pts (40%) with an actionable
mutation identifıed in 9 including; KRAS (3pts), PIK3CA (2pts) and EGFR
(2pts). Germline BRCA (gBRCA) testing was performed in 35 OC pts (65%)
with 24 gBRCA mutations identifıed. Pts were allocated, in order of priority,
where available, to (1) a trial selected on the basis of NGS or gBRCA (’genomic’
35%), (2) a ‘tumor specifıc’ cohort within an early phase trial (15%) or (3) a
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’generic’ study (51%). For the whole cohort there was an overall response rate
(ORR) of 18%with 41% stable disease (SD) andmedian progression free survival
(PFS) and overall survival (OS) of 13 and 46 weeks respectively. Outcomes were
best for pts in the genomic group. Both PFS and OS were signifıcantly longer
with genomic selection (p 0.01 for both, Mantel-cox test) with median PFS of
29.7, 14.2, 8.0 weeks and OS of 84.1, 69.7, 33.6 weeks for genomics, tumor
specifıc and generic studies respectively. The ORR was also greatest for the
genomic cohort (32%) compared to the tumour specifıc (7%) and generic (11%)
groups.Within the heavily pre-treated EC andCC cohorts there was anOS of 30
and 42 weeks respectively. 24% of EC pts had an ORR with a further 24% with
stable disease (SD). There was only 1 response (9%) in the CC cohort, however
SD was seen in 64%. The OS for the OC was 55 weeks with an ORR of 20% and
46% SD. Conclusions: Early phase trials represent a good option for pts with
advanced GYN malignancies. Whilst applicable to all GYN cancers, this is par-
ticularly relevant for EC and CC pts as standard treatment options are limited.
For OC patients (median 3 prior lines of chemotherapy in this cohort) where
standard treatment options exist, early access to phase 1 genomic trials may
result in improved response rates and allow further standard options to be given
subsequently. NGS is feasible in real time and may have a positive impact on
outcome.
#2727 Clinical signifıcance of PTEN inUTUC. Liang-Chen Li,1Hung-Ying
Chiang,1 Ying-Tzu Chen,1 See-Tong Pang,2WenHuiWeng*1. 1National Taipei
University of Technology, Taipei, Taiwan; 2Chang Gung Medical Foundation,
Taoyuan, Taiwan.
Upper tract urothelial carcinoma (UTUC) is a rare malignancy accounts
for about 5% of all urothelial tumours. The cancer cells start in the layer of
tissue urothelium, and found in the renal pelvis, renal calyces or ureters.
When compare the UTUC to the bladder urothelial carcinoma, the patho-
logical and clinical fındings are often look and act alike. Previous studies
indicated that deletion of phosphatase and tensin homologue (PTEN) gene is
common to be found in bladder cancer. As known tumor suppressor gene
PTEN is located on chromosome ten and considered as an important nega-
tive regulator for the PIP3/Akt signaling pathway to promote cell prolifera-
tion and inhibit apoptosis. Thus, this study we aimed to determine clinical
signifıcance of PTEN in UTUC. We collected sixty-eight formalin-fıxed par-
affın-embedded (FFPE) UTUC samples, the tumor stage was according to
American Joint Committee on Cancer (AJCC) with Ta (n15), T1 (n11),
T2 (n10), T3 (n18), T4 (n7) and seven patients with unknown; in
which male no.32, female no.36; the median age is 68 y/o (range 40-85 y/o).
Fluorescence in situ hybridization (FISH) was performed to exam the PTEN
gene copy number or gene structure alterations of UTUC; besides, immuno-
histochemistry (IHC) analysis were used to observe the PTEN protein ex-
pression in the tumor. Our results showed PTENmutations were observed in
twenty-two tumors with heterozygous PTEN deletion; one tumor with ho-
mozygous PTEN deletion, and three tumors with PTEN monosomy. Fur-
ther, heterozygous PTEN deletion was shown signifıcantly associated with
stage of pTa, pT1 and pT2 (P0.048) and history of smoking (P0.030). The
IHC results showed lower expression level was common to be observed in the
tumor area. Our fındings suggest loss of PTEN is associated with the low-risk
group of UTUC but not the high-risk group, the unknown mechanisms
between these two subtypes might be existed. Besides, smoking could also as
a factor highly emerge from genetic alterations in UTUC. In conclusion,
PTEN genomic loss might act a predictive indicator of classifıcation of
UTUC, however, the clinical treatment could be different due to the under-
lying diversity of the molecular activities.
#2728 Frequency and prognostic value of PI3KCA mutations in early
stage of colorectal cancer in Mexican patients. Erika Ruiz-Garcia,1 Alette Or-
tega,1 Antonio Bahena,1 Edith Fernandez,1 German Calderillo,1 Cesar Lopez
Camarillo,2 Laurence Marchat,3 Jorge Guadarrama,1 Abelardo Meneses-Gar-
cia,1 Horacio Astudillo-de la Vega4. 1National Cancer Institute, Mexico City,
Mexico; 2Universidad Autónoma de la Ciudad de México, Mexico City, Mexico;
3Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional,
Mexico City, Mexico; 4Lab Investigacion Traslacional en Cancer, HOCMN SXXI,
IMSS, Mexico City, Mexico.
Background: There are molecular associations between mutated profıles and
microsatelital instability, both related with tumor growth and oncogenic devel-
opment by activating tyrosine receptors families in colorectal cancer (CRC). It is
known that exon 9 and exon 20 (H1047R)mutations in PIK3CA increased PI3K
activity. Moreover, PIK3CA mutations are signifıcantly associated with tumor
recurrence and poor overall survival. The frequency of PIK3CA mutations in
CCRoccurs in 15-20%, being the catalytic subunitmore frequently affected. The
aim of our study was to investigate the frequencies and clinical implications of
these genetic alterations in advanced CRC. Methods: Retrospectively, we ana-
lyzed the initial paraffın embedded tissue block of 71Mexican patientswithCCR
stage II. We evaluated mutations frequency of PIK3CA exon 9 (E542K, E545K)
and exon 20 (H1047R) using qBiomarker Somatic Mutation PCR for real-time
PCR-based. These methodology increases specifıcity, multiplex PCR and allelic
discrimination. The data analysis was done using Ct values and Analysis Web-
portal. Results: We found in our population a frequency of PIK3CA mutations
of 26%.Of those, doublemutants were present in 7%with a higher frequency for
E545K/H1047R. Clinical implication that we found is that any active mutation
of PIK3CA is associated to an increase of recurrence risk (HR 1.86;CI 95%0.46-
7.5), but most important is for E545K mutation (HR 4.17; CI 95% 0.85-20.39),
meanwhile comparing nomutatedwithH1074Rmutated samples there were no
differences in HR (0.53 vs. 0.60, respectively). Conclusions: We found a higher
number of PI3KCA mutations that literature reports and that E545K mutation
have a worst prognostic implication but we need to increase our sample looking
for statistical signifıcance results. Data fromH1047Rmutation raise de hypoth-
esis that it could exist a compensatory mechanism related to structural interac-
tions between both helicoidal and catalitic domains.
#2729 A signifıcant differential sensitivity to AKT inhibitors GSK690693
and MK-2206 2HI was identifıed in primary cells established from a low-
grade mucoepidermoid carcinoma. Ahmad M. Alamri, Priscilla A. Furth.
Georgetown University, Washington, DC.
TheAKTpathway is frequently activated in cancer cells and is a defıned target
for therapeutic intervention.Methods: RNA expression levels of candidate AKT
pathway genes (AREG, EGFR, AKT, mTOR, GSK3/) were defıned following
RNAseq of replicate primary cell cultures (GUMC220 and GUMC221), which
were established independently from two areas of the same low-grade salivary
mucoepidermoid carcinoma (MEC). Protein expression and phosphorylation
levels of the corresponding gene products were characterized using immunohis-
tochemistry on FFPE sections from the original patient tumor, cell pellets, and
cell line generated patient-derived xenografts and through western blotting of
proteins extracted from cells grown under different culture conditions before
and after treatment with AKT inhibitors GSK690693 (ATP-competitive) and
MK-2206 2HCl (allosteric inhibitor). The effects of GSK690693 and MK-2206
2HCl on cell viability were tested at different concentrations ranging from 1.2-
40M in 2D and 3D conditions with three different culture media (Conditional
media ROCK kinase inhibitor Y27632, conditional media without Y27632,
andEpiCult-CBasalTM) usingCellTiter-GloTM.Doxorubicinwas used as a com-
parative control for evaluating the impact of a chemotherapeutic on cell viability
and DMSO as a negative vehicle control. MDA-MB-453 cells were tested as a
positive control for MK-2206 2HCl and GSK690693 sensitivity. Results: Repli-
cate primary cell cultures showed the same chemosensitivity results. MK-2206
2HCl induced a signifıcantly greater reduction in cell viability as compared to
GSK690693 in the MEC primary cells. This differential response was repli-
cated in all three 2D culture medias tested (GUMC220_CMY p0.0017,
GUMC220_CM p0.0004, GUMC220_EpiC p0.0001, GUMC221_CMY
p0.0010, GUMC221_CM p0.0001, and GUMC221_EpiC p0.0041, One-
way ANOVA) with the same pattern reproduced in 3D cultures. Expected
changes in levels of p-AKT(Ser473), GSK3/, p-GSK3/, and p-mTORwere
found following treatment with both drugs as compared to vehicle controls. In
MK-2206 2HCl treated cells, expression levels were all reduced whereas in
GSK690693 treated cells, p-AKT(Ser473), p-AKT(Thr308) were increased and
GSK3/, p-GSK3/, p-mTOR reduced. Conclusion: Characterization of pri-
mary cell cultures using RNAseq led to the identifıcation of a potentially drug-
gable pathway. Direct testing revealed a differential response to the two AKT
inhibitors evaluated. Although the two primary cell cultures were established
from two geographically distinct areas of the same tumor, response to drug
testing was the same and reproducible across different culture modalities. Stud-
ies establish the feasibility of deriving primary cells for drug testing and person-
alized therapy, even from small tumors.
#2730 Image-based single cell-sorting to separate and recover distinct cell
populations from complex heterogeneousmixed tissue: precise sample prep-
aration upstream of FISH. Amanda Gerber,1 Aditi Khurana,2 Lisa Koenig,3
Lindsay Strotoman,4 Lori Millner,4 Valeria Sero,1 Chiara Bolognesi,5 Sabine
Kasimir-bauer,3 Gianni Medoro,5 Matthew Moore,2 Philip Cotter,2 Nicolo
Manaresi,5 Farideh Bischoff1. 1Menarini Silicon Biosystems Inc, San Diego, CA;
2Research Dx, Irvine, CA; 3Universitätsklinikum Essen, Essen, Germany; 4PGXL
Laboratories, Louisville, KY; 5Menarini Silicon Biosystems SpA, Bologna, Italy.
Fluorescent in SituHybridization (FISH) is commonly used for assessment of
chromosomal alterations. Guidelines for determining FISH-based classifıcation
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of clinical biomarkers exist but are based on pre-analytical factors, including
fıxation/sectioning/thickness/age, that can greatly influence biomarker status
determination.Here,weuse single-cell image-basedcell sortingbyDEPArrayTM for
the separation and recovery of pure distinct cell populations prior to FISH.
Methods: A multi-center study to evaluate HER2-FISH based analysis on FFPE
with and without DEPArrayTM pre-processing was conducted using breast tu-
mors classifıed as infıltrating ductal carcinoma (n12), metastatic (n1) and
ductal carcinoma (n1). From each block, four 50-micron thick curls were
sectioned. One curl from each sample was sent to each of four centers (3 US; 1
EU). Each site performed disassociation of curls to generate a single cell suspen-
sion. Cells were then stained and sorted using the DEPArrayTM platform for
recovery of tumor (cytokeratin/vimentin-/DAPI) and stromal (cytokera-
tin-/vimentin/DAPI) cells. Dual-probe FISH for HER2 and centromere 17
was performed on the sorted cells and compared with conventional tissue sec-
tion FISH. Results: Overall,
 90% concordance between the sorted tumor cells
and the conventional HER2 FISH result was observed. Among the 7 HER2
cases, HER2 ratio scores for the sorted tumor cells ranged slightly higher, from
2.60 to 8.95, as compared to the conventional method (from 2.10 to 5.14). In all
cases in which stromal cells were also recovered, an expected normal ratio was
observed, thus verifying that the populations were effıciently separated. Discor-
dance can be attributed to intra-tumoral heterogeneity and the fact that conven-
tional FISH on FFPE requires only a 4-micron section for analysis. Conclusion:
Today, a percentage of patients are likely misclassifıed for the biomarker of
interest as result of pre-analytical factors. We demonstrate here the ability to
overcome these pre-analytic factors and ultimately improve the accuracy in
determining biomarker status using the DEPArrayTM.
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#2731 Identifying circulating tumor DNA in patients with osteosarcoma.
David M. Barris, Michael Fremed, Robert Durbin, Xusheng Zhang, Sajida Pip-
erdi, Wendong Zhang, Shahina Maqbool, Jonathan Gill, Michael Roth, Bang
Hoang, David Geller, Richard Gorlick, Daniel Weiser. Albert Einstein College of
Medicine, Bronx, NY.
Introduction: Osteosarcoma (OS) is the most common primary malignant
bone tumor and primarily affects children and adolescents. During and after
treatment there is no non-invasive test to assess disease response and early re-
lapse. We hypothesize that circulating tumor DNA (ctDNA) can be used to
assess tumor burden, evaluate response to treatment, and monitor for recur-
rence in OS. We effectively tested this hypothesis on a mouse model and have
utilized our methods on a fırst cohort of human patients. Materials and Meth-
ods: Twenty blood sampleswithmatched primary tumormaterial were obtained
from 10 patients with OS who were at various stages of treatment or post treat-
ment. Cell free DNA was isolated from blood collected in Cell-Free DNA blood
collection tubes using the QIamp Circulating Nucleic Acid kit. We performed
massively parallel sequencing (MPS) with the Illumina HiSeq 2500 in the Epig-
enomics Shared Facility (ESF) to a depth of at least 800x using custom designed
probes (Roche NimbleGen SeqCap EZ) capturing genes commonly altered in
OS includingTP53, RB1, ATRX,DLG2,MET, PTEN, and SLC19A1.We aligned
the fastq fıles with BWA, called the variants using Varscan and GATK Haplo-
typeCaller, and annotated the variants with SnpEff. Summary of Data: Using an
initial threshold of 2% of variants, ctDNAwas identifıed in two of the patients in
our study. The fırst patient’s sample, collected at the completion of therapy,
contained a missense mutation in the coding exon of DLG2 at position chr11
84027990 (2.07% of reads). This patient has no radiographic evidence of recur-
rent disease 12months after completion of treatment. In a second patient with 4
samples drawn, a mutation was found in the intron region of RB1 at position
chr13 48986157. The variant was 0.17% of reads upon completion of therapy,
undectable at 3 months, 2.16% of reads at 6 months, and 1.5% of reads at 9
months. The patient is at high-risk for recurrence but is currently disease-free.
Sequencing and analysis of serially collected patient samples, including from 3
patients with recurrent disease, and primary tumor is ongoing. Conclusions:We
have identifıed pathogenic variants in the cell free DNA of patients with no
radiologic evidence ofOS butwho are at high risk for relapse. This is the fırst step
to utilizing a non-invasive test to assess tumor burden, response to treatment,
and likelihood of recurrence. As part of future work, we will lower the threshold
for calling variants and quantify ctDNA abundance in serially collected samples
from treatment and during surveillance, and correlate the fındings with clinical
outcome.
#2732 Novel methods for enrichment of mutations and differentially
methylated sequences from liquid biopsy genomes. Chen Song, Yibin Liu,
Mariana Fitarelli-Kiehl, Ioannis Ladas, Harvey Mamon, Mike G. Makrigiorgos.
Dana-Farber Cancer Inst., Boston, MA.
Presence of excess unaltered, wild-type DNA providing no information of
biological or clinical valuemay oftenmask rare alterations containing diagnostic
or therapeutic clues for cancer.With the surge of high-throughput technologies
there is a growing demand for removing unaltered DNA over large pools-of-
sequences. Here we present nuclease-assisted minor-allele enrichment with
probe-overlap (NaME-PrO), a single-step approach with broad genome-cover-
age that removes WT-DNA prior to DNA-amplifıcation, following which cur-
rent genomic analysis processes remain unchanged. NaME-PrO employs a dou-
ble-strand-DNA-specifıc nuclease and overlapping oligonucleotide-probes
interrogating multiple DNA targets. Following genomic-DNA denaturation, or
upon partial denaturation, the probes form transient double-stranded regions
with their targets, thereby guiding nuclease digestion to selected sites.Mutations
create mismatches that inhibit digestion, thus subsequent amplifıcation yields
DNAwith alterations enhanced at multiple targets. In this manner,WTDNA at
hundreds or thousands of DNA regions can be digested simultaneously. We
demonstrate several-hundred-foldmultiplexedmutation-enrichment in diverse
human samples on multiple clinically-relevant targets in 50-247-plex reactions.
By adjusting conditions it is possible to sequence mutations down to 0.00003%
abundance, essentially isolating mutated-DNA. Application with targeted re-
sequencing of tumor-circulating DNA (cfDNA) demonstrated detection ofmu-
tations at the 0.01-0.1% levels with few sequence reads. In another adaptation of
the same approach in the fıeld of methylation detection, we developed methyla-
tion-sensitive nuclease-assisted minor allele enrichment, MS-NaME. Aberrant
methylation changes, often present in aminor allelic fraction in clinical samples
such as cfDNA, are potentially powerful prognostic and predictive cancer bio-
markers. DuringMS-NaME, oligonucleotide probes targeting unmethylated se-
quences in bisulfıte-treated DNA generate local double stranded regions result-
ing to digestion of unmethylated targets, and leaving methylated targets intact;
and vice versa. We validated MS-NaME by demonstrating enrichment of pro-
moters from cancer-related genes like RARb2, ATM, MGMT and GSTP1 in
multiplexed 177-plex reactions using dilutions of methylated/unmethylated
DNA as well as clinical lung cancer samples andmatched normal tissue. NaME-
PrO and MS-NaME introduce simple, low-cost, broad genomic coverage pro-
cesses that combine seamlessly with next generation sequencing. This reveals
clinically useful DNA alterations that normally would stay undetectable or re-
quire very high read-depth to be detected. Applications in liquid biopsy-based
diagnostics using circulating DNA will be presented.
#2733 Comparison of copy number aberrations (CNAs) between plasma
cell free DNA (cfDNA) and tissue DNA inmetastatic castrate resistant pros-
tate cancer (mCRPC).Chiang-ChingHuang,1MeijunDu,2 LiguoWang,3 Yen-
chen Lin,1 Hua Huang,1 Liewei Wang,3 Liang Wang,2 Manish Kohli3. 1Univer-
sity of Wisconsin, Milwaukee, Milwaukee, WI; 2Medical College of Wisconsin,
Milwaukee, WI; 3Mayo Clinic, Rochester, MN.
Background: Circulating cell-freeDNA (cfDNA) analysis is emerging as a less
invasive approach to assessing tumor genomic alterations in cancer patients.
Although high concordance has been reported between tumor tissue NGS and
cfDNA in studies investigating specifıc genetic alterations, the fıdelity of cfDNA
to tumor tissue DNA in the global genomic scale is largely unknown. In a cor-
relative study of a prospective clinical trial (NCT# 01953640) conducted in
mCRPC stage patients treated with abiraterone acetate/prednisone (A/P), we
evaluated correlation of genomic CNA in tumor DNA obtained from biopsy of
metastatic lesions andmatched plasma cfDNA.Methods:mCRPCpatients (pts)
underwent two image-guided core biopsies of metastases prior to initiation
of A/P (visit 1, V1) and 12 weeks after treatment (visit 2, V2). At both time
points plasma was obtained at the time of the core biopsies and cfDNA was
extracted using DNA Blood Mini Kit (Qiagen, Valencia, CA). High coverage
(for tumor tissue) and low coverage (for cfDNA) whole genome sequencing
reads were fırst mapped to the human genome hg19. Read counts (RC) from
themapped sequence fıles were then binned into 1Mbwindows. The RC ratio
in each genomic bin was calculated by comparing tumor tissue DNA to
lymphocyte gDNA derived from the same patient, and was further log2
transformed, corrected for GC content, and normalized by CGHnormaliter.
The fully normalized log2 ratios data was subjected to segmentation using
DNAcopy algorithm. Results: Between 05/2013 and 09/2015, 92 patients
(pts) were enrolled of which tissue and plasma NGS data both visits was
available for 18 pts. The correlation of CNAs between tumor tissue and its
cfDNA counterpart ranges from 0.013 to 0.83 for V1 samples, and -0.05 to
0.9 for V2 samples. The decreased correlation in some pairs of samples is
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largely due to low tumor content and heterogeneity in the cfDNA. Although
there is a wide range of correlation, commonly shared CNAs were identifıed
in multiple chromosomal regions, including loss in 8p, gain in 8q and chro-
mosome 5 and X. On the other hand, several genomic regions show incon-
sistent CNAs between tumor tissue and cfDNA among 15 pairs of samples in
which cfDNA have large tumor content. These include: loss in 6q, 1p, 2p, 9q,
11q, 13p, 15p, 20p and gain in 8q and 10p in cfDNA but not in tumor tissue;
marked loss in chromosome 22 and gain in p arm of X chromosome in tumor
tissue but much less evident in cfDNA. Conclusion: High concordance of
CNAs between cfDNA and tumor tissue DNA can be achieved given suffı-
cient tumor content of cfDNA. However, more CNAs can be identifıed in
cfDNA than its tumor tissue counterpart. Our result suggests that cfDNA
NGS is a useful tool to investigate clonal evolution associated with cancer
progression.
#2734 Impact of circulating and tissue biomarkers in patients with meta-
static colorectal cancer treated with fırst-line FOLFOX-aflibercept therapy.
Results of the GERCOR VELVET Phase II Study. Annemilai Tijeras-Ra-
balland,1 Armand de Gramont,1 Marielle Chiron,2 Jean-Baptiste Bachet,3 Thi-
erry Andre,4 Dominique Auby,5 Jerome Desramé,6 Baba-Hamed Nabil,7
Lecaille Cedric,8 Valérie Lebrun,9 Christophe Louvet,10 Annette Larsen,11
Christophe Tournigand,12 Sylvie Benner,1 Malika Attia,13 Aimery de Gra-
mont,14 Franck Bonnetain,15 Benoist Chibaudel14. 1AFR Oncology, Paris,
France; 2Sanofı France, Vitry-sur-Seine, France; 3Salpetriere University Hospital,
Paris, France; 4Saint-Antoine University Hospital, Paris, France; 5Mont de Mar-
san Hospital, Paris, France; 6Jean Mermoz Hospital, Paris, France; 7Saint-Joseph
Hospital, Paris, France; 8Clinique Bordeaux Nord, Paris, France; 9Limoges Uni-
versity Hospital, Paris, France; 10Institut Mutualiste Montsouris, Paris, France;
11Inserm U938-Institut Universitaire de Cancérologie/UPMC, Paris, France;
12Henri Mondor Univeristy Hospital, Paris, France; 13GERCOR group, Paris,
France; 14Institut Hospitalier Franco-britannique, Paris, France; 15Inserm UMR
1098- Besançon University Hospital, Paris, France.
Background: The combination of aflibercept to OPTIMOX (VELVET study)
was evaluated in patients with previously untreated advanced colorectal cancer.
A biomarker program was set-up to explore the expression of several tissue
biomarkers at baseline and circulating biomarkers upon treatment cycles to
identify the best monitoring biomarkers of the treatment strategy. Methods:
VELVET was a prospective, single arm phase II trial. Patient’s plasma samples
were collected at baseline, and during induction therapy at day 1 of the fırst 6
cycles. Circulating biomarkers were analyzed usingmultiplexing immunoassays
(31 biomarkers, 3 panels). Assays were conducted on a Biorad Bioplex platform,
expect for PlGF, VEGF-A and Neuropillin-1 which were assessed using ELISA
assays. Tissue biomarker were analyzed at baseline by IHC, using a BOND-Max
autostainer (Leica biosystems). EGFRmutation status were analyzed using next
generation sequencing. Results: Among 49 patients included in the VELVET
study from May 2013 to May 2014, 44 (90%) patients were evaluable for circu-
lating biomarkers expression. The proportion of patients with tumor response
(CR or PR) was higher in patients with high baseline levels of sVEGFR2, sEGFR,
G-CSF, Prolactin and low baseline levels of VEGFA and MIF. Progression-free
survival (PFS) was higher in patients with low baseline levels of Osteopontin
(HR: 0.53; P0.045) and in patients with high baseline levels of VEGF-C (HR:
0.45; P0.014) and sVEGFR3 (HR: 0.50; P0.045). Overall survival was higher
in patients with high sVEGFR3 (HR: 0.36; P0.030) levels. In both responders
and non-responders, sVEGFR-1 and PlGF dramatically increased upon expo-
sure to aflibercept and remained overexpressed for the all course of induction
therapy. Circulation biomarkersmodulationswill be analyzed upon the 6 cycles.
Tumor tissue biomarker assessment at baseline using IHC and theEGFR path-
way mutations status will be added. Conclusions: Exposure to aflibercept is
associated with an increase of sVEGFR-1 and PlGF at cycle 1. Elevated baseline
expression levels of on-target sVEGFR3 predict favorable outcome in patients
treated with aflibercept.
#2735 Targeted molecular profıling of tumor and matched circulating
tumor DNA in patients with early stage endometrioid type endometrial ad-
enocarcinoma. Ana M. Bolivar, Rajyalakshmi Luthra, Meenakshi Mehrotra,
Wei Chen, Bedia A. Barkoh, PeterHu, Rajesh R. Singh, Russell R. Broaddus.The
University of Texas MD Anderson Cancer Center, Houston, TX.
Endometrioid-type endometrial adenocarcinoma (EEA) is themost common
type of gynecological cancer in the USA and the fourth most common cancer in
women. Contrary to other cancer types, its incidence is rising, likely due to its
tight association with obesity. A major clinical problem for EEA patients pre-
senting with early stage disease is identifying those at risk of recurrence, as
extra-vaginal recurrence is incurable. If these at-risk patients could be identifıed
up-front, they could receive more aggressive surgical treatment and adjuvant
radiation therapy/chemotherapy/targeted therapy to help prevent the develop-
ment of incurable recurrences. The long-term goal of our work is to develop a
blood-based molecular diagnostics platform that can help to identify women
with early stage EEA who are at highest risk for tumor recurrence. To achieve
this goal, we designed a proof-of-principal study to determine if it was possible
to detect common EEA associated mutations in circulating tumor DNA
(ctDNA) of early stage EEA patients. From our previous work, we have shown
that 98% (43/44) of EEA patient’s tumors have somatic mutations in CTNNB1,
KRAS, PTEN, and/or PIK3CA. Using a custom panel designed by Swift Biosci-
ences targeting 30 amplicons in these 4 genes, MiSeq NGS analysis was per-
formed on ctDNA extracted from 3mL of frozen plasma using QIAamp circu-
lating nucleic acid kit and on the matching tumor DNA (tDNA) extracted from
FFPE slides using an Arcturus Pico Pure DNA extraction kit from 33 stage I and
II EEA patients (stages in which tumor is confıned to the uterus). NGS data were
analyzed using a custom bioinformatics pipeline. Using a cutoff of 0.5% allelic
frequency (AF) in the ctDNA and 5% in the tDNA, at least one EEA associated
mutation was detected in both ctDNA and tDNA in 5/33 (15%) of cases. Muta-
tionswithmore than 5%AF in the tumor and 0.02-0.49%AF in the cfDNA (total
coverage250X and variant coverage25) were also detected in another 6/33
patients. Each of these 11 cases was re-sequenced at a higher depth (20,000X),
with comparable results. For the remaining 22 patients at least one EEA associ-
ated mutation was detected only in the tDNA, with no mutation detected in
ctDNA. Primary tumor sizemay play a role in detection ofmutations in ctDNA,
as mean tumor size in the group with mutations in both tDNA and ctDNA was
signifıcantly larger (mean 10.4 cm) compared to the group in which mutations
were only present in tDNA (mean 3.6 cm; p0.005). To improve the analytical
sensitivity in the ctDNA and confırm the current fındings, all cases will be ana-
lyzed using digital droplet PCR. Molecular barcodes will also be incorporated
into our custom panel. In this proof-of-principal study, we have demonstrated
that relevant mutations can be detected in the plasma of a subset of patients
when endometrial carcinomas are confıned to the uterus.
#2736 Adigital droplet PCR assay for the quantitation of androgen recep-
tor and splice variant expression in CTCs from metastatic castration resis-
tant prostate cancer patients. Ada Gjyrezi,1 Giuseppe Galletti,1 Areti Strati,2
Seaho Kim,1 Evi Lianidou,2 David M. Nanus,1 Jun Luo,3 Emmanuel Antonara-
kis,3 Scott T. Tagawa,1 Andrew Armstrong,4 Paraskevi Giannakakou1. 1Weill
Cornell Medicine, New York, NY; 2University of Athens, Athens, Greece; 3John
Hopkins Medicine, Baltimore, MD; 4Duke University School of Medicine, Dur-
ham, NC.
Prostate cancer (PC) is the second leading cause of cancer death inmen in the
US. The aberrant functioning of androgen receptor signaling is the central driv-
ing force behind prostatic tumorigenesis and its transition into metastatic cas-
tration resistant disease. Hence, androgen deprivation therapy (ADT) is the fırst
line of treatment for PC patients. However, many patients progress becoming
resistant to ADT therapy, due to the expression of AR splice variants (AR-Vs),
which lack the ligand binding domain and are constitutively active in the nu-
cleus. Expression of the AR splice variant, AR-v7, in circulating tumor cells
(CTCs) isolated from the blood of PC patients was correlated with resistance to
enzalutamide and abiraterone, which are the next generation AR signaling in-
hibitors in CRPC. Further, there is evidence that AR-Vs may convey cross-
resistance, not only to enzalutamide and abiraterone, but also to taxanes, high-
lighting that their assessment in the clinic may have clinical utility. We
developed a novel, specifıc and highly sensitive assay tomeasure mRNA expres-
sion of the AR full length (AR-FL) and the splice variants ARv7 and ARv567es,
by using Droplet Digital PCR in CTCs isolated from CRPC patients. The ana-
lytical specifıcity of the assay was determined by transfecting cells with plasmids
encoding AR-FL, AR-v7 and AR-v567 and showed that each probe detected
signal only in cells expressing the respective transcript. No signal was detected
against genomic DNA, indicating lack of non-specifıc binding. Also, the assay
detected endogenous expression of AR-FL and AR-v7 in VCAP or 22RV1 cells,
while no variant expression was detected in healthy donor blood. The analytical
sensitivity of the assay was determined in a series of serial dilution experiments
that showed sensitivity down to single cell.We then used this assay to determine
the clinical prevalence and expression pattern of each of these variants in CTCs
from about 200 mCRPC patient samples and blood from 40 healthy donors.
CTCs were enriched by EpCAM- or PSMA-based positive selection or CD45
negative depletion in an antigen-agnosticmanner. AR-FLwas detected in80%
of mCRPC samples irrespective of CTC-enrichment technology. AR-v7 was
expressed in 65% of the samples in which in CTCs were enriched either by
PSMA-positive selection or by negative depletion. In contrast, EpCAM-based
CTC enrichment showed lower AR-v7 expression both in terms of expression
CLINICAL RESEARCH: Liquid Biopsies 2: cfDNA
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 697
levels and prevalence. In addition, CTC enrichment following negative deple-
tion showed that 30% of the samples had higher AR-v7 expression levels as
compared to AR-FL. This expression pattern was not observed in the samples
using EpCAM-based selection. Collectively, these data suggest distinct CTC
subpopulations are present in CRPC patient samples, with differential expres-
sion of AR-Vs that could have important predictive and prognostic implica-
tions.
#2737 Development of a clinically actionable, ultra-sensitive multi-onco-
gene panel compatible with ctDNA testing in urine and plasma. Karena A.
Kosco,1MatthewWiggin,2 Peter J. Croucher,1 David Broemeling,2 ShilohGuer-
rero,1 Laura Mai,2 Kurt Krummel,1 Victoria M. Raymond,1 Mark G. Erlander,1
Andre Marziali,2 Karsten Schmidt1. 1Trovagene, Inc, San Diego, CA; 2Boreal
Genomics, Vancouver, British Columbia, Canada.
Background: Circulating tumorDNA (ctDNA) is rapidly emerging as a viable
alternative to tissue molecular diagnostics for the detection of actionable onco-
genic mutations. In non-small cell lung cancer, identifying the emergence of
EGFR T790M in patients receiving fırst line EGFR tyrosine-kinase inhibitors
(TKIs) is a clinical need. Obtaining a tissue biopsy to determine T790M status is
associatedwith signifıcant cost and patientmorbidity. In a retrospective analysis
of the TIGER-X trial, patients had similar therapeutic response to a 3rd genera-
tion TKI, independent of the sample type positive for T790M; tissue, plasma, or
urine. This indicates that non-invasive urine liquid biopsy is a viable diagnostic
option (Wakelee et al, ASCO, 2016). We report on the expansion of single mu-
tation assays to a multiplex-panel of clinically actionable mutations having an-
alytical properties with similar ultra-sensitive detection. Methods: We previ-
ously developed two next generation sequencing methodologies with high
sensitivity and specifıcity for ctDNA detection: 1) A series of individual ultra-
sensitive ctDNA hotspot assays capable of detecting ultra-short DNA fragments
(31-45 base pairs) and a 0.01% lower limit of detection (LLoD). The short sized
amplicons coupledwithmutant allele enrichment enabled high clinical sensitiv-
ity for plasma and urine ctDNA (Reckamp et al, J Thorac Oncol., 2016) 2) A
multiplex panel using sequence-specifıc synchronous coeffıcient of drag altera-
tion (SCODA) technology that enriches for mutant ctDNA to obtain a LL0D of
0.001%-0.03%, (Pel et al, PNAS, 2009; Kidess et al, Oncotarget, 2015). By com-
bining a multiplex of short amplicons with SCODA enrichment capabilities, we
developed an assay enriched for over 200 clinically actionable driver and resis-
tance mutations within 7 oncogenes. Results: An iterative process was used
to design and optimize primer and enrichment probe length and placement to
produce a panel where mean coverage across hotspot regions was within 2 to
3-fold (read uniformity) and greater than 1,000-fold enrichment of mutant
DNA prior to sequencing. Technical validation was performed utilizing in-
house and commercially available model systems for plasma and urine demon-
stratingmutation detection from inputs ranging fromhundreds to fewer than 10
copies and LLoD as low as 0.001%. Clinical performance evaluation of the newly
developed multiplex assay is ongoing using urine and plasma ctDNA from pa-
tients with advanced cancer. Conclusions: High sensitivity is critical when iden-
tifying targetable driver mutations as well as emergence of resistance mutations
which can inform therapeutic decision making. By combining short amplicon
and mutation enrichment technology, we developed an ultra-sensitive ctDNA
assay for use in sample types with highly degraded and fragmented DNA.
#2738 A commutable circulating tumor DNA (ctDNA) reference mate-
rial. Yves Konigshofer,1 Farol L. Tomson,1 Matthew Ryder,1 Russell Garlick,2
Bharathi Anekella1. 1SeraCare Life Sciences, Inc., Gaithersburg, MD; 2SeraCare
Life Sciences, Inc., Milford, MA.
We developed and assessed a novel ctDNA reference material that was de-
signed with an emphasis on commutability. Possessing qualities that are well-
matched with clinical specimens is critical for a reference material, however
many existing methods of preparing ctDNA analogues result in material that is
not commutable for certain assays. For example, sonication of genomic DNA
yields fragments across a broad range of sizes that must be used at greater input
amounts relative to native cell-free DNA (cfDNA) - even after enzymatic end-
repair to reduce damage. This can affect the utility of the reference material for
assays that depend on the ligation of adapters to double-stranded DNA, such as
many hybrid/capture-based Next Generation Sequencing (NGS) assays. If
higher input amounts are not used, then the LOD and precision of such an assay
may appear substantially poorer than expected. At the same time, sonicated
DNA has been shown to be acceptable for amplicon-based ctDNA assays. We
created commutable ctDNA reference material by starting with genomic DNA
from GM24385 cells and mixing with synthetic variant-containing DNA se-
quences at defıned ratios. The use ofGM24385 cells allows for the comparison of
detected variants against theNISTRM8391 high confıdence variants. The use of
synthetic DNApermits addition of large numbers of different cancer-associated
variants at defıned allele frequencies. Fragmentation was followed by size-selec-
tion in order to obtain ctDNA-like sizes. Additional steps were performed to
increase the amount of output material from the size-selection step. The general
method of preparing the reference material is also compatible with native
cfDNA, such as that isolated from cancer patients. The reference material was
submitted to several testing laboratories along with similar sonicated material.
When tested using hybrid/capture-based assays, variant detection was superior
in the novel reference material compared to sonicated DNA when similar
amounts ofmaterial were used as the input.We therefore conclude that our new
reference material has greatly improved commutability compared to existing
materials composed only of sonicated DNA.
#2739 Low-pass whole genome sequencing detects copy number varia-
tions in circulating tumor DNA. Xiaoji Chen, Jill M. Spoerke, Kathryn Yoh,
Walter C. Darbonne, Ling-Yuh Huw, Steven Gendreau, Shih-Min A. Huang,
Mark R. Lackner. Genentech, South San Francisco, CA.
Circulating tumor DNA (ctDNA) is released from necrotic/apoptotic tu-
mor cells into the bloodstream. Recent studies have demonstrated the value
of using ctDNA as biomarkers in cancer diagnosis, prognosis, and drug
resistance. Unlike local tissue biopsy, ctDNA collection and analysis is non-
invasive, allows continuous monitoring of clonal evolution, and provides an
overview of tumor heterogeneity. Copy number variations (CNVs) play an
important role in cancer biology. However, traditional CNV analyses of
ctDNA using droplet digital PCR (ddPCR) and SNP arrays can only assess a
small number of genes due to the low abundance of ctDNA in the majority of
patient samples. Next generation sequencing (NGS) offers a more effıcient
and high-throughput way to study CNVs in ctDNA. Here, we evaluated the
use of low-pass whole genome sequencing (WGS) in determining CNVs in
ctDNA. In this work, cell-free DNA was isolated from 1-5 ml of plasma from
phase II clinical trial patients with metastatic breast cancer and non-small
cell lung cancer (NSCLC) using the QIAamp Circulating Nucleic Acid Kit
(QIAGEN). DNA yield was determined by ddPCR, with a range from 2-4000
ng. Sequencing libraries were prepared using 2-10 ng DNA by the ThruPLEX
Plasma-Seq Kit (Rubicon Genomics). WGS at 0.1x, 0.25x, 0.5x, and 1x cov-
erage was performed on Illumina NextSeq, and data was analyzed using
Nexus Copy Number software (BioDiscovery). As a reference, we sequenced
DNA from peripheral blood mononuclear cells (PBMCs) of 20 healthy do-
nors at the same coverage. Low-pass WGS was also performed on a subset of
matched tumor tissue samples as comparisons. Our results showed that
WGS of ctDNA at 0.5x coverage was effıcient to identify CNVs. CNVs were
detected in ctDNA from about half of the patients analyzed, and in general
CNVs identifıed in ctDNA matched the ones found in tumor tissue from the
same patient. We also found that CNV patterns from different time points of
the same patients clustered together. With this promising system, we will
present CNV analysis in ctDNA from breast cancer and NSCLC patients
enrolled in phase II clinical trials of the PI3K inhibitor pictilisib. We will
evaluate the ability of the method to classify patients into different sub-
groups, monitor tumor progression, and identify drug resistance mecha-
nisms.
#2740 High-throughput and sensitive quantifıcation of circulating tumor
DNA. Yinghui Guan, Oleg Mayba, Shan Lu, Thomas Sandmann, Younjeong
Choi, Walter Darbonne, Vincent Leveque, Lisa Ryner, Eric Humke, Nga W.
Tam, Sundari Sujathasarma, Anna Cheung, Richard Bourgon, Yulei Wang. Ge-
nentech, A Member of the Roche Group, South San Francisco, CA.
Circulating tumor DNA (ctDNA) has a great potential to serve as non-
invasive biomarkers for monitoring disease progression and treatment re-
sponse. However, its broad clinical applications have been hindered by sen-
sitivity, throughput and complexity of existing ctDNA detection methods.
Here we report an adaptation of a multiplex PCR pre-amplifıcation (Pre-
Amp) into the microfluidic multiplex PCR (MMP-Seq) technology for high-
throughput and sensitive quantitation of ctDNA. We have demonstrated
that PreAmp MMP-Seq enabled sensitive (down to 0.6% allele frequency),
reproducible (R20.97), accurate and quantitative mutation detection from
as low as 1.6 ng DNA input. An Empirical Bayesian Model has been estab-
lished to estimate background error rates for every base of amplicons in the
ctDNA panel using data from 43 normal plasmas. 0.1-0.3% of median error
rates were observed across all positions. 149 longitudinal plasma samples
from 12 ovarian and 10 pancreatic cancer patients of PhI DMUC5754A
anti-MUC16 ADC trials were then profıled using PreAmp MMP-Seq. 79%
(11/14) driver mutations found in tissue samples were also identifıed in
matching baseline plasma samples at frequencies well above estimated error
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rates. Moreover, we found that changes of corresponding ctDNA concentra-
tion in post-treatment plasma samples were correlated with changes in tu-
mor burdens and circulating protein marker levels. In conclusion, theMMP-
seq PreAmp workflow provides an inexpensive, reproducible and flexible
solution for mutation detection in plasma DNA samples.
#2741 Assessing theutility of circulating tumorDNAas a surveillance tool
for sarcomas and Li-Fraumeni syndrome using a pre-clinical model. San-
geetha Paramathas, Nathan Lewis, Tanya Guha, Zainab Motala, David Malkin.
The Hospital for Sick Children, Toronto, Ontario, Canada.
Li-Fraumeni Syndrome (LFS) is a hereditary cancer predisposition syndrome
commonly characterized by the presence of inherited mutations in the tumor
suppressor gene TP53. This leads to an early onset of a wide spectrum of tumors
inmultiple organ systems. Current surveillance protocols for early tumor detec-
tion include biochemical screening, MRI and ultrasound scans, colonoscopy
and mammography (for adults). While early detection is associated with im-
proved survival, the complexity of testing, potential to ‘misdiagnose’ tumors
(false positive/negative) and requirement for multiple imaging modalities
makes clinical surveillance challenging to implement and interpret. Liquid bi-
opsies are a recently described diagnostic and prognostic tool that takes advan-
tage of analyzing circulating tumorDNA- fragmented genomicmaterial that are
released into the blood from dying tumor cells. In this proof-of-principle study,
we use mouse xenograft tumor models to assess the dynamic relationship be-
tween tumor burden and ctDNAconcentrations, aswell as resolve the sensitivity
of capturing the presence of lesions in their earliest stages of growth. Longitudi-
nal analyses of ctDNA from serially collected blood were performed on mice
with xenografts of rhabdomyosarcoma (Rh4 and Rh30), osteosarcoma (HOS)
and non-small cell lung carcinoma (H1975) of both localized and simulated
metastatic tumors.We characterized ctDNAusing droplet digital PCR (ddPCR)
for known gene mutations that were specifıc for the cancer cell lines used. We
observe obvious increases in ctDNA with increased tumor burden and a com-
plete clearance of ctDNA after tumor resection. In addition, using themetastatic
model, we have conducted synchronized imaging and blood-based biopsies to
determine the smallest lesion able to be detected in the blood by ctDNA. These
studies provide the foundation for early tumor detection with ctDNA in Trp53
mutant mice that develop spontaneous tumors analogous to LFS. This model
will help further our understanding on the utility of ctDNA as a surveillance and
diagnostic tool for LFS as well as assess its potential for clinical use.
#2742 Cross-platformcomparisonof four leading technologies for detect-
ing EGFRmutations in circulating tumorDNA fromplasma of patients with
non-small cell lung carcinoma. Ting Xu,1 Xiaozheng Kang,1 Xiaofang You,1
Dai Liang,1 Dequan Tian,1 Wanpu Yan,1 Yongbo Yang,1 Hongchao Xiong,1
Zhen Liang,1 Grace Q. Zhao,2 Shengrong Lin,2 Ke-Neng Chen,1 Guobing Xu1.
1Peking University Cancer Hospital and Institute, Beijing, China; 2AccuraGen,
Menlo Park, CA.
Analysis of circulating tumor DNA (ctDNA) is emerging as a powerful tool
for guiding targeted therapy and monitoring tumor evolution in patients with
non-small cell lung cancer (NSCLC), particularly when fresh tissue biopsy is not
available. This study compared the ability of four leading technology platforms
to detect epidermal growth factor receptor (EGFR) mutations (L858R, exon 19
deletion, T790M and G719X) in ctDNA from NSCLC patients. The platforms
included two amplifıcation refractory mutation systems (cobas-ARMS and
ADx-ARMS), a droplet digital polymerase chain reaction platform (ddPCR) and
a next-generation sequencing platform (Firefly NGS). Fifteen EGFR mutations
across twenty NSCLC patients were identifıed.We observed superior sensitivity
and specifıcity of cobas-ARMS, ddPCR and Firefly NGS platforms, while ADx-
ARMS was only suitable for the qualitative detection of EGFR mutations with
allele frequency higher than 1% in plasma samples. We observed high concor-
dance between the plasma and tissue EGFR mutational profıles for three driver
mutations that are known targets of the fırst generation EGFR-TKI therapy
(L858R, E19-dels, and G719X). Discrepancies between plasma and tissue EGFR
mutational profıling could be attributed to spatial and temporal tumor hetero-
geneity. This pilot study illustrates the promise of ctDNA analysis in the context
of treatment evaluation and drug resistance detection, and results will be vali-
dated in follow-up studies.
#2743 Comparison of enhanced Tagged-Amplicon Sequencing and digi-
tal PCR for circulating tumor DNA analysis in advanced breast cancer. Isaac
Garcia-Murillas,1 Matthew Beanney,1 Michael Epstein,2 Karen Howarth,2 An-
drew Lawson,2 Sarah Hrebien,1 Emma Green,2 Nitzan Rosenfeld,2 Nick
Turner1. 1The Institute of Cancer Research, London, United Kingdom; 2Inivata,
Cambridge, United Kingdom.
Background: Circulating tumor DNA (ctDNA) analysis allows non-invasive
detection of tumor mutations and amplifıcations in advanced breast cancer.
Multiple technologies have been developed to analyse ctDNA and here we com-
pared two leading ctDNA detection technologies, enhanced Tagged-Amplicon
SequencingTM (eTAm-SeqTM) and digital PCR (dPCR) assays, in advanced
breast cancer. Methods: We recruited a cohort of 35 women with advanced
breast cancer, of whom 23 had two separate blood samples taken in a standard
EDTA tube processed immediately or in preservative Streck tubes processed up
to 120 hours after venipuncture. Digital PCR was conducted with assays for
hotspot actionablemutations in 3 known drivers in breast cancer: PIK3CA exon
9 and 20, ESR1 ligand binding domain and AKT1 (c.49GA; p.E17K), and
ctDNA sequencing was conducted with eTAm-Seq method using a 35-gene
panel including cancer hotspots, entire coding regions and copy number vari-
ants (CNVs). Results: Across both assays, 37 mutations were detected in 35
patients, with PIK3CA mutation in 13 patients (37%), ESR1 mutations in 10
patients (29%), and no AKT1 mutations. ESR1 mutations were polyclonal in 8
patients, with ctDNA eTAm-Seq method revealing substantially more diversity
in mutations, with up to 8 individual mutations detected in a patient. There was
96.15% agreement for PIK3CAmutation detection between assays (Kappa 0.89,
95% CI 0.743 to 1.000), 100% agreement for ESR1 mutations (Kappa 1.00, 95%
CI 1.000 to 1.000). There was very high correlation in mutation allele frequency
between eTAm-Seq and dPCR (r0.93, 95%CI 0.86 to 0.96, p0.0001). The
sensitivity and specifıcity for HER2 amplifıcation detection by eTAm-Seq was
100% compared to tumor HER2 status. Comparison of immediate processing
and Streck tubes revealed 97.92% agreement (Kappa 0.95, 95%CI 0.868 to 1.000)
formutation calling. Conclusions: This study demonstrates that ctDNA analysis
using eTAmSeq and dPCR have very high agreement in mutation detection in
patients with advanced breast cancer patients. Streck tubes present a robust
alternative to immediate processing of samples. eTAm-Seq and digital PCRhave
high clinical validity in mutation detection.
#2744 Inter-site comparison of performance of an ultra-sensitive se-
quencing technology for circulating tumor DNA. Stephanie Yaung,1 Alex
Lovejoy,1 Dan Klass,1 Fergal Casey,1 Aruna Arcot,1 Melissa Loyzer,1 William
Chiu,2 Nabil Azhar,2 Sophie Beckert,3 Maria Lange,3 Sandra Siemann,3 Sebas-
tian Froehler,3 Shelly Gunn,2 John F. Palma1. 1Roche Sequencing Solutions,
Pleasanton, CA; 2ResearchDx, Irvine, CA; 3Roche Sequencing Solutions, Potsdam,
Germany.
The combination of liquid biopsies and ultra-sensitive next-generation se-
quencing (NGS) holds tremendous promise in oncology for the detection and
surveillance of somatic mutations that correlate with diagnosis, prognosis, re-
sponse prediction, resistance monitoring and tumor burden. We have devel-
oped a capture-based NGS workflow that provides ultra-sensitive detection of 4
mutation classes - single nucleotide variants (SNVs), insertions/deletions, copy
number amplifıcations (CNAs) and fusions - from low input cell-free DNA
isolated from plasma. Sensitivity and specifıcity of 2 different AVENIO ctDNA
Analysis Kits (for Research Use Only) across 3 sites for 48 samples that included
contrived DNA blends with known mutations validated by digital PCR and
normal reference plasma samples were assessed. TheAVENIO ctDNATargeted
Kit (Targeted) was designed to detect mutations in 17 genes, across 80kb, in-
cluded in NCCN Guidelines for solid tumors plus additional variants relevant
for therapy selection. The AVENIO ctDNA Expanded Kit (Expanded) was de-
signed to detectmutations in 77 genes, across 200kb, associatedwith solid tumor
including variants relevant for clinical trial research. Testing sites achieved 100%
sensitivity for SNVs and fusions at 0.5% and 1% allelic frequency, respectively,
from 30 ng of input DNA for both kits. Median coverage of 4,200-6,400X was
greater with the Targeted kit relative to that of 2,700-3,800X with the Expanded
kit. Specifıcity was 100% for the Targeted kit either by sample or variant. The
Expanded kit had a specifıcity of 91.7-100%by sample and 99.7-100%by variant.
At an expected 5X or 8X copy number amplifıcation formultiple genes, both the
Targeted and Expanded kits were 100% sensitive and 93.1-98.4% specifıc per
gene. The specifıcity for fusion detection was 100% for both kits down to 1%
mutant allele frequency. The AVENIO ctDNA Analysis Kits for plasma and
NGS applications provide exquisite sensitivity and specifıcity for the simultane-
ous detection of 4 different mutation classes.
#2745 Evaluation of a new system for collection, stabilization, and purifı-
cation of circulating tumor DNA. Michael Fleischhacker,1 Bernd Schmidt,2
Rohan Baker,3 Susanne Pedersen,3 Natasha Cant,4 Maryam Zahedi-Nejad,4
Thorsten Voss,5 Andrea Ullius,5 Daniel Groelz5. 1University of Halle, Germany;
2DRK-Kliniken Berlin-Mitte, Germany; 3Clinical Genomics, North Ryde, Austra-
lia; 4QIAGEN Ltd., Manchester, United Kingdom; 5PreAnalytiX GmbH, Hilden,
Germany.
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Introduction: The current preanalytical workflows for circulating tumor
DNA (ctDNA) analysis have limitations that affect the accurate detection and
quantifıcation of these plasma cancer biomarkers. Release of genomic DNA
(gDNA) from white blood cells (WBCs) due to cell lysis or apoptosis during
whole blood storage in EDTA tubes creates higher gDNA background levels,
affecting the sensitivity of ctDNA assays. Current tubes that stabilize WBCs
often contain crosslinking reagents, which have negative effects on sensitive
downstream assays, including methylation-based assays. Using ctDNA assays,
the newPAXgene® Blood ccfDNASystem*, consisting of a blood collection tube
with unique, non-crosslinking chemistry and an automated circulating cell-free
DNA (ccfDNA) extraction kit, was evaluated in three research studies.Methods:
Blood samples were collected into paired PAXgene and EDTA tubes and stored
for 7 days at room temperature (RT). ccfDNA was isolated from plasma using
the PAXgene kit or the QIAGENQIAamp® Circulating Nucleic Acid Kit. Study
1: The ccfDNA from lung cancer patients was quantifıed by real-time PCR for
the amount of the ERV sequence (as a measure of the total plasma DNA quan-
tity) and after bisulfte treatment for mSHOX2 as a marker for ctDNA. Study 2:
Blood from healthy donors was spiked with fragmented, fully-methylated
CpGenome DNA. During storage, tubes were intermittently inverted to simu-
late tubes in transit. Subsequent to bisulfıte conversion, PCR assays targeting
ACTB and methylated BCAT1 and IKZF1 DNA were used to determine the
yields of ccfDNA and ctDNA, respectively. Study 3: Restriction enzyme treated
EGFR DNA containing exon 19 deletions and exon 20 and 21 substitutions
(T790M, L858R) were spiked into healthy donors’ blood. ccfDNA was tested
with the QIAGEN therascreen® EGFR Plasma RGQ PCR Kit*. Results: Both
study 1 and 2 demonstrated constant levels of the methylation ctDNAmarkers,
SHOX2, BCAT1 and IKZF1, over the investigated time course. There was no
signifıcant release of gDNA in the PAXgene tube whereas a signifıcant release of
gDNAwas detected in EDTA samples. Likewise, study 3 showed constant EGFR
Ct values in the PAXgene system with reliable mutation detection, whereas the
high DNA concentration from the EDTA system resulted in false-positive call-
ings. Conclusions: The new system allows researchers to accurately detect and
quantify plasma cancer biomarkers from blood samples that have been stored in
the tube for up to 7 days at RT. This includes challenging assays based onmeth-
ylated ctDNA. The system provides the required assay sensitivity to allow the
correct assay interpretation beyond the typical 3–6 hour storage limit for EDTA
tubes. *For Research Use Only. Not for use in diagnostic procedures.
#2746 Detection of tumor-specifıcmutations in plasmaDNA:A potential
esophageal adenocarcinoma biomarker. Matthew Egyud,1 Jennifer Jackson,1
Emiko Yamada,1 Anders Ståhlberg,2 Paul Krzyzanowski,3 Virginia Litle,1 Lin-
coln Stein,3 Tony Godfrey1. 1Boston Medical Center, Boston, MA; 2University of
Gothenburg, Gothenburg, Sweden; 3Ontario Institute for Cancer Research, On-
tario, Canada.
BACKGROUND: Recent studies have shown that tumor-specifıc DNA from
multiple types of tumors can be detected circulating in plasma and this has raised
the possibility of “liquid biopsies” using mutated tumor DNA as a potential
diagnostic and prognostic biomarker. Detection of mutations with allele fre-
quencies below 0.1% remains challenging however given that circulating cell-
free DNA is highly degraded and in low abundance. Detection of multiple dif-
ferent mutations in the same sample presents an additional challenge
particularly when the mutation panel may change from patient to patient. We
have developed a novel approach, called SimSen-Seq, to introduce molecular
barcodes into sequencing libraries with DNA inputs as low as 5ng. Barcodes
enable differentiation of true mutants from background noise introduced by
Taq polymerase errors and permits detection of variant alleles with frequencies
below 0.1%. The barcodes are protected frommis-priming using a hairpin struc-
ture which permits a high degree of multiplexing and flexibility for detection of
multiple mutations from one plasma sample. We are using this technology to
test the utility of liquid biopsy as a biomarker for esophageal adenocarcinoma
(EAC) diagnosis and disease monitoring. METHODS: Blood samples were ob-
tained at a single time point from patients with various stages of EAC and
longitudinal blood samples were also collected from patients undergoing neo-
adjuvant therapy followed by surgery. Tumor samples were obtained from bi-
opsy or resection specimens. Tumor DNAwas sequenced using a targeted EAC
panel to identify mutations in each tumor. SimSen-Seq assays were designed to
identify these mutations in plasma, and hairpin barcodes were attached. Se-
quencing libraries were generated from circulating DNA, sequenced and ana-
lyzed using the barcodes to reduce background noise. RESULTS: Mutations
were identifıed in tumor samples from 37 patients. To date, 29 patients have had
plasma analyzed; 5 stage I, 6 stage II, 13 stage III, and 5 stage IV. Of these 29, the
same mutations have been identifıed in 15 plasma DNA samples (20% stage I,
50% stage II, 54% stage III, 80% stage IV. Six patients demonstrated multiple
mutant alleles in plasma DNA. One patient with detectable pre-treatment
ctDNA underwent serial blood draws during their treatment course, and post-
operative detection of tumor-specifıc markers preceded physical evidence of
disease recurrence. DISCUSSION: SimSen-Seq shows promise as a novel ultra-
sensitive, highlymultiplexed sequencingmethod for identifying rare circulating
mutations. Possible applications include prognostication in early stage patients
and rapidmonitoring of therapeutic response and recurrence. Furtherwork is to
evaluate this is ongoing.
#2747 Plasma DNA methylation marker and hepatocellular carcinoma
risk prediction model for the general population. Hui-Chen Wu,1 Hwai-I
Yang,2 Qiao Wang,1 Chien-Jen Chen,2 Regina M. Santella1. 1Columbia Univ.
School of Public Health, New York, NY; 2Genomics Research Center, Academia
Sinica, Taipei, Taiwan.
Metastases in the later stages of hepatocellular carcinoma (HCC) cause the
majority of deaths associated with the disease, making early detection crucial to
patient survival. Risk models that assess HCC risk in the general population can
be used for risk stratifıcation for further HCC surveillance, however, none have
been validated externally. Methylation of circulating DNA shows potential for
noninvasive and early diagnosis of HCC. Most evidence, however, comes from
cross-sectional studies raising concerns about temporality.We conducted a pro-
spective case-control study nested within a community-based cohort. We mea-
sured methylation levels in of 6 genes (CDKN2A, RASSF1A, STEAP4, TBX2,
VIM, and ZNF154) using pre-diagnostic plasma DNA from 237 HCC cases and
257 matched controls. We found TBX2 hypermethylation was associated with
increased HCC risk, with ORs (95%CI) of 3.7 (1.9-7.2). The associations were
mainly among high-risk subjects; among subjects infected with HBV/HCV, the
OR (95%CI) of TBX2methylation was 5.3 (2.2-12.7). Among subjects with high
risk, the ORs (95%CIs) were 8.9 (1.0-73.9) for Wen-HCC score 
16, 5.6 (2.1-
14.6) for Hung-HCC score 
15, and 7.2 (2.1-24.4) for Michikawa-HCC 
8.
Adding information on TBX2 methylation improved the accuracy of risk mod-
els for a high risk population, with the area under the curve (AUC) of 74% for
TBX2 methylation and Wen-HCC score compared with 64% with Wen-HCC
score alone. The AUCs were 63% for Hung-HCC score and TBX2 methylation,
53% for Hung-HCC score alone, 65% for Michikawa-HCC score and TBX2
methylation and 59% for Michikawa-HCC risk alone. Our fındings suggest the
potential increase in risk assessment discrimination and accuracy from incor-
poration of DNA methylation.
#2748 Liquid biopsy using extracellular vesicular DNA for EGFR muta-
tion testing in the patients with NSCLC. Jae Young Hur,1 Hee Jung Kim,1
Chang-MinChoi,2 Jae Cheol Lee,2 Kye Young Lee1. 1KonkukUniversityMedical
Center, Seoul, Republic of Korea; 2Asan University School of Medicine, Seoul,
Republic of Korea.
Background:Tumor-derivedextracelluar vesicles (EV)havebeenproved to carry
double-stranded DNA including oncogenic mutants and expected to be a novel
biomarker in cancer detection. Liquid biopsy using cell-free (cf) DNA for EGFR
mutation testing is beingactively investigated. In this study,we investigatedwhether
liquidbiopsyusingEVDNAis superior to cfDNAforEGFRmutation testing in the
patients withNSCLC.Methods: EVwas isolated using ultracentrifugation and con-
fırmed by transmission electronmicroscopy and zetasizer in 20 plasma samples (all
tissue-proven EGFRmutated) and 32 bronchoalveolar lavage fluid (BALF) samples
(23 EGFR-mutated including 14 TKI-naïve and 9 TKI resistant, and 9 wild-type).
EV and cf DNA was separately extracted from each samples and EGFR mutation
testingwas performed by peptide nucleic acid (PNA)-clampingmethod. Results: In
20 plasma samples, the concordance rate of EV DNA for tissue EGFR genotyping
was 55% (11/20), while 30% (6/20) in cf DNA. In 32 BALF samples, however, the
sensitivity, specifıcity and concordance rate of EVDNA for activating EGFRmuta-
tionswas 100%(23/23), 100%(9/9), and100%(32/32),while cfDNAshowed73.9%
(17/23), 100% (9/9) and 81.3% (26/32), respectively. The kappa value (p-value) of
EVDNAwas 1.0 (0.001), while it was 0.714 (p,0.001) in the case of cfDNA.As for
9 re-biopsy cases for T790Mdetection inwhich only 3 patients (33%)was proved as
positiveT790M,BALFEVDNA identifıed 2moreT790Mpatients (total 5 among9
patients, 56%)withoutnon-matchingwith tissue typing,whileBALFcfDNAfound
1 more T790M positive patient with missing 1 tissue proven case (total 3 among 9
patients, 33%)ConclusionsLiquid biopsyusingEVDNAis signifıcantly superior to
cf DNA in both plasma and BALF. A little low sensitivity in plasma EV DNA is
supposed to be improved with much more sensitive method such as ddPCR or
BEAMing.LiquidbiopsyusingBALFEVDNAshowedalmost 100%matchingwith
tissue EGFR typing and seems to be highly promising for T790Mdetection. A large
number of clinical trials should be prompted.
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#2749 Liquid biopsy testing allows highly-sensitive detection of plasma
cfDNA mutations in 87 breast cancer-related genes.Maruja E. Lira, Tao Xie,
Shibing Deng, Jennifer Kinong, Jingjin Gao, Zhou Zhu, Nathan Lee, Paul Rejto,
Jadwiga Bienkowska, James Hardwick, Kai Wang, Stephen Huang. Pfızer, Inc.,
San Diego, CA.
Liquid biopsies have the potential to revolutionize the way physicians select
personalized anti-cancer therapies, monitor patient responses to treatment, and
characterize acquired resistance to cancer drugs. New tests that use a simple
peripheral blood draw offer snapshots of a patient’s total tumor DNAmutation
profıle and are attractive because of their minimally-invasive modality and be-
cause they integrate information from both primary and metastatic disease.
Currently,most plasma cell-freeDNA (cfDNA)mutation detection tests used in
clinical research detect known hotspot mutations in a limited number of genes.
Technologies that interrogate multi-gene panels in cfDNA are advancing, but
commercially-available options suitable for clinical use are limited, come at a
high cost, and are not customizable. We designed and developed a customized,
next generation sequencing-based, liquid biopsy assay capable of detecting so-
matic mutations in 87 breast cancer genes involved in cell cycle and estrogen
receptor signaling. Targeted regions (147 Kb) were enriched using hybrid cap-
ture resulting in an average capture specifıcity and uniformity of 65.93% and
96.38%, respectively. When tested on cfDNA from healthy donors (n14), we
demonstrated a level of specifıcity 99.99%. Analytical sensitivity of 0.1% was
established on HapMap and reference mutant cell line DNA. Using a pool of
HapMap genomic DNA (n10), 96% (48/50) of SNPs with expected allele fre-
quency of 0.1% were detected. In reference mutant cell line DNA with 1% or
0.1% mutant allele frequencies, we were able to reliably detect all mutations
present at 1% and mutations at 0.1% in 50% of the cases. Assay validation on
plasma cfDNA with matching tumor from ER, HER2- breast cancer patients
will be presented. In conclusion, we developed a highly sensitive and specifıc
liquid biopsy assay to interrogate 87 breast cancer-related genes. The high level
of specifıcity and sensitivity makes the test ideal not only for detecting known
cancer gene hotspot mutations but also for detection of novel gene mutations
that may arise during treatment as a result of acquired drug resistance.
#2750 Detecting resistance mechanisms in patients on EGFR TKI treat-
ment by liquid biopsy. Laure Sorber,1 Karen Zwaenepoel,1 AnWouters,2 Jans-
sens Annelies,3 Birgitta Hiddinga,3 Jan Van Meerbeeck,3 Filip Lardon,2 Chris-
tian Rolfo,3 Patrick Pauwels1. 1Antwerp University (UA) / Antwerp University
Hospital (UZA), Wilrijk, Belgium; 2Antwerp University (UA), Wilrijk, Belgium;
3Antwerp University Hospital (UZA), Edegem, Belgium.
The rise of liquid biopsy, including themolecular analysis of circulating cell-free
tumor DNA (ctDNA), has enabled real-time follow up of cancer patients who re-
ceive targeted therapy. Here, we report the case of a lung cancer patient (adenocar-
cinoma), initially harboring the activating EGFRL858Rmutation. Blood and tissue
samples were collected during treatment with the EGFR tyrosine kinase inhibitor
(TKI) gefıtinib, and during the appearance of resistance. Analysis of the tissue biop-
sies consisted of EGFR mutational analysis by high-resolution melting analysis
(HRMA) (all tissue samples), immunohistochemistry (IHC) of cMET (sample 2);
FISH analysis of the cMET gene (sample 1 and 3); and next-generation sequencing
(NGS) (sample 3). We performed digital droplet PCR (ddPCR) to detect EGFR
mutationsandcMETamplifıcation inboth tissueandplasmasamples.To thebestof
our knowledge, this is the fırst time that ddPCR is used to screen for cMET ampli-
fıcation in ctDNA. The HRMA analysis of the biopsy during progression under
EGFR TKI treatment revealed the EGFR T790M resistance mutation. Progression
was also seen by radiological examination and this resulted in discontinuation of
gefıtinib treatment. As a third generation EGFR TKI was not available by that
time, the patient was retreated with carboplatin plus pemetrexed, which
resulted in a mixed response. In the second biopsy, only the EGFR activating
L858R mutation was detected by HRMA. IHC analysis revealed a strong
membrane positivity for cMET in 100% of the tumor cells. After progression
upon rechallenging the patient with erlotinib, treatment with osimertinib
(third generation EGFR TKI) was initiated. This resulted in only a partial
response, with some strongly progressing lesions. NGS analysis of the third
tissue biopsy indicated the presence of both the EGFR L858R and T790M
mutations, while ddPCR analysis of the plasma sample only detected the
EGFR L858R mutation. Due to the fast progression, it was opted to also
screen for cMET amplifıcation. DdPCR cMET analysis of the tissue and
plasma resulted in a copy number variation of 10.0 and 3.7, respectively.
FISH analysis confırmed the cMET amplifıcation with a ratio of 3.1 and an
average of 8.4 cMET-signals per nucleus. The results of the ddPCR EGFR and
cMET analysis of both the plasma and tissue samples are now being pro-
cessed to determine the course of the mutational load and the best course of
treatment. As such, real-time follow-up of cancer patients is crucial to detect
the underlying mechanisms of resistance to targeted therapies. Correlation
of molecular analysis with the disease course is key. Our case study highlights
the potential of ctDNA analysis for detection of both the EGFR T790M
resistance mutation and cMET amplifıcation. Hence, tissue biopsies can be
supplemented by liquid biopsies in the screening for resistance mechanisms.
#2751 Automatic DNA extraction system can improve the EGFR
point mutation detection rate of liquid biopsy. Chiho Nakashima,1 Akemi
Sato,1 Tomonori Abe,1 Tomomi Nakamura,1 Kazutoshi Komiya,1 Eisaburo
Sueoka,1 Shinya Kimura,1 Naoko Sueoka-Aragane,1 Junichi Kato,2 Mitsu-
haru Hirai2. 1Saga University, Saga city, Japan; 2ARKRAY Inc., Kyoto, Japan.
Theusefulness of liquid biopsy to detectmutations fromcancer patients has been
well recognized today. However, because themutation detection rates from plasma
DNA were relatively lower than those of tissue re-biopsy, its clinical utility has not
been confırmed yet. As previously we reported, we have developed fully automatic
high-sensitive point mutation detecting system named mutation-biased PCR and
quenched probe (MBP-QP) system for liquid biopsy. Recently, the importance of
pre-analytical procedures for plasma DNA anazysis has been highlighted. In this
study,we examinedwhether the automaticDNAextraction systemcan improve the
mutation detection rate in our MBP-QP system. Sixty-one plasma samples were
obtained from advanced non-small cell lung cancer patients, and plasma DNA ex-
traction was performed from 200l plasma bymanually (200-M), and 200l (200-
A), 1000l (1000-A) plasma by automatically. We used silica membrane spin col-
umn system for manual DNA extraction, and magnet beads system for automatic
DNA extraction procedure. The median DNA concentrations quantifıed by quan-
titative real-timePCRof 200-M, 200-A, 1000-Awere 4.92, 6.00, 20.1 ng/mLplasma,
respectively. In terms of the epidermal growth factor receptor (EGFR) L858R point
mutation detection, the sensitivity of 200-M, 200-A, 1000-A were 36.6%, 58.5%,
77.5%, that of the specifıcity were 93.3%, 100%, 96.7%, and the concordance rates
were 60.6%, 76.1%, 85.7%, respectively. The size distribution of automatically ex-
tractedplasmaDNArepresented twopeaks characteristics at 170bpand5kb. In this
study, we indicate the automatic DNA extraction can improve mutation detection
rates in plasmaDNA.
#2752 Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations
for disease surveillance in bladder cancer. Emil Christensen,1 Karin Birken-
kamp-Demtröder,1 Iver Nordentoft,1 Søren Høyer,2 Kirstin Van Der Keur,3
Kim Van Kessel,3 Ellen Zwarthoff,3 Mads Agerbæk,2 Torben Falck Ørntoft,1
Jørgen Bjerggaard Jensen,1 Lars Dyrskjøt1. 1Aarhus University Hospital, Aarhus
N, Denmark; 2Aarhus University Hospital, Aarhus C, Denmark; 3Erasmus MC
Cancer Institute, Rotterdam, Netherlands.
Background: Disease surveillance in patients with bladder cancer is im-
portant for early diagnosis of progression and metastasis and for optimal
therapeutic treatment. Experimental procedures: Droplet digital PCR
(ddPCR) assays were developed and tumour DNA from two patient cohorts
was screened for FGFR3 and PIK3CA hotspot mutations. One cohort
(NMIBC cohort) included 363 patients with non-muscle invasive bladder
cancer (NMIBC). Another cohort (Cx cohort) included 468 patients with
bladder cancer undergoing radical cystectomy. Urine supernatants (NMIBC
cohort: n216, Cx cohort: n27) and plasma samples (NMIBC cohort:
n39, Cx cohort: n27) from patients harbouring mutations were subse-
quently screened using ddPCR assays. Liquid biopsies were collected from
2003-2015 with up to 11.3 years of follow-up for the NMIBC cohort and from
1995-2009 with up to 13.5 years of follow-up for the Cx cohort. Results and
limitations: In total, 36% of the patients in the NMIBC cohort (129/363) and
11% of the patients in the Cx cohort (44/403) harboured at least one hotspot
mutation in FGFR3 or PIK3CA. Screening of DNA from serial urine super-
natants from the NMIBC cohort showed high levels of tumour DNA (tDNA)
to be signifıcantly associated with later disease progression (p0.003). Fur-
thermore, high levels of tDNA in preoperative urine supernatants and
plasma samples were associated with recurrence in the Cx cohort (p0.068
and p0.016 respectively). A positive correlation between the levels of
tDNA in urine and plasma was observed (corr.0.6). The retrospective
study design and the low volumes of plasma available for analysis were
limitations of the study. Conclusions: Increased levels of FGFR3 and
PIK3CAmutated DNA in urine and plasma is indicative of later progression
and metastasis in bladder cancer.
#2753 Mutational profıles from targeted NGS combine with miRNA-
based liquid biopsy to predict survival in LDCT screening-detected lung can-
cers. Mattia Boeri,1 Carla Verri,1 Cristina Borzi,1 Todd Holscher,2 Matteo
Dugo,1 Andrea Devecchi,1 Elisa Romeo,2 Stefano Sestini,1 Paola Suatoni,1 Ugo
Pastorino,1 Gabriella Sozzi1. 1Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy; 2Gensignia Life Sciences, Inc, San Diego, CA.
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In order to increase cost-effectiveness of low-dose computed tomography
(LDCT) lung cancer screening programs, a change in the management of
screening-detected lung tumors should be considered. The higher percent-
age and the better 5-year overall survival of early stage tumors in LDCT
screening series than in clinical practice argue in favor of screening pro-
grams. On the other hand, the overall limited reduction of mortality ob-
served in screening trials with an observational control arm suggests that
some of the screening-detected early stage tumors might be over-diagnosed.
In our Institution we are trying to address this issue by the development of
complementary biomarkers able to improve detection of aggressive disease.
Targeted next-generation sequencing was performed in 94 LDCT screening-
detected lung tumors resected from subjects participating in 3 screening
trials enrolling 9,248 volunteers. Mutation profıle was associated with sub-
jects’ clinicopathologic features and with the risk profıle of a plasma mi-
croRNA signature classifıer (MSC). Using data available through The Cancer
Genome Atlas database (TCGA), we compared the mutations of a selected
set of non-small cell lung cancer (NSCLC) cases detected in standard clinical
practice to LDCT screening-detected NSCLC cases. The 5-year overall sur-
vival (OS) of screening patients with and without mutations in the tumors
was 64% and 100%, respectively (p0.019). By combining the mutational
status with the MSC, patients were stratifıed into 3 groups with 5-year OS
ranging from 41% to 96% (p0.0001) and the prognostic value was signifı-
cant even when controlling for stage (p0.017). The comparison with TCGA
data revealed a higher number of non-mutated NSCLC among screening
patients (21% vs. 13%), despite the similar spectrum and frequency of mu-
tations. In addition, the difference in 5-year OS between subjects with and
without mutations was exclusively detected in screening patients. The mu-
tation profıle of screening-detected tumors, while similar to that of clinically
detected tumors, was a strong predictor of OS. The combination of tumor
mutational status and a circulating miRNA-based risk classifıer predicts tu-
mor aggressiveness and clinical outcome and may fınd rapid application in
LDCT screening programs.
#2754 Anovel liquid biopsymethod for development of aptamer libraries
that bind blood plasma exosomes frombreast cancer patients.ValeriyDome-
nyuk, Symon Levenberg, Adam Stark, Mark Miglarese, David Spetzler. Caris
Life Sciences, Phoenix, AZ.
Improved technologies capable of characterizing system-wide changes as-
sociated with complex diseases will be required to be able to detect millions
of proteins and their isoforms as well as multi-molecular complexes. We
present a method for developing aptamer libraries using blood plasma exo-
somes that provides unprecedented system-wide coverage of native exo-
somal complexes. To train a naïve aptamer library toward cancer samples
(positive selection), the library (1013 biotinylated ssODN species) was in-
cubated with plasma from individual cancer patients and aptamer-bound
exosomes were isolated using polymer-based precipitation. Negative selec-
tion was performed by contacting the aptamer library with exosomes from
donors without breast cancer and recovering unbound aptamers from the
supernatant. In all, 12 libraries trained toward 12 individual breast cancer
patients were used to probe additional samples. Exosome-bound aptamers
were identifıed and quantifıed by Next Generation Sequencing (NGS) to
build highly accurate signatures for cancer/healthy donor classifıcation. Us-
ing these signatures, cancer patients’ binding profıles were easily distin-
guishable from controls. Interestingly, cancer-trained libraries did not dis-
tinguish any of the negative control samples from each other, indicating that
the selection pressure for cancer was high and noise due to inherent inter-
healthy donor heterogeneity was minimal. Full validation studies are ongo-
ing. Aptamer libraries may ultimately be deployed as a minimally-invasive
diagnostic adjunct in breast and other cancers.
#2755 Comparison of blood based liquid biopsy methodologies for im-
proved risk assessment of prostate cancer (PCa). Yashoda Rajpurohit, Shibu
Thomas, Jaymala Patel, Dong Shen,Michael Gormley, Denis Smirnov, Deborah
Ricci. Janssen R&D, Spring House, PA.
Approximately 28,000 men die from prostate cancer in the US each year.
Predictive biomarkers can provide patient risk assessment to enable thera-
peutic decision making. Compared to tumor, blood based liquid biopsies
offer greater flexibility for noninvasive sample collection and allows for con-
tinuous monitoring of treatment response. While various liquid biopsy sam-
ple types and methodologies are currently available, it is critical to identify
which method offers the highest sensitivity and specifıcity for clinical deci-
sion making. In this study we systematically compared specifıcity and sensi-
tivity of prostate cancer detection using a pre-selected panel of PCa specifıc
mRNA transcripts using four different methodologies. In this prospective
laboratory study, we collected fıve blood tubes from a cohort of 40 metastatic
castrate resistant prostate cancer (mCRPC) patients and 20 age matched
healthy volunteers (HV). Circulating tumor cells (CTCs) were enumerated
and blood samples enriched for CTCs were isolated for mRNA evaluation.
Two tubes of plasma samples were utilized to isolate exosomes using Exo-
RNAeasy columns and CellSearch EpCAM capture respectively, while RNA
was extracted directly from whole blood collected in PAXgene tubes. RNA
isolated from blood samples enriched for CTCs, two exosome preps and
whole blood samples were tested using qPCR (Fluidigm) for a panel of 48
prostate specifıc mRNA transcripts and three endogenous controls previ-
ously shown to be detected in whole blood. Receiver operator analysis (ROC)
was performed to compare expression of mRNA transcripts across all four
methods. Results showed PCa specifıc genes were detected in whole blood,
Exo-52 exosome prep and samples enriched for CTCs, while exosomes iso-
lated using CellSearch EpCAM capture failed to detect any PCa transcripts.
ROC showed ExoRNAeasy exosome prep detected PCa specifıc mRNA tran-
scripts with signifıcantly higher sensitivity and specifıcity compared to three
other methodologies. Area under curve (AUC) for ExoRNA prep 0.65 to 0.75
(average of z score at 3.27 p 0.0023), compared to AUC for PAXgene is 0.55
to 0.83, (average of z score at 2.64 and p0.05) and CTC samples is 0.52 to
0.67, (average of z score at 1.63 and p0.19). For CellSearch exosome
method, the AUC is 0.47 to 0.52, average of z score at 0.66 and p0.32).
These early results support the utility of exosome derived mRNA assay as a
viable alternative to whole blood and CTC based assays. Further testing for
expression of markers associated with prognosis and treatment response is
necessary to warrant its prognostic or predictive clinical utility.
#2756 Multiplexing done differently: flexible, sensitive, and accurate de-
tection of miRNA and protein analytes using Firefly particle technology. El-
naz Atabakhsh, Graeme Doran, Conor Rafferty, Jennifer Heath, Sarah Albert-
son, Peter Gillis, Jonathan Pinney, Russell Neuner, Michael Chipchase, James
Murray, Daniel Pregibon. Abcam, Inc., Cambridge, MA.
Detection of molecular biomarkers in biological fluids is used as an indi-
cator of normal biological processes, pathogenic processes, and response to
therapeutic intervention1,2. Using a combined signature of multiple bio-
markers can better account for patient and epidemiological heterogeneity,
and provide a more accurate indication of patient health2. This has necessi-
tated the development of technologies that can be used for multiplex bio-
marker profıling directly from biofluids such as plasma, serum, and urine.
Conventional assays consume excessive quantities of precious clinical sam-
ples, time and budget when used for discovery and validation of multi-
analyte biomarker signatures. To address this need, we developed the Firefly
Technology platform, which allows for sensitive and accurate detection of up
to 75 protein analytes or 68 miRNAs directly from a biological sample. The
Firefly platform uses patented Firefly® hydrogel particles and a three-region
encoding design that allows for true, in-well multiplexing, providing flexi-
bility over which analytes can be quantifıed in the same well and allowing for
custom panel design. For the detection of protein analytes, the Firefly im-
munoassays use high-performance matched antibody pairs that reduce cross
reactivity between individual analytes, provide up to 5 logs dynamic range,
and typically demonstrate single-digit pg/ml sensitivity, while requiring only
12.5 l biofluid input. Similarly, the Firefly microRNA assay can reliably
detect as few as 1000 microRNA copies per sample with a linear dynamic
range of5 logs, and without the need of prior RNA purifıcation. This assay
utilizes single step RT-PCR signal amplifıcation using universal primers,
thus leveraging PCR sensitivity while eliminating the need for separate re-
verse transcription reactions and mitigating amplifıcation biases introduced
by target-specifıc qPCR. The Firefly assays have been validated in a wide
range of biological samples including plasma, serum, urine and cell culture
supernatant, providing experimental flexibility. The 96well plate assay for-
mat enables high-throughput screening of samples, with readout conducted
on standard flow cytometers, thereby omitting the need for complex and
expensive dedicated instrumentation. Finally, the integrated Firefly Analysis
Workbench software enables easy and rapid data analysis, visualization, and
export in under ten minutes, and includes key features such as standard
curve analysis and publication-quality heatmaps and graphs. Here we pres-
ent data from several studies investigating cytokine profıling in human and
rodent samples, and circulating and tumor microRNA profıles, using the
Firefly Platform. Together, this novel combination of bioinformatics tools
and multiplex, high-sensitivity assays enables rapid discovery and validation
of biomarker signatures from fluid samples.
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#2757 Using liquid biopsies andNGS as tools to analyzemutation burden
and copy number variation in the blood of a patient with triple negative
breast cancer to better inform therapeutic targets. Kellie Howard,1 Kimberly
Kruse,1 Brianna Greenwood,1 Elliott Swanson,1 Mathias Ehrich,2 Christopher
K. Ellison,2 Taylor Jensen,2 Sharon Austin,1 Arturo Ramirez,3 Debbie Boles,4
John Pruitt,4 Elisabeth Mahen,1 Jackie L. Stilwell,3 Eric P. Kaldjian,3 Michael
Dorschner,5 Sibel Blau,6 Marcia Eisenberg,4 Steve Anderson,7 Anup Madan1.
1Covance, Redmond, WA; 2Sequenom Laboratories, San Diego, CA; 3RareCyte,
Inc., Seattle, WA; 4Laboratory Corporation of America® Holdings, Research Tri-
angle Park, NC; 5University of Washington, Seattle, WA; 6Northwest Medical
Specialties, Puyallup, WA; 7Covance, Durham, NC.
The ability to characterize molecular features of cancer from liquid biop-
sies is resulting in the development of innovative health care for patients.
Longitudinal changes in the mutational profıles of DNA isolated from liquid
biopsies are being used to better understand and monitor the development,
progression, and evolution of therapy resistance in cancer patients. To defıne
changes in the mutational landscape and predict drug susceptibilities in
Triple Negative Breast Cancer (TNBC) patients, we used whole exome anal-
ysis to profıle circulating tumor cells (CTCs) and circulating tumor DNA
(ctDNA) from eight selected time points of a patient enrolled in the Intensive
Trial of OMics in Cancer clinical Trial (ITOMIC-001). The patient initially
received weekly cisplatin infusions followed by additional targeted therapy.
Peripheral blood samples were collected at specifıc time points over a period
of 272 days following enrollment in the clinical trial. Our data indicates that
the identifıed mutations in genomic DNA isolated from CTCs and ctDNA
can be used to understand and mitigate the impact of tumor heterogeneity in
addition to identifying clinically relevant mutations at these selected time
points. To further increase the resolution of our analysis, we profıled ctDNA
from these samples to a higher depth targeting only clinically relevant genes.
These analyses increased the sensitivity of detection and identifıed addi-
tional targets that could have been used for therapeutic intervention. In
addition to sequence variants, copy number variations (CNVs) have also
been signifıcantly associated with the development of metastasis and
changes in CNVs have been used to monitor disease progression. We per-
formed a bioinformatics analysis of genomic instability and CNVs across 32
different time points from ctDNA from the same patient throughout the
treatment period. The genomic instability number (GIN) calculated for each
of the 32 time points seems to mirror the overall CTC burden in the patient
at each time point tested. CNV analysis is ongoing and these data sets are
being further analyzed in combination with TCGA data to defıne possible
cancer driver genes for the functional prediction of signifıcant TNBC candi-
date alterations and the results of these analyses will be presented.
#2758 Comparison of cell-free DNA blood collection tubes. Cecille D.
Browne, Margrith E. Mattmann, Marc J. Wycoco, Sheila N. Chen, Rajeswari
Ravichandran, Joel Desharnais, Laura J. Varela, Jonathan D. Browne, Vasco
Liberal, Florence Lee. Biomatrica, Inc., San Diego, CA.
Critical biomarkers such as cell-free DNA (cfDNA) derived from tumors
and circulating tumor cells (CTCs) can be detected and analyzed from a
simple blood draw. These analytes are fragile, prone to degradation, and
present in extremely low quantities. Therefore, proper preservation of these
analytes is necessary to ensure accuracy of test results. Several blood collec-
tion tubes are commercially available for cfDNA applications, and selecting
the ideal blood collection tube for cfDNA impacts test results, sample col-
lection logistics and costs. However, no comprehensive and systematic eval-
uation of performance among these tubes is available. This study evaluates
fıve commercial blood collection tubes: LBgardTM Blood Tube (Biomatrica),
Streck cfDNA BCT® (Streck), PAXgene Blood ccfDNA Tube (PreAnalytiX),
Cell-Free DNA Collection Tube (Roche), and EDTA (BD). Healthy donor
blood samples were collected in each tube type and incubated over several
days at different temperatures. Total plasmaDNAwas subsequently isolated,
and the yield, fold increase versus time 0 and quality of purifıed DNA were
compared. cfDNA controls were also spiked into blood samples collected in
each tube type and measured by droplet digital PCR to determine the mutant
allele frequencies over time. Finally, the yield and quality of cfDNA isolated
from stage IV colorectal cancer blood collected in LBgard Blood Tube, Streck
cfDNA BCT and EDTA were compared. Additionally, the inhibition of he-
molysis and CTC stabilization were also assessed. Our results show that
LBgard Blood Tube, Streck cfDNA BCT, PAXgene ccfDNA Tube and Cell-
Free DNA Collection Tube are superior to EDTA tubes in maintaining
cfDNA yield and quality over 7 days at ambient temperature. LBgard Blood
Tube out-performs all tested blood tubes in inhibiting genomic DNA release
for the longest duration (14 days) and across the widest temperature range
(4°C, 25°C and 37°C). LBgard Blood Tube shows equivalent inhibition of
genomic DNA release to Streck cfDNA BCT for clinical samples, and both
tubes out-perform EDTA blood tubes. LBgard Blood Tube also consistently
shows better CTC stabilization and inhibition of hemolysis over Streck
cfDNA BCT. This comprehensive and systematic study of blood collection
tube performance provides a quantitative and exhaustive assessment of
blood sample stability, allowing researchers to make informed decisions
based on their sample stabilization needs.
#2759 Technical limitations of capture-based, targeted deep sequenc-
ing for the detection of somatic variations in cell-free DNA. Gahee Park.
Seoul National University/ Samsung Genome Institute, Seoul, Republic of
Korea.
Despite widespread applications of capture-based targeted deep sequenc-
ing, its limitations on detecting circulating tumor DNA (ctDNA) have not
been systematically elucidated. Here, we analyze and characterize parame-
ters critically determining its detection limits; depth of coverage and back-
ground errors. The depth increase by usingmore cell-free DNA (cfDNA) was
saturated at around 3000x with 50 ng of cfDNA primarily due to a de-
duplication artifact, which limited the detection sensitivity of the method.
Next, characterizing background errors, we uncovered that a majority of
errors were not derived from biological origins but technical artifacts, espe-
cially during sample preparation and library construction rather than se-
quencing. Thus, it is important to use an appropriate protocol for those steps
minimizing background errors. Considering the depth of coverage and the
background error rate, we estimated the detection limit of the method ap-
proximately to be 0.4% variant allele frequency at 95% confıdence level.
Applying the method to pancreatic cancer patients, we found that the levels
of ctDNAs measured by cfDNA sequencing well correlated with clinical
responses to therapy and/or disease progression, but biopsy-free profıling of
somatic variants was limited by the moderate sensitivity of 72% and PPV of
74% at the variant level. Our results clarify technical limitations of targeted
deep sequencing and provide a guideline for applying the technique to ana-
lyze cfDNA.
#2760 Proof of principle studies for detection of circulating renal cancer
cells from blood samples using diverse technologies. Yvonne Maertens, Ver-
ena Humberg, Julie Steinestel, Martin Boegemann, Andres J. Schrader, Christof
Bernemann. University Hospital Muenster, Muenster, Germany.
Background: During the past years, much progress has been made in de-
tection and analysis of circulating tumor cells (CTCs) in several tumor enti-
ties, including prostate cancer, breast cancer or lung cancer. However, little
is known about circulating tumor cells in patients suffering from clear cell
renal cell carcinomas. The majority of technologies detecting CTCs is based
on expression of epithelial markers on the surface of these cells, e.g. EpCAM.
Additionally, biophysical approaches have been invented to detect CTCs
based on size, invasive capacity or density. In order to be able to detect CTCs
in patient samples, in vitro establishment of the most accurate isolation
procedure followed by precise detection techniques has to be performed.
Aim of our studies was to build a stable in vitro fundament of isolation and
subsequent detection of CTCs in ccRCC patients. Methods: We made use of
4 different technologies, all of which have been approved for detection of
CTCs in distinctive tumor entities. We used EpCAM based positive enrich-
ment of CTCs, Ficoll densitiy centrifugation followed by CD45-positive cell
depletion, rosette formation followed by CD45 positive cell depletion as well
as size and deformability based enrichment technologies by using the Par-
sortix system. Furthermore, by using 4 phenotypically distinct ccRCC cell
lines, we tried to detect markers unique for tumor cells in demarcation to
blood cells. Results: By performing spiking experiments of renal cancer cells,
we found the highest recovery rates by using the size based Parsortix system.
Interestingly, the most established technique of EpCAM based isolation
failed in three out of four cell lines to recover more than 40%. Expression of
well-established markers for ccRCC, like carboanhydrase (CA)-9, could be
detected in renal cancer cell lines. However, expression was also found in
blood samples of healthy donors. Another marker used for immunohisto-
chemical diagnosis of ccRCC, PAX8, showed weak to absent expression in
established renal cancer cell lines. The highest specifıcity to detect renal
cancer cells in blood samples was found when analyzing KRT8 or KRT 19
expression. Conclusion: Our results demonstrate that fırstly, using the Ep-
CAM based CTC enrichment, which is the basis of the CellSearch system,
which up to now is the only methodology approved by the FDA, the majority
of renal cancer cells will presumably not be detected in blood samples. This
seems largely due to low or absent expression of EpCAM on renal cancer
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cells. The usage of the size based Parsortix system showed the highest recov-
ery rates and should therefore be analyzed in more detail on samples of
ccRCC patients. Secondly, an exclusive marker for defıning a renal CTC is
still missing. Some well-established ccRCC markers, like CA-9, failed to
specifıcally detect renal cancer cells in blood samples, as they were either
present also in healthy blood samples or absent in renal cancer cell lines.
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#2761 Adjuvant chemotherapy outcomes of node negative, T1a,T1b,T1c
hormone receptor-negative HER2-positive breast cancer patients. Anu Paul,
Runhua Shi, Prakash Peddi, Gary Burton. LSU Health, Shreveport, LA.
Background: Patients (pts) with early stage HER2neu-positive breast can-
cers have a higher risk of recurrence and death compared to hormone recep-
tor positive patients. NCCN guidelines recommends adjuvant chemother-
apy for Stage II and above HER2-positive breast cancer patients. It is unclear
what benefıt patients with Stage I HER2-positive breast cancer receive from
adjuvant chemotherapy. The current study evaluates the effects of adjuvant
chemotherapy on the survival of early stage ER/PR negative, HER2-positive
breast cancer patients registered to the National Cancer Data base (NCDB)
from 2010-2012. Patients and Methods: 3416 women from the NCDB were
identifıed with Stage I ER, PR negative, HER2-positive breast cancer diag-
nosed between 2010-2012. The primary measured outcome was overall sur-
vival. Pts were grouped by tumor size (T1a,T1b,T1c) and adjuvant chemo-
therapy or no adjuvant chemotherapy. Additionally, patients were also
grouped into lumpectomy with radiation and mastectomy with or without
radiation. Adjusted variables included age, race, Charlson Comorbidity In-
dex (CCI), payer status, income, education, distance travelled, diagnosing/
treating facility and treatment delay. Multivariate Cox regression was used to
investigate the effect of adjuvant chemotherapy on overall survival while
adjusting for other factors. Results: There were a total of 3416 patients, mean
age at diagnosis of 57.9 (range 22-90). The mean age was 56.2 years for the
chemotherapy group and 61.8 for the no chemotherapy group. Pathological
stage distribution was T1a (24.9%), T1b (24.7%) and T1c (50.2%). Adjuvant
chemotherapy was received by 49.5% of T1a, 83.5% of T1b and 95% of T1c
pts. Mean patient follow up was 2.7 years (range 0.05-5 years) In univariate
analysis, the hazard ratio (HR) of death for chemotherapy vs no chemother-
apy in each T stage was: T1a; 1.22 (0.46-3.28), T1b; 0.221 (0.095-0.512), T1c;
0.217 (0.094-0.498). In multivariate analysis, adjusting for other factors in
the model, HR of death was 0.51 (95%CI: 0.26-1.03) for chemotherapy vs no
chemotherapy. The HR of death was 1.92 (95%CI: 1.11-3.32) for pts who
received mastectomy without radiation compared to lumpectomy with radi-
ation. In addition, we observed a HR of 5.16 for CCI score of 2 or above as
compared to score of 0. There was no difference in outcome based on payer
status or race. Conclusion: Patients with early stage T1 a-c HER2-positive
breast cancer had a marginal improvement in overall survival with the addi-
tion of chemotherapy. Patients who underwent lumpectomy with radiation
were also found to have better overall survival compared to mastectomy
without radiation. However, the relatively short follow up and the lack of
cancer recurrence information preclude making defınitive conclusions rela-
tive to adjuvant therapy for pts with these tumors. Longer follow-up and
prospective controlled trials will be needed to quantify these potential ben-
efıts.
#2762 The comparison of allogeneic stem cell transplantation outcomes
between haploidentical donor and international donor: A retrospective
multi-institutional study in Korea. Hyunkyung Park,1 Yoo Jin Lee,2 Sang-Jin
Shin,3 Jayoun Lee,3 Inho Kim,1 Sung-Soo Yoon,1 Silvia Park,4 Hyewon Lee,5
Joonho Moon,2 Jun Ho Jang,4 Youngil Koh1. 1Seoul National University, Seoul,
Republic of Korea; 2Kyungpook National University Hospital, Dague, Republic of
Korea; 3National Evidence-based Healthcare Collaborating Agency, Seoul, Re-
public of Korea; 4Samsung Medical Center, Seoul, Republic of Korea; 5National
Cancer Center, Goyang, Republic of Korea.
Introduction: The successful rate of hematopoietic stem cell transplantation
(HSCT) from HLA-mismatched donor has been increased according to the
development in management of complications including graft versus host dis-
ease (GVHD) and infections. Especially, haploidentical HSCT provides an op-
portunity for all patients who do not have HLA-matched sibling donor. Meth-
ods: In this study, we compared HSCT outcomes between haploidentical
familiar donor and international donor (donors from Japan, China, Germany,
Unites States of America and Taiwan) in acute leukemia patients. We reviewed
the overall survival (OS), relapse free survival (RFS) and complications. Results:
Total 142 acute leukemia patients performed HSCT from 2000 to 2016; 98 pa-
tients underwent haploidentical donor transplantation and 44 patients under-
went international donor transplantation. Major variables such as age, sex, dis-
ease status and the number of CD34 stem cells were not statistically different
between two groups. In survival analysis, there was no signifıcant difference
according to the donor-type. 1-year OS rate for haploidentical transplantation
group was 44.1% and 52.3% for international transplantation group (p0.345).
1-year RFS rate was 36.6% versus 40.9%, respectively (p0.362). In addition, the
incidence of complication events was similar between two groups. The acute
GVHD in haploidentical group and international group were 42.9% and 43.2%
(P0.97), and the infection event within 30days after transplantation were
49.5% in haploidentical group and 34.1% in international group (p0.09). The
cumulative incidence of chronic GVHDwas no signifıcantly different (P0.34),
respectively. Conclusion: These data suggest that HSCT from haploidentital
donor shows similar outcomes including survival outcomes and complications
with international donor transplantation. Therefore, haploidentitial donor
transplantation can be good choice for acute leukemia patients who have no
HLA_matched sibling donor.
#2763 Health-related quality of life among long-term prostate cancer sur-
vivors by primary treatment: A systematic review. Salome Adam,1 Anita
Feller,2 Sabine Rohrmann,1 Volker Arndt2. 1Epidemiology, Biostatistics and Pre-
vention Institute, University of Zurich, Zurich, Switzerland; 2National Institute
for Cancer Epidemiology and Registration, Zurich, Switzerland.
Introduction: Due to improving prognosis for prostate cancer survivors
and increased awareness of late- or long-term treatment effects, monitoring
long-term well-being among prostate cancer survivors has gained increasing
attention. In this systematic review, we identifıed and synthesized studies
comparing health-related quality of life (HRQoL) among long-term prostate
cancer (PC) survivors (i.e. 
5 years past diagnosis) by primary treatment.
Methods: In order to summarize current literature research results, we
searched multiple databases, including Pubmed, Medline, Embase,
PsychInfo, Cinahl, Web of Science and Cochrane Central Register of Con-
trolled Trials to identify all relevant articles. Studies had to assess at least
overall/ general HRQoL plus one HRQoL domain or a minimum of two
HRQoL domains. Two independent reviewers systematically extracted the
content of the included studies. Results: A total of twelve studies were iden-
tifıed (2 from US, 3 from Japan, 6 from Europe, 1 from US/UK); the majority
were observational prospective cohort studies (n7), and two were RCTs.
HRQoL was assessed using the SF-36 (n7) or EORTC QLQ-C30 (n5).
Instruments to assess symptoms included various questionnaires (e.g., EPIC,
IPSS, UCLA and EORTC PR 25). The sample size (all arms combined) was
below 100 in 6 studies, between 100 and 200 in 5 studies, and 780 in one
study. Comparison groups differed across studies. Although, long-term
prostate cancer survivors reported comparable HRQoL to the general pop-
ulation, survivors treated using external beam radiation therapy (EBRT)
reported poorer role, social and role physical functioning and a higher bur-
den of diarrhea, pain, sleep disturbance and nausea/vomiting. Results for
comparisons of different therapies were not consistent. Whereas studies
using the EORTC QLQ-c30 questionnaire did not reveal any statistically or
clinically signifıcant results, studies using the SF-36 showed that survivors
treated with a radical prostatectomy reported better physical and role func-
tioning as well as higher vitality than survivors treated with AS/WW, ADT
and EBRT. However, the latter results were only based on one study. No clear
associations were seen between EBRT and OM. Conclusion: This review
suggests that HRQol among long-term prostate cancer survivors varies ac-
cording to primary treatment. However, it remains unclear which treatment
options are superior with respect to HRQoL since studies yielded conflicting
results, used different comparison groups, or did not have enough power to
draw any fırm conclusions.
#2764 Creating a review process of a digital photo database collected on
NRG NSABP B39/RTOG 0413 phase III clinical trial for evaluation of
cosmetic results from breast conserving therapy (BCT). Ashley Sekhon,1
Ruiqi Zhao,1 Yan Wang,1 Debora Grant,2 Kathryn A. Winter,2 Jennifer
Moughan,2 Douglas W. Arthur,3 Stephen J. Chmura,4 Atif J. Khan,5 Simona
F. Shaitelman,6 Aleix M. Martinez,1 Frank A. Vicini,7 Julia R. White1. 1Ohio
State University, Columbus, OH; 2NRGOncology, Philadelphia, PA; 3Virginia
Commonwealth University, Richmond, VA; 4University of Chicago, Chicago,
IL; 5Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; 6MD Ander-
son Cancer Center, Houston, TX; 721st Century Oncology, Pontiac, MI.
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Introduction: After local control and overall survival, acceptable cosmesis
is the next most important goal of BCT. Digital photos (DP) are commonly
used for assessing cosmesis on clinical trials. On NRG NSABP B39/RTOG
0413, DP at baseline, 1, and 3 years post-radiation were submitted for review
by a panel of breast cancer specialists. Given no current standards for central
DP review, this project seeks to develop a standard for subjective DP evalu-
ation. The initial standardization of the photo database and reliability of the
panel review is described. Methods: De-identifıed DP submitted and stored
at NRG SDMC were downloaded to a secure FTP site. Cases with only 1 time
point, no baseline, or photos from different patients were excluded. A min-
imum photo quality was set, including pre-specifıed criteria for contrast/
light, breast/torso size, and cropping to exclude anatomy above the clavicle
and below the umbilicus. DP were edited with MATLABTM and saved in a
Reformatted Digital Photo Database (RDPD). A training set was created
defıning 4 global cosmetic scores, and each individually assessed criteria of
breast symmetry, shape, skin color, nipple, and scar appearance. A 14 case
calibration set followed the training set. The process for panel review was
adapted from the methods reported in the START and RAPID trials. The
review panel consisted of 6 breast-specifıc radiation oncologists, who re-
viewed in groups of 3. For each session, the training set was reviewed and
calibration set scored. A separate 30 case test set randomly selected from the
RDPD was reviewed by 2 groups of 3. The calibration and test sets were
evaluated for agreement of categorized scores (excellent/good vs. fair/poor).
Results: There were 2064 DP from 892 patients on NRG NSABP B39/RTOG
0413 documenting the anterior view of both breasts. After exclusions, 1,717
reformatted DP were saved in the RDPD. Five 1-3 hour review sessions
resulted in scoring of 777 DP (155 per session). Only 2/777 (0.1%) DP were
deemed poor quality and not able to be scored. There was full agreement in
categorized scores for 12/14 cases (86%; kappa0.82) across the 5 calibra-
tion sets; and 27/30 (90%; kappa0.71) for the 2 test set reviews. Conclu-
sions: Cosmesis DP prospectively collected on a large phase III clinical trial
can be digitally formatted in a systematic fashion for consistent photo qual-
ity, allowing for cosmesis consensus panel review without photo quality bias.
High agreement in categorized scores allowed reviews to be completed by
multiple 3-person review groups. Future work will focus on creating an
updated, semi-automatic analysis tool of these photos for objective evalua-
tion of cosmesis using the same scoring guidelines that can then be compared
to physician reported outcomes. Grant Support: FUJIFILM Medical Sys-
tems/RSNA Research Resident, NCI U10CA180868, U10CA180822.
#2765 Psychosocial predictors of life satisfaction among married women
with breast cancer. Chioma Asuzu, Ngozi Efosa-Urhoghide. University of Iba-
dan, Ibadan, Nigeria.
Introduction: Breast cancer presents a challenge to the totality of a woman’s
life. Correlates of life satisfaction among married women with breast cancer
have not been very well explored. Purpose: This study seeks to determine the
relationship that exists between life satisfaction with depression, cognitive emo-
tional regulation, sexuality, self-concept, dejection, interpersonal conflict and
social support among married women with breast cancer in Southwest Nigeria.
It also seeks to ascertain which of these variables predict life satisfaction among
the respondents. Method: The variables in the study were assessed using modi-
fıed standardized instruments which were revalidated for cultural suitability
after ethical approvals were obtained in each of the 5 centres involved in the
study. The instruments were given to breast cancer patients after informed con-
sent to participate in the study have been obtained. Result: The larger proportion
{148 or 40.5%)} of the participants were in the age range of 46-55 years and 112
(30.7%) had stage III disease. Analysis of data showed that signifıcant linear
relationship exists between life satisfaction ofmarriedwomenwith breast cancer
and depression (r.200**; p.001), self-concept (r.306**; p.001), cogni-
tive emotional regulation (r.398**; p.001), dejection (r.226**; p.001),
interpersonal conflict (r.352**; p.001), anxiety (r.316**; p.001), sexu-
ality (r.305*; p.001) and social support (r.534; p.001). There were also
signifıcant correlations among the independent variables. Conclusion: Psycho-
social factors are potent predictors of life satisfaction among married women
with breast cancer. Based on the fındings, it was recommended that psycho-
social intervention based on the factors identifıed as causative agents of life
satisfaction should be developed and implemented for married individuals.
#2766 Esophageal stenting in resource-limited settings.Michael M. Mwa-
chiro,1 Robert K. Parker,1 Stephen Burgert,1 Justus Lando,1 Sinkeet Rankeeti,1
Robert Chepkwony,1 Emmanuel Kiniga,1 Sanford Dawsey,2 Mark Topazian,3
Russell E. White1. 1Tenwek Hospital, Bomet, Kenya; 2National Cancer Institute,
Bethesda, WA; 3Mayo Clinic, Rochester, MI.
Background: Esophageal cancer is the 6th leading cause of cancer death globally,
with geographical high-risk areas inAsia, theMiddleEast, and eastern and southern
Africa.Esophageal squamouscell carcinoma(ESCC) is themorecommonvariant in
Africa. In Kenya, its incidence is 2nd inmen after prostate cancer and 3rd in women
after breast and cervix-uteri cancers. Late presentation is a common occurrence in
developing countries and ismultifactorial due to challenges in access to health care,
low socioeconomic status and delayed or missed diagnosis. A large percentage of
these tumors are thus unresectable and are only eligible for palliative care via stent-
ing. Our hospital is a 300-bed referral center in southwestern Kenya, which is a
hotspot for ESCC, and we see over 400 cases of ESCC annually. Methods:We have
developed a technique for placement of esophageal self-expanding metallic stents
(SEMS) without fluoroscopy that is safe and easily reproducible. This is an outpa-
tient procedure, with the majority done under conscious sedation, and routine fol-
lowup is not necessary. The tumormargins are noted at time of video endoscopy, a
guidewire is placed, and dilation done with Savary dilators as required. The SEMS
are then loaded on the stent delivery device and deployed into the proper position
based on measurements, and placement is subsequently confırmed via endoscopic
visualization. Results: A total of 3000 SEMShave beenplaced to date at our hospital,
withoutusing fluoroscopy.Themale: female ratiohasbeen1.5:1, andtheaverageage
has been 60.4 years. The distribution of tumor locations was 67% in themiddle and
distal third. The most common complications were tumor overgrowth with ob-
struction and stent migration. Procedure related mortality was 0.3%. Post-proce-
dure improvement indysphagia scorewas seen inover80% , andpatient satisfaction
was high. Initial data puts our post stent survival time around 8 months/ 250 days
Conclusions: Placement of SEMS for ESCC, without fluoroscopy, is a safe and re-
producible procedurewhich has a low rate of adverse events. This procedure results
in effective palliation of a diffıcult disease and can easily be done in resource-limited
settings which have endoscopy capabilities. Current efforts are ongoing to increase
opportunities for training endoscopists in this procedure and for provision of af-
fordable stents in Africa.
#2767 Consistency of standing orders for primary prophylactic CSF
within a national network of community oncology practices: SWOG inter-
group trial S1415CD. Scott Ramsey,1 DawnHershman,2 Ari Bell-Brown,1 Kate
Watabayashi,1 Karma Kreizenbeck,1 Sean Sullivan,3 Aasthaa Bansal,1 William
Barlow,4 Kathryn Arnold,5 Gary Lyman1. 1Fred Hutchinson Cancer Research
Center, Seattle,WA; 2Columbia UniversityMedical Center, New York, NY; 3Uni-
versity ofWashington, Seattle,WA; 4CRAB, Seattle,WA; 5SWOGStatistical Cen-
ter, Seattle, WA.
BACKGROUND: Among the 400,000 individuals undergoing chemotherapy
for breast, colorectal and lung cancer in the US, many are at risk of febrile
neutropenia (FN). Prophylactic colony stimulating factor (CSF) use reduces the
risk of FN, yet studies show that 55%-95% of CSF prescribing is inconsistent
with clinical practice guidelines. There is lack of evidence and ambiguous guide-
lines for CSF use in regimens with an intermediate risk of FN. To address these
issues, we are conducting a pragmatic trial to assess CSF prescribing and to
generate evidence about CSF effıcacy with intermediate risk regimens. To in-
form the design and sample size needs, we conducted a survey of current CSF
order system use within a large network of community oncology practices.
METHODS: The study setting are sites within the NCI Community Oncology
Research Program (NCORP), a national network across the U.S. and Puerto
Rico that conducts multi-site cancer clinical trials. Between January-September
2016, 58 NCORP practices were surveyed on their existing systems for prescrib-
ing CSF prophylaxis. RESULTS 8 clinics (14%) reported that their sites do not
use any standing orders for CSF prophylaxis prescribing. Standing order set
characteristics for the remaining 50 practices are shown in Table 1.
Table 1 Summary of CSF standing order implementation in 50 surveyedNCORP clinics
Breast
Cancer
Regimens
Non-Small
Cell
Lung
Cancer
Regimens
Colorectal
Cancer
Regimens
Order Set
Characteristic
Dose
Dense
N (%)
High
Risk
N (%)
Intermediate
Risk
N (%)
Low
Risk
N (%)
Intermediate
Risk
N (%)
LowRisk
N (%)
Intermediate
Risk
N (%)
Low
Risk
N (%)
Automatically
Included in
Order Set
(Standing
Orders)
46 (82%) 31 (62%) 7 (14%) 0 8 (16%) 0 7 (14%) 0
Automatically
Excluded in
Order Set
0 0 6 (12%) 19 (38%) 5 (10%) 19 (38%) 8 (16%) 19 (38%)
No automatic
ordering- up
to physician
discretion to
add or
exclude
orders
4 (8%) 19 (38%) 37 (74%) 31 (62%) 37 (74%) 31 (62%) 35 (670%) 31 (62%)
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CONCLUSIONS: We observed wide variation in the current application of
standing orders. Intermediate risk regimens had the most inconsistent prac-
tices, with a near equal number of clinics choosing either actively including
or excluding CSF order sets. The majority of clinics using standing orders
included CSF for dose dense and high risk regimens but only 19 (38%)
actively excluded CSF for low risk regimens. These results support the need
for more evidence to inform clearer guidelines on CSF use in intermediate
risk regimens and studies that evaluate the effects of existing CSF standing
orders on guideline adherence and patient outcomes. Funding:PCORI (PCS-
1402-09988) and NCORP grant (5UG1CA189974)
#2768 Treosulfan induces differential gonadal toxicity profıle compared
with Busulfan.Mattan Levi,1 Salomon Stemmer,1 Jerry Stein,2 Ruth Shalgi,1 Irit
Ben-Aharon1. 1Institute of Oncology , Davidoff Center, Rabin Medical Center,
Beilinson Campus, Petah-Tiqva, Israel; 2Schnieder Children Medical Center, Pe-
tah-Tiqva, Israel.
Background: Treosulfan (L-treitol-1,4-bis-methanesulfonate), an alkylat-
ing agent with myeloablative and immunosuppressive traits, has been in-
creasingly incorporated as a main conditioning protocol for hematopoietic
stem cell transplantation (HSCT) in pediatric malignant and non-malignant
diseases. Treosulfan has been shown to present lower toxicity profıle com-
pared with conventional myeloablative regimens such as busulfan. Yet, while
busulfan is considered highly gonadotoxic, the gonadal toxicity profıle of
treosulfan remains to be elucidated. Our aim was to study the short and long
term gonadal effect of treosulfan in comparison to busulfan. Methods: Ma-
ture 2 months old male and 3 months old female mice (“pubertal cohort”)
were injected with treosulfan 2000 mg/kg or busulfan 40 mg/kg and were
sacrifıced one week, one month or six months post drug administration.
Immature male and female mice (“prepubertal cohort”) were injected with
treosulfan 750 mg/kg or busulfan 15 mg/kg and were sacrifıced one week or
three months post drug administration. Testicular function was assessed by
measurements of sperm count and motility, testes and epididymides weight,
serum anti-Mullerian Hormone (AMH) and testicular ID4 or GFRA1
mRNA (markers for stem spermatogonia). Immunohistochemistry was per-
formed to evaluate testicular proliferation (Ki-67), apoptosis (TUNEL) and
meiotic-active spermatocytes (DAZL-PCNA). Ovarian function was as-
sessed by measurements of ovary weight, serum AMH, follicles count and
ovarian SOHLH2, NOBOX of FIGLA mRNA (markers for primordial folli-
cles). Immunohistochemistry was performed to evaluate ovarian prolifera-
tion (Ki-67), apoptosis (TUNEL) and growing follicles (AMH-PCNA). Re-
sults: Treosulfan testicular toxicity was milder compared to busulfan
toxicity, in both mature and immature male mice, while stem spermatogonia
were spared. However, ovarian toxicity of both treosulfan and busulfan was
severe and permanent in bothmature and immature female mice; possibly by
a short term irreversible reduction of reserve primordial follicles in the ova-
ries. Conclusion: Our results indicate that treosulfan exerts a differential
gonadal toxicity profıle compared with busulfan, manifested by mild testic-
ular toxicity and severe ovarian toxicity.
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#2769 Project Survival: Prospective clinical study utilizing multiomics
and artifıcial intelligence to discover novel molecular markers for detection,
stratifıcation, and outcome in pancreatic cancer. Rangaprasad Sarangarajan,1
John Crowley,2 Amy Stoll-D’Astice,2 Valerie Bussberg,3 Cindy Nguyen,1 Leon-
ardo O. Rodrigues,1 Emily Chen,3 Eric Michael Grund,1 Vivek K. Vishnudas,1
Michael Kiebish,1 Viatcheslav R. Akmaev,1Manuel Hidalgo,4 Niven R. Narain,1
A. JamesMoser4. 1BERG, LLC, Framingham,MA; 2Cancer Research And Biosta-
tistics, Seattle, WA; 3BERGHealth, LLC, Framingham,MA; 4Beth Israel Deacon-
ess Medical Center, Boston, MA.
Pancreatic adenocarcinoma is the third leading cause of cancer death and
has an extremely poor response to fırst line therapies. There is a critical
unmet need to discover and implement effective diagnostic panels to stratify
this disease and personalize treatment. Project Survival is a prospective study
designed to discover biomarkers for patient diagnosis, stratifıcation, and
prognostics for pancreatic cancer. The multisite study is in year 2 of enroll-
ing subjects within 6 categories: healthy volunteers with a relative with pan-
creatic cancer (N50), pancreatitis (N50), pancreatic cystic neoplasm
(N50), suspicious pancreatic masses with pathology other than pancreatic
cancer (N50), early stage (N200) and metastatic pancreatic cancer
(N200). The study analyzes matched subject sera, plasma, buffy coat, sa-
liva, urine, and tumor/adjacent normal tissues and integrates them with full
clinical annotation. Multiple time points per subject per year are taken lon-
gitudinally over the course of the six year timeline enabling dynamic mod-
eling. Samples are analyzed by Mass Spectrometry for the proteome, signal-
ing lipidome, structural lipidome, andmetabolome. The BERG Interrogative
Biology® platform utilizes Artifıcial Intelligence to integrate multiomic pro-
fıles with medical annotation and clinical endpoints. Utilizing the power of
the Bayesian Network learner, bAIcisTM (BERG Artifıcial Intelligence Clin-
ical Information System), multiomic profıles were aligned to the longitudi-
nal clinical information and subjected to the AI-algorithms that inferred
probabilistic cause-and-effect relationships among molecular and clinical
variables inferring markers of pancreatic cancer status and defıning the in-
terconnectivity of molecular features with clinical phenotype. Network fea-
tures linking clinical endpoints and key network pressure points will be
identifıed as molecular drivers. The drivers of clinical endpoints will be
analyzed to rank potential biomarkers.
#2770 Bcl-2 overexpression is a predictive biomarker for the combination
of ABT-199 with chemotherapy in diffuse large B-cell lymphoma cell lines.
Ian McConnell, Elyse Anderson, Victor Yazbeck. VCU Massey Cancer Center,
Richmond, VA.
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of
Non-Hodgkin’s Lymphoma. The anti-apoptotic Bcl-2 protein is expressed in
certain DLBCL subtypes such as “Double-Hit” where it mediates resistance
to chemotherapy. ABT-199 is a BH3-mimetic that specifıcally targets Bcl-2,
and has shown excellent clinical activity in several hematological malignan-
cies. The anti-apoptotic protein Mcl-1 mediates resistance to ABT-199, and
can be inhibited with chemotherapy. However, despite variability in the
Bcl-2 expression levels, current clinical trials involving combinations of
ABT-199 and chemotherapy for the treatment of patients with DLBCL use a
one-size-fıts-all approach regardless of Bcl-2 expression levels. We hypoth-
esized that high Bcl-2 expression levels correlates with sensitivity to the
combination of ABT-199 and chemotherapy in DLBCL. We examined the
activity of ABT-199 in four DLBCL cell lines with varying Bcl-2 levels (CAR-
NAVAL, OCI-ly18, SU-DHL-4 and SU-DHL-8) as determined by cell via-
bility (Cell Titer Glo Assay) and apoptosis (Annexin-V/PI staining and
FACS) analyses. CARNAVAL and SU-DHL-8 have the highest and lowest
Bcl-2 expression levels, respectively, as revealed by immunoblotting. Of the
four cell lines, CARNAVAL displayed the highest sensitivity (IC507 nM)
while SU-DHL-8 was resistant (IC50  10 M) with the other 2 cell lines
exhibiting intermediate sensitivity (45.9 nM for OCI-ly18 and 2.6 M for
SU-DHL-4). We then selected CARNAVAL and SU-DHL-8 in order to fur-
ther examine the effect of the combination of ABT-199 with classic chemo-
therapy agents (etoposide and doxorubicin) used in DLBCL treatment. In
CARNAVAL cells, the combination of either chemotherapy with ABT-199
led to a signifıcant decrease in cell viability at 48 hrs compared to each single
agent alone. This was associated with apoptosis induction as measured by
Annexin-V/PI, caspase-3 and PARP cleavage, an increase in -H2AX (asso-
ciated with DNA damage), and decrease in Mcl-1. Unlike CARNAVAL cells,
ABT-199 did not enhance the activity of chemotherapy in SU-DHL-8 cells
that lack Bcl-2 expression. These preclinical results support the use of Bcl-2
overexpression as a predictive biomarker for selecting patients that are likely
to benefıt from the combination of ABT-199 with chemotherapy in DLBCL.
Current efforts are investigating the mechanism of resistance to the combi-
nation.
#2771 Correlation of tumor mutation burden and chemotherapy out-
comes in colorectal cancer. Sachin G. Pai, Benedito Carneiro, Aparna Kalyan,
Ricardo Costa, Irene Helenowski, Alfred Radmeaker, Hiral Shah, Daniel Olson,
Young Chae, Francis Giles. Northwestern University, Chicago, IL.
Background: The Cancer Genome Atlas (TCGA) has identifıed 16% of
colorectal cancers (CRC) to have defects in mechanisms that repair sponta-
neous DNA damage, and consequently have high tumor mutation burden
(TMB). Although, there is accumulating evidence for activity of immuno-
therapy on tumors harboring high-TMB, its impact on response to chemo-
therapy is unknown. Methods: In this retrospective cohort study, we ana-
lyzed progression free survival (PFS) of 74 patients with metastatic CRC (61
colon & 13 rectal cancer) treated at tertiary care oncology clinics and under-
went next-generation sequencing (NGS) of their tumor sample using Foun-
dationOne® (Foundation Medicine Inc., Cambridge, MA). Most recent
available specimen was analyzed at the time of diagnosis of metastatic dis-
ease. TMB was calculated by counting all synonymous and nonsynonymous
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variants as well as indels across a 1.25 megabase coding region spanning 315
genes. Low TMB (TMB-L) and Intermediate/High TMB (TMB- I/H) were
defıned as  5 mutations per base (MB) or 
 6/MB respectively. Demo-
graphic and clinical information (including imaging results, chemotherapy
treatment) were obtained by chart review. Treatment was captured as ‘ox-
aliplatin-based’ if the chemotherapy regimen contained oxaliplatin (i.e.,
FOLFOX, XELOX) or ‘irinotecan-based’ if the regimen contained irinotecan
(i.e., FOLFIRI). Subsequent modifıcations of dose or omission of the drug
due to toxicity were not captured. Continuous variables were reported as
medians and inter-quartile ranges and compared between groups via the
Wilcoxon rank-sum test. Categorical variables were reported as frequencies
and percentages and compared between groups via Fisher’s exact test. Sur-
vival estimates were compared between groups via the log-rank test. Results:
There was no statistically different PFS in TMB-L (n39) compared to
TMB- I/H (n26). (10.0 vs. 5.9 months, P  0.18). In the TMB-L cohort,
irinotecan-based chemotherapy (n25) treated patients had improved PFS
compared to oxaliplatin-based chemotherapy (n10) treated CRC patients
(11.9 vs. 6.5 months, P 0.001). No difference in PFS was observed be-
tween the two treatment cohorts in TMB-I/H group. In stage 2 and 3 colon
cancer patients, there was no difference in time to recurrence in the TMB-L
and TMB-I/H cohorts, when patients were treated with oxaliplatin-based
therapy in peri-operative setting (detailed statistics including survival curves
will accompany fınal presentation). Conclusion: TMB status may be a pre-
dictive biomarker in a subset of patients treated with chemotherapy, specif-
ically in TMB-L cohort. Confırming these fındings in a larger repository of
tissue from studies comparing irinotecan vs. oxaliplatin-based regimen is
recommended.
#2772 BCL-2 family expression profıling may identify distinct molecular
subtypes of multiple myeloma with increased susceptibility to single agent
Venetoclax. JennyWu,1 Caleb Stein,2 Jeremy A. Ross,3 Franklin Peale,1 John D.
Shaughnessy,4 Ryan Van Laar,5 Gareth Morgan,2 Jeffrey M. Venstrom,1 Eliza-
beth A. Punnoose,1 Yanwen Yanwen Jiang1. 1Genentech, Inc., South San Fran-
cisco, CA; 2University of Arkansas Medical Sciences, Little Rock, AR; 3Abbvie,
North Chicago, IL; 4Mt. Sinai School of Medicine, NY; 5Signal Genetics, Little
Rock, AR.
Venetoclax (VEN) is being evaluated in relapsed/refractory multiple my-
eloma (R/RMM) patients as a single agent (NCT01794520). Improved objective
response rates were observed in t(11;14) patients (40% in t(11;14) vs 6% in
t(11;14)), which were shown to associate with a favorable BCL-2 family ex-
pression profıle (highBCL2:BCL2L1 (BCL-XL). Forty percent of t(11;14) pop-
ulation exhibited VEN favorable biomarker profıle with an 88%ORR compared
to 20% in t(11;14) patients with unfavorable profıle. Thus, a favorable BCL-2
family expression profıle may identify certain MM subgroups with increased
sensitivity to the anti-tumor activity of VEN as a single agent. To better under-
stand and identify the patient populations that may benefıt from VEN, we ret-
rospectively analyzed the prevalence of a favorable BCL-2 family expression
profıle in t(11;14) and otherMMmolecular subtypes in two published cohorts
(GSE4581 and GSE9782). Our results showed that BCL2 expression varied sig-
nifıcantly acrossmolecular and cytogenetic subgroups. The t(11;14) subgroup
expressed high BCL2 and the lowest BCL2L1 and MCL1 in both newly diag-
nosed (NDMM) and R/R MM patients. Correspondingly, the t(11;14) MMwas
enriched for the highest ratios of BCL2/MCL1 and BCL2/BCL2L1, further sup-
porting the single agent VEN activity observed in this patient population. Based
on prevalence study in cohort GSE9782, we observed 40%of t(11;14)R/RMM
patients exhibited a favorable BCL-2 family expression profıle, using clinical
defıned cutoffs, thus highly consistent with the VEN single agent trial. Fur-
thermore, this favorable profıle existed in other molecular subtypes, espe-
cially the ones that harbor abnormal MAF (23%) and D3 (37.5%) transloca-
tions, as well as dysregulated expression of cyclinD1 (21.2%)/D1D2
(26.7%). The molecular subgroup with overexpression of cyclin D2 had the
lowest prevalence of the favorable profıle (7.5%). In the NDMM cohort,
overall 27% patients had favorable profıle. More specifıcally, the t(11;14)
patients had the highest (61%) and D2 patients had the lowest (13%) preva-
lence of a favorable BCL-2 family profıle. Collectively, our data suggests that
MM subgroups are associated with distinct BCL-2 family expression profıles,
and that the t(11;14) subgroup is particularly suited for single agent VEN
treatment as indicated by the high prevalence of a favorable BCL-2 family
expression profıle. In addition, we further identifıed patients in the non
t(11;14) MM subgroups with a favorable BCL-2 family expression profıle
that may also potentially benefıt from VEN monotherapy.
#2773 A prospective observational study evaluating c-MET expression
and EGFR gene mutation correlation with erlotinib response in second line
treatment for advanced/metastatic non-small cell lung cancer patients.
Cheol-Kyu Park,1 Yoo-Duk Choi,2 In-Jae Oh,1 Jung-Eun Lee,3 Shin Yup Lee,4
Tae-Won Jang,5 Jeong-Seon Ryu,6 Young-Chul Kim1. 1ChonnamNational Uni-
versity Hwasun Hospital, Hwasun, Jeonnam, Republic of Korea; 2Chonnam Na-
tional University Medical School, Gwangju, Republic of Korea; 3Chungnam Na-
tional University Hospital, Daejun, Republic of Korea; 4Kyungpook National
University Medical Center, Daegu, Republic of Korea; 5Kosin University Gospel
Hospital, Busan, Republic of Korea; 6Inha University Hospital, Incheon, Republic
of Korea.
Background: The c-MET is associated with tumor progression and acquired
resistance to epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs). The aim of this study was to evaluate the prevalence and predic-
tive role of c-MET and EGFRmutation in non-small cell lung cancer (NSCLC).
Methods: This was a multicenter prospective observational study for patients
with stage IV or recurrent NSCLC who had progressive disease after 1st line
chemotherapy and was followed by erlotinib for 2nd line treatment from Sep-
tember 2011 to September 2014. The primary outcome was to measure the rates
of c-MET expression/amplifıcation and EGFR mutation in tumor tissue. MET
expressionwas evaluated by immunohistochemistry (IHC) and gene copy num-
ber was assessed by silver in situ hybridization (SISH). EGFR mutations were
analyzed byCobasTM version 1. Results: A total of 196 patientswere enrolled and
major histologic types were adenocarcinoma (67%). c-MET was overexpressed
(MET IHC-positive) in 44.4% of the patients and dominant in female and non-
squamous histology. c-MET amplifıcation and high polysomy (MET SISH-pos-
itive) were observed in 1.5% and 8.7%, but there was no specifıc clinical charac-
teristics. The detection rate of EGFR mutation was 10.2% (19 deletion: 11,
L858R: 7, exon 20 insertion: 2 cases). The response rate of erlotinib was signifı-
cantly higher in EGFR sensitive mutant group (55% vs. 4%, p0.001) and the
median progression-free survival (PFS) was signifıcantly longer than wild type
(173 vs 58 days, p0.001). c-MET positivity (IHC- or SISH-positive) did not
show signifıcant correlation with response or PFS. Patients with SISH-positive
for c-MET tended to have shorter overall survival (OS) than patients with SISH-
negative (127 vs 303 days, p0.051). Conclusion: In this observational study
with 2nd line erlotinib treatment, we reconfırmed EGFRmutation is strong pre-
dictive marker, and EGFR-TKI use in EGFR wild-type patients should be con-
sidered carefully and may be harmful. c-MET overexpression was related to
some clinical characteristics such as female and non-squamous histology. Al-
though c-MET positivity was not associated with response or PFS, c-MET SISH
may be predictive marker for OS.
#2774 Correlative analysis of systemic markers from a randomized trial
assessing local consolidative therapy for non-small cell lung cancer (NSCLC)
patients with oligometastatic disease. Chad Tang, John V. Heymach, Alexan-
dre Reuben, Hai Tran, James Welsh, Jennifer Wargo, Zhongxing Liao, Anne
Tsao, Eric Prado, Stephen Swisher, JianjunZhang,Daniel Gomez.MDAnderson
Cancer Center, Houston, TX.
Introduction:We present serum correlative analysis from a phase II random-
ized trial to identify markers associated with progression free survival (PFS) in
NSCLC.Methods: NSCLC patients presenting with oligometastatic disease (3
metastases) were enrolled on a multi-institution phase II randomized trial
(NCT01725165). Patients who did not progress after 
3 months of fırst-line
systemic therapy were randomized to upfront local consolidative therapy (LCT
arm) to all sites of disease or at later progression (no-LCT arm). For correlative
analyses, peripheral blood was collected from consenting patients after comple-
tion of initial systemic therapy but prior to randomization (baseline) and at each
follow up. Serum cytokine and angiogenesis factors (CAFs) were analyzed via
magnetic bead-basedmultiplex assay (MerckMillipore). Peripheral blood T cell
receptor (TCR) repertoire was profıled by immunoSEQ (Adaptive Biotechnol-
ogies). Peripheral cell-free DNA (cfDNA) was subjected to next generation se-
quencing of a panel of cancer genes. Comparisons of PFS, the primary endpoint
of this study, were conducted via log-rank test. Results: After enrollment of 74
patients with a median follow up of 19 months, this study was closed early after
the Data Safety Monitoring Committee review determined effıcacy in the LCT
arm. Of 49 randomized patients, correlative blood draws were conducted on 33
patients. Considering all patients, high baseline EGF (cutpoint 50 pg/ml;median
PFS: 5.7 vs 19.8 mo), Eotaxin (cutpoint 110 pg/ml; median PFS: 5.7 vs 21 mo),
TNF alpha (cutpoint 8 pg/ml; median PFS: 3.6 vs 17.9mo), or low baseline GRO
(cutpoint 600 pg/ml; median PFS: 17.9 vs 3.6 mo) were associated with longer
PFS (all P0.05). When considering individual treatment arms, LCT arm pa-
tients exhibiting low baseline MMP-2 (cutpoint 90 ug/ml; median PFS: 17.9 vs
5.3 mo) and no-LCT arm patients exhibiting low baseline GRO (cutpoint 600
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pg/ml; median PFS: 21.0 vs 1.8 mo) or high baseline FGF-2 (cutpoint 58 pg/ml;
median PFS: 2.2 vs 21.0 mo) exhibited longer PFS (all P0.05). TCR repertoire
and cfDNAprofıle analyses are underway.Conclusions: In this exploratory anal-
ysis, we identifıed baseline CAFs associated with PFS. These fınding are being
validated in a larger cohort of patients. If validated, CAFs could be a biomarker
to select patients with oligometastatic NSCLC for aggressive local treatment.
#2775 CPS1 as a therapeutic target and prognostic indicator in LKB1-
inactivated lung adenocarcinoma. Mu¨ge C¸eliktas, Ichidai Tanaka, Satyendra
Chandra Tripathi, Johannes F. Fahrmann, Clemente Aguilar-Bonavides, Pa-
mela Villaobos, Oliver Delgado, Dilsher Dhillon, Jennifer B. Dennison, Edwin J.
Ostrin, Hong Wang, Carmen Behrens, Kim-anh Do, Ali F. Gazdar, Samir M.
Hanash, Ayumu Taguchi. UTMD Anderson Cancer Center, Houston, TX.
Liver Kinase B1 (LKB1), encoded by STK11, is a tumor suppressor and so-
matically mutated in approximately 20% of lung adenocarcinoma. Aside from
the effects of LKB1 inactivation on tumor initiation, LKB1-mutant cancers are
biologically distinct from cancer with functional LKB1, and the loss of LKB1
uniquely confers invasive and metastatic properties in genetically engineered
mousemodels of cancer.While various pathways, including energymetabolism,
cell polarity, and cell growth, are regulated by LKB1 and can play a pleiotropic
role in cancer initiation and progression, no therapies are currently available for
clinical use that specifıcally target LKB1 inactivation. Therefore, elucidation of
the functional mechanisms associated with LKB1 inactivation has translational
relevance. We analyzed proteomic profıles of 45 lung adenocarcinoma cell lines
with and without LKB1 inactivation to identify molecular features associated
with LKB1 inactivation. Carbamoyl phosphate synthase 1 (CPS1) was identifıed
as a markedly overexpressed protein in LKB1-inactivated lung adenocarcinoma
cell lines. CPS1 is the fırst rate-limiting mitochondrial enzyme in the urea cycle,
and plays an intricate role in arginine and pyrimidinemetabolism. CPS1 knock-
down reduced cell growth, decreased levels of metabolites associated with
nucleic acid biosynthesis pathway, and contributed an additive effect when
combined with conventional chemotherapy agents including gemcitabine,
pemetrexed, or CHK1 inhibitor AZD7762. Tissuemicroarray analysis using 305
lung adenocarcinoma tumors revealed that CPS1 was expressed in 65.7% of
LKB1-negative and only 5.0% of LKB1-positive lung adenocarcinomas. In ad-
dition, CPS1 expression was signifıcantly and independently associated with
poor overall survival of lung adenocarcinoma patients (P 0.0001, HR 3.03,
95% CI 1.74-5.25). Concordant with the results of tissue microarray, analysis of
the Cancer Genome Atlas (TCGA) dataset consisting 403 lung adenocarcino-
mas revealed that highCPS1mRNAexpressionwas signifıcantly associatedwith
worse overall survival and is an independent prognostic indicator of lung ade-
nocarcinoma (P  0.005, HR  2.31, 95% CI 1.28-4.16). Our fındings suggest
functional relevance of CPS1 and its association with worse outcome in LKB1-
inactivated lung adenocarcinoma. Therefore, CPS1 is a promising therapeutic
target in combination with other chemotherapy agents, as well as a prognostic
biomarker, enabling us to personalize the treatment of LKB1-inactivated lung
adenocarcinoma.
#2776 Genetic correlations with clinical response to ASTX727 in patients
with myelodysplastic syndromes (MDS). Haley E. Ramsey,1 Shilin Zhao,1
Yaomin Xu,1 Olatoyosi Otoyosi,2 Philip Amrein,3 AmyDezern,4 LauraMichae-
lis,5 David P. Steensma,6 Stefan Faderl,7 Guillermo Garcia-Manero,8 James
Lowder,9 Pietro Taverna,9 Michael R. Savona1. 1Vanderbilt University Medical
Center, Nashville, TN; 2The University of Chicago, Chicago, IL; 3Massachusetts
General Hospital, Boston, MA; 4Johns Hopkins University School of Medicine,
Baltimore, MD; 5Medical College of Wisconsin, Milwaukee, WI; 6Dana-Farber
Cancer Institute, Boston, MA; 7Hackensack University Medical Center, Hacken-
sack, NJ; 8The University of Texas MD Anderson Cancer Center, Houston, TX;
9Astex Pharmaceuticals, Pleasanton, CA.
DNA methyltransferase inhibitors (DNMTis) have been shown to alter the
natural history of MDS and reduce related complications; however, many pa-
tients do not respond to DNMTi therapy or progress with limited effective
secondary options. Therefore, the ability to preselect which patients are most
likely to respond to DNMTis would be useful in personalizing MDS therapy.
Earlier reports noted a trend toward improved response to therapy in the pres-
ence of somatic TET2 mutations (Bejar et al, 2014), and lower response rates in
patients with mutations in DNMT3A (Ley et al, 2010). Treatment with the DN-
MTi decitabine (DAC) requires 5 daily parenteral doses every month adminis-
tered in the clinic. An orally administered DNMTi provides convenience with
the potential for improved compliance, and allows for exploration of different
extended dosing schedules which could produce alternative methylation of the
genome and improve clinical response. DAC is not readily orally bioavailable
due to rapid clearance by cytidine deaminase (CDA) present in the gut and liver.
E7727, a novel CDA inhibitor, is orally bioavailable with an excellent safety
profıle in preclinicalmodels. ASTX727 is a combination of E7727 andDAC, and
has completed phase 1 dose escalation of 44 MDS or CMML patients in which
pharmacokinetic (PK) and pharmacodynamic (PD) parameters of DAC were
replicated with the oral agent. During the dose escalation portion of the Phase 1
trial ofASTX727, bonemarrowaspirateswere obtainedpre- andpost- treatment
from 28 patients (13 clinical responders), and genomic DNA frommarrow cells
was isolated for next-generation sequencing (NGS) with a panel of 37 myeloid
neoplasia-associated genes. Consistent with previous reports, DNMT3A muta-
tions were associated with poor response to ASTX727 (all 4 carriers failed ther-
apy, P 0.028). Conversely, of the 10 patients with TET2mutations, a majority
responded to treatment (6/10, P0.444). ASXL1 mutations showed a complex
combinatorial effect, as all three ASXL1-mutated patients with BCOR muta-
tions, regardless of International Prognostic Scoring System (IPSS) risk cate-
gory, were non-responders while all 3 patients ASXL1 who also carried a TET2
mutation responded. ASTX727 is an oral DNMTi that revealed responses in this
dose escalation Phase I study exhibiting a similar pharmacokinetic profıle and
achieving AUC range of IV DAC. As previously observed with DAC, ASTX727
may lead to improved responses in patients with specifıc gene mutations. This
work shows preliminary effects onmutational burden and allele frequency con-
current with activity of ASTX727. Further analyses of patients treated at the
RP2D in the Phase 2 trial are ongoing.
#2777 TMPRSS2-ERGpredictive value for taxanes resistance according to
prior second-line hormonalmanipulations inmetastatic castration resistant
prostate cancer. Mercedes Marín-Aguilera,1 Òscar Reig,1 Natalia Jiménez,1
Iván Victoria,1 Lydia Gaba,1 Sandra López,1 Javier Prato,2 Maria Verónica
Pereira,1 Teresa Vilella,1 Montserrat Domenech,3 Josep Badal,3 Albert Font,4
Juan JoséGarcía-Mosquera,4Olatz Etxaniz,4 CristinaCarrato,4 Cristina Suárez,5
Joan Carles,5 Fabriccio Racc,5 Pedro Luis Fernández,1 Aleix Prat,1 Begoña Mel-
lado1. 1Hospital Clinic of Barcelona/Institut d’Investigacions Biomèdiques Agust
PI i Sunyer/Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain; 2Hos-
pital Universitario de La Coruña, La Coruña, Spain; 3Fundació Althaia, Barce-
lona, Spain; 4Institut Català d’Oncologia, Badalona, Spain; 5Hospital Universita-
rio Vall d’Hebron, Barcelona, Spain.
Background: TMPRSS2-ERG is a genetic alteration specifıc of prostate can-
cer, present in primary tumors and maintained under castration resistant pros-
tate cancer (CRPC) progression. It results in androgen-driven overexpression of
ERG, which is involved in resistance to taxanes in preclinical models. In prior
work, we found that TMPRSS2-ERG expression in blood correlated with do-
cetaxel resistance in metastatic CPRC. Here, we investigated if TMPRSS2-ERG
expression in primary tumors predicts taxanes resistance in CPRC and the po-
tential impact of prior second-line hormonal manipulations with abiraterone
(A) or enzalutamide (E). Methods: Patients with metastatic CRPC treated with
taxanes were included. Formalin-fıxed paraffın-embedded (FFPE) tumors and
peripheral blood mononuclear cells (PBMCs) fraction were tested for TM-
PRSS2-ERG by RT-qPCR. FFPE from hormone-sensitive disease (primary di-
agnosis) were retrospectively obtained. PBMCs were prospectively collected
prior taxane initiation. TMPRSS2-ERG expression was tested by RT-qPCR.
TMPRSS2-ERG detection was correlated with taxane response and clinical out-
come. Results: A total of 84 tumor samples from 74 patients were included: 65
(87.3%) treated with docetaxel, 19 (25.7%) with cabazitaxel and 10 (13.5%) with
both. Forty-six tumor samples (54.7%) were TMPRSS2-ERG and 38 (45.2%)
TMPRSS2-ERG-. Overall, no correlation between tumor TMPRSS2-ERG ex-
pression and taxanes response or clinical outcome was observed. In 42 (50%)
samples matched tumor and PBMC samples were available at the time of this
analysis: 23 (54.7%) had detectable TMPRSS2-ERG on tissue and 11 (26.2%) on
PBMCs fraction. In 27 patients, taxanes were administered as a fırst-line therapy
and in 15 after A or E progression. TMPRSS2-ERGwas detected in PBMC from
8 (29.6%) and 3 (20%) patients without or with prior A or E. In patients without
prior A or E, TMPRSS2-ERG expression in primary tumors predicted a lower
median PSA-PFS (5.5 vs 10.1 months for TMPRSS2-ERG vs , respectively;
p0.05). Similarly, when analyzing PBMCs samples frompatientswithout prior
A or E, PSA response was observed in 0% of TMPRSS2-ERG vs 55.6% of
TMPRSS2-ERG-patients (p 0.009). Median PSA-PFS, Rx-PFS were 2.9 vs 8.1
months (p  0.01) and 3.2 vs 7.3 (p  0.05), for TMPRSS2-ERG and TM-
PRSS2-ERG-patients. However, no signifıcant differences were found either in
PBMCs or FFPE samples in patients that received A or E prior to taxanes, re-
garding to PSA response, PSA-PFS, Rx-PFS and OS parameters between
TMPRSS2-ERG and TMPRSS2-ERG- samples. Conclusions: The role of
TMPRSS2-ERG in taxane resistance may be different according to prior expo-
sure to second-line hormone-therapy in CRPC. Prior androgen receptor inhi-
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bition may result in TMPRSS2-ERG downregulation and/or activation of alter-
native mechanisms of resistance. Further data according to this hypothesis will
be presented.
#2778 Combination of DNAmismatch repair status andMACC1 expres-
sion in patients with stage II colon cancer: The BIOGRID studies. Ulrich-
Peter Rohr,1 Pia Herrmann,2 Katharina Ilm,2 Hai Zhang,3 Sabine Lohmann,4
Astrid Reiser,4 Andrea Muranyi,5 Janice Smith,2 Susen Burock,6 Marc Oster-
land,2 Katherine Leith,5 Shalini Singh,5 Patrick Brunhoeber,5 Rebecca Bower-
master,5 Jeanne Tie,7Michael Christie,7 Hui-LiWong,7 PaulWaring,7 Kandavel
Shanmugam,5 Peter Gibbs,7 Ulrike S. Stein2. 1Divisional Medical and Scientifıc
Affairs, Roche, Basel, Switzerland; 2Charité Universitätsmedizin Berlin and Max
Delbrück Ctr. for Molecular Medicine, Berlin, Germany; 3Divisional Biomarker
Group, Roche, Basel, Switzerland; 4Roche Diagnostics GmbH, Penzberg, Germa-
ny; 5VentanaMedical Systems, Inc., Tuscon, AZ; 6Charité Comprehensive Cancer
Center, Berlin, Germany; 7University of Melbourne, Melbourne, Australia.
We have previously identifıed the gene Metastasis-Associated in Colon
Cancer 1 (MACC1). MACC1 acts a prognostic biomarker for tumor progres-
sion, metastasis and patient survival for a broad variety of solid cancer types.
Here we assessed if the MACC1 gene could separate stage II colon cancer
patients with profıcient mismatch repair (pMMR) into high- and low-risk
groups who might benefıt from or be spared adjuvant chemotherapy based
on their prognosis. In the Charité 1 discovery cohort (n61), MACC1 ex-
pression andMSI status were assayed by qRT-PCR in cryo-preserved tumors
from CRC patients. MSS/MSI-low/MACC1-low tumors showed better sur-
vival vs. MSS/MSI-low/MACC1-high (P0.0001). Patients with MSS/MSI-
low/MACC1-low tumors had a similar prognosis as patients with MSI-H
tumors. The Charité 2 comparison cohort (n40) was used to translate
MACC1 qRT-PCR analyses to FFPE samples. MACC1 expression was sig-
nifıcantly higher in metachronously metastasizing tumors linked to shorter
relapse-free survival (RFS), independent of the tissue type analyzed (cryo-
preserved or FFPE). Next we translated MACC1 mRNA levels from qRT-
PCR to MACC1 protein levels from immunohistochemistry (IHC) by com-
paring them in consecutive FFPE tumor sections in the BIOGRID 1 training
cohort (n189) enriched for disease recurrence. Chemotherapy-naïve pa-
tients with unfavorable pMMR status separated into MACC1-high and -low
groups. Better RFS was seen in the pMMR/MACC1-low vs. pMMR/MACC1-
high group using MACC1 mRNA and protein expression. pMMR/MACC1-
low expression was seen in 12% and 8% of patients by qRT-PCR and IHC;
interestingly, they had the same favorable prognosis as the defıcient MMR
(dMMR) group. Prognostic and predictive fındings from BIOGRID 1 were
confırmed in the independent BIOGRID 2 validation cohort (n306) unen-
riched for recurrence. Better RFS was again seen in chemotherapy-naïve
patients in the pMMR/MACC1-low (6%) vs. pMMR/MACC1-high group.
No patients with pMMR/MACC1-low phenotype had disease recurrence.
Remarkably, pooling BIOGRID 1 and 2, 5-year RFS was 100% and thus
signifıcantly longer in the pMMR/MACC1-low vs. pMMR/MACC1-high
group (P0.037). Taken together, MACC1 expression, measured by qRT-
PCR or IHC, differentiates patients with unfavorable pMMR status. Patients
with stage II colon cancer and pMMR/MACC1-low tumor status have a
similar favorable prognosis as those patients with dMMR status who might
not benefıt from adjuvant therapy.
#2779 Assessing germline and somatic alterations inDNA repair pathway
in cancer. Gargi D. Basu,1 Tracey White,1 Janine LoBello,1 Ahmet Kurdoglu,1
Jeffrey Trent,2 Sen Peng,2MatthewHalbert,1 Thomas Royce1. 1Ashion, Phoenix,
AZ; 2Translational Genomics Research Institute, Phoenix, AZ.
Introduction: DNA repair genes are involved with repair of single strand
breaks as well as double strand breaks which ultimately maintain the genome
integrity. The genes involved with DNA repair are frequently deregulated in
cancer and these defects can be exploited therapeutically. Our study aims to
explore somatic and germline changes in DNA repair genes across multiple
cancer types. Methods: Genomic profıling was performed on 226 tumor
samples from 24 cancer types with ages ranging 19-82 years. We performed
targeted exome sequencing of 562 genes in tumor and paired normal DNA
which included 112 genes associated with cancer predisposition syndromes.
In addition to identifying genomic changes in 33 key DNA repair genes
(ATM, ATR, ARID1A, BAP1, BARD1, BRCA1, BRCA2, BRIP1, CDK12,
CHEK1, CHEK2, ERCC2, ERCC3, ERCC4, FANCA gene family, MMR
genes, NBS1, PALB2, PTEN, RAD50, RAD51, TP53 and POLE), we also
characterized germline mutations using public databases (ClinVar, En-
sembl). Results: Profıled specimens included breast cancer (17.5%), ovarian
cancer (15%), CRC (11%), NSCLC (10%), uterine (6%), sarcoma (6%) and
other cancers. The most commonly deleted or mutated (somatic) DNA re-
pair genes included TP53 (55%), PTEN (16%), ARID1A (13%), FANCA
(11%), ERCC2 (10%), and ATM, BAP1, CDK12, CHEK2 at 6% each and
BRCA1/2 combined at (9%). Deleterious mutations in MMR genes were
noted in 3.5% (8/226) which included 1 case of germline PMS2-S46I muta-
tion. Interestingly, a 55 yr old male African American CRC patient harbored
germline XPC-P334H mutation along with somatic MLH1-Y548fs. No mu-
tations were found in FANCC, FANCF, FANCG and RAD51. Germline anal-
ysis revealed a total of 47 pathogenic and presumed pathogenic variants out
of which 61.7%(29/47) were DNA repair genes. A total of 13% (30/226) of
cases harbored germline variants in DNA repair genes. Germline events
included 9 cases with BRCA1 and BRCA2 clinically signifıcant mutations.
Presence of loss of heterozygosity (LOH) at the BRCA locus in 5/9 cases and
somatic mutations in 3/9 cases were noted in germline BRCA mutated sam-
ples. Germline and somatic BRCA1 and BRCA2 alterations were present in
10% (22/226) of total cohort and as expected, the majority were present in
breast and epithelial ovarian cancer. Genetic defıciencies in DNA repair
pathway genes are being exploited therapeutically with PARP inhibitors as
well as DNA damaging chemotherapeutics. Conclusions: Exome sequencing
identifıed subsets of patients with loss of function events in DNA repair
genes that may be associated with benefıt from PARP inhibitors and plati-
num agents. Somatic and germline biomarker testing revealed occurrence of
BRCA1/2 as well as other DNA repair gene alterations across multiple can-
cers. It is imperative to explore the DNA repair pathway beyond BRCA1 and
BRCA2 in patient selection for PARP inhibitors and DNA damaging agents
and further investigation of this pathway is warranted in ongoing clinical
trials.
#2780 High nuclear FTH1 protein expression predicts early disease recur-
rence for BRCA1/2 mutation carriers.Antoinette Hollestelle, Mieke Timmer-
mans, Renée Broeren-Foekens, Anita Trapman - Jansen, Carolien H. van
Deurzen, Arzu Umar, John W. Martens, Maartje Hooning. Erasmus Medical
Ctr., Rotterdam, Netherlands.
FTH1 is a 21kD subunit of the ferritin complex, which is involved in intracellular
iron storage. In a previous studywe found that FTH1 proteins can be located either
in the cytoplasm or nucleus and, depending on its cellular localization, is associated
with good or poor prognosis in triple negative breast cancer (TNBC). Furthermore,
cytoplasmic localization of cFTH1 was associated with an increased anti-tumor
(CD8) T-cell / tumor-promoting (CD4) T-cell ratio suggesting an immune
modulatory role for FTH1. In the current study we have assessed the prognostic
value of FTH1 expression for BRCA1/2 mutation carriers. FTH1 proteins were
visualized by immunohistochemistry on a tissue microarray containing primary
breast cancer specimens from 222 BRCA1/2mutation carriers that were diagnosed
between1982and2008.Primarybreast cancers fromBRCA1carrierswerepredom-
inantly of the TNBC subtype, whereas primary breast cancers from BRCA2 muta-
tion carriers were mainly ER-positive. The association between FTH1 expression
andclinical outcomewas evaluatedbyaCoxproportional hazards regressionmodel
using left truncation toadjust for study inclusionbias.Themedian follow-up timeof
the study was 9.2 years. High nuclear FTH1 (nFTH1), but not cytoplasmic FTH1
(cFTH1), was associated with decreasedmetastasis-free and disease-free survival as
comparedwith lownFTH1(multivariableHR3.54, 95%CI1.45-8.66, P0.0056
adjusted for tumor size and nodal status; multivariable HR2.71, 95% CI1.49-
4.92,P0.0011adjusted for tumorsize).NeithernFTH1norcFTH1wereassociated
with breast cancer-specifıc or overall survival. This suggests that high nFTH1 ex-
pression in primary breast cancer predicts earlier disease recurrence for BRCA1/2
mutation carriers. Since we had observed that CD4:CD8 T-cell ratios were in-
creased among TNBCs with high nFTH1, we hypothesize that nFTH1 promotes
recruitment of immune suppressive CD4/FOXP3 regulatory T-cells in TNBC
and BRCA1/2-associated tumors, suppressing CD4/FOXP3 and CD8 T-cell
anti-tumor immunity.
#2781 Exosomal Del-1 as a potent diagnostic marker for breast cancer: A
prospective cohort study. Soo Jung Lee,1 Jeeyeon Lee,1 Yee Soo Chae,1 Jin
Hyang Jung,1HoYong park,1Moon-Chang Baek,2 Pyong-GonMoon2. 1Kyung-
pook National University Medical Center, Daegu, Republic of Korea; 2Cell and
Matrix Research Institute, School of Medicine, Kyungpook National University,
Daegu, Republic of Korea.
Background:We previously demonstrated a diagnostic role of exosomal del-1
with two separated groups of breast cancer patients. In the current study, there-
fore, we aimed to confırm the diagnostic role in a prospective study with breast
cancer by measuring plasma exosomal del-1 before and after surgery. Patients
andmethods: To identify the optimal time of sampling after surgery, serial blood
at day 1, 3, 5, and 7 after surgery was collected from 22 patients with early breast
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cancer. Thereafter, One hundred fıfteen patients with breast cancer who under-
went curative surgery were enrolled in the prospective cohort study to compare
difference in plasma exosomal del-1measured by ELISA at the time of diagnosis
and post-surgery. Results: Among all 22 patients for optimal sampling time after
surgery, exosomal del-1 was higher than 0.5 at the time of diagnosis and then
normalized at POD1. Among 115 patients for the confırmatory set, 109 (94.8%)
patients showed a normalization of del-1 lower than 0.5 after surgery and 10
patients showed del-1 0.4. Median f/u duration of 22months, 9 patients expe-
rienced relapse (4 locoregional and 5 distant), where 3 out of 6 in high group
(0.5), and 2 out of 4 in borderline group (0.4-0.5), and 4 out of 105 in normal-
ized group (0.4). In particular, patients who relapsed in higher del-1 group
showed relatively earlier relapse compared to lower del-1 group. Conclusion: In
a prospective cohort study, we confırmed that exosomal del-1 has a potent di-
agnostic role in breast cancer. Furthermore, del-1 was also identifıed to dramat-
ically decrease after curative surgery. Our current fındings suggest its potential
prognostic role as well as diagnostic role in breast cancer patients.
Changes of Exosomal Del-1 level between baseline and after-surgery (n115)
sampling time baseline after surgery p-value (paired t-test)
Del-1 (mean	SD) 1.237	0.453 0.188	0.124 0.001
#2782 The potential of p4EBP1 expression as predictive biomarker of
mRCC. Sei Naito, Osamu Ichiyanagi, Hiromi Ito, Hidenori Kanno, Tomoyuki
kato, Yuuta Kurota, Atsushi Yamagishi, Mayu Yagi, Toshihiko Sakurai, Hayato
Nishida, Hisashi Kawazoe, Tomohiro Shibasaki, Akira Nagaoka, Norihiko
Tsuchiya. Yamagata University, Yamagata, Japan.
Introduction & objectives: Activation of Akt/mTOR pathway induces 4EBP1
phosphorylation, and enhances cell proliferation, anti-apoptotic effect, and an-
giogenesis in many types of cancers including renal cell carcinoma (RCC). As
mTOR and angiogenetic proteins are main targets in metastatic RCC (mRCC)
treatment. We assessed the correlation with survivals and phosphorylated
4EBP1 (p4EBP1) expression.Materials&methods:We enrolled 254non-mRCC
patients who underwent primary surgery in Yamagata University between 2003
and 2010, and 59 mRCC patients whose resected primary lesion was available.
Immunohistochemistry for p4EBP1 was performed on their FFPE samples. We
assessed correlations between p4EBP1 expression manners and clinical features
(disease-free interval [DFI] for non-mRCC patients, cause-specifıc survival
[CSS] and progression-free survival [PFS] for mRCC patients). The CSS was
calculated from mRCC diagnosis to death or last follow-up date. The PFS was
calculated based on the durations patients were medicated. Univariate analysis
was calculated by log-rank test andmultivariate analysis was calculated by Cox-
regression analysis. Results: Non-mRCC patients with highly p4EBP1 expres-
sion were shorter DFI than those without high expression (p  0.036). Their
5-year disease-free rates were 83.4% and 93.4%, respectively. The independent
poorDFI factorswere high p4EBP1 expression (HR; 3.4, p 0.0054), grade (p
0.0055), and pT stage (p  0.0001). In contrast, mRCC patients with p4EBP1
expression was longer CSS than those without expression (median CSSs; 56.7
and 32.2 months, p  0.0246). The independent poor CSS factors were no
p4EBP1 expression (hazard ratio [HR]; 3.3, p 0.0409), grade 4 (HR; 8.7, p
0.0006), and poor prognostic group onMSKCC criteria (HR; 4.2, p 0.02770).
Expression of p4EBP1 showed statistically longer PFS in mRCC patients with
axitinib (median PFS; 9.2 and 2.5 months, p 0.0255). The similar trends were
shown in patients with other TKIs and mTOR inhibitors. Conclusion: Since
non-mRCC patients with the highly p4EBP1 expression had shorter DFI, ex-
pression of p4EBP1 should indicate aggressive RCC in nature. Nevertheless,
mRCCpatients with p4EBP1 expression had longer survival. These resultsmean
that expression of p4EBP1might be a predictive biomarker for TKIs andmTOR
inhibitors.
#2784 Identifying biomarkers to predict cardiotoxicity of doxorubicin in
individual patients. Liqun Zhao, Baolin Zhang. FDA, Silver Spring, MD.
Doxorubicin is a highly effective anticancer agent but causes cardiotoxicity in
many patients. This study aims to identify biomarkers to predict potential car-
diotoxicity before the onset of cardiac tissue damage and dysfunction in indi-
vidual cancer patients. First, we established a human cellular system to model
the cardiac toxicity of oncology drugs using human induced pluripotent stem
cells-derived cardiomyocytes (iPS-CMs). We tested a panel of clinically used
drugs including anthracyclines (doxorubicin, daunorubicin, epirubicin and ida-
rubicin), 5-FU, Taxol, Trastuzumab, and tyrosine kinase inhibitors (sunitinb,
imatinib, and sorafınib). These drugs displayed varying degrees of cytotoxicity
in iPS-CMs which are generally consistent with their known cardiotoxicity pat-
terns. Second, we found that doxorubicin selectively upregulated the expression
of death receptors in iPS-CMs. As a result, the treated iPS-CMs underwent
spontaneous apoptosis that was further enhanced in the presence of specifıc
cytokines. Based on these fındings, we hypothesize that the baseline levels of the
predefıned cytokines in blood could be predictive of cardiotoxicity associated
with doxorubicin treatment in individual patients. We are currently investigat-
ing the relationships between the levels of the predefıned cytokine signature in
blood and cardiac events in patients who received doxorubicin or related an-
thracycline therapy.
#2785 A comprehensive RNA-based assay for treatment prediction in
non-small cell lung cancer patients.KlaasKok, JaicongWei,AnnaRybczynska,
Martijn Terpstra, Anthonie van der Wekken, Jeroen Hilterman, Ed Schuuring,
Rolf Sijmons, Harry Groen, Anke van den Berg. UMCG, Groningen, Nether-
lands.
Purpose: In late-stage lung cancer an increasing number of genomic aberra-
tions is used to predict either sensitivity to, or resistance against, targeted ther-
apies. These include genemutations, gene fusions, amplifıcations and in the near
future different relevant splice variants. Currently, detection of each type of
aberration is carried out with different tests. We have set out to develop a novel
all-in-one assay to detect the various types of aberrations, e.g. mutations, gene
fusions and overexpression. The latter is assumed to be the biological marker
that is underlying gene amplifıcation. Methods: Our assay is based on the Single
Primer Enrichment Technology (SPET), allowing amplifıcation of a target re-
gion using only a single sequence-specifıc primer. Our fırst custom-designed
panel targets a comprehensive list of hotspots with therapeutic and prognostic
signifıcance in lung cancer, including EGFR, ALK, MET, KRAS, NRAS,
PIK3CA, ROS1, BRAF, FGFR1 and RET. Using total RNA as input, we will be
able to effıciently detect mutations, gene fusions and aberrant expression levels
of selected genes. This test may also detect tumor-specifıc aberrations in plate-
lets. Results: As a proof of principle we analyzed RNA derived from 8 lung
cancer-derived cell lines, from two frozen tumor biopsies, and from 10 FFPE
biopsies all with confırmed genomic alterations by clinically approved assays. In
total, conventional methods detected 18 small mutations, fıve gene fusions and
three gene amplifıcations, that are all covered by our assay. Of these, 14 muta-
tions, and four gene fusions were readily detected with our assay. The detection
of three mutations failed because of low coverage of the target region, probably
due to a less optimal design of the specifıc primer. One small deletion, and one
gene fusion were not detected with our RNA-based assay, despite a high read
coverage. Quantifıcation of the expression level of the amplifıed genes is still
under investigation. Conclusion:Our preliminary data indicate this novel RNA-
based assay not only effıciently identifıes all crucial mutations in lung cancer cell
lines, but also in small frozen and FFPE tumor biopsies of lung cancer patients.
Our next goal is to test this novel method on RNA derived from platelets from
cancer patients, providing a minimal invasive procedure to monitor the state of
disease in those patients.
#2786 EGFR expression and phosphorylation inHNSCCpredict response
to EGFR inhibition but cell lines are not representative for the clinical situa-
tion. Oliver von Ahsen,1 Sami S. Khaznadar,1 Martin Khan2. 1Bayer Pharma
AG, Berlin, Germany; 2Klinikum Dahme-Spreewald, Koenigswusterhausen, Ger-
many.
Introduction: Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer. Survival rates have not been improved for decades and
conventional therapy is effective in only 50% of the patients. Based on broad
expression in up to 80-90% of theHNSCC cases, epidermal growth factor recep-
tor emerged as drug target but clinical effıcacy of EGFR inhibitors in HNSCC is
very limited. We therefore reinvestigated the EGFR expression levels necessary
for response in cell lines and clinical samples. Methods: Standard procedures
were used for IHC. The antibody clone D38B1 was used in 1:900 dilution for 2h
at RT. Stainings were performed using the DAKO Envision system. EGFR ex-
pression and phosphorylation of Tyrosine-1173 were analysed by MSD (Me-
soscale Discovery) in lysates from fresh frozen tumor or exponentially growing
cells. For proliferation assays, 2000 cells per well were grown for 24 h before
addition of inhibitors. Cell culture was continued for 72 h before testing viability
using the CellTiter-Glo® Assay. Results: The majority (11/13) of HNSCC cell
lines responded to theEGFR inhibitor Erlotinib. EGFRwas highly expressed and
phosphorylated in the Erlotinib responsive cell lines. Resistant cell lines dis-
played low level EGFR expression and phosphorylation. However, EGFR ex-
pression and phosphorylation in treatment naive clinical samples were signifı-
cantly below the levels found in responding cell lines. In clinical samples EGFR
was not overexpressed on the cellular level. Based on these fındings, a clinical
response to Erlotinib in HNSCC would not be expected. Conclusion: The prog-
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nostic value of EGFR expression has been used to argue for EGFR as a relevant
target in HNSCC. Although most reviews claim that EGFR is overexpressed in
HNSCC, clear data supporting this position are missing. Early studies tested the
RNA levels and found the EGFR expression in tumors higher compared to
control tissues. Studies using IHC assessed the association of EGFR expression
with disease progression, but no comparison to expression in normal mucosa
was described. Overexpression was based on percentage of positive cells not on
the intensity of expression.We show similar levels of EGFR expression in grow-
ing keratinocytes and tumor cells. The often described overexpression only orig-
inated from a larger number of EGFR positive cells, not on overexpression on
the cellular level. The high expression and functional relevance of EGFR in cell
lines proves that EGFR activity is required for survival in cell culture. Our fınd-
ings lead to the conclusion that this is not representative of the clinical situation.
Defınition of a response threshold for EGFR expression and clinical verifıcation
of this expression level is mandatory for the successful use of a predictive bio-
marker.
#2787 Identifying predictivemarkers of endocrine response in high-grade
serous ovarian cancer using RNA sequencing. Cristina Mapagu,1 Sian Fere-
day,2 Australian Ovarian Cancer Study Group, David D. Bowtell,2 Paul R. Har-
nett,3 Anna deFazio1. 1Westmead Institute for Cancer Research, University of
Sydney, Sydney, Australia; 2Peter MacCallum Cancer Centre, East Melbourne,
Australia; 3Crown Princess Mary Cancer Centre at Westmead Hospital, West-
mead, Australia.
Epithelial ovarian cancer is a complex disease and patients vary consider-
ably in response to treatment. A subset of patients responds well to endo-
crine therapy, however hormone receptor positivity does not predict re-
sponse and there are no biomarkers in clinical use to help select patients that
would benefıt from endocrine agents. We aimed to identify markers of en-
docrine response in high-grade serous ovarian cancer (HGSOC) by analysis
of genes that are differentially expressed in tumors from patients that are
endocrine responders compared with non-responders, combined with anal-
ysis of estrogen (E2) regulated genes that differ between E2 sensitive and E2
insensitive HGSOC cell lines. Methods: Among women recruited to the Aus-
tralian Ovarian Cancer Study, we identifıed 10 HGSOC patients treated with
endocrine therapy (5 responders and 5 non-responders, based on GCIG
CA125 response criteria) and performed RNAseq on cryopreserved tumor
tissue. We also utilized paired E2 receptor (ER) positive HGSOC cell lines,
derived from the same patient, with differential sensitivity to the growth
effect of E2, PEO1 (E2 insensitive) and PEO4 (E2 sensitive). RNA was ex-
tracted following treatment with 0.1 nM E2 (or vehicle) for 24 hrs and gene
expression changes in response to E2 were determined using RNAseq. Ex-
pression of selected ER responsive genes was validated using PCR array.
Differential gene expression was determined using EdgeR. Pathway and
Gene Ontology enrichment analysis of differentially expressed genes were
performed usingMetacore. Results: Between endocrine responders and non-
responders, 27 genes were signifıcantly differentially expressed (False Dis-
covery Rate (FDR)0.05, absolute log2 Fold-Change (FC)
1). In the paired
HGSOC cell lines, signifıcantly more genes were regulated by E2 in E2-sen-
sitive PEO4, compared with E2-insensitive PEO1 (896 genes compared to 56
genes, respectively, FDR0.05, absolute log2FC
1). In response to E2, up-
regulation of NRP1 in PEO1, up-regulation of LTBP1, MYC, PDZK1 and
down-regulation of S100A6 and CYP1A1 in PEO4 were validated by PCR
array profıling of ER-related genes. Genes regulated by E2 in cell lines and
also differentially expressed between endocrine responders and non-re-
sponders included anoctamin 1 (ANO1) and NOTCH-Regulated Ankyrin
Repeat Protein (NRARP). Both were up-regulated in endocrine responders
and also up-regulated by E2 in PEO4. Conclusion: The use of RNAseq in both
tumors and cell line models was able to identify plausible sets of genes with
prior evidence of association with endocrine sensitivity. In breast cancer,
ANO1 has been associated with good prognosis following tamoxifen treat-
ment, while NOTCH signaling, implicated in endocrine resistance, is nega-
tively regulated by NRARP. Further validation is required to test the utility of
these genes as predictive biomarkers that may aid in identifying HGSOC
patients likely to respond to endocrine treatment.
#2788 High ALDH1, S phase fraction, p16INK4A in esophageal squamous
cell carcinoma could predict response to neoadjuvant chemotherapy. Rajeev
Kumar,1 R. Ravi Kannan,1 Akalesh Kumar Verma,1 Anuradha Talukdar,1
Monoj Kumar Deka,1 Ritesh Tapkire,1 Litika Vermani,1 Sankar Kumar Ghosh2.
1Cachar Cancer Hospital and Research Centre, Assam, India; 2AssamUniversity,
Assam, India.
Background: The prevalence of locally advanced esophageal squamous
cell carcinoma (ESCC) remains high despite technological advancements in
its diagnosis. This leads to prolonged multimodality treatment often result-
ing in poor response eventually leading to poor prognosis. Currently, there
are no biomarkers available to predict response to neoadjuvant che-
motherpy. Aldehyde dehydrogenase 1 (ALDH1), human epidermal growth
factor receptor-2 (HER2), p16INK4A, ploidy and S phase fraction are consid-
ered signifıcant biomarkers in various solid malignancies. However, there is
paucity of data on their clinical signifıcance in ESCC. In the present study, we
investigated their signifıcance in predicting the response to neoadjuvant
chemotherapy (NACT) in ESCC patients. Methods: Immunohistochemisty
of ALDH1, HER2, p16INK4A and propidium iodide based cell cycle analysis
through flow cytometer was performed in pre treatment biopsy sample col-
lected from 108 ESCC patients who were presented at a comprehensive can-
cer centre in northeast India and all of them subsequently received neo
adjuvant chemotherapy. Results: ALDH 1, HER2 and p16INK4A were found
positive in 65.7%, 7.4% and 22% of pre treatment ESCC specimens respec-
tively. ALDH1 expression correlates with poor response to neo adjuvant
chemotherapy (P0.001). A signifıcant proportion of poor responders were
found to be smokers (P0.004). Poor responders also tends to correlate with
increased mortality (P0.009). HER2 couldn’t predict response to NACT.
However, all HER2 positive cases were associated with high ALDH1 expres-
sion (P0.034). 50% of those with pathologically complete response were
p16 positive on the contrary only 15% non responders were positive for p16
(P0.001). 84% of the ESCC patients reported aneuploid tumor status and
responder’s were found having high S phase fraction (P0.041). Conclusion:
High ALDH1 expression can predict poor response whereas high p16 and S
phase fraction can indicate good response to neoadjuvant chemotherapy in
ESCC patients. HER2 seems having no clinical signifıcance in the response
assessment of neo adjuvant chemotherapy in ESCC.
#2789 PID, a novel immunofluorescence nanotechnology, as a histopa-
thology-based EGFR biomarker assay enhances predictive power for the Er-
bitux response in subsets of PDXs. Henry Qixiang Li,1 Jia Xue,1 Hisatake
Okada,2 Etsuko Futaya,2 Yoshikazu Kurihara,2 Likun Zhang,3 Xiaoyu An,3
Sheng Guo3. 1Crown Bioscience, Inc., Beijing, China; 2Konica Minolta, Beijing,
Japan; 3Crown Bioscience, Inc., Santa Clara, CA.
Immunohistochemistry (IHC) is the most common used assay for detecting/
quantifying defıned protein biomarkers in specifıc tissue location in clinical/
preclinical settings as prognostic/drug-predictive biomarker assays. However,
IHC suffers from several key drawbacks, limiting its applications, including
semi-quantitative nature, inconsistence, low sensitivity, narrow dynamic detec-
tion range and inadequacy for multi-target analysis, etc. An alternative method
is immunofluorescence (IF), but with even lower usage for its disadvantageous
photo-instability. A sensitive, quantitative and robust assay is thus an urgent/
unmet need. We have recently developed a novel fluorescence nanoparticle
(PID, phosphor integrated dye) with highly compact phosphor inside. PID has
several key advanced features: 1) enhanced fluorescence (30,000x brighter over
the conventional fluorescence and signifıcantly above tissue auto-fluorescence),
2) enhanced photo-stability (stained slide is stable for2 years); 3) highly quan-
titative by broadened detection dynamic range through enumeration of the
bright fluorescent dots (nanoparticles) instead of signal amplifıcation as in IHC
(digital vs. analog); 4) fıne subcellular imaging; 5) potentials for multi-color and
H&E/bright light imaging. PDX is a well-accepted experimental cancer model
mimicking original patients in histo- & molecular pathology(1), as well as drug
response. We previously conducted a series of mouse clinical trial (MCT) of
Erbitux on PDX cohorts of NSCLC, CRC, gastric and esophageal cancers (2,3),
showing specifıc subsets of high-EGRF-expressing PDXs responded to the drug,
where EGFR expression wasmeasured by either RNAseq (mRNA) or IHC (pro-
tein). To assess PID-EGFR as a new biomarker assay platform, we analysed and
compared its quantifıcation to RNAseq and IHC, particularly in terms of the
correlation to the drug effıcacy. Our data demonstrates a greatly enhanced cor-
relation of PID scores to mRNA levels in all cancer types, and to the tumor
growth inhibition of gastric (3) and esophageal (4) carcinoma, but not in CRC
(2) and NSCLC (Li et al., unpublished) as anticipated. The results demonstrated
that PID-EGFR is a signifıcantly improved histopathology based EGFR protein
quantifıcation assay over IHC-EGFR assay, warranting further clinical confır-
mation. References 1. Guo S, et al. Cancer research 2016;76(16):4619. 2. ChenD,
et al. Oncotarget 2015;6(38):40815 3. Zhang L, et al. Sci Rep 2013;3:2992. 4. Zhu
et al. 2016.
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#2790 PRC2mediated repression of SMARCA2 predicts for EZH2 inhib-
itor activity in tumors with SWI/SNF mutations. Thomas Januario, Xiaofen
Ye, Russell Bainer, Bruno Alicke, Margaret Solon, Benjamin Haley, Zora Mod-
rusan, Stephen Gould, Hartmut Koeppen, Robert L. Yauch. Genentech, Inc.,
South San Francisco, CA.
A synthetic lethality caused by EZH2 inhibition in the context of SNF5 mu-
tations is supported by both preclinical and recent clinical data, however the
extent of the synthetic lethal relationship in the context of other SWI/SNF sub-
unit mutations is not well understood. We determined that a subset of
SMARCA4mutant cancer models are sensitive to EZH2 inhibition. EZH2 inhi-
bition resulted in a heterogenous phenotypic response characterized by senes-
cence and/or apoptosis amongst models, and further lead to tumor growth in-
hibition in vivo. The differential sensitivity to EZH2 inhibition was not caused
by a differential pharmacodynamic effect of the drug, nor differences in basal
histone methylation or PRC2 subunit levels. However, expression of the SWI/
SNF subunit, SMARCA2, delineated sensitivity amongst SMARCA4 mutant
models tested. Expression of SMARCA2 further delineated sensitivity amongst
other SWI/SNF mutant models tested, including SNF5 and ARID1A mutants.
We determined that SMARCA2 is under PRC2 mediated suppression and the
derepression of SMARCA2 was necessary for apoptosis, but not senescence, in
response to EZH2 inhibition. SMARCA2has been shown to be concurrently lost
in a high percentage of SNF5 mutant malignant rhabdoid tumors and
SMARCA4 mutant SCCOHT tumors, however we determined that 15% of
SMARCA4 mutant NSCLCs concurrently lose SMARCA2. Our data supports
monitoring SMARCA2 expression as a predictive biomarker for EZH2-targeted
therapies that are currently being developed in the context of SWI/SNF mutant
cancers.
#2791 CDC25A overexpression is correlated with tumor response to ra-
diotherapy in locally advanced rectal cancer. Ming-Yii Huang. Kaohsiung
Medical University, Kaohsiung, Taiwan.
Background. Radiotherapy is increasingly used in preoperative approaches
for locally advanced rectal cancer to reduce local recurrence. However, the prin-
cipal limitation is large variability in response among different individuals due
to tumor heterogeneity. In current study, we compared gene expression profıles
between radiation responder and non-responder in cancerous tissues to identify
radiation-related molecules that can be used to evaluate the tumor response of
radiation.Methods.We investigated fıve genes (CDC25A,VAV1, TP73, BRCA1
and ZAP70) which were signifıcantly related to prognostic factors (tumor size,
advanced stage, invasive depth, lymphnodemetastasis anddifferentiation) from
110 colorectal cancer tissues confırmed bymembrane array and RT-PCRmeth-
ods in our previous study. Therefore, we further investigate those protein over-
expressions by immunohistochemical stain in pretherapeutic rectal cancerous
tissues. The expression profıles were evaluated according to the frequency of
positive staining in the cytoplasm and/or nucleus of cancer cells. Its expression
was classifıed as positive in cases withmore than 50% positive-stained cells, with
other samples being classifıed as negative. Cancer tissues that expressed scores
of  were regarded as the overexpression group, whereas those with scores of
negative staining were regarded as the non-overexpression group. Results. We
focused on these 5 genes and validated datawith pretherapeutic biopsies from36
locally advanced rectal cancer patients, and found that overexpression of
CDC25A, VAV1 and ZAP70 were correlated with tumor response (P0.001,
0.033, and 0.016, respectively). Themultivariate logistic regressions with adjust-
ment of age, sex and stage, CDC25A overexpression more than 2-fold were
signifıcantly correlated with tumor response (OR  2.667, 95%CI  1.591-
4.470, P0.03). Positive fındings of CDC25A immunohistochemistry stainwere
also present in the tumor specimens of responders. Conclusion. We identifıed
radiation-related genes in rectal cancer and demonstrated that CDC25A may
play an important role in response to radiotherapy. These fındings suggest that
CDC25Amay be a novel marker for predicting the effectiveness of radiotherapy
in clinical patients.
#2792 The small molecule imipridone ONC201 is active in tumor types
with dysregulation of the DRD2 pathway. Neel Madhukar,1 Varun Vijay
Prabhu,2 Etienne Dardenne,1 Faye Doherty,3 Alexander VanEngelenburg,3 Ro-
hinton Tarapore,2 Mathew Garnett,4 Ultan McDermott,4 Cyril Benes,5 Wolf-
gang Oster,2 Wafık El-Deiry,6 Mark Stein,7 David Rickman,1 Joshua Allen,2
Olivier Elemento1. 1Weill Cornell Medicine, New York, NY; 2Oncoceutics, Inc,
Philadelphia, PA; 3HistoTox Labs, Inc, Boulder, CO; 4Wellcome Trust Sanger
Institute, Hinxton, United Kingdom; 5Massachusetts General Hospital, Boston,
MA; 6Fox Chase Cancer Center, Philadelphia, PA; 7Rutgers Cancer Institute of
New Jersey, New Brunswick, NJ.
ONC201 is the lead small molecule of the imipridone class of anti-cancer
compounds that is currently being evaluated in phase I/II advanced cancer clin-
ical trials. ONC201 is a highly selective antagonist of the G protein-coupled
receptor dopamine receptor D2 (DRD2) that has exhibited promising anti-can-
cer effıcacy and an exceptional safety profıle. In the current study, we evaluated
the influence of the DRD2 pathway on the responsiveness of tumors toONC201
in preclinical and clinical studies. In vitro and in vivo studies have previously
demonstrated robust ONC201 effıcacy in glioblastoma (Allen et al 2013) and
lymphoma (Ishizawa et al 2016) models. ONC201 Phase I trials have also re-
vealed evidence of clinical benefıt in endometrial cancer (Stein et al 2016). In
vitro effıcacy profıling of ONC201 in the Genomic of Drug Sensitivity in Cancer
(GDSC) collection of cell lines confırmed broad-spectrum anti-cancer effıcacy
with particularly high sensitivity in lymphoma, neuroblastoma, endometrial
and brain cancer. DRD2 is overexpressed in many cancers and DRD2 antago-
nism kills cancer cells via the same signaling pathways that are altered in re-
sponse to ONC201. Results from the Project Achilles screen indicate that anti-
cancer effects of DRD2 knockdown in various tumor types correlated with
overall ONC201 effıcacy. In particular, we noted that lymphoma cells are highly
sensitive to DRD2 knockdown- a tumor type where ONC201 performs well.
Gene expression analysis of samples in the Cancer Genome Atlas (TCGA) re-
vealed high DRD2 expression in ONC201-sensitive tumor types, such as lym-
phoma and glioblastoma, and that high expression of DRD2 in glioma was
associated with a poor prognosis. High DRD2 expression was also observed in
neuroendocrine prostate cancer relative to other prostate cancer subtypes. In
immunohistochemistry analyses of patient-derived tumor tissue microarrays,
DRD2 overexpression was particularly noted in endometrial cancer, neuroblas-
toma and pheochromocytoma relative to normal tissues. The anti-cancer activ-
ity of ONC201 in pheochromocytoma and neuroendocrine prostate cancer was
confırmed in cell viability assays. In ONC201-treated patients, ELISA was used
to quantitate serum prolactin levels, a clinical biomarker of DRD2 antagonism.
A 2-fold mean induction of prolactin, was detected in the serum of ONC201-
treated patients, in accordance with physiological DRD2 antagonism. Interest-
ingly, expression of DRD5 (a D1-like dopamine receptor), which counteracts
DRD2 signaling, was signifıcantly negatively correlated with ONC201 in vitro
potency in the NCI60 and GDSC dataset (P .05). Furthermore, a missense
DRD5 mutation was identifıed in cancer cells with acquired resistance to
ONC201. In conclusion, the DRD2 pathway is expressed in ONC201-sensiive
tumors and may provide biomarkers of response.
#2793 Evidence forWT1 as a potential target for immunotherapy of lethal
ovarian cancer. Julia H. Carter,1 James A. Deddens,2 Gretchen Mueller,1
Thomas G. Lewis,1 Mariah K. Dooley,1 Jackson O. Pemberton,3 Larry E. Doug-
lass1. 1Wood Hudson Cancer Research Lab., Newport, KY; 2University of Cincin-
nati, Cincinnati, OH; 3St Elizabeth Healthcare, Edgewood, KY.
Epithelial ovarian cancer is the leading cause of death from gynecologic can-
cers with 22,280 new cases anticipated in 2016 and 14,240 deaths. Most patients
are diagnosed at late stages and have a poor prognosis. Radical surgery and
chemotherapy are the primary treatment. When relapse occurs there are few
treatment options. The overall survival rate of women with ovarian cancer is
unchanged in 50 years. Approximately 70% of epithelial ovarian cancers are
serous including low grade serous tumors, some of which may evolve from
serous borderline tumors, and high grade serous carcinomas. The latter are
thought to originate in the fallopian tube. There are eight other subtypes of
invasive ovarian cancer. All invasive ovarian cancers have recently been classi-
fıed into two subtypes, Type 1 (indolent) and Type 2 (aggressive). The Wilms’
Tumor 1 (WT1) protein is expressed in some normal tissues including the fal-
lopian tube and ovary aswell as in tumors such as ovarian and breast cancers and
in leukemia. WT1 is a highly immunogenic tumor associated antigen. Mutated
p53 is found in many high grade ovarian cancers. Recent reports indicate that
WT1 and p53 may interact physically and functionally. BothWT1 andmutated
p53 have been suggested as prognostic markers in ovarian cancer. We sought to
determine the role of co-expression of mutated p53 andWT1 in overall survival
of patientswith ovarian cancer.Histologic sectionswere prepared fromarchived
FFPE surgical specimens donated by St. Elizabeth Healthcare (Northern KY)
and fully annotated by hospital records. H&E stained sections were diagnosed
and graded by a board certifıed pathologist (LED) and included histologic sec-
tions from 41 borderline tumors and 98 Type 1 and Type 2 cancers. Adjacent
sections were stained immunohistochemically using monoclonal antibodies
(DAKO) to WT1 and p53. For survival analysis p53 was considered mutated if
75-100% of the tumor nuclei were stained (missense mutations) or if all nuclei
were negative (truncated protein) and WT1 was considered either non-ex-
pressed (no stain) or expressed (some or all nuclei stained). While either mu-
tated p53 or WT1 were prognostic alone of patient survival with Type 1 and
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Type 2 tumors, WT1 was a better predictor as seen by log-rank Chi-square. The
20 year survival probability of patients with tumors negative for both mutated
p53 and WT1 was 70% and was signifıcantly better than other patients (p 
0.0001). The 20 year survival probability for tumors negative for WT1 but ex-
pressing mutated p53 was 41%, and was 9% for tumors expressing WT1 and
non-mutated p53. Patients with tumors expressing bothWT1 and mutated p53
had a 20 year survival probability of 6%. Given these data and the immunoge-
nicity of the WT1 tumor associated antigen we conclude that IHC detection of
mutated p53 andWT1 in invasive ovarian cancers would be useful in stratifying
patients eligible for immunologic approaches targeting WT1 for therapy of le-
thal ovarian cancers.
#2794 Indotecan (LMP400), imidotecan (LMP776) and LMP744: A new
class of non-camptothecin Top1 inhibitors selective for homologous recom-
bination defıcient (HRD) cells. LaetitiaMarzi, Keli Agama, ZoeWeaver Ohler,
Ludmila Szabova, Shyam Sharan, Junko Murai, Muthana Al Abo, Yves Pom-
mier. NCI, Bethesda, MD.
To relax DNA supercoiling during transcription and replication, topo-
isomerase I (Top1) induces transient DNA cleavage complexes, which are
trapped by anticancer drugs, leading to DNA double-strand breaks (DSB)
that need to be repaired by homologous recombination (HR). BRCA1,
BRCA2 and PALB2, which are key components for HR, lead to “synthetic
lethality” with PARP inhibitors. Topotecan and irinotecan (camptothecin
derivatives) are the only FDA-approved Top1 inhibitors. In spite of their
wide usage they are plagued by their chemical instability, being drug efflux
substrates, having short half-life, and dose-limiting bone marrow and gastro
intestinal toxicity. It is now possible to overcome those limitations with the
non-camptothecin indenoisoquinolines (LMP400, LMP776 and LMP744),
which are in clinical trials. To rationally select patients for phase 2 clinical
trials based on cancer-specifıc genomic alterations, we have determined
whether the LMPs present a “synthetic lethality” toward BRCA1, BRCA2 or
PALB2 defıciency, and whether this selectivity could be enhanced by com-
bining them with the recently approved PARP inhibitor, olaparib.Using iso-
genic DT40 cell lines, with BRCA1, BRCA2 or PALB2 defıciencies, we as-
sessed the role of HR in the cellular responses to the LMPs. Survival and cell
cycle modifıcations were tested after treatment with the LMPs as single
agents, as well as in combination with olaparib. We found that BRCA1-,
BRCA2- and PALB2-defıcient cells are 3 to 5 times hypersensitive to the
LMPs (IC50’s for LMP400 and LMP74410 nM for HR-defıcient cells vs. 45
nM forWT cells, and IC50 for LMP776 around 5 nM vs. 18 nM forWT cells).
Cell cycle analyses confırmed the death of these HR-defıcient cells. More-
over, combination treatments showed a signifıcant synergy between each of
the three LMPs and olaparib (Combination index0.7). The HR-defıcient
cells being markedly more sensitive than WT cells (taken as surrogate for
normal tissues) to both treatments, led to a better response to the combina-
tion in those cells.Our results show that the LMPs are active at nanomolar
concentrations, selectively in HR-defıcient cells, indicative of a “synthetic
lethality” of the indenoisoquinolines (LMPs) with HRD genotypes. They also
demonstrate that the LMPs synergize with olaparib. These fındings provide a
rationale for personalized treatment and Phase 2 clinical trials with the in-
denoisoquinolines in combination with PARP inhibitors in HR-defıcient
cancers.
#2795 Integrating multiomics discovery approaches to identify biomark-
ers of therapeutic resistance inmetastatic colorectal cancer through analyses
of multiple sequential tumor and liquid biopsies; Qcroc01: NCT00984048.
Karen Gambaro,1 Maud Marques,2 Ryan Morin,3 Claudia Kleinman,2 Michael
Witcher,2 Simon Turcotte,4 Benoit Samson,5 Bernard Lespérance,6 Yoo-Joung
Ko,7 Richard Dalfen,8 Eve St-Hilaire,9 Lucas Sideris,10 Felix Couture,11 Sabine
Tejpar,12 Ronald Burkes,13 Mohammed Harb,14 Francine Aubin,4 Thierry Al-
cindor,15 Errol Camlioglu,2 Adriana Aguilar,2 Mathilde Couetoux du Tertre1,1
Suzan McNamara,1 Adrian Gologan,2 Petr Kavan,2 Gerald Batist2. 1Quebec-
Clinical Research on Cancer (Q-CROC), Montréal, Quebec, Canada; 2Segal Cen-
cer Centre-Jewish General Hospital, Montréal, Quebec, Canada; 3Simon Fraser
University, Vancouver, British Columbia, Canada; 4Centre Hospitalier de
l’Université de Montréal, Montréal, Quebec, Canada; 5Charles LeMoyne Hospi-
tal, Montréal, Quebec, Canada; 6Sacré-Coeur de Montréal, Montréal, Quebec,
Canada; 7Sunnybrook Health Science Centre, Toronto, Ontario, Canada; 8St.
Mary’s Hospital, Montréal, Quebec, Canada; 9Georges Dumont Hospital, Monc-
ton, NewBrunswick, Canada; 10HôpitalMaisonneuve Rosemont,Montréal, Que-
bec, Canada; 11Hôtel-Dieu de Quebec, Quebec, Quebec, Canada; 12Katholieke
Universiteit Leuven, Leuven, Belgium; 13Mount Sinai Hospital, Toronto, Ontario,
Canada; 14Moncton Hospital, Moncton, New Brunswick, Canada; 15McGill Uni-
versity Health Centre, Montréal, Quebec, Canada.
Colorectal cancer (CRC) is the 2nd leading cause of cancer-related death in
Canada. Clinical responses of metastatic (m)CRC to fırst-line treatment range
from 35 to 60%, but even responders inevitably develop therapeutic resistance.
Studies aiming at understanding mechanisms of resistance have largely investi-
gated primary tumors. However, selective pressures during therapy can lead to
the expansion of resistant clones and tumor heterogeneity. This highlights the
need to characterize the molecular changes of metastasis and plasma over time
of treatment and response to decipher tumor evolution and therapeutic resis-
tance mechanisms. In this multicenter study, 52 tissue samples from liver me-
tastasis were collected at baseline (pre-biopsies) and at the time of resistance
(post-biopsies) in responder and non-respondermCRCpatients (n44) under-
going the same standard fırst-line treatments. Multiple post-biopsies also have
been harvested in 4 patients, to allow the assessment of tumor heterogeneity and
as well as the evolution of the genomic complexity after treatment exposure.
Analyses were carried out across multiple omic platforms to identify resistant
signatures and characterize molecular changes during treatment. Biopsies were
profıled using exome and transcriptome sequencing as well as high-density SNP
array analysis to capture chromosomal anomalies, loss of heterozygosity (LOH)
and copy number variations (CNV). Additionally, serial blood samples were
collected for proteomic, ctDNA and cytokine analysis. Our preliminary analysis
of transcriptomes performed on serial biopsies from a set of 11 patients identi-
fıed genes consistently overexpressed at resistance. Cytogenetics analysis
showed similar genomic profıles of matched pre- and post-biopsies and allowed
the establishment of LOH and CNV catalogues of liver metastasis, while exome
sequencing revealed cumulative somatic mutations over time of treatment,
which suggests subclonal and acquired “driver”mutations of resistance. Plasma-
derived ctDNA analysis was performed to investigate themutational status dur-
ing treatment and whether they correlate with their relative levels in biopsies.
Immune gene expression analysis of a test set of 27 metastases revealed strong
clustering of 7 metastases due to overexpression of transcripts related to active
immune response, allowing to defıne novel subgroups of patients based on im-
mune response status. Our study, using amulti-omic strategy and integration of
independent molecular platforms to profıle liver metastasis samples of re-
sponder and non-responder mCRC patients, constitutes an innovative ap-
proach to identify clinical biomarkers and molecular signature of resistance,
which may enhance individualization of cancer medicine and customized ther-
apy.
#2796 Development of a RAD51-based assay for determining homolo-
gous recombination profıciency and PARP inhibitor sensitivity. Bose S.
Kochupurakkal,1 Kalindi Parmar,1 Jean-Bernard Lazaro,1 Christine Unitt,2
QingZeng,1Hunter Reavis,1 ChiragGanesa,1 ShanZhou,1 Joyce Liu,1 Sangeetha
Palakurthi,1 Kyle Strickland,2 Brooke Howitt,2 Panagiotis Konstantinopoulos,1
Paul Kirschmeier,1 Joseph Geradts,2 Ronny Drapkin,3 Ursula Matulonis,1 Alan
D’Andrea,1 Geoffrey Shapiro1. 1Dana-Farber Cancer Institute, Boston, MA;
2Brigham andWomen’s Hospital, Boston,MA; 3University of Pennsylvania, Phil-
adelphia, PA.
Homologous recombination (HR) repair defıciency confers sensitivity to in-
hibitors of poly(ADP-ribose) polymerase (PARP). To date, the identifıcation of
tumors with impaired HR has relied on genomic features, including mutational
signature, LOH-basedHRD assays or gene expression analyses defıning ‘BRCA-
ness’. These tests analyze history of the tumor rather than providing a functional
assessment of HR status at the time of diagnosis. Therefore, development of a
functional assay for HR status in tumors is essential to make accurate treatment
decisions.Here, we describe a RAD51-based immunohistochemical (IHC) assay
that identifıes HR status. We fırst screened commercial anti-RAD51 antibodies
and identifıed amonoclonal antibody that detects RAD51 foci inHR-competent
normal fıbroblasts and shows no evidence of foci in HR-defıcient (BRCA2/)
VU423 fıbroblasts after -irradiation. Conditions for detecting RAD51 foci in
FFPE samples were identifıed using HR-defıcient and HR-profıcient triple-neg-
ative breast cancer cell lines. HR-defıcient, PARP inhibitor-sensitive cell lines
exhibited high levels of nuclear RAD51 and no evidence of foci, whereas HR-
profıcient, PARP inhibitor-resistant cells had low levels of nuclear RAD51 and
foci. This result was confırmed in a BRCA1-mutated, PARP inhibitor-sensitive
PDX model, where there was no evidence of foci although RAD51 levels were
high. We further evaluated the pattern of RAD51 staining in 13 high-grade
serous ovarian cancer (HGSOC) PDX models, for which sensitivity to olaparib
had been characterized. The only olaparib-sensitive model demonstrated com-
plete absence of RAD51 staining. Among the other 12 olaparib-resistantmodels,
RAD51 foci were detectable, both before and after irradiation. The presence or
absence of RAD51 foci correlated with olaparib sensitivity and not with BRCA
mutation status. Therefore, tumors that are HR-defıcient and PARP inhibitor-
sensitive are characterized by either high RAD51 nuclear staining without foci,
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or absence of RAD51 staining. To validate these fındings, we analyzed RAD51
staining patterns in a cohort of 50 primaryHGSOCs from patients subsequently
treated with platinum-based chemotherapy. Among these 50 samples, 45 dem-
onstrated either RAD51 nuclear staining without foci or an absence of RAD51
staining. Five samples demonstrated RAD51 staining with foci. The median
survivals of these groups were 6.1 and 1.5 years, respectively. In conclusion, we
have developed a robust IHC assay for determining the functional HR-status in
tumor samples. Further work will be required to determine if the staining pat-
terns observed predict PARP inhibitor sensitivity among primary patient sam-
ples. Funded by a Biomarker Supplement to UM1 CA186709, NIH Grant P50
CA168504, SU2C Ovarian Cancer Dream Team and BCRF grant.
#2797 MiR-137 andMiR-496 target Del-1 and affect triple negative breast
cancer progression. Jeeyeon Lee, Yee Soo Chae, Soo Jung Lee, Jin Hyang Jung,
Ho Yong Park, Moon-Chang Baek. Kyungpook National University Medical
Center, Daegu, Republic of Korea.
Background: Although Del-1 was recently proposed as a new biomarker for
early breast cancer in our previous studies, the mechanisms of Del-1 expression
are barely understood. In the current study, we selected two microRNAs (miR-
137 and - 496), potentially affecting Del-1 expression in breast cancer and ex-
amined their impact onDel-1 expression in a variety of breast cancer cell lines to
identify their potential role in Del-1 expression and thereby breast cancer devel-
opment or progression. Methods: Del-1 mRNA and miR-137/- 496 levels were
measured by qRT-PCR among breast epithelial (MCF10A) and cancer cells
(MDA-MB-231, MCF7, SK-BR3 and T-47D). The effects of miR-137/- 496 on
cell proliferation and invasion were detected using MTT, wound healing and
Transwell assays. Furthermore, luciferase reporter assay was used to identify the
direct regulation of Del-1 by miR-137 or - 496 in MDA-MB-231 cells. Plus, we
analyzed the expressions ofmiR-137 or - 496 andDel-1mRNA from 20 patients
with triple negative early breast cancer. Results: miR-137 and - 496 levels were
low in all breast cancer cell lines. As Del-1 mRNA expression was remarkably
higher in MDA-MB-231 compared to the other breast cancer cell lines, further
functional analyses were done with MDA-MB-231 representing triple negative
breast cancer subtype. BothmiR-137 andmiR-496were revealed to directly bind
at the 3’-UTR of Del-1. Del-1 by Luciferase reporter assay and Del-1 expression
was upregulated by inhibitors and reversed by bothmimics of bothmiR-137 and
miR-496. Furthermore, both miR-137 and miR-496 were also demonstrated to
inhibit cell proliferation, migration and invasion of MDA-MB-231, suggesting
that these miRNAs affect cancer progression via Del-1. MiR-137 and miR-496
were remarkably down-regulated in 7 out of 12 triple negative breast cancer
tissues, in particular with high Ki67 and high histologic grade. Conclusion: Al-
though Del-1 was recently introduced as a new biomarker for triple negative
breast cancer, the mechanisms of Del-1 expression were barely identifıed. The
current study fırstly demonstrated that microRNA 137 and 496 are involved in
Del-1 regulation by binding at Del-1 gene, affecting cancer progression by alter-
ing Del-1 expression.
#2798 Identifıcation of gamma secretase inhibitor (GSI)-responsiveGBM
patients: Involvement of NOTCH, p53, and PI3K/MAPK signaling. Chen
Zhang,Martinez-Ledesma Juan, Jie Ding, Feng Gao, ShaofangWu, Xiaolong Li,
Erik Philip Sulman, Dimpy Koul,WKAlfred Yung. The University of TexasMD
Anderson Cancer Center, Houston, TX.
Glioblastoma (GBM) is the most common and lethal primary intracranial
tumor. The recent standard-of-care treatment consisting of surgery, fol-
lowed by radiotherapy and temozolomide, just prolongs the median survival
period of GBM patients to 14.6 months. What impedes the survival is due to
the extensive heterogeneity among GBM patients at both the cellular and the
molecular levels. In our study, we focused on the precision medicine strategy
targeting NOTCH signaling. According to recent Phase I/II clinical trial
results, only a few GBM patients showed satisfactory response to GSIs. How-
ever, little is known regarding how to distinguish GSI-responsive patients.
Here, we illustrated that it required (1) high NOTCH activity, (2) wild-type
p53 and elevated P53 activity, (3) increased MAPK activity, and (4) de-
creased PI3K/AKT activity for GBM to respond to GSIs. In our study, we
tested a series of patient-derived primary glioma stem cells (GSCs) to two
GSIs (RO4929097 and BMS-708163). GSI-sensitive lines were identifıed and
GSI compounds impaired cell viability and sphere formation ability in these
cell lines. GSIs also induced cell death of the sensitive GSCs. To fınd out the
signature of the GSI-sensitive GSCs, we did enrichment and correlation
analyses against RNA sequencing, RPPA, and methylation data of the GSI-
sensitive and resistant GBM lines. We found that GSI-sensitive GSCs har-
bored signifıcantly elevated Notch activity (high NOTCH1 and NICD1 ex-
pression, and low Notch1 methylation). Interestingly, GSI-responsive cells
also possessed increased P53 activity (increased expression of P53 targets-
P21, BAX and TIGAR), high wild-type p53 frequencies, increased MAPK
activity (elevated p-Erk1/2-Thr202/Tyr204 expression), and decreased
PI3K/AKT activity (high PTEN expression and low p-AKT-Thr308, RAP-
TOR, p-4E-BP1-Ser65 expression) (P0.05). In an attempt to strengthen
GSI effect, we showed that MDM2 inhibitor Nutlin-3 (retards P53 degrada-
tion and increases P53 activity) combining RO4929097 exhibited synergistic
effect on suppressing cell viability of GSI-sensitive cells with wild-type p53.
In summary, we elucidated the genetic characteristics (high NOTCH, wild-
type p53, high MAPK, and low PI3K/AKT) of GSI sensitive GSCs. Co-ad-
ministration of Nutlin-3 enhanced GSI function in the subset of GBMs. Our
fındings indicated genetic markers could be used to identify patients respon-
sive to GSIs, providing a new therapeutic strategy to treat this population of
GBM patients.
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#2799 Development of amousemodel of KRASmutated colorectal cancer
tumorigenesis.RadhashreeMaitra,1MadhuKumarVenkatesh,2 TittoAlbyAu-
gustine,1 Carol Chandy,1 Qiang Liu,1 Sanjay Goel1. 1Montefıore Medical Center,
Bronx, NY; 2Albert Einstein College of Medicine, Bronx, NY.
Introduction: Development of a preclinical animal model that mimics KRAS
mutated colorectal cancer disease etiology is essential for validation of new ther-
apeutic interventions. Colorectal cancer patients with tumors harboring KRAS
mutation are excluded from receiving anti EGFR monoclonal antibodies, and
currently have no alternate FDAapproved treatment options available.Ongoing
research requires validations of differentmodalities on a robust preclinical study
platform that will resemble the disease phenotype and genetic profıle. In this
context we have developed viable animal mouse model of colorectal cancer
bearing KRAS mutation that authentically serves as a model for the disease.
Methodology: The C57 BL/6 mice with truncated APC floxed allele was crossed
with heterozygous KRAS floxed outbred mice to generate APCf/f KRAS/f
mouse colony. In another set of breeding APC floxed mice were crossed with
CDX2-Cre-ERT2 mice and selected for APCf/f CDX2-Cre-ERT2 after second
round of inbreeding. The fınalmodel of the disease was generated by the cross of
the two aforementioned colonies when viable APCf/f KRAS/f CDX2-Cre-ERT2
were genotyped and characterized. The model animals were tamoxifen induced
to generate tumors. Micro-PET scan was used to detect and measure tumor
volume.H&E stainingwas done to establish neoplasm and immunohistochem-
istry was performed to determine histological similarities with human FFPE
biopsies. The MSI/MSS status was also determined. Results Ø The newly devel-
oped animalmodel develops colonic tumors upon inductionwith Tamoxifen. Ø
The tumors were malignant as confırmed by H and E staining. Ø The tumors
showed a higher radioactive FDG uptake (SUV) in micro-PET scan Ø The tu-
mors resembled human colorectal cancer tissue Ø Once tumor is generated the
animals died of cachexia and rectal bleeding Conclusion: Heterozygous muta-
tion ofKRASoncogene alongwith deletionmutation ofAdenomatous polyposis
coli (APC) gene is embryonically lethal in animal models. We have successfully
developed a viable animal model of KRAS mutated colorectal cancer with ta-
moxifen inducible tumors harboring KRAS and APC mutations. The tumors
mimic the human disease type both genetically and immunohistochemically.
This model can serve as a robust preclinical platform for understanding the
disease mechanism at the molecular level as well for evaluation of various ther-
apeutic interventions.
#2800 Transforminggrowth factor-beta 2 (TGF-2) antisense oligonucle-
otide (ASO) OT-101 synergizes with chemotherapy in preclinical tumor
models. Osmond D’Cruz,1 Cynthia Lee,1 Vuong Trieu,2 Larn Hwang2. 1Auto-
telic Inc, Costa Mesa, CA; 2Oncotelic Inc, Agoura Hills, CA.
Background: Overexpression of TGF-2 has been implicated in the malig-
nant progression of tumors by inducing immunosuppression, proliferation, an-
giogenesis and metastasis. Clinical failures of TGF- inhibitors in targeting the
tumor promoting arm of TGF- signaling is attributed tomultiple isoforms and
receptor functions. OT-101 (Trabedersen) is a phosphorothioate ASO designed
to specifıcally target human TGF-2 mRNA with superior clinical activity in
patientswithTGF-2-overexpressing tumors.Herein,we report the synergizing
effect of OT-101 with chemotherapy in multiple human tumor xenograft mod-
els for further exploration of clinical combinations. Methods: The in vivo effı-
cacy studies of intraperitoneal (IP, 16 or 50 mg/kg) or subcutanous (SC, 1-64
mg/kg) repeated administration (qdx3/wk or qdx21) of OT-101 as single agent
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and in combination with Gemcitabine (15 mg/kg, qdx2/wk, IP), Dacarbazine
(1-10 mg/kg, qdx4/wk, IP) or Paclitaxel (10 mg/kg, qdx5, IV) were evaluated in
nudemice (10/subgroup) bearing either (i) orthotopic human L3.6pl pancreatic
cancer (PAC), (ii) human metastatic C8161 melanoma, (iii) subcutaneous glio-
blastoma (U87-MG) or (iv) subcutaneous ovarian (SK-OV-3) tumors. Mice
were monitored thrice a week for adverse effects, body weight loss, tumor size
and survival outcome. The incidence of lymphnode and liver surface andmicro-
metastases as well as size and weight of the pancreatic tumors were determined.
Tumor sections were stained with anti-5-bromo-2’-deoxy-uridine antibody to
determine tumor cell proliferation and with anti-CD31/PECAM-1 antibody to
determine vascularization. Results: OT-101 signifıcantly reduced tumor growth
(p  0.0084), lymph node metastasis (p  0.023), and tumor angiogenesis
(p0.0001) in the orthotopic PAC model. Mean tumor vessel density was sig-
nifıcantly reduced (p0.0001) in all groups in comparison to untreated control.
OT-101 demonstrated synergy in tumor growth inhibition and increased sur-
vival in humanmalignantmelanoma (C8161, p 0.038, vs. Dacarbazine alone),
glioblastoma (U87-MG, p 0.001 vs. Paclitaxel) and ovarian (SKOV-3, p0.05
vs. Paclitaxel) cancer models when combined with either Dacarbazine (C8161)
or Paclitaxel (U87-MG and SK-OV-3). No syngergy was observed with Gemcit-
abine (PAC). The combination regimen tested was effective and tolerable. Sig-
nifıcant antitumor activity was achieved at human dose equivalent of 80mg/m2/
day which is well below the optimized clinical dose used for IV infusion of
patients at 140 mg/m2/day. Conclusions: The preclinical data lay the ground-
work for further exploration of combination therapy in the clinic as well as
demonstrating that TGF-2 is a druggable target. Of interest is the preferential
synergy between OT-101 and Paclitaxel or Dacarbazine, but not with Gemcit-
abine.
#2801 Identifıcation of oncogenic/metastatic driver genes that cooperate
with p53 or p53/Rb-loss to induce triple-negative breast cancer.RonakGhan-
bari Azarnier, Agatha Zuchelkowski, Philip.EChung, Zhe Jiang, Eldad Zacksen-
haus. University of Toronto, Toronto General Research Institute, Toronto, On-
tario, Canada.
Triple-negative breast cancer (TNBCs) is an aggressive subtype with poor
prognosis; drug-resistant metastases are common and highly lethal for which
identifıcation of therapeutic targets is of major medical interest. Previously we
demonstrated that deletion of p53 and Rb in mouse mammary epithelium in-
ducedTNBC-like tumors butwith limited capacity tometastasize. Therefore, we
decided to employ sleeping beauty (SB) mutagenesis system that can identify
oncogenic networks responsible to drive primary and metastatic tumors. In
order to do this, we generated mice in which p53 (p53f/f) or p53 plus Rb (p53f/f:
Rbf/f ) are deleted and the SB transposon is mobilized from chromosome 9 as
well as controls in which both p53 and Rb are wild type. Forty primary tumors
and forty metastases from each cohort will be harvested to identify common
integration sites followed by deep sequencing. Then, the top 5-10 candidate
oncogenes/tumor suppressors will be validated to determine whether their loss/
activation would accelerate tumorigenesis/metastasis. H&E staining of mam-
mary tumors collected so far from different genotypes revealed histologically
diverse tumor types which includes but not limited to poorly differentiated
tumors with areas of mesenchymal/spindle-like cells, acinar adenocarcinomas,
andwell differentiated tumors. All mice analyzed developedmultiplemammary
tumors in more than one mammary gland with average latency of 108, 158 and
170 days for p53/Rb deleted (N7), p53 deleted (N12), and wild type mice
(N2), respectively (p  0.05). However, we did not always observe macro
metastases in mice with primary mammary tumors and we decided to perform
primary tumor survival surgery when tumors are oversized and let the mice live
longer to develop metastases. With this technique, 3 out of 4 mice that under-
went tumor removal surgery developed lung metastases when sacrifıced. In to-
tal, lung metastases were observed in 5 out of 28 mice analyzed so far with/
without surgery (18%) which histologically resemble their primary tumors.
Since removing tumors from multiple glands is challenging, we decided to take
a transplantation approach of the primary mammary epithelial cells of mid-
pregnancy (13-16 dpc) p53f/f:Rbf/f:SB females and injecting them into the
mammary glands of 3-4 week old NSG mice. So far, four NSG mice developed
mammary tumors with average latency of 176 days. These tumors resemble
spindle-shape histology. SBmutagenesis can promotemetastasis inmousemod-
els with limited dissemination potential such as themodel proposed herein. The
proposed experiments will identify novel oncogenic events that cooperate with
p53-loss or combined p53/Rb-loss to induce primary and metastatic TNBCs
which may serve as therapeutic targets for this aggressive disease. I have gener-
ated 3 sets of cohort of SBmutagenesis to identify these oncogenic events which
are currently being analyzed in details.
#2802 High fat diet increases development of hepatocellular carcinoma in
glycine N-methyltransferase defıcient mice. Michael N. VanSaun,1 Alisha
Mendonsa,2 Fanuel Messaggio,1 Nagaraj Nagathihalli,1 Lee Gorden3. 1Univ. of
Miami, Miami, FL; 2Seattle Childrens’ Research Institute, Seattle, WA; 3Vander-
bilt University, Nashville, TN.
Introduction: Hepatocellular carcinoma (HCC) is the third leading cause of
cancer deaths worldwide. HCC typically arises in patients with chronic liver
disease or cirrhosis, yet it is increasingly associatedwith non-alcoholic fatty liver
disease (NAFLD), specifıcally nonalcoholic steatohepatitis (NASH) in the ab-
sence of cirrhosis. NAFLD is associated with obesity, metabolic syndrome,
and/or patients with type II diabetes. Our previous studies have shown that high
fat diet induced hepatic steatosis increases proliferation of hepatocytes and the
growth of malignant tumors in a murine model. Glycine N-MethylTransferase
(GNMT) expression is lost in over 95% of HCC, and mice defıcient in GNMT
develop spontaneous HCC by 6 months of age. We hypothesized that GNMT
defıcient mice would have an increased susceptibility for the development and
growth of HCC when a fed high fat diet. Methods: Wildtype and GNMT defı-
cient mice were placed on lean diet (LD, 13% calories from fat) or high fat diet
(HFD, 42% calories from fat) at eightweeks of age. An initial cohort ofmicewere
sacrifıced after 3 months on diet (6 months of age) to assess for early tumor
burden. A second cohort of mice was analyzed by magnetic resonance imaging
(MRI) after 6 months on diet (9 months of age) and then sacrifıced to assess for
late stage disease. All mice were assessed for body weight, liver weight, pancre-
atic weight, and proliferative index (Ki67). Results: GNMT defıcient mice failed
to gain weight when placed on HFD, which remained at levels equivalent to
wildtype LD mice. At three months of age, wildtype mice on HFD had signifı-
cantly enlarged livers due to hepatic steatosis. HFD fed GNMT defıcient mouse
livers were nearly 50% the size of wildtype livers and contained only minimal
fatty deposits. Further, livers from HFD and LD fed GNMT mice were equiva-
lent after 3 months, yet they were larger than wildtype mice fed LD. After six
months on diet, MRI analysis showed signifıcantly larger livers in HFD fed
GNMTmice compared to LD fed GNMTmice due to extensive tumor burden.
All wildtype mice lacked any tumors after six months regardless of diet. Histo-
logical analysis revealed a heightened cellular proliferation via Ki67 staining in
GNMT defıcient livers compared to wildtype livers. In comparison, GNMT
silencing also occurs in pancreatic cancer, yet none of the GNMT defıcient mice
developed pancreatic tumors. However, small focal areas of pancreatitis were
detected regardless of diet. Additionally, pancreatic weight was signifıcantly
decreased in HFD fed GNMT defıcient mice compared the LDGNMT defıcient
mice. Conclusions:While high fat diet did not induce obesity inGNMTdefıcient
mice, it signifıcantly increased cellular proliferation and primary tumor growth
in the liver. Understanding dietary factors that impact themicroenvironment of
the liver and contribute to HCC development and progression is vital to fınding
new therapeutics for this malignancy.
#2803 The NCI mouse repository: Cancer models and miRNA-ES cell re-
source. Parirokh Awasthi, Fitzgerald Debra, Jones N. Stephen. Leidos Biomedi-
cal Research, Inc., Frederick, MD.
The NCI Mouse Repository, located at the Frederick National Laboratory
for Cancer Research (FNLCR), Frederick, Maryland, is an NCI-funded re-
source of approximately 150 genetically-engineered mouse cancer models
and associated strains, includingmice bearing conditional and point-mutant
alleles in cancer-related genes. In addition, the Repository houses a unique
collection of over 1500 different mouse ES cell clones bearing conditionally-
activated miRNA transgenes to facilitate in vivo exploration of miRNA func-
tions. The NCI Mouse Repository makes strains and mESCs available to all
members of the scientifıc community (academic, non-profıt, and commer-
cial). The mouse models and ES cell clones are cryo-archived and distributed
as frozen germplasm or cells. Requests may be placed through the NCI
Mouse Repository website (https://ncifrederick.cancer.gov/Lasp/MouseRe-
pository/Default.aspx). In addition to the request form, this website includes
detailed description for each strain accepted into the Repository and the
associated publications provided by the donating scientist. The miR-harbor-
ing ESCs, originally generated at the Cold SpringHarbor Laboratories for the
NCI, are described in full detail and include validation data for each miRNA
ES cell clone. These resources are available for nominal cost to NCI, NIH,
and other US government-funded investigators, as well as to Investigators at
non-profıt organizations.
#2804 Identifying therapeutically relevant mouse and patient-derived
xenograft (PDX) models of human cancer using the mouse tumor biology
database (MTB) data resource. Dale A. Begley, Debra M. Krupke, Steven B.
Neuhauser, Joel E. Richardson, John P. Sundberg, Janan T. Eppig, Carol J. Bult.
The Jackson Laboratory, Bar Harbor, ME.
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The laboratory mouse is the foremost model organism for interrogating the
genetic and molecular basis of human cancer and is a powerful platform for
identifying therapeutically effective targets for prevention and treatment of can-
cer. Research using genetically engineered mouse models (GEMMs) have led to
important advances in our understanding of the genetic basis of cancer suscep-
tibility, the function of tumor suppressors and oncogenes, and therapy re-
sponses in preclinical and co-clinical studies. Patient Derived Xenograft (PDX)
models are an increasingly importantmodel system for in vivo studies of human
cancer. These models are created by implanting patient tumors into immuno-
defıcient or humanized mouse hosts and are a powerful translational research
platform for preclinical and co-clinical studies. The number ofGEMMandPDX
mouse models increases signifıcantly every year and the diverse cancer-related
data about human cancer models tend to be distributed in ways that makes it
diffıcult for researchers to integrate and interpret the information to fınd the
most relevant model for their research. The Mouse Tumor Biology database
(http://tumor.informatics.jax.org) is an expertly curated resource for informa-
tion and data about genetically defıned mouse strains and PDX models of hu-
man cancer. MTB provides query tools to enable integrated searches and visu-
alization of these varied data, thus facilitating the assessment of novel mouse
models of human cancer and potential preventative and therapeutic treatments.
Enforcement of controlled vocabularies and standard gene, allele and strain
nomenclature within MTB facilitates precise and comprehensive queries of
MTB for pertinent mouse models. MTB contains data from spontaneous or
endogenously induced tumors from genetically defıned mice including tumor
classifıcation, incidence, Quantitative Trait Loci, pathology reports, images and
genetic changes in the tumor (somatic) and background strain (germline) ge-
nomes. The PDX resource enables queries based on tumor type, cancer diagno-
sis and genomic properties of the engrafted tumors. Information in MTB is
obtained from curation of peer-reviewed scientifıc publications and direct data
submissions from individual investigators and large-scale programs. New fea-
tures in MTB include the Faceted Tumor Search Form and a Reported Mouse
Models table linking the most common fatal human cancers to reported equiv-
alent mouse models. MTB contains over 77,000 Tumor Frequencies and over
2,200 Pathology Reports with over 6,600 images from over 4,200 references.
MTB provides access to detailed clinical, pathological, expression and genomics
data from over 400 PDXmodels. Information in MTB is integrated with cancer
models data from other bioinformatics resources including PathBase, the Gene
Expression Omnibus and ArrayExpress. MTB is supported by NCI grant
CA089713.
#2805 A panel of orthotopic glioblastoma multiforme (GBM) patient de-
rived xenograft (PDX) mouse models for effıcacy evaluation of drugs.Mette
M. Jensen,1 Camilla S. Knudsen,1 Lotte K. Kristensen,1 Mette K. Nedergaard,2
Michael J. Wick,3 Kyriakos P. Papadopoulos,3 Anthony W. Tolcher,3 Andreas
Kjaer,4 Carsten H. Nielsen1. 1Minerva Imaging, Copenhagen, Denmark; 2Rig-
shospitalet, Copenhagen, Denmark; 3South Texas Accelerated Research Thera-
peutics (START), San Antonio, TX; 4Department of Clinical Physiology, Nuclear
Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and Univer-
sity of Copenhagen, Copenhagen, Denmark.
Background: Patients with glioblastoma multiforme (GBM) have a poor
prognosis and few treatment options; hence new treatments are needed. Subcu-
taneous patient derived xenograft (PDX) models are increasingly used for effı-
cacy studies in drug development. However, orthotopic implantation confers a
translational advantage as the cancer develops in a microenvironment more
closely mimicking that of the original patient tumor. Also the major impact of
the blood brain barrier that must be taking into account when targeting brain
tumors as GBM in terms of drug bioavailability is better represented in the
orthotopic models. The aim of this study was therefore to develop a panel of
orthotopic GBM PDXmodels for pre-clinical effıcacy studies of new drugs. The
models were then used to study the effıcacy of standard of care such as temozo-
lomide (TMZ) and external radiation therapy (XRT). Methods: Low passage
subcutaneous tumors from six different PDX GBM models designated ST108,
ST112, ST146, ST545, ST610 and ST2473were digested and used for intracranial
stereotactic injection in nude mice. Tumor take and growth was determined by
T2-weighted magnetic resonance imaging (MRI). At confırmed tumor take
mice were either treated with TMZ (100mg/kg/day for 5 days) or whole brain
XRT (2 Gy/day for 5 days). Control groups receiving vehicle or sham XRT were
included depending on treatment regiment. Final endpoint was survival by hu-
mane endpoints and tumors were fıxed in formalin for histological evaluation.
Results:MRI confırmed tumor take in allmodelswithin 5weeks of implantation.
The take rate was 80% across all models. TMZ showed effıcacy in the ortho-
topic ST610 GBM PDX model evaluated by MRI on day 14 (16.2	2.9 mm3 vs.
76.8	13.1 mm3, p0.016), whereas the ST146 model displayed resistance to
TMZ on day 14 (12.7	5.6 mm3 vs. 26.5	11.9 mm3, p0.26). The median sur-
vival was 60 days vs. 14 days in the ST610 model (TMZ vs. vehicle, p0.0005)
and 27 days vs. 13 days in the ST146 model (TMZ vs. vehicle, p0.007). XRT
showed effıcacy in the orthotopic ST2473 model. Tumor volume was signifı-
cantly smaller in treated vs. sham animals 11 days after inclusion (6.9	1.4 mm3
vs. 28.9	3.3 mm3, p0.001). Also, a survival benefıt was observed in XRT
treated animals compared to sham. Histology confırmed the presence of ortho-
topic tumors and typical GBM pathology characteristics such as pseudopalisad-
ing tumor cells surrounding necrosis and micro vascular proliferation were
identifıed. Conclusion: Six different orthotopic GBM PDX models were estab-
lished from low passage subcutaneous PDXmodels. Models sensitive and resis-
tant to TMZ were identifıed and histological GBM characteristics were identi-
fıed. Together, the established panel of orthotopic PDXmodels can be used as a
relevant translational platform for testing of new drugs in a setting that more
closely mimics the GBM tumor microenvironment and the impact of the blood
brain barrier in patients.
#2806 Generation and characterization of mouse model of Pmepa1 con-
ditional knockout in prostate epithelia. Shashwat Sharad, Talai Barbiev,
Yingjie Song, Denise Young, Taduru Sreenath, Albert Dobi, Shiv Srivastava.
Uniformed Services University, Rockville, MD.
Introduction andObjectives: Prostate cancer (CaP) is themost commonnon-
skin malignancy diagnosed in American men and desfunctions of androgen
receptor (AR) plays an essential role in prostate tumorigenesis. PMEPA1 is an
androgen and TGF- -induced gene abundant in prostate, which was identifıed
to degrade AR protein via NEDD4 E3 ligase mediated pathway. Reduced or loss
of PMEPA1 expression, commonly detected in prostate tumors, led to increased
AR protein and activated AR signaling. PMEPA1 inhibited TGF- receptor 1
meditated signaling by a negative feedback loop. It was reported that loss of
PMEPA1 facilitates bone metastasis of CaP through blocking TGF- signaling.
To further investigating the biological function of PMEP1 gene in CaP tumori-
genesis, particularly via AR and TGF-, we generated Pmepa1 prostate condi-
tional knockout mouse model. Methods: C57BL/6 mice were utilized for gener-
ation of Pmepa1 conditional knockout model. Pmepa1 gene was conditionally
deleted inmouse prostate epitheliumbyARR2PB-Cre-Lox system.Malemice of
genotypes of wild-type, Pmepa1 flox/wild-type-ARR2PB-Cre, Pmepa1 flox/
flox-ARR2PB-Cre were euthanized at the age of 3 months for analysis. The
prostate tissue was collected for frozen and formalin fıxation for histology anal-
ysis, and other major organs including heart, lung, liver, spleen, bladder and
testis were also collected for control. The tissue were sectioned and stained with
Hematoxylin & Erosin (H&E). Total RNA and protein were harvested by ho-
mogenizing tissue. The protein levels of Pmepa1, AR and Nkx3.1 were analyzed
by immunohistochemistry (IHC) and immunoblotting, and the transcript levels
of these genes were evaluated by in situ hybridization (ISH) and quantitative-
PCR (Q-PCR). Results: The expression of Pmepa1 proteinwas found to focus on
lateral lobe, consistent with AR protein expression pattern. The data of Q-PCR
and ISH showed that transcript level of Pmepa1 was dramatically suppressed in
Pmepa1 flox/flox and flox/wild-typeARR2PB-Cremice. Compared towild-type
ones, Pmepa1 protein was shown signifıcantly decreased in heterozygous and
homozygous knockout mice by immunoblotting and IHC staining. And the
protein level of AR was stronger in Pmepa1 conditional deleted mouse. There
was no dramatic morphology change in mouse prostate gland by H&E staining.
Conclusions: Conditional deletion of Pmepa1 gene in mouse prostate epithe-
lium led to enhanced AR protein and activating AR signaling. The effects of
Pmepa1 gene loss inmouse prostate gland onother signaling such asTGF- and
prostate tumorigenesis are needed to be further evaluated. Funding: This study
was supported by CPDR, USUHS, HU0001-10-2-0002 to DGM.
#2807 Developing a variety of primary mouse tumor allograft models for
evaluating effıcacy of PARP inhibitor. Gavin Jiagui Qu, Davy Xuesong Ouy-
ang, Li Chen, Likun Zhang, Annie Xiaoyu An, Jie Cai, Henry Q. X. Li. Crown
Bioscience, Inc., Taicang, Jiangsu, China.
Recent success of multiple poly (adenosine diphosphate [ADP]) ribose poly-
merase inhibitors (PARPi) in treating BRCAmutant ovarian cancers has fueled
the development of PARPi in several areas, including expanding its use in other
BRCA mutant or wildtype cancers; exploring resistant mechanisms and over-
coming resistance; seeking for its combination with chemotherapy, radiother-
apy and emerging immunotherapy to achieve persistent effıcacy. Especially con-
sidering the mechanism of action of PARPi, its use can increase the mutational
loads in tumors with defects in homologous recombination and DNA double
strand break repair, which potentiallywould enhance the immunogenicity of the
tumors. Therefore it would be very interesting to test the effectiveness of com-
bining PARPi with anti-PD1/PD-L1 or anti-CTLA4. However, relevant animal
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models are lacking for such studies. Syngeneic mouse tumors offer about 30
viable in vivomodels for proof of concept studies. However, these models suffer
from several limitations: 1) only a few available and responsive to the current
checkpoint inhibitors – for given strains of mouse, there are only very few
choices of cells/disease types; 2) not mimicking patient tumors since they are in
vitro immortalized cell lines; 3) not reflective of patient disease pathways thus
unfıt for common target agents, either in mono- or combination therapy. We
have established allografts of spontaneous mouse tumors (MuPrime®) derived
from genetically engineeredmousemodels (GEMMs) as a new type of immuno-
oncology models with following advantages: 1) its primary nature of “stem cell
diseases” and relevant tumor microenvironment; 2) its diverse cancer types/
strains of mice; 3) engineered oncogenic drivers as seen in human diseases,
deriving from a wide range of available GEMMs, suitable for targeted agents.
Thus far, we have built a small library of allografts and are testing them to
facilitate pharmacological investigation, particularly those of immuno-oncol-
ogy. We have found a few models, including an APCmin/ skin squamous cell
carcinoma and a P53 null sarcoma responded well to PARPi Niraparib. Contin-
uous treatment with Niraparib led to development of partial or complete resis-
tance. We are now profıling the resistant models to fınd out their general muta-
tion loads, as well as specifıc biomarkers render resistant mechanisms. We are
also treating the tumors with mouse PD1 antibody to test whether presumably
enhanced mutation loads would sensitize these tumors to immunotherapy. The
data of these studies will be presented at the meeting.
#2808 Identifıcation of EPHB4 as a tumor suppressor in melanoma.Om-
bretta Salvucci,1 Dragan Maric,2 Giovanna Tosato1. 1NCI/NIH, Bethesda, MD;
2NINDS/NIH, Bethesda, MD.
The Ephrins and Eph are a large family of ligands and receptors with critical
physiologic functions in development and in adulthood. The EphB4 receptor
and its unique ligand EphrinB2 have been implicated in the pathogenesis of a
variety of cancers, but the underlying mechanisms remain unclear. Data from
the Cancer Genome Atlas (TCGA) shows that the survival probability of pa-
tients with melanoma is signifıcantly lower when EphB4 levels in the cancer
tissue are very low compared to the average EphB4 levels inmelanoma, suggest-
ing a role of EphB4 in regulating melanoma progression. We investigated the
role of EphB4 depletion in the regulation of melanoma cell growth. We report,
that EphB4-depleted murine melanoma B16/F10 cells have a growth and sur-
vival advantage in vitro over control cells. This growth advantage is revealed
under conditions of stress generated by hypoxia or nutrients deprivation, which
is common during cancer progression. When inoculated into syngeneic mice,
EphB4-depleted B16F10 cells generate larger tumors than control B16F10 cells.
Initial mechanistic studies have revealed that EphB4-null B16F10 tumors con-
tain fewer apoptotic cells compared to control tumors, have more infıltrating
F4/80macrophages, display increased NG2 pericyte coverage of tumor ves-
sels and pericytes are detected at a distance from CD31 vessels. Thus, we have
generated amousemodel that reflects the tumor-suppressive function of EphB4
in human melanoma and have identifıed potential pathways underlying this
function.
#2809 Role of c-Met in the development and progression of Tpl2-related
skin cancer. Nicole F. Bonan,1 David Kowalski,1 Kaitlin Kudlac,1 Lauren G.
Falkenberg,1 Erik Maradiaga,1 Kira Flaherty,1 Jonathan S. Wiest,2 Katie L. De-
Cicco-Skinner1. 1American Univ., Washington, DC; 2NCI, Rockville, MD.
Cutaneous squamous cell carcinoma (cSCC), a form of non-melanoma skin
cancer, is the second most common form of cancer in the United States, with
over onemillion cases diagnosed annually. Tpl2 (MAP3K8) is a serine threonine
protein kinase in themitogen-activated protein kinase (MAPK) signal transduc-
tion cascade. Tpl2 was identifıed by our laboratory as having a tumor suppres-
sive function in skin carcinogenesis, with Tpl2 knockout mice developing sig-
nifıcantly more papillomas and squamous cell carcinomas than matched
wildtype (WT) controls. Cellular mesenchymal to epithelial transition factor
(c-Met) is a receptor heightened inmalignant skin cancers and involved in Tpl2
signaling.When bound to its ligand, hepatocyte growth factor (HGF), c-Met can
regulate cell proliferation, survival, angiogenesis and invasion. The aim of this
study was to ascertain whether c-Met signaling contributes to the heightened
skin tumorigenesis in Tpl2/ mice. Forty-four WT and Tpl2/ mice were
subjected to a two-stage chemical carcinogenesis protocol for one year to induce
skin tumors. Starting at the time of promotion, half of theWTandTpl2/mice
were placed on normal diet and half received diet plus 30mg/kg Capmatinib, a
pharmacological inihibitor of c-Met. This diet continued for the duration of the
study. No adverse health effects were found inCapmatinib-treatedmice. Similar
to what we previously reported, Tpl2/ mice developed tumors earlier than
WT controls and had statistically higher tumor incidence and overall tumor
burden thanWTmice. The number of tumor bearing Tpl2 / and Tpl2 /
Capmatinib fed mice was similar, although Capmatinib fed mice had a 60%
reduction in overall tumor burden. Studies are underway to determine if Cap-
matinib affected the frequency of malignant conversion in Tpl2/ mice. In
summary, our studies demonstrate that heightened c-Met signaling contributes
to the higher tumor formation in Tpl2/mice and should be evaluated further
as a possible therapeutic target in Tpl2-related skin cancers.
#2810 Using CRISPR/Cas9 to generate primary soft tissue sarcoma in
genetically engineered and wild-type mice. Jianguo Huang,1 Mark Chen,1
Melodi J.Whitley,1 Hsuan-ChengKuo,1 AndreaWalens,1 YvonneM.Mowery,1
David V. Mater,1 William Eward,1 Diana M. Cardona,1 Lixia Luo,1 Yan Ma,1
Christopher E.Nelson,1 JacquelineN. Robinson-Hamm,1CharlesA.Gersbach,1
RebeccaD.Dodd,2DavidG.Kirsch1. 1DukeUniversityMedical Center, Durham,
NC; 2University of Iowa, Iowa City, IA.
Genetically engineered mouse models (GEMMs) that employ site-specifıc
recombinase (SSR) technology are important tools for pre-clinical studies, but
this approach is costly and time-consuming. Here, we show that the CRISPR/
Cas9 system can be used to effıciently complement existing GEMMs of sarcoma
and generate primary sarcomas in wild type mice. Mice with the genotype
KrasLSL-G12D/; Rosa26LSL-Cas9-EGFP/ received intramuscular delivery of an ad-
enovirus expressingCre recombinase and a single guideRNA(sgRNA) targeting
Trp53. Cre-mediated expression of oncogenic Kras and Cas9, in combination
with CRISPR/Cas9-mediated knockout of Trp53, was suffıcient to generate pri-
mary soft tissue sarcomas. These tumors arose with kinetics similar to those
generated using the Cre-loxP system to activate oncogenic Kras and delete
Trp53 alleles. Additionally, we injected an adenovirus containing Cas9 and
sgRNAs targeting Nf1 and Trp53 into the sciatic nerve of wild type mice. These
mice formed malignant peripheral nerve sheath tumors (MPNSTs) in the same
timeframe as MPNSTs generated using the Cre-loxP system to delete Nf1 and
Ink4a/Arf alleles in GEMMs. These data demonstrate that CRISPR/Cas9 can be
used to generate soft tissue sarcomas in wild type mice. Moreover, these results
suggest that this technology can complement existing GEMMs for rapid assess-
ment of tumor-modifying genes. These tools should decrease the time and ex-
pense associated with employing autochthonous mouse models of sarcoma for
preclinical research.
#2811 Comparative study of anti-PD1 and CSF1R inhibition on tumor-
infıltrating lymphocytes and macrophage populations across a panel of syn-
geneic tumor models. Yuki Kato Maves, Hooman Izadi, Elvira C. Talaoc, Deb-
orah Yan, Charlene Echegaray, Andrew Calinisan, Krystal Moya, Heather
Venant, Mitchell Garland, Radhika Iyer, Shounak Gosh, Stephanie Songco, Jay-
ant Thatte, Tommy Broudy. Crown Biosciences, San Diego, CA.
Immunotherapy represents an extremely promising treatment approach for
cancer patients. The success in this fıeld has been signifıed by multiple recent
approvals of checkpoint inhibitors across a range of cancer types. Subsequently,
there is an increasing need to understand why certain patients and diseases
benefıt from these treatmentswhile others donot, aswell as how tomaximize the
benefıts from these treatments. To address some of these questions, we used an
in vivo screening platform, MuScreen, which allows for evaluation of multiple
syngeneicmodels and treatmentmodalities.We have characterized baseline and
treated tumor immune infıltrates for a panel of syngeneic models using flow
cytometry. The correlation between responsiveness and effects of checkpoint
inhibitors (e.g., anti-PD-1), and macrophage targeted agents (e.g., CSF1R inhi-
bition) on immune infıltrates including tumor-associatedmacrophages (TAMs)
were investigated in 6 syngeneic models. Furthermore, M1/M2 polarization of
macrophages was investigated to explore the potential role of these cells in es-
tablishing an immunosuppressed tumor microenvironment that may affect re-
sponse to therapy. Here, we show that the baseline immune cell population
varies across models, and that immune checkpoint inhibitors and macrophage-
targeted agents had variable effıcacy across different tumor models. We also
present the correlation of immune cell infıltration, including tumor infıltrating
lymphocytes (TILs), TAMs, and responsiveness to immunotherapy interven-
tion. Having an in-depth understanding of the immune make up of a model in
which an immunomodulatory compound is screened is paramount for success-
ful translation into the clinic. A well-characterized and fully profıled panel of
syngeneic models such as the MuScreen platform allows for fınding the right
model for screening test compounds to be used alone or in combination with
immunotherapy.
#2812 Development and characterization of the ultra immunodefıcient
B6;129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd (R2G2) mouse model. Sheryl J.
Wildt, Jamie McClellan, Mandy Horn. Envigo RMS, Indianapolis, IN.
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The “R2G2” (B6;129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd) knockout mouse is
the latest advancement to provide an alternative option in the highly immuno-
defıcient mouse model category for the oncology, immunology and other bio-
medical research communities. This model was generated by backcrossing an
IL2rg (common gamma) knockout model to a RAG2 (recombinase activating
gene) knockout model. The resulting mouse lacks various cytokines including
IL-2, IL-4, IL-7, IL-9 and IL-15. In addition, this model lacks B cells, T cells, NK
cells and has a defıcit in lymphocyte development. The R2G2 model is not only
ultra immunodefıcient, but provides amodel that is less leaky andmore tolerant
to gamma radiation than traditional SCID models. This model is particularly
useful for both tumor transplantation and humanization studies. Herein we
describe the development and characterization of the R2G2 model, which in-
cludes breeding history, growth curve, CBC/Chemistry, flow cytometry and
both huHSC and huPMBC humanization studies.
#2813 An interactome analysis for personalized chemotherapy using
PDX/NOGmodels of non-small cell lung cancer. Tsuyoshi Chijiwa,1 Daisuke
Komura,2 Mizuha Haraguchi,3 Akira Noguchi,4 Hidemitsu Sato,5 Hiroaki Ito,5
Haruhiko Nakayama,5 Makoto Katayama,6 Naoki Miyao,3 Naruaki Matsui,3
Yuichi Tateishi,7Hiroshi Suemizu,7 YoshiyasuNakamura,8Daisuke Furukawa,9
Takayuki Isagawa,2 Hiroto Katoh,2 Shumpei Ishikawa,2 Masato Nakamura,9
Yohei Miyagi8. 1Saitama Medical Center, Jichi Medical University, Saitama, Ja-
pan; 2Medical Research Institute, Tokyo Medical and Dental University, Japan;
3Nihon Koukan Hospital, Saitama, Japan; 4St. Marianna University School of
Medicine, Saitama, Japan; 5Kanagawa Cancer Center, Saitama, Japan; 6Kawa-
saki Municipal Hospital, Saitama, Japan; 7Central Institute for Experimental
Animals, Japan; 8Research Institute, Kanagawa Cancer Center, Japan; 9Tokai
University School of Medicine, Japan.
Lung cancer is one of the most commonmalignant diseases in the world, and
its prognosis is generally poor. It is crucial to elucidate the biological mecha-
nisms underlying lung cancer and accelerate the development of new treatment
strategies. Xenografts derived from engrafting fresh surgical specimens directly
into immunodefıcient mice have recently enabled the development of more
relevant in vivo models of human cancers. These patient-derived xenograft
(PDX) models, established by the direct transfer of tumor tissue, retain similar
morphologies, heterogeneities, andmolecular signatures as the original cancers,
and, thus, may be used in promising personalized medicine for cancer. We
previously reported the rapid and effıcient establishment of PDXs using super
immunodefıcient NOG mice (PDX/NOG model). In the present study, we an-
alyzed the gene expression and cancer-stroma interaction profıles of PDXs es-
tablished from NSCLC patients. We also discussed the possibility of individual
PDX/NOG model simulations for personalized cancer chemotherapy. Ten
NSCLC lines of PDX/NOG (Age 43-78 years; 8 men and 2 women; 7 adenocar-
cinoma, 1 adenosquamous carcinoma, 1 squamous carcinoma, and 1 large cell
carcinoma) were presented. In these cases, clinical information regarding che-
motherapy for donor patientswas retrievedwhere possible. Genome sequencing
and comprehensive analyses of tumor-stroma interactions (CAncer-STromal
INteractome analysis, CASTIN) were performed on mRNA. CASTIN showed
tumor-stroma interactions in PDX/NOGcomprehensively and quantitatively at
the gene expression level by distinguishing gene arrangements in human tissue
(Cancer) from mouse tissue (Stroma) as signal strengths (ligand dependency
(%) / receptor dependency (%)). Interactions of EGF(cancer)-EGFR(stroma)
were observed from 1.2 (15%/0%) to 11.5 (94%/80%) as widely-distributed. In-
teractions of VEGFA(cancer)-KDR(stroma) were observed from 49.1 (31%/
51%) to 301.7 (83%/100%) as closely-distributed. These interactions of EGF-
EGFR or VEGFA-KDR in PDX/NOG closely reflected the clinical effectiveness
of an EGFR inhibitor (Cetuximab) or VEGF-A inhibitor (Bevacizumab). The
CASTIN results of PDX/NOG appear to be reliable for clinical simulations of
chemotherapy and will defınitely assist in the selection of the most sensitive
anti-cancer drug. The fast and effıcient establishment of individual PDXs will
contribute to personalized anti-cancer therapies.
#2814 Effect of kif14 overexpression on tumor formation in mice in a
lifespan study. Natalie Pitt, Kamakshi Sishtla, Mehdi Shadmand, Rania Sulai-
man, Anthony L. Sinn, Keith Condon, George E. Sandusky, Timothy W. Cor-
son. Indiana University School of Medicine, Indianapolis, IN.
KIF14 is a mitotic kinesin and microtubule-associated molecular motor that
plays an essential role in the last stages of cytokinesis. In multiple cancer types,
KIF14, overexpression in tumors correlates with stage, aggressiveness, and poor
patient outcomes. There is considerable interest in KIF14 as a possible onco-
gene, since the KIF14 locus is in a common region of genomic gain in multiple
cancers. In this study, wild type BDF-1 mice and a strain constitutively overex-
pressing Kif14, known as Kif14-Tg mice, were evaluated at the end of their
natural lifespan, specifıcally for the occurrence of tumors. There were approxi-
mately fıfty mice per genotype, and eighty of these mice have died. These mice
were necropsied and the following tissues were collected: kidney, liver, lung,
spleen, seminal vesicles, ovary, mammary gland, bone marrow, pituitary gland,
eye, and brain. Any gross nodules were also collected. These tissues were then
fıxed in 10% neutral buffered formalin, processed, sectioned, and stained with
hematoxylin and eosin. Although there was no signifıcant difference in mouse
weights through the lifespan or in the survival curve between the Kif14-Tg and
their wild type littermates, a signifıcant increase in follicular lymphoma and
diffuse large B cell lymphoma was seen in Kif14-Tg mice compared to the wild
typemice. Thirty-threemice developed either a follicular lymphoma or a diffuse
large B cell lymphoma, and twenty-four of those mice were Kif14-Tg mice.
These were the two most common tumors in Kif14-Tg mice. Other lesions and
tumors that were seen in both strains included thymic lymphoma, sarcomas,
myeloid dysplasia, and other carcinomas. Nontumorous lesions were seen in
both strains of mice including hydronephrosis and telangiectasia in multiple
organs. Ballooning degeneration of the lens of the eyes was observed in fıvemice
from the strain Kif14-Tg. Our fınding of increased follicular lymphoma and
diffuse large B cell lymphoma proves the fırst evidence that Kif14 can promote
tumor formation in a wild-type background. This is the fırst evidence that Kif14
may have a role in lymphoma, but complements our earlier fınding that Kif14
overexpression can accelerate tumor formation in a mouse model of retinoblas-
toma. Together, these outcomes further support Kif14’s potential as an onco-
gene.
#2815 Patient derived orthotopic xenograft (PDOX) model developed
from needle biopsy specimen replicated clinical outcomes in advanced pan-
creatic cancer. A-Ra Jeon,1 Sun Il Choi,2 Sang-Jae Park,2 Sung-Sik Han,2 Eun
KyungHong,2 Sun-YoungKong,2MinKyeongKim,1Kyong-AhYoon,3 Young-
Hwan Koh,2 Ju Hee Lee,2Woo Jin Lee,2 Young Hwa Kang,2 SangMyungWoo,2
Yun-Hee Kim2. 1Graduate School of Cancer Science & Policy, National Cancer
Center, Republic of Korea; 2National Cancer Center, Goyang-si, Republic of Ko-
rea; 3Konkuk University, Seoul, Republic of Korea.
Introduction: A patient-derived xenograft (PDX) as a preclinical model can
reflect the pathological and molecular features and drug responsibility of a pa-
tient’s tumor. PDXs have been generated by subcutaneously implanting surgi-
cally resected tumor fragments into immunodefıcientmice.Unfortunately, 80%
of pancreatic cancer patients is unresectable and they showhighly aggressive and
metastatic tumors. In most cases, diagnoses are confırmed histologically and
diagnosed through endoscopic ultrasonography-guided/fıne-needle aspiration
(EUS/FNA) or percutaneous liver biopsy. However, they are not suitable for
subcutaneous implantation into mice due to their threadlike shape and very
small size. Therefore, the lack of patient-derived model system in pancreatic
cancer is in desperate need of new strategy to cover unresectable patients as well
as resectable. Here, we pioneered the development of a unresectable patient-
derived orthotopic xenograft (PDOX) model satisfıed with short period and
high success rate, and made the best use of them as the test model for drug
response. Methods and Results: PDOX models were established with a tech-
nique of direct surgical orthotopic implantation into the pancreatic tail of Athy-
mic nudemice. PDOXmodels using fıne needle biopsy had a higher success rate
of engraftment, nearly 40% (17 cases among 44 cases) in patients with a time to
progression of 6 months. The histopathological characteristics of the PDOX
tumors are similar with those of the patient’s original tissues. Additionally, ge-
netic alterations were retained between patient tissues (F0) and PDOX tumors
(F1F3) from the mutation analysis using a comprehensive cancer panel. For
drug responsibility, we selected refractory or sensitive PDOX groups to Gemcit-
abine and Abraxane based on their clinical information. As results after treat-
ment with Gemcitabine, Abraxane and combination, selected PDOX models
showed the drug sensitivity signifıcantly correlated with the drug responsibility
of original patients. Tumor growthwasmonitored by animalMRI every 2 weeks
during 2 months. Typically, xenograft models using immortalized pancreatic
cancer cell line, CFPAC-1, showed tumor regression to all treatment set. Con-
clusion: Collectively, our PDOX models using needle biopsy specimens can
reflect the characteristics of unresectable patients and give the expectation the
drug responsibility. They furthermore might be valuable in a screening and
development system for targeted therapeutics, which can be applied to a wide
range of pancreatic cancer patients.
#2816 The Jackson Laboratory Repository: Mouse models for cancer re-
search.Deborah Boswell, Stephen Rockwood, Michael Sasner, The JAX Repos-
itory Team. The Jackson Laboratory, Bar Harbor, ME.
The mouse is a well-established model organism for research of the biology,
prevention, diagnosis, and treatment of cancer. Among the advantages of this
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valuable biomedical research tool are a relatively short reproductive cycle, an
accelerated lifespan, and the ease of genetic manipulation and modifıcation.
Serving as a resource to the scientifıc community, the JAX Repository collection
encompasses over 10,000 mouse strains and acquires hundreds of new models
each year. Some of these new models are highlighted in this poster. Many of
these strains have applications for modeling human cancer, including geneti-
cally engineered mouse models for specifıc cancers and xenograft models. Re-
search tool strains, such as cas9-expressing (CRISPR) lines, a suite of immuno-
defıcientmice, and recombinase expressing strains, are available to investigators
to generate customized mutant lines for specialized purposes. JAX offers sup-
plementary research tools that include specialized strain platforms and other
useful resources. The JAX patient-derived xenograft (PDX) cancer model re-
source leverages the immunodefıcient NSG strain for tumor engraftment. The
Repository maintains a searchable online resource to fınd mice (www.jaxmice.
jax.org) and an Oncology Therapeutic Area page (www.jax.org/jax-mice-and-
services/solutions-by-therapeutic-area/oncology) as a launch pad to featured
JAX strains and resources related to oncology research. The Repository has a
rigorous quality control program that inspects and confırms expected mutation
identity and genetic background. JAX mouse lines are also screened for alleles
(GFP, cre, lacZ, etc.) that may contaminate strains in mouse lines shared be-
tween labs—an underappreciated problem that may contribute to inconsisten-
cies of reproducibility. In addition, the Reproductive Sciences group at JAX
safeguards each strain by cryopreservation, and can create cohorts for studies
rapidly using IVF technology. Researchers can submit their strains to be consid-
ered for inclusion in the Repository by using the on-line form available at The
Jackson Laboratory website: www.jax.org/donate-a-mouse. The Jackson Labo-
ratory Repository is supported by the NIH, The Howard Hughes Medical Insti-
tute, and other private charitable foundations.
#2817 Enriched environment inhibits progression of acute myeloid leu-
kemia. Run Xiao, Stephen M. Bergin, Michael A. Caligiuri, Lei Cao. The Ohio
State University Comprehensive Cancer Center, Columbus, OH.
Background: Environmental factors and lifestyle have profound effects in the
initiation, promotion and progression of cancer. Our recent work on environ-
mental enrichment (EE), a housing environment boosting mental health, has
revealed a novel phenotype characterized by a robust reduction in adiposity,
resistance to diet-induced obesity (DIO), enhanced insulin sensitivity, lower
serum IGF-1 and leptin levels, higher serum adiponectin level, enhanced im-
mune functions, and inhibition inmelanoma and colon cancer growth.We have
teased out one key mechanism underlying the anticancer effect of EE: the stim-
ulation of brain-derived neurotrophic factor (BDNF) expression in the hypo-
thalamus and the subsequent activation of a specifıc neuroendocrine axis, the
hypothalamic-sympathoneural-adipocyte (HSA) axis. However, the EE’s effects
on hematologic malignancy are largely unknown. Here we generalized this in-
tervention to acute myeloid leukemia (AML) using the MLL-partial tandem
duplication (PTD) and Flt3-internal tandemduplication (ITD) double knock-in
mouse (MllPTD/WT:Flt3ITD/WT) that recapitulates features of counterpart human
AML. Methods: For transplantation of AML cells, Ly5.2 spleen cells isolated
from leukemic MllPTD/WT: Flt3ITD/WT mice were resuspended in PBS. Syngenic
Ly5.1 recipient C57Bl/6 male mice (CD45.1) were sublethally irradiated (400
cGy). Five to six hours later, leukemic cells (4106 per mouse) were injected
through the lateral tail vein. Those mice were randomly assigned to either stan-
dard laboratory cage (SE) or EE housing. To monitor AML progression, white
blood cell (WBC) counts were measured from peripheral blood. Survival exper-
iments were performed. Results: EEmice had amedian survival 14% longer than
SE mice (SE  36 	 1.1 days, EE  41 	 1.2 days, p  0.038) and improved
hazard rate (log-rank test z  1.99, p  0.047). Based on WBC counts (10.9
k/L), 100% of SE mice and 80% of EE mice had apparent AML at three weeks
post injection. At this time point, EE had a substantially lower WBC counts
(SE 76.9 k/L, EE 26.4 k/L, p 0.0006). WBCs from EE mice had lower
neutrophil, monocytes, eosinophils and basophils counts, but had similar lym-
phocytes, resulting in a reduced neutrophil to lymphocyte ratio. Red blood cell
(RBC) and platelet data were the same except for a slightly reduced mean cor-
puscular hemoglobin concentration (MCHC) in EE mice. At four weeks, EE
mice were substantially more active and mobile than SE mice. At fıve weeks, at
which point 3 SE and 5 EEmice remained alive,WBC counts remained lower in
EE mice. Conclusions: This preliminary work demonstrated EE substantially
improved progression-free survival and conferred a signifıcant survival benefıt.
We will elucidate the underlyingmechanisms of EE’s anti-AML effect by assess-
ing metabolic modulation and immune regulation.
#2818 PDX model of the enriched pleural effusion from advanced lung
cancer patient for testing on targeted drug sensitivity and resistance. Feifei
Zhang,1 Ke Wang,1 Wenhua Xu,1 Yang Yang,1 Kedong Ouyang,1 Shun Lu,2
Danyi Wen,1 Taiping Chen1. 1LIDE Biotech Ltd, Shanghai, China; 2Shanghai
Chest Hospital, Shanghai, China.
Advanced lung cancer of late stage patients is selectively sensitive to available
targeted therapeutics and often developing resistance to the early sensitive drug
treatment. Surgery tumor tissues are usually not available to establish patient
derived xenograft (PDX)models which is critical to evaluate drug sensitivity and
resistance. We applied CD45 magnet beads to enrich the tumor cell population
from pleural effusion specimens of advanced lung cancer. Seven PDX models
were successfully established in this way. Based on genetic profıling of these
models, TKI drug related EGFR mutations and ALK fusion were confırmed
(EGFR: L858R, T790M, Exon 19 insertion; ALK fusion). Further in vivo effıcacy
studies were designed to test on multiple drug sensitivity and resistance includ-
ing Gefıtinib, Erlotinib, Ceritinib, Alectinib, AZD9291. Tumor growth inhibi-
tion (TGI) were well matched with corresponding gene mutations among the
models. In particularly, T790M model was resistant to Erlotinib and quite sen-
sitive for AZD9291. In conclusion, themodels established here are very useful to
test on potency of many current investigational TKI drugs and provide base for
drug resistant model establishment.
#2819 Intestinal estrogen receptor beta attenuates colon cancer signaling
pathways in vivo. Linnea Pettersson,1 Ashish Saxena,2 Trang Vu,2 Jan-Åke
Gustafsson,2 Amena Archer,3 Cecilia Williams3. 1Karolinska Institute, Stock-
holm, Sweden; 2Center for Nuclear Receptors and Cell Signaling, Houston, TX;
3Scilifelab, Stockholm, Sweden.
Colorectal cancer (CRC) is the third most common form of cancer and the
second leading cause for cancer deaths. Several epidemiological, in vitro and in
vivo studies suggest that Estrogen receptor (ER) could be a possible target for
CRC prevention and treatment, but the potential mechanism is not demon-
strated. ER is expressed in intestinal epithelial cells, as well as in some intestinal
immune cells and other tissues. Previous studies have seen increased CRC after
full ER knockout, but it is not clear if this is mediated by intestinal ER. The
specifıc aim of our study is to determine the role of intestinal ER during colon
cancer development in vivo.We deleted ER specifıcally in the intestine epithe-
lia ofmice (iERKO), and induced CRC using Azoxymethane (AOM) andDex-
tran Sulfate Sodium (DSS) treatment. After 9 weeks treatment, all mice pre-
sented colitis and two iERKO mice but none of the wild-type (WT) mice had
developed tumors. qPCR showed that the expression of pro-inflammatory
markers was higher in iERKO treated mice than in untreated or WT mice,
Immunohistochemistry (IHC) of proliferative markers showed that iERKO
exhibited higher cell proliferation in the top of the crypts compared to controls.
After 16 weeks treatment, all mice developed tumors. qPCR showed that the
expression of mesenchymal markers was higher in treated iERKO mice com-
pared to treated WT mice. Our results demonstrate that intestinal ER attenu-
ates colon cancer-related pathways.
#2820 Use of a genetically engineered mouse model and RNA sequencing
to identify genes that are aberrantly regulated bymutant p53 in prostate cells
following irradiation.Ruth L. Vinall,1 Qian Chen,2 George Talbott,3 Neil Hub-
bard,2 Clifford Tepper,2 Alexander Borowsky2. 1California Northstate Univ., Elk
Grove, CA; 2University of California, Davis, Sacramento, CA; 3California North-
state University, Elk Grove, CA.
Our group has previously demonstrated that the Trp53 R270H mutation
can drive prostate cancer (CaP) initiation in a genetically engineered mouse
model, and that the human equivalent, TP53 R273H, can promote develop-
ment of castration resistant growth of LNCaP cells as well as resistance to
commonly used therapeutic agents. The primary objective of the current
study was to identify genes that may contribute to the development of these
gain-of-function phenotypes. Wildtype mice and mice that were heterozy-
gous or homozygous for the Trp53 R270H mutation (referred to as Trp53
/, Trp53/ R270H, or Trp53 R270H/R270H, respectively) that were3
months old were exposed to 5 Gy radiation to activate and stabilize p53,
consequently increasing its expression. Mouse prostates were harvested 6
hours post-irradiation and either processed for subsequent histological/im-
munohistochemistry (IHC) analysis or snap-frozen for subsequent RNA ex-
traction and transcriptome profıling with RNA-Sequencing (RNA-Seq)
analysis. P53 expression was determined by IHC. RNA-Seq data were pro-
cessed to quantify transcript levels and to assess differential gene expression
between the 3 groups. PIN lesions were observed in 3-month-old Trp53
R270H/R270H mice prostates, but not in Trp53 / or Trp53 / R270H
mice prostates. IHC analysis demonstrated that p53 was stabilized in the
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majority of prostate cells from Trp53 /, Trp53 / R270H, or Trp53
R270H/R270H mice 6 hours post-irradiation. RNA-Seq analysis of RNA
isolated from irradiated mice prostates identifıed 1,444 genes that were dif-
ferentially expressed in Trp53/ versus Trp53 R270H/R270H mice pros-
tate cells, and 796 genes that were differentially expressed in Trp53 /
versus Trp53 / R270H mice. Statistically signifıcant differences in gene
expression between the 3 groups were observed for 1,378 genes, including a
number of p53 target genes, such as Cdkn1a, Bax, Bcl2, Kras, Mdm2, and Id4.
Our data identify multiple genes that may contribute to prostate cancer
initiation and/or progression through p53 gain-of-function and loss-of-
function mechanisms. It is possible that further analysis of these genes may
lead to the development of new therapies and/or biomarkers for prostate
cancer patients as well as guide the usage of currently available therapies in
men at risk of developing CaP and CaP patients who harbor TP53mutations.
#2821 Impact of SCIDmouse gender on tumorigenicity, xenograft growth
and drug-responses in patient derived orthotopic xenograft models (PDOX)
of malignant brain tumors. Lin Qi, Mari Kogiso, Yuchen Du, Huiyuan Zhang,
Frank Braun, Holly Lindsay, Sibo Zhao, Sarah Injac, Patricia Baxter, Zhigang
Liu, Yujing Zhang, Jack Su, Adekunle Adesina, AndrewWalter, Jeffery Murray,
Javad Nazarian, Will Parsons, Murali Chintagumpala, Xiao-nan Li. Texas Chil-
dren’s Cancer Center, Houston, TX.
Brain tumor is the leading cause of cancer related death in children. To de-
velop new therapies and to understand tumor biology, many efforts are made to
develop patient derived orthotopic xenograftmousemodels (PDOX). There are,
however, some concerns about the potential impact of animal genders on tumor
take rate, xenograft growth and in vivo drug responses. To systematically ana-
lyze such impact, we retrospectively examined1,000mice of 59PDOXmodels,
including glioblastoma (GBM), medulloblastoma (MB), primitive neuroecto-
dermal tumor (PENT) and ependymoma (EPN) and diffuse intrinsic pontine
glioma (DIPG), in which there were age-matched (within 2 wks differences)
with relatively even numbers of male and female animals. All the animals were
injected with identical number of tumor cells (1x10^5) in the mouse brains
matching that in humanpatients. Animalsweremonitored daily and euthanized
when they were moribund. Differences between male and female mice were
analyzed by t-test. In 25 GBMmodels (15 adult and 10 pediatric) involving 419
mice, there was an average of number of mice was 17.8	9.5 mice per model
(male: female 9.88	5.8:7.93	3.6) (P0.05). In 26 MBmodels with total 488
mice, the average animal numberwas 17.24	8.8mice permodel (male:female
9.54	5.34 :7.71	3.45) (P0.05). The tumor take rate was near 95% in both
male and female mice (P0.05). In GBM models, the survival times was
94.1	21.7 days in male mice and 92.3	20.8 days in female (P0.05); wherease
in MB models, they were 134.95	39.86 day in male and 121.08	31.68 days in
femalemice (P0.05). The impact of animal gender on drug responses in vivo is
essential to the preclinical drug testing. A total of 468mice from 11 GBM, 5MB,
3 EPN, 3 DIPG and 2 PNETwere treated a series of standard and investigational
drugs/compounds, including radiation, oncolytic virus (SVV-001), ABT888,
BMI1-inhibitor, MLN8237, TMZ, Flavopiridol, SYC-435, SYC-719, SYC-836,
Olig 2 inhibitor, VPA, SAHA, Echinomycin, MCB613, and PARPi. The overall
survival times were 104.55	23.63 day in male mice, and 98.64	25.66 in female
mice (P0.05). The only model that exhibited the increased responses in male
mice was found in IC-2305GBM treated with TMZ and PTC-596 (P0.05). In
conclusion, our data demonstrated that the gender of SCID mice does not have
major impact on animal development nor in drug responses, and SCIDmice of
both genders are appropriate for brain tumor PDOX model development.
#2822 Establishing the use of Vortex technology for investigating circu-
lating tumor cells in mouse models of breast cancer. Vishnu Ramani,1 Rakhi
Gupta,1 Melanie Triboulet,1 Corinne Renier,2 Steve C. Crouse,2 Elodie Sollier-
Christen,2 Stefanie S. Jeffrey1. 1StanfordUniversity, School ofMedicine, Stanford,
CA; 2Vortex Biosciences, Menlo Park, CA.
Background: Circulating tumor cells (CTCs) are precursors of metastatic dis-
ease and are an important indicator of the disease progression and outcome of
many cancers. Though several recent studies have advanced our understanding
of CTCs, many critical areas of CTC biology remain largely unexplored.Murine
models of cancer offer a unique opportunity to address this issue. However,
small sample volumes, low number of CTCs, diffıculty to access ports for blood
collection are challenges that diminish the utility of mouse models for studying
CTCs. In our previous studies, we had validated the use of Vortex technology for
the label-free capture of CTCs from blood samples of different cancers. In this
current study, we now report our recent, unpublished data on the adaptation of
Vortex platform for enriching and characterizing murine and human tumor
cells from mouse blood. Methods: By spiking tumor cells into small volumes of
mouse blood (200-400 l) from cardiac puncture, we tested the impact of i)
different dilutions of mouse blood (10X, 20X, 40X); ii) varying numbers of
tumor cells; iii) different cell types (MDA-MB-231, 4T1 and EMT6); and iv)
sample recycling on capture effıciency and purity. Blood was processed through
the Vortex plastic chip and, to accurately identify and enumerate the enriched
tumor cells, we developed a staining protocol that labels human- or murine-
specifıc cytokeratin, vimentin, and CD45. Results: Our results reveal that over a
range of dilutions tested, just after one cycle, 10X dilution of mouse blood was
superior, yielding a capture effıciency of 38.83% and a purity of 33% for MDA-
MB-231 cells, compared to 20X (34.16% effıciency, 31.1% purity), and 40X
(31.83% effıciency, 31% purity) dilutions. We are currently testing whether re-
cycling the blood flow-throughwould increase the recovery. Evenwhen asmany
as7500 tumor cells were spiked inmouse blood, the Vortex platformwas able
to successfully enrich tumor cells with high consistency and purity. Importantly,
wewere now able to successfully isolate human andmurine tumor cell lines with
varying levels of epithelial cell adhesion molecule (EpCAM) expression (4T1 -
high, MDA-MB-231 - moderate to low) spiked into mouse blood. Experiments
confırming the viability and growth rate of cancer cells isolated from mouse
blood using MTT assay will also be presented. Conclusion: In summary, our
results reveal the use of the Vortex technology for studying CTCs in murine
models of cancer, with the ability to handle volumes of blood as low as 200uL
while having a capacity to capture extremely large number of CTCs. While this
study was focused on breast cancer, our workflow is easily adapted to other
malignancies. Studies are underway to grow viable CTCs from tumor bearing
animals and isolated by this platform for subsequent growth in 3D culture sys-
tems for future biologic and drug testing studies.
#2823 Immunodefıcient mice differentially sensitize to estrogen and ex-
hibit severe estrogen-related adverse effects in orthotopic breast cancer
model. Tiina E. Kähkönen,1 Mari I. Suominen,1 Jenni Mäki-Jouppila,1 Jussi
Halleen,1 Azusa Tanaka,2 Michael P. Seiler,2 Jenni Bernoulli1. 1Pharmatest Ser-
vices Ltd, Turku, Finland; 2Taconic Biosciences, Hudson, NY.
Estrogen-induced growth induction and stimulation of hormone receptor
positive breast cancer is commonly acknowledged and thus external estrogen
stimulus is used in animal models to support and accelerate growth of the tu-
mors. However, estrogen is known to have adverse effects in the animals and the
experiments may have to be preliminary terminated due to animal welfare is-
sues. The aim of the study was to characterize and to compare estrogen caused
adverse effects in athymic nude and NOG mice in orthotopic breast cancer
model. Athymic nude (Hsd:Athymic Nude-Foxn 1nu) and CIEA NOG
(NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac, provided by Taconic Biosciences) were
implanted with estrogen (17-estradiol, E2) releasing hormone rods (5g/day)
prior to cancer cell inoculation. 5x106 BT-474 (ER, PR and HER) human
breast cancer cells were inoculated to left inguinal mammary fat pad of the mice
and the tumor growth was monitored by measuring the tumor volumes twice a
week by caliber. The clinical condition and weight development of the mice was
carefully monitored with special attention to E2-caused adverse effects. If the
mice met the termination criteria (i.e. signifıcant weight loss or general worsen-
ing of the overall health) they were sacrifıced individually before the intended
end of the study. Nude mice exhibited severe estrogen-caused adverse effects as
no adverse effect were observed in NOGmice.Most common adverse effect was
redness and skin lesions in the urogenital area observed in 63% of the animals.
More severe effects were observed in the lower urinary track including urinary
stones and bladder obstruction in 67% of the mice. Also internal effects were
observed including appearance change in kidneys and spleen in size and color.
Due to severity of these effects 50% of the mice had to preliminary sacrifıced.
Tumor take (100% vs 85%) and fınal tumor volumes in average (110mm2 vs 120
mm2) were comparable between nude and NOG mice. A clear mouse strain
specifıc impact was observed in the study. Nude mice sensitize to estrogen and
exhibit severe estrogen-related adverse effects as no effects were observed in
NOG mice. In breast cancer studies where E2 supplementation is needed for
suffıcient tumor growth, the choice of mouse strain should be carefully consid-
ered. Special attention should be paid to possible adverse effects keeping inmind
the animal welfare issues.
#2824 Validation of a panel of patient-derived xenograft models for pros-
tate caner and cell line models for preclinical drug evaluation. Nektaria Pa-
padopoulou,1 Jane Wrigley,1 Andrew McKenzie,1 Jason King,1 Louise Wain-
wright,1 Kelly Jones,1 Anne Collins,2 Rajendra Kumari1. 1Crown Bioscience UK,
Loughborough, United Kingdom; 2University of York, York, United Kingdom.
Background: Prostate cancer is the second most common cancer worldwide
formales, and the fourthmost common cancer overall, withmore than amillion
new cases diagnosed. However, progress toward understanding the biology of
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prostate cancer and the development of new therapies has been hampered by the
lack of in vivo models that adequately represent the spectrum of benign, latent,
aggressive, and metastatic forms of the human disease. Here we report the vali-
dation of a panel of patient-derived xenograft (PDX) models and their utiliza-
tion in preclinical studies alongside cell linemodels of prostate cancer.Methods:
Prostate cancer samples obtained from patients undergoing surgery were col-
lected with ethical consent, disaggregated and established subcutaneously in
Rag2/C/mice (The JacksonLaboratory) to generate PDXmodels. Tumor
material was diagnosed on the basis of operative histology and immunohisto-
chemistry (IHC for PSA, androgen receptor expression). Tumor growth in both
Rag2/C/ and NSG mice was evaluated in comparison to cell line models
such LNCaP and PC3M. Briefly tumours were measured 3 times a week and
tumour volumes were estimated using the formula 0.5 (LxW2) bymeasuring the
tumour in two dimensions using electronic callipers for the duration of the
study. For orthotopic PC3M, tumour growth was checked once weekly by bio-
luminescent imaging (BLI). Briefly, the mice were injected (s.c.) with 150mg/kg
D-Luciferin prior to imaging, anaesthetised following administration of D-Lu-
ciferin and placed into the imaging chamber (Spectrum CT) and imaged for
luminescence (ventral view). Results: We have established a bank of transplant-
able prostate cancer PDX and stocks are maintained in liquid nitrogen which
can be resuscitated in in both Rag2/C/ and NSGmice. Two models were
reported to be hormone sensitive and 2 models represented castrate resistant
prostate cancer (CRPC) one of which has a TMPRSS-ETS fusion. In comparison
cell-derived LNCaP requires testosterone to grow whereas the bioluminescent
PC3M CRPC orthotopic model develops metastasis in the liver, lungs, lumbar
lymph nodes, fore limbs and hind limbs representing the late stage of cancer.
Conclusions: We have characterised both cell and patient-derived prostate can-
cer xenograft models which will provide a clinically relevant platform spanning
the different stages of the disease for preclinical drug evaluation.
#2825 Gene expression profıle in genetically engineered mouse model of
lung cancer correlates with that in human lung adenocarcinoma. Imaya-
varamban Lakshmanan, Satyanarayana Rachagani, Moorthy Ponnusamy,
Seema Chugh, Samikshan Dutta, Sakthivel Muniyan, Surinder Batra, Apar
Kishore. University of Nebraska Medical Center, Omaha, NE.
Introduction: Despite recent advances in the understanding of the biology of
lung cancer, there are no agents that can targetKras, themost commonmutation
seen in lung adenocarcinoma. Development of genetically engineered mouse
(GEM) models with krasG12Dand p53R172H will help us to understand the bi-
ology of kras mutated lung cancer and develop specifıc targeted therapeutic
agents. Material and Methods: We have developed two GEM models of lung
adenocarcinoma harboring the KrasG12D mutation [KrasG12D;AdCre (KA) and
KrasG12D; p53R172H;AdCre (KPA)] by conditional activation in the lung. We
performed RNA-seq analysis from KA and KPA tumor tissues and compared
them to normal lungs from littermate controls. The results were compared with
publicly available human data (TCGA, cBioportal). In addition, we have devel-
oped two novel syngeneic cell lines from KA and KPA tumors, which will be
used to test the effıcacy of candidate drugs. Results: Hyaluronan binding protein
(Habp2) was top most upregulated gene [LogFC 12.7 (KA) 10.4 (KPA)] in both
KAandKPA tumor tissues compared to normal. TheTCGAand cBioportal data
suggest Habp2 is overexpressed in lung adenocarcinoma as opposed to other
histologic subtypes. We then analyzed Habp2 associated gene signature and
observed that fıbrinogen alpha chain (FGA), fıbrinogen gamma chain (FGG),
hyaluronan synthase 1 (HES1), serpin peptidase inhibitor, clade E1(Serpine1)
were also upregulated in both models. On comparison of KA and KPA tumors,
we observed that St6galnac1(ST6 N Acetylgalactosaminide Alpha-2,6 Sialyl-
transferase 1) was upregulated only in the KPAmodel, suggesting that p53R175H
mutation leads to St6galnac1 overexpression. Conclusion: Hyaluronan binding
protein (Habp2) was top most upregulated gene in the KA and KPA models,
while St6galnac1expression appeared to be associated with p53R175H mutation.
Gene expression data from our GEM models of lung cancer agree with the
TCGA and cBioportal analyses. Thus these GEM models seem to replicate hu-
man lung cancer and can be used to test drugs for in vivo therapeutic effıcacy,
prior to use in humans.
#2826 A novel intraperitoneal metastatic xenograft mousemodel for sur-
vival outcome assessment of esophageal adenocarcinoma.MdSazzadHassan,
Niranjan Awasthi, Roderich E. Schwarz, Margaret A. Schwarz, Urs von Holzen.
Indiana University School of Medicine-South Bend, South Bend, IN.
Introduction: Esophageal adenocarcinoma (EAC) has become the domi-
nant type of esophageal cancer in United States. EAC is the fastest growing
cancer in the western world and the overall 5 year survival rate of EAC is
below 20 percent. Most patients present with locally advanced or widespread
metastatic disease, where current treatment is largely ineffective. Prognosis
for EAC patients remains poor even with combination therapies due to high
resistance to chemotherapy. Therefore, new therapeutic approaches are ur-
gently needed. Improvement of esophageal adenocarcinoma outcome re-
quires well-characterized animal models in which to evaluate novel thera-
peutics. In this study we aimed to establish a peritoneal dissemination
xenograft mouse model of esophageal adenocarcinoma that would support
survival outcome analyses. Methods: To fınd the best candidate cell line from
7 esophageal adenocarcinoma cell lines of various origin, we injected them
intraperitoneally and subcutaneously into severe combined immunodefı-
ciency (SCID) mice and examined the tumor progression and survival out-
comes. Human esophageal adenocarcinoma cell lines of Caucasian/Hispanic
origin ESO26, OE33, ESO51, SK-GT-2, OE19, OACM5.1C and Flo-1 origi-
nating from gastroesophageal junction, distal esophagus and gastric cardia/
fundus were injected intraperitoneally/subcutaneously into SCID mice. The
peritoneal/xenograft tumor formation and mouse survival were compared
among different groups. Results: All cell lines injected subcutaneously
formed tumors within 3 months at variable rates. All cell lines except
OACM5.1C formed intraperitoneal tumors within 3 months at variable
rates. Median animal survival with peritoneal dissemination was 108 days for
ESO26 cells (5X106), 65 days for OE33 cells (5X106), 88 days for ESO51 cells
(5X106), 76 days for SK-GT-2 cells (5X106), 55 days for OE19 cells (5X106),
45 days for OE19 cells (10X106) and 82 days for Flo-1 cells (5X106). Inter-
estingly, only in the OE19 model all mice (7/7 for 5X106 and 5/5 for10X106)
developed bloody ascites with liver metastasis after intraperitoneal injection.
The median survival time of these animals was the shortest (45 days for
10X106 cells). In addition, median survival was signifıcantly increased after
paclitaxel treatment compared with the control group (57 days versus 45
days, p0.0034) along with a signifıcant decrease of the relative subcutane-
ous tumor volume (p0.023). Conclusion: Peritoneal esophageal adenocar-
cinoma xenografts were successfully established after intraperitoneal injec-
tion of OE19 cells. This animal model of peritoneal dissemination for
survival outcome will provide a useful survival outcome assessment model
for the preclinical evaluation of cancer therapeutics in esophageal adenocar-
cinoma.
#2827 Establishing a mouse model to investigate GRB7-mediated signal-
ing in development and triple-negative breast cancer. Kristopher A. Lofgren,
David R. Meier, Steven E. Cash, Paraic A. Kenny. Gundersen Medical Founda-
tion, La Crosse, WI.
Triple-negative breast cancer (TNBC) lacks expression of the estrogen and
progesterone steroid receptors and HER2; thus TNBC patients cannot benefıt
from the recent successes of targeted therapies, and instead rely on cytotoxic
chemotherapeutic combinations. As such, tumor recurrence is high and patient
prognosis is poor. GRB7 is a cytoplasmic adaptor protein required for cell mi-
gration, invasion, and proliferation in TNBC.We have previously reported that
a high GRB7 mRNA level was the strongest predictor of tumor recurrence in a
cohort of 246 TNBC patients treated with doxorubicin. GRB7 was confırmed in
a smaller, independent cohort as an indicator of poor prognosis. After the ob-
servation of both decreased doxorubicin sensitivity and elevated GRB7 expres-
sion levels in TNBC tumors, we hypothesized that GRB7 was mediating a sig-
naling pathway critical for drug resistance and cell survival. To determine the
role of GRB7 in mouse development and tumorigenesis, the current study fo-
cuses on the Grb7tm1a(EUCOMM)Wtsi knockout-fırst transgenic mouse, in which
the insertion of the 1L2_Bact_P cassette upstream of the critical exons of GRB7
renders an effective knockout of GRB7, and the inclusion of loxP sites flanking
critical exons of GRB7 facilitates the creation of tissue-specifıc, conditional
GRB7 deletions. Herein, we investigate GRB7 expression in the homozygous
Grb7tm1a mouse and derivative tissue-specifıc deletions, and evaluate their suit-
ability for modeling GRB7-mediated events in mammary gland development
and tumorigenesis in a TNBC model. Primary cell lines from the Grb7tm1a
mouse and breast cancer cell lines will then be used to delineate the effects of
altered GRB7 levels on the mechanism of developmental and TNBC cell signal-
ing, respectively.
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#2828 Role of NEFL in aggressive prostate cancer progression. Tanya C.
Burch,1 IanO.Oduor,2DeanA.Troyer,1 JuliusO.Nyalwidhe1. 1EasternVirginia
Medical School, Norfolk, VA; 2Old Dominion University, Norfolk, VA.
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Introduction: Prostate cancer (PCa) is the most prevalent cancer amongst
men and the second most common cause of cancer related-deaths in the US.
Prostate cancer has a heterogeneous spectrum of clinical outcomes with pheno-
types ranging from indolent asymptomatic cases to very aggressive metastatic
and lethal forms. The development of aggressive castration-resistant prostate
cancer and neuroendocrine prostate cancer, which defy currently available
treatments, represent the most challenging aspect of this disease. Our long term
objective is to identify the molecules and characterize the mechanisms that are
involved in PCa disease transformation and progression to aggressive lethal
disease. In this study, we show that the over-expression of NEFL, a putative
tumor suppressor genes (TSG), correlateswith aggressive phenotypes in a subset
of prostate cancers with aggressive neuroendocrine-like features. Identifying
and characterizing mechanisms by which NEFL modulates progression of PCa
will potentially allow for better discrimination of aggressive neuroendocrine
prostate cancers and provide targets for better treatment and clinical manage-
ment opportunities of the disease. Methods:We have compared the mRNA and
protein expression profıles of NEFL prostate cancer cell lines and prostatectomy
tissues with different malignancy phenotypes. Validation of differential NEFL
expression has been done byWestern blot, qRT-PCR, IHC and mass spectrom-
etry. Functional assays and oncogenic properties have been assessed after siRNA
mediated knockdownofNEFLgene aggressive prostate cancer cell lines. Results:
We demonstrate signifıcant correlations between of NEFL expression and the
acquisition of aggressive PCa with neuroendocrine-like phenotypes. This was
validated byWestern blot and qRT-PC. SiRNA knockdown of NEFL suppresses
the invasive andmigratory capacity of PCa cells and tumor colony formation in
soft agar assays. The molecular interactome of NEFL was characterized by LC/
MS/MS. To our knowledge, this study is the fırst to demonstrate that NEFL
up-regulation correlates with a subset of aggressive prostate cancer disease.
Conclusions: We demonstrate that NEFL is differentially expressed in PCa cells
lines and prostatectomy tissues with a signifıcantly higher abundance in cells
with clinically aggressive and lethal neuroendocrine-like malignancy pheno-
types. These fındings are currently being validated using disease stratifıed tumor
micro arrays. Further studies are focusing on uncovering the mechanisms that
are modulated by NEFL and are responsible for PCa disease progression. These
could assist in the development of novel diagnostic and therapeutic strategies for
the disease.
#2829 Identifıcation of transcriptomic signatures of organotropism in
pancreatic cancer metastasis. Yi Zhong, Jun Fan, Jinlong Huang, Christine A.
Iacobuzio-Donahue.Memorial Sloan Kettering Cancer Center, New York, NY.
Metastatic disease is the most common cause of death in pancreatic ductal
adenocarcinoma (PDA) patients. The most common sites of metastatic spread
of PDA are to the liver, lung, and peritoneum. The acquisition of advanced stage
PDA tissue samples has greatly improved our descriptive understanding of pan-
creatic cancer metastasis; however, important aspects of PDA metastatic cell
biology remain poorly understood. We have previously shown that distant me-
tastases arise from genetically evolved subclones within the primary site of PDA.
To understand the biologic basis of PDA metastatic subclone formation we
established a transgenic mouse model of PDA based on heterozygous inactiva-
tion of Tgfbr2 in association with p48-Cre mediated activation of mutant Kras
and Trp53 alleles (KPTC mice). This model revealed that metastatic effıciency
and organotropism are related but independently controlled phenomena by
mutant Trp53 gain of function in association with TGFb signaling. Pertubation
of TGFb signaling reduced liver but not lung metastasis due to a profound
extravasation defıciency characterized by sinusoidal growth and lack of desmo-
plastic stroma compared to KPC mice. Analogous fındings were confırmed in
liver samples from patients indicating their clinical relevance. Portal vein colo-
nization as a direct mode of access to the liver was observed in both mice and
humans. To better understand the cell- autonomous features that promote or-
gan specifıc metastasis, we have established cell lines from primary and meta-
static PDAs of KPC mice representing fıve different target organ sites (liver,
lung, peritoneum, omentum, lymph node). RNAseq and WGCNA performed
on extracted RNA from these established cell lines indicate gene expression
modules that are unique to metastases. Among metastases, gene expression
modules have also been identifıed that are unique to local versus distant metas-
tases. Analyses are ongoing to functionally validate these modules in additional
samples of mouse and human PDA. These fındings establish a novel paradigm
for understanding pancreatic cancer metastasis and the observed clinical laten-
cies of liver versus lung metastases specifıcally. Identifıcation of cell-autono-
mous andmicro-environmental mechanisms that support PDA organotropism
have the potential to reveal novel targets for therapeutic intervention and mod-
ulation of the lethal metastatic phenotype.
#2830 Secreted protein acidic and rich in cysteine antigen and autoanti-
bodies in sera of prostate cancer patients: Potential use in diagnosis /progno-
sis. Anshu Rastogi,1 Andy Martinez,2 Amina Ali,1 Shyh-Han Tan,1 Jennifer
Cullen,1 Yongmei Chen,1 Gyorgy Petrovics,1 Albert Dobi,1 Lakshmi Ravin-
dranath,1 Denise Young,1 Isabell Sesterhenn,3 Jacob Kagan,4 Sudhir Srivastava,4
DavidMcLeod,1 Inger Rosner,5 Shiv Srivastava,6 Alagarsamy Srinivasan7. 1Cen-
ter for Prostate Disease Research, Rockville,MD; 2WRNMMC/Center for Prostate
Disease Research, Rockville, MD; 3Joint Pathology Center, Silver Spring, MD;
4National Cancer Institute, NIH, Bethesda,MD; 5Uniformed Services Univ. of the
Health Sci/WRNMMC, Bethesda, MD; 6Uniformed Services Univ. of the Health
Sci/Center for Prostate Disease Research, Rockville, MD; 7Uniformed Services
Univ. of the Health Sci., Rockville, MD.
Objectives: Improvements in blood based biomarkers for detecting clinically
signifıcant prostate cancer (CaP) or for distinguishing between indolent and
aggressive CaP are critical in enhancing the management of this most common
non-skin cancer of men in the US. These biomarkers include tumor associated
antigens (TAAs) and autoantibodies (AAbs) against TAAs in patient sera.
SPARC/Osteonectin is highly expressed in metastatic cancers (glioblastoma,
melanoma, breast cancer and prostate cancer) and promotes bone metastasis
and epithelial-mesemchymal transition. Our comparative transcriptome analy-
ses of well/moderately differentiated CaP with poorly differentiated CaP, de-
fıned SPARC as central node in the network of genes with common regulatory
elements (NKXH_NKXH_HOX) associating with poorly differentiated CaP.
Further, we reported associations of high levels of SPARC mRNA or protein
with Gleason 8-10 or poorly differentiated primary tumors and association with
metastatic progression. The aims of this study are: i) Quantify SPARC antigen in
the sera CaP patients; ii) Are AAbs against SPARC present in the serum of CaP
patients?; iii) Is there a correlation between SPARCAAb level in patient sera and
disease status? iii) Does SPARC AAb level vary according to distinct ethnic
groups? Methods: Sera from CaP patients and healthy controls were evaluated
for SPARC antigen using a commercial enzyme-linked immunosorbent assay
(ELISA) kit. AAbs against SPARC were determined by ELISA utilizing recom-
binant full-length human SPARC protein as a substrate. For evaluation we used
Caucasian American (CA, n117) and African American (AA, n111) CaP
patients comprisingGleason 6-10, and healthy controls (CA, n52; AA, n45).
Results: SPARC antigen levels in the sera showed a difference in the overall case
versus control groups (p0.0016) and this trend was observed only in AA
(p0.0015) in comparison to CA patients (p0.1709). SPARC AAbs were de-
tected in the sera and the valueswere signifıcant in the overall case versus control
(p.0001) and also inCA (p.0001) andAA (p.0001) CaP patients with levels
signifıcantly lower in patients compared to controls. AAb reactivity for CaP
patients was similar between CA and AA groups. Conclusions: This study dem-
onstrated the presence of AAbs against SPARC inCaP patient serum for the fırst
time. Of note, highly signifıcant differences were noted between CaP patient
(low) and controls (high) sera, across different ethnic groups. These data suggest
further evaluation of SPARC AAbs as a promising serum biomarker for CaP.
Source of Funding: This research was supported by the Center for Prostate
Disease Research, Uniformed Services University Grant HU0001-10-2-0002.
#2831 Identifıcation of cell specifıc expression signatures using NGS
global gene expression profıles from LCM procured breast carcinoma and
adjacent stromal cells. Jeoffrey J. Schageman,1 Kristi Lea,1 Sarah A. Andres,2
Kelli S. Bramlett,1 James L. Wittliff2. 1Thermo Fisher Scientifıc, Austin, TX;
2Univ. of Louisville Health Sciences Ctr., Louisville, KY.
Our goal is to determine relationships of gene expression profıles to patient-
associated characteristics, breast carcinoma pathology and biomarker status
with clinical outcome to improve assessment of prognosis and therapy selection.
Procedures: De-identifıed frozen tissue biopsies of human breast carcinomas
which were collected and stored under stringently controlled conditions were
employed. Patient-related features (e.g., age, race, menopausal status, nodal sta-
tus, clinical treatment and response) and results from biochemical analyses of
established tumor markers (e.g., estrogen and progestin receptors, EGF recep-
tor, HER-2/neu oncoprotein) guided tissue selection. Structural integrity of a
tissue was fırst evaluated by light microscopy of H&E stained sections. To deci-
pher uniqueness and clinical utility of gene expression profıles from specifıc cell
types, Laser Capture Microdissection (LCM) with a PixCell IIeTM (Arcturus®,
Thermo Fisher Scientifıc) was used to non-destructively collect either carci-
noma cells or adjacent stromal cells on CapSureTM LCM caps. A second intact
serial tissue sectionwas processed identically to that of the section used for LCM
as a control. Each of the two independent cell captures from the same tissue
section and the second intact tissue section were independently extracted for
RNA. RNA was assessed for integrity, purifıed and subjected to novel analyses
using the Ion AmpliSeqTM RNA Breast Cancer Research Panel containing 1174
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genes. Sequencingworkflow included templating on the IonChef TMSystemand
multiplexed sequencing on the Ion S5TM XL sequencing system and Ion 540TM
chip. Results: Each sequencing library yielded approximately 4-5 million reads
with a mapping rate of 98% that was achieved after alignment to the human
transcriptome. Each sample was sequenced in triplicate with technical repro-
ducibility near 99% with a mean of 1035 genes classifıed as detected. Cluster
analyses of gene expression profıles revealed clear distinctions between stromal
and carcinoma cells procured by LCM compared to intact tissue driven by
strongly differentially expressed genes such as vimentin (VIM), MPRIP, stan-
niocalcin-2 (STC2) and estrogen receptor beta (ESR2). Conclusions: Collec-
tively, the results indicate that molecular signatures of breast carcinoma cells
procured by LCM reveal unique gene expression profıles compared to those of
the intact tissue section or the adjacent stromal cells. These novel fındings are
likely to discern molecular features unique to a breast carcinoma that may be
related to clinical outcome to improve assessment of patient prognosis and ther-
apy selection. Supported in part by a grant from the Phi Beta Psi Charity Trust
(JLW& SAA) and a CTSPAward from the Commonwealth of Kentucky (JLW).
For research use only.
#2832 Class I histone deacetylase inhibitors impair tumor growth and
metastatic programs.OliverH.Krämer,NicoleKiweler. Institut für Toxikologie
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Ger-
many.
(a) introductory sentence indicating the purposes of the study Metastasis
formation is associated with poor patient prognosis. Epithelial-mesenchymal
and mesenchymal-epithelial (EMT/MET) transition cycles are key for the for-
mation, survival, and homing of metastatic cells. Inhibitors against epigenetic
modulators of the histone deacetylase family (HDACi) are promising, clinically
tested epigenetic drugs that may combat cancer proliferation and spread. (b)
brief description of pertinent experimental proceduresWe chose a systems tox-
icology approach to analyze the relevance of HDACs and their inhibitors for
metastatic cell growth. We combined in vivo tests with morphological, cellular,
functional, and global proteomic analyses. This strategy follows the 3R principle
by Russel and Burch. Of the four classes ofHDACs (I-IV), the class I subgroup is
most important for tumorigenesis. We therefore analyzed how the pharmaco-
logical inhibition of class I HDACs affects the growth and spreading of synge-
neic kidney cancer cells into the lungs of BALB/cmice and how such drugs affect
tumor cell growth, apoptosis, migration, and gene expression patterns control-
ling EMT/MET in transformed kidney and breast cells. Furthermore, we inves-
tigated how the genetic elimination of HDACs affects cancer cell growth and
EMT/MET. We used flow cytometry, immunoblot, immunofluorescence,
qPCR, proteomics on a global scale, RNAi against the class I HDACs HDAC1/
HDAC2, and in vivo tumor analyses. (c) summary of the new, unpublished data
Both the inhibition aswell as the elimination ofHDAC1/HDAC2 evokes growth
arrest, morphological alterations, and apoptosis. HDACi block tumor cell mi-
gration, integrin-dependent cell adhesion, and EMT induced by the cytokine
TGF-. Global proteomics and qPCR analyses illustrate that HDACi disrupt
EMT/METcycles andmetastatic spread.Moreover, these assays reveal pathways
through which HDACi propel cancer cell apoptosis. (d) statement of the con-
clusionsClass IHDACi canmodulate the EMT/METbalance that is required for
the detrimental process of metastasis. Hence, HDACi should be considered
further as clinical treatment option.
#2833 Epithelial cell adhesionmolecule (EpCAM) is associated with pros-
tate cancer progression and chemo-/radio-resistance in vitro and in vivo. Jie
Ni,1 Paul Cozzi,1 Julia Beretov,1 Junli Deng,2 Joseph Bucci,1 Peter Graham,1
Yong Li3. 1St George Hospital, Kogarah, Australia; 2University of New South
Wales, Kogarah, Australia; 3St George Hospital / Univ. of New South Wales,
Kogarah, Australia.
Aims: Prostate cancer (CaP) is themost common cancer inmales in Australia
which caused more than 3000 deaths in 2015. EpCAM is a transmembrane
protein that is expressed at low levels in a variety of human epithelial tissues, but
overexpressed in most solid tumors. Our previous study indicated that EpCAM
was strongly expressed in metastatic CaP cell lines, primary human CaP tissues
and lymph nodemetastasis and is a biomarker involved in CaP progression, and
chemo-/radio-resistance. However, the role of EpCAM in CaP progression and
therapeutic resistance is still uncertain. The aim of this study was to investigate
the role of EpCAM in CaP progression and chemo-/radio-resistance as well as
underlying mechanisms in vitro and in vivo. Methods: EpCAM gene was
knocked down (KD) in PC-3, DU145 and LNCaP CaP cell lines using shRNA.
Proliferation assay, colony formation assay, docetaxel (DTX) and radiation
dose-response assay were carried out to evaluate the effect of KD of EpCAM on
proliferation and therapeutic response of CaP cells in vitro. Subcutaneous (s.c)
and orthotopic CaP animal models were established using PC-3-EpCAM-KD
andPC-3-EpCAM-scramble (scr) control cells inNOD/SCIDmice, to assess the
effect of EpCAM on CaP tumourigenecity, chemotherapy (DTX) and radiation
response. Signal transduction proteins in PI3K/Akt/mTOR signaling pathway,
as well as proliferation, apoptotic and radiation response markers were evalu-
ated by immunohistochemistry in xenografts. Results: KD of EpCAM reduced
CaP proliferative potential and enhanced DTX and radiation sensitivity in three
CaP cell lines. Both s.c and orthotopic EpCAM-KD xenografts displayed sup-
pressed tumor growth and increased DTX and radiation responsiveness com-
pared to EpCAM-scr control xenografts in NOD/SCID mice. Marked down-
regulation of PI3K/Akt/mTOR pathway proteins (p-Akt and p-mTOR) and
proliferation marker (Ki-67) and signifıcant up-regulation of apoptotic
(Caspase-3) and radiation (γ-H2AX) responses to chemo-/radio-therapies were
found in EpCAM-KD xenografts, compared with control xenografts. In addi-
tion, Kaplan-Meier curve analysis demonstrated that KD of EpCAM improved
median survival (MS) of tumor-bearing mice by 21.5 days compared with the
control group (HR26.94, CI95% 4.317-168.1, p0.0004) and that KD of Ep-
CAM improvedMS of tumor-bearingmice which received docetaxel (50mg/kg,
single dose, i.p.) by 11 days (HR20.95, CI95% 3.599-121.9, p0.0007), and
radiotherapy (2Gy/day for 4 days) by 12 days (HR11.00, CI95% 2.11-57.36,
p0.0044) compared with the control group, respectively. Conclusions: Ep-
CAM plays an important role in CaP progression and chemo-/radio-resistance
via PI3K/Akt/mTOR signaling pathway in vitro and in vivo and it is a promising
therapeutic target for the treatment of CaP. EpCAM targeted therapy combined
with chemo-/radio-therapy could be a novel modality for treatment-resistant
CaP.
#2834 Metastatic colorectal cancer: characterization of distinct histologi-
cal growth patterns which demonstrate different response to current treat-
ment regimes. Vincent Palmieri,1 Anthoula Lazaris,2 Hussam Alamri,2 Abdel-
latif Amri,2 Nisreen Ibrahim,1 Pablo Zoroquiain,2 Peter Vermeulen,3 Peter
Metrakos2. 1McGill University, Montreal, Quebec, Canada; 2McGill University
Health Centre - Research Institute, Montreal, Quebec, Canada; 3Translational
Cancer Research Unit (TCRU), GZA Hospitals, Antwerp, Belgium.
Colorectal cancer (CRC) is the thirdmost common cancer in North America,
and the third leading cause of cancer-related death.About 50%of patientswill be
diagnosed with CRC liver metastasis (CRCLM) during the course of their dis-
ease. We have identifıed two major histological growth patterns (HGP) in
CRCLM resected from patients. In the desmoplastic HGP (DHGP), the tumor
cells are enclosedwithin a desmoplastic stromal ring, physically separating them
from the normal liver tissue. In the replacement HGP (RHGP), the tumor cells
replace normal hepatocytes without disrupting adjacent cells or structures
within the liver parenchyma. We have recently shown that patients with RHGP
lesions who received neoadjuvant bevacizumab plus chemotherapy had a worse
pathological response and fıve-year overall survival. Our group has also shown
that RHGP CRCLM is resistant to anti-angiogenic therapy due to it promoting
vessel co-option as ameans of tumor vascularization, rather than VEGF-depen-
dent angiogenesis as seen in DHGP. However, the molecular mechanisms that
drive theCRCLMHGPs remain unknown. This project aims to shed light on the
biological processes that underlie the diversity ofHGPs, with an emphasis on the
key genes and pathways that support the RHGP. To test this, we have: Aim 1)
performed RNAseq on chemonaïve RHGP and DHGP CRCLM lesions to iden-
tify pathways that are signifıcantly upregulated in the RHGP. We have vali-
dated these genes via real-time PCR (RT-PCR), and a subset by immunohis-
tochemistry (IHC). Aim 2) To further refıne the RHGP gene signature and to
examine the effects of cell-cell interactions on hepatocyte and tumor cell
gene expression, individual cells have been isolated from distinct regions
within RHGP CRCLM tissues using laser capture microdissection (LCM),
followed by single-cell transcriptomics analyses. Our preliminary data have
identifıed three major pathways with differentially expressed genes: i. cell
motility, ii. cell junctions, and iii. ECM-receptor interactions, which are
upregulated in RHGP relative to the DHGP and normal liver. A panel of
RHGP-specifıc genes has been identifıed and validated via RT-PCR. We
selected a subset of these genes and are performing IHC to further validate
and locate their expression. We have also performed LCM and are in the
process of performing transcriptomics analyses – the data will be presented.
We expect to gain some insight into the mechanisms responsible for driving
and/or maintaining the RHGP lesions. In the longer term, this work will
result in identifıcation of targets in the HGPs that will help stratify patients in
terms of treatment. It would appear that we have fewer treatment options for
the RHGP patients and it would be important to utilize the data to develop
new treatment strategies for those patients. These new therapies would lead
to further clinical trials.
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#2835 Potential opposing roles of AKT isoforms in indolent versus ag-
gressive prostate cancer. Karina A. Miller,1 Hyun-Kyung Ko,2 Irwin H.
Gelman1. 1Roswell Park Cancer Inst., Buffalo, NY; 2Cleveland Clinic, Cleveland,
OH.
Prostate cancer (CaP) is the most commonly diagnosed non-cutaneous
cancer and the second highest contributor to cancer-related deaths in U.S.
men. Localized CaP has a 5-year survival rate of approximately 100%, but
disseminated, metastatic disease (mCaP) dramatically reduces 5-year sur-
vival to30%. A known driving force in the progression of CaP is activation
of the PI3K/Akt signaling pathway through loss of PTEN, with widespread
effects on cell proliferation and migration. Additional genomic changes,
such as the loss of TP53 or RB1, or the upregulation of MYC, correlate with
increased incidence and aggressiveness of mCaP. However, only a fraction of
men with high levels of circulating and disseminated CaP cells progress to
overt, macro-metastatic disease - the lethal phenotype in CaP. Importantly,
little is known regarding the drivers of indolent vs. aggressive mCaP. We
used two transgenic (Tg) mouse models of mCaP with clinically relevant
genetic alterations which exhibit Akt activation and Rb1 loss, yet one pro-
duces indolent mCaP and the other, systemic aggressive mCaP. Specifıcally,
mice lacking Rb1 and the metastasis-suppressor, SSeCKS/Akap12, develop
high-grade prostatic intraepithelial neoplasia (HG-PIN) and disseminated
disease in the lymph nodes whereas those lacking Pten and Rb1 develop CaP
and aggressive mCaP. The metastasis-suppressing functions of Akap12 re-
lates to its ability to scaffold Src and PKC, thereby attenuating their onco-
genic signaling pathways. We will show data suggesting that the pathological
differences between these two Tg models is based on the differential use of
PI3K-p110 and Akt isoforms, with aggressiveness correlating with the down-
regulation of Smad4, a known metastasis-suppressor in Tg CaP models.
Additionally, differences in Akt isoform usage likely controls the expression
of neurogenesis genes that are especially upregulated in castration-recurrent
CaP that fails second-line androgen receptor antagonist inhibitors such as
enzalutamide. By comparing the differential transcriptomes and signaling
networks in primary-site tumors, lymph node metastases, and CaP cell lines
derived from these two Tg models, several new potential therapeutic targets
have been identifıed that could be exploited to prevent or treat aggressive
mCaP.
#2836 Mitochondrial genomic backgrounds differentially affect nuclear
DNA methylation and gene expression. Carolyn J. Vivian,1 Amanda E.
Brinker,1 Stefan Graw,1 Devin C. Koestler,1 Christophe Legendre,2 Gerald C.
Gooden,3 Bodour Salhia,3 Danny R.Welch1. 1Univ. of Kansas Cancer Ctr., Kan-
sas City, KS; 2Translational Genomics Research Institute, Phoenix, AZ; 3Univer-
sity of Southern California, Los Angeles, CA.
Accumulating data implicate mitochondrial genetics andmetabolism as con-
tributors tometastatic effıciency.With only 13 proteins encoded by themtDNA
genome, the mechanism(s) by which the coordination of multiple genes in-
volved inmetastasis could occur is unclear.Wehypothesized thatmitochondrial
DNA (mtDNA) polymorphisms would differentially regulate nuclear DNA
(nDNA) methylation and gene expression. To test the hypotheses, we created
Mitochondrial Nuclear Exchange (MNX) mice, by transferring an oocyte nu-
cleus from strainx into an enucleated oocyte from strainy. The mice show that
mammary tumor formation and metastasis are regulated by inherited mito-
chondrial polymorphisms (PMID: 26471915). Age-matched,malemouse brains
were collected and pooled from four litter mates representing each of the wild-
type and MNX mice (8 groups). Genome-wide nDNA methylation (Mouse
methyl-Seq) and gene expression (RNA-Seq) were measured and results vali-
dated in independent replicate samples. Signifıcant, selective and reproducible
differential DNAmethylation and gene expression were observed and validated
between strains having identical nDNA, but different mtDNA. While the sig-
nal(s) from mitochondria altering methylation is not fully defıned, the fındings
support the hypothesis and demonstrate howmitochondrial genetic alterations
could be one of several quantitative trait loci involved in complex phenotypes,
such as metastasis. The results also suggest that mtDNA polymorphisms could
serve as predictive biomarkers for cancer aggressiveness. Support: Susan G.
Komen for the Cure (SAC11037), Natl Fndn Cancer Res, Biomedical Research
Training Program, Kansas Bioscience Authority, CA134981, P30-CA168524.
#2837 Differential expression of Protocadherin-7 (PCDH7) in prostate
cancer (PCa) cells: a direct associationbetweenPCDH7and castrate resistant
PCa. Gauri Shishodia,1 Sweaty Koul,1 Qin Dong,1 Hari K. Koul2. 1LSU Health
Sciences Center - Shreveport, Shreveport, LA; 2FWCC/LSUHealth Sciences Center
- Shreveport, Shreveport, LA.
Introduction: PCa is themost commonly diagnosed disease inAmericanmen
and the second leading cause of death among them. Most of PCa deaths are a
result of distant metastasis and due to emergence of castrate resistant PCa. Pro-
tocadherin-7 (PCDH7), a Cadherin superfamily transmembrane protein that is
known to function in cell-cell recognition and adhesion, is reported to be over-
expressed in breast cancer and non-small cell lung cancer (NSCLC). PCDH7has
been shown to mediate brain metastasis of breast cancer. Overexpression of
PCDH7 was reported to be associated with poor clinical outcome of NSCLC.
However, there is no report on involvement of PCDH7 in PCa tumorigenesis
and metastasis. In the present study we evaluated expression of PCDH7 in an-
drogen dependent and androgen independent PCa cells and in TCGA and
Trento/Cornell/Broad 2016 clinical data sets. Materials andMethods: PCa cells-
LNCaP,C4-2b,DU145, PC3, 22Rv1 andRWPE1were used in this study. Protein
expression was checked by Western Blotting. mRNA levels were checked by
quantitative real time PCR. Results: Our data reveal high PCDH7 protein ex-
pression in PC3 cells and low levels of PCDH7 in LNCaP and RWPE1 cells.
qRT-PCR confırmed an increased transcript level of PCDH7 in PC3 and low
levels in LNCaP cells. We also observed elevated transcript levels for PCDH7 in
castrate resistant and Enzalutamide refractory PCa (22Rv1) cells. These data
suggest a direct relationship between castrate resistance and PCDH7 expression.
Our results also show an inverse relationship between PCDH7 and E-Cadherin
and a direct relationship between PCDH7 and EMTmarkers, indicating expres-
sion of PCDH7 is associated with tumor progression. Interestingly, there was no
correlation between PCDH7 with tumor grade or metastasis from TCGA data,
but analysis of NEPC (Trento/Cornell/Broad 2016) data set revealed amplifıca-
tion of PCDH7 in 9% of NEPC tumors. Collectively, these data suggest PCDH7
expression may be associated with advanced PCa in general and NEPC pheno-
type PCa in particular. Conclusion: Our results suggest direct association of
PCDH7 expression and castrate resistance in PCa cell lines. Role of PCDH7 in
castrate resistant PCa needs further evaluation.
#2838 CtBP1 expression depletion on primary tumor deregulatesmiRNA
expression and impairs development of spontaneous metastases on a pros-
tate cancer and metabolic syndrome model. Guillermo N. Dalton, Georgina
Scalise, Juliana Porretti, Cintia Massillo, Paula L. Farré, Paola De Luca, Adriana
De Siervi. Instituto de Biología y Medicina Experimental (IByME) - CONICET,
C.A.B.A, Argentina.
Prostate cancer (PCa) is the second cancer in incidence in men worldwide.
Approximately 20 % of cases continue with advanced or metastatic disease, and
at this stage, it turns out incurable due to the lack of effective therapies. Hence,
the need to identify new actionable targets is crucial.Metabolic syndrome (MeS)
is a physiopathological disorder that increases PCa risk and aggressiveness. C-
terminal Binding Protein (CtBP1) is a transcriptional corepressor that is acti-
vated by NADH binding. Previously our group established aMeS and PCamice
model that identifıed to CtBP1 as a novel link associating both diseases. More-
over, cell adhesion molecules play a signifıcant role in cancer progression and
metastasis. Thus,we found thatCtBP1diminished the capability of PCa cell lines
to adhere to a collagen matrix, directly modulating expression of several cell
adhesion genes, including repression of the epithelial marker CDH1 and induc-
tion of the mesenchymal marker VIM. The aim of this work was to investigate
MeS/CtBP1 impact over PCa progression from in situ prostate carcinoma to
metastatic disease. RNA was isolated from xenografts generated on MeS mice
from CtBP1 depleted PC3 cells (PC3.shCtBP1) or control (PC3.PGIPZ); and
hybridized to a miRNA expression microarray (Affymetrix GeneChip® miRNA
4.0). After data normalization and analysis we identifıed and validated a list of
11 miRNAs regulated by CtBP1 relevant to cell adhesion and PCa progres-
sion. To investigate CtBP1 role in spontaneous PCa metastasis, NOD SCID
gamma (NSG)mice were fed with control or high fat diets during 12 weeks to
induce MeS. Then PC3.shCtBP1 or PC3.PGIPZ cells were injected s.c. on
MeS and control animals. Body weight and tumor size were measured 1 and
3 times a week, respectively. Thirty days after cell inoculation, tumors were
around 1 cm, with no signifıcant differences between treatments; however
mice showed around 20% weight loss. Mice were sacrifıced and tumors,
lungs and livers were collected for RNA isolation and histopathological anal-
ysis. Using human GAPDH specifıc primers and RT-qPCR from lungs, we
found that CtBP1 depletion led to a signifıcant decrease of lung metastases,
especially in the MeS group. In addition, Hematoxylin & Eosin stains from
lung sections detected the lowest number and size of metastatic foci in the
CtBP1 depleted xenografts generated in MeS animals. Gene expression com-
parison between primary tumors and metastases showed that epithelial
markers, such as E-cadherin, were induced in xenografts and almost unde-
tected in metastasis. Accordingly, mesenchymal markers expression, such as
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Vimentin, was low in xenografts and triggered on metastases. Our study
uncovers for the fırst time the role of CtBP1 in PCa progression and its
molecular targets in MeS mice.
#2839 Systematic enrichment analysis of gene expressionprofıling studies
identifıes SPARC dependent consensus pathways implicated in bladder can-
cer.BincyAnu John,Neveen Said.Wake Forest Health Sciences,Winston-Salem,
NC.
Bladder cancer (urothelial cancer of the bladder) is the most commonmalig-
nancy affecting the urinary system with increasing incidence and mortality.
Treatment of bladder cancer has not advanced in the past 30 years. Therefore,
there is a crucial unmet need for novel therapies, especially for advanced disease.
We have recently reported Secreted Protein Acidic and Rich in Cysteine
(SPARC) as a tumor suppressor in urinary bladder cancer that inhibits the mul-
tistep cascades on tumor initiation, progression and metastasis. SPARC gene
and protein expression was among candidates associated with the tumorigenic-
ity of the isogenic T24/T24t cell lines. We reported that SPARC depletion in
human bladder cancer cell lines including T24 cells increased their tumorige-
nicity and metastatic potential. In addition, SPARC protein and transcript ex-
pression are signifıcantly downregulated in advanced urothelial cancer. To gain
insight on themolecular mechanisms of the tumor suppressor effects of SPARC
in urothelial cancer, we did whole transcriptome profıling of T24 cells depleted
of SPARC to identify SPARC-signature associated with bladder cancer invasive-
ness, progression, andmetastasis. Subsequently, we used gene signature enrich-
ment analysis (GSEA) pathway enrichment tools to defıne functionally related
genes that are consistently up- or down- regulated as a function of loss of
SPARC.We found that loss of SPARC expression is associated with enrichment
of multiple oncogenic signaling pathways that are enriched in muscle invasive
urothelial cancer and have been associatedwith poor prognosis. These pathways
include K-ras, Myc-oncogene, p53 pathways as well as DNA damage/repair.
Consistent with our earlier reports, loss of SPARC is associated with genes and
proteins involved in angiogenesis, inflammation and hypoxia. In addition, we
have identifıed novel signatures involved in unfolded protein response, mTOR
signaling, glycolysis and cholesterol metabolism. These comprehensive signa-
tures not only reveal SPARC-dependent networks that cooperate to elicit its
biological responses but enables coherent understanding of the etiology of com-
plex bladder cancer disease. Importantly, these signatures identify novel thera-
peutic opportunities for bladder cancer.
#2840 Integrative approach to biomarker discovery by performing com-
parative analysis of two cancers, hepatocellular carcinoma and endometrioid
endometrial carcinoma, using genetics and transcriptomics from RNA se-
quencing data. Jean-Noel Billaud, Stuart Tugendreich, Debra Toburen. QIA-
GEN Bioinformatics, Redwood City, CA.
Hepatocellular Carcinoma (HCC) and Endometrioid Endometrial Carci-
noma (EEC) are two lethal diseases of public health importance worldwide.
Using QIAGEN’s RNA sequencing solution, we were able to highlight key mo-
lecular and biological processes that indicate similarities in the tumor progres-
sion toward metastasis between one EEC patient and the three HCC patients.
We have identifıed ITGB1-001 isoform as a potential common biomarker be-
tween these two complex cancers. We have also shown these two cancers share
activated pathways such as actin cytoskeleton signaling, and RAF1 as an up-
stream regulator indicating similar transcriptional program between these pa-
tients. Furthermore, we have identifıed as a potential therapeutic target themas-
ter regulator CTGF that connects a network of 286 downstream targets to
invasion of tumor cells. We have fıltered a set of unique variants in the EEC
patient that affect a network of upstream regulators common with HCC. This
approach may be useful in the context of precision or personalized medicine.
Examining the gene expression in tumors from groups of patients with each
disease revealed that at a molecular level, early stages of EEC resemble estab-
lished HBV-positive, HCV-negative, liver cirrhosis positive HCC.
#2841 Investigating drivers of disease progression in invasive lobular car-
cinoma. Nilgun Tasdemir,1 Matthew Sikora,2 Zhu Li,1 Kevin Levine,1 Ahmed
Basudan,1 Soumya Luthra,1 Esther Elishaev,1 Uma Chandran,1 George C.
Tseng,1 Rachel Jankowitz,1 David J. Dabbs,1 Priscilla McAuliffe,1 Nancy E. Da-
vidson,1 SteffıOesterreich1. 1University of Pittsburgh, Pittsburgh, PA; 2University
of Colorado, Denver, CO.
Invasive lobular carcinoma (ILC) is the second most common type of breast
cancer following invasive ductal carcinoma (IDC) and accounts for 10-15%of all
cases. Unlike the masses or lumps formed by IDCs, ILCs grow as small, dis-
cohesive cells in a single-fıle pattern within dense layers of extracellular matrix.
Paradoxically, while patients with ILC display favorable prognostic and predic-
tive factors (ER, PR, HER2, low Ki67), their long-term response to endo-
crine therapy is worse than patients with IDC. Despite such histological and
clinical differences, ILC has remained a gravely understudied subtype of breast
cancer. Thus, there is urgent need to investigate molecular drivers of ILC pro-
gression in order to develop more effective therapeutic strategies and improve
patient outcome. To this end, we used the Nanostring platform to measure the
expression of 577 copy number variation-associated genes in 131 primary ILC
tumors and identifıed two candidate drivers that exhibit higher expression in
tumors frompatientswith recurrent versus non-current disease: CTTN (cortical
actin binding protein) and QSOX1 (quiescin sulfhydryl oxidase). In follow-up
studies, we observed high CTTN and QSOX1 expression in human ILC cell
lines, tumors and patient-derived xenografts. In addition, QSOX1 expression
was further increased in ILC ovarian metastases compared to their matched
primary tumors. In functional in vitro studies, RNAi-mediated inhibition of
CTTN led to decreased adhesion and haptotaxis to Collagen I, while QSOX1
knockdown diminished the growth of human ILC cell lines. We are currently
assessing the in vivo therapeutic utility of CTTN and QSOX1 inhibition in tu-
mor growth andmetastasis using human ILC cell line and patient-derived xeno-
graft mouse models. This study greatly advances our understanding of ILC dis-
easemechanisms and identifıes novel therapeutic targets towards improving the
clinical outcome of patients with this understudied subtype of breast cancer.
#2842 Dissecting the transcriptional profıles of metastatic and primary
disease across cancer types. Laxmi Silwal-Pandit,1 Vigdis Nygaard,1 Hege
Russnes,1 Vegar Johansen Dagenborg,1 Veronica Skarpeteig,1 Olga Østrup,2
SiljeNord,1Vivi AnnFlørnes,3 AnneHansenRee,4 Kjersti Flatmark,1 Anne-Lise
Børresen-Dale,5 Ole Christian Lingjærde,6 Gunhild Mari Mælandsmo1. 1Insti-
tute for Cancer Research, Oslo University Hospital, Oslo, Norway; 2Rigshospitalet
- Copenhagen University Hospital, Oslo, Denmark; 3Oslo University Hospital,
Oslo, Norway; 4Akershus University Hospital, Oslo, Norway; 5Institute for Clini-
cal medicine, University of Oslo, Oslo, Norway; 6Institute for Informatics, Univer-
sity of Oslo, Oslo, Norway.
Cancer metastasis is the principal cause of death in individuals with cancer;
nevertheless, the molecular basis of metastases is poorly understood. Genetic
and epigenetic changes in malignant cells and their interaction with the tumor
microenvironment are presumably key events in the establishment of metasta-
ses. In this study, we pursue to provide insights into potential importance of
various fundamental cancer-related pathways in the metastatic process. We
have performed a pathway - based analysis on mRNA expression data (Agilent
8X60K array) from colorectal liver metastases (CLM; N  38 patients, n  44
metastases), breast lymph-node metastases (BCM; N n 43) and melanoma
lymph-nodemetastases (MLM;N n 44). For each of the 186 pathways in the
KEGG pathway database, each sample is represented as points in a ‘n’ dimen-
sional space according to their gene expression values, where ‘n’ is the number of
genes in the pathway. We fırst calculated centroids for each of the three metas-
tases types (CLM, BCM and MLM) and then calculated the Euclidean distance
between centroids to get a measure of how similar or different each cancer type
is for that particular pathway. The fındings were compared to the corresponding
primary cancer types and normal tissue available from TCGA to uncover bio-
logical processes specifıc to metastases. The pathways were functionally classi-
fıed into genetic information processing, cellular processes, environmental in-
formation processing and metabolic pathways as per KEGG database. Across
metastases from different cancer types, pathways involved in genetic informa-
tion processing (e.g. translation, transcription, protein folding and degradation,
DNA replication and repair) and metabolic pathways were more similar than
the pathways involved in cellular processes (e.g. cell-cycle, apoptosis, adherence
junction), and signal transduction pathways (e.g. Notch, MTOR, JAK STAT)
responsible for environmental information processing. The genetic information
processing pathways were more similar across cancer types also in the primary
setting than the pathways involved in cellular and environmental information
processing, whereas the metabolic pathways were more similar across cancer
types in the metastatic setting compared to the primary setting. Preliminary
fındings suggest that the basic molecular architecture of the primary tumors is
maintained, except for the metabolic pathways, which become more similar in
the metastatic setting; and hence may be a common denominator across cancer
types during metastatic process.
#2843 DNMT3B mediated DNA methylation and epigenetic reprogram-
mingofmetastatic cancer cells. JaeYoung So,1Nicolas Skrypek,1 XiangWang,1
AnandMerchant,1 HowardYang,1Wei-DongChen,1 GangqingHu,2 Bhagelu R
Achyut,1 Meggie Cam,1 Keji Zhao,2 Maxwell Lee,1 Li Yang1. 1NCI/NIH,
Bethesda, MD; 2NHLBI/NIH, Bethesda, MD.
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Approximately 90% of cancer patients die from metastasis. In many cases,
current therapies are designed based on the primary tumor characterization and
are ineffective against metastatic disease. It is not clear whether metastatic can-
cer cells acquire additional genetic and epigenetic alterations, if so, what are the
underlying mechanisms. Using several tumor models, we demonstrated that
DNMT3B, de novaDNAmethyltransferase, was increased inmetastatic nodules
in comparison to that from the primary tumors. DNMT3B knockdown or over-
expression signifıcantly inhibited or increasedmetastatic colonization of cancer
cells. To understand the underlying molecular mechanisms of DNMT3B regu-
lation, we performedDNMT3BChIP-seq, RNA-seq, andDNAmethylation-seq
comparing lung metastases with primary tumors and 4T1 cells. We identifıed
genes that are differentiallymethylated and expressed. Ingenuity Pathway Anal-
ysis revealedDNMT3B targetingmultiple oncogenic signaling pathways. Bioin-
formatics analysis of human databases demonstrated signifıcantly higher ex-
pression levels of DNMT3B in metastases than primary tumors in breast,
prostate and melanoma cancer patients. In summary, our study demonstrated
that DNMT3B as a key epigenetic regulator which plays critical roles for tumor
metastasis. Our work suggests DNMT3B as potential therapeutic targets for
breast cancer patients with metastatic disease.
#2844 Identifıcation of genes associatedwith pancreatic cancermetastasis
by genome-wide CRISPR Cas9 screening. Youjia Li,1 Huiyi Feng,1 Guangjie
Liu,2 Chi HinWong,1 Chi Han Li,1 Yangchao Chen1. 1CUHK,Hong Kong, Hong
Kong; 2GIBH, Guangzhou, China.
Pancreatic cancer is an extremely lethal cancer with a 5-year survival rate of
7%. One major reason why pancreatic cancer is hard to treat is its metastasis
nature. Genes that related to the tumorigenesis and progression of pancreatic
cancer were identifıed after decades of efforts. Several researches had revealed
that pancreatic cancer originated from the successive accumulation of genemu-
tations, especially KRAS2, CNKD2A, TP53 and SMAD4. However, little is
known about genes that regulate pancreatic cancer metastasis. Here we used a
genome wide CRISPR Cas9 screening to identify the gene(s) associated with the
metastasis of pancreatic cancer. We transduced pancreatic cancer cell line with
lentivirus-based genome wide CRISPR sgRNA library to establish mutated cell
library, and orthotopically injected the cell library into nudemice andwaited for
primary tumor growth and metastasis, then collected primary and metastatic
tumors after several months. By next generation sequencing and analysis, we
identifıed some gene candidates which may play important roles on pancreatic
cancer metastasis.
#2845 ARb phosphorylation code associated with lung cancermetastasis.
Jaileene Perez-Morales,1 Darielys Mejias-Morales,2 Bryan Torres-Collazo,3
Harry Negron-Pagan,1 Pedro Santiago-Cardona1. 1Ponce Health Sciences Uni-
versity, Ponce, PR; 2Pontifıcal Catholic University, Ponce, PR; 3University of
Puerto Rico, Ponce, PR.
Lung cancer is characterized by its poor prognosis, aggressiveness, and pro-
clivity for early metastasis. Non-small cell lung cancer (NSCLC) it’s the most
common type of lung cancer with a fıve-year survival rate of 18%. Most predic-
tors of metastasis and recurrence of NSCLC rely on post-resection evaluation of
tumor histology, which is a severe limitation since only 15% of the patients are
diagnosed with resectable disease. Hence, there is a need to characterize bio-
markers with metastasis-predicting value in pre-resection small biopsy speci-
mens. In addition to the proclivity formetastasis, another feature of lung cancers
is the inactivation of the retinoblastoma protein (Rb). The retinoblastoma pro-
tein (Rb) is a tumor suppressor inactivated due to hyper-phosphorylation in
most human cancers, including NSCLC. Our preliminary data relates the Rb
S249/T821 phosphorylation signature to an epithelial-to-mesenchymal transi-
tion (EMT), a trait strongly associated to metastasis. We found that cells that
have hyperphosphorylatedRb in residues S249/T821 express EMTmarkers such
as decreased expression of E-cadherin and integrin 5 as well as increased ex-
pression of N-cadherin, Vimentin, and p-FAK. We propose to focus on the cell
adhesion and migration-related kinase Cdk5 with its activator p39 as the kinase
responsible for engendering the Rb S249/T821 phosphorylation signature. Our
hypothesis is that Rb phosphorylation in S249 and T821 due to CDK5 activity
can have prognostic value by being associated with a metastatic phenotype and
EMT. Studies performed in a tissue microarray in a population of NSCLC ade-
nocarcinoma that had undergone EMT found an up-regulation in p39 and that
its expression is correlated with metastasis. Knockdown of CDK5 induced a
decrease in phosphorylation of Rb S249/T821 with a decrease in E-cadherin
expression. These data suggest that CDK5-dependent phosphorylation of Rb
can affect cell adhesion by regulating E-cadherin. Introducing p39 intoRb hypo-
phosphorylated cell line induced an increase in phosphorylation of Rb residues.
Furthermore, the CDK5-p39-Rb axis might point to the explanation and pre-
diction of the metastatic phenotype in lung cancer.
#2846 Identify urinary biomarkers for colorectal carcinoma liver metas-
tasis. Meng Cai,1 Yulin Sun,1 Jiajia Gao,1 Lina Zhao,1 Fang Liu,1 Wei Sun,2
Zhixiang Zhou,1 Xiaohang Zhao1. 1National Cancer Center/Cancer Hospital,
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing,
China; 2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
& Peking Union Medical College, Beijing, China.
Colorectal cancer (CRC) is the third leading prevalent cause of death from
cancer in adults, and more than one third of CRC patients are accompanied by
liver metastasis. The disease begins as a benign adenomatous polyp, and it sub-
sequently develops into an advanced adenoma and gradually progresses to an
invasive cancer. The driving factors behind CRC comprise a series of successive
accumulated gene mutations that follow the order “APC-KRAS-TP53-DCC”.
Moreover, urine is an important display window for tumor-derived exosomes.
Here, to explore the roles of TP53 in CRC and identify novel urinary biomarkers
for colorectal cancermetastatic to the liver, a comprehensive proteomic analysis
of exosomal proteins from HCT116 TP53-wild type (WT), TP53-knockout
(KO) and constructed TP53 (R273H)-mutant (MT) cells, as well as urine sam-
ples from CRC patients with and without liver metastasis was performed using
the isobaric tag for relative and absolute quantitation (iTRAQ)-2D-LC-MS/MS
strategy. The exosomes from the MT and KO cells exhibited signifıcantly re-
duced sizes compared with theWT cells. A total of 3437 protein groups with
2
matched peptides were identifıed. Specifıcally, hepatocyte growth factor-regu-
lated tyrosine kinase substrate (HGS) was consistently down-regulated in the
exosomes from theMT and KO cells. Functional studies demonstrated that low
HGS levels were responsible for the decreased exosome size. TP53 regulated
HGS expression and thus HGS-dependent exosome formation. Furthermore,
theHGS expressionwas gradually increased concomitantwithCRCcarcinogen-
esis andwas an independent poor prognostic factor. In addition,HGSwas one of
the differentially expressed urine proteins between CRC liver metastasis and
healthy individuals. In conclusion, HGSmediates TP53-regulated exosome for-
mation. HGS may serve as a novel histological and urinary prognostic bio-
marker and a candidate target for therapeutic interventions in CRC.
#2847 Loss of heterozygosity (LOH) within the hypoxia inducible factor
3A (HIF3A) locus in liver metastasis (LM) from primary colorectal cancer
(CRC). Takahito Kitajima, Minoru Koi, Alexander Worix, John M. Carethers.
University of Michigan, Ann Arbor, MI.
Background and Aims: HIF3 is a hypoxia-regulated transcription factor
that represses the effects of HIF1 and HIF2 under hypoxia at transcrip-
tional and posttranslational levels. We previously found that LOH at the
HIF3A locus is frequent in LM (59%) and the expression of HIF3A protein is
reduced in LM compared to primary CRC. At present, the smallest overlap-
ping LOH (SOL-LOH) region has been mapped to the intron 8 of the HIF3A,
spanning from 46,312,911 to 46,315,651 on chromosome 19 in LMs. This
genomic region contains multiple FOXA1 binding sites embedded in the two
DNase I hypersensitive sites (UCSC Genome Browser, https://genome.UC-
SC.edu). About 30% of the human population carries a deletion within our
SOL-LOH region (1000 Genomes Consortium: esv3644527, Chr19:
46,314,109-46,315,478). In this study, we determined whether esv3644527
deletion affects on the expressions of HIF3A, HIF2A, HIF1A and their target
genes under normoxic and hypoxic conditions. Methods: For LOHmapping,
75 resected LMs derived from primary CRC were analyzed for LOH using 8
polymorphic markers. We obtained three EBV-transformed B cell lines with
heterozygous esv3644527 deletion and the one with the homozygous dele-
tion from the Coriell Institute. The expression levels of 23 genes related to
HIF pathways were determined by qRT-PCR. Results and Discussion: The
expression levels of HIF3A mRNA were too low to compare among these B
cell lines by qRT-PCR. However, the expression levels of HIF2A and its
target gene, angiopoietin 2 (ANGPT2), are signifıcantly elevated in B cells
with a homozygous deletion compared to B cells with a heterozygous dele-
tion under both normoxic and hypoxic conditions. These observations are
compatible with the results obtained from a previous study where pulmo-
nary endothelial cells from HIF3A-knockout mice expressed elevated levels
of HIF2A and ANGPT2 (Kobayashi-S et al., Genes Cells, 2015, 20:224-241),
suggesting that deletion of the FOXA1 sites present in this region may reg-
ulate the HIF3A expression. Conclusions: Our results show that about 60%
of LMs exhibit LOH in the 2.7 Kb region surrounding intron 8 of the HIF3A
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locus. Deletion within this region may lead to upregulation of HIF2A and
ANGPT2 by negatively regulating HIF3A expression. To prove our hypoth-
esis, colon cancer cell lines with deleted FOXA1 sites will be assessed.
#2848 Identifying and targeting competing endogenous RNA (ceRNAs)
networks to inhibit lung metastasis in triple negative breast cancer. Pelin
Ersan,1 Unal Tokat,1 Erol Eyupoglu,1 Umar Raza,1 Yasser Riazalhosseini,2 Can
Alkan,1 Denis Thieffry,3 Daniel Gautheret,4 Ozgur Sahin1. 1Bilkent University,
Ankara, Turkey; 2McGill University, Montreal, Quebec, Canada; 3Ecole Normale
Supérieure, Paris, France; 4Université Paris-Sud, Paris, France.
Introduction: Triple negative breast cancer (TNBC), the most aggressive
breast cancer subtype, has high incidence rate of lung metastasis. Not only
protein coding transcripts, but also non-coding transcriptome, such as mi-
croRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have active
roles in cancer progression and metastasis. Additionally, lncRNAs can act as
sponges for miRNAs. Here, we aimed i) to construct the fırst mRNA-
miRNA-lncRNA competing endogenous RNA (ceRNA) network controlling
metastasis in TNBC, and ii) to prevent lungmetastasis by targeting identifıed
central candidate genes. Material/Method: We established primary tumor
and human-in-mouse (HIM) and mouse-in-mouse (MIM) lung metastasis
models using TNBC cell lines in nude and Balb/c mice, respectively. We
visualized both primary andmetastatic tumors using in vivo imaging system,
harvested tumors and performed both RNA and small RNA sequencing. We
obtained differentially expressed miRNAs, mRNAs and lncRNAs between
primary and metastatic tumors. Using several bioinformatics tools, we did
enrichment analyses, miRNA target predictions, and network construction.
Identifıed central lncRNAs were overexpressed or knocked down and will be
tested in in vitro and vivo metastasis-related assays. Results and Conclu-
sions: We obtained 45 and 91 miRNAs which were differentially expressed
between primary and metastatic tumors in HIM and MIM models, respec-
tively. A miRNA family with an established role in metastasis as well as
several other miRNAs was identifıed as highly differentially expressed in the
same direction in both models. Moreover, 1127 and 3350 mRNAs, and 85
and 111 lncRNAs were differentially expressed in HIM and MIM models,
respectively. Metastasis-related processes based on differentially expressed
mRNAs were enriched in the data. We then integrated these three layers of
data, functional enrichments, pathway maps and target predictions to con-
struct the fırst ceRNA network controlling lung metastasis in TNBCs. Cur-
rently, we are testing the functional roles of candidate lncRNAs in in vitro
and in vivo metastasis assays. Ultimately, our study will uncover novel ln-
cRNAs that can be used as potential targets and/or biomarkers in breast-to-
lung metastasis. Funding: This study is supported by TUBITAK-CNRS Bi-
lateral Grant with project number 214S364.
#2849 Identifıcation of active enhancers as potential biomarkers of ag-
gressive colorectal cancer. Zhiquan Wang.Mayo Clinic, Rochester, MN.
Colorectal cancer is the third most common cancer and second leading cause
of cancer-related deaths in the United States. Tumor metastasis is the primary
cause of mortality. Even with aggressive surgical and therapeutic management
approaches, more than one third of patients will develop metastatic disease.
Understanding the molecular changes that drive tumor cells to the metastatic
state is key to developing targeted therapies and identifying early-stage markers
for progression. To identify changes that promote cell invasiveness, a hallmark
of tumor progression, we exposed the pre-metastatic SW-480 colorectal cancer
cell line to multiple rounds of selection for the capacity to invade through a
synthetic extra-cellular matrix. Following repeated selection, invasiveness in-
creased by more than 10-fold. Epithelial markers, such as E-cadherin, were re-
pressed and markers commonly associated with tumor cells that have under-
gone epithelial-mesenchymal transition, such as N-cadherin and Vimentin,
were upregulated. Likewise, invasive cells showed increased affınity for ECM
components. Paired ChIP-seq and RNA-seq revealed likely roles for epigenetic
alterations in driving gene expression changes. Furthermore, the epigenetic
changes followed ordered patterns of activation and inactivation, suggesting
that these epigenetic signatures may provide insight into early mechanisms as-
sociated with epithelial-mesenchymal transition. Collectively, our data suggest
that early epigenetic markers may be better early predictors of colorectal cancer
aggressiveness than gene expression patterns and support the use of this in vitro
metastasis model to study the molecular mechanisms of cancer progression.
#2850 A systems genetics approach reveals Rnaseh2c-immune response
axis that affects metastasis severity in breast cancer. Sarah Deasy, Kent
Hunter. NIH, Bethesda, MD.
Metastatic breast cancer is a devastating disease with a 5-year survival rate of
only 26%. This is due to a lack of effective therapies against established metas-
tases and an inability to identify high risk patients who would benefıt from
specifıc adjuvant therapies to preventmetastatic progression.We have shown in
mouse models that spontaneously arising tumors metastasize with different se-
verity based on the mouse genetic background. Using systems genetics ap-
proaches we have identifıed genes correlated with metastasis and survival in
both mice and humans. Rnaseh2c was identifıed as a novel candidate metastasis
susceptibility gene. This gene encodes a scaffolding subunit of the Ribonuclease
H2 enzyme which removes ribonucleotides misincorporated into the DNA. Ex-
perimentally modulating Rnaseh2c expression in a murine mammary cancer
cell line resulted in signifıcant changes in pulmonarymetastasis, confırming this
gene as a metastasis modifıer. Mutations in Rnaseh2c are known to cause
Aicardi-Goutieres Syndrome, a neurological autoinflammatory disorder that
overlaps clinically with congenital viral infections and the autoimmune disease
Systemic Lupus Erythematosus. Given this, we hypothesized that altered expres-
sion of Rnaseh2c in breast cancer cells affects metastasis by engaging the im-
mune system. To investigate immune system involvement, we analyzed metas-
tasis in immunocompromised mice. T cell defıciency ablated the effect of
reduced Rnaseh2c expression on metastasis, revealing for the fırst time an
Rnaseh2c-immune response axis inmetastasis. Gene ontology pathway analysis
following mRNA-sequencing of Rnaseh2c knockdown and overexpression tu-
mors revealed that 20% of the genes with altered expression are involved in
immune system-related pathways, including T cell signaling and antigen pre-
sentation. Furthermore, genes with signifıcant changes included Type I interfer-
ons, T cell markers, and immune regulators. These results confırm that
Rnaseh2c is a novelmetastasismodifıer gene and validate our hypothesis that the
immune system is mediating the effect of Rnaseh2c on metastasis. This mecha-
nism highlights a potential new target for combination with immune modula-
tory therapies to combat this devastating disease and adds to a panel of genes we
identifıed that together could determine patients with high risk for metastasis.
TUMOR BIOLOGY: Imaging Cancer Metabolism, Therapeutic
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#2851 Cellular glutamine pool size change in response to glutaminase
inhibition detected by kinetic analysis of [18F](2S,4R)4-fluoroglutamine
PET. Austin R. Pantel, Hsiaoju Lee, Shihong Li, Robert K. Doot, Robert H.
Mach, David A. Mankoff, Rong Zhou.University of Pennsylvania, Philadelphia,
PA.
INTRODUCTION: Oncogene-dependent reliance on glutamine is a cancer
vulnerability that can be exploited for therapeutic gain. Inhibitors of glutami-
nase, the enzyme that catalyzes the conversion of glutamine to glutamate, have
been developed and have shown antitumor effects in several tumormodels. The
specifıc and potent glutaminase inhibitor CB-839 demonstratedmarked antitu-
mor effıcacy in a triple-negative breast cancer (TNBC) cell line with inherently
high glutaminase activity (HCC-1806), but not in an estrogen receptor-positive
(ER) cell line with inherently low glutaminase activity. An early phase 1 clin-
ical trial of CB-839 in combination with paclitaxel has shown encouraging re-
sults in TNBC patients. Cell-line specifıc effıcacy of glutaminase inhibitors sup-
ports the need for clinical biomarkers that can predict and evaluate therapeutic
effıcacy. As a minimally metabolized glutamine analog with similar transport
properties, [18F](2S,4R)4-Fluoroglutamine ([18F]4F-Gln) is an ideal radiotracer
to infer glutamine pool size through estimates of tracer distribution volume
(DV). In this study, we demonstrate differences in DV of [18F]4F-Gln in two
xenografts with different levels of glutaminolysis (TNBC vs. ER) using dy-
namic PET imaging, as well as show the effect of anti-glutaminase therapy on
[18F]4F-Gln DV. METHODS: TNBC (HCC-1806) and ER (MCF-7) xeno-
grafts were established in athymic nu/numice.Micewere scanned in a dedicated
animal PET scanner at baseline and after CB-839 administration. Dynamic im-
aging was obtained for one hour upon injection of [18F]4F-Gln (300-350 Ci)
via the tail vein. Kinetic analysis was performed with PMOD. RESULTS:
[18F]4F-Gln uptake was largely reversible with Logan plots demonstrating late
linearity and k3 in a two-compartment (trapping) model was low (less than
0.01/min in most cases). Strong correlation was seen in DV estimates by Logan
plot and a single-compartmental model (R20.9), but not with estimates from a
two-compartment model. MCF-7 xenografts demonstrated greater than 60%
larger DV at baseline than TNBC xenografts indicative of increased cellular
glutamine concentrations inMCF-7 xenografts. An increase inDVwas detected
in TNBC xenografts post-glutaminase inhibition (30%mean change), but not
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in MCF-7 xenografts. CONCLUSION: Estimates of [18F]4F-Gln DV offer the
ability to non-invasively infer tumor glutaminolysis. Low [18F]4F-Gln uptake in
highly glutaminolytic tumors and an increase in [18F]4F-Gln uptake with glu-
taminase inhibition is concordant with changes in cellular glutamine concen-
tration as measured byMR spectroscopy of tumor extracts. Our studies indicate
promise for the use of [18F]4F-Gln as a predictive and pharmacodynamic
marker for glutaminase-targeted therapy. Supported by: Komen
SAC130060, DE-SE0012476, R21-CA198563 We thank Calithera Inc. for pro-
viding CB-839 and Dr. Susan Demo for discussions.
#2852 Monitoring the impact on metabolic flux in vivo of a newly devel-
oped LDH inhibitor using hyperpolarized 13C magnetic resonance spectro-
scopic imaging.Nobu Oshima,1 Shun Kishimoto,1 Kristin Beebe,1 Keita Saito,1
Kazutoshi Yamamoto,1 Jeffery Brender,1 Anastasia Sowers,1 Ganesha Rai,2
Bryan T. Mott,2 David J. Maloney,2 James B. Mitchell,1 Murali K. Cherukuri,1
LeonardM.Neckers1. 1National Cancer Institute, NIH, Bethesda,MD; 2National
Center for Advancing Translational Sciences, NIH, Rockville, MD.
[aim] Increased lactate production is a feature of many neoplasms, and Lac-
tate Dehydrogenase A (LDH-A) plays a key role in conversion of pyruvate to
lactate. LDHA inhibition, therefore, is considered to be a promising approach
toward developing a new therapeutic strategy for cancer treatment focused on
targeting cancermetabolism.Non-invasive imaging approaches able tomonitor
metabolic fluxes in vivo will be useful for this purpose. Hyperpolarized 13C
Magnetic Resonance Imaging (MRI) has been well known as a valuable technol-
ogy to investigate metabolic processes in tumor xenografts, allowing us to per-
form dynamic 13C-metabolic flux analysis in vivo. Use of [1-13C]pyruvate with
this technology provides the ability to monitor LDHA activity in real time
through dynamic observation of conversion of [1-13C]pyruvate to [1-13C]lac-
tate. This study aimed to monitor drug effıcacy of a newly developed LDH
inhibitor (LDHI, obtained from National Cancer Institute Experimental Ther-
apeutics Program, NExT) in a xenograft tumor model using 13C MRI technol-
ogy with hyperpolarized 13C-labeled pyruvate. [Results] Hyperpolarized
[1-13C]pyruvateMR studies were performed before and after LDHI administra-
tion to assess the impact on metabolic flux in vivo. Using hyperpolarized
[1-13C]pyruvateMR Spectroscopy (MRS), we found that lactate production was
signifıcantly suppressed by LDHI administration in MiaPaca (a glycolytic pan-
creatic cancer cell line) tumors, aswas the [1-13C]lactate to [1-13C]pyruvate ratio
([1-13C]-Lac/Pyr), which was calculated from the areas under the curves (AUC)
using time-intensity data. This ratio decreased from 1.08 to 0.128 (88.1% de-
crease) 30 minutes after intravenous administration of the LDHI. In addition,
hyperpolarized [1-13C]pyruvate MRS revealed that LDHI signifıcantly sup-
pressed lactate production in a dose dependentmanner. Furthermore, Chemical
Shift Imaging with 13CMRI demonstrated that the [1-13C]lactate signal in each
voxel clearly decreased, compared to that before LDHI administration. The sum
of [1-13C]lactate signals in the tumor region decreased after LDHI administra-
tion, resulting in a signifıcant decrease in the tumor-specifıc [1-13C] Lac/Pyr
ratio (1.463	0.31 before LDHI to 0.134	0.036 30 minutes after LDHI admin-
istration, a 90.67	2.56% decrease, n3, p0.01). [Conclusions] These results
indicate that hyperpolarized 13C-MRI is a useful method to evaluate on-target
effıcacy of novel LDH inhibitors in vivo, and this technique can be used to
determine optimum dose and exposure time of the LDHI in the tumor region.
The current method can be of great value in providing an in vivo pharmacody-
namic biomarker for this novel anti-cancer therapeutic targeting deregulated
tumor metabolism.
#2853 Imaging tumor metabolism to guide treatment of breast cancer
with drugs targeted at PI3K alpha. Susana Ros, Paula D’Santos, De-en Hu,
Ankita S. Batra, Alan J. Wright, Elizabeth Mannion, Alejandra Bruna, Carlos
Caldas, Kevin M. Brindle. CRUK Cambridge Institute, University of Cambridge,
Cambridge, United Kingdom.
PI3KCA (which encodes the phosphoinositide-3 kinase alpha isoform) is the
most frequently mutated oncogene in breast cancer. Recently, several alpha iso-
form-specifıc PI3K inhibitors have been developed and have entered into early-
phase clinical trials. However, intrinsic and acquired resistance limits their util-
ity. Noninvasive imagingmethods could be used to guide treatment by not only
allowing selection of the most effective drug in individual patients, but also by
detecting intrinsic and acquired resistance. We have been evaluating the effec-
tiveness of a selective PI3K alpha inhibitor, Taselisib (GDC-0032 Genentech
S.A.), by monitoring the rate of [1-13C]lactate production after injection of hy-
perpolarized [1-13C]pyruvate in cell lines and patient-derived xenografts (PDX)
models of breast cancer using 13C magnetic resonance spectroscopic imaging.
Hyperpolarization of the 13C nucleus increases its sensitivity to detection in the
MR experiment by 104 - 105x, thus allowing real time imaging of tumor metab-
olism. Preliminary data suggest that labeled lactate production can distinguish
sensitive and resistant breast cancer models to Taselisib a few days after treat-
ment.We are currently broadening the panel of PDXs analyzed and also includ-
ing genetically engineered mechanistic-models of drug resistance. The present
study highlights the effectiveness of hyperpolarized 13C spectroscopy/spectro-
scopic imaging for detecting early response or resistance to next generation
PI3K inhibitors. This clinically applicable technique can provide insights into in
vivo response in real-time and identify new strategies to increase the effıcacy of
therapy in individual patients.
#2854 The potential of hyperpolarized 13-Cmagnetic resonance spectros-
copy to monitor the effect of combretastatin based vascular disrupting
agents. Ane B. Iversen,1 Morten Busk,1 Lotte B. Bertelsen,1 Christoffer Laust-
sen,1 Ole L.Munk,1 Thomas Nielsen,1 Thomas R.Wittenborn,1 Johan Bussink,2
Jasper Lok,2Hans Stodkilde-Jorgensen,1Michael R.Horsman1. 1AarhusUniver-
sityHospital, Aarhus, Denmark; 2RadboudUniversityMedical Center, Nijmegen,
Netherlands.
Purpose: Targeting tumor vasculature using vascular disrupting agents
(VDAs) is an attractive therapy. These agents induce rapid physiological
changes long before any growth inhibitory effects become apparent. Detecting
these early changes should allow us to predict anti-tumor effects. Hyperpolar-
ized ¹³C magnetic resonance spectroscopy (HPMRS) allows dynamic measure-
ments of the metabolism of 13C-labeled substrates and may be a new approach
for reliably monitoring early effects of VDAs. The aim of this study was to
investigate the potential ofHPMRS to achieve this in a pre-clinicalmodel.Meth-
ods: Mice bearing 200 cubic mm foot implanted C3H mammary carcinomas
were intraperitoneally injected with combretastatin-A4-phosphate (CA4P) or
the A1 analogue OXi4503. Tumor response was assessed by determining necro-
sis development, measured histologically 24-hours after treatment, and tumor
growth time (TGT; time to reach 5 times treatment volume). Estimates of tumor
perfusion and metabolism were performed 3h (CA4P) and 6h (OXi4503) after
treatment. Perfusion was measured from Hoechst 33342 uptake in histological
sections and by dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) at 7-Tesla. Metabolic changes were assessed following intravenous
injection of hyperpolarized [1-¹³C]pyruvate and observing the conversion to
lactatewithHPMRS in a 9.4-Tesla scanner. Additionalmicewere positron emis-
sion tomography (PET) scanned using a Mediso nanoScan PET/MRI scanner
following administration of fluorodeoxyglucose (FDG). Statistical comparisons
were made using a one-way analysis of variance (ANOVA), with signifıcance
level of p0.05. Results: A dose response relationship was found between in-
jected drug doses and both tumor necrosis induction and TGT, with OXi4503
having a larger effect than CA4P. Two equally effective doses were selected for
further analysis (250 mg/kg for CA4P and 50 mg/kg for OXi4503). Both drugs
signifıcantly decreased perfusion relative to controls; the respective mean (with
1 SE) values for CA4P and OXi4503 were decreased to 57% (50-64) and 38%
(28-48) using Hoechst 33342, and 61% (57-65) and 61% (54-68) using DCE-
MRI. FDGuptake (mean tumor-to-brain ratio) also signifıcantly reduced to 43%
(33-53) and 33% (25-41) for CA4P and OXi4503, respectively. However, an
unaltered pyruvate to lactate ratio was found; the values being 98% (89-107) for
CA4P and 113% (102-124) for OXi4503. Conclusion: No change in the HPMRS
values was observed, despite changes in all other parameters, indicating that the
metabolic fate of pyruvate remains unaltered despite reduced delivery of oxygen
and nutrients. This could be because our data provides measures of whole-
tumor mean responses that include a viable metabolically unaltered tumor rim
and a tumor core with no blood flow (i.e., no pyruvate delivery) following VDA
treatment.
#2855 Monitoring tumor growth and oxygen distribution of prostate can-
cer xenografts in vivo using ultrasound and photoacoustic imaging. Qiuhua
Hu,1 Ellca Ratther,1 Katrina Sweeney,1 Pamela J. Russell,1 Colleen C. Nelson,1
Brian W. Tse,2 Elizabeth D. Williams,1 Brett G. Hollier1. 1Australia Prostate
Cancer Research Centre - Queensland, Chronic Disease & Aging, Cancer Pro-
gram, Institute ofHealth&Biomedical Innovation, School of Biomedical Sciences,
Queensland University of Technology, Brisbane, QLD, Australia; 2Preclinical Im-
aging Facility, Translational Research Institute, Brisbane, QLD, Australia.
Introduction: Prostate cancer (PCa) is the second leading cause of cancer-
related death in men. Initially, PCa growth and progression is primarily
driven by androgen stimulation of the androgen receptor (AR). As such, the
standard treatments for PCa target the androgen/AR axis and are collectively
termed androgen targeted therapies (ATTs). In spite of initial tumor regres-
sion, tumor cells ultimately adapt and become resistant to ATTs and prog-
ress to castration resistant PCa (CRPC) or metastatic CRPC. The tumor
microenvironment (TME) has long been recognized to modulate the re-
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sponse of tumors to therapies, however, the impact of ATTs on the TME and
their contribution to the development of resistance has not been investi-
gated. This project aims to evaluate the potential of non-invasive photoa-
coustic imaging combined with ultrasound imaging to assess the alterations
of the TME in response to ATTs in vivo. Methods: PCa cell lines, PC-3
(androgen-independent) and LNCaP (androgen-sensitive), were subcutane-
ously implanted into male severe combined immune defıciency mice. When
the tumor size reached 200-300 mm3, mice were castrated and subsequently
treated with enzalutamide once serum PSA had reached pre-castration lev-
els. Ultrasound and photoacoustic (US-PA) scanning (Vevo LAZR) was per-
formed at intervals during PCa progression to simultaneously assess changes
in tumor growth, anatomical structure, vasculature, and intratumoral oxy-
gen saturation. Results: We provide evidence that US-PA imaging is a feasi-
ble approach to monitor TME and the response of subcutaneous prostate
tumors to ATTs in vivo. PC-3 tumors (nPC-311) showed no response to
castration in volume, but slight changes in total hemoglobin and oxygen
saturation. Growth of LNCaP tumors and their subsequent responses to
castration were variable (nLNCaP10). We identifıed a strong correlation
between ultrasound and caliper-derived tumor volumes in these models and
in the majority of tumors the tumor center was more hypoxic than the
peripheral tumor area, which is likely due to low oxygen and nutrient trans-
mission and/or cell apoptosis. However, in a subset of tumors higher oxygen
levels were observed in the center compared with regions nearer to the skin
surface, a pattern associated with a higher rate of tumor growth compared to
the rest of the cohort. Importantly, we were able to detect a relatively increase
in oxygen levels between pre- and post-castration tumors in individual mice.
Conclusion: We have successfully used a non-invasive imaging method to
simultaneously assess multiple biological parameters in PCa xenografts in
vivo. The information gained in this study will provide a broader view of the
prostate tumor response to ATTs, which has the potential to reveal novel
mechanisms of therapy resistance.
#2856 Measuring tumormetabolism in cancer spheroids and biopsies. Sui
Seng Tee.Memorial Sloan Kettering Cancer Center, New York, NY.
Introductory Sentence: Real-time metabolic flux can be measured non-
invasively using hyperpolarized magnetic resonance spectroscopy in cancer
spheroids as well as tumor biopsies. Experimental Procedures: LnCAP cells
were resuspended in a 1:1 mixture of Matrigel:alginate (1x105 cells/ml) and
grown in a porous hollow fıber (A/G Technology Corporation, NY). [1-13C]
pyruvate was polarized in a SpinLab (General Electric, NY) before dissolving
with appropriate buffers. NMR studies were performed on a 1 TeslaMagritek
Spectrometer (Magritek, CA). HP spectra were acquired (10o degree flip
angle with repetition time of 4s for 25 scans in total). Cell tracking used the
manual tracking function in ImageJ. Xenograft biopsies were obtained from
LnCAP tumors using a 2mm punch. Data Summary: LnCAP cells seeded
sparsely enable cancer spheroid formation remain viable as assessed by Live/
DEAD fluorescent staining. Histological sectioning revealed spheroids of
approximately 200 m in diameter. Direct deposition of these threads into a
5mmNMR tube allows measurement of metabolic flux using hyperpolarized
[1-13C] pyruvate resulting in the formation of [1-13C] lactate. To modulate
metabolism, we used an allosteric AKT inhibitor, MK2206. This drug re-
sulted in relocalization of AKT from the plasma membrane as well as a
reduction in cell motility from 0.72 	 0.04 to 0.46 	 0.03 m/s (n5,
p0.05). Administration of hyperpolarized pyruvate resulted in approxi-
mately 30% of lactate production 24 hr after treatment. Histological staining
of spheroids after treatment revealed sustained decrease of AKT phosphor-
ylation after treatment. These measurements are in good accordance with
measurements of lactate secretion in the same cells grown under standard
conditions, withMK2206 resulting in loss of AKT Ser473 phosphorylation as
early as 2 hr post-treatment, followed by a decrease in lactate secretion in the
media from 5.16	 0.2 to 1.35	 0.05 mM/106 cells (n3, p0.05) 24 hr after
treatment. To ensure that these methods are applicable clinical settings,
LnCAP xenograft biopsies (60mg) were deposited directly into an NMR
tube to measure hyperpolarized [1-13C] pyruvate metabolism. Line-width of
the pyruvate peak was measured to be 1.72 	 0.19 Hz (n3) in the fırst
spectra, demonstrating good homogeneity of the magnetic fıeld and conver-
sion to lactate was observed. Future experiments will focus on measuring the
metabolism of patient-derived xenografts and effects of treatment response.
Conclusions: Metabolic measurements using hyperpolarized pyruvate can
be performed on cancer spheroids as well as biopsies, allowing quantifıcation
of metabolism to complement on-going clinical trials utilizing hyperpolar-
ized MR imaging.
#2858 Immuno-PET with site-specifıc labeled 89Zr-DFO-trastuzumab
improves immuno-reactivity and tumor uptake in a subcutaneous HER2
positive xenograft mouse model of ovarian adenocarcinoma. Lotte K. Kris-
tensen,1 Camilla Christensen,2 Camilla S. Knudsen,1 Mette M. Jensen,1 Brian J.
Agnew,3 Andreas Kjaer,2 Carsten H. Nielsen1. 1Minerva Imaging, Copenhagen,
Denmark; 2Department of Clinical Physiology, Nuclear Medicine & PET and
Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Co-
penhagen, Denmark; 3Thermo Fisher Scientifıc, Eugene, OR.
Introduction: The combination of PET with the specifıcity of monoclonal
antibodies (mAbs), immuno-PET, is an attractive approach to improve tumor
detection and mAb quantifıcation. 89Zirconium (89Zr) is particularly well-
matched for the long circulatory half-life of intact mAbs. Previously, the use of
89Zr has been limited by the lack of suitable methods for stable coupling to
mAbs. In addition, the conventional labeling strategies with random introduc-
tion of a chelator potentially reduce antibody binding and affınity towards tar-
get. Here we demonstrate the application of an enzyme- and click chemistry-
mediated methodology for site-specifıcally labeled 89Zr immuno-PET imaging
probes and compare them to a random labeled probe. Experimental procedures:
Trastuzumab was conjugated to the p-SCN-Bn-Deferoxamine (p-SCN-Bn-
DFO) chelator in three alternate ways: (1) randomly on lysine residues or site-
specifıcally on enzymatically treated glycans using either (2) ß-galactosidase or
(3) endoglycosidase S2. DFO-trastuzumab was radiolabeled with 89Zr (89Zr-
DFO-trastuzumab) and injected into SK-OV-3 tumor-bearing NMRI nude
mice. In addition, a dose-escalation study was performed with co-injection of
either 100 g or 500 g of unlabeled trastuzumab. At 24, 70 and 110 hours
post-injection, mice underwent small animal PET/CT imaging for longitudinal
assessment. Mice were euthanized and organs resected for ex vivo biodistribu-
tion after the last imaging time-point. Additionally, the immuno-reactivity and
tracer stability in buffer and plasma were assessed for all three tracers. Results:
All tracers were found to be stable for up to 5 days post-labeling. PET imaging at
24, 70 and 110hours after injection of 89Zr-DFO-trastuzumab revealed a gradual
increase in tumor uptake and image contrast over the time-course. At 70 hours
post-injection mean tumor uptakes were 6.7	 1.7, 13.9	 3.3 and 15.3	 3.8 %
injected dose per gram tissue (%ID/g), for random, ß-galactosidase or endogly-
cosidase S2 labeled probes, respectively. Site-specifıc labeling signifıcantly in-
creased tumor PET uptake (One-way ANOVA, p  0.0001) at all time-points
compared to random labeling. This was further supported by an immuno-reac-
tivity of 93% for site-specifıc labeled probes compared to 80% for the random
labeled trastuzumab. Titration with unlabeled trastuzumab did not affect tumor
uptake considerably and the ex vivo biodistribution confırmed the data obtained
by in vivo PET imaging. Conclusions: 89Zr-DFO-trastuzumab is well suited for
specifıc immuno-PET imaging ofHER2 positive ovarian cancer and site-specifıc
labeling of trastuzumab presents with markedly higher immuno-reactivity and
tumor specifıcity. These fındings support the further development of site-spe-
cifıc radiolabeled monoclonal antibodies for immuno-PET.
#2859 Sensitive, specifıc detection of Her-2 positive tumors in mice using
superparamagnetic relaxometry (SPMR). Erika C. Vreeland,1 Kayla E. Min-
ser,1 Caroline L. Weldon,1 Andrew Gomez,1 Todor Karaulanov,1 Helen J.
Hathaway,2WilliamH.Anderson,1ChristopherNettles,1Dale L.Huber,3Giulio
Paciotti1. 1Imagion Biosystems, Albuquerque, NM; 2University of New Mexico,
Albuquerque, NM; 3Sandia National Laboratories, Albuquerque, NM.
Superparamagnetic Relaxometry (SPMR) is a non-invasive technique that
utilizes superconducting quantum interference device (SQUID) detectors to
localize and quantify the magnetization of superparamagnetic iron oxide
(Fe3O4) nanoparticles (NPs) specifıcally bound to cancerous tumors. In an
SPMR measurement, polyethylene glycol (PEG) coated NPs are functionalized
with a tumor-targeting monoclonal antibody and injected intravenously. NPs
that reach and bind to the target tissue aremeasured by theMRXTM instrument,
while unbound nanoparticles, such as those freely circulating in the blood-
stream, are not detected. Here, we demonstrate the use of SPMR for specifıc
cancer detection using long-circulating anti-Her2 antibody conjugated Preci-
sionMRX® NPs in vitro and in vivo. The stability and biofunctionality of conju-
gated nanoparticles were measured by dynamic light scattering, gel electropho-
resis, and ELISA. A cell competition assay was developed to measure specifıc
binding of NPs to Her2 positive (BT474) and Her2 negative (MCF7) cells in
vitro. Specifıcity was defıned by the ability of the native antibody to competi-
tively block the binding of the anti-Her2 conjugated NPs to the Her-2 antigen
expressed on the cell surface. For in vivo studies, nude mice with xenograft
BT474 tumors were intravenously injected with anti-Her2 NPs at a dose of 20
mg/kg of bodymass, while control mice were injected with PEG only NPs. Mice
weremeasured individually on theMRXTM instrument at successive time points
over the course of 24 hours. At selected intervals during the 24-hour period,
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blood, tumor, and organs were harvested and analyzed for SPMR signals and
anti-Her2 content. In vitro, the anti-Her2 NPs exhibited specifıc binding to
BT474 cells, with little to no binding inMCF7 cells. In vivo,MRXmeasurements
ofmice injectedwith anti-Her2NPs showed ameasurablemagnetic signal in the
tumor that reached a near maximum approximately four hours after injection.
Conversely, mice injected with unconjugated nanoparticles had no measurable
tumor uptake. Finally, 24 hours post-injection, 4 – 8% of NPs and anti-Her2
weremeasurable in the blood, indicating long-term stability of the NP construct
in circulation. Together, these results suggest targeted delivery of conjugated
NPs to cancerous tissue in vivo and the utility of SPMR for the sensitive and
specifıc detection of cancer in vivo. This work was performed, in part, at the
Center for Integrated Nanotechnologies, an Offıce of Science User Facility op-
erated for the U.S. Department of Energy (DOE) Offıce of Science. Sandia Na-
tional Laboratories is a multi-program laboratory managed and operated by
Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corpora-
tion, for the U.S. Department of Energy’s National Nuclear Security Adminis-
tration under contract DE-AC04-94AL85000.
#2860 89Zr-trastuzumab immunoPET imaging tomonitor src status after
treatment in HER2 breast cancer. Brooke N. McKnight,1 Nerissa T. Viola-
Villegas2. 1Wayne State University, Detroit, MI; 2Karmanos Cancer Institute,
Detroit, MI.
Around 30% of patients with early stage breast cancer have recurrent disease
due to resistance. One of the putative causes of acquired resistance can be attrib-
uted to the hyperactivation of Src kinases, which are particularly stabilized by
aberrant HER2 signaling, which itself is overexpressed in nearly 30% of early
stage breast cancers. HER2 downstream effectors include Src, thus, we aim to
investigate the use of a HER2-specifıc monoclonal antibody positron emission
tomography (PET) probe, 89Zr-trastuzumab, to monitor Src therapy via surro-
gateHER2 expression.Wehypothesize that 89Zr-trastuzumab can be a surrogate
imaging tool for monitoring Src treatment. 89Zr-trastuzumab was previously
developed and has demonstrated excellent specifıcity for breast cancer. Dasat-
inib-treated HER2 BT474 (IC50  1.3 M), SK-BR-3 (IC50  5.5 M), and
JIMT-1 (IC50 8 M) breast cancer cells lines have shown a negative correla-
tion between treatment and HER2. We next conducted tumorigenic studies
using athymic nu/nu mice bearing JIMT-1 or BT474 xenografts, which were
treated for 7 or 14 days with dasatinib (75 mg/kg/day). At the end of each
treatment, the tumors were subsequently imaged with 18F-FDG, and then fol-
lowedby 89Zr-trastuzumab, 24 h later. Imageswere analyzedusingAsiPro (show
version here and decay-corrected to the time of injection. Tumor uptake values
weremeasured by drawing volumes-of-interest, expressed as% injected dose per
gram (%ID/g) of tissue on regions showing the most binding. 18F-FDG did not
demonstrate a predictive response in both treated and placebo tumors, whereas,
HER2 PET was able to show differential response in treated vs. control co-
horts. In JIMT-1 mice imaged with 89Zr-trastuzumab, a two-fold difference
(p  0.01) was observed between untreated and both treated groups (8.0 	
1.5 %ID/g, n 7 vs. 7-day treated: 3.8 	 1.5 %ID/g, n4, and 14-day-treated:
4.5 	 1.3%ID/g, n 4) mice imaged with 89Zr-trastuzumab. Confırmatory ex
vivo western blots of JIMT-1 tumors have shown a decrease in HER2 as treat-
ment time increases, with a decrease in p-Src (Y-416). In vivo studies with
BT-474 xenografts are currently underway. Immunohistochemistry on excised
tumors, as well as treatment on a metastatic patient-derived xenograft model is
currently in progress. We have shown that HER2 PET can potentially be a sur-
rogatemarker of Src treatment. The fındings from this study potentially afford a
powerful tool to non-invasively detect and monitor changes in Src-targeted
therapy in man at the early phases of treatment.
#2861 Dose-dependent tissue distribution and tumor targeting of
Notch3-ADC using fluorescence molecular tomography imaging. Anand
Giddabasappa,1 Parul Gupta,1 Mauricio Leal,2 Jonathan Golas,2 Fengping Li,2
Bing Yang,1 Antonio Esparza,1 Christopher Winkelmann,1 Kenneth Geles3.
1Pfızer Inc, San Diego, CA; 2Pfızer Inc, Pearl River, NY; 3Pfızer Inc, Pearl River,
CA.
Background: NOTCH3, a cell surface receptor involved in cell-cell commu-
nications, is over-expressed or amplifıed in certain human tumors. NOTCH3 is
known to regulate proliferation, differentiation and survival of cancer cells or
cancer stem cells and thus an important therapeutic target. NOTCH3 antibody
drug conjugate (ADC) is comprised of humanized anti-NOTCH3 antibody con-
jugated to an auristatin based cytotoxic payload. NOTCH3-ADC has shown
promising results in pre-clinical tumor models. In this study we evaluated the
kinetics, dose-dependent tissue distribution, tumor accumulation and targeting
specifıcity of the NOTCH3-ADC in OVCAR3 xenograft model using fluores-
cence molecular tomography (FMT) imaging. The NOTCH3-ADC is mouse
cross-reactive thus providing an accurate assessment of biodistribution. Meth-
ods: NOTCH3-ADC was conjugated to the near-infrared dye, AlexaFluor680
(AF680). The in vitro cellular bindingwas evaluated by cell-basedELISA. In vivo
biodistribution was evaluated using OVCAR3 subcutaneous xenograft model.
NOTCH3-ADC-AF680 (1mg/kg; 3mg/kg and 10mg/kg) was injected when the
tumors were 300mm3 and imaged 5 min, 24, 48, 96, 168 and 240 h post-
injection. Ex vivo FMT imaging, pharmacokinetic analysis and immunohisto-
chemistry (IHC) was performed at 48 and 240 h after whole-body perfusion. An
in vivo receptor competition FMT study was performed by injecting excess of
unconjugated anti-NOTCH3 antibody (Ab) or a non-targeted control Ab. Re-
sults: In vitro cell binding studies showed that conjugation of AF680 to
NOTCH3-ADC did not change its binding ability. A dose-dependent tumor
regression was also observed after a single injection of NOTCH3-ADC-AF680.
In vivo FMT imaging showed dose-dependent whole-body clearance kinetics of
NOTCH3-ADC. Dose-dependent accumulation in the tumors was observed
with peak accumulation at 24-48 h post-injection and a slow decline at later
time-points. A maximum accumulation of10 %ID/g was observed which was
independent of the dose of NOTCH3-ADC-AF680. Ex vivo FMT quantitation
of tumor was consistent with the IHC for antibody and LC/MS analysis of re-
leased payload. Pharmacological competition with excess unlabeled control Ab
did not block tumor accumulation of NOTCH3-ADC-AF680, whereas excess
unlabeled NOTCH3-Ab blocked 47% of NOTCH3-ADC-AF680 accumula-
tion. There was no signifıcant specifıc accumulation of NOTCH3-ADC in other
organs as observed by FMT imaging or IHC. Conclusions: These imaging stud-
ies provided understanding of the kinetics, tumor accumulation and biodistri-
bution of NOTCH3-ADC. Further this work showcase the utility of non-inva-
sive FMT imaging in better understanding of pharmacology and behavior of
biologic drugs.
#2862 Tumor-targeting salmonella typhimurium a1-r inhibited angio-
genesis of osteosarcoma cells visualized by color-coded imaging in the in vivo
absorbable gelatin sponge assay. Tasuku Kiyuna. University of California, San
Diego, CA.
INTRODUCTION: We already have reported a color-coded imaging
model that showed the sponge agngiogenesis assay using absorbable gelatin
sponge implanted in nestin-driven green fluorescent protein (ND-GFP)
nude mice and that osteosarcoma cells promote angiogenesis in this sponge
assay. We report here that Salmonella typhimurium A1-R (A1-R) inhibits
angiogenesis of osteosarcoma cells in the sponge angiogenesis assay in ND-
GFP mice. METHODS: Sponge was initially transplanted subcutaneously in
the flank of transgenic ND-GFP nude mice. Seven days after transplantation
of sponge, skin flaps were made and 143B-RFP human osteosarcoma cells
expressing red fluorescent protein (RFP) were injected into the transplanted
sponge. After establishment of tumors in the sponge, the control-groupmice
were treated with PBS via tail-vein injection and A1-R treated group with
A1-R likewise. Skin flaps were made at days 14, 21, and 28 after transplanta-
tion of the sponge to allow imaging of vascularization in the sponge using a
variable-magnifıcation small animal imaging system and confocal
fluorescence microscopy. RESULTS: Vessel length in the sponge was mea-
sured after treatment with FV10-ASW Fluoview software. Nascent blood
vessels grew in the sponge in a time-dependent manner. A random 3 fıelds
were quantifıed in each group). The mean length of ND-GFP expressing
blood vessels in the sponge in mice with A1-R treated group were 9.40, 12.40,
and 10.12 mm/mm2, at days 14, 21, and 28, respectively. The mean length of
ND-GFP expressing blood vessels in the sponge in mice of the control group
were 8.86, 14.50, and 15.81 mm/mm2 on day 14, 21, and 28, respectively.
ND-GFP expressing blood vessels of the mice in the osteosarcoma cells
treated with A1-R had shorter vessels than the control group (on days 28, P
0.05), suggested the extent of nascent blood vessel growth was signifıcantly
inhibited by A1-R treatment. Besides, we evaluated the RFP colored area of
the sponge in both groups, which almost represent the viable tumor size. The
mean RFP colored area of A1-R treated group in the sponge were 4.49, 7.53
and 8.15 mm2, at days 14, 21, and 28, respectively and that of control group
were 3.78, 6.40, and 7.49 mm2 at days 14, 21, and 28, respectively. The size of
possibly viable RFP colored tumor area between A1-R treated group and
control group at days 28 did not show signifıcant area difference, indicated
A1-R treated osteosarcoma cells showed shorter nascent vessel length than
control group, not due to the tumor size difference but due to the difference
of angiogenesis inhibitory effect. As a result of both outcomes above, the
extent of nascent blood vessel growth was signifıcantly inhibited by A1-R
treatment on days 28. CONCLUSION: In the present study, we reported the
effect of angiogenesis inhibition of A1-R in vivo sponge assay, and suggest
A1-R has potential for anti-angiogenic target therapy for osteosarcoma.
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#2863 Magnetic resonance imaging based analysis of tumor growth and
vascular parameters in animal model of GBM following IV formulated of
HET0016 treatments. Ali S. Arbab,1 Meenu Jain,1 Bhagelu Achyut,1 Kartik
Angara,1MohammadH. Rashid,1 Asm Iskander,1 Thaiz F. Borin,1Wenbo Zhi,1
Roxan Ara,1 Irina Lebedyeva,1 Hassan Bagher-Ebadian2. 1Augusta University,
Augusta, GA; 2Henry Ford Health System, Detroit, MI.
Glioblastoma (GBM) is a hypervascular primary brain tumorwith poor prog-
nosis. HET0016 a selective CYP450 inhibitor has been shown to inhibit angio-
genesis and tumor growth. Therefore, to explore novel treatments, we have
generated an improved intravenous (IV) formulation of HET0016withHPßCD
and tested in animal models of human and syngeneic GBM. Tumor growth and
vascular parameters (tumor blood volume, permeability and, extravascular and
extracellular space volume) were determined by in vivo dynamic contrast en-
hanced (DCE) magnetic resonance imaging (MRI). The pharmacokinetics of
HPßCD-HET0016 were evaluated in plasma and tumor tissues using IV and IP
routes of administration. IV treatmentwithHPßCD-HET0016 decreased tumor
growth, tumor blood volume, permeability and, extravascular and extracellular
space volume, when compared with the vehicle group (p0.05). Similar growth
inhibition was also observed in syngeneic GL261 GBM (p0.05). Survival stud-
ies using patient derived xenografts of GBM (PDX), showed prolonged survival
to 25-27 weeks in animals treated combinedly with focal radiation, IVHET0016
and TMZ (p0.05). Administration of a single dose resulted in 7-fold higher
levels of HET0016 in the IV group in plasma and 3.6-fold higher levels in tumor
tissue at 60 min compared to that of IP route. We observed reduced expression
of markers of cell proliferation (Ki-67), decreased neovascularization (laminin
and SMA) and migration (MHC-1) in the treated group (p0.05). Decreased
tumor growth was associated with reduced expression of pro-angiogenic mark-
ers (IL-8, MCP-1, VEGF, HIF-1, and VE-Cadherin), inflammation (p-NFB),
intermediates ofMAPKpathway (p-AKT, p-ERK and p-STAT1, EGFR), arachi-
donic acid metabolism (COX-1, CYP4A11) and increased expression of anti-
angiogenic markers (Ang2, Angiostatin and Tie-2). Our results indicate that the
improved IV formulation of HPßCD-HET0016 is effective in inhibiting tumor
growth through decreasing proliferation, migration, and neovascularization.
Furthermore, HET0016 signifıcantly enhanced sensitivity of TMZ and pro-
longed survival in PDX GBM.
#2864 Tumor targeting and imaging using 64Cu labeled cyclic RGD con-
jugated human serum albumin via click chemistry. Cho Rong Park, Myung
Geun Song, Ji-Yong Park,HyewonYoun, June-KeyChung, JaeMin Jeong, Yun-
Sang Lee, KeonWookKang. Seoul National University, Seoul, Republic of Korea.
PURPOSE: The RGD specifıcally recognizes the integrin v3 which is over-
expressed on various malignant tumors. One major drawback of small peptide
such as RGD, however, is short half-life in the blood,which greatly compromises
their targeting effıcacy. To improve blood circulation time and targeting effı-
cacy, we developed cyclic RGDyK (cRGDyK) conjugated human serumalbumin
(HSA) using click chemistry reaction. METHODS: HSA was conjugated with
DBCO-NHS (dibenzyl cyclooctyne) under physiologically favorable reaction
condition for the preparation of strain promoted azide-alkyne reaction. Using
this reaction group, DBCO-HSA was conjugated with N3-c RGDyK (azido
cRGDyK) for integrinv3 targeting, N3-FNR648 for fluorescence labeling and
64Cu labeled N3-NOTA (3-azidopropyl-NOTA) for radiolabeling. Cell binding
of cRGDyK-HSAwere analyzed with FNR648 labeled probes. Cellular uptake of
64Cu-cRGDyK-HSA were tested for integrin v3 specifıc binding at cell level.
PET images were acquired after tail vein injection of 64Cu-HSA, 64Cu-cRGDyK-
HSA in integrinv3 positive tumor (SK-OV3, ovarian cancer cell line) bearing
BALB/c nude mice. PET signals were quantitatively analyzed with PET image
analysis program, AMIDE. RESULTS: The number of cRGDyK onDBCO-HSA
conjugates was confırmed using MALDI-TOFMS. cRGDyK-HSA was success-
fully conjugated with 64Cu labeled N3-NOTA. Integrin v3 mRNA and pro-
tein was highly expressed in SK-OV3 cell line. At fluorescence labeled probes
were treated in SK-OV3, cRGDyK-HSA were highly bound to cell membrane
and this pattern were decreased with pre-treatment of excess cRGDyK. When
compared to cellular uptake level, 64Cu-cRGDyK-HSA were more accumulated
at integrin v3 positive cells (SK-OV3) than integrin v3 negative cells (P
0.05) and there were no difference in 64Cu-HSA. Serial PET images were ac-
quired 0, 4, 24, 48 hours after tail vein injection of 64Cu-cRGDyK-HSA. Radio-
activity of 64Cu-cRGDyK-HSA in SK-OV3 tumor was higher than that of 64Cu-
HSA. 64Cu-labeled-cRGDyK-HSA can be observed at 48 hours after injection,
which shows longer circulation time in mice. CONCLUSION: We successfully
conjugated cyclic RGDyK to HSA using click chemistry approach. We demon-
strated that cRGDyK-HSA specifıcally bind to integrin v3 in in vitro and in
vivomodel. And in animalmodel, 64Cu-labeled-cRGDyK-HSA can be observed
at 48 hours after injection, which shows longer circulation time. Our results
indicated that cRGDyK-HSAhave a potential to diagnosis and therapy response
monitoring of tumor expressing integrin v3.
#2865 The peptide transporter K16ApoE increases drug delivery across
the blood brain barrier in an experimental animalmodel of melanoma brain
metastases. Synnøve Nymark Aasen,1 Heidi Espedal,2 Olivier Keunen,3 Chris-
topher FlorianHolte,2 Habib Baghirov,4 Rolf Bjerkvig,2 Tine Veronica Karlsen,2
Olav Tenstad,2 Dag Erlend Olberg,5 Gobinda Sarkar,6 Robert B Jenkins,6 Frits
Thorsen2. 1Haukeland University Hospital, Bergen, Norway; 2University of Ber-
gen, Bergen, Norway; 3Luxembourg Institute of Health, Luxembourg, Luxem-
bourg; 4Norwegian University of Science and Technology, Trondheim, Norway;
5Oslo University Hospital, Oslo, Norway; 6Mayo Clinic, Rochester, MN.
Introduction: Patients with brain metastases await a dismal prognosis. Re-
gardless of the continuous progress in drug development, amajor problem is the
delivery of drugs across the blood brain barrier (BBB) and into the metastatic
neoplasms. The BBB excludes almost all compounds, in particular highly
charged, hydrophilic or large compounds, and most of the current chemother-
apeutic agents are thus unable to penetrate the BBB. Varying strategies to tran-
siently open the BBB have been studied previously. Here, we describe a peptide
transporter comprising 16 lysine residues and 20 amino acid residues corre-
sponding to the low density lipoprotein receptor (LDLR) binding domain of
apolipoprotein E (ApoE). We show that the peptide (K16ApoE) is able to tran-
siently open the BBB for drug-delivery into experimental brain metastases. Ex-
perimental procedures: A systemic study of the ability of the peptide to open the
BBBwas conducted by dynamic contrast enhancedmagnetic resonance imaging
(DCE MRI) in nonobese diabetic/severe combined (nod/scid) mice. The BBB
permeability was studied after administering 200 g of the peptide intrave-
nously. Further, cellular effects after treatment with the peptide was investigated
in vitro using confocalmicroscopy, flow cytometry and impedance experiments.
The biodistribution of the peptide was studied in blood plasma and several
organs using 125I labeled K16ApoE. Finally, a treatment study was initiated,
treating the animals with the peptide in combination with the B-RAF inhibitor
Dabrafenib, only Dabrafenib or vehicle. Summary: After injecting the K16ApoE
peptide into the mice, a transient opening of the BBB for up to 4 hours was
clearly demonstrated by DCE-MRI. Microscopy showed that the peptide dis-
rupted brain endothelial cell monolayers, reducing the barrier properties of the
cells. The impedance experiments displayed that the permeability through en-
dothelial cell barriers was increased after treatment with K16ApoE, and a dose-
dependent cell death pattern was observed at higher concentrations of
K16ApoE.The peptide did not affect endothelial cell tight junctions. The biodis-
tribution study showed that the peptide was eliminated from blood plasma in
less than fıve minutes through the kidneys. The treatment study displayed that
the group of animals receiving K16ApoE followed by Dabrafenib had smaller
tumor volumes than the other two animal groups. Conclusions:We have shown
that the peptide opens the BBB and facilitates a therapeutic window of 4 hours.
The peptide did in combination with Dabrafenib decrease the number of exper-
imental brain metastases in our studies. Thus, the current strategy could also
have the potential to improve the treatment of patients with brain metastatic
disease.
#2866 Volumetric optoacoustic imaging of tumor cell death using a tar-
geted imaging agent. Bangwen Xie,1 Michal Tomaszewski,1 André A. Neves,1
Stefanie R. Mullins,2 David Tice,3 Richard Sainson,2 Sarah Bohndiek,1 Robert
W. Wilkinson,2 Kevin M. Brindle1. 1University of Cambridge, Cambridge,
United Kingdom; 2MedImmune Limited, Cambridge, United Kingdom; 3MedIm-
mune LLC, Gaithersburg, MD.
Multispectral optoacoustic tomography (MSOT) generates high-resolution
cross-sectional images in less than a second. MEDI3039, is a newly described
agonist of the TNF-related apoptosis-inducing ligand receptor2 (TRAILR2),
which has been shown in preclinical studies to preferentially induce cell death in
cancer versus normal cells1. We show here that MSOT, when used with a near
infra-red (NIR) fluorophore-labelled protein domain of Synaptotagmin-I
(C2Am-750, 15kDa) that binds to phosphatidylserine (PS) exposed by apo-
ptotic and necrotic cells2, can be used to image MEDI3039-induced cell death
within the entire tumor region. Non-specifıc probe retention was assessed using
a site-directed mutant (iC2Am-680 or iC2Am-750). PS-specifıc binding of
C2Am-750 to MEDI3039-treated TRAIL-sensitive Colo205 and TRAIL-resis-
tant HT-29 human colon adenocarcinoma cells in vitro was evaluated by flow
cytometry and confocal microscopy. The capability of C2Am-750 to detect cell
death in vivo was assessed in mice bearing Colo205 or HT-29 xenografts, fol-
lowing a single dose (0.4mg/kg, i.v.) ofMEDI3039. Allmice then received an i.v.
injection of a 1:1 mixture of 0.1mole/kg C2Am-750 and iC2Am-680 16 h post
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treatment, followed by fluorescence imaging (FLI) measurements using an IVIS
200 camera at 0 and 3 h post probe injection. FLI measurements in treated
Colo205 xenografts showed signifıcantly increased retention of C2Am-750 up-
take versus size-matched untreated tumors (6.0-fold, P value 0.0001), but
there was no signifıcant difference between treated and untreated HT-29 xeno-
grafts. iC2Am-680 retention was negligible in all groups. Next, volumetric
MSOT measurements of C2Am-750 and iC2Am-750 (0.2 mole/kg) retention
in MEDI3039-treated Colo205 tumors were made using an iTheraMedical in-
Vision 256 system at different wavelengths (660-900nm) and time points
(3-24 h). C2Am-750 signal was markedly increased in tumors at 3 h post probe
injection. Maximal C2Am-750 signal appeared in the center of treated tumors,
whereas there was negligible iC2Am-750 retention. Subsequent histological
analyses showed that C2Am-750 signal was strongly correlated with both
cleaved caspase-3 and TUNEL staining of dead cells. We have shown that
real-time volumetric MSOT measurements with a NIR fluorophore-labelled
C2Am, can be used to detect early tumor cell death within the entire tumor
region following TRAILR2 agonist treatment. This study shows that this
imaging technique can be used to characterize tumor heterogeneity and to
determine the most appropriate therapy at an early stage post drug admin-
istration. 1. Swers, J.S. et al. Multivalent scaffold proteins as superagonists of
TRAIL receptor 2-induced apoptosis. Molecular cancer therapeutics 12,
1235-1244 (2013). 2. Alam, I.S. et al. Comparison of the C2A domain of
synaptotagmin-I and annexin-V as probes for detecting cell death. Biocon-
jugate chemistry 21, 884-891 (2010).
#2867 FDG-PET imaging as a potential biomarker of mitochondrial tar-
geting by CPI-613, a novel inhibitor of mitochondrial metabolism. Kiran
Solingapuram Sai,1 Zuzana Zachar,2 Frankis Almaguel,1 Shawn D. Stuart,2 Mi-
chael S. Dahan,2 Moises Guardado,2 Stephanie Rideout,1 Minghui Wang,1
Anirudh Sattiraju,1 Paul M. Bingham,2 Boris Pasche,1 Akiva Mintz1. 1Wake
Forest University School of Medicine, Winston Salem, NC; 2Stony Brook Univer-
sity, Stony Brook, NY.
CPI-613 is a lipoate analogue that has been shown to inhibit the pyruvate
dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (KGDH) com-
plexes selectively in tumor cells (reviewed in Exp.Rev.Clin.Pharma. 7, 837).
These two enzymes control the vast majority of carbon flow into the tricarbox-
ylic acid (TCA) cycle and play a central role inmitochondrial metabolism. PDH
converts pyruvate into acetyl-CoA, which in turn can enter the TCA cycle for
cellular respiration. Since pyruvate is the fınal product of glycolysis, PDH serves
to link glycolysis to the TCA cycle. Early clinical trials with CPI-613 have dem-
onstrated very promising clinical responses in pancreatic cancer, leukemia, and
lymphoma when used in combination with standard chemotherapy. Moreover,
apparently homeostatic responses of tumor cells to CPI-613 inhibition of mito-
chondrial metabolism include compensatory upregulation of glucose uptake.
Thus, we hypothesized that we can use 18F-Fludeoxyglucose (FDG)-PET/CT, a
translational imaging approach that measures cellular glucose uptake, as a bio-
marker for CPI-613 cellular delivery and its targeting of mitochondrial metab-
olism. Therefore, in this work we evaluated the in vitro and in vivo glucose
uptake in cancer cells and tumor xenografts after treatment with CPI-613. To
measure glucose uptake in vitrowe pulsed BxPc3 pancreatic cancer cells with 3H
2-deoxyglucose for 15 or 60 minutes following 2 hours of treatment with CPI-
613. We observed a signifıcant upregulation (100% increase) of cellular 2-de-
oxyglucose uptake, consistentwith a compensatory increase in glucose uptake as
a result of successful targeting of mitochondrial metabolism. We therefore ex-
amined whether this upregulation occurs in vivo using FDG-PET/CT. Mice
bearing BxPc3 flank tumors were treated with 50mg/kg of CPI-613 and under-
went FDG-PET/CT scans 4 hours and 24 hours post-CPI-613 treatment. Similar
to the in vitro response, tumors treatedwithCPI-613 exhibited a 75% increase in
18F-FDG uptake compared to untreated controls at 4 hours post therapy. In the
24 hour post-therapy scans, tumor 18F-FDG was signifıcantly decreased, indi-
cating tumor cell killing, which corresponds to previously published data that
demonstrated effıcacy of CPI-613 against BxPc3 tumor xenografts. These results
indicate the potential for using the initial FDG flare seen on PET imaging as a
biomarker to detect mitochondrial targeting by CPI-613 immediately after CPI-
613 treatment, a strategy that may be used, after further clinical validation, to
stratify responders to this novel mitochondrial inhibitor.
#2868 18F-FDG PET/CT-based early treatment response evaluation of
nanoparticle-assisted photothermal therapy. Jesper Tranekjaer Joergensen,1
Kamilla Norregaard,1Marina SimónMartín,1 FredrikMelander,2 Lotte K. Kris-
tensen,1 Pól Martin Bendix,3 Thomas L. Andresen,2 Lene B. Oddershede,3 An-
dreas Kjaer1. 1University of Copenhagen and Rigshospitalet, Copenhagen, Den-
mark; 2Technical University of Denmark, Copenhagen, Denmark; 3University of
Copenhagen, Copenhagen, Denmark.
Aim: Nanoparticle-assisted photothermal therapy is a new promising thera-
peutic strategy that utilizes photo-absorbing nanoparticles irradiated with near
infrared light to generate a local temperature increase in tumor tissue. Here we
used small animal 18F-FDGPET/CT to evaluate the treatment response of silica-
gold nanoshell (NS)-assisted photothermal therapy in human tumor xenografts
in mice. Method: NMRI nude mice had  106 human neuroendocrine tumor
cells (H727) inoculated into the left flank. After 4-5 weeks, animals were divided
into three groups: one receiving NS and laser irradiation (NS group, n 9), one
receiving saline and laser irradiation (saline group, n 9), and one receivingNS
but no laser irradiation (sham group, n 5). All animals were PET scannedwith
18F-FDG one day before treatment (baseline), followed by iv administration of
either NS or saline. Approximately 24 hours after injection, the animals were
placed on a laser treatment platform and the tumors were irradiated with an 807
nm diode laser for 5 minutes using a laser intensity of 1.8 W/cm2. During irra-
diation, the temperature at the surface of the tumor was measured using ther-
mographic imaging. The mice were 18F-FDG PET scanned again at day 1 after
treatment and tumor growth was followed by caliper measurements with the
humane endpoint defıned as a tumor volume of 1,000mm3. PET andCT images
were co-registered, and regions of interest were manually drawn on whole tu-
mor regions. 18F-FDG uptake was quantifıed as mean percentage of injected
dose per grams of tissue (%ID/g) and the treatment response was evaluated
based on the reduction in tumor uptake of 18F-FDG between baseline and day 1.
Results: Thermographic imaging showed that the tumor surface on average
reached 49.2	 3.3 °C in theNS group. In comparison, the average temperatures
reached 44.5	 1.9 °C in the saline group and 33	 1.0 °C in the shamgroup. This
was consistent with an overall inhibited tumor growth, as well as improved
survival in the NS group compared to the sham and saline groups. The tumor
accumulation of 18F-FDG uptake was comparable between groups at baseline
but PET imaging revealed a signifıcant reduction in tumor uptake at day 1 in the
NS group ( 84	 8 % (day 1/baseline)) compared to the saline ( 108	 21 %;
p 0.01) and sham ( 110	 11 %; p 0.05) groups. Moreover, the change in
18F-FDG tumor uptake (day 1/baseline), was used to stratify animals into re-
sponders and non-responders, where the responding group matched inhibited
tumor growth and improved survival. Conclusion: In this study we showed that
18F-FDG PET could be used for early response monitoring of the therapeutic
outcome of nanoparticle-assisted photothermal therapy in human tumor xeno-
grafts in mice. Based on this, we suggest that PET can also be used for optimi-
zation of therapy, both for guiding treatment planning and early identifıcation of
non-responders for which the treatment strategy should then be changed.
#2869 Comparison of 18F-FDG and 18F-FLT PET imaging for early re-
sponse monitoring of nanoparticle-assisted photothermal cancer therapy.
Kamilla Norregaard,1 Jesper Tranekjaer Joergensen,1 Marina Simón Martín,1
Lene B. Oddershede,2 Andreas Kjaer1. 1Rigshospitalet and University of Copen-
hagen, København N, Denmark; 2University of Copenhagen, København N, Den-
mark.
Aim: Nanoparticle-assisted photothermal therapy relies on photo-absorbing
agents that accumulate in tumors and upon irradiation with near-infrared light,
generate hyperthermal temperatures suffıcient to ablate surrounding cancerous
tissue. In this study, we used small animal PET imaging to compare the tracers
18F-FDG and 18F-FLT, that are glucose and thymidine analogues respectively,
for the assessment of silica-gold nanoshell (NS)-assisted photothermal therapy
in a colorectal cancer mouse model. Method: Mouse colorectal tumors (CT26)
were established subcutaneously in female Balb/c mice by inoculation of
3x105 cells. When the tumors reached a volume of 150 mm3, the animals
were divided into treatment groups receiving either: NS and laser irradiation
(NS group), saline and laser irradiation (saline group), or NS but no laser irra-
diation (sham group). 24 h after intravenous injection of either NS or saline, the
tumors were irradiated for 5 minutes with an 807 nm diode laser with an inten-
sity of 1.5 W/cm2 (day 0) meanwhile the temperature development was moni-
tored using thermographic imaging. To evaluate the treatment response, all
animals were PET/CT scanned with either 18F-FDG or 18F-FLT the day before
treatment (baseline) and two days after treatment (day 2). In addition, the
change in tumor volume was assessed by CT imaging on day 7. Throughout the
study, tumor growth was monitored using caliper measurements and animals
were euthanized when the tumor volume exceeded 1,000 mm3. Regions of in-
terest were manually drawn on the entire tumor volume on co-registered PET
and CT images and the PET tracer uptake quantifıed as the mean percentage of
injected dose per grams of tissue (%ID/g). Results: During laser irradiation,
NS-laden tumors reached hyperthermal temperatures that led to inhibited tu-
mor growth and improved survival compared to the saline and sham treated
groups. In the NS group, PET imaging showed a reduction in tumor uptake of
18
F-FDG of nearly 50% at day 2 compared to baseline. In the saline and sham
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groups the tumor uptake of 18F-FDG was at comparable levels at baseline and
day 2. In addition, a positive correlationwas found between the change in tumor
uptake between baseline and day 2 and the change in tumor volume on day 7 in
all animals scanned with 18F-FDG. Preliminary data from animals scanned with
18F-FLT indicates that the tumor uptake is also strongly reduced after NS-as-
sisted photothermal therapy and that the change in 18F-FLT uptake correlates
with inhibited tumor growth on day 7. Conclusion: Both 18F-FDG and 18F-FLT
PET imaging show great potential for early evaluation of the treatment response
after nanoparticle-assisted photothermal therapy and preliminary data suggest
that both tracers can be used to predict treatment outcome.
#2870 Optical imaging of bombesin and transferrin receptor expression
are as effective as 18FDG in assessing drug effıcacy. Jen-Chieh Tseng, Jeffrey
D. Peterson. Perkin Elmer, Hopkinton, MA.
Physical measurement of tumor volume reduction is the most commonly
used method used to assess tumor progression and treatment effıcacy in mouse
tumor xenograft models, but the detection of tumor size changes can require
repeated drug dosing and tumor measurements for several weeks. However,
18F-FDG PET imaging of altered glucose metabolism can be a more sensitive
tool for early cancer detection/diagnosis as well as treatment assessment; cancer
cells are known to have abnormally increased cellular metabolism that can be
inhibited by drug treatment. To illustrate this, we used HCT-116 human colo-
rectal tumor xenografts in nu/nu mice with sorafenib treatment, a clinically
approved tyrosine protein kinase inhibitor (5 d treatment, 40mg/kg). Treatment
is known to inhibit PDGFR and VEGFR, as well as Raf kinases that regulate
energy metabolism in tumors. Sofıe G8 PET imaging of treated mice using 18F-
FDG revealed a signifıcant drop in tumormetabolismwith as little as 2-3 days of
treatment, a time in which there is typically little or no effect on tumor size. This
approach was relatively low through-put, and required special procedures to
accommodate use of radioactivity, but offered the option of daily imaging of
tumor status. We also explored alternative optical imaging approaches that
could offer higher through-put imaging as well as the potential for multiplex
imaging. There is no fluorescent equivalent of 18F-FDG, so we focused on
bombesin- and transferrin-receptors as potentially useful biomarkers for drug-
induced inhibition in tumor metabolism. Bombesin receptors are upregulated
in a variety of tumors and are important in energy metabolism and tumor
growth. The rapid recycling kinetics also make this receptor highly sensitive to
cellular metabolic changes. Transferrin receptors are also upregulated in most
tumors and provide critical iron transport function vital for their increased
enzymatic, proliferative, and metabolic requirements. We used targeted near
infrared (NIR) fluorescent imaging probes, BombesinRSenseTM 680 (BRS-680)
and Transferrin-VivoTM 750 (TfV-750), to monitor changes in receptor expres-
sion in HCT-116 tumor xenografts during the course of sorafenib treatment.
Interestingly, both BR-680 and TfV-750 FLI on the IVIS® SpectrumCT yielded
data quite similar to our results using 18F-FDG PET; reduction in these probes
can be measured as early as 48-72 hours, in the absence of signifıcant reduction
of tumor size/viability. As expected, both PET and FLI were also highly effective
at imaging sorafenib effects 7-8 days later (3-4 days following a 5-day sorafenib
treatment regimen), with datasets in good agreement with physical measure-
ment of changes in tumor size. These results suggest that BRS-680 and TfV-750
can serve as fluorescent surrogates for 18F-FDG PET both in measuring early
metabolic changes and ultimate therapeutic outcomes following cancer treat-
ment.
#2871 Non-invasive monitoring of the effıcacy of anticancer therapeutic
agent in lung orthotopic xenograft models of NSCLC using Bio-Lumines-
cence Imaging (BLI). Sanchareeka Dey, Sarada Preeta Kalainayakan, Poorva
Ghosh, Li Zhang. University of Texas at Dallas, Richardson, TX.
Non-Small Cell Lung Cancer (NSCLC) patients have a poor rate of survival
owing to diagnosis at a later stage. This necessitates development of novel ther-
apeutic strategies that limit rapid progression of NSCLC and imaging tech-
niques thatmonitor such changes in vivo. There has been a signifıcant growth of
bioluminescence imaging applications in small laboratory animal models in
recent years, owing to its high sensitivity, effıciency, and non-invasive nature.
Our lab has previously demonstrated that a therapeutic agent that disrupts mi-
tochondrial respiration effectively hampers proliferation of NSCLC cell lines in
vitro. With an effort to investigate the potential of this therapeutic agent in
clinical settings, we used a lung orthotopic xenograft mouse model along with
bioluminescence imaging (BLI) to continuouslymonitor the effıcacy of the drug
in vivo. Briefly, we implanted NSCLC cell line transduced with lentiviral parti-
cles carrying luciferase sequence, in the left lung of 6-8 weeks old female NOD/
SCID mice to generate lung orthotopic xenografts. The therapeutic agent was
administered intravenously over several weeks. Tumor growth was then com-
pared between the untreated versus the treated mice, non-invasively through
bioluminescence imaging (Perkin Elmer’s IVIS Lumina III Imager). On sacri-
fıcing the mice, the lungs were harvested, formalin fıxed and paraffın embedded
for Immunohistochemistry. Our BLI data show that in themice treated with the
therapeutic agent, tumors are localized to the left lung (site of implantation) as
opposed to the control mice where the tumors metastasized to the right lung.
The BLI data indicates signifıcant decrease in radiance (total flux in photons per
second) in mice subjected to treatment when compared to control mice. We
show that the therapeutic agent signifıcantly inhibits progression andmetastasis
of human NSCLC cell line orthotopically injected in the lungs of NOD/SCID
mice. The results suggest that itmight be potent anti-cancer drug as it is effective
in a model that recapitulates the natural environment of lung tumorigenesis.
Immunohistochemical studies are underway to discern the mechanistic details.
#2872 Quantitativemass spectrometry imaging of erlotinib in skin rashes
of cancer patients receiving erlotinib. Meiko Nishimura,1 Hiroaki Aikawa,2
MitsuhiroHayashi,2 YuMizutani,1 Kei Takenaka,1 Yoshinori Imamura,1Naoko
Chayahara,3 Masanori Toyoda,1 Naomi Kiyota,1 Toru Mukohara,4 Akinobu
Hamada,2 Hironobu Minami1. 1Kobe University Graduate School of Medicine,
Kobe, Japan; 2National Cancer Center, Japan; 3Kobe Minimally Invasive Cancer
Center, Kobe, Japan; 4Kobe University Hospital, Kobe, Japan.
Background: The development of rashes is the most common adverse event
observed in cancer patients treated with epidermal growth factor receptor-tar-
geted tyrosine kinase inhibitors (EGFR-TKI) such as erlotinib. A signifıcant
relationship exists between the severity of a rash and survival in various cancers.
However, whether erlotinib becomes distributed to the skin and whether its
concentration is higher in a rash than in normal skin of treated cancer patients
remains unknown.Here, using quantitativemass spectrometry imaging (qMSI),
we successfully visualized the distribution of erlotinib in rashes and normal skin
of patients with advanced pancreatic cancer receiving this drug. Methods: We
studied fıve patients with advanced pancreatic cancer who developed rashes
after treatment with gemcitabine (1000 mg/m² by intravenous infusion for 30
minutes on days 1, 8, and 15 every 4 weeks) and erlotinib (given orally at 100
mg/day).We biopsied both rashes and normal skin, and compared the distribu-
tion of erlotinib using matrix-assisted laser desorption ionization mass spec-
trometry imaging (MALDI-MSI). The plasma concentration of erlotinib was
measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Results: Erlotinib concentrations in fıve patients were 2.55 	 1.46 ng/mm3 in
normal skin and 3.18	 1.53 ng/mm3 (mean	 SD) in rashes (p0.123). In four
out of fıve patients, the erlotinib concentration in rashes was higher than that in
normal skin. The epidermis showed the strongest expression of EGFR in skin
as judged by immunohistological staining. Erlotinib showed a greater ten-
dency for distribution to the epidermis than subcutaneous tissue. There was
no correlation between erlotinib plasma concentrations vs. concentrations
in rashes or normal skin. Conclusions: Using qMSI, we, for the fırst time,
visualized the distribution of erlotinib in skin tissue of pancreatic cancer
patients receiving erlotinib. We found a tendency for a higher concentration
of erlotinib in rashes than in normal skin. A greater distribution of erlotinib
to the epidermis than subcutaneous tissue suggests erlotinib may directly
bind EGFR expressed in the epidermis.
#2873 Imaging tumor heterogeneity after multikinase inhibitor ther-
apy in rat hepatocellular carcinoma. Nina M. Muñoz,1 Adeeb A. Minhaj,1
Kiersten L. Maldonado,1 Charles Kingsley,1 Hideyuki Nishiofuku,2 Keith A.
Michel,1 Andrea C. Cortes,1 James A. Bankson,1 Asif Rashid,1 Rony Avr-
itscher1. 1UT MD Anderson Cancer Center, Houston, TX; 2Nara Medical
University, Nara, Japan.
Purpose: To assess tumor tissue perfusion and vascular permeability through
multiparametric functional imaging, and to evaluate their correspondence with
histopathologic parameters of necrosis and hypoxia in a rat model of hepatocel-
lular carcinoma treatedwith amultikinase inhibitor.Materials andMethods Rat
hepatoma McA-RH7777 cells were implanted in the left liver lobe of nineteen
male Buffalo rats. Exactly 2 weeks after tumor inoculation, the animals were
randomly assigned to remain untreated (n10) or to receive a daily dose of 7.5
mg/kg sorafenib by oral gavage (n9) for 2 additional weeks. T2-weighted spin-
echo magnetic resonance imaging (MRI), dynamic contrast-enhanced (DCE)
and contrast-enhanced ultrasound (CEUS) were performed weekly. All tumors
were harvested 4 weeks post-implantation90minutes after injecting 60mg/kg
pimonidazole. Tissue sections were stained for hematoxylin-eosin and pi-
monidazole for quantitative assessment of necrosis and hypoxia, respectively.
Differences between treatment groups were assessed using the Mann-Whitney
test, and the correlation of imaging and histopathology parameters was deter-
mined by Spearman correlation analysis. Results: In spite of the relatively low
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dose and short treatment duration, the response to sorafenib therapy was char-
acterized by a signifıcantly higher median tumor necrosis (60 vs 15%, P 
0.0001) and increased tumor tissue hypoxia (35 vs 18.5% pimonidazole binding,
P  0.0001). Similarly, the sorafenib regimen caused a substantial decrease in
vascular permeability, measured by DCE-MRI Ktrans (P  0.002) as well as
reduction in tumor perfusion evaluated by CEUS peak enhancement (PE)
(P0.043). Our fındings show a strong correlation between the two histopatho-
logic parameters we assessed, tumor tissue necrosis and hypoxia (r  0.645,
P0.002). Furthermore, our results demonstrate signifıcant correlation of func-
tional imaging parameters of vascular permeability, namely DCE-MRI Ktrans
and DCE-MRI normalized initial area under the curve (NIAUC), with histo-
pathologic tissue hypoxia (r0.663, P 0.002, and r0.512, P0.029, re-
spectively). In contrast, histopathologic tumor necrosis appears more strongly
correlated with a functional imaging parameter of tumor perfusion, specifıcally,
CEUS PE (r0.547, P 0.028). Conclusion Tumors exhibited wide hetero-
geneity in vascular perfusion and hypoxia after treatment. Interestingly, func-
tional MRI parameters appear to correlate more strongly with tissue oxygen-
ation, whereas functional CEUS parameters correlate with tumor viability.
Novel predictive imaging biomarkers of treatment response may be developed
through further analyses of spatial tumor heterogeneity in our animal model.
#2874 Inhibition of tumor angiogenesis by Salmonella typhimuriumA1-R
in the in vivoGelfoam color-coded imaging assay. Tasuku Kiyuna,1 Yasunori
Tome,2 Takashi Murakami,1 Ming Zhao,1 Fuminori Kanaya,2 Robert M. Hoff-
man1. 1AntiCancer, Inc, San Diego, CA; 2University of the Ryukyus, Okinawa,
Japan.
We previously demonstrated a color-coded angiogenesis imaging model us-
ing Gelfoam® implanted in nestin-driven green fluorescent protein (ND-GFP)
nude mice in which nascent blood vessels express GFP. In this assay, we dem-
onstrated osteosarcoma promotes angiogenesis.We report here that Salmonella
typhimurium A1-R (S. typhimurium A1-R) inhibits angiogenesis of osteosar-
coma cells in the Gelfoam® angiogenesis assay in ND-GFP mice. Gelfoam® was
transplanted subcutaneously in the flank of transgenic ND-GFP nude mice.
Seven days after transplantation, skin flaps were made and 143B human osteo-
sarcoma cells, expressing red fluorescent protein (RFP), were injected in the
transplanted Gelfoam®. After establishment of tumor in the Gelfoam®, the con-
trol group mice were treated with PBS by tail vein injection. The treated group
was treated by S. typhimurium A1-R, also by tail vein injection. Skin flaps were
made at days 14, 21, and 28 after transplantation of the Gelfoam® in order to
allow imaging of vascularization. The OV100 variable magnifıcation small ani-
mal imaging system and FV1000 confocal fluorescencemicroscope were used to
visualize vascularization. Nascent blood vessels grew in the Gelfoam® in a time-
dependent manner. A random 3 fıelds were quantifıed in each group. The mean
length of ND-GFP-expressing blood vessels in the Gelfoam® in mice were
treated with S. typhimurium A1-R was 9.40, 12.40, and 10.12 mm/mm2, at days
14, 21, and 28, respectively. Themean total length of ND-GFP-expressing blood
vessels in the Gelfoam® in mice of the control group were 8.86, 14.50, and 15.81
mm/mm2 on day 14, 21, and 28, respectively. ND-GFP expressing blood vessels
of the mice in the osteosarcoma cells treated with S. typhimurium A1-R had
shorter vessels than the control group (on day-28, P0.05). There was not a
signifıcant difference in tumor size between the 2 groups, thereby indicating a
specifıc inhibition of angiogenesis by S. typhimurium A1-R. In the present
study, we reported that S. typhimurium A1-R inhibited angiogenesis of human
osteosarcoma cells in the in vivo Gelfoam® color-coded imaging assay.
TUMOR BIOLOGY: Signaling in Cancer Stem Cells
#2875 Knockout of ST8SIA1 inhibits tumorigenesis in triple negative
breast cancer by inducing PTEN and ganglioside GM1 mediated tumor
growth arrest. Khoa Nguyen, Yuanqing Yan, Chandra Bartholomeusz, Naoto
Ueno, Kim-Anh Do, Michael Andreeff, V. Lokesh Battula. UT MD Anderson
Cancer Ctr., Houston, TX.
We found that ganglioside GD2 is a biomarker for breast cancer stem cell
(BCSCs) in triple negative breast cancer (TNBC) and that GD2 biosynthesis is
tightly regulated by enzyme ST8SIA1 (GD3 synthase) in these cells. We have
reported that ST8SIA1 is highly expressed in TNBC and its expression is highly
correlated with TP53 mutations in primary tumors (based on TCGA data set).
Here we hypothesized that ST8SIA1 has a functional role in BCSC mediated
tumorigenesis in TNBC. To test this hypothesis, we deleted ST8SIA1 in SUM159
cells using CRISPR-Cas9 technology. As expected, deletion of ST8SIA1 in
SUM159 cells reduced the absolute number of GD2 cells from 17 	 1.5% to
0.3 	 0.1%. Although there was no signifıcant difference in 2D cell growth,
anchorage-independent growth by soft-agar and the mammosphere formation
assays revealed a complete loss of colony formation in ST8SIA1-KO cells.More-
over, transplantation of ST8SIA1-KO- or Cas9 control- SUM159 cells in mam-
mary fat pad of NSG mice revealed that ST8SIA1-KO cells failed to produce
tumor formation even after a 15-wk after implantation. In addition, most of the
cas9 control cell injected mice died within 4 wk after cell implantation whereas
no deaths were observed in the ST8SIA1-KO cells as long as 100 d after tumor
implantation. To investigate the mechanism involved in tumor growth inhibi-
tion associated with the loss of ST8SIA1 expression, we analyzedmRNA expres-
sion in ST8SIA1-KO- and Cas9 control- SUM159 cells by RNA sequencing. At
p  0.05 and fold change 2, we found 1502 genes down-regulated and 842
genes up-regulated in the ST8SIA1-KO-cells compared to controls. Ingenuity
pathway analysis revealed that several stem cell-associated signaling pathways,
including wnt, stat3, NFB, nanog, and IL8, were down-regulated. Conversely,
the potent tumor suppressor PTENwas induced in the ST8SIA1-KO-cells com-
pared to controls. In addition, gene ontology by gene set enrichment analysis
(GSEA) revealed inhibition of oncogenic signaling pathways including KRAS,
p53, AKT, and RB. We have also identifıed a signifıcant down-regulation of
breast cancer-associated genes including BCL11A, PDGFRb, VCAM1, CXCR4,
and wnt5a. Interestingly DKK1, which acts as an antagonist for wnt--catenin
signaling, was up-regulated in the ST8SIA1-KO cells. These fındings were vali-
dated by qRT-PCR, flow cytometry and western blot analysis. Ganglioside GM1
has been reported to have major in anti-tumor effect by inhibiting ERK signal-
ing. Flow cytometry analysis revealed that ST8SIA-KO cells expressed10-fold
higher GM1 compared to Cas9 control cells. In addition, pERK was down-
regulated in ST8SIA-KO cells, suggesting a loss of tumorigenic potential of these
cells. In conclusion, our data suggests that inhibition of ST8SIA1 in TNBC cells
depletes BCSCs and inhibits tumorigenesis by down-regulating oncogenic path-
ways and up-regulation of PTEN and GM1 mediated signaling.
#2876 Loss of the stem cell and basal lineage regulator LBHdelays onset of
basal-like triple negative breast cancer.Kilan C. Ashad-Bishop, Karoline Brie-
gel. Univ. of Miami, Miami, FL.
There is increasing evidence that basal-like triple negative breast cancer
(TNBC) originates from luminal mammary epithelial cells. Specifıc gene signa-
tures have already been experimentally proven to serve as genetic lineage
switches that, when overexpressed, transform pre-malignant luminal cells to
oncogenic cells with basal, stem-like characteristics. Conversely, depletion of
these genes in oncogenic cells with basal, stem-like characteristics leads to lumi-
nal differentiation. These studies suggest that during the earliest steps of neo-
plastic transformation, specifıc gene sets can alter cell fate decisions and differ-
entiation status inmammary epithelial cells, which ultimately contributes to the
heterogeneity of breast tumors. Our lab has identifıed a novel Wnt/-Catenin
target gene, Limb bud and heart (LBH) that is majorly overexpressed in TNBC.
LBH is a regulator of the basal mammary stem cell lineage and repressor of
luminal differentiation via induction of Np63 and repression of estrogen re-
ceptor alpha. LBH is required for the self-renewal and maintenance of adult
basal mammary stem cells, which tend to be enriched in TNBC. Knockout stud-
ies in mice have shown that genetic ablation of LBH does not impair embryo-
genesis or normal adult organ function, making it a possible therapeutic target.
Using crosses between MMTV-Wnt-1 transgenic mice and K14Cre LBHloxP
knockoutmice, we are studying the effect of LBH ablation in the basal cells of the
mammary epithelium downstream of ectopic Wnt expression in the mammary
gland. We postulated that LBHmay be an effector of Wnt-driven TNBC, there-
fore its inhibition would lead to decreased Wnt-induced mammary gland hy-
perplasia and tumor formation. In our model, LBH ablation in the basal mam-
mary epithelium of female Wnt transgenic mice reduces mammary gland
hyperplasia and delays tumor onset. MMTV-Wnt-1 driven, LBH-null tumors
also exhibit histopathological differences indicative of a luminal to basal conver-
sion. There is an urgent need to elucidate mechanisms underlying TNBC devel-
opment and progression and fınd reliable avenues for treatment. Our data indi-
cates a role for Lbh as a novel effector forWnt-driven TNBC and further studies
may prove antagonism of Lbh to be a novel method to control TNBC progres-
sion.
#2877 IKK-mediated signaling controls prostate tumor initiating cells.
Sara E. Conard, Aaron Ebbs, Albert S. Baldwin. University of North Carolina at
Chapel Hill, Chapel Hill, NC.
The heterogeneous nature of prostate cancer tumors is thought to play an
important role in the decreased effectiveness of existing therapies. Tumor initi-
ating cells (TICs) are capable of self-renewal and comprise a subset of the tumor
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mass. These cells are proposed to drive the growth andmetastasis of tumors, and
are considered to be resistant to traditional cytotoxic and targeted therapies.
Several studies have shown that NF-B signaling is increased in recurrent pros-
tate cancer and enriched in prostate TICs.We sought to determine the potential
of an IKK/NF-B-driven mechanism for inherent or acquired resistance by
IKK-mediated control of a subset of prostate tumor initiating cells. These studies
were performed by using established prostate cancer cell lines, murine prostate
organoids, and a murine prostate cancer animal model. We have found that
inhibition of IKK and IKK, upstream regulators of noncanonical and canon-
ical NF-B signaling, block self-renewal of several PTEN-defıcient prostate can-
cer cell lines. Furthermore, we have also found that IKK is important for tumor-
igenicity and stemness seen in prostate cancer cells as measured by colony
formation and extreme limiting dilution assays. Loss of canonical NF-B (p65/
RelA) decreased stemness while loss of noncanonical did not alter tumorsphere
formation. Interestingly, Pten/ tumors with loss of Ikk or Ikk displayed
decreased levels of self-renewing cells as measured by CD49fhigh expression, a
known prostate basal cell marker. Isolated murine Pten/ cells were 2x more
effıcient than Pten/Ikk/ or Pten/Ikk/ cells in forming prostate
organoids suggesting that loss of Ikk decreased the number of self-renewing cells
needed for formation. Taken together, we conclude that IKK-mediated signal-
ing is important for maintenance of prostate tumor initiating cells and further
studies will address whether IKK-mediated signaling provides a mechanism for
evading current therapies.
#2878 Anti-cancer effects of retinoic acid in CRC occurs via decreased
growth of ALDH cancer stem cells and increased differentiation of stem
cells to neuroendocrine cells. Shirin R. Modarai,1 LynnM. Opdenaker,1 Anin-
ditaGupta,1 JeremyZ. Fields,2 BruceM. Boman1. 1Helen F. GrahamCancer Ctr.,
Newark, DE; 2CaTx, PA.
Our studies on tissues from colon cancer patients show that in the develop-
ment of colorectal cancer (CRC), stem cell (SC) overpopulation underlies tumor
initiation and progression. Because aldehyde dehydrogenase (ALDH) is a
marker for SCs in several tissues and is a key enzyme in retinoid acid (RA)
signaling, we investigated the role of RA signaling in normal and malignant
colonic SCs. Our overall hypothesis is that RA signaling regulates growth and
differentiation of ALDH colonic SCs and dysregulation of RA signaling con-
tributes to SC overpopulation in CRC development. To begin to investigate
underlying mechanisms, we analyzed CRC cell lines/tissues to see if retinoid
receptors RXR and RAR are exclusively expressed in ALDH SCs and if the RA
pathway components change during CRC development. We determined
whether RA signaling influences SC proliferation, differentiation, self-renewal,
and SC population size. RXR & RAR were selectively expressed in ALDH
colonic SCs, but not inMCM2 proliferative cells, suggesting that RA signaling
mainly occurs in SCs. Western blotting/immunostaining of CRCs revealed that
RA signaling components, including RAR and RXR, become overexpressed in
parallel with ALDH overexpression, which coincides with the known overpop-
ulation ofALDH SCs that occurs duringCRCdevelopment. Treatment of cells
with RA ligands (ATRA, 9-cis RA) inhibited proliferation, reduced sphere for-
mation, decreased ALDH SC population size, and induced differentiation
along the neuroendocrine cell (NEC) lineage. Taken together, our fındings in-
dicate that: (1) retinoid signaling, by regulating ALDH colonic SCs, reduces
SC proliferation, self-renewal and SC population size, and promotes SC differ-
entiation to NECs, and (2) dysregulation of RA signaling in colonic SCs likely
contributes to overpopulation of ALDH SCs and CRC growth. Thus, RA sig-
naling, by inducing increased differentiation of the SC population, suggests a
novel therapeutic target.
#2879 Dj-1 confers maintenance of stemness and radioresistance by reg-
ulating EGFRvIII expression in glioma stem cells. Myung-Jin Park,1 Jeong-
YubKim,1Hee-JinKim,1 Ji-SooKim,1 Jeong-ChulKim,1Dea-Hee Lee,2 Yoo-Jin
Na2. 1Korea Institute of Radiological and Medical Sciences, Seoul, Republic of
Korea; 2Korea University, Seoul, Republic of Korea.
DJ-1 is involved in many key cellular processes including cell proliferation,
transcriptional regulation, differentiation, oxidative stress protection, and mi-
tochondrial functionmaintenance. Deregulation of DJ-1 has been implicated in
the pathogenesis ofmany human diseases such as Parkinson’s disease, amyotro-
phic lateral sclerosis, infertility, and cancer. DJ-1 was initially identifıed as an
oncogene product involved in human tumorigenesis in numerous cancer types.
Alteration in expression ofDJ-1 is associatedwith tumorigenesis in several types
of cancers. Herein, we aimed to clarify the effect of DJ-1 on stemness and radio-
resistance of glioma stem cells (GSCs). Firstly, we found that the reduction in
expression of DJ-1 in brain tumor tissues when compared with tumor adjacent
normal brain tissues, as indicated by reduced DJ-1 staining. Knock-down of
DJ-1 inhibited self-renewal activity of GSCs in vitro as evidenced by neuro-
sphere formation, limiting dilution, and soft agar clonogenic assays. DJ-1
knock-down suppressed maintenance of stemness by suppressing the expres-
sion of Notch intracellular domain, Sox2, and phosphorylated STAT3 proteins.
Intriguingly, DJ-1 knock-down inhibited the expression of EGFRvIII in GSCs
which might be the cause of suppression of stemness pathways. In addition,
knockdown of DJ-1 induced apoptosis, reduced cell invasiveness, and sensitized
GSCs to ionizing radiation. Based on these data, we propose that DJ-1 could be
considered as a crucial diagnostics and therapeutics target formalignant glioma.
#2880 GANT61-mediated constraint of Fibulin-5/prorenin receptor/
BMI1 signaling impacts nasopharyngeal carcinoma stemness andmetastasis.
Hsin-Ting Tasi, Chang-Han Chen. Institute for Translational Research in Bio-
medine, Kaohsiung, Taiwan.
Background: Cancer stem cells (CSCs) of NPC exhibit higher tumorigenesis
and metastatic potential. Novel therapies based on molecular targets of CSCs
have become the focus to cure NPC. GANT61, a GLI1 inhibitor, has been re-
ported to exhibit potent anticancer effect on many cancers; here, we evaluated
whether GANT61 has inhibitory effects on NPC-CSCs and further explored the
possible mechanism. Methods: Condition medium was used to enrich NPC
stem-like cells. TheNPC stem-like cells characteristics were examined byQ-RT-
PCR, Western blotting, MTT, BudU, colony formation, sphere formation, and
subcutaneous and metastatic xenograft models. Genetic, pharmacological and
biochemical approaches were applied in NPC stem-like cells to investigate mo-
lecular signals, to assess the effıcacies under the inhibitors treatment, and to
examine the correlation among the molecules in vitro, in vivo and NPC speci-
mens. Results: In the present study, we had demonstrated that NPC tumors-
phere cells (NPC-TCs) possess CSC properties. The proliferation, colony for-
mation, spheroid formation, migration, and invasion of NPC-TCs were
dramatic prevented in the presence ofGANT61 in vitro and in vivo.ChIP reveals
thatGli1 preferentially binds to the Fibulin-5 promoter, andFibulin-5 transcrip-
tional/post-transcriptional levels in NPC-TCs were regulated upon GANT61
treatment. However, ectopic expression of Fibulin-5 in NPC-TCs not only en-
hanced self-renewal and ALDH1 expression, but also reduced the effects of
GANT61-eilicted anti-tumor in vitro and in vivo. We further identifıed that a
novel signaling, prorenin receptor/BMI1 pathway was modulated by Fibulin-5
and involved in Fibulin-5-raised self-renewal capacity of NPC-TCs in vitro and
in vivo. Notably, GANT61 inhibited NPC-TCs phenotypes was associated with
suppression of Fibulin-5/prorenin receptor/BMI1 signaling. Finally, a signifı-
cant correlation was observed among GLI1, Fibulin-5, AT1R and BMI1 in the
specimens of NPC. Conclusions: Our data highlight that Fibulin-5/prorenin
receptor/BMI1 signaling has critical role in maintaining stem-like properties of
NPC-CSCs and can be effıciently targeted byGANT61 representing a preclinical
therapeutic strategy to repress NPC-CSCs.
#2881 CXCL1 and CCL5, induced by ionizing radiation, reprogram non-
tumorigenic cancer cells into cancer stem cells in breast cancer. Justine Bail-
leul-Dubois,1 Nadège Bidan,1 Raphaëlle Mouttet-Audouard,2 Mélanie Arci-
casa,2 Karine Hannebicque,2 Yuki Takayama,3 Samuel Meignan,2 Xuefen Le
Bourhis,1 Chann Lagadec1. 1INSERM U908, Villeneuve d’Ascq, France; 2Centre
Oscar Lambret, Lille, France; 3LIMMS/CNRS-IIS UMI2080, SMMIL-E, Tokyo,
Japan.
Identifıcation of cancer stem cells (CSC) in solid tumors - with self-renewal,
multipotency, tumorigenesis, and therapy resistance capacities - has opened
path to new targeting therapeutic approaches. However, CSC targeting alone
might not be suffıcient to eradicate a tumor. Indeed, recent studies showed that
cancer cells are plastic, and conventional therapies, such as radiotherapy, can
lead to cancer cells (non-CSC) reprogramming into iCSC (induced-CSC). The
goal of our work is to identify the molecular mechanisms responsible for treat-
ment-induced CSC emergence. First, we have shown that conditioned media
from irradiated non-CSC is suffıcient to induce iCSC reprogramming. These
results suggest that cell plasticitymight be actively regulated by diffusible factors
secreted by irradiated cells. By using proteins arrays and ELISA, we demon-
strated that the secretion of a specifıc cocktail of chemokines is induced by
ionizing radiation, such as CXCL1 and CCL5. Interestingly, recombinant
CXCL1 and CCL5 treatments increase the sphere forming capacity (SFC) of
isolated non-CSC treated population. Concomitantly, treatment with neutraliz-
ing antibodies targeting CXCL1 and CCL5 leads to a decreased CSC number
(ALDH cells). We also studied the expression of the corresponding chemo-
kines receptors, by flow cytometry. First, we saw that reprogrammable ALDH-
cells are enriched for CXCL1 and CCL5 receptors expressing cells compare to
unsorted population or ALDH population (CSC). We analysed the repro-
gramming potential of isolated ALDH-/receptor-positive cells versus ALDH/
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receptor-negative cells. TheALDH-/receptor-positive-derived cell population is
more able to form spheres and overcomes the receptor-negative-derived popu-
lation when the two populations are mixed and tested for their sphere forming
capacity. The use of pharmacological inhibitors against the receptors induce a
slight decrease of CSC. Taken together, our results indicate the involvement of
chemokines, in particular CXCL1 and CCL5, in the reprogramming mecha-
nism. To validate the implication of CXCL1 and CCL5 and in a pre-clinical
perspective,we are currently beginning an in vivo experiment to study the effects
of CXCL1 andCCL5 inhibition on tumor development and onCSC enrichment
in vivo.
#2882 The miR-200b-ZEB1 circuit regulates diverse stemness of human
hepatocellular carcinoma. Sen-Yung Hsieh, Su-Chun Tsai. Chang Gung Me-
morial Hospital, Taoyuan, Taiwan.
Background & aims: Hepatocellular carcinoma (HCC) can be derived from
cancer stem cells (CSCs), which contribute to tumor initiation, metastasis,
chemoresistance, and post-treatment recurrence. A great variety of HCC CSCs
resulting in diverse clinical manifestations have been reported. We aimed to
elucidate how CSC diversity is regulated. Methods: MicroRNAs deregulated in
HCC were identifıed by using array-based microRNA profıling. Diversity of
HCCCSCswas assayed by flow-cytometry, in vitro and in vivo assays for tumor-
igenicity. Results: MiR-200b downregulation occurred in early HCC and asso-
ciated with shorter disease-free and overall survival. Ectopic expression of miR-
200b or silencing of ZEB1 led to a decrease in CD13 and CD24 HCC CSCs
and an increase in EpCAM HCC CSCs. MiR-200b directly suppressed BMI1
and ZEB1 expressions. ZEB1 transcriptionally upregulated CD13 and CD24
expression and downregulated EpCAM expression via directly targeting their
promoters. NeithermiR-200b nor ZEB1 had obvious effects on CD133 or CD90
expression. Silencing CD13 or CD24 expression suppressed tumorigenicity of
HCC cells. Ectopic expression of CD24 reversed the suppression of tumorige-
nicity when these HCC cells had been ectopically expressing miR-200b. Clini-
cally, miR-200b downregulation was coupled with ZEB1 upregulation in ap-
proximately two-thirds of HCC patients. ZEB1 expression was positively
correlated with CD13 and CD24 expressions, while EpCAM expression was
positively correlated with miR-200b expression in HCCs. Conclusions: The
miR-200b-ZEB1 circuit is a master regulator of diverse stemness of HCC, which
distincts HCCs into those containing CD13/CD24CSCs from those contain-
ing EpCAM CSCs, and a thus potential target for anti-HCC therapy.
#2883 DoWnt3A-mediated canonical Wnt/Beta-catenin signals regulate
stem cell phenotypes in brain metastasis-specifıc TNBC. Jennifer H. Carlson,
Pradip De, Casey Williams, Nandini Dey, Brian Leyland-Jones. Avera Cancer
Institute, Sioux Falls, SD.
Introduction: Triple negative (TN) and basal-like subtypes portend one of the
worst prognoses in BC and have the most challenging diagnosis among patients
due to the aggressive nature of the disease. BC stem cells (BCSCs) have a distinct
role in breast oncogenesis and CD44()/CD24() BCSCs play an important
role in the clinical behavior of TNBC. Unique growth abilities of BCSCs includ-
ing self-renewal, differentiation potential and resistance to anti-cancer agents
contribute to the development andoverall aggressiveness of recurrentmetastatic
lesions. Patients with TNBC as compared to non-TNBC have signifıcantly
higher incidences of recurrence or distant metastasis and the poorer outcome
has been associated with increased frequency of BCSCs phenotypes. Aim: We
previously reported that Wnt pathway (WP) is associated with metastasis (Dey
et al., 2013) and controls metastasis-associated (MA) tumor cell phenotypes in
TNBC (De et al., 2016) and here we tested the role of WP in the regulation of
BCSCs and MA tumor cell phenotypes using brain-metastasis specifıc TNBC
model (MDA-MB231BR). Methods: MDA-MB231BR cells were stimulated
with WP specifıc ligand or LWnt3A conditioned media (CM) and MA tumor
cell phenotypes were tested following WP inhibition. To model distant metas-
tasis in vitro, we have used a long-term 3D-matrigel assay in the presence of
LWnt3ACM. Four BCSCs markers, CD44, CD44V6, CD24 and CD133 were
selected for the flow cytometric analyses of cells following LWnt3ACM stimu-
lation and downregulation of WP by sulindac sulfıde. Results: Specifıc stimula-
tion of WP by LWnt3ACM led to the clonogenic growth from a single cell.
Inhibition of WP blocked micro-metastatic growth of these colonies. Although
WP stimulation alone did not alter % of CD44()/CD24() population in 2D
format, inhibition of WP following treatment with sulindac sulfıde caused a
signifıcant decrease in the % of CD44()/CD24() population (66%) as com-
pared to the control (79%). To further understand the mechanistic long-term
role of BCSCs during the micro-metastatic 3D growth of colonies, we have
developed a novelmethod to identify the%of BCSCs in themicro-metastatic 3D
colonies. After 15 days of 3D colony growth, cells are recovered from matrigel
and the live cell fraction is analyzed for CD24, CD44, CD44v6 and CD133 by
flow cytometric analysis. We previously presented data demonstrating the
CD44/CD24- fraction is enriched in 3D colonies as compared to correspoding
2D cells. Here we’ve extended our analysis and examined 3D colonies following
either stimulation or inhibition ofWP. Conclusion: Our data demonstrates that
WP mediates the BCSCs phenotype(s) of TNBC in a context-dependent man-
ner. Studies are on-going to delineate the mechanistic role of different BCSCs
markers particularily CD44 and CD44v6 in signaling the formation of WP-
mediatedmicro-metastatic 3D colonies, the results of which will be presented at
the meeting.
#2884 Interferon Beta (IFN-B) re-activates canonical type I IFN signaling
to differentiate breast cancer stem cells (CSCs) and suppress mesenchymal/
CSC driven tumor recurrence.Mary R. Doherty,1 Damian J. Junk,1 HyeonJoo
Cheon,2 George R. Stark,2 Mark W. Jackson1. 1CWRU, Cleveland, OH; 2Lerner
Research Institute, Cleveland Clinic, Cleveland, OH.
Tumor recurrence remains a major therapeutic obstacle to curing breast can-
cer. Cytokines within the breast tumor microenvironment (TME) influence re-
currence following chemotherapy by altering the balance betweenmesenchymal
CSC (MES/CSC) and epithelial non-CSC (EP/non-CSC). Here, we fınd that
transformed breast MES/CSC express elevated levels of Un-phosphorylated In-
terferon StimulatedGene Factor 3 (U-ISGF3), which is composed of STAT1 and
STAT2 lacking phosphorylation of their tyrosine residues, and IRF9. Elevated
expression of the U-ISGF3 proteins in breast cancer has previously been linked
with resistance to ionizing radiation, thus we hypothesized that the U-ISGF3
complex is important for maintaining MES/CSC properties. However, knock-
down of IRF9, the critical DNA binding component of this complex, or STAT1
did not alter the MES/CSC phenotype. Moreover, ISGF3 transcriptional targets
were actually repressed in MES/CSC relative to EP/non-CSC, suggesting that
elevated U-ISGF3 may act as a repressor in MES/CSC. Interestingly, we found
that an MES/CSC program independent of IFN-B, was responsible for mediat-
ing U-ISGF3 expression.We therefore hypothesized that stimulatingMES/CSC
with IFN-B would phosphorylate the ISGF3 proteins and engage canonical
IFN-B mediated inhibition of MES/CSC properties. Acute exposure to IFN-B
led to the phosphorylation of ISGF3 inMES/CSC and induced the transcription
of IFN-B responsive genes. Continuous exposure to IFN-B maintained Phos-
phorylated ISGF3 (P-ISGF3) which partially reverted theMES/CSC phenotype,
resulting in the repression of mesenchymal markers (Vimentin and Slug), re-
expression of Ep/non-CSC markers (CD24) and functionally inhibited colony
formation in soft agar and migratory capability. In line with these observations,
data from triple-negative breast cancer (TNBC) patients confırmed that in-
creased expression of IFN-B responsive genes correlates with decreased expres-
sion of a CSC gene signature, and correlates with improved recurrence-free
survival. Taken together, our fındings demonstrate that IFN-Bmediated signal-
ing promotes the differentiation of MES/CSC by phosphorylating U-ISGF3,
resulting in the suppression ofMES/CSC-driven tumor recurrence. Future stud-
ies will examine the mechanism by which IFN-B mediated P-ISGF3 suppresses
MES/CSC properties and whether elevation of U-ISGF3 can predict which pa-
tients would be candidates for an IFN-B therapy to phosphorylate STAT1 and
STAT2, thus suppressing MES/CSC tumor recurrence.
#2885 Activation of IL1 signaling by HER2 overexpression promotes
breast cancer stem cells. Shou Liu,1 Ji shin Lee,2 Hexin Chen1. 1University of
South Carolina, Columbia, SC; 2Chonnam National University, Republic of
Korea.
Breast cancer is a heterogeneous disease and only a small proportion of cells
known as cancer stem cells (CSCs) have ability to generate tumor. Recently, it
has been reported that HER2 overexpression increase breast cancer stem cells
(BCSCs). However, the underlying mechanism is not clearly known. In this
study, we explored the molecular mechanism how HER2 increase BCSCs. Our
data has demonstratedHER2 induces BCSCs by indirectly activatingNF-kB and
STAT3 signaling. To fıgure out the direct target of HER2, we did themicroarray
and found that HER2 upregulates the expressions of IL1a and IL6, two major
cytokines which directly activates NFkB and STAT3, respectively. Interestingly,
we found that IL1a also indirectly activates STAT3. IL1 induced STAT3 was
blockedwhen IL6was knock out from cells.We found thatHER2 enhances IL1
transcription by activating PU.1 which is known transcription factor of IL1a.
Finally, we studied effect of IL1a on tumorigenesis, and found that IL1 KO
dramatically attenuates the tumor growth in NOD/SCIDmice. Taken together,
we found that HER2 induces BCSCs by upregulating IL1a and IL6 expression.
We for fırst time demonstrating that IL1 plays a critical role in HER2-induced
expansion of BCSC population and may be a potential therapeutic target for
HER2 positive breast cancer.
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#2886 CD44/SMURF1 signaling maintains cancer stem cell-like invasive
cells in head and neck squamous cell carcinoma. Ali Khammanivong,1 Raj
Gopalakrishnan,2 Erin B. Dickerson3. 1University of Minnesota Masonic Cancer
Research Center,Minneapolis, MN; 2University ofMinnesota School of Dentistry,
Minneapolis,MN; 3University ofMinnesotaCollege of VeterinaryMedicine,Min-
neapolis, MN.
Head and neck squamous cell carcinoma (HNSCC) is highly invasive and
resistant to therapies, where treatments often result in high rates of failure and
disease recurrence. A subpopulation of tumor-initiating cancer stem cells (CSC)
is thought to be responsible for metastatic invasion and drug resistance inmany
types of cancer, includingHNSCC.CD44 is a knownCSCmarker inHNSCCbut
its role in maintaining CSC populations is not well understood. We previously
reported that SMAD specifıc E3 ubiquitin protein ligase 1 (SMURF1) inhibition
of bone morphogenetic protein (BMP) signaling is essential for maintaining a
CD44-high CSC-like population in HNSCC. In this study, we sought to deter-
mine how CD44, a receptor for hyaluronic acid (HA) that constitutes a major
component of the tumor stroma, is involved in the regulation of SMURF1 and
the maintenance of a HNSCC CSC phenotype. CSC-like cells were enriched
from HNSCC cell lines as CD44-high cells. CD44 signaling was stimulated by
exogenous HA treatment and inhibited by CD44 knockout (KO) using an in-
ducible CRISPR/Cas9 system. We then assessed changes in SMURF1 protein
level, BMP signaling, transwell migration, Matrigel colony formation, and inva-
sion through three-dimensional organotypic culture (OTC) following CD44
modulation. CD44-high cells were found to have increased extracellular HA
production. Treatment with exogenous HA reduced BMP signaling, as deter-
mined by a reduction in phospho-SMAD1/5/8 levels, and increased transwell
migration of CD44-high cells. CD44-KO reduced SMURF1 protein expression
and inhibited Matrigel colony formation of an invasive and recurrent HNSCC-
derived CD44-high cells but only partially reduced colony formation of a less-
invasive cell line derived froma primaryHNSCC.Knockout of CD44 expression
showed a slight reduction in transwell migration of invasive cells. CD44-high
cells also recapitulated an invasive and CSC-like growth pattern in OTC assays.
In contrast, CD44-KO inhibited OTC invasion and the epithelial-to-mesenchy-
mal transition (EMT) phenotype, resulting in increased apical epithelial growth
and differentiation. CD44 reconstitution appeared to restore the invasive and
EMT phenotype. Based on our current fındings, CD44may be crucial for main-
taining an anchorage-independent and invasive phenotype of HNSCC but plays
a minor role in carcinoma cell migration.
#2887 Macrophage conditionedmedium promotes colon cancer stem cell
phenotype via the hedgehog signaling pathway. Fan Fan, RuiWang, Delphine
R. Boulbes, Huiyuan Zhang, Stephanie S. Watowich, Rajat Bhattacharya, Ling
Xia, Xiang-Cang Ye, Lee M. Ellis. UTMD Anderson Cancer Ctr., Houston, TX.
Background: Contradicting studies have shown that increased macrophages
infıltration in colorectal cancer (CRC) could either result in anti-tumoral or in
pro-tumoral effects. Because of these inconsistencies, we sought to determine
the role of conditioned medium from macrophages, in particular classically
activatedmacrophages, on the development of the CSC phenotype in CRC cells,
which is believed tomediate tumor growth and chemoresistance.Methods:Mu-
rine (CT26) and human (HCP-1) CRC cell lines were treated with conditioned
media (CM) from lipopolysaccharide (LPS)-activatedmurinemacrophages. Vi-
ability studies were performed using theMTT assay, annexinV-FITC assay, and
Western blot analysis. The CSC population was assessed using the sphere-form-
ing assay and aldehyde dehydrogenase assay. Results: The results showed that 1)
murine LPS-activated macrophage CM induced apoptosis in murine and hu-
man CRC cells, 2) murine and human LPS-activated macrophage CM secreted
paracrine factors that promoted the CSC phenotype inmurine and humanCRC
cells via the Sonic hedgehog (SHH)-Gli signaling pathway, which is known to
drive self-renewal and 3) these effects were blocked by depletion of SHH in
macrophage CM. Conclusions: Our data show that LPS-activated macrophages
play an active role in promoting the CSC phenotype through activation of the
SHH-Gli signaling pathway.
#2888 Dopamine signaling and therapeutic resistance in GBM. Seamus P.
Caragher, Cheol H. Park, Fatemeh Atashi, Shivani Baisiwala, Atique U. Ahmed.
Northwestern University, Chicago, IL.
Glioblastoma multiforme (GBM), the most common and aggressive primary
brain tumor in adults, is characterized by aggressive recurrence after conven-
tional treatment, which include surgery followed by radiation and chemother-
apy. This recurrence reilies on GBM cells’ ability to promote therapeutic resis-
tance. The recently developed Cancer Stem Cell (CSC) hypothesis argues that
GBMs are driven by a rare subset of cells called Glioma Stem Cells (GSCs). A
signifıcant corollary of the CSC hypothesis is that GSCs have the ability to sur-
vive intensive radio- and chemotherapy and give rise to recurrent disease. Re-
cent studies from our laboratory and others have shown a high degree of plas-
ticity in GBM cells that indicated normal GBM cells acquire a stem-like state
during anti-glioma therapy. Termed conversion, this molecular process in-
creases the frequency of therapy resistant GSCs and promotes disease recur-
rence. We hypothesize that a drug capable of blocking tumor cell plasticity
would prevent the generation of therapy-resistant GSCs, thereby block GBM
recurrence. Based on this concept, we have developed a plasticity-based high-
throughput drug screening method for GSCs. Our initial screening has identi-
fıed several novel FDA-approved compounds that act as antagonists of neu-
rotransmitter receptors. Further investigation revealed that treatment of
patient-derived xenograft (PDX) GBM lines with temozolomide (TMZ) led to
the formation of a population of cells that express both CD133, a marker of
CSCs, and dopamine receptors 2 and 3 (DRDs) (control mean CD133/
DRD2: 19.7%, TMZ mean: 83.8%, p.0001). PDX lines treated with a dopa-
mine receptor agonist exhibited increased expression of SOX2, OCT4 and c-
Myc, GSC-markers. However, this treatment did not increase the expression of
Ki67 in the GSC compartment, a marker for cell proliferation (mean DMSO:
63.8%, mean TMZ: 57.4%). Thus, DRD signaling may influence the plasticity
driven GSC niche. Utilizing a CD133-reporter cell line, we found that two anti-
psychotics, chlorprothioxene and loxapine, prevented the induction of CD133
expression caused by treatment with TMZ. Finally, we treated PDX lines with
chlorpromazine, a newer version chlorprothioxene, in conjunction with TMZ,
which resulted in increased therapeutic effecacy (p.0001 byMTTassay).Over-
all, these data suggest that dopamine receptor signaling and stress-induced cel-
lular plasticity interact in GBM. We proposed that dopamine receptors repre-
sent a strategy by which specifıc molecular changes induces by canonical
chemotherapeutic agents can be inhibited to prevent the induction of resistance
in surviving cells.
#2889 V-ATPase control of EV signaling in glioma stem cells. Irene Ber-
tolini,1 Andrea Terrasi,1 Andrea Di Cristofori,1 Silvano Bosari,2 Valentina
Vaira3. 1University ofMilan,Milan, Italy; 2University ofMilan&Fondazione Ca’
Granda, Milan, Italy; 3University of Milan & Fondazione INGM, Milan, Italy.
Background: Recent evidences highlighted that GBM secreted microvesicles
(EVs), particularly exosomes (Exo) and large oncosomes (LO), play amajor role in
the cross-talk between tumor cell and non-neoplastic parenchyma. How GBMs
manage to thrive in a highly unfavorable, acidic microenvironment is still unclear,
but recent work from our group has identifıed the vacuolar pump H-ATPase
(V-ATPase) as an important effector of GBM growth and glioma stem cells (GSC)
maintenance. Additionally, in ExoCarta database V-ATPase subunits have been
described inExo fromdifferent cancer cell types. Taken together, these data identify
V-ATPase as an important driver of gliomagenesis, and a novel, actionable thera-
peutic target for disease intervention.However, the role ofV-ATPase in reprogram-
ming the GBMmicroenvironment has not been previously investigated. Methods:
ExoandLOwere isolatedbyan Invitrogenkit and serial centrifugation, respectively,
frommediaofpatients’ derivedGBMneurospheres, enriched inGSC(NS,n12)or
differentiated cultures (n8). For EVs internalization studies, Exo or LO were
stained using FM 1-43 FX dye and the process was followed live for 30’ and at
selected time points (30’-4h-24h), using a confocal microscopy or flow cytometry
(FACS). Electron microscopy, FACS (of Exo stained with CellTrace and SytoRNA
in combination with CD63 coated beads), Nanosight and immunoblotting (for
CD63, CD9 and Clathrin) analyses were used to confırm EVs subtypes. Cultures
from patients’ derived brain tumor margins or primary GBM (differentiated and
not) were used as EVs-recipient cells. miRNA profıling was performed using Taq-
man Low density arrays and analyzed by R packages. Gene Ontology analysis
was performed by DAVID. The study was approved by the Institutional Ethical
Committee. Results: NS are able to produce different EVs, which are internal-
ized by recipient cells after 4 and up to 24 hours of co-culture. Both Exo than LO
from NS are able to signifıcantly increase cell growth in recipient cells (brain
tumor margins and primary GMB differentiated monolayers), and this effect is
stronger with EVs produced by NS with higher V-ATPase expression (V-AT-
PaseHIGH NS). Primary GBM cells after co-culture with EVs are able to produce
a higher number of NS and V-ATPase activity block by BafılomycinA1 in NS-
producing EVs completely revert this effect. Finally, the co-culture of V-AT-
PaseLOW NS with EVs from V-ATPaseHIGH NS increases their motility in colla-
genmatrixes. Atmolecular level, profıling of Exo-derivedmiRNAsdistinguishes
differentiated cultures from NS and, among NS, V-ATPaseHIGH cultures. In
silico analysis and annotation of miRNA target genes from V-ATPaseHIGH–
derived Exo showed an enrichment of cancer, cell cycle and PI3K/Akt pathways.
Conclusions: Altogether, these data point toward the central role of different EV
types in GBM communication and suggest a role of the V-ATPase proton pump
in regulating EV’s contents.
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#2890 MicroRNA-mediated upregulation of theWNT signaling activities
in human breast cancer stem cells. Yohei Shimono,1 Taichi Isobe,3 Andrei
Turtoi,2 Junko Mukohyama,1 Toru Mukohara,1 Akira Suzuki,1 Vincent Cas-
tronovo,2 Hironobu Minami1. 1Kobe University, Kobe, Japan; 2University of
Liege, Liege, Belgium; 3Stanford University, Stanford, CA.
The canonicalWNT signaling plays a critical role in many adult stem cells,
including those of the breast and intestine. The fact that the canonical WNT
signaling is implicated in both stem cell self-renewal and cancer suggests that
normal physiological regulator of stem cell functions might be “hijacked” in
cancer. Adenomatous polyposis coli (APC) is a component of the destruc-
tion complex that destabilizes -catenin and suppresses the activity of the
canonical WNT signaling. MicroRNAs (miRNAs) are important regulators
of stem cell functions. We have previously reported a set of 37 miRNAs that
are upregulated or downregulated in human breast cancer stem cells (BCSCs,
a CD44CD24/lowlineage population of human breast cancer cells) as com-
pared to non-tumorigenic breast cancer cells (NTCs). Among them, miR-200c
targets BMI1 that is a critical regulator of the stem cell maintenance, and
strongly impairs the functions of human BCSCs in vivo. In this study, we com-
pared the expression profıles of miRNAs, mRNAs and proteins between BCSCs
and NTCs isolated from the patient specimens of human breast cancers and
patient-derived tumor xenografts (PDXs) established by their transplantation.
Luciferase assays were performed using the plasmid in which the 3’UTR region
of candidatemRNAwas cloned downstream of a luciferaseminigene. The effect
ofmiRNAs on the activity ofWNT signalingwas evaluated using a TCF reporter
plasmid. Finally, the abilities to form organoids and to form tumors in immu-
nodefıcient mice were evaluated using the human BCSCs infected with the
miRNA inhibitor expressing lentivirus. We found that miR-142 was highly up-
regulated in BCSCs, but was hardly expressed in NTCs in the patient breast
cancer specimens.We confırmed thatmiR-142 targeted the sequence within the
3’UTR of APC mRNA and suppressed APC protein expression. Accordingly,
miR-142 activated the canonical WNT signaling pathway in an APC-suppres-
sion dependent manner. The results of mRNA and protein expression profıling
of the BCSCs isolated fromhumanbreast cancer PDXs suggested that the canonical
WNTsignalingwas activated inBCSCs. Finally, inhibitionofmiR-142 in theBCSCs
suppressed the tumor growth in vivo. These results suggest that the miR-142, a
miRNAfrequently upregulated inhumanBCSCs, couldprovide at least a part of the
molecular mechanism for aberrant activation of the canonical WNT signaling in
breast cancer in which APCmutations are much less frequent than colon cancer.
#2891 Retinoic acid directs breast cancer cell state changes through regu-
lation of TET2-aPKC pathway.Meng-JuWu, Chun-Ju Chang. Purdue Univer-
sity, West Lafayette, IN.
The key molecular mechanism governing the cancer cell state (stem cell-like
state vs. differentiation state) to control the cancer stem cell (CSC) pool remains
elusive. This study provides the fırst evidence showing that all-trans retinoic acid
(ATRA) induces the interaction and chromatin recruitment of a novel RARB-
TET2 complex to epigenetically activate a specifıc cohort of gene targets, includ-
ingMiR-200c. TET2-activatedmiR-200c further targets and suppresses aPKC, a
cell polarity protein that plays a pivotal role in directing asymmetric division of
mammalian stem cells to sustain the stem cell pool. Our data reveals that phar-
macological concentration of ATRA effectively down-regulates aPKC through
activation of miR-200c, leading to a decrease of the stem cell-like populations
fromnon-tumorigenicmammary epithelial cells and non-aggressive breast can-
cer cells. However, aggressive breast cancer cells that manifest TET2-miR200c
dysregulation sustain a CSC pool highly resistant to ATRA, where inhibition of
aPKC directs the resistant CSCs to the luminal cell-like state and sensitization to
Tamoxifen, resulting in abrogation of mammary tumor growth and progres-
sion. Together, these fındings elucidate a novel RARB-TET2-miR200c-aPKC
signaling pathway that directs cancer cell state changes and also provide previ-
ously unidentifıed therapeutic implications for aPKC inhibitors in diminish-
ment of breast CSCs to eradicate breast cancer.
#2892 OncostatinMelicits cellular plasticity through cooperative STAT3-
SMAD3 signaling. Benjamin L. Bryson, Damian J. Junk, Jacob Smigiel, Neetha
Parameswaran,Mary R. Doherty, Courtney A. Bartel,Mark Jackson.CaseWest-
ern Reserve University, Cleveland, OH.
Increasing evidence suggests that tumor cell plasticity promotes metastasis
and tumor recurrence, resulting in cancer patientmortality.While it is clear that
the tumor microenvironment (TME) contributes to tumor cell plasticity, the
specifıc TME factors that actively generate tumor cell plasticity are largely un-
known. Here, we identify TME cytokines that promote epithelial-mesenchymal
plasticity, and acquisition of cancer stem-cell (CSC) properties. A screen of 27
TME cytokines identifıed multiple Interleukin-6 family members as inducers of
mesenchymal/CSC properties, with Oncostatin M (OSM) being the most po-
tent. Importantly, OSM induced plasticity was mediated by STAT3, but also
dependent on TGF- signaling and downstream SMAD3. Inhibition of func-
tional TGF-/SMAD signaling by expressing a dominant-negative TGF- re-
ceptor, treatingwith aTGF- receptor inhibitor, or suppressing SMAD3expres-
sion using a SMAD3-shRNA prevented the OSM-induced mesenchymal/CSC
properties. OSM-activated STAT3 binds to SMAD3 and promotes SMAD3 nu-
clear localization and binding to the SNAIL promoter, increasing transcription
of the SNAIL gene. The epithelial-mesenchymal transition induced by the
STAT3/SMAD3 axis results in a highly invasive and metastatic phenotype and
the emergence of CSC properties, including therapeutic resistance. Importantly,
maintenance of the OSM-induced mesenchymal/CSC state requires sustained
exposure to the cytokine, as removal of OSM results in a marked phenotypic
reversion. A high-throughput screen for small molecule inhibitors of the OSM-
induced mesenchymal/CSC phenotype has been performed and are currently
being confırmed.Wepropose that, targeted blockade of the STAT3/SMAD3axis
in tumor cells may represent a novel therapeutic approach to prevent the plas-
ticity associated with metastasis and tumor recurrence.
#2893 IGF2 is essential for tumor initiating cell activity in human colo-
rectal cancer. Taronish D. Dubash,1 Christine Siegl,1 Sebastian M. Dieter,1
JoachimWeischenfeldt,2 Alexandros P. Drainas,2 Laura Schwarzmueller,1 Mal-
gorzata Oles,2 Balca Mardin,2 Mikolaj Slabicki,1 HuberWolfgang,2 Martin Sch-
neider,3 Jan Korbel,2 Hanno Glimm,1 Claudia R. Ball1. 1National Ctr. for Tumor
Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Ger-
many; 2European Molecular Biology Laboratory (EMBL), Heidelberg, Germany;
3Heidelberg University Hospital, Heidelberg, Germany.
A small fraction of all cells within individual tumours from colorectal cancer
(CRC) patients drives long term tumor growth and metastases in immune-
compromised mice. Targeting these tumor-initiating cells (TIC) may improve
the long-term outcome in advanced CRC. To identify candidate genes which
drive proliferation and survival of TIC, we have performed a large scale high
throughput loss of function shRNA screen in three-dimensional TIC enriched
patient spheroids. Spheroids were transduced with the barcoded Cellecta deci-
pher library comprising 27,500 shRNAs targeting 5043 genes associatedwith cell
signaling pathways (Module 1). Two weeks later, cells were harvested for DNA
isolation, barcode amplifıcation and high-throughput barcode sequencing.
Amongst others, we found 5/6 shRNAs targeting Insulin growth factor 2 (IGF2)
scoring within a 20% depletion threshold, presenting depletion levels very sim-
ilar to positive control shRNAs. mRNA expression profıling and qPCR analyses
demonstrated low to moderate expression of the IGF2 gene product in the ma-
jority of patient spheroid cultures analyzed (n17). In contrast, two out of 15
patient derived spheroid cultures analyzed demonstrated very pronounced
IGF2 overexpression (250 fold). Integrative SCNA profıling, expression and
TADprofıling using the CESAMalgorithm, followed by 4C Seq, demonstrated a
tandem duplication of the IGF2 locus in these two patients which interrupts a
IGF2 adjacent TAD boundary and results in de novo contact domain formation
between the IGF2 promoter and a normally hidden distant super-enhancer. A
dual luciferase reporter assay revealed that the hijacked enhancer is functionally
active in human CRC cells and thereby may drive unphysiological IGF2 expres-
sion following enhancer hijacking. To assess the functional relevance of IGF2
tandem duplications, spheroids were transduced with RFP expressing lentiviral
vectors encoding for 3 shRNAs targeting IGF2 as well as control shRNAs target-
ing EIF3A or scrambled shRNA. Strikingly, IGF2 knockdown led to a marked
reduction of RFP cells in competitive proliferation assays and markedly re-
duced viability assessed by ATPlight assay. Moreover, IGF2 knockdown
strongly reduced tumor formation following xenotransplantation into immune
defıcient NSG mice. These data demonstrate that IGF2 is required for survival,
proliferation and tumor-initiation of primary human TIC enriched spheroids.
Notably, oncogenicmiRNA-483 is encodedwithin intron 8 of IGF2, however, its
function in IGF2 locus tandem duplicated cells remains elusive. Understanding
themechanisms of IGF2 dependency and the role of miRNA-483 in this context
will be essential for the future development of therapeutic approaches targeting
IGF2 expression in this patient subset harbouring tandem-duplications of the
IGF2 locus.
#2894 Epinephrine-induced gamma-secretase/Notch signaling in pancre-
atic cancer stem cells. Xuemin Xu, Chen Hu, Hildegard M. Schuller. Univ. of
Tennessee, Knoxville, TN.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of
cancer deaths with 5-year survivals below 10%. Cancer stem cells represent a
small population of cells in PDAC and are thought to drive the development,
progression, metastasis and drug resistance of this cancer. The Notch pathway
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regulates the self-renewal of pancreatic cancer stem cells as well as angiogenesis
and drug resistance. Gamma-secretase cleaves theNotch-1 receptor, resulting in
release of the Notch intracellular domain (NICD) that then translocates to the
nucleus and activates the transcription of target genes. AberrantNotch signaling
activated by-secretase activity is associatedwith progression, angiogenesis and
drug resistance of PDAC and is being explored as a target for PDAC therapy.
Smoking and psychological stress are risk factors for PDAC. However, the po-
tential modulation of -secretase/Notch by these risk factors has not been inves-
tigated to date. Nicotine and psychological stress both cause hyperactivity of the
sympathetic nervous system and adrenal glands, resulting in increased blood
and organ levels of the stress neurotransmitters norepinephrine (NOR) and
epinephrine (EPI), which are the physiological agonists of beta-adrenergic re-
ceptors (-ARs). In turn, -ARs are coupled to the stimulatory G-protein Gs
that stimulates the formation of intracellular cAMP, which activates multiple
signaling pathways in a cell type-specifıc manner. Using spheroid formation
assays and Western blotting, our data show, -for the fırst time,- that the stress
neurotransmitter Epi signifıcantly increases the self-renewal of pancreatic can-
cer stem cells by increasing the expression of the activated forms (c-terminal) of
the -secretase component presenilin1 and of Notch1 (NICD). These responses
were inhibited by the -AR antagonist (beta-blocker) propranolol and by the
inhibitory neurotransmitter -aminobutyric acid (GABA) that inhibits cAMP
formation via activation of Gi-coupled GABAB receptors. These fındings sug-
gest that the -sexretasesecretase/Notch pathway in pancreatic cancer stem cells
is under regulatory control by neurotransmitters, with Epi as stimulator and
GABA as inhibitor. These data could open up new avenues for the prevention
and therapy of PDAC. Additional experiments are currently underway to fur-
ther investigate mechanistic aspects of this novel concept. Supported by
RO1CA042829 with NIH.
#2895 Octamer-4/microRNA-1246 signaling axis drives Wnt/-catenin
activation in liver cancer stem cells. Stella Chai,1 Kai-Yu Ng,1 Man Tong,1
Eunice Y. Lau,2 Terence K. Lee,2 Kwok Wah Chan,1 Yun Fei Yuan,3 Tan To
Cheung,1 Siu Tim Cheung,4 Xiao Qi Wang,1 Nathalie Wong,4 Chung Mau Lo,1
KwanMan,1 Xin Yuan Guan,1 Stephanie K. Ma1. 1The University of Hong Kong,
Pokfulam, Hong Kong; 2The Hong Kong Polytechnic University, Hong Kong,
Hong Kong; 3Sun Yat-Sen University Cancer Center, Guangzhou, China; 4The
Chinese University of Hong Kong, Hong Kong, Hong Kong.
Hepatocellular carcinoma (HCC), the main type of liver cancer in human, is
one of the most prevalent and deadly malignancies in the world. Despite ad-
vances in therapy, prognosis remains dismal, largely attributed by our limited
understanding on information related to the progressive development of the
disease, particularly in their cancer-initiating and stemcell-like properties.Wnt/
-catenin signaling is activated in CD133 liver cancer stem cells (CSC), a subset
of cells known to be a root of tumor recurrence and therapy resistance in HCC.
However, the regulatory mechanism of this pathway in CSCs remains unclear.
Here, we show that human miRNA, miR-1246, promotes cancer stemness in-
cluding self-renewal, drug resistance, tumorigencity and metastasis by activa-
tion of Wnt/-catenin pathway via suppressing the expression of AXIN2 and
GSK3, two key members of the -catenin destruction complex. This observa-
tion was validated by both in vitro and in vivo functional / cell biological studies
on HCC cell lines with or without miR-1246 expression modulated by lentiviral
based knockdown and overexpression strategies as well as in miR-1246 re-
pressed HCC cells with concomitant expression of wild-type or constitutively
active -catenin. Clinically, high endogenous and circulating miR-1246 was
identifıed in HCC clinical samples and correlated with a worse prognosis. Fur-
ther functional analysis identifıed Oct4 to be the direct upstream regulator of
miR-1246, which cooperatively drive-catenin activation in liver CSCs. In con-
clusion, our fındings not only uncover the non-canonical regulation of Wnt/-
catenin in liver CSCs by Oct4/miR-1246 signaling axis, but also provide a novel
diagnostic marker as well as therapeutic intervention for HCC.
#2896 STAT1 dependent interferon-related DNA damage resistance sig-
nature (IRDS) as a survival mechanism in castrate resistant prostate cancer
(CRPC). Supreet Agarwal, Kerry McGowen, Keith Jansson, Mike Beshiri, Fathi
Elloumi, Maggie Cam, Kathy Kelly. NCI, Bethesda, MD.
Using the organoid culture system and aggressive Pten/Tp53-null mouse
model (GEMM), we have previously shown that the prostate cancer cell popu-
lation harbors two classes of self-renewing luminal progenitors which are resis-
tant to in vivo castration and to androgen receptor (AR) inhibitors (enzalut-
amide) ex vivo. Understanding signaling pathways governing intrinsic survival/
self-renewal ability of luminal progenitors in castrate conditions can highlight
pathways that play a role in acquired drug resistance. To identifymechanisms of
castration resistance in luminal progenitors, we performed RNAseq analysis of
luminal progenitor organoids derived fromwild-type(WT) and Pten/Tp53-null
mice (intact and castrated (two weeks), n5; each). Gene enrichment analysis
identifıed key signaling pathways altered in luminal tumor organoids (AR sig-
naling, lipid metabolism, protein secretion, inflammation etc.) that have also
been described for FACS-purifıed human prostate luminal (CD49flo) fraction.
Interestingly, we found no difference in transcriptional profıles of intact and
castrated tumor organoids, suggesting intrinsic survival ability of luminal pro-
genitors upon castration. Of note, we observed most signifıcant enrichment of
STAT1-dependent IRDS in luminal progenitor tumor organoids relative to wild
type luminal organoids. IRDS comprises of a subset of STAT1-driven genes that
have been previously associated with survival of cancer cells and with breast
cancer therapy resistance. Our analysis of human prostate cancer datasets re-
vealed IRDS as a prognostic marker for progression in the TCGA primary pros-
tate cancer cohort (p0.05). Further, high IRDS-expressing CRPC samples
(SU2C dataset) were enriched for low AR signaling (r0.33, p0.05). CRPC
patients in IRDS-hi cohort showed enrichment for cancer stem cell phenotype
and for genes associated with drug resistance, Consistent with the bioinformat-
ics analysis real time PCR, immunofluorescence and western blot analysis of
ex-vivo organoid cultures of castration-resistant Pten/Tp53-null tumor or-
ganoids showed higher protein expression of STAT1 and IRDS genes in luminal
tumor organoids relative to luminal WT organoids. In vivo, castrated prostate
tumors showed higher STAT1 levels than the intact tumors. Treatment with
enzalutamide of luminal tumor organoids resulted in time dependent increase
in STAT1 expression. STAT1 KD in tumor organoids decreased number of
progeny organoids in subsequent generations suggesting either a direct or indi-
rect effect upon self-renewal. Overall, our initial fındings suggest STAT1 depen-
dent signaling as a potential mechanism of androgen-independent survival in
prostate cancer.
#2897 Oncogenic Kras activation in gastric adenocarcinoma promotes
cancer stemcell phenotypes includingmetastasis&chemotherapy resistance.
Changhwan Yoon,1 Kevin K. Chang,1 Jacob Till,2 Sandra W. Ryeom,2 Sam S.
Yoon1. 1Memorial Sloan Kettering Cancer Center, New York, NY; 2Abramson
Family Cancer Research Institute, Philadelphia, PA.
INTRODUCTION: The Cancer Genome Atlas found that the receptor ty-
rosine kinase (RTK)-Ras signaling pathway is altered in half of gastric adeno-
carcinomas (GAs). We added oncogenic Kras to the Atp4b-Cre;Cdh1fl/fl;
Trp53fl/fl mouse model of GA and found accelerated tumorigenesis and
metastasis. We also found Kras activity to be higher in gastric cancer stem-like
cells (CSCs). Thus we hypothesized that Kras activty is critical for maintenance
of gastric CSCs and promotes CSC phenotypes. METHODS: Human and mu-
rine GA cell lines were examined. The effect of Kras pathway inhibition was
examined in GA spheroid cells and monolayer cells in various in vitro assays.
Kras activity and Kras pathway inhibition was examined in CSCs, primary tu-
mors and metastases in our GAmouse model. The combination of chemother-
apy andKras pathway inhibitionwas tested in humanGAxenografts. RESULTS:
Kras inhibition with shRNA orMEK inhibitor PD0325901 decreased the ability
of GA cells to form spheroids and deceased expression of the stem cell transcrip-
tion factor, Sox2. CD44() gastric CSCs had 65.8-75.4%highermigration, 64.2-
79.5% higher invasion, and 63.1-70.2% more anchorage-independent growth
compared to unselected cells. These properties could all blocked by 71.1-82.7%
with Kras shRNA or PD0325901. In our GAmouse model, PD0325901 starting
at 6 weeks of life increased median survival from 76 days to 95 days. Primary
tumors and metastases from these mice with and without treatment with MEK
inhibition are being analyzed for level of CD44CSCs, Kras activity, and extent of
metastases. Gastric CSCs were resistant to 5-fluorouracil and cisplatin chemo-
therapy, and this chemotherapy resistance could be reversed in human GA
xenografts transducing cells with Kras shRNA. CONCLUSION: Kras is more
active in gastric CSCs than non-CSCs and promotes malignant phenotypes in-
cluding metastasis and chemotherapy resistance. Kras pathway inhibition can
block these CSC phenotypes, and thusmay prove useful in various combination
therapies.
#2898 ST8SIA1 is up-regulated in triple negative breast cancer and its
expression is positively correlated with TP53 mutations and a cancer stem
cell gene signature.V. Lokesh Battula, Yuanqing Yan, Khoa Nguyen, Kim-Anh
Do, Michael Andreeff. UTMD Anderson Cancer Ctr., Houston, TX.
We discovered ganglioside GD2 as a breast cancer stem cell (BCSCs) marker
in triple negative breast cancer (TNBC). GD2 biosynthesis is tightly regulated by
the enzyme ST8SIA1 (GD3 synthase). However, expression of ST8SIA and its
association with different breast cancer sub-types is not known. Here we hy-
pothesize that ST8SIA1 is up-regulated in TNBC or “basal-type” breast tumors
and associated with stemness in primary breast tumors. To investigate ST8SIA1
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expression in primary tumors, we analyzed RNAseq data from the cancer ge-
nome atlas (TCGA) data base, which includes data from 1105 primary and
metastatic breast tumors as well as adjacent normal tissues. We found that
ST8SIA1 expression varied widely among different breast tumors. Interestingly,
“basal-type” tumors expressed the highest levels of ST8SIA1 compared to all
other types of breast cancers including luminal-A or luminal-B or HER2-en-
riched tumors (p  0.01). In addition, TNBC (n  115) expressed 4.6-fold
higher ST8SIA1 levels compared to hormone receptors positive tumors includ-
ing ER or PR or HER2 tumors (n  852, p0.001). Survival analysis by
log-rank test indicated that patients with ST8SIA1high tumors survive shorter
(median survival 2.6 years) compared to patients with ST8SIA1low tumors (me-
dian survival 4.3 years). Next, we investigates the association between
ST8SIA1expression and the most commonly mutated genes in breast cancer.
We chose the top 20 most frequently mutated genes in TCGA dataset and ex-
amined their correlation with ST8SIA1 mRNA expression. We found that,
among the top 20 mutations, TP53 had a very strong positive correlation with
ST8SIA1 expression (p  0.00001). In fact, the expression of ST8SIA1 was 
2-fold higher in TP53-mutated compared to wild type tumors. The other posi-
tively correlated mutation was a nuclear envelop protein called the spectrin
repeat containing protein (nuclear envelope 1 or SYNE1; p 0.05). Mutations
in GATA3 were the most negatively correlated (p  0.001) with ST8SIA1 ex-
pression. Interestingly, GATA3 plays a role in epithelial cell differentiation in
the mammary gland, supporting the notion that ST8SIA1 is a stem cell-associ-
ated gene. In addition, correlation of ST8SIA1 mRNA expression with other
genes revealed that FOXA1, the protein which is co-expressed with GATA3 and
serves as negative predictor of “basal-type” of breast cancer, was down regulated
in ST8SIA1high tumors. In conclusion, ST8SIA1 is associated with “basal-type”
TNBC tumors and it has a strong positive correlation with TP53 mutations and
negative correlation with GATA3 mutations. Knowing that TP53 mutations
have a major role in tumorigenesis and drug resistance, these data suggest that
ST8SIA1 could be a potential therapeutic target in patients with TP53-mutant
TNBC.
#2899 Hypoxia-inducible factor 1-maintains sarcoma stem-like cells in
hypoxic regions of tumors and promotesmigration and invasion via upregu-
lation of platelet-derived growth factor receptors. Kevin K. Chang, Changh-
wan Yoon, Sam S. Yoon. Memorial Sloan Kettering Cancer Center, New York,
NY.
Introduction: Sarcomas often thrive in hypoxic conditions to proliferate
and metastasize. To survive in such an environment, sarcomas upregulate
hypoxia inducible factor-1 (HIF-1), which enhances the transcription of
over 150 genes mediating tumor metabolism, angiogenesis, and metastasis.
HIF-1 may be important for the maintenance of a subset of tumor cells
referred to as “sarcoma stem-like cells” or SSCs. Platelet-derived growth
factor receptor (PDGFR) is important in mesenchymal biology and may be a
potential target of HIF-1. Methods: Three human sarcoma cell lines were
examined: HT1080 (fıbrosarcoma), SK-LMS-1 (leiomyosarcoma), and
DDLS8817 (dedifferentiated liposarcoma). Cell lines were grown as spher-
oids on ultra-low attachment dishes to enrich for SSCs. The roles of HIF-1
and PDGFR-/ in promoting SSC phenotypes, such as migratory/invasive
capacity, were assessed via several in vitro assays under hypoxic conditions.
Results: Sarcoma cell lines grown as spheroids had increased levels of
HIF-1 and increased phosphorylation of PDGFR-/ as compared to when
grown as monolayers; these effects were even more pronounced when sar-
coma spheroids were grown under hypoxic conditions. Hypoxic conditions
also increased migratory and invasive capacity in spheroid cells by 65-73% as
compared to normoxic conditions. HIF-1 knockdown using shRNA in the
three cell lines decreased expression of self-renewal proteins and decreased
spheroid formation by 67-80%. HIF-1 knockdown decreased expression of
epithelial-mesenchymal transition (EMT) transcription factors and reduced
migratory and invasive capacity by 80-87% under normoxic conditions and
85-87% under hypoxic conditions. Phosphorylation of PDGFR-/ was de-
creased in sarcoma cell lines following HIF-1 knockdown under normoxic
and hypoxic conditions. PDGFR-/ inhibition with imatinib reversed che-
motherapy resistance in normally resistant SSCs, and treatment of HT1080
xenografts with doxorubicin chemotherapy and imatinib reduced tumor for-
mation by 85% as compared to control and by 77% as compared to chemo-
therapy alone. Conclusions: The HIF-1/PDGFR axis supports the mainte-
nance of SSCs, especially under hypoxic conditions, and promotes SSC
phenotypes such as migratory/invasive capacity and chemotherapy resis-
tance. Combining chemotherapy with PDGFR-/ inhibition may be a
promising strategy to reverse chemotherapy resistance and prevent metas-
tasis in sarcomas.
#2900 Sigma-1 receptor control tumorigenic and stem cell-like phenotype
in human cancers. Gianluca Civenni,1 Martina Marchetti,1 Shusil Pandit,1 Ce-
leste De Monte,1 Federica Sereni,1 Jessica Merulla,1 Sabrina Zadic,1 Marco
Losa,1 Sara Allegrini,1 Domenico Albino,1 Sarah Mapelli,1 Erik Laurini,2 Bern-
hard Wunsch,3 Sabrina Pricl,2 Giuseppina M. Carbone,1 Carlo V. Catapano1.
1Institute of Oncology Research, Bellinzona, Switzerland; 2University of Trieste,
Trieste, Italy; 3University of Münster, Munster, Germany.
Tumor-initiating stem-like cancer cells drive tumor progression, metastasis
and treatment failure. Understanding the pathways driving self-renewal and
expansion of cancer stem-like cells (CSCs) in human cancers may provide ac-
tionable therapeutic targets for developing novel treatment strategies.Metabolic
reprogramming andmitochondrial homeostasis are emerging as key features of
CSCs. The sigma-1 receptor (Sig-1R) is a ligand-activated chaperone protein
localized at the ER-mitochondria membrane and involved in inter-organelle
signaling, mitochondrial homeostasis and stress response. Sig-1R is up-regu-
lated in many human cancers, although its role in tumorigenesis is unclear.
Here, we examined the role of Sig-1R on survival and expansion of cancer cells
with stem-like properties using genetic knockdown and selective pharmacolog-
ical antagonists. Transient and stable depletion of Sig-1R using small interfering
RNAs (siRNAs) and short hairpin RNAs (shRNAs), respectively, affected clono-
genic and tumor-sphere forming capability of prostate cancer cell lines. Cell
proliferation and viability under standard culture conditions were minimally
affected. Selective high affınity Sig-1R antagonists also suppressed clonogenicity
and tumor-sphere formation, reproducing the effects of genetic depletion. No-
tably, stable Sig-1R knockdown with shRNAs drastically reduced development
of tumor xenografts in mice, indicating a reversal of tumorigenic and stem-like
properties upon depletion of Sig-1R. Sig-1R knockdown impaired mitochon-
drial functionwith reducedmitochondrialmembrane potential (flow cytometry
JC-1 assay) and respiratory capacity (Seahorse Mito Stress assay). These effects
were more evident under metabolic stress induced by glucose starvation and
were associated with drastic changes in morphology and intracellular distribu-
tion of mitochondria. Similar metabolic effects were seen with selective Sig-1R
antagonists. These fındings indicate that Sig-1R sustains tumorigenic properties
by enhancing mitochondrial homeostasis and metabolic adaptability of stem-
like cancer cells ensuring their long-term survival and self-renewal capability.
Targeting the Sig-1Rwith selective antagonists could be an innovative approach
to cancer treatment capable of preventing survival and expansion of tumor-
initiating stem-like cancer cells in human cancers.
#2901 Wnt/p53 regulate stemness of mucoepidermoid carcinoma cells in
vitro.Christie Rodriguez-Ramirez, April Andrews, ShaomengWang, Jacques E.
Nor. University of Michigan-Ann Arbor, Ann Arbor, MI.
Mucoepidermoid carcinoma (MEC) is the most common malignant sali-
vary gland cancer, yet very little is known about the pathobiology of this
disease. As a result, no mechanism-based therapies have been developed for
the treatment ofMEC. Little to no response has been observed with the use of
conventional chemotherapies. Consequently, standard of care is limited to
surgery and/or radiation therapy, resulting in high patient morbidity. Work
done by our group showed that cancer stem cells (CSCs), identifıed by
ALDHhighCD44high cells, are drivers of MEC tumorigenesis. MI-773 is an
inhibitor of the MDM2/p53 protein-protein interaction that results in p53
accumulation and activation of p53-mediated signaling. Our group found
that treatment of MEC cell lines (UM-HMC-1, UM-HMC-3A, UM-HMC-
3B) with sub-lethal doses of MI-773 signifıcantly decreases the CSC popula-
tion in vitro and in xenograph tumors. Moreover, recent studies have impli-
cated p53-regulated mi-RNAs in the transcriptional regulation of several
components of the Wnt/beta-Catenin pathway. We hypothesize that the
canonical Wnt and p53 pathways crosstalk to regulate MEC stem cell main-
tenance. To address this hypothesis, we isolated or measured the fraction of
the CSCs via flow cytometry, conducted sphere assays that measure survival/
self-renewal of CSCs, and used western blots for cell signaling studies. We
found that Wnt1, active beta-Catenin, and p53 protein levels are higher in
CSCs than the non-CSCs in MEC cell lines. Moreover, we found that MI-773
reduces the expression of keyWnt pathway proteins, such asWnt1 while also
decreasing the number of spheres formed by MEC cells. Opposite results are
observed when p53 is silenced. Notably, inhibiting the beta-Catenin pathway
with PNU74654 or JW67 also decreases the fraction of CSCs and inhibits
sphere formation. Collectively, these results indicate that both the Wnt and
p53 pathways are important forMEC stem cell maintenance. Revealing path-
ways important for MEC stem cell maintenance will help identify effective
mechanism-based therapies to sensitize MEC to conventional chemothera-
pies. This work was funded by grants R01-DE21139 and R01-DE23220 from
the NIH/NIDCR.
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#2902 Epithelial-type CD133 stem-like lung cancer cells emerge higher
drug resistance through MDFIC-mediated Wnt/-catenin signaling path-
way. Chao-Ju Chen,1 Chih-Jen Yang,1 Ming-Shyang Huang,1 Yu-Peng Liu2.
1Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 2Kaohsiung Med-
ical University, Kaohsiung, Taiwan.
Background: The epithelial-to-mesenchymal transition (EMT) has been
described to promote drug resistance and cancer stem cell (CSC) properties.
Many studies demonstrated that a major proportion of circulating tumor cell
(CTC) exhibits EMT and CSC characteristics. A recent fınding revealed the
presence of epithelial type (EpCAM) CTC was associated with poor out-
come, whereas the mesenchymal type (EpCAM-) CTC were not. We there-
fore hypothesize that the epithelial-type CSC may exhibit higher drug resis-
tant ability. Methods: We isolated epithelial type (E) and mesenchymal
type (E-) CD133 cells and CD133- cells from PC14 lung cancer cell line by
fluorescence assisted cell sorting. We used western blot, QPCR, immunoflu-
orescence, sphere formation assay and tumor xenograft assay to characterize
the 4 subpopulations. The drug resistant ability was determined by cell via-
bility assay and in vivo drug response assays. The drug resistant signature
was identifıed by comparing the gene expression profıle from four subpopu-
lations and Gene Expression Omnibus (GEO) database. Knockdown and
overexpression of MDFIC in PC14 subpopulations were established by using
lentivirus vectors. Immunoprecipitation and subcellular fractionation were
performed for drug resistant mechanism investigation. Results: The epithe-
lial type PC14 CD133 cells (E/CD133 subpopulation) exhibited higher
sphere formation ability and was more resistant to the treatment of chemo-
therapy agents compared to the mesenchymal type CD133 cells
(E-CD133 subpopulation) in vitro and in vivo. Gene expression profıling
showed 86 genes were bioinformatically predicted as drug resistant signature
and were correlated with the disease free survival of the patients with lung can-
cer. Among these genes, themRNA level of 20 genes were signifıcantly related to
the patient’s prognosis in theGSE31210 dataset.Human I-mfa domain-contain-
ing protein (MDFIC) was highly expressed in E/CD133 subpopulation.
Knockdown and overexpression ofMDFICmodulates drug resistance ability in
cancer cells. MDFIC increased the level of free -catenin through binding and
stabilizing the axin-GSK3---catenin destruction complex and increased the
transcriptional activity of Wnt/-catenin signaling. Conclusion: The epithelial-
typeCD133 stem-like lung cancer cells aremore resistant to the chemotherapy
through MDFIC-mediated Wnt/-catenin signaling activation.
#2903 1-Methoxyphaseollidin:Novel gamma secretase inhibitor targeting
notch-1 signaling in breast cancer stem cells. Venkatesh Kolluru,1 Deeksha
Pal,1 Becca Baby,1 Houda Alatassi,1 Arun Kumar Sharma,2 Murali Ankem,1
Chendil Damodaran1. 1University of Louisville, Louisville, KY; 2Pennsylvania
State University, Hershey, PA.
We recently showed that twodifferentALDH andCD44/CD24/low breast
cancer stem cells (BSCSs) exhibited stem cell characteristics that include self-
renewal, extensive proliferation, the ability to formnon-adherent spherical clus-
ters, chemotherapy resistance and highNotch1 expression.We have identifıed a
compound compound: 6-(3-methylbut-2-enyl) coumestrol (Pso) and treatment
with Pso resulted in growth inhibition and an EMT phenotype in both BCSCs
and BC cells. Oral Pso administration at physiologically achievable doses (25
mg/kg/BW) suppressed the growth of BCSCs and BC xenografts without toxic-
ity. In the current studies, we identifıed several novel Pso-derived analogs that
may be more potent than the parent compound. One such compound, 1-me-
thoxyphaseollidin (1MP), obtained via three main functional group changes: (i)
translocation of the isoprenyl moiety from the phenyl ring fused to the pyran
ring (as in Pso) to the phenyl ring adjacent to the furan ring, (ii) removal of the
carbonyl group from the pyran ring, and (iii) introduction of amethoxy group at
the 1-position, inhibited Notch1 activity and growth of both BSCS and BC cells
at nM concentration (IC50: 300nM), which is 100 times more potently than Pso
in cell culture models. Molecular studies suggest that 1MP inhibits Notch sig-
naling pathways (Hes1, Hey1 and Presenilin) in both BCSC and BC cells.
Further, downregulation of AKT signaling (pAKT (S473), p65 and BCl-2
were seen in 1MP treated cells. Docking studies suggest that 1MP binds
outside of the catalytic unit of -secretase and induces a conformational
change, resulting in Notch1 inhibition in both BCSCs and BC cells. More
importantly, administration of 1MP signifıcantly inhibited the growth of
BCSC and BC tumors without causing gastrointestinal toxicity in tumor-
bearing mice. H&E staining suggests that 1MP treated tumors show infıltrate
to margins are less as compared to vehicle treated mice’s. We believe target-
ing notch1 signaling and optimizing 1MP could be an effective therapeutic
strategy for treating breast cancer.
#2904 Targeting cancer stem-like cells in triple negative breast cancer cells
through non-canonical notch signaling. Fokhrul Hossain,1 Claudia Sorren-
tino,1 Ayse Bilyeu,1 Judy Crabtree,1 Antonio Pannuti,1 Todd Golde,2 Barbara
Osborne,3 Lucio Miele1. 1LSUHSC, New Orleans, LA; 2University of Florida, FL;
3UMass Amherst, MA.
Triple negative breast cancer (TNBC) is a heterogeneous group of clinically
aggressive diseases. TNBC patients have high risk of recurrence and metastasis,
and current treatment options remain limited. Cancer stem-like cells (CSCs)
have been linked to cancer initiation, progression and chemotherapy resistance.
Therefore CSC-targeted therapies are keenly sought. There is strong evidence
for the involvement of Notch signaling in TNBC. Notch1 is highly expressed in
Basal-like 1 (BL1) and especially Mesenchymal-Stem-Like (MSL) TNBCs. Ex-
pression of Notch1 and its ligand Jagged1 correlate with poor prognosis. More-
over, strong evidence supports key roles of different Notch paralogs in breast
CSCs. Here, we demonstrate that Notch1 promotes cell survival in MDA-MB-
231 cells, representative of MSL TNBC, in part by activating NF-B. Notch
activation by Jagged1-expressing stromal cells enhances transcription of the
anti-apoptotic gene cIAP-2 (BIRC3), a known NF-B target. This event is de-
pendent on recruitment to the cIAP-2 promoter of NF-B subunits, IKK and
Notch1. Short term exposure of MDA-MB-231 cells (MSL, PTEN wild-type),
but not MDA-MB-468 cells (BL1, PTEN-null) to recombinant Jagged1 leads to
AKT phosphorylation. This is suppressed by dual mTORC1/2 inhibitors, AKT
inhibitors and IKK inhibitors but not Everolimus (mTORC1-selective inhibi-
tor). These observations support a model where canonical and non-canonical
mechanisms downstream of Notch1 trigger AKT phosphorylation and NF-B
activation in PTEN wild type TNBC cells. Rapid AKT phosphorylation down-
streamofNotch1 requiresmTORC2, PI3K and IKK, and contributes toNF-B
activation. This suggests a bidirectional crosstalk between the IKK and AKT
arms of this Jagged1-activated pathway.We demonstrate that recombinant Jag-
ged1 increases the cellularmetabolism of TNBC cells and knockdown ofNotch1
or IKK by siRNA decreases mitochondrial respiration and glycolysis. We have
found that CSCs derived from MDA-MB-231 cells have increased Notch1, p-
AKT, and oxidative metabolism. AKT inhibition or IKK inhibition decreases
both mitochondrial respiration and glycolysis of TNBC derived CSCs. Pharma-
cological inhibition of Notch cleavage by gamma secretase inhibitor (PF-
03084014) in combination with AKT inhibitor (MK-2206) or NF-B inhibitor
(Bay11-7082) blocks CD90hi or CD44CD24low sorted secondary mammo-
spheres formation. These data suggest that combination treatments affecting
Notch, NF-kB and AKT pathways have potential therapeutic importance in
targeting CSCs of TNBC cases with wild type PTEN and high Notch1 expres-
sion.
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#2905 Clinical and genomic resistance to second generation androgen
blockade in paired biopsies of metastatic castration-resistant prostate can-
cer. G. Celine Han,1 Justin Hwang,1 Stephanie A. Mullane,1 Carrie Cibulskis,2
Zhenwei Zhang,1 Rana R. McKay,1 PCF-SU2C Dream Team, Scott L. Carter,1
William C. Hahn,1 Mary-Ellen Taplin,1 Eliezer M. Van Allen1. 1Dana-Farber
Cancer Inst., Boston, MA; 2Broad Institute, Boston, MA.
Background: Recent “next generation” androgen deprivation therapies
(ADT), such as abiraterone and enzalutamide, have improved survival in pa-
tients with castrate-resistant prostate cancer (CRPC). Despite therapy, most
patients develop resistance to these agents. We investigated the genetic basis of
tumor evolution and clinical resistance to next generation ADT in CRPC by
using whole exome sequencing (WES) on paired pretreatment and post-resis-
tance biopsies from CRPC patients. Methods: Matched “trios” of germline, pre-
treatment and post-resistant tumor samples were obtained from 7 patients
treated with abiraterone (n4) and enzalutamide (n3) and WES was per-
formed. Clinical data, including PSA and radiographicmeasurements, was used
to classify patients as intrinsically resistant or initially responsive to treatment.
Quality control, mutation and indel calling, copy number variation identifıca-
tion were performed using analytical pipelines at the Broad Institute. Tumor
purity and ploidy were inferred, and phylogenetic analysis was performed using
ABSOLUTE and Phylogic, respectively to identify resistance associated altera-
tions in the context of clinical phenotypes. Results: We identifıed multiple pu-
tative mechanisms and genetic categories of resistance to next generation ADT
in CRPC. One abiraterone patient acquired an AR mutation (L702H) in the
post-treatment sample, previously reported to be associatedwith poor outcomes
and to confer resistance to this therapy. Amplifıcation of MYC was associated
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with resistance in two other abiraterone patients with pre-existing AR gain: one
patient with initial response to therapy acquired a focal gain of MYC in the
resistant sample, and the other harbored a pre-existing MYC amplifıcation, but
had no response to therapy. In three enzalutamide patients, all acquired altera-
tions in cell cycle genes (CDKN2A mutation, focal amplifıcations in regions
spanningCDK4/6, andCCND3 focal amplifıcation) at the time of resistance that
were absent in pre-treatment tumors. In parallel, we confırm CDK4/6 overex-
pression was suffıcient to promote enzalutamide resistance in prostate cancer
cell models. Additional candidate genomic events associated with CRPC were
also implicated with this approach, such as RSPO3 amplifıcation. Conclusion:
This study outlines an approach to identify clinical genetic resistance mecha-
nisms of next generation ADT in CRPC through integration of genomic data
from serial biopsies, clinical patient outcomes, and preclinical functional screen-
ing. These fındings confırm previously known potential resistancemechanisms,
such as AR and MYC activation, and suggest putative mechanisms linked to
therapeutic agents, which may inform novel targets for treating CRPC patients.
#2906 Characterization of genetic intratumor heterogeneity of colorectal
cancer and matching organoids. Sigrid S. Arnadottir,1 Maria Jeppesen,2
Philippe Lamy,1 Iver Nordentoft,1 Michael Knudsen,1 Søren Vang,1 Mogens R.
Madsen,3 Jacob Thastrup,4 Ole Thastrup,4 Claus L. Andersen1. 1Dept. of Molec-
ularMedicine, Aarhus University Hospital, Aarhus, Denmark; 2Digestive Disease
Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark;
3Surgical Research Unit, Department of Surgery, Herning Regional Hospital,
Herning, Denmark; 42cureX, Birkerød, Denmark.
Background: In the recent years it has become evident that intratumor heter-
ogeneity of solid tumors, such as colorectal cancer (CRC), complicates develop-
ment of effıcient therapy strategies. A minor clone of the tumor might have the
ability for treatment resistance and hence the ability for re-establishing the tu-
mor.Organoid cultures derived from the patients’ tumors can be used for ex vivo
drug screening prior to treatment of the patient. However this approach is only
effıcient if the organoids represent the heterogeneity of the tumor. In this study
we aim to characterize the genetic intratumor heterogeneity of CRCby perform-
ing whole exome sequencing (WES) on multiple biopsies per tumor, and to see
howwell the heterogeneity is reflected inmatching organoid cultures. Methods:
From fıveCRCpatients, three biopsieswere collected fromseparate areas of each
tumor. Each biopsy was divided in two: one half was fresh frozen for DNA
purifıcation, and the other half was grown in vitro as organoid culture. When
available, lymph node metastases (LNMs) were included. WES was performed
using SeqCap EZ Exome v3.0, and Illumina NextSeq500. Matched germline
DNA was used as reference to identify somatic mutations and copy number
variations (CNVs) using Mutect2 and FACETS, respectively. Results: Each tu-
mor contained multiple mutations that were present in all biopsies and in the
organoids as well, representing a common ancestral branch. However all tumor
biopsies and organoids also contained private mutations. These constituted on
average 10% of the mutations (range 3-18%) indicating spatial genetic hetero-
geneity in all tumors. Each organoid hadprivatemutations not seen in the tumor
area of origin and vice versa, indicating that each area containedmultiple clones
and only a subset was represented in the organoids. The extent of mutational
differences between organoids and their area of origin was similar to the muta-
tional differences between tumor areas. Implying that organoids do not reflect
their local origin better than a single biopsy reflects the whole tumor. In one
patient with LNMs it was observed that the mutational profıle of the metastases
resembled only one of the examined tumor areas. Surprisingly, not all the an-
cestral mutations found in the tumor biopsies were observed in the LNMs,
suggesting that at least two clones co-existed in the area of origin and just one of
these formed the metastases. Conclusion: In the fıve patients studied; spatial
genetic heterogeneity was observed, meaning that multiple biopsies are needed
to picture the whole tumor. Genetic heterogeneity was also observed between
primary tumor and metastases and our data support that the metastases were
formed from a single cancer clone that did not dominate the primary tumor.
From a genetic point of view, organoids do not seem to fully reflect the tumor
area of origin and less so the whole tumor, indicating that care should be taken
when using organoids as models of the primary tumor.
#2907 Extracellular matrix remodeling triggered by lysyl oxidase inhibi-
tion promote the lung adenocarcinoma to squamous cell carcinoma transi-
tion independent of LKB1 status. Shun Yao, Hongbin Ji. Institute of Biochem-
istry and Cell Biology, Shanghai Institute for Biological Sc, Shanghai, China.
Introduction: Lung adeno-squamous cell carcinoma represents as the most ma-
lignant subtype of non-small cell lung cancer.Wehavepreviously shown that Lkb1-
defıciency triggered the lung adenocarcinoma (ADC) to squamous cell carcinoma
(SCC) transition (AST) in mice through extracellular matrix remodeling, in which
lysyl oxidase (LOX) plays an important role. Considering the high frequency of P53
mutations in human lung cancer, we reason it’s attractive to test if LOX inhibition
could modulate the lung cancer plasticity and subtype transition independent of
LKB1 status.Methods: KrasG12D/P53L/L (KP)micewere used to treat with BAPNor
DPA,twoLOX inhibitors, daily via intraperitoneal injection post 4weeks ofAdeno-
Cre infection for 6-8 weeks and then harvested the lungs for pathological analyses.
The histology and expression of relatedmarkers were analyzed byH&E, IHC stain-
ing, quantitative PCR andwestern blot. Results: BAPN/DPA treatment could result
in a dramatic reduction of collagen deposition.We found no signifıcant changes of
total tumor number, but decreased average tumor size and tumor burden in treat-
ment groups. Detailed pathological analyses showed that a few tumors from treat-
mentgroupdisplayed typical squamouspathology,with theexpressionof squamous
markers P63 and K14. In contrast, the tumors from control groups were adenoma-
tous pathology and only expressing ADC markers TTF1 and SP-C. We further
found that either BAPN or DPA treatment in KP mice promoted apoptosis and
inhibited cell proliferation in ADC. Interestingly, we found the transited SCC
showed almost no growth arrest and low apoptosis rate after BAPN or DPA treat-
ment, indicative of the resistance to LOX inhibitors. ECM deprivation is a major
cause of oxidative stress that contributes to the accumulation of reactive oxygen
species (ROS) through the deregulation of certain metabolic pathways. We then
checked the level of 8-hydroxydeoxyguanosine (8-oxo-dGuo), a marker of DNA
oxidativemodifıcation by ROS. In treatment groups, 8-oxo-dGuowas signifıcantly
lower in SCC thanADC. In our previouswork done inKLmodel, we found that the
ROS level was signifıcantly up-regulated by LKB1 inactivation, which functionally
modulated the AST. However, in KP mouse model, either LKB1 or p-AMPK level
showedno signifıcant changewith orwithout BAPN/DPA treatment. Conclusions:
These data demonstrated that pharmacological LOX inhibition could trigger the
ADC to SCC transition independent of LKB1 status, highlight a non-cancer-cell
autonomous role inphenotypic transition.Moreover, this lineage transition confers
lung cancerwith strong survival capability under environmental stress aswell as the
acquisition of drug resistance.
#2908 Single-cell genetic analysis of ductal carcinoma in situ with and with-
out synchronous invasive breast cancer by multiplex FISH delineates specifıc
patterns of tumor clonality and heterogeneity. Irianna Marie Torres,1 Leanora
Hernandez,1 Jausheng Tzeng,2 Russell Schwartz,3 Alejandro Schaffer,4 Edward
Gertz,4 Stephen Brower,2 Miguel Sanchez,2 Gert Auer,5 Kerstin Heselmeyer-Had-
dad,1RiedThomas1. 1NationalCancer Institute,Rockville,MD; 2EnglewoodHospital
and Medical Center, Englewood, NJ; 3Carnegie Mellon University, Pittsburgh, PA;
4NCBI, Bethesda, MD; 5Karolinska Hospital, Stockholm, Sweden.
We previously studied synchronous Ductal Carcinomas in Situ (DCIS) and In-
vasive Ductal Carcinomas (IDC) using a novel approach of multiplexing FISH
probes that allows us to simultaneously assess the copy numbers of up to 20 loci
within intact nuclei providing new insights into tumor clonality and heterogeneity.
A high degree of chromosomal instability already in DCIS, and frequently, but not
always, a direct clonal evolution from DCIS to IDC was detected. We now ask
whether thisdegreeof instability is alsopresent inDCIS thatdidnotprogress to IDC
and are therefore analyzing FFPE material from 20 patients with either low-grade
and high-grade DCIS who did not present with invasive breast carcinoma during
their follow-up (5-10 years), in addition to 10 patientswho presentedwith synchro-
nous IDC. The multiplex FISH assay used targets fıve oncogenes (COX2, MYC,
CCND1,HER2, ZNF217) and three tumor suppressor genes (DBC2,CDH1, TP53)
frequently altered in breast carcinomas. To date, we have analyzed two paired cases
of synchronousDCIS and IDC,DCIS-IDC3and4, and three cases ofDCISwithout
IDC, OP-DCIS 1, 4 and 5. The paired cases exhibited very similar aberration pat-
terns for synchronous DCIS and IDC indicating the invasive carcinoma is closely
related to the DCIS lesion. Specifıcally, themajor clones in DCIS 3 (low-grade) and
IDC 3 showed a diploid tumor cell population with a gain of COX2, and losses of
DBC2,MYC, TP53, andHER2. Of note, the only difference observed was a gain of
ZNF217 in the DCIS which was not seen in the major clone of the invasive carci-
noma. The other paired case, DCIS 4 (high-grade) and IDC4, showedmajor clones
of triploid tumor cell populationswithgainsofCOX2,CCND1andMYCand losses
ofDBC2,CDH1, TP53 andZNF217. The threeDCIS caseswithout synchronous or
subsequent IDC exhibited varying degrees of aberration and complexity patterns in
their clonal populations. CaseOP-DCIS 1, a high-gradeDCIS, revealed a tetraploid
cell populationwhich showed amajor clonewith an amplifıcation of CCND1 and a
MYC gain combined with losses of DBC2, CDH1, TP53 and HER2. A low-grade
DCIS, OP-DCIS 4, exhibited a diploid cell population with a major clone showing
loss of CDH1 as the only aberration. The third case OP-DCIS 5 (low-grade DCIS)
exhibited a diploid cell population with one major clone showing losses of CDH1,
MYC,DBC2, TP53, HER2 andCCND1.Our preliminary observations show a ten-
dency of diploid lesions with a predominance of loss patterns for low-grade DCIS,
while high-grade DCIS seem to reveal higher ploidy with more complex gain and
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loss patterns. However, also low-grade DCIS with mainly loss patterns progress to
invasive cancers as seen in case DCIS-IDC3. We expect that the analysis of the
remainingcaseswill furtherelucidate thedynamicsofDCIS lesionswhichwillhope-
fully help to assess and stratify progression risk in patients with DCIS.
#2909 High-precision quantifıcation of clonal evolution during compar-
ative treatments of triple negative breast cancer. Hyunsoo Kim,1 Pooja Ku-
mar,1 Francesca Menghi,1 Eliza Cerveira,1 Mallory Romanovitch,1 Guru
Ananda,1 Joshy George,1 Henry Chen,2 Susan Mockus,1 Chengsheng Zhang,1
Yan Yang,2 James Keck,2 R. Krishna Murthy Karuturi,1 Carol Bult,3 Charles
Lee,1 Edison Liu,3 Jeffrey H. Chuang1. 1The Jackson Laboratory for Genomic
Medicine, Farmington, CT; 2The Jackson LaboratoryMice, Clinical, andResearch
Services, Sacramento, CA; 3The Jackson Laboratory forMammalianGenetics, Bar
Harbor, ME.
Population heterogeneity within tumors is essential to the development of
drug resistance. However, precise quantifıcation of cellularity levels of subpopu-
lations, and in particular how they evolve in response to treatment, has been
challenging. Here we describe the high precision characterization of subclonal
evolution within triple-negative breast cancer patient-derived xenografts
(PDXs) generated from three patients. For each patient model, we established
multiple PDXs and treated them in cohorts of 5-10 mice each for the therapies
cyclophosphamide, doxorubicin, cisplatin, or docetaxel, with treatments lasting
one month. In all three patient models, the average behavior across mice was a
reduction in size in response to docetaxel, but growth under doxorubicin and
cyclophosphamide. For cisplatin treatment, one of the three models showed
tumor shrinkage while the other two models showed continued growth but at a
rate lower than the doxorubicin or cyclophosphamide cohorts. To determine the
evolutionary behaviors underlying these observations, we initially performed
exome panel sequencing of 34 residual tumor samples from these and untreated
xenografts. Computational mutation and copy number analysis indicated sam-
ple-specifıc differences in tumor populations both in response to treatment and
due to genetic drift. However, they also revealed measurement uncertainties
related to exome capture effıciency, locus-specifıc read counts, and computa-
tional copy number estimation that limited quantitative inference of evolution-
ary behaviors. To solve this problem we used droplet digital PCR (ddPCR) to
measure variant allele frequencies and local copy number at selected loci from
the prior residual tumors as well as additional samples from replicate cohort
treatments and cultured conditionally reprogrammed progenitor cells. In total
we performed 1665 ddPCR measurements across 150 cancer samples. These
ddPCRmeasurements reduced sample-specifıc uncertainty in variant allele fre-
quency to2% and copy number to0.2, allowing for precise identifıcation of
subclones and their cellularities in each sample. We observed several common
modes of evolution within these tumors including selective sweeps, spatial dif-
fusion, and stable coexistence between distinct subpopulations. In the samples
from one patient model, we observed frequent symbiotic growth of two distinct
subpopulations having differential cisplatin sensitivity, such that the degree of
clonal selection during cisplatin treatment was proportional to the tumor vol-
ume change on a mouse-to-mouse basis. This study demonstrates how high
precision genomic characterization across comparatively treated samples can
reveal treatment-relevant subclonal ecology, as well as the mutations that dis-
tinguish populations with different behaviors.
#2910 Inter metastatic genetic heterogeneity is a characteristic feature of
recurrent pancreatic cancer.Hitomi Sakamoto, Alvin Makohon-Moore, Marc
Attiyeh, Liguo Zhang, Christine A. Iacobuzio-Donahue.Memorial SloanKetter-
ing Cancer Center, New York, NY.
Pancreatic cancer (PDA) is a 4th leading cause of cancer death with an overall
5-year survival of 8%. Surgical resection remains the only option for cure but
only 10-15% of newly diagnosed patients are eligible. While surgery clearly pro-
vides a survival benefıt compared to those patients who do not undergo poten-
tially curative resection, the vast majority of patients will recur in the pancreatic
remnant, liver, lungs, and/or peritoneum. Thus, there is an unmet need to better
understand the fundamental features of recurrent disease. To explore the fun-
damental genomic features of recurrent PDA, patients were selected from par-
ticipating Gastrointestinal Cancer Rapid Medical Donation Program (GI-
CRMDP). 10 patients who underwent surgical resection; 8 patients had a
whipple procedure, 2 patients had a distal pancreatectomy and each patient
received a different type of chemotherapy after surgery, was evaluated. We per-
formed 250x whole exome sequencing (WES) of 82 unique samples from these
10 patients, using frozen samples from autopsy and FFPE tissues frommatching
surgical specimen. In addition to the treatment naïve primary tumor, one or
more samples of the local recurrence andmultiple metastases were studied. The
mean depth of coverage for all samples was 317x. Copy number variations were
assessed by FACETs. MSK-IMPACT was performed for orthogonal validation
of a subset of variants. We found that compared to the treatment naïve resected
tumor, recurrent disease contained novel mutations in genes associated with
MAPK and PI3K signaling. Themost commonmutational signature was Signa-
ture 1 followed by Signature 3. All patients who received a platinum drug as a
form of therapy had a greater proportion of Signature 3 and 9 mutations in the
recurrent disease than the primary tumor. Phylogenetic studies revealed that
recurrent disease is the result of three patterns: 1) dissemination of disease to
distant organs before surgery was performed, 2) dissemination of disease after
surgery from residual microscopic disease in the pancreatic remnant, or 3) de-
velopment of a second primary tumor in the remnant pancreas. This third sce-
nario was identifıed in one of six additional patients studied by IMPACT. We
conclude that recurrent pancreatic cancer is multifactorial, and at least two of
these scenarios could be eliminated by total pancreatectomy, thereby increasing
the rate of cure by surgical resection. Our study serves as a window to an under-
standing of the clonal dynamics of recurrent pancreatic cancer.
#2911 Single cell mass cytometry analysis of human lung adenocarci-
noma. Deon B. Doxie, Jonathan M. Lehman, Yong Zou, Maria S. Ortega, Car-
oline E. Maier, Jonathan M. Irish, Pierre P. Massion. Vanderbilt Univiersity,
Nashville, TN.
Introduction: Lung cancer is the leading cause of cancer-related mortality in
the world. Lung adenocarcinoma is the most common subtype. Tumor hetero-
geneity among adenocarcinomas presents a challenge in themanagement of the
disease. Understanding heterogeneity may have implications in understanding
the biological processes driving progression. Single cell platforms like mass cy-
tometry offer an opportunity to profıle tumor heterogeneity and to identify
populations of driven by the activation of signaling pathways. Methods: Adeno-
carcinomaswere collected at the time of surgery and dissociated into suspension
and cryopreserved.Mass cytometry analysis of tumors and adenocarcinoma cell
lines was performed with a 30 marker antibody panel and rhodium intercalator
dye to identify dead cells. The antibody panel included markers to characterize
identity, cell cycle status, and signaling events. Biaxial gating or unsupervised
analysis approaches SPADEand viSNEwere used to comparemajor populations
of cells. Results: Validation of mass cytometry panels was performed with ade-
nocarcinoma cell lines and human tumors. Adenocarcinoma cell lines PC9
(lung), A549 (lung), H520 (squamous) and SW620 (colon) exhibited phenotyp-
ically distinct cells between samples by expression of cytokeratin, CK7, and
EGFR. Furthermore, PD-L1 expression was expressed on subsets within cell
lines. Disaggregation of tumors was optimized with dissociation that included
collagenase and DNase to release viable cells within 1 hour. Detection of viable
cells was optimized with rhodium intercalator viability dye and histone H3 to
identify nucleated cells. Using the 30 marker panel and viSNE analysis four
populations were identifıed within tumors as infıltrating leukocytes, endothelial
cells, fıbroblast, and epithelial tumor cells. Epithelial cells were found to exhibit
cellular heterogeneity between patients based on the expression of cytokeratin,
CK7, TTF1, EGFR, vimentin, CD44, andMET. Preliminary signaling data iden-
tifıed basal kinase activity active in infıltrating leukocytes and cancer cells. Can-
cer cells and infıltrating immune cells had basal p-STAT5 activation, and cancer
cells had high basal p-AKT implicated in dysregulated cell growth. Conclusions:
Populations of infıltrating stromal cells and epithelial (cancer) cells were iden-
tifıed in lung adenocarcinoma. The single cell phenotyping from tumors was
consistent with the profıle found in two lung adenocarcinoma cell lines. Prelim-
inary differences in basal signaling pathways responsible for growth were ob-
served within adenocarcinoma cell populations. This work demonstrates the
feasibility of mass cytometry to identify and characterize tumor heterogeneity.
Work is underway to defıne phenotypes within the epithelial and leukocyte
populations that could predict tumor behavior and immune responsewithin the
microenvironment. This work is supported by NCI CA196405 to PPM.
#2912 Size based enrichment and sorting ofOv90 cancer cells and clusters
with a new multistage fıltration cartridge reveals distinct phenotypes. Anne
Meunier,1 Sara kheireddine,1 J. Alejandro Hernández-Castro,1 Teodor Veres,2
David Juncker1. 1McGill University, Montreal, Quebec, Canada; 2National Re-
search Council of Canada, Boucherville, Quebec, Canada.
Background: Circulating tumor cells (CTCs) are released in blood from the
primary tumor, but although very heterogeneous both in size and marker ex-
pression, are very rare and provide information not available from the primary
tumor. The identifıcation of CTC cells and clusters could advance our under-
standing of metastasis and help personalize therapy.1,2 Notably, CTC clusters
were shown to have a higher metastatic potential than single cells3 but the pro-
cess remains poorly understood. We present a multistage fıltration system with
pore sizes from 20 down to 8 m for the size-selective enrichment of Ov90
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ovarian cancer cells and clusters from blood. Each captured cell population was
released, cultured and characterized independently. Methods: We developed a
3D printed multistage fıltration cartridge and polymer fılters with 20, 15, 12, 10
and 8 m-diameter pores. Filters were stacked from 20 (top) to 8 m (bottom)
and used to enrich and sort Ov-90 cells spiked in 1:6mL of blood:PBS. Captured
cells were released by removing individual fılters from the cartridge, reverse
flowingOSEmedium, and then cultured separately. Results: Ov-90 clusters were
found mostly on the top fılter (20 m) and interestingly, few small clusters (3-4
cells) were found on the 8 and 10m fılters, suggesting alignment of cluster cells
as they pass through the pores.4 Cell and nucleus diameters were measured, and
a general correlationwas found between fılter pore size and cell and nucleus size.
Interestingly, nucleus size was found to be the single most signifıcant parameter
in determining passage of single cells and small clusters through pores. Follow-
ing cell culture, two distinct phenotypes were observed: cell captured on small
pore fılters (8-12 m) grew primarily in a monolayer. Cells captured on fılters
with larger pores (15-20 m) fırst grew as monolayer, but rapidly formed cell
aggregates that subsequently detached from the surface. Staining for E-Cad-
herin, a cell-cell adhesion protein, revealed a loss of expression of cells from fılter
with larger pores. Conclusion:We developed a newmultistage fıltrationmethod
and selectively enriched and sorted cells based primarily on their nucleus size.
We identifıed two Ov-90 populations with different growth behaviors with low
E-cadherin expression on the cells forming clusters, which is known to correlate
with metastasis. The application of multistage fılters may also reveal different
CTC populations based on nucleus and cell size. References: (1) Baccelli, I. et al.
A. Nat. Biotech. 2013, 31, 539-544. (2) Pecot, C. V. et al. Cancer discovery 2011,
1, 580-586. (3) Cheung, K. J. et al. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, E854-
E863. (4) Au, S. H. et al. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 4947-4952.
#2913 Emergence of RAS or EGFR mutant clones affects duration of re-
sponse to EGFR blockade in colorectal cancers. Sabrina Arena,1 Beth Van
Emburgh,1 Giulia Siravegna,1 Luca Lazzari,1 Giovanni Crisafulli,1 Giorgio
Corti,2 Benedetta Mussolin,2 Federica Baldi,3 Michela Buscarino,2 Alice Barto-
lini,2 Emanuele Valtorta,4 JoanaVidal,5 Beatriz Bellosillo,5 Giovanni Germano,2
Filippo Pietrantonio,6 Agostino Ponzetti,7 Joan Albanell,5 Salvatore Siena,4 An-
drea Sartore-Bianchi,4 Federica Di Nicolantonio,1 Clara Montagut,5 Alberto
Bardelli1. 1University of Torino, Candiolo, Italy; 2Candiolo Cancer Institute -
FPO, Candiolo, Italy; 3University of Torino, Torino, Italy; 4Niguarda Cancer
Center, Milano, Italy; 5Hospital del Mar, Barcelona, Spain; 6Istituto Nazionale
dei Tumori, Milano, Italy; 7San Giovanni Battista Hospital, Torino, Italy.
Cetuximab and panitumumab are monoclonal anti-EGFR antibodies (mo-
Abs) currently used for the treatment of advanced RAS wild type colorectal
cancers (CRC). Emergence of acquired resistance invariably limits the effıcacy of
these agents, and the dynamics of clonal evolution during anti-EGFR blockade
are poorly understood. At progression, RASmutations represent themost com-
mon genetic alterations, while EGFR extracellular domain (ECD)mutations are
acquired by a smaller cohort of patients. We found that the mutation profıle
correlates with the clinical outcome of patients; in particular those who develop
RAS mutations upon EGFR blockade achieve reduced tumor shrinkage and
shorter duration of response respect to patients in which EGFR ECDmutations
emerge during therapy. We investigated in preclinical models the potential role
of RAS and EGFR ECDmutations during the emergence of acquired resistance,
by tracking the evolution of clones in a genetically barcoded population of CRC
cells chronically treated with cetuximab. We observed that therapeutic (target
therapy, chemotherapy) and environmental (reduced nutrient condition) pres-
sures differentially shape the clonal composition of CRC cell populations, lead-
ing to the emergence of clones with the highest fıtness in presence of the external
pressure. In conclusion, a multistep clonal evolution process characterizes the
development of drug resistance and is associated with the clinical outcome of
CRC patients treated with anti-EGFR antibodies.
#2914 Molecular characterization with single-cell resolution of CTCs and
FFPE specimens from the same lung adenocarcinoma patients reveals the
extent of intra-tumor heterogeneity. Mario Terracciano,1 Francesco
Gelsomino,2 Francesco Bacchi,1 Francesca Fontana,1 Claudio Forcato,1 Alberto
Ferrarini,1 Michelangelo Fiorentino,3 Valentina Del Monaco,1 Giulio Bassi,1
Chiara Mangano,1 Chiara Bolognesi,1 Paola Tononi,1 Genny Buson,1 Gianni
Medoro,1 Nicolò Manaresi,1 Michele Tognetto,2 Andrea Ardizzoni2. 1Menarini
Silicon Biosystems SpA, Castel Maggiore, Bologna, Italy; 2Policlinico Sant’Orsola –
Malpighi, Bologna, Italy; 3Policlinico Sant’Orsola-Malpighi, Bologna, Italy.
Introduction: Intra-tumor heterogeneity can hide genomic and genetic fea-
tures, which may be key driver of disease progression. Routinely, only one bio-
logical specimen per patient is generally analyzed, which may only partially
represents the genetics of the tumor. Here we report a multi-approach analysis
of Circulating Tumor Cells (CTCs) and formalin-fıxed paraffın-embedded
(FFPE) tumor tissue-derived cells (TCs) obtained from the same patients, to
investigate the underlying genetic heterogeneity. Methods Peripheral blood
(PB) and FFPE tumor tissue were collected from two advanced lung adenocar-
cinoma patients, treated with cisplatin-pemetrexed and carboplatin-pem-
etrexed respectively as fırst line therapy. The fırst patient was previously diag-
nosed an ALK-traslocation and treated with an ALK-inhibitor. PB was enriched
with either an EpCAM-based or EpCAM-independent method: the cell output
of the latter was stained with Cytokeratin-PE, CD45-APC and DAPI. Matched
FFPE sectionswere obtained frompleural effusion cell blocks for the fırst patient
or from primary tumor tissue for the second one; after dissociation, cells were
stained with Vimentin-APC, Keratin-FITC and DAPI. The DEPArrayTM plat-
form was used to detect and collect pure single CTCs or TCs, along with WBCs
or stromal cells as controls. Whole genome amplifıed DNA of single CTCs and
TCs was used to profıle genome-wide copy-number aberrations (CNAs) using
the Ampli1TM LowPass kit; single nucleotide variants were analyzed on CTCs
WGA products and on pools of TCs using Ampli1TM CHP custom panel and
DEPArrayTM OncoSeek panel respectively. Results: No clinically signifıcant
variants were detected in CTCs and FFPE samples; however the copy-number
profıles of single TCs and CTCs revealed an overabundance of gains and losses,
confırming the aberrant nature of tumor cells. In the fırst patient, all single cells
showed a pattern of shared alterations, with a common amplifıcation of the
genome region comprising MYC gene (also confırmed by depth-of-coverage in
targeted panel). A hierarchical unsupervised clustering clearly separatedWBCs,
from the group of TCs and CTCs, characterized by some emerging clones and
low inter-cell heterogeneity. The analysis of the copy-number profıles of cells
from the second patient showed an opposite situation; unsupervised clustering
of low-pass profıles highlighted an independent group formed by single TCs
clearly distinct from the highly heterogeneous cluster formed by CTCs. Conclu-
sions: The precision granted by analysis of pure cells derived from multiple
specimens from the same patient, together with the combination of low-pass
whole-genome sequencing and targeted sequencing, reveals unexpected genetic
similarities and diversities, and provides fundamental information to under-
stand intra-tumor heterogeneity.
#2915 The timing of mutational burst events impact the growth of
tumors in the colon. Chelsie K. Sievers, Tien N. Vo, Perry J. Pickhardt,
Bryan D. Pooler, Kristina A. Matkowskyj, Dawn M. Albrecht, Quincy Rose-
marie, Michael A. Newton, Richard B. Halberg. University of Wisconsin,
Madison, WI.
Basic and clinical scientists believe that benign polyps in the colon prog-
ress to cancers through the slow, stepwise accumulation of mutations. Inter-
estingly, only a small percentage of all tumors progress, whereas a signifıcant
number remain static in size, regress, or resolve completely. The mecha-
nisms underlying these differential fates are unknown, and mechanisms of
tumor evolution during this premalignant phase are still under investigation
and continued debate. We previously reported that sub-clonal diversity
arises early in small human adenomas and contributes to the growth of
tumors in the colon. An emerging hypothesis is that colorectal tumors form
and progress via a process of punctuated equilibrium, where multiple copy
number alterations andmutational events happen simultaneously in a burst-
like fashion. In this study, we prospectively test this concept using a mouse
model in which tumor induction is spatially and temporally controlled via a
non-surgical delivery of adenovirus expressing CRE recombinase and a tem-
porally controlled mutational burst via administration of the carcinogen
Azoxymethane. Tumors are induced at a similar rate regardless the timing of
the burst relative to tumor induction with a mean tumor incidence of 62% at
three weeks post induction. However, tumor growth may be affected by the
timing of the burst. Animals that had amutational burst event prior to tumor
induction or those that had a late mutational burst event had a lower average
in vivo growth rate compared to controls and those with an early burst event,
but the average in vivo tumor size was comparable across all groups. Taken
together, these preliminary data provide evidence that the timing of a muta-
tional burst event contributes to tumor growth. This prospective experiment
is being extended through computer modeling and statistical inference to
compare in silico mutational landscapes to a cohort of colon polyps removed
from patients at normal screening. The fındings will provide new insights
into the earliest stages of tumorigenesis.
#2916 The clonal evolution of glioblastoma. Jennifer Brooke Goldstein,1
Ravesanker Ezhilarasan,1 Mona Jaffari,1 Alessandro Carugo,1 Giulio Draetta,1
Roeland Verhaak,2 Sahil Seth,1 Erik Sulman,1 Phillip Andrew Futreal1. 1UTMD
Anderson Cancer Ctr., Houston, TX; 2The Jackson Laboratory, ME.
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Background: Glioblastoma (GBM) is an aggressive cancer that often recurs de-
spite multimodal therapy. Median survival is 12-15 months. Genomic profıling
studies have shown marked tumor heterogeneity with distinct mutations among
treated and untreated samples. The Cancer Genome Atlas (TCGA), revealed that
mutations inTP53,CDKN2A,PTEN,EGFRandNF1arepredominant inuntreated
tumors. Of 19 patients who progressed on therapy, seven samples were hypermu-
tated with mutations in mismatch repair proteins, mainly MSH6. We proposed to
use the Cellecta Lentiviral-based tagging library, a novel model system to assess the
roleof intratumorheterogeneity (ITH) in thepresumptive tumor-initiating fraction
of primary GBM and in the development of resistance to temozolomide (TMZ).
From a pool of 30,000,000 barcodes, the system enables the genetic integration of a
unique barcode sequence into each cell. Each barcode can be quantitatively tracked
via next-generation sequencing, allowing for dynamic monitoring of the subclonal
architecture. Methods: GSC 272 and 627 (sensitive and resistant to TMZ) were
derived from core biopsies of GBMpatients. Cells were transduced with a lentiviral
vector containing luciferase. Cells were expanded and infected with the Cellecta
Lentiviral library. Multiplicity of infection was determined. Transduced cells were
injected into B6.Cg-Foxn1nu/J mice brains using a guide screw system. Half of the
mice were treated with TMZ via gavage at two weeks. Brain tumors were removed
and total DNA was extracted. Barcode inserts were amplifıed and the Illumina Se-
quencing platformwas used for barcode quantifıcation. Additionally, whole exome
sequencing was performed to assess mutation status. Results: Confırmation of lu-
ciferase signal hasbeenperformedusing aLuciferaseReporterAssay.Multiplicity of
infection was found to be 0.15 and 1 for GSC 6-27 and 272 respectively. Initial
methylation studies showedGSC272 tohavemethylationofMGMTwhileGSC627
didnot.Therewasnodifference inOS in theTMZResistant (GSC627)untreatedvs.
treated cohort (with a median OS of 55 days in both groups (N 23 vs 25 respec-
tively, P 0.563). TMZ Sensitive (GSC 272) untreatedmice did not survive as long
as the treated cohort (N 24 vs. 25, Median OS 43 vs. 206 days, P 4.61e-09).
Barcode and whole exome sequencing results is currently being analyzed. Conclu-
sions: The Cellecta lentiviral tagging system is an innovative way to track ITH and
clonal evolution in glioblastoma orthotopic models. We hope to discover novel
insights into TMZ treatment response and resistance.
#2917 High complexitymolecular indexing reveals that time-dependent cell
plasticity underpins response to EGFR targeted therapy.Aaron Boudreau, Rich-
ard Bourgon,Marie Evangelista.Genentech, Inc., South San Francisco, CA.
Non-small-cell lungcancer (NSCLC)patientsharboringepidermalgrowth factor
receptor (EGFR)-mutant tumors often receive erlotinib, a 1st generation EGFR in-
hibitor, as a frontline therapy. Althoughmany patients initially experience positive
response with erlotinib treatment, resistance invariably occurs in the majority of
cases - however, it remains unclear the full extent by which resistance is pre-deter-
minedby genomic aberration, stochastic bypotentially epigeneticmechanisms, or a
combination thereof. Using a lentiviral DNA barcode library to molecularly index
PC-9, an EGFR mutant (exon 19 del. E746-A750) cell line model, we used next-
generation DNA sequencing to trace the fate of over 1.6 million individual cells
following erlotinib treatment. Similar to previous reports, we show that multiple
subpopulations are present in PC-9 cells - those that are exquisitely sensitive to
erlotinib, and those that are inherently resistant, representing2% of the popula-
tion. Surprisingly, in the absence of erlotinib treatment, we show that cells cultured
over time transitioned between these two stateswhilemaintaining population equi-
librium. Using mathematical modeling, we identifıed several parameters of state
switching or flux that were required to maintain this dynamic equilibrium. Under-
standing themolecular basis by which cells maintain cell state plasticitymay enable
new strategies to limit intra-tumor heterogeneity and may ultimately improve re-
currence-free survival in NSCLC following erlotinib therapy.
#2918 Analysis of matched pre and post cisplatin-treated muscle-invasive
bladder cancer reveals a candidate cisplatin mutational signature. David Liu,1
Daniel Keliher,2 Philip Abbosh,3 Kent Mouw,1 Diana Miao,1 Mariel Boyd,4 Jean
Hoffman-Censits,5Gopa Iyer,4 SaraTolaney,1 JaegilKim,6GadGetz,6 ScottCarter,1
JoaquimBellmunt,1 Elizabeth R. Plimack,3 Jonathan E. Rosenberg,4 EliezerM.Van
Allen1. 1Dana Farber Cancer Institute, Boston, MA; 2Brown University, Providence,
RI; 3Fox Chase Cancer Center, Philadelphia, PA; 4Memorial Sloan Kettering Cancer
Center, New York, NY; 5Sidney Kimmel Cancer Center at Thomas Jefferson Univer-
sity, Philadelphia, PA; 6Broad Institute of Harvard andMIT, Cambridge, MA.
Background:Mutational signaturesof exposure toDNAdamagingagents suchas
UV irradiation, tobacco, and temozolomide have been described; however a cispla-
tinmutational signaturehasnotbeen identifıed.Weanalyzedmutational changes in
matched pre- and post-cisplatin based neoadjuvant chemotherapy (NAC)-treated
muscle-invasive bladder cancer (MIBC) samples to identify a cisplatin mutational
signature.Methods:Whole exome sequencing andmutation callingwas performed
on matched germline and pre- and post-cisplatin based NAC (MVAC and GC)
tumor samples from 46 MIBC patients with gross residual disease (
 pT2) at cys-
tectomy. After quality control, samples from 30 patients were analyzed. For each
tumor, we characterized single nucleotide mutations (CA, CT, CG, TA,
TC, TG) within a tri-nucleotide context, and used an optimized non-negative
matrix factorization (NMF) to discover signatures of mutational processes in pre-
NAC tumors, post-NAC tumors, and among mutations unique to the post-NAC
samples. We compared our discovered signatures to previously described human
mutational signatures and to a signature of cisplatin exposure in a DT40 (chicken
lymphoblast) cell line (normalized for a humanexome context).We also performed
strand asymmetry analysis to search for evidence of transcription-coupled repair.
Results: In both pre and post-NAC tumors we identifıed mutational signatures
matching those attributed toAPOBEC activity and nucleotide excision repair path-
way defects, consistent with past studies in MIBC. In post-NAC tumors we identi-
fıed an additional novel mutational signature, withmodest overall cosine similarity
(0.61) to theDT40 cisplatin signature, but similarCAandTAmotifs. Therewas
a strong correlation in inferred mutational activity (Pearson R  0.98) when we
replaced the novel signature with the DT40 signature in the post-NAC tumors,
whichwashighlyunlikely tobedue to chance (p0.001, empiric null distribution).
Further,we foundevidenceof transcriptional strandbias inCA(p0.00025) and
TA (p  4.2e-06) motifs with depletion of coding strand mutations, consistent
with transcription coupled repair of platinum crosslinks at GpG andApGmotifs in
the non-coding strand. Finally, wewere able to rediscover the novel signaturewhen
limiting analyses to mutations unique to post-NAC tumors, consistent with muta-
tional activity during chemotherapy. Conclusions: Analysis of matched pre- and
post- cisplatin treated MIBC identifıed a novel signature in post-cisplatin treated
samples that (1) has mutational activity similar to a preclinical cisplatin mutational
signature; (2) has a transcription strand bias consistent with known repair charac-
teristics of platinum-induced DNA damage; and (3) arises in tumors following cis-
platin chemotherapy. This may represent a cisplatin-induced mutational signature
in human tumors.
#2919 Quantitativemapping of epidermal growth factor receptor activation
in single breast cancer cells treated with targeted therapies. Phuong Le, Kristo-
pherKilian,AndrewSmith.University of Illinois atUrbanaChampaign,Urbana, IL.
Twenty percent of breast cancers are triple-negative, lacking estrogen receptor,
progesterone receptor, and HER2. There is currently no specifıc FDA-approved
targeted therapy for triple-negative breast cancer patients. Approximately half of
triple-negative breast cancers overexpress epidermal growth factor receptor
(EGFR), however phase II trials have only shown a 5% response rate with targeted
inhibition. A quantitative analysis of EGFR signaling pathway dynamics of single
cells at the singlemolecule level has the potential to shed light on themechanism of
lack of response to targeted therapy, as well as the cell-to-cell heterogeneity of re-
sponse. Here, we combine single-molecule 3D imaging of EGFR using fluorescent
quantum dots (QDs) with cell geometry normalization by micro-patterning to
quantitatively map EGFR endocytosis in single cancer cells. Triple negative MDA-
MB-231 cells conformed to defıned geometries (rectangular with different aspect
ratios) were grown on soft polyacrylamide gels after micro-contact printing islands
of fıbronectin. Two color QD conjugates of EGFR and its ligand, EGF, are used to
track ligandbindingandreceptor internalizationuponactivation in theabsenceand
presence of different families and dosages of pharmaceutical EGFR inhibitors. We
demonstrated thatmicrocontact-printingnormalizes cell geometrywhilemaintain-
ing EGFR localization so that EGFR signaling response can be quantitatively as-
sessed on a single-cell basis and that QD conjugates can specifıcally label EGFR and
EGF.Quantitative single-molecule imaging at single-cell level revealed high level of
heterogeneity in the amount and spatial localization of EGF binding and EGFR
endocytosis among the cell population in the presence and absence of EGFR inhib-
itor, gefıtinib.Using thisplatform,wewill investigate if spatial organizationofEGFR
clusters within individual cells contribute to single-cell heterogeneous response to
EGFR inhibitors. We anticipate quantitative mapping of EGFR activity with drug
treatmentwill help to elucidatewhyEGFRdrug treatments fail andprovide ameans
to develop combination therapy to address heterogeneity in triple negative-breast
cancer.
#2920 Characterizing humanmelanoma treatment response in vivo using
single-cell mass cytometry analysis of longitudinal tumor biopsies. Deon B.
Doxie,1 Allison R. Greenplate,1 Kirsten E. Diggins,1 Caroline E. Maier,1 Jeffrey
A. Sosman,2Mark C. Kelley,1 JonathanM. Irish1. 1Vanderbilt Univiersity, Nash-
ville, TN; 2Northwestern University, Chicago, IL.
Introduction: Metastatic melanoma that harbor BRAFV600E mutations
are treated with inhibitors that inhibit MAPK signaling downstream of
BRAF. Although these treatments improve patient survival, the majority of
tumors develop resistance. It is increasingly clear that the presence and
emergence of cell subsets in the tumor microenvironment shapes treatment
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responses. Mass cytometry is a single cell platform capable of measuring35
proteins on millions of tumor cells. Here, mass cytometry was used to char-
acterize matched tumor samples obtained before, during, and after therapy
in order to quantify the impact of therapy on tumor cell populations. Meth-
ods: Melanoma tumors from adults with metastases were biopsied or surgi-
cally resected from 12 patients with consent. Patients received two weeks of
BRAFV600E inhibitor dabrafenib followed by two weeks of dabrafenib and
MEK inhibitor trametinib. Tumors were enzymatically digested and cryo-
preserved with protocols for mass cytometry (Leelatian and Doxie et al.,
Cytometry B 2016). Samples were stained with a 30 antibody panel focused
on melanoma identity and markers of lineage and traffıcking for leukocytes,
fıbroblast, and endothelial cells. Viable nucleated cells were identifıed by
total histone H3 and rhodium dye exclusion. Expert biaxial gating and viSNE
analysis were used to identify, computationally map, and track populations
and their subsets over time. Tissue microarrays were also analyzed by his-
tology to confırm fındings observed by mass cytometry. Results: More than
99% of cells were characterized and fell into one of the four major popula-
tions. Melanoma phenotypes included loss of MHC class I and/or expression
of one or more markers of identity including SOX10, SOX2, nestin, S100,
andMCAM. Signifıcant decreases in nestin, MCAM,MHC I and S100 (p
0.01, p  0.05, p  0.05, and p0.05, respectively) were observed in cells
after treatment. Decreases in nestin and S100 populations identifıed by
mass cytometry were observed in histology analysis of TMAs from matched
tumors. Analysis of pre- and post-therapy melanoma cells and BRAF mu-
tated cell lines indicated pre-therapy tumor cells had phenotypes most sim-
ilar to cell lines. Strikingly, 6hrs or 1 day of treatment of cell lines with
dabrafenib and trametinib did not result in decrease in nestin expression.
The nestin low post-therapy phenotype of melanoma tumor cells was present
in all melanoma cell lines at a low abundance (average of 7.0%/ 3.9% in
cell lines, N  7). Conclusions: Single cell analysis and longitudinal moni-
toring of patient’s revealed tumor ecosystems experience rapid changes in
cellular diversity during targeted therapy. Lower nestin expression distin-
guished treated melanoma tumor cells. The in vitro results suggest that in
vivo remodeling of the tumor microenvironment results from a shift in
host-tumor cellular interactions and not a direct response to inhibitors.
#2921 Integrated exome- and single cell RNA-sequencing reveals a clone’s
genomic instability andmultifaceted fıtness.Noemi Andor,1 Carlo C.Maley,2
Hanlee P. Ji1. 1Stanford Univ., Palo Alto, CA; 2Arizona State University,
Tempe, AZ.
DNA-damage therapy is the main line of defense against most cancers, espe-
cially at advanced stages of progression. DNA-damage therapy damages the
cell’s DNA.We have identifıed that a cell’s cumulative extent of DNA damage -
even when successfully repaired - is an indicator for future tolerance to new
insults. This fınding points to a quantitative measure of genomic instability as
biomarker of sensitivity to DNA-damaging agents. However, quantifying
genomic instability is diffıcult, especially because each individual tumor harbors
clones with their own distinct genomic characteristics. Here we address the
challenge of quantifying the complex phenotype of genomic instability across
the clonal subpopulations that coexist within an individual tumor.We identifıed
coexisting clones from bulk-exome sequencing and calculated the copy number
profıle of each clone’s genome. We integrated mutations detected in both, sin-
gle-cell RNA-sequencing (scRNA-seq) and exome sequencing, to assign single
cells to clones. Because cells in G2/M phase of the cell cycle (further referred to
as G2/M clones) have twice the ploidy compared to cells in other cell cycle
phases, their presence represents an opportunity for validation. Using 15 gastric
cancer cell lines - each sorted by cell cycle phase - we validated: i) clone-specifıc
copy number and ii) assignment of single cells to clones. Here, the predicted size
of G2/M clones is an indicator of how correct we quantify clone-specifıc copy
number. The degree to which expression of cell cycle genes is exclusive to G2/M
clones is an indicator as to how correct we assign single cells to clones. In addi-
tion to the dominant quiescent clone and the G2/M clone, we identifıed other
discrete subclones in a subset of cell lines, suggesting that genetic intra-tumor
heterogeneity is sometimesmaintained in-vitro. This approach identifıed clone-
specifıc markers that can be used for cytometry separation of cells of specifıc
clonal subpopulations. Overall, we demonstrate the power of combining exome
sequencing and scRNA-seq to reveal how many clones are present in a tumor
sample, how genomically unstable each clone is and how fıt is each clone.When
combined, these two techniques synergize into a powerful strategy to investigate
the relationship between genomic instability, clone fıtness and DNA-damage
sensitivity.
#2922 Targeting physical and stromal sources of tumor heterogeneity
with photodynamic therapy-based combinations. Imran Rizvi,1 Utkan
Demirci,2 TayyabaHasan1. 1MassachusettsGeneralHospital, Boston,MA; 2Stan-
ford University School of Medicine, Canary Center for Early Cancer Detection,
Palo Alto, CA.
Tumor heterogeneity and drug resistance to conventional therapies remain
major causes of treatment failure, recurrence and dismal survival rates for pa-
tients with advanced stage cancers. A range of cellular, architectural, and phys-
ical cues in the tumor microenvironment influence the intrinsic and acquired
resistance mechanisms that lead to treatment failure. These include communi-
cation with heterocellular stromal partners and physical forces such as hydro-
dynamic shear stress, which remain understudied as determinants of tumor
heterogeneity and variability in treatment response. Strategies that leverage pho-
todynamic therapy (PDT), a mechanistically-distinct modality, to regionally
target and prime stubborn tumor populations may be essential to overcoming
key barriers to durable cancer management while minimizing toxicity from
traditional agents. A multi-faceted approach is needed to evaluate and optimize
PDT-based combination therapies, including the development of bioengineered
3D models that integrate cues such as physical forces and heterotypic cellular
communication. Here the impact of hydrodynamic stress and stromal biology is
evaluated in the context of ovarian cancer (OvCa). Metastatic OvCa spreads
predominantly via flushing of ascites along preferential fluidic pathways and
communicates with the local microenvironment, including the extracellular
matrix (ECM) and tumor endothelial cells (TECs), to form peritoneal implants.
A microfluidic model that supports 3D tumor growth was developed to investi-
gate the role of fluidic stress on the heterogeneity of metastatic OvCa. The mo-
tivation for this study was based on clinical observations that the most stubborn
tumors are often found in regions such as the peritoneal gutter, which is sub-
jected to fluidic stress from ascites and is a common site of resistance and recur-
rence. Tumor nodules cultured under flow showed increased epithelial-mesen-
chymal transition (EMT) compared to non-flow cultures. Molecular and
morphological changes consistent with EMT included a transcriptionally-regu-
lated signifıcant decrease in E-cadherin, a signifıcant increase in vimentin, and
signifıcant decrease in fractal dimension, a metric adapted to quantify spindle-
like morphology. A concomitant signifıcant post-translational upregulation of
epidermal growth factor receptor (EGFR) expression and activation, and
chemoresistance was seen. The impact of heterotypic communication between
TECs and OvCa cells was investigated in a 3D model. Tumors grown in the
presence of TECs were differentially susceptible to chemotherapy and benzo-
porphyrin derivative (BPD)-based PDT and showed increased heterogeneity in
response to treatment. This heterogeneity was overcome by PDT priming of
tumors prior to chemotherapy. The potential value of using bioengineeredmod-
els to guide customized PDT-based combinations will be presented.
#2923 Label-free enrichment and integrated full-lengthmRNA transcrip-
tome analysis of single live circulating tumor cells from breast cancer pa-
tients.NaveenRamalingam,1Yi FangLee,2 Lukasz Szpankowski,1AnneLeyrat,1
Brian Fowler,1 Jovina Tan,3 Chong Tracy Lu,1 Ninez Delos Angeles,3 Chad
Sanada,1 Cassandra Greene,1 Kyle Hukari,1 Andrew Wu,2 Yoon-Sim Yap,4 Jay
West,1 Ali Asgar Bhagat2. 1Fluidigm Corporation, South San Francisco, CA;
2Clearbridge BioMedics Pte Ltd, Singapore, Singapore; 3Fluidigm Singapore Pte
Ltd, Singapore, Singapore; 4National Cancer Centre, Singapore, Singapore.
Background: Label-free methods for isolating circulating tumor cells (CTCs)
are attractive because they provide an opportunity to analyze a larger set ofCTCs
that may otherwise be missed due to variable or no expression of protein (label)
markers. Understanding genetic and functional heterogeneity inCTCs allows us
to gain insight into the mechanisms underscoring metastasis, drug resistance,
and tumor aggressiveness. Currently, a simple workflow for isolation and mo-
lecular characterization of singleCTCs bymRNAsequencing is lacking. In order
to address this challenge, we developed a label-free workflow to isolate CTCs
from breast cancer patients for full-length mRNA sequencing analysis by inte-
grating the ClearCell® FX System with the PolarisTM system. The ClearCell FX
system processes blood samples from cancer patients and enriches for CTCs in a
label-free antibody-independent manner. The low level of nonspecifıcally iso-
lated white blood cells from ClearCell FX is further depleted on the Polaris
system by negative enrichment of viable CTCs. This unique integration of sys-
temswill enable researchers to perturb singleCTCs in a controlled environment,
monitor and measure the response due to perturbation, and link these response
measurements to downstream genomic and transcriptomic analysis. Method
and Results: CTCs from 7.5 mL of peripheral blood sample from breast cancer
patients were enriched using ClearCell FX. To differentiate larger blood cells
from putative CTCs, we stained the enriched cells with Alexa Fluor® 647-con-
jugated CD45 and CD31 to identify leukocytes and endothelial cells, respec-
TUMOR BIOLOGY: Tumor Evolution and Heterogeneity 1
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017746
tively. Calcein AM (live cell marker) and CellTrackerTM Orange (universal cell
marker) were added to identify live cells. Single CTCs were selected on Polaris
(Fluidigm) system, lysed and reverse-transcribed, and cDNAwere preamplifıed
on the Polaris integrated fluidic circuit (IFC). Sequencing libraries were gener-
ated using the Nextera® kit and sequenced on Illumina® MiSeqTM and NextSe-
qTM systems. We successfully processed blood samples from four patients. Se-
quenced data showed high-quality metrics, with read depth of up to 2.5 million
reads (MiSeq) or 60 million reads (NextSeq), with a low percentage of mapped
reads to ribosomal RNA and mitochondrial RNA. Unsupervised hierarchical
clustering of gene expression data showed clustering by patient, but consider-
able heterogeneity was also observed among the CTCs from the same patient.
We will provide insights into full-length mRNA transcriptome of single CTCs
from triple negative breast cancer patient. Conclusion:We present the feasibility
of integrating twomicrofluidics platforms to capture single CTCs for transcrip-
tome and functional study. Our data suggests that the heterogeneity of tumor
sample and characterization of metastatic processes can be elucidated from sin-
gle-cell mRNA sequencing of CTCs.
#2924 CirculatingDNAdemonstrates convergent evolution and common
resistance mechanisms during treatment of colorectal cancer. Alain R. Thi-
erry,1 Brice Pastor,1 Zhi-QinCamilla Jiang,2 anastasia Katsiampoura,2 Christine
Parseghian,2 Jonathan Loree,2 Michael J. Overman,2 Cynthia Sanchez,1 Safıa El
Messaoudi,3 Marc Ychou,4 Scott Kopetz2. 1INSERM U896, Montpellier, France;
2MD Anderson Cancer Center, Houston, TX; 3DiaDx SAS, Montpellier, France;
4Institut du Cancer de Montpellier, Montpellier, France.
Malignant tumors shed cell free DNA into the blood stream. Analyzing this
new biological source may have important implications in a shift towards per-
sonalized medicine for diagnosing and/or monitoring malignancies. We re-
cently showed the fırst clinical validation and clinical utility of circulating DNA
(cfDNA) analysis in oncology by testing RAS/BRAF hotspot mutations in
plasma frommetastatic colorectal cancer patients (mCRC) (NatMed. 2014 Apr;
20(4):430-5). In addition, liquid biopsies allow the tracking of clonal dynamics
and detection of mutations during treatment. We evaluated under blinded con-
ditions the ability of cfDNA to detect RAS/BRAFmutations in the plasma of 42
mCRC patients treated on a phase Ib/II trial of FOLFOX and dasatnib, with or
without cetuximab. Prior to treatment, sequencing of archival tissue detected
mutations in 25/42 patients (60%), while the cfDNA assay detectedmutations in
37/42 patients (88%). Our cfDNA assay was able to detect mutations with allele
frequencies as low as 0.01%. After exposure to treatment, 41/42 patients (98%)
had a cfDNA detected RAS/BRAFmutation. Of 22 patients followed with serial
measurements who were RAS/BRAF mutant at baseline, 11 (50%) developed a
second mutation following treatment and 3 (14%) no longer had detectable
levels of another mutant allele. Of RAS/BRAF wild type tumors at baseline, 4/5
(80%) developed new mutations. Patients may harbor mutations at very low
frequency down to 0.01% before initiation or during treatment revealing the
need of a high sensitive technique to detect mutant subclones. cfDNA quantita-
tive measurements from this study closely mirrored changes in CEA and CT
scan results, highlighting the importance of obtaining quantitative data beyond
themere presence of amutation. Combined qualitative and quantitative cfDNA
analysis allows tracking acquired resistance by studying the real-time clonal
evolution of the tumor and might help physicians to adjust patient treatment.
Our fındings demonstrate the development of new RAS/BRAF mutations in
patients regardless of whether they had pre-existing mutations in the pathway,
demonstrating a convergent evolutionary pattern.
#2925 Distribution of copy number alterations defınes clonal populations
involved in colorectal cancer evolution. Isabel Quintanilla, ElenaAsensio,Ma-
ria Pellisé, Antoni Castells, Miriam Cuatrecasas, Jordi Camps. IDIBAPS, Barce-
lona, Spain.
Colorectal cancer progresses in a multi-step manner with adenoma being the
most well-known precursor lesion. Malignant polyp, an adenoma that contains
a focus of adenocarcinoma, is a suitable model to study the colorectal tumor
evolution. Although the mutations that lead adenoma to evolve into carcinoma
have been previously described, the copy number changes involved in this ma-
lignant transformation have not been fully explored. To understand how these
genomic alterations contribute to carcinogenesis, we used sequential fluores-
cence in situ hybridization using probes for the oncogenes EGFR, MYC, CDX2,
and ZNF217 and the tumor suppressor genes SMAD7 and APC in order to
analyze the copy number changes in 23 cases ofmalignant polyps and 10 cases of
lowgrade dysplasia (LGD) adenomas based on single cell analyses.We found the
levels of genomic heterogeneity increased from LGD adenomas to malignant
polyps, with the adenoma component having a lower degree of chromosomal
instability than the adenocarcinoma component. Despite the intercellular het-
erogeneity, we observed different patterns of evolution. The gain of ZNF217was
the earliest event as it was found to be in some cases of the LGD adenoma, and
was also important in the neoplastic transformation of malignant polyps. Other
notable genomic imbalances we observed during the malignant transformation
were the gain of CDX2 and the loss of SMAD7. Interestingly, in a signifıcant
proportion of cases we observed the gain of all loci analyzed to be the decisive
step in the transition from adenoma to carcinoma, suggesting a whole genome
duplication event. Lastly, in half of the malignant polyps studied the main clone
in the carcinoma component was already present in the adjacent adenoma com-
ponent, although in some cases at a low frequency only detected by single cell
analysis. Our data suggest that copy number changes are early events in colorec-
tal carcinogenesis that candetermine the evolution fromadenoma to carcinoma.
#2926 Histologically defıned intratumoral sequencing uncovers evolu-
tionary cues into conserved molecular events driving gliomagenesis.Antony
Prabhu, Pravin Kesarwani, Shiva Kant, Stewart Graham, Prakash Chinnaiyan.
William H. Beaumont Hospital, Royal Oak, MI.
Glioblastoma (GBM) represents an archetypal example of a heterogeneous
malignancy, harboring regions of invasion, necrosis, and vascularization. To
begin to understand the diverse molecular consequences of this complex tumor
ecology, we analyzed RNA-seq data generated from commonly identifıed intra-
tumoral structures in GBM that were isolated and enriched using laser capture
micro-dissection. Structures included the infıltrative, leading edge, central tu-
mor core, and cellular regions in areas of necrosis. From this RNA-seq database
consisting of 119 structural regions from 37 individual tumors generated from
12,000 hematoxylin and eosin histologic images, we validated signifıcant in-
tra-tumoral heterogeneity in GBM, with cells derived from the infıltrating lead-
ing edge almost exclusively harboring the proneural molecular subtype, while
cells in regions of necrosis displaying themesenchymal subtype. In addition, we
made the striking observation that when evaluating the tumors transcriptional
profıles in the context of their derived structural regions, there was a relative
small amount of inter-tumoral heterogeneity in GBM, with signifıcant cluster-
ing of transcriptional profıles of specifıc structural regions from different tu-
mors. To begin to understand the specifıc molecular events driving regional
growth and their contributory role in gliomagenesis, we analyzed the transcrip-
tional programs in the context of evolutionary progression. This level of analysis
identifıed numerous pathways associated with neuronal receptor signaling, au-
tophagy, and fatty acidmetabolism as early events in tumorigenesis. Traditional
cancer related signaling pathways emerged as key mediators driving progres-
sion, with glioma and p53 signaling ranking highest on the list. As the tumor
progressed to harbor regions of necrosis, in addition to expected changes in
VEGF and tumor signaling, we uncovered global metabolic changes associated
with progression, with metabolic pathways comprising 10 of the top 20 path-
ways unique to this region. Collectively, these fındings suggest that the observed
intra-tumoral heterogeneity in GBM may be a conserved, predictable conse-
quence to its complex microenvironment and therapeutic strategies rationally
designed to target these unique, unequivocally present tumor cell biomes may
lead to therapeutic gains in this otherwise fatal malignancy.
#2927 Proteogenomic heterogeneity in metastatic lung adenocarcinoma
revealed from rapid/warm autopsy. Nitin Roper, Tapan K. Maity, James Gao,
Abhilash Venugopalan, Xu Zhang, Romi Biswas, Constance Cultraro, David
Kleiner, Stephen Hewitt, Javed Khan, Guha Udayan. National Cancer Institute,
Bethesda, MD.
Introduction: Intratumor heterogeneity has been characterized among mul-
tiple cancer types. However, in lung adenocarcinoma, recent work has been
limited to early stage primary tumors and intertumor heterogeneity has not been
well-studied. Most importantly, an integrated tumor heterogeneity analysis at
the level of somatic variants, copy number, transcript and protein expression,
and the phosphoproteome is outstanding. Methods: In order to characterize
both intra-tumor and inter-tumor heterogeneity of metastatic lung adenocarci-
noma, we applied whole exome sequencing, RNA-seq, CNV-seq andmass spec-
trometry-based proteomic analyses on 33 tumor regions from metastatic sites
including lung, liver and kidney, obtained by rapid/warm autopsy from 4 pa-
tients with Stage IV lung adenocarcinoma. The autopsy procedure was initiated
between 2-4 hours of death. Results: We found considerable intertumor heter-
ogeneity with organ-specifıc, branched evolution that was consistent across
DNA, RNA and protein analyses. Intratumor heterogeneity differed depending
on oncogene-status: oncogene-negative tumors (without RTK/RAS/RAFmuta-
tions or known fusion gene) had signifıcantly higher genomic intratumor het-
erogeneity than oncogene positive tumors. The degree of heterogeneity at the
genomic and proteomic level was patient-specifıc. The proteomic analysis com-
plemented genomic variants-based clonal evolution analysis. High-confıdence
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driver mutations (KRAS, EGFR, TP53, CTNNB1) uniformly occurred early in
the evolution of metastatic lung adenocarcinoma consistent with the concept of
these mutations as likely ‘founders’. In contrast, other known driver mutations
occurred more often in later stages among specifıc organ branches. Notably,
oncogene-negative tumors carried signifıcantly more driver mutations than on-
cogene-positive tumors suggesting that genomic alterations may have a larger
role in themetastatic process versus the early evolution of lung adenocarcinoma
in oncogene-negative vs. oncogene-positive tumors. Among all patients, lung
cancer specifıc focal copy number alterations frequently occurred within meta-
static branch points. Single metastatic site biopsies would therefore be unlikely
to capture all signifıcant driver mutations and copy number alterations, partic-
ularly among oncogene-negative tumors. Conclusion: Metastatic lung adeno-
carcinoma evolves through a branched, organ-specifıc, process with acquisition
of signifıcant driver mutations and copy number changes, particularly among
oncogene-negative tumors. The branched evolution is ultimately influenced by
proteomic and phosphoproteomic alterations affecting key signaling pathways
that may not be always a result of genomic changes.
#2928 Pervasive associations between mutational processes and driver
mutations across cancer types. Daniel P. Temko,1 Benjamin Schuster-Boeck-
ler,2 Simone Severini,1 Ian Tomlinson,2 Trevor Graham3. 1University College
London, London, United Kingdom; 2University of Oxford, Oxford, United King-
dom; 3Barts Cancer Institute, QueenMary University of London, London, United
Kingdom.
More than 30 distinct mutational signatures, each the result of an underlying
mutational process, have now been described in human cancers – we have
sought to address the extent to which these mutational processes shape the
spectrum of driver mutations across cancer types. Using publicly available
genomic data from 10,188 cancers across 22 common cancer types, we have
statistically assessed the association betweenmutational process activity and the
presence of individual pathogenic driver mutations. Specifıcally, we determined
the sample-specifıc exposures for eachmutational signature. For each recurrent
driver mutation in each cancer type, we tested for a difference in the exposure to
each mutational signature in samples with the driver mutation compared to
those without. We used an independent analysis based on the causal SNV(s) for
each driver mutation to test our hypothesis that many of the associations be-
tween driver mutations and mutational signatures are causative in nature. Our
method is novel in linking specifıc pathogenic amino-acid changes to muta-
tional process activity. This allows us to investigate mutational causality in car-
cinogenesis, and permits us to delineate the inter-related effects ofmutation and
clonal selection. Our data indicate that both extrinsic (mutagen driven) and
intrinsic (DNA replication and repair) associated mutational processes have
pan-cancer associations with multiple distinct driver mutations, many of which
are causative in nature. Of particular note is the identifıcation of a pan-cancer
driving role for both theAPOBECandmicrosatellite instability (MSI) associated
mutational processes, an early causative role for defective DNAproof reading in
colorectal and endometrial cancers, and the identifıcation of a general ‘muta-
tional sensitivity’ to oncogenic PIK3CA mutations in many cancer types. In
addition, our analysis also provides quantitative understanding of the relative
effects of the distinct evolutionary forces ofmutation and selection, via a detailed
analysis of the mutually exclusive mutations to the IDH1 and IDH2, and KRAS
and BRAF, genes respectively. Taking into account mutational signatures, our
data suggest preferential selection for IDH1R132H compared to other common
IDH1 and IDH2 mutations and preferential selection for KRAS G12D com-
pared to other commonKRAS and BRAFmutations, in a subset of cancer types.
These data demonstrate the functional importance of mutational processes in
shaping the landscape of driver mutations across cancer types, informing our
understanding of the relative effects ofmutation and selection in carcinogenesis.
Our study has ramifıcations for both cancer prevention, by providing knowledge
of how removing mutagen exposure could impact carcinogenesis, and for treat-
ment choice by indicating the relationship ofmutational processes and the likely
presence of actionable or resistance mutations.
#2929 Exploratory evolved strategies that limit cancer growth for possible
new therapeutic strategies. Dominique Abrahams,1 Arig Ibrahim Hashim,1
Kim Luddy,1 Robert Gillies,1 Robert Gatenby,1 Joel Brown2. 1Moffıtt Cancer
Center, Tampa, FL; 2University of Illinois, Chicago, IL.
Strong selection can promote mammalian evolution of a remarkably diverse
phenotypic range over a short period of time.With appropriate selection forces,
we tested the hypothesis that laboratory animals can evolve phenotypes that are
resistant to the growth of implanted tumors. We propose that strong selection
can produce evolution of different strategies to generate resistance to the growth
of inoculated tumors,1. Changes in the supportive cell layer that decrease limited
growth of cancer cell populations. 2. Increase of immunologic response to tumor
antigens. Hence, we examined the evolution of resistance in immuno-compe-
tent and immuno-defıcient mice. Fixed number of cells from luciferase tagged
LL/2 (Lewis lung carcinoma) cancer cells were implanted in groups of 10 male
C57BL/6 and SCID mice. All tumor cells were obtained from frozen samples of
a single large tumor population to eliminate any contribution from tumor cell
evolution. Tumor growth in each animal was measured by calipers and lu-
ciferase imaging. The two animals that exhibited the slowest tumor growth in
each cohort were bred with females from the same litter. Over 12 generations,
the selection pressures resulted in emergence of SCID mice in which tumors
grew at approximately 1/10th the rate compared their initial generation. The
immunocompetent C57BL/6 mice evolved signifıcant changes in immune-me-
diated parental tumor cell killing but this has yet resulted in signifıcantly delayed
tumor growth because the LL/2 cells rapidly evolve resistance strategies. Injec-
tion of the same tumor cells into unevolved wild type strains of both SCID and
C57BL/6 mice produced rapid tumor growth identical to that seen in the fırst
generation.Using immunohistochemistrywe observed decrease in blood supply
among generations, proliferation, and apoptosis while no differences were ob-
served in Glut-1 and CA-9 expression. To investigate this observation, fırst we
examined changes in the molecular characteristics of the tumor cells during
in-vivo growth by microarray on tumor cells isolated from “fınal” adapted cell
population(s) in the animals that have been selected to decrease tumor growth
compared to the wild type as well as normal cells in parallel. Our results showed
that there are 158 genes different between tumors growing in the evolved and
selected mice, among them are genes involved in extracellular matrix organiza-
tion, hence we used second-harmonic generation (SHG) microscopy to image
and quantify collagen, our results showed signifıcant increase in collagen at the
edge as well as the core of the tumor of the evolved mice compared to wild type
mice. In conclusion our evolutionary study has reduced tumor growth in SCID
mice but has had limited success in the C57BL/6. The SCID mice adaptation to
tumor was likely through alteration in function of the supportive cell layer (Col-
lagen), thus generating biomechanical forces and protective cellular events dur-
ing tumor progression at early stages.
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#2930 Nichemicroenvironments essential for tumor heterogeneity of pri-
mary cancer cells. Shiki Fujino,1 NorikatsuMiyoshi,2 Masayuki Ohue,2 Yusuke
Takayashi,2Masayoshi Yasui,2HidekazuTakahashi,1 NaoyukiHaraguchi,1 Jhu-
nichi Nishimura,1 Taishi Hata,1 Tsunekazu Mizushima,1 Yuichiro Doki,1 Ma-
saki Mori1. 1Osaka University, Osaka, Japan; 2Osaka Medical Center for Cancer
and Cardiovascular Diseases, Osaka, Japan.
Primary culture of cancer cells derived from each patient’s tumor can provide
important information of the “individual tumor.” It is general to use cell lines in
basic research fıled. However, cell lines are quite different from clinical cancers.
Clinical cancer tissues are composed of not only cancer cells but also tumor
microenvironments such as stromal cells and tumor vessels. The primary cul-
ture method of clinical cancer with tumor niche microenvironments has not
been optimized. We have developed a simple 2D-culture method for primary
colorectal cancer (CRC). We obtained 30 samples from surgically resected tu-
mor. They weremechanically and enzymatically digested and fıbrotic tissue and
bacteria were excluded using customized two size fılters. And we cultured the
obtained cells on a matrigel-coated plate with embryonic stem (ES) cells culture
medium.Wenamed these cultured cancer cells, “isolated-tumor derivedCancer
Cells (iCCs).” All iCCs grew and about 80 % of iCCs were successfully passaged.
Twenty-three iCCs were transplanted into the subcutaneous layer of NOD-
SCID mice, and the tumor growth and histology of iCCs were examined. The
morphology was similar to each parental clinical tumor. And microarray anal-
ysis showed that RNA expression of iCCs was similar to each parental tumor.
Furthermore, we examined the culture medium; our modifıed ES culture me-
dium (ES-cultured iCCs) and 10% FBS medium (serum-cultured iCCs). The
expression of surface markers regarding cancer stem cells such as CD44 and
CD24 were different between ES-cultured iCCs and serum-cultured iCCs, and
drug sensitivity of iCCs were also different. FACS analysis and immunocyto-
chemistry revealed that iCCs contained PDGFR-positive cells. The results of
multi-drug sensitivity assay were different between iCCs and cell lines especially
in PDGFR inhibitor. Strong correlations were observed between the results of
multi-drug sensitivity assay of iCCs and clinical outcomes of chemotherapy.We
report an innovative primary culture method and the in vivo and in vitro anal-
yses of iCCs, leading to the future application.
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#2931 Targeting membrane-bound carbonic anhydrases in breast cancer
to intervene in the metastatic phenotype. Mam Y. Mboge,1 Zhijuan Chen,1
Brian P. Mahon,2 Chingkkuang Tu,1 Alyssa S. Wolff,1 John V. Mathias,1 Fabri-
zio Carta,3 Claudiu T. Supuran,3 Rob McKenna,1 Susan C. Frost1. 1Univ. of
Florida, Gainesville, FL; 2National Institutes of Health, Bethesda, MD; 3Univer-
sita degli Studi di Firenze, Italy.
Breast cancer is the second leading cause of cancer related deaths among
women in the United States. Despite the tremendous progress that has been
made towards treating localized tumors, nearly 40,000 women die each year,
predominantly from metastatic drug resistance. The tumor microenvironment
plays a pivotal role in determining tumor growth, invasion, metastasis, and
therapeutic success or failure. Therefore, a therapy targeting the tumormicroen-
vironment is needed to suffıciently preserve the quality of life of cancer patients,
by inhibiting metastasis. Elevated levels of Carbonic anhydrase IX (CAIX) ex-
pression in primary breast cancers is a marker for highly aggressive and meta-
static tumors, especially of the triple negative subtype (TNBC). It is also associ-
ated with hypoxia, extracellular acidifıcation, and poor prognosis. Low pH
(values of 6.5-6.8) is toxic to normal cells in the tumor microenvironment
while enhancing cancer cell proliferation and tumor growth. Our goal was to
compare the structure of a CAIX-mimic bound to ureidosulfonamide inhibitors
with the biological activity of these inhibitors in triple negative and estrogen
receptor positive (ER) breast cancer cell lines. CAIX is a reversible enzyme and
at low pH (high proton concentration), the enzyme will consume protons, rais-
ing pH. Our hypothesis is that CAIX inhibition, in the context of an acidic
microenvironment, will dysregulate its ability to maintain the acidic pH pre-
ferred by cancer cells which favors their growth andmigration. In this study, we
have shown the interaction of sulfonamide-based inhibitors with aCAIX-mimic
using X-ray crystallography. These structures show that the inhibitors make
multiple contacts within the active site cavity. This is consistent with the inhib-
itor-induced decrease in CAIX activity and to some extent expression. We have
also investigated the effect of CA inhibition on breast cancer cell growth, prolif-
eration, activation of cell death pathways and migration. This reveals that, al-
though CA inhibition with the sulfonamide-based compounds inhibits cell
growth and migration, it does not activate apoptotic pathways. In total, these
observations indicate that CAIX is a viable small molecular drug target for the
treatment of metastatic breast cancer.
#2932 Immuno-inhibitory pathway, TIM-3/Galectin-9, in lung adenocar-
cinoma: clinical and in vitro analysis. Mikio Oka, Yoshihiro Ohue, Koji Ku-
rose, Yumi Nishio, Midori Isobe, Eiichi Nakayama. Kawasaki Medical School,
Kurashiki, Japan.
Introduction and Purpose: Recently, immune checkpoint therapy has been
incorporated into treatment of solid cancers including lung cancer, resulted in
prolonged survival benefıt. Checkpoint inhibitors target on PD-1/PD-L1 or
CTLA-4 immuno-inhibitory molecules in immune or cancer cells. However,
checkpoint therapy in lung adenocarcinoma (LAD) showed less than 20% re-
sponse rate, suggesting existence of other immuno-inhibitory pathways. There-
fore, we focused on T cell immunoglobulin andmucin domain 3 (TIM-3) on the
CD4 and CD8 T-cell surface and its ligand Galectin-9 in tumor cells, and ana-
lyzed the expression and function in LAD cells and tissues. Materials andMeth-
ods: TILs and PBMCs were obtained from 11 patients with LAD, and 194 LAD
tissues resected surgically were analyzed. Expression of immuno-inhibitory
molecules (PD-1, TIM-3, BTLA, LAG-3) was examined by flow cytometry using
FACS on TILs and PBMCs, and PD-L1 and Galectin-9 expressions in LAD
tissues was analyzed by immunohistochemistry using tissue microarray. To in-
vestigate soluble Galectin-9 released from LAD cells, EGFR-mutated PC-9 and
EGFR-wild-typeOU-LC-SK cells were treatedwith EGFR-TKI afatinib at a con-
centration of 10 nM for 3 days. Then, the amount of Galectin-9 in culture su-
pernatant was measured by ELISA. To investigate T-cell apoptosis induction by
Galectin-9, established XAGE1-specifıic CD8 cloned T-cells were incubated
with Galectin-9 protein for 8 hrs. Results: Increased expression in TILs com-
pared to PBMCs was observed on PD-1 and TIM-3, but not on BTLA or LAG-3
in CD4 and CD8 T-cells. In LAD tissues, the frequencies of high PD-L1 and
Galectin-9 expression in the tumor cell membrane or cytoplasm were 49% and
31%, respectively (in squamous cell carcinoma, the frequencies were 32% and
16%, respectively). Furthermore, correlated expression of PD-L1, Galectin-9
and CD3 (T-cell infıltration) was observed at the periphery of the tumor nest.
Those fındings suggest the relevance of the PD-1/PD-L1 and TIM-3/Galectin-9
pathways in the tumor microenvironment of LAD. Next, soluble Galectin-9
released from the LAD cells was measured. Galectin-9 was detected only in the
medium of EGFR-mutated LAD cells following treatment with afatinib. More-
over, apoptosis was induced in TIM-3-positive CD8 T-cell clones following
interaction with Galectin-9 protein and this was inhibited by the addition of
anti-Galectin-9 or an anti-TIM-3 antibody. The fındings suggested that a signif-
icant amount of Galectin-9 could be released from LAD cells and induced T-cell
apoptosis in tumor microenvironment. Conclusions: Our results suggested the
relevance of the PD-1/PD-L1 and TIM-3/Galectin-9 immuno-inhibitory path-
ways in the tumormicroenvironment of LAD, and that release of soluble Galec-
tin-9 from LAD cells could negatively regulate T-cell function. For successful
immune checkpoint therapy in LAD, simultaneous inhibition of TIM-3/Galec-
tin-9 pathway may be needed.
#2933 Involvement of CXCL12-CXCR7 axis in adipocyte-induced TNBC
metastasis. Hyeongjwa Choi,1 Rosa Mistica C. Ignacio,1 Carla R. Gibbs,1 Eun-
sook Lee,2 Samuel E. Adunyah,1 Deok-Soo Son1. 1Meharry Medical College,
Nashville, TN; 2Florida A&M University, Tallahassee, FL.
Breast cancer (BC) is the most frequent tumor in women worldwide. Al-
though its mortality has signifıcantly decreased owing to advanced therapies,
triple negative breast cancer (TNBC) is still diffıcult to treat because of lack of
estrogen receptor, progesterone receptor and HER-2. TNBC accounts for 12-
24% of total BC and contributes to the aggressiveness and poorer outcomes. The
risk of BC increases signifıcantly in obese women.Obesity is also associatedwith
the worse clinical prognosis of BC. But the underlying mechanisms between
obesity and BC, particularly TNBC, remain unclear. Therefore, we compare the
molecular mechanisms by which human adipocyte conditioned media (CM)
affect TNBC cells (BT549) and non-TNBC cells (MCF7A). Adipocyte CM had
no effect on the proliferation of both TNBC and non-TNBC cells. However,
adipocyte CM enhanced signifıcantly migration in TNBC cells compared to
non-TNBC cells. Next, we examined the signaling pathway by which adipocyte
CM promote migration of TNBC cell. AKT and ERK were activated in both
TNBC cells and non-TNBC cells. However, phospho-STAT3 was signifıcantly
increased in TNBC cells. Also, N-cadherin, a marker for epithelial to mesenchy-
mal transition (EMT), was increased at the late time point in TNBC cells. Fur-
thermore, CXCR7 was specifıcally increased in TNBC cells after treatment with
adipocyte CM using a PCR array. CXCR7 is chemoattractive to CXCL12 which
is highly expressed in the lung, the bone marrow, and the liver, common sites of
BCmetastasis. Taken together, the results indicate that adipocyte CMmay pro-
mote metastasis of TNBC cells through the CXCL12-CXCR7 axis by activating
STAT3.
#2934 Neoadjuvant chemotherapy influence changes of the immune re-
sponse in non-small cell lung carcinomas immune response in non-small cell
lung carcinomas. Edwin Roger Cuentas,1 Carmen Behrens,2 Jaime Rodriguez-
Canales,2 Mei Jiang,3 Apar Pataer,3 Arelene Correa,3 Stephen Swisher,3 Boris
Sepesi,3 Annikka Weissferdt,3 Neda Kalhor,3 Jiexin Zhang,3 Jack Lee,3 John
Heymach,2 Cesar Moran,3 Jianjun Zhang,3 Don Gibbons,3 Ignacio Wistuba3.
1UTMDAndersonCancer Ctr., Houston, TX; 2UTMDAndersonCancer Center.,
Houston, TX; 3UT MD Anderson Cancer Center, Houston, TX.
Background: The clinical effıcacy observed with PD-1/PD-L1 inhibitors in
non-small cell lung carcinoma (NSCLC) has prompted to characterize the im-
mune response in lung tumors treatedwith chemotherapy. The aimof this study
was to determine the changes of the immune microenvironment in surgically
resected NSCLCs from patients who received and did not receive neo-adjuvant
chemotherapy. Methods: We studied formalin-fıxed and paraffın embedded
(FFPE) tumor tissues from 112 stage II/III resected NSCLC, including 61 che-
motherapy-naïve (adenocarcinoma, ADC33; squamous cell carcinoma,
SCC28) and 51 chemotherapy-treated (ADC31; SCC20) tumors. mIF was
performed using the Opal 7-color fIHC KitTM, scanning in the VectraTMmulti-
spectral microscope and analyzed using the inFormTM software (Perkin Elmer,
Waltham, MA). The markers studied were grouped in two 6-antibody panels:
Panel 1, AE1/AE3 pancytokeratins, PD-L1 (clone E1L3N), CD3, CD4, CD8 and
CD68; and Panel 2, AE1/AE3, PD1, Granzyme B, FOXP3, CD45RO and CD57.
Results: Positive PD-L1 expression (5%) in malignant cells (MCs) was de-
tected in 48% (n53/112) of NSCLCs. Overall, chemotherapy-treated tumors
showed signifıcantly higher percentages of MCs expressing PD-L1 (median,
19.52%) than chemotherapy-naïve cases (median, 1.54%; P0.008). Higher
densities of lymphocytes expressing CD3 (P0.021), CD4 (P0.05), CD57
(P0.001), CD45RO (P0.019), and PD-1 (P0.016) were detected in che-
motherapy-treated NSCLCs compared with chemo-naïve tumors. In contrast,
lower densities of FOXP3 regulatory T cells and CD68macrophages but not
statistical signifıcant were detected in chemotherapy-naïve tumors when com-
pared with chemotherapy-treated cases. Following chemotherapy ADCs exhib-
ited signifıcantly higher levels of CD57 (P0.008) and high density of PD-1
expressing by CD45RO cells (P0.016) than chemotherapy-naïve tumors.
Chemotherapy-treated SCCs demonstrated higher density of TAMs CD68,
CD57,CD45RO and PD-1 cells than chemotherapy-naïve tumors (P0.05).
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In chemotherapy-treated cancers, lower levels of CD4 helper T cells was asso-
ciated with worse overall survival (OS; P0.04) in univariate analysis. In che-
motherapy-treated ADC patients, lower levels of CD68-positive (P0.010) and
higher levels of FOXP3-positive cells correlated with worse OS (P0.044). Con-
clusions: Neo-adjuvant chemotherapy-treated NSCLCs exhibited higher levels
of PD-L1 expression and T cell subsets regulation compared to chemotherapy-
naïve tumors, suggesting that chemotherapy activates specifıc immune response
mechanisms in lung cancer. These results provide an inclination towards the
design of clinical trials combining neo-adjuvant chemotherapy and immuno-
therapy prior to surgical resection of locally advanced NSCLC. (Supported by
CPRIT MIRA and UT Lung SPORE grants, and MD Anderson Moon Shot
Program).
#2935 Sex disparity in the response of the immune microenvironment to
colon cancer liver metastases. Simon Milette,1 Ni Wang,2 Stéphanie Perrino,2
PninaBrodt1. 1McGill University,Montreal, Quebec, Canada; 2Research Institute
of the McGill University Health Centre, Montreal, Quebec, Canada.
Background: Metastasis remains the most life-threatening aspect of malig-
nant disease and a major clinical challenge. Myeloid-derived suppressor cells
(MDSC) and regulatory T lymphocytes (Tregs), which are frequently found in
the tumor microenvironment, are known to impair immune surveillance and
promote a state of immune tolerance that leads to metastatic expansion. Previ-
ously, we have shown that the incidence of colon carcinoma livermetastases was
reduced in TNF receptor 2 (TNFR2) defıcient female mice, as a consequence of
reduced recruitment of MDSCs and Tregs into the liver. Intriguingly however,
no reduction in liver metastasis or MDSC/Treg accumulation was observed in
TNFR2 defıcient male mice, suggesting that their recruitment and survival were
distinctly regulated. The objective of this study was, therefore, to elucidate the
mechanisms underlying the sex disparity observed in the response of the im-
mune microenvironment to liver metastases, in particular the role of sex hor-
mones in immune response regulation in this context. Methods Hormone-ab-
lated female mice were generated using surgical ovariectomy (OVX). Estrogen-
deprived mice, sham-operated controls and hormone reconstituted OVX mice
were injected with syngeneic murine colon carcinoma MC-38 cells via the in-
trasplenic/portal route and experimental liver metastases enumerated 2 weeks
later. MDSCs and Tregs recruited into the livers of tumor-bearing mice were
analyzed 7-10 days post-tumor injection using flow cytometry, as well as IHC
performed on liver cryostat sections. Results: We found that the number of
experimental liver metastases was markedly reduced in ovariectomized female
mice, as compared to sham-operated controls but was restored in estradiol sup-
plemented OVX mice. Reduced incidence of hepatic metastases in OVX mice
correlated with reduced accumulations of CD11bGr-1 myeloid cells (MD-
SCs) and CD4Foxp3 cells (Tregs) at metastatic sites. IHC also revealed an
increasedCD8 : CD4Foxp3 (i.e. cytotoxic T cell : Treg) ratio around hepatic
metastases in OVX mice as compared to sham-operated controls. Estradiol re-
constitution in OVX mice restored MDSC and Treg cell accumulation to the
levels observed in control mice. Conclusion: Together, our data identify female
sex hormones asmajor players in the regulation of the tumor immunemicroen-
vironment and a potential contributing factor in the patients’ response to im-
mune-based cancer therapy. Supported by the Canadian Institute for Health
Research, MDEIE and FRSQ.
#2936 Molecular characterization of the immune subclass of hepatocellu-
alr carcinoma. Daniela Sia,1 Yang Jiao,1 Iris Martinez,1 Olga Kuchuk,1 Carlos
Villacorta Martin,1 Manuel Castro deMoura,2 Juan Putra,1 Genis Camprecios,1
Swan Thung,1 Samuel Waxman,1 Vincenzo Mazzaferro,3 Manel Esteller,2 Au-
gusto Villanueva,1 Josep Maria Llovet1. 1Icahn School of Medicine at Mount
Sinai, New York, NY; 2IDIBELL, Hospital Universitari Bellvitge, Barcelona,
Spain; 3Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Background: Immune checkpoint inhibitors have emerged as a promising
therapeutic approach in different solid tumors, including hepatocellular carci-
noma (HCC). Nonetheless, little is known about the immune-component of
HCC or potential biomarkers of response to these therapies. Aims: To perform
comprehensive characterization of theHCC immunological profıle and to iden-
tify biomarkers to select immunotherapy candidates. Methods: We performed
gene expression array deconvolution through non-negativematrix factorization
in 228 resected HCCs. Characterization of the transcriptional landscape was
conducted using1,000 signatures representing distinct immune cells by gene
set enrichment and nearest template prediction analyses. Presence of immune
infıltration, tertiary lymphoid structure (TLS), PD-1 and PD-L1 immunostain-
ingswas investigated using immunohistochemistry.DNAmethylation profıle of
450K CpG sites was analyzed to identify those with signifıcant differences for
each group. Extensive validation of the immune classifıer was performed in 728
independent HCC samples. Results: Overall, an immune-related subclass of
HCC was identifıed in27% of patients. The immune subclass was character-
ized by gene signatures identifying immune cells (i.e. T cells, TLS, cytotox,
p0.001), signatures of response to immune checkpoint therapy (p0.001),
presence of high immune infıltration (p0.01), TLS (
5 foci, 19/51 vs 33/168,
p0.01) and PD-1 and PD-L1 protein expression (p0.05). The methylation
levels of 363 CpG sites in 192 immune response gene promoters were able to
capture the Immune class (ANOVA, p0.05, 0.2 Tukey test). Integration
with HCC molecular classifıcations revealed signifıcant enrichment of the Im-
mune subclass with IFN and S1 (p0.001) and exclusion of the CTNNB1 and S2
(p0.001) subclasses. The immune class contains two distinct microenviron-
ment-based types: A) Exhausted immune response type (35%) characterized
by stromal activation, T cell exhaustion signatures, and presence of immuno-
suppressive components such as TGFB, LGALS1, M2 macrophages and path-
ways able to recruit myeloid-derived-suppressor cells (FDR0.01); and B) Ac-
tive immune response type (65%) characterized by overexpression of adaptive
immune response genes and IFN signaling (p0.001). Tumors within the active
immune response type showed a trend towards better survival vs rest (p0.07).
Conclusions: Around 27% of HCC patients belong to the Immune class, char-
acterized by activation of immune cells and signatures of response to immuno-
therapies. Within this subclass, two distinct types have been characterized by
presenting active or exhausted immune responses, a feature that provides the
rationale for precision medicine-based therapies.
#2937 Utilizingmultiplex chromogenic IHC and digital image analysis to
evaluate immune cell content and spatial distribution within NSCLC tumor
tissue. Lorcan Sherry,1 Mark Anderson,1 Marianne Cowan,1 Lee Dawson,2
Richard Bystry,2 Sarah-Jane Green2. 1OracleBio, Biocity Scotland, United King-
dom; 2Asterand Bioscience, Royston, United Kingdom.
Chromogenic-based immunohistochemistry (IHC) is an established tech-
nique utilized within oncology R&D, allowing cells to be visualized within
the context of their tumor microenvironment. However, when quantifying
chromogenic stained sections via digital image analysis, the number of tar-
gets is usually limited due to constraints in deconvolving more than 3 chro-
mogens present on the same tissue section image. The purpose of this study
was to apply a customized algorithm, including a 5-colour deconvolution
process to triplex chromogen IHC plus hematoxylin stained Non-Small Cell
Lung Carcinoma (NSCLC) tumor tissues in order to quantify immune cell
content and spatial distribution within both tumor and stroma regions of
interest (ROI). A multiplex IHC assay was developed and applied to FFPE
sections of NSCLC tumor tissue to stain epithelial tumor cells (Pan CK,
yellow), CD8 cells (purple) and FoxP3 nuclei (brown), counterstained
with hematoxylin (blue). Immunostained whole slide images were generated
for image analysis. A customized algorithm, which included a 5-chromogen
color deconvolution process, was utilized within the Indica Labs HALO
platform to separate the four IHC chromogens (including counterstain) and
a fıfth color (black) representing carbon deposit artefacts. Nuclear objects
were formed by applying weighted optical density values for the brown,
purple and blue colors, which were positive for either CD8 or FoxP3 and
counterstain. A classifıer was developed to automatically segment tumor
from stroma. Each positive cell type was identifıed, using defıned size and
shape parameters, and quantifıed within each ROI. IHC multiplex staining
highlighted CD8 cells and FoxP3 nuclei to be present in both tumor and
stroma compartments. Analysis data demonstrated the number of tumor
and stroma CD8 cells was 120 and 554 cells per mm2, while the number of
tumor and stroma FoxP3 nuclei was 20 and 19 nuclei per mm2. This gave
a CD8:FoxP3 ratio of 6 within the tumor and 29 within the stroma. The
average distance of CD8 cells in the tumor or stroma to their nearest
FoxP3 nuclei was 92m and 174m respectively. The average distance of
CD8 cells to their nearest tumor cell was 39m while the average distance
of FoxP3 nuclei to their nearest tumor cell was 29m. This study demon-
strated multiplex chromogenic IHC as a valuable approach for quantifying
multiple cell types within the context of their tumor microenvironment.
Furthermore, up to fıve chromogen colors can be separated utilizing a cus-
tom 5-plex analysis algorithm, leading to a more in-depth evaluation of
immune cell types present and their spatial distribution. This propounds a
greater potential for interpretation of therapeutic mechanistic responses
within the tumor microenvironment.
#2938 Tumour-associated macrophage polarisation and re-education
with oncolytic viruses.Munitta Muthana,1 Emer Murphy,1 Amy Kwan,1 Nat-
alie Winder,1 Joe Conner2. 1Univ. of Sheffıeld Medical School, Sheffıeld, United
Kingdom; 2Virttu Biologics, United Kingdom.
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Tumor-associated macrophages (TAMs) promote key processes in tu-
mour progression through their plasticity and capacity to become polarised
by tumours to have an immunosuppressive phenotype. However, the plas-
ticity of these cells provides an opportunity for therapeutic ‘reprogramming’
towards a classically activated inflammatory phenotype thus preventing tu-
mour-associated immunosuppression and inducing anti-tumour immunity.
Oncolytic viruses (OV) represent a new class of anti-cancer therapeutics that
promote anti-tumour responses through selective tumour cell killing and the
induction of systemic anti-tumour immunity. We propose that TAMs can be
targeted using an OV, leading to altered macrophage polarization and a
reduction in tumour growth and metastasis. Experimental Design: In-vitro,
cytotoxicity, viral replication and cytokine expression was assessed in a panel
of primary human and murine macrophages following exposure to Sephre-
vir, an ICP34.5-deleted oncolytic herpes-simplex virus currently in Phase
1/2a trials. In-vivo, murine TS1-PyMT cells were implanted into the mam-
mary fat pads of female FVB mice to establish a syngeneic immunocompe-
tent mouse model of breast cancer. Tumour growth and overall survival were
assessed following administration of Sephrevir given either by intratumoural
(I.T) or intravenous injection (I.V). Immune cell enumeration and protec-
tive immunity were assessed post-mortem by immunofluorescence and flow
cytometry. Results: Both primary human and mouse macrophages served as
a host for oncolytic viral replication. Sephrevir was also found to attenuate
TAM phenotypes as evidenced by increased “M1” receptor signatures (e.g.
CD40, CD80, CD86, MHC II), increased pro-inflammatory gene expression
(e.g. IL-1, IL-6, IL-8, CXCL10, TNF-a) and increased nitric oxide produc-
tion. I.T and I.V administration of Sephrevir led to marked tumour shrink-
age as well as the recruitment of cytotoxic T cells. Moreover, TAM polarisa-
tion was evident based on a change in signature with TAMs becoming
skewed to IL-12hi/IL-10lo and a change in the iNOS/arginase1 ratio. Conclu-
sions: Our results demonstrate that Sephrevir is associated with in vivo anti-
tumour effects and importantly can be used for manipulating the phenotype
of the abundant macrophage population located within the tumour mi-
croenvironment.
#2939 Tumor associated myeloid cell transcriptome signatures in an in-
ducible Kras-positive lung adenocarcinoma murine model. Clifton L. Dal-
gard,1 Mouna Lagraoui,1 Gauthaman Sukumar,1 Celeste Huaman,1 Corey A.
Carter,2 BrianC. Schaefer1. 1Uniformed ServicesUniversity, Bethesda,MD; 2John
Murtha Cancer Center, Bethesda, MD.
Tumorigenesis is modifıed by dynamic activities in the tumor microenvi-
ronment and mechanisms driving these alterations during tumor progres-
sion may be tumor- and patient-specifıc. Of well-established functions for
tumor-associated stromal cells (e.g. angiogenesis, chemotaxis) immune sys-
tem regulation by the tumor microenvironment is less well understood in
their mechanism and effects. However, diminished activity of antigen-spe-
cifıc T cell lymphocytes tumor cytotoxicity is tumor promoting and recent
cancer immunotherapy have targeted immune inhibitory checkpoints (e.g.
anti-PD-L1) to restore T cell activity. Recent studies suggest that tumor-
associated myeloid cells play a role in immunosuppression in several human
cancers, including lung cancer. We hypothesize that early tumors of the lung
promote changes in the phenotype of tumor-proximal myeloid cells, estab-
lishing an immunosuppressive microenvironment. As a component to ob-
serve this immunosuppressive role for myeloid cells, we performed specifıc
transcriptome profıling of myeloid cells by immunomagnetic selection of
CD11b-positive cells from lung tumors of a murine inducible Kras-positive,
p53-negative cancer model. RNA sequencing of isolated myeloid cells as a
function of tumorigenesis duration (3-18 weeks) establishes the kinetics of
gene expression changes associated with tumor-supporting and immune-
suppressing functions. Genome-wide expression analysis of myeloid cells
between tumor-inducing adenovirus-Cre injected and normal control sub-
jects resulted in identifying 1,883 genes with differential expression. Gene set
enrichment analysis resulted in the stratifıcation of samples by well-estab-
lished gene signatures and tumor-promoting activity for angiogenesis (32
genes), lung tissue remodeling (47 genes) and cell survival (11 genes). Inter-
estingly, a signifıcant downregulated gene signature was observed in tumor-
associated myeloid cells for immune cell chemotaxis (12 genes) and positive
regulation of immune system activation (12 genes). These non-canonical
gene signatures may identify a myeloid phenotype for immunosuppressive
function with altered expression of genes such as L-selectin (Sell), C-C
chemokine receptor type 7 (Ccr7), C-C motif chemokine (Ccl20) and
CMRF35-like molecule 7 (CD300lb). The results shown are fırst steps in our
tasks to defıne the phenotypes and mechanisms linking myeloid cells to
tumor-associated immunosuppression in lung cancer.
#2940 TH17: mediators of metastatic growth acceleration after surgery.
Vikas Sud, Samer Tohme, Dirk J. van der Windt, Hai Huang, Allan Tsung.
University of Pittsburgh, Pittsburgh, PA.
Surgery is known to accelerate the growth and progression of metastases in
patients undergoing oncological resections with 50-60% patients having recur-
rent metastasis after resection making it a major reason for treatment failure.
This impedes the effıcacy of adjuvant chemotherapy and overall prognosis of the
patient. Studies have proved that inflammatory cascade initiated by surgery that
increases metastatic growth and progression is mediated through a specifıc
mechanism of neutrophil cell death called Neutrophil Extracellular Traps
(NETs). We investigated the mechanism of how NET formation after surgical
stress increases metastatic growth by influencing a pro-tumor microenviron-
ment in order to specifıcally identify targets for perioperative therapy to keep
metastases dormant and improve the effect of chemotherapy and overall prog-
nosis. 12 week oldmale C57BL/6Jmice (WT) andmice inwhichNET formation
was inhibited, ie,WTmice injectedwithDNAse and global homozygous knock-
out of peptidyl arginine deaminase 4 (PAD4), an essential nuclear protein for
NET formation, underwent splenic injection of 100,000 cells of themurine colo-
rectal cancer cell line, MC-38, followed with either 70% hepatic ischemia-reper-
fusion (IR) for 60minutes after 7 days or no IR. Liverswere harvested atmultiple
time points and assessed for changes in both innate and adaptive immune cell
populations by flow cytometry. On gross examination, the livers of the NET
defıcient mice had fewer tumors as compared to the WT mice. Mice, which
underwent IR after tumor cell injection in both groups showed an increase in
nodules formation versus those with just tumor cell injection, however were still
more in WT than NET defıcient mice. Flow cytometry revealed a decrease in
both TH17 (0.36% of T cells in no IR mice vs 0.0036% in IR mice) and CD8 cells
(71% of T cells in no IRmice vs 34.8% in IRmice) in mice subjected to IR versus
those with only tumor injection. We found that increased tumors after surgical
stress, whichweremediated byNET formation, were caused due to a decrease in
anti-tumor activity of CD8 cells regulated via TH17 cells. If controlled in the
perioperative period, it may reduce acceleration in metastatic foci and improve
the overall prognosis. We are further investigating the mechanism of NETs
influencing the tumor immune environment.
#2941 Inhibition of hypoxia-induced ectonucleoside triphosphate diphos-
phohydrolase 2 (ENTPD2) restrains myeloid-derived suppressor cell (MDSC)
accumulation and sensitizes tumors to immune checkpoint inhibition.
David Kung-Chun Chiu, Aki Pui-Wah Tse, Iris Ming-Jing Xu, Robin Kit-Ho
Lai, Hui-yu Koh, Felice Ho-Ching Tsang, Larry Lai Wei, Chun-Ming Wong,
Irene Oi-Lin Ng, Carmen Chak-Lui Wong. Univ. of Hong Kong, Hong Kong,
Hong Kong.
Background and Objective: Rapidly expanding knowledge on cancer immu-
nology has introduced promising anti-cancer therapeutic approaches which in-
volve the activation of T cells to combat cancer cells. Accumulating studies have
indicated that the effıcacy of immunotherapies is critically determined by the
stromal cell components in tumors.Myeloid-derived suppressor cells (MDSCs),
are regarded as one of the major immune cell types that possess immunosup-
pressive activities against T cells which allow cancers to escape immune surveil-
lance and become non-responsive to immune checkpoints blockade. To in-
crease the effıcacy of immunotherapy, novel strategies to targetMDSC in tumors
are warranted. Hypoxia, oxygen (O2) shortage, frequently occurs in tumors due
to abnormal vasculature. Using hepatocellular carcinoma (HCC) as amodel, we
have previously observed MDSC preferentially accumulates in hypoxic regions
of human HCC tissues. Here, we aim to identify hypoxia-induced therapeutic
targets that are critical for MDSC accumulation in tumors. Experimental Pro-
cedures: Transcriptome sequencing in multiple HCC cell lines exposed to hyp-
oxia and normoxia and HCC clinical specimens was performed to identify po-
tential hypoxia-induced genes relevant to HCC development. MDSCs were
isolated from HCC-bearing mice by magnetic bead sorting for different func-
tional assays. LC-MSwas performed to evaluate the level of extracellular metab-
olites. Flow cytometry was used to detect the frequencies of tumor-infıltrating
MDSCs in orthotopic and subcutaneous HCC mouse models. Results: We
showed that hypoxia, through stabilization of hypoxia-inducible factor-1 (HIF-
1), induced ectoenzyme, ectonucleoside triphosphate diphosphohydrolase 2
(ENTPD2/CD39L1), in cancer cells, causing its over-expression inHCCclinical
specimens. Over-expression of ENTPD2 was found as a poor prognostic indi-
cator for HCC patients. Mechanistically, we demonstrated that ENTPD2 con-
verted extracellular ATP to 5’-AMPwhich prevents the differentiation ofmono-
cyticMDSCs to dendritic cells, therefore promoting themaintenance ofMDSCs
in vitro and in vivo. Therapeutically, we found that ENTPD2 inhibitor POM-1
restrainedMDSC accumulation and tumor growth, substantially enhancing the
effıciency and effıcacy of immune checkpoints inhibitors. Conclusion: Our
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study reveals a novelmechanismwhereby hypoxia/HIF-1 in cancer cells governs
tumor-infıltratingMDSCs. Our data suggest that ENTPD2may be a good prog-
nostic marker and therapeutic target for cancer patients especially those receiv-
ing immune therapy.
#2942 Immunophenotypes in young-onset colorectal cancer. M E. van
Herk,MLee,MRytterdahl,ME.Kop,AF.Ramalheiro, R vanderBreggen, T van
Wezel, H Morreau, E S. Jordanova, N F. de Miranda. Leiden university medical
centre, Leiden, Netherlands.
Colorectal cancer accounts for ten percent of new cancer cases and is the
fourth most frequent cause of cancer-related deaths worldwide. In recent years,
mainly due to screening programs,more patients are diagnosed in early stages of
tumor progression, leading to a higher survival rate. However, the incidence of
young (50) patients diagnosed with colorectal cancer has been on the rise.
These patients often have a poor prognosis due to the fact that tumors are
diagnosed at advanced stages of tumor progression. To our knowledge, no study
has yet characterized immunophenotypes and immune evasive mechanisms
specifıcally in young-onset colorectal cancers. To that end we have investigated
the expression of HLA class I and PD-L1 in over 200 colorectal cancers derived
from young-onset ( 50 years-old) patients. Furthermore, we applied a novel
multispectral immunofluorescence technology to perform multiparameter im-
munophenotypingwithCD3, CD8, PD-1, PD-L1, CD163, andKi-67 in the same
cohort. We describe that HLA class I expression is maintained in the large
majority of tumors allowing thus the development of neo-antigen targeted ther-
apies. Interestingly, reduced expression of HLA class I but not total loss was
associated with liver metastases, which suggests a specifıc selective pressure at
this organ that might warrant tailored immune therapeutic interventions. As
previous studies on colorectal cancer demonstrated, PD-L1 expression is limited
and often restricted to immune cell compartments. The presence of immune cell
infıltrates was related to the mutation background of tumors but also to their
HLA class I phenotype: tumors with altered HLA class I expression were more
likely to present traces of lymphocyte-mediated anti-tumor immunity. Retained
HLA class I expression in the majority of colorectal cancers associated with low
infıltration by effector immune cells suggests the therapeutic induction of anti-
tumor immune responses in young-onset colorectal cancers, for instance, by
means of neo-antigen-targeted therapies. We are currently assessing the fre-
quency of natural recognition of neo-antigens in an autologous setting in young-
onset, late-stage colorectal cancers. This work was supported by the Fight Colo-
rectal Cancer-Michael’sMission-AACRFellowship in Young-Onset, Late-Stage
Colorectal Cancer Research awarded to N.F.C.C. de Miranda (15-40-1645-
DEMI).
#2943 MYC functions as a master switch for natural killer cell-mediated
immune surveillance of lymphoidmalignancies. Srividya Swaminathan,Adri-
ane Mosley, Crista Horton, Daniel F. Liefwalker, Anja Deutzmann, Renumathy
Dhanasekaran, Arvin Gouw, Andrew Gentles, Martin Eilers, Holden T.
Maecker, Dean W. Felsher. Stanford University, Stanford, CA.
The MYC oncogene drives the pathogenesis of many hematopoietic malig-
nancies, including Burkitt’s lymphoma (BL) and Acute Lymphoblastic Leuke-
mia (ALL). These malignancies are often “oncogene-addicted” to MYC. Using
mass cytometry (CyTOF), we demonstrate that MYC-addicted T-ALL excludes
specifıc immune subsets from the tumor microenvironment implicated in im-
mune surveillance, including natural killer (NK) cells. MYC inhibition clears
malignant lymphocytes from the spleen and restores the normal splenic NK
composition. Concordantly, peripheral blood of T-ALL patients have reduced
percentages of activated NK cells as compared to healthy individuals. We show
that MYC excludes activated NK cells from sites of lymphomagenesis by sup-
pressing ERK1/2-STAT1/2-Type I IFN signaling, in both murine and human
lymphomas. Furthermore, MYC-associated BL patients with higher than me-
dian expression of STAT1/2, and cytotoxicNK cell genes, PRF1 andGranzymes,
have favorable clinical outcomes. Hence, oncogenic MYC appears to causally
and reversibly suppress NK-mediated immune surveillance during lymphom-
agenesis.
#2944 miR-130a and -145 reprogram myeloid derived suppressor cells
and enhance anti-tumor immunity.Hiroki Ishii,1 SumanK.Vodnala,1 Bhagelu
R. Achyut,2 Christine M. Hollander,1 Ashish Lal,1 Li Yang1. 1National Cancer
Institute, Rockville, MD; 2Georgia Regents University, Augusta, GA.
Myeloid derived suppressor cells (MDSCs) are increased in tumor bearing
condition, and elicit immunosuppression via type 2 polarization. We have
previously reported that TGF- signaling in MDSCs is essential for tumor
metastasis. TGFR2, a receptor essential for TGF- signaling, is elevated in
MDSCs. Deletion of Tgfbr2 in MDSCs, the gene encoding TGFR2, signif-
icantly decreased tumor metastasis. However, it is unclear how TGFR2 is
regulated in MDSCs. We identify microRNA-130a and -145, which directly
target Tgfbr2 in MDSCs and inhibit the expression of TGF- receptor II
(TRII). Both miRs levels were lower in MDSCs from advanced tumor bear-
ing mice correlating to increased TRII level. Overexpression of miR-130a
or -145 in MDSCs shift their immunological phenotype from type 2 to type 1
polarization. Moreover, tumor metastasis was signifıcantly suppressed in
myeloid specifıc miR-130 transgenic mice. In pre-clinical mouse models, the
number of lung metastasis was signifıcantly decreased when mice were
treated with combination therapy of miR-130a or -145 with paclitaxel when
compared with miR-130a, -145, or paclitaxel alone. We proposed that repro-
gramming of MDSCs by miR-130a and -145 could be a novel strategy in
therapeutic treatment for breast cancer metastasis.
#2945 Impact of intratumoral mature dendritic cells on prognosis of the
patients with esophageal squamous cell carcinoma. JunyaNishimura, Hiroaki
Tanaka, YuichiroMiki, Tatsuro Tamura, Tatsunari Fukuoka, Go Ohira, Masat-
sune Shibutani, Sadaaki Yamazoe, Kenjiro Kimura, Takahiro Toyokawa,
Hisashi Nagahara, Ryosuke Amano, Kazuya Muguruma, Kiyoshi Maeda, Kosei
Hirakawa, Masaichi Ohira. Osaka City University Graduate School of Medicine,
Osaka, Japan.
[Background] Promising effıcacy of the immunotherapy with anti-PD-1
antibody for esophageal squamous cell carcinoma (ESCC) is expected. Tu-
mor-infıltrating lymphocytes (TILs)have been found to be associated with
favorable outcome of patients in many cancers including ESCC. However,
the contributing factor of TILs in the primary tumor remains unclear. Den-
dritic cells (DCs) are the most potent antigen-presenting cells to induce
cytotoxic T lymphocytes. [Purpose] The aim of this study was to examine the
correlation of mature dendritic cells with CD8 cells in the tumor in order to
clarify the impact of DCs on locally infıltrated lymphocytes in ESCC. [Object
and Methods] Formalin-fıxed, paraffın-embedded blocks of primary lesions
were collected from 80 patients with ESCC who underwent surgical treat-
ment at Osaka City University Hospital. Immunohistochemical analysis us-
ing anti-LAMP-3 antibody and CD8 antibody was used to evaluate intratu-
moral DCs and TILs. The number of LAMP-3DCs and TILs were counted
at400 magnifıcation.We divided the 80 cases into two groups according to
the median number of intratumoral DCs and TILs to examine the clinico-
pathological features. [Results] LAMP-3DCs were predominantly ob-
served in peritumoral area and sparsely found in intratumoral area, whereas
CD8T cells distributed between both peritumoral and intratumoral areas.
The number of DCs was signifıcantly associated with increasing TNM stage.
For example, the median number of DCs was 59.9 in pathological T1, 34.2 in
T2/3, 62.4 in pN1, 34.1 in pN1/2/3. In addition, many patients with high
infıltaraion of DCs had positive lymphatic invasion (Ly). The number of
intratumoral DCs was signifıcantly correlated with the number of TILs
which were observed in intratumoral regions. Patients in the high infıltration
of DCs group showed a signifıcant better prognosis than patients in the low
infıltration group. Double staining showed that LAMPDC-CD8T cell
clusters were seen in peritumoral area.
#2946 Prognostic effect of tumor-infıltrating immune cell composition in
non-small cell lung cancer by histology.Menno Tamminga, T. Jeroen Hilter-
mann, Ed Schuuring, Rudolf S. Fehrmann, Harry J. Groen. University Medical
Centre Groningen, Netherlands.
Introduction: The immune system plays an important role in tumor pro-
gression and treatment response, for example with the new immune modu-
lating therapies. In lung cancer the effect of the individual immune cell types
is unclear. In our study, we used publicly available expression data to fınd
evidence whether there are differences in the composition of immune cell
fractions within the microenvironment between squamous cell carcinoma
and adenocarcinoma of the lung. Methods: We searched the Gene Expres-
sion Omnibus (GEO) for human NSCLC samples. Analysis was confıned to
samples hybridized to the Affymetrix HG-U133 Plus 2.0 (GEO accession
number GPL570) platforms. Expression profıles were downloaded and cu-
rated for duplicates and corrupt fıles. Different immune cell fractions were
estimated using CIBERSORT and the LM22 leukocyte signature matrix. We
combined this information with available clinical data. We used Cox regres-
sion analyses to evaluate the prognostic impact of the different immune
fractions and Mann-Whitney U tests to test signifıcant differences. Results:
Comparing the immune cell composition of adenocarcinoma (n587) and
squamous cell carcinoma (n254), we observed in adenocarcinoma in-
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creased percentages of naïve and memory B-cells, resting and active CD4
T-cells, regulatory T-cells, active NK cells, monocytes, M2 macrophages,
resting dendritic cells and resting mast cells, and decreased percentages of
plasma cells , CD8 T-cells, follicular helper cells, resting NK cells, gamma
delta T-cells, M0 and M1 macrophages and active mast cells. In adenocarci-
noma, a higher percentage of memory B-cells in the immune infıltrate was
associated with increased survival (HR 0.97, 95% CI 0.95-0.99, p0.02),
while higher percentages of neutrophils (HR of 1.07, 95% CI 1.01-1.13,
p0.02), M0 macrophages (1.02, 95% CI 1.01-1.04, p0.01) and follicular
helper cells (1.07, 95% CI 1.02-1.13, p0.01) were associated with a worse
survival. In both histologies, the resting mast cell immune fraction showed a
positive association with survival (adenocarcinoma HR 0.96, 95% CI 0.93-
0.99, squamous cell carcinoma HR 0.93, 95% CI 0.89-0.98, p0.01 in both
histologies).In squamous cell carcinoma, a borderline association with a
worse prognosis was observed with the naïve CD4 T-cell fraction (HR of
1.1, 95% CI 1.00-1.22, p0.053) and the regulatory T-cell fraction (HR of
1.11, 95% CI 0.99-1.24, p0.067). Conclusion: In NSCLC signifıcant differ-
ences in intratumoral immune cell composition were observed between ad-
enocarcinoma and squamous cell carcinoma.
#2947 Intratumoral injection of the toll-like receptor 4 agonist G100 in-
duces a T-cell response in the soft tissue sarcoma microenvironment. Yong-
woo D. Seo,1 Edward Y. Kim,1 Ernest U. Conrad,2 Ryan B. O’Malley,1 Sara
Cooper,3 BaileyDonahue,3 LeeD.Cranmer,4Hailing Lu,5 FrankHsu,5 Elizabeth
T. Loggers,4 Taylor Hain,3 Darin J. Davidson,1 Lynn Bonham,4 Venu G. Pillar-
isetty,1 Gabrielle M. Kane,1 Stanley R. Riddell,3 Robin L. Jones,4 Seth M. Pol-
lack3. 1University of Washington, Seattle, WA; 2Seattle Childrens Hospital, Seat-
tle, WA; 3Fred Hutchinson Cancer Research Center, Seattle, WA; 4Seattle Cancer
Care Alliance, Seattle, WA; 5Immune Design, Seattle, WA.
Introduction: Soft tissue sarcomas (STS) are heterogeneous mesenchymal
tumors which are both morbid and lethal. G100 is a stable oil-in-water emul-
sion of glucopyranosyl lipid adjuvant, a highly potent toll-like receptor 4
(TLR4) agonist, which has been utilized for intratumoral (IT) injections and
as vaccine adjuvants without signifıcant toxicity. We hypothesized that IT
G100 would induce a robust local and potentially systemic anti-tumor im-
mune response in the STS microenvironment, leading to improved out-
comes. Methods: 15 metastatic STS patients who had a superfıcial injectable
lesion were treated with weekly IT G100 for 8-12 weeks; 12 patients received
concurrent radiation for 2 weeks at the start, while 3 got IT G100 alone for 6
weeks prior to radiation. Biopsies and blood were collected pre and post
treatment, and flow cytometry was performed on fresh tumor samples. T-cell
receptor (TCR) deep sequencing of tumor-infıltrating lymphocytes (TIL)
and peripheral blood mononuclear cells (PBMC) was performed on 7 pa-
tients. RECIST v1.1 and the Common Terminology Criteria for Adverse
Events were used to monitor clinical outcomes. Results: Patients had a me-
dian of 3 (05) prior lines of therapy and mean tumor size of 5.6cm
(120cm). No grade 3 or higher treatment-related toxicity was observed,
and local tumor control was achieved in 93% (14/15). 6 (40%) had stable
disease after treatment, and 1 (P06) had complete regression of injected
tumor. This tumor had a high percentage of infıltrating pre-treatment im-
mune cells (12% CD45 on flow cytometry versus 2.7% for all other tumors).
TCR sequencing showed that the increase in clonality of PBMC after treat-
ment was greater in P06 (389%) compared to 6 other patients (mean 34%).
There was also higher overlap in TCR sequence between TIL versus PBMC
after treatment (13% versus 22%), suggesting systemic expansion of tumor-
specifıc T-cells. In 7 patients evaluable for tumor-associated macrophages
(tumors with 1000 CD45CD11b cells), 71% had a shift from an M2 to
M1 phenotype. In all patients who received G100 alone, there was an increase
in T-cell infıltration into tumor after treatment. In one patient (P14), the
proportion of CD3 live cells in tumor went from1% to 62%; of these, 51%
were CD4 and 44% were CD8. TIL from P14 had a 251% increase in
clonality after treatment; at the same time, percentage of live tumor cells that
were PD-L1 increased from 0.02% to 1.3%. Conclusion: IT G100 provides a
potentially viable agent for local control of metastatic STS. With or without
radiation, G100 appears to shift the tumor microenvironment into a more
inflammatory state with signifıcant infıltration of T cells. The increase in
clonality in PBMC and TIL, as well as increased overlap of tumor-associated
versus peripheral TCR sequences, suggest induction of a tumor-specifıc re-
sponse. Combination of G100 with other immunomodulators may further
enhance the adaptive anti-tumor response.
#2948 Adistinct CD8 tumor infıltrating lymphocyte subset is associated
with high TIL density, enhanced cytotoxicity and improved survival in pa-
tients with lung cancer.Anusha Preethi Ganesan,1 OliverWood,2 EvaGarrido-
Martin,3 Serena Chee,2 TobyMellows,3 James Clarke,3 Daniela Samaniego-Cas-
truita,1 Divya Singh,1 Gregory Seumois,1 Aiman Altezani,4 Edwin Woo,4 Peter
Friedman,3Gareth Thomas,3 EmmaKing,3 Tilman Sanchez-Elsner,3 Panduran-
gan Vijayanand,1 Christian H. Ottensmeier2. 1La Jolla Inst. for Allergy & Immu-
nology, SanDiego, CA; 2Cancer Sciences Unit, University of Southampton, South-
ampton, United Kingdom; 3University of Southampton, Southampton, United
Kingdom; 4Southampton Univeristy Hospital NHS Trust, Southampton, United
Kingdom.
High tumor infıltrating lymphocyte (TIL) density predicts for good prognosis
in several cancers and therapies that boost the anti-tumor responses of cytotoxic
lymphocytes (CTLs) have shown promise in the clinic. However, clinical re-
sponses to currently available immunotherapeutic agents vary considerably, the
molecular basis of which is unclear. We performed global transcriptional pro-
fıling of CTLs in tumors and adjacent non-tumor tissue from 36 patients with
early stage lung cancer to defıne the molecular features associated with robust-
ness and heterogeneity of anti-tumor immune responses. We observed major
differences in the transcriptional program of tumor-infıltrating CTLs (CD8
TILs) that is shared across tumor subtypes. Pathway analysis revealed enrich-
ment of genes in cell cycle, TCR activation and co-stimulation pathways, indi-
cating tumor-driven expansion of presumed tumor antigen-specifıc CTLs. We
also observed marked heterogeneity in the expression of molecules associated
with TCR activation and immune checkpoints, and their expression was posi-
tively correlated with the density of tumor-infıltrating CTLs. Interestingly, TIL-
high tumors were also enriched for a distinct CD8 tumor infıltrating lympho-
cyte subset that appeared to have enhanced cytotoxicity and independently
predicted improved survival in patientswith lung cancer. In summary, we defıne
the molecular fıngerprint of tumor-infıltrating CTLs and identify a number of
novel targets thatmay be important inmodulating themagnitude and specifıcity
of anti-tumor immune responses in lung cancer.
#2949 TGF- is a keymediator ofNK cell dysfunction in gliolastoma.Hila
Shaim, Abdullah Alsuliman, Konrad Gabrusiewicz, Jun Wei, John Yu, Rafet
Basar, May Daher, Lucila Kerbauy, MayelaMendt, MuharremMuftuoglu, Li Li,
Enli Liu, Nobuhiko Imahashi, Sonny Ang, Young Gi, Pinaki Banerjee, David
Marin, Richard Champlin, Elizabeth Shpall, Amy Heimberger, Katayoun Rez-
vani.MD Anderson Cancer Center, Houston, TX.
Background: NK cells play a crucial role in the antitumor immune response
and are involved in controlling tumor formation, progression and metastases.
Glioblastoma (GBM) is the most devastating brain tumor, associated with very
poor prognosis. While immunotherapy emerged as a promising approach for
anti cancer therapy,GBMappears immune resistant.Here,we studied the role of
NK cells in targeting glioblastoma and possible mechanisms of NK immune
evasion. Methods: NK cells were isolated from freshly resected GBM tissue,
matching peripheral blood and the blood of healthy controls. Flow cytometry
was used to characterize the cells and their ability to produce cytokines, and
chromium release assaywas perfumed to assess their cytotoxicity. In vitro assays
were performed by co-culturing GBM stem cells (GSCs) with healthy donor NK
cells. Results: We found that whereas NK cells were abundant in primary GBM
tissue and could effıciently target GBM stem cells (GSCs), GBM infıltrating NK
cells (TiNKs) displayed an abnormal phenotype with downregulation of many
activating receptors including CD16, NKG2D, DNAM, NKp30, NKp46, 2B4
and NKG2C and upregulation of inhibitory proteins such as PD-1. This inhib-
itory phenotype was associated with impaired NK cell function when compared
with NK cells isolated from the peripheral blood of patients and healthy donors.
GSC-NK cell-cell contact resulted in release of TGF- by GCSs, which in turn
led to NK dysfunction through constitutive activating of the p-Smad pathway.
TGF- activation, in turn, is partially mediated by the matrix metalloproteases
MMP-2 and MMP-9, secreted by GSCs upon contact with NK cells and en-
hanced upon TGF- exposure. We demonstrated that inhibition of the TGF-
axis, in particular by the small molecule inhibitor, galunisertib, can prevent
GSC-induced NK cell dysfunction but is unable to inactivate the p-Smad path-
way, thus, cannot reverse existing dysfunction. Conclusions: Our results indi-
cate that NK-GBM cross-talk plays an important role in tumor escape and high-
light the importance of developing future adoptive transfer therapies with the
intent of limiting tumor escape from antitumor immunity.
#2950 Biomarkers of immune infıltration for multiplex immunofluores-
cence in breast cancer.April Swoboda, Galina Khramtsova, Lise Sveen, Andrey
Khramtsov, Rita Nanda, Olufunmilayo Olopade. University of Chicago Medi-
cine, Chicago, IL.
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Introduction: Only a subset of patients have a clinical response to cancer
immunotherapy. The molecular mechanisms that mediate the immunolog-
ical response or tolerance to treatment are just beginning to be understood.
Several tumor signaling pathways are involved in those mechanisms: Wnt/
-catenin, STAT3, NFkB, PI3K/PTEN/AKT, and TP53. To characterize the
tumor, its immune infıltrate, and its microenvironment, we examined ex-
pression of several biomarkers and determined the relationships among
them in various breast cancer subtypes. Methods: 148 breast cancer (BCa)
cases from the University of Chicago Breast Cancer SPORE tissue bank
under IRB approved protocols were classifıed into four biological subtypes
based on immunohistochemical (IHC) staining: luminal A, luminal B, Her2
and basal-like. IHC staining for PD-L1, CD8, FoxP3, CD68, CD163, and
-catenin was performed on tissue microarrays. CD8 and FoxP3 cells
were counted manually and recalculated for 1 mm2. Macrophage phenotype
was determined using single and double staining with CD68 for total popu-
lation and CD68/CD163 for M2. CD68 and CD163 cells were counted
manually, confırmed by Image Analysis, and recalculated for 1 mm2. PD-L1
and -catenin (membrane-associated, cytosolic and nuclear) were scored as
negative, weak positive, moderate, and strong. Results: The study cohort
subtypes were 20.9% basal-like, 10.4% Her2, 58.3% luminal A, and 10.4%
luminal B. The ratio of M2 to M1 cells increased with disease progression
(p0.001). Her2 and basal-like subtypes had a signifıcantly higher percent-
age of M2 cells as compared to the luminal A subtype (p0.001). The cases
with M2 macrophage phenotype had a higher ratio of FoxP3 regulatory T
cells (Tregs) to cytotoxic CD8 cells. PD-L1 expression was present in 23%
of specimens. However, the intensity of expression was markedly different
across the BCa subtypes. PD-L1 high expressing tumors had, on average,
greater FoxP3 cell infıltrate and low or absent CD8 T cells. The ratio of
FoxP3 Tregs to CD8 cells in basal-like tumors were 1.7, 2.5, and 4 -fold
higher than in Her2, luminal A, and luminal B tumors, respectively (p0.05
for all correlations). There was a statistically signifıcant decrease in mem-
brane-associated -catenin in tumor compared to normal tissue
(p0.0001). The proportion of tumors positive for cytosolic or nuclear
-catenin in basal-like tumors was statistically higher than all other tumor
subtypes. High -catenin nuclear protein expression was predominantly
observed in tumors that lacked CD8 T cells. Ongoing analysis will evaluate
the association of these biomarkers with clinical outcomes. Conclusions and
Future Directions: Our data suggests that IHC using a panel of antibodies
may be a robust and suitable method for evaluating level of immune infıltra-
tion. Future studies will evaluate multiplex immunofluorescence of multiple
biomarkers in breast tissue.
#2951 The tumor microenvironment in cholangiocarcinoma is domi-
nated by an immunosuppressive infıltrate. Nathania M. Figueroa, Brian Belt,
Ankit Patel, Booyeon Han, Margaret Hill, William Alexander, Michael O’Dell,
Aditi Murthy, Kelli Connolly, Scott A. Gerber, Aram Hezel, David Linehan.
University of Rochester Medical Center, Rochester, NY.
Purpose: To characterize the dynamics of the immune response to cholangio-
carcinoma (CCA) in a genetically engineered mouse model of CCA in order to
identify immune pathways susceptible to targeted immunotherapies. Experi-
mental Design: Geneticallymodifıedmice with targeted Kras activation and loss
of p53 (Alb-Cre/LSL-KRASG12D /p53Lox/) in the liver spontaneously develop
CCA recapitulating the histopathologic features of human disease. To evaluate
the in vivo immune response to CCA, tumors from Kras-p53 mice and normal
livers were excised and processed for histologic examination, flow cytometry,
and gene expression analysis. Immunohistochemistry (IHC) and flow cytometry
were performed on myeloid and T cell markers to distinguish immune cell
subsets. Cell lines established from isolated CCA tumors were used to assess the
functional impact between the immune system and tumor cells in co-culture
in-vitro studies. Results: Kras-p53 murine hepatic tumors were highly desmo-
plastic with a heavy fıbrotic stromal compartment. IHC analysis demonstrated a
prominent inflammatory leukocyte infıltrate compared to normal liver. Flow
cytometry of single cell tumor suspensions showed the immune reaction was
dominated by CD11b monocytic (Ly6C) and granulocytic (Ly6G) my-
eloid cells, andFoxp3 regulatoryT cells (T reg). In vitro studies revealed tumor
educatedmyeloid cells expressedhigher levels of genes associatedwith an immuno-
suppressive phenotype, including Arginase 1 (p0.007). Invasion assays analyz-
ing themigrationpotential ofCCAcell lines co-culturedwithCD11b cells showed
increased invasive properties in these tumor cells when compared to naive controls
(p0.0001). Additionally, increased tumor-initiating properties were seen by
qRT-PCR in tumor cell lines having undergone similar co-culture experiments.
These data suggest the immune response to CCA is predominantly immunosup-
pressive and tumor supportive. Conclusion: CCA tumors from Alb-Cre/LSL-
KRASG12D /p53Lox/mice have a prominent immunosuppressive infıltrate recapit-
ulating features of the immune reaction in human disease. Thus, Kras-p53 mice
provide an ideal model to test targeted immunotherapy for the treatment of CCA.
#2952 The novel cathepsin L/K inhibitors KGP94 and KGP207 prevent
M0 toM2macrophage differentiation andmacrophage-mediatedpro-tumor
functions. Samantha S. Dykes, Dietmar W. Siemann. University of Florida,
Gainesville, FL.
Tumor-associatedmacrophages playmany important roles in tumor progres-
sion, including facilitating tumor cell invasion and angiogenesis. Due to their
numerous pro-tumor functions, tumor-associated macrophages represent an
important cell population in the design of targeted anti-cancer therapies. Inter-
leukin-4-mediated activation of macrophages resulted in an M2-like, or pro-
tumor macrophage phenotype, often associated with increased expression of
proteases including the lysosomal cathepsin L. Cathepsin L is important in both
macrophage and tumor cell invasion, whereby secreted cathepsin L degrades the
extracellular matrix, allowing for cell infıltration. The present study examined
the role of cathepsin L in M0 to M2 differentiation and macrophage-mediated
tumor cell invasion using the novel cathepsin L/K inhibitors KGP94 and
KGP207 [Dr. Kevin Pinney, Baylor University]. KGP94 and KGP207 prevented
M2macrophagemotility and invasion in in vitromigration and invasion assays.
Moreover, KGP94 and KGP207 reduced macrophage-stimulated invasion of
4T1 murine breast cancer cells. Together, these data suggested that cathepsin L
was necessary for macrophage invasion and motility and for macrophage-me-
diated invasion of breast cancer cells. KGP94 and KGP207 treatment partially
prevented IL-4-stimulated M0 to M2 differentiation of macrophages as deter-
mined by a decrease in the IL-4-induced expression of the M2 marker Argi-
nase-1 upon drug treatment. Additionally, exogenous recombinant cathepsin L
partially stimulated the expression of Arginase-1 inM0macrophages. Together,
these data suggest that cathepsin L plays a role in macrophage M0 to M2 differ-
entiation. In conclusion, the novel cathepsin L/K inhibitorsKGP94 andKGP207
prevented M0 to M2 differentiation, macrophage invasion, and macrophage-
stimulated invasion of breast cancer cells. These data highlight the importance of
cathepsin L inmacrophage functions and suggest that cathepsin L inhibition is a
viable approach for the treatment of tumors associated with high macrophage
infıltration.
#2953 Tumor-associated macrophages infıltration highly associated with
PD-L1 expression in gastric cancer. Kazuto Harada,1 Jeannelyn S Estrella,1
Arlene M Correa,1 Lang Ma,1 Xiaoquan Dong,1 Yan Xu,1 Wayne L Hofstette,1
Kazuki Sudo,1HisashiOnodera,2 Koyu Suzuki,2 Akihiro Suzuki,2 Randy L John-
son,1 Zhenning Zhenning,3 Shumei Song,1 Jaffer A Ajani,1 Hisashi Onodera2.
1UT MD Anderson Cancer Ctr., Houston, TX; 2St. Lukes University, Tokyo, Ja-
pan; 3First Hospital of China Medical University, Houston, China.
Objectives: programmed death ligand 1 (PD-L1) is key protein for tumor to
acquire the evacuation form T cell immune response and PD-L1 inhibitors are
useful for an immune checkpoint blockade therapy. Tumor-associated macro-
phages (TAM) facilitate not only tumor cell progression, but also immunosup-
pression, which prevent tumor cell attack by T cell. Therefore, TAM is consid-
ered to be associated with PD-L1 expression, however it remain unclear in
gastric cancer (GC).Methods:We performed immunohistochemical staining of
PD-L1, CD68 (pan-macrophage) andCD163 (M2macrophage) in 217GC sam-
ple tissuemicroarray. The area of CD68 andCD163 positive cells were evaluated
by using by theCytoplasmicV2.0 algorithmon theAperio ImageScope software.
Results: 31 samples (14.3%) were positive for PD-L1 expression. The mean of
rate for CD68 andCD163 positive area were 6.8	0.38% and 6.2	0.30%, respec-
tively. CD163 positive macrophage infıltration is signifıcantly more in diffuse
type tumor than in intestinal type tumor (diffuse (n111): 6.9%, intestinal
(n91): 5.3%, p0.0056), but CD68 positive macrophage infıltration is similar
in both type (p0.38). Interestingly, PD-L1 expression tumor have signifıcantly
more CD68 and CD163 positive macrophage infıltration (CD68: PD-L1 nega-
tive 6.3%, positive 10.4%, p0.0002, CD163: PD-L1 negative 5.7%, positive
9.2%, p0.0001). PD-L1 expression and CD68 and CD163 positive area had no
relationship between any clinicopathological features. Conclusions: Macro-
phages infıltration in GC is highly associated with PD-L1 expression of tumor
cells. M2macrophage infıltration is signifıcantly associated with diffused type of
GAC. This result suggests that TAM infıltration is associated with the immuno-
suppression through upregulating PD-L1 expression in GC cells. Thus, macro-
phages infıltration can serve as a potential therapeutic target.
#2954 The role of hedgehog signaling in breast cancer progression
throughmacrophage polarization.AnnHanna, Lalita A. Shevde.University of
Alabama at Birmingham, Birmingham, AL.
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The tumor microenvironment is comprised of stromal cells that constantly
crosstalk with the cancer cells. Stromal cells, specifıcally tumor infıltrating im-
mune cells, secrete cytokines and chemokines that regulate host responses to
cancer through tumor-suppressing or tumor-promoting mechanisms. Macro-
phages within the tumor microenvironment are very plastic and can modulate
different functions that promote tumor growth or tumor suppression, depend-
ing on their phenotype. Classically activatedmacrophages (M1) suppress tumor
growth by mounting a pro-inflammatory immune response; while alternatively
activated macrophages (M2) promote tumor progression by inducing an anti-
inflammatory response which suppresses immune system function. Hedgehog
(Hh) signaling is essential for normal mammalian embryonic development by
modulating vital functions such as cell proliferation, differentiation, and angio-
genesis. Although the Hh signaling pathway is tightly controlled, it often is
deregulated, thus promoting tumorigenesis and tumor progression. Aberrant
Hh signaling has particularly been implicated in breast cancer progression and
metastasis. In this project, we investigate the role of Hh signaling in polarizing
cancer associated macrophages toward the tumor-promoting M2 phenotype in
a breast cancer model. We have discovered that using small molecule inhibitors
to inhibit Hh signaling attenuates the cytokine profıle associated with M2 mac-
rophages, while adding recombinant Hh ligand potentiates it. Our data thus far
supports a role for Hh signaling in alternatively polarizing macrophages. We
hypothesize that Hh inhibitors will reduce the abundance of M2 macrophages
and prevent metastasis.
#2955 Gr1-MDSCs and Tregs modulate the prostate cancer progression.
Sanjay Kumar,1 James Stokes,1 Udai Singh,2 Karyn Scissum Gunn,1 Upender
Manne,3 Selvarangan Ponnazhagan,3 Manoj K. Mishra1. 1Alabama State Univ.,
Montgomery, AL; 2University of South Carolina, SC; 3University of Alabama
Birmingham, AL.
Myeloid-derived suppressor cells (MDSCs) and Regulatory T cells (Tregs)
are themajor components of immunosuppressive network that play a critical
role in tumor immune evasion. The mechanisms by which tumors induce
expansion of suppressive cells and the crosstalk between Gr1-MDSCs (Gr1,
CD11b, F4/80) and Tregs relative to TGF- secretion remain incom-
pletely defıned. Prior studies have suggested that MDSCs may contribute to
Treg recruitment in cancer. Herein, the goal of this investigation is to exam-
ine the role of TGF-mediated generation of Tregs and Gr1-MDSCs during
prostate cancer progression and clearance. To achieve this goal, matrigel
system was used along with transgenic adenocarcinoma of mouse prostate
(TRAMP-C1, C2 and C3 cell) in C57BL/6 mice. Interestingly, TRAMP-C3
cells are characterized as non-tumorigenic; however, TRAMP-C1 and
TRAMP-C2 cells do form tumor. Mice were administered with serial log
concentration of TRAMP (C1, C2 and C3) cells along with the matrigel.
After three weeks, matrigels along with or without tumor were excised from
tumor bearing mice, single cell suspensions was prepared and cells were flow
analyzed for GR1MDSCs and Tregs. Additionally, the TGF- level was also
estimated (colorimetric) in culture supernatant in context to MDSCs and
Treg expansion. Our initial fındings suggest that the expression of Gr1-
MDSCs (Gr1, CD11b, F4/80) and Foxp3 Tregs increased in
TRAMP-C1 and C2 as compared to TRAMP-C3 bearing C57BL/6 mice.
These fındings indicate that the modulation of Gr1-MDSCs and Tregs could
help in tumor suppression.
#2956 Chemical library screen identifıes compounds that target S100A8/
S100A9 complex and MDSC accumulation. Eunmi Lee,1 Maria Ouzounova,1
Raziye Piranlioglu,1 Abdeljabar El Andaloussi,1 Sena Arbag,2 Gang Zhou,1
Hasan Korkaya1. 1Augusta Univ. Cancer Ctr., Augusta, GA; 2Hacettepe Univer-
sity, Ankara, Turkey.
We previously demonstrated that MDSC subsets accumulated in primary
tumor and distant organs regulate tumor plasticity. The mouse transcriptome
analysis of in vitro co-cultures and samples from syngeneic mouse model re-
vealed that granulocytic subset of myeloid-derived suppressor cells (gMDSCs)
from metastatic 4T1 tumor bearing mice regulate several hundred genes in tu-
mor cells upon co-culture. The top genes are S100A8, S100A9, MMP8, FPR1,
CCL3, and TGF2 which also predicted poor survival in human solid tumors
including breast cancer. Therefore, we called these 6 genes as “metastatic gene
signature”. It has been reported that S100A8/S100A9 heterotetramer, called cal-
protectin, play a key role in inflammation-associated cancer progression. To
investigate the role of calprotectin (S100A8/A9) in tumor-mediated immuno-
suppression and metastasis, we fırst utilized Tasquinimod, a small molecule
targeting S100A9 only. However, Tasquinimod treatment of 4T1 tumor-bearing
mice had a moderate anti-tumor activity which may be due to a limited activity
on granulocyticMDSCaccumulation. In addition, we determined that therewas
a signifıcant upregulation of S100A8 inMDSCs fromTasquinimod treatedmice.
This data suggested that inhibiting only S100A9 leads to activation of S100A8
and thus may be ineffective targeting of MDSCs. We therefore run a computa-
tional screen of the NCI chemical library against the crystal structure of calpro-
tectin (S100A8/S100A9) and identifıed 40 lead compounds.We then performed
in vitro screening assay to identify compounds that inhibit MDSC induction.
We identifıed 3 compounds that signifıcantly suppressed gMDSC differentia-
tion.We are currently performing in vivo studies with these 3 candidate drugs in
our murine breast cancer model and will present our fındings at the AACR
meeting. We believe that this study will provide a novel drug targeting S100A8/
S100A9 heterotetramer, a key molecule in MDSC induction and its regulatory
functions during tumor progression.
#2956A Cancer invasion of mammary epithelial cells in 3D culture shows
YAP-independentmechanotransduction. Joanna Y. Lee, Jessica Chang, Sung-
min Nam, Ovijit Chaudhuri. Stanford University, Stanford, CA.
83% of non-invasive breast cancers are diagnosed as ductal carcinoma in situ
(DCIS). While some DCIS tumors remain confıned in the mammary duct, others
progress into invasive ductal carcinoma (IDC). The mechanisms underlying inva-
sion arenotwell understood.Current diagnosticmethods cannot accurately predict
whichDCIScaseswill progress to IDC,andunnecessary treatmentaffects long-term
healthandqualityof life,withradiationpotentiallypromotingmalignancy-inducing
mutations. One possible regulator of invasion may be extracellular matrix (ECM)
stiffness. Increased ECM stiffness has been correlated with invasion and 3D culture
models of normal mammary epithelium show that enhanced stiffness induces an
invasive phenotype. However, the mechanisms underlying stiffness-induced inva-
sion remainunclear. Studieshaveconvergedupon the fınding thatYAP, a transcrip-
tional regulator that is deregulated in diverse cancers, is the transducer of ECM
stiffness. However, these studies were primarily performed in 2D culture and in-
volved col-1, a ligand that activates distinct signaling pathways and is not normally
found in the BM. Here, we examined the gene expression profıles of 3D cultured
MCF10A cells during stiffness-induced invasionwith andwithout col-1.We gener-
ated interpenetrating networks (IPNs) of reconstituted basementmembrane (rBM)
and alginate, which allow stiffness to be tuned in the absence of col-1 and indepen-
dentlyof cell adhesion ligandconcentrationandmatrixpore size.Traditionallyused
hydrogels composed of rBM and col-1, with stiffness tuned by increasing concen-
trations of col-1,were also produced for 3Dculture.Our results show that enhanced
3D stiffness increasesMCF10A cell invasion and proliferation in both the presence
and absence of col-1. However, in contrast to results from 2D culture, invasive
phenotypes in 3D cultured cells did not correlate with nuclear localization of YAP,
indicating lack of YAP activity. The dispensible nature of YAP in 3D stiffness sens-
ing was supported by RNA-seq analysis, which showed a lack of increased gene
expression of YAP downstream targets in conditions of enhanced stiffness. RNA-
seq identifıed 389 differentially expressed genes in response to enhanced 3D culture
stiffness. By relating these genes to transcription factors using ChIP-Seq data pro-
videdbyENCODE,we identifıedp300,FOS,STAT3,NELFE,andTAF1aspotential
mechanotransducers of stiffness-induced invasion. Furthermore, highly expressed
stiffness-induced geneswere validated by immunofluorescence to identify potential
indicators for invasion. Our RNA-seq results may lead to the development of a
PCR-based prognostic that allows accurate determination of cancer invasion risk in
breast cancer patients, informing course of treatment.
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#2957 T-cell receptor immunosequencing reveals novel insights into the
immune response to humanpancreatic cancer.YongwooD. Seo,1 FlorenciaG.
Jalikis,1 Xiuyun Jiang,1 Marissa Vignali,2 Harlan Robins,3 Venu G. Pillarisetty1.
1University of Washington, Seattle, WA; 2Adaptive Biotechnologies, Seattle, WA;
3Fred Hutchinson Cancer Research Center, Seattle, WA.
Introduction: Despite advancements in therapy, pancreatic ductal adenocar-
cinoma (PDA) remains an aggressive cancer with highmortality. It is character-
ized by dense inflammation, including many T cells; however, it is unclear
whether these T cells signify a true antitumor response. In the setting of disap-
pointing early results of immunotherapy in PDA, we sought to gain a deeper
understanding of the tumor-associated T-cell response. Methods: With IRB ap-
proval, we obtained archival resected PDA tumors in paraffın-embedded blocks
from 54 patients. We performed histopathology to identify blocks containing
lymphnodes (LN) and performedT-cell receptor (TCR) immunosequencing on
DNA extracted from immediately adjacent tissue. To address possible intratu-
moral heterogeneity, we analyzed duplicate samples from separate blocks for 10
TUMOR BIOLOGY: Tumor Microenvironment 3
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 755
patients. Productive clonality was defıned as 1-Pielou’s evenness for TCR rear-
rangements encoding a functional protein; TCR fraction was calculated from
number of observed templates and the amount of input DNA. Two-tailed t-tests
were used to compare subgroups. TCR sequence overlap between each of the 10
pairs of duplicate samples were calculated at the amino acid level. Results:
Among samples that did not contain LN,meanTCR fractionwas 0.27, andmean
clonality was 0.15 (typical peripheral blood mononuclear cell clonality is 0.08).
TCR fraction was positively correlated with clonality (R20.23, p0.007),
though this correlation was only signifıcant in patients who received neoadju-
vant chemotherapy (R20.19, p0.03). TCR fraction was higher in patients
with positive nodal status (0.32 vs. 0.23, p0.02), but lower in patients who
received neoadjuvant therapy (0.22 vs. 0.33, p0.02). There was no survival
difference between high or low TCR fraction or clonality. Samples containing
LN (not included in previous analyses) had higher TCR fraction (0.49 vs. 0.27,
p0.0001) but lower clonality (0.09 vs. 0.15, p0.0002); this relationship was
maintained regardless of nodal status. Among 10 pairs of duplicate samples,
there was 53% mean overlap of TCR amino acid sequences, compared to 0.1%
for pairs of unmatched samples (p0.0001). Conclusion: Here we demonstrate
evidence of clonal expansion of T cells in the human PDA microenvironment.
Extensive overlap of TCR sequences between two distinct samples for each of 10
pairs analyzed further suggests that the clonal expansion may be specifıc to
tumor antigens. Neoadjuvant therapy may also influence clonal expansion, as
only treated patients had a positive correlation between TCR fraction and clon-
ality. Finally, the presence of a lymphnode appears to skewTCR sequencing data
toward a less clonal but more numerous population. This suggests that the most
rigorous analysis of TCRs in a solid tumor microenvironment needs to exclude
blocks that contain lymph nodes in order to characterize the true intratumoral
population of T cells.
#2958 Transcriptome analysis of astrocytoma versus non-neoplastic hu-
man microglia. Thais Fernanda Galatro,1 Antonio M. Lerario,2 Sueli M. Oba-
Shinjo,1 Bart J. Eggen,3 Suely K. Marie1. 1University of São Paulo, São Paulo,
Brazil; 2University of Michigan, Ann Arbor, MI; 3University of Groningen, Gro-
ningen, Netherlands.
Diffuse gliomas are primary brain tumors characterized by infıltrative growth
and high heterogeneity, rendering the disease mostly incurable. Advances in
genetic analysis revealed that molecular alterations predict patients’ overall sur-
vival and clinical outcome. However, glioma tumorigenicity is not exclusively
caused by its genetic alterations. The crosstalk between tumor cells and the
surrounding microenvironment plays a crucial role in modulating glioma
growth and aggressiveness. The most abundant non-neoplastic cells in this mi-
croenvironment belong to the myeloid lineage, comprising CNS-resident mi-
croglia and infıltrating monocytes/macrophages (iTAMs). Understanding the
dynamics between tumor and myeloid cells and the changes leading to pro-
tumorigenic activation of innate immunity cells would elucidate potential treat-
ment alternatives. Microglia were isolated from the parietal cortex of 16 autopsy
samples of cognitively intact humans (non-neoplastic, NN) and from 6 glioma
samples (three GBMs, one anaplastic astrocytoma and two low grade astrocy-
toma, TU-glia), and their mRNA expression profıle was determined by deep
sequencing. The comparison of these transcriptome datasets provided an in-
comparable landscape of the crosstalk between immune and tumor cells. Our
preliminary analysis shows that differences betweenNNmicroglia andTU-uglia
go beyond inflammation specifıc genes. While there is overexpression of anti-
inflammatory markers (CD163, IL2RA, CXCL2 and TGFB1), implying pro-
tumorigenic characteristics, there is also high expression of genes indicative of
an acute, pro-inflammatory response, such as IL1B, CCL5, CCR7 and TNFA.
Further analysis showed that TU-uglia expressed high levels of genes related to
extracellular matrix (ECM) remodeling, such as fıbronectin (FN1) and tenas-
cin-C (TNC), as well as their ligands (ITGA4 and ITGB1), indicating that mi-
croglia, and not tumor cells, might be the main source for those proteins in the
tumor microenvironment. We were also able to collect one sample of iTAMs
from a GBM case. Despite not providing a signifıcant number for statistical
analysis, we can already see major differences in gene expression between this
sample and our TU-uglia cohort. We identifıed surface receptors differentially
expressed between both cell types (i.e.: ROBO1 and PDGFRA for TU-uglia,
MARCO and MET for iTAMs), as well as transcription factors associated with
stemness and proliferation, such as KLF4, SOX2 and OCT4 (the last two exclu-
sive for TU-uglia). These results demonstrate that different activation signaling
pathways occurwithin the same tumor sample.Microglia and iTAMs are subject
to a number of signals from different clones of tumor cells, driving different
responses along the progression of the disease, increasing its tumorigenicity.
Better knowledge of this dynamics will help improve our understanding of glio-
mas and alternative treatment options.
#2959 Changes in the tumor stroma after MFP treatment in a MPA-in-
duced murine mammary carcinoma model. Gonzalo Ricardo Sequeira,1 Ana
Sahores,1 Tomas Dalotto-Moreno,1 Silvia Vanzulli,2 Laura Polo,1 Virginia No-
varo,1 Caroline Lamb,1 Mariana Salatino,1 Claudia Lanari1. 1Inst. de Biología y
Medicina Experimental, Buenos Aires, Argentina; 2Academia Nacional de Me-
dicina, Buenos Aires, Argentina.
The role of the immune system in the regression ofmammary carcinomas using
endocrine therapies has beenpoorly investigated. Themain goals of this studywere:
a) to evaluate differences in antiprogestin-induced regression of hormone receptor
positivemammary carcinomas growing in immunocompetent or immunodefıcient
mice; b) to characterize the tumor infıltrating immune cells inmifepristone (MFP)-
treated murine mammary carcinomas and c) to evaluate whether MFP treatment
elicits immune protection in tumor re-challenge assays. Bone marrow (BM) cells
from BALB/c-GFPmice were intravenously inoculated into NSGmice to establish
the NSG/BM-GFPmouse model. GFP cells were detected in spleen, bone marrow,
and blood from NSG/BM-GFP mice two months after BM-GFP cell inoculation.
The murine mammary carcinoma 59-2-HI, originally induced by the administra-
tion of medroxyprogesterone acetate to BALB/c mice, regresses completely after
MFPtreatment.Tumorswereorthotopically inoculated intoNSGorNSG/BM-GFP
female mice two months after BM grafting. When the tumors reached a size of
approximately50mm2, lowdoseMFPpellets (0.2mg)wereadministered inorder to
inhibit tumor growth. To characterize the infıltrating immune cells, tumors were
excised after drug administration, disaggregated, and isolated cellswere analyzedby
FACs. For the re-challenge assay, tumors were excised 6 days after MFP treatment
and animals were orthotopically re-inoculated with the same tumor in the opposite
flank. Sham operated animals were used as controls. MFP inhibited the growth of
tumors transplanted in either NSG or NSG/BM-GFP and no differences were
observed between both groups, suggesting that the immune system is not a key
factor mediating antiprogestin-induced tumor regression. Tissue remodeling was
associated with an increase in lymphocytes (CD8; T cells) and macrophages
(CD11b F480; p&lt0.01 at day 3 and 6), and a decrease in the Treg subpopula-
tion (CD4 CD25 Foxp3; p&lt0.05). These results led us to hypothesize that
antiprogestin treatment could elicit a protective antitumor immune memory re-
sponse by delaying tumor recurrence. To test this hypothesis we performed re-
challenge assays using animals in which primary tumors have been previously ex-
cised.All tumorsof controlmice reached the ethical limit size (200mm2)beforeday
47, while only half of the tumors in theMFP-treated group reached this size by this
time (hazard ratio: 1.98).We conclude that antiprogestins induce tumor regression
regardless of the presence of an impaired immune system and that the reduced
intra-tumor Treg/CD8 ratio observed in regressing tumors might be used as a
predictive marker of treatment response. The re-challenge experiments agree with
the hypothesis that regressing tumors expose intracellular antigens that generate a
protective immune memory response, which in turn, could be associated with the
long free relapse survival induced by endocrine therapy.
#2960 Adipocytes sequester and metabolize daunorubicin. Xia Sheng,1
Jean-Hugues Parmentier,1 Jonathan Tucci,1 Hua Pei,2 Omar Cortez-Toledo,1
Christina Dieli-Conwright,3 Matthew Oberley,1 Michael Neely,1 Etan Orgel,1
Stan Louie,2 Steven D. Mittelman1. 1USC/Children’s Hospital Los Angeles, Los
Angeles, CA; 2USC School of Pharmacy, Los Angeles, CA; 3USC School of Den-
tistry, Los Angeles, CA.
Obesity is associated with poorer outcome from many cancers, including
childhood acute lymphoblastic leukemia (ALL).We have previously shown that
adipocytes protect ALL cells from the anthracycline, daunorubicin (DNR). We
therefore investigated whether adipocytes sequester and/or metabolize DNR in
the ALLmicroenvironment. Using fluorescence and LC/MSmeasures, we dem-
onstrated that adipocytes absorb DNR, reducing the intracellular DNR concen-
tration in co-cultured BV173 ALL cells (after 48 hours, median fluorescent in-
tensity of ALL cultured with adipocytes was 1.7	1.0 vs. 5.0	1.7 of those
cultured alone, p0.01). Mouse adipocytes convert DNR to the less active me-
tabolite, daunorubicinol (DNR-ol); over 48 hours, media DNR decreased to
0.1	0.2 (vs. 24.8	8.76 ng/mL in control wells). At the same time, DNR-ol
increased to 15.0	1.9 (vs. 0.7	0.6 in control wells; both p0.05). Similar con-
version of DNR to DNR-ol was observed in both mouse adipose explants and
human adipose tissue biopsy samples ex vivo. qPCR confırmed human subcu-
taneous adipose tissue expresses several enzymes capable of metabolizing DNR,
including AKR1A1, 1B1, 1C1, 1C2, 1C3, 7A2, and CBR1 and 3 (expression
ranged between 20 and 195% -actin). Using immunohistochemistry, we con-
fırmed expression of AKR1C1, 1C2, and 1C3 in bone marrow adipocytes of
children during the fırst month of treatment for ALL. Finally, two hours after an
intravenous dose of DNR in mice, we found that the DNR-ol to DNR ratio was
higher in subcutaneous (0.60	0.26) and omental (0.55	0.21) adipose than in
white blood cells (0.16	0.11), bonemarrow (undetectable DNR-ol), and spleen
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(undetectable DNR-ol). Together, these data demonstrate that adipocytes se-
quester and inactivate DNR, likely due to their expression of AKR and CBR
enzymes. These fındings uncover a novel and important mechanism which
could promote local anthracycline resistance by cancer cells in microenviron-
ment rich in adipocytes, such as bone marrow, omentum, and breast.
#2961 Targeting stromal-derivedDickkopf-3 (DKK3) for the treatment of
pancreatic ductal adenocarcinoma (PDAC). Liran Zhou,1 Hongmei Husted,1
Todd Moore,1 Mason Lu,1 Defeng Deng,1 Yan Liu,1 Vijaya Ramachandran,1
Thiruvengadam Arumugam,1 Baoan Ji,2 Huamin Wang,1 Jeffrey E. Lee,1 Craig
D. Logsdon,1 Rosa F. Hwang1. 1UT MD Anderson Cancer Ctr., Houston, TX;
2Mayo Clinic, Rochester, MN.
Introduction: We and others have shown that pancreatic stellate cells (PSCs)
in the tumor-associated stroma of PDAC promote tumor progression and resis-
tance to therapy but the precise mechanisms are unclear. We investigated the
role of PSC-derivedDKK3, amember of theDickkopf family of glycoproteins, in
PDAC progression, metastasis and response to chemotherapy. Methods: We
evaluated expression of DKK3 in human PDAC tissue and cell lines, human
PSCs and in a genetically engineered mouse model (GEMM) of PDAC. The
paracrine and autocrine effects of DKK3 on PDAC and PSCs were examined by
treatment with exogenous DKK3 and gain- and loss of function assays for pro-
liferation, migration, invasion, and gemcitabine-induced apoptosis. The effects
of DKK3 on PDAC progression and metastasis were determined by shRNA
neutralization and genetic ablation in orthotopic xenograft models and the KPC
autochthonous model of PDAC. We developed novel monoclonal antibodies
(mAbs) against DKK3 and tested their ability to neutralize DKK3 and prolong
survival in mouse models of PDAC. Results: DKK3 was expressed at 4.5 times
higher levels in human PDAC by Affymetrix profıling compared to normal
pancreas and was present in 99% (118/119) of samples on a tissue microarray
with moderate to high expression in 59%. In a GEMM of PDAC, DKK3 ap-
peared early with preneoplastic PanIN lesions with increased expression in in-
vasive carcinoma. DKK3 was strongly expressed by PSCs with minimal to no
expression in PDAC cells and knockdown by shRNA reduced PSC proliferation
and migration by 60% and 84% compared to controls (p0.001). Treatment of
Panc1 and BxPC3 cells with DKK3 stimulated migration and invasion by 100-
300% (p0.001) and proliferation of DKK3-silenced Panc1 cells was decreased
by 80% (p0.001). Overexpression of DKK3 in L3.6pl cells increased colony
formation in gemcitabine by90% (p0.001) with 65% reduction in apoptosis
(p0.01), indicating that DKK3 contributes to PDAC resistance to chemother-
apy. When we ablated DKK3 in KPC mice by breeding with DKK3-knockout
mice, tumor growthwas inhibited and survival increased by 45% (p0.0002). In
addition, fewer PanIN lesions developed in DKK3-null mice suggesting that
DKK3 may contribute to the early developmental stages of PDAC. DKK3 neu-
tralizing mAbs abrogated DKK3-mediated induction of PDAC cell migration,
invasion and resistance to gemcitabine in vitro. Furthermore, treatment with
DKK3 mAb signifıcantly inhibited primary tumor growth, reduced peritoneal
metastases and prolonged survival in an orthotopic model of PDAC by 43%
compared to control mAb (p0.005; HR 0.24, 95% CI 0.01-0.30). Conclusions:
These data are the fırst report, to our knowledge, of a tumor-promoting function
ofDKK3 and our results suggest that neutralization ofDKK3may be an effective
approach as a primary treatment for PDAC and to enhance responsiveness to
chemotherapy.
#2962 Mechanobiology of epithelia on native basement membrane and
relevance for cancer invasion.Marija Plodinec,1 Philipp Oertle,1 Daphne Ass-
geirson,1 Willi Halfter,2 Serenella Eppenberger Castori,3 Ellen C. Obermann,1
AlexandreGlentis,4 Roderick Y. LIM1. 1Univ. of Basel, Basel, Switzerland; 2Univ.
of Pittsburgh, Pittsburgh, PA; 3Univ. Hospital Basel, Basel, Switzerland; 4Institute
Curie, Paris, France.
The onset of metastasis occurs when cancer cells invade and breach the base-
ment membrane (BM) that provides mechanical support to epithelial tissues.
Yet, it remains unclear what triggers cancer cells to breach the BM, and how
’triggered’ cells in fact breach theBM.Wehave established an in vitro assay using
native BM interface for culturing epithelial cells. Using atomic forcemicroscopy
(AFM)with other high-resolutionmicroscopies and TER (trans-epithelial resis-
tance), we have correlated themechano-cellular attributes of the BM/epithelium
interface to its biochemical and structural properties.We demonstrated that the
internal limiting membrane (ILM) isolated from human retinas acts as a native
substrate for culturing epithelial cells in terms of BM composition, architecture
and stiffness. These are required to act jointly in order to achieve apico-basal
polarity, tissue barrier formation and stiffness properties of the epithelial layer
similarly to secretory epithelia in vivo. The native BM serves several advanta-
geous over reconstituted Matrigel, an ECM extracts that originates frommouse
tumor ascites. Besides variations in thickness and biochemical composition, we
fınd that Matrigel is mechanically 100-fold more compliant (i.e., softer) than
native BMs. When tumorigenic variants of cells are used, we demonstrated that
cancer cell invasion is associatedwith a decrease in cellular stiffness correlated to
changes in cell and BM morphology. In addition, we showed that activation of
ß1 integrin by the stiffness and architecture of the native alpha - 5 laminin chain
has a key role, not only as previously thought formaintenance of cell polarity but
also for the establishment of a physiological mechanophenotype. On the other
hand it is well know that during cancer progression in vivo, cancer cells can
perforate the BM using proteolysis. Whether stromal cells also play a role and
what kind of role in this process is unclear. Therefore, we asked if carcinoma
associated fıbroblasts (CAFs) isolated from cancer patients promote cancer cell
invasion through a BM. In the presence of CAFs, moderately invasive cancer
cells invade in a matrix metalloproteinaseindependent manner. Using live im-
aging and atomic force microscopy, we showed that CAFs actively pull, stretch
and soften the BM, forming gaps through which cancer cells can migrate. By
exerting contractile forces, CAFs alter the organization and the physical prop-
erties of the BM, making it permissive for cancer cell invasion. Finally, we pro-
pose that, in addition to proteolysis, mechanical interactions between CAFs and
BMrepresent an alternativemechanismof BMbreaching.Given theirmechano-
biological relevance, native BMs allow us to further understand how mecha-
nosignaling occurs between the epithelia and the surrounding stromal layers at
the BM interface during cancer invasion and progression.
#2963 Inhibition of stromal p38MAPK abrogates breast cancer metasta-
sis. Sheila A. Stewart,1 Bhavna Murali,1 Qiaho Ren,1 Xinming Su,1 Kevin Flan-
nagan,1 Xianmin Luo,1 Jasmine Sponagel,1 Yujie Fu,1 Elise Alspach,1 Kathlees
Leahy,1 Roberta Faccio,1 Kathleen Weilbaecher,1 Joseph Monahan2. 1Washing-
ton University, St. Louis, MO; 2Confluence Life Sciences, St. Louis, MO.
Bone metastasis is a devastating and fatal complication of breast cancer for
which we lack effective therapies. Thus, identifying therapies that effectively
limit metastases will signifıcantly reduce comorbidities and improve long-term
survival. Recently we demonstrated that the p38MAPK pathway sustains the
pro-tumorigenic senescence-associated secretory phenotype (SASP) and target-
ing this pathway limits the tumor-promoting capabilities of senescent cells and
cancer-associated fıbroblasts (CAFs). Because we found that a signifıcant per-
centage of p38MAPK-dependent SASP factors are expressed in the stroma as-
sociatedwith breast cancer lesions, we askedwhether targeting p38MAPK could
limit primary and metastatic breast cancer growth. While p38MAPK inhibition
modestly limited primary tumor growth, we found that its inhibition signifı-
cantly reduced breast cancer bone metastases by specifıcally targeting the stro-
mal compartment. Further, p38MAPK inhibitionwas as effective as paclitaxel at
limiting tumor growth in the bone but in contrast to paclitaxel, which failed to
protect from cancer-induced bone loss, p38MAPK inhibition also protected
against devastating bone loss. This contrasts our p38MAPKapproach fromzole-
dronic acid, which limits bone loss but fails to slow tumor growth in already
engrafted tumors. Analysis of the mechanism(s) responsible for this reduced
metastasis suggests that p38MAPK inhibition targets reactive and/or senescent
osteoblasts within the bones of animals harboringmetastatic lesions. Becausewe
fınd that senescent osteoblasts are present in human bone, we postulate that they
promote metastatic outgrowth and thus p38MAPK inhibition limits the pro-
metastatic activities of these cells. Finally, we will present recent data from our
preclinical model that demonstrates that inhibition of the p38MAPK pathway
can drastically reduce metastasis from the primary site. We propose that
p38MAPK is an important stromal-specifıc therapy for breast cancer metastasis
to the bone.
#2964 Stromal Hedgehog pathway activation suppresses growth and me-
tastases of lung adenocarcinoma. Sahba Kasiri, Baozhi Chen, Alexandra Wil-
son, Umaru Barrie, UmmayMarriam, ZhiqunZeng, LucGirard, JamesKim.UT
Southwestern, Dallas, TX.
Aberrant activation of the Hedgehog (Hh) signaling pathway, a crucial devel-
opmental pathway, drives the tumor growth of Gorlin-type cancers. However,
recent data suggest that paracrine activation of the pathway is tumor suppressive
rather than oncogenic in sporadic epithelial cancers. The role of the pathway in
non-small lung cancer is poorly understood. Thus, we explored the role of stro-
mal Hh pathway activation in growth of lung tumor epithelia. Human lung
adenocarcinoma cell lines were used to probe SHHmRNA and protein expres-
sion. Co-culture of high SHH expressing cell lines with murine embryonic and
lung fıbroblasts were used to confırm and probe the role of paracrine SHH
expression on the growth of lung cancer cells. The in vivo role of paracrine SHH
was tested using autochthonous lung cancer models with conditional
KRASG12Dactivation, p53 loss, and SHH loss compared to wild-type SHH. In
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human lung adenocarcinomapatients, higher expression of SHHmRNA in lung
adenocarcinoma correlated with poor overall and progression free survival. A
scan of 35 human lung adenocarcinoma cell lines revealed heterogeneous ex-
pression of SHH and IHHwith high expression found predominantly inmutant
K-Ras lines. Co-culture of high SHH expressing tumor epithelial cells and Shh-
Light2 reporter cell lines demonstrated that SHH activated the fıbroblast re-
porter in a paracrine manner, rather than an autocrine effect on cancer cells.
Treatment with the SMO inhibitor, KAAD-cyclopamine, also inhibited the
growth of tumor epithelial cells in co-culture with NIH-3T3 fıbroblast cells but
the effect was decreased when co-cultured with lung fıbroblasts. Genetic loss of
SHH in an autochthonous mouse model, LSL-KrasG12D/;Trp53fl/fl; Shhfl/fl
(KPS) did not affect overall survival compared to LSL-KrasG12D/;Trp53fl/fl (KP)
mice However, early inhibition of the Hh pathway by anti-SHH/IHH antibody,
5E1, on KP mice resulted in signifıcantly worse survival rates with increased
metastatic burden compared to IgG treatment. Analysis of KP tumors revealed
unexpected high levels of IHHmRNA by in situ hybridization that may account
for the survival differences seen between genetic ablation and pharmaceutical
inhibition of the Hh ligands. In conclusion, the Hh signaling pathway acts upon
lung stromal cells in a paracrine fashion. Inhibition of Hh activity in vivo wors-
ened mortality rate due to increase in tumor growth and metastases. Further-
more, mutant Kras lung cancers express high levels of IHH that dominates the
tumor suppressive effect of our mouse models.
#2965 Myeloid depletion reverses established T-ALL growth in vivo.Todd
A. Triplett, Aram Lyu, Wesley Godfrey, Lauren I.E. Ehrlich.University of Texas
at Austin, Austin, TX.
T cell acute lymphoblastic leukemia (T-ALL) is a hematological cancer that
arises from developing T-cells. Most T-ALL research has focused on elucidating
cell-intrinsic genetic permutations that promote tumor proliferation and sur-
vival, which has resulted in a detailed description and understanding of the
geneticmutations associated with T-ALL in patient cells. However, to date these
studies have not resulted in effective targeted therapies, which may potentially
be due to the heterogeneity of genetic lesions within and between patients or the
acquisition of new mutations. Thus, we need to broaden our understanding of
other factors promoting T-ALL growth to identify alternative therapeutic tar-
gets that are effective acrossmutational landscapes. To this end, our studies seek
to identify extrinsic signals in the tumor microenvironment that enable T-ALL
growth. Our previous studies used a systematic and unbiased evaluation of en-
dogenous stromal subsets from the thymic TME to reveal that myeloid cells,
primarily dendritic cells (DC), were necessary and suffıcient for ex vivo survival
of T-ALL cells. Furthermore, transcriptional profıling revealed elevated expres-
sion of Igf1r and Igf1 by T-ALL and DC from the TME, respectively. Using
multiplemolecular approaches, inhibition of IGF1R revealed that IGF1R signal-
ing was necessary for DC-mediated survival of T-ALL from multiple tumor
locations. These fındings have relevance to humanT-ALL as pervasive TEC-free
regions containing extensive DC networks were evident in T-ALL patient sam-
ples, and previous studies have verifıed that IGF1R, a direct target of NOTCH1,
is expressed at high levels in T-ALL patients. In these studies, we sought to
determine whether myeloid cells were required for tumor survival in vivo. After
transplantation, tumors became established systemically in lymphoid and non-
lymphoid tissues of the recipients. Immunofluorescence analysis revealed exten-
sive myeloid networks around and between T-ALL tumor cells in multiple tis-
sues. As for primary tumors, transplantedT-ALL cells also required the presence
of DC from the TME for survival ex vivo. Importantly, myeloid cell depletion in
transplanted hosts with established T-ALL resulted in substantial reduction in
tumor cell burden in all tissues examined, thus demonstrating a fundamental
role for these cells in supporting T-ALL in vivo. To identify key survival path-
ways activated in T-ALL cells by myeloid cells, we have compared comprehen-
sive trancscriptomic and phosphoproteomic profıling from tumor cells in the
presence or absence of myeloid cells in transplant models. Preliminary analysis
of T-ALL versus WT thymocytes has confırmed hyper-activated IGF1R signal-
ing, as indicated by hyper-phosphorylation of downstream targets, such as IRS1.
Collectively, these studies provide the fırst evidence that myeloid cells directly
support T-ALL in vivo, suggesting that these cells and their associated signals
may be auspicious therapeutic targets.
#2966 Stromal platelet derived growth factor receptor-beta (PDGFRbeta)
promotes breast cancer progression. Gina M. Sizemore, Anisha M. Hammer,
Katie A. Thies, Steven T. Sizemore, Anthony J. Trimboli, B. Eason Hildreth,
Raleigh D. Kladney, Arnab Chakravarti, Gustavo Leone, Michael C. Ostrowski.
Ohio State University, Columbus, OH.
Over the past decade it has become evident that the tumormicroenvironment
(TME) actively participates in carcinogenesis. Tumor-associated fıbroblasts, for
example, modulate neighboring tumor epithelium through growth factor secre-
tion to initiate and promote tumor growth. The platelet derived growth factor
receptors (PDGFRs), PDGFRalpha and PDGFRbeta, are receptor tyrosine ki-
nases activated by PDGF that may be critical and actionable mediators of breast
tumor-stromal communication. PDGFRs are predominately expressed in breast
tumor stroma while their cognate ligands are specifıcally expressed in tumor
epithelium and associated endothelium. In some cancers, tumor-derived
PDGFs act on theTME to recruit tumor associated fıbroblasts; however, this role
has not been described in breast cancer. To begin to evaluate a role for PDGFR-
beta, we utilized publicly available gene expression data to confırm upregulation
in tumor stroma compared to tumor epithelium. Importantly, PDGFRB is in-
creased in tumor stroma compared to normal stroma. To directly test whether
stromal PDGFR activation promotes tumor growth, we co-injected murine
mammary tumor cells with or without PDGFR-expressing mouse mammary
fıbroblasts (MMFs) orthotopically in FVB/N mice. MMF inclusion increased
tumor cell proliferation as well as associated angiogenesis while systemic treat-
ment with imatinib mesylate, a small molecule inhibitor for PDGFR, restored
both proliferation and angiogenesis back to baseline. These fındings indicated
the importance of PDGFR signaling in tumor initiation leading us to develop a
mousemodel of stromal-specifıc PDGFRbeta activation using the Fsp-cre trans-
gene previously published by our group (henceforth referred to as “PDGFRbeta
mutant”). PDGFRbeta mutant mammary glands exhibit increased tertiary side-
branching and epithelial proliferation confırming a stromal-specifıc PDGFR-
beta effect on neighboring epithelium during development. Further, MMFs iso-
lated from the PDGFRbeta mutant mice exhibit increased motility towards
PDGF-B expressing tumor cells in vitro, which implies increased response and
recruitment of themutantMMFs towards an expanding tumor. To test whether
PDGFRbeta mutant mice harbor a mammary TME supportive of increased tu-
mor growth, we injected murine mammary tumor cells orthotopically into ei-
ther control or PDGFRbeta mutant mice fınding that the time required to meet
early removal criteria (tumor &gt1.2cm3) was shorter in the mutant mice com-
pared to controls. Ongoing studies are evaluating whether systemic PDGFR
inhibition will abrogate this observed increase in tumorigenesis. In summary,
our data suggest that stromal PDGFRbeta signaling is pro-tumorigenic in breast
cancer and that inhibition using well-described PDGFR inhibitors could be a
valid therapeutic approach for women whose tumors express increased PDGF-
to-PDGFR tumor-stromal signaling.
#2967 Pancreatic cancer cell growth requires lipids released by tumor-
induced stroma autophagy. Petrus R. De Jong,1 Sean-Luc Shanahan,2 Morgan
A. Brand,1 Alejandro D. Campos,1 Anagha Srirangam,1 Nikolas Marino,1 Clau-
dia P. Miller,1 Olga Zagnitko,1 Adam D. Richardson,1 David A. Scott,1 Brian P.
James,1 AndrewP.Hodges,2 Ally Perlina,2 AlexeyM. Eroshin,2 Randall French,3
Malene Hansen,2 Sally A. Litherland,4 Andrew M. Lowy,3 J. Pablo Arnoletti,5
Garth Powis1. 1SBP NCI-Designated Cancer Center, La Jolla, CA; 2SBP Medical
Discovery Institute, La Jolla, CA; 3University of California, San Diego, La Jolla,
CA; 4Florida Hospital Cancer Institute, Orlando, FL; 5Institute for Surgical Ad-
vancement/ Florida Hospital Center for Specialized Surgery, Orlando, FL.
Pancreatic ductal adenocarcinoma (PDAC) is non-resectable in the majority
of patients and highly resistant to chemotherapy, resulting in a poor survival.
The tumor microenvironment and hypoxia are important modifıers of cancer
progression in PDAC. Understanding the metabolic vulnerabilities of PDAC in
the harsh tumor microenvironment may lead to novel therapeutic approaches
with improved clinical effıcacy. First, we found that PDAC cells showed benefı-
cial effects of co-cultured stroma cells, but only under lipid-free serum condi-
tions. To study the metabolic crosstalk between cancer cells and stroma inmore
detail, we performed an untargeted metabolomic screen of PDAC cells and
fıbroblasts co-cultured in normoxia and hypoxia, and performed RNA-seq pro-
fıling in parallel. We found that stromal cells are metabolically more responsive
to co-culture than cancer cells. PDAC cells induce catabolic carbohydrate and
protein metabolism in stromal cells, particularly in hypoxia. In contrast, 13C-
based metabolic flux assays demonstrated that stromal cells display enhanced
anabolic lipidmetabolism in co-culture with PDAC cells. Furthermore, de novo
synthesized 13C-labeled fatty acids in stromal cells were taken up by PDAC cells.
In particular, PDAC cells showed extensive scavenging of lysophospholipids
(lyso-PLs) from the culture medium, which was increased in co-culture under
hypoxic conditions. These data were confırmed by analyzing portal vein
plasma samples isolated from pancreatic cancer patients before and after
surgery. In addition, we found metabolites and expression levels of meta-
bolic enzymes from the glycerophospholipid pathway to be enriched in
PDAC cells in co-culture and hypoxia. By using fıbroblasts, human pancre-
atic stellate cells and patient-derived cancer-associated fıbroblasts (CAFs),
we demonstrate direct transfer of lyso-PLs from stromal to PDAC cells via
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lipid droplets. The transfer of lyso-PLs was abrogated by pharmacological
inhibitors of autophagy, or by siRNA-mediated knockdown of autophagy
genes in stromal and tumor cells. These data suggest that PDAC cells cause
stroma cells to undergo autophagy, and reprogram stroma metabolism to
obtain complex lipid species for their metabolic needs in the lipid-starved
tumor microenvironment.
#2968 Examining the role of breast cancer Neuregulin1 and macrophage
ErbB3 in intravasation. Ramon Cabrera, Serena Chiang, Jeffrey Segall. Albert
Einstein College of Medicine, Bronx, NY.
The purpose of our studies is to investigate the role of Neuregulin1
(NRG1) and ErbB3 signaling between breast cancer cells andmacrophages in
facilitating tumor cell intravasation. The interaction of breast cancer cells
with other cell types within the tumor microenvironment plays an important
role in metastasis. These interactions are thought to influence tumor cell
invasion and intravasation, two important steps in the process of metastasis.
Our studies are specifıcally interested in examining the signaling occurring
between tumor cells and macrophages. Previous studies have established the
presence of paracrine signaling between breast cancer cells and macro-
phages, where colony stimulating factor 1 (CSF-1) produced by the tumor
cells stimulates the production of epidermal growth factor (EGF) by macro-
phages, leading to chemotactic invasion of the tumor cells. In addition to this
paracrine loop signaling between tumor cells and macrophages, it has been
seen that macrophage expression of ErbB3, a member of the EGFR family of
receptor tyrosine kinases, may play a role in facilitating tumor cell invasion.
In order to examine the effects of signaling between tumor cells and macro-
phages in intravasation, we utilize an in vitro transendothelial migration
(iTEM) assay. This assay uses transwells coated with matrigel and endothe-
lial cells in order to mimic the entry of tumor cells into blood vessels. We
show that using an ErbB3 blocking antibody results in a signifıcant reduction
of macrophage-induced transendothelial migration of breast cancer cells.
Additionally, reduction of expression of the ErbB3 receptor ligand Neuregu-
lin1 in tumor cells yields a similar result. Stimulation of macrophages with
NRG1 leads to increased expression of Jagged1 (JAG1), a ligand of the Notch
receptor. Activation of the Notch receptor pathway has been shown to be
involved in tumor cell invasion. Overall our studies look to further examine
the interaction between tumor cells and macrophages, and these observa-
tions indicate that ErbB3, NRG1, and JAG1 could all serve as novel targets in
metastasis and the tumor microenvironment.
#2969 Paracrine effect of the endothelium on prostate cancer cells.
Verónica Torres-Estay, Patricia Fuenzalida, Catalina Ascencio, Carla Cem-
brano, Daniela Carreño, Néstor Corro, Viviana Montecinos, Gareth Owen,
Xavier Figueroa, Julio Amigo, Juan Carlos Saéz, Alejandro Godoy. Pontifıcia
Universidad Católica de Chile, Santiago, Chile.
Prostate cancer (CaP) is themost commonly diagnosed cancer and the second
leading cause of cancer deaths among males in the United States. Androgen
deprivation therapy (ADT) is the standard treatment for advanced ormetastatic
CaP. However, during ADT, CaP progresses from an androgen-sensitive (AS-
CaP) to a more aggressive, and eventually lethal, castration-resistant (CRPC)
phenotype. There is evidence to suggest that the prostate tumor mass is under
tight control of endothelial microvasculature due to an increase in angiogenesis
by tumor cells. Nevertheless, now there is evidence to support that this influence
is not one-directional and that the endothelial cells secrete a large number of
active substances (angiocrine factors), whichmay directly or indirectly influence
tumor growth and progression. However, the direct impacts of the endothelium
onprostate tumor progression or themolecularmechanisms that are involved in
this communication remain unclear. Here we investigated the potential influ-
ence of endothelium-derived paracrine factors on prostate cancer biology and
the role of connexins in these interactions, since connexins play a major role in
cell-cell communication and form a bidirectional signaling pathway to assemble
gap junctions and alter cell behaviors. We measured the effect of conditioned
media (CM) obtained fromaprimary culture of human endothelial cells isolated
from umbilical vein (HUVEC) on viability, proliferation, migration and inva-
sion of CaP cell lines (LNCaP, LNCaP-C4-2 and PC3) and in the metastatic
potential by in vivo assays using co-injection of CaP cell with HUVEC or injec-
tion of CaP cells pre-incubated with CM from HUVEC in a zebrafısh embryo
model. Finally, we studied the expression and the role of connexins on this
stimulation using pharmacological (GJIC inhibitors) approaches. All together,
our results showed that CM from endothelial cell induces an increases in the
viability and proliferation in all CaP cell lines (LNCaP, LNCaP-C4-2 and PC3)
but only increasesmigration of the CRPC cell lines (LNCaP-C4-2 and PC3).We
also observed in our in vivo model that endothelial cells either through cell-cell
interaction or by paracrine communication increases the metastatic ability of
the CaP cells. Moreover, the increase in viability and migration of CaP cells
observed with CM from endothelial cells was blocked using inhibitors of gap
junctions. Real-time PCR analyses detected an up-regulation of Cx43 mRNA
after exposition to CM from endothelial cells. Our data suggest that angiocrine
communication between endothelial cells and CaP cells increases proliferation
and migration of more aggressive CaP cells which could be important for the
acquisition of the aggressive phenotype of the disease, and this interaction could
be mediated by Cx43. Delineation of such critical players may culminate in
identifying therapeutic targets or biomarkers to counteract CaP, especially ad-
vanced CaP.
#2970 Mitigating tumor-stroma metabolic symbiosis for cancer therapy.
Dhruv Kumar, Jacob New, Vikalp Vishwakarma, Hemant Chavan, Partha Kas-
turi, Sufı M. Thomas. Kansas University Medical Center, Kansas City, KS.
Head and neck squamous cell carcinoma (HNSCC) affects 40,000 patients
annually and is associatedwith50% 5-year survival. There is an urgent need to
better understand the biology of the disease in order to develop more effective
therapeutic approaches. HNSCC tumors are dysplastic with up to 80% fıbro-
blasts. We recently reported that tumor-associated fıbroblasts (TAFs) make
HNSCC more aggressive. Furthermore, we reported that TAFs produce hepa-
tocyte growth factor (HGF), which binds to the c-Met receptor expressed on
HNSCC todrive aggressiveness. Althoughwedidnot detectHGF secretion from
HNSCC cell lines, we reported that paracrine activation of c-Met by TAF-se-
creted HGF facilitates HNSCC progression. Reciprocal signaling between the
tumor and stroma has been reported in several cancers to facilitate tumor
growth, invasion and resistance to therapy. Recent studies have shown that
c-Met activation promotes glycolysis. Although highly glycolytic, the mecha-
nisms regulating HNSCC glycolysis remain unknown. We show that TAF-se-
creted HGF through c-Met activation on HNSCC (a) induces aerobic glycolysis
accompanied by lactate production, and b) regulates expression of basic fıbro-
blast growth factor (bFGF). Studies have shown that HNSCC tumors have high
lactate levels resulting from increased glycolysis, and this correlates with re-
duced survival. Our data demonstrate that TAF-secreted HGF increases key
glycolytic enzymes including hexokinase II. Furthermore, HGF increases glyco-
lysis and lactate production from HNSCC. We demonstrate that HGF also in-
creases levels of the bidirectional lactate transporter, monocarboxylate trans-
porter 1 (MCT1). We demonstrate that MCT1 levels are increased in both
HNSCC and TAFs under co-culture conditions. In addition, HGF stimulation
increases levels of MCT1 in HNSCC indicating a possible mechanism whereby
HNSCC remove the excess lactate generated during glycolysis. Themechanisms
whereby HNSCC tumors survive highly acidic conditions remain unknown.
SinceMCT1 levels are increased in TAFs as well, we sought to determine if TAFs
utilize the lactate as a carbon source to generate energy. Indeed, we found that
bFGF secreted byHNSCC, binds to its cognate FGF receptor (FGFR) onTAFs to
facilitate latate utilization through mitochondrial oxidative phosphorylation
(OXPHOS). Thus there exists ametabolic symbiosis betweenHNSCC andTAFs
that contribute to tumor growth. Through these studies, we delineate the mech-
anisms of glycolysis regulation in HNSCC and demonstrate that inhibition of
the cross-talk between HNSCC and TAFs can be used as a novel therapeutic
approach.
#2971 The prognostic relevance of inflammatory cytokines and growth
factors elaborated from adipose-derived stem cells in breast cancer. Nicole
Werwie,1 Kelsey Sadlek,1 Eric Lundstrom,1 Daniel Berrebi,1 Gerald Hobbs,1
Linda Vona-Davis2. 1West Virginia University, Morgantown, WV; 2West Vir-
ginia University Cancer Institute, Morgantown, WV.
Introduction: Given the high rates of obesity and aggressive breast cancers, it
is paramount to understand how adipose tissue supports the tumor microenvi-
ronment. We previously found that adipose-derived stem cells cultured with
triple-negative tumor cells enhanced the expression of numerous pro-inflam-
matory cytokines. This fınding is signifıcant as it could explain, in part, how
obesity contributes to worse outcomes in breast cancer. To further expand this
study, we probed the Cancer Genome Atlas (TCGA) breast invasive carcinoma
dataset for the expression profıles of the inflammatory cytokines we found to be
highly up-regulated in vitro. We predicted TCGA data would demonstrate a
correlation between cytokine overexpression and worse clinical scenarios.
Methods: Cytokines and growth factors were measured in the media of adipose
stromal cells and MDA-MB-231 tumor cells via membrane-based antibody ar-
ray. To validate clinical signifıcance, we compared each cytokine’s mRNA ex-
pression profıle, available fromprimary tumor samples of TCGAbreast invasive
carcinoma dataset (n  1,005), to indices of tumor progression and survival
status. For survival analysis, samples were dichotomized as high or low expres-
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sion by individual cytokines (z score
 1.5). Cytokine and growth factor expres-
sion was further stratifıed according to molecular subtype of breast cancer (lu-
minal A, luminal B, HER2, triple negative) and receptor status. Ingenuity
pathway analysis (IPA) was performed to identify candidate markers related to
obesity or inflammation. Results: High levels of FGF7 and CCL5 protein were
found in the conditioned media of tumor and adipose stem cell co-cultures and
together they showed a signifıcant impact on breast cancer survival within
TCGA data. FGF7, CCL5, together with CCL2, IL6, and IL6R were further ana-
lyzed for expression across molecular subtypes of breast cancer. IL6R, CCL5,
and CCL2 expression varied signifıcantly between breast cancer subtypes, with
mean expression highest in triple-negative tumors. After dichotomizing the
samples for estrogen receptor status, IL6R, CCL5, and CCL2 showed signifı-
cantly higher mean expression in ER negative tumors. Greater expression of
these cytokines in tumors was correlated with reduced patient survival in triple-
negative tumors and ER negative subtypes. IPA analysis indicated IL6, IL6R,
CCL5, and CCL2, but not FGF7, cooperate through inflammatory pathways to
promote tumor progression. Conclusions: Genomic data analysis supports in
vitro fındings that IL6R, CCL5, and CCL2 overexpression, either independently
or synergistically, predict a worse prognosis in breast cancer. For adipose-
driven, hormone receptor negative breast tumors, these cytokines and growth
factors could serve as novel therapeutic targets. (Supported by NIH
P20GM103434 and NIGMS U54GM104942).
#2972 SPINK1, a soluble factor released by the therapy-damaged tumor
microenvironment, promotes prostate cancer resistance. Fei Chen,1 Da Fu,2
Eric Lam,3 Yu Sun1. 1Institute of Health Sciences, Shanghai Institutes for Biolog-
ical Sciences, CAS, Shanghai, China; 2Shanghai Tenth People’s Hospital, Tongji
University School of Medicine, Shanghai, China; 3Department of Surgery and
Cancer, Imperial College London, London, United Kingdom.
Cancer evolution is driven by not only the genetic and/or epigenetic altera-
tions of cancer cells, but also diverse factors that are derived from the surround-
ing tumor microenvironment (TME). Upon chemotherapy or radiation, stro-
mal cells in the TME become senescent and develop a senescence-associated
secretory phenotype (SASP) that is characterized by secretion of a large number
of cytokines, chemokines, growth factors, and proteases. Inmost cases, the SASP
is functionally regulated by the DNA damage secretory program (DDSP) and
pathophysiologically responsible in vivo for disease exacerbation. We recently
disclosed signifıcant upregulation of the serine protease inhibitor Kazal type I
(SPINK1) in primary normal human prostate fıbroblasts after exposure to DNA
damaging agents. SPINK1plays critical roles in cancer cell proliferation, survival
and motility in multiple human malignancies, but its influence as a soluble
TME-associated factor on cancer progression remains unknown. In this study,
we performed a series of molecular and cellular studies to defıne the biological
roles of SPINK1 in an activated TME. Promoter analysis indicated that SPINK1
expression in the fıbroblasts is regulated by multiple transcriptional factors in-
cluding the NF-B complex in response to genotoxic stress. Fibroblast-derived
SPINK1 can signifıcantly enhance the aggressiveness of prostate cancer cells
including accelerated proliferation, increased migration, elevated invasion and
more importantly, enhanced chemoresistance. SPINK1 triggers a typical epithe-
lial-mesenchymal transition (EMT) in cancer cells, a process mediated by
EGFR/PI3K/Akt and MAPK/Erk signaling pathways. Consistent with the in
vitro data, our in vivo studies suggested that SPINK1 expression in the prostate
TME substantially promoted cancer survival and disease progression. Clinical
investigation revealed increased expression of SPINK1 in the stroma ofmultiple
organ types including the prostate, lung and breast of cancer patients after che-
motherapy, implying the systemic induction of SPINK1 by anticancer agents.
Overall, our study demonstrates that SPINK1 is a soluble biomarker of thera-
peutically damaged TME and represents a potentially exploitable molecular tar-
get in human prostate cancer clinics.
#2974 Obesity-induced modifıcations in the mammary gland microenvi-
ronment promote TNBC progression even after weight loss. Alyssa J. Cozzo,
Ottavia Zattra, Alex J. Freemerman, Liza Makowski. UNC-Chapel Hill, Chapel
Hill, NC.
Obesity contributes to 20% of US female cancer deaths and is linked to in-
creased risk for triple negative breast cancer (TNBC), as well as increased risk of
vascular invasion, metastasis, andmortality in breast cancer patients. We previ-
ously showed that obesity-induced elevation of hepatocyte growth factor (HGF)
signaling through its receptor, cMET, accelerated development of tumors in the
C3(1)-TAg GEMM of TNBC compared to low fat diet (LFD)-fed lean controls.
Weight loss signifıcantly reduced HGF/cMET signaling in normal mammary
glands and cMET in tumors, and reversed high fat diet (HFD)-driven tumor
progression, while crizotinib-mediated cMET inhibition limited tumor devel-
opment and microvascular density in both lean and obese C3(1)-TAg mice. To
differentiate tumor-intrinsic versus microenvironment-associated mecha-
nisms, we employed an orthotopic transplant model of a C3(1)-TAg TNBC cell
line to investigate tumor growth dynamics in lean, obese, or formerly obese
(FOb) microenvironments. We hypothesized that TNBC tumors derived from
leanC3(1)-TAgmice and transplanted into obesemicewould growmore rapidly,
contain more macrophages (MFs) and exhibit greater blood vessel density than
tumors in lean or FOb mice due to obesity-induced MF and/or endothelial
secretion of HGF. At 8 weeks of age, female FVB/NJ mice were randomized to
diet groups (N20/diet): 1) lean (LFD, 10% kcal from fat), 2) obese (HFD, 60%
kcal from fat) 3) or FOb (HFD, 5 weeks; LFD, 5 weeks). Following 10 weeks on
diets mice were injected with 2x105 luciferase-tagged C3(1)-TAg cells. Tumor
volumewasmeasured by calipers. At 21 days post-injectionmice were sacrifıced
for tissue collection. Normal mammary gland, tumors, and tumor-adjacent ad-
ipose tumor-draining lymphnodewere collected for histological examination
and gene expression analysis. Mammary fat pad mass in obese FVB/NJ mice
(0.27 g) was signifıcantly greater than lean (0.14 g) or FOb animals (0.11 g)
(P0.0001). Tumor volume at sacrifıce was signifıcantly greater in obese vs lean
animals (190 mm3 vs 89.96 mm3, respectively; P0.05). However, mean fınal
tumor volume in FOb animals (148.0 mm3) did not differ signifıcantly from
either lean or obese mice. Our fındings show that obesity accelerated tumor
progression relative to lean mice. C3(1)-TAg cells transplanted into FOb mice
resulted in an intermediate rate of tumor growth, suggesting that obesity-medi-
ated changes to the microenvironment were not fully corrected by weight loss
despite normalization of body weight and adiposity. To elucidate how the FOb
mammary microenvironment persists in driving TNBC tumor promotion,
planned analyses include histological examination of candidate mediators, in-
cluding MF infıltration and regional lymph node metastasis by diet group, as
well as quantifıcation of pro-growth and pro-angiogenic signaling molecules
(e.g., HGF, VEGF, Ang2) in lysates of tumors and tumor-adjacent adipose.
#2975 Collagen type XI alpha 1 confers cisplatin chemoresistance in ovar-
ian cancer through inhibitor of apoptosis proteins (IAPs).Miran Rada,1 Jen-
nifer Cha,2 Jessica Sage,1 Sandra Orsulic,3 Dong-Joo Cheon1. 1Albany Medical
College, Albany, NY; 2Rensselaer Polytechnic Institute, Troy, NY; 3Cedars-Sinai
Medical Center, Los Angeles, CA.
Ovarian cancer is themost lethal gynecological cancer, which affects one in 70
females in theUnited States during their lifetime.While cisplatin is the frontline
treatment for ovarian cancer, chemoresistance severely limits the treatment suc-
cess. The goal of this study is to identify novel therapeutic targets to overcome
cisplatin resistance.We recently identifıed Collagen type XI alpha 1 (COL11A1)
as a novel biomarker associated with cisplatin resistance in ovarian cancer.
COL11A1 is a component of the tumor stroma and its expression is restricted to
cancer-associated fıbroblasts (CAFs) adjacent to tumor cells.We further showed
that COL11A1 protects ovarian cancer cells from cisplatin-induced apoptosis,
yet the underlyingmechanism is largely unknown. To understand themolecular
mechanism by which COL11A1 protects cancer cells from cisplatin-induced
apoptosis, we overexpressed COL11A1 in ovarian cancer cells and performed
RNA-Seq. Our RNA-Seq data revealed that COL11A1 did not change the levels
of genes involved in cisplatin transport, inactivation, and DNA repair pathways
in cancer cells, which are well-established mechanisms to confer cisplatin resis-
tance. Rather, COL11A1 enhances the expression of the Inhibitors of Apoptosis
Proteins (IAPs), including XIAP, BIRC2 (c-IAP1) and BIRC3 (c-IAP2). Using a
full-length COL11A1 protein, geneticmanipulation, and co-culturemethod, we
confırmed that COL11A1 signifıcantly increases the expression of IAPs upon
cisplatin treatment. The inhibition of XIAP, BIRC2 and BIRC3 with an IAP
antagonist BV6 attenuated the ability of COL11A1 to inhibit cisplatin-mediated
apoptosis. Our data indicates that COL11A1 activates Akt, and Akt is known to
phosphorylate XIAP at serine-87, which protects it from ubiquitination and
degradation in response to cisplatin. Collectively, our data identify IAP as a
mediator of COL11A1’s action in blocking cisplatin-induced apoptosis.
#2976 Critical role of spatial location of hypoxia and its association with
astrocytes in the resistance of brain tumor to therapy. Chiu-Min Lin, Chi-
Shiun Chiang. National Tsing-Hua University, Hsinchiu, Taiwan.
Many reports have shown that hypoxia and gliosis could promote tumor cells by
shielding from the immune response and relapsing, but their roles on brain tumor
therapies are still unclear. Using an invasive murine astrocytoma tumor model,
ALTS1C1, we found that tumor invasion front is associated with a specifıc hypoxia
region, naming tumorperipheral hypoxia, contributes to brain tumor therapy resis-
tant and may be responsible for tumor recurrence after the therapy. Using this
tumor model, we found that the overgrowing tumor caused the shortage of vessels
and resulted in the hypoxia in the early stage of tumor progression, which is con-
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ventionally called chronic hypoxia or avascular hypoxia.When tumor continues to
grow, a rim of hypoxia area was formed at tumor edge and subsequently activated
nearby astrocytes. At the same time, the outward reactive astrocytes enhanced tu-
mor invasion into normal parenchyma tissues. As a result, a specifıc hypoxia was
produced in tumor peripheral, which has relative high microvascular density
(MVD) and is associated with highly reactive astrocytosis. We explored the role of
this region on the response to therapies. By quantitative counting the apoptotic
tumor cells across the tumor cross-section following radiation- or chemo-therapy,
we found that cells at the active astrocytic region (the peripheral region) are more
resistant than cells in tumor core. These results indicate that the peripheral hypoxia,
not thechronichypoxia, is themaincauseof the failureofbrain tumor therapy.Most
importantly, we found that the formation of tumor peripheral hypoxia might be
associated with the activation of astrocytes. Therefore, tactics that can suppress as-
trocytosis and prevent the formation of peripheral hypoxia may be alternative ap-
proaches for complementing the shortage of traditional brain tumor therapy.
#2977 Secretory autophagy in tumor associated fıbroblasts promotes head
andnecksquamouscell carcinomaprogressionandemergesasanovel therapeu-
tic target. Jacob New, Levi Arnold, Megha Ananth, Sameer Alvi, Wen-Xing Ding,
Sufı M. Thomas.University of KansasMedical Center, Kansas City, KS.
As the fıfth most common cancer worldwide, head and neck squamous cell car-
cinoma (HNSCC) is a leading global health burden. Despite therapeutic advance-
ments, the survival rate has remained relatively unchanged for the last fıfty years. To
improve treatment and survival, there is a need to better understand the underlying
biology of this disease. The tumor microenvironment’s role in promoting cancer
progression and resistance to therapy has gathered great attention. In HNSCC, the
predominant microenvironment cell type is tumor associated fıbroblasts (TAFs).
Studies in our lab and others have demonstrated the signifıcant tumor promoting
role ofTAFs; however, little is understoodof the underlying biology ofTAFs. In this
study, we identify that TAFs have upregulated an unconventional pathway of secre-
tion: secretory autophagy. Although paradigmatically a degradation pathway, there
has been a growing appreciation for a novel role of autophagy in cellular secretion.
We hypothesized HNSCC induces secretory autophagy in the TAFs, modulating
secreted factors responsible for tumor progression. We assessed the role of au-
tophagy inhibition in alleviating TAF-facilitated HNSCC progression, and uncov-
ered a signifıcant reduction in proliferation, migration, and invasion of the cancer
cells. This was achieved by both siRNA knockdown of Beclin-1, and therapeutic
inhibition of the lysosome through chloroquine.We discovered that NFs placed in
co-culture with HNSCC had a signifıcantly upregulated level of autophagy marker
LC3-II. By characterizing the role of known HNSCC secreted factors in inducing
TAF autophagy, we identifıed basic fıbroblast growth factor is responsible for the
LC3-II accumulation. To understand which TAF factors are secreted by an au-
tophagy dependent mechanism, we assessed TAF-conditioned media in the pres-
enceof autophagyknockdown.Key cytokines, suchas IL-6 and IL-8,were identifıed
as autophagy dependent. Rescue of these cytokines in autophagy inhibited TAF-
conditionedmediarestoredHNSCCmigration.Althoughautophagyhasbeen iden-
tifıed as upregulated in a variety of cancer types, noonehas previously characterized
the role of autophagy in HNSCC, and both early pre-clinical and clinical studies of
autophagy inhibition as a cancer therapy have been limited by the lack of a specifı-
cally targeted inhibitor.We demonstrate a signifıcant decrease inHNSCC progres-
sion in preclinical models by using a new and highly specifıc small molecule inhib-
itor of autophagy, SAR405, which inhibits Vps34, an upstream autophagy pathway
kinase. In summary, we uncover a novel role for secretory autophagy in the tumor
microenvironment which promotes tumor progression, and can be uniquely tar-
geted for therapy.
#2978 Discrete super-enhancer networks in pancreatic cancer cells and
cancer associated fıbroblasts are targeted and modulated by triptolide.
Pawan Noel, Serina Ng, Ruben Muñoz, Daniel Von Hoff, Haiyong Han. Trans-
lational Genomics Research Institute (TGen), Phoenix, AZ.
Background: Pancreatic cancer (PC) is the 3rd leading cause of adult cancer
death in the USA. Pancreatic ductal adenocarcinoma (PDAC) accounts for
90% of all PC cases and has a dismal 5-year survival rate of 6%, mostly due
to lack of reliable methods for early detection, and limited treatment options. A
unique, highly fıbrotic and hypo-vascularized tumor stroma or “desmoplastic
reaction” (DR) forms the major barrier to currently available therapeutics. Ac-
tivated cancer associated fıbroblasts (CAFs) play an important role in driving
and maintaining the DR in PDAC. Thus therapeutic regimens that reprogram
pancreatic CAFs can potentially enhance sensitivity to anti-tumor agents and
may improve patient outcomes. Recent studies implicate the role of super-en-
hancers (SE) in maintaining cell specifıc gene expression networks in both nor-
mal and diseased cells. Here we aim to defıne SE networks in pancreatic CAFs
and epithelial tumor cells and explore the role of triptolide in modulating SE
signatures. Methods: Using genomic techniques on control vs triptolide treated
pancreatic tumor and CAF cells, we measured occupancy of BRD4 and acety-
lated histone 3 at lysine27 (H3K27ac), marks of active SEs, using ChIP-seq.
RNA-seq revealed differentially regulated genes via SEmodulation by triptolide.
Immunoblottingwas performed to validate the effect of triptolide on the protein
signature associated with dysregulated SEs. Results: Top ranked SEs between
BRD4 and H3K27ac marks showed extensive overlap, but were highly distinct
between cancer cells and CAFs. The SEs in tumor cells associated with genes
related to transcription (e.g.POLR2E, PARK7, MYC), whereas those in CAFs
associated with genes involved in desmoplasia/fıbrosis (e.g. COL1A1, COL1A2,
TGFBI). Triptolide signifıcantly altered SE activation at diverse and discrete
genomic loci in both cell types. Specifıcally, SE regions associated with COL1A2
andTGFBI showed reducedH3K27ac binding inCAFs exposed to triptolide but
not in tumor cells, which showed reduced histone signal at RNA Pol II region.
Transcriptional deregulation by triptolide exceeded in CAFs vs tumor cells
(1282 vs 23 genes upregulated, 1496 vs 321 genes downregulated). Finally, trip-
tolide resulted in reduced expression of BRD4 andRNAPol II in both tumor and
CAFs, while c-MYC and Collagen I were specifıcally and signifıcantly down-
regulated in tumor and CAFs, respectively. Conclusions: Our results suggest
that pancreatic CAFs and tumor cells harbor distinct SE networks that are char-
acteristic of their different cell types and states. Triptolide might exert its anti-
tumor activity by potentially targeting distinct SEs in different cells. Epigenetic
reprogramming of transcription by exploiting SE modulating compounds like
triptolide alone or in combination with current standard of care may provide
more effective treatment options for PC patients.
#2979 Inhibition of palladin in cancer associated fıbroblast impedes pan-
creatic ductal adenocarcinoma associated desmoplasia. Jennifer I. Alexan-
der,1 Edna Cukierman2. 1Drexel University College of Medicine, Philadelphia,
PA; 2Fox Chase Cancer Center, Philadelphia, PA.
Pancreatic Ductal Adenocarcinoma (PDAC) claims 97% of patient lives in
less than 5 years after diagnosis. Treatment of PDAC is challenged by the colla-
gen-rich, highly dense, fıbrous-like extracellular matrix (ECM) known as des-
moplasia. Desmoplasia is initiated by activated cancer associated fıbroblasts
(CAFs) and disseminates throughout the stromal compartment in a vicious
cycle involving alterations to the physical/structural and biochemical pathways
in neighboring naïve fıbroblasts that ultimately enriches the CAF population.
This desmoplastic-ECM (D-ECM) encapsulates the tumor mass, thereby limit-
ing therapeutic perfusion. Paradoxically, ablation of D-ECM induces a more
aggressive PDAC progression. Although the underlying biology remains un-
clear, the D-ECM is a consequence of cytoskeletal rearrangements occurring
amid the CAFs. The goal of this study is to delineate the cytoskeleton dynamics
engaged as a potentialmechanism to restore the innate tumor-suppressive prop-
erties of a normal ECM. As such, this study focuses on the actin cross-linker
palladin which has been identifıed as an independent prognostic marker in
PDAC progression.We postulate palladin has an isoform-specifıc role in PDAC
desmoplasia as well as cancer progression. Using an in vivo-mimetic 3D fıbro-
blast-derived ECMmodel, we explore the isoform-specifıc role of palladin dur-
ing D-ECM onset as well as during D-ECM-induced CAF activation in PDAC
patient derived CAFs in which the major palladin isoforms (isoforms 3 and 4)
were knocked out via CRISPR/Cas9 gene editing.Using these cells, we examined
the activation status of the CAFs while characterizing the ECM produced via
quantitative immunoblots, real-time polymerase chain reaction, and detailed
microscopy analyses. We then validated the effects of palladin knockout CAFs
activity in influencing krasmutated cancer cells’metabolic activity, invasion and
proliferation. Our data indicates palladin isoforms 3 and 4 expression are nec-
essary to drive CAF activation as well as perpetuate the D-ECM phenotype
whereby knockdown of either isoform prevents CAF activation while limiting
cancer cell behavior. Additionally, the ECMsproduced by the palladin knockout
CAFs were no longer capable of activating naïve fıbroblast in addition to de-
creasing the inherent aggressive nature of kras-mutant cancer cells. These re-
sults are similar to previous fındings regarding the restrictive nature of a normal
ECM on CAF activation and cancer cell behavior. These fındings suggest that
palladin isoforms 3 and 4 are required for desmoplastic onset and D-ECM-
induced fıbroblastic activation and cancer cell progression. Together, these re-
sults propose manipulation of specifıc palladin isoforms could signify a strategy
to restore a normal tumor-suppressive stroma in PDAC.
#2980 Cystathionine-beta-synthase (CBS)-derived hydrogen sulfıde (H2S)
supports proliferation, migration and bioenergetics in colon cancer-associated
fıbroblasts (CAFs). Katalin Modis, Manjit Maskey, Paul Johnson, Csaba Szabo,
Mark R. Hellmich, Celia Chao.Univ. of TexasMedical Branch, Galveston, TX.
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Introduction: Our group has recently demonstrated that CBS, one of the H2S-
producingenzymes, is abundantlyoverexpressed inhumancolorectal cancer (CRC)
tissue specimens resulting in an increased H2S production. In order to extend our
observations, we have now compared, using immunohistochemistry, CBS expres-
sion in carcinoma-associated fıbroblasts (CAFs) compared to normal colonic fıbro-
blasts (NCFs) in human colon adenocarcinoma samples. The overall goal of our
studies is to characterize how the CBS/H2S axis contributes to the malignant phe-
notype of the CAFs in the tumor microenvironment. Methods: Human CAFs and
NCFs were collected from CRC under an IRB approved protocol and cultured in
vitro.Westernblot analysis of bothNCFandCAFwasperformed todetermineCBS
protein expression levels. SiRNA/shRNA-mediated silencing of CBS in CAFs was
performed. A pharmacological inhibitor of CBS, aminooxyacetic acid (AOAA), in
both CAF and NCF cultures was also utilized. Hydrogen sulfıde (H2S) levels were
measured using the fluorogenic probe 7-Azido-4-methylcoumarin. We also per-
formed proliferation assays using a coulter counter in CAFs, NCFs, and CAFs sub-
jected to siRNA/shRNA-mediated CBS silencing or AOAA. Control cells were
transduced with shNT vectors. Cells were also treated with the slow-releasing H2S
donor GYY4137. We also conducted cell migration assays in transwell chambers
(migrationofCAFs toward conditionedmedia (CM)collected either fromHCT116
cells or normal colonmucosal cells (NCM356). Finally, the XF24 Extracellular Flux
Analyzer (Seahorse) was used to measure bioenergetic function in CAFs subjected
to siRNA/shRNA-mediated silencing of CBS or treated with AOAA. Results: CBS
protein expression andH2S production in CAFs was increased compared toNCFs.
TheH2Sdonor,GYY4137, increased theproliferationrateofCAFsbutnotofNCFs.
CBS silencing or AOAA treatment reduced CAF migration toward conditioned
media from HCT116 cells. Genetic or pharmacological inhibition of CBS in CAF
cells suppressed key bioenergetic parameters including basal respiration, ATP pro-
duction, maximal respiratory capacity, and spare respiratory capacity compared to
NCF cells or CAF shNT cells. Conclusions: Thus, CBS/H2S axis serves as a mecha-
nism to support CAFs’ function. In these cells, H2S contributes tomaintaining their
bioenergetic functions, which, in turn, promotes their proliferation and migration
toward colon cancer cells.Wehypothesize that theseprocessesmay contributeCRC
progression.
#2981 Identifıcation of circulating stroma-related biomarkers for pancre-
atic ductal adenocarcinoma. Andrea Resovi,1 Luca Porcu,1 Alessia Anastasia,1
PaolaAllavena,2 Paola Cappello,3 Anna Falanga,4 Giulia Taraboletti,1Mariarosa
Bani,1 Dorina Belotti,1 Raffaella Giavazzi1. 1Istituto di ricerche farmacologiche
Mario Negri,Milano e Bergamo, Italy; 2Humanitas Clinical and Research Center,
Rozzano, Italy; 3CeRMS, University of Torino, Torino, Italy; 4Department of Im-
munohaematology and Transfusion Medicine, Bergamo, Italy.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive ep-
ithelial malignancies characterized by a relevant amount of tumor stroma. It is
usually diagnosed late and has limited treatment options. Plasmatic markers
capable of detecting the disease in its early stages and monitoring treatment
effectivenessmight change the fate of PDACpatients. This study investigates the
potential value of circulating stroma-related molecules as PDAC biomarkers
capable to detect the disease and to monitor treatment response. Thirty-eight
stroma-related candidate biomarkers were selected from published proteomic
studies on PDAC. Levels of thesemolecules were tested by ELISA andMultiplex
Luminex assays in a fırst cohort of plasma samples from PDAC patients and
healthy subjects. Thirteen molecules -extracellular matrix proteins and proteo-
lytic fragments, matrix-degrading enzymes and their inhibitors, growth factors
and adhesion molecules-, were found to be differentially expressed in PDAC
plasma compared to healthy subjects. A second analysis in an independent co-
hort of PDAC patients, chronic pancreatitis patients and healthy controls con-
fırmed the previous fındings and allowed restricting the number of biomarkers
up-regulated in the plasma of PDAC patients. The plasma analysis of two genet-
ically engineered mouse models of pancreatic cancer [Pdx-1-Cre;LSL-KrasG12D
and Pdx-1-Cre;LSL-KrasG12D/;LSL-Trp53R172H/] revealed an up-regulation
of four markers in association with PanIN development, indicating their poten-
tial role in the early diagnosis of pancreatic cancer. These markers were also
elevated in the plasma of mice bearing patient derived orthotopic PDAC xeno-
grafts (PDAC-PDX), but not in a mouse model of caerulein-induced chronic
pancreatitis. Their level was associated with PDAC-PDX tumor growth and
response to gemcitabine combined with nab-paclitaxel. In conclusion this anal-
ysis has identifıed a panel of stroma-related potential biomarkers associatedwith
tumor progression and drug response of PDAC. Supported by Associazione
Italiana per la Ricerca sul Cancro (AIRC 5 per mille grant n. 12182) and Fonda-
zione “EugenioMorandi”ONLUSper lo studio e la cura dei tumori del pancreas.
#2982 Metastatic and non-metastatic colorectal cancer cells differentially
regulate fıbroblast cell cycle via extracellular vesicles.Rahul Bhome, LouiseM.
House, Tilman Sanchez-Elsner, StephenM.Thirdborough, Emre Sayan, AlexH.
Mirnezami. University of Southampton, Southampton, United Kingdom.
Cancer-associated fıbroblasts are critical to tumor progression. There ex-
ists a dynamic crosstalk between cancer and stromal compartments, which
maintains a permissive tumor microenvironment. Extracellular vesicles
(EVs) play a signifıcant role in this intercellular communication. Colorectal
cancer (CRC) cells can be categorized according to epithelial-mesenchymal
transition (EMT) status, and therefore metastatic capacity. We aimed to
investigate the effect of EMT on EV-mediated cancer-fıbroblast signaling.
CRC cell lines (DLD-1, HCT116, SW620 and SW480) were characterized by
western blotting to determine EMT status. EVs were isolated from condi-
tioned media by serial centrifugation and validated by transmission electron
microscopy, western blotting and nanoparticle tracking analysis. Fluores-
cently labeled EVs and cells were detected and evaluated by flow cytometry
and fluorescence microscopy. Increasing concentrations of EVs from CRC
cells were co-cultured with fıbroblasts for 24h. Activation/inhibition of sig-
naling pathways was examined by western blotting. EVmicroRNA (miRNA)
profıles were obtained, validated by qPCR and submitted for target and
pathway analysis. DLD-1, HCT116 and SW620 cells express E-cadherin and
are considered epithelial, whereas SW480 lacks E-cadherin, expresses
ZEB-1, and is considered mesenchymal. EVs were spherical, enriched in
ALIX, TSG101, CD63 and had amean diameter of 90nm. EVs fromCRC cells
were shown to transfer directly to primary ex vivo patient-derived fıbroblasts
and fıbroblast cell lines. Transfer of EVs from epithelial CRC cells abrogated
ERK activity in fıbroblasts, even at the lowest concentration, and was asso-
ciated with reduced fıbroblast proliferation, whereas EVs frommesenchymal
cells had no effect. MiRNA profıling of EVs from epithelial and mesenchy-
mal CRC cells showed a 10-fold upregulation of miR-143-3p in epithelial
compared to mesenchymal EVs. MiRNA target analysis and experimental
validation show that miR-143-3p directly targets KRAS and HRAS, provid-
ing a potential miRNA-orchestrated mechanism of action for the downregu-
lation of fıbroblast ERK activity in the tumor microenvironment. Impor-
tantly, CRC cellular ERK activity is not reflected in fıbroblasts treated with
CRC EVs, suggesting that EVs do not directly transmit ERK protein or
mRNA. However, miRNAs are the most stable EV cargo, and we show that
epithelial but not mesenchymal CRC EVs contain upregulated miRNAs,
which target critical components of the ERK pathway. Downregulation of
ERK activity has been shown to induce fıbroblast senescence, a phenotype
linked to cancer progression. We hypothesize that differential regulation
occurs because epithelial CRC cells are juxtaposed with fıbroblasts in the
tumor core, where senescent cancer associated fıbroblasts are frequently
observed, whereas mesenchymal CRC cells are at the invasive front or in the
circulation.
#2983 Tumor induced stromal STAT1 deregulates mammary tissue ho-
meostasis and accelerates breast cancer. Victoria R. Zellmer, Patricia M. Sch-
nepp, Sarah L. Fracci, Xuejuan Tan, Erin N. Howe, Siyuan Zhang. University of
Notre Dame, Notre Dame, IN.
The tumor microenvironment (TME) – the dynamic tissue space in which the
tumor exists – plays a signifıcant role in tumor initiation and is a key contributor in
cancer progression. Little is known about the tumor-induced changes in the adja-
cent tissue stroma.Herein,wesought toexplore tumor-inducedchanges in theTME
at themorphological andmolecular level to further characterize cancer progression.
We show that tumor-adjacent mammary glands (TAGs) display altered branch
morphology, increased expression of SMA particularly in myofıbroblasts, and an
increasedcapacity to formmammospheres in2Dsuspensionculture. FACSanalysis
showed that TAGs contain an increased number of Lin-CD24/CD49 enriched
mammary gland stem cell (MaSCs) population, suggesting deregulated tissue ho-
meostasis in TAGs.We conducted comparative transcriptomics onTAGs and con-
tralateral control glands. Meta-analysis on differentially expressed genes from our
RNA-seq dataset plus two breast cancer stromal patientmicroarray datasets identi-
fıed shared upregulation of STAT1, which we verifıed in tumor-adjacent tissues.
Knockdown of STAT1 in caveolin-defıcient mouse embryonic fıbroblasts (CAFs)
cocultured with human breast cancer cells altered cancer cell proliferation, further
suggesting the role of STAT1 as a stromal contributor of tumorigenesis. Further-
more, in our proof-of-concept in vivo experiment, co-treatmentwith fludarabine, a
FDA-approved STAT1 activation inhibitor and DNA synthesis inhibitor, in com-
binationwithdoxorubicin, showed enhanced therapeutic effıcacy in treatingmouse
mammary gland tumors. Our results demonstrate that stromal STAT1 expression
could promote tumor progression and is a potential therapeutic target for breast
cancer.
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#2984 The chemokine CCL2/CCR2 signalingmediated fıbroblasts-cancer
cells crosstalk promotes basal like breast cancer progression. Min Yao, Wei
Bin Fang, Fang Fan, Nehemiah Alvarez, Patrick E. Fields, Nikki Cheng. Univ-
erisity of Kansas Medical Center, Kansas City, KS.
Cancer associated fıbroblasts are the most abundant stromal cells in breast
cancer, but their function in cancer progression has not been fully understood.
We previously identifıed that the chemokine CCL2 was highly expressed in
breast cancer associated fıbroblasts, and high stromal CCl2 expression predicted
poor outcome in basal like breast cancer. CCL2 is known to recruit monocyte/
macrophage and promotes cancer progression. We previously found that re-
combinant CCL2 can directly signal to breast cancer cells and promote cell
survival and invasion in vitro. In this study, we aimed to determine the func-
tional importance of CCL2 signaling mediated fıbroblast-cancer cell interac-
tions in breast cancer progression. We used a fıbroblast and cancer cell co-graft
mouse model as the main functional assay. We generated primary fıbroblasts
frommousemammary tumor and human breast cancer, and confırmedmost of
they expressed high level of CCL2.When co-graftedwith the human basal breast
cancer cell lineMCF10A-CA1D into nudemice, fıbroblasts enhanced xenograft
growth. Stable knockdown of CCL2 expression from fıbroblasts signifıcantly
reduced its ability in tumor growth promotion, while knockdown CCL2 from
cancer cells did not. Decreased CCL2 production from fıbroblasts resulted in
increased apoptosis and autophagy in tumor samples. To determine the impor-
tance of direct CCL2 signaling to cancer cell, we generated the CCL2 receptor
CCR2 mutant CA1D cancer cell lines by CRISPR-Cas9 targeting technology.
Mutation of CCR2 in cancer cell signifıcantly reduced tumor growth when co-
grafted with CCL2 secreting fıbroblasts. Lastly, we tested continuous delivery of
CCL2 neutralizing antibody in the co-graft tumormodel, but observedminimal
therapeutic effect. Further examination of blood CCL2 level revealed an in-
creased production of CCL2 from fıbroblasts and mouse host after antibody
treatment, which may contribute to the lack of therapeutic effect. In summary,
our studies demonstrated the importance of CCL2/CCR2 signaling mediated
fıbroblasts-cancer cell interaction in basal like breast cancer progression. The
CCL2 signaling pathway can be potentially served as therapeutic target, but
requires development of effıcient targeting strategy.
#2985 Interaction between the malignant melanoma cell of the primary
lesion and the metastatic lesion. Takaharu Hatano,1 HIsashi Motomura,1
Heishiro Fujikawa,1Masakazu Yashiro,2 Kishu Kitayama3. 1Department of plas-
tic and reconstructive surgery, Osaka City University Graduate School of Medi-
cine, Osaka, Japan; 2Department of Surgical Oncology, Osaka City University
Graduate School of Medicine, Oncology Institute of Geriatrics and Medical Sci-
ence, OsakaCityUniversity Graduate School ofMedicine, Osaka, Japan; 3Depart-
ment of Surgical Oncology, Osaka City University Graduate School of Medicine,
Osaka, Japan.
Introduction: The prognosis of patients with malignant melanoma is ex-
tremely poor because of the frequent metastasis. We have occasionally expe-
rienced the clinical cases that malignant melanoma patients rapidly devel-
oped distant metastases after the surgical resection of primary cancer lesion.
These cases suggested that a primary tumor may control a metastatic tumor.
We hypothesized that primary melanoma cells might produce a factor(s)
which regulate the progression of metastatic melanoma cells. Then we in-
vestigated the growth and invasion interaction between primary malignant
melanoma cells and high metastatic melanoma cells. Materials and methods:
We used two malignant melanoma cell lines, B16 as a parent primary mela-
noma cell line and a selected daughter cell line B16/BL6 with high metastatic
ability. We investigated the invasive interaction between the parent B16 cells
and daughter B16/BL6 cells in vitro. The conditionedmedium from B16 cells
and B16/BL6 cells was added to B16 cells or B16/BL6 cells. Then we exam-
ined the effect of these conditionedmedium on themotility and proliferation
of melanoma cells by MTT assay or invasion assay at 24hours and 72 hours
after the addiction of the conditioned medium. Results: The conditioned
medium from B16 cells signifıcantly (p0.02) suppressed the invasion abil-
ity of B16/BL6 cells at 24 hours after the addiction of the conditioned me-
dium. In contrast, the invasion ability of B16 cells were not affected by the
conditioned medium from B16/BL6 cells at 24 hours. Each conditioned me-
dium did not affect on the proliferation of both melanoma cell lines. On the
other hand, at 72 hours after the addiction of the conditioned medium from
B16 cells signifıcantly (p0.000003) suppressed the growth of B16/BL6 cells.
Conclusion: Primary melanoma cells might down-regulate the progression
of metastatic melanoma cells by a soluble factor(s).
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#2986 Atezolizumab in metastatic TNBC (mTNBC): Long-term clini-
cal outcomes and biomarker analyses. Peter Schmid,1 Cristina Cruz,2 Fadi
S. Braiteh,3 Joseph Paul Eder,4 Sara Tolaney,5 Irene Kuter,6 Rita Nanda,7
Cathie Chung,8 Philippe Cassier,9 Jean-Pierre Delord,10 Michael Gordon,11
Yijin Li,12 Bo Liu,12 Carol O’Hear,12 Marcella Fasso,12 Luciana Molinero,12
Leisha A. Emens13. 1Barts Cancer Institute, Queen Mary University London,
London, United Kingdom; 2Vall d’Hebron University Hospital, Barcelona,
Spain; 3Comprehensive Cancer Centers of Nevada, Las Vegas, NV; 4Yale
School of Medicine, New Haven, CT; 5Dana Farber Cancer Institute, Boston,
MA; 6Massachusetts General Hospital, Boston, MA; 7University of Chicago
Medical Center, Chicago, IL; 8The Angeles Clinic and Research Institute, Los
Angeles, CA; 9Centre Leon Berard, Lyon, France; 10Institut Claudius Regaud,
Toulouse, France; 11Pinnacle Oncology Hematology, Scottsdale, AZ; 12Genen-
tech, Inc., South San Francisco, CA; 13Johns Hopkins University School of
Medicine, Baltimore, MD.
Introduction. Triple negative breast cancer (TNBC) has a poor prognosis
and limited treatment options. Atezolizumab (atezo) is a humanized mAb
that inhibits the binding of PD-L1 to PD-1 and B7.1, thus restoring tumor-
specifıc T-cell immunity. Atezo was evaluated in an expansion cohort of
mTNBC patients (pts) in a Phase Ia study (NCT01375842). Methods. Enroll-
ment was initially limited to TNBC pts with PD-L1 on 
5% of tumor-
infıltrating immune cells (IC2/3), then opened to pts regardless of PD-L1
status. Pts received atezo IV in 1L or 2L q3w at 15 or 20 mg/kg or 1200 mg
for 1 y with option to be retreated at PD, or until loss of clinical benefıt. ORR
was assessed by RECIST v1.1 and irRC, to capture non-conventional re-
sponses. Baseline PD-L1 expression on IC was centrally scored as IC0/1/2/3
(VENTANA SP142 assay). Pretreatment tumors and on-therapy biopsies
were evaluated for TILs, CD8 T cells and macrophages by IHC. Results. As of
Mar 31, 2016, 115 mTNBC pts were safety evaluable; atezo was generally well
tolerated. There were no additional safety signals from prior report (Emens
AACR 2015). 112 pts with FU
12 wk were evaluable for response. Based on
irRC, ORR in 1L and 2L pts were 26% and 11%, respectively. ORR for
PD-L1 IC2/3 pts were 17% vs 8% in IC0/1. mDoR was 21.1 mo (3 to 34).
mOS of responders (n15) was not reached (4 to 37mo) with no deaths
as of data cutoff. mOS of non-responders who lived
 6 wk (n87) was 9 mo
(1 to 19 mo). OS rates in all pts at 1, 2, and 3 y were 41%, 22% and 22%,
respectively. OS rates at 1, 2, and 3 y for PD-L1 IC2/3 were 45%, 28% and
28%, respectively. Pts whose tumors had 10% TILs or 
1.35% CD8 in the
tumor center trended toward higher ORR and longer OS. Atezo increased
intratumoral TILs, CD8, macrophages and IC PD-L1 expression, but no
response association was observed. Conclusions. In mTNBC, atezo was well
tolerated. Responders showed durable clinical benefıt. Response rates were
higher in 1L or PD-L1 IC2/3 pts. Baseline TILs and CD8 were associated with
greater clinical benefıt.
Table. Effıcacy
Responses per RECIST v1.1 (irRC effıcacy results presented in text)
1L
n  19
2L
n  93
PD-L1
IC2/3
n  71
PD-L1
IC0/1
n  37
All
N  112
ORR, %
(95%CI)
26%
(9, 51)
7%
(2, 14)
13%
(6, 23)
5%
(1, 18)
10%
(5, 17)
CR, n 2 1 3 0 3
PR, n 3 5 6 2 8
SD, n 3 12 10 4 15
CBR, % 42% 19% 27% 16% 23%
Median
(range)
DoR, mo
21
(8 to 26)
NE
(3 to 13)
21
(3 to 26)
NE
(10 to 10)
21
(3 to 26)
OS
1L
n 19
2L
n 94
PD-L1
IC2/3
n 71
PD-L1
IC0/1
n 38
All pts
N 113
1 y OS
(95% CI)
63%
(37, 89)
37%
(26, 47)
45%
(32, 58)
37%
(21, 53)
41%
(31, 51)
2 y OS
(95% CI)
47%
(14, 80)
18%
(8, 27)
28%
(15, 41)
NE 22%
(12, 32)
3 y OS
(95% CI)
NE 18%
(8, 27)
28%
(15, 41)
NE 22%
(12, 32)
CBR; clinical benefıt rate, defıned as CR, PR or SD for 
12 weeks. DoR, duration of
response; NE, not evaluable.
, censored.
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#2987 Validation and clinical feasibility of a comprehensive genomic profıl-
ing assay to identify likely immunotherapy responders through tumor muta-
tional burden (TMB).Daniel S. Lieber,1 Mark R. Kennedy,1 Douglas B. Johnson,2
Jonathan E. Rosenberg,3 Marcin Kowanetz,4 Joel R. Greenbowe,1 Garrett M.
Frampton,1 Caitlin F. Connelly,1 Alexa B. Schrock,1 Jeffrey S. Ross,1 Philip J. Ste-
phens,1 SirajM.Ali,1 VincentA.Miller,1DavidA. Fabrizio1. 1FoundationMedicine,
Inc., Cambridge, MA; 2Vanderbilt University, Nashville, TN; 3Memorial Sloan Ket-
tering Cancer Center, New York, MA; 4Genentech, Inc., South San Francisco, CA.
Background: Patients across a range of disease types have demonstrated robust
anddurable responses using checkpoint inhibitor therapies (CPITs).Given the lim-
itations of immuno-histochemical based testing, identifying a unifıed, quantitative
metric to determine potential response to CPITs remains an urgent need. Tumor
mutational burden (TMB) measures the number of somatic protein coding muta-
tions per target sequence in a tumor specimen. This measure has been associated
with response and survival formultiple CPITs across an array of indications. In this
study we describe Foundation Medicine’s (FMI) work to develop and validate a
TMB result as part of our comprehensive genomic profıling assays and summarize
clinical feasibility in NSCLC, melanoma and bladder cancer. Methods: We devel-
oped an analysismethod todetermineTMBbasedondata fromour comprehensive
genomic profıling assays. TMB is calculated by counting all synonymous and non-
synonymous somatic variants across 315 or 405 genes, excluding germline altera-
tions and known or likely driver alterations. The mutation count is normalized by
the coding target territory to achieve amutation density ofmutations permegabase
(mut/Mb).Todetermineaccuracy,wecomparedTMBvalues fromourcomprehen-
sive genomic profıling assay against a CLIA-validated whole-exome sequencing
(WES) method on 29 patients. Precision was assessed over 10 clinical samples rep-
licated 4-6 times. Lower limit of sample tumor purity was determined through di-
lutions of tumor/normal pairs from 80% to 5% tumor. Clinical feasibility was as-
sessed by analyzing TMB versus immunotherapy-based survival in a cohort of 65
metastatic melanoma patients, 150 urothelial carcinoma patients and 463 NSCLC
patients. Additionally, we examined the relationship betweenTMBandmicrosatel-
lite instability status (MSI), an independent biomarker associated with response to
CPITs.Results: FoundationMedicine’sTMBmeasureprovidesaccurateandprecise
results across a range of tumormutational burden values on sampleswith as little as
20% tumor purity. Using cohort specifıc thresholds, TMB was signifıcantly associ-
ated with improved survival to CPITs in NSCLC, melanoma and bladder cancer.
Using data from over 40,000 patient samples, we also show signifıcant overlap be-
tween high TMB and highMSI samples and show thatMSI-High specimens repre-
sent a subset of TMB-High specimens. Conclusions: We have developed and vali-
dated the tumormutational burden (TMB)biomarker aspart of our comprehensive
cancer genomic profıling assays. Initial clinical feasibility results demonstrate that
TMB can be used to predict the likely response to anti-PD-1/PD-L1 CPITs across a
growing number of indications including NSCLC, melanoma and bladder cancer.
#2988 Immunogenomic analyses of tumor cells andmicroenvironment in
patients with advanced melanoma before and after treatment with niv-
olumab. Timothy A. Chan,1 Nadeem Riaz,1 Jonathan J. Havel,1 Vladimir Ma-
karov,1 Alexis Desrichard,1 Jennifer S. Sims,1 F. Stephen Hodi,2 Salvador Mar-
tín-Algarra,3 William H. Sharfman,4 Shailender Bhatia,5 Wen-Jen Hwu,6
Thomas F. Gajewski,7 Craig L. Slingluff,8 Sviatoslav M. Kendall,1 Han Chang,9
John-William Sidhom,10 Jonathan P. Schneck,11 Nils Weinhold,1 Christine E.
Horak,9 Walter J. Urba12. 1Memorial Sloan Kettering Cancer Center, New York,
NY; 2Dana-Farber Cancer Institute, Boston, MA; 3University of Navarra, Pam-
plona, Spain; 4The Sidney Kimmel Comprehensive Cancer Center at Johns Hop-
kins, Baltimore, MD; 5University of Washington, Seattle, WA; 6University of
TexasMDAndersonCancer Center, Houston, TX; 7University of ChicagoGordon
Center for Integrative Science, Chicago, IL; 8University of Virginia, Charlottes-
ville, VA; 9Bristol-Myers Squibb, Princeton, NJ; 10Johns Hopkins University, Bal-
timore, MD; 11Johns Hopkins School of Medicine, Baltimore, MD; 12Earle A.
Chiles Research Institute, Portland, OR.
Background: Response to checkpoint blockademay be dependent on tumormu-
tational load and the presence of antigen-specifıc effector T cells in the tumor mi-
croenvironment; however, howblockademodulates these featuresduring therapy is
unclear.We assessed genomic changes in tumors frompatients (pts)with advanced
melanoma receiving nivolumab (nivo) who progressed on ipilimumab (ipi-P) or
were ipinaive (ipi-N). Methods: Tumor biopsies were collected pretreatment and 4
weeks post fırst nivo dose from ipi-Nor ipi-P pts treatedwith nivo 3mg/kgQ2W in
the phase 1 open-label CA209038 study (NCT01621490). Biopsies from68 ptswere
analyzed by whole exome, transcriptome, and/or TCR sequencing (paired biopsies
from 41, 42, and 34 pts, respectively). Results: Objective response rate (ORR) in the
overall cohort (n85) was 27%with similar ORR in ipi-N and ipi-P cohorts. In the
genomic cohort (n68),ORRwas23%with a similarnumberof complete orpartial
responses (CR/PR) in ipi-N and ipi-P pts (n7 and n8, respectively). Prior to
treatment,mutational andneoantigen loadwere comparable, regardless of previous
treatment. Following nivo treatment, both mutational and neoantigen load were
reduced 5-fold in pts who responded (CR/PR; n9) and 1.2fold in pts with stable
disease (SD,n13) comparedwitha1.1-fold increase inptswithprogressivedisease
(PD, n19). Intratumoral heterogeneity analysis before and after nivo demon-
strated that CR/PR pts generally lost tumor mutation clones/subclones. Novel tu-
mormutation cloneswere observed inon-treatment samples from2CR/PRpts and
all pts who progressed on nivo. Transcriptome analyses revealed signifıcant in-
creases in distinct tumor immune cell subsets (CD8 T cells and NK cells) and
immune checkpoint gene expression (LAG3, CTLA4, PCDC1, and CD274 [PD-
L1]) following nivo, which were more pronounced in pts with CR/PR vs PD (log2
fold-changes of 1.24, 1.07, 1.71, and 0.74, respectively). Consistent with the tran-
scriptome analyses, tumorinfıltrating lymphocytes, as assessed by immunohisto-
chemistry, generally increased following nivo in pts who responded: 2.8 vs 1.9-fold
change inCR/PR/SD vs PD in the ipi-P cohort; 4.8 vs 1.8-fold change inCR/PR/SD
vsPD in the ipi-N cohort.Differences in treatment-relatedTCR repertoire diversity
changes were apparent between pts who responded within the ipi-N and ipi-P co-
horts: a decrease in the evenness of T-cell clonotype distribution was observed
amongptswithCR/PR/SDrelative toptswithPDinthe ipi-Ncohort (P0.036),but
not in the ipi-P cohort. Conclusion: Nivo and ipi modulate T-cell repertoire and
tumormutational heterogeneity inptswith advancedmelanoma, presentingpoten-
tial mechanisms of action underlying successful nivo therapy. These data also show
that prior ipi treatmentmay influence biological response to nivo, but further inves-
tigation is warranted.
#2989 Expression of immune checkpoints proteins and their prognostic rel-
evance in prostate cancer. Claudia Hube-Magg, Cornelia Schroeder, Ronald Si-
mon, Martina Kluth, Till Krech, Franziska Büscheck, Frank Jacobsen, Doris Höfl-
mayer, Lars Budäus, Hartwig Huland, Markus Graefen, Guido Sauter, Thorsten
Schlomm.Univ. Medical Ctr. Hamburg-Eppendorf, Hamburg, Germany.
Immune checkpoint proteins including programmed death ligand 1, 2 (PD-L1,
PD-L2) and B7-H3 play important roles for immune evasion inmany cancer types.
PD-L1 isanestablished therapeutic target in lungcancerand inagrowingnumberof
other indications. The clinical success of PD-L1 inhibitors has accelerated the devel-
opment of drugs also targeting PD-L2 andB7-H3. In prostate cancer, studies on the
prevalence and clinical relevance of these proteins have been inconclusive.Here, we
performed immunohistochemical analysis ofPD-L1,PD-L2andB7-H3 inour large
prostate cancer prognosis tissuemicroarray (TMA) containing tissue samples from
more than 17,000 patients. Normal prostate glands were negative for PD-L1 and
B7-H3, but positive for PD-L2. We found that 47% of 12,808 interpretable cancers
showed B7-H3 expression, and 92% of 9,463 cancers showed PD-L2 expression,
while expression of PD-L1was virtually absent (0.2%of 17,392 tumors) in epithelial
cells. Stroma cells and immune cells were entirely negative for PD-L1 and B7-H3,
while some faint staining of lymphocytes was occasionally observed for PD-L2. In
cancers, PD-L2 and B7-H3 staining had different prognostic impact, which de-
pended on the ERG status: B7-H3 expression was linked to young patient age, ad-
vancedstage,highGleasongrade, lymphnodemetastasis (p0.0001each),presence
of PTEN deletion (p0.0001), and poor prognosis in ERG negative cancers
(p0.0001), while PD-L2 expression was linked to benefıcial tumor features and
goodprognosis exclusively in tumorswithERGfusion(p0.0001). Inamultivariate
analysis including pT stage, Gleason grade, nodal stage, resection margin and pre-
operative PSA level, B7-H3 expression was an independent prognostic factor
(p0.0004). In summary, the results of our study identify a subset of youngpatients
with ERG negative aggressive prostate cancers that might benefıt from anti-B7-H3
therapy in the future. PD-L2expressionappears toprotect tumors fromprogression
and does not seem to be suitable as a potential target in prostate cancer. PD-L1
expression is extremely rare in this disease, suggesting that only few prostate cancer
patients might benefıt from PD-L1 inhibitors.
#2990 Polyfunctional anti-CD19CART cells determined by single-cellmul-
tiplexproteomics associatedwith clinical activity inpatientswithadvancednon-
Hodgkin’s lymphoma. John Rossi,1 Patrick Paczkowski,2 Yueh-wei Shen,1 Kevin
Morse,2BriannaFlynn,2AlainaKaiser,2ColinNg,2KyleGallatin,2TomCain,2Rong
Fan,3 SeanMackay,2 JamesHeath,4 StevenA. Rosenberg,5 JamesN.Kochenderfer,6
JingZhou,2AdrianBot1. 1Kite Pharma, SantaMonica, CA; 2IsoPlexis, Branford, CT;
3Yale School of Engineering and Applied Science, Yale University, New Haven, CT;
4Division ofChemistry andChemical Engineering,California Institute ofTechnology,
Pasadena, CA; 5Surgery Branch, National Institutes of Health, Bethesda, MD; 6Ex-
perimental Transplantation and Immunology Branch, National Institutes of Health,
Bethesda, MD.
Introduction: Autologous anti-CD19 CAR T cells have shown promising
clinical effıcacy in B cell malignancies, with T cell expansion and blood levels
for IL-15, IL-10 and Granzyme B as correlates of objective response and
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toxicity (Kochenderfer et al. J Clin Oncol 2016; 34:LBA3010). It is unclear,
however, which key immune programs in CAR T cells impact their in vivo
expansion and clinical outcome. We evaluated in detail the functionality of
anti-CD19 CAR T cells by using single-cell proteomics analysis (Lu et al.
PNAS 2015;113:607-615). We explored how the polyfunctionality of pre-
infusion CAR T cell products, post-stimulation with the CD19 antigen in
vitro, associated with CAR T cell expansion in vivo and objective response.
Methods: Product T cells were separated into CD4 or CD8 T cell subsets
using microbeads. CD4 or CD8 fractions were then co-cultured with
CD19-K562 targets or NGFR-K562 control cells, at a 1:2 ratio for 20 hrs.
Single cells were then analyzed using a 32-plex panel of secreted cytokines,
chemokines, and cytotoxic molecules. Specifıcally, T cells were loaded onto a
single-cell barcode chip capable of assaying 32 secreted proteins/cell. The
polyfunctional profıle and strength (pSI) of each sample was determined (Ma
et al. Cancer Discov 2013;3:418-429) and analyzed relative to in vivo expan-
sion of the CAR T cells and patient response to the CAR T cell therapy. CAR
T cell expansion in blood was measured by quantitative PCR. Results: Single-
cell pSI of patient CAR T cells showed a statistically signifıcant association
(p  0.011) with objective response (complete or partial response) to the
therapy. While product pSI showed variability across patients, the median
pSI was 2 times higher for responders versus non-responders. The poly-
functional profıles for both CD4 and CD8 cells were dominated by ef-
fector molecules, stimulatory cytokines and chemokines. Polyfunctional
CD4 and CD8 subsets with IFN-, IL-8 and/or MIP-1 correlated best
with patient outcome, with CD8 T cells showing co-expression of Gran-
zyme B, and CD4 T cells also comprising IL-17AIL8 and IL5IL8
subsets. While CAR expansion in vivo also correlated with objective re-
sponse (p  0.032), the association between product pSI and CAR cell ex-
pansion in vivo did not reach statistical signifıcance (p 0.079), suggesting
that they bring independent contributions to predicting objective response.
In support of that, a composite index integrating pSI and CAR T cell expan-
sion in vivo associated best with clinical response (p  0.005). Conclusion:
Polyfunctionality of CAR T cells, in conjunction with their expansion in
vivo, correlates with clinical outcome in an anti-CD19 CAR T cell clinical
trial. Single-cell multiplexed proteomics measurements may provide power-
ful insight into the clinical performance of CAR T cell products. [J.R. and
P.P. contributed equally to this study.]
#2991 Integrative analysis ofmolecular and drug response data from clin-
ical samples and PDTXs to identify pharmacogenomic associations in breast
cancer.Maurizio Callari, RajbirN. Batra, Ankita Sati Batra,WendyGreenwood,
Suet-Feung Chin, Alejandra Bruna, Oscar M. Rueda, Carlos Caldas. University
of Cambridge, Cambridge, United Kingdom.
Breast cancer is the most common cancer among women showing high clin-
ical and molecular heterogeneity. Current clinical management causes patients
overtreatment with implications on both patients’ quality of life and healthcare
costs. Moreover, intrinsic or acquired tumor resistance to treatment leads to
incurable metastatic progression in a signifıcant proportion of patients. Conse-
quently, there is an urgent need for better predictive biomarkers and a better
understanding of the mechanisms driving response to treatment. As part of the
METABRIC initiative, we fully molecularly characterized 2000 breast primary
tumors, measuring gene expression, copy number aberration, somatic muta-
tions and methylation. In addition, a biobank of breast cancer patient-derived
tumor xenograft (PDTX) models (n92) has been generated in our lab and a
comprehensivemolecular characterizationwas also obtained.We recently dem-
onstrated that breast cancer PDTXs maintain originating cancers intra-tumor
heterogeneity, hence representing a more relevant preclinical model than cell
lines. An ex-vivo drug screening was performed in these models generating
response data (IC50 and AUC) for 100 different drugs, including ‘best in class‘
PI3K, PARP andCDK4/6 inhibitors, novel biological and chemical inhibitors of
HER2, ER, IGF1R andHER3, as well as standard of care agents. Here we derived
signatures of pathway activation/disruption by integrating different data types
in the METABRIC cohort. Their association with previous breast cancer classi-
fıcations, as well as their prognostic signifıcance was studied. The predictive
power of these signatures was investigated in the PDTX cohort to identify novel
pharmacogenomics associations. They were tested independently as well as in
combination, to derivemolecular predictors of response to treatment.We found
known and novel associations between genomic/transcriptomic features and
drug response. For example, our results confırmed the known association be-
tween estrogen receptor-related genes and response to tamoxifen treatment.We
also identifıed markers of response to inhibitors of the PI3K/AKT/mTOR path-
way. Selected fındingswere validated in clinical cohorts aswell as in independent
PDTX models. In conclusion, by integrating molecular data from large cohorts
of clinical samples andPDTXwehave generated a computational framework for
the systematic identifıcation of pharmacogenomics associations in breast cancer
and to generate hypothesis for rational drug-drug combinations.
#2992 Identifıcation of NOTCH1 inactivating mutation as a therapeutic
vulnerability to PI3K/mTORpathway inhibition in head andneck squamous
cell carcinoma (HNSCC). Vaishnavi Sambandam, Li Shen, Pan Tong, Tuhina
Mazumdar, Curtis Pickering, Jeffrey N. Myers, Jing Wang, Mitchell Frederick,
Faye M. Johnson.MD Anderson Cancer Center, Houston, TX.
Background: Genomic alterations in the PI3K/mTOR pathway occur in 54%
of HNSCC patients. However, clinical trials of PI3K/mTOR pathway inhibitors
had limited success even in those tumors with pathway alterations, including
PIK3CA mutations. To target genomic alterations in HNSCC, we tested the
effıcacy of 7 PI3K/mTOR pathway inhibitors in 59 HNSCC cell lines and deter-
mined the association between drug sensitivity and molecular characteristics in
order to identify biomarkers of response. Methods: We systematically analyzed
the association between drug sensitivity and genomic alterations in 59 HNSCC
lines. Results: NOTCH1mut lines are signifıcantly sensitive to PI3K/mTORpath-
way inhibitors: GSK2126458 (13/16), BYL719 (6/16), PQR309 (13/16), BKM120
(14/16), BEZ235 (12/16), BAY806942 (14/16) and GDC0980 (13/16 lines). In
contrast to PIK3CAmut cell lines, all 7 NOTCH1mut lines tested underwent ap-
optosis (14.3 fld; P0.005). After PI3K/mTOR inhibition, NOTCH1mut lines
showed signifıcantly reduced clonogenic growth in vitro (0.4/ 0.9 fold in HN31/
PCI15B; P0.05) and signifıcant tumor growth inhibition in vivo using ortho-
topic oral xenograft mouse models (1.7 and 2 fold in UMSCC22A and HN31;
P0.01). To determine if NOTCH1 mediates resistance, we conditionally ex-
pressed cleaved NOTCH1 by Dox-inducible system in a NOTCH1mut line
(UMSCC22A). This rescued PI3K/mTOR inhibitor-induced apoptosis (0.5 fold;
P0.05) and reduced colony formation in vitro. As no canonical pathways ac-
count for the underlying mechanism of sensitivity, wemeasured the level of 301
proteins by reverse phase protein array (RPPA) in 3 NOTCH1mut and 3
NOTCH1
WT
lines afterGSK2126458 treatment.Glutaminase andGlutamateDe-
hydrogenase were differentially expressed in NOTCH1mut lines. Thus, we hy-
pothesized that PI3K/mTOR inhibition in NOTCH1mut lines induced reactive
oxygen species (ROS)-mediated apoptosis via metabolic alterations. Consistent
with this hypothesis, NOTCH1mut lines exhibited increased ROS production;
Metabolic pathway inhibitors targeting Glycolysis, Pentose Phosphate pathway
andGlutaminolysis, in combinationwithGSK2126458decreased cell viability in
NOTCHWT lines. Conclusion: In contrast to PIK3CAmut cells, NOTCH1mut
HNSCC cells underwent apoptosis after PI3K/mTOR pathway inhibition in
vitro and decreased tumor size in vivo. The ectopic activation of NOTCH1
rescued NOTCH1mut HNSCC cells from PI3K/mTOR inhibitor-mediated apo-
ptosis. The underlying mechanism may involve differential effects on tumor
metabolism and ROS production. This work is signifıcant because inactivating
NOTCH1 mutations, which occur in 18% of HNSCC patients and SCCs of the
lung, esophagus, and other sites, may serve as a biomarker for response. Our
future work may uncover previously unknown crosstalk between the PI3K/
mTOR and NOTCH pathways in SCCs.
CLINICAL RESEARCH: Innate Immune Mechanisms in Cancer
Treatment
#2993 STING signaling in breast tumor microenvironment modulates
immune checkpoint blockade effıcacy in the neu-N mouse model of breast
cancer. Jeremy B. Foote,1 Marlene Kok,1 JamesM. Leatherman,1 Todd D. Arm-
strong,1 BridgetMarcinkowski,1 David B. Kanne,2 ElizabethM. Jaffee,1 Thomas
W.Dubensky,2 LeishaA. Emens1. 1JohnsHopkinsUniversity, School ofMedicine,
Baltimore, MD; 2Aduro BioTech, Berkley, CA.
Background: The presence of tumor infıltrating T cells (TILs) is associated
with improved clinical outcomes in multiple tumor types and is also neces-
sary for response to immune checkpoint blockade. While T cell responses to
some tumors occur spontaneously, the majority of cancers are not naturally
recognized by the immune system. The lack of response is attributed primar-
ily to insuffıcient T cell infıltration into the tumor microenvironment
(TME). Activating the STING pathway represents one strategy for increasing
infıltration of T cells into the TME. This induces interferon- (IFN-) pro-
duction, leading to dendritic cell (DC) activation and priming of tumor
antigen specifıc CD8 T cells that mediate tumor regression. The intratu-
moral injection (IT) of ML-RR-S2-CDA (ADU-S100), a synthetic cyclic di-
nucleotide STING agonist, has antitumor effıcacy in several aggressive
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mouse tumor models, including B16 melanoma, CT26 colon carcinoma,
Panc02 pancreatic carcinoma, and 4T1 triple negative breast cancer. How-
ever, the impact of antigen-specifıc tolerance on tumor regression associated
with STING-activation remains poorly understood. Therefore, we evaluated
the effıcacy of IT ADU-S100 in both non-tolerant parental FVB/N and the
immune tolerant neu/N transgenic mice bearing established HER-2 breast
tumors. Methods: First we fırst evaluated the impact of IT ADU-S100 on
tumor regression, survival, innate sensing, and priming of HER-2 specifıc
CD8 T cells in both tumor-bearing non-tolerant FVB/N control and toler-
ant neu/N mice. Then we determined whether modulating the most highly
expressed immune checkpoints on tumor infıltrating CD8 T cells enhanced
intratumoral STING activation with ADU-S100 in the tolerant neu/Nmouse
model of HER-2 breast cancer. Results: ADU S-100 induced HER-2-spe-
cifıc CD8 T cell priming and durable tumor clearance in 100% of non-
tolerant, FVB/N mice. In contrast, ADU S-100 failed to suffıciently prime
HER-2-specifıc CD8 T cells in tolerant neu/Nmice, delaying tumor growth
and clearing tumors in only 10% of mice. No differences in IFN- produc-
tion, DC priming, or HER-2-specifıc CD8 T cell traffıcking were detected
between FVB/N and neu/N mice. However, activation and expansion of
HER-2-specifıc CD8 T cells was defective in neu/N mice. Immune cell
infıltrates of untreated tumor-bearing neu/N mice expressed high levels of
PD1 and OX40 on CD8 T cells, and high levels of PD-L1 on both myeloid
and tumor cells. Modulating PD-L1 and OX40 signaling combined with IT
ADU S-100 enhanced HER-2-specifıc CD8 T cell activity, clearing tumors
from 40% of neu/N mice. Conclusions: Intratumoral STING activation syn-
ergizes with PD1 pathway-blockade and OX40 receptor stimulation to over-
come immune tolerance and prime tumor antigen-specifıc CD8 T cell re-
sponses that mediate effective tumor regression.
#2994 Engineered STING-targeting immunotherapy delays B16 mela-
noma tumor growth and signifıcantly improves animal survival as com-
pared to an immune-checkpoint inhibitor. Andrea Amalfıtano, Fadel S.
Alyaqoub, Yasser A. Aldhamen, Abdulraouf Abbas, Cristiane Pereira-Hicks,
Sarah Godbehere, Christopher M. Waters. Michigan State University, East
Lansing, MI.
Background: The stimulator of interferon genes (STING) is a cytosolic
innate sensor activated by cyclic di-nucleotides (CDNs) including the bac-
terially derived bis-(3=-5=)-cyclic-dimeric-guanosine monophosphate (c-di-
GMP), leading to the induction of type I interferons. We recently published
that an engineered adenovirus (Ad) vector delivering a potent, bacterially
derived diguanylate cyclase (AdVCA0848) in vivo can generate sustained
c-di-GMP levels in vivo and induce benefıcial immune responses, including
induction of IFN-, activation of NK cells and DCs, as well as enhance
antigen-specifıc T cell responses. Here, we determined if in vivo use of Ad-
VCA0848 can also induce potent anti-tumor responses. Methods: Experi-
ments to be presented include those that subcutaneously placed 150,000
B16F10 melanoma cells into C57BL/6 mice. On day 7 post tumor implant
(PTI), tumor-bearing mice were randomly divided into control groups (re-
ceiving intra-tumoral (i.t.) vehicle treatments or Ad controls, 	 i.p admin-
istration of non-specifıc antibodies) and experimental groups, (single i.t.
administrations with 2x1010 vps of AdVCA0848 alone, or in combination
with repeated i.p. administrations of 200 g of an anti-PD1 antibody (RMP-
1-14) on days 7,11,15 and 19 PTI. Results: As compared to appropriate
controls, we have repeatedly found that a single i.t. injection of AdVCA0848
signifıcantly slowed B16 tumor growth (p0.01), a result that correlated
with high levels of animal survival (p0.001). These levels of effıcacy signif-
icantly exceeded those achieved with lone use of a PD-1 inhibitor. Under
these same conditions, combined use of the AdVCA0848 therapy with anti-
PD1 treatments trended to further improve animal survival (50% survival at
day 27 PTI), as compared to lone use of either therapy (36.4% and 26.7%
survival at day 27 PTI for AdVCA0848 and PD-1 treatments, respectively).
Multiple innate and adaptive immune response readouts and immunohisto-
logical evaluations will be presented. Conclusions: The growth of established
B16 melanoma tumors was rapidly inhibited after a single i.t. treatment with
the engineered STING activator AdVCA0848, and this effıcacy resulted in
signifıcant improvements in animal survival, at rates that were also signifı-
cantly better than those achieved using a PD-1 antagonist. Furthermore, the
i.t. administration of AdVCA0848 trended to show further improved effıcacy
when combined with a PD-1 antagonist, suggesting synergy. The Ad-
VCA0848 platform is a novel, off the shelf immune-therapeutic that can now
be justifıed for use to improve anti-tumor responses in melanoma, augment
currently approved FDA immune therapies for melanoma (such as PD-1
targeted therapies), as well may show effıcacy in other aggressive cancers.
#2995 Development of a novel highly potent TLR8 selective agonist for
cancer immunotherapy.YuxunWang, Heping Yang, LongshengWang, Guan-
gliang Fu, Fang Bao, Fang Liu, Shuwen Ren, Huanping Li, Haixia Ji, Yajun Yu,
ZhihengWu, Panhu Zhu,Hui Xu, YaqiaoGao, PeiWang, ShoujunChen, Daxin
Gao. Denovo Pharmatech, Shanghai, China.
The cancer drug discovery fıeld is experiencing unprecedented revolution
accompanied by growing excitement from researchers, drug developers, pa-
tients and investors, partly due to recent clinical success of cancer immunother-
apy. Human immune defense system comprises both innate and adaptive im-
mune pathways. All the targets drugged by the recently approved cancer
immunotherapeutic agents including the immune checkpoint proteins PD-1,
PD-L1 and CTLA-4 function in adaptive immune pathways. In contrast, targets
involved in the innate immune pathway have not matured to regulatory ap-
proval for systemic use though several candidates are now in preclinical and
clinical development. Drugs targeting innate immunity represent great oppor-
tunity for more rapid and broader spectrum anti-cancer effect than adaptive
immunity. Furthermore, combinations of drugs targeting innate and adaptive
immunity are expected to produce strong synergistic effıcacy owing to their
complementary nature as body’s immune defense. Toll-like receptors (TLRs)
are a family of proteins that recognize pathogen associated molecular patterns
(PAMPs). Their primary function is to activate innate immune responses while
also involved in facilitating adaptive immune responses. Different TLRs exert
distinct functions by activating varied immune cascades. TLR8 is more broadly
expressed in immune cells than other TLRs such as TLR7 and TLR9. One of the
major causes of cancer immunotherapy failure is potent suppression of immune
response by Treg cells. TLR8 is the only TLR that has been shown to be necessary
and suffıcient to reverse the suppressive function of Treg cells leading to strong
tumor inhibition. Therefore, agonists targetingTLR8 are expected to be effective
cancer therapy.However, there is no approvedTLR8 selective agonist at present.
There is only oneTLR8 selective agonist in clinical development. Through struc-
ture-based drug design, we discovered a novel, highly potent and selective small
molecule TLR8 agonist, DN-A1. DN-A1 exhibited strong in vitro cellular activ-
ity with EC50 at 4.23 nM, about 30-fold more potent than the only drug candi-
date in clinical trials. The activity was highly selective for TLR8 over other TLRs.
DN-A1 displayed superior in vitro ADMET and in vivo PK profıles. DN-A1
showed clean CYP profıle with IC50 over 10 M for all major CYP isoenzymes
tested including 3A4, 1A2, 2C9, 2C19 and 2D6. DN-A1 had favorable hERG
parameterwith IC50 over 30Mwhereas the reference compound’s hERG IC50
was 3.84Msuggesting potential cardiac toxicity. DN-A1 signifıcantly impeded
tumor growth as a single agent and was well-tolerated in mouse tumor models.
Taken together, DN-A1 warrants further development as a potential best-in-
class preclinical drug candidate for TLR8-mediated cancer immunotherapy.
#2996 Immune checkpoint protein VISTA suppresses Toll-like receptor
signaling and the production of inflammatory cytokines.Wenwen Xu,1 Ying
Yuan,2 Na Li,1 Yongwei Zheng,1 Kamal Rajasekaran,1 Halli Miller,1 Michael
Olson,1 Demin Wang,1 Subramaniam Malarkannan,1 Li Wang1. 1Medical Col-
lege of Wisconsin, Milwaukee, WI; 2Shanghai University of Traditional Chinese
Medicine, Shanghai, China.
Introduction: V-domain Ig suppressor of T-cell activation (VISTA, gene
Vsir) is an inhibitory immune-checkpoint molecule that suppresses CD4 and
CD8 T cell activation. Previous studies have shown that Vsir/ mice devel-
oped chronic inflammatory phenotypes, and Vsir/ CD4 and CD8 T cells
were hyper-responsive towards self- and foreign antigens. Whether VISTA reg-
ulates innate immunity is still unknown. Methods: Peritoneal macrophages
fromWT or Vsir/mice were isolated and stimulated with TLR agonists such
as CpG (TLR9), R848 (TLR7), LPS (TLR4), Pam3csk4 (TLR2), and poly (I:C)
(TLR3). Alternatively, human monocyte THP-1 cells overexpressing VISTA
were stimulated by TLR2 agonist Pam3CSK4. The activation of TLR signaling
pathways and the production of inflammatory cytokines were examined by
Western Blotting, gel shift assay, or ELISA. The ubiquitination status of key
signaling molecules such as TRAF6, IRAK1/4 and MyD88 was examined by
immunoprecipitation and Western Blotting. To examine the role of VISTA in
regulating TLR-mediated inflammatory responses in the context of cancer vac-
cine, tumor-bearing mice were treated with VISTA-specifıc monoclonal anti-
body (mAb) and a peptide vaccine containing TLR agonists. The production of
inflammatory cytokines and chemokines within the tumor microenvironment
(TME) was examined via quantitative RT-PCR. Results: Vsir/ macrophages
were hyper-responsive towards TLR2/4/7/9 agonists, but not TLR3 agonist, re-
sulting in increased production of inflammatory cytokines IL-6, IL-12, and
TNFa. Analysis of signaling cascade revealed that VISTA inhibited the activa-
tion of MyD88-dependent TLR signaling, via suppressing the activation of
MAPKS and the acitvation of transcription factors AP-1 andNF-kB. Consistent
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with the role of VISTA in regulating TLR-mediated innate immunity, treatment
with VISTA-blocking mAb augmented levels of inflammatory cytokines and
chemokines within the TME, and synergized with TLR/peptide vaccine, result-
ing in an optimal therapeutic outcome. Conclusions: Our study establishes that
VISTA critically regulates the inflammatory responses ofmyeloid cellsmediated
by TLR signaling. In the context of cancer vaccine therapy, VISTA-blocking
mAb treatment enhanced levels of inflammatory cytokine and chemokines
within the TME, which is critical for the development of optimal tumor-specifıc
T cell responses and the tumor-controlling therapeutic outcome.
#2997 The tetravalent bispecifıc antibody AFM13 engages and primes in-
nate immune cells for anti-cancer immunity. Jens Pahl,1 Joachim Koch,2 Uwe
Reusch,2 Thorsten Gantke,2 Adelheid Cerwenka,1 Martin Treder2. 1German
Cancer ResearchCenter, Heidelberg, Germany; 2AffımedGmbH,Heidelberg, Ger-
many.
AFM13 is a tetravalent bispecifıc antibody with bivalent binding to both CD30
andCD16A. It has been shown to engageNK-cells throughCD16Awith high affın-
ity and specifıcity, resulting in strong NK-cell cytotoxicity, and is currently being
tested in Phase 2 monotherapy and in combination with pembrolizumab in Phase
1b clinical trials. We have previously shown that AFM13-dependent activation of
NK-cell cytotoxicity towards CD30 tumor cells is more pronounced than that of
anti-CD30mAbs. In addition, AFM13 enhances NK-cell sensitivity to low doses of
IL-2andIL-15, leading toan increasedNK-cell proliferativepotential.Here,wehave
extended the panel of phenotypic markers on NK-cells that are modulated after
exposure to CD30 tumor cells in the presence of AFM13. Targeting some of these
markersmayenable thedevelopmentofnovel combination therapies.Moreover,we
have analyzed the kinetics of NK-cell responses to AFM13 exposure. Even though
short-term exposure to AFM13 signifıcantly enhanced NK-cell cytotoxicity, long-
term exposure led to a partial, transient functionally exhausted phenotype in vitro,
which could be fully restored by cytokine stimulation for several days in the absence
of AFM13. Importantly, these recovered cells displayed high cytotoxicity towards
CD30 target cells in the presence of AFM13. Interestingly, the transient NK-cell
exhaustionwas not related to the expression of typical exhaustionmarkers or insuf-
fıcient levels of perforin and granzyme. These datamaywarrant the development of
novel metronomic application regimens of AFM13. Further studies imply that im-
munecells other thanNK-cells are able to inhibit growthofCD30 tumorcells inan
AFM13-dependentmanner. This appears to be strictly dependent onCD16A and a
specifıc cytokinemilieu.Taken together,AFM13specifıcally enhances thecytotoxic,
proliferative and cytokine-producing potential of NK-cells, parameters that can be
utilized tomonitor NK-cell responses during AFM13 therapy. Moreover, based on
our data, engagement ofCD16A cells to the tumor sitemight enable several innate
immuneeffector functionswithin the tumormicroenvironment for synergistic anti-
tumor activity.
#2998 Elotuzumab can costimulate NK cell responses by engaging
SLAMF7. Tatiana Pazina,1 Ashley Mentlik James,1 AlexanderW. MacFarlane,1
Natalie A. Bezman,2 Robert F. Graziano,2 Michael D. Robbins,2 Adam D. Co-
hen,3 Kerry S. Campbell1. 1Fox Chase Cancer Ctr., Philadelphia, PA; 2Bristol-
Myers Squibb, Princeton, NJ; 3University of Pennsylvania, Philadelphia, PA.
Elotuzumab (Elo) is an IgG1 monoclonal antibody targeting SLAMF7 (CS1,
CRACC, CD319) protein, which is highly and uniformly expressed on multiple
myeloma cells. Improved survival has been observed inmultiple myeloma patients
treatedwithElo in combinationwith immunomodulatory drugs such as dexameth-
asone and lenalidomide. Previous work showed that the main mechanism of Elo
action in vitro is CD16-mediated antibody dependent cellular cytotoxicity (ADCC)
via Fc interactionwithCD16 (FcRIIIa) receptor onNKcells.However, SLAMF7 is
also expressed onNK cells where it transmits an activating signal.We hypothesized
that Elo can directly activate NK cells via SLAMF7 ligation. Utilizing non-fucosy-
lated Elo that has higher affınity to CD16 and Elo mutant that has an Fc region
mutation that abrogates binding to CD16, we confırmed that Elo promotes NK cell
activation anddegranulation in aCD16-dependentmanner. Specifıcally, non-fuco-
sylatedElohadhigherpotency,whereasElomutantdidnot stimulatedegranulation
or CD69 expression. To test for co-stimulatory effects of Elo and Elo mutant we
measured calciumsignaling responses triggeredby those antibodies in combination
with antibodies to engage the activating receptors NKp46 and NKG2D. Elo or Elo
mut alone had no effect on calcium signaling, but when added in combinationwith
multimeric engagement of NKp46 andNKG2D both antibodies co-stimulated cal-
cium signaling responses. We conclude that Elo stimulates NK cells via interaction
with CD16, but direct engagement with SLAMF7 can also transduce co-activating
signals to potentiate calcium signals generated through NKp46 and NKG2D in a
CD16-independent manner. Our results provide evidence that direct engagement
with SLAMF7 by Elo has the potential to reduce the threshold of NK cell activation
triggered through other activating receptors.
#2999 NKG2A checkpoint receptor expression on tumor-infıltrating
CD8 T cells restrains effıcacy of immunotherapy. Thorbald van Hall,1 Na-
dine vanMontfoort,1 Sytse Piersma,1 Marjolein Sluijter,1 Marij J. Welters,1 Pas-
cale André,2 Nicolai Wagtmann,2 Sjoerd H. van der Burg1. 1Leiden University
Medical Center, Leiden, Netherlands; 2Innate Pharma, Marseille, France.
The inhibitory receptor CD94-NKG2A is expressed on subsets of NK cells and
cytotoxic CD8 T cells, but not CD4 T helper cells. It’s ligand is the non-classical
MHC class I molecule HLA-E, commonly over-expressed in human cancers. We
previously demonstrated that high HLA-E expression in ovarian carcinoma and
NSCLC may neutralize the survival benefıt of T cell infıltration, suggesting that
NKG2A could represent an immune checkpoint that tumors may exploit for im-
muneevasion.WethusexaminedNKG2AexpressiononhumanandmouseTumor
Infıltrating Lymphocyte (TIL) populations and tested blockade of this receptor in
mouse tumormodels.Multicolor flow cytometry analysis showed higher frequency
of NKG2ACD8 T cells in TIL samples obtained from biopsies of human head-
and neck- carcinomas (n17) compared to peripheral blood CD8 T cells. Fre-
quency ofNKG2ATILwas higher in patients withmeasurable immune reactivity
to HPV16-viral antigens than in patients without tumor immunity (14.8% vs 4.7%,
respectively). Interestingly, only subsets of the NKG2A T cells co-expressed other
inhibitory receptors, including PD-1 and TIM3, suggesting the existence of a ‘ded-
icated’ T cell subset for NKG2A. In our mouse tumor models we observed similar
fındings and,moreover, demonstrated that therapeutic vaccines comprising tumor
antigens increased the frequency of NKG2A-positive CD8 TIL up to 80%. Sim-
ilarly, expression of Qa-1, the mouse homologue of HLA-E, on tumor cells also
increased after therapeutic vaccination. As a proof of concept that the NKG2A -
Qa-1 axis limits the effıcacy of immunotherapy, NKG2A blocking antibodies were
applied in the TC-1 model together with therapeutic peptide vaccination. Combi-
nation treatment with vaccine and NKG2A blockade signifıcantly improved the
therapeutic effıcacy compared to the vaccine alone, both in terms of survival
(P0.05, median survival 44 vs 31 days) as well as overall response rate, defıned as
decreased tumor size of more than 30% (93.8% vs 43.8%, respectively). Similar re-
sultswere obtained inQa-1-defıcientmice, suggesting thatQa-1 on tumor cells is of
importance. In conclusion, inhibitory receptor NKG2A is enriched on CD8 TIL
and functions as an immune checkpoint that restrains therapeutic effıcacy of a can-
cer vaccine.
CLINICAL RESEARCH: Predictors and Drivers of Pediatric
Tumors
#3000 Defıning the subclonal landscape of high-risk neuroblastoma. Jo
Lynne Harenza, Maura A. Diamond, Derek A. Oldridge, Olivia Padovan-Mer-
her, Pichai Raman, Yael P. Mosse, John M. Maris. Children’s Hospital of Phila-
delphia, Philadelphia, PA.
We recently showed that relapsed neuroblastoma (NB) tumors harbor an in-
creased somatic mutational burden, enriched for ALK or RAS-MAPK activating
lesions, nominating targeted therapeutic strategies for a condition that is largely
incurable. We also showed that these mutations can be present in subclonal tumor
cell populations at diagnosis, suggesting that they may contribute to acquired che-
moradiotherapy resistance. We hypothesize that subclonal mutations in NB onco-
genes are common at diagnosis, are biomarkers for treatment failure, and can be
targeted in conjunction with standard chemotherapy to improve patient survival.
Here, we focus on the fırst aspect of this broad hypothesis by presenting the sub-
clonal landscape of diagnostic, high-risk neuroblastomas. A meta-analysis of our
previously published primary/relapse (N23), whole exome (N232) and whole
genome (N159)diagnostic data, and recent sequencing studyof 78diagnostic and
67 relapse cases were used to inform design of a custom amplicon panel for ultra-
deep sequencing. The 28-gene panel covers 57 mutations in frequently mutated
genes. Here, 250 high-risk primary tumors were sequenced to an average depth of
50,000X. More subclonal mutations were called (mean36) compared to clonal
alterations (mean3), demonstrating the complex subclonal architecture in these
tumors.We validated fıve clonalALKmutationswe originally discovered and iden-
tifıed 15 additional pathogenic ALK mutations with mutant allele frequencies
(MAFs) ranging from 0.03-23%. Known ALK activating mutations were found at
codons 1170, 1174, 1196, 1245, 1275 in 15 of 38 diagnostic primary tumors. This
39.5% frequency ismuchhigher than the 14% frequency defıned by us using Sanger
or other sequencing methods. Improvement of subclonal mutation detection of
actionable, relapse-specifıc drivermutations demonstrates the clinical utility of uti-
lizing this sequencing methodology at diagnosis to enable timely improvement of
outcomes for children with high-risk refractory NB.
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#3001 Germline mutations in cancer predisposition genes and risk for
subsequent neoplasms among long-term survivors of childhood cancer in the
St. Jude LifetimeCohort.ZhaomingWang,1 Carmen L.Wilson,1 John Easton,1
DaleHedges,1 Qi Liu,2 GangWu,1Michael Rusch,1Michael Edmonson,1 Shawn
Levy,3 JenniferQ. Lanctot,1 Eric Caron,1 Kyla Shelton,1 KelseyCurrie,1Matthew
Lear,1 Heather L. Mulder,1 Donald Yergeau,1 Celeste Rosencrance,1 Bhavin Va-
dodaria,1 Yadav Sapkota,1 Russell J. Brooke,1 WonjongMoon,1 Evadnie Ramp-
ersaud,1 Xiaotu Ma,1 Shuoguo Wang,1 Ti-Cheng Chang,1 Stephen Rice,1 An-
drew Thrasher,1 Aman Patel,1 Cynthia Pepper,1 Xin Zhou,1 Xiang Chen,1
WenanChen,1Angela Jones,3 BradenBoone,3DeoKumar Srivastava,1 Chimene
A. Kesserwan,1 Kim E. Nichols,1 James R. Downing,1 Melissa M. Hudson,1 Yu-
taka Yasui,1 Leslie L. Robison,1 Jinghui Zhang1. 1St. Jude Children’s Research
Hospital, Memphis, TN; 2University of Alberta, Edmonton, Alberta, Canada;
3HudsonAlpha, Huntsville, AL.
Childhood cancer survivors are at increased risk of subsequent neoplasms (SN),
largely considered to be therapy-related. Studies of cancer predisposition genes
(CPGs) and risk of SN among long-term survivors are lacking. We characterized
germlinemutations in CPGs in childhood cancer survivors to determine their con-
tribution to SN risk. Whole genome (30x) and exome (100x) sequencing was per-
formed for 2988 5 year survivors of childhood cancer (1629 leukemia/lymphoma,
332 CNS, 1027 other solid tumors, 53% male, median follow-up 28 [range 6-55]
years). Survivors underwent a comprehensive clinical assessment, treatment expo-
sures were abstracted from medical records, and SN were validated by pathology
reports.Germlinemutations in 63CPGswere classifıedusing theAmericanCollege
ofMedical Genetics and Genomics guidelines as previously described (Zhang et al.
NEJM2015).Logistic regression, adjusting forage, sexandrace,wasused toevaluate
associationsbetweenmutationstatus, cancer therapyandtheSNrisk.1062SNswere
diagnosed in 437 survivors, of whom 98 developed
2 histologically distinct SNs.
Median age at SN and time to fırst SNwas 38.2 (range 3.3-67.4) and 29.2 (0.9-48.4)
years, respectively. Common SNs were basal cell carcinoma (542 in 153 survivors),
meningioma (201 in 100), thyroid (64 in 64), and breast cancer (58 in 50). Cumula-
tive incidence of SN at age 45 was 25.5% (95% CI: 22.9-27.9). 169 survivors (5.7%)
had a pathogenic/likely pathogenic (P/LP) mutation in a CPG, consisting of 97
single nucleotide variations, 63 insertion/deletions and 9 copy number alterations
(49% of mutations not in ClinVar). Frequently mutated genes were: RB1 (n41),
NF1 (n22), BRCA2 (n13), BRCA1 (n12) and TP53 (n10). Our data con-
fırmedknownassociations betweenCPGmutations and specifıc primary diagnoses
includingRB1mutations in32of 41 (78%)ofbilateral and7of 57 (12%)ofunilateral
retinoblastoma survivors, 22NF1 (20 of 332CNS survivors), 4 SUFU (all inmedul-
loblastoma survivors) and 5WT1mutations (all inWilms’ tumor survivors). Anal-
yses revealed novel associations betweenCPGmutations and SN risk. Among 1326
survivors not exposed to radiation therapy (non-RT), 62 SNs developed in 54 sur-
vivors, of which 15 (24.2%) occurred in P/LP mutation carriers. Non-RT exposed
survivorswith a P/LPmutation had an increased risk of SN (OR5.6, 95%CI2.6-
12.0, P0.001) and the odds of developing
2 distinct histologic types of SNs was
increased by 23.6-fold (95% CI5.4-102.7, P0.001). In 1662 RT exposed survi-
vors, P/LP-mutation carriers had anodds ratio of 2.3 (95%CI0.9-6.0, P0.08) for
developing
2distinct histologic types of SNs.Our fındings indicate that a substan-
tial proportion of non-RT exposed childhood cancer survivors who develop one or
more SN carry aCPGmutation, and should be referred to genetic testing and coun-
seling services.
#3002 Therapeutic targeting of PGBD5-induced DNA repair dependence
in pediatric solid tumors. Anton Henssen,1 Casie Reed,1 Eileen Jiang,1 Wong
Wai,1 Elisa de Stanchina,1 Yasumichi Kuwahara,2 Hajime Hosoi,2 Johannes H.
Schulte,3Neil Ganem,4 JohnPetrini,5 AlexKentsis1. 1Mem. SloanKettering Can-
cer Ctr., New York, NY; 2Kyoto Prefectural University of Medicine, Tokyo, Japan;
3Charité- Universitätsmedizin Berlin, Berlin, Germany; 4Boston University, Bos-
ton, MA; 5Molecular Biology Program, New York, NY.
Despite intense efforts, the cure rates of childhood solid tumors are not satisfac-
tory. Resistance to intensive chemotherapy is common, and targets for molecular
therapies are largely undefıned, particularly for tumors caused by aberrant develop-
mental and epigenetic factors. We have now found that the majority of childhood
solid tumors, rhabdoid tumors, neuroblastoma, medulloblastoma and Ewing sar-
coma, express an active DNA transposase PGBD5. Using functional genetic ap-
proaches, we observed that mouse and human cells defıcient in non-homologous
end joining (NHEJ) DNA repair cannot tolerate the expression of PGBD5. In a
chemical screen of DNA repair inhibitors, we identifıed the ATR/ATM inhibitor
AZD6738as a specifıc sensitizerofPGBD5-dependentDNAdamageandapoptosis.
Ectopic expressionofPGBD5was suffıcient to inducehypersensitivity toAZD6738,
and endogenous PGBD5 was necessary for its anti-tumor effects. We found that
PGBD5-expressing tumor cells accumulateunrepairedDNAdamage in response to
AZD6738 treatment, and undergo apoptosis in both dividing andG1 phase cells in
the absence ofmeasureableDNAreplication stress.Accordingly,AZD6738 exhibits
nanomolar potency against the majority of neuroblastoma, medulloblastoma, Ew-
ing sarcoma and rhabdoid tumor cells tested, while sparing non-transformed hu-
man andmouse embryonic fıbroblasts in vitro. Finally, AZD6738 exhibits excellent
single-agent activity against high-risk neuroblastoma and medulloblastoma xeno-
grafts, with induction of apoptosis and tumor regression in vivo. These fındings
delineate a therapeutically actionable synthetic lethality for the majority of child-
hood solid tumors.
#3003 Exome analysis of known hereditary cancer genes in 122 children
with rhabdomyosarcoma. Talia Wegman-Ostrosky,1 Rajesh Patidar,1 Sivasish
Sindiri,1 Jack Shern,1 Douglas S. Hawkins,2 Daniel Catchpoole,3 Jun S. Wei,1
Stephen Skapek,4 Javed Khan,1 Douglas R. Stewart1. 1National Cancer Institute,
Bethesda, MD; 2Seattle Children’s, Seattle, WA; 3University Of Sydney, Sydney,
Australia; 4UT Southwestern Department of Pediatrics, Dallas, TX.
Introduction: Rhabdomyosarcoma (RMS) accounts for 5% of all pediatric
cancer and is themost prevalent soft tissue tumor in childhood and adolescents.
RMS is thought to arise fromprimitivemesenchymal stemcells directed towards
myogenesis. Between 7-33% of RMS cases arise from a hereditary cancer syn-
drome, like LFS or NF1. We analyzed germline genetic variants in hereditary
cancer genes in 122 childrenwith RMS.Methodology: In 122 childrenwith RMS
and 1001 cancer-free adults, we examined germline exome data to determine the
frequency of genetic variants in 51 cancer genes known to underlie syndromes
associated with RMS. DNAwas extracted from blood or buccal cells using stan-
dard methods. Exome enrichment was performed with NimbleGen SeqCap EZ
Human Exome Library v3.0UTR, on an Illumina HiSeq. Annotation of each
exome variantwas performedusing a custom software pipeline.We evaluated all
variants that passed quality controls with a population minor allele frequency
(MAF)0.1%. The cataloging of the variants was based on the ACMG classifı-
cation as pathogenic (P), likely pathogenic (LP), or variable of unknown signif-
icance. Results:We compared the age, gender, histologic type and localization of
the primary RMS of the patients with and without P/LP variants in the 51 genes.
In the patients without P/LP variants, the mean age of diagnosis was 5 years and
the most frequent site of diagnosis was head and neck. In the group with P/LP
variants, the mean age of diagnosis was 10 years, and the most frequent site was
pelvis. In the 51 genes that were analyzed we found 9 P and 12 LP variants in 15
genes: TP53, ATM, MSH6, PMS, DICER1, FANCA, RECQL4, PTEN, WRN,
RB1, BUB1B, RET, APC, FANCM and TSC2; genes with 2 variants include
WRN, PTEN, BUB1B, FANCA and RET. Most of the variations were stopgain,
follow by missense, frameshift insertion and splicing genetic variations. Ten of
this genes are associated with an autosomal dominant pattern of inheritance. In
one 15-year-old female patient with an alveolar RMS in the paraspinal area we
foundP/LP variants in PTENandPMS2. The frequency of P/LP variants in cases
was 16% and 3% in controls. Conclusions: To our knowledge, this is the fırst
study where multiple germline variation where analyses in children with RMS.
We found P/LP variation in 16% of all the cases (pending orthogonal confırma-
tion); the mean age of diagnosis was 10 years old and their primary tumor site
was in the pelvis (50%). Identifıcation of P/LP variation in genes underlying
RMS-associated syndromes has implications for follow-up, screening andman-
agement of these patients and their families. We acknowledge the Children’s
Oncology Group in helping to assemble the RMS cohort.
#3004 Comparison of somatic alterations in the genome and transcrip-
tome of 1,705 pediatric leukemia and solid tumors: a report from the Chil-
dren’s Oncology Group (COG) - NCI TARGET Project. XiaotuMa,1 Yu Liu,1
Yanling Liu,1 Michael Edmonson,1 Charles Gawad,1 Xin Zhou,1 Yongjin Li,1
Michael Rusch,1 John Easton,1 Mark Wilkinson,1 Leandro C. Hermida,2 Sean
Davis,2 Malcolm Smith,2 Jaime Guidry Auvil,2 Paul Meltzer,2 Ching C. Lau,3
Elizabeth Perlman,4 John M. Maris,5 Soheil Meshinchi,6 Stephen P. Hunger,5
Daniela S. Gerhard,2 Jinghui Zhang1. 1St Jude Children’s Research Hospital,
Memphis, TN; 2National Cancer Institute, NIH, Bethesda,MD; 3Texas Children’s
Cancer and Hematology Centers, Houston, TX; 4Ann and Robert H. Lurie Chil-
dren’s Hospital of Chicago, Chicago, IL; 5Children’s Hospital of Philadelphia,
Philadelphia, PA; 6Fred Hutchinson Cancer Research Center, Seattle, WA.
To discover common and sub-type specifıc somatic alterations affecting key
biological processes in pediatric cancers, we analyzed point mutations, copy
number alterations, gene fusions and structural alterations detected frompaired
tumor-normal whole genome sequencing (n655), whole exome sequencing
(n1,108), andRNA-seq data (n913) of 1,705 leukemia and solid tumors. Our
cohort consists of 693 B-lineage Acute Lymphoblastic Leukemia (B-ALL), 264
T-ALL, 211 Acute Myeloid Leukemia (AML), 318 Neuroblastoma (NBL), 128
Wilms Tumor (WT), and 91Osteosarcoma (OS) with amedianmutation rate of
0.28-0.58 perMb.We identifıed 130 potential driver genes based on signifıcance
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of variant recurrence and pathogenicity within each cancer type and across all
cancer types. Seventy-two (55%) driver genes were signifıcant in one cancer
type, thirty eight were signifıcant in  1 leukemia subtype, thirteen (NRAS,
WT1, MYCN, PTEN, TP53, KRAS, RB1, ATRX, PTPN11, MLLT1, BCOR,
SETD2, NF1) were signifıcant in both leukemia and solid tumor while the re-
maining seven (MGA, SF3B1, ASXL1, BCORL1, STAG2, ACTB, NIPBL) were
signifıcant only in pan-cancer analysis. The number ofmutated driver genes per
sample ranged from 0.8 in WT to 5.8 in T-ALL, lower when considering only
point mutations (from 0.3 in NBL to 3.1 in T-ALL). The most frequently mu-
tated biological processes affecting both leukemia and solid tumor were tran-
scription factors (56% of samples), cell cycle (41%), epigenetic regulators (36%),
Ras signaling (21%), PI-3K (11%), and the MYC complex (7%). By contrast, the
JAK signaling pathway was mutated only in leukemia (16%) while mutations in
the NOTCH signaling pathway were exclusive to T-ALL (77%). Aberrant tran-
scription may also affect the normal function of a driver gene. For example, the
RAS signaling pathwaywasmutated in B-ALL (35%), T-ALL (15%), AML (37%)
and NBL (4.3%). Aside from the known KRAS 4a isoform found in all cancer
types, we discovered two novel KRAS isoforms present in 71.1% of B-ALL,
67.9% of T-ALL, 71.3% of AML and 3.0% of NBL but not in WT or OS. Allele-
specifıc expression (ASE) was detected in 205 (6.8%) of 3,016 expressed somatic
mutations, and 97% (32 out of 33) of truncationmutations on autosomes exhibit
reduced expression of the mutant allele likely due to nonsense mediated decay.
Two ASE mutations, WT1 D447N in a cytogenetically normal AML and JAK2
D873N in a B-ALL, were selected for single-cell sequencing and successfully
validated. Only 44% of our driver genes match those identifıed in adult cancer.
This, coupled with our fınding that point mutations only accounted for 48% of
the driver alterations, may provide new insight into the design of precision
treatment for pediatric cancer. Our presented data will be made public at NCI’s
Genome Data Commons (gdc.cancer.gov) and can be explored on our Protein-
Paint data portal (pecan.stjude.org).
#3005 Whole-genome sequencing identifıed novel non-codingmutations
causal of oncogene activation in T-cell acute lymphoblastic leukemia.Maox-
iang Qian,1 Shaoyan Hu,2 Hui Zhang,1 Yu Guo,3 Jin Yang,2 Xujie Zhao,1 Lin
Wan,2 Jun Lu,2 Jian Pan,2 Meimei Chang,3 Shirley K. Kham,4 Yong Cheng,1
Chunliang Li,1 Allen E. Yeoh,4 Anders Skanderup,3 Jun J. Yang1. 1St. Jude Chil-
dren’s Research Hospital, Memphis, TN; 2Children’s Hospital of SoochowUniver-
sity, Suzhou, China; 3Genome Institute of Singapore, Singapore; 4National Uni-
versity Children’s Medical Institute, Singapore.
There is growing evidence that non-coding sequences in human genome of-
ten function as transcriptional regulatory elements of protein-coding genes. In
fact, germline polymorphisms and somatically acquired mutations within reg-
ulatory DNA can profoundly alter chromatin structure and modify gene tran-
scription, directly contributing to tumorigenesis. However, there is a paucity of
unbiased genome-wide characterization of somatic non-coding mutations in
cancer. Using T-cell acute lymphoblastic leukemia (T-ALL) as a model disease,
we herein report a systematic interrogation of driver non-coding genomic alter-
ations by paired whole-genome and transcriptome sequencing of 31 children
with T-ALL. To identify non-codingmutationswith potential regulatory impact
in a genome-wide fashion, our analytical pipeline consisted of 3 approaches: 1)
the “hotspot analysis” for recurring mutations at the nearby positions, 2) the
“regional recurrence analysis” for predefıned regulatory regions with signifıcant
enrichment of non-codingmutations, 3) the “transcriptional factor analysis” for
mutations that potentially result in gain/loss of transcription factor binding sites
and alter expression of adjacent genes. Remarkably, T-ALL oncogenes LMO1
and TAL1 emerged as loci with the most signifıcant recurring non-coding mu-
tations. At the LMO1 locus, 3 patients (9.7%) showed an identical single-nucle-
otide mutation proximal to the transcription start site of the long isoform of
LMO1. This recurringmutation resulted in the gain of a canonical Myb binding
site (AACGG) and 120-fold increase in LMO1 transcription compared to
patients with wildtype genotype. TAL1 overexpression was observed in 15 pa-
tients, of whom 11 had intrachromosomal rearrangement (STIL-TAL1 fusion).
The remaining 4 patients had somatic insertion that created a MYB-mediated
super enhancer, consistent with recent reports. LMO1 enhancer mutation was
further confırmed in an independent validation cohort (N26), in which we
additionally identifıed a novel intrachromosomal rearrangement between
MED17 and LMO1 resulting in transcriptional activation of the latter. In a panel
of T-ALL cell lines, LMO1 enhancer mutation was again associated with dra-
matic overexpression of LMO1, an active enhancer histone mark (H3K27ac),
Dnase hypersensitivity, and allele-specifıc binding of MYB. Interestingly, we
also observed robust binding of TAL1, CREBBP, RUNX1, ETS1, ELF1 and RNA
Polymerase II at this site. Reporter gene assay confırmed the MYB-mediated
transcription activation effects of this LMO1 enhancer mutation in vitro. In this
genome-wide investigation of non-coding mutations in T-ALL, we identifıed
novel enhancermutations with drastic effects on oncogene activation. Our fınd-
ings expand the understanding of how genomic alterations in regulatory DNA
contribute to cancer pathogenesis.
#3006 Oncogenic activity of H3.3 K27M in a spontaneous DIPG mouse
model. Jon D. Larson, Lawryn H. Kasper, GangWu, Yiping Fan, David Finkel-
stein, Hongjian Jin, Barbara S. Paugh, Andre B. Silveira, Beisi Xu, Xiaoyan Zhu,
Junyuan Zhang, Helen R. Russell, Peter J. McKinnon, DavidW. Ellison, Jinghui
Zhang, Suzanne J. Baker. St. Jude Children’s Research Hospital, Memphis, TN.
Pediatric diffuse high-grade gliomas (HGG) cause a devastatingly poor out-
come. Diffuse intrinsic pontine gliomas (DIPG) are brainstem HGGs found
almost exclusively in children and represent approximately 50 percent of all
pediatric HGGs. Recurrent, clonal somatic mutations in histone H3 are a mo-
lecular hallmark that distinguish the genetic mechanisms underlying pediatric
and adult HGG, and indicate a strong link between epigenetic dysfunction and
pediatric brain tumorigenesis. H3 K27M mutations found in nearly 80 percent
of DIPGs and over half of non-brainstemHGGs occurring in thalamus or other
midline structures, induce a dominant loss of genome-wideH3K27me3. In con-
trast, mutually exclusive H3.3 G34R/V mutations occur in approximately 14
percent of cortical HGG tumors in older children through young adulthood
suggesting a distinct developmental origin compared to K27Mmutant tumors.
DNAmethylation and gene expression patterns distinguish G34R/V and K27M
tumors, but the oncogenic mechanisms and reasons for brain region selectivity
of histone mutations remain uncertain. To study these mutations in the devel-
opingmammalian brain and investigate how they contribute to oncogenesis, we
generated conditionally activated, epitope-tagged knock-in mice to express
K27M, G34R or non-mutated H3.3 proteins from the endogenous H3f3a locus.
Untransformed embryonic neural precursor or astrocyte cells expressing H3.3
K27MdemonstratedH3K27me3 loss and a growth advantage in vitrowith brain
region-specifıc, stage-dependent expression and epigenetic signatures. DIPGs
frequently harbor genetic alterations in TP53 and PDGFR in addition to H3.3
K27M, and mice with induced brain-specifıc Trp53 deletion plus mutated
PDGFRV544ins expression developed spontaneous HGG in vivo. Induction of
H3.3 K27M signifıcantly accelerated PDGFRV544ins;Trp53 knockoutHGG for-
mation involving the brainstem. Importantly, the non-mutated H3.3 epitope-
tagged protein did not affect tumor burden or latency. The H3.3 K27M tumors
recapitulate characteristics observed in human DIPG including histopatholog-
ical features, strong nuclear K27M expression and robust loss of H3K27me3
throughout the tumors. We relate the genetic, epigenetic and transcriptional
landscapes of these models to primary pediatric DIPG to help identify their
developmental origins and oncogenicmechanisms downstream of histoneH3.3
K27M.
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#3007 Tobacco smoking, alcohol use and risk of hepatocellular carcinoma
and intrahepatic cholangiocarcinoma:The LiverCancer PoolingProject. Jes-
sica Leigh Petrick,1 Peter T. Campbell,2 Jill Koshiol,1 Jake E. Thistle,1 Gabriella
Andreotti,1 Laura E. Beane-Freeman,1 Julie E. Buring,3 AndrewT. Chan,3 Dawn
Q. Chong,4 Michele M. Doody,1 Susan M. Gapstur,2 John Michael Gaziano,3
Edward Giovannucci,5 Barry I. Graubard,1 I-Min Lee,3 Linda M. Liao,1 Martha
S. Linet,1 Julie R. Palmer,6 Jenny N. Poynter,7 Mark P. Purdue,1 Kim Robien,8
Lynn Rosenberg,6 Catherine Schairer,1 Howard D. Sesso,3 Rashmi Sinha,1 Meir
J. Stampfer,3 Marcia Stefanick,9 Jean Wactawski-Wende,10 Xuehong Zhang,3
Anne Zeleniuch-Jacquotte,11 Neal D. Freedman,1 Katherine A.McGlynn1. 1Na-
tional Cancer Institute, Bethesda, MD; 2American Cancer Society, Atlanta, GA;
3Brigham andWomen’s Hospital, Boston, MA; 4Massachusetts General Hospital
and Harvard Medical School, Boston, MA; 5Harvard School of Public Health,
Boston, MA; 6Boston University, Boston, MA; 7University of Minnesota, Minne-
apolis, MN; 8GeorgeWashington University,Washington, DC; 9Stanford Univer-
sity School ofMedicine, Stanford, CA; 10University at Buffalo, Buffalo, NY; 11New
York University School of Medicine, New York, NY.
Background: Since 1980, liver cancer has been among the most rapidly
increasing cancer types in the United States (US), with 5-year survival rates
of approximately 17%.While tobacco and alcohol are known to be associated
with primary liver cancer, it is unclear whether they only increase the risk of
hepatocellular carcinoma (HCC), the most common type of liver cancer, or
whether they also increase risk of intrahepatic cholangiocarcinoma (ICC),
second most common histologic type. Additionally, it is unclear what
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amount of alcohol consumption is associated with an increased risk of liver
cancer. As liver cancer is a rare cancer type, we conducted a study of pooled
data from the National Cancer Institute Cohort Consortium to examine the
associations between smoking and alcohol use and liver cancer, stratifıed by
histologic subtype. Methods: In the Liver Cancer Pooling Project, a consor-
tium of US-based cohort studies, we pooled data from 1,518,741 individuals
(HCC n1,423, ICC n410) in 14 cohorts. Multivariable-adjusted hazard
ratios (HRs) and 95% confıdence intervals (CI) were estimated using pro-
portional hazards regression. Cubic splines were used to model the associa-
tion between alcohol and liver cancer risk. Results: Compared to never
smokers, both former and current smokers at study baseline had an in-
creased risk of ICC (HR1.32, 95% CI: 1.03-1.68 and HR1.47, 95% CI:
1.07-2.02, respectively) and HCC (HR1.24, 95% CI: 1.08-1.43 and
HR1.86, 95% CI: 1.57-2.20, respectively). This fınding was consistent for
heavier smoking intensity, longer duration of smoking, andmore pack-years
of smoking. Heavy alcohol consumption was associated with an 87% in-
creased risk of HCC (HR
7 drinks/day v. non-drinker1.87, 95% CI: 1.41-2.47) and a
non-signifıcant 68% increased risk of ICC (HR
5 drinks/day v. non-drinker1.68, 95%
CI: 0.99-2.86). Risk of HCC signifıcantly increased at 4.5 alcoholic drinks per day,
while risk of ICCwasnon-signifıcantly increasedwith any amount of consumption.
Conclusions: These fındings suggest that, in a US population, cigarette smoking is
associatedwith an increased risk of both histologic subtypes of primary liver cancer
-HCC and ICC. In contrast, alcohol consumptionwas primarily associatedwith an
increased risk of HCC. These results suggest that smoking cessation and alcohol
reduction programs could be important intervention opportunities for these lethal
cancer types.
#3008 Obesity, physical activity, and breast cancer survival among older
breast cancer survivors in the CPS-II Nutrition Cohort. Maret L. Maliniak,
Alpa V. Patel, Marjorie L. McCullough, Peter T. Campbell, Corinne R. Leach,
Susan M. Gapstur, Mia M. Gaudet. American Cancer Society, Atlanta, GA.
Background: Body mass index (BMI) and physical activity and their rela-
tion to breast cancer-specifıc survival have not been well-studied in older
survivors (
65 years of age at diagnosis), despite their comprising nearly
half of today’s 3.5 million breast cancer survivors. Additional data are
needed to determine if specifıc guidelines for older survivors are warranted.
Objective: To examine the associations of pre- and post-diagnosis BMI and
recreational physical activity with breast cancer-specifıc and all-cause mor-
tality among women with non-metastatic breast cancer, overall and stratifıed
by age 65 years at diagnosis. Methods: In the Cancer Prevention Study-II
Nutrition Cohort, 4,927 women diagnosed with breast cancer between 1992
and 2011 completed biennial surveys and were followed for cause-specifıc
mortality. Pre-diagnosis exposures were assessed at the questionnaire com-
pleted 
6 months before diagnosis, and post-diagnosis exposures were as-
sessed at the fırst questionnaire completed
2 years after diagnosis to avoid
capturing short-term changes due to treatment. BMI was computed as
weight (kg) divided by height squared (m2). Physical activity was based on
the summary MET-hours/week of recreational activity. Multivariable Cox
proportional hazards models were used to calculate hazard ratios (HR) and
95% confıdence intervals (CI). Results: Over a mean follow-up time of 9.8
years after diagnosis, 1,394 deaths, including 452 from breast cancer, oc-
curred. The median age at diagnosis was 70 years (77% 
65 years). Com-
pared with normal weight (BMI 18.5-25 kg/m2), class II-III obesity (BMI

35 kg/m2) was associated with higher risk of breast cancer-specifıc mor-
tality in pre-diagnosis (HR: 2.2; 95% CI: 1.5-3.2) and post-diagnosis analyses
(HR: 1.6; 95% CI: 1.0, 2.5), although the association was limited to women

65 years of age at diagnosis. Pre-diagnosis but not post-diagnosis BMI was
positively associated with all-cause mortality among both age groups (P-
trend 0.0001). Pre-diagnosis physical activity was not associated with
breast cancer-specifıc mortality overall or in either age group. There was a
signifıcant inverse trend for post-diagnosis physical activity and breast can-
cer-specifıc mortality overall (P-trend0.03) and among women 65 years
of age at diagnosis (P-trend0.01) but not among women 
65 years of age
at diagnosis (P-trend0.21). Pre- and post-diagnosis physical activity were
signifıcantly associated with reduced all-cause mortality in both age strata.
Conclusion: Our results suggest that pre- and post-diagnostic morbid obe-
sity is associated with increased risk of death from breast cancer in older, but
not younger, breast cancer survivors. Conversely, physical activity may re-
duce risk of breast cancer death in survivors 65 years of age at diagnosis.
However, both were associated with overall longevity, regardless of age.
#3009 Lipid-lowering drug use and risk of fatal prostate cancer in the
Atherosclerosis Risk in Communities (ARIC) Study. Alison M. Mondul,1
Corinne E. Joshu,2 John Barber,2 Anna Prizment,3 Nrupen Bahvsar,4 Josef
Coresh,2 Elizabeth Selvin,2 Aaron Folsom,3 Elizabeth A. Platz2. 1Univ. of Mich-
igan, Ann Arbor, MI; 2Johns Hopkins Bloomberg School of Public Health, Balti-
more, MD; 3University of Minnesota, Minneapolis, MN; 4Duke University, Dur-
ham, NC.
Background: Studies show that lipid-lowering medications, particularly
statins, may be protective for more aggressive prostate cancer. Lethal pros-
tate cancer is often considered an optimal outcome in epidemiologic studies
when the aim is to identify modifıable risk factors with the potential to
reduce morbidity and mortality from this disease, yet this outcome remains
understudied. Further, lipid drug use and prostate cancer risk is understud-
ied in black men, whose risk of fatal prostate cancer is 2-3 times higher than
that of white men. Thus, we studied lipid medication use and fatal prostate
cancer risk in the ARIC Study, which includes 25% black participants.
Methods: The ARIC Study is a prospective cohort that included 15,792 par-
ticipants (7,082 men) recruited from four US communities. We conducted a
prospective cohort analysis of 6,547 men who attended visit 2 (1990-1992,
the start of the statin era) and were followed for cancer death through 12/31/
2012. Death from prostate cancer (n90) as the underlying cause was ob-
tained from death certifıcates supplemented with medical records. Updated
information on medication use was collected throughout the study fol-
low-up during study visits and annual telephone calls. Lipid medication use
was modeled as a time-dependent variable in two ways: 1) current use (yes/
no), and 2) duration of use (10, 
10 years). Cox proportional hazards
regression was used to estimate the hazard ratio (HR) and 95% confıdence
interval (CI) of prostate cancer death overall and by race. All models were
adjusted for age (years), race, and study center. Additional models were
further adjusted for height, BMI, smoking, diabetes, and education. Results:
The prevalence of lipid medication use was 17% by visit 4, partway into the
statin drug era, and 76% of those medications were statins. After adjustment
for age, race, and study center, men who used lipid medications were statis-
tically signifıcantly less likely to die from prostate cancer than men who did
not use lipid medications (HR0.56, 95% CI0.33-0.95). This fınding was
slightly attenuated after further mutlivariable adjustment (HR0.62, 0.36-
1.08). The statistically signifıcant inverse association appeared to be re-
stricted to men who used lipid medications for 
10 years (vs. never use:
HR0.39, 95% CI0.19-0.82, p-trend0.02). Lipid medication use was in-
versely associated with a reduced risk of prostate cancer death in both white
and black men. Conclusions: Use of lipid medications was associated with a
lower risk of fatal prostate cancer in both black and white men. Whether the
fact that black men are less likely to receive/take lipid medications could
partly explain the black-white disparity in prostate cancer in the US requires
further study. Support: NHLBI contracts, NCI grant, NPCR
#3010 Broad reduction in cancer incidence in patients treated with war-
farin: a prospective cohort study.Gry S.Haaland,1 Ragnhild S. Falk,2Oddbjørn
Straume,1 James B. Lorens1. 1University of Bergen, Bergen, Norway; 2University
of Oslo, Oslo, Norway.
BACKGROUND: Evidence shows that the vitamin K-antagonist warfarin, a
popular anti-coagulant in clinical use for decades, has anti-tumor activity. This
is recently attributed to disruption of post-translational modifıcation of Gas6,
the common ligand of the Axl receptor tyrosine kinase family. Gas6-Axl signal-
ing is associated with malignancy and is required for tumoriogenesis and pro-
gression in several preclinical cancer models. Warfarin is shown to inhibit Axl
signaling-dependent malignant traits and enhance anti-tumor immune re-
sponses at doses that do not achieve anticoagulation. The objective of this study
is to investigate the association between warfarin use and cancer incidence in a
large unselectedNorwegian cohort. Our results reveal a remarkable reduction in
cancer incidence associated with warfarin use across a wide range of tumor
types. METHODS: A cohort selected from the Norwegian population registry
included all persons born between 1924-1954, living inNorway 2006-2012 (n1
256 725).We cross-referenced this cohort using the uniqueNorwegianNational
ID Number to: 1) the Cancer Registry of Norway and retrieved information on
all cancer cases 2006-2012; 2) information on fılledwarfarin prescriptions (ATC:
B01AA03) from the Norwegian Prescriptions Database (2004-2012). Warfarin-
use was defıned 6 months and minimum 2 years between fırst warfarin pre-
scription and cancer diagnosis. We also performed a subgroup analysis on per-
sons prescribed warfarin for atrial fıbrillation/flutter (n33 313) compared to
non-users. Mantel-Haenzel method was used to calculate the incidence rate
ratio (IRR), adjusting for sex and age. RESULTS: In this cohort, 92 942 persons
were classifıed as warfarin users, and we observed 132 687 cancer cases in the
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7-year study period.We observed a signifıcantly lower sex and age-adjusted risk
for cancer development across all malignancy types in the warfarin user group
compared to the non-user group (IRR: 0.842, 95% CI, 0.824-0.861). The associ-
ation was similar among many cancers including major types (prostate IRR:
0.687,95% CI 0.653-0.722; lung IRR: 0.801, 95% CI 0.749-0.856; breast IRR:
0.903, 95% CI 0.817-0.998). Given the expected confounding effect of throm-
botic disease on cancer incidence, we conducted a subgroup analysis among
patients prescribedwarfarin for atrial fıbrillation/flutter (AF-group), a subgroup
with reduced comorbidity. Warfarin users in the AF-group showed a stronger
overall cancer risk reduction (IRR: 0.619, 95%CI 0.592-0.646), including all ma-
jor cancer types, particular lung cancer. (Prostate, IRR: 0.604, 95%CI 0.552-
0.662; Lung IRR: 0.391, 95%CI 0.332-0.460; Breast IRR: 0.720, 95%CI 0.594-
0.871) CONCLUSION: We show that warfarin use is associated with a broad
cancer protective effect in a large unselected patient cohort. Subgroup analysis of
arrhythmia patients to reduce confounders reinforced the notion that warfarin
exerts important anti-tumor effects.
#3011 Dietary fat, fatty acids, and ovarian cancer risk: Preliminary fınd-
ings from the Shanghai Women’s Health Study. Eftitan Y. Akam,1 Harvey J.
Murff,2 Yong-Bing Xiang,3 Nikhil K. Khankari,1 Hui Cai,1 Xiao O. Shu,2 Wei
Zheng,2 Alicia Beeghly-Fadiel2. 1Division of Epidemiology, Department of Med-
icine, Vanderbilt University Medical Center, Nashville, TN; 2Division of Epide-
miology, Department of Medicine and Vanderbilt-Ingram Cancer Center, Van-
derbilt University Medical Center, Nashville, TN; 3Department of Epidemiology,
Shanghai Cancer Institute, Shanghai, China.
Introduction: Dietary fat is an essential nutrient for human growth and de-
velopment, but epidemiological studies have linked excess fat to the develop-
ment of multiple malignancies. The few existing studies on ovarian cancer risk
are inconsistent, possibly due to differences in sources and subtypes of fat. For
example, omega-3 (n-3) polyunsaturated fatty acids (PUFAs) are thought to be
antineoplastic, while omega-6 (n-6) PUFAs may promote carcinogenesis. Ap-
proach: We evaluated dietary fat in relation to ovarian cancer risk in the pro-
spective Shanghai Women’s Health Study (SWHS). Intake levels were deter-
mined from food frequency questionnaires (FFQ) administered at baseline and
during follow-up; specifıc nutrient components were based on the sum of spe-
cifıc foods multiplied by nutrient content from the Chinese Food Composition
Table. Cox proportional hazards regression was used to estimate relative risks
(RR) and 95% confıdence intervals (CI) for dietary fat and fatty acid components
categorized into quintiles. Minimal models included age and residual adjust-
ment for total energy intake; fully adjusted models also included education,
years of menstruation, years of oral contraceptive use, parity, years of breast-
feeding, family history of ovarian cancer, smoking, drinking, NSAID use, BMI,
and physical activity. Results: Among 73,144 SWHS participants, we identifıed a
total of 219 ovarian cancer cases in 1,114,828 person-years of follow-up. We
found signifıcant dose-response relationships between increasing total PUFA
(P-trend0.032) andn-6PUFA (P-trend0.022) intakes anddecreased ovarian
cancer risk. In bothminimally and fully adjustedmodels, women with the high-
est quintile of total dietary PUFAswere approximately 35% less likely to develop
ovarian cancer (RR0.65, 95% CI: 0.43-1.00), and women with the highest n-6
PUFA intake had a nearly 40% lower risk (RR0.61, 95% CI: 0.40-0.93). Total
fat, monounsaturated fat, and n-3 PUFA intake were not signifıcantly related to
ovarian cancer risk. Conclusions: Findings from our preliminary analysis of a
large prospective cohort of Chinese women suggest that total PUFA intake may
be protective of ovarian cancer, and that this association may be driven by n-6
rather than n-3 PUFAs. Further evaluation, including stratifıcation, sensitivity
analysis, and evaluation of source of dietary fatty acids, is currently underway.
#3012 Long-term aspirin use and total and cancer-specifıc mortality. Yin
Cao,1 Meir Stampfer,2 Walter Willett,2 Donna Spiegelman,2 JoAnn Manson,3
Eric Rimm,2 Molin Wang,2 Shuji Ogino,3 Charles Fuchs,4 Edward Giovan-
nucci,2 Andrew Chan1. 1Massachusetts General Hospital and Harvard Medical
School, Boston, MA; 2Harvard T.H. Chan School of Public Health, Boston, MA;
3Brigham and Women’s Hospital and Harvard Medical School, Boston, MA;
4Dana Farber Cancer Institute, Boston, MA.
Background: Long-term follow of clinical trials of aspirin for the prevention
of cardiovascular disease have shown that aspirin may be associated with a
reduced risk of death from cancer, including colorectal, esophageal, and lung
cancer, and possibly breast and prostate cancer. However, the potential benefıts
of aspirin use, at a range of doses and duration of use, on total and cancer-
specifıc mortality have not been examined in large prospective cohort studies
with long-term follow-up. Methods: We examined the association between as-
pirin use and subsequent total and cancer-specifıc mortality, at a range of doses
and duration of use, among 86,206 women in the Nurses’ Health Study (1980-
2012) and 43,977men in theHealth Professionals Follow-up Study (1986-2012).
Participants with a history of cancer, heart disease, or stroke were excluded.
Aspirin use was assessed at baseline and updated every 2 years with greater than
90% follow-up. Cox proportional hazards models were used to compute hazard
ratios as estimates for age- and multivariable-adjusted relative risks (RRs) and
95% confıdence intervals (CIs). Results: During up to 32 years of follow-up,
22,094 women and 14,749 men died, and 8,271 women and 4,591 men died of
cancer. Compared with nonregular use, regular aspirin use was associated with
lower risk of total mortality (multivariable-adjusted RR 0.93; 95% CI 0.90-0.95
for women and RR 0.89; 95% CI 0.86-0.93 for men), which was primarily due to
a lower risk of dying from any cancer (RR 0.93; 95%CI 0.89-0.97 for women and
RR 0.85; 95% CI 0.80-0.90 for men), especially colorectal cancers (RR 0.69; 95%
CI 0.59-0.81 for women and RR 0.70; 95% CI 0.57-0.85 for men), breast cancers
(RR 0.89; 95% CI 0.79-0.99), prostate cancers (RR 0.77; 95% CI 0.65-0.90), and
lung cancers in men (RR 0.86; 95% CI 0.74-0.99). The benefıt of aspirin on
cancer mortality appeared evident with use of at least 0.5 to 1.5 standard aspirin
tablets perweek for bothmen andwomen; and theminimumduration of regular
use associated with lower cancer mortality was 6 years. Conclusions: Long-term
aspirin use was associated with reduced risk of total mortality, primary due to
reduced risk of dying from cancers.
#3013 Duration of oral contraceptive use and the prevention of gyneco-
logic cancers: Modifıcation by modifıable factors. Kara A. Michels, Louise A.
Brinton, RuthM. Pfeiffer, Britton Trabert.Division of Cancer Epidemiology and
Genetics, National Cancer Institute, NIH, Bethesda, MD.
Background: Although oral contraceptive (OC) use is ubiquitous in the
United States, the influence of OCs on the development of cancers is not fully
understood. In 2013, an Agency for Healthcare Research and Quality Evidence
Report identifıed several data gaps with regard to OC use and its associations
with cancer, including a need to understand if associations are consistent across
subpopulations of users, including smokers and obese women. Methods: To
address this data gap, we used Cox proportional hazards models to examine
duration of OC use (never/less than 1 year [reference], 1 to 4, 5 to 9, 10 years)
and subsequent development of incident ovarian or endometrial cancer among
participants in the NIH-AARP Diet and Health Study. We further examined
effect modifıcation by a variety of modifıable risk factors, including body mass
index (BMI), cigarette smoking, alcohol consumption, and physical activity, via
interaction terms and a likelihood ratio test. Models were adjusted for age, race,
age at menarche and the modifıers of interest. Results: For ovarian cancer
(n1,241 cases, 149,502 non-cases), a reduction in riskwas conferred byOCuse
that linearly decreased with duration of use (hazard ratios [HR] ranging from
0.83 to 0.60 across categories of duration). We also identifıed linear, inverse
associations between increasing duration of OC use and ovarian cancer risk
across most potential modifıers. Some of the most pronounced reductions were
observed among long-term OC users (10 years) who were current smokers
(HR compared to non-users of 0.44, 95% confıdence interval [CI] 0.20, 0.97) or
who engaged inmoderate physical activity (0.44, CI 0.23, 0.85). For endometrial
cancer (n2,337 cases, n112,132 non-cases), we observed pronounced reduc-
tions in risk associated with long-term OC use among women with obese BMIs
(0.36, CI 0.25, 0.52) and those who exercised rarely (0.40, CI 0.29, 0.56) or
moderately (0.50, CI 0.33, 0.75). However, long-term use was not associated
with risk reductions among women with BMIs of less than 25 or among women
who exercised at least three times per week. Conclusions: OC use is consistently
associated with reduced risks of ovarian cancer across most strata of modifıable
risk factors. For endometrial cancer risk, OC use seems to offer the greatest risk
reduction amongwomen in previously identifıed high-risk categories (i.e., over-
weight/obese BMI, physically inactive), fındings which merit further discussion
as these women may be more likely to have comorbid conditions that would
contraindicate OC use (e.g., hypertension, diabetes).
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Identifıcation of Molecular Targets
#3014 BCL3 over-expression contributes an in vivo growth advantage in a
B-cell lymphoma xenograft model and is a risk factor for ibrutinib relapse in
CLL. Timothy L. Chen, Bonnie K. Harrington, Larry Beaver, Amy S. Ruppert,
NylaA.Heerema,Xiaoli Zhang,HaticeGulcinOzer,Amy J. Johnson, JenniferA.
Woyach, ErinHertlein, JohnC. Byrd.TheOhio State University, Columbus, OH.
Chronic lymphocytic leukemia (CLL) relies on chronic B-cell receptor
(BCR) signaling, and as such is effectively treated with Bruton’s tyrosine
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kinase (BTK) inhibitors. However patients who relapse on BTK inhibitors
such as ibrutinib have an extremely poor prognosis without additional in-
tervention. Therefore, identifying and characterizing risk factors that pre-
dict relapse to BTK inhibitors is important. A series of 308 CLL patients have
been enrolled on various ibrutinib clinical trials at the Ohio State University.
Seven of these patients were identifıed to carry the translocation t(14;19),
which leads to over-expression of B-cell leukemia 3 (BCL3), Of these 7, 6
(85%) have relapsed on ibrutinib while only 27% of patients (83/308) overall
have progressed. BCL3 is known to regulate NF-B transcription and influ-
ence B-cell function, and we found that overall BCL3 expression is increased
in CLL compared to normal B-cells, therefore hypothesized that BCL3 may
provide a competitive advantage to promote ibrutinib resistance. In order to
test the role of BCL3 in ibrutinib resistance using an in vitro system, we
overexpressed BCL3 or an empty vector (EV) control in ibrutinib responsive
B-cell lines (BCL3 was at least 2-fold over-expressed relative to endogenous
BCL3). Cells were treated with vehicle or 1uM ibrutinib for 1 hour followed
by a washout, and proliferation and viability were evaluated at various time
points. Ibrutinib inhibited cell proliferation and induced apoptosis, however
BCL3 expression did not abrogate these effects. However, while examining
BCR signaling proteins we found that BCL3 expression enhanced phosphor-
ylation of BTK, suggesting that BCL3 stabilizes activated BTK to circumvent
ibrutinib treatment. We next engrafted these EV or BCL3 over-expressing
cells into the left or right flank, respectively, of immune-compromised
(NSG) mice. Mice were sacrifıced when either tumor reached a volume of
2000cm3, and the tumors were isolated and weighed. Tumors which devel-
oped from the BCL3 over-expressing cells at sacrifıce were larger than those
which developed from the EV cells by an average of 1332g. We also evaluated
a disseminated tumor model where HBL-1 EV or BCL3 over-expressing cells
were injected via the tail vein. Disease was monitored by weekly peripheral
blood flow cytometry for human CD19. We saw that 6 of 11 mice intrave-
nously engrafted with HBL-1 BCL3 present with peripheral disease when the
mice meet removal criteria, whereas only 1 of 11 mice engrafted with HBL-1
EV cells developed peripheral disease. We conclude that the presence of
t(14;19) indicates a higher risk of relapse in patients undergoing ibrutinib
therapy, and these patients should be closely monitored for evidence of
progression. Our studies also suggest that BCL3 promotes more aggressive
disease in a lymphoma xenograft model, and may be involved in tumor
migration in vivo.
#3015 Selective inhibition of mutant KRAS cell and tumor growth by
PHT-7.3, an inhibitor of the KRas signaling nanocluster protein Cnk1.
Roisin Delaney,1 Marco Maruggi,1 Martin Indarte,2 Robert Lemos,1 Geoff
Grandjean,3 Lynn Kirkpatrick,2 Garth Powis1. 1Sanford Burnham Prebys
Medical Discovery Institute, La Jolla, CA; 2PHusis Therapeutics Inc., La Jolla,
CA; 3Sanford Burnham Prebys Medical Discoavery Institute, La Jolla, CA.
Activating mutations of KRas is the most common proto-oncogenic event
in human cancer but there remains no effective therapy for patients harbor-
ing mutated KRas (mut-KRas). Despite intense efforts, tight nucleotide
binding, few defıned pockets, and redundant localization signals have im-
peded the development of compounds that bind or inhibit KRas. We have
identifıed connector enhancer of kinase suppressor of Ras 1 (Cnk1) as a
critical mediator for growth driven by mut-KRas in human cancer cells.
Cnk1 co-localizes with mutant KRas at the membrane and deletion of Cnk1
abrogates KRas activation and the activation of the Ras effectors Ral and
Rho. Cnk1 deletion caused cells with mutant KRas to accumulate at the G1
checkpoint similar to selective deletion of mutant KRas itself. Following a
screen and initial structural optimization a small molecule probe compound
PHT-7.3 was identifıed and shown to bind selectively to the pleckstrin ho-
mology PH domain of Cnk1 preventing Cnk1 andmut-KRas co-localization.
PHT-7.3 inhibited mut-KRas but not wt-KRas non small cell lung cancer
(nsclc) cell growth, and selectively blocks mut-KRas downstream signaling
in cells. PHT-7.3 exhibited cytostatic antitumor activity in the mut-
KRas(G12S) A549 and mut-KRas(G12V) H441 nsclc xenografts, but not in
the wt-KRas H1975 nsclc xenograft. Mut-KRas downstream signaling was
inhibited by PHT-7.3 in the xenografts with downregulation of activated
Rho and Ral signaling. PHT-7.3 showed further increased antitumor activity
in A549 xenografts in combination with erlotinib or trametinib. Thus, the
work identifıes the PH domain of Cnk1 as a druggable target whose inhibi-
tion selectively blocks mutant-KRas activation, and PHT-7.3 as a lead agent
in the development of therapies for KRas tumors.
#3016 Identifıcation of protein argininemethyltransferase 1 as novel epi-
genetic vulnerability in KRAS/p53 mutant PDAC primary patient models.
Virginia Giuliani, Bhavatarini Vangamudi, Erika Suzuki, Meredith Miller,
Chiu-Yi Liu, Alessandro Carugo, Christopher Bristow, Guang Gao, Jing Han,
Yuting Sun, Ningping Feng, Edward Chang, Joseph Marszalek, Jeffrey Kovacs,
Maria Emilia Di Francesco, Carlo Toniatti, Timothy Heffernan, Philip Jones,
Giulio Draetta. UTMD Anderson Cancer Ctr., Houston, TX.
Pancreatic ductal adenocarcinoma (PDAC) is a rapidly progressing disease
associated with less than 10% 5-year survival rate. Various treatment regimens
failed to improve survival of PDACpatients, thus a critical need exists to identify
druggable targets essential for tumor maintenance. We developed a powerful in
vivo platform that enables the identifıcation of new molecular drivers in the
PDAC context where activating mutation of KRAS gene and loss of p53 domi-
nate the genetic landscape. Through an in vivo loss of function screen performed
in KRAS/p53 mutant PDAC primary patient models, we identify protein argi-
nine methyltransferase 1 (PRMT1) as top scoring hit. This novel dependency in
PDACwas subsequently validated inmultiple PDACmodels using both shRNA
mediated as well as CRISPR base genetic inhibition and we demonstrated that
PRMT1 knockdown induces a signifıcant growth inhibition in vitro. Methyl-
ation of arginine 3 on histone H4 (H4R3me2a) as well as global arginine meth-
ylation was also evaluated and showed a dramatic reduction upon PRMT1
knockdown, correlating observed phenotype with target engagement. To fur-
ther confırm a role for PRMT1 in tumor maintenance, we developed inducible
PRMT1 knockdown in a primary patient model and showed a dramatic tumor
growth inhibition (TGI) in vivo upon PRMT1 knockdown. PRMT1 is the pri-
mary enzyme responsible for arginine asymmetric demethylation, however
other members of the Type I family are also involved in this process and we
evaluated the role of protein arginine methyltransferase 4 (PRMT4) and 6
(PRMT6) in our workhorse model. Surprisingly, no signifıcant phenotypic re-
sponse was observed upon genetic inhibition of PRMT4 or PRMT6 suggesting
no redundancy between different PRMT type I and a unique dependency on
PRMT1. To strengthen and complement the genetic validation, we leveraged a
PRMT Type I inhibitor and confırmed in vitro results as well as in vivo effıcacy
at tolerated doses (xenograft vs allograft). Key models have been prioritized in
order to inform on PRMT1 dependency and to refıne responder population.
Our research has identifıed and validated for the fırst time an arginine methyl-
transferase as a novel genetic vulnerability in PDAC and strongly suggest
PRMT1 as a new therapeutic opportunity in PDAC cancers.
#3017 Inhibition of YAP/TAZ-dependent transforming properties in
LATS1/2 deleted RPE1 cells by MAPKAPK5 targeting.Min Hwan Kim, Joon
Kim. Korea Advanced Institute of Science and Technology, Daejeon, Republic of
Korea.
Purpose: Recent evidence suggests the Hippo pathway effectors YAP/TAZ
play important roles in tumor pathogenesis, including tumorigenesis, metasta-
sis, and drug resistance. Loss of LATS1/2, the negative regulators of YAP/TAZ,
has been reported in various human tumors, and suggested to activate YAP/
TAZ in tumorigenic process. However, the molecular consequence of LATS1/2
genetic loss in benign human cells has not been addressed, and therapeutic
targets for tumors with LATS1/2 loss have not been explored. We aimed to
investigate the transforming potential of LATS1/2 loss in humanRPE1 cells, and
to fınd targetable kinases that support YAP/TAZ activation in tumors with
LATS1/2 loss Method: To examine the effect of LATS1/2 loss, both LATS1 and
LATS2 alleles were deleted by CRISPR-Cas9 genome editing in RPE1-hTERT
cells. YAP/TAZ activity of LATS1/2-null RPE1 cells was measured by immuno-
fluorescence (IF) staining and qRT-PCR. Transforming properties of LATS1/2
loss were monitored on both 2-dimensional (2D) and 3D culture, and the cen-
trosome number and DNA contents of cells were determined by IF and pro-
pidium iodide staining. LATS1/2-null RPE1 cells were subjected to an image-
based kinome-wide siRNA library screening for identifying YAP/TAZ
downregulating hits. Results: The LATS1/2-null RPE1 cells showed persistent
nuclear localization and transcriptional activation of YAP/TAZ. In contrast to
wild-type RPE1 cells, the LATS1/2-null RPE1 cells showed high proliferation
rate, loss of contact inhibition, and sphere formation capacity in matrigel 3D
culture, demonstrating transforming activity of LATS1/2 loss. Moreover,
LATS1/2 knockout caused genomic instability and centrosome overduplication
in RPE1 cells that might be related to defects in mitotic checkpoint regulation.
Next, we performed an image-based siRNA library screening to fınd potential
therapeutic targets for tumors with LATS1/2 loss. We found that the inhibition
of a p38 MAPK pathway component, MAPKAPK5, suppresses YAP/TAZ nu-
clear localization and activation in LATS1/2-null RPE1 cells.MAPKAPK5 phys-
ically interacted with YAP, and RNAi-mediated MAPKAPK5 inhibition de-
creased YAP/TAZ protein level and transcriptional activity. MAPKAPK5
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depletion resulted in suppression of LATS1/2-null RPE1 cell proliferation on 2D
culture as well as sphere formation capacity on 3D culture. Conversely, consti-
tutively activeMAPKAPK5mutant expression in RPE1 cells induced YAP/TAZ
nuclear enrichment. Conclusion: These results suggest that LATS1/2 genetic
loss drives transforming properties in human RPE1 cells, and MAPKAPK5 in-
hibition suppresses YAP/TAZ activation induced by LATS1/2 loss. We suggest
that MAPKAPK5 is a novel positive regulator of YAP/TAZ and may serve as a
therapeutic target for YAP/TAZ-driven tumors.
#3018 RET rearrangements as promising therapeutic targets in breast
cancer. Bhavna S. Paratala,1 Jeffrey S. Ross,2 Casey B. Williams,3 Whitney
Petrosky,1 Kirstin A.Williams,3 Jon Chung,2 Sonia C. Dolfı,1 Shridar Ganesan,1
Siraj Ali,2 Brian Leyland-Jones,3 KimM.Hirshfıeld1. 1Rutgers Cancer Institute of
New Jersey, New Brunswick, NJ; 2Foundation Medicine, Cambridge, MA; 3Avera
Cancer Institute Center for Precision Oncology, Sioux Falls, SD.
Background: Receptor tyrosine kinase alterations have played a signifıcant
role in therapeutic decisions for cancer due to their oncogenic nature and re-
sponse to targeted smallmolecule kinase inhibitors. Increased genomic profıling
of tumors using hybrid-capture based next-generation sequencing approaches
now reveal the presence of previously unknown fusions and alterations involv-
ing kinases in a diverse set of cancers. Here we report the presence and thera-
peutic signifıcance of recurrent and novel fusions involving RET, a known on-
cogenic tyrosine kinase receptor, in breast cancer. Methods: Comprehensive
genomic profıling on formalin-fıxed, paraffın embedded patient tumor tissues
was performed using FoundationOne platform that covers the entire coding
region for 315 cancer-related genes and introns of 28 genes involved in rear-
rangements at a depth of 500-1000X (Foundation Medicine, MA). Out of 23
rearrangements, two representative RET fusion expression vectors were synthe-
sized and expressed in non-tumorigenic cell lines (breast MCF10A and mouse
3T3 fıbroblasts) and were evaluated for RET kinase signaling, drug response,
and tumorigenicity. Results: RET gene fusions, the canonical NCOA4-RET and
a novel, noncanonical RASGEF1A-RET fusion, were identifıed in two separate
breast cancers and both include exons required to retain the intact kinase do-
main of Ret. The novel RASGEF1A-RET fusion includes the non-coding region
of RASGEF1A potentially resulting in a truncated RET protein using an alter-
nate internal start site in exon 11 of RET. In vitro characterization of both
fusions expressed in mouse 3T3 and human MCF10a cell lines revealed consti-
tutive kinase activation and subsequent downstream signaling as evidenced by
phosphorylation ofRet, Erk andAkt. This is the fırst reported noncanonical RET
rearrangement resulting in a 5’ truncated but functional RET kinase. Non-tu-
morigenic cell lines with stable expression of either rearrangement showed
transformed phenotypes assessed by changes in morphology, enhanced growth
rate, colony forming ability, and tumor formation in mice. RET fusion-trans-
formed cells were exquisitely sensitive to treatment with RET inhibitors when
evaluated in both short-term and long-term functional assays. NCOA4-RET
was found by CGP in an index case of metastatic ER/HER2 breast cancer
that had radiographic evidence of disease progression while on trastuzumab,
pertuzumab, and anastrazole. Subsequent treatment with cabozantinib plus
anastrazole led to a rapid clinical and radiographic response. Conclusion: CGP
techniques involving hybrid-capture based approaches can identify previously
unreported but recurrent RET gene fusions in breast cancer. Here, we show that
RET fusions including both canonical and non-canonical complex rearrange-
ments are functional and may represent promising therapeutic targets in se-
lected breast cancer patients.
#3019 The role ofTACC3 in theprogression fromductal carcinoma in situ
to invasive breast cancer. Loredana Campo, Maya Mathew, Eun-Kyoung
breuer, William Small. Loyola University Medical Center, Maywood, IL.
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer with the
potential to become invasive/metastatic. The development of DCIS to invasive
breast cancer is an important aspect of breast tumor aggressiveness, however,
little is known about the genetic and molecular alterations involved in this pro-
gression.Also, analysis ofmolecularmarkers and genetic signatures ofDCIS and
invasive breast cancer have failed to identify transition-specifıc biomarkers or
pathways. Hence, identifying the molecular mechanisms by which DCIS pro-
gresses to invasive breast cancer is critical for the success of diagnosis, prognosis
and therapy of breast cancer. Members of the transforming acidic coiled-coil
(TACC) protein family are key players in the maintenance of centrosome
integrity, the regulation of microtubule assembly, and spindle stability dur-
ing mitosis. TACC3 has been shown to be involved in the regulation of
centrosome-microtubule dynamic networks, cell growth and differentiation,
and transcription/gene expression through interactions with other mole-
cules. Mounting evidence indicates that high levels of TACC3may contribute to
breast cancer development. Here, we investigated the signifıcance of TACC3 in
the transition of DCIS to invasive breast cancer. First, we examined the expres-
sion of TACC3 in non-tumorigenic human mammary epithelial MCF10A cells
and MCF10DCIS.COM cells, which are known to form DCIS-like lesions in
mice and to progress to invasive cancer, and found that the expression ofTACC3
is elevated inMCF10DCIS.COM cells compared toMCF10A cells. By analyzing
tissue microarray data, we found that expression of TACC3 gradually increased
from normal breast to DCIS, and further increased in invasive breast cancer. In
addition, ectopic expression of TACC3 in MCF10DCIS.COM cells promoted
cell proliferation, migratory and invasive capabilities as well as the epithelial-
mesenchymal transition (EMT)-like phenotype. Moreover, MCF10DCIS.COM
cells stably expressingTACC3 exhibited increased expression of stemnessmark-
ers. Interestingly, a small molecule inhibitor of TACC3, KHS101 treatment in
MCF10DCIS.COM cells signifıcantly suppressed cell proliferation and the
PI3K/AKT signaling pathway while having little effect on MCF10A cells. Our
fındings, therefore, suggest that TACC3 may play an important role in the pro-
gression fromDCIS to invasive breast cancer and that targetingTACC3 could be
a promising new therapeutic strategy for DCIS patients.
#3020 Novel therapeutic targets in head and neck cancer.Maria Kondra-
tyev,1 Aleksandra Pesic,1 Troy Ketela,1 Azin Sayad,1 Stephano Marastoni,1 Carl
Virtanen,1 Laurie Ailles,1 Soroush Samadian,1 Mikhail Bashkurov,2 Marianne
Koritzinsky,3 Brad Wouters3. 1UHN, Oakville, Ontario, Canada; 2Lunanfeld,
Toronto, Ontario, Canada; 3UHN, Toronto, Ontario, Canada.
HNSCC is 6th most common malignancy in the world. Despite advances in
diagnosis and treatment, the survival rates remain low due to frequent recur-
rences the biology of which remains unclear. Using functional genomic technol-
ogies, we identifıed new therapeutic targets for metastatic disease in HNSCC.
Whole genome shRNA screens were conducted in matched sets of cell lines
derived from primary tumors and respective metastatic sites, identifying genes
essential for cell survival only following metastasis. To test if knockdown of
selected targets inhibitsmetastasis in a therapeutic setting, we established ortho-
tropic model of HNSCC that metastasize to lymph nodes in the mouse. Com-
ponents of Notch pathway were identifıed as essential for survival of cells de-
rived from metastatic sites. Whole exome sequencing identifıed a novel
mutation in one of the EGF domains of Notch3 that was acquired only in the
metastatic line. Utilizing CRISPRmethodology, we established that “fıxing” the
mutation results in reversal of metastatic phenotype of the cells, making them
Notch independent similar to their primary tumor counterparts. Mutations in
EGF domains have been reported to influence interaction with specifıc ligands,
dictating which ligand can activate Notch signaling. Our data indicate that a
distinct set of target genes is induced upon interaction betweenNotch3 and Jag2
ligand. Furthermore, our results indicate that suppression of Notch3 improves
survival in mice bearing orthotropic tumors derived from the metastatic HN-
SCC lines. Overall, our data demonstrate that metastatic cells from head and
neck tumors acquire dependency onNotch3 signaling. Novel treatments target-
ing components of this pathwaymay prove effective in targetingmetastatic cells
alone or in combination with conventional therapies.
IMMUNOLOGY: Adaptive Immunity in the Tumor
Microenvironment
#3021 CCR5 inhibition:macrophage repolarization therapy for colorectal
cancer. Niels Halama,1 Inka Zoernig,1 Anna Berthel,1 Christoph Kahlert,2 Fee
Klupp,3 Meggy Suarez-Carmona,1 Karsten Brand,3 Juergen Krauss,1 Felix
Lasitschka,3 Alexis Ulrich,3 Juergen Weitz,2 Martin Schneider,3 Markus
Buechler,3 Laurence Zitvogel,4 Thomas Herrmann,5 Axel Benner,6 Christina
Kunz,6 Stephan Luecke,6 Christoph Springfeld,1 Christine S. Falk,7 Dirk Jaeger1.
1National Ctr. for Tumor Diseases, Heidelberg, Germany; 2University Hospital
Dresden, Dresden, Germany; 3University Hospital Heidelberg, Heidelberg, Ger-
many; 4Institute Gustave Roussy, Paris, France; 5Medizinische Klinik Idar-Ober-
stein, Idar-Oberstein, Germany; 6German Cancer Research Center, Heidelberg,
Germany; 7Hannover Medical School, Hannover, Germany.
In patients with metastatic colorectal cancer (CRC), the local immune re-
sponse influences the clinical course. An in-depth analysis of the invasive mar-
gin of human CRC liver metastases revealed a distinct immunological microen-
vironment.Within this microenvironment, two distinct subsets of myeloid cells
induce an influx of T cells into the invasive margin via CXCL9/CXCL10. CCL5
is produced by these T cells and stimulates pro-tumoral effects via CCR5, creat-
ing an exploitive loop. CCR5 was found on macrophages, lymphocytes and on
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the vast majority of tumor cells. Inhibition of CCR5 in patient-derived func-
tional in vitro organotypic culture models showed a promising macrophage
repolarizationwith anti-tumoral effects. These effects aremediated by activation
of an antiviral program in macrophages, leading to interferon and reactive ox-
ygen species production and subsequent selective tumor cell death. These anti-
tumoral effects were confırmed in a phase I trial with a CCR5 antagonist in 14
patients with liver metastases of advanced refractory CRC. Treatment with the
oral CCR5 Inhibitor was very well tolerated and objective responses were seen,
especially in combination with previously ineffective chemotherapy. Biopsies
revealed mitigation of tumor-promoting inflammation within the tumor tissue,
confırming the validity of the explant model and highlighting the feasbility of
this approach. It furthermore shows the proof-of-concept for macrophage re-
polarization in cancer patients.
#3022 Novel hydrocarbon stapledpeptide inhibitors suppresses-catenin
dependent cancer growth and immunomodulates colorectal tumors. Da-
vid Zhu,1 Joy Jin2. 1WntRx/Lab Central, Boston, MA; 2Harvard University,
Boston, MA.
Mutations in several components of the canonical Wnt pathway function as
drivers in a range of common solid tumor cancers, including about 90% of
sporadic colorectal cancers (CRCs), the thirdmost common cancer in theUS. In
particular, activation of -catenin (-cat), a keyWnt signaling component, can
initiate tumorigenesis in the intestine and promote cancer stem cell metasta-
sis6,7. As such, targeting the Wnt pathway is an attractive approach to the de-
velopment of cancer therapeutics. However, Wnt inhibitors tested to date, in-
cluding those that disrupt -cat activity, have either had limited effıcacy or
unacceptable side effect profıles1. Here, we developed a potent and robust, se-
lective lead compound targeting oncogenicWnt activity by disrupting the highly
specifıc interaction of -cat with its co-activators BCL9/B9L, which has been
shown to abrogate transactivation. By using hydrocarbon stapled peptide tech-
nology and an acutely sensitive high throughput biochemical screening assay,
we have identifıed several promising peptides that possess a strong pharmaco-
kinetic profıle. These peptides (i) exhibit robust activity in mouse models; (ii)
inhibit cancer cell proliferation, metastasis, and stem cell progression; and (iii)
modulate the immunemicroenvironment, demonstrating the feasibility of such
peptide development and selection. Synergy is demonstrated between the sta-
pled peptides and anti-PD1 antibodies, which has signifıcant implications for
combination therapy with commercial immune checkpoint blockers that have
become standard of care for second-line melanoma treatment. These peptides
represent a promising new potential therapeutic class for patients with CRC, for
which traditional chemotherapy and targeted inhibitors have had limited ther-
apeutic success.
#3023 The antitumor activity of immunotoxins is enhancedby tofacitinib.
Nathan Simon,1AntonellaAntignani,1 StephenHewitt,1MassimoGadina,2Ma-
sanori Onda,1 Christine Alewine,1 David Joseph Fitzgerald1. 1National Cancer
Institute, Bethesda, MD; 2National Institute of Arthritis andMusculoskeletal and
Skin Disease, Bethesda, MD.
Treatment outcomes of certain aggressive cancers have not improved signif-
icantly in the last decade, necessitating development of new therapies. Recom-
binant immunotoxins (IT) are fusion proteins consisting of the enzymatic do-
main of a cytotoxin linked to an antibody fragment targeting a cellular surface
protein. While the combination of selective targeting and potent cell-killing
make ITs well suited for targeted cancer therapy, clinical experience has indi-
cated that patients can generate anti-toxin neutralizing antibodies after one cy-
cle of treatment.Mice treatedwith the FDA-approved JAK inhibitor, tofacitinib,
produced signifıcantly lower anti-toxin antibody titers, suggesting that tofac-
itinib could be used in combination with immunotoxins to improve therapeutic
effıcacy. Accordingly, the combination of tofacitinib and IT was tested both in
vitro and in vivo using two models of aggressive human cancers: pancreatic
ductal adenocarcinoma and triple-negative breast cancer. In vitro combination
studies examined the effects on oncogenic signaling pathways and looked for
enhancement of cytotoxic potency. Results demonstrated some tofacitinib-me-
diated inhibition of key signaling pathways but no enhancement of immuno-
toxin killing. By contrast, when xenograft tumor models were challenged, im-
munotoxin activity was enhanced greatly by co-treating with tofacitinib.
Tofacinib treatments alone did not demonstrate any antitumor activity. The
combination of tofacitinib and immunotoxin decreased tumor growth and ex-
tended survival compared to either treatment alone. Examination of post-treat-
ment tumor samples and sera from mice indicated that JAK inhibition resulted
in alterations of the tumor microenvironment, including a decrease in cancer-
promoting cytokine levels and reductions in recruitment of suppressive im-
mune cells to tumor tissue. This study demonstrates that the inhibition of the
JAK-STAT pathway can signifıcantly enhance the ability of cytotoxin-based
therapeutic agents to elicit anti-tumor effects through alteration of the tumor
microenvironment.
#3024 CD4 outperformCD8 centralmemory-derivedCART cells,me-
diating persistent antitumor responses and long-term eradication of glio-
blastoma.Dongrui Wang, Renate Starr, Brenda Aguilar, Alfonso Brito, Brenda
Chang, Aniee Sarkissian, Behnam Badie, Michael E. Barish, Stephen J. Forman,
Christine E. Brown. City of Hope, Duarte, CA.
Purpose: To compare antitumor effector function mediated by CD4 and
CD8 chimeric antigen receptor (CAR)-T cells targeting IL13 receptor 2
(IL13R2) for treatment of glioblastoma (GBM). Experimental Design: CD4
and CD8 IL13R2-specifıc CAR-T cells, derived from enriched central mem-
ory T cells (Tcm), were evaluated for their antitumor potential both in vitro by
recursive challenge with GBM cells and in vivo in established orthotopic GBM
xenograftmodels. Further,GBM-stimulatedCD4 andCD8CAR-T cellswere
examined for their exhaustion- and memory-associated phenotypes at tran-
scriptional and protein levels, which would account for their differential antitu-
mor activity. Results: While CD8 CAR-T cells mediated robust short-term
cytolytic effector function, they became rapidly exhausted and lost antitumor
potential after repeated stimulation with tumor cells. CD4 CAR-T cells, by
contrast, persisted and retained effector potency even after repetitive tumor
challenge. CD4-mediated cytotoxicity acted through the granzyme B/perforin
pathway and was independent of the CD8 cells. Activated CD4CAR-T cells
augmented the proliferation of CD8 cells, but failed to protect the CD8 cells
against stimulation-induced exhaustion. In NSGmice bearing GBMxenografts,
CD4CAR-T cell treatment led to long-term tumor-free survival, while CD8
CAR-T cell treated mice showed short-term tumor regression followed by anti-
gen-positive relapse and associated T cell exhaustion. Upon GBM stimulation,
CD4 cells expressed less co-inhibitory receptors andmorememory-associated
markers than the CD8 T cell subset. Further, a comprehensive transcriptional
analysis revealed that when activated, CD4 cells retained expression of genes
involved in survival- and self-renewal-related pathways, indicating a less ex-
hausted status and a better functional persistence in comparison to the CD8
cells. Conclusion:We observed a superior anti-GBMactivitymediated byCD4
CAR-T cells over the CD8 subset, featured by their ability to maintain long-
term immune response and reduce stimulation-induced exhaustion. It is thus
inferred that the frequency of CD4 cells could be an important criteria for
evaluating the effıcacy of CAR-T cells as immunotherapeutic products.
#3025 Preclinical characterization of a novelmonoclonal antibody target-
ing a neo-antigen expressed in ovarian and GI malignancies. Kristen Zeligs,1
Philip M. Arlen,2 Kwong Tsang,2 Lidia Hernandez,3 Massimo Fantini,2 Chris-
tina M. Annunziata3. 1Walter Reed National Military Medical Center, Bethesda,
MD; 2Precision Biologics, Inc., Rockville, MD; 3National Cancer Institute,
Bethesda, MD.
Objectives: We have developed a novel humanized IgG1 monocolonal anti-
body, NEO-201, which targets a neoantigen expressed on ovarian and GI ma-
lignancies. This antigen has homology to CEACAM; however, it has specifıcity
to tumor tissues and not normal tissues. Our aimswere as follows: (1) to evaluate
the expression of this antigen on tumor cell lines derived from various ovarian
and GI cancers; and (2) to determine the functionality of NEO-201. Methods:
Expression of the antigen was identifıed by western blot analysis and flow cy-
tometry. Functionality was determined by an antibody dependent cell-mediated
cytotoxicity (ADCC) assay using the antigen-expressing cell lines identifıed by
western blot analysis. Cell lines not expressing the antigen were used as negative
controls. The effector cells used in theADCC assay were natural killer (NK) cells
isolated from PBMCs of normal donors and high-affınity activated NK (haNK)
cells. haNK cells are NK-92 cells genetically engineered to express the high-
affınity variant of human CD16 (FcgRIIIA-V158) and the human IL-2 gene.
haNK cells have little or no inhibitory expression of killer cell immunoglobulin-
like receptors, a unique feature that may optimize their highly cytotoxic activity
against a broad range of malignancies. Results: Using western blot analysis, 2 of
5 ovarian cancer cell lines (OV90 andPE01) and 1 of 2 colorectal cancer cell lines
(LS174T) stained positively for NEO-201. Flow cytometry analysis on ovarian,
colorectal, andpancreatic cancer cell lines confırmed the expression of theNEO-
201neoantigen on1of 2 ovarian cancer cell lines (OV90), 1 of 2 colorectal cancer
cell lines (LS174T), and 2 of 2 pancreatic cancer cell lines (ASPC-1 and CFPAC-
1). ADCC assay was performed using OV90 and ASPC-1 tumor cell lines. Cell
lines not expressing the neoantigen were used as negative controls. Killing of
tumor cells expressing the neoantigen was also observed with NEO-201 alone;
however, the lysis was signifıcantly augmented when NK cells from the PBMCs
of normal donors or haNK cells were included in the ADCC assay. Conclusions:
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These fınding demonstrate that theNEO-201 neoantigen is expressed on several
tumor cell lines representing ovarian and GI malignancies. NEO-201 canmedi-
ate ADCC activity in the presence of NK cells and NK cell lines. In addition,
NEO-201 can induce apoptosis in tumor cell lines expressing the NEO-201
neoantigen. Furthermore, preliminary studies demonstrated that this neoanti-
gen is expressed in numerous cancer types (not shown). In vivo studies as well as
IND-related studies are planned.
#3026 Targeting GPX4 in tumor-associated stromal cells increases in-
flammatory-cell infıltration. Shrikanta Chattopadhyay,1 Cherrie Huang,1
NinibBaryawno,1Nicolas Severe,1VasanthiViswanathan,2CarlottaCosta,1Da-
vid Scadden,1 Stuart Schreiber2. 1Massachusetts General Hospital, Boston, MA;
2Broad Institute, Cambridge, MA.
The lack of a T-cell inflamed microenvironment in tumors limits respon-
siveness to many immunotherapies. T-cell exclusion is often mediated by a
dense infıltration of fıbroblast-like stromal cells. Up to 55% of triple-negative
breast cancers have ‘stroma-rich’ tumors with markedly lower T-cell inflam-
mation. Here we report a therapeutic strategy that can potentially convert
stroma-rich tumors into T-cell inflamed tumors by forcing stromal cells to
secrete 5-lipoxygenase products which are powerful chemo-attractants for T
cells. We were initially interested in identifying selective inhibitors of stro-
mal-cell function. To achieve this, we used phenotype-based small-molecule
screening in which the phenotype of stroma-induced cancer cell migration
in vitro was a surrogate for stroma-induced metastasis in vivo. We identifıed
a compound, RSL3 that inhibited this migration. RSL3 was selectively cyto-
toxic to stromal cells over cancer cells, in comparisons of immortalized cell
lines as well as comparisons of patient-derived primary breast cancer cells to
cancer-associated fıbroblasts (CAFs). We therefore undertook studies to
identify its mechanism of action. RSL3 was recently reported to target the
redox enzyme glutathione peroxidase 4 (GPX4). GPX4 metabolizes lipid
peroxides so we performed metabolomic profıling of RSL3-treated stroma-
cancer co-cultures and found elevated arachidonic acid products of lipoxy-
genase enzymes. Stromal cells were found to contain 10-fold higher levels
of lipoxygenase products than carcinoma cells. Blocking either 5-lipoxygen-
ase (5-LO) or 15-lipoxygenase (15-LO) with selective inhibitors abrogated
RSL3’s cytotoxicity to stromal cells. Thus, high lipoxygenase activity in stro-
mal cells increases their susceptibility to GPX4 inhibition. Because 5-LO
products like leukotriene B4 are powerful chemo-attractants for myeloid
cells and T cells, we studied the impact of GPX4 knockdown in vivo using
xenografts of cancer cells co-injected with stromal cells. GPX4 knockdown
resulted in a large increase in myeloid-cell infıltration into tumors but, sur-
prisingly, T-cell infıltration was suppressed. We reasoned that 15-LO prod-
ucts are immunosuppressive based on recent fındings that 15-LO gene am-
plifıcations are inversely correlated with T-cell infıltration in breast cancers
in The Cancer Genome Atlas. Consistent with this, GPX4 inhibition of stro-
ma-cancer co-cultures suppressed T-cell chemotaxis but combined inhibi-
tion of GPX4 and 15-LO signifıcantly enhanced T-cell chemotaxis over un-
treated controls in vitro. We are undertaking in vivo testing of this
combination. In summary, our unbiased chemical biology approach has re-
vealed a therapeutic strategy to promote T-cell inflammation. We envision
this to be a priming strategy for stroma-rich cancers to become responsive to
a variety of different immunotherapies thereby unleashing their full curative
potential.
#3027 Dissectingmechanisms of anti-PD-1 therapy withmassively paral-
lel single-cell RNA-sequencing. Brian C. Miller,1 Marc H. Wadsworth,2 Kevin
Bi,1 Travis K. Hughes,2 Robert Manguso,1 Arlene H. Sharpe,3 Alex K. Shalek,2
Nicholas Haining1. 1Dana-Farber Cancer Inst., Boston, MA; 2Massachusetts In-
stitute of Technology, Cambridge, MA; 3Harvard Medical School, Boston, MA.
Anti-PD-1 therapy is an important new treatment option for many differ-
ent types of malignancies, but overall response rates are less than 40%. Lim-
ited understanding of how anti-PD-1 treatment changes the tumor immune
microenvironment is a barrier to identifying rational combination therapies
and understanding mechanisms of immunotherapy resistance. To overcome
this barrier, we set out to understand the mechanisms by which anti-PD-1
therapy augments the anti-tumor immune response using single-cell
genomics. We have developed a massively parallel single-cell RNA-sequenc-
ing platform (“Seq-Well”) that uses a fabricated chip with nearly 100,000
nanowells into which barcoded beads and individual cells are distributed
prior to lysis and RNA capture. We used this platform to comprehensively
defıne the global expression profıle of all major immune lineages in the
tumor microenvironment in a mouse tumor model of immunotherapy. Mice
were implanted with the B16F10 melanoma transplantable model of cancer
and treated with anti-PD-1 or control antibodies. Tumors were harvested
and CD45 tumor-infıltrating leukocytes isolated by FACS. In a single ex-
periment we were able to sequence the transcriptomes of over 600 individual
cells, allowing us to clearly distinguish different immune lineages within the
tumor microenvironment. We detect two transcriptionally distinct popula-
tions of CD8 T cells, one that is highly proliferative (as marked by Ki-67),
and one that has higher expression of cytotoxic markers (i.e. perforin). The
Ki-67hi population is enriched for a gene expression signature from termi-
nally exhausted CD8 T cells in chronic viral infection, suggesting that this
is a more exhausted subset. Treatment with anti-PD-1 globally alters the
tumor microenvironment, including enriching for CD8 T cells in the Prfhi
subpopulation compared with the Ki-67hi more terminally exhausted popu-
lation. Studies to understand changes in the immune infıltrate of immuno-
therapy resistant tumors are currently ongoing. In conclusion, massively
parallel single-cell RNA-sequencing allows us to dissect the mechanisms by
which checkpoint blockade controls tumor growth, revealing shifts in the
differentiation state of exhausted CD8T cells induced by checkpoint block-
ade.
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Breakthroughs in the Control, Function, and Drivers of
Oncogenesis
#3028 Reactive oxygen species inducednuclear translocationof c-METvia
INTERNET mechanism. Mei-Kuang Chen,1 Yi Du,2 Yu-Yi Chu,3 Mien-Chie
Hung2. 1The University of Texas Health Science Center at Houston, Graduate
School of Biomedical Science, Houston, TX; 2The University of Texas MD Ander-
son Cancer Center, Houston, TX; 3National Cheng Kung University, Tainan,
Taiwan.
c-MET is one of the receptor tyrosine kinases (RTKs) that are overexpressed
inmalignant cancer types including breast cancer. c-MET is traditionally known
for its role in signaling transduction from the cell surface, our recent publication
provided evidence that c-MET can be translocated into the nucleus and phos-
phorylate PARP1 in response to reactive oxygen species (ROS) stimulation (Du
et al. Nat Med 2016). Oxidative stress is a common phenomenon in cancer cells
due to alteration of metabolism, and constitutive oxidative stress related to ROS
has been observed in breast cancer cells. In this study, we demonstrated that
hepatocyte growth factor (HGF) as well as hydrogen peroxide (H2O2) can in-
duce retrograde translocation of c-MET holoreceptor via a membrane-bound
vesicle transport mechanism and translocate into the nucleus through INTER-
NET (integral traffıcking from the ER to the nuclear envelope transport path-
way) (Wang et al. J Biol Chem 2012) in breast cancer cells.While c-METnuclear
transportation increases dramatically under H2O2 treatment, our fındings pro-
vide a putative mechanism by which breast cancer cells adapt to oxidative stress
and suggest that INTERNET might be a general nuclear translocation mecha-
nism shared among RTKs.
#3029 An in vivo role for Argonaute 2 in KRAS driven pancreatic cancer.
Sunita Shankar, Jean Tien, Vijaya L. Dommeti, Sylvia Zelenka-Wang, Ingrid A.
Apel, Jiaqi Shi, ChandanKumar-Sinha, ArulM.Chinnaiyan.University ofMich-
igan, Ann Arbor, MI.
Oncogenicmutations inRASprovide a compelling yet intractable therapeutic
target. Using co-immunoprecipitation mass spectrometry, we recently identi-
fıed an interaction between RAS and Argonaute 2 (AGO2), the core component
of the RNA silencing machinery exerting translational control of mRNA tran-
scripts. RAS and AGO2 co-sediment and co-localize in intracellular endomem-
brane bound organelles. The AGO2 N-terminal domain directly binds the
KRAS Switch II region, irrespective of GDP/GTP bound to RAS. Functionally,
we observed that AGO2 was required for maximal oncogenic KRAS levels and
AGO2 knock-down attenuates cell proliferation in mutant KRAS-dependent
cells. Intriguingly, AGO2 mediated microRNA processing (RISC activity) was
attenuated in cancer cells expressing mutant KRAS compared to those express-
ing wild type RAS. Yet, these initial investigations using cell line models do not
reveal a clear role for AGO2 in KRAS driven oncogenesis. Therefore, we probed
the role of AGO2 in the well-established pancreatic ductal adenocarcinoma
(PDAC)mouse model driven by oncogenic KRAS. Towards this end, we gener-
ated LSL-KrasG12D; Pft1a Cre; AGO2flox/flox (KCA) mice. Preliminary anal-
ysis (8-10 weeks of age) suggests that compared to LSL-KRASG12D (KC) mice,
homozygous loss of AGO2 results in increased KRAS driven Acinar to Ductal
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Metaplasia (ADM) phenotype considered as precursors of PanIN (pancreatic
intraepithelial neoplasia) andPDAC.Thismirrors the phenotype of loss ofDicer
in the samemodel further reinforcing a role formicroRNAs in restrainingKRAS
oncogenic programs. Yet unlike Dicer, loss of AGO2 alone did not cause any
gross or histological changes in the development of the mouse pancreata. In an
effort to understand the underlyingmechanisms that are regulated byAGO2,we
also studied the activated levels of a variety of signaling molecules in pancreata
obtained from different genotypes. Primary analysis indicates that wild type
RAS levels are elevated duringAGO2 loss and has a bearing on PDAC initiation.
Using bothWestern blot and Immunohistochemical analyses, we demonstrate a
previously unknown and critical role forAGO2 inKRAS-MAPK signaling path-
way.
#3030 Mutant p53-driven metastasis explored utilizing a traceable, con-
ditional osteosarcoma model. Rasoul Pourebrahimabadi, Yun Zhang, Mark J.
McArthur, Guillermina Lozano.MD Anderson Cancer Center, Houston, TX.
TP53 is the most frequently mutated gene in cancer and missense mutations
in particular account for the majority of mutations. Mutant p53 proteins exert
oncogenic Gain-of-Function (GOF) properties that contribute to increased mi-
gration and invasion in culture andmetastasis in vivo. To elucidate howmutant
p53 drives metastasis, we developed a traceable somatic osteosarcoma model
that initiates with a single p53 mutation (p53R172H or p53R245W), or p53 loss
specifıcally in osteoblasts using Osx-cre. To mark tumor cells, we utilized the
mTmG allele which expresses membrane-targeted Tomato (mT) prior to Cre-
mediated excision andmembrane-targeted green fluorescent protein (mG) after
excision so the tumor cells becomeGFP and the stromal cells remainRFP. In
this high penetrant, short latency mouse model, tumor micro-metastasis can be
detected by GFP expression in the context of a normal stroma and immune
system. The cohort has developed osteosarcoma with complete penetrance and
an average survival of 304	 65 day. We observed metastasis in 55% of p53
mutant osteosarcomas which was signifıcantly higher than 26% metastasis ob-
served in p53 null tumors (p0.01). In p53 mutant osteosarcomas, the metas-
tasis rate was found signifıcantly associated with low p53 copy number. Spectral
karyotyping (SKY) on early passage cells derived from somatic p53 mutant tu-
mors exhibited marked aneuploidy with modal chromosome numbers near tet-
raploid. To characterize the transcriptional profıle associated with mutant p53
GOF, we analyzed and compared the RNA-Seq transcriptomes of eight tumors
derived from p53R172Hmutant mice with eight p53 null tumors. Comparative
analysis of gene expression identifıed a signature of snRNA genes to be strongly
associated with mutant p53 gain of function. Functional annotation of upregu-
lated genes inmutant tumors was also highly enriched for chromatinmodifying
enzymes. These fındings contribute to our understanding of the role of mutant
p53 GOF in metastasis. Our long term goal is to study how tumor-stromal
interactions affect tumor development and metastasis. This understanding will
have broad translational signifıcance in diagnosis and treatment of tumors with
mutant p53.
#3031 PHIP is a therapeutic target for triple negative solid tumors.David
De Semir,1 Vladimir Bezrookove,1 Mehdi Nosrati,1 Altaf A. Dar,1 Nathan Salo-
monis,2 Richard W. Sagebiel,1 Pierre Desprez,1 Robert J. Debs,1 Dirk Schaden-
dorf,3 Mohammed Kashani-Sabet1. 1California Pacifıc Medical Center Research
Institute, San Francisco, CA; 2Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH; 3University Hospital Essen, Essen, Germany.
Targeted therapy relies on the classifıcation of tumors according to the major
molecular drivers of the malignant phenotype, which can then help decide the
therapeutic treatment. However, a substantial subset of solid tumors does not
express these markers, exemplifıed by the triple-negative subtype of breast can-
cer. Sharedmolecular factors that promote the progression of these tumors, and
that represent a target for their therapy, are missing. We previously described a
role for PHIP (Pleckstrin Homology domain-Interacting Protein) in the pro-
gression of melanoma, and demonstrated PHIP activation in triple-negative
melanomas. Analysis of the TCGA profıling efforts in melanoma, breast and
lung cancer revealed PHIP expression to be enriched in triple-negative breast
cancer and in the bronchiad subtype of triple-negative lung cancer. Here we
show the broad-based role of PHIP in the progression of triple-negative sub-
types of three solid tumors (breast and lung cancer, and melanoma) defıned by
different mutational drivers and targeted therapies. By using a shRNA-based
targeting of PHIP in in vitro and in vivo models, we have suppressed the malig-
nant phenotype of triple-negative MDA-MB-231 and MDA-MB-436 human
breast carcinoma cells. In addition, PHIP knockdown resulted in signifıcant anti
tumor effects in H1703 and Calu3 human lung cancer cells lackingmutations in
EGFR, KRAS, and ALK, and in two short-term triple wild type melanoma cul-
tures lackingmutations in BRAF, NRAS, andNF1. Suppression of PHIP expres-
sion resulted in inhibition of both tumor cell proliferation by cell survival and
colony formation assays and invasion intomatrigel in each of the tumormodels
examined, and was accompanied by suppression of pAKT, CCND1, TLN1, and
ITG1 expression when assessed by western-blot or quantitative immunofluo-
rescence. The PHIP protein contains two bromodomains that can be therapeu-
tically targeted by small molecules. However, the functional activity of the PHIP
bromodomains has been poorly characterized. We show that PHIP co-localizes
with and binds to the acetylated histone modifıcation H4K91ac, and that both
are coordinately regulated upon growth factor stimulation suggesting a new
function for PHIP as a chromatin remodeler. To conclude, our results identify a
novel role for PHIP in the progression of solid tumors lacking the major molec-
ular drivers, and suggest PHIP as a druggable target for the therapy of these
malignancies.
#3032 Direct regulation of alternative splicing by Smad3 through PCBP1
is essential to the tumor-promoting role of transforming growth factor
beta1. Veenu Tripathi, Katherine M. Sixt, Xuan Xu, Ying E. Zhang. National
Cancer Institute, NIH, Bethesda, MD.
In advanced stages of cancers, TGF-  promotes tumor progression in con-
junction with inputs from receptor tyrosine kinase pathways. However, the
mechanisms that underpin the signaling cooperation and convert TGF-  from
a potent growth inhibitor to a tumor promoter are not fully understood. In this
work we report that TGF- directly regulates alternative splicing of cancer stem
cell marker CD44 through a phosphorylated T179 of SMAD3-mediated inter-
action with RNA-binding protein PCBP1. We show that TGF-  and EGF re-
spectively induce SMAD3 and PCBP1 to colocalize in SC35 positive nuclear
speckles, and the two proteins interact in the variable exon region of CD44
pre-mRNA to inhibit spliceosome assembly in favor of expressing the mesen-
chymal isoformCD44s over the epithelial isoformCD44E.We further show that
the SMAD3-mediated alternative splicing is essential to the tumor-promoting
role of TGF-  and has a global influence on protein products of genes instru-
mental to epithelial to mesenchymal transition and metastasis.
#3033 The PRL family of tyrosine phosphatases as a novel drug targets in
acute lymphoblastic leukemia. Jessica S. Blackburn. University of Kentucky,
Lexington, KY.
The aggressive and unpredictable behavior of acute lymphoblastic leukemia
(ALL) presents a major clinical challenge in both the pediatric and adult setting.
The development of new and better chemotherapies for this disease requires a
detailed understanding of the genes and pathways that drive ALL malignancy.
Phosphatases are emerging as newdrug targets with important roles in leukemia
progression. To determine the extent to which phosphatases play a role in ALL
malignancy, we used CRISPR/Cas9 to knock out expression of 255 individual
phosphatases in human T-cell acute lymphoblastic leukemia cell lines and
screened for deleterious effects on cell viability. Top hits from this screen in-
cluded the protein tyrosine phosphatase type IVa family, also known as the
PRLs. PRL3 is genomically amplifıed in a subset of human T-ALL, and more
than 50% of human ALL patients have signifıcantly higher expression of PRL2
and/or PRL3, compared to normal lymphocytes, suggesting that these PRLsmay
play an important role in ALLmalignancy. TransgenicMyc-induced ALLmod-
els in zebrafısh showed that overexpression of PRL2 and PRL3 signifıcantly
shortened latency of primary and relapse ALL, enhanced leukemia stem cell
self-renewal (PRL2) and prevented apoptosis after standard chemotherapy
treatment (PRL3). Finally, a specifıc PRL inhibitor strongly induced apoptosis of
PRL-expressing ALL cells in a dose-dependent manner, in both zebrafısh mod-
els in vivo and human cell lines in vitro. We have identifıed several FDA-ap-
proved, general phosphatase inhibitors that have potent anti-PRL activity and
are capable of killingALL cells in vitro. Current work is focused onmoving these
inhibitors into pre-clinical testing using patient-derived xenografts. Pull-down
approaches are also being used to identify the substrates of PRL phosphatase
activity that are critical to ALL survival and may represent new, tractable drug
targets for the treatment of ALL.
#3034 A programmed ribosomal frameshifting defect potentiates the
transforming activity of the JAK2-V617F mutation. Yousuf A. Khan,1 Sergey
O. Sulima,2 Joe Kendra,1 VivekM. Advani,1 John E. Jones,1 Joseph Briggs,1 Kim
de Keersmaecker,2 Jonathan D. Dinman1. 1University of Maryland College Park,
Potomac, MD; 2KU Leuven Department of Oncology, Leuven, Belgium.
The JAK-STAT pathway is one of the major mechanisms through which
cellular proliferation, differentiation, migration, survival and apoptosis are reg-
ulated in response to external stimuli. Promiscuous activation of this pathway is
a major driver in the pathogenesis of myeloproliferative neoplasms, often char-
acterized by clonal expansion of maturemyeloid cells. The JAK2-V617F allele is
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the most common and well characterized mutation linked to this class of leuke-
mias. A change ofG toT at nucleotide 1849 of the coding sequence (CDS) results
in substitution of valine to phenylalanine at codon 617. JAK2-V617F mutant
cells have strongly increased activation of JAK-STAT signaling, which can par-
tially be explained by its ability abolish inhibition of kinase activity and increase
the Km of the enzyme. It is however unclear if these effects are suffıcient to
explain the strong activation of the JAK-STAT pathway induced by the V617F
mutation. Here, we demonstrate that this mutation destabilizes a programmed
-1 ribosomal frameshift (-1 PRF) signal in the JAK2mRNA, leading to decreased
rates of -1 PRF promoted by this element. There is an inverse relationship be-
tween -1 PRF and mRNA stability. Thus, decreased -1 PRF results in increased
abundance of the JAK2 mRNA and increased JAK2 protein expression. Prior
studies established that elevated expression levels of JAK proteins are suffıcient
to transform cells in vitro, suggesting that -1 PRF may normally help to limit
JAK2 expression. Silent protein coding changes in the -1 PRF signal slippery
sequence ablating JAK2 frameshifting also increased JAK2 expression and phe-
nocopied the transforming activity of JAK2-V617F in cell culture. Further, the
combination of the V617F and slippery site mutations conferred an additive
effect on cellular transformation. The presence at least three additional -1 PRF
signals in the JAK2 mRNA suggests that -1 PRF plays a signifıcant role in con-
trolling JAK2 expression.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: High
Throughput Genomics Dissecting Cancer Development and
Vulnerabilities
#3035 Decomposing oncogenic transcriptional signatures to generate
maps of divergent cellular states.William J. Kim,1 William C. Hahn,1 Jill Me-
sirov,2 Pablo Tamayo2. 1Dana-Farber Cancer Institute, Cambridge, MA; 2Uni-
versity of California San Diego, San Diego, CA.
The systematic sequencing of the cancer genome has provided a powerful
framework for identifying genetic alterations in cancer. However, a deeper un-
derstanding of the functional consequences of these alterations is necessary to
guide appropriate therapeutic strategies. Here, we describe Onco-GPS (Onco-
Genic Positioning System), a data-driven analysis framework, and associated
experimental and computational methodology, to organize individual tumor
samples with shared oncogenic alterations onto a referencemap defıned by their
underlying cellular states. Using this approach, we generated series of RAS/
MAPK sub-signatures that reflect known and novel downstream pathways.
These sub-signatureswere then used to classifyKRAS andBRAFmutant cancers
into sub groups or cell states, as represented in the novel visual paradigm “On-
coGPSmap”. OncoGPS approach was fırst applied to cancers with BRAFmuta-
tions. The approach not only accurately classifıed three groups of BRAFmutant
cancers that aligned with sensitivity to BRAF inhibitors, but also identifıed re-
sistancemechanisms associated with each state, validating the overall approach.
OncoGPS also identifıed four major cell states associated with KRAS mutant
cancers. Further characterization of the four cell states showed that multiple
molecular features representing epithelial-EMT states and activation of NF-B
pathway delineated two major “axes” of KRAS mutant cancers. In addition to
the pathways and cell states defıned in each group, the OncoGPS approach is
able to identify effective drug combinations which was experimentally tested
and confırmed. These results show that the Onco-GPS is an effective analytic
framework to explore the complex landscape of oncogenic cellular states across
cancers, and a powerful framework to summarize knowledge, establish relation-
ships, and generate more effective disease models for research or as part of
individualized precision medicine paradigms.
#3036 Real-time genomic characterization of metastatic pancreatic can-
cer to enable precision medicine. Andrew J. Aguirre,1 Scott Carter,1 Nicholas
Camarda,1ArezouGhazani,1 JonathanNowak,1AnnacarolinaDa Silva,1 Lauren
Brais,1 Dorisanne Ragon,1 Devin McCabe,1 Lori Marini,1 Kristin Anderka,2
Karla Helvie,1 Nelly Oliver,1 Ana Babic,1 Paul Shyn,3 Douglas Rubinson,1 Anuj
Patel,1 James Cleary,1 Nadine McCleary,1 Matthew Kulke,1 Thomas Clancy,1
Leona Doyle,1 Jason Hornick,1 Christine Ardito-Abraham,4 Ruth Yu,5 Michael
Downes,5 Ronald Evans,5 Richard A. Moffıtt,6 Jen Jen Yeh,6 William C. Hahn,1
Charles Fuchs,1 Robert Mayer,1 Nikhil Wagle,1 David Tuveson,7 Levi A. Gar-
raway,1 Brian M. Wolpin1. 1Dana-Farber Cancer Institute, Boston, MA; 2Broad
Institute, Cambridge, MA; 3Brigham and Women’s Hospital, Boston, MA; 4The
Lustgarten Foundation, Bethpage, NY; 5Salk Institute, La Jolla, CA; 6University of
North Carolina, Chapel Hill, NC; 7Cold Spring Harbor Laboratory and The Lust-
garten Foundation, Cold Spring Harbor, NY.
Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth-leading
cause of cancer-related death in theUnited States and is projected to become the
second leading cause by 2030. Most patients present with advanced disease and
die within 12 months of diagnosis. Recent genomic studies of primary pancre-
atic cancer resection specimens have identifıed severalmolecular alterations and
genomic subtypes of the disease that may guide precision medicine approaches
to clinical management. However, the molecular landscape of metastatic PDAC
has been less well characterized. Moreover, biopsy-driven studies in metastatic
PDAC have been historically very challenging due to the aggressive course of
this disease as well as the low-volume and heterogeneous nature of biopsies that
makes deepmolecular characterizationdiffıcult. Insuffıcient genomic analysis of
a patient’s tumor early in their disease course is amajor barrier to enrollment on
clinical trials of targeted therapies. To address these limitations, we have imple-
mented a multi-disciplinary clinical and research biopsy protocol to enable real
time comprehensive molecular characterization of metastatic PDAC biopsy
specimens. We have performed core needle biopsies of metastatic lesions in the
liver or peritoneal cavity in 42 patients at the time of initial presentation. A low
rate of complications was observed, with only a single patient having a self-
limited hemorrhagic complication after liver biopsy. On average, 4-6 separate
biopsy specimens were collected from each patient for histopathology and
genomic analysis. Whole exome sequencing (WES) was performed in a CLIA-
certifıed laboratory and a comprehensive molecular report of somatic altera-
tions and selected pathogenic germline variants was returned to the referring
clinician with a typical turn-around time of 3-5 weeks. We observed a striking
incidence of recurrent germline and somatic alterations in DNA-damage repair
genes, such as BRCA2, ATM andCHEK2.We also observed alterations in genes
with known therapeutic implications, such as BRAF, RNF43, STK11 and ROS,
and in select cases, these results guided choice of second or third line therapy. In
parallel toWES, we performed RNA sequencing on bulk tumor tissue and read-
ily identifıed expression signatures defıning multiple subtypes of tumor and
stroma thatmay have prognostic or therapeutic implications for tumor- or stro-
ma-directed therapies. Collectively, these results demonstrate the feasibility and
value of real-time genomic characterization of metastatic PDAC and provide a
path forward for improved stratifıcation and enrollment of PDAC patients on
molecularly defıned clinical trials.
#3037 Dissecting treatment resistance in patients with ovarian cancer and
PDX-models using single-cell RNA-sequencing. Benjamin Izar,1 Itay Tirosh,2
Elizabeth Stover,1 Asaf Rotem,1 Parin Shah,1 Mike Cuoco,2 Chris Rodman,2
Joyce Liu,1 Ursula Matulonis,1 Orit Rozenblatt-Rosen,2 Levi Garraway,1 Aviv
Regev2. 1Dana-Farber Cancer Institute, Cambridge, MA; 2Broad Institute, Cam-
bridge, MA.
Background: Ovarian cancer (OvCa) is frequently associated with malignant
effusions, which are complex ecosystems with heterogeneous populations of
malignant cells and non-malignant cells. Bulk RNA-seq or whole-exome se-
quencing (WES) only reflect average cellular behavior and thereby mask intrin-
sic cell diversity with potential relevance for treatment resistance. Approach: To
overcome some of these barriers, we applied single-cell RNA-sequencing
(scRNA-seq) to malignant and non-malignant cells isolated from patients with
platinum treatment resistant disease. Furthermore, we used patient-derived
xenograft (PDX) cohorts, in which we isolated cells for scRNA-seq from vehicle
tumors (VEH), treated the other models with carboplatin, and harvested cells at
the time of minimal residual disease (MRD) or disease progression (PROG).
Results: To date, we have profıled 12000 single cells from 12 patients with
treatment naïve (n3) or platinum-resistant disease (n9), including sequen-
tial sampling in 3 patients with resistant disease. We observed signifıcant inter-
and intra-individual transcriptional heterogeneity in malignant cells. A recur-
rent pattern across resistant patients was the differential expression of inflam-
matory pathways in a subset of cells. In a patient with three consecutive speci-
mens, we observed increasing accumulation of cells expressing a cell state
characterized by tumor necrosis factor alpha (TNF-a) signaling, Importantly,
these cells were genetically identical to the entire population, supporting the
hypothesis that non-encoded mechanisms conferred treatment resistance. In a
BRCA-mutant patient, unbiased analysis identifıed a stemness program in a
subpopulation of cells, which was genetically identical to other cells, indicating
phenotypic conversion. To systemically interrogatemechanisms of resistance to
platinum therapy, sequenced single cells isolated fromPDXmodels at three time
points (VEH, MRD and PROG). In a BRCA-WT PDX model, resistant cells
isolated at MRD and PROG shared a transcriptional program that was domi-
nated by expression of a STAT3 program. Ex vivo cultures from platinum-
resistant patients were exquisitely sensitivity to JAK/STAT3-inhibitor. Live cell
imaging revealed that STAT3-inhibition prevented spheroid formation, attach-
ment and clearance through a mesothelial monolayer in vitro. Conclusion: Our
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results indicate that non-encoded mechanisms play an important role in the
development of treatment resistance in ovarian cancer. Our initial studies indi-
cate an important role of inflammatory pathways in treatment resistance, in
particular STAT3 signaling, which can be overcome with specifıc inhibitors at
nanomolar concentrations. These data suggests that single-cell profıling can be
performed on clinical ovarian cancer specimens andmay yield novel therapeutic
avenues for patients with treatment-resistant ovarian cancer.
#3038 Bridging the gap between NGS data and its usability: cancer gene
discovery throughmassive-scale transcriptomic analyses anddevelopmentof
a powerful web-tool for dissemination of these fındings. Yashar Niknafs,
NicholasMolen, Balaji Pandian,Matthew Iyer, Arul Chinnaiyan.Univ. ofMich-
igan, Ann Arbor, MI.
Background: In a prior transcriptomic analysis focusedon lncRNA interrogation
using some of these data, we discovered tens of thousands of novel lncRNAs (Iyer
and Niknafs et al, Nature Genetics, 2015). Building on this analysis, we recently
developed amarkedly improved bioinformatics tool for novel gene/isoformdiscov-
ery frommassive RNA-seq datasets named TACO (Niknafs et al, NatureMethods,
In press, tacorna.github.io). TACO produces high-fıdelity transcript structure pre-
dictions from large RNA-seq datasets.We now set out to comprehensively leverage
both TACO and the publicly available RNA-seq data for discovery of novel tran-
scriptional cancer associations. Additionally, in order to widely disseminate these
fındings inanaccessiblemanner,wehavebuilt aweb-tool thatprovides the scientifıc
community access to these data and analyses. Methods: We have downloaded, cu-
rated, and processed 23,623 RNA-seq samples largely from the TCGA, ICGC,
GTEx, and CCLE, comprising 37 tissue types and over 35 cancer types. RNA-seq
data processing was performed using STAR, Cufflinks, Kallisto, and TACO. The
web tool for visualization and access to these data and analyses was built using a
JavaScript-based server infrastructure (Noje.js) and a relational PostgreSQL data-
base. Results: Generation of a consensus transcriptome from this large-scale RNA-
seq dataset via TACO resulted in the discovery of tens of thousands of novel tran-
scriptional elements, including intergenic non-coding RNAs and novel splice
isoforms of known genes. Such an expansive RNA-seq cohort that includes many
normal tissue samples enabled statistically powerful cancer association expression
analyses that revealed amyriad of novel cancer genes, especially in tissues for which
there was previously little-to-no normal tissue RNA-seq data (e.g., brain and pan-
creas). Many of these novel transcriptional elements discovered using TACOwere
also found to be cancer associated. We have built a web-tool to facilitate further
analysis and discovery using these data and analyses by the scientifıc community.
The web-tool provides a powerful and intuitive interface for researchers with little-
to-no bioinformatics expertise to leverage large-scale RNA-seq datasets. Conclu-
sion:Herewepresent the largest reportedcompendiumofRNA-seqdata, andreveal
many novel cancer gene associations. Using a new, powerful gene discovery tool,
TACO,we identify amultitudeofnovel transcriptional elements that are also cancer
associated. Despite the abundance of publicly available RNA-seq data, necessary
computing resources, data storage, and bioinformatics expertise are barriers to us-
ability of these data by scientifıc community. Our RNA-seq expression web-tool
bridges this gap, and enables users to powerfully interrogate cancer expression
across dozens of tumor and tissue types.
#3039 Combinatorial CRISPR-Cas9 gene knockout to enable genetic in-
teraction mapping in human cells. John Paul Shen, Dongxin Zhao, Roman
Sasik, Jens Luebeck, Ana Bojorquez-Gomez, Katherine Licon, Trey Ideker,
Prashant Mali. UCSD, La Jolla, CA.
Genetic interactions, in particular negative or ‘synthetic-lethal’ interactions for
which simultaneousdisruptionof twogenes causes cell killing, have implications for
therapeutic development. The feasibility of this approach has been demonstrated
with the recent approval of the drug olaparib, an inhibitor of PARP1, specifıcally for
tumors with loss-of-function mutations in BRCA1/2. However, beyond olaparib,
further applications of synthetic-lethal cancer therapy have been limited by poor
understanding of the important genetic interactions in a cancer cell, and how these
vary fromonecancer type toanotheror frompatient topatient.Toenable systematic
mapping of these genetic interaction networks, we developed a CRISPR-Cas9
screeningmethodology for knocking out single and pairs of genes in high-through-
put. Here, we combined multiplex targeting with array-based oligonucleotide syn-
thesis to create dual-gRNA libraries coveringup to 10^5defıned genepairs. In these
libraries, each construct bears twogRNAs,with eachgRNAdesigned to target either
a gene or a scrambled non-targeting sequence absent from the genome. We con-
ducted genetic interaction screens by transducing the dual-gRNA lentiviral library
into apopulationof cells stably expressingCas9,maintaining these cells in exponen-
tial growth over the course of four weeks, then sampling the relative changes in
gRNAs at days 3, 14, 21 and 28 post-transduction. To robustly quantify gene fıtness
and genetic interactions, we developed a computational analysis framework that
integrates all samples across themultiple days of the experiment.Using thismethod
we evaluated all pairwise gene knockout combinations among a panel of 73 genes
divided between tumor-suppressor genes (TSG) and cancer-relevant drug targets
(DT); including negative controls this amounted to a total of 23,652 combinations.
Experiments were performed in three cancer cell lines: HeLa, A549 and 293T. In
total 162 therapeutically relevant interactions were identifıed, of which 146 (90.1%)
were private to one cell line. None of the interactions were observed in all three cell
lines. These patterns replicated in low throughput assays with combinatorial drugs
at 80% precision. In summary, we have introduced a combinatorial CRISPR-Cas9
genetic interactionmapping technology that successfully identifıesmany therapeu-
tically-relevant genetic interactions in cancer and shows the great importance of
cellular context on the architecture of the genetic interaction network. Recognizing
that there will be great diversity in genetic interaction between different tumors it
will be important to perform future studies across a large number of samples, which
is enabled by the high-throughput method we have developed.
#3040 Functional genomic screening identifıesUSP11 as a novel regulator
of ER transcription in breast cancer. Lisa Dwane,1 Aisling E. O’Connor,2
Laoighse Mulrane,2 Annette M. Dirac,3 Karin Jirstrom,4 John P. Crown,5 Rene
Bernards,3 William M. Gallagher,2 Tríona Ní Chonghaile,1 Darran P.
O’Connor1. 1Royal College of Surgeons Ireland, Dublin, Ireland; 2Conway Insti-
tute, University College Dublin, Dublin, Ireland; 3Netherlands Cancer Institute,
Dublin, Netherlands; 4Malmö University Hospital, Dublin, Sweden; 5St Vincent’s
University Hospital, Dublin, Ireland.
Approximately 70% of breast cancers overexpress the estrogen receptor 
(ER) and depend on this key transcriptional regulator for growth and differ-
entiation. The discovery of novel mechanisms controlling ER function repre-
sent major advances in our understanding of breast cancer progression and
potentially offer attractive new therapeutic opportunities. Here, we investigated
the role of deubiquitinating enzymes (DUBs), which act to remove ubiquitin
moieties from proteins, in regulating transcriptional activity of ER in breast
cancer. To identify DUBs involved in the regulation of ER transcriptional
activity, we performed an RNAi loss-of-function screen using a library of
shRNA vectors targeting all human DUB genes. The DUB library consisted of
pools of four non-overlapping shRNAs targeting all 108 known or putative
DUBs (432 shRNAs in total). We found that suppression of a number of DUBs
markedly repressed or enhanced the activity of an estrogen-response-element
(ERE) luciferase reporter following estradiol (E2) stimulation. Of particular in-
terest, suppression of the BRCA2-associated DUB, USP11, was found to down-
regulate ER transcriptional activity. Subsequent validation using two individ-
ual siRNAs targeted to USP11 revealed a notable reduction in expression of
endogenous ER target genes in the ZR-75-1 cell line, as quantifıed using qRT-
PCR. Immunoprecipitation of ER revealed no physical interaction with
USP11, however E2 stimulation resulted in translocation of USP11 to the nu-
cleus, suggesting a potential role in E2-induced transcription. Furthermore,
USP11 expression was found to be upregulated in the estrogen-independent cell
line LCC1 when compared to their parental MCF7 cells. Knockdown of USP11
in LCC1 cells resulted in decreased mRNA expression of a panel of ER target
genes, suggesting a role for USP11 in an estrogen independent setting. To sup-
port the prognostic relevance of USP11, immunohistochemical staining of a
breast cancer tissuemicroarray (n144) was performed. Kaplan-Meier analysis
of this cohort revealed a highly signifıcant association between poor overall
survival (OS) (p0.030) and breast cancer-specifıc survival (BCSS) (p0.041).
In silico analysis of publically available breast cancer gene expression datasets
further supported an association between high USP11 mRNA levels and poor
prognosis. We observed a signifıcant correlation between high expression of
USP11 mRNA in ER-positive patients and poor distant metastasis-free survival
(DMFS) (HR 2, CI 1.37-2.91, p0.00023). This correlation was also signifıcant
in ER-positive patients who had received endocrine therapy only (HR 2.9, CI
1.63-5.15, p0.00015). These results suggest a role for USP11 in driving cellular
growth and identify USP11 as novel therapeutic target in breast cancer.
#3041 Duplex Sequencing detects cancer-associated mutations arising
during normal aging: Clonal evolution over a century of human lifetime.
Jesse J. Salk,1 ElisabethMaritschnegg,2 Paul Speiser,2 Robert Zeillinger,2 Rosana
Risques,1 Lawrence A. Loeb1. 1University of Washington, Seattle, WA; 2Medical
University of Vienna, Vienna, Austria.
High-throughputDNAsequencing has fundamentally changed practice stan-
dards in clinical oncology. We can now systematically examine the dysfunc-
tional genes and pathways of individual tumors and can often pair these with
targeted therapies. Moreover, NGS has improved our ability to resolve molecu-
lar heterogeneity, such as results from evolving subclones within a tumor or
admixtures of cancer-derived andnormalDNA in liquid biopsies.However, this
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remains imperfect. With standard NGS, sequencing errors create a background
that obscures variants present at less than 1-2%. Methods of tag-based error
correction improve accuracy, but most rely on hemimolecular tagging and are
thus still limited by certain types of errors caused by DNA damage. Our group
pioneered Duplex Sequencing, an error correction technology that indepen-
dently genotypes and compares both single-stranded halves of individual DNA
duplexes. This approach improves sequencing accuracy by 100,000-fold and
allows detection of a singlemutation among tenmillion unmutated nucleotides.
We carried out Duplex Sequencing on uterine lavages from women with and
without high-grade serous ovarian cancer to determine the sensitivity for iden-
tifying tumor-derived TP53 mutations as a screening test. Under blinded con-
ditions we detected tumor-derived mutations in 80% of cancer cases. However,
in addition, we found that nearly all women, including those without cancer,
carried very low frequency TP53mutations that did not originate from a tumor.
These could not be explained by technical errors, as they exhibited a strong
signature of positive selection, indicated by higher-than-random non-synony-
mous fraction, substantial clustering in cancer-associated hotspots and a spec-
trum, exonic distribution and predicted pathogenicity closely mirroring TP53
mutations in cancer databases. Furthermore, abundance of these “biological
background” mutations increased with age. To more broadly investigate the
extent of clonal evolution in normal aging, we used Duplex Sequencing to ex-
amine tissue specimens from two individuals without cancer, differing in age by
101 years. We assessed relative mutation load in 22 cancer-associated genes and
one non-cancer associated gene in 19 different tissues. Initial results indicate
that the extent of age-associatedmutation accumulation varies by organ and the
pattern of apparent clonal selection is influenced by both tissue type and genetic
context. Our fındings illustrate the near-universal presence of cancer-like mu-
tations arising from age-associated processes inmultiple non-neoplastic tissues.
Somatic clonal evolution appears to be a ubiquitous part of human life. Beyond
many biological implications, this highlights an important specifıcity challenge
that must be accounted for when using ultra-accurate sequencing technologies
for cancer screening and other sensitive diagnostics.
MOLECULARANDCELLULARBIOLOGY /GENETICS: The
Riddle of theNoncoders: New Functional Roles formiRNAs, Long
Noncoding RNAs, andmRNAs
#3042 MIR142 loss-of-function mutations promote leukemogenesis
through derepression ofASH1L resulting in increasedHOX gene expression.
Juo-Chin Yao,1 Terrence N. Wong,1 Maria Trissal,1 Rahul Ramaswamy,1 Yap-
ing Sun,2 Pavan R. Reddy,2 Daniel C. Link1. 1Washington University in St. Louis,
St. Louis, MO; 2University of Michigan, Ann Arbor, MI.
MIR142 mutations have been identifıed in acute myeloid leukemia (AML)
and non-Hodgkins lymphoma. In AML, all MIR142 mutations localize to the
miR-142-3p seed sequence.We show thatmutatedMIR142 is unable to suppress
several well-known targets of miR-142-3p. Interestingly, the mutations of miR-
142-3p result in their preferential loading into the RNA-induced silencing com-
plex, leading to the degradation of miR-142-5p. Accordingly, miR-142-5p ex-
pression is decreased in MIR142 mutated AML. Hence, MIR142 mutations in
AML disrupt both miR-142-3p/5p functions. Thus, we modeled the effect of
MIR142mutations on hematopoiesis usingMir142/mice.We show that loss
of miR142 results in signifıcant increases in myeloid hematopoietic stem/pro-
genitor cells (HSPCs), including granulocyte-macrophage progenitors, my-
eloid-biased multipotent progenitors (CD150 CD48 Flk2 Kit Sca lin-
eage) and CD229 myeloid-biased HSCs (CD150 CD48 Kit Sca
lineage). In contrast, there are signifıcant decreases of megakaryocyte-ery-
throid progenitors and erythroid precursors. Although the number of HSCs is
normal inMir142/mice, HSC transplantation suggest that they are myeloid-
biased. In AML, MIR142 mutations are commonly found in conjunction with
mutations of IDH1/2. To assess the importance of this association, we trans-
duced wildtype or Mir142/ HSPCs with retrovirus expressing IDH2 R172K
and then transplanted into lethally irradiated recipients. Expression of IDH2
R172K alone was suffıcient to induce a lethal myeloproliferative neoplasm
(MPN). In contrast, Mir142/ alone did not result in MPN. However, loss of
Mir142 cooperates with IDH2 R172K to produce a more severe MPN, with
increased CD34 blasts and more severe anemia. Moreover, secondary trans-
plantation shows thatMir142/ x IDH2R172K cells but not IDH2R172K cells
effıciently engraft and induce MPN, suggesting that loss of miR142 increases
leukemia-initiating activity. We identify the histone methyltransferase ASH1L
as a target gene of miR142 that contributes to altered hematopoiesis in
Mir142/ mice. The 3’-untranslated region of ASH1L has four miR-142-3p
binding sites, and luciferase reporter assay shows that miR142 suppresses its
translation by 80%.Consistentwith this observation,Ashl1 protein expression is
3-fold higher in Mir142/ bone marrow. ASH1L is a key positive regulator of
HOXgene expression. Accordingly, we observedmarkedly (5-10 fold) increased
HoxA9/A10 expression in myeloid progenitors in Mir142/ mice. Likewise,
HoxA9/A10 expression is increased in CD34 blasts from Mir142/ x IDH2
R172K transplantedmice. Of note, increasedHoxA9 expression has been shown
to cooperatewithmutant IDH1 to induceAML inmice. Together, these fındings
support a model in which loss-of-function mutations of MIR142 contribute to
hematopoietic malignancies by derepressing ASH1L and inducing HOXA9/10
gene expression.
#3043 A novel Cpa3-Cre; miR-9fl/fl mouse reveals a functional role for
miR-9 in promoting mast cell invasion via up-regulation of CMA1. Joelle M.
Fenger,1 Feng Xu,1 Xaioli Zhang,1 Peter Y. Yu,1 Misty D. Bear,2 Shanice L.
Reynolds,1 Michael L. Pennell,1 Vincenzo Coppola,1 William C. Kisseberth,1
Stephen J. Galli,3 Cheryl A. London1. 1TheOhio StateUniversity, Columbus, OH;
2Kansas State University, Manhattan, KS; 3Stanford University, Columbus, CA.
Introduction: Our laboratory previously demonstrated that miR-9 promotes
the invasive properties of normal andmalignant mast cells and that overexpres-
sion of miR-9 is associated with spontaneous metastasis in canine mast cell
tumors (MCTs), a well-established large animal model of malignant mast cell
disease. The purpose of this study was to further investigate the biologic effect
andmechanisms by whichmir-9 enhances normal mast cell invasion. Methods:
Bone marrow-derived mast cells (BMMCs) were generated from Cpa3-Cre;
miR-9fl/fl, and Cpa3-Cre; miR-9fl/fl mice and Taqman miRNA assays were
used to quantify mature miR-9 expression. BMMCs were evaluated for differ-
ences in proliferative capacity, the ability to migrate through Matrigel, sensitiv-
ity to degranulation, and the expression and release of growth factor expression
and release following chemical stimulation. RNA sequencing was performed by
the OSUCCC Genomics Resource and changes in protein and mRNA expres-
sion were validated with Western blotting and quantitative PCR. Results and
Conclusions: We generated a transgenic mouse carrying a floxed STOP-miR-9
transgene (miR-9fl/fl) in which expression of miR-9 occurs only after Cre-
mediated recombination and crossed these mice with Cpa3-Cre mice which
express Cre recombinase under the control of the carboxypeptidase A3 (Cpa3)
promoter, restricting expression of miR-9 to mast cells and basophils. Bone
marrow-derived mast cells (BMMCs) derived from Cpa3-Cre;miR-9fl/fl mice
signifıcantly enhanced the invasive phenotype of mast cells. Moreover, the en-
forced expression of miR-9 in BMMCs markedly changed the production and
release of cytokine and growth factors in response to chemical stimulation, in-
cluding substantial up-regulation of IL-4, IL-13, and GM-CSF transcript and
enhanced TGF-1 release. RNA sequencing revealed a unique transcriptional
profıle associated with miR-9 over-expression in the Cpa3-Cre;miR-9fl/fl de-
rived BMMCs and identifıed increased expression of several mast cell-restricted
proteases involved in extracellular matrix and tissue remodeling including
CMA1 and MCP-6. Furthermore, transduction of Cpa3-Cre;miR-9fl/fl de-
rived BMMCs with CMA1 shRNA abrogated miR-9-dependent mast cell inva-
sion. Studies are underway to investigate the regulatory pathway mediated by
miR-9 that contributes to CMA1 up-regulation and promotes the invasive phe-
notype. In summary, these data provide evidence supporting a critical role for
miR-9 in mast cell invasion and suggest that dysregulation of miR-9 may con-
tribute to pathologic conditions involvingmast cell-mediated tissue remodeling.
#3044 Rapiddecay of engulfed extracellularmiRNAbyXRN1exonuclease
promotes transient epithelial-mesenchymal transition. Joséphine Zangari,1
Marius Ilie,1 Florian Rouaud,2 Laurie Signetti,1 Mickaël Ohanna,2 Robin Di-
dier,2 Barnabé Roméo,1DanaGoldoni,1 NicolasNottet,3 Cathy Staedel,4 Jocelyn
Gal,5 Bernard Mari,3 Baharia Mograbi,1 Paul Hofman,1 Patrick Brest1. 1Univer-
sité Côte d’Azur, FHU Oncoage, Nice, France; 2Université Côte d’Azur, Nice,
France; 3Université Côte d’Azur, Valbonne, France; 4Université de Bordeaux,
Bordeaux, France; 5Université Côte d’Azur, Antoine Lacassagne Cancer Center,
Nice, France.
Background: Extracellular vesicles (EVs) have been shown to play an impor-
tant role in intercellular communication as carriers of DNA, RNA and proteins.
While the intercellular transfer of miRNA thorough EVs has been widely stud-
ied, the stability of extracellularmiRNA (ex-miRNA) once engulfed by recipient
cell remains to be determined. Materials and Methods: Lung cancer cells (A549
cell line) were incubated with neutrophils or their supernatant or isolated EVs
from these supernatant. Kinetics of expression of miR-223-3p were followed by
RT-qPCR. FOXO1 expression and EMT expression markers were used as end-
points to follow effective effect or miR-223-3p in recipient cells. Results: We
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identifıed the ex-miRNA-directed phenotype to be transient due to the rapid
decay of the ex-miRNA. We demonstrated that the ex-miR-223-3p transferred
from neutrophils to cancer cells was functional as demonstrated by the de-
creased expression of its target, FOXO1, and the occurrence of epithelial-mes-
enchymal transition reprogramming. We showed that the engulfed ex-miRNA,
unlike endogenous miRNA, was unstable, enabling dynamic regulation and a
return to a non-invasive phenotype within less than 8 hours. This transient
phenotype could be modulated by targeting XRN1/PACMAN exonuclease. In-
deed, its silencing was associated with slower decay of ex-miR-223-3p and sub-
sequently prolonged the invasive properties. Conclusion: We showed that the
“steady step” level of engulfed miRNA (ex-miR-223-3p) and its subsequent ac-
tivity was dependent on the presence of a donor cell in the surroundings to
constantly fuel the recipient cell with ex-miRNAs and of XRN1 exonuclease,
which is involved in the decay of these imported miRNAs.
#3045 Engineering Mesenchymal Stem Cells (MSCs) to support tumor-
targeted delivery of exosome-encapsulated microRNA-379. Killian P.
O’Brien, Katie Gilligan, Sonja Khan, Brian Moloney, Kerry Thompson, Pierce
Lalor, Peter Dockery, Helen Ingoldsby, Michael J. Kerin, Roisin M. Dwyer. Na-
tional University of Ireland Galway, Galway, Ireland.
Mesenchymal Stem Cells (MSCs) are multipotent stromal cells known to
migrate specifıcally to the sites of tumors and metastases, raising potential as
tumor-targeted delivery vehicles for therapeutic agents. MSCs secrete exosomes
containing genetic material including microRNAs (miRs), that are effectively
taken up by cells. Previous work has shownmiR-379 to be signifıcantly reduced
in breast tumor tissue, highlighting a potential tumor suppressor role. This study
aimed to establish amechanism of action for miR-379, and to engineerMSCs to
secrete exosomes enriched with the miR for tumor-targeted delivery. Methods:
RNA was isolated from breast tumors and matching lymph node metastases
from the same patients, and miR-379 expression quantifıed by RQ-PCR.
HCC1954 breast cancer cells were transducedwith lentivirus to express elevated
miR-379 (HCC-379) or a control sequence (HCC-NTC). Cells were implanted
into the mammary fat pad (MFP) of mice and tumor progression monitored.
Subsequently, MSCs were transduced to generate MSC-379 and MSC-NTC.
MSC-secreted exosomes were isolated by differential centrifugation, microfıl-
tration and ultracentrifugation. The morphology, size and number of isolated
exosomes was characterized using Transmission ElectronMicroscopy,Western
Blot andNanoparticle TrackingAnalysis respectively. ExosomalmiRswere ana-
lysed by RQ-PCR. MFP tumors were established using HCC1954-luciferase
cells, followed by IV injection of MSC-379 or MSC-NTC cells, or sequential
doses of exosomes derived from either cell population. Results: miR-379 expres-
sion was signifıcantly reduced in lymph node metastases compared to primary
tumors from the same patients (p0.009), supporting a tumor suppressor role.
Analysis of HCC-379 and HCC-NTC tumor growth In Vivo showed no differ-
ence in tumor size, however an increase in tumour necrosis (5-50%) and de-
crease in lymph node invasion was observed in HCC-379 tumors. Investigation
of a potential role for miR-379 in regulating COX-2, revealed an inverse rela-
tionship (r  -0.48, p0.02) at a mRNA level, further confırmed at a protein
level. MSC-379 cells showed no signifıcant change in migratory or proliferative
capacity In Vitro. MSC-secreted exosomes were confırmed to be the correct
morphology and size (30-120nm), and to express the exosome-associated pro-
teinCD63.An increase inmiR-379 (5 fold)was observed in exosomes secreted
by MSC-379 compared to MSC-NTC cells. Administration of MSC-379 or
MSC-NTC cells, or exosomes derived from either cell population, was well tol-
erated In Vivo with no adverse effects observed. Monitoring tumor response to
therapy using IVIS is ongoing. Conclusion: The data presented supports miR-
379 as a potent tumor suppressor in breast cancer, mediated in part through
regulation of COX-2. Engineering tumor-targeted MSCs to secrete exosomes
enriched with miR-379 holds exciting potential as a novel therapy for breast
cancer.
#3046 Identifıcation of lncRNAs involved in regulation of androgen re-
ceptor splice variants inprostate cancer throughCRISPR-Cas9-based screen.
Tsui-Ting Ho, Pratirodh Koirala, Nanjiang Zhou, Yin-Yuan Mo. Univ. of Mis-
sissippi Medical Ctr. Cancer Inst., Jackson, MS.
Prostate cancer is the second leading cause of death in men in the USA.
Despite the high initial response rates to androgen deprivation therapy (ADT),
these tumors ultimately develop the resistance, i.e., castration-resistant prostate
cancer (CRPC). One of the contributing factors is constitutive expression of
androgen receptor (AR) splice variants such as AR3, amajor splice variant iden-
tifıed in clinical specimens. However, little is known about long non-coding
RNAs (lncRNAs) on regulation of AR splicing. In this study, we generate
CRISPR/Cas9-based libraries against a focus group of lncRNAs and an AR3
mini-gene reporter to identify lncRNAs involved in regulation of AR splicing.
The principles of this screening system is that only sgRNAs capable of promot-
ing AR3 expression will be enriched in SAM (Synergistic Activation Mediator)
library, whereas these clones are lost from the knockout gRNA library after
selection. This screen identifıes several candidate lncRNA sgRNAs and dual
gRNAs (targeting Lnc-DC/ Har1B/ LINC00568/ DHRS4-AS1/ SNHG5). Fur-
ther characterization confırms the regulation of their corresponding endoge-
nous genes and AR3 expression. Importantly, overexpression of Lnc-DC in-
creases AR3 level and enhances tumor cell growth in response to androgen
deprivation. Moreover, while ectopic expression of DHRS4-AS1 increases,
DHRS4-AS1 knockout suppresses AR3. Finally, rescue experiments restore the
ability of DHRS4-AS1 to induce AR3, further supporting a role for Lnc-DC and
DHRS4-AS1 in AR3 regulation. Together, we demonstrate that the CRISPR/
Cas9-based screening system provides a powerful tool for lncRNA research. As
a result, these lncRNAsmay serve as biomarkers to predict the response to ADT
or therapeutic targets for treatment of CRPC.
#3047 PRC2-mediated silencing of circRNA CDR1as drives miR-7-inde-
pendent melanoma metastasis. Doug Hanniford,1 Rana Moubarak,1 Jochen
Imig,1 Alejandro Ulloa,1 Beatriz Sanchez Sendra,1 Alcida Karz,2 Iman Osman,1
Ioannis Aifantis,1 Eva Hernando1. 1New York University School of Medicine,
New York, NY; 2Duke University, Durham, NC.
Circular RNAs are a novel class of non-coding RNAs with functions that
remain poorly characterized in normal and pathological conditions. CDR1as is
a non-canonical circRNA observed to act as a sponge for miR-7 in brain tissues.
Analysis of RNA-seq data of melanocytes and melanoma cell lines and short-
term cultures revealed loss of CDR1as expression as a hallmark of melanoma
cells. We confırmed silencing of CDR1as in melanoma cells and tissues by RT-
qPCR using divergent primers. Clinically, we observed CDR1as loss associated
with metastatic progression and poor patient outcomes in a cohort of fresh-
frozen melanoma tissue samples. Depletion of CDR1as in melanoma cell lines
enhanced invasion in vitro and lung metastasis in vivo, demonstrating func-
tional signifıcance of CDR1as silencing. Surprisingly, CDR1as depletion had no
clear effect on miR-7 activity in melanoma cells, and miR-7 inhibition was in-
suffıcient to rescue CDR1as silencing-induced invasion. Moreover, GSEA anal-
yses of proteomic profıling of melanoma cells depleted of CDR1as revealed
reductions of proteins involved in oxidative phosphorylation (OXPHOS) and
mitochondrial function, suggesting CDR1as loss may alter metabolism of mel-
anoma cells. Mining of CLIP-Seq data sets and subsequent RIP-PCR revealed
direct interactions of CDR1aswith the IGF2BP family of proteins andTARDBP,
each of which are involved in regulation of mitochondrial function. These data
suggest that CDR1as could regulate the subcellular localization and/or function
of proteins involved inOXPHOS andmitochondrial respiration. To understand
the upstream mechanism driving CDR1as loss in melanoma, we sought to ex-
amine the primary transcript from which CDR1as arises. Interestingly, exami-
nation of the CDR1as locus revealed an upstream long non-coding RNA,
LINC00632, as a plausible primary transcript of CDR1as. CDR1as and
LINC00632 expression is strikingly correlated across human tissues and inmel-
anoma cell lines (r.65). Moreover, depletion of LINC00632 using GapmeRs
reduced expression of CDR1as, suggesting they arise from the same precursor
transcript. Intriguingly, from data mining of ChIP-Seq datasets, we observed
that the PRC2-dependent repressive chromatin mark H3K27me3, is abundant
in the genomic locus of LINC00632 in melanoma cells. We validated the pres-
ence of H3K27me3 at LINC00632 by ChIP-PCR in melanoma cells lacking
CDR1as expression. Strikingly, treatment of such melanoma cell lines with the
EZH2 inhibitor, GSK126, induced robust re-expression of both CDR1as and
LINC00632, and removal of H3K27me3 at LINC00632. Our data document that
CDR1as is epigenetically silenced inmelanoma, and its loss promotesmelanoma
invasion and metastasis. Moreover, CDR1as loss could contribute to metabolic
adaptations during metastasis through misregulation of RNA binding proteins.
#3048 A noncoding function of TYRP1 mRNA promotes melanoma
growth. Marie-Dominique Galibert,1 David Gilot,1 Mélodie Migault,1 Laura
Bachelot,1 Fabrice Journe´ 2 Alijosja Rogiers,3, Emmanuelle Donnou-Fournet,1
ArianeMogha,1 NicholasMouchet,1 Marie-Laure Pinel-Marie,4 BernardMari,5
Tristan Montier,6 Sebastien Corre,1 Arthur Gautron,1 Florian Rambow,3 Petra
El Hajj,2 Rania Ben Jouira,7 Sophie Tartare-Deckert,7 Jean-ChristopheMarine,3
Brice Felden,4, Ghanem Ghanem2. 1CNRS UMR6290 - IGDR / University of
Rennes, Rennes, France; 2Institu Jules Bordet, Universite´ Libre de Bruxelles, Brus-
sels, Beligum; 3VIB Center for Cancer Biology, Leuven, Belgium; 4INSERMU835,
Universite´ de Rennes I, Rennes, France; 5CNRS UMR 7275, Sophia Antipolis,
France; 6INSERM U1078, Universite´ de Bretagne Occidentale, Universite´ Euro-
pe´ enne de Bretagne, Brest, France; 7INSERM U1065, C3M, Nice, France.
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RNAs competition to bind miRNA has been proposed to influence biological
systemswhether theseRNAs are implicated in diseases onset is unclear.Here, we
report that TYRP1 mRNA, in addition to encoding tyrosinase-related protein 1
(TYRP1), indirectly governs cell proliferation by sequestering miR-16 on non-
canonical miRNA response elements (MREs). Consequently, sequestered
miR-16 is no longer able to repress its mRNA targets such as RAB17, which we
show is involved in melanoma cell proliferation and invasion. Restoration of
miR-16 tumor suppressor function can be achieved in vitro by silencing TYRP1
or increasingmiR-16 expression levels. Importantly, TYRP1-dependentmiR-16
sequestration can also be overcome in vivo using small oligonucleotides that
mask miR-16 binding sites on TYRP1 mRNA. Together, our fındings assign a
pathogenic noncoding function to TYRP1 mRNA and underscore miRNA dis-
placement as a new antimelanoma targeted therapeutic approach.
TUMOR BIOLOGY: Early Stages of Metastatic Dissemination
#3049 Tracing the origin of disseminated tumor cells in breast cancer
using single-cell sequencing. JonasDemeulemeester,1 ParveenKumar,2 ElenK.
Møller,3 Silje Nord,3 David C. Wedge,4 April Peterson,5 Randi R. Mathiesen,3
Renathe Fjelldal,3 Masoud Z. Esteki,2 Koen Theunis,2 Elia F. Gallardo,2 Jason
Grundstad,5 Elin Borgen,3 Lars O. Baumbusch,3 Anne-Lise Børresen-Dale,3
Kevin P. White,5 Vessela N. Kristensen,3 Peter Van Loo,1 Thierry Voet,2 Bjørn
Naume3. 1The Francis Crick Institute, London, United Kingdom; 2KU Leuven –
University of Leuven, Leuven, Belgium; 3Oslo University Hospital, Oslo, Norway;
4Wellcome Trust Sanger Institute, Cambridge, United Kingdom; 5University of
Chicago, Chicago, IL.
Background. Single-cell micro-metastases of solid tumors often occur in
the bonemarrow. These disseminated tumor cells (DTCs) may resist therapy
and lay dormant or progress to cause overt bone and visceral metastases. The
molecular nature of DTCs remains elusive, as well as when and from where
in the tumor they originate. Here, we apply single-cell sequencing to identify
and trace the origin of DTCs in breast cancer. Results. We sequence the
genomes of 63 single cells isolated from six non-metastatic breast cancer
patients. By comparing the cells’ DNA copy number aberration (CNA) land-
scapes with those of the primary tumors and lymph node metastasis, we
establish that 53% of the single cells morphologically classifıed as tumor cells
are DTCs disseminating from the observed tumor. The remaining cells rep-
resent either non-aberrant ‘normal’ cells or ‘aberrant cells of unknown ori-
gin’ that have CNA landscapes discordant from the tumor. Further analyses
suggest that the prevalence of aberrant cells of unknown origin is age-depen-
dent, and that at least a subset is hematopoietic in origin. Evolutionary
reconstruction analysis of bulk tumor and DTC genomes enables ordering of
CNA events in molecular pseudo-time and traced the origin of the DTCs to
either the main tumor clone, primary tumor subclones, or subclones in an
axillary lymph node metastasis. Conclusions. Single-cell sequencing of bone
marrow epithelial-like cells, in parallel with intra-tumor genetic heteroge-
neity profıling from bulk DNA, is a powerful approach to identify and study
DTCs, yielding insight into metastatic processes. A heterogeneous popula-
tion of CNA-positive cells is present in the bone marrow of non-metastatic
breast cancer patients, only part of which are derived from the observed
tumor lineages.
#3050 Polymorphisms in the arntl2 promoter affect breast cancer metas-
tasis susceptibility. Ngoc-Han Ha, Kent Hunter. National Cancer Institute,
Bethesda, MD.
Breast cancer mortality is primarily due to metastatic lesions rather than
primary tumors, yet relatively little is known regarding the mechanisms of met-
astatic breast cancer, making it diffıcult to identify patients who are at risk for
metastatic disease. Our hypothesis suggests that inherited germline mutations
contribute tometastatic disease and that these single nucleotide polymorphisms
(SNPs) could be used to predict outcome in breast cancer patients. To investi-
gate the effect of inherited SNPs on metastasis, we used a mouse genetics ap-
proach comparing strains with high (FVB) and low (MOLF) metastatic pheno-
types and identifıed Arntl2, a circadian rhythm transcription factor, as a gene
whose differential expression predicted outcome in breast cancer patients. To
identify SNP differences in Arntl2 between MOLF and FVB, we performed
whole genome sequencing ofMOLF and compared it to the FVB genome. Over-
lapping the data with DNase hypersensitivity sites revealed 10 SNPs in the pre-
dicted promoter of Arntl2. To test the causative role of the SNPs on Arntl2
expression in vivo, metastatic cell lines were engineered using the CRISPR-Cas9
approach to specifıcally replace the FVBArntl2 promoter with that ofMOLF. In
agreement with our hypothesis, substitution of the MOLF promoter reduced
Arntl2 transcript levels and subsequently decreased lung metastases in ortho-
topic implantation assays. In vitro pulldown experiments with strain-specifıc
promoter probes revealed potential differential binding of chromatin modifıer
proteins, demonstrating the signifıcance of the SNPs in regulating Arntl2 tran-
scription. Finally, analysis of SNPs associated with Arntl2 expression in a cohort
of Chinese breast cancer patients revealed signifıcant correlation of Arntl2 ex-
pression with overall survival, validating this gene as a marker in humans. Since
Arntl2 is a transcription factor, current studies are focused on identifying
Arntl2-regulated genes to investigate downstream pathways involved in metas-
tasis. This study has important implications regarding the role of circadian
rhythm in cancer progression andprovides a potentialmechanism to explain the
increased risk of breast cancers in nightshift workers. Furthermore, this pro-
vides the fırst evidence that transcriptional control elements can be engineered
using CRISPR-Cas9 to establish the causative role of SNPs in inherited suscep-
tibility to cancer metastasis.
#3051 Mechanism of early dissemination andmetastasis in Her2mam-
mary cancer. Kathryn Harper,1 Maria Soledad Sosa,1 David Entenberg,2 He-
dayatollah Hosseini,3 Julie Cheung,1 Rita Nobre,1 Alvaro Avivar-Valderas,1
Chandandaneep Nagi,1 Nomeda Girnius,4 Roger Davis,4 Eduardo Farias,1 John
Condeelis,2 Christoph A. Klein,3 Julio A. Aguirre-Ghiso1. 1Icahn School of Med-
icine at Mount Sinai, New York, NY; 2Albert Einstein College of Medicine, New
York, NY; 3University of Regensburg, Regensburg, Germany; 4University of Mas-
sachusetts Medical School, Worcester, MA.
Metastasis is the leading cause of cancer related deaths and these lesions
develop from disseminated cancer cells (DCC) that can remain dormant.
Metastasis initiating cells are thought to originate from a subpopulation
present in progressed invasive tumors. However, DCCs detected in patients
before the manifestation of breast cancer metastasis contain fewer genetic
abnormalities than primary tumors or than DCCs from patients with metas-
tases. These fındings and those in pancreatic cancer and melanoma models
argued that dissemination might occur during early stages of tumor evolu-
tion. Yet, the mechanisms that might allow early-disseminated cancer cells
(eDCC) to complete all steps of metastasis were unknown. Here we show that
in early lesions (EL), before any overt primary tumor (PT) masses are de-
tected, there is a sub-population of Her2/P-p38lo/P-ATF2lo/TWISThi/E-
cadherinlo early cancer cells that are invasive and disseminate to target or-
gans. Intra-vital imaging and organoid studies of early lesions revealed that
Her2 eDCC precursors locally invaded, intravasated and lodged in target
organs. Her2 eDCCs activated a Wnt-dependent EMT-like dissemination
program but without complete loss of epithelial phenotype that was reversed
by Her2 or Wnt inhibition. Surprisingly, while the majority of eDCCs are
TWISThi/E-cadherinlo and dormant, they eventually initiate metastasis. Our
work identifıes a mechanism for early dissemination whereby Her2 aber-
rantly activates a program similar tomammary ductal branching that spawns
eDCCs capable of forming metastasis after a dormancy phase.
#3052 Defıning the role of EMT in breast cancer dormancy andmetastasis
in vivo. Kay T. Yeung, Jing Yang. UC San Diego, San Diego, CA.
Breast cancer patients can develop metastases from dormant tumor cells
years after primary tumor resection and treatment. Despite the clinical sig-
nifıcance of metastatic latency, the exact cellular and molecular events reg-
ulating tumor dormancy remains largely unknown due to challenges in de-
tecting single dormant tumor cells in vivo and characterizing the dormant
tumor microenvironment. A developmental program termed Epithelial
Mesenchymal Transition (EMT) has been shown to play an important role in
tumor cell dissemination, tumor dormancy, and chemoresistance. During
EMT, stationary epithelial cells lose their epithelial characteristics, including
adherent junctions and apical-basal polarity, and acquire mesenchymal
shape and properties. These cells gain the ability to migrate into the circula-
tion, lodge into a distant organ, and form dormant tumor niches. We have
previously shown that reversal of EMT is a key driving force in dormant
tumor cell proliferation and macrometastasis formation in a skin carcinoma
mouse model. Here, we present a novel metastatic breast cancer mouse
model in which HER2-driven primary breast tumor cells are labelled with
red fluorescent protein with inducible EMT transcription factor TWIST1.
We established this mouse model by crossing the TetON-TWIST1 mice with
the MMTV-rtTA mice to generate the MMTV-rtTA/TetON-TWIST1 dou-
ble transgenic mice. To generate HER2-driven breast tumors in these mice,
we administered concentrated lentivirus that expresses both the HER2 gene
and the tdTomato fluorescent marker under one promoter via intraductal
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injection. This allows for rapid and synchronized development of primary
tumors which recapitulate the formation of sporadic human breast cancer
which arises in single cells in otherwise normally developed breast tissue.
TWIST1 expression in the luminal layer of the mammary gland was then
induced via oral doxycycline. Upon expression of TWIST1, Her2-driven
breast tumor cells were found in circulation and in the lungs as micrometas-
tases. We determined that disseminated breast tumor cells mostly remained
in dormancy until TWIST expression was switched off by doxycycline with-
drawal. We showed that tumor dormancy is partly due to the inability to
reverse EMT and regain proliferative capacity. Lastly, using our mouse
model to track disseminated breast cancer cells, we will characterize the
associated dormant residing niche to further our understanding of tumor
dormancy in connection with EMT and immune escape.
#3053 Stability and stemness of the hybrid epithelial-mesenchymal phe-
notype. Mohit Kumar Jolly,1 Dongya Jia,1 Satyendra C. Tripathi,2 Steve
Mooney,3 Muge Celiktas,2 Samir M. Hanash,2 Sendurai A. Mani,2 Kenneth J.
Pienta,4 Eshel Ben-Jacob,1 Herbert Levine1. 1Rice University, Houston, TX; 2UT
MD Anderson Cancer Center, Houston, TX; 3University of Waterloo, Waterloo,
Ontario, Canada; 4Johns Hopkins University, Baltimore, MD.
Transitions between epithelial and mesenchymal phenotypes – EMT and
MET – are hallmarks of cellular plasticity during embryonic development
and cancer metastasis. During these transitions, cells can also adopt a hybrid
epithelial/mesenchymal (hybrid E/M) phenotype enabling them to migrate
collectively as observed during gastrulation, wound healing, and clusters of
Circulating Tumor Cells (CTCs). The hybrid E/M phenotype has largely
been tacitly assumed to be ‘metastable’, i.e. transient state. Here, we integrate
mathematical modeling with in vitro experiments to identify certain ‘phe-
notypic stability factors’ (PSFs) - GRHL2, OVOL2 and NP63 that can
stabilize a hybrid E/M phenotype. We show that H1975 (NSCLC cell line)
cells can display a hybrid E/M phenotype stably and migrate collectively, a
behavior that is impaired by knockdown of GRHL2 or OVOL2. Further, our
computational model predicts that these PSFs can also associate hybrid E/M
phenotype with high tumor-initiating potential, a prediction strengthened
by the observation that the higher levels of one or more of these PSFs may
predict poor patient outcome. Overall, our results suggest that a hybrid E/M
phenotype need not be ‘metastable’, and bolster the notion that a hybrid E/M
phenotype, but not necessarily full EMT, associates with aggressive tumor
progression.
#3054 Tracing EMTwith fluorescent biosensors (chromobodies) in living
cancer cells. Julia Maier, Theresa Plaga, Stefanie Egetemaier, Bjoern Traenkle,
Ulrich Rothbauer. University of Tuebingen, Reutlingen, Germany.
Epithelial-mesenchymal transition (EMT) is a complex cellular program,
involved in the progression of epithelial cancers to a metastatic stage. During
this process characteristic epithelial marker proteins are repressed in favor of
mesenchymal biomarkers, such as the intermediate fılament protein vimen-
tin. There is an ongoing need for reliable cell-based EMT model systems,
which can be adapted to screening campaigns for novel anti-metastatic ther-
apies. Imaging-based screening systems are restricted to endpoint immuno-
fluorescence studies that provide only little information about the dynamics
of the process, or to ectopic expression of EMTmarkers, fused to fluorescent
proteins. However, overexpression of EMT marker proteins, particularly
vimentin, have been shown to influence the EMT phenotype of the cells.
Here we introduce chromobodies as an innovative technology to monitor
EMT in living non-small lung cancer cells. Chromobodies are fluorescently-
labeled single-domain-antibodies that are functional within in living cells
and directly target endogenous proteins. We generated chromobodies
against the EMT biomarkers vimentin, actin and -catenin and stably intro-
duced them into the genome of A549 cells. Upon induction of EMT with
transforming growth factor  (TGF- ), we could visualize the dynamic
reorganization of endogenous vimentin, actin and -catenin in the estab-
lished EMT chromobodymodels in 2D as well as 3D cell culture. By means of
these chromobody cell lines we further developed a 2D high content analysis
system to visualize and quantify spatiotemporal changes of the endogenous
biomarkers vimentin and actin during the EMT process. In a proof-of-prin-
ciple screen, using known EMT-affecting reagents (e.g. TGF receptor I in-
hibitors LY364947 and SB505124) as well as EMT-unrelated agents, we were
able to show that this high content analysis system can be applied to select
compounds that inhibit TGF--induced EMT. In summary, live cell imaging
of EMT markers with chromobodies provides a novel versatile approach
to study EMT in real time and allows the identifıcation of EMT inhibitors
as potential candidates for anti-metastatic therapies by high content screen-
ing.
#3055 A permanent lung imaging window reveals, for the fırst time, the
steps of extravasation, seeding and growth of earlymetastatic dissemination.
Sonia E. Voiculescu, YarongWang, Maja Oktay, John Condeelis, David Enten-
berg. Albert Einstein College of Medicine, Bronx, NY.
Metastatic disease is the major cause of cancer mortality and is responsible
for over 1/2 million deaths each year in the U.S. alone. Of the three most
common sites of metastasis observed clinically (bone, lung and liver), the
most diffıcult to study using intravital microscopy is the lung; a delicate
organ in perpetual motion. We have recently developed and validated an
implantable, permanent, lung imaging window which allows high-resolu-
tion multiphoton imaging of the intact, breathing (without ventilation), mu-
rine lung over days to weeks of repeated imaging. This window does not use
vacuum to immobilize the lung tissue thereby avoiding well know artifacts
associated with vacuum lung windows. Using our new window, we have been
able to visualize, with single cell resolution, the steps of metastasis in a
clinically relevant, spontaneously-metastasizing murine breast cancer
model. We present the fırst direct visualization of tumor cell arrival, extrav-
asation, and progression tomicro-metastases. Further, we have observed, for
the fırst time, the activity of the tripartite structure called Tumor MicroEn-
vironment of Metastasis (TMEM) in metastatic lung lesions directly demon-
strating the mechanism of dissemination from metastatic lung tumors. Us-
ing this approach to imaging live lung tissue serially, within a single animal,
we are investigating the mechanisms underlying the fate of tumor cells ar-
riving in the lung with the ultimate goal of directly identifying signals behind
seeding and survival of metastatic tumor cells and their responses to inter-
ventions in real time.
TUMOR BIOLOGY: Tumor and Stromal Cell Interactions
#3056 Genetic deletion of insulin-like growth factor binding protein-7
(IGFBP7)promoteshepatocellular carcinoma (HCC): anovel role of IGFBP7
in regulating antitumor immune surveillance. Maaged A. Akiel, Chunqing
Guo, Xia Li, Devaraja Rajasekaran, Rachel G. Mendoza, Nidhi H. Jariwala,
Chadia L. Robertson,MarkA. Subler, Jolene J.Windle, Paul B. Fisher,Devanand
Sarkar. Virginia Commonwealth University, Richmond, VA.
In the US, the incidence and mortality rates of hepatocellular carcinoma
(HCC) are alarmingly increasing since no effective therapy is available for the
advanced disease. Activation of IGF signaling is a major oncogenic event in
diverse cancers, including HCC. Insulin-like growth factor binding protein-7
(IGFBP7) inhibits IGF signaling by binding to IGF-1 receptor (IGF-1R) and
functions as a potential tumor suppressor for hepatocellular carcinoma (HCC).
IGFBP7 abrogates tumors by inducing cancer-specifıc senescence and apoptosis
and inhibiting angiogenesis. We now document that Igfbp7 knockout
(Igfbp7/) mouse shows constitutive activation of IGF signaling, presents
with pro-inflammatory and immunosuppressivemicroenvironment, and devel-
ops spontaneous tumors in lungs and liver and markedly accelerated carcino-
gen-induced HCC. Loss of Igfbp7 resulted in increased proliferation and de-
creased senescence in hepatocytes and mouse embryonic fıbroblasts that could
be blocked by an IGF-1 receptor inhibitor. A signifıcant inhibition of genes
regulating immune surveillance was observed in Igfbp7/ livers which was
associated with marked inhibition in antigen cross-presentation by Igfbp7/
dendritic cells. IGFBP7 overexpression inhibited growth of HCC cells in synge-
neic immunocompetent mice which could be abolished by depletion of CD4
or CD8 T lymphocytes. Our studies unravel modulation of immune response
as a novel component of pleiotropic mechanisms by which IGFBP7 suppresses
HCC. Even though HCC has an immunosuppressive milieu, immune targeted
therapies are beginning to demonstrate signifıcant objective responses in clinical
trials. IGFBP7might be an effective anti-HCC therapeutic by directly inhibiting
cancer cells and stimulating an anti-tumor immune response.
#3057 Gut microbiome controls liver metastasis. Chi Ma, Qiong Fu, Tim
Greten. NCI/NIH, Bethesda, MD.
Aim: The gut microbiome can modify tumor immunity and has been
suggested to be involved in the development of liver cancer. However, it
remains unknown how the gut microbiome controls hepatic immune re-
sponses. This study was designed to exam the effect of the gut microbiome on
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liver antitumor immunity, and to study potential mechanism. Experimental
procedure: Antibiotic cocktail in drinking water was given to remove mouse
gut microbiota. Control mice were kept on regular water. EL4 thymoma cells
were injected s.c. to induce spontaneous liver metastasis. B16 melanoma and
CT26 colon cancer cells were injected intrasplenically to form liver metas-
tasis. Lung metastasis was induced by tail injection of tumor cells. Results:
Antibiotic cocktail effıciently depleted gut bacteria. Removing gut commen-
sal bacteria did not affect the growth of primary s.c. tumors, but impaired
formation of liver metastasis in different models. The inhibitory effect on
liver metastasis by removing gut microbiome was found after intrasplenic
injection of tumor cells to form liver metastasis using both B16 melanoma
and CT26 colon cancer tumor cells. Interestingly, formation of lung metas-
tasis caused by tail vein injection of B16 cells was not impaired by antibiotics
treatment, suggesting a liver specifıc effect. The inhibition of liver metastasis
by antibiotic treatment was absent in Rag1 knockout mice, suggesting that
the mechanism is mediated by the adaptive immune system. Conclusion:
Our results suggest that the gut microbiome affects the liver immune mi-
croenvironment and modulates antitumor immunity.
#3058 Syndecan-1mediates breast cancer metastasis to the brain through
IL-8 and PECAM-1 signaling. Sierra Mosticone Wangensteen,1 Megan
Sayyad,1 Madhavi Puchalapalli,1 Megan Sullivan,2 Jamie Singh,1 Briana Ratch-
ford,1 Jayda Abrams,1 Majid Jahromi,1 Bin Hu,1 Michael Idowu,1 Jennifer Kob-
linski1. 1Virginia Commonwealth University, Richmond, VA; 2NorthShore Uni-
versity Health System, Evanston, IL.
Brain metastasis is a devastating, late-stage event affecting approximately
10-30% of breast cancer patients. However, it is not well understood how
breast cancer cells migrate across the blood-brain barrier (BBB) and invade
into the brain. Syndecans (Sdcs) are cell surface heparan sulfate proteogly-
cans (HSPGs) that have previously been linked to breast cancer progression
and metastasis. Preliminary fındings from our lab indicate that Sdc1 may be
involved in breast cancer metastasis to the brain. In clinical samples from
breast cancer patients with brain metastases, 67% of the brain metastasis
samples stained positive for Sdc1 expression. In an experimental mouse
model of metastasis, we found that silencing expression of Sdc1 in MDA-231
breast cancer cells greatly reduced metastasis specifıcally to the brain, with
no difference in lung or bone metastases. Additionally, silencing expression
of Sdc1 in MDA-231 cells resulted in a reduction in cancer cell migration
across an in vitro BBB transwell model system. These fındings prompted us
to investigate the mechanism through which Sdc1 facilitates breast cancer
cell migration across the BBB. Since BBB endothelial cell junctions have been
reported to be disrupted in metastasis to the brain, immunofluorescence was
performed to examine localization of junction proteins in our BBB model
following addition of conditioned medium (CM) from MDA-231 non-si-
lenced (NS1) control and Sdc1KD cells. We observed disruption in PE-
CAM-1 localization at BBB endothelial cell junctions upon addition of CM
from MDA-231 NS1 cells with markedly less disruption occurring upon
treatment with CM from Sdc1KD cells. These results suggest that paracrine
factors secreted from MDA-231 cells may facilitate breast cancer cell migra-
tion across the BBB by affecting PECAM-1 localization on BBB endothelial
cells. By performing a cytokine array using CM from MDA-231 cells, we
determined that Sdc1KD CM contained lower levels of IL-8 than MDA-231
NS1 cell CM. These fındings were confırmed by ELISA, qRT-PCR, and mul-
tiplex analysis. We then went on to treat endothelial cells in the xCELLigence
in vitro BBBmodel systemwith IL-8 and observed a suffıcient decrease in cell
index readings, suggesting that IL-8 affects BBB barrier permeability. Taken
together, our results suggest that Sdc1 supports breast cancer cell migration
across the BBB through a signaling mechanism involving IL-8 and PE-
CAM-1. Elucidating this mechanism will allow for the development of ther-
apeutic strategies to combat breast cancer cell metastasis to the brain.
[S.M.W. and M.S. contributed equally to this work.]
#3059 UHRF1 defıciency exerts anti-tumor immune responses in non-
small cell lung cancer. Handan Xiang, Junying Chen, Xiao-Fan Wang. Duke
University, Durham, NC.
Immune surveillance is essential for effective tumor clearance. However, the
tumor microenvironment is typically impermissive for proper stimulation of
both innate and adaptive immune populations. Epigenetic inhibitors have re-
cently been shown to function as immune sensitizing reagents in the suppressive
microenvironment. In our search for novel epigenetic regulators with immuno-
modulatory functions, we found ubiquitin-like with PHD and ring fınger do-
main-containing protein 1 (UHRF1) being crucial for the suppression of im-
mune activation. Loss of UHRF1 in cancer cells led to signifıcant reduction of
tumormasses in a syngeneic lung cancermodel. The tumor shrinkagewas due to
increased infıltration of T cells with the enhanced ability to proliferate and pro-
duce IFN-gamma. Mechanistically, lung cancer cells defıcient of UHRF1 had
elevated expression of endogenous retrovirus genes due toDNAdemethylation,
which associated with enhanced type I interferon responses. Type I interferons
are potent antitumor effector molecules by promoting immune cell infıltration
into the tumormicroenvironment, yet they can also dampen T cell activation by
upregulating PD-L1 expression in tumor cells. Surprisingly, UHRF1 defıcient
cancer cells failed to upregulate PD-L1 even in the presence of excessive type I
interferons, indicative of additional regulatory pathways for PD-L1. We further
found that UHRF1 directly interacted with PD-L1 promoter regions and that
UHRF1 promoted PD-L1 transcription. Therefore, the inhibition of UHRF1
augmented type I interferon responses while diminished PD-L1 expression,
which synergistically contributed to the immune activation phenotype. More-
over, in non-small cell lung cancer (NSCLC) patients, UHRF1 expression was
positively correlatedwith PD-L1 expression as well as poor prognosis. Together,
our data suggested that UHRF1 represents a novel immuno-oncology target for
NSCLC.
#3060 Role of curcumin in targeting cancer-associated fıbroblasts and
modulation of tumor microenvironment in dendritic cell-based immuno-
therapy. Sheefa Mirza,1 Nayan Jain,1 Rakesh Rawal2. 1Gujarat University,
Ahmedabad, India; 2The Gujarat Cancer and Research Institute, Ahmedabad,
India.
INTRODUCTION: Cancer associated fıbroblasts (CAFs), main component
of tumormicroenvironment (TME),modulate the recruitment and functions of
tumor-associated immune cells by secreting various growthhormones,miRNAs
and cytokines; thus having an important role in generation of immunosuppres-
sive TME which is yet to be elucidated. Curcumin is known to have various
properties including capability to modulate numerous target proteins including
transcription factors, receptors, kinases, cytokines, enzymes and growth factors.
Thus, aim of the study was to evaluate the effect of miRNAs and cytokines
released by lung cancer patients’ derived CAFs and to assess immunomodula-
tory potential of curcumin on DC maturation by targeting these CAFs through
modulating their TME.METHODOLOGY: CAFs were cultured from lung can-
cer patient derived tumor tissue biopsy and characterised using CAF-specifıc
markers. Further, immature DCs (imDCs) were differentiated in presence of
rGM-CSF and rIL-4 for 5-6 days. These imDCs were cultured in the presence of
conditioned media derived from CAFs (CAFs-CM) as well as NFs (Normal
Fibroblasts, NFs-CM) at day 6 for 48 hours to evaluate the effect of CAFs onDC
maturation. Mature DCs (mDCs) were characterized by the presence of matu-
ration markers CD80, CD83, CD86 and CTLA4 using qRT-PCR. Moreover,
expression of miR-221, miR-222, miR-155, miR-142-3p and miR-146a was as-
sessed to evaluate the role of epigenetic regulators on DCmaturation. Cytokine
profıling of CAFs-CM as well as CAFs-CM treated with curcumin was con-
ducted. RESULTS: -SMAVimentin cells were considered as CAFs. A sig-
nifıcant upregulation of CD80, CD83 and CD86 was observed when cultured in
the presence of NFs-CM while a remarkable downregulation of these markers
was found when cultured in CAFs-CM. CTLA-4 was down regulated in
NFs-CMas compared toCAFs-CM, suggesting the role of CAFs in generation of
regulatory DCs. Amongst all miRNAs, miR-146a was shown to be up regulated
dramatically in CAF-DCs (DCs cultured in CAFs-CM) as well as in CAFs-CM,
suggesting the immunosuppressive role of miR-146a. Further, an increased ex-
pression of miR-146a was positively correlated with increased expression of
anti-inflammatory cytokines like IL-6, IL-10, TGF- and decreased expression
of TNF- (pro-inflammatory) in CM derived from CAF-DCs. Moreover, cur-
cumin had the potential to convert regulatory DCs facilitated by CAFs into
mDCs, which were characterized by high expression of co-stimulatory mole-
cules, low expression of CTLA4, lower levels of immune suppressive cytokines
production, lower levels of miR-146a. CONCLUSION: These fındings provide
insight into understanding the immunomodulatory role of curcumin in target-
ing CAFs and modulating the tumor microenvironment, thus enhancing anti-
tumor immune response in DC based therapy.
#3061 Tumor-derived PAI-1 promotes macrophage M2 polarization by
stimulating an autocrine IL-6 /STAT3 pathway.MartaH. Kubala, Veronica R.
Placencio, Yves A. DeClerck. Children’s Hospital Los Angeles, Los Angeles, CA.
Macrophages can exhibit a spectrum of activation states ranging from a
pro-inflammatory and antitumorigenic M1 (CD80; IL-12high; iNOShigh) to
a pro-tumorigenic M2 [CD163; IL-10high; CD206; Arg (mouse)] pheno-
type. Plasminogen activator inhibitor-1 (PAI-1) is overexpressed in many
cancers and although it acts as a protease inhibitor it is paradoxically corre-
lated with poor outcome. PAI-1 exerts its pro-tumorigenic role via pro-
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angiogenic and anti-apoptotic functions. Increasing evidence points to-
wards the importance of PAI-1 in inflammation and tumorigenesis, but its
influence on the immune component of the tumor microenvironment has
not yet been investigated. Here we report a novel observation that PAI-1 is a
regulator of macrophage polarization. We observe that in PAI-1 KO mice
xenotransplanted with 3 human cancer cell lines (HT1080, A549, HCT116)
in which PAI-1 was knocked down (KD), tumors were less infıltrated with
macrophages with lower Arg expression compared to WT mice implanted
with PAI-1 pos. tumors. We demonstrate that recombinant PAI-1 through
its uPA interactive domain increased the expression of M2 polarization
markers (CD163, IL-10) and decreased or did not affect the expression of M1
polarization markers (iNOS, CD80) in human peripheral blood monocytes.
Further investigation demonstrated that treatment of monocytes with PAI-1
induced a rapid (2 h.) increase in IL-6 mRNA and secretion
(4 h) of the protein that was followed by phosphorylation (8-24 h.) of signal
transduction and activation of transcription 3 (STAT3) in monocytes. Fur-
ther linking STAT3 activation to PAI-1, we observed a decreased pSTAT3 in
monocytes co-cultured with HT1080 cells upon PAI-1 downregulation. We
found that STAT3 activation was downstream of IL-6 and responsible forM2
polarization, as the blockage of the IL-6 receptor with a function blocking
antibody (tocilizumab) or inhibition of STAT3 activation by a JAK2/STAT3
inhibitor (ruxolitinib) prevented M2 polarization of monocytes by PAI-1.
The contribution of PAI-1 to M2 polarization of macrophages was tested in
PAI-1 KO mice implanted with human tumors in which PAI-1 expression
was controlled by doxycycline. These experiments demonstrated that induc-
tion of PAI-1 in established tumors increased the presence of tumor associ-
ated macrophages (TAM) (F4/80) and decreased the presence of M1
(iNOS) TAM. Further supporting the presence of an autocrine PAI-1/IL-6
pathway in macrophage polarization in human cancers, a meta-analysis of
gene expression array data indicated strong correlations between PAI-1 and
IL-6 expression in breast (P0.05) and colon (P0.01) cancers and be-
tween PAI-1 and CD163 in colon cancer (P0.0001). The data thus identify
a new pro-tumorigenic function for PAI-1 in the communication between
tumor cells and macrophages where tumor-derived PAI-1 activates an auto-
crine IL-6/STAT3 pathway that promotes M2 polarization.
#3062 Metformin inhibits TGF-induced stromal ECM remodeling to
impede invasion in ovarian cancer. Peter C. Hart, Shermeen Sheikh, Ernst
Lengyel, Iris Romero. University of Chicago, Chicago, IL.
Recently, our group has elucidated thatmetformin, the commonly usedmed-
ication for type 2 diabetes, has anti-ovarian cancer (OvCa) effects in preclinical
models and use of the drug is associated with improved OvCa survival in retro-
spective epidemiological studies. While the cytotoxic effects of metformin in
ovarian cancer cell lines is well demonstrated, the impact of metformin on tu-
mor-stromal interactions in the tumor microenvironment is not well defıned.
Currently, our work has focused on the impact of metformin on the tumor
microenvironment and cancer cell behavior in physiologic models of tumor
metastasis. Using a 3D organotypic model, we demonstrate that OvCa cell inva-
sion is inhibited by metformin. In evaluating the molecular mechanism medi-
ating this effect we show that OvCa cells co-cultured with stromal cells or stim-
ulatedwith TGF1 upregulate the production of the extracellularmatrix (ECM)
proteins fıbronectin and collagen 1 and that this effect is attenuated by met-
formin. Interestingly, metformin’s inhibition of ECM production was not de-
pendent on AMP-activated kinase (AMPK), a common metformin target. To
expand on this fınding we performed label-free shotgun proteomics and identi-
fıed collagens, fıbronectin and TGFBR2 to be among the proteins most highly
repressed in response to metformin exposure in OvCa cells. Finally, we identi-
fıed that this repression of ECM remodeling by metformin was associated with
an overall reduction in TGFBR2 expression and consequent SMAD/STAT3 ac-
tivity. Taken together, our data indicate that metformin may have novel targets
in the tumor microenvironment where it targets pro-tumorigenic effects of the
stromal compartment by repressing TGF-dependent stromal cell ECM secre-
tion, thereby inhibiting ovarian cancer invasion and metastasis.
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EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Determinants of Drug Sensitivity and Resistance
#3063 Predicting effıcacy of c-Met targeting therapy in autocrine and
paracrine tumor cell lines.Veronica S. Hughes, DietmarW. Siemann.Univ. of
Florida, Gainesville, FL.
Tumor cells frequently harbor abnormalities in signaling pathways, leading to
increased migration, invasion, survival, angiogenesis, and proliferation. C-Met
is one such commonly aberrant pathway. Because of its effects on tumor cells,
c-Met has been a target of interest for anti-metastatic therapies. Clinical trials of
c-Met inhibition select patients based on total Met expression, or amplifıcation
of the Met gene. However, c-Met inhibitors target the activated pathway. We
therefore predict that phospho-Metwill be a bettermarker for patient sensitivity
to, and hence selection for, c-Met inhibitor trials. C-Met is activated by the
endogenous ligand Hepatocyte Growth Factor (HGF). In order to mimic the
paracrine signaling during in vitro experiments, many studies add exogenous
HGF at concentrations of 25-50 ng/mL. However, these concentrationsmay not
be representative of in vivo conditions. HGF serum levels of healthy humans is
0.4 ng/mL.WhileHGF levels do rise in cancer patients, it is unusual to see serum
levels higher than 1 ng/mL. Conditioned media from several cell lines (MDA-
MB-231, PC-3, DU145, LNCaP, OS156, OS521, U87, U118, RKO, KHT, SCC7,
and RIF) was collected to analyze for secretion of HGF in conditioned media.
These cells were then examined for basal phosphorylation of Met. The cell lines
that secreted HGF also had higher levels of phospho-Met in comparison to
non-HGF-secreting cell lines. Importantly, levels of totalMet did not predict for
levels of phospho-Met. Inmigration and invasion assays, theHGF-secreting cell
line KHT was found to be sensitive to the c-Met inhibitor BMS-777607.The
non-HGF-secreting cell line DU145 only became sensitive to the inhibitor when
high, non-physiologic exogenous levels of HGF (25-50 ng/mL) were add-
ed.These results suggest that autocrine activation of the c-Met pathwaymay be a
factor in predicting sensitivity to c-Met inhibition. This may indicate the exis-
tence of a subset of patients most likely respond to c-Met inhibition therapy.
Furthermore, consideration of exogenous HGF concentration should be con-
sidered when conducting preclinical trials of c-Met inhibitors, as addition of
exogenous HGF may change the apparent effıcacy of the inhibitor.
#3064 Retinoic acid: An effective therapy for basal-like breast cancer.
Krysta Mila Coyle, Cheryl A. Dean, Dejan Vidovic, Ian C. Weaver, Carman A.
Giacomantonio, PaolaMarcato.Dalhousie Univ., Halifax, Nova Scotia, Canada.
We have identifıed a novel strategy to identify breast cancer patients who will
benefıt from an existing anti-cancer agent, retinoic acid (RA).While RA has not
yet achieved success in the treatment of breast cancers, we hypothesized that it
can be an effective therapy for a subset of triple-negative breast cancer (TNBC)
patients. TNBC is among the most aggressive breast cancers, and lacks targeted
therapies. TNBCs can be further subtyped into basal-like and claudin-low,
which differ in gene expression and drug sensitivities. Understanding the mo-
lecular basis of these subtypes will lead to the development of more effective
treatment options for TNBC. To test this hypothesis, we performed tumor
growth assays on TNBC cell lines and patient-derived xenografts (PDXs). We
found that RA treatment decreased the tumor growth of four basal-like TNBC
cell lines (MDA-MB-468, HCC70, SUM149, HCC1937). In contrast, RA in-
creased the tumor growth of two claudin-low TNBC cell lines (MDA-MB-231,
MDA-MB-436). Gene expression andmethylation analysis of these affected cell
lines revealed subtype-specifıc expression of RA-inducible genes due to silenc-
ing by DNA methylation, e.g. of the RA-inducible tumor-suppressor gene
RARRES1. RARRES1 is silenced by methylation in claudin-low cell lines, but is
hypomethylated and expressed in basal-like cells. Use of the subtype-specifıc
expression and methylation profıles allowed us to accurately predict the re-
sponse of 4 PDXs toRA treatment. Continued classifıcation of TNBCs into these
two subtypes will enable clinical use of RA, in part due to the subtype-specifıc
hypomethylation of RA-inducible tumor suppressor genes includingRARRES1.
Wehave identifıed additional subtype-specifıc biomarkerswhich canpredict the
response of patient tumors to RA treatment, thus identifying a novel targeted
therapy strategy for TNBCs.
#3065 High throughput screen identifıesHSP90 as a potential therapeutic
target in models of advanced PCa, with notable effıcacy in the absence of
PTEN and p53. Keith H. Jansson,1 John K. Simmons,1 Caitlyn Fuller,1 John
Tucker,1 Ross Lake,1 Supreet Agarwal,1 Michael Beshiri,1 Lei Fang,1 Lauren
Stahl,1 JuanJuanYin,1 AianNeil Alilin,1 PaulG.Hynes,1 JacobCawley,1 Rajarshi
Guha,2 Xiaohu Zhang,2 R. Mark Simpson,1 Craig Thomas,2 David Proia,3 Kath-
leen Kelly1. 1National Cancer Institute, Bethesda, MD; 2NCATS, MD; 3C4 Ther-
apeutics, Cambridge, MA.
Castrate resistant prostate cancer (CRPC) remains the primary cause of mor-
tality for prostate cancer (PCa) patients. Several therapies are currently ap-
proved for use against CRPC, consisting mostly of androgen receptor (AR)
signaling inhibitors and toxic anti-microtubule chemotherapeutics that do not
score long-term durable responses. Recent deep-sequencing analysis studies
have elucidated the complex and heterogeneous landscape of CRPC, highlight-
ing the necessity to develop effective targeted therapies against specifıc CRPC
subtypes or therapies effective against numerous subtypes of CRPC. PTEN and
p53 are two of the most frequently altered genes in CRPC, and are associated
with therapy resistance and a poor clinical prognosis. The objective of this study
was to identify and subsequently validate therapeutic targets against models of
advanced PCa, specifıcally in the absence of PTEN and p53. Using non-biased
high throughput screening technology, we identifıed HSP90 inhibitors to be
potent and effıcacious against amodel of PTEN/p53 null PCa.HSP90 is a critical
regulator of prostate cancer cell signaling homeostasis, and recently developed
second generation compounds targeting HSP90 are effective against genotypi-
cally heterogeneous panels of cancer cell lines and have favorable safety param-
eters in the clinic. Screening results and subsequent validation efforts in vitro
identifıed ganetespib as the most potent HSP90 inhibitor, with effıcacy that
translated into established human PCa cells lines. Ganetespib also displayed
strongly inhibitory activity against PTEN/p53 null progenitor cells, a plastic
subpopulation of PCa believed to be partly responsible for therapy resistance. In
vivo, ganetespib completely inhibited progression of PIN to invasive adenocar-
cinoma in the Pten/Tp53 null PCa mouse model, leading to a signifıcant reduc-
tion in tumor weight. Expanding from the mouse model to clinically predictive
PDX-derived LuCaPmodels of human PCa, we found that ganetespib displayed
a range of activity against a genotypically diverse array of 11 LuCaP organoids ex
vivo. Furthermore, the PTEN null/p53 altered LuCaP 136 displayed a robust
response to ganetespib in vivo, with ganetespib causing a signifıcant reduction in
tumor growth. Mechanistic interrogation in vitro, ex vivo, and in vivo revealed
ganetespib induced effects to bemultifactorial andmodel specifıc, with unifying
trends being inactivation of PI3K signaling and modulation of cell cycle regula-
tory proteins. In all, these data indicate that inhibition of HSP90 is a novel
therapeutic to treat advanced PCa via multifactorial perturbation of growth
regulatory pathways.
#3066 Inhibition of hsp90 by auy922 preferentially kills mutant KRAS
colon cancer cells by activating Bim through ER stress. Chun Yan Wang, Su
Tang Guo, Jia Yu Wang, Xu Guang Yan, Margaret Farrelly, Yuan Yuan Zhang,
Fen Liu, Hamed Yari, Ting La, Fu Xi Lei, Lei Jin, Chen Chen Jiang, Xu Dong
Zhang. University of Newcastle, Newcastle, Australia.
Colon cancer is one of the most common and deadly malignancies (1). De-
spite recent advances in early diagnosis and the development of molecularly
targeted therapy, the overall survival of patients with metastatic colon cancers
remains disappointing (1). This is often associated with resistance of colon can-
cer cells to systemic therapies resulting from oncogenic mutations of KRAS that
drive activation of multiple downstream signalling pathways important for cell
survival and proliferation. Here we report that mutant KRAS colon cancer cells
are neverthelessmore susceptible to apoptosis induced by the heat shock protein
90 (HSP90) inhibitor AUY922 than those carrying wild-type KRAS. Although
AUY922 inhibited HSP90 activity with the comparable potency in colon cancer
cells irrespective of their KRASmutational statuses, those with activating muta-
tions of KRAS were markedly more sensitive to AUY922-induced apoptosis.
This was associated with upregulation of the BH3 only proteins Bim, Bik, and
PUMA. However, only Bim appeared essential, in that knockdown of Bim abol-
ished, whereas knockdown of Bik or PUMA only moderately attenuated apo-
ptosis induced by AUY922. Mechanistic investigations revealed that endoplas-
mic reticulum (ER) stress was responsible for AUY922-induced upregulation of
Bim, which was inhibited by a chemical chaperone or overexpression of GRP78.
Conversely, siRNAknockdownofGRP78orXBP-1 enhancedAUY922-induced
apoptosis. In addition, AUY922 inhibited the growth of mutant KRAS colon
cancer xenografts through activation of Bim that was similarly associated with
ER stress. Taken together, these results suggest that AUY922 is a promising drug
in the treatment ofmutantKRAS colon cancers, and that agents that enhance the
apoptosis-inducing potential of Bim may be useful to improve the therapeutic
effıcacy.
#3067 Galectin-3, a target for KRAS-addicted lung cancer. Laetitia Seguin,
Maria F. Camargo, Hiromi I. Wettersten, Shumei Kato, Tami von Schalscha,
Kathryn C. Elliott, SaraM.Weis, David A. Cheresh.UC San Diego, La Jolla, CA.
KRAS-mutant cancers are notoriously therapy-resistant. While responsible
for oncogenesis, mutant KRAS or the sustained activation of KRAS-driven ef-
fectorsmay ormay not be required throughout the course of cancer progression.
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Thus, understanding which tumors remain dependent on oncogenic KRAS
could lead to the identifıcation of unique vulnerabilities and opportunities to
treat them.We previously discovered that the carbohydrate-binding Galectin-3
(Gal-3) brings together KRAS with integrin v3 at the cell membrane in epi-
thelial cancer cells to promote tumor progression.Here, we show that by directly
binding to the cell surface receptor integrin v3, Gal-3 drives addiction to
oncogenic KRAS by enhancing macropinocytosis and reducing mitochondrial
reactive oxygen species (ROS). This pathway drives increased expression of
SOD2, a superoxide dismutase that clears mitochondrial ROS to protect against
cell death. Targeting Gal-3 with a clinically active drug decreases macropinocy-
tosis and increases ROS to eradicate KRAS-addicted lung cancer in patient-
derived xenografts and spontaneous KRAS-driven lung cancer in mice. Our
work reveals Gal-3 as a druggable target for KRAS-addicted lung cancer, and
indicates integrin v3 as a biomarker to identify this dependence.
#3068 Proteotoxic stress associated with mTORC1 activation in ovarian
carcinoma: proteasome inhibition as a therapeutic strategy. M. Herman
Chui, Patricia Shaw, Robert Rottapel. University of Toronto, Toronto, Ontario,
Canada.
Genetic profıling studies of high grade serous ovarian carcinoma have re-
vealed recurrent alterations in themTORC1 signalling network (e.g. mutations/
copy number alterations in PTEN, TSC1, TSC2, and PIK3CA) and pathway
activation, detected by phospho-4E-BP1, has been associated with poor progno-
sis. We sought to characterize functionally the role of mTORC1 signalling and
its therapeutic implications in ovarian cancer. Treatment of ovarian cancer cell
lines with rapamycin resulted in inhibition of mTORC1 signalling and de-
creased rate of protein synthesis. However, irrespective of PTEN mutation sta-
tus, only mild cytostatic effects were achieved even with high concentrations of
rapamycin. We next examined the phenotypic consequences of mTOR activa-
tion, using siRNA directed against TSC2. Surprisingly, we observed striking
growth inhibition in the majority of ovarian cancer cell lines, whether grown
under adherent monolayer culture or in 3-dimensional spheroid culture condi-
tions.WhilemTORC1pathway activationwas confırmed biochemically, knock-
down of TSC2 also resulted in activation of the unfolded protein response
(UPR), with elevated levels of phospho-EIF2 and ATF4, consistent with the
accumulation of misfolded proteins in the endoplasmic reticulum. From a ther-
apeutic standpoint, the resulting burden on the ubiquitin-proteasome system
should render these cells particularly sensitive to proteasome inhibition. We
show that treatment with the proteasome inhibitor, bortezomib, causes in-
creased accumulation of detergent-insoluble poly-ubiquinated proteins and for-
mation of larger and more abundant cytoplasmic protein aggregates in siTSC2-
transfected compared to scrambled siRNA-transfected ovarian carcinoma cells.
This was accompanied by a more pronounced UPR stress response, including
induction of pro-apoptotic CHOP, and suppression of autophagy, resulting in
marked cytotoxicity. Conversely, we show that inhibition of protein synthesis by
cycloheximide renders tumor cells resistant to bortezomib. Increased resistance
to bortezomib was also noted when cells were grown as spheroids, a condition
associated with suppression of mTORC1 signalling and decreased protein syn-
thesis. This resistant phenotype of tumour spheroids however was ameliorated
with TSC2 knockdown. Our fındings demonstrate that protein homeostasis is
fınely-tuned in ovarian cancer and that mutations in mTORC1 pathway com-
ponents do not necessarily imply “oncogene addiction”. In early-stage clinical
trials, bortezomib has achieved notable responses in a few patients. Ovarian
carcinomas with genetic alterations causing increased mTORC1 signalling may
be particularly amenable to treatment with proteasome inhibitors.
#3069 The S-phase checkpoint function of MGMT provides an unex-
pected rational route to profoundly increase the effıcacy of anticancer anti-
metabolites in cell culture and xenograft models. AGM Mostofa, Debasish
Basak,HanumanthaMadala, SurendraR. Punganuru,Kalkunte S. Srivenugopal.
Texas Tech Univ. Health Sciences Ctr., Amarillo, TX.
MGMT is an anti-mutagenicDNA repair protein highly expressed not only in
brain tumors, but also breast cancers, melanoma and colon cancers, and confers
drug resistance. Recently, we showed that human MGMT has non-repair
functions with vital roles in cell cycle; MGMT underwent PCNA-dependent
degradation in the S-phase along with p21cip1 and CDT1 proteins. MGMT
inactivation byO6-benzylguanine (BG) or a pool of shRNAs in asynchronous or
G1/S-phase synchronized cells led to the activation of a checkpoint resulting in
a signifıcant inhibition of DNA synthesis and greatly diminished progression of
cells into S-phase.We hypothesized that the replication stress caused byMGMT
inactivation will provide a means to combine the S-phase specifıc drugs for
synergistic cytotoxicity. We screened the sensitivity of a panel of colon cancer
and glioblastoma cell lines with this combination using MTT and clonogenic
growth assays. Annexin V/PI and acridine orange/ EtBr cell stainings were used
to quantify apoptosis. MGMT inhibition/depletion signifıcantly reduced the
IC50 (5 to 10-fold) for different antimetabolites (5-FU, gemcitabine, Ara-C) and
enhanced the overall apoptotic cell death (5-fold). Nevertheless, the synergis-
tic effects strongly depended on time and administration schedule of these two
agents. Thus, a pretreatment of BG orMGMT shRNA followed by 5-FU for or a
simultaneous treatment of the two were far less cytotoxic than the antimetabo-
lite fırst followed by BG or shRNA as in the post-treatment mode.While the pre
or simultaneous MGMT inhibition signifıcantly prolonged the antimetabolite-
induced S-phase arrest, the BG-post-treatments resulted in the abrogation of
antimetabolite-induced cell cycle block and rapid progression into premature
mitosis and apoptosis. We observed an increased activation of checkpoint ki-
nases (pChk1 or pChk2) during pre or simultaneous treatments. In contrast, the
post-MGMT inhibition interfered with S-phase checkpoint activity and had an
abnormal CDK2 activation. Finally, we verifıed the therapeutic potentiation of
antimetabolites by BG using the HT29-luc2 subcutaneous xenografts developed
in nude mice. BG (60mg/Kg), 5-FU (30 mg/Kg), gemcitabine (100 mg/Kg) and
Ara-C (40 mg/Kg/dose) were administered through i.p. route once a week for 7
weeks. Tumor growth revealed a 50 to 70% more reduction in combination
groups (antimetabolitesBG) compared with drugs alone. No signifıcant
changes in mouse body weight, liver functions, and whole blood counts were
noted. A marked downregulation of ki-67 and increased levels of apoptotic
markers (cleaved caspase-3, cleaved PARP) in was evident in tumor tissues.
Collectively, our data suggest that MGMT inhibition is a rational strategy not
only for alkylating agents but also for antimetabolites as well (supported by
CPRIT RP130266 & RP170207 grants to KSS).
#3070 Lenalidomide and SMAC mimetic LCL161 show combination ac-
tivity in cells harboring loss of chromosome 5q.NafeezaHafeez, Alex Gaither,
Dale Porter. Novartis, Cambridge, MA.
LCL161 is a small molecule SMAC mimetic that binds to cIAP1, cIAP2, and
XIAP and sensitizes cancer cells to TNF-alpha as well as other inducers of cell
death. An siRNA screen was performed in the SK-OV-3 cancer cell line to iden-
tify genes that when knocked down prevent LCL161-mediated cell death. As
expected, siRNAs targeting RIPK1 rescued cells from LCL161-induced death.
Unexpectedly, siRNAs targeting GPR68 also rescued cells from LCL161-in-
duced death. Since knockdown ofGPR68 has been reported to rescuemyelodys-
plastic syndrome (MDS)-derived cells harboring loss of chromosome 5q from
lenalidomide treatment, we tested for combination activity with lenalidomide
plus LCL161 in 7-day in vitro proliferation assays. Interestingly, combination
activity was observed in the SET-2 cell line harboring cytogenetic features of
MDS including loss of chromosome 5q. These data suggest that, in combination,
LCL161 may improve responses to lenalidomide in subsets of MPN and MDS
patients and potentially additional contexts where lenalidomide is active.
#3071 Exploring the molecular mechanism underlying SETD2-PI3K
synthetic-lethal interaction in renal cell carcinoma (RCC). Esteban Terzo,1
Jeanne Chiang,2 W. Kimryn Rathmell1. 1Vanderbilt University Medical Center,
Nashville, TN; 2University of North Carolina, Chapel Hill, NC.
Epigenetic regulators are emerging as major drivers of renal cell carcinoma
(RCC). SETD2, a tumor suppressor commonly mutated in RCC, is the sole
enzyme responsible for tri-methylating histone H3 on lysine 36 (H3K36me3) of
actively transcribed genes. We recently discovered that SETD2 also trimethy-
lates the non-histone target -tubulin on lysine 40 (-TubK40Me3) of mitotic
microtubules.We have demonstrated that mutations altering SETD2’s ability to
trimethylate H3K36 and -TubK40 are associated with genomic instability in
cancer progression.We hypothesized that defective SETD2methylating activity
gives rise to deleterious cell signaling cascades that promote the tumorigenic
features of SETD2 loss. Preliminary data show that RCC-derived 786-0 cells that
are deleted for SETD2 (SETD2-KO) or harbor pathogenic mutations are more
sensitive to treatment with the PI3K-specifıc inhibitor TGX-221 than their
wild type counterparts. Phosphatidylinositol 3kinases (PI3Ks) are a family of
lipid kinases that coordinate signals from growth factors, cytokines and other
environmental cues, translating them into intracellular signals controlling di-
verse signaling pathways. Several members of the PI3K/AKT signaling pathway,
including the PI3K  and  isoforms, are frequently mutated in a variety of
cancers, making this pathway a prime drug target for anti-cancer therapy. These
pathways control numerous biological processes, such as cell proliferation,
growth, and motility. Examination of structurally variant SETD2 mutants sug-
gests that the loss of SETD2 methylating activity mediates this interaction, and
future studies will examine the functional consequences of inhibiting this path-
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way. In summary, these data suggest a synthetic-lethal type of interaction be-
tween SETD2 loss (and specifıcally loss of methylating activity) and an aberrant
PI3K/AKT pathway.
#3072 A clinical pharmacodynamic biomarker assay that distinguishes
potentially repairable, cytotoxic drug-induced DNA double strand breaks
(DSBs) from DSBs associated with apoptotic cell death. Angie B. Dull,1 Deb-
orah Wilsker,1 Robert J. Kinders,1 Ralph E. Parchment,1 David Evans,1 Beverly
A. Teicher,2 James H. Doroshow2. 1Leidos Biomedical Research, Inc., Frederick
National Laboratory for Cancer Research, Frederick, MD; 2National Cancer In-
stitute, Bethesda, MD.
The effectiveness of certain classes of cytotoxic cancer therapeutics likely de-
pends on whether drug-induced DNA damage is successfully repaired or not,
with the latter situation leading to mutations and strand breaks. However, dou-
ble strand breaks (DSBs) also occur independently of genotoxic insults during
apoptotic cell death caused by many drug classes, as well as natural biological
processes. We have developed an immunofluorescent confocal microscopy as-
say that uses a biomarker profıle suitable for individual cell analysis designed to
distinguish between DSBs caused by apoptosis and those caused by direct DNA
damage from cytotoxic drug action. -H2AX is an established biomarker for
DSBs and activated cleaved caspase 3 is an executioner caspase important for
apoptosis, which leads to nuclear condensation, DNA fragmentation, plasma
membrane blebbing, and subsequent cell death. Our assay defınes the DSBs of
apoptosis by co-localized -H2AX and cleaved caspase 3 in individual cells,
while defıning the DSBs from early drug effects of DNA damaging chemother-
apeutics by -H2AX induction in the absence of cleaved caspase 3. Building on
our published fındings that topotecan strongly induces -H2AX and DSBs
within 1-4 hours in vitro and in vivo, we observed exposure-dependent increases
in -H2AX /cleaved caspase 3 double positive cells at later time points, both in
an HT29 in vitro spheroid model and an MDA-MB-231 xenograft model. Fit-
for-purpose studies in the MDA-MB-231 xenograft model treated with birini-
pant, a SMACmimetic and IAPderegulator that does not directly produce lethal
DSBs, demonstrated a dose-dependent increase in cellular co-localization of
-H2AX/cleaved caspase 3 consistent with birinipant induced apoptosis and the
established mechanism of action of this compound. Clinical feasibility was es-
tablished in a canine clinical trial using formalin-fıxed paraffın-embedded
(FFPE) 18-gauge needle biopsies: two novel indenoisoquinolines, indotecan
(LMP400) and indimitecan (LMP776), increased tumor cell co-localization of
-H2AX/cleaved caspase 3 in tumor samples obtained on day 5 of qdx5 treat-
ment. This PD biomarker assay of early and late DSB response to drug exposure
could have important applications for elucidation of mechanisms of action of
anticancer drugs and the development of investigational agents. Funded byNCI
Contract No. HHSN261200800001E.
#3073 Potential predictive biomarkers of clinical responses for a novel
CDC7-selective inhibitor TAK-931.Kenichi Iwai,1 Tadahiro Nambu,1 Osamu
Kurasawa,1 Noriko Uchiyama,1 Ryo Dairiki,1 Yukiko Yamamoto,1 Satoru
Nishizawa,1 Mengkun Zhang,2 Yuko Ishii,2 Huifeng Niu,2 Akihiro Ohashi1.
1Takeda Pharmaceutical Company, Fujisawa, Japan; 2Takeda Pharmaceuticals
International, Cambridge, MA.
Cell division cycle 7 (CDC7) is a serine/threonine kinase, which plays impor-
tant roles in initiation of DNA replication by phosphorylating MCM2. Kinase
activity of CDC7 is controlled by its binding protein DBF4 in a cell-cycle depen-
dentmanner. Here we developed a potent CDC7 inhibitor TAK-931 (IC50 0.3
nM) as a cancer therapeutic drug candidate, which exhibits a time-dependent
ATP-competitive kinetics to its ATP-binding pocket. The selectivity studies us-
ing the 308 kinases revealed120-fold selectivity of TAK-931 for CDC7 kinase
inhibition compared to other kinase inhibitions. Treatment with TAK-931 sup-
pressed the cellular MCM2 phosphorylation at Ser40, resulting in a delayed S
phase progression, checkpoint activation, apoptosis, and potent growth sup-
pression in various cancer cell lines. Furthermore, oral administration of TAK-
931 as a single agent caused a signifıcant antitumor activity inmultiple xenograft
models which include both cell line-based xenografts and patient-derived xeno-
graft (PDX) models. These results demonstrate that TAK-931 is a highly potent
and selective inhibitor of CDC7 kinase, and causes a potent antiproliferation
both in vitro and in vivo studies using various cancer cells. Next, to identify
potential predictive biomarkers to guide patient-selection strategies, in vitro cell
panel screening of TAK-931 usingwas tested for its ability to antiproliferation in
246 cell lines, which includes both solid and hematological cancer cells. TAK-
931 inhibited proliferation of multiple cancer cell lines, with mean concentra-
tion producing a half-maximal response (EC50) values ranging from 29.1 nM
to 30 M (median 554.5 nM). While the wide range of TAK-931 antipro-
liferative spectrum was observed, neither doubling speed nor CDC7 expression
profıle did predict tTAK-931 sensitivity in cancer cell lines. A correlative study
of the tumor geneticmutations in relation to antiproliferative activity that KRAS
mutant cancer cells were more sensitive to TAK-931 compared to KRAS non-
mutant cell lines (p0.05). We also confırmed this KRAS-associated antiprolif-
erative effect of TAK-931 in the SW48 isogenic cell lines of KRAS mutations
(G12V, G13D). The ectopic expressions of G12V- and G13D-KRAS mutations
increased the TAK-931 sensitivity compared to the KRAS-wild parental SW48
cell line. Given that KRAS mutations are frequently detected in clinical pancre-
atic tumors, we next conducted in vivo effıcacy studies using pancreatic PDX
models. Consistent to our hypothesis from in vitro studies, KRAS-mutant pan-
creatic PDX tumors were more sensitive to TAK-931 than the KRAS-wild pan-
creatic tumors; all KRAS-mutant pancreatic PDX models we tested exhibited
60% TGI. Our fındings suggest that the KRAS-mutant pancreatic tumors
could be the potential candidate for the TAK-931 target indication.
#3074 Selective lethality of cisplatin in pancreatic cancer is dependent on
mitotic functions of BRCA2. Barbara Orelli, Hans C. Maurer, Carmine Pal-
ermo, Steven A. Sastra, Kenneth P. Olive. Columbia Univ. Irving Comp. Cancer
Ctr., New York, NY.
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy with a
5-year survival rate of just 8%. Mutations in BRCA2 are among the most com-
mon known germline alterations that predispose to PDA. While the sensitivity
of BRCA2-mutant breast and ovarian tumors to platinum compounds has long
been recognized, the recent approval a PARP inhibitor in BRCA2-mutant ovar-
ian cancer confers hope that such tumorsmight be targetedwith greatly reduced
toxicity. To test whether PDA exhibits a similar genetic susceptibility to these
agents, we carried out preclinical intervention studies in Kras/p53-mutant ge-
netically engineered mouse models (KPC mice) with or without the additional
mutation of BRCA2 (KPCB2mice).Mice were enrolled based on 3D ultrasound
imaging criteria to assure similar initial tumor burden, and tumor growth was
monitored longitudinally by ultrasound. To our surprise, loss of Brca2 failed to
sensitize pancreatic tumors to Parp inhibition and did not provide additional
benefıt in combination with cisplatin treatment. By contrast, cisplatin induced
substantial regressions in most KPCB2 tumors, leading to a3-fold increase in
overall survival, while having no effect on the growth or survival of mice with
wild-type BRCA2. More surprisingly, the effıcacy of cisplatin was not shared
with oxaliplatin, even at higher doses. While BRCA2 is primarily known for its
role in homology-directed repair, a network biology analysis of the function of
BRCA2 in human pancreatic cancer led us to investigate the role of BRCA2 in
mitosis. Wild type BRCA2 protein localizes to the midbody- a structure formed
during the fınal stages of telophase- and plays and poorly understood role in the
fınal abscission of cytoplasm between two dividing cells. Timelapse video mi-
croscopy of KPCB2 tumor cells treated once weekly for 2 hours with cisplatin
revealed the frequent induction of endoreduplication and eventual formation of
polyploid giant cells subsequent death. Similar cells were found throughout
KPCB2 tumors during regression in response to cisplatin treatment, but were
largely absent from tumors in other treatment arms. Mechanism studies found
that BRCA2 defıcient PDA cells are susceptible to replicative stress following
cisplatin treatment that selectively leads to the formation of radial chromosomes
that cannot be resolved duringmitosis. These studies argue for the consideration
of cisplatin-based (rather than oxaliplatin-based) regimens for the treatment of
BRCA2-mutant pancreatic tumors.
#3075 Analysis of microRNA profıles involved in the resistance to triflu-
ridine. Kenta Tsunekuni,1 Jun Koseki,2 Masamitsu Konno,2 Ayumu Asai,2
Norihiro Nishida,2 Hugh Colvin,2 Koichi Kawamoto,2 Yuichiro Doki,2 Masaki
Mori,2 Hideshi Ishii3. 1Taiho Pharmaceutical, Tokushima, Japan; 2Osaka Uni-
versity, Osaka, Japan; 3Osaka University, Tokushima, Japan.
Background: Trifluridine (FTD) is a key component of the novel oral antitu-
mor drug trifluridine/tipiracil, which was approved for the treatment of patients
withmetastatic colorectal cancer refractory to standard chemotherapies. A com-
prehensive analysis of miRNA profıles was performed in cell lines resistant to
FTD established by ourselves, in order to explore the underlyingmechanisms of
resistance to the drug. Method: We established subline resistance to FTD
through continuous administration and increasing dose of the drug for 5
months using the colorectal cancer cell line DLD-1. Total RNA was extracted at
intervals whilst establishing FTD resistant sublines, andmiRNA expression was
analyzed by microarray. The expression of miRNA that was signifıcantly down-
regulated in the FTD resistant subline was knocked down to test its involvement
in resistance to FTD. Cell viability was evaluated by crystal violet cytotoxicity
test. Results: The established FTD-resistant sublines showed more than 22-fold
higher resistance to FTD and no cross-resistance to 5-FU. miRNA and mRNA
clustered in the genome locus located in chromosome 9, 9p22.32 were down-
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regulated in the FTD-resistant cell line, one of which was the miRNA let-7d-5p,
which is one of the let-7 family and is known to target oncogenes and several key
components of the cell cycle and cell proliferation. Anti-let-7d-5p treated
DLD-1 was less sensitive to FTD than compared to control. The IC50 values of
FTD were 16.8 M and 7.6 M for the anti-let-7d-5p treated cells and control
respectively. On the other hand, overexpression of let-7d-5p in DLD-1 using
let-7d-5pmimic increased the sensitivity to FTD compared to control. The IC50
values of FTD were 3.7 M and 13.9 M in the let-7d-5p overexpression cells
and control respectively. 5FU sensitivity was only altered slightly in anti- let-
7d-5p treated or let-7d-5pmimic treated cells. These data suggest that let-7d-5p
is more relevant to sensitivity for FTD than that of 5FU. Conclusion: Let-7d-5p
expression level influenced FTD sensitivity more effectively than 5FU. It sug-
gests that the let-7d-5p is a potential predictive marker for trifluridine/tipiracil
treatment in the clinical setting.
#3076 A novel nanoparticle formulation of doxorubicin is clearly differ-
entiated from free doxorubicin in overcoming resistance mechanisms in
chemo-resistant tumors. Véronique Trochon-joseph, Christelle Zandanel,
Caroline Lemarchand, Vincent Hayes, Séverine Rochas, Yamina Rayah, Jean-
Louis Labernardière, Graham Dixon. Onxeo, Paris, France.
Background and Aims. Chemo-resistance in hepatocellular carcinoma
(HCC) tumor cells can bemediated by severalmechanisms includingP-gp efflux
pumps and drug sequestration by the autophagy process. This study investigates
the potential of doxorubicin loaded nanoparticle (NP) to reverse chemo-resis-
tance by these mechanisms compared to free doxorubicin. We present the pre-
clinical evaluation of anti-tumor effects of NP as monotherapy and in combina-
tion with standard agents used in treatment of HCC, pancreatic and sarcoma
cancers. A phase III clinical study comparing NP to Best Standard of Care (Re-
live study) in patients with advanced HCC is in the fınal stages of recruitment
with preliminary results expected in 2H 2017. Methods. Tumor cell lines were
incubated with drugs in cell proliferation assay. In vivo effıcacy of NP alone (4-8
mg/kg) or in combination with current and investigational treatments for pan-
creatic cancer (e.g. Gemcitabine, Erlotinib, Abraxane) and HCC (Sorafenib,
Regorafenib and Lenvatinib) were performed in mouse tumor models using
tumor weight as primary endpoint. In all experiments NP was compared to
administration of free doxorubicin. Doxorubicin quantifıcation in tumor and
organs to asses PK and biodistribution was also performed using an LC/MS
based method. Autophagy was measured by cell proliferation in the presence of
inhibitors e.g.. Concanamycin A, Hydroxychloroquine sulfate added 30 min
before incubation with the test compound. Results. NP showed a dose-depen-
dent inhibition of cell proliferation in all resistant cancer cell lines tested with a
superior activity compared to free doxorubicin and other tested drugs. In con-
trast to free doxorubicin, NP showed consistent anti-proliferative activity in the
absence/presence of inhibitors of P-gp pumps and autophagy. In a range of in
vivomodels,NPwas preferentially takenupby the tumor tissue and signifıcantly
reduced tumor growth when compared with free doxorubicin and with at least
equivalent reduction in tumor growth compared to current treatments. Further-
more NP administered in combination with current treatments signifıcantly
increased the inhibitory effect of each drug without additional toxicity (as mea-
sured by no change in body weight). The results comparing effıcacy of NP alone
and in combination in HCC, pancreatic and sarcoma cancer models will be
presented. Conclusions. These results demonstrate that NP is clearly differenti-
ated from free doxorubicin, in 1) overcoming resistance mechanisms linked to
efflux and autophagy, and 2) having a superior biodistribution profıle both of
which results in signifıcantly enhanced activity on chemo-resistant tumors. NP
also provides an opportunity to combine with other agents, enhancing activity
without increasing toxicity. The implications of these results on the further
development of NP will be discussed.
#3077 Tumor cells with acquired resistance to EGFR inhibitors and over-
expression or activation of AXL, MET and FGFR1 are insensitive to single-
agent treatment targeting AXL, MET or FGFR. Jordi Bertran-Alamillo,1
Miguel Angel Molina-VIla,1 Cristina Teixidó,1 Jordi Codony-Servat,1 Ana Gi-
ménez-Capitán,1 Carles Codony-Servat,1 Silvia García-Román,1 Erika Al-
deguer,1 Sonia Rodríguez,1 Rafael Rosell2. 1Pangaea-Biotech, Barcelona, Spain;
2Institut Catala d’Oncologia, Badalona, Spain.
Background: Aberrant activity of the MET, FGFR1 and AXL receptors has
been associated with the development of resistance to fırst, second and third
generation EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated non-small
cell lung cancer (NSCLC) patients. Methods: We obtained 6 resistant lines by
treating EGFR-mutated (exon 19), TKI sensitive PC9 cells with increasing con-
centrations of gefıtinib or erlotinib. The p.T790M resistance mutation emerged
in two cell lines (GR1, GR4), which remained sensitive to osimertinib, a third
generation EGFRTKI. Six new cell lines to resistant to “second line” osimertinib
were generated fromGR1 and GR4 by exposure to increasing concentrations of
the inhibitor. Finally, six more cell lines resistant to “fırst line” osimertinib were
derived from the PC9 parental cells. All resistant cell lines were genotyped for
selected genes (including EGFR) and characterized for AXL, MET and FGFR1
expression and activation by Q-RT-PCR, immunohistochemistry and Western
blotting. The effects of AXL (BGB324), MET (crizotinib, capmatinib) and
FGFR1 (nindetanib) inhibitors on the parental and the 18 resistant cell lines
were analyzed byMTT and, in some cases, by colony formation. AXLwas stably
silenced in some of the resistant cell lines. Results: All cell lines resistant to “fırst
line” gefıtinib, erlotinib and osimertinib maintained the exon 19 EGFR sensitiz-
ing mutation. In contrast, three of the resistant cell lines to “second line”
osimertinib lost the exon 19 and the p.T790M mutations. In two more, the
p.T790M dropped to low allelic fractions (1% and 0.03%). Regardless of the
EGFR status, AXL overexpression was themost common event related to EGFR
TKI resistance in our panel of 18 cell lines, with FGFR1 andMEToverexpression
or activation as less frequent events. In proliferation assays, the IC50 of the
EGFRTKI resistant cell lines for BGB324 (AXL inhibitor) was indistinguishable
from the IC50 of the parental, EGFR TKI sensitive cell line. Similar results were
obtained in the case of capmatinib, crizotinib (MET inhibitors) and nintedanib
(FGFR inhibitor). Stable silencing of AXL on some of the AXL-overexpressing
resistant cell lines had no effects in terms of doubling times, morphology of cells
or sensitivity to EGFR TKIs. In combination experiments, the effect of BGB and
MET inhibitors was found to be additive. Conclusions: In tumor cell linemodels
of acquired resistance to EGFRTKIs, overexpression or activation of AXL,MET
and FGFR1was not associated to sensitivity to single-agent treatmentwithAXL,
MET or FGFR inhibitors. Multitargeted approaches might be more effective in
this setting.
#3078 The role of extracellular vesicles in chemotherapy resistance in gas-
tric cancer. EdsonCassinela,Michele C. Landemberger, Gabriela P. deOliveira,
Vilma Regina Martins. A.C. Camargo Cancer Center, Sao Paulo, Brazil.
Gastric adenocarcinoma (GAd) is the fourth most common cancer and the
second cause of cancer death in the world. Chemotherapy has been largely used
to treat this disease however acquired drug resistance is a common event and is
associated to the development of new more aggressive clones of tumor cells.
Herein, a gastric adenocarcinoma cell line (AGS) resistant to the 5-fluorouracil
(rAGS-FU) was generated in order to establish mechanisms associated to ac-
quire drug resistance. In the presence of 5-FU (10M) resistant cells show a 2-3
times higher proliferation ratio than parental cells, a plating effıciency of 38%
compared to 1% of parental cells and a higher invasive phenotype. Remarkable,
when compared to parental cells, rAGS-FU resistant cells secreted 2-3 times
more extracellular vesicles, EVs (85-175nm). When parental cells were treated
with EVs from rAGS-5-FU resistant cells they acquired the same phenotype of
the latter cells regarding higher proliferation, plating effıciency and invasion.
The proteomic analysis of parental and rAGS-FU cells showed 306 differentially
expressed proteins, while 66 differentially expressed proteins were found when
EVs secreted from these cells were compared. Our data suggest that cells resis-
tant to chemotherapy have a more aggressive phenotype and are able to transfer
these characteristics to non-resistant cells. These fındings point to mechanisms
of chemoresistancemediated by components that are carried from cell to cell by
EVs, what may indicate novel approaches that can be addressed to impair drug
resistance and improve treatment response. Supported by FAPESP.
#3079 Activation of CCN1 signaling in solid tumor cells diminishes re-
sponse to a histone deacetylase inhibitor: A dark side of HDACIs. Arnab
Ghosh, Priyanka Ghosh, Gargi Maity, Sushanta K. Banerjee, Snigdha Banerjee.
VAMedical Center, Kansas City, MO.
Background and Objective: Histone deacetylase (HDAC) inhibitors are clin-
ically proven epigenetic-based drugs for hematological cancers. However, the
impact of these inhibitors on solid tumors is disappointing and debatable. Re-
cent studies have shown that the solid tumor cell lines are less sensitive to a
HDAC inhibitor Vorinostat (suberoylanilide hydroxamic acid; SAHA) as com-
pared to hematological cell lines. However, it remains elusive why solid tumor
cell lines respondedweakly toHDAC inhibitors. Previously, it has been reported
that CCN1/Cyr61 plays critical role in invasive front and drug resistance in
breast and pancreatic cancer. Thus, our goal is to determine whether CCN1
signalling impair activity of SAHA in breast and pancreatic cancer cells. Meth-
ods: To test this objective, various breast cancer cell lines (MCF-7, ZR-75-1,
MDA-MB-231, HCC-70) and pancreatic cancer cell lines (BxPC-3, AsPC-1 and
Panc-1) were treated with SAHAwith different does and times. Levels of CCN1
and its downstream signalling molecules were determined in SAHA-treated or
untreated cell extracts using Western blotting. In addition, cell viability, migra-
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tion and sphere formation were examined in parental and CCN1-depleted cells
in the presence or absence of SAHA. Results and Conclusions: Here we have
shown that CCN1 was upregulated in various breast and pancreatic cancer cell
lines following SAHA treatment via epigenetic mechanism. Distribution of
CCN1 in the nucleus and cytoplasmwas also drastically altered in SAHA-treated
cells. Normally, CCN1 expression was detected in the cytoplasm. However, fol-
lowing SAHA treatment, CCN1 expression was located predominantly in the
nucleus. Functionally, CCN1 had dual outcome in these cells. The cell viability
assay indicated that CCN1-positve breast cancer or pancreatic cancer cells were
more sensitive to SAHA as compared to CCN1-negative cells. CCN1 ablation by
neutralizing antibody treatment inMDA-MB-231 cells signifıcantly suppressed
the inhibitory effect of SAHA in MDA-MB231 cells. However, aggressive phe-
notype such as migration towards SDF-1 and sphere-formation were markedly
elevated in SAHA treated cells as compared to untreated cells. These effects of
SAHA were rescued by CCN1-depletion. Collectively, these studies indicat that
CCN1 activation limits the response to SAHA in solid tumor cells and thus
suggesting that combination therapy of SAHA and CCN1-inhibitor could be an
ideal therapeutic approach tomakeHADAC inhibitor sensitive to solid tumors.
#3080 Y-box binding protein 1 is crucial in acquiring drug resistance in
advanced renal cell carcinoma. Ninadh M. D’Costa, Peter Raven, Zheng Tan,
Werner Struss, Sebastian Frees, ClaudiaChavez-Munoz,Alan I. So.University of
British Columbia, Vancouver, British Columbia, Canada.
Objective: Investigating the role of Y-box binding protein 1 (YB1) in drug resis-
tant advanced kidney cancer. Background: Renal cell carcinoma (RCC) is the 6th
most common malignancy with approximately 1,800 deaths in 2015 and 2.3% an-
nual increase in Canada. Despite the partial or total surgical removal of kidney in
patients with localized RCC, metastatic patients are treated with tyrosine kinase
inhibitors (TKIs) in a purely palliative approach. However, TKI-resistance
(Sunitinib) is developedafter amedian timeof 10-14months.Therefore, identifying
the factor(s) responsible for TKI-resistance development and disease advancement
in RCC is imperative. It is now widely recognized that evolutionarily conserved
Y-boxbindingprotein1 (YB1) is essential for cell growthandsurvival.Upregulation
of YB1 in numerous cancer types was found to be positively correlated with tumor
growth, metastasis and drug-resistance development. YB1 is also involved in inter-
cellular communication through its secretion in the tumor microenvironment by
cell-surface transporters, ABC-transporters. Summary of the data: Endothelial cells
(HUVEC) were co-cultured with Caki-1DC (Sunitinib-resistant, developed in our
lab) andCaki-1WT(Sunitinib-sensitive)RCCcell-lines, and increasedmigrationof
HUVEC was observed with Caki-1DC compared to Caki-1WT. A drastic increase
inYB1and itsdownstreamtargetABCB1inCaki-1DCcompared toCaki-1WTcells
was alsodetected.Consistentwithprevious reports,weobservedgranular structures
in the Caki-1DC cells that support potential secretion of YB1 into the tumor mi-
croenvironment. Moreover, blocking ABCB1 reverted the Caki-1DC cells to being
drug-sensitive. Experimental procedures: Caki-1WT and Caki-1DC were co-cul-
turedwithHUVECcells followedby scratch assay to test forHUVECcellmigration
andassociated secretory factors.Westernblot andqPCRwereused todetermine the
protein and mRNA levels respectively between the two cell-lines. Immuno-histo-
chemical staining was carried out on the RCC tumors from Sunitinib-sensitive and
resistantmousemodels (developed in our animal facility).Granular structureswere
observedusing immunofluorescence staining against YB1. Presto-bluewas used for
cell biomass assay following different drug treatments. Summary: The molecular
function of YB1 inRCCand its potential in targeted therapy is notwell understood.
Therefore, understanding the function of YB1 inmetastatic RCC and in drug-resis-
tance development is of vital importance. Our data suggests that inhibition of YB1
may slow disease progression and, possibly, revert the drug resistance mechanism.
The results from this study have the potential to introduce YB1 inhibitors in con-
ventional RCC chemotherapy, alone or in combination, to improve survival in ad-
vanced kidney cancer patients.
#3081 Precision medicine for patients with advanced small cell lung can-
cer treatedwith novel therapeutic agents in a phase I clinical trials unit. Joline
S. Lim, Samuel J. Harris, Malaka Ameratunga, Raghav Sundar, Joo Ern Ang,
Dearbhaile Collins, Maxime Chénard-Poirier, Alvaro I. Garces, Stan B. Kaye,
Juanita Lopez, Udai Banerji, Johann S. de Bono, TimothyA. Yap.RoyalMarsden
Hospital, London, United Kingdom.
Introduction: Small cell lung cancer (SCLC) is aggressive and relapse is inev-
itable. Novel therapies in the context of phase I (Ph1) clinical trials should be
considered in this setting. Next generation sequencing (NGS) identifying puta-
tive driver mutations may aid therapy allocation in such trial settings. Methods:
Retrospective analysis of characteristics and clinical outcomes of patients (pts)
with advanced SCLC referred to the Phase I Clinical Trials Drug Development
Unit at the Royal Marsden Hospital between 1992 and 2016, using electronic
patient records. Results: 85 pts with advanced SCLC were included, of which 45
pts were allocated to 1 trial each (48 allocations). Of these, 21 (46.7%) pts
started 1 trial, with a total of 24 trials commenced. Of the 64 pts who were
unable to commence trials, 43 (67.2%) had rapid disease progression, 11 (17.2%)
sought other therapies, 5 (7.8%) declined Ph1 trials, and 5 pts did not enrol for
other reasons. Pts had a median of 2 previous lines of treatment (range:1-3). 13
pts had tumormolecular profıling with high coverage targeted NGS, yielding 22
distinct mutations; Aberrations in DNA damage repair (DDR) pathway were
most common: TP53 (53.8%), FANC (30.8%), ATM (15.4%), ATR, BARD1 and
CHEK2 (7.7% each). All pts found to have 1 DDR pathway mutation had
platinum sensitive disease (disease progression 90 days from last platinum
dose) in fırst line setting. Other mutations found include ALK, APC, AR,
AXIN1, DDB2, ERBB2, mTOR, PI3K, NOTCH, NTRK17, PDGFR, RB1, RET,
STK11, FKT3 and VGFR2. Pts were most commonly treated with novel inhibi-
tors against PARP (n9), PI3K/AKT (n3), PD-1 (n2) andBCL (n2). Ther-
apies were generally well tolerated with no dose limiting toxicities observed. Of
9 pts who received PARP inhibitors, 1 achieved a RECIST partial response (PR)
and remained on trial for 16 weeks; 4 achieved RECIST stable disease (SD) for a
median of 17 weeks (range:10.9-31.1 weeks). 1 exceptional responder whose
tumor harbored multiple somatic aberrations (TP53, FANCF, AR, ERBB2,
NOTCH2) was enrolled on 3 sequential phase I trials - she achieved durable
RECIST SDon a PARP inhibitor (31.1weeks), RECISTPRwith a PD-1 inhibitor
(38.7 weeks), and durable RECIST SD with carboplatin/ATR inhibitor (27.9
weeks). Platinum sensitivity in the fırst line setting predicted for improved dis-
ease control (RECIST PR/SD 73.3% vs 0%, p0.05) and longer duration on trial
(14 vs 4weeks, p0.05).Discussion.Novel therapeutic agentswithin the context
of a dedicated Ph1 trials unit werewell tolerated and led to preliminary signals of
antitumor activity. Targeted NGSmay aid in the identifıcation of pts with puta-
tive gene aberrations, potentially predicting for response to novel therapies. Ph1
trials should be considered earlier in the pt’s disease course to maximize their
prospects of trial enrolment.
#3082 Defıcient NOXA in HER2-amplifıed breast cancer drives kinase
inhibitor resistance. Konstantinos V. Floros,1 Kyung-A Song,1 Timothy L.
Lochmann,1 Mark T. Hughes,1 Daniel A. Heisey,1 Hisashi Harada,1 Bin Hu,1
Jennifer Koblinski,1 Andrew J. Souers,2 Joel D. Leverson,2 Anthony C. Faber1.
1VCU, Richmond, VA; 2Abbvie, Chicago, IL.
The purpose of this study is the development of a novel combination therapy
that targets HER2-amplifıed breast cancer. About one quarter of breast cancers
harbor amplifıcation of HER2. HER2 is a transmembrane receptor tyrosine ki-
nase (RTK) belonging to the ERBB family of receptors (ERBB1-4). Upon hetero-
and homo-dimerization, HER2 activates several key intracellular pathways, reg-
ulating many cellular functions including proliferation and survival. HER2 in-
hibitors (HER2i) (e.g. the receptor tyrosine kinase (RTK) inhibitor, lapatinib)
are now part of standard care for treating HER2-amplifıed breast cancers. How-
ever, despite their anti-cancer benefıt, these drugs have limited effıcacy asmono-
therapies, which contrasts to other RTK inhibitors in other RTK-driven cancers.
To better understand this apparent dichotomy, in the present study, we evalu-
ated potential modifıers of HER2i therapy. Here, we found that the pro-apopto-
tic NOXA, a member of the B-cell CLL/lymphoma 2 (BCL2) family which acts
mainly via inhibitory binding of the pro-survival MCL-1, was markedly down-
regulated in breast cancers compared to other cancers, and this was largely
attributed to the HER2-amplifıed subset. Experimentally, overexpressing
NOXA or silencing MCL-1 dramatically sensitizes HER2 amplifıed breast can-
cer cell lines to lapatinib via apoptosis. Consistently, pharmaceutical inhibition
of MCL-1 sensitizes HER2-amplifıed breast cancers to lapatinib in vitro and in
vivo. Mechanistically, disruption of MCL-1:BIM complexes and MCL-1:BAK
underlie dual HER2i/MCL-1i therapy. Therefore, defıcient NOXA expression
constitutes a bonafıde apoptotic block in HER2 amplifıed breast cancers, con-
tributes to mitigated HER2i responses, and presents a rational combination
therapy that may improve HER2i responses.
#3083 Prior irradiation results in elevated programmed death 1 (PD-1) in
T cells.RenxiangChen,1DeguanLi,2 Albert J. Fornace,1HenghongLi1. 1George-
town Lombardi Comp. Cancer Ctr., Washington, DC; 2Institute of Radiation
Medicine, Chinese Academy of Medical Sciences and Peking Union Medical Col-
lege, Tianjin, China.
It is well known that radiation has long-lasting effects on the immune system.
In this study we address the question whether these radiation-induced adverse
effects on T cell activation are associated with alterations of T cell inhibitory
receptors. Expression levels of inhibitory receptors on T cells were analyzed at
multiple post-radiation time points ranging from one to four weeks in mice
receiving whole body irradiation. The level of the checkpoint receptor, PD-1, on
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different T cell subpopulations was determined. Our results showed that prior
irradiation resulted in signifıcant elevated expression of PD-1 in both CD4
and CD8 populations. T cells with elevated PD-1 mostly were either central
memory or naïve cells. In addition, the feedback induction of PD-1 expression in
activated T cells declined with time after radiation. Taken together, the elevated
PD-1 level observed at weeks after radiation exposure is connected to T cell
dysfunction. Similar changes were seen in samples from tumor patients receiv-
ing radiotherapy. Recent preclinical and clinical studies have shown that radia-
tion alters the immune-modulatory microenvironment in tumor tissue, and
implies that a combination of radiotherapy and T cell checkpoint blockade im-
munotherapy including targeting the PD-L1/PD-1 axis may potentiate the an-
titumor response. Therefore, understanding the dynamic changes in PD-1 levels
in T cells after radiation should help in the development of a more effective
therapeutic strategy.
#3083A C6-ceramidenanoliposomes sensitize paclitaxel resistant ovarian
cancer cells to chemotherapy treatment. Danielle C. Llaneza, Tye G. Deering,
Samantha G. Sherwood, John R. Cornelison, Mark Kester, Charles N. Landen.
University of Virginia, Charlottesville, VA .
Ovarian cancer is the fıfth leading cause of cancer deaths among women, and
the majority of women are diagnosed at advanced stages resulting in poorer
outcomes and survival rates. One of the driving forces behind these outcomes is
the development of chemoresistance, and subsequent proliferation and invasion
of tumor cells. In a patient-derived xenograft model of ovarian cancer, we iden-
tifıed the sphingosine pathway as signifıcantly enriched in tumors after treat-
ment with conventional chemotherapy. In order to target the sphingosine path-
way, we investigated the potential effects of combining paclitaxel with C6-
ceramide nanoliposomes in paclitaxel-resistant ovarian cancer cell lines,
HeyA8-MDR and SKOV3-TR. Ceramide has been shown to be a key player in
several processes important for tumor suppression including apoptosis, au-
tophagy, and cell cycle arrest. We administered paclitaxel and C6-ceramide to
HeyA8-MDR and SKOV3-TR cell lines in vitro and measured cell viability and
expression of apoptotic and autophagic proteins. Results showed that in both
cell lines, C6-ceramide signifıcantly decreases the IC50 dose of paclitaxel, com-
pared to control ghost nanoliposome treated cells. The IC50 of paclitaxel de-
creased in HeyA8-MDR cells from 400nM to 150nM, and in SKOV3-TR cells
from 1000nM to 450nM.Western blot analyses indicate that combination treat-
ment increases expression of apoptotic (cleaved caspase-3) factors in HeyA8-
MDR cells, and autophagic (LC3) factors in SKOV3-TR cells, over single
agent treatment or control. Paclitaxel is known to increase expression of
apoptotic factors while decreasing expression of autophagic factors. Cer-
amide may increase both apoptotic and autophagic factors. In an orthotopic
mouse model with the HeyA8-MDR line, combination treatment of pacli-
taxel and C6-ceramide resulted in signifıcantly decreased tumor burden
(1.38g / 0.74), compared to control ghost (p  0.022, 2.81g / 1.57),
C6-ceramide alone (p  0.078, 2.50g / 1.58), and paclitaxel alone (p 
0.005, 2.48g/ 0.75) groups. The combination of C6-ceramide and pacli-
taxel may prove useful in elucidating and targeting underlying chemoresis-
tance mechanisms in ovarian cancer.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Differentiation Therapy
#3084 Therapeutic implications of sex hormone signaling in melanoma.
Christopher Natale, Junqian Zhang, Ankit Dahal, Todd Ridky. University of
Pennsylvania, Philadelphia, PA.
Female gender, early age of fırst birth, andmultiparity are associated with less
aggressive melanoma; however, the mechanisms underlying the apparent clini-
cal benefıt are undefıned. Previously we reported that 17-estradiol drives me-
lanocyte differentiation throughG-protein coupled estrogen receptor (GPER), a
nonclassical sex hormone receptor. Here, we use genetically-defıned human
skin xenograft melanoma to show that pregnancy antagonizes oncogenic BRAF
and inhibits melanomagenesis. Transient GPER activation drives stable mela-
nocyte differentiation that persists after removal of the activating ligand. Con-
sistent with this, brief exposure of melanoma cells to GPER agonists prior to
xenografting inhibited subsequent tumor growth. Systemic treatment with
GPER agonists cooperated with PD-1 blockade in melanoma bearing mice to
greatly prolong survival longer than that observed with either agent alone. The
combination of differentiation-based therapies with immunotherapy may have
signifıcant therapeutic benefıt for melanoma.
#3085 SY-1425 (tamibarotene), a selective RAR agonist, shows synergis-
tic anti-tumor activity with hypomethylating agents in a biomarker selected
subset of AML.Michael R. McKeown, Emily Lee, Chris Fiore, Matthew L. Ea-
ton, Christian C. Fritz, Eric Olson. Syros Pharmaceuticals, Cambridge, MA.
In patients with acute myeloid leukemia (AML) ( 60 years) and myelodys-
plastic syndrome (MDS), the use of hypomethylating agents (HMAs) may ex-
tend survival, but cure rates are very low and new treatment approaches are
needed. HMAs, such as azacitidine, work by inhibiting DNMT1, leading to
depletion of DNA methylation in the tumor cells. Hypomethylation, in turn,
leads to the re-expression of genes associated with differentiation and growth
arrest. We have recently explored the potent and selective RAR agonist SY-
1425 in a genomically defıned subset of AML. SY-1425 binds to RAR and
causes a transition from repression to strong activation of target genes, thus
reprogramming the tumor cells toward terminal maturation in RARA-high
AML models, supporting our recently initiated Phase 2 trial in a biomarker-
selected subset of AML and MDS (NCT02807558). Based on potential mecha-
nistic synergy, we evaluated SY-1425 in combination with HMAs and identifıed
a synergistic anti-proliferative effect. In RARA-high AML cell lines, but not
RARA-low, the combination of SY-1425 with either azacitidine or decitabine
showed synergistic anti-proliferative effects on the cells, with combination in-
dices less than 0.5 over a range of concentrations from0.01 to 100nMof SY-1425
and 0.1 to 1MofHMAs. SY-1425 and azacitidine were also co-administered to
a disseminated patient-derived xenograft (PDX) mouse model of RARA-high
AML. The combination demonstrated superior reduction of tumor burden vs
either therapy alone, leading to deeper and more durable responses with less
than 1% detectable tumor burden. A follow-up study in the RARA-high PDX
model investigated different treatment schedules of SY-1425 and azacitidine
over a period of 56 days, supporting a regimen that maximizes anti-tumor ac-
tivity and tolerability.Mechanistic studies usingRNA-seq andChIP-seq inAML
cell linemodels have revealed that while azacitidine had onlymoderate suppres-
sive or activating effects over a broad set of genes, the addition of SY-1425 in
RARA-high models resulted in strong and specifıc induction of genes bound by
RAR. It is hypothesized that azacitidine acts to prime the tumor cells for re-
programming by SY-1425. The loss ofmethyl-cytosine residues following azaci-
tidine treatment lowers the barrier to SY-1425 mediated gene induction. It was
observed that the two agents work cooperatively to promote terminal differen-
tiation and decrease proliferation of the AML tumor cells, with the potential for
increased clinical benefıt in a subset ofAMLdefıned by aRARA super-enhancer.
Based on the largely non-overlapping clinical toxicity profıles of azacitidine and
SY-1425, supported by the observed tolerability of the combination in preclini-
cal models, these fındings provide a strong rationale for a planned study of this
combination in biomarker selected, newly diagnosed AML patients.
#3086 Inhibitors of the enzyme dihydroorotate dehydrogenase, overcome
the differentiation blockade in acute myeloid leukemia.Andreas Janzer,1 Da-
vid Sykes,2 StefanGradl,1 Steven Ferrara,3 SvenChristian,1 ClaudiaMerz,1 Hen-
rik Seidel,1 Andreas Bernthaler,1 Mathias Wawer,3 David T. Scadden2. 1Bayer
Pharma AG, Berlin, Germany; 2Massachusetts General Hospital, Boston, MA;
3Broad Institute of MIT and Harvard, Boston, MA.
The prognosis for adults diagnosed with acute myeloid leukemia (AML) re-
mains poor, with a fıve-year survival of only 25%. This prognosis is even more
dismal in older patients who are not well enough to receive standard induction
chemotherapy. Speaking to the need for new therapies is the fact that our ther-
apeutic backbone - a combination of cytarabine and an anthracycline - remains
unchanged since 1973. The promise of differentiation therapywas realized in the
small subset of patients diagnosed with acute promyelocytic leukemia (APL).
Here, treatment in the form of all-trans retinoic acid (ATRA) and arsenic triox-
ide inverted the survival curve; where APL was once the worst form of myeloid
leukemia, it now carries the best prognosis, with a fıve-year survival exceeding
85%. The goal of this study was thus to develop differentiation therapy for pa-
tients with non-promyelocytic AML with the question: “Can we identify small
molecules that overcome myeloid differentiation arrest?” A phenotypic differ-
entiation screen in a HOXA9 driven leukemia model followed by target decon-
volution, identifıed DHODH as an unexpected target for overcoming differen-
tiation arrest inAML.Weused 2 potent smallmolecule inhibitors ofDHODHto
validate this initial fınding: Brequinar, a known DHODH inhibitor and an in
house compound BAY DHODHi. In several in vitro experiments we demon-
strated induction of AML differentiation in a dose dependent fashion. Interest-
ingly, these effects could be completely rescued by addition of uridine, confırm-
ing target specifıcity. Treating mice in multiple genetically diverse AML in vivo
models with a DHODH inhibitor led to tumor growth reduction and AML
differentiation. Expression analysis of leukemia cells explanted frommice xeno-
grafts treated with a DHODH inhibitor demonstrate an early onset of differen-
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tiation markers indicating a direct role of DHODHwith the onset of differenti-
ation in vivo. The mechanism for selective vulnerability of leukemia cells
to DHODH inhibition remains under investigation. Despite the observation
that DHODH is expressed in all cells, normal and malignant, mice can tolerate
DHODH inhibitor therapy for more than 100 days without weight-loss or other
concerning side-effects. Thus, our pre-clinical studies point towards DHODH
as a new metabolic target in the differentiation treatment of AML. Hopefully,
small molecule DHODH inhibitors will provide a much-needed differentiation
therapy for patients with acute myeloid leukemia.
#3087 Forced induction of differentiation in osteosarcoma tumor initiat-
ing cells.Margaret Ellen White, Maria V. Guijarro, Steven Ghivizzani, Charles
P. Gibbs. Univ. of Florida College of Medicine, Gainesville, FL.
Osteosarcoma (OS) is a highly malignant bone cancer that is defıned histo-
logically by the secretion of immature osteoid. The chemotherapeutic regimen
has not changed in the last 40 years and similarly, the fıve-year survival rate
remains at 60%, with the majority of fatalities arising from metastases in the
lungs. OS is believed to originate from osteogenic committed progenitors, in-
volving disruption of extracellular matrix synthesis in favor of proliferation. In
previous work, our lab has developed a method to selectively identify Tumor
Initiating Cells (TICs) in OS xenografts based on their ability to activate a tran-
scriptional reporter comprised of a human OCT4 promoter linked to green
fluorescent protein (GFP) coding sequence. Clonally derived, stably transfected
OS Oct4/GFP TICs are capable of initiating and maintaining the growth of
heterogeneous tumors and driving disease progression. The loss of GFP expres-
sion and tumorigenic capacity occurs during tumor formation in response to
cues within the tumor microenvironment, resulting in adoption of a specialized
secretory phenotype as an adaptive survival mechanism: a phenotypic change
similar to that seen in physiological differentiation. During skeletal formation,
Bone Morphogenetic Proteins (BMP) play key roles in osteogenic maturation.
Because the OS lineage of origin suggests an innate sensitivity to BMP proteins,
we hypothesize that BMP stimulation will force the induction of differentiation
in OS TICs and will impair the ability of these cells to initiate and maintain
tumor growth. To fırst probe that OS TICs respond to BMP stimulation, we
detected by flow cytometry the expression of BMP Receptors Type II and 1A in
two primary OS-derived cell lines (OS521 and OS156), with similar expression
seen in Mesenchymal Stem Cells. Furthermore, by treating OS TICs with BMP
heterodimers - BMP2/7 and BMP4/7 - we observed an activation of canonical
BMP signaling, suggesting a functional and intact signaling network. BMP4/7
stimulation ofOS521 TICs in vitro showed an increase in cells in theG1 phase of
the cell cycle, visualized by DAPI, and higher p21 and p27 expression than
controls, shown in immunoblotting. On the other hand, BMP4/7 treatment of
OS156 TICs reduced its invasion capacity through a complex of Fibronectin and
Bovine Serum Albumin by 33% (p 0.00144) compared to untreated controls.
Strikingly, in vivo studies revealed that time to tumor onset of BMP4/7 pre-
treated OS521 TICs in NSGmice at a dose of 3x104 cells was signifıcantly longer
than in controls (p0.0003). In summary, our data suggests a reduction of OS
tumorigenicity due to a BMP4/7 induced differentiation-based response. Such a
differentiation-based therapy could become a more effective and safer alterna-
tive to cytotoxic chemotherapy. Future studies include TIC treatment with hyp-
oxia, adenosine, and calcium, to investigate the underlyingmechanisms respon-
sible for BMP involvement in the tumorigenic capacity of osteosarcoma.
#3088 Combination of 4SC-202 and IFN- restores mature APC pheno-
type in AML cells.Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler,
Svetlana Hamm. 4SC AG, Planegg-Martinsried, Germany.
Acute myeloid leukemia (AML) is characterized by a differentiation block
resulting in accumulation of immature myeloid cells. Differentiation therapy,
e.g. with all-trans retinoic acid (ATRA) has become a part of standard treatment
for the acute promyelocytic leukemia variant of AML. Other agents like cyto-
kines andHDAC inhibitorswere shown to enhance differentiation ofAMLcells,
which results in apoptosis induction or re-sensitization to ATRA. However, a
differentiation therapy resulting in the restoration of antigen presenting func-
tion of AML cells would be a more desirable asset, since such cells will be able to
induce or enhance immune response against residual malignant AML cells.
Here, we analyzed the impact of 4SC-202 alone and in combination with differ-
ent cytokines on differentiation of AML cell lines THP-1, HL-60 andMOLM-13
(AML-M4, -M2, and -M5 class, respectively). Myeloid lineage markers CD11b,
CD86, CD14 and HLA-DR were analyzed by flow cytometry and quantitative
PCR.Cytokine productionwasmeasured using Luminexmultiplex system. Fur-
thermore, chromatin immunoprecipitation (ChIP) was performed to assess the
direct impact of 4SC-202 on promoter histone acetylation of differentiation
genes. 4SC-202 is an orally available clinical stage epigenetic small molecule
inhibitor which specifıcally targets histone deacetylases HDAC class I isoen-
zymes 1-3 as well as the lysine-specifıc demethylase LSD1 (KDM1A). 4SC-202
treatment of AML cell lines resulted in a dose-dependent increase of myeloid
differentiation genesCD86 and ITGAM(CD11b) onmRNAandprotein level.
On the chromatin level, 4SC-202 correspondently induced an upregulation of
chromatin activation marks like acetylation of histone H3 lysine 9 and 27
(H3K9ac, H3K27ac) at the promoters of these genes. Interestingly, reference
compounds likeATRA, bexarotene,GM-CSF andTNF-were not as effıcacious
as 4SC-202 in the induction of differentiation markers in AML cells, whereas
IFN- strongly induced MHC class II molecules HLA-DR and myeloid lineage
marker CD14. Finally, the combination of 4SC-202 and IFN- resulted in a
strong and complementary induction of differentiation and APC markers
CD11b, CD14, CD86 and HLA-DR resulting in a CD86high/HLA-DRhigh phe-
notype whichwas able to produce pro-inflammatory cytokines. In summary, we
demonstrate that 4SC-202 induces differentiation of AML cells of different sub-
types and thus provide promising preclinical data for applying this novel epige-
netic modulator for differentiation therapy of AML.Moreover, themature APC
phenotype induced by the combination of 4SC-202 and IFN- may further
suggest an application in consolidation treatment of AML to enhance or even
elicit a tumor-specifıc T-cell response against residual malignant AML cells pre-
venting AML recurrence.
#3089 CombiningMEK andHDAC inhibitors as a therapeutic strategy to
promote differentiation of colorectal cancer. Laura J. Jenkins, Ian Y. Luk,
Janson W. Tse, Jennifer Mooi, Amardeep S. Dhillon, John M. Mariadason. Ol-
ivia Newton John Cancer Research Institute, Heidelberg, Australia.
The fıve-year survival rate for patients withmetastatic colorectal cancer is less
than 15%, necessitating an urgent need to develop novel therapeutic strategies
for this disease. Loss of differentiation is associatedwithworse overall survival in
colorectal cancer, suggesting that strategies to re-induce differentiation may
provide clinical benefıt. Differentiation therapy is effective in the treatment of
acute promyelocytic leukemia but whether this approach can be effıcacious in
treating colorectal cancer is unknown. Inhibitors of the MAPK signaling path-
way including the MEK inhibitor Trametinib can induce markers of differenti-
ation in colorectal cancer cells. Trametinib also induces expression of Cdx-2, a
knowndriver of colonic cell differentiation. Similarly, histone deacetylase inhib-
itors (HDACi) induce markers of differentiation in multiple tumor cell lines,
including colon cancer cells. The aim of this study was to assess the potential
therapeutic benefıt of combiningMEK (Trametinib) andHDAC (Panobinostat)
inhibitors to further promote differentiation in colorectal cancer cells, and to
elucidate the mechanistic basis for this effect. Combination treatment of HT29
and T84 cells with Trametinib and Panobinostat signifıcantly enhanced mRNA
andprotein expression of the differentiationmarkersCadherin 17 (CDH17) and
Keratin 20 (KRT20), compared to either agent alone. Trametinib also induced
expression of Cdx-2, an effect that was enhanced upon combination treatment
with Panobinostat. Notably, Cdx-2 knockdown attenuated CDH17 and KRT20
induction by the combination, establishing a direct role for Cdx-2 in differenti-
ation induction by the Trametinib/Panobinostat combination. Concomitant
with inducing differentiation, the drug combination also invokedmore apopto-
sis than either agent alone. To validate these fındings in vivo, HT29 cells grown
as xenografts were treated with Trametinib and Panobinostat alone and in com-
bination. Mice treated with the combination had signifıcantly smaller tumours
thanmice treated with vehicle or either agent alone. Consistent with the in vitro
fındings, immunostaining of the tumour xenografts demonstrated a strong in-
crease in CDH17, KRT20 and Cdx2 expression upon treatment with the drug
combination. Collectively, this study highlights a drug combination strategy to
re-induce differentiation for the treatment of colorectal cancers.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Drug
Delivery Technology and Antibody Technology
#3090 LY3207447, a tetravalent bispecifıc antibody targeting VEGFR2
and angiopoietin-2, provides amore effıcient anti-angiogenic therapy and an
alternative for combination. Jonathan Tetreault,1 Sudhakar Chintharlapalli,1
Donmienne Leung,2 Damien Gerald,3 Linda Lee,1 Rowena Almonte-Baldo-
nado,3 Lysiane Huber,1 Jianghuai Xu,2 Bharathi Ramamurthy,2 Jennifer
Pereira,1 JohnnyCroy,1 Jirong Lu,1 Ling Liu1. 1Eli Lilly and Company, Indianap-
olis, IN; 2Eli Lilly and Company, San Diego, CA; 3Eli Lilly and Company, New
York, NY.
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Angiopoietin-2 (Ang-2) is released from endothelial cells only in response to
stimulus (e.g. wound healing, tumor growth) and facilitates blood vessel sprout-
ing and inhibits pericyte-endothelial cell interaction via Tie2 signaling. In tu-
mors, Ang-2 is up-regulated and acts togetherwith theVEGF/VEGFR2pathway
to stimulate tumor angiogenesis andmetastasis. While therapeutic intervention
using antagonists to the VEGF/VEGFR2 pathway has proven to be successful in
limiting disease progression in a number of different clinical settings, there is an
obvious need for an improved response. In various preclinical mouse angiogen-
esis or xenograft models, the combination treatment with anti-Ang2 antibody
and the VEGF/VEGFR blocker provided additional benefıt over inhibiting the
individual pathway. Here as an alternative to combo therapy, we have engi-
neered a tetravalent IgG-scFv bispecifıc antibody, LY3207447. LY3207447 is an
immunoglobulin G4 (IgG4) antibody, comprising of VEGFR2 antibody derived
from ramucirumab and a C-terminally fused single-chain variable fragment
(scFv) targeting Ang2. LY3207447 binds to both the extracellular domain of
VEGFR2 and solubleAng2with high affınity and blocks binding ofAng2 to Tie2
and VEGF to VEGFR2, and therefore inhibits signaling. We have shown that
LY3207447 blocks binding of human Ang-2 to human Tie2-Fc by an ELISA
assay and neutralizes Ang-2 induced phospho-Tie-2, but not Ang-1 induced
phospho-Tie-2 in CHO cells overexpressing Tie-2 receptor. Moreover,
LY3207447 neutralizes human VEGF165-induced phospho-VEGFR2 stimula-
tion, cord formation and cell proliferation in human endothelial colony forming
cells (ECFCs) and human dermal microvascular endothelial cells (HMVEC-d).
LY3207447 blocks human and cyno VEGFR2, but not rodent VEGFR2. For
anti-Ang2 arm, LY3207447 blocks human, cyno and mouse Ang2. Pre-clinical
evaluation of LY3207447 in mouse retinal angiogenesis model resulted in an
abrogation of angiogenesis. Combination studies using a rodent-specifıc surro-
gate VEGFR2 blocking antibody, DC101, with parental Ang2 antibody from
which the scFv was derived from, inhibited both tumor growth and metastasis,
resulting in increased survival compared to monotherapies in mouse xenograft
model. These data establish VEGFR2/Ang2 bispecifıc antibodies as a promising
anti-angiogenic, anti-metastatic and anti-tumor agent for the treatment of can-
cer in combination with other therapies.
#3091 Response of C4.4A-positive patient-derived xenograft models of
ESCC, HNSCC and bladder cancer to BAY1129980, a C4.4A-targeted anti-
body drug conjugate. Joerg Willuda,1 Carol Pena,2 Christoph Kneip,1 Patricia
E. Carrigan,1 Hans-Georg Lerchen,3 Lars Linden,3 Bertolt D. Kreft1. 1Bayer AG,
Berlin, Germany; 2Bayer AG, Whippany, NJ; 3Bayer AG, Wuppertal, Germany.
C4.4A (LYPD3) is a cancer- and metastasis-associated transmembrane cell
surface protein which is expressed at high frequency and density in multiple
tumor types including squamous and non-squamous non-small cell lung carci-
noma ((NSCLC), head & neck squamous cell carcinoma (HNSCC), esophageal
squamous cell carcinoma (ESCC) and bladder cancer. C4.4A expression is re-
stricted to a limited number of tissues (e.g. suprabasal layer of skin) making
C4.4A an attractive target for the treatment of cancer with a C4.4A-targeted
antibody-drug conjugate (ADC). BAY 1129980 (C4.4A-ADC), is an ADC con-
sisting of a fully human C4.4A-targeting monoclonal antibody (technology li-
censed from BioInvent) conjugated via a novel, non-cleavable alkyl hydrazide
linker to a novel, highly potent auristatin W, an antimitotic agent (technology
licensed from Seattle Genetics, Inc.). This C4.4A-ADC has been previously
shown to be effıcacious in C4.4A positive cell line-derived and PDX models of
NSCLC.Herewe present newpreclinical effıcacy data of C4.4A-ADC in patient-
derived xenograft (PDX) models of ESCC, HNSCC and bladder cancer. Models
were selected based on tumor C4.4A levels as determined by mRNA levels and
immunohistochemistry (IHC), the latter of which allowed ranking of models
according toH-score, percentage of C4.4Apositivity, and staining intensity (0 to
3) in the cell membrane. Representative C4.4A-positive models were selected
for in vivo effıcacy studies (n7 each): 4HNSCC, 4 ESCC and 2 bladder cancers.
C4.4A-ADC was administered as one cycle (Q4Dx3) at doses of 7.5 and 15
mg/kg, and effıcacy was assessed up to 4 weeks post treatment for optimum
tumor growth inhibition (TGI). In ESCCmodels a response to C4.4A ADCwas
seen in ES0190 (TGI of 77%; 15mg/kg) and in ES0195 (59%). InHNSCCmodels
an ADC effect on tumor growth was observed in HN10847 (46%), HN9619
(34%), and HN10321 (22%). Finally, both bladder models tested were sensitive
to treatment, with a transient response seen in BL0597 (41%) and a strong and
complete tumor growth control in BL5001 (93%,) which was superior to cispla-
tin. The data show that C4.4A-positive PDX models of ESCC, HNSCC and
bladder cancer can respond to C4.4A-ADC. C4.4A expression served as a
marker for preselection of the models. Nevertheless, other factors may affect
response and sensitivity of these tumor models, such as sensitivity to tubulin
inhibition, ADC uptake and intracellular processing. In summary, these data
support further exploration of the potential of BAY 1129980 in HNSCC, ESCC
and bladder cancer in addition to NSCLC. A Phase 1 clinical trial of BAY
1129980 is ongoing (NCT02134197).
#3092 U3-1402a, a novel HER3-targeting ADC with a novel DNA topo-
isomerase I inhibitor, demonstrates a potent antitumor effıcacy. Suguru
Ueno,1 Kenji Hirotani,1 Reimar Abraham,2 Sabine Blum,2 Birgit Franken-
berger,2 Mauricio Redondo-Muller,2 Johannes Bange,2 Yusuke Ogitani,1 Akiko
Zembutsu,1 Koji Morita,1 Takashi Nakada,1 Shuji Majima,1 Yuki Abe,1 Toshi-
nori Agatsuma1. 1Daiichi Sankyo Co., Ltd., Tokyo, Japan; 2Daiichi Sankyo Eu-
rope Co., Ltd. (Former U3 Pharma), Munich, Germany.
Background: HER3 (human epidermal growth factor receptor 3) is a member
of HER family, and overexpressed in breast cancer, NSCLC, melanoma, gastric
cancer and pancreatic cancer patients‘ tissues. U3-1402a is an antibody-drug
conjugate (ADC) comprised of a fully human anti-HER3monoclonal immuno-
globulin G1 (IgG1) antibody (U3-1287) covalently conjugated via a cleavable
peptide linker to exatecan derivative (DXd). The DXd is released after internal-
ization of U3-1402a and leads to apoptosis of the target tumor cells by the
inhibition of topoisomerase I. This ADC achieves a high drug-to-antibody-ratio
(DAR7 to 8)with homogeneous conjugationwith the topoisomerase I inhibitor.
The aim of this study was to preclinically evaluate the effıcacy of U3-1402a in
breast cancer models. Materials and methods: In order to evaluate the pharma-
cological potential of U3-1402a, in vitro and in vivo studies were performed. In
vitro growth inhibition assay evaluated the sensitivity of U3-1402a in HER3-
positive human breast cancer cell line (HCC1569) and HER3-negative human
cervical carcinoma cell line (C33A). Cells were treated with U3-1402a or
MAAA-1181 (payload ofU3-1402a) depending on its concentration (U3-1402a:
0.153 to 10 000 ng/mL, MAAA-1181: 2.44 to 160,000 pg/mL). In vivo growth
inhibition study evaluated the dose-dependent sensitivity ofU3-1402a inHER3-
positive breast cancer xenograft model, MDA-MB-453. In addition, several
xenograft models with different HER3 expression were tested with its sensitivity
to U3-1402a. These models were HCC1569 (human breast cancer cell line,
HER3 IHC score 3),MDA-MB-453 (human breast cancer cell line, HER3 IHC
score 2), NIBIO-G016 (human gastric cancer patient-derived xenograft,
HER3 IHC score 1) and MDA-MB-231 (human breast cancer cell line, HER3
IHC score 0). Results: In vitro study, U3-1402a exhibited anti-tumor killing
activity in HER3-positive human breast cancer cell line, HCC1569. C-33A hu-
man cervical carcinoma cell line was not sensitive to U3-1402a even MAAA-
1181 itself exhibited anti-tumor killing activity to this cell line. In vivo study,
U3-1402a showed dose-dependent anti-tumor killing activity in a HER3-posi-
tive breast cancerMDA-MB-453 xenograftmodel. Finally, in vivo tumor regres-
sion was only observed in HER3 2 and 3 models. Conclusions: U3-1402a
preclinically exhibited its effıcacy in breast cancer model in vitro and in vivo. In
vivo effıcacy was correlated with HER3 expression. These studies suggest that
U3-1402a, a novel HER3-targeting ADC, would be effıcacious in a broader pa-
tient population with HER3 expression like breast cancer, melanoma, NSCLC,
gastric cancer and pancreatic cancer.
#3093 Expression of DLL3 in metastatic melanoma, glioblastoma and
high-grade extrapulmonary neuroendocrine carcinomas as potential indica-
tions for rovalpituzumab tesirine (Rova-T; SC16LD6.5), a delta-like protein
3 (DLL3)-targeted antibody drug conjugate (ADC). Laura R. Saunders,1 Sam-
uel A. Williams,1 Sheila Bheddah,1 Kumiko Isse,1 Sarah Fong,1 Marybeth A.
Pysz,1 Himisha Beltran,2 Loredana Puca,2 Verena Sailer,2 Juan M. Mosquera,2
Yu Yin,3 Jiaoti Huang,3 Andrew J. Armstrong,3 Jorge Garcia,4 Cristina Magi-
Galluzzi,4 VadimKoshkin,4 Petros Grivas,4 Farhad Kosari,5 John Cheville,5 Jus-
tin C.Moser,5 Thomas J. Flotte,5 Thorvardur Halfdanarson,5 AaronMansfıeld,5
Konstantinos N. Leventakos,5 Julian R. Molina,5 Douglas W. Ball,6 Barry D.
Nelkin,6 Jill E. Shea,7 Courtney L. Scaife,7 Scott J. Dylla1. 1AbbVie Stemcentrx,
South San Francisco, CA; 2Weill Cornell Medicine, NewYork, NY; 3Duke Univer-
sity School of Medicine, Durham, NC; 4Cleveland Clinic, Cleveland, OH; 5Mayo
Clinic, Rochester, MN; 6Johns Hopkins, Baltimore, MD; 7University of Utah, Salt
Lake City, UT.
Expression of DLL3 was examined in additional tumor types, as it was found
to be highly expressed in tumor-initiating cells (TIC) in small cell lung cancer
(SCLC), where a DLL3-targeted antibody drug conjugate (ADC), rovalpitu-
zumab tesirine (Rova-T; SC16LD6.5; Saunders et al. 2015 Sci Transl Med
7:302ra136)) exerted clinically meaningful anti-tumor effects in a phase I trial
(Spigel et al. 2016 Lancet Oncology; In Press). DLL3 expression was profıled by
qRT-PCR, ELISA and immunohistochemistry inmultiple tumor types. Patient-
derived xenografts (PDX) from melanoma and ovarian small cell carcinoma
were established and used for effıcacy studies to determine the ability of Rova-T
to impact tumor growth and TIC frequency. DLL3 expression was seen in met-
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astatic melanoma (55%), low grade gliomas (90%), glioblastoma (70%), medul-
lary thyroid cancer (65%), carcinoids (33%), dispersed neuroendocrine tumors
in the pancreas (9%), bladder (57%) and prostate (24%), testicular cancer (90%),
and lung adenocarcinomas with neuroendocrine features (80%). Unlike SCLC,
where DLL3 does not predict clinical outcome on standard therapies, DLL3
expression negatively correlateswith overall survival inmelanoma and small cell
bladder cancer. In mice bearing DLL3 positive melanoma PDX, treatment with
a single dose of Rova-T resulted in effective and durable responses (100 days),
which correlated with a signifıcant impact on TIC frequency. Similarly, in mice
bearing DLL3-positive ovarian small cell PDX, a single dose of Rova-T resulted
in effective and durable responses (100 days). Our results show that DLL3 is
expressed in many neuroendocrine tumors (lung, ovarian, prostate, bladder,
etc), metastatic melanoma, medullary thyroid cancer, low-grade gliomas and
glioblastoma. Given pre-clinical results showing effıcacy of Rova-T in mela-
noma and ovarian small cell carcinoma, as well as encouraging clinical data with
Rova-T in patients with recurrent/refractory SCLC, clinical evaluation of
Rova-T in DLL3-positive melanoma, glioblastoma, medullary thyroid cancer
and other high-grade neuroendocrine carcinomas is warranted. A “basket” trial
enrolling patients with DLL3-positive solid tumors is now recruiting patients
(NCT02709889).
#3095 ThedevelopmentofCPI as anovel, next-generationDNA-targeting
payload for ADCs. Jennifer Kahler,1 Maureen Dougher,1 Jane Xu,1 Matthew
Doroski,2 Andreas Maderna,3 Russell Dushin,2 Stephane Thibault,3 Mauricio
Leal,1 Madan Katragadda,4 Christopher J. O’Donnell,2 Matthew Sung,1 Puja
Sapra1. 1Pfızer, Pearl River, NY; 2Pfızer, Groton, CT; 3Pfızer, La Jolla, CA; 4Pfızer,
Cambridge, MA.
DNA targeting drugs represent one of cornerstones of anti-cancer therapy for
both hematologic and solid tumor indications. Low potency anti-DNA com-
pounds (e.g. platins, anthracyclines) are included in many standard-of-care
(SOC) regimens, however theirmodest activity and overall toxicity profıles limit
their therapeutic potential. To increase the therapeutic window for DNA-dam-
aging agents, high potency anti-DNA compounds with enhanced anti-tumor
activity have been delivered to tumors as payloads of targetingmodalities such as
antibody-drug conjugates (ADCs). Herein, we describe the development of a
novel DNA-damaging compound comprised of a dimeric structure of cyclopro-
pylpyrrolo[e]indolones (CPIs) that was designed to alkylate DNA and generate
toxic interstrand crosslinks (ICLs). In response to the CPI-induced formation of
ICLs, CPI treatment of cells primarily activates the Fancomia anemia DNA
damage response pathway, whereas other successful DNA-damaging ADC pay-
loads such as calicheamicin activate double-strand break response pathways.
CPI shows860-fold greater potency than calicheamicin in a panel of cell lines
derived from a broad spectrum of tumor indications. Importantly, this new CPI
payload retains potent activity in calicheamicin- and SOC-resistant tumormod-
els (including overcoming overexpression of drug efflux pumps). When evalu-
ated as payloads on anti-CD33 targeting ADCs, the CPI conjugate showed dra-
matically improved effıcacy over the corresponding calicheamicin conjugates in
MDR tumor models. As a site-specifıc conjugate, the CPI ADC shows en-
hanced in vivo stability and possesses a wider therapeutic window than the
corresponding conventional calicheamicin conjugate and other leading DNA-
damaging conjugates on the CD33 platform.
#3096 Mechanisms of synergy of carboplatin and an EphA2-targeted do-
cetaxel antibody-directed nanotherapeutic. Walid S. Kamoun,1 Andrew J.
Sawyer,1 Christine Pien,1 Alexander Koshkaryev,1 Lia Luus,1 Samantha Merri-
gan,1 Gang Sun,1 Sergey Kozin,2 Zhaohua Richard Huang,1 Suresh K. Tippa-
raju,1 Dmitri B. Kirpotin,1 Hannah Xu,1 Vasileios Askoxylakis,1 Patrick C.
Reynolds,3 Daryl C. Drummond1. 1Merrimack, Cambridge,MA; 2Massachusetts
General Hospital, Boston, MA; 3Texas Tech University, Lubbock, TX.
Platinum-taxane combinations are widely used to treat solid tumors either in
fırst or later lines of therapy. While effective in many settings, platinum-taxane
combinatorial regimens are limited by toxicities.We have recently developed an
antibody directed nanotherapeutic (MM-310) encapsulating a docetaxel prod-
rug, targeted to Ephrin receptor A2 (EphA2). Preclinical investigation of MM-
310 revealed that the liposomal formulation leads to prolonged docetaxel expo-
sure of the tumor with decreased exposure of normal tissues leading to a shift in
toxicity profıle and potentially enabling more safe and effective combinations
with platinum-based chemotherapeutics. In this study, we evaluated the activity
of MM-310 in combination with carboplatin in several xenograft tumor models
and compared it to the activity of free docetaxel in combinationwith carboplatin
at equitoxic dosing. Tolerability of MM-310 in combination with carboplatin in
mice was evaluated, including assessing hepatotoxicity. Biodistribution, micro-
distribution, in vivo tumor growth, and mouse survival studies were performed
in lung and ovarian cell line-derived (CDX) and patient-derived xenograft
(PDX) models. MM-310 in combination with carboplatin was found to be well
tolerated, enabling dosing of both drugs at high doses with maximum tolerabil-
ity when the drugs were dosed three days apart. Carboplatin increased nano-
therapeutic delivery to the tumor in aCDXmodel of triple negative breast cancer
and in a PDXmodel of ovarian cancer. In vivo studies in lung and ovarian cancer
xenograft models showed signifıcant synergy betweenMM-310 and carboplatin
when compared to the monotherapies, as well as when compared to free do-
cetaxel with carboplatin, leading to a signifıcant increase in tumor growth delay
and survival (docetaxel/ carboplatin vs. MM-310/carboplatin, 0 vs 50% com-
plete tumor regression, 24 vs 80 daysmedian time to regrowth). Additionally, in
the same studies, MM-310 and carboplatin was better tolerated than free do-
cetaxel and carboplatin. In conclusion, we found that MM-310 in combination
with carboplatin was signifıcantly better tolerated and more effective than free
docetaxel in combinationwith carboplatin.Mechanistically, the synergistic anti-
tumor activity ofMM-310with carboplatinmay be partially due to a carboplatin
mediated enhancement of nanotherapeutic delivery. The increased preclinical
activity of the MM-310/carboplatin combination, together with the high toler-
ability following scheduling optimization tested in mice, makes this combina-
tion a promising regimen that warrants evaluation in clinical trials.
#3098 Nanotherapeutics for combination drug and gene therapy in treat-
ing glioblastoma multiforme. Angela A. Alexander-Bryant,1 Breanne Hou-
rigan,1 Michael Lynn,2 Jeoung Soo Lee1. 1Clemson University, Clemson, SC;
2Greenville Health System, Greenville, SC.
Gliomas represent approximately 80% of all malignant brain tumors, and
glioblastoma multiforme (GBM), the most aggressive type, accounts for nearly
half of all gliomas. Despite treatment strategies including surgery, radiation, and
chemotherapy, the 5-year survival rate for brain cancer is only 35%. New ther-
apeutic strategies are necessary to improve the outcomes of this disease. Che-
motherapy with DNA alkylating agents is commonly used in treatment for
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GBM. Research has shown that better therapeutic response of GBM tumors to
alkylating agents and increased survival rate is indicative in patients with epige-
netic silencing of O6-methylguanine-DNA methyltransferase (MGMT), a gene
responsible for DNA repair. Therefore, we propose a treatment strategy com-
bining drug and gene therapy to target and silence MGMT to sensitize cells to
treatment with temozolomide (TMZ) or lomustine (CCNU), both DNA alky-
lating agents. We previously developed cationic, amphiphilic copolymer poly-
(lactide-co-glycolide)-g-polyethylenimine (PgP) and demonstrated its utility
for nucleic acid delivery. Here, we examine the ability of PgP as a drug and
siRNA delivery carrier to overcome drug resistance and improve anticancer
activity through combination drug and gene therapy for GBM treatment. PgP
micelles were designed and synthesized for delivery of hydrophobic drugs in the
PLGA core and negatively charged nucleic acids in the positively charged PEI
shell through electrostatic interactions. RNA binding and polyplex stability as-
says were performed using agarose gel electrophoresis. Cytotoxicity of TMZ,
CCNU, and/or PgP/siMGMTpolyplexes was determined byMTT assay. Silenc-
ing of MGMT on the protein and mRNA level was determined using western
blotting and qPCR, respectively. Our results demonstrated that PgP effectively
forms stable complexes with siRNA and protects siRNAs from serum- and ri-
bonuclease-mediated degradation, confırming the potential of the polyplex for
in vivo delivery. We demonstrated that PgP/siMGMT polyplexes mediate
knockdown of MGMT protein as well as a signifıcant56% and68% knock-
down of MGMTmRNA in T98G GBM cells compared to cells treated with PgP
complexed with non-targeting siRNA (siNT) at a 60:1 and 80:1 nitrogen:phos-
phate (N:P) ratio, respectively. Further, co-treatment of PgP/siMGMT
polyplexeswithTMZorCCNUenhanced anticancer activity inT98GGBMcells
compared to treatment with the PgP/siMGMT polyplex, TMZ, or CCNU alone.
Future studies will determine effıcacy of drug-loaded and siRNA-complexed
PgP for combination therapy in vitro aswell as using a xenograft GBMmodel for
local delivery. Successful combinatorial drug and gene therapy using PgP may
overcome drug resistance and improve therapeutic outcomes for patients with
glioblastoma.
#3099 pH-regulated hydrophilicity/hydrophobicity-, surface charge-re-
versible and redox sensitive nanogels for anticancer drug delivery.HaoYang,
QinWang, Fuying Li, Yanhong Zhu, Lu Gan, Xiangliang Yang.Huazhong Uni-
versity of Science and Technology, Wuhan, China.
Long circulation in blood, enhanced tumor accumulation and penetration,
effıcient cellular internalization and intracellular drug release are major chal-
lenges in the development of ideal anticancer drug delivery systems. Although
several strategies have been reported to improve therapeutic effıcacy, they
mainly meet one or a few features which can not circumvent all the barriers.
Here the stimuli-responsive zwitterionic nanogels were developed to overcome
the sequential physiological barriers in cancer chemotherapy. The nanogels
were constructed via a simple precipitation polymerization method by using
temperature-sensitive monomer N-isopropylacrylamide (NIPAM) pH-respon-
sive monomermethylallyl amine (MAA) and betaine-based zwitterionic mono-
mer sulfobetaine methacrylate (SBMA) with in vivo anti-protein adsorption
property as comonomers, and disulfıde bonds-containing N, N’-bis(acryloyl)
cystamine (BAC) as crosslinker. Volume phase transition temperature (VPTT)
and surface charge of the preparednanogelswere precisely controlled by altering
the feedingmolar ratio of these comonomers. Remarkably, Thenanogels possess
ultra-pH sensitive hydrophilicity/hydrophobicity reversible property, in which
the nanogels were hydrophilic in the blood (pH 7.4, 37 °C) for prolonged circu-
lation, while they were rapidly switched to hydrophobic with similar size and
surface charge at acidic tumor pH, resulting in enhanced tumor accumulation
and penetration and strong internalization by normal cancer cells andCSCs. For
effıcient lysosomal escape and intracellular drug release, the nanogels were pos-
itively charged at lysosome pH, which allowed them to be transported into the
cytosol where the loaded cargo DOX was released from the nanogels with the
introduction of intracellular high GSH concentration to exert cytotoxicity. This
study indicated that pH-dependent hydrophilicity/hydrophobicity-, surface
charge-reversible and redox sensitive nanogels might be used as potential carri-
ers for anticancer drugs, which provided a foundation for designing an effective
drug delivery system for cancer therapy.
#3100 Nanoformulated Talazoparib and Olaparib for enhanced delivery.
Paige Baldwin,1 Rajiv Kumar,1 Edward Favours,2 Karen Liby,3 Raushan Kur-
masheva,2 David Kozono,4 Srinivas Sridhar1. 1Northeastern University, Boston,
MA; 2University of Texas Health Science Center San Antonio, San Antonio, TX;
3Michigan State University, East Lansing, MI; 4Dana Farber Cancer Institute,
Boston, MA.
Introduction: PARP inhibitors such as Talazoparib and Olaparib exploit de-
fıciencies in DNA repair pathways, making them attractive candidates for treat-
ment of a number of different cancers. These drugs are particularly effective
when used in combination with other DNA damaging agents such as chemo-
therapeutics and radiation therapy. Combination trials, however, have resulted
in severe toxicities, necessitating either dose reduction or delay. Dose reduction
leads to suboptimal dosing and provides little therapeutic benefıt compared to
monotherapy. Systemically administered nanoparticles offer a more effective
way to selectively accumulate drugs in tumors and bypass toxicities associated
with oral delivery. We have developed nanoparticle delivery systems for both
Olaparib and Talazoparib in order to improve tumor accumulation while by-
passing the toxicity associated with oral administration. Methods: Lipid nano-
formulations of Olaparib and Talazoparib have been developed and character-
ized in regard to size, surface charge, drug loading, release, and stability.
NanoTalazoparib has been tested in vitro in breast cancer cell lines including
W0069, W780, and HCC1937 which exhibit BRCA1 and 2 mutations, and Na-
noOlaparib in the lung cancer cell line Calu-6 which also has a defective FA-
BRCA pathway. Mice have been treated with NanoOlaparib and NanoTalazo-
parib alone and in combination with radiation or temozolomide in order to
evaluate toxicity. Therapeutic effıcacy studies are currently underway. Results:
The nanoformulations have been formulated to encapsulate a clinically relevant
dose of either Talazoparib or Olaparib and release at 37°C over a period of days,
while remaining stable during storage at 4°C. In vitro, both nanoformulations
show the same activity as free drug with IC50s in the nanomolar range for these
cell lines with varying defıciencies in the BRCA pathway. Mice have shown no
appreciable weight loss during treatment with either nanoformulation alone or
in combination with other treatment modalities. Conclusion: Nanoformula-
tions of Talazoparib and Olaparib have been developed and characterized to
demonstrate activity in vitro and tolerable doses in vivo. We have found that
mice tolerate NanoTalazoparib at higher doses when combined with Temozo-
lomide than when given oral Talazoparib. The sustained release from the nano-
particles allows for the nanoformulation to be administered less often than the
daily administration for oral drug and the improved tolerability opens the door
for combination therapy with both chemotherapeutics and radiation therapy.
Therapeutic effıcacy studies are underway and we expect that as a monotherapy
NanoTalazoparib will be more effective at lower doses than oral Talazoparib,
based on the longer circulation time andmore selective accumulation in tumors.
We also anticipate that combination therapy will be more effective with the
nanoformulation, as the maximum tolerated dose is higher than that of the oral
drug.
#3101 Hyperthermia at the single-cell level for disseminated cancer dis-
ease with immuno-magnetic nanoparticles. Tetsuya Kagawa,1 Hiroyuki
Kishimoto,1 Toshiaki Ohara,1 Hiroshi Tazawa,1 Shunsuke Kagawa,1 Takeshi
Nagasaka,1 Satoshi Nohara,2 Ichiro Kato,2 Adarsh Sandhu,3 Hiromichi Aono,4
Toshiyoshi Fujiwara1. 1Okayama University Graduate School of Medicine, Den-
tistry and Pharmaceutical Sciences, Okayama, Japan; 2Meito Sangyo Co., Ltd,
Nagoya, Japan; 3Graduate School of Information & Engineering, University of
Electro-Communications, Tokyo, Japan; 4Graduate School of Science and Engi-
neering, Ehime University, Ehime, Japan.
Hyperthermia using magnetic nanoparticles and alternating magnetic fıeld is
promising for cancer therapy. In most cases, the usefulness of this magnetic
nanoparticle-based hyperthermia has been shown by applying magnetic nano-
particles to tumor tissue such as a subcutaneous tumor with direct injection
technique; however, if the magnetic nanoparticles can be cancer cell-specifıcally
delivered at the cellular level, the magnetic fıeld hyperthermia would have the
potential to treat various sorts of disseminated cancer diseases. The aim of this
study is to prove this concept. Maghemite nanoparticles (MNPs) were conju-
gated with the anti-HER2 antibody (Tmab) for cancer targeting, and the Tmab-
MNPs were applied to the co-culture flask containing both HER2-expressing
breast cancer AU565 cells and normal fıbroblast FEF3 cells. Thirtyminutes later
from the Tmab-MNPs administration, the medium was removed and the cells
were washed to remove excess Tmab-MNPs. Prussian blue iron staining and
immunostaining for Tmab showed co-localization of the maghemite nanopar-
ticles and Tmab only on the cancer cells, which suggested that MNPs conjuga-
tion with Tmab was successful and that cancer specifıc delivery of MNPs at the
cellular level was achieved in vitro. Moreover, application of alternating current
magnetic fıeld at 280 kHz for 1 hour caused apoptotic-like cell death only to
cancer cells without any cell damage to normal fıbroblast FEF3 cells. Intracellu-
lar hyperthermia using cancer-specifıc antibody-modifıed magnetic nanopar-
ticles have the potential to be applied to the treatment of disseminated cancer
diseases.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Drug Delivery Technology and Antibody Technology
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017794
#3102 Quantitation of nanoparticle delivery of AZD2811, an aurora ki-
nase B inhibitor, to tumor tissues in mouse PDX models of solid cancers.
Colin Howes,1 Susan Ashton,2 Elizabeth Pease,1 Richard J. Goodwin,1 Joanne
Wilson,1 Aaron Smith,1 Matthew Ling,1 Nicole Strittmatter,1 Douglas Fergu-
son1. 1AstraZeneca, Cambridge, United Kingdom; 2AstraZeneca, Macclesfıeld,
United Kingdom.
A polymeric nanoparticle (NP) formulation of AZD2811, a selective aurora
kinase B inhibitor, is currently under clinical development for the treatment of
both haematological and solid tumour diseases. Whilst the exploitation of nan-
otechnology to achieve targeted delivery of cancer drugs to solid tumours has
been pursued for several years, it has achieved only limited success. A key re-
quirement is the delivery and quantitative assessment of tumour distribution;
the so-called ’enhance permeability and retention (EPR) effect’. But this has
been reported to offer less than a 2-fold increase in drug delivery to solid tu-
mours relative to healthy organs using conventional NPs, resulting in drug con-
centrations that are insuffıcient for most cancers (Nakamura et al, Bioconj.
Chem. 2016.). It is therefore important to have the capability to evaluate their
distribution in preclinical models and potential for clinical progression. Deliv-
ery of AZD2811-NP in solid and haematological cancers each require different
characteristics : Delivery to solid tumours, relies on exploitation of the EPR
effect to achieve effıcacious advantage over the drug alone through accumula-
tion and release in the target tissue. The latter, treatment in haematological
cancers, does not exploit the EPR effect, but is reliant on the extended pharma-
cokinetics ofNPdelivery and accumulation in bonemarrow through reticuloen-
dothelial system uptake to provide effıcacious levels of drug whilst reducing side
effects and overcoming the need, in the case of Barasertib (the pro-drug of
AZD2811), continuous infusion for several days. Techniques to quantify drug
delivery to tumour tissues in PDXmousemodels of colorectal, lung and ovarian
cancer have been developed to determine the extent of solid tumour distribu-
tion, allowing direct comparison with conventional drug distribution using la-
belled AZD2811. The effect of NP delivery of AZD2811 is to favourably alter the
physical distribution of drug into the tumour tissue in themodels examined. The
effect has been quantifıed by measuring the relative distribution of
AZD2811-NP to other reference tissues, and additionally by comparison with
the tumour concentration of drug delivered in a conventional formulation. By
the fırst measure, we found an approximately 90 to 280-fold increase (in AUC)
across these PDXmodels in AZD2811 concentration in tumour compared with
muscle as the reference tissue. By the secondmeasure, we found a 70 to 150-fold
increase in AZD2811-NP compared with non-nanoparticle AZD2811 in tu-
mour tissue at 4h post administration of the drug. The results demonstrate the
benefıt of drug delivery using polymeric nanoparticles in these three PDX tu-
mour mouse models, increasing our confıdence in successful translation to the
clinic.
#3103 Nanoengineered mesenchymal stem cells for targeted lung cancer
therapy. Swayam Prabha,1 Tanmoy Sadhukha,2 Buddhadev Layek1. 1Univ. of
Minnesota, Minneapolis, MN; 2AlbanyMolecular Research Inc.(AMRI), Albany,
NY.
Solid tumors are characterized by increased interstitial fluid pressure and
enhanced solid stress, contributing to poor intra–tumoral penetration of nano
drug carriers. This offsets the benefıts of enhanced permeation and retention
effect often attributed to these drug carriers. We have developed a novel cell
based targeting approach usingmesenchymal stem cells (MSCs) as cellular drug
carriers.MSCs have been indicated in the tumor-targeted therapy owing to their
selective ability to home to tumors. Our work is focused on non–genetic mod-
ifıcation of MSCs by incorporating nanoparticles loaded with chemotherapeu-
tics to create cellular drug depots capable of homing to tumors and releasing
drugs over a sustained period of time. Nano–engineered MSCs were manufac-
tured by incubatingMSCs with 100g/mL of paclitaxel loaded (18.5% w/w pac-
litaxel) PLGA nanoparticles for 4 hours at 37°C without affecting their viability
and migration potential. Anti-cancer effıcacy of nano-engineered MSCs was
evaluated in the A549 lung tumor model. Bioluminescence imaging was used to
monitor tumor growth. Animals that developed tumors (lung bioluminescence
between 0.5 106 – 1 106 photons/sec) were randomly divided into different
treatment groups. Animals received 1 million nano-engineered MSCs (equiva-
lent to 5mg/kg of paclitaxel) or 106MSCs that were either unmodifıed or loaded
with equivalent concentration of blank nanoparticles. The animals were then
re-dosed with half the initial dose of MSCs every two weeks. Additional groups
of animals received three doses of 40mg/kg of nanoparticle-encapsulated or free
paclitaxel once everyweek. Treatment with nano-engineeredMSCs resulted in a
signifıcant inhibition of the lung tumor growth (p 0.01) compared to that with
other controls. It was interesting to note that despite being dosed at a signifı-
cantly lower concentration of paclitaxel (17.5mg/kg vs. 120mg/kg total dose),
nano-engineered MSCs were signifıcantly more effective than free paclitaxel or
paclitaxel nanoparticles, suggesting better delivery to the tumor. The biodistri-
bution studies and pharmacokinetic analysis indicated a rapid migration and
enhanced retention of the nano–engineered MSCs to the lung tumors. Our
studies demonstrated that nano-engineered MSCs are effıcient carriers for tu-
mor-specifıc drug delivery. Funding: R01EB022558
#3104 Rotatingmagnetic beads for enhanced drug delivery: characteriza-
tion of bead velocity, imaging, and adherence to cellularmonolayers.Herbert
Engelhard,1 Zachary Gaertner,1 Adam Levin,1 Ankit Mehta,1 SeanMorris,2 Mi-
chael Sabo,2 Frances Creighton2. 1Univ. of Illinois at Chicago, Chicago, IL; 2Pulse
Therapeutics, St. Louis, MO.
Background: Superparamagnetic iron oxide nanoparticles (SPIONs) have
been touted as promising vehicles for enhancing drug delivery for cancer, stroke,
and other diseases. Unfortunately, successful clinical use has been hampered by
the problem of scale, since the attractive force between iron particle andmagnet
is inversely proportional to at least the fourth power of the intervening distance.
Utilization ofmagnetically-induced rotary traction (MIRT) offers a way to over-
come this obstacle. Here, we present initial data from the use of a new two-part
system consisting of: 1) a patented rotatingmagnet, and 2)magneticmicrobeads
(MBs), which have been optimized for MIRT. Methods: MBs and the rotating
magnet were provided by Pulse Therapeutics (St. Louis, MO). MBs consist of
single-crystallinemagnetite cores (70 nm), which form aggregates in response
to a magnetic fıeld. Here, the fıeld is generated by a neodymium-boron-iron
permanentmagnet, which is rapidly rotated causingMBs to counter-rotate (like
meshed gears) at physiologic distances, and move by means of surface traction.
Movement of MBs through PBS, DMEM with 5% serum, and 100% serum was
measured 7.5 to 30 cm from the magnet. Suspensions of the particles were im-
aged at different concentrations by MRI and CT scan. 3 cancer cell lines (U87,
E297, LKB1-KO), and normal vascular endothelial cells, were maintained using
standard tissue culture technique. For adhesion studies, cells were grown in
6-well plates to confluence, treated with 10 uL MBs for 30 min., washed with
PBS, imaged with standard light microscopy, digitized, then analyzed using
Image J. Results: In our experiments, MBs moved readily through PBS, DMEM
and serum at distances from 7.5-30 cm; with a maximum velocity at 22.5 cm
(0.45 / 0.04 cm/sec, for serum). While MR imaging produced signifıcant
artifact as expected, MBs were clearly seen by CT scan. Adhesion of the MBs to
the cancer cell lines was markedly higher than to the endothelial cells (10.9-
12.0X) and to fıxed cells, used as controls. Conclusions: MBs are easily rotated
and moved at physiologic distances, even through 100% serum, by means of
surface traction, and can be imaged by CT scan. Adhesion ofMBs to cancer cells
is signifıcantly greater than to endothelial cells. These features show that the
Pulse system is an extremely promising one, for use in magnetic drug targeting
in the clinical setting.
#3105 Targeting microRNAs in brain tumors with oligonucleotide nano-
particle conjugates. Nilmary Grafals,1 Blanca I. Quiñones,1 Pablo E. Vivas,1
Gabriel Barletta2. 1University of Puerto Rico,Medical Sciences Campus, San Juan,
PR; 2University of Puerto Rico, Humacao Campus, Humacao, PR.
Glioblastoma Multiforme (GBM) is the deadliest type of primary brain
tumor being responsible for more than 14,000 deaths annually. The survival
rate of GBM patients from time of diagnosis is 5 months if left untreated
and 15 months with standard care of treatment. Despite great research
efforts in the last 30 years, GBM survival rate has only increased by 2%.
This is mostly due to high recurrence, treatment resistance, and the exis-
tence of the blood brain barrier (BBB) which restricts drug delivery to the
tumor tissue. Therefore, the development of novel therapeutic modalities
able to cross the BBB is urgently needed. MicroRNAs (miRNAs) are small
(18-22 nt.) non-coding RNAs that regulate gene expression at the post-
transcriptional level by binding to the 3’UTR of target mRNAs. Several
dysregulated miRNAs have been reported in all tumor types, including
GBM. Targeting oncogenic miRNAs with oligonucleotide miRNA inhibi-
tors (OMIs) in vitro has shown therapeutic potential. However, in vivo
administration requires the development of nanocariers capable of increas-
ing the stability of OMIs in circulation and improving their delivery to
target tissues. In addition, nanocarriers that can overcome the BBB are
needed. The most studied and promising nanocarriers are gold nanopar-
ticles (AuNP) and liposomes. While AuNPs have bioimaging and micros-
copy advantages, liposomes are clinically preferred. Therefore, we propose
encapsulating OMIs-AuNPs to BBB targeted liposomes. In this study we
present the characterization of miRNA inhibitors conjugated to AuNP.
Briefly, 15 nm AuNP were functionalized to OMIs by two different
techniques: Salt aging functionalization method and PEG and surfactant
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assisted conjugation method. Afterwards, both nanoconjugates were ana-
lyzed for particle size, zeta potential and loading capacity. The PEG and
surfactant assisted functionalization proved to be superior in all of the
analysis, resulting in 30 nm OMIs-AuNPs with a zeta potential of -8 mV
and a loading capacity ratio of 64 oligonucleotides per AuNP. Further
characterization studies such as cell internalization and cytotoxicity are
under evaluation.
#3106 Targeted delivery via Elastin Like Polypeptide: Biodistribution of a
doxorubicin derivative in MDA-MB231 human breast cancer xenografts in
mice. Sonja Dragojevic,1 Jung Su Ryu,1 Felix Kratz,2 Drazen Raucher1. 1Univer-
sity of Mississippi Medical Center, Jackson, MS; 2CytRx Corporation, Freiburg,
Germany.
The anticancer agent doxorubicin has been widely used in the treatment of a
variety of hematological malignancies and solid tumors. Despite doxorubicin’s
effıciency in eradicating tumor cells, severe damage to healthy tissues, alongwith
cardiotoxicity, limits its use in clinics. To overcome adverse side effects, improve
patient safety, and enhance therapeutic effıcacy, we have designed a thermally
responsive biopolymer doxorubicin carrier that can be specifıcally targeted to
tumor tissue by locally applying mild hyperthermia (41 degrees C). The devel-
oped drug vehicle is composed of: a cell penetrating peptide (SynB1) to promote
tumor and cellular uptake; thermally responsive Elastin like polypeptide (ELP);
and the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (DOXO-
EMCH) containing a pH-sensitive hydrazine linker that releases dox in the
acidic tumor environment. We used the in vivo imaging system, IVIS, to deter-
mine the biodistribution of doxorubicin-delivered ELP in MDA-MB231 triple
negative human breast cancer cell line xenografts in nude mice. Tumor bearing
mice were treated with a single IV injection of 10mg/kg doxorubicin equivalent
dose with free doxorubicin, thermally responsive SynB1 ELP 1-DOXO, and a
thermally nonresponsive control biopolymer, SynB1 ELP 2-DOXO. Following a
2 hour treatment with hyperthermia, tumors showed a 2-fold higher uptake
when treated with SynB1 ELP 1-DOXO compared to free doxorubicin. Accu-
mulation of the thermally non-responsive control SynB1 ELP2 -DOXO was
comparable to free doxorubicin, indicating that an increase in dox accumulation
with ELP is due to aggregation in response to thermal targeting. Higher levels of
SynB1 ELP1 -DOXO and SynB1 ELP2 -DOXOwith respect to free doxorubicin
were observed in kidneys. Fluorescence intensity from hearts of animals treated
with SynB1 ELP1 - DOXO show a 5-fold lower accumulation of doxorubicin
than the same dose of free doxorubicin. SynB1-ELP1-DOXObiopolymers dem-
onstrated a 6-fold increase in tumor/heart ratio in comparison to free doxoru-
bicin, indicating preferential accumulation of the drug carrier in tumors. Over-
all, thermally targeted polymers are a promising therapy to enhance tumor
targeting and uptake of anticancer drugs and to minimize free drug toxicity in
healthy tissues, representing a great potential for clinical application.
#3107 Targeting nanotherapeutics to the invasive glioblastoma margin
via the cell surface receptor Fn14.Aniket S. Wadajkar, Jimena G. Dancy, Nina
P. Connolly, Jeffrey A. Winkles, Graeme F. Woodworth, Anthony J. Kim. Uni-
versity of Maryland, Baltimore, Baltimore, MD.
The most common and deadly form of primary brain cancer, glioblastoma
(GBM), is characterized by signifıcant intratumoral heterogeneity, high vascu-
larity, and infıltrative growth. Delivering effective and sustained treatments to
the invading GBM cells without worsening damage to the adjacent brain is a
major challenge. We aim to develop an innovative, local delivery approach that
couples chemotherapy-loaded brain penetrating biodegradable nanoparticles
with tumor cell-targeting capabilities and convection enhanced delivery (CED).
We formulated sub-100 nm sized, close to neutrally charged, poly(lactic-co-
glycolic acid)-poly(ethylene glycol) (PLGA-PEG) nanoparticles with5% w/w
carmustine (BCNU) payload coatedwith a fıbroblast growth factor-inducible 14
(Fn14) antibody to specifıcally target Fn14-positive brain-invading tumor cells.
We observed that PLGA surface modifıcation using non-adhesive PEG allowed
nanoparticles to rapidly move through brain tissue in ex vivo rat brain slices,
potentially increasing the distribution of delivered therapeutics.We showed that
Fn14-targeted nanoparticles were able to selectively bind to recombinant Fn14
but not to brain extracellular matrix proteins in surface plasmon resonance
assays, as well as diffuse within brain tissue in multiple particle tracking assays.
In addition, when administered intracranially, Fn14-targeted nanoparticles
showed improved brain tumor retention in C57BL/6 mice bearing orthotopic
KR158B tumors compared to non-targeted nanoparticles. We propose that tar-
geting treatments to invading cancer cells using non-adhesive nanoparticles will
limit non-specifıc interactions within brain and tumor tissue and thereby allow
specifıc interactions at target structures and increase the BCNU therapeutic
index. To test this hypothesis, we plan to determine the therapeutic effıcacy of
Fn14-targeted and non-targeted, non-adhesive nanoparticles, capable of releas-
ing BCNUover a 3week period, by intracranial CED injections inC57BL/6mice
bearing orthotopic KR158B invasive tumors.
#3108 Gemcitabine nanoparticles show in vitro effıcacy inmurine pancre-
atic ductal adenocarcinoma. Samantha T. Tucci,1 Hamilton Kakwere,1 Azadeh
Kheirolomoom,1 Jai W. Seo,1 Elizabeth Ingham,1 Chang-Il Hwang,2 Katherine
Ferrara1. 1University of California, Davis, Davis, CA; 2Cold Spring Harbor Lab-
oratory, Cold Spring Harbor, NY.
Our goal is to develop nanotherapeutics for the treatment of pancreatic ductal
adenocarcinoma (PC). Squalenoylated Gem (SqGemNPs) and Gem-loaded
temperature sensitive liposomes (GemTSLs) were synthesized and the resulting
effıcacy was compared to that of gemcitabine (Gem) andAbraxane®. Squalenoy-
lation is the conjugation of squalene, a cholesterol precursor, to a drug and
enhances in vivo delivery, half-life, and therapeutic effıcacy [1]. All particles
were evaluated in vitro in both a monolayer and organoid culture of the
KrasLSL-G12D/; Trp53LSL-R172H/; Pdx-Cre (KPC) model. The organoid
culture allows for phenotypicmaintenance that is otherwise lost withmonolayer
culturing [2]. SqGem andCholesterol-PEG2k co-assembled into SqGemNPs via
nanoprecipitation to yield particles of 210	 150nmwith 35wt%Gem.Gemwas
loaded into TSLs by complexing copper to Gem inside multilamellar liposomes
comprised ofDPPC:DSPE-PEG2K:DSPC (50:5:15) to yield particles of 110	 26
nmwith 1.7 wt%Gem. KPC cells were plated as bothmonolayers andMatrigel™
suspensions and organoid-cultured cells were plated in Matrigel. Cells were
incubated with free Gem, SqGemNPs, pre-heated Gem-TSLs, or Abraxane. At
48h, cell survival was assessed using an MTT assay (Invitrogen, Carlsbad, CA).
In monolayer-cultured cells, SqGemNPs was the only tested therapeutic to
achieve 100% cell death (which occurred at a concentration of 50 uM). All other
treatments reached a plateau of effıcacy as a function of concentration. Two
anticipated trendswere confırmed;monolayer-cultured cells weremore respon-
sive to all treatments than organoid-cultured cells, and cells plated in Matrigel
were less responsive to therapy than those plated as amonolayer.We found that
the effıcacy of preheatedGemTSLswas similar to freeGem in all cell cultures and
thus release from the TSLs was validated. In the organoid culture, the IC50 of
SqGemNPs was 0.12 	 0.04 uM compared to 0.19 	 0.04 uM for free Gem,
although both reached a plateau of effıcacy at 70% cell death. The effıcacy of
Abraxane, GemTSLs and Gem plateaued at 45%, 77% and 70% cell death, re-
spectively in organoids. In future studies, two techniques to increase drug avail-
ability in PC tumorswill be evaluated: SqGemNPsplus high intensity ultrasound
ablation, which can increase drug accumulation by 50-fold [3] and GemTSLs
plus ultrasound hyperthermia to locally release Gem at a high concentration
within the tumor vasculature. 1 Couvreur, P. et al. Nano Lett 6, 2544-2548,
doi:10.1021/nl061942q (2006). 2 Boj, S. F. et al. Cell 160, 324-338, doi:10.1016/
j.cell.2014.12.021 (2015). 3 Wong, A. W. et al. J Clin Invest 126, 99-111, doi:
10.1172/Jci83312 (2016).
#3109 Ultrasound-mediated delivery and distribution of polymeric nano-
particles in the normal brain parenchyma and melanoma metastases.Habib
Baghirov,1 Sofıe Snipstad,1 Einar Sulheim,1 Sigrid Berg,2 Rune Hansen,2 Frits
Thorsen,3 Yrr Mørch,4 Catharina de Lange Davies,1 Andreas Åslund1. 1Norwe-
gian University of Science and Technology, Trondheim, Norway; 2Norwegian
University of Science and Technology; SINTEF Medical Technology, Trondheim,
Norway; 3Molecular Imaging Center and Kristian Gerhard Jebsen Brain Tumour
Research Centre, University of Bergen, Bergen, Norway; 4SINTEF Materials and
Chemistry, Trondheim, Norway.
The blood-brain barrier (BBB) prevents the passage of nearly all drugs into the
brain, hindering brain cancer treatment. Nanoparticles (NPs) have emerged as
promising drug delivery vehicles, due to incorporation of poorly soluble drugs,
functionalization for controlled and sustained release and combination of drug
delivery with imaging. Transport of NPs across the BBB, however, is equally
complicated and can benefıt from versatile BBB opening techniques. Focused
ultrasound (FUS) in combination with microbubbles (MBs) ensures safe and
reversible opening of the BBB.Herewe used FUSwith a novel platformbased on
MBs stabilized by poly(isohexyl cyanoacrylate) (PIHCA) NPs to permeabilize
the BBB and transport NPs into the brain in a melanoma metastasis model.
Intracardiac injection of patient-derived humanmelanoma cells was performed
in immunodefıcient mice. Brain melanoma metastases developed four weeks
post-injection. A novel ultrasound system able to generate 1.1 MHz and 7.8
MHzFUSduring the same experimentwas used for FUS treatments. Selection of
the treatment area was guided by magnetic resonance imaging. BBB was dis-
rupted by FUS at 1.1 MHz, while FUS at 7.8 MHz was used to enable acoustic
radiation force and, hopefully, push NPs farther into the extracellular matrix
away from blood vessels. Successful BBB opening was verifıed using a gadolini-
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um-based contrast agent. After the FUS treatment, the brains were either frozen
or fıxed in formalin for histological examination. NP transport across the BBB
and distribution in the brain parenchyma were assessed using confocal micros-
copy with advanced image analysis. Levels of P-glycoprotein (P-gp), an integral
component of the BBB, were determined using immunohistochemistry. FUS in
combination with PIHCANP-MBs successfully opened the BBB with an acous-
tic pressure of 0.38MPa.NPswere transported across the BBB anddistributed in
the brain parenchyma in amanner dependent on the extent of BBB opening. NP
were also delivered to melanoma metastases, although at this stage of tumor
development their accumulation in metastases was limited compared to the
surrounding tissue, possibly due to reduced vascularization of metastases. Little
effect of 7.8 MHz FUS was observed, possibly because FUS at 1.1 MHz already
increasedNPdistribution in the brain tissue. FUS exposure induced some extent
of red blood cell extravasation. P-gp levels were not altered immediately after
sonication. Overall, our results indicate that combiningNPs andMBs in a single
unit, such as the one used in our study, can be used to deliverNPs across the BBB
in a substantial amount, showing its potential in NP-aided drug delivery to the
brain.
#3110 Optimizing nanoparticle surface properties using SPR for
improved therapeutic effıcacy against triple-negative breast cancer
tumors. Jimena G. Dancy, Aniket S. Wadajkar, Graeme F. Woodworth, Jef-
frey A. Winkles, Anthony J. Kim. University of Maryland, Baltimore, Balti-
more, MD.
Many of the nanoparticle (NP) formulations approved for clinical use in
solid tumor therapy provide only modest improvements in patient survival.
This is in part due to NP tumor penetration barriers, including a dense and
complex extracellular matrix (ECM) and an elevated interstitial fluid pres-
sure, which hinder the penetration of drugs and NPs into and within tumors
limiting therapeutic effıcacy. Using polystyrene (PS) particles over the size
range of 20-100 nm, we recently tested how particle size impacted NP diffu-
sion in a well-characterized tumor ECM preparation (Matrigel) and in tri-
ple-negative MDA-MB-231 breast cancer xenografts by multiple particle
tracking (MPT) and intravital microscopy. We also investigated the effect of
PEG surface density on the diffusion of60 nm PS NPs in the same models.
Nonspecifıc binding of the NPs to tumor ECM components was determined
by a surface plasmon resonance (SPR) binding assay, which was then com-
pared to the NP diffusion results. Furthermore, biodegradable PLGA NPs
with various surface PEG densities and two clinically-relevant NPs, PEGy-
lated liposomal doxorubicin (Doxil) and non-PEGylated albumin-bound
paclitaxel (Abraxane), were evaluated by SPR to evaluate their potential
tumor penetration ability. These studies demonstrated that NPs as large as
60 nm, but less than 110 nm in diameter, diffuse rapidly within tumor ECM
and tumor xenograft tissues ex vivo if they are densely coated with PEG. The
penetration of these NPs within the same tumor models was found to be
highly dependent on surface PEG density. Intravital microscopy of NP
spread in living tissue confırmed a signifıcant difference in tumor tissue
penetration between the 60 and 110 nm PEG-PS NPs, as well as between
PEG-coated and uncoated NPs. Non-specifıc binding of NPs to tumor ECM
components was assessed by SPR, which revealed a positive correlation with
the particle diffusion results consistent across multiple particle types, in-
cluding PS and biodegradable NPs. SPR assays revealed that Abraxane binds
signifıcantly to tumor ECM which has the potential to limit particle disper-
sion with tumor tissue. Studies to extend these fındings to drug-loaded,
molecularly-targeted biodegradable NPs are underway. We have success-
fully encapsulated paclitaxel to the polymer backbone of PLGA containing a
low-molecular weight PEG coating. Additional surface modifıcations have
been made to enable NP targeting to Fn14-positive triple-negative breast
tumors. In summary, we have developed a NP platform that can diffuse and
penetrate within tumor tissue and selectively target tumors. Using this ap-
proach, we can optimize therapeutics versions to improve drug effıcacy while
limiting many of the side effects and risks of free drug and non-targeted
therapies.
#3111 Validated Antibody Database: A curated database of antibodies
cited in formal publications.Hanqing Xie. Labome, Princeton, NJ.
Currently research antibodies have a serious quality problem, which is one of
the major contributing factors to the irreproducibility of published reports.
Labome organizes antibody applications cited in formal publications and has
developed Validated Antibody Database (VAD). VAD, a manually curated da-
tabase, compiles commercial and non-commercial antibodies whose specifıci-
ties and applications have been independently reported in published results
from formal articles. Labome prioritizes the curation of articles with knockout
studies and monoclonal antibodies. One of the benefıts of our curation effort is
the identifıcation of cross-reactive species and novel applications for antibodies,
which are often developed for human/mouse proteins and tested by suppliers for
a limited number of applications. Labome registers many antibodies having
cross-reactivitieswithmodel organisms such as flies, worms, zebrafısh, and frogs
and with novel applications from the literature. The current version released in
September 2016 is based on over 50000 formal publications and is freely acces-
sible for online browsing.
#3111A ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-
based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate
cancers. Francesca Zammarchi,1 Simon Chivers,1 Karin Havenith,1 David G.
Williams,2 Lauren Adams,2 Maria Mellinas-Gomez,2 Simon Corbett,3 Peter
Tyrer,2 Francois D’Hooge,2 Song Cho,4 Nazzareno Dimasi,4 Mary Jane Hin-
richs,4 Phil W. Howard,2 John A. Hartley,3 Patrick H. van Berkel1. 1ADC Ther-
apeutics, London, United Kingdom; 2Spirogen/MedImmune, London, United
Kingdom; 3University College London, London, United Kingdom; 4MedImmune,
Gaithersburg, MD.
Prostate-specifıc membrane antigen (PSMA) is an attractive target for an
ADC approach as it is over-expressed by virtually all prostate cancers and its
expression is highest in poorly-differentiated, metastatic and castration-resis-
tant cases. PSMA has limited expression in non-prostatic tissues, it is not se-
creted or cleaved by PSMA-expressing cells, and it is constitutively internalized,
a process that may be accelerated by specifıc antibody binding. ADCT-401/
MEDI3726 is an ADC composed of a monoclonal antibody (J591), directed
against human PSMA, site-specifıcally conjugated (drug-to-antibody ratio of
1.8) to a highly cytotoxic DNA cross-linking PBD dimer with a valine-alanine
dipeptide linker. In vitro, ADCT-401/MEDI3726 demonstrated potent and spe-
cifıc cytotoxicity in a panel of PSMA-expressing prostate cancer cell lines,
whereas its activity was greatly reduced in PSMA-negative cell lines. In vivo,
ADCT-401/MEDI3726 showed strong antitumor activity against CWR22Rv1
and LNCaP human-derived prostate cancer xenograft models. In the
CWR22Rv1model, a tumorwith low, heterogeneous PSMAexpression, ADCT-
401/MEDI3726 achieved dose-dependent antitumor activity when adminis-
tered as single dose at either 0.33 or 1 mg/kg, which resulted in signifıcant
increase in survival compared to the vehicle-treated animals. Moreover, a single
dose of ADCT-401/MEDI3726 showed remarkable superior antitumor activity
compared tomultiple doses of another PSMA-targeted ADC stochastically con-
jugated to the auristatin payload vcMMAE with a DAR of 4. In the LNCaP
model, ADCT-401/MEDI3726 resulted in dose-dependent antitumor activity
when dosed once at 0.11, 0.33 or 1 mg/kg. In the PSMA-negative prostate can-
cer-derived PC3 xenograft model, ADCT-401/MEDI3726 and an isotope-con-
trol ADC showed limited tumor growth inhibition highlighting target-mediated
antitumor activity. ADCT-401/MEDI3726 demonstrated potent and specifıc in
vitro and in vivo antitumor activity in prostate cancer-derived models of differ-
ing levels of PSMA and this warrants further development of this ADC into the
clinic.
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#3112 Roles of asialoglycoprotein receptor 2 in gastric cancer progression.
Haruyoshi Tanaka. Nagoya Univ. Graduate School of Medicine, Nagoya, Japan.
Background: Hepatic metastasis and relapse contribute to the high incidence
of gastric cancer (GC)-related fatalities, and represent a frequent and crucial
problem for oncologists. Knowledge of the unique molecular attributes to he-
patic metastasis will improve our understanding of the biology of metastatic GC
and facilitate development of specifıc biomarkers and appropriate targeted ther-
apies, leading to effıcacious personalized treatment. Methods: Transcriptome
and bioinformatics analyses were conduct to identify a candidate molecule that
specifıcally mediate hepatic recurrences of GC. Small interfering RNA (siRNA)
experiments to determine the effect of knockdown on phenotype. Expression
levels of the candidate molecule was determined in the gastric tissues of 200
patients with GC. Results: Asialoglycoprotein receptor 2 (ASGR2), a membrane
traffıcking protein, was identifıed as a candidate biomarker specifıc to hepatic
metastasis. Transcription levels of ASGR2 were differential among GC cell lines
and increased compared to a control nontumorigenic epithelial cell line. Inhib-
iting ASGR2 expression decreased the invasion and migration abilities of GC
cells. Increased expression of ASGR2 mRNA in GC tissues was signifıcantly
associated with lymphatic involvement, vessel invasion, advanced stage and he-
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paticmetastasis. In patient subgroup of stage IIGC, thosewith increasedASGR2
expression had signifıcantly shorter overall and disease-free survival than those
without. Conclusions: ASGR2may represent a biomarker for hepatic metastasis
of GC and as a target for therapy.
#3113 Knockdown of cell division cycle-associated 8 (CDCA8) suppresses
hepatocellular carcinoma growth via the upregulation of tumor suppressor
ATF3. Tae-Won Jeon,1 Min Ji Ko,1 Yu-Ri Seo,1 In Hye Baik,1 Ilseon Hwang,1
Hun-Mo Ryoo,2 Jin Young Kim,1 Keon Uk Park,1 Yun-Han Lee1. 1Keimyung
University School of Medicine, Daegu, Republic of Korea; 2Daegu Catholic Uni-
versity, Daegu, Republic of Korea.
Background: Hepatocellular carcinoma (HCC) is the thirdmost lethal cancer
worldwide which remains a major challenge due to poor prognosis and limited
treatment options. Cell division cycle associated 8 (CDCA8) is known as a com-
ponent of a chromosomal passenger complex required for stability of the bipolar
mitotic spindle and it is commonly overexpressed in humanHCC.However, the
functional role of CDCA8 in HCC progression remains to be clarifıed. In this
study, we hypothesized if targeting of CDCA8 with small interfering (si) RNA
could alter the course of HCC progression. We also investigated the molecular
mechanism thatmediatesHCCcell death caused byCDCA8 silencing.Methods:
Human HCC cell lines, Huh1 and Huh7, were transfected with CDCA8 siRNA
and tested for growth inhibition and apoptotic induction usingMTS, FACS and
microscopic analysis. To obtain insights into the molecular changes in response
to CDCA8 knockdown, global changes in gene expression were examined using
RNA sequencing. Results: siRNA silencing of CDCA8 inhibited HCC cell
growth and long-term colony formation by blocking cell cycle progression and
by inducing apoptotic cell death. RNA sequencing data showed that, represen-
tatively, the anti-proliferative effects were driven by a subset of molecular alter-
ations including the upregulation of tumor suppressive ATF3 and GADD34
genes and the downregulation of BGLAP, a key regulator of cell growth and
invasiveness. Subsequent Western blot analysis affırmed that CDCA8 silencing
induces the increase in the levels of ATF3 and GADD34 and the decrease in
phosphorylated Akt in both Huh1 and Huh7 cells. Also, the same condition
decreased the levels of PARP-1 and pro-caspase 3, accelerating apoptosis. Of
importance, silencing of CDCA8 expression effectively suppressed HCC tumor
growth in a murine xenograft model. Conclusion: These fındings suggest that
targeting CDCA8 could be an attractive option for molecular therapy of HCC.
#3114 The role of prostaglandin signaling in human glioblastoma cell
activities and growth in vitro and in vivo. Jiange Qiu,1 Yifeng Du,2 Qianqian
Li,2 Zhi Shi,1 Jianxiong Jiang2. 1JinanUniversity, Guangzhou, China; 2University
of Cincinnati Academic Health Center, Cincinnati, OH.
Glioblastoma multiforme (GBM) constitutes the most frequent and aggres-
sive form of malignant brain primary tumors. Despite current combined treat-
ment involving surgery, chemotherapy and radiation therapy, the median sur-
vival of GBM patients is only about one year, with less than 3-5% of patients
surviving over 5 years. Cyclooxygenase-2 (COX-2) is overexpressed in glioblas-
toma, and its expression level is highly positively correlated with the tumor
grade. As a major enzymatic product of COX-2, prostaglandin E2 (PGE2) me-
diates inflammatory processes within the brain and facilitates progression of
many chronic inflammation-associated neurological diseases via its four down-
stream receptors - EP1-EP4. We hypothesize that selectively targeting these
receptors might provide an alternative therapeutic strategy for GBMwith more
specifıcity than generic blockade of the entire COX-2 cascade. In this study, two
engineered human GBM cells with or without activated COX-2 were used to
explore the PGE2 signaling involved in the development and progression of
GBM. COX-2 activation by LPS or its overexpression facilitated migration, in-
vasion, and transformation of these GBM cells in vitro. Moreover, the COX-2-
mediated GBM cell activities were substantially suppressed by selective antago-
nists of PGE2 receptors that are highly expressed in these cells. Furthermore, the
tested PGE2 receptor selective antagonists also suppressed the growth of GBM
cells in vivo. In sum, our results suggested the inflammatory PGE2 signaling is
involved in human GBM cell inflammation, migration, invasion and transfor-
mation through its downstream receptors, and should be explored as alternative
molecular targets for novel GBM therapies.
#3115 Characterization of CDCA1 protein as a novel prognostic bio-
marker and therapeutic target for oral cancer. Thang Manh Phung,1 Atsushi
Takano,1 Yoshihiro Yoshitake,2 Masanori Shinohara,2 Yoshinori Murakami,1
YataroDaigo1. 1The Institute ofMedical Science, TheUniversity of Tokyo, Tokyo,
Japan; 2Kumamoto University, Kumamoto, Japan.
Oral cavity carcinoma (OCC) is one of the most common causes of cancer-
related death worldwide. Current therapies for OCC still show poor clinical
outcomewith fıve-year survival rate of less than 63%. Therefore, next generation
biomarkers and therapeutic strategies for OCC are eagerly awaited.We selected
genes thatwere specifıcally overexpressed in themajority ofOCCusing our gene
expression profıle database, and identifıed cell division cycle associated 1
(CDCA1) that appeared to encode nuclear protein as a candidate. Immunohis-
tochemical analysis using tissue microarray covering 99 OCC tissues detected
that CDCA1 protein was expressed in 67 cases of 99 OCC tissues (68%), but not
in normal oral epithelia. In addition, high levels of CDCA1 protein expression
was signifıcantly associated with poor prognosis for OCC patients (P 0.0244
by log-rank test). Furthermore, knockdown of CDCA1 expression by siRNAs
signifıcantly inhibited the growth of tumor cells. Moreover, flow cytometric
analysis, multiple apoptosis assays, and live cell imaging experiment revealed
that CDCA1 could be important for the growth and survival of OCC cells,
probably through the regulation of mitotic prophase and/or apoptosis. Our
fındings suggest that CDCA1 is likely to be a novel prognostic biomarker and a
therapeutic target for OCC patients.
#3116 Dysregulated cholesterol synthesis is a therapeutic vulnerability in
glioblastoma. Diane M. Kambach, Alan S. Halim, A. Gesine Cauer, Qian Sun,
Carlos A. Tristan, Orieta Celiku, AparnaH. Kesarwala, Uma Shankavaram, Eric
Batchelor, Jayne M. Stommel. National Cancer Institute, Bethesda, MD.
A hallmark of cellular transformation is the evasion of contact-dependent
inhibition of growth. To fınd new therapeutic targets for glioblastoma, we
looked for pathways that are inhibited by high cell density in normal astrocytes
but have lost this regulation in glioma cells. Here we report that at high cell
density, normal astrocytes turn off cholesterol synthesis but glioma cells keep
this pathway on. Correspondingly, cholesterol pathway upregulation is associ-
ated with poor prognosis in glioblastoma patients. Densely-plated glioma cells
increase oxygen consumption to synthesize cholesterol, resulting in a decrease
in reactive oxygen species, TCA cycle intermediates, and ATP, but without a
compensating increase in aerobic glycolysis. This constitutive cholesterol syn-
thesis is controlled by the cell cycle, as it can be turned off by cyclin dependent
kinase inhibitors and it correlates with disabled cell cycle control though loss of
p53 and RB. Finally, glioma cells, but not astrocytes, are sensitive to cholesterol
synthesis inhibition downstream of the mevalonate pathway, suggesting that
specifıcally targeting cholesterol synthesis might be an effective treatment for
glioblastoma.
#3117 Eribulin is a novel TERT-targeting inhibitor that penetrates into
intracerebrally grown glioblastomas and suppresses their growth in mice.
Masamichi Takahashi,1 Shunichiro Miki,1 Yuko Matsushita,2 Kohei Fukuoka,2
Yoshiko Maida,2 Mami Yasukawa,2 Mitsuhiro Hayashi,2 Akinobu Hamada,2
AkitakeMukasa,3 RyoNishikawa,4 Kenji Tamura,1 Yoshitaka Narita,1 Kenkichi
Masutomi,2 Koichi Ichimura2. 1National Cancer Center Hospital, Tokyo, Japan;
2National Cancer Center Research Institute, Tokyo, Japan; 3The University of
Tokyo, Tokyo, Japan; 4SaitamaMedical University InternationalMedical Center,
Hidaka, Japan.
[Introduction] No effective molecular targeting therapy has been clinically
developed for patientswith glioblastoma (GBM)despite of intense genome anal-
ysis. Approximately 60-80% of GBM harbor mutations in the promoter region
of TERT that leads to its upregulation, making it the most common single ge-
netic abnormalities in GBM. TERT, a reverse-transcriptase subunit of telomer-
ase, has been an attractive candidate for therapy target because of their observed
upregulation in a wide variety of cancers, including GBMs, a phenomenon that
presumably helps maintain telomeres for their indefınite proliferation. It has
been reported recently that TERT has an RNA-dependent RNA polymerase
(RdRP) activity, with which TERT is involved in maintenance of stem cell phe-
notype and mitotic progression. We have previously identifıed eribulin as a
specifıc inhibitor of RdRP activity of TERT through drug screening and shown
that eribulin suppressed growth of ovarian cancers with high TERT expression.
In order to investigate an effıcacy of eribulin as a novel TERT-targeted therapy
against GBM, we investigated the antitumor effect of eribulin in cultured cell
and brain tumor model using GBM cell lines. [Methods] The TERT promoter
status was examined in 20 glioma cell lines. Seven cell lines were subjected to in
vitro cytotoxicity assay. U87MG was either subcutaneously or intracranially
transplanted in athymic mice. Tissue or plasma concentration of eribulin was
measured by LC-MS/MS. [Results] All GBM cell lines tested that harbored
TERT promoter mutations including U87MG, U251MG, U118MG as well as
several patient-derived glioblastoma sphere culture cells were highly sensitive to
eribulin, IC50 below 1nM. Intraperitoneal administration of eribulin com-
pletely suppressed the growth ofU87MGsubcutaneous tumor innudemice, and
the RdRP activities in treated tumors were signifıcantly decreased in a dose-
dependent manner. In the brain tumor model, a high concentration of eribulin
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was detected in the brain tumor tissues as early as 15 minutes after intravenous
injection of eribulin, which remained stable even 24 hours later when the plasma
concentration of eribulin became undetectable. Finally, intraperitoneal admin-
istration of eribulin signifıcantly prolonged the survival of mice with intracere-
brally transplanted U87MG xenograft (p0.001). [Conclusion] Our results
showed that eribulin effıciently transfers into brain tumor tissues and has a
strong antitumor effect against GBM cells through inhibition of RdRP activity.
Eribulin thus appears to be a promising novel TERT-targeting therapeutic agent
against GBM. A clinical trial is being scheduled.
#3118 Histological subtypes correlate with distinct genetic abnormalities
in defıning therapeutic targets in medulloblastoma. Samuel Gelnick,1 Anub-
hav G. Amin,1 Molly Gordon,1 Raphael Salles Scortegagna de Medeiros,2 Nelci
Zanon,2 RajMurali,1Meena Jhanwar-Uniyal1. 1Dept. of Neurosurgery, NewYork
Medical College, Valhalla, NY; 2Hospital Santa Marcelina, Sao Paulo, Brazil.
Medulloblastoma (MB) is the most common primary pediatric malignant
brain tumor. Genetic classifıcation and distinct histologic subtypes defınes MB
into 4 groups: classic (WNT), sonic hedgehog (Shh), group 3 and group 4. In
addition, recent studies have provided evidence that p53 abnormalities is seen in
various sub-groups of MB and that p53-mutated SHH MBs commonly harbor
genetic anomalies including MYCN and GLI2 amplifıcations, which confers
drug resistance. Here, we test the hypothesis that specifıc immunohistological
markers, their correlation with the amplifıcation of the oncogene MYC, and
abnormalities in tumor suppressor gene p53, may defıne their metastatic poten-
tial.Materials andMethods: Immunohistological analysis ofMB tumors (n41)
was evaluated for the expression of glioma transcription factor 1 (GLI-1), Grb2-
associated binding protein 1 (GAB-1), natriuretic peptide receptor (NPR), volt-
age-gated potassium channel (KV1) and mutant p53. FISH analysis was per-
formed to determine MYC amplifıcation or iso- P53. p53-mutant MB cell line
was used to investigate the signaling pathway leading to proliferation,migration,
and drug resistance usingHDAC (LBH-589) andPI3K/mTOR (BKM-120/rapa-
mycin) inhibitors. Results: we showed that: 1) GAB-1 was highly expressed in
the Shh group (82%) and KV1 expression was evenly distributed in all subtypes;
2) No obvious correlation with expression of GLI-1, GAB-1, NPR, or KV1 with
metastasis was seen; 3)Analysis of loss of p53 and overexpression ofMYCvaried
in each subtype; 4) Combined Treatment with LBH-589 and BKM-120 reduced
cell proliferation,migration and S-phase entry, however,MB cells were resistant
to BKM -120 treatments, while LBH-589 caused massive apoptosis; 5) Tumor
formation was suppressed by BKM-120 given with mTOR inhibitors. Conclu-
sion: the result of this study suggests that expression of GLI-1, GAB-1, NPR,
KV1 and p53 was important in defıning the subgroups of MB, although their
metastatic potential remains to be understood. MB cells shows reduced cell
proliferation, cell cycle andmigration, when treatedwithHDAC inhibitor LBH-
589, however these cells display complete drug resistance to PI3K inhibitors.
#3119 Identifıcation of genetic drivers in HER2enriched/HER2negative
breast cancer. Susana Garcia Recio,1 Cheng Fan,1Marni Siegel,1 Joel S. Parker,1
GinaN.Duronio,1Aleix Prat,2 CharlesM. Perou1. 1University ofNorthCarolina,
Chapel Hill, NC; 2Hospital Clinic of Barcelona, Barcelona, Spain.
Background: The non-basal triple negative breast cancer (Non Basal-TNBC)
tumors, also called the luminal androgen receptor (LAR) subtype, make up
20% of all new TNBC cases and is limited to multi-agent chemotherapy.
TNBC is considered one of the leading causes of cancer-associated mortality
amongst women in the USA with a high number of patients dying of metastatic
disease. Some metastases that arise from luminal primary tumors lose their
luminal features and become a HER2-enriched (HER2E) subtype, but remain
clinically HER2 negative (HER2E/HER2-). The molecular features that drive
these HER2E/HER2- tumors may also represent key checkpoints of metastatic
progression.Within this HER2E/HER2- subtype, besides the androgen receptor
(AR), FGFR4 has been shown to be expressed, but its functional role remains
unknown. FGFR4 is a tyrosine kinase receptor involved in proliferation, survival
andmigration during embryonic development and cancer.We hypothesize that
in addition to AR, that FGFR4 may be a driver of HER2E/HER2- tumors and
that the therapeutic targeting of this gene/protein might improve patient out-
comes. Objective: Our objective is to identify themechanism of action of FGFR4
in HER2E/HER2- tumors as well as additional genetic drivers of HER2E TNBC
subtype. Methods: We performed computational analysis of databases (TCGA,
METABRIC) and the analysis of matched breast cancer primary tumors and
metastases to detect genetic drivers. We ran microarrays on two FGFR4 stably
transfected luminal HER2-/ER cell lines (MCF7 and T47D) and also treated a
Luminal B cell line (MDA-MB-453; HER2high/AR/ER-) and HER2E cell line
(CAMA-1; HER2low/ARmed/ER/low) with a FGFR4 inhibitor using a time
course strategy. Results: Through the analysis of microarrays using all 4 cell
lines, we identifıed a gene expression signature of FGFR4-activity enriched in
genes involved in proliferation, cell junctions and cell differentiation. The
FGFR4-associated signature of upregulated genes was enriched in HER2E and
Basal-like subtypes and the downregulated genes enriched in the Luminal sub-
types. To identify predictors of chemotherapy response, we evaluated FGFR4-
associated gene signatures in the diagnostic (pre-treatment) samples of
MDACCneoadjuvant dataset of 500 tumors. The high expression of the FGFR4-
induced gene signature predicted pathological complete response (T.test P
0.001). Conclusions: FGFR4may play an important role in the progression of
Luminal disease and has been identifıed as a new genetic driver of HER2E/
HER2- subtype making it an attractive option as a therapeutic target. We are
further testing these genetic predictions using Patient Derived Xenograft (PDX)
mouse models.
#3120 Application of a lectin as a drug carrier for glycan-targeting cancer
therapy. Tatsuya Oda,1 Osamu Shimomura,1 Hiroaki Tateno,2 Jun Hi-
rabayashi,2 Masayuki Noguchi,1 Shigeru Chiba,1 Makoto Asashima,2 Nobuhiro
Ohkohchi1. 1Institute of Clinical Medicine, Univ. of Tsukuba, Tsukuba, Ibaraki,
Japan; 2National Institute of Advanced Industrial Science and Technology
(AIST), Tsukuba, Ibaraki, Japan.
Various cancers such as pancreatic ductal adenocarcinoma (PDAC) remain
intractable despite recent advances in tumour-targeting antibody drugs. Al-
though the outermost coating of every cell type is predominantly composed of
cell-specifıc glycans, antibody strategies have hit walls of technical diffıculties in
intentional glycan targeting, and medico-economic burden. Lectins, proteins
with glycan-binding potential, could be used as an alternative scaffold; however,
the prejudice that all lectins mediate harmful haemagglutination limited its use
only in experimental and diagnostic applications. Here, we show the successful
in vivo application of a lectin as a drug carrier for cancer therapy. We have
employed rBC2LC-N lectin since this has already shown a specifıc affınity be-
tween PDAC cell-surface glycans. When a lectin-drug conjugate (LecD) was
developed by fusion with a bacterial exotoxin, the 50% inhibitory concentration
(1.04 pg/ml0.0195 pM) was 1000 times lower than that of conventional im-
munotoxins (on the order of ng/ml). In addition, we have revealed that
rBC2LC-N lectin was safely administrable to mice without haemagglutination.
Administration of this LecD in a PDACmouse model of subcutaneous nodules
and peritoneal dissemination, generated prominent therapeutic effects. The uti-
lization of lectins as an in vivo drug-carrier targeting cancer glycan shows real-
istic potential when paired with advanced lectin engineering technologies, and
their applications could be expanded by coupling with small molecule and/or
nanoparticle drugs.
#3121 Validation of protein kinaseD1 as a prognostic factor and pharma-
cological target for the treatment of breast cancer.Caroline Spasojevic,1Marie
Regairaz,2 Sophie Vacher,1 Franck Assayag,1 JeanMarc Ricort,2 Elisabetta Mar-
angoni,1 Ivan Bièche,1 Christian Auclair2. 1Institut Curie, Paris, France; 2Ecole
normale supérieur de Cachan, Cachan, France.
Tamoxifen-resistant ER positive (ER) breast cancers and triple-negative
breast cancers represent two aggressive subgroups of mammary tumors with
limited treatment options and a poor prognosis. Thus, there is still an urgent
need to develop and improve targeted pharmacological treatments against these
estrogen-independent cancers. Recent data from our group suggest that the
protein kinase D1 (PKD1) participates in the development and/or maintenance
of the estrogen-independent phenotype in breast cancer. Indeed, up-regulating
PKD1 conferred anchorage-independent growth to estrogen-dependentMCF-7
cells in the absence of-estradiol. In addition, we found that high PKD1mRNA
levels were associated with a worse prognosis in tamoxifen-treated tumors.
PKD1 is a serine-threonine kinase encoded by the prkd1 gene and belongs to the
protein kinase D (PKD) family, a novel subgroup of the calcium and calmodu-
lin-regulated kinases (CAMK). The PKD family also includes PKD2 and PKD3
which share a high homology with PKD1. The objective of the present study was
to determine whether PKD1 could be a prognostic factor and/or a pharmaco-
logical target for the treatment of breast cancer. Expression of prkd1, prkd2 and
prkd3 was analyzed by RT-qPCR in 527 breast cancer specimens (181 ER-
tumors including 102 triple negative tumors and 346ER tumors).We showed
that higher prkd1 mRNA levels were associated with a lower metastasis-free
survival in the overall breast cancer population (p0.015). prkd1 prognostic
value was even stronger in ER- tumors (p0.00042) and in triple negative
tumors (p0.0043). Conversely, prkd1 expressionwas not associatedwith prog-
nosis in ER tumors. Interestingly, high prkd2 and prkd3 mRNA levels were
associated with a better prognosis in the entire cohort (p0.0074 and p0.028
respectively). We have developed PKD1 inhibitors in collaboration with the AB
Science pharmaceutical company and screened the ability of thirty-fıve com-
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pounds to inhibit anchorage-independent growth ofMCF-7 cells in the absence
of estrogens. The antitumor activity of two PKD1 inhibitors is currently being
evaluated in vivo against patient-derived breast cancer xenografts. In conclu-
sion, our results show that high prkd1 expression is a bad-prognosis factor in
breast cancer and that PKD1 could be a relevant therapeutic target for the treat-
ment of breast cancer, in particular those harboring an estrogen-independent
phenotype.
#3122 Pharmacogenomicprofıling to identify novel therapeutic strategies
in colorectal cancer. Jarle Bruun,1 Peter W. Eide,1 Kushtrim Kryeziu,1 Anita
Sveen,1 Astrid Murumägi,2 Matthias Kolberg,1 Mariliina Arjama,2 Olli Kallion-
iemi,2 Ragnhild A. Lothe1. 1Institute for Cancer Research, Oslo Univ. Hospital,
Oslo, Norway; 2Institute for Molecular Medicine Finland, Helsinki, Finland.
Colorectal cancer (CRC) is amongst themost frequent cancersworldwide and
the fourth most common cause of cancer mortality. Surgery is the standard
treatment of care, while chemotherapy and/or radiotherapy are offered to sub-
groups of patients according to disease stage. Current guidelines do not have
suffıcient accuracy to identify chemotherapy responders, resulting in under- or
overtreatment of many patients.To discover novel therapeutic strategies for
CRC we performed a high-throughput drug screen containing 461 approved
and preclinical drugs on a representative panel of 42 CRC cell lines. Integrative
pharmacogenomic profıles were explored by matching data from gene expres-
sion, exome sequencing, copy number and reverse-phase protein arrays. These
analyses identifıed defıned molecular subgroups sensitive to targeted drugs like
Inhibitors of EGFR, IGF-1R and downstream signaling mediators like B-Raf,
MEK, PI3K/AKT, as well as inhibitors of aurora mitotic kinases, heat shock
protein 90 and p53. Additionally, a correlation betweenmicrosatellite instability
and sensitivity against topoisomerase-I inhibitorswas found. Comparison of the
most sensitive and the most resistant cell models against HSP90 inhibitors indi-
cated that drug sensitivity does not depend on target expression but is likely
attributed to the cell line-specifıc expression of client proteins. Real-time cell
analyses measured with the xCELLigence system demonstrated a strong impact
on cell proliferation but not on the migration of HSP90-sensitive cells treated
with HSP90 inhibitors as compared to resistant cells. These integrative analyses
have unraveled pharmacogenomic relationships that if validated in in vivo
model systems, might be used to stratify patients for therapeutic intervention in
biomarker guided clinical trials.
#3123 Identifıcation of TIFA as a novel therapeutic target in acute my-
eloid leukemia. Pei-Yu Wu,1 Tong-You Wade Wei,1 Ting-Jung Wu,2 Ming-
Daw Tsai1. 1Academia Sinica, Taipei, Taiwan; 2Chang GungMemorial Hospital,
Taoyuan, Taiwan.
Aurora A-dependent NF-B signaling portends poor prognosis of cancers
including acute myeloid leukemia (AML). Our previous study demonstrated
that phosphorylation-dependent oligomerization of TRAF-interacting protein
with FHA domain (TIFA) triggers the activation of NF-B. The present study
identifıes that Aurora A is an essential kinase for the Thr9 phosphorylation of
TIFA, and that TIFA functionallymediates theAuroraA-drivenNF-B survival
pathway inAML.Overexpression of TIFAoccurred concurrentlywithAuroraA
and NF-B signaling factors in de novo AML patients but not healthy individ-
uals, and also correlated with poor prognosis. Silencing of TIFA specifıcally
attenuated leukemic cell growth and enhanced chemosensitivity of AML cells
via down-regulation of pro-survival factors Bcl-2 and Bcl-XL that support NF-
B-dependent anti-apoptotic events. In addition, molecular targeting of TIFA
perturbed leukemic cytokine secretion and signifıcantly lowered the IC50 of
chemotherapeutic drugs to treat AML cells. Furthermore, in vivo delivery of
TIFA-inhibitory fragments potentiates the clearance of leukemicmyeloblasts in
the bone marrow of xenograft-recipient mice via enhanced chemotoxicity, sim-
ilar to the effect of anti-inflammatory drug treatments. Collectively, we pro-
posed that TIFA functionally supports the positive feedback between TNF-,
Aurora A, and NF-B to facilitate AML survival signaling, and impairment in
this pathway can enhance the effıcacy of AML treatments.
#3124 Expression and therapeutic implications of cyclindependent kinase
4 (CDK4) in osteosarcoma. Yubing Zhou, Francis Hornicke, Zhenfeng Duan.
Massachusetts General Hospital, Boston, MA.
Overexpression and/or hyperactivation of cyclin-dependent kinase 4 (CDK4)
has been found inmany types of human cancers, and a CDK4 specifıc inhibitor,
palbociclib, has been recently approved by the FDA for the treatment of breast
cancer. However, the expression and the therapeutic potential of CDK4 in os-
teosarcoma remain unclear. In the present study, CDK4 was found to be highly
expressed in human osteosarcoma tissues and cell lines as compared with nor-
mal human osteoblasts. Elevated CDK4 expression correlated with metastasis
potential and poor prognosis in osteosarcoma patients as determined by immu-
nohistochemical analysis in a human osteosarcoma tissue microarray (TMA).
CDK4 inhibition by either palbociclib or specifıc small interference RNA
(siRNA) exhibited dose-dependent inhibition of osteosarcoma cell proliferation
and growth, accompanied by suppression of the CDK4/6-cyclinD-Rb signaling
pathway. Flow cytometry analysis showed that CDK4 knockdown arrested os-
teosarcoma cells in the G1 phase of the cell cycle and induced cell apoptosis.
Furthermore, inhibition of CDK4 signifıcantly decreased osteosarcoma cell mi-
gration in vitro determined by the wound healing assay. These data highlight
that CDK4 may be a potential promising therapeutic target in the treatment of
human osteosarcoma.
#3125 Therapeutic implications of mTORC1 and mTORC2 inhibitors in
genetically heterogeneous glioblastoma. Anubhav G. Amin, Arthur Wang,
Alex Braun, Michael Tobias, Raj Murali, Meena Jhanwar-Uniyal. Dept. of Neu-
rosurgery, New York Medical College, Valhalla, NY.
Glioblastoma (GB) is the most common malignant primary brain tumor,
which is characterized bymarked intra-tumor genetic heterogeneity in receptor
tyrosine kinases (RTK) genes. Aberrations in the RTK/PI3K/Akt pathways in
GB leads to an abnormal signaling pathway of mechanistic target of Rapamycin
(mTOR). mTOR exists in two distinct complexes, namely, mTORC1 and
mTORC2,which are involved in regulation of cell survival, growth, andmotility.
In this investigation, we test the hypothesis that the genetic heterogeneity of
GBM cells and its stem cells with respect to the expression of EGFR and/or
PDGFR may defıne the treatment effıcacy of RTK inhibitors with or without
PI3K/ mTOR inhibitors. We demonstrated that GB tumors over-expressed
PDGFR and EGFR at range of 80% and 30%, respectively, with varying degree
of overlap. Combined treatment with the inhibitors of PDGFR (AC 710) or
EGFR (gefıtinib), with or without inhibitors of mTORC1 (rapamycin) or
mTORC1/2 (Torin1 and Torin 2), led to suppression of cell proliferation, cell
cycle, cell migration and drug resistance in GB cells to varying degrees that
correlated with EGFR or PDGFR expression. Downstream signaling pathway
substrates of mTORC 1 and 2, namely pS6k and pAkt, respectively, were sup-
pressed by combined treatments of RTK and mTORC1/2 inhibitors. Further-
more, GB stem cell self-renewal and growth was also suppressed with combined
treatments. The combination of AC710 plus mTORC1/2 inhibitor, Torin2, was
the most effective. These fındings underscore the usefulness of determining
PDGFR and EGFR status when considering viable PI3K/mTOR inhibitors for
targeted treatment of GB.
#3126 H3B6527, a selective andpotent FGFR4 inhibitor for FGF19-driven
hepatocellular carcinoma. Anand Selvaraj, Erik Corcoran, Heather Coffey,
Sudeep Prajapati, Ming-Hong Hao, Nicholas Larsen, Jennifer Tsai, Takashi Sa-
toh, Kana Ichikawa, Julie Jaya Joshi, Raelene Hurley, Jeremy Wu, Chia-Ling
Huang, Suzanna Bailey, Craig Karr, Pavan Kumar, Victoria Rimkunas, Crystal
Mackenzie, Nathalie Rioux, Amy Kim, Sandeep Akare, George Lai, Lihua Yu,
Peter Fekkes, John Wang, Markus Warmuth, Peter Smith, Dominic Reynolds.
H3 Biomedicine Inc., Cambridge, MA.
Hepatocellular carcinoma (HCC)has limited treatment options and generally
poor prognosis. Recent genomic studies have identifıed FGF19 as a driver on-
cogene in HCC. FGF19 is a gut secreted hormone that acts in the liver through
FGFR4 to regulate bile acid synthesis. Consistent with the notion that FGF19 is
a driver oncogene in HCC, transgenic mice overexpressing FGF19 form liver
tumors and genetic ablation of FGFR4 prevented tumor formation. These data
suggest targeting FGFR4 would have therapeutic benefıt in HCC with altered
FGF19 signaling. While a number of Pan-FGFR inhibitors are being clinically
evaluated, their application to FGF19-driven HCC may be limited by their
FGFR1-3 related dose limiting toxicities. Using structure guided drug design, we
have generated a highly selective covalent FGFR4 inhibitor, H3B-6527. Bio-
chemical and cellular selectivity assays showed that H3B-6527 is 300 fold
selective towards FGFR4 compared to other FGFR isoforms. Addition of H3B-
6527 to FGF19 amplifıed HCC cell lines led to dose dependent inhibition of
FGF19/FGFR4 signaling and concomitant reduction in cell viability. In a panel
of 40 HCC cell lines, H3B-6527 selectively reduced the viability of cells that
harbor FGF19 amplifıcation and showedno effect in FGF19non-amplifıedHCC
cell line models. Oral dosing of H3B-6527 to mice led to dose-dependent phar-
macodynamic modulation of FGFR4 signaling and tumor regression in FGF19
altered HCC cell line derived xenograft models. H3B-6527 demonstrated inhi-
bition of tumor growth in an orthotopic liver xenograft model of FGF19 altered
HCC grown in nude mice. Importantly, the inhibition of tumor growth oc-
curred at doses that were well tolerated in mice and no evidence of FGFR1-3
related toxicities were observed at effıcacious doses. In a panel of 30 HCC pa-
tient-derived xenograft (PDX) models, H3B-6527 demonstrated tumor regres-
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sions in the context of FGF19-amplifıed tumors. In addition, H3B-6527 showed
antitumor activity and tumor regressions in PDX models with high FGF19 ex-
pression but no FGF19 amplifıcation. The mechanism for FGF19 overexpres-
sion in the absence of gene amplifıcation is under investigation. In conclusion,
our preclinical studies demonstrate that FGF19 expression is a predictive bio-
marker for response to FGFR4 inhibitor therapy.Genomic analysis of public and
proprietary data sets indicates that at least approximately 30% of HCC patients
exhibit altered FGF19 expression and could potentially benefıt from H3B-6527
monotherapy treatment.
#3127 Roles of ERKs-RSK2 signaling in human cancers. Yong Yeon Cho.
The Catholic Univ. of Korea College of Pharmacy, Bucheon-si, Republic of Korea.
RSK2 is a member of p90RSK superfamily consisted with RSK1-4 and
MSK1-2, and has suggested involving in many cellular processes including cell
proliferation, differentiation, transformation and cancer development. Accu-
mulating data obtained by our 16-year researches strongly demonstrated that
RSK2 is a key player in cell transformation and cancermetastasis.We found that
ectopic expression of RSK2 induced anchorage-independent cell transforma-
tion. Notably, knockdown of RSK2 strongly suppressed constitutive active-Ras
(CA-Ras)-induced foci-formation, EGF-induced cell transformation and cancer
cell growth in anchorage-independent condition. The results obtained from
human skin cancer tissue array demonstrated that total protein levels and RSK2
activity were higher in cancer tissues than that of normal tissues. Molecular
targeting of RSK2 or ERK1 and 2 with natural compounds demonstrated that
ERKs-RSK2 signaling pathway plays a key role in cell transformation and cancer
development. Moreover, inhibition of ERKs-RSK2 signaling suppressed NF-B
activity in JB6Cl41 cells. The EGF-induced NF-B activity was abrogated up-
regulation of COX-2 mRNA expression and COX-2 protein levels by inhibition
of ERKs-RSK2 signaling pathway. Interestingly,magnolin, a specifıc inhibitor of
ERK1 and ERK2, suppressed ERK-mediated MMP-2 and NF-B-mediated
MMP-9 expression. In addition, we found that the protein expression of N-
cadherin involved inmetastasis wasmarkedly attenuated by inhibition of ERKs-
RSK2 signaling pathway. Notably, magnolin suppressed the migration and in-
vasion of lung cancer cells in a dose-dependent manner. Taken together, these
results demonstrated that targeting of ERKs-RSK2 signaling is benefıcial for the
chemoprevention, and anti-invasion and -migration in cancer metastasis. Key
words: MAPK pathway, Transformation, Metastasis, Molecular targets
#3128 TRPM7 regulates glioma cell proliferation and migration through
different function domains. Mingli Liu. Morehouse School of Medicine, At-
lanta, GA.
Background: Transient Receptor Potential Melastatin-related 7 (TRPM7) is a
non-selective cation channel fused with a functional kinase domain. TRPM7
channel expression is aberrant in numerous cancers. We have previously re-
ported that suppression of TRPM7 inhibits the proliferation, migration, and
invasion of malignant human glioma cells using A172 glioma cell line and brain
tissue of human glioma [CNSNeuroscience&Therapeutics 2015,21(3):252-61].
We further found that TRPM7 channels regulate glioma stem cell growth/pro-
liferation through STAT3 and Notch signaling pathways [Cellular Signaling,
2014; 26: 2773-2781]. Since TRPM7 is a bifunctional protein with channel and
-kinase domain,we next investigatedwhether the changes in glioma cancer cell
proliferation andmigrationmight be caused through channel domain-mediated
and/or kinase domain mediated TRPM7 activation. Methods: 1) A172 cells ex-
pressing wild-type human TRPM7 (wtTRPM7) or constructs in which the-ki-
nase domain was deleted (
kinase) or rendered inactive with a point mutation
in the ATP binding site of the -kinase domain (K1648R) were studied. 2) The
effects of TRPM7 on glioma cell proliferation and invasion were determined
using MTT assay and transwell invasion assay by TRPM7 expression using wt-
TRPM7,
kinase, and K1648R, respectively. Results: 1) Treatment of A172 cells
with 
kinase and K1648R signifıcantly increased TRPM7 expression demon-
strated by Western blot assay. 2) The cell invasion was signifıcantly reduced
when treated with 
kinase and K1648R which indicate that TRPM7 kinase
activity is required for changes in cell migration and invasion. 3) The cell pro-
liferation was not signifıcantly changed when treated with 
kinase and K1648R
which indicate that TRPM7 channel rather than kinase activity is required in cell
growth of A172 cells. Conclusion: TRPM7 regulates glioma cell proliferation
andmigration/invasion through different function domains. The channel activ-
ity of TRPM7 is required for the cell growth while the kinase domain is required
for the cell migration/invasion. The fınding is important for designing and de-
veloping drugs targeting TRPM7 in human malignancies.
#3129 Patient-derived tumor xenografts (PDXs) recapitulate the antitu-
mor activity of novel therapies in metastatic breast cancer (MBC) patients
(pts). Mafalda Oliveira,1 Javier Pascual,2 Cristina Cruz,1 Alberto Gris,1 Marta
Palafox,1 Alba Llop,1 Marta Castroviejo,1 Cristina Viaplana,1 Yasir H Ibrahim,3
Joaquin Arribas,1 Javier Cortés,4 José Baselga,5 Jordi Rodón,1 Judith Balmaña,1
Rodrigo Dienstmann,1 Cristina Saura,1 Violeta Serra1. 1Vall d’Hebron Institute
of Oncology, Barcelona, Spain; 2Hospital Universitario Virgen de la Victoria,
Málaga, Spain; 3Blenis Lab, Weill Cornell Medicine, New York, NY; 4Hospital
Ramón y Cajal, Madrid, Spain; 5Memorial Sloan Kettering Cancer Center, New
York, NY.
PDXs are preferred laboratory models that recapitulate the biology of pts’
tumors. We aimed to assess if the antitumor activity of novel therapies in PDXs
correlates with the observed activity in the corresponding MBC patient, which
would support cross-analysis of drug/genotype vulnerabilities. MBC pts eligible
for clinical trialswere offered a research biopsy and establishment of PDX, under
an IRB-approved protocol. Biopsies were implanted in nude mice subcutane-
ously. Upon successful engraftment, models were expanded for drug testing,
specifıcally with the same drug/combination given to the patient. This is a ret-
rospective analysis of our MBC patient/PDX (Pt/PDX) co-clinical trial cohort.
Pts’ outcomes were measured as: RECIST response, clinical benefıt [CB: partial
response (PR) or stable disease (SD)4months], and time to progression [TTP:
time until RECIST progressive disease (PD), in months). PDX endpoints were
measured as: TTP (time until 25% increase in tumor volume, in days), response
(WHO criteria, at week 3), and relative area under the curve (rAUC) of treated
versus vehicle. A concordant Pt/PDX response was defıned as CB in pts whose
paired PDX showed PR/SD, or no-CB in pts whose paired PDX showed PD. Pts
outcomes and PDX endpoints were correlated using Spearman ´s test.We iden-
tifıed 10MBCpts (7TNBC, 3HR; all biopsies from skin/subcutaneous lesions)
with corresponding PDX, treated with paired therapies (7 molecularly
matched): 3 lurbinectedin (BRCA1-mut), 3 olaparib (BRCA1-mut), 1 AZD5363
 fulvestrant (AKT1-mut), 1 AZD5363 paclitaxel, 1 buparlisib, 1 eribulin. In
9/10 cases we found concordant Pt/PDX responses (6 cases with no-CB in pa-
tient/PD in PDX, 3 with CB/SD; and 1 lurbinectedin case with no-CB/PR). Two
pts had biopsy for PDX implantation at progression of paired therapy and were
excluded from TTP analyses. In cases with concordant Pt/PDX response, we
found a signifıcant correlation between RECIST response in pts and rAUC in
PDX (0.82, p0.03), a trend for comparable TTP in pts and TTP in PDX
(0.67, p0.10), but no correlation between RECIST response in pts and
response at week 3 in PDX (0.46, p0.30). In this cohort of MBC pts, we
found high concordance in Pt/PDX response. Our results suggest that rAUC in
PDX may be the best read-out to identify relevant drug/genotype associations
that can potentially be translated to patient benefıt. Data will be updated with
additional ongoing PDX experiments.
#3130 CYP3A5 positively regulates androgen receptor signaling in pros-
tate cancer cells: Potential for therapeutic targeting. Ranjana Mitra, Pri-
yathamGorjala, Oscar B. Goodman. Roseman University of Health Sciences, Las
Vegas, NV.
Purpose: Prostate cancer is the most common malignancy and second
leading cause of cancer-specifıc mortality in US men. The androgen receptor
(AR) plays a major role in promoting growth and progression of prostate
cancer and thus has been successfully targeted therapeutically. Therapeutic
resistance to androgen deprivation therapy (ADT) accounts for much of the
morbidity and mortality attributable to prostate cancer. Therapeutic resis-
tance is typically accompanied by insuffıcient blockade of AR activation,
whose initial step involves translocation of AR to the nucleus. Previously we
demonstrated that CYP3A5 facilitates the nuclear translocation of AR, pro-
moting prostate cancer growth. Targeting CYP3A5 and blocking AR nuclear
translocation may override therapeutic resistance to ADT, representing a
novel approach for treating men with advanced prostate cancer. This work
focuses on understanding the role of CYP3A5 in regulating AR nuclear
translocation process and its subsequent promotion of prostate cancer
growth. Methods: AR nuclear translocation is tightly regulated through a
process involving several chaperones, multiple cofactors, and kinases, in-
cluding HSP90, HSP70, HSP40 and HSP27. Complexed HSP90 maintains
the AR as an inactive receptor in the cytoplasm. Upon androgen binding and
activation, AR associates with HSP27, then translocates to the nucleus where
it activates transcription of AR regulated genes responsible for prostate can-
cer growth. To decipher the role of CYP3A5 in this AR translocation process
we performed a series of co-immunoprecipitation experiments with
CYP3A5 and components of HSP90-AR complex, at different stages of AR
translocation process. We used extracts of LNCaP transfected with a
CYP3A5-Flag-tagged construct with either Flag-agarose or HSP90 and AR
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antibodies with A/G beads for immunoprecipitation. Results: Our co-immu-
noprecipitation experiments using CYP3A5-Flag transfected LNCaP ex-
tracts demonstrate that CYP3A5 associates with the HSP90-AR complex that
helps to maintain AR in a form that can be readily activated by androgen.
Using Flag-agarose in co-immunoprecipitation experiments, we demon-
strated that CYP3A5 is a component of the HSP90-AR complex, associating
with AR, HSP90, HSP70 and HSP40 each which are chaperones regulating
AR nuclear translocation. We further confırmed the presence of CYP3A5 in
the HSP90-AR complex by co-immunoprecipitation using HSP90 and AR
antibodies in combination with A/G beads instead of flag-agarose. Conclu-
sion: Our current fınding supports the notion that CYP3A5 is a part of the
HSP90-AR complex and positively regulates AR nuclear translocation.
Therefore, targeting CYP3A5 to block AR nuclear translocation may be a
therapeutic adjunctive approach in advanced prostate cancer.
#3131 Ubiquitin ligases: a new target for RNAi therapy of hepatocellular
carcinoma. Dominique Leboeuf,1 Timofei Zatsepin,1 Daniel G. Anderson,2
Konstantin Piatkov1. 1Skolkovo Institute of Science and Technology, Moscow,
Russian Federation; 2Koch Institute for Integrative Cancer Research at MIT,
Cambridge, MA.
Hepatocellular carcinoma (HCC) is the fıfthmost common cancer worldwide
and the third leading cause of cancer-related deaths in the world. HCC is a very
aggressive cancer, resistant to all conventional chemotherapies and capable of
acquiring resistance to Sorafenib, which is the only approved chemotherapeutic
drug for HCC. This highlights the need to look for new therapeutic options and
improve the survival of patients with advancedHCC. TheN-end rule pathway is
an emerging player in the fıeld of cancer biology, because of its capacity to
positively regulate many hallmarks of cancer including angiogenesis, cell prolif-
eration, motility and survival. Therefore, the N-end rule pathway offers the
potential to be a target for highly effective anti-tumor treatment. The aim of this
study is to investigate the role of the N-end rule pathway in the context of
hepatocellular carcinoma in vivo. We used siRNA-mediated RNA interference
as the main approach for selective downregulation of the four N-end rule-de-
pendent cognate ubiquitin ligases: UBR1, UBR2, UBR4 and UBR5. Initial
screening of siRNAs was performed in Hepa 1-6 cells, followed by in vitro phe-
notyping using proliferation assays, migration assays, and TUNEL assays. The
most potent siRNA against Ubr1, Ubr2, Ubr4 and Ubr5 were formulated into
lipid nanoparticles (LNPs) and injected into mice in order to modulate the
function of the N-end rule in vivo. We have confırmed that Ubr1, Ubr2, Ubr4
and Ubr5 are overexpressed in Hepa 1-6 cells and in mouse liver tumors, in
comparison to normal liver. Upon transfection of siRNAs in Hepa 1-6 cells or
injection of LNPs loaded with the same siRNAs into mice, we obtained success-
ful down regulation of Ubr1, Ubr2, Ubr4 and Ubr5 both in vitro and in vivo (in
the liver and in tumor tissue). We have also demonstrated that down regulation
of these fourUbr proteins negatively affects cellmigration andproliferation, and
renders cells more susceptible to apoptosis. Bi-weekly injections of the LNPs in
mice for a period up to 6weeks effıciently downregulates the expression ofUbr1,
Ubr2, Ubr4 and Ubr5 without any toxic effects. Indeed, we found no signifıcant
increase of ALT, AST or total bilirubin in the blood compared to controls.
Considering that all fourUbrs are overexpressed inmouse liver tumors, and that
the N-end rule plays a major role in many key pathways of cancer development,
we expect that even a partial down regulation of this pathway will have promi-
nent effects on tumor development and progression due to the suppression of
tumor vascularization, cell proliferation and viability.
#3132 Inhibition of the integrin V3 improves the effect of bexarotene
in the treatment of cutaneous T-cell lymphoma (CTCL). Florencia Cayrol,1
Victoria Revueta,2 Alejandra Paulazo,1 Mercedes Debernardi,1 Maria Celeste
Diaz Flaque,1 Helena Sterle,1 Leandro Cerchietti,2 Graciela Cremaschi1. 1Bio-
medical Research Institute, Buenos Aires, Argentina; 2Weill Cornell Medical Col-
lege, New York, NY.
CTCL are exposed to a complex paracrine and endocrine environment that
influence their progression from skin to visceral disease. One of the most com-
mon treatments for CTCL is RXR agonists or “rexinoids” such as bexarotene
(BEX). The most prevalent side effect of rexinoids (95% of patients) is the
development of hypothyroidism hence these patients are prophylactically
treated with thyroid hormone (TH). Paradoxically, we recently found (PMID:
25488971) that TH can activate transcriptional programs required for prolifer-
ation of CTCL. We also found that the effects of TH on CTCL are mediated
through the activation of two different receptors, the classical nuclear TR and a
membrane receptor integrin V3. Our aim was to study how the anti-lym-
phoma activity of BEX is modifıed by the activation of TR and V3 during the
TH replacement therapy, and unknown topicwith clinical implications.We fırst
evaluate the cell viability of CTCL cells HuT78 and MJ treated with BEX in
presence and absence of physiological levels of TH. As expected, BEX decreased
the viability of CTCL cells, however in presence of TH both effects decreased by
25-60% and 20-50% on HuT78 andMJ cells. However, hypothyroidism is asso-
ciated with a higher dissemination of TCL cells in syngeneic mice. Thus, to
evaluate the impact of TH replacement therapy in BEX-treated mice, we im-
planted TCL EL-4 cells subcutaneously in C57BL/6mice.When tumors reached
75 mm3, mice were randomized in three groups: vehicle, bexarotene alone
(BEX) and bexarotene with T4 replacement (to reach euthyroidism) (BEX-T4).
Tumor growth signifıcantly decreased in both bexarotene arms (vs. vehicle).
However, in contrast to mice receiving BEX-T4, mice receiving BEX alone
showed a decreased infıltration of tumor-suppressive immune cells. Specifıcally,
these tumors had decreased NK and CD3CD8 cells due to BEX-induced
hypothyroidism. This indicates that although TH could decrease the effect of
BEX in CTCL cells, the hypothyroidism would impact in the local antitumor
response. Thus determine if the inhibition of the non-canonical THmembrane
receptor integrin V3 would decrease the pro-survival effect of TH on CTCL
treated with BEX.We found that either, V3 silencing or the pharmacological
inhibitor Cilengitide, not only avoided the pro-survival effect of TH but in-
creased the anti-lymphoma activity of BEX-T4 by 15-35% in CTCL cells. To
evaluate the molecular program underpinning these effects, we conducted
RNA-sequencing in HuT78 cells treated with BEX-T4 in presence of siRNA for
TR, V3 or controls. Among the top pathways we identifıed genes involved in
“apoptosis”, “angiogenesis” and “IL6-JAK-STAT3 signaling” as differentially
expressed in si-V3 vs. the others. These genes were independently validated
by using Cilengitide. Our data suggest that inhibition of the non-canonical TH
receptor, the integrin V3, could be an effective strategy to improve BEX
treatment in CTCL
#3133 NF-B-dependent inflammatory responses offset sorafenib cyto-
toxicity in hepatocellular carcinoma via TIFA. Tong-YouWadeWei,1 Pei-Yu
Wu,1 Ting-Jung Wu,2 Ming-Daw Tsai1. 1Academia Sinica, Nangang Dist., Tai-
wan; 2Chang Gung Memorial Hospital, Linko, Taiwan.
Sorafenib is the promising fırst-line drug to treat advanced hepatocellular
carcinoma (HCC), with the acquired resistance within 6months inmost treated
patients. The epithelial-mesenchymal transition (EMT)-driven cancer metasta-
sis contributes to sorafenib resistance via multiple signaling pathways, but the
underlying molecular mechanism remains elusive. Recent studies showed that
inflammatory cytokines TNF- functionally initiates EMT through NF-Bme-
diated Snail activation in HCC, and that TRAF-interacting protein TIFA sus-
tains the positive feedback loop between TNF- and NF-B that enhances
chemoresistance in AML. Here we investigated the functional link between
TIFA-regulated NF-B inflammatory signaling and sorafenib resistance as a
potential therapeutic target in the treatment of HCC. We showed that severe
hepatitis induced in HCC mice promoted intrahepatic metastasis concurrently
with NF-B-driven EMT via Snail, and that HCC patients with hepatitis dis-
played poorer responses to sorafenib and unfavorable clinical outcome. In sup-
port, inflammatory TNF- stimulation promoted levels of TIFA, NF-B signal-
ing factors, and EMT axis independent of sorafenib treatment, while silencing of
TIFA or RelA perturbed sorafenib-dependent cytokine secretion in HCC cells.
In addition, silencing of TIFA or RelA suppressed pro-survival factors Bcl-2 and
Bcl-XL, and promoted pro-apoptotic factor BAX in response to sorafenib treat-
ment in vitro. Consequently, HCC cells regained sorafenib chemosensitivity
upon silencing of TIFAorRelA through promoted apoptosis. To further explore
the therapeutic relevance, shRNAs were delivered using the liver-tropic adeno-
associated virus serotype 8 in mice with orthotopic HCC xenografts, and results
showed that targeting TIFA or RelA specifıcally enhanced sorafenib chemotox-
icity resulting in more prominent tumor regression. Our results collectively
showed that TIFA and NF-B support inflammatory responses to offset
sorafenib cytotoxicity, and that their targeting are therapeutically effective con-
comitant with sorafenib treatment in HCC.
#3134 Hierarchical genemaster regulators of papillary and anaplastic thy-
roid cancer phenotype.Neha Yashpal Tuli, Craig Berzofsky, RachanaManiyar,
Sanjukta Chakraborty, Ghada Ben Rahoma, Sarnath Singh, Jan Geliebter, Raj K.
Tiwari, Sanda Iacobas, DumitruA. Iacobas.NewYorkMedical College, Valhalla,
NY.
The incidence of thyroid cancer (TCa) has doubled in the last decade. Papil-
lary thyroid cancer (PTC), that comprises of 80% of all TCas, is treatable with
great outcomes. However, undifferentiated anaplastic thyroid cancer (ATC),
with very poor prognosis, is considered a clinical challenge and currently a
losing battle. Moreover, the molecular mechanisms responsible for various
forms of TCa are largely unknown. We believe that the cells of histopathologi-
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cally distinct regions of a heterogeneous thyroid tumor are governed by different
sets ofmaster gene regulators. The smartmanipulation of suchmaster geneswill
be able to selectively destroy cancer cells but not normal tissue, opening a novel
and much more effective avenue in the thyroid cancer targeted gene therapy.
Our analysis established the gene hierarchical governance in each region based
on their Gene Commanding Height (GCH). GCH is a measure that combines
the gene expression coordination with other genes and the expression stability
among biological replicas provided by the internal homeostatic mechanisms.
Here, we provide experimental evidence that standard papillary (BCPAP) and
anaplastic (8505C) human thyroid cancer cell lines have different master regu-
lators. We identifıed the master regulators of BCPAP and 8505C, and deter-
mined their GCH. Transfection ofmaster gene regulators of a particular cell line
has signifıcantly larger effects on the cell line they command than on other cells.
We found that the stable transfection with TMEM194A, a nuclear envelope
protein, regulated twice more genes in BCPAP than in 8505C cells. The analysis
using human thyroid cancer cells reaffırmed our hypothesis of the existence of
hierarchical master gene regulators and that the phenotypic changes can be
manipulated with the introduction of these genes. We further validate these
concepts using human thyroid biopsy samples.We found substantial differences
in the GCH scores of cancer versus normal tissue of a surgically removed
32.0mmpapillary carcinoma from the left lobe of a 33y oldmale. Because of such
differences between the cancer region and the normal tissue, manipulation of
cancer regulators is expected to affect the cancer cells in a greater degree than the
normal cells. These results suggest that we have defıned a master gene regulator
hierarchy in thyroid cancer and extrapolation of this analysis to compare ana-
plastic and papillary thyroid cancer will lead to novel gene therapeutic modali-
ties. Our long-term goal is to identify master regulators of cancer nodules for
each patient and develop personalized cancer therapy targeting these master
regulators.
#3135 Benzaldehyde suppresses the binding activity of overexpressed 14-
3-3 to multiple signaling proteins in cancer cells. Jun Saitoh, Hideyuki Saya.
Keio Univ School Of Med, Shinjuku Ku Tokyo, Japan.
Benzaldehyde is the simplest aromatic aldehyde constituent of almonds and
many fruits. Anticancer effect of Benzaldehyde was fırst reported in 1980, and
multi-institutional clinical trials were performed in those days in Japan. How-
ever, trial was over without determination of effectiveness, only its’ safety was
confırmed. The underlying mechanism why Benzaldehyde specifıcally sup-
presses growth of someparticular cancer cells but not that of normal cells has not
been elucidated. Therefore, we attempted to clarify themechanismof anticancer
effect of Benzaldehyde. We have previously reported that, in pancreatic cancer
cell BxPC3 and in non-small cell lung cancer cell A549, Benzaldehyde inhibits
PI3K/AKT/mTOR, STAT3,NFB and ERKpathways, those aremajor signaling
pathways activated in cancer cells. Effects of Benzaldehyde onmultiple signaling
pathways are found to be derived from regulation of 14-3-3 family proteins
which interact with phosphorylation sites of various proteins ofmultiple signals.
In BxPC3 cells, Benzaldehyde treatment reduced the phosphorylation levels of
14-3-3-binding sites. Moreover, we ectopically expressed seven isoforms of 14-
3-3 in HEK293T cells and found that Benzaldehyde treatment signifıcantly sup-
pressed association of 14-3-3	 with client proteins such as mTOR, Rictor, cRaf,
STAT3 and FOXOs. The interaction of other isoforms of 14-3-3 with their client
proteins was also partially reduced. But, the expression levels of those seven
14-3-3 isoforms were not signifıcantly changed. Here we further analysis the
Benzaldehyde-mediated 14-3-3	 regulation, inHEK293 cells overexpressing 14-
3-3	. Benzaldehyde signifıcantly suppressed mTOR pathway while it was not
observed in parental HEK293 cells. Furthermore, we performed pull down assay
by using 14-3-3	GST tagged recombinant proteins and lysates ofHEK293T and
BxPC3 and found that Benzaldehyde treatment suppressed the interaction of
14-3-3	 with cRaf, TSC2 and other 14-3-3	 client proteins. From these data, we
confırmed that Benzaldehyde is an inhibitor of the overexpressed 14-3-3	. Re-
cent reports have shown that 14-3-3	 is overexpressed in many cancers and acts
as a signaling hub controlling the network of oncogenic pathways, suggesting
that overexpressed 14-3-3	 associates with carcinogenesis, metastasis and resis-
tance for chemotherapy and radiation. Hence, Benzaldehyde is considered to be
a new molecular target agent of 14-3-3	 which promote and maintain cancer
signals.
#3136 Unveiling the therapeutic potential of Tanshinone I on telomerase
activity and shelterin complex in myeloma. Raman Kumar, Rehan Khan, Ni-
dhi Gupta, Tulika Seth, Alpana Sharma. All India Institute of Medical Sciences,
New Delhi, India.
Background and Objectives: Multiple myeloma (MM) defınes as monoclonal
antibody producing abnormal plasma cells inhabiting bone marrow (BM). It in-
volves multiple genetic mutations where different signaling pathways get deregu-
lated hence showing malignant features of myeloma. Increased relative telomerase
activity (RTA) and altered levels of shelterin complex molecules (TRF1, TRF2,
POT1,RAP1,TIN2,TPP1) alongwith its associatedmolecules (TANK-1&PINX1)
are underlying principle behind several malignancies. Thismaiden attempt aims to
study expression levels of these molecules in myeloma and revealing therapeutic
potential of TanshinoneI (TanI) alone or in combination with lenalidomide by tar-
geting telomerase activity and shelterin molecules. Methodology:Newly diagnosed
50MMpatients & 20 controls were recruited for BM aspiration with their consent.
RTA,mean telomere length, relativemRNAandprotein levelswere studied in study
subjects. Clinical parameters were recorded; correlationwas studied between all the
studied genes at mRNA levels and between genes and patients’ clinical parameters;
ROC curves were plotted of all genes. Anti cancer potential of TanI and lenalido-
mide or their combination were studied with different assays on myeloma cells
(RPMI8226 & U266). Results:Signifıcantly (p0.05) high relative mRNA expres-
sion were found of all molecules except PINX1 which was signifıcantly lowered in
patients compared tocontrols andwascorrelatingwithdisease severity andprogres-
sion. Similarly, higher RTA and lowered mean telomere length was observed in
patients. Statistically signifıcant correlationwasobservedbetweengenes, telomerase
activity and with clinical parameters. ROC curves analysis showed very high sensi-
tivity and specifıcity for TRF2 genes and Telomerase activity. Thus, RTA and shel-
terin complex along with associated factors does play role in causing myeloma and
its progression. TanI caused signifıcant toxicity at low doses inmyeloma cells while
lenalidomidedidnot have any toxicity. Cell deathwas enhancedwhen combination
of both (TanI lenalidomide) drugs were used as observed in Annexin-V/PI and
Tunel assay. TanI and its combination with lenalidomide signifıcantly down regu-
latedprotein expressionofTANK1,TPP1, andRAP1 inmyelomacells compared to
untreated cells. Conclusions:In nutshell, study implies that increased RTA along
with alteredmRNA and protein expression of shelterin complexmolecules with its
associated partners might play role in pathogenesis and progression ofMM. Stage-
wise signifıcant increased expression and correlation of these molecules with each
other andwithclinical parameters showed their role aspotential bio-marker inMM.
Signifıcant down-regulation of RTA and apoptosis by TanI alone or combination
with lenalidomide suggests that TanI might have synergizing effect with lenalido-
mide in causing cytotoxicity inMyeloma.
#3137 Breast cancer anti-estrogen resistance 4 (BCAR4) is a novel onco-
gene in lung cancer.KieunBae,1MinkyongLee,2DaseulYoon,1Yun-HeeKim,2
Kyong-Ah Yoon1. 1Konkuk University, Seoul, Republic of Korea; 2Graduate
School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of
Korea.
BCAR4was identifıed as tamoxifen resistance relatedgene inbreast cancerdue to
its function to activate estrogen-independent cell growth. Instead of estrogen recep-
tor, ERBB2 and ERBB3 geneswere activated by BCAR4 in tamoxifen resistant cells.
Recently, the functionofBCAR4as a longnon-codingRNA(lncRNA)was reported
to regulateanon-canonicalHedgehog/GLI2pathway inbreast cancer.However, the
associationofBCAR4and lung cancerhasnot been identifıed.Here,wedescribe the
oncogeniceffectofBCAR4inhumanlungcancer.ExpressionpatternofBCAR4was
examined in lung cancer cell lines, primary tumor tissues, and adjacent normal
tissues.BCAR4washighlyexpressed in71%of lungcancercell linesandespecially in
43% of cancer tissues of lung adenocarcinoma patients who did not harbor the
activational mutations of EGFR nor KRAS. Exogenous expression of BCAR4 pro-
tein promoted cell growth of non-tumorigenic bronchial epithelial cell line, BEAS-
2B, and lung cancer cell line, NCI-H1299.We also confırmed the oncogenic feature
of BCAR4 by colony forming assay using stably expressing cells. These effects were
notably reduced after knockdown of BCAR4 by small interfering RNA. BCAR4
encoded a functional protein and its overexpression resulted in the enhanced mi-
gration than controls cells. This result proposed a similar role of BCAR4 in lung
cancer considering its previously reported role in breast cancer metastasis.We also
detected a fusiongeneofBCAR4 ina lung cancer tissueby analyzingRNA-sequenc-
ingdata.BCAR4proteinaswell as its fusion formshowedthe improvedtumorigenic
feature in themouse xenograftmodelwith lung cancer cells.We compared the gene
expressionpattern inBCAR4overexpressedcells to identify thepossiblemechanism
of the oncogenic effect of BCAR4. Cyclin D1, Cyclin E, and MMP1 mRNA and
protein levels were signifıcantly increased after BCAR4 overexpression. However,
downstream genes of GLI2 signaling were not altered by protein expression of
BCAR4 arguing an alternative role for lncRNABCAR4. Our results suggest a novel
oncogenic role of BCAR4 protein in lung cancer.
#3138 Mechanism based quality control (MBQC) for the four-herb Chi-
nese medicine formulation, PHY906(YIV-906) and other herbal products.
Wing Lam,1 Yongshen Ren,1 Fulan Guan,1 Zaoli jiang,1WilliamCheng,1 Shwu-
Huey Liu,2 YungChi Cheng1. 1Yale Univ. School of Medicine. Dept. of Pharma-
cology, New Haven, CT; 2Yiviva Inc, New York, NY.
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PHY906(YIV-906), a four-herb Chinesemedicine formulation, is inspired by
an 1800 year-old Chinese formulation called Huang Qin Tang historically used
to treat gastrointestinal symptoms. PHY906 can increase the anti-tumor activity
of immunotherapy antibodies or chemotherapies while promoting damaged
intestinal tissue recovery. Several clinical studies showed that PHY906 had po-
tential to increase the therapeutic index of cancer treatments (chemotherapy,
radiation) by prolonging life and improving patient quality of life.When in vivo
activities of three different clinical batches (number 6, 10, 11) of PHY906 and F
(which is commercial batch of Huang Qin Tang, HQT) was compared to their
similarity of chemical profıles, the two set results could not be completely
matched. For example, F had very different in vivo activities from PHY906-10
but F clustered closely to PHY906-10 based on their chemical profıles. This
information concludes that chemical profıle analysis without excluding irrele-
vant chemicals is not suffıcient to evaluate the in vivo activities of a polychemcial
mixture. Therefore, we included another two biological platforms based on the
in vivo mechanism of action of PHY906 for the quality control. First, we tested
the activity of different batches of PHY906 and F on our signaling transduction
activity response (STAR) platform which including 18 luciferase reporter cell
lines and 2 enzymatic assays. The results of correlation analysis and clustering
analysis based on the results from STAR could bematched to in vivo activities of
different batches of PHY906 and F. Second, we tested the effect of different
batches of PHY906 and F on a set of genes which based on our previous DNA
array data in cell culture and the mechanism action of PHY906. Again, the
results of correlation analysis and clustering analysis based on qRT-PCR could
be matched to to in vivo activities of PHY906 and F. In conclusion, the quality
control of a herbal product should be dependent on its usage. Appropriate bio-
logical assays based on its mechanism action should be developed for QC for
particular usage. Chemical fıngerprint has limitation unless irrelevant chemicals
had been fılter out. Similarity index is only useful when relevant information is
used. Mechanism based quality control could be used for other herbal products.
This work was supported by grant (1PO1CA154295-01A1) fromNational Can-
cer Institute (NCI), NIH, USA. Dr. Yung-Chi Cheng is a fellow of National
Foundation for Cancer Research (NFCR), USA.
#3139 In vivo functional analyses of cancer gene variants for cancer driver
identifıcation and drug discovery. Jingjing Jiang,1 Tengfei Yu,2 Ying Yan,2Wei
Du,2 Tingting Tan,2 Xuqin Yang,2 Jiali Gu,2 Ling Qiu,2 Xin K. Ye,2 Zhenyu Gu2.
1GenenDesign USA Co, Ltd., Menlo Park, CA; 2GenenDesign Co, Ltd., Shanghai,
China.
Precision oncology requires identifying and understanding of cancer genome
changes in a patient tumor tissue and fınding the best cancer therapy targeting
the changes. Although many cancer gene targets have been validated so far,
next-generation genomic profıle analyses have uncovered much more cancer
gene variants with unconfırmed functions. Developing methods to functionally
evaluate mutations/variants and understand their roles in cancer development
and drug responses, such as drug resistance or synthetic lethality, will be critical
in cancer treatment decision support. In addition, in some clinical cases, multi-
ple treatment choices such as multiple drug combinations exist. Developing
cancer models which can test multiple treatments will provide direct compari-
son of those therapies and select the best options. At GenenDesign, we have
performed drug tests on mouse “avatars”, which are also known as Patient-
Derived Xenograft (PDX)models. They are personalized cancermodels derived
from patient tumor samples with cancer mutation profıles and drug responses
very similar to the corresponding cancer patients. Drug screenings were carried
out in avatars by testing chemotherapies or targeted drugs against specifıc cancer
gene mutations and variants. Selected drugs or drug combinations from avatar
studies have been applied to corresponding patientswith highly consistent treat-
ment outcome. From genomic profıle analysis of our near 1500 PDX tumor
models in cancer types such as lung, colorectal, gastric, liver, and esophageal, we
are able to identify a large number of cancer gene mutations/variants, gene
fusions, as well as gene copy number and RNA expression changes in major
cancer signal pathways such as EGFR,Her2, c-Met/ALK, Ras/Raf, FGFRs, PI3K/
Akt,Wnt, Notch, DNA repair, cell cycle regulation, angiogenesis. Many of these
gene aberrations are potential drug targets and have been functionally tested in
PDX models with approved drugs or clinical drug candidates. The mutation/
variant information and drug response information generated from PDXmod-
els have been organized into our Precision Cancer Information Lab database.
Patient tumor DNA test results have been used for searching genetically
matched PDX models in our database. Once matched PDX models are identi-
fıed, the available drug response information can be used as evidence for clinical
treatment decision. In addition, the matched PDXmodels can also been used to
test more treatment options such as different combinations and new clinical
drug candidates.
#3140 MUC1 expression as a prognosis marker and a new therapeutic
target in patient with duodenal adenocarcinoma. Satomi Shiba, Atsushi Miki,
Hideyuki Ohzawa, Takumi Teratani, Yasunaru Sakuma, Joji Kitayama, Alan
Kawarai Lefor, Naohiro Sata. Jichi Medical University, Shimotsuke-si, Japan.
Background: Mucin1 (MUC1) is a glycoprotein as a member of the mucin
family. The expression has been associated with poor prognosis in patients with
several types of cancer. Duodenal cancer is rare, therefore details are not known
including carcinogenesis and clinical treatment. We verify the association of
MUC1 expression and prognosis in patient with duodenal adenocarcinoma.We
also assess the function ofMUC1 in vitro.Materials andMethods: Between 1989
and 2014, eighteen patients of duodenal adenocarcinoma with surgery at Jichi
Medical University Hospital were included in this study. MUC1 expression was
evaluated immunohistochemically with anti-MUC1 antibody to examine the
association ofMUC1 expression and prognosis clinicopathologically. A human-
derived duodenal cancer cell line, HuTu-80, is used for the experiments of inva-
siveness and proliferation in vitro. The invasive capacity was evaluated by trans-
fection of siRNA into HuTu80 withmatrigel invasion assay. Viability assay with
the anti-MUC1 peptide GO201 was assessed to determine whetherMUC1 asso-
ciate with cell growth of duodenal adenocarcinoma. Results: Seven cases were
MUC1 positive and 11 were MUC1 negative immunohistochemically. TMN
staging was not associated with MUC1 expression. Kaplan-Meir analysis
showed a poor prognosis with MUC1 positive patients in cumulative overall
survivals (MUC1 positive : MUC1 negative, 18M : 52M; HR:20.6, 95%CI 3.247-
130.7,p0.002). Lymph nodemetastasis ofMUC1 positive patients (71.4%) was
signifıcantly higher than MUC1 negative patients (9%) (p  0.01). In vitro
experiment, the expression of MUC1 was confırmed by RT-PCR and flowcy-
tometry. Knockdown experiment with transduction of siRNAs to HuTu80 de-
creased the expression of theMUC1 gene. Transduction of siRNAs signifıcantly
reduced invasive capacity (47.02	21.65%, 95%CI 3.046-102.9, p 0.04).
Growth of HuTu80 cells was inhibited by GO201 (5 M : 95%CI 0.109-0.3565,
10M :95%CI 0.024-0.389 p0.0001). Conclusions: MUC1 expression is a pre-
dictive marker for poor prognosis in patients with duodenal adenocarcinoma.
Functional Interference ofMUC1 core protein reduces cell growth and invasive-
ness. Taken together, MUC1 is associated with malignant potential and a novel
target for the treatment.
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#3141 Combined cetuximab and pemetrexed therapy enhances cytotoxic-
ity against crizotinib-resistant non-small cell lung cancer cells by downregu-
lating thymidylate synthase. Hwang-Phill Kim,1 Sae-Won Han,2 Sang-Hyun
Song,1 Tae-You Kim2. 1Seoul National Univ. Cancer Research Inst., Seoul, Re-
public of Korea; 2Seoul National University Hospital, Seoul, Republic of Korea.
Although non-small cell lung cancer (NSCLC) cells with anaplastic lym-
phoma kinase (ALK)-rearranged initially show a dramatic response to crizo-
tinib, these cells eventually develop resistance to crizotinib. This resistance is
caused by secondary mutations and copy number gain in the ALK gene. How-
ever, other resistance mechanisms through activation of the bypass tracts have
yet to be clearly elucidated. To investigate themechanisms of acquired resistance
to ALK fusion-directed treatment in NSCLC, we generated crizotinib-resistant
NSCLC cell lines in vitro through chronic exposure of an ALK fusion NSCLC
line (SNU2292) to crizotinib. Interestingly, the resultant SNU2292-CR cells
maintained activation of epidermal growth factor receptor (EGFR) and ex-
pressed increased levels of transforming growth factor alpha (TGF-), an EGFR
ligand. Additionally, we found that thymidylate synthase (TS) was overex-
pressed in SNU2292-CR cells compared with the parental cells. We showed
reduction of TS enhanced synergistic inhibition of cell proliferation when ce-
tuximab, an EGFR inhibitor, was combined with pemetrexed, a TS inhibitor. As
a result, combined therapy was found to exhibit a synergistic growth inhibitory
effect against crizotinib-resistant cells by downregulating TS expression. Taken
together, these results support a potential role of activation of the bypass tracts in
acquired resistance to ALK-directed treatment in ALK-rearranged NSCLC, and
provide insights into strategies for preventing and/or overcoming this resistance
in patients.
#3142 Aberrantly expressed microRNAs drive the development of ac-
quired Erlotinib resistance in non-small cell lung cancer. Arpita S. Pal,1 Ale-
jandra Agredo,2 Andrea L. Kasinski1. 1Purdue University, West Lafayette, IN;
2Universidad Nacional de Colombia, Bogota, Colombia.
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Lung cancer is the leading cause of cancer-related deaths in the world. Non-
small cell lung cancer (NSCLC) accounts for85%of the cases. NSCLCpatients
frequently harbor causal gene mutations. Epidermal Growth Factor Receptor
(EGFR), an NSCLC causal gene, is mutated in 10-35% of NSCLC patients. Pa-
tients with EGFR activating mutation are treated with a tyrosine-kinase inhibi-
tor, Erlotinib, specifıcally targeting EGFR. However, most patients develop Er-
lotinib resistance within a year. Although multiple mechanisms are involved in
the development of Erlotinib resistance, the role of microRNAs in mediating
Erlotinib resistance is largely unexplored.MicroRNAs (miRNAs) are small non-
coding RNAs that regulate normal cellular physiology. In cancers, miRNAs are
severely dysregulated, contributing tomultiple cancer processes, including drug
response. Despite the involvement of miRNAs in cancer, their direct role as
drivers of drug resistance remain understudied, therefore, there is a critical need
to understand the role of miRNAs in inducing Erlotinib resistance. To this end,
we propose an unbiased two-prong approach to identify the miRNAs that drive
the development of Erlotinib resistance. Therefore, miRNAs are either being (i)
overexpressed, or (ii) silenced in Erlotinib sensitive cells with the hypothesis that
perturbed miRNA levels will drive Erlotinib resistance. Erlotinib sensitive
NSCLC cell lines, EKVX andH322Mwere identifıed from the NCI-60 Develop-
mental Therapeutics Project and their Erlotinib dose response curves were es-
tablished. To perform the miRNA overexpression screen, EKVX and H322M
cells stably expressing renilla and fırefly luciferase genes were generated, which
will be used tomonitor cell number and transfection effıciency, respectively. The
luciferase-expressing cells will be transfected with a library of 2,019 individually
arrayed human miRNAs and cell growth in the presence of Erlotinib will be
monitored. The second prong of the study will identify miRNAs, that when lost,
confer Erlotinib resistance. 400-fold coverage of small guide RNA (sgRNA) li-
brary of theCRISPR-Cas9 systemwas transduced inCas9 overexpressing EKVX
cells, to knockout21,000 human encoded genes (1800 miRNA genes). Cells
are being cultured in the presence of 75% or 90% growth inhibitory concentra-
tions (GI75 or GI90) of Erlotinib so that only cells with sgRNAs against genes
critical for Erlotinib response, survive and growdue to acquired resistance.DNA
from these cells will be harvested, the sgRNAs sequenced, and compared to the
sgRNAs present in Erlotinib-untreated cells. Successful completion of this proj-
ect will identify miRNAs that drive Erlotinib resistance and may contribute
towards development ofmiRNA therapeutics to enhance Erlotinib sensitivity of
NSCLC tumors.
#3143 FBW7mutationsmediate resistance of colorectal cancer to targeted
therapies by blocking Mcl-1 degradation. Jingshan Tong, Shuai Tan, Fang-
dong Zou, Jian Yu, Lin Zhang. UPCI, Pittsburgh, PA.
Colorectal cancer (CRC), the second leading cause of cancer-related deaths in
the US, has been treated with targeted therapies. However, the mechanisms of
differential responses and resistance of CRCs to targeted therapies are not well
understood. In this study, we found that genetic alterations of FBW7, an E3
ubiquitin ligase and a tumor suppressor frequentlymutated inCRCs, contribute
to resistance to targeted therapies. CRC cells containing FBW7 inactivatingmu-
tations are insensitive to clinically used multi-kinase inhibitors of RAS/RAF/
MEK/ERK signaling, including regorafenib and sorafenib. In contrast, sensitiv-
ity to these agents is not affected by oncogenic mutations in KRAS, BRAF,
PIK3CA, or p53. These cells are defective in apoptosis due to blocked degrada-
tion of Mcl-1, a pro-survival Bcl-2 family protein. Deleting FBW7 in FBW7-
wild-type CRC cells abolishes Mcl-1 degradation and recapitulates the in vitro
and in vivo drug resistance phenotypes of FBW7-mutant cells. CRC cells se-
lected for regorafenib resistance have progressive enrichment of pre-existing
FBW7 hotspot mutations, and are cross-resistant to other targeted drugs that
induce Mcl-1 degradation. Furthermore, a selective Mcl-1 inhibitor restores
regorafenib sensitivity in CRC cells with intrinsic or acquired resistance. To-
gether, our results demonstrate FBW7 mutational status as a key genetic deter-
minant of CRC response to targeted therapies, and Mcl-1 as an attractive ther-
apeutic target.
#3144 Prediction ofALKmutations associatedwith acquired resistance to
lorlatinib. Satoshi Yoda, Leila Dardaei, Manrose Singh, Jeffrey A. Engelman,
Alice T. Shaw, Aaron N. Hata. Massachusetts General Hospital, Charlestown,
MA.
Anaplastic lymphoma kinase (ALK) rearrangements are important therapeu-
tic targets in non-small cell lung cancer. They are currently treated with the
fırst-generation ALK inhibitor crizotnib followed by more potent, second-gen-
eration ALK inhibitors, such as ceritinib, alectinib, or brigatinib. We reported
different spectrums of ALK resistance mutations in the biopsies from patients
progressing on these drugs. G1202R mutation was found more frequently after
treatmentwith second generationALK inhibitors. In addition to these drugs, the
third-generationALK inhibitor lorlatinib is currently being evaluated in phase 2
clinical trial. Ba/F3models indicated that all single ALKmutants are sensitive to
lorlatinib and some compoundALKmutations are resistant to lorlatinib. In this
study, we performed acceleratedmutagenesis screen on Ba/F3models to predict
the resistance mutations which potentially emerge in the patients treated with
lorlatinib. Briefly, Ba/F3 cells expressingwild type EML4-ALKormutant EML4-
ALK containing C1156Y, F1174C, L1196M, G1202R, or G1269A were exposed
to N-ethyl-N-nitrosourea (ENU). After a 24-hour incubation in normal media,
the cells were seeded in 96-well plates and incubated in lorlatinib for 4 weeks.
ALK kinase domain was sequenced in clones growing in lorlatinib to identify
possible newmutations. As a result, Ba/F3 cells harboring wild type EML4-ALK
did not show any mutation on ALK kinase domain. Crizotinib was used as a
control to validate the effıciency of mutagenesis. We identifıed eight different
mutations in clones growing in crizotinib, and those were reflecting the spec-
trum of mutations in the crizotinib-treated patients. Ba/F3 cells with mutant
EML4-ALK showed additional compound mutations after incubation with lor-
latinib. Those mutations included L1196M  L1198F and G1202R  L1198F
which showed high resistance to lorlatinib in Ba/F3 models. Ba/F3 cells with
different mutant EML4-ALK showed a distinct spectrum and different fre-
quency of additional mutations. In conclusion, this study predicted that no
single mutation would emerge to confer resistance to lorlatinib. Thus, com-
pound mutations and ALK-independent mechanisms become essential mecha-
nisms for lorlatinib resistance.
#3145 Mechanismsof resistance toFGFR-targeted therapy inbladder can-
cer. Geoffrey A. Pettitt, Helen R. McPherson, Carolyn D. Hurst, Julie E. Burns,
OliviaA.Alder,MatthewC.Dunning,Margaret A. Knowles.University of Leeds,
Leeds, United Kingdom.
Fibroblast growth factor receptor 3 (FGFR3) overexpression, pointmutations
or gene fusions are found in80%of nonmuscle-invasive and15%ofmuscle-
invasive bladder cancer. FGFR inhibitors have entered clinical trials in advanced
bladder cancer however, as with other targeted therapies, intrinsic and acquired
resistance are expected to limit treatment effıcacy. We have used an in vitro
model to explore possible mechanisms of resistance. The urothelial cancer cell
line RT112 expresses an FGFR3-TACC3 fusion protein and is sensitive to FGFR
inhibition. Isogenic resistant cell lines, termed R1, R2 and R3, were derived by
long-term culture of RT112 in the presence of the FGFR inhibitor PD173074.
Compared to parental RT112, R1 and R2 show reduced proliferation and have a
moremesenchymal morphology, decreased expression of FGFR3 and increased
expression of N-cadherin. R3 has a faster growth rate, more epithelial morphol-
ogy and lower N-cadherin expression than R1 and R2. The changes inmorphol-
ogy and gene expression between parental and resistant derivatives R1 and R2
were reversed when the resistant cells were cultured without PD173074 for 4
passages. Despite this, the cells retained their resistance when re-exposed to
PD173074. Exome sequencing, RNAmicroarray analysis and phospho-receptor
tyrosine kinase array data on the parental cells and resistant derivatives and will
be presented. Our data suggests that diverse mechanisms of resistance occur
following prolonged FGFR inhibition.
#3146 TargetingANXA3 in combinationwith sorafenib for the treatment
of hepatocellular carcinoma. Man Tong,1 Steve Luk,1 Noelia Che,1 Jin Ding,2
Terence KW Lee,3 Stephanie Ma1. 1Univ. of Hong Kong, Faculty of Medicine,
Pokfulam, Hong Kong; 2Eastern Hepatobiliary Surgery Hospital, SecondMilitary
Medical University, Shanghai, China; 3The Hong Kong Polytechnic University,
Hong Kong, Hong Kong.
Sorafenib is the only FDA-approved tyrosine kinase inhibitor for targeted
therapy in advancedHCC.Nevertheless, its effıcacy is limitedwith only amodest
improvement in patient outcome, likely due to acquired resistance. In-depth
understanding of themolecular mechanism of sorafenib resistance is warranted
for the development of novel treatment strategies. Recent studies by us and
others have characterized liver tumor-initiating cells (T-ICs) to be a possible
source of resistant and recurrent tumors and a plausible target for HCC treat-
ment. Our group has previously identifıed CD133 to be a functional marker of
liver T-ICs and found annexin a3 (ANXA3) to regulate cancer and stem cell-like
properties in this subset of cells. Interestingly, our recent observations also
found CD133 liver T-ICs to be more resistant to sorafenib. Sorafenib resistant
clones, established inHepG2 andHuh7 cells by continuous exposure to increas-
ing concentrations of sorafenib, displayed enhanced abilities to migrate, invade,
self-renew, and initiate tumor formation in immunodefıcient mice, as well as
higher expression of stemness associated genes. These two sorafenib resistant
cell lines and two other sorafenib resistant HCC patient-derived xenografts es-
tablished in a similar manner were also found to be enriched for CD133 and
ANXA3 expression. Sorafenib resistant clones with ANXA3 stably suppressed
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were re-sensitized to sorafenib treatment and had diminished ability tomigrate,
invade, self-renew and initiate tumor growth in vivo, further substantiating the
role of ANXA3 in mediating sorafenib resistance in HCC. Mechanistically, an
activated PKC/ERK/FRA2 signaling axis was found to be responsible for driving
this phenomenon. Clinically, ANXA3 expression was also found to have prog-
nostic value as a higher ANXA3 expression in HCC patients who have received
sorafenib treatment was correlated with poor overall survival. The combinato-
rial use of a homemade ANXA3 neutralizing antibody and sorafenib on HCC
patient derived xenografts is nowbeing investigated as a potential new treatment
regimen for combating sorafenib resistance in HCC.
#3147 Comprehensive characterization of the role of T-type calcium
channels in glioblastoma. Ying Zhang,1 Nichola Cruickshanks,1 Fang Yuan,1
BaominWang,1Mary Pahuski,1 JuliaWulfkuhle,2 IselaGallagher,3 Alexander F.
Koeppel,1 Sarah Hatef,1 Christopher Papanicolas,1 Jeongwu Lee,4 Eli Bar,5 Da-
vid Schiff,1 Stephen D. Turner,1 Emanuel Petricoin,3 Lloyd L. Gray,6 Roger
Abouander1. 1Univ. of Virginia, Charlottesville, VA; 2George Mason University,
Charlottesville, VA; 3George Mason University, Manassas, VA; 4Cleveland Clinic
Lerner Research Institute, Cleveland, OH; 5CaseWestern Reserve University Neu-
rological Surgery, Cleveland, OH; 6Cavion LLC, Charlottesville, VA.
Glioblastoma stem cells (GSCs) have been implicated in tumor resistance to ra-
dio- and chemotherapy. Proliferation of GSCs reportedly requires calcium influx
throughT-type calciumchannels (Cav3.2). In this studywe investigated the expres-
sion, function, mechanism of action and therapeutic targeting of Cav3.2 with the
FDAapproved and repurposed drugMibefradil in glioblastoma (GBM), andGSCs.
We found thatCav3.2 is highly expressed in themajority of humanGBMspecimens
and all GCSs. TCGA data analysis demonstrated that approximately 11% of GBM
tumors have upregulated Cav3.2 and that overexpression of Cav3.2 is associated
withworse prognosis. Furthermore, we demonstrated thatMibefradil inhibits GSC
growth and survival and sensitizes GSCs to Temozolomide (TMZ) chemotherapy.
Mibefradil inhibited hypoxia inducible factor HIF1a and induced GSC differentia-
tion. To investigate the mechanism of action of Mibefradil, were performed pro-
teomic and transcriptomic screenings of Mibefradil-treated GSCs using reverse
phase protein arrays and RNA-seq, followed by functional rescue experiments. In-
hibition of Cav3.2 with Mibefradil signifıcantly altered multiple cancer regulatory
signaling pathways and molecules as well as the transcription of oncogenes and
tumor suppressors. Among other, Mibefradil suppressed GSC growth through in-
hibition of pro-survival pathways such as AKT/mTOR, whilst simultaneously in-
ducing apoptosis through upregulation of survivin, BAX and cleavage of caspase 9
andPARP.Notablyalso,RNA-deepsequencingofMibefradil treatedGSCsrevealed
an increase in expression of tumor suppressors such as TNFRSF14 andHSD17B14
along with a decrease in the expression of several oncogenes such as PDGFA,
PDGFB and TGFB1. We also assessed the therapeutic effects of Mibefradil, on es-
tablished GSC-derived xenografts. Oral administration of Mibefradil signifıcantly
inhibited tumor growth, prolonged animal survival and sensitized tumors to inhi-
bition byTMZand radiation. This study represents the fırst comprehensive charac-
terization of Cav3.2 in GBM and GSC. The data establish Cav3.2 inhibition by the
repurposed FDA-approved drugMibefradil as a new strategy for GBM therapy.
#3148 Activation of Src signaling mediates acquired resistance to ALK
inhibition in lung cancer. Ryohei Yoshida, Takaaki Sasaki, Shunsuke Oku-
mura, Yoshinobu Ohsaki. Asahikawa Medical University, Asahikawa city, Hok-
kaido, Japan.
Anaplastic lymphoma kinase (ALK) fusion oncogenes occur in around
3%-5%non-small cell lung cancer (NSCLC) cases. VariousALK inhibitors are in
clinical use for the treatment ofALK-NSCLC, including the fırst generationALK
inhibitor, Crizotinib, and recently the more highly potent Alectinib and Cer-
itinib. However, most tumors eventually become resistant to ALK specifıc in-
hibitors. To address themechanisms underlying the development of ALK inhib-
itor resistance, we used iTRAQ quantitative mass spectrometry and phosphor-
receptor tyrosine kinase arrays to investigate intracellular signaling alterations
in ALK inhibitor resistant NSCLC cell lines. Src signaling was identifıed as an
Alectinib resistance mechanism, and combination treatment with ALK and Src
inhibitors was highly effective for inhibiting the growth of ALK inhibitor resis-
tant cells in vitro and inmouse xenograftmodels. Furthermore, phospho-recep-
tor tyrosine kinase activation and downstream PI3K/AKT signaling was effec-
tively blocked by inhibiting Src in Alectinib resistant cells. Finally, we showed
that the combined use of ALK and Src inhibitors inhibited the growth of other
ALK-NSCLC cell lines, including those that were Ceritinib or Lorlatinib resis-
tant. Our data suggest that targeting Src signaling may be an effective approach
to the treatment of ALK–NSCLC with acquired resistance to ALK inhibitors.
#3149 Identifıcation of genes associated with the cisplatin resistance in
cervical cancer cells expressing E545K mutation.Wani Arjumand,1 Nicholas
Jette,1 Jb McIntyre,2 Prafull Ghatage,3 Corinne M. Doll,4 Susan P. Lees-Miller5.
1Department of Biochemistry & Molecular Biology; Arnie Charbonneau Cancer
Institute, Robson DNA Science Centre, University of Calgary, Calgary, Alberta,
Canada; 2Translational Laboratory, Tom Baker Cancer Centre, University of
Calgary, Calgary, Alberta, Canada; 3Department of Gynecologic Oncology, Uni-
versity of Calgary, Calgary, Alberta, Canada; 4Department of Oncology, Arnie
Charbonneau Cancer Institute, Robson DNA Science Centre, University of Cal-
gary, Calgary, Alberta, Canada; 5Department of Biochemistry &Molecular Biol-
ogy and Department of Oncology, Arnie Charbonneau Cancer Institute, Robson
DNA Science Centre, University of Calgary, Calgary, Alberta, Canada.
The phosphatidylinositol-3 kinase (PI3K)/AKT/ mTOR signaling pathway is
activated in several human cancers and activation is frequently mediated by
“hotspot”mutations including E542K, E545K andH1047R in the PIK3CA gene.
Approximately 30% of cervical cancer patients have the PIK3CA-E545K muta-
tion. Cisplatin with radiotherapy (RT) is the standard treatment of cervical can-
cer world-wide, used in both the radical and post-operative adjuvant settings.
However, details of the molecular mechanisms responsible for cisplatin resis-
tance remain unclear. We previously reported PIK3CA mutation in patients
with earlier stage (IB/II) cervical cancer was associated with poor survival
(McIntyre et al. Gynecol Oncol. 2013, PMID:23266353), and in our recent study
we observed that PIK3CA-E545K mutation renders cervical cancer cells more
resistant to cisplatin or cisplatin plus RT and results in a more migratory phe-
notype than isogenic cell lines with wild type-PIK3CA. Moreover, these pheno-
types are reversed by the PI3K inhibitor GDC-0941/Pictilisib (Wani et al. On-
cotarget. 2016, PMID:27489350). The aim of the present study is to identify the
expression of genes related to cisplatin resistance in cervical cancer cells engi-
neered to express PIK3CA-E545K.Microarray analysis identifıed 161 genes that
were up-regulated and 189 that were down-regulated in the cervical cancer cells
stably expressing PIK3CA-E545K, some of which are involved in well-charac-
terized mechanisms that could be relevant to cisplatin resistance. We are cur-
rently validating some of those genes by Real-time PCR that will help us to
determine the mechanism of PIK3CA-E545K induced cisplatin resistance and
enhanced migration in cervical cancer cells expressing PIK3CA-E545K and ex-
tending our in vitro fındings to animalmodels. Together, our data will provide a
useful basis for screening candidate targets for risk stratifıcation and provide
valuable information for potential targeted intervention in patients whose tu-
mors harbor cisplatin-resistant molecular characteristics.
#3150 PLCG2C2-domainmutations co-occurwithBTK andPLCG2 resis-
tance mutations in chronic lymphocytic leukemia undergoing treatment
with the BTK inhibitor ibrutinib. Dan Jones, Jennifer A. Woyach, Weiqiang
Zhao, Sean Caruthers, Huolin Tu, Joshua Coleman, John C. Byrd, Amy J. John-
son, Gerard Lozanski. The Ohio State University, Columbus, OH.
Background: The Bruton agammaglobulinemia tyrosine kinase (BTK) acti-
vates B-cell receptor signaling through activation of phospholipase C gamma 2
(PLCG2). Clinical resistance to the Bruton tyrosine kinase (BTK) inhibitor ibru-
tinib in chronic lymphocytic leukemia (CLL) is highly associated with emer-
gence of the BTK C481 mutations that prevent ibrutinib covalent binding.
PLCG2 mutations also occur in these ibrutinib-resistant samples but the spec-
trum of mutations and their occurrence with BTK changes have not been fully
delineated. Materials andMethods: All peripheral blood samples with adequate
depth of sequencing coverage were included from CLL patients receiving ibru-
tinib (with or without other therapies) that were submitted from Ohio State
University (OSU) to the OSU James Polaris Molecular Laboratory. Genomic
DNA was extracted from negatively selected B cells and deep sequencing of the
entire coding regions of BTK andPLCG2performed using a custom IonTorrent
Ampliseq panel. Amean depth of greater than 1000Xwas obtained with hotspot
mutations validated down to 1% variant allele fraction (VAF) in the B cell prep-
arations using orthogonal mutation-specifıc detection methods. Results:
Among 1063 CLL samples from 380 patients who received ibrutinib, BTK C481
resistancemutations were identifıed in 79 (20.8%) patients including 20 patients
that also had co-occurring PLCG2 mutations. 11 patients (2.9%) had PLCG2
mutations without accompanying BTK C481 alterations for a cumulative inci-
dence of PLCG2mutations in 8.2% of ibrutinib-treated patients. These included
previously describedmutations in the SH2 and SH3 domain of PLCG2 (R665W,
S707F, A708P and L845F) but also previously uncharacterized mutations in the
PLCG2 C2 domain that were seen in 12 patients (3.2%). C2 domain mutations,
always seen in association with another PLCG2 and/or BTK resistance muta-
tion, affected codons 1140-1144 that include the highly conserved aspartic acid
residues that bind calcium and mediate membrane localization in other C2-
domain containing proteins. In sequential samples, PLCG2 C2-domain muta-
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tions tracked at similar levels to the co-occurring BTK and PLCG2 resistance
mutations indicating their presence in the same population of CLL cells. Con-
clusions: Mutations in three different PLCG2 structural domains commonly
co-occur with BTK C481 mutations. The identifıcation of PLCG2 mutations in
the calcium-regulated C2 domain expands the possible mechanisms that can
produce PLCG2 activation following ibrutinib treatment. The diversity of recur-
rent mutations observed supports the need for complete PLCG2 sequencing for
full characterization of ibrutinib-treated CLL samples.
#3151 Loss of Axin1 drives acquired resistance toWNTpathway blockade
in colorectal cancer cells carrying RSPO3 fusions. Gabriele Picco,1 Consalvo
Petti,2 Alessia Centonze,1 Erica Torchiaro,2 Alberto Bardelli,1 Enzo Medico1.
1University of Torino, Candiolo Cancer Institute, Candiolo, Italy; 2Candiolo Can-
cer Institute, Candiolo, Italy.
In colorectal cancer (CRC), WNT pathway activation by genetic rearrange-
ments of RSPO3 is emerging as a promising target. However, its low prevalence
severely limits availability of preclinical models for in-depth characterization.
Using a pipeline designed to suppress stroma-derived signal, we fınd that RSPO3
“outlier” expression in CRC samples highlights translocation and fusion tran-
script expression. Outlier search in 151 CRC cell lines identifıed VACO6 and
SNU1411cells as carriers of, respectively, a canonical PTPRK(e1)-RSPO3(e2)
fusion and a novel PTPRK(e13)-RSPO3(e2) fusion. Both lines displayedmarked
in vitro and in vivo sensitivity to WNT blockade by the porcupine inhibitor
LGK974, associated with transcriptional and morphological evidences of WNT
pathway suppression. Long-term treatment of VACO6 cells with LGK974 led to
the emergence of a resistant population carrying two frameshift deletions of the
WNT pathway inhibitor AXIN1, with consequent protein loss. Suppression of
AXIN1 in parental VACO6 cells by RNA interference conferred marked resis-
tance to LGK974. These results provide the fırst mechanism of secondary resis-
tance to WNT pathway inhibition.
#3152 Acquired resistance to the third-generation EGFR inhibitor
ASP8273 is associated withMET or NRAS gene amplifıcations in preclinical
models. Kiichiro Ninomiya,1 Kadoaki Ohashi,2 Shuta Tomida,2 Hiroe Kaya-
tani,1 Tomoki Tamura,1 Hisao Higo,1 Go Makimoto,1 Takashi Ninomiya,2
ToshioKubo,2 Eiki Ichihara,2 Akiko Sato,2 KatsuyukiHotta,2Masahiro Tabata,2
Katsuyuki Kiura2. 1Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences, Okayama city, Japan; 2Okayama University Hos-
pital, Okayama city, Japan.
Background. Third-generation EGFR tyrosine kinase inhibitors (TKIs) such
as osimertinib and ASP8273 demonstrated biologic activity in patients with
non-small cell lung cancer (NSCLC) harboring the EGFR T790M mutation;
however, acquired resistance inevitably develops and the mechanisms of have
not been fully elucidated. This study evaluated potential mechanisms of resis-
tance to ASP8273. Materials and Methods. ASP8273 was kindly provided by
Astellas Pharma Inc. PC-9 cells harboring EGFR 19del and RPC-9 cells harbor-
ing EGFR 19delT790Mwere used as cell models to explore alternativemolec-
ular mechanisms of acquired resistance to ASP8273. Resistant cell lines (PC-
9ASR and RPC-9ASR) were established from each cell line after continuous
exposure to ASP8273 for 6 months. Results. Other EGFR-TKIs, including
osimertinib, afatinib, or gefıtinib, did not inhibit cell growth and acquired EGFR
mutations were not detected in either of ASP8273 resistant cell lines. The PC-9-
based model was fırst analyzed. The 50% inhibitory concentration (IC50) of
ASP8273was 45-fold higher in PC-9ASR cells (1,216 nmol/L) than in the paren-
tal PC-9 cells (27 nmol/L). A receptor tyrosine kinase array showed that MET
phosphorylation was increased in PC-9ASR cells relative to PC-9 cells. Single-
cell cloning revealed that PC-9ASRc2 cells harbored MET gene amplifıcation,
but other clones (c1, c3, c4, and c5) did not; these results suggest that heteroge-
neous cells comprised the resistant cell lines. Consistently, the combination of
EGFR inhibitors (ASP8273 or gefıtinib) with MET inhibitors (crizotinib or
SGX-523) inhibited cell proliferation in vitro. In vivo, concomitant dosing of
ASP8273 with crizotinib consistently inhibited this resistant tumor xenograft
model. The RPC-9-based model was then assessed. The IC50 of ASP8273 was
40-fold greater in RPC-9ASR cells (1,393 nmol/L) than in the parental RPC-9
cells (32 nmol/L). Next-generation sequencing showed signifıcant NRAS gene
amplifıcation and no NRAS mutations in RPC-9ASR cells. EGFR 19del
T790M was maintained in the resistant cells. Western blot analysis and an
active RAS pull-down kit confırmed that NRAS protein was signifıcantly over-
expressed and that NRAS-GTPase activity was much higher in RPC-9ASR cells
than in the RPC-9 parental cells. As expected, inhibition of RAS signaling using
a MEK inhibitor (selumetinib or trametinib) in addition to ASP8273 overcame
the resistance in vitro. Interestingly, a combination of MEK inhibitors with
another third-generation EGFR-TKI, osimertinib, had no effect on the RPC-9
resistant cells. Conclusions. These studies suggest that a bypass signaling path-
way, such asMETgene amplifıcation, or activation of theRAS signaling pathway
plays a role in ASP8273 resistance in lung cancer cells harboring EGFR muta-
tions. (This work was supported by KAKEN 16K19454 and 15H04830.)
#3153 Transcriptome differences in tyrosine kinase inhibitor-resistant
clones of EGFR-mutant lung cancer using a new microfluidic assay for con-
current single-cell RNA and targeted DNA sequencing. Say Li Kong,1 Hu-
ipeng Li,1 Dave Ruff,2 Joyce An Yi Tai,1 Elise T. Courtois,1 Huay Mei Poh,1
Dawn Pingxi Lau,3 Audrey Ann Liew,1 Gek San Tan,4 Tony Kiat Hon Lim,4
Daniel Shao Weng Tan,3 Shyam Prabhakar,1 Axel M. Hillmer1. 1Genome Insti-
tute of Singapore, Singapore, Singapore; 2Fluidigm, South San Francisco, CA;
3National Cancer Centre Singapore, Singapore, Singapore; 4Singapore General
Hospital, Singapore, Singapore.
Resistance to therapy is one of the major causes of cancer-associated death.
While a number of mechanisms for the development of resistance to epidermal
growth factor receptor, EGFR-targeting drugs in lung cancer have been de-
scribed, most genomic and transcriptomic studies have focused on analyzing
bulk samples that can only provide an average measurement over the entire
mixture of cell populations of a tumor. With this approach, it is diffıcult to
resolve cell-to-cell variability of drug resistance within a heterogeneous tumor.
In order to accurately describe and eventually delineate the underlying causes of
cancer progression, it requires the analysis of single cells on both, the transcrip-
tomic and the genomic level. Only the co-detection ofmutations and expression
features in individual cells allows to defıne the connection between the two. We
therefore aimed to establish a new methodology for concurrent evaluation of
transcriptomic and genomic features within the same single cell on the Fluidigm
C1 system. We applied this protocol to an EGFR-mutant lung cancer cell line,
PC9, that has developed resistance to tyrosine kinase inhibitor, TKI treatment
after prolonged exposure to sublethal doses of Gefıtinib. We amplifıed cDNA
and selected genomic EGFR regions of the TKI responsive and resistant PC9
clones from a total of 300 single cells. We used our in-house single cell’s
analysis pipeline for parallel processing of transcriptome and variants detection.
In addition, a novel algorithm, NODES was used to normalize the single cell
RNAseq data and detect differentially expressed genes. The differential tran-
scriptome and emergence of the EGFRT790M resistancemutation in relation to
the TKI response were evaluated. We observed up-regulation of receptor ty-
rosine kinase AXL in the resistant cell lines. This observation is in agreement
with previous fındings thatAXL is the key player that promotes TKI resistance in
lung cancer. In addition, we found up-regulation of other genes that have not
been previously described. Cumulatively, this method allows us to dissect the
underpinnings of the TKI resistance mechanism and enables us to identify bio-
marker for specifıc cellular features that are connected with resistance and
thereby with lung cancer patient’s response to TKI treatment.
#3155 Harnessing synthetic rescues to evaluate andmitigate resistance to
cancer therapy. Avinash D. Sahu,1 Joo Sang Lee,1 Eytan Ruppin,1 Silvio Gut-
kind,2 ZhiyongWang2. 1University ofMaryland, College Park, College Park,MD;
2University of California, San Deigo, CA.
Signifıcance: The emergence of resistance to cancer therapy remains a
pressing challenge, as evident from numerous recent investigations identi-
fying molecular events conferring resistance to cancer drugs. Here we dem-
onstrate that many of these molecular events can be attributed to synthetic
rescue (SR) genetic interactions, where altered activity of a specifıc (termed
rescuer) gene restores cell viability caused by the inactivation (including
through gene deletion or targeted pharmacological repression) of another
gene. Methods: We present a computational approach termed INCISOR,
which analyzes molecular, survival, and phylogenetic cancer data to predict
SR genes pairs that are under positive selection and their presence decreases
patient survival. It further screens for causal SR pairs that show in vitro
evidence of rescue. Results: We applied INCISOR to mine 8000 patients’
omics and clinical data in TCGA to identify the fırst genome-wide SR net-
work, composed of SR interactions common to many cancer types. The
predicted SRs match drug-specifıc molecular resistance signatures that have
been recently published in arduous clinical studies (with accuracy of 0.8
AUC). They chart pathways of resistance on a genome scale and as we show,
can predict response and resistance to themajority of current cancer drugs in
patients. We conducted new experiments to test new predicted SR-based
combination therapies. Each combination consisted of a primary cancer
drug and a second adjuvant therapy inhibiting a predicted key rescuer of the
primary drug. Five of the 7 predicted combinations tested synergistically
sensitized all the fıve head and neck cell lines to the original primary thera-
pies. These results were further substantiated via siRNA knockdowns of the
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predicted rescuers in combination with the original treatment, confırming
the effects observed with pharmacological inhibition. Focusing on mTOR, a
major cancer driver gene, we combined drug treatment and pooled-shRNA
to validate the rescue effect of 8 out of 10 predicted rescue interactions
involving mTOR in a head and neck cancer cell-line. Finally, we analyzed
patient-derived mouse 960 xenografts (PDX) treated with 25 different drug
combinations. Mice exhibit much better progression-free survival when
treated with a drug combination predicted by INCISOR compared with the
mice treated with the primary drug alone, testifying to the in-vivo benefıts of
SR-based synergistic treatments. Conclusions: This work presents a new
paradigm harnessing synthetic rescue gene-gene interactions to counteract
resistance to cancer treatment. Future implementations of this approach will
have two broad implications in the precision medicine era, fırst for deter-
mining the most effective treatment regimen based on the molecular char-
acteristics of individual patient’s tumor; second for identifying supplemental
drugs to counteract resistance to existing primary therapies.
#3156 Multiple acquired resistance mechanisms against third generation
EGFR-TKI osimeritinib in non-smal cell lung cancer cells. Kei Namba, Ka-
zuhiko Shien, Takahiro Yoshioka, Hidejiro Torigoe, Hiroki Sato, Hiromasa
Yamamoto, Junichi Soh, Kazunori Tsukuda, Shinichi Toyooka. Okayama Uni-
versity, Okayama city, Japan.
Background: Osimertinib (AZD9291; Tagrisso) is a third generation epider-
mal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) known to be
effective against the EGFR-T790M variant, which is accounts for half of the
acquired resistance mechanisms to the fırst generation EGFR-TKIs. However,
resistance to osimertinib is likely to progress and the study of potential
osimertinib-resistance mechanisms in advanced is necessary. In this study, we
investigated themolecular and cellular profıles of the acquired resistance cells to
osimertinib in EGFR-mutant non-small cell lung cancers. Materials and
Methods: Five EGFR-mutant cell lines were exposed to osimertinib by stepwise
escalation or high-concentration exposure methods, and resistant sublines to
osimertinib were established. The molecular profıles and cellular phenotypes of
these resistant sublines were characterized. Results: EGFR-C797S mutation
which was reported to be a major mechanism of resistance to osimertinib in
clinical samples was not detected in established resistance cells by using direct
sequencing. Several osimertinib-resistance cell lines displayed MET amplifıca-
tion, and some of these cells were sensitive to the combination of osimertinib
plus MET inhibitor crizotinib. However, one cell line that displayed MET am-
plifıcation was not sensitive to this combination therapy. On the other hand,
several osimertinib-resistance cell lines displayed epithelial-to-mesenchymal
transition (EMT) features. The HCC827-derived subline established by the
high-concentration exposure method exhibited not only EMT features but also
cancer stem cell (CSC)-like properties, including aldehyde dehydrogenase iso-
form 1 (ALDH1A1) and ATP binding cassette subfamily B member 1 (ABCB1)
overexpression. Conclusion: We established osimertinib-resistant cells and
found that MET amplifıcation, EMT, and CSC -like features were observed.
These fındings may provide clues to overcome acquired resistance to EGFR-
TKIs. In some cell lines, however, the mechanisms of acquired resistance to
osimertinib were not revealed yet.
#3157 Osimertinib (AZD9291) is effective against NSCLC cells harboring
EGFR exon 20 insertion mutations. Yusoo Lee,1 Tae Min Kim,2 Dong-Wan
Kim,2 Yong-Oon Ahn,1 Soyeon Kim,1 Bhumsuk Keam,2 Miso Kim,2 Dae Seog
Heo2. 1Seoul National University Cancer Research Institute, Seoul, Republic of
Korea; 2Seoul National University Hospital, Seoul, Republic of Korea.
Background: Although EGFR exon 20 insertion mutation is the third most
common among EGFR-mutant NSCLC, this mutant clones are resistant to the
fırst-generation EGFR TKIs. In addition, the effıcacy of the second or third-gener-
ation EGFR TKIs is unknown in NSCLC with EGFR exon 20 insertion mutation.
Methods: Various EGFR exon 20 insertion mutations were introduced into Ba/F3
cells as follows: A763_Y764insFQEA in C-helix; and V769_D770insASV,
D770_N771insNPG, D770_N771insSVD, P772_H773insPR, H773_V774insNPH,
H773_V774insH, and H773_V774insAH in loop following C-helix. The patient-
derived SNU-3173 cell line was developed in a patient with EGFRH773_V774insAH
mutation.Ba/F3 cells transfectedwithEGFRexon20 insertionmutations andSNU-
3173were exposed to the EGFRTKIs (the 1st-generation gefıtinib and erlotinib; the
2nd-generationdacomitinib and afatinib; and the 3rd-generation rociletinib, olmu-
tinib, nazartinib, and osimertinib) and cell viability assays were performed. In addi-
tion, immunoblotting was performed to evaluate the downstream signals of EGFR
pathway. Results: Cell viability assay showed that EGFR exon 20 insertionmutants
are resistant to the 1st-generation EGFR TKIs, except for EGFRA763_Y764insFQEA-
mutant Ba/F3 cells. IC50 values of the 2nd-generation EGFR TKIs are fıve to hun-
dred-folds lower than the 1st-generation EGFR TKIs. The 2nd-generation EGFR
TKIs were effective against EGFR exon 20 inserted Ba/F3 cells and down-regulated
EGFRdownstreamsignals.The3rd-generationEGFRmutation-selective inhibitors
showed a moderate effıcacy except osimertinib that was effective and down-regu-
latedEGFRdownstreamsignals. In addition, SNU-3173 cellsweremoderately toxic
to afatinib (IC50 46.2	5.2 nM) as well as osimertinib (IC50 403.2	3.0 nM).
IC50 values of EGFR exon 20 insertionmutation Ba/F3 cells
IC50 (nM) FQEA ASV SVD NPG PR H AH NPH
Gefıtinib 32.7 525.7 752.7 1597.0 1363.0 2581.0 2259.0 1701.0
Erlotinib 22.3 486.9 338.3 765.7 798.2 1523.0 1438.0 562.1
Dacomitinib 0.0024 3.5 5.7 15.0 205.0 608.4 556.3 12.3
Afatinib 0.008 2.34 4.9 11.4 94.7 297.7 204.4 25.4
Rociletinib 219.7 367.1 91.5 131.2 1093.9 3710.0 5085.4 498.7
Olmutinib 76.0 82.1 95.6 64.5 332.6 952.4 1406.6 337.1
Osimertinib 3.6 8.1 8.9 128.2 247.2 128.2 880.3 38.2
Nazartinib 28.3 22.3 36.6 57.6 747.8 872.1 1606.8 118.0
Conclusions: Overall, osimertinib showed effectiveness against NSCLC cells
with EGFR exon 20 insertion mutations. Our results warrant a clinical trial of
osimertinib in NSCLC patients with EGFR exon 20 insertion mutations.
#3158 In vivo acquired resistance to an emibetuzumab analogue inMET-
amplifıed gastric xenografts can be overcome by a MET-targeting antibody
mixture or PIK3CA/AKT/mTOR inhibition. Sofıe Ellebæk Pollmann,1
Emanuel Frank Petricoin,2 Valerie Calvert,2 Shruti Rao,3 Simina Boca,3 Subha
Madhavan,3 Ivan David Horak,1 Andreas Kjær,4 Michael Kragh,1 Thomas
Tuxen Poulsen1. 1Symphogen, Ballerup, Denmark; 2George Mason University,
Manassas, VA; 3Georgetown University, Washington, DC; 4University of Copen-
hagen, Copenhagen, Denmark.
Aberrant over-activation of MET receptor tyrosine kinase is involved in
driving malignancies such as gastric and non-small cell lung cancer
(NSCLC), and in the development of resistance to EGFR-targeting therapeu-
tics. This has led to the development of several MET-targeting agents in the
form of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies
(mAbs), many of which are in clinical development. However, resistance to
MET-targeted agents is an emerging problem. This study aims to understand
mechanisms underlying resistance development to an analogue of emibetu-
zumab, a mAb targeting MET. Upon long term in vivo treatment, emibetu-
zumab-resistant tumors and cell lines were generated, isolated, and charac-
terized to investigate their acquired resistance mechanisms. Extensive
reverse phase protein array and network analysis were used to characterize
the proteomic profıles of three resistant cell lines, revealing three distinct
resistance profıles, one involving activation of the PI3Kinase/AKT/mTOR
pathway. We further show, how these resistance mechanisms can be over-
come by treatment with other targeting therapeutics both in vitro and in
vivo. Two of the models demonstrated in vivo sensitivity to Sym015, a novel
mixture of twomAbs targeting non-overlapping epitopes of MET, partly due
to ADCC, indicating that Sym015 can overcome acquired resistance to emi-
betuzumab. The third model demonstrated a marked increase in PI3Kinase/
AKT/mTOR pathway activation. This activation translated into induced
cancer cell and tumor growth, which could be inhibited by agents targeting
PI3Kinase, AKT, or mTOR. This study thus points to treatment of patients
with acquired resistance to single targeting MET mAbs with PI3Kinase/
AKT/mTOR-targeting agents or a MET-targeting antibody mixture such as
Sym015.
#3159 Lysosomal membrane permeabilization as potential mediator of
resistance in pancreatic neuroendocrine tumors.TabeaWiedmer, RasmusM.
Frank,Mario P. Tschan, Aurel Perren, IlariaMarinoni.University of Bern, Bern,
Switzerland.
Sunitinib, an anti-angiogenic tyrosine kinase inhibitor, is approved for treat-
ment of pancreatic neuroendocrine tumors (pNETs). However, its effıcacy is
greatly limited due to resistance. Sunitinib is a lysosomotropic drug, thus accu-
mulates in lysosomes, leading to their destabilization and to lysosomal mem-
brane permeabilization (LMP), which in turn can lead to cell death. Autophagy
might be activated for clearance of damaged lysosomes, thus promote survival
and act as a mechanism of resistance. We found that the autophagy inhibitor
chloroquine increases sunitinib effıcacy in pNET cell lines and in a transgenic
mouse model of pNETs. Interestingly, chloroquine is a lysosomotropic drug as
well and the response towards sunitinib and chloroquine in pNET cell lines
correlated with lysosome-associated membrane protein 2 (LAMP2) levels,
which influence lysosome stability.Wehypothesized that sunitinib and the com-
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bination with chloroquine induce LMP in pNETs and that LMP leads to activa-
tion of the transcription factor EB (TFEB), master regulator of genes involved in
lysosomal biogenesis and autophagy, leading to therapy resistance. We found
that LMP increased upon combined treatment of sunitinib and chloroquine
compared to single treatment in pNET cell lines. Treatment of pNET cell lines
with sunitinib or chloroquine led to activation of TFEB as assessed by nuclear/
cytoplasmic fractionation and western blotting. Additionally, sunitinib signifı-
cantly increased the expression of TFEB target genes, which were further up-
regulated upon combinationwith chloroquine. Interestingly, activation of TFEB
and upregulation of TFEB target genes was more pronounced in the more resis-
tant pNET cell line with respect to reduced viability and increased apoptosis.
Our data indicate that sunitinib and chloroquine activate TFEB in pNET cell
lines, leading to autophagy as a survival mechanism. Upon massive LMP or if
autophagy is dysfunctional, cell death is induced. Based on our data, we suggest
the combination of sunitinib and chloroquine as a treatment option for pNET
patients and that TFEB could be an interesting therapeutic target in combination
with lysosomotropic drugs.
#3160 Sustained MAPK activation as a mechanism of resistance to
osimertinib plus selumetinib in models of EGFR-mutant cancer.David Westo-
ver,1 Catherine B. Meador,1 Eiki Ichihara,1 Hayden F. Byrd,1 Cath Eberlein,2
Yingjun Yan,1 Darren A. Cross,2 Christine M. Lovly1. 1Vanderbilt-Ingram Cancer
Center, Nashville, TN; 2AstraZeneca Oncology, Cambridge, United Kingdom.
INTRODUCTION: Osimertinib is a third-generation, mutant-selective epider-
mal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) recently ap-
proved for the treatment of T790M-positive EGFR-mutant lung cancer. The mu-
tant-selectivenatureofosimertinib improves its tolerabilityby limiting its inhibition
of wild-type EGFR compared to fırst- and second-generation EGFR inhibitors,
making it agoodcandidate for rationally-designedcombination therapies.Onesuch
combination, osimertinib plus the MEK inhibitor selumetinib (AZD6244; ARRY-
142886), is currently being studied as part of the phase 1b TATTON trial
(NCT02143466). Previous work by our group demonstrated that selumetinib may
delay or reverse resistance to osimertinib in some cases; however, we anticipate that
resistance to this combination will ultimately develop in patients. Here, we investi-
gate acquired resistance to osimertinib and selumetinib combination therapy in
vitro and in vivo. DESIGN: In cells sensitive to osimertinib plus selumetinib (here-
after referred to as combination-sensitive cells), ERK phosphorylation was moni-
toredviaWesternblotover the courseof a7-day treatmentwith200nMosimertinib
plus 1 M selumetinib. To detect RAS-GTP, an active RAS precipitation was per-
formed in combination-sensitive and combination-resistant cell lines following
treatment with osimertinib. In combination-resistant cells, pharmacologic inhibi-
tors of variousMAPKpathway componentswere used to assesswhether they could
restore potency.Western blot analysis was used to confırm on-target effects. Lastly,
an analysis of differences in gene expression between four isogenic sets of combina-
tion-sensitive and combination-resistant cell lines is currently ongoing. RESULTS:
In cell lines that are sensitive to growth inhibitionby the combinationof osimertinib
plus selumetinib, we observed complete re-activation of theMAPKpathway after 5
days of continuous exposure to both inhibitors. Additionally, RAS activity was ele-
vated in combination-resistant cell lines, and these cells remained sensitive to the
ERK inhibitor SCH772984. Likewise, the addition of a pan-RAF inhibitor restored
the growth inhibitory effects of osimertinib plus selumetinib in combination-resis-
tant cells, suggesting that incomplete inhibition of MAPK is responsible for resis-
tance in these cells. Furthermore, an alternative MEK inhibitor, trametinib, was
effıcacious in combination with osimertinib in cell lines that were resistant to
osimertinib plus selumetinib. CONCLUSION: These data identify a potential
mechanism of resistance to a combination therapy that is currently being tested in
the clinic. Specifıcally, these data demonstrate that re-activation of theMAPKpath-
way is amechanismof resistance to osimertinib plus selumetinib and that this path-
way is still targetable in combination-resistant cells.
#3161 TPX-0005, an ALK/ROS1/TRK inhibitor, overcomes multiple resis-
tance mechanisms by targeting SRC/FAK signaling. Dayong Zhai, Wei Deng,
JohnHuang, Evan Rogers, J. Jean Cui. TP Therapeutics, Inc., San Diego, CA.
ALK,ROS1, andTRK inhibitorshave achievedmarkedeffıcacy in treating cancer
patients expressing abnormal ALK, ROS1 or NTRK genes. However, the initial
successof these therapies is rapidlyovershadowedwith thedevelopmentof acquired
resistance. In addition, approximately 30-40% of ALK  or ROS1 NSCLC pa-
tients fail to respond to initial crizotinib treatment, representing intrinsic resistance.
Target gene amplifıcation, acquired resistance mutations, bypass signaling, epithe-
lial-mesenchymal transition (EMT) and metastasis are the common resistance
mechanisms. None of the current ALK, ROS1 or TRK inhibitors can overcome
bypassorEMT-basedresistancewhenappliedasa single agent therapy.TPX-0005 is
a potent kinase inhibitor against WT and mutated ALK, ROS1 and TRK family
kinases, especially the clinically signifıcant solvent frontmutations. At clinically rel-
evant concentrations, TPX-0005 also inhibits JAK2, SRC and FAK that are impor-
tant targets in modulating multiple resistance mechanisms. H2228 lung cancer cell
line endogenously expresses EML4-ALKv3 andwas reported to be resistant toALK
inhibitor TAE684.Upregulation of the bypass signaling kinase EGFR, EMTmarker
vimentin, and cancer stem-like marker CD44 was reported in H2228 cells, likely
leading to intrinsic resistance toALK inhibitors. In the anti-proliferation assay, both
crizotinib and ceritinib were resistant in H2228 cells with IC50 values around 1000
nM, however, TPX-0005 was able to overcome the intrinsic resistance with an IC50
of 100 nM. InH2228 cells, TPX-0005 suppressed the phosphorylation of SRC, FAK
and paxillin with IC50 values in a range of 80-100 nM, and downregulated the ex-
pression of EGFR, CD44, and vimentin with IC50 values around 100 nM. In addi-
tion, TPX0005 inhibited the phosphorylation of the oncogenic transcription/trans-
lation factorYB-1withanIC50valuearound100nMinH2228cells.YB-1 is involved
inmany aspects of gene expression control that lead to tumor cell growth and drug
resistance, includingmodulationofEGFRupregulation,EMT,andcancer stemness.
Therefore, it was postulated that inhibition of SRC/FAK by TPX-0005 suppressed
the phosphorylation of YB-1, leading to the downregulation of EGFR, CD44 and
vimentin, andeventually to anti-proliferationeffect onH2228cells.TPX-0005dem-
onstrated an in vitro anti-metastatic activity by inhibiting cell migration in both
H2228 cells and HT1080 human fıbrosarcoma cells. Taken together, the potent
kinase inhibitory activities against SRC/FAK signaling provide a unique polyphar-
macology profıle to TPX-0005 for combatting multiple resistance mechanisms si-
multaneously, including a broad spectrumof acquiredmutations, bypass signaling,
EMT, cancer stemness, andmetastasis.
#3162 HRAS G12V predicts for innate resistance to PI3K inhibition in
head and neck squamous cell cancer. Kara M. Ruicci,1 Ren Sun,2 Morgan
Black,1 Nicole Pinto,1 John Yoo,1 Kevin Fung,1 Danielle Macneil,1 Lauire Ail-
lies,3 Joseph S. Mymryk,1 Paul C. Boutros,2 JohnW. Barrett,1 Anthony C. Nich-
ols1. 1Western University, London, Ontario, Canada; 2Ontario Institute for Can-
cer Research, Toronto, Ontario, Canada; 3University of Toronto, Toronto,
Ontario, Canada.
Introduction: Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer worldwide, with an incidence of600 000 new cases per
year and a 50%mortality rate for advanced disease. Themutational landscape of
HNSCC has been recently elucidated, introducing the possibility for targeted
therapeutic approaches. PIK3CA—which encodes the -catalytic subunit of
PI3K (PI3K)—is themost frequently altered actionable target inHNSCC, how-
ever it is not presently clear which patients benefıt most from PI3K-inhibition.
BYL719 is a leading PI3K inhibitor in clinical development for HNSCC. We
previously examined the responses of a large panel of genetically-characterized
HNSCC cell lines to BYL719 and identifıed activatingHRASG12Vmutations as
strongpredictors for BYL719 resistance.Herewe examine if thismutation is able
to individually modulate BYL719 response through overexpression and knock-
down studies. Methods: To determine if HRAS G12V was able to modulate
BYL719 sensitivity, we knocked down HRAS in HRAS G12V and HRAS wild-
type (WT) cell lines usingRNA interference, and then treated cells over 10-point
dose ranges with BYL719. Sensitivity was determined by calculating IC50 (half-
maximal inhibitory concentration) values at 72 hours using PrestoBlue®. Con-
structs expressing wildtype (WT) HRAS or HRAS G12V were transfected into
BYL719-sensitive cells for overexpression studies and cells were selected using
G418 Sulfate for 1 month. Proliferation and BYL719 sensitivity (IC50 values)
were measured as described. Immunoblotting was used to examine activity of
the PI3K-AKT axis with and without BYL719 (1M) for 24 hours. Results &
Conclusions: HRAS knockdown sensitized HRASG12V lines to BYL719 (lower
IC50), but did not affect the response of WT HRAS cells. WT HRAS and HRAS
G12V overexpression signifıcantly increased cellular proliferation and pro-
moted BYL719 resistance. In HRAS G12V cell lines, we observed high levels of
active phosphorylated AKT (S473/T308), even in the presence of BYL719. Col-
lectively these fındings highlight the predictive role of HRAS G12V for innate
BYL719 resistance and contribute to our understanding of which patients may
respond best on BYL719 therapy.
#3163 Discovery of a kinome signature predicting sensitivity and resis-
tance to RAF-MAPK pathway inhibitors in melanoma. Riet Hilhorst,1 Mo-
hammed Krayem,2 Adrienne van den Berg,1 Fabrice Journe,2 Liesbeth
Hovestad-Bijl,1 Tim van den Hooven,1 Rik de Wijn,1 Philippe Aftimos,2 Gha-
nem Ghanem,2 Rob Ruijtenbeek1. 1PamGene International BV, ’s-Hertogen-
bosch, Netherlands; 2Institut Jules Bordet, Université Libre de Bruxelles, Brussels,
Belgium.
Introduction: RAF-MAPK pathway inhibition with BRAF inhibitors or the
combination of BRAF andMEK inhibitors has become the mainstay of therapy
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of metastatic melanoma harboring BRAF V600 mutations with a response rate
as high as 50-75 %. Aminority of patients present with primary resistance while
all patients develop secondary resistance. We explored a reversed translational
approach using a novel multiplex kinase assay to fırst identify individuals not
responding to therapy using baseline biopsy samples and second to understand
the mechanism of resistance using patient-derived cell lines. Method: Pre-dose
tissues from 4 non-responders and 3 responders to vemurafenib monotherapy,
all harboring the V600E mutation, were profıled for Serine-Threonine Kinase
(STK) activities on a PamChip® peptide microarray in the presence and absence
of dabrafenib. For molecular studies three melanoma cell lines, all with BRAF
V600Emutations, weremade resistant to vemurafenib. Protein Tyrosine Kinase
(PTK) and STK activities in lysates of sensitive or resistant cells were measured
/ dabrafenib, trametinib or both. Lysates were blotted against a selected
panel of (phospho)proteins. Results: In tissue lysates, concentration-dependent
ex vivo inhibition with dabrafenib was stronger in the patients that were clinical
responders than in non-responders. This difference in inhibition of STK activity
by dabrafenib was confırmed in the cell lines that were made resistant against
vemurafenib. IC50s for the sensitive cell lines were below 0.5 M and varied
from 10-21 M for cell lines with acquired resistance. PTK activity was in-
creased in resistant cell lines. STK activity was lower, but large differences exist
among the cell lines. Common features of resistance were increased activity of
receptor tyrosine kinases, Src family kinases and AKT signaling. These results
were confırmed byWestern blot analysis. Dabrafenib (10M) caused inhibition
of STK activity while trametinib (10M) gave some activation. Dabrafenib (0.5
M) gave strong inhibition of PTK activity, both in tissue and cell lines. Tra-
metinib had hardly any inhibitory effect. Interestingly, the combination of dab-
rafenib and trametinib had an antagonistic effect on the STK activity and a
synergistic effect on PTK activity, resulting in a stronger inhibition of kinase
activity. Conclusion: Resistance of tumors and cell lines to vemurafenib can
affect kinase activity profıles as detected pre-dose using amultiplex kinase assay.
Dabrafenib inhibition of PTK and STK activity is stronger in sensitive cell lines.
The overall activation of kinases in a lysate uponMEK inhibition suggests MEK
as suppressor of kinase activity. Resistance to MAPK pathway inhibitors could
be linked to an increase in tyrosine kinase activity and AKT pathway activity.
Biomarkers are needed to identify patients in need of combinedMAPKpathway
inhibition.
#3164 A comprehensive analysis of autopsied specimens and patient-de-
rived cell lines inALK-positive lung cancerswith rapid acquired resistance to
alectinib. Go Makimoto,1 Kadoaki Ohashi,2 Kazuya Nishii,2 Shuta Tomida,2
Hiroe Kayatani,1 Tomoki Tamura,1 Hisao Higo,1 Kiichiro Ninomiya,1 Takashi
Ninomiya,2 ToshioKubo,2 Eiki Ichihara,2 Akiko Sato,2 KatsuyukiHotta,2Masa-
hiro Tabata,2 Katsuyuki Kiura2. 1Okayama University Graduate School of Med-
icine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan; 2Okayama
University Hospital, Okayama City, Japan.
Background: Alectinib, a highly selective anaplastic lymphoma kinase (ALK)
tyrosine kinase inhibitor (TKI), demonstrated a stunning disease control rate
(95.7%) and unprecedentedmedian progression-free survival (not reached: 95%
CI: 20.3-) (Lancet Oncology 2013, ASCO 2016, Abstract #9008). However, ac-
quired resistance to alectinib is inevitable; some ALK-positive lung tumors rap-
idly acquire alectinib resistance. Therefore, we sought to investigate the mech-
anism of the rapid resistance to alectinib using clinical samples and patient-
derived ALK-positive cell lines. Materials and Methods: Autopsied samples
(primary lung tumors and metastatic tumors from the esophagus, liver, and
bilateral kidney) were obtained from a 51-year-old male with advanced ALK-
positive lung cancer. The lung tumors acquired resistance to fırst-line treatment
of alectinib in three months, and subsequent treatment with ceritinib or crizo-
tinib showed only a moderate and temporary effect. We established novel ALK-
positive cell lines; ABC-14 was established from a pleural effusion after alectinib
treatment, and ABC-17 was established from patient-derived xenograft (PDX)
tumors of autopsied liver metastases. Western blot analysis, immunostaining, a
receptor tyrosine kinase assay, fluorescence in situ hybridization (FISH), and
next-generation sequencing were performed. Results: ALK overexpression was
confırmed in all autopsied samples by immunostaining. PCR revealed that
ABC-14 harbored the EML-4/ALK fusion variant 3. An in vitro cell proliferation
assay showed that ABC-14 exhibited resistance to alectinib (IC50 1 M), but
was sensitive to crizotinib (IC50  98 nM). The receptor tyrosine kinase assay
revealed the activation ofMET and EGFR inABC-14. Quantitative RT-PCR and
FISH confırmed MET gene amplifıcation. Quantitative RT-PCR also indicated
the overexpression of an EGFR ligand, EGF, TGF- but no EGFRmRNA over-
expression. The combination of crizotinib (dual ALK/MET-TKI) and an EGFR-
TKI, gefıtinib, showed an additive inhibitory effect on cell growth compared
with each drug alone in vitro. ABC-17 showed resistance to both alectinib and
crizotinib; consistently showed no activation of MET and no MET gene ampli-
fıcation. Interestingly, ABC-17 showed metastatic ability in the lung in NOG
mouse PDXmodels. Conclusion: Themechanismof rapid resistance to alectinib
may be complicated and heterogeneous. Crizotinib combined with gefıtinib,
which inhibits the ALK, EGFR, and MET pathways, may represent one potent
strategy against alectinib resistance. Further next-generation sequencing of clin-
ically relevant samples should provide deeper insights into its resistance. (This
work was supported by KAKEN 16K19454 and KAKEN 15H04830.)
#3165 3D culture may better represent trastuzumab resistance associated
with PIK3CA mutation than 2D culture. Takashi Tatara,1 Toru Mukohara,2
Rina Tanaka,1 Yohei Shimono,1 Masanori Toyoda,1 Naomi Kiyota,1 Midori Hi-
rai,1 YoshihiroKakeji,1HironobuMinami1. 1KobeUniversityGraduate School of
Medicine, Kobe, Japan; 2Kobe University Hospital, Kobe, Japan.
Background: It is becoming clear that presence of PIK3CAmutations is asso-
ciated with lower pathological complete response rate in patients with HER2-
overexpressing breast cancer when treated with trastuzumab-based chemother-
apy in neo-adjuvant settings. On the other hand, in in vitro studies using
traditional 2-dimentional (2D) cell culture, differential cellular or biochemical
response to trastuzumab between PIK3CA-mutant (mt) and -wild-type (wt)
cells has not been clearly demonstrated. Further, while tumor shrinkage is oc-
casionally observed in breast cancer patients who are treated with trastuzumab
as a single agent, cyto-toxic effect of trastuzumab is not simulated in 2D culture
models. Recently, many studies reported 3-dimensional (3D) cell culture mim-
ics in vivo environment better than 2D culture. Therefore, we hypothesized that
3D culture better represents clinically-observed trastuzumab resistance associ-
ated with PIK3CA mutation than 2D culture, and decided to comparatively
investigate cellular and biochemical response to trastuzumab in HER2-amlifıed
PIK3CA-mt and -wt cell lines cultured in 2D and 3D environments. Method:
HER2-amplifıed breast cancer cell lines, BT474 (PIK3CA-wt), and UACC893
andMDA-MB361 (PIK3CA-mt) were seeded (day 0) and allowed to grow in 2D
and 3D (NanoCluture Plate®, ORGANOGENIX, Kanagawa, Japan) cell culture
plates. On day 3, trastuzamab (10g/ml) and/or BKM120 (1 and 5M), a PI3K
inhibitor, were added. The effect of the drugs on cell growth was evaluated with
WST-8 assay on days 3 through 7. Apoptosis and cell signaling were evaluated
using Western blot on day 6 and days 3 through 5, respectively. Result: In
PIK3CA-wt BT474, treatment with trastuzumab led to decrease in cell number,
indicating cyto-toxic effect, only in 3D culture but not in 2D culture. In
PIK3CA-mt UACC893 and MDA-MB-361 cell lines, treatment with trastu-
zumab resulted in no cellular reduction either in 2D or 3D cultures. Consis-
tently, increase in cleaved PARP, indicative for apoptosis, was observed only in
3D-cultured BT474 but not in 2D-cultured BT474 or two PIK3CA-mt cell lines.
Furthermore, in BT474, greater decrease in phosphorylation of AKT (p-AKT)
was observed in 3D culture than in 2D culture. In PIK3CA-mutant cell lines,
trastuzumab did not change level of p-AKT regardless of cell culture conditions.
In PIK3CA-mutant UACC893, combined treatment with trastuzumab and
BKM120 resulted in greater increase in expression of cleaved PARP than either
drug alone. Conclusion: Trastuzumab-induced inhibition of PI3K/AKT path-
way and resultant apoptosis in HER2-overxpressing PIK3CA-wt cells may be
observed in 3D culture, which may be simulating cyto-toxic effect of trastu-
zumab by itself observed in clinic. Furthermore, 3D cell culture represents the
resistance to trastuzumab associated with PIK3CAmutation better than 2D cell
culture.
#3166 Loss of PARP1 in human cancer cells confers resistance to PARP
inhibition via activation of innate immune signaling. Rajib Ghosh, Sanchita
Roy, Sonia Franco. Johns Hopkins Univ. School of Medicine, Baltimore, MD.
Purpose: PARP inhibitors (PARPi) are FDA-approved for the treatment of
ovarian cancer and in clinical trials for the treatment of other malignancies.
PARPi block the catalytic site of PARP1, a poly(ADP-ribose) polymerase that
catalyzes the repair of DNA single-strand breaks (SSBs) and double-strand
breaks (DSBs). Although cancer cells harboring defects in Homologous Recom-
bination (HR) are particularly sensitive to PARPi, disease progression is even-
tually observed due to the emergence of resistant cells. To address the mecha-
nisms leading to PARPi resistance and identify novel preventive strategies, we
have generated and characterized multiple human cancer cell lines genetically
engineered to acquire PARPi resistance via depletion of PARP1. Experimental
Procedures: We used CRISPR/Cas9D10A (“double nickase”) to introduce DSBs
within exon 2 of PARP1 in human cancer cell lines HCT116 and HEK293T.
After allowing for repair via endogenous error-prone pathways, single cell-de-
rived subclones were screened by immunoblotting with an antibody to PARP1.
PARP1 “knock out” (KO) clones were further analyzed for proliferation, cell
cycle distribution and sensitivity to DNA damaging agents, including ionizing
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radiation (IR) and the PARPi olaparib. Radiation response was assessed using
proliferation and clonogenic assays, immunofluorescence (IF) for -H2AX and
immunoblotting for ATM substrates phospho-KAP1 (Ser824) and phospho-
CHK2 (Thr68). Finally, differential gene expression between PARP1-profıcient
and defıcient HCT116 and HEK293T cells was analyzed by RNA-Seq. Findings:
Although genetic depletion of PARP1 initially led to signifıcant death of
HCT116 andHEK293Tmass cultures, surviving cells could be isolated to estab-
lish stable PARP1 KO clones. Relative to PARP1-profıcient controls, HCT-
116PARP1-/- and HEK293TPARP1-/- cells exhibited decreased proliferation and
clonogenic capacity in vitro and decreased growth in vivo. In addition, loss of
PARP1 led to radiosensitivity and persistent activation of cell cycle checkpoints,
delayed kinetics of -H2AX foci resolution and persistent ATM signaling after
IR. In contrast, PARP1 loss induced resistance to the PARPi olaparib in both
lines. PARP1 reconstitution using either stable or transient approaches resulted
in only a partial rescue of these phenotypes. RNA-Seq analyses revealed in-
creased expression of innate immune signaling and inflammatory cascades upon
PARP1 loss, including type I/III interferons and their inducible genes. Conclu-
sions: PARP1KOhuman cancer cellsmay represent a valuable preclinicalmodel
to investigatemechanisms underlying resistance to PARP inhibitors observed in
the clinical setting. Loss of PARP1 triggers activation of “viral mimicry” in can-
cer cells, suggesting that drugs targeting this pathwaymay synergize with PARPi
to kill cancer cells and prevent the emergence of resistance.
#3167 MIF-induced stat3 activation promotes resistance to MEK block-
ade in KRAS mutant colorectal cancer cells. Seul-Ki Cheon,1 Hwang-Phill
Kim,1 Ye-Lim Park,1 Si Hyun Lee,1 Jun-Kyu Kang,1 Yoojoo Lim,2 Sang-Hyun
Song,1 Sae-WonHan,2 Tae-YouKim2. 1Seoul National University, Seoul, Repub-
lic of Korea; 2Seoul National University hospital, Seoul, Republic of Korea.
Although MEK blockade has been highlighted as a promising anti-tumor
drug, it has poor clinical effıcacy in KRAS mutant colorectal cancer. Several
feedback systems have been described in which inhibition of one intracellular
pathway leads to activation of a parallel signaling pathway, thereby decreasing
the effectiveness of single-MEK targeted therapies. In this study, we describe a
feedback mechanism in which MEK inhibition leads to activation of macro-
phage migration inhibitory factor (MIF)-induced stat3 signaling pathway in
KRASmutant colorectal cancer (CRC) cells. We found that KRASmutant CRC
cells with refametinib, MEK inhibitor, induced MIF secretion and resulted in
activation of Stat3. MIF knockdown by siRNA partially restored sensitivity to
refametinib in KRAS mutant cells. In addition, combination with refametinib
and 4IPP, a MIF inhibitor, effectively reduced the activity of stat3 and MAPK,
more than single agent treatment. As a result, combined therapy was found to
exhibit a synergistic growth inhibitory effect against refametinib-resistant cells
by downregulatingMIF expression. These results reveal that MIF-induced stat3
activation evoked an intrinsic resistance to refametinib. Our results provide the
basis for a rational combination strategy against KRAS mutant colorectal can-
cers, predicated on the understanding of cross-talk between the MEK and MIF
pathways.
#3168 Overcoming acquired drug resistance by TPX-0005, anALK, ROS1
and pan-TRK inhibitor. Wei Deng, John Huang, Dayong Zhai, Evan Rogers,
Jean Cui. TP Therapeutics, Inc., San Diego, CA.
The inevitable development of clinical drug resistance presents a common
challenge for targeted cancer therapy. In non-small cell lung cancer (NSCLC)
patientswithALKandROS1 rearrangements, the emergence ofmutations in the
targeted oncogenes was identifıed as one of the mechanisms that confer drug
resistance. In particular, a group ofmutations known as solvent frontmutations,
such as ALKG1202R and ROS1G2032R, render common resistance to ALK and
ROS1 inhibitors. Similar solvent front mutations, such as TRKAG595R and
TRKCG623R, have also been identifıed in cancer patients with rearrangement of
NTRK family genes who developed resistance to TRK-targeted therapies. TPX-
0005, a compact three-dimensionalmacrocyclicmolecule, was designed to com-
pletely locate at the adenine binding site of ATP in order to effıciently target the
active kinase conformation and systematically circumvent the steric interfer-
ence from various clinical resistant mutations, especially the solvent front mu-
tations. TPX-0005 is an orally available and potent ATP-competitive inhibitor
against ALK, ROS1, TRKA, TRKB and TRKC recombinant kinases and their
corresponding clinical resistant mutants. TPX-0005 demonstrated potent anti-
proliferative activity in the range of sub-nanomolar to low nanomolar in a num-
ber of human cancer cell lines and engineered stable cell lines expressing the
targeted oncogenes or their solvent frontmutants, accompanied by inhibition of
target phosphorylation and concomitant inactivation of downstream effectors
such as ERK, AKT and STAT3. In patient derived xenograft tumor models,
TPX-0005 treatment resulted in signifıcant regression of tumors harboring the
oncogenic ALK, ROS1 and TRKC fusions. Moreover, in a series of mouse xeno-
graft tumormodels, TPX-0005 exhibitedmarked anti-tumor activity not only in
tumors harboring the wildtype oncogenic targets but also in tumors harboring
the oncogenes with the solvent frontmutations via inhibition of the target phos-
phorylation. Taken together, these pre-clinical studies have demonstrated the
potent activities of TPX-0005 against not only wild type oncogenic ALK, ROS1,
TRK fusions but also their corresponding solvent front mutations, which will
bring in a new therapy for cancer patients resistant to currently available ALK,
ROS1, and TRK inhibitors in clinic.
#3169 SerpinB2 enhances invadopodia-like structure protrusions and is
down-regulated in acquired gefıtinib-resistant non-small cell lung cancer
cells. Song Yi Bae,1 Donghwa Kim,2 Hyen Joo Park,2 Woong Sub Byun,2 Ji-
Young Hong,2 Hye-Jung Lee,2 Sang Kook Lee2. 1MIT, Cambridge, MA; 2Seoul
National University, Seoul, Republic of Korea.
Non-small cell lung cancer (NSCLC) is a major type of lung cancer which
accounts for approximately 80-85% of all lung cancers. The targeted thera-
pies have signifıcantly improved the survival of advanced NSCLC patients,
but the failure of targeted therapy due to the resistance to epidermal growth
factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefıtinib, is
now considered a major problem. SerpinB2 is a component of the urokinase
plasminogen activator (uPA) system and has been recognized as a biomarker
for the progression and metastasis of lung cancer. We found that SerpinB2 is
down-regulated in gefıtinib-resistant (H292-Gef) cells compared to ge-
fıtinib-sensitive (H292) cells. The low SerpinB2 levels in H292-Gef cells were
also associated with an enhancement in invasiveness and increase in the
length of invadopodia-like structures in the cells. The effect on invasiveness
and gefıtinib sensitivity was confırmed by knockdown and overexpression of
SerpinB2. In addition, an antitumor agent yuanhuadine (YD) was used to
test the possibility to overcome the resistance through the up-regulation of
SerpinB2. YD effectively elevated SerpinB2 levels and suppressed invasive
properties in H292-Gef cells. Collectively, these fındings demonstrate the
prospective role of SerpinB2 as a novel biomarker for acquired gefıtinib
resistance and a potential target for NSCLC treatment. Acknowledgement
This study was funded by Basic Science Research Program through the Na-
tional Research Foundation of Korea (NRF) funded by the Ministry of Edu-
cation (2015R1D1A1A02062012).
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#3170 MCAMmodulates small cell lung cancer chemoresistance via PI3k/
Akt/Sox2 signaling pathway. Satyendra C. Tripathi,1 Johannes F. Fahrmann,1
Muge Celiktas,1 Mitzi Aguilar,1 Kieren D. Marini,2 Mohit K. Jolly,3 Hiroyuki
Katayama,1 Hong Wang,1 Eunice N. Murage,1 Jennifer B. Dennison,1 D. Neil
Watkins,4 Herbert Levine,3 Edwin J. Ostrin,1 Ayumu Taguchi,1 Samir M. Ha-
nash1. 1MDAnderson Cancer Center, Houston, TX; 2Hudson Institute ofMedical
Research, Australia; 3Rice University, Houston, TX; 4Garvan Institute of Medical
Research, Australia.
Despite favorable responses to initial therapy SCLC relapse occurs within a
year exhibiting a multidrug resistant phenotype. Due to limited accessibility of
patient tissues for research purpose, SCLC patient derived xenografts (PDXs)
have provided the best opportunity to address this limitation. We sought to
identify novel mechanisms involved in SCLC chemoresistance. Through in-
depth proteomic profıling, we identifıed MCAM as a markedly upregulated
surface receptor in chemoresistant SCLC cell lines that exhibited amesenchymal
phenotype and in chemoresistant PDXs compared to matched treatment-naïve
tumors. MCAM is a cell membrane protein whose expression has been impli-
cated in multiple human cancers. MCAM expression is also detected in lung
adenocarcinoma; however, its expression and role in SCLC is still not been
explored. MCAM knockdown in chemoresistant cells reduced cell proliferation
and decreased the IC50 inhibitory concentration of chemotherapeutic drugs.
MCAM was found to modulate sensitivity of SCLC cells to chemotherapeutic
drugs through up-regulation ofMRP1/ABCC1 expression and of the PI3K/AKT
pathway in a SOX2 dependent manner. Metabolomic profıling revealed that
MCAM can modulate glutamic acid and lactate production in chemoresistant
cells with a distinct metabolic phenotype sustaining low oxidative phosphoryla-
tion. MCAM may serve as a novel therapeutic target to overcome chemoresis-
tance in SCLC.
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#3171 Analysis of ‘drug addiction’ mechanisms in the drug-resistant
ROS1-rearranged cancer cells. Hayato Ogura,1 Jun Adachi,2 Takeshi To-
monaga,2 Naoya Fujita,1 Ryohei Katayama1. 1The Cancer Chemotherapy Ctr.,
JFCR, Tokyo, Japan; 2Lab. of ProteomeResearch, National Institute of Biomedical
Innovation, Health and Nutrition, Osaka, Japan.
ROS1-rearrangednon-small-cell lung cancer (NSCLC) is observed in approx-
imately 1% of lung cancer patients. Crizotinib, ALK/ROS1/cMET tyrosine ki-
nase inhibitor (TKI), showedhigh effect against ROS1-rearrangedNSCLC in the
clinical trials and is approved in US and EU. However, the cancers inevitably
relapse due to the acquired resistance such as ROS1-G2032R mutation. We
previously reported that cabozantinib could overcome those secondary muta-
tions mediated crizotinib-resistance. Based on this fınding, we tried to establish
cabozantinib-resistant ROS1 mutant cells by ENU mutagenesis screening. Sur-
prisingly, we found out a few CD74-ROS1 mutant clones that only grew in the
presence of low-dose cabozantinib. Namely, these mutant clones were “ad-
dicted” to cabozantinib. When the fluorescent labeled cabozantinib addicted
ROS1mutant cells were co-cultured with non-addicted CD74-ROS1-WT-BaF3
cell in the presence or absence of low-dose cabozantinib, the drug-addicted cells
became dominant in the low-dose cabozantinib, and CD74-ROS1-WT cells be-
came dominant in the absence of it. To analyze the molecular mechanism of
“drug-addiction” in the addicted CD74-ROS1mutant cells, we performed com-
prehensive analysis such as inhibitor screening, cDNA microarray, and phos-
phoproteome analysis. As the result, we observed that the expression and phos-
phorylation of CD74-ROS1 in the addicted cells were excessively upregulated
within 24 hours after removal of cabozantinib or other ROS1 inhibitors, such as
crizotinib or lorlatinib.We also observed that the apoptosis was induced in these
cells upon ROS1 inhibitor removal, whereas ROS1 mediated growth signaling
were simultaneously activated. Consistent with this, cDNAmicroarray analysis
revealed that the expression of both cell survival and cell death related genes
were changed by ROS1 inhibitor removal. Furthermore, we identifıed that sev-
eral proteins were highly phosphorylated by excessive ROS1 activation origi-
nated fromROS1 inhibitor removal. These observations suggest that these drug-
addicted cells were died by excessive oncogenic signaling, and the appropriate
oncogene signaling by low-dose TKI made them survive and grow without in-
ducing apoptosis. Thus, the excessive oncogene signaling has “double-edged
sword” characteristics for cancer cell viability and those characteristics could be
a new therapeutic target.
#3172 Inhibition of coiled coil domain containing protein 69 (CCDC69)
enhance platinum-mediated apoptosis in ovarian cancer cells. Long Cui, Jo-
sephKwong, Chi ChiuWang.The Chinese University of Hong Kong, Hong Kong,
Hong Kong.
Background and Objective: Molecular mechanisms of chemo-resistance in
ovarian cancer are poorly understood. To identify gene involved in ovarian
cancer chemo-resistance, 135 ovarian cancer patients with intact chemo-re-
sponse information from The Cancer Genome Atlas (TCGA) database were
included. Our analysis revealed that the level of CCDC69mRNA is differentially
expressed between chemo-sensitive group and chemo-resistant group. More-
over, there was a signifıcant negatively correlation between CCDC69 promoter
methylation and mRNA expression. The aim of the study is to examine the role
of CCDC69 in the underlying mechanism of chemo-resistance. Methods: The
expression levels of CCDC69 were detected in chemo-sensitive ovarian cancer
A2780, chemo-resistant A2780cis and SKOV3 cell lines using quantitative RT-
PCR and immunoblots. Promoter methylation status of CCDC69 were investi-
gated by bisulfıte sequencing. Silencing CCDC69 in A2780cis and SKOV3 cells
were performed by Small-interfering RNAs (siRNAs) and CRISPR-Cas9. Cell
viabilities after cisplatin treatment were evaluated by MTT and colony forma-
tion assays. Apoptosis was assessed by Annexin V/PI staining and caspases 3/8
activity. Cell cycle distributions andmitochondrial membrane potential (
m)
were measured by flow cytometry. Relevant pathway proteins were determined
by immunoblotting assays. Results: Heavy CpGmethylation (73.1% and 74.3%)
was found in A2780 and A2780cis cells. Restoration in the expression of
CCDC69 were found in A2780 and A2780cis cells after 5-Aza-dC treatment. In
fact, the expression levels of CCDC69 were about 3-4 fold higher in chemo-
resistant A2780cis cells than its parental chemo-sensitive A2780 cells. Inhibition
of CCDC69 in chemo-resistant A2780cis cells by si-RNA signifıcantly increased
sensitive to cisplatin treatment (p0.05). When knockout CCDC69 in chemo-
resistant A2780cis and SKOV3 cells by CRISPR-Cas9, the CCDC69KO chemo-
resistant A2780cis and CCDC69KO SKOV3 cells were also shown increased
sensitive to cisplatin treatment (p0.001). Moreover, treating CCDC69KO
A2780cis cells with cisplatin, abolished G1 and G2/M arrest, more cleaved
caspase 3&8 activities, greater
m loss and higher levels of Bax were observed.
When restoring CCDC69 expression in CCDC69KOA2780cis cells by transient
transfection, it attenuated sensitivity to cisplatin. By immunoblotting, dis-
ruption of p14ARF-Mdm2-p53 cell cycle and/or apoptosis pathway, en-
hancement of MDM2 expression, and increase of p53 nuclear export were
found in CCDC69KO A2780cis cells. Additionally, inhibition of c-Myc en-
hance cisplatin sensitivities in CCDC69KOA2780cis cells, overexpression of
c-Myc reduce apoptosis in CCDC69KO SKOV3 cells. Summary: Our results
show that silenced CCDC69 expression induced platinum-mediated apopto-
sis in ovarian cancer cells by abrogating c-Myc mediated apoptosis and cell
cycle control networks.
#3173 AKT1low quiescent cancer cells persist after neoadjuvant chemo-
therapy in triple-negative breast cancer patients. Sheheryar Kabraji,1 Xavier
Sole,2 Ying Huang,3 Clyde Bango,3 Michaela Bowden,3 Aditya Bardia,2 Dennis
Sgroi,4 Massimo Loda,3 Sridhar Ramaswamy2. 1Massachusetts General Cancer
Center, Boston, MA; 2Massachusetts General Hospital Cancer Center, Boston,
MA; 3Dana Farber Cancer Institute, Boston, MA; 4Massachusetts General Hos-
pital, Boston, MA.
The mechanisms that allow triple negative breast cancer tumors to survive
neoadjuvant chemotherapy are incompletely understood. Evidence suggests
that proliferative heterogeneity may contribute to primary chemotherapy resis-
tance in patients with triple negative breast cancer. AKT1low quiescent cancer
cells (QCCs) are a quiescent, epigenetically plastic, and chemotherapy resistant
subpopulation initially identifıed in experimental cancermodels. Here, we iden-
tify QCCs in primary and metastatic human breast tumors using automated,
quantitative, immunofluorescencemicroscopy coupledwith computational and
statistical analysis. We show that QCCs exist as non-random and heteroge-
neously distributed clusters within primary tumors. In addition, these QCC
clusters persist after treatment with multi-agent, multi-cycle, neoadjuvant che-
motherapy in both residual primary tumors as well as nodal and distant metas-
tases in patients with triple negative breast cancer. Together, these data qualify
QCCs as a non-geneticmechanismof chemotherapy resistance in triple negative
breast cancer patients that warrants further study.
#3174 GCN5 regulates ATMmediated DNA repair responsible for onset
of acquired resistance in leukemia. Sameer J. Salunkhe, JyothiNair, EkjotKaur,
NehaChaoudhary, Sanket Shah,Ketaki Patkar,DevAnand,NavinKhattry, Syed
K. Hasan, Shilpee Dutt.Advanced Centre for Treatment Research and Education
in Cancer. TMC, Navi Mumbai, India.
Abstract Introduction- Resistance to therapeutics targeting topoisomerase 2
is a major problem in the treatment of leukemia. Cells which survive and give
rise to relapsed leukemia are known to modulate different pathways like down-
regulation of drug target, reduced drug accumulation, and improved DNA re-
pair; ultimately leading to survival of drug resistant cells. Here, we wanted to
identify the earliest detectable changes occurring when cells become resistant to
topoisomerase 2 inhibitors. Methodology- We generated early and late stage
drug (doxorubicin) resistant leukemic sub cell line fromK562 andTHP-1 parent
cells, HL-60/MX2 resistant sub cell line of HL60 was also used for this study.
Molecular changes were analyzed by electron microscopy, quantitative PCR,
western blotting, immunofluorescence, flow cytometry, molecular inhibitors
and MTT assay. Results were further confırmed in blast cells of AML (n44)
patient samples collected for this study. Furthermore, meta-analysis for survival
was done from microarray expression data of 221 patient samples using Prog-
noScan. Results- We mapped molecular changes acquired by leukemic cells
during evolution from Early Drug Resistant Population (EDRP) to Late Drug
Resistant Population (LDRP). We found unlike LDRP, EDRP cells do not pos-
sess known bona fıde drug-resistance mechanisms namely limited drug accu-
mulation, reduced DNA damage or expression of drug target. Instead they sur-
vive by acquiring ’poised epigenetic state’ that enhanced their DNA repair.
Mechanistically, GCN5, a histone acetyl transferase get selectively upregulated
in EDRP cells mediating higher H4K16 acetylation levels and consequent eu-
chromatin state of EDRP. Upon Doxorubicin treatment, H4K16ac facilitate
higher ATM recruitment and activation causing effıcient activation of H2AX,
NBS1, BRCA1, Chk2 andMcl-1, accelerating DNA repair and survival of EDRP
cells. Inhibition of GCN5 with Doxorubicin treatment signifıcantly reduces
H4K16ac levels, ATM recruitment and cell survival of EDRP cells. Similarly,
ATM inhibition along with Doxorubicin completely ablates EDRP but not
LDRP. Furthermore, baseline AML patient samples (n44) showed signifı-
cantly higher GCN5 expression in MRD positive compared to MRD negative
samples. Additionally, meta-analysis of 221 AML patients showed increased
GCN5 expression associates with poor survival of AML patients. Conclusion-
We identify GCN5 expression as marker that defınes onset of resistance in leu-
kemia andGCN5mediatedATMactivation viaH4K16ac as a novel non-genetic
route facilitating EDRP cell survival with enhancedDNA repair. These data also
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highlight the clinical relevance of targeting GCN5 and ATM during early resis-
tance to prevent emergence of diffıcult to treat stable diverse resistance in leu-
kemia.
#3175 Context-dependent role of ARF for response to chemotherapy in
muscle invasive bladder cancer. Lijie Rong, Tomasz Owczarek, Takashi Ko-
bayashi, Cory Abate-Shen.ColumbiaUniv. Irving Comp. Cancer Ctr., NewYork,
NY.
Muscle invasive bladder cancer (MIBC) is a signifıcant cause of cancer death,
in part because there are relatively few treatments and these have limited effı-
cacy. Our studies show that expression of 14ARF (aka ARF), one of the major
transcripts encoded by the CDKN2A tumor suppressor locus, is frequently up-
regulated inMIBC, particularly inmore aggressive disease subtypes. Our results
further show that accumulation of ARF protein in the nucleolus is associated
with poor outcome and reduced response to chemotherapy. Using both geneti-
cally-engineered mouse (GEM) models and human xenograft models of MIBC,
we demonstrate that tumors expressing ARF display poor response to treatment
with the platinum-based chemotherapy agent cisplatin. This is mediated in part
by expression of the integrin-binding protein ITGB3BP (CENPR) and reflects
ARF-dependent inhibition of protein translation, which is attenuated by drug
treatment. Our fındings reveal an unexpected context-dependent role for ARF
in modulating drug response in bladder cancer through its ability to regulate
protein translation.
#3176 Inhibition of HER2/-catenin signaling by penfluridol overcomes
resistance to paclitaxel in breast cancer. Nehal Gupta, Parul Gupta, Sanjay
Srivastava. Texas Tech University Health Sciences Center, Amarillo, TX.
Paclitaxel is a fırst line treatment option for patients with metastatic breast
cancer. However, inherited or acquired resistance is a limiting factor for
therapy with paclitaxel. The mechanism of paclitaxel resistance remains ob-
scured and hinders the development of therapeutic strategies. HER2 is an
oncogene overexpressed in about 30% of breast cancer patients and plays
role in drug resistance leading to poor prognosis. To identify more clinically
relevant mechanism of paclitaxel resistance, we developed resistance to pac-
litaxel inMCF-7 and 4T1 breast cancer cell lines. The continuous exposure to
paclitaxel for several months resulted in 1000 fold resistance in MCF-7
cells and 100 fold resistance in 4T1 cells. Western blot analysis showed
enhanced expression of HER2, -catenin and downstreammolecules such as
TCF/LEF, c-Myc, Cyclin D in these resistant cells. We have recently demon-
strated that penfluridol, an anti-psychotic drug, suppresses the growth of
triple negative metastatic breast cancer cells (Ranjan and Srivastava, Cancer
Res 2016; 76(4): 877-890), giving us the rationale to evaluate whether pen-
fluridol inhibits HER2 and -catenin signaling. Our current results showed
that penfluridol treatment not only suppressed HER2 but also inhibited
-catenin expression. We also observed down regulation of LEF-1/TCF,
Cyclin D1 and c-Myc expression with penfluridol treatment in paclitaxel
sensitive as well as resistant cells resulting in reduced survival of cells. Our
results further showed that penfluridol treatment synergistically enhanced
the growth suppressive effects of paclitaxel in MCF-7 and 4T1 paclitaxel
resistant cells. Treatment of paclitaxel resistant 4T1 cells with 1.5M of
penfluridol in combination with 50nM of paclitaxel resulted in 65% of cell
growth suppression whereas either treatment alone was not cytotoxic at all.
We also observed an enhanced down regulation of proteins involved in
paclitaxel resistance such as HER2, -catenin, c-Myc and Cyclin D1 as well
as increase in apoptotic markers such as Cl-PARP and Cl-Caspase3 when
paclitaxel treatment was combined with penfluridol in resistant cells. Taken
together, our results provided a novel insight into the mechanism of resis-
tance to paclitaxel and also opened new avenues for application of penfluri-
dol in cancer therapeutics. Further detailed mechanistic and in vivo studies
are in progress. (Supported in part by RO1 grant CA129038, awarded by
National Cancer Institute, NIH).
#3177 KITENIN leads to resistance against temozolomide through en-
hancement of cancer stemness factors in mouse glioma model. Kyung-Hwa
Lee, Eun-Jung Ahn, Shin Jung, Jae-Hyuk Lee, Kyung-Keun Kim, Kyung-Sub
Moon.ChonnamNational University HwasunHospital &Medical School, Hwa-
sun-gun, Republic of Korea.
Background: Recently, a new research spotlighted the role of KITENIN (KAI1
COOH-terminal interacting tetraspanin) on glioma invasiveness and progres-
sion, associated with the up-regulation of EMT (epithelial-mesenchymal tran-
sition) and cancer stemness markers. In this study, furthermore, it is investi-
gated whether KITENIN leads to resistance against TMZ through enhancement
of cancer stemness factors using mouse glioma model. Materials and Methods:
TMZ-resistant T98G cell line (T98G/TR)was developed. EMT and cancer stem-
ness markers and KITENIN expression were assessed by Western blotting and
qRT-PCR. With KITENINmodulated U251 (knockdown) and GL261 (overex-
pression) cells, cell viability and apoptotic cell death factors after TMZ treatment
were evaluated. Biological role of KITENINonTMZ-resistancewas investigated
usingmagnetic resonance imaging (MRI) and immunofluorescence analysis for
tumor sections of orthotopic glioma model. Using human glioma samples and
primary cells, the mechanistic link between KITENIN and cancer stemness fac-
tors was confırmed. Results: T98G/TR cells showed increased expression of the
KITENIN and EMT and cancer stemness factors. Also, In vitro assays revealed
that KITENIN knockdown inhibited cell viability against TMZ treatment,
whereas KITENIN overexpression promoted their viability, via apoptotic cell
death pathway. In orthotopic glioma models, mice implanted with KITENIN-
overexpressed cells showed resistance to TMZ on MRI and histopathological
examination. The expression of KITENIN/ALDH1 or KITENIN/CD44 were
co-localized and signifıcantly higher in tumor sections of mouse transplanted
with KITENIN-overexpressed cells than in tumor sections of mouse trans-
planted with control cells. Genetic down-regulation of KITENIN for KITENIN-
overexpressed cell line and primary glioma cells led decreased expression of
ALDH1 andCD44. In human glioma samples, high expression of KITENINwas
closely related with high expression of ALDH1. Conclusion: KITENIN affects
TMZ-resistance in malignant gliomas through induction of ALDH1 and CD44.
Therefore, it could be suggested that KITENIN is therapeutic target to overcome
TMZ-resistance of malignant gliomas.
#3178 The p53 tumor suppressor protein paradoxically drives chemo-
resistance in human medulloblastoma cells through suppressing the mTOR
AKTpathway.AishaNaeem,MuhammadU.Choudhry,Maria L. Avantaggiati,
Olga C. Rodriguez, Chris Albanese. Georgetown Univ., Washington, DC.
Medulloblastoma (MB) accounts for approximately 25% of childhood brain tu-
mors with 70% of the cases occurring in children under 10. Prognosis for children
less than three years old is considerably worse and, due to its destructive effects on
the developing nervous system, irradiation is largely avoided in this age group. The
p53 pathway is considered a key determinant of anti-tumor responses in many
tumors; however, its role in the regulation of cell survival, chemo-sensitivity and
chemo-resistance inMB ismuch less well defıned. It has been shown that p53 path-
way defects, mutations and nuclear levels increase signifıcantly fromMB diagnosis
to relapse and correlate with an adverse prognosis. We recently reported on the
highly novel and unexpected fınding that both the genetic (sh-RNA) and chemical
silencingof p53 led to a signifıcant increase in cell deathby thedrugVMYinMBcell
lines with elevated basal p53 (e.g. in D556 cells which express wild type p53 and in
DAOY cells that containmutant p53) asmeasured by colony forming assays, DNA
degradation assays and annexin-V staining, suggesting a surprising commonality in
the p53 signaling in both cell lines despite the differences in their p53 status. Equally
surprising was the observation that the silencing of p53 in D556 cells enhanced cell
death by the clinically used drugs doxorubicin and vincristine. Conversely, we now
fınd that suppressing p53 with sh-RNA in D283 cells, which express much lower
levels of wild type p53 compared to D556, resulted in the more classical chemore-
sistanceprofıle, suggestinga formofp53 ’addiction’ inD556andDAOYcells.Mech-
anistically,weobserved that suppressingp53with sh-RNAinD556cells treatedwith
VMY or doxorubicin signifıcantly increased the levels of phosphorylated Chk1,
S6K, gH2AX, and MDM2. Importantly, phospho-mTOR levels were also signifı-
cantly increased in the D556/p53 sh-RNA cells and the suppression of mTOR en-
hanced chemoresistance. These somewhat paradoxical fındings suggest that acti-
vatedAkt/mTORmay induceMB cell death and that suppression ofmTORby p53
enhances chemoresistance.Our data provide newmechanistic insights into the role
of p53 in primitive neuroectodermal tumors and may provide new approaches for
enhancing the clinical outcome of patients withMB.
#3179 The effect of eribulin resistant mechanism in breast cancer on mi-
croenvironment. Wataru Goto, Shinichiro kashiwagi, Koji Takada, Katsuyuki
Takahashi, Tsutomu Takashima, Satoru Noda, Naoyoshi Onoda, Shuhei To-
mita, Kosei Hirakawa,Masaichi Ohira.Osaka City University, Abeno-ku, Osaka,
Japan.
Backgorund: Erbulin, a nontaxane, synthetic microtuble dynamics inhibitor,
is currently in clinical use for advanced or metastatic breast cancer. Eribulin
treatment results in improved tumor perfusion in breast cancer and induces the
remodeling of tumor vasculature and a reversing effect on the epithelial to mes-
enchymal transition (EMT) of cancer cells. Although eribulin signifıcantly in-
creased overall survival by monotherapy, most breast cancer cells acquire resis-
tance to eribulin after a series of treatments. The development of resistance to
chemotherapy appears to have become amajor clinical problemof breast cancer.
In this study, we established two eribulin-resistant cell lines, and investigated the
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mechanisms underlying the development of eribulin resistance in breast cancer
cells. Material and Methods: Eribulin-resistant breast cancer cell lines were ob-
tained by culturing MDA-MB-231 and MCF-7 cells with stepwise increases in
the concentration of eribulin for more than 6-months. The relative eribulin
resistance of each eribulin-resistant cell line was determined using aMTT assay.
To confırm the expression of proteins related to drug resistance, we examined
multidrug resistance protein 1 (MDR1), end-binding 1 (EB1) and E-cadherin by
western blot analysis. To investigate the effect of eribulin, a flow cytometry
analysis for cell-cycle distribution was performed. In addition, we produced
MDA-MB-231, MDA-MB-231/Eribulin, MCF-7 andMCF-7/Eribulin subcuta-
neous xenografts, and analysed protein expression by immunohistochemical
study of surgically resected tissues from xenografts. Results: Compared to pa-
rental cell lines, eribulin-resistant cell lines had a higher resistance to eribulin.
Eribulin-resistant cell lines acquired resistance to not only eribulin, but also
paclitaxel, vinorelbine, doxorubicin, and fluorouracil. After eribulin treatment,
MDA-MB-231/Eribulin cell lines showednomorphological change, and expres-
sion of E-cadherin did not increase. Also, cell cycle distribution and expression
of EB1 did not exhibit signifıcantly differences from parental cell lines. On the
other hand, PD-L1 was overexpressed in eribulin-resistant cell lines compared
to parental cell lines. Additionally, eribulin-resistant cell lines exhibited in-
creased level of MDR1 protein. Conclusion: Our established eribulin-resistant
cell lines may suppress eribulin effect of inhibiting microtube, EMT, and im-
mune evasion mechanism. These should be useful tools for identifying new
mechanism of eribulin resistance.
#3180 Chemotherapeutical agent triggers transient resistance of cancer
cells by promoting ABCB1 intercellular transfer. XiaokunWang,1 Dongjuan
Qiao,2 Likun Chen,1 Liyan Huang,1 Meng Xu,1 Zhen Chen,1 Fang Wang,1
Zhesheng Chen,3 Musheng Zeng,1 Li-Wu Fu1. 1Sun Yat-Sen Univ. Cancer Ctr.,
Guangzhou, China; 2Department of Chemistry, College of Life Science and Tech-
nology, Jinan University, Guangzhou, China; 3Department of Pharmaceutical
Sciences, College of Pharmacy and Health Sciences, St. John’s University, NY.
Multidrug resistance remains a major impediment to successful chemother-
apy. In clinical chemotherapy, some patients often develop chemoresistance
quite rapidly, the underlyingmechanism remains elusive. Herein, we report that
a transient exposure to chemotherapeutic agents can acutely promote the inter-
cellular transfer of ABCB1 through stimulating Rab8B-mediated secretion of
microvesicles (MVs) containing ABCB1 in drug-resistant donor cells, and pro-
moting parallelly the endocytic recycling of ABCB1 in recipient tumor cells via
the downregulation of Rab5. Sensitive recipient cells take up these ABCB1-
incorporatedMVs by a clathrin- and dynamin 2- dependent endocytic pathway,
thereby acquiring a transient resistance to chemotherapeutic agents which are
ABCB1 substrates.More fascinatingly, ABCB1molecules can locally or distantly
transfer to recipient tumor cells and respond to chemotherapeutical drug in the
xenograft tumor models. In some cases of patients with NSCLC, a variable in-
crease of ABCB1 surface expression was also detected in the peripheral blood
monocyte subpopulations after they received the fırst chemotherapy. Our fınd-
ings proposed a novel molecular mechanism of how sensitive cancer cells rap-
idly acquire the emergency resistance to chemotherapeutic agents by stimulat-
ing intercellular transfer of ABCB1. The precise modulation of this process may
provide a valid therapeutic strategy to alleviate theMDR phenotype for success-
ful treatment.
#3181 A novel topoisomerase II 90 kDa isoform in etoposide resistant
human leukemia K562 cells produced as a result of alternative RNA process-
ing.RaguKanagasabai,1 Lucas Serdar,1 SoumendrakrishnaKarmahapatra,1 Co-
rey A. Kientz,1 Mary K. Ritke,2 Terry S. Elton,1 Jack C. Yalowich1. 1Ohio State
Univ. College of Pharmacy, Columbus, OH; 2University of Indianapolis, India-
napolis, IN.
DNA topoisomerase II (TOP2) is a prominent target for anticancer drugs
whose clinical effıcacy is often limited by chemoresistance. We previously char-
acterized acquired resistance to etoposide (VP-16) in a cloned human K562
leukemia cell line, K/VP.5, containing reduced TOP2. In the present study,
using an antibody specifıc for the amino-terminus of TOP2, immunoassays
indicated the existence of twoTOP2 isoforms, 170 and 90 kDa, present inK562
leukemia cells and in the etoposide resistant K/VP.5 cells. TOP2/90 expression
was dramatically increased in etoposide-resistant K/VP.5 compared to parental
K562 cells. We hypothesized that TOP2/90 was the translation product of
novel alternatively processed pre-mRNA, confırmed by 3’-RACE, PCR, and se-
quencing. TOP2/90 mRNA includes retained intron 19 which harbors an in-
frame stop codon, and two consensus poly(A) sites. The processed transcript is
polyadenylated. TOP2/90 mRNA encodes a 90,076 Da translation product
missing the carboxyl-terminal 770 amino acids of TOP2/170, replaced by 25
unique amino acids through translation of the exon 19/intron 19 ’readthrough’.
Immunoassays, utilizing antisera raised against these unique amino acids, con-
fırmed that TOP2/90 is expressed in both cell types, with overexpression in
K/VP.5 cells. Immunodetection of Complex of Enzyme-to-DNA (ICE) and sin-
gle cell gel electrophoresis (Comet) assays demonstrated that K562 cells trans-
fected with a TOP2/90 expression plasmid, exhibited reduced etoposide-me-
diated TOP2-DNA covalent complexes and decreased etoposide-induced
DNA damage, respectively, compared to similarly treated K562 cells transfected
with empty vector. Since TOP2/90 lacks the active site tyrosine (Tyr805) of full
length TOP2, these results strongly suggest that TOP2/90 exhibits dominant-
negative properties. . In separate studies the TOP2/90 mRNA splice variant
was found to be expressed in most human tissues suggesting that this novel
protein isoform may play a role in both intrinsic chemosensitivity as well as in
acquired resistance. Further studies are underway to characterize the mecha-
nism(s) by which TOP2/90 plays a role in acquired resistance to etoposide and
other TOP2 targeting agents. In addition, future studies will be directed to
examine the RNA processingmechanism(s) operational that suppress intron 19
splicing in TOP2 pre-mRNA.
#3182 Cytoskeletal modulation results in increased tumor survival and
drug resistance through attenuation of p53 dependent apoptosis.Victoria E.
Wang,1 John Doench,2 David Root,2 Rene Bernards,3 Jeffrey Settleman,4 Frank
McCormick1. 1UCSF, San Francisco, CA; 2Broad Institute, Cambridge, MA;
3Netherland Cancer Institute, Amsterdam, Netherlands; 4Genentech, South San
Francisco, CA.
11One of the major challenges to eradicating cancer involves the evolution of
drug resistant clones and persistence of residual disease that escapes our current
limit of detection butmay proliferate upon cessation of therapy. Thesemicroscopic
foci of residual diseases often exhibit stem-cell like properties and are intrinsically
more resistant to drug therapy. A better understanding of the mechanisms under-
lying the innate drug resistance of these cellular populations may lead to improved
treatment strategies, resulting inmore durable remissions and ultimately improved
patient survival. We utilize functional genomic platforms to identify mechanisms
responsible for thepersistence of drug tolerant cells.Agenomewide shRNAenrich-
ment screen was performed using the c-Met addicted cell line GTL-16 to identify
genes whose knockdown conferred DTP survival. Inhibition of the RhoA-ROCK-
myosin pathway promotes drug resistance in a variety of tumor models, including
those treated with either targeted therapy or conventional chemotherapy. Further-
more, pharmacological validation using multiple small molecule inhibitors of
ROCK1 phenocopied both myosin heavy chain (MYH9) and light chain (MYL12)
shRNAknockdown.More recently, utilizing a combination of gene expression and
biochemical approaches,wehave identifıed attenuationof p53 induced apoptosis to
be a key event inmediating survival of these drug tolerant persisters. Reactivation of
p53 using nutlin results in increased cell death. These fındings demonstrate that
modulation of cytoskeleton is an important, but underappreciated, mechanism of
drug resistance acrossmany tumor types. These downstream effectorsmay serve as
novel therapeutic targets for intervention and also biomarkers to stratify patients
and their response to treatment.
#3183 Proteomic characterization of aromatase inhibitor resistant mam-
mospheres reveal the presence of a novel nuclear chaperone. Syreeta L. Tilgh-
man,1 Jamal Pratt,2 Shawn D. Llopis,2 A. Michael Davidson,1 Rashidra R.
Walker,1 Patrick Carriere,3 Ian R. Davenport,2 Wensheng Zhang,2 Karen
Zhang2. 1Florida A&MUniversity, Tallahassee, FL; 2Xavier University of Louisi-
ana, New Orleans, LA; 3Morehouse School of Medicine, Atlanta, GA.
Postmenopausal women with early-stage metastatic estrogen-dependent
breast cancer are generally treated with aromatase inhibitors (AIs) (e.g., letro-
zole). However, acquired resistance remains a major clinical obstacle. Previ-
ously, our group revealed a global proteomic signature of a letrozole-resistant
cell line (LTLT-Ca) associated with hormone independence, enhanced cell mo-
tility and epithelial to mesenchymal (EMT). Given recent evidence suggesting a
convergence of EMT and cancer stem cells (CSC), we chose to utilize a two-
dimensional (2D) vs three-dimensional (3D) culture system to compare the
proteome of LTLT-Ca cells, as 3D culture not only enriches for CSC, but more
accurately recapitulates the tumor microenvironment, morphology, function
and response to therapy compared to conventional 2D culture. We hypothesize
utilizing a novel systems biology approach may reveal previously unconsidered
molecular changes that could aid in understanding complex signaling networks
and be exploited as therapeutic targets. To address this hypothesis ovariecto-
mized immunocompromised female mice were inoculated in the mammary fat
pad with LTLT-Ca or letrozole sensitive cells (AC-1) and intratumoral putative
CSC marker expression was assessed by immunohistochemistry. Results indi-
cate LTLT-Ca tumors were CD44high/CD24low while AC-1 tumors were CD44-/
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CD24low. Mammosphere formation assays were conducted and LTLT-Ca cells
formed mammospheres at a 3.4-fold higher index than AC-1 cells. A quantita-
tive proteomic analysis of whole cell lysates from LTLT-Ca (2D adherent cells)
versus LTLT-Ca (3Dmammospheres) was conducted. Results identifıed signif-
icant protein expression changes within a panel of 1010 proteins; 173 were up-
regulated and 186 downregulated (p0.05, fold change 1.20). Additionally,
functional enrichment analyses were performed and 19 gene ontology (GO)
terms and one KEGG pathway (hsa03010:Ribosome) were over-represented
(BH adjusted p-value 0.01) by the cognate genes. Notably, there was a 35.04-
fold increase in midasin (MDN1), a nuclear chaperone protein required for
maturation and nuclear export of pre-60S ribosome subunit. Increased MDN1
expression was strongly correlated with highly tumorigenic breast cancer
spheres. Additionally, Kaplan-Meier survival plots demonstrate that increased
MDN1 levels were positively correlated with decreased relapse free survival in
estrogen receptor negative breast cancer, and is constitutively expressed as
breast tumors progress from atypical ductal hyperplasia to ductal carcinoma in
situ to invasive, metastatic breast cancer. The TGCA database was interrogated
and MDN1 was frequently amplifıed or mutated in breast tumors. Taken to-
gether our study for the fırst time implicates a role for ribosomal assembly in AI
resistant cells enriched for CSCs and underscores a potential for MDN1 in the
progression and responsiveness to therapy.
#3184 Autophagy regulation by vacuolar-ATPases: A contributingmech-
anism of chemo-resistance in ovarian cancer.Arpita Kulshrestha, Gajendra K.
Katara, Safaa A. Ibrahim, Alice Gilman-Sachs, Kenneth D. Beaman. Rosalind
Franklin University of Medicine and Science, North Chicago, IL.
In ovarian cancer (OVCA), the main obstacle in the clinical usefulness of
platinum based drugs is the eventual emergence of chemo-resistant tumors.
Exposure of cancer cells to platinum drugs such as cisplatin elicits a stress re-
sponse that leads to the induction of coping mechanisms favoring cancer cell
survival. Autophagy induction is the primary protective mechanism in cancer
cells that also contributes to cisplatin resistance. A tightly regulated pH is im-
perative for autophagy and the role of major pH regulators is therefore vital to
this process. Vacuolar ATPases (V-ATPases) are the multi-subunit proton
pumps that regulate intra/extra-cellular pH in cancer. Its ‘a2’ isoform (V-AT-
Pase-a2) is located at the plasma membrane and early/late endosomal compart-
ments. We previously found that this isoform is overexpressed on cisplatin re-
sistant cells (cis-R) and its inhibition sensitizes cis-R cells to platinum drugs. In
continuation with our efforts, the present study was performed to understand
what alterations in the autophagy process occur upon V-ATPAse-a2 inhibition
and how these contribute to cisplatin sensitization. Expression profıling of ovar-
ian cancer cells lines (A2780-cis R and TOV-112D- cis R) revealed that upon a2
inhibition, the basal levels of autophagosome membrane protein, LC3B were
enhanced compared to control cis-R cells as determined by flow cytometry and
western blot analysis. Upon cisplatin treatment, the LC3B levels were further
enhanced in a2 inhibited cis-R cells compared to control cells. Further, we ob-
served a signifıcantly increased expression of the autophagy protein, beclin-1 in
these cells as compared to control cells. In addition, the inhibition of V-ATPase-
a2v increased the protein levels of SQSTM1/p62, a known substrate for the
autophagy process. The enhanced LC3B and P62 levels suggest an accumulation
of the autophagosomes due to an altered autophagy flux upon V-ATPase-a2v
inhibition. The study provides a rationale for the utility of V-ATPase-a2 inhib-
itors in combination with standard drugs as a novel strategy to improve the
treatment effıcacy of the chemoresistant ovarian cancer.
#3185 Adipocyte-derived hydrogen peroxide promotes chemoresistance
to daunorubicin in leukemia cells. Jean-Hugues Parmentier,1 Christina M.
Dieli-Conwright,2 StevenD.Mittelman1. 1Children’sHospital of LosAngeles, Los
Angeles, CA; 2University of Southern California, Los Angeles, CA.
Background: Adipocytes protect acute lymphoblastic leukemia (ALL) cells
from several chemotherapeutic drugs. This protection is associated with an ox-
idative stress response in adipocytes. Since adipocytes are known to release re-
active oxygen species, and anthracyclines are sensitive to inactivation mediated
by hydrogen peroxide (H2O2), we investigated whether adipocyte release of
H2O2 into the micro-environment might contribute to drug resistance of ALL
cells. Methods: Pre-B lymphoblast/myeloblast BV173 cells in complete media
(CM) were co-cultured for 3 days in transwells over 3T3-L1 fıbroblasts or adi-
pocytes. Viable cells were determined by Trypan blue exclusion for BV173 cells.
Leukemia ConditionedMedia (LCM)was prepared fromBV173 cultured for 48
hrs. Total antioxidant capacity was measured by ABTS-based assay. H2O2 re-
leased in the extracellular compartment of adipocytes was monitored with Am-
plex Red and ROS-Glo. Results: BV173 cells were protected from DNR in pres-
ence of 1 mM H2O2 (9.34	2.15x104 vs. 3.33	1.01x104 viable cells with and
without H2O2, p0.03). Interestingly, this protection was only observed when
pyruvate was present in the culture media at equimolar concentrations with
H2O2 (DNR: 4.14	2.14x104; DNRpyruvate: 4.17	1.53x104; DNRH2O2:
3.77	2.74x103; DNRpyruvateH2O2: 3.21	0.59x105, p0.02). Adipocytes
released H2O2 into the media measured with Amplex Red fluorescence in a
time-dependent manner signifıcantly more than fıbroblasts (1.96-fold,
p0.001). LCM potentiated adipocyte H2O2 released (1.5-fold over CM,
p0.05). Human adipose tissue biopsies from breast cancer survivors also re-
leased H2O2 (4.37x103 RFU for biopsies vs. 0.65x103 RFU for HBSS, 90 min,
n5). Co-culture of adipocytes and BV173 cells increases the survival of BV173
to DNR treatment (1.55	0.34x105 vs. 6.88	2.91x103 viable cells with and with-
out adipocytes, p0.006). Adipocyte-mediated protection of BV173 cells was
reversed in a dose-dependent manner by adding the H2O2-inactivating enzyme
catalase to the extracellular media (7.28	1.44x104 vs. 15.58	3.48x104 viable
cells with andwithout 500U/ml catalase, p0.01). Conclusion: These data show
that adipocytes release H2O2, which in the presence of pyruvate, protects ALL
cells from DNR. Further work is needed to determine whether adipocytes se-
crete signifıcant amounts of H2O2 in the bone marrow micro-environment to
contribute to anthracycline resistance.
#3186 Taxane resistance in prostate cancer: A role formiRNA 181a.Cam-
eron M. Armstrong, Chengfei Liu, Wei Lou, Allen C. Gao. UC Davis, Sacra-
mento, CA.
Introduction: Docetaxel (DTX) is one of the primary drugs used for treating
castration resistant prostate cancer (CRPC). Unfortunately, over time patients
invariably develop resistance to DTX therapy and their disease will continue to
progress. The mechanisms by which resistance develops are still incompletely
understood. This study seeks to determine the involvement of miRNAs, specif-
icallymiR-181a, inDTX resistance inCRPC.Methods: Total RNA fromparental
C4-2B prostate cancer cells and DTX resistant C4-2B cells (C4-2B TaxR) was
submitted for small RNAdeep sequencing.Datawas analyzed to ascertainwhich
miRNAs expressions weremost altered in C4-2B TaxR cells compared to paren-
tal cells. Having identifıed an increase in miR-181a in resistant cells, its expres-
sion was modulated in C4-2B and C4-2B TaxR cells by transfecting them with
miR-181amimics or antisense, respectively. Following transfection, cell number
was determined after 48 h with or without DTX. Cross resistance to cabazitaxel
induced by miR-181a was also determined. Western blots were used to deter-
mine ABCB1 protein expression and rhodamine assays used to assess activity.
Phospho-p53 expression was assessed by western blot and apoptosis was mea-
sured by ELISA in C4-2B TaxR cells with inhibitedmiR-181a expression with or
withoutDTX.Results:miR-181a is signifıcantly upregulated inC4-2BTaxR cells
compared to parental C4-2B cells as analyzed by small RNA sequencing. Over-
expression of miR-181a in C4-2B cells confers DTX and cabazitaxel resistance.
Knockdown of miR-181a in C4-2B TaxR cells re-sensitizes them to treatment
with both DTX and cabazitaxel. miR-181a knockdown alone induced apoptosis
in C4-2B TaxR cells which is further enhanced by DTX. We next assessed if
miR-181a altered expression or activity of ABCB1, which is overexpressed/ac-
tive in C4-2B TaxR cells and promotes resistance to DTX by pumping the drug
out of cells. We found that miR-181a does not impact ABCB1 expression or
activity. Since we previously demonstrated that phospho-p53 can modulate
DTX sensitivity, we determined if miR-181a can alter p53 expression in C4-2B
TaxR cells. Knockdown of miR-181a in C4-2B TaxR cells induced phospho-p53
expression, suggesting that miR-181a induced resistance to DTX is mediated by
inhibition of phospho-p53 expression. Conclusions: Overexpression of miR-
181a inC4-2BTaxR cells contributes to their resistance toDTXand inhibition of
miR-181a expression can restore treatment response. This is due, in part, to
modulation of p53 phosphorylation and induction of apoptosis.
#3187 Role of exosome secretion in the survival of enzalutamide-resistant
prostate cancer cells: Syntaxin 6 as a novel therapeutic target. Taylor C. Peak,
Nicole P. Kasica, Gati K. Panigrahi, Sierra L. Patterson, Ravi Singh, Ashok K.
Hemal, Rhonda L. Bitting, Gagan Deep. Wake Forest Baptist Medical Center,
Winston-Salem, NC.
Prostate cancer (PCa) is the most commonly diagnosed malignancy in the
United States and remains the second leading cause of cancer deaths among
American men. PCa deaths are typically the result of metastatic castration-re-
sistant PCa (mCRPC). Recently, enzalutamide (Enz), an oral AR inhibitor, was
approved for treating patients with mCRPC, and has signifıcantly improved
patient survival. But, invariably all PCa patients eventually develop resistance
against Enz and die from mCRPC. Therefore, novel strategies aimed at over-
coming Enz-resistance are urgently needed to improve the survival of PCa pa-
tients. Exosomes (extracellular vesicle, 40-150 nm in size) have previously been
shown to communicate oncogenic signals and to promote growth and metasta-
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sis; however, their role in drug resistance has not been fully elucidated. There-
fore, we set out to better understand exosomes role in themechanismunderlying
Enz-resistance in PCa cells. We isolated exosomes secreted by Enz-sensitive (S)
and -resistant (R) PCa cells by ultracentrifugation. Complete characterization of
these exosomes followed using nanoparticle tracking analysis (NTA), transmis-
sion electron microscopy, proteomics, and western blotting. MTT and trypan
blue exclusion assays were used to evaluate cell viability. Results showed that
Enz-resistant C4-2B-R cells secreted signifıcantly higher amount (2.67 fold) of
exosomes compared to sensitive C4-2B-S cells, but without any signifıcant
change in exosome size. Proteomics analysis revealed signifıcantly lesser num-
ber and amounts of proteins loaded in exosomes secreted by C4-2B-R cells
compared to C4-2B-S cells. Western blotting validated these results, and in
general less loading was observed for several exosomal biomarker proteins (e.g.
CD63, Lox, TSG101, and MMP9). Of note, AR-V7, a variant of the androgen
receptor, was upregulated in C4-2B-R cells as well in their exosomes. In order to
better understand the biological signifıcance of increased exosome production
with concomitant decreased protein expression, we administered C4-2B-R-de-
rived exosomes to C4-2B-S cells. Interestingly, exosomes from resistant cells
signifıcantly reduced the survival of C4-2B-S cells . This suggested not only that
the resistant cellswere utilizing exosomes to secrete Enz, but that these exosomes
were being taken up by the sensitive PCa cells, thus leading to enhanced sensitive
cell death. The inhibition of exosome biogenesis inC4-2B-R cells usingGW4869
(20 M) and dimethyl amiloride (1 g/mL) strongly decreased their cell viabil-
ity, and also increased their sensitivity towards Enz treatment.We also observed
strong upregulation of syntaxin 6 in Enz-resistantC4-2B-R cells. Together, these
results identifıed a uniquemechanismunderlying drug-resistance, and also offer
a novel target to treat Enz-resistant CRPC.
#3188 ER-stress induced translational regulationbyRGS2 leads to tumor-
promoting microenvironment and chemoresistance. Hye-Young Min, Shin-
Hyung Park, Ho Jin Lee, Jaebeom Cho, Myungkyung Noh, Seung Yeob Hyun,
Ho-Young Lee. Seoul National Univ., Seoul, Republic of Korea.
Lung cancer is the leading cause of the cancer-related death worldwide. De-
spite extensive efforts for the cure of lung cancer, the effectiveness of currently
available therapeutic regimens has beenmarginal and limited, and recurrence is
still an inevitable consequence of anticancer therapies. Therefore, mechanistic
understanding on the progression and relapse of lung cancer and fınding out
relevant targets are essential for development of effıcacious therapeutic strate-
gies. We have investigated mechanisms of chemoresistance by using subsets of
lung cancer cell lines carrying acquired resistance to chemotherapies. These
chemoresistant sublines of NSCLC cells exhibited a prominent downregulation
of in vitro tumor activities, including proliferation, metabolism, and protein
synthesis, but displayed increased tumor growth in vivo. Additional studies
revealed that the chemoresistant sublines experienced increased secretion of
various soluble factors that led to increases in proliferation and stemness of
drug-naïve cancer cells and recruitment of macrophages, establishing tumor
microenvironment (TME) prone to tumor recurrence. We further demonstrate
a pivotal role of regulator of G protein signaling 2 (RGS2) in tumor-promoting
cell-cell communications, ultimately leading to chemoresistance. RGS2 dis-
rupted chemotherapy-induced apoptosis and secretion of soluble factors in-
volved in cellular communications in TME by regulating unfolded protein re-
sponses, a typical cellular event associated with downregulation of protein
synthesis. Mechanistically, RGS2 induced proteasome-mediated protein degra-
dation of a component of eukaryotic translation initiation factor complexes
through direct interaction, resulting in blockade of the CAP-dependent protein
translation. RGS2 expression was elevated in tumors derived from patients with
lung cancer compared with normal counterparts and signifıcantly associated
with poor clinical outcomes. These fındings suggest that RGS2 is a novel bio-
marker responsible for chemoresistance by establishing tumor-promoting TME
and can be a potential therapeutic target for the treatment of lung cancer with
chemoresistance.
#3189 Neuronal transcription factor BRN2 is an androgen suppressed
driver of neuroendocrine differentiation in prostate cancer. Jennifer L.
Bishop,1 Daksh Thaper,1 Sepideh Vahid,1 Ravi S. Munuganti,1 Paul Ahn,1
Alastair Davies,1 Kirsi Ketola,1 Ka Mun Nip,1 Dong Lin,1 Yuzhuo Wang,1 Hi-
misha Beltran,2 Amina Zoubeidi1. 1Vancouver Prostate Ctr., Vancouver, British
Columbia, Canada; 2Weill Cornell Medical College, New York, NY.
Neuroendocrine prostate cancer (NEPC) is an incurable, rapidly progressing
and lethal disease. NEPC is increasingly recognized as a highly therapy resistant
tumor variant that evolves from castration-resistant prostate cancer (CRPC) in
a subset of patients treated with potent androgen receptor (AR) pathway inhib-
itors like enzalutamide (ENZ). Importantly, mechanisms by which the AR di-
rectly controls the emergence of NEPC fromCRPC under the selective pressure
of ENZ remain elusive. As the AR is the cornerstone therapeutic target in men
with CRPC, understanding its contribution to the development of NEPC is
critical to better implement current standard-of-care therapies such as ENZ, and
to identify novel therapeutic targets for this incurable disease. Hallmarks of
NEPC are resistance to ENZ and the loss or reduced activity of the AR. Thus, we
hypothesized that a consequence of ENZ treatment and resistance in CRPC is
relief of AR-mediated suppression of factors that drive NEPC. To investigate
this, we developed amodel of prostate cancer thatmimics clinical progression to
CRPC and ENZ resistance (ENZR CPRC). Mirroring what is observed in some
patients who progress on ENZ, 25% of our ENZRCRPC tumors and derived cell
lines showed strong reduction in classic activity of the AR and a NEPC pheno-
type. By interrogating NEPC-like ENZR CRPC and ENZ-treated CRPC tumors
and cell lines with RNA-Seq andmechanistic in vitro and in vivo studies, as well
as human tumors with RNA-Seq and IHC, we identifıed the master neural tran-
scription factor BRN2 as a central and clinically relevant driver of NEPC differ-
entiation. Specifıcally, we found AR binding in the BRN2 enhancer directly
represses BRN2 transcription and this release drives NEPC marker expression
and aggressive growth of ENZRCRPC. Our data also reveal a striking overlap of
AR and SOX bindingmotifs in the enhancer region of BRN2 creating a compet-
itive binding scenario between AR and SOX2, another cell-fate determining
transcription factor associated with NEPC. We discovered that upregulation of
BRN2 further enhances SOX2 expression and that a BRN2-SOX2 interaction
contributes to NEPC differentiation. Importantly, we found BRN2 is highly
expressed in humanNEPC andmetastatic CRPC, especially in patients with low
AR activity, highlighting its clinical relevance to disease that is diffıcult to treat
with mainstay therapies. These data underscore the consequences of potent AR
inhibition in CRPC, revealing a novel mechanism of AR-dependent control of
NEPC via direct suppression of BRN2. This work uncovers BRN2 as a clinically
relevant potential therapeutic target to prevent emergence of NEPC fromENZR
CRPC.
#3190 Using a genome-wide shRNA screen to investigate the mechanism
of stroma-conferred gemcitabine resistance in pancreatic ductal adenocarci-
noma. Graham D. Mills, Nicolas Erard, Frances M. Richards, Gregory J. Han-
non, Duncan I. Jodrell. Cancer Research UK Cambridge Institute, Cambridge,
United Kingdom.
The purpose of this study is to identify mechanisms of resistance to gemcit-
abine in pancreatic ductal adenocarcinoma (PDAC) using an in vitro coculture
system. The inherent resistance of PDAC to fırst line treatments such as gemcit-
abine has been attributed to the dense fıbrotic stroma. Targeting stromal com-
ponents, in particular cancer-associated fıbroblasts (CAFs), the activated form
of pancreatic stellate cells (PSCs), is a promising avenue for therapeutic inter-
vention. We have demonstrated previously the induction of gemcitabine resis-
tance when co-culturing KRAS G12D; p53 R172H; Pdx-cre (KPC) mouse
PDAC-derived tumour cells with SMA fıbroblast-like cells from PDAC tu-
mour (FLCs), in comparison to PDAC cells co-cultured with PSCs or in mon-
oculture. This resistance-inducing effect is specifıc to cells of mesenchymal phe-
notype, is transient in nature and a product of cell-cell contact. To investigate the
exact mechanism by which PDAC cells become resistant to gemcitabine in co-
culture, we undertook a genome-wide shRNA depletion viability screen, infect-
ing KPC mouse PDAC cells with a pooled shERWOOD UltramiR shRNA li-
brary both in mono- and co-culture with FLCs, in the presence and absence of
gemcitabine. Next-generation sequencing and differential expression analysis,
using DESeq2, identifıed shRNAs depleted through 6 cycles of gemcitabine
treatment in coculture, indicating they target genes driving the resistance effect.
Pathway analysis of differential expression using MetaCore implicated DNA
damage repair and protein modifıcation pathways in the gemcitabine resistance
effect. Depletion of p97, ATR, or Chk1 all sensitised PDAC cells to gemcitabine
in coculture, corroborating fındings with translational value in previous studies.
Further evaluation is ongoing using validation shRNA dropout assays in com-
bination with targeted literature reviews to collate a candidate list of targetable
genes with translational value in preventing and combating chemotherapy re-
sistance in patients with PDAC.
#3191 Daytime blue-enriched LED light-induced circadian amplifıcation
of the nighttime melatonin signal increases sorafenib sensitivity in human
hepatocellular carcinoma via enhanced suppression of the Warburg effect.
Robert T. Dauchy, David T. Pointer, Aaron E. Hoffman, Melissa A. Wren-Dail,
Shulin Xiang, Lin Yuan, David E. Blask, Victoria P. Belancio, Steven M. Hill.
Tulane Univ. School of Medicine, New Orleans, LA.
Over 36,000 people in the United States will be diagnosed with hepatocellular
carcinoma (HCC) in 2016, the second leading cause of cancer death worldwide.
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Metabolic pathways within the liver and in HCC are highly regulated by the
central circadian clock in the suprachiastmatic nucleus (SCN). The SCN drives
nighttime production of the circadian anti-cancer hormone melatonin by the
pineal gland in rats and humans. We have shown that the nighttime circadian
melatonin signal suppresses the Warburg effect (aerobic glycolysis) in human
breast cancer xenografts and that blue-enriched light (460-480 nm) from LEDs
at daytime (bLAD), amplifıes the nighttime circadianmelatonin signal by 7-fold
in rats over cool white fluorescent (CWF) lighting. Here we tested whether
daytime exposure of tissue-isolated HepG2 xenograft-bearing male nude rats to
bLAD amplifıes the nighttime melatonin signal to increase tumor sensitivity to
nighttime administered sorafenib (FDA-approvedmulti-kinase inhibitor) treat-
ment via enhancing suppression of the Warburg effect. Animals were random-
ized to 6 subgroups (n  4): CWF Groups I, 12 h light:12 h dark (LD,12:12)
(CWF vehicle) and II (CWF sorafenib); bLADGroups III (LD,12bLAD:12)
(bLAD  vehicle), IV (bLAD  sorafenib), V (bLAD  S20928 MT1/MT2
receptor blocker), and VI (bLAD S20928 sorafenib). Drug treatments be-
gan when tumors were 2.5 g estimated weight. Plasma nighttime melatonin
levels were 7-fold higher in Groups III-VI, compared to Groups I and II. Tumor
latency-to-onset of growth and growth rates were markedly delayed and de-
creased, respectively, in Group III compared to Group I. Sorafenib induced
tumor regression at a rate that was 2-fold higher in the bLAD- vs CWF-exposed
rats. Tumor glucose uptake and lactate production (Warburg effect) at the mid-
dark phase were signifıcantly reduced in CWF-exposed rats receiving sorafenib
vs vehicle. In vehicle-treated bLAD-exposed rats, theWarburg effect was signif-
icantly decreased vs CWF-exposed rats receiving vehicle. In bLAD sorafenib-
treated rats, the Warburg effect was reduced by an additional 51% (glucose
uptake) and 89% (lactate production), respectively, vs CWF sorafenib-treated
rats. Melatonin receptor blocker S20928 completely prevented the effects of
bLAD and bLAD  sorafenib on the Warburg effect and made these tumors
completely resistant to sorafenib-induced tumor regression. These fındings are
the fırst to show in vivo that: 1) nighttime circadian sorafenib therapy inhibited
the Warburg effect and induced HepG2 tumor regression under CWF lighting
conditions, and 2) the bLAD-amplifıed nocturnal circadian melatonin signal
increased tumor sensitivity to sorafenib-induced regression by enhancing amel-
atonin receptor-mediated suppression of the Warburg effect.
#3193 Treatment of high Trop-2-expressing triple-negative breast cancer
(TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous
recombination repair (HRR) rescuemediated byRad51.ThomasM. Cardillo,
Ali A. Mostafa, Diane L. Rossi, Donglin Liu, Chien-Hsing Chang, Robert M.
Sharkey, David M. Goldenberg. Immunomedics, Inc., Morris Plains, NJ.
Purpose: IMMU-132 is an antibody-drug conjugate composed of a human-
ized anti-Trop-2 IgG conjugated via a cleavable linker to SN-38, a topoisomerase
I inhibitor and active component of irinotecan. It is currently under clinical
investigation in a range of solid tumors (NCT01631552). We investigated the
hypothesis that IMMU-132, through its targeting of Trop-2 in solid tumors, will
be superior to irinotecan in overcoming Rad51-mediated HRR repair of DNA
breaks in TNBC tumors with high Trop-2 expression. Methods: Rad51 and
DNA-breaks (-H2A.X) were determined by Western blot. Cells with different
Trop-2 levels were exposed to IMMU-132 for 24 h (25 - 100 nM SN-38 equiva-
lents), including squamous cell lung carcinoma (SK-MES-1; 30,000 Trop-2/
cell) and TNBC (HCC1806,90,000 Trop-2/cell and MDA-MB-231,30,000
Trop-2/cell). Also, two Trop-2-transfectants of MDA-MB-231, designated C13
and C39 (4- and 25-fold higher Trop-2 levels, respectively), were likewise ex-
posed to IMMU-132. Mice bearing MDA-MB-231, C13, or C39 tumors were
treated with irinotecan (MTD, 40 mg/kg; q2dx5) or IMMU-132 (0.5 mg; 9 g
SN-38 equivalent, twice wkly x 4). Tumors were measured and mice weighed
twice weekly. Study survival endpoint was tumor progression to1.0 cm3. Re-
sults: SK-MES-1 and HCC1806 are sensitive to IMMU-132 therapy whereas
MDA-MB-231 is resistant. IMMU-132 mediated a 2-fold increase in Rad51
levels inMDA-MB-231 cells, but had no effect in SK-MES-1 or HCC1806. At 25
nM IMMU-132, there were lower levels of DNA breaks detected in MDA-MB-
231 relative to SK-MES-1 and HCC1806 (2-fold increase in MDA-MB-231 vs.
3-fold). At higher concentrations of IMMU-132 (100 nM), all 3 cell lines
demonstrated similar levels of DNA breaks (5-fold above background), sug-
gesting that higher levels of SN-38 can overcome Rad51-mediated repair. Both
the C13 and C39 clones had a similar response as parental MDA-MB-231 upon
IMMU-132 exposure. Mice bearingMDA-MB-231, C13, or C39 tumors treated
with irinotecan demonstrated signifıcant improvements in median survival
times (MST) compared to saline (P0.0009). As expected, IMMU-132 was no
different than saline in mice bearing MDA-MB-231 tumors (MST21d and
19.5d, respectively). However, in mice bearing high Trop-2 C13 and C39 tu-
mors, IMMU-132 provided a signifıcant survival benefıt compared to irinote-
can-treated mice (MST70d vs. 35d, respectively for C13 and70d vs. 28d for
C39; P0.0007), supporting the hypothesis that IMMU-132 is able to deliver
more SN-38 to tumors with high Trop-2 than can be achieved by irinotecan, and
can thus overcome Rad51-mediated HRR. Conclusion: IMMU-132, with its
unique SN-38-delivery platform, has the potential to provide clinical benefıt
both to chemo-sensitive solid tumors with low Trop-2 expression, as well as to
chemo-resistant tumors with high Trop-2 expression.
#3194 A new mechanism of drug resistance in cancer: extracellular ATP-
induced resistance throughATP internalization and upregulation of protein
phosphorylation in Akt and ERK pathways. Xuan Wang, Yunsheng Li, Yan-
rong Qian, Yanyang Cao, Xiaozhuo Chen. Ohio University, Athens, OH.
The opportunistic uptake of extracellular molecules has been named as a key
emerging hallmark of cancer metabolism[1]. Extracellular ATP (eATP) levels of
various cancer types are 103 to 104 times higher than those in their correspond-
ing normal tissues[2]. However, the biological signifıcance of the high ATP con-
centrations is not clear. We recently reported that cancer cells uptake extracel-
lular ATP via different endocytoses to enhance growth, survival, and drug
resistance to tyrosine kinase inhibitors (TKIs)[3 ,4]. We hypothesized that eATP
induces resistance to TKIs by endocytoses-mediated internalization of eATP,
which competes with TKIs for the ATP-binding site of receptor TKs (RTKs),
phosphorylating and activating RTKs and RTK-mediated signaling pathways.
In contrast to previous reports that synthesized intracellular ATP (iATP) eleva-
tion contributed acquired drug resistance, here we report a novel intrinsic drug
resistance in which eATP was internalized and substantially increased iATP
levels and promoted cancer cell drug resistance to the TKI sunitinib in human
NSCLC A549 cells. The iATP level elevation and drug resistance were mediated
primarily bymacropinocytosis. The resistance was reducedwhenmacropinocy-
tosis was suppressed by inhibitors or an siRNA knockdown of a key micropi-
nocytosis protein PAK1. Intracellularly, the elevated iATP upregulated phos-
phorylation of PDGFR and proteins/enzymes in the PDGFR-mediated Akt-
mTOR and Raf-ERK signaling pathways, resulting in reduced apoptosis
triggered by sunitinib. Furthermore, both in vitro and in A549 tumors, eATP
partially restored phosphorylation levels of PDGFR and PDGFR-mediated pro-
teins/enzymes suppressed by sunitinib. The resistance cannot be accounted for
by the overall purinergic receptor-mediated signaling, glycolysis, or mitochon-
drial OXPHOS. These results strongly suggest that the eATP-elevated intracel-
lular ATP levels reversed the inhibition of TKIs by using the mechanism we
hypothesized, linking for the fırst time the ATP-rich tumor microenvironment
with cancer drug resistance. All these fındings signifıcantly expand our under-
standing of the roles of extracellular ATP in cancer, and offer new anti-drug
resistance targets. 1. Pavlova N, Thompson C. Cell Metab. (2016) 23:27-47. 2.
Falzoni et al., Interface Focus.(2013) 3: 20120101. 3. Qian Y, Wang X, et al.,
Cancer Lett. (2014)351: 242-5. 4. Qian Y, Wang X et al., Mol Cancer Res (2016)
14:1087-96.
#3195 DYRK1B inhibitors prevent pharmacologic quiescence and sensi-
tize lung cancers to EGFR inhibitors. Maria Vilenchik,1 Alexandra Kuz-
netsova,1 Michael Frid,1 Yuriy Gankin,1 Marc Duey,1 Neal Rosen2. 1Felicitex
Therapeutics Inc., Newton, MA; 2Memorial Sloan Kettering Cancer Center, New
York, NY.
Many oncoproteins that activate signaling dysregulate cell growth by activat-
ing the cyclinD/cdk4, cdk6 complex and abrogate in the G1 checkpoint (mutant
RAS, BRAF, PIK3CA, EGFR etc.) Inhibition of these oncoproteins inhibits cy-
clinD expression and kinase activity as well as RB phosphorylation and results in
G0/G1 arrest and apoptosis. It has been posted that cells arrested in G0/G1 are
protected from cell death. DYRK1B kinase plays an important role in physio-
logic quiescence by maintaining the viability of cells arrested in the G0/G1
phases of the cell cycle. DYRK1B regulates the G0/G1 transition by phosphory-
lating cyclin D1 and p27, whereby destabilizing cyclin D1 and stabilizing p27.
The balance between these two proteins is essential for maintenance of cells in
G0 (quiescent) state. DYRK1B is sparsely expressed in healthy tissues yet is
overexpressed in patient samples with variety of neoplasms, including NSCLC.
Cancer and normal cells exhibit differential sensitivity to DYRK1B inhibition.
Whereas DYRK1B appears essential for survival of cancer cells either endoge-
nously expressed or upregulated, its inhibition in healthy cells was not cytotoxic
and hadno effect on the cell cycle distribution.Wehypothesized that ifDYRK1B
is required for maintenance of quiescence, its inhibition would enhance the
effects of inhibitors of oncogenic signaling. We used a selective, ATP competi-
tive DYRK1B inhibitor to test this idea. EGFR inhibitors are effective in non-
small cell lung cancers with mutant EGFR and induce G0/G1 block and some
apoptosis. These drugs signifıcantly extend survival, but acquired resistance al-
most always supervenes. In vitro, the anti-proliferative response of lung tumors
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with mutant EGFR to EGFR inhibitors was shown to be primarily due to the
entry of cells into a quiescent (G0) state associatedwith an induction ofDYRK1B
expression. Moreover, addition of a DYRK1B inhibitor reversed the quiescent
state in cells exposed to EGFR inhibitors. Combined therapy of EGFR TKIs and
the DYRK1B inhibitor signifıcantly enhanced the antitumor response compare
to either drug alone. Specifıcally, it is shown that treatment with osimertinib
results in an increase of cells in G0 state: 63% as compared to non-treated cells,
29%. The induction of quiescence is prevented when cells are treated with the
combination of osimertinib and DYRK1B inhibitor and massive apoptosis is
observed: 62% compared to 12% with osimertinib alone. It is important to note
that co-treatmentwithDYRK1B inhibitor not only prevented the entry of cancer
cells into quiescence but also depleted pre-existent reservoir of quiescent cancer
cells. The results suggest that inhibition of EGFR causes tumor cells to enter into
a DYRK1B-dependent quiescent state in which DYRK1B is required for their
survival. Inhibition of DYRK1B dramatically enhances the antitumor activity of
EGFR inhibition and may improve outcome in patients.
#3196 Genetic and pharmacologic approaches to overcome epithelial to
mesenchymalmediated chemoresistance in breast cancer.Michael J. Crowley,
Nasser Altorki, Vivek Mittal, Dingcheng Gao. Weill Cornell Medical College,
New York, NY.
Development of resistance to conventional chemotherapy remains a major
barrier to effective treatment of breast cancer. We and others have recently
demonstrated in breast and pancreatic cancer models that epithelial-mesenchy-
mal transition (EMT) may not be a critical mediator of cancer metastasis, how-
ever, it contributes to cancer drug resistance (Fischer et al. Nature 2015; Zeng et
al Nature 2015). Importantly, blocking EMT throughmiR-200 family abrogated
chemoresistance, indicating potentials for clinical translation. Using our novel
EMT lineage tracing system, we have performed both genetic (CRISPR/Cas9
mediated genome-wide targeted mutagenesis) and pharmacological (high-
throughput small molecule libraries) screens, to identify potential candidates to
overcome EMT-mediated chemoresistance in breast cancer metastasis. The
identifıedmolecules provide not only novel mechanistic insights but also attrac-
tive anti-metastatic strategies for breast cancer treatment and the design of fu-
ture clinical trials.
#3197 Splicing factors and the role ofNavitoclax in drug-resistant ovarian
cancer.HelenM. Coley,1 Laura Lattanzio,2 Ornella Garrone,2 MarcoMerlano,2
Daniela Vivenza,2 Cristiana Lo Nigro,2 Nelofer Syed,3 Alistair Thompson,4
Bhavya Rao,4 Tim Crook5. 1Univ. of Surrey, Guildford Surrey, United Kingdom;
2Ospedale Carle, Cuneo, Italy; 3Imperial College, London, United Kingdom;
4Dundee Medical Centre and University, Dundee, United Kingdom; 5Southend
Hospital, Southend, United Kingdom.
Alternative RNA splicing allows processing of a pre-mRNA into various ma-
ture mRNAs. In this waymultiple protein products can be derived from a single
gene. In cancer it is known that specifıc splice variants may facilitate malignant
transformation and therapeutic resistance. Our current studies focus on the
problem of drug resistance in ovarian cancer and we have approached this in a
variety of ways. Following sequencing analysis of a panel of ovarian cancer cell
lines we identifıed the RNA splicing factors TCERG and SRSF2 as being reduced
in drug resistant ovarian cancer cell lines, compared with their drug sensitive
counterpart. TCERG is important in regulating the splicing of variant forms of
the BClx gene: BClxL (long form) and BClxs (short form). There are clear impli-
cations for drug resistancewhereby lowTCERG results in reduced BClx splicing
to yield the pro-apoptotic BClxs form. In the SKOV-3 human ovarian cancer cell
line panel both paclitaxel resistant SKOV-3TaxR and SKOV-3CR carboplatin
resistant cells showed reduced levels of TCERGmRNA using qPCR analysis. In
addition, qPCR analysis for BClxl and BClxs levels indicated increased ratio of
long:short form with drug resistance: SKOV-3 parent line ratio 1.0; SKOV-
3TaxR 1.8; SKOV-3CR 1.65. Western immunoblotting showed relatively de-
creased levels of Bax protein in drug resistant versus drug sensitive cell line in
line with a reduced apoptotic reduced. We then explored the use of Navitoclax
(ABT0263), the small-molecule Bcl-2 family protein inhibitor for Bcl-xL, Bcl-2
and Bcl-w in our cell line panel. Navitoclax in combination with paclitaxel for
48h gave rise to signifıcantly increased apoptotic response in drug-resistant ver-
sus drug sensitive ovarian cancer cell line counterparts, using the Annexin V
assay with PI, indicative of re-sensitisation to paclitaxel. Synergistic effects were
also seen for the parental cell line but the effects were more marked for the
resistant cell lines. Our futureworkwill also involve the use of clinical biopsies of
ovarian cancer cases.
#3198 Using a genome-wide CRISPR-Cas9 knockout library to identify
therapeutic combinations in oral cancer. Megan Ludwig, Andrew Birkeland,
Sai Nimmagadda, Sue Foltin, Aditi Kulkarni, Hui Jiang, Thomas Carey, Chad
Brenner. University of Michigan, Ann Arbor, MI.
Oral squamous cell carcinoma (OSCC) has remained a disease with poor
survival for decades with few novel treatment options. We anticipate great po-
tential for personalized targeted therapies, facilitated by recent characterizations
of the mutational landscape of OSCCs. Combinations of targeted therapies may
have greater effıcacy through inhibiting compensatory pathways. For example,
targeting EGFR has had limited success. To identify synergistic combinations
with EGFR-targeted therapy, we introduced Genome-scale CRISPR-Cas9
Knock-Out (GeCKO) libraries into OSCC cell lines. CRISPR-Cas9 generates
individual genetic knockouts through targeted gene editing. We used a pool of
CRISPRs targeting over 18,000 genes to perform genome-scale screening for
drivers of sensitivity to EGFR-targeted therapy. Upon selection of the OSCC
GeCKO pool, we identifıed gene knockouts in the FGFR pathway that increased
sensitivity to the EGFR inhibitor gefıtinib. Using resazurin viability assays we
tested combinations of EGFR and FGFR inhibitors in 14 OSCC cell lines. Six/14
(43%) of the cell lines were responsive to the combination, indicating that the
FGFR pathway is an alternate mechanism of resistance to EGFR-targeted ther-
apy in some tumors. In complement, we again used CRISPR-Cas9 to generate a
syngeneic EGFR knockout (KO) OSCC cell line. The parent OSCC cell line is
responsive to the EGFR and FGFR dual inhibition, and the EGFRKO derivative
retains sensitivity to FGFR-targeted monotherapies. We expect that this EGFR
KO cell line will be a useful tool in further evaluating the compensatory mech-
anism of the FGFR pathway. OSCC remains a common and frequently lethal
cancer with great potential for the development of personalized targeted thera-
pies. Here, we describe the use of genome-wideCRISPR-Cas9 library to discover
the synergistic combination of EGFR and FGFR inhibition. Further investiga-
tion suggests the FGFR pathway is a common compensatory mechanism to
EGFR inhibition. We hope to use this approach to identify additional compen-
satory mechanisms of resistance to targeted therapies with the eventual goal of
translating these fındings to clinic.
#3199 Diverse non-FLT3molecularmechanisms of crenolanib resistance.
Haijiao Zhang,1 Anna M. Schultz,1 Samantha Savage,1 Daniel Bottomly,1 Beth
Wilmot,1 ShannonK.McWeeney,1 Christopher Eide,1HoangHo,2 Yee L. Lam,2
Richard Sweat,2 Jaime Faulkner,1 Evan Lind,1 JeffreyW. Tyner1. 1OregonHealth
& Science University Knight Cancer Institute, Portland, OR; 2Arog Pharmaceuti-
cals, Inc., Dallas, TX.
FMS-like tyrosine kinase 3 (FLT3) activating mutations are primary molecu-
lar targets for the treatment of acute myeloid leukemia (AML) due to high
prevalence and unfavorable prognosis. Several type II FLT3 inhibitors have
shown clinical benefıts but acquisition of secondary FLT3 mutations was re-
ported as a common mechanism of resistance. Previous studies showed that
crenolanib, a type I FLT3 inhibitor, had clinical activity without acquisition of
secondary FLT3 mutations. To identify the molecular mechanisms associated
with crenolanib sensitivity and resistance, we performed exome sequencing on
crenolanib treated patients with FLT3-mutant multiply relapsed or refractory
AML. Baseline mutational analysis revealed distinct mutational profıles in pa-
tients with prior FLT3 inhibitor exposure, especially in the following pathways:
NRAS, IDH1, WT1 and RUNX1. Further analysis of patients who had poor
response to crenolanib showed mutations in other cell signaling genes such as
NRAS and PTPN11. Variant allele frequency (VAF) analysis showed that these
mutations sometimes occurred in subclones independent of the FLT3mutation-
bearing clone or sometimes were acquired by the FLT3mutation-bearing clone.
To characterize the influence of these mutations on crenolanib sensitivity, we
transduced genes of interest into cell lines harboring FLT3 activating mutations
and treated these cells with crenolanib at various concentrations. Signifıcantly
increased crenolanib IC50 and IC90were observed inNRASG12VMOLM14 and
PTPN11 A72D/FLT3 D835 Ba/F3 cells relative to the respective control NRAS
WT MOLM14 and PTPN11 WT/FLT3 D835 Ba/F3 cells. Notably, addition of
trametinib restored crenolanib sensitivity and demonstrated synergistic cyto-
toxic effects on cells with FLT3 and NRAS or PTPN11 mutations. In addition,
increases in TET2 nonsense/frameshift mutations were observed in patients
who did not respond to crenolanib. VAF analysis demonstrated that TET2 mu-
tations co-occurred with FLT3 mutations. We also observed that bone marrow
cells fromFLT3-ITDknock-in/TET2 knock-outmice are resistant to crenolanib
at low concentrations, but remain sensitive to azacytidine at the same level as
FLT3-ITD knock-in/TET2WT cells. The remaining patients exhibited a diverse
spectrum of secondary mutations associated with chromatin modifıers, cohe-
sion, spliceosomes and transcription factors which mostly expanded during
treatment, suggesting an elaborate genetic/epigenetic mechanism of resistance
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to crenolanib. Our data suggest that comprehensive sequencing should be car-
ried out on patient samples prior to treatment to identify and pre-emptively
target problematic clones. In addition, even with high VAF FLT3 mutations,
although FLT3 inhibitormonotherapy provide some clinical benefıt, combining
agents targeting cooperative lesions will be imperative to eradicate both the
dominant clone and resistant subclones and improve patient responses.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Novel
Molecular Targets 2
#3200 TargetingPHF5A for the treatment of glioblastomaandotherMyc-
driven cancers. Andrew J. Mhyre,1 Shanon Turnbaugh,1 Shelli M. Morris,1 Hu
Xin,2 Patrick J. Paddison,1 Marc Ferrer,2 James M. Olson1. 1Fred Hutchinson
Cancer Research Center, Seattle, WA; 2National Institutes of Health, Bethesda,
MD.
Glioblastoma multiforme (GBM) is one of the most aggressive and invasive
types of brain cancer, but targeted treatment options remain elusive. The stan-
dard of care (surgery chemotherapy and radiation) falls far short of where it
should be with two-year survival rates less than 10%. Using stem cell isolates
from GBM patients, we found that perturbing PHF5A, a component of the
spliceosome machinery, was lethal and caused hundreds of genes to be mis-
spliced. These mis-splicing events included both exon skipping and intron in-
clusions. In contrast, similar levels of PHF5A suppression in normal control
stem cells and astrocytes failed to induce cell death and mis-splicing, indicating
that PHF5A plays a specifıc role in the cancer biology. Moreover, when normal
astrocytes were transformed with the Myc oncogene, they became sensitive to
PHF5A perturbation. Taken together, these results suggested that specifıcally
inhibiting PHF5A would be an effective therapy for glioblastoma and other
Myc-driven cancers. Specifıcally targeting PHF5A would also likely result in
reduced side-effects seen with general spliceosome inhibitors. Unfortunately,
there are currently no known inhibitors that target PHF5A. In order to discovery
novel PHF5A inhibitors, we created amini-genemis-splicing reporter assay that
was sensitive to both general spliceosome inhibitors and PHF5A perturbation.
In a 96-well assay format, the assay was robust with a 200-fold assay window and
Z’ values over 0.8. Following miniaturization to a 1536-well format, we con-
ducted a high throughput screening (HTS) campaign testing 450,000 small mol-
ecule compounds. The initial hits were retested and counter-screened yielding
381 confırmed actives and we are further interrogating these actives in second-
ary and tertiary assays. Future efforts will focus on developing an SARof the lead
and backup series and identifying potential liabilities that will be addressed, if
necessary, in further lead optimization efforts. We are enthusiastic about the
potential of developing a targeted PHF5A inhibitor as a novel and effective
therapy for patients and their families fıghting GBM and other Myc-driven
cancers.
#3201 Therapeutic potential of anti-angiogenic multimodal biomimetic
peptide in hepatocellular carcinoma. Mustafa A. Barbhuiya, Adam C. Mi-
rando, Brian W. Simons, Ghali Lemtiri-Chlieh, Jordan J. Green, Aleksander S.
Popel, Niranjan B. Pandey, Phuoc T. Tran. Johns Hopkins University School of
Medicine, Baltimore, MD.
Hepatocellular carcinoma (HCC) related mortality ranks second worldwide
and stands one step behind lung cancer. Due to the asymptomatic nature of the
cancer, early diagnosis is a major problem. Currently only liver transplantation
is curative for early stage hepatocellular cancer. There are other multidisci-
plinary treatment options like radiation and chemotherapy available for ad-
vancedpatients.However, chemotherapy resistance is a commonproblem in the
treatment of liver cancer. Newer therapeutics are needed for bettermanagement
of advanced HCC. Angiogenesis and lymphangiogenesis are processes that are
vital for tumorigenesis and metastasis. HCC is known to be a hypervascular
tumor andmany pro-angiogenic proteins are found signifıcantly overexpressed
in HCC.We explored the therapeutic potential of the anti-angiogenic and anti-
lymphangiogenic, biomimetic peptide SP2043 developed by our group in HCC.
Hepatocellular carcinoma cell lines HuH-7, Hep3b and HepG2 showed signifı-
cant disruption of cell adhesion and migration following treatment. Further-
more, SP2043 was found to impair microvascular endothelial cell (MEC) tube
formation induced by HepG2 tumor conditioned media and to signifıcantly
inhibit HepG2 tumor xenograft growth compared to untreated controls. The
peptide drug was also found to improve the survival of autochthonous Myc
induced HCC in a transgenic mouse model from two weeks to four weeks. We
discovered the peptide to be amulti-modal anti-angiogenic drug that also inhib-
its IGF1R and MET signaling pathways in HCC cell lines. We also found that
SP2043 treatment reduced the microvascular density in both subcutaneous and
autochthonous liver tumorswith reduced tumor cell proliferation and increased
apoptosis. This study shows the therapeutic potential of SP2043 in the treatment
of hepatocellular carcinoma.
#3202 Pharmacologic modulation of Sigma1 induces autophagic degra-
dation of programmed death-ligand 1 in cancer cells. Christina M. Maher,
Jeffrey D. Thomas, Charles G. Longen, Derick A. Haas, Halley M. Oyer, Jane Y.
Tong, Felix J. Kim. Drexel University College of Medicine, Philadelphia, PA.
Emerging evidence suggests that Sigma1 (also known as sigma1 receptor) is a
unique ligand-operated integral membrane chaperone or scaffolding protein
that contributes to cellular protein homeostasis. Previously, we found that treat-
ment of various cancer cell lines with some prototypic small molecule modula-
tors of Sigma1 can engage endoplasmic reticulum (ER) associated protein ho-
meostasis pathways including the unfolded protein response and autophagy.
Programmeddeath-ligand 1 (PD-L1) is a type 1 integralmembrane glycoprotein
that is processed and transported through the ER and secretory pathway of
tumor cells. PD-L1 expressed at the surface of tumor cells can act as a T-cell
inhibitory checkpoint molecule that inactivates tumor infıltrating immune cells
that express PD-1, its cognate receptor. Here, we show that Sigma1 physically
associates with PD-L1. In triple negative breast and androgen-independent
prostate cancer cells, PD-L1 protein levels are suppressed by both RNAi medi-
ated knockdown of Sigma1 and pharmacological modulation of Sigma1. We
observe decreased cell surface and intracellular levels of PD-L1 by flow cytom-
etry and biochemical subcellular fractionation respectively, which corresponds
with a dose-responsive decrease in functional PD-L1/PD-1 interaction in a co-
culture of cancer cells and T-cells. Inhibitors of autophagy block this suppres-
sion of PD-L1 protein levels, suggesting PD-L1 is degraded away by autophagy
after Sigma1 modulation. Through confocal microscopy, we show that Sigma1
modulation results in colocalization of PD-L1 and GFP-LC3, a marker of au-
tophagosomes. From these conclusions, we hypothesize that autophagic degra-
dation of nascent PD-L1 after Sigma1modulation plays a key role in preventing
the transport of functional PD-L1 to the plasmamembrane. Together, these data
demonstrate that Sigma1 modulators have the potential to act as novel thera-
peutic agents in PD-1/PD-L1 blockade strategies.
#3203 Targeting tumor hypoxia with prodrug conjugates of potent small-
molecule inhibitors of tubulin polymerization. Kevin G. Pinney,1 Mary Lynn
Trawick,1 Ralph P.Mason,2 Li Liu,2 David J. Chaplin,3 Blake A.Winn,1 Laxman
Devkota,1 TracyE. Strecker,1 JeniGerberich,2AlexWinters,2 YifanWang,1Mat-
thew T. MacDonough1. 1Baylor University, Waco, TX; 2University of Texas
SouthwesternMedical Center, Dallas, TX; 3Mateon Therapeutics, Inc., South San
Francisco, CA.
Regions of pronounced hypoxia in malignant tumors represent an oppor-
tunity for selectivity in drug activation, and hence targeting and delivery. In
this study, a series of bioreductively activatable prodrug conjugates (BAPCs)
of small-molecule inhibitors of tubulin polymerization were synthesized and
evaluated in biochemical and biological studies. The BAPCs are designed to
be biologically inert until selectively cleaved under hypoxic conditions, by
reductase enzymes found in the tumor, to release potent effector anticancer
agents. BAPCs were evaluated in the following assays: (1) cytotoxicity using
the regular sulforhodamine B assay (normoxic conditions) to confırm their
reduced cytotoxicity in cancer cells in culture compared to the effector
agents; (2) cleavage under anoxic conditions by the reductase enzyme,
NADPH cytochrome P450 oxidoreductase (POR), that is implicated in the
bioreductive cleavage of compounds with nitrothiophene and nitroimidaz-
ole triggers; and (3) differential cytotoxicity under hypoxic versus normoxic
conditions in cancer cell lines with the established bioreductive compound
tirapazamine (TPZ) as the control. The POR assay was modifıed by the
addition of protocatechuate 3,4-dioxygenase to ensure anoxic conditions,
and Triton X-100 to facilitate solubilization of the BAPCs. A series of un-
substituted, methyl, and gem-dimethyl nitrothiophene- and nitroimidazole-
triggered prodrug conjugates (BAPCs) of two experimental anticancer
agents (KGP03 and KGP18) were synthesized. KGP03 and KGP18 were in-
spired by the natural product combretastatin A-4 (CA4). A unique attribute
of the selected anticancer agents is that both bind tubulin at the colchicine
site, inhibit tubulin polymerization into microtubules, and thus function as
pronounced cytotoxic, anti-proliferative agents in human cancer cell lines
and as vascular disrupting agents (VDAs). The assays were validated with a
series of nitrothiophene analogues of CA4 (Thomson et al., Mol. Cancer
Ther. 2006 5:2886). In our evaluation of this series, the gem-dimethyl nitro-
thiophene analogue of CA4 was effıciently cleaved by POR and gave an
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average differential hypoxia cytotoxicity ratio (HCR: GI50 values of nor-
moxic/hypoxic conditions) of 41 in the human A549 lung carcinoma cell
line. The corresponding prodrug of combretastatin A-1 had an HCR  26.
The monomethyl nitroimidazole BAPCs of KGP03 and KGP18 produced
positive HCRs in our initial assays. In preliminary studies, the CA4 BAPC
demonstrated antivascular activity in an orthotopic syngeneic breast tumor
mouse model (4T1/BALB/c). In the POR assay, the gem-dimethyl nitrothio-
phene analogue of KGP03 was completely cleaved in 24 h. Biological evalu-
ation of these BAPCs indicates the occurrence of selective, hypoxic activa-
tion resulting in release of the potent inhibitors of tubulin polymerization
(CA4, CA1, KGP03, KGP18).
#3204 Tryptophan 318/324, the target of C-terminal binding protein
(CtBP) inhibitors, plays a critical role in CtBP enzymatic activity, oligomer-
ization and transcriptional coregulation. Martin M. Dcona,1 Benjamin L.
Morris,1 Priyadarshan K. Damle,1 Zaid Nawaz,1 Michael J. Dennis,1 Sahib J.
Singh,1William E. Royer,2 Keith C. Ellis,1 Steven R. Grossman1. 1Virginia Com-
monwealth University, Richmond, VA; 2University of Massachussetts, Worcester,
MA.
C-terminal Binding Proteins (CtBP) 1 and 2 constitute a family of oncogenic
transcriptional co-regulators overexpressed in tumor tissues that are associated
withworse prognostic outcome and aggressive tumor characteristics inmultiple
cancer types. Specifıcally, CtBP has been found to repress expression of genes
responsible for apoptosis and EMT (eg. BIK and CDH1) and promote expres-
sion of genes that partake in the migration of cancer cells and those that are
responsible for enhanced drug resistance (eg. TIAM1 andMDR1). CtBP2 is also
critically required for colon cancer stem cell self-renewal. CtBP is unique among
transcription co-regulators in harboring a conserved D-isomer specifıc 2-hy-
droxyacid dehydrogenase (D2DH) domain, which reduces an alpha-keto acid
substrate to an alpha-hydroxy acid in the presence of NADH. The presence of
NADH also facilities oligomerization of CtBP, leading to assembly of higher
order complexes of CtBP with both DNA binding transcription factors and
histonemodifying enzymes that then leads tomodulation target genes.We have
identifıed hydroxyimino-3-phenylpropanoic acid and its 4-chloro derivative
(HIPP; 4-Cl-HIPP) as potent substrate competitive inhibitors of the CtBP dehy-
drogenase (IC50’s240nM, 180 nM), which also disrupt CtBP oligomerization,
promoter localization, and transcriptional regulation. Co-crystallization of
HIPP andCtBP1/2 indicated a strong
-
 interaction between theHIPP phenyl
ring and the indolyl ring in tryptophan W318/324 of CtBP1/2, indicating that
this tryptophan is critical to CtBP interaction with HIPP inhibitors, dehydroge-
nase function, and quaternary structure. Of note W318/324, though conserved
in CtBP1/2, is unique among D2DH, suggesting that a better understanding of
W318/324 role and function in CtBP structure and function is critical to opti-
mizing design of inhibitors that targeting this evolutionary unique residue
among dehydrogenases. To further elucidate the mechanism of action in catal-
ysis and oligomerization, as well as functional importance for transcription of
CtBP2 W324, we analyzed enzyme kinetics, oligomerization, transcriptional
co-regulatory activity and cell migration in a series of CtBP2 W324 mutants
overexpressed in breast and colon cancer cell lines with concomitant knock-
down (siRNA) or knockout (CRISPR/Cas9) of CtBP2. Our data demonstrates
that mutation of W324 abrogated dehydrogenase activity, oligomerization,
transactivation of the validated CtBP target gene TIAM1 and induction of mi-
gration. In summary, our fındings suggest that the W324 residue is critical for
CtBP2’s function and its unique conservation in CtBP1/2 vs. other dehydroge-
nases will allow the development of high specifıcity CtBP W318/324 inhibitors
to limit potential toxicity due to off target inhibition of related metabolic dehy-
drogenases.
#3205 A nanomolar potency small-molecule compound against castra-
tion-resistant and bone metastatic prostate cancer. Kenza Mamouni,1 Lajos
Gera,2 Xin Li,1 Daqing Wu1. 1Augusta University, Augusta, GA; 2University of
Colorado Denver, Aurora, CO.
A standard treatment for prostate cancer (PCa) is androgen deprivation ther-
apy (ADT) that suppresses androgen receptor (AR) signaling axis. Although
initially responsive, most patients receiving ADT eventually develop metastatic
castration-resistant prostate cancer (CRPC), with more than 90% of them ex-
hibiting bone metastases. A mechanism by which CRPC cells evade ADT is the
expression of constitutively active AR variants (AR-Vs), such as the well-char-
acterizedAR-V7. Recentlywe developedGH501, a flurbiprofen-modifıed small-
molecule compound, and investigated its anti-cancer activity andmechanism of
action in pre-clinical models of CRPC. At nanomolar range, GH501 effectively
induces cell cycle arrest and apoptosis in CRPC cells regardless of their resis-
tance status to enzalutamide treatment. RNA-seq analysis of GH501 combined
with Western blotting analysis identifıed key targets implicated in CRPC pro-
gression, including the full-length AR, AR-V7 variant, and other important
genes implicated in CRPC progression. Importantly, low doses of GH501 effec-
tively inhibit the skeletal growth of CRPC in a xenograft model without obvious
in vivo toxicities. These preclinical results indicate that GH501 is a promising
small-molecule compound that can be further developed for the treatment of
lethal prostate cancer.
#3206 A potent and selective CSF-1R inhibitor, DCR-0064, inhibits col-
ony stimulating factor 1 signaling in vitro and in vivo. Chu-Bin Liao, Shao-
Zheng Peng, Chen-Hsuan Ho, Chao-Pin Lee, Jia-Ming Chang, Hung-Jyun
Huang, Sian-Yi Ciou, Yu-Chih Pan, Yu-Kai Chen.Development Ctr. for Biotech-
nology, Xizhi City, Taiwan.
Tumor-associatedmacrophages (TAMs) aremajor components of leukocytic
infıltrate of tumors. It has been reported that high TAMs density is associated
with poor clinical prognosis. Within the tumor microenvironment, TAMs rely
on signaling through CSF-1/CSF-1 Receptor kinase axis to promote tumor
growth, angiogenesis, and metastasis. Therefore, decrease of TAMs density in
tumors through inhibition of CSF-1R kinase is considered a potential target for
drug development. In this study, we report that a novel small molecule DCR-
0064 inhibits CSF-1R kinase with IC50 value below 10 nM and possesses speci-
fıcity for CSF-1R over other tyrosine or serine/threonine kinases. DCR-0064
selectively inhibits CSF-1 induced growth ofM-NFS-60myeloid cells and effec-
tively suppresses intracellular CSF-1R activation with IC50 value less than 100
nM. The potency and selectivity of DCR-0064 is superior to the current lead
CSF-1R inhibitor, PLX3397, which is in phase III clinical development for treat-
ing tenosynovial giant cell tumor. The selectively growth inhibitory activity of
DCR-0064 is consistent with inhibition of CSF-1R signaling. Oral administra-
tion of DCR-0064 reduces TAMs density in vivo in mice. DCR-0064 is being
developed as a candidate for preclinical development.
#3207 Targetting proteasome function by inhibition of the proteasome
deubiquitinase USP14. Stig T. Linder,1 Padraig D’Arcy,2 Xiaonan Zhang1.
1Karolinska Inst. Cancer Center, Stockholm, Sweden; 2Linköping University,
Linköping, Sweden.
The 20S proteasome core particle has evolved as an important target for anti-
cancer drug development. We previously identifıed the small molecule b-AP15
as a novel class of proteasome inhibitors that function by abrogating the deu-
biquitinating (DUB) activity of the 19S regulatory particle. An optimised lead of
b-AP15 (VLX1570) has been approved by the FDA for clinical studies and is
currently in clinical trials for relapsed multiple myeloma. VLX1570 has also
shown promising activity in Ewings sarcoma and paediatric leukemias. b-AP15
and VLX1570 bind to the proteasome DUB ubiquitin-specifıc protease-14
(USP14) in vitro and in exposed cells (CETSA). Binding and inhibition of enzy-
matic activity is believed to be due to targeting Cys114 in the active site. The cell
death response to b-AP15/VLX1570 is distinct from that of 20S proteasome
inhibitors. Thus, the sensitivity to these compounds is unaffected by overexpres-
sion of BCL2-family proteins and unaffected by p53 status. We here show that
b-AP15 induces direct effects on mitochondria, possible explaining this phe-
nomenon.We also provide additional understanding of drug-target interactions
using a series of compounds identifıed by screening. Our fındings demonstrate
promising antiproliferative activities of USP14 inhibitors in vitro and in vivo.
#3208 AZD1775 modulates kinetochore component Wee1-CDC2 and
NF-B signaling as potential therapeutic targets in head and neck squamous
cell carcinoma. Zhengbo Hu,1 Anthony Saleh,2 Jianghong Chen,2 Carlson So-
phie,2 Yi An,2 Clavijo Paul,2 Ru Wang,2 Shaleeka Cornelius,2 Zhong Chen,2
Carter VanWaes2. 1The First Hospital of Shaoguan, Guangdong, Shaoguan, Chi-
na; 2NIDCD/NIH, Bethesda, MD.
Recent fındings in The Cancer Genome Atlas (TCGA) analysis of head and
neck squamous cell carcinomas (HNSCC) revealed frequent alterations affect-
ing the cell cycle andNF-B pathway, which are critically involved in cancer cell
proliferation and survival. We hypothesized that commonmechanism(s) could
coordinate cell cycle and NF-B cell survival signaling in HNSCC. Recently, we
established anNF-Blactamase reporterUM-SCC-1 cell line and performed
genome-wide RNAi screening to explore this hypothesis. We identifıed genes
involved in the cell cycle and related to components of the kinetochore that
co-modulate NF-B activity. Among these targets, WEE1 kinase is currently
under investigation as a therapeutic target of inhibitorAZD1775 inHNSCC.We
found that WEE1-CDC2 axis protein levels were higher in a panel of HNSCC
lines than in normal humanoral keratinocytes (HOK). To further investigate the
potential cross-talk between WEE1 cell cycle regulation and NF-B activation,
we showed that treatment of HNSCC cells with AZD1775 decreased NF-B
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transcriptional activation and decreased TNF-induced phosphorylation of
IKKs and RELA subunit. Furthermore, AZD1775 inhibited NF-B regulated
proteins modulating the cell cycle and survival, including p21, CyclinD1, BCL2
and BCL-XL. These changes also correlate with alteration in cell cycle and sur-
vival detected by flow cytometry, as tumor cells treated by AZD1775 exhibited
increased G2/M phase and sub-G0 fragmented DNA, and decease in G1/S
phases.WEE1 inhibitor AZD1775 inhibited tumor cell proliferation and colony
formation in a dose-dependentmanner, and exhibited combinatory effects with
cisplatin chemotherapy in tumor xenografts. Thus,we identifıed the novel cross-
talk between WEE1-CDC2 and NF-B signaling, potentially implicating de-
creased NF-B prosurvival signaling in the anti-tumor activity of Wee1 inhibi-
tors. (Supported by NIDCD/NIH intramural projects ZIA-DC-000016, 73, and
74; NIDCD core facility: advanced imaging, ZIC DC000081).
#3209 Polo-like kinase 1 as a new molecular target for small cell lung
carcinoma. Noro Rintaro, Masahiro Seike, Fenfei Zou, Akihiko Miyanaga,
Kaoru Kubota, Akihiko Gemma. Japan, Tokyo, Japan.
No target therapies are presently available in the treatment of small-cell lung
cancer of Lung (SCLC). Therefore there is a need to develop new therapeutic
agents. The protein kinases are a family of genes that play critical roles in various
signaling pathways. Some cancer cells show addiction to constitutive activation
of certain signaling pathways for proliferation and survival. To identify new
drug targets for SCLC, we screened a panel of small interfering RNAs (siRNAs)
that target 720 genes encoding humanprotein kinases and related proteins using
SBC5 SCLC cell (SN38 (irinotecan hydrochloride) resistant cell). PLK1 inhibi-
tion suppressed cell proliferation strongest among 20 signifıcant promising total
genes using different 5 SCLC cells as a varidation study). PLK1 mRNA expres-
sion was signifıcantly higher than other pathological phenotypes among 20 cell-
lines and the 200 clinical samples consist of three independent cohorts. The
patients with high PLK1 expresssion was signifıcantly associated with poor
prognosis in SCLC patients. Furthermore we investigated the change of SN 38
sensitivity and preventing from SN38 resistance after knockdown PLK1. Our
results indicated that PLK1 inhibitor as BI 2536 andVolasertib, was a promising
molecular target therapy for pharmacologic intervention in SCLC in both
monotherapy and the combination therapy with SN38.
#3210 Targeting PTP4A3 phosphatase in ovarian cancer with the potent
noncompetitive inhibitor JMS-631-053. John S. Lazo,1 Paula Pekic,1 Alex
Cheung,1 Kelley McQueeney,1 Joseph Salamoun,2 Peter Wipf,2 Charles N.
Landen,1 Elizabeth R. Sharlow1. 1Univ. of Virginia, Charlottesville, VA; 2Univ. of
Pittsburgh, Pittsburgh, PA.
PTP4A3 is a highly attractive molecular target for ovarian cancer (OvCa).
Elevated levels of PTP4A3 mRNA and protein in human ovarian tumors corre-
late with disease progression, poor prognosis and poor survival. Genetic deple-
tion of PTP4A3 inOvCa cell lines diminishes their ability tomigrate and reduces
their in vivo tumorigenicity while PTP4A3 overexpression increases tumor cell
migration, invasion, and dissemination. Together, these data suggest PTP4A3 is
a novel molecular target for OvCa; however, the lack of potent and selective
PTP4A3 small molecule inhibitors has hindered PTP4A3’s defınitive validation
in OvCa and in other cancers. To drive the pharmacological validation of
PTP4A3, we developed JMS-631-053 (7-imino-2-phenylthieno[3,2-c]pyridine-
4,6(5H,7H)-dione), a potent (Ki3 nM in vitro), specifıc, noncompetitive,
PTP4A3 inhibitor. JMS-631-053 inhibited cellular migration, invasion, and col-
ony formation in soft agar. Potent OvCa cell-based effects were observed by
profıling JMS-631-053 against a panel of 8 OvCa cell lines using a 2D drug
susceptibility assay, with EC50 values as low as 600 nM. Likewise, JMS-631-053
killedOvCa 3D spheroids, including those derived fromhigh grade serousOvCa
cell lines, with EC50 values as low as 300 nM. The OvCa drug resistant cell lines
(i.e., A2780CP20 and HeyA8MDR) retained responsiveness to JMS-631-053
(using 2D and 3D culturing conditions) suggesting that inhibition of PTP4A3
may be a viable therapeutic strategy for chemoresistant OvCa. Preliminary data
also suggests that JMS-631-053 synergizes with cisplatin when used in combi-
nation studies. Hence, JMS-631-053 will be a valuable chemical tool for further
validation of PTP4A3 as an OvCa target as well as provide potential leads for
future drug discovery.
#3211 Inhibition of autophagy potentiates cytotoxicity of CX-5461 treat-
ment in chemoresistant epithelial ovarian cancer. Robert Cornelison,1 Dan-
ielle C. Llaneza,1 Yulia Petrova,1 Zachary C. Dobbin,2 David A. Schneider,2
Charles N. Landen1. 1University of Virginia School of Medicine, Charlottesville,
VA; 2University of Alabama at Birmingham, Birmingham, AL.
Epithelial ovarian cancer remains a deadly diagnosis with poor prognosis and
patients succumbing to chemoresistant disease in 80% of cases. Mechanisms of
chemoresistance are numerous, but we have identifıed ribosomal biogenesis
basal machinery as being a common upregulated signaling network in response
to chemotherapeutic insult. Tumors treated with chemotherapy showed dra-
matic increases in size andmorphology of nucleoli, suggesting global changes in
ribosomal synthesis with stress. We next sought to use the RNA Polymerase I
inhibitor CX-5461 to identify biologic changes in targeting ribosomal machin-
ery that may allow resensitization to chemotherapy. CX-5461 induced au-
tophagy, senescence andmitotic catastrophe in ovarian cancer cell lines Overall,
13 ovarian cancer lines examined were highly sensitive to Pol I inhibition by
MTT, with IC50s ranging from 25nM to 2M, and chemoresistant lines were
generally more sensitive to CX-5461. In p53mutant cells CX-5461 appears to be
primarily cytostaticwithmitotic catastrophe being a relatively rare event accom-
panying cytokinesis failure. This could be indicative of the cells successfully
using autophagy to decrease ribosome requirements and evade treatment.
When treated in combinationwith chloroquine as an autophagy inhibitor IC50s
decreased to 550nM in HeyA8 (from 2M), 70nM for HeyA8MDR (from
191nM), 110nM in SKOV3 (from 595nM) and 60nM for SKOV3TR-ip2 (from
109nM) with abundant multinucleated cells, suggesting synergy between ribo-
somal synthesis and autophagy inhibitors in vitro. Chloroquine administration
appears to push cell to mitotic catastrophe after co-administration with CX-
5461, thereby enhancing cytotoxicity over cytostatic endpoints after treatment,
even inmulti-drug resistant cell populations. Inhibition of autophagy appears to
enhance effıcacy of RNAPolymerase I inhibition in both sensitive and chemore-
sistant populations, prompting a potential new approach to chemoresistant dis-
ease.
#3212 ONC201 shows effıcacy in BRCA-defıcient cancer cells and synergy
with PARP inhibitors in glioblastoma, breast, prostate, and ovarian cancers.
Marie D. Baumeister,1 Ozan C. Küçükkase,2 Varun V. Prabhu,3 David T.
Dicker,4 Josh E. Allen,3 Wafık S. El-Deiry4. 1Lewis Katz School of Medicine,
Philadelphia, PA; 2Bog˘aziçi University, Istanbul, Turkey; 3Oncoceutics Inc, Phil-
adelphia, PA; 4Fox Chase Cancer Center, Philadelphia, PA.
BRCA1 and BRCA2 are involved in control of DNA repair by homologous
recombination (HR). Germline mutations in these genes substantially increase
lifetime risk of developing breast, ovarian and other cancers. BRCA-defıcient
tumors show increased sensitivity to therapies that target defectiveHR. Sporadic
tumors lacking germline BRCAmutations but sharing themolecular features of
BRCA-mutant tumors may respond to these types of therapies as well. PARP
inhibitors represent a form of targeted therapy for HR-defıcient tumors that
have been approved in ovarian cancer and are being tested in clinical trials in
breast cancer, metastatic castration-resistant prostate cancer, and glioblastoma.
Our lab has previously identifıed a smallmolecule calledONC201 in a screen for
compounds capable of inducing the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) gene. Our lab has previously reported that ONC201
induces an integrated stress response that involves ATF4/CHOP and inactivates
pro-survival kinasesAkt andERK.The latter leads to decreased phosphorylation
of transcription factor FOXO3a, its nuclear translocation, and induction of tran-
scription of the target gene TRAIL. A fırst-in-human clinical trial showed that
the compound is well tolerated, achieves a therapeutic pharmacokinetic profıle,
exhibits biological activity. It has since entered multiple phase I/II trials.
ONC201 has anti-proliferative and pro-apoptotic effects in a wide range of tu-
mor types including BRCA-defıcient breast and ovarian cancers (n10), with
GI50 values in the low micromolar range. Treatment with ONC201 induces
surface TRAIL and inhibits Akt activity in BRCA defıcient breast and ovarian
cancers. PARP inhibitors have been previously shown to upregulate DR5
through transcription factor CHOP, sensitizing solid tumors to TRAIL. Resis-
tance to PARP inhibitors can occur through PI3K/Akt pathway activation, and
PI3K/MEK blockade improves their anti-tumor effects. We observed synergy
between ONC201 and PARP inhibitors olaparib and rucaparib in BRCA-defı-
cient breast and ovarian cancer cell lines in cell viability assays with combination
indices (CI) ranging from 0.4 - 0.8. Robust synergy was also observed in prostate
cancer and glioblastoma cells. The mechanisms of the observed synergy are
currently under investigation. These results indicate that ONC201 possesses
single agent activity in BRCA-defıcient cancer cells and that the combination of
ONC201 with PARP inhibitors represents a promising synergistic therapeutic
approach that could be exploited in multiple solid tumors.
#3213 AntagonismofD2-like dopamine receptors plays a role inOnc201’s
anticancer effects.Christina Leah B. Kline, Amriti Lulla, JessicaWagner, David
Dicker, Marie Baumeister, Sophie Oster, Wafık El-Deiry. Fox Chase Cancer
Center, Philadelphia, PA.
ONC201/TIC10 is a fırst-in-class small molecule inducer of TRAIL that
causes early activation of the integrated stress response and inactivates both Akt
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and ERK. Its promising safety profıle and broad spectrum effıcacy in vitro has
been confırmed in Phase I/II trials in several advanced malignancies. Biochem-
ical and reporter assays have shown that ONC201 is a selective and competitive
antagonist of the D2-like receptors, specifıcally, dopamine receptor D2 (DRD2)
and dopamine receptor D3 (DRD3) with a KD value of3 M. The theme that
dopamine and dopamine receptors are important in cancer has emerged in the
literature. We hypothesize that ONC201’s interaction with DRD2 is critical for
ONC201’s anticancer effects. Co-treating HCT116 and RKO colorectal cancer
cells with ONC201 and dopamine or the selective D2-like receptor agonist su-
manirole partially abrogated ONC201-induced ATF4/CHOP expression and
apoptosis. Knocking down DRD2 expression using siRNA negated ONC201’s
effects on viable cell count. Overexpressing DRD2 in a cancer cell line that has
very low levels of DRD2, increased ONC201-induced PARP cleavage. Quanti-
tative RT-PCR analyses showed that cells that have acquired resistance to
ONC201 did not express detectable mRNA levels of the D2-like receptors. To
further determine the anti-tumor potential of targeting the D2-like receptor, we
treated different cancer cell lines with other D2-like receptor antagonists. Sim-
ilar to ONC201, the D2-selective antagonist L-741,626 decreased cell viability
and induced apoptosis in a number of cancer cell lines. In contrast to ONC201,
however, L-741,626 has a poor therapeutic index. Our fındings show that the
ability of ONC201 to inhibit D2-like receptors contributes to ONC201’s anti-
proliferative and pro-apoptotic activity. Ongoing work is aimed at elucidating
the mechanisms by which antagonism of D2-like receptors can promote apo-
ptotic cell death, especially with regard to ATF4/CHOP/DR5 and Akt/ERK/
Foxo3a/TRAIL, which have been shown to be stimulated in ONC201-treated
and -sensitive tumor cells.
#3214 Systematic drug repurposing for faster cures of pediatric cancer
identifıes that Digoxin prolongs survival in a PDOX model of group 4 me-
dulloblastoma. Lei Huang,1 Sarah G. Injac,2 Hong Zhao,1 Qi Lin,2 Mari Ko-
giso,2 Chris T.Man,2 Xiao-Nan Li,2 Ching C. Lau,3 Stephen T.Wong1. 1Houston
Methodist Research Institute, Houston, TX; 2Texas Childrens Hospital, Houston,
TX; 3Connecticut Children’s Medical Center, University of Connecticut School of
Medicine, Hartford, CT.
Background: Medulloblastoma (MB) is the most common malignant brain
tumor of childhood. While the current standard care for MB leads to long term
survival in approximately 75 % of patients; recurrent and refractoryMB contin-
ues to have dismal outcomes. In addition, long term survivors face signifıcant
treatment-related sequelae especially poor neurocognitive outcomes. Drug re-
positioning for known drugs is a promising potential strategy not only for drug
discovery but also for accelerated translation into the clinical setting. To system-
atically explore thousands of known drugs available, we integrated computa-
tional biology and empirical biology methods to fınd old drugs for new indica-
tions in MB. Results: A non-parametric, bootstrapping based simulated
annealing (NPBSA) algorithm was employed to identify driver signaling path-
ways for over 1,800 patients with Group 3 and Group 4MB through an integra-
tive analysis on theirmRNAexpression, DNA-copy number, DNA-methylation
and DNA-seq profıles. Then, drug functional networks were constructed based
on gene expression profıles under drug treatment as well as chemical structures
and were clustered into drug modules with potential mechanisms of action. By
evaluating targeted effects of 1,309 drugs fromconnectivitymapdatabasewithin
each drug module in driver signaling pathways, we identifıed a group of known
cardiac glycosides that top ranked among the total drug candidates for the
Group 3 and 4MB subtypes. In addition to traditional chemotherapeutic agents,
members of the cardiac aminoglycoside family were repeatedly identifıed as
potential therapeutic agents for MB. These fındings were validated in multiple
MB-derived cell lines which showed high rates of growth inhibition by cardiac
aminoglycosides compared to controls. To evaluate if this growth inhibition in
vitro correlated to prolonged survival in vivo, an extensively characterized pa-
tient-derived orthotopic-xenograft (PDOX) model of Group 4 MB (ICb-
1078MB) was treated with digoxin (2mg/kg i.p.) for 2 cycles of 14 days. Digoxin
treatment signifıcantly prolonged survival to 113 days from amedian of 92 days
in untreated controls (p0.001). Histological evaluation of recurrent tumors
following digoxin treatment demonstrated changes in the pattern of tumor
spread, vascularity and necrosis compared to untreated controls. Conclusions:
Leveraging big data in the domains of pharmacogenomics and the notion of
drug functional networks and driver signaling pathways represents a powerful
tool to repurpose known drugs for new indications in pediatric cancers. Using
this integrative biology approach, we identifıed the cardiac aminoglycosides
family generally and Digoxin, specifıcally, as potential novel agents in the treat-
ment of pediatric medulloblastoma.
#3215 Therapeutic potential of dual-function small molecules for breast
cancers. Nicole Nicholas,1 Alfredo Velena,1 Scott Grindrod,2 Mira Jung1.
1Georgetown University, Washington, DC; 2Shuttle Pharmaceuticals INC, Rock-
ville, MD.
Epigenetic silencing of tumor suppressors is an important mechanism in tu-
mor initiation and progression. A tumor suppressor gene, BRCA1, is part of
complex molecules in the repair of DNA double-strand breaks (DSBs), and loss
of BRCA1 contributes to both sporadic and inherited breast tumor progression.
Furthermore, recent studies have shown that the ataxia-telangiectasia mutated
(ATM) activity is abnormal in breast cancer. Therefore, we tested the hypothesis
that the dual-functional drug that fused the HDAC inhibitor with an ATM
activator may enhance killing of breast cancer (BC) cells by increasing ATM
activation. In addition, the expression of ATM may enhance the synergistic
antitumor effects of HDAC inhibitors in combination with radiotherapy. To
determine theHDAC inhibitory potency, SP-1-303was screened against a panel
of Class I and Class II HDAC enzymes in vitro and identifıed as a pan-HDAC
inhibitor (IC50120 nM). Western blot confırmed that SP-1-303 increased
acetylated histone H3/H4, -tubulin, and phosphorylation of ATM within 30
min - 4 h in a time-dependent manner. Using two ER positive BC cell lines
(MCF7 and T-47D), two triple negative breast cancer (TNBC) cell lines (MDA-
MB-231 and HCC 1937), and one normal breast epithelial cell line as a control
(MCF10A), the effects of SP-1-303 on cell growth and cell death were examined
by performing cytotoxicity assays and flow cytometry. SAHA and Tamoxifen
were used as controls. SP-1-303 conferred the values of cytotoxicity (IC50) for
the ER positive BC cells in a range of 0.25-0.4M,while the values are in a range
of 1-3 M for TNBC and 12 M for normal breast epithelial cells, respectively.
Flow cytometry (FACS) analyses demonstrated signifıcant increases inG1 arrest
(81%) in MCF7 cells and a further enhancement in the G1 phase (91%) in
combinationwith radiation. The data implies themechanismof action from this
drug—cancer cells are being arrested in theG1 phase of the cell cycle, a radiation
sensitive phase, suggesting that SP-1-303 may have a synergistic effect with
radiation on cell killing. Taken together, SP-1-303 had the largest impact on ER
positive breast cancer over TNBC. These data imply that an increased cell death
is occurring in ER positive breast cancers from these dual-action molecules
throughHDAC inhibition and increased ATM activation, suggesting that SP-1-
303 alone or its combination with radiotherapy may improve clinical effıcacy.
#3216 Attenuation of pancreatic tumor growth by a small molecule tubu-
lin inhibitor. Vivek K. Kashyap, Bilal B. Hafeez, Qinghui Wang, Saini Setua,
Andrew Massey, Aditya Ganju, Murali M. . Yallapu, Duane D. Miller, Wei Li,
Meena Jaggi, Subhash C. Chauhan. University of Tennessee Health Science Cen-
ter, Memphis, TN.
Introduction: Pancreatic cancer (PanCa) is one of the most fatal cancers and
is ranked as the fourth common cause of cancer-related deaths among bothmen
and women in the US. The management of PanCa is exceptionally diffıcult due
to the extremely poor response to available chemotherapeutic drugs. Microtu-
bules are dynamic structures composed of --tubulin heterodimers that are
essential in cell division and are important targets for several clinical drugs
(paclitaxel, docetaxel and vinblastine). However, clinical use of these tubulin-
targeting drugs have toxicity and drug resistance issues in cancer patients. Thus,
identifıcation of more potent non-toxic inhibitors of -tubulin is urgently re-
quired for cancer therapy purposes. In this study, we have identifıed a synthetic
compound (ABI-231) which is a potent inhibitor of -tubulin and evaluated its
therapeutic effıcacy against PanCa in vitro, and in vivomodel systems.Methods:
ABI-231 ((2-(1H-indol-3-yl)-1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl)) -
methanonewas synthesized and characterized in our department. Effect of ABI-
231 on proliferation, migration and invasion of human PanCa cells (ASPC1,
HPAFII, andPANC1)was performedby in vitro functional assays (MTS,wound
healing, and Boyden chamber migrations). Effect of ABI-231 on the expression
of -tubulin isoforms was determined and compared with other clinical inhib-
itors of -tubulin by Western blot, and qRT-PCR. Moreover, the effect of ABI-
231 on the expression of-tubulin III in PanCa cells was determined by confocal
microscopy. Therapeutic effıcacy of ABI-231 against PanCa was evaluated in an
ectopic xenograft mouse model. Results: ABI-231 treatment inhibited cell pro-
liferation, invasion, migration and colony formation abilities of PanCa cells in a
dose-dependent manner (1-100 nM) compared to vehicle treated group. Aber-
rant expression of-tubulin III is involved in aggressiveness and drug resistance
of various type of cancers including PanCa. ABI-231 effectively inhibited the
protein levels and mRNA expression of total -tubulin (TBB), TBB1, TBB2c,
TBB3 and TBB4 in PanCa cells via destabilization. Our confocal microscopy
results further showed inhibition of -tubulin in ABI-231 treated PanCa cells.
Upregulation of micro RNA 200c (miR-200c) has been shown to inhibit the
expression of -tubulin III in cancer cells. ABI-231 treatment of PanCa cells
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showed signifıcant (p0.01) induction of miR-200c as determined by qRT-
PCR. ABI-231 administration (intra-tumoral; 50g/mouse), three times/week
signifıcantly (p0.01) inhibited the growth of ASPC1 cells derived xenograft
tumors in athymic nude mice. Conclusion: Taken together, our results suggest
that ABI-231 is a potent -tubulin inhibitor and chemotherapeutic agent which
could be used for the treatment of pancreatic cancer.
#3217 Novel prostamide, 15-deoxy-delta12,14 prostamide J2, displays ac-
tivity against melanoma in vitro and in vivo: potential role of endoplasmic
reticulum stress. Daniel A. Ladin, Li V. Yang, Timothy L. Fitzgerald, Rukiyah
Van Dross. East Carolina Univ., Greenville, NC.
Melanoma is themost aggressive and deadly form of cutaneous neoplasm in the
United States, representing a major clinical challenge. Our lab previously demon-
strated that the endocannabinoid, arachidonoyl ethanolamide (AEA), induced cell
death in non-melanoma skin cancer (NMSC) cells through the cyclooxygenase-2
(COX-2) mediated formation of novel J-series prostamides (PMJs). We were the
fırst to chemically synthesize the primarymetabolite, 15-deoxy-
12,14 prostamide J2
(15d-PMJ2), which displayed potent and selective cytotoxicity in NMSC cells. As
such, we hypothesize that the selective cytotoxicity of 15d-PMJ2 would be observed
in other forms of skin cancer, includingmelanoma. B16F10murinemelanoma cells
and nontumorigenic Melan-A cells were treated with different concentrations of
15d-PMJ2 for 24 hours and cell viability wasmeasured usingMTS assays. At 5M,
15d-PMJ2 decreased viability by 63% in B16F10 cells, while Melan-A viability was
not affected. To verify that cell deathwas due to apoptosis, the cleavage of apoptotic
markers caspase-3 and PARP was examined by conducting Western blot analysis.
15d-PMJ2 markedly increased caspase-3 and PARP cleavage only in B16F10 mela-
noma cells. Previous studies in NMSC indicated that 15d-PMJ2 induced ER-stress
and apoptosis. To investigate the mechanism of 15d-PMJ2-mediated death in mel-
anoma, we examined ER-stress responses. Melan-A and B16F10 melanoma cells
were treated with 5M15d-PMJ2 and evaluated for CHOP10 and p-PERK expres-
sion by Western blot analysis. B16F10, but not Melan-A cells exhibited a notable
increase in CHOP10 and p-PERK expression when treated with 15d-PMJ2. To fur-
ther examine the role of ER-stress on 15d-PMJ2 mediated apoptosis, B16F10 cells
were pretreated with the ER-stress inhibitors salubrinal and 4-phenylbutyric acid
(PBA).Both salubrinal andPBAdecreasedactivationof caspase-3/7, suggesting that
ER-stress plays an important role in 15d-PMJ2mediated tumor cell death. Todeter-
mine the anti-melanoma activity of 15d-PMJ2 in vivo, B16F10 allograft tumors
grown inC57BL/6miceweredosed subcutaneouslywith0.5or5.0mg/kg15d-PMJ2
for 5 days. Tumors treated with 15d-PMJ2 exhibited signifıcantly reduced growth
and mean weights compared to vehicle and untreated animals. TUNEL analysis of
tumor tissues indicateda largepresenceofnecrotic andapoptotic cells in15d-PMJ2-
treated tumors compared to vehicle and untreated tumors. To determine whether
15d-PMJ2 inducedER-stress invivo, tumorswereassayed forp-PERKandCHOP10
levels by immunohistochemistry (IHC). These markers were signifıcantly elevated
in 15d-PMJ2-treated tumors. Similarly, the viability of primarypatient-derivedmel-
anomacellswas signifıcantlydecreasedby15d-PMJ2.These fındings suggest that the
novel prostamide, 15d-PMJ2, possesses potent and selective anti-melanoma activity
in vitro and in vivo.
#3218 Molecular function of PARP inhibition in glioblastoma. Christo-
pher Aldrighetti, Barbara Huebert, Delphine Quenet. University of Vermont,
Burlington, VT.
Glioblastoma (GBM) is the most common primary malignant brain tumor,
whose major biomarkers are the DNAmethylation status of the promoter for O6-
methylguanine-DNA-methyltransferase (MGMT) and the loss/mutation of the tu-
mor suppressor phosphatase and tensin homolog (PTEN). Despite treatment com-
bining surgery, radiotherapy and chemotherapy with the alkylating agent
temozolomide (TMZ), patient survival remains poor and recurrence is virtually
inevitable, due to TMZ resistance. Poly(ADP-ribose)polymerase-1 (PARP-1) is a
nuclear protein involved inmultiple facets of DNA repair and transcriptional regu-
lation. This enzyme catalyses the transfer and polymerization of ADP ribose units
from NAD to form branched polymers of ADP-ribose, called poly(ADP-ribose)
(PAR), covalently attached to heterologous acceptor proteins or PARP-1 itself.
There is a growing interest in PARP inhibitors (PARPi) for their clinical potential in
cancer treatment. Because of the importance of PARP-1 activity in themaintenance
of genomic integrity and DNA repair, treatment with PARPi as adjuvant to TMZ
chemotherapy can be benefıcial in GBM. PARPi are currently in clinical trials for
patients with GBM (NCT02152982, NCT01390571, NCT01514201), and one of
themis aphase II/III studyof thePARPiveliparib forpatientswithnewly-diagnosed
GBM (NCT02152982). However, the molecular role of PARP-1 and its activity in
GBM remains elusive. Using cellular andmolecular approach, we are assessing the
effectiveness of the PARPi veliparib compared to standard treatment with TMZ in
PTEN-mutated GBM and TMZ-resistant GBM cell lines. By understanding the
biology of PARP inhibition inGBM,wewill establish a specifıcmolecular signature
that predicts the effıcacy of PARPi treatment in patients diagnosed with GBM.
#3219 Targeting lipidmetabolismandER stress in renal cell carcinomaby
englerinA.Ayse Batova,1 DiegoAltomare,2 KimE. Creek,2 Robert K. Naviaux,1
Lin Wang,1 Kefeng Li,1 Erica Green,2 Richard Williams,1 Jane C. Naviaux,1
Mitchell Diccianni,1 Alice L. Yu1. 1UCSD, San Diego, CA; 2University of South
Carolina, Columbia, SC.
Renal cell carcinoma (RCC) is among the top tenmost common forms of cancer
and is the leading malignancy of the kidney. Clear cell renal carcinoma (cc-RCC),
the most frequent type of RCC, is one of the most refractory cancers with an inci-
dence that is on the rise. The two-year survival rate for patients with metastatic
disease is under 20% despite approved targeted therapies. Hence, there is an urgent
need to investigate novel agents. Screening of plant extracts in search of new anti-
cancer agents resulted in the discovery of englerin A (EA), a guaiane sesquiterpene
with potent cytotoxicity against RCC and a small subset of other cancers. Although
a few cellular targets have been identifıed for EA, in most instances, modulation of
these targets required concentrations of EA much higher than that required to kill
tumor cells highly sensitive to EA. Hence, it is still not clear what mechanisms
account for the cytotoxicity of EA in tumor cells highly sensitive to EA. Unlike any
prior study, the current study used a systems biology approach to explore themech-
anism(s) of action of EA.Metabolomics analyses were conducted after treatment of
humanRCCA498 cells with 100 nMEA for 24 and 48 h. Pathway analysis revealed
that 88% of themetabolic disturbance associated with englerin A at 24 hwas due to
changes in lipid metabolism. In particular, among the top metabolites, several cer-
amidesandglucosylceramides increasedup to18-and178-fold, respectively.On the
other hand, all sphingomyelins decreased up to 5.5-fold. Furthermore, EA induced
depletion in phosphatidylcholine, phosphatidylglycerol, and phosphatidylethano-
lamine phospholipids. At 48 h of englerin A treatment, the main fındings from
pathway analysis were the accumulation of fatty acylcarnitine derivatives, purines,
pyrimidines, and phosphatidyl serine phospholipids, as well as the depletion of re-
duced glutathione indicating dysfunctional mitochondria and oxidative stress.
Moreover, microarray analyses determined that EA (100 nM) induced ER stress
signaling and an acute inflammatory response including interferon signaling, likely
due to the generation of ceramideswhichwere toxic to bothA498 andUO-31 renal
cancer cells. Quantitative PCR and Western Blot analyses confırmed that EA in-
duced both the unfolded protein and acute inflammatory response. Furthermore,
fluorescence confocal microscopy revealed that EA at 25 nM disrupted the mor-
phology of the ER confırming the deleterious effect of EA on the ER. Collectively,
our fındings suggest that cc-RCC is highly sensitive to disruptions in lipid metabo-
lism and ER stress and that these vulnerabilities can be targeted for the treatment of
cc-RCC and possibly other lipid storing cancers. Furthermore, our results also sug-
gest that ceramidesmay be amediator of someof the actions of EA. Lastly, the acute
inflammatory response induced by EAmaymediate anti-tumor immunity.
#3220 Smallmolecules related to adrenomedullin reduce tumorburden in
a mouse model of colitis-associated colon cancer. Laura Ochoa-Callejero,1
Josune García-Sanmartín,1 Sonia Martínez-Herrero,1 Susana Rubio-Media-
villa,2 Alfredo Martínez1. 1Ctr. for Biomedical Research of La Rioja (CIBIR),
Logrono, Spain; 2Hospital San Pedro, Logrono, Spain.
Adrenomedullin (AM) expression is elevated in colon cancer patients and a
correlation between higher AM levels and lower disease-free survival has been
described in Japan. Nevertheless, the influence of AM in colon cancer is some-
what controversial: on the one hand, antibodies against either the peptide or the
receptor reduce the growth of xenografted tumors, whereas application of the
peptide clearly reduces inflammation and clinical severity in human and mouse
models of colitis, which is an important risk factor for colon cancer. To investi-
gate the contribution of AM and its gene-related peptide, proadrenomedullin
N-terminal 20 peptide (PAMP), to the progression and potential treatment of
colon cancer we have studied the effects of several small molecules (SM) related
to AM and PAMP on a mouse model of colon cancer. Colon tumors were
induced by intraperitoneal injection of a carcinogen: 10 mg/Kg azoxymethane,
followed by 3 cycles of a colitis-inducing chemical: 2.5% dextran sulfate sodium
(DSS) in the drinkingwater for aweek followed by 2weeks of regularwater. Four
SM were tested: 16311 (a negative modulator of AM), 145425 (a positive mod-
ulator of AM), 87877 (a negative modulator of PAMP), and 106221 (a positive
modulator of PAMP). For each SM, 4 experimental groups ofmaleC57BL6mice
were used: i) Control group (injected with vehicle and drank regular water); ii)
ControlSM (vehicle, regular water, and injected with the SM 3 times a week at
a concentration of 20 nm/Kg); iii) Cancer group (injected with AOM and drank
DSS); and iv) CancerSM (treated with AOM, DSS, and the SM). At the end of
the experimental procedures, animals were sacrifıced and the colon was ex-
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tracted and analyzed. None of the mice belonging to groups i and ii developed
any tumor or had any pathological fınding, indicating that the SMs do not
present overt toxicity. All mice in groups iii and iv developed colon neoplasias
ranging from carcinomas in situ to adenocarcinomas. No signifıcant differences
were found among mice treated with PAMPmodulators indicating that PAMP
may not play a major role in colon cancer or that the PAMP-related SMs were
not very effective. On the other hand, mice that received SM 16311 had a higher
severity index (p0.001) and weight loss (p0.05) than their control counter-
parts, whereasmice injectedwith SM145425had a lower number of tumors than
their controls (p0.001). These results suggest that AM may have a protective
role during the progression phase of colon cancer, and that treatment with AM
or with positive modulator SMs may represent a novel treatment for colon
cancer. This study was funded by Instituto de Salud Carlos III (PI13/02166),
FEDER, and Junta Provincial de La Rioja de la Asociación Española Contra el
Cáncer (AECC).
#3221 Kevetrin induces p53-dependent and independent cell cycle arrest
and apoptosis in ovarian cancer cell lines representing heterogeneous histol-
ogies. Ashok Kumar,1 David P. Brennan,1 Karima Chafai-Fadela,1 Sylvia A.
Holden,1 Siya Ram,1 Geoffrey I. Shapiro,2 Krishna Menon1. 1Cellceutix Corpo-
ration, Beverly, MA; 2Dana-Farber Cancer Institute, Boston, MA.
Ovarian cancer (OC) is a molecularly and histologically heterogeneous dis-
ease; however, standard treatment is the same for all subtypes. High-grade se-
rous OC initially responds to chemotherapy; however, low-grade serous and
clear cell OC are relatively chemoresistant. Limited treatment options are avail-
able upon recurrence. p53mutations are found in over 90%of high-grade serous
OC. Low-grade serous OC harbor wild type p53, but contain other mutations.
During later stages of OC, tumors are a heterogeneous population of mutant
cells; thus, development of a novel drug that addresses these molecular differ-
ences is highly desirable. Previously, we showed that Kevetrin stabilized wild
type p53 and induced transcriptional targets in human lung carcinoma. We
sought to validate Kevetrin as a potential treatment for OC with varied p53
status. Endometrioid carcinoma (A2780, wt p53), atypical non-serous clear cell
(SKOV-3, deleted p53), and high-grade serous (OVCAR-3,mutant p53)OC cell
lines were treated with Kevetrin. Kevetrin induced apoptosis in all three OC
cell lines, as assayed by cleavage of PARP and caspase-3. Studies showed signif-
icant increases in p53 and p21 protein levels in A2780 cells in 24 to 48 hours;
however, in OVCAR-3, Kevetrin downregulated oncogenic mutant p53. RNA
levels of p53 and p21 were quantifıed by qRT-PCR 8 to 72 hours after treatment.
No signifıcant changes were observed in p53mRNA, whereas an increase in p21
mRNAwas observed in all three cell lines. InA2780, Kevetrin also induced levels
of PUMA in a dose-dependent manner. To establish that Kevetrin mediates
increased p21 expression requiring p53 in A2780 cells, p53 was depleted by
siRNA. p53 depletion reduced p21 expression, as assayed by FACS, indicating
p53 directs p21 expression in a dose-dependent manner after Kevetrin treat-
ment. In an in vivo xenograft study in immunocompromised nudemice bearing
established A2780 tumors, Kevetrin treatment inhibited tumor growth at well-
tolerated doses. Themode of action in vivo also showed enhanced expression of
p21 in tumor tissue, indicating p53 pathway activation in A2780 tumors. In
contrast, in SKOV-3 cells and xenografts, a p53 independent increase in p21
expression was observed. In OVCAR-3 cells,Kevetrin altered the expression of
three microRNAs (miRNA-27a, miRNA-1274b, miRNA-25), that are known to
be dysregulated inOC, in a time-dependentmanner. To gain further insight into
the mechanism of action in cells with diverse p53 status, RNA-Seq is being
performed in the three cell lines and tumor tissue from mice before and after
Kevetrin exposure. In summary, Kevetrin has promise as an effective therapeu-
tic agent for endometrioid, non-serous clear cell, and high-grade serous OC,
with molecularly diverse p53 status. A Phase 1 clinical study was completed and
a Phase 2 clinical study in ovarian cancer is scheduled to begin January 2017.
#3222 Disulfıram equivalent to doxorubicin in reducing quantitative os-
teosarcomametastatic tumor burden in a validated orthotopicmousemodel.
Mitchell S. Fourman,1 Adel Mahjoub,2 Jared A. Crasto,1 Jonathan Mandell,2
David C. Hirsch,1 Jessica Tebbets,2 Rebbeca Watters,2 Kurt R. Weiss2. 1Univer-
sity of PittsburghMedical Center, Pittsburgh, PA; 2University of Pittsburgh, Pitts-
burgh, PA.
Introduction: The fıve-year survival of patients with osteosarcoma (OS) with
lung metastases is as low as 15%. Our group has shown that disulfıram, a FDA-
approved aldehyde dehydrogenase inhibitor, inhibit osteosarcoma proliferation
and metastasis in vitro. Here we compare the quantitative effects of disulfıram
and doxorubicin on metastatic OS burden in a orthotopic mouse model using
near-infrared indocyanine green (ICG) angiography. Methodology: In an IA-
CUC-approved protocol, 60 immunocompetent balb/c mice were given tibial
trans-physeal injections of 500KK7M2mouse OS cells into their left hindlimbs.
Legs were amputated 4 weeks after OS injection, andmice were euthanized with
ex vivo lung retrieval 10 weeks after OS injection. Animals in the doxorubicin
group (n20) were administered 2 mg/kg retro-orbitally each week, starting 2
weeks after OS injection to simulate the start of therapy only after a clinical
tumor was palpable. Disulfıram (n20) 50mg/kg was administered retro-orbit-
ally daily, also starting 2 weeks after OS injection. Controls (n20) received no
therapy. Quantitative near-infrared imaging of the hindlimb and lungs was per-
formed by injecting 20 uL of 25 mg/cc ICG retro-orbitally 24 hours prior to
amputation and lung salvage, respectively. ICG reliably extravasates specifıcally
into tumor mass when injected 24 hours prior to fluorescence measurements.
Fluorescence analysis was performed using Novadaq SPY (Novadaq, Bonita
Springs, FL) andNIH ImageJ (Bethesda,MD). Statistical analysiswas performed
using Prism 6.0 (GraphPad, LaJolla CA) using Fisher’s Exact Test and a one-way
analysis of variance with Tukey’s post-test as indicated. Signifıcance was defıned
as p .05. All numbers are represented as mean	 standard deviation, and are
described in arbitrary perfusion units (APU). Results: Both disulfıram (2.4	 1.7
APU) and doxorubicin (0.8	 1.7 APU)-treated animals demonstrated a signif-
icantly decreased metastatic tumor burden compared to untreated controls
(6.4 	 3.4 APU, p  .01). This fınding was independent of hindlimb fluores-
cence (p .05). No signifıcant differences were noted between the doxorubicin
and disulfıram groups using Tukey’s post-test (p .76). Nineteen of 20 control
animals developed metastatic disease, compared to nine of 19 surviving disul-
fıram-treated and two of 12 surviving doxorubicin-treated (both p  .01) ani-
mals. No animals died prematurely in the control group, while one animal died
in the disulfıramgroup (5%mortality) and eight animals died in the doxorubicin
group (40%mortality, p .05 compared to controls). Conclusion: In ourmodel
ofmetastatic OS, disulfıram appears to have potent anti-metastatic properties. It
may also be better tolerated by hosts.Molecular analysis of disulfıram and doxo-
rubicin-treated primary and metastatic tumors is ongoing, which can help us
understand the mechanism behind disulfıram’s anti-tumor effect.
#3223 Novel tubulin inhibitor DJ101 targets the colchicine binding site
and suppresses melanoma growth and metastasis. Kinsie Arnst, Dong-Jin
Hwang, Duane D. Miller, Wei Li. Univ. of Tennessee Health Science Ctr., Mem-
phis, TN.
Interfering with microtubule dynamics is a validated approach for anti-
cancer treatment and by selectively targeting the colchicine binding site on
tubulin, microtubule destabilizing agents can evade mechanisms of drug
resistance that commonly develop with other antimitotic agents such as
taxanes and vinca alkaloids. We have recently reported the discovery of a
potent and metabolically stable tubulin inhibitor (DJ101) that specifıcally
targets the colchicine binding site on the beta tubulin subunit, disrupts tu-
bulin polymerization and effectively circumvents drug efflux pumps that
decrease the effıcacy of existing tubulin inhibitors. To further pre-clinically
evaluate DJ101 as a novel tubulin inhibitor and confırm its mechanism of
action, we fırst visually demonstrated the ability of DJ101 to disrupt micro-
tubule dynamics and elucidated the changes in microtubule structure and
cell morphology through immunofluorescence techniques. Furthermore, we
solved the crystal structure of DJ101 in complex with tubulin to determine its
molecular interactions with the protein. We then demonstrated the signifı-
cant in vitro potency of DJ101 against a panel of metastatic melanoma cell
lines harboring major clinically relevant mutations observed in tumors and
also validated its cytotoxicity against a broader array of NCI-60 cell lines.
Further analysis revealed that DJ101 effectively thwarted anchorage-depen-
dent melanoma colony formation and drastically hindered cell mobility and
motility of those cancer cells. We further ascertained that DJ101 shows neg-
ligible off-target effects for major physiologically important receptors and
ion channels, suggesting a good safety profıle. Encouraged by the prelimi-
nary results from our in vitro assessment, we evaluated the in vivo activity of
DJ101 in two different mouse models. At a dose of 30 mg/kg via i.p. injec-
tions, DJ101 nearly completely suppressed tumor growth in a human A375
melanoma xenograft model. It also appreciably inhibited metastasis poten-
tial in a murine B16F10 lung metastasis model at the same dose. In conclu-
sion, we have described a microtubule destabilizing agent that targets the
colchicine binding site on tubulin, confırmed its mechanism action, deter-
mined its potency in a vast array of cancer cell lines, particularly metastatic
melanoma, demonstrated its inhibitory effect on cellular proliferation, mo-
tility and migration, and evaluated its anticancer potential in terms of tumor
growth inhibition and metastasis in two in vivo models. Our fındings offer a
compelling rationale to further develop and advance DJ101 as a tubulin
inhibitor for cancer therapy.
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#3224 Cucurbitacin D inhibits prostate tumor growth via targeting glu-
cose metabolism. Mohammed Sikander,1 Bilal Bin Hafeez,1 Shabnam Malik,1
AdityaGanju,1 Fathi T.Halaweish,2MuraliMohanYallapu,1 SubhashC. Brook-
ings,1 Meena Jaggi1. 1University of Tennessee Health Science Center, Memphis,
TN; 2South Dakota State University, Brookings, SD.
Background: Emergence of hormone-refractory PrCa (HRPC) after the anti-
androgen therapy, cancermetastasis and chemo-resistance are themajor hurdle
for the treatment of prostate cancer (PrCa) patients. Accumulative evidence
suggests that altered glucosemetabolism is one of themechanisms formetastatic
PrCa cell survival and chemo-resistance. Therefore, identifıcation and genera-
tion of natural/or synthetic pharmacological agents that can limit altered glu-
cose metabolism might be highly useful for the treatment of metastatic and
chemo-resistant PrCa. Cucurbitacins have shown potent anti-cancer and gluca-
gonostic activities along with severe liver toxicity. Thus, a focus on developing
different analogues of cucurbitacin is being pursued by scientifıc community.
Herein, we report that Cucurbitacin D, an analogue of cucurbitacin, suppresses
the growth of metastatic PrCa cells in vitro and in vivo via targeting glucose
metabolism and its associatedmolecular targets.Methods:HRPC cells (PC3 and
DU145) was used as a model system. Effect of Cucurbitacin D on PrCa cell
proliferation and apoptosis was performed byMTS, xCELLigence and Annexin
V assays. Effect of Cucurbitacin D on clonogenic potential of PrCa cells was
examined by colony formation assay. In silico analysis was performed to study if
Cucurbitacin D interacts with GLUT1 receptor. Effect of Cucurbitacin D on
glucose metabolism of PrCa cells was performed bymetabolic shift, glucose and
lactate uptake assays. Effect of CucurbitacinD treatment on keymolecules of cell
survival and glucose metabolism signaling pathways in PrCa cells was analyzed
byWestern blot and qRT-PCR analyses. Therapeutic effıcacy of Cucurbitacin D
against PrCa was evaluated in an ectopic PrCa xenograft mouse model. Results:
Cucurbitacin D (0.1 to 1 M) treatment signifıcantly (P0.01) inhibited the
growth and metastatic potential of PrCa cells in a dose-dependent manner.
Cucurbitacin D effectively induced apoptosis in PrCa cells as shown by en-
hanced Annexin V staining and PARP protein cleavage and arrested cells in
G2/Mphase viamodulation of cell cycle regulatory proteins (inhibition of cyclin
D1/E and Mcl-1 and induction of p21 and p27). Cucurbitacin D treatment
dose-dependently decreased the lactate production, glucose uptake in PrCa cells
which was correlated by suppressed expression of GLUT1 and its profıcient
dockingwithGLUT1 (with binding energy for this complex is -8.5 kcalmol-1). It
has been reported that miR-132 targets the GLUT1, interestingly, Cucurbitacin
D replenished the expression of miR-132 in PrCa cells. These growth inhibitory
effects of Cucurbitacin Dwere confırmed in PrCa xenograft mousemodel while
administered intra-tumorally (1 mg/kg body weight thrice/week). Conclusion:
Our results suggest that Cucurbitacin D is a novel modulator of glucose metab-
olismwhich could be a promising therapeuticmodality alone or in combination
of conventional chemotherapeutic agents for PrCa.
#3225 SHetA2 targets mortalin-p53 interaction in differential induction
of apoptosis in ovarian cancer over normal cells. Satish Kumar Ramraj,1 Rich-
ard Pelikan,2 Vishal Chandra,1 Doris Benbrook1. 1University of Oklahoma
Health Sciences Center, OklahomaCity, OK; 2OklahomaMedical Research Foun-
dation, Oklahoma City, OK.
Introduction: Identical TP53 mutations observed in fallopian tube pre-neo-
plastic lesions and high grade serous ovarian cancer (HGSOC) from the same
patient suggest that these mutations drive ovarian carcinogenesis. While ele-
vated p53 protein expression caused by these mutations increase cell survival,
persistently high levels can cause apoptosis. Mortalin (HSPA9) is a chaperone
protein which plays a major role in protecting cancer cells from p53-mediated
apoptosis by binding to p53 and preventing it from translocating to the nucleus
where it transactivates apoptosis-inducing genes and to themitochondria where
it inhibits Bcl-2 and induces Bax pore formation. SHetA2 is an anti-cancer drug
that bindsmortalin and induces apoptosis in cancer, but not in normal cells.We
hypothesized that release of p53 frommortalin contributes to themechanism of
SHetA2-induced apoptosis in cancer, but not in normal cells. Methods: SHetA2
effects on mortalin and p53 interaction and subcellular localization were evalu-
ated by co-immunoprecipitation in cell extracts and fluorescent cytochemistry
of human ovarian cancer cell lines and tissues and human fallopian tube secre-
tory epithelial cells (hFTSECs) cultures and tissues. Effects of SHetA2 and ma-
nipulations ofmortalin and p53 expression, function and localization in ovarian
cancer cells were measured using the MTS dye to detect viable cells, Flow cyto-
metric analysis of Annexin-V/PI cell staining to detect apoptosis and a PCR
array tomeasure p53 regulated gene expression. Results: Mortalin bound to p53
in protein extracts of cultures and tissues from ovarian cancer, but not from
hFTSECs. SHetA2 caused dose-responsive apoptosis in associationwith nuclear
and mitochondrial accumulation of p53 in ovarian cancer cell lines harboring
wild type or S215R, L130V TP53 mutants, but not in hFTSECs. Mortalin over-
expression or p53 knockdown reduced SHetA2 cytotoxicity in ovarian cancer
cells. Mortalin knockdown, p53 overexpression, and chemical inhibitors of p53
transcription (Pifıthrin-) and p53 mitochondrial localization (Pifıthrin-)
were lethal to ovarian cancer cells at effective concentrations and therefore in-
effective tools for probing the SHetA2 apoptosis mechanism. In the A2780 cell
line containing wild type p53, SHetA2 caused2 fold regulation of p53 signal-
ing genes (p21, FOXO3, IGF1R, MDM4, SESN2, SIAH1, DR5, CAPS2, CCNE1,
CDC25A, E2F1, PCNA and TP63). Our analysis of p53 mutations using The
Cancer GenomeAtlas (TCGA) data revealed that majority of HGSOC exhibited
p53 mutations spanning from exon 3-9, with the majority being missense mu-
tations in the DNA binding domain associated with increased protein stability
and gain of function. Conclusion: Release of wild type and mutant p53 proteins
from mortalin contributes to the mechanism of SHetA2-induced apoptosis in
cancer cells and does not occur in healthy cells. Funded by R01CA196200.
#3226 The apoptotic mechanism of MT-6, a mitotic inducer, in human
ovarian cancer cells. Chen Mei-Chuan. Taipei Medical University, Taipei, Tai-
wan.
Patients with ovarian cancer are typically diagnosed at an advanced stage, result-
ing inpoorprognosis since there are currentlyno effective early-detection screening
tests for women at average-risk for ovarian cancer. Here, we investigated the effects
of MT-6, a derivative of moscatilin, in ovarian cancer cells. Our investigation
showed thatMT-6 inhibited theproliferationandviabilityofSKOV3ovariancancer
cells with submicromolar IC50 values. MT-6-treated SKOV3 cells showed signifı-
cant cell cycle arrest atG2/Mphase, followedbyan increase in theproportionof cells
in a sub-G1 phase. In addition, MT-6 induced a concentration-dependent increase
in mitotic markers, mitotic kinases, cell cycle regulators of G2/M transition, and
apoptosis-relatedmarkers in SKOV3cells.MT-6 treatment also inducedmitochon-
drialmembranepotential loss, JNKactivation, andDR5expression.Cotreatment of
cells with the JNK inhibitor SP600125 considerably attenuatedMT-6-induced apo-
ptosis, mitochondriamembrane potential loss, DR5 upregulation, and suppression
of cell viability. MT-6 also inhibited tumor growth in an SKOV3 xenograft model
without signifıcant body weight loss. Together, our fındings suggest that MT-6 is a
potent anticancer agent with tumor-suppressive activity in vitro and in vivo that
could be further investigated for ovarian cancer therapy in the future.
#3227 Novel Marmelin analog DBQ targets Notch signaling pathway in
colon cancer stem cells. Dharmalingam Subramaniam,1 Sivapriya Pon-
nurangam,1 Prasad R. Dandawate,1 Gaurav Kaushik,1 OssamaW. Tawfık,1 Roy
A. Jensen,1 Santimukul Santra,2 Subhash B. Padhye,3 Scott J. Weir,1 Shrikant
Anant1. 1University of Kansas Medical Center, Kansas City, KS; 2Pittsburg State
University, Pittsburg, KS; 3Interdisciplinary Science and Technology Research
Academy, Pune, India.
Background: Colon cancer is the second leading cause of death in the United
States. Previously, we have reported that the identifıcation of a novel compound
Marmelin fromAegle marmelos and potent anti-colon cancer activity.We have
developed novel Marmelin analogue THB from this structure showed potent
anti-cancer activity and its inhibitory constant value was 10 M. From this, we
developed a second series of analogs, of which DBQ is even more potent than
THB. The current study is designed to determine whether DBQ affects colon
cancer stem cells and identify a mechanism. Method: Colon cancer cell lines
HCT116 and SW480 and normal colon epithelial cells were used in the study.
Cell growth was measured by hexoseaminidase and clonogenicity assays. Apo-
ptosis was determined by measuring caspase 3/7 activities. Colosphere forma-
tion assay and FACS sorting were used for stem cells. For in vivo effects, we
performed studies in HCT116 tumor xenografts. Immunohistochemistry was
determined for stem cell markers and Notch signaling proteins. Results: DBQ
treatment induced signifıcant dose-dependent inhibition of proliferation and
colony formation of HCT116 and SW480 cells, but not that of the normal FHC
colon epithelial cells. DBQ also signifıcantly reduced the number and size of
colospheres, suggesting effects on stem cells. In addition, DBQ reduced the
levels of colon stemcellmarker proteinsDCLK1, LGR5, andCD44.Weobtained
further confırmation by flow cytometry, where DBQ treatment reduced the
number of DCLK1 cells. We next determined whether DBQ affects the Notch
signaling, a pathway that is important in maintaining CSC population.
Notch receptor and its ligands are up-regulated in human colon cancer tis-
sues. DBQ treatment signifıcantly downregulated the expression of all four
Notch isoforms, its ligands Jagged 1, 2 and DLL1, 3, 4 and downstream target
protein Hes1. Notch activation requires cleavage by the -secretase complex.
DBQ treatment inhibits the expression of -secretase complex proteins. To
confırm that DBQ effect is thorough downregulating Notch activation, we
ectopically expressed the Notch Intracellular domain. DBQ effect was signif-
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icantly mitigated in this condition. To determine the effect of DBQ on tumor
growth in vivo, we administered DBQ intraperitoneally (5 mg/kg bw) every
day for 21 days in mice carrying HCT116 tumor xenografts. DBQ treatment
signifıcantly suppressed tumor xenograft growth, with notably lower tumor
volume and weight. Western blot and immunohistochemistry analyses dem-
onstrated signifıcant inhibition of CSC marker proteins DCLK1, LGR5 and
CD44 and also the Notch signaling proteins in the DBQ-treated xenograft
tissues. Conclusion: Together, these data suggest that DBQ treatment sup-
presses colon cancer growth that targets stem cells in part by inhibiting
Notch signaling pathway.
#3228 Development and characterization of in vitro assays to detect and
quantitate tubulysin B hydrazide in biological samples.Nikki L. Parker, Jon-
athan M. Shillingford, Melissa Nelson, Joseph A. Reddy, Christopher P. Lea-
mon. Endocyte, West Lafayette, IN.
EC1456 is a folate-targeted small molecule drug conjugate (SMDC) of tubu-
lysin B hydrazide (TubBH) that is currently in Phase I clinical studies for treat-
ment of patients with folate receptor (FR)-positive tumors. The ability to detect,
quantitate, and localize drug in tissues and biological fluids is particularly im-
portant for the characterization of its biodistribution and pharmacodynamic
properties. To aid in the biological characterization of our targeted TubBH con-
jugates, our lab had a rabbit polyclonal antibody produced against TubBH for
use in various assays. An IgG-purifıed fraction of antiserumwas used to develop
competitive ELISA, immunohistochemical, and flow cytometry methods for
analysis of biological samples, such as xenograft tumors from animals dosed
with drug. Before assay development, a direct ELISA was performed to deter-
mine antibody titer and specifıcity. TheTubBHantibody showed excellent bind-
ing to immobilized TubBH, whereas a rabbit IgG negative control antibody had
minimal binding. Next, a competitive ELISA was developed in which soluble
TubBH competed for antibody binding to immobilized antigen.Multiple exper-
imental parameters were optimized, including coating antigen concentration,
antibody dilution, and sample matrix extraction method. Using the optimized
conditions, the resulting standard curves for TubBH in acetonitrile-extracted
KB tumor sample matrix showed good sensitivity and dose-response. It was
determined that, in addition to untargeted TubBH, the antibody could also be
used to quantitate intact EC1456, as well as a metabolite of the drug lacking the
hydrazide. The utility of the antibody was further demonstrated utilizing a
PSMA-targeted version ofTubBH.Once optimized, the ELISAmethodwas used
to analyze FR-positive KB and FR-negative A549 xenograft tumor homogenates
from animals dosed with either EC1456 or untargeted TubBH. The levels of
TubBH were higher 4h-post EC1456 dose in the FR-positive KB tumors com-
pared to the FR-negative A549 tumors; however, levels were similar after 24h.
Moreover, untargeted TubBH resulted in lower tumor concentrations of the
drug compared to EC1456 in KB tumors. An immunohistochemical method
developed using the antibody showed strong, focal, cytoplasmic staining in
FFPE tumor sections of KB tumors from animals dosed with EC1456, while no
staining was observed in tumors from undosed animals. Finally, the antibody
was successfully used to detect cell surface FR-bound EC1456 on fıxed and
unfıxed KB cells in vitro by flow cytometry. This experiment confırmed that the
antibody is able to recognize the conjugate even when it is situated in the FR
binding pocket. Collectively, these results show that this antibody against
TubBH can be used as a powerful tool for analysis of tumor drug uptake for
folate-targeted TubBH in xenograft models and could hold great potential for
use in patient sample analysis as well.
#3229 Drug repurposing of topiramate in obesity-driven endometrial
cancer.Arthur-QuanTran, Stephanie A. Sullivan, Chunxiao Zhou,DavidKauf-
man, Victoria Bae-Jump. University of North Carolina at Chapel Hill, Chapel
Hill, NC.
Introduction: Topiramate (TPM) is a B-D-fructopyranose sulfamate that acts by
inhibitingcarbonicanhydrases (CAs)andhasbeen implicatedasanovel inhibitorof
angiogenesis. TPM is commonly used for the treatment of epilepsy and migraine
headaches; however, when combined with phentermine, TPM can induce weight
loss. Due to its weight loss and anti-angiogenic properties, we assessed TPM’s po-
tential as an anti-tumorigenic agent in endometrial cancer (EC), a highly obesity-
driven disease. Methods: Cell proliferation was assessed by MTT assay after expo-
sure to TPM for 72 hours in the HEC-1A, KLE, Ishikawa and ECC-1 EC cell lines.
Two representative cell lines, ECC-1 and Ishikawa, were used to analyze apoptosis,
cell cycle progression, cell adhesion and invasion. Apoptosis was analyzed by An-
nexin V-FITC assay. Inhibition of adhesion and invasion by TPMwere assessed by
ELISA and transwell assay, respectively. Cell cycle progression was evaluated by
Cellometer.Western immunoblottingwas performed to assess downstream targets
of the MAPK and mTOR pathways. The LKB1fl/flp53fl/fl EC mouse model was uti-
lized to assess the in vivo effects of TPM. AdCre was injected at six weeks of age to
induce invasive EC. Eight wks following AdCre injection, mice (N10 per group)
were treatedwithplaceboorTPM(200mg/kg/day, oral) for fourweeks.The expres-
sion of phosphorylated-S6 and Ki-67 was assessed by IHC. Results: TPM inhibited
cell proliferation in a dose dependent manner in all four EC cell lines (IC50
range1500-3000 mM). Treatment with TPM resulted in G1 arrest and induction
of apoptosis (p0.05). TPMalso reduced adhesion and invasion in the EC cell lines
(p0.05), with a corresponding decrease in VEGF expression. In addition, TPM
signifıcantly inhibited phosphorylation of p42/44 and S6 in the EC cell lines. Lastly,
TPMdecreased tumorweight in the LKB1fl/flp53fl/flmice by 68%compared to those
treatedwith placebo (p0.05), accompanied by a reduction in Ki-67 and phospho-
rylated-S6 expression (p0.05). Conclusion: TPM inhibited cell proliferation and
tumor growth in EC cell lines and an EC mouse model. Therefore, TPM may be
worthy of drug repurposing as an anti-tumorigenic agent in EC, with the potential
added benefıt of weight loss in this obesity-linked disease.
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#3231 Identifying high quality, potent and selective pyrimidinylthienopy-
rrolone inhibitors of ERK1/2 kinase: LY3214996. Gaiying Zhao, William T.
McMillen, Shufen Cai, Baohui Zhao, Matthew Whitesell, Wenjuan Wu, Karen
Huss, Bryan Anderson, Xiu-Juan Yuan, Susan Jaken, Lisa Kindler, Robert S.
Flack, Denis McCann, Brian Mathes, Andrew J. Dropsey, Jennie Walgren, Eu-
nice Yuen, JasonManro, Xueqian Gong, Guillermo Cortez, JohnathanMcLean,
Michael J. Rodriguez, RamonV. Tiu, Shripad V. Bhagwat, Sajan Joseph. Eli Lilly
and Company, Indianapolis, IN.
The ERK/MAPK pathway plays a central role in the regulation of critical
cellular processes and is activated in more than 30% of human cancers. While
targeting upstream nodes with RAF and MEK inhibitors has proven effective
clinically, resistance frequently develops through reactivation of the pathway.
ERK inhibitors have the potential to address resistance caused by ERK reactiva-
tion. Herein, a potent, selective small molecule ERK1/2 inhibitor is described.
LY3214996 possesses an optimal balance of potency (hERK1 IC50 5 nM, hERK2
IC50 5nM, pRSK IC50 0.43 M), solubility (FaSSIF solubility at pH 6.5 0.133
M), PK properties (dog, AUCoral 23800 nM*hr, CL 12.1 mL/min/kg, bioavail-
ability 75.4%), IVTI (TED50 16 mg/kg pRSK1) and demonstrated signifıcant
in vivo effıcacy in several human cancer xenograft models. LY3214996 is cur-
rently undergoing early clinical evaluation.
#3232 Development of novel Btk inhibitor, CB988 targering ibrutinib-
resistant Btk C481S mutant.Wataru Kawahata, Tokiko Asami, Takayuki Irie,
Yasuhiro Iwata, Takao Kiyoi, Masaaki Sawa. Carna Biosciences, Kobe, Japan.
Introduction: Bruton’s tyrosine kinase (Btk) is a member of the Tec family of
cytoplasmic tyrosine kinase. Btk plays a crucial role in the BCR signaling, essen-
tial for B-cell development, and Btk has been recognized as a validated thera-
peutic target for B-cell malignancies. Ibrutinib, the fırst FDA-approved Btk in-
hibitor, has been appreciated as a promising targeted therapy for patients with
Bcell malignancies. Ibrutinib covalently binds to the Cys481 residue of Btk to
inhibit Btk enzymatic activity, but recent studies suggested that the C481S mu-
tation in Btk disrupts the irreversible binding of ibrutinib, and resulted in ibru-
tinib-resistance in patients. Therefore a non-covalent Btk inhibitor is highly
demanded to overcome ibrutinib resistance. Material and methods: We pro-
duced two conformationally different Btks, an activated form of Btk (Btk[A])
and an unactivated form of Btk (Btk[U]) by treating Btk protein with ATP
(autophosphorylation) or with Lambda Protein Phosphatase (dephosphoryla-
tion), respectively. To evaluate cellular potency of Btk inhibitors, phosphoryla-
tions of Btk and PLC-  were analyzed by Western blotting in Ramos cells, a
human Burkitt’s lymphoma cell line. ABC-type DLBCL cell line, OCI-Ly10 was
used to evaluate anti-tumor effıcacy of Btk inhibitors. The ibrutinib-resistant
Btk[C481S] mutant was produced to assess effıcacy of compounds against the
drug resistant enzyme. Kinase selectivity profıling was performed to confırm
inhibitor selectivity. Results: Based on structure activity relationship studies, we
identifıed a novel Btk inhibitor, CB988 as a highly selective non-covalent Btk
inhibitor. CB988 exhibited remarkable activity for the both conformations of
Btks with sub-nanomolar enzyme inhibitory potency in a reversible manner
(IC50  0.78 and 0.09 nM for Btk[A] and Btk[U], respectively). These results
suggested that CB988 preferentially binds to an inactive conformation of Btk. In
cellular assays, CB988 strongly reduced Tyr223 phosphorylation of Btk at nano-
molar concentration, and decreased phosphorylation of PLC- in Ramos cells.
Furthermore, CB988 signifıcantly reduced the proliferation of OCI-Ly10 cells.
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More importantly, CB988 potently inhibited the ibrutinib-resistant Btk[C481S]
mutant in vitro (IC50 0.6 nM), which differs from other covalent Btk inhibi-
tors. Conclusions: Btk[C481S] mutation have been reported in ibrutinib re-
lapsed CLL and MCL patients. Novel non-covalent Btk inhibitor, CB988
strongly inhibited Btk[C481S] mutant enzyme, suggesting that CB988 has the
potential to treat patients who are relapsed/refractory to ibrutinib.
#3233 Design and synthesis of BPR1K653 and its derivatives targeting the
back pocket of Aurora kinases for selective isoform inhibition. Ya-Hui Chi,
Chun-Ping Chang, Yi-Yu Ke, Wen-Hsing Lin, Hsing-Pang Hsieh. National
Health Research Institutes, Miaoli County, Taiwan.
Guided by computational modeling addressing the back pocket of Aurora
kinases, several novel chemical analogs of BPR1K653were designed and synthe-
sized in two steps with 30-66% yields. All synthesized compounds were evalu-
ated by Aurora-A and Aurora-B enzymatic kinase activity assays, cellular phos-
phorylation inhibition assays and cell viability assays. Of them, compound 3a
that exhibits no substitution at phenylurea showed similar inhibition activity to
Aurora-A and -B. Compounds 3b and 3c which harbor tertiary amino group at
meta position of phenylurea showed 10-15 fold inhibition selectivity for Auro-
ra-A over Aurora-B in enzymatic assays. In addition, 3b and 3c were more than
200 fold superior in inhibiting T-loop autophosphorylation of Aurora-A com-
pared to Aurora-B in HCT116 colon carcinoma cells. On the other hand, com-
pound 3d with a 4-hydroxypiperidinyl group at ortho position preserves Auro-
ra-B inhibition activity.Molecular docking study revealed that the various steric
interaction between the compound and residues in the back pocket of Aurora
kinases determines their inhibition selectivity.
#3234 Development of potent and selective antibody-drug conjugates
with pyrrole-based KSP inhibitors as novel payload class. Hans-Georg Le-
rchen,1 Sven Wittrock,2 Nils Griebenow,1 Mario Lobell,1 Anne-Sophie Reb-
stock,1 Yolanda Cancho-Grande,1 Beatrix Stelte-Ludwig,1 Christoph Mahlert,1
Simone Greven,1 Anette Sommer,2 Sandra Berndt,2 Carsten Terjung,1 Heiner
Apeler,1 Bertolt Kreft,2 Rolf Jautelat1. 1Bayer AG, Wuppertal, Germany; 2Bayer
AG, Berlin, Germany.
The number of cytotoxic payload classes with different modes-of-action
which have been successfully employed in antibody-drug conjugates (ADC) is
still rather limited. So far, onlyADCswithmicrotubule inhibitors, DNAbinding
payloads or topoisomerase I inhibitors have been advanced into clinical testing.
To this end, the identifıcation of ADC payload classes with a novel mode of
action will increase therapeutic options and potentially help to overcome resis-
tance. Inhibitors of kinesin spindle protein (KSP/Eg5) have generated interest
due to their high antitumor potency. However, transferring the preclinical po-
tency of small molecule KSP inhibitors (KSPis) into highly effıcient clinical
regimens with a suffıcient therapeutic window has remained challenging. We
have investigated a new pyrrole subclass of KSPis which showed subnanomolar
potency against a large panel of tumor cell lines for their utility as a novel payload
class in ADCs. Towards this goal different attachment sites for linkers have been
explored in the KSPi molecule which were found compatible with cleavable
and/or non-cleavable linkers. Subnanomolar potency and selectivity of ADCs
with antibodies targeting either HER2, EGFR or TWEAKR could be demon-
strated in vitro. For selected ADCs, the intracellular traffıcking and metabolite
formationwas investigated andKSP inhibitionwas confırmed as theADCmode
of action. Depending on the linker composition differential profıles of the ADC
metabolites with regard to efflux, cellular permeation, and bystander effect have
been achieved. Moreover, specifıc accumulation in the tumor versus other tis-
sues was demonstrated in biodistribution studies in vivo. In conclusion, KSP
inhibitors have been established as a versatile new payload class for the genera-
tion of highly potent and selective ADCs.
#3235 Development of potent and selective inhibitors for ATR: An adju-
vant forDNAdamage based chemotherapeutics. SivapriyaKirubakaran,Vijay
Thiruvenkatam Thiruvenkatam, Althaf Shaik. Indian institute of technology,
Gandhinagar, India.
Inhibition of DNA damage checkpoint and repair function has been a chal-
lenging as well a promising approach in cancer therapy. ATR kinase is one of the
keymediator of DNAdamage responsewhich induces cell cycle arrest andDNA
repair via its downstream proteins. Blocking ATR has proved to prevent the
Chk1 pathway from stalled replication fork and enhances the replication stress
and premature mitotic entry. In addition inhibition of ATR can selectively sen-
sitize the cancer cell to radio and chemotherapy, due to defective DNA damage
signaling through the loss of ATM or p53 mutation in cancer cell. Due to its
inherent role in DDR, ATR has been explored as a potential target in enhancing
the effect of radiation and chemo-therapy in addition enables highly selective
targeting the cancer cell through synthetic lethality. Despite the attractiveness of
ATR inhibition in the cancer therapy, specifıc ATR inhibitors have remained
indefınable. Further, there is a limited proof of concept data for ATR inhibition.
Considering these facts and challenges we will be presenting some preliminary
results with respect to In-silico design, synthesis and evolution of potential and
selective inhibitors for ATR. References Llona-Minguez, S., Hoglund, A.,
Jacques, S. A., Koolmeister, T. & Helleday, T. Chemical strategies for develop-
ment of ATR inhibitors. Expert Rev Mol Med 9, 10 (2014). Wagner, J. M. &
Kaufmann, S. H. Prospects for the Use of ATR Inhibitors to Treat Cancer. Phar-
maceuticals 3, 1311-1334 (2010). Liu, Q. et al. Characterization of Torin2, an
ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res 73, 2574-
2586 (2013).
#3236 Delivering selective and cell-active inhibitors of V804M mutant
RET kinase through structure-guided drug discovery. Allan M. Jordan,1 Re-
becca Newton,1 BohdanWaszkowycz,1 Richard Bayliss,2 Habiba Begum,1 Dan-
iel Burschowsky,3 Aude Echalier,3 Samantha Hitchin,1 Colin Hutton,1 Shaun
Johns,1 Stuart Jones,1 Li-Ying Lin,3 Mark Richards,2 Chitra Seewooruthun,3
Alex Stowell,1 Ian Waddell,1 Mandy Watson,1 Donald Ogilvie1. 1Cancer Re-
search UK Manchester Inst., Manchester, United Kingdom; 2University of Leeds,
Leeds, United Kingdom; 3University of Leicester, Leicester, United Kingdom.
Activating gene fusions in the RET receptor tyrosine kinase have been found
to drive 1-2% of lung adenocarcinomas and therefore offer an attractive target
for targeted therapy. Whilst non-selective tyrosine kinase inhibitors with RET
activity are effıcacious in this setting, their use is generally limited by dose lim-
iting toxicity associated with their more potent activity versus other targets,
specifıcally KDR (VEGFR2) in the case of cabozantinib and vandetanib. Given
this limitation, there is considerable interest in developingmore selective inhib-
itors of RET kinase. Tyrosine kinase inhibitors are prone to early clinical failure
due tomutations in the kinase ATPase binding domain, which render the kinase
catalytically active but no longer sensitive to drug treatment. Such mutations
often occur in the so-called “gatekeeper” region and in this specifıc case, resis-
tance is predicted to arise from a Val-Met or Val-Leu mutation at residue 804.
Through a combination of computational methods, structural biology and drug
design, we have identifıed and further optimized a series of inhibitors of the
V804Mmutant RET kinase which show sub-micromolar cellular activity in cells
driven byV804MRET.Moreover, these agents show excellent selectivity against
thewtRETkinase andKDR.As such, these agentsmayoffer valuable start-points
for second-generation RET inhibitors for use in patents who relapse after treat-
ment with fırst generation selective RET inhibitors.
#3237 Development of direct inhibitors of KRAS mutants for the treat-
ment of cancer. Xiaohong Tian, Guoyan Geng, Jian Hui Wu. Lady Davis Insti-
tute, Jewish General Hospital, Montréal, Quebec, Canada.
OncogenicKRASmutations occur in 30%of all human cancer.All attempts
to develop inhibitors of oncogenic KRAS have failed to reach the clinic for
decades and promote the perception of ’undruggable’ KRAS proteins. Given the
recent advances in understanding of mechanism of oncogenic KRAS, there is
renewed enthusiasm toward development of direct inhibitors of KRAS. In a
recent breakthrough, Shokat et al. discovered a “pocket,‘ where they designed a
series of mutant-specifıc small molecular inhibitors that are covalently binding
to the mutant Cys 12 in KRAS protein (KRAS G12C). In human cancer, G12C,
G12D and G12V are the predominant KRAS mutants. The G12C mutation
accounts for 29,700 new diagnoses annually (lung, colon and pancreatic). The
G12D andG12V, annually account for 53,700 and 39,100 new cancer diagnoses,
respectively, occurring most frequently in Pancreatic ductal adenocarcinoma
(PDAC) (51%G12D and 30%G12V) and colorectal cancer (45%G12D and 27%
G12V). Thus, there is an urgent need to develop direct inhibitor of KRAS 12D
and 12V mutants. By computer-aided drug design techniques, we have discov-
ered a series of novel chemical inhibitors that potently inhibit KRAS G12D
mutant in reporter assays usingHEK293 cells and inWestern blot analysis using
PANC10.05 and SNU-C2B cells, which express endogenous KRAS G12D mu-
tant. The direct binding of our compounds with KRAS G12D mutant was con-
fırmed by Surface Plasmon Resonance (SPR) analysis. Our compounds also
inhibit KRASG12Vmutant. Chemical optimization of these initial hits as direct
inhibitors of multiple KRAS mutants is in progress.
#3238 Design, synthesis and evaluation of a novel series of BLM helicase
inhibitors. Yusuf Ali, Xiangrong Chen, SimonWard, Frances Pearl. University
of Sussex, Brighton, United Kingdom.
Helicases are enzymes that unwind DNA or RNA. As a result, they are de-
scribed as ‘guardians of the genome’ and play roles in key processes such asDNA
replication, RNA transcription, translation, DNA repair and DNA recombina-
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tion. Certain helicases have also been implicated in the DNA damage response
(DDR) andwith an increasing interest growing in these enzymes,more helicases
are likely to be implicated in DNA damage repair as understanding grows. Tar-
geting proteins involved in DDR has recently gained promise as a selective che-
motherapeutic strategy due to the high level of genomic instability in cancer
cells. One of these helicases, Bloom syndrome protein (BLM), is particularly
implicated in homologous recombination (HR), a key pathway in the repair of
double strand breaks. The role of BLM in DNA repair and its complex interac-
tions with key proteins in these networks suggest it may be a good chemother-
apeutic target. The fırst BLM helicase inhibitor to be characterised was ML216.
However, ML216 does not seem to be highly specifıc to BLM as it also inhibits
DNA unwinding of the closely related WRN helicase. Furthermore, the poor
solubility and permeability of this series which would prevent reliable in-vitro
data from being generated. Potent and selective inhibitors targeting BLM heli-
case can increase understanding of its function in human cells and role and
relevance in DNA damage repair. Furthermore, the tool can also be used in
synthetic lethality screens to assess the potential of BLM inhibition as a chemo-
therapeutic option. As a result, the discovery of a novel series of potent and
selective BLM inhibitors with improved physiochemical properties were sought.
In this work, 672 active hits of the NIH Molecular Libraries Small Molecule
Repository (MLSMR) qHTS screen onBLMhelicase, which have been deposited
in the PubChemBioAssay database [AID2386], were analysed and 10 serieswere
selected for in-house testing on a BLM helicase unwinding assay. This led to the
medicinal chemistry investigation of a single series that is relatively potent com-
pared to inhibitors of other human helicases. Efforts have been undertaken to
establish primary SAR and to improve the activity of the compound to0.1M
as well as further improve the physiochemical properties of this series. This
series has shown positive binding data usingmicroscale thermophoresis (MST).
Very few inhibitors of human helicases have used biophysical techniques to
validate binding and the use of MST for this purpose has not been reported.
Further biological efforts are underway to validate the series through in vitro
SCE assays and co-crystallisation methods.
#3239 Selective tumor targeting with 5-substituted pyrrolo[2,3-d]pyrimi-
dineswith heteroatombridge substitution.AleemGangjee,1 RishabhMohan,1
Manasa Ravindra,1 Adrianne Wallace-Povirk,2 Carrie O’Connor,2 Aamod
Dekhne,2 Zhanjun Hou,2 Larry H.Matherly2. 1Duquesne University, Pittsburgh,
PA; 2Wayne State University School of Medicine, Detroit, MI.
Three specialized systems exist for membrane transport of folates and antifo-
lates across biological membranes. The reduced folate carrier (RFC) is ubiqui-
tously expressed in tumors and normal tissues. Folate receptors (FR)  and ,
and the proton-coupled folate receptor (PCFT) exhibit narrow patterns of tissue
expression and serve specialized physiologic roles. FRs are expressed in a num-
ber of cancer cells (e.g., FR in ovarian cancer and non-small cell lung cancer;
FR in acute myelogenous leukemia), whereas PCFT is expressed in a large
number of human solid tumors but not leukemias. FRs are either inaccessible to
the circulation (FR) or are nonfunctional (FR) in normal tissues. PCFT trans-
port is limited in most normal tissues, given the requirement of acidic pH for
optimal activity. These properties facilitate tumor targeting of cytotoxic com-
pounds with specifıcities for PCFT or/and FR transport. Clinically used antifo-
lates such as methotrexate and pemetrexed are substrates for RFC and their
uptake by both normal tissues and tumors confers dose-limiting toxicity due to
limited tumor selectivity. We previously reported a 5-substituted pyrrolo[2,3-
d]pyrimidine antifolate with a 4-carbon bridge and a phenyl glutamate side
chain (AGF127). Previous studies of related 6-substituted pyrrolo[2,3-d]pyrimi-
dines established that the nature and length of the bridge region plays an impor-
tant role in determining tumor cell potency and transport selectivity. Thus, it
was of interest to vary the length and insert heteroatoms into the side chain
-(CH2)4- of AGF127, including -(CH2)n-S- (compound 1, n 3 and compound
2, n  4) and -(CH2)n-O- (compound 3, n 3 and compound 4, n  4), to
determine the impact on drug potency and transport selectivity. The novel an-
alogswere tested as growth inhibitors against engineeredChinese hamster ovary
(CHO) cells expressing human FR (RT16), RFC (PC43-10), and PCFT (R2/
PCFT4). AGF127 showed potent inhibition of CHO cells expressing FR (IC50
 8.6 nM), and reduced activity toward CHO cells expressing RFC (57 nM) or
PCFT (840 nM). Compounds 1, 2, and 3, showed reduced inhibitions toward
FR-expressing RT16 cells (4-35-fold) compared to AGF127; however, com-
pound 4 was equipotent to AGF127. Like AGF127, none of the series were
effective PCFT substrates. Compound 3, like AGF127, inhibited RFC-express-
ing PC43-10 cells (IC50 37 nM); RFC activity was reduced 6- to20-fold for
compounds 1, 2, and 4. Toward FR-, RFC-, and PCFT-expressing KB human
tumor cells, the order of potency was 4 AGF127 2 3 1. Compound 4
was also more active (15-fold) than pemetrexed with KB cells. Collectively, the
potent and selective activity of compound 4 toward FR-expressing tumor cells
and limited activity toward RFC-expressing cells offers signifıcant advantages
over AGF127 and clinically used non-targeted antifolates, suggesting that fur-
ther preclinical evaluation is warranted.
#3240 Designer peptides targeting epidermal growth factor as novel anti-
breast cancer agents. Emmanuel Yawson,1 Angel Garcia,2 Husamuldeen
Dhari,1 Rajendram V. Rajnarayanan1. 1SUNY at Buffalo, East Amherst, NY;
2Tougaloo College, Jackson, MS.
Triple negative breast cancer (TBNC) is the only major type of breast cancer
for which no specifıc FDA approved target therapy is available to improve pa-
tient outcomes. TNBC lacks the usual breast cancer targets estrogen receptor
(ER), progesterone receptor (PR) and HER2/neu receptor. Studies have shown
that TBNC does express the epidermal growth factor receptor and has recently
emerged as one of the potential targets inTBNC. Epidermal growth factor (EGF)
mediates several cellular functions and processes such as survival, motility, dif-
ferentiation, proliferation and death. When it is released by epidermal tissues,
EGF binds to cell surface receptors such as the Epidermal growth factor receptor
(EGFR) causing a conformational changewhich facilitates its dimerization. This
receptor dimerization triggers its tyrosine kinase-mediated signal transduction
activity. Apart from EGF, EGFR is reported to bind to Transforming growth
factor alpha (TGF-), Argos and Potato Carboxypeptidase inhibitor (PCI). All
of these proteins have unique structuralmotifs which targets EGFR. PCI’s struc-
ture consisting of three disulfıde bridges presents a unique knot like binding
motif resembling EGF and is able to compete with EGF for its binding site on
EGFR preventing receptor dimerization thereby antagonizing its action. We
have used an integrated computational drug discovery approach to generate
several PCI derived peptidic ligands targeting EGFR protein-protein interac-
tions. PCI- peptides bind to EGFR in silico and block EGFR-mediated cell
growth, proliferation andmigration in vitro. We believe these designer peptidic
inhibitors will provide structural andmechanistic clues towards novel therapeu-
tics to combat TNBC.
#3241 Peptide power: A PSMA-targeted CT20 nanoparticle to fıght pros-
tate cancer. Orielyz Flores,1 Daniel Nierenberg,1 Ana C. Carr,1 Rania
Bassiouni,1 Arati Limaye,1 Santimukul Santra,1 Charalambos Kaittanis,2 An-
nette Khaled,1 Jesus Manuel Perez3. 1University of Central Flordia, Orlando, FL;
2Memorial Sloan Kettering Cancer Center, New York, NY; 3Cedar Sinai Medical
Center, Los Angeles, CA.
Chemotherapeutic agents within targeted nanoparticles typically trigger cell
death not only in tumors cells but also in normal cells that non-specifıcally
uptake these nanoparticles. An alternative approach would be to target the de-
livery of a therapeutic agent that is toxic to cancer cells while less toxic to non-
tumor cells. To accomplish this, a Bax-derived peptide (CT20) was developed as
a selective cancer-targeting agent, and a folate-decorated hyperbranched poly-
ester (HBPE) nanoparticle was employed to deliver the peptide to prostate-
specifıc membrane antigen (PSMA) () prostate cancer cells. The receptor-
targeting capability of folic acid towards PSMA () in prostate cancer was
examined using a fluorescence activatable probe, folate-S-S-doxorubicin, and
the PSMA inhibitor 2-PMPA. Additionally, a folate-decorated HBPE nanopar-
ticle was utilized to targeted-deliver the CT20 peptide to prostate cancer cells in
vitro as well as in athymic mice. CT20-encapsulated folate (folate-CT20) nano-
particles were used to determine cell cytotoxicity against PSMA-positive and
-negative cells using flow cytometry. Furthermore, cytotoxicity of folate-CT20
nanoparticles towards murine macrophages was evaluated to determine the
consequences of non-specifıc uptake; the FDA-approved doxorubicin was used
for comparison. Cell death associated with CT20 was determined through a
violet ratiometric membrane asymmetry probe combined with SYTOX AAD-
vanced dead cell stain to evaluatemembrane asymmetry andmembrane perme-
ability. Folate-CT20 nanoparticles’ tumor-targeting and tumor-killing effıcacy
was evaluated in athymicmice bearingPSMA() tumors andPSMA(-) tumors.
Nanoparticles were delivered intravenously through the tail vein and the tumor
size was assessed with calipers and ultrasound. Folate-S-S-Doxorubicin was up-
taken specifıcally by PSMA () prostate cancer cells showing fluorescence
within 12 hours and cell death within 24 hours. Cells that were preincubated
with 2-PMPA followed by folate-S-S-Doxorubicin demonstrated no cell-associ-
ated fluorescence or cytotoxicity. Similarly, folate-decorated nanoparticles were
only internalized by PSMA () cells. Cytotoxicity of folate-CT20 nanoparticles
towards PSMA () cancer cells occurred within 48 hours, while no changes
occurred in PSMA (-) cells. When murine macrophages were treated with
PSMA-targeting nanocarriers and doxorubicin individually, signifıcant cyto-
toxicity only occurred in doxorubicin-exposed cells. In vivo, folate-CT20 nano-
particles were capable of preventing further PSMA () tumor growth and
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caused PSMA () tumor regression in some cases.Moreover, minimal liver and
spleen damage was observed. Herein, we demonstrate that the CT20 peptide is
capable of displaying specifıc lethality towards PSMA () prostate cancer cells
and that folate-CT20 nanoparticles are promising vehicles to deliver CT20 in
vitro and in vivo.
#3242 Synthetic analogs of curcumin as modulators of multidrug resis-
tance-linked ABC transporters.Megumi Obara,1 ShinobuOhnuma,1 Eduardo
E. Chufan,2 Masaharu Ishida,1 Katsuyoshi Kudoh,1 Norihiko Sugisawa,1 Hideo
Ohtsuka,1 Takeshi Naitoh,1 Hiroyuki Shibata,3 Yoshiharu Iwabuchi,4 Suresh V.
Ambudkar,2 Michiaki Unno1. 1Tohoku University Graduate School of Medicine,
Sendai, Japan; 2Laboratory of Cell Biology, Center for Cancer Research, National
Cancer Institute, NIH, Bethesda, MD; 3Depertment of Clinical Oncology, Akita
University Graduate School of Medicine, Akita, Japan; 4Department of Organic
Chemistry, Tohoku University Graduate School of Pharmaceutical Sciences, Sen-
dai, Japan.
Cancer patients often develop resistance to anticancer drugs. ATP-binding
cassette (ABC) transporter-mediated drug efflux is one of the mechanisms re-
sponsible for development of resistance to anticancer drugs. The present study
investigates the use of curcumin, a natural product and a dietary constituent of
turmeric, which inhibits the function of three ABC drug transporters including
ABCB1, ABCC1 andABCG2.However, limited bioavailability of curcumin pre-
vents its use formodulation of the function of these transporters in the clinic.We
focused on curcumin analogs that were synthesized at Tohoku University and
have been shown to exhibit higher bioavailability than natural curcumin to test
whether the synthetic analogs also inhibit the function of ABC drug transport-
ers. To investigate this, KB-V1 andK562/BCRP cell lines overexpressingABCB1
and ABCG2were used for the experiments. For these studies, we screened nine-
teen synthetic analogs of curcumin for their effect on the transport function of
ABCB1 andABCG2 by flow cytometry. Four curcumin analogs, GO-Y030, GO-
Y078, GO-Y168 and GO-Y172 inhibited efflux of mitoxantrone mediated by
ABCG2 and sensitizedABCG2-expressingK562 leukemic cells to the anticancer
drug, SN-38 in cell toxicity assays. Some of the curcumin analogs (GO-Y030,
GO-Y078, GO-Y172) stimulated ATPase activity of ABCG2 at nanomolar con-
centrations (EC50  480 	 0.06, 790 	 0.10, 930 	 0.12 nM). In addition,
GO-Y030, GO-Y078, GO-Y168, GO-Y172 analogs also inhibited photolabeling
of ABCG2 inMCF-7-FL plasmamembranes with iodoarylazidoprazosin, which
is transported by this transporter. These data demonstrate that similar to cur-
cumin, synthetic curcumin analogs also interact at the drug-binding pocket of
ABCG2. In aggregate, these results suggest that non-toxic synthetic curcumin
analogs with increased bioavailability may be useful to reverse ABCG2-medi-
ated resistance to anticancer agents.
#3243 Development of specifıc DNA aptamers against programmed cell
death-1 (Anti-PD1-Apt) for diagnosis and treatment of cancers. Santhana
Gowri Thangavelu Devaraj,1 Lokesh Ganesh Lakshmana Rao,2 Youli Zu,1 Jenny
C. Chang,1 Swaminathan P. Iyer1. 1HoustonMethodist Research Institute, Hous-
ton, TX; 2The University of Texas Health Science Center at Houston, Houston,
TX.
Cancer cells have an extraordinary ability to escape immune response by
modulating proteins that regulate immune checkpoints and their cognate li-
gands. Programmed cell death protein (PD-1), a cell surface receptor expressed
on T cells is one such immune checkpoint receptor when bound to its ligands-
PDL1 or PDL2 transmits an inhibitory signal. Such modulation often leads to
inhibition of T-cell activation and subsequent escape of tumors from immune
surveillance. Recently, several FDA approved therapeutic antibodies have been
successfully developed that target PD-1/PD-L1 axis and allow the immune sys-
tem to enhance its anti-cancer effects. Aptamers are synthetic small molecule
ligands composed of short, single-stranded oligonucleotides ranging from 30 to
60 bases in length. Based on their highly specifıc 3-dimensional conformation,
aptamers, analogous to the antibodies can recognize and bind to their targets
with high affınity. Also, the nucleic acid component has several advantages over
the protein counterparts- such as ease of production under less stringent condi-
tions, long shelf life and low cost. Here, we report the development of several
PD-1 specifıc aptamers by systematic evolution of ligands by exponential en-
richment (SELEX) technology against endogenous immunoprecipitated PD-1
protein using DNA library with a complexity of 1014. Following several rounds
of SELEX, the selected aptamers sequenced by high throughput Next-Genera-
tion Sequencing (NGS) were found to have highly conserved regions. Six PD-1
specifıc aptamers (Anti-PD1-Apt) were then assessed for target validation using
leukemic cell lysates (cell lines and primary patient samples) and were found to
bind to the PD-1 in its native state. The selected Anti-PD1-Apt were able to
specifıcally pull down the PD-1 protein from the lysates mimicking PD-1 anti-
body. The specifıc interaction of the Anti-PD1-Apt was also demonstrated by
flow cytometry and fluorescent microscopy. As expected, Anti-PD1-Apt was
able to bind to PD-1 with Kd of  500 picomolar affınity as assessed by Bio-
Layer Interferometry. Furthermore, we also characterized and confırmed Anti-
PD1-Apt biological activity using an PD-1/PD-L1 cell-based assay using PD-1/
NFAT reporter-Jurkat cells. We have observed several fold induction of NFAT
luciferase reporter activity (Relative Luciferase Units) in PD-1/NFAT reporter-
Jurkat cells co-cultured with HEK293 cells overexpressing PD-L1 and TCR ac-
tivator in the presence of Anti-PD1-Apt compared to control. Our preliminary
data also demonstrate robust Anti-PD1 blockade in Mixed Lymphocyte Reac-
tion (MLR) along with induction of Th1 cytokines Interferon-gamma and IL-2
from different donor sets of PBMCs. We will present additional - in vivo anti-
tumor response data at the upcoming AACR Annual Meeting at Washington
DC, 2017.
#3244 Treatment of endometrial cancer cells with a new small tyrosine
kinase inhibitor targeting mutated fıbroblast growth factor receptor-2. Se-
bastien Taurin,1 Chieh-Hsiang Yang,1 Maria Reyes,1 Sungpil Cho,1 Elke A. Jar-
boe,1 Theresa L.Werner,1DemetriusM.Coombs,2 PaulChen,3MargitM. Janát-
Amsbury1. 1University of Utah, Salt Lake City, UT; 2Drexel University College of
Medicine, Philadelphia, PA; 3Advenchen Laboratories, Moorpark, CA.
Endometrial cancer (EC) is the most common uterine malignancy in indus-
trialized countries and is the most frequent gynecologic cancer in the United
States with an estimated 60,050 new cases in 2016. Traditionally observed in
peri-, postmenopausal women, the incidence rate of EC has steadily increased
among younger women of reproductive age over the past two decades partially
owing to a more sedentary lifestyle and rampant obesity epidemic. Surgery in
combination with either radio- and or chemotherapy is commonly curative for
the early stage of the disease. However, patients with recurrent or metastatic
disease, who only respond poorly to cytotoxic chemotherapy are in desperate
need of therapeutic alternatives as are patients of reproductive age. Thus, inno-
vative, safe and more effective therapies are mandated. Several studies have
demonstrated the increased expression of various tyrosine kinase receptors in-
volved in the development of EC. We hypothesized that a targeted therapeutic
approach using a pan-tyrosine kinase inhibitor would prevent the proliferation
and progression of EC. Anlotinib (AL3818) is amulti-targeted receptor tyrosine
kinase inhibitor targeting vascular endothelial growth factor receptors 1 to 3
(VEGFR1-3), stem cell factor receptor (C-kit), platelet-derived growth factor
(PDGF), and fıbroblast growth factor receptors 1 to 3 (FGFR1-3). We tested a
panel of seven human endometrial cancer cell lines (AN3Ca, Ishikawa, HEC1A,
HEC1B, KLE, MFE280 and MFE296) to assess the cytotoxicity of anlotinib in
vitro. A lower IC50 value was observed in AN3Ca cells (25 nM), a cell line
characterized by a high level of expression of an FGFR2 mutant protein, while
cell lines expressing FGFR2 wild-type are less sensitive to anlotinib (HEC1A: 33
M, or HEC1B:36 M). Somatic mutations of FGFR2 have been observed in
12% of EC, indicating the potential for this drug in a subset of EC patients. In
summary, these results suggest improved effıcacy of anlotinib for the treatment
of ECs expressing an increased level of FGFR2 mutant proteins. The safety and
effıcacy of anlotinib are currently being evaluated in an orthotopic AN3Ca
mouse model of EC. Experimental groups include a tumor bearing control not
subjected to any treatment, anlotinib alone, carboplatin/paclitaxel, a combina-
tion of anlotinib and carboplatin/paclitaxel. Primary study endpoints include
tumor growth retardation, the delayed onset of local metastases as well as re-
duced toxicity as secondary endpoint.
#3245 Preclinical evaluation of the imipridone family of small molecules,
including analogues of clinical-stage anti-cancer small molecule ONC201,
reveals potent anti-cancer effects ofONC212. JessicaWagner,1 C. LeahKline,1
Gary Olson,2 Bhaskara Nallaganchu,2 Richard Pottorf,2 Varun Prabhu,3 Martin
Stogniew,3 Joshua Allen,3 Wafık El-Deiry1. 1Fox Chase Cancer Center, Philadel-
phia, PA; 2Provid Pharmaceuticals, Monmouth Junction, NJ; 3Oncoceutics, Phil-
adelphia, PA.
We previously identifıed a novel, potent anti-cancer smallmoleculeONC201,
which upregulates the integrated stress response (ISR) through ATF4/CHOP/
DR5 and acts as a dual inactivator of Akt and ERK, leading to TRAIL gene
activation. After completing a fırst-in-human phase I clinical trial that revealed
exceptional safety, therapeutic pharmacokinetic (PK) profıle and tumor engage-
ment, ONC201 is under investigation in several advanced cancer Phase I/II
trials. Given the unique imipridone core chemical structure of ONC201, we
synthesized a family of analogues in an effort to identify additional chemical
family members with distinct therapeutic properties. Based on in vitro potency
improvements in human cancer cell lines and therapeutic window approxima-
tions with normal human fıbroblasts, select analogues were investigated in ani-
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mals for toxicity, maximum tolerated dose (MTD), and antitumor effıcacy.
ONC212 is one of the most promising new imipridones that was further evalu-
ated to establish the PK profıle, oral bioavailability, and effıcacy in tumor types
that are less sensitive to ONC201. Compared to ONC201, we noted distinct and
more rapid kinetics of activity as well as improved potency in multiple human
cancer cell lines in vitro.ONC212has a broad therapeuticwindow, an acceptable
PK profıle, and is orally well-tolerated in mice. With no evidence of toxicity at
effıcacious doses in both colon and triple negative breast cancer, we have begun
further evaluation of antitumor effıcacy studies in ONC201-resistant tumor
types. Effıcacy studies with ONC212 are ongoing in melanoma models that are
sensitive to ONC212 but less sensitive to ONC201 in vitro. Preliminary data
indicates potent tumor growth reduction by ONC212 in vivo in ONC201-resis-
tantmelanoma xenografts.With a wide safetymargin, potent antitumor activity
in ONC201-insenstive tumors, and drug-like characteristics, ONC212 is being
further developed as a drug candidate from the new imipridone class of com-
pounds that complements the spectrum of activity of ONC201.
#3246 Development of small-molecule STAT3 transcription factor inhib-
itors. Kazi S. Nahar, Shirin Jamshidi, Maria Thanou, David E. Thurston,
Khondaker Miraz Rahman. King’s College London, London, United Kingdom.
Oncogenic transcription factors are an increasingly important target for an-
ticancer therapies, as their inhibition could allow the “reprogramming” of tu-
mour cells, leading to apoptosis or differentiation from the malignant pheno-
type. STAT3 induces the transcription of genes that control differentiation,
inflammation, proliferation, and tumour cell invasion, and its over-expression
has been implicated in many tumour types. Although cancer cells are often
dependent upon activation of STAT3, non-tumour cells are fairly tolerant of loss
of its function, most likely reflecting redundancies in normal signal transduc-
tion. Thus, STAT3 inhibitors have a high therapeutic potential. A combination
of in silico design and pharmacophore-based approaches have been used to
design a novel series of inhibitors capable of disrupting STAT3 dimerisation by
interacting with the hexapeptide pocket of the SH2 domain of the STAT3 pro-
tein.Members of the initialmedicinal chemistry optimisedmature ligand library
had signifıcant STAT3-dimerization inhibition activity with potencies ranging
from 33% to 59% inhibition. They also had sub-micromolar to low micromolar
cytotoxicity (IC50 0.6 M to 2.6 M) in the STAT3-dependent cell line MDA
MB231, with good selectivity ratios compared to STAT3-null cell lines. Three of
the most potent library members were selected for molecular dynamics simula-
tion studies of their interaction with the STAT3 protein, and for their ability to
down-regulate STAT3-dependent genes in cell lines using RT-PCR. In the mo-
lecular dynamics studies it was shown that the compounds interact with eight
key amino acid residues (i.e., Ala703, Pro704, Arg1317, Asn1442, Gln1355,
Gln1357, Thr1354 and Thr1443) within the SH2 domain, and in the RT-PCR
experiments they were found to down-regulate the STAT3-dependent genes
survivin, cyclin D1, fascin and BCL-2 in comparison to the housekeeping gene
GAPDH in the STAT3-dependent cell lineMDAMB 231. Themost active com-
pound was also evaluated in a preliminary human tumour xenograft assay in
immune-compromised mice bearing MDAMB 231 tumours, and was found to
have signifıcant tumour growth inhibition properties (at 0.5 mg/kg, two doses
on day 1 and day 3). Although further work is required to confırm the proposed
mechanism of action, it may be possible to further develop this novel series of
molecules toward clinical evaluation in man.
#3247 Discovery of a novel drug that affects centrosome clustering.Dilan
B. Jaunky, Kevin Larocque, Javier Porro Suardiaz, DanYang, Emma J. Furze, Pat
Forgione, Alisa Piekny. Concordia University, Montreal, Quebec, Canada.
Our goal is to identify molecular regulators of a mechanism that occurs
uniquely in cancer cells, and to develop a selective anti-cancer drug. Most che-
motherapies are non-selective, causing severe side-effects. In additions, cancers
often develop resistance to some of the more commonly used chemotherapies.
To expand the repertoire of available drugs, and to design drugs that are selec-
tive, we need to identify molecules that regulate the physiological changes that
occur primarily in cancer cells. For example, cancer cells in many hard-to-treat
cancers have aberrant centrosomes, which may be supernumerary or frag-
mented. During mitosis, these aberrant centrosomes must cluster to form bipo-
lar spindles for successful division. Thus, targeting a process like centrosome
clustering is ideal, since it is not necessary in healthy cells. We synthesized a
small, stable scaffold with amenability to structure-activity-relationship studies,
and found several analogues with IC50 values 50 nM, depending on the cancer
cell line. Preliminary tests showed that these compounds prevent tumors from
forming and/or cause their regression in vitro. We performed cell biological
studies to characterize their mechanism of action. In several different types of
cancer cells, these compounds causemitotic arrest and centrosome declustering
at concentrations where they have little affect on non-cancerous cells. Live im-
aging revealed that within minutes of adding the compounds to HeLa cells
expressing GFP-tagged tubulin, we observed rapid microtubule depolymeriza-
tion and centrosome declustering. After washing out the compound, microtu-
bule polymerization recovered, but the mitotic spindles were multipolar. Add-
ing similar concentrations of Nocodazole, a microtubule-depolymerizing drug,
also caused rapidmicrotubule depolymerization, but after washing out the drug,
the spindles were bipolar. We are in the process of identifying the molecular
target of these compounds to provide crucial insight to the mechanism govern-
ing centrosome clustering, and are continuing to perform SAR studies to obtain
compounds with higher effıcacy and selectivity.
#3248 Identifıcation and optimization of a highly active, cross reactive
Complex-1 inhibitor. Jeffrey Mowat, Sven Christian, Carolyn Sperl, Alexander
Ehrmann, Stephan Menz, Judith Guenther, Roman Hillig, Marcus Bauser, An-
drea Haegebarth, Wolfgang Schwede. Bayer Pharma AG, Berlin, Germany.
Mitochondria are key regulators of both energy supply and apoptotic cell
death. The mitochondrial electron transport chain (ETC) consists of four en-
zyme complexes that transfer electrons fromNADH to oxygen. During electron
transfer, the ETC pumps protons into the inter-membrane space, generating a
gradient across the innermitochondrialmembrane that is used byComplexV to
drive ATP synthesis. Recent publications have shown that tumor cells harboring
specifıc mutations (LKB1, mIDH and others) are more sensitive to Complex I
inhibition, potentially providing an opportunity for selectively targeting tumor
cells. Based on a high throughput screen (HTS), we identifıed new, albeit mod-
erately active, lead structures with cross reactivity between mouse and human
Complex 1. SAR elaboration of the lead structure allowed for optimization of the
potency, although compounds still suffered from low metabolic stability. Fur-
ther improvement of the in vitro and in vivo PK properties fınally permitted in
vivo animal studies.Herein,we report for the fırst time the preclinical profıle and
structure of a highly active, optimized, human/mouse cross-reactive Complex I
inhibitor that allowed for the further investigation into the therapeutic potential
of Complex I inhibition in cancer.
#3249 Thymoquinone inhibits elongation factor 2 kinase signaling axis by
inducing tumor suppressor miR-603 in triple negative breast cancer cells.
Nashwa N. Kabil, Recep Bayraktar, Nermin Kahraman, Bulent Ozpolat. MD
Anderson Cancer Center, Houston, TX.
Triple negative breast cancer (TNBC), is a highly heterogeneous and aggres-
sive subtype of breast cancer (BC), which poses a signifıcant clinical challenge.
TNBC constitutes about 15-20 % of BC cases, and is characterized by lack of
estrogen (ER), progesterone (PR) and human epidermal growth factor 2 (HER2)
receptors. Thus, patients cannot benefıt from targeted therapies such as anti-
estrogens (eg.Tamoxifen) and anti-HER2 (eg.trastuzumab) treatments. There-
fore, identifıcation of new molecular targets and treatment strategies are highly
warranted to improve patient outcome.We previously reported that elongation
factor 2 kinase (EF-2K) is highly expressed in TNBC cell lines and is associated
with poor patient survival and prognosis. Furthermore, in vivo targeting of
EF-2K by siRNAnano-therapeutics inhibited cell proliferation,migration/inva-
sion, and signifıcantly decreased tumor growth in 2 different orthotopic TNBC
mouse models (MDAMB-231 and MDAMB-436). Collectively, our work sug-
gests that EF-2K is an excellent novel therapeutic target in TNBC. In search of a
potential safe and effective EF-2K inhibitor, we identifıed Thymoquinone (TQ),
a dietary natural compound, known to have diverse anti-cancerous properties in
several in vitro and in vivo models, including TNBC. However, the mechanism
bywhich TQmediates its effects are not well elucidated. Our current study is the
fırst to demonstrate that TQ inhibits protein andmRNAexpression of EF-2K, as
well as its clinically signifıcant downstream targets such as Src/FAK, PI3K/AKT,
and CyclinD1; resulting in a signifıcant decrease in proliferation, migration/
invasion of TNBC cells. To determine the molecular mechanism by which TQ
inhibits EF-2K expression, we investigated if TQ induces tumor suppressor mi-
croRNAs that we identifıed to bind to the 3’-UTR of EF-2K. We found that TQ
inducesmiR-603 expression, which we had reported to directly bind and inhibit
EF-2K expression; resulting in decreased TNBC growth and progression, both
in vitro and in vivo. Furthermore, we showed that inhibition of nuclear factor
kappa B (NF-B) (a well established target for TQ), also induces miR-603 and
inhibits EF-2K expression in TNBC cells. In conclusion, our study is the fırst to
show that TQ treatment decreases EF-2K expression through modulating the
NF-B/miR-603 axis; ultimately resulting in decreased cell proliferation,migra-
tion/invasion of TNBC. Our data suggests a novel molecular mechanism for TQ
that represents a potential therapeutic strategy in inhibiting TNBC tumor
growth and progression.
CANCER CHEMISTRY: Drug Design and Optimization Strategies
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017830
#3250 Computational drug repositioning and biochemical validation of
piperlongumine as a potent therapeutic agent for neuroendocrine prostate
cancer. Kamlesh Kumar Yadav, Khader Shameer, Ben Readhead, Jennifer A.
Stockert, Cordelia Elaiho, Shalini S. Yadav, Benjamin S. Glicksberg, Kipp W.
Johnson, Christine Becker, AndrewKasarskis, AshutoshK. Tewari, Joel T. Dud-
ley. Icahn School of Medicine at Mount Sinai, New York, NY.
Introduction and Objectives: Neuroendocrine prostate cancer (NEPC) is a
highly lethal and drug-resistant variant of prostate cancer (PCa). We have used
a genomics-based drug-repositioning approach and identifıed compounds with
therapeutic activity against NEPC. One of the compounds- piperlongumine
(PL) is a natural product constituent of the fruit of the Long pepper (Piper
longum). The effıcacy of this drug was tested in the NEPC cell line model NCI-
H660 and compared to several other PCa cell lines in a modifıed WST-1 assay.
Pre-clinical testing in mouse xenograft models of NEPC was also undertaken.
Finally, the ability of piperlongumine to inhibit p-STAT3 signaling and promote
apoptosis was measured by western blot analyses. Methods: PCa cell lines (LN-
CaP, 22Rv1, Du145, PC3, H660 and RWPE) were grown in complete media
(RPM1 10%FBS, Advanced DMEM 5%FBS or Keratinocyte-SFM) and treated
with piperlongumine for 3 or 7 days. IC50 valueswere generated fromWSTassay
data using Prism6. Nude mice (n5) were injected with 1.5x106 H660 cells on
each flank, and intraperitoneally administeredwith either 2.5mg/kgPL (n3) or
DMSO (n2) daily for 3 weeks after tumors formed 200mm3 in volume. Tumor
volumewasmeasured daily with calipers.Western blot analyses were performed
on protein lysates extracted from tumors and PCa cells treated with 0-10 Mof
drug. Results: PLwas highly effective in inhibiting the growth ofH660 cells (IC50
 0.4M) compared to LNCaP, 22Rv1, Du145, PC3, and RWPE cells. This was
consistent with an increased level of cPARP1 in H660 cells when compared to
other prostate cancer cell lines. On average, the growth rate of untreated tumors
was 2.7 times greater than those treated with PL. Similar to previous reports
suggesting PL to inhibit STAT3 activity, treated H660 cells exhibited inhibition
of STAT3phosphorylation. Conclusions:Using computational drug reposition-
ing approaches we have identifıed several lead compounds forNEPC.One of the
compound piperlongumine, a water-soluble plant product with no known side
effects inhibits the growth of the highly drug-resistant NEPC cell line H660.
Source of Funding: Deane Prostate Health, Icahn School of Medicine at Mount
Sinai. Both Shalini S Yadav and Kamlesh K Yadav are supported by the Prostate
Cancer Foundation Young Investigator Awards. Research in Dudley’s lab is
supported by grants fromNational Institutes of Health R01 DK098242 and U54
CA189201.
#3251 Evaluating the effıcacy of transferrin-targeted, resveratrol-loaded
liposomes in treating glioblastoma. Aditi Jhaveri, Vladimir Torchilin. North-
eastern University, Boston, MA.
Purpose: This study evaluated the effıcacy of a natural polyphenol resveratrol
(RES) loaded into liposomes (RES-L) which are modifıed with transferrin (Tf)
(Tf-RES-L), to specifıcally direct it to glioblastoma (GBM) cells. RES is known to
act on both the bulk tumor cells (BTCs) as well as the highly resistant tumor-
initiating cell (TIC) population within GBMs. However, low aqueous solubility,
chemical instability, poor pharmacokinetics and low bioavailability severely
limit its use as a free drug. We developed RES-L with an aim to counter these
drawbacks and to eradicate the BTC and TIC populations in GBMs. Since both
these sub-populations also over-express Tf receptors, we exploited this feature
for the target-specifıc delivery of Tf-RES-L in GBM. We hypothesize that Tf-
RES-L will show an improved effıcacy versus the free drug or non-targeted
liposomes and will act as an effıcacious platform for delivery of RES. Methods:
The neurosphere (NS) assay was used to develop TIC models using GBM cell
lines. The NS were characterized using in vitro limiting dilution assays (LDA)
and expression of the surfacemarker CD133. RES-Lswere prepared by thin-fılm
rehydration method and Tf was attached to the liposomes using an in-house
conjugation protocol. Liposomes were characterized for their size, charge, mor-
phology and drug-loading effıcacy. Rhodamine labeled, Tf-targeted formula-
tions were tested for their association with and internalization into cells using
flow cytometry and confocal microscopy, respectively. Cytotoxicity assays, oxi-
dative stress measurements, apoptosis assays and cell-cycle analyses were car-
ried out for the GBM monolayers and NS cultures. In vivo tumor-inhibition
studies were carried out using a mouse model of GBM. Results: NS cultures
showed the presence of TICs as determined fromLDAs andCD-133 expression.
RES inhibited the anchorage-independent growth of GBM NS. All RES formu-
lations induced a time and dose-dependent cytotoxicity in cells. At low concen-
trations, Tf-RES-Ls were signifıcantly more cytotoxic compared to free RES or
RES-L. RES formulations arrested GBM cells in the S-phase of the cell-cycle at
low concentrations and exhibited a pro-oxidant effect at higher concentrations
inducing signifıcant oxidative stress only in GBM cells but not in primary hu-
man astrocytes. Tf-RES-L induced signifıcantly higher levels of apoptosis ac-
companied by activation of caspases 3/7 in GBM cells compared to the free drug
and non-targeted RES-L. The Tf- targeted formulations also associatedwith and
internalized into GBM cells signifıcantly better than the non-targeted counter-
parts. Conclusions: RES effectively eliminates both, the BTCs and TICs in glio-
blastoma, and its encapsulation in Tf-modifıed liposomes still further improves
its effıcacy compared to the free drug or drug in non-targeted liposomes. Tf-
RES-Ls thus seem like a very promising nanomedicine candidate for further
development to treat GBM.
#3252 Synthesis of N-substituted [Benzoylamino]-3-Ethyl-1,2,3,6-tetra-
hydropyridines as potential anti-cancer agents. Elizabeth Henderson, Mad-
havi Gangapuram, Suresh Eyunni, Kinfe Redda, Tiffany Ardley. Florida A &M
University, Tallahassee, FL.
Chronic inflammation is believed to promote cancer through cellular and
genomic damage. Inflammation creates a microenvironment within the tissue
that enhances cell proliferation. In 2016,AmericanCancer Society estimates that
1,685,210 new cancer cases are expected to be diagnosed in the United States.
Cyclooxygenase (COX) is an enzyme found to play an essential role in inflam-
mation and converts arachidonic acid to prostaglandin-like molecules. The
three isomers of COX are COX-1, COX-2, and COX-3. COX-2 has been found
to be up-regulated in inflammation and some cancers, such as breast cancer and
prostate cancer. Tetrahydropyridines (THPs) developed by our research group
were effective in inhibiting inflammation, COX, and the growth of some breast
cancer cells. Previous research has shown that pharmacological activities of the
THPderivatives depend greatly on the nature andposition of the substituents on
the THP ring structure. Here, we present the synthesis of a series of novel THP
derivatives. 3-Ethylpyridine is reacted with O-mesitylenesulfonylhydroxyl-
amine (O-MSH) to furnish N-amino-3-ethylpyridinium mesitylenesulfonate.
The reaction of N-amino-3-ethylpyridinium mesitylenesulfonate with substi-
tuted acid chlorides gives the stable crystalline pyridinium ylides. A sodium
borohydride reduction of ylides furnishes the target compounds, N-substituted
[benzoylamino]-3-ethyl-1,2,3,6-tetrahydropyridines. Five novel N-substituted
[benzoylamino]-3-ethyl-1,2,3,6-tetrahydropyridines were synthesized, puri-
fıed, and characterized. The evaluation of these compounds cytotoxicity studies
on MCF-7 estrogen receptor positive breast cancer cells, MDA-MB-231 estro-
gen receptor negative breast cancer cell lines, and Ishikawa cells, using the Cell-
Titer-Glo (CTG) luminescent cell viability assay is underway. This research was
supported by the National Center for Research Resources and the National
Institute of Minority Health and Health Disparities of the National Institutes of
Health through Grant Number 8 G12MD007582-28.
#3253 Targeting G-quadruplex nucleic acids: a series of-carboline alka-
loids with new skeletons from the seeds of Peganum harmala. Kaibo wang,1
Huiming Hua,2 Danzhou Yang1. 1Purdue University, West Lafayette, IN; 2She-
nyang Pharmaceutical University, China.
G-quadruplexes are DNA secondary structures implicated in essential phys-
iological and pathological processes, such as tumorgenesis. Small molecules
which can stabilize or induce G-quadruplex formation have potential as antitu-
mor agents through the alteration of oncogene expression levels or the disrup-
tion of telomere maintenance. Targeting G-quadruplex nucleic acids, we
screened 17medicinal plants for binding activity to a model G-quadruplex d(T-
TGGGTT)4 system by 1H NMR experiment. We found that the crude extract of
Peganum harmala L. seeds showed the most potential binding activity and spe-
cifıc cytotoxicity against the PC-3 cancer cell line with an IC50 value of 13.65
g/mL. Subsequently, 1H NMR and bioassay co-guided isolation of the extract
of P. harmala L. was performed and obtained 21 new alkaloids, including 10
novel -carboline alkaloids with unprecedented carbon skeletons, and 12
known analogues. Their structures including the absolute confıgurations were
determined by extensive analysis of spectroscopic data, X-ray crystallography,
ECD calculations, and ECD exciton chirality approaches. The antiproliferative
activities and G-quadruplex binding activities were evaluated for these newly
discovered and previously reported alkaloids. Some of the isolates showed pro-
nounced cytotoxic effects with IC50 values below 10 M and signifıcant G-
quadruplex binding activities. More interestingly, pegaharmine D (4), which
showed the strongest G-quadruplex interaction, exhibited signifıcant cytotoxic
activity against HL-60, PC-3 and SGC-7901 cell lines, with IC50 values of 3.81	
0.32, 11.52	 0.62, and 15.16	 0.42M, respectively. The G-quadruplex inter-
actions positively correlated with antiproliferative activities suggesting these
-carboline alkaloids may exert their anti-cancer effects through G-quadruplex
interactions. This work contributed a practical strategy at fırst time for the dis-
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covery of novel G-quadruplex ligands from natural products and provided po-
tential insights for using -carboline alkaloids as anticancer lead compounds
specifıcally targeting G-quadruplexes.
#3254 Identifıcation of potent anti-tumor agents from the LOPAC library
using aunifıed 2D/3Dcell culture screening approach.ViswanathDas, Tomáš
Fürst, Soňa Gurská, Petr Džubák, Marián Hajdúch. Institute of Molecular and
Translational Medicine, Olomouc, Czech Republic.
Two-dimensional (2D) cultures of immortalized cancer cells have played a
signifıcant role cancer drug discovery and development process for decades.
However, the limitations imposed by the long-term cultures of cancer cell lines
are becoming increasingly apparent only recently. Therefore, there is a general
shift towards three-dimensional (3D) cell cultures, which effectively mimic tu-
mor complexities, for lead optimization and to accelerate translation research.
3D cell cultures not only model the in vivo architecture of tumors, but 3D-
derived cells also retain numerous signatures of cancer stem cells compared to
parental cells in 2D. In this study, using a unifıed 2D and 3D cell culture screen-
ing approach, we screened the LOPAC library from Sigma-Aldrich as a proof-
of-concept study. The drug screening was performed using parental colorectal
cancer HCT116 cells as a model cell line. 3D-derived cultures were generated
from multicellular spheroids of HCT116 cells. Additionally, utilizing lightsheet
fluorescence microscopy (LSFM), we studied the tissue penetration of drugs in
spheroids of HCT116 and cells expressing hypoxia-inducible factor-1 (HIF-
1). We identifıed cc. 200 compounds from the LOPAC library that showed
increased activity in 3D-derived cultures. A dose–response relationship study of
top 20% compounds further confırmed the preferential activity of these drugs in
3D than 2D cultures. Next, studies in spheroid cultures resulted in the identifı-
cation of fıve lead compounds with potent spheroid-size reducing effects. Three
of these compounds were kinase inhibitors, one HIF-1 inhibitor, and one in-
terestingly, a monoamine oxidase inhibitor. LSFM studies in HCT116-HIF-1
spheroids showed that two kinase inhibitors and the HIF-1 inhibitors signifı-
cantly altered spheroid hypoxia, and presumably spheroid growth. We believe
that this proof-of-concept study will further highlight the advantages of a com-
bined 2D/3D screening approach for drug discovery and development, and con-
sequently enable downstream testing at reduced cost.
PREVENTION RESEARCH: Strategies and Biomarkers for
Clinical Prevention
#3255 Circulating adipose stromal cells (CASCs) as a potential biomarker
of response to weight loss interventions in obese women at high risk for
breast cancer.Hailey Baker, Amy L. Kreutzjans, Jennifer L. Nydegger, Teresa L.
Phillips, Richard C. Hasting, Dan A. Dixon, Bruce F. Kimler, Carol J. Fabian.
Univ. of Kansas Medical Ctr., Kansas City, KS.
BackgroundObesity is a modifıable risk factor for breast cancer in the United
States. White adipose tissue is increased in obese (BMI  30 kg/m2) women,
releasing estrogens and pro-inflammatory cytokines. Adipose stromal cells play
a key role in releasing estrogens, while circulating adipose stromal cells (CASCs,
characterized as CD34CD31-CD45-) home to tumor sites and promote angio-
genesis and vascularization. CASCs have been correlated with BMI in both can-
cer andnon-cancer patients.However, BMI alone as amarker of adiposity has its
limitations.We examinedwhether CASCs correlate with additionalmeasures of
adiposity in women who are at high risk for development of breast cancer.
MethodsWomen at high risk for development of breast cancer butwithout prior
breast cancer were recruited for random periareolar fıne needle aspiration
(RPFNA), DEXA body composition, anthropomorphic assessment, and non-
fasting venous blood collection. Mononuclear cells were isolated and the fre-
quency of CD34brightCD31-CD45- cells was assessed by flow cytometry. Results
CASC frequency ranged from 0 to 0.018% (median 0.001%) for 13 non-obese
and 20 obese women. There was no association between CASC frequency and
BMI (range 19 - 46 kg/m2), either as a linear correlation or when dichotomized
at a BMIof 30 kg/m2.However, therewere tendencies for greaterCASC frequen-
cies in pre-menopausal women, women with greater waist circumference
(p0.050), and women with visceral fat mass greater than 50%. With limited
numbers, therewas no apparent association ofCASC frequencywith cytology or
proliferation (Ki-67) of benign breast epithelial cells acquired by RPFNA. Con-
clusions This is the fırst study to investigate CASC frequency in a cohort of
women at high-risk for development of breast cancer. Our results to date do not
show an association between CASC frequency and obesity (BMI). However,
associations with other indices of visceral fat suggest that evaluation of circulat-
ing adipose stromal cells could have value as a biomarker of response in clinical
trials of obese breast cancer survivors and high risk women undergoing weight
loss (especially fat mass) interventions.
#3256 Risk of second primary cancers in women diagnosed with endome-
trial cancer in German and Swedish cancer registries.Tianhui Chen. Zhejiang
Academy of Medical Sciences (ZJAMS), Hangzhou, China.
Background: Along with the increasing incidence and favorable prognosis,
more women diagnosed with endometrial cancer may develop second primary
cancers (SPCs). Nevertheless, most of previous studies have limitations such as
small study samples or investigations for selected SPC only. Additionally, to our
knowledge, investigations on the risk of a specifıc SPC after endometrial cancer
in two different populations have not been reported. We aimed at investigating
risk of second primary cancers (SPCs) in women diagnosed with endometrial
cancer in Germany and Sweden to provide insight into etiology and prevention
strategies for SPCs.Methods: Endometrial cancer patients diagnosed at age15
years in Germany during 1997-2011 and in Sweden nationwide during 1997-
2012 were selected. For both German and Swedish datasets, standardized inci-
dence ratios (SIRs), calculated as the ratio of observed to expected numbers of
cases, were used to assess the risk of a specifıc SPC in women diagnosed with
endometrial cancer. The expectednumber of a SPCafter endometrial cancerwas
calculated from the strata-specifıc fırst same cancer incidence rates in the Swed-
ish and German general population, respectively, multiplied by the correspond-
ing person-years in women with endometrial cancer. Person-years at risk were
accumulated for each patient, starting at the date of diagnosis of the fırst endo-
metrial cancer, and terminating on the diagnosis date of a SPC, date of death,
date of emigration, or end of follow-up (end of 2011 forGermany andof 2012 for
Sweden), whichever came fırst. Results: Among 46,929 endometrial cancer sur-
vivors in Germany and 18,646 in Sweden, overall 2,897 and 1,706 SPCs were
recorded, respectively. Signifıcantly elevated SIRswere observed inGermany for
ovarian (SIR1.3; 95%CI:1.1-1.5) and kidney cancers [1.6 (1.3-1.8)], while in
Sweden the SIRs were 5.4 (4.6-6.3) and1.4 (1.0-1.9), respectively. Elevated risk
for second ovarian endometrioid carcinoma was pronounced after early (55
years) onset endometrial cancer in Germany [9.0 (4.8-15)] and Sweden [7.7
(5.1-11)].In Germany elevated risks were found for second ovarian endometri-
oid carcinoma after endometrioid histology of fırst endometrial cancer [6.3 (4.0-
9.4)] and for second kidney cancer after clear cell histology of endometrial can-
cer [4.9 (1.6-11)]. Conclusions: We found exceptionally elevated risk of second
ovarian endometrioid carcinoma after endometrial cancer of the same histology
or of early onset. Kidney cancer was also increased, particularly after endome-
trial cancer of clear cell histology. Cancer prevention strategies should focus on
these cancers after endometrial cancer diagnosis.
#3257 Molecular characterization of the human stomach microbiota in
gastric cancer patients.Guoqin Yu,1 Javier Torres,2 NanHu,1 RafaelMedrano-
Guzman,3 Roberto Herrera-Goepfert,4 Michael S. Humphrys,5 Lemin Wang,1
Chaoyu Wang,1 Ti Ding,6 Jacques Ravel,5 Philip R. Taylor,1 Christian Abnet,1
Alisa Goldstein1. 1National Cancer Institute, Rockville, MD; 2InstitutoMexicano
del Seguro Social, Mexico; 3UnidadMedica de Alta Especialidad Oncología, Mex-
ico; 4Instituto Nacional de Cancerología, Mexico; 5University of Maryland School
of Medicine, Baltimore, MD; 6Shanxi Cancer Hospital, China.
Background Helicobacter pylori (Hp) is the primary cause of gastric can-
cer but we know little of its relative abundance and other microbes in the
stomach, especially at the time of gastric cancer diagnosis. Here we charac-
terized the taxonomic and derived functional profıles of gastric microbiota
in 157 non-malignant gastric tissue samples from two different sets of gastric
cancer patients, and compared them with microbial profıles of oral, stool,
nasal, vagina and skin samples from Human Microbiome Project. Results
We show that Hp is the most abundant member of gastric microbiota in both
Chinese and Mexican samples (51% and 24% respectively), followed by the
genera commonly seen in the oral microbiota. Taxonomic (phylum) profıles
of stomach microbiota largely resembled oral microbiota when the Helico-
bacter reads were removed. The functional profıles of stomach microbiota,
however, were distinct from those found in other body sites and had higher
inter-subject dissimilarity. Gastric microbiota composition did not differ by
Hp colonization status or stomach anatomic site, but did differ between
paired non-malignant and tumor tissues in either Chinese or Mexican sam-
ples. Conclusions Our study is the fırst to show that Hp is the dominant
member of the gastric microbiota in many gastric cancer patients rather than
diminished or depleted as traditionally believed. Our results provide insights
on the gastric microbiota composition and function in gastric cancer pa-
tients, which may have important clinical implications.
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#3258 Genomic analyses defıne molecular subtype of lung squamous cell
carcinoma. Ji Won Lee,1 Ahreum Kim,1 Jong-Yeon Shin,2 Young Tae Kim,1
Jeong-Sun Seo1. 1Seoul National University, Seoul, Republic of Korea; 2Genomic
Medicine Institute (GMI), Seoul, Republic of Korea.
Lung squamous cell carcinoma, which account for 25 percent of all lung
cancers, have not been well characterized owing to a lack of systematic under-
standing of molecular pathogenesis. We performed the whole-exome and tran-
scriptome sequencing from 101 tumors andmatched normal samples from Ko-
rean patients. Somatic mutations and gene expression defıned two intrinsic
subtypes: (1) classical subtype; (2) immunogenic subtype. Classical subtype dis-
played upregulation of cell cycle related genes and enriched for gene mutations
(TP53, NAV3, NFE2L2, CDKN2A, PIK2CA, KEAP1 and RB1) involved in cell
proliferation, squamous differentiation and oxidative stress. Immunogenic sub-
type had more tumor-infıltrating immune cells than classical type. More pro-
portion of adaptive immune cells was also detected in immunogenic subtype.
Immune genes, involved in adaptive immune response, were also upregulated in
immunogenic subtype. Taken together, our fınding revealed that each subtype
has different immune mechanisms in lung squamous cell carcinoma and pro-
vides potential opportunities for therapeutic development.
#3259 The genomic landscape of premalignant lung squamous cell carci-
noma lesions. Joshua Campbell,1 Xijun Zhang,2 Samjot S. Dhillon,3 Catalina
Perdomo,1 Sarah Mazzilli,1 Yaron Geshalter,1 Gang Liu,1 Sherry Zhang,1 Han-
qiao Lin,1 Jessica Vick,1 Christopher Moy,4 Stefano Monti,1 Evan Johnson,1
Matthew Meyerson,5 Steven Dubinett,6 Suso Platero,4 Matthew Wilkerson,2
Clifton Dalgard,2 Marc Lenburg,1 Mary Reid,3 Jennifer Beane,1 Avrum Spira1.
1Boston University School of Medicine, Boston, MA; 2Uniformed Services Univer-
sity, Bethesda, MD; 3Roswell Park Cancer Institute, Buffalo, NY; 4Janssen Phar-
maceuticals, Spring House, PA; 5Dana Farber Cancer Institute, Boston, MA;
6University of California, Los Angeles School of Medicine, Los Angeles, CA.
Background: Lung squamous cell carcinoma (SqCC) arises in the epithelial
layer of the bronchial airway and is often preceded by the development of pre-
malignant lesions. However, not all premalignant lesions progress to lung SqCC
andmany regress without therapeutic intervention. Understanding the somatic
alterations that contribute to progression of premalignant lesions in the airway
will allow us to identify biomarkers for early detection and develop therapeutic
strategies for early intervention. Methods: Airway biopsies were obtained from
high-risk smokers undergoing lung cancer screening by auto-fluorescence bron-
choscopy and chest CT at the Roswell Park Cancer Institute. For each subject
(n30), multiple premalignant lesions were sampled repeatedly over time
(n144 samples). One biopsy from each regionwas sent for pathological review
while another biopsy was taken for molecular studies. DNA was also isolated
from the blood or cytologically normal bronchial brushings to serve as a
matched normal control. Exome capture was performed using the Illumina
TruSeq Rapid Exome kit and sequenced to a mean depth of coverage of 120x at
Uniform Services University and Walter Reed National Military Medical Cen-
ter. Results: The median number of somatic mutations across all premalignant
lesions was 0.73 per megabase (range: 0.10 - 9.8 perMb) and displayed amodest
association with histological grade (p0.07). Themost frequently mutated lung
cancer genes included KMT2C (12%), NOTCH1 (11%), FAT1 (6%), TP53 (5%),
and CDKN2A (1%). Known oncogenic hotspot mutations were observed in
PIK3CA (1%) and KRAS (1%). The majority of lesions did not have overlap-
ping sets of mutations with other samples from the same patient, indicating that
most of these lesions arose from clonally distinct populations. The two lesions
with the relatively high mutation rates (7/Mb) were taken from adjacent sites
over two time points in the same individual with a prior history of lung squa-
mous cell carcinoma. These lesions had a signifıcantly overlapping set of muta-
tions including FAT1 indicating a common evolutionary ancestor. Conclusions:
The somatic alterations observed in known cancer genes such as TP53, KMT2C,
NOTCH1, and FAT1 may be among the earliest driver events in lung SqCC
development and may be useful as biomarkers for early detection as well as
targets for lung cancer interception.
#3260 Training for cancer surgery in SubSaharanAfrica.Mohamed Jalloh,
Serigne Magueye Gueye. Hôpital General Grand Yoff, Dakar, Senegal.
BACKGROUND: Low- and middle-income countries (LMICs) face both
training and infrastructural challenges for surgical care, particularly for cancer.
Practitioners chargedwith caring for these patients have few options for basic or
advanced training. OBJECTIVES: To describe the training options for cancer
surgery in Sub SaharanAfricaMETHODS:Thedifferentmethods of training are
described and the advantages and limits of each methods is highlighted. RE-
SULTS: Training during residency and onsite fellowship are a good option but
requires an appropriate number and capacity of training programme. Interna-
tional fellowships have the limitation of readjustment back home for the trained
fellow. Onsite International training missions like IVUmed’s missions have the
advantage of “TeachOne, ReachMany” outcomewhere a whole team in trained
in accordance of local needs and the participation of all stakeholders. CONCLU-
SIONS: Long-term program commitments; effective communication; and a
shared vision among the program site, the coordinating nongovernmental or-
ganization, and supporting organizations facilitate the development of thriving
surgical teaching programs capable of serving local communities and conduct-
ing outreach training.
#3261 Gene methylation biomarkers in sputum as a classifıer for lung
cancer risk. Maria A. Picchi,1 Shuguang Leng,1 Guodong Wu,1 Donna M.
Klinge,1 Cynthia L. Thomas,1 Elia Casas,1 Christine A. Stidley,2 Sandra J. Lee,3
Seena Aisner,4 Jill M. Siegfried,5 Suresh Ramalingam,6 Fadlo R. Khuri,7 Daniel
D. Karp,7 Steven A. Belinsky1. 1Lovelace Respiratory Research Inst., Albuquer-
que, NM; 2University of New Mexico, Albuquerque, NM; 3Dana-Farber Cancer
Institute, Boston, MA; 4Rutgers New Jersey Medical School, New Brunswick, NJ;
5University of Minnesota, Minneapolis, MN; 6Winship Cancer Institute of Emory
University, Atlanta, GA; 7MD Anderson Cancer Center, Houston, TX.
Lung cancer is the leading cause of cancer death primarily because it is often
diagnosed at an advanced stage. Results from the National Lung Screening Trial
(NLST) showed that CT screening can reduce lung cancermortality by 20%, but
the high number of false positives and need for additional testing suggest that
better risk classifıcation of smokers prior to screening could savemore lives with
less cost and improved effıciency. Furthermore, eligibility criteria forNLSTwere
restricted to smokers ages of 55-74 with30 pack-years of smoking and 15y
since smoking cessation, which captures only 40% of incident lung cancer
cases. Molecular biomarkers could augment current risk stratifıcation used to
select smokers for screening.We have shown that gene specifıc promoter hyper-
methylation detected in sputum provides an assessment of fıeld cancerization
within the lungs of smokers that in turn predicts lung cancer. The current study
addressed whether our validated 8-genemethylation panel could be extended to
improve the existing risk prediction model used to recommend people for a CT
screen by evaluating methylation in 487 resected Stage I lung cancer patients
from the ECOG-ACRIN5597 trial (fıeld of injury remains), 1378 current and
former smokers from the Lovelace Smokers cohort (LSC) and 718 current and
former smokers from the PLuSS cohort. Our initial analysis was restricted to
individuals from each cohort who met NLST criteria for CT screening (n371
ECOG-ACRIN, n466 LSC and n597 PLuSS). Themethylation prevalence of
all 8 genes was signifıcantly increased in resected lung cancer patients compared
to cancer-free smokers (odds ratios 1.6 to 8.9). The area under the receiver
operator characteristic curve (AUC) was used to evaluate classifıcation accuracy
of different logistic regression models. Classifıcation accuracy for clinical risk
factors alone was 74-76%, methylation alone, 82-86%; and clinical risk factors
plus methylation, 87-90% (p10-9 - 10-16). Setting the sensitivity at 95% im-
proved specifıcity from 25% to 54%with bothmethylation and clinical factors in
themodel. Assessment of the performance of the genemethylation panel in all of
the cancer patients and smokers did not reduce classifıcation accuracy or in-
crease specifıcity. Implementation of gene methylation biomarkers for screen-
ing could be a paradigm shift for lung cancer management by providing a much
improved risk assessment model that will allow for expanding the number of
smokers considered for screening, decreasing by one-third the actual number
referred, and reducing mortality through increasing the CT positive predictive
value. (Supported largely by R01 CA095568 and in part P30 CA118100)
#3262 Alternative strategies of screening and surveillance of patients with
Von-Hippel Lindau syndrome to reduce radiation exposure and potential sub-
sequent cancer risk.NeigeMY Journy.National Cancer Institute, Bethesda, MD.
Background: Von-Hippel Lindau (VHL) syndrome is a rare genetic disorder
that predisposes individuals to benign andmalignant tumors, including pancre-
atic neuroendocrine tumors and renal cell carcinoma. Guidelines recommend
abdominal Computed Tomography (CT) scans to be performed every one or
two years starting in adolescence or young adulthood for screening or surveil-
lance for these tumors. Objective: To assess radiation exposures resulting from
alternative strategies of screening and surveillance by abdominal CT scans, and
projecting potential cancer risks subsequent to these exposures.Methods:Organ
radiation doses were estimated using a dedicated computational solution for CT
dosimetry, on the basis of protocols routinely used at one U.S. cancer research
center in 2012-2015. Subsequent Lifetime Attributable Risks (LARs) of cancer
incidence were projected for lifelong nonsmokers, using a dedicated radiation
risk assessment tool and accounting for the reduced life expectancy of individ-
uals diagnosed with VHL.We assumed additive effects between VHL gene mu-
tation and radiation exposures. Results: Based on a standard CT protocol, an-
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nual scans over a lifetime starting at age 15 are associated with cumulative colon
doses of 1.8 Gy at age 30, 3.8 Gy at age 50. The associated LARs of cancer
incidence would be 1–2% at age 50, and 11–32% at age 80. Delaying age at
screening start to 21 years would reduce the projected risks to1% at age 50 and
15%at age 80.A frequency of one scan every two years (as used for surveillance
of cystic pancreatic lesions) would be associatedwith LARs of1% at age 50 and
10% at age 80. The current use of a new CT protocol (dual energy virtual
non-contrast CT) at the department would reduce radiation exposures and po-
tential subsequent risks by more than 50%. Conclusion: Annual CT screening
and surveillance for pancreatic and renal tumors in VHL patients can be asso-
ciated with high radiation exposures.WhenMagnetic Resonance Imaging is not
appropriate as an alternative imaging technique, delaying age at surveillance
start or reducing the frequency of CT scans could signifıcantly reduce the po-
tential radiation-related risks, provided that these strategies remain benefıcial
for patients. Optimized CT protocols can also dramatically reduce radiation
exposures. The present study is currently extended to confırm our dose esti-
mates based on CT protocols against individual radiology data, and consider
other genetic syndromes. Ultimately, this study should help defıning surveil-
lance strategies with optimal risk-benefıt balance.
#3263 Is Latin America ready for the use of genomics in cancer care and
control. Sandra Perdomo,1 Angela Torres,1 Javier Olivier,2 Cecilia Frecha,3 Ro-
salía Quezada-Urban,4 Clara Estela Díaz-Velasquez,4 Felipe Vaca4. 1El Bosque
University, Bogota, Colombia; 2Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina; 3ICBME Instituto Universitario Hospital Italiano de Buenos Aires,
Buenos Aires, Argentina; 4Universidad Nacional Autónoma de México, Mexico
DF, Mexico.
In Latin American (LA) countries cancer is the second most frequent cause of
death after cardiovascular disease.Disease patterns have changed from infectious to
chronic, thepopulation is increasing andbecoming elderly, and countries lackplan-
ning to respond adequately to this epidemiological and socio-demographic transi-
tion. By 2025 and increment of nearly 30% of new cases and 35% of deaths from
cancer are predicted. Genomic studies have profoundly changed cancer manage-
ment from improved cancer diagnosis to reformulating cancer prognosis and treat-
ment. However, all these key advances have been mainly concentrated in highly
developed nations and little is known about the capacities and needs of cancer
genomics in the LA context. In order to evaluate the capacity and development of
cancer genomics in LA, we collected available information for all countries in Cen-
tral, South America and Cuba. Data reviewed included: number of NGS platforms,
number of cancer research institutions, research groupsworking in cancer genetics,
publications on cancer genetics and genomics in the last 10 years, educational pro-
gramsongenomics and relatednational cancer control policies.Currently, there are
a total of 212 NGS platforms in LA.Mexico and Brazil are the countries with more
users, andPeru andEcuador have the fewest. 118 research groups in SouthAmerica
have been working in cancer genetics and started developing cancer genomics re-
lated projects. No data on research groups was available for countries in Central
America. In the last 10 years, 231 articles in cancer genetic/genomic related topics
were published by authors affıliated to LA institutions. Educational programs in
genomics are scarce, almost exclusive of graduate programs and few applied to
cancer. Twelve countries in LA have national cancer control plans (NCCP). All
NCCPs reviewed consider secondary prevention strategies for early diagnosis, op-
portune treatment anddecrease ofmortality, areaswhere genomic analysis couldbe
implemented. Only 5 NCCPs include cancer research as an action plan to increase
cancer prevention strategies and reduce both incidence and mortality. Despite the
recent advances in introducing cancer genomics knowledge and application in LA,
the region lacksdevelopmentof integratedgenomic researchprojects, improveduse
of platforms, associated educational programs and health policies that might focus
on themost frequent cancers and could impact cancer care.
#3264 Evaluating heart-hate variability, salivary cortisol and physical ac-
tivity as predictors of cancer-related fatigue recovery in breast-cancer survi-
vors over a 12 week period by use of a smartphone application. Annina Julia
Seiler,1 Vanessa Klaas,2 Gerhard Tröster,2 Kyle W. Murdock,1 Diana A. Chiri-
nos,1 Luz M. Garcini,1 Christopher P. Fagundes3. 1Department of Psychology,
Rice University, Houston, TX; 2Wearable Computing Laboratory, Department of
Information Technology and Electrical Engineering, ETH Zurich, Zurich, Swit-
zerland; 3Department of Psychology, Rice University; Department of Behavioral
Science, The University of Texas MD Anderson Cancer Center, Houston, TX.
Introduction Cancer-related fatigue (CRF) is one of the most prevalent and
debilitating problems in breast cancer survivors (BCS) that can persist many
years beyond successful cancer treatment. Parasympathetic nervous system ac-
tivity (measured via heart-rate variability; HRV), cortisol dysregulation and de-
creased physical activity are plausible, but understudied contributors to CRF.
Repeated daily measurements of CRF and tracking daily physical activity over a
12-week period should give more information regarding temporal patterns of
CRF amongBCS.Objective The purpose of this study is 1) to investigate patterns
of CRF in fatigued BCS over time; 2) to assess HRV, salivary cortisol and level of
physical activity as predictors of cancer-related fatigue (CRF) in BCS over a
12-week period; and 3) to explore whether a smartphone application interven-
tion results in increased daily physical activity, as well as improved HRV, sali-
vary cortisol and CRF in BCS relative to healthy female controls over a 12 week
period.MethodsA total of 30 fatigued breast cancer survivors (FACIT-F score
34) and 30 aged-matched female controls will be randomly assigned to either an
intervention or control group. Both groups will receive a smartphone applica-
tion tracking daily physical activity. While the intervention group will receive
this application with feedback regarding their daily physical activity, the control
groups will receive the application without feedback. Behavioral data will be
collected by means of GPS and Wi-Fi for localization, and accelerometer, ba-
rometer, magnetometer and gyroscope for activity recognition. HRV and sali-
vary cortisol will be collected at rest, as well as during and after a signifıcant
stressor (Trier Social Stress Test). Fatigue will be measured by the FACIT-F
Scale, which will be completed at baseline (T1), 4 weeks (T2) and 12 weeks (T3).
Group differences will be tested by one-way analysis of variance (ANOVA) and
intervention effectswill be analyzed usingmixedmodelswith repeatedmeasure-
ments. Hypotheses We hypothesize that HRV, cortisol dysregulation and level
of physical activity at baseline can predict CRF-recovery over a 12-week period.
The smartphone application will be associated with improved physical activity
in the BCS intervention group and that changes of physiological correlates of
CRF can be observed (i.e., HRV and salivary cortisol). Conclusion This study
will examine associations between HRV, salivary cortisol, physical activity and
CRF in BCS over time. The results of this study may provide insight into factors
that contribute to the development, persistence and/or consequences of CRF by
use of an innovative mobile application.
#3265 Characterization of epithelial oral dysplasia in non-smokers: work-
ing towards precision medicine. Leigha D. Rock,1 Miriam P. Rosin,2 Lewei
Zhang,1 Batoul Shariati,1 Denise M. Laronde1. 1Univ. of British Columbia, Van-
couver, British Columbia, Canada; 2Simon Fraser University, Burnaby, British
Columbia, Canada.
Objectives: Although tobacco usage is still one of the strongest risk factors
associated with oral cancer risk, there is a subset of non-smokers who develop
oral cancer. Tobacco cessation efforts have resulted in a drop in oral cancer rates
associated with this habit, leading to a growing interest in the increased propor-
tion of cases occurring among non-smokers (NS). Lesions with oral epithelial
dysplasia (OED) are at risk of progressing to oral cancer. Not only is the natural
history of OED in NS poorly understood, but the path to interception of disease
in NS is poorly defıned. There is a gap in the knowledge surrounding the clini-
copathological and genetic characterization, and the risk of progression in this
growing category. This information is critical to the evolution of precisionmed-
icine in this subgroup. The aim of this study was to: 1) Describe the molecular
and clinicopathological features of OED in NS as compared to smokers in lon-
gitudinal follow-up; and 2) To compare progression rates and time to progres-
sion in NS and smokers with OED. Methods: The study focused on cases with
histologically confırmedmild ormoderate OED in follow-up in theOral Cancer
Prediction Longitudinal Study. Clinicopathological data, including lesion site,
size, texture, colour, consistency, border characteristics, fluorescence visualiza-
tion (FV), and toluidine blue (TB) retention, were collected in addition to de-
tailed smoking history. A genomic based marker test (gMART) which uses loss
of heterozygosity (LOH) at key chromosomal loci to stratify lesions to progres-
sion risk, was performed on baseline biopsies. Progression was considered to be
advancement to severe dysplasia, carcinoma in situ, or squamous cell carci-
noma. Results: Out of 231 OED, 30% were NS related, based on self-reported
smoking status. Although there were more smokers with OED than NS, a sig-
nifıcantly higher proportion of the OED underwent malignant transformation
inNS (P.048). Although not signifıcant, time to outcomewas also faster in this
group. Most clinical features were equally predictive except for lesion site. Ever
smokers (ES)weremore likely to haveOEDat the floor ofmouthwhileOEDwas
more likely to occur at the tongue or gingiva (P.001) in NS. LOH risk patterns
were strongly associatedwith progression (moderate riskOR4.84; high risk
OR 28.1; P.001) and equally sensitive in both NS and ES subgroups. Conclu-
sions: These fındings support the premise that progressive lesions in NS and ES
have some similar genetic underpinnings, and emphasize the need for clinicians
to consider the molecular genomic profıles in the triage of OED. LOH markers
can sort high-risk lesions, despite risk habits, and should be an important con-
sideration in the treatment of OED. This marker is of particular use in the
targeting of candidates for chemoprevention.
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#3266 Oral rinse point of care test to predict head and neck cancer. Mi-
chael J. Donovan,1 Kris Curtis,2 GregGinn,3 Elizabeth J. Franzmann4. 1Mt. Sinai
School of Medicine, New York, NY; 2Vigilant Biosciences, Ft. Lauderdale, FL;
3Samco and Associated, Cicero, IN; 4University of Miami, Miami, FL.
Background: Head and neck squamous cell carcinoma (HNSCC) is the 6th
most common cause of cancer mortality throughout the world affecting some
50,000 people in the US and 600,000 worldwide each year. The ability to detect
the disease in a potentially malignant phase and earlier stage could have signif-
icant impact on overall outcome. Previous studies have demonstrated that a
combined salivary CD44, a tumor-initiatingmarker, and total protein assay was
able to aid in the diagnosis of HNSCC. We sought to understand the perfor-
mance characteristics of these biomarkers in a prospective population using a
qualitative, point-of-care assay (POC) which consists of a cassette with a color-
imetric read-out based on a pre-determined threshold for both CD44 and total
protein. We also performed results from same samples with a quantitative lab-
based test. Methods: Saline oral rinse specimens (5ml) from 134 patients (84
HNSCC cases; 50 controls) were obtained from biorepositories. Samples were
thawed, gently swirled, placed in a standard collection cup. 600ul were removed
for lab assay prior to POC test. The tapered end of the POC cassette was sub-
merged in rinse for 20’; levels of CD44 and total protein (TP) were evaluated by
two operators. POC test results were compared between operators and with lab
test results using Cohen’s kappa coeffıcient andMcNemar’s test, sensitivity(Se),
specifıcity(Sp), NPV and PPV. Results: 95%HNSCC patients (cases) weremean
60 years of age, 60% male, 97% white and 74% smokers vs. 43 years, 28%, 96%
and 0% respectively, for controls. POC was positive with either CD44 or TP
above threshold. Weighted kappa yielded 75% and 72% for CD44 and TP re-
spectively between operators. With a prevalence of 9.27: POC: NPV 94%, PPV
10%; variable TP cut-off produced Se71-84% and Sp30%-50%. McNemar and
Kappa for both lab CD44 and TP vs POC indicated moderate agreement; inde-
pendently both POC and lab produced NPV90%. Conclusions: Concordance
of the POCassay betweenoperators andmoderate agreementwith a quantitative
lab assay provides supportive evidence for clinical application of the POC assay
as an aid in the diagnosis for HNSCC. Additional studies are underway to con-
fırm these observations.
#3267 Combined effect of multiple gene polymorphisms on cancer risk
stratifıcation.Radhika Gade Andavolu,1 Olivia Rodriguez,1 Anastasia Al Ruba-
kovic,1 Catherine Stafford,1 Murthy V. Andavolu2. 1Genetic Research Inst. of the
Desert, Rancho Mirage, CA; 2Eisenhower Medical Center, Rancho Mirage, CA.
CyclinD1 (CCND1)G870Apolymorphismhas been known to be a risk factor
in multiple cancers. Cyclin D1 is a cell cycle regulator frequently mutated, am-
plifıed and overexpressed in a variety of tumors. Activation and over expression
of CCND1 have been found in variety of tumors and alterations in CCND1 are
thought to be involved in carcinogensis. CCND1 polymorphism A870G inter-
feres with splicing and studies showed DNA damage in cells from subjects with
’A’ allele to bypass G1/S check point of the cell cycle control mechanism more
easily than damage in cells with G allele (wild type). A single base pair polymor-
phism (exon 4, G870A) in the CCND1 gene affects gene splicing. This identifı-
cation and validation of contributing genetic factors such as single-nucleotide
polymorphisms (SNPs) represents a critical step in the advance toward person-
alized medicine. Several gene expression correlation studies have been done but
to our knowledge studies have not been reported on SNP’s of ERBB2 gene, ESR
gene and CCND1 combined effect correlating with high risk. In this study, we
examined the relationship between ERBB2 (codon 655), Estrogen receptor (ER
Intron1 TC) and cyclin D1 (Exon 4) polymorphic additive effect in cancers
more specifıc to breast cancer. Genomic DNA was extracted from whole blood
samples collected on study. The SNPs were tested by the PCR-restriction frag-
ment length polymorphism (PCR-RFLP) method. Our results show individuals
carrying CCND1 ’A allele in combination with variant ERBB2/BsmAI uncut
allele are signifıcantly high (P0.004) in cancer patients (N232) as compared
to controls. (N222). Similarly individuals carrying CCND1 Variant ’A ’ allele
in combination with ESR ’C’ Allele showed high frequency with p0.009. Both
these combinations showed a strong and signifıcant association with cancer but
individually, ERBB2 variant did not show any signifıcant association, ESR gene
showed a borderline association and CCND1 showed strong association inde-
pendent of these two gene polymorphisms. Earlier few studies have shown no
association of ERBB2 mutation in agreement with the previous reports. In con-
clusion our data suggests that in complex diseases a single gene may not con-
tribute to show its effect but in combination may show a profound effect in
evaluating the risk.
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#3268 Obesity, circulating 25-hydroxyvitamin D, and C-reactive protein
levels in cancer survivors. Lin Yang,1 Adetunji T. Toriola2. 1Medical University
of Vienna, Wien, Austria; 2Washington University School of Medicine, St Louis,
MO.
Aim: Circulating 25-hydroxyvitamin D (25-OHD) levels may be associated
with cancer prognosis. It is, however, unclear if low 25-OHD levels in cancer
survivors is a surrogate for obesity, which also influences cancer prognosis. To
address this, we evaluated the associations of body mass index (BMI) with cir-
culating 25-OHD levels among cancer survivors using data from the National
Health and Nutrition Examination Survey (NHANES). Further, we determined
if this association is modifıed by inflammation, as determined by circulating
C-reactive protein (CRP) levels, since obesity is a pro-inflammatory state and
vitamin D defıciency is associated with higher inflammatory markers. Method:
Data on cancer survivors in fıve waves of NHANES (2001-2010) were aggre-
gated. Multiple linear regression models were used to evaluate the associations
of BMI with circulating 25-OHD levels, adjusting for confounders (age, gender,
race, smoking status, and season of blood draw). We stratifıed our analyses by
CRP levels into low 1mg/L, moderate 1.1-3.0mg/L and high 3.1-9.9mg/L.
Results: There were 1,306 cancer survivors (mean age60.8 years, mean
BMI28.0 kg/m2) with detailed data for analyses. The prevalent cancer types
were breast (19.6%), prostate (19.6%), cervix (10.0%), and colon (8.9%). Circu-
lating 25-OHD levels were 7.43 nmol/L lower (95%CI: 3.06 to 11.81) among
obese cancer survivors (BMI30kg/m2) compared to those with BMI25kg/
m2. In analyses stratifıed by CRP levels, we observed no such association among
cancer survivorswith lowCRP levels.However, among thosewithmoderate and
high CRP levels, obese cancer survivors had statistically signifıcantly lower 25-
OHD levels compared to those with BMI 25kg/m2; (-8.87, 95%CI: -16.28 to
-1.24) among those with moderate CRP levels and -9.85, (95% CI: -17.00 to
-2.71) among those with high CRP levels. Conclusion: Obesity is associated with
lower circulating 25-OHD levels in cancer survivors. This appears, however, to
be limited to those with evidence of systemic inflammation.
Table 1. Multivariable-adjusted associations between BMI and ciruclating
25-OHD levels among cancer survivors in the NHANES 2001-2010 (n1306);
stratifıed by CRP levels.
Circulating 25-OHD (nmol/L)
BMI category (kg/m2) Beta-coeffıcient (95% CI) p*
Overall, n1306
25 reference
25.0 – 29.9 -2.91 (-7.49 to 1.37) 0.18
 30 -7.43 (-11.81 to -3.06) .001
Low CRP levels (1.0 mg/L), n348
25 reference
25.0 – 29.9 -0.64 (-9.09 to 7.91) 0.88
 30 -4.00 (-11.59 to 3.59) 0.3
Moderate CRP levels (1.1-3.0 mg/L), n498
25 reference
25.0 – 29.9 -2.44 (-9.27 to 4.38) 0.48
 30 -8.76 (-16.28 to -1.24) 0.02
High CRP levels (3.1-9.9 mg/L), n460
25 reference
25.0 – 29.9 -7.63 (-13.94 to -1.33) 0.02
 30 -9.85 (-17.00 to -2.71) 0.008
*Adjusted for age, gender, race, body mass index, and smoking status
#3269 Impact of gender on survival of the patients with esophageal squa-
mous cell carcinoma at a single institute in China. Jian Liang Lu,1 Jian Liang
Lu,2 Rui PingXu,3 Bei Li,2 Li XinWan,4MingYaoChen,5 Chun Jiang Liu,6 Zhan
QiangHan,7 Fang Fang Shen,8 Jian Bo Zhao,9 Hai ZhouGuo,10Wei Cao,11 Bing
Yu Fan,2 Li Dong Wang2. 1School of Basic Medical Sciences, Xinxiang Medical
University, Xinxiang, China; 2Henan Key Laboratory for Esophageal Cancer Re-
search, The First AffıliatedHospital of ZhengzhouUniversity, Zhengzhou,Henan,
China; 3Anyang TumorHospital, Anyang, Henan, China; 4Department of Oncol-
ogy, Nanyang City Center Hospital, Henan, China; 5Department of Thoracic
Surgery, Henan Province People’s Hospital, Zhengzhou, China; 6Department of
Gastroenterology, Xunxian People’s Hospital, Hebi, China; 7Department of .Pa-
thology, Zhenping County People’s Hospital, Nanyang, China; 8Department of
Oncology, The Third Affıliated Hospital of Xinxiang Medical College, Xinxiang,
China; 9Department of Gastroenterology, The Second Affıliated Hospital, Zheng-
zhou University, Zhengzhou, Henan, China; 10Department of Thoracic Surgery,
The First AffıliatedHospital of ZhengzhouUniversity, Zhengzhou, Henan, China;
11Department of Oncology, Zhengzhou Central Hospital, Henan, China.
PREVENTION RESEARCH: Strategies and Biomarkers for Clinical Prevention
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 835
Esophageal cancer (EC) has been well documented with predominant occur-
rence in male and with major histopathological type of esophageal squamous
cell carcinoma (ESCC) in China. However, the influence by gender on ESCC
survival is largely unknown in China. The present study was thus undertaken to
elucidate the impact by gender on survival of Chinese patients with ESCC. A
total of 17,969 ESCC patients was enrolled in this study, including 11,127 males
with a mean age of 60.2	8.6 and 6842 females with a mean age of 61.0	8.4.All
the patients were from ESCC database in Henan Key Laboratory for Esophageal
Cancer Research of the First Affıliated Hospital, ZhengzhouUniversity (1975 to
2015). Only the patients with T2–4N0–1M0–1 were enrolled in this study.
Based on the diagnosed time, the patients were classifıed into two groups, group
I (1996–2005, 6885/38.3%) and group II (2006–2015, 11084/61.7%). The fol-
lowed–up was undertaken until October, 2016. Kaplan–Meier models were for
describing the survival curves and Cox proportional hazards models were un-
dertaken to observe the risk of death of male and female. The results demon-
strated that the male patients had a poor survival than female (258.17,
P0.001). Furthermore, similar results were observed for the two different pe-
riods of 1996–2005 (221.08, P0.001) and 2006–2015 (234.67,
P0.001). The present results indicate that gender is an independent survival
factor for ESCC and the female patients with ESCC have a dramatic prolonged
survival thanmale patients in China. [Supported by Doctoral Team Foundation
of the First AffıliatedHospital of ZhengzhouUniversity (2016-BSTDJJ-03),Nat-
ural Science Foundation of Henan Province (20161110) and Corresponding
author: Li Dong Wang, email:ldwang2007@126.com]
#3270 Association of low-carbohydrate diet and macronutrient intake
with colorectal cancer survival. Mingyang Song,1 Kana Wu,2 Jeffrey Meyer-
hardt,3 Omer Yilmaz,4 Shuji Ogino,5 Charles Fuchs,3 Edward Giovannucci,2
Andrew T. Chan1. 1Massachusetts General Hospital, Boston,MA; 2Harvard T.H.
Chan School of Public Health, Boston, MA; 3Dana-Farber Cancer Institute, Bos-
ton, MA; 4Massachusetts Institute of Technology, Cambridge, MA; 5Dana-Far-
ber/Harvard Cancer Center, Boston, MA.
Background:Metabolic reprogramming is a hallmark of cancer characterized by
the switch from oxidative phosphorylation to aerobic glycolysis. Accumulating ev-
idence suggests that reducingdietary carbohydrate intakemayamelioratemetabolic
reprogramming and suppress proliferation of tumor cells. However, the clinical
benefıt of carbohydrate restriction remains unknown. Objective: To examine the
low-carbohydrate diet andmacronutrient intake after colorectal cancer diagnosis in
relation to mortality among stage I-III patients. Methods: We evaluated data on
1,303 colorectal cancer patients in theNurses’Health Study (1980-2012) andHealth
Professionals Follow-up Study (1986-2012) who completed a validated food fre-
quencyquestionnaire at least oneyear after diagnosis.Anoverall low-carbohydrate-
diet score was created based on the percentage of energy as carbohydrate, fat, and
protein (a higher score reflects a higher intake of fat and protein and a lower intake
of carbohydrate). We also created an animal- and vegetable-based low-carbohy-
drate-diet score on the basis of the intake from animal and vegetable food sources,
respectively.Weprospectively assessed the associationof the low-carbohydrate-diet
score andmacronutrient intake with CRC-specifıc and overall mortality using Cox
proportional hazards regression.Multivariable hazard ratios (HRs) and 95% confı-
dence intervals (CIs) were estimated after adjusting for a variety of potential con-
founding factors, including age, sex, cancer stage, grade of differentiation, subsite,
alcohol use, smoking status, physical activity, body mass index, regular use of aspi-
rin, total calorie, and intakeof folate, calcium, fıber, processed redmeat, andvitamin
D. Results: We observed 584 deaths, of which 132 were classifıed as colorectal can-
cer-specifıc deaths over amedianof 10 years of follow-up.Noassociationwas found
for overall and animal-based low-carbohydrate-diet score with colorectal cancer-
specifıcmortality, with theHR comparing the highest to the lowest quartiles of 0.92
(95% CI, 0.77-1.09, P for trend0.33) for the overall score and 0.99 (95% CI, 0.84-
1.17, P for trend0.94) for the animal-based score. In contrast, vegetable-based
low-carbohydrate-diet score was associated with lower colorectal cancer-specifıc
mortality (HR, 0.67, 95% CI, 0.53-0.85, P for trend0.001). Replacement of carbo-
hydrate with fat, particularly vegetable fat, was associated with lower mortality of
colorectal cancer (HR per 10%-energy substitution, 0.49, 95% CI, 0.29-0.85, P for
trend0.01). Similar resultswere found for all-causemortality.Conclusion:Among
patients with colorectal cancer, replacing carbohydrates with vegetable fat may re-
duce the risk of all-cause and colorectal cancer-specifıc mortality.
#3271 Evaluation of bone health in breast cancer survivors compared to
cancer-free women: A prospective study within a young familial risk cohort.
Cody A. Ramin,1 Betty J. May,1 Richard B. Roden,2 Dana Petry,3 Deborah K.
Armstrong,2 Kala Visvanathan1. 1Johns Hopkins Bloomberg School of Public
Health, Baltimore, MD; 2Johns Hopkins Kimmel Cancer Center, Baltimore, MD;
3Johns Hopkins School of Medicine, Baltimore, MD.
Background: Bone loss has been consistently reported among long-term older
breast cancer (BC) survivors. However, it remains unclear how early and to what
degreeBCsurvivors experiencebone loss compared to their cancer-freepeers and to
what extent this can be attributed to age and premature menopause. Methods: We
studied 796 women (210 BC survivors, 586 cancer-free) with familial risk of breast
and/or ovarian cancer in theBreast andOvarian Surveillance Service (BOSS) cohort
at Johns Hopkins Hospital. Survivors were diagnosed with stage I-III BC5 years
prior to baseline (mean time from diagnosis to enrollment1.4 years; mean age at
diagnosis47 years). Osteopenia and osteoporosis were ascertained based on self-
reported physician diagnosis in baseline and follow-up questionnaires. Prevalent
cases of osteopenia or osteoporosis were excluded. Multivariable (MV)-adjusted
Coxproportionalhazardmodelswereused to estimatehazard ratios (HRs) and95%
confıdence intervals (CIs) of osteopenia and osteoporosis incidence amongBC sur-
vivors compared to cancer-free women. MV models were adjusted for age, race,
menopause status, body mass index, physical activity, smoking, hormone replace-
ment therapy and early oophorectomy. Results: BC survivors were slightly older
(meanage48vs. 45years),more likely tobepost-menopausal (51%vs. 29%)andhad
higher current vitaminDuse (21%vs. 8%) compared to cancer-freewomen.During
a mean follow-up time of 6.2 years, 77% of BC survivors and 60% of cancer-free
women reported having1 bone density examand 115 incident osteopenia and/or
osteoporosis cases were identifıed (75% osteopenia only). In MV-adjusted models,
BC survivors had 66%higher risk of being diagnosedwith osteopenia and/or osteo-
porosis compared to cancer-freewomen (HR1.66, 95%CI1.11-2.47). BC survi-
vors with no current vitaminD or calciumuse had 76% and 93%higher osteopenia
and/or osteoporosis risk compared to cancer-free women, respectively (MV
HR1.76, 95% CI1.14-2.72; MV HR1.93, 95% CI1.15-3.24). BC survivors
ever treated with chemotherapy or hormone therapy had higher osteopenia and/or
osteoporosis risk compared to cancer-free women (MV HR2.00, 95% CI1.14-
3.50;MVHR1.79, 95%CI1.14-2.82, respectively).Analyses restricted towomen
with no change inmenopause status during follow-upwere only slightly attenuated
(MV HR1.58, 95% CI0.96-2.59). Conclusion: Our results demonstrate that
bone loss is signifıcantly greater than and occurs early in young BC survivors com-
pared to cancer-freewomen even after taking into consideration increasing age and
premature menopause. Our fındings also provide support for a baseline evaluation
ofbonedensityatdiagnosiswithsubsequentmonitoring inyoungBCsurvivorswith
familial risk. Further analyses are ongoing to evaluate the effect of specifıc BC treat-
ments on bone health in this cohort.
#3272 Differences in prostate tumor characteristics and survival among
religious groups in southernThailand.ChristianAlvarez,1 Laura Rozek,1Hut-
cha Sriplung,2 Alison M. Mondul1. 1Univ. of Michigan School of Public Health,
Ann Arbor, MI; 2Prince of Songkla University, Hat Yai, Thailand.
Background: The incidence andmortality rates of prostate cancer are expected to
increase in thenext twodecades in southernThailand. In addition, survival rates are
lower compared to more developed countries such as the US. Differences in the
incidence of prostate and other cancers have been observed among the two most
predominant religious groups in Thailand, Buddhists andMuslims, possibly due to
different dietary and cultural practices between them. However, to our knowledge,
no studies have examined differences in cancer survival in these two populations.
Thus, we examined differences in tumor characteristics at diagnosis and survival in
Buddhist and Muslim men with prostate cancer in southern Thailand. Methods:
Songkhla, Thailand is a southern province located on the eastern side of theMalay-
sian Peninsula with a relatively large Muslim population (25%). 855 incident pros-
tate cancer cases from the population-based Songkhla cancer registrywere included
in this study.Data collected by the registry include age at diagnosis, tumor stage and
grade, and vital status. Complete data were available from 1990-2013. Age at diag-
nosis and tumor characteristics were compared across religious groups using the
Wilcoxon test for age and the2 test for categorical variables.Median survival time
and 5- year survival rates were calculated using the Kaplan Meier method, and
differences by religious group were evaluated using the log-rank test. Cox propor-
tional hazards models were used to estimate the hazard ratio (HR) and 95% confı-
dence interval (CI) for mortality after adjustment for age at diagnosis, stage, and
grade. Results: Of the 855 prostate cancer cases, 89.6% were Buddhists and the rest
Muslims. Age, stage, and grade at diagnosis were all similar across religious groups
(p0.72, 0.33, and 0.46 respectively). The median survival time after diagnosis of
prostate cancerwas signifıcantly longer (p0.05) inBuddhists3.7years (95%CI:3.2,
4.2) compared to Muslims 2.8 years (95%CI: 1.7, 4.0). The probability of surviving
after fıve years was 39.6% (95%CI: 35.7%, 43.4%) and 31.8% (95%CI: 21.1%, 42.9%)
inBuddhists andMuslims, respectively. After adjustment for age at diagnosis,Mus-
limmen were more likely to die after diagnosis with prostate cancer than Buddhist
men (HR: 1.37, 95%CI: 1.04, 1.79).This fındingwasunchangedafter further adjust-
ment for stage and grade at diagnosis (HR: 1.31, 95% CI: 1.00, 1.72). Conclusions:
Muslims in Songkhla, Thailand had a higher risk of death after diagnosis of prostate
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cancervs.Buddhists.Thisassociationcouldnotbeexplainedbydifferences in tumor
characteristics at diagnosis. Understanding what risk factors may underlie the
poorer survival observed among Muslims may inform targeted interventions for
prostate cancer among the Muslim population in southern Thailand. Next steps
include examining this association in additional geographic areas across Thailand.
#3273 Analysis of causes of death in patients with esophageal squamous cell
carcinoma in China. Xiang Yang Zhang,1 Jian Po Wang,2 Rui Ping Xu,2 Ya Qin
Hou,1 Xiu Jian Chen,3 Ai Li Li,4 Xi Chen,5 Shuang Yin Han,6 Wei Xing Zhao,7 Li
Sun,1 MinWang,1 Wen Ting Fu,1 Li DongWang1. 1The First Affıliated Hospital of
Zhengzhou University, Zhengzhou, China; 2Anyang Tumor Hospital, Anyang, Chi-
na; 3Huaxian People’s Hospital of Henan Province, Huaxian, China; 4TumorHospi-
tal of Linzhou, Linzhou, China; 5Puyang City Oil Field General Hospital, Puyang,
China; 6Henan Provincial People’s Hospital, Zhengzhou, China; 7The First Affıliated
Hospital of XinxiangMedical University, Xinxiang, China.
In China, more than 80% of the esophageal cancer occurs in farmer village, and
most of the esophageal cancer patients die at village home. Therefore, the cause of
death for esophageal cancer patients has not been well characterized. The present
study was thus undertaken to determine the causes of death in patients with esoph-
ageal squamous cell carcinoma (ESCC) to provide more information for further
prevention and accurate treatment after ESCC diagnosed. All the 8,838 ESCC pa-
tients with a detailed cause of death in this study were derived from the ESCC
database (1973-2015) inHenanKey Laboratory for Esophageal Cancer Research of
the First Affıliated Hospital, Zhengzhou University, China. All the patients were
categorized by age (50 years and50 years), gender (male and female) and path-
ological stage (early,middle and later stage). Chi-Square testwas used to analyze the
differences in different groups. The results demonstrated that, of the 8,838 died
ESCC patients, there were 5,713males (64.6%) with amean age of 60.95	9.43 and
3,125 females (35.4%)withameanageof 61.95	9.47.Notably, 69.5%of thepatients
died within fıve years after diagnosis, and the 1-, 3- and 5-year death after diagnosis
for these died ESCC patients were 1622 (18.4%), 2960 (33.5%) and 1557 (17.6%),
respectively.Overall, themajorcauseofdeath forESCCwasdue toESCCrecurrence
and metastasis (8500, 96.1%), and followed by cardiovascular disease (121, 1.4%),
different infections (68, 0.8%), second cancer (52, 0.6%), accident (25, 0.3%), suicide
(22, 0.2%), anduncertain cause (50, 0.6%). Furthermore, themajor cause of death in
males and femaleswas similar (p0.05) and the cause of death by ESCC recurrence
andmetastasis, cardiovascular disease, different infections, second cancer, accident,
suicide and uncertain cause was 96% (5485) 1.5% (84), 0.8% (44), 0.6% (34), 0.3%
(18), 0.2% (16), 0.6% (32), respectively in males and 96.5% (3015), 1.1% (37), 0.8%
(24) 0.6% (18), 0.2% (7), 0.2% (6) and0.6% (18), respectively in females. Thepresent
resultsdemonstrate that recurrenceandmetastasis are themajor causeofdeathboth
inmale and female for ESCC (96%). It is noteworthy that there are 0.2 percent of the
ESCC patients have suicide which call formore attention of psychotherapy on can-
cer patients. [Supported by the Science and Technology Major Projects of Henan
Province of China (161100311300), and Correspondence to: Li Dong Wang, the
National Key Research and Development Program of China and Correspondence
to: Li DongWang. Email: ldwang2007@126.com]
#3274 The impact of pregnancy on breast cancer survival: A retrospective
analysis based on national data. Shu-Chun Chuang,1 Ching-Hung Lin,2 Yen-
ShenLu,2ChaoA.Hsiung1. 1NationalHealthResearch Institutes,Miaoli County,
Taiwan; 2National Taiwan University Hospital, Taipei, Taiwan.
Introduction: With the increasing incidence of breast cancer in young women
and the delaying fırst term pregnancy age, the incidence of pregnancy-associated
breast cancer is expected to increase.Theaimof thecurrent studywas toexamine the
impact of pregnancy on breast cancer survival using national registry data.Material
andMethods: The breast cancer caseswere identifıed from theTaiwanCancer Reg-
istry.All fırst primary invasivebreast cancer casesdiagnosedbetween2002and2014
were identifıed. The studywas restricted to caseswhowere 20-50 years old andwere
stage I to III diseases. Pregnancy and delivery outcomes up to 5 years before the
cancer diagnoses were abstracted from the National Health Insurance database.
Thosewhowere not pregnant during this timewere defıned as non-pregnant cases.
The data were then linked to the Taiwan national death certifıcate database for vital
status, the causes, and the dates of death. Years of follow-upwas calculated from the
dateofbreast cancerdiagnosis to thedateofdeathorDecember31,2014.Thehazard
ratios (HR) and the 95% confıdence intervals (CI) of the association between preg-
nancy and breast cancer survival were estimated using cox proportional hazard
models. Results: Among the 30,479 breast cancer cases, 90 were diagnosed during
pregnancy (0.3%),347werediagnosedwithinayearafterdelivery (1.1%),410 (1.3%)
within 1-2 years after delivery, 1583 (5.2%) within 2-5 years after delivery, and 249
(0.8%) were pregnant after breast cancer diagnosis. By the end of 2014, 2932 cases
were dead (17 cases diagnosed during pregnancy (18.9%) and 69 cases diagnosed
within a year after delivery (19.9%)). The major cause of death was breast cancer
(89%). Compared to non-pregnant cases (9.3% dead), the HRs were 1.91 (95%
CI1.17-3.12) for those who were diagnosed during pregnancy and 1.92 (95%
CI1.48-2.48) for those who were diagnosed within a year after delivery, adjusted
for age and year of breast cancer diagnosis. After adjustment for tumor characteris-
tics and treatment, theHRwere 1.84 (HR1.04-3.28) and 1.29 (HR0.92-1.80) for
breast cancer diagnosed during pregnancy and within a year after delivery, respec-
tively. For those who received systemic therapy, 80% of them started within 90
days. However, for subjects diagnosed during pregnancy, only 63% of them started
systemic treatmentwithin 90 days. Conclusion: Pregnancy-associated breast cancer
is associated with higher mortality compared to non-pregnant breast cancer. Ad-
justed for tumor characteristics and treatment attenuated the association.
#3275 The impact of tumor locations on survival of the patients with
esophageal squamous cell carcinoma. Yan Jin,1 Yan Jin,2 Fu You Zhou,3 Ran
Wang,1 Zhi Qiang Li,4 Zhi Cai Liu,5 Dao Cun Wang,6 Yin Li,7 Ping Lu,8 Peng
Yuan Zheng,9 ChangWei Feng,10 Guo Qiang Kong,11 Shao Hua Han,1 Li Dong
Wang1. 1Zhengzhou University, Zhengzhou, China; 2Xinxiang Medical Univer-
sity, Xinxiang, China; 3Anyang Tumor Hospital, Anyang, China; 4The Third
People’s Hospital of Huixian, Xinxiang, China; 5Tumor Hospital of Linzhou,
Linzhou, China; 6The People’s Hospital of Puyang, Puyang, China; 7Cancer Hos-
pital of Henan Province, Zhengzhou, China; 8The First Affıliated Hospital of
Xinxiang Medical University, Xinxiang, China; 9The Fifth Affıliated Hospital of
Zhengzhou University, Zhengzhou, China; 10The Second Affıliated Hospital of
Zhengzhou University, Zhengzhou, China; 11The First Affıliated Hospital of
Henan University of Science and Technology, Luoyang, China.
In contrast to western population with majority of adenocarcinoma at lower
third segment, esophageal cancer in China occurs predominantly in the middle
third segment of the esophagus and squamous cell carcinoma (ESCC) remains
the major histopathological type. The mechanism for the dramatic difference in
terms of tumor location and histological type is not clear. Obviously, the differ-
ent tumor locations will have impact on optimal choice of treatment, and may
have different lymph drainage which will then influence the lymph node metas-
tasis. The present study was thus undertaken to characterize the impact of dif-
ferent tumor locations (cervical, the upper, middle, lower thoracic portion) on
survival of the ESCC patients fromHenan inNorthern China. All the patients in
this study were from the ESCC database in Henan Key Laboratory for Esopha-
geal Cancer Research of the First Affıliated Hospital, Zhengzhou University. Of
the 62,311 ESCCpatients enrolled in this study, there were 37,263males (59.8%)
with a mean age of 59.61	9.62 and 25070 females (40.23%) with a mean age of
60.45	9.68. The ratio of male to female was 1.49:1 (P  0.01). These patients
were classifıed into four groups with different periods based on diagnosed time,
group I (1975 to 1984, 6.51%), group II (1985 to 1994, 21.91%), group III (1995
to 2004, 30.98%) and group IV (2005 to 2016, 40.59%). Based on the 6th version
of UICC criteria, the tumor locations were recorded as cervical, upon, middle
and lower third segments. The followed–up was undertaken until 2016. The
SPSS21.0 software and Kaplan–Meier survival analysis and Log Rank test were
used to evaluate the survival of different locations. The results demonstrated that
the most common location for ESCC was in the middle third segment (64.5%),
followed by upon third segment (19.00%), lower third segment (15.10%) and
cervical segment (1.40%) (P0.001). Log Rank test showed that the ESCC at
lower segment had the best survival, followed by middle and upon segments.
The cervical segment hadworsen survival (P0.01). The present results indicate
that the tumor location has obvious impact on ESCC survival, further studies
need to elucidate the mechanism. [Supported by Doctoral Team Foundation of
the First Affıliated Hospital of Zhengzhou University (2016–BSTDJJ–03), Nat-
ural Science Foundation ofHenanProvince (20161110) andCorrespondence to:
Li Dong Wang, Email: ldwang2007@126.com].
#3276 Impact of the different treatments on the survival of advanced
esophageal squamous cell carcinoma. Rang Cheng,1 Fu You Zhou,2 Neng
ChaoWang,2 RanWang,1 Wei PengWang,3 Xian ZengWang,4 Wen Bin Yue,5
Jian Wei Zhou,6 Zhan Hui Miao,7 Guang Cheng Ding,8 De Chao Bu,9 Li Dong
Wang1. 1The First Affıliated Hospital of Zhengzhou University, Zhengzhou, Chi-
na; 2Anyang TumorHospital, China; 3CixianHospital, China; 4The People’s Hos-
pital of Linzhou, China; 5Puyang City Oil Field General Hospital, China; 6Henan
Provincial People’s Hospital, Zhengzhou, China; 7The First Affıliated Hospital of
Xinxiang Medical University, China; 8The Fifth Affıliated Hospital of Zhengzhou
University, Zhengzhou, China; 9Luoyang Institute of Information Technology In-
dustries, China.
Esophageal squamous cell carcinoma (ESCC) remains oneof the leading cause of
cancer-related death inChina.Moreover,more than 90%of theESCCpatients have
been in the advanced stage when diagnosed, the 5-year survival is very poor even
though the medical techniques have been improved in the past decades. Although
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the accumulated evidences have suggested the crucial role of genetic changes in
esophageal carcinogenesis, the target therapy based on these genetic changes is
largely in the very beginning, and radical esophagectomy and radiochemotherapy
remain the chief choice for ESCC treatment at present. The present study was thus
designed to evaluate the effıcacy of the present treatmentmethods in China to pro-
vide more information for optimal choice in advanced ESCC treatment. The en-
rolled 20,712 ESCC patients in this study were from the ESCC database in Henan
Key Laboratory for Esophageal Cancer Research of the First Affıliated Hospital,
ZhengzhouUniversity. Of the patients, there were 12,818males with amean age of
59.59	8.2 and 7,894 females with amean age of 60.34	8.3. All the 20,712 patients
were confırmed by histopathology as ESCC at II to IV stage (advanced stage) and
classifıed into three groups basedon the treatmentmethods: radical esophagectomy
(R0) alone (17,577, 84.8%), R0 plus radiochemotherapy (2,510, 12.1%) and ra-
diochemotherapy alone (625, 3.1%). The followed-up was undertaken until 2016.
The SPSS21.0 software and Kaplan-Meier survival analysis and Log Rank test were
used to evaluate the effıciencyof different treatments. The results demonstrated that
the overall median survival time for the three groups was 5.81 years, 4.82 years and
2.85 years, respectively (P0.001).Moreover, comparedwith surgery alone,R0plus
radiochemotherapy did not prolong survival of the advanced patients. Obviously,
much efforts, especially combined with genetic application are much desirable to
improve the survival for theadvancedESCCpatients. [SupportedbyNationalHigh-
Tech Research and Development Program of China (SQ2015AA0202183), Project
for Characteristic and Advantage Discipline of Henan Province (20151208) and
Correspondence to: Li DongWang, Email: ldwang2007@126.com]
#3277 The influence of cancer on working poor and working non-poor
cancer survivors’ work productivity, employment and quality of life. Helen
Nichols,1 Kathleen Tracy,2 Paula Rosenblatt,2 Robin Vanderpool,3 Jennifer
Swanberg1. 1Univ. of Maryland School of Social Work, Baltimore, MD; 2Univ. of
Maryland School of Medicine, Baltimore, MD; 3Univ. of Kentucky College of
Public Health, Lexington, KY.
Employment issues are cited as one of the most common unmet psychosocial
needsof cancer survivors; specifıcally, patients indicate theywantmore information
onhow tonavigateworkingduring their illness, the return toworkprocess andhow
to manage the immediate and long-term effects on job productivity. Yet, most on-
cology care providers feel limited in their ability to address this topic with patients,
citingminimal guidance, limited access to resources they feel clients need to achieve
work-related goals, and concerns regarding their knowledge of how cancer may
impact work. Likewise, supervisors of employees diagnosed with cancer are ill-pre-
pared to manage the needs of cancer survivors beyond the standard referral to hu-
manresources.One limitationof the existing researchoncancer andemployment is
that most studies have only examined these issues among higher income andmore
educated cancer survivors. The employment experiences of low-wage and less edu-
cated cancer survivors have been understudied. This is a signifıcant gap in the re-
search on cancer survivorship andwork given themassive growth of low-wage jobs
in the US since the 2008 Great Recession. The employment circumstances are sig-
nifıcantly different for workers in low-wage jobs than they are for other workers.
Thus, the effects of cancer on the work productivity of working poor and working
non-poor may vary and consequently may have different effects on long-term em-
ployment andquality of life for cancer survivors. This study addresses this gap in the
cancer survivorship literature by examining whether there is variation in the effects
of cancer on the work productivity of working poor and working non-poor cancer
survivors and its radiating effects on employment and the quality of life of cancer
survivors. Using data from theMedical Expenditure Panel Survey (MEPS) and the
MEPSCancerSurvivorshipSupplement, this secondarydata analysiswill studycan-
cer survivors who were employed at the time of their cancer diagnosis, comparing
the effects of cancer on work productivity among working poor and working non-
poor respondents and determining whether differences in work productivity influ-
ence long-term employment and quality of life. Preliminary results indicate that a
higher percentage of working poor cancer survivors were less productive at work
due to cancer and reported lower current employment rates and quality of life indi-
cators in comparison to working non-poor survivors. Study results could help on-
cologymedical teams, supervisors, and human resources professionals assist work-
ing cancer survivors during this transition period in their lives.
#3278 Particulate matter and traffıc-related exposures in relation to
breast cancer survival. Natalie DuPre,1 Elizabeth M. Poole,2 Michelle D. Hol-
mes,1 Jaime E. Hart,1 Peter James,1 Andrew Beck,3 Peter Kraft,1 Francine
Laden,1 Rulla Tamimi1. 1Harvard T.H. Chan School of Public Health, Boston,
MA; 2Channing Division of Network Medicine, Brigham & Women’s Hospital
and Harvard Medical School, Boston, MA; 3Beth Israel Deaconess Medical Cen-
ter, Boston, MA.
Background: Outdoor air pollution is considered a human carcinogen by the
International Agency for Research on Cancer, particularly for its influence on
lung cancer incidence and prognosis. While air pollution has not been consis-
tently associated with breast cancer incidence, only one study has examined the
impacts of air pollution on survival from breast cancer and was unable to con-
sider important predictors of breast cancer mortality. We assessed whether PM
exposures (PM2.5, PM2.510, and PM10) were associated with breast cancer specif-
ic-death and all-cause mortality. Methods: The Nurses’ Health Studies (NHS
and NHSII) are ongoing nationwide cohorts with detailed longitudinal data on
medical history, addresses, lifestyle factors, and causes of death. We included
womenwith confırmed Stage I-III breast cancer and collected additional clinical
information from medical records. PM was estimated using GIS-based spatio-
temporal models linked to addresses between 1989-2007. We performed Cox
proportional hazards models to assess associations of breast cancer specifıc-
death and overallmortalitywith PMexposures starting at diagnosis and updated
over follow-up through June 2014. Results: There were 1,211 breast-cancer spe-
cifıc deaths among 8,936 women with Stage I-III breast cancer. Overall, in-
creases in PM were not associated with breast cancer survival (PM2.5: HR1.09
95% CI 0.87, 1.36; PM2.5-10: HR1.03 95% CI 0.85, 1.24; PM10: HR1.05, 95%
CI 0.89, 1.24, each per 10g/m3).However, each 10g/m3 increase in PM2.5was
associated with breast cancer death among participants with Stage I disease after
adjusting for clinical, demographics and pre-diagnostic lifestyle factors
(HR1.69 95%CI 1.16, 2.47) and after additionally adjusting for post-diagnostic
lifestyle factors (HR1.64 95%CI 1.11, 2.43). Furthermore, PM exposures were
associatedwith a 9-12% increase in all-causemortality. Conclusion:Overall, PM
exposures were not associated with breast cancer survival; however, increases in
PM2.5 did appear to adversely impact prognosis among Stage I breast cancer
patients. Acknowledgments: This work was funded by the NIH T32 CA 09001
and by a grant from the SusanG.Komen for theCure ® (IIR13264020).We thank
the NHS and NHSII participants and coordinators.
#3279 Circulating inflammatory biomarker C-reactive protein and radio-
therapy-related pain in breast cancer patients. Eunkyung Lee,1 Omar L. Nel-
son,1 Carolina Puyana,1 Cristiane Takita,1 Jean L.Wright,2Wei Zhao,1 Isildinha
M. Reis,1 Rick Lin,1 Jennifer J. Hu1. 1Univ. of Miami, Miami, FL; 2Johns Hopkins
University, Baltimore, MD.
Background: Breast cancer is the most frequently diagnosed cancer and the sec-
ond leading cause of cancer death in American women. Post-surgery adjuvant ra-
diotherapy (RT) signifıcantly improves clinical outcomes. However, many patients
develop treatment-related pain that negatively impacts quality of life.Methods:We
evaluated an inflammatory biomarker, C-reactive protein (CRP) in RT-associated
pain in a prospective study of 366 breast cancer patients (64%Hispanicwhites, 20%
African Americans, 16% non-Hispanic whites) undergoing RT. In each patient, we
measured pre- and post-RT plasma CRP levels using a highly-sensitive ELISA kit.
Pain score was assessed at pre- and post-RT as themean of four pain severity items
(i.e., pain at its worst, least, average, and now) from the Brief Pain Inventory. Pain
scores of 4-10 were considered clinically-relevant pain. Association between pain
and CRP levels was evaluated using logistic regression models after adjusting for
potential confounders. Results: Overall, 16%patients at pre-RT and 31%patients at
post-RT had pain. In multivariable analyses, RT-related pain score change4 was
signifıcantly associated with CRP change1mg/L (OR3.24, 95%CI1.33, 7.88),
age 50 (OR3.27, 95%CI1.20, 8.92), and 3 comorbidity conditions
(OR5.91, 95%CI1.33, 26.82). Conclusion: This is the fırst study to suggest that
increased inflammatory biomarker, CRP level was associated with RT-related pain.
Impact: Future larger studies arewarranted to validate our fındings and facilitate the
discovery and development of anti-inflammatory agents to protect patients from
RT-relatedpain and improvequality of life inbreast cancerpatients undergoingRT.
#3280 Associations between ALDH1A1 polymorphisms, alcohol con-
sumption, and mortality among Hispanic and non-Hispanic White women
diagnosed with breast cancer: The Breast Cancer Health Disparities Study.
Zhiyu Xia,1 Avonne E. Connor,1 Kathy B. Baumgartner,2 Richard N. Baumgart-
ner,2 Stephanie D. Boone,2 Lisa M. Hines,3 Esther M. John,4 Roger K. Wolff,5
Martha L. Slattery5. 1Johns Hopkins Bloomberg School of Public Health, Balti-
more, MD; 2University of Louisville, Louisville, KY; 3University of Colorado, Col-
orado Springs, Colorado Springs, CO; 4Cancer Prevention Institute of California,
Fremont, CA; 5University of Utah, Salt Lake City, UT.
ALDH1A1 is amarker of normal tissue stem cells and cancer stem cells, where it
is involved in self-renewal, differentiation and self-protection. ALDH1A1 is also
associatedwith alcohol sensitivity and dependence, and functions in the detoxifıca-
tion of acetaldehyde. Few epidemiological studies have examined the association
betweenALDH1A1 andmortality amongwomenwith breast cancer (BC). To date,
none of these studies have included Hispanic women or evaluated the modifying
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effectof alcohol consumption.Usingdata fromtheBreastCancerHealthDisparities
Study, we evaluated the associations between nine SNPs of ALDH1A1 (rs348481,
rs168351, rs1888202, rs63319, rs722921, rs348461, rs348463, rs7027604, rs1424482)
and overall mortality among 1134 Hispanic and 1160 non-Hispanic white (NHW)
women diagnosed with incident invasive BC. Demographic and lifestyle factors
were collected via in-person interviews. Modes of inheritance were considered for
each SNP accordingly using their genotypes.Multivariate Cox proportional hazard
regression models were used to calculate hazard ratios (HRs) and 95% confıdence
interval (CIs). Models were adjusted for percentage of Native American (NA) an-
cestry, BC summary stage, and study site. To detect effect modifıcation, interaction
terms were created between percentage of NA ancestry (low 0.28 versus high
0.28), alcohol consumption (ever versusnever) and theSNPs.The likelihood ratio
test was used to evaluate whether the interaction terms were signifıcant. The Bon-
ferroni correction was used to adjust for multiple comparisons. After a median
follow-up timeof11years fromBCdiagnosis todeath, a totalof542deathsoccurred.
The following four SNPs were signifıcantly associated with overall mortality:
rs1424482 (HRCC1.33; 95% CI 1.04-1.70), rs63319 (HRAA1.30; 95% CI 1.06-
1.60), rs7027604 (HRAA1.37; 95%CI 1.11-1.70), and rs722921 (HRTA/AA0.78;
95%CI 0.64-0.96). However, only rs7027604 remained signifıcant after adjustment
for multiple comparisons (Padj0.035). Among women with low NA ancestry,
rs63319 signifıcantly increased risk of mortality (HRAA 1.55; 95% CI 1.20-1.99),
while a non-signifıcant inverse associationwas observed amongwomenof highNA
ancestry. Among ever drinkers, rs1888202 signifıcantly decreased risk of mortality
(HRCG/GG0.62; 95%CI 0.45-0.85), while a non-signifıcant inverse associationwas
observed among non-drinkers. The adjusted P-values for these interactions were
not signifıcant.This studyprovides evidence that rs7027604 is associatedwithworse
prognosis after BC diagnosis among Hispanic and NHW women. Future BC sur-
vival studies examining the relationship between ALDH1A1 and mortality should
also explore the modifying effects of alcohol consumption with rs1888202 and NA
ancestry with rs63319.
#3282 Common chronic medical conditions in pancreatic cancer: impact
on overall survival. Ahmed O. Abousamra, David Fogelman, Vijayashri Ralla-
palli, Akram Shalaby, Milind Javle, Renato Lenzi, Linus Ho, Donghui Li, Manal
Hassan. UTMD Anderson Cancer Ctr., Houston, TX.
Background: We aimed to categorize the most common comorbid medical
conditions in pancreatic cancer (PC) patients and to determine whether these
conditions have impact on the overall survival (OS). Methods: Between January
2000 and 2014, 2165 patients with pathologically confırmed adenocarcinoma of
the pancreas consented to participate in a clinico-epidemiological study at the
University of Texas MD Anderson Cancer Center. We reviewed the electronic
medical records of all patients to identify the prevalence of four chronic medical
conditions, including systemic hypertension, hyperlipidemia, type 2 diabetes,
and alteredmorphology of the pancreas. Prevalence of each chronic disease was
assessed andmedian survival was estimated by using theKaplan-Meier product-
limit method, and signifıcant differences between the survival times were deter-
mined by using the log-rank test. Results: Among all patients, 950 (43.9%) had
history of hypertension, 516 (23.8%) had hyperlipidemia, 585 (27%) had type 2
diabetes. Radiological and pathological records indicted presence of steatosis
(0.4%), fıbrosis (1.9%), and pancreatitis (9.9%). The prevalence of hyperlipid-
emia anddiabeteswas signifıcantly higher inmen (27.9%, 30.2%) than inwomen
(18.2%, 22.8%) respectively; P value.01. We found no signifıcant variation in
the prevalence of hypertension and altered pancreaticmorphology betweenmen
and women. Hypertension was more frequent among African American pa-
tients while diabetes was more common among Hispanics and African Ameri-
cans. No signifıcant variations in the distribution of other conditions by ethnic-
ity. Median survivals of PC patients by comorbidities are presented in table 1.
Conclusion: Chronicmedical conditions are commonly reported by PCpatients
and the prevalence of these conditionsmay vary by gender. However, the impact
of these conditions may not signifıcantly affect the survival of the patients. The
interaction treatment choices with these conditions still needs to be elaborated
in future studies.
OS (months), 95%CI of PC patients by comorbidities
Comorbidity Yes No P value
Hypertension 10.9(10-11.7) 11.6(10.7-12.4) .09
Hyperlipidemia 12 (11.8-13.1) 10.9(10.2-11.6) .4
Diabetes Mellitus 9.7(8.4-11.1) 11.4(10.7-12.1) .1
#3283 Adjuvant therapy associatedwith improved survival in gall bladder
cancer: A single institution retrospective study. LakshminarayananNandago-
pal,1 Martin J. Heslin,1 John R. Porterfıeld,1 Rojymon Jacob,1 Peng Li,1 James
Posey,2 Ravikumar Paluri1. 1University of Alabama at Birmingham, Birming-
ham, AL; 2Thomas Jefferson University, Philadelphia, PA.
Introduction: The survival outcome of resected gallbladder carcinoma re-
mains poor. We conducted a retrospective study to examine factors affecting
patient outcomes in resectable gallbladder carcinoma. Methods: We retrospec-
tively collected data on patients treated at our institution between January 2005
and June 2015 from the electronic medical record using a standardized data
collection tool. The univariate Cox proportional hazard model was used for
evaluating predictors of overall survival. Kaplan-Meier method was used to
compare time-to-events among subgroups and the p values were calculated by
the log-rank method. Overall survival (OS) was defıned as the time between
surgery and death, or censored at the last follow-up date. Progression-free sur-
vival (PFS) was defıned as the time to recurrence or death. Results: Of 67 evalu-
able patients, 65.7% were female. While clinical staging determined 51% to be
stage 2 or less, interval portal lymphadenectomy and hepatic resection upstaged
20% to stage 3 or 4. Adjuvant chemotherapy (CT)was given to 18%and adjuvant
chemoradiation (CRT) to 15%. About 46% did not receive any post-operative
treatment and data was not available in 21%. On multivariate analysis, albu-
min 3.5g/dl, LN involvement and pathological (p)Stage2were independent
predictors of OS and PFS. Median 5 yrs OS and PFS of pstage 2 was 54% and
54% respectively. Median 5 yr OS and PFS of stage 3 was 10.9% and 5.8%
respectively. Adjuvant therapywas administered commonly for stage 3 and 4 (20
patients) compared to stage 1 and 2 (2 patients). In stage3, adjuvant therapy
improved OS (17.5% vs 8.9% for surgery alone) and PFS (12% vs 0%). Adjuvant
chemoradiation for stage 3/4 had better median OS advantage compared to
chemotherapy alone (54m vs 15m, p0.0008). Conclusion: The use of adjuvant
treatmentmay improve long-term disease control in patients with node positive
tumors. A signifıcant difference between CRT and CT was demonstrated in our
series and needs further validation in a larger cohort.
Overall survival (OS) and progression-free survival (PFS) among various subgroups
Group (n)
Median OS
(months)
5 year
OS
Median PFS
(months)
5 year
PFS
stage 1&2 (21) NA 54% NA 54%
stage 3&4 (46) 13.4 10.9% 9.4 5.8%
Surgery Adjuvant
treatment (22)
25.1 15.9% 16.9 10.9%
Surgery alone (31) 26.1 34.4% 21.3 31.8%
Surgery CRT (10) 54.2 35% 45.7 24%
Surgery CT (12) 14.9 0% 13.4 0%
Stage 3 and 4- Surgery
Adjuvant treatment (20)
27.3 17.5% 22.5 12%
Stage 3 and 4- Surgery
alone (15)
2.7 8.9% 2.1 0%
#3284 Diminished survival in second primary melanoma exposed by the
counting method: an underutilized statistical approach in clinical oncology.
Maris S. Jones,1 Jihey Lee,1 Myung-Shin Sim,2 Delphine J. Lee,3 Mark B. Faries1.
1JohnWayne Cancer Institute, SantaMonica, CA; 2UCLADepartment of Biosta-
tistics, Los Angeles, CA; 3Los Angeles Biomedical Institute, Torrance, CA.
Objective: To determine the impact of second primary melanoma (SPM) on
patient survival using an established statistical methodology underutilized in
oncology research. Introduction: Patients with cutaneous melanoma are at in-
creased risk for SPM. Traditional statistical methods for calculating the risk of
SPMare limited.We analyzed SPMs as timedependent covariates of the primary
melanoma (PM). In contrast to other methods of SPM analysis, this process did
not assume the SPM existed at the time of PM diagnosis. Methods: 12,325 pa-
tientswithAJCC stage 0-IV cutaneousmelanoma and thosewho later developed
a SPM were identifıed from the John Wayne Cancer Institute melanoma data-
base. Standard descriptive statistics were utilized to compare the PM and SPM
groups. Then multivariate analysis via the counting method was performed to
examine the impact of SPM on overall survival (OS) and melanoma specifıc
survival (MSS). Results: Of PM patients, 969 (7.86%) developed a SPM. Prog-
nostic primary tumor characteristics tended to be better in patients with SPM
than without SPM including Breslow thickness, Clark level, ulceration status,
histologic type and stage (Table 1). Despite the favorable initial presentation of
SPM patients, MSS and OS were signifıcantly worse when compared with PM
only patients (OS: HR 1.23, 95% CI 1.01-1.37, MSS: HR 1.32, 95% CI 1.15-1.52).
Conclusion: This is the largest single-institution study to utilize the counting
method to analyze SPM survival. Patients with SPM are at increased risk for
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death overall and due to melanoma despite traditionally favorable clinicopath-
ologic characteristics. Based on these data, lifelong surveillance remains critical
to detect subsequent primary cutaneousmelanomas and recurrences in patients
with history of a PM.
Table 1 Clinical and histopathologic features of PM and SPM
PM SPM P-value*
Number of patients 11356 969
Age at diagnosis, mean	 SD 49.73	 16.69 51.12	 16.05 0.013
Sex
Female
Male
4885 (43.02%)
6471 (56.98%)
377 (38.91%)
592 (61.09%)
0.013
First seen stage
0/I/II
III
IV
Unk
6752 (59.46%)
2836 (24.97%)
1594 (14.04%)
174 (1.53%)
638 (65.84%)
206 (21.26%)
99 (10.22%)
26 (2.68%)
0.001
Primary site
Head/Neck
Trunk
Lower Extremity
Upper Extremity
Unknown
2887 (25.42%)
4611 (40.60%)
2576 (22.68%)
1264 (11.13%)
18 (0.16%)
273 (28.17%)
368 (37.98%)
185 (19.09%)
119 (12.28%)
24 (2.48%)
0.001
Breslow thickness
 1.0
1.01 - 2.00
2.01 – 4.00
 4.00
Unknown
3768 (33.18%)
2519 (22.18%)
1697 (14.94%)
845 (7.44%)
2527 (22.25%)
348 (35.91%)
173 (17.85%)
85 (8.77%)
34 (3.51%)
329 (33.95%)
0.001
Ulceration
Yes
No
Unknown
1529 (13.46%)
6902 (60.78%)
2925 (25.76%)
80 (8.26%)
589 (60.78%)
300 (30.96%)
0.001
Clark level
I
II
III
IV
V
Unknown
803 (7.07%)
1934 (17.03%)
2837 (24.98%)
3610 (31.79%)
565 (4.98%)
1607 (14.15%)
121 (12.49%)
191 (19.71%)
209 (21.57%)
224 (23.12%)
25 (2.58%)
199 (20.54%)
0.001
Histological type
ALM
In situ
LMM
NM
SSM
Others
Unknown
113 (1.01%)
634 (5.67%)
345 (3.09%)
1853 (16.58%)
4466 (39.96%)
520 (4.65%)
3245 (29.04%)
1 (0.10%)
102 (10.65%)
44 (4.59%)
91 (9.5%)
313 (32.67%)
21 (2.19%)
386 (40.29%)
0.001
Eye color
Blue/Grey
Brown/Black
Green/Hazel
Unknown
2393 (21.07%)
1398 (12.31%)
1741 (15.33%)
5824 (51.29%)
252 (26.01%)
114 (11.76%)
159 (16.41%)
444 (45.82%)
0.001
Early adult hair color
Black
Dark brown
Light brown
Dark red/Auburn
Light red/Ginger
Fair/Blonde
Unknown
117 (1.03%)
1671 (14.71%)
806 (7.1%)
568 (5.0%)
52 (0.46%)
2243 (19.75%)
5899 (51.95%)
13 (1.34%)
130 (13.42%)
99 (10.22%)
56 (5.78%)
4 (0.41%)
214 (22.08%)
453 (46.75%)
0.001
Skin color
Dark/Medium
Fair
Unknown
926 (8.15%)
4467 (39.34%)
5936 (52.51%)
65 (6.71%)
442 (45.61%)
462 (47.68%)
0.001
ALM, acral lentiginousmelanoma; LMM, lentigomalignamelanoma; NM, nodular mel-
anoma; SSM, superfıcial spreading melanoma.
#3285 Predictors of plasma 25-hydroxyvitamin D concentrations among
breast cancer survivors. Woo-Kyoung Shin,1 Zisun Kim,2 Hyun Jo Youn,3 Ji-
hyoung Cho,4 Jung Eun Lee1. 1Seoul National University, Seoul, Republic of
Korea; 2Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea;
3ChonbukNationalUniversityMedical School, Jeonju,Republic ofKorea; 4Keimyung
University School of Medicine, Daegu, Republic of Korea.
Background: A review of recent evidences suggests that circulating 25-hy-
droxyvitamin D (25-OHD) concentrations are associated with better prognosis
among breast cancer survivors. However, little is known about modifıable fac-
tors for vitamin D status among breast cancer survivors. We aimed to explore
demographic, lifestyle, and clinical factors associated with vitamin D status
among breast cancer survivors. Methods: We included a total of 207 breast
cancer survivors aged 21-79 years who were enrolled between 2015 and 2016 at
three large hospitals. Participants had been diagnosed with stage I to III primary
breast cancer and had breast cancer surgery at least 6months before enrollment.
We asked participants about demographic, socioeconomic, and lifestyle factors.
Clinical data were extracted from medical records. Dietary intake was assessed
using 3-day dietary records. Plasma 25-OHD concentrations were measured by
the electrochemiluminescence immunoassay. We fıt a multivariable linear re-
gressionmodel to predict plasma plasma 25(OH)Dwith all candidate predictors
with p  0.1 in the univariate analysis. Result: Mean value (SD) of plasma
25(OH)D concentrations were 23.75	 12.15ng/ml among users of supplement
containing vitaminD, and 13.35	 8.62ng/ml among non-user. In the univariate
linear regression models, we identifıed the following independent predictors
associated with plasma 25-OHD concentrations: vitamin D intake from supple-
ment, calcium intake from supplement, vitaminD from food, use of any supple-
ment, body mass index (BMI), months after diagnosis, season of blood draw,
daily sun exposure during the last 2 years, smoking habit, skin change after
sunburn, suncap use, parity, and ER status. When we included all of these pre-
dictors in the multivariate linear regression models, we found that use of any
supplement ( 1.19 for use vs. nonuse, p0.001), BMI at diagnosis ( -0.08
for 1 kg/m2 increment, p0.02), season of blood draw (  0.83 summer vs.
spring, p0.008; and  0.75 fall vs. spring, p0.01), and daily sun exposure
during the last 2 years ( - 0.0005 for 1minute increment, p0.02). Predicted
models explained 23.95% of the total variability in plasma 25-OHD concentra-
tions. Conclusions:We found that supplemental use, BMI at diagnosis, season of
blood draw, and daily sun exposure during the last 2 years were associated with
plasma 25-OHD concentrations among Korean breast cancer survivors. Future
studies are needed to investigate the role of vitamin D in the progression of
breast cancer amongKorean breast cancer survivors. Funding information: This
research was supported by the Basic Science Research Program through the
National Research Foundation of Korea (NRF) funded by the Ministry of Sci-
ence, ICT & Future Planning (NRF-2014R1A2A2A01007794).
#3286 Correlation between vitamin D levels and DNA repair capacity in
breast cancer patients stratifıedbymolecular subtypes.CarmenOrtiz,1 Jarline
Encarnación,1 Ralphdy Vergne,2 Wanda Vargas,1 Jaime Matta1. 1Ponce Health
Sciences University-Ponce Research Institute, Ponce, Puerto Rico; 2University of
Puerto Rico at Ponce, Ponce, Puerto Rico.
Vitamin D exists as vitamin D2 and D3, which are metabolized to 25-hy-
droxyvitamin D [25(OH)D], the major circulating vitamin D metabolite. Be-
sides its physiological functions, vitaminD levels have also been studied as a risk
factor for several hormonal cancers including breast cancer (BC). Worldwide,
BC accounts for nearly a quarter of all cancers in women. Nutritional studies
report that vitamin D intake is associated with a lower BC risk. Several discrep-
ancies exist regarding the role of serumvitaminD inBC risk.While some studies
report BC risk reduction by vitamin D only in premenopausal, others propose
that it only occurs in postmenopausal women. BC tumors may () or may not
(-) have three hormonal receptors: estrogen (ER), progesterone (PR), andHER2.
Based on their status, four principalmolecular BC subtypes have been identifıed:
luminal A (ER/, PR/, HER2-), luminal B (ER/, PR/, HER2),
HER2 (ER, PR, HER2), and triple negative (TN) (ER, PR, HER2).
If BC is analyzed in terms of molecular subtypes, low vitamin D levels have been
associated with aggressive phenotypes and worse prognosis. Vitamin D also
influences estrogen synthesis. Since we have previously shown that a low DNA
repair capacity (DRC), measured through the nucleotide excision repair path-
way, is a risk factor for BC and vitamin D has also been found to affect DNA
repair, the focus of this study is to examine the role of plasma vitamin D levels
and DRC in BC. The main aim is to elucidate whether there is an association
between vitamin D and DRC levels among the four molecular BC subtypes. We
hypothesize that a negative correlation between 25(OH)D and DRC levels will
be observed among these subtypes. As an initial effort, 47 BC cases and 20
controlswithout BCwere selected fromour large BC cohort.DRCwasmeasured
in lymphocytes of untreated women using the host cell reactivation assay. Pa-
thology reports were examined to divide BC cases according to their molecular
BC subtype: luminal A (n13), luminal B (n11), HER2 (n10), and TN
(n13). Plasma 25(OH)D levelsweremeasured using theUniCelDxCSystemat
a CLIA-certifıed lab. Our results show a negative correlation between 25(OH)D
and DRC levels (p0.04). Statistically signifıcant differences were found for
vitamin D levels among the different groups (p0.0019, ANOVA). Moreover,
higher 25(OH)D levels (47.97	2.4 ng/mL)were found inER-BC cases (p0.03,
t-test). When comparing vitamin D levels in BC subtypes, a signifıcant differ-
ence was found in HER2 and TN groups when compared with the control
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group (p0.05, Kruskal-Wallis). Based on these preliminary results we con-
clude that plasma vitamin D levels may be correlated with DRC levels in women
withBC.Ongoing studieswith a larger sample size are aimed at elucidatingmore
precisely the potential association between vitamin D and DRC in these molec-
ular BC subtypes.
#3287 Associations of whole food and lifestyle-based inflammation scores
with all-cause, cancer- and cardiovascular disease-specifıcmortality.Doratha
Byrd,1 Ashley Holmes,1 Suzanne Judd,2WDana Flanders,1 RoberdM. Bostick1.
1Emory University, Atlanta, GA; 2University of Alabama Birmingham, Birming-
ham, AL.
Chronically higher levels of inflammation have been implicated in the etiol-
ogy of cancer and othermajor chronic diseases. Contributors to chronic inflam-
mation likely include diet, physical activity, obesity, and smoking.Wedeveloped
dietary (DIS), lifestyle (LIS), and overall (OIS) inflammation scores to charac-
terize the aggregate of pro- and anti-inflammatory exposures, and investigated
associations of the scores with all-cause, cancer- and cardiovascular disease
(CVD)-specifıc mortality in the prospective Reasons for Geographic and Racial
Differences in Stroke Study (REGARDS) (n21,426). The components of the
scores were selected based on biological plausibility and previous literature. The
dietary components included processed meats, red meat, white meat, fısh, nuts,
legumes, coffee, tea, dairy products, refıned and whole grains, and nine other
botanical categories. The lifestyle components included bodymass index, smok-
ing status, alcohol intake, and exercise level. Associations of each score compo-
nent with a panel of biomarkers of inflammation in a subset of 577 male and
female, black and white, chronic disease-free participants in REGARDS were
assessed usingmultivariable linear regression, and the resulting beta coeffıcients
were used to weight each score component. For each study participant, the
weighted score components were summed to produce the scores such that a
higher score was more pro-inflammatory. The scores were categorized accord-
ing to quintiles of their distributions among all REGARDS participants at base-
line, and their associations withmortality were assessed usingmultivariable Cox
proportional hazards regression. Over an average of 7.89 years follow-up, 2,964
individuals died, including 854 from cancer. With increasing levels of each
score, there was increasing risk for all-cause, cancer- and CVD-specifıc mortal-
ities. For those in the highest relative to the lowest quintiles of the OIS, DIS, and
LIS, the multivariable-adjusted hazard ratios (95% confıdence intervals) for all-
cause mortality were: 2.16 (1.87, 2.49; Ptrend0.0001), 1.25 (1.10, 1.41;
Ptrend0.0001), and 1.94 (1.69, 2.24; Ptrend0.0001), respectively. The corre-
sponding fındings for cancer mortality were 1.79 (1.38, 2.32; Ptrend0.0001),
1.20 (0.95, 1.50; Ptrend0.10), and 1.83 (1.42, 2.37; Ptrend0.0001), respectively,
and for CVD mortality 2.38 (1.83, 3.09; Ptrend0.0001), 1.28 (1.02, 1.61;
Ptrend0.03), and 1.90 (1.49, 2.42; Ptrend0.0001). These results suggest that
pro-inflammatory diets and lifestyles may be associated with higher risk for
all-cause, cancer- and CVD-specifıc mortality.
#3288 Effects of concomitantmetformin and statins on overall survival of
pancreatic cancer patients: results from SEER-Medicare data analyses.
Jian-Yu E,1 Shou-En Lu,2 Yong Lin,2 Judith M. Graber,3 David Rotter,1 Lanjing
Zhang,4 Gloria M. Petersen,5 Kitaw Demissie,2 Grace Lu-Yao,6 Xiang-Lin Tan1.
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; 2Rutgers School of
Public Health, Piscataway, NJ; 3Rutgers, The State University of New Jersey, Pis-
cataway, NJ; 4University Medical Center of Princeton, Plainsboro, NJ; 5Mayo
Clinic, Rochester, MN; 6Sidney Kimmel Cancer Center, Philadelphia, PA.
Purpose: Growing mechanistic and epidemiologic evidence suggests that
both metformin and statins have anti-cancer effects and are associated with
reduced pancreatic cancer mortality. However, the joint effect of combination
statin/metformin on pancreatic cancer mortality is unknown. By applying a
robust analytic approach,we aim to examine the association betweenmetformin
and/or statin use and overall survival in a large cohort of patients with primary
pancreatic adenocarcinoma (PDAC). Patients and Methods: 12,572 elderly pa-
tients with primary PDAC diagnosed between 2008 and 2012 were identifıed by
using the Surveillance, Epidemiology, and End Results (SEER), and the detailed
information onmetformin and statin usewas extracted fromMedicare PartD.A
Cox proportional hazard model with time-varying covariate adjusted for the
propensity score was applied to assess the association of metformin and /or
statin use with overall survival while controlling for potential confounders. Re-
sults: Of total 12,572 PDAC patients (median age 76 years), 11,526 (91.77%)
patients died before the study ended with a median follow-up of 3.8 months
(interquartile range: 1.4-10.1). By the time-varying covariate analysis, statin use
was signifıcantly associated with an improved overall survival [Hazard ratio
(HR), 0.938; 95% confıdence interval (CI), 0.898 to 0.979], and more pro-
nounced in post-diagnosis statin users (HR, 0.693; 95% CI, 0.555 to 0.864).
However, metformin use was not signifıcantly associated with overall survival
(HR, 1.011; 95% CI, 0.939 to 1.091), neither in pre-diagnosis users (HR, 1.015;
95% CI, 0.970 to 1.061) nor in post-diagnosis users (HR, 0.990; 95% CI, 0.866 to
1.131). Additionally, no superior benefıcial effect was observed for dual users
(HR, 0.998; 95% CI, 0.947 to 1.053). Conclusions: Exposures to statin, not met-
formin, was signifıcantly associated with reduced overall mortality of PDAC,
indicating potential benefıts of statin use on improving survival among PDAC
patients. Further prospective validation is required to confırm these fındings.
#3289 Cutaneous melanocytic nevi and risk of melanoma deaths in
women and men: a prospective study. Wen-Qing Li, Hao Geng, Eunyoung
Cho, Abrar Qureshi. Brown University, Providence, RI.
Background: Increased number of common acquired melanocytic nevi
(moles) has been associated with an increased risk of melanoma. It is unclear
whether melanocytic nevi may predict melanoma deaths. We prospectively ex-
amined the association between number of melanocytic nevi and risk of mela-
noma deaths based on 77316 women from the Nurses’ Health Study (NHS) and
32454men from theHealth Professionals Follow-up Study (HPFS).Methods: In
both cohorts, diagnosis ofmelanomawas reported biennially and pathologically
confırmed. Deaths were confırmed by next of kin or the National Death Index.
Information on the number of moles with 3 mm diameter on the upper ex-
tremity was collected in 1986. We used Cox regression models to evaluate the
associations between number of melanocytic nevi and risk of melanoma deaths
in the overall cohorts as well as only among melanoma cases. Results: A total of
2450 cases of melanoma were documented (1545 in NHS and 905 in HPFS), out
of whichwe identifıed 192 incident deaths due tomelanoma (87 inNHS and 105
in HPFS) during the follow-up (1986-2012). Increased number of melanocytic
nevi was associated with melanoma deaths; the multivariate-adjusted hazard
ratio (HR) for 3 or more melanocytic nevi compared with no nevi on the upper
extremitywas 2.55 (95%confıdence interval (CI): 1.52-4.28) forwomen and 3.97
(95% CI: 2.54-6.22) for men. A secondary analysis further found that increased
number of melanocytic nevi was associated with both lethal melanoma (mela-
noma cases that died of melanoma) and non-lethal melanoma. Among mela-
noma cases, increased number of melanocytic nevi was independently associ-
ated with risk ofmelanoma deaths inmen, with aHR of 1.89 (95%CI: 1.17-3.05)
for 3 ormoremelanocytic nevi. The association persisted even after adjusting for
Breslow thickness ofmelanoma and appeared particularly stronger among those
with lower Breslow thickness (P for interaction0.03). However, number of
melanocytic nevi was not signifıcantly associated with risk of melanoma deaths
among melanoma cases in women (HR1.03, 95% CI: 0.61-1.76 for 3 or more
nevi). Conclusion: Increased number of melanocytic nevi was signifıcantly as-
sociatedwith risk ofmelanomadeaths in our cohorts of women andmen.Ahigh
number of melanocytic nevi may independently predict the risk of melanoma
deaths among men with melanoma.
#3290 Cancermortality by antiarrhythmic druguse in a population-based
cohort of Finnishmen.Kalle J. Kaapu,1 TeemuMurtola,1 Kirsi Talala,2 Kimmo
Taari,3 Teuvo Tammela,4 Anssi Auvinen1. 1University of Tampere, Tampere,
Finland; 2Finnish Cancer Registry, Helsinki, Finland; 3University of Helsinki,
Helsinki, Finland; 4Tampere University Hospital, Tampere, Finland.
Introduction: In-vitro studies have suggested that antiarrhythmic drug
digoxin might restrain the growth of cancer cells by inhibiting Na/K-AT-
Pase. A non-selective beta-blocker sotalol has similar effect on K-channels.
We evaluated the association between cancer mortality and digoxin, sotalol and
general antiarrhythmic drug use in a retrospective cohort study. Materials and
methods: The study population consists of 78,615 men originally identifıed for
the Finnish Randomized Study for Screening of Prostate Cancer. Men were
55-69 years old at baseline. Prevalent prostate cancer cases were excluded; no
exclusions were made based on other cancer types. Information on antiarrhyth-
mic drug purchases was collected from the national prescription database. We
used Cox regressionmethod to analyze the overall cancermortality and individ-
uallymortality from themost common causes of cancer death. Results: A total of
8,064 men (10.3%) had used antiarrhythmic drugs. Of these 5,668 had used
digoxin and 2,540 had used sotalol. During the median follow-up of 16.9 years
after baseline 26,790 (34.1%) men died, of these 8,225 (30.7% of deaths) due to
cancer. Overall cancer mortality was elevated among antiarrhythmic drug users
compared to non-users (HR 1.25, 95% CI 1.12-1.40). Similar results were ob-
served for digoxin (HR 1.44, 95%CI 1.26-1.63) but not for sotalol (HR 0.92, 95%
CI 0.68-1.24). Furthermore, the antiarrhythmic drug use was associated with
elevated risk of lung-cancer death (HR1.76 95%CI 1.46-2.14).However, the risk
associations disappeared in long-term use. When we restricted the analysis to
cancer cases only, no differences were observed in survival after the cancer
diagnosis for any cancer type. Conclusion: Cancermortalitywas elevated among
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users of antiarrhythmic drugs compared to non-users. This association is prob-
ably due to the differences between users and non-users as it was related to
short-term use, and disappeared in long-term use. Use of digoxin or sotalol was
not associated with improved cancer-specifıc survival.
#3291 Development of a novel prognostic scoring system for patient se-
lection in immune checkpoint inhibitor phase 1 clinical trials. Shiraj Sen,
Kenneth Hess, David Hong, Aung Naing, Sarina Piha-Paul, Filip Janku, Siqing
Fu, Holly Liu, Yunfang Jiang, Rahil Khanji, Daniel Karp, Apostolia Tsimberi-
dou, Nizar Tannir, Funda Meric-Bernstam, Vivek Subbiah. University of Texas
MD Anderson Cancer Center, Houston, TX.
Purpose: To develop a prognostic scoring system for selecting patients for im-
mune checkpoint inhibitor (ICI) phase 1 clinical trials. Background: The Royal
Marsden Hospital (RMH) and MD Anderson (MDA) prognostic scoring systems
have been validated for patients in phase 1 clinical trials treated with cytotoxic che-
motherapy and targeted therapy, but no such scoring system has been validated to
help select patients entering ICI clinical trials. Methods: We analyzed clinical data
from patients treated in phase 1 ICI clinical trials (with anti-CTLA4 and anti-PD1
antibody therapy) at theMDAnderson Center for Targeted Therapy. Sixteen clin-
ical factors were studied. Recursive partitioning analysis identifıed cut-points for
each clinical factor and a Cox proportional hazards regression model was used to
identify factors independently affecting overall survival. Results: Among 172 pa-
tients treatedwith ICI therapy (105CTLA4-based and 67 PD1-based) between Jan-
uary2013andNovember2015, themedianagewas60years (range: 19-86years) and
87 (51%) were male. The most common tumor types treated included renal cell
carcinoma(n25; 15%),non-small cell lungcancer (n21; 12%),melanoma(n
17; 10%), sarcoma (n  14; 8%), gastrointestinal stromal tumors (n  10; 6%),
prostate cancer (n 6; 3%), and colorectal cancer (n 6; 3%). Seven factors were
independently associated with signifıcantly worse overall survival: age 52 years
(hazard ratio [HR] 1.59, 95% confıdence interval [CI] 1.1-2.4), EasternCooperative
Oncology Group performance status1 (HR 2.81, 95% CI 1.3-6.3), lactate dehy-
drogenase466U/L(HR2.1,95%CI1.4-3.2),platelet count300109/L (HR1.8,
95%CI 1.2-2.8), absolute neutrophil count4.9 109/L (HR 2.3, 95%CI 1.5-3.5),
absolute lymphocyte count1.8 109/L (HR3.3, 95%CI 1.9-5.7), and livermetas-
tases (HR1.8, 95%CI1.2-2.6).An indexwascreatedwhereby thecohortwasdivided
into four riskgroupsbasedonthenumberof factorspresent: 0-2, 3, 4,or5-6.Median
overall survival was 24.2 months (0-2), 11.6 months (3), 8.0 months (4), and 3.8
months (5-6); log rank test, p 0.0001. The Harrell c-index of this scoring system
was 0.72, indicating signifıcant predictability. Conclusion: We have developed a
novel “MDA ICI” prognostic scoring system incorporating seven clinical parame-
ters with prognostic signifıcance for patients in phase 1 clinical trials treated with
immune checkpoint inhibitors. Unlike in the RMH and MDA prognostic scoring
systems, albumin level and number ofmetastatic sites did not independently corre-
latewithoverall survival. Prospective evaluationandexternal validationofournovel
prognostic scoring system iswarrantedandmayhelpbetter select patients for future
clinical trials of checkpoint inhibitors.
#3292 Cause-specifıcmortality of nonmetastatic prostate cancer patients.
Katarina Matthes,1 Giulia Pestoni,1 Dimitri Korol,2 Mieke Van Hemelrijck,3
Sabine Rohrmann1. 1Institute for Epidemiology, Biostatistics and Prevention,
University of Zurich, Zurich, Switzerland; 2Cancer Registry Zurich and Zug, Uni-
versity Hospital Zurich, Zurich, Switzerland; 3Cancer Epidemiology Group, Divi-
sion of Cancer Studies, King’s College London, London, United Kingdom.
Background: Prostate cancer (PCa) is the most frequent incident cancer in
men in Switzerland. One of the major challenges in the treatment of PCa is to
reliably distinguish between patients at risk of dying as a direct result of the
disease and those more likely to die of other causes. The purpose of this study
was to assess the associations of age and risk group based on stage, grade and
PSA level with primary treatment of non-metastatic PCa patients, and to evalu-
ate whether this treatment was associated with cardiovascular death or prostate
cancer specifıc mortality (PCSM). Methods: Population-based data from the
Cancer Registry of Zurich and Zug in Switzerlandwere used.We identifıed 1919
non-metastatic PCa patients diagnosed between 2000 and 2009 who were living
in the City of Zurich. PCa risk groups were stratifıed into three groups based on
T stage, Gleason score and initial PSA concentration as described by D’Amico
(low-risk: T1-2a, and Gleason score6, and PSA10 ng/mL; intermediate
risk: T2b and/or Gleason score 7 and/or PSA 10 and20; high-risk:
T2c or Gleason score 8-10 or PSA  20). Multiple imputation methods were
applied to deal with missing risk group information. We distinguished between
surgical procedures, radiotherapy, androgen deprivation therapy (ADT), active
surveillance, and watchful waiting. Fine and Gray competing risk regression
analysis was used to estimate sub-distribution hazard ratios for the outcomes
cardiovascular death, PCSMor other-causemortality. Results: Unadjusted com-
peting risk model revealed an increased risk of cardiovascular death for patients
with ADT (HR2.00 [1.27 - 3.14]), or watchful waiting compared to surgery
(HR 2.19 [1.58 - 3.02]). However, after adjustment for age and risk group, an
increased risk of cardiovascular death was no longer observed (ADT HR1.51
[0.93 - 2.46], watchful waiting HR 1.31 [0.91 - 1.89]). Only men80 years of
age still had an increased risk of cardiovascular death. Furthermore, we observed
an increased adjusted risk of PCSM inmenwithADT (HR2.84 [1.97 - 4.01]) or
under watchful waiting (HR1.78 [1.29 - 2.46]) compared to surgery, for men
70 years (HR 4.18 [2.18 - 8.00]) compared to men  70 years old, and for
patients with intermediate risk (HR2.69 [1.34 - 5.39]) and high risk (HR6.37
[3.30 - 12.30]) compared to patients with low risk. Discussion: The study sug-
gests that ADT use for non-metastatic PCa patients may not be associated with
an increased risk of cardiovascular death in general, but with an increased risk of
PCSM. This is likely explained by the more frequent ADT use in older men and
in men with a high-risk PCa. In addition, we observed that older men and men
with an intermediate- or high-risk PCa had an increased risk of PCSM.
#3293 Impact of the invasive depth on lymphnodemetastasis and survival
in Chinese patients with esophageal squamous cell carcinoma. Xin Song,1 Fu
You Zhou,2 Hai Jun Yang,2 Xue NaHan,1 Tang Juan Zhang,1 Lian Qun Zhang,2
Ning Liu,1 Jing Li Ren,3 Zhi Wei Chang,1 Xin Tian,1 Hai LingWang,1 Hui Fang
Tan,1 Li Dong Wang1. 1The First Affıliated Hospital of Zhengzhou University-
Zhengzhou University, Zhengzhou, China; 2Anyang Tumor Hospital, Anyang,
China; 3The SecondAffıliatedHospital of ZhengzhouUniversity, ZhengzhouUni-
versity, Zhengzhou, China.
The lymph node metastasis (LNM) has been well recognized as one of the
major risk factors affecting the survival of the patients with esophageal squa-
mous cell carcinoma (ESCC). However, it is a dilemma to determine the LNM
status before surgery. The invasive depth (T stage) of ESCC could be determined
either with computed tomography or ultrasound endoscopy andmay reflect the
severity of LNM. Thus, the present study was designed to determine the impact
of tumor invasive depth on LNM status and survival in ESCC patients with
T1-4N0M0. The enrolled 30,514 ESCC patients in this study were from the
ESCCdatabase inHenanKey Laboratory for Esophageal Cancer Research of the
First Affıliated Hospital, Zhengzhou University. Of the patients, there were
18346males with anmean age of 59.2	8.9, and 12168 females with anmean age
of 59.7	8.7. All the patients had been performed radical esophagectomy with-
out radiotherapy and chemotherapy before surgery, and the invasive depth re-
cords were retrieved from the medical records in hospitals after surgical resec-
tion. Based on the 6th version of UICC criteria, the invasive depth (T) was
classifıed as Tis, and T1-4. Of the 30,514 ESCC patients, 20,288 cases were suc-
cessfully followed until the end of 2015. The Logistic regression method were
used to determine the correlation between T stage and LNM status. The Kaplan-
Meiermethodwas applied to analyze the survival in different groups. The results
showed that, of the 30,514 ESCC patients, there were 3324 (10.9%) patients with
TisT1, 9616 (31.5%) with T2, 17249 (56.5%) with T3 and 325 (1.1%) with T4.
Accordingly, from Tis&T1 to T4, the number of the patients with positive LNM
were 554 (16.7%), 3392 (35.3%), 7737 (44.9%) and 205 (63.1%), respectively.
Logistic regression analysis indicated the risk of LNM was dramatically in-
creased from 2- to 8-folds with the T stages from Tis&T1 to T4, with OR values
of 2.725 (T2: 95%CI: 2.465-3.013), 4.067 (T3: 95%CI: 3.695-4.477) and 8.542
(T4: 95%CI: 6.699-10.892), respectively. Interestingly, seventeen percent of the
patients with Tis&T1 stages had occurred positive LNM, indicating that LNM
may occur in very early stage of ESCC. Kaplan-Meier analysis showed that T
staging was obviously associated with the survival in ESCC patients with nega-
tive LNM (P value  0.05). Overall, the present results indicated a strong cor-
relation between invasive depth and LNM status, suggesting that the invasion
depth may be one of crucial markers to reflect the LNM in ESCC. The invasive
depth could be used as an promising indicator for LNM status judgment in
clinical TNM staging and prognosis for ESCC. [Supported by the Joint Funds of
the National Natural Science Foundation of China (U1301227), the General
ProgramofNational Natural Science Foundation of China (81472323) andCor-
respondence to: Li Dong Wang, Email: ldwang2007@126.com]
#3294 Breast cancer extent and survival in diabetic women in a Finnish
population based cohort. Mika Murto,1 Miia Artama,2 Kala Visvanathan,3
Teemu Murtola4. 1Pirkanmaa Hospital District, Tampere, Finland; 2National
Institute for Health and Welfare, Helsinki, Finland; 3Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD; 4University of Tampere, Tampere, Fin-
land.
Introduction: Breast cancer and diabetes are two major health problems for
women. Around 1.7 million new breast cancer cases are diagnosed each year,
making breast cancer the most common cancer type in women. Number of
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people with diabetes is estimated to be 415 million worldwide, thus one in 11
adults have diabetes. However, evidence on the association between diabetes
and breast cancer prognosis is controversial. We estimated breast cancer extent
at diagnosis and survival in a Finnish population-based cohort of female breast
cancer patients.Materials andmethods: All newly diagnosed breast cancer cases
among women in Finland between 1995 and 2013 were identifıed from compre-
hensive national Finnish Cancer Registry. To minimize possible bias due to
differing participation in cancer screening the study population was limited to
women with at least one mammography screening before the diagnosis. In total
45,786 cases were included in our study cohort. Information on recorded diag-
noses of diabetes, hypertension, hypercholesterolemia and obesity from in- and
outpatient hospital visits during 1995-2013 were obtained from national Care
Register for Health Care maintained by National Institute for Health and Wel-
fare. Logistic regression was used to evaluate the risk of having cancer extended
to axillary lymph nodes or beyond at diagnosis. Cox regression was used to
evaluate risk of breast cancer death and overall mortality after the diagnosis.
Analyses were adjusted for age, comorbidities and number of mammography
screens before the diagnosis. Survival analyses were further adjusted for tumor
extent and primary treatment. Results: In total 1,419women had diabetes. Com-
pared to non-diabetic women, breast cancerwasmore often advanced to axillary
lymph-nodes (OR 1.19; 95% CI 1.05-1.34) or metastatic at diagnosis (OR 1.58;
95% CI 1.26-1.97) in diabetic women. Nevertheless, during the median fol-
low-up of 6.9 year after the diagnosis, risk of breast cancer death did not differ
between diabetic and non-diabetic women (0.99; 95%CI 0.81-1.21). Overall risk
of death was elevated among diabetic women (HR 1.34; 95% CI 1.19-1.51).
Conclusion: Diabetic women have more often advanced tumor extent at diag-
nosis compared to non-diabetic women. However, diabetes did not affect dis-
ease-specifıc survival within 6.9 years after the diagnosis.
#3295 Incidence of skeletal related events (SREs) among prostate cancer
patients treatedwith androgendeprivation therapy (ADT) inAbuja,Nigeria.
Oseremen I. Aisuodionoe-Shadrach,1 Sadiq N. Abu,2 Felix E. Magnus,2 Charles
Ugwu,2 Felix N. Kolo2. 1University of Abuja & University of Abuja Teaching
Hospital, Abuja, Nigeria; 2University of Abuja TeachingHospital, Abuja, Nigeria.
Background: Skeletal related events (SREs) are one or more of the following
conditions, occurring concurrently with or after the fırst bone metastasis: frac-
tures, radiotherapy to bone and spinal cord compression. SREs occur in men
with prostate cancer (CaP) and may result from androgen deprivation therapy
(ADT). The purpose of this study was to determine the incidence of SREs in
patientswithCaP treatedwithADT in our practice.Methods: Eligible caseswere
newly diagnosed patients with CaP seen at the University of Abuja Teaching
Hospital (UATH), Abuja, Nigeria between January 2012 and December 2015
with bone metastases and treated with ADT. Data compiled from only retriev-
able patient’s medical records showed tumor diagnosis, laboratory and radiol-
ogy results. SREs included spinal cord compression, surgery to bone, pathologic
fracture and radiation to bone. Results: All 142 cases of CaP reviewed who
received ADTwere fırst diagnosed as AJCC stage IV prostate cancer. More than
half the patients were 65 years of age with a mean (SD) of 68.3 (	 9.5) years.
Serum PSA range was 1.4- 2461.58 ng/ml with a mean (SD) of 113.7 (	 288.9)
ng/ml.We identifıed 29 patients (20.5%)who had one ormore SREs: spinal cord
compression (19.1%), pathological fractures (1.4%) and radiotherapy to the af-
fected bone (1.4%) being the most common SREs. Albeit fıfty (35.2%) more
patients had bone pains which was localized to the lumbo-sacral spine in 52% of
them, only two patients had internal fıxation to stabilize pathological fractures
and bone radiotherapy respectively. ADT in the patients was orchiectomy,
LHRH, anti-androgens and complete androgen blockade (CAB) {orchiectomy
or LHRH plus anti-androgens} in 14(9.8%), 3(2.1%), 44(30.9%) and 81{57%}
patients respectively. Conclusions: Albeit some clinical trials have found that
36-41% of high-risk metastatic prostate cancer patients developed SREs during
3 years of follow-up, our review of this hospital-based cohort of patients with
prostate cancer receiving ADT did not show the incidence of SREs to be as high
aswhat has been reported. Additional studies to explore the incidence of SREs in
patientswithmetastatic hormone refractory prostate cancer in our environment
may be relevant.
#3296 Survival among lung cancer patients in the U.S. Military Health
System: a comparison with the SEER population. Jie Lin,1 Christine Kama-
mia,1 Derek Brown,1 Stephanie Shao,1 KatherineA.McGlynn,2 Joel A.Nations,1
Corey A. Carter,1 Craig D. Shriver,1 Kangmin Zhu1. 1Walter Reed National
Military Medical Center, Bethesda, MD; 2National Cancer Institute, Rockville,
MD.
The U.S. military health system (MHS) provides universal access to its bene-
fıciaries. However, little is known about whether the universal access has trans-
lated into improved patient outcomes.We compared survival among non-small
cell lung cancer (NSCLC) cases in MHS with that of NSCLC cases from the
general U.S. population. TheMHS data were obtained from The Department of
Defense’s (DoD) Automated Central Tumor Registry (ACTUR). The U.S. pop-
ulation data were drawn from the National Cancer Institute’s (NCI) Surveil-
lance, Epidemiology, andEndResults (SEER) program18 registries (1973- 2012)
which represents 27.8% of the U.S. population. NSCLC patients in ACTUR and
SEERwhowere diagnosed between January 1, 1987 andDecember 31, 2012were
included. The ACTUR and SEER cases were then matched by age group, sex,
race, and year of diagnosis group at a matching ratio of 1:4, which comprised of
16,257 cases from ACTUR and 65,028 cases from SEER. Kaplan-Meir curves
and log-rank test were used to compare overall survival between the two popu-
lations. Multivariable Cox proportional hazards models for matched data were
used to estimate hazard ratios (HRs) and 95% CI with adjustment for potential
confounders. Compared to the SEER cases, the ACTUR cases were more likely
to be diagnosed at stage I or stage II (P0.0001) and less likely to be diagnosed
at stage IV. ACTUR cases also had a lower percentage of poorly differentiated
tumors than did SEER cases, who had a higher percentage of well differentiated
andmoderately differentiated tumors (P0.0001). Kaplan-Meir survival curves
showed signifıcantly better survival among ACTUR cases than SEER cases (Log
Rank P0.001). In Cox proportional hazards model analysis, ACTUR cases
exhibited signifıcantly better overall survival than did SEER cases (HR0.78,
95% CI0.76 to 0.81). The survival advantage of ACTUR cases remained after
stratifıcation on cancer stage, age group, sex and race. Further analyses revealed
that ACTUR cases were more likely to receive surgery for early-stage (stages I
and II) tumors (OR1.41, 95% CI1.28 to 1.55), and radiation therapy for late
stage (stages III to IV) tumors (OR1.09, 95% CI1.03 to 1.15). Our results
suggest that the survival of NSCLC patients in theMHS is better than that in the
general population, implying that lung cancer care and programs within the
MHS has translated into improved patient outcomes.
#3297 Survival predictors of Burkitt’s lymphoma in children, adults and
elderly in the United States during 2000-2013. Fahad Mukhtar,1 Paolo Bof-
fetta,2HarveyA.Risch,3 JongY. Park,4OmonighoM.Bubu,1 LindsayWomack,1
Thuan V. Tran,5 Janice C. Zgibor,1 Hung N. Luu1. 1University of South Florida,
Tampa, FL; 2Mount Sinai School of Medicine, New York, NY; 3Yale University,
New Haven, CT; 4H. Lee Moffıtt Cancer Center and Research Institute, Tampa,
FL; 5Vietnam National Cancer Hospital, Hanoi, Viet Nam.
Background. Burkitt’s Lymphoma (BL) has three peaks of occurrence, in chil-
dren, adults and elderly, at 10, 40 and 70 years respectively. To the best of our
knowledge, no study has been conducted to assess predictors of survival in the
three age groups. We hypothesized that the predictors of survival may differ by
age group.We, therefore, sought to determine the predictors of survival for BL in
these three groups: children (15 years of age), adults (40-70 years of age) and
elderly (70 years of age). Methods. Using the Surveillance, Epidemiology, and
End Results (SEER) database covering the years 2000-2013, we identifıed 797
children, 1,994 adults and 757 elderly patients newly diagnosed with BL. We
used Cox proportional hazards regression models to determine prognostic fac-
tors for survival for each age group. Results. Five-year relative survival in BL for
children, adults and elderly were 90.4%, 47.8%, and 28.9%, respectively. Having
at least stage II disease andmultiple primaries were associated with higher mor-
tality in the elderly group. In adults, multiple primaries, stage III or IV disease,
African American race and bone marrow primary were associated with in-
creased mortality whereas stage IV disease and multiple primaries were associ-
ated with worse outcome in children. Conclusion. These fındings demonstrate
commonalities and differences in predictors of survival that may have implica-
tions for management of BL patients. Financial Support: This work was sup-
ported by the US National Institutes of Health/National Cancer Institute
1P20CA210300-01 (PI: ShuXO,TranT/Sub-contract-PI: LuuHN) and theUni-
versity of South Florida start-up grant (PI: Luu HN).
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#3298 Diindolylmethane and its halogenated analogues induce autophagy
in human prostate cancer cells via induction of the astrocyte-elevated gene-1
(AEG-1). Hossam Draz,1 Alexander Goldberg,1 Thomas Sanderson,1 Stephen
Safe2. 1INRS-Institute Armand Frappier, Laval, Quebec, Canada; 2Texas A&M
University, College Station, TX.
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3,3=-diindolylmethane (DIM) and its halogenated derivatives (ring-DIMs)
are recently shown to induce protective autophagy in human prostate cancer
cells. The mechanism of induction of autophagy by DIM has not been eluci-
dated. As DIM is a mitochondrial ATP synthase inhibitor, we hypothesized that
DIM and ring-DIMs induce autophagy via alteration of AMP/ATP ratio and
activation of AMPK signaling in prostate cancer cells. Autophagic activity was
monitored by LC3B-I to LC3B-II conversion in LNCaP and C42B prostate can-
cer cells. Autophagic vacuoles were examined using Cyto-ID autophagy detec-
tion kit and transmission electronmicroscope (TEM). Protein levels for AMPK,
pAMPK, acetyl-CoA carboxylase (ACC), pACC, AEG-1, pULK-1 and -actin
were measured by western blot. AMPK and AEG-1 gene expression was down-
regulated using siRNA. DIM and ring-DIMs induced autophagy by increasing
autophagic vacuoles and LC3B-I to LC3B-II conversion in LNCaP and C42B
cells. These compounds also induced AMPK,ULK-1 andACC phosphorylation
in a time dependent manner. Interestingly, DIM, 4,4= dibromoDIM and 7,7=
dichloroDIM induced the oncogenic protein AEG-1 time dependently in LN-
CaP and C42B cells. Downregulation of AEG-1 or AMPK inhibited DIM- and
ring-DIM-induced autophagy. Pretreatment with ULK1 inhibitor MRT 67307
or siRNAs targeting AEG-1 or AMPK potentiated the cytotoxicity of DIM and
ring-DIMs. Interestingly, downregulation of AEG-1 induced senescence in cells
treated with toxic concentrations of DIM or ring-DIMs, and inhibited the onset
of apoptosis in response to DIM or ring-DIMs. In summary, we identifıed a
novel mechanism for DIM- and ring-DIM-induced protective autophagy, via
induction of AEG-1 and activation of AMPK. Our fındings could help towards
the development of novel drug therapies for prostate cancer that include selec-
tive autophagy inhibitors as adjuvants.
#3299 Radiation induced p53-dependent cytoprotective autophagy fails
to reduce radiation sensitivity in H460 non-small cell lung cancer cells. Jing-
wen Xu,1 Tareq Saleh,2 Liliya Tyutynuk-Massey,2 Yingliang Wu,1 David A.
Gewirtz2. 1Shenyang PharmaceuticalUniversity, Shenyang, China; 2VCUMassey
Cancer Ctr., Richmond, VA.
Our previous studies showed that radiation-induced autophagy could be ei-
ther cytoprotective or nonprotective in A549 non-small cell lung cancer cells,
HN30 and HN6 head and neck cancer cells and 4T1 breast tumor cells, and that
this functional difference was related to the status of p53 in the cells (i.e. cyto-
protective autophagy in p53 wild type (wt) cells and nonprotective autophagy in
cells with mutant or null p53) [1]. Despite the fact that inhibition of autophagy
has been proposed as a strategy to overcome resistance to radiation and chemo-
therapy, there is little direct information in support of the premise that the
induction of autophagy confers resistance. As an example, studies in HCT-116
cells that are either wt or null in p53 demonstrate essentially identical radiation
sensitivity [2], although the nature of radiation induced autophagy was not
determined in these cell lines. To address this question, p53 wt and p53 null
H460 cell lines were utilized to evaluate whether cytoprotective autophagy ac-
tually suppressed radiation sensitivity. Acridine orange staining, flow cytomet-
ric analysis and western blotting (LC3B, p62, Atg5) showed that following ex-
posure to 6Gy of radiationwtp53 and p53-null H460 cells exhibited a signifıcant
induction of autophagy. p53 wt H460 cells showed sensitization to radiation
upon pharmacological autophagy inhibition and Atg5 knock down. However,
pharmacological inhibition of autophagy and knock down of Atg5 genes failed
to influence sensitivity to radiation in p53-null H460 cells. Furthermore, clono-
genic survival assays showed that while exposure to radiation induced a dose-
dependent (2, 4, 6, 8 Gy) decrease in clonogenicity in both p53wt and p53-null
H460 cells, radiation sensitivity was not decreased in the p53 wt cells. Taken
together, these fındings indicate that cytoprotective autophagy may not actually
alter the nature of radiation (and possibly chemotherapeutic) sensitivity in tu-
mor cells. [1] Chakradeo, S, et al. Mol Pharm (2015): [2] Lindgren, T, et al. Int J
Rad Biol (2015). Acknowledgments: We would like to thank Dr. Santiago Lima
(Virginia Commonwealth University) for the H460 p53-null cells.
#3300 Inhibition of autophagy by 3-MA enhances the effect of ursolic
acid-induced apoptosis in hepatoma SK-Hep-1 cells. Chuang Wan-Ling, Lin
Ping-Yi, Chen Yao-Li. Changhua Christian Hospital, Changhua City, Taiwan.
Purpose: The aimof this study is to investigate the autophagic effect ofUrsolic
Acid (UA) on hepatoma SK-Hep-1 cells. Methods: The cytotoxicity of UA in
hepatoma SK-Hep-1 cells was measured by MTT assay, the accumulation of
acidic vesicular organelles was measured by FACS, the protein expression of
LC3-II was detected by immunofluorescence staining, and the autophagic pro-
tein expression was evaluated by western blotting. Hepatoma SK-Hep-1 cells
treated with a combination of autophagy inhibitor 3-Methyladenine (3-MA)
and UA, then use Annexin V/PI Double Staining and western blotting to detect
apoptosis and apoptotic protein levels. StatisticalAnalysesDatawas expressed as
the mean	 standard deviation and were compared using the Student’s t-test. A
p value of0.05 was considered to indicate statistical signifıcance. All statistical
analyses were performed using GraphPad Prism software, version 4.0 (Graph-
Pad Software, Inc., La Jolla, CA, USA). Preliminary Results: SK-Hep-1 cells
treated with different concentrations of UA (0, 20, 40, and 60 M). Regarding
the results, the half-maximal inhibitory concentration (IC50) was 45.9 and 36.6
M for 24 and 48 h, respectively. The FACS results showed that when increase
the dose of UA could increase the percentages of autophagic populations. The
anti-autophagic proteins such as Beclin, Atg-5, Atg-7, and LC3-II, in our results
showed that UA decreased the protein expression of mTOR, PI3K, and p62 and
PI3K/Akt/mTOR expression. Immunocytochemistry staining showed that SK-
Hep-1 cells treated with UA increased the protein expression of LC3-II. The
combination treatment of 3-MA and UA signifıcantly increased the apoptotic
cell death asmonitored by increased protein expression of Caspase-3 and PAPR.
Conclusions: UA could induced autophagy in hepatoma SK-Hep-1 cells
through inhibition of mTOR and PI3K signaling pathways. SK-Hep-1 cells
treated with UA exhibited LC3-/LC3-II conversion, increased protein expres-
sion levels of Beclin, Atg-7, and Atg-5 along with reduced protein expression
levels of p62. UA-induced apoptosis was enhanced by the treatment of au-
tophagy inhibitor 3-MA. Our fındings may assist in the development of novel
chemotherapeutic agents for the treatment of malignant types of liver cancer.
#3301 A three-pronged attack on cancer cells: Inductionof non-protective
autophagy, inhibition of lysosomal acidifıcation and promotion of energetic
impairment. Nethaji Muniraj,1 Arumugam Nagalingam,1 Panjamurthy Kup-
pusamy,2 Neeraj K. Saxena,2 Dipali Sharma1. 1Johns Hopkins Sidney Kimmel
Comp. Cancer Ctr., Baltimore, MD; 2University of Maryland, Baltimore, MD.
Background and Aim: Cancer cells undergo cytoprotective autophagy and
evade chemotherapy therefore many clinical trials are investigating the effıcacy
of autophagy inhibition in combination with chemotherapy. At the functional
level, autophagic process can be cytoprotective, cytotoxic, cytostatic or nonpro-
tective. We investigated strategies to convert cellular autophagic response to
non-protective autophagy which does not interfere with therapeutic regimens
exploiting bioactive molecules. Methods: Utilizing in vivo xenograft models, we
established that Withaferin A (WA), a bioactive molecule fromWithania Som-
nifera inhibits breast tumorigenesis. Autophagy studies were conducted utiliz-
ing immunoblot, RT-PCR, and immunofluorescence analyses for autophagy
markers, transmission electronmicroscopy and confocal imaging. The fusion of
autophagosome and lysosome was examined by using GFP-LC3/LysoTracker-
red and GFP-LC3/mCherryRAB7A. Protein degradation activity of lysosomes
and ATP levels were examined by DQ-BSA assay, Cathepsin activity and quan-
titative ATP assay. Results: WA inhibited growth and induced apoptosis in
breast cancer cells resulting in inhibition of breast carcinogenesis in vivo. Al-
thoughWA increased tumor suppressor LKB1which is known to be involved in
autophagy, WA-mediated increased cleavage of Light Chain 3 type II (LC3-II)
and punctated LC3-II staining was LKB1-independent. The redistribution of
EGFP-LC3 from cytosol to autophagosome indicated increased formation of
autophagosomes in WA-treated cells. However, WA-induced increased au-
tophagosome-formationwas notmediated by increased activation of autophagy
by upstream processes but was due to blockade of lysosomal-degradation as
evident by higher level of sequestosome 1 (SQSTM1/p62) and decreased turn-
over of LC3. WA was found to be a potent lysosomal deacidifıcation agent
capable of blocking autophagic flux. Accordingly, inhibiting autophagy by
blocking formation of autophagosomes or elevating lysosomal pH did not in-
terfere with WA-mediated growth-inhibition. WA blocked autophagic flux de-
creasing recycling of cellular fuels leading to reduced energy supply. Investigat-
ing this alternative mechanism, we discovered that indeed, WA reduced ATP
levels and increased phosphorylation ofAMP-activated protein kinase (AMPK).
Modulating substrates for tricarboxylic acid (TCA) cycle with methyl pyruvate
protected WA-treated cells while 2DG potentiated WA-induced cell death.
Conclusion: Our results indicate that WA induces a non-protective autophagy
and blocks energy fuels in cancer cells by reducing ATP levels and inhibiting
lysosomal acidifıcation hence offering a three-pronged approach to facilitate
cancer cell death. WA might be a useful strategic addition to chemotherapy
regimens to evade cytoprotective effects of autophagy.
#3302 Autophagy is required for cell survival under L-asparaginase-in-
duced metabolic stress in acute lymphoblastic leukemia cells. Jun Inoue,1
Hiroyoshi Takahashi,1 Kimiyoshi Sakaguchi,2 Masatoshi Takagi,3 Shuki Mizu-
tani,3 Johji Inazawa1. 1Dept. ofMol. Cytogenetics, TokyoMedical &Dental Univ.,
Tokyo, Japan; 2Department of Pediatrics, Hamamatsu University School of Med-
icine, Shizuoka, Japan; 3Department of Pediatrics and Developmental Biology,
Tokyo Medical & Dental Univ., Tokyo, Japan.
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L-asparaginase has been used for more than three decades in acute lympho-
blastic leukemia (ALL) patients and remains an essential drug in the treatment of
ALL. Poor response to L-asparaginase is associated with increased risk of ther-
apeutic failure inALL.However, both themetabolic perturbation andmolecular
context of L-asparaginase-treated ALL cells has not been fully elucidated. Here
we identify that treatment with L-asparaginase results in metabolic shutdown
via the reduction of both glycolysis and oxidative phosphorylation, accompa-
nied by mitochondrial damage and activation of autophagy. The autophagy is
involved in reducing reactive oxygen species (ROS) level by eliminating injured
mitochondria. Inhibition of autophagy enhances L-asparaginase-induced cyto-
toxicity and overcomes the acquired resistance to L-asparaginase in ALL cells.
The ROS-p53 positive feedback loop is an essential mechanism of this synergis-
tic cytotoxicity. Thus, our fındings provide the rationale for the future develop-
ment of combined treatment of L-asparaginase and anti-autophagy drug in ALL
patients.
#3303 Survivin negatively-regulates autophagy through interference with
the formation of Atg5-Atg12-Atg16L complex in breast cancer cells. Hsiu-
Han Chan,1 Mohane Selvaraj Coumar,2 Siao-Muk Cheng,1 Shing-Ling Tsai,1
Chun-Hui Lin,1 Shang-Hung Chen,3 Euphemia Leung,4 Chun Hei Antonio
Cheung1. 1National Cheng Kung Univ. College of Medicine, Tainan, Taiwan;
2Pondicherry University, Puducherry, India; 3National Health Research Insti-
tutes, Tainan, Taiwan; 4The University of Auckland, Auckland, New Zealand.
Survivin, a member of the inhibitors-of-apoptosis proteins family, is highly
expressed in different cancers and its expression is correlated with tumorigene-
sis and tumor metastasis. At the cellular and molecular levels, Survivin is a dual
functions protein that promotes mitosis and also inhibits apoptosis. In this
study, we found that Survivin is a novel negative-regulator of autophagy. Mo-
lecular analysis and computational modeling revealed that Survivin negatively
regulates the formation of Atg5-Atg12 conjugates, which plays important roles
in the process of autophagosome elongation, in breast cancer cells. It also neg-
atively regulates the expression and activity of cathepsin L in cells. Interestingly,
we found that Survivin binds to p62/SQSTM1 and LC3B and is also an au-
tophagic substrate protein, inwhich its expression is in part directly regulated by
autophagy at the protein level. Finally, mechanistic study revealed YM155, a
Survivin inhibitor that was originally developed to inhibit Survivin gene tran-
scription, downregulates Survivin expression in part through autophagic pro-
tein degradation. Taken together, fındings of this study provide newmechanistic
insights into both molecular functions and regulations of Survivin and the mo-
lecular mechanism of actions of YM155, a drug currently undergoing clinical
trials for cancer treatment.
#3304 Inhibition of autophagy enhancesmitochondria-mediated apopto-
sis in malignant mesothelioma cells by cisplatin and sulforaphane. Yoon Jin
Lee,1 David M. Lee,2 Hae Nam,1 Sang Lee1. 1Soonchunhyang Univ. College of
Medicine, Cheon-An Choong-Nam, Republic of Korea; 2University of Maryland,
College Park, MD.
Drug resistance to current chemotherapy regimens has been considered a cell
survival adaptive response in malignant mesothelioma cells. Therefore, new
strategies to enhance the apoptotic signal and overcome resistance to chemo-
therapeutics are necessary to improve treatment outcomes for this deadly dis-
ease.Here, the effect of sulforaphane, an isothiocyanate compoundderived from
glucoraphanin present in cruciferous vegetables, on enhancing anticancer role
of cisplatin was investigated inmalignantmesothelioma cells. At concentrations
showing little toxicity in normal human mesothelial MeT-5A cells, the com-
bined treatment with both compounds exhibited synergistic growth-inhibiting
and apoptosis-promoting effects, as demonstrated in a series of pro-apoptotic
events including reactive oxygen species (ROS) accumulation, loss ofmitochon-
drial membrane potential, up-regulation of p53, increased Bax/Bcl-2 ratio, acti-
vation of caspase-3, and the occurrence of a sub-G0/G1 peak with an increase in
the cells with pyknotic and fragmented nuclei, Annexin V-PE(), and G2/M
phase transition delay in the cell cycle. The levels of phosphorylation of bothAkt
andmTORwere decreased by the combined treatment, whichwas accompanied
by a signifıcant increase in the level of autophagosomal marker protein LC3-II
and the accumulation of acidic vesicular organelles. Furthermore, scavenging of
ROS by antioxidant N-acetylcysteine inhibited both the apoptosis and au-
tophagy, while the inhibition of autophagy by bafılomycin A1 potentiated apo-
ptotic cell death following the combination treatment of sulforaphane and cis-
platin, indicating the cytoprotective role of autophagy counteracts apoptosis of
malignant mesothelioma cells. Considering the pro-oxidant-based combina-
tional approach, our data provide a rationale for targeting cytoprotective au-
tophagy as a potential therapeutic strategy for malignant mesothelioma.
#3305 Autophagic induction through upregulation of sestrin-2 transcrip-
tion and mRNA stability mediates the anticancer effect of new compound
ChlA-F. Xiaohui Hua,1 Chuanshu Huang,1 Xueru Wu,2 Jingxia Li3. 1Nelson
Institute of Environmental Medicine, New York University, Tuxedo Park, NY;
Wenzhou Medical University, China; 2Departments of Urology, New York Uni-
versity School of Medicine, New York, NY; 3Nelson Institute of Environmental
Medicine, New York University, Tuxedo Park, NY.
ChlA-F is a novel conformation-derivative of Cheliensisin A (Chel A), which
is a new styryl-lactone isolated from Chinese Herb Goniothalamus cheliensis
Huand shows potent antitumor potential effect both in vitro and in vivo. How-
ever, the anticancer activity and its potential mechanisms underlying ChlA-F
action have never been explored. In present study, we evaluated the potency of
ChlA-F on anchorage-independent growth and its association with autophagic
responses in human high grade invasive bladder cancer cells. We found that
ChlA-F signifıcantly inhibited anchorage-independent growth of human blad-
der cancer cells by induction of autophagy in a sestrin2(SESN2)-dependent
Fashion. Our results revealed that ChlA-F treatment specifıcally induced SESN2
expression via increasing its both gene transcription andmRNAstability.On the
one hand, ChlA-F treatmentmarkedly attenuatedDicer protein abundance, and
in turn abolished miR-27a maturation and further relieved miR-27a directly
binding to SESN2 mRNA 3=UTR, thereby promoting SESN2 mRNA stabiliza-
tion. On the other hand,ChlA-F treatment promoted Sp1 abundance and con-
sequently mediated SESN2 transcription. Moreover, either knockdown of Sp-1
or ectopic expression of miR-27a could abolish the autophagic response and
reversed the inhibition of anchorage-independent growth in human bladder
cancer cells. These results demonstrate that anticancer effect of ChlA-F is me-
diated by its activating autophagic pathway through promoting both SESN2
mRNA transcription and stabilization,which offers novel insights into the anti-
cancer effect of ChlA-F on bladder cancer and provides a therapeutic alternative
against human bladder cancer.
#3306 Inhibition of ribosomal protein S6 (rpS6) phosphorylation and cell
proliferation by a novel chloroquine analog in lung cancer cells. Juan Sironi,
Evelyn Aranda, Lars Nordstroem, Roman Perez Soler, Edward L. Schwartz. Al-
bert Einstein College of Medicine, Bronx, NY.
Autophagy is an evolutionarily conserved self-defensemechanism that allows
tumor cells to overcome stress during oncogenesis and after treatment with
chemotherapy. It is the basis of clinical trials using the autophagy inhibitors
chloroquine (CQ) and hydroxychloroquine (HCQ). While searching for novel
agents targeting autophagy, we discovered a compound, named EAD1, that is
structurally related to CQ but is up to 16-fold more potent an inhibitor of au-
tophagy and of lung cancer cell proliferation than CQ. Interestingly, one of the
cell lines whose proliferation was inhibited by EAD1 were H1650 NSCLC cells.
This was surprising asH1650 cells have a biallelic deletionwithin theAtg7 locus.
Atg7 is a critical component of the canonical autophagy pathway and its loss
renders cells autophagy-defıcient. This observation was confırmed in H460
Atg7-knockout cells. That these cells had the same sensitivity to EAD1 (and
HCQ) as did cells with an intact autophagy pathway suggests that inhibition of
autophagy was not the mechanism by which those drugs inhibit cell prolifera-
tion.We therefore conducted exploratory experiments to identify other possible
sites of action of EAD1. The onlymolecular change we observed with EAD1was
the selective inhibition of ribosomal protein S6 (rpS6) phosphorylation, which
correlatedwith its inhibition of cell proliferation. rpS6 is a component of the 40S
ribosome subunit, and is only one of two ribosomal proteins known to be phos-
phorylated in a regulated manner. The decrease in rpS6 phosphorylation also
occurred in the Atg7-defıcient cells, indicating it was not a consequence of au-
tophagy inhibition. rpS6 regulates cell size, survival, and migration. Consistent
with these reports, we found that EAD1 caused a signifıcant decrease in the size
of the H460 cells (when controlled for cell cycle distribution), and this decrease
was not seen with HCQ. rpS6 is phosphorylated and activated by two known
families of kinases, p70 S6K and p90 RSK, that are downstream targets of the
mTORC1 and the RAS/MEK/ERK pathways, respectively. However, we have
not seen any changes in the expression or phosphorylation of the members of
these pathways, leading us to hypothesize that EAD1 is either having a direct
effect on rpS6, or that it is blocking the kinase activity of an already activated
p70S6K or p90RSK. Further studies are needed to determine the role of rpS6 in
cancer cells, and to assess if it is a viable target for future drug development.
#3307 Induction of autophagy as amechanismof therapeutic resistance in
head and neck cancer. Jaimee C. Eckers, Adam D. Swick, Tyler Fowler, Justin
Skiba, Kwangok P. Nickel, Randall J. Kimple.University of Wisconsin-Madison,
Madison, WI.
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Background: In the curative setting for head and neck cancer (HNC) a com-
monly used treatment is radiation combined with the anti-EGFR monoclonal
antibody cetuximab (CTX).However, despite decades of research into improved
treatments, therapeutic resistance remains a major challenge for this malig-
nancy with roughly 40% of patients developing recurrent disease.We are study-
ing the molecular mechanisms by which radiation and cetuximab induce au-
tophagy and how this process can be modulated to improve the effıcacy of
therapy. Methods: We evaluated a panel of both human papillomavirus (HPV)
positive and negative HNC cell lines for autophagic response to both CTX treat-
ment and ionizing radiation (XRT). Induction of autophagy was detected by
immunoblot flux assays for LC3 and p62 and by immunofluorescent staining of
autophagic vesicles. siRNA knockdown of EGFR, LAMPT4B, ULK1, Beclin1
and others was used to probe the involvement of different signaling molecules.
The addition of specifıc autophagy inhibitors, such as the ULK1 inhibitor SBI-
0206965, to CTX or XRT treatment was tested to determine whether the reduc-
tion of autophagic response reduced cell survival in a clonogenic survival assay.
Induction of apoptosis was analyzed by immunoblot against cleaved Caspase
and PARP and AnnexinV staining. Results: Flux assays revealed that both CTX
and XRT induced autophagy in a time and dose dependent manner. Immuno-
fluorescent staining of LC3 to identify autophagic vesicles showed that a rela-
tively small fraction of the total cell population is able to induce this response.
Specifıc siRNA knockdown of EGFR and LAMPT4B was able to abrogate the
induction of autophagy in response to both CTX and XRT. Involvement of
alternative downstream pathways involving either ULK1 and Beclin1 or p53 in
response to either treatment is under investigation. To determine whether
blockade of cytoprotective autophagy can help overcome therapeutic resistance,
we tested specifıc autophagy inhibitors in combination with either CTX or XRT
treatment. The addition of the ULK1 inhibitor to CTX or XRT induced apopto-
sis as shown by caspase activity, AnnexinV staining, and reduced cell survival in
clonogenic assays. Conclusions: Autophagy may play a critical and protective
role in how head and neck cancers respond to therapeutic stress. The addition of
specifıc autophagy inhibitors to standard treatmentsmay provide a way to over-
come resistance to therapy.
#3308 Mitophagy induction and interferencewith cancer-specifıc apopto-
sis in SHetA2-treated cells. Vishal Chandra,1 Andrew Long,2 Chioniso Pa-
tience Masamha,3 Doris Mangiaracina Benbrook1. 1University of Oklahoma
Health Sciences Center (OUHSC), Oklahoma City, OK; 2Universitätsklinikum
Hamburg-Eppendorf, Hamburg, Germany; 3Butler University, Indianapolis, IN.
Background: SHetA2 is a small molecule flexible heteroarotinoid (Flex-Het)
compound that exhibited in-vivo cancer therapeutic and chemoprevention ac-
tivity, lack of mutagenicity or teratogenicity, and a pharmacologic profıle suit-
able for an oral drug. First-in-human clinical trials of SHetA2 for ovarian cancer
prevention and cervical cancer treatment are in development. Autophagy is
induced in cancer cells by a wide variety of therapeutic drugs and commonly
interferes with the drugs effıcacies. Because SHetA2 binds to mortalin and in-
ducesmitochondrial damage and apoptosis in cancer, but not in healthy cells, we
hypothesized that this drug induces mitochondria-selective autophagy (mi-
tophagy) in cancer, but not healthy cells; and that the mitophagy interferes with
SHetA2-induction of apoptosis. Methods: Cultures of human ovarian and cer-
vical cancer cell lines and human ovarian surface epithelium (HOSE) were
treated with various concentrations and combinations of SHetA2, 3-methylad-
enine (3-MA), Beclin-1 siRNA, and caspase inhibitors. Autophagy was evalu-
ated by electron microscopy (EM) and fluorescent imaging of LC3B processing
in cells and byWestern blot (WB) analysis of p62, Beclin-1 andLC3Bprocessing.
Mitophagy was measured by EM of cells and WB analysis of BNIP3 total levels
and co-immunoprecipitation with LC3B in protein extracts. Apoptosis was
measured by Annexin-V and propidium iodide staining of cells and by WB
analysis of caspase 9 and 3 and PARP-1 cleavage. Result: Induction of autophagy
by SHetA2 treatment was demonstrated by the development of double-mem-
braned autophagosomes and accumulation of the processed LC3B II in cancer,
but not in HOSE cells. Mitophagy was demonstrated by the presence of mito-
chondria inside the autophagosomes and by reduction of total BNIP3 in associ-
ation with increased BNIP3/LC3B complexes in SHetA2 treated cells. Au-
tophagic flux was demonstrated by gradual reduction of p62. Conversion of
autophagy to apoptosis was associated with reappearance of basal p62 levels and
cleavage of Beclin-1, PARP-1, and caspases 9 and 3 about 24 hours after initia-
tion of treatment. Interference of the autophagy with apoptosis was demon-
strated by increased levels of apoptosis in cells co-treated with SHetA2 and
autophagy inhibitors (3-MA or Beclin-1 siRNA) along with reduced apoptosis
in cells co-treatedwith SHetA2 and an autophagy inducer (rapamycin). Thiswas
observed in cell lines harboring mutant or no p53, but not in an ovarian cancer
cell linewithwild type p53. Conclusion: SHetA2-induction of autophagymay be
initiated by mitochondrial damage and reduces, but does prevent, SHetA2-me-
diated apoptosis in ovarian and cervical cancer cell lines, but not in a cell line
with wild type p53 or inHOSE cells. Combination of SHetA2with an autophagy
inhibitor may improve the therapeutic effıcacy in clinical trials of patients har-
boring mutant or loss of p53 protein. Funded by: RO1CA196200 and
RO1CA200126.
#3309 Tumor-treating fıelds decrease proliferation and clonogenicity of
patient-derivedWHOgrade IVglioma cell lines. SharonK.Michelhaugh, Sam
Kiousis, AdrianneWallace-Povirk, SandeepMittal.Wayne State University, De-
troit, MI.
Despite decades of research, effıcacious treatments for malignant glioma tu-
mors are limited. Tumor-treating fıelds (TTFields) are FDA-approved for the
treatment of newly-diagnosed and recurrent glioblastoma. In this study, in vitro
experiments comparing TTFields to untreated controls were performed on pa-
tient-derived grade IV glioma cell lines to determine the effects of TTFields on
cell proliferation and clonogenicity. Methods: Studies utilizing patient tumor
specimens were approved by the Wayne State University Institutional Review
Board and written informed consent was obtained from participants. Patient
tumor specimens (glioblastoma and gliosarcoma) were collected immediately
following microsurgical resection. Single-cell suspensions from the tumor tis-
sues were prepared by enzymatic and mechanical disruption. Equal numbers of
cells were plated on plastic coverslips in DMEM/F12 media supplemented with
10% fetal bovine serum. TTFields were applied at 200 kHz to half of the cover-
slips. Culture media was replaced every day. At the conclusion of the 2 week
treatment, cell proliferation was assessed with the XTT assay and cells were
harvested and replated for clonogenic assays (10,000 cells/well). The resulting
colonies were fıxed and stained with crystal violet and counted with an auto-
mated colony counter. Control vs. TTFields treated groups were compared by
two-tailed t-tests. Results: The two-week TTFields treatment signifıcantly re-
duced cell proliferation in both the glioblastoma (41.6 	 11.1 % control; n4;
p0.001) and in the gliosarcoma (41.6 	 16.6 % control; n4; p0.002) as
measured by XTT assay. The clonogenic assay revealed that the number of col-
onies generated from both cell lines was reduced by TTFields treatment. For the
glioblastoma cell line, control cells yielded 847 colonies with an average diame-
ter of 462.8	 5.6 Mwhile TTFields-treated cells yielded 561 colonies with an
average diameter of 435.1 	 7.3 M, which was a statistically signifıcant de-
crease (p0.0022). For the gliosarcoma cell line, control cells yielded 809 colo-
nies vs. 144 colonies from the TTFields treated cells, although the average diam-
eter of the colonies was unchanged between groups (control 375.1	 176.1 M;
TTFields 362.9 	 196.0 M). Conclusions: In vitro application of TTFields
markedly reduced cell proliferation and clonogenicity in both patient-derived
WHOgrade IVglioblastoma and gliosarcoma cell lines. This is the fırst report on
the in vitro effects of TTFields on gliosarcoma.
#3310 Atg7 overexpression promotes bladder cancer invasion via au-
tophagic removal of AUF1 protein and subsequently increased RhoGDI2
mRNA stability in vitro and in vivo. Junlan Zhu, Yang Li, Chuanshu Huang,
Haishan Huang. New York Univ. School of Medicine, Tuxedo Park, NY.
Autophagy is the basic catabolicmechanism regulating degradation of unnec-
essary or dysfunctional cellular components and is regulated by the autophagy-
related gene 7 (Atg7). Since invasive bladder cancer (BC) can progress to life
threatening metastases, understanding the molecular mechanisms underlying
BC invasion is of tremendous importance for potentially reducing the mortality
of this disease. In the present study, we for the fırst time found that the Atg7 was
remarkably upregulated in human BC cell lines and the BBN-induced mouse
invasive BCs, which is consistent with our most recent fınding in human BCs.
The knockdown of Atg7 in human BC cells dramatically inhibited cancer cell
invasion, suggesting that Atg7 is a key player in regulation of BC invasion.
Mechanistic studies revealed that Atg7 overexpression was mediated by miR-
190, which was highly upregulated at transcriptional level in BC tissues and cell
lines, and was able to bind to 3=-UTR of atg7 mRNA for its stabilization. More-
over, Atg7-mediated autophagicmechanism could removeAUF1protein and in
turn reduced AUF1 interaction with rhogdi2 mRNA, resulting in elevation of
rhogdi2mRNA stability, and subsequently leading to BC cell invasion. Remark-
ably, inhibition ofAtg7-mediated autophagy led toAUF1protein accumulation,
RhoGDI2 downregulation and BC cell invasion attenuation. Collectively, our
results demonstrate that overexpressed Atg7mediates BC cell autophagy, which
removes AUF1 protein, thereby reducing its binding with rhogdi2 mRNA and
subsequently leading to elevation of rhogdi2 mRNA stability and protein ex-
pression, further promoting BC invasion. The identifıcation of miR-190/Atg7
autophagic mechanism regulating AUF1/RhoGDI2 expression provides a sig-
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nifıcant insight into understanding the nature of BC invasion, and is also highly
potential for developing autophagy-based-specifıc therapeutic strategy for treat-
ment of human BC patients.
#3311 The alteration in key regulator genes of autophagy is mainstream
mechanismof therapy resistance and impact prognosis of acutemyelogenous
leukemia (AML): results fromdiagnosis genomic analysis on 148 consecutive
patients treated with intensive chemotherapy and long-term survival follow-
up.Giovanni Marconi,1 Cristina Papayannidis,1 Maria Chiara Fontana,1 Anto-
nella Padella,1 Anna Ferrari,1 Eugenia Franchini,1 Stefania Paolini,1 Maria Chi-
ara Abbenante,1 Chiara Sartor,1 Francesca Volpato,1 Viviana Guadagnuolo,2
Silvia Lo Monaco,1 Elena Tenti,1 Andrea Ghelli Luserna Di Rora,1 Valentina
Robustelli,1 Nicoletta Testoni,1 Giorgia Simonetti,1 Emanuela Ottaviani,1 Gio-
vanni Martinelli1. 1Institute of Hematology, Bologna, Italy; 2Cellply, Bologna,
Italy.
Introduction: There are no clear evidences if autophagy can lead to therapy
resistance or favor apoptosis in cancer; it can function as a pro-apoptotic mech-
anism, or it can improve stresses survival clearing damaged mitochondria and
proteins accumulation. Levels and activity of pro-apoptotic and anti-apoptotic
proteins, particularly bcl-2 and p53, high levels of cAMP, and a complex made
by pink/park could play as fulcrum of this yin and yang effect of autophagy. Our
study aims to defıne the role of autophagy inAML, and to establish if gain or loss
in autophagy could reduce the patients’ chance to respond to induction, and to
worsen OS. Methods: We analyzed 148 consecutive newly diagnosed non M3
AMLpatients treatedwith induction chemotherapy regimens containing at least
one dose of anthracycline. We screened all patients for TP53, FLT3, NMP1
mutations; we performed Affymetrix SNP array 6.0 or Cytoscan HD. Survival
datawere collected prospectively, with amedian follow-up of 18months. Results
Autophagy alteration (gene group 1: ULK1 CHR11; ULK1 CHR17; BECN1;
ATG14; AMBRA1; UVRAG; ATG9A; ATG9B; PIK3C3; PIK3R4) were related
to lower Complete Remission rate (CR%) after induction in univariate (p.001)
and multivariable regression with age, karyotype, secondary AML, TP53 muta-
tion (p.014); autophagy alteration shown to conferworstOS (p.001) andwas
signifıcantly associated with complex karyotype and TP53 mutation (p.001).
We detected signifıcant differences in term of survival independently both in
gain and loss in group 1 genes(p.001). Furthermore, we investigated genes in
AMPK pathway (group 2: SESN1; PRKAA1 CHR 3; PRKAB1: PRKAA1 CHR 1:
PRKAG1 CHR11; PRKAG1 CHR 7; PRKAG3; PRKAB1) and other genes that
could be related to a switch from a physiological role of autophagy to a resiliency
mechanism (group 3: CCND1; BCL2; PINK1; PARK2; TP53; MDM1; MDM4):
alterations in those genes were shown to confer worst OS (p.001 in both
groups); Alteration in group 2 and group 3 were related to lower CR% after
induction (p.001 in both groups).Whole Exome Sequencing on 56 patients in
our set did not found any signifıcant mutation in genes we analyzed with the
exception of TP53. Conclusions: Our work investigates for the fırst time with a
genomic approach the role of autophagy in AML. We found that both gain and
loss in autophagy key regulator genes are associated with poor prognosis and
therapy resistance. A loss in autophagy could enhance proliferation and block
apoptosis; a gain could give cell resiliency, favoring cytoplasm turnover, dam-
aged mitochondria elimination, and neutralizing oxidative damages. Acknowl-
edgements: ELN, AIL, AIRC, PRIN, Progetto Regione-Università 2010-12, FP7
NGS-PTL project.
#3312 A novel plate-based assay for screening autophagic activity in 2D
and 3D cell culture models. Dan F. Lazar,1 Amani A. Gillette,2 Braeden L.
Butler,1 Christopher T. Eggers,1 Brock F. Binkowski,1 Gediminas Vidugiris,1
Michael R. Slater,1 Dongping Ma,1 James J. Cali1. 1Promega Corporation, Mad-
ison, WI; 2University of Wisconsin, Madison, WI.
The critical importance of autophagy in cell health and its proposed role in
disease-relevant biology, including cancer, inflammation, and immunology, has
increased the need for more effective assays to screen for agents that modulate
autophagic activity. Here we utilize NanoLuc Binary Technology (NanoBiT) to
develop a homogeneous plate-based assay to measure autophagic flux in cell
culture models. In this approach, an exogenous LC3B (Atg8) fusion protein was
tagged on its N-terminus with an 11 amino acid peptide (HiBiT) and stably
expressed in mammalian cells, including U2OS and HEK293. After exposure to
various treatment conditions, cellular levels of this novel autophagy reporter
were determined by addition of a lytic detection reagent containing Large BiT
(LgBiT). LgBiT rapidly associates with HiBiT in the cell lysate, producing a
bright, luminescent enzyme in the presence of the furimazine substrate. The
bright signal allows low levels of expression of the reporter, maximizing the
assay response, and the signal is stable, allowing assay ofmultiple 96- or 384-well
plates in the same experiment. In response to autophagic stimuli, including
nutrient deprivation and various mTORC inhibitors (e.g., PP242 and rapamy-
cin), autophagic degradation of expressed LC3 reporter was evident by reduced
assay signal. In contrast, in response to both upstream (e.g., 3-MA and wort-
mannin) and downstream (e.g., bafılomycin A1 and chloroquine) inhibitors of
the autophagy pathway, degradation of the autophagic reporter was effectively
blocked and assay signal was consistently increased as predicted. Compound
effects were time dependent and stratifıed according to expected potency and
effıcacy of the test agents employed. The use of a mutant reporter based on
LC3G120A further demonstrated the specifıcity of the wild-type LC3 reporter
for the detection of autophagic activity. When assayed in 384-well plates with
automation, HEK293 autophagy reporter cells produced Z’ values of 0.7 in
response to autophagy induction with PP242, while subsequent blockade of
autophagy with bafılomycin A1 resulted in Z’ values of 0.8. This data, and
subsequent LOPAC library screening, indicates the potential utility of this assay
method for HTS applications. In addition, the HEK293 autophagy reporter cells
can be induced to form 3D cell spheroids, thus allowing investigation of assay
performance in this more complex model. Autophagy reporter levels increased
with increasing spheroid size (up to 650 m diameter tested) in a manner pro-
portional to a surrogatemeasure of viable cell number. Importantly, both induc-
tion and inhibition of autophagic activity was easily detected following PP242
and bafılomycin A1 treatment, respectively. Using this novel plate-based assay
system for the determination of autophagic flux, it is possible to screen test
agents and quantitatively determine both the potency and effıcacy of autophagy
modulation.
#3313 Autophagic ovarian cancer cells exhibit substantially enhanced sen-
sitivity to Crizotinib. Alicia M. Blessing, Yan Wang, Weiqun Mao, Lan Pang,
Zhen Lu, Robert C. Bast. UTMD Anderson Cancer Ctr., Houston, TX.
One of the major factors contributing to poor outcomes for patients with
ovarian cancer is the persistence of dormant, drug resistant cancer cells after
primary surgery and chemotherapy. Recurrent, progressively growing ovarian
cancer metastases are generally well vascularized and may only have a small
fraction of cancer cells undergoing autophagy. By contrast, the persistent, drug
resistant, dormant cancer cells that remain on the peritoneal cavity after con-
ventional treatment tend to be poorly vascularized. In this nutrient-poor, avas-
cular microenvironment autophagy is widespread and can be found in more
than 80% of cases. Drugs that regulate survival in autophagic cancer cellsmay be
much more active when administered as maintenance therapy than when used
to treat gross primary or recurrent disease. Using unbiased siRNA screens, we
have identifıed target genes that regulate the survival of ovarian cancer cells that
are undergoing autophagy that has been induced by the re-expression of
DIRAS3 or by amino acid starvation. Knockdown of the anaplastic lymphoma
kinase (ALK) signifıcantly reduced survival of ovarian cancer cells that were
undergoing autophagy. Importantly, the FDA-approved ALK inhibitor, Crizo-
tinib, exhibited signifıcantly greater toxicity after induction of autophagy by
upregulation of DIRAS3 (ARHI) in OVCAR8, CAOV3, and SKOv3 ovarian
cancer cells. Induction of autophagy by upregulation ofDIRAS3 in SKOv3 ovar-
ian cancer cells reduced the IC50 of Crizotinib from 7.44M 	 0.04708 to
2.129M 	 0.06152 (P0.05). Conversely, siRNA knockdown of DIRAS3 in
CAOV3 cells with endogenously high DIRAS3 expression and baseline au-
tophagy increased the IC50 of Crizotinib from 204 nM	 0.01265 to 267 nM	
0.01715 (P0.05). Our studies in cell culture suggest that Crizotinib might pro-
vide an effective agent to eliminate autophagic, dormant drug resistant ovarian
cancer cells that remain after conventional cytoreductive surgery and combina-
tion chemotherapy. Subsequent studies will evaluate the effect of Crizotinib in
xenograft models of DIRAS3-induced ovarian cancer dormancy.
#3314 Synergistic effects of chemotherapy-induced autophagy and epige-
netic remodeling. Liliya Tyutyunyk, Joseph Landry, Tareq Saleh, David
Gewirtz. Virginia Commonwealth University, Richmond, VA.
Cytotoxic chemotherapyhas been shown to enhance tumor cell immunogenicity
by promoting the secretion of damage-associatedmolecular pattern (DAMP)mol-
ecules which, in turn, stimulates the immune response. These effects can be further
stimulated by combining chemotherapy with an immunotherapy designed to en-
hance effector cell (CD8 T cell or NK cell) anti-tumor activity. Our studies demon-
strate that knockdown of the epigenetic regulator NURF increases DNA damage
(gammaH2AX staining) and autophagy (acridine orange staining) in breast tumor
cells exposed to doxorubicin and enhances growth inhibition as well as suppressing
the capacity of the cells to recover and proliferate. Similar increases in autophagy
wereobservedusinga smallmolecule inhibitorofNURF, suggesting thatNURFcan
be targeted therapeutically. Sensitization was not observed with ionizing radiation
or cisplatin. Studies are in progress to assess the nature of autophagy in the NURF
KD and NURFWT cells, distinguishing between the cytoprotective, cytotoxic, cy-
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tostatic and nonprotective forms.HowNURF regulates doxorubicin inducedDNA
damage is being investigated bymapping sites of damage genomewide. It is antici-
pated thatenhancedcell autonomous tumorcell sensitivity inconcertwith improve-
ments in tumor cell antigenicity (cell non-autonomous sensitization) achieved by
NURFdepletioncould improveanti-tumor immunogenicity, achieve tumor regres-
sion, reducemetastasis, and possibly achieve long term remission in breast cancer.
#3315 Cancer cells upregulate autophagy as a survival mechanism in re-
sponse to tumor treating fıelds (TTFields). Yaara Porat, Anna Shteingauz,
Moshe Giladi, Rosa S. Schneiderman, Tali Voloshin, Mijal Munster, Roni Blat,
Eilon D. Kirson, Uri Weinberg, Yoram Palti. Novocure, Haifa, Israel.
Tumor treating fıelds (TTFields)areanestablishedanti-neoplastic treatmentmo-
dality in patients with glioblastoma. TTFields are delivered via noninvasive applica-
tionof low-intensity, intermediate-frequency, alternatingelectric fıelds to the region
of the tumor.Previous studieshave shown thatTTFields treatment lead to increased
cellular granularity, which is often associated with autophagy. Autophagy has been
shown to regulate cell survival and proliferation under stress conditions and to
influence cellular response to cytotoxic drugs. This study evaluated the role of au-
tophagy in cancer cells treated with TTFields. Immunoblot analysis showed signif-
icant elevations in levels of lipidated Microtubule Associated Protein Light Chain
(LC3-II) in TTFields-treated glioma and lung cancer cells. Increased autophagy
following TTFields application in these cell lines was also detected using fluores-
cence microscopy, where punctate distribution of LC3-II was observed. TEM mi-
crographs demonstrated the presence of autophagy typical, autophagosome-like
structures in TTFields-treated U-87 MG cells. Combination of TTFields with au-
tophagy inhibitors, chloroquine and melfoquine, resulted in a signifıcant dose-de-
pendent reduction in cell growth compared with TTFields treatment alone. Inhibi-
tion of autophagy with chloroquine triggered apoptosis as indicated by elevated
levels of AnnexinV/7AAD double staining. Increased levels of autophagic flux in
TTFields-treated cells were not associated with reducedmTOR activity, which was
monitored by p70S6K phosphorylation immunoblot analysis. TTFields are known
to exert anti-mitotic effects by disrupting highly dipolar structures that play critical
roles in mitosis. Our results demonstrate that TTFields additionally induce cellular
autophagy by an mTOR-independent mechanism. TTFields- treated cell lines ap-
pear to utilize autophagy as a survival mechanism. Thus, inhibition of autophagy
sensitizes tumor cells to TTFields treatment, resulting in elevated apoptotic cell
death.Future studiesarewarranted toexamine theextent towhichTTFields-elicited
autophagymay affect treatment outcomes and to investigate the therapeutic impli-
cations of combining TTFields with autophagy inhibitors in vivo.
#3316 Mieap, the mitochondria-eating protein, induces cell death by eat-
ing unhealthymitochondria.YasuyukiNakamura,Masayuki Tsuneki,Makoto
Yamamoto, Hirofumi Arakawa. National Cancer Ctr. Research Inst., Tokyo, Ja-
pan.
Mieap, a p53-inducible protein, controls mitochondrial quality by repairing
or eliminating unhealthy mitochondria. Mieap suppresses murine intestinal tu-
mor via its mitochondrial quality control (1). Mieap-regulated mitochondrial
quality control is frequently inactivated in human colorectal cancer (2). To ex-
plore the role of the Mieap-regulated mitochondria quality control function in
human colorectal cancer tissues, we examined the Mieap expression in primary
colorectal cancer tissues by performing immunohistochemical analysis with an-
ti-human Mieap antibody. Mieap expression was very low in normal colorectal
epithelial cells, whereas the strong expression of theMieap protein was detected
in the hypoxic cell death regions of colorectal adenoma and adenocarcinoma,
suggesting the role of Mieap in hypoxic cell death. Overexpression of Mieap in
vitro induced large vacuole structures (MIV: Mieap-induced vacuole) in
HCT116 colorectal cancer cells (Mieap-defıcient colorectal cancer cells). MIV
engulfed and degraded unhealthy mitochondria, leading to caspase-dependent
cancer cell death. Re-expression of Mieap in HCT116 cells resulted in striking
suppression of tumor growth in vivo. These results suggest that Mieap plays a
critical role in hypoxic tumor cell death via lysosomal degradation of unhealthy
mitochondria. (1) Tsuneki et al. Mieap suppresses murine intestinal tumor via
its mitochondrial quality control. Sci. Rep. 5: 12472 (2015). (2) Kamino et al.
Mieap-regulated mitochondrial quality control is frequently inactivated in hu-
man colorectal cancer. Oncogenesis 5: e181 (2016).
#3317 Autophagy protects ovarian cancer cells from olaparib-induced
toxicity. Janice M. Santiago-O’Farrill,1 Safıa Essien,2 Mary Figueroa,1 Lan
Pang,1 Ravi Amaravadi,3 Zhen Lu,1 Robert C. Bast1. 1UT MD Anderson Cancer
Center, Houston, TX; 2College of Technology, University of Houston, Houston,
TX; 3Abramson Cancer Center and Department of Medicine, University of Penn-
sylvania,, Philadelphia, PA.
Ovarian cancer (OC) is the most lethal gynecologic malignancy. Persistence
of dormant, drug resistant cancer cells is one of themajor factors that contribute
to poor outcomes. The Poly (ADP) ribose polymerase (PARP) inhibitor, olapa-
rib, has shownpromising anti-cancer activity andhas been approved by the FDA
for the treatment of ovarian cancer with BRCA1/2 mutations. Olaparib targets
DNA repair mechanisms within cancer cells and induces apoptosis. Both pre-
clinical and clinical data indicate that effıcacy of olaparib can be decreased by
acquired resistance. One mechanism of resistance involves autophagy. Au-
tophagy can degrade organelles and long-lived proteins to provide energy for
cancer cells under nutrient poor conditions or in the presence of stress. The
energy provided from autophagy is used to fuel the DNA repair process and
metabolic needs in cancer cells. Autophagy can protect cancer cells from che-
motherapy or can enhance the response to certain drugs. In this study, we have
asked whether autophagy protects OC cells against the cytotoxic effects of ola-
parib or augments damage.We fırst determined PARP activity using amodifıed
PARP activity assay in different OC cell lines. Olaparib-induced autophagy was
determined by punctate localization of GFP-LC3, conversion of LC3I to LC3II
on protein blots and electron microscopy. To test whether autophagy contrib-
utes to the resistance of OC cells to olaparib, we determined the impact of
autophagy inhibition on the sensitivity ofOC cells to olaparib by either using the
pharmacologic inhibitors chloroquine (CQ), LYS05 or short interfering RNA
(siRNA) against ATG7. Upon investigation of a potential mechanism of olapa-
rib-induced autophagy we evaluated the production of reactive oxygen species
(ROS) and the expression of JNK, Ataxia-telangiectasiamutated (ATM),mTOR
andp70S6K. Inhibition of PARPby olaparib treatment, decreased PARP activity
in a dose- dependent manner, leading to DNA damage judged by phosphoryla-
tion of γ-H2AX. Olaparib treatment decreased cell growth, caused cell cycle
arrest and signifıcantly enhanced apoptosis in 5 of 5 OC cell lines. Olaparib
induced autophagy in 8 of 8 OC cell lines. Both pharmacologic and genetic
inhibition of autophagy increased OC cells sensitivity to olaparib and induced
apoptosis in 5 of 6 OC cell lines. Furthermore, flow cytometry and western blot
analysis demonstrated that olaparib treatment increased ROS production and
increased the phosphorylation of JNK andATMwhile decreasing the phosphor-
ylation of mTOR and p70S6K. Taken together, our data described autophagy as
a potential mechanism of olaparib resistance in OC that may depend upon the
activation of ATM and JNK by ROS downregulating pmTOR and p70S6K.
Combination of olaparib with CQ, LYS05 or other autophagy inhibitor may
provide a novel strategy to increase the effıcacy of olaparib in OC. Current
studies are underway to test our hypothesis in vivo.
#3318 A critical role for c-Jun N-terminal kinase in autophagy and cell
survival of breast cancer cells.RohitMunagala, Carol Joseph, Annie Liu, Kebin
Liu, Muthusamy Thangaraju, Patricia V. Schoenlein.Medical College of Georgia
Cancer Center, Augusta University, Augusta, GA.
Antiestrogen resistance is the major impediment to the eradication of estro-
gen receptor positive (ER) breast cancer. Approximately 30% of ER breast
tumors initially responsive to antiestrogen therapy will acquire resistance. One
approach to reducing the occurrence of acquired antiestrogen resistance is to
identify and target key signaling nodes that specifıcally attenuate the ability of
antiestrogens to kill cancer cells. Toward this goal, we identifıed MEK/
MAPK1/2 as a key molecular target based on the general inability of antiestro-
gens to effectively blockMEK1/MAPK1/2-mediated phosphorylation of BimEL
in breast cancer cells. BimEL is a pro-apoptotic member of the BH3 family of
proteins that is inactivated (degraded by the proteasome) when phosphorylated
by MAPK1/2. The combination of an antiestrogen andMEK1 inhibitor robust-
ly-induced BimEL-dependent breast cancer cell apoptosis (Periyasamy-
Thandavan et al., 2012). However, a subpopulation of breast cancer cells survive
this combined treatment via an autophagy-dependentmechanism. Based on the
key role of JNK in regulating autophagy in cancer cells via BimEL phosphoryla-
tion, we hypothesized that JNK was a key effector of autophagy in breast cancer
cells surviving antiestrogen treatment when used as a single agent or in combi-
nation with a MEK inhibitor. To test this hypothesis, we utilized the selective
JNK inhibitor SP600125 as a single agent or in combination with estradiol (E2),
4-hydroxytamoxifen (4-OHT), and/or U0126 (a selective MEK1 inhibitor).
Treatments were conducted with the antiestrogen-sensitive cell lines MCF-7
andT-47D and the antiestrogen resistant cell line TR5, previously derived in our
laboratory by a step-wise 4-OHT selection. Effects on cell death (determination
of apoptosis) and autophagy (determination of autophagy levels and flux) were
evaluated for the various hormonal treatments conducted in the presence or
absence of JNK inhibition. These studies showed that: (1) targeting JNK in
antiestrogen sensitive breast cancer cells induces apoptosis with caspase-depen-
dent cleavage of PARP as a surrogate marker of apoptosis; (2) JNK activity is
elevated in antiestrogen resistant TR5 cells and JNK inhibition induces TR5 cell
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death; and (3) antiestrogen sensitive and resistant breast cancer cells dying as a
result of JNK inhibition can show extensive cytosolic vacuolization with the
autophagy protein LC3 (ATG8) localized to the aberrant vacuoles. Overall, our
results support the conclusion that JNK plays a key autophagy-dependent sur-
vival role in breast cancer cells. Ongoing studies aim to identify the specifıc JNK
protein(s) that disrupt autophagy and enhance death of breast cancer cells to-
ward the goal of identifying specifıc molecular targets to block autophagy in
breast cancer cells.
#3319 Elevating adipokine adiponectin level can induce cytotoxic au-
tophagy in breast cancer cells and potentiate the effıcacy of chemotherapeu-
tic regimens: preclinical studies. Seung J. Chung,1 Ganji Purnachandra Naga-
raju,2 Arumugam Nagalingam,1 Nethaji Muniraj,1 Panjamurthy Kuppusamy,3
AlyssaWalker,1 Juhyung woo,1 Balázs Győrffy,4 Edward Gabrielson,1 Neeraj K.
Saxena,3 Dipali Sharma1. 1Johns Hopkins University, Baltimore, MD; 2Emory
University, GA; 3University of Maryland, Baltimore, MD; 4Hungarian Academy
of Sciences, Hungary.
Adiponectin, an adipocytokine secreted by adipocytes in the breast tumor
microenvironment, negatively regulates cancer cell growth hence increased
levels of adiponectin are associated with decreased breast cancer growth.
However, its mechanisms of action remain largely elusive. We report that
adiponectin induces a robust accumulation of autophagosomes, increases
LC3II and decreases p62/SQSTM1 in breast cancer cells. Adiponectin-
treated cells and xenografts exhibit increased expression of autophagy-re-
lated proteins. Lysotracker-Red-staining and tandem-mCherry-GFP-LC3
assay show that autophagosomes/lysosomes fusion is augmented upon adi-
ponectin treatment. Adiponectin signifıcantly inhibits breast cancer growth
and induces apoptosis both in vitro and in vivo, and these events are pre-
ceded by autophagy, which is integral for adiponectin-mediated cell death.
Accordingly, blunting autophagosomes-formation, blocking autophago-
somes-autolysosome fusion or genetic-knockout of BECN1/Beclin1/ATG7
effectively impedes adiponectin induced growth-inhibition and apoptosis-
induction. Mechanistic studies show that adiponectin reduces intracellular
ATP levels and increases AMPK phosphorylation leading to ATG1 activa-
tion. AMPK-inhibition abrogates adiponectin-induced ATG1-activation,
LC3II-turnover and p62-degradation while AMPK-activation potentiates
adiponectin’s effects. Further, adiponectin-mediated AMPK-activation and
autophagy-induction are regulated by upstream master-kinase LKB1, which
is a key node in anti-tumor function of adiponectin as LKB1-knockout
abrogates adiponectin-mediated inhibition of breast tumorigenesis and mo-
lecular analyses of tumors corroborate in vitro mechanistic fındings. Adi-
ponectin increases the effıcacy of chemotherapeutic agents. Notably, high
expression of adiponectin receptor, adiponectin and BECN1 signifıcantly
correlates with increased overall survival in chemotherapy-treated breast
cancer patients. Collectively, these data uncover that adiponectin induces
autophagic cell death in breast cancer and provide in vitroa and in vivo
evidence for the integral role of LKB1-AMPK-ATG1 axis in adiponectin-
mediated cytotoxic-autophagy.
#3322 Elucidation of the signaling pathways that mediate berberine-
induced effects in cancer cells. Basabi Rana, Rong Ke, Kanchan Vishnoi,
Navin Viswakarma, Subhasis Das, Ajay Rana. University of Illinois at Chi-
cago, Chicago, IL.
Resistance towards standard therapeutic regimens and evasion of apoptosis
are some of the hallmarks of advanced forms of cancer, which include Sorafenib-
resistance in hepatocellular carcinoma (HCC), castration-resistance in prostate
cancer. Development of effective therapeutic strategies that can target these
resistant forms is critically needed. In an effort to understand the molecular
mechanism mediating resistance in cancer, in previous studies utilizing Tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant cancer cells
we showed that combination of TRAIL along with the PPAR ligand Troglita-
zone (TZD) can sensitize them towards apoptosis. Using more molecular ap-
proaches these studies identifıed the serine/threonine protein kinase, AMP-ac-
tivated protein kinase (AMPK) as a mediator of TRAIL-TZD-induced
apoptosis. Since AMPK seemed to be a major mediator of this apoptosis, in the
current studies we utilized the natural compound Berberine (BBR), a known
activator of AMPK in combination with TRAIL. These demonstrated a signifı-
cant reduction of cell viability (MTT assay) and induction of apoptosis (caspase
activation) when treated with a combination of TRAIL and BBR. This apoptosis
is attenuated in cells overexpressingAMPK-dominant negative (DN), suggest-
ing an involvement of AMPK inmediating this. To understand the downstream
targets and the mechanism involved, an apoptosis PCR array analysis was per-
formed, which suggested induction of TNFRSF10B (DR5) gene expression by
BBR. In addition, knockdown of DR5 expression attenuated TRAIL-BBR-in-
duced apoptosis, suggestingDR5 to be a potential target of BBR in this apoptotic
cascade. Future studies will include determining any crosstalk of AMPK in BBR
signaling to modulate DR5 pathway. Our earlier studies also demonstrated an
involvement of -catenin in mediating cancer cell resistance. Stabilizing muta-
tions and overexpression of -catenin has been reported in many cancers, most
profoundly in HCC leading to an activation of Wnt/-catenin signaling. To
understand any role of -catenin in TRAIL-BBR-induced apoptosis, we deter-
mined the effect of BBR on -catenin pathway. These revealed a signifıcant
attenuation of -catenin protein expression by BBR in various HCC cells in a
time and dose-dependent manner. BBR treatment also attenuated -catenin/
TCF-induced transcriptional activity, indicating antagonism of -catenin path-
way. Our studies indicate that combination of TRAIL and AMPK activator BBR
might be an effective means of antagonizing -catenin pathway and ameliorat-
ing TRAIL resistance via DR5 in advanced forms of cancer.
#3323 Anticancer activity of medicinal plant and neuroglioma. Michael
Quincy Shivers. Jackson State University, Jackson, MS.
Neuroglioma, also called gliocytoma, is one of the commonmalignant tumors
in central nervous system at present. Neuroglioma can make aggressive growth
around brain tissue, so complete radical treatment can be realized by single
excision. Nutritional and botanical treatments have been found useful in treat-
ing neuroglioma and other types of cancers. Vernonia amygdalina (VA) is a
valuable medicinal plant that is widespread in East andWest Africa. It has been
reported to have not only diverse therapeutic effects for many tropical diseases,
but has recently been shown to possess anti-cancer properties. Therefore, the
goal of this research was to determine the therapeutic mechanisms of VA leaf
extracts in the management of brain tumor. To achieve this goal, Human H4
neuroglioma cells were treated with different concentrations of Vernonia
Amygdalina for 24 hr. Cell survival was determined byMTs assay. The extent of
oxidative cell/tissue damage was determined by measuring malondialdehyde
(lipid peroxidation biomarker) concentrations by spectrophotometry. Cell ap-
optosis wasmeasured by flow cytometry assessment (AnnexinV/PI assay). Data
obtained from theMTS assay indicated that VA signifıcantly (p 0.05) reduced
the viability of in H4 cells in a concentration-dependent manner. We detected a
signifıcant (p  0.05) increase in malondialdehyde (MDA) concentrations in
VA-treated glioblastoma cells compared to the control. Flow cytometry data
showed a strong concentration-response relationship between VA exposure an-
nexin V/PI positive cells. Taken together, our fınding indicates that VA induced
cytotoxicity and apoptosis in H4 cells is associated with the formation of MDA,
a by-product of lipid peroxidation and biomarker of oxidative stress. At thera-
peutic concentrations, VA-induced cytotoxic and apoptotic effects in H4 cells is
mediated by oxidative stress.
#3324 FATE1 promotes mitochondrial hyperfusion and supports main-
tenance of mitochondrial networks following apoptosis stimulation. Anne
Hamacher-Brady,1 Verena Lang,2 Nathan R. Brady1. 1Johns Hopkins University,
Baltimore, MD; 2German Cancer Research Center, Heidelberg, Germany.
FATE1 (fetal and adult testis expressed 1), also known as the cancer-testis
antigen BJ-HCC-2, is expressed in testis and tumor tissues. FATE1 was recently
described as a major survival factor in tumor cells of various origins, by medi-
ating the degradation of the pro-apoptotic BH3-only protein Bik (Maxfıeld et al.,
in Nat Commun 2015 Nov 16;6:8840) and through ER-mitochondrial uncou-
pling (Doghman-Bouguerra et al., in EMBO Rep 2016 Sep;17(9):1264-80). In-
terestingly, FATE1 shares high sequence homology with the mitochondrial
Drp1 receptor MFF (mitochondrial fıssion factor). We thus investigated a pos-
sible role of FATE1 impact on mitochondrial morphology following the stimu-
lation of apoptosis in cancer cells. We found that, similar to MFF, FATE1 is
localized to outer mitochondrial membranes and, unlike MFF, additionally lo-
calized to the endoplasmic reticulum. Importantly, in contrast to MFF, FATE1
overexpression does not recruit Drp1 to mitochondria, and instead promotes
hyperfusion of mitochondrial networks. Co-immunoprecipitation experiments
and reconstitution of Mfn2 or Mfn1 in double knockout mouse embryonic
fıbroblasts indicate a role for the mitochondrial fusion protein Mfn2, but not
Mfn1. As FATE1 overexpressing cancer cells were more resistant to mitochon-
drial fragmentation in response to TNF and valinomycin treatments, we pro-
pose FATE1 as a novel regulator of mitochondrial morphology changes occur-
ring during apoptosis, with possible implications in FATE1-mediated resistance
of cancer cells to chemotherapy.
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#3325 Ginkgetin, a biflavonoid derived from leaves of Ginkgo biloba, in-
duces autophagic cell death in non-small cell lung cancer via p62. Jian Shu
Lou, Cathy Bi, Gallant Chan, Tina Dong, Karl Tsim. The Hong Kong University
of Science and Technology, Hong Kong, Hong Kong.
Chemotherapeutic drugs in the treatment of non-small-cell lung carcinoma
(NSCLC) are usually mediated by induction of apoptosis; this usually results in
drug resistant during the therapy.Many compounds fromnatural resource have
been shown to trigger autophagy in promoting cell death, and therefore which
could be a novel treatment for cancer. Ginkgetin, a biflavonoid from Ginkgo
biloba leaves (Ginkgoaceae), was shown its anticancer effects recently. The leaf
ofG. biloba is being recorded as a safe herbal drug inPharmacopoeia fromChina
and Europe. Here, the possible development of ginkgetin as an anticancer drug
was demonstrated. Ginkgetin induced the death in A549 (NSCLC) with an IC50
lower than that of cisplatin. This anticancer effect of ginkgetin was also illus-
trated in NSCLC xenograft nude mice model. Transmission electronic micro-
scope revealed that ginkgetin-induced autophagy was the main cause of cell
death. Autophagy inhibitors, 3-methyladenine and chloroquine but not apopto-
sis inhibitor Z-VAD-FMK, rescued ginkgetin-induced cell death. Reciprocally,
the induction of autophagy by rapamycin promoted ginkgetin-induced cell
death, as well as the formation of p62-TRAF6-mTOR. During autophagy, p62 is
hypothesized to be a target of ginkgetin-induced autophagic cell death. This
notion is supported by several lines of evidence. The application of ginkgetin
blocked fully the expression of p62 in cultured A549, and in contrast the over
expression of p62 reduced ginkgetin-induced autophagy and cell death concom-
itantly with the decline on autophagosome formation. In parallel, the modula-
tion onp62 expression could regulateNrf2 activity andROS level in the presence
of ginkgetin. Thus, autophagy could act as an inducer in ginkgetin-induced cell
death, and p62 was proposed to be a possible target during this process. Here,
ginkgetin exhibited promising anticancer effect in NSCLC via autophagy, a sig-
naling very different to orthodox chemotherapeutic drug cisplatin. Besides,
ginkgetin is a phytochemical from G. biloba that is considered as a safe herbal
supplement, and no obvious toxicity was observed in xenograft nude mice.
Therefore, ginkgetin is proposed to be a potential compound for the develop-
ment of novel anticancer drug. Acknowledgements: This study was supported
by Hong Kong Research Grants Council Theme-based Research Scheme (T13-
607/12R), GRF (663012, 662713, M-HKUST604/13), TUYF15SC01 and Foun-
dation of The Awareness of Nature (TAON12SC01) to Karl Tsim.
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#3326 Identifıcation of a novel androgen receptor co-regulator in prostate
cancer. Aymen A. Shatnawi,1 Sridhar Acharya Malkaram,2 Efrosini Tsouko,3
Daniel E. Frigo4. 1Univ. of Charleston, Charleston, WV; 2West Virginia State
University, Charleston, WV; 3University of Texas MD Anderson Cancer Center,
Houston, TX; 4University of Houston, Houston, TX.
Prostate cancer (PC) is one of the most frequently diagnosed tumors in the
United States, affecting one in six men during their lifetime and second only to
lung cancer as a cause of cancer death in men. One of the major drivers of
prostate cancer is the androgen receptor (AR). It has been shown that deregula-
tion of AR co-regulators play a crucial role in PC through modulating the tran-
scriptional activity of the receptor. While the importance of the AR complex is
well established, there is still an incomplete understanding of what all the asso-
ciated co-regulators are and how they modulate AR signaling. Here, we have
identifıed that the inhibitor of growth family member 4 (ING4), a protein that
has been implicated in the pathogenesis of several solid tumors such as gastric
and breast cancer, is a novel AR co-regulator. Overexpression of ING4 increased
AR activity in an androgen-dependent manner as assessed using luciferase re-
porter gene assays. Supporting a role as a potential AR co-activator, RNANext-
Generation Sequencing of prostate cancer cells with ING4 knocked down re-
vealed a repression of endogenous AR/R1881-activated genes and expression of
AR/R1881 suppressed genes. Further, mining of existing clinical datasets re-
vealed that the ING4gene expression is de-regulated inPCs compared relative to
normal tissue and tracks with poor patient prognosis. Collectively, the current
fındings strongly support the involvement of ING4 in AR signaling and PC
progression and development.
#3327 Sortilin controls the EGFR nuclear translocation. Hussein Al
Akhrass, Thomas Naves, Marie-Odile Jauberteau, François Vincent, Fabrice
Lalloué. University of Limoges, Limoges, France.
The epidermal growth factor receptor (EGFR) deregulations play a central
role in cancer progression. EGFR generates extra- and intracellular signals
through various pathways, including its release in the tumormicroenvironment
through extracellular vesicles, as well as the nuclear EGFR signaling. That ulti-
mately results in oncogenic signals promoting the tumor aggressiveness. Our
previous report showed that sortilin, a member of the VPS10P sorting proteins,
is associated with EGFR to allow its secretion through exosomes in non-small
cell lung cancer (NSCLC) cells. Furthermore, sortilin is mainly present in the
Golgi which is an essential compartment involved in the EGFR bypass towards
the nucleus. Therefore, our aim is to investigate the potential role of sortilin in
EGFR nuclear translocation. EGFR and sortilin translocation into the nucleus
has been validated by proximity ligation assay and confocalmicroscopy analysis.
Moreover, to study the sortilin function in the EGFR nuclear translocation, we
resorted to the NSCLC cell line A549 in which the sortilin expression was si-
lenced using a shRNA delivery. Subcellular fractionations and nuclear protein
extractions were performed to study the impact of the sortilin loss on the EGF-
induced EGFR nuclear translocation. EGF stimulation highly increases the nu-
clear translocation of the EGFR and sortilin complex. Interestingly, sortilin de-
pletion signifıcantly decreases the EGF-induced EGFR nuclear translocation in
the A549 cells. Strikingly, sortilin-depleted cells exhibit an overexpression of
EGFR target genes (MYC, ABCG2, AURKA and CCND1) compared to the
control cells. These results suggest that the overexpression of the EGFR target
genes is independent of EGFR nuclear translocation in sortilin-depleted cells.
Thus, we analyze the activation of the known transcription factors directly in-
volved in the control of EGFR up-regulated genes to determine whether they are
activated in sortilin-depleted cells. Moreover, to better understand the sortilin-
dependent EGFR nuclear translocation, we compare functional properties (pro-
liferation, migration and angiogenesis assays) of sortilin-depleted and control
cells. Altogether, our fındings suggest a key role of sortilin in the regulation of the
EGFR nuclear transport, towards the control of target genes that are widely
involved in cancer progression.
#3328 Protochadherin 7 acts through SET and PP2A to potentiateMAPK
signaling by EGFR and KRAS during lung tumorigenesis. Xiaorong Zhou,1
Barrett L. Updegraff,1 Yabin Guo,1Michael Peyton,1 Luc Girard,1 Jill E. Larsen,2
Xian-Jin Xie,1 Yunyun Zhou,3 Tae Hyun Hwang,1 Yang Xie,1 Jaime Rodriguez-
Canales,4 Pamela Villalobos,4 Carmen Behrens,4 Wistuba I. Ignacio,4 John D.
Minna,1 Kathryn A. O’Donnell1. 1UT Southwestern Medical Center, Dallas, TX;
2QIMR Berghofer Medical Research Institute, Brisbane City, Australia; 3Univer-
sity of Mississippi Medical Center, Jackson, MS; 4MD Anderson Cancer Center,
Houston, TX.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated
deaths worldwide. Given the effıcacy of membrane proteins as therapeutic tar-
gets in humanmalignancies, we examined cell-surface receptors that may act as
drivers of lung tumorigenesis. Here we report that Protocadherin 7 (PCDH7), a
transmembrane receptor and member of the Cadherin superfamily, is fre-
quently overexpressed in NSCLC tumors, and high expression of PCDH7 is
associated with poor clinical outcome. PCDH7 overexpression synergizes with
KRAS and EGFR to induce MAPK signaling and tumorigenesis. Conversely,
PCDH7 depletion suppresses ERK activation, sensitizes cells toMEK inhibitors,
and reduces tumor growth. PCDH7 potentiates ERK signaling by facilitating
interaction of protein phosphatase PP2A with its potent inhibitor, the SET on-
coprotein. By establishing a previously unanticipated oncogenic role for PCDH7
in lung tumorigenesis, these results provide proof-of-concept support for the
development of novel therapies that target PCDH7 at the cell surface of NSCLC
cells. Experiments to evaluate the role of Pcdh7 in Kras-mediated lung tumori-
genesis in vivo using autochthonous mouse models, which we expect to lend
further support for therapeutic targeting of this protein, are in progress.
#3329 Combinatorial blockade of ERBB receptors in HER2 low breast
cancer. Mireia Berdiel-Acer,1 Eileen Reinz,1 Khalid Abnaof,1 Sara Burmester,1
Rainer Will,2 Ulrike Korf,1 Stefan Wiemann1. 1Division Molecular Genome
Analysis, DKFZ, Heidelberg, Germany; 2Genomics and proteomics core facility,
DKFZ, Heidelberg, Germany.
Large number of breast cancer patients clinically classifıed as HER2 negative,
show low/moderate levels of HER2 along with other ERBB receptors. Concom-
itant blockade of EGFR, ERBB2 and ERBB3 with specifıc therapeutic antibodies
(cetuximab, trastuzumab/pertuzumab and lumretuzumab, respectively) ap-
pears as a benefıcial approach to improve survival of patients who have failed to
previous treatment strategies. Additionally, ERBB3 expression has been re-
ported as a trastuzumab resistance mechanism in HER2 positive subtypes.We
have confırmed a specifıc pattern of ERBB receptors expression in different
breast cancer subtypes. Individual and combined blockade of the receptors with
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therapeutic antibodies has been tested in vitro using a metabolic viability assay
(Cell Titer Glo) and their effects in cell cycle status measured by BrdU staining.
All four therapeutic antibodies bind to the respective extracellular domains in-
hibiting downstream signaling pathways. Response to individual treatment is
cell dependent and correlates with EGFR expression in the triple negativeMDA-
MB-468 but not in luminal T47D cancer cell line. Response of T47D cells to
lumretuzumab is higher when combinedwith pertuzumab or trastuzumab, sug-
gesting ERBB2/ERBB3 dimer as the most relevant one, an effect more evident
upon ectopic addition of NRG1 (only ligand for ERBB3). Long exposure of
MDA-MB468 cells to cetuximab induces ERBB3 expression and increases its
sensitivity to cetuximab when combined. As well as, in the HER2 BT474 can-
cer cell line resistant to trastuzumab, higher levels of ERBB3 also make cells
more sensitive to alternative anti-ERBB therapies. To establish the role of ERBB4
(no specifıc therapeutic antibody) in the whole ERBB network, stable knock-
down regulation (shRNA) has been performed in T47D cells. Although treat-
ment ofHER2 overexpressing breast tumors has been successful, targeting other
ERBB members in a HER2 moderate/low scenario seems to be a promising
approach in combinatorial therapies; even in resistant cell lines. Thus, better
characterization of ERBBnetwork should help to pave theway for a personalized
treatment of HER2 low breast cancer. [U.K.:Deceased March, 2016]
#3330 MUC1* targeting CAR T. Cynthia Carol Bamdad, Andrew K. Stew-
art, Benoit J. Smagghe, LukeT.Deary,Victoria L.Kohler, JaredL.Dietz.Minerva
Biotechnologies, Waltham, MA.
Purpose: Over 75% of all solid tumor cancers are characterized by aberrant ex-
pression of MUC1. Yet to date, no effective MUC1 targeting therapeutic has suc-
ceeded. The purpose of this body of work was to develop an antibody therapeutic
that would effectively treat MUC1 positive solid tumor cancers, without damaging
healthyMUC1positive tissues. Experimental Procedures:MUC1 is a heavily glyco-
sylated transmembraneproteinwhose expression is restricted to theapical borderof
healthy epithelial tissues but uniformly expressed over cancerous tissues. We dis-
covered that the cancer-associated formofMUC1 is transmembrane cleavageprod-
uct that remains after cleavage and release of the bulk of the extracellular domain.
We named cleaved MUC1, MUC1* (muk 1 star), and showed that it is a growth
factor receptor that is activated by ligand-induceddimerization of its small extracel-
lular domain. We also showed that 100% of pluripotent human stem cells express
MUC1* but cleavage stops with the onset of differentiation. By studying stem cells
and cancer cells in parallel, we sought to develop antibodies that would only recog-
nizeMUC1* as it is expressedoncancerous tissues butwouldnot recognizeMUC1*
as it exists on some healthy cells and tissues. Summary New Data: We previously
showed thatwehaddeveloped antibodies that recognized the cleaved, growth factor
receptor form, MUC1* but not full length MUC1. However, MUC1 is cleaved to a
healthy formofMUC1*on, for example, pluripotent stemcells, hematopoietic stem
cells and stem cells of intestinal crypts. We now report that we have developed
monoclonal antibodies that only recognize the cancerous form of MUC1* and do
not recognize these healthy forms of MUC1*. To demonstrate that we have suc-
ceeded in deciphering the differences between cancerous MUC1* and healthy
MUC1*, we also developed a set of monoclonal antibodies that only recognize
healthy MUC1*. Thousands of human cancerous versus normal tissue specimens
attest to the specifıcity of these antibodies. Cancer-specifıc anti-MUC1* antibodies
(Fabs) alone blocked the growth ofMUC1* positive breast and hormone refractory
prostate cancers in animals, with no detectable adverse effects.On the basis of tissue
safety studies and effıcacy studies, a clinical candidate antibody MNC2 has been
identifıed, humanized and incorporated into more than 20 CAR constructs.
huMNC2-scFv-CAR T cells display typical cytokine release only when co-cultured
with MUC1* positive cancer cells. huMNC2-scFv-CAR T cells selectively kill
MUC1* positive cancers, while stimulating T cell expansion. Conclusions: The rel-
evant target for anti-cancer drugs is the extracellular domain of MUC1*, not full
length MUC1. MUC1* is a growth factor receptor that is activated by NME family
growth factors. Subtle differences between MUC1* as expressed on healthy stem-
like cells andMUC1* expressed on cancerous cells has allowed the development of
cancer-specifıc MUC1* antibodies, especially suited for cancer immunotherapies.
#3331 PID1, a candidate tumor suppressor in pediatric and adult brain
tumors, is a novel interacting partner for a cell surface receptor. Anat Erd-
reich-Epstein, Xiuhai Ren. Children’s Hospital Los Angeles/University of South-
ern California, Los Angeles, CA.
BACKGROUND: PID1 is higher in fat fromobese patients and is an inhibitor of
insulin receptor signaling. We reported that PID1 is a novel inhibitor of medullo-
blastoma and glioma cell growth, and its mRNA level is highly correlated with sur-
vival across multiple independent datasets of these tumors. PID1 harbors a phos-
photyrosine binding domain and is predicted to interact with proteins harboring
NPXY motifs. We therefore hypothesized that PID1 will interact with phosphoty-
rosine-binding (PTB) domain containing protein(s) thatmay be important in brain
tumors, andwillmodulate its/their signaling.Herewe reportPID1 interactionswith
one of these proteins and determine its biological consequences. METHODS: Ex-
periments consisted of immunoprecipitations, transient transfections, and western
blotting. Functionally, assays included cell culture, flow cytometry for proliferation
using BrdU/7AAD and apoptosis using AnnexinV/7AAD. Plasmids were pCMV-
AN-HA-PID1(2) or control or the protein of interest in pcDNA3.1. Cell lines used
were glioblastoma,medulloblastoma, atypical teratoid rhabdoid (ATRT), HEK293,
and cells defıcient or intact in PID1. RESULTS: We demonstrate co-immunopre-
cipitation of PID1with a receptor that is considered important in cancer. Immuno-
precipitationwas both inHEK293Tcells overexpressing bothproteins and innative
brain tumor cell lines with/without overexpression. While tyrosine in the NPXY
motifs was not required for the interaction, mutating the kinase domain of the
receptor or overall inhibition of tyrosine phosphorylation impaired the interaction
with PID1. Different domains in PID1 differentially co-immunoprecipitated with
the receptor. Interestingly, mouse embryo fıbroblasts without PID1 showed in-
creased growth factor-dependent tyrosine phosphorylation of this protein and in-
creased growth factor-induced proliferation. Identity of the receptor will be dis-
closed at the meeting. CONCLUSIONS: These data point to PID1 as a novel
interacting partner and regulator of this receptor’s biological effects and signaling in
brain tumors.
#3332 Aberrant expression of CSF1R in melanoma is driven through an
endogenous viral promoter and it contributes to malignant growth and the
acquisition of resistance against BRAF inhibition. Orsolya Giricz,1 Yongkai
Mo,1 Caroline Y. Hu,1 Yiting Yu,1 Kith Pradhan,1 Matthias Bartenstein,1 Nan-
dini Ramachandra,1 Veronika Polishchuck,1 Kimberly B. Dahlman,2 Tushar
Bhagat,1 Hoa Nguyen,3 Bernice Matusow,3 Rafe Shellooe,3 Elizabeth Burton,3
Paraic Kenny,1 John Greally,1 Jeffrey Sosman,2 Gideon Bollag,3 Brian West,3
Amit Verma1. 1Albert Einstein College of Medicine, Bronx, NY; 2Vanderbilt Uni-
versity Medical Center, Nashville, TN; 3Plexxikon, Berkeley, CA.
Epigenetic changes in cancer are thought to contribute to regulation of invasion
andmetastasis. To study this at a genome-wide level in melanoma we analyzed the
methylome of 44 cases ofmalignantmelanoma.We sawwidespread demethylation
in melanoma occurring preferentially outside of CpG islands. Comparison of pri-
mary andmetastatic lesions showeddemethylation occurs early during carcinogen-
esis with few additional alterations in advanced tumors. The colony stimulating
factor-1 receptor was aberrantly expressed and hypomethylated in nearly all cases.
The expression of CSF1R was validated by IHC on primary tumors and by qPCR
andWestern blotting in BRAFmutant andWT cell lines. CSF1R can be aberrantly
expressed via an upstream LTR element in Hodgkin’s lymphoma. After analyzing
our patient samples and the cell lines, we have found this aberrant transcriptmay be
the dominant form in melanoma as well. Expression of one of its ligands IL34 was
also shown in the cell lines by both ELISA and qPCR pointing to a potential auto-
crine regulatory loop. The effects of a small molecule inhibitor, PLX3397 as well as
shRNA-mediated knockdown of the receptor were investigated in 2D and 3D cell
culture. We saw inhibition of cell growth, smaller colony size, increased apoptosis
and decreased invasiveness - suggesting a functional role for CSF1R in melanoma.
Treatment ofmelanomawith smallmolecule inhibitors of BRAFV600E is effective
for a time, but resistance invariably develops. The feedback activation of EGFR,
BRAF amplifıcation, BRAF splice variants and others are known to aid in the acqui-
sition of resistance and the rebound activation of theMAPK-pathway.We are sug-
gesting a role for CSF1R in this process. In Western experiments, the rebound of
phospho-ERK after BRAF inhibitor treatment was accelerated with the addition of
CSF1R ligands, or delayed with PLX3397, also attenuating AKT phosphorylation.
Melanoma cells stably expressing shRNA against CSF1R recapitulated the effects of
the inhibitor. Assaying the cells at different time points during a long-term V600E
inhibitory experiment, we saw increasing levels of the transcription factor RUNX1,
followed by increasing levels of IL34 and of the receptor, as well as its maturation,
evidenced by the appearance of the high MW form. Utilizing shRNA-mediated
knockdown of RUNX1 resulted in lower levels of the CSF1R and IL34 transcripts
and delayed the rebound. Analysis of primary RNA-Seq data showed an increase in
RUNX1, CSF1R and IL34 expression in resistant tumors. Co-inhibition of CSF1R
andBRAFwas also tested and resulted in synergistic blockade of cell growth in vitro
and xenograft growth in vivo. TheCSF1R inhibitor, PLX3397 is currently in clinical
trials forglioblastoma,prostate, breast cancers andother cancers.Thesedatapresent
a preclinical rationale for its study inmalignant melanoma.
#3333 The receptor tyrosine kinaseAXLmediates nuclear translocationof
the epidermal growth factor receptor. Toni M. Brand,1 Mari Iida,1 Kelsey L.
Corrigan,1 Cara M. Braverman,1 John P. Coan,1 Bailey G. Flanigan,1 Andrew P.
Stein,1 Ravi Salgia,2 Jana Rolff,3 Randall J. Kimple,1 Deric L. Wheeler1. 1Univ. of
Wisconsin-Madison, Madison, WI; 2City of Hope, Duarte, CA; 3Experimental
Pharmacology and Oncology Berlin-Buch GmbH, Berlin, Germany.
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The epidermal growth factor receptor (EGFR) is an important therapeutic
target in patients with various cancers. Unfortunately, resistance to anti-EGFR
therapeutics is common. Previous studies in our laboratory identifıed twomech-
anisms of resistance to the EGFR monoclonal antibody cetuximab: First, the
nuclear translocation of EGFR bypasses the inhibitory effects of cetuximab; and
second, the receptor tyrosine kinase AXL mediates cetuximab resistance by
maintaining EGFR activation and downstream signaling. On the basis of these
fındings, we hypothesized that AXL could mediate the nuclear translocation of
EGFR in the setting of cetuximab resistance.We found that NSCLC cetuximab-
resistant clones and patient-derived xenografts (PDXs) had increased abun-
dance of nuclear EGFR (nEGFR) and AXL. Cellular fractionation techniques,
super resolution microscopy, and electron microcopy revealed that genetic loss
of AXL diminished the nuclear translocation and accumulation of EGFR. Build-
ing on previous studies indicating that SRC family kinases (SFKs) and HER
family ligands mediate the nuclear translocation of EGFR, we found that AXL
knockdown down-regulated the expression of the SFKs YES and LYN, and the
ligand neuregulin-1 (NRG1). Furthermore, AXL knockdown decreased the in-
teraction between EGFR and HER3 and the nuclear abundance of HER3. Nu-
clear localization of EGFR could be rescued only upon simultaneous overexpres-
sion of Lyn and NRG1 in cells depleted of AXL. Collectively, these data uncover
a previously unrecognized role for AXL in regulating the nuclear translocation
of EGFR and suggest that AXL-mediated SFK activation and NRG1 expression
are necessary and suffıcient to regulate this process.
#3334 The FGFR4-388Arg variant exerts pro-tumorogenic effects in lung
cancer by inducing an EMT phenotype. Álvaro Quintanal-Villalonga,1 Rocío
Suárez,1 Laura Ojeda-Márquez,1 Santiago Ponce-Aix,1 Amancio Carnero,2 Luis
Paz-Ares,1 Irene Ferrer,1 Sonia Molina-Pinelo1. 1H12O-Cnio, Madrid, Spain;
2IBIS, Sevilla, Spain.
The FGFR4-388Arg allele, where an arginine substitutes a glycine in the 388
codon of the FGFR4 gene, has been associated to poorer patient outcome in
different tumor types. In lung cancer, the variant has been related to shorter
overall survival in adenocarcinoma (ADC) patients, while no relationship with
squamous cell carcinoma prognosis (SCC) has been reported. Mechanistically,
the FGFR4-388Arg variant has been related to increased MAPK pathway acti-
vation and to EMT in prostate cancer in vitro models. Furthermore, the variant
has been associatedwith higher STAT3 signaling inmurinemodels of breast and
lung cancer. However, so far the molecular biology for this FGFR4 variant in
lung cancer patients has not been addressed. We overexpressed the FGFR4-
388Gly and FGFR4-388Arg variants in lung cancer cell lines from different
histologic backgrounds and performed tumorogenicity surrogate assays and
downstream signaling activation assessment. In the generated stable cell lines,
we also determined the expression of EMT markers. Furthermore, we deter-
mined the FGFR4 variant and the FGFR4 and N-cadherin mRNA expression in
a cohort of NSCLC patients (N65) and correlated these data to patient out-
come.We reported that FGFR4-388Arg increases tumorogenicity in lung cancer
cell lines. Mechanistically, these functional effects seem to be mediated by
MAPK and STAT3 overactivation and by the induction of an EMT phenotype,
which includes N-cadherin increased expression. In fact, this induction of N-
cadherin protein expression by the FGFR4-388Arg variant seems to be respon-
sible for the pro-oncogenic effects reported. In NSCLC patient tumor samples,
the FGFR4-388Arg variant correlates with higher N-cadherin expression and
with poorer survival. In conclusion, the FGFR4-388Arg variant is a potential
prognostic biomarker inNSCLC, includingADCand SCCpatients. This variant
increases tumorogenesis through the activation of MAPK and STAT3 signaling
pathways and through the promotion of an EMT phenotype.
#3335 Role of TGF-beta type III receptor in cell migration, invasion, and
proliferation. Anthony Ziccarelli, John Di Guglielmo. University of Western
Ontario, London, Ontario, Canada.
This study aims to investigate the role of Transforming Growth Factor-beta
type III receptor on tumor metastasis through cell migration and invasion. Me-
tastasis is responsible for 90% of cancer related deaths. An important step in the
metastatic process is the epithelial to mesenchymal transition (EMT) of cancer
cells, which is stimulated by TGF. The binding of TGF to its type II receptor
(TRII) triggers the phosphorylation of ser/thr kinase TGF type I receptor
(TRI), and receptor-regulated Smad (R-Smad) which translocates to the nu-
cleus and alters gene transcription. The activity of this pathway is affected by
receptor localization on the cell membrane, while the presence of TRI/II com-
plex in clathrin-coated pits propagates TGF signaling. However, TRI/II com-
plex relocation tomembrane lipid rafts reduces signaling. A TGF receptor that
lacks kinase activity, type III (TRIII), regulates TGF signaling through mul-
tiple roles. Previous investigations have determined TRIII sequesters TGF
ligand to reduce signaling, while also presenting TGF to TRII to increase
signaling. TRIII has also been shown to bind type I and type II TGF receptors
independently, and reverse their membrane partitioning from membrane lipid
rafts to clathrin-coated pits. This TRIII induced relocation ofTRI/II increases
receptor half-life, alteringTGF signaling.Many cancers demonstrate increased
expression of TRIII, suggesting that this protein is influential in the metastatic
pathway. Interestingly, conflicting studies have shown that metastasis is stimu-
lated when TRIII is either overexpressed or knocked-down. Overexpression of
exogenous TRIII and knockdown of endogenous TRIII using siRNA were
used to explore alterations in cell migration and invasion potential. TGF sig-
naling, receptor expression, membrane partitioning, and protein interaction
analyses were performed usingWestern blotting, sucrose-density ultracentrifu-
gation, and immunoprecipitation techniques. Immunofluorescent transwell as-
says measured relative cell migration and invasion through Matrigel. Transfec-
tion of TRIII demonstrated both the punctate and membrane localization of
TRIII, while inhibiting transwell migration. The ability of transfected cells to
migrate and invade through transwell assays clarifıed the impact of TRIII ex-
pression onmetastatic processes. Finally, both the overexpression and silencing
of TRIII resulted in signifıcantly different cancer cell migration and invasion
profıles when compared to untransfected cell lines. TRIII expression and ac-
tivity modify cellular migratory and invasive potential through the modulation
of the TGF signaling pathway, altering epithelial tomesenchymal transitioning
and therefore tumor metastasis.
#3336 Comparison of epithelial mesenchymal transition mediated TKI
resistancNSCLC cells containingwild type EGFRandmutant EGFR.Tsatsral
Iderzorig, Sanjana Singh, Gagan Chhabra, Neelu Puri. Univ. of Illinois at Chi-
cago, Rockford, IL.
Epithelial tomesenchymal transition (EMT) is a vital process in development
and of metastasis and occurs when epithelial cell lose their polarized structure,
by reducing adherent junction proteins E-cadherin, Claudin and ZO-1 on the
membrane. Cells with EMT are elongated spindle like structures due to upregu-
lation ofmesenchymalmarkersVimentin andN-cadherin. EMTmaybe respon-
sible for resistance tomolecular targeted therapies such as tyrosine kinase inhib-
itors (TKIs) against EGFR which is used in patients with activated EGFR
mutations. However, these patients acquire resistance to TKIs after prolonged
use. This acquired resistance to TKIs may also be due to a secondary T790M
mutation in the kinase domain which could be responsible for inducing EMT.
EMT is regulated by p120-catenin which interacts with the Kaiso factor in the
cell nucleus and inhibits the transcriptional repressor activity of Kaiso factor.
Kaiso factor represses Wnt target genes such as ZEB-1. The binding of p120-
catenin to Kaiso factor also increases Wnt signaling which results in loss of
E-cadherin. Cells undergoing EMT can acquire cancer stem-cell like character-
istics by expressing stem-cell marker ABCB1. Thus we investigated EMT char-
acteristics in TKI-resistant NSCLC cells, H2170 ER (Erlotinib resistant), H358
ER and H1975. To determine modulation of EMT biomarkers in TKI-resistant
cells, H1975 with L858R and T790Mmutations was compared to TKI-sensitive
cell line H3255 with L858R mutation, using immunoblotting, and qPCR. Ex-
pression of stem-cell markers ABCB1 and EMT biomarker E-cadherin are mea-
sured using flow cytometry. Key EMT-related proteins such as PRMT-1, Slug,
Snail, Twist, p120-catenin, and Vimentin were upregulated by 3.2, 3.18, 6.2,
1.68, 4 and 6.5 fold, respectively, and E-cadherin, Claudin and ZO-1were down-
regulated by 89%, 90% and 99% fold as compared to the H3255 TKI-sensitive
cell line.We also observed upregulation of N-cadherin, ZEB-1 and Vimentin by
2.4, 2.6, and 12 fold and downregulation of E-cadherin by 50% in H1975 by
qPCR. Immunofluorescence studies for Vimentin showed that H1975 cells were
more elongated and stratifıed as compared to the H3255 that had polarized
structures. 90% colocalization of p120-catenin and Kaiso factor was seenH1975
cells whereas 10% colocalizationwas seen inH3255 cells. Flow cytometry results
indicated that there was signifıcant increase in expression of stem cell marker
ABCB1 in TKI resistant cells H2170 ER, H358 ER and H1975 in comparison to
H2170 P(Parental), H358 P and H3255 TKI sensitive cells. In conclusion, our
results indicate that EMT is mediated through PRMT-1, which methylates
Twist, transcriptional repressor of E-cadherin along with Slug and Snail in
H1975 cells with T790M mutation. Cancer stem-cell marker ABCB1 is specifıc
for TKI resistant NSCLC cells which exhibit EMT.
#3337 The G protein-coupled P2Y6 pyrimidoceptor increases tumorigen-
esis potential of epithelial cell in colorectal cancer associated to colitis.Mor-
gane Placet, Caroline M. Molle, Djordje M. Grbic Grbic, Guillaume Arguin,
Sameh Geha, Fernand-Pierre Gendron. Université De Sherbrooke, Sherbrooke,
Quebec, Canada.
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BACKGROUND: Carcinogenesis is a complex process induced by various
genetic mutations, which is characterized by 3 phases. The initiation phase,
inflammation is predominant, as in colitis-associated carcinogenesis, and in-
volves the active recruitment of immune cells like macrophages, dendritic cells
and T cells. The promotion and progression phases are respectively tied to dys-
plasia and carcinoma and metastasis. Inflammatory bowels disease (IBD), in-
cluding colitis, induces an unbalance in pro- and anti-inflammatory cytokines, a
breakage in the epithelial barrier, pathogens infıltration and leucocytes recruit-
ment and activation. During inflammation, nucleotides are released in a large
amount in the extracellular environment. The P2Y6 receptor was associated
with IBD where its expression was increased in T cells infıltrating inflamed
colonic tissue and on the epithelial cells of the inflamed tissue. In this context,
activation of the P2Y6 receptor may contribute to the formation of a tumor-
promoting environment by modulating the immune response and establish-
ment of tumors.METHODS: Colorectal cancer associated to colitis was induced
in P2ry6 gene knockout mice (P2Y -/- 6 ) using azoxymethane, as a carcinogen,
and dextran sulfate sodium challenges as a promoting agent. Mice were eutha-
natized and the number and size of tumor measured. Tissues were fıxed and
stainedprior to histological characterization. The impact of P2Y6Ractivation on
apoptosis and NFB pathway was determined by western blotting, and the im-
pact on inflammatory cytokines balance and mucus layer were analyzed by his-
tology and qPCR of differentmarkers. RESULTS: Invalidation of the P2ry6 gene
inmice lead to a reduction in the number of colorectal tumors in our AOM-DSS
model. We have linked this observation to the protective role of P2Y6R toward
TNF-induced apoptosis of cancerous epithelial cells. Furthermore, P2Y6R reg-
ulates the balance between pro- and anti-inflammatory cytokines in inflamma-
tory conditions, and maintain the integrity of the epithelial barrier by modulat-
ing the density of themucus layer. CONCLUSION: In this study, we have shown
that P2Y6R could contribute to colorectal cancer colitis associated by blocking
the apoptotic process, modulating the cytokine network, and regulating the
integrity of the mucus layer. These results suggest that P2Y6R can be a prime
target to reduce colorectal cancer colitis associated.
#3338 A role for FGFR4 in growth and survival of Ewing sarcoma cells.
Justin J. Montoya,1 Daniel H. Wai,1 David W. Lee,1 Peter A. Azorsa,2 Oliver B.
Pepper,2 Robert J. Arceci,1 David O. Azorsa1. 1Phoenix Children’s Hospital,
Phoenix, AZ; 2University of Arizona College of Medicine - Phoenix, Phoenix, AZ.
Ewing sarcoma is the second most common cancer of bone and soft tissue
arising in children and young adults. Although the survival rate has improved
for patients treated for localized disease, the survival rate for patients with met-
astatic tumor remains lower than 30%. In order to identify novel therapeutic
targets and to better understand the genes involved in growth and survival of
Ewing sarcoma, we employed a functional genomics approach based on siRNA
screening. Four Ewing sarcoma cell lines, TC-32, TC-71, SK-ES-1 and RD-ES,
were transfected with a library of siRNA targeting 287 cancer-associated genes.
The resulting siRNA screening data for each cell line were normalized and sta-
tistical cut-offs were determined. The results indicated that siRNAs targeting
Fibroblast Growth Factor Receptor 4, FGFR4 were among the most effective in
reducing cell viability in all four of the Ewing sarcoma cell lines. Validation of the
siRNA screens showed that siRNAs to FGFR4, reduced viability much greater
that those to FGFR1, FGFR2, or FGFR3. Furthermore, siRNA targeting FGFR4
were able to induce caspase 3 activity. FGFR4 protein is expressed on Ewing
sarcoma cells as determined by western blot analysis, although expression levels
were lower compared to FGFR4 expression on rhabdomyosarcoma cells. Tar-
geting FGFR activity in Ewing sarcoma cells using a pan-FGFR inhibitors PD-
173074 and BGJ-398 demonstrated that Ewing sarcoma cells were sensitive to
FGFR inhibition. Furthermore, treatment of Ewing sarcoma cells with the selec-
tive FGFR4 inhibitor BLU9931 resulted in growth inhibition and decreased ERK
signaling. These results indicate that FGFR4 may play an important role in
growth and survival of Ewing sarcoma and could serve as a potential therapeutic
target for this disease.
#3339 Muscarinic acetylcholine receptor subtype 3 regulates gastric stem
cell expansion and gastric cancer progression by controlling YAP activation.
Yoku Hayakawa,1 Mitsuru Konishi,1 Kosuke Sakitani,2 Kazuhiko Koike,1 Tim-
othy Wang3. 1University of Tokyo, Tokyo, Japan; 2Columbia University, NY;
3Columbia University, New York, NY.
Within the gastrointestine, nerves help to regulate both normal and neoplas-
tic stem cell dynamics. Several previous studies suggested that cholinergic nerve
signaling plays an important role in gastrointestinal cancer development, but the
exact underlying mechanism has not been clarifıed. In this study, we examined
the role ofmuscarinic acetylcholine receptor subtype 3 (M3R) in gastric homeo-
stasis and cancer development by using mouse models and human cancer cell
lines. In situ hybridization revealed M3R expression in gastric stem cell zone,
and its expressionwasmarkedly upregulated in gastric cancer cells.We knocked
out M3R in Lgr5 gastric stem cells in Lgr5-CreERT; M3Rflox/flox mice, and
found that deletion of M3R inhibited clonal expansion of Lgr5 cells in regen-
erative states. In a gastric tumor model of Mist1-CreERT; Apcflox/flox mice,
knockout of M3R dramatically suppressed tumor growth. RNA sequencing
analysis of these tumors revealed that several important pathways were signifı-
cantly inhibited in M3R knockout samples, including YAP/TAZ pathway. We
established M3R-expressing gastric cancer cell lines, and western blotting, lu-
ciferase assay, and RT-PCR analysis confırmed that acetylcholine (ACh) agonist
activates YAP pathway throughM3R. YAP is upregulated in approximately half
of gastric cancer patients, and its expression is signifıcantly associated with dis-
ease stage and histological form. This M3R-YAP axis activates the gastric stem
cell niche and offers a compelling target for tumor treatment and prevention.
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#3340 Identifıcation of CARM1/PRMT4 as a novel therapeutic target for
AML. Sarah M. Greenblatt, Pierre-Jacques J. Hamard, Takashi Asai, Na Man,
Concepcion Martinez-Caja, Fan Liu, Stephen Nimer. University of Miami, Mi-
ami, FL.
Chromatin modifying enzymes, and specifıcally the protein arginine methyl-
transferases (PRMTs) have emerged as important targets in cancer. PRMT4, also
known as CARM1, is overexpressed in a number of cancers, including breast,
prostate, pancreatic, and lung cancer. Our lab reported the overexpression of
PRMT4 in the context of acute myeloid leukemia (AML), showing that more
than 70% of cytogenetically normal AML patients have up-regulation of
PRMT4. Here, we investigated the role of PRMT4 in normal hematopoiesis and
leukemia development. In order to study the role of PRMT4 in normal hemato-
poiesis, Prmt4-floxedmicewere crossedwithVav1-cremice purchased from the
Jackson Laboratory. Inducible Prmt4 conditional KO mice were generated by
crossing Prmt4-floxed mice with Mx1-Cre mice and Prmt4 gene excision was
induced by poly(I:C). Using this hematopoietic specifıc knockout system, we
show that loss of PRMT4has little effect on normal hematopoiesis, but promotes
the differentiation of hematopoietic stem and progenitor cells. Next we evalu-
ated the role of PRMT4 in leukemia development using leukemia transplanta-
tion models driven by fusion oncoproteins. Strikingly, the knockout of PRMT4
completely abrogates leukemia initiation in fetal liver transplantation models
driven by the AML1-ETO or MLL-AF9 fusion proteins. We further character-
ized the mechanism for the leukemia-specifıc dependence on PRMT4 using
leukemia cell lines and found that knockdown of PRMT4 impairs cell cycle
progression, decreases proliferation, and induces rapid apoptosis. To examine
PRMT4 dependent changes in gene expression in a leukemia system, we used
lentiviral vectors that express RFP and shRNAs directed against PRMT4. We
knocked down PRMT4 in four leukemia cell lines or normal human cord-blood
derived CD34 cells. Gene set enrichment analysis showed that all four leuke-
mia cell lines with knockdown of PRMT4 signifıcantly down-regulated E2F
target genes compared to the scrambled control. Chromatin immunoprecipita-
tion analysis (ChIP) confırmed the presence of PRMT4 and H3R17 dimethyla-
tion at the promoter regions of E2F1 targets. The PRMT4 conditional knockout
mice and PRMT4 knockdown experiments both suggest that the loss of PRMT4
protein has a selective effect on leukemia cells compared to normal hematopoi-
etic stem and progenitor cells. Collectively, this work suggests that targeting
PRMT4 through chemical inhibitionmay be an effective therapeutic strategy for
AML and other cancers with up-regulation of PRMT4.
#3341 Epigenetic deregulation of the Hippo pathway in muscle-derived
sarcomas. T. S. Karin Eisinger, Shuai Ye. Univ. of Pennsylvania School of Med-
icine, Philadelphia, PA.
Soft tissue sarcomas are an aggressive group of roughly 65 mesenchymal malig-
nancies diagnosed in 200,000 people worldwide annually. The treatment approach
for sarcomas has not changed signifıcantly in 25 years. Furthermore, recent se-
quencing efforts have revealed that consistent oncogenicmutations are rare inmus-
cle cancers. As a result, these tumors are not sensitive to most available targeted
therapeutics, which specifıcally interfere with the functions of mutant oncogenic
pathways.We are investigating the possibility that together with p53 or RB1muta-
tion/loss, alterations in chromatin state and epigenetic regulation rather than onco-
genic mutation, are required for sarcoma transformation. Based on our current
fındings we are testing the hypothesis that epigenetic deregulation of Angiomotin
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(AMOT), a novel tumor suppressor we have identifıed, is critical for sarcomagen-
esis.AMOTishighly expressed indifferentiatedhumanmuscle tissuebut is silenced
in muscle-derived sarcomas including undifferentiated pleomorphic sarcoma
(UPS), a commonly diagnosed and aggressive subtype. Furthermore, ectopic ex-
pressionof thep130 isoformofAMOTsignifıcantly inhibitsUPSproliferation.This
fınding is consistent with the only known function of AMOT in cancer cells, which
is to sequester theHippopathwayeffectorYAP1and facilitate itsdegradation.YAP1
is a pro-proliferation transcriptional activator and deletion of Yap1 in the
KrasG12D/; Trp53fl/fl autochthonous mouse model of UPS. Importantly, treat-
ment of sarcoma cells and tumors with the epigenetic inhibitors SAHA and JQ1
restores p130 AMOT expression, inhibits Yap1, and dramatically reduces sarco-
magenesis in vivo. Interestingly, SAHA/JQ1 treatment also induces expression of
muscle markers including MYOD and p57 suggesting that epigenetic modulation
promotes differentiation aswell as inhibiting proliferation. Gene expression studies
of control and Yap1-defıcient tumors revealed that Yap1 controls NF-B signaling.
We have performed H3K27Ac ChIP-seq and super-enhancer analysis of human
UPS tumors to determine whether NF-B targets are important in human sarco-
mas. These analyses revealed that NF-B is the most transcriptionally active path-
way in UPS. Together these data suggest that persistent YAP1-mediated NF-B
signaling promotes sarcomagenesis. In normal undifferentiatedmuscle cellsNF-B
signaling is essential forproliferationand inhibitionofdifferentiation.Wehavenow
shown that SAHA/JQ1-mediated YAP1 inhibition subsequently decreases NF-B
activity, underscoring the ability of epigenetic therapies to decrease tumorigenesis
andenhancedifferentiation.Our fındings suggest thatpharmacologicalmodulation
of chromatin modifıers will allow us to regain epigenetic control over the Hippo
pathway and its downstream targets. Thuswehave an opportunity to fınally change
the treatment paradigm for these patients with novel targeted therapeutics.
#3342 Hippo signaling promotes sarcomagenesis through the NF-kB
pathway. Shuai Ye, Koreana Pak, Jennifer Shah, Susan Chor, Shaun Egolf, Glo-
riaMarino, T.S. Karin Eisinger-Mathason.Univ. of Pennsylvania School ofMed-
icine, Philadelphia, PA.
Nearly 200,000 individuals worldwide are diagnosed with a form of soft-
tissue sarcoma (STS) every year. Due to a lack of novel targeted therapeutics
sarcoma for these malignancies treatment has not changed signifıcantly in 25
years. Therefore, the discovery of novel targets and mechanisms is critical.
One promising avenue the Hippo pathway, which we have identifıed as a key
regulator of sarcomagenesis in undifferentiated pleomorphic sarcoma
(UPS), a commonly diagnosed and aggressive subtype of sarcomas. Inacti-
vation of the pathway, promotes nuclear localization of YAP1, a transcrip-
tional co-activator that promotes proliferation. Whereas, many studies have
defıned YAP1’s transcriptional targets in epithelial tumors and normal tis-
sues, its role in mesenchymal tumors is unclear. Here, we confırm that in-
creased YAP1 mRNA expression correlates with worse overall survival in
UPS patients. To defıne mechanisms of YAP1-mediated sarcomagenesis, we
developed a novel genetic mouse model in which YAP1 is conditionally
deleted in UPS tumors. Microarray analysis of these tumors revealed that
YAP1 loss inhibits expression of NF-B targets. We have performed ChIP-
seq and super-enhancer analysis of human UPS tumors and found that many
of the 900 identifıed super enhancers regulate expression of NF-B targets
that are dependent on YAP1 in our system. This fınding is particularly rele-
vant as NF-B is a key regulator of muscle cell proliferation and suppresses
myoblast differentiation. Together, these data suggest that upregulation of
YAP1 activity promotes NF-B-mediated proliferation and inhibits differ-
entiation, resulting in sarcomagenesis. Importantly, we have discovered that
a combination of JQ1, a BET family inhibitor, and SAHA, a histone deacety-
lase inhibitor, decreases YAP1 expression, YAP1 protein stability, and sar-
coma cell proliferation. SAHA/JQ1 treatment signifıcantly increased expres-
sion of Angiomotin (AMOT), which binds YAP1, sequesters it in the
cytoplasm, and facilitates it degradation. We have also found that AMOT
expression is lost in sarcomas, likely due to epigenetic suppression. Consis-
tent with these observations, SAHA/JQ1 treatment also decreased gene ex-
pression of YAP1 targets and caused re-expression of the muscle differenti-
ation markers p57, MEF2C, and MYOD1. We have investigated the effect of
of SAHA/JQ1 in vivo and found dramatic inhibition of tumor growth, as well
as reduced YAP1 expression, and increased AMOT expression. Importantly
SAHA/JQ1 treatment also inhibited NF-B activity. Our studies have re-
vealed for the fırst time that YAP1 expression is epigenetically modulated
through AMOT de-regulation in sarcomas, resulting in elevated NF-B ac-
tivity and sarcomagenesis. SAHA/JQ1 treatment re-establishes epigenetic
control of the Hippo pathway reducing proliferation and enhancing differ-
entiation. Ultimately, we will determine whether this approach represents a
novel course of targeted treatment for sarcoma patients.
#3343 RNA demethylase alkbh5 supports breast cancer growth and pro-
gression. Vijay Kumar Eedunuri, Panneerdoss Subbarayalu, Subhapriya Raja-
manickam,AbdelfattahNourhan, BenjaminC.Onyeagucha, SantoshTimilsina,
Pooja Yadav, Manjeet K. Rao. Greehey Children’s Cancer Research Inst., San
Antonio, TX.
N6-methyladenosine (m6A) is one of the most prevalent internal modifıca-
tions in eukaryoticmessengerRNA.This dynamic and reversiblemodifıcation is
installed by methyltransferase complex consisting of three subunits: Methyl-
transferase-like protein 3 (METTL3), Methyltransferase-like protein 14
(METTL14) and Wilms tumor 1-associating protein (WTAP), and erased by
two independent demethylases, Fat mass and obesity associated protein (FTO)
and AlkB homolog 5 (ALKBH5). RNA demthylase ALKBH5 has been reported
to play vital roles in several biological processes. However, very little is known
about the role of ALKBH5 in cancer in general and breast tumorigenesis in
particular. In this study, we report that ALKBH5 promotes breast cancer growth
and progression. Using in vitro and in vivo models, we show that silencing of
ALKBH5 inhibits breast cancer growth and invasion. Importantly, our studies
reveal thatALKBH5mediates its pro-tumorigenic function by regulating several
microtubule associated genes including KIF2C, PLK1,MAPRE1 and RCC2 that
are critical for spindle formation or assembly during mitotic progression. Inter-
estingly, ALKBH5 target genes KIF2C and MAPRE1 are highly expressed in
breast cancer patients and their higher expression is strongly correlated with
lower survival of breast cancer patients.We believe that an optimal level of RNA
methylation of key target genes is critical for normal cell cycle progression and
any alteration in the levels of RNAmethylation may alter activity or expression
of these genes resulting in unabated cell proliferation.
#3344 AKT mediates transcriptional regulation of H3K4 demethylase in
PTEN null prostate cancer.Mohammad Imran Khan, Suvasmita Rath, Qateeb
Khan, Vaqar M. Adhami, Hasan Mukhtar. Univ. of Wisconsin-Madison, Madi-
son, WI.
Oneof the commoncontributors to thepre-dispositionofmosthumancancers is
inappropriate activation of AKT due to loss of its negative regulator PTEN. Acti-
vatedAKTregulates changes inmetabolic processes such as acetyl-CoAproduction
that impacts chromatin. AKT phosphorylates a wide variety of histonemodulating
enzymes including acetyltransferases and methyltransferases resulting in their hy-
peractivation or inhibition. Therefore, understanding the impact ofAKT inhibition
on global histone modifıcation would be ideal to identify novel histone modifıers
regulated byAKT.Weperformedunbiased and comprehensive profıling of histone
modifıcations in prostate specifıc PTENknockoutmice treatedwith anAKT inhib-
itor (Perifosine, 10mg/kg body weight daily for 4 weeks) and observed that AKT
inhibition signifıcantly induces di and tri methylation of H3K4, concomitant with
reduction acetylation of H3K9. Changes in other histone modifıcations such as
H3K36 and H3K79 methylation and acetylation were not observed. Mechanisti-
cally,we observed thatAKT inihibiton reduces the expressionofH3K4methylation
related histone demethylases KDM5 family, especially KDM5B expression at tran-
scriptional level. Similar observations were noted at translational level also. To fur-
ther understand the transcriptional regulation of KDM5B by AKT we focused on
miR-137 andmiR-138 as these have been shown to transcriptionally regulateH3K4
demethylases. We observed that AKT activation negatively regulated miR-137 but
not miR-138 levels, which further transcriptionally represses KDM5B expression.
Overexpression of miR-137 signifıcantly reduced KDM5B and increased H3K4 di
and tri methylation levels but failed to change AKT phosphorylation. Genetic
knockdown of AKT or inhibition of AKT phosphorylation increased miR137 and
reduced both KDM5B levels. Overall, we observed that AKT transcriptionally reg-
ulates KDM5Bmainly via repression ofmiR137. Our data identify amechanism by
which PI3K/AKT signalingmodulates the prostate cancer epigenome through reg-
ulating H3K4 methylation and KDM5B expression. Additional studies that assess
the impact of AKT inhibiton on genome occupancy of H3K4methylation will help
in the identifıcation of targets and devise novel strategies to enhance the therapeutic
effıcacy of PI3K/AKT inhibitors that are currently in clinical development.
#3345 Selective killing of SMARCA2- and SMARCA4-defıcient tumors by
inhibition of EZH2: In vitro and in vivo preclinical models. Elayne Chan-
Penebre, Kelli Armstrong, Allison Drew, Alexandra R. Grassian, Igor Feldman,
Maria Roche, Peter Ho, Dorothy Brach, Alejandra Raimondi, Robert A. Cope-
land, Richard Chesworth, Jesse J. Smith, Scott A. Ribich. Epizyme, Inc., Cam-
bridge, MA.
The histone methyltransferase EZH2 is the enzymatic subunit of the polycomb
repressive complex 2 (PRC2) that catalyzes the methylation of H3K27 thereby re-
pressing target gene transcription. EZH2 is amplifıed, overexpressed, ormutated in
multiple cancer types,most notably Follicular Lymphoma (FL) and germinal center
Diffuse Large B-cell Lymphoma (GCB-DLBCL). We previously reported that pre-
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clinical models of malignant rhabdoid tumors, which are defıcient in the SWI/SNF
core component INI1 (SNF5, SMARCB1), are selectively killed by potent and selec-
tive inhibitors of EZH2. Here we report another class of SWI/SNF-altered cancers
named small cell carcinoma of the ovary hypercalcemic type (SCCOHT) that is
dependent on EZH2 activity. SCCOHT is a very aggressive form of cancer that
respondspoorly to conventional therapywithaone-yearoverall survival rateofonly
50%. Very few novel agents have been approved for this indication; thus there is a
need for targeted therapeutics in SCCOHT. SMARCA4 and SMARCA2 are co-
inactivated in this tumor type thathasmanyrhabdoid features.Wedemonstrate that
tazemetostat, an EZH2 inhibitor currently in phase 2 clinical trials, induces potent
and selective killing in SMARCA2 and SMARCA4-defıcient ovarian cell lines. In
addition to small molecule inhibitor data, we conducted functional genomics stud-
ies withCRISPRpooled screening, and confırmed that SCCOHT is also sensitive to
CRISPR-mediated EZH2 gene ablation. Dose-dependent anti-tumor effects were
observed upon tazemetostat treatment in SCCOHT xenografts defıcient in both
SMARCA2 and SMARCA4.We also report on additional non-ovarian tumor types
with dual SMARCA2/SMARCA4 loss includingNSCLC that exhibit EZH2 depen-
dence representing additional potential therapeutic indications for tazemetostat
treatment.
#3346 Epigenetic downregulation ofmiRNA-34a andmiRNA-449 induce
epithelial-mesenchymal transition and acquired resistance to ceritinib. Sun
Min Lim,1 Mi Ran Yun,2 Kyoung Ho Pyo,2 Seong Keun Kim,3 Seon-Kyu Kim,4
Yong Sung Kim,4 Mirang Kim,4 Byoung Chul Cho1. 1Yonsei Univ. College of
Medicine, Seoul, Republic of Korea; 21JE-UK Institute for Cancer Research, Seoul,
Republic of Korea; 3CHA University, Seongnam, Republic of Korea; 4Korea Re-
search Institute of Bioscience & Biotechnology, Republic of Korea.
Background:Treatment with ALK tyrosine kinase inhibitors elicits profound
initial antitumor responses in ALK fusion-positive patients with lung adenocar-
cinoma.However, patients invariably develop acquired resistance toALK inhib-
itors. Although the recent functional genetic studies characterized the mecha-
nism of resistance to ALK inhibition, epigenetic mechanism of acquired
resistance is poorly understood. Method: We established in vivo and in vitro
models of acquired resistance to ceritinib and crizotinib usingH3122 andH2228
cells. For in vivo model, mice with established H3122-derived tumors were
treated with ceritinib to derive ceritinib-resistant tumors. To investigate the
epigenetic mechanisms of resistance, we performed methylated DNA binding
domain sequencing (MBD-seq) for DNAmethylation and chromatin immuno-
precipitation-sequencing (ChIP-seq) for histone modifıcations associated with
enhancers (H3K4me1 and H3K27ac) of H3122 and H3122 ceritinib-resistant
(LR) cells. We also performed in situ hybridization of miR-34 and miR-449 in
patient samples. Results: Epithelial-to-mesenchymal transition with AXL acti-
vation was found in multiple in vitro and in vivo ALK-rearranged lung cancer
models with acquired resistance to ceritinib. Genome and epigenome-wide
analysis identifıed that miR-34a and miR-449a are decreased with loss of
H3K27ac, while AXL and mesenchymal genes are increased in the process of
acquired resistance. We confırmed that miR-34a and miR-449 were involved in
AXL-dependent epithelial-mesenchymal transition (EMT) by treating mimics
and inhibitors of miR-34a and miR-449a. In addition, pharmacological inhibi-
tion ofAXLor ectopic expression ofmiR-34a ormiR-449a restored sensitivity to
ceritinib in H3122-LR cells. Histone deacetylase (HDAC) inhibitor, panobinos-
tat, synergistically induced anti-proliferative effects with ceritinib in resistant
cells. Treatmentwith panobinostat led to increased expression ofmiR-449awith
increased H3K28ac signal in H3122 LR cells. Panobinostat also reversed EMT
phenotype by downregulating N-cadherin and upregulating E-cadherin expres-
sion. Additionally, combination of panobinostat and ceritinib induced en-
hanced antitumor effıcacy in acquired resistant xenograft models. To clinically
validate our preclinical fındings, we measured the expression of miR-34a and
miR-449 by in situ hybridization in 5 matched ALK-rearranged lung cancers
obtained from individuals both before and after ALK inhibitor treatment. We
detected decreased expression of miR-34a andmiR-449 in 3 of 5 samples (60%).
Conclusion: Our fındings demonstrate that H3K27ac remodeling is a crucial
event in ceritinib resistance and inhibition of both ALK and HDAC could pre-
vent or overcome acquired resistance to ALK inhibitors in individuals with
ALK-rearranged lung cancer.
#3347 Exploring the role of ASXL family of genes in enabling oncogenic
AR-signaling in prostate cancer. Abhijit Parolia, Xuhong Cao, Arul Chinnai-
yan. University of Michigan, Ann Arbor, MI.
Prostate cancer (PCa) is the second leading cause of cancer-related mor-
tality in North American men. In recent years, there has been mounting
evidence establishing the centrality of epigenetic mechanisms in PCa initia-
tion and progression. Accordingly, various epigenetic genes have been de-
scribed to collaborate with the androgen receptor (AR) in enabling its onco-
genic transcriptional program and aberrantly restoring its activity in
metastatic castration resistant PCa (mCRPC). Concordantly, our lab has
recently described two epigenetic genes, BRD4 &MLL2, as key co-activators
of the AR signaling complex. Furthermore, we have demonstrated the ther-
apeutic benefıts of inhibiting the activity of these genes in advanced PCa.
Thus, in a setting where invariably all metastatic PCa patients progress to
evolve resistance to anti-AR therapy, epigenetic genes emerge as potent co-
targets with the promise to improve patient outcomes. To To identify novel
AR-collaborating genes, as part of a multi-institutional consortium, our lab
had performed comprehensive molecular profıling of 150 mCRPC patient
tumors. This study revealed multiple genetic aberrations in chromatin mod-
ifıer genes. Interestingly, this list comprised of recurrent mutations in the
ASXL family of genes in about 5% of the cases. ASXL family members are
epigenetic scaffolding proteins that assemble chromatin modifıers and tran-
scription factors to specifıc genomic loci with histone modifıcations. Al-
though intricately involved in the genesis of acute myeloid leukemia, hith-
erto, no study has comprehensively described the role of ASXL genes in PCa
biology. Two members of this family, ASXL1 and ASXL2, are robustly ex-
pressed in PCa. Co-immunoprecipitation assays revealed that these proteins
also reside in the AR-signaling complex. Notably, siRNA-mediated inhibi-
tion of these genes dramatically attenuated proliferation of AR-dependent
PCa cells, but had minimal effect on non-neoplastic prostate cells. These
preliminary results strongly implicate ASXL genes in the oncogenic re-pro-
gramming of AR-activity and warrant further investigation towards explor-
ing of their therapeutic value in currently incurable mCRPC.
#3348 UniD: unifıed and integrated diagnostic pipeline for malignant
gliomas based on DNA methylation data. Jie Yang, Qianghu Wang, Lihong
Long, Ravesanker Ezhilarasan, Erik Sulman. MD Anderson Cancer Center,
Houston, TX.
Prognostic and predictive molecular diagnostics for patients with gliomas typi-
cally rely onmultiple assays, requiring large amounts of tissue and high cost. DNA
methylation has been utilized to identify prognostic subsets and high-throughput
platformsexist that are suitable for archival tissue.Therefore,wedevelopedaunifıed
and integrateddiagnosticpipeline that canassessmultipleprognostic andpredictive
biomarkers using only the Illumina Infınium Methylation array. This pipeline in-
cludes two parts: data processing and diagnostic biomarkers. Data processing starts
from the raw data and followed with quantitative sample, probe, and batch quality
control. Thediagnostic biomarkers include a gliomamethylation assay that predicts
radiation response (GaMA); tumor classifıcation enriched for TCGA expression
subclasses; copy number alterations including phosphatase and tensin homolog
(PTEN) loss, epidermal growth factor receptor (EGFR) amplifıcation, and chromo-
somes1p/19q co-deletion;CpG islandmethylationphenotype (G-CIMP); isocitrate
dehydrogenase (IDH) mutation, and O6-methylguanine-DNA methyltransferase
(MGMT)promoter hypermethylation.WHOgrade II-IV gliomaswere analyzed in
both publically available and institutional datasets. A signature was identifıed to
effectively distinguished radiation resistant from radiation sensitive glioma stem-
like cells (GSCs). Signature has been applied to 272 TCGA GBM samples from
patients who received standard radiotherapy (RT). The survival analysis showed
that the subgroup with RT-sensitive and RT-resistant have signifıcant difference in
survival time (log-rank test p-value 0.0016). Gene expression subclasses predic-
tion biomarker was build by using the revised TCGA gene expression subclasses as
gold standard. The prediction accuracy in test data set was 83.5% in the homoge-
neous subgroup, 71.0% in the semi-heterogeneous subgroup, and 62.1% in the het-
erogeneous subgroup. The prediction accuracy decreased as tumor heterogeneity
increased.Certain copynumber alteration eventswerepredictedbydeveloping spe-
cifıc signatures. Revised methylation signatures were developed for IDHmutation
and G-CIMP status respectively, which can identifıed 99% of those samples. 230
GBM samples with 450k data available were tested with MGMTmethylation-spe-
cifıc real-time PCR forMGMTmethylation status. Themethylation-basedMGMT
prediction accuracy reached about 90%. In summary, we have developed a single,
FFPE-basedpipeline for unifıed and integrated determination ofmultiple biomark-
ers of malignant glioma.
#3349 A regulatory circuit HP1 gamma/miR-451a/c-Myc promotes pros-
tate cancer progression. Ruimin Huang,1 Cunjie Chang,2 Jiakuan Liu,2 Xiao-
jing Huang,2 Lan Shen,2 Dianzheng Zhang,3 Jun Yan2. 1Shanghai Institute of
Materia Medica, Chinese Academy of Sciences, Shanghai, China; 2Model Animal
Research Center of Nanjing University, Nanjing, China; 3Philadelphia College of
Osteopathic Medicine, Philadelphia, PA.
Heterochromatin protein 1 gamma (HP1 gamma), as a reader of the histone
codes, is involved in the determination of higher order of chromatin structure. It
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has also been implicated in carcinogenesis of various cancer types. However, the
role of HP1 gamma in prostate cancer (PCa) progression and the underlying
molecular mechanisms remain largely unknown. Using the public microarray
data from GEO and TCGA database, we found that HP1 gamma was upregu-
lated in PCa, comparing with benign prostate tissues. PCa patients with higher
level of HP1 gamma had shorter disease-free survival, indicating that HP1
gamma level can serve as prognostic marker in PCa patients (p  0.016). In
addition, depletion of HP1 gamma by shRNA in PCa cells not only repressed
proliferation and induced apoptosis, but also impaired tumorigenicity in vitro
and in vivo.We also found that c-Myc was capable of upregulating HP1 gamma
by directly binding to the E-box element in the fırst exon of HP1 gamma gene,
and the upregulatedHP1 gamma, in turn, repressed the expression of miR-451a
by enhancing H3K9 methylation at the promoter region of miR-451a. Further-
more, reduction of miR-451a signifıcantly reversed HP1 gamma loss-induced
PCa cell apoptosis, whereas miR-451a overexpression repressed cell survival by
targeting and downregulating c-Myc. The association among mRNA and pro-
tein expression levels of c-Myc, HP1 gamma and miR-451a were further con-
fırmed in human clinical samples using Spearman correlation analysis. There-
fore, we propose that an HP1 gamma/miR-451a/c-Myc regulatory circuit exists
in PCa cells and this circuit plays a crucial role in PCa progression.
#3350 Cell-free DNA fragmentation patterns analyzed in over 15000 can-
cer patients reveal changes associated with tumor somatic mutations and
result in improved sensitivity and specifıcity of somatic variant detection.
Diana Abdueva, Helmy Eltoukhy, Darya Chudova, AmirAli Talasaz. Guardant
Health Inc, Redwood City, CA.
Background:Cell-freeDNA(cfDNA) isolated fromplasmaconsistsofDNAfrag-
ments surviving clearance of dying cells and bloodstream traffıcking. In cancer,
these fragments carry the footprintof tumor somaticvariationaswell as itsmicroen-
vironment. Since genomic distribution of cell free DNA fragments was shown to
reflect nucleosomal occupancy in hematopoietic cells, we hypothesized that (a) het-
erogeneous patterns of cfDNApositioning would be associated with distinctmuta-
tions in patient tumors and (b) integration of fragmentation patterns into analysis
would allow increased sensitivity and specifıcity of somatic mutation detection.
Methods: cfDNA fragment length and position distributions as well as associated
somatic genomicprofıles of over15,000patientswithadvanced-stage clinical cancer
were determined by a highly accurate, deep-coverage (15,000x) ctDNA NGS test
targeting 70 genes (Guardant360). An integrative data analysis of variant-free frag-
mentomics domain across different driver mutations was performed to identify
patterns associated with detected somatic alterations. Results: We discovered dis-
tinct classes of fragmentomics subtypes signifıcantly enriched in samples with dif-
ferent genomic subtypes. An independent cohort of samples with known HER2
immunohistochemistry status was interrogated to confırm discovered association
between fragmentation patterns and HER2 status. Integrating fragmentomics am-
plifıcation signaturewithERBB2 copynumber analysis has resulted in 42% increase
in the sensitivity and 7% increase in specifıcity of detection. Observed lung adeno-
carcinoma fragmentomics subtypes co-occured with mutually exclusive genomic
alterations and previously described intrinsic molecular subtypes of lung cancer.
Conclusions: Fragmentomics classifıcation of cancer cfDNAprovides independent
evidence for observed somatic variation and underlying tumor microenviroment,
leading to higher sensitivity and accuracy of variant detection.
#3351 Aberrant RNA editing of GLI1 promotes malignant regeneration
in multiple myeloma. Elisa Lazzari,1 Nathaniel Delos Santos,1 Christina Wu,1
Heather Leu,1 Gabriel Pineda,1 Shawn Ali,1 Caitlin Costello,1 Mark Minden,2
Raffaella Chiaramonte,3 Leslie Crews,1 Catriona Jamieson1. 1University of Cali-
fornia, San Diego, San Diego, CA; 2University of Toronto, Toronto, Ontario,
Canada; 3University of Milan, Milan, Italy.
Introduction: Despite novel therapies, most of multiple myeloma (MM) pa-
tients relapse as a result of clonal evolution in inflammatory microenviron-
ments. Adenosine-to-inosine (A-to-I) RNA editing, driven by inflammatory
cytokine-responsive adenosine deaminase acting onRNA1 (ADAR1), promotes
cancer progression by enhancing survival and self-renewal ofmalignant progen-
itor cells. Amplifıcations of chromosome 1q21, containing IL-6R and ADAR1
loci, occur frequently in high-riskMMpatients, who frequently develop second-
ary plasma cell leukemia (PCL) and have shorter survival. While increased IL-6
signaling has been linked to relapse andA-to-I editing contributes to therapeutic
resistance in a broad array of malignancies, the role of ADAR1 in MM patho-
genesis has not been elucidated. This study aimed to investigate whether pro-
inflammatory cues in MM activate ADAR1 editing thereby promoting malig-
nant regeneration. Procedures: Publicly available primary patient datasets were
analyzed and validated in a separate cohort of biobanked primary samples and
humanmyeloma cell lines. Lentiviral vector-mediated activation or knockdown
ofADAR1, or treatmentwith extrinsic pro-inflammatory stimuli, was utilized to
probe the functional impact of RNA editing activity inMMmodels. Site-specifıc
qPCR was used to quantify RNA editing in specifıc cancer stem cell-associated
loci. Functional effects of ADAR1 activity were assessed in in vitro survival and
self-renewal assays, and in novel in vivo PCL xenografts. Results: Patients har-
boring 1q21 amplifıcation showed signifıcant and stage-dependent increases in
ADAR1 expression. In a set of separate primary PCL samples, aberrant RNA
editing in the coding region of the Hedgehog (Hh) pathway transcription factor
GLI1 was observed in high ADAR1-expressing samples. Notably, increased
GLI1 editing, previously reported to have increased capacity to activate its tran-
scriptional targets, was detected in serially transplantable, patient-derived xeno-
graft models. Furthermore, abolition of ADAR1 editase activity impaired GLI1
editing. Lastly, in vitro pro-inflammatory IL-6 stimulation, or continuous expo-
sure to the immunomodulatory drug lenalidomide led to increased ADAR1
mRNAandprotein levels, with a concomitant induction ofRNAediting activity.
Conclusions: In MM, 1q21 amplifıcation has been linked to progression. We
provide new evidence linking expression and activity of ADAR1, located on
1q21, and disease stage. Because ADAR1 induces transcript recoding, A-to-I
editing could contribute to the marked transcriptomic diversity typical of ad-
vanced MM.While the Hh pathway has been linked to cancer stem cell genera-
tion in human MM, here we identifıed a primate-specifıc mechanism of Hh
pathway activation in MM through RNA editing-dependent stabilization of
GLI1. Together, both genetic and microenvironmental factors modulate epi-
transcriptomic deregulation of cancer stem cell pathways in MM.
#3352 Genome-wide enhancer identify signature predictive of metastatic
phenotypes in bladder cancers. Sohyoung Kim,1 Lyuba Varticovski,1 Qizong
Lao,1 Songjoon Baek,1 Michael L. Nickerson,1 Myong-Hee Sung,1 Lars Gront-
ved,1 Thompson Bethtrice,1 Dan Theodorescu,2 Piyush K. Agarwal,1 Michael
Dean,1 Gordon Hager1. 1NCI/NIH, Bethesda, MD; 2Department of Pathology,
Denver, CO.
In urothelial bladder cancer accurate identifıcation of grade and stage is crit-
ical for optimal treatment to achieve robust disease control and long-term sur-
vival. However, among the initially superfıcial tumors, which are non-invasive
and highly treatable, 20 to 25 % recur, progress to invasive tumors, and metas-
tasize during the patients’ lifetime. Thus, the challenge is to provide risk strati-
fıcation during the initial diagnosis in order to identify those patients who are
unlikely to progress while offering radical therapy to those who are at risk. To
address this issue, the fıeld has heavily focused on the discovery of fewmutations
in potential driver genes. However, recent fındings indicate that deregulation of
enhancers can play a major role in cancer progression. In this study, we em-
ployedDNase-Seq to detect enhancer activities genome-wide in 16 bladder can-
cer cell lines (BLCs) that included three lineages (T24, UMUC3, 253J lineages)
with different tumorigenic andmetastatic potentials, and thus representmodels
of cancer progression and metastasis development. We analyzed the gain and
loss of enhancer activity in each BLC lineages as well as in metastatic cell lines
relative to non-metastatic cell lines. Our analysis in the T24 lineage revealed a
striking feature, a dramatic loss of intronic and distal DHSs (DNase I Hypersen-
sitive sites), during the initial transition to tumorigenic type. During metastatic
progression, new enhancer classes emerged and there was an enrichment for
association with target organ-specifıc genes. The analysis of differential DHSs
between metastatic and non-metastatic BLCs identifıed an enhancer signature
enriched with lost DHSs inmetastatic BLCs where nearby genes were associated
with cellular movement/invasion functions. Lost DHSs were also present near
key factors such as PPARG, RXRA, FOXA1, TP63, and GATA3, which play a
role in urothelial development and differentiation, and the transcription activity
of those genes were correlated with the change of enhancer activity. This study
identifıed a set of DHSs that are associated with cancer progression in bladder
cancer, and provides a potential clinical application for developing prognostic
markers to predict the risk of developing aggressive disease.
#3353 An epigenetic biomarker panel in HPV related oropharyngeal
squamous cell carcinoma. Shuling Ren,1 Daria A. Gaykalova,2 Theresa Guo,2
Zubair Khan,2 Mizuo Ando,1 Sunny Haft,1 Joseph A. Califano1. 1University of
California, San Diego, La Jolla, CA; 2Johns Hopkins Hospital, Baltimore, MD.
HPV related head and neck squamous cell carcinoma (HNSCC) is known to
occur in a separate patient population in comparison to tobacco relatedHNSCC,
and also exhibits less mutational, genetic, and chromosomal alterations, and a
different composition of epigenetic alterations. In particular, HPV is present in
up to 70% of oropharyngeal squamous cell carcinoma (OPSCC), and is driving
the increase in incidence rates of OPSCC. Given the precedent for successful
screening for cervical cancer, it is attractive to consider similar population based
screening forHPV relatedOPSCC.Here, we developed an epigenetic biomarker
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panel that can be combined with high risk HPV DNA detection with potential
utility in screening. We performed high throughput qMBD-seq analysis on 50
primary HPV positive OPSCC samples and 25 UPPP normal samples. Subse-
quently, we performed an outlier analysis and ranking strategy of 100 bp seg-
mented regions within this discovery cohort and defıned 20 differentially meth-
ylated regions to be used as biomarkers for detection. Simultaneously, we
validated these 20 biomarker candidates using TCGAmethylation array dataset
and found that the methylation levels of these 20 candidates in HPV positive
OPSCC were signifıcantly higher than those in normal samples. Moreover, we
created QMSP assays for these genes, and validated EMBP1 and KCNA3 in a
separate validation cohort including tissue and saliva from 46 HPV related OP-
SCC and 25 normal controls. The sensitivity and specifıcity values for EMBP1,
KCNA3 or both in tissue and saliva are shown. EMBP1 has a high sensitivity in
tissue and a high specifıcity in saliva, while KCNA3 has a high specifıcity in both
tissue and saliva. A panel including both genes has an extremely high sensitivity.
Ultimately, we defıned a panel of two differentially methylation regions that has
a high sensitivity in tissue. This study might serve as a diagnostic biomarker
development trial for HPV OPSCC detection with potential application for de-
velopment of a population based screening test.
Sensitivity and specifıcity for HPV related OPSCC in tissue and saliva
Tissue Tissue Saliva Saliva
Gene Sensitivity Specifıcity Sensitivity Specifıcity
EMBP1 97.7% 83.3% 13.3% 94.7%
KCNA3 76.7% 92.0% 13.3% 94.7%
EMBP1& KCNA3 100.0% 84.0% 13.0% 84.2%
#3354 Histone deacetylase-1 promotes urothelial cell migration and inva-
sion bymodulating p63-pMLC2 signaling.Kirtiman Srivastava, Conor Breen,
Karen McCloskey. Queen’s University Belfast, Belfast, United Kingdom.
Background: Altered expression of histone deacetylases (HDAC) and p63
transcription factor are associated with poor prognosis in invasive urothelial
tumors. The current study focused on HDAC-evoked epigenetic modifıca-
tion of p63 and its downstream effects. Methods: Primary human urothelial
cells (HUC) and urothelial cancer cell lines (HT1376, T24, TCCSUP) were
cultured either on human bladder fıbroblast-embedded collagen-I to estab-
lish 3D-organotypic rafts or as 2D-monolayers. Scratch wound assay was
used to study the rate of cell migration before studying the differential
mRNA and protein expressions of HDAC1,2,3, p63, p21, p27, Rho-kinase1
(ROCK1), 14-3-3 eta and myosin light chain-2 (MLC2). Results: T24 and
TCCSUP cells exhibited invasive incidents on 3D-organotypic rafts, which
coincided with their enhanced cell migration capabilities. qPCR and West-
ern blotting analysis demonstrated enhanced expression of HDAC1,
HDAC3, p27, p-p27-Thr157 and 14-3-3 eta alongside depleted levels of p63,
ROCK1, pMLC2-Ser19, pMLC2-Thr18-Ser19 and p21 in invasive cells com-
pared to normal (N5, p0.05). These results coincided with the loss of
stress fıber formations visualized by immunofluorescence detection of F-ac-
tin in invasive cells indicating that cytoskeletal reorganizationmay be pivotal
for cell migration. Treatment with HDAC inhibitors (vorinostat (pan) and
entinostat (HDAC1, 3)) attenuated the number of invasive incidents in T24
and TCCSUP cells, restored expression of p63, p21, pMLC2-Ser19, pMLC2-
Thr18-Ser19 (N5, p0.05), and normalized expression of 14-3-3 eta and
p-p27-Thr157. Reappearance of stress fıber formations traversing across the
cell after HDAC inhibitor treatments was supportive of these results, while
nuclear enrichment of p27 indicated its enhanced cytoplasm-to-nuclear traf-
fıcking. Transient knockdown of HDAC1 in the invasive population mim-
icked the effect of HDAC inhibitors (N5, p0.05), while successive deple-
tion of p63 appeared to abolish the effects of HDAC1 knockdown by
upregulating 14-3-3 eta and depleting ROCK1 expression, respectively. Con-
clusions: Inhibition of HDAC1 activity attenuates urothelial cell migration
and invasion by restoring the expression of p63 which, (a) upregulates the
expression and activity of ROCK1, and (b) suppresses the expression of
14-3-3 eta, thereby alleviating the cytoplasmic p27 levels and facilitating the
pMLC2-mediated cytoskeletal remodeling. These fındings provide further
support and mechanistic evidence for the potential use of HDAC inhibitors
to treat invasive/poor-prognosis bladder cancer.
#3355 Identifıcation of a novel network ofmiRNAs that regulate stemness
in colorectal cancer. Shusuke Toden,1 Takatoshi Matsuyama,1 Elizabeth
Hutchins,2 Kendall Jensen,2 Ajay Goel1. 1Baylor UniversityMedical Center, Dal-
las, TX; 2Translational Genomics, Phoenix, AZ.
Background and Aims: Accumulating evidence suggests that a subset of can-
cer cells also known as the “cancer stem cells” (CSCs) influence various clinical
outcomes in cancer, including tumor recurrence, metastasis and resistance to
chemotherapy. Recently stemness has been recognized as a dynamic state gov-
erned by epigenetic modifıers including miRNAs. Despite identifıcation of sev-
eral self-renewal associated miRNAs, miRNA profıle of CSCs remains unclear.
Herein, we characterized miRNA expression of CSCs with high vs. low CD44v6
expression through RNA-Seq. Subsequently, we investigated the clinical signif-
icance of a novel miRNA identifıed from this systematic discovery approach.
Methods: Colorectal CSCs from HCT116 and HT29 cells were grown as spher-
oid-derived cancer stem cells (SDCSCs). CD44v6 and CD44v6- CSCs were
subdivided by FACS and characterized by small RNA-Seq. Differentially ex-
pressedmiRNAswere subsequently confırmed inCD44v6CSCs and chemore-
sistant cells. The expression of one such candidate, miR-1246, was assessed in a
clinical cohort (n  144) by qRT-PCR. Results: MiRNA profıling identifıed a
unique overall pattern of CD44v6 SDCSCs indicative of high self-renewal ca-
pacity. We noted that a panel of established self-renewal suppressive-miRNAs
were downregulated (including miR-34a, 101 and 200 family) in CD44v6
CSCs, and discovered upregulation of previously unreported miRNAs (miR-
1246, 3605, 3182 and 4284). KEGG pathway analysis indicated that these miR-
NAs regulate Akt-MAPK and Wnt signaling pathways. Subsequently, we se-
lected miR-1246 and validated its expression in CD44v6 SDCSCs and
chemoresistant cells. Clinically, the expression of miR-1246 was signifıcantly
elevated in CRC tissues compared to corresponding normal mucosa, and this
occurred in a stage-dependent manner in primary CRCs. Furthermore, the ex-
pression of CD44v6 positively correlated with miR-1246 in CRC tissues. High
miR-1246 expression resulted in poor disease free and overall survival. Conclu-
sion: Using a systematic and comprehensive approach, we have identifıed a
unique network of dysregulated miRNAs in CD44v6 CSCs indicative of high
degree of stemness features in cancer. In particular, we identifıedmiR-1246 to be
frequently overexpressed in CSCs as well as chemoresistant cells and its expres-
sion was associated with poor prognosis in CRC patients. Collectively, we have
identifıed a unique group of previously unreported miRNAs which appear to
have important mechanistic roles in CSCs and could serve as a promising pre-
dictive biomarkers for recurrence and prognosis in patients with CRC.
#3356 Novel evidence forAZIN1RNAediting-mediated oncogenic role in
colorectal cancer. Kunitoshi Shigeyasu,1 Shusuke Toden,2 Yoshinaga Oku-
gawa,3 Jinsei Miyoshi,2 Takeshi Nagasaka,1 Toshiyoshi Fujiwara,1 Leilei Chen,4
Ajay Goel2. 1Okayama University, Okayama, Japan; 2Baylor University Medical
Center, Dallas, TX; 3Mie University, Mie, Japan; 4National University of Singa-
pore, Singapore, Singapore.
Introduction: Colorectal cancer (CRC) is the thirdmost frequent malignancy
in males and second most common disease in females worldwide. CRC patho-
genesis is intimately associated to lifestyles, such as diet, obesity, and smoking.
Multiple evidences have revealed that these risk factors can trigger specifıc epi-
genetic alterations and subsequently promote carcinogenesis. Recently, adeno-
sine (A)-to-inosine (I) RNA editing has been shown to be a potential epigenetic
event in human cancers. One of the most important RNA editing gene targets is
the antizyme inhibitor 1 (AZIN1), and edited AZIN1 promotes accumulation of
ornithine decarboxylase and polyamines, leading to promotion and develop-
ment of carcinogenesis. However, the oncogenic role and the clinical signifı-
cance of RNA editing in CRC has not been investigated, which led us to under-
take this present study. Materials and methods: We systematically and
comprehensively investigated RNA editing in the AZIN1 gene using the RNA
editing site specifıc PCR (RESSqPCR) in CRC patients. We further validates
these results usingmultiple independent cohorts of CRC patients comprising of
329 colorectal cancer and adenoma patients. In addition, we performed a series
of functional assays to elucidate the functional role of AZIN1 RNA editing in
CRC pathogenesis. Results: Using RESSqPCR, AZIN1 RNA editing levels were
analyzed in two CRC cohorts. AZIN1 editing levels were signifıcantly higher in
cancer tissues at all stages (I thru IV) compared with normal mucosa. Addition-
ally, AZIN1 was highly edited in colorectal adenoma tissues compared to adja-
cent normal mucosa, suggesting this epigenetic event to be critical in normal-
adenoma-carcinoma cascade. Additionally, the expression of RNA editing
enzyme (ADAR1) was also upregulated in cancerous tissues compared to nor-
mal mucosa, and positively correlated with AZIN1 editing levels. To interrogate
whether AZIN1 editing has an oncogenic role, overexpression of edited-AZIN1
inCRCcell lines resulted in increased cell proliferation, invasion,migration, and
stemness. More importantly, AZIN1 editing was signifıcantly enhanced in can-
cer stem cells, suggesting its importance for the development and maintenance
of stemness features. Finally, establishment of xenograft tumors in an animal
model resulted in signifıcantly larger tumors in edited vs. wild type-AZIN1
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Epigenetics 3
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 857
groups. Taken together, these results highlight the oncogenic role of AZIN1
RNA editing in CRC. Conclusion: Our systematic and comprehensive study,
which is fırst of its kind, reveals that AZIN1 RNA editing is novel epigenetic
alteration that promotes an oncogenic behavior in colorectal cancer. In addition
to its functional role, AZIN1 editing levels may be one of the important facilita-
tors of adenoma-carcinoma sequence in CRC and serve as an important clinical
biomarker in this disease.
#3357 Heritable methylation marks associated with breast cancer risk.
Melissa C. Southey,1 Jihoon E. Joo,1 James G. Dowty,1 Roger L.Milne,2 EEMing
Wong,1 Pierre-Antoine Dugué,2 Dallas English,1 John L. Hopper,1 Daivd E.
Goldgar,3 Graham G. Giles2. 1The University of Melbourne, Melbourne, Austra-
lia; 2Cancer Council Victoria, Melbourne, Australia; 3Huntsman Cancer Insti-
tute, Melbourne, UT.
While most epigenetic marks are reprogrammed during early embryogenesis,
some studies have reported Mendelian-like inheritance of germline DNA methyl-
ation in particular cancer susceptibility genes.We aimed to identify heritablemeth-
ylationmarks associatedwith breast cancer susceptibility by studying 25Australian
multi-generational families with multiple cases of breast cancer who were not
known to carry mutations in breast cancer susceptibility genes. Peripheral blood
DNAmethylationwasmeasuredatapproximately480,000genetic loci (methylation
sites) for 210members of these families using the InfıniumHumanMethylation450
BeadArray.We developed and applied a new statisticalmethod to identify heritable
methylation marks based on complex segregation analysis. Carrier probabilities
were estimated for the 1000 most heritable methylation marks, based on family
structure but not disease status, andCox proportional hazards survival analysis was
used to test for associations between these carrier probabilities and breast cancer.
After correcting for multiple testing, we identifıed 11 methylation marks whose
correspondingcarriersprobabilitieswere signifıcantly associatedwithbreast cancer.
Three marks clustered within 200 base pairs of the noncoding RNA miR886. We
found evidence for these marks to be associated with aggressive (but not non-ag-
gressive) prostate cancer risk in a population-based prostate cancer study. The as-
sociation with breast cancer risk was replicated for three of the eleven marks in an
independent population-based breast cancer study. Our work demonstrates the ef-
fıcacy of our novel approach for identifying heritablemethylationmarks associated
with breast cancer. This methodology may provide insights into other disease set-
tings where known lifestyle exposures and genetic risk variants do not fully explain
the familial relative risk.
#3358 Epigenetic signatures associated with patient outcome in thyroid
carcinoma.Mariana Bisarro dos Reis,1 Caroline Moraes Beltrami,2 Mateus Ca-
margo Barros-Filho,2 Fabio Albuquerque Marchi,2 Hellen Kuasne,2 Skirant
Ambatipudi,3 Zdenko Herceg,3 Luiz Paulo Kowalski,2 Silvia Regina Rogatto1.
1Vejle Hospital, Vejle, Denmark; 2AC Camargo Cancer Center, Brazil; 3Interna-
tional Agency for Research on Cancer, France.
BACKGROUND: Thyroid cancer (TC) is the most frequent endocrine neo-
plasia composed essentially by well-differentiated tumors (90%). These tumors
generally are indolent and the patients show a favorable outcome.However, a set
of TC patients presents aggressive outcome. Global deregulation of DNAmeth-
ylation has been described as involved in thyroid cancer (TC) development. In
this study, DNA methylation profıle was performed aiming to identify a prog-
nostic signature in TC. PATIENTS AND METHODS: The methylation profıle
of 50 non-neoplastic thyroid tissues (NT), 17 benign thyroid lesions and 74 TC
(60 papillary, 8 follicular, 2 Hürthle cell, 1 poorly differentiated and 3 anaplastic
thyroid carcinomas) were investigated using the Methylation 450 Human
Infınium®BeadChip platform (Illumina). The data were normalized and ana-
lyzed using SVA, wateRmelon and LIMMA packages. The threshold delta beta
of 0.2 and adjusted p-value0.05were used to identify differentiallymethylated
probes among the histological subtypes. The delta beta of 0.1 and adjusted p-
value 0.05 were used in the prognostic features analysis in WDTC (well dif-
ferentiated thyroid cancer) cases. An epigenetic classifıer according to WDTC
was identifıed using diagonal linear discriminant analysis. The resultswere com-
pared with The Cancer Genome Atlas (TCGA) database. RESULTS: Methyl-
ation analyses revealed a specifıc epigenetic profıle according to the histological
subtypes. A global hypermethylation was observed in benign lesions and follic-
ular carcinomas, while papillary and undifferentiated carcinomas were widely
hypomethylated compared with NT. An epigenetic signature comprising 21
probes differentially methylated (delta beta 0.1) was able to predict poor out-
come in WDTC patients. This classifıer reveled 63% of sensitivity and 92% of
specifıcity, which was confırmed by TCGAdatabase (64% of sensitivity and 88%
of specifıcity). Using the established signature, we were able to confırm the
involvement of poor prognosis markers with high-risk scores (multivariable
analysis; P0.001). CONCLUSION: Thyroid tumors showed different methyl-
ation profıle according to the histological subtypes. Genes regulated by methyl-
ation in TC and associated with the tumor development were identifıed and
confırmed by TCGA. In addition, a meaningful algorithm was designed and
confırmed as capable to predict recurrence inWDTC. FINANCIAL SUPPORT:
FAPESP (2015/20548-5) and National Institute of Science and Technology in
Oncogenomics (FAPESP 2008/57887-9 and CNPq 573589/08-9), CNPq
(302606/2011-4).
#3359 TET1 mediated hypomethylation activates oncogenic signaling
pathways in triple negative breast cancer. Charly Ryan Good, Andrew Kelly,
Jozef Madzo, Jaroslav Jelinek, Jean-Pierre Issa. Fels Inst. at Temple Univ. School
of Medicine, Philadelphia, PA.
Triple negative breast cancer (TNBC) is a subtype of breast cancer that occurs in
15-20% of patients, and is defıned by tumors that do not overexpress the estrogen,
progesterone andHER2 receptors. This aggressive subtype has a signifıcantlyworse
overall survival compared to non-TNBC and importantly, these patients lack op-
tions for targeted therapy. To identify novel subtype-specifıc therapeutic targets, we
must fırstunderstand thebiologicalunderpinningsof thedisease.DNAmethylation
is a hallmark of cancer, as it can regulate gene expression of both tumor suppressor
genes and oncogenes. We have found that TN tumors have widespread genome-
wide hypomethylationwhen compared to other breast cancer subtypes and normal
breast controls. TET1 is a DNA demethylase that converts 5-methyl cytosine into
5-hydroxymethyl cytosine, which can be further oxidized into un-methylated cyto-
sine.Todetermine ifTET1couldpossibly play a role inTNBChypomethylation,we
analyzed genome-wide DNA methylation, DNA mutation and RNA-seq datasets
from the TCGA breast cancer cohort. We identifıed a subset of TN patients that
upregulate TET1 and display DNA hypomethylation. To identify the hypomethy-
lated TET1 target genes, we computed Spearman correlations between TET1 ex-
pression andmethylation% for 450,000 sites (450Karray) across 67TNBCpatients.
Filtering for sites with r-0.3 revealed 42,559 sites negatively correlated with TET1
expression. Cluster analysis of the sites that lose methylation compared to normal
breast (12,807 CpG sites) revealed two distinct clusters. Cluster 1 (42% of TNBC
cases) were TET1 high and hypomethylated, while cluster 2 (58%) lookedmore like
normal breast controls. Gene set enrichment analysis of the hypomethylated genes
revealed Hippo Signaling, Pathways in Cancer and PI3K-Akt Signaling as signifı-
cantly enriched, with p0.001. In addition, only 4% of patients in cluster 1 have
mutations/genomic alterations in the PI3K pathway, compared to 29% of cluster 2
patients, p0.01.Most strikingly, analysis of phosphorylated EIF4EBP1RPPApro-
teomicdata revealedTET1highpatientshave increasedPI3Kpathwayactivity, even
though they lackmutations in the pathway, p0.02.We hypothesize that the PI3K
hyper-activation, in part, can be explained by TET1 upregulation and target gene
demethylation. In TET1 knock outMDA-MB-231 cells, we observed a reduction in
phosphorylated 4E-BP1, suggesting loss of PI3K activity is concomitant with loss of
TET1 as well as decreased cellular proliferation (p0.01). Furthermore, breast can-
cer cell lines with high TET1 (but not lowTET1) are sensitive to drugs targeting the
PI3K/ERK pathway (XMD8-85, AZ628, TGX221). In addition to explaining and
predicting PI3K inhibitor sensitivity in breast cancer, our studies may establish
TET1 as a TNBC specifıc oncogene that could serve as a novel druggable target for
therapeutic intervention.
#3360 Targeted catalytic inhibition of EZH2 synergizes with low-dose
HDACi in malignant rhabdoid tumors.Dean Popovski,1 Elizabeth M. Algar,1
Catherine R. Cochrane,1 Anette Szczepny,1W. Samantha Jayasekara,1 DavidM.
Ashley,2 Peter Downie,3 D. Neil Watkins,4 Jason E. Cain1. 1Hudson Institute of
Medical Research, Clayton, Australia; 2Barwon Health, Geelong, Australia; 3Mo-
nash Children’s Hospital, Clayton, Australia; 4Garvan Institute of Medical Re-
search, Darlinghurst, Australia.
Malignant Rhabdoid Tumor (MRT) is a rare pediatric cancer of the kidney
and CNS that is resistant to current treatment protocols. MRT is genetically
characterized byhomozygous inactivation of SMARCB1, a critical subunit of the
SWI/SNF chromatin-remodeling complex. Next-generation sequencing data
suggests that inactivation of SMARCB1 is the primary driver mutation, impli-
cating epigenetic deregulation in the pathogenesis ofMRT. Recently, we showed
that sustained treatment of MRT cell lines with low-dose Panobinostat
(LBH589), inhibited tumor growth by driving multi-lineage differentiation in
vitro and in vivo. Furthermore, re-expression of physiological levels of
SMARCB1 in G401 MRT cells phenocopied the low-dose LBH589 treatment
and led to growth inhibition, senescence and terminal differentiation in vitro
and in vivo. Enhancer of Zeste homolog 2 (EZH2), a core subunit of the Poly-
comb Repressive Complex 2 (PRC2), confers transcriptional silencing via the
addition of methyl groups to Lysine 27 of Histone 3 (H3K27me3), and is a
transcriptional target of SMARCB1. EZH2 expression and H3K27me3 were
drastically reduced following sustained low-dose LBH589 treatment and re-
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expression of SMARCB1 in G401 MRT cells. Sustained siRNA knockdown of
EZH2 in G401 cells resulted in reduced cell growth and changes in mRNA
expression similar to those observed following low-dose LBH589 treatment and
SMARCB1 re-expression. Treatment of MRT cells with the EZH2-catalytic do-
main inhibitor, GSK-126, had no effect on EZH2 expression and only partially
reduced H3K27me3 and cell growth at doses 1nM-10M suggesting important
non-catalytic EZH2 function. However, MRT cells treated in combination with
low-dose LBH589 and GSK-126, lost EZH2 and H3K27me3 expression and ex-
hibited signifıcantly reduced cell growth in vitro compared to single agent con-
trols, revealing a synergistic relationship. Similar effects were observed in an in
vivo xenograftmodel, with low-dose LBH589 andGSK-126 treatment leading to
a marked reduction in tumor growth, not observed with single agent treatment.
This data suggests EZH2 is an important mediator of MRT proliferation and
differentiation and provides evidence for dual therapeutic targeting of EZH2
with low-dose HDACi in MRT.
#3361 Methylome differences in differentiated thyroid cancers and be-
nign adenomas. Josena K. Stephen, Kang Mei Chen, Jason Merritt, Indrani
Datta, Dhananjay Chitale, George Divine, Maria J. Worsham. Henry Ford Hos-
pital, Detroit, MI.
Many recent studies examining aberrant DNAmethylation in thyroid cancer
are restricted to either candidate genes or genome-wide methylation in specifıc
thyroid tumor subtypes. The goal of this study was to identify differentially
methylated genes globally and their association with molecular pathways and
signaling networks. Commonmutations in papillary thyroid cancer (PTC), fol-
licular thyroid cancer (FTC), follicular adenoma (FA) and normal thyroid were
also examined. Genome-wide methylation profıling using the Infınium
HumanMethylation450FFPE (formalin fıxed paraffın embedded) BeadChipAr-
ray was performed on 24 thyroid cases (8 PTC, 8 FTC, 4 FA and 4 normal
thyroid). Ingenuity Pathway Analysis (IPA) was utilized to assess the roles of
signifıcantly differentially methylated genes in biological functions, signaling/
metabolic pathways, and networks. Common mutations in 4 genes (BRAF,
NRAS, HRAS, and KRAS) were assessed using TaqMan Mutation Detection
assay. Twelve genes were signifıcantly differentially methylated among 4 com-
parison groups: cancer vs normal, cancer vs adenoma, PTC vs normal, and PTC
follicular variant (PTC-FV) vs PTC-Classic. CTU1 andHLA-DPB1 were signif-
icantly hypermethylated and AARS2, TMSB10, RNF216L, KIF15, KIAA1143,
and SLC2A13 were signifıcantly hypomethylated between cancer and normal.
Signifıcant differential hypermethylation was noted for PNPLA7 and NPC1L1
in cancer vs adenoma and SNX6 in PTC-FV vs PTC-Classic. NT5C1B was hy-
permethylated and AARS2 was hypomethylated in PTC vs normal. IPA identi-
fıed 2 gene networks, involving 11/12 genes, characterized by 1) Cellular devel-
opment, Cellular growth and proliferation, Connective tissue development and
function and 2) Drug metabolism, Cell-mediated immune response, Cellular
development. NT5C1B was involved in all 4 highly ranked canonical nucleotide
degradation pathways. Several signifıcant bio-functions involved NPC1L1.Mu-
tations of NRAS codon 61 were identifıed in 1 sample each of FTC-Classic,
PTC-FV and FA and BRAF V600E in one PTC-Classic sample. Differential
methylation of AARS2, CTU1, HLA-DPB1, SLC2A13, PNPLA7, NPC1L1,
NT5C1B and SNX6 suggest potential markers for discriminating thyroid can-
cers from adenomas and normal. NT5C1Bwas noted in highly ranked canonical
pathways, suggesting a role in nucleotide degradation. Pathway analysis of dif-
ferentially methylated genes support important biological processes in thyroid
cancer pathogenesis. Supported by JFCI/CRAG A20038
#3362 PBRM1regulates the transcriptionof cell adhesion genes in ccRCC.
Basudev Chowdhury. Purdue Univ., West Lafayette, IN.
Advances in parallel sequencing have facilitated the recent identifıcation of Poly-
bromo-1 (PBRM1), a component of the PBAF (Polybromo-associated-BRG1- or
BRM-associated factors) chromatin remodeling complex, as the second most fre-
quently mutated gene in clear-cell renal cell Carcinoma (ccRCC). While several
studies have described the diversity of PBRM1mutations in ccRCC and established
themutation of PBRM1as a “driver” of ccRCCcarcinogenesis, little is known about
thebiological signifıcanceofPBRM1.With the intentof shedding lighton themech-
anistic rolesofPBRM1,wehave employedNextGenerationSequencing todelineate
the transcriptional profıle of cellular models of ccRCC with or without PBRM1
expression and identifıed genes associated with cell adhesion to be regulated by
PBRM1in2Dmonolayer cultures. Since2Dcultures lack thearchitectural complex-
ities to support studies pertaining to cellular adhesion, we evaluated the role of
PBRM1 in 3D culture on BasementMembraneMatrix to provide a physiologically
relevant analysis of gene expression and the resulting cellular phenotype. The
results showed that of the 97 cell adhesion genes identifıed to be upregulated
by PBRM1 in 2D cultures, 45 were also upregulated in 3D cultures and a
subset of 32/45 genes underwent increased gene expression in 3D with re-
spect to 2D cultures. The gene expression profıle of candidate genes were
verifıed by qPCR and Western Blotting. Mining The Cancer Genome Atlas
(TCGA) publicly available data, we were able to correlate the gene expression
profıles of cell adhesion genes identifıed in 3D cultures with those of ccRCC
patients bearing at least 1 copy of the PBRM1 gene. Furthermore, we per-
formed a PBRM1-ChIP-seq to map the genome-wide targets of PBRM1 and
revealed the association of PBRM1 occupancy at proximal regulatory regions
of 8/45 cell adhesion genes. All of these taken together, indicate a role for
PBRM1 in regulating the gene expression of cell adhesion genes which act as
important players in cellular morphogenesis and responsiveness to changes
in the external environment. Disruption of cell adhesion is believed to affect
signal transduction and pave the way facilitating metastasis in neoplastic
cells. Currently we are investigating the effect of loss-of-PBRM1 on Epithe-
lial to Mesenchymal Transition (EMT) and metastasis in ccRCC.
#3363 Enhancer signature profıling identifıes novel enhancer clusters for
transcription factors in lung cancer. Stephanie Tuminello, Hideo Watanabe,
Takashi Sato. Icahn School of Medicine Mount Sinai, New York, NY.
Wepreviouslydiscovered that the targeted focusof themost signifıcant amplicon
in squamous cell lung cancer lies on the SOX2 gene locus, a product of which is a
critical regulator in specifying squamouscell lineages in thedevelopment atdividing
foregut to counteract with NKX2-1, which specifıes tracheal and later lung lineages
and is the most signifıcantly amplifıed gene in lung adenocarcinoma. Cell lines
harboring such amplifıcation from respective lung cancer subtypes are dependent
on the expression of these lineage-determining factors for their survival. However,
the amplifıcations of these factors represent only 10-15% of lung cancer, it remains
unknownwhatother lineageprogramstheremainingmajority relyupon.Posttrans-
lational modifıcations of histone proteins assign different functional regions of the
genome,which leads tochromatinstates that create stableexpressionpatternsmain-
taining cellular fates. Studies ongenome-wide enhancers have revealed thepresence
of large enhancer clusters, which are typically enriched in the proximity of lineage
factor genes that establish a program defıning cellular identity. To identify novel
subsets of lung cancer defıned by chromatin modifıcation on lineage-determining
factors,wemadeuseofahistonemodifıcationmarkerH3K27Ac, typicallypresentat
active enhancers. We profıled H3K27Ac by ChIP-seq in 24 cell lines (14 lung ade-
nocarcinoma, 4 squamous cell carcinoma, 4 small cell lung cancer and 2 breast
carcinoma), identifying thousands of active enhancers, i.e. H3K27Ac enriched, and
hundreds of super-enhancers (SEs) defıned by ROSE algorithm per cell line. As a
proof of principle, we found a locus adjacent toNKX2-1 gene as one of the SEs in an
NKX2-1-amplifıed cell line NCI-H3122, suggesting this approach can detect a lin-
eage program that is overridden by cancer cells. We performed unsupervised hier-
archical clustering analyses on signals at SEs adjacent to transcriptional regulatory
genes and identifıed unique subsets segregated primarily by their lineages. Several
SEs on transcription factors are common betweenmultiple cell lines from the same
lineage (e.g., SOX2 and TP63 in squamous cell lineage andNKX2-1 in lung adeno-
carcinoma lineage).We identifıed 6 lung adenocarcinoma cell lines that contain SE
at the locus ofNR4A2, a signifıcantlymutated gene in lung adenocarcinomas, and 2
other lines at the locus of HOPX, a lineage transcription factor for alveolar type I
cells. These results suggest that this approach can reveal novel enhancers on lineage
factors in a subset of lung cancers.
#3364 DNA methylation loss at an enhancer site of the DNA repair gene
TREX2 is an epigenetic feature in multiple cancers. Christoph Weigel,1 Jitti-
porn Chaisaingmongkol,2 Christine Kuhmann,1 Irene Santi,3 Volker Winkler,3
Olga Bogatyrova,1 Justo L. Bermejo,3 Tsun L. Chan,4 Felix Lasitschka,5Manfred
H. Bohrer,6 AlexanderMarx,7 FrankAutschbach,8 RolandHeyni-vonHaußen,9
Gerhard Dyckhoff,10 Klaus-Wolfgang Delank,6 Karl Hoermann,11 Burkard M.
Lippert,12 Gerald Baier,13 Andreas Dietz,14 Christopher C. Oakes,1 Christoph
Plass,1 Heiko Becher,3 Peter Schmezer,1 Heribert Ramroth,3 Odilia Popanda1.
1German Cancer Research Center, Heidelberg, Germany; 2Chulabhorn Research
Institute, Bangkok, Thailand; 3University of Heidelberg, Heidelberg, Germany;
4The University of Hong Kong, Hong Kong, China; 5University Hospital Heidel-
berg, Heidelberg, Germany; 6Medical Hospital, Ludwigshafen, Germany; 7Uni-
versity Medical Centre Mannheim, University of Heidelberg, Mannheim, Ger-
many; 8SLK-Clinics Heilbronn, Heilbronn, Germany; 9Klinikum Darmstadt,
Darmstadt, Germany; 10Head and Neck Surgery, University of Heidelberg,
Heidelberg, Germany; 11University Hospital of Mannheim, Mannheim, Germa-
ny; 12Head and Neck Surgery, Heilbronn, Germany; 13Academic Teaching Hos-
pital, Darmstadt, Germany; 14University of Leipzig, Leipzig, Germany.
The onset of numerous cancers is strongly associatedwith exposure to genotoxic
agents and is counteracted by cellular DNA repair mechanisms. However, the tu-
morigenic potential of genotoxic carcinogens varies widely among individuals. It is
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still uncertain which genetic and epigenetic traits shape cancer onset and progres-
sion in the general population.While genetic aberrations inDNA repair genes have
been linked to cancer risk, less is known about the importance of epigenetics for the
regulationof these genes. In order to identifyDNAmethylation alterations in laryn-
geal cancerwe carriedout targetedDNAmethylation analysis at singleCpGsites via
mass spectrometry.Wefocusedouranalysison fıveDNArepair-associatedgene loci
previously foundtobealtered inheadandnecksquamouscell carcinoma.Wereport
loss of DNA methylation at the three prime repair exonuclease 2 (TREX2) gene
locus in laryngeal cancer (n161) and adjacent normal tissue (n58) samples of
patients from a German population-based case-control study. Following screening
of tumor tissues from Chinese colorectal cancer patients as well as previously pub-
lished data from the Cancer Genome Atlas (TCGA), we identifıed TREX2methyl-
ation loss as a frequent trait inmultiple cancers.We further characterized the regu-
latory activityof the affectedTREX2siteusing chromatin immunoprecipitationand
luciferase reporter assays in cell models from different tumor types. Differential
TREX2 methylation affects a CCAAT/enhancer binding protein alpha (CEBPA)
binding site serving as a gene enhancer which drives the expression of TREX2 from
a previously uncharacterized gene promoter.We also observed a strong association
betweenTREX2methylationandTREX2protein expressiondeterminedvia immu-
nohistochemistry in laryngeal tumors. Finally, we found a signifıcant association
between overall survival and loss of TREX2 methylation in laryngeal cancer, with
TREX2methylation lossbeingaprotective factor.Our fındingshighlightaprofound
regulatory role of epigenetic mechanisms for TREX2 in tumors, and underline the
usefulness of TREX2DNAmethylation as a biomarker for patient stratifıcation.
#3365 Epigenetic inactivation of PTPRT and sensitivity to STAT3 inhibi-
tion in lung cancer. Malabika Sen, Audrey Kindsfather, James G. Herman.
University of Pittsburgh Cancer Institute, Pittsburgh, PA.
Signal Transducers and Activators of Transcription-3 (STAT3), a potent onco-
genic transcription factor is persistently activated in several malignancies including
lung cancer. Protein Tyrosine Phosphatase Receptor-T (PTPRT) is an endogenous
inhibitor of STAT3 transcriptional activity, and is methylated in many types of
human cancer. Loss-of-function of PTPRTbypromotermethylation contributes to
STAT3mediatedgrowthandsurvival andrepresentoneof theplausiblemechanism
of STAT3 hyperactivation. We report identifıcation of hypermethylation in CpG
islands of the PTPRTpromoterwhich correlateswith its transcriptional silencing as
well as expression of pSTAT3 protein and STAT3 target genes in both lung cancer
cell lines and primary human tumors. Analyses of the TCGA (TheCancerGenome
Atlas) data revealed thatPTPRTpromoter is frequentlyhypermethylated in a subset
of lung squamous cell carcinoma and approximately 25% of adenocarcinoma tu-
mors in associationwith downregulation of PTPRTmRNAexpression. This obser-
vation was verifıed in vitro using lung cancer cell lines. Out of the 7 lung cancer cell
lines examined, one lung cancer cell line showed lack ofmethylation (only unmeth-
ylated sequences) of the PTPRT promoter region and revealed mRNA expression
(H520). All 6 cell lines which showed PTPRT promoter methylation had nearly
absent PTPRTmRNAandhadhigh levels of pSTAT3Tyr705,whileH520had little or
no pSTAT3Tyr705 protein expression. Silencing of PTPRT using siRNA in H520,
where PTPRT was not endogenously silenced by promoter hypermethylation, re-
sulted in the upregulation of the STAT3 target genes such as cyclin D1 and Bcl-XL
mRNA and protein expression as well as increased pSTAT3Tyr705 level. Analyses of
themethylation status in the PTPRT promoter region in primary lung tumor sam-
ples revealed methylation in one of the 3 tumor samples. This correlated with in-
creased STAT3 target genes (cyclinD1 andBcl-XL)mRNAexpression. In lung can-
cer cell lines, PTPRT promoter methylation is associated with sensitivity to STAT3
inhibition. Our data suggests that silencing of PTPRT by promoter hypermethyl-
ation is a frequentmechanismof STAT3hyperactivation, and targetingSTAT3may
be an effective molecular targeted approach in the treatment of this subset of lung
cancer.
#3366 Loci-specifıc differences in bloodDNAmethylation for early detec-
tion of hepatocellular carcinoma. Katarzyna Lubecka,1 Megan Beetch,1 Jay
Qiu,1 Lucinda Kurzava,1 Kirsty Flower,2 Samer Gawrieh,3 Suthat Liangpun-
sakul,3 Naga Chalasani,3 James M. Flanagan,2 Barbara Stefanska1. 1Purdue Uni-
versity, West Lafayette, IN; 2Imperial College London, London, United Kingdom;
3Indiana University School of Medicine, Indianapolis, IN.
Late onset of clinical symptoms in hepatocellular carcinoma (HCC) results in
late diagnosis and poor disease outcome. It is estimated that early detection of
HCCwould increase the cure rate from 5% to 80%. Thus, identifying new effec-
tive tools with reliable and quantifıable biomarkers is of high importance. Such
tools are currently missing. Aberrations in the DNA methylation patterns, an
important early event in carcinogenesis, have been shown to differentiate HCC
tumors from normal tissues. However, these changes as diagnostic markers
would have a high application in clinics only if detectable by minimally invasive
tests like a blood test. In the present study, we performed a comprehensive
evaluation of DNA methylation profıles in blood DNA collected from 24 HCC
patients (cases) who provided samples after diagnosis and from 24 controls,
enrolled by the Indiana Biobank. Cases were matched with controls on gender,
age, ethnicity, hepatitis C infection, and diabetes. We used HumanMethylation
450K BeadChip array for genome-wide DNAmethylation analysis and pyrose-
quencing for validation of DNA methylation differences. We identifıed 7,047
CpG sites differentiallymethylated between cases and controls with p0.05 and
intraclass correlation coeffıcient (ICC) 0.5. The change in DNA methylation
within the top 14 CpG sites corresponding to 12 genes (probes) was technically
validated using pyrosequencing. Five probes were hypomethylated and 7 probes
were hypermethylated in cases vs. controls. Those probes constitute candidate
biomarkers that could be used in early detection of HCC only if detectable at
pre-diagnostic stages.We therefore selected 4 out of 12 probes that presented the
highest differences in post-diagnostic cases. We then verifıed DNAmethylation
changes at those 4 probes in blood samples collected from 21 patients at the time
when theywere clinically considered cancer free (pre-diagnostic) and developed
HCCwithin 4 years of follow-up.We confırmed thatmethylation at all 4 selected
probes discriminates pre-diagnostic cases from matched healthy controls. One
of the strongest differences was detected within an enhancer of PCGF3 (differ-
ence-0.12, ICC0.84). PCGF3 is a component of a Polycomb groupmultipro-
tein repressive PRC1-like complex and was found to be over-expressed in HCC
tumors and inmany other types of cancer according toOncomine database. Our
present study establishes for the fırst time differences in DNA methylation at
specifıc CpG sites that are detectable in blood of individuals both before and
after conventional diagnosis with HCC as compared with healthy individuals.
The identifıed probes have high potential to be developed into early detection
HCC biomarkers once validated in a larger cohort of individuals at risk. This
research was supported by the ACS Institutional Research Grant and Showalter
Trust Award granted to BS.
#3367 The clinical signifıcance of epigenetic microRNA-137 silencing in
patients with ulcerative colitis. Yuji Toiyama,1 Yoshinaga Okugawa,1 Koji
Tanaka,1 Toshimitsu Araki,1 Keiichi Uchida,1 Masato Kusunoki,1 C. Richard
Boland,2 Ajay Goel2. 1Mie University, Tsu, Japan; 2Baylor University Medical
Center, Dallas, TX.
Background: Although present guidelines recommend periodic colonoscopy
with multistep biopsies for surveillance of ulcerative colitis (UC)-associated
colorectal cancer (CRC), it remains unclear about the effectively. To improve the
surveillance, more effective markers are needed to identify patients at high risk
for UC-CRC. MicroRNA (miRNA)-137 is often methylated in sporadic CRC.
Methylation of thismiRNAalso occurs in an age-dependentmanner, suggesting
a potential “fıeld defect”, and possibly an early event in colitis-associated carci-
nogenesis. The objective of this study was to determine whether a methylation-
related “fıeld defect” ofmiR-137 could be exploited clinically to identify individ-
uals with UC who are at increased risk for developing neoplasia. Materials &
Methods: We conducted four-step analysis using 387 samples from 238 UC
patients of two independent cohorts, which included 152 patients without neo-
plasia (matched specimens obtained from cecum, transverse colon and rectum
for each patient), 17 with dysplasia, and 69 with cancers (neoplasms and corre-
sponding rectal mucosa). We performed bisulfıte pyrosequencing to quantify
miR-137 promotermethylation levels of these samples. Results: In non-neoplas-
tic UC patients, methylation levels ofmiR-137 were signifıcantly higher in rectal
mucosa than in proximal cecummucosa (7.0	 2.8% vs. 4.9	 2.0%, P0.0001),
and were associated with age at diagnosis (P0.0009), age at operation
(P0.0004) and disease duration (P0.009) in rectal mucosa. In addition,
methylation levels ofmiR-137 were signifıcantly higher in dysplasia (P0.0001)
and CRC (P0.0001) compared to non-neoplastic UC mucosa. In addition,
miR-137 methylation levels in rectal mucosa from patients with neoplasia (dys-
plasia or cancer) were signifıcantly higher compared to methylation in patients
without neoplasia, suggesting the existence of ’fıeld defect’ in rectalmucosa from
patients with neoplasia. Receiver operating characteristic (ROC) analysis re-
vealed that methylation levels of miR-137 in rectal mucosa successfully differ-
entiated patients with CRC from those without (AUC: 0.8). Furthermore, mul-
tivariate logistic regression analysis revealed that miR-137 methylation in rectal
mucosa emerged as an independent predictor of UC-CRC (OR: 5.55;
P0.0148). Finally, ROC analysis was performed to validate the fındings and
revealed thatmethylation levels ofmiR-137 could discriminateUCpatientswith
vs. without neoplasia, with almost same AUC value (0.76). Conclusions: Meth-
ylation of miR-137 occurs in an age- and cancer-dependent manner in UC
patients. Analysis of miR-137 methylation levels in rectummay be a biomarker
for identifıcation of UC patients at greatest risk for UC-CRC.
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#3368 Omics data integration analysis in high grade serous ovarian can-
cer: results from three studies. Yanina Natanzon,1 Madalene Earp,1 Julie M.
Cunningham,1 Kimberly R. Kalli,1 Stacey J. Winham,1 Sebastian M. Armasu,1
Melissa C. Larson,1 Chen Wang,1 David D. Bowtell,2 Dale W. Garsed,2 Ellen
Goode1. 1Mayo Clinic, Rochester, MN; 2Peter MacCallum Cancer Center, Mel-
bourne, Australia.
High grade serous ovarian cancer (HGSOC) is a complex disease in which initi-
ation and progression have been associated with genemutation, DNAmethylation
changes, genetic variation, and epigenetic processes. Variation in several suscepti-
bility regions and cancer-typical global methylation patterns have been observed in
HGSOC; however, this knowledge has not been compelling in understanding HG-
SOC intiation or progression. As ingetration of genomic, epigenomic, and tran-
scriptomic data has increased mechanistic understanding in other cancers, we hy-
pothesized that tumor methylation alone or in combination with germline genetic
variation influences tumor gene expression in HGSOC.We examined three nested
models using an Elastnic Net (ENET) penalized regressionmethod while adjusting
for somatic copy number (CNV): a) germline genotype and tumor DNA methyl-
ation(fullmodel), b)genotypeonly, andc)DNAmethylationonly.Weincluded339
cases from The Cancer Genome Atlas (TCGA), 54 cases fromMayo Clinic, and 78
cases from the Australian Ovarian Cancer Study (AOCS). Genotyping and copy
number calls on germline DNA, expression, methylation and copy number on so-
matic samples were collected and analyzed on different platforms separately at each
study site.We excluded genes with low overall expression and thus analyzed a total
of 11,922 genes available in three datasets ( Ensembl IDs, 500kb window up- and
downstream). In general, combining genomic data inHGSOC did not reveal a role
for germline genetic variation in altering gene expression. However, inmethylation
onlymodels79geneswereassociatedwithdifferential expression in theTCGAcases
(permutationmultiple testing adjusted p-val0.05), in theMayo cases (unadjusted
p-val0.05)andAOCScases (unadjustedp-val0.05).Aknowntummorsuppres-
sor (FBXW7) was associated with differential expression in the three datasets at
p-val0.01. This work demonstrates the feasibility, utility, and statistical power of
ENET gene-level analyses incoporatingmaximal genomic information.
#3369 EpigeneticDNAmethylationprofılingof triple negative breast can-
cer: a quantitative NGS approach. Kimberly M. Arnold,1 Adam G. Marsh,2
Jennifer Sims-Mourtada3. 1University of Delaware, Newark, DE; 2Genome Pro-
fıling LLC, Newark, DE; 3Helen F. Graham Cancer Ctr., Newark, DE.
Triple negative breast cancer (TNBC) is an aggressive disease with a high degree
ofgenomic instability.TNBCpatientshavepoorprognosis and the riskofmetastasis
and death is increased for women who relapse within four years of treatment com-
pared to other breast cancer subtypes. Currently, there are no reliable prognostic
markers to identify which population is at risk for early relapse and the molecular
mechanism for disease recurrence is notwell understood. Epigenetic changes, espe-
cially DNA methylation, are common in breast cancer and have been found to be
associated with increasedmetastatic capability. Therefore, themethylation states of
genes inTNBCtumorscompared tonon-tumorbreast tissuewasexamined inorder
to identify potential biomarkers and therapeutic targets in TNBC. Matched tumor
and adjacent non-tumor tissue from patients with TNBC were obtained following
surgical resection and genomic DNA was extracted. Epigenetic profıling of TNBC
tumors and non-tumor tissue was performed using a highly sensitive and quantita-
tive analytics platform, which utilizes methylation sensitive restriction endonu-
cleases to detect changes in methylation of CpG sites. Millions of CpG sites exist
within the human genome andmany of these are alteredwith tumor formation and
progression, therefore, changes inmethylationprofıles ofCpGsitesmaybeuseful as
a diagnostic and/or prognostic biomarker in TNBC patients. Non-metric multidi-
mensional scalingordinationanalysisof theCpGsites revealedhighlydistinctmeth-
ylation patterns between tumor andnon-tumor tissue.Approximately 326 sites had
a signifıcant methylation score difference (p&lt0.0025) between TNBC tumor and
non-tumor tissue, with most of the CpG sites having greater than 2-fold change in
methylation status. Analysis of functional gene classes using KEGG classifıers re-
vealed a signifıcant change inmethylation patterns of genes involved in response to
infections and other immune related functions. Additionally, the top ten geneswith
hyper- or hypomethylated sites within TNBC tumors when compared to non-tu-
mor tissue were identifıed. Interestingly, Gli-1 was one of the top hypomethylated
genes. Gli-1 has been shown in our lab and others to have signifıcance in chemore-
sistanceandrecurrence inTNBCpatients. Immunohistochemical analysis ofTNBC
tumors revealed Gli-1 overexpression in TNBC tumors compared to non-tumor
tissue. Expression levels of Gli-1 in TNBC tumors correlated with stage (p&lt0.001)
and recurrence free (p&lt0.0213) and overall survival (p&lt0.017). Thus, analysis of
CpGmethylated sites inTNBCtumorsandnon-tumor tissue revealeddifferences in
epigenetic profıles allowing for distinction between tumor and non-tumor tissue.
Genes in TNBC tumors with signifıcant changes in methylation status may be po-
tential candidate genes that serve as adiagnosticorprognostic biomarker forTNBC.
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#3370 Comparative analyses of multi-omics profıles reveal distinctive
molecular signatures of young Asian breast cancers. Yeon Hee Park,1 Ying
Ding,2 Soo-Hyeon Lee,3 Hae Hyun Jung,1 Woosung Chung,1 Soonweng Cho,4
Jin-Ho Kim,1 Shibing Deng,2 Yoon-la Choi,1 Julio Fernandez,2 Se Kyung Lee,1
Seok Won Kim,1 Jeong Eon Lee,1 Ji-Yeon Kim,1 Jin Seok Ahn,1 Young-Hyuck
Im,1 Seok Jin Nam,1 Woong-Yang Park,1 Zhengyan Kan2. 1Samsung Medical
Center, Seoul, Republic of Korea; 2Pfızer, Inc., San Diego, CA; 3Pfızer, Inc., Seoul,
Republic of Korea; 4Johns Hopkins University, Baltimore, MD.
Breast cancers (BC) in younger, premenopausal patients (YBC) tend to be
more aggressive with worse prognosis, higher chance of relapse and poorer
response to endocrine therapies compared to breast cancers in older patients.
The proportion of YBC (age  40) among BC in East Asia is estimated to be
16-32%, signifıcantly higher than the 7% reported in Western countries. In ad-
dition, approximately half of the Asian BC patients were premenopausal com-
pared to 15-30% in theWest. To characterize themolecular bases of Asian YBC,
we have performed whole-exome sequencing (WES) and whole-transcriptome
sequencing (WTS) on tumor andmatched normal samples from 168Korean BC
patients consisting of 106 YBC cases (age 40) and 62 OBC cases (age 40).
We then performed comparison analyses with the TCGA BC cohort consisting
of 1,116 tumors from primarily Caucasian patients, also grouped by age into
YBC (age  40), IBC (40  age  60) and OBC (age  60). We performed
logistic regression analyses to identify differentially expressed (DE) genes and
pathways among age-based cohorts while controlling for the confounding ef-
fects of molecular subtype, tumor purity and stage.Within the Asian cohort, we
found that estrogen response, endocrine therapy resistance, and various metab-
olism pathways are up-regulated in YBCs while cell cycle, proliferation and
inflammatory pathways are up-regulated in OBCs. To separately examine mo-
lecular signatures from tumor, stroma and normal compartments, we used non-
negative matrix factorization (NMF) analyses to virtually dissect bulk tumor
expression data and identifıed 14 factors including 3 factors associated with
normal tissues, 1 factor associated with stroma and 1 factor associated with
tumor infıltrating leukocytes (TILs). By examining the correlation between
pathway gene expression and NMF factors, we inferred that DE pathways such
as fatty acid metabolism, bile acid biosynthesis, and epithelial-to-mesenchymal
transition (EMT) were mainly active in stromal and normal tissue compart-
ments. The TIL factor was signifıcantly enriched in Asian BCs relative to Cau-
casian BCs with the highest TIL factor weight observed in Asian OBCs. Using
gene expression signatures representing distinct types of TILs, we classifıed the
combined cohort into three subtypes of varying TIL activities. Consistent with
results from the NMF analysis, the TIL-high subtype is also signifıcantly en-
riched in Asian BCs relative to Caucasian BCs. To our knowledge, this is the fırst
large-scale multi-omics study of Asian breast cancer. Comparative analyses of
multi-omics profıles from Asian and primarily Caucasian BC cohorts identifıed
distinguishing molecular signatures associated with Asian BCs. Further, many
signatures appeared to be specifıc to non-tumor compartments within bulk tu-
mor, indicating that young Asian BCs may harbor distinctive tumor microen-
vironment.
#3371 Aldh expressing stem cellsmediate tumor initiation andmetastasis
in triple negative breast cancers across different ethnicities.EvelynM. Jiagge,1
Shukmei Wong,2 Rabia Gilani,1 Sean Mcdermott,3 Lisa Newman,4 Jessica
Bensenhaver,4 MaxWicha,1 John Carpten,2 Sofıa Merajver1. 1Univ. of Michigan
Health System, Ann Arbor, MI; 2Translational Genomic Institute, Phoenix, AZ;
3University ofMichigan,AnnArbor,MI; 4Henry FordHealth System,Detroit,MI.
TNBC is the only subtype of breast cancer for which there are no approved
targeted therapies. In the US, its incidence is highest in women with African
ancestry (AA); in western sub-Saharan Africa, single-institution studies show
that TNBC constitutes 40- 80% of all breast cancers. Given the Caucasian/AA
survival disparity in breast cancer, there is an urgent need to fınd actionable
targets in TNBC of all ethnicities, but especially in TNBC in AA, which are
suspected to bemore aggressive. Breast cancer stem cells, the small population of
cells that have been shown to mediate breast tumor initiation, metastasis, and
resistance to conventional therapy have also been reported to mediate the het-
erogeneity of TNBC and are especially abundant in TNBC in AA women. Here,
we sought to better understand the biology of TNBC by fınding genes and path-
ways that are differentially expressed in the stem cell population of patient de-
rived xenografts (PDX) from TNBC fromGhanaian (G), AA and Caucasian (C)
women and the effect of these differentially expressed genes on the stem cell
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phenotype in these primary tumors. We isolated the ALDH and the CD44/
CD24- stem cell populations from the bulk cells from 15 PDXs using flow cy-
tometry. We performed RNA sequencing (Illumina HiSeq platform) on the
isolated populations andbulk cells (45). Comprehensive bioinformatics analyses
led to the identifıcationof highly signifıcantly differentially expressed genes and
pathways between the cell populations. By principal component analysis, the
tumors were very heterogeneous. However, the ALDH cells separated out
from the CD44/CD24- and the bulk cells. We identifıed 14 genes that were
simultaneously differentially expressed between the ALDH vs the CD44/
CD24- as well as ALDH VS bulk (p-value0.001, FDR 0.05). The 3 most
signifıcant genes wereMMP2 and PCDH7, both known to be involved in breast
cancer metastasis and CPXM1, a carboxylase. Inhibiting MMP2 expression in
the PDX cells grown in suspension resulted in signifıcant reduction in the
ALDH cell population. Also, the ALDH and not the CD44/CD24- cells
formed spheres in serum freemedia. TheWNT,MAPK andTGF-beta pathways
known to mediate metastasis were all signifıcantly up-regulated in the ALDH
population with down regulation of biosynthetic pathways which were up-reg-
ulated in the CD44/CD24- population. Further studies are ongoing on path-
way modulation in ALDH1 cells based on these fındings. Our data demon-
strate that theALDH stem cell population is enriched for tumor initiating cells
in aggressive TNBCs across different ethnicities. These cells may play a role in
mediating the aggressive behavior of TNBC’s found in African women.
#3372 Differential exon usage in the HER2 subtype of breast cancer iden-
tifıed with RNA-seq and proteomic data. Praveen Kumar Raj Kumar,1 Tao
Liu,2 Lori A. Sturtz,1 Albert Kovatich,3 Marina A. Gritsenko,2 Vladislav A.
Petyuk,2 Brenda Deyarmin,1 Viswanadham Sridhara,1 James Craig,1 Jason E.
McDermott,2 Anil K. Shukla,2 Ronald J. Moore,2 Matthew E. Monroe,2 Bob-
bie-Jo M. Webb-Robertson,2 Jeffrey A. Hooke,3 Leigh Fantacone-Campbell,3
Leonid Kvecher,1 Jianfang Liu,1 Jennifer Kane,1 Jennifer Melley,1 Stella Somi-
ari,1 Joji Iida,1 StephenC. Benz,4 JustinGolovato,4 ShahroozRabizadeh,5 Patrick
Soon-Shiong,5 Richard D. Smith,2 Richard J. Mural,1 Karin D. Rodland,2 Craig
D. Shriver,6 Hai Hu1. 1Chan Soon-Shiong Institute of Molecular Medicine at
Windber, Windber, PA; 2Pacifıc Northwest National Laboratory, Richland, WA;
3Henry Jackson Foundation, Rockville, MD; 4NantOmics, Culver City, CA;
5NantWorks, Culver City, CA; 6Murtha Cancer Center, Walter Reed NMMC,
Bethesda, MD.
Background: Heterogeneity between different breast cancer tumors plays an
important role in patients’ survival outcomes, and such tumor heterogeneity
unveiled by transcriptome and proteome are often in disagreement.We hypoth-
esize that alternative splicing of mRNA could explain heterogeneity within in-
trinsic breast cancer subtypes. Methods: Cases used in this study were drawn
from the Clinical Breast Care Project where breast cancer patients were con-
sented using an IRB-approved protocol. Fifty breast tumors were selected and
processed by laser microdissection. RNA and protein were extracted from tis-
sues using the Illustra triplePrep kit (GE Healthcare). Paired-end mRNA se-
quencing was performed using the Illumina HiSeq platform. Paired-end reads
were preprocessed using PRINSEQ and splice-aligned to the genome using
GSNAP software. Gene counts were measured using HTSeq while Exon counts
used the DEXSeq. Differential expression was called at 10% false discovery rate.
Proteome Discoverer with Byonic node was used for analyzing the quantitative
global proteomics dataset, and we were able to quantitate 8600 proteins. All
other analyses were performed using Perl and R. Results: The number of se-
quencing reads for the 50 cases ranged from 60 million to 410 million reads.
After preprocessing, an average of 93% of reads was mapped, and 36,700 genes
were identifıed among 50 tumor samples. PAM50 algorithmwas used for intrin-
sic subtype calls, yielding 16 Basal, 8 Her2, 19 Luminal A (LA) and 7 Luminal
B tumors. Unsupervised clustering of the 8Her2 cases using the PAM50 genes
and highly varying proteins resulted in different clustering patterns, with the
latter clustering 6 of the 8 Her2 cases with two distinct 3-case sub-clusters.
Between these two sub-clusters, there were 10 differentially expressed (DEX)
genes and 25 DEX proteins, but none of the 25 proteins were mapped to the 10
DEX genes. Thismotivated us to investigate the DEX exons, andwe found 7,076
DEX exons between the Her2 sub-clusters, and 9 of the 25 DEX proteins were
matched to genes bearing DEX exons. For comparison, we performed the same
analyses between similarly clustered Basal and LA sub-clusters. Even though the
number of DEX genes between Basal (8) and LA (18) sub-clusters were compa-
rable to that between the Her2 sub-clusters, DEX exons were much lower for
both subtypes (616 & 157), and none of the DEX proteins (3 & 7) mapped to
DEX exons or genes for either subtype. Conclusions: Our fındings imply that
there is more proteomic-level heterogeneity in the Her2 subtype than in Basal
and LA subtypes, which could be due to alternative usage of exons (alternative
splicing). If such heterogeneity is associated with patients’ survival outcomes
then our results will further stress the importance of alternative splicing in breast
cancer. The views expressed in this article are those of the author and do not
reflect the offıcial policy of the Department of Defense, or U.S. Government.
#3373 The use of long-read sequencing to determine the structure of the
Her2 amplicon in breast cancer. Jeffrey Rosenfeld,1 Sara Goodwin,2 Shridar
Ganesan1. 1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; 2Cold
Spring Harbor Laboratory, Cold Spring Harbor, NY.
HER2 amplifıcation is present in 15% of breast cancers, and is present in
small subsets of other cancer types including gastric and lung cancers. Therapy
targeting HER2 is now routinely used in treatment of HER2-amplifıced breast
cancer and has changed the natural history of this disease. The region of chro-
mosome 17q12 containing Her2 contains many genes, and little is known about
the actual genomic alterations that underlie the amplifıcation event. While it is
known that parts of the amplicon exist in multiple copies in a tumor, the exact
structure of the duplicated region is not known and their relative orientation and
positions in the genome is not clear. There is the potential for rearrangements
between the genes and for different segments of the amplicon to exist and varied
copy numbers. There is no clear way to assemble the complete structure of this
region using short reads, as they cannot resolve repetitive regions and identify
junction reads. Long read sequencing has the potential to overcome these limi-
tations, however the sequencing depth is limited and diffıcult to apply to large
genomes. To apply long read sequencing to a limited part of the cancer genome,
we have usedNimblegen target enrichment coupled withOxfordNanopore and
Pacifıc Bioscience sequencing in an attempt to sequence and assemble the Her2
amplicon. The error rate of the sequencers are not of concern since we are not
looking at base-pair level variation. Instead, our need is for long reads that can
span the gene boundaries and repetitive elements to give complete structure of
the amplicon. Nimblegen custom capture probes were designed for the 2mb
chromosomal region containing Her2. DNAwas extracted from 3 breast cancer
cell lines and enriched using the Nimblegen kit. This DNA was then sequenced
with long reads on theMinIon and the PacBio to allow for complete assembly of
the region. The DNA was assembled to determine the structure of the HER2
amplicon in each cell line. These results may give new insight into themolecular
events that led to formation of the HER2 amplicon.
#3374 APA isoform diversity in triple negative breast cancers. Ayse Elif
Erson-Bensan, Begum H. Akman, Merve Oyken, Hizlan H. Agus, Esra Yavuz,
Murat Erdem, Tolga Can.METU, Ankara, Turkey.
Alternative polyadenylation (APA) plays a role in gene expression regulation
generally by shortening of 3=UTRs and relieving microRNA-mediated repres-
sion. Therefore, APA is gaining increased attention as a potential mechanism to
activate oncogenes. Owing to high proliferative indices of triple negative breast
cancers (TNBCs), we hypothesized APA to cause 3=UTR length changes in this
aggressive subgroup of breast cancers. Our probe-basedmeta-analysis approach
identifıed 3=UTR length alterations where the signifıcant majority was shorten-
ing events (70%, 113 of 165) of mostly proliferation-related transcripts in over
500 TNBC patients compared with normal breast tissue. Representative short-
ening events correlated with increased protein levels and relapse free survival of
patients, suggesting functional signifıcance of isoform variability. To begin ad-
dressing the underlying mechanisms of 3=UTR shortening, we turned to APA
machinery proteins. We detected variable expression of APA machinery pro-
teins in different breast cancer subtypes but CSTF2 (cleavage stimulation factor
2) has the most prominent overexpression in breast cancer cells. Therefore,
among potential regulators of 3=UTR shortening, we further investigated the
role of CSTF2 in proximal polyA signal selection. Because some of the TNBC
patients are EGFR positive, we found EGF treatment to cause increased CSTF2
levels. Higher CSTF2 levels indeed correlated with further shortening of the
3=UTRs. Accordingly, RNAi-induced silencing of CSTF2 decreased the prolif-
erative rate of cancer cells. Therefore, our integrated approach revealed a pattern
of 3=UTR length changes in TNBC patients and a potential link between APA
and EGF signaling. Further studies are underway to investigate the mechanistic
link between EGF signaling and regulation of 3=UTR lengths. (This work is
funded by TUBITAK 112S478 and 114Z884)
#3375 High caveolin-1 expression in a cohort ofAfricanAmericanwomen
with triple-negative breast cancer. Lisa L. Baumbach-Reardon,1 Julie Getz,2
Mary Ellen Ahearn,1 Davyd Teoh,3 Christophe Legendre,1 Mark Pegram,4 John
Carpten5. 1TGen (The Translational Genomics Research Institute), Phoenix, AZ;
2National Center for Toxicological Research, Jefferson, AR; 3Arizona State Uni-
versity, Phoenix, AZ; 4Stanford University School of Medicine, Stanford, CA;
5University of Southern California, Los Angeles, CA.
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In the U.S., the incidence rates of breast cancer (BC) among Caucasian (CA)
women are lower than those of African American (AA), however, AA women
have a signifıcantly higher mortality rate. AA women often present at a younger
age, with later stage and higher grade tumors. In fact, AA women are 3 times
more likely to be diagnosed with the more aggressive molecular subtype, triple-
negative breast cancer (TNBC), than CA women. Socioeconomic and lifestyle
factors may be contributory; however, it is imperative that we investigate the
underlyingmolecular biology thatmay be the cause of health disparities between
AA and CA with TNBC. In this study, gene expression profıling, using the
Almac BC DSA Research Tool, was performed on archived FFPE samples, ob-
tained from CA and AA women diagnosed with early stage (Node 0) TNBC.
Unsupervised hierarchical clustering revealed a pattern of differential gene ex-
pression in the AA cohort compared to CA. Using the TNBC type: A Subtyping
Tool for TNBC, we found a distinct distribution pattern of TNBC molecular
subtypes in the AA cohort, which was very different than the CA cohort; Basal-
like (14%), Immunomodulatory (43%) and Mesenchymal (43%). Gene expres-
sion analyses, comparing the AA and CA cohort (fold change  2.0, p-value
.05), resulted in 190 deferentially expressed genes (DEG). Pathway enrich-
ment analysis conducted in MetaCore GeneGo, revealed that the DEGs were
over-represented in cytoskeletal remodeling, cell adhesion, tight junctions, and
immune response in the AA TNBC cohort. Furthermore, several genes in the
Wnt/-catenin pathways were over-expressed in the top 10-enrichment path-
ways. We validated our results using RT-qPCR and identifıed Caveolin-1
(CAV1) as being signifıcantly expressed in the AA-TNBC cohort (p-value 1.22 x
10-05). An independent cohort of FFPE samples, fromAA and CAwomen with
early stage TNBC, was used to create a tissue microarray (TMA). Immunohis-
tochemistry results showednodifference in localization ofCav1 between theAA
and CA cohorts, however, the AA cohort had signifıcantly higher levels of Cav1
staining (p-value 0.04). Additionally, using RT-qPCR, we demonstrated that
CAV1 mRNA was signifıcantly higher in the AA TNBC Cohort (p-value 0.48).
Furthermore, endogenous Cav1 was shown to be highly over-expressed in a cell
line panel of TNBC, in particular, those of the mesenchymal and basal-like
molecular subtype. Finally, using siRNA, we demonstrated that CAV1 silencing
resulted in a signifıcant decrease in cell proliferation, for each of the TNBC cell
lines while it showed no effect on the luminal ER cell lines. Our combined
study results suggest that CAV1 over -expression may be a biological contribu-
tor to the observed health disparity between AAwomen and CA diagnosed with
early stage TNBC.
#3376 Reprogramming the estrogen signaling network is a potential
mechanism for human breast tumorigenesis. David Chi,1 Hari Singhal,2
Lewyn Li,2 HenryW. Long,2 Judy E. Garber,2 Myles A. Brown2. 1Harvard Med-
ical School, Boston, MA; 2Dana-Farber Cancer Institute, Boston, MA.
Background: The estrogen receptor (ER) is expressed in approximately 70% of
sporadic breast cancers and is known to activate genes driving cell proliferation.
Much work in the fıeld has characterized the mechanisms of ER signaling behind
cancer progression and eventual metastasis, and therapeutic targeting of the ER
signaling pathway has proven effective. However, little is known regarding the role
of ER in the initial process of transformation. SinceERpossesses pro-differentiation
roles in normal breast development yet becomes one of the drivers of breast cancer,
altered ER function is then likely a crucial early step.We seek to investigate the role
ofERfromtheperspectiveof thenormalbreast toallowformechanistic insights into
breast tumorigenesis. Methods: To model the normal breast epithelium, viable tis-
sue specimens from patients undergoing reduction mammoplasty were obtained
andenriched forbreast epithelial cells via fluorescence-activatedcell sorting (FACS).
Fresh-frozenERbreast tumor sampleswere thenobtained for comparison.RNA-
seq, ChIP-seq for ER, and genome-wideCRISPR screening in the presence of estro-
gen stimulation in both normal breast and breast tumor were performed. These
various modalities of genomic data were then integrated and analyzed to identify
patterns in breast tumorigenesis. Results: Gene expression profıling via RNA-seq of
breast epithelial cells from seven reductionmammoplasties reveals a drastically dif-
ferent andmuted normal response to estrogen stimulation.Genes that promote cell
cycling and cell proliferation were down-regulated in normal breast but were up-
regulated in breast cancer cells. Furthermore, differential ER binding alone via ER
ChIP-seq is capable of segregating ten primary breast tumors from seven normal
breast tissues with very few overlapping sites. Deeper motif analysis reveals the en-
richment of novel transcription cofactor GRHL2 in the binding sites most closely
associated toERbreast cancer. Further fındingsvia genome-wideCRISPRscreens
reveal GRHL2 as an essential gene in luminal ER breast cancer with predictive
ability in cancer risk andprognosis.Conclusions:Cellular reprogrammingof theER
signaling network may alter the functioning phenotype of normal mammary epi-
thelial cells andoffer insights into the series of eventsnecessary fordevelopingbreast
cancer. Notably, ER activation does not promote cellular proliferation in normal
mammary epithelial cells, and the interactionwith transcriptional cofactors such as
GRHL2 can be a driving mechanism for breast tumorigenesis. Unraveling the dif-
ferential ER signaling in normal mammary epithelium and breast cancer will en-
hanceourunderstandingof breast cancer andaid thedevelopmentofmore effective
prevention strategies and targeted therapeutics.
#3377 Simultaneous analysis of themutational landscape andRNAandpro-
tein expression profıle of HER2-positive breast cancer using 3D BiologyTM.
Sarayna Chumsri,1 Daniel J. Serie,1 Brian M. Necela,1 Jennifer M. Kachergus,1 Bi-
anca C. Axenfeld,1 Gokhan Demirkan,2 GavinMeredith,2 P. Martin Ross,2 Anisha
Kharkia,2 Erin Piazza,2 Afshin Mashadi-Hossein,2 Sarah Warren,2 Sarah A.
McLaughlin,1 Joseph Beechem,2 Gary Geiss,2 E. Aubrey Thompson1. 1Mayo Clinic
Florida, Jacksonville, FL; 2NanoString Technologies, Seattle, WA.
Background:Understandingheterogeneitywithin individualbreast tumors iskey
to the ability to predict therapeutic outcome.Molecular heterogeneity is commonly
evaluatedbasedongenomic features, includingmRNAabundance, genecopynum-
ber events, and somaticmutations.The expressionprofıle andactivation state of key
proteins is widely recognized as another key element in defıning tumor heterogene-
ity. We have taken advantage of NanoString 3D Biology™ technology (for research
use only) and curated nCounter Vantage 3DTM Solid TumorAssay to interrogate a
survey panel of HER2-positive breast tumors with the ultimate goal of determining
key relationships between multiple genomic and proteomic profıles in individual
tumors. Methods: We analyzed samples from 24 HER2 breast cancer patients
usingNanoString technology to quantify the expressionprofıle for over 25 total and
phospho signaling proteins, including PI3K/MAPK/EGFR/HER2, 770mRNA cor-
responding to 13 canonical cancer pathways, and 104 somatic mutations and small
INDELS that are commonly associated with cancer, including 8 known PIK3CA
mutations. These analyses were carried out in a matched fresh frozen and FFPE
samples on the nCounter paltform.Datawere analyzed by nSolver to identify geno-
type specifıc expression profıles across the 24 samples. Results: In our proof-of-
concept data set, we successfully demonstrate that NanoString’s 3D biology Tech-
nology shows concordance across both FFPE and fresh frozen sample types for
DNA, RNA, and protein. NanoString analysis also showed high concordance to
gold-standard techniquesused to assess genotype andRNAexpressionprofıles. The
combinationofdigitalDNA,RNA,andproteindata fromourHER2breast cancer
samples yielded potentially actionable data based on mapping of mutational status
as the driver of key differences in protein expression and mRNA abundance of the
signaling targets profıled. This work sheds new light onHER2 breast cancer biol-
ogy and the interplay between genomic and proteomic profıles while setting the
stage for future studies that further probe thedifferences observed in this sample set.
Conclusions: Simultaneous analysis of mutational status (SNV) and expression at
the level of bothmRNA and protein promises to enable amore detailed view of the
relationship betweengenotype and the biological and clinical behavior of key tumor
types. The NanoString Vantage 3DTM Solid Tumor platform provides a rapid, reli-
able, and economic means of assessing these analytes simultaneously. The applica-
tion of these analytes to models that make clinically actionable predictions will re-
quire additional analyses of large sample cohorts, but such analysis is quite feasible
using a variety of sample types. Acknowledgements: Supported in part by grants
from theBreastCancerResearch Foundation and the 26.2withDonnaFoundation.
#3378 Whole exome sequencing identifıes recurrent alterations of genes
in malignant phyllodes tumors in nine Korean individuals. Jihui Yun,1
Hyeong-GonMoon,2 Tae-Kyung Yoo,2 Eunshin Lee,2 Jeesoo Chae,1 SamHur,2
Jiwoo Lee,2 Jong-Il Kim,1Dong-YoungNoh2. 1Seoul National University College
ofMedicine, Seoul, Republic of Korea; 2Seoul National University Hospital, Seoul,
Republic of Korea.
Phyllodes tumors of the breast are rare fıbroepithelial neoplasms with variable
clinical behavior accounting for about 1%of all breast neoplasms. Phyllodes tumors
are classifıed into benign, borderline, andmalignant grades on the basis of histolog-
ical features. Among those categories,Malignant phyllodes tumor has a higher pro-
pensity for local recurrence anddistantmetastasis, however themalignant potential
of phyllodes tumors is diffıcult to assess on initial pathologic examination. In previ-
ous studies, an important role of mediator complex subunit 12 (MED12) in phyl-
lodes tumors has been frequently revealed.However, except that, genetic abnormal-
ities that drive tumor initiation and progress inmalignant phyllodes tumor remain
still unclear.Here, byperformingwhole exomesequencingof9malignantphyllodes
tumors with matching normal cases, we frequently observed mutations inMED12
(3/9, 33.34%). Additionally, non-silent mutations in p53(TP53) and epidermal
growth factor receptor (EGFR) were recurrently identifıed. Whole-gene amplifıca-
tions of EGFRwere also found in six cases (6/9, 66.67%).We suggest that EGFRhas
an underlying role in malignant phyllodes tumors. This study identifıes potential
therapeutic targets in malignant phyllodes tumors, including EGFR.
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#3379 Massively parallel sequencing analysis of breast adenomyoepithe-
liomas reveals the heterogeneity of the disease and identifıes a subset driven
by HRAS hotspot mutations. Felipe C. Geyer,1 Kathleen A. Burke,1 Anqi Li,1
Anastasios D. Papanastatiou,1 Fresia Pareja,1 Anne S. Schulteis,1 Charlotte K.
Ng,1 Salvatore Piscuoglio,1 Marcia Edelweiss,1 Luciano G. Martelotto,1 Pier
Selenica,1 Maria R. Filippo,1 Gabriel S. Macedo,1 Achim Jungbluth,1 Hannah Y.
Wen,1 Juan Palazzo,2 Zsuzsanna Varga,3 Emad Rakha,4 Ian O. Ellis,4 Brian Ru-
bin,5 Britta Weigelt,1 Jorge S. Reis-Filho1. 1Memorial Sloan Kettering Cancer
Center, NewYork,NY; 2Thomas JeffersonUniversityHospital, Philadelphia, Phil-
adelphia, PA; 3University Hospital Zurich, Zurich, Switzerland; 4Nottingham
University Hospitals, Nottingham, United Kingdom; 5Cleveland Clinic, Cleve-
land, OH.
Adenomyoepithelioma (AME) is a rarebiphasicproliferativebreast lesion,which
may resemble salivary gland epithelial-myoepithelial carcinomas (EMCs). Most
AMEs have an indolent clinical course, butmalignant transformation and local and
distant recurrences have been reported. We sought to defıne the mutational land-
scape of AMEs and investigate the functional impact of recurrent likely pathogenic
mutations identifıed in these tumors. Nineteen AMEs were subjected to whole-
exome massively parallel sequencing (MPS, n7) or targeted capture MPS using
MSK-IMPACT assay (n12). Somatic genetic alterations and the cancer cell frac-
tion of mutations were defıned using state-of-the-art bioinformatics algorithms.
Selected genes (i.e. HRAS and PIK3CA) were subjected to Sanger sequencing in a
series of 17 additional AMEs (total n36). Non-tumorigenic mammary epithelial
cells (i.e. MCF10A, MCF10A with the PIK3CAH1047R mutation and MCF12A),
which are estrogen receptor (ER)-negative, were utilized for 2D and 3D functional
studies. Of 36 cases, 22 were ER-positive and 14 were ER-negative. MPS analysis
revealed a low mutation burden and HRASQ61 and PIK3CA hotspot mutations in
6/19 (32%) and 11/19 (58%) AMEs, respectively. All HRASQ61 and all but one
PIK3CA mutations were clonal. ER-positive and ER-negative AMEs were funda-
mentally histologically and genetically distinct.Whilst ER-positiveAMEs displayed
recurrent PIK3CAmutations (50%, 11/22) but lacked HRAS mutations, ER-nega-
tive AMEs displayed, in addition to PIK3CA mutations (57%, 8/14), recurrent
HRASQ61 mutations (57%, 8/14). HRASQ61 mutations co-occurred with PIK3CA
mutations (50%,4/8),PIK3R1deletions (12.5%,1/8)and/orCDKN2Ahomozygous
deletions (25%, 2/8). HRASQ61mutations, but not PIK3CAmutations, were signif-
icantly associatedwithER-negativity (100%vs21%), concurrent carcinoma (50%vs
7%), axillarymetastases (38% vs 0%), high proliferation (63% vs 4%), necrosis (63%
vs 11%) and nuclear pleomorphism (75% vs 29%). In vitro forced HRASQ61R ex-
pression in MCF10A and MCF12A cells resulted in increased proliferation and
transformation. In 3D organotypic cell cultures, forced HRASQ61R resulted in a
highly disorganized growth pattern, a partial loss of epithelial phenotype and acqui-
sition of aberrant myoepithelial differentiation, which was more overt in PIK3CA-
mutantMCF10Acells. In conclusion,AMEs are phenotypically and genetically het-
erogeneous. Whilst PIK3CA hotspot mutations occur across the spectrum of
lesions, HRASQ61 hotspot mutations are restricted to ER-negative AMEs, which
should arguably be classifıed as breast EMCs. Our genomic and functional analyses
are consistent with the notion that HRASQ61 mutations are driver events in the
pathogenesis of ER-negative AMEs and may be suffıcient for the acquisition of
myoepithelial differentiation in breast cells.
#3380 Synthetic lethal interaction between ARID1A mutation and BET
bromodomain inhibition in ovarian clear cell carcinoma. Katrien Berns,1 Jo-
seph J. Caumanns,2 E Marielle Hijmans,1 Annemiek Gennissen,1 Bastiaan
Evers,1 Bea A.Wisman,2 Gert JanMeersema,2 Cor Lieftink,1 Roderick L. Beijer-
sbergen,1 Hiroaki Itamochi,3 Ate G. van der Zee,2 Steven de Jong,2 René Ber-
nards1. 1Netherlands Cancer Institute, Amsterdam, Netherlands; 2University
Medical Center Groningen, Groningen, Netherlands; 3Iwate Medical University
School of Medicine, Iwate, Japan.
Introduction: Current treatment for advanced stage ovarian clear cell cancer is
severely hampered by a lack of effective systemic therapy options, leading to a poor
outlook for these patients. Given that ARID1A is inactivated by mutation in over
50% of ovarian clear cell carcinomas, we pursued an ARID1A synthetic lethal
screening strategy to identify druggable targets inOCCC.Experimental procedures:
We performed synthetic lethal kinome short hairpin (shRNA) screens in a large
panel (n14) of OCCC cell lines having different ARID1A mutation status. Hit
validation was performed with isogenic ARID1A ko cell line pairs and in (patient-
derived) xenograft mouse models. Summary of the data: We show here that BRD2
inhibition is synthetic lethalwithARID1Amutation inovarianclearcell cancercells.
Importantly, inhibiting the BET family of proteins, to which BRD2 belongs, with
smallmolecules specifıcally inhibitsproliferationofARID1Amutatedcell linesboth
in vitro and in ovarian clear cell cancer xenografts and patient-derived xenograft
models.Wedemonstrate thatARID1Aloss leads toupregulationof theWNTligand
WNT10B, possibly causing aWNT dependency in the ARID1Amutant lines. BET
inhibitors cause a reduction inWNT10B expression andWNT target genes such as
MYC, JUNandWISP1,providingapotential explanation for theobserved synthetic
lethal interactionwithARID1A loss. Conclusions: Our study uncovered a new syn-
thetic lethal interaction between ARID1A mutation and BET bromodomain inhi-
bition, suggesting a new treatment strategy for ARID1A mutant ovarian clear cell
carcinomas.
#3381 TERT promoter mutation in granulosa cell tumours of the ovary:
Prevalence and prognostic signifıcance. Jessica A. Pilsworth,1 Dawn R. Co-
chrane,2 Zhouchunyang Xia,1 Hugo M. Horlings,3 Winnie Yang,1 Melissa K.
McConechy,4 Satoshi Yanagida,5 Anniina E. Färkkilä,6 Adele P. Wong,7 Genny
Trigo-Gonzalez,2 S.W. Grace Cheng,2 Yikan Wang,2 Ali Bashashati,2 Gregg B.
Morin,1 Esther Oliva,7 Sohrab P. Shah,1 David G. Huntsman1. 1University of
British Columbia, Vancouver, British Columbia, Canada; 2BC Cancer Agency,
Vancouver, British Columbia, Canada; 3Netherlands Cancer Institute, Nether-
lands; 4McGill University, Montreal, Quebec, Canada; 5The Jikei University
School of Medicine, Japan; 6University of Helsinki, Finland; 7Massachusetts Gen-
eral Hospital,, MA.
Granulosa cell tumours (GCTs) of the ovary account for 90% of sex cord-
stromal tumours and have a high recurrence rate up to 50%. A missense
mutation in the FOXL2 gene (c.402CG; pC134W) is a defıning feature of
GCT and is used as a robust marker for diagnosis. However, other than the
FOXL2 mutation the pathogenesis and the driving pathways remain un-
known. Determining secondary genetic events in GCTs is essential to under-
standing and improving prognosis. In a pilot study, we completed an analysis
of whole genome sequencing of ten GCTs and matched normal cases to
generate a comprehensive catalogue of coding and non-coding events. We
identifıed a TERT promoter mutation (c.228CT) in 50% of these cases.
TERT is normally inactivated in somatic tissues; however, this promoter
mutation has been shown to re-activate transcription of TERT.We validated
this TERTmutation in an international cohort of 300 GCTs and found it was
present in approximately 25% of cases overall. These TERT promoter muta-
tions have been used to revise the molecular classifıcation of other cancer
types such as gliomas. In GCT, we found that this TERT mutation was
correlated with a signifıcantly worse survival outcome in patients with pri-
mary GCT (p0.005). Further, we found that this TERT mutation was pres-
ent in a larger proportion of recurrent cases. Thus, this mutation may denote
a novel subtype of GCT with a worse prognosis. Previous research has shown
that TERT activation is evident in over 90% of cancers and is a fundamental
step in tumourigenesis that enables unlimited proliferation. This TERT pro-
moter mutation in GCT provides an explanation of how granulosa cells
escape atresia and attain immortality. Thus, we hypothesize a mechanism in
which the FOXL2 mutation prevents apoptosis and the TERT mutation al-
lows limitless proliferation for oncogenes to transform granulosa cells. How-
ever, the current cell models of GCT lack relevant functional pathways and
do not recapitulate the biology of these tumours. Therefore, we are develop-
ing more suitable cell models to test our hypothesis. We believe that under-
standing the interaction between these TERT and FOXL2 mutations may
lead to novel cancer cell-specifıc targeted therapies.
#3382 Comparative genomic and pathway analysis of ovarian cancer, be-
nign tumors, and normal tissues detect alterations in several metabolic pro-
grams in ovarian cancer. Pourya Naderi Yeganeh,1 Zahra Bahrani-Mostafavi,1
Christine Richardson,1 David L. Tait,2 M Taghi Mostafavi1. 1UNIV. Of North
Carolina Charlotte, Charlotte, NC; 2Carolinas Medical Center, Charlotte, NC.
Introduction: The high mortality rate of ovarian cancer is mainly due to
asymptomatic early stages of the disease. Currently used detection markers lack
high sensitivity and specifıcity and generate large number of false positives from
benign and normal subjects. Therefore experimental approaches capable of dis-
tinguishing the signatures of malignancy are required to improve the current
states of biomarkers. This study aims to identify genetic abnormalities in ovarian
cancer that contribute to cancer progression and developments. Methodology:
This study was conducted on 67 whole tissue microarrays samples processed
using Affymetrix HG-Focus chip, including 18 non tumorous samples (N), 14
benign tumor samples (B), 30 malignant ovarian samples (M), 3 borderline
malignant samples, and 2 ovarian cancer cell lines. Differential expression (DE)
analysis was conducted through Analysis of Variance methods (ANOVA) be-
tween malignant samples and non-malignant samples (M vs. B and N). DE
results were modifıed to False Discovery Rate (FDR 0.05). Further pathways
analysis was conducted on DE genes to identify pathways with dysregulated
elements. Pathway identifıcationwas performed by enrichment analysismethod
based onKEGGannotated pathways. P-valueswere calculated usingChi-Square
test (FDR0.05). Further enrichment analyses were performed by MSigDB
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GSEAportal. Results: 826DE genes were foundwith fold change 2. PDGFRA,
TACSTD2, ABCA8, STAR, and C7 exhibited the highest rates of fold change
(more than 14 fold). Enrichment Analysis of Hallmarks reveals several hall-
marks of cancer related terms including EMT, G2M, E2F targets, P53 pathways,
and Apoptosis. Pathway analysis identifıes 26 pathways with dysregulated com-
ponents many of which are categorized as metabolic pathways including Ascor-
bate Metabolism, Metabolism of xenobiotics by cytochrome, Drug metabolism
cytochrome P450, and Glutathione Metabolism. Gene Ontology Enrichments
identify several signifıcant enrichments including: Response to Endogenous
Stimulus, Regulation of Cell Proliferation, Tissue Development, Regulation of
Cell Death, and Cell Cycle Process. Conclusions: DE analysis and Pathway can
reveal dysregulatedmetabolic programs in ovarian cancer and the results of GO,
Pathway, and hallmarks enrichment analysis are consistent with mechanistic
differences between malignant tumors and other types of pathology. The inclu-
sion of benign tumors and non-malignant ovarian tissues contribute to more
accurate identifıcation of disease profıle. As expected, our data support mecha-
nisms of P53mutations inmalignancy and tumor progression. These results can
be used to identify suchmechanisms inmore detail as the detectedDE genes can
be used to generate hypothesis set for detection of ovarian malignancy signa-
tures.
#3383 Exome sequencing in dedifferentiated ovarian mucinous carci-
noma. Kaori Sanuki,1 Kentaro Nakayama,1 Kohei Nakamura,1 Masako
Ishikawa,1 Tomoka Ishibashi,1 Hitomi Yamashita,1 Ruriko Ono,1 Toshiko Mi-
namoto,1 Kosuke Yoshihara,2 Satoru Kyo1. 1Shimane Univ. Faculty of Medicine,
Izumo, Japan; 2School of Medicine, Niigata Univ., Niigata, Japan.
Mucinous ovarian tumor represent a distinct histotype of epithelial ovarian
cancer and is thought to begin as a mucinous adenoma that progresses in a slow
stepwise fashion. Dedifferentiatedmucinous ovarian carcinoma is a rare type of
carcinoma with a few reports and a progressive and poor prognosis. While the
molecular genetic features of ovarian mucinous carcinoma is now well known,
the pathogenesis of dedifferentiatedmucinous carcinoma is largely unknown. In
order to comprehensively analyse somatic mutations in dedifferentiated muci-
nous carcinoma, we applied exome sequencing to the DNA of a sample of affın-
ity-purifıed, dedifferentiated mucinous carcinoma. Through comparative anal-
yses of normal cells from the same patient, we identifıed several genes that were
mutated in this tumor. P53, which encodes a well-known tumor suppressor
protein, and KRAS, which encodes a well-known oncoprotein, had previously
been implicated in ovarianmucinous carcinoma. The othermutated genes were
previously unknown to be involved in mucinous carcinoma. CEP170 encodes a
microtubule-binding protein that controls the targeting of the kinesin-13 de-
polymerase protein to the mitotic spindle, and kinesin-13 family influence the
dynamics of microtubule growth and shrinkage. CEP170 genemutationmay be
related to inability of a cell division properly. CEP170mutations were identifıed
with a prevalence of 33.3% in dedifferentiated mucinous ovarian carcinoma.
Currently, CEP170 gene knock down assay and engineered expression of
CEP170 assay in ovarianmucinous carcinoma is being performedwhethermor-
phologic change is observed. In summary,CEP170maybe one of the responsible
gene in carcinogenesis of differentiated mucinous carcinoma.
#3384 Comprehensive genetic analysis ofmyxofıbrosarcomaand compar-
ison with other soft tissue sarcomas. Yasuhide Takeuchi,1 Annegret Kunitz,2
Hiromichi Suzuki,1 Kenichi Yoshida,1 Yuichi Shiraishi,3 Teppei Shimamura,4
Kenichi Chiba,3 Hiroko Tanaka,3 Nobuyuki Kakiuchi,1 Yusuke Shiozawa,1
Akira Yokoyama,1 Tetsuichi Yoshizato,1 Kosuke Aoki,1 Yoichi Fujii,1 Hideki
Makishima,1HironoriHaga,5 SatoruMiyano,3 FrederikDamm,2 SeishiOgawa1.
1Department of Pathology and Tumor Biology, Graduate School of Medicine,
Kyoto University, Kyoto, Japan; 2Department Hematology, Oncology and Tumor
Immunology, Charite University Hospital, Berlin, Germany; 3Laboratory of DNA
information Analysis, Human Genome Center, Institute of Medical Science, The
University of Tokyo, Tokyo, Japan; 4Division of System Biology, Graduate School
of Medicine, Nagoya University, Nagoya, Japan; 5Department of Diagnostic Pa-
thology, Kyoto University Hospital, Kyoto, Japan.
Background:Myxofıbrosarcoma (MFS) is a relatively common subtype of soft
tissue sarcomas (STSs) in the elderly, which is characterized by the proliferation
of pleomorphic spindle cells with varying degrees of themyxoid component and
on the basis of this unique histological picture, together with other clinical char-
acteristics, is separated from other STSs. However, the genetic basis of MFS is
poorly understood. Aims andMethods: The purpose of this study is to clarify the
comprehensive registry of genetic alterations in MFS and other STSs using
whole exome/genome sequencing (WES/WGS) of paired tumor/normal DNA
from 41 samples with MFS, combined with the WES data of 25 samples with
MFS and 234 with STS, which were available from The Cancer Genome Atlas
(TCGA) database. WGS was performed in 2 cases. Data for DNA methylation
and gene expression from the TCGA registry were also analyzed. Moreover, the
genetic basis of mixed histological components characteristic of MFS and its
chronological changes was interrogated usingmulti-regional and/ormulti-time
points sampling. Results: A total of 8,661mutationswere identifıed inWES of 66
primary MFS samples with a median of 131.2 mutations/sample, which were
dominated by age-related C to T transitions at CpG sites.WGS (n 2) detected
491 and 198 somatic structural variations in each case, which suggested MFSs
have undergone complex chromosomal rearrangements. Most frequently mu-
tated genes included TP53 (n  19, 28.8%), ATRX (n  10, 15.5%), and RB1
(n  8, 12.1%), which were also detected in several types of STSs (n  234) at
similar frequencies with no mutations being specifıcally associated with MFS
compared to other STSs. However, interestingly, STSs were reproducibly clus-
tered into four distinct subtypes based on DNA methylation and gene expres-
sion (Cramér’s V  0.73), regardless of the histological classifıcation. These
subtypes based on DNAmethylation and gene expression showed stronger cor-
relations with the prognosis (p-value: 0.025, 0.028, respectively) than the histo-
logical classifıcation (p-value 0.528). Paired multi-regional sampling (n 4)
analysis disclosed high degrees of intratumor heterogeneity with less than 27%
(range 9.5-26.6%) mutations being shared by different sampling. Multi-time
points sampling analysis (n 6) showed that the number of mutations did not
signifıcantly differ between primary and relapsed tumors (p-value  0.35).
There were no recurrent morphological feature-associated or relapse-specifıc
mutational/copy number alterations. Conclusions: MFS is characterized by fre-
quent mutations in TP53, ATRX, and RB1. STSs, including MFS, are classifıed
into 4 distinct subgroups based on DNA methylation and gene expression,
which correlated well with clinical outcomes. There were high degrees of intra-
tumor heterogeneity in terms of mutations, which however, showed no clear
correlation with morphological features.
#3385 Genomic landscapes of pulmonary sclerosing hemangioma. Seung-
Hyun Jung,1Min Sung Kim,1 Sun Shin,2Mi-RyungHan,2 Yu Jin Cho,2 So Youn
Kim,2 Sug Hyung Lee,1 Yeun-Jun Chung2. 1Cancer Evolution Research Center,
The Catholic University of Korea, Seoul, Republic of Korea; 2Integrated Research
Center for Genome Polymorphism, Catholic University of Korea, Seoul, Republic
of Korea.
Pulmonary sclerosing hemangioma (PSH) is a benign tumor that usually
presents as a solitary, well-defıned mass in the lung. The PSH predominantly
affects females with a higher incidence in the Far East. Histologically, the
tumor cells in PSH consist of two cell types (cuboidal epithelial and polygo-
nal stromal cells). Immunohistochemical and ultrastructural studies have
identifıed that both cells are derived from undifferentiated respiratory epi-
thelium that is the histologic origin of lung adenocarcinoma as well. Previous
studies have shown that PSH and adenocarcinoma in the lung share some
immunohistochemical and genetic features. However, as for somatic muta-
tions, whereas many driver genes for lung adenocarcinomas have been iden-
tifıed, there have not been any candidate driver mutations identifıed in PSHs,
except for low frequency mutations in -catenin and TP53. Frequent so-
matic mutations identifıed in lung adenocarcinomas such as KRAS and
EGFR have not been detected in PSH, suggesting that genomic alterations of
these two lung tumors might be different from each other. Also, there is no
evidence of PSH progression to lung cancers. These earlier data indicate that
despite the common cellular origin of PSH and lung adenocarcinoma, ge-
netic mechanisms for their development may be different. Based on the
established concept that PSH is a true tumor, we hypothesize that it may
harbor somatic mutations. In this study, we conducted whole exome se-
quencing of 44 PSHs and identifıed recurrent somatic mutations of AKT1
(43.2%) and -catenin (4.5%). We used a second subset of 24 PSHs to con-
fırm the high frequency of AKT1 mutations (overall 31/68, 45.6%; p.E17K,
33.8%) and recurrent -catenin mutations (overall 3/68, 4.4%). Of the PSHs
without AKT1 mutations, two exhibited AKT1 copy gain. AKT1 mutations
existed in both epithelial and stromal cells. In two separate PSHs from one
patient, we observed two different AKT1mutations, indicating they were not
disseminated but independent arising tumors. Since the AKT1 mutations
were not found to co-occur with -catenin mutations (or any other known
driver alterations) in any of the PSHs studied, we speculate that this may be
a single most common driver alteration to develop PSHs. Our study revealed
genomic differences between PSHs and lung adenocarcinomas including a
high rate of AKT1 mutation in PSHs. These genomic features of PSH discov-
ered in the present study provide clues to understanding the biology of PSH
and for differential genomic diagnosis of lung tumors.
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#3386 Brazilian melanoma genome project: mutational landscape based
on whole-genome sequencing. Vinicius L. Vazquez,1 Adriane Evangelista,1
HenriqueC. Silveira,1CamilaCrovador,1Andre L.Carvalho,1CristovamScapu-
latempo-Neto,1 Jin Lee,2 Gilles Landman,3 Joao P. Kitagima,2 Rui M. Reis1.
1Barretos Cancer Hospital, Barretos, Brazil; 2Mendelics, Sao Paulo, Brazil;
3UNIFESP - Sao Paulo Federal University, Sao Paulo, Brazil.
Melanoma is the most aggressive form of skin cancer with increasing preva-
lence in Brazil. The comprehensive molecular profıling of these tumors and the
recent genomic classifıcation has improved the knowledge ofmelanoma biology
and foster the identifıcation of potential clinical biomarkers. The aim of this
project, as part of the International Cancer Genome Consortium (ICGC) is to
perform a genomic profıle by whole genome sequencing (WGS) of Brazilian
melanomas patients.We reported theWGS using Illumina paired-end sequenc-
ing strategy (30 X-fold coverage) of 66 cases (45% primary and 55% meta-
static) and respective matched normal. Overall we observed an average of 46K
mutations/genome. The most frequent type of substitutions identifıed were:
CT (22.5%), TC (6.4%), TG (4.4%), TA (2.9%), CA (2.8%) and CG
(1.7%). A signifıcative difference between frequency of CT substitutions was
observed among histological subtypes, i.e., acral lentiginous (11.3%), nodular
(31.2%) and superfıcial spreading (25.9%). Among the classic genes involved in
melanoma biology, we found that 31.8% of patients had BRAFmutations, being
the V600E the most frequent (82.6%). A total of 6.1% of patients had NRAS,
3.0% showed KRAS, one case (1.5%) showed HRAS, and 12.1% showed NF1
mutations. TERT promoter mutation (C250T) was found in 28.8% of patients.
TP53 mutations found 4.5% and RB1 in 1.5% of cases. Oncogenic KIT and
PDGFRA mutations were observed in 6.1%and 1.5%, respectively. BRAF,
NRAS, HRAS, KRAS and NF1 mutation were mutually exclusive. BRAF and
TERT mutations were signifıcantly more frequent in superfıcial than acral len-
tiginous melanomas. We showed that Brazilian melanoma patients exhibit a
high number of single mutations and a similar mutation profıle to the one re-
ported in other populations. Acral/lentiginous melanoma subtype, which is a
common subtype in our setting, showed a distinct mutation frequency. Further
analysis will extend to other relevant genes and will also include the study of
additional genomes to reach the goal of genomic landscape of 100 Brazilian
melanomas cases.
#3387 Mutational analysis in metastatic melanoma to the breast and ova-
ry: correlation with clinic-pathological and immunohistochemical fındings.
Alessio Giubellino, Vanessa Moreno, Xu Naizhen, Liqiang Xi, Mark Raffeld,
Maria Merino. National Cancer Institute, Bethesda, MD.
Metastatic malignant melanoma or stage IV melanoma is the most deadly
skin cancer, claiming an estimated 10,000 deaths every year. The occurrence of
metastatic malignant melanoma to the breast and ovary is uncommon, and can
represent a challenge for the diagnosis and clinical management. We investi-
gated and correlated the morphologic, immunohistochemical and molecular
aspects of these tumors. Morphologic analysis of the cases revealed a predomi-
nance of epithelioid pattern, and few of these were associated withmore spindle
cell areas. Most of the tumor cells aberrantly expressed high levels of PD-L1,
especially in the metastatic melanoma to the breast. Other relevant melanoma
targets for immunotherapy were also explored by immunohistochemistry. Of
note, most of the metastatic tumors were negative for NY-ESO. The mutational
analysis of these metastatic lesions, using next generation sequencing for the
detection of cancer gene mutations including rare mutations at low frequency,
found an heterogeneous mutational landscape, reinforcing the importance of
personalized treatments. Mutations in RAS gene family members in these met-
astatic tumorswere themost frequent in our samples, followed byCDKN2Aand
CTNNB1 mutations. Other less frequent mutations were also detected, includ-
ing ATM and KIT. Interestingly, one rapidly progressive melanoma metastatic
to the breast in a young patient had areas of spindle cell morphology and no
commonmelanoma gene mutations. Overall, our cases illustrate the pathologic
and molecular variability of metastatic malignant melanoma to uncommon or-
gans of involvement, such as breast and ovary, and provide novel insights into
their diagnostic and clinical management algorithm.
#3388 Copy number alteration in primary melanoma. D. Timothy
Bishop,1 Anastasia Filia,2 Alastair Droop,1 Joey Diaz,1 Mark Harland,1 Jon
Laye,1 Juliette Randerson-Moor,1 Julia A. Newton-Bishop1. 1University of Leeds,
Leeds, United Kingdom; 2Imperial College, London, United Kingdom.
The systematic analysis of the genomic characteristics ofmelanoma primaries
has been infeasible given the limited size of these formalin-fıxed paraffın embed-
ded (FFPE) lesions. Further studying a clearly ascertained, deeply phenotyped
patient population allowsmeaningful extrapolation of the prevalence of distinct
genomic features and investigation of the association of these features with life-
style exposures and germline profıles. For these reasons,we focused on a recently
recruited patient cohort, the LeedsMelanoma Cohort (LMC) consisting of 2184
recruits from a distinct geographical region of Northern England; the only se-
lection applied to recruitment was to only include those whose melanoma was
less than 0.75 mm Breslow thickness in the early years of recruitment. Tumor
samples from 703 cases have been analyzed for genome-wide gene expression
(Pozniak et al, thismeeting). For this study, we wanted to explore the prevalence
of copynumber alterations (CNA) and themutationprofıle of tumors (reflecting
the association of CTmutations with UV exposure, the primary environmen-
tal risk factor) and so we have adopted a next-generation sequencing (NGS)
approach. Tumor blocks were recovered from local pathology laboratories for
those cases already deceased at the time that this CNA analysis was initiated plus
those survivingmore than 5 years post diagnosis at this same time. Blocks at risk
of being compromised for clinical purposes by sampling for this research study
were excluded from sampling; this amounted to almost 50% of identifıed sam-
ples. A total of 333 NGS libraries were sequenced on an Illumina GAII or HiSeq
sequencer to produce 100bp paired-end reads (either 5 or 1 per lane). DNA
reads were aligned andmapped achieving approximately 1.8x coverage (9.4x for
those at 1 per lane); the number of reads falling within each 10kb window was
adjusted for GC content and mappability and compared to a composite normal
FFPE sample to determine local copy number. We adopted various approaches
to assess the informativeness of the methodology. (i) Replicate samples showed
high reproducibility (all p  0.0001). (ii) Focused analysis of the CDKN2A
region with segmentation analyses to determine CNA breakpoints yielded high
quality, biologically plausible data revealing multiple copy number events. 67%
of samples showed no CNA across the 4Mb region covering CDKN2Awhile, as
expected, only a small proportion of CNAs did not involve CDKN2A. Four
common distinct patterns were observed. Copy number loss ranged from 20kb
to  4 Mb. (iii) A germline CNA could reliably be identifıed from the tumor
data. (iv) CDKN2A expression levels correlated with estimated copy number.
We have shown that small FFPE melanomas can be characterized for genomic
alterations using NGS opening up the potential for studies associating epidemi-
ological and germline profıle with the resulting tumor. 1. Newton-Bishop, J.A.,
et al. (2009) JClinOncol, 27, 5439-5444. FundedbyWorldwideCancerResearch
and Cancer Research UK.
#3389 Integrated genomic analyses reveal frequent TERT aberrations in
acral melanoma.Winnie S. Liang,1 William Hendricks,1 Jeffrey Kiefer,1 Jessica
Schmidt,2 Shobana Sekar,1 John Carpten,1 David W. Craig,1 Jonathan Adkins,1
Lori Cuyugan,1 Zarko Manojlovic,1 Rebecca F. Halperin,1 Adrienne Helland,1
Sara Nasser,1 Christophe Legendre,1 Laurence H. Hurley,3 Karthigayini Siva-
prakasam,1 Douglas B. Johnson,4 Holly Crandall,4 Klaus J. Busam,5 Victoria
Zismann,1 Valerie De Luca,1 Jeeyun Lee,6 Aleksandar Sekulic,2 Charlotte E.
Ariyan,5 Jeffrey Sosman,7 Jeffrey Trent1. 1TGen (The Translational Genomics
Research Institute), Phoenix, AZ; 2Mayo Clinic, Scottsdale, AZ; 3University of
Arizona, Tucson, AZ; 4Vanderbilt University Medical Center, Nashville, TN;
5Memorial Sloan-Kettering Cancer Center, New York, NY; 6Samsung Medical
Center, Seoul, Democratic People’s Republic of Korea; 7Northwestern University,
Chicago, IL.
Genomic analyses of cutaneous melanoma (CM) have yielded biological and
therapeutic insights, but understanding of non-ultraviolet (UV)-derived CMs
remains limited. Deeper analysis of acral lentiginous melanoma (ALM), a rare
sun-shielded melanoma subtype associated with worse survival than CM, is
needed to delineate non-UV oncogenic mechanisms. We thus performed com-
prehensive genomic and transcriptomic analysis of 34 ALM patients. Unlike
CM, somatic alterations were dominated by structural variation and absence of
UV-derived mutation signatures. Only 38% of patients demonstrated driver
BRAF/NRAS/NF1 mutations. Contrasting with CM, we observed PAK1 copy
gains in 15% of patients, and somatic TERT translocations, copy gains, and
missense and promoter mutations, or germline events, in 41% of patients. We
further show that in vitroTERT inhibition has cytotoxic effects on primaryALM
cells. These fındings provide insight into the role of TERT in ALM tumorigen-
esis, and reveal preliminary evidence that TERT inhibition represents a potential
therapeutic strategy in ALM.
#3390 Clonal evolution in uveal melanoma.Matthew G. Field,1 Hima An-
bunathan,2 Michael A. Durante,1 Louie Cai,1 Karam Alawa,1 Christina L. Deca-
tur,1 Stefan Kurtenbach,1 Anne Bowcock,2 J. William Harbour1. 1University of
Miami, Miami, FL; 2Imperial College London, London, United Kingdom.
Introduction: Uveal melanoma is the most common primary cancer of the
eye and frequently gives rise to lethal metastatic disease. Uveal melanoma
can be divided into two prognostic subgroups based on gene expression
profıling: class 1 (low metastatic risk) and class 2 (high metastatic risk).
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Uveal melanoma is also notable for a characteristic set of driver mutations
that cluster into two groups. The fırst group consists of mutually exclusive
gain-of-function mutations in members of the Gq signaling pathway
(GNAQ, GNA11, CYSLTR2 and PLCB4), which are present in almost all
uveal melanomas. These mutations are not prognostic, and are thought to
represent initiating events that are insuffıcient alone to cause full malignant
transformation. The second group consists of near-mutually exclusive mu-
tations in BAP1, SF3B1, and EIF1AX. These are thought to occur later in
tumor progression and are prognostic of patient outcome. These molecular
features are associated with characteristic chromosome copy number varia-
tions (CNV). The purpose of this study was to investigate the life history of
primary uveal melanomas by inferring the intratumoral evolution of these
genetic events. Methods: Exome or whole genome sequencing data from 151
primary uveal melanomas were evaluated with a new bioinformatic pipeline
for calling mutations and CNVs. Data from this analysis were used in down-
stream subclonality algorithms to determine intratumor evolutionary pat-
terns within individual tumor samples. Results: A Gq mutation was found
in 98.7% of tumors, which were all mutually exclusive with each other. BAP1
mutations were found in 46%, SF3B1 mutations in 23%, and EIF1AX muta-
tions in 14% of tumors, all of which were mutually exclusive with each other
except for 4 cases. We identifıed novel driver mutations in 20% of the re-
maining tumors. In most samples that contained a BAP1 or SF3B1 mutation,
this driver mutation and associated CNVs were present in 100% of tumor
cells. However, in 14% of cases with BAP1 mutations, 100% of tumor cells
exhibited monosomy 3, but a BAP1 mutation was present in a smaller sub-
clone, suggesting that the BAP1 mutation occurred after the loss of chromo-
some 3. In tumors with EIF1AX mutations, this mutation was consistently
found in 100% of tumor cells, with 6p gain being found in a smaller subclone
in 45% of cases, suggesting that 6p gain usually occurs after the EIF1AX
mutation in this subgroup of tumors. Conclusions: The driver mutations and
associated CNVs that are characteristic of uveal melanoma occur very early
in tumor evolution and are followed by the accumulation of silent passenger
mutations, consistent with a punctuated evolution model in which an initial
“big bang” is followed by neutral non-Darwinian evolution. These unex-
pected fındings alter prevailing theories of uveal melanoma progression, and
could have a signifıcant impact on patient management.
#3391 Next generation sequencing paves the way for personalized medi-
cine in pheochromocytoma and paraganglioma patients and their families.
Laura Gieldon,1 Susan Richter,2 Andreas Rump,1 Karl Hackmann,1 Andreas
Tzschach,1 Graeme Eisenhofer,2 Mariola Pe˛czkowska,3 Aleksander Prejbisz,3
Evelin Schröck,1 Barbara Klink1. 1Institut für Klinische Genetik, Medizinische
Fakultät Carl Gustav Carus, TechnischeUniversität Dresden, Dresden, Germany;
2Institut für Klinische Chemie und Laboratoriumsmedizin, Medizinische
Fakultät Carl Gustav Carus, TechnischeUniversität Dresden, Dresden, Germany;
3Institute of Cardiology, Department of Hypertension, Warsaw, Poland.
More than 35% of pheochromocytomas and paragangliomas (PPGL) are
thought to occur due to an underlying genetic predisposition. 18 suscepti-
bility genes have been identifıed for PPGL, which explain app. 30% of famil-
ial cases. Further PPGL predisposition genes, however, remain to be discov-
ered. In addition, identifıcation of biomarkers for malignancy also remains a
current challenge since histologic assessment does not suffıce discrimination
of malignant PPGLs. Personalized screening protocols, risk stratifıcation
measures and surveillance guidelines are needed for PPGL patients and their
family members at risk. We performed panel sequencing for 94 tumor pre-
disposition syndrome (TPS) genes and identifıed 12 pathogenic germline
mutations in 60 PPGL patients. Two of these patients were identifıed with
NF1-mutations although they did not meet the diagnostic criteria for Neu-
rofıbromatosis. Thus, TPS gene panel sequencing proved superior to routine
Sanger sequencing since mutations were identifıed in genes that would have
routinely been excluded from analysis. Combining results of immunohisto-
chemistry as well as biochemical profıling by measuring Krebs-cycle metab-
olites and genetic analyses of tumors we were able to reclassify variants of
uncertain signifıcance (VUS) as either pathogenic mutations or polymor-
phisms in several patients. Three incidentally found pathogenic mutations in
CHEK2 and MSH2 prompted further analyses such as testing for microsat-
ellite instability in order to evaluate possible effects on PPGL development.
For patients in whom no underlying mutation could be detected we per-
formed custom candidate gene panel sequencing of tumor derived-DNA.
Whole exome sequencing (WES) was carried out in 15 cases highly suspi-
cious for a genetic background in order to identify new candidate predispo-
sition genes that will further be evaluated in the patient cohort and in func-
tional studies. We will also present guidelines for diagnostics, surveillance
and prevention of PPGL for patients and their family members.
#3392 Genomic analysis of prostate cancer in Korean men. Se Song Jang,1
Min Jung Kim,1 Dong Wan Hong,2 Jae Young Joung,2 Sung Han Kim,2 Kang
Hyun Lee,2 Weon Seo Park,2 Jong-Il Kim1. 1Seoul National University, Seoul,
Republic of Korea; 2Center for Prostate Cancer National Cancer Center, Goyang,
Republic of Korea.
Prostate cancer currentlyhas the fıfthhighest incidence rate inKoreanmales, and
is the most common cancer in western males. Prostate cancer is the second most
common malignancy in men worldwide, and is responsible for approximately
250,000 cancer-related deaths annually. The search for accurate biomarkers and
characterization of prostate cancer is critical for evolution of accuratemanagement
of prostate cancer. Previous studies have identifıed that several genomic alterations
in prostate cancer including TMPRSS2-ERG fusion, PTEN deletion and SPOP sin-
gle nucleotide variants (SNVs), themajority of which are fromwestern population.
In order to investigate the somatic mutations of Korean prostate cancers, we per-
formedwhole exome sequencing on 51 prostate cancer patient’s tumor tissues, and
matched normal tissue. For the accurate detections of structural variations, we ad-
ditionally performed whole genome sequencing on 9 matched pairs (tumor, nor-
mal). A total of 738 somatic non-silent variants affecting 692 distinct genes were
identifıed. In addition to already known genes such as SPOP, FOXA1, TP53 and
PTEN, we also found previously uncharacterized genes such as GRIN2A, LRP1,
FNDC1 and LRP1B.Of the 40mutated genes acrossmultiple cases,missense SNVs
of SPOP (10/60 cases, 16.7%) were the most frequent, followed by missense and
splice-site SNVs of GRIN2A (5/60 cases, 8.3%). Mutations in low-density lipopro-
tein-related protein encoded by LRP1 and LRP1B affected considerable portion of
all cases (7/60, 11.7%), describe the probable relation between lipidmetabolism and
prostate cancer.We found TMPRSS2-ERG fusion in 4 of 9 whole genome samples.
Moreover, 5 samples had8pwhole armdeletion,which is found frequent inwestern
prostate cancers. As a result, we describe the genomic patterns of genetic variations
and structural variations involved in prostate cancer of Korean population.
#3393 Genomic analysis of multi-site fresh prostate samples. Marina A.
Parry,1 Shambhavi Srivastava,1 Alessio Cannistraci,1 Hui Sun Leong,1 Syed Ali,1
Jenny Antonello,1 Vijay Ramani,2 Maurice Lau,2 Jonathan Shanks,2 Daisuke
Nonaka,2 Pedro Oliveira,2 Noel Clarke,2 Crispin Miller,1 Ged Brady,1 Nathalie
Dhomen,1 Esther Baena,1 Richard Marais1. 1CRUK Manchester Institute, Man-
chester, United Kingdom; 2The Christie NHS Foundation Trust, Manchester,
United Kingdom.
Prostate cancer is the most common cancer in males in the UK with
40,000 cases diagnosed every year and10,000 deaths. Recent multi-plat-
form genomic studies have revealed a very complex picture of the disease,
with no clear subcategories linking to the histopathological markers cur-
rently used in clinical practice. The multifocal and heterogeneous nature of
the disease suggests that single biopsy sites may be missing valuable sub-
clones which contribute to the etiology of the disease. To address this, we
obtained fresh core biopsies from multiple sites (4-8) in the prostate from
eight high-risk patients undergoing prostatectomies at the Christie NHS
Foundation Trust. The tissues were immediately processed by the pathology
department and each core divided in two, one for genomic analysis and one
for parallel disease modeling (patient derived xenografts (PDXs), patient-
derived cell lines and organoids). The cores were cryo-sectioned and H&E
analysis performed at the top, middle and bottom of each core. These were
reviewed by a pathologist and tissue was micro dissected prior to simultane-
ous DNA and RNA extraction of normal and tumor tissue. Blood for germ-
line DNA and plasma for circulating free DNA (cfDNA) was also obtained.
Our study comprises eight patients with two or more tumor sites (2-4), some
bifocal, which were analyzed using whole exome sequencing (WES), copy
number aberration (CNA) profıling, transcriptomic analysis and methyl-
ation profıling. The most frequent aberration identifıed was loss of 8p
(NKX3-1) in 6/8 patients (12/24 tumor cores). Loss of 13q (RB1) was ob-
served in 5/8 patients (8/24 tumor cores), but never in all cores from a single
patient, suggesting a late event. Loss of 5q (CHD1) was identifıed in 4/8
patients (11/24 tumor cores). Loss of 6q (MAP3K7), 10q (PTEN), amplifıca-
tion of 8q (MYC) and TMPRSS2-ERG fusion were identifıed in 3/8 patients.
Some copy number events were only observed in either one patient or one
tumor core demonstrating extensive inter and intra-patient heterogeneity.
SPOP was the only gene affected by recurrent mutations across patients, but
different amino acids were affected within and between patients. Mutations
in PTEN, TP53, APC, BRAF and ERCC3, were also identifıed, among many
others. The most signifıcantly overexpressed gene was ERG, seen in patients
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with the TMPRSS2-ERG fusion. Changes in gene expression differed be-
tween cores from the same patients, reflecting the heterogeneity at the DNA
level. These data will be analyzed in conjunction with the results from disease
modeling to investigate the functional impact of these changes and cfDNA
analysis is underway to understand which tumor clones are entering the
bloodstream. The multifocal and genomically heterogeneous nature of pros-
tate cancer is highlighted by this data and is likely to impact on precision
medicine approaches for this disease. We will correlate the molecular pro-
fıling of our patient tumors with their clinical data in order to identify targets
for further validation.
#3394 CGP identifıes largely non-overlapping high tumor mutational
burden and HRD genomic alterations in 721 clinically advanced prostate
acinar adenocarcinoma cases. Ninad Dewal,1 Yuting He,1 Richard J. Lee,2 Al-
exa B. Schrock,1 Jon Chung,1 ChristopherHoimes,3 Zachary R. Chalmers,1 Gar-
rett M. Frampton,1 James X. Sun,1 Primo N. Lara,4 Neeraj Agrawal,5 Paul Mat-
thew,6 Philip J. Stephens,1 Vincent A. Miller,1 Jeffrey S. Ross,1 Siraj M. Ali1.
1Foundation Medicine, Inc., Cambridge, MA; 2Massachusetts General Hospital,
Boston, MA; 3Case Western Reserve University School of Medicine, Cleveland,
OH; 4University of California, Davis Comprehensive Cancer Center, Sacramento,
CA; 5University of Utah School of Medicine, Salt Lake City, UT; 6Tufts University
School of Medicine, Boston, MA.
Background: Effective therapies for the management of castrate resistant
prostate cancer are lacking.We performed comprehensive genomic profıling
(CGP) on advanced prostate carcinomas (PC) in the course of clinical care to
identify genomic alterations that could suggest benefıt from targeted, im-
mune- and PARP inhibitor therapeutic strategies. Methods: DNA was ex-
tracted from 40 microns of FFPE specimen from 721 clinically advanced PC
cases. CGP was performed using a hybrid-capture, adaptor ligation based
next generation sequencing assay to a mean coverage depth of over 500X. All
four classes of genomic alterations (GA) - base substitutions, insertions and
deletions, gene fusions, and copy number alterations (amplifıcations and
losses) - were identifıed. Results: Of the 721 PC patients - men with median
age of 65 (range 34 - 88) - CGP was performed on 335 (46.5%) prostate
specimens and 386 (53.5%) specimens from metastatic sites. The most com-
mon genes altered were TP53 (N336, 46.6%), PTEN (N254, 35.2%), TM-
PRSS2-ERG (N214, all fusions, 29.7%), AR (N173, 24%), and MYC
(N105, 14.6%). Median tumor mutational burden (TMB) for this series
was 3.6 mut/Mb (range 0 - 305). AR and MYC amplifıcations were enriched
in metastatic tumors compared to primary tumors (p  0.001 for both).
Alterations characteristic of homologous recombination defıciency (HRD)
were found in15% of cases, including homozygous deletions and truncat-
ing mutations in BRCA2 in 79 (11%) samples, as well as truncating muta-
tions in ATM in 41 (5.7%) samples, with only 3 samples possessing altera-
tions in both genes. Cases with these HRD-relevant alterations possessed
overall higher genomic loss of heterozygosity (LOH) content than did those
without (p 0.02). HRD and non-HRD cases had median TMB of 4.8 versus
2.7 mut/Mb, respectively, and mean TMB of 10.4 versus 4.0 mut/Mb (p 
0.01). Only 2.6% of non-HRD cases were TMB-high (20 mut/Mb or more),
versus 8.4% of HRD cases, a small but signifıcant enrichment in the latter.
Conclusions: CGP for advanced PC cases identifıes largely non-overlapping
TMB-high and HRD positive cases, suggesting benefıt from immunothera-
peutics and PARP inhibitors respectively. Further investigation will assess
whether HRD pathway alterations result in genomic LOH in the context of a
hypermutated tumor, and enrichment or exclusivity with other GA in pros-
tate carcinoma.
#3395 Alternative splicing of the MEAF6 gene promotes neuroendocrine
prostate cancer development.AhnR. Lee, Yinan Li, Ning Xie, Colin C. Collins,
Xuesen Dong. University of British Columbia, Vancouver, British Columbia,
Canada.
In response to the selection pressures exerted by potent androgen receptor
(AR) pathway inhibitors (ARPI), adenocarcinoma prostate cancer (PCa) cells
can undergo an adaptive process of cellular phenotype reprogramming termed
neuroendocrine trans-differentiation. With this AR-bypass mechanism of sur-
vival emerges a lethal treatment-resistant PCa subtype called treatment-induced
neuroendocrine PCa (t-NEPC). t-NEPC is becoming a major clinical issue as it
is estimated to affect 25% of advanced-stage PCa patients with the level of
incidences predicted to rise as a result of the extensive applications of ARPI in
the clinic. This underscores the gravity of our aims to delineate the molecular
underpinnings of t-NEPC to inform future therapies that prevent or mitigate
t-NEPC development. In this study, we have identifıed a splice variant of the
MYST/Esa1-associated factor 6 (MEAF6) gene, MEAF6-1, that is highly ex-
pressed in t-NEPC tumor biopsies as well as neuroendocrine cell lines of pros-
tate and lung cancers. We show that the neuronal RNA splicing factor, SRRM4,
stimulates MEAF6-1 splicing. Enhanced MEAF6-1 expression in prostate ade-
nocarcinoma cell lines does not induce neuroendocrine trans-differentiation of
these cells. Rather, it stimulates cell proliferation, anchorage-independent cell
growth, invasion, and xenograft tumor growth. Gene microarray identifıed that
these MEAF6-1 actions are in part mediated by the ID1 and ID3 genes. These
fındings suggest that the MEAF6-1 variant does not induce neuroendocrine
differentiation of prostate cancer cells, but facilitates t-NEPC progression
through accelerating proliferation of cells that have acquired neuroendocrine
phenotypes.
#3397 Post-mortem examination of an aggressive case of medullary thy-
roid cancer characterised by catastrophic genomic abnormalities. Darran P.
O’Connor,1 Sudipto Das,1 Deirdre Kelly,2 Bruce Moran,3 Kathleen Han,2 Niall
Mulligan,2 Ciara Barrett,2 Patrick Buckley,1 Peter McMahon,2 J McCaffrey,2
Henrik van Essen,4 Kate Connor,1 Bauke Ylstra,4 Diether Lambrechts,5William
M. Gallagher,3 Catherine M. Kelly2. 1Royal College of Surgeons in Ireland, Dub-
lin, Ireland; 2Mater Misericordiae University Hospital, Dublin, Ireland; 3Univer-
sity CollegeDublin, Dublin, Ireland; 4VUUniversityMedical Center, Amsterdam,
Netherlands; 5Vesailus Research Center, Leuven, Belgium.
Catastrophic genomic alterations may drive aggressive cancer phenotypes.
We describe a diagnostically challenging and rapidly fatal case of medullary
thyroid carcinoma (MTC) occurring in a young,morbidly obesemanpresenting
with diffuse bone marrow involvement and disseminated intravascular coagu-
lation. Whole-exome (WES) and shallow whole-genome sequencing (sWGS)
were carried out for the primary tumour, adjacent normal, bonemarrow tissues,
multiple metastases and blood samples derived from the patient. We identifıed
three germline single nucleotide polymorphisms (SNPs) within the RET proto-
oncogene that remained undetected using routine hospital genetic testing pro-
cedures. One variant (L769L) has been previously reported to be associated with
aggressive MTC presentation yet remains untested for in the routine diagnosis
ofMTC. Supported by fındings frombothWES and sWGS,we report for the fırst
time in thyroid cancer on the occurrence of a “chromothripsis-like pattern”,
which involved shattering of chromosome 4 leading to complete abrogation of
normal chromosomal function, along with dramatic widespread copy number
aberrations across both primary tumour and bone marrow samples. Based on
the somatic variants identifıed, we describe the evolutionary pathway of the case,
showing that bone marrow metastasis occurred separately to other metastatic
sites. The presence of disease-associated SNPs within the RET proto-oncogene
supports their inclusion as part of routine genetic testing for MTC cases. The
copy number aberrations and chromothripsis-like pattern affected a much
broader range of genes than single mutations and may have led to the wide-
spread chromosomal instability evident, possibly contributing to the rapid fatal
course of the case. These results provide a rationale for the application of com-
prehensive genomic analysis of cancers presenting with unusual and aggressive
phenotypes to facilitate more appropriate therapeutic options and diagnoses.
#3398 The genomic and transcriptomic analysis of nine widely invasive
follicular thyroid carcinomas (wiFTC) in Korean patients. Angela Byuri
Cho,1 Seong-Keun Yoo,1Min-Hwan Sohn,1 Jong-Yeon Shin,1 Su-jin Kim,2 Eun
Kyung Lee,3 Young Joo Park,2 Jeong-Sun Seo1. 1Seoul National Univ. Genomic
Medicine Institute, Seoul, Republic of Korea; 2Seoul National Univ. Hospital,
Seoul, Republic of Korea; 3National Cancer Center, Goyang-si, Gyeonggi-do, Re-
public of Korea.
Widely invasive follicular thyroid carcinoma (wiFTC) can be characterized
from minimally invasive follicular thyroid carcinoma (miFTC) as it exhibits
poor prognosis with frequent distant metastasis. We have reported that miFTC
shows similar mutational and transcriptional spectrum when compared to fol-
licular adenoma (FA). Here, we performed whole-exome and transcriptome
sequencing on wiFTC samples to defıne their aggressive biological features by
comparing with 30 miFTCs and 26 FAs. Well-known miFTC and FA driver
genes, NRAS (66.67%), HRAS (11.11%), and EIF1AX (11.11%), were identifıed
in wiFTC. TERT mutation was found in all samples which can explain its ag-
gressive feature. Chromosome 17p/q amplifıcation was found in most wiFTC
samples aswell as 22qdeletion that is frequently aberrant inH/K/NRASmutated
thyroid cancers. Most of wiFTCs were classifıed as RAS-like (66.67%) and a few
were BRAF-like (22.22%) and NBNR (11.11%) molecular subtypes. From dif-
ferentially expressed gene analysis, we found 1,832 and 1,384 up-regulated and
down-regulated genes when wiFTC was compared to miFTC and FA together.
wiFTC hadmany overlapped down-regulated genes as poorly differentiated and
anaplastic thyroid carcinoma which also supports its aggressiveness. Through
weighted correlation network analysis we have established gene expression net-
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works, highly associated with wiFTC, that have SIRT6 and TGFBR2 as the cen-
tral nodes. In this study, we demonstrated the distinctive mutational and tran-
scriptional characteristics of wiFTC hence found the underlying molecular
mechanism for its aggressiveness.
#3399 Genomic analysis of melanoma evolution following a 30 year dis-
ease-free interval. Jerry J. Miller,1 Kristopher A. Lofgren,2 Sarah R. Hughes,1
Steven E. Cash,2 David R. Meier,2 Paraic A. Kenny2. 1Gundersen Health System,
La Crosse, WI; 2Gundersen Medical Foundation, La Crosse, WI.
The rate of ultra-late recurrence (beyond 10-15 years) of cutaneous mel-
anoma has been estimated to be between 2.0-6.9% from large case series. Two
major factors complicate the interpretation of these data. Firstly, the risk of
second primary melanoma is approximately 5% creating uncertainty about
whether at least some of these late onset tumors might be independent of the
original lesion. Secondly, in the majority of cases, the original pathology
specimen is no longer available for comparative analysis. Accordingly, pu-
tative late recurrences are diffıcult to unambiguously distinguish from a new
primary melanoma. We identifıed a patient with a second melanoma diag-
nosed after a 30 year disease-free interval, and sought to determine if this
new lesion was a recurrence of the original melanoma. We report the
genomic sequence analysis of the exomes of two melanoma lesions isolated
from the same individual in 1985 and 2015, and their comparison to each
other and to the germline DNA of the patient. Identifıcation of many shared
somatic mutations between these lesions prove a lineal relationship span-
ning 30 years. Unlike prior reports of ultra-late melanoma recurrence, the
availability of the original tumor and the use of comprehensive genomic
analysis allowed us to confırm that the second lesion is truly a recurrence.We
demonstrate the acquisition of numerous additional mutations during the
three decade asymptomatic period. This is, to our knowledge, the longest
disease-free interval that has been rigorously confırmed in melanoma or any
other solid tumor type. These data highlight the low but very long-lasting
risk of recurrence in this patient population.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Genotype-Phenotype Associations
#3400 Progression of epidermal growth factor receptor (EGFR)-indepen-
dent colorectal cancer.CarolinaMantilla Rojas,1 YuMing,2 David Threadgill1.
1Texas A&M Univ., College Station, TX; 2University of North Carolina, Chapel
Hill, NC.
When combined with standard of care treatment for colorectal cancer
(CRC), the use of monoclonal antibodies or small molecule inhibitors
against epidermal growth factor receptor (EGFR) show modest effıcacy in
the clinic. Early detection efforts and more effective therapies have reduced
mortality, yet CRC remains the second mostly deadly cancer in the United
States with approximately 50,000 deaths expected this year. Thus, it is im-
perative to better understand the mechanisms governing molecular progres-
sion of CRC. Primary and secondary resistance to anti-EGFR therapies oc-
curs in approximately 80% of the patients with CRC. Mutations in Kras
explain some non-responding CRCs, but even in cancers lacking Kras mu-
tations, little is known about which cancers are likely to respond to EGFR
targeted treatment, suggesting an alternative and EGFR-independent CRC
progression mechanism. In this study, we used a conditional Egfr allele
(Egfrf) within the ApcMin/mouse model and identifıed EGFR-independent
tumors with faster growth rates than those developing in EGFR-wild type
mice. To assess aggressiveness of EGFR-independent tumors, we used a
metastatic CRC mouse model containing conditionally inactivated Apc al-
leles (Apcf/f) in combination with a conditionally active allele of Kras
(KrasLSL-G12D). It has been reported that delivery of Cre recombinase-ex-
pressing adenovirus to the distal colon of these mice results in tumors that
progress to carcinoma within 20 weeks, and liver metastases develop in
approximately 20% of mice at 24 weeks. We discovered a 10% increase in the
penetrance of tumors arising in the absence of EGFR (Egfrf/f, Apcf/f, KrasLSL-
G12D/). Endoscopic analysis suggests an increase in tumor multiplicity in
EGFR-defıcient tumors when compared with tumors developing in EGFR-
wild-type mice. Biweekly colonoscopies confırmed that colonic tumors have
a faster growth rate in the absence of EGFR. High-frequency abdominal
ultrasound suggests liver metastasis at 16 weeks in 20% of mice lacking
EGFR. These fındings demonstrate the existence of an EGFR-independent
mechanism by which CRC can arise and progress. Moreover, tumors lacking
EGFR grow larger than those developing under normal EGFR activity and
may be a more aggressive form of CRC. We also have evidence that ERBB3
and ERBB4, related EGFRs, mediate compensatory and alternative path-
ways, suggesting an important role for these receptors in the progression of
EGFR-independent CRC. This study will advance our understanding of
ERBB family biology during colonic tumorigenesis, ultimately contributing
to better therapies for CRC.
#3401 Role of membrane-associated guanylate kinase inverted 2 in ad-
vanced and castration-resistant prostate cancers. Bao Le, Kimberly Hammer,
Katya Frantskevich, Irene Ong,Wei Huang, Paul Marker.University of Wiscon-
sin-Madison, Madison, WI.
Background: Prostate cancer is the most common non-cutaneous malig-
nancy for men in the U.S. Patients with advanced and/or metastatic prostate
cancer are commonly treated with androgen deprivation therapy. Unfortu-
nately, incurable castration resistant prostate cancer commonly develops 2-3
years after initial treatment. Methods: To identify candidate cancer genes
involved in the development of castration resistance, the Sleeping Beauty
(SB) transposon system and androgen-sensitive LNCaP cell line were used in
a forward mutagenesis screen designed to model the transition from andro-
gen sensitive to androgen insensitive prostate cancer. MAGI-2 was identifıed
in the screen as a common insertion site gene, potentially involved in the
transition to androgen independence. Clinical signifıcance of MAGI-2 in
prostate cancer was further supported by human TCGA data. Functional
assays were used to confırm the involvement of MAGI-2 in prostate cancer
progression. Results: MAGI-2 expression was prognostic for patient survival
outcome. Ectopic expression of MAGI-2 in 22Rv1 cells resulted in a decrease
in cell proliferation and colony formation in in vitro studies. At the molec-
ular level, overexpression of MAGI2 induced a suppression of known andro-
gen responsive genes. MAGI-2 overexpression also limited the growth of
grafts compared to empty vector grafts in in vivo xenograft models. Conclu-
sion: MAGI-2 was identifıed in a forward mutagenesis screen modeling the
development of castration resistant prostate cancer. Human protein expres-
sion data from patient tissues supported a possible role for MAGI-2 in pros-
tate cancer. Functional studies confırmed the potential involvement of MA-
GI-2 in prostate cancer progression. Future studies are seeking to elucidate
the functional role andmechanism-of-action forMAGI-2 in prostate cancer.
Ultimately, this may identify MAGI-2-regulated signaling pathways as ther-
apeutic targets for prostate cancer.
#3402 The impact of germline single nucleotide polymorphisms (SNPs) in
ERBB-family genes and genes associated with homologous recombination
defıciency (HRD) on response to taxotere, platinumand trastuzumab (TCH)
based therapy in the treatment of HER2-positive breast cancer patients. Ste-
phen F. Madden,1 Sinead Toomey,1 Simon Furney,2 Malgorzata Milewska,1 Jo-
anna Fay,1 ElaineW. Kay,1 John Crown,3 Susan Kennedy,3 Bryan T. Hennessy,1
Alex J. Eustace1. 1Royal College of Surgeons in Ireland, Dublin, Ireland; 2Univer-
sity College Dublin, Dublin, Ireland; 3St Vincent’s University Hospital, Dublin,
Ireland.
BACKGROUND: We have shown that ERBB (EGFR, ERBB2, ERBB and
ERBB4) germline single nucleotide polymorphisms (SNPs) have a negative im-
pact on the outcome of trastuzumab treated HER2-positive breast cancer (BC)
patients. Currently TCH (taxotere, platinum and trastuzumab) based therapy is
used to treat early stage HER2-positive BC. We investigate the importance of
germline SNPs in ERBB genes and those genes involved in homologous recom-
bination defıciency (HRD), on how patients respond to TCH therapy. PA-
TIENTS AND METHODS: ERBB/HRD SNPs were identifıed in a panel of 32
HER2-positive BC patients by next generation sequencing (NGS). Agena Mas-
sArray analysis confırmed the genotype of these SNPs in a further 157 women.
Kaplan-Meier estimates and Cox regression analysis identifıed that both ERBB/
HRD SNPs were associated with relapse free survival (RFS) in patients who
received a TCH based treatment versus those who received alternate therapies.
Protein extracted from formalin fıxed paraffın embedded tumours (n60), was
run on an RPPA platform to measure expression and phosphorylation of pro-
teins (69 antibodies). Logistical regression identifıed protein levels associated
with the presence/absence of ERBB/HRD SNPs that were signifıcantly associ-
ated with RFS. RESULTS: Ten ERBB/HRD SNPs were profıled in 157 trastu-
zumab treated HER2-positive BC patients. The minor alleles of the ERBB2
(rs1136201), ERBB3 (rs2229046) and BARD1 (rs2070096) SNPs signifıcantly
associatedwith aworseRFS in patientswho receivedTCHbased therapy relative
to those who had the reference allele (ERBB2: HR2.67 (CI1.05-6.78),
p0.04; ERBB3 rs2229046: HR4.95 (CI1.91-12.79), p9.75x10-4; BARD1:
HR3.27 (CI 1.16-9.17), p0.02). The impact of ERBB/HRD SNPs on RFS
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was not observed in patients who did not receive TCH treatment. The minor
allele of the RNF8 rs2284922 SNP is associated with a worse RFS (RNF8:
HR12.42 (CI2.00-77.19), p6.89x10-3) relative to those who had the refer-
ence allele only in patients who did not receive TCH treatment. RPPA analysis
identifıed that patients who received TCH therapy and had the minor allele of
the ERBB3 SNPs were signifıcantly associated with the expression of HER2, p27
and MEK1/2 (rs2229046; minor allele associated with low expression of p27
(p7.22103) and with high expression of HER2 (p6.5310-3); rs773123,
minor allele associatedwith low expression of p27 (p5.3810-4) andwith high
expression of MEK1/2 (p6.24x10-3). CONCLUSIONS: The presence of germ-
line ERBB/HRD SNPs may play an important role in how a patient responds to
TCH based therapy, and clinical assessment of these SNPs by targeted genetic
screening of patients’ blood may allow for stratifıcation of patients prior to
treatment.
#3403 Telomere shortening in pancreatic cancer is correlated to KRAS
mutation.YokoMatsuda,1 Naotaka Izumiyama,1Mutsunori Fujiwara,2 Naoshi
Ishikawa,1 JunkoAida,1 Kaiyo Takubo,1 Toshiyuki Ishiwata,1 TomioArai1. 1To-
kyo Metropolitan Geriatric Hospital & Inst. of Gerontology, Tokyo, Japan; 2Jap-
anese Red Cross Medical Center, Tokyo, Japan.
Background: Pancreatic cancer is characterized by genomic complexity
and chromosomal instability, and atypical mitotic fıgures are morphological
features of this phenotype. Previously we have reported that approximately
30% of total mitosis in pancreatic cancer was atypical including multipolar,
lag-type, ring and asymmetrical mitosis, and anaphase bridges, and the num-
ber of total mitosis and atypical mitosis in pancreatic cancers was correlated
with aggressive phenotype and prognosis (Pancreatology, 2016). In the pres-
ent study, we clarifıed the relation between atypical mitotic fıgures, telomere
length, and genetic abnormality in the pancreatic cancer. Methods: We sur-
veyed the mitotic fıgures of the normal epithelium, pancreatic intraepithelial
neoplasias (PanINs), and pancreatic cancers using surgically resected pan-
creatic cancer specimens (n40). Telomere length was analyzed using quan-
titative fluorescent in situ hybridization technique. We also analyzed muta-
tions of Kras codon 12 and 13 by PCR and microsatellite instability by
immunohistochemical staining of MLH1, MSH2, MSH6 and PMS2. Results:
Pancreatic cancer and duodenal epithelium showed signifıcantly higher mi-
totic indices as compared with the duct, acinar cells, and PanINs. Normal
mitosis was also higher in pancreatic cancers and the duodenal epithelium,
while atypical mitosis was signifıcantly elevated only in pancreatic cancers.
Number of total mitosis and atypical mitosis were negatively correlated with
telomere length, suggesting that telomere shortening plays important roles
in cancer proliferation and chromosomal instability. In comparison with
normal ducts, telomere length was decreased in PanIN-1, -2 and -3 and
cancer. Furthermore, telomere length was gradually shorter among PanIN
grades. Most of pancreatic cancers harbored mutations in Kras codon 12,
and pancreatic cancer cases with Kras mutation showed shorter telomere
length as compared with cases without Kras mutation. All pancreatic cancer
cases in the present study were microsatellite stable. Conclusion: Our data
strongly suggest that telomere shortening occurs in the early stages of pan-
creatic carcinogenesis and progresses with precancerous development. Telo-
mere shortening and chromosomal instability in the duct epithelium plays
key roles on carcinogenesis of the pancreas.
#3404 Loss ofAbi1 abrogates lungmetastasis in thePyMTmousemodel of
breast cancer. Angelina Regua,1 Isabelle Bichindaritz,2 Tiffany Caza,1 Julie
White,3 Robert Adamiecki,1 Mira Krendel,1 Gennady Bratslavsky,1 Leszek
Kotula1. 1Upstate Medical University, Syracuse, NY; 2SUNY Oswego, Oswego,
NY; 3Memorial Sloan-Kettering Cancer Center, New York, NY.
This study aims to elucidate the role of Abelson interactor 1 (Abi1), a key
protein in the WAVE regulatory complex, in mammary carcinogenesis and
metastasis. Breast cancer is the second-leading cause of mortality in women
in the United States with an estimated 200,000 new cases and over 40,000
deaths this year. Despite current treatment modalities, breast cancer patients
often relapse after only a few years of treatment thus emphasizing the need
for better therapeutic targets. Abi1 is an adaptor protein mainly associated
with the WAVE (Wiscott-Aldrich syndrome protein family verprolin ho-
mologous) regulatory complex and Arp2/3 (Actin-related proteins 2 and
3)-mediated actin cytoskeleton remodeling. Our bioinformatic and gene ex-
pression analyses of human tumor data indicates that Abi1 is frequently
upregulated in invasive breast cancers, is associated with poor survival, and
may promote an aggressive breast tumor phenotype. Downregulation of
Abi1 also abrogates motility and invasion of breast cancer cells, most likely
through inactivation of both Src and PI3 kinase as well as certain matrix
metalloproteases. We therefore hypothesize that Abi1 positively regulates
breast tumor progression and invasion through dysregulation of these cell
signaling pathways. To determine the role of Abi1 in breast tumor progres-
sion, we used a Cre-lox system to conditionally delete Abi1 in the mammary
tissue of PolyomaMiddle T (PyMT) breast cancer mice. Abi1 knockout (KO)
and control mice were palpated bi-weekly to determine tumor latency and
tumors were measured with a caliper to determine total tumor burden. We
are currently analyzing changes in tumor kinetics as a result of conditional
Abi1 knockout in the mammary epithelium of PyMT mice. Our preliminary
studies of indicate slowed tumor growth in Abi1 KO PyMT mice. Western
blot analyses of Abi1 KO mammary tumors indicate concomitant loss of
WAVE complex proteins supporting our previous fındings thatWAVE com-
plex integrity is dependent on Abi1. Most interestingly, Abi1 null PyMT
mice exhibit signifıcantly reduced incidence of lung metastasis, supporting
our hypothesis that Abi1 promotes invasion by breast cancer cells. In sum-
mary, Abi1 loss leads to reduction of lung metastasis in PyMTmice, possibly
through inactivation of key cell signaling and proliferation pathways such as
Src and PI3 kinase. This work will establish Abi1 as a potential prognostic
marker and therapeutic target in metastatic breast cancer.
#3405 Screening for two recurrent BRCA1mutations in Tunisian women
with triple negative breast cancer.Wijden Mahfoudh,1 Inchirah Bettaib,1 Sal-
louha Gabbouj,1 Noureddine Bouaouina,2 Lotfı Chouchane,3 Abdelfattah
Zakhama1. 1Faculty of Medicine of Monastir, Monastir, Tunisia; 2Department of
Radiation Oncology, CHU Farhat Hached, Sousse, Tunisia; 3Department of Ge-
netic Medicine, Weill Cornell Medical College, Doha, Qatar.
Triple-negative breast cancers (TNBC) lack expression of oestrogen, pro-
gesterone and HER2 receptors. Reports to date indicate that up to 20 % of
TNBC patients harbour germline BRCAmutations; however, the prevalence
of mutations may vary with ethnic group and with geographic region. In the
Tunisian population, as yet a limited number of BRCA germline mutations
have been reported. Tow recurrent mutations were found in exon 5 and 20 in
BRCA1 gene (c.211dupA and c.5266dupC). To investigate the contribution
of BRCA1 gene mutations to TNBC in Tunisia, we screened the exons 5 and
20 of BRCA1 gene in 20 TNBC patients by direct sequencing. In our study,
we identifıed the c.5266dupC mutation in BRCA1 exon 20 in 2 of 20 triple-
negative patients with a prevalence of 10%. Our study is the fırst investiga-
tion on the role of BRCA1 gene in TNBC in Tunisia. In this study, we show
that targeting only the exon 20 in BRCA1 gene allows detection of a substan-
tial percentage of mutations in Tunisian TNBC patients.
#3406 Hereditary risks ofmale breast cancer in amulti-gene panel testing
cohort. Elizabeth C. Chao,1 Mary Pritzlaff,2 Summerour Pia,2 Rachel McFar-
land,3 Shuwei Li,2 Jill Dolinsky,2 David Goldgar,4 Hermela Shimelis,5 Fergus
Couch,5 LaDuca Holly2. 1UC Irvine, Newport Beach, CA; 2Ambry Genetics, Aliso
Viejo, CA; 3UC Irvine, Irvine, CA; 4University of Utah, Newport Beach, CA;
5Mayo Clinic, Rochester, MN.
While the population-based risk for breast cancer in males remains rela-
tively low (1:1000), inherited predisposition can signifıcantly raise this to as
high as 10%, in men who carry a mutation in the BRCA2 gene. Lifetime
breast cancer risks of 1-2% have also been reported in men who carry a
mutation in BRCA1. These risks, as well as elevated risks of prostate, pan-
creatic, and melanoma cancers, are important to discuss in families diag-
nosed with Hereditary Breast and Ovarian Cancer Syndrome, which is often
viewed as being clinically relevant only to the women in an affected family.
However, beyond the BRCA1/2 genes, limited data is available on hereditary
predisposition to male breast cancer. We analyzed clinical histories and
molecular results from multi-gene panel testing for hereditary cancer pre-
disposition in a cohort of 715 men affected by breast cancer. A total of 708
male breast cancer patients were eligible for inclusion in the fınal analysis.
Molecular testing included analysis of 5 to 59 genes for DNA coding se-
quence and copy number variants by next-generation sequencing and mi-
croarray. Genetic variants identifıed were classifıed according to a 5-tier
system using previously validated algorithms1,2. Only those variants classi-
fıed as pathogenic or likely pathogenic were included in the analyses as
positive for a mutation. Overall, a mutation was detected in 18% of these
men. Four subjects carried a mutation in two different breast cancer predis-
position genes. BRCA2 and CHEK2 were the most frequently mutated genes.
The risk of breast cancer was signifıcantly elevated compared to public con-
trols in individuals with a mutation in BRCA2 (odds ratio (OR)13.9;
p1.92x10-16), CHEK2 (OR3.8; p6.24x10-24) and PALB2 (OR6.6,
p0.01). Average age was similar amongst men with (63.5	2.7 years) and
without (62.3	1.2 years) mutations, as were clinical and family histories of
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additional cancers. The high overall diagnostic yield suggests the utility of
testing all male breast cancer patient regardless of age or family history by
multigene panel testing, and provides data to support risk-based counseling
and medical recommendations for screening and/or prevention in male mu-
tation carriers. 1. 1. LaDuca et al. Genet Med. 2014 Nov;16(11):830-7 2. 2.
Richards et al. Genet Med. 2015 May;17(5):405-24
#3407 Side effects of BRAF inhibitors mimic RASopathies. Alicia Sfecci,1
Alain Dupuy,2 Monica Dinulescu,1 Catherine Droitcourt,1 Henri Adamski,1
Smail Hadj-Rabia,3 Sylvie Odent,4 Marie-Dominique Galibert,4 Lise Bous-
semart4. 1CHU de Rennes, Rennes, France; 2Rennes 1 University, Rennes, France;
3Hôpital Universitaire Necker-Enfants malades, Paris, France; 4Université de
Rennes 1, Rennes, France.
Recent advances in targeted anticancer therapies have substantially im-
proved the prognosis of several cancers but they are not free of side effects.
These side effects are, however, clearly distinct from those induced by clas-
sical cytotoxic chemotherapies, likely because targeted therapies are de-
signed to interfere with specifıc oncogenic signaling pathways and not to
inhibit cell proliferation in general.We, therefore, evaluated whether specifıc
side effects of BRAF inhibitor therapies would resemble symptoms seen in
patients with RASopathies, in which the MAPK pathway is affected and
which includes Costello, Noonan and Cardio-Facio-Cutaneous syndromes.
To this end, we collected a cohort of 18 patients with genetically confırmed
RASopathies that were followed between 2012 and 2016 at the University
Hospital of Rennes, France and that were evaluated based on their personal
medical history and a clinical examination. Strikingly, RASopathy patients,
particularly those with Cardio-Facio-Cutaneous syndrome, showed symp-
toms resembling those that we and others have previously seen in genetically
characterized patients undergoing BRAF inhibitor treatment. These symp-
toms included keratosis pilaris, wavy hair, sparse eyelashes/eyebrows, poor
hair growth, palmo-plantar hyperkeratosis in areas of pressure, verrucous
papillomas, nevi efflorescence, and increased cancer risk. Nevertheless,
BRAF-inhibitor treatment can also lead to side effects not typically found in
patients with RASopathies, including acneiform dermatitis and vemu-
rafenib-specifıc phototoxicity, which may even increase under a combined
BRAF/MEK inhibition. These results suggest that the side effects of BRAF
inhibition that are similar to symptoms in patients with RASopathies are due
to direct targeting of the MAPK pathway in BRAF-non-mutated (wild type)
cells while those that are dissimilar represent off-target effects that do not
affect the MAPK pathway. We hope that this type of comparative analysis
may lead to a better understanding of the multiple effects of targeted thera-
pies and perhaps prompt modifıcations in the targeted therapy approach to
minimize these side effects.
#3408 Telomere length and TERT promotermutations in cutaneousmel-
anoma. Sivaramakirishna Rachakonda,1 Barbara Heidenreich,1 Eduardo
Nagore,2 Rajiv Kumar1. 1GermanCancer Research Center, Heidelberg, Germany;
2Instituto Valenciano de Oncologia, Valencia, Spain.
Telomeres at chromosomal ends are comprised of multiple short repeat
sequences. In humans TTAGGG repeats account for telomere length ranging
10-15 kb. Telomere sequences are mainly double stranded that end in a
single stranded G-rich tail of 150-200 nucleotides. Telomeres in somatic cells
undergo gradual shortening due to inherent limitations of DNA replication
and limited levels of specialized enzyme telomerase that adds the repeats at
chromosomal ends to maintain homeostasis. We previously reported so-
matic mutations in the core promoter of the telomerase reverse transcriptase
(TERT) gene that lead to increased transcription of catalytic subunit and
tumor specifıc telomerase reactivation. Telomere length per se is associated
with risk in different cancers. In this study, we measured leukocyte telomere
length using real-time PCR in 1469 melanoma patients and compared with
that in 1158 matched healthy controls. The melanoma patients had statisti-
cally signifıcantly longer telomeres than matched controls (t-test; P 6X10^-
10). Mendelian randomization, carried out using two polymorphisms rep-
resented by rs1317082 and rs7726159 that associated with telomere length in
genome wide association studies, showed association between increased
telomere length and melanoma risk with an odds ratio of 2.3 (95% confı-
dence interval 1.8-2.8). When measured in blood tissues from a melanoma
family with the germline -57AC TERT promoter mutation, the carriers
had longer telomeres (median 1.12) than the non-carriers (median 0.87).
The TERT promoter mutations create binding motifs for E-twenty six (ETS)
transcription factors and in stem cell the presence of the promoter mutations
resulted in continued TERT expression and telomerase activity following
differentiation into adult cells. Individuals with the germline TERT pro-
moter mutations develop melanoma with an early age of onset and rapid
progression to metastases; two individuals in the family who lived past me-
dian age of onset developed several other malignancies, besides melanoma.
Thus, dysregulated telomerase leads to a severe phenotype. In an analogy, we
hypothesize that association of longer rather than shorter telomeres with an
increased risk of melanoma reflects stochastic increased telomerase levels
due to common genetic variation. In contrast, the telomere length was
shorter in tumors from unrelated melanoma patients with (121) than with-
out (170) somatic TERT promoter mutations (P 1X10^-5), which reflects the
selection of the mutations at telomere crisis. Thus, a dynamic but controlled
system evolved around telomere homeostasis when dysregulated leads to an
increased cancer risk and affects tumor progression.
#3409 Age of cancer onset differentiated by sex andTP53 codon change in
Li-Fraumeni Syndrome patient population. Lauren Erdman,1 Ben Brew,2 Ja-
sonBerman,3AdamShlien,1AndreaDoria,1DavidMalkin,1AnnaGoldenberg1.
1University of Toronto/Hospital for Sick Children, TORONTO,Ontario, Canada;
2Hospital for Sick Children, TORONTO, Ontario, Canada; 3Dalhousie Universi-
ty/IWK Health Centre, TORONTO, Nova Scotia, Canada.
Introduction:Li-Fraumeni Syndrome (LFS) is a highly penetrant auto-
somal dominantly inherited cancer predisposition disorder. Germline mu-
tations of the TP53 tumor suppressor gene cause80% of LFS and confer an
increased risk of a range of early onset cancers, as well as of second tumors
even in the absence of a family history of cancer. For this reason, we previ-
ously reported the implementation of a comprehensive life-long clinical sur-
veillance protocol for individuals with a germline TP53 mutation for early
tumor detection. Here, we set out to build a predictive model of age of onset
of cancer in LFS patients to inform this screening protocol aiming to make it
more targeted. We identify characteristics that differentiate the age of cancer
onset consistently, across multiple LFS patient cohorts. Methods:The LFS
cohort at Toronto’s Hospital for Sick Children (SickKids) (n 171 patients)
was used as a discovery set to identify factors that distinguish age of onset
among LFS patients. This project focused specifıcally on patient character-
istics such as sex and mutations within TP53, both as they appear on the
genome and manifest in the protein, as predictors for age of onset. These
predictors were tested in an exponential parametric survival model. Findings
from the SickKids discovery set were tested for replication in the Interna-
tional Agency for Research on Cancer (IARC) TP53 database (n  2374
patients). Results:In the discovery cohort, female sex was associated with a
1.53 fold later age of cancer onset than in males (p  0.019). This did not
replicate in the IARC TP53 set with 0.99 fold earlier onset for females than
males (p 0.843). However, in the discovery set, there appears to be a point
at which female and male age of onset converges at 43 years. Controlling for
onset before vs after 43 years in our replication set shows 1.12 (p 0.0204)
times later age of cancer onset in females than in males which is the same
direction and signifıcance as in our discovery set. The discovery cohort also
showed 2.23 (p  0.08) later cancer onset for individuals with a germline
Arginine to Cysteine (ArgCys) codon change (model signifıcance p 
0.047). This fınding replicated in the IARC TP53 data set which showed
individuals with an ArgCys codon change having onset 1.29 (p  0.043)
times later than those with a TP53 mutation that did not result in this codon
change. Conclusions:Our study identifıed two LFS patient characteristics,
sex and TP53 ArgCys codon change, which consistently differentiate age of
cancer onset within the LFS patient population. Females under the age of 43
when compared to males under the age of 43 appear to have later tumor
onset, an effect which disappears after the age of 43. Individuals with an
ArgCys TP53 codon change are expected to have later onset cancer than
those with TP53mutations that do not result in this change. Future work will
disentangle these fındings further and build a more comprehensive predic-
tive model of cancer onset in LFS patients.
#3410 Phenotypic characterization of allelic variation within the HEAT
repeats of the mechanistic target of rapamycin. Patricia A. Wiley,1 Joy Gary,2
ZawPhyo,1 ShulingZhang,1Amanda Sciorillo,3DorianFraizer4. 1NationalCan-
cer Institute, Bethesda, MD; 2Center for Disease Control and Prevention, GA;
3Marymount University, Arlington, VA; 4University of Maryland, Balitimore
County, Baltimore, MD.
The mammalian target of rapamycin (mTOR), a protein in the phospho-
inositide 3-kinase (PI3K) pathway important to cell cycle regulation, is fre-
quently activated in cancer. This signaling pathway regulates cell growth and
metabolism, and when dysregulated in cancer, it contributes to tumor an-
giogenesis and growth. mTOR contains two distinct complexes, MTORC1,
and MTORC2. MTORC1 plays a role in biosynthesis, while MTORC2 helps
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with cellular metabolism. It has been shown that mTOR knockout models
are embryonically lethal to mice. However, lower levels of functional mTOR
have been shown to be benefıcial and slow cancer progression. Allelic vari-
ation occurs within inbred strains of mice, including BALB/c mice. One
allelic variant in mTOR, R628C, which contributes to tumor susceptibility
has been identifıed in BALB/c mice. This single amino acid change occurs in
the HEAT repeats of mTOR. HEAT repeats have been shown to facilitate
binding partner interactions, dimerization, and localization. Studies on mu-
tations found within the HEAT repeats in several proteins have altered pro-
tein function and emphasize the structural importance of HEAT repeats. The
goal of this study is to further elucidate the functional signifıcance of HEAT
repeats in TOR function and how allelic variation in the HEAT repeats may
contribute to tumor susceptibility. Characterization of this allelic variant has
shown stress inputs, such as irradiation, lead to a more severe phenotype and
reduced mTORC1/2 signaling. Subsequent in vitro studies using a tetracy-
cline inducible expression system (T-RExTM) have shown differential bind-
ing to mTORC1/2 complex partners in cells expressing the Balb/c allele.
Additional studies are being performed to assess other complex binding
partners, dimerization state and localization of the allelic variant. Our fınd-
ings will model mTOR signaling activation mechanisms in humans to aid in
development of new cancer treatments.
#3411 Rare BRCA2 K3326X increases susceptibility to sporadic pancre-
atic ductal adenocarcinoma: a PANDoRA study. Ofure M. Obazee,1 Gabriele
Capurso,2 Angelo Andriulli,3 Pavel Soucek,4 Ewa Małecka- Panas,5 Juozas
Kupcinskas,6 Rudolf Kaaks,7 Maria Gazouli,8 Thilo Hackert,9 Aldo Scarpa,10
Giulia M. Cavestro,11 Claudio Pasquali,12 Hermann Brenner,13 Daniele
Campa,14 Raffaele Pezzilli,15 AndreaMambrini,16 BeatriceMohelnikova-Duch-
onova,17 Ugo Boggi,18 Jakob Izbicki,19 Pavel Vodicka,20 Elzbieta Iskierka-
Jazdzewska,21 Federico Canzian1. 1German Cancer Research Centre (DKFZ),
Heidelberg, Germany; 2Digestive and Liver Disease Unit, Pancreatic Disorders
Clinic, S. Andrea Hospital, University Sapienza, Rome, Italy; 3Division of Gastro-
enterology and Research Laboratory, Department of Oncology, IRCCS Scientifıc
Institute and Regional General Hospital “Casa Sollievo della Sofferenza”, San
Giovanni Rotondo, Italy; 4Laboratory of Pharmacogenomics, Biomedical Centre,
Faculty ofMedicine in Plzen, Charles University in Prague, Plzen, Czech Republic;
5Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Po-
land; 6Department of Gastroenterology, LithuanianUniversity ofHealth Sciences,
Kaunas, Lithuania; 7GermanCancer Research Centre (DKFZ), Division of cancer
epidemiology, Heidelberg, Germany; 8Department of BasicMedical Sciences, Lab-
oratory of Biology, Medical School National and Kapodistrian University of Ath-
ens, Michalakopoulou 176, Athens, Greece; 9Klinik für Allgemein-, Viszeral- und
Transplantationschirurgie, Im Neuenheimer Feld 110, Heidelberg, Germany;
10ARC-Net, Applied Research on Cancer Centre, University of Verona, Verona,
Italy; 11Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San
Raffaele University, IRCCS San Raffaele Scientifıc Institute, Milan, Italy; 12De-
partment of Surgery, Oncology and Gastroenterology -DiSCOG, University of
Padova, Padova, Italy; 13Division of Clinical Epidemiology and Aging Research,
German Cancer Research Centre (DKFZ), Heidelberg, Germany; 14Dipartimento
di Biologia, Università di Pisa, Pisa, Italy; 15Pancreas Unit, Department of Diges-
tive System, Sant’Orsola-Malpighi Hospital, Bologna, Italy; 16Massa Carrara On-
cological Department, Azienda USL Toscana Nord Ovest, Carrara, Italy; 17De-
partment of Oncology, Palacky University Olomouc and University Hospital
Olomouc, Olomouc, Czech Republic; 18Division of General and Transplant Sur-
gery, Pisa University Hospital, Pisa, Italy; 19Department of General-, Visceral-
and Thoracic-Surgery, University Medical Center, Hamburg, Germany; 20Insti-
tute of ExperimentalMedicine, CzechAcademy of Science, Prague and Institute of
Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prague,
Czech Republic; 21Department of Hematology, Medical University of Lodz, Po-
land, Lodz, Poland.
Background: The incredibly poor outlook of pancreatic cancer patients under-
scores an urgent need for early diagnostic markers. Pancreatic cancer ranks third
most-frequent among BRCA1/2-defıcient cancers with germline mutations de-
tected in10%of sporadic cases.Germlinevariants inbreast cancer tumorsuppres-
sor BRCA2 have been reported to increase predisposition to several cancers includ-
ing pancreatic tumors. Rare K3326X (rs11571833, c.9976AT) which introduces a
premature stopcodon thus truncating theprotein,haspreviouslybeen implicated in
familial PDAC, but not in sporadic cases. A frameshift pathogenic mutation
c.6503delTT (rs11571658, p.Leu2092Profs) reported to occur in tandem with
K3326X in breast and ovarian cancer families, has also been speculated to influence
risk associations due to linkage disequilibrium between both variants. Method and
results: K3326X was genotyped in 2,969 sporadic cases and 4,700 controls using
Taqman chemistry and fıdelity of genotypes assessed based on concordance of in-
ternal replicates and negative controls. K3326X was observed in 1.2% of cases and
0.8% of controls. Odds ratios (ORs) and associated 95% confıdence intervals (CIs)
were estimated by multivariate unconditional logistic regression with adjustment
for age, sex and regionoforigin.Wealsoperformeda stratifıed analysis basedonage
at diagnosis to estimate the risk association between K3326X and early-onset pan-
creatic cancer. To rule out the likely shared effect of the c.6503delTT mutation on
sporadic PDACrisk,we also sequencedDNAfromcarriers ofK3326X in this study.
We found K3326X to be associated with increased risk of developing sporadic
PDAC ((OR 1.71, 95% CI 1.18 - 2.49), P 0.005). This risk was considerably
higher among cases aged 50 years and younger (OR 2.13, 95% CI 1.10 - 4.11,
P 0.03). Furthermore, carriers of K3326X did not bear the c.6503delTTmutation
thus confırming that the observed risk effect was not influenced by the latter. Con-
clusion: These robust associations implicate K3326X in the etiology of sporadic and
early-onset PDAC, and thereforewarrant replication aswell as functional studies to
elucidate the role of K3326X in DNA repair mechanisms.
#3412 Functional knockout of ATRX or DAXX permits the alternative
lengtheningof telomeres (ALT)mechanism inprostate cancer cells.MindyK.
Graham. Johns Hopkins School of Medicine, Baltimore, MD.
A key hallmark of cancer is unlimited replication, which requires cancer cells
to evade replicative senescence induced by short telomeres. The majority of
cancers overcome this critical replication barrier by upregulating the telomerase
enzyme, a telomere-specifıc reverse transcriptase. However, a subset of cancers
lack telomerase, and telomeres are maintained by employing the Alternative
Lengthening of Telomeres (ALT) pathway, which is dependent on homologous
recombination. Across a variety of tumor types, our laboratory and others have
reported a robust correlation between ALT and recurrent cancer-associated so-
matic inactivating mutations in the ATRX-DAXX chromatin remodeling com-
plex. In a previous comprehensive cancer survey of ALT, we reported that ALT
was highly prevalent in some tumor types (e.g. astrocytomas, sarcomas, pancre-
atic neuroendocrine tumors), but we did not observe any ALT-positive primary
prostate cancer (out of 1,176 analyzed). However, we subsequently found a
subset ofmetastatic prostate cancers that harborALT, suggesting thatmutations
giving rise to ALT in this disease are unique to metastatic prostate cancer. Here,
we have created the fırst prostate cancer cell lines exhibiting ALT, with the
explicit purpose of molecularly characterizing ALT in prostate cancer and iden-
tifying promising therapeutic targets for men with ALT-positive lethal meta-
static prostate cancer. Inactivating mutations in either ATRX or DAXX using
the CRISPR/Cas9n system were introduced into the genetically well-character-
ized, telomerase-positive (ALT-negative) prostate cancer cell lines, LAPC-4 and
CWR22Rv1. Resulting mutant subclones were compared to their parental (or
empty vector) counterparts. In these new models, abolishing ATRX expression
was suffıcient to induce the ALT phenotype in both LAPC-4 and CWR22Rv1, as
assessed by multiple biomarkers of ALT, including the presence of bright telo-
meric FISH foci, ALT-associated PML bodies (ABPs), and extrachromosomal
telomere c-circles. Interestingly, abolishing DAXX expression induced ALT in
only a subset (3/5) of LAPC-4 DAXX KO clones, and a subset (4/19) of
CWR22Rv1DAXXKOclones.We have successfully activated theALT telomere
maintenance phenotype in two prostate cancer cell lines through CRISPR-me-
diated targeted gene deletion. We are currently utilizing these isogenic cell lines
to further characterize and elucidate the underlying biology of cancers harbor-
ing ALT, with the goal of pharmacologically targeting the molecular features
unique to the ALT phenotype (e.g. ATR inhibition). The identifıcation of ALT-
specifıc drugsmay pave the way for the development of new targeted treatments
for the subset of men with ALT-positive lethal metastatic prostate cancer, and
more broadly, other ALT-positive cancers. ALT is easily detected in clinical
tissue samples, and thus would serve as a predictive biomarker for personalized
medicine.
#3413 Identifıcation of a novel cancer predisposition variant associated
with risk of CMM and other cancers.Craig C. Teerlink,1 John G. Zone,1 Sancy
A. Leachman,2 Lisa A. Cannon-Albright1. 1Univ. of Utah Health Sciences Ctr.,
Salt Lake City, UT; 2Oregon Health and Science University, Portland, OR.
Introduction: In a search for the responsible CMM predisposition gene/vari-
ant, whole exome sequencing was performed on a pair of related CMM cases
(cousins) from an extended high-risk Utah CMMpedigree showing evidence of
linkage to chromosome band 1q41. Methods: Standard bioinformatics tools
were used to identify rare or novel variants shared in the 2 related CMMcases in
a CMMpedigree showing 1q41 linkage. Sanger sequencing and a Taqman assay
were used to confırm the original variants, and to confırm segregation of the
variant in other cancer-affected relatives. Taqman assay of the variant in inde-
pendent Utah CMM cases (n491) and controls (n207) was performed. Re-
sults: A novel variant in SLC30A10 (rs 550245711, Chr1q41:220091798 C-T
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(G-A -strand) SLC30A10: NM_018713: exon3:c.G757A:p.V253M) was shared
by the 2 related CMM cases (cousins) in the 1q41 linked pedigree. A combina-
tion of Sanger sequencing and Taqman assay in 5 additional related CMM cases
in the pedigree identifıed 4 who carried the variant. Two untested pedigree-
member parents of variant carriers (obligate carriers) were diagnosed with can-
cer of another site. A combination of Sanger sequencing andTaqman assay in 12
additional relatives diagnosed with cancers of other sites (small intestine, thy-
roid, breast, bladder, and endometrial) who ranged from closely (fırst degree), to
distantly (fıfth-degree), related to a carrier CMM case identifıed 4 additional
cancer-affected carriers (small intestine, breast, and endometrial cancers). None
of 491 independent CMM cases or 207 controls was observed to carry the vari-
ant. ExAc frequency for the variant in Non-Finnish Europeans 5/66,062. The
Cosmic ID is COSM3710592 and the variant has been confırmed as a somatic
mutation in an oral squamous cell carcinoma. The variant is predicted to be
damaging in 7 out of 8 algorithms considered, and has a GERP score of 6.08.
Conclusions: A novel variant in SLC30A10, an important and evolutionarily
conserved manganese and zinc transporter, was identifıed in a region of linkage
in an extended CMMhigh-risk pedigree. The variant is shared by 6 CMM cases,
2 stomach cancer cases, 1 small intestine cancer case, 2 breast cancer cases and 1
endometrial cancer case within a 5 generation pedigree originally studied for a
signifıcant excess of CMM. Functional validation studies are underway.
#3414 Novel MGMT variant association in Mexican patients with astro-
cytoma. Liliana Gomez-Flores-Ramos,1 Talia Wegman-Ostrosky2. 1Institute of
Biomedical Research, UNAM. National Cancer Institute, INCAN, Mexico City,
Mexico; 2National Cancer Institute, NIH, Bethesda, MD.
Introduction: Astrocytomas are the most common and lethal brain tumors
with amedian survival of 15months.Different biomarkers have arisen to classify
and treat this type of tumors; one of these markers is MGMT. The methylation
status of this gene is a prognostic and predictive factor. The MGMT (O-6-
Methylguanine-DNAMethyltransferase) is involved in the cellular response to
the effects of O6-methylguanine (O6-MeG) in DNA. Repairs alkylated guanine
in DNA by transferring the alkyl group at the O-6 position to a cysteine residue
in the enzyme. The dysregulation of this methylation is critical in the develop-
ment of certain cancers. Objective: To identify germinalMGMT gene variations
in patients with astrocytoma.Material andmethods: 55 randomly selectedMex-
ican patients diagnosedwith astrocytoma between 2008-2014were consented to
perform the molecular analysis of the whole gene and 5´UTR and 3´UTR re-
gions of MGMT at Ion Torrent platform. Each amplifıed region had a depth of
minimum 1500x. Ion Reporter software was used to analyze the genetic variants
and using Integrative Genomic Viewer we confırmed that each variant had a
Phred higher than 25. Genotypic frequencies were compared withHapMapMex
and Mexican ancestry population from the 1000 Genomes project. Results. In
lymphocytes DNA, eight genetic variants were found, and two of them were
statistically signifıcant risk factors: rs7896488 alternative allele A with a fre-
quency of 15% in patients with astrocytoma, and only 4% of the control group
(OR5.53, IC 1.96-15.59 p  0.0007) and rs2308326 ancestral allele C, where
93% of the patients were carriers of allele C in contrast with 73% of controls
(OR5.39, IC 2.29-12.69 p  0.000019). These variants are non-coding single
nucleotide polymorphisms, rs7896488 is a 3= UTR genetic variant, while
rs2308326 is an intronic variant. Conclusion:Our study found twonew risk SNV
for Astrocytoma in a Mexican population.
#3415 RNF43 somatic mutations in endometrioid ovarian cancers occur
in the setting of synchronous endometrioid endometrial cancers. Defne L.
Levine,1 Fanny Dao,2 Narciso Olvera,2 Katherine LaVigne,1 David B. Solit,1
Petar Jelinic2. 1Memorial Sloan Kettering Cancer Center, New York, NY; 2NYU
Perlmutter Cancer Center, New York, NY.
Introduction: Somatic frameshift mutations in RNF43 have previously been
fıltered out in cancer genome sequencing projects given that they occur in ho-
mopolymer tracts and resemble polymerase slippage errors. Two RNF43 hot-
spot mutations have been identifıed and validated in endometrioid endometrial
cancer (EEC) and appear to negatively regulateWnt signaling. These frameshift
mutations occur at codons R117 and G659. Due to shared clinical and morpho-
logic features of EEC and endometrioid ovarian cancer (EmOC), we determined
the frequency of RNF43 somatic mutations in EmOC. Methods: We reviewed
the clinical and pathologic features of EmOC samples diagnosed from 2006 to
2015, retrieved from laboratory databases and institutional archives. DNA was
extracted from formalin-fıxed, paraffın-embedded tumor samples using stan-
dard protocols. Sanger and next-generation sequencing (NGS) were used to
screen for hotspot mutations at codons R117 and G659 with custom designed
primers. NGS at each hotspot was coveredwith aminimum sequencing depth of
400X. Results: Forty-seven EmOCpatients with available tumor specimenswere
identifıed and included in the analysis. Themedian age at diagnosis was 55 years
old (range 34-84). The majority of patients had FIGO stage I or stage II disease
(n38, 81%). Thirteen (28%) patients had synchronous endometrial endo-
metrioid or mixed histology tumors. Two (4.3%) RNF43 somatic mutations at
codon G659 were identifıed in both Sanger and NGS from the EmOC tumor
specimens. No mutations at codon R117 were identifıed. The allele fractions of
the G659mutations were 4.3% and 2.8% seen in 33 and 18 reads with a coverage
of 775X and 646X, respectively. A review of pathology reports indicated that
both mutated samples had synchronous EECs. These twomutated samples rep-
resent 15.4% of cases diagnosed with synchronous EmOC and EEC in this co-
hort. Conclusions: RNF43 somatic mutations are uncommon in EmOCs and
associated with synchronous EECs. Recent massively parallel sequencing data
suggests that EmOCs in the setting of synchronous EECs are clonally related and
disseminated cells are related to nearby anatomic structures. Our data supports
that RNF43 somaticmutations inEmOCare clonally expanded fromEECs likely
through trans-tubal migration.
#3416 Clarifying the biological signifıcance of the CHK2 K373E somatic
mutation discovered in The Cancer Genome Atlas database. Masayoshi Hi-
gashiguchi,1 Izumi Nagatomo,1 Takashi Kijima,1 Osamu Morimura,1 Kotaro
Miyake,1 Toshiyuki Minami,2 Shohei Koyama,1 Haruhiko Hirata,1 Kota Iwa-
hori,1 Takayuki Takimoto,1 Yoshito Takeda,1 Hiroshi Kida,1 Atsushi Kumano-
goh1. 1Osaka University Graduate School of Medicine, Osaka, Japan; 2UC San
DiegoMoores Cancer Center and Sanford Consortium for RegenerativeMedicine,
University of California, San Diego, CA.
Identifıcation of somatic mutations that contribute to cancer development
leads not only to more precise understanding of cancer pathogenesis, but
also development of novel molecular targeted therapies. Analyses of cancer
genomes using high-throughput sequencing technology are currently con-
ducted as international collaborative research projects, and the results of
those analyses are deposited in public databases, allowing everyone in the
world to access to these data. To identify a somatic mutation that plays an
important role in cancer pathogenesis, we counted the occurrences of each
somatic mutation found in the TCGA lung adenocarcinoma dataset and
became interested in the CHK2 K373E mutation (c1117AG), which was
present in 31 of 542 patients. The K373E mutation impaired CHK2 auto-
phosphorylation at Thr383 and Ser516. In vitro kinase assay revealed that the
K373E mutation markedly attenuates CHK2 kinase activity. Growth curves
showed that wild-type CHK2 substantially suppressed cell proliferation, but
this effect was lost in the K373E mutant in HCT-15 harboring tetracycline-
inducible CHK2. Clonogenic assays revealed that wild-type CHK2 promoted
survival after ionizing radiation and this pro-survival function was impaired
in K373E CHK2. The results of western blotting and RT-PCR suggested that
the p53-independent induction of p21 by CHK2might underlie these effects.
Therefore, we identifıed a somatic mutation that contributes to cancer
pathogenesis, using information in a public database. This kind of attempt is
expected to lead to discovering new ’driver’ mutations in the future.
#3417 The impact of p53 codon 72 SNP upon aging and longevity in
mouse models. Yuhan Zhao, Lihua Wu, Xuetian Yue, Cen Zhang, Jun Li, Jian-
mingWang, Zhaohui Feng,Wenwei Hu. Rutgers Cancer Institute of New Jersey,
New Brunswick, NJ.
p53 has dual functions on longevity. p53 plays a crucial role in tumor
suppression to prevent early death due to cancer. However, it has been sug-
gested by animal models that constitutively increased p53 activity accelerates
the decline of stem/progenitor cells’ self-renewal function during aging pro-
cess, which leads to a reduced lifespan. In humans, the role of p53 in aging
and longevity has not been well established. As a haplo-insuffıcient gene, p53
is under the tight regulation in cells. Attenuation of p53 function contributes
greatly to tumorigenesis. p53 codon 72 single nucleotide polymorphism
(SNP) with either an arginine (R72) or a proline (P72) at codon 72 is a
naturally occurring common SNP that can influence the activity of p53. The
P72 allele is weaker than the R72 allele in inducing apoptosis and suppressing
cellular transformation. Individuals with the P72 allele have increased can-
cer risk compared to the R72 allele. However, it is unclear whether the
change of p53 activity in humans by functional SNPs could impact upon
longevity. A perspective study with an aging human population showed that
P72 allele is associated with longer survival despite its increased risk for
cancer development. These fındings strongly suggest that p53 activity is
reversely associated with aging, and SNPs in the p53 pathway could impact
upon the life span in humans. In this study, we employed a mouse model
system with knock-in of human p53 gene (Hupki) carrying either R72 or P72
SNP to investigate the impact of p53 codon 72 SNP upon longevity and its
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underlying mechanism. Mice with p53 P72 allele showed weaker transcrip-
tional activity than the R72 allele toward a subset of p53 target gene, suggest-
ing that these mice retain the function of p53 codon 72 SNP in human. We
found that although mice with p53 P72 have increased cancer risk compared
to mice with p53 R72, mice with p53 P72 that escaped tumor development
showed longer lifespan compared to mice with p53 R72 that do not develop
tumor. Mice with p53 P72 displayed a delay in aging process compared to
mice with p53 R72; mice with p53 P72 have slower reduction in bone density,
dermal thickness and wound healing ability during aging process. We com-
pared the effects of p53 codon 72 SNPs on stem cell population and function
as a possible mechanism that contributes to their difference in longevity.
Compared tomice with p53 R72, mice with p53 P72 allele have lower number
of long-term stem/progenitor cells and better self-renewal function during
aging process. Consistently, aging mice with p53 P72 allele exhibited better
long-term stem cell ability of engraftment and repopulation than aging mice
with p53 R72 allele as evaluated by bone marrow transplantation assay.
Taken together, results from this study demonstrate that p53 codon 72 SNP
has a direct impact on aging and longevity, and strongly support the role of
p53 in regulation of stem/progenitor cells’ function and longevity.
#3418 Additional mutation in PTPN11 gene promotes tumorigenesis of
theNF1 genemutated cells.YoshimiArima, RitsukoHarigai, Ryo Sato, Toshiki
Takenouchi, KenjiroKosaki,Hideyuki Saya.KeioUniversity, School ofMedicine,
Tokyo, Japan.
The NF1 tumor suppressor gene encodes neurofıbromin and is a func-
tional Ras GTPase-activating protein (RasGAP) involved in negatively reg-
ulating the Ras signal by accelerating the conversion of activated Ras-GTP to
inactive Ras-GDP. NF1 gene germline mutations cause Neurofıbromatosis
type 1 (NF1, von Recklinghausen disease). We hypothesized that additional
genetic alterations promote the malignancy of NF1-associated tumors. To
test our hypothesis, we inoculated a GFP-labeled human NF1-defıcient cell
line, sNF96.2-GFP, which has a frame-shift mutation (c.3683delC,
p.Asn1229MetfsTer11) in the NF1 gene, into the renal sub-capsules of im-
munodefıcient mice. A subclonal cell line, the A-1 cell, was established from
the developed tumor. We found that A-1 cells show much higher tumori-
genic activity and phosphorylation status of MEK and Akt than the parental
sNF96.2-GFP cells. We analyzed the genomic DNA of both the sNF96.2 and
the A-1 cells by using the next-generation sequencing and our medical ex-
ome panel of 4813 genes, which are known to be responsible for most human
genetic disorders. We identifıed 18 heterozygous variants within coding re-
gions of 17 genes that were present in the A-1 cells, but not in the original
sNF96.2 cells. We found a single base substitution (c.1508GT,
p.Gly503Val) in the PTPN11 gene, which encodes the tyrosine phosphatese
SHP-2, and is associated with the regulation of the Ras signaling pathway. It
is critical to note that constitutional gain-of-function mutations in the
PTPN11 gene cause Noonan Syndrome in humans due to activation of the
Ras pathway. To determine the role of PTPN11 mutation in NF1-associated
tumors, we established a cell line overexpressing PTPN11mut in sNF96.2-
GFP cells. We inoculated parental cells and PTPN11mut cells into the subcu-
taneous of nude mice, and we found that PTPN11mut cells showmuch higher
tumorigenic activity than the parental sNF96.2-GFP cells. Our data suggests
that this additional gene mutation in PTPN11 promotes the malignant char-
acteristics of NF1-associated tumors.
#3419 Uncovering the functional relevance of FBXW7mutations in endo-
metrial cancer.Mary Ellen Urick, Bo Hong, Meghan L. Rudd, DaphneW. Bell.
NIH, Bethesda, MD.
The goal of this study is to elucidate the functional consequences of
FBXW7 mutations in the context of endometrial carcinoma (EC). EC is a
heterogeneous disease, consisting of multiple histological subtypes associ-
ated with distinct clinical outcomes. Endometrioid endometrial cancer is the
most commonly diagnosed subtype and is associated with an overall favor-
able prognosis. Less common but more clinically aggressive subtypes that
contribute disproportionately to patient deaths include clear cell and serous
ECs. We previously reported that FBXW7 is somatically mutated in 10% of
endometrioid, 13% of clear cell and 29% of serous ECs. FBXW7 functions as
a substrate-recognition protein within a SKP/CUL1/F-Box ubiquitin ligase
complex, which targets numerous proteins for ubiquitin-mediated proteo-
somal degradation. Although FBXW7 is a known tumor suppressor, the
functional consequences of these mutations have not yet been fully eluci-
dated in the context of EC. As a means to this end, we utilized shRNA and
Western blotting to identify proteins that are upregulated following FBXW7
depletion in ARK1 serous EC cells. Among proteins that were consistently
upregulated were cyclin E1 and cMYC. We treated EC cells harboring en-
dogenous FBXW7mutations and those with wildtype FBXW7 with a protea-
some inhibitor to confırm that EC cells regulate cyclin E1 and cMYC through
proteasome degradation. Furthermore, we identifıed three EC cell lines that
harbor endogenous mutations in FBXW7 and show that these cell lines ex-
hibit delayed degradation of these substrates compared to EC cells express-
ing wildtype FBXW7. Finally, we generated expression constructs for wild-
type FBXW7 and six recurrent mutants found in EC. We show that
transient exogenous overexpression of fıve out of six recurrent FBXW7 mu-
tant constructs in two different serous EC cell lines resulted in increased
levels of phosphorylated cMYC and cyclin E1 compared to wildtype
FBXW7. These results suggest that not all recurrent FBXW7 mutations are
functionally equivalent. Our fındings begin to reveal the molecular conse-
quences of FBXW7 mutations in EC and ongoing studies are aimed at eluci-
dating additional functional consequences of these aberrations in the con-
text of EC.
#3420 Mutational status, expression and functional behaviors of
FAM134B in colorectal cancer. Farhadul Islam,1 Vinod Gopalan,1 Riajul Wa-
hab,1 Katherine Ting-wei Lee,1 Afraa Mamoori,1 Cu-tai Lu,2 Robert A Smith,3
Alfred K-Y Lam1. 1Griffıth University, Gold Coast, Southport, Australia; 2Gold
Coast Hospital, Gold Coast, Southport, Australia; 3Queensland University of
Technology, Brisbane, Australia.
Background: Family with sequence similarity 134B (FAM134B) is an ER-
autophagy regulator and involved in the pathogenesis of neuronal disorders,
vascular diseases and carcinomas. In colorectal carcinomas, FAM134B plays
important role in the pathogenesis and associated with aggressiveness of the
disease. However, the frequency of mutations, expression pattern and func-
tional roles in cell have never been studied in colorectal cancer. Objectives:
To investigate FAM134B mutations in tissues samples from patients with
colorectal cancer and cell lines. Also, the expression of FAM134B at protein
and mRNA levels were examined. In addition, functional roles of FAM134B
in colon cancer were studied. Methods: Mutations in FAM134B sequence in
eighty-eight cancer tissues and matched non-cancer samples was studied by
high-resolution melt curve analysis followed by Sanger sequencing.
FAM134B expression was studied and quantifıed in cell lines and cancer
tissues samples using immunofluorescence, immunocytochemistry, West-
ern blot and real-time PCR. In vitro functional assays were performed to
unveil the molecular roles of FAM134B in colon cancer pathogenesis fol-
lowed by shRNA-mediated silencing in cells. Mouse xenotransplantation
model was used to confırm the functional behavior of FAM134B in colon
cancer. Results: In this study, 46.5% (41/88) patients with colorectal cancer
were identifıed as FAM134B mutations positive. Thirty-one novel patho-
genic mutations were detected. Of the 31 mutations, 8 novel frameshift mu-
tations caused nonsense-mediated mRNA decay and associated with gender
of the patients, presence of metachronous cancer, size, T staging, presence of
distant metastases and positivity of microsatellite instability (MSI) in the
cancer (p  0.05). FAM134B expression in cancer cells derived from ad-
vanced stages (stage III; SW48 and stage IV; HCT116) of colon cancer was
signifıcantly (p0.01) reduced when compared to non-neoplastic colon cells
(FHC) and cancer cells derived from stage II colon cancer (SW480). Expres-
sion of FAM134BmRNA in cancer tissues was noted signifıcantly (p0.001)
downregulated when compared to that of non-cancer tissues samples.
FAM134B suppression signifıcantly (p0.05) increased the proliferation of
colon cancer cells, remarkably increased (34-52%; p0.05) the clonogenic,
migration capacity, and increases the proportion of cells in S phase of cell-
cycle (p0.01). Xenotransplantation model showed that larger and higher-
grade tumors were formed in mice treated with FAM134B knockdown cells.
Conclusion: In vitro and in vivo functional studies implied that FAM134B
acts as a cancer inhibitor in colon cancer. Also, FAM134B mutation is com-
mon in colorectal cancer and the association of mutation with adverse clin-
ical and pathological parameters are in concur with the tumour suppressive
property of the gene.
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#3421 Pharmacological inhibition of histone methylation attenuates
TGF induced EMT characteristics in pancreatic cancer. Hardik R. Mody,
Rajgopal Govindarajan. OSU College of Pharmacy, Columbus, OH.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Genotype-Phenotype Associations
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017874
Epithelial-to-MesenchymalTransition (EMT) is a tumor cell remodelingprocess
that drives progression of several epithelial solid tumors including pancreatic tu-
mors. Transforming growth factor (TGF)  signaling is a key promoter of EMT
pathway and remains an attractive target for curtailing tumor progression.Here we
present a strategy for investigating inhibitorsofTGF signaling inpancreatic cancer
via reprograming of miRNAs.We fınd a carbocyclic adenosine analog and histone
methyl transferase inhibitor, 3-deazaneplanocin A (DZNep) to signifıcantly atten-
uate the TGF signaling induced EMT characteristics in pancreatic ductal adeno-
carcinoma (PDAC). Specifıcally, we fındDZNep treatment to restore expression of
selective epigenetically silenced miRNAs (mir-663a, miR-4787-5p, and miR-202)
that inhibit endogenous TGF1 ligand and receptor expression via RNA interfer-
ence. Consequently, DZNep signifıcantly attenuated both exogenous and endoge-
nous TGF-induced EMT response. Lentiviral overexpression of mir-663a, miR-
4787-5p or miR-202 reduced tumor cellular proliferation and EMT phenotypic
characteristics similar toDZNep in cultured pancreatic cancer cells, whereas locked
nucleic acids inhibitionofmiRNAs abrogated such effects. In anorthotopic pancre-
atic cancermousemodel, DZNep and all threemiRs reduced overall tumor burden
in pancreas and metastatic load in liver, lungs and spleen. Together, these fındings
suggest epigenetic reprograming of miRNAs by synthetic histone methylation re-
versal agents as a potentially viable approach for attenuating TGF signaling path-
way involved in pancreatic cancer progression.
#3422 miR-200c-driven mesenchymal-to-epithelial transition as a thera-
peutic target in uterine carcinosarcomas. Jill H. Tseng,1 Maria Bisogna,1 Lien
N. Hoang,1 Narciso Olvera,2 Douglas A. Levine,2 Petar Jelinic2. 1MSKCC, New
York, NY; 2NYU Langone Medical Center, New York, NY.
Introduction and purpose of study: Uterine carcinosarcoma (UCS) is an aggres-
sive and raremalignancywith poor prognosis and limited treatment options. These
biphasic tumors, consisting of epithelial and mesenchymal components, are hy-
pothesized to evolve from less aggressive endometrial adenocarcinomas (EACs)
throughepithelial-mesenchymal transition (EMT).EMTis a reversible process, and
mesenchymal-epithelial transition (MET) has been shown to decrease tumor ag-
gressiveness. Inducing MET has been suggested for treatment of cancers with a
mesenchymal phenotype. In our studies, we investigated the importance of EMT in
theevolutionofUCSbydepletingmiR-200, a familyofmicroRNAscritical forEMT,
in EAC cell lines.We also explored the role of miR-200 overexpression as a driving
force for MET in UCS with a focus on fınding novel therapeutic approaches to the
treatmentof this aggressivedisease.Experimentalprocedures:To testwhetherUCSs
evolve from EACs, we depleted miR-200b/c in EAC cell lines, Ishikawa and MFE-
280. For the MET studies, we stably overexpressed miR-200c in UCS cell lines,
SNU685 and JHUCS1. Gene expression was measured using TaqMan and whole
transcriptome sequencing (RNA-seq) assays. Immunoblotting was performed on
the EMT-relevant proteins. Cell adhesion and in vitro cell proliferation were mea-
sured using commercially available assays. In vivo tumor growth of JHUCS1 miR-
200c-overexpressed cells was measured in xenografted mice. Summary of the data:
Compared to EAC cells, UCS cells had undetectable miR-200c expression. Deple-
tion ofmiR-200b/c in EAC cells resulted in expected increasedZEB1 and decreased
E-cadherin expression. The lack of increased N-cadherin, vimentin and morpho-
logic changes, even in the presence of exogenous TGF- suggests partial EMT in-
duction. Overexpression of miR-200c in UCS cells resulted in full MET, with a
decrease in ZEB1, ZEB2, N-cadherin and vimentin and an increase in E-cadherin.
Increased cellular adhesion was observed along with typical MET morphologic
changes. miR-200c overexpression led to inhibited UCS cell proliferation andmet-
abolic activity. Overexpression ofmiR-200c in vivo resulted in substantially smaller
tumors compared tomice bearing controlUCS cells. Conclusions:Our data suggest
thatmechanismsadditional to, orother thanEMT,arenecessary for theevolutionof
UCS fromEAC.UCS cell lines, however, readily undergo robustMET in the setting
of increased miR-200c expression rendering them less aggressive. These fındings
suggest that miR200 overexpression through advanced microRNA therapeutics
may lead to new options for the treatment of uterine carcinosarcomas.
#3423 Elucidation of the role of miR-575 on tumorigenesis in glioblas-
toma. Ashley N. Gray,1 Tiantian Cui,1 Marjolein Geurts,2 Pierre Robe,2 Joseph
McElroy,1 Erica Hlavin Bell,1 Arnab Chakravarti1. 1The Ohio State University,
Columbus, OH; 2University Medical Center of Utrecht, Netherlands.
Glioblastoma (GBM) patients currently face poor survival outcomes with an
average survival rate less than 15 months, with only 3-5% of patients survive
more than 36months. Although themechanisms of tumorigenesis are still being
elucidated, miRNAs are promising candidates to explore as novel and prognos-
tic biomarkers in GBM. MiRNAs are small regulatory molecules that play a
crucial role in carcinogenesis via repression of oncogenes and tumor-suppressor
genes either transcriptionally or post-transcriptionally. Our clinical data
(n268) shows that miR-575 is one of the top miRNAs associated with GBM
overall survival (FDR: 0.0036, p-value: 5.77E-05) by univariate analysis (Nano-
String Technologies; Seattle, WA). This study was designed to investigate the
expression and function of miR-575 in GBM. Basal expression of miR-575 was
fırst detected in GBM cell lines prior to functional experimentation. Cell prolif-
eration, colony formation, migration and invasion assays were performed to
understand the role of miR-575 in GBM.We found that overexpression of miR-
575 signifıcantly increased cell proliferation and cellmotility in LN229 andU251
cell lines. Additionally, BLID, a tumor-suppressor gene, was negatively regu-
lated by miR-575 at the transcriptional level by qRT-PCR, which will be further
investigated at the post-transcriptional level by western blot. Up-regulation of
miR-575 in GBM cell lines suggests that it could be acting as an oncogene by
degrading themRNAofBLID. Luciferase assays also showednegative regulation
of BLID expression bymiR-575, supporting our hypothesis and fındings in other
cancers. In conclusion, miR-575 might act as an oncogene in GBM, and BLID
may be a putative target gene of miR-575. This mechanism could potentially be
useful as a novel prognostic biomarker for GBM patients after further in vitro
and in vivo validation. Funding: 1R01CA169368 (PI: Houghton; Co-I:Chakra-
varti); 1R01CA11522358 Multiple-PI R01: Chakravarti (PI); Xia (PI);
1R01CA1145128 Baroukhim (PI); Chakravarti (Co-PI) 7/2015-6/2020;
R01CA108633 (PI:Chakravarti); 1RC2CA148190 (Scientifıc PI: Chakravarti).
#3424 Role of miR-489 in mammary gland development and Her2 medi-
ated tumorigenesis. Yogin Patel, Mithil Soni, Shou Liu, Hexin Chen. Univ. of
South Carolina, Columbia, SC.
HER2 overexpression is linked with poor prognosis and outcome in breast can-
cer. In our previous study, we have foundmiR-489 was specifıcally down regulated
byHER2overexpression.RestorationofmiR-489 inmultiple breast cancer cell lines
signifıcantly inhibited cell growth in vitro anddecreased tumor growth in xenograft
mice.Tostudy roleofmiR-489 inHer2mediated tumorigenesis, for the fırst timewe
generated MMTV-miR-489 transgenic mice, which overexpress miR-489 specifı-
cally in mammary gland. Our qRT-PCR data has confırmed transgenic mice have
signifıcantly more miR-489 expression than FVB mice. We used western blot to
furthervalidateourmodel systemandfoundsignifıcantdownregulationofmiR-489
targets DEK and PTPN11. To fınd out whethermiR-489 has any role inmammary
gland development, mammary gland whole mount was performed from wild type
FVB mice and MMTV-miR-489 mice at different age. Mammary gland from
MMTV-miR-489mice demonstrated reduction in growth at early age. Our immu-
nohistochemistry staining demonstrated signifıcantly reduction in Ki-67 positive
cells inMMTV-miR-489mammary gland at early age, further confırming reduced
growth in MMTV-miR-489 mice. However, we found no signifıcant effect on
weight of litters ofMMTV-miR-489 female since after 8-weekmammary glandwas
able to recover growth. To fınd out effect of miR-489 overexpression on Her2 me-
diated tumorigenesis, we generated double transgenicmiceMMTV-Her2/miR-489
by crossing MMTV-miR-489 mice with MMTV-Her2 mice. We have observed
signifıcant delay in tumor onset and reduced tumor growth inMMTV-Her2/miR-
489 mice compare to MMTV-Her2 mice. We have also observed less number of
metastatic site in lungbyperformingHandEstainingof lung.Our IHCdata showed
reduction in PTPN11 andDEK inmiR-489 overexpressmammary tumor. Surpris-
ingly,we found signifıcant reductionofmiR-489 expression inmammary tumorsof
MMTV-Her2-miR-489 when compared with normal mammary gland of same
mice. Overall, our results indicated miR-489 overexpression suppresses mammary
gland development at early age, reduced mammary tumorigenesis and decrease
lungmetastasis by targeting PTPN11 andDEK.
#3425 MiR-215-5p is a tumor suppressor in colorectal cancer targeting
EGFR ligand epiregulin and its transcriptional inducer HOXB9. Petra Falte-
jskova-Vychytilova,1 Jana Merhautova,1 Pablo Conesa-Zamora,2 Katerina
Slaba,3 TanaMachackova,1 Marek Svoboda,4 Marek Vecera,1 Jitka Mlcochova,1
Jaroslav Juracek,1 Jiri Sana,1 Parwez Ahmad,1 Natalia Gablo,1 Ondrej Slaby1.
1Masaryk University CEITEC MU, Brno, Czech Republic; 2Santa Lucia Univer-
sity Hospital, Cartagena, Spain; 3Masaryk Memorial Cancer Institute, Brno,
Czech Republic; 4Masaryk University CEITEC MU, Masaryk Memorial Cancer
Institute, Brno, Czech Republic.
Growing evidence suggests that microRNAs (miRNAs) are involved in the
development and progression of colorectal cancer (CRC). In the present study,
deregulation and functioning of tumor suppressive miR-215-5p was evaluated
in CRC. In total, 448 tumor tissues and 325 paired adjacent healthy tissues have
been used for miRNA expression analyses. We proved that miR-215-5p is sig-
nifıcantly downregulated in tumor tissues compared to non-tumor adjacent
tissues and its decreased levels correlate with the presence of lymph node me-
tastases, tumor stage, and shorter overall survival in CRC patients. To identify
specifıc cellular processes affected by ectopic expression of miR-215-5p, a series
of in vitro experiments have been performed using transient transfection of
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miR-215-5p mimics into four CRC cell lines. Increased levels of miR-215-5p
signifıcantly reduced proliferation, clonogenicity, and migration of CRC cells,
lead to cell cycle arrest inG2/Mphase and p53dependent induction of apoptosis.
The ability of miR-215-5p to inhibit tumor growth was confırmed in vivo by use
of NSGmice model and stable cell line over-expressing miR-215-5p. Finally, we
proved epiregulin andHOXB9 to be the direct targets ofmiR2155p by luciferase
assay and western blot analyses. Since epiregulin is EGFR ligand andHOXB9, is
its transcriptional inducer, we suggest, that the main molecular link between
miR-215-5p and CRC cells phenotypes presents the EGFR signaling pathway,
which is one of the canonical pathogenic pathways in CRC. This work was
supported by Ministry of Health of the Czech Republic, grant nr. 15-33158A,
15-34553A, 15-31627A, 15-34678A, 16-31314A, 16-31765A and by grant of
Czech Grant Agency nr. 16-18257S.
#3426 miR-133a function in the pathogenesis of dedifferentiated liposar-
coma. Peter Y. Yu, Hans Iwenofu, Raphael E. Pollock, Denis C. Guttridge.Ohio
State University, Columbus, OH.
Background: Sarcomas aremalignant heterogeneous tumors ofmesenchymal
derivation. Dedifferentiated liposarcoma (DDLPS) exhibits aggressive biologi-
cal behavior with an 80% local recurrence rate and the development of metasta-
sis in approximately 20% of patients. To identify and characterize the molecular
alterations that contribute to the development and progression of DDLPS, our
laboratory characterized a unique miRNA expression signature associated
with human DDLPS tissue compared to paired subjacent normal tissue. We
found that several muscle-specifıcmiRNAs (myomiRs), miR-1, -133a, and -206,
were signifıcantly underexpressed in liposarcoma tissues. Interestingly, these
miRNAs have recently been shown to have tumor suppressor functions inmany
human cancers. The objective of this study is to characterize the biological and
molecular consequences of miR-133a in DDLPS. Methods: Taqman real-time
PCRwas used to evaluate expression levels ofmyomiRs in humanDDLPS tissue,
normal fat tissue, and available human DDLPS cell lines. To evaluate the effects
of miR-133a expression on DDLPS cell line behavior in vitro, cells were stably
transduced with miR-133a vector or empty lentiviral vector and the effects on
cell cycle, proliferation, apoptosis, and migration were assessed. Agilent Sea-
horse Bioanalyzer system was used to assess metabolism. We performed an in
silico search for predicted targets of miR-133a using target prediction databases
and compared these target genes to known genes that are highly expressed in
human DDLPS tissue. Results: The expression levels of myomiRs were signifı-
cantly decreased in humanDDLPS tissue compared to normal human fat as well
as in human DDLPS cell lines compared to a human preadipocyte cell lines.
Overexpression of miR-133a decreased cell proliferation, decreased glycolysis,
and increased spare respiratory capacity. There was no signifıcant effect on cell
cycle, apoptosis, or migration. Using in silico target gene analysis, we identifıed
18 potential targets of miR-133a. These preliminary results suggest that miR-
133a regulates metabolism and proliferation, and its dysregulation might con-
tribute to the oncogenic phenotype of DDLPS. Signifıcance: We have demon-
strated that enforced expression of miR-133a decreased proliferation and
metabolism in human DDLPS cells. We have identifıed putative gene targets of
miR-133a and are currently dissecting themolecularmechanism bywhichmiR-
133a may mediate proliferation and metabolism in DDLPS cell lines. Taken
together, these data suggest thatmiR-133amight play a tumor suppressor role in
DDLPS, thereby generating new potential targets for therapeutic intervention to
alter the course of this disease.
#3427 Targeting MUC13 to overcome the survival mechanisms for im-
proved response to chemotherapy. Saini Setua, Sheema Khan, Murali M. Yal-
lapu, Stephen W. Behrman, Nadeem Zafar, Meena Jaggi, Subhash C. Chauhan.
University of Tennessee Health Science Center, Memphis, TN.
Background: Pancreatic cancer (PanCa) is a third leading cause of cancer-
related deaths in the US due to late diagnosis and development of chemoresis-
tance. Therefore, understanding molecular mechanisms that confer survival
benefıt to PanCa cellsmay offer new therapeutic strategies for PanCa treatment-
.Mucin, MUC13 aberrantly expressed in PanCa,promoting cancer growth and
progression and these effects are abrogated bymicroRNA-145 (miR-145) resto-
ration. Unlike other cancer types, PanCa is highly resistant to Tumor necrosis
factor (TNF)-related apoptosis inducing ligand (TRAIL) that emerges as one of
the most promising experimental cancer therapeutic drugs.Herein, we demon-
strate the integration of novel approach to overcome chemoresistance and offer
TRAIL-based therapeutic strategies. Methods: MUC13 expressing and null sta-
ble PanCa cells were generated to investigate the role of MUC13 in cell surviv-
al.miR-145 mimics were used to investigate the effect of MUC13 silencing in
promoting survival and inhibiting apoptosis in presence of TRAIL using West-
ern blotting, cell proliferation (MTT), Acridine orange staining and flow cytom-
etry apoptosis assays(cell cycle, Annexin V/7AAD staining). Various distinct
domain specifıc constructs of MUC13 were constructed such as the mucin (),
Beta () sea urchin sperm protein enterokinase arginine (SEA) domain and
cytoplasmic (CD) domains and transfected into MUC13 null Panc-1 cells to
identify the role of different domains in eliciting survival benefıt to PanCa cells.
Results: Results demonstrate that MUC13 expression blocks activation of
caspase-8 and death receptor-mediated apoptosis in PanCa cells in response
toTRAIL treatment as observed through Western blotting and flow cytometer.
Inhibition ofMUC13 using shRNAknockdown ormiR-145 restoration resulted
in the TRAIL-mediated increase in apoptotic cell death as evidenced by Annex-
inV/ 7AAD and sub G0 population, as well as rendered PanCa cells sensitive to
treatment with drugs, such as paclitaxel. Additionally, cells treated with TRAIL
in combination with paclitaxel or Abraxane showed enhanced apoptosis on
inhibition of MUC13 expression using miR-145 restoration. Further investiga-
tion showed that cytoplasmic domain ofMUC13 (MUC13-CD) is indispensable
for blockingcaspase-8 activation and PARP cleavage, indicating that the
MUC13-CD blocks TRAIL-induced signaling upstream to Bid by inhibiting
caspase-8 activation. Conclusion: These observations suggest that MUC13 con-
tributes to the survival advantage in PanCa cells in response to treatment with
drugs or death inducing ligands such as, Tumor necrosis factor related apopto-
sis-inducing ligand (TRAIL) which can be strategically overcome by miR-145
replenishment. These fındings indicate that MUC13 silencing sensitizes PanCa
cells towards TRAIL therapy and counteracts chemoresistance mechanisms in
PanCa that may lead to novel combination therapies for PanCa treatment.
#3428 Tamoxifen differentially regulates miR-29b-1 and miR-29a de-
pending on endocrine sensitivity in breast cancer. PennMuluhngwi, Carolyn
M. Klinge. University of Louisville School of Medicine, Louisville, KY.
Acquired endocrine-resistance occurs in  40% of estrogen receptor 
(ER) breast cancer patients after tamoxifen (TAM) or aromatase inhibitor
therapy. MicroRNAs (miRs) are dysregulated in breast cancer, but their contri-
bution to endocrine-resistance is not yet completely understood. Microarray
analysis of miRNAs in TAM-sensitive MCF-7 versus TAM-resistant LY2 breast
cancer cells (derived fromMCF-7 cells) identifıed differential regulation ofmiR-
29b-1 and miR-29a. miR-29a and miR-29b-1, which are co-transcribed as a
single primary-miR, were repressed by TAM inMCF-7 and stimulated by TAM
in LY2 cells. We confırmed these observations by real time qPCR inMCF-7 and
LY2 cells and observed that 4-OH-TAM(4-OHT) also downregulatedmiR-29b-
1/a in LCC2 and LCC9 endocrine-resistant cells. These changes were at the
primary transcriptional level. The role of these two miRs in endocrine-resistant
breast cancer is unknown. We tested the hypothesis that the TAM-stimulated
increase in miR-29b-1/a promotes endocrine-resistance by downregulating tar-
gets that contribute to TAM’s antiproliferative/pro-apoptotic activity. Our goals
were to: 1) Determine if ER was responsible for TAM regulation of miR-29b-
1/a expression; 2) Determine the functional role(s) of miR-29b-1/a; 3) Identify
specifıc miR-29b-1/a target genes that are differentially regulated by 4-OHT in
MCF-7 versus LCC9 and LY2 cells. Knockdown of ER blocked 4-OHT inhibi-
tion of miR-29b-1/a in MCF-7 and 4-OHT simulation of miR-29-b-1/a tran-
scription in LCC9 and LY2 cells. Transient over-expression of miR-29b-1/a
inhibited proliferation ofMCF-7, LCC9, and LY2 cells and decreasedmigration
and colony formation of LY2 cells. Repression ofmiR-29b-1/a has no signifıcant
effect on MCF-7, LCC9, or LY2 cell proliferation. Repression of miR-29-b-1/a
did not sensitize the TAM-resistant cells to growth inhibition by 4-OHT. We
observed that the bona fıde miR-29 target gene, DICER1, was inhibited by
4-OHT in LY2 cells and anti-miR29b-1 or anti-miR-29a decreased the suppres-
sion of DICER1 by 4-OHT. These data suggest that 4-OHT-ER increases miR-
29b-1/a which target and downregulate DICER 1 in endocrine resistant breast
cancer cells. Future studies will identify other targets of miR-29b-1/a to better
understand the pathways leading to acquired endocrine resistance.
#3429 Oncogenic function of miR-23b-3p in hepatocellular carcinoma.
Hiroshi Tanabe, Masamichi Hayashi, Hiroyuki Sugimoto, Keisuke Kurimoto,
Sho Hirabayashi, Mitsuro Kanda, Hideki Takami, Yokiko Niwa, Naoki Iwata,
Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Goro Nakayama, Masahiko
Koike, Tsutomu Fujii, Michitaka Fujiwara, Yasuhiro Kodera.NagoyaUniversity
Graduate School of Medicine, Nagoya, Japan.
Background: miR-23b has been identifıed as various cancer-related biomarkers.
Interestingly, it works as an oncogenic miRNA in lymphoma, renal cancer and
glioma, while it works as a tumor suppressor miRNA in pancreatic cancer, bladder
cancer and prostate cancer (Donadeli M et al, Cancer Lett, 2014). We have previ-
ously reportedmiR-23b-3pas aoncomiR inNSCLCs (BegumS,HayashiMet al, Sci
Rep, 2015). To fınd the correlation to other carcinogenesis, we focused onmiR-23b
function inhepatocellular carcinoma (HCC).Methods:miR-23b-3pexpressionwas
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examined in 9 HCC cell lines (SK-Hep1, HuH2, HLE, PLC/PRF/5, HuH1, HuH7,
HLF, Hep3B, HepG2). The downstream of miR-23b-3p overexpression was exam-
ined by Cancer Pathway Finder (Qiagen). Results were applied to 125 clinical HCC
samples (2002-2011 surgically resected). Results: Transfection experiments were
performed for HepG2 (miR-23b-3p highly expressed) by siRNA and for SK-Hep1
(lowly expressed) bymiRNAmimic.Cancer cell proliferationwas activatedbymiR-
23b-3p overexpression, and diminished by its inhibition. In order to fınd the asso-
ciated genes,miR-23b-3p overexpressed SK-Hep1 cells were comparedwith paren-
tal SK-Hep1 cells by global gene expression analysis. ANGP1, ERCC5 and G6PD
genes were upregulated, while KDR,WEE1,OCLNgenes were downregulated.We
also detected additional two genes (AUH and MICU3) by TargetScan Release 5.2.
Clinical HCC samples were divided into miR-23b-3p upregulated 48 cases (38%)
and downregulated 77 cases (62%). Upregulated cases were correlated with aged
patients (P0.015), capsule invasion positive (P0.039) and serosal invasion posi-
tive (P0.049). Also, they showed signifıcantly poor recurrence free survival
(HR1.64, P0.037, 95%CI:1.03-2.59) and overall survival (HR3.10, P0.001,
95%:1.57-6.29) in multivariable analysis. Conclusion: miR-23b-3p increased the
HCC cell proliferation, and indicated the invasive type of HCCs. It functions as a
oncogenic biomarker in HCCs andmight be a therapeutic target.
#3430 Deep sequencing-based microRNA expression signature in head
and neck squamous cell carcinoma: dual strand of microRNA-150 acts as
tumor suppressors.Keiichi Koshizuka,1 Nijiro Nohata,2 Toyoyuki Hanazawa,1
NaokoKikkawa,1 Ichiro Fukumoto,1 TakayukiArai,1AtsushiOkato,1 Yoshitaka
Okamoto,1 Naohiko Seki1. 1Chiba University Graduate School of Medicine,
Chiba, Japan; 2Moores Cancer Center, University of California, CA.
Head and neck squamous cell carcinoma (HNSCC) is the sixthmost common
cancer in the world and 500 000 cases are diagnosed every year. In spite of
considerable advances in multimodality therapy, including surgery, radiother-
apy and chemotherapy, the overall survival rate for patients with HNSCC is
50%. Patients with HNSCC are usually diagnosed at a late stage and local
tumor recurrence and distant metastasis occur after conventional therapies.
Application of genomic approaches might elucidate novel molecular pathways
underlyingHNSCC and thereby improve therapeutic approaches to the disease.
The discovery of noncoding RNAs (ncRNAs) in the human genome was an
important conceptual breakthrough for cancer research in the post-genome
sequencing era. Among ncRNAs, the microRNAs (miRNAs) are small ncRNA
molecules (18-25 nucleotides in length) that regulate the expression of protein-
coding/non-protein-coding genes by repressing translation or cleaving RNA
transcripts in a sequence-specifıc manner. Accumulating evidence has demon-
strated pivotal roles for miRNAs in human cancer pathogenesis. To seek out
differentially expressed miRNAs in HNSCC cells, we newly constructed the
deep-sequencing based miRNA expression signature by using laryngeal and
hypopharyngeal clinical specimens. Our present data showed that a total of 160
miRNAs (44 upregulated and 116 downregulated) were identifıed as aberrantly
expressed miRNAs in cancer tissues. Based on the signature, we focused on the
dual strand of pre-miR-150, miR-150-5p and miR-150-3p in HNSCC signature
because of these miRNAs signifıcantly reduced in cancer tissues, suggesting
these miRNAs act as antitumor miRNAs in this disease. However, the role of
thesemiRNAs onHNSCC cells is still ambiguous. InmiRNAbiogenesis, it is the
general consensus that processing of the pre-miRNA through Dicer1 generates
amiRNAduplex (a passenger strand and a guide strand), and that the passenger
strand has degradation and no regulatory activity and disintegrates in cells. Our
present data showed that both miRNAs, miR-150-5p and miR-150-3p signifı-
cantly suppressed cancer cell migration and invasion. Moreover, gene expres-
sion data and in silico database analysis showed that Integrin A3 (ITGA3), In-
tegrin A6 (ITGA6) and Tenascin C (TNC) were direct regulation of both
antitumor miRNAs. A large number of cohort study by TCGA showed that
overall survival of high expression of ITGA3, ITGA6 and TNC groups were
signifıcantly shorter than that of low expression of these expression groups (p
0.0177, p  0.0237 and p  0.026, respectively). These target genes acted as
oncogenes anddeeply contributed toHNSCCpathogenesis.Dual strand ofmiR-
150 functioned as tumor suppressors based on themiRNA expression signature
of HNSCC. Identifıcation of miRNA-mediated cancer networks may provide
novel molecular pathogenesis of the disease.
#3431 The oncogenic role of miR-150-5p in triple-negative breast cancer.
Bruna M. Sugita,1 Yara Zabala,2 Aline Fonseca,2 Rodrigo Almeida,1 Yuriy
Gusev,2 Simina Boca,2 Iglenir J. Cavalli,1 EnilzeM. Ribeiro,1 Luciane R. Cavalli2.
1Federal University of Parana, Curitiba, Brazil; 2Georgetown University, Wash-
ington, DC.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast can-
cer that confers disease recurrence, treatment resistance and high mortality
rates. MicroRNAs are a class of noncoding RNAs, that when dysregulated, im-
pact tumorigenesis through the control of the expression of multiple mRNA
targets involved in critical cancer signaling pathways. MiR-150-5p has been
shown to control the expression of several driver oncogenes and/or tumor sup-
pressor genes involved in these critical pathways. Its pattern of expression varies
according to the cancer type; it has been observed mostly downregulated in
hematological diseases andGI cancers, and upregulated in hormonal dependent
cancers, such as prostate and breast cancer. Themain objective of this study was
to assess the patterns of expression of miR-150-5p in TNBC and determine its
functional role in affecting the tumor phenotype. Archived paraffın samples of
113 patients with ductal breast carcinoma (56 of the TNBC and 57 of the non-
TNBC subtype) and 49 adjacent normal tissue (ANT), obtained from the the
pathology tumor bank of Lombardi Comprehensive Cancer Center, Washing-
ton DC, were profıled for miRNA using the wide-genome Nanostring platform
and a Taqman specifıc miRNA-150-5p assay. Signifıcant overexpression levels
of miRNA-150-5p were observed in the tumor tissues when compared to the
ANT and in the TNBC cases when compared to the non-TNBC cases, demon-
strating its tumor and TNBC subtype specifıcity, respectively. Overexpressed
levels of miRNA-150-5p were also preferentially observed in the TNBC cases
from patients that presented with LN metastasis and breast cancer recurrence,
indicating its association with poor prognosis. Interestingly, the TNBC of Afri-
can-American patients, which is the ethnic groupmostly affected by this cancer
subtype, presented overexpression levels of this miRNA when compared to the
Non-Hispanic White patients. Functional analysis performed in the TNBC cell
lines,MDA-MB-231 andHCC1806, showed after transfectionwithmiR-150-5p
inhibitor, reduced levels on cell proliferation, clonogenicity, migration, drug
resistance and expression of the EMT promoter markers, SLUG and SNAIL.
These fındings, indicate an oncogenic type of action of miRNA-150-5p in
TNBC. In summary, miRNA-150-5p is upregulated in TNBC clinical cases in
association with poor prognostic parameters and its functional inhibition, di-
rectly confers to the cells a reduction of their tumorigenic phenotype. Funding:
This project was supported by the Georgetown University Center of Excellence
in Regulatory Science and Innovation (CERSI U01FD004319), a collaborative
effort between the university and the U.S. Food and Drug Administration to
promote regulatory science through innovative research and education. This
research does not necessarily reflect the views of the FDA. Scholarship to B.S.
was provided byCoordenação deAperfeiçoamento de Pessoal deNível Superior
(CAPES).
#3432 microRNA expression reflects site specifıcity of metastatic colorec-
tal cancer. Bastian Fromm,1 Eirik Høye,1 Diana Domanska,2 Christin Lund-
Andersen,1 Annette Torgrund Kristensen,1 Vegar J. Dagenborg,1 Paul H. Boett-
ger,3 Torveig W. Abrahamsen,1 Steinar Solberg,4 Stein G. Larsen,1 Bjørn
Edwin,4 Eivind Hovig,1 Susanne Lorenz,1 Kjersti Flatmark1. 1Oslo University
Hospital - The Norwegian Radium Hospital, Oslo, Norway; 2University of Oslo,
Oslo, Norway; 3PHMB Research Consulting, Austria; 4Oslo University Hospital -
Rikshospitalet, Oslo, Norway.
Colorectal Cancer (CRC) is one of the leading causes of cancer related deaths
in the western world, and metastatic progression is the dominating cause of
mortality. The primary site of CRCmetastasis is the liver, followed by the lungs
and peritoneal cavity, and prognosis for patients with metastatic CRC (mCRC)
is poor, with only 10 % fıve-year survival. Although much is known about pro-
gression andmetastasis of CRC; how primary CRC (pCRC) differs frommCRC
on the molecular level and potential differences between metastases located in
different organs are incompletely understood. This is important for our under-
standing of the disease, but also could have signifıcant implications with respect
to treatment. MicroRNAs have been shown to be key elements in cancer pro-
gression, but recent reports on CRC failed to consistently identify microRNA
signatures of metastatic progression. We have addressed this using a smallRNA
sequencing approach to analyze primary tumors and a set of liver, lung and
peritoneal metastases, including corresponding adjacent tissue (colon, liver,
lung, peritoneum). Further, we use the highly curated and updated microRNA
reference MirGeneDB.org, the novel pipeline MirAthon - including a correc-
tion-algorithm of benign tissue microRNA signatures for tumor or metastatic
samples, and we compare pCRC and site specifıc metastases separately. We are
able to show that microRNA profıles of mCRC are distinct to pCRC in a site-
specifıc manner. We identify a small panel of differentially expressed microR-
NAs including isoforms (isomiRs) hidden under a layer of benign signatures
that we confırmed in other available datasets, too. Our fındings will help better
understand metastatic progression and site-specifıcity in CRC and could be
potential biomarkers for mCRC. Our work identifıes microRNA signatures of
mCRC and suggest that microRNA signatures reflect mCRC site specifıcity.
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Furthermore, the results underline the importance of using a curated reference
formicroRNAstudies, and to differentiatemetastases based on their localization
ab initio.
#3433 Epigenetic silencing of miR-214-3p is associated with resistance to
p53-induced apoptosis throughup-regulationof gankyrin expression inhep-
atocellular carcinoma. Kohichiroh Yasui, Naoto Iwai, Kei Terasaki, Yasuyuki
Gen, Yoshito Itoh. Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death
worldwide. MicroRNAs (miRNAs) are small non-coding RNAs that regulate
gene expression and can act as tumor suppressors or oncogenes. To identify
miRNA involved in the development of HCC, a genome-wide miRNA gene
expression analysis was performed using the human miRNA microarray (Agi-
lent) in paired HCC tumors and non-tumorous liver tissues from patients with
primary HCC. The array-based miRNA expression profıles were validated by
quantitative PCR. We also screened for genes with promoter DNA hypermeth-
ylation using a genome-wide DNA methylation microarray analysis (the Illu-
mina HumanMethylation27 BeadChip) in the same samples. We found that
miR-214-3p were signifıcantly down-regulated by aberrant promoter hyper-
methylation in HCC tumors compared to the non-tumorous liver tissues. We
identifıed PSMD10, which encodes gankyrin, as a direct target of miR-214-3p
using luciferase assay and immunoblotting. Gankyrin, an oncoprotein com-
monly overexpressed in HCC, binds to MDM2, a major E3 ubiquitin ligase for
p53, and increases ubiquitylation and degradation of p53. Our experiments
showed that reduced miR-214-3p expression was associated with resistance to
p53-induced apoptosis through up-regulation of gankyrin expression in HCC
cells. In conclusion, our results suggest that epigenetic silencing of tumor sup-
pressor miR-214-3p is involved in hepatocarcinogenesis through up-regulation
of gankyrin expression.
#3434 Loss of regulation of -Catenin expression by miR-214 and onco-
genic role of miR-214 in metastatic melanoma cells. Kirthana Prabhakar,
Ashika Jayanthy, Vijay Setaluri. University of Wisconsin, Madison, WI.
Dysregulation of -catenin facilitates melanoma metastasis by activating the
transcription of oncogenes like Myc, CyclinD1 and TCF-1. It is important to
understand the regulation of -catenin to develop strategies to target Wnt sig-
naling for melanoma treatment. MicroRNAs are small non-coding RNAs that
are primarily involved in post-transcriptional regulation of target genes. Hence,
miRNAs can be used to manipulate protein levels by causing instability of the
transcript or by inhibiting translation. MiR-214 has been documented as regu-
lator of-catenin in cancer cells other thanmelanoma cells. The role ofmiR-214
in regulation of -catenin has not been investigated. In this study, we investi-
gated regulation of-catenin bymiR-214 inmelanoma cell lines and studied the
effect of overexpression miR-214 on the malignant phenotype of metastatic
melanoma cells and their sensitivity to MAP kinase inhibitors. Our data show
that -catenin is upregulated in a panel of metastatic melanoma cells and the
expression levels of -catenin is negatively correlated with endogenous expres-
sion of miR-214. However, overexpression of miR-214 by transfection with a
miRNAmimic did not show signifıcant decrease in-cateninmRNAor protein
expression. RNA-Seq showed that multiple isoforms of -catenin transcript are
present in melanoma where the binding site is absent or mutated. The alterna-
tively spliced transcript with no binding site for miR-214 is seen to be more
abundant than the other isoforms. Paradoxically, overexpression of miR-214
increased survival, proliferation and migration of metastatic melanoma. In ad-
dition, miR-214 overexpression decreased their sensitivity to vemurafenib and
selumetinib. In melanoma cells with acquired resistance (in vitro), miR-214
overexpression further enhanced their resistance to MEK inhibitor, but not
vemurafenib. In light of the published studies that proposed thatmiR-214 acts as
tumor suppressor by negatively regulating -catenin, our study is interesting
sincewe fınd that inmetastaticmelanomamiR-214 has oncogenic role.Ongoing
studies are aimed at understanding the mechanisms by which miR-214 pro-
motes malignant behavior of melanoma cells.
#3435 Profıling miRNAs in breast epithelial progenitor cells during
branching morphogenesis and EMT in 3D culture. Eirikur Briem,1 Bylgja
Hilmarsdottir,2 Zuzana Budkova,1 Saevar Ingthorsson,1 Magnus K. Magnus-
son,1 Thorarinn Gudjonsson1. 1University of Iceland, Reykjavik, Iceland; 2Oslo
University Hospital, Oslo, Norway.
In this study we investigate the role of miRNA-203a in branching morpho-
genesis and epithelial to mesenchymal transition (EMT) in breast cell lines.
D492 is a breast epithelial cell line with stem cell properties. D492 generates
luminal- andmyoepithelial cells and in 3D culture forms structures reminiscent
of terminal duct lobular units of the breast. When cocultured with endothelial
cells subset of D492 cells undergo EMT as evidenced by spindle shapemorphol-
ogy, E- to N cadherin switch and loss of keratin expression.We have established
an endothelial-inducedmesenchymal subline fromD492 referred to as D492M.
Here we use D492 and D492M as a model to investigate miRNA expression
patterns during different stages of branching and in EMT. We performed small
RNA-sequencing onD492 andD492M in 3D cultures.Wewere able to pinpoint
miRNAs that are associated with epithelial integrity and suppressing EMT. We
have recently shown that miRNA-200c-141 convert D492M back to the epithe-
lial phenotype (Hilmarsdottir et al. G&D 2015). MiRNA-203a is also down-
regulated in D492M. Here we overexpress miRNA-203a in D492 and D492M.
Methylation analysis reveal that the promoter area of miRNA-203a is not
methylated in D492M.When miRNA-203a is overexpressed in D492M, cells
change phenotype from elongate, mesenchymal-like phenotype to more
cuboidal epithelioid phenotype, show reduced cell proliferation, less ability
to form colonies in low attachment cultures, less ability to migrate and
reduced invasion capability. When D492MmiRNA-203a is co-cultured with
endothelial cells in 3D culture they partially regain the ability to form
branching structures similar to D492. D492MmiRNA-203a show reduced ex-
pression of EMT transcription factors SNAI2 and ZEB1. When cultured on
transwell fılters, D492M forms stratifıed squamous epithelial layer while
D492MmiRNA-203a form single squamous layer. In conclusion, miRNA-203a
induces partial epithelial phenotype in D492M as evidenced by morphology
and marker expression. We also conclude that three dimensional cultures of
D492 and D492Mwork well as a model system to investigate miRNA expres-
sion during branching morphogenesis and in EMT.
#3436 MiR-194 modulates paclitaxel resistance in ovarian cancer cells
through the regulation of MDM-2 expression. Koji Nakamura,1 Kenjiro
Sawada,2 Akihiko Yoshimura,2 Erica Nakatsuka,2 Yasuto Kinose,3 Seiji Mabu-
chi,2 Tadashi Kimura2. 1Saiseikai Nakatsu Hospital, Osaka-shi Osaka, Japan;
2Osaka University, Suita-shi Osaka, Japan; 3Penn Ovarian Cancer Research Cen-
ter, Philadelphia, PA.
Purpose: Ovarian cancer is the most lethal gynecologic malignancy. Plati-
num-paclitaxel combination chemotherapy is the current standard postopera-
tive care for patients with advanced ovarian cancer. Despite developments in
current chemotherapy regimens in the last decades, overall 5-year survival rate
for patients with advanced disease remains approximately 30%, mainly due to
primary or acquired drug resistance. Therefore, overcoming chemoresistance
remains the great challenge in ovarian cancer management. However, mecha-
nisms underlying chemoresistance to paclitaxel have not been fully understood.
The aim of this study is to identify key miRNAs which regulate paclitaxel resis-
tance in ovarian cancer and to pursue those potential as therapeutic targets.
Methods: Using two serous ovarian cancer cell lines, SKVO3ip1 and HeyA8,
paclitaxel resistant ovarian cancer cell lines were established by a continuous
exposure of paclitaxel. MiRNA PCR arrays were performed and miR-194 was
found to be one of down-regulatedmiRNAs in paclitaxel-resistant cell lines. The
effect of miR-194 on paclitaxel resistance was assessed by transducing the pre-
cursor miRNA into ovarian cancer cells. In silico analysis revealed MDM-2 is
one possible putative target of miR-194 and it was assessed using luciferase
reporter assay. Since MDM-2 is one of key regulator of P53 ubiquitination, the
effect ofmiR-194 on cell cycle in ovarian cancer cell was assessed. To analyze the
impact of miR-194 and MDM-2 expression on patient survival, Kaplan-Meier
and log-rank methods were used using The Cancer Genome Atlas (TCGA)
dataset. Results: While IC50 values of SKOV3ip1 and HeyA8 were 5.0 nM and
3.5 nM respectively, those of paclitaxel resistant cell lines, named as
SKOV3ip1-TR and HeyA8-TR, were both over 300 nM. In both resistant cell
lines, miR-194 was found to be down-regulated compared with their parental
cell lines. Up-regulation of miR-194 sensitized resistant cells to paclitaxel. Con-
versely, its downregulation induced paclitaxel resistance in parental cells. Lu-
ciferase reporter assay revealed that miR-194 directly suppressed MDM-2 tran-
scriptional activity. In resistant cell lines, MDM-2 was up-regulated compared
with their parental cell lines. MiR-194 induced P21 upregulation and G1 phase
arrest in resistant cell lines through the downregulation of MDM-2. In TCGA
dataset, high MDM-2 expression was associated with shorter progression-free
survival of ovarian cancer patients (concrete data, p0.046). Conclusion: miR-
194 acts as a tumor suppressor miRNA through the sensitization to paclitaxel
and can be considered as a therapeutic option to overcomepaclitaxel-resistant in
ovarian cancer patients.
#3437 Targeting microRNA-143 in glioblastoma in vivo increases tumor
growth. Eunice Lozada-Delgado,1 Fatma Valiyeva,2 Maria Marcos,1 Pablo Vi-
vas1. 1University of Puerto Rico, San Juan, PR; 2University of Puerto Rico Com-
prehensive Cancer Center, San Juan, PR.
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The purpose of this study is to assess the biological role of themicroRNA-143
(miR-143) in Glioblastoma multiforme (GBM). GBM is the most common and
lethal of all brain tumors. In the United States, the incidence of GBM is about
17% of all primary brain tumors and about 60-75% of all Astrocytomas (Amer-
ican Brain Tumor Association, 2014). The standard therapy is surgical tumor
removal followed by chemotherapy and radiotherapy. However, many patients
recur after treatment and the median survival rate for GBM has remained 15
months for the past 20 years. Thus, novel therapies for GBM treatment are
urgently necessary. MicroRNAs (miRNAs) are a class of small non-coding
RNAs (18-22 nucleotides in length) that regulate gene expression at the post-
transcriptional level. MiRNAs bind to the 3=-untranslate region (UTR) of mes-
sengerRNAs (mRNAs) and regulate protein synthesis. Several deregulatedmiR-
NAs have been identifıed in all cancer types includingGBM. In this studywe aim
to thoroughly uncover the role of miR-143 by using GBM cell lines, mouse
models and patient samples. Total RNA was isolated from FFPE samples from
brain tumor patients. TaqMan-based Real-time PCR showed that the relative
expression of miR-143 was higher in GBM patients compared to control indi-
viduals, and with paired surrounding non-cancerous tissue. Furthermore, GBM
cells transiently transfected with a miR-143 oligonucleotide inhibitor showed
reduced cell proliferation (68.5%) (clonogenicity assay), increased apoptosis and
cell cycle arrest of GBM cells in the S phase (Flow cytometry andWestern blots).
In vivo studies using primary GBM cells injected in the flank of nude mice
showed that repeated doses of miR-143-inhibitor liposomal formulation in-
creased the tumor size compared with control mice. These contradictory results
could be due to effects of the microenvironment where the tumor is growing.
Further studies will bemade using intracranial injections in an orthotopic xeno-
graft mouse model to confırm this hypothesis. Western blot analysis and lu-
ciferase reporter assays are also underway to identify novelmiR-143 target genes
in GBM cells. This research project is being supported by: PRCTRC: NCRR
(U54 RR 026139-01A1), NIMHD (8U54 MD 007587-03), and RCMI: MBRS-
RISE,NCRR (2G12-RR003051) andNIMHD(8G12-MD007600) from theNIH.
#3438 Dual-strands pre-microRNA-150 (miR-150-5p andmiR-150-3p) act
as tumor suppressor in prostate cancer.AtsushiOkato,1 Takayuki Arai,1 Akira
Kurozumi,1MayukoKato,1 YusukeGoto,1 Keiichi Koshizuka,1 SatokoKojima,2
Tomohiko Ichikawa,1 Naohiko Seki1. 1Chiba University, Chiba-shi, Japan; 2Tei-
kyo University Chiba Medical Center, Chiba-shi, Japan.
Background: Prostate cancer (PCa) is the second most common cause of
cancer and the sixth leading cause of cancer death among men in the world.
Androgen signaling through the androgen receptor (AR) is an important onco-
genic pathway for PCa progression. The initial response rate of PCa to androgen
deprivation therapy (ADT) can be up to 80%, but most patients experience
disease relapse and progress to castration-resistant prostate cancer (CRPC). Al-
though several clinical trials, such as molecularly-targeted therapies for CRPC
have been carried out, these treatments provide limited benefıts and, are not
curative. Therefore, identifıcation of effective biomarkers for detection of CRPC
andunderstanding themolecularmechanisms of androgen-independent signal-
ing and metastatic signaling pathways underlying PCa using current genomic
approaches would help to improve therapies for and prevention of the disease.
Currently, numerous studies have indicated that miRNAs are aberrantly ex-
pressed in several cancers, including CRPC. In this study, we constructed a
miRNA expression signature to identify miRNA regulated RNA networks in
CRPCusing autopsy specimens frompatientswithADT.Based on the signature,
dual-strands of pre-miR-150 (miR-150-5p and miR-150-3p) were signifıcantly
reduced in CRPC specimens. The aim of this study was to investigate the func-
tional signifıcance of both strands of miR-150-5p and miR-150-3p and these
miRNAs regulated RNA networks in CRPC. Results: Downregulation of miR-
150-5p and miR-150-3p were validated in hormone naive PCa and CRPC spec-
imens compared to non-cancerous prostate tissues (p 0.0001). Restoration of
miR-150-5p andmiR-150-3p signifıcantly suppressed cancer cell migration and
invasion in PCa cell lines (P  0.0001). Gene expression data and in silico
database analysis showed that Sparc/Osteonectin, Cwcv AND Kazal-Like Do-
mains Proteoglycan 1 (SPOCK1)was regulated by bothmiRNAs.Knockdownof
SPOCK1 inhibited cancer cell aggressiveness. Overexpression of SPOCK1 was
observed in PCa clinical specimens. Conclusions: InmiRNA biogenesis, it is the
general consensus that processing of the pre-miRNA through Dicer1 generates
amiRNAduplex (a passenger strand and a guide strand), and that the passenger
strand has degradation and no regulatory activity and disintegrates in cells. Our
present data showed that both strands of pre-miR-150 (miR-150-5p and miR-
150-3p) inhibited cancer cell aggressiveness, suggesting these miRNAs as tu-
mor-suppressors. Identifıcation ofmiRNA-mediated cancer networksmay pro-
vide novel molecular pathogenesis of the disease.
#3439 MicroRNA-34a epigenetically silences epithelial-mesenchymal
transitions (EMT)-TFs in metastatic breast cancer cells. Saber Imani, Chunli
Wei, Jingliang Cheng, Junjiang Fu. Southwest Medical University, Luzhou,
China.
MicroRNA-34a (miR-34a) as key regulator of tumor suppression gene poten-
tially plays a profound role in the tumorigenesis and progression of several
cancers including breast cancer. In the present study, we invstigated the expres-
sion, targets and functional effects of miR-34a and its correlation with tumour
characteristics and clinical outcome in the epithelial tomesenchymal transitions
(EMT) stage of metastatic breast cancer (MBC). We focused to analyze EMT-
inducing transcription factors (EMT-TFs)/miR-34a feedback loop, like
TWIST1, SLUG,ZEB1/2,NOTCH1, onpromotesMBCmigration, invasion and
metastasis. We found that miR-34a potently inhibits NOTCH1, ZEB1 protein
expression activity in breast cancer cells. Importantly, the miR-34a do not have
any inhibitory effects upon the SLUG and ZEB2. Using quantitative reverse
transcription-PCR and western blot analysis, we showed that average pre-miR-
34a expression is down regulated in human metastatic breast tissues as com-
pared to normal human breast and negatively correlates with clinicopathologi-
cal features ofMBC patients. Ectopic expression ofmiR-34a inmetastatic breast
cancer cell-line BT-549 signifıcantly inhibited cell proliferation,migrations, sur-
vival and cell invasion, but no clear effect on cancer cell growth. We provide
indication that these regulatory pathways may stabilize epithelial and mesen-
chymal states, individually. We have consequently revealed that miR-34a is
downregulated inMBC tissues and that it suppresses tumor growth by affecting
several malignancy endpoints via downregulation of multiple EMT-TFs. Muta-
tional or epigenetic inactivation of the EMT-TFs/miR34a pathway probably
alterations the equilibrium of these regulations toward EMT and themesenchy-
mal state and thereby contributes to metastasis. The results also suggest that
miR-34a could serve as a potential therapeutic agent forMBC. Funding support:
This work was supported by the NSFC (81172049, 81672887), Corresponding
author email:fujunjiang@hotmail.com;fujunjiang@swmu.edu.cn
#3440 MicroRNA-mediated modulation of radioresistance of glioma
stem cells. Rajbir Singh, Kamalakannan Palanichamy, Saikh Jaharul Haque,
Arnab Chakravarti. The Ohio State Univ., Columbus, OH.
Glioblastoma (GBM) is the most common primary tumor of the central ner-
vous system, with its deadly nature owing to a high rate of invasion and angio-
genesis. A key player in the GBM pathogenesis is a distinct subpopulation of
tumor cells which are capable of self-renewal, highly angiogenic and possess the
potential for extensive proliferation and multi-lineage differentiation. This cell
population termed Glioma Stem Cells (GSCs) is highly resistant to the chemo-
and radiotherapies and plays an important role in tumor initiation, progression,
and recurrence. In response to radiation therapy, GSCs are capable of triggering
the activation ofmultiple signaling pathways includingWnt,Notch, andHedge-
hog, and their DNA damage repair system is proactive. Taken together, the
efforts to foster therapeutic interventionswill prove futile, without fırst targeting
the GSC population. The miRNA network adds a dimension of regulatory con-
trol, which serves to maintain pluripotency and reprograms multiple stemness
and radioresistance promoting pathways. However, not much information is
available that could provide mechanistic insights regarding how specifıc miR-
NAs modulate radioresistance pathways. Our initial efforts involving a global
screening of microRNA profıles in different GSCs after radiation treatment re-
sulted in identifıcation of multiple microRNAs that were signifıcantly altered in
response to radiation. Based on our preliminary data, we selected 7 microRNAs
as potential candidates, with each having several targets in Notch, Wnt, PI3K/
Akt, and Hedgehog signaling pathways. In order to unfold the role of each of
identifıed microRNAs, we used specifıc lentiviral constructs to create overex-
pression/knockdown of each microRNA in GSCs. Using these stable GSC
clones, we carried out multiple in vitro studies to analyze the effects of the
respective alteration in relation to radioresistance and stemness phenotypes.
Other phenotypic studies included growth kinetics, cell proliferation, invasive-
ness, apoptosis and cell cycle. We also carried out an extensive in silico analysis
to identify the potential targets of these microRNAs. This was followed by ana-
lyzing various downstream components of the target genes. Additionally, we
carried out a context-based assessment of the overall effects to probe if there is an
integration of one ormore pathways that could lead to radiation sensitivity. Our
in vitro fındings also revealed their roles in regulating stemness and metastatic
ability in vivo. Lastly, our study provides a basis for understanding the role of
miRNAs in radioresistance phenotype and furthermore, it may lead towards
another tool to inhibit GSC proliferation and/or survival. Funding:
R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01 (NCI), Brain
Tumor Funders Collaborative Grant, and TheOhio State University CCC (all to
AC).
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#3441 A novel lncRNA-mediated YAP1 signaling pathway activation in
epithelial ovarian cancer. Xianzhi Lin, Rosario I. Corona, Simon A. Gayther,
Dennis L. Hazelett, Kate Lawrenson. Cedars-Sinai Medical Center, Los Angeles,
CA.
Background: The long noncoding RNA (lncRNA) urothelial cancer associ-
ated 1 (UCA1) is upregulated inmany cancer types, including ovarian cancer. In
high grade serous ovarian cancers (HGSOCs), we had previously found that
UCA1 expression negatively correlates with patients’ total survival and disease-
free survival and that UCA1 knockout signifıcantly impairs tumor growth in
vivo. In addition, UCA1 promotes ovarian cancer cell growth via activating the
YAP1 signaling pathway. Purpose: Our present study aims to dissect the molec-
ular mechanisms underlying YAP1 signaling activation by UCA1. Methods: To
characterize the UCA1 interactome, we utilized a modifıed in vivo RNA anti-
sense purifıcation method (UCA1-iRAP). This UCA1-iRAP method uses
streptavidin-coupled magnetic beads to pull down biotin-labeled antisense
probes which are complementary to the target RNA. In such a way, UCA1 RNA
will be specifıcally enriched together with its in vivo-associated proteins, RNAs
and/or genomic DNA, which can be profıled usingmass spectrometry (MS) and
next generation sequencing (NGS), respectively. Results: Using UCA1-iRAP
RNA-Seq and UCA1-iRAP protein MS, we comprehensively annotated the
UCA1-interacting RNAs as well as UCA1-associated proteins. Interestingly
many of the proteins identifıed were not known to have RNA-binding potential.
Integration of NGS and MS data with multilayered functional and molecular
characterization of UCA1 knockout, knockdown and overexpression models
identifıed a YAP1 modulator involved in UCA1-mediated regulation of YAP1
signaling. Through repressing this YAP1 modulator via direct RNA-protein
interaction, UCA1 promotes nuclear translocation of YAP1, resulting in activa-
tion of YAP1 target genes expression. Conclusions: Our analyses indicate, for
the fırst time, that UCA1 promotes ovarian cancer cell growth by activating
YAP1 signaling via direct interaction with a YAP1 modulator. The interaction
between UCA1 and this YAP1 modulator leads to activation of YAP1 signaling
by nuclear translocation of YAP1. In summary, we characterize a novel UCA1-
YAP1 signaling axis active in HGSOCs and also reveal that oncogenic lncRNA’s
binding potential of cytoplasmic signaling proteins could be a common mech-
anism of post-translational control of signaling pathways deregulated in cancer.
#3442 The long non-coding RNA GHSROSmediates expression of genes
associated with tumor growth, metastasis and adverse disease outcome. Pat-
rick B. Thomas,1 Penny L. Jeffery,1 ElizaWhiteside,2 CarinaWalpole,1 Michelle
Maugham,1 Lidija Jovanovic,1 Jennifer H. Gunter,1 Colleen C. Nelson,1 Adrian
C. Herington,1 Rakesh Veedu,3 Lisa K. Chopin,1 Inge Seim1. 1Queensland Uni-
versity of Technology/ Translational Research Institute, Brisbane, Australia;
2University of Southern Queensland, Toowoomba, Australia; 3Murdoch Univer-
sity/ Western Australian Neuroscience Research Institute, Perth, Australia.
Long non-coding RNAs (lncRNAs) play key regulatory roles in cancer pro-
gression and are emerging therapeutic targets. The objective of this study was to
investigate the expression and function of the lncRNA GHSROS in prostate
cancer. Quantitative RT-PCR revealed that GHSROS is highly expressed in a
subset of prostate cancers (Gleason score 8-10; z-score 1; Mann-Whitney-
Wilcoxon test P0.0021). Forced overexpression of the lncRNA stimulated cell
migration in vitro in the PC3 (1.82 	 0.35, P0.006; Student’s t-test), DU145
(1.94	 0.34, P0.017), andLNCaP (1.27	 0.02, P0.0002) prostate cancer cell
lines. Cell proliferation was increased in GHSROS overexpressing PC3 (3.36	
1.91, P0.029), DU145 (1.749 	 0.59, P0.026), and LNCaP (1.39 	 0.26,
P0.040) prostate cancer cell lines. These results were recapitulated in NOD/
SCIDmice, with increased tumor growth andKi67 immunohistochemical stain-
ing in PC3 (P0.0040) and DU145 (P  0.036) xenografts overexpressing the
lncRNA.High-throughput transcriptome sequencing (RNA-seq) identifıed 400
differentially expressed genes in GHSROS overexpressing PC3 cells, with en-
richment of genes associated with motility, migration and regulation of cell
growth. Further interrogation of the 400 gene set usingOncomine conceptmap-
ping, and interrogation of publicly-available clinical prostate cancer data sets,
revealed a 34-gene signature associated with poorer disease outcome and meta-
static progression. Preliminary analysis of The Cancer Genome Atlas (TCGA)
data, suggest that the signature has potential as a prognostic indicator for disease
free- or overall survival in numerous cancers. Finally, locked antisense oligonu-
cleotide (LNA-ASO) inhibition of endogenous GHSROS reciprocally regulated
cell growth (Student’s t-test; RNV124: -1.14 	 0.06, P0.049 and RNV104L:
-1.18 	 0.05, P0.030, migration (RNV124: -1.96 	 0.11, P0.004) and gene
expression changes, supporting the observations from forced GHSROS overex-
pression experiments.In summary, we provide evidence that GHSROS is a pros-
tate cancer associated lncRNA that promotes a gene expression signature which
enhances the propensity for metastasis and adverse disease outcomes. We also
demonstrate that GHSROS can be targeted using antisense oligonucleotides.
Further studies on this lncRNA may provide new prognostic and therapeutic
opportunities.
#3443 Functional andmechanistic characterization of oncogenic long in-
tervening non-coding RNA Linc-CHD1L-1 in hepatocellular carcinoma. Fe-
lice H. Tsang, DanielW. Ho, Irene O. Ng, Jack C.Wong. The University of Hong
Kong, Hong Kong, Hong Kong.
Hepatocellular carcinoma (HCC) is one of the most common and lethal can-
cers worldwide. Due to the asymptomatic nature of HCC, many patients were
diagnosed at advance stages and available therapeutic options are very limited.
Therefore, a better understanding of the molecular mechanism underlying
hepatocarcinogenesis is urgently needed and is crucial for the development of
effective treatment. Long intervening non-coding RNAs (lincRNAs) are emerg-
ing class of regulatory RNA involved in diverse molecular processes. In this
study, we aimed to interrogate lincRNAs expression in HCC and identify novel
lincRNAs that contribute to hepatocarcinogenesis. To investigate the global ex-
pression profıle of lincRNAs in human HCCs, next-generation transcriptome
sequencing (RNA-Seq) was performed in 16 pairs of HBV-associated primary
HCCs and their corresponding non-tumorous liver tissues. Interestingly, the
lincRNA expressions in human HCCs can be unambiguously segregated from
their non-tumorous counterparts by unsupervised clustering analysis, suggest-
ing that global lincRNA expression profıles between tumors and non-tumors
were remarkably different. From this analysis, we identifıed linc-CHD1L-1 as
the most signifıcant up-regulated lincRNA in HCCs. Clinically, linc-CHD1L-1
was overexpressed in over 80% of HCC patients. Linc-CHD1L-1 expression
level in tumors was also shown to be a promising marker for HCC diagnosis.
Functionally, knockdown of linc-CHD1L-1 by shRNAs had signifıcantly re-
ducedHCC cell proliferation and cell migration in vitro. Besides, knockdown of
linc-CHD1L-1 in HCC cells also substantially abrogated tumorigenicity in sub-
cutaneous tumor model. Mechanistically, the expression of linc-CHD1L-1 was
signifıcantly and positively correlated to the expression of its neighboring genes
located on the chromosome 1q. Knockout of linc-CHD1L-1 by CRISPR/Cas9
also signifıcantly repressed its neighboring genes expression, suggesting that
linc-CHD1L-1may positively regulate gene expression in a cis-manner. Finally,
DAVID pathway analysis performed on linc-CHD1L co-expressed protein cod-
ing genes further suggested that linc-CHD1L-1 was signifıcantly co-expressed
with genes that are involved in transcription and chromatin modifıcations. In
conclusion, overexpression of linc-CHD1L-1 contributes to hepatocarcinogen-
esis by promotingHCC cell proliferation andmigration through transcriptional
and epigenetic mechanisms.
#3444 LINC00152 regulates cell proliferation via p38 signaling and over-
expression predicts poor patient survival in lung cancer. Shumei Feng, Jie
Zhang,Wenmei Su, Shengbin Bai, Lei Xiao, ZhuwenWang, Jules Lin, Rishindra
Reddy, Andrew Chang, David Beer, Guoan Chen. Univ. of Michigan Medical
School, Ann Arbor, MI.
Lung cancer is a molecularly-heterogenous disease and the leading cause of
cancer mortality. The molecular basis for this heterogeneity remains incom-
pletely understood. In the past few years, long non-coding RNAs (lncRNAs)
have emerged as novel mechanisms inmediating cancer biology, althoughmost
lncRNAs are still undiscovered. LINC00152 has been identifıed as highly asso-
ciated with the tumorigenesis and development in gastric cancer, colon cancer
and hepatocellular carcinoma, however, the expression level and its oncogenic
roles in lung cancer remains unknown. In the present study, we employed next
generation RNA sequencing analysis to reveal dysregulated lncRNAs in lung
cancer utilizing datasets of 461 lung adenocarcinomas (LUAD) and 156 normal
lung tissues from 3 separate institutions. We found that LINC00152 was 4-fold
(p0.001) overexpressed in lung tumors as compared to their adjacent normal
tissues with AUC  0.8 in these 3 data sets. Patients with high LINC00152
expression have signifıcantly poorer survival than those with low expression
(log-rank test, p 0.003).We verifıed this diagnostic/prognostic potential in an
independent cohort of lung tumor tissues by quantitative RT-PCR. Cell prolif-
eration and colony formation ability were decreased after knockdown of
LINC00152 using siRNAs in lung cancer cell lines. The expression of
LINC00152was found primarily in the cytoplasmby qRT-PCR analysis. Tricho-
statin A treatment indicated that histone acetylation could be one of the mech-
anisms underlying LINC00152 overexpression in NSCLC and cell-based analy-
ses showed p38 signaling was mainly affected by LINC00152 in vitro. Taken
together, our study suggests that LINC00152 is involved in lung tumor growth,
may have potential as diagnostic/prognostic marker and that further character-
ization of this lncRNA as a novel therapeutic target for lung cancer is warranted.
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#3445 ZFAS1 is upregulated in GBM tissue and affects viability and mi-
gration of GBM cells in vitro. Jiri Sana,1 Marek Vecera,1 Romana Butova,1
Jaroslav Juracek,1 Tana Machackova,1 Parwez Ahmad,1 Natalia Anna Gablo,1
Kamila Souckova,1 Leos Kren,2 Radim Lipina,3 Martin Smrcka,2 Ondrej Slaby1.
1Masaryk Univ., Brno, Czech Republic; 2University Hospital Brno, Brno, Czech
Republic; 3University Hospital Ostrava, Ostrava, Czech Republic.
Introduction: Glioblastoma multiforme (GBM) is the most frequent primary
brain tumor of astrocytic origin characterized by very poor prognosis. Despite
conventional therapeutic protocol the prognosis of GBM patients is very poor
with median of overall survival ranging between 12 and 15 months from diag-
nosis. Therefore, many fınancial charges and lot of effort is spent in research of
new therapeutic approaches that could prolong the survival of GBM patients.
Long non-coding RNAs (lncRNAs) are a relatively new class of noncoding gene
regulators playing critical roles in tumor biology, including GBM. From this
perspective, lncRNAs seem to be promising therapeutic targets inGBMpatients.
Material and Methods: We performed next-generation sequencing analysis of
fresh-frozen histopatologically confırmed 45 GBM tissues and 5 non-tumor
brain tissues obtained from non-dominant anterior temporal cortexes resected
during surgery for intractable epilepsy. Informed consent approved by the local
Ethical Commissionwas obtained fromeach patient before the treatment. rRNA
depletion and cDNA library preparation were performed with GeneRead rRNA
Depletion Kit (Qiagen) and NEXTflex Rapid Directional qRNA-Seq Kit (Bioo
Scientifıc), respectively. Sequencing was held using NextSeq 500 High Output
Kit and NextSeq 500 instrument (both Illumina). Statistical analysis evaluated
24 087 protein-coding and 8 414 non-coding RNAs and their sequential variants
with non-zerou RPKM (Reads Per Kilobase of transcript per Million mapped
reads) at least in one sample. We used CLC genomic workbench for the align-
ment and target counts. Targeted regulation of ZFAS1 level have been carried
out by the transient transfection of specifıc siRNA in GBM stable cell lines
(A172, T98G, U87MG, U251). Viability and migration were analyzed in vitro
using MTT and scratch wound healing assay, respectively. Results: Statistical
analysis has revealed 274 (P 0.01) deregulated lncRNAs in GBMs in compar-
ison with non-tumor brain samples.Moreover, the results have showed also 489
deregulated proten-coding RNAs with P value less than 0.001 and 26 protein-
coding RNAswith P value less than 0.000001. For subsequent in vitro functional
analyses was chosen one of the most upregulated lncRNAs in GBM samples
ZFAS1. Targeted downregulation of this molecule led to the signifıcant reduc-
tion of viability in all examined GBM cell lines. Decreasing of proliferation
potential was observed only in A172 a U251 cell lines. Conclusion: We have
demonstrated a deregulation of many lncRNAs and protein-coding RNAs in
GBM tissue in comparison with non-tumor brain tissue. Moreover, ZFAS1, one
of the most upregulated lncRNAs in GBM tissue, is involved in regulation of
viability and migration of GBM cell lines in vitro. This work was supported by
Ministry of Health of the Czech Republic, grant nr. 15-33158A, 15-34553A,
15-31627A, 15-34678A, 16-31314A, 16-31765A and by grant of Czech Grant
Agency nr. 16-18257S.
#3446 Melatonin suppresses hepatocellular carcinoma progression via ln-
cRNA-CPS1-IT-mediated HIF-1 inactivation. Tong Hong Wang,1 Chi Hao
Wu,2 Chau Ting Yeh,1 Kung Hao Liang,1 Chuen Hsueh,1 Chi Yuan Chen3.
1Chang Gung Memorial Hospital, Tao-Yuan, Taiwan; 2Taipei Medical Univer-
sity, Taipei, Taiwan; 3Chang Gung University of Science and Technology, Tao-
Yuan, Taiwan.
Background: Melatonin, the main pineal hormone that relays light/dark
cycle information to the circadian system, was recently reported to have
intrinsic antitumor activity in various cancers. However, the detailed regu-
latory mechanisms associated with antitumor activity of melatonin are not
well understood yet. Moreover, limited studies have addressed the role of
melatonin in hepatocellular carcinoma (HCC), the major life-threatening
malignancy for both sexes in Taiwan. Hence, in this study, we investigated
the antitumor activity of melatonin on HCC and explored its regulatory
mechanism. Methods: Human hepatoma cell lines HepG2 and Huh7 were
treated with melatonin followed by functional assays to dissect antitumor
effect of melatonin in HCC. The whole transcriptome sequence analysis was
performed to explore the long non-coding RNAs (lncRNAs) involved in the
anti-HCC activity of melatonin. Further, quantitative RT-PCR, western blot,
immunohistochemistry assays, and in vivo animal model experiments were
performed to elucidate the regulatory mechanism of lncRNAs in melatonin-
mediated HCC suppression. Results: Melatonin signifıcantly inhibited cell
proliferation, migration, and invasion capacity of HCC cell lines, while the
expression of transcription factor FOXA2 was signifıcantly induced in cells
treated with melatonin. The increase in expression of FOXA2 resulted in
upregulation of lncRNA-CPS1-IT1 expression, which in turn reduced bind-
ing and activation of Hsp90 with HIF-1. The inactivation of HIF-1 re-
sulted in the suppression of epithelial-mesenchymal transition (EMT) pro-
gression and HCC metastasis. Furthermore, the results of the in vivo animal
model experiments also validated the tumor-suppressor role of melatonin
via a reduction in tumor growth. Conclusions: Taken together, our fındings
suggested that melatonin inhibited HCC progression by modulating ln-
cRNA-CPS1-IT1-mediated EMT suppression and further supported mela-
tonin as a promising therapeutic agent for the treatment of HCC.
#3447 Down-regulation of long non-coding RNA MALL-2 is associated
with metastasis and poor survival in lung adenocarcinoma. Ha X. Dang, Ni-
cole M. White, Emily B. Rozycki, Christopher A. Maher. Washington Univ.
School of Medicine, St. Louis, MO.
Lung adenocarcinoma accounts for 40% of lung cancers and is among
the deadliest cancers worldwide. Patients with metastatic lung adenocarci-
noma exhibit poor outcome with the average 5-year survival of 1%. Long
non-coding RNAs (lncRNAs) have recently emerged as having critical roles
in tumorigenesis. While a subset of lncRNAs have been shown to promote
tumor invasion and metastasis, little is known about the role of lncRNAs in
metastatic lung adenocarcinoma. Therefore, we analyzed publicly available
microarray and RNA-Seq gene expression datasets that include primary and
metastatic tissues. Through this meta-analysis we discovered 98 metastasis
associated lncRNAs that were dysregulated in metastatic tumors compared
to non-metastatic tumors (MALLs). Notably, only two lncRNAs (MALL-2
andMALL-36) were found to be down-regulated in primary tumors, relative
to normal tissue, and even further down-regulated in metastatic tumors
relative to primary tumors. Gene set enrichment analysis revealed that
MALL-2, the most down-regulated lncRNA in metastasis, was coexpressed
with protein-coding genes enriched with biological concepts associated with
repressing tumor growth and metastasis. Furthermore, we found that
FOXA2, ametastasis repressor gene, was highly coexpressed withMALL-2 in
lung cancer. A pan-cancer analysis using 7,000 TCGA RNA-Seq tumor
samples across 20 cancer types revealed that MALL-2 was also down-regu-
lated and coexpressed with FOXA2 in multiple cancers suggesting the con-
served regulatory relationship between the two genes. We confırmed that
FOXA2 expression was decreased upon knock-down of MALL-2 and silenc-
ing MALL-2 resulted in a signifıcant increase in cellular migration in lung
adenocarcinoma cell lines. Last, we found that low expression of MALL-2
was consistently associated with poor overall survival across multiple inde-
pendent lung adenocarcinoma cohorts. Taken together, our integrative anal-
ysis has revealed MALL-2 that acts as a repressor of lung adenocarcinoma
metastasis by regulating FOXA2 and could serve as a biomarker of lung
adenocarcinoma patient outcome.
#3448 LncRNA HAND2-AS1 inactivates neuromedin U (NMU) and in-
hibits tumor invasion and metastasis in endometrioid endometrial carci-
noma. Xueying Yang, Yu Zhao, Kun Sun, Yuying Li, Jiajian Zhou, Jianzhang
Wang, Hao Sun, Chi Chiu Wang, Joseph Kwong, Huating Wang, Tony Kwok
Hung Chung. The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Background: Endometrioid endometrial carcinoma (EEC) is one of the
common cause of cancer-related mortality in women. Despite progress in
diagnostics and treatment of EEC, its prognosis remains poor. Mounting
evidence suggest that long noncoding RNAs (lncRNAs) function in mutiple
human cancers. Aberrant lncRNA expression may predict tumor outcome of
patients and have served as diagnostic or prognostic markers. In this study,
we investigated the expression levels and functions of lncRNAs in EEC.
Methods: Differentially expressed lncRNAs involved in EEC were identifıed
by using publically available RNA-Seq data. The expression of 18 dysregu-
lated lncRNA candidates was verifıed in 5 NE tissues, 5 EEC tissues and 5
EEC cell lines (HEC1-A, HEC1-B, AN3CA, KLE and RL95-2) by real-time
polymerase chain reaction (PCR). Further, we selected the most misex-
pressed lncRNA and confırmed the expression level of the lncRNA in 59 EEC
tissues and 24 NE tissues by real-time PCR and correlated the lncRNA ex-
pression levels with the clinical pathological characteristics. The promoter
methylation assay was used to analyze the methylation level of the lncRNA in
EEC. The lncRNA methylation status was confırmed by bisulfıte genomic
sequencing. Cell proliferation assays, wound healing assays, and invasion
and migration assays were performed to determine the biological functions
of the lncRNA in EEC cells. To discover the direct targets of the lncRNA in
EEC, we performed RNA-sequence analysis in EEC cells overexpressed with
the lncRNA and target genes were further studied by functional studies in
vitro (knockdown assay and overexpression rescue assay). Results: We dis-
covered that HAND2-AS1, a lncRNA transcribed antisense adjacent to
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Heart and Neural Crest Derivatives Expressed 2 (HAND2), was signifıcantly
downregulated lncRNA in EEC. HAND2-AS1 and HAND2 was frequently
downregulated in EEC tissues, especially in poor differentiated tumor tis-
sues. Downregulation of HAND2-AS1 and HAND2 was correlated with tu-
mor grade, lymph node metastasis and recurrence of EEC patients. HAND2-
AS1 and HAND2 was co-downregulated by promoter hypermethylation in
EEC. HAND2-AS1 suppressed EEC cell migration and invasion but not cell
growth. Similarly, HAND2 also inhibited EEC cell migration and invasion
indicating that HAND2-AS1 and HAND2 have a concordant role in the
progression of EEC. Moreover, the anti-tumorigenic effect of HAND2-AS1
was mediated by downregulating NMU, which had an oncogenic role in
EEC. Conclusions: Our fındings provide the fırst evidence that HAND2-AS1
is a critical tumor suppressor in EEC and may constitute a prognostic bio-
marker in EEC.
#3449 Genistein inhibits renal cancer progression through long non-cod-
ing RNAHOTAIR suppression.Mitsuho Imai-Sumida, ShahanaMajid, Pritha
Dasgupta, Priyanka Kulkarni, Sharanjot Saini, Divya Bhagirath, Taku Kato,
Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Guoren Deng, Varah-
ram Shahryari, Yuichiro Tanaka, Rajvir Dahiya, Soichiro Yamamura.UCSF VA
Medical Ctr., San Francisco, CA.
Genistein, a soy isoflavone, has been shown to have anticancer effects on
various cancers in vitro and in vivo including renal cancer. Long non-coding
RNAs (lncRNAs) are differentially expressed in various tissues and have
important functions in cellular processes such as cell proliferation, motility
and apoptosis in various malignancies. HOX transcript antisense RNA
(HOTAIR) is a lncRNA localized in the Homeobox C gene cluster on chro-
mosome 12. HOTAIR interacts with the polycomb repressive complex 2
(PRC2), which enhances H3K27 trimethylation and represses the expression
of tumor suppressors. In various cancers, HOTAIR is highly expressed and
involved in their progression and metastasis. In this study, we investigated
the molecular mechanisms of genistein action through a novel pathway that
represses HOTAIR. We found that HOTAIR expression is higher in renal
cancer cell lines compared to normal controls. Genistein treatment was
found to signifıcantly decrease HOTAIR expression in renal cancer cells
(786-O and ACHN cells). Genistein treatment also reduced expression of
epithelial-to-mesenchyme transition (EMT)-related proteins (ZEB1, Vi-
mentin and Snail), causing reduced cell migration, invasion, and increased
apoptosis. We performed RNA immunoprecipitation assays, and found that
genistein inhibits HOTAIR binding to PRC2. One of the other EMTmarkers,
a tight junction protein ZO-1, is upregulated by genistein. We are currently
investigating if genistein represses PRC2 recruitment to the ZO-1 promoter
by inhibiting binding of HOTAIR to PRC2. Our results indicate that
genistein is a potent therapeutic agent for renal cancer.
#3450 Identifıcation of a novel lncRNA involved in Bcr-Abl mediated
cellular transformation. Jilong Chen,1 Xuefei Wang2. 1Fujian Agriculture and
Forestry University, Fuzhou, China; 2Chinese Academy of Sciences, Beijing,
China.
Aberrant expression of long noncoding RNAs (lncRNAs) is associated with
various human cancers.However, little information is available about functional
involvement of lncRNAs in tumorigenesis of chronic myeloid leukemia (CML)
induced by Bcr-Abl oncogene. In this study, we performed a comprehensive
analysis of lncRNAs in human CML cells using an lncRNA cDNA microarray
combined with drug treatment.We identifıed an lncRNA termed lncRNA-up38
that was critically involved in Bcr-Abl-mediated cellular transformation. We
found that expression of lncRNA-up38 was greatly upregulated by inhibiting
Bcr-Abl kinase activity in K562 cells and leukemic cells derived from CML
patients. Furthermore, our experiments demonstrated that lncRNA-up38 acted
as a key regulator of 4EBP1 functioning during Bcr-Abl-mediated cellular trans-
formation.Moreover, silencing lncRNA-up38 promoted leukemic cells survival
and enhanced Bcr-Abl-mediated tumorigenesis, whereas forced expression of
lncRNA-up38 sensitized leukemic cells to undergo apoptosis and inhibited Bcr-
Abl-induced tumorigenesis. Additionally, our experiments have begun to ad-
dress themechanism of how lncRNA-up38 is regulated in the leukemic cells and
showed that Bcr-Abl repressed lncRNA-up38 expression through c-Myc-de-
pendent signaling. Taken together, these results reveal that Bcr-Abl-mediated
cellular transformation is associated with downregulation of tumor-suppressor
lncRNA-up38 and suggest a potential strategy for the treatment of Bcr-Abl-
positive leukemia.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Mitosis,
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#3451 Depletion of Mastl kinase inhibits cancer growth by induction of
mitotic catastrophe in breast cancer. Yoon Yina, Jae Sung Kim. Korea Inst. of
Radiological Medical Sci., Seoul, Republic of Korea.
Targeting mitotic kinase is an emerging anticancer strategy with promising
pre-clinical results. Mastl is an essential mitotic kinase regulating mitotic pro-
gression by inactivation of a tumor suppressor protein phosphatase 2A (PP2A).
However, it is unclear whether inhibition of Mastl kinase can kills tumor cells.
Here, we show that Mastl inhibition selectively kills cancer cells by induction of
mitotic catastrophe in breast cancer cells. We found that Mastl overexpression
was tightly associated with tumor progression and poor prognosis in breast
cancer. Mastl depletion with specifıc siRNAs induced cell death in Mastl high
breast cancer cells, but not in Mastl low breast cancer cells. Interestingly, Mastl
depletion did not affect the viability of normal cells. In addition,Mastl depletion
reduced the oncogenic properties of breast cancer cells. Furthermore, we found
that Mastl depletion caused mitotic catastrophe. Therefore, our data indicate
that inhibition of Mastl can selectively kill breast cancer cells by induction of
mitotic catastrophe, providing that targeting Mastl kinase is a very useful ap-
proach for breast cancer treatment.
#3452 The cohesin subunit STAG1 is a hardwired genetic dependency of
STAG2 mutant cancer cells. Petra Van Der Lelij,1 Simone Lieb,2 Julian Jude,1
Gordana Wutz,1 Catarina Pereira,3 Katrina Falkenberg,1 Jozef Ban,4 Heinrich
Kovar,4 ToddWaldman,5 Francisco Real,3 Mark Pearson,2 Norbert Kraut,2 Jan-
Michael Peters,1 Johannes Zuber,1 Mark P. Petronczki2. 1The Research Institute
of Molecular Pathology, Vienna, Austria; 2Boehringer Ingelheim RCV, Vienna,
Austria; 3CNIO: Spanish National Cancer Research Centre, Madrid, Spain;
4CCRI- Children’s Cancer Research Institute, Vienna, Austria; 5Georgetown
School of Medicine, Washington, DC.
Recent genome analyses have identifıed recurrent mutations in subunits of
the cohesin complex in human cancer. Cohesin is a chromosomal factor that is
essential for sister chromatid cohesion and cell division and that contributes to
gene regulation and DNA repair. Deleterious mutations in the cohesin subunit
STAG2 have been detected in about 20% of bladder cancer, 15% of Ewing sar-
coma and 6% of AML/MDS patients. The mechanistic involvement of cohesin
mutations in the pathogenesis of human malignancies is currently under active
investigation.We hypothesized that the loss of STAG2 could alter the properties
and functionalities of the cohesin complex leading to unique vulnerabilities of
STAG2mutant cells. UsingCRISPR/Cas9 andRNAi in isogenic solid cancer and
leukemic models we identifıed STAG1, a STAG2 paralog, as a strong and clean
genetic vulnerability of STAG2mutant cells. Mechanistically, STAG1 loss abro-
gates sister chromatid cohesion specifıcally in STAG2mutant but not wild-type
cells leading tomitotic catastrophe, defective cell division and apoptosis. STAG1
inactivation inhibits the proliferation of disease relevant STAG2mutant but not
wild-type bladder cancer and Ewing sarcoma cell lines. Restoration of STAG2
expression in a mutant bladder cancer model alleviates the dependence on
STAG1. Our results demonstrate that the cohesin subunits STAG1 and STAG2
act redundantly to support sister chromatid cohesion and cell viability in human
cells. We have identifıed STAG1 as a hardwired, context independent vulnera-
bility of STAG2 mutant cancers. Specifıc synthetic lethalities elicited by recur-
rent cohesinmutations in human tumors hold the promise for the development
of selective therapeutics.
#3453 Progression through mitosis promotes PARP inhibitor induced
cytotoxicity in homologous recombination defıcient cancer cells. Pepijn M.
Schoonen,1 Peter Bouwman,2 Floris Foijer,3 Madalena Tarsounas,4 Sohvi Blat-
ter,5 Jos Jonkers,2 Sven Rottenberg,5 Marcel A. Vugt, van1. 1University Medical
CenterGroningen,University of Groningen, Groningen,Netherlands; 2Division of
Molecular Pathology and Cancer Genomics Netherlands, Amsterdam, Nether-
lands; 3European Research Institute for the Biology of Ageing, University of Gro-
ningen University Medical Center Groningen, Groningen, Netherlands; 4Oxford
Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom;
5Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Swit-
zerland.
Mutations in homologous recombination (HR) DNA repair genes BRCA1
and BRCA2 predispose to tumorigenesis. HR-defıcient cancers are hypersensi-
tive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can acquire resis-
tance and relapse. The mechanisms underlying PARP inhibitor resistance are
only partially understood. This lack of knowledge in part stems from incomplete
understanding of howPARP inhibitors induce cytotoxicity inHR-defıcient can-
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cers. The aim of this study was to investigate the contribution of mitotic failure
to PARP inhibitor-induced cytotoxicity. Using theDNA fıber assay we observed
compromised replication fork protection upon BRCA2 depletion, which was
aggravated upon PARP inhibition. In accordance with the loss of replication
fork stability, we found increased FANCD2 foci in interphase cells upon BRCA2
depletion, and a signifıcant further increase when BRCA2-depleted cells were
treated with PARP inhibitor as assessed by immunofluorescence. Importantly,
these replication lesions were not resolved prior to mitotic entry, as increased
numbers of FANCD2 foci were observed in mitotic cells of BRCA2-depleted
cells, which were further increased upon PARP inhibitor treatment. Subse-
quently we found that inmitosis, BRCA2 or BRCA1 and Brca2 or Brca1 deletion
resulted in elevated levels of chromatin-bridges and lagging chromosomes
which were greatly enhanced after PARP inhibition. Live-cell microscopy
showed that chromatin bridges in anaphase often lead to cytokinesis failure with
subsequent multinucleated progeny cells or cell death. Furthermore, PARP in-
hibitor-induced multinucleated cells failed clonogenic outgrowth and high per-
centages of multinucleated cells were found in vivo in the remnants of Brca2
-/-
;
p53-/- and Brca1-/-;p53-/- mammary mouse tumors upon PARP inhibitor
treatment, suggesting that mitotic progression promotes PARP inhibitor-in-
duced cell death. Indeed, enforced mitotic bypass through EMI1 depletion ab-
rogated the cytotoxic potential of PARP inhibitor sensitivity and indicates that
progression throughmitosis promotes cell death in response to PARP inhibitors
in HR-defective cells. These fındings add to our understanding how PARP in-
hibition induces cytotoxicity. Furthermore, these results provide starting points
in tackling tumor resistance to PARP inhibitors, and point at combination ther-
apies which could potentiate the effects of PARP inhibitors for the treatment of
HR-defıcient tumors.
#3454 Autophagy governs tumorigenic effects followingmitotic slippage.
Karen C. Crasta, Bing Cheng, Ke Guo.Nanyang Technological Univ., Singapore,
Singapore.
Antimitotic drugs are often administered as fırstline chemotherapy in several
malignancies. However, their clinical success is often limited by acquired
chemoresistance and disease relapse. The anti-proliferative basis of these drugs
is induction of mitotic arrest culminating in cell death. Mitotic slippage occurs
when cells exit mitosis and “slip” into interphase without chromosome segrega-
tion and cytokinesis. Little is known about how cells post-slippage influence
outcome of treatment. Here, we demonstrate that post-slippage cells exhibit
paracrine pro-tumourigenic potential following senescence and senescence-as-
sociated secretory phenotype development. This occurs in an autophagy-p53
axis-dependent manner, with autophagic inhibition in post-slippage cells by-
passing senescence and leading to cell death. Indeed, the autophagy inhibitor
Chloroquine and microtubule poisons synergistically inhibited tumour growth
in mice. Hence, regimens targeting the senescence phenotype could provide a
potential effective combinatorial strategy with antimitotic drugs. Sensitivity to
this combinatorial treatment was dependent on p53 status, an important factor
to consider before treatment.
#3455 Cystatin C decreases proliferation of melanoma cells by affecting
mitosis length.HannaWallin,1KerstiAlm,2MagnusAbrahamson1. 1LundUni-
versity, Lund, Sweden; 2Phase Holographic Imaging, Lund, Sweden.
Cystatin C is a small secreted protein, produced by most cells in the body
and found in signifıcant quantities in all body fluids. It is the major inhibitor
of extracellular cysteine protease activity in mammals because of its rapid
binding to virtually all known cysteine proteases of families C1 (cysteine
cathepsins) and C13 (mammalian legumain). Cystatin C has also been
shown to inhibit viral replication within cells and display protective effects
against cancer cell invasion. The protein has recently been shown to get
internalized into cancer cells, providing an explanation to possible intracel-
lular effects of the inhibitor. The purpose of the present study was to eluci-
date possible direct effects of cystatin C on cancer cell growth, by use of
holometric imaging to analyze proliferation rate as well as to monitor the
mitosis phase in real-time. Human A375 melanoma cells were cultured with
and without addition of physiological quantities of cystatin C added to the
culture medium (1micromolar fınal concentration). The cultures were mon-
itored for up to 3 days in a standard incubator using a HoloMonitor M4
instrument. Settings were optimized to allow accurate counting of cells
throughout the experiment by analysis of images captured, revealing an
inhibitory effect on overall cell proliferation rate by cystatin C addition to the
cultures. To analyze the migration and cell division of individual cells, im-
ages were captured at short intervals allowing tracking and monitoring of
cell morphology with respect to parameters such as thickness/density and
area. Parameters could be set to defıne start of the mitosis phase indicated by
a distinct rounding-up of cells and followed until a natural stop at cytokine-
sis, whereafter the daughter cells could be continuously tracked. These anal-
yses revealed qualitative differences in the normal migration behavior of the
A375 cells under study as a result of cystatin C addition. Moreover, the
mitosis phase was considerably prolonged in cells grown in cystatin C con-
taining medium, indicating that the proliferation-inhibiting effect of the
protease inhibitor may be through its direct action on proteolytic processes
in the actual mitosis phase. This fınding justifıes in-depth studies on addi-
tional cancer cell types to reveal how general the anti-proliferative effect of
cystatin C is and how it can be explored to possibly control cancer cell growth
and spread. The use of real-time holometric imaging of growing cells should
be a most useful tool in such studies.
#3456 Centromere gene misregulation is a major source of chromosomal
instability in human cancers and predicts patient response to specifıc thera-
pies.Weiguo Zhang,1 Jian-HuaMao,1Wei Zhu,2 AnshuK. Jain,3 Ke Liu,1 James
B. Brown,1 Gary H. Karpen1. 1Lawrence Berkeley National Lab, Berkeley, CA;
2Cellular Biomedicine Group, Inc., Shanghai, China; 3Yale School of Medicine,
New Haven, CT.
Chromosomal instability (CIN) is a cancer hallmark that contributes to tu-
mor heterogeneity and other malignant properties. Aberrant centromere func-
tion causes CIN through chromosomemissegregation in experimental systems.
CENP-A is a histone H3 variant found at centromeres. Centromere is regulated
epigenetically by replenishing CENP-A chromatin during cell divisions. This
process requires a dedicated CENP-A chaperone called HJURP and other fac-
tors. However, we are lack of a comprehensive understanding about whether
these proteins are involved in clinical cancers, and how centromere misregula-
tion may contribute to cancer development. Here, basing on our previous fınd-
ings in Drosophila melanogaster, we identifıed a conserved mutual protection
mechanism between CENP-A andHJURP between flies and human cells, where
their physical interaction protects each other from being targeted for degrada-
tion.Moreover, we showed thatHJURP stability is regulated both in vitro and in
vivo by the Anaphase Promoting Complex/Cyclosome (APC/C) ubiquitin E3
ligase.We further demonstrated that CENP-A andAPC/C compete for the same
binding site on HJURP. Using isogenic breast cancer cell culture progression
series, we found thatmany centromere proteins are progressively overexpressed
at the protein level during tumorigenesis. These results led us to hypothesize that
overexpression of centromere proteins may cause centromere misregulation
andCIN, and contribute to human cancers. To test the idea, we developed a CES
(Centromere and kinetochore gene Expression Score) signature that quantitates
the mRNA levels of 14 key genes required for centromere structure in cancers.
High tumor CES values strongly correlate with increased copy number altera-
tions and mutation frequencies across many cancer types, and prognosticate
poor patient survival for many cancers. High CES values also signify high levels
of genomic instability that sensitize cancer cells to additional genotoxicity. In-
deed, the CES signature forecasts patient response to adjuvant chemo- or radio-
therapy for lung and breast cancers. In conclusion, we demonstrate regulation of
HJURP by APC/C ubiquitin E3 ligase, mutual protection between the key cen-
tromere proteins CENP-A and HJURP, and a mode of misregulation of centro-
mere protein genes in human cancers.We show the effıcacy of theCES signature
as a potential biomarker to identify patients who likely respond to specifıc treat-
ments, thus spare the non-responding patients from less effective treatments.
These fındings are expected to help address the over-treatment problem preva-
lent in cancer treatments. Our approach validates the critical importance of
incorporating basic knowledge of chromosome segregation pathways into can-
cer research and clinical applications.
#3457 Stable aneuploid cells are more sensitive to TTK inhibition than
chromosome instable cell lines. Marion A.A. Libouban,1 Jeroen A.D.M. de
Roos,2 Joost C.M. Uitdehaag,2 NicoleWillemsen-Seegers,2 SaraMainardi,1 Jelle
Dylus,2 Jos de Man,2 Bastiaan Tops,3 Jules P.P. Meijerink,4 Zuzana Storchová,5
Rogier C. Buijsman,2 René H.Medema,1 Guido J.R. Zaman2. 1NKI, Amsterdam,
Netherlands; 2Netherlands Translational Research Center B.V, Oss, Netherlands;
3Radboud University Medical Center, Netherlands; 4Princess Máxima Center for
Pediatric Oncology, Netherlands; 5University of Kaiserslautern, Germany.
Inhibition of the spindle assembly checkpoint kinase TTK causes chromo-
some mis-segregation and tumor cell death. High levels of TTK correlate with
chromosomal instability (CIN), which can lead to aneuploidy. To investigate the
potential relationship of CIN and sensitivity to TTK inhibition, we performed
CIN analysis in human cancer cell lines from different tumor tissue origins and
with different relative sensitivity to the selective TTK inhibitor NTRC 0066-0
[1]. By time lapse microscopy we observed that treatment with TTK inhibitor
resulted in overriding of the mitotic checkpoint, irrespective of cell line sensi-
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tivity. Aneuploid but chromosomal stable cell lines weremore sensitive than cell
lines that already displayed high levels of CIN. In sensitive cell lines, treatment
with TTK inhibitor induced acute chromosome mis-segregration. On the con-
trary, in populations of cells that already showed high levels of CIN, there was
only a small additional fraction of cellsmis-segregating their chromosomes. The
resistant cell lines were all hypo-triploid instable cell lines, which are thought
to be derived from cells with a double diploid genome (tetraploid cells) that have
lost certain chromosomes. Next, we studied the effect of NTRC 0066-0 on three
cell lines evolved via tetraploidization of the colorectal adenocarcinoma cell line
HCT 116 referred as tetraploids. The tetraploids have low levels of CIN and
were recently shown to display low level multidrug resistance against various
cytotoxic agents and several targeted drugs. Proliferation of the tetraploids was
inhibited with the same potency as the diploid parental cell line by three TTK
inhibitors. Parental and tetraploids were also equally sensitive to reversine, a
compound that is often used as a TTK reference inhibitor but whose selectivity
has been disputed. In surface plasmon resonance binding experiments we mea-
sured a 800 times more potent binding of reversine to TTK over Aurora B. In a
comparative cancer cell panel profıling study with 122 different anti-cancer
agents [2], reversine clustered together with TTK inhibitors, demonstrating that
in cells reversine acts as a TTK inhibitor. Finally, we show that NTRC 0066-0
inhibits the proliferation of primary human patient-derived colorectal cancer
organoids with potencies similar to that of immortalized cancer cell lines. In
contrast, treatment with TTK inhibitor did not reduce the viability T cell acute
lymphoblastic leukemia cell samples, which are non-proliferating cells and very
sensitive to classic chemotherapeutic agents, such as daunorubicin. These data is
consistentwith the function of TTKas a spindle assembly checkpoint kinase that
is only active in proliferating cells. Consequently, TTK inhibitor therapy is ex-
pected to spare non-dividing cells, whereas it may be used to target stable ane-
uploid tumors. [1] Maia et al. (2015) Annals of Oncology; [2] Uitdehaag et al.
(2016) Molecular Cancer Therapeutics.
#3458 Role of zyxin in mitosis and colon cancer. Jiuli Zhou, Jixin Dong,
Yuanhong Chen, Xingcheng Chen, Seth Stauffer, Yongji Zeng. University of
Nebraska Medical Center, Omaha, NE.
Zyxin is a LIM domain protein that is concentrated at sites of cell-cell adhe-
sion,where it is proposed to dockproteins involved in cytoskeletal dynamics and
signaling. Recently, Zyxin has been shown to promote LATS degradation and
YAP activation inHippo Pathway. Here,We have identifıed a novel mechanism
for phospho-regulation of Zyxin in mitosis and its biological signifıcance in
colon cancer. We found that the mitotic kinase cyclin-dependent kinase 1
(CDK1) phosphorylates Zyxin in vitro and in vivo at serine 281, serine 308 and
serine 344 during antimitotic drug-inducedG2/Mphase arrest and unperturbed
mitosis. Moreover, Zyxin mitotic phosphorylation-defıcient mutant (Zyxin3A,
harboring S281A/S308A/S344A) was suffıcient to suppress colon cancer cell
proliferation and migration. We further demonstrated that depletion of Zyxin
resulted in impaired colon cancer tumorigenesis in vitro and in vivo through
inhibiting F-actin cytoskeleton and YAP activity. Importantly, these observa-
tions could be fully rescued by re-expression of wild type Zyxin, but not
Zyxin-3Amutant. Expression profıle analysis revealedCDK8 (cyclin-dependent
kinase 8) as a mediator downstream Zyxin/YAP. Inhibition of CDK8 pheno-
copied knockdown of Zyxin in colon cancer cells. Ectopic expression of CDK8
substantially restored the tumorigenic ability of Zyxin depletion cells in vitro
and in vivo. Expression levels of Zyxin and CDK8 are both elevated in colon
tumors and are negatively correlatedwith survival. Together, our fındings reveal
a novel layer of regulation for Zyxin inmitosis and defıne the Zyxin-YAP-CDK8
axis as a novel oncogenic regulator in colon cancer.
#3459 BRCA1 controls the cell division axis and governs ploidy and phe-
notype in humanmammary cells.ZhengchengHe,1 OksanaNemirovsky,1 Na-
garajan Kannan,2 Connie Eaves,3 Christopher A. Maxwell1. 1University of Brit-
ish Columbia, Vancouver, British Columbia, Canada; 2Mayo Clinic, Vancouver,
MN; 3British Columbia Cancer Research Agency, Vancouver, British Columbia,
Canada.
BRCA1 defıciency alters the relative proportions of progenitor cells in pre-
neoplastic mammary tissue, and typically associates with breast cancers charac-
terized by genomic instability and a basal-like cell phenotype. Oriented division
of progenitor cells is one mechanism these cells use to maintain tissue homeo-
stasis, and to suppress tumor formation. We now show that shRNA-mediated
reduction of BRCA1 levels in non-tumorigenic and immortalized or freshly
isolated, normal humanmammary cells alters their plane of divisionwith graded
consequences that include the induction of aneuploidy in progeny cells, pertur-
bation of polarity in spheroid cultures, and inhibition of clonal growth with
favored expression of basal features. We also demonstrate a requirement for
BRCA1 in establishing cortical asymmetry of NUMA-dynein complexes. Muta-
tion of a single BRCA1 allele (BRCA1 185delAG/) altered the division axis of
isolated cells but their defıcient spindle positioning was supervised by CDH1-
positive adherens, which sustained oriented divisions and produced colonies
with luminal features. These fındings reveal a previously unrecognized conse-
quence of mutant BRCA1 on the cell division axis, post-mitotic integrity and
phenotype control in normal human mammary epithelial cells.
#3460 TBK1 regulates mitotic progression by modulating spindle assem-
bly checkpoint in cancer cells. Neha Jaiswal, Smitha Pillai, Namrata BoraSin-
ghal, Srikumar Chellappan.H.Lee Moffıtt Cancer Center and Research Institute,
Tampa, FL.
TANK Binding Kinase 1 (TBK1) is a non-canonical IkB kinase that contrib-
utes to KRAS-driven lung cancer. It is activated by phosphorylation of Serine-
172 by TLR and RIG1 signaling, and this circuit triggers phosphorylation of
IRF3 and IRF7, activation ofNFBand the expression of proinflammatory genes
and interferons. In addition to its role role in regulating innate immunity, TBK1
also promotes oncogenesis by phosphorylating Akt and enhancing cell survival
and by promoting autophagy and mitophagy. TBK1 is also induced under hy-
poxic conditions and expressed at signifıcant levels inmany solid tumors. TBK1
also contributes to prostate cancer dormancy and drug resistance by inhibiting
mTORand to tamoxifen resistance of breast cancer cells by enhancing transcrip-
tional activity of ER. Recent studies fromour lab revealed a novel role for TBK1
in regulating mitosis. It was found that levels of phospho-TBK1 increases and
localizes to centrosomes and the mitotic spindles during mitosis. Depletion of
TBK1 was shown to trigger defects in spindle apparatus and prevents mitotic
progression (Pillai et al., Nature Communications, 2015). TBK1 physically in-
teracts and phosphorylates centrosomal protein CEP170 and mitotic apparatus
protein NuMA. At the same time, it is not clear whether TBK1 regulates mitosis
mymodulating the Spindle Assembly Checkpoint (SAC). Our results show that
TBK1 colocalizeswithCdc20 on the centrosomes.Additionally, TBK1-inhibited
cells showed an increase in the colocalization of BUBR1 and Cdc20, with en-
hanced recruitment of BUBR1 to kinetochores. To further study how TBK1
affects SAC, lung andbreast cancer cellswere depleted ofTBK1byCRISPR/Cas9
mediated genome editing. Cells depleted of TBK1 showed very few cells in the
mitotic stage; those that enteredmitosis had residual levels of TBK1 and showed
multipolarity and unusually stable and bundled microtubules. TBK1 knockout
cells not only showed aberrant mitotic structures and had elevated levels of SAC
components including BUBR1 and Cdc20. Surprisingly, level of mitotic Cyclin
B1 remained unchanged in spite of elevated levels of Cdc20 indicating a possible
inactivation of Anaphase Promoting complex (APC/C). Also, percentage of Cy-
clin B1 positive cells was signifıcantly high inmitotic cells enriched using double
thymidine block in the presence of TBK1 inhibitor BX795 (R9BX) and
MRT67307 (R9MRT) as compared to untreated mitotic cells (R9). Further,
double thymidine blocked released cells displayed elevated levels of SAC com-
ponents upon treatment with TBK1 inhibitors. All these fındings suggest that
TBK1 facilitates mitotic progression through satisfying SAC.
#3461 The Nek2 mitotic kinase drives centrosome amplifıcation, mitotic
dysfunction, and invasion in mammary epithelial and breast cancer cells.
Yainyrette Rivera-Rivera,1 Mihaela Marina,2 Miyoung Lee,3 Harold I. Saave-
dra1. 1Ponce Health Sciences University, Ponce, PR; 2Meditech Media, Atlanta,
GA; 3Emory University, Childrens Healthcare of Atlanta, Atlanta, GA.
Despite fındings reported by The Cancer Genome Atlas (TCGA) that the
most common human tumors have undergone at least one genomic doubling,
the roles of polyploidy and chromosome instability (CIN) in cancer are poorly
understood. Defective mitosis, and centrosome amplifıcation (CA) are major
sources ofCIN,which generally associateswith poor prognosis of patients. Prev-
alence of CA and CIN in hormone receptor negative (ER-PR-Her2- or ER-PR-
Her2) breast cancer patients, who have the poorest outcomes among all intrin-
sic subtypes, suggest that CA and CIN play major roles in the disease. CA in
breast cancers correlates with poor survival, metastasis and high tumor grade,
suggesting roles in tumor progression. Our laboratory, using an inducible
K-RasG12D transgenic mouse that directed its expression tomammary epithelial
cells, demonstrated CA appeared in precancerous mammary epithelial lesions,
suggesting a role in tumor initiation. Despite these observations, the role of CA
as cancer driver or promoter has not been tested experimentally. To understand
that role, drivers of CA in cancer must be identifıed, and our laboratory showed
that dysregulated E2F1, E2F2 and E2F3a, and their mitotic targets, including
Nek2, TTK, and SgoI sustain CA and CIN in mammary epithelial and breast
cancer cells. In fact, orthotopic models of breast cancer demonstrated that si-
lencing of E2F3 leads to slow tumor growth that correlates with reducedmitosis,
CA and Nek2 levels. We fınd that overexpression of the E2F target Nek2 in
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non-transformed mammary epithelial cells results in large acinar structures,
CA, CIN, and changes in relevant EMT markers that include vimentin. Our
fındings indicate that deregulated E2F pathway contribute to mammary tumor-
igenesis in part by deregulating kinases that controlmitosis, includingNek2, and
in turn these affect mitotic progression, CIN, EMT and invasion. Thus, centro-
some/kinases downstream of the E2F pathway may represent future targets for
intervention in highly-malignant HR- breast cancers.
#3462 Investigating the role of GSK3 in the mitotic checkpoint.Maisha S.
Rashid. University of Toledo, Toledo, OH.
Progression through the cell cycle is regulated by multiple checkpoints that
ensure genomic integrity and proper cell division. The spindle assembly check-
point (SAC) monitors bi-orientation of chromosomes on the mitotic spindle,
and signals assembly of the mitotic checkpoint complex (MCC) at unattached
kinetochores. This checkpoint prevents unequal segregation of chromosomes
and thus maintains genomic stability. Our data shows a novel role for glycogen
synthase kinase 3 beta (GSK3) in regulation of the mitotic checkpoint. GSK3
is a ubiquitous multifunctional Ser/Thr kinase with distinct roles in different
types of cancer. Following pretreatment with spindle toxins which arrest cells in
mitosis, GSK3 inhibitors, SB 415286 (SB), RO-81220 (RO) and LiCl, induce
mitotic exit in multiple cancer cell lines. GSK3 knockout mouse embryo fıbro-
blasts (MEFs) showed a similar decreased mitotic index in the presence of spin-
dle toxins. Similarly, the mitotic checkpoint was weakened when we performed
GSK3 knockout in HeLa cells using transiently expressed CRISPR/Cas9. More
detailed analysis showed decreased kinetochore localization of checkpoint pro-
teins Mad1, Mad2, BubR1 and Bub1 in SB415286-treated Hela cells and gsk3-/-
MEFs in the presence of spindle toxins. The assembly of MCC also decreases in
the presence ofGSK3 inhibition aswitnessed by decreasedMad2 associatedwith
BubR1. Overexpression of GSK3 in Hela cells results in an increase in mitotic
index compared to untransfected cells, consistent with our results with inhibi-
tors and knockouts. GSK3 is a key kinase in the Wnt-signaling pathway, the
mis-regulation of which has been associated with cancer. Our data shows an
increase in taxol-induced mitotic arrest in response to WNT-C59, a compound
that disrupts processing of Wnt ligands to inhibit Wnt signaling. This observa-
tion suggests that the strength of the mitotic checkpoint can be modulated by
external signaling molecules.
#3463 Mitotic regulation of the tumor suppressor phosphatase PHLPP1.
Agnieszka T. Grzechnik, Alexandra C. Newton. University of California, San
Diego, La Jolla, CA.
The PH domain Leucine-rich repeat Protein Phosphatases (PHLPP) are tu-
mor suppressors originally discovered for their ability to directly dephosphory-
late and inactivate the pro-survival kinase Akt, a key transducer of growth factor
signaling. In the decade since this discovery, a number of other PHLPP targets
have been elucidated, but still little is known about the molecular mechanisms
governing the function and regulation of PHLPP itself. Here we report that
PHLPP1 is hyperphosphorylated duringmitosis and that, additionally, PHLPP1
suppresses the phosphorylation of the mitotic kinase CDK1. Specifıcally, we
show that PHLPP1 undergoes an electrophoretic mobility shift in mitotic cells
that is lost when lysates are treated in vitro with lambda phosphatase, suggesting
that PHLPP1 is phosphorylated during mitosis. In addition to a cell cycle-de-
pendent change in its post-translational modifıcations, PHLPP1 suppresses the
phosphorylation of the main mitotic cyclin dependent kinase, CDK1, at Tyr15,
an inhibitory phosphorylation that must be removed in order for cells to prog-
ress through mitosis. First, Tyr15 phosphorylation is increased in phlpp1-/-
mouse embryonic fıbroblasts (MEFs) compared to wild-type MEFs. Second,
pharmacological inhibition of PHLPP1 in wild-typeMEFs results in an increase
in Tyr15 phosphorylation. Activation of keymitotic kinases, such as CDK1, and
inactivation of phosphatases is required for the large increase in protein phos-
phorylation that occurs during mitosis. As such, reversible protein phosphory-
lation plays a role in regulating proper progression through mitosis, which is
essential as errors in mitosis can result in aneuploidy, a hallmark of cancer. Our
data support a previously undescribed role for PHLPP1 in regulating mitotic
progression, potentially providing novel insight into how PHLPP suppresses
tumorigenesis.
#3464 CRISPR-mediated inactivation of ATRX and DAXX in pancreatic
neuroendocrine tumor cell lines. Anthony J. Rizzo, Jacqueline A. Brosnan-
Cashman, Mindy K. Graham, Alan K. Meeker, Christopher M. Heaphy. Johns
Hopkins University School of Medicine, Baltimore, MD.
Cancer cells must fınd a way to subvert replicative senescence in order to
achieve cellular immortality. While most malignancies ( 90 %) overcome this
critical barrier by reactivating the telomerase enzyme, a telomere-specifıc re-
verse transcriptase; other cancers (5 - 10 %) utilize a telomerase-independent
pathway of telomere maintenance, referred to as Alternative Lengthening of
Telomeres (ALT). ALT is thought to utilize homologous recombination and DNA
damage repair (DDR) machinery to maintain the chromosome ends. Importantly,
thismechanismappears to be cancer-specifıc anddependent on alterations in chro-
matin dynamics at the telomeres, almost invariably facilitated by inactivatingmuta-
tions in the genes, ATRX and DAXX. The protein products of these genes are re-
sponsible for thedepositionofhistonevariantH3.3at repetitive regionsofDNA(e.g.
telomeres) and when altered, the affected cells tend to exhibit the ALT phenotype.
Pancreatic neuroendocrine tumors (PanNETs) are an example of a tumor type that
often employs the ALT pathway with coincident somatic mutations in either the
ATRX or DAXX genes. PanNETs are the second most common pancreatic malig-
nancy, with only 40% of affected patients surviving past 10 years. Recently, we and
others have demonstrated that in primary PanNETs, ALT is an independent prog-
nostic marker, associated with aggressive clinicopathologic behavior and reduced
recurrence-free survival. In addition, current data suggest that ALT-positive cancer
cells are sensitive to inhibition of theDNA-damagemediator, ATR. In light of these
fındings, there seems to be an opportunity to developALT specifıc therapeuticmo-
dalities that would have considerable clinical utility. Models of ALT-positive Pan-
NETpathology are needed to further progress in this direction, unfortunately, there
are currently no ALT-positive PanNET cell lines. BON1 and QGP1, the two well
characterizedPanNETcell lines that are available, are bothALT-negative and retain
expression of telomerase, ATRX, and DAXX. In an attempt recapitulate the ALT
phenotype in a PanNET cell line, we derived a panel of isogenic cell lines from both
BON1 andQGP1by utilizing theCRISPR-Cas9 nickase system to targetATRXand
DAXX. In both cell lines, we have successfully established 5 independent subclones
with inactivatingmutations in eitherATRXorDAXX, validatedbySanger sequenc-
ing.Weare currently characterizing thesenovel subclones for thehallmarksofALT,
including the presence of ultrabright telomeric foci, dramatic telomere length het-
erogeneity, and the presence of extrachromosomal telomeric DNA (e.g. c-circles).
Once validated, we plan to investigate whether these ATRX or DAXX-defıcient
subclones are more sensitive to DDR pathway inhibition (i.e. ATR, ATM, CHK1
and CHK2) pharmacologically or with RNA interference in order to identify new
therapeutic strategies for PanNETs.
#3465 Context-dependent effects of ATRX loss on telomere biology in
glioma cells. JacquelineA. Brosnan-Cashman,1MingYuan,1 Anthony J. Rizzo,1
Kaylar M. Myers,1 Walter T. Barry,1 Christine Davis,1 David M. Esopi,1 Dinesh
Rakheja,2 Eric H. Raabe,1 Charles G. Eberhart,1 Christopher M. Heaphy,1 Alan
K.Meeker1. 1JohnsHopkins University School ofMedicine, Baltimore,MD; 2Uni-
versity of Texas Southwestern Medical Center, Dallas, TX.
Telomeres progressively shorten with each cell division, leading to critically
short telomeres during tumorigenesis. While most cancers activate telomerase
to maintain their telomeres, a subset of cancers utilize a recombination-based
process known as alternative lengthening of telomeres, or ALT. ALT has been
widely characterized mostly in the context of immortalized cells, and character-
istic features include ultrabright telomeric foci, colocalization of telomere foci
with PML (ALT-associated PMLbodies, orAPBs), extrachromosomal telomeric
DNA (e.g. c-circles), and overall telomere length heterogeneity. While the over-
all rate of ALT in cancer is low (roughly 5%, overall), the prevalence of ALT is
concentrated in certain cancer subtypes, including gliomas. Gliomas employing
ALT have a common genomic signature: inactivating mutation of ATRX, a
chromatin-modifying protein that functions at the telomeres. In order to study
the role of ATRX loss in the biology of ALT in cancer, we have characterized a
panel of six human cell lines derived from pediatric high grade glioma, two of
which are ALT() and lack functional ATRX. Furthermore, in four pediatric
and three adult high grade glioma cell lines that endogenously express functional
ATRX, we knocked out ATRX using CRISPR/Cas9n and knocked down ATRX
expression using a stable shRNA-mediated approach. Knockout or knockdown
of ATRX was successful in these seven glioma cell lines. Overall, knockout
and/or knockdown of ATRX induced the formation of ultrabright telomeric
foci, as assessed by telomere FISH, in two out of seven glioma cell lines.
However, the effect of ATRX loss on formation of c-circles and APBs was
more variable: the presence of ultrabright telomeric foci was not predictive
of the presence of c-circles or ALT-associated PML bodies. These results
indicate that ATRX loss, alone, is not necessarily suffıcient to activate the
ALT pathway in gliomas. Further examination of ALT-competent and ALT-
resistant cell lines from our cohort will yield clues as to additional ALT-
associated gene expression changes. In addition, our results suggest that
previously identifıed hallmarks of ALT (notably c-circles and APBs) may be
more variable in cancer cells compared to immortalized normal cell lines.
The ALT pathway is an intriguing target for synthetic lethality in the cancer
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subtypes that employ it; our hope is to better understand the ALT phenotype
in cancer so that wemay effectively translate ALT-specifıc therapeutics to the
clinic.
#3466 ALT-positive pediatric high grade glioma cells display chemosen-
sitivity to ATR pathway inhibition. Jacqueline A. Brosnan-Cashman,1 An-
thony J. Rizzo,1 Ezgi Goger,1 Kaylar M. Myers,1 Reza Zarinshenas,1 Christine
Davis,1 Ming Yuan,1 Dinesh Rakheja,2 Eric H. Raabe,1 Charles G. Eberhart,1
Christopher M. Heaphy,1 Alan K. Meeker1. 1Johns Hopkins University School of
Medicine, Baltimore, MD; 2University of Texas Southwestern Medical Center,
Dallas, TX.
Overcoming the end-replication problem is a major hurdle for cancer cells
due to progressive telomere shortening that results from excessive cell division
during tumorigenesis.While most cancers activate telomerase to maintain their
telomere length, about fıve percent of cancers use a telomerase-independent
telomere maintenancemechanism, termed alternative lengthening of telomeres
(ALT). Despite its low overall frequency in cancer, ALT is enriched in several
cancer subtypes, including pediatric high grade glioma (HGG). Previouswork in
our laboratory suggests that nearly half of pediatric HGG utilize the ALTmech-
anism. To date, therapeutic options are largely ineffective for children with
HGG, reflected in the dismal fıve-year survival rate, which is less than 33 percent.
Our goal is to better harness ALT as a clinical marker in pediatric HGG, specif-
ically by identifying drugs that target ALT-positive cancers. In order to study
ALT in this context, we obtained and characterized a panel of six pediatric HGG
cell lines. Two of the six cell lines in this panel display hallmarks of the ALT
pathway. To assess the potential of ALT as a therapeutic biomarker in pediatric
HGG, we measured cell viability in the presence of inhibitors, stratifying our
analysis by ALT status. ALT is predicted to occur via a homologous-recombina-
tion-based mechanism. As such, we focused our attention on inhibitors of the
DNA damage response, as well as agents that induce DNA damage. Treatment
with inhibitors of DNA-PK, RAD51, and MRE11 did not result in signifıcant
differences in cell viability when stratifıed by ALT status, nor did treatment with
temozolomide or hydroxyurea. However, inhibitors of ATR (VE-821, VE-822/
VX-970, and AZD-6738) and CHK1 (MK-8776) led to signifıcantly greater re-
ductions in cell viability in ALT-positive cells. In order to further our under-
standing of themechanism through which ATR inhibition preferentially targets
ALT-positive cell lines, we examined the effect of these inhibitors on ALT-
specifıc properties, such as the presence of ultrabright telomeric foci and extra-
chromosomal telomeric DNA (c-circles). Preliminary results indicate that ATR
inhibition does not diminish theseALT-associated properties and, therefore, the
differential sensitivity to these agents is unlikely to be due to directly blocking the
ALT telomere maintenance mechanism. Continued study of the effect of ATR/
CHK1 inhibition on ALT-positive cells will yield further insight into the mech-
anism of ALT-specifıc toxicity. Overall, we have identifıed ATR/CHK1 as a
promising pathway to target for ALT-positive pediatric HGG. Our goal is to
better understand the relationship between ATR/CHK1 signaling and ALT in
order to effectively translate this observation to the clinic, both for pediatric
HGG and for other ALT-positive cancers.
#3467 ADAXX-KIFC3 fusion potentiates alternative lengthening of telo-
meres in osteosarcoma. Sarah F. Clatterbuck Soper,1 Soyeon A. Showman,1
Kathryn E. Driest,2 Joshua J. Waterfall,1 Robert L. Walker,1 Marbin A. Pineda,1
Yuelin J. Zhu,1 Yonghong Wang,1 Corbin D. Ester,1 Sven Bilke,1 Paul S. Melt-
zer1. 1National Cancer Institute, Baltimore, MD; 2Stanford University, Palo Alto,
CA.
Proliferating cells must enact a program of telomere lengthening to counter-
act the chromosome end replication problem. In most types of cancer cells,
telomeres are maintained through the action of the ribonucleoprotein telomer-
ase, but some cancer cells, particularly those of mesenchymal origin, utilize an
alternative method of telomere repair and lengthening termed the alternative
lengthening of telomeres (ALT) pathway. Since telomere maintenance is essen-
tial for tumor cell immortality, better understanding of the ALT mechanism
could potentially reveal drug targets that could be used to develop novel thera-
pies for tumors that use ALT. It has been previously observed that ALT tumors
frequently carry mutations in ATRX, which partners with the protein DAXX in
a chromatin remodeling complex, but how these mutations facilitate the ALT
pathway is not well understood. Work in our lab identifıed an ALT-positive
osteosarcoma cell line, identifıed here as OS1, in which DAXX has undergone a
fusion event with the non-canonical kinesin KIFC3.We fınd that knockdown of
the DAXX-KIFC3 fusion neither impairs ALT nor cell proliferation, suggesting
that the fusion represents a loss of function. Furthermore, inducible restoration
of wild-type DAXX, reversibly abrogates ALT function in this cell line. One of
the hallmarks of ALT is localization of telomeres and DNA recombination ma-
chinery to nuclear PML bodies, resulting in formation of ALT- associated PML
Bodies, or APBs. Thus it may be considered that changes in PML body compo-
sition represent a key aspect of the ALT mechanism. We observe that in OS1
both DAXX and ATRX fail to localize to PML bodies. This fınding is consistent
with the fact that the DAXX-KIFC3 fusion results in loss of a C-terminal SUMO
interactionmotif that normally mediates PML body interaction. Leveraging our
inducible system, using biochemical and imaging approaches, we are working to
defıne the role of DAXX in maintaining PML body composition.
#3468 Comprehensive analysis of telomere length and telomere mainte-
nance mechanisms across 31 human cancer types. Floris P. Barthel,1 Siyuan
Zheng,2 Roel G. Verhaak1. 1The Jackson Laboratory for Genomic Medicine,
Farmington, CT; 2The University of Texas MD Anderson Cancer Center, Hous-
ton, TX.
Telomeres cap chromosome ends and prevent chromosomal fusions. In the
majority of somatic cells telomere shortens with each cell division. Cancer cells,
on the other hand,maintain telomere length (TL) through reactivation of telom-
erase or alternative lengthening of telomere (ALT). Though closely related to
cancer hallmarks such as chromosomal instability, telomere length has not been
systematically analyzed in cancer. We used DNA sequencing to infer TL in
18,430 samples across 31 cancer types. Tumor TL was shorter compared to
normal TL but tended to be longer in testicular germ cell tumors, sarcomas and
gliomas. TL in non-neoplastic leukocyte and solid tissue samples was negatively
correlated with patient age and varied between lineages, with kidney samples
showing the longest TL and leukocytes the shortest. Amongst tumors, 73% ex-
pressed telomerase reverse transcriptase (TERT), which was associated with
mutations of the TERT promoter (23%), focal amplifıcations (6%), gene fusions
(1%) and structural variants of the promoter (4%) and gene body (3%). Isoform
analysis revealed that the full-length TERT transcript was dominantly expressed
compared to the enzymatically inactive minus beta variant in all cancer types.
TERT expression was positively associated with predicted telomerase activity,
inferred from comparison of known ALT and non-ALT tumor samples. Distal
breakpoint positions involved in TERT promoter structural variants demon-
strated increased levels of H3K27ac and H3K4me1, suggesting displaced en-
hancer elements. We additionally detected hypermethylation of the TERT pro-
moter in 69%, and found an unexpected association with TERT expression.
Combined, 95% of TERT expressing tumors was found positive for at least one
potential genomic or epigenetic regulatory event. Six percent of tumors did not
express TERT and harbored somaticmutations, deletions, gene fusions or struc-
tural variants in ATRX or DAXX, both of which have been shown to be tightly
associated with ALT. These tumors demonstrated decreased of ATRX expres-
sion in combination with signifıcantly longer TL and expression of telomeric
repeat containing RNA (TERRA). Interestingly, 21% of the cohort did not ex-
press TERT and was ATRX wild-type. In this double wild-type group, unsuper-
vised analysis identifıed positive correlations between telomere length, TP53
and RB1 alterations. Predicted telomerase activity in the double wild type and
ATRX or DAXX altered groups was signifıcantly lower compared to TERT ex-
pressing tumors. Gene expression was found to be TL dependent, with genes
nearby telomeres showing a negative correlation (increased expression with
shorter TL) whereas genes far away from telomeres showed a positive correla-
tion and (increased expression with longer TL). Our analysis provides insights
into the various modalities associated with TERT expression and provides a
landscape of determinants of telomere length in cancer.
#3469 Identifıcation of novel human telomerase associated protein by
mass spectrometry. Jing Wang,1 Xuezhi Bi,2 Shang Li1. 1Duke-NUS Graduate
Medical School, Singapore, Singapore; 2Bioprocessing Technology Institute (BTI),
A*STAR, Singapore, Singapore.
Telomeres are nucleoprotein structures at the ends of eukaryotic chromo-
somes that prevent them from degradation, recombination, and end-to-end
fusion. Telomere consists of DNA repeats, which in human is of the sequence
TTAGGG, and it is bound by a group of proteins called shelterin complex.
Telomere is synthesized by telomerase. Telomerase is absent in most human
somatic cells while it is up-regulated in 90% of cancer cells, in which telom-
erase plays an essential role in cancer cells’ replicative immortality. However,
telomerase is only present at approximately 250molecules per cancer cell. To
exert its function of elongating telomere, telomerase has to fınd the end of
telomeres which needed to be elongated. However, how telomerase is pre-
cisely recruited to telomere ends is not clearly understood. To better under-
stand the recruitment process of telomerase, we initially screened and sub-
sequently identifıed novel binding proteins of hTERT, the catalytic subunit
of telomerase, through a pull-down assay using cancer cell lines with endog-
enously Flag-tagged hTERT. Using mass spectrometry (MS), we were able to
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identify a promising interesting protein. Further, direct interaction between
TERT and this protein was validated. Then, we found that this protein can
also interact with the shelterin component, TRF1 (Telomeric repeat-binding
factor 1), which binds to double stranded telomeric DNA. Furthermore,
from previous published reports, this protein was shown to interact with
single-stranded telomeric DNA binding protein POT1 (Protection of Telo-
meres 1) in the shelterin complex. Functionally, overexpression of this pro-
tein in cancer cell lines can result in the elongation of telomeres, while
knock-down or knock-out of the protein results in the shortening of telo-
mere. In conclusion, we identifıed an hTERT-binding protein that affects
telomere maintenance which may be involved in telomerase recruitment
process. In the long run, it could serve as a potential therapeutic target for
cancers.
#3470 The promyelocytic leukemia (PML) protein modulates rate and
localization of homologous recombination in human cell lines with the alter-
native lengthening of telomeres (ALT) pathway. Walter Barry, Christopher
Heaphy, Alan Meeker. Johns Hopkins School of Medicine, Baltimore, MD.
The promyelocytic leukemia protein (PML) is tightly associated with a defın-
ing feature of the cancer specifıc, telomerase-independent telomere-mainte-
nance pathway known as alternative lengthening of telomeres (ALT); therefore,
PML is an important potential target for chemotherapeutics. Cells running ALT
contain large accumulations of telomeric DNA and RNA in the nucleoplasm
that are frequently coated in a polymer shell of PML protein. These structures
are known asALT-associated PMLbodies (APBs). APBs have been postulated to
bemajor sites of the telomeric sequence homologous recombination believed to
be the basis of telomeremaintenance inALT. ACRISPR based strategy was used
to knock out the PML gene in two widely used ALT positive osteosarcoma-
derived human cell lines; U2OS, and SAOS2. Knockout clones from both cell
lines continued to proliferate past passage 90without crisis, and knockouts were
validated at the genetic and protein levels by Sanger sequencing and western
blotting, respectively. Chromosome orientation fluorescent in situ hybridiza-
tion (COFISH) was carried out to determine the number of telomere sequence
exchanges occurring in a single cell cycle in these knockouts. A twofold increase
in telomere-specifıc exchanges, presumably telomere sister chromatid ex-
changes (T-SCE), over the parental line was detected. Intrachromosomal ex-
changes not specifıc to telomeres were also analyzed by the harlequin chromo-
some stainingmethod.A signifıcant increase in these types of exchangeswas also
observed. In conclusion, the presence of PML is not required for ALT to con-
tinue to function, and may be acting to modulate homologous recombination
frequency and location in ALT positive cells.
#3471 Replication of megabase-size alpha-stellite DNA arrays in human
centromere. Indri Erliandri. National Cancer Institute, Bethesda, MD.
Alphoid centromere array is composed by 171 bp AT rich alphoid monomer
that tandemly arranged into high order repeat unit up to 4 MB array. Hallmark
of centromeric DNA is CENPB box, a 17 bp motif that is a binding site of
CENPB. As the chromosomal site that regulates the precise and accurate chro-
mosome segregation, understanding DNA replication in centromere will reveal
insight into faithful chromosome segregation that potentially influence cellular
behavior in normal and cancer cell. The present of active replicons within al-
phoid centromere array are detected by enrichment of nsDNA abundance. This
fınding is supported by evident of Orc2, Cdt1 and Treslin accumulation on the
alphoid centromere array. Chromatin fıber analysis revealed that inter origin
distance within alphoid centromere array is irregular. CENPB depletion that is
affected centromeric chromatin structure enhances DNA replication activity
within alphoid centromeric array, indicates centromeric chromatin landscape
alteration affected centromeric DNA replication dynamic.
#3472 Separase overexpression defınes a new subset of acute myeloma
leukemia patients characterized by highCD34 andMYC levels.Giorgia Simo-
netti,1 Antonella Padella,1 Simona Righi,2 Maria Chiara Fontana,1 Marco Man-
frini,1 Cristina Papayannidis,1 Giovanni Marconi,1 Carmen Baldazzi,1 Mari-
anna Garonzi,3 Alberto Ferrarini,3 Massimo Delledonne,4 Nicoletta Testoni,1
Elena Sabattini,2 Giovanni Martinelli1. 1University of Bologna, Bologna, Italy;
2Sant’Orsola Malpighi Hospital, Bologna, Italy; 3University of Verona, Verona,
Italy; 4Personal Genomics, Verona, Italy.
The endopeptidase Separase, encoded by the ESPL1 gene, plays a key role in
faithful segregation of sister chromatids by cleaving the cohesin complex at the
metaphase to anaphase transition. Its overexpression associates with aneuploidy
and bad prognosis in solid tumors. Little is known in Acute Myeloid Leukemia
(AML). We profıled the genomic landscape of 405 and 78 AML cases by SNP
array (SNP 6.0 and Cytoscan HD, Affymetrix) and whole exome sequencing
(100 bp, paired-end, Illumina), respectively. Bone marrow blasts from 61 pa-
tients were analyzed by gene expression profıling (HTA 2.0, Affymetrix). Sepa-
rase expression was determined by Immunohistochemistry (1:600 antibody di-
lution Abnova, clone 6H6) in 44 AML and 4 control bone marrow specimens.
One patient exhibited a nonsynonimous mutation in ESPL1 (1.3%), which was
predicted to alter the protein function. Moreover, ESPL1 copy number gain was
observed in 5/405 cases (1.2%): 2 hyperdiploid AML, one trisomy 12 and 2 cases
with a short gain at 12q. Notably, protein level detection in one of the 12q-gain
cases confırmed Separase overexpression. To determine the incidence of Sepa-
rase overexpression, we performed Immunohistochemistry on additional 43
AML. Separase was overexpressed in 29/44 AML (66%, Separase-high), being
comparable to control marrow biopsies in the remaining 15 samples (Separase-
low). Sixty-two percent of Separase-high AML were aneuploid. However, no
signifıcative association was observed, as previously reported for mutations in
the cohesin genes in AML. Separase overexpression correlated with increased
patients’ age (median age 64 vs. 57 years, p.01), 17-fold upregulation of CD34
(p.004) and a trend towards reduced overall survival (6-years follow-up).
Separase overexpression was not mutually esclusive with cohesin gene muta-
tions, it co-occurred with NPM1 and FLT3 lesions and frequent mutations in
genes involved in protein post-translational modifıcation and ubiquitination
(p.04). Separase-low cases were enriched formutations in RAS signaling path-
way (NRAS, KRAS, NF1, RIT1, GRAP2, RALGDS; p4.5x10-5) and in cell mi-
gration-related genes (LIMS2, S1PR1, PPIA, PLXNB1, FAT1). Separase-high
cases also showed a defıned transcriptomic profıle, characterized by reduced
expression of HOXA/B family genes, the DNA damage repair gene ATM, the
p53 regulator MDM2 and forced expression of the cell cycle markers CDC20,
AURKB, NUSAP1 and of MYC, independently of chromosome 8 gain. Taken
together, our data suggest that genomic lesions targeting ESPL1 are a rare event
in AML. However, Separase overexpression is a common feature and defınes a
new subset of AML cases with a distinct gene expression profıle, which may
benefıt of innovative targeted therapies including CDC20 and bromodomain
inhibitors. Supported by: ELN, AIL, AIRC, progetto Regione-Università
2010-12 (L. Bolondi), FP7 NGS-PTL project.
#3473 Functional analysis of the KIF22 in human prostate cancer cells.
Rina Sakamaki,1 Shungo Saito,1 Tatsuya Kitano,1 Tadashi Nittami,1 Jieun Seo,2
Akimitsu Takagi,3 Hitoshi Ishiguro,4 Hiroji Uemura,5 Masatoshi Watanabe1.
1Yokohama National Univ., Yokohama, Japan; 2Seoul Natl. Univ., Seoul, Repub-
lic of Korea; 3Yakult Centl. Inst., Kunitachi, Japan; 4Kanagawa Acad. Sci. Tech.,
Kawasaki, Japan; 5Yokohama City Univ. Med. Ctr., Yokohama, Japan.
In the previous study, we identifıed genes that were differentially expressed be-
tween monolayers and spheroids in prostate cancer cell lines. The KIF22 gene was
extracted as one of candidate genes related with spheroid formation and multicel-
lular resistance. KIF22 is one of the kinesin superfamily proteins that are microtu-
bule-dependentmolecularmotorproteinswithDNA-bindingcapacity.KIF22plays
an important role in eukaryotic cell mitosis and macromolecule transportation.
Alteration of KIF22 expression and function may lead to cancer development and
progression. In this study, we explored the function of the KIF22 in prostate cancer
cell lines, DU145 and LNCaP using the KIF22 siRNA. The KIF22 mRNA levels in
LNCaP andDU-145monolayerswere detected, and time-dependently increased in
both spheroids. The inhibition of KIF22mRNA using siRNA affected cell prolifer-
ation in DU145 and LNCaP spheroids as well as monolayers. In addition, this sup-
pression causedG2/M arrest and apoptosis in both cell lines. In clinical samples, its
mRNA expression was signifıcantly higher in tumor portions than in non-cancer-
ous portions. However, the inhibition of KIF22mRNAdid not affect cell migration
and invasion in DU145 and LNCaP cells. These fındings suggest that KIF22 may
play an important role in prostate cancer proliferation, especially spheroid forma-
tion, and have the potential to be targeted for prostate cancer treatments such as
combination therapy with docetaxel.
#3474 Depletion of SPECC1L inhibits colorectal cancer cell proliferation.
Rajat Bhattacharya, Ling Xia, Fan Fan, Rui Wang, Delphine Boulbes, Xiang-
Cang Ye, David Hawke, Lee Ellis.MD Anderson Cancer Center, Houston, TX.
Introduction: Despite the numerous drugs available for patients with meta-
static colorectal cancer (mCRC), median overall survival for this group of pa-
tients remains at20-24months, with no signifıcant advances in the last 7 years.
In the US 50,000 patients die each year from mCRC refractory to systemic
therapy. Inhibiting angiogenesis as a therapy has led to a great deal of enthusi-
asm. However, the overall benefıt of classical-antiangiogenic therapy remains
modest and has not lived up to their expectations in treating CRC. Our recent
studies suggest that VEGF intracrine signaling, rather than autocrine/paracrine
signaling, regulates cell survival in CRC cells. Further studies to understand the
signifıcance and mechanisms of this novel function have led us to identify fac-
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tors that intracellularly interact with VEGF. Our studies further indicate that
one such interacting protein, SPECC1L, may have a signifıcant role in CRC cell
proliferation and may be a potential target in mCRC therapy. Methods: Lysates
from CRC cells expressing Myc-tagged VEGF protein were immunoprecipi-
tated and analyzed bymass spectrometry to identify VEGF-interacting protiens.
SPECC1L was identifıed as a co-precipitated protein with high level of confı-
dence. SPECC1L was depleted using siRNA and effects of such depletion on
CRC cell growth and morphology were measured by cell growth assays (MTT),
microscopy, FACS and western blot analyses. Localization of the protein and its
interaction with microtubules and actin were visualized by immunostaining of
FLAG-tagged recombinant SPECC1L protein. Results: SPECC1L was identifıed
as a protein that co-immunoprecipitated with Myc-tagged VEGF in CRC cells
using mass spectroscopy. Previous literature suggests a role for SPECC1L in cell
division. As a fraction of VEGF overexpressing CRC cells have a large multinu-
cleated phenotype, likely arising due to defects in cell division, it was hypothe-
sized that aVEGFmediated regulation of SPECC1Lmay lead to such phenotype.
Depletion of SPECC1Lby siRNAs inmultipleCRCcell lines led to strong defects
in cell division. The effects of SPECC1L depletion were manifested as accumu-
lation of doublet-cells failing to complete cytokinesis following mitosis and re-
sulted in reduced cell proliferation. Failure to complete cell division also led to
the formation of multinucleated cells and enhanced cell death. Conclusions:
Inhibition of SPECC1L strongly inhibits CRC cell proliferation and enhances
cell death. Thus targeting SPECC1L has the potential for developing therapeu-
tics that reduce viability of CRC cells and improve survival of colorectal cancer
patients. These studies were supported by the Gillson-Longenbaugh Founda-
tion.
#3475 Inhibitory effects of ZFP36L1 and ZFP36L2 on the cell prolifera-
tion in human colorectal cancer cells. Fat-Moon Suk, Ya-Ting Chen, Yu-Chih
Liang. Taipei Medical University, Taipei, Taiwan.
ZFP36 family members include ZFP36 (also named TTP and TIS11),
ZFP36L1 (also called BRF1, ERF1 or TIS11B) and ZFP36L2 (also called
BRF2, ERF2 and TIS11D), which belong to the CCCH-type zinc fınger pro-
tein with 2 tandem zinc fınger region (TZF). These ZFP36 family proteins
can function as RNA-binding protein through binding to AU-rich elements
(AREs) in the 3= untranslated region (3= UTR) of mRNA, which promote the
mRNA degradation or translation repression. Previously, ZFP36 has been
found to inhibit cell proliferation through p53-dependent manner. In this
study, we’d like to investigate whether ZFP36L1and ZFP36L2 have anti-
proliferative activity as same as ZFP36 work. Tetracycline-inducible (Tet-
On) system was used to induce the overexpression of ZFP36L1 or ZFP36L2
proteins in T-REx-293 cells by doxycycline (Dox) treatment.While ZFP36L1
or ZFP36L2 was overexpressed, we found that cell proliferation was dramat-
ically inhibited, but didn’t cause cell death signifıcantly. The importance of
TZF was confırmed by using TZF mutants, and found that cell proliferation
was deprived in HEK-293 cells with overexpression of ZFP36L1 mutant
(C135/173R). Using western blot analysis, it was revealed that expression
level of p53 protein was increased after the overexpression of ZFP36L1 or
ZFP36L2 protein. Whereas, the levels of cell cycle-related proteins including
cyclin B1, cyclin D1, cyclin A2 and p21 were decrease. Next, three human
colorectal cancer cells HCT116 p53/, HCT116 p53-/- and SW620 (mutated
p53) cells were used and ZFP36L1 or ZFP36L2 gene was transduced into
these three cells by lentivirus. Overexpression of ZFP36L1 or ZFP36L2 also
inhibited the cyclin D1 protein expression and cell proliferation in these
three cells, however, increased the p53 and p21 protein expression in
HCT116 p53/ cells, and decreased the c-Myc expression only in SW620
cells. On the other hand, knockdown of ZFP36L1 or ZFP36L2 increased cell
proliferation, and mutation in TZF of ZFP36L1 (C135/173R) or ZFP36L2
(C174/212R) lost their anti-proliferative abilities in these three cells. Taken
together, the results suggest that ZFP36L1 and ZFP36L2 play a negative role
in cell proliferation of human colorectal cancer cells, and the underlying
mechanisms might be mediated through downregulation of cyclin D1 and
p53-independent pathway.
#3476 Effect of long term treatment with BRACO 19 on HeLa prolifera-
tion and senescence.Ana Flavia Reis Guimaraes, DiêgoM. de Oliveira.Univer-
sity of Brasilia, Brasilia, Brazil.
Telomerase, the enzyme responsible for the length maintenance of telomeres
is expressed in about 85% of cancer cells, being a key to tumorigenesis. Telom-
erase inhibitor drugs have been studied as a promising cancer therapy due to its
specifıcity, with less side effects than conventional approach. However, the ef-
fects expected from these therapy require many cell divisions, and the conse-
quences of these long-term therapies are poorly understood. This work evalu-
ated the effects of a long term treatment in cancer cells (HeLa) using BRACO-19,
a G-quadruplex-interactive molecule, evaluating the consequences of its use in
cell viability and its potential to induce senescence. Telomerase positive HeLa
cells were grown inDMEMmedium supplementedwith 10% fetal bovine serum
at pattern conditions. Culture medium was changed every 2 days. For prelimi-
nary citotoxicity assay, cells were seeded in 96 wells plate at 3.2x104 cells/cm2,
incubated for 24 hours and treated for 24 hours with increasing concentrarions
of BRACO-19 and vehicle (0.1% H2O). Cell viability was measured by MTT
assay. For the long-term treatment, a subtoxic concentration was chosen. The
cells (5.5x102 cells/cm2) were grown under continuous presence of the drug or
0.02%H2O for 11weeks. During the long-term exposure to BRACO-19, the cells
were splitted every 7-20 days, depending on its proliferation rate, viable and
unviable cells were counted at these points through trypan blue dye exclusion
assay. -Galactosidase (-gal) activity was used as cell senescence marker to
evaluate the senescence after 24 hours treatment and after a long exposure to the
telomerase inhibitor. Changes in cell morphology were accessed by phase con-
trast microscopy. The short-term (24h) treatment with BRACO-19 showed a
dose-dependent effect on cell viability. The IC50% for HeLa was 5.25 M. The
subtoxic concentration of 1M was used for long-term treatment, showing ef-
fect on cell proliferation in a way that HeLa cells exposed to the drug showed
their proliferative profıle decreased when compared to control. Furthemore, no
senescent cells were found in control group, even after many passages; on the
other hand, 24 hours and long-term exposure to BRACO-19 led to senescence.
Long-term treatment was also associated with visual changes on cell morphol-
ogy. The telomerase inhibitor BRACO-19 showed an expected dose-dependent
effect on HeLa cells at short-term exposition, since cytotoxic effect of this com-
pound has been demonstrated in several cell lines, but the impact of the long-
term treatment on cell proliferation pattern points BRACO-19 as a potential
prototype of a new telomere related drug for cancer therapy. Also, it was dem-
onstrated the senescence inducing action of this drug, perhaps due to erosion of
HeLa telomeres. These results show that HeLa is sensitive do BRACO-19 even
under subtoxic concentrations. Its effectiveness against other cell lines and tu-
mors is under investigation.
#3477 Rosehip (Rosa canina) extracts prevent AKT-mediated cell prolif-
eration and migration in triple negative breast cancer cells. Patrice Cagle,
Patrick Martin. North Carolina A&T State Univ., Greensboro, NC.
Triple Negative Breast Cancer (TNBC) is an aggressive form of breast cancer,
characterized by its lack of the human epidermal growth factor receptor-2, the
estrogen receptor, and the progesterone receptor. AKT has been shown to pro-
mote cell proliferation andmigration in triple negative breast cancer. Currently,
the existing targeted therapy is of minimal benefıt in TNBCs. Furthermore,
adverse side effects and the emergence of drug-resistant cancer cells are of great
concern. Natural products have received growing interest in recent years as an
alternative medicine with potential anti-oncogenic properties. Rosehip extracts
have been used as dietary supplements to relieve symptoms associated with
gastrointestinal disorders and arthritis, and in our laboratory it has been shown
to prevent cell proliferation in glioblastomas. This study investigated the effıcacy
of rosehip extracts in preventing proliferation andmigration of a triple negative
breast cancer cell line (HCC1395). HCC1395 cells treated with rosehip extracts
(1mg/mL -25ng/mL) demonstrated a signifıcant decrease in cell proliferation.
The observed decrease in cell proliferation was equal to or better than the de-
crease of cell proliferation observed when inhibitor of the AKT (LY294002, 20
M) signaling pathway was utilized. Rosehip extracts also demonstrate anti-
migratory potential. Additionally, pretreatment of this cell line with rosehip
extracts selectively decreased AKT, p70S6K, and S6K phosphorylation suggest-
ing these extracts prevent TNBCcell proliferation andmigration by blocking the
AKT signalingmechanism.Western blot analysis and apoptosis studies demon-
strate that rosehip extracts inhibit cell proliferation without promoting apopto-
sis, but induce cell cycle arrest. To investigate the potential clinical application of
rosehip extracts we examined whether rosehip extracts could enhance the che-
motherapeutic properties of Doxorubicin (20M), a chemotherapeutic agent
used to treat breast cancer. Rosehip extracts demonstrated a greater anti-prolif-
erative effect than Doxorubicin alone and is equally effective in combination
with Doxorubicin. These data suggest that rosehip extracts are capable of de-
creasing cell proliferation and migration in a triple negative breast cancer cell
line by blocking the AKT signaling pathway and by regulating the cell cycle.
Moreover, rosehip extracts demonstrate a greater inhibition of cell proliferation,
when given alone and combination with Doxorubicin. This investigation dem-
onstrates that rosehip extracts may serve as either an alternative or complimen-
tary treatment to current chemotherapeutic regimens for triple negative breast
cancer.
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#3478 Expression of the transcribed ultraconserved region Uc.63 in
prostate cancer. Yohei Sekino, Keisuke Goto, Ririno Honma, Yoshinori Shige-
matsu, Naoya Sakamoto, Kazuhiro Sentani, Naohide Oue, Jun Teishima, Akio
Matsubara, Wataru Yasui. Hiroshima University, Hiroshima, Japan.
Prostate cancer (PCa) is themost prevalent cancer amongmen and the second
leading cause of cancer related death in western world. Currently, there is a lack
of effective treatment options for advanced PCa. Understanding the molecular
mechanisms in prostate cancer development and progression would allow the
identifıcation of novel prognostic markers or therapeutic targets. The tran-
scribed-ultraconserved regions (T-UCRs) are novel class of noncoding RNAs
that are absolutely conserved (100%) between orthologous regions of the hu-
man, rat and mouse genomes. Some studies showed that T-UCRs exhibit dis-
tinct profıles in various human cancers. We examined the expression profıle of
representative 26 T-UCRs using qRT-PCR in 12 PCa tissues and 10 non-neo-
plastic prostate tissues, and found that the expression of Uc.63 was higher in
PCa tissues than that in non-neoplastic tissues. Further analysis revealed that the
expression ofUc.63 signifıcantly correlatedwith higher PSA levels (p 0.007)
and higher Gleason score (p  0.001). In order to verify biological function of
Uc.63 in PCa, we fırstly transfected Uc.63 expression vector into LNCaP
cells expressing low level of Uc.63. MTT assay and wound healing assay re-
vealed that overexpression ofUc.63 signifıcantly increased the cell growth and
migration. We also confırmed that downregulation of Uc.63 using siRNA in
DU145 and PC3 expressing high level of Uc.63. Knockdown of Uc.63 de-
creased the cell growth and migration. A recent report indicates that T-UCRs
may act as endogenous competing RNA. miR-130b was found to have binding
sites within the Uc.63 using online software. We examined the expression of
miR-130b by qRT-PCR in PCa tissues and non-neoplastic prostate tissues. We
found a signifıcant downregulation of miR-130b in PCa tissues compared with
non-neoplastic prostate tissues, which fıgured out that there was a signifıcant
inverse correlation between Uc.63 and miR-130b in PCa (p  0.002). The
expression of miR-130b in LNCaP was higher than that in DU145 and PC3. It
has been shown thatMMP2 is a direct target of miR-130b.Western blot analysis
and qRT-PCR revealed thatMMP2 expression was higher in LNCaP cells trans-
fected with Uc.63 expression than that in LNCaP cells transfected with empty
vector. These results suggest that Uc.63may contribute to the progression of
PC through miR-130b interaction.
#3479 Identifıcation and characterization of clinically relevant long non
coding RNA PLUCAT1 in lung adenocarcinoma. Sudhanshu Shukla, Lanbo
Xiao, Brendan Veeneman, Yuping Zhang, Yashar Niknafs, Sethuramsundaram
Pitchiya, Arul Chinnaiyan. University of Michigan, Ann Arbor, MI.
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death
worldwide. Disease subtypes include lung adenocarcinoma (LUAD) and lung
squamous carcinoma (LUSC) and LUAD accounts for nearly 50% of lung ma-
lignancies. Late diagnosis and limited chemotherapy options are the primary
reason for poor prognosis and even among patients diagnosed early with Stage 1
disease, recurrence occurs in 35-50% of cases. Lack of discriminatory biomark-
ers has hampered clinical and therapeutic management, as current practice
tends to group all patients together. Several attempts to develop gene signatures
from microarray datasets to stratify risk among lung adenocarcinoma patients
have not yielded clinical utility due to poor cross validation and lack of robust-
ness. The development of RNA-Seq methodologies now enables accurate quan-
tifıcation of transcriptional abundance that is reproducible and reliable. Capi-
talizing on this technology and large datasets such as the cancer genome atlas
(TCGA) as well as individual efforts, thousands of cancer samples are available
for analysis to facilitate deeper understanding of the disease. One major discov-
ery resulting from large RNA-Seq datasets are functional long noncoding RNAs
(lncRNAs; exceeding 200 nucleotides in length) that can be expressed in tissue-,
linage- and cancer-specifıc expression patterns. In our previous study we iden-
tifıed a highly signifıcant prognostic marker set using 255 TCGA LUAD pa-
tients. In the training cohort, 96 genes had prognostic associationwith p0.001,
including 5 long noncoding RNAs (lncRNAs). Stepwise regression generated a
four-gene signature, including one lncRNA. Signature high risk cases had worse
overall survival (OS) in the TCGA validation cohort (HR3.07, 95%CI2.00-
14.62). The four-gene signature was then validated in two independent patient
cohorts. The signature consisted of three protein coding gene and a lncRNA
(PLUCAT1). Knockdown studies showed that the lncRNA promoted lung cell
growth in vitro. Also, inhibition of PLUCAT1 using both siRNA and ASOs
induced cellular senescence in lung cells. Further, RNA pull down followed by
mass-spec identifıed QKI as a binding partner of PLUCAT1. QKI is a tumor
suppressor gene shown to change splicing pattern inmany cancer types.Wenow
show that PLUCAT1-QKI interaction has functional consequences and changes
splicing pattern of signifıcant number of genes as assessed by RNA sequencing.
Taken together, we have identifıed PLUCAT1, a member of 4 gene prognostic
signature, as a robust prognostic marker for lung adenocarcinoma prognosis.
We also, show that PLUCAT1 binds with tumor suppressor QKI and inhibits
QKI activity.
#3480 2=-O-ribose tRNAmethylation in S. cerevisiae and implications for
ovarian cancer. Frank Doyle,1 Rebecca E. Rose,2 Daniele Fabris,2 Lauren En-
dres3. 1SUNY Polytechnic Institute, Albany, NY; 2University at Albany, Albany,
NY; 3SUNY Polytechnic Institute, Utica, NY.
tRNAs are among the most chemically modifıed molecules of the cell, yet our
understanding of how thesemodifıcations influence cell behavior remains poor.
Much of the research to date has been focused on identifying specifıc modifıca-
tion events, particularly those that increase or decrease in response to oxidative
stress. Less attention has been given to understanding how tRNAmodifıcations,
and theirmodifying enzymes (tRNAmethyltransferases, or TRMs), regulate the
cell’s response to reactive oxygens,molecules that are known to influence cancer
initiation, survival and malignant progression. Our overall idea is that tRNA
modifying enzymes respond to oxidative stress by catalyzing themodifıcation of
target tRNAs, and that this in turn influences the translation of transcripts that
encode proteins that limit the potentially harmful effects of reactive oxygens.
Herewe used S. cerevisiae as amodel eukaryote system to test the hypothesis that
2=-O-ribose tRNA methylation protects cells against the cytotoxic effects of re-
active oxygens. 2=-O-ribose TRM deletion mutants (TRMs 3
, 7
, 13
 and
44
) were exposed to H2O2, rotenone and acetic acid in order to produce intra-
cellular reactive oxygens. In growth and colony forming assays, each deletion
strain was more sensitive to the killing effects of these toxicants when compared
to the wild-type strain (BY4741), and the most pronounced effect was observed
for the TRM3
 mutant. We next performed a quantitative analysis of global
changes in tRNA modifıcations in response to H2O2 using mass spectrometry.
We found that severalmethyl-basedmodifıcations (i.e. 2=-O-methyl -adenosine,
-guanosine, and -cytidine) were signifıcantly decreased in TRM3
 and 7
mu-
tants, providing a direct link between oxidative stress and 2=-O-ribose tRNA
methylation. These results support that 2=-O-ribose methyltransferase activity
plays a cytoprotective role against oxidative stress in S. cerevisiae. Given the
connections between reactive oxygens and cancer, we used cBioPortal to search
for gene alterations of the human homolog of TRM3, TARBP1, in the genome
datasets of The Cancer Genome Atlas. Interestingly, TARBP1 was found to be
amplifıed in a signifıcant proportion of breast, ovarian and liver cancers. From
these observations, a new hypothesis emerged: increased 2=-O-ribose methyl-
transferase activity contributes to a cancer phenotype by enabling cancer cells to
maintain reactive oxygens at sub-lethal levels that promote survival and malig-
nant progression. Thus far, preliminary results show that cultured ovarian can-
cer cells have elevated levels of TARBP1 relative to normal ovarian cancer epi-
thelial cells, providing a useful model system to test this hypothesis in future
studies.
#3481 Leveraging protein coding gene expression profıles to accurately
impute lncRNA transcriptome of cancer cells. Aritro Nath, Paul Geeleher, R.
Stephanie Huang. The University of Chicago, Chicago, IL.
Long noncoding RNAs (lncRNAs) represent a large, diverse and tissue-spe-
cifıc class of transcripts that are involved in gene regulation. Recent large-scale
cancer sequencing efforts indicate that lncRNAs are an important component of
the cancer transcriptome, andmay play a critical role in carcinogenesis and drug
sensitivity. Accurate profıling of lncRNAshowever remains a challenge owing to
signifıcantly lower expression levels than mRNA, requiring deep paired-end
total RNA sequencing, which can be prohibitively expensive. Additionally, pre-
vious generation microarrays that constitute a vast majority of GEO and Array-
Express datasets do not provide comprehensive lncRNA coverage. Here we pro-
pose a lncRNA expression imputation (LEXI) framework to reconstruct the
lncRNA transcriptome of cancer cells using their mRNA expression profıles.
Our goal is to provide a tool that enables the harnessing of enormous wealth of
publicly available cancer mRNA datasets and discover novel lncRNAs associ-
ated with carcinogenesis and drug sensitivity. The LEXI approach is based on
learning patterns of mRNA expression associated with each lncRNA across a
diverse cohort of cancer cells and then predict lncRNA expression profıle of
uncharacterized cells. We developed LEXI by evaluating the performance of
various machine-learning algorithms benchmarked in a cross-validation study
across a cohort of 675 cancer cell lines and 9755 pan-cancer tissues.We adapted
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the LEXI framework based on optimal performance and computation time and
show that LEXI accurately predicts lncRNA expression profıles in both cell lines
and tissues. To demonstrate the utility of LEXI, we reconstruct the lncRNA
transcriptome of over 1000 cell lines and 2000 TCGA samples, and compare
with RNAseq measured lncRNA levels in corresponding samples. We further
show expression levels of MALAT1, HOTAIR, CCAT1 and other established
cancer-associated lncRNAs are accurately predicted across cancer types, and can
be used to discover novel associations in uncharacterized phenotypes. LEXI will
be available as a free resource for researchers to easily obtain lncRNA profıles
using their own mRNA data.
#3482 SNORD-X in glioblastoma: regulation and functional analysis.
Shikha Gupta,1 Prerana Jha,1 Chitra Sarkar,2 Ritu Kulshreshtha1. 1Indian Insti-
tute of Technology Delhi, Delhi, India; 2All India Institute of Medical Sciences,
Delhi, India.
Glioblastoma Multiforme (GBM) is a kind of brain tumor which arises from
astrocytes present in the brain. It represents approximately 15% of all primary
brain tumor and has been considered as one of the deadliest type of cancer with
very poor prognosis. Thus, there is an urgent need to identify novel targets for
GBM therapy. Recently, non-coding RNAs (ncRNAs) such as miRNAs and
lncRNAs have emerged as one of the promising tools as diagnostic or prognostic
biomarkers and as novel targets for therapy. There are recent evidences that
small nucleolar RNAs (snoRNAs), a subtype of ncRNAs might also play a key
role in various cancers. In this context, we aimed at studying the role of snoRNAs
in GBM. For this, we did snoRNA profıling in GBM patients and found that a
particular cluster of snoRNA called SNORD-X was highly downregulated in
adult as well as pediatric GBM patients. We also found SNORD-X promoter to
be methylated and shows maternal imprinting. We next did functional analyses
of SNORD-X by generation of an overexpression construct. Our preliminary
data suggests that overexpression of SNORD-X in GBM cell lines (U87MG and
A172) increases cell proliferation in vitro. It also enhances the colony forming
capability of GBM cells. Further, its overexpression causes decrease in apoptosis
in a caspase-dependent manner. A target analysis of SNORD-X was done using
RNAhybrid software. We found EGR1, DCUN1D3 and BRCA1 to be the direct
targets of SNORD-X using a combination of qRT-PCR and wild-type/mutated
3=UTR luciferase analyses. Overall, our work shows for the fırst time correlation
and functional analysis of SNORD-X cluster in GBM.
#3483 Genome-wide analysis of the antisense transcriptome in cancer.
Raquel Boque-Sastre, Manuel Castro de Moura, Antonio Gomez, Sònia Guil,
Manel Esteller. IDIBELL, L’Hospitalet del Llobregat (Barcelona), Spain.
Natural antisense transcripts (NATs) are the most abundant class of long
noncoding RNAs (lncRNAs). Importantly, NATs are one of the most unknown
ncRNAs. However, due to their highly gene locus-specifıc effects, NATs may
provide a unique entry point for therapeutic intervention in targeted gene reg-
ulation. For this reason we are interested in studying the regulation of sense/
antisense transcription in cancer related locus. In our previous work we found
that, at the important cancer-related locus vimentin (VIM) there is a previously
uncharacterized antisense transcript (VIM-AS1), which is transcribed head-to-
head with VIM gene. This antisense transcript enhances R loop formation; it
allows the binding of transcription factors asNF-kB, lownucleosomeoccupancy
and the transcription of VIM gene. Our results are the fırst example of R loop
mediated enhancement of gene expression involving head-to-head antisense
transcription at cancer related locus. We also observed that in colon and breast
cancer there was a positive expression correlation between VIM and VIM-AS1
and we have observed that hypermethylation silences both transcripts in colon
primary tumors. In the present work we have seen that this positive correlation
between sense and antisense transcripts is present in most of the tumor types
from patients that we have obtained fromGenomic Data Commons Data Portal
(GDCPortal). Importantly this positive correlation correlates better in the cases
in which the antisense transcript is downregulated or maintains the expression
than in tumors where VIM and VIM-AS1 are up-regulated. Furthermore, we
wanted to see if the cellular function is also coordinated. VIM is a component of
the intermediate fılament family of proteins that has an important role in epi-
thelial mesenchymal transition. We found that specifıc depletion of VIM-AS1
results in a decrease of VIM expression, and now we have found that this deple-
tion produces lowmigration rate and more invasion capability, as expected. On
the other hand, the mechanisms used by antisense transcripts to regulate their
corresponding sense mRNAs are not fully understood and in view of these
results we are investigating from a genome-wide perspective the regulation of
sense/antisense transcription, the involvement of R loop structures and DNA
methylation in cancer. For this, we have applied a number of techniques:
RNAseq strand specifıc, Illumina’s HumanMethylation450 Bead Chip array,
RNAseq strand specifıc with overexpression of RNaseH (which specifıcally de-
grades the RNA in RNA/DNA hybrids), and DRIPseq (which immunoprecipi-
tates the hybridsDNA-RNAs). The analysis of these data sheds light on the study
of the role of sense/antisense transcripts in cancer-related locus.
#3484 A long non-coding RNA, H19, as a novel therapeutic target for
pancreatic cancer metastasis. Toshiyuki Ishiwata,1 Hisashi Yoshimura,2 Yoko
Matsuda,3 Naoshi Ishikawa,1 Kaiyo Takubo,1 TomioArai,3 JunkoAida1. 1Tokyo
Metropolitan Institute ofGerontology, Tokyo, Japan; 2NipponVeterinary andLife
Science University, Tokyo, Japan; 3Tokyo Metropolitan Geriatric Hospital and
Institute of Gerontology, Tokyo, Japan.
Long non-coding RNAs (lncRNAs) comprise mRNA-like transcripts longer
than 200 ribonucleotides and lack signifıcant open reading frames. Recently,
long non-coding RNAs have been reported to play important roles in epigenetic
regulation, and acts on precursors or inhibitor of micro RNA. In our previous
studies, we injected PANC-1, human pancreatic cancer cells into the spleens of
NOG mice, and established a lung metastasis-derived cell line from lung meta-
static nodules. Lung metastasis derived pancreatic cells had a high metastatic
ability to liver and lungs compared with the parental cells (Matsuda et al., Am J
Pathol, 2014). To examine the different gene expressions between the lung me-
tastasis derived cells and parental cells, we performed a DNA microarray anal-
ysis.We found that 11 genes were expressed at greater than 10-fold levels in lung
metastasis derived cancer cells compared to their parental cells. H19 showed an
82.4-fold increase in expression levels, and it was the secondmost increased and
the only non-protein coding gene in the 11 genes. H19 is an imprinted lncRNA
transcribed exclusively from the maternal allele and H19 gene produces a 2.3
kilo base pair long non-coding RNA. Two microRNAs, miR-675-3p and miR-
675-5p are embedded in the exon1 of H19 and these miRNAs are reported to
correlate with cell proliferation. H19 is an oncofetal RNA expressed in develop-
ing embryos and in tumors including bladder, breast, gastric, pancreatic, hepa-
tocellular, and prostate cancers. Studies have shown that H19 enhances cancer
invasion and metastasis; however, its role in cancer remains debatable. We ex-
amined the roles of H19 in pancreatic cancer growth and metastasis. Quantita-
tive RT-PCR analysis using human pancreatic cancer tissues showed that H19
was more highly expressed in cancer tissues than the adjacent normal tissues in
11 of 18 cases. Branched DNA in situ hybridization analysis using tissue mi-
croarrays showed that H19 was detected in 17% (23/139) of invasive ductal
carcinomas, and its expression positively correlated with higher histological
tumor grades (P 0.0001).H19was expressed in 9 pancreatic cancer cell lines at
various levels. Overexpression of H19 in PANC-1 cells induced higher motili-
ties, whereas H19 inhibition using shRNA and siRNA showed opposite results;
however, cell growth rates were unaffected in vitro. Expression levels of miR-
675-3p and miR-675-5p altered as similar to the H19 levels in both H19 in-
creased PANC-1 cells andH19decreased cells. Tail vein injection ofH19 shRNA
vector-transfected PANC-1 cells markedly inhibited metastasis in the liver and
lungs of immunodefıcient mice. These fındings suggest that H19 plays an im-
portant role in pancreatic cancermetastasis andH19 is a novel therapeutic target
for metastasis of pancreatic cancer.
#3485 Identifıcation and characterization of circular RNAs in cancer.
Charlotte A. Thrue,1 Andreas Petri,1 Marianne B. Løvendorf,1 Karen Dybkær,2
Dimitrios Papaioannou,3 Ramiro Garzon,3 Sakari Kauppinen1. 1Aalborg Uni-
versity, København SV, Denmark; 2Aalborg University, Aalborg, Denmark; 3The
Ohio State University, Columbus, OH.
Circular RNAs (circRNAs) are an abundant class of non-coding RNAs that
are formed by a backsplice event resulting in formation of covalently closed
circular RNAmolecules. The effıciency of backsplicing is inferior to linear splic-
ing, however, due to their long half-lives circRNAs can accumulate to high levels
in cells. Functional characterization of a few circRNAs has shown that they can
act as endogenous microRNA sponges and transcriptional regulators; one ex-
ample is CDR1as/ciRS-7, which has been shown to act as a sponge for miR-7.
However, the functions of most circRNAs are still unknown. To study the po-
tential role of circRNAs in cancer, we identifıed exonic circRNA candidates by
analysing ENCODE RNAseq data from a panel of cancer cell lines. We used
chimeric alignment detection implemented in the STAR aligner and subsequent
fıltering of output fıles to identify chimeric alignments consistent with circRNA
backsplice sites. The circular nature of the identifıed putative circRNAs was
validated by testing their resistance to RNase R digestion, and sequences sur-
rounding the backsplice sites were used as target recognition sequences for de-
signing LNA-modifıed gapmer antisense oligonucleotides (ASOs) to specifıcally
knock down the circular isoforms of the RNA transcripts. Data from ongoing
studies on knockdown of several abundant circRNAs in cancer cell lines, assess-
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ment of the specifıcity of backsplice-targeting ASOs relative to the linearmRNA
counterparts, and analyses to identify biological effects of modulating circRNA
levels in cultured cells will be presented.
#3486 RBM3 causes differential expression lncRNA in colon cancer cell
lines. Afreen Asif Ali Sayed, Dharmalingam Subramaniam, Shahid Umar, Sufı
M. Thomas, Shrikant Anant. University of Kansas Medical Center, Kansas City,
KS.
Introduction:Colon cancer is the thirdmost commonly diagnosed cancer and
leading cause of cancer-related deaths in the United States. It usually begins as a
benign growth that transforms into a malignant adenocarcinoma through ge-
netic changes in tumor suppressor genes and oncogenes. Cancer stem cells are a
rare group of cells within a tumor that have self-renewal capacities andwith high
potency for tumor relapse and metastasis. Wnt/-catenin is one of the major
pathways deregulated in colon cancer and also important in stem cell self-re-
newal. Wnt/-catenin signaling is important in maintaining intestinal homeo-
stasis and the stem cell niche, but aberrant activation of the pathway increases
the stem cell population leading to aggressive cancer.Wedetermined that RBM3
induces stem-like characteristics in colon cancer cells in part, by enhancing
Wnt/-catenin-induced GSK3 inactivation. We are further evaluating the
mechanism by which RBM3 increases Wnt/ -catenin signaling leading to in-
creased stemness. Methods: HCT116 and DLD1 cell lines were used in this
study.We used a PCR array to identify specifıcWnt pathway proteins regulated
by RBM3, in HCT116 RBM3 overexpressing cells and compared it to vector
control cells. RNA-IP was performed to confırm if RBM3 bound to Wnt3a and
LRP6. ChIP was performed for identify -catenin target gene cMyc. RNA seq
was performed to identify differential gene expression and also differential ln-
cRNA expression. RNA-Immunoprecipitation seq was performed to identify
RBM3 protein bound cellular proteins. Ingenuity pathway analysis was per-
formed for all the sequencing data. Results: Our data demonstrate that several
Wnt pathway genes includingWnt3a and LRP6 are upregulated in RBM3 over-
expressing cells. To identify mRNA regulated by RBM3, we performed RNA-IP
for RBM3.We found that RBM3 was associated with the mRNA forWnt3a and
LRP6. The ingenuity pathway analysis for RNA seq shows expression of genes
involved in cell growth, proliferation and metastasis like Jun, LAMC2, Myc,
NR2F2, NT5E etc. when RBM3 is overexpressed in the cells, showing a role of
RBM3 in cancer progression. The seq data also shows differential expression of
lncRNA especially those involved in cancer like CCAT1 and SNHG16. The
ingenuity pathway analysis for RNA-IP seq also shows increase in molecules
involved in proliferation and cell movement. In-vivo studies were also per-
formed to confırm role of RBM3 in tumorigenesis. Conclusion: RBM3 increases
stemness by activating -catenin pathway possibly through Wnt3a and LRP6.
RBM3 overexpression causes differential expression of lncRNA and also in-
creases expression of genes involved in cell growth and proliferation possibly by
interacting with its target mRNAs.
#3487 Identifıcation and validation of PCAT14 as prognostic biomarker
in prostate cancer. Lanbo Xiao, Sudhanshu Shukla, Xiangy Zhang, Yashar
Niknafs, Rohit Malik, Arul Chinnaiyan.University of Michigan, Ann Arbor, MI.
Background: Early detection of prostate cancer, largely facilitated by the ad-
vent of PSA screening, has also been attributed to over-diagnosis and overtreat-
ment of this disease. While stratifying patients into risk groups based on clini-
copathologic features is currently used to guide treatment decisions, it is clear
that current stratifıcation approaches need to be further refıned to allow better
personalization of therapy. Thus, identifying molecular biomarkers to distin-
guish indolent versus aggressive disease would address an unmet need in the
clinical management of prostate cancer. Advances in next-generation sequenc-
ing technologies have enabled thorough characterization of cancer transcrip-
tomes, especially in unraveling the realm of non-coding RNAs (ncRNAs). In
particular, lncRNAs, a class of ncRNAs, have gained increasing attention as
biomarkers due to their tissue- and cancer-specifıc expression profıle. Thus,
lncRNAs may be relevant in the clinical management of prostate cancer (PCa).
Methods and Results: Here we assembled and analyzed a large RNA-seq dataset,
from 585 PCa patient samples, including benign prostate tissue and both local-
ized and metastatic PCa to discover and validate differentially expressed genes
associated with disease aggressiveness. We performed Sample Set Enrichment
Analysis (SSEA) and identifıed genes associated with low versus high Gleason
score in the RNA-seq database. Comparing Gleason 6 versus 9 PCa samples,
we identifıed 99 differentially expressed genes with variable association to Glea-
son grade as well as robust expression in prostate cancer. The top-ranked novel
lncRNA PCAT14, exhibits both cancer and lineage specifıcity. On multivariate
analysis, low PCAT14 expression independently predicts for BPFS (P .00126),
PSS (P .0385), and MFS (P .000609), with trends for OS as well (P .056).
An RNA in-situ hybridization (ISH) assay for PCAT14 distinguished benign
versus malignant cases, as well as high versus low Gleason disease. In prostate
cancer cell lines, the endogenous PCAT14 levels are induced by CRISPR/SAM
technique, which signifıcantly suppresses cell invasion. Conclusion: By per-
forming differential expression analysis between prostate cancer with low vs
high Gleason scores, we identifıed lncRNA PCAT14 as a prostate cancer- and
lineage- specifıc biomarker of indolent disease. We show that PCAT14 is an
AR-regulated transcript and its overexpression suppresses invasion of prostate
cancer cells. Moreover, in multiple independent datasets, PCAT14 expression
associates with favorable outcomes in prostate cancer and adds prognostic value
to standard clinicopathologic variables.
#3488 RNA-sequencing reveals etiology-specifıc dysregulation of PIWI-
interacting RNAs in head and neck squamous cell carcinoma. Aswini R.
Krishnan, Avinaash Korrapati, Angela E. Zou, Yuanhao Qu, Pin xue Li, Hao
Zheng, James Kwok, Weg M. Ongkeko. University of California, San Diego, La
Jolla, CA.
Head and neck squamous cell carcinoma (HNSCC) represents the sixth
deathliest cancer worldwide and the second fastest growing cancer in many
developing countries. A cancer characterized by heterogeneity, HNSCCs are
known to display varied genetic alterations based on a variety of epidemiological
and clinical factors, including etiology, making it challenging to comprehen-
sively profıle and treat the disease. New studies have shown that non-coding
RNAs (ncRNAs) may provide a promising means by which to explore HNSCC
pathogenesis due to their diverse genetic and epigenetic roles and their recent
emergence as potential biomarkers for cancer. In this study, we decided to in-
vestigate etiology-specifıc alterations of PIWI-interacting RNAs (piRNAs), the
largest class of ncRNAs that have roles in silencing of retrotransposons, hetero-
chromatin modifıcation, and germ cell maintenance, in HNSCC. We particu-
larly focused on smoking, the most prevalent risk factor of HNSCC, and HPV,
the fastest growing cause of the disease today.Using 466HNSCCRNA-sequenc-
ing datasets from The Cancer Genome Atlas (TCGA), we identifıed 58 piRNAs
signifıcantly differentially expressed inHNSCC current smokers vs. normal life-
long nonsmokers and 39 piRNAs signifıcantly dysregulated in HNSCC
HPV16() vs. normal HPV(-) cohorts, with 29 piRNAs commonly implicated
in both etiologies (p 0.05). Of the 58 piRNAs implicated in smoking-related
HNSCC, 4 piRNAs were found to signifıcantly associate with clinical variables
and 1 transcript with patient outcome, with similar results for HPV-mediated
piRNA dysregulation (Kruskal-Wallis, Cox regression, p 0.05). In particular,
we recognized transcripts NONHSAT081250, NONHSAT123636, andNONH-
SAT108298 for their correlations with tumor stage, metastatic status, and/or
anatomic site, as well as presence of commonmutations and copy number vari-
ations in HNSCC. We then analyzed mRNA expression data for the same 466
samples from TCGA and found PIWI proteins PIWIL1 and PIWIL2 to be im-
plicated in smoking-related and HPV-related HNSCCs respectively, and also to
associate with piRNA candidate expression levels (p 0.05). We subsequently
validated the dysregulation of all signifıcant piRNA and PIWI protein candi-
dates in vitro in cigarette-treated and HPV E6/E7-overexpressing normal oral
epithelial cells. While a comprehensive understanding of the functional and
mechanistic relevance of a vast majority of non-coding transcripts remains yet
to be found, our fındings reveal the potential of these genes to mediate a variety
of etiology-specifıc clinical and genomic aberrancies in HNSCC and provide
novel insights to thwart the progression of this disease.
#3489 Noncoding RNA distribution in clear cell renal cell cancer: small
RNA-seq data. Srinivas V. Koduru, Dino J. Ravnic. PennState University, Her-
shey, PA.
Small noncoding RNAs (sncRNAs) play pivotal roles in biological processes
and may prove to be a tool in cancer diagnosis, prognosis, and treatment. Non-
codingRNAs such asmicroRNAs (miRNAs), piwi-interacting-RNAs (piRNAs),
long noncoding RNA (lncRNAs) and small nuclear/nucleolar RNAs (sn/snoR-
NAs) have recently been investigated to identify their role in cancer. Approxi-
mately 62,700 new cases of kidney cancer are expected each year in the United
States leading to 14,240 deaths, with rates rising over the past 20 years. Nearly
90% of all kidney cancers will be renal cell carcinoma, of which 70% will be a
clear cell renal cell carcinoma (ccRCC) subtype.When detected earlymost cases
can be treated effectively, however there is a lack of early detection tests. We
sought to identify molecular markers for early detection and diagnosis. We
downloaded publically available (NIH bioproject PRJNA162397) ccRCC small
RNA sequence raw data for noncoding RNA analysis. 22 ccRCC and 11 non-
tumor renal cortex patient samples were evaluated. Data was analyzed by
PartekFlow software. sRNA-seq data was annotated to miRNAs with 69 miR-
NAs aberrantly expressed in ccRCC with 37 being upregulated (top fıve: miR-
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122, miR-210, miR155, miR-224 andmiR-21) and 32 being downregulated (top
fıve: miR-200c, miR-502, miR-20b, miR10a and miR-204). Utilizing MetaCore
software for pathway analysis the majority of expressed miRNAs were involved
in metabolism related signaling pathways. Examining data for piRNAs revealed
22 which were signifıcantly expressed (8 upregulated and 14 downregulated).
Investigation of lncRNAs revealed 15 to be downregulated and 27 upregulated.
We also uncovered 2 mitochondrial rRNAs, 10 miscRNAs, 1 snRNA, 7 snoR-
NAs, and 5 rRNAs in ccRCC samples. Our comprehensive analysis of publically
available small RNA-seq data identifıed numerous sncRNAs associated with
ccRCC. Pending further validation, they may prove useful as early detection
biomarkers in this common cancer.
#3490 Interrogation of small RNA-seq data for small noncoding RNA in
human colon cancer. Srinivas V. Koduru,1 Angelique Nyinawabera,2 Dino J.
Ravnic,1 Amit K. Tiwari2. 1Pennsylvania State University, Hershey, PA; 2Univer-
sity of Toledo, Toledo, OH.
Genomic analysis of the human transcriptome has beenmade possible only in
last decade by next generation sequencing (NGS). Recent advancements inNGS
has further allowed us to look into small non-coding RNAs (sncRNAs) such as
microRNAs (miRNAs), Piwi-interacting-RNAs (piRNAs), long non-coding
RNAs (lncRNAs) & small nuclear/nucleolar RNAs (sn/snoRNAs). Recently, the
roles of sncRNAs in biological processes have been implicated in biomarker
development for diagnosis, prognosis &therapy. In the present study, 50 colon
cancer patient’s small RNA sequencing raw data was downloaded from NIH
bioproject (PRJNA266667; 7TNMstage II& 43TNMstage III)which contained
27 female & 23male samples. 24 samples hadmetachronousmetastasis (MM)&
26 non-metachronous metastasis (NMM). The small RNA-seq data was ana-
lyzed using PartekFlow. In depth analysis showed aberrant expression of 48
miRNAs (all upregulated) in TNM-III vs TNM-II specimens & 20 miRNAs (17
upregulated & 3 downregulated) in MM vs NMM. Further investigation of dys-
regulated miRNA through pathway analysis confırmed that the majority of the
miRNAs were involved in cancer signaling pathways. Analysis of piRNA found
unusual expression of 60 piRNAs (57 upregulated & 3 downregulated) in TNM-
III vs TNM-II & 31 piRNAs (28 upregulated & 3 downregulated) in MM vs
NMM. Further analysis of long non-coding RNAs, we found 77 lncRNAs were
signifıcantly expressed in TNM-III vs TNM-II &18 lncRNAs in MM vs NMM.
We also, investigated small nuclear/nucleolar RNAs (sn/snoRNAs), miscRNAs
&mtRNAs, we identifıed 37 snRNAs, 105 snoRNAs, 28miscRNAs& 5mtRNAs
in TNM-III vs TNM-II whereas 2 snRNAs, 11 snoRNAs, 57 miscRNAs & 8
mtRNAs in MM vs NMM were identifıed. In summary, our comprehensive
analysis on publicly available small RNA-seq data identifıedmultiple small non-
coding RNAs that need to be further explored for their use in the prognosis,
diagnosis & therapy of colon cancer.
#3491 A role for the long non-coding RNA GHRLOS in cancer. Esha T.
Shah, Penny Jeffery, Patrick Thomas, Inge Seim, Lisa Chopin. Ghrelin Research
Group, Translational Research Institute-Institute of Health and Biomedical Sci-
ences, Queensland University of Technology, Brisbane, Australia.
Long non-coding RNA (lncRNA) genes are abundant in the human genome,
and many are now recognized as oncogenes and/or tumor suppressors. We
previously characterized the structure of GHRLOS, an antisense gene on the
opposite strand of the multifunctional ghrelin gene (GHRL), however, its ex-
pression and function in disease has not been described. To this end, using The
Cancer Genome Atlas (TCGA) data set, we revealed that GHRLOS is differen-
tially expressed in a number of cancers. In particular, expression was elevated in
endometrial cancer (1.2 - fold; P 7.1 10-3Welch’s two-sample t-test; n 24
vs. n 175) and prostate cancer (1.2-fold; P 3.7 10-6; n 52 vs. n 498)
compared to normal tissues. Using qRT-PCR (and commercial cDNA panels)
we confırmed that GHRLOS expression was upregulated in endometrial cancer
(1.96-fold, P 0.005 Welch’s two-sample t-test, n 5 vs. n 17) and prostate
cancer (2.46-fold, P  0.0045 Welch’s two-sample t-test, n  5 vs. n  21)
compared to normal tissues. Initial studies, using siRNA designed to silence
endogenous GHRLOS expression, signifıcantly reduced cell migration in the
PC3 prostate cancer cell line (0.47-fold change, P  0.042 Kruskal-Wallis test,
n  2) conversely, preliminary data using forced GHRLOS overexpression in-
creased migration and proliferation. Taken together, we show that the long
non-coding RNA GHRLOS is differentially expressed in tumor tissue and reg-
ulates cell migration and proliferation; possibly bymodulating alternative splic-
ing of the overlapping, multifunctional ghrelin gene locus. Targeting GHRLOS
could provide a valuable and novel way to target the ghrelin axis in disease.
Ongoing studies aim to validate in vitro functional results in complementary
mouse xenograft models and identify genes and pathways regulated by this
novel lncRNA.
#3492 Subtype-specifıc expression of small non-coding RNAs in breast
cancer. JaanaM.Hartikainen,1 SamiHeikkinen,2Maria Tengström,3Veli-Matti
Kosma,4 Arto Mannermaa4. 1School of Medicine, Institute of Clinical Medicine,
Pathology and ForensicMedicine, and Cancer Center of Eastern Finland, Univer-
sity of Eastern Finland, Kuopio, Finland; 2Institute of Biomedicine, University of
Eastern Finland, Kuopio, Finland; 3School of Medicine, Institute of Clinical Med-
icine, Oncology, and Cancer Center of Eastern Finland, University of Eastern
Finland, and Cancer Center, Kuopio University Hospital, Kuopio, Finland;
4School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Med-
icine, and Cancer Center of Eastern Finland, University of Eastern Finland, and
Imaging Center, Kuopio University Hospital, Kuopio, Finland.
We have performed a small RNA-sequencing (RNA-Seq) experiment to
fınd candidate small non-coding RNAs (ncRNAs) in breast cancer (BC) for
the identifıcation of signatures that aid in the prediction of therapy respon-
siveness, prognosis or patient outcome. We used 195 invasive BC tumor and
20 benign breast tissue samples from the Kuopio Breast Cancer Project
(KBCP) study material. KBCP material is collected from a genetically homo-
geneous population of Eastern Finland, and includes fresh-frozen and FFPE
breast tissue samples, EDTA blood samples and serum, as well as compre-
hensive background/lifestyle information, clinical, treatment and follow-up
data extending over 20 years. This well-defıned material enables the identi-
fıcation of factors associating with BC risk, different stages of disease pro-
gression and outcome. Total RNA was extracted from the fresh-frozen BC
and benign breast tissue using the Ambion mirVana miRNA Isolation Kit.
Small RNA-Seq was performed using the Illumina TruSeq Small RNA Li-
brary Prep kit and the Illumina MiSeq next-generation sequencing instru-
ment. Analyses were concentrated in PIWI-interacting RNAs (piRNAs) and
other non-miRNA small ncRNAs (sncRNAs). Bioinformatic analysis com-
menced with quality control and preprocessing steps including read quality
assessment (FastQC), adapter trimming (TRIMMOMATIC), and removal of
e.g. ribosomal RNA reads (Bowtie). Preprocessed reads were aligned
(Tophat) to human reference transcriptomes (piRNABank and GENCODE
non-miRNA sncRNAs), followed by data conversions e.g. for visualization
(samtools, IGVtools). Gene-wise read counts were collected using summa-
rizeOverlaps R package, and statistically differentially expressed (DE) genes
were identifıed using DESeq2 R package. We fırst compared the small RNA
expression in the benign breast tissue with invasive BC and observed in total
635 sncRNAs and 94 piRNAs with differential expression (PAdj0.05). Of
these 520 sncRNAs and 73 piRNAs were upregulated, and 115 sncRNAs and
21 piRNAs downregulated in the invasive tumors compared to benign breast
tissue. When comparing the luminal BC subtype with triple-negative BC
(TNBC) we observed 204 DE (PAdj0.05) sncRNAs and 32 piRNAs. Of
these, 103 sncRNAs and 18 piRNAs were upregulated, and 101 sncRNAs and
14 piRNAs downregulated in TNBC compared to luminal tumors. Differen-
tial expression was also observed between ER (estrogen receptor) negative
and ER positive invasive tumors. Of the 242 DE sncRNAs and 32 piRNAs,
105 sncRNAs and 12 piRNAs were upregulated, and 137 sncRNAs and 20
piRNAs downregulated in ER positive BC compared to ER negative. Prelim-
inary results of hierarchical clustering and principal component analysis of
normalized log2 piRNA and sncRNA expression levels revealed the potential
for fınding differences between BC subtypes. The subsequent statistical anal-
ysis enabled us to identify individual piRNAs and other sncRNAs as candi-
date druggable biomarkers for e.g. TNBC patients.
#3493 LncRNA as potential target in drug-resistant melanomas. Rosaura
Esteve-Puig,1Martina Sanlorenzo,2 IgorVujic,3 Kevin Lai,1MarinVujic,1Dallas
Mould,1 Kevin Lin,1 Juan Oses-Prieto,1 Shreya Chand,1 Christian Posch,3 Alma
Burlingame,1 Susana Ortiz-Urda1. 1University of California, San Francisco, San
Francisco, CA; 2University of Turin, Turin, Italy; 3Rudolfstiftung Hospital, Aca-
demic Teaching Hospital, Vienna, Austria.
Melanoma is the most common lethal form of skin cancer. Activating muta-
tions in BRAF and RAS oncogenes account for over 80% of all melanomas and
hyper-activate the MAPK cascade. Despite major advances in targeted mela-
noma therapies over the past decade, drug resistance limits their effıcacy. Long
noncoding RNAs (lncRNAs) are a new class of genes that do not encode pro-
teins, which have been characterized as epigenetic regulatory molecules. Ln-
cRNAs have emerged as important players in cancer, potential predictors of
therapeutic responses and targets for new treatments; however, their functions
and precise molecular mechanisms remains largely unexplored. Our study aims
to fınd novel potential targets involved in the acquisition of resistance toMAPK
inhibitors. We identifıed an intergenic lncRNA (lincRNA) highly differentially
expressed in drug-resistant melanoma samples, called MAPK Inhibitor Resis-
tance Associated Transcript (MIRAT). We determined that MIRAT is localized
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mainly in the cytoplasm and plays a role in modulating the signal transduction
pathways without regulating the genomic neighborhood. We discovered that
MIRAT is upregulated in early drug tolerance to MAPK inhibition. Mechanis-
tically, the gene overexpression and silencing of MIRAT, as well as preliminary
RNA-protein interaction results, showed that it modulates the MAPK signal
transduction pathway by binding to a downstream target of MEK. Collectively,
these results highlight the relevance of cytoplasmic lincRNA’s and their role in
oncogenic signaling pathways, and further suggest that lncRNAs and their pro-
tein-binding partners may serve as novel potential targets for overcoming drug
resistance in melanoma.
#3494 Dissecting the cellular expression and subcellular localization of
lncRNAs implicated as prognostic biomarkers in non-small cell lung carci-
nomas by RNA ISH. Courtney M. Anderson, Na Li, Xiao-Jun Ma, Emily Park.
Advanced Cell Diagnostics, Newark, CA.
Background: Long non-coding RNAs (lncRNAs) are involved in many bio-
logical processes, including epigeneticmodifıcation, cell differentiation, and ap-
optosis. More recently, lncRNAs have emerged as unique biomarkers that may
be associated with a physiological or diseased state, and several lncRNAs have
been identifıed as prognostic markers in a wide variety of human cancers. Be-
cause lncRNAs do not translate into protein, their discovery in the tumor is
entirely dependent upon RNA detection. The majority of lncRNAs are also
expressed at very low levels compared to mRNAs and may be more heteroge-
neously expressed than mRNAs. Therefore, detection of lncRNAs in tumor bi-
opsies requires a highly sensitive and specifıc detectionmethod that can discern
single-cell and subcellular localization of lncRNA expression. Methods: Single-
molecule RNA in situ hybridization (ISH) is a well-suited method for the detec-
tion of lncRNAs in tumor biopsies because it allows for the visualization of single
RNAmolecules with morphological context. To interrogate the expression pat-
tern of lncRNAs within the tumor and its microenvironment, we performed
RNA ISH using the RNAscope assay on FFPE tissue microarrays consisting of
archived tissue samples of 53 primary non-small cell lung carcinoma (NSCLC)
tumors and 4 adjacent normal lung tissues. We examined the expression of 4
lncRNAs which have been implicated as potential prognostic markers of lung
cancer: AFAP-AS1, ANRIL,HOTAIR, andUCA1. Results: These lncRNAswere
detected in approximately 40-60% of the 53 NSCLC tumor cores and in none of
the 4 adjacent normal lung tissues. Expression of these 4 lncRNAs was observed
predominantly in tumor cells, with little to no detection in the stroma. Some
lncRNAs displayed a heterogeneous expression pattern, with some tumor cell
foci displaying strong lncRNA signal while other foci in the same tumor did not
display signal. Furthermore, some lncRNAs displayed heterogeneous cell ex-
pression in the same foci, with some cells expressing very high levels of lncRNA
while other cells in the same foci had little to no lncRNA expression. An evalu-
ation of each lncRNA in serial sections revealed that 6 of the 53 NSCLC tumors
expressed all 4 lncRNAs in the same tumor foci. Lastly, little to no signal was
observed for the prostate cancer-specifıc lncRNA PCA3 in the NSCLC tumors
and no PCA3 expression was detected in adjacent normal lung tissues. Conclu-
sions: These results demonstrate the ability of the RNAscope ISH assay to detect
potential lncRNA biomarkers in lung cancer samples in situ, allowing for the
identifıcation of expression heterogeneity within the tissue environment and
precise tumor expression patterns of lncRNAs. Identifıcation of the subcellular
localization and cell-to-cell expression patterns of lncRNAs can facilitate greater
understanding about their specifıc biological roles in cancer and other diseases.
#3495 The DNA methylation landscape of long noncoding RNAs in hu-
man cancer. Da Yang, Zehua Wang, Bo Yang, Min Zhang, Zhiyuan Wu. Uni-
versity of Pittsburgh, Pittsburgh, PA.
Integrating multi-dimensional genomic and epigenetic data from the TCGA,
ENCODE and CCLE projects, we comprehensively characterized the epigenetic
landscape for lncRNA genes in 9837 tumor samples across 33 cancer types. This
analysis revealed that lncRNAs can be both epigenetically silenced and activated
by DNA methylation alteration in the promoter region, which is in striking
contrast to the well-documented hypermethylation of protein-coding gene pro-
moters in tumor. To determine the corresponding transcriptional changes of
lncRNAswith epigenetic alterations in tumors, we applied a heuristic strategy to
identify the epigenetic silenced and activated lncRNA by integrating the tran-
scriptome of 58,648 lncRNAs from 6475 TCGA RNA-seq fıles. This analysis
characterized a patient-centric matrix with DNA methylation status of 3380
epigenetically regulated lncRNAs across 6475 tumor samples. Some epigeneti-
cally-activated lncRNAs exhibited an “on or off” pattern with completely no
expression in normal tissues, which potentiated them as promising diagnostic
biomarkers. To rule out the interference of tumor associated stromal and im-
mune cells in lncRNA analysis, we investigated the RNA-seq and DNAmethyl-
ation profıles of 784 cell lines from breast, lung, and bladder cancer. Most of
epigenetically regulated lncRNAs identifıed in tumor samples showed promi-
nently negative correlation between their expression and promoter methylation
in cancer cell lines. We then validated the epigenetically activated lncRNAs by
performing decitabine treatment on cell lines. The decitabine treatment led to a
dosage and time-dependent induction of lncRNA expression and loss of DNA
methylation at lncRNA promoter. Further survival analysis indicated that epi-
genetically activated lncRNAswere generally correlatedwith poor survivalwhile
the epigenetically silenced lncRNAs were generally correlated with good sur-
vival. Among the epigenetically silenced lncRNAs are well-documented tumor
suppressor lncRNAs such as MEG3. And lncRNA oncogenes, such as MINCR,
are epigenetically activated in multiple cancer types. To delineate the relation-
ship between lncRNAs and known cancer pathways, we performed mutual ex-
clusive analysis by combining the lncRNA epigenetic landscape with known
protein-coding tumor genes alterations in same tumors. This analysis nomi-
nated several lncRNAs as novel members in cancer pathways, including TP53,
PI3K, and EGFR cascades. Indeed, functional experiment validation focus on
the top epigenetically activated lncRNA (EPIC1) demonstrated that EPIC1 is a
potential oncogene. In breast and ovarian cancer cell lines, EPIC1 promotes
cancer cell colony formation and increases cell viability by promoting cell cycle
pathway. Collectively, our integrative study provides a resource for investigating
lncRNAs in cancer and lays the groundwork for the development of novel diag-
nostics biomarkers and treatments.
#3496 Longnon-codingRNAs in colorectal cancer.AlenaOpattova,1 Fábio
Miguel Ferreira,2 Jozef Horak,1 Sona Vodenkova,3 Pavel Vodicka1. 1Institute of
Experimental Medicine, Prague, Czech Republic; 2Research Centre of IPO-Porto,
Porto, Portugal; 3Third Faculty of Medicine, Charles University, Prague, Czech
Republic.
Colorectal cancer (CRC) is the third most common type of cancer worldwide
and the second most common cause of cancer related deaths in Europe. Since
Countries of Central Europe (Czech Republic, Slovakia, Hungary) have one of
the highest rates both for incidence andmortality of CRC,CRCbecame a serious
health, social and economic problem. CRC pathogenesis involves multiple ge-
netic events. On behalf of a strong experimental work, there is still lack of pre-
dictive, prognostic and treatment-response related biomarkers. Long non-cod-
ing RNAs (lncRNA) are non-protein coding transcripts longer than 200
nucleotides. Deregulation of lncRNAs is often seen in a variety of human dis-
eases, including cancer. Taken together, this makes lncRNAs the potential reg-
ulators of cancer progression, therapeutic targets or markers of treatment effı-
cacy. The main aim of our present study was to defıne expression patterns of
lncRNAs in colorectal tumor tissue and defıne their role in cancer cell prolifer-
ation, survival and DNA damage response (DDR). In the fırst part of our study,
we analyzed the expression profıle of 83 lncRNA known to be associated with
cancer progression in cohort of CRC tumor tissues and adjacent mucosa. We
found 12 upregulated lncRNAs (p0.05) and 10 downregulated lncRNAs
(p0.05). Our results have been replicated on larger set of patients (100 CRC
patients) and those lncRNAs associated with cell proliferation, survival and
DNA damage response are functionally tested on colorectal cell lines (HCT116,
HCT116 p53-/-) in vitro. Defınition of role of lncRNA as a tumor suppressors or
oncogenes in CRC etiology may lead to better understanding of regulation of
CRC carcinogenesis. Furthermore, understanding the role of lncRNA in DDR
may contribute to better treatment response of CRC patients and to defıne
markers of individual treatment response. Acknowledgement: GACR 15-
14789S, AZV 15-27580A, GAUK800216, AZV 15-26535A, SUSCEPTCOST
LD14050
#3497 Network-based systematic inference of lncRNA activity in breast
cancer.MatthewUng, DanielMattox, GeorgeWang, ChaoCheng.Geisel School
of Medicine at Dartmouth, Hanover, NH.
The production of lncRNA is widespread across the human genome, yet the
functions of lncRNAs and the phenotypes resulting from their activation have
remained largely unstudied. In cancer, several lncRNAs have been found to
associate with disease development and poor patient prognosis including
HOTAIR and MALAT1. Recent studies have been performed using lncRNA
microarrays or re-annotated probes from coding gene microarrays to systemat-
ically investigate their roles in cancer. However, datasets from lncRNAmicroar-
rays are typically not accompanied by comprehensive clinical information that
can be used to draw associations between lncRNA expression and clinical phe-
notypes. Furthermore, lncRNA stability and cellular localization is highly vari-
able suggesting that expression-based inference of lncRNA activity may not
always be an accurate measure of its activity. To address this issue, we introduce
an activity-based approach whereby we analyze the expression of lncRNA target
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genes to infer lncRNA activity. Specifıcally, we construct a breast cancer specifıc
lncRNA-target gene network from RNA-seq data using a network reconstruc-
tion algorithm. We then apply this network to several breast cancer microarray
datasets to systematically investigate lncRNA activity and their association with
clinical phenotypes. Notably, we fınd that certain lncRNAs are active in specifıc
molecular subtypes of breast cancer even though their expression levels do not
reveal signifıcant differences. Lastly, we performed survival analysis to system-
atically screen for novel lncRNAs whose activity associate with patient progno-
sis. Our results suggest that activity-based inference of lncRNAs can identify
novel lncRNAs that may serve as therapeutic targets or biomarkers in breast
cancer.
#3498 Characterization of a novel metastatic lung cancer associated ln-
cRNA.Nicole M.White, Emily B. Rozycki, Ha X. Dang, Christopher A. Maher.
Washington University School of Medicine, Saint Louis, MO.
Lung cancer is the leading cause of death worldwide with the majority of
patients presenting withmetastasis andmoreover, developing resistance to cur-
rent treatments. One promising therapeutic area is the novel class of long non-
coding RNAs (lncRNAs). While emerging evidence implicates them in cancer,
lncRNA biology is still largely unexplored in tumor metastasis. To elucidate the
function of lncRNAs in lung cancer, our lab used transcriptome sequencing
(RNA-Seq) to discover 120 long non-coding RNAs (lncRNAs) that are enriched
in metastatic tumors compared to their corresponding primary lung tumors,
which we have named Metastasis Associated Lung cancer LncRNAs (MALLs).
Notably, metastatic tumors were enriched for differentially expressed protein-
coding genes targeted by Polycomb Repressive Complex 2 (PRC2). In lung can-
cer studies show that the catalytic subunit of PRC2, EZH2 (an H3K27 methyl-
ase), is overexpressed, associates with poor prognosis, promotes tumor
progression, and epigenetically represses genes to promote metastasis. Specifı-
cally, we have found MALL-1 to be (i) highly up-regulated in lung cancer; (ii)
promotes proliferation andmigration/invasion, hallmarks of oncogenic pheno-
types; (iii) binds to EZH2; and (iv) cooperatively represses well-known PRC2
target genes associatedwithmetastasis in patients. Further, we foundMALL-1 to
be altered in multiple solid tumors thus suggesting a critical conserved onco-
genic role ofMALL-1 in solid tumor progression.We believeMALL-1 promotes
aggressive disease through its interactions with, and recruitment of the PRC2
complex to chromatin, to epigenetically modify genes associated with metasta-
sis.
#3499 Differentially expressed small noncoding RNAs in triple-negative
breast cancer. Srinivas V. Koduru,1 Amit K. Tiwari,2 Ashley Leberfınger,1
Sprague W. Hazard,1 Yuka Imamura Kawasawa,1 Milind Mahajan,3 Dino J.
Ravnic1. 1Pennsylvania State University-Hershey, Hershey, PA; 2University of
Toledo, Toledo, OH; 3Icahn School of Medicine, Mount Sinai, New York, NY.
Cancer is the second leading cause of death in theUnited States and is amajor
public health concern worldwide. Basic, clinical and epidemiological research is
leading to improved cancer detection, prevention, and outcomes. Recent tech-
nological advances have allowed unbiased and comprehensive screening of ge-
nome-wide gene expression. Small non-coding RNAs (sncRNAs) have been
shown to play an important role in biological processes and could serve as a
diagnostic, prognostic and therapeutic biomarker for specifıc diseases. Recent
fındings have begun to reveal and enhance our understanding of the complex
architecture of sncRNA expression including miRNAs, piRNAs, sn/snoRNAs
and their relationships with biological systems.We used publicly available small
RNA sequencing data that was derived from 24 triple negative breast cancers
(TNBC) and 14 adjacent normal tissue samples to remap various types of
sncRNAs.We found a total of 55miRNAs were aberrantly expressed (p0.005)
in TNBC samples (8 miRNAs upregulated; 47 downregulated) compared to
adjacent normal tissues whereas the original study reported only 25 novel miRs.
In this study, we used pathway analysis of differentially expressed miRNAs
which revealed TGF-beta signaling pathways to be profoundly affected in the
TNBC samples. Furthermore, our comprehensive re-mapping strategy allowed
us to discover a number of other differentially expressed sncRNAs including
piRNAs, sn/snoRNAs, rRNAs,miscRNAs and nonsense-mediated decay RNAs.
We believe that our sncRNA analysis workflow is extremely comprehensive and
suitable for discovery of novel sncRNAs changes, which may lead to the devel-
opment of innovative diagnostic and therapeutic tools for TNBC.
#3500 Epstein-Barr virus BART noncoding RNAs modulate host gene
expression for virus latency leading to oncogenesis in epithelial cells. Rob
Verhoeven, BoboWing-Yee Mok, Shuang Tong, Honglin Chen. The University
of Hong Kong, Hong Kong, Hong Kong.
Epstein-Barr virus (EBV) effıciently establishes and maintains a state of la-
tency in resting B cells, with persistent asymptomatic infections occurring in
more than 95% of the human population worldwide. Besides causing lifelong
infections in resting B cells in the majority of people, EBV has been found to
associate with several human cancers occurring in immune competent individ-
uals, in which the virus expresses very few viral proteins in EBV infected cancer
cells through a distinct viral latency program. It is believed that this type of
mechanism has been adopted by EBV to allow the virus to evade host immune
surveillance. Nasopharyngeal carcinoma (NPC) is prevalent in southern China,
Southeast Asian countries and someAfrican countries but uncommon in rest of
the world. In NPC 100% of cancer cells are infected with EBV, and EBV is
recognized one of themajor etiological factors. However, the details of howEBV
maintains latency and contributes to the oncogenesis of NPC remain mostly
elusive. Notably, EBV abundantly expresses a family of non-coding RNAs de-
rived from the BamHI A region of the viral genome (BARTs). It is hypothesized
that this family of viral non-coding RNAs is key to maintaining viral latency,
evading immune surveillance and triggering oncogenesis in EBV associated tu-
mors. We have shown a mechanism for the regulation of the abundant expres-
sion of BARTs in NPC which involves the constitutive activation of NF-B
signaling typically observed in NPC cells and have also identifıed a regulatory
loop through which BARTs support EBV latency in NPC. Using high through-
put RNA-seq analysis we further demonstrated that BART RNAs modulate
expression of cellular genes associated with anti-inflammatory and immune-
modulating properties, oxidoreductase activity, and cell migration and invasion
in NPC cells. BART non-coding RNAs are predominantly localized in the nu-
cleus and associate with the CBP/p300 complex. Our data showed that EBV
BARTsmodulate genes responsive to themitochondria-associated adaptermol-
ecule (MAVS) through halting cellular Pol II in the promoter region and down-
regulating gene expression. In the nucleus, BART non-coding RNAs modulate
chromatin acetylation through interactionwithCBP/p300.We have generated a
working model with evidence showing that Epstein-Barr virus shuts off most of
the viral proteins to evade immune surveillance, but through expression of high
levels of BART non-coding RNAs can modulate cellular gene expression to
provide an optimal environment formaintenance of viral latency in cancer cells.
Alteration of cellular gene expression by EBV BART non-coding RNAs for
establishment and maintenance of EBV latency in epithelial cells can therefore
lead to the oncogenic process for EBV associated tumors.
#3501 Prognostic value of a 4 lncRNA signature in patients with non-
small cell lung cancer: a lncRNA expression analysis. XiaoRan Long,1 Hui-
Yun Wang,1 ChunLei Ge,2 Xin Song,2 MeiYin Zhang,1 XiaoFeng Zhen3.
1caner center of Sun Yet-sen University, Guangzhou, China; 2Cancer Bio-
therapy Center of the Third Affıliated Hospital of Kunming Medical Univer-
sity, KunMing, China; 3Rutgers Cancer Institute of New Jersey and Depart-
ment of Pharmacology, Robert Wood Johnson Medical School, Rutgers
University, New Brunswick, NJ.
Recently, increasing evidence indicates that lncRNA plays an important role
in the cancer development and progression. In this study, we are aimed to iden-
tify lncRNA signature for predicting survival of non-small cell lung cancer
(NSCLC) patients. A total of 366 NSCLC cases, which were divided into a train-
ing and validation set, were detected by lncRNA microarray (containing 2412
lncRNA probes), and another 73 cases as an independent set were analyzed by
qRT-PCR. LncRNA microarray analysis identifıed a total of 305 differentially
expressed lncRNAs (138 up-regulated and 167 down-regulated) between
NSCLC and normal tissues in the training set.We then validated themicroarray
data by qRT-PCR analysis of 5 lncRNAs (2 up-regulated and 3 down-regulated)
in 30 pairedNSCLC and adjacent lung tissues randomly selected from the train-
ing set. We then used a stepwise forward process to select the best combination
of lncRNAs with the most signifıcance in prediction of NSCLC prognosis and a
4-lncRNA prognostic signature was established, which was signifıcantly associ-
ated with overall survival (hazard ratio [HR]: 3.563, 95% confıdence interval
[CI]: 2.118-5.995, P0.001) anddisease-free survival (HR: 3.236, 95%CI: 2.116-
4.940, P0.001) in the training set. This prognostic signature was validated in
the validation (OS, HR: 3.186, 95% CI: 1.849-5.488, P0.001; DFS, HR: 2.967,
95% CI: 1.949-4.517, P 0.001) and independent sets (OS, HR: 4.703, 95% CI:
1.923-11.50, P 0.001; DFS, HR: 4.549, 95% CI: 2.139-9.674, P 0.001). This
4-lncRNA signature has been demonstrated as an independent prognostic fac-
tor, which signifıcantly improves the prognostic accuracy of TNM staging sys-
tem in a combined model as assessed by ROC curve analyses in the three sets,
respectively. Therefore, the 4-lncRNA signature has potential prognostic role in
NSCLC patients.
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#3502 RNAi screen identifıed novel long non-coding RNAs involved in
cell growth control, migration, and invasion. Tse-Chun Kuo, Sheng-Chieh
Hsu, Hui-Ju Chou, Pei-Shan Li, Szu-Huei Wu, Yen-Ling Yu, Jen-Shin Song,
Hsing-Jien Kung. NHRI, Taiwan, Zhunan Town, Miaoli, Taiwan.
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast
cancer often associated with poor prognosis. Owing to the lack of therapeutic
targets, patients with TNBC tend to rely on standard chemotherapy; however,
chemo-resistance often develops in TNBC as a result of deregulated cell death
control like inmany other tumors. Long non-coding RNAs (lncRNAs) are tran-
scripts longer than 200bp and have little or no protein-coding capacity. Al-
though once considered as transcriptional noise, signifıcant numbers of ln-
cRNAs are now known as modulators of protein expression and functions and
are implicated in a range of developmental processes and diseases. As many of
them influence oncogenes and tumor suppressors in cancer, they represent ex-
cellent biomarkers as well as potential targets for therapy. In order to gain more
insight on cell death regulation and to seek potential targets for TNBC, we
employed an RNAi screen targeting 2231 lncRNAs in MDA-MB-231 TNBC
cells. By using changes in cell metabolic activity (MTT assay) as readouts for
primary screen and changes in cell number as confırmation, our unbiased screen
identifıed two novel lncRNAs that drastically reduced cell proliferation when
depleted. In addition to cell growth, the two lncRNAs also contribute to cancer
cell migration and invasion. Interestingly, our gene profıling analyses and RNA
immunoprecipitation studies show the two lncRNAs are involved in signaling
cascades known to promote mammary tumorigenesis including EGF and
-catenin. We are now trying to delineate the detailed molecular mechanism(s)
by which the two lncRNAs contribute to TNBC tumorigenesis. Together, our
current results suggest a possibility for the two novel lncRNAs as drug targets in
triple-negative breast cancer.
#3503 Transcriptome analysis reveals differentially expressed lncRNAs
between oral squamous cell carcinoma and healthy oral mucosa. Lu Feng,
John R. Houck, Pawadee Lohavanichbutr, Chu Chen. Fred Hutchinson Cancer
Research Center, Seattle, WA.
Objective:Oral cavity and oropharyngeal squamous cell carcinoma (OSCC) is
a major cancer type in the head and neck region. To better understand the roles
long non-coding RNA (lncRNA) play in OSCC carcinogenesis, we compared
the genome-wide gene expressions of lncRNA in OSCC and in the oral mucosa
from healthy individuals. Materials and methods: We compared the expression
levels of 3,054 probe sets for lncRNAs between 167 OSCCs and 45 healthy con-
trols using an Affymetrix HG U133 plus 2.0 array dataset. We validated the top
differentially expressed lncRNAs in three independent datasets in the Gene Ex-
pression Omnibus (GEO) repository: GSE42743, GSE9844, and GSE6791. We
further tested the differential expression of the three lncRNAs showing the high-
est fold change by quantitative RT-PCR in a subset of 20 OSCCs and 10 control
samples. Results: We found 658 lncRNA transcripts (790 probe sets) to be sig-
nifıcantly differentially expressed betweenOSCC and healthy oralmucosa using
a criteria of FDR0.01, with 36 of them (39 probe sets) showing more than a
2-fold change. Among the 36, 14 (15 probe sets) lncRNAs were validated in all
three independent datasets using the criteria FDR0.01: LOC441178, C5orf66-
AS1, HCG22, FLG-AS1, CCL14/CCL15-CCL14, LOC100506990, TRIP10,
PCBP1-AS1, LINC01315, LINC00478, COX10-AS1/LOC100506974, MLLT4-
AS1, MIR31HG, and DUXAP10/LINC01296. The differential expressions of
LOC441178, HCG22 and C5orf66-AS1 were verifıed by qRT-PCR. Conclusion:
We identifıed a number of differentially expressed lncRNAs using transcrip-
tomic data betweenOSCCs and healthy oralmucosa. Further investigations into
their potential role in OSCC carcinogenesis or to serve as OSCC biomarkers
and/or therapeutic targets are warranted.
#3504 High expression of lncRNA-ATB and miR-21 as a biomarker in
human hepatocellular carcinoma. Eunhye Lee,1 Gyeonghwa Kim,1 Se
Young Jang,2 Yong-Hun Choi,1 Yu Rim Lee,2 Won Young Tak,2 Young Oh
Kweon,2 Soo Young Park,2 Keun Hur1. 1Department of Biochemistry and Cell
Biology & BK21 Plus KNU Biomedical Convergence Program, Kyungpook
National University School of Medicine, Daegu, Republic of Korea; 2Depart-
ment of Internal Medicine, Kyungpook National University Hospital, Daegu,
Republic of Korea.
Non-coding RNAs (ncRNAs) including microRNAs (miRNAs) and long
non-coding RNAs (lncRNAs) have emerged as novel gene-regulators. The aim
of this study was to determine the clinical relevancies of 2 lncRNAs (lncRNA-
ATB and MEG3) and 2 miRNAs (miR-21 and miR-31) in hepatocellular carci-
noma (HCC). We analyzed clinical specimens from 100 pairs of HCC and
matched normal liver (NL) tissues. MiRNAs and lncRNAs expression levels
were evaluated by quantitative real-time PCR. In addition, we determined the
clinical signifıcance of the ncRNAs expression in matching tissue and serum
exosome samples from HCC patients. MiR-21 signifıcantly increased in HCC
(P0.01) compared to corresponding NL tissues. LncRNA-ATB was signif-
icantly up-regulated in HCC (P0.05); however, lncRNA-MEG3 was down-
regulated in HCC (P0.05) tissues. In addition, expression of miR-21 and
lncRNA-ATB was signifıcantly associated with the tumor size and poor
prognosis of HCC patients. More importantly, expression of serum exo-
somal lncRNA-ATB and miR-21 was more signifıcantly associated with
HCC progression and poor patients survival compared to its’ tissue expres-
sion. We conclude that non-coding RNAs (lncRNA-ATB and miR-21) ex-
pression has the potential to serve as biomarkers for prognosis and targeted
therapy in HCC patients.
#3505 The expression of two key longnon codingRNAs involved in repro-
gramming, linc-ROR and lin-P21, in gastric cancer. Mitra Khalili,1 Pouran-
dokht Farhangiyan,1 Somayeh Jahandoost,1 Fatemeh Kamali2. 1Zanjan Univer-
sity of Medical Sciences, Zanjan, Islamic Republic of Iran; 2Tehran University of
Medical Sciences, Teharn, Islamic Republic of Iran.
Introduction: Gastric cancer (GC) is the second leading cause of cancer-
related death in the world and the most common cancer in southeast of
Caspian Sea (Golestan province) and northwest of Iran (Ardabil). Based on
cancer stem cell (CSC) hypothesis, there are similarities between process of
somatic cell reprogramming, embryogenesis and tumorigenesis. Malfunc-
tion of signaling pathways that are essential for normal development also
involved in the tumor initiation and CSC formation. In recent years long
noncoding RNAs (lncRNAs), more than 200 nt in length, have been highly
regarded as promising biomarkers for early diagnosis and prognosis of can-
cers. Reprogramming-Related Long Intergenic Noncoding RNA (lincRNA-
ROR) plays as modulator in the reprogramming of human induced pluripo-
tent stem cells (iPSCs) and also maintenance of embryonic stem cells (ESCs).
On the other hand, lincRNA-P21 induced by P53 and prevents the somatic
cell reprogramming by silencing of pluripotency gene promoters. In this
project, motivate to CSCs, we evaluated the expression level of lincRNA-
ROR and linc-P21 in samples of patients with gastric cancer and also in
human gastric cancer cell lines (AGS and MKN45) and human embryonal
carcinoma cell line (NT2). Methods: Thirty pairs of gastric samples, includ-
ing gastric adenocarcinoma and their matched non-tumor tissue samples,
were collected from the Iran National Tumor Bank (INTB). Cell lines were
cultured in the RPMI1640. Total RNA of samples and cell lines was extracted
using TRIZOL reagent (invitrogene). cDNA synthesis was performed by
PrimeScript™ 1st strand cDNA Synthesis Kit (TAKARA) and real time PCR
was performed by using TaqMan master mix (TAKARA) on Step one Plus™
instrument (ABI). Gene expression analysis performed by GenEx software
program. Results: Despite of reports indicating the high expression of linc-
ROR in some cancers, our results showed no expression for linc-ROR in
gastric samples (both tumor and non tumor) and also gastric cancer cell
lines. But NT2 embryonal carcinoma cell line revealed high expression of
linc-ROR compared to AGS and MKN45cell lines. According to our expec-
tation, linc-P21 represents a signifıcant decrease in tumor versus non tumor
samples (p0.01) in different grads of malignancy and also in AGS and
MKN45 versus to NT2 cell line. Conclusion: Dysfunction of linc-ROR and
lincRNA-P21 has reported in some cancers. According to our results, it
seems that the expression of linc-ROR is limited to embryonic stem cells and
hasn’t remarkable expression in gastric samples and cell lines. Based on the
low expression of linc-P21 in tumor samples, it seems that linc-P21 functions
as a tumor suppressor.
#3506 ncRNA regulation of eribulin response in neuroblastoma. Yiqiang
Zhang,1 Xiuye Ma,1 Xiaojie Yu,1 Harsh Patolia,2 Zhenze Zhao,3 Liqin Du,3 Al-
exander Pertsemlidis1. 1University of Texas Health Science Center at San Anto-
nio, San Antonio, TX; 2Virginia Tech Carilion School of Medicine, Roanoke, VA;
3Texas State University, San Marcos, TX.
Introduction: Neuroblastoma (NB) is the most common cancer in infants
and the most common extracranial solid tumor in children, accounting for
15% of all childhood cancer deaths. The overall prognosis for those with
high-risk or relapsed disease remains poor despite the standard therapies of
surgery, radiation, and high dose chemotherapy. We have previously shown
that altering levels of specifıc microRNAs (miRNAs) can improve cellular
response to microtubule-targeting agents (MTAs) and that exposure to
MTAs results in dramatic changes in microRNA expression. Methods: Li-
braries of chemically synthesized ncRNA mimics and inhibitors, including
both miRNAs and lncRNAs, are screened to identify ncRNAs that regulate
neuroblastoma cell viability or sensitize neuroblastoma cells to specifıc mi-
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crotubule-targeting agents. Candidate targets are validated using qRT-PCR,
protein quantifıcation, and luciferase reporter assays. The response of neu-
roblastoma cells to perturbations in candidate ncRNA levels is assessed
through flow cytometric analysis of cell cycle phase distribution, density and
anisotropy of microtubule bundles, and through colony formation and
caspase activation assays, and validated in mouse xenograft models. Net-
works of miRNAs, mRNAs and lncRNAs are derived from combining com-
plementary cellular response with potential regulatory interactions. Results:
We previously reported the identifıcation of miRNAs and lncRNAs that
signifıcantly decrease or increase neuroblastoma cell viability. Here, we ex-
tend those observations to drug response. We fırst demonstrate that the
microtubule-targeting agent eribulin has both short-term and long-term
effects, as reflected by a signifıcant alteration in microtubule structure in
response to high doses for short times and arrest at the G(2)/M phase of the
cell cycle in response to low doses for long times. We next show that altering
intracellular levels of ncRNAs that sensitize cells to eribulin both alters mi-
crotubule density and anisotropy and recapitulates the effect of eribulin
treatment. Finally, we show that complementarity of effect between miRNAs
and lncRNAs is accompanied by potential regulatory interaction. Conclu-
sions: Taken together, our results suggest that the response of neuroblastoma
cells to eribulin is mediated by a regulatory network that includes different
coding and non-coding RNA species. While these RNAs may have intrinsic
value as biomarkers or therapeutic agents, either individually or in combi-
nation, the vulnerabilities that they uncover may be exploited with pathway-
specifıc perturbations. This project was supported by NIH R01 CA129632
and CPRIT Training Grant RP140105.
#3507 PVT1 exons 4A, 4B, and 9 are overexpressed in aggressive prostate
cancer, and PVT1 exon 4Bmay distinguish between indolent and aggressive
prostate cancer. Akintunde T. Orunmuyi,1 Adeodat Ilboudo,2 Olabiyi G.
Ogun,3 Cuong Bach,2 S A. Adebayo,3 Ayo A. Salako,4 E Oluwabunmi Olapade-
Olaopa,1 Olorunseun O. Ogunwobi5. 1University of Ibadan, Ibadan, Nigeria;
2Hunter College CUNY, New York, NY; 3University of Ibadan and University
College Hospital (UCH), Ibadan, Nigeria; 4Obafemi Awolowo University Teach-
ing Hospital, Ile Ife, Nigeria; 5Hunter College CUNY andWeill Cornell Medicine,
New York, NY.
Aggressive prostate cancer (PCa) disproportionately affects males of African
ancestry (MoAA). However, the underlyingmolecular mechanisms are unclear.
Chromosome 8q24 is a PCa susceptibility locus that harbors the PVT1 non-
coding gene.We previously demonstrated that PVT1 exon 9may be involved in
aggressive PCa. Moreover, using the most recent full-genome variability panel
from the 1000 Genomes project, we recently identifıed a string of 75 SNPs in a
26-kb region spanning PVT1 exons 4A and 4B as consistently showing the
highest level of genetic differentiation between African and non-African popu-
lations. However, the expression of PVT1 exons 4A, 4B, and 9 in prostate tissues
ofMoAA has never been investigated. Our aimwas to determine the expression
of PVT1 exons 4A, 4B, and 9 in histologically confırmed normal prostate (n7),
benign prostate (n11) and malignant prostate tissue (n11) from prostatec-
tomy or transrectal ultrasound-guided biopsies in Nigeria, a sub-Saharan Black
African population. Nine patients had tumor tissues with Gleason score  8.
Tissues were collected in compliance with Institutional Ethics Board approved
protocols. RNA extraction, cDNA synthesis, and quantitative-PCR were per-
formed to analyze mRNA expression of PVT1 exons 4A, 4B, and 9. There was a
statistically signifıcant difference in the relative expression of PVT1 exons 4A
(F(2,82)9.031, p  0.000), 4B (F(2,82)5.294, p  0.007) and 9
(F(2,82)4.788, p  0.011) between groups as determined by one-way
ANOVA.Tukey posthoc test showed statistically signifıcant differences between
relative mean expression of PVT1 exons 4A, 4B and 9 in prostate tumor tissues
versus normal prostate tissues: PVT1 exon 4A (prostate tumor: 3.15	0.497, 95%
CI [2.13, 4.17]), (benign prostate: 1.74	0.163, 95%CI [1.41,2.07]), and (normal
prostate: 1.28	0.141, 95% CI [0.989, 1.57]); PVT1 exon 4B (prostate tumor:
2.217	0.360, 95% CI[1.47, 2.95]), (benign prostate: 1.17	0.176, 95% CI
[0.821,1.53]), and (normal prostate: 1.25	0.169, 95% CI [0.900, 1.60]); PVT1
exon 9 (prostate tumor: 1.71	0.190, 95% CI [1.32, 2.10]), (benign prostate:
1.26	0.148, 95% CI [.967,1.57]), and (normal prostate: 0.944	0.151, 95%
CI[0.630, 1.25]). Paired t-test showed a signifıcant difference in the expression
profıle for PVT1 exon 4B in prostate tumors with Gleason score 8
(2.98	0.539, 95% CI [1.90,4.06]) as compared to those with Gleason score7
(1.32	0.340, 95% CI [0.645,2.07]) with p0.009. These results show that over-
expression of PVT1 exons 4A, 4B and 9 is characteristic of PCa in MoAA.
Further, PVT1 exons 4B and 9 overexpression are specifıc for PCa, and PVT1
exon 4B may distinguish between indolent and aggressive PCa in MoAA.
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#3508 EWS-FLI1 represses Rho-actin signaling via MRTFB/YAP-1/
TEAD perturbation in Ewing Sarcoma. Anna M. Katschnig,1 Maximilian O.
Kauer,1 Raphaela Schwentner,1 Eleni M. Tomazou,1 Markus Linder,2 Cornelia
N. Mutz,1 Javier Alonso,3 Dave N. Aryee,1 Heinrich Kovar1. 1Children’s Cancer
Research Inst., Vienna, Austria; 2Institute of Cancer Research of the Medical
University Vienna, Vienna, Austria; 3Unidad de Tumores Solidos Infantiles, In-
stituto de Investigación de Enfermedades Raras, Madrid, Spain.
Ewing Sarcoma (EwS) is an aggressive pediatric bone tumor driven by the
aberrant fusion-oncogene EWS-FLI1, which deregulates hundreds of genes by
either activation (EWS-FLI1-correlated genes) or repression (EWS-FLI1-anti-
correlated genes). Several EWS-FLI1-anticorrelated genes are involved in cyto-
skeletal processes and typically regulated by Rho/F-actin signaling. The Rho
pathway is a crucial regulator of cell movement and cellular plasticity. Given the
fact that EwS cells are highly prone tometastasize wewere interested in studying
a potential EWS-FLI1-mediated deregulation of Rho signaling. Activation of
Rho triggers G- to F-actin polymerization thereby enabling nuclear transloca-
tion of the myocardin-related transcription factors MRTFA (MKL-1) and
MRTFB (MKL-2). MRTFs typically serve as transcriptional co-activators of the
transcription factor SRF regulating several cytoskeletal key players.We used the
A673/TR/shEF cell line, harboring a doxycycline inducible sh-EWS-FLI1 plas-
mid, to interrogate the role of MRTFA/B in the EwS gene regulatory network
upon EWS-FLI1-high and -low conditions. Strikingly, MRTFB transcriptional
activity was overall repressed by EWS-FLI1. Furthermore, knockdown of
MRTFB under EWS-FLI1-low conditions antagonized the re-activation of
EWS-FLI1-anticorrelated genes. ChIP-seq revealed a strong overlap of MRTFB
and EWS-FLI1 chromatin binding. MRTFB binding was signifıcantly enriched
in distal (enhancer) regions of EWS-FLI1-anticorrelated genes, especially upon
EWS-FLI1-low conditions. Of note, an overrepresentation of TEADmotifs, but
not SRF binding motifs, was observed in these regions suggesting a potential
involvement of TEAD transcription factors in the regulation of the MRTFB/
EWS-FLI1 reciprocally regulated targets. In linewith this fınding, target genes of
the mechano sensitive YAP/TAZ/TEAD pathway (CTGF, CYR61, SERPINE1)
were found among the MRTFB-bound EWS-FLI1-anticorrelated genes. Ge-
nome-wide expression profıling upon combined knockdown of EWS-FLI1 and
all four TEADs confırmed that TEAD regulates EWS-FLI1 target genes antago-
nistically. ChIP-qPCR for selected genes validated this fınding demonstrating
increased TEAD binding to shared MRTFB/EWS-FLI1 target genes upon de-
creased EWS-FLI1 occupation. Our data suggest that MRTFB/YAP-1/TEAD
directly regulate EWS-FLI1-anticorrelated targets. Since, in addition, EWS-FLI1
is known to indirectly perturb F-actin polymerization, we propose a model of
dual EWS-FLI1 driven MRTFB/YAP-1/TEAD perturbation by direct and indi-
rect mechanisms downstream of Rho/F-actin signaling.
#3509 EWS/FLI regulates transcriptional activation via length-dependent
GGAA microsatellites. Kirsten M. Johnson, Cenny Taslim, Stephen L. Less-
nick. Nationwide Children’s Hospital, Columbus, OH.
Objective: The purpose of this study is to investigate how EWS/FLI transcrip-
tionally activates gene targets via polymorphic GGAA microsatellites. Ewing
Sarcoma is a pediatric bone malignancy initiated by a t(11;22) chromosomal
translocation that produces the EWS/FLI oncoprotein. EWS/FLI transcription-
ally activates and represses its target genes to mediate oncogenic reprogram-
ming. Expression of its up-regulated targets correlates with EWS/FLI binding to
associated GGAA microsatellites, which show length polymorphisms. These
microsatellite polymorphisms may critically affect EWS/FLI-responsiveness of
key gene targets. For example, NR0B1 is necessary for EWS/FLI mediated on-
cogenic transformation, and we found a “sweet-spot” of 20-25 repeat length as
optimal for EWS/FLI mediated transcriptional activity at NR0B1 through clin-
ical observation and in vitro studies. The mechanism underlying this optimal
length is unknown.Methods:We explored the stoichiometry and binding affın-
ity of EWS/FLI for different repeat lengths through biochemical studies, includ-
ing fluorescence polarization, and immunoprecipitation assays, combined with
bioinformatics analysis. Additionally, use of EWS/FLI mutant constructs has
been critical for elucidating particular binding behavior of EWS/FLI at different
microsatellite repeat lengths. Results: Fluorescence anisotropy studies demon-
strate that FLI binding affınity is independent of GGAAmicrosatellite length. In
contrast, the stoichiometry of protein to DNA binding increases in specifıc in-
cremental patterns with increasing microsatellite repeats. EWS/FLI mutants in-
form on binding, suggesting a complex relationship between microsatellite
length and transcriptional activity. Conclusion: Overall our data suggests a
model inwhich theDNAbinding domain ofmultiple FLImonomers function as
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independent binding units to facilitate transcriptional activity in a length-de-
pendent manner. The EWS portion appears to be critical for in vivo binding of
genomic DNA globally. We propose that GGAA microsatellites are necessary
and suffıcient for EWS/FLI-mediated oncogenic transformation and that repeat
length affects optimal DNA binding stoichiometry and transcriptional activity.
#3510 A role for the Ewing’s sarcoma breakpoint protein EWS in ERG-
induced prostate tumorigenesis. Vivekananda Kedage, Nagarathinam Sel-
varaj, Taylor R. Nicholas, Justin A. Budka, Travis J. Jerde, Peter C. Hollenhorst.
Indiana University, Bloomington, IN.
The TMPRSS2-ERG gene fusion occurs in one-half of prostate tumors and
results in expression of ERG, an ETS family transcription factor that promotes
prostate tumorigenesis. Another 5-10% of prostate tumors have similar rear-
rangements that result in over-expression of other ETS family members such as
ETV1, ETV4, and ETV5. However, not all ETS family members are oncogenic,
and normal prostate cells express at least 15 of these other ETS factors. There-
fore, it is important to understandmechanisms that differentiate oncogenic ETS
factors fromnon-oncogenic ETS factors.We have recently discovered that ERG,
ETV1, ETV4, and ETV5, and no other ETS factor can directly bind the protein
EWS.This is striking, as EWS is fused to various ETS factors in the chromosomal
rearrangements that cause Ewing’s sarcoma. We demonstrate that fusion of
EWS to any ETS protein is suffıcient for that protein to function like ERG in
prostate cells. Furthermore, the EWS-ERG interaction is required for ERG to
activate an oncogenic gene expression program and for ERG-mediated tumor-
igenesis. Therefore, these fındings reveal a conserved oncogenic mechanism for
prostate cancer and Ewing’s sarcoma. In prostate cancer, aberrant over-expres-
sion of an ETS factor that naturally interacts with EWS, brings EWS to ETS-
bound regions. In Ewing’s sarcoma this interaction is forced by the presence of
an EWS/ETS fusion protein. Therefore, this model predicts that treatments that
target EWS function would be effective in both types of cancer.
#3512 Ikaros regulation of theBCL6/BACH2 axis and its clinical relevance
in acute lymphoblastic leukemia. Chunhua Song,1 Zheng Ge,2 Jianyong Li,3
BaoanChen,2 ElanoraDovat,1 KatarinaDovat,1 JonathonPayne,1 SinisaDovat1.
1Pennsylvania State University College of Medicine, Hershey, PA; 2Zhongda Hos-
pital, Medical School of Southeast University, Nanjing, China; 3The First Affıli-
ated Hospital of Nanjing Medical University, Nanjing, China.
B-Cell CLL/Lymphoma 6 (BCL6) is a proto-oncogene that is highly expressed
in acute lymphoblastic leukemia (ALL). BTB and CNC Homology 1 Basic Leu-
cine Zipper Transcription Factor 2 (BACH2) is a suppressor of transcription.
The BACH2-BCL6 balance controls selection at the pre-B cell receptor check-
point by regulating p53 expression. However, the underlying mechanism and
the clinical relevance of the BCL6/BACH2 axis are unknown. Here, we found
that Ikaros, a tumor suppressor encoded by IKZF1, directly binds to both the
BCL6 and BACH2 promoters where it suppresses BCL6 and promotes BACH2
expression in B-cell ALL (B-ALL) cells. Casein kinase 2 (CK2) inhibitors in-
crease Ikaros function thereby inhibiting BCL6 and promoting BACH2 expres-
sion in an Ikaros-dependentmanner.We also found that the expression of BCL6
is higher while BACH2 expression is lower in patients with B-ALL than normal
bonemarrow control. High BCL6 and low BACH2 expression is associated with
high leukemic cell proliferation, unfavorable clinical and laboratory features,
and inferior outcomes. Moreover, IKZF1 deletion is associated with high BCL6
and low BACH2 expression in B-ALL patients. CK2 inhibitors increase Ikaros
binding to the promoter of BCL6 and BACH2 and suppress BCL6 while pro-
moting BACH2 expression in the primary B-ALL cells. Our data indicates that
Ikaros regulates expression of the BCL6/BACH2 axis in B-ALL. High BCL6 and
low BACH2 expression are associated with Ikaros dysregulation and have a
potential effect on the development of B-ALL.
#3513 Decoding the role of myocyte enhancer factor 2C in chronic my-
eloid leukemia disease progression. Soumen Chakraborty. Institute of Life Sci-
ences, Bhubaneswar, India.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder of hema-
topoietic stem cell and is marked by the presence of the Philadelphia chromo-
some, a reciprocal translocation occurring between the long arm of chromo-
some 9 and 22 resulting in the formation of a fusion BCR-ABL1 oncogene
which encodes a constitutively active non-receptor tyrosine kinase. Clinically,
the disease progresses through three phases: an initial chronic phase, accelerated
phase and terminal blast phase, which is marked by increased production of
immature myeloid precursor cells. Earlier we have shown that BCR-ABL medi-
ated repression of miR-223 results in the activation of mef2C and ptbp2 in
chronic myeloid leukemia. Transcription factor MEF2C, required for cell sur-
vival and proliferation, is important for lymphopoiesis, and its ectopic expres-
sion inmyeloid progenitors antagonizesmyelopoiesis.We reported thatMEF2C
expression increases as the disease progresses from chronic phase to blast phase
and by knocking down MEF2C in a CML cell line we showed that it negatively
correlates with the CEBPA expression, a granulocytic transcription factor. Ima-
tinib, the drug of choice for CML, abrogates MEF2C expression and reverses
CEBPA repression both in the cell line and the primary cells. In the present study
we observed that when the cells were treated with anisomycin it degraded
MEF2C expression in 16hrs which imatinib can achieve after 24hrs. Investiga-
tors have demonstrated that anisomycin acts as a potent signaling agonist, syn-
ergizing with growth factors and phorbol esters to superinduce immediate-early
genes such as c-fos, fosB, c-jun, JunB, and JunD. However here blocking the
MAPKkinases with inhibitors didn’t reverse the inhibition suggesting that these
pathwaysmay not be involved in the anisomycinmediatedMEF2C degradation
in CML. Mef2c gene consists of three alternative exons, 1/2, skipping exon 
and 3=splice site γ. In order to characterize the role of mef2c gene in CML, fırst
we investigated the different isoforms of mef2c in CML cell line (KCL22) by
amplifıcation of the whole mef2c gene and cloning the same in a TOPO vector.
Several clones were checked and sequenced. Two different types of isoforms
(1 - γ and 1 - γ-) were found to coexist in KCL22 cells along with an
exclusion of 9 bases (AACACAGGT) from the splice junction of exon 4 and 5,
which was not reported earlier. However, K562 cells along with KYO-1 and
LAMA-84 showed the presence of 9 bases. Nine base pair deletion was also
observed inCMLpatient samples (bothCP andBC). Interestingly sequencing of
the mef2C genomic region from the cell lines and the same patient samples
showed the presence of 9 bases. The different isoforms were transduced in
mouse lineage negative bone marrow cells and also transplanted in mice either
alone or in combination with BCR-ABL to study the effect of the isoforms in
disease progression, the results of which will be discussed.
#3514 Assessing the role of CREB in fıbrolamellar hepatocellular carci-
nomawithPRKACA-DNAJB1 fusionprotein.AnjuKarki,1Michael J. LaQua-
glia,1 Amanda M. Dios,2 Ghazaleh Sadri-Vakili,2 Khashayar Vakili1. 1Boston
Childrens Hospital, Harvard Medical School, Boston, MA; 2Mass General Insti-
tute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard
Medical School, Boston, MA.
Introduction: Fibrolamellar Hepatocellular Carcinoma (FLHCC) is a rare
form of liver cancer that occurs predominantly in adolescents or young adults.
Curing or prolonging the lives of patients with FLHCC is extremely challenging.
Despite aggressive surgical resections of primary tumors as well as metastatic
lesions, outcomes tend to be poor due to lack of effective chemotherapy. Previ-
ous studies have demonstrated the presence of PRKACA-DNAJB1 fusion pro-
tein in the majority of FLHCC patients. DNAJB1 is a heat shock protein and
PKA is a kinase that phosphorylates numerous substrates including cAMP-
regulatory element-binding protein (CREB), a proto-oncogenic transcription
factor. Therefore, we sought to examine whether the presence of the fusion
protein in FLHCC is associated with increased CREB phosphorylation. Meth-
ods: We analyzed tumor and matched non-neoplastic liver tissue from 7 pedi-
atric patientswith a pathologic diagnosis of FLHCC.We assessed the presence of
the PRKACA-DNAJB1 fusion protein using PKA antibody, as well as total
CREB and phosphorylated (p-CREB) using immunoblot analyses with specifıc
antibodies. Results: Immunoblot analysis using anti-PKA antibody confırmed
the occurrence of PRKACA-DNAJB1 fusion transcripts in 6/7 (86%) FLHCC
tumor samples. Immunoblot analyses of the 6 patients with the fusion protein
revealed a trend towards a decrease in p-CREB expression in tumor samples
compared to non-neoplastic tissue controls (p0.15). Conclusions: The pattern
of p-CREB in FLHCC with PRKACA-DNAJB1 fusion protein suggests that the
fusion protein does not exert its proto-oncogenic effects through the transcrip-
tional activity of CREB.
#3515 LHX9 is a novel oncogene bypassing KRAS addiction. Seav Huong
Ly,1 Chao Dai,1 Andrew L. Hong,2 Nina Ilic,1 Elsa B. Krall,1 William C. Hahn1.
1Dana Farber Cancer Institute/Broad Institute of Harvard andMIT, Boston,MA;
2Boston Children’s Hospital/Dana Farber Cancer Institute/Broad Institute of
Harvard and MIT, Boston, MA.
Background:Oncogenicmutations of RAS are detected in approximately 30%
of human cancers. KRAS is highly mutated in pancreatic, colorectal and lung
cancers. Direct therapeutic targeting of Ras and its membrane association has
been challenging due to high affınity of GTP to Ras and unexpected mechanism
of alternative post-translational modifıcation. While few inhibitors of down-
stream RAS effectors - MAPK and PI3K pathways - show some clinical effıcacy,
they are complicated by complex feedback loops, and as single agents are not
effective inKRAS-mutant cancers. Combination therapiesmay be promising yet
limited by narrow therapeutic window. Identifıcation of alternative strategies to
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directly inhibiting RAS andMAPK/PI3K pathways is key to address this unmet
need. Methods: To this end, we performed a genome-scale open reading frames
screen to identify genes capable of restoring viability to KRAS-dependent cells
following KRAS suppression. We tested the top 5-standard-deviation hits in
low-throughputmanner.One of the top hits included LIMhomeobox 9 (LHX9),
a homeobox family transcription factor essential for mouse gonad, limb, and
brain development. While LHX9 is amplifıed in several cancers, little is known
regarding its roles in cancers. We used hypothesis-driven as well as unbiased
approaches including RNA-seq, ChIP-seq, and IP-mass spectrometry to inves-
tigate the basis of LHX9-mediated bypass of KRAS dependency. Results: We
showed that LHX9 rescued KRAS suppression in multiple cell lines as well as
xenograft. LHX9 overexpression substituted for KRAS in KRAS-driven xeno-
graft. Moreover, in activated-MEK-overexpressing HA1E cells, LHX9 formed
tumors as robustly as myristoylated AKT. LHX9 rescued KRAS suppression by
both restoring KRAS-dependent pathways and activating KRAS-independent
pathways. First, LHX9 reactivated the main KRAS effectors - MAPK and PI3K
pathways and conferred resistance toMEK inhibitor Trametinib. Second, using
ChIP- and RNA-seq, we observed LHX9 binding to promoters/enhancers of
genes whose expression was regulated by KRAS, particularly YAP1. Third,
LHX9 increased expression and activation of KRAS-independent genes, includ-
ing STAT3. Conclusions: Here, we identifıed LHX9 as a novel bypass of KRAS
addiction. Multiple unbiased approaches revealed at least three mechanisms by
which LHX9 rescued KRAS suppression. Our fındings contribute to our under-
standing of KRAS biology. Further investigation of downstream effectors of
LHX9 may highlight potentially novel therapeutic targets for KRAS-dependent
cancers.
#3516 RUNX1 controls EGFR signaling pathway in non-small cell lung
cancer cells. Akihiko Matsuo. Graduate School of Medicine, Kyoto University,
Kyoto, Japan.
Epidermal growth factor receptor (EGFR) is a promising target for anticancer
therapy for non-small lung cancer (NSCLC). Mitogen-inducible gene 6 (Mig6)
is known to be a negative feedback regulator of EGFR. Mig6 inhibits EGFR
kinase activity and promotewild-type EGFR traffıcking to the degradation path-
way. Down-regulation of Mig6 is found in poor prognostic NSCLC. Previous
gene array analysis results suggested thatMig6 is downregulated by runt-related
transcription factor 1 (RUNX1), yet the detailed relationship between RUNX1
and Mig6 in NSCLC has not been elucidated. Herein we demonstrate that
RUNX1 inhibition is effective for wild-type EGFR NSCLC. Tet-inducible
shRNAmediated RUNX1 knockdown in wild-type EGFR cell line LU99A led to
the increased expression of Mig6 and decreased expression of phosphorylated
form of EGFR as well as deactivation of EGFR/ERK pathway. RUNX1 knock-
down subsequently induced apoptosis in LU99A cells. Silencing of Mig6 in
LU99A cells promoted the proliferation of these cancer cells and increased ex-
pression of phosphorylated form of EGFR, highlighting the importance of this
EGFR signaling cascade in themaintenance of wild-type EGFRNSCLC. Indeed,
RUNX1overexpression promoted cell proliferation and decreased expression of
Mig6 and increased phosphorylated form of EGFR. Notably Mig6 knockdown
in RUNX1 knockdown LU99A cells increased their proliferation rates, indicat-
ing thatMig6 plays an important role in RUNX1-mediated pro-oncogenic path-
way.We next examined the effıcacy of a novel small molecule which specifıcally
binds and inhibits the RUNX1 (We named it as CM). CM was drastically effec-
tive for wild-type EGFR NSCLC cell lines A549 and LU99A which are naturally
resistant to EGFR Tyrosine kinase inhibitor: gefıtinib. In addition, CM sup-
pressed tumor growth of xeno-transplanted A549 cells in immune-defıcient
mice in vivo. Our study underscores the importance of RUNX1 inhibition ther-
apy in the management of gefıtinib-resistant NSCLC patients.
#3517 FOXC1 promotes pancreatic cancer cell proliferation andmetasta-
sis. Ramadevi Subramani,1 Fernando A. Camacho,1 Carly Levin,1 Joshua Me-
del,1 Sai Navana Kolli,2 Sushmita Bose Nandy,1 Diego A. Pedroza,1 Rajkumar
Lakshmanaswamy1. 1Texas Tech Univ. Health Sciences Ctr. El Paso, El Paso, TX;
2University of Texas, El Paso, El Paso, TX.
BACKGROUD: Pancreatic cancer is one of themost aggressive cancers due to
ineffective treatment options and its highmetastatic abilities. This highlights the
signifıcance for the development of effective modalities to treat this deadly dis-
ease. Dysregulation of IGF-1R signaling has been shown to be involved in the
invasive and metastatic potential of several cancer types. Currently, the mecha-
nism by which IGF-1R promotes pancreatic cancer is not well understood. Our
preliminary transcription factor profıling array indicated that FOXC1 was reg-
ulated by IGF-1R. Therefore, in the present study, we investigated the role of
FOXC1 in pancreatic carcinogenesis. METHODS: Western blot and qRT-PCR
analysis were done to measure the expression levels of FOXC1 in a panel of
pancreatic cancer cell lines along with normal pancreatic cells. IHC analysis of
the levels of FOXC1by tumor stage in humanpancreatic ductal adenocarcinoma
tissues and normal pancreas tissue was performed using tissue microarray. Im-
munofluorescence analysis was performed to compare the expression levels of
FOXC1 in normal and pancreatic cancer cells. To investigate the role of FOXC1
on pancreatic cancer cell growth and metastasis, we used an RNA interference
approach to silence FOXC1 in HPAC pancreatic cancer cells. MTS assay was
performed to study the cell viability. Metastatic capabilities of FOXC1 silenced
HPAC cells were examined using matrigel invasion, scratch assay, and soft agar
colony forming assays. To further confırm, Western blotting analysis was done
to evaluate the key intermediates involved in proliferation, epithelial mesenchy-
mal transition, and apoptosis. Exogenous expression of FOXC1 in MIAPaCa-2
cells was also used to understand the oncogenic role of FOXC1 in pancreatic
cancer. To further validate, xenograft studies with FOXC1 silenced HPAC cells
were performed. RESULTS: Expression of FOXC1 was upregulated in pancre-
atic cancer cell lines. Silencing FOXC1 in HPAC cells drastically decreased the
cell viability; however, it did not alter the viability of normal pancreatic cells.
Furthermore, it also signifıcantly reduced the invasive, migratory, and colony
forming abilities of pancreatic cancer cells. Targeting FOXC1 signifıcantly al-
tered the key signaling molecules involved in proliferation, EMT, and apoptosis
of HPAC cells. Exogenous overexpression of FOXC1 in MIAPaCa-2 cells also
validated the oncogenic role of FOXC1. HPAC xenograft models further dem-
onstrated the therapeutic role of FOXC1 in pancreatic cancer. CONCLUSION:
To conclude, our results suggest that silencing FOXC1 effectively targets pan-
creatic cancer cells suggesting that it could be a potential novel therapeutic
option.
#3518 Brg1 plays a critical role in PanIN formation through regulating
Sox9 expression. Motoyuki Tsuda,1 Akihisa Fukuda,1 Satoshi Ogawa,1 Kenji
Masuo,1 Norihiro Goto,1 Yukiko Hiramatsu,1 Yu Muta,1 Kozo Ikuta,1 Yoshito
Kimura,1 YoshihideMatsumoto,1 Yutaka Takada,1 Takuto Yoshioka,1 Takahisa
Maruno,1 Haruhiko Akiyama,2 Kyoichi Takaori,1 Shinji Uemoto,1 Tsutomu
Chiba,1 Hiroshi Seno1. 1Kyoto University, Kyoto, Japan; 2Gifu University, Gifu,
Japan.
Background: Mutations of SWI/SNF chromatin remodeling complexes are
one of the hallmarks of human pancreatic ductal adenocarcinoma (PDA).
Brahma related gene 1 (Brg1) is a catalytic ATPase subunit of SWI/SNF com-
plexes and Brg1 is silenced in about 10% of human PDA. Recent study revealed
that Brg1 inhibits formation of intraductal pancreatic mucinous neoplasm
(IPMN) and IPMN-derived PDA in the context of oncogenic Kras and that
IPMNs originate from adult pancreatic ductal cells, demonstrating a tumor sup-
pressive role of Brg1. However, the role of Brg1 in the formation of pancreatic
intraepithelial neoplasia (PanIN) from acinar cells and PanIN-derived PDA is
not fully understood. Aim: To investigate the functional role of Brg1 in the
formation of PanINMethods and Results:We generated Ptf1a-CreER; KrasG12D;
Brg1f/f (KBC) mice, in which Brg1 is deleted exclusively in adult pancreatic
acinar cells along with expression of oncogenic Kras upon tamoxifen induction
of Cre activity and assessed spontaneous acinar-to-ductal metaplasia (ADM)
and PanIN formation. We found that ADM and PanIN formation was signifı-
cantly decreased in KBC mice compared with littermate controls. Next, we in-
duced caerulein-acute pancreatitis to KBC mice and assessed for pancreatitis-
induced tumorigenesis. We found that PanINs were decreased in KBC mice
compared with littermate controls, although pancreatitis-induced ADMs were
widely observed in KBC mice. Since Brg1 is known to critical regulator of p53,
mutant p53 allele was crossedwithKBCmice. Unexpectedly, even in the context
of mutant p53, loss of Brg1 signifıcantly deceased PanIN formation. These re-
sults suggest that Brg1 plays a tumor-supportive role in acinar cell-derived Pa-
nIN formation in various contexts. Primary acinar cell culture experiments re-
vealed that ADM formation was markedly reduced in the absence of Brg1 and
that Sox9 expression was downregulated in Brg1-depleted acinar cells. Further-
more, we confırmed that Sox9 expression is downregulated in Brg1-depleted
ADMs/PanINs compared with Brg1-retained ADMs/PanINs by immunohisto-
chemistry. To determine the functional relationship between Brg1 and Sox9, we
generated Ptf1a-CreER; KrasG12D; Brg1f/f; Sox9OEmice, in which Sox9 is consti-
tutively overexpressed. Remarkably, Sox9 overexpression canceled the pheno-
type of decrease in PanIN formation by Brg1 deletion. Furthermore, to investi-
gate whether Brg1/Sox9 axis is observed in human PanIN-derived PDAs, we
performed immunohistochemistry of Brg1 and Sox9 in human PanIN-derived
PDAs. In 27 human PDAs, all of 5 PDAs with low Brg1 expression had low Sox9
expression. Conclusions: Our results suggest that Brg1 plays a critical role in
acinar cell-derived PanIN formation in part through regulating Sox9 expression
positively. Our data underscore a cell-type specifıc, context-dependent role of
Brg1 in the initiation of PDA formation.
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#3519 TGF- pathway alteration in pancreatic neuroendocrine tumors:
characterization of a novel SMAD3 translocation. Emanuela Brunetto,1 Greta
Grassini,1 Valeria De Pascali,1 Anna Talarico,1 Francesca Invernizzi,1 Michaela
Bowden,2 Massimo Loda,2 Luca Albarello,1 Massimo Falconi,1 Lorenza Pec-
ciarini,1 Maria G. Cangi,1 Claudio Doglioni1. 1San Raffaele Scientifıc Institute,
Milano, Italy; 2Dana-Farber Cancer Institute, MA.
Pancreatic neuroendocrine tumors (PanNETs) are the second most common
malignancy of the pancreas, and the only curative option is represented by surgery.
PanNETs can be classifıed as well- or poorly- differentiated, based on histology.
Poorly-differentiated neuroendocrine carcinomas (NECs) represent less than 10%
of cases, but they are highly malignant and associated with poor prognosis, and,
most importantly, the inconsistency in their clinical management is due to the in-
suffıcient data on NEC genetic features. In order to widen our knowledge of Pan-
NET genetic alterations, we performed RNASeq analysis (using Illumina NextSeq
platform) of a group of 18 PanNETs and 2 NECs. TopHat-Fusion algorithm iden-
tifıed, amongothers, a fusion involvingSMAD3transcription factor andCCDC149;
the alteration of SMAD3 in a poorly differentiatedNECwas particularly interesting
since SMAD3 is involved in TGF-b signaling, which has an oncogenic role in ma-
lignant cells. The SMAD3-CCDC149 fusion was confırmed in the index case by
RT-PCR using primers spanning the breakpoint, followed by Sanger sequencing.
The fusion was also detected by FISH analysis performed on both FFPE and frozen
samples. By both FISH analysis and Sanger sequencing we identifıed two other
poorly-differentiated NEC samples characterized by the presence of the SMAD3-
CCDC149 translocation. Immunohistochemical (IHC) staining revealed that the 3
tumors, positive for the SMAD3-CCDC149 fusion, were characterized by nuclear
localization of SMAD3. In order to test the hypothesis that the fusion generates an
active form of SMAD3 that localizes exclusively within the nucleus, we transfected
BON-1 cell line with plasmids containing either SMAD3 full length or SMAD3
truncated form (the latter mimics the fusion product) showing that only the trun-
cated form of SMAD3 had an exclusively nuclear localization. Interestingly, FISH
analysis performed on 3 well-differentiated PanNET samples did not detected the
presence of the SMAD3-CDC149 translocation and IHC analysis showed cytoplas-
mic localization of SMAD3. Moreover, IHC analysis performed on a cohort of 40
cases of non-pancreatic neuroendocrine tumors (NETs) revealed that only poor-
differentiated tumors showeda signifıcant percentageof sampleswithnuclear local-
ization of SMAD3. These data support the hypothesis that the translocation is a
typical phenomenon of poorly-differentiated tumors and suggests that it could be
involved also in non-pancreatic NETs. In this study we identifıed a previous un-
known SMAD3 translocation in poor-differentiated NECs, which generates an ac-
tiveSMAD3form.Deepening theknowledgeof the fusionproductwill shed lighton
PanNET genetic alterations, opening the way to new therapeutic strategies.
#3520 PBRM1 inactivation in renal cell cancer altersmaster transcription
factor hub composition to repress instead of activate epithelial-differentia-
tion. Xiaorong Gu, Francis Enane, Reda Mahfouz, Tomas Radivoyevitch, Bart-
lomiej Przychodzen, Yvonne Parker, Daniel Lindner, Brian Rini, Yogen Saun-
thararajah. Cleveland Clinic, Cleveland, OH.
Clear cell renal cell cancers (RCC) universally inactivate PBRM1 (single allele
deletion 100%, bi-allelic deletion/mutation 40%), however, the mechanisms
by which PBRM1 loss contributes to RCC-genesis are unknown. Of 4000
genes consistently less expressed in RCC than normal renal cortex,30% were
kidney differentiation genes by gene ontology analysis, e.g., 394 (10%) sup-
pressed genes had specialized renal epithelial functions of cation transport, cell
adhesion and excretion (TCGA). Suppression of hundreds of epithelial-differ-
entiation genes suggested disruption to the core transcription factor circuit
(protein network hub) activating this program. This master transcription factor
hub contains PAX2, PAX8, GATA3 and LHX1, shown by murine knock-outs
and human pedigrees with renal defects, and confırmed by our protein interac-
tome studies. Of these master transcription factors, PAX2 and PAX8 expression
was preserved in RCC compared to normal kidney, but downstream GATA3
and LHX1 expression was markedly decreased (2 to 4-fold) even though PAX8
localized at these target genes by chromatin immunoprecipitation - this sug-
gested compromised PAX8 transcription activating function. PAX8 protein in-
teractome in RCC cells indicated that PBRM1 is a PAX8 coactivator, and intro-
duction of PBRM1 into PBRM1-haploinsuffıcient RCC cells (ACHN) by
transfection increased activation of GATA3,WT1 andHNF4A, decreasedMYC
protein, increased p27/CDKN1B protein that mediates cell cycle exits by termi-
nal differentiation, produced morphological changes of epithelial differentia-
tion, and decreased proliferation. Coactivator versus corepressor recruitment by
master transcription factors is a dynamic interchange, and the protein interac-
tome studies indicated PBRM1 loss unbalanced stoichiometry of the PAX8-
associated protein hub towards corepressors including DNMT1. Depletion of
DNMT1 by non-cytotoxic concentrations of decitabine (0.5 M) produced a
remarkable shift from corepressors to coactivators in the PAX8 protein interac-
tome, accompanied by terminal epithelial-differentiation as observed with
PBRM1 reintroduction. Cell cycle exits by differentiation do not require p53/
p16, and this effect was also produced in vivo in a subcutaneous xenograftmodel
of TP53-mutated refractory/relapsed RCC, especially when decitabine in vivo
pharmacology was optimized for non-cytotoxic DNMT1-depletion by avoiding
a high Cmax and increasing its half-life and distribution into solid tissue, by
administration of low dose in combination with an inhibitor of the enzyme
cytidine deaminase that degrades decitabine. PBRM1 loss in RCC thus alters
composition of a master transcription factor hub to repress instead of activate
terminal epithelial-differentiation, an effect that can be reversed pharmacolog-
ically for novel, p53/p16-independent differentiation-restoring therapy.
#3521 Non-canonical activation of AR signaling by histone deacetylase
SIRT1. Shih-Bo Huang, Dinesh Thapa, Suleman S. Hussain, Roble G. Bedolla,
Guiming Li, Robert L. Reddick, Zhao Lai, Hung-I H. Chen, Yidong Chen, Rita
Ghosh, Addanki P. Kumar. University of Texas Health Science Center at San
Antonio, San Antonio, TX.
SIRT1, a nicotinamide adenine dinucleotide (NAD)-dependent deacetylase,
is a member of multigene family of Sirtuins. Traditionally SIRT1 is a known
player in enhancing longevity. SIRT1 can target both histone and non-histone
proteins to regulate diverse activities including cellular stress resistance,
genomic stability, energy metabolism and tumorigenesis. Disruption of SIRT1
in the prostate results in the formation of prostatic intraepithelial neoplasia
(PIN) lesions, suggesting a role for SIRT1 in the development of PIN, a precursor
lesion for prostate cancer (PCA). Paradoxically, an oncogenic role for SIRT1was
reported as evidenced by development ofmicro-invasive prostate carcinomas in
Pten/-/Sirt1tg mice. Therefore, SIRT1 may possess both oncogenic and tumor
suppressor activities in a context-dependent manner and its role in human can-
cer remains controversial. To address these paradoxical fındings, we examined
the role of SIRT1 in prostate pathogenesis using stably silenced for SIRT1 pros-
tate cancer cell lines. Silencing SIRT1 in androgen responsive LNCaP cells re-
sulted in (i) morphological changes indicative of clustering and epithelial mes-
enchymal transition (EMT); (ii) signifıcant reduction in their ability to form
colonies on soft agar; and (iii) increased autophagic flux. Similarly, silencing
SIRT1 resulted in reduced proliferative, colony forming andmigratory ability of
androgen independent PC-3 cells. Furthermore, notably, genes involved in nu-
clear receptor (PXR/RXR/FXR/PPAR) and kinase (AMPK, MSP-RON, and
RhoA) signaling are signifıcantly altered as evidenced by RNA-seq analysis in
these cells. Remarkably, SIRT1KD cells showed decreased expression of AR and
its target genes including PSA, TMPRSS-2, FKBP-5 and PMEPA1. Interestingly,
SIRT1KD reduced PSA-luciferase activity under both normal physiological and
androgen deprivation growth conditions with no signifıcant effect on nuclear or
cytosolic levels of AR. More importantly, SIRT1 KD cells showed increased
sensitivity to growth under androgen deprivation conditions. Intervention with
resveratrol (RES, known SIRT1 activator) reduced incidence of HGPIN in pros-
tate specifıc PTEN KO mouse model with no signifıcant differences in the ex-
pression of AR or SIRT1. Consistent with these in vivo observations, SIRT1 had
no signifıcant impact on RES-induced growth inhibition. Taken together, these
data indicate that SIRT1 could potentially contribute to androgen indepen-
dence, independent of classical AR signaling. Our study demonstrates that
SIRT1 may not play an essential role in mediating RES-induced tumor growth
inhibition and that SIRT1 may confer resistance to androgen deprivation ther-
apy and sustains cell survival, suggesting that combination of SIRT1 inhibitors
and ADTmight be a potential strategy for advanced PCA treatment. Supported
by CPRIT RP 150166 and NCI CA 137518 (APK).
#3522 Structural characterization of androgen receptor variant 7 in
prostate cancer. Fatma Özgün,1 Zeynep Kaya,1 Halil Bayraktar,2 Selen
Manioğlu,2 Doğancan Özturan,1 Nathan Lack1. 1Koç University School of
Medicine, Istanbul, Turkey; 2Koç University Department of Chemistry, Istan-
bul, Turkey.
Prostate cancer is an extremely common disease that affects one in every
sevenmen in their lifetime. The standard care for late-stage cancer is designed to
inhibit the activation of androgen receptor (AR). While this therapeutic ap-
proach is initially effıcient, the cancer almost always develops resistance and
gives rise to castration-resistant prostate cancer (CRPC).When therapy fails, the
median survival of patients who suffer from CRPC is 12-16 months. It is critical
to understand the mechanism of CRPC better to ameliorate the outcome of
late-stage prostate cancer patients. AR is a transcription factor that consists of an
N-terminal domain (NTD), aDNAbinding domain (DBD) and a ligandbinding
domain (LBD). Upon activation by androgen, an intramolecular interaction
between NTD and LBD occurs. The AR translocates into the nucleus where it
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forms a homodimer. It binds to the promoter and enhancer elements of the AR
target genes and triggers gene transcription. It has been demonstrated in many
clinical studies that AR is important for the progression of prostate cancer in-
cluding CRPC. In CRPC, although androgen production and binding is inhib-
ited, how the AR can still be activated is a fundamental question to be answered.
One of the several different mechanisms proposed is the alternative splicing of
the AR generating truncated AR variants that lack LBD. These variants do not
require androgens to be activated and they are intrinsically resistant to clinically
approved therapeutics. Despite the fact that the AR variants have been shown to
be critical in late-stage prostate cancer, the mechanism of gene transcription
initiation by the AR variants is not well-known. We propose to characterize the
mechanism of the AR variant activation. Since ARV7 is the most commonly
observed variant, we utilize ARV7. We develop a FRET based methodology to
identify how ARV7 dimers form and to test if full-length AR is necessary for
transcriptional activation mediated by ARV7. We are able to demonstrate pos-
sible intermolecular interaction between the full length AR and ARV7 measur-
ing the FRET intensity between the fluorophores attached to the N and C termi-
nus of two proteins. FRET measurements are analyzed by tracking single cells
and recording the FRET intensities during the process. Our preliminary data
suggest that the full-length AR and ARV7 may interact in the presence of an-
drogen. ARV7 is always localized in the nucleus whereas the AR requires andro-
gen to be activated and translocates into the nucleus. Being in close proximity,
putative interaction between the AR andARV7 occurs in the nucleus. Addition-
ally, we use NTD and DBD point mutants to determine critical positions of
intermolecular interaction between them. Supporting the signifıcance of ARV7
in prostate cancer, our results clarify the dimerization process. It gives an op-
portunity to test clinical drugs currently in development to effectively inhibit
ARV7 activation.
#3523 Arginyltransferase1 as a novel suppressor of prostate cancermetas-
tasis.Michael Birnbaum, Akhilesh Kumar, WilliamMorgan, Fangliang Zhang.
Univ. of Miami, Miami, FL.
Arginylation is a post-translational modifıcation wholly mediated by Argin-
yltransferase 1 (Ate1). Our studies have shown that Ate1 and arginylation are
upregulated during stress conditions. In addition, it was recently shown that
Ate1-defıcient fıbroblasts demonstrate cancer-like characteristics including
genomic instability and mutagenesis. While Ate1’s role in cancer is poorly un-
derstood, our preliminary studies suggest that Ate1 is an important regulator of
metastasis and cancer progression in prostate cancer models. In this study, our
data suggests that Ate1 is essential for normal cell stress response in conditions
including cellular oxidant, apoptosis inducing drugs, and radiation. Further, we
show that a loss of Ate1 in LnCaP prostate cancer cells increases anchorage-
independent growth in the soft-agar assay, and that a loss of Ate1 in PC-3 pros-
tate cancer cells increases matrigel invasion in the Boyden chamber assay. To
text how Ate1 affects metastasis in vivo, PC-3 cells with Ate1 or control shRNA
were orthotopically implanted into the prostates of immunocompromisedmice
to observe metastasis. While very little metastasis was observed in PC-3 control
cells, PC-3 cells with reduced Ate1 achievedmuch higher levels of metastasis. In
conclusion, our data suggests that the loss of Ate1 in prostate cancer promotes
cancer progression phenotypes and cell survival. In future studies, we will ex-
amine if Ate1 levels in human prostate cancers in prostate cancer prognosis.
#3524 HOXB13 collaborates with AR to alter the cellular phenotype of
prostate epithelial cells through cytokeratin 14 upregulation. Dorhyun
Johng, Charles M. Ewing, William B. Isaacs. Johns Hopkins University, Balti-
more, MD.
Prostate cancer (PCa) is a commonly diagnosed disease with one of the high-
est heritability estimates among cancers. Among germline variations that ac-
count for PCa heritability, a recurrent mutation (G84E) in HOXB13 is associ-
ated with a 3 to 6 fold increase in PCa risk. HOXB13 is a prostate-specifıc
transcription factor that plays a role in prostate development. Other mutations
in HOXB13 in PCa patients have further implicated HOXB13 in PCa biology.
The goal of this study is to generate HOXB13 cell linemodels of normal prostate
to examine the role of HOXB13 in driving cellular differentiation and/or trans-
formation. To this end, we utilized 957E/hTERT, a cell line derived from a
radical prostatectomy specimen, as a model for normal prostate epithelial cells.
HOXB13 WT or G84E was stably expressed in 957E/hTERT with a lentivirus
system in the presence and absence of exogenous AR. HOXB13 caused a mor-
phology changewhereby an epithelialmorphology transitioned to a fıbroblastic-
like structure. Cells adopted elongated bodies with a frequent appearance of
lamellipodia. The morphologic conversion was transient in AR- cells but was
maintained in AR cells. Analyses of epithelial cell markers using qPCR re-
vealed a change in the epithelial cell marker profıle (AR-: no change p63,
CD49f2, K52, K141, K182; AR: no change p63, CD49f, K5, K141,
K182). K14 upregulationwas striking with a10 fold increase. AR alone could
upregulate K14 to a level comparable to HOXB13-induced K14 in AR- cells,
which was surprising since AR mainly functions in luminal cells where K14
expression is turned off. Coexpression of HOXB13 and AR had a synergistic
effect in K14 upregulation. Despite the morphology change suggestive of EMT,
vimentinwas downregulated byHOXB13 inAR- andAR cells. In vitro growth
assays showed that HOXB13 reduced the proliferation rate of AR cells but not
AR- cells. Gap closure assays revealed that HOXB13 does not induce a qualita-
tive change in migration. Similar results were obtained with G84E models. Our
study demonstrates that HOXB13 may have a potential function in dictating a
cell fate in the epithelial lineage as evidenced by a change in the epithelial cell
marker profıle. Conclusively, HOXB13 andAR can drive K14 by themselves and
in collaboration. This fınding is exciting in light of the recent discovery (Cheung
KJ et al. 2016) that K14 is not merely a basal cell marker but a major mediator of
collective invasion in breast cancer. During breast development, K14 is ex-
pressed in the cap cells at the growing tips of mammary ducts invading into the
fat pad. K14 driven by HOXB13 in collaboration with ARmay regulate prostate
epithelial budding into the surroundingmesenchyme during development. Hy-
pothetical dysregulation of this embryonic programming byHOXB13mutation
could predispose a carrier to PCa. This study warrants the need for HOXB13
mouse models to test these fundamental questions.
#3525 PDEF promote prostate cancer luminal/epithelial differentiation
and inhibit tumor progression. FengtianWang,1 Sweaty Koul,1 Prakash Srini-
vasan Timiri Shanmugam,1 Qin Dong,1 Hari K. Koul2. 1Louisiana State Univer-
sity Health Sciences Center-Shreveport, Overton Brooks VA Medical Center,
Shreveport, LA; 2Louisiana State University Health Sciences Center-Shreveport,
Overton Brooks VAMedical Center, FeistWeiller Cancer Center, Shreveport, LA.
Conventional therapies produce a high rate of cure for patients with localized
prostate cancer (PCa), but there is no effective treatment for castration resistant
metastatic PCa. Transcription factors by association with enhancer and super-
enhancer elements are key drivers of cell identity. Our previous studies have
shown that Sam Pointed Domain Ets Transcription Factor a.k.a. Prostate De-
rived Ets Factor (SPDEF/PDEF), inhibits cell migration, invasion and clono-
genic activity in PCa cells and there is a graded loss of PDEF with increasing
Gleason Score in PCa patient samples. PDEF has been reported to be one of the
cell identity transcription factors in LNCaP cells. We proposed that PDEF func-
tions as a putative tumor metastasis suppressor. Others have shown an increase
in Twist1, a bHLH transcription factor, was positively correlated with Gleason
Grading. Present study was designed to investigate the role of PDEF and inter-
play between PDEF and Twist1 in PCa. PC3 cells were stably transfected with
PDEF/control PABABE vectors. Gene expression changes were monitored by
Affymetrix microarray. Microarray was analyzed with GSEA. qRT-PCR was
performed to confırm gene expression and IHC, IF and IB analysis were per-
formed to visualize protein expression. Chip-seq data (SRP002475) was aligned
with Bowtie. Peaks were identifıed by MACS and visualized using IGB. PDEF/
Twist1 expression data was extracted from GSE16560. GraphPad was used to
generate KM survival analysis of PCa patients. Our results show that PDEF
expression is limited to epithelial/luminal cells of the prostatic glands. We ob-
served that expression of Twist1 was down regulated in PC3 cells following
PDEF expression. Analysis of gene expression data from ourmicroarray studies
revealed that PDEF re-expression was associated with negative enrichment of
gene sets involvedwith cellmigration andpositive enriched of gene sets involved
with epithelial/luminal differentiation. Chip-seq analysis revealed a binding of
PDEF to KRT8/18 promoter region. These data suggest that PDEF inhibits core
metastasis related genes through promoting a program of luminal/epithelial
differentiation. In clinical samples of PCa, expression of PDEF was inversely
associated, while expression of Twist1 was positively associated with Gleason
grade. PDEF and Twist1 was able to predict patient survival, moreover inte-
grated PDEF and Twist1 expression was able to better predict PCa patient sur-
vival as compared to PDEF or Twist1 alone. PDEF inhibits cell migration and
metastasis in part by down-regulating Twist1 level and promoting luminal/
epithelial differentiation. Loss of PDEF combined with gain of Twist1 expres-
sionmay serve as a potential biomarker set for distinguishing lethal PCa from an
indolent disease. Additional studies are underway to gain further insights into
the role of PDEF in PCa progression andmetastasis. Acknowledgement: FWCC
support and Chair commitment funds (Koul H).
#3526 The expression of MELK, a growth regulator of triple-negative
breast cancer, is regulated by p53. Lakshmi Reddy Bollu, Powel H. Brown,
Abhijit Mazumdar, Dekuang Zhao, Yanxia Ma. MD Anderson Cancer Center,
Houston, TX.
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Background: Triple negative breast cancer (TNBC) is the most aggressive
form of breast cancer with poor prognosis. Due to frequent distant metastasis
and lack of successful targeted therapies, the overall survival rate in TNBC pa-
tients is signifıcantly lower than estrogen receptor positive (ER) and HER2 pos-
itive breast cancers. To identify potential druggable targets, previously, we per-
formed a gene expression analysis and identifıed protein kinases that are highly
expressed in TNBC. Through these studies, we discovered that the expression of
maternal embryonic leucine zipper kinase (MELK) is highly elevated in TNBCs
and correlatedwith p53-mutation status andmetastasis-free survival. Inhibition
ofMELK reduced the growth and invasiveness of p53mutant breast cancer cells.
Methods: In this study, we analyzed the association of MELK expression with
p53 status using publicly available datasets, and examined the role of wild-type
and mutant P53 in regulating MELK expression. MELK expression at mRNA
and protein levels were determined through Q-RT-PCR and western blotting
analysis respectively. The association of p53 and MELK expression was deter-
mined using Oncomine analysis. We also investigated the effect of p53 knock-
down and overexpression onMELK expressing using Q-RT-PCR, western blot-
ting and promoter luciferase assays. Results: Analysis of publicly available
datasets revealed that MELK expression is highly elevated p53-mutant breast
cancer independent of estrogen receptor status. Consistent with observation,
high MELK expression was found in p53-mutant cells compared to p53 wild-
type cells. Through luciferase, western blotting and Q-RT-PCR assays, we dis-
covered that the increased expression of MELK in TNBC cells is due to inacti-
vation of p53 wild-type function. Consistently, over expression of p53 wild-type
in p53-Null cells, using doxycycline inducible system reduced MELK promoter
activity and expression. Similarly, inhibition of p53wild-type by over expression
of p53-mutants in p53-wild-type cells also increasedMELK expression through
dominant-negative effect. In contrast, knockdown of p53-mutants or over ex-
pression of p53-mutants in p53-null cells did not alter MELK expression. Fi-
nally, through promoter deletion studies coupled with luciferase studies, we
identifıed a potential p53-response region inMELK promoter. Conclusion: Our
results suggest that the expression of MELK, a critical regulator of growth and
invasion of TNBCs, is regulated by the tumor suppressor gene, p53 wild-type.
Inactivation of p53 wild-type either gene deletion or mutations induces the
expression of MELK. These results suggest that MELK is a promising target for
the treatment of women with p53-mutant TNBC. This work was supported by
Susan G Komen Promise Grant (PB, SH, GM), SAB Komen grant (PB) and
Young Foundation grant (PB).
#3527 Clarifıcation of the molecular mechanism for cancer development
in Xp11.2 translocation renal cell carcinoma. Masaya Baba,1 Ying Huang,2
Takanobu Motoshima,1 Hisashi Hasumi,3 Yukiko Hasumi,2 Mitsuko Furuya,3
Yoji Nagashima,4 Masahiro Yao,3 Yuichi Oike,1 Tomomi Kamba,1 Laura S.
Schmidt,5 W. Marston Linehan2. 1Kumamoto University, Kumamoto, Japan;
2National Cancer Institute, National Institutes of Health, Bethesda, MD; 3Yoko-
hama City University, Yokohama, Japan; 4Tokyo Women’s Medical University,
Tokyo, Japan; 5Leidos Biomedical Research, Inc., Frederick National Lab, Fred-
erick, MD.
Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a newly defıned
subset of RCC, which have chromosomal translocations involving the TFE3
transcription factor atXp11.2.All translocations seen inXp11.2 tRCC, including
PRCC-TFE3, PSF-TFE3, ASPL-TFE3, CTLC-TFE3 and NONO-TFE3 produce
chimeric TFE3 genes, which encode fusion TFE3 proteins retaining the basic
helix-loop-helix leucine zipper (bHLH-Zip) structure for DNA binding, sug-
gesting that these fusion TFE3 proteins function as oncogenic transcription
factors. To clarify the molecular mechanism for Xp11.2 tRCC development, we
have established cell lines, which express fusion TFE3 proteins (NONO-TFE3,
PRCC-TFE3, PSF-TFE3) in a doxycycline dependent manner. Genes upregu-
lated universally in all fusion TFE3 cell lines upon doxycycline addition were
identifıed. In addition, we have generated an Xp11.2 translocation RCC mouse
model, in which a floxedNeomycin cassette followed by a PRCC-TFE3 cDNA is
inserted in the Rosa26 locus. By crossing thesemice with cadherin 16-Cre trans-
genic mice, we can induce kidney specifıc PRCC-TFE3 expression resulting in
RCC development. We will report and discuss the role of fusion TFE3 target
genes in our mouse model and in clinical samples of Xp11.2 tRCC. Funded in
part by FNLCR Contract HHSN261200800001E to LSS.
#3528 PTCH53 as a potential secondary modifıer in Li-Fraumeni syn-
drome. Anna J. Pan,1 Benjamin Brew,2 Lauren Erdman,1 Anna Goldenberg,2
David Malkin2. 1The University of Toronto, Toronto, Ontario, Canada; 2The
Hospital for Sick Children, Toronto, Ontario, Canada.
Germlinemutations in the TP53 gene have been established as the underlying
genetic event in Li-Fraumeni syndrome (LFS), predisposing affected families to
a wide spectrum of early onset cancers. Despite rapid progress in elucidating the
role of wild-type p53 in maintenance of genome stability, and mutant p53 in
cellular transformation, much of the molecular basis underlying LFS remains
unclear. Lack of predictability in age of onset, type(s) of cancers, and likelihood
of subsequent malignancies prompts further research to examine secondary
modifıers on the underlying TP53 genotype. Patched-domain containing 4
(a.k.a PTCHD4 or PTCH53) is a repressor of canonical Hedgehog signaling that
is also described to be transcriptionally activated by p53. Furthermore, our
group has identifıed signifıcant hypomethylation at the PTCH53 locus in a mu-
tant TP53 LFS cohort, compared toTP53wildtype carriers. These results suggest
a potential role of PTCH53 in modifying LFS phenotype. The study examines
the expression profıle of PTCH53 in the presence of different germline TP53
mutations using primary LFS patient-derived fıbroblasts, and aims to elucidate
the functional role of PTCH53. PTCH53 transcriptional expressionwas assessed
using digital droplet PCR in 10 LFS non-transformed fıbroblast cell lines repre-
senting a spectrum of heterozygous germline TP53 mutations. Our data dem-
onstrate that PTCH53 expression indeed depends on TP53 genotype where
different TP53mutations correspondwith varied PTCH53mRNA levels. None-
theless, mutant TP53 fıbroblasts have overall lower PTCH53 transcripts com-
pared to wild-type TP53 fıbroblasts. Fold-change increase in PTCH53 expres-
sion was detected upon doxorubicin and -irradiation induced activation of the
p53 protein. These results suggest that induction of p53 via DNA damage acti-
vates a signaling cascade involving PTCH53up-regulation. Further experiments
will examine the functional consequences to PTCH53 de-regulation via shRNA
knockdown and CRISPR knockout models, and will examine possible modify-
ing effects of PTCH53 on the functional phenotype (cell viability, colony forma-
tion and migration potentials) of cell lines harboring different p53 mutants.
Elucidating the functional profıle of PTCH53 in the context of Li-Fraumeni
syndrome will contribute to understanding the complex molecular basis under-
lying this cancer predisposition syndrome.
#3529 Investigating the in vivo role of the EHF transcription factor in
intestinal epithelial differentiation. Camilla M. Reehorst, Ian Y. Luk, Rebecca
Nightingale, Mercedes Davalos-Salas, Amardeep S. Dhillon, John M. Mariada-
son. Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.
Objective: Poor tumor differentiation status is associated with worse patient
outcome in colorectal cancer. However, the molecular basis for loss of differen-
tiation in colon cancer is not well understood.We have found that the transcrip-
tion factor Ets homologous factor (EHF) is highly expressed in the normal hu-
man and mouse colonic epithelium and is down-regulated in poorly-
differentiated colorectal cancer cell lines. The aimof this studywas to investigate
the role of EHF in regulating normal colonic epithelial cell differentiation in
vivo. Methods: A novel mouse model was generated in which the Ets DNA
binding domain (exon 8) of EHF was flanked by loxP sites (EHFlox/lox). To
inactive EHF in the intestinal epithelium, EHFlox/loxmice were crossed toVillin-
CreERT2mice and recombination induced by tamoxifen treatment. Tamoxifen
and vehicle treated mice were monitored weekly for up to one year. At each
endpoint, tissue was collected and the effect of EHF deletion on intestinal cell
proliferation and differentiation assessed by qRT-PCR and immunohistochem-
istry. Results: Targeted inactivation of EHF in the small intestinal and colonic
epithelium following tamoxifen treatment was confırmed at the DNA and RNA
level. EHF inactivation in the intestinal epithelium had minimal effect on sur-
vival, weight gain and overall health of the animals. Furthermore, loss of EHF
did not markedly affect cell proliferation or the overall architecture of the intes-
tinal epithelium. Finally, EHF inactivation also hadminimal effect onmarkers of
absorptive, enteroendocrine or Paneth cell differentiation but did reduce the
number of goblet cells in the colonic epithelium. Conclusion: EHF does not play
a major role in regulating cell proliferation in the mouse intestine but may play
a role in regulating goblet cell differentiation. The role of EHF in intestinal
tumourigenesis and response to stress are currently being investigated.
#3530 KITENINworks as a fıne regulator of ErbB4 expression in colorec-
tal cancer tissues in addition to E3-ubiquitin ligase Nrdp1. Jeong A Bae,1 Eun
Gene Sun,1 Yoo-Seung Ko,1 Hui Jeong Choi,1 Chaeyong Jung,1 Kyung-Hwa
Lee,2 Ik Joo Chung,3 Kyung-Sub Moon,4 Young Hyun Yu,5 Hyung-Ho Ha,5
Hangun Kim,5 Kyung Keun Kim1. 1Chonnam Natl. Univ. Medical School, Med-
ical Research Center for Gene Regulation, Kwangju, Republic of Korea; 2Chon-
namNatl. Univ. Medical School, Dept of Pathology, Kwangju, Republic of Korea;
3ChonnamNatl. Univ. Medical School, Dept of Hematology-Oncology, Kwangju,
Republic of Korea; 4Chonnam Natl. Univ. Medical School, Dept of Neurosurgery,
Kwangju, Republic of Korea; 5SunchonNational University, College of Pharmacy,
Sunchon, Republic of Korea.
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Purpose: Understanding the complex biological functions of E3-ubiquitin
ligases may facilitate the modulation of E3-ubiquitin ligases as a promising ap-
proach for the development of novel anticancer drugs. We recently identifıed
that the KITENIN/ErbB4-Dvl2-c-Jun axis works as a novel unconventional
downstream signal of epidermal growth factor in colorectal cancer (CRC) tis-
sues and that the immunohistochemical expression of KITENIN/ErbB4 was
highly expressed in tumor tissues from advanced CRC stage. However, the de-
tailedmechanisms that explain the higher levels of ErbB4 in colon cancer tissues
are largely unknown. Here we investigated whether E3-ubiquitin ligases partic-
ipate in the operation of the KITENIN/ErbB4-Dvl2-c-Jun axis and in the main-
tenance of elevated KITENIN/ErbB4 complex in CRC. Results & Discussion:
We found that Nrdp1, an E3-ligase for ErbB3/ErbB4, interacted with KITENIN
(KAI1 C-terminal interacting tetraspanin) to form a functional KITENIN/
ErbB4/Nrdp1 complex and is responsible for down-regulating Dvl2 within this
complex. Interestingly, ErbB4 was resistant to degradation by Nrdp1 in
KITENIN/Nrdp1-co-transfected CRC cells, and KITENIN bound to the C-ter-
minal coiled-coil domain of Nrdp1. Chemical blockade of ErbB kinase did not
block the action of EGF to increase in total/phospho-ErbB4 and phospho-ERK
in KITENIN/ErbB4-cotransfected cells, whereas it blocked the action of EGF in
ErbB4 alone-transfectedCRCcells. In humanCRC tissues, higher expressions of
ErbB4 and KITENIN and lower expression of Dvl2 was observed in stage IV
samples than in stage I, but a low level ofNrdp1was expressed in both stages and
it did not differ signifıcantly by stage. These results indicated that Nrdp1 is
necessary for the reduction in Dvl2 to generate c-Jun in the EGF-KITENIN/
ErbB4-c-Jun axis, butmore importantly, elevatedKITENINprotects KITENIN-
bound ErbB4 from Nrdp1-mediated degradation via physical collaboration be-
tween theKITENIN/ErbB4 complex andNrdp1, but not viamodulation of ErbB
kinase activity. Thus, KITENIN functions in the maintenance of a higher ex-
pression level of ErbB4 in advanced CRC tissues, independent of ubiquitin-
mediated degradation via Nrdp1. Conclusion: Our present fındings add a new
component to our understanding of the molecular events underlying the regu-
lation of ErbB4 expression level in CRC tissues: KITENIN is also a fıne regulator
of ErbB4 expression in addition to E3-ubiquitin ligase Nrdp1.
#3531 YAP1-mediated circadian oscillation in sarcoma. Gloria Marino,
Shuai Ye, Koreana Pak, Jennifer Shah, Jason Godfrey, Susan Chor, Shaun Egolf,
T.S. Karin Eisinger-Mathason. Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA.
Soft tissue sarcomas have presented a unique challenge to researchers due to
their heterogeneity. One common mechanism underlying more than 25% of
diagnosed sarcomas is the deregulation of the Hippo pathway, a critical signal-
ing cascade that responds to cell contact inhibition, among other factors, and
negatively regulates cell proliferation. In quiescent cells the pathway remains
“on,” which maintains activation of a kinase cascade that phosphorylates and
degrades YAP1. However, inactivation of the pathway stabilizes YAP1 allowing
it to translocate to the nucleus and activate transcription of pro-proliferative
gene targets. Microarray analysis of muscle tissue from the LSL-KrasG12D/;
Trp53fl/fl (KP) mouse model of undifferentiated pleomorphic sarcoma (UPS)
revealed that YAP1 deletion (KPY) reduces cell proliferation and increases ex-
pression of circadian rhythm genes including PER1. UPS is a commonly diag-
nosed and aggressive type of muscle-derived sarcoma. The KP model recapitu-
lates human UPS morphologically and histologically, as well as by gene
expression profıling. Although PER1 has primarily been characterized as a neg-
ative regulator of the circadian clock, upregulation of PER1 is known to modu-
late the G2/M cell cycle checkpoint at both the protein and mRNA level inde-
pendent of p53. However, our fındings represent a novel link between the
circadian clock and the hippo pathway. Notably, deletion of YAP1 in KP tumors
leads to a statistically signifıcant 2.5 fold increase in expression of PER1. The
study has two specifıc aims: 1) to identify the YAP1-dependent function of PER1
in sarcoma and 2) determine whether YAP1 directly or indirectly regulates
PER1.We have validated themicroarray results in KP tumor derived cell lines as
well as in KP and KPY tumor tissue. I have also confırmed PER1 suppression in
KP cells under YAP1 short hairpin RNA conditions. Our lab has previously
observed that treatment with epigeneticmodulating drugs JQ1, a BET inhibitor,
and SAHA, an HDAC inhibitor, signifıcantly decreased sarcoma growth in vivo
and in vitro when administered alone and had an additive effect when com-
bined. These effects can be explained in part by the fınding that treatment with
these inhibitors signifıcantly reduces YAP1 expression. Under these conditions,
as well as YAP1 knockdown conditions, I demonstrated via qRT-PCR andwest-
ern blot that PER1 is signifıcantly increased at both the protein and transcrip-
tional levels in KP cells. Additionally, preliminary evidence from an MTT pro-
liferation assay showed loss of PER1 increased sarcoma cell proliferation.
Further supporting the hypothesis that PER1modulation impacts sarcoma pro-
liferation, it has been reported that MyoD, the master regulator of muscle cell
differentiation, is itself a clock-controlled gene. Together, these results suggest
that YAP1 represses PER1 expression in sarcoma, and that epigenetic treatments
can cause re-expression of PER1which functions to inhibit cell proliferation and
may promote differentiation.
#3532 No REST in Merkel cell carcinoma. Emil Chteinberg,1 Christopher
Sauer,1 Lisa D. Schiffelers,1 Jonathan P. Eben,1 Dorit Rennspiess,1 Christopher
B. Buck,2Veronique J.Winnepenninckx,1AnnaK.Kurz,3 Ernst J. Speel,1Martin
Zenke,4 Axel zur Hausen1. 1Maastricht University Medical Center, Maastricht,
Netherlands; 2National Cancer Institute, Bethesda, MD; 3University Hospital
Aachen, Aachen, Germany; 4University Hospital RWTH Aachen, Aachen, Ger-
many.
Introduction:Merkel cell carcinoma (MCC) is a highly aggressive skin cancer
of the elderly and immunosuppressed patients. More than 80% of MCCs are
associated with the recently identifıed Merkel cell polyomavirus (MCPyV).
MCCs reveal a trilinear differentiation characterized by neuroendocrine (chro-
mograninA and synapthophysin), epithelial (e.g. CK20) and pro/pre B-cell lym-
phocytic (e.g. Pax5 and TdT) marker expression. The cellular origin of MCCs
still remains obscure. Based on the combined expression of TdT, Pax5 and
immunoglobulins (Ig), including clonal Ig rearrangements we have recently
hypothesized that pre/pro B-cells might constitute the cellular origin of MCC.
We aimed to understand the neuroendocrine expression of chromogranin A
and synapthophysin which is known to be negatively regulated by the Re-1
silencing transcription factor (REST) in MCC cells. We assessed REST expres-
sion in MCPyV-positive and -negative MCCs and MCC cell lines in order to
gain insights into the regulation of neuroendocrine differentiation inMCC cells.
Methods: The expression of REST in MCC was tested by immunohistochemis-
try (IHC) in 22 formalin fıxed and paraffın embedded MCC tissues. In addid-
tion,MCPyV-positive (MKL-1 andMKL-2) andMCPyV-negative (MCC13 and
MCC26) MCC cell lines and the B-ALL cell-line REH as positive control were
tested for REST expression. RT-PCR was used to confırm the results of the cell
lines on the transcriptional level. In addition, the regulation of the REST expres-
sion by methylation was investigated with the demethylating agent 5-aza-2=-
deoxycytidin. Further the methylation status of the 3 CpG islands of the REST
promoter was analysed with a methyl specifıc PCR. Results: All MCCs except
one were completely devoid of REST expression as tested by IHC. All MCCs
were negative for REST but synaptophysin and chromogranin A positive. The
MCPyV-positive cell lines MKL-1 andMKL-2 did not express REST but indeed
expressed both neuroendocrine markers. The MCPyV-negative cell lines
MCC13, MCC26 and the B-ALL cell line were positive for REST expression and
negative for these neuroendocrine markers. On RNA level these results were
confırmed. The demethylation of the CpG islands of the REST promoter did not
lead to an increase of the REST expression in MKL-1 and MKL-2 on the tran-
scriptional or translational level. Initial MSP results did not reveal any methyl-
ation of the 3 CpG islands of the REST promoter. Conclusion: The lack of REST
expression inMCCand inMCPyV-positiveMCCcell lines, in combinationwith
REST expression inMCPyV-negative cell lines point to an important role of the
MCPyV in the regulation of REST expression inMCC.This is emphasized by the
results of 5-aza-2=-deoxycytidin treatment of theMCC cell lines. Our datamight
provide the basis of neuroendocrine gene expression in MCC which possibly
originates from early B cell.
#3533 Connections between NF-B misregulation and carcinogenesis.
Donian I. Chyong,1 Aurian Naderi,1 Chase Lee,1 Ty Arpornsuksant,1 Allison
Lu,1 Megha Dilip,1 Margaret Zhang,1 Young-Joon Surh,2 Eun-Ji Lee,2 Hye-
Kyung Na3. 1George Walton Comprehensive High School, Marietta, GA; 2Seoul
National University, Seoul, Republic of Korea; 3Sungshin Women’s University,
Seoul, Republic of Korea.
In this review poster, we researched the function, regulation, and structure of
NF-B as it relates to carcinogenesis. Found in almost all animal cells, nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-B) is a transcription
factor that plays various roles in cellular proliferation, cell survival, inflamma-
tion, and T cell activation. There are two different NF-B signaling pathways:
the canonical pathway and the non-canonical pathway. NF-B forms a p50/Rel
A heterodimer in the canonical pathway and a p52/ Rel B heterodimer in the
non-canonical pathway. NF-B protein is normally sequestered in the cyto-
plasm as an inactive complex with a B inhibitor (IB) protein. Outside stimuli
such as reactive oxygen species (ROS) and tumor necrosis factor alpha (TNF-)
activate cell surface receptors such as Toll-Like Receptors (TLRs) and Receptor
Activators of NF-B (RANK). These surface receptors, in turn, activate IB
kinase (IKK). IKK phosphorylates IB, which causes ubiquitination of IB, sig-
naling proteasomes to degrade it. NF-B then enters the nucleus through a
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nuclear pore and forms a transcription complex with coactivators and RNA
polymerase. NF-B binds to specifıc DNA-binding sites to induce transcription.
One of the target genes of NF-B encodes IBs, so NF-B regulates its own
activity through a negative feedback loop. Because the cell maintains storage of
the signaling protein NF-B in the cytoplasm, NF-B allows the cell to respond
to sudden stimuli by activating quick changes in gene expression. Because pro-
teins that promote cellular proliferation and cell survival are mainly transcribed
throughNF-B activation, uncontrolled overactivation of this transcription fac-
tor has major implications in carcinogenesis. Many types of cancer cells have
high levels of constitutively active NF-B. Mutations in the genes for NF-B
itself or its inhibitors such as IBs often found in cancer cells can cause cells to
accelerate their proliferation or confer resistance to apoptosis. Some types of
cancer cells secrete signaling molecules, inducing improper NF-B activity. Be-
cause of the tumor promoting characteristics of NF-B activation, a focus of
current research is to fınd methods of suppressing NF-B to kill cancer cells or
slow their growth. We designed a 3D-printed model of the p50/RelA NF-B
protein using Jmol to highlight the relationship between its structure and func-
tion.
#3534 FAT1: A potential target of NFkB (RelA) in GBM.Chitrangda Sriv-
astava,1 Khushboo Irshad,1 Parthaprasad Chattopadhyay,1 Chitra Sarkar,1 Ash-
ish Suri,1 Subrata Sinha,2 Kunzang Chosdol1. 1All India Institute of Medical
Sciences, New Delhi, India; 2National Brain Research Center, Gurgaon, India.
FAT1 is a large transmembrane protein (502 kD), reportedly having dual role
in different human cancers. Our lab has reported oncogenic role of FAT1 over-
expression in glioblastoma multiforme (GBM, grade IV glioma) increasing mi-
gration-invasion aswell as tumor inflammation andHIF1 activity.Morris et al.
(2013), have reported that glioma patients with low FAT1-expressing tumors
have signifıcantly (p0.037) longer survival (Rembrandt dataset), suggesting
high FAT1 expression to have adverse effect on GBM patient survival. Since
NFB is a major transcription factor overexpressed in GBM and involve in
regulatingmany oncognes at transcriptional level. There are no reports available
on FAT1 upstream regulation. Therefore in this studywe investigated the role of
NFkB (RelA) in regulating FAT1 expression in GBM. In-silico analysis of FAT1
promoter predicted binding sites for several transcription factors including
NFkB (RelA) having multiple binding motifs with high matrix score. We as-
sessed themRNA expression correlation of FAT1 andNFB target gene (BCL2)
in small cohort of GBM tumors (n16). A signifıcant positive correlation
(0.647, p0.01) was established between FAT1 and BCL2 in GBM tumors com-
pared to normal brain (Clontech). In a sequential bioinformatics study, we an-
alyzedTCGAGBMdataset and found signifıcantly elevated expression of FAT1,
RelA, IKBKB andRelA target genes (BCL2,MMP9 and Serpine) inGBM tumors
(n430) as compared to normal brain (n10). In survival analysis of TCGA
dataset {Grouped into high (n100) and low FAT1 expression (n100)}, low
FAT1 expressing patients showed higher survival, corroborating the observa-
tion ofMorris et al 2013. The role ofNFkB (RelA) in FAT1 expression regulation
was further analyzed in in-vitro in U87MG (GBM) cell line. We overexpressed
and chemically inhibited NFkB using RelApBABE expression vector and PDTC
respectively. There was increased FAT1expression in cells overexpressingNFkB
and this effect could be reversed on NFkB inhibition, suggesting that RelA plays
an important role in regulation of endogenous FAT1 expression. Furthermore,
to confırm the regulatory role of NFB (RelA) on FAT1 expression, 2-kb FAT1
promoter (pGLF2) and sequential 5’ deletion constructs (pGLF2A, pGLF2B,
pGLF2C and pGLF2D) with different RelA binding sites were cloned into lu-
ciferase basic vector (pGL3B) and analyzed for their activity by in vitro luciferase
assay. Among all constructs, 5’ deletion construct (pGLF2C) containing single
consensus binding site for RelA and least no. of repressor sites, showed highest
luciferase activity in U87MG. Furthermore, site directed mutagenesis of RelA
consensus binding site decreased luciferase activities by three-fold as compared
to the wild type construct, pGLF2C. The endogenous binding of RelA on FAT1
promoter was confırmed by ChIP (chromatin-immunoprecipitation) assay.
Conclusively, our study for the fırst time identifıed NFkB (RelA) transcription
factor as a potential regulator of FAT1.
#3535 Methylation regulates HEY1 expression in glioblastoma.Maheed-
hara Reddy Guda,1 Andrew J. Tsung,1 Swapna Asuthkar,1 Collin M. Labak,1
Yining Lu,1 Sarah E. Martin,1 Prasad V. Durbaka,2 Kiran K. Velpula1. 1Univer-
sity of Illinois College ofMedicine at Peoria, Peoria, IL; 2Yogi VemanaUniversity,
Kadapa, India.
Glioblastomamultiforme (GBM) remains one of themost lethal and diffıcult-
to-treat cancers of the central nervous system despite the existence of multi-
modal therapeutic approaches. The poor prognosis in GBM patients is due in
part to its resistance to available treatments, which calls for identifying novel
molecular therapeutic targets. In this study, we identifıed an interesting bio-
marker,Hairy/Enhancer-Of-Split relatedwithYRPWMotif (HEY1), amediator
of Notch signaling, which contributes to the pathogenesis of GBM. Datamining
studies and our immunohistochemistry and immunoblot analysis showed that
HEY1 is highly expressed in GBM patient specimens. Recent studies indicate
that methylation status may control the expression of cancer phenotype. Our
studies using bisulphite sequencing on the patient samples showed that HEY1
promoter was hypermethylated in the normal brain when compared to GBM
specimens. Treatment on the 4910 and 5310 xenograft cell lines with sodium
butyrate (NaB) greatly decreased HEY1 expression owing to its promoter hy-
permethylation with a concomitant increase in DNMT1 expression confırming
that promoter methylation regulate the HEY1 expression in GBM. NaB treat-
ment also induced cell apoptosis as evaluated by flow cytometric analysis. Silenc-
ing HEY1 reduced invasion, migration and proliferation in 4910 and 5310 cells.
Further, immunoblot and q-PCR analysis demonstrated the existence of a po-
tential positive regulatory loop between HEY1 and p53. Additionally, DNA
microarrays with HEY1 recombinant protein demonstrated good correlation
with p53 and provided various bonafıde targets of HEY1. Collectively, these
studies suggest HEY1 as an important predictive marker for GBM, thus indicat-
ing a potential target for future GBM therapy.
#3536 The role of Nuclear factor I transcription factors in glioma. Kok
Siong Chen, Linda J. Richards, Jens Bunt. The University of Queensland, Bris-
bane, Australia.
Gliomas are the most common brain tumors in adults. Among the malignant
gliomas, grade IV glioma, or glioblastoma (GBM), is the most aggressive form.
Despite harsh treatments such as surgery, radiotherapy and chemotherapy, the
median survival of GBM patients remains at just 12-15 months. GBM tumors
could originate from cells of the glial lineage that have escaped the normal glial
differentiation mechanisms. Therefore, by applying knowledge about normal
glial development, we might understand how pathways that normally drive dif-
ferentiation are affected in these tumors. If reactivating these pathways induces
the differentiation of proliferative tumor cells, we could use this as a novel target
for therapy. Our research is focused on the Nuclear factor I (NFI) transcription
factors, one of the key factors to induce glial differentiation during normal de-
velopment and is implicated in glioma. In insertional mutagenesis glioma
mouse models, Nfı genes are consistently disrupted, suggesting a role for NFI in
glioma initiation. Furthermore, loss of NFIB is common in human astrocytoma,
while loss of NFIA is associated with oligodendroglioma. To determine whether
loss of Nfı alters glioma initiation, progression or tumor histology, we have
crossed inducible glioma mice with conditional Nfı deletion mice to follow tu-
mor initiation and progression using fluorescence imaging and immunohisto-
chemistry. Based on analyses of glioma mRNA expression data sets, NFIB ex-
pression correlates inversely with tumor grade and survival. Using
immunofluorescence, we determined that both NFIA and NFIB are mainly ex-
pressed within the non-proliferative cells in GBM tissue, suggesting that NFI
may play a direct role in tumor cell differentiation. To establish whether NFI
expression can indeed inhibit tumor proliferation and induce differentiation,
U251 GBM cells were transfected with NFI. While overexpression of NFIA and
NFIB reduced cell proliferation, an NFI dominant-negative protein enhanced
proliferation. We are currently validating these fınding in vivo by electroporat-
ing NFI expression constructs into patient-derived GBM xenografts in mice.
Our preliminary data show NFIB electroporated cells are indeed differentiated
and non-proliferative. Our data suggests that NFI-mediated glial differentiation
can be induced in glioma to inhibit tumor growth and may prevent recurrence.
Hence, activation of NFI could be a potential target for a glial differentiation-
based approach to treat glioma.
#3537 Otx2 and c-Myc association drives tumor progression in medullo-
blastoma molecular subtypes 3/4. Yining Lu,1 Maheedhara R. Guda,1 Swapna
Asuthkar,1 Ian Purvis,1 CollinM. Labak,1 Neha Jain,1 David J. Daniels,2 Sarah E.
Martin,1 Andrew J. Tsung,1 Kiran K. Velpula1. 1Univ. of Illinois College of Med.
at Peoria, Peoria, IL; 2Mayo Clinic, Rochester, MN.
Medulloblastoma (MB) is a pediatric brain tumor comprising of four molec-
ular subgroups, with Group 3 and 4 tumors characterized by particularly poor
prognosis. While research has advanced our understanding of MB, there is still
a pressing need for new knowledge of the functional processes underlying its
progression due to a scarcity of therapeutics. Recent studies have identifıed
Orthodenticle homeobox 2 (Otx2), a cerebellar transcription factor, to be highly
expressed in MB Group 3/4 subtypes. Datamining studies from Northcott and
Robinson datasets revealed co-expression of Otx2 and c-Myc in Group 3/4 tu-
mors. DAB staining conducted in human MB specimens showed increased ex-
pression of Otx2 and c-Myc. Colocalization studies confırmed datamining re-
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sults. Next, we used a clinical Otx2 inhibitor, all-trans retinoic acid (ATRA), in a
PDX cell line, P9, and in UW228 cells. Western blot analysis demonstrated
reduced levels of c-Myc along with Otx2. In another experiment, we used the
c-Myc/Max inhibitor 10058-F4 and observed comparable results to Otx2 inhi-
bition. Real time PCR and immunocytochemistry experiments confırmed the
aforementioned results. Further, treatment with ATRA and 10058-F4 showed
reduced proliferation andmigratory abilities in p9 andUW228 when compared
to their respective controls. Mass spectrometry conducted on immune-precipi-
tated Otx2 in P9 cells revealed a plethora of novel interaction partners that drive
tumor growth and progression. In addition, western blot analysis in ATRA
treated cells showed reduced expression of Max, suggestive of the existence of a
feedback loop that link with Otx2 and c-Myc. Collectively our studies highlight
Otx2 as a potential contributor to the malignant phenotype and describe its role
in mediating the aggressiveness of Group 3/4 medulloblastoma.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Regulation of Metabolic Pathways in Cancer
#3538 Enhanced dependence on lipid metabolism is a cellular adaptation
to acidic microenvironment. Smitha Pillai, Jonathan W. Wojtkowiak, Mehdi
Damaghi, Robert Gatenby, Robert Gillies.Moffıtt Cancer Center, Tampa, FL.
Malignant tumors exhibit altered metabolism and consume higher levels of
glucose compared to surrounding normal tissue, resulting in highly acidic mi-
croenvironment. Adaptation to acidic conditions is a pre-requisite for tumor
cells to survive and thrive and to out-compete the stroma intowhich they invade.
Acid adaptation is associated with chronic activation of autophagy as well as
redistribution of the lysosomal proteins to the plasma membrane. These pro-
cesses are major survival mechanisms adopted by tumor cells under acidic con-
ditions. We have also observed that under acidic conditions, there is a rapid,
reversible and robust increase in the accumulation of cytoplasmic lipid droplets
(adiposomes) in a panel of breast cancer cells. Adiposomes are dynamic organ-
elles that store neutral lipids surrounded by a shell of proteins and a phospho-
lipid monolayer. Breast cancer cells when grown in acidic media accumulated
adiposomes as revealed by nile red and perilipin-2 staining followed by confocal
microscopy. The acid-induced lipogenic phenotype persists even when the cells
are grown in de-lipidated serum, indicating that the source of lipids is de-novo
and endogenous. When cells were treated with inhibitors of fatty acid synthesis
such as TOFA, an inhibitor of Acetyl CoA Carboxylase or FAS inhibitor C75,
adiposome formation at low pH was attenuated. Inhibition of either lipid ana-
bolic or catabolic pathways was specifıcally cytotoxic in acid-adapted cells, but
not in control cells where the FAS inhibitor, C75, is selectively toxic under acidic
conditions. Additionally, when treated with etomoxir, an inhibitor of carnitine
palmitoyltransferase 1, the rate limiting step in eta-oxidation, acid adapted
cells showed increased sensitivity. To investigate the role of de novo fatty acid
synthesis further, we employed high resolution NMR spectroscopy to measure
13C enriched lactate isotopomers following metabolism of D-[1,2-13C] glucose.
These analyses showed that glucose flux through the pentose phosphate pathway
(PPP) was signifıcantly (2.5 fold) higher in low pH exposed cells, compared to
controls, representing a major shift in glucose metabolism from Embden Mey-
erhof to PPP, which results in increased production ofNADPH, necessary for de
novo lipid synthesis. Additional metabolic profıling using the Seahorse XF re-
vealed that cells at low pH had higher rates of oxygen consumption (OCR) and
that this was reversible. Further, we investigated the role of various acid sensing
G-protein coupled receptors such as OGR1, TDAG8 and GPR4 in transducing
the acid signal that results in the accumulation of lipid droplets. CRISPR/Cas9
mediated depletion of these receptors indicates that theymight play amajor role
in inducing adiposome accumulation under acidic conditions. Taken together,
increased dependence on lipid metabolism by cancer cells under acidic condi-
tions reveals novel therapeutic vulnerabilities.
#3539 Oncogenic KRAS promotes the hexosamine biosynthetic pathway
in NSCLC. Christian Ruiz, John A. Haley, Irina Zaitseva, John D. Haley, Geof-
frey D. Girnun. Stony Brook University, Stony Brook, NY.
Mutations in the proto-oncogene KRAS (KRASmut) are one of the most com-
mon oncogenic mutations in NSCLC cancer, with approximately 25% of lung
tumors containing KRASmut. Cancer cells require extensive metabolic repro-
gramming in order to sustain their proliferative state. Recent studies highlight a
role for KRASmut in driving altered cancer metabolism as part of its mechanism
of action. We used targeted metabolomics in an effort to identify alterations in
metabolic pathways controlled by Krasmut. We show that KRASmut, but not
wildtype KRAS, increases several metabolites in the hexosamine biosynthetic
pathway (HBP). The HBPmetabolizes glucose and glutamine to produce UDP-
N-acetylglucosamine (UDP-GlcNAc) which is the obligate substrate for O-Gl-
cNAcylation, a carbohydrate post-translational modifıcation on cytosolic and
nuclear proteins. Levels of O-GlcNAcylation have been shown to be elevated in
many cancers including NSCLC. Currently we are investigating the mecha-
nism(s) and role of the Krasmut induced HBP on cancer cell metabolism and
growth.
#3540 Targeting obesity-related cancer progression with novel leptin re-
ceptor antagonists.Crystal C. Lipsey, AdrianaHarbuzariu, RubenR.Gonzalez-
Perez.Morehouse School of Medicine, Atlanta, GA.
Obesity is a global health issue that has been identifıed as a risk factor for
several types of cancer. High levels of body fat and circulating leptin are typical
identifıers of obesity in humans and animals. Leptin is a 16kD protein hormone
which is secreted by adipocytes, and maybe secreted from cancer cells, that
functions to control satiation via leptin receptor binding. However, obese indi-
viduals often develop “leptin resistance”, which is a mechanism that leads to the
accumulation of excess leptin. Increased binding of leptin to its receptor (OB-R)
due to leptin resistance has been associated with disease progression and poor
prognosis in human cancers. Our group has previously shown that leptin-me-
diated cancer cell proliferation is inhibited by the LPrA2 (leptin peptide receptor
antagonist 2).We have prepared novel leptin antagonists and tested their ability
to block leptin-induced survival and chemoresistance to Paclitaxel (TAX) and
Gemcitabine (GEM) in cancer cells and derived tumorspheres (pancreatic:
PANC-1, MiaPaca2 and triple negative breast cancer: MDA-MB231 andMDA-
MB468). Western blot protein analyses showed the ability of the antagonists to
specifıcally inhibit leptin-induced phosphorylation of STAT3, and expression of
cyclin D, and Notch1 in cancer cells. Additionally, potential toxicity of antago-
nistswas tested usingMTTassaywith concentrations up to 100Xhigher than the
effective dose in non-malignant breast cells (MCF-10A). Data generated show
no toxicity of the novel antagonists in vitro. Leptin-induced proliferation of
breast cancer and pancreatic cancer cells (120-160%) was signifıcantly inhibited
by the novel antagonists. In addition, leptin-mediated progression of S-phase
was also reduced by the antagonists. Leptin increased TAX and GEM chemore-
sistance in cells and tumorspheres that were effıciently inhibited by the antago-
nists. These data suggest that the new antagonists could be equally or more
effective than LPrA2 for adjuvant treatment of cancer. Acknowledgements: This
work has been supported by Pilot Project Award fromMSM/Tuskegee Univer-
sity/UAB Cancer Center partnership grant 5U54CA118638; PC SPORE Grant
from UAB to RRGP, and facilities and support services at Morehouse School of
Medicine (1G12RR026250-03; NIH RR 03034 and 1C06 RR18386).
#3541 Metabolic signature characterization in prostate cancer mediated
by heme-oxygenase 1.Valeria G. Antico Arciuch, Nicolas Anselmino, Federico
Schuster, Alejandra Paez, Florencia Cascardo, Javier Cotignola, Geraldine
Gueron, Elba Vazquez. Laboratory of Cancer & Inflammation, Buenos Aires,
Argentina.
Prostate cancer (PCa) is the second leading cause of cancer-associated death
in men, being bone metastases the main cause of mortality. Energetic metabo-
lism alterations have become a new hallmark of cancer, since variations in a
single gene can orchestrate changes in metabolic pathways and confer an adap-
tive advantage. Heme-oxygenase 1 (HO-1) exerts an antitumoral role in PCa
inhibiting cell proliferation, migration, tumor growth and angiogenesis. The
aimof this workwas to assess the role ofHO-1 in themetabolic signature of PCa.
Through RNA-Seq we found a set of metabolic genes deregulated under phar-
macological induction (hemin treatment) or genetic induction of HO-1 in PC3
cells. STAR andATP5L2were found upregulated, whileHMGCS2, PRODHand
ACOT12 were downregulated. These genes encode for steroid hormonemetab-
olism, ATP synthesis, ketogenesis, proline and lipidmetabolism. The analysis of
the deregulated genes (2-fold) under HO-1 modulation by Gene Ontology re-
vealed alterations in several metabolic pathways such as steroid, tyrosine and
lipid metabolism, and ion transport. Bone is the only site of PCa progression,
and bone cells are able to produce factors that increase the growth and survival
of tumor cells favoring progression. However, the molecular nature of this in-
teraction remains to be elucidated. Our preliminary results performed on co-
cultures of PC3 cells (treated or not with hemin) with Raw264.7 (pre-osteoclas-
tic) or MC3T3 (pre-osteoblastic) cells demonstrate that HO-1 is able to direct
the metabolic fate of bone precursor cells due to the deregulation of glycolytic
genes. HO-1 induction in PC3 cells downregulated the expression of PKM2 and
LDHA in co-cultured Raw264.7 and MC3T3 cells (p 0.05). Based on our re-
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Oncogenic Transcription Factors
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017904
sults, we proposeHO-1 as a key regulator of themetabolic status of PCa cells and
a powerful mediator capable of redefıning the metabolic signature of bone pre-
cursor cells, thus, favoring the establishment of a less aggressive phenotype.
#3542 Coordination of glutamine and glucose metabolism in pancreatic
cancer. Enza Vernucci, Venugopal Gunda, Surendra Shukla, Pankaj K. Singh.
UNMC, Omaha, NE.
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer re-
lated deaths in the United States. Due to early metastasis by the time it is diag-
nosed it advances to advanced stages and becomes unresectable. Oncogene me-
diated metabolic reprogramming has been shown to promote the growth,
maintenance and metastasis of tumors in pancreatic ductal adenocarcinoma.
Pancreatic tumors route majority of glucose and glutamine for biomass gener-
ation and maintenance of redox potential. The aim of this study was to investi-
gate the link between glutamine and glucose metabolism in pancreatic cancer
cells. We primarily focused on the role of glutamine mediated regulation of
glucose metabolism. We observed that glutamine deprivation reduces pancre-
atic cancer cell growth as suggested by the previous studies. We further investi-
gated how pancreatic cancer cells adapt to glutamine deprived conditions. We
observed that glucose uptake increases signifıcantly upon glutamine depriva-
tion. However, GLUT1 expression showed a contrasting decreased expression
under conditions of glutamine deprivation. Using tandem mass spectrometry
based metabolomic analysis we observed that glutamine deprivation does not
alter glycolysis. However, the TCA cycle, amino acid metabolism and glutathi-
one metabolism were signifıcantly impacted in glutamine deprived cells. We
noticed a signifıcant increase in the levels of hydroxyglutarate and succinyl CoA
levels in the TCA cycle. These changes were accompanied with an increase in
GSH toGSSG ratio that reflects a possibility for alternative pathways involved in
redox maintenance under glutamine deprived conditions. Hence, we conclude
that glutamine metabolism signifıcantly impacts the uptake and metabolism of
glucose in pancreatic cancer cells.
#3543 Targeting the metabolic mevalonate pathway with statins as anti-
breast cancer agents. Jenna van Leeuwen, Aleksandra Pandyra, CarolynGoard,
Peter J. Mullen, Rosemary Yu, Linda Z. Penn. Princess Margaret Cancer Centre,
Toronto, Ontario, Canada.
The statin family of drugs target the mevalonate pathway and have been used
for decades in the control of hypercholesterolemia, however recent evidence
suggests these approved agents may also be useful as anti-cancer therapeutics
(see our recent Nature Review Cancer article1). For example, statins can trigger
tumor-specifıc apoptosis and two independent pre-op clinical trials in breast
cancer, evaluating cholesterol-lowering doses of fluvastatin and atorvastatin,
resulted in breast tumor shrinkage due to decreased growth and increased apo-
ptosis. Our hypothesis is that statins have utility as anti-breast cancer agents. To
maximize effıcacy and speak to personalized medicine, our objectives are to
develop biomarkers to distinguish which patients will benefıt from the addition
of statins to their treatment regimen and how best to use statins in combination
with other agents to augment anti-tumor effıcacy. To identify biomarkers of
statin sensitivity we evaluated fluvastatin activity across a panel of BCa cell lines
and showed that the basal, estrogen receptor-negative subtypewere signifıcantly
sensitive to statin-induced apoptosis. As this included the diffıcult-to-treat triple
negative BCa (TNBCa) we have extended this work and further evaluated a
panel of TNBCa cell lines for statin sensitivity. From these results we are iden-
tifying features associated with robust apoptosis in response to statin exposure.
To identify how best to use statins, we conducted two unbiased screens and have
shown that blocking the restorative feedback response to statin exposure poten-
tiates statin-induced apoptosis. This is reversible with exogenous mevalonate,
reinforcing that this is an on-target effect. We also identifıed another approved
agent, dipyridamole, as able to potentiate the anti-cancer activity of statins.
Mechanistically we have shown that dipyridamole blocks the feedback response
to statin exposure. We have extended these studies and shown that the combi-
nation of statins and dipyridamole is effective against TNBCa both in vitro and
in vivo. Thus, we provide essential pre-clinical data to support the further eval-
uation of statins and dipyridamole in BCa. Reference: Mullen, P.J. et al. The
interplay between cell signalling and themevalonate pathway in cancer. Nat Rev
Cancer. 16, 718-731 (2016).
#3544 Leptin-Notch crosstalk axis: A novel target for pancreatic cancer.
Adriana Harbuzariu, Crystal C. Lipsey, Ruben R. Gonzalez-Perez. Morehouse
School of Medicine, Atlanta, GA.
Background: Pancreatic cancer (PC) has consistently been the fourth cancer-
related cause of death in United States for more than 10 years. Its dismal prog-
nosis is due to the aggressive behavior, late detection, lack of reliable biomarkers
and low response to chemotherapy. Obesity, characterized by high levels of
leptin, correlates to low PC survival. Notch and leptin signaling have been asso-
ciated with increased tumor growth and chemoresistance. We have previously
shown that leptin induces proliferation of PC cell lines, increases Notch expres-
sion, PC stem cells (PCSC) and tumorsphere formation. Hypothesis: Leptin
increases PC chemoresistance through its crosstalk to Notch signaling pathway
that is essential for the expansion of PCSC. Methods: To test whether a leptin-
Notch crosstalk axis is involved in PC-chemoresistance, human PC (Mi-
aPaCa-2, Panc-1 and BxPC-3) cells were cultured in serum-free medium con-
taining leptin, Gemcitabine and 5-Fluorouracil (5-FU) in combination with
DAPT (-secretase inhibitor) and leptin signaling inhibitor bound to iron-oxide
nanoparticles (IONP-LPrA2). PC cells were cultured with leptin and allow to
form primary and secondary tumorspheres, enriched in PCSC. Tumorspheres
were treated with the compounds described for 7-14 days. Number and size of
tumorspheres were recorded, and expression of leptin receptor, OB-R and se-
cretion of leptin were determined by Western blot (WB) and ELISA, respec-
tively. Additionally, the levels of Notch, PCSC and EMTmarkers, pluripotency
associated genes (Oct-4, Sox-2 andNanog) andATP-binding cassette transport-
ers (ABCB1, ABCG2 and ABCC5) were determined using flow cytometry and
WB. Results: PC cells expressed Leptin/OB-R system, suggesting an autocrine
role in PC progression and chemoresistance. Leptin induced the formation of
primary and secondary tumorspheres and increased their expression of Notch,
EMT and pluripotency markers. Additionally, chemotherapeutics induced PC
survival and the expression of ATP-binding cassette transporters in tumors-
pheres that was reinforced by leptin actions. Blockade of leptin signaling via
IONP-LPrA2 and Notch activation via DAPT reduced leptin-induced molecu-
lar effects, PCSC and tumorsphere growth. Conclusion: Present data suggest
that obesity, through leptin-induced Notch signaling, could increase chemore-
sistance in PC patients. Inhibition of leptin-Notch axismay be novel therapeutic
strategy for PC, which may improve chemotherapeutic effıcacy and increase
survival in PC patients, particularly in obese contexts. Acknowledgements: this
work has been supported by a Pilot Project Award from MSM/Tuskegee Uni-
versity/UAB Cancer Center partnership grant 5U54CA118638; PC SPORE
Grant from UAB to RRGP, and facilities and support services at Morehouse
School of Medicine (1G12RR026250-03; NIH RR 03034 and 1C06 RR18386).
#3545 Glucose-dependent regulation of PXR is modulated by AMPK. Pe-
ter O. Oladimeji. St. Jude Children’s Research Hospital, Memphis, TN.
The sensitivity of patients to drugs depends on the pharmacokinetics of the
drugs, but largely on the bioavailability of the drugs in the body. Orally admin-
istered drugs must pass through the intestinal wall and the portal circulation to
reach the liver; both are sites of fırst-pass metabolism. Thus, many drugsmay be
metabolized before optimal plasma concentrations are reached, or before get-
ting to target tissues, resulting in diminished drug effıcacy and acquired drug
resistance. Among the several drug-metabolizing enzymes (DME) is cyto-
chrome P450 (CYP) enzyme 3A4, the most abundant in the liver, metabolizes
approximately 50 percent of marketed drugs and a main target of pregnane X
receptor (PXR) In addition, transporters including MDR1 are also regulated by
PXR. There is increasing evidence that drug metabolism can be affected by
energy metabolism and vice versa. PXR has been implicated to have a complex
role in energy homeostasis, and increased drug clearance was observed in un-
treated diabetic patients. The elimination of any chemotherapeutic agents in
humans is markedly dependent on the relative expression and activity of the
variousDMEs and drug transpoters. The heterotrimeric AMP-activated protein
kinase (AMPK) serves as a monitor of cellular energy status in most eukaryotic
cell, and is activated under energy stress conditions. Interestingly, AMPK is also
regarded as a tumor suppressor in various cancers because of its inhibitory
effects on anabolic processes that are important for tumor development. Despite
the knowledge of the cross-regulation between drug metabolism and energy
metabolism, the molecular pathways of this interaction remain vague. In our
study, we exposed HepG2 cells to varying glucose concentrations and observed
that PXR is greatly induced in high glucose conditions. This fınding is consistent
with clinical observation of increased drug clearance in untreated diabetic pa-
tients. We demonstrate that AMPK modulates PXR transcriptional activity. As
such, the pharmacological manipulations of AMPK activation status show an
inverse relationship with PXR activity. Activation of AMPK was shown to de-
crease PXR activity as observed by decreased CYP3A4 transcription, and con-
sistent with that a potentiation of response to drugs. Interestingly, we observed
that PXR is not a direct target of AMPK: it remains to be determined what the
intermediary between AMPK and PXR is. Taken together, our studies identify
novel links between the energy status of the cell, the activation of AMPK and
down regulation of PXR.
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#3546 LIN28B/MYC loop regulates aerobic glycolysis and tumor acidic
microenvironment to promote cancer stemness and cancer progression.
Chong Chen,1 Lipeng Bai,1 Fengqi Cao,1 ShengnanWang,1 Yan Liu,1 Jian Guo,1
Qin Si,1 Rong Xiang,2 Yunping Luo1. 1Chinese Academy of Medical Science,
Beijing, China; 2Nankai University, Tianjin, China.
Substantial evidences have proven that targeting cancer addictive metab-
olism could suppress tumor progression. Tumor microenvironment (TME)
supports the development of metabolic reprograming of tumor cells. The
function of cancer stem cells (CSCs) closely related with its own metabolic
alteration. However, the relationship between CSCs’ metabolic reprogram-
ing and their supportive TME, as well as underlying mechanism remains
largely unknown. In this study, we have demonstrated a novel mechanism
that the LIN28B/MYC positive regulation loop could promote the aerobic
glycolysis of cancer cells and glycolysis-derived lactate and further enhance
the cancer stemness to facilitate tumor progression. 1) Metabolic analysis
revealed that glycolysis (ECAR) was suppressed after LIN28B was knocked
down in MDA-MB-231 or H1299 cancer cells respectively. Consistently,
both the glucose-uptake and lactate-secretion were attenuated in shLIN28B
cancer cells. Importantly, either the glucose accumulation in cancer tissues
or lactate secretion in serum was reduced in mouse injected with shLIN28B
cancer cells. 2) Metabolic analysis revealed that CSCs possessed higher
ECAR and higher level of LIN28B, MYC and HIF1a. Furthermore, glycoly-
sis-derived lactate not only increase the proportion of ALDH cells, but also
enhance the tumorsphere forming ability and mobility of cancer cells. 3)
MicroRNAs screening analysis revealed that 6 miRNAs were up-regulated
above 2 folds after LIN28B was knocked down in MDA-MB-231 cells. Met-
abolic analysis revealed that miR-34a-5p could suppress the aerobic glycol-
ysis (ECAR) in MDA-MB-231 cells. 4) LIN28B inhibitor could reduce the
expression of LIN28B and MYC in vitro and then suppressed tumor growth
and metastasis in vivo. Taken together, our study demonstrated that
LIN28B/MYC loop could sustain the aerobic glycolysis of cancer cells and
then enhance the function of CSCs via regulating the tumor acid microen-
vironment, thus, established the LIN28B/MYC as a central node in connect-
ing tumor metabolism and tumor microenvironment, and could serve as a
therapeutical target.
#3547 B cell receptor signaling regulates cellular metabolism in Chronic
Lymphocytic Leukemia. Hima V. Vangapandu, Ondrej Havranek, William G.
Wierda, Michael J. Keating, Richard Eric Davis, Christine M. Stellrecht, Varsha
Gandhi. UTMD Anderson Cancer Ctr., Houston, TX.
Peripheral bloodB cells in chronic lymphocytic leukemia (CLL) are quiescent,
yet have an active RNA transcription and protein translation processes, suggest-
ing that these malignant lymphocytes may be metabolically active. However,
CLL metabolism and its relationship to disease biology has not been well-ex-
plored. In our previous investigation, we reported that compared with prolifer-
ative B-cell lines, metabolic fluxes of oxygen and lactate were low in quiescent
peripheral blood B lymphocytes from CLL patients (Vangapandu, H.V. et al,
AACR 2014). In 45 patient samples tested, glycolysis (extracellular acidifıcation
rate, ECAR) was consistently low (1 to 15 mpH/min/5 x 105 lymphocytes),
whereas, oxygen consumption rate (OCR) varied considerably (5 to 190 pMoles/
min/5 x 105 lymphocytes). Among the prognostic factors, high OCR correlated
stronglywithZAP70positivity, unmutated IGHVstatus, greater2M levels and
higher Rai stage. In contrast, glycolytic flux (ECAR) from same patient samples
did not associate with prognostic factors. Further, OCR did not vary on the basis
of frequently occurring cytogenetic abnormalities, 13q14, 17p, and 11qdeletions
or trisomy 12. Since, ZAP 70 and IGHV unmutated status are associated with
augmented B-cell receptor (BCR) pathway signaling, we tested the impact on
OCR after genetic ablation of B-cell receptor (CH2 region of IgM). A CRISPR-
Cas9-mediated BCR knockoutmitigated OCR in amalignant B cell line without
impacting the rate of proliferation. A critical node in the BCR pathway is PI3
Kinase and PI3K isoforms,  and  are involved in B-cell malignancies. Consis-
tent with BCR ablation results, knocking out PIK3CD (codes for catalytic sub-
unit ), dramatically reducedOCRandECAR. Pharmacological inhibitors of the
PI3K pathway, duvelisib (a PI3K / inhibitor in phase III clinical trials) or
idelalisib (FDA approved PI3K  inhibitor) also decreased OCR. Direct inhibi-
tion of AKT with MK-2206 showed similar results. Collectively, these data sug-
gest that CLL cellular metabolism is associated with prognostic factors and
linked to BCR signaling pathway. Since, the PI3K inhibitors used in our study
are being tested clinically for patients with CLL, investigations on the impact on
metabolomics during therapy and translation of results to combination strate-
gies need to be explored.
#3548 Hypoxia-induced Cystathionine--synthase (CBS) expression: im-
pact on colonic epithelial cells metabolism, proliferation and migration.
Ches’Nique M. Phillips, John R. Zatarain, Michael E. Nicholls, Craig Porter,
Steven Widen, Ketan Thanki, James W. Randall, Judith L. Hellmich, Manjit
Maskey, Suimin Qiu, Thomas G. Wood, Nadiya Druzhyna, Bartosz Szczesny,
Katalin Modis, Csaba Szabo, Celia Chao, Mark R. Hellmich.University of Texas
Medical Branch, Galveston, TX.
Introduction: We have reported aberrant overexpression of CBS in human
colorectal cancers, where its activity (H2S production) promotes tumor progres-
sion and metastasis. New data show that CBS expression increases in adenoma-
tous polyps. The aims of this studywere to identify possiblemechanisms forCBS
upregulation and determine the biological impact of its upregulation using a
premalignant colonic epithelial cell lineNCM356.Methods: Induction ofCBS in
response to LPS, TLR2&4 agonists, and hypoxia was assessed by immunoblot-
ting. CBS overexpression was achieved using lentiviral expression vector
(pReceiver-Lv103, GeneCopoeia™) in NCM356 cells. Global metabolic profıling
(Metabolon, Durham) was performed on cellular extracts from NCM365 over-
expressing cells (CBS-hi) and vector-transduced controls. High-resolution re-
spirometry (Orobors Oxygraph-2k) assessed bioenergetics. H2S levels were
measured using the fluorogenic probe 7-Azido-4-methylcoumarin. A Coulter
counter was used to assess cell proliferation rates. Transwell assays were used to
assess cell migration. CBS activity was inhibited with aminooxyacetic acid
(AOAA). Results: CBS protein expression was increased by 3-fold in pNCM
after 2 and 24 hr of hypoxia (1% O2). Treatment with LPS but not the TLR
agonists increased CBS expression 2-fold. Metabolic profıling of CBS-hi cells
and controls identifıed 85 metabolites that were differentially expressed (65
increased and 20 decreased; p0.05 Welch’s 2-Sample t-Test). The metabolite
lanthionine, which is produced by the CBS-dependent condensation of cysteine
to produce H2S, showed the largest increase (12.3-fold increase, p1.5E-06). A
4-fold increase in basal H2S production wasmeasured in CBS-hi cells compared
to control cultures. High-resolution respirometry showed that CBS-hi cells ex-
hibited a signifıcant increase in maximum respiration rate, reserve respiratory
capacity and increased citrate synthase activity, suggesting increased cellular
mitochondria mass. Treatment of CBS-hi cells either with pentose phosphate
pathway inhibitor (oxythiamine) or lactate dehydrogenase inhibitor (XF-11)
reducing growth by 90% and25% at day 5, respectively; the inhibitors had no
effect on the vector control cells. Exposure of NCM356 cells to hypoxic condi-
tions resulted in increasedmigration to conditionedmedia (p0.001, NCM356
normoxia vs. hypoxia); inhibition of CBS using AOAA attenuated the hypoxia-
induced migration. Conclusions: Hypoxia and LPS can induce CBS expression
in a premalignant colonic epithelial cell line. Upregulation of CBS has a board
impact on cellular metabolism including enhanced flux through the transsulfu-
ration, glycolytic and pentose phosphate pathways, resulting in enhanced cellu-
lar bioenergetics, growth and migration. These data suggest that enhance CBS
activity may be involved the adenoma to carcinoma sequence.
#3549 C-MYC sensitizes GBM with primitive features to glutamine me-
tabolism disruption. Brad Andrew Poore, Isabella Taylor, Jeffrey Rubens, Alli-
son Hanaford, Micah Maxwell, Charles Eberhart, Eric Raabe. Johns Hopkins
Medical Insts., Baltimore, MD.
Glioblastoma (GBM) is among themost lethal of known human cancers, with
a median survival of less than 15 months. The highly infıltrative nature and
genetic heterogeneity of GBM renders treatment diffıcult. Therefore, better and
more targeted therapies are needed for patients withGBM. There is a newWHO
subset of GBM that contains primitive neuronal components (GBM-PNC).
These tumors can arise from a histologically classic GBM, and often the GBM-
PNC portions of the tumor contain C-MYC or N-MYC amplifıcations. High
MYC expression is known to alter cellular metabolism, increasing reliance on
glutamine, which may create opportunities for therapeutic intervention. We
hypothesized that depriving GBM-PNC cells of glutamine using metabolic in-
hibitors would suppress growth and tumorigenicity. To create genetically ap-
propriate GBM-PNCmodels, we derived cortex (CTX) human neural stem cells
and transformed them through lentiviral expression of mutant p53, constitu-
tively-activeAKT andhTERT. Transformedneurosphereswere then lentivirally
transduced with either C-MYC or BMI1. These models formed aggressive tu-
mors inmice and recapitulated the histological features of GBMwith expression
of NESTIN, GFAP, and MAP2. When treated with the glutamine metabolic
inhibitors DON or Acivicin, transformed neurospheres that expressed C-MYC
had decreased cellular proliferation (BrdU incorporation, P0.05) and in-
creased apoptosis (cleaved caspase-3 expression, P0.05) while neurospheres
expressing BMI1 had no statistically signifıcant changes. Additionally, cells
overexpressingC-MYChad an increased expression of glutaminase, an essential
enzyme for glutamine incorporation into the TCA cycle. We hypothesize that
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C-MYC expression sensitizes GBM-PNET cancer cell lines to DON or Acivicin
inhibition through greater reliance upon glutamine for its TCA cycle interme-
diates. In addition C-MYC upregulates multiple glutamine transporters, which
may also be used to transport DON and/or Acivicin inside the cell, conferring
increased sensitivity. After further validating glutamine metabolic inhibitors in
orthotopic xenografts and investigating the mechanism of action by metabolo-
mics, we anticipate that metabolic inhibitors may have a therapeutic role in
GBM-PNC.
#3550 Glycolysis signals to Akt and promotes tumor proliferation and
immune evasion. Ivan J. Cohen, Inna Serganova, Avi Albeg, Mayuresh Mane,
David Sardar, Masahiro Shindo, Ronald Blasberg. Memorial Sloan Kettering
Cancer Center, New York, NY.
While the PI3K/Akt pathway has been shown to directly upregulate glycolysis
in cancer cells, signaling in the reverse direction has not been studied in detail.
We studied the novel hypothesis that glycolysis can signal to the Akt pathway,
and that this crosstalk can lead to increased tumor proliferation and immune
evasion. We used the murine 4T1 triple-negative breast cancer cell line for our
studies. Depletion of Lactate Dehydrogenase A (LDHA) has been shown to lead
to decreased tumor growth and metastasis formation, providing a link between
glycolysis and tumor proliferation. Building upon this result, we show that Akt
activation is dependent on glycolytic rates, as LDHA-depleted 4T1 cells show
decreased phospho-Akt (pAkt) levels. Further, pAktwas found to decrease upon
acute (5-20min) inhibition of glycolysis using two glycolytic inhibitors, 2-deoxy-
glucose (2DG) and 3-bromo-pyruvate (3BP). We hypothesize that a glycolytic
metabolite or enzyme is responsible for the observed cross-talk between glyco-
lysis and Akt, and these studied are under way. We also show that T-cells are
excluded from control 4T1 tumors, and that LDHAdepletion in tumors leads to
dramatically increased T-cell infıltration and survival (40% of mice are long-
term survivors). Lactate, the end product of glycolysis, has been shown to be
toxic to T-cells, and LDHA-depleted tumors produce less lactate compared to
controls. Thus, we propose that inhibiting tumor glycolysis leads to a less acidic
microenvironment, leading to increased T-cell infıltration. Further, PTEN ex-
pression has been shown to be inversely correlated with PDL1 expression in
human triple-negative breast cancer, suggesting that the PI3K/Akt pathway can
promote PDL1 expression. Having established that glycolysis can promote Akt
activation, we are also studying if PDL1 is regulated by glycolysis through Akt.
#3551 Targeting glutamine addiction of PIK3CA mutant colorectal can-
cers. Yiqing Zhao. Case Western Reserve Univ., Cleveland, OH.
Glutamine addiction is a major metabolic reprogramming event that occurs
in cancer cells. Many tumors exhibit oncogene-dependent addiction to glu-
tamine. PIK3CA, which encodes the p110 catalytic subunit of phosphatidyl-
inositol 3-kinase , is the most frequently mutated oncogene in human cancers.
However, whether PIK3CA mutations reprogram cancer metabolism is an im-
portant unaddressed question.Herewe show that oncogenic PIK3CAmutations
render colorectal cancers (CRCs)more dependent on glutamine to growth. As a
metabolite, glutamine is fırst converted to glutamate by glutaminase (GLS) and
then to -ketoglutarate (-KG) by either a transaminase or a glutamate dehy-
drogenase. Calithera Biosciences recently developed a potent GLS inhibitor
called CB-839, which is currently in phase I clinical trials in cancer patients.
Using isogenic colorectal cancer cell lines with either WT or mutant PIK3CA
allele knockout, we demonstrated that CRCs with PIK3CAmutations are more
sensitive to growth inhibition by CB-839. Remarkably, combination of CB-839
with 5-FU induces regression xenograft tumors in PIK3CA mutant CRC mod-
els, suggesting that this combinational therapymay be effective approach to treat
CRC patients whose tumors harbor PIK3CA mutations. Mechanistically, mu-
tant p110 up-regulates gene expression of glutamate pyruvate transaminase 2
(GPT2) through an AKT-independent PDK1-RSK2-ATF4 signaling axis,
thereby facilitating conversion of glutamate to -KG. Together, our data estab-
lish oncogenic PIK3CA mutations as a cause of glutamine addiction in CRCs
and that targeting glutamine metabolism may be effective approach to treat
CRCs with PIK3CA mutations.
#3552 Selective inhibition of copper metabolism as a novel approach to
treat triple-negative breast cancer. Olga Karginova,1 Claire Weekley,1 Akila
Raoul,1 Alhareth Alsayed,2 Tong Wu,1 Chuan He,1 Olufunmilayo I. Olopade1.
1The University of Chicago, Chicago, IL; 2Rosalind Franklin University of Medi-
cine and Science, North Chicago, IL.
Rationale: Treatment of patients with triple-negative breast cancer (TNBC)
remains challenging due to unpredictable disease progression and acquired re-
sistance to chemotherapy. Finding novel targets in TNBC is important for the
development of anticancer therapy. Cancer cells frequently adapt to cytotoxicity
of existing pharmacological agents by exploiting metabolic pathways. Elevated
copper metabolism and adaptations to oxidative stress have been linked to can-
cer progression. Copper chelation with tetrathiomolybdate (TM) was reported
to control disease progression, especially in patientswithTNBC.However, long-
term consequences of global copper depletion are still under investigation. An
alternative strategy is provided by a recently developed smallmolecule DCAC50
that blocks the copper transfer interface of two major copper chaperons,
ATOX-1 and CCS. Protein levels of ATOX-1 and CCS are elevated in TNBC
cells compared to normal cells. Thus, we hypothesized that disrupting copper
transport by targeting ATOX-1 and CCS with DCAC50 may suppress TNBC
progression. Results: We investigated effıcacy and potency of novel small mol-
ecule DCAC50 to induce cytotoxicity in a panel of TNBC cells lines. DCAC50
reduced cell proliferation in dose-dependent manner, measured by MTS assay.
IC50 doses ranged from 3-10uM. Most importantly, DCAC50 induced apopto-
sis in TNBC cells, detected by Caspase 3/7 activity and Annexin V/PI staining.
As expected, DCAC50 elevated intracellular copper levels. Moreover, TNBC
cells treatedwithDCAC50had signifıcantly higher levels of oxidized glutathione
(GSSG) and caused increased oxidation of DCF-DA reagent, demonstrating
elevated oxidative stress. Surprisingly, activity of CCS downstream target,
SOD1, was not affected by selective inhibition of copper transport with
DCAC50; suggesting that intracellular copper accumulation and oxidative stress
is mediated by ATOX-1 inhibition. Interestingly, copper depletion with TM
inhibited SOD1 activity but failed to signifıcantly impact oxidative stress in
TNBC cells. Recognizing DCAC50 generates oxidative stress triggering apopto-
sis in TNBC cells we evaluated benefıts of combining DCAC50 treatment with
paclitaxel. Multi-drug combination dose-response analysis revealed that co-
treatment induced synergistic cytotoxicity and resulted in favorable dose reduc-
tion of both drugs. Conclusions: Selective inhibition of copper metabolism with
novel small molecule DCAC50 elevates oxidative stress triggering apoptosis in
TNBC cells. This approachmay be valuable in combination with chemotherapy
especially when tumor cells acquire resistance to fırst line therapy in TNBC.
Ongoing studies comparing selective inhibition of copper transport to global
copper chelation, and investigating effıcacy and biological activity of DCAC50
in vivo will help further estimate benefıts and clinical relevance of this approach
for treatment of TNBC patients.
#3553 Mutant KRas-mediated AKT2 activation supports lung cancer
growth by activating complex II-driven mitochondrial metabolism. Kwan-
Hee Park, Ho-Young Lee. Seoul National University, Seoul, Republic of Korea.
Non-small cell lung cancer (NSCLC), the most common type of lung cancer
(comprising 80-85 %), is a leading cause of cancer-related death worldwide.
KRASmutation is smajor driver oncogene inNSCLC.Constitutive activation of
K-Ras via oncogenicmutations plays a key role in development and progression
of NSCLC, and is an important target for drug development. Indeed, drugs that
target RAF-MAPK and PI3K, the well-established downstream pathways of K-
Ras, are being evaluated in the clinic. However, to date, no effective treatments
specifıcally targeting K-Ras have reached the clinic. A new direction for anti-Ras
therapies targeting Ras-mediated altered cellular metabolism is implied by re-
cent studies. Hence, as an attempt to investigate novel therapeutic targets to
suppress KRAS-driven NSCLC, we assessed metabolic changes in NSCLC cell
line and mouse model systems with oncogenic K-Ras mutations. We show that
activation of Ras causes metabolic alterations, leading to aerobic glycolysis. In-
terestingly, despite the changes in the glycolytic pathway, NSCLC cell line and
mouse models carrying K-Ras mutation revealed an elevated mitochondrial
membrane potential, superoxide production as well as maximal oxygen con-
sumption rate. Moreover, blockade of mitochondrial respiration effectively re-
ducedmutant KRas-driven neoplastic phenotypes in NSCLC cell lines vitro and
lung tumor formation in vivo. In contrast, blockade of glycolysis was not effec-
tive in the mutant KRas-driven tumorigenic activities. Mechanistically, mutant
KRas-mediated activation of Akt2 led to increased expression of succinate de-
hydrogenase subunit A (SDHA) through increased protein stability by blocking
proteasome-mediated degradation, resulting in mitochondrial complex II-de-
pendent respiration. Our study suggests that induction of mitochondrial com-
plex II-dependent respiration is an important mechanism by which oncogenic
mutant KRas induces metabolic changes and ROS stress in NSCLC cells, con-
tributing to lung carcinogenesis. Our fındings elucidate potential metabolic tar-
gets that may provide novel therapeutic strategy for treating NSCLCwith onco-
genic KRAS mutations.
#3554 The combined effect of afatinib and metformin on glycolytic regu-
lation in EGFR-mutant non-small cell lung cancer. Pedro Barrios-Bernal,
Norma Yanet Hernandez-Pedro, Giovanny Soca-Chafre, Mario Orozco-Mo-
rales, Oscar Arrieta. Instituto Nacional de Cancerologia, Mexico City, Mexico.
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Background: The metabolic features of cancer cells allows their rapid prolif-
eration and escape from apoptosis. Novel targeted treatments are being devel-
oped for metabolic dysregulation of malignant cells. There is a growing body of
evidence regarding the effects of metformin on the multiple pathways that reg-
ulate carcinogenesis.Metformin interactswith insulin growth factor signaling to
reduce proliferation and migration of cancer cells. This drug has profound ef-
fects on the mitochondrial respiration rate and ATP production. Metformin
affects multiple cellular pathways via the activation of AMP-activated protein
kinase (AMPK) by liver kinase 1 (LKB1), decreasing growth factor signaling and
proliferation via mTOR inhibition. Metformin has been demonstrated to sensi-
tize EGFR tyrosine kinase inhibitor (TKI)-resistant lung cancer cells by revers-
ing the EMT and decreasing IL-6 signaling activation. Antiproliferative syner-
gism between metformin and the multikinase inhibitor sorafenib via AMPK
activation has also been demonstrated in NSCLC cells harboring KRAS muta-
tions. Hypothesis: The Metformin-Afatinib treatment has synergistic effect on
cytotoxicity and reduces theWarburg effect by regulating the EGFR and AMPK
signaling pathways in Non-Small Cell Lung Cancer (NSCLC). Objective: Deter-
mine the effect of the combined Afatinib-Metformin treatment on NSCLCwith
different mutational status of EGFR. Methods: Cell lines with different muta-
tional status of EGFR: A549, H1975 and HCC827 (ATCC) were used. Once the
IC50 of afatinib and metformin were found, different combinations were made
to determine whether there was a synergistic, additive or antagonistic effect
using theCompusyn software. Cell viabilitywasmeasured by theMTTassay and
apoptosis was evaluated by flow cytometry. Results: The IC50 values of Afatinib
for each cell line were as follows: 7 M (A549), 2 M (H1975) and 4nM
(HCC827) and the IC50 values forMetforminwere 15mM(A549) 5mM(H1975)
and 8mM (HCC827). We found a synergistic effect in H1975 for the combina-
tion of 3M Afatinib plus 15mM Metformin. In A549 we found a synergistic
effect in all combinations. Finally, in HCC827 the combination of 5 nM and 4
nM Afatinib plus 8 nM metformin showed a synergistic effect. The apoptosis
rate was increased up to 47% in all combinations for A549 cells. The combina-
tion of 3nMAfatinib and 8mMMetformin induced 59% apoptosis in HCC827.
Finally, H1975 induced 46% of apoptosis in the combination that showed syn-
ergistic effects. Conclusions: Afatinib-Metformin showed synergistic effects in a
dose-dependent manner in three different cell lines of NSCLC.
#3555 Lipid droplets, a novelmetabolic target in glioblastoma.FengGeng,
JeffreyGuo, XiangCheng, XiaoningWu,ChunmingCheng, ArnabChakravarti,
Deliang Guo. The Ohio State University, Columbus, OH.
Lipid metabolism reprogramming is a novel feature of malignancies. Identi-
fying the vulnerability of lipid alteration in tumor cells provides a newwindow to
treat cancer. Here, we unraveled that glioblastoma (GBM) patients containing
high levels of lipid droplets (LDs), special organelles storing cholesterol esters
and triglycerides in cells, presented poor survival. We found that LDs largely
formed in tumor tissues from GBM patients, but rarely in low grade of gliomas
and normal brain tissues, demonstrating that LDs might serve as a novel diag-
nostic biomarker and prognostic marker for GBM. We further revealed that
sterol O-acyltransferase 1 (SOAT1), the key enzyme controlling cholesterol es-
terifıcation and LD formation, is highly expressed and correlated with LD prev-
alence in tumor tissues from GBM patients. Genetic or pharmacologic inhibi-
tion SOAT1 using avasimibe, a phase III clinical trial drug in human
atherosclerosis patients, signifıcantly suppressed GBM growth and prolongs
survival in xenograft models. Moreover, we found that inhibiting SOAT1 sup-
pressed sterol regulatory element-binding protein-1 (SREBP-1), a key transcrip-
tion factor playing a central role in lipid synthesis, underlying the molecular
mechanism of targeting SOAT1-mediated GBM growth suppression. In sum-
mary, our data demonstrate that LDs/cholesterol esters uniquely formed in tu-
mor tissues provides an ideal target to specifıcally inhibit GBM cells whereas
sparing normal brain tissues, and reveal that blocking cholesterol storage via
targeting SOAT1 represents a promising strategy for GBM treatment.
#3556 Nrf2 promotes esophageal cancer cell proliferation via metabolic
reprogramming and ROS detoxifıcation. Yuki Kitano, Yoshifumi Baba,
Shigeki Nakagawa, KosukeMima, Hiroshi Sawayama, Masaaki Iwatsuki, Yasuo
Sakamoto, Yo-ichi Yamashita, Naoya Yoshida, Hideo Baba. Graduate school of
Medical science Kumamoto University, Kumamoto, Japan.
Background: Cancer cells consume large amount of energy andmaintain high
levels of anabolism to promote cell proliferation via metabolic reprogramming.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master transcription reg-
ulator of stress and promotes metabolic reprogramming to support cell prolif-
eration in various type of cancers. In particular, esophageal cancer was regarded
as one of the most aggressive tumors of gastrointestinal cancer. However, the
effect of metabolic reprogramming in esophageal cancer tissues was not fully
understood. In this study, we investigated the prognostic signifıcance of Nrf2,
impacts onmetabolic reprogramming and reactive oxygen species (ROS) detox-
ifıcation in esophageal cancer. Methods: We immunohistochemically evaluated
the protein expression ofNrf2 in the surgically resected specimens in 201 esoph-
ageal cancer patients. By using esophageal cancer cell lines, we examined the
change of phenotype and the regulation of ROS, compared control cells with
Nrf2 depletion cells. Moreover, we measured the levels of metabolites in the
esophageal cancer cell lines by using mass spectrometry and identifıed the met-
abolic pathway Nrf2 promoted. Results: We revealed that high expression of
Nrf2 in esophageal cancer was associated with tumor recurrence (P0.0004)
and poor prognosis (P0.0001) by immunohistochemical analysis using re-
sected specimen. In TE-11, the esophageal cancer cell line with high expression
of Nrf2, depletion of Nrf2 dramatically decreased cell growth and enhanced G1
cell cycle arrest and apoptosis in vitro assay. In that situation, we showed that
ROS which was not removed by Nrf2 detoxifıcation activated p38 mitogen acti-
vated protein kinase (MAPK) pathway and promoted G1 cell cycle arrest and
apoptosis. Furthermore, metabolome analysis compared control cells with Nrf2
depleted cells showed that Nrf2 can strongly promoted metabolic reprogram-
ming to glutathionemetabolism, which synthesized the essential fuels for cancer
progression. The mechanism Nrf2 promoted glutathione metabolism was that
Nrf2 regulated the levels of main enzymes (GCLM, GCLC, and xCT) catalyzing
glutathione synthesis. Conclusions: The expression of Nrf2 was up-regulated in
some esophageal cancer cell lines and resected tumor specimen. And, high ex-
pression of Nrf2 in esophageal cancer was associated with poor prognosis. Our
in vitro assay revealed that Nrf2 appeared to promote esophageal cancer cell
proliferation via metabolic reprogramming and ROS detoxifıcation. Therefore,
strategies to pharmacologicallymanipulate the level and / or activity ofNrf2may
have potential to reduce tumor growth and improve the prognosis of esophageal
cancer patients.
#3557 miR-155 positively regulates glucose metabolism via PI3K
p85<alpha>-FOXO3a-cMYC axis in breast cancer. Sinae Kim, Eunji Lee,
Suhwan Chang.Univ. of Ulsan College of Med./AsanMedical Ctr., Seoul, Repub-
lic of Korea.
Breast cancer is the most common cancer for women worldwide. Although
the oncogenic roles of miR-155 in cancer have been reported, the metabolic
function of miR-155 in breast cancer has not been fully elucidated. In this study,
we have investigated how the energy metabolic shift occurs after a genetic inac-
tivation or knockdown of miR-155. To this end, we performed metabolic
profıling of the miR-155ko/ko or miR-155/ko primary cancer cells, obtained
from mouse breast cancer model. We found, in the absence of miR-155, less
glucose uptake and glycolysis in tumor cells. Mechanistically, we revealed
PIK3R1(Phosphoinositide-3-Kinase, Regulatory Subunit1, p85alpha) and
FOXO3a (Forkhead transcription factor of the O class 3a) are major targets that
trigger the metabolic shift. Furthermore, we showed cMYC level was conse-
quently decreased in the absence of miR-155 that results in the down-regulation
of proteins playing in glucose uptake and Glycolysis. This fınding is further
confırmed inmouse allograft model. Finally, we show themiR-155 expression is
positively correlates with either energy metabolite levels or standardized uptake
values (SUV) of fluoro-deoxy glucose (FDG)-PET Images in triple negative
breast tumors. Taken together, our study demonstrates a novel mechanism by
which the miR-155 controls energy metabolism in breast cancer, through PI3K
p85alpha-FOXO3a-cMYC axis.
#3558 Src regulation of peroxisome proliferator-activated receptor
gamma (PPAR) in lipid metabolism of lung cancer. Tuyen N. M. Hua, Ai
N. H. Phan, Yangsik Jeong. Yonsei University Wonju College of Medicine,
Wonju, Republic of Korea.
Metabolic reprogramming, recently becoming one of the cancer hallmarks, is
linked to oncogenic signal transduction to fınd a better solution for cancer ther-
apy. As one of key mediators in oncogenic signal transduction, non-receptor
tyrosine kinase Src is known to drive cancer progression by promoting cell
proliferation, metastasis, and drug resistance. Although previous studies re-
ported that Src promotes fat accumulation and suppresses browning of white
adipocytes, little is known about the mechanistic role of Src in cancer metabo-
lism. Here we report that Src mediates lipid mobilization by suppressing tran-
scriptional activity of PPAR, a key regulator of lipid metabolism. Firstly, we
found Src suppression of PPAR activity which, interestingly, turned out to be
independent of Src kinase domain or a known Src phosphorylation site of
PPAR at tyrosine 78. Since the treatment of Src inhibitor (e.g., SU6656, PP2)
could rescue Src-driven PPAR suppression by possibly changing Src confor-
mation, we might suggest the involvement of Src-PPAR interaction in the
regulatory mechanism.Mechanistically, further in vitro experiment showed Src
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inhibitor treatment recovered expression of PPAR target genes such as fatty
acid binding protein 4 (FABP4) and cluster of differentiation 36 (CD36) in a
subset of non-small cell lung cancer cell lines. The increase of FABP4 and CD36
expression was associated with the reduction of lipid droplets, suggesting the
role of Src regulation of PPAR in lipid mobilization. Collectively, this fınding
provides better understandings about the role of Src in cancer lipidmetabolism,
and an insight into therapeutic combination of targeting oncogenic signal trans-
duction and lipid metabolism to treat cancer.
#3559 Functional characterization of HNF4 in gastric cancer. Chang
Xu,1 Wen Fong Ooi,2 Aditi Qamra,2 Patrick Tan1. 1Cancer Science Institute of
Singapore, Singapore, Singapore; 2Genome Institute of Singapore, Singapore, Sin-
gapore.
Gastric cancer (GC) is a leading cause of cancer mortality worldwide and
particularly common in East Asia. Transcription factors are frequently ampli-
fıed or overexpressed in GC andmight contribute to tumorgenesis, however the
underlying mechanisms largely remain unknown. Our previous data indicates
that HNF4 is a common target of three amplifıed transcription factors
(GATA4, GATA6 and KLF5) in gastric cancer. HNF4 had also been found to
be related to diverse aspects of tumorigenesis. In liver and colon cancers, there
are reports indicating that the targets of HNF4 are mainly involved in inter-
mediary metabolism, however, its tissue-specifıc downstream targets and path-
ways have not been systemically studied yet. Therefore, a comprehensive func-
tional characterization ofHNF4 is required to identify its tissue-specifıc role in
gastric cancer. In this study, we analyzed the expression features of HNF4 in
GC, and found the expression level of HNF4 is signifıcantly higher in early
stage tumor and in CIN and MSI compared to GS and EBV subtypes of GC
according to TCGA classifıcation method. In addition, we performed the
HNF4 ChIP in GC cell lines, and the results revealed a number of HNF4
binding sites inGC.Comparisonwith the publishedChIP-seq data of Caco2 and
HepG2 cell lines indicated the existence of GC-exclusive targets. Furthermore,
functional annotation analysis revealed that the GC-exclusive targets are signif-
icantly related to the negative regulation of cellular metabolic process compared
to the common targets. These preliminary data suggests that HNF4might play
a tissue specifıc role in GC, especially in metabolic related processes. Through
further target validation and biological function studies, this study hopes to
systemically investigate of HNF4’s role in GC tumorigenesis, especially in me-
tabolism related pathways.
#3560 6-diazo-5-oxo-norleucine resistant MYC-driven medulloblastoma
tumors are sensitive to inhibition of glutaminase suggesting a possible glu-
taminase-independent mechanism of resistance. Allison Rose Hanaford,
Bradley Poore, CharlesG. Eberhart, EricH. Raabe. JohnsHopkinsUniv. School of
Medicine, Baltimore, MD.
Increased MYC levels can alter cellular metabolism, creating a reliance on
glutamine. Glutamine PET and MRI spectroscopy demonstrate that aggressive
brainmalignancies have increased uptake of glutamine and increased glutamate
relative to normal brain, suggesting that agents targeting glutamine metabolism
may be active in brain tumors. 6-diazo-5-oxo norleucine (DON) is a glutamine
analog that was tested extensively in adult and pediatric malignancies but never
advanced beyond phase I clinical trials. We hypothesized that DON would be
effective against theMYC-driven subgroup of the pediatric brain tumormedul-
loblastoma. DON treatment increased the median survival of mice bearing
D425Med xenografts by 246 percent (26 days for vehicle treatedmice compared
to 90 days DON treated mice, p0.0018) and the median survival of mice bear-
ing the MYC-driven patient derived xenograft MED211 by 80 percent (49 days
for vehicle treatedmice compared to 88 days for DON treatedmice, p0.0017).
We also tested DON prodrugs designed for improved oral bioavailability and
CNS penetration. Our novel DON prodrugs increased the median survival of
mice bearing MYC-driven D425MED orthotopic xenografts by 60 percent (22
days for vehicle treated mice compared to 35 days for prodrug treated mice,
p0.01). In non-human primates, our DON prodrugs exhibited superior 10-
fold enhanced CSF/plasma ratio versus regular DON. Though DON treatment
causes a dramatic increase in survival, resistance eventually develops. To inves-
tigate the mechanism of DON resistance, we tested the effect of other glutamine
metabolic inhibitors onmultiple cell lines generated fromDON-resistant xeno-
grafts. DON-resistant xenograft derived cell linesmaintainedDONresistance in
culture, but were sensitive to treatment with the glutaminase inhibitor com-
pound 968 and the glutamine analog Acivicin. Compound 968 treatment de-
creased growth of DON-resistant cell lines by an average of 79 percent
(p0.0008), and Acivicin treatment decreased growth by an average of 78 per-
cent (p0.00003). Glutaminase catalyzes the fırst step in glutamine metabo-
lism–the conversion of glutamine to glutamate. The sensitivity of DON-resis-
tant cells to glutaminase inhibition indicates continued tumor reliance on
glutaminase activity. We are continuing to investigate the mechanism DON
resistance, with the goal of developing a rational combinatorial therapy to treat
resistant tumors. This knowledge could increase the potential utility of DON as
a clinical agent.
#3561 UCP2=s tumor-promoting role via regulating lipid signaling and
PLC -1 activity. Annapoorna Sreedhar, Yunfeng Zhao. Louisiana State Uni-
versity Health Sciences Center, Shreveport, LA.
Mitochondrial abnormalities are long suspected to play important roles in
tumor cell differentiation, proliferation and metabolism. Dysfunction of mito-
chondrial-dependent processes appear to be key features of cancerous cells.
Among many such abnormal features of cancerous cells, a mitochondrial un-
coupling protein 2 (UCP2) is shown to be up-regulated in various aggressive
human cancers. Uncoupling proteins are a family of mitochondrial proteins
present in the inner mitochondrial membrane whose physiological role is to
decrease membrane potential and reactive oxygen species (ROS) production.
UCP2 over-expression recently been proposed as a novel survival mechanism
for cancer cells. However, till date, the exact role of UCP2 in cancer remains
inconclusive. We recently reported that UCP2 appears to be a key regulator of
cell proliferation, cell cycle and cell death during skin tumorigenesis. Using
JB6P

cells that overexpress UCP2, we showed that UCP2 expression correlated
closely with cell proliferation and cell transformation. Moreover, inhibition of
UCP2, decreased colony formation and 3D culture growth. Since UCP2 is the
crucial player in the regulation of reactive oxygen species, and mitochondrial
bioenergetics, we wanted to dissect out the role of UCP2 in redox regulation and
tumor promotion. Our data demonstrated that UCP2 differentially regulated
ROS. UCP2 upregulation, decreased superoxide production, whereas increased
hydrogen peroxide production with a concomitant increase in manganese su-
peroxide dismutase (MnSOD) expression and activity. Furthermore, hydrogen
peroxide was responsible for induction of lipid peroxidation and PLC-1 acti-
vation in UCP2 overexpressed cells. Moreover, PLC-1 activation enhanced
tumorigenecity. Strikingly, pharmacological and siRNA mediated inhibition of
PLC-1 markedly reduced colony formation and 3D growth in vitro. Lastly,
restricting hydrogen peroxide production with hydrogen peroxide scavenger
catalase, suppressed lipid peroxidation and dampened PLC-1 activity. Taken
together, our data suggest that hydrogen peroxide might be the mediator of
UCP2=s tumor promoting role, and pharmacological disruption of PLC-1,
and/or hydrogen peroxide may have clinical utility for UCP2-overexpressed
cancers. This research was funded by NCI and Feist-Wellier Cancer Center of
LSUHSC-S
#3562 Anovel TGF- signaling pathway promotes a slow growing pheno-
type of cancer cells in response to glutamine insuffıciency.DanHe,1 Chengq-
ian Yin,2 Shuo Qie,3 Shuyang Chen,2 Nianli Sang1. 1Drexel University, Philadel-
phia, PA; 2Boston University School of Medicine (Current affıliation), Boston,
MA; 3Medical University of South Carolina (Current affıliation), Charleston, SC.
Glutamine is a critical nutrient for proliferating cells and most tumor cells.
Glutamine addiction as one of the dramatic tumor cell adaptive metabolisms is
characterized by increased glutaminolysis. To better understand how tumor
cells respond to glutamine defıciency, we culturedHep3B cells in glutamine free
media supplemented with ammonia, and isolated survival clones (MM01).
These clones are capable of perpetual survival in glutamine free media with
ammonia, but assume a slow growing phenotype, which represents the model
adapted to long-term glutamine insuffıciency. ComparingMM01 andHep3B by
microarray-based genome-wide gene expression profıling, we identifıed func-
tional activation of Smad2/3 in MM01 cells, suggesting that long-term glu-
tamine insuffıciency activates a TGF- signaling pathway. We have validated
that glutamine insuffıciency triggers Samd2 phosphorylation, which in turn,
stimulates the expression of p15INK4B, providing a link to the slow growing
phenotype. To elucidate how glutamine insuffıciency triggers TGF- signaling,
we examined the effects of glutamine insuffıciency on the expression levels of
TGF- family ligands, and found that Inhibin-E, a newly discovered inhibin
subunit isoform in the TGF- superfamily, is up-regulated at both mRNA and
protein levels in MM01. Luciferase assays demonstrate that glutamine insuffı-
ciency enhances the activity of Inhibin-E promoter. Furthermore, we show
that overexpressing Inhibin-E is suffıcient to induce Smad2/3 activation and
growth inhibition in Hep3B cells. Taken together, our data suggest that In-
hibin-E likely plays a crucial role in cell adaptation to metabolic stress, facili-
tating cancer cell survival by slowing down biosynthesis and proliferation. A
better understanding of the novel Inhibin-E-triggered TGF- signaling path-
way may provide potential new therapeutic targets for cancer treatment.
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#3563 Potential role for a phosphoserine aminotransferase 1 andpyruvate
kinase M2 (PSAT1:PKM2) functional interaction in lung cancer cells.
Rumeysa B. Sit, Traci Kruer, James Bradley, Michael Merchant, John O. Trent,
Brian F. Clem. Univ. of Louisville, Louisville, KY.
Cellular production of serine provides precursors for numerous anabolic re-
actions, particularly for proteins and nucleic acid synthesis and for one carbon
metabolism, and this pathway has been demonstrated to be elevated in many
different cancer types. In addition, metabolites within serine synthesis can stim-
ulate other processes required for neoplastic growth, including glucose metab-
olism, specifıcally through the activation of the glycolytic enzyme pyruvate ki-
nase M2 (PKM2). However, the complete mechanism by which serine
biosynthesis facilitatesmetabolic or cellular changes necessary for tumor growth
are unclear and is further confounded by the observation that suppression of
serine biosynthetic enzymes disrupts tumorigenesis even in the presence of ex-
ogenous serine. Phosphoserine aminotransferase 1 (PSAT1), the second enzyme
in serine synthesis, catalyzes the conversion of 3-phosphohydroxypyruvate to
phosphoserine and increased expression correlates with poorer overall survival
in lung cancer patients. In order to determinewhether PSAT1may contribute to
lung cancer progression, PSAT1 expression was stably silenced in A549 and
H358 lung cancer cells. Although a modest change in cell proliferation was
observed upon PSAT1 knock-down compared to control, there was a robust
decrease in soft-agar colony formation in both cell types. PSAT1 suppression
was accompanied by distinct morphological changes and an increase in E-cad-
herin expression, suggesting a potential switch in the epithelial-mesenchymal
transition (EMT), which underlies the metastatic potential of cancer cells. Ac-
cordingly, PSAT1 suppression resulted in a decrease in cellular motility as dem-
onstrated through wound healing assays. To ascertain whether specifıc PSAT1
mediated protein:protein interactions may contribute to the pro-tumorigenic
potential of serine metabolism, we performed GST-PSAT1 pull-down assays
that revealed a potential direct association with PKM2, which was confırmed by
co-immunoprecipitation. In vitro recombinant enzyme assays found that
PSAT1 activates PKM2, but not PKM1 and, addition of serine or fructose-1,6-
bisphosphate further activated PKM2, suggesting that PSAT1-dependent stim-
ulation is distinct from other allosteric modulators. Lastly, based on in silico
modeling, site-directed mutagenesis of PKM2 identifıed amino acid residues
required for this protein interaction. Taken together, elucidating the functional
role of PSAT1-PKM2 in lung cancer cells may yield valuable information about
the relationship between serine-glucosemetabolism and EMT transition in can-
cer cells and provide an additional therapeutic target for cancer treatment.
#3564 Silencing pfkfb2 enhances paclitaxel sensitivity bymodulatingme-
tabolism of p53 wt ovarian and breast cancer cells and xenografts. Hailing
Yang, Shu Zhang, WeiqunMao, Ahmed A. Ahmed, Nicholas B. Jennings, Cris-
tian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Anil K. Sood, Xiao-Feng Le,
Zhen Lu, Robert C. Bast. UTMD Anderson Cancer Ctr., Houston, TX.
Breast cancer is the most common cause and epithelial ovarian cancer the
fourth most common cause of cancer death among women in the developed
world. While breast cancer can be cured in 70% of cases, only 30% of ovarian
cancer patients remain free from disease long term. Paclitaxel is an integral
component of primary therapy for both forms of cancer, but less than half of
breast and ovarian cancers respond to the drug. Enhancing the response to
primary therapy with paclitaxel could improve outcomes for women with both
diseases. In recent years several kinases have been identifıed that regulate the
sensitivity of cancer cells to paclitaxel by inhibiting centrosome splitting or en-
hancingmicrotubule stability.Much less attention has been given to kinases that
affect paclitaxel sensitivity bymodulating cancer cellmetabolism.Wepreviously
performed siRNA kinome-screens to identify molecular targets whose de-
creased expression overcomes paclitaxel resistance and increases paclitaxel sen-
sitivity in ovarian cancer cells. We showed that 20% of the potential kinase
targets whose knockdownmodulates paclitaxel sensitivity participate in glucose
and energy metabolism. Among these, a leading candidate was 6-phospho-
fructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2), an isoform of the gly-
colytic enzyme phosphofructokinase (PFK2). PFKFB2 is overexpressed in a
fraction of ovarian and breast cancers. Knockdown of PFKFB2 inhibited clono-
genic growth of ovarian and breast cancer cell lines and enhanced paclitaxel
sensitivity in the cell lines withwt TP53. Liposome encapsulated PFKFB2 siRNA
signifıcantly inhibited tumor growth and enhanced sensitivity to paclitaxel in
xenografts derived from ovarian cancer cell lines. Knockdown of PFKFB2 in-
creased glycolysis, decreasing the flowof glycolytic intermediates to the pentose-
phosphate pathway with reduced G6PD activity in wt TP53 cancer cell lines.
With decreased NADPH, ROS accumulated after PFKFB2 knockdown, stimu-
lating phosphorylation of JNK, inducing G1 cell cycle arrest, and initiating ap-
optosis dependent upon upregulation of p21Cip1 and Puma which are down-
stream targets of TP53. Our studies have shown for the fırst time that PFKFB2, a
glycolytic enzyme, drives tumor cell growth and regulates paclitaxel sensitivity
by inducing apoptosis and G1 cell cycle arrest. These fındings highlight a re-
markable degree of coordination between cancer metabolism with cell prolifer-
ation and chemo-sensitivity, which may provide a novel target in patients with
ovarian cancers and breast cancers where TP53 function remains intact.
BIOINFORMATICS AND SYSTEMS BIOLOGY: Sequencing
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#3565 Recurrently detected germline mutation of FLT3 (D358V) associ-
ated with prevalence of hematopoietic malignancy and prognosis of AML
patients. Seulki Song. Cancer Research Institute, Seoul, Republic of Korea.
FLT3 is most frequently mutated gene in acute myeloid leukemia patients.
While somatic mutation of FLT3 is well known, germlinemutation of FLT3 and
predispose to AML remain poorly understood. Here we identify a germline
FLT3 p.D358V affected prognosis of AMLpatients.We performedwhole exome
sequencing (WES) using 76 patients’ saliva sample to detect FLT3 germline
mutation in buccal epithelial cell and demonstrate FLT3 p.D358Vmutation for
6 patients among 76 patients. The frequency of FLT3p.D358Vmutation inAML
patients is signifıcantly higher in general population (p9.50E-07), suggesting
association of FLT3mutation with AML predisposition. Asian population espe-
cially carried this locus more than other ethic population. When we compared
between AML patients and general population of Asian, the chi-square p-value
was 0.07 and odd ratio was 2.26. Overall survival was signifıcantly reduced in
patients who had FLT3 p.D358V mutation (p0.03) and disease free survival
was show a tendency of reducing in the patients with FLT3 p.D358V mutation.
#3566 The long tail of signifıcantly mutated genes in prostate cancer.
Joshua Armenia,1 Stephanie Mullane,2 Jianjiong Gao,1 Debyani Chakravarty,1
Ritika Kundra,1 Franklin Huang,2 Celine Han,2 Dan Robinson,3 Levi A. Gar-
raway,,4 Peter Nelson,5 Mark Rubin,6 Mary-Ellen Taplin,2 Wassim Abida,1
Charles L. Sawyers,1 ArulM. Chinnaiyan,7 PhilipW. Kantoff,1 Johann S. Bono,8
Nikolaus Schultz,1 Eliezer M. Van Allen2. 1Mem. Sloan Kettering Cancer Ctr.,
New York, NY; 2Dana-Farber Cancer Institute, Boston, MA; 3Center for Trans-
lational Pathology,University ofMichigan,AnnArbor,MI; 4Dana-FarberCancer
Institute, Boston, MI; 5Fred Hutchinson Cancer Research Center, Seattle, WA;
6Weill Cornell Medical College, New York, NY; 7University of Michigan, Ann
Arbor, MI 48109, MI; 8The Institute of Cancer Research, London, United King-
dom.
Background: The mutational landscapes of primary and metastatic prostate
cancer (PCa) have been robustly analyzed in multiple whole exome sequencing
(WES) studies. We hypothesized that an aggregate, uniform analysis of all data
generated to datewould enable discovery of new signifıcantlymutated genes and
pathways not previously associated with PCa, and shed more light onto the
genetic differences between primary and metastatic PCa. Methods: We uni-
formly analyzed WES data of 1,021 tumor and matched germline primary and
metastatic PCa (686 primary, 335metastatic). We performedmutational signif-
icance analysis using statistical and biological approaches to determine recur-
rently altered genes and pathways. Results: We identifıed 117 signifıcantly mu-
tated genes (Mutsig q0.1) in PCa. These include epigeneticmodifıers [KMT2C
(6%), KMT2D (6%), and KDM6A (2.7%)] and regulators of the SWI/SNF com-
plex [SMARCA1 (1.1%), ARID1A (1.5%), ARID1B (1.3%), ARID2 (1.3%), and
PBRM1 (0.7%)]. Interestingly, genomic alterations in chromatin remodelers
(MLL, SWI/SNF) appear to be signifıcantly mutually exclusive with ETS fusions
and SPOP mutations (p0.001, Fisher’s test), indicating that these mutations
may represent a novel distinct oncogenic driver in prostate cancer. Among the
novel PCa related pathways, the splicing pathway was found to have oncogenic
mutations in key drivers such as SF3B1 (1.1%), U2AF1 (0.5%), and FUBP1
(0.4%), a novel splicing regulator involved in the regulation of MDM2 splicing.
We also found truncating mutations in SPEN, a hormone inducible transcrip-
tional repressor, in 2.8% of samples, similar to the frequency observed in breast
tumors, and these mutations appear to be signifıcantly associated with AR mu-
tations (p0.01, Fisher’s test). Our analysis also uncovered mutations in CUL3
(1.3%) and KLHL20, components of an E3-ubiquitin ligase complex that inter-
acts with SPOP to promote the degradation of critical PCa genes (AR, SRC).
KLHL20, CUL3, and SPOPmutations aremutually exclusive. Finally, a compar-
ison of primary and metastatic samples identifıed alterations that are associated
with metastatic disease, including AR amplifıcations and mutations, and loss of
TP53, PTEN, and RB1. At lower frequency, metastatic tumors showed enrich-
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ment inmutations inMLLs (KMT2C/D), APC, CDK12, BRCA2, CTNNB1, and
amplifıcations of MYC and CCND1. Conclusions: Through aggregation and
uniform genomic analysis, we refıned the map of somatic mutations in PCa and
identifıed cancer genes and pathways not previously associatedwith this disease.
Our fındings may inform patient stratifıcation and translational investigation.
#3567 Sequencing the human TCR repertoire on the Ion S5™ System.
Denise S. Topacio-Hall,1 Tim Looney,2 Yongming Sun,2 Lauren Miller,1 Eliza-
beth Linch,1 Geoffrey Lowman,1 Lifeng Lin,2 Mark Andersen,1 Fiona Hyland,2
Ann Mongan2. 1Thermo Fisher Scientifıc, Carlsbad, CA; 2Thermo Fisher Scien-
tifıc, South San Francisco, CA.
Next-generation Sequencing (NGS) is proving an important tool in increas-
ing understanding of the human immune system, and thereby cancer immunol-
ogy. -T cells are the primary constituents of human cell-mediated adaptive
immunity. The antigen specifıcity of each-T cell is encoded in the 500-600 bp
transcript encompassing the variable portion of the rearranged TCR and
TCR subunits, which can be read via NGS in a process termed repertoire
sequencing. Until now, the main challenge the fıeld faces is the lack of a tech-
nology that can provide a contiguous read of 600 bp tominimize the complexity
of designing bias-prone primers and informatics challenges of stitching short
reads. Here we leverage the long read capability of Ion 530™ chip to comprehen-
sively sequence all three CDR domains of the TCR chain. The Ion 530™ chip
offers greater than 15 M productive reads, allowing a multiplex of 2-4 samples
with suffıcient coverage for most repertoire profıling studies. Initial testing with
Leukocyte total RNA demonstrates that this multiplex PCR assay produced
repertoires that were much more similar to data derived from 5’RACE protocol
than the commonly used BIOMED2 primer set. This result suggested that the
use of long readsminimizes bias by allowing targeting of less variable regions. To
further assess the performance of the assay, we designed a model system of 30
plasmid controls containing common human T-cell CDR3 sequences. Each
plasmid was amplifıed individually and sequenced to confırm the detection of a
single clonal population. Analytical sensitivity of the assay and accuracy of the
accompanied analysis solution were further evaluated by spiking in plasmid
concentrations from 10 pg to 0.0001 pg (5 million to 50 copies) in a background
of 100 ng cDNA reverse transcribed from leukocyte total RNA. Results showed
the assay offers linearity over 5 orders ofmagnitude of decreasing input concen-
tration. In summary,wehave demonstrated aNGSworkflow forTCR sequenc-
ing that offers multiplex flexibility on Ion S5 with sample to answer in less than
48 hours. For Research Use Only. Not for use in diagnostic procedures.
#3568 Variant analysis of LY6 genes in TCGA ovarian cancer. Krithika
Bhuvaneshwar, Midrar Al Hossiny, Yuriy Gusev, SubhaMadhavan, Geeta Upa-
dhyay. Georgetown University, Washington, DC.
Background Human Ly6 gene family has been associated with stem cell
marker Sca-1 in murine cancer. Sca-1 is known to regulate TGF-b signaling,
Wnt signaling & it is important in cancer progression and metastasis in mouse
models. Human Ly6 genes are associated with poor clinical outcome in human
cancers. Previous studies have shown that this family of genes is highly expressed
inOvarian&Breast cancer compared to normal tissues. Overexpression of these
genes was found to be correlated with poor outcome in overall and metastasis
free survival. Recent studies have also shown that human Ly6 genes are associ-
ated with tumor immune escape& drug resistance. In this poster, we explore the
variants in Ly6 and related genes in the TCGA Ovarian Cancer (OV) data col-
lection. Materials and Methods We fırst downloaded RNA-seq data of primary
tumor tissues from 21 TCGA OV patients from CGHUB (https://cghub.uc-
sc.edu/), and after quality control, aligned to human reference genome using
tool RSEMon theGlobusGenomics platform. TheBAMfılewas sorted andPCR
duplicates were removed. Variant calling was done on BAM fıles based on Ge-
nomeAnalysis Toolkit (GATK)’s best practices, to obtain amulti sample variant
call fıle (VCF). After getting the multi sample VCF fıle, we used SnpEff and
Annovar software to annotate and predict the functional effects of variants on
genes. SnpSift toolboxwas used to fılter out variants by extracting only variant of
Ly6 genes (and other genes of interest) that passed the quality check, and cate-
gorized the output into 4 different groups according to the impact (High, Mod-
erate, Modifıer, Low). To see if these variants were germline or somatic, DNA-
seq from a second set of 22 TCGA Ovarian cancer samples (tumor tissue and
normal blood samples) were used. BAM fıles were downloaded and variants
were called using the SevenBridges system. The same fıltering stepswere applied
as above. Results In Set 1, we found variants inCD59, LY6E and LYPD6mutated
in all the 21 cases. We found two stop-loss mutations in CD59 gene, which is
responsible for regulating the immune response, tumor cell growth and apopto-
sis. We found a total of 3794 unique variants short-listed in Set 1, and a total of
8879 unique variants short-listed in Set 2. It was expected to see more variants
from the DNA-seq data compared to the RNA-seq data. Among these, 103
unique variants were common to both Set 1 and Set 2. Variants in ESR1, CD44
andLYPD6 familyweremutated inmost samples in both Set 1 and Set 2.We also
performed survival analysis on variants present in RNA but not in DNA, and
found variants in LY6E, PINLYP, LYPD5, ZNF283 signifıcant w.r.t overall sur-
vival. Conclusion We found a total of 3794 unique variants (from short-listed
set) in Set 1 (TCGAOVRNAseq data), and a total of 8879 unique variants (from
short-listed set) in Set 2 (TCGA OV DNAseq). There were total of 103 unique
variants common to Set 1 and Set 2. We see evidence of LY6 variants in non-
coding regions of RNA (not in DNA) to be signifıcantly associated with overall
survival.
#3569 Comparative RNA-seq analysis reveals dys-regulation of major ca-
nonical pathways in ERG-inducible LNCaP cell progression model of pros-
tate cancer. Parameet Kumar,1 Joyeeta Chakraborty,2 Raghunath Chatterjee,2
Gauthaman Sukumar,1 Clifton L. Dalgard,1 Kevin Babcock,1 Albert Dobi,1 Ta-
duru L. Sreenath,1 Roopa Biswas1. 1Uniformed Services University of the Health
Sciences, Bethesda, MD; 2Indian Statistical Institute, Kolkata, India.
Prostate Cancer (CaP) is the most common non-cutaneous form of cancer in
men and is the second leading cause of cancer mortality in men in the USA. In
human CaP, gene fusion between androgen responsive regulatory elements at
the 5’ untranslated region of TMPRSS2 and ETS-related genes (ERG) is present
in at least 50% of the prostate tumors. To identify and investigate the underlying
mechanisms of ERG-associated CaP, we developed ERG-inducible LNCaP cell
system. In this present study, we investigated the unique cellular transcriptome
associated with over-expressed ERG in CaP cells. Our data from comprehensive
transcriptome analyses, illustrate a distinct signature that distinguishes ERG-
dependent and ERG-independent CaP. The data highlight the signifıcant heter-
ogeneity among the transcript. Out of the 527 differentially expressed genes, 232
genes were up-regulated and 295 genes were down-regulated in response to
ERG. Subsequent, in silico analyses indicate that these differentially expressed
geneswere associatedwithmanypathways and functions. Themost signifıcantly
differentially expressed genes were associated with cell cycle regulation. The
top-ranked biological functions affected by ERG over-expression include Cell
Cycle (p 1.42E-04), Cellular Growth and Proliferation (p 1.23E-04), Cellu-
lar Development (p 1.23E-04), Cell Death and Survival (p  1.37E-04), and
Cellular Assembly andOrganization (p 1.42E-04). Further analyses indicate a
strong association with known cancer networks. The top-ranked canonical
pathways enriched in ERG-positive compared to ERG-negative LNCaP cells
include, Cell Cycle Control of Chromosomal Replication (p2.69E-16), Role of
CHK Proteins in Cell Cycle Checkpoint Control (p3.16E-11), Cell Cycle:
G2/M DNA Damage Checkpoint Regulation (p1.34E-09), Role of BRCA1 in
DNADamageResponse (p4.05E-08) andEstrogen-mediated S-phase Entry (p
5.51E-08). These fındings indicate new insights into the complexity of TM-
PRESS2-ERG gene fusion, and may help understand mechanistic pathways
which promote growth and progression of CaP.
#3570 Germline structural variant detectionwith variation graphs.Eric T.
Dawson,1 Erik Garrison,2 Adam Novak,3 Benedict Paten,3 Jordan Eizinga,3
Glenn Hickey,3 Stephen Chanock,1 Richard Durbin2. 1National Cancer Insti-
tute, Rockville, MD; 2Wellcome Trust Sanger Institute, Hinxton, United King-
dom; 3University of California Santa Cruz, Santa Cruz, CA.
Structural variants play a major role in many cancers. However, classical
methods of detection rely on searching for mapping signatures and a perpetual
“rediscovering” of variants relative to the reference. A more effıcient technique
would be tomap directly against known variants.We present a novelmethod for
detecting known structural variants in next-generation sequencing data using
variation graphs. Variation graphs are reference-like structures that succinctly
encode the variation present within a population. Existing tools enable reads to
be effıciently mapped against this graph structure. We are able to speed up
queries for the presence or absence of variants by reducing the operation to a
simple lookup in an external index. The current implementation of our variation
graph approach is open source and publically available as part of the variation
graph toolkit (https://github.com/vgteam/vg). Our method of variant typing on
variation graphs has great potential tomodel and assess the complexity of cancer
genomes while remaining effıcient enough to make analysis tractable.
#3571 Precise somatic mutation prediction in the absence of matching
normal DNA. Irina Kalatskaya, Quang Trinh, Melanie Spears, John Bartlett,
Lincoln Stein.Ontario Instittute for Cancer Research, Toronto, Ontario, Canada.
Accurate identifıcation of somaticmutations is an essential fırst step formany
cancer studies. It is usually done by comparing the genome of the tumour to the
reference genome sequence derived from a normal tissue taken from the same
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donor. However, there are a number of possible scenarios in which matched
normal tissues might be not available for comparisons. It is most commonly
encountered when performing analysis on retrospective studies with human
tissues from clinical trials or pathology archives when normal samples were not
collected in the fırst place or patient consent precludes examination of normal
tissue or germline variants. Another common scenario is the use of a cancer cell
line as an experimental model, many of which have no information on the
donor’s normal genome. In this work, we describe an algorithm to identify
somatic single nucleotide variants (SNVs) in Next Generation Sequencing
(NGS) data in the absence of normal samples using a machine learning ap-
proach. Our algorithm was evaluated using a family of supervised learning clas-
sifıcations across six different cancer types and 1,600 samples, including cell
lines, fresh frozen tissues, and formalin-fıxed paraffın-embedded (FFPE) tissues.
In addition, our algorithm was tested with both deep targeted sequencing and
whole exome sequencing strategies. The algorithm correctly classifıed between
95% and 98% of somatic mutations with F1-measure ranges from 75.9% to
98.6% depending on the tumour type. We have released the algorithm as a
software package called ISOWN (Identifıcation of SOmatic mutations Without
matching Normal tissues), which is available as Open Source under Apache
License 2.0 from https://github.com/ikalatskaya/ISOWN.
#3572 Characterizationof chromosomal allelic imbalances throughRNA-
seq. Francis A. San Lucas,1 Yihua Liu,1 Zachary Weber,2 Erik Ehli,2 Gareth
Davies,2 Paul Scheet1. 1MDAnderson Cancer Center, Houston, TX; 2Avera Insti-
tute for Human Genetics, Houston, SD.
Transcriptome sequencing (mRNA-seq) is becoming a very versatile tech-
nique for profıling tumors, extending beyond its original intent of transcript
quantifıcation, identifıcation of alternative transcripts, and detection of gene
fusions. For instance, through recent advancements in RNA-seq data analyses,
one can now computationally assess allele-specifıc gene expression and generate
profıles of expressed somatic mutations. Here, we demonstrate the ability to
identify chromosomal allelic imbalances (AI) through detection of haplotype-
specifıc patterns in gene transcripts. This class of RNA-based observations may
potentially reveal DNA-level chromosomal allelic imbalances or uncover large
regions of transcription deregulation. From the TCGAUterine Carcinosarcoma
project, we downloaded exome and RNA sequencing data for 48 patients’ tu-
mor/normal sample pairs in addition to their clinical annotations. We also
downloadedAffymetrix SNP6-basedDNAcopy number event callsmade by the
TCGA for use as a gold standard when evaluating the AI calls in the exome and
RNA-seq.AI calls weremade in both the exome andRNA-seq data by: (1) calling
1000 Genomes genotypes in the sequencing data, (2) phasing haplotypes and
then (3) characterizing haplotype imbalances using a tool that we developed
called hapLOHseq. hapLOHseq applied to the exome and RNA-seq data both
resulted in a 72% specifıcity for identifying the gold standard AI events. In
RNA-seq data we detected 43% of the chromosomal AI events identifıed in the
exome sequencing data.When considering AI events specifıcally detected in the
RNA-seq and not the gold standard (RNA-specifıc AI), the data suggest that
higher RNA-specifıc AI loads could be negatively associated with survival (p-
val  0.076), with higher RNA-specifıc AI load patients having a median sur-
vival of 771 days compared to 1526 days for those patients with lower loads of
RNA-specifıc AI. In conclusion, our results suggest that analysis of chromo-
somal AI in RNA-seq has equal specifıcity for detecting DNA-level AI when
compared to exome sequencing, although at lower sensitivities. Clinically, our
analyses suggest that patients with higher RNA-specifıc AI load may have a
worse overall survival prognosis. The AI we are identifying in the RNA-seq
samples may reflect large-scale transcription defects, resulting in a negative im-
pact on the survival of patients. One possible cause of RNA-specifıc allelic im-
balance could be the presence of cis mutations that impact a large-region of the
transcription of one of the two haplotypes. Currently, we are identifying areas
for improvement in our analytical methods, while interrogating and character-
izing exome and RNA-seq AI in additional data sets.
#3573 VariED: an integrated database of variants and gene expression
profıles for genetic diseases. Li Mei Chiang,1 Chien Yueh Lee,1 Liang Chuan
Lai,2 Mong Hsun Tsai,3 Tzu Pin Lu,4 Eric Y. Chuang1. 1Graduate Institute of
Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei,
Taiwan; 2Graduate Institute of Physiology, National Taiwan University, Taipei,
Taiwan; 3Institute of Biotechnology, National Taiwan University, Taipei, Tai-
wan; 4Department of Public Health, Institute of Epidemiology and Preventive
Medicine, National Taiwan University, Taipei, Taiwan.
It is now widely believed that low-frequency variants may play an important
role in cancers. In addition, low-frequency variants are usually closely related to
populations. To identify the disease-associated variants, several projects are now
underway to build a reference of genetic variations from different populations.
Furthermore, massive tools and databases are available to compare the dynamic
gene expression among different organs and predict functional effects of genetic
variants. These resources aid to identify genetic roots of cancers in populations
easier. Despite the existence of population allele frequency information, gene
expression databases and functional effects of protein mutations, a comprehen-
sive platform providing an integrated annotation database in human genetic
variants, is still lacking. In the study, we proposed a web-based database to
determine potential variations in cancers with collected variant information
from current common databases and integrated those data to provide compre-
hensive analyses. The web-site offers a function to upload a variant call format
(VCF) fıles for variants annotation. Importantly, we integrated population allele
frequency information from NHBI GO Exome Sequencing Project (ESP), 1000
Genomes Project and Tohoku Medical Megabank Project to help users fıgure
out the correlation between disease and population. Additionally, we also col-
lected gene expression profıles fromTheHumanProteinAtlas, ExpressionAtlas
and NCBI SRA in different organs of human, mouse, and zebrafısh respectively
to reflect the relationship between gene expression and genetic variations in a
specifıc organ. Overall, the database aids to predict protein functions in muta-
tions, analyze population allele frequency and gene expression information
fromprovided variants of diseases. In the result, we use three EGFRmutations to
display the proposed system. A recent study has reported that Asian patients
with non-small cell lung cancer (NSCLC) carrying a higher rate of EGFRmuta-
tions than non-Asian patients. These mutations, such as chr7:55241708GC
(G719A), chr7:55249005GT (S768I) and chr7:55259515TG (L858R), are
found approximately in 30% of Asian (Japanese) patients. In functional predic-
tion results, these sites are exonic and nonsynonymous mutations. The REVEL
scores of three EGFR mutations are 0.824, 0.765 and 0.961, and gerp scores
are 5.5, 5.85 and 5.71, respectively. Both REVEL and gerp show high scores
for severe damage of protein structure in themutations.According to the results,
researchers can infer that the three mutations are pathogenic variants implying
the nucleotide positions with a higher constraint.
#3574 A survey of mutations in biomedical literature using a machine
based approach. Takahiko Koyama, Kahn Rhrissorrakrai, Laxmi Parida. IBM
Research, Yorktown Heights, NY.
Introduction: Being able to characterizemutations for both pathogenicity and
drug response is indispensable to the analysis of tumor genomics and the devel-
opment of therapeutic options. While a great deal of data has been deposited in
various structured, genomic databases, a large portion of insights are primarily
and often times solely found in biomedical literature.Medline contains about 26
million literature citations; a number that is unrealistic for a human to read.
Thus machine based approaches are needed to comprehensively capture the
landscape of reported mutations. Method: An automated pattern matching
method is utilized to extract mutations from Medline abstracts as presented in
HumanGenomeVariation Society (HGVS) format andRefSNPs (rs) number. A
typical HGVS proteinmutation is described as [reference amino acid][position]
[new amino acid], as in p.His1047Arg,His1047Arg, or simplyH1047R inHGVS
format. This method identifıes and consolidates all mentioned protein muta-
tions and their alternate formulations. Result: Over 300,000 unique abstract-
mutation pairs were identifıed including 90,000 unique mutations. Well known
cancer mutations such as BRAF V600E, JAK2 V617F and EGFR L858R are
among the most frequent appearing in oncology literature. At the other end,
51,000 mutations are mentioned in just a single abstract, 16,000 mutations in
two abstracts, 7,600 in three abstracts, and so forth. Conclusion: The number of
mutations appearing in Medline abstracts represents just a small portion of the
2 million unique coding mutations contained in the COSMIC database. While
we expect the actual coverage of mutations by literature to be more comprehen-
sive if this approach is extended to the full text body, the number would likely
remain small compared with the total reported COSMICmutations. One of the
great challenges in oncology is characterizing variants of unknown signifıcance
(VUS), and by fırst extracting all reported mutations, even those mentioned in
only one article, and their specifıc biological context, we can begin to identify
broader patterns inmutations’ pathogenicity and their impact on drug response.
#3575 Frequency of imaging fındings suspicious for and suggestive of
cancer between three different hospitalswithin a single health system.Lauren
F. Comisar, Hanna M. Zafar, Darco Lalevic, Christopher Pizzurro, Charles E.
Kahn,Mitchell Schnall, Tessa S. Cook.University of Pennsylvania, Philadelphia,
PA.
Outpatient imaging rates have risen over the past two decades. Imaging fınd-
ings representing possible cancer are commonly detected on these exams and
require follow-up. Our health system utilizes a standardized coding scheme,
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similar to the breast imaging and reporting data system (BI-RADS), to classify
the malignant potential of masses on all abdominal and pelvic imaging exams;
two of these categories are suspicious (for masses that clearly represent malig-
nancy) and suggestive (for masses that may represent malignancy). These codes
are used at three hospitals in a single health system: a university hospital, a
community hospital, and a Level 1 trauma center. Our objective was to evaluate
the frequency of imaging fındings suspicious for or suggestive of malignancy in
the liver, kidneys, pancreas, and adrenals between outpatients and inpatients at
these three hospitals. Over 1600 suspicious and suggestive masses were discov-
ered in one year: 843 in the liver, 499 in the kidneys, 152 in the pancreas, and 137
in the adrenal glands.Masses suspicious for cancer were unevenly distributed by
patient location. In the liver and kidneys, suspiciousmasses weremore common
in outpatients at all three hospitals; in the pancreas and adrenal glands, suspi-
cious masses were more common in inpatients. Suspicious masses were un-
evenly distributed bymodality. The proportion ofMRI examswhere at least one
organ was coded as suspicious was higher than the proportion of CT exams.
Masses suspicious for cancer were unevenly distributed across the three hospi-
tals. Liver masses suspicious for cancer were twice as likely to be discovered at
the university hospital compared to the community hospital and the Level 1
trauma center (present in 2% vs. 0.7% vs. 0.6% of all livers evaluated, respec-
tively). Adrenal masses suspicious for cancer were also more commonly de-
tected at the university hospital (present in 0.3% vs. 0.1% vs. 0.1% of adrenal
glands evaluated, respectively). A similar trend was observed for renal and pan-
creatic lesions. Masses coded as suggestive of malignancy (rather than clearly
suspicious for malignancy) were more frequently detected at the university hos-
pital. This was particularly evident in adrenal lesions where 0.3% of adrenal
glands evaluated at the university hospital were suggestive of malignancy com-
pared to 0.06% at the community hospital and 0.03% at the Level 1 trauma
center. A similar trend was observed for pancreatic lesions. In conclusion, this
novel database of standardized codes for abdominalmasses provides insight into
howmasses suspicious for and suggestive of cancer are coded variably by organ,
patient location, andmodality between three different hospitals within the same
urban academic health system. Further investigation will be needed to deter-
mine the influence of patient case mix, referral patterns, and radiologist charac-
teristics that contribute to these observed differences.
#3576 Accurate identifıcation of somatic mutations in cancer patient
specimens in the lack of normal tissue by targeted high-throughput sequenc-
ing. Francisco M. De La Vega,1 Sean Irvine,2 DavidWare,3 Kurt Gaastra,3 Yan-
nick Pouiliot,4 Len Trigg3. 1Stanford University, Stanford, CA; 2Real Time
Genomics, Inc., Hamilton, New Zealand; 3Real Time Genomics, Hamilton, New
Zealand; 4TOMA Biosciences, Foster City, CA.
Tumor molecular profıling is rapidly becoming the standard clinical test for
selecting targeted therapies in refractory cancer patients. DNA extracted from
patient samples is enriched for cancer genes and sequenced to identify action-
able somatic mutations therein. A major challenge arises when tumor-derived
data is analyzed in the absence of normal tissue data, as it is common in clinical
scenarios. The distinction between somatic and germline variants become diffı-
cult, leaving clinicians to resort to crude heuristic fıltering. We present here a
variant calling software, developed under quality system regulation protocols,
capable of accurately identifying somatic mutations from targeted next-genera-
tion sequencing data. A novel Bayesian Network approach models the distribu-
tion of reads harboring germline and somatic mutations, estimates the contam-
ination from normal tissue in the sample, scores somatic mutations, and
imputes germline variants, withoutmatching normal tissue data. This approach
also allows joint analysis ofmultiple specimens from the same patient (e.g. FFPE
and ctDNA), when available, improving the limit of detection. To improve spec-
ifıcity, our caller can also utilize prior information from different databases
including somatic mutations, germline variation, and healthy controls data, in a
principled fashion.We validated ourmethod by analyzing data from the TOMA
OS-Seq 131 cancer gene panel using the Illumina platform. Sample inputs
ranging from 2-600ng of DNAwere sequenced to a depth of1000X, achiev-
ing on target rates 73% and uniformity  3.2 fold 80 penalty. Through
adaptors with molecular barcodes we measured a median duplicate rate2.
We analyzed somatic mutations simulated at various variant allele fractions
on a background of data from reference samples from the Genome-in-a-
Bottle consortium, data on a dilution series from two reference samples, and
several commercial control and clinical samples, including matched FFPE,
PBMC, and ctDNA specimens. In the absence of normal tissue, our method
scores each variant with respect to their likelihood of being somatic or germ-
line. We show that, as compared to other commonly used methods, our
algorithm can achieve a higher true positive rate whilst controlling a false
discovery rate of 1%. We also show that jointly analyzing serial samples (e.g.
ctDNA), we can improve sensitivity of shared variants. In conclusion, in
contrast to currently used academic software developed for research proj-
ects, we observe that our caller outperforms these software and is particularly
well suited for the clinical use cases.
#3577 Splice expression variation analysis (SEVA) for differential gene
isoform usage in cancer. Bahman Afsari,1 Theresa Guo,1 Michael Considine,1
Dylan Kelley,1 Emily Flam,1 Liliana Florea,1 Patrick Ha,2 Donald Geman,1 Mi-
chael F. Ochs,3 Joseph A. Califano,4 Daria A. Gaykalova,1 Alexander V. Favo-
rov,1 Elana J. Fertig1. 1Johns Hopkins University, Baltimore, MD; 2University of
California, San Francisco, CA; 3The College of New Jersey, Ewing, NJ; 4University
of California, San Diego, CA.
Alternative splicing events (ASE) are a signifıcant component of expression
alterations in cancer, and have been demonstrated to be critically important in
the development of malignant phenotypes in a variety of tumors. These alterna-
tive gene isoforms alter cell-signaling networks and serve as a hidden source of
tumor-driving alterations not identifıed inmulti-omics analyses. Recent studies
have demonstrated that reads from RNA-seq data can infer gene isoforms ex-
pressed in a single sample. Therefore, RNA-seq data of tumors offers the oppor-
tunity to systematically evaluate expressed gene isoforms and identify splicing
events in cancer samples. To characterize a cancer specifıc ASEs landscape, it is
essential to perform differential splice variant expression analysis to identify
isoformvariants that are unique to tumor samples compared to normal tissue. In
spite of the breadth of ASE algorithms, few have been validated in primary
tumor samples. Currentmethods for differential splice variant analysis compare
mean expression of gene isoforms in sample groups. Because these variants are
tumor-specifıc, ASEs are expected to have more variable exon junction expres-
sion than normal samples. Therefore, current differential ASE analysis algo-
rithms fromRNA-seqmay not account for heterogeneous gene isoformusage in
tumors. To address this, we introduce Splice Expression Variability Analysis
(SEVA) to detect differential splice variation usage in tumor and normal sam-
ples and accounts for tumor heterogeneity. This algorithm compares the degree
of variability of junction expression profıles within a population of normal sam-
ples relative to that in tumor samples. The performance of SEVAwas compared
with two existing algorithms, EBSeq and DiffSplice, in simulated and real RNA-
seq data. Simulated data suggest that SEVA is robust and computationally effı-
cient relative to EBSeq andDiffSplice. In contrast to EBSeq andDiffSplice, SEVA
was able to identify alternative splicing events independent of overall gene ex-
pression differences. Finally, additional validation was performed using RNA-
seq data for primary tumor data from HPV-positive oropharynx squamous cell
carcinoma (OPSCC) tumors and normal samples from both TCGA and an in-
dependent tumor cohort of 46 OPSCC tumors and 25 normal samples. In these
tumor samples, SEVA fınds cancer-specifıc ASEs in genes that are independent
of their differential expression status. Moreover, SEVA fınds approximately
hundreds of splice variant candidates, manageable for experimental validation
in contrast to the thousands of candidates foundwith EBSeq orDiffSplice. These
candidates include experimentally validated splice variants in HNSCC from a
previous microarray study. Based on performance in both simulated and real
data, SEVA represents a robust algorithm that is well suited for differential ASE
analysis, particularly in RNA-sequencing data from heterogeneous primary tu-
mor samples.
#3578 Methyl2Acetyl: predicting epigenetic and transcriptomic activity
from DNA methylation. Xiang Chen. St Jude Children’s Research Hospital,
Memphis, TN.
DNAmethylation and histonemodifıcations are interconnected and interde-
pendent epigenetic mechanisms that regulate chromatin accessibility in cells.
They establish cell’s developmental identity and modulate individual response
to endogenous developmental stimuli and environmental changes. Chromatin
immunoprecipitation followed by sequencing (ChIP-seq) is a popular assay to
study genomewide histone modifıcation profıles. However, ChIP-seq assays re-
quire relatively large amounts of starting materials (ranging from 105 cells
using a low cell number protocol to 107 cells in a standard protocol), which
remains as a major obstacle for precious biological samples including primary
tumor specimens. On the other hand, tagmentation-based whole genome bisul-
fıte sequencing (TWGBS) protocol enables unbiased assessment of the genome-
wide methylation pattern using3,000 cells. Therefore, a quantitative relation-
ship between DNA methylation and epigenetic/transcriptomic activity is in
great demand. In the current study, we developed Methyl2Acetyl, a machine
learning framework to infer promoter epigenetic activities (e.g. H3K27Ac en-
richment) using TWGBS data as input. The proposed model utilizes random
forest learners, which allow automatic extraction of complex interactions
among DNAmethylation features surrounding transcription start sites. We ap-
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plied Methyl2Acetyl to a set of pediatric solid tumor samples with high quality
H3K27Ac ChIPseq data to evaluate its performance. The model accurately pre-
dicted promoter H3K27Ac enrichment in independent test samples (Pearson
correlation against measured enrichment: 0.81 	 0.02). To further test the ro-
bustness of our model, we trained a Methyl2Acetyl model on solid tumors and
applied it to a set of 10 pediatric leukemia samples. Despite dramatic global
methylome differences between solid tumors and leukemia,Methyl2Acetyl pre-
dicted promoter H3K27Ac enrichment showed strong concordance with target
gene expression level in the same sample (Pearson correlation: 0.75 	 0.02,
classifıcation AUC: 0.89 	 0.01). Collectively, our data suggested that DNA
methylation is predictive of promoter active histone modifıcation enrichment
and gene expression activity. Epigenetically active promoters can be imputed
from TWGBS data in samples with limiting starting materials.
#3579 A novel algorithm to identify TCR-binding somatic mutations
from human cancers. Priyanka Shah, Kiran V. Paul, Malini Manoharan, Am-
itabha Chaudhuri, Ravi Gupta.MedGenome Inc., Foster City, CA.
A large number of pre-clinical and clinical studies have strongly implicated
that combining cancer-derived neo-antigen vaccines with checkpoint control
inhibitors will enhance priming and expansion of tumor-specifıc naïve and
memory T-cells resulting in superior effıcacy and durability of response. The
neo-antigens, derived from somatic mutations are prime candidates for cancer
vaccines, not subjected to host’s central and peripheral tolerance. Identifying
potential T-cell engaging neo-epitopes among a large number of somatic muta-
tions is like fınding a specifıc needle in a stack of needles. Currently, the available
T-cell neo-epitope prioritization pipelines rely primarily on two attributes - the
class-I HLA-binding affınity of the mutant peptide compared to the wild-type
counterpart, and the level of expression of the mutated gene in tumor cells. The
higher the binding differential, and higher the expression level of the mutant
allele, the greater is the likelihood for the peptide to be presented on antigen-
presenting cells. These approaches however fall short of predicting whether the
HLA-bound peptide will engage T-cells by binding to T-cell receptors (TCRs).
We have developed a novel algorithm to predict the binding of HLA-peptide
complexes to TCRs by analyzing the physico-chemical composition of the
amino acids and their positional biases in the 9-mers from crystal structures of
HLA-peptide-TCR complex. We applied machine learning approach to build a
classifıcation model that can predict whether a given 9-mer peptide is a TCR-
binder or not by identifying whether an amino acid at a given position carries
key features that will facilitate interaction with the TCR. We applied this ap-
proach to positive and negative TCR interactions selected from Immune
Epitope data base (IEDB). We tested multiple classifıcation approaches and
found that Random Forest and ClassifıcationviaRegression methods provided
the best performance. We achieved more than 99% accuracy at 10-fold cross
validation on both training and unseen test datasets. We further validated our
model using positive and negative peptides curated from published papers re-
porting clinical trial results of checkpoint control inhibitors. The performance of
the two classifıcationmodelswas evaluated on twodifferent TCR-binding assays
- dextramer binding and IFN- release. TheClassifıcationviaRegressionmethod
showed a higher positive predictive value for the dextramer-binding assay,
whereas the Random Forest method showed a higher positive predictive value
for the IFN- ELISPOT assay, suggesting subtle differences between the two
classifıcation methods. The inclusion of the TCR binding step to our T-cell
neo-epitope prioritization pipeline increased accuracy of prediction, reduced
false positives and selected potential neo-epitopes to a manageable number for
testing in cell-based assays.
#3580 GATKCNV: copy-number variation discovery from coverage data.
Mehrtash Babadi, David I. Benjamin, Samuel K. Lee, Andrey Smirnov, Aaron
Chevalier, Lee Lichtenstein, Valentin Ruano Rubio. Broad Institute of MIT and
Harvard, Cambridge, MA.
We propose and evaluate a novel algorithm for inferring germline and so-
matic copy number variation from whole exome sequencing (WES) and whole
genome sequencing (WGS) data. Starting with the depth of aligned short reads
from a cohort of samples, we use a Bayesian model for learning sequencing bias
and simultaneously detecting CNV events using a hidden Markov model for
change-point detection. A unifıed framework is used to call both germline and
somatic CNVs. Denoising and event discovery are performed self-consistently
to achieve maximum accuracy. In contrast to previous methods, our model
naturally accounts for mixed sex cohorts and can detect events on sex chromo-
somes. Furthermore, we can detect excessively noisy samples and extract useful
information within a probabilistic framework. Our implementation can also
utilize Spark clusters, enabling the processing of larger cohorts and allowing for
improved runtime performance. We benchmark the newmethod for precision,
recall, and reproducibility of both germline and somatic variants. Evaluations
are performed on a cohort ofWES samples fromTheCancerGenomeAtlas with
matching WGS data. For germline variants, we use blood normal samples and
compare our calls on WES data against Genome STRiP calls on WGS data. We
fınd thatGATKCNVyields remarkably higher precision and recall compared to
XHMM and CODEX software packages. For somatic variants, we compare our
calls against TITAN and fınd a remarkably high concordance.
#3581 GATK ACNV: allelic copy-number variation discovery from SNPs
and coverage data.AaronChevalier, Lee Lichtenstein,Andrey Smirnov, Samuel
K. Lee, Mehrtash Babidi, David I. Benjamin, Valentin Ruano-Rubio. Broad In-
stitute, CAMBRIDGE, MA.
The presence of somatic copy-number alterations in tumor genomes can be
used to predict both patient sensitivity to treatments as well as outcomes. The
inclusion of allelic data improves statistical power to detect copy-number events
and allows for discovery of copy-neutral events. We present GATK ACNV, an
allelic copy-number variation method built on the Genome Analysis Toolkit.
ACNV is a tool for detecting somatic copy-number activity from whole exome
and whole genome sequencing data by segmenting the genome into regions of
constant copy number and estimating copy ratio and minor-allele fraction in
those regions. ACNV uses a novel probabilistic model to account for reference
bias (optionally using a panel of normals), which improves the estimation of
minor-allele fraction. We combine this with the coverage model from GATK
CNV by segmenting with a unifıed hiddenMarkovmodel, improving the statis-
tical power to detect copy-number variation. We validate ACNV using a purity
series of the cell line HCC1143 and cancer samples from The Cancer Genome
Atlas. Our results show that ACNV is able to discover regions of somatic copy-
number activity accurately and with high resolution in both whole exome and
whole genome sequencing data.
#3582 Copy number estimation from targeted and shallow sequencing in
cancer samples. Andrea J. OHara, Zhiwei Che, Soheil Shams. BioDiscovery, El
Segundo, CA.
Next-generation sequencing (NGS) is mainly used to obtain sequence vari-
ants (SNVs). However, obtaining copy number results from NGS has gained
momentum in both research and clinical applications. Targeted panel sequenc-
ing has been a popular method to achieve high depth of coverage for certain
regions of interest at an affordable cost compared to whole genome sequencing.
Shallow whole genome sequencing, where average read-depth can be as low as
0.1x, provides a cost savings-approach for identifıcation of large copy number
variant (CNV) events; it has been utilized in various application areas, including
oncology. Here we introduce the BAM (MultiScale Reference) algorithm, cur-
rently inNexusCopyNumber, to functionwith shallow and targeted sequencing
data, as well as WGS and WES, using a novel dynamic binning approach. This
approach uses a HiddenMarkovModel to segment the genome into target areas
using the reads in targeted regions and the backbone areas using the off-target
reads and additional areas. It uses coarse binning in the backbone areas that
provides copy number base line aswell as large copy number events anduses fıne
binning in target areas to provide high resolution copy number detection in
targeted regions. ShallowWGSdata and targeted panelNGSdata, aswell asWES
with normal depth of coverage, were used for the testing. The results were com-
paredwith those frommicroarray and/or other algorithms inNexusCopyNum-
ber, BAM ngCGH (matched) and BAM (pooled reference). GC correction
schemes based on a range of window size and presence or absence of GC probe
content were applied to the data and assessed for overall quality. Differences in
overall read-depth resulted in variable sample quality across the cohorts, how-
evermost sample qualitywas adequate for copy number estimation and a quality
threshold was assessed. Among the samples tested, the best quality after GC
correction comes from the 50kb region sizewith orwithout the probes. Next, the
copy number profıles of the samples fromWES andmicroarray were compared
for accuracy. Using microarray results as a reference for assessing calls greater
than 5MB, no false positive and one false negative call were observed; the single
false negative call was attributable to low-level mosaicism in the tumor sample.
Results indicate that relative copy number can be estimated and is comparable to
the results achieved withmicroarray for the same targeted regions. This analysis
series was then repeated using a secondary cohort of unrelated samples sub-
jected tomicroarray and targeted panel NGS to validate results. The BAM (Mul-
tiScale Reference) method has been tested in a variety of cancer samples. This is
an ideal tool for copy number estimation with NGS results in cancer samples
because it provides a way for non-matched-pair analysis with genome, exome
and targeted NGS.
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#3583 Computational analysis of mutations on neural signaling factors
existing in childhood cancer. Claudia Machicado. Universidad Peruana Cay-
etano Heredia, Lima, Peru.
The role of the nervous system in adult tumor progression has been hypoth-
esized. In contrast, the involvement of nervous system in childhood cancer is still
unknown but it results of particular interest. The main objective of this study is
to identify whether mutations in neuron signaling proteins are present in pedi-
atric cancer. Additionally this study foresees to determine the effect of mutation
on the protein structure and function and to elucidate if differences between
solid and hematopoietic pediatric tumors exist in terms of neural signaling. The
genomic data of pediatric cancers available in the Pediatric Cancer Data Portal
(PeCan) were mined looking for point mutations in the genes of interest. The
analysis comprised a set ofwell recognized neuron signaling factors including 50
neurotrophic growth factors, 23 axon guidance molecules and 47 neurotrans-
mitter receptors. Missense mutations were retrieved per gene and tumor type.
The effect of each mutation on the protein function was predicted through
BioMuta, a well curated and annotated database. Our results showed the exis-
tence of genetic mutations in neuron signals across 16 childhood tumor types.
Neuroblastoma (NBL) was the most mutated solid tumor with a total of 26
mutated genes out of 120 study genes. B-cell Acute Lymphoblastic Leukemia
(BALL) was the most frequently mutated hematopoietic malignancy resulting
with 17mutated genes out of 120 study genes. EGFRwas themostmutated gene
within the group of neurotrophic molecules, with 14 missense mutations across
6 different tumor types. A total of 8 out of 14 mutations reported in EGFR were
classifıed as damaging mutated phenotype and these were present in NBL, gli-
oma, BALL and Acute Myeloid Leukemia (AML). EPHA3, ROBO3, RBP1, and
PLXNB1 were the most frequently mutated genes within the group of axon
guidance molecules, with 3 missense mutations each one across 7 tumor types,
most of them categorized as damaging mutations. GRIN2B was the most fre-
quently mutated gene within the group of neurotransmitter receptors with 3
missensemutations including one damagingmutation found inNBL.Anumber
of damaging mutations here identifıed corresponded to “Gain of function” mu-
tations such as the T790M EGFR driver mutant present in pediatric AML. The
genetic mutations here compiled on neurosignaling molecules may increase the
response of tumor cells to neurotransmitters, axon guidancemolecules and neu-
rotrophic factors that ultimatelymay boost their growth andmetastatic capacity.
Our data show that neurotrophic factors as well as axon guidancemolecules and
neurotransmitter receptors are structurally and functionally altered in child-
hood cancer patients, both in hematopoietic and solid tumors. The influence of
nervous system in the tumorigenesis and cancer progressionmayhave a relevant
role thus raising important implications for future therapies for childhood can-
cer.
#3584 Statistical considerations in tumor only variant calling. Paul Little,1
D. Neil Hayes,1 Joel Parker,1 Jose Zevallos2. 1UNC Lineberger Comprehensive
Center, ChapelHill, NC; 2Department of Otolaryngology/Head andNeck Surgery,
Chapel Hill, NC.
Targeted exome sequencing and variant calling involves comparing a pa-
tient’s tumor and normal sequencing to identify mutated loci within clinically
actionable (CA) genes. However sequencing matched normal (MN) increases
the marginal cost greatly relative to the amount of genomic information pro-
vided sincemost bases are unchanged.MNmay not be available or in some cases
poor quality of the MN sequencing may hinder the interpretation of results.
Without the MN control, with the expected mix of sequencing errors, artifacts,
and mis-mapped regions, germline (GM) variants will further contaminate the
list of variant calls (VCs) with up to 10,000 alternate loci. Some reports address
TO sequencing challenges and these have signifıcant limitations. In general,
more controls leads to both higher computational costs and risk of selecting low
quality controls.We aim to return several dozenVCs using a reasonable number
of controls. We propose using information obtained from pooling high quality
normal samples and GM/somatic databases and applying a set of fıltering crite-
ria for a cohort of tumor only (TO) samples to exclude the majority of false
positive (FP) VCs while retaining those that are CA. Through benchmarking
paired tumor normal (PTN) samples, we aim to fınd the minimum controls
needed to reach an adequate sensitivity (SENS), specifıcity (SPEC), and fınal
number of VCs. We selected a cohort of patients with clinically validated muta-
tions from a clinical trial of NGS in cancer (LCCC1108: NCT01457196). From a
cohort we selected a subset of 100 patients with a spectrum of clinical and
genomic parameters relevant to a robustmethod.All patientswere PTN samples
as well as CLIA confırmation of relevant CA mutations. We developed a set of
fıltering and annotations processes to allow VC annotation of the cohort which
did not include the MN and compared to results obtained from PTN sequenc-
ing. Samples were sequenced using hybrid capture technology and Illumina
brand paired-end sequencing. VCs were combined using Strelka, UNCseqR,
and Cadabra and annotated with Oncotator. SENS and SPEC are used to quan-
tify the pipeline’s performance by treating the fıltered PTN VCs and clinically
validated as gold standard. Overlaps in the tumor and pooled normal cohort
(PNC) samples were avoided. With respect to a larger set of high quality muta-
tions called by the PTN pipeline, the TO method documented on average 95%
SENS and 99% SPEC for variant detection. The method showed a tradeoff
between SENS and FP rate allowing for small drops in SENS for large decreases
in the numbers of FP (4-5% decrease in SENS from 99% to 95%) resulted in 90%
decrease in FP VCs with a fınal average of 70 fıltered VCs per sample. Results
suggest that analyzing PTN targeted exomeNGS samples as TO and obtaining a
disjoint PNC selected based on sequencing quality metrics can achieve high
SENS and SPEC with a reasonable number of fıltered VCs. Also benchmarking
aids in excluding controls from the PNC that may miss CA calls.
#3585 Determination of gene amplifıcations with a next-generation se-
quencing cancer panel. Ina L. Deras, AaronWise, Chen Zhao, Christine Glide-
well-Kenney, Phillip Le, Elizabeth Upsall Aderhold, KarenGutekunst. Illumina,
San Diego, CA.
TruSight® Tumor 15* (TST15) uses next-generation sequencing technology
to detect somatic point mutations, insertions, and deletions in 15 genes that are
commonly mutated in solid tumors. It accurately detects low-frequency muta-
tions with lowDNA input and is optimized for formalin-fıxed, paraffın-embed-
ded (FFPE) tumor tissue. The test is a multiplexed PCR panel that includes
primers to support amplifıcation detection in the EGFR, ERBB2, and MET
genes. Here we describe development of a bioinformatics analysis method to
enable detection of these gene amplifıcations. DNA extracted from 31 FFPE
samples with amplifıcations in EGFR, ERBB2, or MET—some with dual ampli-
fıcations—were diluted with DNA extracted from 18 normal FFPE samples to
create a total of 67 unique samples at low-level amplifıcation. Undiluted and
diluted samples were assessed for quality based on amplifıability (
Cq or library
yield) and tested with TST15. For comparison, the samples were also tested with
droplet digital PCR (ddPCR) to determine the copy ratio of target to wild type.
For amplifıable samples, the TST15 algorithm was able to detect amplifıcations
in EGFR and ERBB2 at ddPCR ratios of 1.4 and 1.6, respectively. ddPCR was
unable to accurately quantify low MET amplifıcations; therefore, expected
ddPCR ratioswere used for comparison. TheTST15 algorithmwas able to detect
amplifıcations in MET samples at an expected ddPCR ratio of 1.3. Poor sample
quality (i.e., high 
Cq or low library yield) impaired amplifıcation detection. In
some samples, the presence of multiple amplifıcations also impaired detection.
The addition of this algorithm to the TST15 workflow will allow researchers to
more accurately characterize tumor samples by detecting somaticmutations and
amplifıcations simultaneously. *For Research Use Only. Not for use in diagnos-
tic procedures.
#3586 Comprehensive assessment of mouse contamination removal
strategies from patient-derived xenograft model sequencing data. Ryan P.
Abo, Zehua Chen, Shannon Bailey, Hao Wang, Sharvari Gujja, Pengwei
Yang, Jim Lund, Jeff Gulcher, Tom Chittenden.WuXi NextCODE Genomics,
Cambridge, MA.
Patient-derived xenograft (PDX)models of human tumors are an important and
widely used platform for cancer research. Cancer drug development relies on PDX
models to screen drugs and characterize tumor biology for potential drug targets. It
has beenwell established that PDXmodelsmaintain similar biology as their original
tumors, including histological patterning, gene expression, single-nucleotide vari-
ants, and copy number alterations. Using short-read sequencing technology to pro-
fıle and characterize genomic alterations within PDX tumor models is becoming a
commonpractice in cancer research.Mouse readcontamination is a relevant source
of noise in PDX tumor sequencing data and needs to be addressed prior to down-
stream analyses. Therefore, a key consideration for downstream analysis of PDX
sequencing data, such as determining variant calls or gene expression values, is
effectively removing contaminating mouse sequence. Removing contamination
from PDX sequencing data is necessary for accurate and reproducible downstream
analyses. A limited number of studies establishing best practices for handling PDX
sequencing data exist. Thus, we set out to compare different strategies for removing
mouse contamination fromPDXtumor sequencingdata forDNAandRNAusing a
set of controlled experimental in silico datasets and data from PDX tumors. We
designed a set of in silico experiments using these sequencing data to assess a range
of approaches for removing contaminating mouse reads from human data. Our
experiments used a set of publically available human and mouse DNA and RNA
sequencingdataavailable at theSRAsite. Subsetsof the rawhumanandmouse reads
were mixed at different ratios and analyzed with fıve different approaches: 1) raw
alignment to the human reference genome, 2) fıltering with the Xenome algorithm
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followed by alignment to the human genome, 3) alignment to the human reference
genome followed by fıltering with the XenofılteR algorithm, 4) mouse-human hy-
brid reference genome alignment, and 5) our novel NextCODE approach. We as-
sessed thesensitivityandspecifıcityofeachprocedure for removingmousesequence
and maintaining human sequence for downstream analyses. We also assessed the
effects of each fıltering procedure on gene expression quantifıcation and variant
calling.Our results introduce anovel, improvedmethod for removingmouseDNA,
facilitating better-quality data for downstream analysis.
#3587 Intratumoral divergence of copy number alterations in NSCLC.
Yasminka A. Jakubek,1 Smruthy Sivakumar,1 Louise C. Strong,1 Humam Ka-
dara,2 Paul Scheet1. 1UTMD Anderson Cancer Center, Houston, TX; 2American
University of Beirut, Beirut, Lebanon.
Intratumoral heterogeneity has been increasingly established as a critical phe-
notype of cancer genomes. Its characterization at the DNA level is based on the
identifıcation of somatic mutations consisting of single nucleotide variants
(SNVs) and copy number alterations (CNAs), which include deletions, amplifı-
cations, and copyneutral loss of heterozygosity. Currently,mostmethods for the
detection of intratumoral heterogeneity use an implicit “infınite sites”model for
both SNVs and CNAs. While this may often be appropriate for SNVs, we dem-
onstrate its violation for CNAs in unstable cancer genomes. Here, we propose a
novel method to identify CNAs that were created by independent mutational
events but alter the same genomic region. Our method identifıes regions where
the germline heterozygous signals (allelic intensities for DNA arrays or frequen-
cies for next-generation sequencing) shift toward different parental haplotypes
between different samples from the same tumor, thus indicative of divergent
tumor clones. In this context we defıne a divergent CNA as one found on mul-
tiple samples from the same tumor but with different chromosomal changes
giving rise to the CNAs. We applied our method to data from core needle biop-
sies extracted from the tumors of 31 non-small cell lung cancer (NSCLC) pa-
tients and processed using Illumina SNP arrays.We overlapped CNA calls from
the same tumor, and then tested whether overlapping segments showed diver-
gent CNAs. We observe instances of divergent CNAs in 23 of the 31 patient
tumors comprising 260 in total (median 5 divergent CNAs per tumor). Strik-
ingly, one tumor had 34. We then assessed whether the level of recurrent muta-
tion correlated with clinical or genomic features.While there was no association
with smoking or histology,we did observe a positive association between the rate
of divergence and somatic mutations (including loss) in putative genome “gate-
keeper” genes, p53 andCDKN2A (P 0.001).We detected divergent CNAs that
spanned shared genomic regions in three or more NSCLC tumors. These in-
cluded large ( 1Mb) events in chromosome 6 (q13-14, q21-22, q25) and chro-
mosome 21 (q22), as well as smaller events, which included the integrin collagen
receptor locus ITGA1-PELO-ITGA2, 8p23.1, 8q24.3, 18q11.2 (ZNF521 gene),
and 21q21.3, which has bindings sites for GATA2, GATA3, and STAT3. Our
observed divergent genomic alterations represent half of the total number ex-
pected since imbalances of the same haplotype will not be observable in such
data. In summary, our approach allows for the detection of genomic regions that
are divergently altered. This information may support methods to identify
CNAs under positive or negative selection in the tumor microenvironment as
well as regions of increased genomic instability. This provides an added dimen-
sion to intratumoral heterogeneity analysis for a more comprehensive charac-
terization of cancer genomes.
#3588 Computational method to identify non-coding cancer drivers. Eric
Minwei Liu, Priyanka Dhingra, Alexander M. Fundichely, Ekta Khurana.Weill
Cornell Medicine, New York, NY.
Cancer is caused by mutations in driver genes - yet 25% patients do not
show anymutations in known drivers.99% somatic mutations obtained from
whole-genome sequencing localize to regions that do not code for proteins and
many of these non-coding mutations regulate gene expression. Although vari-
ants in protein-coding regions have received the majority of attention, numer-
ous studies have now noted the importance of non-coding variants in cancer -
for example, mutations in the promoter of the TERT gene. Identifıcation of
functional non-coding variants that drive tumor growth remains a challenge
and a bottleneck for the use of whole-genome sequencing in the clinic. Cancer
drivers are generally identifıed by the high frequency at which their mutations
occur across patients.However,mutation rate is highly heterogeneous across the
genome and many non-driver elements show higher mutation frequency than
others, such as regions bound by transcription factors (TFs) in melanoma or
regions replicating late during cell division in colon cancer. We have developed
a novel computational approach to predict non-coding cancer drivers that dif-
ferentiates between regions highly mutated due to positive selection (true driv-
ers) vs those due to mutation rate heterogeneity (false positives). This method
integrates the signals of high functional impact of variants with the recurrence of
variants across multiple tumor samples to identify the elements that showmore
and higher functional impact mutations than expected randomly. Our method
controls for multiple covariates of mutation rates, such as replication timing,
histone modifıcation marks and open chromatin regions to identify the non-
coding cancer drivers. The functional impact is predicted using the FunSeq
scheme that uses the properties of ENCODE elements (including conservation,
TF motif disruption and network properties) within a weighted scoring scheme
to predict deleteriousness of non-coding variants. I will present the details of this
method and discuss the ongoing efforts to analyze 2,900 tumor whole-ge-
nomes in the ‘Pan-Cancer Analysis of Whole Genomes, PCAWG’ consortium.
#3589 A systematic approach toward gene annotation of the hallmarks of
cancer. Jeff Kiefer,1 Sara Nasser,1 JohnGraf,2 Chinnappa Kodira,2 FionaGinty,2
LeeNewberg,2Anup Sood,2Michael E. Berens1. 1TGen, Phoenix, AZ; 2GEGlobal
Research, Niskayuna, NY.
The hallmarks of cancer consist of ten categories that serve as an organizing
principle and framework for understanding neoplastic disease. The ten hall-
marks include activating invasion and metastasis, avoiding immune destruc-
tion, deregulating cellular energetics, enabling replicative immortality, evading
growth suppressors, genome instability and mutation, inducing angiogenesis,
resisting cell death, sustaining proliferative signaling, and tumor-promoting in-
flammation. In order to facilitate the use of the hallmarks of cancer in genomic
studies, we have undertaken a systematic methodology to map genes to each
individual hallmark of cancer. Assignment of genes to the individual hallmarks
was performed leveraging gene ontology (GO) annotations. Specifıcally, for
each hallmark, a term list was generated by cancer research experts, with biolog-
ical terms associated with each hallmark. This term list was used to search and
identify matching GO terms. Matched terms were then mapped to the highest,
most specifıc, representative, non-redundant GO term in the GO hierarchy.
Genes for each term were restricted by selecting only human taxon, and high
confıdence experimental evidence codes. For specifıc GO terms, where present,
the Regulation of ’GO term’ category was included. The genes for each GO term
for each hallmark were combined in a non-redundant list of genes for each
hallmark. In the case of the evading growth suppressors category, a different
strategy was employed. In this instance, genes were identifıed through ’tumor
suppressor’ gene/protein annotation in the DGIdb resource and UniProt. Ad-
ditionally, text-mining methods on biomedical research literature were used to
defıned a high confıdence list of genes for this hallmark. As an example use case
of the hallmarks we applied them to the analysis of the TCGA Pan-Cancer
RNAseq data set. Clustering across the individual hallmarks led to interesting
differences within particular tumor tissue types, as well as shared hallmarks for
other tumor types. For example, use of the genome instability and mutation
hallmark for Pan-Cancer clustering, revealed a tight tissue-based cluster of low-
grade gliomas and GBMs. This result suggests the importance of this hallmark
expression in this tumor type. This high confıdence mapping of genes to hall-
marks of cancer provides a unique dataset to facilitate analyses of cancer genome
data.
#3590 Somatic variation discovery with GATK4. Geraldine A. Van der
Auwera. Broad Institute, Cambridge, MA.
The Genome Analysis Toolkit or GATK, developed at the Broad Institute, is
currently one of the most widely used software toolkits for germline short vari-
ant discovery and genotyping in whole genome and exome data. GATK4 is the
next generation ofGATK; it runs faster and coversmore ground, adding somatic
SNVs, Indels and CNVs to its variant discovery portfolio. Given the breathtak-
ing increase in the amount of genomic data produced in recent years, GATK
development has come to tackle multiple challenges: a) reflect the cutting-edge
of science in terms of depth as well as breadth of analyses offered, b) scale to
petabytes of data and c) provide a way to navigate the tradeoff between turn-
around-time and cost of analyses. GATK4 addresses all of these challenges
through a complete redesign and reimplementation of the original GATK soft-
ware. This new version greatly expands the toolkit’s scope of action within the
variant discovery space by improving somaticmutation calling and adding copy
number, structural variant and tumor-heterogeneity analysis tools. For the es-
tablished tools and algorithms composing theGATKBest Practices pipelines for
short variant discovery (includingMuTect2, the next generation of the DREAM
challenge-winning somatic SNVcallerMuTect, developed originally in theCan-
cer Genome Analysis group at the Broad Institute), GATK4 is a substantial
upgrade that streamlines the tools’ operation, providing functionally equivalent
results in a much faster timeframe through greatly increased effıciency and
leaner engineering. Designed with cloud infrastructure inmind (although it still
runs on local infrastructure), GATK4 is implemented with support for Apache
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Spark, makes key operations hundreds of times faster than previous generations
of GATK and comes with end-to-end pipeline implementations that run out of
the box on select cloud platforms.
#3591 A newmethod to infer clonal sequences and phylogenies from per-
sonal tumor genome profıles. Sayaka Miura,1 Karen Gomez,1 Oscar Murillo,2
Sudhir Kumar1. 1Temple Univ., Philadelphia, PA; 2Baylor College of Medicine,
Houston, TX.
Tumor progression involves the evolution of clonal cell populations that
mutate and spread in the body. Genetic profıling has revealed the presence of
extensive variation in tumor samples from individual patients. However, a
tumor sample for genetic profıling is mixture of different clonal cell popu-
lations and needs to be decomposed into clonal sequences to infer the evo-
lutionary history of the tumor. Therefore, we have developed a new method,
CloneFinder, and show that the clone sequences present in each tumor sam-
ple can be accurately inferred from the analysis of multiple tumor sample
profıles with our new CloneFinder method. CloneFinder is unique in its use
of molecular evolutionary principles to deduce clone sequences at a single-
nucleotide resolution along with their frequencies in each sample. It per-
forms better than existing methods, which we found to produce incorrect
numbers of clones, clone sequence errors, errors in clonal phylogenies, and
biased estimates of cancerous cells in tumors. Application of CloneFinder to
a large number of empirical datasets revealed that both early and recently
evolved tumors contain ancestral clones at high frequencies. Therefore, our
new method provides new insights into the clonal structure of tumors and
their evolution within a personal life time.
#3592 Improved indel detection in RNA-seq data via assembly based re-
alignment reveals expressed Epidermal Growth Factor Receptor indels in
Lung Adenocarcinoma. Lisle E. Mose, D. Neil Hayes, Charles M. Perou, Joel S.
Parker. UNC - Lineberger Cancer Center, Chapel Hill, NC.
Insertions and deletions in the transcriptome can potentially have signif-
icant impact on function and can be clinically actionable. A number of meth-
ods have recently been developed that improve indel detection in DNA by
utilizing realignment and/or localized assembly to aid in discovering muta-
tions that are more diffıcult to detect than single nucleotide polymorphisms.
While signifıcant effort has been put into these methods in the context of
DNA discovery, RNA-Seq has not received the same attention. For example,
the widely used Genome Analysis Toolkit (GATK) recommends removal of
splice junctions from all reads prior to proceeding with variant calling meth-
ods that are very similar to those used for DNA. We hypothesize that utiliz-
ing splice junctions to augment localized assembly across exon-exon bound-
aries can improve read alignments resulting in improved variant detection in
RNA-Seq data. We have developed an update to the Assembly Based Re-
Aligner (ABRA2) that makes use of splice junction information to aid in
realignment of reads. We assessed indel detection performance using the
BEERs RNA-Seq simulator. Two million simulated reads of length 100nt
were generated across 1000 human genes. In order to test more complex
indel detection, the simulator was modifıed to generate an even distribution
of 1391 indels of length 1 to 100. The simulated reads were aligned using
STAR and subsequently realigned using ABRA2. Freebayes and GATK were
run against the non-realigned STAR output resulting in indel detection sen-
sitivity of 15% and 18% with precision of 97% and 88% respectively. Free-
bayes was then run against the ABRA2 realignments resulting in an approx-
imately 4 fold increase in indel detection sensitivity of 67% while
maintaining precision of 97%. In frame deletions in Epidermal Growth Fac-
tor Receptor (EGFR) have oncogenic potential, can be indicators for Ge-
fıtinib or Erlotinib treatment, and are frequently detected in lung cancer via
DNA sequencing. Among 514 TCGA Lung Adenocarcinoma RNA-Seq sam-
ples, ABRA2 revealed 73 in frame coding indels in EGFR ranging in length
from 3 to 24 bases, including 58 deletions in exon 19 of length 15 bases. This
represents a 3 fold increase relative to what was initially reported from DNA
by TCGA. Further, in the absence of ABRA2, only 5 in frame coding indels
are detected in RNA, the largest of which is a 9 base deletion. We have
presented here ABRA2, a new version of the Assembly Based ReAligner that
is capable of accurately realigning RNA-Seq reads containing variations that
are currently not well handled by widely used aligners and variant callers,
thus improving accuracy of variant detection in RNA-Seq.
REGULATORY SCIENCE AND POLICY: Advancing Clinical
Trial Design in Regulatory Science and Policy
#3594 Adaptively randomized seamless-phase multiarm platform trial:
Glioblastoma Multiforme Adaptive Global Innovative Learning Environ-
ment (GBM AGILE). Donald A. Berry,1 Todd Graves,2 Jason Connor,2 Brian
Alexander,3 Timothy Cloughesy,4 Scott M. Berry,2 Anna Barker,5 for the GBM
AGILE Global Alliance. 1UT MD Anderson Cancer Ctr., Houston, TX; 2Berry
Consultants, LLC, Austin, TX; 3Dana Farber Cancer Institute, Boston, MA; 4The
Ronald Reagan UCLA Medical Center, Boston, CA; 5Arizona State University,
Phoenix, AZ.
Traditional phase 3 clinical trials compare an experimental arm with control.
They ineffıciently use patients, time, and fınances. Dramatic and rapid changes
in biology makes such trials untenable. We describe an alternative drug devel-
opment strategy that we are using in a particular setting, the trial GBM AGILE
(GlioblastomaMultiformeAdaptiveGlobal Innovative Learning Environment).
The trial’s design employs many innovations. Some aspects are similar to those
of I-SPY 2 (see 4 articles in July 7, 2016 NEJM) but GBM AGILE extends I-SPY
2 in many ways. (1) It is a Bayesian platform trial that simultaneously evaluates
many treatment arms (including combinations) from many companies. (2)
Arms are added to the trial at any time and leave when they have been evaluated,
whether positively or negatively. (3) An arm’s sample size is adaptive and based
on frequent analyses of the trial results. (4) Every arm has an initial stage in
which it is randomized adaptively: arms performing better in disease subtypes
are assigned with higher probability to such patients. (5) An arm that performs
suffıciently well in a disease subset moves seamlessly into a small (50-patient)
confırmatory, registration stage in the same subset, with equal randomization
against control. (6) All experimental arms are compared against a common
control arm that is assigned to 20%of patients in every subtype; a bridgingmodel
takes advantage of havingmany arms in the trial andmany comparisons among
arms, and enables indirect randomization comparisons of all arms with all con-
trols. (7) Patient subtypes are defıned by line of therapy, MGMT methylation
status for newly diagnosed patients, and biomarkers associated with targeted
therapies, although adaptive randomization enables us to draw conclusions
about off-target effects. The many possible subtypes means that there are many
possible drug indications. So there aremany possible “error types” and no single
defınition of statistical power. For example, the trial may conclude that a drug’s
indication is “recurrent, biomarker-positive” disease when in truth it is “all re-
current” disease. We show how the design addresses this issue and we defıne
“pure type I error.” GBMAGILE’s primary endpoint is overall survival (OS). To
make the design more effıcient we incorporate evaluations of patients’ statuses
over time using a longitudinal model based on periodic MRI assessments and
performance status. The longitudinal model and its components are not end
points but rather provide auxiliary information that enables multiply imputing
OS for surviving patients.We represent the trial’s coordinating committees that
are made up of more than 150 enthusiastic and devoted disease experts and
advocates from around the globe, including fromAustralia and China. The U.S.
FDA has been enormously helpful in designing GBM AGILE, especially as re-
gards its potential for drug and biomarker registration. Our approach provides a
model for other diseases, including those outside of cancer.
#3595 Under-reporting of research biopsies in clinical trials in oncology.
Christine M. Parseghian, Kanwal Raghav, James Yao, Lee M. Ellis, Alda Tam,
Michael J. Overman. U.T. MD Anderson Cancer Center, Houston, TX.
Purpose: Research biopsies are frequently incorporated into clinical trials in
oncology, and are often amandatory requirement for trial enrollment.However,
limited information is available regarding the extent and completeness of re-
search biopsy reporting. Methods: We identifıed a cohort of therapeutic clinical
trials wherein at least one image-guided non-diagnostic research biopsy was
performed between 1/2005 and 10/2010 from a large interventional radiology
database at MDAnderson Cancer Center. Study protocols were compared with
the highest level of corresponding publication as a manuscript, registry report,
or abstract. Results: A total of 866 research biopsies were performed across 46
clinical trials (median 19 biopsies/trial). After a median follow-up time of 5.8yrs
from study completion, 35 trials (76%) had published manuscripts (18 reported
biopsy results), 8 (17%) had either a registry or abstract report (1 reported biopsy
results), and 3 (7%) were not reported. In total, 19 trials (41%) reported biopsy
results. Of these 19 trials, 6 (32%) trials under-reported the number of biopsies
performed. Only 14 of 32 (42%) trials with mandatory research biopsies re-
ported on these biopsies. Comments regarding biopsy quality/adequacy were
reported in only 5 trials. Complications from these biopsies occurred in 39 pts
(grade 3 in 6 pts) in 8 trials, but only 1 (13%) trial reported biopsy complications.
Factors associated with better reporting of research biopsies are shown in the
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Table. When limited to only published manuscripts, results were unchanged.
Academic sponsorship and a larger number of biopsies, especially serial biop-
sies, were associated with increased reporting of research biopsies. Conclusion:
Despite ethical obligations to report research biopsies, 59%of trials donot report
on these biopsies. Although complications occur, they are rarely reported. Clin-
ical trial design efforts to ensure that an adequate number of research biopsies
are obtained may lead to improved reporting of research biopsy biomarker re-
sults.
Variable N Trials reporting biopsies (%) P-value
Mandatory or optional biopsy 1
Mandatory (/- optional) 33 14 (42)
Optional 13 5 (38)
Total number of biopsies per trial 0.002
10 19 3 (16)
10-30 22 11 (50)
30 5 5 (100)
Trials with serial biopsies (No. of pts.) 0.0001
1-5 11 0 (0)
5 18 13 (72)
Study sponsorship 0.03
Industry 24 6 (25)
Academic 22 13 (59)
Clinical trial 0.77
Multicenter 21 8 (38)
Single center 25 11 (44)
Phase of clinical trial 0.51
I or I/II 33 15 (45)
II or III 13 4 (31)
#3596 Howmany tumor indications should be initially studied in clinical
development of next generation immunotherapies. Cong Chen,1 Qiqi Deng,2
Linchen He,3 DevanMehrotra,1 Eric H. Rubin,1 Robert A. Beckman4. 1Merck &
Co., Inc., Collegeville, PA; 2Boehringer Ingelheim Pharmaceuticals Inc, Ridgefıeld,
CT; 3New York University, NY; 4Georgetown University Medical Center, DC.
An experimental oncology immunotherapy may have the potential to be ef-
fective in a large number of tumor indications. Once a recommended Phase II
dose (RP2D) is determined, under resource constraint, a natural strategy is to
conduct Phase II proof-of-concept (POC) trials in two waves. A cohort of po-
tential tumor indications is selected for the fırst wave investigation and the
second wave investigation in a different cohort of tumor indications is initiated
only after the drug has been demonstrated to be effective in the fırst wave.
Immunotherapy development is a dynamic environment with rapidly evolving
mechanistic understanding, constant flow of new data and frequent changes in
the competitive landscape. Howmany tumor indications should be investigated
in the fırst wave given the uncertainties? We attempt to answer this question by
maximizing a benefıt-cost ratio, defıned to be the expected number of effective
tumor indications correctly identifıed in the two waves divided by the expected
total sample size for the POC trials in the two waves and the total sample size for
the Phase III trials triggered by those with a positive outcome in the fırst wave. It
is found that the optimal number of the fırst wave POC trials is in a range of
approximately three to six, which may vary with the resource constraint but is
otherwise robust to the key factors we have considered. A recommendation is
made on how much resource should be invested in the fırst wave.
#3597 Experiences and lessons from innovative dose escalation designs in
early phase oncology. Jiawen Zhu,1 Ulrich Beyer,2 Somnath Sarkar,1 Gwen
Nichols,1WilliamPao,2 Daniel Sabanés Bové2. 1F. Hoffmann-La Roche Ltd, New
York, NY; 2F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Introduction: Since 2010, Roche-sponsored early development trials in on-
cology have successfully implemented innovative dose escalation (D/E) strate-
gies including modifıed continual reassessment methods (CRM) and other
Bayesian adaptive designs. Compared to standard 33 designs, these methods
allow for flexibility to address a variety of clinical questions and to estimatemore
accurately a molecule’s maximum tolerated dose (MTD). However, CRM de-
signs are sometimes considered as complex and diffıcult to implement and are
not easily understood by clinicians (LeTourneau et al., 2009, Iasonos et al. 2014).
Here, we share our experiences and learnings from the initial exploration, intro-
duction, and wide-spread implementation of CRM in early oncology clinical
trials. Methods: We conducted a thorough internal review of the current statis-
tical methods and clinical strategies used in CRM designs. In addition, we sys-
tematically collected feedback on the internal experience through surveys and
interviews of participating biostatisticians, pharmacologists, clinicians and op-
erationsmanagers. Results: CRMs using two parameter logistic regressionmod-
els and escalation with overdose control (Neuenschwander et al., 2008) are the
most commonly used CRM designs in Roche-sponsored oncology D/E trials.
Compared to trials in which 33 designs are used, we experienced signifıcant
advantages with CRM designs including: flexibility in cohort sizes; formal inte-
gration of relevant prior pre-clinical/clinical knowledge of the dose-toxicity re-
lationship; and contribution of all dose limiting toxicities (DLTs) to an MTD
determination.On the other hand,we learned about some limitations. TheCRM
designs modeled binary DLT events where the grade of an event was not con-
sidered. Thus, in a cohort where severe DLT event(s) were observed, clinical
judgment typically superseded theCRMrecommendation towards a lower dose;
this decision rule was a priori defıned in the protocol. In certain situations,
inconsistent prior-information in the dose-toxicity relationship was observed.
Therefore, prior assumptions had to be carefully assessed through simulations
usingmultiple dose-toxicity scenarios. Conclusions: Overall, utilization of CRM
designs was considered benefıcial to Roche early development trials. Based on
our experience, CRMdesigns are flexible and can be tailored to address a variety
of clinical research questions. Trial simulation analyses were critical for us to
understand the performance of CRM designs, including the accuracy of esti-
mated MTD, trial duration/sample size, and sensitivity to prior assumptions.
Furthermore, the introduction and implementation of CRM designs required
and promoted strongmultidisciplinary collaborations, especially during the de-
sign and study protocol set-up phases and the D/E recommendation phase.
ENDOCRINOLOGY: Nuclear Receptors and Endocrine Oncology
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#3602 Novel BRCA1 mimetic 35446HCl inhibits growth of anti estrogen
resistant breast cancer cells through the NF–B pathway. Shyam Nathan,
Eliot M. Rosen. Georgetown University, Washington, DC.
Nearly a third of breast cancer patients develop resistance to antiestrogen
treatments although the estrogen receptor ER- continues to affect cell survival
and proliferation. Thus there is a need for new interventions to inhibit ER-
function. Based on high-resolution mapping, we proposed interaction sites on
both BRCA1 and ER- in a three-dimensional model of BRCA1. Utilizing this
model, we identifıed a class of compounds that fıts into a predicted BRCA1-
binding cavity within ER-, mimics the ability of BRCA1 to repress ER- activ-
ity, and functions differently than other antiestrogens. Previous publication has
shown that the 1st generation BRCA1 mimetic compound (A7) reduced prolif-
eration and inhibited ER- activity in antiestrogen-sensitive and resistant breast
cancer cells with negligible non-specifıc toxicity. More importantly we have
shown that the 2nd generation compounds (35446, 4631) partially restored sen-
sitivity to Tam/ICI-resistant cells (LCC9), caused dissociation of ER- from a
model estrogen response element (ERE) inMCF-7 cells, and inhibited growth of
LCC9 tumor xenografts at nontoxic concentrations utilizing compound 35446-
HCl (35446 prepared as a hydrochloride salt). The focus of this study is the
mechanism of action of 35446-HCl compound’s inhibition of ER-, which in-
cludes inhibition of a major signaling pathway and mode of cell death. Eight
genes identifıed from RNA-seq in LCC9 cells treated with BRCA1 mimetic A7
were verifıed by qPCR using 35446-HCl. One verifıed gene is the NF-B activa-
tor IKKB, which is linked to therapy resistance. Treatment with 35446-HCl
inhibited IKKB expression and proliferation in LCC9 cells compared to un-
treated Control at 48 and 72 hrs (p0.0001). Transcriptional activity from the
p65 promoter as measured with a luciferase assay was decreased in the presence
of BRCA1mimetic treatment (p0.0001). Expression of downstream targets of
NF-B, including genes known to inhibit apoptosis, was reduced (p value rang-
ing from 0.05- 0.001). Apoptosis due to 35446-HCl treatment was verifıed by
caspase-7 cleavage and increased TUNEL staining at both 48 and 72 hrs. In silico
analysis of the IKBKB promoter within 10kb upstream of the transcription start
site identifıed one putative full ERE and fıve putative half ERE sites. Of these,
35446-HCl inhibited the interaction of ER- with the full ERE (p0.0001) and
fıve half ERE (p value ranging from  0.05- 0.001) sites upstream of the IKKB
start site in LCC9 cells as well as Tam resistant/ER- mutated T47Dco cells.
These results identify a mechanism of a novel compound that can overcome
antiestrogen resistance.
#3603 Optimizing combination therapy against antiestrogen-resistance
in estrogen receptor positive breast cancer. Lauren M. Gutgesell, Rui Xiong,
Jiong Zhao, Debra A. Tonetti, Gregory R. Thatcher. University of Illinois at
Chicago, Chicago, IL.
REGULATORY SCIENCE AND POLICY: Advancing Clinical Trial Design in Regulatory Science and Policy
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017918
Approximately 75% of breast cancer incidences are Estrogen Receptor posi-
tive (ER). Treatment of ER breast cancer with antiestrogen endocrine ther-
apy targets the proliferative mechanisms of ER using selective ER modulators
(SERMs), such as tamoxifen, and selective ER downregulators (SERDs), such as
fulvestrant. The resistance to endocrine therapy, either innate or acquired, is
clinically diagnosed in up to 50% of patients within 5 years of treatment. Anti-
estrogen therapy of ERmammary cancer cells in vitro and in xenografts does
not cause complete cell death or regression. Through the use of combination
therapy to target the remaining sub-population of cells, complete regression can
be predicted. Our lab has developed endocrine tamoxifen-resistant models
through prolonged exposure to tamoxifen, estrogen deprivation, and overex-
pression of PKC, a pro-survival pathway component, in addition to a fulves-
trant-resistant model through prolonged exposure to fulvestrant. Investigation
of the resistance mechanisms will provide insight into potential, combinatorial
targets for overcoming endocrine resistance in ER breast cancer. Use of sphe-
roidal 3D cell culture provides a physiologically relevant model with suffıcient
throughput for drug discovery. Establishing spheroids and subsequent treat-
ment predicts the effıcacy of combination treatment on tumor regression. Tar-
geting pathways associatedwith increased prevalence of resistance, such as CDK
4/6, can be employed for clinical therapy. Using both novel in-house and clinical
SERMs and SERDs, we have used these multiple cell lines to discover combina-
torial targets using both mechanistic and unbiased screening approaches. The
use of combination endocrine therapy in tamoxifen-resistantmodels has shown
antiproliferative synergy, and is able to enhance tumor regression in xenografts.
By optimizing combinatorial endocrine treatment against both fulvestrant- and
tamoxifen-resistance, novel therapeutic approaches are being developed for
ER breast cancer.
#3604 Effect of a new oral SERD AZD9496 on ER mediated signaling in
xenograft model of postmenopausal breast cancer. Gauri J. Sabnis,1 Armina
Kazi,2 Amanda Schech,3 Stephen Yu,4 Olga Golubeva,5 Angela Brodie4. 1West
Coast University, Los Angeles, CA; 2Loyola UniversityMaryland, Baltimore,MD;
3St. Mary’s College of Maryland, St. Mary’s City, MD; 4University of Maryland
School of Medicine, Baltimore, MD; 5University of Maryland Greenebaum Can-
cer Center, Baltimore, MD.
Aromatase inhibitors (AIs) have made signifıcant improvements in the treat-
ment outcomes of patients with breast cancer. However, tumors may eventually
acquire resistance. One of the proposed mechanisms of resistance to AIs is
overexpression of ER and cross-talk of ERwith growth factor receptors. Stud-
ies including our own have shown that downregulation of ER with fulvestrant
may provide benefıt in the treatment of AI-resistant breast cancer. Fulvestrant
has been employed in the clinic as either fırst or second line treatment for ER
positive breast cancers alone or in combinationwith AIs. Studies have suggested
that further escalation of dose may provide further benefıt. However, dose esca-
lation of fulvestrantwhich is administered via intramuscular injection is diffıcult
due to its poor solubility. To overcome this shortcoming of an injectable drug, a
novel orally active SERD (selective estrogen receptor downregulator), AZD9496
was developed. We evaluated the effect of AZD9496 on the growth of hormone
sensitive and anastrozole resistant breast cancer tumors using MCF-7Ca xeno-
graft model of postmenopausal breast cancer. Mice bearing xenografts of MCF-
7Cawere then treatedwith fulvestrant (1mg/d-sc) orAZD9496 (5mg/kg/d-po),
alone or in combination with anastrozole (200g/d-sc) for 23 weeks. Tumors
were measured weekly and growth rate was calculated. AZD9496 was signifı-
cantly better at inhibiting the growth of tumors compared to control (p0.001)
and anastrozole (p0.04) while being equally effective as fulvestrant (p0.99).
In the second study, effıcacy of AZD9496 was evaluated on against anastrozole
resistantMCF-7Ca xenografts. Tumorswere treatedwith anastrozole (200g/d)
for 13 weeks. During this time, the tumors initially regressed but eventually
began to grow and had doubled in volume. At this time-point, they were re-
grouped to receive second line treatment. Single agent AZD9496wasmarginally
signifıcant compared to continued anastrozole treatment (p0.07). Neverthe-
less, second line treatment with AZD9496 was equally effective as fulvestrant
(p0.36). AZD9496 treatment was also equally effective in reducing the expres-
sion of ER protein in MCF-7Ca xenografts as fulvestrant. Next, we measured
the effect of AZD9496 on the mouse uterus. Uterine weight of mice treated with
AZD9496 was not signifıcantly different from mice that were treated with an-
drostenedione (p0.99). Furthermore, AZD9496 did not decrease the expres-
sion of ER in the uterus, confırming its selectivity for mammary ER.
AZD9496 treatment was also able to reduce intratumoral aromatase activity.
However, it was not due to direct inhibition of the enzyme, but due to reduction
in ERmediated signaling. These results suggest that AZD9496 may be a better
alternative to fulvestrant due to its oral bioavailability, selectivity for mammary
ER, and ability to reduce aromatase activity while being equally effective as
fulvestrant.
#3605 The role of androgen receptor in invasive lobular breast carcinoma.
Hillary Stires, Rebecca B. Riggins. Georgetown University, Washington, DC.
The leading problem for women with estrogen receptor  (ER) breast cancer –
approximately 70% of all breast cancers – is that while the majority of tumors
initially respond to anti-estrogen treatment includingTamoxifen and aromatase
inhibitors, they will develop endocrine resistance. A histological subset of breast
cancer called invasive lobular carcinoma (ILC) accounts for 15% of all breast
cancer cases and approximately 90% of ILC are ER-positive. Despite clinical
markers suggesting a better prognosis for ILC compared to the more common
invasive ductal carcinoma (IDC), recent data suggests women with ILC develop
Tamoxifen resistance at a higher rate than IDC. New strategies for treating
hormone refractory tumors are needed that not only overcome anti-estrogen
resistance, but also present a more tolerable side effect profıle and have fewer
dose-limiting toxicities than adjuvant chemotherapy. The majority of ER-posi-
tive breast cancers also express androgen receptor (AR) and while AR presence
in breast cancer is controversial, increased expression of AR leads to Tamoxifen
resistance in IDC cell lines. Since ILChasmoreAR expression than IDC, the role
of AR in ILC was studied by treating cells with the non-aromatizable androgen
dihydrotestosterone (DHT) and the synthetic androgen R1881 as well as the
anti-androgen Enzalutamide. We have previously begun to characterize a Ta-
moxifen resistant variant of the ILC cell line Sum44PE termed LCCTam cells. In
both Sum44PE and LCCTam cells, AR protein expression increases in response
to androgens, an action that is blocked by Enzalutamide. Interestingly, andro-
gens do not promote growth in ILC cells, but Enzalutamide is still able to inhibit
growth. These results suggest Enzalutamidemay be an effective alternative ther-
apy for women with ILC. Future studies will focus on whether regulation of
nuclear receptor co-factors influences differences in AR signaling in ILC.
#3606 RBP2 promotes tamoxifen resistance by altering ER function and
activating IGF1R and EGFR/HER2 signaling in histone methylation-depen-
dent and -independent manners in breast cancer. Hee-Joo Choi,1 Taekwon
Son,2 Hyung-Yong Kim,1 Kyueng-Whan Min,1 Young-Ha Oh,1 Jeong-Yeon
Lee,1 Gu Kong1. 1Hanyang Univ., Seoul, Republic of Korea; 2Seoul National
Univ., Seoul, Republic of Korea.
Retinoblastoma binding protein 2 (RBP2, also known as JARID1A), a mem-
ber of the JARID1 family of histone H3 lysine K4 demethylases, has been con-
sidered to have an oncogenic potential in several types of human cancers includ-
ing breast cancer. Although physical interaction between RBP2 and estrogen
receptor (ER), a crucial factor for hormone-dependent breast cancer, has been
implied, the role of RBP2 in ER-positive (ER) breast cancer remains largely
unknown. Here, we demonstrate that RBP2 is a novel therapeutic target for
tamoxifen resistance in ER breast cancer as an ER co-regulator and an activa-
tor of receptor tyrosine kinase (RTK) signaling. In large cohorts of breast cancer
patients including METABRIC, high expression of RBP2 was associated with
poor response to tamoxifen therapy in ER breast cancer. Consistently, RBP2
induced tamoxifen resistance in ER breast cancer both in vitro and in vivo.
Using RNA-sequencing analysis, we identifıed that many RBP2 target genes are
overlapped with ER-dependent- and tamoxifen resistance-associated genes.
Mechanistically, RBP2 induced not only hyperactivation of ER-dependent tran-
scription but also estrogen agonist activity of tamoxifen-bound ER via the inter-
action with ER, thus increasing the expression of NRIP1, a co-repressor of ER.
RBP2 also formed a transcriptional repressive complex with ER, NRIP1, and
HDAC1 to induce H3K4 demethylation-mediated epigenetic gene silencing of
IGFBP4 and IGFBP5, leading to the activation of IGF1R and its downstream,
PI3K/AKT pathway. Furthermore, enhanced AKT phosphorylation by RBP2
was mediated by not only IGF1R but also EGFR/HER2 signaling via increasing
the stability of EGFR and HER2 proteins in a demethylase activity-independent
manner. We further confırmed that combinational treatment with tamoxifen
and PI3K inhibitor BKM120 restored tamoxifen sensitivity in RBP2-overex-
pressing breast cancer. Taken together, these fındings suggest that RBP2 medi-
ates tamoxifen resistance in ER breast cancer by altering ER activity and acti-
vating IGF1R and EGFR/HER2 signal pathways in both a histone methylation-
dependent and -independent manner. Therefore, RBP2 may be a promising
prognostic marker and therapeutic target for endocrine therapy-resistant breast
cancer.
#3607 Metastasis-associated protein 1 negatively regulates expression of
androgen receptor in ER-positive breast cancer cells. SeungSu Kim. Seoul Na-
tional University, Seoul, Republic of Korea.
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Androgen receptor (AR) is expressed in more than 80% of ER-positive breast
cancer and its expression is correlated with better prognosis in ER-positive
breast cancer. However, little is known about the regulation of AR expression in
breast cancer. We have previously reported that metastasis-associated protein 1
(MTA1), a cancer-promoting gene that is overexpressed in breast cancer, in-
creases the expression of ER in breast cancer. Here, we investigated the role of
MTA1 on AR expression in three different ER-positive breast cancer cell lines.
First, small interfering RNA-mediated knockdown of MTA1 increased protein
and mRNA expression of AR in MCF7, T47D, and ZR75-1. Overexpression of
MTA1 down-regulated expression of AR in these cell lines. Activity of the re-
porter-encoding AR promoter (-2408 bp  1126 bp) was decreased in the
presence of MTA1 in a dose-dependent manner. Analysis of the chromatin
immunoprecipitation sequencing data (http://encodeproject.org/ENCODE) re-
vealed thatMTA1may bind to 1 kilo base downstream of AR transcription start
site. Together, our results demonstrated thatMTA1 negatively regulates expres-
sion of AR in breast cancer cells. These results suggest that the negative regula-
tion of ARmay be associated with the cancer promoting effects ofMTA1, which
may provide a therapeutic opportunity against ER-positive breast cancer.
#3608 RAD140, an orally available selective androgen receptor modula-
tor, inhibits the growthofAR/ERpositive breast cancer cell line- andpatient-
derived xenograft models. Ziyang Yu, Suqin He, Jeffrey Brown, Chris Miller,
Jamal Saeh, Gary Hattersley. Radius Health, Inc., Waltham, MA.
Breast cancer is the most frequently diagnosed malignancy for women in the
US with 246,660 new cases predicted in 2016. Histological and molecular char-
acterization of breast cancer has led to improved understanding of the hetero-
geneity of this disease and development of therapeutic modalities tailored for
each disease subtype. Hormone receptor positive breast cancers, which repre-
sent 75% of breast cancer cases, are routinely treatedwith therapies targeting the
estrogen receptor (ER) axis, including aromatase inhibitors or anti-estrogens,
either alone or in combinationwith other agents. Recent studies have shown that
the androgen receptor (AR) is widely expressed across all subtypes of breast
cancer, withARdetected in 75-95%of ER positive tumors.Mounting preclinical
evidence from has demonstrated that AR agonists can suppress AR and ER
positive (AR/ER) breast cancer cell growth. Furthermore, prior to the devel-
opment of ER-targeted therapy, androgenswere used to treat breast cancerswith
favorable clinical responses. RAD140 is an oral, nonsteroidal, nonaromatizable
selective androgen receptor modulator (SARM) with a distinct tissue selectivity
profıle and mechanism of action. Here we examined the molecular activity of
RAD140 in breast cancer cells and evaluated its effıcacy using AR/ER breast
cancer xenograft models. The tissue-specifıc activity of RAD140 was examined
using androgen response element (ARE)-driven reporter assay in AR/ER
ZR75 breast cancer cells and AR LNCaP prostate cancer cells. RAD140 was
shown to be a potent AR agonist, comparable to dihydrotestosterone (DHT), in
breast cancer cells, but did not induce AR activity in prostate cancer cells, while
DHT demonstrated full AR agonist activity. In vivo anti-tumor effıcacy of
RAD140 as monotherapy, compared with fulvestrant, or in combination with a
CDK4/6 inhibitor (palbociclib) or mTOR inhibitor (everolimus) was evalu-
ated in AR/ER patient derived xenograft (PDX) models and cell line-de-
rived xenograft (CDX) models. Tumor-bearing mice were randomized into
treatment groups and received vehicle, RAD140, fulvestrant, palbociclib,
everolimus or combinations of RAD140 with palbociclib or everolimus. Tu-
mor volume and growth was measured to evaluate effıcacy. At the end of the
study, plasma and tumor samples were collected for pharmacokinetic and
pharmacodynamic analysis. In AR/ER breast cancer PDX models,
RAD140 treatment led to substantial tumor growth inhibition that was
greater than that seen with fulvestrant. Furthermore, combination of
RAD140 with palbociclib or everolimus produced further enhanced anti-
tumor effıcacy in these models. In summary, RAD140 demonstrated tissue-
selective AR agonism with marked anti-tumor activity in AR/ER breast
cancer CDX and PDXmodels, together with enhanced anti-tumor activity in
combination with a CDK4/6 inhibitor or mTOR inhibitor.
#3609 RAD140, a selective androgen receptor modulator, has a differen-
tiated mechanism of action in AR/ER positive breast cancers. Ziyang Yu,
Suqin He, Dannie Wang, Jeffrey Brown, Jamal Saeh, Gary Hattersley. Radius
Health, Inc., Waltham, MA.
Recent studies have shown that the androgen receptor (AR) is widely ex-
pressed across all subtypes of breast cancer, with AR detected in 75-95% of
estrogen receptor (ER) positive tumors. Prior to the development of ER-targeted
therapy, androgens were used to treat breast cancers with favorable clinical
responses. The lack of tissue-selectivity and understanding of mechanism of
action of classic androgens led to its declined use in this disease. Selective an-
drogen receptor modulators (SARMs) are a class of molecules developed as
tissue selective non-steroidal androgens that modulate AR signaling. However,
the effect of SARMsonAR signaling in breast cancer cells is notwell understood.
RAD140 is an orally available SARMwith potent anabolic activity inmuscle and
bone but a highly attenuated effect in seminal vesicles and prostate. Its effıcacy is
being evaluated in in vivo xenograft models of AR/ER breast cancer. To fur-
ther our understanding of the mechanism of action of RAD140 in breast cancer
cells, we examined the effects of RAD140 onAR and ER signaling pathways. The
specifıcity and selectivity of RAD140 were examined using competitive binding
assays forAR, ER, glucocorticoid receptor (GR) andprogesterone receptor (PR),
and using an AR reporter assay in AR/ER ZR-75 breast cancer cells and LN-
CaP prostate cancer cells. RAD140 was found to bind AR with high affınity and
specifıcity, with 250-fold target selectivity over the next nuclear receptor PR. The
AR reporter assay results demonstrated a potent AR agonist activity of RAD140
inZR-75 breast cancer cells but not in LNCaPprostate cancer cells, in contrast to
the full agonist activity of DHT seen in both cell types. RAD140 treatment led to
substantial tumor growth inhibition in AR/ER breast cancer xenografts. Sam-
ples of RAD140-treated xenografts were analyzed by immunocytochemistry,
western blotting and quantitative real-time PCR to evaluate the modulation of
AR and ER pathways. It was found that the expression of knownAR target genes
includingKLK2, FKBP5 and the tumor suppressor gene, ZBTB16, were potently
induced in RAD140-treated tumors. Furthermore, RAD140 led to substantial
suppression of known ER target genes including progesterone receptor (PR),
TFF1 andGREB1. In conclusion, RAD140 is a potent tissue-selectiveAR agonist
in AR/ER breast cancer cells with robust activation of AR targets genes, and a
unique mechanism of action that leads to the suppression of ER signaling, and
marked anti-tumor activity.
#3610 Synergy between androgen receptor (AR)-targeting agents seviter-
onel (SEVI) or enzalutamide (ENZA) and mTOR or HER2 pathway-target-
ing agents in breast cancer. Michael A. Gordon,1 Nicholas D’Amato,1 Jessica
Christenson,1 Beatrice Babbs,1 Haihua Gu,1 JuliaWulfkuhle,2 Emmanuel Petri-
coin,2 Anthoy Elias,1 Jennifer K. Richer1. 1Univ. of Colorado Anschutz Medical
Campus, Denver, CO; 2George Mason University, Manassas, VA.
Background: AR is expressed in60% of HER2 and up to 50% of triple nega-
tive breast cancer (TNBC)with growing evidence thatARplays a role in BC growth
and survival. Next-generation AR-targeting agents including SEVI (selective
CYP17-lyase and AR inhibitor) and ENZA (AR inhibitor) have shown promise in
preclinical and clinical models of prostate cancer and are currently being evaluated
in BC. Approved therapeutics targetingmTOR such as everolimus (EVEROL) and
HER2-targetingagentsprovide signifıcantclinicalbenefıt in someBCpatients;how-
ever, de novo and acquired resistance remain critical issues that may be partially
attributed tocompensatoryARaction.Hypothesis:Due tocross-regulationbetween
AR and the HER2/PI3K/mTOR pathway in BC, targeting AR in combination with
approved agents for these pathways may improve responses. Methods: Human BC
cell linesHER2 (BT474,BT474-HR20,SKBR3)andTNBC(MDAMB453,BT549)
and an AR TNBC mouse mammary carcinoma model (Met-1) were used. Cells
were treated with multiple doses of AR-targeting agents SEVI or ENZA and
EVEROL, alone or in combination and assayed over time using IncuCyte instru-
mentation and combination indices calculated using Calcusyn. Anchorage inde-
pendencewas testedbygrowthonsoft agar.Pathwaycomponentgenesandproteins
were measured. In vivo, NOD/SCID mice with HER2 trastuzumab-resistant
BT474-HR20 xenografts were treated with ENZA, EVEROL, or the combination.
Similar in vivo experiments with SEVI are ongoing. Results: Both SEVI and ENZA
signifıcantly inhibited proliferation of both HER2 and TNBC cell lines. Both sig-
nifıcantly inhibited growth on soft agar in l Met-1 cells (p0.0005 for SEVI,
p0.032 for ENZA). Using 9 dose combinations of EVEROLwith SEVI or ENZA,
synergy was observed in multiple cell lines in vitro, but only in lines containing
activating PIK3CAmutations. DHT induced a cell line-specifıc increase in pHER2
and/or pHER3 that was attenuated by AR inhibition. EVEROL alone caused an
increase in total AR, pHER2, and pHER3, and these effects were also abrogated by
AR inhibition. In vivo, ENZA inhibited BT474-HR20 xenografts, and combining
ENZA with EVEROL decreased tumor viability more than either single agent
(p0.001, repeated measures ANOVA). Similar in vivo studies with SEVI are
planned. Conclusion: Agents targeting AR synergize with EVEROL. Combination
therapies targeting AR and the mTOR and HER2/HER3 pathways may provide
benefıt forHER2andTNBCpatients. SEVIwasa stronger inhibitorof anchorage-
independent growth than ENZA and will thus be further investigated in combina-
tionwithapprovedHER2/PI3K/mTORpathway-directed therapeutics invivo.This
work was funded by DOD BCRP - Clinical Translational Award BC120183
W81XWH-13-1-0090 to JKR and 0091 to AE and R01 CA187733 to JKR
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#3611 Proteasome subunit PSMD1 participates in p53 degradation and
regulates proliferation of breast cancer cells. Toshiyuki Okumura,1 Kazuhiro
Ikeda,1 Wataru Sato,1 Kuniko Horie-Inoue,1 Satoshi Inoue,1 Satoru Takeda,2
Koji Okamoto3. 1Saitama Medical University, Saitama Prefecture, Japan; 2Jun-
tendo University School of Medicine, Tokyo, Japan; 3National Cancer Center
Research Institution, Tokyo, Japan.
Breast cancer is the most common cancer among women in developed coun-
tries. Generally, 70% of primary breast cancer patients express estrogen recep-
tor, thus endocrine therapy is often effıcient for the disease using antiestrogen
such as tamoxifen as well as aromatase inhibitor. During long-term therapy,
however, a substantial proportion of women recurrent and acquire resistance to
endocrine therapy. Understanding of the mechanism underlying acquired en-
docrine resistance would be a fırst step toward overcoming hormone-refractory
cancer. In this study, we identifıed candidate genes that contributed to tamox-
ifen resistance in MCF-7 breast cancer cells by functional screening based on
short hairpinRNA (shRNA) library.We found that several candidate geneswere
overexpressed in breast cancer patients and their abundance was positively as-
sociated with poor prognosis of cancer patients in clinical database. Moreover,
the genes associated with poor prognosis also showed positive association with
shorter survival for patients treated with tamoxifen. Expression levels of these
candidate genes were upregulated in hydroxytamoxifen (OHT)-resistant
MCF-7 cells (OHTR) compared with parental cells. Proliferation of OHTR cells
was repressed by siRNAs targeting 26S subunits, non-ATPase 1 (PSMD1) and
tetraspanin12 (TSPAN12). Furthermore, knockdown of PSMD1 inhibited cell
cycle progression and p53 protein degradation. p21 and 14-3-3, target genes of
p53, were upregulated by PSMD1 knockdown. These fındings would be used for
the development of alternative diagnostic and therapeutic options for endo-
crine-resistant breast cancers.
#3612 Combination FGFR4 and ER-targeted therapy for invasive lobular
carcinoma. Kevin Levine,1 Jian Chen,1 Matthew Sikora,2 Nilgun Tasdemir,1
George Tseng,1 Shannon Puhalla,1 Rachel Jankowitz,1 David Dabbs,1 Priscilla
McAuliffe,1 Adrian Lee,1 Steffı Oesterreich1. 1University of Pittsburgh, Pitts-
burgh, PA; 2University of Colorado, CO.
Background: Invasive Lobular Carcinoma (ILC) is an understudied subtype
of breast cancer. Distinctive properties of ILC include growth patterns, meta-
static behavior, receptor status (almost universally estrogen receptor (ER) pos-
itive), and survival outcomes (Long-term survival is lower in patients with ER
ILC compared to the other main histological subtype, invasive ductal carci-
noma). Our lab recently generated six long-term estrogen deprivation (LTED)
models of ILC cells. We performed RNA-Sequencing on these six LTED cell
lines and identifıed differentially expressed genes compared to their parental
cells cultured with estrogen.We overlapped these results with a previously pub-
lished analysis of a tamoxifen-resistant ILC cell line and found that FGFR4 is the
most consistently overexpressed gene in the setting of acquired resistance to
endocrine therapy in ILC cells. Hypothesis FGFR4 is an important mediator of
resistance to endocrine therapy in ILC. Methods: To study the role of FGFR4 in
acquired resistance to endocrine therapy, we used siRNA,multiple shRNAs, and
specifıc small molecule inhibition for growth assays of ILC cells. To study the
role of FGFR4 in de novo resistance to endocrine therapy, we collected 129 well
curated ER ILC tumor specimens. We performed gene expression analysis on
the pre-treatment samples using a custom NanoString panel. Results: FGFR4
inhibition decreases parental and LTED ILC cell growth in classic 2D growth
conditions, in the setting of ultra-low attachment, and in colony formation as-
says.Mechanistically, FGFR4 and estrogen signaling are antagonistic in parental
ILC cells. In our clinical samples, increased expression of FGFR4 is predictive of
shorter time to distant recurrence. Conclusion: FGFR4 may play an important
role in both acquired and de novo resistance to endocrine therapy in ILC. Future
studies will assess the effıcacy of combining FGFR4 inhibitors with ER-targeted
therapy for patients with ILC.
#3613 Development of chemically modifıed peptide inhibitor ERAP tar-
geting BIG3-PHB2 complex on hormone-resistant breast tumor. Toyomasa
Katagiri, Tetsuro Yoshimaru. Tokushima Univ., Tokushima, Japan.
Approximately 70% of breast cancer cells express estrogen receptor alpha
(ER), anddependon estrogen (E2) for proliferative andmetastatic activity. The
current endocrine therapies for breast cancer aremainly based on targeting ER
signaling using selective ERmodulators, ER downregulators, and aromatase
inhibitor. However, up to 50% of patients with ER-positive tumors either ini-
tially do not respond or become resistant to these drugs. The precise molecular
mechanisms for the endocrine resistance contributes to be an active area of
research. Therefore, identifying the factors and pathways responsible for resis-
tance and defıning ways to overcome it lead to develop novel molecular-target
therapies to endocrine resistance. Recent fındings support that the Brefeldin
A-inhibited guanine nucleotide-exchange protein 3-prohibitin 2 (BIG3-PHB2)
complex plays a crucial role in E2/ER signaling modulation in these cells.
Moreover, specifıc inhibition of the BIG3-PHB2 interaction using ER activity-
regulator synthetic peptide (ERAP: 165-177 amino acids) derive from a helical
BIG3 sequence, a dominant-negative peptide inhibitor leads to the signifıcant
anti-tumor effect. However, duration of its effect is very short for clinical use.
Here, we report the development of the chemically modifıed ERAP using sta-
pling methods (stapled ERAP) to improve duration of its antitumor effects. The
stapled ERAP specifıcally inhibited the BIG3-PHB2 interaction, thereby exhib-
iting the long-lasting suppressive activity and their intracellular localization
without membrane-permeable polyarginine sequence supposedly through the
formation of stable -helix structure induced by the stapling. Importantly, a
combination of stapled ERAP and tamoxifen caused a synergistic inhibitory
effect in breast cancer cell growth. Tumor bearingmice treatedwith every 7 days
with stapled ERAP treatment effectively prevented the BIG3-PHB2 interaction
as well as daily treatment, leading to the complete regression of E2-dependent
tumor in vivo. Our fındings suggest that the stapled ERAP may be a promising
anti-tumor drug to suppress the growth of luminal-type breast cancer in clinical
use.
#3614 Antibody validation revises estrogen receptor beta research. Sandra
Andersson,1Mårten Sundberg,1 Nusa Pristovsek,1 Ahmed Ibrahim,2 Philip Jon-
sson,3 Borbala Katona,1 Carl-Magnus Clausson,1 Agata Zieba,1Margareta Ram-
ström,1Ola Söderberg,1 CeciliaWilliams,2 AnnaAsplund1. 1UppsalaUniversity,
Uppsala, Sweden; 2KTH Royal Institute of Technology, Solna, Sweden; 3Univer-
sity of Houston, Houston, TX.
The discovery of estrogen receptor  (ER/ESR2) in 1996 was a landmark
discovery. Its homology with breast cancer pharmacological target and predic-
tive biomarker estrogen receptor  (ER /ESR1) raised hopes for improved
endocrine therapies. However, after twenty years of intense research the thera-
peutic promises have notmaterialized.We here perform a rigorous validation of
13 anti-ER antibodies, and demonstrate that the vast majority are unspecifıc.
Using well-characterized controls and a panel of validation methods, we con-
clude that only the rarely used monoclonal antibody PPZ0506 targets ER in a
specifıcmanner in immunohistochemistry.We applied this antibody for protein
expression profıling in 44 normal and 21 malignant human tissues, and found
that detection of ER protein is limited to testis, ovary, placenta, lymphoid cells,
granulosa cell tumors, and a subset ofmalignantmelanoma and thyroid cancers.
This expression pattern aligns well with RNA-seq data, but contradicts a multi-
tude of studies.Wedid not fınd evidence that normal or cancerous humanbreast
express ER protein. Our study highlights how inadequately validated antibod-
ies can lead an exciting and promising fıeld astray.
#3615 Combined targeting of estrogen receptor alpha and nuclear
transport pathways remodel metabolic pathways to induce apoptosis and
overcome tamoxifen resistance. Eylem Kulkoyluoglu-Cotul,1 Zeynep Madak-
Erdogan,1 Yosef Landesman,2 Kinga Wrobel1. 1University of Illinois Urbana-
Champaign, Urbana, IL; 2Karyopharm Therapeutics Inc., Newton, MA.
There is a critical need for novel therapeutic approaches to re-sensitize recur-
rent ER () tumors to endocrine therapies. The objective of this study was to
elucidate mechanisms of improved effectiveness of combined targeting of ER
and XPO1, a nuclear transport protein in overcoming endocrine resistance.
UsingCignal Finder pathway analysis, Seahorsemetabolic profıling andGC/MS
whole metabolite profıling, we found that combination of 4-OH-Tam and Se-
linexor (SXR), being evaluated in multiple later stage clinical trials in patients
with relapsed and /or refractory hematological and solid tumor malignancies,
inhibited Akt phosphorylation by changing the localization of the kinase. Since
we observed dramatic changes in Akt activity we hypothesized that glucose
utilization pathways andmetabolic profıle of breast cancer cells would change in
the presence of 4-OH-Tam and SXR. These cells were more dependent on mi-
tochondria for energy production. Their glucose and fatty acid dependency
decreased in the presence of SXR and cells weremore dependent on glutamine as
themitochondrial fuel source.We showed that combined targeting ofXPO1 and
ER rewires metabolic pathways, increase demand onmitochondria and causes
increased production of ROS that would eventually lead to apoptosis. Re-mod-
elling metabolic pathways to regenerate new vulnerabilities in endocrine-resis-
tant tumors is novel, and given the need for better strategies for improving
therapy response of relapsed ER () tumors, our fındings show great promise
for uncovering the role ER-XPO1 crosstalk plays in reducing cancer recur-
rences.
ENDOCRINOLOGY: Nuclear Receptors and Endocrine Oncology Therapies
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 921
#3616 Potential therapeutic use of Estrogen Receptor  agonist in the
prevention and progression of breast cancer usingHER-2/neumousemodel.
Kumaraguruparan Ramasamy, Cathy Samayoa, Naveen K. Krishnegowda,
Ratna K. Vadlamudi, Rajeshwar R. Tekmal. University of Texas Health Science
Center at San Antonio, San Antonio, TX.
Breast cancer is the most common cancer among women worldwide. Hor-
mone-mediated therapy to treat estrogen receptor alpha (ER) positive breast
cancers include the use of ER antagonist, Tamoxifen, aromatase inhibitors and
other compounds that degrade ER. Unlike ER, ER has been shown to have
tumor-suppressive function in various cancers, including breast cancer. Recent
studies have identifıed, synthesized, and tested the clinical safety of ER-selec-
tive agonists. Given the tumor-suppressive properties of ER, it may be possible
to use these compounds to induce or activate the ER and test their role in the
chemoprevention and blocking the progression of breast cancer.We have inves-
tigated the therapeutic utility of ER agonists in the prevention and progression
of breast cancer using MMTV-HER2/neu mice transgenic mouse model.
MMTV-HER2/neu mice develop premalignant lesions at 4-5 months, and tu-
mors starting at month 7 due to overexpression of the HER2/neu proto-onco-
gene. MMTV-HER2/neu mice were treated with an ER agonist, LY500307
examined the prevention and progression of mammary cancers in these mice.
When compared to controls, ER agonist-treated mice exhibited a signifıcant
decrease in the development of preneoplastic changes. Differential gene expres-
sion analysis revealed a signifıcant change in the expression of a number of genes
in response to LY500307 treatment. Pathway analysis identifıed an enrichment
for chemokines signaling pathways, particularly TNF, in blocking the develop-
ment of preneoplastic changes resulting from treatment with ER agonists. Our
studies also show a decrease in the formation of mammary tumors in HER-2/
neu mice with preexisting preneoplastic changes when treated with LY500307.
This study suggests that ER agonist treatment may be a valuable therapeutic
option for the prevention in women at increased risk of breast cancer and in
blocking the progression of hormone receptor positive breast tumors.
#3617 A paradigm shift for insulin-like growth factor 1 receptor function
in triple negative breast cancers. Alison Obr, Sushil Kumar, Raymond Birge,
Teresa Wood. Rutgers University-NJMS, Newark, NJ.
Signaling through the insulin-like growth factor type 1 receptor (IGF-1R) is
complex in breast cancers. Early studies reported that expression of the IGF-1R
correlated with estrogen receptor (ER) expression and predicted a favorable
phenotype. Moreover, loss of IGF-1R has been associated with breast tumor
progression into a more undifferentiated phenotype. We have generated and
characterized a mouse line containing both MMTV-Wnt1 and MMTV-
dnIGF-1R (kinase dead-IGF-1R) transgenes (referred to subsequently as bigenic
mice) that leads to increased mammary tumor initiation and metastasis. These
data support the hypothesis that the IGF-1R functions in suppressingmetastasis
in certain contexts and subtypes of triple negative breast cancers (TNBCs). Re-
cent analyses of TCGA human datasets support the relevance of our model in
human TNBCs that have reduced IGF-1R expression and increased expression
of Wnt1 and the Frizzled co-receptor Lrp6. We have identifıed alterations in a
number of target genes that potentially regulate metastasis in the bigenic pri-
mary tumors including increases in interleukin-6 (IL-6), Slug, Vimentin, Zeb
1/2 and decreases in E-cadherin expression as assessed by Qiagen specifıc qPCR
and single gene qPCR. Furthermore, a subset of anti-inflammatory chemokines
and cytokines were assessed by a targeted qPCR array revealing increases in
interleukin-4, interleukin-10, and C-Cmotif chemokine ligand-2 and decreases
in tumor necrosis factor-alpha in the bigenic tumors indicating a tumor associ-
ated macrophage phenotype. By flow cytometry analysis, the ratio of CD4 T
cells to CD8 T cells is increased in the bigenic tumors suggesting a tumor
promoting immune microenvironment. However, increased expression of IL-6
in the bigenic tumors is specifıc to the luminal tumor cells, and inhibition of
IGF-1R in the MCF7 human breast cancer cell line results in increases in IL-6,
Slug, and Zeb 1/2 expression suggesting the tumor cells activate EMT and a
pro-tumorigenic microenvironment in response to decreased IGF-1R. More-
over, inhibition of IGF-1R in human breast cancer cells and MMTV-Wnt1
mouse tumor cells results in increased cell motility and invasion as assessed by
the xCELLigencemotility assay. Taken together, our data support the hypothesis
that IGF-1R acts as a negative regulator of mediators that promote migration,
invasion, and metastasis in TNBCs.
#3618 PELP1 cytoplasmic mislocalization favors estrogen-induced sig-
naling via AIB1 in ER breast cancer models. Thu H. Truong, Julie H. Os-
trander, Carol A. Lange. University of Minnesota Masonic Cancer Center, Min-
neapolis, MN.
Luminal breast cancers account for 75% of cases and express (ER) and
frequently contain a range of progesterone receptor (PR) positive cells. ER and
PR are steroid hormone receptors (SR) that rapidly and dynamically shuttle
between the cytoplasm and the nucleus, a process that allows for essential cross-
talk with cytoplasmic signaling pathways that serve as direct inputs to SR tran-
scriptional functions. During disease progression, aberrant hormone signaling
often leads to expression of altered SR gene programs and endocrine resistance.
An emerging biomarker of increased risk and aggressive cancer behavior is
cytoplasmic PELP1. Our lab was the fırst to show that PELP1 forms a functional
signaling and transcriptional complex with ER and PR to regulate novel estro-
gen-driven SR target genes associated with endocrine resistance. PELP1 is pri-
marily nuclear in normal breast tissue, but cytoplasmic localization of PELP1
(cyto-PELP1) is observed in 40-58% of invasive tumors. To elucidate the impact
of PELP1mislocalization on SR signaling pathways and transcription programs,
we have generated SR breast cancer cell models expressing vector, wild-type
(nuclear) PELP1, and cyto-PELP1. Our studies show that cells expressing cyto-
PELP1 exhibit increased mammosphere formation relative to WT-PELP1 or
vector control cells in response to estrogen. Moreover, we have identifıed AIB1
(ER co-activator) as a robust binding partner for cytoplasmic, but not nuclear
PELP1, through mass spectrometry. This interaction occurs in a hormone-de-
pendent manner as shown by co-immunoprecipitation assays. AIB1 activation
(i.e. phosphorylation levels) is increased in cyto-PELP1 cells relative to WT-
PELP1 or control cells. Knockdown of AIB1 reduces cyto-PELP1 protein levels
and leads to decreased gene expression of key pro-inflammatory and immune
regulatory cyto-PELP1 target genes.Our results reveal novel cytoplasmic actions
of AIB1 and highlight the signifıcance of delineating the impact of dynamic
PELP1 shuttling/mislocalization with respect to altered hormone/SR-driven
target gene expression in luminal breast cancer progression.We conclude direct
signaling inputs to SR complexes are profoundly altered in the context of PELP1
mislocalization and interaction with AIB1. Our fındings are relevant to mecha-
nisms of endocrine resistance that may be targeted by inhibitors of the
PELP1/SR interaction.
#3619 Role of MTDH in estrogen-regulated gene expression. Xiangbing
Meng, Yujun Li, Jesus Gonzalez Bosquet, shujie yang, Kristina W. Thiel, Kim-
berly K. Leslie. Univ. of Iowa College of Medicine, Iowa City, IA.
Disruption of estrogen signaling is widely associated with the development of
breast, endometrial, and ovarian cancers. As a multifunctional mediator of car-
cinogenesis, metadherin (MTDH)/AEG-1 overexpression has been associated
with numerous types of cancers, with reported roles in tumor initiation, prolif-
eration, invasion, metastasis and chemoresistance. At the molecular level,
MTDH has been shown to interact with proteins that drive tumorigenesis, in-
cluding NF-B, PLZF, BCCIP and SND1. Through analysis of the Cancer
GenomeAtlas (TCGA) datasets for ER-positive endometrial and breast cancers,
we found that over 25% of all gene expression correlated with MTDH. Using
Affymetrix microarrays, we characterized the differences in gene expression
between estrogen-treated parental andMTDH-defıcient endometrial and breast
cancer cells. We also explored a possible interaction betweenMTDH and ER by
immunoprecipitation and found that MTDH and ER associated in both breast
and endometrial cancer cells in response to estrogen. Reciprocal co-immuno-
precipitation analysis demonstrated that acute estrogen stimulation promoted
the interaction ofMTDHwith ER in the nucleus. These data suggest thatMTDH
and ER interact in the nucleus with estrogen treatment, and MTDH/ER co-
regulated genes may have functions in drug resistance, metastasis and tumor
progression.
#3620 RARalpha interactome in breast cancer, the S100 calcium binding
protein A3 binds tothe retinoid receptor. Mineko Terao. Istituto di Ricerche
Farmacologiche Mario Negri, Milano, Italy.
All-trans-retinoic acid (ATRA) is used in the treatment of acute promyelo-
cytic leukemia. ATRA is endowed with promising anti-tumor activity in other
tumor types, including breast cancer. In breast cancer, the anti-tumor activity of
ATRA is mediated by the retinoid nuclear receptor, RAR (EMBO Mol Med.
2015 7:950-972). RAR is a ligand-dependent transcriptional factor, which is
part of nuclear complexes regulating the expression of target genes. Todefıne the
RAR interactome in breast cancer cells we took a proteomic approach. We
performed mass-spectrometric analysis of RAR immuno-precipitates from
nuclear extracts of anATRA-sensitive breast cancer cell line over-expressing the
receptor. We identifıed 30 proteins differentially interacting with RAR in the
absence/presence of ATRA. Three of these proteins FABP5, HSP27 and S100A3
interact with RAR in the absence of ATRA and their binding to the receptor is
dramatically reduced upon addition of the retinoid ligand. Binding of the three
proteins to RAR was validated by different types of immuno-precipitation
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experiments. We focused our attention on S100A3, a calcium binding protein
whose function is largely unknown. Pull-down and Far-Western experiment
indicated that S100A3 binds directly to RAR. Binding is specifıc to this nuclear
receptor isotype as similar interactions with S100A3 are not observed with
RAR, RAR or RXR. S100A3 over-expression inhibitedRAR ligand-depen-
dent transcriptional activity, suggesting that the calcium-binding protein is a
co-repressor. We designed specifıc shRNAs targeting S100A3 and we are in the
process of evaluating their functional effects on ATRA-dependent anti-tumor
activity in retinoid sensitive breast cancer cell lines.
#3621 Characterization of the effects of estrogen receptor alpha Y537S
and D538G mutations on receptor pharmacology. Steven J. Hartman,1 Tracy
Kleinheinz,1 Jonathan White,2 Stephen Daly,2 Ria Goodwin,2 Wei Zhou,1 Jun
Liang,1 Xiaojing Wang,1 Daniel F. Ortwine,1 Lori Friedman,1 Martin
O’Rourke,2 CiaraMetcalfe,1 Robert A. Blake1. 1Genentech, Inc., South San Fran-
cisco, CA; 2Charles River Laboratories, Harlow, United Kingdom.
The frontline therapy for estrogen receptor alpha (ER) positive Breast Can-
cer (ERBC) involves various forms of endocrine therapy, consisting of either
Selective Estrogen Receptor Modulators (SERMs) or aromatase inhibitors. An
emerging mechanism of ERBC resistance to endocrine therapy, and conse-
quently disease relapse, has been associated with a set of “hotspot” mutations in
and near to helix-12 of the ER ligand binding domain. Selective Estrogen Re-
ceptorDegraders/Down-regulators (SERDs) represent an important pharmaco-
logical strategy being applied to develop treatments for resistant ERBC. Here,
we compare 2 of themost frequent ER hotspotmutations (Y537S andD538G),
with ERwildtype (WT) and the ability of a set of SERM/SERDs and other ER
ligands to bind, antagonize, degrade/stabilize ER and affect cell proliferation.
Common themes that emerged included the observation that the concentration
of each drug required to bind, antagonize or degrade ERY537S or ERD538G
was typically higher than that required for ERWT, although the extent of the
shift varied between drugs and the type of measurement. An unexpected obser-
vation was that 4-hydroxy-tamoxifen (a major active metabolite of tamoxifen)
stabilized nuclear ER Y537S protein. This represents a potential mechanism
that may limit the effıcacy of Tamoxifen in treating ER Y537S ERBC.
#3622 Crosstalk between automethylation and phosphorylation tightly
regulatesG9a andGLP coactivator functionwith steroid hormone receptors.
Coralie Poulard,Michael Stallcup.University of SouthernCalifornia, Los angeles,
CA.
Hormone-activated steroid receptors (SR) bind to specifıc regulatory ele-
ments on DNA and recruit coregulators which remodel chromatin, regulate
assembly of the transcription complex, and regulate transcription of their target
genes. As for many coregulators, the lysine methyltransferases G9a and GLP
function in both activation and repression of transcription depending on the
target gene. Indeed, G9a and GLP catalyze methylation of H3K9, a well-known
repressive mark, but can also act as coactivators of SR (e.g. estrogen receptor 
and glucocorticoid receptor or GR). G9a and GLP can form homo- and het-
erodimers via interactions between their C-terminal domains. At the molecular
level, we established that GLP, as well as G9a, is methylated on the N terminal
domain of the protein, which is the region implicated in coactivator function.
This event is required for the recruitment of HP1g, while HP1g binding to G9a
and GLP is inhibited by aurora B-mediated phosphorylation of G9a or GLP
adjacent to the methylation site. In transient reporter gene assays, mutations of
G9a and GLPmethylation sites signifıcantly decreased their coactivator activity
with GR. Inversely, inhibition of Aurora kinase B activity increased the reporter
gene activation. In addition, inhibition of the kinase activity of Aurora B in-
creased the expression of endogenous GR target genes positively regulated by
G9a and GLP, while depletion of HP1g inhibited their expression. Moreover
methylated G9a or GLP can form a ternary complex with HP1g and GR in cell
lines, and HP1g was recruited to the GR binding sites of the target genes posi-
tively regulated by G9a and GLP (but not on GR target genes that do not require
G9a or GLP). Interestingly, the subset of GR target genes positively regulated by
G9a and GLP contains some genes involved in cellular movement. At the phys-
iological level, we established that G9a and GLP act as coactivators of GR target
genes that mediate glucocorticoid repression of cell migration, which accompa-
nies epithelial-to-mesenchymal transition associated with cancer progression.
In this study we demonstrated that G9a and GLP methylation is required for
their coactivator function with GR, because it facilitates recruitment of HP1g
which functions selectively as a coactivator for genes positively regulated byG9a,
GLP andGR. Inversely, G9a andGLPphosphorylation antagonizes these effects.
This competition could be involved in the switch to determine whether G9a and
GLP function as coactivator or corepressor on specifıc target genes. Defıning the
specifıc molecular functions of SR coregulators and how their recruitment and
actions are coordinated is key to understanding how transcription is regulated
and will suggest new targets in steroid hormone regulated cancer and in other
steroid hormone-related diseases.
#3623 Preclinical effıcacy of the selective GR antagonist, CORT125134.
Hazel Hunt, Joseph Belanoff, Thad Block, Stacie P. Shepherd. Corcept, Menlo
Park, CA.
The role of activation of the glucocorticoid receptor (GR) in the response of
several solid tumor types to chemotherapy has been reported by several groups.
Skor et al1 have demonstrated that the non-selectiveGR antagonistmifepristone
canpotentiate the effect of paclitaxel in amouse xenograft derived fromahuman
triple negative breast cancer (TNBC) cell line. GR activation is thought to play a
role in the regulation of pro- and anti-apoptotic genes. Isikbay et al2 have dem-
onstrated the benefıts of combining androgen deprivation therapy with GR an-
tagonism inprostate cancer xenograftmodel. Signaling viaGRappears to be able
to compensate for lack of androgen receptor signaling, and to contribute to
castrate resistance. CORT125134 is a novel, selective GR antagonist being de-
veloped for the treatment of a variety of solid tumors, in combination with an
appropriate standard of care agent. CORT125134 is currently being studied in a
Phase1/2 study in solid tumors, in combinationwith nab-paclitaxel. The effıcacy
of CORT125134 in combination with standard of care agents has been investi-
gated in mouse xenograft models of several tumor types. Previous reports of the
benefıt of adding a GR antagonist to chemotherapy in a TNBC model and an
ovarian cancer model have been confırmed. An enhancement of the anti-tumor
effect of castration by the addition of a GR antagonist has been confırmed in a
model of prostate cancer. In addition, CORT125134 has been shown to provide
a signifıcant improvement in the effıcacy of paclitaxel in a pancreatic cancer
model. In a MIAPaca-2 xenograft model, paclitaxel was given i.v. every 4 days
either alone or in combination with CORT125134. The combination provided
signifıcantly better tumor group inhibition than paclitaxel alone (p0.0001).
These encouraging results in a pancreatic cancer model extend the potential
utility of GR antagonism in a variety of solid tumor types. In the TNBC model,
alternative dosing regimens have been investigated, and suggest that stress dur-
ing dosing is a confounding factor in these studies. 1. Skor MN, Wonder E,
Kocherginsky M, et al. Glucocorticoid receptor antagonism as a novel therapy
for triple negative breast cancer. Clinical Cancer Res. 2013;19(22):6163-6172. 2.
IsikbayM,Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to
resistance to androgen-targeted therapy in prostate cancer. HormCancer. 2014;
5(2):72-89.
#3624 CAR T cells targeting ICAM-1 trigger strong antitumor effects
against advanced human thyroid tumors. Irene M. Min, Yogindra Vedvyas,
Enda Shevlin, Marjan Zaman, Brian Wyrwas, Weibin Wang, Susan Park, Mau-
reen Moore, Theresa Scognamiglio, Rasa Zarnegar, Thomas J. Fahey, Moonsoo
M. Jin.Weill Cornell Medicine, New York, NY.
Introduction: Poorly differentiated thyroid cancer and anaplastic thyroid
cancer (ATC) are rare yet inherently lethal malignancies with limited treatment
options. Manymalignant tumors, including papillary thyroid cancer (PTC) and
ATC, are associated with increased expression of intercellular adhesion mole-
cule-1 (ICAM-1), providing a rationale for utilizing ICAM-1-targeting agents
for the treatment of aggressive types of thyroid cancer. Therefore, we developed
a third-generation chimeric antigen receptor (CAR) targeting ICAM-1 to lever-
age adoptive T cell therapy as a new treatment modality against advanced thy-
roid cancer. Methods: We created a fırefly luciferase-expressing human ATC
model in mice that develops systemic metastases very rapidly. ATC engrafted
mice were treated with human peripheral blood T cells modifıed with a lentivi-
rus encoding an ICAM-1 specifıc CAR (ICAM-1-CAR) to investigate their ther-
apeutic effıcacy. Tumor burden was longitudinally measured by whole body
bioluminescence imaging of luciferase-positive tumor cells. Effector:target as-
says consisting of ICAM-1-CAR T cells co-cultured with multiple malignant
and non-malignant target cells were used to investigate specifıc target cell death
and ’off-tumor’ toxicity in vitro using luminescence and flow cytometry. Results:
ICAM-1-CAR T cells demonstrated robust and specifıc killing of PTC and ATC
cell lines in vitro. Strikingly, despite heterogeneous expression of ICAM-1 in
ATC cell lines, addition of cytotoxic CAR T cells induced increased ICAM-1
expression by T cell-derived interferon gamma such that all cell lines became
targetable by ICAM-1-CAR T cells. Patient-derived, poorly differentiated PTC
cells overexpressed ICAM-1 and were also mostly eliminated by autologous
ICAM-1 CAR T cells in vitro. In mice with systemic ATC, a single administra-
tion of ICAM-1-CAR-T cells at a clinical dosemediated signifıcant tumor killing
with a 100-fold reduction in primary tumor burden compared to pre-treatment.
Reductions in tumor burden persisted for over 80 days and treated mice dem-
onstrated signifıcantly improved survival without toxicity. Conclusion: Our
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fındings are the fırst demonstration of the potential for CAR-T cell therapy for
metastatic, advanced thyroid cancers. ICAM-1-CAR T cells demonstrated sig-
nifıcant therapeutic effıcacy in vitro and in vivo and extended survival benefıts in
animal models.
#3625 Thyroid hormone, thyroxine, promotes cell proliferation and
-catenin activation in colorectal cancer.Yee-Shin Lee,1Meng-Ti Hsieh,1 Yu-
Tang Chin,2 Aleck Hercbergs,3 Paul J. Davis,4 Han-Chung Wu,5 Hung-Yun
Lin1. 1Taipei Medical University and Academia Sinica, Taipei, Taiwan; 2Wan-
FangMedical Center, TaipeiMedical University, Taipei, Taiwan; 3The Cleveland
Clinic, Cleveland,OH; 4AlbanyCollege of Pharmacy andHealth Sciences, Albany,
NY; 5Academia Sinica, Taipei, Taiwan.
Backgrounds: Being a crucial hormone regulating growth, metabolism and
various physiological processes, the status of thyroid hormone has long been
implicated in cancer risks and tumor developments. In the present study, we
aimed to look at the role of thyroid hormone, thyroxine (T4), in colorectal cancer
cell proliferation and -catenin activation, which is highly involved in both
normal and oncogenic developments of the gut. Materials and Methods: The
effects of T4 in colorectal cancer cell lines HCT 116 (APC wild type) and HT-29
(APC mutant) as well as the primary cells derived from colorectal cancer pa-
tients were studied. Cell proliferation was evaluated according to cell counting,
MTT assay and qRT-PCR. The activation of -catenin was examined using
Western blotting, qRT-PCR and immunoprecipitation. Results: The results
showed that T4 increased the cell number of both HCT 116 and HT-29 cells
compared to the untreated cells. In both cell lines, T4 induced nuclear -catenin
accumulation and the protein levels of WNT/-catenin targets Cyclin D1 and
c-Myc. ThemRNA expression of CTNNB1was elevated by T4 in HCT 116 cells,
but not in HT-29 cells. In APCwild type HCT 116 cells, T4 increased theWNT4
mRNA expression and decreased the association between -catenin and the
WNT-regulated -catenin destruction complex. Moreover, the cell numbers of
T4-treated primary cells were higher compared to the untreated cells while the
mRNA expressions of proliferative genes PCNA, CCND1 and c-Myc were ele-
vated by T4. In the primary cells, T4-induced nuclear -catenin accumulation,
protein levels of Cyclin D1 and c-Myc, andmRNA expressions of CTNNB1 and
WNT4 were also observed. Conclusions: T4 promoted cell proliferation and
-catenin activation in colorectal cancer. In the cells with different APC muta-
tion status, the activation of -catenin was regulated by different mechanisms.
#3626 Anti-cancer effect of ulipristal acetate in uterine leiomyosarcoma.
Jeong-Won Lee, Ji-Eun Hong, Young-Jae Cho, Chel Hun Choi, Duk-Soo Bae,
Hye-Kyung Jeon, Jae Ryoung Hwang. Samsung Medical Center, Seoul, Republic
of Korea.
Objectives: Uterine leiomyosarcoma (LMS) is a rare uterine malignancy that
arises from the smooth muscle of the uterine wall. Although LMS is an aggres-
sive tumor associated with a high risk of recurrence, current radiotherapy and
chemotherapy is limited role in the treatment. Therefore, the introduction of a
new therapy for LMS of the uterus is urgently needed. Ulipristal acetate (UPA,
selective progesterone receptor modulator) is used for pre-operative treatment
of moderate to severe symptoms of uterine fıbroids because UPA-treated fı-
broids shown about inhibition of proliferation and induction of apoptosis and
remodeling of the extracellular matrix. However, anti-cancer effect of LMS has
not yet been reported. This study was designed to investigate preclinical effıcacy
of UPA as anti-cancer agent in LMS cells. Methods: We treated UPA in human
LMS cells including SK-UT-1 andMESSA to evaluate the effect on cell prolifer-
ation usingMTT assay. To check the apoptosis according to UPA treatment, we
performed ELISA in LMS cells. In addition, in vivo therapy experiments of UPA
were done using xenografts using SK-UT-1 andMESSA in nudemice. SK-UT-1
or MESSA cells were injected s.c, into mice (n 10 per group) and these were
randomly assigned to two groups: PBS (control), oral UPA 2mg/kg once daily.
All specimens were fıxed in 4% paraformaldehyde and paraffın-enclosed for
examination. Sections 4 m thick were stained with TUNEL and immunohis-
tochemistry. Result: UPA signifıcantly inhibited the cell survival the growth and
increased the apoptosis in SK-UT-1 and MESSA cells. In in vivo experiments,
UPA signifıcantly decreased the tumor growth in both mice with SK-UT-1 and
MESSA cells compared with control (both p0.001). Moreover, the immuno-
histochemical analysis using in vivo tumor samples showed that UPA treated
group decreased Ki-67 expression and increased apoptosis revealed by TUNEL
assay compared with control. Conclusions: We found that UPA have anti-can-
cer-effects in LMS cells via the action to cell proliferation and apoptosis through
in vivo and in vivo tests. Further studies using patient-derived tumor xenograft
model (Avatar mice) and detailed mechanisms of anti-cancer effects for UPA
will be needed.
#3627 Validation of PPARG and RXRA as drivers of bladder cancer. Jon-
athan T. Goldstein,1 Craig Strathdee,1 Fujiko Duke,1 Juliann Shih,1 Matthew
Meyerson2. 1Broad Institute, Cambridge, MA; 2Dana Farber Cancer Institute,
Boston, MA.
A subset of muscle-invasive bladder cancer (BLCA) is typifıed by PPARG
pathway activation. PPARG focal gene amplifıcation occurs in 15% of bladder
cancer patients, and similarly, 5% of BLCA patients possess hotspot mutations
in the requisite heterodimer partner of PPARG, RXRA (S427F, S427Y).We used
genetic perturbation to study the role of PPARG in bladder cancer. Our results
show that overexpression of RXRA and PPARG mutant alleles activate expres-
sion of PPARG and PPARA target genes in a ligand-independent manner, and
that bladder cancer cell lines are dependent on PPARG for viability. These fınd-
ings suggest that PPARGmay be a promising therapeutic target for treatment of
bladder cancer.
IMMUNOLOGY: BITES Bispecifıcs and Checkpoints
#3628 T cell-dependent bispecifıc antibody anti-CD79b/CD3 as a poten-
tial therapy for B-cell malignancies. PeiyinWang, Maria Hristopoulos, Robyn
Clark, Yvonne Chen, Diego Ellerman, Mary Mathieu, Christoph Spiess, Jessica
Li, Cecile Chalouni, Siddharth Sukumaran, Eric Stefanich, Jeffrey Wallin, Rob-
ert Li, Tanja Zabka, Klara Totpal, Mark Dennis, Allen Ebens, Stephen Gould,
Andrew Polson, Liping Laura Sun. Genentech Inc., South San Francisco, CA.
T-cell recruiting bispecifıc antibodies and antibody fragments have been used
to harness the cytotoxic potential of T cells for cancer treatment. We have ad-
opted a knobs-into-holes antibody format and produced T-cell dependent
bispecifıc antibodies (TDB), as full length, humanized IgG1 antibodies with
natural antibody architecture, which allow one arm to target various B cell an-
tigens while the other arm recruits T cells by binding to the CD3 subunit of the
T-cell receptor. One B cell antigen targeted is CD79b, a component of the B cell
receptor complex, which has been clinically validated by an anti-CD79b anti-
body-drug conjugate (ADC) as a safe and effective therapeutic target for B cell
malignancies (Leukemia 2015 Pfeifer et.al). In the present work, we show that
anti-CD79b/CD3 TDB is active against lymphoma cells with a wide range of
CD79b antigen levels in vitro. In addition, anti-CD79b/CD3 TDB appears to be
insensitive to the status of cellular signaling pathways in lymphoma cells as it is
active against cell lines that are resistant to the BTK inhibitor ibrutinib or an
anti-CD79b ADC with a cleavable tubulin inhibitor as the payload. In vivo,
anti-CD79b/CD3 TDB administration inhibited tumor growth in B-cell lym-
phomaxenograftmodels and resulted in potent B-cell depletion in the blood and
spleens in a humanized murine model. To assess the safety of targeting CD79b
with a T-cell recruiting bispecifıc antibody in non-human primates, a surrogate
anti-cynoCD79b/CD3 TDB with comparable in vitro potency was produced
with a target arm that recognizes cynomolgus monkey CD79b and the same
anti-CD3 arm. In a single dose pharmacokinetic/pharmacodynamics/safety
study, anti-cynoCD79b/CD3 TDB administration at 1mg/kg resulted in potent
B cell depletion, as well as T cell activation and proliferation, which was assessed
by flow cytometry on blood and lymphoid tissue and immunohistochemistry on
lymphoid tissue. The pharmacokinetic properties of anti-cynoCD79b/CD3
TDB resembled that of IgG antibodies; though with a faster clearance likely due
to CD79b antigen internalization and enhanced binding to CD3 when com-
pared to previously described anti-CD20/CD3 TDB. Transient cytokine release
was observed as elevated levels of IL-2, IL-6, IFN-gamma and TNF-alpha were
detectedwithin 24 hours following administration. Anti-cynoCD79b/CD3TDB
was well-tolerated in the majority of dosed animals without toxicologically sig-
nifıcant fındings. Collectively, these preclinical data suggest anti-CD79b/CD3
TDB can be a potential therapeutic agent in B cell malignancies.
#3629 Engineering a novel asymmetric head-to-tail 21 T-cell bispecifıc
(21 TCB) IgG antibody platform with superior T-cell killing compared to
11 asymmetric TCBs. Christian Klein,1 Christiane Neumann,1 Tanja Fauti,1
Tina Weinzierl,1 Anne Freimoser-Grundschober,1 Inja Waldhauer,1 Linda
Fahrni,1 Sylvia Herter,1 Erwin van Puijenbroek,1 Sara Colombetti,1 Johannes
Sam,1 Sabine Lang,1 Sherri Dudal,2 Wolfgang Schäfer,3 Jörg T. Regula,3 Samuel
Moser,1 Oliver Ast,1 Ralf Hosse,1 Ekkehard Mössner,1 Peter Brünker,1 Marina
Bacac,1 Pablo Umana1. 1Roche Pharma Research & Early Development,
Schlieren, Switzerland; 2Roche Pharma Research & Early Development, Basel,
Switzerland; 3Roche Pharma Research & Early Development, Penzberg, Ger-
many.
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T cell bispecifıc antibodies that recruit and engage T cells for tumor cell killing
through binding to the T cell receptor (TCR) upon binding to a tumor antigen
(TA) and subsequent crosslinking have attracted broad interest. Here, we de-
scribe a novel asymmetric head-to-tail 21T cell bispecifıc antibody (21TCB)
platformcharacterized by the fusion of a flexible Fab fragment to theN-terminus
of the CD3e Fab of a heterodimeric asymmetric bispecifıc TA-CD3e IgG1 anti-
body in head-to-tail geometry via a flexible linker. The resulting TCB is mon-
ovalent for CD3e (KD 70-100 nM) and binds bivalently with avidity to the TA on
the target cell. Correct heavy chain pairing is enabled by knob-into-holes tech-
nology, correct light chain pairing by CrossMAb technology or using a common
light chain. This enables production with standard processes in CHO cells. To
exclude FcgR-mediated unspecifıc TCR and FcgR co-activation resulting in un-
specifıc cytokine release, Fc- effector functions (ADCC, ADCP, CDC) are abol-
ished by introduction of P329G LALA mutations while FcRn binding and IgG-
like pharmacokinetic properties are retained as shown in mouse and
Cynomolgus. For comparative profıling, the following TCBs were generated
with specifıcity for the tumor antigens MCSP/CSPG4, FOLR1/FRalpha,
CD19 and CD20: 21 TCBCD3-inside, 21 TCBCD3-outside, one-armed 11
TCBCD3-inside and a classical asymmetric 11 IgG TCB. In vitro Jurkat-NFAT, T
cell killing, activation and proliferation assays show that both 21 TCB formats
mediate superiorpotencyof killing (forCSPG4,FOLR1,CD19,CD20) and superior
absolute killing (forCSPG4,CD19) compared to the respective classical asymmetric
11 IgGTCB. Surprisingly, the 21TCBCD3-inside formatwas found to be superior
inpotency compared to the21TCBCD3-outside format, although its bindingaffınity
for CD3e is reduced. These data confırm that TCBsmediate extremely potent T cell
killing with fM-pM EC50 values based on CD3e antibodies with affınities of only
70-100 nM. Notably, for CD19 both, 21 TCBCD3-inside and one-armed 11
TCBCD3-inside,mediate comparable potency andoverall killing, andbothwere supe-
rior compared to the asymmetric 11 IgG TCB. These data underline the impor-
tance of the head-to-tail geometry with two Fabs on one arm attached to each other
via a flexible G4S-linker. Finally, using 21 and 11 FOLR1TCBswe demonstrate
that bivalent binding allows better differentiation in killing of cells with high vs. low
FOLR1 expression as compared to monovalent binding. Taken together, we dem-
onstrate that the 21TCBCD3-inside is themost potent, effıcacious andversatileTCB
design. Due to its orientation with the CD3e Fab inside, it allows the conversion of
existing antibodies into potent TCBswithout format restriction. Based on this plat-
form,CEACD3TCB (RG7802, Phase I/Ib) andCD20CD3TCB (RG6026, Phase I)
have entered clinical trials.
#3630 Preclinical evaluation of a BiTE® antibody construct with extended
half-life that targets the tumor differentiationmarkermesothelin.Alexander
Sternjak,1 Fei Lee,2 Joachim Wahl,1 Dan Rock,2 Oliver Thomas,1 Sabine
Stienen,1 Ralf Lutterbuese,1 Patrick Hoffmann,1 Tobias Raum,1 Peter Kufer,1
Benno Rattel,1 Angela Coxon,3 Matthias Friedrich,1 Julie Bailis2. 1Amgen, Inc.,
Munich, Germany; 2Amgen, Inc., South San Francisco, CA; 3Amgen, Inc., Thou-
sand Oaks, CA.
Bispecifıc T cell engager (BiTE®) antibody constructs redirect T cells to induce
lysis of tumor cells. The anti-CD19/CD3 BiTE® Blincyto® can deplete target cells
in both the blood and tissue compartment in B cellmalignancies, suggesting that
the BiTE® mechanism of action will also be effective against solid tumors. The
tumor differentiation antigen mesothelin (MSLN) is an attractive target for the
BiTE® approach. MSLN is highly expressed in80% of ovarian and pancreatic
tumors and mesothelioma. Expression of MSLN in normal tissues appears re-
stricted to mesothelial cell surfaces such as the pleural, pericardial, and perito-
neal layer. Here, we report the preclinical characterization of an anti-MSLN/
CD3 BiTE® antibody construct with extended half-life. The BiTE® antibody
construct bindsMSLN and CD3 with low nM affınity and has low pM cytotoxic
activity against MSLN-positive ovarian, pancreatic and lung cancer cell lines in
vitro. Activity of the anti-MSLN/CD3 BiTE® antibody construct is observed at
low effector to target cell ratios, and in cancer cells that express low levels of
MSLN. This BiTE® antibody construct is also cytotoxic to cell lines that are
resistant to chemotherapy. In mice, signifıcant tumor growth inhibition of an
established ovarian tumor xenograft model was achieved by IV dosing of the
anti-MSLN/CD3 BiTE® antibody construct every 5 days. Pharmacokinetic eval-
uation of the anti-MSLN/CD3 BiTE® antibody construct in non-human pri-
mates demonstrated a half-life of 4-10 days. The potency and specifıcity of the
anti-MSLN/CD3 BiTE® antibody construct, together with projected ability to
dose once a week IV in humans, supports development of this BiTE® for treat-
ment of MSLN-positive tumors.
#3631 Delivery of a CD20 transferrin receptor VNAR bispecifıc antibody
to the brain for CNS lymphoma. Frank S. Walsh, Krzysztof Wicher, Jaroslaw
Szary, Pawel Stocki, Michael Demydchuk, Lynn Rutkowski. Ossianix, Philadel-
phia, PA.
Penetration of the blood brain barrier (BBB) remains a signifıcant hurdle in
the development of biologic therapeutics for CNS-related cancers. Antibody-
based molecules typically do not cross the BBB in amounts required for thera-
peutic effıcacy. Receptor-mediated transporters in the luminal membrane of
brain capillary endothelium, which normally transport circulating endogenous
peptides and proteins, offer a non-invasive approach for the delivery of thera-
peutic molecules to the brain.Using a combination of in vitro and in vivo phage
display technology, we isolated a panel of cross species (rodent, primate and
human) binders to the transferrin receptor 1 (TfR1) from synthetic libraries of
shark variable antigen receptors (VNARs). Initially, the anti-TfR1 VNARs were
fused to an immunoglobulin Fc backbone for testing in mice. At therapeutic (2
mg/kg) doses delivered by tail vein injection, high levels of the VNAR-Fc anti-
bodies were found in the brain after 18 hours, which exceeded 5% of the plasma
levels. Brain fractionation studies showed that the VNAR-Fc antibodies to TfR1
translocated to the brain parenchyma and were not retained in the capillaries.
The lead anti-TfR1 VNAR was then used to target aberrant B cells in the brain
for conditions such as cerebral lymphoma where existing CD20 therapies to not
penetrate the CNS at therapeutic doses. A family of anti-CD20/TfR1 bispecifıc
molecules were produced by linking the small VNAR to either the N- and C-
terminus of heavy and light chains to create both monovalent and bivalent
fusions . We used rituxan as the CD20 agent. The bispecifıcs were assessed for
binding to the two cognate antigens and then tested for brain penetration after
tail vein injection.At least 4 different formats gave excellent brain penetration 18
hours after dosing at 3.75mg/kg. Unmodifıed rituxan had a brain plasma ratio of
0.25 in line with published data while the best anti-TfR1-rituximab bispecifıc
formats were between 2 to 5%. The bispecifıc formats also retain antibody-
dependent cell-mediated cytotoxicity and will be further tested for brain pene-
tration in non-human primates and in rodent models of CNS lymphoma. If
these results successfully translate from rodents to larger animals, the peripheral
delivery of a brain penetrant CD20/TfR1 bispecifıc antibody would provide a
safer andmore effective alternative to CD20 antibody delivery by the intrathecal
route and could have broad utility in B cell driven brain cancer.
#3632 BiTE® antibody constructs for the treatment of SCLC. Michael J.
Giffın, Ed K. Lobenhofer, Keegan Cooke, Tobias Raum, Jennitte Stevens, Pedro
J. Beltran, Angela Coxon, Paul E. Hughes. Amgen, Inc., Thousand Oaks, CA.
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor
with a poor prognosis and limited therapeutic options. Most patients present
with extensive stage disease, where recent advances in immunotherapies, in-
cluding bi-specifıc T cell engager (BiTE®) antibody constructs, represent a prom-
ising new therapeutic approach. BiTE® molecules have demonstrated durable
complete responses in the clinic in hematological malignancies. Similar to he-
matological malignancies, SCLC is also a widely-disseminated malignancy that
shows very high response rate to fırst line therapies with high rates of disease
recurrence, features which may support effıcacy of the BiTE® modality. Next
generation sequencing (NGS) identifıed Delta-like Ligand 3 (DLL3) as a highly
specifıc tumor associated antigen for SCLC, with consistent expression in tu-
mors and very low expression in normal tissues. Tumor expression of DLL3
protein was confırmed by IHC, with 30 of 35 SCLC tumors staining positive for
DLL3. DLL3 BiTE® antibody constructs showed low pM potency in vitro and
also demonstrated signifıcant inhibition of tumor growth in vivo in an ortho-
topic model of SCLC. A half-life extended (HLE) BiTE® targeting DLL3 demon-
strated antibody-like pharmacokinetic properties in single-dose studies in non-
human primates (NHP), with a half-life of 11 days. This is predicted to support
every other week dosing in humans. The combination of high potency and
excellent PK properties suggests that HLE BiTE®moleculesmay provide a useful
tool for targeting residual disease in SCLC patients whose tumors express DLL3.
#3633 Anti-SSTR2	 anti-CD3 bispecifıc antibody induces potent killing
of human tumor cells in vitro and inmice, and stimulates target-dependentT
cell activation in monkeys: A potential immunotherapy for neuroendocrine
tumors. Sung-Hyung Lee, Seung Y. Chu, Rumana Rashid, Sheryl Phung, Irene
W. Leung, Umesh S. Muchhal, Gregory L. Moore, Matthew J. Bernett, Suzanne
Schubbert, ConnieArdila, Christine Bonzon, Paul Foster,David E. Szymkowski,
John R. Desjarlais. Xencor, Monrovia, CA.
Somatostatin receptor 2 (SSTR2) is highly expressed in neuroendocrine tu-
mors (NETs) and small cell lung cancer (SCLC). Treatment options for NETs
include somatostatin analogs and radionuclides; however, such therapies suffer
from short half-life, modest effıcacy, and toxicities due to inhibition of other
SSTRs. Reasoning that a targeted immunotherapy against SSTR2would provide
a new therapeutic modality for NETs, we designed XmAb18087, a humanized
and affınity-optimized bispecifıc antibody that engages T cells to stimulate redi-
rectedT cell-mediated cytotoxicity (RTCC)of SSTR2 tumor cells. XmAb18087
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possesses an Fc domain that maintains long half-life, yet lacks binding to Fc
receptors to reduce Fc-mediated effector functions. XmAb18087 stimulated ro-
bust RTCC of SSTR2 cell lines including medullary thyroid carcinoma (TT),
lung carcinoma (A549), and CHO cells overexpressing SSTR2, with EC50s of
1 to 100 ng/ml. XmAb18087 also upregulated CD69 and CD25 activation
markers on CD4 and CD8 T cells. T cell responses were target-specifıc, because
SSTR2 cell lines were not depleted, and because a control bispecifıc (anti-RSV
x CD3) was ineffective. In addition, XmAb18087 (3 mg/kg weekly) reduced
tumor burden of an established A549 xenograft in NSGmice engrafted with 107
human PBMC.We next assessed XmAb18087 activity in cynomolgus monkeys.
As SSTR2 is not expressed in peripheral blood, target cell depletion cannot be
monitored in vivo. However, CD3 bispecifıcs induce effects such as lymphocyte
extravasation, cytokine induction, andT cell activation, which can serve as phar-
macologicmarkers for activity in target organs. XmAb18087 dosed once at 30 or
60 g/kg rapidly activated peripheral T cells, as quantifıed by CD69 and CD25
induction (peaking at8-12 hr). T cells rapidly extravasated from blood, with a
nadir by 8 hr. Cytokines IL6 and TNF were rapidly induced, peaking at1-8 hr
and returning to baseline by 48 hr. To explore repeat dosing, XmAb18087 was
dosed at 1 or 10 g/kg on Days 0 and 7 in a second study. The fırst dose of both
1 and 10 g/kg again stimulated peripheral T cell activation, extravasation, and
cytokine induction. These responses decreased markedly after the second dose,
suggesting that SSTR2 target cells remained depleted for at least 7 days. In
summary, these results on human cells, inmice, and inmonkeys support clinical
assessment of XmAb18087 in SSTR2 cancers including NETs and SCLC. In
monkeys, T cell activation, extravasation, and cytokine induction were readily
measured in peripheral blood and are indicative of T cell-mediated depletion of
SSTR2 target cells. Importantly, these responses may also serve as useful sur-
rogate markers of NET depletion in clinical trials of XmAb18087.
#3634 A novel tumor-targeted 4-1BB agonist and its combination with
T-cell bispecifıc antibodies: an off-the-shelf cancer immunotherapy alterna-
tive to CAR T-cells. Christina Claus, Claudia Ferrara, Sabine Lang, Rosmarie
Albrecht, Sylvia Herter, Maria Amann, Sandra Richards-Grau, Johannes Sam,
Sara Colombetti, Marina Bacac, Christian Klein, Pablo Umana. Roche Innova-
tion Center Zurich, Zurich, Switzerland.
Immune cell costimulation via 4-1BB agonism has shown anti-tumor activity
in the clinic and is an important element of next-generation chimeric-antigen-
receptor (CAR) adoptive T-cell therapy approaches. However, the clinical de-
velopment of fırst-generation, 4-1BB agonistic antibodies has been hampered by
signifıcant hepatic toxicity. Activity of such fırst-generation, 4-1BB agonistic
antibodies typically depends on their hyperclustering via Fc-gamma-receptor
(FcgR)-binding. Here we describe a next generation, tumor-targeted 4-1BB ag-
onist whose activity is independent of FcgR-binding. The molecule consists of
an IgG fusion protein composed of a trimeric, human 4-1BB ligand (4-1BBL), a
targeting Fabmoiety recognizing fıbroblast activation protein (FAP), and a het-
erodimeric Fc region engineered to be devoid of interactions with FcgRs and
C1q. The molecule mediates potent costimulation of CD8 T-, CD4 T- and NK-
cells, but only in the presence of FAP-expressing cells, such as cancer associated
fıbroblasts, which are highly prevalent inmany solid tumors. This FAP-targeted
4-1BB agonist is signifıcantly more potent and effıcacious than fırst generation,
standard 4-1BB agonistic antibodies when compared side-by-side in preclinical
models.We show its activity in a variety of preclinicalmodels including reporter
cell assays, assays with primary T- and NK-cells, ex-vivo assays with patient
tumor-derived material including cancer cells, stroma cells and tumor-infıltrat-
ing lymphocytes, fully immunocompetent murine tumor models (employing a
surrogate, murinized molecule targeting murine FAP and carrying murine
4-1BBL), and in human hematopoietic stem cell-humanized mice with human
tumor xenografts. We also demonstrate its activity in combination with check-
point inhibitors and with T-cell redirecting approaches, such as a CEA-CD3
T-cell bispecifıc antibody. We show that hepatic toxicity of fırst generation,
standard 4-1BB antibodies is dependent on FgR interactions and the next gen-
eration, FcgR-independent and FAP-targeted molecule described here is safe
and does not induce any hepatotoxicity in preclinical models including non-
human primates where it was tested at doses of up to 50 mg/kg and where it
showed a long circulatory half-life. Its combination with T-cell bispecifıc anti-
bodies induces amassiveT cell accumulation in the tumor, accompaniedwith an
elevated CD8/Treg ratio, as compared to the respective monotherapies. There-
fore, we conclude that the tumor-targeted cross-linking of 4-1BB provides a safe
and effective way for the co-stimulation of T cells for cancer immunotherapy
and its combinationwith T-cell bispecifıc antibodiesmay provide an alternative,
but more convenient, off-the-shelf approach to CAR T-cell therapies. The mol-
ecule is scheduled to enter clinical trials soon.
#3635 Improved T Cell activation bioassays to advance the development
of bispecifıc antibodies and engineered T cell immunotherapies. Richard L.
Somberg, Pete Stecha, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong, Jey
Cheng. Promega Corp., Madison, WI.
T cells play a central role in cell-mediated immunity and can mediate long-
term, antigen-specifıc, effector andmemory responses. In recent years, a variety
of immunotherapy strategies aimed at inducing, strengthening or engineering T
cell responses have emerged as promising approaches for the treatment of dis-
eases such as cancer and autoimmunity. Currentmethods used tomeasureTCR-
mediated T cell proliferation and cytokine production rely on primary PBMCs
as a source of T cells, which must be stimulated via co-culture with APCs or
anti-TCR/CD3 antibodies. These assays are laborious and highly variable due to
their reliance on donor primary cells, complex assay protocols and unqualifıed
assay reagents. As a result, these assays are diffıcult to establish in quality-con-
trolled drug development settings. To overcome this barrier, we developed two
reporter-based bioluminescent T cell activation bioassays that can be used for
the development of bispecifıc antibodies and engineered T cell immunothera-
pies. The assays consist of Jurkat T cells genetically engineered to express lu-
ciferase downstream of either NFAT or IL-2 response elements. The T cell acti-
vation bioassays reflect themechanisms of action of biologics designed to induce
TCR and/or CD28-mediated T cell activation, as demonstrated using anti-CD3
and/or anti-CD28 antibodies as well as blinatumomab, a bispecifıc antibody that
simultaneously binds CD3 expressed on T cells and CD19 expressed on malig-
nant B cells. The bioassays are pre-qualifıed according to ICH guidelines and
show assay specifıcity, precision, accuracy and linearity required for routine use
in potency and stability studies. Finally, our data illustrate the use of reporter-
based T cell activation bioassays for characterizing andmeasuring the activity of
engineered chimeric antigen receptor T cells.
#3636 Potent antitumor activity of duvortuxizumab, a CD19 	 CD3
DART
®
molecule, in lymphoma models. Liat Izhak,1 Dana E. Cullen,1 Maha
Elgawly,1 Leopoldo Luistro,1 Syd Johnson,2 Jaime Bald,1 A Kate Sasser,1 Sriram
Balasubramanian1. 1Janssen Research & Development, LLC, Spring House, PA;
2MacroGenics, Inc., Rockville, MD.
Duvortuxizumab (JNJ-64052781 or MGD011) is a CD19 x CD3 DART® pro-
tein designed to engage and redirect CD3 T-cells to eliminate CD19 B-cells
through T-cell-mediated cytotoxicity. Duvortuxizumab displays potent killing
activity in lymphoma cell lines and animal models and is currently in clinical
development for the treatment of B-cell malignancies. Here we examined du-
vortuxizumab activity alone and in combination with standard chemotherapy
regimens in preclinical lymphoma models. Duvortuxizumab plus bendamus-
tine increased T-cell mediated cytotoxicity of CD19 Raji and DOHH2 lym-
phoma cells in the presence of isolated human pan T-cells (effector:target 
10:1). Minimal inhibition of T-cell activation was observed at bendamustine
concentrations up to 40 M. A Burkitt’s lymphomamodel was used to evaluate
the in vivo effects of duvortuxizumab plus bendamustine. NOD scid gamma
mice were subcutaneously implanted with Daudi tumor cells and inoculated
with either peripheral bloodmononuclear cells or purifıed, activated humanpan
T-cells. Duvortuxizumab was dosed at 0.5 mg/kg (7, twice weekly); benda-
mustine was dosed once at 25mg/kg on day 1. Dosing with bendamustine alone
inhibited tumor growth by 79% (p0.0002) whereas duvortuxizumab alone
resulted in complete tumor regression with no signs of relapse for up to 90 days.
Dosing with duvortuxizumab plus bendamustine resulted in complete and du-
rable tumor regression and elimination. Analysis of tumor-infıltrating lympho-
cytes (TILs) 3 days after the start of therapy showed that bendamustine inhibited
CD3 T-cell infıltration and activation whereas duvortuxizumab increased
both. The combination showed greater activation of CD4 and CD8 T-cells.
At 48 days after the last duvortuxizumab dose, TILs had a large percentage of
CD3

CD45RA- CCR7- cells, indicative of effector memory T-cells. This activa-
tion was accompanied by higher expression of PD-1 on T-cells and PD-L1 on
tumor cells. Similar effects were seenwhen duvortuxizumabwas combinedwith
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). In vitro,
a decrease in T-cell activation was observed with duvortuxizumab/CHOP,
which may have been caused by inclusion of prednisone; however, cytotoxicity
against tumor cells wasmaintained. In a patient sample-derivedmodel of diffuse
large B-cell lymphoma, duvortuxizumab (twice weekly for 4 consecutive weeks)
in combinationwith CHOP (given once) resulted in rapid tumor regression that
wasmore sustained than CHOP treatment alone. In summary, duvortuxizumab
has potent anti-tumor activity as a single agent and in combination with stan-
dard chemotherapy in lymphoma preclinical models. Duvortuxizumab-medi-
ated tumor killing and T-cell activation were maintained or increased in the
IMMUNOLOGY: BITES Bispecifıcs and Checkpoints
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017926
presence of multiple chemotherapeutics, suggesting the potential clinical utility
of combining duvortuxizumabwith standard therapies in the treatment of B-cell
malignancies.
#3637 Co-targeting of PD-1 and CTLA-4 inhibitory pathways with bispe-
cifıc DART® and TRIDENT™molecules.Gurunadh R. Chichili, Kalpana Shah,
Ross La Motte-Mohs, Alex Berezhnoy, Daorong Liu, Jessica Hill, Leilei He,
Christine Shoemaker, Jennifer Brown, Kurt Stahl, Hua Li, Jonathan Li, Sergey
Gorlatov, JimTamura,ValentinaCiccarone, RalphAlderson, EzioBonvini, Paul
A. Moore, Syd Johnson.MacroGenics, Rockville, MD.
Introduction: Immunotherapywith the combination ofmonoclonal antibod-
ies (mAbs) that block PD-1 (nivolumab) and CTLA-4 (ipilimumab) has shown
clinical benefıt beyond that observedwith eithermAb alone.We have developed
PD-1 x CTLA-4 bispecifıc proteins aimed at inducing antitumor immunity
through simultaneous blockade of both checkpoint molecules. Two proteins, a
tetravalent PD-1 x CTLA-4 bispecifıc DART® protein (bivalent for both PD-1
and CTLA-4) and a trivalent PD-1 x CTLA-4 TRIDENT™ protein (bivalent for
PD-1 butmonovalent for CTLA-4) were engineered; the TRIDENT protein was
designed to promote CTLA-4 blockade through avidity when bound to PD-1 on
cells co-expressing both receptors, thus favoring PD-1 over CTLA-4 blockade in
cells that do not co-express both molecules. Methods: Proteins were engineered
from humanized PD-1 and CTLA-4 mAb sequences and demonstrated favor-
able biophysical properties. Binding assays were performed by ELISA or flow
cytometry. Co-ligation of PD-1 and CTLA-4 was assessed in an enzyme-frag-
ment complementation assay (DiscoverX). T-cell activation was tested in re-
porter cells, staphylococcus enterotoxin B-stimulated PBMCs or MLR assays.
Results: Both DART and TRIDENT proteins showed equivalent potency in
binding immobilized recombinant PD-1 or PD-1-expressing cell lines, inhibi-
tion of PD-1 interactionwith PD-L1 or PD-L2 as well as reversal of PD-1/PD-L1
mediated T-cell signal inhibition. In all assays, both formats showed activities
that were comparable to those of the precursor PD-1 mAb. With respect to
CTLA-4, the DART protein showed aminor potency loss in binding to CTLA-4
expressing cells, inhibition of CTLA-4/B7 interaction and reversal of T-cell sig-
nal inhibition compared to the precursor mAb. The TRIDENT protein, how-
ever, showed substantial lower potency than the DART protein in all CTLA-4
assays, consistent with the monovalent nature of the CTLA-4 arm. Importantly,
in cells that co-express both receptors, DART and TRIDENT proteins show
comparable co-engagement of PD-1 and CTLA-4, as shown by enzyme-frag-
ment complementation, suggesting that anchoring through PD-1 compensates
for the decreased CTLA-4 avidity of the TRIDENT molecule when both target
receptors are expressed. Similarly, in T-cell co-activation assays, both DART
and TRIDENT proteins showed a comparable increase in IFN-gamma response
that recapitulated that observed with the combination of the individual parental
mAbs. Conclusion: Both PD-1 x CTLA-4 DART and TRIDENT bispecifıc mol-
ecules block PD-1 and CTLA-4 pathways, with the TRIDENT protein demon-
strating a PD-1-biased binding preference, consistentwith its design intended to
reduce CTLA-4 blockade in the absence of PD-1 co-expression. Both molecules
showed comparable T-cell activation activity. Further development of bispecifıc
PD-1 x CTLA-4 molecules for cancer treatment is warranted.
#3638 AMX-168, a long-acting, tumor protease-sensitive bispecifıc pre-
cursor for the treatment of solid malignancies. Bee-Cheng Sim. Amunix Op-
erating Inc., Mountain View, CA.
Bispecifıc T cell engagers (BiTE®) recruit highly cytotoxic host CD3 T cells
for destruction of tumor antigen-specifıc malignant cells. Bearing a defıned sin-
gle-chain antibody fragment (scFv) binding toCD3onT cells and a selected scFv
binding to tumor-specifıc antigen, BiTE-based antibodies suffer from a narrow
therapeutic window and short t1/2, requiring careful dose administration and
continuous infusion for effıcacy. To overcome these limitations, Amunix has
developed the ProTIA (Protease Triggered Immune Activators) platform by
incorporating its proprietary XTEN® protein polymer half-life extension tech-
nology into the design of such T cell-dependent bispecifıc cytotoxic payload
(BCP). An engineered protease cleavage site positioned between the BCPmoiety
and adjoining XTEN creates the novel, long-acting prodrug ProTIA molecule.
Insertion of the unique protease site enables selective cleavage of ProTIA by
tumor-associated proteases, facilitating localized release of active BCPs in tumor
tissues. Amunix’ lead ProTIA molecule, AMX-168, is in development for treat-
ment of epithelial cancer associated ascites. AMX-168 consists of an EpCAM
scFv coupled to an CD3 scFv that is linked to an XTEN protein sequence of
defıned length containing the embedded protease cleavage site. AMX-168 is
shown to release the active EpCAM-CD3 BCP by tumor-specifıc proteases
cleaving intact XTEN. Importantly, protease-treated AMX-168 BCP exhibits
(1), high specifıcity for EpCAM and CD3 targets; (2), achieves low picomolar
caspase activity in a panel of EpCAM human cancer lines in the presence of
human PBMC; (3), induces expression of CD25 and CD69 T cell activation
markers; and (4) release of key hallmark cytokines within 24 h when incubated
with amixture of EpCAM tumor cells and PBMC. The t1/2 ofEpCAM-CD3
ProTIA in mice is 32 h vs 3.5 h for its BCP counterpart, indicating potential for
weekly dosing in humans. The in vivo effıcacy of AMX-168 was evaluated in
human colorectal HCT-116 tumor cells  PBMC in NOD/SCID mice. AMX-
168 and its BCP-only moiety demonstrated therapeutic effıcacy vs vehicle, with
%TGI of 97% and 82%, respectively. AMX-168 demonstrated considerable sus-
tained tumor regression compared to the BCP-onlymoiety, supporting effıcient
conversion of AMX-168 to the active BCP at tumor site, and improved tumor
exposure of the long-acting AMX-168 compared to the BCP-only entity. Safety
assessment of EpCAM-CD3 ProTIA for uncontrolled cytokine release in the
presence of PBMCbut not EpCAM target cells, demonstrated ProTIA induces
signifıcantly less cytokine production compared to the BCP-onlymoiety. AMX-
168 is currently in preclinical development with an expected IND/CTA fıling by
the end of 2017. Successful proof-of-concept studies of AMX-168 support fur-
ther development of a broad pipeline of ProTIA therapeutics addressing a spec-
trum of common and advanced malignancies.
#3639 Therapeutic targeting of tumorigenic EphA2/EphA3 brain tu-
mor initiating cells with bi-specifıc antibody in human glioblastoma.
Maleeha Qazi,1 Parvez Vora,1 Chirayu Chokshi,1 Chitra Venugopal,1 Max Lon-
don,1 Amy Hu,2 Minomi Subapandtiha,1 Mohini Singh,1 Jarrett Adams,2 Jason
Moffat,2 Sachdev Sidhu,2 Sheila K. Singh1. 1McMaster University, Hamilton,
Ontario, Canada; 2University of Toronto, Ontario, Canada.
Glioblastoma (GBM), the most aggressive primary human brain tumor, car-
rier a dismal prognosis and is increasingly characterized by cellular and genetic
intra-tumoral heterogeneity (ITH). Many of the 14 members of the erythropoi-
etin-producing hepatocellular carcinoma receptor (EphR) family and their eph-
rin ligands are expressed inGBMcells and constitute potentialmolecular targets
for novel therapeutic agents. We hypothesize that multiple members of the
EphR family play a critical role in orchestrating the clonal evolution of GBM
progression. Individual Eph receptor targeting strategies have shown onlymod-
est pre-clinical success, likely because single agent therapy cannot target the
degree of ITH inGBM.Using a highly specifıc human Eph receptormonoclonal
antibody (mAb) panel (EphR profıler), we identifıed fıve Eph receptors with
dysregulated expression in recurrent GBM as compared to primary GBM.With
our unique chemoradiotherapy-adapted, patient-derived xenograft model of
GBM, we identifıed EphA2 and EphA3 expression to be upregulated after ther-
apy. Here we show that EphA2 and EphA3 co-expressionmarks a highly tumor-
igenic cell population in recurrent GBM with higher in vitro and in vivo self-
renewal and proliferation capacity as compared to EphA2/EphA3-, EphA2-/
EphA3 or EphA2-/EphA3- cells. Lentiviral mediated knockdown of EphA2
and EphA3 blocks this self-renewal and proliferation capacity in recurrent
GBM. Through further characterization using mass cytometry (CyTOF) assay,
we fınd that EphA2 and EphA3 is co-expressed with multiple brain tumor ini-
tiating cell (BTIC)markers (CD133,CD15, Bmi1, Sox2, Integrin6 andFoxG1).
Considering the important role of EphA2/EphA3 cells in GBM tumorigen-
esis and recurrence, we generated a bi-specifıc antibody (bsIgG) that co-targets
EphA2 and EphA3. In vitro treatment of GBM with bsEphA2/A3 IgG led to
pharmacological blockade of phosphorylated EphA2. We then assessed the in
vivo effıcacy of the bsEphA2/A3 IgG to block GBM tumor growth in our PDX
model, and found that treatment with intracranial bsIgG resulted in non-inva-
sive and signifıcantly smaller lesions. The striking reduction in tumor burden in
recurrent GBM after co-targeting of EphA2 and EphA3 validates the premise of
our therapeutic strategy of targeting multiple EphRs. Discovering the clonal
composition of recurrent GBM will enable us to target cellular subpopulations,
and this ITH, with selective compounds that inhibit BTIC and Eph receptor
activity with minimal off-target effects. Comprehensive Eph receptor profıling
of individual patient-derivedGBMwill allowus to develop a therapeutic strategy
for each patient’s tumor, employing polytherapy with mAbs against Eph recep-
tors expressed at recurrence.
#3640 Novel humanized anti-Sialyl-Tn, anti-CD3 bispecifıc antibodies
demonstrate tumor andT-cell specifıcity for immune activation at the tumor
site. David A. Eavarone, Jillian Prendergast, Patricia E. Rao, Jenna Stein, Jeff
Behrens, Daniel T. Dransfıeld. Siamab Therapeutics, Newton, MA.
Tumor-associated carbohydrate antigens (TACAs) historically have been
challenging targets for antibody therapeutics. Sialyl-Tn (STn) is a cancer specifıc
antigen that is expressed on the surface of carcinomas including ovarian, colon,
prostate, and pancreatic tumors but is rarely present in normal tissue. STn ex-
pression has been linked to innate immune suppression, a chemoresistant phe-
IMMUNOLOGY: BITES Bispecifıcs and Checkpoints
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 927
notype, metastasis, and poor prognosis. Previous attempts to target this antigen
in the clinic with synthetic glycan vaccines proved safe but lacked effıcacy. We
have developed humanized bispecifıc antibodies targeting STn and CD3 for
T-cell recruitment and activation at the tumor site. These bispecifıc antibodies
were selected for optimal tumor targeting using our glycan microarray that
enriches for candidates whose binding is protein-independent and glycan spe-
cifıc. STn-selective binding was demonstrated. Current lead candidates exhib-
ited low nanomolar EC50 binding in flow cytometric assays against both STn
expressing tumor cells and T cells. Quantifıcation of T-cell activation and T-cell
induced tumor killing in vitro provides a basis for the further clinical develop-
ment of these bispecifıc antibody candidates.
#3641 EGFR/CD16A TandAbs are effıcacious NK-cell engagers with fa-
vorable biological properties which potently kill EGFR tumors with and
without Ras mutation. Michael Kluge, Kristina Ellwanger, Uwe Reusch, Ivica
Fucek, Michael Weichel, Torsten Haneke, Stefan Knackmus, Joachim Koch,
Martin Treder. Affımed GmbH, Heidelberg, Germany.
Constitutive EGFR activation plays an important role in the pathophysi-
ology of various solid cancers, such as colorectal cancer, non-small cell lung
cancer or squamous cell carcinomas of the head and neck. Tyrosine kinase
inhibitors (TKI) and monoclonal antibodies (mAbs), which interfere with
signal transduction and activation of EGFR, are approved for treatment of
such cancers. However, intrinsic or acquired resistance to these treatments
has been described for many patients. Natural killer cells (NK-cells) are
important effectors of innate immunity and NK-cell engagers have shown
evidence of improved safety in patients compared to T-cell engagers. To
specifıcally utilize the cytotoxic potential of NK-cells to eliminate EGFR-
expressing tumors, we developed tetravalent bispecifıc EGFR/CD16A Tand-
Abs comprising fully human Fv domains recognizing human and cynomol-
gus EGFR and CD16A. TandAbs recognizing epitopes in the extracellular
domain of EGFR differing from epitopes targeted by other mAbs were char-
acterized. Lead candidate AFM24 shows superior cytotoxicity in terms of
ADCC (main mode of action) and reduced inhibition of EGFR-mediated
phosphorylation compared to cetuximab. Importantly, inhibition of EGFR-
signaling is believed to contribute to skin toxicity caused by therapeutic
mAbs and TKI’s. AFM24=s cytotoxic activity was tested against EGFR
tumor cell lines including some carrying a Ras mutation, which is a negative
prognostic biomarker and renders cells less susceptible to cetuximab or pa-
nitumumab. The cetuximab-resistant CRC cell line HCT-116 or the NSCLC
cell line A549 (both with Ras mutations) were effıciently killed with EGFR/
CD16A TandAbs in vitro. In vivo data in the HCT-116 model indicate anti-
tumor effıcacy of AFM24, while no effıcacy of cetuximab was seen. Impor-
tantly, AFM24 does not activate NK-cells without target cell binding and
does not bind to any other members of the EGFR family. While binding and
cytotoxic effıcacy of many therapeutic mAbs are impaired by serum IgG, no
substantial change in AFM24=s binding affınity to NK-cells was observed in
the presence of high concentrations of human IgG. In calcein-release cyto-
toxicity assays with NK-cells as effectors, we showed that the presence of IgG
had only little inhibitory effect on AFM24 effıcacy compared to cetuximab.
In addition, competition of an anti-CD16 mAb with AFM24 in cytotoxicity
assays was substantially lower than with cetuximab. Taken together our data
demonstrate that AFM24 is a highly potent human antibody displaying fa-
vorable biological properties over existing mAbs. This human/cynomolgus
cross-reactive agent is currently in preclinical development to treat EGFR
malignancies and has the potential to exhibit a favorable side effect profıle
and reduced toxicity and to overcome resistance to other targeted anti-EGFR
therapeutic agents.
#3642 Tumor-antigen expression-dependent activation of the CD137 co-
stimulatory pathway by bispecifıc DART® proteins. Liqin Liu,1 Chia-Ying K.
Lam,2 Vatana Long,1 Lusiana Widjaja,1 Yinhua Yang,1 Kalpana Shah,1 Doug
Smith,2 Joanna Pan,2 Syd Johnson,1 Ezio Bonvini,1 Paul Moore1. 1MacroGenics,
Rockville, MD; 2MacroGenics, South San Francisco, CA.
Introduction: CD137 (4-1BB) is a co-stimulatory molecule expressed by acti-
vated T and NK cells that, upon interaction with its CD137 ligand, further
supports cell activation, proliferation and survival. Activation via CD137 holds
great promise for cancer immunotherapy; however, current CD137 agonistic
interventions are associated with systemic safety concerns. To develop a thera-
peuticmodality that reduces the potential for systemicCD137 effects, we applied
the DART® bispecifıc platform to generate proteins that can induce tumor-an-
tigen dependent T-cell activation. Methods: DARTmolecules were constructed
containing anti-CD137 variable regions together with either anti-HER2 or anti-
EphA2 variable regions. DART binding properties were evaluated by ELISA or
flow cytometry; signaling responses assessed using a NF-B luciferase reporter
cell line expressing CD137. Co-stimulatory activity was characterized with pri-
mary human T cells in the presence or absence of tumor target antigen-express-
ing cells. Results: ELISA and flow cytometry analysis demonstrated that both
HER2 x CD137 and EphA2 x CD137 DART molecules bind their respective
target antigens. Co-culturing of a CD137/NF-B reporter cell line with tumor
lines expressing HER2 or EphA2 revealed tumor antigen-dependent CD137
pathway activation by HER2 x CD137 and EphA2 x CD137 DART molecules,
respectively. To evaluate the effects of HER2 x CD137 and EphA2 x CD137
DART molecules on T-cell responses, co-stimulation T-cell assays were per-
formed. In the presence of the relevant antigen-positive cell line, each respective
DARTmolecule was able to promote T-cell proliferation and cytokine release in
a HER2 or EphA2-dependent manner. No T-cell co-stimulation was observed
by either DART molecule in the absence of antigen-expressing tumor cells.
Furthermore, the level of tumor antigen-dependent co-stimulation supported
by the DART molecules correlated with the level of tumor target expression.
Consistent with the preferential induction of CD137 by the CD8 T cell subset,
CD137-based DART proteins induced a substantial increase in the fraction of
CD8 centralmemory and effectormemory T cells in the presence of the proper
tumor antigen expressing cells. Conclusions: HER2 x CD137 and EphA2 x
CD137 DART proteins promote T-cell co-stimulation in a tumor antigen-de-
pendent manner and may provide an opportunity to target the CD137 co-stim-
ulatory pathway for cancer immunotherapy, while limiting systemic T-cell ac-
tivation and related side effects.
#3643 INCAGN1876, a unique GITR agonist antibody that facilitates
GITR oligomerization. Ana M. Gonzalez,1 Mariana L. Manrique,1 Lukasz
Swiech,1 Thomas Horn,1 Jeremy Waight,1 Yuqi Liu,1 Shiwen Lin,1 Dennis Un-
derwood,1 Ekaterina Breous,2 Olivier Leger,2 Volker Seibert,2 TahaMerghoub,3
Roberta Zappasodi,3 Gerd Ritter,4 David Schaer,3 Kevin N. Heller,5 Kimberli
Brill,5 Peggy Scherle,5 Gregory Hollis,5 Reid Huber,5 Marc van Dijk,2 Jennifer
Buell,1 Robert Stein,1 Nicholas S.Wilson1. 1Agenus Inc, Lexington, MA; 2Agenus
Inc/ 4-Antibody, Basel, Switzerland; 3Memorial Sloan Kettering Cancer Center,
NewYork, NY; 4The Ludwig Institute for Cancer Research, NewYork, NY; 5Incyte
Corporation, Wilmington, DE.
Glucocorticoid-induced TNFR family related protein (GITR, CD357 or
TNFRSF18) is a member of the tumor necrosis factor receptor superfamily
(TNFRSF). Like other T cell co-stimulatory TNFR family members, GITR uti-
lizes multiple oligomerization states to regulate the initiation of downstream
signaling during T cell activation by antigen presenting cells (APCs). The for-
mation of receptor superclusters, comprised of two or more trimeric molecules,
has been defıned for multiple TNFRs as a means of regulating downstream
signal amplifıcation. For co-stimulatory TNFRs, like GITR, CD137 and OX40,
signaling outcomes in T cells are primarily mediated via the NFB pathway that
promotes cell survival and effector cell activities in response to suboptimal T cell
receptor (TCR) stimulation. It has been hypothesized that the manipulation of
the oligomeric states of co-stimulatory TNFRs using antibodies may have ther-
apeutic utility in enhancing the activity of tumor-reactive T cells, either as single
agents or in combination with other immunomodulatory or immune education
strategies. Here we describe a structure-based analysis of two functionally dis-
tinct classes of anti-human GITR antibodies that stabilize unique conforma-
tional states of the receptor. INCAGN1876, a human IgG1 monoclonal anti-
GITR antibody, was found to engage a conformational epitope located within a
-turn of the extracellular domain of GITR. This antibody binding sitemodifıed
the equilibrium of GITR monomer, dimer and trimers to promote receptor
oligomerization, resulting in downstream NFB signaling. Notably, this mode
of INCAGN1876 receptor engagement enabled it to effectively activate the
GITR pathway in recently primed T cells. By contrast, a second reference anti-
GITR antibody required concomitant TCR co-engagement in order tomodulate
the GITR pathway. High content confocal analysis was used to evaluate the
kinetics of GITR clustering by both classes of anti-GITR antibody, confırming
our T cell functional analysis. The ability of INCAGN1876 to engage and effec-
tively activate GITR on recently primed T cells may enable them to overcome
suppressive features of the tumor microenvironment. Notably, INCAGN1876
was shown to promote T cell co-stimulation both as a single agent and in com-
bination with other antibodies targeting PD-1, CTLA-4 and OX40. Finally, we
compared the pharmacologic activity of INCAGN1876 to Fc variants of this
antibody with diminished binding to the inhibitory Fc receptor (FcR),
CD32B. The superiority of an IgG1 antibody in these assays was consistent with
the potential to achieve optimal GITR clustering by FcRs, while maintaining
the potential for FcR-mediated effector cell activity directed toward intratu-
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moral GITRhigh regulatory T cells. INCAGN1876 is currently under evaluation
in Phase 1/2 studies in subjects with advanced metastatic solid tumors
(NCT02697591).
#3644 Combination of OX40L fusion protein with an anti-tumor vaccine
reduces lung metastasis and prolongs survival in a murine model of meta-
static triple negative breast cancer. Anthony S. Malamas,1 Scott A. Ham-
mond,2 Jeffrey Schlom,1 JamesW.Hodge1. 1National Cancer Institute, Bethesda,
MD; 2MedImmune, Gaithersburg, MD.
OX40 is a costimulatory receptor on activated T-cells that potentiates the
proliferation, survival, andmemory formation of the CD4 and CD8 immune
populations upon its interaction with OX40L on antigen presenting cells. The
engagement of OX40 on regulatory T-cells (Tregs) with its ligand has also been
shown to inhibit their suppressive capabilities. The use of exogenous OX40L
agonists for cancer immunotherapy is particularly attractive in combination
with cancer vaccines in order to boost the immune activity of antigen specifıc
T-cells and overcome self-tolerance and immunosuppressivemechanisms of the
tumor.We investigated the effıcacy of this strategy in the 4T1murinemammary
tumor model of metastatic triple-negative breast cancer by combining an
OX40L fusion protein (OX40L-FP) with a poxvirus-based cancer vaccine
(MVA-Twist-TRICOM) that induces T-cell responses specifıc to the tumor an-
tigen Twist, a transcription factor highly expressed in lung metastases.
OX40L-FPwas administered 3 and 6 days after the prime and boost vaccinations
to maximize its interaction with OX40 on activated T-cells. As single agents,
OX40L-FP and MVA-Twist-TRICOM had minimal effect on the formation of
lungmetastases in 4T1 tumor-bearingmice. However, when combined, the two
immunotherapies signifıcantly decreased the number of metastatic colonies per
lung, and prolonged survival after surgical resection of the primary tumor. An-
tibody depletion studies demonstrated that the observed anti-tumor effects were
mediated by both CD4 and CD8 T-cells. Immune subset analysis revealed
that the combination therapy increased the total number of CD4Foxp3- and
CD4 effector memory T-cells in both the lung and periphery compared to the
monotherapy controls. More importantly, the two agents synergistically in-
duced greater CD4 Twist-specifıc T-cell responses, as determined by ex vivo
proliferation assays using T-cells isolated from the lung and spleen that were
stimulated with Twist protein. Although the combination had no added effect
on the number of total CD8 and CD8 effector memory T-cells in relation to
the vaccine monotherapy, tetramer staining revealed a signifıcant increase in
CD8T-cells that were specifıc for Twist.We also observed a greater number of
CD8 T-cell memory precursors, as well as a greater number of IFN-produc-
ing CD8 T-cells in both the lung and periphery. Tregs isolated from the lung
and splenic tissue were found to be signifıcantly less suppressive following the
combination therapy, compared to those isolated from mice that received the
OX40L-FP and MVA-Twist-TRICOM single agent treatments. This study pro-
vides the rationale for pairing OX40 agonists with cancer vaccines to stimulate
CD4 and CD8 T-cell responses, while inhibiting Treg function, as a way to
induce specifıc immunity and clearance of metastatic tumors.
#3645 Preclinical characterization of a multi-specifıc DARPin molecule
targeting PD1 andVEGF. Jennifer Krieg, SchieggDieter, Taylor Joanna, Chris-
tel Herzog, Laurent Juglair, Nicolo Rigamonti, Mischa Mueller, Ulrike Fiedler,
Michael Tobias Stumpp, Dan Snell. Molecular Partners AG, Schlieren-Zurich,
Switzerland.
Background: Combination therapy of immune-modulating drugs with mo-
dalities targeting tumor cells directly or the tumor stroma are increasing in
clinical investigation and practice. In particular, the combination of immune
checkpoint modulators targeting PD1 and molecules targeting the tumor
stroma, like anti-VEGF therapeutics, are being utilized inmultiple permutations
and have shown promising results. We have developed a new class of protein
therapeutics DARPin® molecules for simultaneous targeting of PD1 and VEGF.
Themulti-specifıc PD1 andVEGF targetingmoleculeswere tested for inhibition
of PD1 and VEGF mediated functions in cellular functional assays and in syn-
geneicmousemodels.Methods: Inhibition of human PD1 functions were tested
in cell binding assays, a reporter cell assay (Promega) and in human primary
T-cell assays like mixed lymphocyte reaction (MLR). VEGF-A inhibition was
tested in functional assays showing inhibition of VEGFR2 signaling. Molecules
targetingmurine PD1were analyzed in cell binding assays and splenocyte assays
aswell as in syngeneicmousemodels. The anti-tumoral-effect wasmonitored by
calipermeasurement and onT-cell infıltration and angiogenesis by immunohis-
tochemistry. Results: The multi-specifıc human PD1-VEGF targeting DARPin®
molecule inhibits PD1 mediated downregulation of T-cell receptor signaling in
a reporter cell assay in the range of the benchmark antibody Nivolumab. Potent
picomolar inhibition of VEGF mediated VEGFR2 signaling was also demon-
strated for the molecule. Moreover the molecule showed potent inhibition of
PD1 in an MLR assay to a similar level as compared to Nivolumab. A murine
surrogate molecule was also produced and showed potent PD1 inhibition in
vitro. Syngeneic mouse models demonstrate a strong anti-tumoral effect of the
surrogate molecule and an increase in the infıltration of T-cells into the tumor
was observed upon treatment. The anti-tumoral effect was strongest by combin-
ing the anti-PD1 function with the anti-VEGF function. This indicates that the
multi-specifıc DARPin® molecule is functional, shows potency beyond blocking
of only PD1 or VEGF and has a strong potential for therapeutic benefıt in the
clinic. Conclusions: We have generated a multi-specifıc PD1 and VEGF target-
ing DARPin® molecule which is potently active in blocking PD1 and VEGF
mediated functions in tumor growth and immunity. The potency of the mole-
cule goes beyond targeting PD1 or VEGF alone and has a strong potential for
therapeutic benefıt in the clinic. * DARPins are small repeat proteins, designed
to bind targets with high affınity and specifıcity, and which can be combined in
a modular fashion to produce multi-functional agents.
#3646 Characterization of the novel antibody drug conjugate MEN1309
and its target antigen Ly75.Alessandro Bressan,1 Alessio Fiascarelli,1 Giuseppe
Merlino,1 Corrado Carrisi,1 Daniela Bellarosa,1 Rachel Dusek,2 Rahel Awdew,2
Sudha Swaminathan,2 Arnima Bisht,2 To Uyen T. Do,2 San Lin Lou,2 Dee Aud,3
Jonathan Terrett,3 Keith Wilson,3 Christian Rohlff,4 Monica Binaschi1. 1Men-
arini Ricerche S.p.A., Pomezia (RM), Italy; 2Oxford BioTherapeutics, Inc., San
Jose, CA; 3CytomxTherapeutics, South San Francisco, CA; 4Oxford BioTherapeu-
tics, Ltd., Abingdon, UK, Abingdon, United Kingdom.
Ly75 (CD205,DEC-205) is a type I transmembrane glycoprotein and aC-type
lectin receptor involved in antigen uptake and processing, mainly expressed by
antigen presenting cells (APC). The short cytoplasmic tail contains motifs for
amino acid-based endocytosis, making this receptor an ideal target antigen for
an antibody drug conjugate (ADC)-based antitumoral therapy. MEN1309 is a
novel fully humanized ADCwhich binds to Ly75 with high affınity as shown by
ELISA and FACS analysis. The antibody is conjugated to a maytansinoid DM4,
a potent tubulin inhibitor, through a cleavable linker.The ability of Ly75 to
internalize the antibody after binding was determined using an immunofloures-
cence assay that showed a rapid, effıcient, andnear complete internalization over
a one hour time course.The expression of Ly75 mRNA and protein was investi-
gated in human cancer cell lines derived from different histotypes and revealed
high expression in pancreas, bladder, triple negative breast cancer (TNBC) cells
and in diffuse large B-cell lymphoma (DLBCL). Indeed, MEN1309 shows a
powerful (pM range) in vitro cytotoxic activity on different cancer cell lines
expressing Ly75, whereas it exerts a weaker effect on antigen-negative cells.
Besides the mechanism of action (MoA) of MEN1309 as an ADC, the putative
effıcacy of the antibody to drive an ADCC response was investigated through in
vitro binding and functional assays. In spite of a high binding affınity of
MEN1309 to FcRIIIa, no ADCC response was observed, suggesting that the
high internalization rate of the antigen could hamper the triggering of NK re-
sponses.Moreover, in order to characterize the functional role of Ly75 in cancer
cell lines, its expression was downregulated by siRNA demonstrating an inhibi-
tion of the proliferation rate in cells from different histotypes.Finally, we inves-
tigated if some cancer cell lines could show a higher expression of two intergeni-
cally spliced forms derived from Ly75 and DCL-1 genes recently reported in
literature. We found that the intergenically spliced forms were expressed on
average 30 fold less than CD205 mRNA in all the cancer cell lines analyzed,
suggesting that these variants derive just from an intergenic readthrough with-
out a specifıc transcriptional regulation.
#3647 Therapeutic activity of effector function-enhanced, non-fucosy-
lated anti-CD40 antibodies in preclinical immune-competent rodent tumor
models. Shyra J. Gardai, Weiping Zeng, Che-Leung Law. Seattle Genetics, Both-
ell, WA.
Recent success of immune checkpoint inhibitors (CPIs) in the clinic under-
scores the role of cancer immune surveillance and the therapeutic potential of
targeting immune receptors. Unlike CPIs, many members of the TNF receptor
superfamily (TNFRSF), e.g., CD40, 4-1BB, OX-40, and GITR deliver agonistic
signals to immune cells that may directly activate antitumor immune responses
and, in combination with CPIs, may improve outcomes of active immunother-
apy. Sugar-Engineered Antibody (SEA)-CD40 is a non-fucosylated, humanized
IgG1 anti-human CD40 monoclonal antibody currently being evaluated in a
phase 1 clinical trial in solid tumors and lymphoma. It binds FcR3A with
higher affınity and demonstrates enhanced immune stimulatory activity com-
pared to its parent dacetuzumab. An SEA version of an anti-mouse CD40 anti-
body (mouse IgG2a), SEA-1C10, has been generated. As expected, SEA-1C10
bound to mouse FcRIV, the functional homolog of human FcR3A inmice, at
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a higher affınity than parent 1C10. Enhanced FcRIV engagement by SEA-1C10
translated into stronger antitumor activity in the CD40 (-) B16F10 melanoma
and CD40 () A20 lymphoma models. In the A20 model, tumor free mice that
survived the initial A20 tumor implantation and SEA-1C10 treatment were re-
challenged with live A20 cells. Twenty nine out of thirty one such tumor free
mice rejected A20 tumor re-engraftment, suggesting that a strong memory im-
mune response was elicited by SEA-1C10 treatment. The SEA-1C10/anti PD-1
combination also showed greater antitumor activity compared to SEA-1C10 or
anti-PD-1 alone, supporting the hypothesis that stimulation of antigen-present-
ing cells by agonistic CD40 signaling can complement immune checkpoint in-
hibition. In addition, a transgenic (TG) mouse strain has been generated in
which the endogenous Cd40 locus is inactivated by the targeted insertion of a
human-mouse chimeric CD40 gene. This allows for incorporation of the extra-
cellular domain of human CD40 while keeping the transmembrane and cyto-
plasmic domains ofmouseCD40. Lineage-restricted expression of theCD40TG
on B cells and monocytes was confırmed. CD40 TG cells responded to
SEACD40-mediated agonistic signaling in vitro by secreting CD40 signature
cytokines and up-regulating the costimulatory molecules CD86 andMHC class
II. Treatment of CD40 TG animals with SEA-CD40 resulted in cytokine induc-
tion and B-cell depletion. Similar to studies in human PBMCs and non-human
primates, SEA-CD40 induced more robust cytokine production and immune
cell activation than its fucosylated parent dacetuzumab. These experimental
systems will be further applied to address clinically important questions includ-
ing mechanism(s) of anti-tumor effects, biomarkers indicating immune activa-
tion, dosing strategies, and timing of combinatorial regimens with CPIs.
#3648 Targeting glypican-2 in neuroblastoma via single domain anti-
body-based immunotoxins and chimeric antigen receptor T cells. Nan Li,1
Haiying Fu,2 Stephen Hewitt,1 Dimiter Dimitrov,3 Javed Khan,1 Mitchell Ho1.
1National Institutes of Health, Bethesda, MD; 2Jilin University, Changchun, Chi-
na; 3National Institutes of Health, Frederick, MD.
Neuroblastoma is the most common extracranial solid tumor in children.
Approximately 45% of patients receiving standard therapy relapse and ulti-
mately succumb to metastatic disease. One of the major challenges in the treat-
ment of neuroblastoma andother pediatric cancers is the lack of effective targets.
As such, there is an urgent need for a new therapeutic target. Here we demon-
strate that glypican-2 (GPC2) protein is highly expressed in nearly half of neu-
roblastoma cases. High GPC2 expression has been correlated with poor overall
survivalwhen compared to patientswith lowGPC2 expression. The reduction of
GPC2 expression inhibits neuroblastoma cell growth and induces tumor cell
apoptosis through downregulation of Wnt/-catenin signaling. We have dis-
covered a group of human single domain antibodies specifıc for GPC2 and have
used them to make two forms of antibody therapeutics, antibody-toxin conju-
gates (immunotoxins) and chimeric antigen receptor (CAR) T cells. Treatment
with the immunotoxin inhibits proliferation of GPC2-positive neuroblastoma
cells in vitro and mouse models. The CAR T cells targeting GPC2 suppress the
growth of neuroblastoma xenograft tumors and eradicate disseminated neuro-
blastomas inmice.Our study establishesGPC2 as a new target of antibody-based
cancer therapy and demonstrates that single domain-based antibody therapeu-
tics can be used in the treatment of neuroblastoma.
#3649 Combination of mesothelin-targeted immune-activating fusion
protein and anti-PD-L1 augments antitumor immunity and prolongs sur-
vival in murine model of ovarian cancer. Yang Zeng, Binghao Li, Qiuyan Liu,
Patrick Reeves, Ann Sluder, Jeffrey Gelfand, Timothy Brauns, Mark Poznansky,
Huabiao Chen.Massachusetts General Hospital, Boston, MA.
Background and Purpose: Although immunotherapy as an adjuvant to sur-
gery and chemotherapy has been investigated in ovarian cancer (OC) as ameans
of reducing tumor recurrence and improving survival, there remains a signifı-
cant unmet need for combinatorial strategies to enhance the antitumor immune
response. The purpose of this study was to develop a novel combination immu-
notherapy for OC, utilizing our novel fusion protein to target and generate a
cellular immune response to mesothelin (MSLN) in conjunction with blockade
of the PD-1/PD-L1 checkpoint to restore the function of cytotoxic T cells in
order to enhance cancer control andprolong survival. Experimental Procedures:
Luciferase-expressing ID8 cells were employed to establish an intraperitoneal
ovarian tumormodel in immunocompetent C57BL/6mice. The effıcacies of the
MSLN-targeted immune-activating fusion protein (VIC-008), PD-L1, and the
combinationwere evaluated.Mice received 4 intraperitoneal (i.p.) treatments of
VIC-008 fromday 7 post tumor inoculationweekly, and 6 treatments ofPD-L1
i.p. every other day from 4 weeks post inoculation. Tumor growth was moni-
tored by in vivo imaging of luciferase activity. Survival timewas calculated as life
span from the day of tumor inoculation. In immunological studies, mice were
sacrifıced 7 weeks after tumor cell inoculation. Immune cells from lymph nodes,
ascites and tumors were stained with antibodies against multiple immune cell
markers and profıled by flow cytometry. Results: VIC-008, PD-L1 or combi-
nation treatment delayed tumor growth. The combination treatment resulted in
the greatest prolongation in survival, followed by PD-L1 treatment and then
VIC-008 treatment. Improved survival was associated with increased levels of
intratumoral CD3CD8T cells (P0.0001). The combination treatment also
reduced the proportion of CD4CD25Foxp3 Treg cells (P0.0001) in the
lymph nodes. An increased number of CD8CD27CD44 memory T cells
(P0.0134) were observed in ascites in the combination treatment group.
CD11bCD11c dendritic cells were enriched in ascites in VIC-008 treatment
(P0.0019) and combination treatment groups (P0.0010). More
CD11cCD38 (M1) (P0.0361) and fewer CD206CD106 (M2)
(P0.0285) macrophages were found in the tumors of the combination treat-
ment group. Conclusion: Our results suggest that, through activating dendritic
cells and enhancing antigen presentation and cross-presentation, VIC-008 aug-
ments antitumor CD8T cell responses and facilitates generation ofmemory T
cells when combined with PD-1/PD-L1 blockade, providing long-term antitu-
mor effects. Our fındings demonstrate for the fırst time a mechanistic rationale
for combining VIC-008 and PD-L1 in treatment of OC in mice, positioning
this combination therapy as a potential promising new immunotherapeutic ap-
proach for OC.
#3650 Preclinical evaluation of the PARP inhibitor rucaparib in combi-
nation with PD-1 and PD-L1 inhibition in a syngeneic BRCA1mutant ovar-
ian cancer model. Liliane Robillard,1 Minh Nguyen,1 Andrea Loehr,1 Sandra
Orsulic,2 Rebecca S. Kristeleit,3 Kevin Lin,1 Mitch Raponi,1 Thomas C. Hard-
ing,1 Andrew D. Simmons1. 1Clovis Oncology, Inc., Boulder, CO; 2Cedars-Sinai,
Los Angeles, CA; 3University College London, Cancer Institute, London, United
Kingdom.
Background: Rucaparib (CO-338) is an oral small molecule inhibitor of poly-
(ADP-ribose) polymerase (PARP)-1, PARP-2 and PARP-3 that has shown clin-
ical activity in patients with BRCA1 and BRCA2 mutated advanced ovarian
cancer. Monoclonal antibodies against programmed death receptor-1 (PD-1)
and programmed death-ligand (PD-L1) have also shown effıcacy in advanced
ovarian cancer patients. It has been reported that BRCA1 and BRCA2 mutated
tumors have a higher mutational load and increased CD8 T cell infıltration,
suggesting that the combination of rucaparib and immune checkpoint inhibi-
tion may be complementary. However, PARP inhibition has also been reported
to have an immunosuppressive effect in preclinical studies. Methods: Subcuta-
neous syngeneic models using the BRCA1 wild-type C2Km (P53-/-, myc, Kras-
G12D, Akt-myr) and BRCA1 mutant BrKras (BRCA1-/-; P53-/-; myc; Kras-
G12D; Akt-myr)murine ovarian cell lines were developed in themurine FVB/N
background. Antibodies targeting PD-1 (RMP1-14) and PD-L1 (10F.9G2) were
dosed by intraperitoneal injection at 5-10 mg/kg twice weekly, while rucaparib
was administered by oral gavage at 150 mg/kg twice daily. Treatment was initi-
ated at a tumor volume of150mm3 (n15/group). Animals were dosed for 21
days, and tumors were allowed to regrow to day 76. Results: In vitro cytotoxicity
assays demonstrated that rucaparib was 155-fold more potent in the BRCA1
defıcient BrKras cell line (IC50  84 nM) than the isogenic BRCA1 wild-type
C2Km cell line (IC50  13 M). An in vivo study using the syngeneic BrKras
model was performed in mice treated with: vehicle, rucaparib, PD-1, PD-L1,
rucaparibPD-1, and rucaparibPD-L1. All monotherapy and combination
groups resulted in signifıcant tumor growth inhibition and were followed for
survival analysis. The median survival time (MST) and % cures (defıned as
undetectable growth at Day 76 post-tumor implantation) for vehicle, PD-L1,
PD-1 and rucaparib monotherapy treated animals was 34 days (0%), 41 days
(13%), 76 days (40%) and 76 days (56%), respectively. The rucaparibPD-1
and rucaparibPD-L1 combination groups demonstrated greater effıcacy than
the monotherapies, with a MST of 76 days (100%) and 76 days (88%), re-
spectively. Dose response and immune profıling studies are ongoing. In vivo
studies were also performed in the BRCA1/2 wild-type models EMT-6, Pan02,
and MC38. As expected, as a single agent, rucaparib showed limited activity in
these homologous recombination competent models, whereas a range of tumor
growth inhibitionwas observedwithmonotherapy PD-L1 treatment.No impact
on anti-tumor activity was observed in animals treated with rucaparibPD-L1
as compared to PD-L1monotherapy in the BRCA1/2 wild-type syngeneic mod-
els examined. Conclusions: The combination of rucaparibwith PD-1 andPD-L1
inhibition improved survival in a BRCA1 mutant syngeneic model.
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#3651 Preclinical examination of the effects of MT-3724, an engineered
toxin body targeting CD20, in mantle cell lymphoma. Shengjiang Huang,
Taylor Bell, Yang Liu, Hui Guo, Carrie Li, Makhdum Ahmed, Laura Lam, Hui
Zhang, Zhihong Chen, Michael L.Wang, Leo Zhang, Krystle Nomie.University
of Texas MD Anderson Cancer Center, Houston, TX.
Mantle cell lymphoma (MCL) accounts for 6-8% of all non-Hodgkin lym-
phoma cases and is a therapeutic challenge. MCL is characterized by the expres-
sion of different B-cell markers such as CD-19, CD-20 and BSAP/PAX5, and
CD-20 is strongly expressed and can be used as a potential target. MT-3724 was
developed by Molecular Templates and is an engineered toxin body (ETB) tar-
geting CD-20.MT-3724 binds CD-20 and forces its own internalization into the
target cell where it subsequently self-routes to the cytosol to enzymatically and
permanently inhibit protein synthesis via ribosome inactivation. By selectively
and specifıcally targeting CD20-positive cells, MT-3724 may decrease cell pro-
liferation and induce apoptosis in MCL. We tested the effects of MT-3724 by in
vitro cell proliferation in 3 ibrutinib-sensitive cell lines and 5 ibrutinib-resistant
cell lines (4 primary resistant and 1 acquired resistant). We also measured the
levels of apoptotic cells in both ibrutinib-sensitive and -resistant cell lines treated
with MT-3724 by Annexin V/ PI staining. Lastly, we conducted an in vivo effı-
cacy assay of MT-3724 in aMCL PDXmodel resistant to a wide-range of drugs,
including ibrutinib. MT-3724 inhibited cell proliferation effectively and effı-
ciently in most ibrutinib-sensitive and ibrutinib-resistant cell lines in a dose-
dependent manner. IC50  500 ng/ml was characterized as sensitive to MT-
3724, and IC50 500 ng/mlwas considered resistant toMT-3724. Regarding the
ibrutinib-sensitive cell lines, the 3 cell lines (Jeko-1, Mino and Rec-1) were sen-
sitive toMT-3724 with IC50 values of 139.1, 309.3 and 457.7 ng/ml, respectively.
Regarding the ibrutinib-resistant cell lines, 4 cell lines (Maver-1, JVM-13,
Jeko-R and Granta519) were sensitive to MT-3724 with IC50 values of 124.6,
155.1, 266.2 and 442.4 ng/ml, respectively, and 1 cell line (Z-138)was resistant to
MT-3724 (IC50 1231 ng/ml). However, no signifıcant differences in IC50 val-
ueswere found between ibrutinib-sensitive and -resistant cell lines (p 0.36). In
a time-dependent assay, 300 ng/mlMT-3724 also reduced cell proliferation in 2
ibrutinib-sensitive cell lines (Mino and Jeko-1) and 2 ibrutinib-resistant cell
lines (Jeko-R andMaver-1) over time. Furthermore, MT-3724 also induced cell
apoptosis in both ibrutinib-sensitive (Jeko-1) and -resistant (Jeko-R and
Maver-1) cell lines. Lastly, MT-3724 was administered intraperitoneally for
three consecutive weeks in a PDX model resistant to a wide-range of targeted
agents. Interestingly, MT-3724 dramatically reduced tumor burden and in-
creased survival (median of 27 days) of the PDXmice.MT-3724 is the fırst toxin
engineered body targeting CD-20 used in MCL, which may be a potential ther-
apeutic candidate for MCL, especially for drug-resistant cases.
#3652 Combinational activity of LAG3 and PD-1 targeted therapies is
signifıcantly enhanced by the addition of phosphatidylserine targeting anti-
bodies and establishes an anti-tumormemory response inmurine triple neg-
ative breast cancer. Michael J. Gray, Jian Gong, Jeff T. Hutchins, Bruce D.
Freimark. Peregrine Pharmaceuticals, Tustin, CA.
Previous studies utilizing NanoString immune profıle analysis demonstrated
that intratumoral levels of LAG3 (lymphocyte activation gene 3) mRNA in-
creased in response to phosphatidylserine (PS) and PD-1 targeting antibodies in
murine triple negative breast cancers (TNBC). This suggests LAG3 acts to atten-
uate immune system activation during I/O therapies - and that PD-1 and LAG3
function cooperatively in suppressing immune system activation. Here we show
that adding PS targeting antibodies can further enhance the effectiveness of
antibodies targeting LAG3 and/or LAG3PD-1. We fırst examined expression
of LAG3 and PD-1 in the murine TNBC model E0771 and found that tumor
associated T-cells (CD4 and CD8) have expression of both markers. Mice
implanted with TNBC tumors were next treated with antibodies targeting PS,
PD-1, and LAG3 alone and in combination with each other. Interestingly, the
addition of PS targeting antibodies not only increased the effectiveness anti-
PD-1 effectiveness as previously observed, but also enhanced anti-LAG3 treat-
ment, showing that PS targeting antibodies are capable of augmenting addi-
tional I/O therapeutic regimens. Comparison of anti-PD-1LAG3
combination vs. single anti-PD-1 or anti-LAG3 treatments showed moderately
more anti-tumor activity than single treatments, however the addition of PS
targeting antibodies to either checkpoint inhibitor was as equally effective in
inhibiting tumor growth as observed in the anti-LAG3PD-1 treatment. Fur-
ther comparison of antibody treatments targeting PD-1LAG3 vs. PSPD-
1LAG3 demonstrated that the addition of PS targeting antibodies resulted in a
signifıcant decrease in tumor growth with complete tumor regression in 80% of
the animals (along with the ability to completely reject secondary TNBC chal-
lenge) compared to 0% in the anti-PD-1LAG3 treatment group. Immunopro-
fıling showed that the addition of PS targeting antibodies to these checkpoint
therapies, including the combination of anti-PD-1LAG3, resulted in a pheno-
type associated with enhanced immune system activation and immune-surveil-
lance including increased tumor infıltrating lymphocytes (TILs) with upregula-
tion of T-cell associated activation pathways, increased Th1 to Th2 profıle, and
enhanced antigen presentation processing /presentation mechanisms along
with cytokines associatedwith immune systemactivation.Overall our data dem-
onstrate that adding PS targeting antibodies to clinically relevant therapies, in-
cluding PD-1 and LAG3, may signifıcantly enhance their ability to activate and
redirect the host immune system into recognition and elimination of tumor cells
compared to single and combinational treatments that lack PS targeting anti-
bodies.
#3653 Combining ERY974, a novel T cell-redirecting bispecifıc antibody
targeting glypican-3, with chemotherapy profoundly improved antitumor
effıcacy over itsmonotherapy in xenograftmodel.Yuji Sano, Yumiko Azuma,
Toshiaki Tsunenari, YasukoKinoshita, YokoKayukawa,HironoriMutoh, Yoko
Miyazaki, Takahiro Ishiguro, Shohei Kishishita, Yoshiki Kawabe, Mika Endo.
Chugai Pharmaceutical Co., Ltd, Japan.
Background: ERY974 is a humanized IgG4 bispecifıc T cell-redirecting anti-
body (TRAB) currently in Phase 1 clinical trial (NCT02748837). ERY974 con-
sists of a common light chain and two different heavy chains that respectively
recognize glypican-3 (GPC3) andCD3. The Fc portion of ERY974 ismodifıed to
lose FcRbinding to preventGPC3-independent Fc-mediated effector function.
However, binding activity to FcRn, an important factor in the PK profıle of IgG,
is maintained. ERY974 simultaneously binds to GPC3 on the cancer cell surface
and to CD3 on the T cell surface, and induces TRAB-dependent cellular cyto-
toxicity mediated by the potent effector function of T cells. ERY974 shows
strong antitumor activity against gastric, lung, ovarian, head& neck, and esoph-
ageal cancer-derived xenograft tumors in a non-obese diabetic/severe combined
immunodefıciency (NOD-SCID) mouse model injected with human T cells.
Cancer immunotherapy, as represented by immune checkpoint inhibitors such
as PD-1, PD-L1, and CTLA-4 antibodies, has recently been demonstrating re-
markable clinical benefıt in various tumor types. However, the number of pa-
tients who have survival benefıt is limited, and combining cancer immunother-
apy with other agents is required to improve the effıcacy. Although ERY974
monotherapy is expected to show clinical activity based on the preclinical data,
we examined whether further improvement of ERY974-induced effıcacy is at-
tained by combinationwith chemotherapy.Method&Results:We evaluated the
combination effect of ERY974 with chemotherapy against xenograft tumors of
MKN45 (gastric cancer) or NCI-H446 (lung cancer) either in a NOD-SCID
mousemodel injectedwith humanTcells or in a humanizednon-obese diabetic/
shi-scid/IL-2Rnull model in which differentiated human T cells are constitu-
tively supplied. Although ERY974 monotherapy shows only minor antitumor
effect against MKN45 and NCI-H446, combination therapy remarkably en-
hanced effıcacy. In particular, ERY974 in combination with paclitaxel or cispla-
tin in NCI-H446 tumors caused a tumor disappearance without regrowth for a
long period. Conclusion: These preclinical data suggest the possibility that the
strategy of combining ERY974 with chemotherapy may succeed in increasing
the clinical benefıt. Now the combination effect is being further investigated to
clarify the mechanism.
#3654 AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively
with PD-1 blockade in primary human T cell assays and in a non-human
primate pharmacodynamic (PD) model. Elise E. Drouin,1 David Savitsky,1
Ana M. Gonzalez,1 Randi Gombos,1 JeremyWaight,1 Xia Yang,1 Mithun Khat-
tar,1 Benjamin Morin,1 Mark Findeis,1 David Schaer,2 Taha Merghoub,2 Gerd
Ritter,2 Antoine Tanne,1 Marc van Dijk,3 John M. Goldberg,1 Daniel Levey,1
JohnCastle,3 Jean-Marie Cuillerot,1 Jennifer S. Buell,1 Robert Stein,1 Nicholas S.
Wilson1. 1Agenus, Inc., Lexington, MA; 2Memorial Sloan Kettering Cancer Cen-
ter, New York, NY; 3Agenus, Inc. / 4-Antibody, Basel, Switzerland.
Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell
deathprotein 1 (PD-1)play importantnon-redundant roles innegatively regulating
T cell immune responses. Therapeutic blockade of CTLA-4 or PD-1 pathways has
been demonstrated to enhance T cell reactivity to tumor-specifıc antigens, translat-
ing to a signifıcant improvement in overall survival. This anti-tumor effect can be
further augmented when PD-1 and CTLA-4 antagonist antibodies are co-adminis-
tered. The therapeutic impact of this combination is exemplifıed by the approval of
this combination for advanced melanoma, as well as clinical benefıt of the combi-
nationobserved inNSCLC,mRCC, andmost recently,mUC.AGEN1884, a human
IgG1antibodydirectedagainstCTLA-4, potently inhibitsCTLA-4binding toCD80
andCD86, resulting in enhanced T cell responsiveness in vitro, as well as in a vacci-
nation model in non-human primates. A Phase 1 clinical study (NCT02694822) is
currently ongoing to evaluate the safety and pharmacokinetic (PK)/pharmacody-
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namic (PD) relationships in patients with advanced solid tumors. AGEN2034 is a
human IgG4 antibody that binds selectively to PD-1 with high affınity and potenti-
ates T cell responsiveness via the blockade of PD-L1 and PD-L2 binding to PD-1.
Here we evaluated the pharmacologic effect of combining AGEN1884 with
AGEN2034, and other molecules targeting the PD-1/PD-L1 pathway, on primary
human T cell immune responses. AGEN1884 combined effectively with
AGEN2034, and other antibodies targeting the PD1/PD-L1 pathway, to promote
superior T cell immune responses compared to monotherapies. Consistent with
these in vitro fındings, the co-administration of AGEN1884 with an anti-PD-1 an-
tibody in cynomolgusmonkeys (Macaca fascicularis) induced a dynamic PD effect,
including aproliferativeT cell response inperipheral blood, as compared to animals
receiving either antibody alone. Finally, co-administration of an anti-mouse
CTLA-4 antibody togetherwithAgenus’ tumor-specifıc neo-epitope-based vaccine
(AutoSynVax™) in mice induced effective amplifıcation of vaccine-driven T cell
responses, compared to animals that received the vaccine alone. These data further
exemplify the versatility of harnessing antibody-mediated CTLA-4 blockade to in-
fluence apical events involved in T cell priming by antigen presenting cells. Taken
together, these in vitro and in vivo fındings demonstrate that the combination of
AGEN1884 with PD-1 pathway blockade or with neo-epitope-based vaccines has
the potential to provide therapeutic activity that is superior to that of either check-
point- or vaccine-basedmonotherapies.
#3655 Biomarker strategy to guide the clinical development of
ImmTACTMmolecules, a novel class of bispecifıc T cell engaging biologic
drugs. Cheryl McAlpine,1 David Krige,1 Sandra Herrero-Gonzalez,1 Sarah Frank-
lin,1 JacobHurst,1WilliamShingler,1 SanjayPatel,1Andy Johnson,1DebbieParker,1
Christina M. Coughlin,2 Namir J. Hassan,1 Bent K. Jakobsen1. 1Immunocore Ltd.,
Abingdon, United Kingdom; 2Immunocore Ltd., Philadelphia, PA.
IMCgp100, a fırst in class immunotherapy, is a T cell redirecting bispecifıc
biologic comprising an affınity enhanced T-cell receptor specifıc for gp100 and
an anti-CD3 scFV. Phase I/IIa data has provided evidence of a favourable safety
profıle, and durable responses in both cutaneous and uvealmelanoma have been
observed. To complement the clinical studies we have developed a comprehen-
sive biomarker strategy to aid our understanding of pharmacodynamics, patient
response and potential mechanisms of resistance which includes analysis of
markers in both the tumour and periphery. The data obtained to date provide
evidence of the pharmacodynamic effects of themolecule including chemokine/
cytokine release, in both the tumor and periphery, and lymphocyte infıltration
into tumors. In addition, changes in the levels of certain chemokines following
the fırst dose of IMCgp100 were associated with tumor shrinkage. The bio-
marker strategy we have developed forms the basis for the support of the on-
going Ph II development of IMCgp100 in both cutaneous and uveal melanoma
and for other ImmTACmolecules, as single agents and in combination, for the
treatment of solid tumours.
#3656 Implication for checkpoint therapeutics: Expression of co-stimula-
tory and co-inhibitory molecules in melanoma cells. Rachana R. Maniyar,
Sanjukta Chakraborty, Neha Tuli, Ghada Ben Rahoma, Sarnath Singh, Jan
Geliebter,MarcWallack, Raj K. Tiwari.NewYorkMedical College, Valhalla, NY.
Melanoma is one of the deadliest forms of skin cancer, with a dim prognosis
whenmetastasized, leading to the highest number of skin cancer related deaths.
In recent years there has been a focus on the use of checkpoint inhibitor thera-
pies like anti-CTLA-4, anti-PD-1 and anti-PD-L1 to treat melanoma. PD-L1,
HVEM and VISTA expression on cancer cells has been shown to promote im-
mune evasion and tumor survival. CTLA-4, when engaged on tumor cells leads
to their apoptosis and LIGHT signaling leads to recruitment of T cells and
effective tumor clearance. Thus, since these molecules do not function in isola-
tion, we need to consider tissue pleiotropy and the expression of co-stimulatory
and co-inhibitory molecules on tumor tissue. Our laboratory has characterized
and established fıve primary patient derived melanoma cell lines, MEL-2,
MEL-V, 3MM,KFMandGLM-2. In an effort to understand tumor tissue pleiot-
ropy, we conducted a comprehensive expression pattern screening of eight co-
inhibitory and ten co-stimulatory molecules by RT-PCR. Among others,
VISTA, a CD4T cell suppressor, HVEM, an immune evasion regulator, LAG3
and TIM3, potential immune checkpoint targets, were seen to be differentially
expressed in these primary cell lines. Current therapies target CTLA-4, PD-1
and PD-L1, which also exhibit varying expression in our primary cell lines,
pointing to the importance of considering tissue expression of these molecules
when administering these novel immunotherapies. Additionally, 80% of mela-
noma patients are positive for the BRAFV600E genetic lesion and are adminis-
tered vemurafenib (PLX4032), an inhibitor of the overactive mutated BRAF.
Our in vitro studies show that treatment with PLX4032, changed the expression
of CTLA-4 and PD-L1 in these primary cells. We observed a decrease in PD-L1
protein expression in MEL-V and GLM-2 and an increase in PD-L1 protein
expression inMEL-2 andKFM, the four BRAFV600Epositive cell lines. CTLA-4
protein expression demonstrated an upward trend on treatment with PLX4032.
This synergy observed between treatment with drugs targeting genetic lesions
and the expression of immunomodulatory molecules warrants characterization
of tumor biopsies prior to designing an effective combinatorial therapy regime.
Our long term goal is to optimize combinatorial immune and drug therapies
directed against both co-stimulators and checkpoint inhibitors.
#3657 Phosphatidylserine-targeting antibodies enhance anti-tumor ac-
tivity of a tumor vaccine in a HPV-induced tumor model. Genevieve Weir,1
TaraQuinton,1 Jeff T. Hutchins,2 BruceD. Freimark,2Marianne Stanford1. 1Im-
munovaccine, Inc., Halifax, Nova Scotia, Canada; 2Peregrine Pharmaceuticals,
Inc., Tustin, CA.
Antibodies targeting phosphatidylserine (PS) have been shown to induce an-
ti-tumor responses by induction of tumor-specifıc T cells. Based on this obser-
vation, we evaluated the responses of PS and PD-1 targeting antibody therapy to
enhance anti-tumor responses of a HPV16 peptide vaccine formulated in De-
poVax™ (DPX) in mice bearing HPV-transformed C3mouse tumors. The addi-
tion of PS-targeting antibody (mch1N11) to DPX/metronomic cyclophosph-
amide (mCPA) immunotherapy prolonged survival in comparison to mice
receiving an isotype control in combinationwithDPX/mCPA.When anti-PD-1
was added tomch1N11mCPA, therewas no increase in survival. The addition
of mch1N11 to DPX/mCPA immunotherapy had no effect on tumor growth or
survival in the aggressive B16-F10 model. TIL analysis revealed an increase in
CD8 T cells, antigen specifıc CD8 T cells and PD-1 T cells in the tumor
with mch1N11 treatment. The expression of surface markers for macrophages
(CD68high, F4/80) and dendritic cells (CD11c) were also increased in the tu-
mors of mice treated withmch1N11. RT-qPCR analysis of the tumor confırmed
higher mRNA expression of T cells markers (CD8, Granzyme B, PD-1) and
antigen presenting cell markers (F4/80, CD74). In the spleen, expression of cell
surfacemarkers formonocytes (CD11b) andPD-1Tcells (CD8)were elevated
in groups treated with mch1N11 in combination with anti-PD-1. Combined,
these fındings indicate that in this model, PS-targeting antibodies can enhance
the activity of phagocytic cells involved in antigen presentation. We have found
that PD-1 expression increases as anti-tumor activity increases, therefore these
results also provide an indication that antibodies targeting PS enhance the anti-
tumor immune response induced by DPX/mCPA therapy. The observations
suggest that PS-targeting antibodies may enhance therapeutic vaccines for the
treatment of cancer.
IMMUNOLOGY: Dendritic Cells as Critical Immune Targets
#3658 Dendritic cells dictate the responsiveness of PD-L1 blockade in
cancer. Maud Mayoux,1 Marieke F. Fransen,2 Andreas Roller,3 Ines Matos,1
Vesna Pulko,1 Vaios Karanikas,1 Pablo Umana,1 Christian Klein,1 Ferry A. Os-
sendorp,2 Wei Xu1. 1Roche Innovation Center Zurich, Schlieren, Switzerland;
2Leiden UniversityMedical Center, Leiden, Netherlands; 3Roche Innovation Cen-
ter Basel, Basel, Switzerland.
Recent advances in cancer immunotherapies with PD-1/PD-L1 pathway
blockade have transformed the way that cancer is being treated, leading to du-
rable responses and prolonged overall survival. The general thinking is that
PD-1/PD-L1 blockade reinvigorates tumor-infıltrating PD-1 T cells with ex-
hausted phenotypes. However, a mechanistic understanding on why only a sub-
set of patients (10-30%) responds to checkpoint inhibition remains largely un-
known, as does the exact immune mechanism of PD-1/PD-L1 blockade. Here,
we discovered that PD-L1 blockademediates anti-tumor immunity via dendritic
cells. In human blood, in vitro and ex vivo dendritic cells (DCs) express both
PD-1 and PD-L1, and an activation signal via TLR agonists triggers downregu-
lation of PD-1 to empower the T cell stimulatory capability of DCs. In contrast,
tolerogenic DCs remain PD-1 positive, correlating to T cell-unresponsiveness.
Anti-PD-L1Ab directly inducesmaturation ofDCs and renders them capable of
stimulating T cell proliferation. Similarly, anti-PD-L1 Ab treatment in tumor-
bearing mice induces massive infıltration and activation of CD11c DCs in the
spleen and draining lymph node, indicating that PD-1 is a negative regulator in
DCs. Furthermore, ablation of DCs prior to anti-PD-L1 Ab treatment in an
established MC38 tumor model in CD11c-DTR mice suggests a crucial role of
DCs in mediating response to PD-L1 treatment. In support of the preclinical
evidence that DCs are the primary target of anti-PD-L1 Ab, we analyzed RNA-
seq data from tumor biopsies at baseline in patients with renal cell carcinoma
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prior to treatment with atezolizumab and found that the abundance of genes
related to cross-presenting DC subsets (such as XCR1) correlates with a survival
advantage in response to atezolizumab (HR0.13, median OS is 16.2 months in
patients with DC gene score50% versus NR (not reached) in those50%). In
conclusion, we discovered abundance of tumor-infıltrating DCs as a novel bio-
marker that can predict the clinical response of PD-L1 blockade. We postulate
that checkpoint inhibition directly on tumor-infıltrating DCs likely contributes
to amplifıcation of Ag-specifıc priming of tumor-specifıc T cells.
#3659 WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC
vaccines in AML patientsmount specifıc immune responses and impact pro-
gression free survival. Iris Bigalke,1 Guri Solum,1 Dag Josefsen,1 Yngvar
Fløisand,1 Kirsti Hønnåshagen,1 Lisbeth Skoge,1 Signe Spetalen,1 Stein Sæbøe-
Larssen,1 Dolores J. Schendel,2 Gunnar Kvalheim1. 1Oslo University Hospital,
Oslo, Norway; 2Medigene Immunotherapies GmbH, Germany.
Patients diagnosed with acute myeloid leukemia (AML) may not be eligible for
curative intensive treatment due to co-morbidity factors or age. Here we report
results of 5 AML patients in morphological remission after incomplete induction/
consolidation chemotherapy treatedwith dendritic cells (DCs) targetingWT-1 and
PRAME.DCswere produced as described previously (Subklewe et al 2014), using a
maturation cocktail containing the TLR 7/8 ligand R848. These DCs show a polar-
ized release of IL-12p70 combined with low IL-10 upon stimulation. 2.5 or 5E6
DCs per antigenwere injected intradermally onceweekly for 4weeks (wks), inwk 6
and thereafter at monthly intervals. Blood and bone marrow (BM) samples were
collected at regular intervals.Minimal residual disease (MRD)wasmeasured inBM
byquantitativePCRofWT-1andPRAMEexpressionandbymorphology. Immune
responses were assessed by analysis of intracellular interferon gamma expression or
proliferation following stimulationwithpeptides spanningWT-1, PRAME,hTERT
andsurvivinorafter stimulationwithautologousWT-1andPRAMEDCs.A57year
old woman with intermediate risk M4 AML was vaccinated over 22 months after
chemotherapy. Five weeks after start of vaccination she mounted strong CD8 re-
sponses against PRAMEcombinedwith an increase in hTERT response, suggesting
epitope spreading.WT-1 signals in BM showed low positive levels throughout vac-
cination, but she remains in morphological remission 33 months after end of che-
motherapy (EoC). A 50 year old man withM2 intermediate risk AML, initially not
eligible for BM transplantation, showed specifıc immune responses against WT-1
during 10 months of vaccination. Due to Bell’s Palsy he was treated with cortisone
which immediately reduced the vaccine effect, accompanied by increase of blasts in
thebonemarrow.Followingnew induction therapyhe receivedBMtransplantation
and is currently in CR. A 68 year old woman with M1 intermediate risk AML is
under vaccination for 24 months. WT-1 signals in BM continue to be slightly ele-
vated without any sign of morphological relapse. CD4 responses and low CD8 re-
sponses aredetected againstWT-1, PRAMEandhTERT.A73year oldwomanwith
M1 good risk AML relapsed after 6 months of DC vaccination without mounting
specifıc immune responses. DC treatment was combined with 5-Azacytidine with-
out any immunological and clinical effects. A 59 year old woman with good risk
AML has been vaccinated for 14 months and is in remission for 21 months since
EoC. WT-1 in BM remains slightly elevated whilst the initially positive PRAME
signal is negative. Our results show that in 4 out of 5 AML patients fast TLR-polar-
ized DC vaccination induced or supported specifıc T cell responses. 3 patients con-
tinue to be in CR after 21, 25 and 33 months respectively, following suboptimal
primary chemotherapy. Immune responses are under investigation andwill be pre-
sented.
#3660 Blocking the DC-HIL receptor reverses the T-cell suppression in-
duced by proliferating myeloid-derived suppressor cells in common cancer
types. Masato Kobayashi,1 Jin-Sung Chung,1 Muhammad Beg,1 Yull Arriaga,1
Udit Verma,1 Kevin Courtney,1 John Mansour,1 Barbara Haley,1 Saad Khan,1
Yutaka Horiuchi,2 David Harker,1 Purva Gopal,1 Ponciano D. Cruz,1 Kiyoshi
Ariizumi1. 1UT Southwestern Medical Center at Dallas, Dallas, TX; 2Faculty of
Medicine, Saitama Medical University, Saitama, Japan.
Myeloid-derived suppressor cells (MDSC) are themost potent suppressors of
T-cell function, and their exponential proliferation in cancer states counteracts
the benefıts of immunotherapy given to these patients. Having discovered the T
cell-inhibitory DC-HIL receptor, we showed that DC-HIL is responsible for
MDSC’s T-cell suppressive function.We found thatmelanoma patients (but not
healthy controls) harbor in the blood an expanded population of DC-HIL
MDSC, whose suppressor effects in vitro can be blocked by our 3D5 anti-DC-
HIL mAb. To determine whether similar outcomes apply to non-melanoma
cancers, we recruited patients with metastases from bladder (BL, n4), breast
(BR, n11), colon (CO, n44), kidney (KI, n6), lung (LU, n20), pancreatic
(PA, n17), and prostate (PR, n9) cancer. FACS analysis of blood samples
showed all cancer types (except LU) were associated with elevated blood HLA-
DRno/low CD14 MDSC vs. age-matched controls (n21, median of 0.5%). %
DC-HILMDSC in PBMC was also signifıcantly high in all cancer types; me-
dian of 2.5% for BL; 1.7% for BR; 3.5% for CO; 3.6% for KI; 0.3% for LU; 1.8% for
PA; and 4.8% for PR, vs. 0.04% for healthy controls. MDSC in all cancer types
showed highDC-HIL-positivity (20-90% vs. 8% for controls).We assayed T-cell
suppressor activity by purifying MDSC and T-cells from the same patient and
co-culturing them at varying cell ratios, with co-stimulators. Activity was deter-
mined by % suppression in IFN- secretion, which was correlated with % DC-
HIL-positivity of MDSC. MDSC from KI (n3) were more suppressive than
those from CO and PA, with suppressor activity correlating with DC-HIL-pos-
itivity: Pearson’s r for 0.5 for CO (n13) and 0.73 for PA (n8). We evaluated
effects of anti-DC-HIL mAb on co-cultures of MDSC/ T-cells from cancer pa-
tients (n25). ThemAb restored IFN- secretion by30% in 8/15 cases of CO;
4/8 of PA, and 2/2 of KI. To determine whether DC-HILMDSC migrate into
cancer sites, lesional specimens fromCOpatients (n5) with high blood counts
of DC-HIL MDSC were immunohistochemically stained for CD14 and DC-
HIL expression:DC-HILwas absent from all cancer cells, but present strongly in
manyCD14 cells surrounding the cancers. This outcome contrasts starklywith
melanoma, in which DC-HIL was expressed highly by the cancer cells sur-
rounded by only a few DC-HIL CD14 cells. Finally we evaluated in vivo
effects of blocking DC-HIL using a mouse model of MC38 colon cancer, which
is DC-HILneg. MC38 tumor challenge induced DC-HIL Gr1lowLy6Chigh
MDSC in the tumor site. Intravenous infusion of anti-DC-HIL mAb into mice
with pre-established MC38 tumor signifıcantly inhibited tumor growth by 50-
70%, reduced blood levels of MDSC, and enhanced cytotoxic T-lymphocyte
response. Our fındings support DC-HIL blockade as a potential treatment for
metastatic cancers, with high blood levels of DC-HIL MDSC as a prognostic
marker for the best responders.
#3661 Breaking down the barrier restricting infıltration and differentia-
tion of APC in the tumor microenvironment with a fırst-in-class antibody
targeting Semaphorin4D, and rational combination therapies. Elizabeth E.
Evans,1HolmBussler,1 CrystalMallow,1ChristineReilly,1 SeboldTorno,1Maria
Scrivens,1 Cathie Foster,1 Alan Howell,1 Stephen R. Comeau,1 Leslie Balch,1
Alyssa Knapp,1 John E. Leonard,1 Terrence L. Fisher,1 Siwen Hu-Lieskovan,2
Antoni Ribas,2 Ernest S. Smith,1 Maurice Zauderer1. 1Vaccinex, Rochester, NY;
2UCLA, Los Angeles, CA.
Purpose: We expand mechanistic fındings in preclinical studies to dem-
onstrate that antibody blockade of Semaphorin 4D (SEMA4D, CD100) re-
duces expansion of MDSC and shifts the balance of myeloid cells within the
TME to facilitate tumor rejection. Effıcacy is further enhanced when com-
bined with various immunotherapies. Design of Phase 1b/2 combination
trials of VX15/2503, a humanized IgG4 antibody targeting SEMA4D, with
immune checkpoint inhibition will be presented. Methods: Anti-SEMA4D
antibodies were evaluated alone and in combination with other immuno-
therapies in various preclinical models. Anti-tumor activity and immune
response was characterized by immunohistochemistry, flow cytometry,
functional assays, and cytokine, chemokine and gene expression analysis. A
Phase I trial for single agent VX15/2503 was completed, and several 1b/2
combination immunotherapy trials are planned. Results: SEMA4D restricts
migration of monocytes and promotes expansion of suppressive myeloid
cells in vitro. Strong expression of SEMA4D at the invasive margins of ac-
tively growing tumors in vivo restricts the infıltration and modulates polar-
ization of leukocytes in the TME. Antibody blockade of SEMA4D facilitated
recruitment of activated DCs and T lymphocytes in preclinical models. M-
MDSCs were signifıcantly reduced in tumor and blood following treatment.
A signifıcant shift towards increased Th1 cytokines (IFN, TNF) and CTL-
recruiting chemokine CXCL9, with concurrent reduction in Treg-, MDSC-
and M2-macrophage promoting chemokines (CCL2, CXCL1, CXCL5) was
observed. Accordingly, Teff:Treg ratio (3x, p0.005) and CTL activity (4x,
p0.0001) were increased. These coordinated changes in the tumoral im-
mune context are associated with durable tumor rejection and immunologic
memory in murine colon, breast, and melanoma models. Importantly, anti-
SEMA4D treatment can further enhance activity of co-administered immu-
notherapies and chemotherapy. For example, the combination with immune
checkpoint inhibitor anti-CTLA-4 causes complete tumor regression in
100% of mice, as compared to 22% with monotherapy (p0.01). Additional
studies of combinations with other immunomodulators, including treat-
ment of established tumors with HDAC inhibitor Entinostat, will be pre-
sented. Conclusions: SEMA4D blockade represents a novel mechanism to
promote functional immune infıltration into the tumor and enhance immu-
notherapy. VX15/2503 treatment was well tolerated in a Phase I multiple
ascending dose trial in patients with advanced refractory solid tumors. Phase
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1b/2 trials of combination therapy with avelumab in NSCLC patients who
are immunotherapy naïve, and combinations with anti- anti-PD-1 and/or
anti-CTLA-4 in melanoma and HNSCC patients who are refractory to PD1
inhibitors are planned in 2017.
#3662 Activation of CD40 while inhibiting IL6/STAT3 using oncolytic
viruses induces mature DCs with high cytokine production but blocks PDL1
expression. Emma Eriksson,1 Ioanna Milenova,1 Jessica Wenthe,1 Anna Dim-
berg,1 Rafael Moreno,2 Gustav Ullenhag,1 Ramon Alemany,2 Angelica Loskog1.
1Uppsala University, Uppsala, Sweden; 2IDIBELL, Barcelona, Spain.
The tumor microenvironment (TME) consists of tumor cells and stroma,
including fıbroblasts, blood vessels, immune cells and extracellular matrix. The
TME supports tumor progression, metastasis as well as resistance to cancer
therapeutics. In pancreatic cancer, the TME is dense due to overproduction of
collagen and the tumor is infıltrated with suppressive myeloid cells such as M2
macrophages andmyeloid suppressor cells. One key regulator ofmyeloid cells is
CD40, a receptor expressed on a variety of cell types. CD40/CD40L signaling
results in production of cytokines and chemokines by myeloid cells but also
endothelial and epithelial cells to alert the immune system of immediate danger.
4-1BB is expressed by lymphocytes and dendritic cells (DCs). Stimulation via
4-1BBL drives lymphocyte expansion and regulates memory formation. IL6 sig-
naling leads to STAT3 phosphorylation in myeloid cells and tumor cells leading
to suppressive phenotypes, tumor proliferation, and angiogenesis. Further,
STAT3 signaling enhances production of TGFb, which in turn leads to overex-
pression of collagen. We have constructed a family of oncolytic adenoviruses
(LOAd) activating the CD40, 4-1BB and/or inhibiting IL6 signaling. The LOAd
viruses (-, 700, 703, 713) were investigated for their capacity to activate human
monocyte-derived DCs as well as their effect on pancreatic tumor cells and
stroma (fıbroblastic stellate cells, endothelial cells) using flow cytometry, MTS
assay and ProSeek Proteomics. The LOAd viruses expressing a trimerized
CD40L, 4-1BBL and/or a scFv IL6R showed effıcient oncolysis of tumor cells but
primary stellate cells were unaffected. However, stellate cells reduced tumor-
promoting factors such as FGF5, PlGF, amphiregulin, Gal3, TGFb and collagen
type I. Dendritic cells increased costimulators, cytokines as well as chemokines
but PDL1was not expressedwhen IL6/STAT3was blocked. Infected endothelial
cells upregulated receptors important for lymphocyte transmigration (ICAM,
VCAMandE-Selectin). Taken together, our data demonstrates that it is possible
to utilize oncolytic adenoviruses to spark immune activation at the same time
changing biological processes via STAT3blockade and/orCD40/4-1BBpathway
activation to reduce factors that promotes tumor progression.
#3663 Ananti-CD4depleting antibody reverses regulatoryT-cell-induced
suppression of dendritic cells while preventing nonspecifıc CD4 T cell re-
sponses in tumor-bearing mice. Satoshi Ueha,1 Haru Ogiwara,1 Shoji Yoko-
chi,2 Yoshiro Ishiwata,2 Francis Shand,1 Shohei Hori,3 Kazuhiro Kakimi,4 Sa-
toru Ito,2 Kouji Matsushima1. 1The University of Tokyo, Tokyo, Japan; 2IDAC
Theranostics, Inc, Tokyo, Japan; 3RIKEN, Yokohama, Japan; 4The University of
Tokyo Hospital, Tokyo, Japan.
Administration of an anti-CD4 depleting antibody induces tumor-specifıc
CD8

T cell responses in tumor-bearingmice, although themechanisms under-
lying this phenomenon remain unclear. CD4 Foxp3 regulatory T cells (Treg)
impair antigen presentation by DCs through CTLA4-mediated down-regula-
tion of CD80/CD86. In the present study, we investigated the effects of an anti-
CD4 depletingmonoclonal antibody (mAb) onDC responses in the B16F10 and
LLC subcutaneous tumormodels, and compared these effects with those of Treg
targeting therapy. Administration of anti-CD4 mAb up-regulated CD80/CD86
in tumor-infıltrating DCs, and in migrating-type but not resident-type DC sub-
sets in the tumor-draining lymph node. The upregulation of CD80/CD86 on
these DC populations was correlated with increased proliferation of tumor-
specifıc CD8 T cells in the tumor-draining lymph node. Anti-CD4 mAb-in-
duced CD80/CD86 up-regulation and tumor-specifıc CD8 T cell responses
were remarkably higher than that induced by an anti-CD25 depletingmAbor an
anti-CTLA4 blocking mAb, and were equivalent to that induced by diphtheria-
toxin-induced selective depletion of Tregs in Foxp3-DTRmice. Importantly, the
activation of CD4 conventional T cells and B cells in the peripheral lymph
nodes that was observed following Treg depletion was not observed following
anti-CD4 mAb administration. In conclusion, anti-CD4 depleting antibody
therapy is an effective way to evoke anti-tumor CD8T cell responses by revers-
ing regulatory T cell-induced suppression of dendritic cells, and to reduce the
risk of severe autoimmunity in cancer patients.
#3664 CDX-1402, adendritic cell targeted fusionproteindesigned to elicit
immunity to mesothelin and HER2 expressing tumors. Li-Zhen He,1 Jenifer
Widger,1 James Testa,1 Laura Mills-Chen,1 Biwei Zhao,1 Jeff Weidlick,1 Crystal
Sisson,1 Anna Wasiuk,1 Laura Vitale,1 Joel Goldstein,1 Henry Marsh,2 Tibor
Keler,1 VenkyRamakrishna1. 1Celldex Therapeutics, Inc., Hampton, NJ; 2Celldex
Therapeutics, Inc., Needham, MA.
The use of mAbs to target antigens to the endocytic receptor Dec205 on
dendritic cells (DC) is an effective means to elicit helper and cytolytic T cell
responses in the presence of appropriate adjuvants to activate DC. We have
translated this concept to clinical studies using a fully human Dec205-specifıc
mAb genetically altered to include the entire NY-ESO-1 cancer antigen (CDX-
1401), which when combined with TLR agonists results in effective stimulation
of both cellular and humoral NY-ESO-1-specifıc responses in cancer patients
(Dhodapkar MV et al., Sci. Transl. Med. 6:232-251, 2014). Building on this
concept, we developed a new fusion protein in which the Dec205 mAb is engi-
neered to carry two tumor-related antigens in tandem [ECDs of mesothelin
(MSLN) and HER2]. HER2 and MSLN are broadly expressed in selected tumor
types and provide an expanded opportunity for this immunotherapy approach.
We previously generated an anti-mouse DC-targeted HER2 vaccine (Dec205-
HER2) and a MSLN vaccine (Dec205-MSLN) and demonstrated in mouse
studies that they were potent in eliciting strong and broad CD4 T cell immunity,
cross priming of CD8T cells and humoral responses specifıc forHER2 orMSLN
antigens, respectively. In this workwe tested the impact of expressing two tumor
antigens in the same construct on the immune responses to each antigen. Mice
of various genetic backgrounds were immunized with equimolar amount of
Dec205-HER2 (6.8 g), Dec205-MSLN (5 g) or Dec205-MSLN-HER2
(8.3 g) in combination with poly IC-LC plus anti-CD40 or anti-CD27 as adju-
vant. Similar levels of CD4 andCD8T cell responses upon single or dual antigen
vaccination were observed in the assessment of intracellular cytokines and
IFN-ELISPOT after ex vivo stimulation with peptide pools derived from either
HER2 or MSLN. High titers of anti-HER2 and anti-MSLN IgG, including IgG1
and IgG2a, were elicited upon Dec205-MSLN-HER2 vaccination. Both hu-
moral and cellular responses were boosted by multiple dosing of the vaccine.
Based on these data we developed CDX-1402 using our anti-human Dec205
mAb genetically fused toMSLN andHER2. CDX-1402 was shown to effectively
deliver these antigens to human DC in vitro for activation of antigen-specifıc T
cells. In vitro stimulation of healthy volunteer circulatingT cells with autologous
DC treated with CDX-1402 plus TLR agonist resulted in T cell cultures that
produced IFN onlywhen presentedwithCDX-1402-treatedDCs orDC loaded
with a select panel of HLA-I/II synthetic peptides derived from either MSLN or
HER2 but not with control peptides. We also observed that T cells sensitized to
CDX-1402 recognize cancer cell lines that express the vaccine antigen andHLA.
Altogether, the data lend support for the use of CDX-1402 as a novel immuno-
therapeutic for treatment of multiple cancer types expressing MSLN and/or
HER2.
#3665 Tumor Treating Fields (TTFields) plus anti-PD-1 therapy induce
immunogenic cell death resulting in enhanced antitumor effıcacy. Tali Vo-
loshin, Orna Tal-Yitzhaki, Noa Kaynan, Moshe Giladi, Anna Shteingauz, Mijal
Munster, Roni Blat, Yaara Porat, Rosa S. Schneiderman, Shay Cahal, Aviran
Itzhaki, Eilon D. Kirson, Uri Weinberg, Yoram Palti. Novocure, Haifa, Israel.
Tumor Treating Fields (TTFields) are an effective anti-neoplastic treatment
modality delivered via noninvasive application of low intensity, intermediate
frequency, alternating electric fıelds. TTFields is approved for the treatment of
both newly diagnosed and recurrent glioblastoma. TTFields interrupt cancer
cell mitosis by disrupting microtubules and septin fılaments, which play key
roles in mitosis. The mitotic effects of TTFields include abnormal chromosome
segregation and ER stress, which trigger different forms of cell death. We eval-
uated the in vitro and in vivo effects of TTFields combined with an immune
checkpoint inhibitor (anti-PD1) on immunogenic cell death.Murine Lewis lung
carcinoma (LLC) and ovarian surface epithelial (MOSE) cells were treated with
TTFields using the inovitroTM system. Levels of calreticulin (CRT) on the sur-
face of treated cells and intracellular ATP levels were evaluated using flow cy-
tometry. Highmobility group box 1 (HMGB1) secretion wasmeasured using an
ELISA assay. Mice were implanted with LLC cells were treated with TTFields,
anti-PD-1, or a combination of the two modalities. Tumor volume was moni-
tored; flow cytometry analysis was performed for phenotypic characterization of
infıltrating immune cells. TTFields induced elevated cell surface expression of
CRT, decreased intracellular ATP levels, and promoted HMGB1 secretion. In
vivo, the combined treatment of lung tumor-bearing mice with TTFields plus
anti-PD-1 led to a signifıcant decrease in tumor volume compared to anti-PD-1
alone or to the control group. Signifıcant increases in CD45 tumor infıltrating
cells were observed in the TTFields plus anti-PD-1 group. Infıltrating cells dem-
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onstrated a signifıcant upregulation of surface PD-L1 expression. Both F4/
80CD11b cells and CS11c cells exhibited higher tumor infıltration and
elevated PD-L1 expression as compared to infıltrating immune cell in the con-
trol group. Our results demonstrate that TTFields treatment potentiates immu-
nogenic cell death in cancer cells. Combining TTFields with specifıc immuno-
therapies such as anti-PD-1 may enhance antitumor immunity and result in
increased tumor control.
#3666 Chemotherapeutic sensitivity of myeloid-derived suppressor cells
during cancer therapy is dictated by selective expression of clusterin. Nhan
Tu, Thu Le Trinh, Jun-Min Zhou, Danielle L. Gilvary, Domenico Coppola,
Sheng Wei, Julie Y. Djeu.Moffıtt Cancer Center, Tampa, FL.
Diverse chemotherapeutic agents, including Docetaxel, have been reported
by us and others to specifıcally targetmyeloid-derived suppressor cells (MDSCs)
whichmediate tumor-associated immune repression. However, themechanism
is unknown. To fınd a less toxic anticancer drug, we focused onCurcuminwhich
exhibits natural anti-oxidant and antitumor activities with low toxicity to nor-
mal cells. Here, we demonstrate that curcumin, like Docetaxel, promotes cyto-
toxic function against tumor cells and depletesMDSCpopulations in vivo and in
vitro. In 4T1mammary tumor-bearing BALB/cmice treated with curcumin, we
observed dose-dependent tumor reductions in mice treated with curcumin
compared to DMSO controls, indicating that curcumin can be an effective an-
titumor agent. To elucidate the mechanism, we embarked on examining differ-
ent populations of myeloid-derived suppressor cells (MDSCs). Flow cytometric
analysis of splenic cells from tumor bearers indicated that the antitumor effect
by curcumin is due to depletion of immunosuppressive Ly6G granulocytic
(G)-MDSC lineage with selective promotion of Ly6C monocytic (M)-MDSC
towards the CCR7F4/80M1 subset. Furthermore, the increase inM1MDSCs
correlated with greater T-cell adaptive immune response and cytotoxicity
against 4T1 tumor cells. Since clearance ofG-MDSCswasmediated by apoptosis
as evidenced by our Annexin V staining, we hypothesized that clusterin (sCLU),
a potent anti-apoptotic protein, unrelated to the Bcl-2 family, may be the under-
lying mechanism by which M-MDSCs and M1 cells are selected out following
treatment of curcumin. Western blot analysis revealed that sCLU was, indeed,
differentially expressed in M1-MDSCs but not in G-MDSCs. Antisense-CLU
transfection intoM-MDSCs reduced chemoresistance not only to curcumin but
also to Docetaxel, confırming the critical involvement of CLU in selective sur-
vival of M-MDSCs. Using both curcumin and Docetaxel we confırmed that
sCLU works by binding Bax, preventing its translation to the mitochondria to
initiate apoptosis. For clinical relevance, we examined human breast cancer
samples and noted that the tumor microenvironment is replete with immature
CD33MDSCs which lack sCLU expression, unlike infıltratingmature CD68
macrophages which possess high sCLU expression. Our results taken together
indicate that selective survival of M-MDSCs under chemotherapy dictate their
survival advantage, allowing for maturation into M1 cells and promotion of
adaptive T cell immunity against cancer.
#3667 Promotion of immunogenicity using epigenetic modulation and
immune checkpoint inhibition inmousemodels of breast cancer.Evanthia T.
Roussos Torres, Hayley Ma, Brian Christmas, Todd Armstrong, Elizabeth M.
Jaffee. Johns Hopkins University, Baltimore, MD.
Checkpoint inhibition is a very successful treatment strategy in cancers that
are naturally immunogenic by attracting T cells into the tumor microenviron-
ment (TME) and promoting cytotoxic signaling pathways. While this strategy
has shown some effıcacy inmetastatic breast cancer, most breast cancers are not
highly immunogenic likely due to an immunosuppressive microenvironment
and a lack of tumor antigen expression and recognition. One strategy to trans-
form the breast TME into one that is immune responsive, is to use epigenetic
modulation to expose tumor antigens, promote cytokine production, thus, at-
tracting inflammatory cells into the tumor. Epigenetic modulation also has the
potential to affect activation and traffıcking of myeloid derived suppressor cells
(MDSCs), known to alter the immunogenicity of the TME and thus, sensitizing
tumors to checkpoint modulation. We hypothesize that combinatorial therapy
primes the TME by increasing immunogenicity via alteration of T cells and
MDSCs. We also hypothesize that combination therapy will signifıcantly affect
immune modulatory pathways. Alterations in these could serve as a functional
read out of combinatorial therapy.We are using aHer-2/neu (neu-N) transgenic
mouse model which through the use of various syngeneic cell lines has the
capability to inform the response of Her2 and triple negative subtypes of breast
cancer to immunotherapy. This model enables us to study the effıcacy of differ-
ent combinations of an epigenetic agent, the histone deacetylase inhibitor enti-
nostat, and checkpoint inhibitors anti -programmed cell death protein (PD1)
and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies, on
tumor growth and metastatic progression, and to help identify co-stimulatory
and inhibitory factors regulating T cell and MDSC responses. Characterization
of tumor infıltrating lymphocytes and their functional capabilities are being
investigated in primary tumors andmetastases using fluorescence-activated cell
sorting and immunohistochemistry. Thus far, there is a signifıcant improve-
ment in survival and delay in tumor growth inmice inoculatedwith neu express-
ing tumor cells treated with combination anti-PD1, anti-CTLA4 and entinostat
aswell aswith anti-PD1 in combinationwith Entinostat. Preliminary results also
suggest that epigenetic modulation with entinostat in combination with check-
point inhibition improves the immune response within these tumors as evi-
denced by increased CD8/T-regulatory cell infıltration, and increased mono-
cytic-MDSCs into the TME. There are ongoing survival studies testing this
combination therapy in mice inoculated with triple negative breast tumor cells.
Future studies will further delineate the mechanisms by which epigenetic ther-
apy alters the function of the inflammatory response to immunotherapy.
#3668 Oncolytic adenoviruses expressing OX40L or GITRL immune
modulators show antitumor effect on immune-competentmouse breast can-
cer models. Francisco W. Puerta Martinez, Yisel A. Rivera, Teresa Nguyen,
Xuejun Fan, Jared M. Henderson, Shifat Rehnuma, Mohammad B. Hossain,
Hong Jiang, Juan Fueyo, Candelaria Gomez Manzano. MD Anderson Cancer
Center, Houston, TX.
Metastasis of advanced stage cancers remains as the main cause of morbidity
and mortality in oncologic patients. Metastatic cancers, especially those that
metastasize to the brain, are generally resistant to conventional therapies. Thus,
more innovative and effıcacious therapies are urgently needed. Therapeutic
goals are the specifıc targeting ofmalignant cells, shrinkage of stablished tumors,
prevention and/or eradication of metastases and, ultimately, induction of a spe-
cifıc anti-tumor immune response. In this study we tested the effıciency of a
treatment regimen consisting of oncolytic adenoviruses combined with specifıc
immune regulators to prevent tumor progression andmetastasis. In order to do
so, mouse metastatic breast cancer cells 4T1 or 66c14, were orthotopically im-
planted in female BALB/cmice. The resulting primary tumors were treated with
multiple doses of third generation adenoviruses targeting different immune
checkpoints, such as, OX40/OX40L and GITR/GITRL pathways in the immune
synapse. The treatment with these adenoviral constructs resulted in T cells acti-
vation and reduction of the metastases in 50% of the mice. In addition, the size
and number of the metastases detected in lungs were signifıcantly lower com-
paring with those observed in the control groups. Survival rates were also sig-
nifıcantly different (P  0.046) when compared to controls. FACS analysis of
isolated tumor-infıltrating lymphocytes, as well as, splenocytes showed that
OX40/OX40L or GITR/GITRL immune therapies were able to activate and in-
crease the number of cytotoxic T cells and suppress tumor anergy. In summary,
we demonstrated for the fırst time that Delta-24-RGDOX and Delta-24-
GREAT, expressingOX40L andGITRL respectively, display antitumor effect on
immune competent models of metastatic breast cancer.
#3669 Screening platform for development of antibody-drug conjugates
against novel targets at the National Research Council of Canada.Maria Luz
Jaramillo,1 Luc Meury,1 Patrice Bouchard,1 Allan Matte,1 Anne Marcil,1 Mauro
Acchione,1 Jennifer Hill,2 Francois Fauteux2. 1National Research Council, Mon-
tréal, Quebec, Canada; 2National Research Council, Ottawa, Ontario, Canada.
One of the most promising of the next generation of biologic-based cancer
therapeutics builds on themolecular targeting abilities of antibodies by combin-
ing them with drugs to generate highly specifıc antibody-drug conjugates
(ADCs). However, the development of ADCs requires time-consuming selec-
tion of the antibody for every target and cancer type.High-throughput screening
technologies based on the use of conjugated secondary antibodies provide a fast
and effıcient surrogate assay from which to identify which antibodies are best
internalized and suitable for immunoconjugate development into ADCs. As
part of its integrated antibody development initiative, NRC has isolated and
characterized anti-mouse Fc and anti-humanFcmonoclonal antibodies to serve
as very selective detective reagents for various IgG isotypes.We have shown that
these secondary antibodies are species specifıc, selective and of high affınity.
When conjugated to pH sensitive fluorophores, we have used them to specifı-
cally identify internalizing antibodies against tumor targets, which were later
validated as ADCs. Furthermore, these secondary conjugates exhibit high spe-
cifıc potency and low background toxicity once conjugated to linkered drugs.
This approach allow us to optimize the selection of an antibody for a particular
target, tumor type, linker and drug for ADC development. NRC will present
results of a screen of 285 mouse antibodies against 20 different targets in 7
different cancer cell lines, using either MCC-DM1 or vc-MMAE-conjugated
secondary antibodies. The NRC ADC discovery platform is combining this
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methodologywith our proprietarymRNA andDNA expression database for the
selection of appropriate ADC targets. NRC Biologics and Biomanufacturing
program is in the process of screening thousands of NRC antibodies generated
against a variety of cancer-associated cell surface targets to deliver a steady pipe-
line of ADCS as part of its drug discovery efforts. This functional screening
platform further promotes the integration and advancement of NRC’s capabil-
ities and strengths in the area of biologic-based therapeutics lead candidate
selection, including quality attributes and characterization and biomanufactur-
ing. The combined expertise in cell biology, high throughput screening, anti-
body generation and selection, bioinformatics and expression analysis forms the
foundation by which NRC can establish strategic collaborations with other Ca-
nadian or international partners to develop antibodies into novel ADC biolog-
ics.
#3670 Treatment of epithelial ovarian cancer with folate receptor (/)
targeted chemotherapy is enhanced by CTLA-4 blockade: Learning from an-
imal models. Yingjuan Lu, Theresa P. Johnson, Leroy W. Wheeler, Alex M.
Lloyd, Vicky A. Cross, Elaine M. Westrick, Nikki L. Parker, Christopher P.
Leamon. Endocyte, West Lafayette, IN.
Epithelial ovarian cancer (EOC) remains to be the most lethal form of gyne-
cologic malignancies despite aggressive cytoreductive surgery (i.e. debulking)
followed by standard chemotherapy. The alpha folate receptor (FR) has long
been recognized as a tumor target for EOC due to its frequently intense overex-
pression (80%) in themost common serous histotype. Recently, the beta folate
receptor (FR) has been discovered on tumor-associated macrophages (TAMs)
which are present at various densities in solid tumors but are also found abun-
dant in malignant ascites of EOC patients. The ascites TAMs are strongly im-
munosuppressive, and high TAM frequency is correlated with poor patient
prognosis and treatment resistance. Respectively, tumor- and TAM-associated
FR and FR are both functionally active which allows for folate-targeted de-
livery of small-molecule drug payloads via receptor-mediated endocytosis. Us-
ing flow cytometry, we characterized total ascites cells harvested from human
IGROV1 xenograft (hFR) andmurine ID8-CL15 syngeneic (mFR) models at
the time of euthanasia. Approximately 70% of IGROV1 and 25% of ID8-Cl15
ascites TAMs (F4/80 CD11b) were found to express a functional mFR.
While ascites fluids from bothmodels caused a dramatic reduction of FR func-
tionality on tumor cells in-vivo and ex-vivo, FR expression and functionality
on ascites TAMs were largely unaffected. Interestingly, in the ID8-CL15 model,
the ratio of ascites CD8 T cells to CD4 T cells decreased as total FR func-
tionality on TAMs increased. Two small-molecule folate-drug conjugates with
different mechanisms of action showed activity in extending the survival of
tumor-bearing animals. While CTLA-4 blockage alone was completely inactive
in the ID8-CL15 model, a combination regimen signifıcantly enhanced the ac-
tivity of a folate conjugate carrying a potent DNA cross-linking agent. Our data
suggest that EOC treatmentmay require amulti-pronged approach by targeting
both FR-expressing tumor cells and FR-expressing TAMs. In addition, im-
mune checkpoint inhibitors may further enhance the FR-targeted therapeutics
by modulating the ascites tumor microenvironment.
#3671 Anti-PD-1 treatment may potentiate the radiation-induced lung
injury. Jianxin Xue,1 Shisuo Du,1 You Lu,2 Adam Dicker,1 Bo Lu1. 1Thomas
Jefferson Hospital, Philadelphia, PA; 2West China Hospital, Sichuan University,
Chengdu, China.
Purpose: Combination of radiation therapy and anti-PD1 immunotherapy
has been investigated both in the lab and in the clinic. Pneumonitis is a rare but
potentially fatal toxicity of ant-programmed death-1 (PD-1) monoclonal anti-
bodies (mAbs). The purpose of our study is to address whether anti-PD-1mAbs
will potentiate radiation-induced lung toxicity andmortality in a murine model
using Small Animal Radiation Research Platform (SARRP) for lung-targeting
irradiation (IR). Methods: Both lungs of male C57bl/6 mice were targeted for
20Gy using the SARRP. Mice were stratifıed into 4 treatment groups receiving
IgG, anti-PD1, IR  IgG, or IR  anti-PD1. IgG or anti-PD-1 mAbs adminis-
trated via i.p. injection, with a dosage of 10mg/kg, twice per week for fıve doses.
Acute lung injury was assessed by H&E staining and flow cytometry to measure
CD4 or CD8 positive T lymphocytes. A duplicate study (n10) was per-
formed to determine long-term survival following lung irradiation. Results:
30 days following lung irradiation, lung tissues exhibited abnormal alveoli,
with exudates and inflammatory cells in the alveolar septa (H&E staining).
The extent of these changes was more prominent in IRanti-PD-1 group.
Moreover, there were signifıcantly (2.1 fold increase; p0.05) more CD8
cytotoxic T lymphocytes, rather than CD4 cells lymphocytes, in the irradi-
ated lung tissues in the group of IRanti-PD1 compared to that of IRIgG.
Up to 120 days post IR, 90%mice survived in the group of IRIgG while 70%
mice survived in the IRanti-PD-1 group (p0.657). Conclusions: Anti-
PD-1 mAbs potentiates the radiation-induced pneumonitis, likely mediated
by increased CD8 cytotoxic T lymphocytes. Anti-PD-1 mAbs may increase
the radiation-related mortality although it was not statistically signifıcance
at the day 120 following IR. Care should be taken for excessive lung toxicities
in ongoing clinical trials of combining thoracic RT and anti-PD1 therapy.
We will collaborate with NRG to further investigate clinical lung toxicities
from combining thoracic radiotherapy with Nivo in the ongoing RTOG 3505
though analyzing the collected biospecimens.
#3672 Semaphorin 4D in human head&neck cancer: A promising predic-
tive biomarker for the peri-tumoral stromal phenotype. Rania H. Younis,1
Roshanak Derakhshandeh,2 Ahmed Sultan,1 Haiyan Chen,1 Kyu Lee Han,1
Tonya J. Webb2. 1Univ. of Maryland School of Dentistry, Baltimore, MD; 2Univ.
of Maryland School of Medicine, Baltimore, MD.
Semaphorin 4D in human head and neck cancer: A promising predictive
biomarker for the peri-tumoral stromal phenotype The search for biomarkers
that can predict the tumor stromal phenotype in cancer patients is a challenge in
the fıeld. Semaphorin 4D (Sema4D), known for its various effects in the nervous,
vascular and immune system, plays an important role in regulating pro and
anti-inflammatory responses. It is over-expressed in Head and Neck cancer
(HNC) as well as in other epithelial malignancies. We have recently described
that HNC-associated Sema4D modulates the inflammatory profıle to an im-
mune-suppressive phenotype by inducing the expansion of myeloid derived
suppressor cells. The purpose of this studywas to determine the prognostic value
of Sema4D as a biomarker for immune suppression in human HNC tissue and
sera. Immunohistochemistry showed Sema4Dve/high tumors to correlate posi-
tively with Stage III disease (p0.014), and nodal metastasis (p0.117).
Sema4D
ve/high
tumors correlated directly with dense fıbrotic peri-tumoral
stroma (p0.0001) and inversely with tumor-associated inflammatory cells
(TAIs) (p0.0006). Knockdown of Sema4D inHNC cell lines resulted in signif-
icant reduction of TGF-1 production (p0.0016). Sema4Dve/high tumor cells
inversely correlated with the programmed death ligand 1 (PDL-1) positive tu-
mors. Finally, Sema4D was detected in sera of HNC patients at higher levels
compared to healthy donors (p 0.0001). In conclusion, we present a novel
Sema4Dve/high HNC tumor phenotype; with dense fıbrotic peri-tumoral
stroma. We also present Sema4D as a diagnostic biomarker in sera of HNC
patients that can also be a promising predictor of the tumor stromal phenotype.
This is of clinical interest as a predictive biomarker and a promising target for
co-inhibition to sensitize patients for standard immunotherapy. [1-4] Refer-
ences: 1. Younis RH, Han KL andWebb TJ. Human Head and Neck Squamous
Cell Carcinoma-Associated Semaphorin 4D Induces Expansion ofMyeloid-De-
rived Suppressor Cells. J Immunol. 2016; 196(3):1419-1429. 2. Basile JR, Cas-
tilho RM,Williams VP andGutkind JS. Semaphorin 4D provides a link between
axon guidance processes and tumor-induced angiogenesis. ProcNatl Acad SciU
S A. 2006; 103(24):9017-9022. 3. Gajewski TF. The Next Hurdle in Cancer Im-
munotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenviron-
ment. Semin Oncol. 2015; 42(4):663-671. 4. Fisher TL, Reilly CA, Winter LA,
Pandina T, Jonason A, Scrivens M, Balch L, Bussler H, Torno S, Seils J, Mueller
L, Huang H, Klimatcheva E, Howell A, Kirk R, Evans E, et al. Generation and
preclinical characterization of an antibody specifıc for SEMA4D. MAbs. 2016;
8(1):150-162.
#3673 Preclinical toxicology and pharmacology for the 4-1BB/HER2
bispecifıc PRS-343: A fırst-in-class costimulatory T cell engager. Marlon J.
Hinner, Rachida-Siham Bel Aiba, Thomas Jaquin, Sven Berger, Manuela Dürr,
Corinna Schlosser, Andrea Allersdorfer, Christine Rothe, Louis A.Matis, Shane
A. Olwill. Pieris Pharmaceuticals, Inc., Freising, Germany.
Background. 4-1BB (CD137) is a key costimulatory immunoreceptor and a
highly promising therapeutic target in cancer. To overcome toxicity and effıcacy
limitations of current 4-1BB targeting antibodies, we have developed PRS-343, a
4-1BB/HER2 bispecifıc based on Anticalin® technology. We have previously
reported on the generation and characterization of PRS-343 with regard to pre-
clinical proof-of-concept and basic drug-like properties.1 Here, we describe the
preclinical dataset supporting initiation of a fırst-in-patient trial. Methods and
Results. The pharmacology of PRS-343 was investigated by ex vivo assays based
on mixed culture of human PBMC and tumor cell lines. We fınd that 4-1BB
costimulated T cells prominently increase production of IL-2, GM-CSF, TNF-
and IFN-. Using a set of immortal cancer cell lines spanning a range of HER2
surface copy numbers, we identifıed a copy number threshold above which
PRS-343 reliably elicited T cell costimulation with a high potency and an EC50
in the subnanomolar range. PRS-343was well tolerated in a repeat-dose study in
cynomolgus monkeys, with no overt toxicity and no signifıcant drug-related
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toxicological fındings. Pharmacokinetic assessment confırmed dose-propor-
tional exposure of the animals during the course of the study. In a mouse model
of human PBMC-induced xenograft-vs-host disease (xGvHD), PRS-343 did not
show an acceleration of xGvHD development, in contrast to a 4-1BB targeting
benchmark. Again utilizing ex vivo assays, we found no PRS-343 induced T cell
costimulation in a panel of primary cells, showing that physiological levels of
HER2 are insuffıcient for activation. In a cytokine release assay, proinflamma-
tory cytokine induction byPRS-343 in the absence of a primaryTCR stimulation
was negligible. Conclusion. The ex vivo experiments described indicate that
HER2 expression level is expected to be a reliable marker for patient stratifıca-
tion for PRS-343. The toxicology assessment of PRS-343 indicates that the be-
nign toxicity profıle of trastuzumab is retained in PRS-343 with regard to HER2
targeting, and that PRS-343 is expected to elicit its costimulatory effects strictly
on T cells also receiving a primary TCR signal and strictly localized to HER2-
positive tumors. This is in agreement with in vivo mouse model data showing
PRS-343 leads to tumor-localized CD8 T cell expansion,1 and supports the
potential of PRS-343 as an effıcacious yet well tolerable 4-1BB costimulating
agent. The reported data is the basis for the trial design of a fırst in patient Phase
1 trial with PRS-343. 1Cancer Immunol Res 2016;4(11 Suppl):Abstract nr B016.
#3674 Local irradiation promotes antitumor immunity and abscopal ef-
fect of antigen-specifıc immunotherapy by enhancing dendritic cell matura-
tion. Ming-Cheng Chang, Jason Chia-Hsien Cheng, Ying-Cheng Chiang. Na-
tional Taiwan Univ. Hospital, Taipei, Taiwan.
Background: Ionizing radiation therapy (RT) is a well-established method to
eradicate locally advanced tumors. Whether or no local RT can enhance the
potency of an antigen-specifıc DNA vaccine and the possible underlying mech-
anismwere evaluated.Materials andMethods: The number of E7-specifıc CD8
cytotoxic T cell precursors and anti-E7 Abs from Tumor-bearing mice treated
with local RT (6Gy twice per week) and the CTGF/E7 DNA vaccine were eval-
uated. Abscopal effects were alsomonitored. HMGB-1andDCmaturation from
local irradiation were analyzed by flow cytometry. The ratio of effector-to-sup-
pressor cells in the tumor microenvironment was also investigated. Results:
Tumor-bearing mice treated with local RT (6Gy twice per week) and the
CTGF/E7 DNA vaccine exhibited a dramatic increase in the number of E7-
specifıc CD8 cytotoxic T cell precursors, higher titers of anti-E7 Abs, a signif-
icant reduction of tumor size, and longer survival. The combination of local RT
and the CTGF/E7 vaccine also elicited abscopal effects on non-irradiated local
subcutaneous and distant pulmonary metastatic tumors. Local irradiation can
induce the expression of HMGB-1 in apoptotic tumor cells and stimulate DC
maturation, which results in inducing antigen-specifıc immune responses. In
addition, local irradiation, although inducing Treg cells, can eventually increase
a higher ratio of effector-to-suppressor cells in the tumor microenvironment.
Conclusions: Local irradiation can enhance the antigen-specifıc immunity and
antitumor effects on local and distant metastatic tumors generated by an anti-
gen-specifıc DNA vaccine. Irradiation combined with antigen-specifıc immu-
notherapy is a potential new strategy for cancer therapy.
#3675 Novel immune oncology strategy for targeted cytotoxic lymphocyte
activation. Eric Lazier,1 Sarah Hein,2 John Westwick,2 Dan Watkins,2 Alexan-
der S. Krupnick3. 1University of North Carolina, Durham, NC; 2Courier Thera-
peutics, Houston, TX; 3University of Virginia, Charlottesville, VA.
High-dose interleukin 2 (IL2) therapywas the fırst FDA-approved immunother-
apy, andstillhasanexceptionallyhigh true long-termcurerate formetastatic cancer.
However, IL2 therapy has fallen out of favor due to systemic toxicity and off-target
side effects. We have recently described a novel fusion cytokine comprised of a
mutant formof IL2with inhibited-receptorbindingandanNKG2D-bindingviral
decoy protein calledOrthopoxMajorHistocompatibilityComplexClass I-like Pro-
tein (OMCP). Unlike wild-type IL2, our fusion cytokine (OMCP-mutIL2) binds to
and activates only NKG2D expressing cytotoxic lymphocytes. This targeted IL2
activity results in superior effıcacyanddecreased toxicityoverwild-type IL2 therapy.
Here, we present data which further establishes the superior effıcacy of OMCP-
mutIL2 therapy as measured by biomarkers such as systemic cytokine production
and tumor lymphocyte infıltration. Additionally, we present data which evaluates
OMCP-mutIL2 therapy as a potentiator of PD1 checkpoint inhibitor therapy. To
evaluate tumor lymphocyte infıltration mice with established Lewis Lung Carci-
noma (LLC) flank tumors were treated for three days with either saline, wild type
IL2, or OMCP-mutIL2 and tumor infıltrating lymphocytes evaluated flow cyto-
metrically.A trend for increased tumor infıltratingNKcellswas evident forboth IL2
andOMCP-mutIL2 treatedgroupsover saline controls, andOMCP-mutIL2 tended
to increase tumor infıltrating CD8 T cells over either IL2 or saline controls was
evident as well. Additionally, tumor infıltrating CD8 T cells in IL2-treated mice
had a higher level of exhaustion over OMCP-mutIL2 treated mice as measured by
PD-1 expression. Tumor infıltrating CD4 T cells also showed a trend toward a
Foxp3 regulatory phenotype in IL2 treated mice over OMCP-mutIL2. To study
cytokine serum profıle mice were treated with high dose OMCP-mutIL2 with or
without NK depletion and serum cytokine levels measured by cytometric bead ar-
ray. Serum cytokine analysis of mice treated with supra-therapeutic doses of
OMCP-mutIL2 did not reveal an increase in pro-inflammatory cytokines TNF-,
IFN-, and IL-6. A signifıcant increase in serum levels of G-CSFwas evident inNK
cell suffıcientmice treatedwithOMCP-mutIL2.Combination immunotherapywas
initiatedby the additionofPD-1blockade (cloneRMPI-14) toOMCP-mutIL2 ther-
apy in a lung LLC tumormodel. Combination therapy led to near complete control
of LLC growth in the lung compared to OMCP-mutIL2 or PD-1 blockade alone.
The data presented here suggest that in addition to our previously published data
suggesting increased safety of OMCP-mutIL2 over high-dose IL2 therapy, OMCP-
mutIL2 therapymay be functionally superior to classic high-dose IL2 therapy. Con-
tinued development of OMCP-mutIL2 is ongoing.
#3677 Early effects of CSF-470 melanoma vaccine plus adjuvants in im-
mune cell stimulation. Maria B. Pampena,1 Estefanía P. Juliá,1 Yamila S.
Rocca,2 Paula A. Blanco,1 María M. Barrio,1 José Mordoh,1 Estrella M. Levy1.
1Centro de Investigaciones Oncológicas CIO-FUCA, Ciudad de Buenos Aires, Ar-
gentina; 2Fundación Instituto Leloir IIBBA-CONICET, Ciudad de Buenos Aires,
Argentina.
Background: In a Phase II/III clinical trial (CASVAC-0401, NCT01729663),
cutaneous melanoma (CM) patients (pts) stages II/III were randomized to re-
ceive CSF-470 vaccine or IFN- (2:1). Vaccine CSF-470 is composed of four
lethally-irradiated allogeneic CM cell lines; BCG (Bacillus Calmette-Guérin)
and rhGM-CSF were used as adjuvants. At the end of the Phase II part of the
study (30 pts), a higher distant-metastases-free-survival was observed in vacci-
nated pts. All vaccinated pts developed inflammation at the vaccination site.
Therefore, in an attempt to understand these fırst steps of immune reaction,
leukocytes migration, cytokines synthesis and monocyte phagocytosis pro-
moted by the vaccine components were studied in vitro. Methods: Cell migra-
tion of healthy donors’ leukocytes or mononuclear cells (MN) towards vaccine
components was assayed in 0,5 m transwells. Cytokines were measured by
ELISA in supernatants of CSF-470 vaccine and MN (1:1, 0,5x106 each) cocul-
tures. For phagocytosis assays, CM cell lines were labeled with PKH67 lipophilic
dye, irradiated, and cocultured with purifıed monocytes. After 24 hs, cultures
were stained with CD14 and double staining (CD14PKH67) was analyzed by
flow cytometry. Results: In migration assays, CSF-470 vaccine induced higher
attraction of leukocytes as compared to culture medium (p0.003, unpaired-T-
test). GM-CSF exerted little attraction, although combined with BCG it in-
creased the migration triggered by CSF-470 (vaccine vs vaccine plus adjuvants,
p0.034, unpaired-T-test). When using MN, CSF-470 alone or plus adjuvants,
highly attracted monocytes, which represented 10%-65% of the migrating
CD45 population (before migration 6-15%) (p0.0001, paired-T-test). In the
lymphocyte population, natural killer cells were mainly attracted towards the
vaccine either with or without adjuvants, representing 12%-33% of total mi-
grated lymphocyte population (before migration 4-25% ) (p0.002, paired-T-
test). Regarding cytokine production, 6 hs cocultures of CSF-470 vaccine plus
adjuvants andMN,promotedTNFproduction (385	217pg/ml). IFN release
was detected in CSF-470:MN cocultures after 48 hs (109,2 pg/ml). BCG appears
to be the most important adjuvant for production of these proinflammatory
cytokines. IL-10, but not IL-12p70, was also detected. Interestingly, approxi-
mately 60% of monocytes phagocytosed CSF-470 cells after 24 hs of coculture,
either in the presence or absence of adjuvants. Conclusions: Our in vitro results
suggest that recruitment of leukocytes, mostly from the innate immune system,
is an early event after CSF-470 vaccine  BCG  GM-CSF interaction with
immune cells. Also, early release of TNF and IFN proinflammatory cytokines
and effıcient vaccine phagocytosis by monocytes would favor subsequent anti-
gen processing and presentation. Further experiments will be performed to ad-
dress the initial steps triggered after CSF-470 vaccination.
#3678 Muc4 nanovaccine and checkpoint blockade based combination
immunotherapy for pancreatic cancer. Kasturi Banerjee,1 Shailendra Gau-
tam,1 WaseemMohd. Nasser,1 Prakash Kshirsagar,1 Kathleen Ross,2 Gaelle Sp-
agnol,1 Abhijit Aithal,1 Paul Sorgen,1 Surinder Kumar Batra,1 Sushil Kumar,1
Balaji Narasimhan,2 Maneesh Jain1. 1University of Nebraska Medical Center,
Omaha, NE; 2Iowa State University, Iowa, IA.
Background: Pancreatic cancer (PC) is a highly metastatic and therapy-resistant
malignancy characterized by immunosuppressive tumor microenvironment
(TME) mucin overexpression. MUC4 is most differentially overexpressed mucin
and functionally contributes todisease aggressiveness and is thus ideal candidate for
targeted therapies. Tumor cells are also known to express programmeddeath ligand
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1 (PD-L1) to suppress effector immune cells activity via PD-L1-PD-1 axis. We de-
veloped a novel vaccine using recombinant MUC4 fragments and exploiting adju-
vant-like properties of amphiphilic polyanhydride-based nanoparticle delivery sys-
tem. The strong involvement of MUC4 in disease aggressiveness and PD-L1 in
immunosuppression makes a compelling case for their combined targeting. We
hypothesize that combinedoverexpressionofMUC4andPD-L1 expression inpan-
creatic tumormicroenvironmentcontributes to immunosuppressiveandaggressive
tumor behavior. Methods: Recombinant MUC4 fragment was encapsulated into
polyanhydride nanoparticles (20:80 CPTEG:CPH) via nanoprecipitation. Murine
PC cell lines (KCT960) derived from spontaneous pancreatic cancer mouse model
(KPC mice) were transfected with human MUC4 expressing construct known as
KCT960-mini-MUC4 cells for in-vivo studies. Flow cytometry, immunoblotting,
PCR and immunofluorescence techniques were utilized to perform to characterize
the immune response and target expression. Results: MUC4 nanovaccine immu-
nized mice exhibited slower tumor growth kinetics than unimmunized control
mice. We investigated tumor infıltrating lymphocytes (TILs) and necrosis in the
tumor bed.We observed a positive correlation betweenTILs and tumor regression.
Accumulation of infıltrating CD8 and CD4T cells was greater inmice receiving
theMUC4-NanovaccinecomparedtosolubleMUC4deliveredwithblanknanopar-
ticles, indicating the benefıt of sustained availability of antigen via encapsulation.
However, we did not observe complete tumor regression and ex vivo studies indi-
cated induction of IFN-gamma by MUC4 vaccine. Based on this, we rationalized
that PD-L1 expression by MUC4-expressing tumor cells suppressed and inhibited
the therapeutic benefıts of thenanovaccine in-vivo.Weobserveddifferential surface
expression of PD-L1 on endogenouslyMUC4 expressing andnegative PC cell lines.
Paired analysis of MUC4 CRISPR knockdown and scrambled Capan-1 cell lines
further suggested similarpositive correlation.Conclusion:MUC4nanovaccine sup-
pressed tumor progression in-vivo indicating its potential for immunotherapy of
PC. Positive correlation observed between MUC4 and PD-L1 in PC cell lines sug-
gests an underlying molecular mechanism for establishing an immunosuppressive
and aggressive PC tumor microenvironment and provides a strong rationale for
evaluating MUC4 vaccine in combination with immune checkpoint blockade
agents.
#3679 VEGF-A is increased and correlates with MDSC-driven immune
suppression, systemic inflammation, nutritional impairment andpoor prog-
nosis in patients with cancer.Masahiko Shibata, Kenji Gonda, Takahiro Naka-
jima,Koji Kono,Hiroyuki Suzuki, Seiichi Takenoshita.FukushimaMedicalUni-
versity, Fukushima, Japan.
Vascular Endothelial Growth Factor (VEGF) is a key factor for tumor
progression through induction of angiogenesis and other actions including
immune alteration. Myeloid-derived suppressor cells (MDSC) are a major
type of immune-suppressing cell that appear in cancer or inflammation and
that have been reported to express the VEGF-receptor and to be activated by
VEGF. To study the clinical importance of VEGF and MDSC for cancer,
peripheral blood was collected from patients with gastrointestinal, ovarian,
breast, thyroid and pulmonary cancers. Peripheral blood mononuclear cells
(PBMC) were separated using a Ficoll-density gradient and were used for the
detection of MDSC (CD11bCD14-CD33) using flow cytometry and for
cytokine-production assays. For these assays, PBMC were stimulated with
PHA and the production of cytokines including IL-12 (Th1 inducer), IL-10,
(anti-inflammatory cytokine) and IL-17, (pro-inflammatory cytokine), were
measured over 24 h using ELISAs. Serum concentrations of IL-10 and VEGF
were also measured using ELISAs. The serum levels of both VEGF and
MDSC were signifıcantly increased in almost all types of cancer tested and
signifıcantly correlated with each other. Their levels also signifıcantly corre-
lated with neutrophil/lymphocyte ratios (NLR) (inflammation marker) and
CRP levels, and were inversely correlated with the PHA-stimulation index
(SI) (cell mediated immune responses marker) and serum concentrations of
rapid-turnover protein (RTP) (nutrition marker). VEGF levels also corre-
lated with serum concentrations of IL-10 and VEGF, and production of
IL-17, and inversely correlated with production of IL-12. The prognosis of
stage IV colorectal cancer with high VEGF was signifıcantly worse than that
with low VEGF. In thyroid cancer, the number of MDSC was signifıcantly
higher, NLR and CRP levels were higher, and RTP levels were lower in
patients with undifferentiated carcinoma than in those with differentiated
carcinoma including papillary and follicular carcinomas. Thus VEGF was
increased in cancer and correlated with immune suppression driven by
MDSC, inflammation and malnutrition. Although cancer immunotherapy is
currently in use for a number of cancers, MDSC have been reported to be a
major inhibitor of cancer immunotherapy even in cases in which an immune
checkpoint inhibitor was used. An anti-VEGF treatment strategy has now
been established in combination with chemotherapy for many types of can-
cer. Among various types of anti-MDSC trials, anti-VEGF treatment seems
to be an effective adjuvant therapy of cancer immunotherapy.
#3680 Cancer-killing viruses combined with tumor-targeting immune
checkpoint modulation elicits an in situ vaccination effect and expansion of
tumor-specifıc T cells responsible for effıcacious systemic anti-cancer activ-
ity. Hong Jiang, Andrew Dong, Yisel Rivera-Molina, Karen Clise-Dwyer, Xue-
jun Fan, Francisco W. Martinez, Teresa Nguyen, Verlene Henry, Caroline Car-
rillo, Candelaria Gomez-Manzano, Juan Fueyo. UT MD Anderson Cancer Ctr.,
Houston, TX.
Oncolytic viruses are cancer-selective and disrupt immunosuppression
within the tumor, but they show suboptimal effıcacy in patients. Immune check-
point modulation is effıcacious in a variety of cancers but is associated with
nonspecifıc T-cell activation and a limited effect in tumors with a nonimmuno-
genic microenvironment. We hypothesized that combining these two strategies
likely resulted in both effıcacious and specifıc cancer therapy. Therefore, we
constructed oncolytic adenovirusDelta-24-RGDOXexpressing the immune co-
stimulator OX40L and tested its activity in orthotopic GL261-C57BL/6 glioma
and B16-C57BL/6 melanoma mouse models. Compared to its predecessor Del-
ta-24-RGD, Delta-24-RGDOX was more effective to induce inflammatory acti-
vation within the tumors, enhanced the capability of the tumor cells to directly
activate cancer-specifıc T cells and the proliferation of the cell population
through OX40L expression on the cell surface, resulting in specifıc anti-tumor
immunity. To track the expansion and migration of tumor-specifıc T cells dur-
ing virotherapy, we fırst injected OVA-specifıc CD8 T cells from OT-I/Luc
transgenic mice in the fırst tumor derived from B16-OVA cells, followed by
Delta-24-RGDOX injection in the same tumor. Monitoring the T cells with
bioluminescent imaging revealed that the viral injection greatly augmented the
T cell population than the PBS treatment within the tumor, and promoted the T
cell migration to distant B16-OVA tumor but not to B16 tumor, suggesting local
viral treatment enhanced the expansion of tumor-specifıc T cells and themigra-
tion of these cells to a distant tumor with the same tumor antigen. Consistently,
flow cytometry analysis with OVA-tetramer staining showed that virus treat-
ment greatly increased the frequency of OVA-specifıc CD8 T cells in the local
and distant tumors, peripheral blood and spleen (from high to low frequency).
70-80% cells of this cell population were CD44 CD62L that are markers for
central memory T cells. Hence, this new virus was effıcacious to inhibit the
virus-injected tumor and distant tumor, prolong the survival of the treatedmice
and induce immune memory specifıc to the virus-injected tumor type. Impor-
tantly, intratumoral injection of Delta-24-RGDOX and an anti-PD-L1 antibody
synergized to reject gliomas and signifıcantly increased survival in mice. Our
data demonstrate that combining an oncolytic virus with tumor-targeting im-
mune checkpointmodulation elicits potent in situ cancer vaccination and skews
the injected tumor microenvironment from tumorigenic to immunogenic, re-
sulting in a local expansion of the tumor-specifıc T cells. Moreover, this local
effect is capable to extend to distant tumors, achieving specifıc and long-lasting
systemic therapeutic effıcacy.
#3681 A patient derived ex vivo platform CANScript™ predicts distinct
therapeutic outcomes to multiple PD-1 checkpoint inhibitors in single tu-
mor biopsies. Padhma Radhakrishnan,1 Vasanthakumar Sekar,2 Nilesh Bri-
jwani,2 Priyanka Chevour,3 Babu Balakrishnan,2 Dency D Pinto,2 Muthusami
Oliyarasi,2 Debapriya G. Mehrotra,2 Manjusha Biswas,2 Sabitha K S,4 Koda-
ganur S. Gopinath,5 ArkasubhraGhosh,3M sGanesh,6 AshokM. Shenoy,4 Sara-
vanan Thiyagarajan,2 BiswanathMajumder,2 Aaron Goldman1. 1Mitra Biotech,
Woburn, MA; 2Mitra Biotech, Bangalore, India; 3Grow Research Lab, Bangalore,
India; 4Kidwai Memorial Institute of Oncology, Bangalore, India; 5Bangalore
Institute of Oncology, Bangalore, India; 6Vydehi Institute of Oncology and Re-
search Centre, Bangalore, India.
Background: Emerging clinical evidence using immunotherapy in recent
years has demonstrated its power to suppress tumor growth by releasing the
brakes on the immune system. For example, blockade of immune check-
points, such as PD-1, has revolutionized treatment options for patients with
aggressive cancers such as head and neck squamous cell carcinoma
(HNSCC). However, clinical responses to PD-1 inhibition vary widely
among patients while majority of them do not show any anti-tumor re-
sponse. Multiple FDA-approved drugs against the same immune check-
points have resulted in globally distinct outcomes in the clinic. There is a
huge unmet need to understand these disparities at the individual patient
level and to maximize the clinical benefıts of these agents. Methods: Here, we
employed a patient-derived ex vivo model, CANScript™ (Majumder B et al.
Nature Commun 2015 Feb 27;6:6169 and Goldman A et al. Nature Commun
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2015 Feb 11;6:6139), which recreates the native 3D tumor microenviron-
ment, autocrine-paracrine dynamic and response to therapy by incorporat-
ing fresh tumor tissue and autologous immune cells with immunotherapy
agents. Utilizing late stage HNSCC (N50) we interrogated phenotypic re-
sponse to two FDA-approved PD-1 inhibitors, Pembrolizumab
(KEYTRUDA) and Nivolumab (OPDIVO). To do this, we used a compre-
hensive panel of immunological assays to evaluate changes in the immune
compartments by flowcytometry and immunohistochemistry (primarily
CD8, CD45, FOXP3, CXCR4, CD68, PDL1, PD1), multiplex cytokine pro-
fıling (IL6, IL8, IFN-g, IL10, IL12, Perforin, GranzymeB), along with func-
tional/phenotypic effects including tumor proliferation, histological
changes and cell death. Results: The data demonstrated that CANScript™
preserves the tumor-immune contexture and native heterogeneity across
different clinical stages and patients. Importantly, we observed that PD-1
blockade resulted in patient-specifıc therapeutic response, which was char-
acterized by differential distribution and maintenance of infıltrating CD8
and CD4 lymphocytes, distinct patterning of cytokines linked to func-
tional dysregulation, and changes in tumor proliferation and apoptosis. In-
terestingly, data suggest that both Pembrolizumab and Nivolumab act on the
same immune network axis but trigger functionally diverse phenotypes in the
tumor immune compartment and distinct antitumor effects within an individ-
ual patient tumor. Conclusion: Together, these fındings demonstrate the utility
of CANScript™ as an ex vivo platform to predict therapeutic response of immune
checkpoint inhibitors at the individual patient level. It also highlightsmechanis-
tic variations that could impact clinical outcome of these agents having the same
molecular target. Such information can re-shape our understanding of patient
selection and rational combinations for novel immune checkpoint inhibitors.
#3682 Synergistic immunostimulatory effects and therapeutic benefıt of
combined histone deacetylase and bromodomain inhibition in non-small
cell lung cancer.Dennis O. Adeegbe,1 Yan Liu,1 Patrick Lizotte,2 Yusuke Kami-
hara,1Mark Awad,3 David Barbie,3 Jerome Ritz,1 Simon Jones,4 StevenQuayle,5
Peter Hammerman,1 Kwok-KinWong1. 1Dana Farber Cancer Institute, Boston,
MA; 2Belfer Institute for Applied Cancer Science, Boston, MA; 3Brigham and
Women’s Hospital, Boston, MA; 4Acetylon Pharmaceuticals, Inc, Boston, MA;
5Acetylon Pharmaceuticals Inc, Boston, MA.
Effective therapies for non-small cell lung cancer (NSCLC) remain chal-
lenging despite an increasingly comprehensive understanding of somatically
altered oncogenic pathways. It is now clear that therapeutic agents with
potential to impact the tumor immune microenvironment potentiate im-
mune-orchestrated therapeutic benefıt. This study evaluated the immuno-
regulatory properties of two classes of drugs that modulate the epigenome,
histone deacetylase (HDAC) and bromodomain inhibitors with a focus on
key cell subsets that are engaged in an immune response. By evaluating
human peripheral blood and NSCLC tumors, we show that the selective
HDAC6 inhibitor ricolinostat promotes phenotypic changes associated with
enhanced T-cell priming and function of antigen presenting cells. The bro-
modomain inhibitor JQ1 attenuated CD4Foxp3 T regulatory cell sup-
pressive function and synergized with ricolinostat to facilitate immune-me-
diated tumor growth arrest, leading to prolonged survival of mice with lung
adenocarcinomas. Collectively, our fındings highlight immunomodulatory
effects of two epigenetic modifıers that together promote T-cell-mediated
anti-tumor immunity and demonstrate their therapeutic potential for
NSCLC treatment.
#3683 Melphalan stimulates dendritic cell and CD8 T cell expansion by
inducing immunogenic cell death in melanoma cells. Junko Johansson, Ro-
berta Kiffın, Per Lindnér, Peter Naredi, Roger Olofsson Bagge, Anna Martner.
University of Gothenburg, Gothenburg, Sweden.
Background: Regional hyperthermic perfusion with the alkylating agent mel-
phalan is a treatment option for patients with metastatic melanoma confıned to
the limbs or the liver. Following a single perfusion, tumors often decrease grad-
ually in size during several months, suggesting an immune-mediated mecha-
nism of action, in addition to the direct cytotoxic effects of melphalan. This
study was designed to characterize the immunogenic effects of melphalan. Ma-
terials and methods: We have established an in vitro model of regional hyper-
thermic perfusion where human melanoma cell lines are exposed to melphalan
at 40oC for 1 h, thus mimicking the currently employed clinical protocol. The
melphalan-exposedmelanoma cells were analyzed formarkers of immunogenic
cell death and were co-cultured with peripheral blood mononuclear cells (PB-
MCs) in the presence or absence of IL-2. The number and activation status of
various immune populations were analyzed by flow cytometry. Results: Mel-
phalan exposure triggered the expression of several immune-relatedmarkers on
melanoma cells, including calreticulin, MHC class I, Hsp70 and PD-L1. Mel-
phalan-treated, but not untreated melanoma cells, triggered an increase in den-
dritic cell (DC) numbers along with a dramatic expansion of CD8 T cells in
co-cultured PBMCs. The expanded CD8 T cells showed an activated pheno-
type with the majority of cells belonging to the effector memory subtype. Con-
clusions: Melanoma cells exposed to melphalan undergo immunogenic cell
death and trigger DC expansion with subsequent expansion and activation of
CD8 T cells. We propose that these events may contribute to the anti-tumor
effıcacy of regional hyperthermic perfusion with melphalan in metastatic mela-
noma.
#3684 Inhibition of STAT3 by antisense oligonucleotide treatment de-
creases the immune suppressive tumor microenvironment in syngeneic and
GEM tumor models. Rich Woessner,1 Vasu Sah,1 Patricia McCoon,1 Shaun
Grosskurth,1 Nanhua Deng,1 Rachel DuPont,1 Deborah Lawson,1 Lourdes
Pablo,1 Corinne Reimer,1 Marco A. De Velasco,2 Hirotsugu Uemura,3 Juliana
Candido,4 Paul Lyne1. 1AstraZeneca Pharmaceuticals LP, Waltham, MA; 2Kin-
dai University Faculty of Medicine, Osakasayama, MA; 3Kindai University Fac-
ulty of Medicine, Osakasayama, Japan; 4Barts Cancer Institute, Queen Mary
University, London, MA.
AZD9150, a gen2.5 antisense oligonucleotide (ASO) targeting human
STAT3, has improved drug-like properties compared to previous generation
ASO therapeutics, including increased stability and resistance to nucleases, re-
duced proinflammatory effects, and enhanced potency. We have previously re-
ported that in tumors, STAT3 ASOs are taken up preferentially in stromal and
immune cells of the tumor microenvironment (TME). Since AZD9150 is selec-
tive for human STAT3, we used a surrogate ASO (muSTAT3 ASO) to explore
the pharmacodynamics of ASO-mediated STAT3 inhibition in syngeneic and
genetically engineered mouse (GEM) tumor models, focusing on effects in the
TME. In mice bearing subcutaneous CT-26 tumors, treatment with muSTAT3
ASO at 50 mg/kg, s.c., on a qdx5/wk schedule decreased STAT3 levels in im-
mune cell subsets in the tumor and in circulating leukocytes by 40 - 60%, similar
to the decrease in STAT3 achievable in circulating leukocytes in human patients
after AZD9150 treatment. In aNanostring analysis (nCountermouse immunol-
ogy panel) of CT-26 tumors from muSTAT3 ASO treated mice, CD163 (M2
immune suppressive macrophage marker) was the gene most consistently and
signifıcantly downregulated, by an average of 84% in three independent exper-
iments, and was confırmed by immunohistochemistry (IHC). Flow cytometry
analysis of myeloid subpopulations - tumor associated macrophages (F4/80
TAMs), monocytic myeloid derived suppressor cells, and granulocytic cells -
showed a decrease in TAMs averaging 69% across three independent experi-
ments. The analysis was extended to include IHC for arginase (Arg, a marker of
functional immune suppression activity). Subpopulations of cells identifıed in-
cluded Arg, CD163, and ArgCD163. Treatment with muSTAT3 ASO
decreased these populations by 79%, 88% and 97% respectively, compared to
control treatment. These populations were also analyzed in two GEM tumor
models - the KPC pancreatic cancer model, and a PTEN -/- prostate cancer
model - which have a TME more representative of that found in tumors in the
clinic. While the specifıc changes varied across the models, likely reflecting dif-
ferences in TME makeup, a reduction in immune suppressive cell populations
was present in both GEMmodels, including a decrease in CD163 cells of 79%
(along with modest antitumor activity) in the PTEN -/- prostate model after
muSTAT3 ASO treatment. These results indicate that selective STAT3 inhibi-
tion can reduce immune suppressive cell populations in the TME, and suggest
that STAT3 inhibition has the potential to enhance the antitumor activity of
T-cell targeted therapies, such as those targeting the PD1-PDL1 axis. In support
of this hypothesis, we observed that addition of muSTAT3 ASO to anti-PD-L1
Ab treatment signifıcantly enhanced the antitumor activity of PD-L1 Ab treat-
ment in two subcutaneous syngeneic tumor models, CT-26 and A20.
#3685 Antigen-capturing nanoparticles improve the abscopal effect and
cancer immunotherapy. Yuanzeng Min. UNC Chapel Hill, Chapel Hill, NC.
Introduction: Cancer immunotherapy, the utilization of patients’ own im-
mune system to treat cancer, has emerged as a powerful new strategy in cancer
treatment. The main limitation of this strategy is the low long-term durable
response rate. Therefore, there has been high interest in developing strategies to
further improve cancer immunotherapy.We hypothesized that antigen-captur-
ing nanoparticles (AC-NPs) could improve immune responses to checkpoint
inhibitor. The NPs can induce the abscopal effect by capturing tumor antigens
released during radiotherapy and improve the presentation of antigens to pro-
fessional antigen presenting cells (APCs). Methods: We developed several types
of antigen-capturingNPs (AC-NPs) using poly (lactic-co-glycolic acid) (PLGA),
a biocompatible and biodegradable polymer. The surfaces of nanoparticles were
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modifıed to enable capturing tumor antigens released after radiotherapy. Un-
modifıed PLGA NPs absorb antigens via hydrophobic-hydrophobic interac-
tions. AC-NPs with positive charged bind antigens through ionic interactions.
AC-NPs having maleimide group on the surface (Mal AC-NP) bind to antigens
by reaction to thiol groups of antigens. The B16-F10 tumor, a syngeneic mouse
melanoma model on C57BL/6 mice was employed to evaluate the effıcacy of
AC-NPs to improve immune responses of checkpoint inhibitor combining ra-
diotherapy. Results: The in vivo effıcacy study showed that AC-NPs can signif-
icantly improve the effıcacy of PD-1 treatment in the B10F10 melanoma
model, which generates up to 20% cure rate as compared to 0%without AC-NP.
Mechanistic studies demonstrated that the AC-NPs can drain to lymph node
and be took up by APCs, which indicate that they are able to deliver captured
antigens during radiotherapy to APCs. In the meantime, it was found that there
are signifıcant increases in CD4 and CD8 T cell to Treg ratios, which indicate
an expansion of the T-helper cells and cytotoxic T cells. We also found that
AC-NPs can induce increased level of antitumor cytokine interferon- (IFN-)
following stimulation ex vivo, which implied that AC-NPs were able to elicit
systemic T cell activation. Therefore, a novel strategy for improving cancer im-
munotherapy with nanotechnology was presented by our work. Acknowledge-
ments: The authors would also like to thank our funding sources. A.Z.W., J.E.T.,
S.T., and J.M.D are supported by funding from theNational Institutes ofHealth/
National Cancer Institute (U54CA198999, Carolina Center of Cancer Nano-
technology Excellence (CCNE)-Nano Approaches to Modulate Host Cell Re-
sponse for Cancer Therapy). B.V. is supported by funding fromUNCUniversity
Cancer Research Fund, Paul Calabresi Oncology K12 Award and UNC CCNE
Pilot Grant. A.Z.W. is also supported by funding from the NIH/NCI (U54
CA151652 and R01 CA178748) for this work. A.Z.W. was also supported by
funding from the NIH/NCI (R21 CA182322).
#3686 Generation of an off-the-shelf cell-based platform (PDC-vac) for
active antitumor immunotherapy. Joel Plumas,1 Kevin Lenogue,1 Alexandre
Walencik,2 Jean-Paul Molens,3 Laurence Chaperot,3 Martin Pule4. 1PDC*line
Pharma, La Tronche, France; 2EFS Pays de Loire, Nantes, France; 3EMR UGA-
EFS-INSERM U1209-CNRS 5309, La Tronche, France; 4University College Lon-
don, London, United Kingdom.
The development of effıcient vaccines for the treatment of cancers in combi-
nation or not with other agents such as checkpoint inhibitors represents amajor
public health issue but remains a challenge. A dozen of vaccine drug products is
expected to be marketed in the next few years. In this context, off-the-shelf and
potent platforms are more attractive than individualized vaccines that are tai-
lored to each patient in many aspects. We have recently developed a new cell-
based vaccine approach named PDC*vac (formerly GeniusVac). This cell-based
vaccine was developed thanks to the establishment, from leukemic PDC, of
unique human PDC line (PDC*line).We have previously shown the potential of
peptide-loaded PDC*line to induce strong and fully functional HLA-A*02:01-
restricted anti-tumor immunity in vitro and in vivo (Aspord et al, 2010, 2012).
PDC*mel (GenusVac-Mel4), our fırst product is currently developed for the
treatment of melanoma patients (NCT01863108). The high effıciency of
PDC*vac renders the strategy very attractive for further clinical developments in
active immunotherapy fıeld. Our aim is to optimize PDC*vac technology by
passing use peptides and render the vaccine easier to manufacture. We engi-
neered our PDC*line using retrovirus to force the endogenous expression of one
ormore tumor or viral antigenic peptides or whole tumor/viral proteins (gp100,
tyrosinase, Melan-A, Mage-A3, CMVpp65, flu, EBV) that broaden the panel of
antigens presented. Data obtaining with different polypeptide and protein gene
coding constructions and the expansion of multi-specifıc antigen-specifıc T-
cells at the same time will be presented. Moreover, we will present how we
succeed to obtain 100% of effıcacy in antigen presentation by the PDC*line
engineered to express tumor proteins or polyepitopes.We have validated the use
of retrovirus constructs to create a new generation of an “off-the-shelf” cancer
vaccines highly potent to stimulate antitumor-specifıc T-cells.
#3687 Bexarotene activates type 1 antigen presenting cells, increases tu-
mor infıltrating CD8 T-cells, and augments the anti-tumor activity of che-
motherapy in breast cancer. Sasha Elizabeth Stanton, Ekram Gad, Lauren R.
Corulli-Rastetter, Mary L. Disis. Univ. of Washington, Seattle, WA.
Bexarotene is an oral rexinoic receptor (RXR) agonist that has anti-prolifer-
ative activity in breast cancer. RXRs are nuclear receptors that heterodimerize,
including with the retinoic acid receptor (RAR), to activate transcription for
processes including cellular differentiation, embryonic development, prolifera-
tion, andmetabolism.We have demonstrated that bexarotene can enhance can-
cer vaccine effıcacy by synergizingwith amulti-antigen vaccine to prevent breast
cancer in the TgMMTV-neumodel. Bexarotene as a single agent increased CD8
T-cell tumor infıltration. We therefore questioned the mechanism by which
bexarotene acted as an immunomodulatory drug. Evaluating RXR expression in
human peripheral bloodmonocytes (PBMC) (n10), we found that RXR is not
expressed in NK T-cells or B-cells and in only a minority of CD4 (5.1 	 4%)
and CD8 T-cells (3.6 	 3%). RXR, however, is expressed in 24.9	13% of
macrophages, 38.6	 14% of plasmacytic dendritic cells (pDC), and 33.1	 16%
of monocytic dendritic cells (mDC). PMBC treated with increasing doses of
bexarotene for 48 hours had increased co-stimulatoryCD40 expression onmDC
(p0.0011 between 0 and 20 uM bexarotene) and increased type 1 cytokine
release including IL-1 (p0.03 between 0 and 20 uM bexarotene) and TNF
(p0.02 between 0 and 20 uM bexarotene) but not type 2 cytokine release of
IL-10 (p0.21) and IL-4 (p0.5). These data demonstrate that bexarotene can
activate type 1 dendritic cells Since activated type 1 dendritic cells are effective at
presenting tumor antigens from dying tumor cells, we wanted to determine if
bexarotene could increase type 1 immunity in the tumor and thereby enhance
the effıcacy of paclitaxel chemotherapy. In TgMMTV-neu mice with 100 mm3
established spontaneous tumors (n5), 50 mg/kg bexarotene inhibited tumor
growth by 49% and increased the influx of intratumoral CD8T-cells by 61% as
compared to PBS treated mice (p0.01). 10 mg/kg paclitaxel inhibited tumor
growth by 57% and increased intratumoral CD8T-cells by 45% as compared to
PBS treatedmice (p0.003). Paclitaxel and bexarotene together inhibited tumor
growth by 83% (p0.02 compared to bexarotene or paclitaxel alone) and in-
creased intratumoral CD8 T-cell infıltrate by 58% as compared to PBS treated
mice (p0.01). Bexarotene could both activate type 1APC and increase theCD8
T-cell infıltrate in the tumor and enhance the effıcacy of paclitaxel. These data
suggest concurrent adminstration of immunomodulatory bexarotene with pac-
litaxelmay result in augmentation of the anti-tumor activity of chemotherapy in
breast cancer.
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#3688 Imprime PGG, a novel innate immune therapeutic in phase 2 clinical
development, induces mobilization of monocytes and focalized recruitment of
innate immune cells to tumor sites. Steven Leonardo, Nadine Ottosson, Keith
Gorden, Takashi Kangas, Xiaohong Qiu, Ross Fulton, Benjamin Harrison, Adria
Jonas, RichardWalsh, Katie Ertelt, Jamie Lowe, RichardHuhn, JeremyGraff, Nan-
dita Bose, Mark T. Uhlik. Biothera Pharmaceuticals, Inc., Eagan, MN.
Immune checkpoint inhibitors (CPI) have shown compelling clinical ef-
fıcacy in multiple tumor types, though only in a minority of treated patients.
Signifıcant research and clinical development are focused on expanding CPI
effıcacy. Imprime PGG is a novel, IV administered 1,3/1,6 -glucan PAMP
(pathogen-associatedmolecular pattern) that activates innate immune effec-
tor cells to enhance tumor killing, to repolarize the suppressive myeloid cells
of the tumor microenvironment and to activate the antigen presentation
capability of dendritic cells, macrophages and monocytes. In multiple pre-
clinical models, Imprime enhances the anti-tumor effıcacy of CPIs. Imprime
is now in multiple phase 2 clinical studies in combination with the CPI,
pembrolizumab. We sought to understand more precisely how Imprime
activates the innate immune system to enable a concerted innate and adap-
tive anti-cancer immune response. Using multispectral fluorescence IHC we
now show that Imprime induces focalized recruitment of innate immune
cells to tumor bearing tissue. In the B16F10 experimental metastasis model,
Imprime dosed in combination with the tumor-targeting antibody TA-99
can nearly completely repress the outgrowth of pulmonary metastases across
a 19 day time course. At 24h post-Imprime treatment, the presence of
Ly6G neutrophils was evident throughout the lung tissue. At later time
points (72h and beyond) the formation of immune cell clusters was readily
evident in lungs from Imprime treated mice and rarer in control mice or
mice treated only with TA-99. These immune cell clusters were predomi-
nately localized to arterioles near B16 tumor sites and comprised of multiple
immune cell subtypes including macs, B cells, T cells as well as a monocyte
population that are CD11b, Ly6G- and F4/80- and strongly positive for
MHCII. Consistent with these preclinical fındings, IV administration of Im-
prime to healthy human volunteers increased neutrophil and monocyte mo-
bilization into peripheral blood 2-3 fold 4h post infusion. Imprime treatment
also resulted in a signifıcantly increased subset of CD16monocytes that are
known to have higher antigen presentation capability and express higher
levels of the activation markers CD86, PD-L1, and HLA-DR (MHCII). Fur-
thermore, RNA expression profıling of whole blood from Imprime-treated
volunteers shows increased expression of the CCL3, CCL4, IL-1 and
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TNF-, functional mediators produced by these monocyte populations. To-
gether, these data show that Imprime drives the concerted activation of
multiple innate immune subtypes and promotes the appearance of unique
monocyte populations that may be critical for an Imprime-induced anti-
cancer immune response.
#3689 Jak3mutations in colorectal neoplasia-Preliminarydataonanot so
silent minority. Martin Tobi,1 Xiaoping Zhao,2 Darshana Jhala,3 Rebecca Ro-
driguez,4 Fadi Antaki,5 Edi Levi,5 Paula Sochacki,5 John Lieb,3 MaryAnn Ram-
bus,6 TapanGanguly,7Martin Bluth,8Michael J. Lawson9. 1SaginawVAMedical
Ctr and Medical Disciplines, Central Michigan University College of Medicine,
Saginaw,MI; 2Detroit VAMCR&D,CentralMichiganUniversity College ofMed-
icine, Detroit, MI; 3Philadelphia VAMC and the University of Pennsylvania
School of Medicine, Philadelphia, PA; 4Philadelphia VAMC, Philadelphia, PA;
5Detroit VAMedical Ctr andWayne State University School ofMedicine, Detroit,
MI; 6Detroit VA Medical Ctr, Detroit, MI; 7University of Pennsylvania School of
Medicine, Philadelphia, PA; 8Wayne State University School ofMedicine, Detroit,
MI; 9Kaiser Permanente Medical Center, Sacramento, CA.
As a tumorigenesis model, colorectal cancer is associated with multiple gene
mutations accumulating progressively but also has mutations that may alter
disease course and provide a therapeutic target. Good examples of this are EGFR
and VEGF. In melanoma, PD-1 interactions involving the immunobiome are
therapeutically important. We conducted a study to detect potential mutations
that might enhance therapy in colorectal cancer guided by expression of p87, a
product of innate immune system Paneth cells. Methods: Adnab-9 immunohis-
tochemistry or ELISA was used to defıne signifıcant p87 Adenoma-associated
antigen fıeld effects (FE) in 10 patients with 1cm large high grade dysplastic
adenomas (LHiGDA) and 3 with smaller high grade dysplastic adenomas
(SHiGDA).Wepostulated that SHiGDAare not immunologically recognized by
host defenses leading to negative outcomes. We used Ion Torrent™ sequencing
(ITS) to fındmutations in DNA (QiaAmp kit) extracted from 4 normal-appear-
ing colonic segments taken from1patient in each group.Novelmutations found
on ITS would then be sought using PCR with appropriate primers and subse-
quent sequencing of the PCR product circulating DNA extracted from available
serum samples. These samples were taken from the Large- and SHiGDA groups
described above and from 17 patients undergoing colonoscopy for diverse indi-
cations. Results: p87 FEwere found in 40% of 10 LHiGDA and 0% of 3 SHiGDA
patients. The ITS in the 2 representative patients showed unique mutational
fıelds in: KRAS, APC, p53 in the LHiGDA and Jak3, PIK3Ca, p53, APC in the
SHiGDApatient, both of whom lacked p87 FE. PCR using the Jak3 primers used
in the ITS and subsequent sequencing revealed the same non-synonymous mu-
tation in the serum of a FAP patient after colonic resection and an additional
colonic segment of the selected ShiGDApatient but not in his serum.Other Jak3
mutations were found in 1 of 8 LHiGDA, 1 (the selected patient) of 3 SHiGDA,
1 of 7 patients with FAP and 1 of 10 colonoscopy patients with a family history of
colorectal cancer with a FE and an untoward outcome. The selected SHiGDA
patient subsequently contracted and died of NSCLC adenocarcinoma. The pos-
itive LHiGDA and FAP patients had a severely dysplastic anal condyloma and
severe pancreatitis, respectively. Overall, the non-synonymousmutation occur-
ring in the non-FAP SHiGDA patient occurred in the absence of p87 FE. Con-
clusions: In this pilot studywe demonstrate the presence of Jak3mutations likely
associated with the lack of p87 expression in patients with high grade dysplastic
adenomas and 1 FAP patient. Most of these patients had a clinical course which
may have differed from their group members suggesting an altered immune
system milieu. If confırmed in SHiGDA and FAP, Jak 3 mutations, associated
with the SCID and late onset combined immunodefıciency, may allow for inter-
vention with currently available medications to potentially avert a deleterious
clinical outcome.
#3690 The leukocyte chemoattractant chemerin modulates PTEN via
CMKLR1 in human tumors. Keith R. Rennier, Ping Wang, Robert Crowder,
Russell K. Pachynski.Washington University School of Medicine in St.Louis, St.
Louis, MO.
Background: Recent data in preclinical models has shown that phosphatase
and tensin homolog (PTEN) loss correlated with decreased tumor immune cell
infıltration as well as decreased response to T cell-based immunotherapy.
Chemerin (RARRES2) is a recently identifıed endogenous leukocyte chemoat-
tractant shown to recruit innate immune cells through its G-protein coupled
receptor CMKLR1. Chemerin/RARRES2 is commonly downregulated in pros-
tate and other cancers (e.g. sarcoma) compared to their normal tissue counter-
parts. Methylome-wide studies in multiple tumor types have identifıed
RARRES2 as being one of the most hypermethylated genes, potentially leading
to decreased chemerin expression. Our previous preclinical studies showed that
forced overexpression of chemerin in tumors was capable of recruiting immune
effector cells, including T cells, into the tumormicroenvironment and suppress-
ing tumor growth. Methods: In order to study the effects of chemerin overex-
pression on tumor cell intrinsic processes we exposed prostate and sarcoma
tumor lines to exogenous recombinant chemerin in vitro. Evaluation of PTEN
was performed at both the mRNA and protein levels, using both quantitative
PCR and Western blotting, in comparison with normal prostate epithelia
RWPE-1 aswell as PTEN-null PC3 cells as controls. in vitro invasion assayswere
performed to investigate the functional impact of chemerin exposure on tumor
intrinsic activity. Knockdown of CMKLR1 using siRNA was performed to de-
termine its role in tumor response. Results: Using both prostate and sarcoma
tumor lines, we found exogenous chemerin was able to signifıcantly upregulate
PTEN expression at both themRNA and protein levels in a dose-responseman-
ner. Exposure to chemerin did not result in increased apoptosis or altered in
vitro proliferation. Importantly, chemerin treatment signifıcantly decreased in
vitro tumor invasion.Knockdown studies showedCMKLR1 abrogation resulted
in restored tumor migration, suggesting a link between this GPCR and PTEN
expression and activity. Conclusions: For the fırst time, to our knowledge, we
have shown a link between chemerin and PTEN expression and activity in both
prostate and sarcoma tumor lines. Our collective study shows chemerin’s ability
to upregulate PTEN activity and to mitigate tumor cell migration via CMKLR1.
This work has functional implications on both tumor cell intrinsic and extrinsic
responses to chemerin-based immunotherapeutic strategies. Further studies are
needed to investigate the interaction between chemerin and PTEN signaling,
and its connection to oncogenic signaling pathways manipulated in malignant
tumors. Additionally, future in vivo studies using these tumor lines will help
further elucidate the chemerin-PTEN axis and its role in tumor immunosurveil-
lance. We hypothesize that increased chemerin-driven PTEN activity may help
facilitate an improved immunotherapy response and functional ability to attack
cancer cells.
#3691 Analysis of germline BRCA1/2 mutation associated breast and
ovarian tumors reveals distinct pathways of immunosuppression. Adam
Kraya, Kara N. Maxwell, Brandon M. Wenz, Bradley Wubbenhorst, Nicole
Lunceford, Amanda Barrett, Jennifer J. Morrissette, Michael D. Feldman, Susan
M. Domchek, Robert H. Vonderheide, Katherine L. Nathanson. University of
Pennsylvania, Philadelphia, PA.
BRCA1 and BRCA2 are essential homologous recombination (HR) repair
proteins; germline mutations confer elevated risk for breast and ovarian cancer.
Defects in BRCA can lead to immune-related effects including depletion of
peripheral T-cell pools and increased somatic mutational burden. We investi-
gated the immunophenotypic properties of breast and ovarian cancers associ-
ated with germline BRCA1/2 mutations. We determined neoantigen load in 16
breast and 26 ovarian tumors with germline BRCA1/2 mutations and 50 non-
BRCA tumors for each disease using whole exome sequencing data from the
TCGA. Although neoantigen load (IC50500 nM) was variable across tumors,
it did not differ between BRCA1/2 mutant and non-BRCA tumors. Leveraging
RNAseq data from the TCGA, we investigated immune-related transcriptomic
features within each disease. Cytolytic index, a measure of PRF1 and GZMA
expression, was higher in non-BRCA tumors than BRCA1/2 mutant for breast
(p0.01) tumors and correlatedmore closely with neoantigen load than in non-
BRCA tumors (Breast: BRCA r2-0.15, non-BRCA r20.237). Class I HLA
expression also correlated with cytolytic index (p0.05) in non-BRCA tumors
but not BRCA1/2 mutation associated tumors for both breast and ovarian can-
cers, suggesting more robust antigen-driven adaptive immunity in non-BRCA
tumors. HLA expressionwas signifıcantly lower (p0.01) amongBRCAmutant
breast tumors, indicating immune escape by HLA down-regulation. We classi-
fıed non-BRCA breast tumors by their level of HR defıciency (HRD score), as
HRD by both BRCA and non-BRCA mediated mechanisms can lead to in-
creased somatic mutational burden. Non-BRCA breast tumors irrespective of
HRD score exhibited evidence of a more inflamed phenotype than BRCA1/2
mutant tumors, indicated by higher inferred immune cell infıltration, immune
checkpoint expression, and chemokine expression (all p0.01). To investigate
potential mechanisms of immune escape in BRCA1/2 vs non-BRCA tumors, we
compared canonical gene sets (MsigDb) across the two cohorts. Expression of
extracellular matrix (ECM) proteins was higher in BRCA1/2 breast and ovarian
tumors (q0.02), suggesting that BRCA1/2 tumors may exclude immune cells
via a dense ECM as observed for colorectal cancer andmelanoma. Among Penn
BRCA1/2 tumors (19 breast, 20 ovarian), neoantigen load did not differ from
TCGA BRCA1/2 tumors. We directly measured immune cell infıltration via
tumor immunohistochemistry in 12 breast and 14 ovarian Penn BRCA1/2 tu-
mors.We found that CD3 andCD8T cell infıltrationwas signifıcantly lower
in BRCA1/2 tumors with PTEN deletion (p0.05), a known correlate of ECM
IMMUNOLOGY: Inflammation in the Tumor Microenvironment
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 941
remodeling in breast and ovarian cancer. Our work provides early evidence that
BRCA1/2 breast and ovarian tumors mitigate intratumoral adaptive immunity
by T-cell exclusion, so that despite higher mutational burden, they may not
respond to checkpoint blockade.
#3692 Long-lived pancreatic ductal adenocarcinoma slice cultures enable
precise study of the immunemicroenvironment.Xiuyun Jiang, David Seo, Jae
Chang, Eslam Nigjeh, Sheng Pan, Florencia Jalikis, Venu Pillarisetty.University
of Washington, Seattle, WA.
Introduction: Pancreatic ductal adenocarcinoma (PDA) remains a deadly dis-
ease that is rarely cured. Given the recent successes with immunotherapy for
othermalignancies and the fact that PDA is heavily infıltrated by effector T cells,
we postulate that accurate modeling of the PDA immune microenvironment
would allow us to unveil mechanisms of immunosuppression that could be
overcome for therapeutic benefıt. Methods: PDA tumors were collected from
the operating room and transported in cold media to the laboratory, where
250m slices were cut using a vibratome and placed on 0.4m pore size mem-
brane inserts pre-coated with collagen gel and culture. Proliferation was mea-
sured using MTT assay and weight-adjusted optical density. Slices were fıxed in
4% PFA for imaging after live immunofluorescence (IF) staining or for subse-
quent immunohistochemistry (IHC) prior to imaging. For proteomic analysis,
slices were digested with trypsin and analyzed by mass spectrometry. To assess
for immune cell migration into the tumor slices, isolated autologous splenocytes
were stained with CFSE and added to the slice culture and imaged using IF after
6 days. Results: Using light microscopy, we confırmed that cultured slices main-
tain their baseline morphology, architecture and surface area over 9 days in
culture. The MTT assay showed stable growth over the same period; IHC for
Ki-67 and cleaved Caspase-3 corroborated a similar pattern of proliferation and
apoptosis after 6 days culturewhen compared to day 1. T cells (CD3, CD8 and
FOXP3), macrophages (CD68, CD163, and HLA-DR), and stromal myo-
fıbroblasts (SMA) were confırmed to be present through day 6 using IHC.
Quantitative proteomic analysis of over 3000 proteins showed that only 2-3% of
proteins showed signifıcant changes of abundance greater than 2 fold after 6
days in culture.However, when slicewere challengedwith cytotoxic drugs (stau-
rosporine and cyclohexamide), there was a time- and dose-dependent response
in proliferation and apoptosis compared with controls. The demonstration of
the live and dynamic microenvironment was performed fırst via live multicolor IF
including PDAcells (EpCAM), fıbroblasts (fıbronectin) and immune cells (both
CD11b and CD8 cells) within the microenvironment. Furthermore, co-culture
of CFSE-labeled splenocytes on top of slices for 6 days. Z-stacked live confocal im-
aging confırmed their migration from the surface into the slice microenvironment.
Conclusion: Our study demonstrates that the PDA slice culture maintains original
tumormicroenvironment, andoverallproteomicproductionanddynamic function
response in vitro. The slice culture model thus represents a novel platform to eval-
uate both pharmaceutical and cell-based immunotherapies for mechanisms of ac-
tion and potential synergism, effects on specifıc cell types of themicroenvironment,
and tumor-specifıc immunogenic potential.
#3693 Single cell RNA-Seq of primary lymphomas reveals the diverse
transcriptional states of the cancer immunologicmilieu.Noemi Andor,1 Erin
Simonds,2 Jiamin Chen,1 ChristinaWood,1 Susan Grimes,1 Debra Czerwinski,1
Grace Zheng,3 Ronald Levy,1 Hanlee P. Ji1. 1Stanford Univ., Stanford, CA;
2UCSF, San Francisco, CA; 310X Genomics, Pleasanton, CA.
Follicular lymphoma (FL) is an incurable B-cell malignancy that has the po-
tential to transform into highly aggressive, lethal lymphomas. To resolve the
cellular characteristics of the underlying cancer immunologic milieu at single
cell resolution, we leveraged droplet-based barcoding technology for highly par-
allel single cell RNA-Seq. We analyzed the transcriptomes across tens of thou-
sands of indviidual cells derived from fıve primary FL tumors (average 5,000
cells per sample). These tumors were obtained via direct surgical biopsies. In
parallel, we conducted multi-dimensional flow cytometry that orthogonally
confırmed our characterization of the various cell types including the various
subsets of T cells that existed within each tumor. We identifıed multiple cellular
subpopulations, matching known hematopoietic lineages that were present
within each tumor. Despite some common features, such as MYC and BCL
overexpression, transcriptional patterns and regulatory programs destinguished
the different tumors from each other. We compared the transcriptional profıles
of malignant cellular subpopulations to the matched normal B-cells within each
sample. Malignant B-cells were characterized by expression of restricted immu-
noglobulin light chain type (either kappa or lambda), BCL2 expression, and
CD20 expression. In each case a minor population of normal B-cells was char-
acterized by expression of the opposite light chain type and a pattern of gene
expression common toB cells in all tumor samples andnormal peripheral blood.
Tumor B cells consistently demonstrated downregulation of-2-microglobulin
and for those cases that harbored a founder CREBBP mutation, a downregula-
tion of MHC II, that would cause an alteration in antigen presentation and
evasion of the T cell immune system. Moreover, we characterized the transcrip-
tional profıles of the infıltratingT-cell populationswithin each tumor, providing
a high-resolution perspective of immunologic cellular interactions. Overall, we
identifıed the diverse transcriptional states at single cell resolution among dif-
ferent tumors and discovered specifıc genes that were aberrantly expressed com-
pared to normal B cells within the same microenvironment. Our fındings pro-
vide an unprecedented resolution of distinct immune lineages as seen by
transcriptionally characterized cell diversity. Studies using single cell genomics
may have implications for considering immunotherapeutic effıcacy.
#3694 FOXP1 suppresses immune cell migration in breast tumors. Push-
pamali De Silva,1 Soizic Garaud,1 Roland de Wind,1 Gert Van den Eynden,2
Anaïs Boisson,1 Cinzia Solinas,1 Edoardo Migliori,1 Hugues Duvillier,1 Denis
Larsimont,1 Martine Piccart-Gebhart,1 Karen Willard-Gallo1. 1Institut Jules
Bordet, ULB, Brussels, Belgium; 2GZA Hospital Sint-Augustinus, Antwerp, Bel-
gium.
Tumor infıltrating lymphocytes (TIL) play an essential role in mediating re-
sponse to chemotherapy and improving clinical outcomes in breast cancer (BC).
Extensive TIL infıltration is characterized by their organized into tertiary lym-
phoid structures (TLS). TIL infıltration and TLS formationmay be regulated, in
part, by transcription factors (TF) controlling cytokine/chemokine production
within the tumor microenvironment. The forkhead box protein 1 (FOXP1) is a
TF shown to be abnormally expressed in a variety of human tumors and play an
important role in T cell cytokine production. Therefore we aimed to study
FOXP1-mediated regulation of TIL in BC. Investigation of FOXP1 expression in
public microarray data from untreated BC patients, BC cell lines [Luminal A
(MCF7), HER2 (BT474) and triple negative (TN; MDA-MB231)] and pro-
spectively collected formalin-fıxed paraffın-embedded (FFPE) primary breast
tissues showed that FOXP1 is repressed at transcript andprotein level inHER2
or TNbreast tumors compared to estrogen receptor positive tumors (Luminal A
and B). Moreover HER2 and TN subtypes, which showed decreased FOXP1
levels, are 2 well known highly infıltrated BC. Based on our hypothesis that
FOXP1 could play a role on immune cell infıltration in breast tumors, data
analysis of the prospective BC cohort showed that high FOXP1 (FOXP1hi) ex-
pression is signifıcantly associatedwith a lower percentage of TIL andnumber of
TLS compared to FOXP1 low (FOXP1lo) tumors. To investigate the impact on
specifıc cytokines/chemokines involved in TIL recruitment and/or TLS forma-
tion, FOXP1 was silenced inMCF7 (FOXP1hi tumor cell line) or upregulated in
MDA-MB-231 (FOXP1lo tumor cell line) followed by gene expression analysis
using a RT-qPCR based human cytokine/chemokine array. FOXP1 repression
upregulated major T and B cell chemoattractant chemokines and overexpres-
sion repressed most of these molecules in the cell line experiments. Next we
analyzed major chemoattractant molecule expression in FOXP1lo and FOXP1hi
prospective breast tumors and found that FOXP1hi tumors having a signifıcant
decrease in CXCL9, CXCL10, CXCL11, CXCL13, CX3CL, CCL20, IL2, and
IL21. A migration assay (Transwell chambers) done using healthy donor (HD)
PBMC showed a signifıcant increase in total lymphocytes migrated towards
FOXP1 repressed tumor conditioned media (TCM) of MCF7 compared to the
TCM of control or medium alone. Finally analysis of lymphocyte migration to
FOXP1lo and FOXP1hi tumor supernatants (SN) from primary tumors that we
consistently prepare without enzymatic digestion, showed that there was a sig-
nifıcant decrease in number of lymphocytes migrated towards FOXP1hi tumor
SN including themigration rates of individual T andB lymphocytes populations
compared to FOXP1lo tumor SN. These data suggest that FOXP1 could play a
critical role in establishing effective anti-tumor immune responses by negative
regulation of TIL via suppression of cytokine/chemokine expression in breast
tumors.
#3695 The interplay between neutrophils &It CDThe interplay between
neutrophils and CD8 cell improves survival in human colorectal cancer.
Valeria Governa,1 Emanuele Trella,1 Valentina Mele,1 Raul Droeser,1 Serenella
Eppenberger-Castori,2 Luigi Maria Terracciano,2 Giandomenica Iezzi,1 Giulio
Cesare Spagnoli1. 1UniverityHospital Basel, Basel, Switzerland; 2Institute of Pha-
tology, Basel, Switzerland.
Purpose: Tumor infıltration by different T lymphocyte subsets is known to be
associated with favorable prognosis in colorectal cancer (CRC). Still debated is
the role of innate immune system. We investigated clinical relevance, pheno-
types &it functional features of CRC infıltrating CD66b neutrophils &it their
crosstalk with CD8 T cells. Experimental design: CD66b &it CD8 cell
infıltration was analyzed by immunohistochemistry on a tissue microarray in-
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cluding650 evaluable CRC samples. Phenotypic profıles of tissue infıltrating
and peripheral blood CD66b cells were evaluated by flow cytometry.
CD66b/ CD8 cells crosstalk was investigated by in vitro experiments. Re-
sults: CD66b cell infıltration in CRC is signifıcantly associated with increased
survival. Interestingly, neutrophils frequently co-localize with CD8 T cells in
CRC. Functional studies indicate that although neutrophils are devoid of direct
antitumor potential, co-culture with peripheral blood or tumor associated neu-
trophils (TANs) enhances CD8 T cell activation, proliferation and cytokine
release induced by suboptimal concentrations of anti-CD3 monoclonal anti-
body (mAb). Moreover, under optimal activation conditions, CD8 cells ini-
tially stimulated in the presence of CD66b cells show decreased expression of
PD-1 “exhaustion” marker and are signifıcantly less susceptible to apoptosis
induced by T- cell receptor triggered re-stimulation. Importantly, combined
tumor infıltration by CD66b and CD8 T lymphocytes is associated with
signifıcantly better prognosis, as compared to CD8 T cell infıltration alone.
Conclusions: Neutrophils enhance the responsiveness of CD8 T cells to TCR
triggering. Accordingly, infıltration by neutrophils enhances the prognostic sig-
nifıcance of CRC infıltration by CD8 T cells, suggesting that they might effec-
tively promote antitumor immunity.
#3696 Tumor-intrinsic PD-L1 alters tumor chemokines, NK cell traffıck-
ing and function, and renders distant PD-L1 null tumors responsive toPD-
L1.Curtis A. Clark,1 Harshita B. Gupta,1 Alvaro Padron,1 Deyi Zhang,1 Vincent
Hurez,1 Mary Jo Turk,2 Rong Li,1 Tyler Curiel1. 1The University of Texas Health
Science Center at San Antonio, San Antonio, TX; 2Geisel School of Medicine at
Dartmouth, Hanover, NH.
Programmeddeath ligand (PD-L) 1 is expressed onmany tumors and inhibits
anti-tumor T cells through programmed death (PD)-1. Tumor PD-L1 predicts
PD-L1 treatment effects, but mechanism(s) for PD-L1- tumor response to
PD-L1 are unclear. Our studies suggest tumor-intrinsic PD-L1 signals and
spatially varied PD-L1 expression may contribute to response deviation. We
used PD-L1 B16 melanoma (ctrl) and made PD-L1KO by CRISPR. PD-L1
slowed ctrl but not PD-L1KO B16 growth in mice as expected, but PD-L1KO also
responded to PD-L1 if ctrl B16 was on the trans flank. PD-L1 elicited similar
CD3 T cell infıltration into ctrl vs. PD-L1KO tumors, but without detectable
B16-specifıc T cell increase. CD11b cell infıltration was similar in ctrl and
PD-L1KO. Strikingly, NKp46 and NK1.1 natural killer (NK) cells infıltrated
PD-L1KO  ctrl. NK cells increased signifıcantly (2-fold) after PD-L1 in
PD-L1KO vs. ctrl, along with NK effector functions (e.g., IFN-). Tumor PD-L1
altered tumor chemokines (e.g., CXCL12, CCL2) that could explain traffıcking.
CD4 andCD8T cells chemotaxed to PD-L1KO slightly ctrl (with slightly
PD-1 T cells) in transwells, but NK cells migrated2-fold more to PD-L1KO
vs. ctrl (with increased activation (e.g., PD-1, CD69), also seen in vivo). We
observed that tumor 2 microglobulin (B2M) expression was suppressed by
tumorPD-L1. TumorPD-L1 alteration of immune infıltrates by altering chemo-
kines is a novel mechanism for PD-L1 TIL control. These data also indicate that
tumor PD-L1 blunts NK cell infıltration in B16 and reduces B2M, which could
boost NK cell anti-tumor activity. These changes correlate with rescuedPD-L1
response of PD-L1KO B16. As PD-L1 did not increase B16-specifıc T cells in
PD-L1low, we hypothesize that rescue of PD-L1 response is in part NK cell-
mediated. Preliminary in vivo NK cell depletion PD-L1 experiments impli-
cate a role for NK cells in PD-L1KO tumor response, but more work is needed to
identifymechanisms. Effects extend beyondB16 as ctrl (PD-L1)MB49 bladder
cancer cells in trans elicitedPD-L1 response of PD-L1KOMB49 tumors.Mouse
breast and ovarian cancers, and human ovarian and bladder cells exhibit similar
PD-L1-intrinsic effects. Finally, PD-L1 directly altered tumor cell chemokine
production in vitro, suggesting additional, novel PD-L1 treatment mecha-
nisms requiring more study. Ourmodels are useful to understand PD-L1 (and
likely PD-1) responses based on tumor PD-L1 expression and will help defıne
strategies to improve responses in PD-L1low tumors, and possibly poorly re-
sponsive PD-L1 tumors.
#3697 The impact of HER3 signalingmediated PD-L1 regulation in triple
negative breast cancer. Ayane Yamaguchi,1 Eiji Suzuki,1 Kosuke Kawaguchi,2
Mariko Nishie,1 Moe Tsuda,1 Takeshi Kotake,1 Masakazu Toi1. 1Kyoto Univ.
Hospital, Kyoto, Japan; 2Massachusetts General Hospital, Harvard Medical
School, Massachusetts, MA.
Triple negative breast cancer (TNBC) is still diffıcult to treat partly because of
lacking specifıc target. Although 50-70% of TNBC expresses EGFR, it is less
sensitive to the treatment of EGFR inhibition for TNBC as compared to the
effıcacy of HER2 inhibition for HER2-positive breast cancer. Several phase II
study on EGFR blockade treatment has been reported, however it has not ap-
plied in a clinical setting yet. It was reported that residual tumors after treatment
with EGFR-targeted antibodies showed increased HER3 abundance leading to
EGFR/HER3 receptor dimerization. The signals ofHER3/EGFRdimerization to
PI3K/AKT/mTOR pathways are thought to be involved in cancer survival, pro-
liferation and also up-regulation of PD-L1 expression. Thus, we hypothesized
that up-regulation ofHER3 signal caused by anti-cancer treatmentmight induce
PD-L1 expression and inhibit host anti-tumor immunity. In this study,we tested
the relationships between HER3 signal and PD-L1 expression by using three
basal-like breast cancer cell line; MDA-MB-231, HCC70, and MDA-MB-468.
MDA-MB-231 is HER3-negative, and HCC70 and MDA-MB-468 are HER3-
positive cell lines.We addedneureglin 1 (NRG1:HER3 ligand) to those three cell
lines and analyzed PD-L1 expression of protein by flowcytometry andmRNAby
qRT-PCR. Both protein and mRNA level of PD-L1 on HCC70 and MDA-MB-
468 treated with NRG1 are increased as compared with those without NRG1
while there was no change of PD-L1 expression of MDA-MB-231 either with or
withoutNRG1. In order to confırm the signifıcance of potential treatment target
of HER3, we evaluated HER3 expression in biopsy samples by immunohisto-
chemistry before neoadjuvant chemotherapy (NAC) including all phenotypes.
Thirteen pathological complete response (pCR) cases after NAC and 6 non pCR
cases were included.We scored theHER3 stainability from 0 to 3 and found that
non pCR cases showed signifıcantly higher HER3 score than pCR cases (84.6%
and 33% respectively, p0.0149). Although further study is needed, these results
suggest that HER3 signal possibly regulates PD-L1 expression in HER3-positive
basal-like breast cancer and treatment with anti-HER3 targeting therapy com-
binationwith an immune checkpoint inhibition therapy forHER3positiveNAC
resistant patients might be warranted.
#3698 Associations of the immune microenvironment with PD-L1 copy
number alterations and PD-L1 expression in resected non-small cell lung
cancer. Katsuhiro Yoshimura,1 Yusuke Inoue,1 Tomoaki Kahyo,1 Akikazu Ka-
wase,1 Masayuki Tanahashi,2 Hiroshi Ogawa,2 Naoki Inui,1 Kazuhito Funai,1
Kazuya Shinmura,1 Hiroshi Niwa,2 Takafumi Suda,1 Haruhiko Sugimura1.
1Hamamatsu University School of Medicine, Hamamatsu, Japan; 2Seirei Mika-
tahara General Hospital, Hamamatsu, Japan.
Background: The relationships between tumor PD-L1 expression and the
tumor immune microenvironment (TIM) have gained attention in a variety of
cancers including non-small cell lung cancer (NSCLC). However, the relevance
of TIM according to the tumor PD-L1 copy number alterations (CNAs) whose
signifıcance have been shown in several malignancies remains to be uncovered.
Methods: We evaluated PD-1, CD8, and Foxp3 lymphocytes in tumor nest
and surrounding stroma separately using microarrayed 636 resected NSCLC.
Their associations with PD-L1 CNAs and PD-L1 expression were analyzed.
Tumor-infıltrating lymphocytes (TILs) were counted under high-power fıelds
(200). PD-L1 CNAs were assessed with fluorescent in situ hybridization, and
were classifıed into three categories (amplifıcation, polysomy, and disomy).
PD-L1 expression was evaluated using immunohistochemistry (clone E1L3N),
and positivity of5% was used as the cut-off. Results: In the entire cohort, the
median age was 68 years (23-88 years). The cohort comprised 444 (68.0%) men
and 197 (30.2%) never-smokers. The median follow-up duration was 3.6 years.
The numbers of TILs in stroma were much greater than those in tumor nest.
Smoking history and squamous histology were signifıcantly associated with im-
mune cell infıltration in both stroma and tumor nest, except for CD8 TILs in
stroma. There were 20 tumors with PD-L1 amplifıcation (1.7%) and 84 tumors
with polysomy (13.2%). PD-L1 expression was positive in 201 tumors (30.8%).
In tumor nest, the numbers of individual TILs signifıcantly increased according
to the increase of PD-L1 copy number (Kruskal-Wallis, p  0.001 for PD-1,
p 0.001 for CD8, and p 0.0087 for Foxp3). In stroma, only PD1 TILs
were signifıcantly associated with PD-L1 CNAs (p  0.0032), and CD8 TILs
tended to correlate with PD-L1 CNAs (p  0.079). The numbers of CD8,
PD-1, and FOXP3 TILs were signifıcantly greater in PD-L1-positive tumors
than in PD-L1-negative tumors, in both tumor nest and stroma (p  0.001).
Neither kind of TILs, PD-L1 expression, nor PD-L1 CNAs alone was indepen-
dent prognostic factor for overall survival in a multivariate analysis with Cox
hazards models. However, when the PD-L1 copy numbers were combined with
Foxp3 TILs, cases with tumor high PD-L1 copy numbers (5 copies per nu-
cleus) and high Foxp3TILs had independently worse prognoses in both tumor
nest and stroma infıltration (hazard ratio (HR), 4.38; 95% confıdence interval,
2.26-8.49, for tumor nestmodel. HR, 1.96; 95%CI, 1.04-3.68, for stromamodel).
Conclusion: CD8, Foxp3, and PD-L1 lymphocytes in tumor nest were sig-
nifıcantly associated with PD-L1 CNAs and PD-L1 expression. Cases with both
increased PD-L1 copy numbers and Foxp3 TILs have independently worse
survival outcomes. Additional data of other TIL subgroups related to PD-L1
CNAs and expression will be discussed.
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#3699 Activation of NK cells cytotoxicity mediated by alveolar macro-
phages in the lung against murine melanoma metastases by combined aero-
sol immunotherapy. Michele Sommariva,1 Valentino Le Noci,1 Elda Tagli-
abue,2 Andrea Balsari,1 Lucia Sfondrini1. 1University of Milan, Milan, Italy;
2Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy.
INTRODUCTION: Taking advantage of aerosol for repeated local applications
in the lung, we previously demonstrated that combination of Poly(I:C) and CpG-
ODN, TLR3 and 9 ligands capable to activate innate effectors, induced a signifıcant
antitumor effect against B16 melanoma lung metastases, which correlated with a
strong activationofNKcells.We investigated the sequenceof events that lead toNK
cells activation by aerosolized TLR agonists in the lung. Although NK cells express
certain TLRs, controversies exist regarding their direct responsiveness or depen-
dence on macrophages. Alveolar macrophages have several unique features both
promoting host defense mechanisms against invading microorganisms, but also
establishing an immunosuppressive microenvironment to avoid inflammatory re-
sponses to inhaledparticles.Our fındings, establishing thesequenceofeventsof lung
immunecells activation,might represent thebasis for thedevelopmentof combined
aerosol therapies that favor NK cell triggering. EXPERIMENTAL PROCEDURE:
Alveolar macrophages and NK cells were recovered by bronchoalveolar lavage and
spleen of C57BL/6 mice, respectively. Mice i.v. injected with 5105 B16 cells were
treated starting 7 days later every three days with aerosolized Poly(I:C)/CpG-ODN
alone or combined to nebulizedmyeloid derived suppressive cells (MDSC)-deplet-
ingRB6-8C5antibody. Immunecell populationsandexpressionofM1/M2markers
were analysedby flowcytometry andRealTimePCR, respectively, indigested lungs.
Cytotoxic activity of NK cells was assessed by 51Cr release assay. RESULTS: In vitro
TLR3/TLR9 stimulation induced IFN- secretion bynaïveNKcells, but an increase
in their cytotoxicity was detected only whenNK cells were cocultured with alveolar
macrophages pretreated with the two agonists. Alveolar macrophages from mela-
noma lungmetastases-bearingmice treatedwith aerosolizedTLRagonists also pro-
moted NK cell cytotoxicity ex vivo. Moreover, naïve alveolar macrophages incu-
bated with activated NK cells from lungs of melanoma metastases-bearing mice
aerosolized with TLR9/TLR3 agonists, up-regulated M1- and downregulated M2-
related genes, suggesting a bidirectional crosstalk between NK cells and macro-
phage. Thus, TLR agonists-activated lungmacrophages promoteNKcell cytotoxic-
ity and, reciprocally, NK cells have the potential to shape the macrophage
programming to M1-like phenotype. Our results also indicated that this positive
interplay can be further improved by the depletion of myeloid derived suppressive
cells that exert a negative effect on macrophage activation. CONCLUSION: This
studypoints to thepromiseofcombinationsof immunotherapeuticagentsdelivered
locally by inhalation to promote macrophages-NK cell activation in the lung as a
novel strategy to treat lung cancer patients.
#3700 Prognostic value of the expression of NKG2D and CD96 in early
stage non-small cell lung cancer (NSCLC). Marcin Skrzypski,1 Michał Marc-
zyk,2 Amelia Szymanowska,1 Anna Kowalczyk,1 Agnieszka Maciejewska,1
Ryszard Pawlowski,1 Wojciech Biernat,1 Joanna Polan´ska,2 Jacek Jassem1.
1Medical Univ. of Gdansk, Gdansk, Poland; 2Silesian University of Technology,
Gliwice, Poland.
Background: Immune checkpoint inhibitors showed impressive activity in
advanced NSCLC and are expected to be effective in postoperative treatment of
early disease. New therapies aimed at T and NK cell activation are in develop-
ment to expand treatments options. It is conceivable that markers of ’inflamed’,
’immune system ignorant’ and ’immune system excluding’ tumor phenotypes
may be predictive for specifıc immune-targeting therapies. Aim: We assessed
prognostic value of expression of CD8() T and NK cell markers: CD96 and
NKG2D in early stage NSCLC. In addition, we analyzed expression of 11 tran-
scripts of APOBEC genes with hypothesis that APOBEC inducedmutation bur-
den may affect tumor immunogenicity or host adaptive immunity responsive-
ness. Methods: mRNA levels were measured by RT-PCR in frozen tumor tissue
from65NSCLC stage I-IIIA patients who underwent pulmonary resection (75%
lung adenocarcinoma, 33% never-smokers, 44% with subsequent dissemina-
tion), and in 11 NSCLC cell-lines. The relative gene expression (vs. 5 normal-
ization genes) was compared between groups that did and did not disseminate,
and in relation to clinico-pathological features. Results: After Bonferroni cor-
rection for multiple testing, NKG2D and CD96 mRNA expression was signifı-
cantly lower in tumors with subsequent dissemination (p.adj.0.045). Out of 11
APOBEC genes, expression of AICDA,APOBEC3A andAPOBEC3Gwas lower
in tumors with subsequent dissemination (p.unadj.0.025). The NSCLC lines
did not express NKG2D, CD96, AICDA or APOBEC3A. The Spearman corr.
coeff. between the expression of NKG2D, CD96 and APOBEC3G were 0.8.
AICDA expression was correlated with CD96, NKG2D and APOBEC3G with
Spearman corr. coeff. in the range of 0.5-0.62. Expression of CD96 and NKG2D
was signifıcantly lower in tumors with vs. without subsequent brain metastasis
(p.unadj.0.048). The negative prognostic impact of low NKG2D and CD96
expressionwas independent frompatient smoking status (FC1, irrespective of
smoking status). In the subset of never-smokers, the fold difference of NKG2D
expression between tumors with vs. without subsequent dissemination was par-
ticularly pronounced (HR0.37; p.unadj.0.023). In multivariate Cox analysis
including stage, CD96 and NKG2D expression was signifıcantly correlated with
distant metastasis free survival (p0.028). The expression of CD96, NKG2D
and APOBEC genes was not related to gender or NSCLC histological type. IHC
co-localization and mRNA expression experiments at the background of other
more established markers are planned. Conclusions: Low expression of CD96
and NKG2D in early stage NSCLC may be predictive for high propensity to
dissemination, including metastasis to the brain. The expression of APOBEC
transcripts does not seem to correlate with metastatic potential.
#3701 Mutant p53 cancers reprogram tumor-associated macrophages via
exosomalmiR-1246.TomerCooks,1 Ioannis S. Pateras,2 LisaM. Jenkins,1 Keval
M. Patel,3 Ana I. Robles,1 JamesMorris,4 Tim Forshew,5 Ettore Appella,1 Vassi-
lis G. Gorgoulis,2 Curtis C. Harris1. 1NCI-NIH, Bethesda, MD; 2University of
Athens, Athens, Greece; 3Addenbrooke’s Hospital, Cambridge, United Kingdom;
4Cambridge Research Institute, Cambridge, United Kingdom; 5UCLCancer Insti-
tute, London, United Kingdom.
TP53 mutants (mutp53) are involved in the pathogenesis of most human
cancers. Specifıcmutp53 proteins gain oncogenic functions (GOF) distinct from
the tumor suppressor activity of the wild-type protein. Tumor-associated-mac-
rophages, a hallmark of solid tumors, are typically correlated with poor progno-
sis. Here we report a non-cell-autonomousmechanismwherebymutp53 cancer
cells reprogram TAM to a tumor supportive and anti-inflammatory state. The
colon cancer cells harboring GOF mutp53 selectively shed miR-1246-enriched
exosomes. Uptake of these exosomes by neighboringmacrophages triggers their
miR-1246 dependent reprogramming into a cancer-promoting state. Mutp53-
reprogammed TAM favor anti-inflammatory immunosuppression with in-
creased activity of TGF-. These fındings, observed also in colon cancer pa-
tients, strongly support a microenvironmental GOF role for mutp53 in actively
engaging the immune system to promote cancer progression and metastasis.
#3702 Quantitative imaging ofmetabolic changes inmacrophage subsets.
TiffanyM. Heaster,1 David L. Elion,2 Rebecca S. Cook,2 Melissa C. Skala3. 1Uni-
versity of Wisconsin-Madison, Madison, WI; 2Vanderbilt University, Nashville,
TN; 3Morgridge Institute for Research, Madison, WI.
Macrophages play an important role in tumor therapeutic response. How-
ever, currentmethods cannot image heterogeneities inmacrophage activity on a
single-cell level over timewithin intact, living samples.Macrophagemetabolism
is closely linked to macrophage function, as M1-like macrophages rely on aero-
bic glycolysis and M2-like macrophages rely on fatty acid oxidation and oxida-
tive phosphorylation. Thus, we propose to develop optical metabolic imaging
(OMI) using two-photon microscopy to monitor cell-level changes in macro-
phage polarization and functional activity. OMI exploits the auto-fluorescence
intensities and lifetimes of the metabolic co-enzymes NAD(P)H and FAD, and
has been previously used to dynamically image in vivo tumors with cell-level
resolution. The optical redox ratio (fluorescence intensity of NAD(P)H divided
by FAD) provides a global measure of redox balance within individual cells. The
fluorescence lifetimes of NAD(P)H and FAD provide information in protein-
binding activities in metabolic reactions. OMI was used to monitor metabolic
changes inmacrophages on a single-cell level during polarization and after met-
abolic perturbations. RAW264.7macrophages were stimulated towards anM1-
or M2-like phenotype, and imaged with OMI at 24, 48, and 72 hours post-
polarization. M1- and M2-like macrophages exhibited signifıcant differences
(p0.05) in redox ratio and FAD fluorescence lifetime values at 48 and 72 hours
post-polarization. The M1-like and M2-like character of the macrophages were
validated with quantitative polymerase chain reaction (qPCR) analysis. Popula-
tion density modeling of single-cell metabolism established differences in intra-
sample heterogeneity across subsets over time. M1- and M2-like macrophages
were also treated with 2-deoxy-glucose (glycolysis inhibitor), etomoxir (fatty
acid oxidation inhibitor), and cyanide (oxidative phosphorylation inhibitor.
Treatment with etomoxir caused a signifıcant decrease in redox ratio inM2-like
macrophages (p0.05) with no signifıcant effect on M1-like macrophages. In
contrast, the redox ratio decreased in M1-like macrophages upon inhibition of
glycolysis (p0.05). Comparable to previously published data, inhibition of ox-
idative phosphorylation in both groups yielded a decreased NAD(P)H mean
lifetimes (p0.05) and increased FAD mean lifetimes (p0.05). These results
establish OMI as a method to image heterogeneity in macrophage populations
within intact, living samples. This method could be used to understand macro-
phage interactions in the microenvironment of intact in vivo tumors.
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#3703 A genomic characterization of testicular germ cell tumor immune
microenvironment. Daniel P. Hollern, Katie Hoadley, Benjamin Vincent,
Charles M. Perou, TCGA Testicular Germ Cell Tumor Analysis Working
Group. University of North Carolina, Chapel Hill, NC.
Testicular germ cell tumors (TGCT) are a histologically diverse set of
tumors and the most common cancer type in young men. As part of the
TCGA effort, we analyzed tumors from 133 patients including 4 patients
with asynchronous double primary TGCTs (137 primary tumors) by histo-
pathologic, genomic, epigenomic, transcriptomic, and proteomic methods.
We noted molecular signatures of various immune cells were greater in
seminomas than other histologies. Specifıcally, we fınd seminomas show
elevation of expression signatures for B-Cells, Cytotoxic T-Cells, Th17 Cells,
and T-regulatory cells. This increase in immune cells were accompanied by
high expression of specifıc cytokines and key immune checkpoint molecules
such as CTLA4, LAG3, and PD-L1. Strong positive correlations were iden-
tifıed between immune cell signatures and increases in T-Cell and B-Cell
receptor diversity measures. Interestingly, increases in receptor diversity
also showed strong positive associations to gene expression signatures for
anti-tumor immune responses. This indicates that anti-tumor immune re-
sponses in seminomas may be polyclonal. We found no evidence for rela-
tionships between immune cells and mutation load, neoantigen load, or
detected viruses. We do observe that seminomas have signifıcantly high
expression of the testis specifıc antigens, yet the contribution of these anti-
gens to the immune response did not show strong or uniform statistical
indications. Instead, the strongest association between expanded immune
cells populations in seminomas were the presence of activating mutations in
KIT accompanied by elevation of gene expression of signatures associated
with KIT and expression of MHC class I and II genes. Together, these data
describe the immune microenvironment of seminomas and suggest altera-
tions and events in the kit pathway as being critical to the nature of the
immune microenvironment in seminomas.
#3704 Targeting M2-tumor associated macrophages (M2-TAMs) using
enriched glycoproteins in lethal prostate cancer. Jelani C. Zarif, James R.
Henandez, Weiming Yang, Hui Zhang, Kenneth J. Pienta. Johns Hopkins Uni-
versity School of Medicine, Baltimore, MD.
Prostate cancer is a leading cause of cancer-related deaths of men in the U.S.,
and in the past year, over 30,000 men died from this disease. While localized
prostate cancer is highly treatable by surgical resection and radiation, cancer that
has metastasized remains incurable. Alternatively activated macrophages, also
known as M2-macrophages, primarily scavenge debris and in the process, pro-
mote angiogenesis andwound repair.M2-macrophages are phenotypically sim-
ilar to M2 tumor-associated macrophages (M2-TAMs) have been reported to
associate with solid tumors such as prostate cancer to facilitate epithelial to
mesenchymal transition (EMT), tumor invasiveness, metastasis, and resistance
to therapy. As an invasive species within the tumor microenvironment, this
makes M2-TAMs an ideal therapeutic target in prostate cancer. The purpose of
this project is to develop novel therapeutics that will directly target M2-TAMs
for destruction and subsequently attenuate prostate tumor growth, progression,
and metastasis. Our hypothesis is to determine if targeting of M2-TAMs by
using enriched surface antigens that are targeted by antibody-drug-conjugates
(ADCs), be an effective therapy for lethal prostate cancer while simultaneously
eliciting an immune response. To identify novel surface antigens expressed on
M2-macrophages, we developed a novel method of creating homogenous pop-
ulations of human macrophages from CD14monocytes in vitro. Our homog-
enous M1 macrophages secrete pro-inflammatory cytokines and our M2 mac-
rophages secrete anti-inflammatory cytokines as well as VEGF. We then
performed solid-phase extraction ofN-linked glycopeptides (SPEG) followed by
liquid chromatography-tandem Mass Spectrometry (LC-MS/MS) on our ho-
mogenous macrophage populations. We discovered fıve novel peptides that are
enriched exclusively on M2-macrophages relative to M1 macrophages and
CD14 monocytes. Lastly, we determined if these surface antigens, found en-
riched on M2 macrophages, were also expressed in human metastatic castrate-
resistant prostate cancer (mCRPC). Using mCRPC tissues from rapid autopsies
supplied by theDepartments of Urology and Surgical Pathology, wewere able to
determine M2-macrophage infıltration by using immunohistochemistry and
flow cytometry. The studies described here outline a method of altering the
tumor immune microenvironment. To target M2 macrophages, we used small
peptides as well as antibody drug conjugates (ADCs) that targeted the enriched
surface glycoproteins expressed on M2-macrophage. We then tested their effı-
cacies in vitro and in a syngeneic prostate tumor mouse model to assess tumor
shrinkage and effector and cytotoxic T Cell infıltration. By identifying specifıc
markers on M2-TAMs, we predict that this method of targeting will provide a
better prognosis for patients who have been diagnosed with lethal prostate can-
cer.
#3705 Targeting interleukin-1 to increase cetuximab effıcacy in head and
neck cancer. Madelyn Espinosa-Cotton,1 Ayana J. McLaren,2 Adam T. Koch,3
Andrean L, Simons1. 1The University of Iowa, Iowa City, IA; 2Lincoln University,
LincolnUniversity, PA; 3Loma LindaUniversity School ofMedicine, Loma Linda,
CA.
Treatment for head and neck squamous cell carcinoma (HNSCC) patients
includes the epidermal growth factor receptor (EGFR) monoclonal antibody
cetuximab. However, response to cetuximab is low and resistance remains a
critical issue. Therefore, it is imperative to develop strategies to enhance tumor
response to this drug. Inflammation plays an important role in tumor progres-
sion by increasing the release of cytokines that promote tumor cell survival. Our
prior work has shown that a variety of pro-inflammatory cytokines involved in
tumor survival are upregulated upon treatment with EGFR inhibitors in HN-
SCC cells, suggesting that poor tumor response to EGFR inhibitors may be due
to increased tumor-associated inflammation. Our lab has shown that the in-
creased proinflammatory tumor response due to EGFR inhibition may be acti-
vated by interleukin-1 (IL-1) signaling, suggesting that the IL-1 pathwaymay be
an important target to enhance the effıcacy of anti-EGFR therapy. Here we
investigated the effect of IL-1 blockade onHNSCC tumor response to cetuximab
treatment. We found that cetuximab induced IL-6 secretion from SQ20B HN-
SCC cells and knockdown of the adapter protein MyD88, which is essential for
IL-1 signaling, suppressed IL-6 secretion at baseline and in response to cetux-
imab treatment. Similarly, knock down of the IL-1 receptor (IL-1R) decreased
baseline and cetuximab-induced IL-6 secretion, although IL-1R knockdown did
not improve response to cetuximab in SQ20B xenografts in vivo. We addition-
ally blocked IL-1 signaling using a recombinant IL-1R antagonist (IL-1RA).
IL-1RA pre-treatment reduced baseline and cetuximab-induced IL-6 secretion
in vitro. Although IL-1RA did not signifıcantly enhance SQ20B tumor response
to cetuximab, IL-1RA as a single agent signifıcantly suppressed tumor growth in
female mice but not in male mice. Finally, treatment with a human-specifıc
neutralizing IL-1 alpha (IL-1) antibody (but not IL-1 beta (IL-1)) reduced
baseline and cetuximab-induced IL-6 secretion in vitro, and signifıcantly in-
creased SQ20B tumor response to cetuximab in vivo. Altogetherwe propose that
targeting IL-1 specifıcally may be a viable strategy to improve HNSCC tumor
response to cetuximab.
#3706 Validation of human and mouse myeloid panels on the NanoS-
tring® nCounter® Platform. Sushil Kumar,1 SarahWarren,2 TizianaCotechini,1
Terry Medler,1 Christina Bailey,2 Joseph M. Beechem,2 Joseph M. Beechem,2
LisaM.Coussens3. 1OregonHealth and ScienceUniversity, Portland, OR; 2Nano-
String Technologies, Seattle,WA; 3Oregon Health and Science University, Seattle,
WA.
Introduction: The innate immune system profoundly influences cancer de-
velopment as well as its response to various therapeutic approaches. Multiple
myeloid cell lineages are central to the innate immune response during cancer
and have been found to regulate diverse cellular processes encompassing im-
mune suppression, angiogenesis, invasion, metastasis, and drug resistance.
NanoString has collaborated with the laboratory of Prof. Lisa M. Coussens to
develop research gene panels for quantitative and qualitative analysis of various
myeloid subsets by evaluating relative enrichment of genes that mark recruit-
ment and presence of select myeloid subtypes (e.g., granulocytes, dendritic cells,
monocytes, macrophages, mast cells), their cell function, activation and effector
status. Methods: Gene content for human and murine versions of the myeloid
panels were developed from an in-house high content proteomic screen of mac-
rophage activation (unpublished), genomic analysis of human tumor associated
macrophages (unpublished), and data mining from publically available datasets
featuring myeloid transcriptomes. In total, 692 genes were included in the hu-
man panel and 675 genes in the murine panel. The panels were optimized to
work across a range of sample types including fresh frozen tissues, formalin-
fıxed paraffın-embedded (FFPE) samples, peripheral blood mononuclear cells
and cell lysates. Results: To validate the panel content, we are profıling myeloid
infıltrates in syngeneic murine models of mesothelioma and mammary tumor-
igenesis by flow cytometric analysis and the nCounter myeloid panels. Since the
quality of the myeloid tumor response can skew toward adaptive immune acti-
vating (Th1) or suppressive (Th2) phenotypes, we will profıle the same tumor
samples with the NanoString PanCancer Immune Profıling panel to evaluate T
cell activation status by gene expression and flow cytometry as well as global
immune response. Finally, myeloid complexity and T cell activation status in
both primary tumor and lung metastases will be evaluated by NanoString to
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assess regulation of adaptive immune responses by the innate compartment in
distinct tumor microenvironments. Conclusions: Upon validation with these
assays, the myeloid gene panels may provide insight into how the innate im-
mune system regulates cancer development and response to therapeutic pres-
sure. Improved characterization of the myeloid compartment may lead to
greater insight into the fundamental biology of tumor-immune interactions,
novel therapeutic strategies, and other applications.
#3707 Tumor-associated neutrophils with antigen-presenting features in
early-stage human lung cancer. Jason Stadanlick, Abhishek Rao, Michael An-
nunziata, Edmund Moon, Shaun O’brien, Pratik Bhojnagarwala, Michael Feld-
man,Wayne Hancock, Jose Conejo-Garcia, Sunil Singhal, Stephen Albelda, Ev-
geniy Eruslanov. University of Pennsylvania, Philadelphia, PA.
To date there has been an increasing focus on the interactions between in-
flammatory myeloid cells and T cells in the tumor microenvironment because
cytotoxic anti-tumoral T cells represent the chief effector mechanism of anti-
tumoral immunity. Tumor-associated neutrophils (TANs) represent a signifı-
cant portion of inflammatory cells in lung tumors; however, whether specialized
neutrophil subpopulations capable of regulating T cell responses exist in human
cancers is unknown. Our goal was to identify subsets of TANs and determine
their specifıc roles in the regulation ofT cell responses in patientswith early stage
lung cancer. An extensive phenotypic analysis of 55 early-stage human lung
tumors revealed that TANs, defıned as CD11bArg1MPOCD66bCD15
cells, contained two major sub-populations. One subset of “canonical” TANs
expressed classic neutrophil markers. A second subset of TANs displayed a
combination of neutrophil markers plus markers (CD14HLA-
DRCCR7CD86) normally expressed on antigen-presenting cells (APC).
We termed this unique neutrophil population “APC-like hybrid TANs”. The
frequency of these hybrid TANs varied widely within lung cancers and ranged
from 0.5-25% of all TANs. Interestingly, the frequency of this hybrid population
declined as tumors enlarged, and they were almost completely absent in tumors
greater than 5 cm in diameter. Mechanistically, we determined that low doses of
IFN- and GM-CSF in the tumors were required for the development of APC-
like hybrid neutrophils. The high proportion of hybrid TANs (10% of all
TANs) directly correlated with the presence of IFN- and GM-CSF in the au-
tologous tumor tissue. Using bone marrow-derived immature granulocytes,
which were found to have prolonged survival in vitro, we discovered that these
APC-like hybrid neutrophils originate from CD11bCD15CD10-CD16-/low/
int neutrophil progenitors in the presence of IFN- and GM-CSF or in tumor-
conditioned media. Functionally, the APC-like hybrid neutrophils are superior
to canonical neutrophils in their ability to: 1) stimulate antigen non-specifıc
autologous T cell responses 2) directly stimulate antigen-specifıc autologous
memory T cell responses, 4) augment NY-ESO-1 specifıc effector T cell re-
sponses by providing a co-stimulatory signals through the OX40L, 4-1BBL
CD86, CD54 molecules, and 5) cross present tumor-associated antigen as IgG-
immune complex. In summary, we provide the fırst evidence of two subsets of
TANs in lung cancer. All TANs had an activated phenotype and could support
(rather than inhibit) T cell functions to some degree. However, we identifıed a
subset of TAN in early-stage lung tumors that can undergo a unique differenti-
ation process resulting in formation of specialized subset of APC-like hybrid
neutrophils. These hybrid neutrophils may provide new opportunities to boost
the effıcacy of vaccines based on cytotoxic T lymphocyte induction
#3708 RAS-MAPK signal is required for enhanced PD-L1 expression in
human lung cancers. Hidetoshi Sumimoto, Atsushi Takano, Koji Teramoto,
Yataro Daigo. Shiga University of Medical Science, Otsu, Japan.
Ectopic programmed cell death ligand 1 (PD-L1) expression in non-small cell
lung cancers (NSCLCs) is related to immune evasion by cancer, and it is a
molecular target of immune checkpoint therapies. Since the precisemechanisms
responsible for ectopic PD-L1 expression remains obscure, we analyzed the
molecular mechanisms of ectopic PD-L1 expression in human lung cancers,
focusing on the MAPK signal. Because we found a higher frequency of EGFR/
KRAS mutations in NSCLC cell lines with high PD-L1 expression (p 0.001),
we evaluated the relationships between downstream signals and PD-L1 expres-
sion, particularly in three KRAS-mutant adenocarcinoma cell lines. The MEK
inhibitor U0126 (20 M) signifıcantly decreased the surface PD-L1 levels by
50-60% compared with dimethyl sulfoxide (p 0.0001). Phorbol 12-myristate
13-acetate stimulation (100 nM, 15 min) increased (p  0.05) and two ERK2
siRNAs as well as KRAS siRNAs decreased (p 0.05) PD-L1 expression. Post-
transcriptional mechanism by miR-200s appears not to be in general under the
downstream of MAPK in the PD-L1 expression. The transcriptional activity of
the potential AP-1 site (4785 to5056 from the transcription start site) in the
PD-L1 gene was demonstrated by luciferase assays, which was inhibited by
U0126. The chromatin immunoprecipitation assay demonstrated the binding of
cJUN to the AP-1 site. Two STAT3 siRNAs decreased PD-L1 expression by
10-32% in two of the three KRAS-mutant lung adenocarcinoma cell lines (p
0.05), while the PI3K inhibitor LY294002 (40M)did not change the expression
level. Supervised cluster analysis and gene set enrichment analysis between the
PD-L1-high and -lowNSCLCs revealed a correlation between PD-L1 expression
and genes/pathways related to cell motility/adhesion. These results indicate that
MAPK signaling is the dominant downstream signal responsible for ectopic
PD-L1 expression at a transcriptional level, in which STAT3 is also involved to
some extent. Furthermore, MAPK signaling may control the expression of
PD-L1 and several genes related to enhanced cell motility. Our fındings suggest
that MAPK is important for determining PD-L1 expression, which could be
useful for targeted therapies against lung cancers.
#3709 Deciphering the impact of tumor genetics on immune cell infıltra-
tion in major solid cancer types. Jan Budczies,1 Michael Bockmayr,1 Frederick
Klauschen,1 Abrecht Stenzinger,2 Carsten Denkert1. 1Charité - Universitätsme-
dizin Berlin, Berlin, Germany; 2Heidelberg University Hospital, Heidelberg, Ger-
many.
With the advent of immune therapies including inhibition of the PD-1/PD-L1
axis there is an urgent need to identify cancer patients that benefıt from these
therapies and to overcome mechanisms of resistance. Here, we analyzed the
impact of tumor genetics on the composition of tumor microenvironment
across 21 solid cancer types from the TCGA project. Using specifıc mRNA
markers of 10 cell populations (MCPcounter), we estimated the content of T
cells, CD8 T cells, cytotoxic lymphocytes, B lineage cells, NK cells, monocytic
lineage cells, myeloid dendritic cells, neutrophils, fıbroblasts and endothelial
cells in tumor tissues. Immune cell compositions were correlated with muta-
tional load, the activity of 27mutational signatures (MutSigs) andPD-L1mRNA
expression. Correlation strength was assessed using Spearman’s rho statistics.
Multiple testingwas addressed using the Benjamini-Hochbergmethod and FDR
control at 5%. MutSig 1 (clock-like, age-related) showed signifıcant positive
correlations with immune cell infıltrations in low-grade gliomas, negative cor-
relations in breast cancer, melanoma, stomach cancer, lung and prostate adeno-
carcinoma, but no signifıcant correlations in the remaining 15 cancer types. Of
the two APOBEC-related signatures, MutSig 2 showed positive signifıcant cor-
relations with immune cell infıltrates in cervical cancer, bladder cancer, lung
adenocarcinoma, head and neck cancer and thyroid cancer, MutSig 13 in breast
and cervical cancer. In particular, correlation of MutSig 2 with cytotoxic lym-
phocytes was signifıcant in cervical cancer, bladder cancer and lung adenocar-
cinoma (R  0.29, R 0.17 and R  0.17), the corresponding correlation of
MutSig 13 in breast cancer (R  0.17). MutSig 4 (tobacco smoke-related)
showed a positive signifıcant correlationwith CD8T cells andNK cells in lung
adenocarcinoma (R 0.15 and R 0.14). In contrast, correlation of MutSig 4
with immune cell infıltrates was non-signifıcant or negative in head and neck
cancer. In colorectal cancer, MutSig 6 (defective mismatch repair) showed sig-
nifıcant positive correlations with NK cells, cytotoxic lymphocytes, monocytic
lineage cells and neutrophils infıltration (R 0.45, R 0.37, R 0.23 and R
0.19). PD-L1mRNAexpression and immune cell infıltrates correlated positively
in all 21 cancer types. In particular, correlation with monocytic lineage cells was
positive and signifıcant in all cancer types and strong (R  0.50) in 12 cancer
types. Correlationwith T cells was positive and signifıcant in 18 cancer types and
strong in 10 cancer types. In summary, pan-cancer analysis ofDNAandRNAseq
data showed that specifıc mutational signatures contribute to cancer cell immu-
nogenicity, while the ubiquitous clock-likemutational process did not positively
correlate with immune cell infıltrates in 20 of 21 cancer types. Moreover, PD-L1
mRNA expression strongly correlated with infıltrates of immune cells in the
majority of cancer types.
#3710 Components ofHLAclass Imolecules influence pancreatic cancer cell
proliferationandmigration.Bailee Sliker,1Cassie Liu,1 BrittanyPoelaert,1HCarlo
Maurer,2 Kenneth P. Olive,2 Joyce C. Solheim1. 1University of Nebraska Medical
Center, Omaha, NE; 2Columbia University Medical Center, New York, NY.
Human leukocyte antigen (HLA)class Imolecules are composedof aheavy chain
with three isoforms (-A, -B, and –C) and a light chain (beta 2-microglobulin or
2m). These molecules are best known for their role within the immune system, in
which theypresent antigens to cytotoxicTcells.Thesemoleculeshavebeen found in
some tumor models to be down regulated as a form of immune escape; however,
recent studies in breast, gastric, and lung cancer have correlated high expression
levels ofHLA class I with a poorer patient prognosis.2mhas also been found to be
high in expression in many cancers, and it has been implicated in promoting renal
cancer progressionby increasingproliferation andmigration.Whether any compo-
nents of the HLA class I molecule contribute to the pathogenesis of other cancers,
IMMUNOLOGY: Inflammation in the Tumor Microenvironment
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017946
such as pancreatic cancer, has not been elucidated. Our recent results show that
human pancreatic cancer cell lines have high total and cell-surface expression of
2m,HLA-A, andHLA-B, with the exception of one pancreatic cancer cell line that
we found exhibits low expression ofHLA-B. Furthermore, differential gene expres-
sion analysis performed on laser capture-microdissected human pancreatic cancer
patient samples revealed thatHLA-B expression is not reduced in pancreatic ductal
adenocarcinoma cells, compared to precursor (PanIN) epithelial or stromal cells.
Together, our results indicate that pancreatic cancer cells have not selectively down
regulatedHLAclass Imolecule expression.Thisobservationsuggests thatHLAclass
I molecules might provide some benefıt to pancreatic cancer cells that counterbal-
ances any risk of immune attack caused by HLA class I molecules. To examine
whether the components of the HLA class I molecule actually confer potential ad-
vantages to pancreatic cancer cells, we transfected siRNA specifıc for 2m, HLA-A
heavy chain, or HLA-B heavy chain into several pancreatic cancer cell lines and
evaluated theeffectson theirproliferationandmigration.Down-regulationof either
2morHLA-Bexpressionslowed theproliferationofonepancreatic cancer cell line,
whereas down-regulation of HLA-A expression had the inverse effect on the same
cell line. Two other pancreatic cancer cell lines had an opposite phenotype: prolif-
erating more slowly whenHLA-A expression was reduced, but more rapidly when
HLA-B expressionwas decreased. Our investigation of the impact of down regulat-
ing HLA class I molecule components on the migration of pancreatic cancer cells
showed the same trends with each cell line as we had observed in our proliferation
analyses. In conclusion, we found that pancreatic cancer cells express substantial
levels ofHLAclass Imolecule components, and that these components signifıcantly
influence the proliferation andmigration of pancreatic cancer cell lines in amanner
that varies forHLA-AversusHLA-B, and that also varies inpatternamong the types
of pancreatic cancer cell lines.
#3711 R-Ras is required for T cell traffıcking in high endothelial venues
and implicated in anti-tumor immunity. Andrew M. Chan,1 Xiaocai Yan,2
Wai Nam Liu,1 Mingfei Yan1. 1Chinese University of Hong Kong, Hong Kong,
Hong Kong; 2The Medical College of Wisconsin, Milwaukee, WI.
R-Ras belongs the RAS superfamily of small GTP-binding proteins impli-
cated in cell adhesion signaling. Unlike classical Ras proteins, R-Ras is not acti-
vated by growth factor receptors. Rather, its GTPase activity is modulated by
molecules implicated in cell-cell adhesion including semaphorins and notch.
Using an R-Ras knockout mouse strain, we have previously reported that R-Ras
is required for murine Dendritic cell functions. Further characterization of this
mouse strain revealed reduced cellularity of peripheral lymph nodes (PLNs) by
40% with T cell regions in the paracortex in which high endothelial venules
(HEV) resided were less prominent when compared with wild-type (WT)mice.
Consistently, immunohistological analysis for MECA-79, a marker of mature
HEV, showed a 3- to 4-fold decrease in staining intensity. This is correlated with
a 30-40% reduction in the number of CD62L CD4 and CD8 T cells in PLNs.
Furthermore, R-Ras null T cells had reduced proliferative and homing capacity
when compared withWT.More importantly, we demonstrated for the fırst time
that the chemokine CCL21 was able to stimulate the GTP-loading of R-Ras
within 15 seconds of addition. Indeed, R-Ras null T-cells displayed reduced
binding to soluble ICAM-1 as well as to 2H-11 endothelial cells. To explore the
role of R-Ras in anti-tumor immunity, B16/F10 melanoma cells were injected
subcutaneously to WT and R-Ras null mice. In addition, a mouse breast tumor
model was generated ineither WT or R-Ras-null genetic background. Tumor
development and the number of infıltrating immune cells were analyzed to
examine if R-Ras was involved in either anti- or pro-tumor immune responses.
This work was supported by NIHCA78509 (AMC), MH59771 (AMC). MYwas
supported by Hong Kong PhD Fellowship Scheme (PF12-13584) and AMCwas
supported by the Lo Kwee-Seong Seed Fund, and a General Research Fund
Grant, 14120915, from Hong Kong University Grants Committee.
#3712 Mechanistic link between phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit alpha (PIK3CA) activity and PDL1 expression in
head and neck squamous cell carcinoma (HNSCC). Rebecca C. Hoesli, Nicole
L.Michmerhuizen, VivekNair, ChloeMatovina, Elizabeth Leonard,MatthewE.
Spector, Carol R. Bradford, Mark E. Prince, Andrew C. Birkeland, J Chad
Brenner. University of Michigan, Ann Arbor, MI.
Introduction: HNSCC is an immunosuppressive disease, with multiple func-
tional and quantitative defects contributing to immune evasion and tumor es-
cape. One of the identifıed areas for therapy development is the Programmed
Death-1 (PD-1)/ProgrammedDeath Ligand 1 (PD-L1) pathway, as this pathway
has been hypothesized to allow cancer cells to evade the immune system by
promoting T cell anergy and apoptosis. Pembrolizumab, a PD-L1 inhibitor, has
recently been approved for the treatment of recurrent/metastatic HNSCC. As
regulation of PD-L1 expression could play an important role in the effectiveness
of therapy, we further explored the regulation of PD-L1 expression in HNSCC
cells. Specifıcally, we targeted our investigation by evaluating the effects on ex-
pression of one of the most frequently mutated genes in HNSCC, PIK3CA. We
evaluated this with and without interferon-, which has previously been shown
to affect PD-L1 expression, possibly through activation of the STAT1 pathway.
Methods: HPV and HPV- HNSCC cell lines were grown in cell culture and
treated with selective and non-selective PI3K inhibitors, in combination with
interferon-. After 72 hours, cells were harvested and flow cytometry was used
to measure the expression of PD-L1. Protein expression of various pathway
intermediaries was evaluated via western blot to better delineate themechanism
of PD-L1 upregulation. Results: Treatment with selective PI3K inhibitors in
combination with interferon- in several cell lines signifıcantly increased ex-
pression of PD-L1, beyond the increase noted after treatment with interferon-
alone. Maintenance of STAT1 phosphorylation correlated with upregulation of
PD-L1 expression, while total STAT1 expression remained stable. The majority
of the cell lines maintaining STAT1 phosphorylation were HPV, but a few
HPV- cell lines alsomaintained this phosphorylation with a correlating upregu-
lation in PD-L1 expression. Additionally, mutation in PIK3Ca despite HPV-
status was noted to maintain phosphorylation of STAT1 with upregulation of
PD-L1 expression. Conclusions: Treatment with PI3K inhibitors in combina-
tion with interferon- signifıcantly upregulated PD-L1 expression in several cell
lines, suggesting a possible synergistic effect. Since PD-L1 expression correlated
with maintenance of phosphorylation of STAT1, these results suggest a pivotal
link between PIK3CA signaling, STAT1 activity and PD-L1 expression in
PIK3CA aberrant HNSCC.
#3713 Higher numbers of cancer stem cells in the peripheral blood of
children with B-ALL upon conventional chemotherapy.Mohamed L. Salem.
Tanta University, Tanta, Egypt.
Background: Acute lymphocytic leukemia (ALL) is biologically and clin-
ically considered as a heterogeneous neoplasm of lymphoid progenitor cells
in the bone marrow (BM). 15- 20 % of children with ALL who achieve an
initial remission, will show relapse. One potential mechanism behind this
relapse could be the emergence of cancer stem cells (CSCs) which are con-
sidered the driving force of tumourigenesis due to their ability of self-re-
newal as well as the emergence of immune regulatory cells including my-
eloid-derived suppressor cells (MDSCs) and regulatory T cells (Treg). Aim:
the main aim of this study was to analyze the numbers of CSCs and correlate
these numbers with the numbers of blast cells, MDSCs and Treg cells in
children with B-ALL before and after induction of chemotherapy. Materials
and Methods: CSCs were defıned as CD45dimCD19CD10CD34CD38-,
MDSCs were defıned as Lin-HLA-DR-CD33CD11b and Treg cells were
defıned as CD4CD25CD127-. The frequencies of these cells were analyzed
in the peripheral blood of B-ALL patients before (n 10) and after (n 10)
induction of chemotherapy using flow cytometry. Results: Signifıcant in-
creases in the numbers of CSCs were shown in B-ALL patients after induc-
tion of chemotherapy as compared to newly diagnosed patients (7.6	 8.3 vs.
2.7	 2.4, P0.05). The numbers of CSCs in ALL patents before and after
induction of chemotherapy inversely correlated with the numbers of the
blast cells. Additionally, the numbers of MDSCs and Treg cells were higher
and lower, respectively, in patients after induction of chemotherapy as com-
pared to before chemotherapy. Conclusion: Our results indicate that chemo-
therapy of B-ALL patients results in emergence of high numbers of CSCs and
MDSCs which might be contributing, respectively, to tumor relapse and
creation of systemic immune suppression. This pilot study opens a new
avenue to investigate the mechanism mediating the emergence of these cells
on larger population of B-ALL patients at different treatment stages.
#3714 Muc5ac plays an essential role in promotion of k-ras mutant lung
cancer.Misha Umer,1 Amber M. Cumpian,1 Nasim Khosravi,1 Zoulikha Azze-
gagh,1 Maede Mohebnasab,1 Mauricio S. Caetano,1 Edwin J. Ostrin,1 Ignacio I.
Wistuba,1 Burton Dickey,1 Humam Kadara,2 Christopher M. Evans,3 Seyed J.
Moghaddam1. 1UTMDAnderson Cancer Center, Houston, TX; 2American Uni-
versity of Beirut, TX; 3University of Colorado School of Medicine, Denver, TX.
Worldwide, lung cancer is the leading cause of cancermortality, and cigarette
smoking (CS) is its principal cause. However, several studies have found that
smokers with chronic obstructive pulmonary disease (COPD), an inflammatory
disease of the lung, have an increased risk of lung cancer (3 to 10-fold) compared
to smokers with comparable cigarette exposure but without COPD. Impor-
tantly, among smokers with COPD, even following withdrawal of cigarette
smoke, inflammation persists and lung function continues to deteriorate as does
the increased risk of lung cancer. These facts suggest a strong link between
COPD-related lung inflammation and lung cancer, however, the precise mech-
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anistic link is not known. Mucociliary dysfunction andmucin hyperproduction
are important features of COPD with inflammation being the major trigger.
Interestingly, lung cancer with mucin overexpression has higher malignancy
potential and poor prognosis, which around 76% having mutations in K-ras
oncogene, the most frequent oncogenic mutation in lung adenocarcinoma.
Taken these together, we hypothesized that mucins contribute to promotion of
K-ras mutant lung cancer by inflammation. Here we fırst investigated whether
Muc5ac, predominant airway mucin that plays a primary role in inflammatory
lung diseases, is predictive of clinical outcome in KRAS-mutant human lung
adenocarcinomas. We determined Muc5ac mRNA expression by array analysis
of 150 lung adenocarcinomas from patients that did not received neoadjuvant
therapy and we found that, Muc5ac mRNA level was a signifıcant predictor of
poor disease-free survival in KRAS-mutant lung adenocarcinomas. We have
further found increased mucin and high expression of Muc5ac in lung tumor
tissues of the mice with airway specifıc expression of a mutant form of K-ras
(CC-LR mice). Then, we crossed previously developed Muc5ac knockout (KO)
mice to CC-LR mice in order to develop a K-ras mutant lung cancer mouse
model with lack of Muc5ac (CC-LR/Muc5ac KO mice). This resulted in a sig-
nifıcant tumor reduction by 54% (2.2-fold) in lung of CC-LR/Muc5ac KO
mice compared to age and sexmatched controlCC-LRmice. Lung inflammation
was evaluated by analysis of bronchoalveolar lavage fluid and revealed a signif-
icant reduction (3-fold) in number of macrophages, and levels of IL-6 and IL-17
in CC-LR/Muc5ac KO mice compared to CC-LR control mice. Immunohisto-
pathological analysis of lung sections confırmed lower inflammation, decreased
tumor number and size, less adenomatous lesions, and reduced tumor cell pro-
liferation and angiogenesis in CC-LR mice with lack of Muc5ac compared to
control CC-LR mice. Our experimental results suggest that Muc5ac has an es-
sential role in promotion of K-ras mutant lung cancer through autocrine cell
intrinsic and paracrine immune cell mediated mechanisms.
#3715 Analysis of tumor infıltrating lymphocytes and in vitro exhausted
T-cellmodels to identify unique Immuno-Oncology targets. James Ackroyd,1
Joanne Berry,1 Yaoyao Fu,2 Jason Allen,1Martin Barnes,1 Alexander Patterson,1
Angelo Kaplan,2 Christian Rohlff,1 Haining Huang,2 Livija Deban,1 Robert
Boyd1. 1Oxford BioTherapeutics Ltd, Abingdon, United Kingdom; 2Oxford Bio-
Therapeutics Inc, San Jose, CA.
In cancer, T cells are exposed to persistent antigen stimulation and/or
inflammatory signals. Such prolonged stimulation is often associated with
deterioration of T cell effector functions resulting in a functional state
termed ’exhaustion’. Exhausted T cells are characterized by expression of
multiple inhibitory receptors, loss of cytolytic function and decline in cyto-
kine production capability. T cell exhaustion is likely associated with ineffı-
cient control of tumor progression. Identifıcation of cell surface proteins
involved in induction and maintenance of the exhausted state could inform
novel immunomodulatory cancer therapies. To comprehensively investigate
cell surface signature of the exhausted state and identify potential immuno-
oncology (I-O) targets, we conducted in-depth expression profıling of mem-
brane proteins from intact tumors (Colorectal, Pancreatic, Lung, Breast and
Prostate cancer), different in vitro models of T cell exhaustion and primary
tumor-derived lymphocytes (Colorectal, Breast and Lung cancer) by tar-
geted proteomics for known cell type and activation markers. Using pro-
teomic expression analysis and statistical clustering analysis methods, novel
I-O targets were identifıed in both the in vitro models of T cell exhaustion
and primary tumor-derived lymphocytes (TILs). The cancer specify of novel
I-O targets was then interrogated using the expression profıling of cell mem-
brane proteins from intact tumors. Using this approach we identifıed most
known T cell inhibitory receptors (PD-1, CTLA-4, BTLA, TIM-3, KIRs,
LAG-3 and TMIGD2) and their described ligands (B7-H1 to B7-H7). To
generate more precise expression data to validate I-O targets emerging from
the above discovery approaches and their known interacting partners we
analyzed single tumors using an integrated evaluationmethodology. Tumors
were subject to multiple parallel analysis steps: (i) proteomic analysis of the
tumor and TILs; (ii) TILs were subject to flow cytometry analysis for specifıc
proteins; (iii) tumor tissue sections were subject to immuno-histochemical
analysis for specifıc proteins. The multiple analysis platforms were inte-
grated by key cell type and functional markers allowing the different types of
information provided by each technique to be placed in an overall 3-D tumor
context. We present one example of a potential I-O target identifıed using
our integrated proteomic discovery approach which is further validated at
the expression level using multiple whole tumor and TIL analyses.
#3715A Effusions of mesothelioma patients: What’s in it for immuno-
therapy. Elly Marcq,1 Jorrit DeWaele,1 Jonas van Audenaerde,1 Eva Lion,2 Eva
Santermans,3 Niel Hens,3 Patrick Pauwels,4 Jan P. van Meerbeeck,5 Evelien L.
Smits1. 1Center for Oncological Research, University of Antwerp, Antwerp, Bel-
gium; 2Laboratory of ExperimentalHematology, University of Antwerp, Antwerp,
Belgium; 3Interuniversity Institute for Biostatistics and Statistical Bioinformatics,
Hasselt University, Diepenbeek, Belgium; 4Department of Pathology, Antwerp
University Hospital, Antwerp, Belgium; 5Thoracic Oncology/MOCA, Antwerp
University Hospital, Antwerp, Belgium.
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a poor
prognosis for which new therapeutic strategies are available. Data derived from
a small number of mesothelioma patients suggest that blocking immune check-
points could offer new treatment opportunities. Gaining more insight in the
immunological aspect of the tumormicroenvironment (TME) inMPM is essen-
tial to develop an effective immunotherapy. In this context, we investigated
expression of the immune checkpoint molecules TIM-3, LAG-3, PD-1 and its
ligand PD-L1 on cells in human pleural (collected via thoracocentesis, n6) and
ascites (collected via paracentesis, n5) MPM fluids and identifıed different
subsets of immune cells in the TME using multicolor flow cytometry. Different
types of immune cells in the fluids could be detected, with predominant occur-
rence of CD3CD4 T cells, CD64 macrophages and CD11cCD303 den-
dritic cells (DCs). CD3CD8T cells, CD3-CD56 natural killer (NK) cells and
CD19B cellswere also present to a lesser extent.WhileCD4 andCD8Tcells
and CD64macrophages could be detected in all samples, this was not the case
for the other cell types. Ascites fluids contained more podoplanin (PDPN)
tumor cells compared to pleural fluids (average 3.0% vs 0.3%). PD-1T cells and
NKcells could be detected in all pleural and 80%of the ascites samples. 64%of all
samples contained LAG-3-expressing cells, most frequently in pleural fluids. In
all samples CD4 T-cells and NK cells showed TIM-3 expression and in 82% of
the samples TIM-3 was also expressed on CD8 T-cells. In all ascites samples
PD-L1 was expressed on DCs, B cells, macrophages and PDPNMPM tumor
cells. PD-L1 was also expressed on DCs in all pleural samples while in 67%, 83%
and 83% of those samples CD19, CD64 and PDPN cells were PD-L1,
respectively. Based on the mean fluorescence intensity PDPN tumor cells
showed the highest PD-L1 expression in both fluids. In conclusion, we provide a
detailed analysis of a diversity of immune cells present in MPM fluid samples.
We are the fırst to demonstrate TIM-3 and LAG-3 expression in mesothelioma
effusions. Statistical analysis is ongoing to investigate whether there are differ-
ences between both fluid types and whether there are associations between the
cellular composition of the fluids and survival of the patients. The fınding of
expression of PD-1, PD-L1, TIM-3 and LAG-3 on immune cells in MPM fluids
warrants further investigation of the effect of immune checkpoint blockade in
MPM, with TIM-3 and LAG-3 as interesting new targets.
CLINICAL RESEARCH: Clinical Laboratory and Imaging
Correlates
#3716 Exploring the signifıcance of PARP-1 expression for therapy and
clinical PET/CT imaging of PARP-1 in ovarian cancer. Mehran Makvandi,
Austin Pantel, Lauren E. Schwartz, Kuiying Xu, Chia-Ju Hsieh, Hyoung Kim,
Shi-Hong Li, Robert Doot, Sharon Lee, Fiona Simpkins, Roger A. Greenberg,
David A. Mankoff, Robert H. Mach, Lilie Lin. University of Pennsylvania, Phil-
adelphia, PA.
Introduction: Poly(ADP-ribose) Polymerase 1 (PARP-1) is a multi-faceted
enzyme that plays a signifıcant role in DNA single-strand break and double-
strand break repair. PARP inhibitors are emerging targeted therapeutics that
inhibit the catalytic activity of PARP-1 and trap it onDNAproducing poisonous
lesions that result in cell death. While there is a vast body of pre-clinical and
clinical data supporting the use of PARP inhibitors in cancers that express ho-
mologous recombination defıciencies like mutations within BRCA1/2 genes,
there is an inadequate characterization of PARP-1 expression patterns in this
context. Through pre-clinical studies we have explored the dynamics of PARP-1
expression in response to genotoxic stress, as well as the consequences of
PARP-1 deletion for PARP inhibitor therapy inBRCA1defıcient ovarian cancer.
In parallel, our group has performed the fırst clinical PET imaging study in
epithelial ovarian cancermeasuring PARP-1 in vivo using [18F]FluorThanatrace
([18F]FTT). Methods: CRISPR/Cas9 mediated PARP1 gene deletion was per-
formed in BRCA1 defıcient ovarian cancer cell lines. Next, in vitro cell viability
assays were performed to evaluate the relative potency of clinically used PARP
inhibitors and cisplatin. Following genotoxic stress the dynamics of PARP-1
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expression were evaluated. In parallel clinical PET/CT imaging of PARP-1 was
performed in epithelial ovarian cancer patients with correlative tissue histology.
Results: Our studies indicate there is a spectrum of PARP-1 expression in epi-
thelial ovarian cancer and in vitro BRCA1mutants show higher PARP-1 expres-
sion compared to non-BRCA mutants. In addition, PARP-1 expression is re-
quired for PARP inhibitor effıcacy in vitro and is eithermore signifıcant or equal
to BRCA1 mutational status. Also, high PARP-1 expression corresponded with
platinum sensitivity in vitro. Furthermore, we observed PARP-1 expression in-
creased in response to genotoxic insult relative to DNA damage measured by
gH2AX. Lastly, our observations have been further supplemented by clinical
[18F]FTT PET/CT images in ovarian cancer patients, which showed a spectrum
of PARP-1 expression that corresponded with DNA damage measured by
gH2AX. Conclusion: PARP-1 expression has the potential to identify functional
DNA repair defıciencies and to provide a biomarker for assessing response to
DNA damaging therapies. In complement, clinical PET imaging with [18F]FTT
offers a novel technology to determine PARP-1 expression in ovarian cancer
patients and warrants further study.
#3717 New therapies for the treatment of BRAF/NRAS wild type mela-
noma.Marco Ranzani,1 Kristel Kemper,2 Magali Michaut,2 Oscar Krijgsman,2
Vivek Iyer,1 Anneliese Speak,1 Jeremie Nsengimana,3 Kim Wong,1 Vera
Grinkevich,1 Nanne Aben,2 Martin Del Castillo Velasco-Herrera,1 Clara Alsi-
net,1Marcela Sjoberg,1Mamunur Rashid,1 GemmaTurner,1 Fiona Behan,1 Em-
manuelle Supper,1Nicola Thompson,1GrahamBignell,1 KenDutton-Regester,4
Antonia Pritchard,4 Chi Wong,1 Ultan McDermott,1 Nicholas K. Hayward,4
Kosuke Yusa,1 Julia Newton-Bishop,3 Lodewyk Wessels,2 Mathew Garnett,1
Daniel Peeper,2 David Adams1. 1Wellcome Trust Sanger Inst., Cambridge,
United Kingdom; 2The Netherlands Cancer Institute, Amsterdam, Netherlands;
3University of Leeds, Leeds, United Kingdom; 4QIMR Berghofer, Medical Re-
search Institute, Brisbane, Australia.
Melanoma represents the common tumor whose incidence has increased
themost in the last 30 years and causes more than one death every hour in the
US alone. Despite signifıcant advances in targeted and immunotherapies,
most patients cannot still be cured. Our aim is to identify new drug combi-
nations that are synergistic in BRAF/NRAS wild type melanoma, a sub-type
representing 30% of cases for which targeted therapies are not currently
available. We high-throughput screened a collection of 20 BRAF/NRAS wild
type melanoma cell lines with 180 drug combinations (60 library drugs used
at 5 different concentrations combined with 3 clinically relevant anchor
drugs) and generated over 8000 survival curves . We found that 25% of cell
lines are highly sensitive to a combination of nilotinib plus trametinib and
confırmed this fınding with 2 independent assays. We further validated the
drug synergy fırstly using an independent collection of BRAF/NRAS wild
type melanoma cell lines (n7), then a collection of BRAF/NRAS wild type
patient derived xenotransplant cultures (n3), and fınally with a collection
of BRAFV600E and NRASQ61 melanoma cell lines (n12). Further, we gener-
ated a gene expression signature of cell lines that display synergy for the
nilotinib/trametinib combination, and used it to classify human melanomas
from Leeds Melanoma Project (N171) and TCGA (n470) cohorts. Tu-
mors classifıed as “synergistic-like” (27.9 and 36.7%, respectively) are asso-
ciated to decreased overall and recurrence free survival (P0.05), suggesting
that our combination might be effective in a relevant fraction of aggressive
tumors. In order to identify drug resistance mechanisms we deployed a
genome-wide CRISPR/Cas9 screen. We found that loss of the tuberous scle-
rosis complex can confer resistance to nilotinib/trametinib, and validated
this mechanism using clonal engineered lines. Since tuberous sclerosis com-
plex genes are mutated in 10% of melanomas, this approach can help to
identify patients potentially refractory to the treatment. We also investigated
the molecular mechanism of nilotinib/trametinib synergy by analysing the
level of several phosphoproteins upon treatment. We discovered that the
nilotinib/trametinib combination synergistically reduce the level of P-ERK
in synergistic cell lines but not in cell lines resistant to the drug combination,
thus pointing out the MAPK pathway dependence of the synergy. This fınd-
ing provides a putative marker to identify tumors responsive to the treat-
ment. Finally, we tested in vivo the nilotinib/trametinib combination in a
patient derived xenotransplant mouse model and showed that the combina-
tion is well tolerated and signifıcantly more effective than the 2 drugs alone
(P0.01). These data suggest a strong clinical translation potential for nilo-
tinib/trametinib combination and pave the way to the development of clin-
ical trials for BRAF/NRAS wild type melanoma.
#3719 Bicyclic peptides for PET imaging of MT1-MMP expressing tu-
mors. Daniel Teufel,1 Helen Harrison,1 Spencer Campbell,1 Catherine Stace,1
Edward Walker,1 Robert J. Lutz,1 Peter Park,1 Matthias Eder,2 Ulrike Bauder-
Wüst,2 Ursula Schierbaum,2 Karin Leotta,2 Klaus Kopka,2 Uwe Haberkorn2.
1Bicycle Therapeutics Limited, Cambridge, United Kingdom; 2German Cancer
Research Center (DKFZ), Heidelberg, Germany.
The Bicycle® technology is based on repertoires of short peptides displayed on
the surface of bacteriophages which can be modifıed with homo-trifunctional
organochemical scaffolds, thus creating large diverse libraries of constrained,
bicyclic peptides. These large combinatorial libraries have been extensively used
for iterative selections to identify high affınity binding peptides to awide array of
targets, including receptors, interleukins and proteases. Bicyclic peptides are
chemically synthesized macrocyclic entities with drug-like properties that ex-
hibit sub-nanomolar affınities and exquisite selectivity towards targets. Unlike
biologics, their synthetic nature allows facilemodulation ofmetabolic and phar-
macokinetic properties, as well as site-specifıc conjugation to effector molecules
such as fluorophores, radionuclides, and cytotoxic drugs. In the present work,
novel phage display derived bicyclic peptides were identifıed targeting the ma-
trix metalloproteinase 14 (also known as MT1-MMP), a tumor associated sur-
face protein overexpressed in a variety of cancers (i.e. lung, breast). A prototype
bicyclic peptide with high affınity to MT1-MMP (Kd at1 nM) was identifıed,
and confocal microscopy using fluoresceinated bicyclic peptide derivatives
shows target-dependent internalisation in MT1-MMP cells. In the in vivo
mouse, selective tumor binding in an MT1-MMP xenograft model is demon-
strated for a DOTA conjugate loaded with Ga-68 or Lu-177. Upon proteolytic
optimization of the prototype bicycle peptide, a striking enhancement in tumor
signal is observed in biodistribution studies. Compared to radiolabeled antibod-
ies directed against the same target, the lead compound showed fast background
clearance ( 1 %ID/g for all organs apart from kidneys) resulting in high imag-
ing contrast in PET studies as early as 30 minutes post injection. Importantly,
most of the non-tumor associated bicyclic peptide rapidly clears into the blad-
der. Together, tumor targeting bicyclic peptides can, through their small size
and high selectivity, facilitate effıcient penetration and visualization of tumors in
vivo, demonstrating their potential as diagnostic imaging agents in profıling and
therapeutic management of patients.
#3720 Biological and clinical relevance of PD-L1 expression in tumor and
inflammatory cells in NSCLC. Carlos Bais, Chris Morehouse, Brandon W.
Higgs, Rebelatto Marlon, Keith Steele, Xiaoping Jin, Li Shi, Susana Korolevich,
Ashok Gupta, Koustubh Ranade.Medimmune, Bethesda, MD.
Background: High PD-L1 expression has been shown to be associated with
improved clinical outcomes to anti-PD-1/L1 therapies in NSCLC and other
indications. However, only a fraction of the PD-L1 high patients (pts) respond.
PD-L1 can be induced by IFNG and expressed in tumor cells (TC) and inflam-
matory cells (IC). Improving our ability to predict patient benefıt from anti-PD-
1/L1 therapies requires a better understanding of associations between PD-L1
expression in TC and/or IC and outcome. Here we explore the relationship
between patterns of IHC PD-L1 expression in TC and IC, gene expression, and
clinical outcome.Methods: CP1108/NCT01693562was a nonrandomized phase
1/2 trial evaluating durvalumab in pts with advanced NSCLC or other solid
tumors. As of 29 APR 2016, 368 previously treated NSCLC pts received dur-
valumab12months with a median 18.8 months follow up. Pts with25% TC
or IC were scored TC and/or IC, respectively. Results: TC PD-L1 pts
(includes IC and IC- PD-L1 pts) had improved survival compared to TC-
PD-L1 pts. TC and ICPD-L1 pts had: improved survival compared to TC/
IC-, TC-/IC, or TC-/IC- PD-L1 pts. However, prevalence of TC/IC was
lower than TC. Twenty-one genes signifıcantly differed between TC/IC,
TC/IC-, TC-/IC, andTC-/IC- PD-L1patient subsets, the vastmajority being
well-known IFNG-inducible genes andmostly over-expressed in the TC/IC
subset. Conclusions: TC and IC PD-L1 pts had the highest levels of IFNG-
inducible gene expression, a key biological feature that distinguishes PD-L1 IHC
positive from negative pts. Thus, in addition to PD-L1 IHC, the predictive value
of IFNG should be investigated in additional relevant studies.
Selection
Criteria
Prevalence of
Biomarker
Positive
BiomarkerPositive/
negative
median OS log-rank p HR cox p
TC 158/276(57%) 15.67/7.73 0.0091 0.69 0.046
TC/IC 70/276(25%) 25.63/8.37 7.46E-06 0.34 5.24E-05
TC/IC- 88/276(32%) 10.5/13.97 0.094 1.5 0.032
TC-/IC 50/276(18%) 9.07/13.23 0.83 0.96 0.84
TC-/IC- 68/276(25%) 5.77/14.03 0.00084 1.66 0.012
All comers: median OS: 11.2 months (N304)
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#3721 DLL3 analysis of circulating tumor cells predict treatment outcome
in phase 1 rova-T study in small cell lung cancer. Somdutta Roy, Kevin Mar-
tinez, Archana Dilip, Holger Karsunky, Scott Dylla. Abbvie Stemcentrx, South
San Francisco, CA.
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with
early dissemination and poor prognosis that accounts for 15-20% of all lung
cancer cases worldwide. Most cases are inoperable and biopsies to investigate
SCLC biology are rarely obtainable. Circulating tumor cells (CTCs), which are
prevalent in SCLC, present a readily accessible liquid biopsy. Here we present
CTC data from aggressive, late stage SCLC patients who were enrolled on a
Phase 1 trial studying Rova-T (anti-DLL3 antibody drug conjugate). CTCs were
captured using a microfluidic platform (IsoFlux) that uses flow control and
immunomagnetic capturing of epithelial cell surface marker (EpCAM)-positive
cells. CTCs were isolated before dosing (baseline) of Rova-T and at successive
time points post treatment. CTCs from each time point were distinguished and
enumerated using DAPI, EpCAM and the cytoplasmic marker (pan-CK), in
addition to the absence ofCD45. EnrichedCTCswere also collected for RT-PCR
for expression analysis of genes confırmed to be absent in blood cells. The num-
ber of CTCs varied among the 58 baseline samples collected, ranging from
5-1000 CTCs per 7.5ml of blood.When the CTCs were assessed for DLL3 target
expression, 37/58 baseline samples expressed DLL3 by RT-PCR. Interestingly,
the expression of DLL3 on the baseline CTCs correlated with treatment out-
come.When additional time points after treatment were enumerated for CTCs,
patients that presented with DLL3 expression on CTC at baseline showed a
signifıcant decrease in CTCs after treatment. This suggests that Rova-T might
kill DLL3-expressing CTCs. These data support continued investigation of
DLL3 expression on CTC in SCLC patients with the goal of facilitating a liquid
biopsy able to assess DLL3 status as a prospective companion diagnostic for
Rova-T.
#3722 In vitro induced regulatory T cells for understanding the nature of
peripherally induced regulatory cells in relation to cell mediated immuno-
therapy for cancer.Upendra P.Hegde, NityaG. Chakraborty.Univ. of Connect-
icut Health Ctr., Farmington, CT.
Background: pTregs are appearing to be one of the major obstacles of cellular
immunotherapy of cancer. Tumor specifıc in vivo inducedCytotoxic T lympho-
cytes (CTL) are rapidly eliminated with concomitant expansion of pTreg cells.
In humanmelanoma in ex vivo condition, tumor antigen specifıc CTL generated
with CD8 cells persisted for months while ex vivo induced CTL with whole
PBL stimulatedwithMart-127-35 A2 (tumor antigen) pulsed autologousDC, died
within three weeks. Whereas Influenza (Flu 58-66) antigen specifıc CTL contin-
ued to expand and remained functional beyond four weeks. Method: Peripheral
blood and tumors were obtained from patients diagnosed with metastatic mel-
anoma after informed consent. Blood derived dendritic cells, PBL, CD4 and
CD8 cells were isolated for in vitro co-cultures with Mart-1 or Flu peptide
pulsed autologous DC or autologous tumor cells. CD8 CTL response and
CD4 positive Treg responses were measured. Freshly obtained tumor tissue
derived lymphocytes (TIL) were also used for the study. Results: Our results
show that CTL response against Flu survived longer in culture with total PBL
thanCTL response againstMart-1 in identical culture conditions. CTL response
using autologous tumor cells with PBL in culture lasted for a shorter duration
but growth of Treg cells were observed. Cytokine analysis with expanding Treg
cells showed secretion of IL-10 upon re-stimulation with autologous DC or
anti-CD3 ab. Similarly, CD4 cells isolated from freshly obtained tumor tissue
(TIL, representing in vivo condition), suppressed T cell activation and secreted
high amount of IL-10 upon re-stimulation. Conclusion: These fındings sug-
gested that in vitro induced iTreg from cultures or pTreg from TILs (in vivo),
work identical way, to negatively regulate effector immune response by secreting
IL-10. Further analysis with iTregs for their use of metabolic pathways would be
important to identify the specifıc signaling molecules used by autologous (per-
son specifıc) pTregs , as target molecules, to block the expansion of such pTregs
for the better outcome for CTL mediated immunotherapy for cancer.
#3723 Assessing the reproducibility of computer-aided nodule assess-
ment and risk yield (CANARY) method to characterize lung adenocarcino-
mas. Erica C. Nakajima,1 Michael P. Frankland,2 Tucker Johnson,3 Sanja L.
Antic,1 Ronald A. Karwoski,3 Bennett Landman,1 Heidi Chen,1 Ronald C.
Walker,1 Brian J. Bartholmai,3 Tobias Peikert,3 Srinivasan Rajagopalan,3 Pierre
P. Massion,1 FabienMaldonado1. 1Vanderbilt University Medical Center, Nash-
ville, TN; 2Vanderbilt University, Nashville, TN; 3Mayo Clinic, Rochester, MN.
This study assessed the inter-user reproducibility of Computer-AidedNodule
Assessment and Risk Yield (CANARY), a novel analytical tool that risk stratifıes
lung adenocarcinomas (ADCs) according to defıned computed tomography
(CT) structural characteristics. CANARY detects nine distinct voxel signatures
in ADCs based on standard CT imaging, thereby defıning nodule characteristics
correlating with patient outcomes, and corresponding to invasion or lepidic
growth histologically. A software user segments the borders of each ADC prior
to voxel analysis, introducing potential variability into the assessment. While
CANARY is a promisingmethod, it requires validation of the analytical variabil-
ity between users and prediction of accuracy in an independent cohort. To
evaluate the reproducibility of CANARY analysis, three independent users who
are not part of the CANARY development team segmented and analyzed 50
biopsy-confırmed primary lung ADCs from Vanderbilt University Medical
Center. The CT scans of ADCs were selected retrospectively based on the fol-
lowing criteria: ADC-histology proven on biopsy, diagnosed between 2009-
2015, less than 3cm in greatest diameter, and stages IA-IV. Users followed a
standard operating procedure established at the Mayo Clinic, and were blinded
to clinical characteristics and patient outcomes. Results: To measure inter-user
variability of ADC voxel composition, the intraclass correlation coeffıcient
(ICC)was calculated based upon the percentage of each voxel subtypewithin the
whole ADC. An ICC of 1 reflects high reproducibility between users. Amongst
all 50 ADCs, the average ICC for all nine voxel types was 0.828 (95% CI 0.76,
0.895). The ICC of the four voxel types associated with invasive features on CT
was 0.865 (95% CI 0.805, 0.924). ICCs were also calculated using a logarithmic
transformation for data normalization, generating an ICC of 0.745 (95% CI
0.663, 0.826) for all nine voxel types, and an ICC of 0.995 (95% CI 0.993, 0.997)
for the four voxel types associated with invasion. Conclusions: (1) CANARY
analysis of lungADCvoxel signatures appears to be reproducible amongst users,
making it a reliable tool for the evaluation of ADC voxel density. (2) Correlation
of invasive signatures associated with more aggressive ADCs was nearly perfect
amongst users. Additional validation metrics for CANARY with larger datasets
are being evaluated, including the accuracy of tumor prognostic predictions
between users and analysis of ADC datasets from other institutions.
#3724 PDL1 protein expression and tumor mutation burden in hemato-
logic malignancies: correlation with Hodgkin and high grade lymphoma.
Lina Abdul Karim,1 Peng Wang,1 Jose de Guzman,1 Brandi Higgins,1 Joeffrey
Chahine,1 Christine Sheehan,2 Bhaskar Kallakury,1 Jeffrey S. Ross2. 1Medstar
Georgetown University Hospital, Washington, DC; 2Albany Medical College, Al-
bany, NY.
Background: The success of anti PD–1 therapy inHodgkin lymphoma has led
to clinical trials in other types of lymphomas. However, there is limited data on
PD–L1 expression in acute leukemias. In this study, we analyzed PD–L1 protein
expression and tumor mutational burden in various hematologic malignancies
including leukemias, lymphomas and myelomas. Methods: In the IHC cohort,
formalin fıxed paraffın embedded sections from 92 hematologic malignancies
including acute myeloid and lymphoblastic leukemia (AML, ALL), Hodgkin
lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), low-grade non-
Hodgkin lymphoma (LGNHL) and myeloma were immunostained using the
FDA approved PD-L1 IHC 22C3 pharmDx assay [monoclonal mouse anti-
PD–L1 antibody (DAKO clone 22C3)]. Any perceptible partial or complete
membrane staining in all viable tumor cells was scored as follows: 1%-nega-
tive, 1-49%-low level and 50%-high level PD-L1 expression. In the second
cohort of 2064 cases, comprehensive genomic profıling (CGP) was performed
using a hybrid–capture, adaptor ligation assay to a mean depth of672X. Tu-
mor mutation burden (TMB) was calculated from a minimum of 1.11MB of
sequenced DNA as previously described and reported as mutations/MB. High
PD–L1 expressionwas noted in 100%ofHL.DLBCL showed signifıcantly higher
PD–L1 positivity compared to LGNHL (p0.01). No correlation for PD–L1
expression was noted between AML and ALL (p 0.2). On CGP analysis of the
second cohort, TMBwas signifıcantly higher inDLBCL as compared to LGNHL
(p0.0001). Conclusion: The high PD-L1 expression in both HL and DLBCL
and high TMB in DLBCL may be linked to enhanced responsiveness to check
point inhibitor therapy in these cancers. PD-L1 expression and TMB are rela-
tively infrequent and at low levels in acute leukemias. Additionally, novel anti
PD–1/PD–L1 therapeutic strategies are worthy of consideration for both ad-
vanced stage refractory/relapsed acute myeloid and lymphoblastic leukemias.
Results: PD-L1 expression and TMB are tabulated below.
PD-L1 IHC TMB (mutations/MB)
Tumor
type n
Low
Positive
High
Positive
Total
Positive (%) n >10.0 >20.0
AML 21 5 0 5/21(24%) 5 0% 0%
ALL 32 12 0 12/32(38%) 1 0% 0%
HL 10 0 10 10/10(100%) 36 8% 8%
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Results: PD-L1 expression and TMB are tabulated below.
PD-L1 IHC TMB (mutations/MB)
Tumor
type n
Low
Positive
High
Positive
Total
Positive (%) n >10.0 >20.0
DLBCL 10 4 4 8/10(80%) 253 44% 15%
LGNHL 10 2 0 2/10(20%) 93 0% 0%
Myeloma 9 2 0 2/9(22%) NA NA NA
#3725 Neoadjuvant everolimus as a targeted therapy for early stage breast
cancer. Bing Xu, Casey Williams, Brian Leyland-Jones. Avera Cancer Institute,
Sioux Falls, SD.
Introduction: Everolimus is an oral mTOR inhibitor. It is used for its antitu-
mor effect in breast cancer. This study summarizes the clinical outcomes and
noted adverse events from sequencing-derived combination treatments that in-
clude everolimus in the neoadjuvant setting. Material andMethods: To date, 57
breast cancer patients have been enrolled to clinical trial NCT02470715 and
treated in the neoadjuvant setting. The data presented here focus specifıcally on
17 patients that have long enough follow up and that have been treated with
everolimus-based combinations. FoundationOne© test and Theralink© assay
was used for genomic profıling and proteomic analysis respectively. Clinical
outcomeswere assessed at the time of surgery. A pathological complete response
was defıned as the absence of residual disease. Results: Everolimus was pre-
scribed for the patients in this study based on the fındings from their genomic or
proteomic testing, targeting PI3K/AKT/mTORpathway. The evidence for using
everolimus in ER patients (n13) includes alterations in PIK3CA (n9),
PTEN (n3), FGFs (n2), and phospho-S6 ribosomal protein (Ser235/236).
4E-BP1 (phospho-S65) was targeted in the Her2 (n1) patient. PIK3CA
(n2) and PIK3C2B (n1) presented in the 3 triple negative (TN) patients.
Everolimus and paclitaxel was used in all patients as the backbone combination
while trastuzumab was added for Her2 patients and hormonal therapy was
added for ER patients. Aromatase inhibitors were used in most of the cases as
hormonal therapy in ER patients while goserelin was used in 3 cases for pre-
menopausal patients. Pazopanib and trametinib were added to two of the TN
patients and palbociclib was added for one ER /Her2- patient targeting other
alterations. From the 17 patients (clinical stage I to III) treated with everolimus
in the neoadjuvant setting, pathological complete response was achieved in 4
(23%) patients (2 ER, 1 Her2 and 1 TN). 65% (n11) patients had partial
response (10 ER, 1 TN). Only one TN patient did not response to the neoad-
juvant treatment. Over half of the patients (59%) tolerated the treatment well
while 6 patients (35%) developed adverse events which resulted in a change of
regimen.Grade 3 and above adverse events includingmucositis, cough and fever
were observed in ER/Her2- patients who were treated with everolimus 
paclitaxel hormonal therapy. The symptoms were managed by a dose reduc-
tion or a period of treatment hold. One ER/Her2 patient treated with
everolimuspaclitaxel anastazole trastuzumabdeveloped aUTI, diarrhea,
mucositis and edema after 7 weeks of treatment. Treatment was stopped in this
case. Conclusion: Based upon our fındings, everolimus is an effective drug in the
neoadjuvant treatment of early stage breast cancer. Even though the numbers
are small, our outcomes show signifıcant promise. Adverse events related to the
treatment were manageable and did not negatively impact our ability to give the
treatment in most cases.
#3726 INCB52793 JAK1 inhibitor synergizes with ATRA to inhibit ex-
pansion of AML. Haley E. Ramsey,1 P. Brent Ferrell,1 Melissa A. Fischer,1 Ag-
nieszka E. Gorska,1 Caroline Maier,2 Jeremy Norris,2 Melissa Farrow,2 Danielle
Guiterrez,2 James Pino,2 Sandra Zinkel,1 Carlos Lopez,2 Holly Koblish,3 Mat-
thew Stubbs,3 Peggy Scherle,3 JonathanM. Irish,2 Richard Caprioli,2 Michael R.
Savona1. 1Vanderbilt UniversityMedical Center, Nashville, TN; 2Vanderbilt Uni-
versity, Nashville, TN; 3Incyte Corporation, Wilmington, DE.
Dysregulated JAK/STAT signaling is known to drive myeloproliferative neo-
plasms, and targeting JAK1 and JAK2 has led to improvement in morbidity and
mortality in these diseases. While dose-dependent anemia and thrombocytope-
nia limit the use of JAK2 inhibition, selectively targeting JAK1 has been explored
as a means to suppress inflammation and STAT-associated neoplastogenesis.
Recently, INCB52793 was found to be 100-fold selective for JAK1 over JAK2,
and it has recently been explored in the clinic in solid tumors and acute myeloid
leukemia (AML). In a large high throughput screen, we detected synergistic
effects between INCB52793 and all-trans retinoic acid (ATRA) in several non-
promyelocytic AML cell lines. In another in vitro assay, human primary AML
blasts exposed to INCB52793 exhibited a marked increase in both CD13 and
CD86, two markers indicative of cellular differentiation. Given these fındings,
we tested this combination in an in vivo murine model of AML. Human leuke-
mia cells were injected into the tail vein of sublethally irradiated NSGS mice
which were then treated days 7-35 post-transplant with ATRA, INCB52793,
ATRA/INCB52793, or vehicle. Weekly monitoring for peripheral human
CD45 cells revealed that the INCB52793/ATRA combination effectively de-
creased the expansion of leukemic cells. At 35-40 days, signifıcant decreases in
tumor burden were seen within the bone marrow (BM) and spleens of
INCB62793/ATRA treated mice. Bone marrow and splenic cells were also ana-
lyzed by mass cytometry, simultaneously measuring 35 signaling, differentia-
tion, and cell death attributes per-cell. The few remaining human cells in the
INCB62793/ATRA combo group synergistically displayed 30-fold decreases in
CD38, 8-fold increases in CD34, and attained high levels of p-STAT3 and p-
STAT5, potentially implying a resistant progenitor population. Label free pro-
teomics revealed signifıcant fold changes in in vitro INCB52793/ATRA treated
cells. Proteins related to cellular differentiation mechanisms, such as SMAD3,
BCL11A, RUNX2, HNRNPLL, and SAMHD1, were elevated between 24 to 48
hours post treatment supporting our hypothesis that JAK1 inhibition enhanced
ATRA induced differentiation. Targeting retinoic acid receptor and JAK1 to-
gether synergistically resulted in the decreased expansion of multiple AML cell
lines, and preferential reduction of AML cells from the blood, spleen and bone
marrow of treated mice in vivo. Common CD34-CD38 tumor cells were elim-
inated, and rare remaining CD34 AML cells displayed high p-STAT3 and
p-STAT5 levels after INCB52793/ATRA therapy.While ATRA is a critical com-
ponent in the therapy of acute promyelocytic leukemia (M3), it has not been
successfully employed in other AML. These preliminary data represent a poten-
tial for INCB52793/ATRA therapy in non-M3 AML.
#3727 Plasma inhibitory activity (PIA) is a possible pharmacodynamic
marker for clinical development of a next generation pan-TRK inhibitor,
ONO-5390556. Ryohei Kozaki, Ryu Fujikawa, Hikaru Kato, Natsuka Goto,
Toshio Yoshizawa. Ono Pharmaceutical, Osaka, Japan.
Background: Colorectal cancer andMammary analogue secretory carcinoma
harboringNeurotrophic tyrosine receptor kinase (NTRK/TRK) gene rearrange-
ments developed resistance to Entrectinib, ALK/ROS/TRK inhibitor.We previ-
ously demonstrated that the next generation pan-TRK inhibitor,ONO-5390556
may potently overcome Entrectinib-resistance mutations. Furthermore, inhibi-
tion of Trk phosphorylation in tumors has excellent correlation with the in vivo
anti-tumor effect by ONO-5390556 (AACR2016, Kozaki et al). Purpose: Accu-
rate measurement of target inhibition in a phase 1 clinical trial is critical to
informing selection of appropriate doses for ONO-5390556 in more advanced
clinical trials. Plasma inhibitory activity (PIA) assay has recently been per-
formed as a surrogate assay in clinical trials of FLT3, MET and ALK kinase
inhibitors. The assay employs the incubation of Tyrosine Kinase expressing cell
lines in aliquots of plasma collected at various time points from patients treated
with TKI. Herein, we report the preclinical evaluation of PIA assay in accor-
dance with an inhibition of TRK phosphorylation in tumors. Methods: KM12
cells, human colorectal cancer cell lines expressing TPM3-TRKA, were im-
planted subcutaneously into nude mice. Mice were randomized when the mean
tumor volume was 150-600 mm3. Tumors and blood were collected frommice,
2, 4, 7 and 24 hours after the single treatment of ONO-5390556 with the doses of
0.06 and 0.6 mg/kg. The collected tumors were disrupted and phosphorylated
TrkA in tumors was detected by Electrochemiluminescence (ECL). In a PIA
assay, KM12 was incubated in plasma from the collected blood for 4 hours and
phosphorylated TrkA in the cells was detected by ECL.. Results: Treatment with
ONO-5390556 at doses of 0.06, 0.6 mg/kg resulted in a signifıcant inhibition of
Trk phosphorylation in tumors up to 24 hours. Compared to inhibition of P-
TRK in tumors, the inhibition of P-TRK in PIA sustained until 7 hours but
rapidly decreased at 24 hours after administration. The levels of both tumors and
PIA showed in a dose-dependent inhibition and an excellent correlation until 7
hours. Inhibition of TRK phosphorylation (PIA/Tumor, %)0.06 mg/kg
(2,4,7,24h) : 56.3/41.4 (PIA/Tumor, %), 51.9/53.5, 43.0/66.5, -5.5/51.30.6 mg/kg
(2,4,7,24h) : 90.2/84.3, 88.4/93.0, 87.4/95.7, 8.3/83.3Conclusion: We have vali-
dated the PIA assay that correlates with the inhibition of P-TRK in tumors. Our
results demonstrated that the potential utility of PIA as a PD marker may con-
tribute to determining the effective dose of ONO-5390556 in the clinical devel-
opment.
#3728 Imaging biomarkers of aromatase-inhibitor induced joint pain.Brian
A.Goldstein,MihraTaljanovic, PavaniChalasani,C.KentKwoh,AmandaHadden,
RussellWitte, JessicaMartinez.University of Arizona, Tucson, AZ.
Estrogen receptor positive (ER) breast cancer patients undergoing treat-
ment with aromatase inhibitors (AI) tend to discontinue the supplement
when to painful side effects appear. It is believed that women with AI-in-
duced musculoskeletal syndrome (AIMSS) have specifıc physiological con-
ditions that differentiate them from women with normal aging-related in-
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flammatory processes (e.g., rheumatoid arthritis or RA). Ultrasound shear
wave elastography (USWE) provides a real-time, quantitative assessment of
the elastic modulus of soft tissue, which is a potential biomarker that is
altered in women with AIMSS. Because USWE is a completely noninvasive
technique available on state-of-the-art clinical ultrasound scanners, it can be
readily applied to study patients who undergo AI treatment and help predict
adverse effects during therapy. A Siemens s3000 clinical scanner and 9 MHz
linear probe were used for USWE of the hands and wrists in postmenopausal
women on AI, postmenopausal women with RA and healthy postmeno-
pausal women. The scans included an evaluation of major wrist tendons,
nerve, and joints with shear wave velocities ranging from 0.5 to 15 m/s,
which are directly related to the local shearmodulus – an absolute measure of
tissue stiffness. The ultrasound images and raw shear wave data were then
analyzed in MATLAB-TM using a custom graphical user interface (GUI) to
calculate the distribution of velocities (or shear moduli) in a user-defıned
region of interest (ROI). The results were exported to a spreadsheet in Excel
for further analysis and comparison among the different groups. Initial re-
sults suggest the shear wave velocity and estimated Young’s modulus ()
were signifıcantly higher in AI patients (14.6 	 0.2 m/s, 642 	 17 kPa)
compared to RA (6.84 	 1.1 m/s, 143 	 43 kPa) and healthy (7.58 	 0.9
m/s, 174 	 42 kPa) patients. These values suggest that the mechanical
properties of tendons in the wrist may change during treatment with AI and
contribute to joint pain in these subjects. It is critical that ER patients on AI
complete their full treatment. As a potential biomarker of AIMSS and asso-
ciated pain, USWE may help predict which patients are most susceptible to
these side effects, promote early intervention to reduce or eliminate symp-
toms, and help increase adherence to AI therapy.
#3729 Tumor-specifıc antibody labeling of pancreatic cancer in a patient-
derived orthotopic xenograft (PDOX) mouse model using a fluorescent hu-
manized anti-CEA antibody. Thinzar Lwin,1 Takashi Murakami,1 Robert M.
Hoffman,1 Paul J. Yazaki,2Michael Bouvet1. 1University of California, SanDiego,
La Jolla, CA; 2City of Hope Medical Center, Duarte, CA.
Introduction: Delineation of tumor margins is critical in oncologic surgery,
particularly in resection of pancreatic cancer. Surgeons are limited in visualiza-
tion with bright light surgery. Fluorescence guided surgery (FGS) can help sur-
geons better visualize all potential cancer cells during the operation. In the pres-
ent study, we show that the use of an anti-CEA antibody conjugated to an 800
nm NIR fluorescent dye can selectively label pancreatic cancer in both pancre-
atic cancer cell lines and patient derived xenograft mouse models (PDOX). Ma-
terials/Methods: BxPC3-GFP cells or pancreatic cancer tissue specimens were
grafted into flanks of nudemice. Both types of tumorswere allowed to growuntil
1 cm. Fragments tumors (2 mm3) were grafted onto the pancreatic tail of recip-
ient mice to create PDOX models. After tumors reached 7-10mm in size, 75 ug
of Anti-CEA-800 dye was injected into the tail-vein (LI-COR 800 CW IRDye®,
Lincoln, NE). Mice were imaged via the Maestro CRI imaging system (Perkin
Elmer, Waltham, MA) 24 hours after injection. Results: Images obtained after
fluorescent antibody injection showed that anti-CEA-800 specifıcally labeled
both the cell-line-derived tumors and patient-derived tumors with an adequate
tumor to background contrast at 24 hours. The dye co-localized with GFP in
tagged tumor cells lines. GFP fluorescence had poor penetration if covered by
overlying tissue, which was not an issue with the anti-CEA-800 dye. The dye
allowed clear identifıcation of the tumor and tumormargin. In theBxPC-3 based
tumor, the dye allowed identifıcation of a small 1mmsatellite lesion in the spleen
that would otherwise have been missed. Conclusions: Fluorescent humanized
anti-CEA-800 antibody specifıcally labeled orthotopically implanted pancreatic
cancer xenografts from cell lines and patient derived tissue. Tumor-specifıc flu-
orescence imaging clearly identifıed the primary tumor and satellite lesion. The
800nm wavelength allowed deeper tissue penetration, particularly in areas of
tumor covered by normal pancreatic parenchyma. Humanized anti-CEA anti-
bodies conjugated to a radio-labeling agent and LI-COR 800 dye is already in
Phase I/II trials. Humanized anti-CEA conjugated with the IR-800 dye is a
promising agent for future clinical FGS applications.
#3730 Early metabolic response to tumor-treating fıelds in patients with
recurrent glioblastoma. Sandeep Mittal, Geoffrey R. Barger, Edit Bosnyák,
Varun B. Shah, Csaba Juhász.Wayne State University, Detroit, MI.
PURPOSE. Tumor-Treating Fields (TTFields) is an FDA-approved treat-
ment approach for patients with both newly-diagnosed and recurrent glioblas-
toma. The main purpose of the present study was to explore if amino acid
positron emission tomography (PET) is able to detect an early, objective meta-
bolic tumor response during the fırst months of TTFields therapy. METHODS.
Patients with MRI signs of recurrent glioblastoma eligible for TTFields along
with maintenance temozolomide were recruited for PET scanning with al-
pha[C-11]-methyl-L-tryptophan (AMT) at baseline (before start of TTFields
application) and up to 3 months later. Serial MRIs were also performed in 1-2
months intervals. AMT accumulation in the MRI-detected tumor mass was
measured by standardized uptake values (SUVs), and PET-based tumor vol-
umes were also calculated. Interval changes of these PET variables were com-
pared to changes in areas of MRI enhancement. RESULTS. Out of 7 recruited
patients, 5 showed appropriate compliance (75%) with the device and under-
went follow-up PET. Four of the 5 patients showed a clear metabolic response
during TTF treatment on PET imaging. Two patients, who received TTFields
treatment only (in addition to maintenance temozolomide), showed 25% and
100% decrease of PET-based tumor volumes, respectively. MRI was stable (pa-
tient #1) or showed increasing contrast enhancement (#2) during the same pe-
riod. In this latter patient, TTFields was continuedwith bevacizumab treatment,
leading to decreased contrast enhancement and further decrease of AMTuptake
on a second follow-up PET. In two other patients (#3 and #4), TTFields were
combined with bevacizumab rescue treatment. Patient #3 showed a markedly
decreased tumoral AMT uptake and metabolic volume along with stable MRI
enhancement. Patient #4 showed interval decrease of tryptophan PET uptake 2
months after initiation of TTFields therapy. Finally, patient #5 showed an inter-
val expansion of the PET-based tumor volume along with MRI progression
during a 2-month follow-up despite TTFields combined with bevacizumab and
carboplatin. CONCLUSIONS. This is the fırst study to demonstrate an objective
metabolic response of recurrent glioblastoma within 1.5-3 months after initia-
tion of TTFields. The data suggest that amino acid PET can identify early re-
sponders to TTFields therapy.
#3731 A novel multidimensional cfDNA assay for real time analysis of
chemotherapy response. Pavan P. Shah, Katherin Patsch, Naim Matasci, An-
jana Soudararajan, Patricia Diaz, David B. Agus, Daniel Ruderman, Mitchell E.
Gross. Lawrence J. Ellison Institute for Transformative Medicine of USC, Los
Angeles, CA.
Due to its non-invasive nature and transient lifespan (30mins), circulating cell
free DNA (cfDNA)may provide novel insights into cancer evolution and response
to therapy. Here, we have developed a multidimensional cfDNA assay to measure
patients’ responses to chemotherapy on a time scale that would be impossible using
traditional biopsy methodologies. We extracted cfDNA from plasma collected im-
mediately before and after infusion of cytotoxic chemotherapy, and 24 hours after
treatment.We developed assays to (1) quantify cfDNA via qPCR of a 288 base pair
amplicon of Long InterspersedNuclear Elements (LINE1), (2) determine theDNA
Integrity Index based on additional analysis of 115bp and 516bp LINE1 amplicons,
and (3) analyze androgen receptor exon 8 via targeted deep sequencing. We ana-
lyzedcfDNAextracted from17patientswithmetastatic castration-resistantprostate
cancer through sequential application of these 3 assays. Median PSA levels were 69
(0-2223)ng/dl,Hgb12(8.2-15)g/L,AlkPhos117(35-879) IU/mL.Deepsequencing
ofARexon8 revealed 6 of the 17patients presentedwith 1-2 SNVs (H874Y,T877A,
D890HorD879Y) at1% frequency. Considering LINE1 quantifıcation alone, the
average change pre/post chemotherapy was 38.78 pg/mL (0.5-292.0 pg/mL). A va-
riety of responses was noted including: 8 of the patients expressed elevated LINE1
levels post-treatment when compared to baseline, and 5 expressed depressed levels.
Importantly, therapy did not affect tumor subclones equally, as demonstrated by
sequencing and quantitation of mutant AR exon 8 species. Additional data on
changes inDNA Integrity Indexwill be presented.We conclude that cytotoxic che-
motherapy produces immediately observable effects on cfDNA. The effect of do-
cetaxel chemotherapy on distinct clones within the tumor can be measured within
hours. Now that a short-time dynamics response has been demonstrated, follow up
studieswill beperformed involvingmorepatients todetermine theprognosticvalue.
#3732 Analytical performance of TruSight® Tumor 170 on small nucleo-
tide variations and gene amplifıcations usingDNA from formalin-fıxed, par-
affın-embedded (FFPE) solid tumor samples.DannyChou, XiaoChen,Austin
Purdy, Li Teng, Byron Luo, Chen Zhao, Laurel Ball, Allan Castaneda, Katie
Clark, Brian Crain, Anthony Daulo, Manh Do, Tingting Du, Sarah Dumm,
Yonmee Han, Michael Havern, Chia-Ling Hsieh, Tingting Jiang, Suzanne Jo-
hansen, Scott Lang, Rachel Liang, Jennifer S. LoCoco, Jaime McLean, Yousef
Nassiri, Jason Rostron, Jennifer Silhavy, June Snedecor, Natasha Talago, Kevin
Wu, Clare Zlatkov, Ali Kuraishy, Karen Gutekunst, Sohela De Rozieres, Mat-
thew Friedenberg, Han-Yu Chuang, Anne C. Jager. Illumina, San Diego, CA.
Expanding the paradigm of solid tumor profıling from single-gene testing
to comprehensive panels presents many challenges. One such challenges is
the ability of these panels to detect genetic alterations from FFPE samples,
where the DNA is of low abundance and often heavily compromised. Despite
these challenges, next-generation sequencing (NGS) offers the ability to as-
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sess multiple variants simultaneously in an ever-expanding list of relevant
tumor genes. To that end, Illumina developed a comprehensive, hybrid cap-
ture-based NGS assay targeting 170 key cancer genes that is FFPE optimized.
The assay consists of a DNA workflow for the identifıcation of single and
multiple nucleotide variants (SNVs, MNVs), small insertions and deletions
(indels), gene amplifıcations, as well as a RNAworkflow for the identifıcation
of splice variants and gene fusions. Following sequencing on the NextSeq® or
HiSeq® instruments, the analytical pipeline initiates variant calling. The
DNA aligner and variant callers were fırst optimized against the simulated
read data from40,000 COSMIC[1] mutations reported in the exons of the
170 genes. To reduce false positive variant calling due to systematic errors,
each variant call was evaluated against its locus specifıc background error
distribution. This distribution was compiled from a panel of FFPE normal
samples and was also used to normalize against systematic bias in read cov-
erage to increase the accuracy of amplifıcation calling. Furthermore, gene
amplifıcation calling was improved by the addition of enhancer probes to the
hybrid capture pool. The analytical sensitivity and specifıcity of TruSight®
Tumor 170* was assessed on a large collection of FFPE samples and reference
material. A panel of 72 cancer samples, including multiple tissue types, ref-
erence standards, and cell line and FFPE mixes were used to evaluate the
limit of detection. The samples contained 533 SNVs, 80 indels including
deletions up to 30 base pairs and insertions up to 31 base pairs, 4 MNVs, and
31 gene amplifıcations, characterized by orthogonal testing methods. Using
40 ng DNA input, detection sensitivity of the 1000 variants (including
replicates) tested at variant allele frequencies down to 5% was at 99.6%,
while detection sensitivity of gene amplifıcations as low as 1.45x to 2.2x was
at 98%. For limit of blank samples, a panel of 24 normal samples was used.
Again using 40 ng DNA input, we show 99% specifıcity for small variant
calling and95% specifıcity for gene amplifıcation calling. These data dem-
onstrates the TruSight® Tumor 170 is able to detect multiple variant types
within a single sample at low nucleic acid input, while exhibiting high ana-
lytical sensitivity and specifıcity for low allele fraction detection. [1] Forbes,
et al. (2015) *For Research Use Only. Not for use in diagnostic procedures.
#3733 Adenine nucleotide translocase2 mediates 18F-FDG uptake in ded-
ifferentiated thyroid cancer. Chul-Hee Lee, Hyewon Youn, Seock-Jin Chung,
Ha Kim, Cho Rong Park, Mi Jeong Kim, Young Joo Park, SunWook Cho, Keon
Wook Kang, June-Key Chung. Seoul National University, Seoul, Republic of Ko-
rea.
Objectives: 18F-fluorodeoxyglucose (FDG), an analogue of glucose, provides
valuable functional information based on the increased glucose uptake and gly-
colysis in malignant tumor cells. Although both glucose transporter-1
(GLUT-1) and hexokinase2 (HK2) activity have been considered to associate
with FDG uptake, the molecular mechanisms that determine FDG uptake are
still largely unknown. Adenine nucleotide translocase 2 (ANT2) in the mito-
chondria inner membrane was reported to relate with tumor malignancy. We
investigated the correlation between FDG uptake and Glut-1, HK2, and ANT2
expression in thyroid cancers throughout various spectrums of differentiation
status. Methods: N-thy-ori (normal human thyroid cells), WRO (follicular can-
cer), BHP10-3 and TPC-1 (papillary cancer), and FRO (anaplastic cancer) were
used for this research. GLUT-1, HK2, and ANT2 expressions were measured by
western blot. ANT2 siRNAs and pcDNA3.1-ANT2 vectors were used to modify
ANT2 expression. FDG uptakes were measured in thyroid cells and human
embryonic kidney cells (293FT) with HK2 or ANT2 transfection. For patient
tissue analysis, 95 thyroid tissue-array cores were evaluated, and which are clas-
sifıed 36 as normal, 44 as poorly differentiated (PD), and 15 as anaplastic thyroid
cancer (ATC). ANT2 expression was measured by immunostaining, scored
from 1 to 5. Results: FDG uptake in thyroid cancer cells was increased in ana-
plastic andpoorly differentiated cells (P0.001).GLUT-1 expressionwas higher
in both TPC-1 and FRO than other cells. Whereas, HK2 was expressed only in
cancer cells. ANT2 was expressed only in FRO cells and the highest FDG accu-
mulation was also observed in FRO. ANT2 siRNA showed decreased FDG up-
take (0.55-fold) and ANT2 overexpression increased FDG uptake (1.7-fold). In
293FT cells, HK2 and ANT2 transfection increased FDG uptake (P0.01). PD
tissues (mean  41.7, SD  19.7) and ATC (mean  48.0, SD  25.6) tissues
from patients showed higher ANT2 expression than normal (P0.05). Conclu-
sion: We showed that ANT2 was expressed only in anaplastic thyroid cancer
cells, and this was related to FDG uptake. Higher level of ANT2 expression was
observed in dedifferentiated cancer, and this indicates that ANT2 can be used as
a marker of malignancy in thyroid cancer.
#3734 Pharmacokinetics of sacituzumab govitecan (IMMU-132), an anti-
body-drug conjugate (ADC) targeting Trop-2, in patients with diverse ad-
vanced solid tumors. Robert M. Sharkey,1 Allyson J. Ocean,2 Alexander N.
Starodub,3 Aditya Bardia,4Michael Guarino,5Wells A.Messersmith,6 JordanD.
Berlin,7 Vincent J. Picozzi,8 RebeccaMoroose,9William A.Wegener,1 Pius Ma-
liakal,1 Serengulam V. Govindan,1 David M. Goldenberg1. 1Immunomedics,
Inc., Morris Plains, NJ; 2Weill Cornell Medicine, New York, NY; 3Indiana Uni-
versity Health Center for Cancer Care, Goshen, IN; 4Massachusetts General Hos-
pital Cancer Center, Boston, MA; 5Helen F Graham Cancer Center, Newark, DE;
6University of Colorado Cancer Center, Aurora, CO; 7Vanderbilt-Ingram Cancer
Center, Nashville, TN; 8Virginia Mason Cancer Center, Seattle, WA; 9University
of Florida Health Cancer Center, Orlando, FL.
BACKGROUND: Sacituzumab govitecan (IMMU-132), an ADC targeting
Trop-2, an antigen present in many solid tumors, uses SN-38, a topoisomerase I
inhibitor that has nanomolar potency derived from irinotecan (IRI), and a pH
sensitive linker that releases SN-38 gradually (in vitro, 50% released per 1 day in
serum). Clinical studies in patients (pts) with diverse solid tumors have shown
manageable toxicity (dose-limiting neutropenia, diarrhea but lower incidence
than IRI) and encouraging effıcacy. METHODS: Conjugate and IgG were mon-
itored in pts given 8 (N  24) or 10 mg/kg (N  29) by ELISA. SN-38 and
glucuronidated SN-38 (SN-38G) were measured by reversed-phase HPLC.
SN-38 and SN-38G levels are expressed as the amount of drug dissociated from
the conjugate (i.e., Free SN-38) and the amount bound to the IgG (Total SN-38).
UGT1A1 status was determined in baseline blood sample from 146 pts. RE-
SULTS: IMMU-132 cleared with a half-life of 11.7-18.9 h, depending on the
assay, while the IgG half-life was 4-5 days, which agrees with in vitro drug-
release data. Levels of Free SN-38 at 30 min or 1 d after injection were 2%
and 5%of Total SN-38, respectively, indicatingmost SN-38 in serum is bound
to the conjugate. Free SN-38 clears with a half-life of20 h, which is consistent
with SN-38 clearance in IRI therapy. No correlation was found between Free
SN-38 in serum at 30 min and the incidence of severe neutropenia. Total and
Free levels of SN-38G were similar, supporting in vitro results indicating that
SN-38 is not glucuronidated while bound to the IgG. Free SN-38G levels were
lower than Free SN-38 (SN-38G/SN-38AUC ratio 0.52), explaining the lower
incidence of severe diarrhea. PK parameters for 8 and 10 mg/kg group were
similar; no major differences in toxicity. UGT1A1 status showed 43% and 44%
with *1*1 and *1*28 haplotype, respectively, and 13% with *28*28 haplotype,
which is associated with higher risk of severe neutropenia and diarrhea for IRI
therapy. With IMMU-132, 58% of the *28*28 pts had severe neutropenia com-
pared to40% of the *1*1 and *1*28 pts, and 16% of the *28*28 pts had grade 3
diarrhea compared to 5-8% of the *1*1 and *1*28. In 3 of 4 cancer indications,
objective response rate and clinical benefıt ratio favored the 10 mg/kg group.
CONCLUSION: IMMU-132 cleared as predicted from in vitro serum stability
data, with no difference between the 8 and 10 mg/kg groups. Current data show
neutropenia did not correlate with Free SN-38 levels in serum at 30min, and low
SN-38G levels support the lower incidence of severe diarrhea.While pts with the
*28*28 haplotype had a somewhat higher incidence of severe neutropenia or
diarrhea than *1*1 and *1*28 pts, the overall incidence of each is small, suggest-
ing toxicity management rather than screening is appropriate. With no major
difference in safety and PK, but improved responses with 10 mg/kg, 10 mg/kg is
selected for future clinical studies.
#3735 Detection ofmicrosatellite instable colorectal cancers from routine
NGS panel sequencing data.Volker Endris, Martina Kirchner, Matthias Kloor,
Anna-Lena Volckmar, Magnus von Knebel Doeberitz, Roland Penzel, Peter
Schirmacher, Albrecht Stenzinger. Univ. of Heidelberg, Heidelberg, Germany.
Introduction: In about 15% of all colorectal cancers, microsatellite instability
(MSI) caused by defects in theDNAmismatch repairmachinery can be detected.
MSI driven tumors have a better prognosis compared to microsatellite stable
(MSS) tumors and show good response to drugs targeting the PD-1-PD-L1 axis.
Current molecular diagnostic procedures for colorectal cancer are primarily
focused on the detection of oncogenic mutations in RAS family genes by either
classical Sanger sequencing or next-generation sequencing. Routine testingof
MSI status for therapeutic purposes is still rare and usually carried out by a
different array of methods including PCR and immunohistochemistry. Experi-
mental procedures: In our routine diagnostic CRC screening, we sequenced
more than 600 colorectal tumors with an entity specifıc customized 180 ampli-
con NGS panel encompassing HotSpot regions of 31 genes. This panel includes
several homopolymeric regions of genes that are known to be affected by MSI.
We retrospectively analysed this data set forMSI signatures, including deletion/
insertion mutations in 20 different homopolymeric regions (7) and muta-
tions/deletions of MLH1, MSH3, MSH6 and TGFBR2. Cases with an MSI sig-
nature detected by panel sequencing were reevaluated by PCR-based screening
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(Bethesda panel). Results: From the 20 homopolymeric regions analyzed, several
loci showed deletion/insertion mutations in MSI-positive patients. The highest
discriminatory power presented a homopolymeric region within the ACVR2A
gene showing a high analytical sensitivity and specifıcity towards MSI predic-
tion. In combinationwith the readout of additional homopolymeric regions and
the mutation status of MLH1, MSH3, MSH6 and TGFBR2, a sensitive and spe-
cifıc detection algorithm forMSI can be obtained from routine panel sequencing
data. In conclusion, using only one assay, this approach facilitates simultaneous
detection of mutations in RAS genes (and other druggable targets) and the MSI
status in CRC As the assay is tissue sparing and time saving it may be advanta-
geous over classic test approaches that are currently being employed in routine
diagnostics.
#3736 Characterization of tumor cells and assessment of PD-L1 expres-
sion in pleural effusions of metastatic non-small cell lung cancer patients.
Jeffrey C. Thompson,1 Samantha L. Savitch,2 Ryan Fan,2 Stephanie S. Yee,2
Christian A. Powers,2 Gordon Yu,3 Lauren Gebrian,1 Chandra Rao,4 Steve
Gross,4 Michael Feldman,3 Anil Vachani,1 Erica L. Carpenter2. 1Division of Pul-
monary, Allergy, and Critical Care Medicine, Thoracic Oncology Group, Depart-
ment ofMedicine, Perelman School ofMedicine, University of Pennsylvania, Phil-
adelphia, PA; 2Division of Hematology-Oncology, Department of Medicine,
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 3De-
partment of Pathology and Laboratory Medicine, Hospital of the University of
Pennsylvania, Philadelphia, PA; 4Janssen Pharmaceutical, Johnson & Johnson,
PA.
Introduction: Malignant pleural effusions (MPE) occur as a frequent compli-
cation of advanced non-small cell lung cancer (NSCLC), and denote a poor
prognosis. Cytological evaluation of MPEs has a sensitivity of only 40-60%. The
CellSearch technology (Janssen Diagnostics, LLC) is an FDA approved method
of detecting rare circulating tumor cells (CTCs) in blood. Assessment of pleural
fluid samples using CellSearch provides an approach to enrich often undetect-
able CTCs and phenotype these cells for markers of interest. PD-L1 staining of
tumor tissue is essential for determining patient candidacy for checkpoint in-
hibitor therapy, however, tissue can often be diffıcult to obtain. Here, we dem-
onstrate the feasibility of applying the CellSearch CTC enrichment platform to
measure PD-L1 expression and enumerate tumor cells in MPE of NSCLC pa-
tients. Methods: This was a single center, prospective observational study of
NSCLC patients with a pleural effusion. The anti-human CD274 (PD-L1) anti-
body (Biolegend) was used as a marker with the CellSearch CXC CTC kit and
was detected in the open 4th channel of the CellTracks Analyzer. Determination
of CTC PD-L1 expression was validated through peripheral blood spiking ex-
periments. 7.5ml of pleural fluid was collected from NSCLC patients, preserved
in CellSave tubes and processed within 72 hours. Identifıcation and enumera-
tion of CTCs was performed using the CellTracks Analyzer. We then compared
CellSearch results to conventional cytological analysis. Results: Pleural effusion
samples from 66 patients between the ages of 43 and 80 (median69) were
obtained following thoracentesis. The majority of patients were former (40;
60.6%) or never (21; 31.8%) smokers. At the time of effusion, 23 (34.8%) patients
were on a therapeutic regimen: 10 (15.2%) were receiving chemotherapy, 9
(13.6%) were on an EGFR or ALK TKI, and 5 (7.6%) were on a checkpoint
inhibitor. CTCs were detected in 63 of 66 samples using the CellSearch system.
Among the 66 pleural effusions, cytological evaluation determined 40 samples
were malignant and 26 were benign. CellSearch detectedmore CTCs in patients
with a MPE (median 1798, range: 7 to 114,920) compared to patients with a
benign effusion (median 8, range: 0 to 953; p0.005). In the MPE group, 18
(45.0%) samples demonstrated10% PD-L1 positivity with 9 (22.5%) samples
showing 50% PD-L1 positivity. Conclusion: The CellSearch CTC enumera-
tion and characterization platform can be successfully adapted for detection of
CTCs inMPE ofNSCLCpatients. Our preliminary results suggest this approach
may be a useful, non-invasive diagnostic adjunct for the determination of aMPE
and assessment of PD-L1 expression in NSCLC patients. Further study is war-
ranted to determinewhat role this test could play in assessing patients for check-
point inhibitor therapy and its relationship with tissue based tests.
#3738 Use of tumor mRNA expression for patient selection in a phase I
study of the pan-fıbroblast growth factor receptor inhibitor BAY 1163877.
Peter Ellinghaus,1MatthiasOcker,2 SebastianBender,1 ChristophKneip,2 Stuart
Ince,3 Markus Joerger,4 Martin Schuler5. 1Bayer AG, Wuppertal, Germany;
2Bayer AG, Berlin, Germany; 3Bayer HealthCare Pharmaceuticals Inc, Whip-
pany, NJ; 4Kantonsspital St. Gallen, Zürich, Switzerland; 5West German Cancer
Center, University Hospital Essen, Essen, Germany.
BAY 1163877 is a potent and selective, oral, small molecule pan-FGFR inhibitor
with anti-tumor activity in a wide range of cancer types. In vivo profıling in xeno-
graft models identifıed tumor FGFR mRNA levels as a predictor of drug effıcacy.
Anti-tumor effıcacy was largely independent of the tumor type surveyed or the
FGFR isoform being overexpressed. Preclinical models included a patient-derived
squamous head and neck cancer (HNSCC) xenograft (PDx) model overexpressing
FGFR3mRNA, a bladder cancer PDxmodel overexpressing FGFR2mRNA, and a
squamous esophageal cancer PDx model overexpressing FGFR1 mRNA. Against
this background, clinical proof-of-concept was assessed by enrolling patients into
the stratifıed expansion cohort of a Phase 1 study of BAY 1163877 (NCT01976741)
basedon tumorFGFR1-3mRNAlevels. FGFR1-3mRNAwasquantifıed in archival
or newly obtained FFPE tumor biopsies by RNA in situ hybridization (RNAscope,
ACD) and digital transcript counting (NanoString). In total, biopsies from 500
patients were studied for FGFR1-3 mRNA expression levels. Based on preclinical
xenograft experiments showing that low tomoderate FGFR1-3mRNAoverexpres-
sion was not suffıcient for a robust drug response, only patients with an RNAscope
score of 3 or 4 (range 0-4) or a normalized Nanostring signal of 800 counts were
eligible for enrollment. By applying these stringent criteria, FGFR1-3 mRNA posi-
tivity was on average observed with a 2- to 3-fold higher prevalence than published
data for genetic aberrations of FGFRs in the respective tumor types (including am-
plifıcations, translocations, mutations).We further identifıed FGFRmRNA() tu-
mor types in which genetic FGFR aberrations have not been previously reported.
FGFR1-3 mRNA positivity ranged from 10% in lung adenocarcinoma to 45% in
squamousnon-small cell lungcancer (sqNSCLC)and54%inHNSCC.AsofAugust
2016,57FGFRmRNA()patientswereenrolledandtreatedwithBAY1163877.Six
patients experienced a partial remission (PR) by RECIST v1.1 criteria; including an
FGFR3mRNA() HNSCC patient without FGFR3 amplifıcation or translocation,
an FGFR1mRNA() adenoid cystic carcinoma patient, and an FGFR1mRNA()
sqNSCLC patient (both without FGFR1 gene amplifıcation), as well as an FGFR3
mRNA() bladder cancerpatientwithoutFGFR3amplifıcation,mutationor trans-
location. These results suggest that high FGFR1-3 mRNA expression identifıes pa-
tients sensitive toFGFR inhibition.Thispopulation includespatientswithandwith-
out genetic aberrations of FGFR1-3 encoding genes. In summary, an mRNA
expression-based selectionapproachmay identify abroaderpatientpopulationwith
potential benefıt from BAY 1163877, including tumor types not previously associ-
ated with altered FGFR signaling.
#3739 Comparison of technologies for EGFR analysis within a subset of a
randomized clinical trial. Mirko Marabese,1 Massimo Broggini,1 Martin
Reijans,2 Cedric Gouedard,3 Geert Maertens,2 Erwin Sablon,2 Monica Gan-
zinelli,4 Marina C. Garassino,4 Samuel Murray5. 1Mario Negri Inst. for Pharma-
col. Research, Milan, Italy; 2Biocartis, Mechelen, Belgium; 3BioPath Innovations
SA, Athens, Greece; 4Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy; 5Biomarker Solutions Ltd, London, United Kingdom.
Background: EGFR mutation analysis is laborious often requiring5 work-
ing days andmultiple slices of formalin-fıxed paraffın-embedded (FFPE) tissue.
Idylla™ is a fully integrated, automated molecular diagnostics platform combin-
ing speed, ease of use, high sensitivity, multiplexing capabilities, offering sensi-
tive detection of 52mutations including insertions and deletions in exons 18-21.
Methods:We assessed 149 cases from the phase III TAILOR study (Garassino et
al, Lancet Oncology 2013;14:981-8), where EGFR was centrally assessed. Rela-
tive concordance between study entry classifıcation to TAILOR (Sanger se-
quencing), Idylla™ and next generation sequencing (NGS) for EGFRwere inves-
tigated. Single unprocessed sections were used per Idylla™ and NGS following
pathological review. NGS was performed using the AmpliseqTM Colon and
Lung Cancer Panel v2 on an Ion Torrent PGM™ (Thermo Fisher) in a reference
laboratory3; Idylla™ (Biocartis NV) was performed at Biocartis1. Samples and
study genotypes were blinded to NGS and Idylla™. Results: There were 132 eli-
gible calls to compare NGS vs Idylla™ (14 fails NGS, 1 Idylla™, 2 both); 108 to
compare Sanger vs Idylla™ (38 fails Sanger, 2 Idylla™, 1 both); 101 to compare
Sanger vs NGS (31 fails Sanger, 7 NGS, 9 both). For NGS, a minimum coverage
of 500 reads was set at a clinically relevant LOD of 5% mutant allelic frequency
for calls. Comparison NGS vs Idylla™: 46 EGFR (34.8%) mutation positive by
Idylla™, 43 (32.6%) by NGS; Sensitivity 93.48%; Specifıcity 100.00 %. Compari-
son Sanger v Idylla™: 41 EGFR (38.0%) mutation positive by Idylla™, 38 (35.2%)
by Sanger; Sensitivity 85.37%; Specifıcity 95.52 %. Sanger v NGS: 39 EGFR
(38.6%) mutation positive by NGS, 39 (38.6%) by Sanger; Sensitivity 87.18%;
Specifıcity 91.94 %. Of 16 NGS failures 14 were reportable by Idylla™. Conclu-
sions: Idylla™ proved to be a reliable platform for rapid EGFR mutational status
evaluation. Compared toNGS and Sanger sequencing Idylla™ has several advan-
tages: its ease of use, hands on time5 mins, all-inclusive lyophilized cartridge
requiring only one section of 5m FFPE, restricted secondary manipulation
errors in a busy workflow. Positive and Negative predictive values for both
Idylla™ and NGS were excellent. Although NGS offers signifıcant additional
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clinical data availability through multiplexing, the number of samples classifıed
as inadequate for NGS (14/16 giving result with Idylla™) indicates a likely re-
quirement of more sample robust platforms in diagnostic workflows.
#3740 The pursue of geneticmechanisms underlying supreme response to
pazopanib treatment. Emmanouil Saloustros,1 Helen Latsoudis,2 Despoina
Vassou,2 Irene Stratidaki,2 Niki-Antonia Gounalaki,2 Vasiliki Fadouloglou,2 Io-
annis Drositis,1 Emmanouil Kontopodis,1 Kitty Pavlakis,3 Dimitrios Mavrou-
dis,4 Nikolaos Androulakis,1 Dimitrios Kafetzopoulos2. 1General Hospital of
Heraklion ’Venizelio’, Heraklion, Greece; 2Institute ofMolecular Biology and Bio-
technology, FORTH, Heraklion, Greece; 3National and Kapodistrian University
of Athens, Athens, Greece; 4University General Hospital of Heraklion, Heraklion,
Greece.
Aim: Studying exceptional responders to standard treatments may provide
broader insights into the genetic mechanisms underlying such responses and
suggest therapeutic options that weren’t previously apparent. In this study we
unravelled the genetic signature of undifferentiated sarcoma in order to disclose
the molecular mechanisms that may underlie the patient’s exquisite sensitivity
to Pazopanib. Methods: A female patient withmassive undifferentiated gyneco-
logical sarcoma experienced a dramatic response to Pazopanib that made deb-
ulking surgery possible. We performed whole exome sequencing on DNA iso-
lated from both blood and formalin fıxed paraffın-embedded (FFPE) tumour
employing Ion Torrent technology. Variant annotation was performed using
the Ion ReporterTM v5.0 (MA, USA) tool after application of specifıc fılters.
Subsequent curation of annotated data was completed using a combined semi-
automated data analyses workflow developed by Minotech Genomics Facility
with the implementation of two in house-developed lists regarding 24 pazo-
panib-related genes, and 96 angiogenesis-associated genes. We also performed
targeted sequencing of Ion Ampliseq Comprehensive Cancer panel (CCP) that
is strategically designed to interrogate coding DNA sequences and splice vari-
ants across 409 tumour suppressor genes and oncogenes. Results:Whole exome
sequencing was conducted at 20x coverage for 91.9% and 60.5% of 19,000
genes for germline and FFPE DNA samples, respectively. Targeted sequencing
was conducted at 20x for97% of 409 genes of the comprehensive cancer panel.
Comparative analyses revealed two variants common in germline and FFPE
samples, localized in LTK(p.Val541Ile) and FGFR4 (p.Gly388Arg). Interest-
ingly, examination of the annotated data for biologically plausible mechanisms
revealed 2 yet uncharacterized heterozygous variants in two other members of
the FGFR family, FGFR2 (c.2183AG, p.Asn728Ser) and FGFR3 (c.2050GA,
p.Val684Ile) that were present only in the FFPE samples. Even though both
variants residewithin the catalytic tyrosine kinase domains, they are predicted to
exert tolerated effects on the encoded FGFR2 and FGFR3 proteins. Since,
Asn728Ser is highly conserved among different kinases of the FGFR family we
chose this variant to predict a possible effect on Pazopanib binding. Specifıcally,
protein structure simulation of FGFR2 revealed that asparagine residue at posi-
tion 728 is located in the external side of the drug binding cavity and is thus
predicted to not affect Pazopanib binding. Conclusion: We pursue the possible
genetic or somaticmodifıers underling the excessive response to Pazopanib. The
detection of two, yet uncharacterised, variants in knownPazopanib targets high-
lights the potential of next generation sequencing in disclosing the genetic sig-
nature of undifferentiated sarcomas in relation to the activity and effectiveness
of certain therapeutic agents.
#3741 Improving Gleason scoring in prostate cancer: Development and
clinical value of theMolecular Integrative Quantitative Gleason (MIQ-Glea-
son).Ronald Simon,MartinaKluth,Maximilian Lennartz, ClaudiaHube-Magg,
Sarah Minner, Maria Christina Tsourlakis, Stefan Steurer, Markus Graefen,
HartwigHuland, Lars Budäus, Guido Sauter, Thorsten Schlomm.Univ.Medical
Ctr. Hamburg-Eppendorf, Hamburg, Germany.
We have recently shown that quantifıcation of Gleason 4 patterns (Q-Glea-
son) provides strong prognostic information beyond traditional Gleason grade
groups (33, 34, 43, 8, 9-10) in prostate cancer, and that the prognostic
power of Q-Gleason scoring can be further improved if Gleason 5 patterns are
integrated to build the Integrative Quantitative Gleason (IQ-Gleason) score, a
continuous value ranging from 0 – 117.5. The current study was undertaken, to
determine whether (and how) factoring in molecular markers could further
improve the predictive power. We selected deletions of PTEN and 6q (by FISH
analysis) as well as DNA ploidy information obtained by flow cytometry as
examples for established molecular prognostic markers that provided strong
and independent prognostic information in our study cohort of more than
17,000 prostate cancers. A “molecular score” was established for these markers
including “penalty” points for presence of deletions/aneuploidy and “bonus”
points for lack of deletions/diploid DNA status. Penalty and bonus points were
separately determined for each parameter based on differences in the recurrence
rate between cancers with and without deletions or aneuploidy. The “penalty”
points were then added to the IQ-Gleason score points while the “bonus” points
were subtracted from the IQ-Gleason in order to obtain theMiQ-Gleason score.
The MiQ-Gleason provided strong prognostic information in univariate analy-
sis (p0.0001) and in multivariate models including PSA level, pT / pN stage,
and status of the resectionmargin. Comparison of Reciever Operator character-
istics (ROS) between theMiQ-Gleason and the quantitative Gleason or classical
Gleason revealed only a slight increase of the prognostic power for the MiQ-
Gleason (AUC0.781) as compared to the IQ-Gleason (AUC0.771), while a
massive difference was found as compared to the classical Gleason grade groups
(AUC0.719). In summary, our data demonstrate the power of quantitative
Gleason scoring strategies as compared to classical Gleason grade groups. That
adding selected molecular features improved predicitive power only slightly
demonstrates how diffıcult it is for molecular markers to compete with opti-
mized morphological grading systems. However, the use of more and better
molecular testing may provide further improvement beyond quantitative Glea-
son scoring.
#3742 Exposure burden for patients during an experimental study using a
dual-energy contrast-enhanced spectralmammography.KamilaRawojc,1Ka-
mil Kisielewicz,2 Anna Dziecichowicz,2 Monika Tomaszuk,2 Anna Cepiga,2
Jankowska Anna,2 Cieśla Izabela,2 Najberg Dominika,2 Luczynska Elzbieta,2
BartoszKieltyka3. 1TheUniversityHospital, Krakow, Poland; 2Maria Sklodowska
– CurieMemorial Cancer Center and Institute of Oncology, Krakow, Poland; 3M.
Smoluchowski Institute of Physics, Jaiellonian University, Krakow, Poland.
Mammography provides early micro-calcifıcation recognition, that is im-
portant for further breast cancer (BC) diagnosis. Imaging choice for BC
detection is X-ray mammography (MG) with the use of high-resolution dig-
ital modality combined with iodinated contrast agents. However, a conven-
tional MG has some sensitivity limitations, especially in patients with
densely treated breasts. Moreover, MG contributes radiation risk for BC that
is correlated with an exposure to ionizing radiation. Patients, for whom MG
study does not give a clear interpretation are often further diagnosed by
contrast-enhanced breast MRI, the most sensitive BC detection technique.
Alternatively, it is limited by higher costs, lower availability and increased
false positives. Dual-energy contrast-enhanced spectral mammography
(CESM) is a new method applied in BC that enables accurate detection of
malignant breast lesions similar to breast MRI. The aim of this study was to
compare the usefulness of CESM versus MG in BC detection. Additionally,
doses given to the BC patients during imaging were compared. In this study,
250 consecutive women (144 MG vs. 105 CESM), that were screened using
mammography between 2011 and 2014 were retrospectively enrolled in the
study. The comparison of entrance surface air kerma and mean glandular
dose values for both options were recorded, respectively and analyzed using
different statistical and retrospective approach. Results of presented study
showed that CESM might be a new diagnostic tool allowing an accurate
detection of BC lesions, giving results similar to those received from mag-
netic resonance imaging. A good agreement found between sensitivity of the
method and tumour diameters measurements based on CESM, supports this
tool as a potential replacement for breast MRI in the preoperative evaluation
of BC patients. However, a radiation burden for patients might be signifı-
cantly higher than that for a standard full-fıeld digital mammography pro-
cedure. In summary, each method has its own benefıts with respect to spe-
cifıc applications that are further discussed in the study.
#3743 Magnetic resonance imaging shrinkage patterns after neoadjuvant
chemotherapy for breast carcinomas: Correlation with molecular subtypes.
Tsuyoshi Mori, Kaori Tomida, Mina Kitamura, Sachiko Sakai, Yuki Kawai, To-
moharu Shimizu, Tomoko Umeda, Tomoyuki Ueki, Sachiko Kaida, Toru Mi-
yake, Hiroya Iida, Hiroya Akabori, Naomi Kitamura, Tsuyoshi Yamaguchi, Hi-
romichi Sonoda, Shigeyuki Naka, Masaji Tani. Shiga university of medical
science, Otsu, Japan.
Background: Neoadjuvant chemotherapy (NAC) is widely performed for
patients with locally advanced breast carcinomas. It is important to obtain
precise information using imaging modalities about the distribution of re-
sidual carcinomas after NAC to predict the success of breast conserving
surgery. However, the relationship between magnetic resonance imaging
(MRI) shrinkage patterns and molecular subtypes of breast carcinomas has
not yet been investigated. Methods: We analyzed the MRI shrinkage and
pathological patterns of residual carcinomas after NAC in 54 consecutive
breast carcinomas. The shrinkage patterns were classifıed into fıve catego-
ries: Type I and II (concentric shrinkage with or without any surrounding
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lesion), type III (shrinkage with residual multinodular lesions), type IV (dif-
fuse contrast enhancement in the entire quadrant), and non-visualization.
Results: The most commonMRI shrinkage pattern was type I (39%) followed
by non-visualization (26%). The most common pathological shrinkage pat-
tern was type III (33%), followed by type II (28%) and non-visualization
(22%). The concordance rates of the MRI patterns of non-visualization and
type I were signifıcantly lower than those of the MRI patterns of type II, III,
and IV (p  0.018). Moreover, in the luminal subtypes, the concordance
rates of the MRI patterns of non-visualization and type I were signifıcantly
lower than those of the MRI patterns of type II, III, and IV (p  0.026);
however, in the non-luminal subtypes, this correlation was not signifıcant.
Conclusions: The results of the present study suggest that the cases withMRI
shrinkage patterns of non-visualization and type I require caution regarding
the surgical margins compared with the other types, especially the luminal
subtypes.
#3744 Offıce cervicoscopy in the diagnosis of HPV infection. Atef Dar-
wish. Assiut Univ., Assiut, Egypt.
Introduction: Since the association between certain oncogenic (high-risk)
strains of HPV and cervical cancer is well established. Searching for HPV be-
came a basic step in all screening programs. LaboratoryHPV testing is costly and
unavailable in developing countries. Objective: To compare the diagnostic indi-
ces of offıce cervicoscopy against cytology and punch biopsy for detection of
underlying HPV lesions in women with suspicious cervix. Design: An analytic
cross-sectional research design Setting: Early cervical cancer Detection Unit of
the Women’s Health University Hospital. Assiut, Egypt. Patients and methods:
A total of 274 non-pregnant women with clinical diagnosis of suspicious cervix
were included in this study. After cervical smearing with Ayre’s spatula, they
were subjected to cervicoscopy utilizing 2.6 mm telescope and a 3.2 mm outer
sheath offıce hysteroscope. Evaluation of the vulva, vagina, ectocervix, endocer-
vical canal and the endometrial cavity were done. The cervix was then painted
with saline, acetic acid and Schiller’s iodine stains successively as used during
colposcopic examination. Abnormal lesions were biopsied using punch biopsy
forceps. Cytologic evaluation relied on both classic and non-classic (secondary)
criteria for the diagnosis of HPV including ‘mild koilocytosis,‘ mild dyskerato-
cytosis,‘ hyperchromatic nuclei, bi- andmultinucleation, and cleared cytoplasm.
Punch biopsies were taken from every case based on cervicoscopic localization
after staining. Results:. The main complaint was abnormal vaginal discharge in
197 cases (71.4%) . Pap smear sampling was negative for HPV in 188 cases
(68.6%) and positive in 86 cases (31.4%). Cervicoscopic fındings suggestive of
HPV infection were positive in 77 cases ( 28.1% ) and negative in 197 cases
(71.9% ). Gold stand histopathology diagnosed HPV in 53 cases only (19.3%).
All diagnostic indices of cervicoscopy signifıcantly improved after combination
with cytology positive results except false positive results.. Conclusions: Cervi-
coscopy as a simple, cheap and offıce procedure can be used as a quick screening
tool of HPV infection in women with suspicious cervix. It has the advantage of
screening of the rest of the genital tract. In the absence of laboratory HPV
testing, cervicoscopy in conjunction with cytology screening of high-risk cases
should be encouraged.
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#3745 Dual-switch TCR: A two-ligand system to control PRAME TCR-
modifıed T cell proliferation and death using inducible MyD88/CD40 and
caspase-9. Tsvetelina Pentcheva-Hoang,1 Tania Rodriguez,1 David Torres,1
Ana Korngold,1 Jeannette Crisostomo,1 MyLinh T. Duong,1 Matthew Collin-
son-Pautz,1 J. Henri Bayle,1 Mirjam HM Heemskerk,2 J.H. Frederik Falken-
burg,2 Annemarie Moseley,1 Kevin M. Slawin,1 David Spencer,1 Aaron E. Fos-
ter1. 1Bellicum Pharmaceuticals, Inc., Houston, TX; 2Leiden University Medical
Center, Leiden, Netherlands.
T cells engineered to express the  and  chains of antigen-specifıc T cell
receptors (TCRs) have shown promise as a cancer immunotherapy treatment;
however, durable responses have been limited by poor persistence of gene-mod-
ifıed T cells. Additionally, severe toxicities, including patient deaths, have oc-
curred upon infusion of large numbers of TCR-modifıed T cells. To enhance T
cell persistence while providing a safeguard against life-threatening toxicity, we
developed a dual-switchTCR platform that uses a rapamycin (Rap)-induced
caspase-9 (iRC9) together with a rimiducid (Rim)-controlled activation switch,
inducible MyD88/CD40 (iMC). The  TCR sequence derived from an HLA-
A2-restricted, PRAME-specifıc T cell clonewas synthesized and placed in-frame
with iMC, comprising signaling domains fromMyD88 and CD40 fused to tan-
dem Rim-binding mutant FKBP12v36 domains to generate the iMC-PRAME
TCR. Caspase-9 was fused to FRB and wild-type FKBP12 domains and cloned
in-frame with a selectable marker, truncated CD19 (
CD19), to generate iRC9-

CD19 retrovirus. All modules were separated by 2A polypeptide, bond-skip-
ping sequences. Activated human T cells were dual-transduced with iMC-
PRAME TCR and iRC9-
CD19 viruses and subsequently enriched for CD19
expression using magnetic selection. iMC and iRC9 were activated by exposing
transduced T cells to 10 nM Rim or Rap, respectively. Proliferation, cytokine
production and cytotoxicity of TCR-modifıed T cells were assessed in co-culture
assays with U266 (myeloma) and THP-1 (AML) cells in the presence or absence
of inducible ligands. T cells transduced with iMC-PRAME TCR and iRC9-

CD19 showed effıcient and stable expression for TCR and 
CD19 post-CD19
selection (82	9% CD3V1, 96	2% CD3CD19). In coculture assays, du-
al-switch PRAME TCR-modifıed T cells demonstrated specifıc lysis of HLA-
A2PRAME THP-1 and U266 tumor cells compared to an irrelevant TCR
(CMVpp65-specifıc)-modifıedT cells with orwithout iMCactivation.However,
Rimexposure induced a 42-fold induction of IL-2 (9	0.3 versus 385	180pg/ml
IL-2) and resulted in 13-fold greater expansion of TCR-modifıed T cells. The
expression of iRC9 did not interfere with TCR function, nor with the synergy
betweenTCRand iMCactivation. Furthermore, exposure toRap triggered rapid
apoptosis of dual-switch TCR-modifıed T cells (72	5% Annexin-V with Rap
versus 14	4% without drug), indicating that the suicide switch is also func-
tional. iMC is a potent “Go” switch that utilizes rimiducid to provide costimu-
lation to TCR-engineered T cells. In addition, iRC9 is a novel rapamycin-induc-
ible suicide switch that can eliminate T cells in case of severe toxicity. This
iMC-enhanced iRC9-incorporating TCR is the fırst reported prototype of a dual
switch TCR-engineered T cell therapy to increase effıcacy, durability and safety
of adoptive T cell therapies.
#3746 Plasma membrane spanning and linker-domains from tumor ne-
crosis factor receptor superfamily (TNFRSF) proteins provide novel func-
tionality to chimeric antigen receptors (CARs) expressed in human T cells.
Dina Schneider, Ying Xiong, Darong Wu, Boro Dropulic, Rimas Orentas. Len-
tigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, MD.
Chimeric antigen receptor T cells redirected to the B cell antigen CD19
(CAR19) have shown effıcacy in the treatment of B-lineage acute lymphocytic
leukemia, and are being evaluated in other hematologic malignancies as well.
The prevalent confıguration of CAR19 for clinical application is comprised of
the extracellular single chain targeting domain (scFv) derived from the FMC63
antibody, aCD8 linker and transmembrane domain, aCD137 signaling domain,
and a CD3-zeta signaling domain. Transmembrane domains from other immu-
nologically-active proteins, including CD3, CD28, or CD4, and spacer domains
from IgG have been employed as structural components of CARs as well. The
relationship between the composition of the CAR linker and transmembrane
domain and CAR T function is, however, poorly understood. We hypothesized
that CAR transmembrane and linker domains derived from proteins of the
tumor necrosis factor receptor superfamily (TNFRSF), whose expression is as-
sociated with normal T cell functions, may optimize the anti-tumor activity of
CAR19. Therefore, primary human T cells were transduced with lentiviral ex-
pression vectors (LV) expressing new combinations of linker and transmem-
brane sequences encoded by various TNFRSF members. Specifıcally, the linker:
transmembrane domain combinations were: CD8:CD4, CD8:TNFRSF19,
TNFRSF19:TNFRSF19, truncated TNFRSF19:TNFRSF19, TNFRSF9:TNFRSF9
and TNFRSF16:TNFRSF16. We found that CAR T cells comprised of trans-
membrane domains derived from either TNFRSF19 or TNFRSF9 were superior
to theCD8 transmembraneCAR19 in tumor killing, and in the induction of IFN
gamma, TNF alpha, IL-2, and GM-CSF cytokine secretion in vitro, upon co-
culturewith leukemia cell line targets.Moreover, TNFRSF19-expressingCAR19
T cells were superior to the CD8 transmembrane CAR19 in the elimination of
engrafted Raji cells (a Burkitt’s lymphoma line) in an NSG leukemia mouse
model. On the other hand, the transmembrane domain derived from
TNFRSF16/LNGFR, a low affınity neurotrophin receptor, created aCAR19 con-
struct that had no functional activity either in vitro or in vivo, despite high levels
of surface CAR expression in human T cells. In conclusion, the magnitude of
CART response can be enhanced by the use of novel linker and transmembrane
domains derived from TNFRSF19 and TNFRSF9. Thus, the transmembrane
domain can play a determining role in CAR T function beyond a direct topo-
graphical connection between the extracellular and the intracellular domains of
the chimeric protein. Studies are underway to elucidate the mechanistic role of
TNFRSF-derived linker and transmembrane domains in CAR T function.
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#3747 msa2 biotin-binding CAR combined with biotinylated tumor-spe-
cifıc antibodies or DNA aptamers for universal cancer immunotherapy. Ja-
son J. Lohmueller,1 James D. Ham,2 Olivera J. Finn1. 1University of Pittsburgh
School of Medicine, Pittsburgh, PA; 2Carnegie Mellon University, Pittsburgh, PA.
Chimeric antigen receptor T cells (CAR-Ts) are highly promising as cancer
therapeutics, but the creation of CARs for new antigens remains a laborious
process. As an alternative strategy researchers are designing universal “tag-
CARs” that instead of directly recognizing tumor antigens, recognize tags on
tumor-specifıc antibodies bound to tumor cells, thereby activatingT cell effector
functions. Here we report the creation of a novel tag-CAR that uses the high
affınity monomeric streptavidin 2 (msa2) biotin binding domain to target can-
cer cells labeled with biotinylated tumor-specifıc antibodies or DNA aptamers.
We constructed lentiviral vectors encoding msa2 CARs with three different
signaling architectures - CD28-zeta, CD28-OX40-zeta, and 4-1BB-zeta. After
confırming that each msa2 CAR was effıciently expressed on the surface of
Jurkat and primary human T cells, we found that plate-immobilized biotin was
capable of specifıcally inducing T cell activation markers and cytokine produc-
tion. We then stained a variety of cancer cell lines with various tumor-specifıc
biotinylated antibodies or DNA aptamers targeting tumor antigens such as
MUC1, CD19, CD20, and EGFR and found that the stained cells specifıcally
activated the msa2-CAR cells and led to cytokine production. We are currently
investigating the ability of msa2-CAR cells to lyse antibody and aptamer-bound
cancer cells andwill be assessing their ability to shrink tumors in a human tumor
xenograft mouse model.
#3748 Development of anti-humanmesothelin chimeric antigen receptor
(CAR) messenger RNA (mRNA) transfected peripheral blood mononuclear
cells (CARMA) for the treatment of mesothelin-expressing cancers.
Chien-FuHung,1 Xuequn Xu,1 Linhong Li,2 YingMa,1 Qiu Jin,1 Angelia Viley,2
Cornell Allen,2 Pachai Natarajan,2 Rama Shivakumar,2 Madhusudan V.
Peshwa,2 Leisha E. Emens3. 1Johns Hopkins University, Baltimore, MD; 2Max-
Cyte, Inc., Gaithersburg, MD; 3Sidney Kimmel Comprehensive Cancer Center,
Johns Hopkins University, Baltimore, MD.
CD19-targeted chimeric antigen receptor (CAR)-engineered T/NK-cell ther-
apies can result in durable clinical responses in B-cell malignancies. However,
CAR-based immunotherapies have been less successful in solid cancers. This is
partly due to specifıcity for shared tumor antigens also present on normal host
tissues that leads to ’on-target/off-tumor’ toxicity. We therefore developed a
non-viral approach using repeated infusions of mesothelin-specifıc messenger
RNA (mRNA) CAR-transfected T cells to permit prospective control of ’on-
target/off-tumor’ toxicity. Early trials provided preliminary evidence of the
safety and anti-tumor activity of this strategy, but the ex vivo selection, activa-
tion and expansion of lymphocytes is laborious and expensive. We therefore
explored the feasibility of using a rapid, automated, closed system for cGMP-
compliant mRNA CAR transfection into freshly isolated peripheral blood
mononuclear cells for clinical scale manufacture (CARMA). The resulting cryo-
preserved cellular product expressed CAR in95% of cells, and recognized and
lysed tumor cells in an antigen-specifıc manner. Expression of CAR was detect-
able for 5-7 days in vitro, with a progressive decline of CAR expression related to
in vitro cell expansion. In a murine ovarian cancer model, a single intra-perito-
neal (IP) injection of CARMA resulted in the dose-dependent inhibition of
tumor growth and prolonged the overall survival (OS) of mice. Multiple weekly
IP injections of the optimal CARMA dose enhanced disease control and further
prolongedOS, both of which improvedwith an increasing number of injections.
No signifıcant off-tumor toxicities were observed. These data support further
investigation of serial IP CARMA administration as a potential treatment for
ovarian cancer and other mesothelin-expressing tumors involving the perito-
neum, and provide preclinical proof of principle of CARMA for solid tumors.
#3749 Genetic blockade of the protein tyrosine phosphatase SHP1 aug-
ments CAR T cell activity against PDL1 expressing solid tumors. Edmund
Moon, Soyeon Kim, Naomi Saint Jean, Shaun O’Brien, Steven Maceyko, Jing
Sun, Carl June, Steven Albelda. Univ. of Pennsylvania, Philadelphia, PA.
Background: Immunotherapy using chimeric antigen receptor (CAR)T cells has
demonstratedprofound,durable success inhematologicmalignancies. Solid tumors
present hurdles to the successful application ofCARTcells.One is the upregulation
of inhibitory receptors (IRs), like PD1 and CTLA4, many of which rely on shared
signaling molecules to shut off T cell activation. One such molecule is SHP1 (Src
homology region 2 domain-containing phosphatase-1) which dephosphorylates
key components of T cell receptor (TCR) signaling. We have engineered a unique
dominant-negative SHP1 (dnSHP1) that is able to augment CAR T cell control of
PDL1 positive solid tumors.Materials andMethods: The humanmesothelioma cell
line, EMP, was transduced to express high levels of mesothelin and PDL1
(EMMESO-PDL1). Activated human T cells from healthy donors were lentivirally
transduced to express a mesothelin-directed CAR (mesoCAR) with and without a
dnSHP1. MesoCAR and mesoCAR/dnSHP1 T cells were cocultured with tumor
cells x 18hrs and specifıc lysis was measured. These T cells were also restimulated
with plate-bound anti-CD3 overnight and were subjected to intracellular flow cy-
tometry staining (ICS) of cytokines. NSGmice were injected subcutaneously in the
flanks with 5x106 EMMESO-PDL1 tumor cells. After tumors established and grew
to150mm3, mice were randomly assigned to one of the following treatments: 1)
non-transduced (NTD)T cells, 2)mesoCART cells, 3)mesoCART cells sodium
stibogluconate (SSG; a chemical inhibitorof SHP1), 4)mesoCAR/dnSHP1Tcells.T
cells were injected IV once at a dose of 10x106 T cells/mouse. SSGwas administered
IM at 20mg/kg every 2 days. Tumors weremeasured serially. At the end,mice were
sacrifıced, tumors were harvested, digested, processed into single cell suspension,
and subjected to flowcytometry analysis. The tumor infıltrating lymphocytes (TILs)
were also isolated and tested for function ex-vivo. Results/Conclusion: In vitro,me-
soCART cells demonstrated suppressed lysis of EMMESO-PDL1 tumor cells com-
pared to EMMESO cells. MesoCAR/dnSHP1 T cells were able to lyse EMMESO-
PDL1 andEMMESO tumor cellswith similar effıciency.Anti-CD3 restimulation of
Tcells revealed enhanced secretionofTNF-alphaand IL2bymesoCAR/dnSHP1vs.
mesoCAR T cells as measured by ICS. In vivo, SSG injections had minimal impact
onmesoCART cell control of tumors, whereasmesoCAR/dnSHP1 T cells demon-
strated signifıcantly enhanced control of EMMESO-PDL1 tumor growth compared
tomesoCARTcells (60%greater decrease in tumorvolumecompared tomesoCAR
T cells). TIL infıltration was 3-fold higher in tumors harvested from mice that re-
ceived mesoCAR/dnSHP1 T cells compared to other groups. Isolated mesoCAR/
dnSHP1 TILs demonstrated the greatest ex-vivo lysis of fresh tumor cells. DnSHP1
engineering is a powerful and novel way of blocking the suppression of CART cells
by PD1 and other similar IRs.
#3750 Micromolar affınity CAR T cells to ICAM-1 achieves rapid tumor
elimination while avoiding systemic toxicity. Enda Shevlin, Spencer Park, Yo-
gindra Vedvyas, Marjan Zaman, Susan Park, Irene M. Min, Moonsoo M. Jin.
Weill Cornell Medicine, New York, NY.
Introduction: Adoptive immune therapy has achieved great success in eradicat-
ing blood-borne cancers, prominently, theCD19CARTcells inB cell leukemia and
lymphomas. However, CAR T cell therapy in solid tumors has been limited due to
the scarcity of tumor antigens that are deemed safe for targeting. One strategy to
overcome scarcity of tumor antigen is by tuning the affınity of CAR to limit T cell
reaction with cells overexpressing target antigen while sparing cells with basal level
expression. To rigorously test the idea of “affınity tuning”,we built variants ofCARs
possessing one million-fold difference in affınity spanning low nanomolar to high
micromolar affınity to a target antigen, and examined the influence of CAR affınity
on the rate of tumor killing and systemic toxicity. Methods: Antigen-binding do-
main of CARwas built from the inserted or I domain belonging to integrin LFA-1.
Affınity of CAR expressed in T cells was confırmed by ICAM-1 binding by flow
cytometry. For invivo study,micewith systemicgrowthof ICAM-1positive thyroid
tumorwere used, where tumors grew in lungs, liver, and bones. Tumor growth and
killing were monitored by whole body luminescence imaging. Sera were collected
for cytokine analysis. Body weight, cytokine profıle, and overall behavior were used
to assess the severity of systemic toxicity. Results: CAR T cells with a step-wise, one
million-fold variation in affınity to ICAM-1 resulted in a rate of target killing in
proportion to the increase in affınity and in ICAM-1 density. Owing to cross-reac-
tionofhumanLFA-1withmurine ICAM-1, the influenceofCARaffınityoneffıcacy
and on-target, off-tumor toxicity was tested in mice bearing ICAM-1 positive hu-
man tumors. In vivo tumor elimination by CAR T cells was in contrast to in vitro
affınity-dependent rate of target killing, demonstrating that micromolar affınity
CAR T cells was superior to nanomolar affınity T cells in both tumor killing and
safety aspects. Highest affınity CAR T cells led to uniform death of the host, caused
by on-target, off-tumor toxicity, and high level cytokine release. Conclusion: Our
study is the fırst comprehensive report examining the effect of CAR affınity on the
rateof tumorkilling, effıcacy, and toxicity. In contrast to invitro tumorkilling effect,
the increase in affınity of CAR beyond certain threshold was deleterious to T cell
persistence and associated with more frequent tumor relapse. Our study highlights
thatCARTcells approximatingnatural T cell receptor affınity ismore effıcacious in
eliminating tumors with overexpressed antigens, and is safer by avoiding potential
reaction with normal cells with basal expression of the same antigen.
#3751 Allogeneic EGFRvIII chimeric antigen receptor T cells for treat-
ment of glioblastoma. Oi Kwan Wong,1 Mathilde Dusseaux,2 Jing-Tyan Ma,1
Melinda Au,1 Sophie Leduc,2 Joyce Chou,1 Jessica M. Yu,1 Marjorie Bateman,1
Thomas Pertel,1 Kevin C. Lindquist,1 Julianne Smith,2 Barbra Sasu,1 Shu-Hui
Liu1. 1Pfızer Inc., South San Francisco, CA; 2Cellectis, France.
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Glioblastomamultiforme (GBM) is ahighly aggressive formofbrain tumorswith
a 5-year survival rate of less than 10%. Standard-of-care combining radiation ther-
apy with temozolomide only yields a median survival of 14.6 months and more
effective therapeutic options to extendpatient lives are urgently needed. EGFRvari-
ant III (EGFRvIII) is a tumor specifıcmutant of EGFR found in 25-30%ofGBMbut
not expressed in healthy tissues. EGFRvIII is formed by an in-frame deletion of
exons 2-7 of the wild-type EGFR which leads to removal of 267 amino acids in the
extracellular domain of the receptor. The truncated receptor loses its ability to bind
ligandsbutacquiresconstitutivekinaseactivity.The lackofnormal tissueexpression
makes EGFRvIII an ideal target for developing CART therapy.Most CART thera-
pies in clinical development use the patients’ ownT cells forCARTmanufacturing.
Our approach is to develop an “off-the-shelf” CAR-T treatment for GBM using
healthy donor T cells with the TCR (T-cell receptor) disrupted to prevent graft-
versus-host disease. This allogeneic approach could circumvent challenges faced by
some patients due to limited availability and quality of their own T cells and rapid
progress of their diseases, and has the potential to reduce the high cost associated
with autologous CART therapy. Using phage panning and hybridoma approaches,
we generated a series of humanized and fully human EGFRvIII antibodies with a
wide range of affınities. Recombinant EGFRvIII protein binding by Biacore and
FACS assays using EGFRvIII and EGFR wild-type expressing cells demonstrated
that these antibodies are highly specifıc for EGFRvIII. The antibodies were con-
verted to ScFvs and cloned into a CAR vector. Subsequently, EGFRvIII CARs were
transduced intoprimaryhumanTcells for functional studies.Wedevelopeda series
of assays to evaluate CAR expression, degranulation activity and target dependent
cytotoxicity. Our goal is to select CAR candidate that is safe, persistent and has
potent target dependent cytotoxicity.
#3752 FATE-NK100: A novel NK cell-mediated cancer therapy. Frank
Cichocki,1 Barham Valamehr,2 Ryan Bjordahl,2 Bin Zhang,1 Dhifaf Sarhan,1
Sarah Cooley,1 Bruce Blazar,1 Betsy Rezner,2 Paul Rogers,2 Chad Green,2 Stew-
art Abbot,2 Daniel Shoemaker,2 ScottWolchko,2 Jeffrey S.Miller1. 1University of
Minnesota, Minneapolis, MN; 2Fate Therapeutics, San Diego, CA.
Natural killer (NK) cells are innate lymphoid cells that mediate immune re-
sponses against pathogens and cancer. HumanNK cells are distinguished by the
surface phenotype CD3-CD56, and maturation of CD56dim NK cells is associ-
ated with acquisition of CD57. Rather than being an immunosenescence
marker, CD57 acquisition represents a shift toward greater effector function,
including increased CD16 signaling (Fc receptor responsible for triggering an-
tibody-dependent cellular cytotoxicity), more potent cytotoxicity and enhanced
inflammatory cytokine production after target cell engagement. The main chal-
lenge in enriching forCD57NKcells using current ex vivo expansionprotocols
is that interleukin (IL)-15, the cytokine that drives NK cell proliferation and is
critical for NK cell survival, preferentially expands less mature NK subsets that
fail to terminally differentiate in culture. Our group has developed a novel NK
cell expansion method that overcomes this barrier. Peripheral blood mononu-
clear cells from are depleted of CD3T cells and CD19 B cells and cultured for
7 days with IL-15 and a small molecule inhibitor of glycogen synthase kinase
3-beta (GSK3), a multifunctional kinase downstream of the PI(3)K pathway.
Compared to vehicle control, addition of the GSK3 inhibitor led to a substan-
tial increase (2.2-fold	 0.19, n23, p0.0001) in the CD57 NK cell popula-
tion, and total CD3-CD56NKcells were highly enriched (90.9%	 2.2) relative
to pre-culture CD3/CD19 depletion (23.3%	 2.5) (p0.0001).We used a high-
resolution imaging approach to analyze in vitro NK cell-mediated killing of the
ovarian tumor cell line SKOV-3 and the lung carcinoma line A549. We demon-
strate that NK cells from CD3/CD19-depleted peripheral blood products cul-
tured for 7 dayswith theGSK3 inhibitor exhibit signifıcantlymore rapid killing
kinetics and overall tumor killing relative to NK cells cultured for 7 days with
IL-15 and the vehicle control. Superior tumor control of NK cells cultured with
IL-15 and theGSK3 inhibitor was also observed against SKOV-3 tumor cells in
a murine xenogeneic adoptive transfer model that included IL-2 injections. We
have scaled our process to manufacture a GMP product (referred to as FATE-
NK100) for clinical use. Using an apheresis product from a donor containing
21.5 x 108 CD57NK cells, we achieved 6.4-fold NK cell expansion resulting in
a fınal GMP-grade product containing 158 x 108 CD57NK cells. The cytotox-
icity of these ex vivo expanded NK cells in response to SKOV-3 cells is superior
to that of CD3/CD19-depleted haploidentical NK cells activated overnight with
either IL-2 or IL-15 (representing the NK products used in current clinical tri-
als). These data have been presented to the FDA in preparation for a clinical trial
of FATE-NK100 in lymphodepleted patients with advanced AML anticipated
for Q1 2017.
#3753 Identifıcation of antibodies against a novel tumor-associated
MHC/peptide-target and generation of highly specifıc and potent HLA-
A*02MMP1-003/CD3 TandAbs. Toni Weinschenk,1 Erich Rajkovic,2 Uwe Re-
usch,2MichaelWeichel,2 Kristina Ellwanger,2 Ivica Fucek,2Michael Tesar,2 Do-
minikHinz,3VeraMolkenthin,3 SebastianBunk,1NorbertHilf,1Oliver Schoor,1
Dominik Maurer,1 Kerstin Mock,1 Carsten Reinhardt,1 Martin Treder2. 1Im-
matics Biotechnologies GmbH, Tübingen, Germany; 2AffımedGmbH,Heidelberg,
Germany; 3Abcheck s.r.o., Plzen, Czech Republic.
Tumor-associated antigens for effective and safe T-cell engagement are very
limited, leaving a need to open up the therapeutic target space. Targeting dis-
ease-specifıcMHC/peptide complexes with bispecifıc T-cell-recruiting antibod-
ies is a highly attractive strategy to address this need, but so far, generation of
antibodies against these peptides has been reported to be challenging. Immatics’
unique target discovery engine XPRESIDENT® holds the promise of identifying
novel tumor-associatedMHC/peptide complexes by providing direct and quan-
titative evidence for their presence on a large collection of primary human tumor
and normal tissue specimens. By this approach, MMP1-003, an HLA-A*02-
binding peptide originating frommatrixmetallopeptidase 1 (MMP1), was iden-
tifıed as a promising therapeutic target presented by several tumor types, includ-
ing colorectal and lung cancer, but absent on normal tissues. These fındings are
underlined by RNAseq analysis of the source antigen which also points to
MMP1 being a highly attractive tumor-associated target. Consequently, a fully
human antibody phage display library was screened to identify highly specifıc
single chain antibodies, whichwere shown to recognize the purifıedHLA-A*02/
MMP1-003-complex in ELISA assays as well as on peptide-pulsed HLA-A*02
T2 cells. The best candidates were reformatted into bispecifıc tetravalent Tand-
Abs® through Affımed´s proprietary platform using a human/cyno-cross-reac-
tive CD3-binding domain for T-cell engagement. Specifıc target recognitionwas
confırmed for theTandAbs in binding and cytotoxicity assays on peptide-pulsed
T2 cells. HLA-A*02/peptide-complexes selected from the broad normal tissue
immunopeptidome with a high degree of sequence similarity to the HLA-A*02/
MMP1-003-complex served as controls to confırm the specifıcity and hence the
low risk of off-target binding. The most promising candidates were tested on a
panel of endogenously target-expressing cancer cell lines covering MMP1 /-
and HLA-A*02 /- expression profıles, as well as the source proteins for the
most closely related control peptides. The lead TandAb showed excellent target
specifıcity across a wide range of peptide-pulsed and endogenously expressing
cell lines as well as potent cytotoxicity with picomolar EC50. In summary, we
have identifıed a tumor-associated MMP1-derived peptide in an HLA-A*02
context by exploiting the knowledge of tumor and healthy tissue immunopep-
tidomes using XPRESIDENT®. Overcoming the existing barrier of developing
antibodies targeting specifıc MHC/peptide complexes, we generated and char-
acterized highly specifıc and potent T-cell-recruiting TandAbs. These hold the
potential to open up the therapeutic target space for T-cell engagement by pro-
viding access to intracellular proteins that are presented in a disease-specifıc
manner as MHC/peptide complexes.
#3755 Renewable and genetically engineered natural killer cells for off-
the-shelf adoptive cellular immunotherapy. Ryan Bjordahl,1 Frank Cichocki,2
Raedun Clarke,1 Svetlana Gaidarova,1 Brian Groff,1 Paul Rogers,1 Stacey
Moreno,1 Ramzey Abujarour,1 Greg Bonello,1 Tom Lee,1Weijie Lan,1Matthieu
Bauer,1 Dave Robbins,1 Betsy Rezner,1 SarahCooley,2 BruceWalcheck,2 Stewart
Abbot,1 Bruce Blazar,2 Scott Wolchko,1 Daniel Shoemaker,1 Jeffrey S. Miller,2
BahramValamehr1. 1Fate Therapeutics, SanDiego, CA; 2University ofMinnesota
Cancer Center, Minneapolis, MN.
The unique attributes of a combinatorial tumor recognition system, dimin-
ished off-tumor cytotoxicity, and multifaceted effector function make natural
killer (NK) cells a prime candidate for a universal approach to cancer immuno-
therapy. In addition, NK cells are the principal mediator of antibody-directed
cellular cytotoxicity (ADCC).However,NKcell function is often impaired in the
setting of cancer, reducing the effectiveness of the endogenous immune system
and the therapeutic effıcacy of monoclonal antibodies. To address the need for
advanced and combinatorial cancer therapies, we developed a unique and effec-
tive strategy to create a renewable source of engineered “off-the-shelf” NK cells
with augmented function, including enhancedADCCandpersistence. Key chal-
lenges associated with genetic editing, limited expansion, persistence and vari-
ability of peripheral blood (PB)-derivedNK cells were overcome by utilizing our
induced pluripotent stem cell (iPSC) technology as the unlimited starting ma-
terial for the reproducible and consistent derivation of engineered NK cells.
Through targeted transgene integration, we produced a clonal iPSC master cell
line to continuously produce NK cells engineered to uniformly express a high
affınity, non-cleavable version of CD16 (hnCD16-NK). In directed differentia-
tion, the hnCD16-NK cells displayed homogeneous expression of CD16
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(95%) and a mature CD56NK cell phenotype, as exhibited by expression of
KIR, NCRs, DNAM-1, and NKG2D. In contrast to endogenous CD16 expres-
sion, the engineered hnCD16molecule was shown to be cleavage resistant upon
NK cell activation (95% CD16 hnCD16-NK vs.10% CD16 PB-derived
NK cell, upon target cell-mediated activation), and demonstrated enhanced an-
tibody binding compared to PB-derived NK cells expressing the low-affınity
variant. In addition to increased expression of the cytolytic molecules perforin
and granzyme B and enhanced direct cytotoxicity against tumor targets,
hnCD16-NK cells displayed superior ADCC capacity and cytokine production
in response to CD16 stimulation. Importantly, manufacture of hnCD16-NK
cells was proven to be highly scalable, delivering up to 107 fold expansion over a
35 day period. The maintained proliferative capacity can be in part associated
with longer telomere length seen in hnCD16-NK cells. Furthermore, deletion of
classical human leukocyte antigen molecules and ectopic expression of immu-
nosuppressive proteins engineered at the iPSC level provided the ability of
hnCD16-NK cells to potentially overcome the host histocompatibility barrier
and to improve persistence in the allogeneic setting. In conclusion, the preclin-
ical data presented herein highlight the therapeutic value of hnCD16-iNK cells
as an ideal ADCC-mediated “off-the-shelf” NK cell-based immunotherapeutic
product with augmented persistence, anti-tumor capacity, manufacturing reli-
ability and preclinical effıcacy.
#3756 Effıcient generation of CAR T cells by site-specifıc gene addition
into the TRAC locus. Baeckseung Lee,Wai-Hang Leung, Mark Pogson, Jordan
Jarjour, Alexander Astrakhan. bluebird bio, Seattle, WA.
Genetically engineered T cells represent a promising new approach to the
treatment of cancer. Positive results in recent clinical trials exploiting T cells
engineered to express chimeric antigen receptors (CARs) have highlighted the
potential for these cell-based therapies in patients with B cell malignancies. To
extend these successes to a broader range of tumor types may require additional
T cell engineering beyond simple CAR addition, such as gene knockout and/or
coupling deletion of a target gene with site-specifıc addition of a CAR transgene.
To this end, we have developed a genome editing strategy for the simultaneous
elimination of an endogenous target gene with site-specifıc addition of a CAR
via homology-directed repair (HDR). To demonstrate the utility of this ap-
proach, we used a previously characterized megaTAL (an engineered nuclease
created by the fusion of an engineered meganuclease and a transcription activa-
tor-like (TAL) -DNA binding domain) specifıc for the T cell receptor alpha
constant region gene (TRAC). Delivery of this megaTAL to primary human T
cells via mRNA electroporation results in effıcient and specifıc disruption of the
TRAC locus (Boissel et al, 2013). To achieve simultaneous target gene disruption
with site-specifıc CAR transgene insertion, we designed an adeno-associated
virus (AAV) vector forDNA template delivery encoding theCARand flanked by
regions of DNA homologous to the genome immediately surrounding the
megaTAL cleavage site. Co-delivery of the megaTAL and AAV encoding a
CD19-CAR with TRAC homology arms resulted in50% CARTRAC- cells.
In vitro assays of cytotoxicity and cytokine responses against CD19 Nalm-6
cells confırmed that TRAC-targeted CD19-CAR T cells were comparable to
CD19-CAR T cells generated by lentiviral transduction. Interestingly, a similar
level of CAR T cell function was observed even though TRAC-targeted CD19-
CART cells expressed lower amounts of the CAR, as determined by flow cytom-
etry. Similar CAR integration effıciency and functional effıcacy was observed
using a TRAC-targeting AAV vector containing a distinct B cell maturation
antigen (BCMA)-specifıc CAR. These fındings demonstrate megaTAL-medi-
ated targeted gene addition as a feasible, effıcient, and potentially safer approach
for generation of gene-edited CAR T cell product. Moreover, the ability to com-
bine the disruption of a target gene with the site-specifıc integration of the CAR
eliminates the need for randomly integrating viral vectors while satisfying the
potential need for more complex genome-edited T cell products.
#3757 Ewing Sarcoma regression by Allo-MHC/Chm1 specifıc T cells
without GVHD. Uwe Thiel,1 Sebastian Schober,1 ingo Einspieler,1 Andreas
Kirschner,1 David Schirmer,1 Thomas Grünewald,2 Irene Teichert-von Lüt-
tichau,1 Guenther Richter,1 Poul Sorensen,1 Stefan Burdach1. 1TU-München,
Munich, Germany; 2LMU-München, Munich, Germany.
Background: Chondromodulin-I (CHM1) sustains malignancy in Ewing sar-
coma (ES). Refractory ES carries a dismal prognosis and patients with bone
marrow (BM) metastases do not survive irrespective of therapy. We assessed
HLA-A*02:01/ CHM1 specifıc allorestricted T cell receptor (TCR) wildtype and
transgenic cytotoxic (CD8) T cells against ES. Patients and Methods: Three
refractory HLA-A2 ES patients were treated with HLA-A*02:01/peptide spe-
cifıc allorepertoire-derived (i.e. allorestricted) CD8 T cells. Patient #1 received
up to 4.8x105/kg body weight HLA-A*02:01- allorestricted donor derived wild
type CD8 T cells. Patient #2 received up to 8.2x106/kg HLA-A*02:01- donor
derived and patient #3 up to 6x106/kg autologous allorestricted TCR transgenic
CD8 T cells. All patients were treated with the same TCR complementary
determining region 3 allorecognition sequence for CHM1319. Results: HLA-
A*02:01/CHM1319 specifıc allorestricted CD8 T cells showed specifıc in vitro
lysis of all patient-derived ES cell lines. Therapy was well tolerated and did not
cause graft versus host disease (GVHD). Patients #1 and #3 showed slow pro-
gression, whereas patient #2, while having BM involvement, showed partial
metastatic regression associated with T cell homing to involved lesions.
CHM1319 TCR transgenic T cells could be tracked in his BM for weeks. Conclu-
sions: CHM1319-TCR transgenic T cells home to affected BM and may cause
partial disease regression. HLA-A*02:01/antigen specifıc allorestricted T cells
proliferate in vivo without causing GVHD.
#3758 The effıcacy of CD133 BiTEs and CAR-T cells in preclinical model
of glioblastoma. Parvez Vora,1 Chirayu Chokshi,1 Maleeha Qazi,1 Mohini
Singh,1 Chitra Venugopal,1 SujeivanMahendram,1 Jarrett Adams,2 David Bakh-
shinyan,1 Max London,2 Jess Singh,2 Minomi Subapanditha1,1 NicoleMcFarlane,1
James Pan,2 Jonathan Bramson,1 Sachdev Sidhu,2 Jason Moffat,2 Sheila Singh1.
1McMasterUniversity,Hamilton,Ontario,Canada; 2University ofToronto,Toronto,
Ontario, Canada.
Glioblastoma (GBM) is a uniformly fatal primary brain tumor, characterized
by a diverse cellular phenotype and genetic heterogeneity. Despite the use of
multi-modal treatment including surgical resection, radiotherapy and chemo-
therapy, the outcome of patients with GBM remains poor. Numerous studies
have implicated CD133 brain tumor initiating cells (BTICs) as drivers of
chemo- and radio-resistance in GBM.We recently demonstrated that a CD133-
driven gene signature is predictive of poor overall survival and targeting
CD133 treatment-refractory cells may be an effective strategy to block GBM
recurrence. Chimeric antigen receptors (CARs) and bispecifıc T-Cell engaging
antibodies (BiTEs) present promising immunotherapeutic approaches that have
not yet been validated for recurrent GBM. Using CellectSeq, a novel methodol-
ogy that combines use of phage-displayed synthetic antibody libraries andDNA
sequencing, we developed the CD133-specifıc monoclonal antibody ‘RW03=.
We constructed CD133-specifıc BiTEs that consist of two arms; one arm recog-
nizes the tumor antigen (CD133) while the second is specifıc to CD3 antigen.
The dual binding specifıcity was confırmed using flow cytometry. Using
CD133high and CD133low primary GBM lines, we validated the binding of
BiTEs to CD133 cells. Further analysis showed binding of BiTEs to human T
cells known to express CD3 within a population of healthy donor peripheral
blood mononuclear cells. We observed BiTEs redirecting T cells to kill GBMs,
with greater effıciency observed in CD133high GBMs, validating BiTE target
specifıcity. Incubating T-cells with BiTEs and the CD133high GBMs resulted in
increased expression of T cell activation markers. In parallel, we derived the
single chain variable fragment (scFv) frompreviously generated RW03 and gen-
erated a second-generationCAR.Anti-CD133 scFvwith amyc tagwas cloned in
frame with a human CD8 leader sequence, CD8a transmembrane domain,
CD28, and hCD3	 signaling tail in the lentiviral construct pCCL-
NGFR. Fol-
lowing lentiviral packaging, the T cells isolated from PBMCs were transduced
with CD133 CAR construct. After successful T cell engineering, the expression
of 
NGFR and myc tag was analyzed using flow cytometry to confırm the effı-
ciency of transduction and surface expression of anti-CD133 respectively.
CD133-specifıc CAR-T cells were cytotoxic to CD133 GBMs. Co-culturing
CD133 CAR-T cells with GBMs triggered T cell activation and proliferation.
Treatment of GBM tumor-bearing mice with CD133-specifıc CAR-T cells
yielded extended survival in mice and signifıcant reductions in brain tumor
burden. The results of this study will establish a translational research program
that will form the basis of early phase clinical trials of a promising CD133-based
therapeutic strategy for patients with GBM.
#3759 PiggyBac-manufactured anti-BCMA Centyrin-based CAR-T ther-
apeutic exhibits improved potency and durability. David Hermanson,1 Bur-
ton E. Barnett,1 Srinivas Rengarajan,1 Rebecca Codde,1 Christopher E. Martin,1
XinxinWang,1 Yening Tan,1 Jenessa B. Smith,1 JinHe,2 RohitMathur,2 Sattva S.
Neelapu,2 Jing Yang,2 Eric M. Ostertag,1 Shedlock J. Devon1. 1Poseida Thera-
peutics, San Diego, CA; 2The University of Texas MD Anderson Cancer Center,
Houston, TX.
Chimeric antigen receptor (CAR)Tcells havebeen extremely effective in treating
acute lymphoblastic leukemia and have shown promise against other malignancies
includingmultiplemyeloma (MM). However, relatively poor potency and durabil-
ity continue to limit effıcacy. Addressing these shortcomings, we have developed a
novelCAR-T cell therapeuticwith enhanced stemcellmemory phenotype, reduced
immunogenicity, and no evidence of tonic activity. P-BCMA-101 employs a
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BCMA-specifıc Centyrin rather than a single chain variable fragment (scFv) for
antigendetection and is engineeredusingpiggyBac (PB).Centyrins are fully human
andhave similar binding affınities but are smaller,more thermostable andpredicted
tobe less immunogenic thana scFv. Furthermore,PBmodifıcationofhumanTcells
requires only in vitro transcribed mRNA and plasmid DNA, eliminating the need
for lentivirus or –retrovirus and resulting in time and cost savings. Additionally,
the increased cargo capacity of PBpermits the incorporation of a safety switch and a
selectable gene into the product. The former is incorporated for optional depletion
invivo incaseof adverse events and the latter allowsenrichmentofCARTyrin cells
using the non-genotoxic drug methotrexate (MTX), leading to greater consistency
in patient product material. Characterization of P-BCMA-101 revealed 70% of
cells possessed a stem-cell memory phenotype (i.e. CD45RA CCR7 CD62L
CD95) and95% of the cells were CARTyrin. In addition, no tonic signaling or
T cell exhaustionwas observed, highlighted by low levels of PD-1, Lag3, andTim-3.
Cells exhibit specifıc and robust in vitro target-cell killing, cytokine production, and
proliferation in response to BCMA tumor cells. In vivo anti-tumor effıcacy of
P-BCMA-101 has been evaluated inNSGmice bearing luciferaseMM.1S cells, an
aggressive humanMM-derived cell line, monitoring tumor growth by biolumines-
cent imaging (BLI). Following tumor implantation, animals received a single IV
administrationof either 4 x 106 or 12 x 106 P-BCMA-101 cells. All untreated control
animals succumbed to disease within four weeks of the treatment date. Conversely,
tumor burden was reduced to the limit of detection by BLI within 7 days of p-
BCMA-101 treatment. As opposed to lentivirus-based products in the same animal
model, P-BCMA-101 persists and expands in the animals, eliminates tumors from
relapse and prolong survival, with most animals surviving 100 days post-tumor
implant. Finally, the effectiveness of the safety switchhasbeendemonstratedboth in
vitro and in vivo. P-BCMA-101 is the fırst-in-class of Centyrin-based CAR thera-
peuticsmodifıedusingPBand is predicted tohave improvedpotency anddurability
given the phenotype and non-immunogenic properties of Centryrins. We plan to
initiate a phase I clinical trial of P-BCMA-101 for the treatment of patients with
relapsed and/or refractoryMM.
#3760 Preclinical optimization of a low cost PiggyBac transposase (PB)
generatedCD19-specifıc chimeric antigen receptor T cell (CART19) product
for a fırst in man trial using local hospital cell manufacture. David Bishop,1
Ning Xu,2 Sylvie Shen,2 Tracey O’Brien,2 David Gottlieb,1 Alla Dolnikov,2 Ken-
nethMicklethwaite1. 1Westmead Institute forMedical Research, Sydney, Austra-
lia; 2Children’s Cancer Institute, Sydney, Australia.
BACKGROUND: CAR19 T cells show remarkable effıcacy against relapsed/re-
fractory B cell malignancies. PiggyBac offers a less complex andmore cost effective
means for generating CAR19 T cells compared to viral vectors typically used, so we
aimed to use PiggyBac to generate a product suitable for translation to the clinic.
METHODS: CAR19 T cells utilizing the CAR1928z construct have been found to
performwell in vitrobuthadpoor invivo effıcacy andpersistence,most likelydue to
deleterious FcR interactions via the IgG1 Fc-containing CAR spacer domain.We
designed two new CARs and replaced the IgG1 Fc component of the spacer with a
(G4S)3 linker.We used either CD28 or 4.1BB co-stimulatory domains (CAR19h28z
and CAR19h41BBz, respectively), and generated CAR19 T cells using electropora-
tionof PiggyBac transposon and transposase plasmids.Cellswere expandedover 22
days throughCD19 stimulationwith IL-15 support. The two newCARswere com-
pared to CAR1928z in vitro and their in vivo activity was assessed over 12 weeks in
NSG mice xenografted with B-ALL. RESULTS: CAR19 T cell products generated
using PiggyBac showed vigorous expansion (minimum 120-fold) and robust CAR
expression (80% T cells in fınal product). T cells generated using CAR19h28z
displayed CD4 predominance (mean 85%) while CAR19h41BBz showed greater
CD8 predominance (mean 62%). Naïve and central memory T cells constituted 30
to 45% of CAR19 T cells in all products. IFN- production was specifıc to CD19
targets and was demonstrated in both CD4 and CD8CAR19 T cells. CD19 spe-
cifıc dose-dependent cytotoxicity was seen with all products, although to a signifı-
cantly lower degreewithCAR19h28z. In vivo, a single dose of either CAR19h28z or
CAR19h41BBz T cells 1 week after B-ALL injection signifıcantly delayed leukemia
progression compared to untreatedmice (medianOS: 42 days for untreated vs82
days [median not reached] for eachCAR19T cell product, P0.05). CAR19T cells
could be detected in peripheral blood, bone marrow and/or spleen of treated mice.
CONCLUSIONS:CAR19Tcells generatedwithPiggyBac, utilizingoptimizedCAR
constructs without IgG1 Fc-containing spacers and with either CD28 or 4.1BB co-
stimulatory domains, had potent activity against B-ALL in preclinical studies. We
selected CAR19h41BBz to proceed to a fırst inman clinical trial of PiggyBac gener-
ated CAR19 T cells. The low cost and simplicity of our manufacturing process uti-
lizing electroporationwith PiggyBac elements and patient-derivedmaterialsmeans
that decentralized, local hospital production is feasible. We predict that CAR T cell
productionwithPiggyBacwill greatly improveaccessibility toCAR19Tcell therapy.
#3761 Specifıc and dynamic tumor antigen-specifıc immune responses
were elicited in patients with hepatocellular carcinoma after cell-based im-
munotherapy. Yanyan Han,1 YeWu,2 Chou Yang,2 Jing Huang,2 Yabing Guo,2
Li Liu,2 Ping Chen,1 DongyunWu,1 Junyun Liu,1 Jin Li,1 Xiangjun Zhou,1 Jinlin
Hou2. 1HRYZ Biotech Co., Shenzhen, China; 2State Key Laboratory of Organ
Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Re-
search, Department of Infectious Diseases, Nanfang Hospital, Southern Medical
University, Guangzhou, China.
Hepatocellular carcinoma (HCC) is one of the most common cancers in China
and frequently occurswith chronic hepatitis B virus (HBV) infection.To investigate
whether cell-based cancer immunotherapy induces tumor specifıc immune re-
sponses in patients with HCC and provides clinical benefıts, as well as to elucidate
themost immunogenic tumor associated antigens (TAAs),multiple antigen stimu-
lating cellular therapy (MASCT)was applied in addition to standardof care.Mature
dendritic cells (DCs) and activated T cells prepared for MASCT were generated
from autologous peripheral blood mononuclear cells (PBMCs). DCs were loaded
with a peptide pool ofmultipleHCC-related tumor antigens, andT cells were stim-
ulated by these DCs. Thirteen patients with HCC received repeated MASCT after
tumor resection during which their immune responses were examined. After three
courses of MASCT, the frequency of regulatory T cells in the patients’ PBMCs sig-
nifıcantly decreased (p  0.001), while the antigen peptide pool-triggered T cell
proliferation (p 0.001) and IFN production (p 0.001) were signifıcantly en-
hanced. The specifıc T cell responses against each antigen in the pool were detected
in elevenpatients, butwith individualizeddistinct patterns.Themost immunogenic
TAAs for HCC are survivin, CCND1, and RGS5. Moreover, the antigen-specifıc
immune responses observed in tumor-free patients’ PBMCs were signifıcantly
stronger than that in the patients with recurrence (p  0.037). Conclusion: Our
study demonstrates thatMASCT is well-tolerated by patients with HCC and elicits
strong and dynamic immune responses specifıcally against multiple tumor associ-
ated antigens, whichmay correlate with clinical outcomes.
#3762 Superior T cell activity of a membrane-proximal binding antibody
when targetingGlypican-3with an antibody-coupledT-cell receptor (ACTR)
armed T cell. Greg Motz,1 John Shin,1 Kathleen Whiteman,1 Birgit Schultes,1
Tapasya Pai,1 LoriWestendorf,2 Seth Ettenberg,1 Travis Biechele,2 Django Suss-
man,2 Heather Huet1. 1Unum Therapeutics, Cambridge, MA; 2Seattle Genetics,
Bothell, WA.
Glypican-3 (GPC3) is aGPI-anchoredmember of the heparan sulfate proteogly-
can family.GPC3 is an oncofetal antigen expressed transiently during fetal develop-
ment with re-expression duringmalignant transformation. GPC3 is an ideal tumor
target as expressionhas been found innumerous epithelialmalignancies,withhigh-
est expression in hepatocellular carcinoma (HCC) and non-small cell lung carci-
noma (NSCLC), and normal tissue expression is highly restricted (Baumhoer D.,
Am J Clin Pathol, 2008.). Adoptive T-cell therapy with single-chain variable frag-
ment (scFv)-derived chimeric antigen receptors (CARs) has transformed cancer
therapy, but the broad applicability of this approach has been limited in part by
safety concerns due the constitutive expression of a biologically active targeting
receptor. The Antibody-Coupled T-cell Receptor (ACTR) platform is a universal,
engineeredT-cell therapydesigned to engage theFcdomainof therapeutic antibod-
ies opsonized to tumor cells to mediate anti-tumor activity. ACTR activity is there-
fore both regulatable and flexible, providing enhanced therapeutic control and im-
proved safetyof theTcell therapy.UsingbothHCCandNSCLCtumor cell lines,we
testedapanelofwild-typeandafucosylatedantibodieswithsimilarbindingaffınities
that bound to regions spanning theGPC3protein acrossunique epitopes.We found
that for GPC3 targeting antibodies, the greatest activity in a Jurkat-NFAT reporter
assay was observed for the afucosylated antibody that bound GPC3most proximal
to the membrane. Further, the antibody that bound membrane proximal also had
the most potent activity in primary ACTR T cell cytotoxicity and cytokine release
assays. The physical distance between T cells and tumor targets has been previously
determined to impact T cell activation for both peptide-MHC and CAR-T interac-
tions. Similarly, our results demonstrate a potential relationship between spatial
distanceof tumor targets andTcells indetermining the activityACTRtransducedT
cells when targeting GPC3. Our data demonstrate that ACTRT cell activity is anti-
body-specifıc and dose-titratable, highlighting both effıcacy and improved safety of
the ACTR T cell platformwhen targeting GPC3 solid tumormalignancies.
#3763 UCART22: allogenic adoptive immunotherapy of leukemia by tar-
geting CD22 with CAR T-cells. Agnès Gouble,1 Cécile Schiffer-Mannioui,1
Severine Thomas,1 Anne-Sophie Gautron,1 Laurent Poirot,1 Julianne Smith2.
1Cellectis, Paris, France; 2Cellectis, New York, NY.
Adoptive immunotherapy using autologous T-cells endowed with chimeric an-
tigen receptors (CARs) has given rise to long-term durable remissions and remark-
able objective response rates in patients with refractory leukemia, raising hopes that
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awider application of CAR technologymay lead to a new paradigm in cancer treat-
ment.However, a limitation of the current autologous approach is that CART-cells
must bemanufactured on a ‘per patient basis‘. To overcome this limitation,we have
developed a standardized platform for manufacturing T-cells from third-party
healthy donors to generate allogeneic ‘off-the-shelf‘ engineered CART-cell-based
frozen products. Our allogenic platform utilizes the Transcription Activator-Like
Effector Nuclease (TALEN) gene editing technology to inactivate the TCR con-
stant (TRAC) gene, signifıcantly reducing the potential for T-cells bearing alloreac-
tiveTCR’s tomediateGraft-versus-HostDisease (GvHD).Wehavepreviouslydem-
onstrated the precise and effıcient disruption of the the TRACgene by gene editing,
yielding up to 85%ofTCR-negative cells. This allows the production of TCR-
defıcient T-cells that no longer mediate alloreactivity in a xeno-GvHD mouse
model. In the clinic, the proof of concept of the applicability of our allogeneic plat-
form was achieved with early compassionate use for patients treated with
UCART19, an allogeneic engineered CAR T-cell product directed against CD19.
UCART19 clinical trials are currently ongoing. Here, we have developed T-cells
targetingCD22which is expressedon tumor cells from themajority of patientswith
B-cells leukemia. In a fırst step, we have screened multiple antigen recognition do-
mains in the context of different CAR architectures to identify effective CAR candi-
dates displaying activity against cells expressing variable levels of the CD22 antigen.
As a safety feature, T-cells are engineered to co-express a depletion gene, rendering
them sensitive to the monoclonal antibody rituximab. Several constructs of deple-
tion genes have been evaluated in the context of the CD22CAR. In addition, exper-
iments in an orthotopic ALL mouse model using UCART22 cells demonstrated
important anti-tumor activity in vivo. The ability to carry out large scale manufac-
turing of allogeneic, non-alloreactive CD22 specifıc T-cells from a single healthy
donor can offer the possibility of an off-the-shelf treatment that would be immedi-
ately available for administration to a largenumber of leukemicpatients.UCART22
could also offer an alternative to patients who may relapse with CD19-negative
tumors after CD19 CAR T-cell treatment.
#3764 Targeting GPR64 in pediatric sarcomas with CAR transgenic T
cells. David Schirmer,1 Isabel Storz,1 Karin Wisskirchen,2 Regina Feederle,3
Oxana Schmidt,1 Hinrich Abken,4 Crystall Mackall,5 Ulrike Protzer,2 Stefan
Burdach,1 Günther H. Richter1. 1Technical University Munich, Munich, Ger-
many; 2Technical UniversityMunich, Helmholtz ZentrumMunich,Munich, Ger-
many; 3Helmholtz Zentrum Munich, Munich, Germany; 4University Hospital
Cologne, Cologne, Germany; 5Stanford University, Stanford, CA.
Introduction: Ewing Sarcoma (ES) is the second most common bone malig-
nancy in children and young adolescents with a high potential of dissemination
into lung and bones. Patients with disseminated disease into the bone have an
approximate long-term survival rate of only 10%, compelling the search for new
therapeutic treatment modalities like engineered T cell therapy. Here the ther-
apeutic potential of chimeric antigen receptor (CAR) transgenic T cells directed
against G-protein coupled receptor 64 (GPR64) was examined. Experimental
procedure: Two different monoclonal antibodies (mAb) directed against the
extracellular region of GPR64 were generated and characterized. Subsequently,
retroviral constructs containing second generation CARs together with the scFv
fragments of the respective mAbs were designed. Constructs consisting of dif-
ferent spacers and co-stimulatory elements were compared (dIgG1-CD28-
CD3z vs. CD8a-4-1BB-CD3z). Primary lymphocytes were transduced and
tested in vitro via flow cytometry, ELISpot and xCelligence assay as well as in
immunodefıcient xenograft mice. Results: Antibodies specifıcally stained ES
cells as determined by flow cytometry and immune histology. The signal inten-
sity was reduced after RNAimediated down-regulation of GPR64 in ES cell lines
confırming specifıcity of the isolated mAbs. Following sequence determination
of those mAbs two different CAR constructs were designed. Retroviruses con-
taining such CARs transduced primary lymphocytes with high effıciency. The
CAR transgenic T cells were enriched for CD8CAR cells via microbead iso-
lation and demonstrated strong proliferative capacities in vitro. Furthermore,
target structures were specifıcally recognized as determined by ELISpot and
xCelligence assays but dIgG1-CD28 CAR T cells derived from one hybridoma
revealed hints of early exhaustion via auto-activation. Conclusion: CAR trans-
genic T cells targetingGPR64 show a promising approach to transfer the success
of CARs in hematological malignancies to solid tumors. The cells generated in
this study show strong specifıcity towards GPR64 and are able to control tumor
cell growth. Since GPR64 expression is not restricted to ES but also up-regulated
in a number of carcinomas derived from prostate, kidney or lung, GPR64-spe-
cifıc CARs may also be a future treatment option for other tumor entities.
#3765 IND-EnablingGLP study to support a clinical trial of dual adoptive
cell therapy combining stem cells and T cells engineered with an NY-ESO-1
TCR. Cristina Puig-Saus, Giulia Parisi, Paige Krystofınski, Angel Garcia-Diaz,
Salemiz Sandoval, James McCabe, Ruixue Zhang, Gardenia Cheung-Lau, Nhat
Truong, Justin Saco, Sara Komenan, Agustin Vega-Crespo, Mignonette H Ma-
cabali, Begoña Comin-Anduix, Beata Berent-Maoz, Donald Kohn, Paula Ka-
plan-Lefko, Antoni Ribas. UCLA, Los Angeles, CA.
T cell receptor (TCR) engineered adoptive T cell transfer (ACT) has shown
remarkable antitumor effıcacy in several clinical trials. However, lowpersistence
of modifıed cells limits long-term clinical responses. To overcome this hurdle,
we propose a clinical trial co-administering geneticallymodifıedT cells and stem
cells both expressing an NY-ESO-1 TCR such that the engrafted stem cells gen-
erate a source for constant renewal of modifıed T cells. Here we report a pre-
clinical IND-enabling study performed at UCLA under Good Laboratory Prac-
tice (GLP) compliance to assess whether co-administration impacts (I) safety;
(II) engraftment and cell lineage differentiation of genemodifıed stem cells; and
(III) persistence of adoptively transferred T cells and stem cell-derived progeny.
We performed 12 optimization studies to defıne the optimal conditions for TCR
gene modifıed ACT and TCR gene modifıed hematopoietic stem cell (HSC)
bone marrow transplantation (BMT). Sixty-four HLA-A2/kb transgenic mice
were myelodepleted and received syngeneic BMT with Lineage depleted bone
marrow (Lin-) cells transduced with the LV-NYESO-1 TCR/sr39TK and ACT
with T cells transduced with the RV-NYESO-1 TCR. Control groups were as
follows: untreated mice, mice receiving mock transduced Lin- cells and T cells,
mice receiving transduced Lin- cells and mock transduced T cells, and mice
receivingmock transduced Lin- cells and transduced T cells (n 16 per group).
Overall survival at 3 months was 87.5%; no signifıcant differences in survival
were observed among cohorts. After BMT we observed a decrease in body
weight, elevation in creatinine kinase and transaminases, and gonadal germ cell
ablation in all cohorts. Three months after BMT, all blood cell lineages were
reconstituted in surviving mice. Using digital droplet PCR and flow cytometry,
we confırmed that transduced stem cells engrafted and their progeny persisted
long term. In the bone marrow, NY-ESO-1 TCR was expressed intracellularly
among progenitor cells (Lin-, LSK and HSC) as well as all hematopoietic cell
lineages within the spleen (CD8 T cells, CD4 T cells, NKT cells, B cells and
granulocytes). Co-administration with gene modifıed T cells and stem cells did
not affect engraftment, cell lineage differentiation or persistence of the gene
modifıed stem cells. Moreover, co-administration with stem cells did not affect
persistence of adoptively transferred T cells. These data demonstrate that 1)
NY-ESO-1 TCR genetically modifıed stem cells engraft and differentiate into all
hematopoietic cell lineage progeny, which persists at 3 months; 2) adoptively
transferred NY-ESO-1 TCR T cells persist at 3 months; 3) co-administration of
stem cells and T cells genetically modifıed to express an NY-ESO-1 TCR is safe
and does not negatively impact stem cell engraftment, lineage differentiation
and progeny persistence or T cell persistence.
#3766 MG7-car, a fırst-in-class T-cell therapy for gastric cancer. Jijun
Yuan. Shanghai Genechem Co., Ltd., Shanghai, China.
Gastric Cancer, with increasing incidence and mortality, has become a major
public health problem in China. According to the most recent study in China,
Gastric Cancer is the secondmost common cancer with an incidence of 680,000
cases andmortality of close to 500,000 cases. Therefore, it is important to fınd an
effective way to treat the gastric cancer. MG7 antigen is a highly specifıc gastric
cancer antigen identifıed by immunohistochemistry in late 80’s, unfortunately
most work since then has been focused on MG7 antigen as a diagnosis marker
without any treatment approach. Chimeric Antigen Receptor (CAR) T cell ther-
apy is a newly developed technique called adoptive cell transfer. T cells from the
patient are able to recognize and kill the tumor cell by grafting a tumor specifıc
antigen binding single chain variable fragment (scfv) onto the T cell. In the past
couple of years, CART therapy has demonstrated tremendous success in eradi-
cating hematological malignancies, but no big improvement has been achieved
in solid tumors. In this study, we converted an MG7 antibody into a scfv and
engineered the T cell as an MG7-CART for the treatment of Gastric Cancer. To
our knowledge, this is the fırst CART therapy being studied on gastric cancer.
First to investigate the Gastric Cancer specifıcity ofMG7 antigen, we did immu-
nohistochemistry study on 485 samples (including 325 gastric cancer samples).
It showed that MG7 antigen can’t be detected in normal gastric samples (0/50)
and only 8% in chronic atrophic gastritis samples (4/50), but the positive rate
increased to 58% and 70% in gastric dysplasia tissues (35/60) and gastric cancer
tissues samples (227/325). At the same time, we compared MG7 antigen with
other cancer biomarkers in gastric cancer tissues. Within 50 cancer samples,
MG7 antigen has positive rate of 73%, much higher than the other markers,
including CA199 (53%), CEA (51%), CA72-4 (31%) and CA125 (14%). For
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MG7-CAR, we converted theMG7 antibody to a scfv without losing any antigen
binding affınity and “scfv-CD8-41BB-CD3z” structure was used for the MG7-
CAR. The study showed that the MG7-CAR can be well expressed with trans-
duction rate close to 40%. The in vitro data showed that MG7-CART can effı-
ciently kill gastric cancer cell line KATO3, but not colorectal cancer cell line
SW620 with cancer antigen CEA overexpressed. The cytokine release assay also
showed that IFN-gamma releasing result is highly correlated to the cell killing
result. In order to further estimate the effıcacy of the MG7 CAR, we set up a
patient derived xenograft (PDX) model with gastric samples highly expressing
bothCEAandMG7 antigen.With one time intratumoral injection of 1.5million
CART cells, bothMG7CART andCEACART regressed the PDXmodels, while
theMG7CARThas the better effıcacywith complete regression observed in 80%
of the PDX models. Our work demonstrated that MG7 antigen is very specifıc
for gastric cancer and can be a novel treatment target by applying CAR T cell
therapy.
#3767 Identifıcation of a novel and a sharedH3.3K27Mmutation derived
neoantigen epitope and H3.3K27M specifıc TCR engineered T cell therapy
for glioma. Zinal Chheda,1 Gary Kohanbash,1 John Sidney,2 Kaori Okada,1
Naznin Jahan,1 Diego Carrera,1 Payal Watchmaker,1 Kira Downey,1 Shuming
Liu,1 Shruti Shrivastav,1 Sabine Mueller,1 Ian F. Pollack,3 Angel M. Carcaboso,4
Alessandro Sette,2 Yafei Hou,1 Hideho Okada1. 1UCSF, San Francisco, CA; 2La
Jolla Institute for Allergy and Immunology, La Jolla, CA; 3University of Pittsburgh
School of Medicine, Pittsburgh, PA; 4Hospital Sant Joan de Deu Barcelona, Spain.
Brain cancers are the leading cause of cancer relatedmortality in children and
young adults with median overall survival of 9-10 months and hence represents
a signifıcant unmet medical need. Genome-wide sequencing efforts of pediatric
gliomas have identifıed a recurrent and shared missense mutation in the gene
encoding the replication-independent variant of histone 3,H3.3. Approximately
70% of diffuse intrinsic pontine gliomas (DIPG) and 50% of thalamic and other
midline gliomas harbor the amino acid substitution from lysine (K) to methio-
nine (M) at the position 27 of H3.3 gene. Tumor specifıc missensemutations are
not subjected to self-tolerance and can be suitable targets (neoantigens) for
cancer immunotherapy. Herein, we evaluated whether theH3.3K27Mmutation
can induce specifıc cytotoxic T lymphocyte (CTL) response in HLA-A2 T
cells. In vitro stimulation of HLA-A2 donor derived CD8 T cells with a
synthetic peptide encompassing the H3.3K27Mmutation (H3.3K27M epitope)
induced CTL lines which recognized not only T2 cells loaded with the synthetic
H3.3K27M epitope peptide but also lysed the HLA-A2 DIPG cells which en-
dogenously harbor the H3.3K27M mutation. On the other hand, the CTL lines
did not react to either HLA-A2 but H3.3K27M- negative DIPG cell lines or
H3.3K27M positive but HLA-A2 negative DIPG cells. The H3.3K27M epitope
peptide but not the non-mutant counterpart indicated an excellent binding af-
fınity (Kd 151nM) to HLA-A2 based on competitive binding inhibition assay.
From CTL clones with high and specifıc affınities to HLA-A2-H3.3K27M-te-
tramer, cDNAs for T cell receptor (TCR) alpha and beta chains were cloned into
a retroviral vector. HumanHLA-A2 T cells transduced with the TCR demon-
strated antigen specifıc reactivity as well as anti-glioma responses in vitro. Pep-
tide titration assays suggested that the H3.3K27M specifıc TCR had the half-
maximal reactivity for peptide recognition of around 100nM. Furthermore,
critically important for safety of clinical application, alanine scanning demon-
strated that the key amino acid sequence motif in the epitope of the TCR reac-
tivity is not shared by any known human protein. Finally, intravenous adminis-
tration ofT cells transducedwithH3.3K27Mspecifıc TCR signifıcantly inhibited
the growth of intracranial HLA-A2 H3.3K27M positive glioma xenografts in
immune defıcient NSG mice. These data provide us with a strong basis for
developing peptide based vaccines as well as adoptive transfer therapy using
autologous T cells transduced with the H3.3K27M specifıc TCR. Acknowledge-
ments: This study is supported by the NIH/NINDS (1RO1NS096954), V Foun-
dation and Parker Institution for Cancer Immunotherapy.
#3768 CAR T cells specifıc for CD19 can be redirected to kill CD19 nega-
tive tumors. Christine Ambrose, Lihe Su, Lan Wu, Roy R. Lobb, Paul D.
Rennert. Aleta Biotherapeutics, Natick, MA.
Introduction. Remarkable progress has been made in the treatment of re-
lapsed/refractory Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma
with CAR-CD19 T cells. In contrast, progress against CD19-negative hemato-
logical cancers and solid tumors has been limited. Intensive efforts to optimize
cellular therapeutics for better effıcacy include provision of cytokine support
and countering immunosuppression. However, lack of suffıcient antigen is a
signifıcant additional hurdle that CAR-T therapeutics for solid tumors must
overcome. We present a novel strategy to utilize CD19 for sustained antigen
presentation in order to promote cellular therapeutic expansion, effıcacy and
persistence. The strategy, called IMPACT (IntegratedModules oPtimize Adop-
tive Cell Therapy), employs a methodology that is modular in design and and
can be applied to diverse antigens and tumor types, yet retains the well-estab-
lished advantages of CAR T cells directed to CD19. Experimental Procedures. A
3rd generation CAR-T was constructed in a lentiviral vector using the FMC63
anti-CD19 scFv for antigen recognition. A second expression cassette, cloned
downstream of the CAR-T cassette, was constructed using a secretion signal
sequence and exons 1 - 4 of the human CD19 protein linked in frame to a
trastuzumab-derived Vh/Vl sequence. This integrated-gene module thus en-
codes a fusion protein (FP): CD19-anti-HER2-scFv. Results. ELISA and flow
cytometry analyses were used to demonstrate bridging between HER2 cells
and the FMC63 mAb via the CD19 domain of the FP. ELISA analyses further
demonstrated wild type binding of the 2 FP domains (i.e. CD19/FMC63 and the
scFv/HER2). In vitro cytotoxicity studies showed robust redirected killing of
HER2 (CD19-) tumor cells by CAR19 T cells that is mediated by the secreted
FP. The effıciency of cytotoxicity was enhanced by the presence of CD19 B
cells. A tumor xenograft model was used to demonstrate effective killing in vivo
when HER2 BT474 cells were injected in one flank and CD19 RAMOS cell
were injected in the opposite flank, but not when HER2 cell were injected
alone. Thus, in vivo, redirected killing required CD19 cells for expansion and
persistence suffıcient to promote anti-HER2 cytotoxicity. Conclusions. A
CD19-anti-HER2-scFv FP was able to redirect the cytotoxicity of CAR19 T cells
in order to kill HER2 tumor cells. In vivomodeling demonstrated that CAR-T
cell expansion by CD19 recognition enabled effıcient HER2 cell cytotoxicity.
The IMPACT technology is modular, allowing for FPs having diverse protein
domains paired with diverse, distinct scFvs to allow CAR T cells to CD19 or
other targets to be used to kill any tumor. We have further developed the tech-
nology to address antigens of utility for hematopoietic and solid tumors, includ-
ing BCMA, ROR1, and PD-L1. The technology is broadly applicable and syner-
gistic with existing cellular therapies.
#3769 Stem cell-engineered invariant natural killer T cells for cancer ther-
apy. Lili Yang, Drake Smith, Siyuan Liu, Sunjong Ji, Bo Liu.Univ. of California,
Los Angeles, Los Angeles, CA.
Invariant natural killer T (iNKT) cells comprise a small population of  T
lymphocytes. They bridge the innate and adaptive immune systems andmediate
strong and rapid responses to many diseases, including cancer, infections, aller-
gies and autoimmunity. However, the study of iNKT cell biology and the ther-
apeutic applications of these cells are greatly limited by their small numbers in
vivo (0.01-1% in mouse and human blood). Here, we report a new method to
generate large numbers of iNKTcells inmice throughT cell receptor (TCR) gene
engineering of hematopoietic stem cells (HSCs). We showed that iNKT TCR-
engineered HSCs could generate a clonal population of iNKT cells. These HSC-
engineered iNKT cells displayed the typical iNKT cell phenotype and function-
ality. They followed a two-stage developmental path, fırst in thymus and then in
the periphery, resembling that of endogenous iNKT cells. When tested in a
mouse melanoma lungmetastasis model, the HSC-engineered iNKT cells effec-
tively protected mice from tumor metastasis. This method provides a powerful
and high-throughput tool to investigate the in vivo development and function-
ality of clonal iNKT cells in mice. More importantly, this method takes advan-
tage of the self-renewal and longevity of HSCs to generate a long-term supply of
engineered iNKT cells, thus opening up a new avenue for iNKT cell-based im-
munotherapy.
#3770 CAR-T cell harboring a camelid single domain antibody as a target-
ing agent to kill tumors expressing VEGFR2. Heman Chao, Baomin Tian,
Marni Uger, Wah Wong. Helix BioPharma Corp., Toronto, Ontario, Canada.
Modulation of the immune system is showing tremendous promise in the
treatment of malignancies. In addition to checkpoint inhibitors that re-activate
T cells present in the tumormicroenvironment, exogenously transduced chime-
ric antigen receptor (CAR) T cells are providing excellent responses in clinical
trials for the treatment of leukemias. In this study, we describe CAR-T cells that
target VEGFR2-expressing tumors. Angiogenesis is the process of new blood
vessel formation and is essential for a tumor to grow beyond a certain size.
Tumors secrete the pro-angiogenic factor vascular endothelial growth factor
(VEGF), which acts upon local endothelial cells by binding to vascular endothe-
lial growth factor receptors (VEGFR). As VEGFR2 is also expressed by a variety
of tumors, we investigated the utility of anti-VEGFR2 CAR-T cells as a method
to treat VEGFR2-expressing tumors. Camelid antibodies are small (14 kD) sin-
gle chain antibodies. To generate a camelid antibody targeting the extracellular
domain of VEGFR2, a llama was immunized with recombinant VEGFR2/Fc. A
phage display library was generated and screened to identify an antibody with
high binding affınity to VEGFR2. The selected antibody was expressed in the E.
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coli. BL21 (DE3) pT7 system. The purifıed antibody was characterized by SEC,
LC-MS peptide mapping and ELISA. CAR-T cells were engineered to express
the camelid anti-VEGFR2 antibody in combination with the CD28 and 4-1BB
costimulatory molecules and the CD3 zeta chain. Tumor cells were screened for
expression of VEGFR2, and theHL-60 acute promyelocytic leukemia, ZR-75-30
breast ductal carcinoma and NCI-H23 non-small cell lung adenocarcinoma
were identifıed. Co-incubation of anti-VEGFR2 CAR-T cells with the VEGFR-
2-expressing cell lines resulted in dose-dependent target cell toxicity as mea-
sured by LDH release. In addition, T cell activity was confırmed, as high levels of
IL-2 and IFN-were detected in the cell culturemedia. These results suggest that
anti-VEGFR2 CAR-T may be useful in directly targeting VEGFR2-expressing
tumors. We previously showed the utility of camelid antibodies in CAR-T con-
structs as anti-CEACAM6 CAR-T cells show both in vitro and in vitro effıcacy
against the pancreatic tumor Bx-PC3. The use of the a camelid V21 antibody to
target VEGFR2-expressing tumors provides hope that camelid single domain
antibodies can be developed for CAR-T therapies.
#3771 Concurrent GVAX and anti-OX40 therapy in murine intracranial
glioma model.Nusrat Jahan, Hammad Talat, William T. Curry.Department of
Neurosurgery, Massachusetts General Hospital, HarvardMedical School, Boston,
MA.
Introduction: Malignant glioma is the most aggressive brain tumor with a
median survival time of less than 1.5 years post diagnosis despite standard treat-
ments. However, recent advancements in immunotherapy hold signifıcant
promise. Irradiated whole tumor cell vaccination stimulates antitumor immu-
nity and prolongs survival in mice with intracranial glioma tumors. We have
shown that vaccination and immune checkpoint blockade is synergistic and
these efforts are underway in the clinic. In contrast to immune checkpoint block-
ade, agonist stimulation of OX40, a member of the TNFR/TNF superfamily that
is expressed on activated CD4 and CD8 T lymphocytes increases T cell prolifer-
ation, clonal memory differentiation, and cytokine release. We hypothesized
that subcutaneous vaccination with irradiated GM-CSF expressing glioma cells
(GVAX) would, therefore, synergize with systemic delivery of stimulating anti-
OX40 antibody and provide effective immunity against intracranial gliomas.
Methods: Gl261 cells were implanted in the right frontal lobes of syngeneic
c57/bl6mice using a stereotactic implantation technique.Mice received concur-
rent subcutaneous injection of irradiated GM-CSF expressing glioma cells and
intraperitoneal injection of OX40 antibody, either monotherapy, or control
treatment on days 3, 6 and 9 following tumor implantation. Results: Combina-
tion immunotherapy with irradiated GM-CSF expressing glioma cells and in-
traperitoneal delivery of agonist monoclonal antibody against OX40 was more
effective than either therapy alone and prolonged survival in mice with estab-
lished intracranial GL261 tumors. Elispot analyses of peripheral lymphocytes
revealed that combination immunotherapy reverses the Th2 cytokine skew that
is induced by the presence of intracranial glioma. OX40 signaling alone and in
combinationwith vaccination drove high levels of interferon gamma expression
by splenocytes harvested from glioma-bearing animals, while IL-10 expression
was little changed. In the tumor microenvironment, vaccination improves the
CD8 /FoxP3 T lymphocyte ratio, while OX40 ligation overcomes tumor-
driven lymphocyte exhaustion, demonstrated by reduced expression of PD1 and
LAG3, measured by flow cytometery 2 weeks after initiation of treatment. Con-
clusions: Combination treatment with GVAX and OX-40 agonist antibody in-
creased survival in mice bearing intracranial gliomas and are mechanistically
complementary.
#3772 Amulti-scale survey to assess the impact of inflammatory diseases
of the abdominal cavity and prostate cancer severity. Khader Shameer, Kam-
lesh Kumar Yadav, Li Li, Shalini S. Yadav, Benjamin Glicksberg, Irtaza Khan,
KippW. Johnson,Marcus A. Badgeley, Cordelia Elaiho, Ben Readhead, BrianA.
Kidd, Andrew Kasarskis, Joel T. Dudley, Ashutosh K. Tewari. Icahn School of
Medicine at Mount Sinai, New York, NY.
Introduction andObjectives: Prostate cancer (PCa) is themost common can-
cer detected inmen (181,000 annual cases), and nearly 26,000Americanmendie
each year due to PCa and related complications. Reports have shown that PCa is
more aggressive when its comorbid with inflammatory diseases. However, the
correlations and risks attributed to inflammatory diseases of the abdominal cav-
ity and oncophenotypes are not known. Methods: To investigate how inflam-
matory pathways and PCa genes induce aggressive oncophenotypes in the set-
ting of PCa, we have compiled a multiscale survey that includes data from
surgical observations, inflammatory phenotypes, clinical registries, biomarkers
andmousemodels.We applied an integrative informatics approach with exper-
imental validation to understand the associations between inflammatory dis-
eases (e.g., Crohn’s disease, ulcerative colitis, collagenous colitis, indeterminate
colitis, ischemic colitis, diverticulitis, hernia, etc.) and PCa. Results: We found
distinct patterns of shared molecular features—gene sets, pathways, and net-
works—and comorbidities across inflammatory disease and PCa. For example,
we found that diverticulitis tend to increase inflammation in the abdominal
cavity and could potentially lead to aggressive prostate oncophenotypes. To test
abdominal inflammation and PCa correlation, we induced inflammation in a
mousemodel of hiatus hernia, which resulted in an increase in the expression of
the combinedmarkers of inflammation and PCa (TGFB, TNFA, and IL6). Eval-
uation of pathology stage, Gleason scores and physical attributes of previous
inflammation observed during robotic prostatectomy surgery also reveals trend
towards aggressive tumor characteristics with an increase in inflammation.
Gene-set overlap analyses showed that several inflammatory disease and pros-
tate cancer genes share genetic modules. Conclusion: Collectively, our fındings
provide the fırst set of computational, experimental and clinical evidence to
recommend clinicians to evaluate the impact of inflammatory disease induced
oncophenotypes in patients with PCa. Given that 1.3 million patients undergo
prostate-specifıc antigen (PSA)-triggered invasive trans-rectal biopsy, the pres-
ent fındings in combination with PSA could facilitate the identifıcation patient
subset with aggressive cancer. Stratifying patients at risk for prostate cancer who
are undergoing surgical interventions of abdominal cavity for inflammation
diseases could also evaluate other non-surgical or therapeutic strategies. Fund-
ing acknowledgements: AKT is supported by grants fromProstateCancer Foun-
dation and Deane Prostate Health. JT is supported by grants from National
Cancer Institute NCI-U54-CA189201-02, National Center for Advancing
Translational Sciences NCATS-UL1TR000067 and Clinical and Translational
Science Award (CTSA).
#3773 Tapping CD4T cells for cancer immunotherapy. SébastienWälchli,
Marit R. Myhre, Nadia Mensali, Anne Fåne, Kari Lislerud, Gunnar Kvalheim,
GustavGaudernack, ElseM. Inderberg.OsloUniversityHospital-TheNorwegian
Radium Hospital, Oslo, Norway.
T-cell based immunotherapy represents an attractive strategy for the
treatment of cancer. Whereas cellular anti-tumor immune responses have
typically been attributed to CD8 T cells, CD4 T cells play a critical role in
tumor elimination and the priming and maintenance of CD8 T-cell re-
sponses. Recent fındings have highlighted new opportunities for CD4 T cells
in cancer immunotherapy. We have isolated CD4 T cells reactive against
tumor antigens from patients who experienced clinical benefıt from treat-
ment with cancer vaccines targeting antigens such as hTERT, survivin and
frequent neoantigens such as frameshift mutated TGFRII. Strong T-cell
responses against the vaccine or unrelated cancer antigens suggesting
epitope spreading correlated with enhanced survival and tumor regression
in late stage cancer patients. These HLA class II restricted T-cell clones
recognised target cells loaded with long peptides or protein and for some
CD4 T cell clones we could also show direct tumor recognition. TCRs were
expressed in expanded third-party T cells by mRNA electroporation or ret-
roviral transduction and tested for functionality. Both CD8 and CD4 T
cells expressing the TCRs produced TNF-, IFN- and redirected T cells had
the capacity to kill following co-incubation with their targets. Selecting
highly functional CD4 T-cell clones reactive against tumor-associated or
-specifıc antigens from patients with clinical responses after treatment with
immunotherapy is a successful method for identifying highly functional
HLA class II restricted TCRs for adoptive immunotherapy. These HLA class
II-restricted TCRs may be of therapeutic value both in haematopoietic ma-
lignancies and in melanoma where tumor cells frequently express HLA class
II. Furthermore, combining HLA class I- and class II-restricted TCRs for
T-cell redirectionmay provide amore potent therapeutic effect in adoptive T
cell therapy.
#3774 A high-throughput process for the development and characteriza-
tion of chimeric antigen receptors (CARs). Sabarinath Venniyil Radhakrish-
nan,1 Adam Miles,2 Djordje Atanackovic,1 Tim Luetkens1. 1Huntsman Cancer
Institute, University of Utah, Salt Lake City, UT; 2Wasatch Microfluidics, Salt
Lake City, UT.
INTRODUCTION: Chimeric antigen receptors (CARs) expressed by T cells
bind to surface antigens via a single-chain variable fragment (scFv) and are able
to elicit potent anti-tumor effıcacy. To our knowledge no rapid CAR develop-
ment platforms exist to facilitate the high-throughput generation and character-
ization of novel CARs to allow head-to-head comparisons and to determine the
influence of scFv properties on CAR T cell activation, phenotype, and persis-
tence. EXPERIMENTAL PROCEDURES: We have established a rapid process
for the development of functional novel CARs using fully human antibody
phage display, vector systems for bacterial andmammalian expression, aswell as
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high-throughput functional and biochemical characterization assays. We vali-
dated individual parts of the workflow using different tumor antigens and com-
pleted the entire workflow for one model antigen expressed on the surface of
multiplemyeloma cells. An initial population of scFvs against themodel antigen
was selected from a large naïve fully-human antibody phage display library by
panning. The reactivity of the polyclonal phage population was then confırmed
by time-resolved fluorescence before reformatting into various monoclonal
binder formats. We established a high-throughput flow cytometry assay simul-
taneously determining CAR surface expression and antigen binding. In addi-
tion, we adapted protocols for small-scale lentiviral transduction and expansion
of primary CAR T cells followed by a sensitive, high-throughput luciferase-
based cytotoxicity assay. Finally, in collaborationwithWasatchMicrofluidicswe
performed high-throughput surface plasmon resonance measurements as well
as epitope binning of candidate binding domains. RESULTS:We obtained 1,323
scFvs after two rounds of antibody phage selection. The subsequent bacterial
screen of 163 clones identifıed 23 unique monoclonal binders. In a comparison
of all 23 binders in different formats we determined that none of the traditional
screening formats, including soluble scFv or scFv-Fc fusion constructs, corre-
latedwithCARbinding. CAR constructswith high expression and antigen bind-
ing were found to have affınities in the low nanomolar range (18-22nM) and
evidenced strong killing of human cancer cell lines spontaneously expressing the
antigen (53-79% killing at an effector:target ratio of 10:1), but not healthy cells
expressing lower levels of the antigen. Importantly, in amurine xenograftmodel
of multiple myeloma we observed specifıc killing of tumor cells and no overt
toxicities. CONCLUSION: We show that our process allows the generation,
screening, as well as functional and biochemical characterization of novel CARs
within 2 months. Our approach enables researchers to easily carry out head-to-
head comparisons allowing comprehensive lead identifıcation and the determi-
nation of binding domain properties which may shape CAR T cell function and
phenotype.
CLINICAL RESEARCH: Liquid Biopsies 3: Circulating Tumor
Cells, Extracellular Vesicles, and Exosomes
#3775 Hydrogel-assisted pathological study of the circulating tumor cells
fıltered from the renal cell carcinoma patients’ blood. Yoon-Tae Kang,1
Young Jun Kim,1 Tae Hee Lee,1 Hee Jin Chang,2 Hyun-Moo Lee,3 Young-Ho
Cho1. 1KAIST, Daejeon, Republic of Korea; 2National Cancer Center, Goyang,
Republic of Korea; 3Samsung Medical Center, Seoul, Republic of Korea.
Introduction: Circulating tumor cells (CTCs), defıned as tumor cells de-
tached from the primary tumor site and circulating in the peripheral blood,
are a promising marker to get the information about tumor status and met-
astatic potential. However, the limited detection ability as well as their biased
specifıcity of current CTC isolation struggle from understanding the com-
prehensive characteristics of CTCs. In addition, previous CTC isolation de-
pending on epithelial cell adhesion molecule (EpCAM) antibody make their
cytological and pathological study hard. We developed the methods which
capture CTCs based on their size and deformability, and construct a hydro-
gel-assisted cell block for verifying the diagnostic utility for various cancer-
associated immuno-markers and their pathological studies. Methods: Two
renal cell carcinoma cell lines, SN12C and 769P, and 7 different cancer
patients’ blood with renal cell carcinoma were used. To fınd the applicable
markers for diagnosing renal cell carcinoma, we constructed the cell blocks
of two cell lines. For the encapsulation of the cells, 4 % alginate was prepared
by dissolving in deionized water under constant stirring at 85 °C. Then, the
separately prepared renal cancer cells were gently mixed into the dissolved
alginate solution. After careful mixing, the solution was loaded into calcium
chloride solution drop by drop using volume pipette, followed by 15 min of
further incubation with constant stirring. Next, the cell-containing beads
were applied to the commonly used procedure for paraffın tissue blocks, and
8 different cancer-associated immuno-markers (EpCAM, CK (AE1/AE3),
CAM5.2, EMA, CD10, CA IX, RCC, and vimentin) were stained with each
dissected cell blocks. The CTCs from the 7 clinical samples were isolated by
tapered-slit fılter, and cell containing slides were immunohistochemically
stained and examined by pathologist. Results: The four markers, EpCAM,
CK (AE1/AE3), CD10, and vimentin in the SN12C cell block were highly
expressed. The three markers, CK (AE1/AE3), CD10, and vimentin in the
769-P cell block were predominantly expressed. The EpCAM, CK (AE1/
AE3), and CD10 are chosen as the potential immunomarkers for CTC-based
diagnosing for RCC. In the clinical study using the 0.5-3.0 ml of blood
samples, CTCs were successfully isolated and detected immunohistochemi-
cally in 57.1 % (4 of 7) of patients and ranged from 1 to 5. Of 4 CTC positive
samples, two had CK (AE1/AE3) positive, each one had EpCAM and CD10
positive CTCs, respectively. Discussion and conclusion: Although the vi-
mentin is highly expressed in both cell blocks, due to diffuse positivity for
leukocyte, single use of vimentin for cancer diagnosis is limited. This com-
prehensive study including immuno-markers screening and their applicabil-
ity test with clinical samples demonstrates the clinical utility of the present
device and hydrogel-assisted cell block for CTC isolation and cancer studies.
#3776 Examination of ERCC1 status in circulating tumor cells as a prog-
nostic tool for patients with nasopharyngeal carcinoma. Edwin P. Hui,1
Brigette BY Ma,1 KC Allen Chan,1 Charles ML Chan,1 SC Cesar Wong,2 Ka Fai
To,1 Herbert HF Loong,1 Frankie KF Mo,1 Roger KC Ngan,3 Anthony TC
Chan1. 1Chinese Univ. of Hong Kong, Shatin, NT, Hong Kong; 2Hong Kong Poly-
technic University, Hong Kong, Hong Kong; 3Queen Elizabeth Hospital, Hong
Kong, Hong Kong.
Investigation of the expression pattern of DNA-repair protein excision
repair cross-complementation group 1 (ERCC1) has been reported to allow
selection of patients with non-small cell lung cancer who are likely to benefıt
from cisplatin-based therapy. Recent evidence suggests that ERCC1 expres-
sionmay also fınd prognostic use in patients with nasopharyngeal carcinoma
(NPC).We evaluated ERCC1 expression and genotype fromNPC tissues and
peripheral bloodmononuclear cells of patients with NPC. ERCC1 expression
was detected in 61/77 cases (79.2%) with varying intensities, where high
ERCC1 expression signifıcantly associated with worse relapse-free survival
(RFS) (HR 2.34, 1.06-5.16, p0.036). In addition, the presence of ERCC1
C118T genotype was signifıcantly associated with favorable RFS and overall
survival (OS) in a subgroup of patients with undetectable post-treatment
plasma EBV DNA. These fındings support a prognostic role for ERCC1
examination in NPC. However, the invasive nature of obtaining biopsy sam-
ples for tumor marker studies is a major hindrance of this approach. To
facilitate the investigation of ERCC1 expression in a noninvasive manner, we
have developed a negative selection immunomagnetic method for isolating
circulating tumor cells from patient blood. Cell line spike-in experiments
reveal a mean recovery rate of 66% for NPC cells with greater than 99%
removal of non-targeted blood cells. Specifıcity of CTC identifıcation was
confırmed by detection of the expression of the Epstein-Barr virus encoded
small RNA (EBER) in the CTCs. This method also allowed the simultaneous
analysis of the expression of multiple protein markers including CD45, cy-
tokeratin and ERCC1. It is expected that the development of noninvasive
methodologies for tumor marker studies will facilitate their clinical applica-
tion for improved patient care and monitoring in the future.
#3777 RNAprofıles of circulating tumor cells and extracellular vesicles for
therapy stratifıcation of metastatic breast cancer patients. Corinna Keup,1
Siegfried Hauch,2 Linda Plappert,2 Markus Sprenger-Haussels,2 Pawel Mach,1
Mitra Tewes,3 Bahriye Aktas,1 Hans-Christian Kolberg,4 Rainer Kimmig,1 Sa-
bineKasimir-Bauer1. 1Department of Gynecology andObstetrics, UniversityHos-
pital of Essen, Essen, Germany; 2QIAGEN GmbH, Hilden, Germany; 3Depart-
ment of InternalMedicine (Cancer Research), University Hospital of Essen, Essen,
Germany; 4Clinic forGynecology andObstetrics,Marienhospital Bottrop gGmbH,
Bottrop, Germany.
Background: Blood analytes, as liquid biopsies, are discussed to be surrogate
markers for therapy stratifıcation of metastatic breast cancer (MBC) patients.
Repeated analysis is enabled by the minimal invasive nature of blood draw.
Analysis of RNA enclosed in circulating tumor cells (CTCs) or extracellular
vesicles (EVs)may be sensitive enough to detect disease progression earlier than
contemporary visual stagingmethods. A prediction of the ideal therapy strategy
via characterization of CTCs or EVs would be even more benefıcial. Here we
compare RNAprofıles of CTCs andEVs inMBCpatients to get insight into their
feasibility for therapy stratifıcation. Patients and methods: Blood was collected
from 10 MBC patients at the time of disease progression (T0) and at two con-
secutive clinical staging time points (T1 and T2) during therapy. Two cohorts
were separated according to RECIST criteria a) Overall Responder showed re-
sponse at T1 and T2 and b) Late Non-Responder displayed stable disease or
partial remission at T1, but showed progressive disease at T2. CTCs were iso-
lated from 5ml blood by positive immunomagnetic selection targeting EpCAM,
EGFR and HER2 (AdnaTest EMT2/StemCell Select TM, QIAGEN, Germany).
EVs were isolated from 4 ml pre-fıltered plasma by affınity-based binding to a
spin column (exoRNeasy, QIAGEN, Germany). mRNA bound to Oligo-dT
beads was purifıed and reverse transcribed (AdnaTest EMT2/StemCell Detect
TM, QIAGEN, Germany). Pre-amplifıed cDNA was analysed by a multimarker
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qPCR (AdnaPanel TNBC, QIAGEN, Germany). RNA profıles of 18 genes (in-
cludingAKT2, ALK,AR, AURKA, BRCA1, cKIT, cMET, EGFR, ERCC1,HER2,
HER3, KRT5, mTOR, NOTCH1, PARP1, PI3K, SRC1, GAPDH) were normal-
ized by data of healthy donors (n20) and CD45 served as leukocyte control in
the CTC preparation. Results: In general, data analysis showed great differences
in RNA profıles of EVs and CTCs. However, PI3K and SRC1 signals were found
in similar frequencies in the EV and CTC fraction. HER2, HER3, cKIT or cMET
signals signifıcantly correlated with disease progression by analysis of either
CTCs or EVs (p0.001). In EVs, BRCA1 signals positively indicated response,
while AR and KRT5 signals were related to a negative response. No marker was
exclusively found in CTCs to correlate to the therapy-response course. In CTCs
and EVs, however, similar signal courses for PI3K and cMETwere found across
all time points, revealing PI3K as potential positive response marker and cMET
as potential negative response marker in both blood analytes. Conclusions: Ex-
pression profıling in CTCs as well as in EVs is enabled by the described work-
flows. Preliminary data indicated great differences in RNA profıles of EVs and
CTCs. The amount of included patients is continuously increased to validate the
preliminary results obtained until now.
#3778 PD-L1 expression on circulating tumor cells and its comparison
with tumor tissues in Japanese lung cancer patients.Hiroaki Akamatsu,1 Ya-
suhiro Koh,1 Satomi Yagi,2 Satoshi Kambayashi,1 Ayaka Tanaka,1 Kuninobu
Kanai,1 Atsushi Hayata,1 Nahomi Tokudome,1 Keiichiro Akamatsu,1 Masayuki
Higuchi,2 Hisashige Kanbara,2 Masanori Nakanishi,1 Hiroki Ueda,1 Nobuyuki
Yamamoto1. 1Wakayama Medical University, Wakayama, Japan; 2Hitachi
Chemical Co., Ltd., Japan.
Background: Blockade of programmed death receptor-1 (PD-1) pathway is
effective against solid tumors including lung cancer. AlthoughPD-ligand 1 (PD-
L1) expression on tumor tissue is expected as a potent predictive biomarker, its
detection remains challenging due to its dynamic and unstable status. Circulat-
ing tumor cells (CTCs) have potential as an alternativematerial for non-invasive
and real-time diagnosis. Here, we evaluated the PD-L1 expression on CTCs in
patients with lung cancer and investigated the agreement between tumor tissues
and CTCs. Material and methods: CTCs were captured and immune-stained
using microcavity array system. CTCs were defıned as those positive for DAPI
and cytokeratin (CK) and negative for CD45. PD-L1 expression on CTCs was
evaluated by addition of the process of PD-L1 immunocytochemistry. For CTCs
detection, 3 ml of peripheral whole blood was collected from the patients who
consented in written form and PD-L1 immunohistochemistry was performed
using corresponding tumor tissues. Results: Sixty-seven lung cancer patients
were enrolled in the study between July 2015 and April 2016 at Wakayama
Medical University. Patient characteristics were as follows: median age 71
(range, 39 to 86); male 72%; stage II-III/IV, 15/85%; non-small cell lung cancer
(NSCLC)/small cell lung cancer (SCLC)/Other, 73/21/6%. CTCs were detected
in 66 out of 67 patients (median 19; range, 0 to 115) andmore than 5 CTCs were
detected in 78% of patients. PD-L1-expressing CTCs were detected in 73% of
patients and the proportion score (PS) of PD-L1-expressing CTCs ranged from
3% to 100%, suggesting intra-patient heterogeneity of PD-L1 expression on
CTCs. Signifıcantly more PD-L1-expressing CTCs were detected in patients
without EGFRmutations than thosewith EGFRmutations (P 0.0433). Tumor
tissues were available from 28 patients and were immune-stained for PD-L1.
Seven showed the PS of PD-L1-expressing tumor cells 1%, 11 showed 1-49%,
and 10 showed 50%. No positive correlation was observed on PD-L1 expres-
sion between tumor tissues and CTCs based on PS (R2 0.0034). Three adeno-
carcinoma cases with PD-L1-positive tumor tissue did not harbor any PD-L1-
expressing CTCs and conversely, three adenocarcinoma cases with PD-L1-
negative tumor tissue harbored PD-L1-expressing CTCs, showing the
discrepancy between tumor tissues and CTCs. It is also noteworthy that SCLC
patients had perfect agreement on PD-L1 expression between tumor tissues and
CTCs. Conclusions: PD-L1 expression was detectable on CTCs in lung cancer
patients and intra-patient heterogeneity of its expression was observed. There
was no agreement between tumor tissues andCTCsonPD-1 expression. Further
investigation is warranted to better understand the clinical signifıcance of PD-
L1-expressing CTCs.
#3779 Incorporating in-line sample pre-enrichmentwithFACSand single
cell mRNA-seq to facilitate isolation and characterization of prostate cancer
circulating tumor cells. Liping Yu, Silin Sa, Michael Tycon, Xiaoyang Alice
Wang. BD Biosciences, San Jose, CA.
For decades, circulating tumor cells (CTCs) have been used as biomarkers
to indicate disease progression and survival in patients with metastatic tu-
mors. Detection of CTCs is an attractive, non-invasive blood test for early
diagnosis of many types of cancer. However, CTCs are present at extremely
low frequency in blood, and it is challenging to recover them in typical
multi-step sample processing workflows. EpCAM, the widely accepted
marker for CTC, has been found being down regulated in protein expression
and RNA expression analysis in many cases thus EpCAM-dependent CTC
detection might not be sensitive enough. We have developed a new sample
pre-enrichment technology incorporated in line with fluorescence activated
cell sorting (BD FACS™) platforms to demonstrate a one-step sample pro-
cessing workflow to minimize cell loss and maximize CTC recovery. The
pre-enrichment technology combines magnetic depletion of white blood
cells and acoustic removal of lysed red blood cells, sending enriched tumor
cells directly to a cell sorter for single CTC isolation. The in-line enrichment
and sorting technology has shown 90% removal of CD45 cells and over
90% recovery of target cells going through the system. Furthermore, we have
incorporated molecular indexing technology for next generation sequencing
(NGS) into the single CTC isolation to streamline gene expression analysis.
We conducted a pilot study in which prostate cancer cell lines PC3, DU145,
and LNCaP were spiked in healthy donors’ peripheral blood, quantitatively
recovered, and individually sorted into 96-well BD™ Precise barcoded plates
using a BD Influx™ sorter equipped with the in-line pre-enrichment module.
The sorted cells were then sequenced for a prostate cancer targeted gene
panels with approximate 100 genes, including EpCAM. Single cell sorting
and sequencing were also performed on cell line cells directly and confırmed
the workflow did not affect the gene expression. In LNCaP and PC3 cells,
EpCAM was not the high expression marker in the genes analyzed, and its
protein expression was also heterogeneous. The highly expressed genes dis-
covered by single cell mRNA sequencing such as GSTP1 and CAV1 were
investigated to provide additional cell surface markers for more sensitive
CTC detection. Finally, CTCs from blood samples collected from prostate
cancer patients were isolated based on marker panels beyond EpCAM and
characterized at the single cell level. The differences between gene expression
profıles of patient sample CTCs and cancer cell line cells were revealed.
#3780 Bio-competition-based smart NanoVelcro Chip for isolation and
gene expression analysis of circulating tumor cells from prostate cancer pa-
tients. Jie-FuChen,1Mo-Yuan Shen,2 Chun-Hao Luo,2 ShirleyCheng,1 Sangjun
Lee,3 Shuang Hou,3 Edwin M. Posadas,1 Hsian-Rong Tseng,3 Hsiao-Hua Yu2.
1Cedars-Sinai Medical Ctr., Los Angeles, CA; 2Academia Sinica, Taipei, Taiwan;
3University of California, Los Angeles, Los Angeles, CA.
Introduction andObjective: Circulating tumor cells (CTCs) are being used in
efforts to identify important transcriptomic features such as androgen receptor
(AR) splicing variants in prostate cancer (PCa) and othermalignancies. The low
abundance of CTCs and the fragility of the genetic materials create a need for
tools that obtain high-quality signals with great effıciency. Poly(3,4-ethylene-
dioxythiophene) (PEDOT) is a stimulation-responsive nanomaterial which al-
lows for rapid and gentle cell purifıcation through the use of bio-competition
between pheylboronic acid and carbohydrates. We hypothesized that a combi-
nation of PEDOT with the NanoVelcro cell affınity assay (NanoVelcro-PBA
Chip) would yield a tool that could minimize contamination from white blood
cells andmaximize cell viably andmolecular intactness. In this study, we bench-
marked the effıciency of this platform for purifıcation of CTCs from blood spec-
imens and the feasibility of using this approach for detection of PCa-related
RNA signatures from purifıed CTCs. Methods: The capture and release effı-
ciency of NanoVelcro-PBA Chip was tested using PCa cell lines (LNCaP, PC3,
22Rv1) and artifıcial blood samples with PCa cells mixed with healthy donor
blood. Variations on operating conditions were tested including the capturing
antibodies on the NanoVelcro substrate, incubation time, sorbitol concentra-
tion, and bio-competition time. Impact was measured on process effıcacy and
cell viability. Blood specimens from17PCapatientswere processed usingNano-
Velcro-PBA chip. Analysis focused detection of full length AR (AR-FL), AR
splicing variant 7 (AR-V7), KLK3 (prostate-specifıc antigen, PSA), FOLH1
(prostate-specifıc membrane antigen, PSMA), and long-noncoding RNA
SChLAP1 (second chromosome locus associated with prostate-1) using quanti-
tative RT-PCRmethod. Results: The combination of NanoVelcro substrate, PE-
DOT nanomaterial, and capturing antibody exhibits the highest cell capture
effıciency (up to 80%). The highest cell release effıciency and viability was
achieved by bio-competitionwith 100mol/200L sorbitol solution for 30min-
utes. PCa-relatedRNA signalswere detected in 16/17CTC() PCa patients, and
was detectedmore frequently in patients withmetastatic disease andwith higher
expression level. Conclusions: We have developed a novel CTC purifıcation
platform, NanoVelcro-PBA Chip. This platform is capable of purifying CTCs
with high effıciency and while retaining cell viability and molecular integrity.
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This in turn allows for detection of disease-relevant RNA signals. Further this
new tool is beingmoved into clinical studies that will validate its performance in
CTC purifıcation and subsequent RNA detection.
#3781 Expression of neuroendocrine markers in circulating tumor cells
from patients with prostate cancer visceral metastases. Jamie M. Sperger,
Anupama Singh, David Niles, Charlotte N. Stahlfeld, David J. Beebe, Joshua M.
Lang. University of Wisconsin, Madison, WI.
Purpose: Therapeutic resistance to Androgen Receptor (AR) targeted thera-
pies in patients with Castration Resistant Prostate Cancer (CRPC) is complex
and originates from a wide range of molecular alterations including AR point
mutations, gene rearrangements and splice variant expression. An aggressive
subtype of CRPC involves neuroendocrine de-differentiation that is often found
in patients with visceral metastases. To evaluate neuroendocrine signatures in
patients progressing on AR targeted therapies, we measured gene expression in
circulating tumor cells (CTCs) as a minimally-invasive approach to examine
putative resistance mechanisms to AR targeted therapies. Methods: We utilized
the VERSA platform, an integrated CTC capture and analysis technology, to
capture CTCs using antibodies for EpCAM or TROP2 in parallel. mRNA was
extracted on chip from live cells for comparison of gene expression profıles for
markers of neuroendocrine de-differentiation (SYP, CHGA, GHGB, MYCN,
NCAM) and the AR signaling pathway. Fixed PBMC were stained and imaged
with fluorescence microscopy and CTCs were enumerated by defıning CTCs as
EpCAM or TROP2 captured, intact nuclei, negative for CD45/CD11b/CD14/
CD34 and cytokeratin positive. Synaptophysin or Chromogranin A protein ex-
pression was quantifıed in individual CTCs and compared to tumor biopsy
results where available. Results: Expression of the Synaptophysin (SYP) gene
was found in 39% of the patients in our initial 18 patient cohort. These patients
could be split into two groups. Group 1 patients had low AR expression with
minimal detection of AR target genes. Of these four patients, three had visceral
metastases. Group 2 patients had high levels of AR expression including expres-
sion of the splice variants ARV7 and ARV9, and robust expression of KLK3
(PSA) andPSMA.Of these three patients, two had visceralmetastases. Subsets of
the patients in both groups also exhibited expression of genes identifıed in neu-
roendocrine prostate cancer includingChromogranin B,MYCN, andNCAM.A
subset of the patients tested for gene expression are being screened for CTC
detection of proteinmarkers of neuroendocrine phenotypes includingChromo-
granin A and Synaptophysin. Conclusions: We report the fırst identifıcation of
neuroendocrine gene expression signatures in CTCs from patients with CRPC
experiencing disease progression on advanced AR targeted therapies. These sig-
natures may serve as predictive biomarkers of resistance to AR targeted thera-
pies. Future studies will evaluate these signatures in prospective clinical trials.
#3782 Genetic analysis using a novel high-purity enrichment system for
circulating tumor cells independent of epithelial cell antigen. Hidenori
Takagi,1 Masahiro Kozuka,1 Hiroshi Ito,1 Soo Hyeon Kim,2 Mitsuharu Hirai,1
Teruo Fujii2. 1ARKRAY, Inc., Kyoto, Japan; 2Institute of Industrial Science, The
University of Tokyo, Tokyo, Japan.
Background Genetic analysis of circulating tumor cells (CTCs) is useful as a
liquid biopsy. However, there are 3 challenging issues in processing of CTC
samples for clinical use of the analysis: [1] numerous residual blood cells in
processed samples, [2] loss of CTCs that do not express epithelial markers, and
[3] very laborious process. Here, we developed a novel system capable of over-
coming all of these problems.MethodsOur CTC analysis system is composed of
3 steps: [1] fıltering of whole blood followed by immunostaining and magnetic
labeling of cells trapped on the fılter, [2] depletion ofwhite blood cells (WBCs) in
the cells recovered from the fılter by magnetic separation, and [3] trapping the
resultant cells at an observation chamber in a microfluidic enrichment device
using dielectrophoresis, followed by recovering them as a concentrated sample
after fluorescence microscope observation. SNV and CNV analysis was con-
ducted using the collected concentrated sample, and the system performance
was substantiated. Genetic mutations of the cells in the collected sample were
detected by the Quenching Probe method. On the other hand for CNV
analysis, cells in the collected concentrated sample were immobilized on
slide glass and analysis of gene amplifıcation conducted by FISH. Results
With SNV analysis, our system successfully detected EGFR, KRAS or
PIK3CAmutations of cancer cell lines spiked in 8mL of whole blood (Table).
The detection sensitivity of our method was 1 cell/mL, and both the cancer
cells and their genetic mutations were detected within 9 hours of starting the
processing of whole blood. Additionally, with CNV analysis, HER2 gene
amplifıcation was confırmed with cell lines spiked in 8 mL of blood. This
detection result was obtained within 48 hours. Conclusion Our system
would be useful for the analysis of gene mutations in a wide range of CTC
types independent of certain epithelial antigens, such as CK and EpCAM,
and can be used for various genetic analyses.
Results of spiking test for SNV analysis
Spiked
cell
lines
Expected
count[cells/8ml]
No. of
detected spiked
cells [cells]
No. of
detected
remained
WBCs [cells]
Detected
genotypes
NCI-H1975 12 9 79 EGFR L858R
NCI-H1650 8 2 25 EGFR exon19 deletion
SW620 8 6 48 KRAS codon12, 13
SNU-1 12 4 154 KRAS codon12, 13
MCF-7 7 7 341 PIK3CA G1633A
#3783 Circulating tumor cells measured in the pulmonary vein and the
radial artery during surgery of non-small cell lung cancer. Menno Tam-
minga,1 Sanne deWit,2 Joost F. Swennenhuis,2 Caroline van deWauwer,1 Theo
J. Klinkenberg,1 T. Jeroen Hiltermann,1 Harry J. Groen,1 Leon W. M. Terstap-
pen2. 1UniversityMedical Centre Groningen, Netherlands; 2University of Twente,
Enschede, Netherlands.
Background: The number of circulating tumor cells (CTC) detected by the Cell-
Search system is low or absent in 7.5 mL of venous peripheral blood of metastatic
andnon-metastatic non-small cell lung cancer (NSCLC)patients.Our hypothesis is
that CTC can be detected in the pulmonary vein draining the lobe containing the
primary tumor before its removal and would be influenced by manipulation of the
lobe during surgery. Methods: Patients with early stage NSCLC undergoing open
lobectomy were included. During surgery, blood was drawn centrally (pulmonary
vein draining the lobe containing the tumor) and peripherally (radial artery) at two
timepoints: directly after thoracotomyand identifıcationof thedrainingpulmonary
vein (T1) and just before closureof thedrainingpulmonaryvein aftermanipulation,
dissection and closure of the pulmonary artery (T2). EpCAMCTCwere detected
by CellSearch. The EpCAM CTC depleted sample was subsequently fıltered
through 5m micosieves and fluorescently labeled for identifıcation of EpCAM-
CTC (DAPI, Cytokeratin and CD45-). Results: So far, three patients have been
included. Remarkably, cell clumps were detected among EpCAM CTC at T1 in
the pulmonary vein in all patients, and as well at T2 in patient #3. CTC in the
pulmonary vein at T1weremorphologically different than those detected at T2 and
in the arteries. Experiments to confırm malignancy of both subtypes of CTC are
pending, using chromosome aneuploidy status and copy number variation analysis
to compare them with the resected tumor. Conclusion: In early stage NSCLC high
amounts single and clumps of CTC are observed in the draining pulmonary vein
during surgery. The amountmeasured in the radial artery is lower, indicating loss of
CTC in the circulatory system before peripheral measurement. If the cells found
really are CTC that are shed from the primary tumor during surgery, it will have
clinical consequences for the surgery techniques used.
EpCAM and EpCAM-Circulating tumor cells found during surgery in non-small cell
lung cancer
Patient #1 Patient #2 Patient $3
#CTC/7.5mL EpCAM EpCAM- EpCAM EpCAM- EpCAM EpCAM-
Baseline (T0) NA NA NA NA 3 2
Draining vein T1 *85 35 *10 4 *50 130
Draining Vein T2 1 5 19 11 *101 10
Radial artery T1 1 2 0 5 0 0
Radial artery T2 2 1 0 1 0 12
Radial Artery T13 NA NA NA NA 0 2
Radial artery T15 NA NA NA NA 0 5
Radial artery T25 NA NA NA NA 2 1
*Presence of CTC clusters
#3784 Expression of estrogen receptor specifıc signaling transcriptome in
epithelial cell adhesion molecule (EpCAM) captured circulating tumor cells
from patients with breast cancer. Ashok Singh, Jamie M. Sperger, Jennifer
Schehr, Tessa Witkowski, Beth A. Weaver, Mark E. Burkard, Joshua M. Lang.
Univ. of Wisconsin-Madison, Madison, WI.
Background: Breast cancer (BC) is the second leading cause of cancer related
death in American women. There is a critical need for new biomarkers to evaluate
treatment response and emergingmechanisms of resistance. The identifıcation and
characterizationofnewbiomarkers suchasCirculatingTumorCells (CTCs)maybe
helpful tools for these purposes as well as understanding the biology of metastatic
BC.Methods: Blood samples were processed with a Ficoll gradient to isolate nucle-
ated cells. CTCs were isolated from these samples using an exclusion-based sample
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preparation technologyknownas theVERSA(VersatileExclusion-basedRareSam-
ple Analysis) platform. EpCAM positive CTCs were captured in the VERSA fol-
lowed by mRNA extraction for gene expression profıling for the estrogen receptor
(ER) and other breast cancer relevant targets. CTCs were defıned as Hoechst posi-
tive, CD45/CD11b/CD14 negative, and cytokeratin positive. Captured CTCs were
evaluated for ER protein staining intensity and localization. Results: The VERSA
platform was validated to capture and enumerate CTCs from patients with breast
cancer using EpCAM capture and immunofluorescent staining for intact nucleus,
ER, and cytokeratin while negative for multiple immune markers (CD45, CD11b,
CD14). The VERSA can capture cells with90% capture effıciency with EpCAM
antibody in MCF7 and T47D cell lines. ER specifıc transcriptome analysis in BC
patientCTCs andcell lineswasperformed.Weevaluated expressionofER signaling
pathway, prognostic, metastatic/EMT; stemness; epithelial markers with concor-
dant expression of RPLPOandHPRT1.We identifıed expression of ER in 6 out of 7
BC samples. Expression of PR andHER2 in a subset of samples confırms capture of
breast cancer cells for further molecular interrogation. Conclusion: In conclusion,
we report the expression profıles of ER signaling genes in EpCAM captured CTCs
fromBCpatients.These toolswill beused to compare subpopulationsofCTCs from
patients with BC as predictive and pharmacodynamic biomarkers of response to
targeted therapies or chemotherapies.
#3785 Self-sorting microwells to isolate and expand single circulating tu-
mor cells. Joost F. Swennenhuis,1 Kiki C. Andree,1 Fikri Abali,1 Michiel Ste-
vens,2 Joska Broekmaat,2 Fiona F. Passanha,1 Cees J. van Rijn,3 Leon W. Ter-
stappen1. 1Twente University, Enschede, Netherlands; 2Vycap bv, Deventer,
Netherlands; 3Wageningen University, Wageningen, Netherlands.
Introduction: Circulating tumor cells (CTCs) can be isolated from blood and
serve as a source of tumor material. Expansions of CTCs may permit functional
treatment-effıcacy tests in combination with genetics, epigenetics and proteomics
screening.Wepresent a fastworkflowto isolate, capture, growand imagecells inside
a self-sorting microwell chip using the VyCAP single cell isolation platform. After
seeding single cells in a microwell chip, they can grow inside the chip or can be
transferred to a tissue culture plate for clonal expansion or downstream analysis.
Materials and methods: The Rosette-Sep™ Human CD45 depletion cocktail (Stem
Cell Technologies) was used to enrich spiked cells from 1ml of fresh EDTA blood.
Cells were stained with CellTrace™ violet for tracking spiked cells, calcein for live
cells, ethidium bromide for dead cells, -CD45-PERCP as negative marker and
-EpCAM-AF647 as positive marker. After density gradient separation using Fi-
coll-Paque™, the cell suspensionwasmeasured and quantifıed using flow cytometry
for Rosette-Sep™ effıciency. Cell suspensions were seeded in the self-sorting micro-
well chips using a negative pressure of 40-70 mbar using the VyCAP Filtration
system. After seeding single cells in the microwells, the chips were imaged with the
VyCAPPuncher systemandeither placed immediately into culturemedium for cell
expansion or selected cells were transferred into a 96 well tissue culture plate. Cell
expansion in microwell chips and plates was followed up to 14 days. Results: Cul-
tured MDA-MB-231 and MCF-7 cells were single-cell-trapped in the microwells
with an effıciency of 82%	 9% and 74%	 15% respectively, after direct fıltration
without enrichment. Immediately after capturing in microwells 93% of the MCF7
cells were viable. Rosette-Sep™ enriched MDA-MB-231 and MCF-7 cells with an
effıciency of 73% 	 6% and 74% 	 7% respectively, when measured with flow
cytometry. The Rosette-Sep™ procedure followed by capture of the MDA-MB-231
andMCF-7cells in themicrowells resulted inaneffıciencyof50%	11%and52%	
11% respectively. 92% of the cells were found back in a culture plate after punching
of single cells fromthechip, andof these cells, 80%werealive4hoursafterpunching.
82% of these cells were alive and still growing after 14 days. In total 53% of cells
spiked in blood, could be found back in the cups of which after punching into
individual wells, 77% were alive and growing. Conclusion: We present a single cell
captureand isolationmethod forclonal expansionofviable tumorcells.TheVyCAP
single cell isolation platformused for these experiments provides an easy separation
of the single cells from a CTC enriched cell suspension and allows on-chip expan-
sion as well as immediate separation of the CTCs into culture plates. About 50% of
spiked cells could be retrieved inside themicrowell chip and of these 77%were alive
after punching into individual wells of a culture plate.
#3786 Multicenter evaluation of technology platforms for the enumera-
tion of circulating tumor cells. Sebastian Bender,1 Merlin V. Lütke-Eversloh,2
Rui P. Neves,3 NNikolas H. Stoecklein,3 Leon W. Terstappen,4 Barbara Bag-
giani,5 Martin H. Neumann,1 Thomas Krahn,1 Klaus Pantel,6 Thomas
Schlange1. 1Bayer AG,Wuppertal, Germany; 2Bayer AG, Berlin, Germany; 3Uni-
versity Hospital of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Ger-
many; 4Faculty of Science and Technology, Enschede, Netherlands; 5Menarini/
Silicon Biosystems, Bologna, Italy; 6University Cancer Center Hamburg/
Eppendorf, Hamburg, Germany.
Metastasis represents thedeadliest featureof cancer,which is fueledbycirculating
tumor cells (CTCs) being released into the bloodstream from the primary tumor. In
addition to the clinical value of CTC enumeration for metastatic risk assessment,
CTCs are considered to be a minimally invasive source for studying the molecular
and genetic features of the disease as well as response to anticancer therapy. Given
the molecular heterogeneity of CTCs, which includes loss of epithelial surface
marker expression, several microfluidic and fıltration technology platforms were
developed to overcome the limitations of surface marker dependent CTC enrich-
ment. Here we describe the efforts of the Innovative Medicines Initiative (IMI)
consortium CANCER-ID (www.cancer-id.eu), which represents a joint undertak-
ing of experts from academia and pharmaceutical industry, in generating compar-
ative data using different CTC enrichment platforms in a multicenter ring trial. To
address clinically relevant subtypes of Non-Small Cell Lung Cancer (NSCLC), dif-
ferent NSCLC cell lines were profıled for genetic aberrations (mutations and copy
number aberrations), expression of epithelialmarkers (epithelial cell adhesionmol-
ecule (EPCAM) and cytokeratins) as well as cell size. Cell lines were selected to
generate spike-in samples using blood of healthy volunteers with informed consent
in a centralizedway.Analysiswasperformedby at least threeCANCER-IDpartners
using different CTC enrichment technologies including the Siemens fıltration de-
vice, the Parsortix PR1,VyCap fıltration and theCellSearch system.To ensure qual-
ity and comparability of results, CANCER-ID partners established standard opera-
tion procedures (SOPs) for pre-analytic sample handling including sample fıxation,
storageandshipment.Special attentionwaspaidonthedevelopmentofSOPs for the
actual CTC enrichment procedure and the integration of downstream applications
including single cell isolation by DEPArray™ followed by Ampli1™ WGA and mo-
lecular and genetic characterization of isolated cells. Epitope-independent enrich-
ment by fıltration ormicrofluidic devices was evaluated by using NSCLC cells with
substantially different cell size. In addition, comparative data on spike-in samples
was generated using the EPCAM-expression dependent CellSearch system, which
failed to detect EPCAM-negative tumor cells. In conclusion, the evaluation of dif-
ferent CTC enrichment technologies and the integration of workflows for down-
streamanalysis of single cells blaze the trail for thenextphaseof IMI’sCANCER-ID,
which includes the analysis of real-life NSCLC patient material. This work is sup-
ported by IMI JU& EFPIA (grant no. 115749).
#3787 EpCAM- and EpCAM circulating tumor cells in metastatic pros-
tate and breast cancer patients: a multicenter study. Sanne de Wit,1 Kiki C.
Andree,1 Joost F. Swennenhuis,1 Elisabetta Rossi,2 Mariangela Manicone,3 Ric-
cardo Vidotto,3 Rita Zamarchi,3 Marianna Alunni-Fabbroni,4 Elisabeth K.
Trapp,4 Marie Tzschaschel,5 Brigitte Rack,4 Rita Lampignano,6 Hans Neu-
bauer,6 Tanja Fehm,6MarianneOulhen,7 EmelineColomba,7 Françoise Farace,7
Mateus Crespo,8 Penelope Flohr,8 Gemma Fowler,8 Mariane Sousa Fontes,8 Jo-
hann S. de Bono,8 Leon WMM Terstappen1. 1University of Twente, Enschede,
Netherlands; 2University of Padova, Padova, Italy; 3IOV-IRCCS, Padova, Italy;
4Ludwig-Maximilians-University, Munich, Germany; 5Ulm University, Munich,
Germany; 6Heinrich-Heine University, Duesseldorf, Germany; 7Gustave Roussy,
Université Paris-Saclay, Villejuif, France; 8Institute of Cancer Research, Sutton,
United Kingdom.
Introduction: The presence of circulating tumor cells (CTC) enumerated by
the CellSearch system in blood of patients with cancers of epithelial origin is
strongly associated with a poor prognosis of these patients. CTC are enriched by
targeting the EpCAM antigen, raising the question which EpCAM subtypes are
present as well in patients. In the EU-FP7 CTCTrap program, we investigated
the presence of EpCAM- CTC in blood samples after depletion of EpCAM
CTC by CellSearch. Studies were performed and validated at the participating
laboratories by distribution and analysis of blood samples spiked with cancer
cells and by testing blood from 73 metastatic prostate and 22 metastatic breast
cancer patients. Methods: Blood samples were processed according to the stan-
dard operating procedures and tools developed in the program (https://www.ut-
wente.nl/tnw/mcbp/protocolsandtools/). First, CellSearch was performed for
EpCAM CTC, followed by fıltration and fluorescent labeling of the blood
discarded by CellSearch for EpCAM- CTC. To validate the procedures across
the 6 participating clinical sites, 3x 3 tubes with aliquots of healthy donor blood,
spiked with either PC3,MDA-MB-231 or no cells, were prepared at one site and
shipped to all other sites for simultaneous processing. Metastatic prostate and
breast cancer patients were processed with the same procedures. Results: 27% of
PC3 cells were recovered by CellSearch and 21% by fıltration, leaving 52% un-
accounted for. For MDA, 26% were recovered by CellSearch and 18% by fıltra-
tion, leaving 56% accounted for. Differences in recovery between sites were not
signifıcant. In patients both EpCAM and EpCAM- CTC were detected (see
table). Conclusion: In a multicenter study EpCAM and EpCAM- CTC were
present in blood of metastatic prostate and breast cancer patients. Spiking ex-
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periments showed that the developed methods can be further improved to in-
crease the CTC yield. Molecular characterization of the CTC subtypes and rela-
tion with clinical outcome is ongoing.
%metastatic cancer patients with EpCAM and EpCAM- CTC
% prostate cancer
patients (n73)
% breast cancer
patients (n22)
CellSearch
CTC EpCAM
CellSearch
CTC EpCAM
# CTC 0 1-4 4 Total 0 1-4 4 Total
Microsieve
CTC EpCAM-
0 11 8 19 38 18 5 9 32
1-4 6 7 16 29 9 9 14 32
4 8 6 19 33 14 14 9 36
Total 25 21 54 41 27 32
#3788 Monitoringofmultimodality immunecheckpoint inhibitor treatment
effıcacy inmetastaticmelanomapatients throughmolecular analysis of circulat-
ing tumor cells. Selena Lin,1 Stella Lam,1 ShuichiOhe,1KevinTran,1 IreneRamos,1
Ali Asgar Bhagat,2 Chwee Teck Lim,3 Steven J. O’Day,1 Leland Foshag,1 Dave
Hoon1. 1John Wayne Cancer Institute, Santa Monica, CA; 2Clearbridge Biomedics
Pte Ltd, Singapore; 3National University of Singapore, Singapore.
There is a dire need for molecular tools that canmonitor therapy effıcacy and
prognosis in melanoma patients who suffer from distant metastasis. Blood bi-
opsies offer a minimally invasive platform for clinicians to monitor melanoma
patients. In particular, the molecular analysis of circulating tumor cells (CTCs)
would be advantageous as they reflect both mutation and transcriptome profıle
of the tumor. However, the isolation and assessment of a minimal number of
CTCs present in 10 ml of blood still remains challenging. To address the needs
for more informative molecular CTC assays, our group used well-established
blood-based melanoma mRNA CTC biomarkers to demonstrate utility in sev-
eral multicenter phase II/III clinical trials through a direct quantitative RT-PCR
approach. Here, we employed the microfluidics-based ClearCell® FX system
(Clearbridge BioMedics) system, non-antibody based approach to develop a
dual molecular assay to characterize CTCs for our previously established mela-
nomamRNAbiomarkers (MART1, TRP2,MAGEA3, PAX, andGALNCT) and
the clinically-actionable BRAF V600E mutation (mt). The assay was optimized
for CTC isolation from whole blood using three BRAF V600E () melanoma
cell lines and demonstrated sensitivity for 25melanoma cells in 10ml (107 cells)
of blood. Immunofluorescence (IF) staining of the melanoma associated anti-
gens verifıed CTCs were of melanoma origin post-isolation in stage IV patients.
Next, the assay was subjected to 100 blood samples collected from 56melanoma
stage III/IV patients. We identifıed CTCs in 94% of pre-operative (pre-op) pa-
tients (n15/16) as determined by detection of 2 mRNA markers. BRAF
V600E mt was detected in 100% of pre-op patient (n5/5) CTCs with BRAF
V600E () tumors using a sensitive droplet digital PCR (ddPCR) assay. Bloods
from patients undergoing active mono/combination immunotherapy (ipili-
mumab, nivolumab, pembrolizumab) were also evaluated by our CTC bio-
marker panel. Serial bleeds (2-5 bleeds) from 22 patients were profıled and
correlated with clinicopathological factors. To facilitate further biomarker iden-
tifıcation predictive of therapy response, CTCs isolated from stage IV patients
undergoing immunotherapy were cultured to develop spheres and eventually
primary cell lines, and further analyzed by deep RNA sequencing. This study
developed a unique platform to analyze patientCTCs formelanomabiomarkers,
and provides a potential platform to identify novel CTC-derived melanoma
biomarkers indicative of multimodality treatment effıcacy.
#3789 Simultaneous visual assessment of RNA and protein expression in
circulating tumor cells using the AccuCyte-Cytefınder system. Arturo B.
Ramirez,1 Sarah B. Crist,2 Tyler Yeats,2 Jeffrey L. Werbin,1 Jackie L. Stilwell,1
Eric P. Kaldjian1. 1RareCyte, Inc., Seattle, WA; 2University of Washington, Seat-
tle, WA.
Background. Circulating tumor cells (CTCs) provide real-time information
regarding patient tumor phenotype, including RNA expression. This informa-
tion may be valuable in guiding care of cancer patients. Simultaneous RNA and
protein assessment has been reported previously in large populations of cells.
Here, we describemethods to simultaneously evaluate RNA and protein expres-
sion on rare single CTCs using the AccuCyte – CyteFinder system (RareCyte).
Methods. To establish RNA detection in model CTCs (mCTCs), we used SkBr3
cells spiked into blood and the isolated buffy coat was processed by AccuCyte
onto microscope slides. RNAscope® in-situ hybridization (ISH, Advanced Cell
Diagnostics) was performed to detect Her2, UBC (positive control) and dapB
(negative control) expression in mCTCs. A process to simultaneously stain for
RNA and protein was then developed to allow identifıcation of mCTCs by pro-
tein expression of cytokeratin (CK) and EpCAM and measurement of gene
expression with RNAscope. Various blood collection tubes were tested to mea-
sure gene expression, protein expression, and cell recovery up to 48 hours after
blood draw. Image analysis softwarewas developed to automatically analyze and
count RNA dot number from 40x z-stack images of mCTCs. Finally, clinical
samples were stained with the combined RNA/protein assay. Results. Using
RNAscope, Her2 and UBC expression could be detected in all SkBr3 cells and
was negative in surrounding white blood cells (WBC). Using blood collected
into EDTA tubes and processed immediately after spike-in, there were an aver-
age of 29 Her2 mRNA dots and 20 UBC dots/cell; negative control dapB gave 1
dot/cell. Using CK and EpCAM expression for mCTCs identifıcation, recovery
of mCTCs was over 95%. The RNA/protein assay was compared using blood
collected and stored in EDTA, CellSave®, Cell-Free DNA®, Cell-Free RNA®,
Cyto-Chex®, andRareCyte BCT tubes. At 48 hours, Cell-Free RNA tubes had the
highest number of RNA dots/cell – about half as many dots/cell compared to
fresh EDTA samples. Clinical samples were successfully stained with the RNA/
protein assay. Conclusions. We have developed a protocol that identifıes rare
mCTCs using protein staining, and measures RNA expression by RNAscope
ISH. This assay may be a useful clinical tool for the real-time investigation of
CTC gene expression in cancer patients.
#3790 Circulating tumor cells at disease recurrence in patients with head
and neck cancer after curative therapy. Jason Chia-HsunHsieh,1 Ting-Hsiuan
Yeh,1 Hung-Ming Wang,1 Yung-Chang Lin,1 Nina Ming-Jung Lin,1 Siou-Ru
Ye,1 Jane Ying-Chieh Lee,1Min-HsienWu2. 1Chang GungMemorial Hospital at
Linkou, Taiwan, Taoyuan, Taiwan; 2Chang Gung University, Taoyuan, Taiwan.
Background: Circulating tumor cell (CTC) has been prognostic and predic-
tive in numerous types of cancer; however, its role in early diagnosis of relapse
remains unclear. Methods: Eighty-six patients were prospectively enrolled be-
tween March 2015 and June 2016. Among these patients, 51 head and neck
squamous cell carcinoma (HNSCC) patients had suspicious recurrent lesion(s),
whilst 35 HNSCC patients were newly diagnosed. CTC test was performed by
negative selection strategy and CD45-negative and EpCAM-positive cells were
identifıed as CTCs. Biopsy on suspicious lesion(s) and CTC analysis were per-
formed simultaneously. We analyzed the differences of CTC numbers among
HNSCC patients with true recurrence, biopsy-negative and newly-diagnosed.
Results: Mean	standard deviation(SD) of CTC numbers in baseline at diagno-
sis (n35), true recurrence (n40) and biopsy-negative (n11) groups were
41.98	32.02, 81.75	64.91 and 16.55	6.82 cells/mL, respectively. The differ-
ence of CTC numbers among three groups was signifıcant (P 0.001). CTCs
(mean	SD) among different failure types were 110.89	84.69, 105.67	50.77,
73.31	37.82 and 59.11	54.09 in lung metastasis, second primary tumor, ex-
trapulmonary metastasis and locoregional recurrence respectively and signifı-
cantly different (P 0.049). Also, CTC numbers between fırst cancer (baseline
at diagnosis) and second primary tumorwere different (P 0.004). Conclusion:
CTCs numbers are signifıcantly higher in true recurrence than the biopsy-neg-
ative group when a patient had a lesion suspected to be a recurrence. CTC test
may be useful to help distinguish true recurrence in HNSCC patients after cu-
rative therapy.
#3791 Clinical signifıcance of EpCAM-negative and CEA-positive circu-
lating tumor cells in gastric carcinoma. Yuichiro Miki, Masakazu Yashiro,
Tomohisa Okuno, Kishu Kitayama, Tatsuro Tamura, Takahiro Toyokawa, Hi-
roaki Tanaka, KazuyaMuguruma, Kosei Hirakawa, Masaichi Ohira.Osaka City
Univ. Grad. School of Medicine, Osaka, Japan.
Background: It has been reported that the examination of circulating tumor cells
(CTCs) isbenefıcial forpredicting tumor stageor treatment response.Theepitherial
cell adhesionmolecule (EpCAM) and cytokeratin has been used as epithelialmark-
ers for the identifıcationofCTCs. Since theepithelial-mesenchymal transition isone
of malignant phenotype of cancer cells, it is necessary to investigate other markers
whichmight detectmesenchymal CTCs. Aim: This study aims to clarify the clinical
signifıcance of EpCAM negative and CEA positive CTCs in patients with gastric
cancer. Methods: Forty patients who underwent operation for gastric cancer were
enrolled in this study. A total of 10ml peripheral blood samples were obtained pre-
operatively. Informed consent to participate in this study was obtained from all of
the patients before their surgery. This study was approved by the Human Ethics
ReviewCommittee of ourUniversity. After collection ofmononuclear cell fraction,
these cells were stained by PAPI, anti-CD45, anti-EpCAM, anti-cytokeratin, and
anti-CEA (CD66e) antibody. We enumerated the number of cells which showed
EpCAM, cytokeratin, and CEA positive expression among CD45 negative cells.
ROC analyses were performed for investigating predictive value of these cell counts
for distantmetastasis.We examined association between these cell counts and clin-
icopathological features.Results:ROCanalyses revealed that theAUCforpredicting
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distant metastasis using EpCAM, Cytokeratin, and CEA positive cell counts were
0.583, 0.638, and 0.769, respectively. The median number of EpCAM negative and
CEApositive cellswas231 (range: 0-61897).Thecell countsofEpCAMnegativeand
CEA positive cells were signifıcantly associated with Tumor depth (p0.0084),
lymph node metastasis (p0.0107), and tumor size (p0.023). Conclusions: CEA
might be usefulmarker for detecting high risk of recurrence in patients with gastric
cancer.
#3792 Improved isolation and detection of circulating tumor cells of pan-
creatic cancer patients with characterization by mutational analysis. Oliver
von Ahsen, Nora Brychta, Thomas Krahn. Bayer Pharma AG, Berlin, Germany.
Introduction: Isolation of circulating tumor cells based on cell surfacemarkers is
often hindered by epithelial to mesenchymal transition with loss of epithelial anti-
gens. Low numbers of CTCs and fewer cases of CTC positive pancreatic cancer
compared toothercancers (e.g.breast cancer) lead to theassumption thatpancreatic
tumors do not release CTCs as frequently or that the pancreatic CTCs lack EpCAM
expression. Isolation of CTCs based on their size is independent of EMT-like phe-
notypical changes.We therefore compared a fıltration-based isolationmethodwith
anEpCAM-based isolationmethod.WeoptimizedCTCdetectionbyusing ahighly
sensitive anti-cytokeratin antibody panel for the detection of cancer cells withmod-
erate cytokeratin expression. In order to use isolated CTCs as liquid biopsy for
tumor characterization and treatment selection, downstream analysis is necessary.
We here show the feasibility of mutational analysis of isolated CTCs by castPCR.
Methods: EpCAM high, medium and low cells were enriched and isolated by an
EpCAM-based immunomagnetic procedure (IsoFlux) and a fıltration device (Sie-
mens) to determine recovery rates of both methods. Isolated cells were detected by
an improved immunofluorescent staining with an anti-Cytokeratins, anti-EpCAM
andanti-PBMCpanel andcharacterizedbycompetitiveallele-specifıcTaqManPCR
(castPCR) forKRASmutations. Results: Cytokeratin expression is crucial for detec-
tion of CTCs in a high background of blood cells. Improvement of the staining
protocol helps to increase the sensitivity of detection. The fıltration based approach
is superior to the surface antigen-based isolation.With the size-dependent method
weobtaineda recovery rateof 52%even forEpCAM-lowcells compared toonly1%
based on the immune-affınity purifıcation. Cells isolated by fıltration can be char-
acterized for expression of therapeutic targets by immunostaining. The utility of the
sizedependentplatformfor subsequent functional characterizationof theCTCswas
also demonstrated by detection of k-ras mutations in single isolated CTCs by cast-
PCR. Conclusion: For CTCs undergoing EMT, fıltration yields higher recovery
compared to the standard surface antigen (EpCAM)-based methods. Isolation by
fıltration also allows formutational analysis which can be used to confırm the iden-
tity of the isolated cell as CTC. In addition,mutational analysis of CTCs can be used
to guide the treatment of patients. Use of liquid biopsies for treatment selectionwill
facilitate truly personalizedmedicine.
#3793 Discovery and isolation of enormous number of circulating tumor
cells in breast cancer patient’s blood based upon cell attachment property.
Yeon-a Choi, Hyun Ju Han, Ae-Ran Choi, Jeong Dong Lee, Gun Min Kim,
Hyung Seok Park, Seho Park, Seung Il Kim, Joohyuk Sohn. Yonsei UnivMedical
Center, Seoul, Republic of Korea.
Circulating tumor cells (CTCs) are detached from primary tumors into the
bloodstream and known to play a role in tumor metastasis. CTCs are known to
be rare, estimated at 1-10 CTCs among 1010 blood cells in a milliliter of blood.
Most of existing technologies for CTC enrichment are based on marker expres-
sion or size. However, recent studies have suggested that CTCsmay have a wide
range of marker expression and sizes. The number of CTCs that is isolated from
the patient’s blood is fewer than expected. This infrequent and unreliable detec-
tion impedes the clinical use of CTCs. We adopted a concept that presumptive
CTC would have differential attachment properties compared toWBC in tissue
culture plate because it originated fromcarcinomawhere tumor cells attach each
other. To prove the concept, we spiked breast cancer cell lines into 7.5ml of
healthy blood. RBC was removed by Ficoll. Diluted peripheral blood mononu-
clear cells were incubated with 5% CO2 in cell culture incubator for 2h at 37°.
After a thorough rinsewith 1PBS, the plates were treatedwith 10mMEDTA to
detach cells from the bottom. The cells collectedwere followed by lysis andDNA
extraction, or placed on glass slide and stainedwith anti-CD45, -CK, -HER2, and
DAPI. Typically, slides were analyzed by confocal microscope or Metafer slide
scanning platform for enumeration of cells. 7.5 mL of peripheral blood was
collected from breast cancer patient, and handled as described above. Our
method showed higher detection sensitivities for 6 breast cancer cell lines. We
verifıed that breast cancer cell lines were collected more than 80% of spiked cell
number in 2hours. This technique is applied to isolation ofCTCs in actual breast
cancer patients, and unexpectedly considerable numbers of CTCs were ob-
served.We found in a range of CTCs from 0.5 105 to 1 106 per ml of blood.
These numbers are in striking contrast to previous studies. CTCs were observed
in 61 of 114 samples (53.51%) frommetastatic breast cancer patients and 15 of 48
samples (31.25%) from early breast cancer patients. We also discovered that
there are various sized CTCs, and categorized these CTCs according to their
diameter; small (5 M), medium (5-10 M), and large (10 M) CTCs. All
three types of CTCs appeared in large numbers. HER2 and EpCAM expression
of CTC vary by patients and didn’t always coincide with expression in primary
tumor. In summary, we have developed a promising strategy for CTC isolation
by using the preference of cancer cells to adhere to cell culture plates. We have
demonstrated that this is a simple yet very effıcient approach to isolateCTCs and
broadly applicable to capturing heterogeneous CTCs populations indepen-
dently of their marker expression and size. Our study discovered that enormous
amount of CTCs are existing in the blood of breast cancer patient in a variety of
sizes.
#3794 Selective isolation of epithelial to mesenchymal transitioned circu-
lating tumor cells in NSCLC using novel magnetic nanocubes. Dhananjay
Suresh, ShreyaGhoshdastidar, SoumavoMukherjee, AbilashGangula, Anandhi
Upendran, Raghuraman Kannan. University of Missouri, Columbia, MO.
The 5-year survival rate for early to advanced NSCLC patients is 10-5%.
Once the tumor metastasizes, the survival rate often drops below 1%. One of
the major challenges is to select the patient for appropriate therapy, and the
selection process involves invasive biopsy that is diffıcult to recurrently per-
form during treatment. Recent studies have shown that liquid biopsy is an
attractive alternative. Liquid biopsy involves analysis of either CTCs or
ctDNA to understand the tumor therapy. Isolating entire tumor cells provide
an opportunity to perform whole genome sequencing for in depth under-
standing of the tumor. However, frequent changes in cancer signaling and
acquired mutations during treatment lead to drug resistance that cannot be
diagnosed using current CTC techniques. These oncogenic biochemical
modifıcations that are often associated with metastasis involve upregulation
of epithelial to mesenchymal transition (EMT) pathway that change the
elasticity of tumor cells for easy shedding into the blood stream. Conse-
quently, EMT transition leads to depletion in epithelial markers such as
EpCAM and cytokeratin that are to be targeted. This effect largely limits the
use of present technologies utilizing EpCAM as a marker to isolate the CTCs.
We hypothesized that these cells can be captured by targeting surface mark-
ers that are overexpressed in EM transitioned CTCs. For example, markers
such as EGFR and HER2 have been shown to be overexpressed pre and post
EMT tumors and therefore can present as a new strategy for non-invasive
diagnosis before and during treatment. In this study we have shown that
EGFR and HER2 receptors are overexpressed in EGFR and KRAS mutated
NSCLC cells. We artifıcially activated EMT in NSCLC cells and compared
the surface biomarker concentrations. Furthermore, we used protein analy-
sis data using western blotting to identify our targets after EMT. Based on the
biomarker concentrations, we designed and developed magnetic nanocubes
(MNC) surface attached with antibodies to target the selected biomarkers to
capture EMT CTCs. The capture effıciency of these magnetic nanocubes was
compared in multiple cell lines (HCC827 and A549). Overall we could
achieve capture as low as 10 spiked cells in our study. In conclusion, cancer
markers such as EGFR and HER-2 that are highly expressed in tumors, once
shed as CTCs can be targeted for diagnosis. Therefore, we have developed a
novel method to capture EMT CTCs with high selectivity and this method
presents a minimally-invasive method for real-time monitoring of patients
during drug treatment.
#3795 Dynamic acquisitionofHER2 expressionon circulating tumor cells
in gastric cancer patients correlates to developing therapeutic resistance. Yi-
lin Li,1 Xiaotian Zhang,1 Dan Liu,1 Jifang Gong,1 Daisy Dandan Wang,2 Peter
Lin Ping,2 Lin Shen1. 1Peking University Cancer Hospital & Institute, Beijing,
China; 2Cytelligen, San Diego, CA.
Introduction: It has been hypothesized that molecular characters of circu-
lating tumor cells (CTCs) is dynamically evolved during cancer develop-
ment. However, how the evolutive CTC subtypes support tumor progression
and drug resistance remains unclear. In this study, converted phenotypic
HER2 expression and karyotypic chromosome 8 ploidy of CTCs in gastric
cancer patients who developed therapeutic resistance were systematically
investigated. Methods: Ninety-eight prospectively enrolled patients with di-
agnosis of advanced gastric cancer (AGC) were histo-pathologically classi-
fıed into 2 cohorts of HER2 (hHER2, 53 patients, subjected to the com-
bined chemo- and anti-HER2 targeted therapy), and HER2- (hHER2-, 45
patients, subjected to chemotherapy alone). Integrated EpCAM-indepen-
dent subtraction enrichment and immunostaining-fluorescence in situ hy-
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bridization (SE-iFISH) was applied to monitor and characterize HER2 ex-
pression and chromosome 8 ploidy of CTCs in patients following multiple
courses of therapy until disease progression. Results: HER2 expression on
CTCs was heterogeneous and interconverted compared to its relatively sta-
ble status on primary tumor. Among those prior-to-therapy patients,
HER2 CTCs were only detected in 30.2% (16/53) hHER2 patients, which
whereas can also be detected in 29.5% (13/44) hHER2- cohort. Following
several courses of therapy, additional 34% (18 out of 53, total: 34% previ-
ous 30.2%  64.2%) in hHER2 and 15.9% (7 out of 44, total: 15.9% 
previous 29.5%  45.4%) in HER2- cohort revealed acquired HER2 expres-
sion on CTCs. Acquired HER2 phenotype on CTCs closely correlated to
the decreased therapeutic effıcacy. Twenty one patients in hHER2 and 8 in
hHER2- cohorts have developed therapeutic resistance at the time of analy-
sis. Among those patients, HER2 CTCs were identifıed in 19 of hHER2
(19 out of 21, 90.5%) and 6 of hHER2- cohorts (6 out of 8, 75%), respectively.
Further karyotyping of CTCs in those patients developing therapeutic resis-
tance indicated that most of the CTCs with acquired HER2 expression had
multiploid (5) chromosome 8, implying that aneuploid chromosome 8 in
acquired HER2 CTCs were likely relative to development of therapeutic
resistance, both chemotherapy alone and the combined chemo- and targeted
therapy. Genomic profıling of the single CTC subtyped by iFISH upon phe-
notypic HER2 expression and karyotypic chromosome 8 ploidy is currently
under investigation. Conclusion: Dynamic profıling gene signature and mo-
lecular characterization of CTCs might be signifıcant in terms of predicting
therapeutic resistance, and further help select an alternative effective inter-
vention to overcome the acquired therapeutic resistance.
#3796 An intravascularmagneticwire for high-throughput in vivo enrich-
ment of rare circulating cancer biomarkers.Ophir Vermesh, Amin Aalipour,
Tianjia J. Ge, Yamil Saenz, Yue Guo, Seung-min Park, Yoshiaki Mitsutake, Mi-
chael Bachmann, Chin Chun Ooi, Kerstin Mueller, Hamed Arami, Alfredo
Green, Shan X. Wang, Sanjiv S. Gambhir. Stanford University, Stanford, CA.
Background: Liquid biopsies have longpromised to enable earlier cancer diagno-
sis and tailored therapy.However, circulating tumor cells (CTCs) are extremely rare
(1-10 cells permL blood), limiting their clinical utility. There are too fewCTCs in a
standard 5-10 mL blood sample for culture and drug susceptibility testing, or for
comprehensively profıling a molecularly heterogeneous cancer and its metastases
for drug resistance mutations. To achieve large-scale CTC enrichment, new strate-
gies are needed that can rapidly and effectively interrogate large blood volumes.
Aim: To design a flexible magnetic wire capable of high-throughput intravascular
enrichment and retrieval of rare biomarkers, includingCTCs, from the entire circu-
lating blood volume to attain a much higher biomarker yield for earlier cancer de-
tection and personalized treatment.Methods:We present a promising platform for
in vivo enrichment of rare biomarkers, the Magnetic Wire for Intravascular Re-
trieval and Enrichment (MagWIRE): a flexible, self-contained magnetic wire con-
sisting of a string of small magnets with alternating polarities, achieving high local
fıeld gradients along its entire length to capture magnetically labeled targets from a
large surrounding volume. The platform is proposed to work as follows: Blood
biomarkers are immunomagnetically labeled by injecting a patient with antibody-
coated magnetic particles (MPs), similar to FDA-approved Feraheme®. The Mag-
WIRE is then inserted through a standard IV catheter into a superfıcial vein in the
arm or through an existing chemotherapy port to magnetically capture passing
MP-boundbiomarkers.Withinanhour,5 litershascirculated througha2-3-mm-
diameter human vein, allowing most of the patient’s blood volume to be sampled.
The magnets can then be displaced from the MagWIRE sheath to elute the bound
targets into buffer for downstream analysis. We performed proof-of-concept dem-
onstrations in: 1) a closed-loop blood circulation system consisting of a pump, tub-
ing, and a blood reservoir, and 2) in vivowithin a porcine ear veinmodel. Tomodel
CTC capture, we targeted H1650 lung cancer cells with 1-m superparamagnetic
iron oxide particles coated with antibodies against epithelial cell adhesionmolecule
(EpCAM), a commonly usedCTCmarker.We couple theMagWIREwith a unique
approach for rapid (10 seconds)magnetic labeling ofCTCs in flow for immediate
downstream capture by the wire on a single pass. Results: Considerable gains are
achievable by sampling from large volumes, even at relatively low capture effıcien-
cies. In our closed-loop setup, the MagWIRE demonstrated capture effıciencies in
whole blood of 56.14/-15.80% for pre-labeled cells and 10.17/-5.41% for cells
labeled in flow. In a porcine earmodel, we captured cells with effıciencies up to 8%,
corresponding to 80-fold enrichment when integrated over a 5-liter blood volume
compared with a 5mL blood draw.
#3797 Non-invasive identifıcation of tumor cells using near infrared com-
position imaging system. Yasuhiro Koh, Satoshi Kambayashi, Hiroaki Aka-
matsu, Nahomi Tokudome, Hiroki Ueda, Nobuyuki Yamamoto. Wakayama
Medical University, Wakayama, Japan.
BACKGROUND: Circulating tumor cells (CTCs) are expected to be utilized for
decision-making in precision cancer medicine and further elucidation of cancer
biology. However, it remains challenging to detect and isolate CTCs without any
damages, that is critically important to analyze the molecular and biological prop-
erties of CTCs. Near infrared (NIR) imaging is one of the emerging technologies in
themedical fıeld and expected to be applied to visualization of blood vessels, nerves,
andmusclesunder the skinormucosa.Hereweattempted toapply theNIR imaging
technologies to distinguishing tumor cells fromnormal blood cells.METHODS:To
obtain NIR images, real-time composition imaging system Compovision® (Sumi-
tomoElectric Industries, Ltd.) was used. This system is equippedwith anNIR spec-
trographic camera and this cameraprocesseshyperspectral data, inwhich eachpixel
has spectraldata insteadofavisible image in thewavelengthbandof1,000-2,350nm.
The X-axis and Y-axis of the sensor chip correspond to the spatial direction and
wavelength. Thus, hyperspectral data stores both image and spectral information.
For this feasibility study, lung cancer cell lines with varying EpCAM expression
levels such as A549, PC-9, PC-14, H23 were used. Lymphocytes and red blood cells
were obtained from the peripheral blood of healthy volunteers. Phosphate-buffered
saline (PBS) was used as a negative control. After we obtained NIR hyperspectral
data, multivariate analysis such as principal component analysis (PCA) was per-
formed for precise analysis. RESULTS: We were able to obtain the hyperspectral
data from all the lung cancer cell lines, lymphocytes, red blood cells and PBS alone
and the spatially averaged spectrumwas extracted from each data. Then the spectra
were converted to absorption spectra and analyzed by PCAusing theUnscrambler®
X (CAMO Software) in the wavelength range of 1,000-2,200 nm. Two principal
components were selected from results to separate data. Two-dimensional PCA
score plot showed the clear segregation between tumor cells and normal blood cells
such as lymphocytes and red blood cells, indicating the potential of non-invasive
detection of tumor cells. In addition, obtained spectra from both EpCAM-express-
ing and EpCAM-non-expressing tumor cells were successfully segregated from
those from normal blood cells. According to these results, it is suggested that segre-
gating cells based on the difference in cytoskeletal components between epithelial
cells andblood cells is feasible using theNIR imaging technology.CONCLUSIONS:
Using theNIRcomposition imaging technology,wewereable toobtain thedifferent
spectral characteristics between tumor cells and normal blood cells, suggesting that
this technology holds the potential to detect and isolate CTCs without any invasive
labeling. This should be further explored for its application to the identifıcation of
CTCs.
#3798 Multiplex phenotyping of circulating cancer associated macro-
phage-like cells in patients with solid tumors. Daniel L. Adams,1 R Katherine
Alpaugh,2 Thai H. Ho,3 Steven H. Lin,4 Jeffrey R. Marks,5 Raymond Bergan,6
Stuart S. Martin,7 Saranya Chumsri,8 Cha-Mei Tang,9 Massimo Cristofanilli10.
1Creatv MicroTech, Inc., Monmouth Junction, MD; 2Fox Chase Cancer Center,
Philadelphia, PA; 3Mayo Clinic Cancer Center, Phoenix, AZ; 4MD Anderson
Cancer Center, Houston, TX; 5Duke University, Durham, NC; 6Oregon Health
and Science University, Portland, OR; 7University of Maryland, Baltimore, MD;
8Mayo Clinic Cancer Center, Jacksonville, FL; 9Creatv MicroTech, Inc., Potomac,
MD; 10Northwestern University, Chicago, IL.
Background: Circulating cancer associated macrophage-like cells (CAMLs)
are cancer specifıc giant cells circulating in the blood of patients with solid
tumors. Since their discovery, few studies have been done to elucidate their
lineage or phenotypic identity. The diffıculty in classifying CAMLs is exempli-
fıed by their expression of multiple heterogeneous markers that defy conven-
tional identifıcation. Recently, we described a restaining method (QUAS-R) to
screen individual cells using an array of up to 15 biomarkers. We used this
method to screen CAMLs isolated from 152 cancer patient samples in 4 types of
solid tumors to classify CAMLs by phenotypic immunostaining. These data
suggest that CAMLs are a morphologically diverse and phenotypically hetero-
geneous population of cancer specifıc giant cells with overlapping myeloid, ep-
ithelial, and endothelial phenotypes. Methods: This multi-institutional study
used peripheral blood samples from 152 cancer patients (stage I-IV) from breast
(n42), lung (n39), renal cell carcinoma (36) and prostate (n35). Blood was
processed by the CellSieve™ microfıltration technique at 5 institutions and
stained for cytokeratin 8, 18 & 19, EpCAM, and CD45. After identifıcation/
imaging, the QUAS-R (Quench, Underivatize, Amine-Strip and Restain) tech-
nique was used to quench fluorescence signal of cells and then restain with
vimentin/CD146/CD144, CD14/CD11b/CD41, CD11c/CD68/TIE2, or CD34/
CD41/CD61.After staining,QUAS-Rwas again used to remove the fluorescence
and samples restained with a third panel. Each patient sample was stained,
quenched and restainedwith the abovementioned panels. Results: In agreement
with a number of studies, CAMLswere found in 86%of cancer patients (n131/
152), with increased detection from stage 1 (71%), followed by stage 2 (94%),
stage 3 (88%) to stage 4 (88%). Breast cancer had the most CAMLs per sample
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(14.1 cells/7.5mL), followed by prostate (6.8), renal cell carcinoma (4.9) and lung
(3.2). CD34 was most prevalent, found on 88% of CAMLs, followed by cytoker-
atin (81%), CD41 (79%), CD61 (78%), CD45 (75%), CD14 (72%), vimentin
(63%), EpCAM (56%), CD146 (53%), CD68 (44%), CD11c (38%), TIE-2 (25%)
and CD11b (0%). Based on our results, CAMLs seem to express overlapping
phenotypes from a variety of lineages i.e. macrophage (CD14/CD68/CD11c),
epithelial (cytokeratin/EpCAM), endothelial (CD146/TIE-2) and megakaryo-
cyte (CD41/CD61). Conclusions: Although identifıcation of CAMLs is straight-
forward by morphological criteria (size and nuclear profıle), their identifıcation
and lineage remains undetermined. We report the fırst mass screening of
CAMLs to determine phenotypic expression. These data suggest that CAMLs
cannot be grouped into any known cell subtype based on their expression pro-
fıles and represent a heterogeneous and variably differentiated population
whose biological consequences in cancer remain under investigation.
#3799 Technical validation of a micro-flow cytometry platform for pros-
tate cancer biomarker discovery. Desmond Pink,1 Robert Paproski,1 Deborah
Sosnowski,1 Lian Willetts,1 Eric Hyndman,2 John D. Lewis1. 1Univ. of Alberta,
Edmonton, Alberta, Canada; 2University of Calgary, Edmonton, Alberta, Can-
ada.
The analysis of extracellular vesicles (EVs) in biofluids is an expanding area of
biomarker discovery. To be effective, a diagnostic test must differentiate EVs
originating from cancer cells versus non-cancerous origins, and also defıne bio-
markers enriched in cancer EVs. Our team has developed a micro-flow cytom-
etry platform using the Apogee A50 to analyze prostate cancer (PCa) EVs in
different biofluids. While flow cytometry is powerful tool for quantitative and
qualitative evaluation of cellular biomarkers, direct translation of most applica-
tions to EVs is challenging. For example, EVs in biofluids typically range in size
from 50-1000nm, and are present as low refractive index, polydisperse popula-
tions. We have optimized 30 assay parameters for the identifıcation of prostate
specifıc EVs so that disease specifıc biomarkers may be evaluated. To illustrate
the sensitivity of the system, conditioned media from palmitoylated-GFP-LN-
CaP cells was used as a positive signal sample. When spiked into increasing
concentrations of unstained plasma EVs, the GFP spike was detected linearly,
even when present as low as 0.03% of the total EV population. Furthermore, the
rate of positive signal/uL sample was quantitative after 15-30 seconds of sample
analysis. The platform also permits high throughput analysis using a 96 well
plate autosampler. To show sample reproducibility, we analyzed both low and
high positive-signal samples over an 8hr sampling window. Low positive sam-
ples (120events/uL; 0.1% of total EVs) had a 4%CVover 96 samples whereas the
high positive signal samples (2300events/uL, 1.0% of total EVs) had a 2.2% CV.
Similar CVs have been obtained with CD9 and CD63. Analysis of sample ali-
quots over multiple days shows less than 6% CV. Conventional flow cytometers
acquire tens of thousands of events while the Apogee system is able to collect
millions of events with several parameters/event, in a high throughput manner.
This generates a signifıcant amount of data for which we have designed a unique
machine learning approach to detect specifıc EV populations within the whole
sample. In this manner, we utilize all data from the sample and not simply a
subjectively defıned area of interest. Using fresh samples from the clinic we have
standardized a 2hr arm-freezer protocol for the collection and preservation of
serum and plasma. Comparison studies in LNCaps and PC3 cells of 5 antibodies
against PSMA, indicated the J591 anti-PSMAmonoclonal antibody as a selective
marker for prostate cancer EVs. Positive signal for this antibody was linearly
titrated in both a LNCaP EV system and plasma EVs from metastatic prostate
cancer patients. Specifıcity was shown by saturating a plasma system with un-
conjugated J591 and then reacting with PE-conjugated J591. Using the A50
micro-flow cytometry platform, the J591 antibody to identify prostate specifıc
EVs, and a unique machine learning algorithm, we identifıed a multiple bio-
marker, diagnostic signature for PCa.
#3800 Analysis of circulating tumor exosomes: their ability to serve as a
biomarker for recurrence in lung cancer. Nicholas Serrano, John Blue, Asim
Alam, Christopher S. Rabender, Elisabeth Weiss, Mitchell S. Anscher, Ross B.
Mikkelsen, Vasily A. Yakovlev. VCUMassey Cancer Ctr., Richmond, VA.
Objectives: Exosomes (Exos) are 30-150 nm wide nanovesicles originating
from the endosomal network and are found in most body fluids. Production of
Exos increases in cancer, making Exos potential biomarkers. Exos are a funda-
mental driver of intercellular communication by transferring proteins, lipids
and miRNA. Analysis of Exos and their interaction with the microenvironment
may uncover cellular pathways involved with disease progression. We hypoth-
esized that Exosmay serve as a liquid biopsy for tumor recurrence.Materials and
Methods: Six lung cancer patients (LCPs) were prospectively enrolled on an IRB
approved study. Exos were precipitated and purifıed with a Norgen kit from 0.7
ml of blood samples collected prior to, during and 6 months after radiation
therapy (RT). Exos numbers were quantifıed by Exocet Exosome Quantitation
Kit (System Biosciences). Total exosomal RNA was isolated by the Norgen
RNA/DNA/Protein Purifıcation kit. For the miRNAs expression profıling we
used the miRCURY LNA™ Universal RT microRNA PCR assay (Exiqon) and
ExiLENT SYBR® Green Maser Mix (Exiqon). Expressions of 10 different miR-
NAs (let-7a-5p,miR-20a-5p,miR-21-5p,miR-30b-5p,miR-106a-5p,miR-146a-
5p, miR-155-5p, miR-200b-5p, miR-203a, miR-208a) for all samples were de-
termined. Human lung fıbroblasts (MRC-5s) in serum-free medium for 24 hrs
were treated with Exos, TGF- (positive control) or PBS (negative control) to
determine their relative effects on MRC-5 proliferation. Results: Of the 6 LCPs,
2 had limited stage small cell and 4 had non-small cell at diagnosis. Three pa-
tients were diagnosed with recurrence at the time of their post-RT blood draw.
SixmiRNAs demonstrated signifıcantly different expressions between recurrent
and non-recurrent groups of LCPs: let-7a-5p, miR-20a-5p, miR-21-5p, miR-
106a-5p, miR-155-5p, and miR-203a. MRC-5 proliferation increases 2-fold
when treated with Exos from blood collected prior to RT compared to PBS (p
0.01). There is 2-fold increase compared to TGF- (p  0.03). Plasma Exos
levels decrease during RT as do their relative effects on MRC-5 proliferation
when compared at equivalent numbers. Exos collected at 6 months from pa-
tients with recurrence signifıcantly stimulated MRC-5 proliferation (p 0.03),
whereas Exos from patients without recurrence do not.Western blot analyses of
MRC-5 cells stimulated with Exos revealed decreased PTEN but enhanced
CDC25A expression and increased AKT and SMAD phosphorylation, regard-
less of when the Exos were collected. Conclusions: Recurrent and non-recurrent
groups of LCPs demonstrated signifıcant differences in exosomal miR profıle
before and after RT. Exos from untreated LCPs, and recurrent LCPs after RT,
stimulate MRC-5 proliferation and possible conversion to CAFs. Our results
suggest that Exos could serve as a “liquid biopsy” to assess the potential for
recurrence when imaging modalities are equivocal.
#3801 A novel sensitive flow-cytometry based platform for isolation and
molecular characterization of circulating tumor single cells and clusters.
Neha Bhagwat,1 Charles H. Pletcher,2 Ling Wang,3 William DeMuth,2 Keely
Dulmage,3 David Balli,1 Stephanie S. Yee,4 Liping Yu,5 Jonni S. Moore,2 Ben Z.
Stanger,1 Eric P. Dixon,3 Erica L. Carpenter4. 1Division of Gastroenterology, De-
partment of Medicine, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, PA; 2Department of Pathology and LaboratoryMedicine, Perelman
School of Medicine, Philadelphia, PA; 3BD Technologies, Research Triangle Park,
NC; 4Division of Hematology and Oncology, Department of Medicine, Perelman
School of Medicine, University of Pennsylvania, Philadelphia, PA; 5BD Biosci-
ences, San Jose, CA.
Circulating tumor cells (CTCs) are shed from solid tumors and found at ex-
tremely low frequencies in the blood of patients in most cancers. A subset of these
cells can seed and give rise to metastases, which is the primary cause of cancer-
relatedmortality. Isolation and characterization of these cells fromblood as a ’liquid
biopsy’ can be a sensitive, non-invasive method for early detection, disease moni-
toring and therapy selection. CTCs can be found even at early disease stages in
preclinicalmodels andpatients.There is increasingevidence that clustersofCTCs in
blood are associated with higher metastatic potential; however, effıcient isolation
and interrogation of these rare clusters is challenging. In this study, we utilize an
in-line rare cell enrichment platformdevelopedbyBectonDickinson (BD), coupled
with theBDFACSTM Influx cell sorter to rapidly isolate both single cells and clusters
from blood. This platform utilizes magnetic particle-based depletion of unwanted
leukocytes and combines acoustic focusing to remove red blood cells and debris
while enriching for rare cells of interest. We achieved 30-fold enrichment of tumor
cells spiked into blood along with6-fold improvement in sort effıciency with the
enrichment process as compared to without. Importantly, the large 200m nozzle
and lowsheathpressure (3.5psi)on the Influxminimizes shear forces andmaintains
cell viability and integrityof clustersduring sorting, therebyenablingdiscrimination
of single cells and clusters based on side scatter. Using this strategy, we could sort
enriched populations of viable cell clusters (range 2-10 cells). Finally, this workflow
can be seamlessly integrated with downstream molecular analysis such as next-
generation sequencing.We successfully performedwhole-transcriptome single-cell
sequencing (sc-RNAseq) on cells isolated with this streamlined platform where
pooled cells andbulkRNAwereusedas comparisons.Asproof of principle,weused
this optimized workflow to isolate and characterize CTCs from a pancreatic cancer
mouse model (KPCY) in which all tumor cells are labeled with Yellow Fluorescent
Protein (YFP).We sortedYFPCTCs andCD45white blood cells (WBCs) from
the blood of 7 KPCY mice along with YFP cells from the matched tumor. We
recovered an average of 88 CTCs/ml of blood (range 5–258). RNA sequencing was
completed on pooled and single cells from all samples. Epithelial genes including
Krt18 and Krt19 as well as lineage specifıc genes such as Sox9 were signifıcantly
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overexpressed inCTCsand tumors compared toWBCs, suggesting theutilityof this
approach. This integrated CTC workflow provides a sensitive approach to identify
pancreatic cancer-specifıc markers, which will be evaluated for their ability to im-
prove sensitivity of positive-selectionofCTCs inpatient blood and for development
of a clinically relevant diagnostic assay.
#3802 Anovel uracil-DNAglycosylase,UdgX, as a newbiochemical tool to
directly detect uracils in DNA. Jessica Stewart,1 Shanqiao Wei,1 Madhurima
Datta,2 Umesh Varshney,2 Ashok Bhagwat1. 1Wayne State University, Detroit,
MI; 2Indian Institute of Science, Bangalore, India.
The enzyme activation-induced deaminase (AID) is essential to the B lym-
phocyte development and antibodymaturation. It converts cytosines inDNA to
uracil. The unregulated expression of AID in many B cell cancers is correlated
with an increased load ofmutations. AID also promotes DNA strand breaks and
is required for chromosomal translocations such as IgH/Myc in these tumors.
Wehave previously showed that B cell cancer cell lines andpatient tumorswhich
express AID at high levels also have high levels of uracil in their genomic DNA.
We accomplished this by excising the uracils using a uracil-DNA glycosylase
(Ung) and labeled the resulting in an abasic site with an aldehyde reactive chem-
ical (ARP). ARP contains a biotin tag and it was detected using a fluorescently
labeled streptavidin. The results from this assay showed B cell tumors have as
much as 100-fold higher levels of genomic uracils. Further development of this
assay has allowed the detection of uracils in the blood plasma and buffy coat of B
cell cancer patients. This “liquid biopsy” assay technique has the potential to
work as a simple surveillance tool for B cell cancer patients who are in remission.
In addition, we are exploring the possibility of a direct detection of uracil in
DNA, which would provide greater sensitivity to this assay and simplify it. A
unique uracil-DNAglycosylasewas recently isolated fromM. smegmatis, UdgX,
that binds covalently to uracils in DNA. We are developing multiple ways to
detect uracil-DNA-UdgX complexes and amplifying the resulting signal. We
expect that this will allow us to directly visualize uracils in B-NHL tumors and
detect uracils in circulating B-NHL tumor DNA from a drop of patient plasma.
#3803 Characterization of fluid biopsy using the HD-SCA platform to
re-stratify intermediate-risk organ-confıned prostate cancer patients. Pay-
maneh D. Malihi,1 Kenneth Pienta,2 James Hicks,1 Michael Gorin,2 Carmen
Ruiz Velasco,1 Anders Carlsson,1 Anand Kolatkar,1 Mariam Rodriguez Lee,1
Michael Morikado,1 Peter Kuhn1. 1University of Southern California, Los Ange-
les, CA; 2Johns Hopkins Hospital, Baltimore, MD.
Recent studies have demonstrated that even with current risk stratifıcation of
intermediate-risk organ-confıned prostate cancer patients, 30-50% of patients
are incorrectly categorized and overtreated. As the second leading cause of can-
cer in men, 90% of prostate cancer patients are diagnosed at organ-confıned
stages, where radical prostatectomy (RP) is the “golden standard” of treatment.
However, deferring intervention is becoming a more popular option for low-
risk patients, with a 15-year progression-free survival of 95%. High-risk patients
greatly benefıt fromRP,with a 5-year progression-free survival of 85%,while the
decision to proceed with RP is not so candid for intermediate-risk patients.
Using the high-defınition single cell assay (HD-SCA) platform, circulating tu-
mor cells (CTCs) from peripheral blood (PB) and disseminating tumor cells
(DTCs) from bone marrow aspirate (BMA) will be analyzed for morphological,
genomic, and proteomic profıling. We hypothesize that by using morpho-pro-
teo-genomic parameters wemay develop predictivemarkers for amore accurate
stratifıcation of intermediate-risk patients, offering a more personalized treat-
ment for each individual. Preliminary data shows 86% (n43) of PB samples
and 5% (n40) of BMA are positive for Cytokeratin (CK) expressing rare cir-
culating cells, as defıned by5 cells/mL. The incidence of CK cells in PB did
not correlate with PSA, Gleason score, or clinical parameters. However, inci-
dence of CK cells in PB was higher in high-risk group, though not statistically
signifıcant (p0.784) when compared to intermediate-risk groups. Addition-
ally, higher levels ofCKexpression (p0.0001), asmeasured by relative intensity
of fluorescent staining, were detected in cells detected in PB of high-risk patients
relative to intermediate- and low-risk groups as measured by an analysis of
variance (ANOVA) statistical model. Low levels of genomic aberrations are
observed in all CK rare circulating cells (5%, n118), which may speak to the
fact that these patients are in early stages of their disease. The use of theHD-SCA
platform to characterize the fluid biopsy may result in the identifıcation of pre-
dictive markers of treatment response for intermediate-risk patients, resulting
in reduction of overtreatment.
#3804 Comprehensive comparison of bisulfıte conversion kits: A guide for
optimal sensitivity and specifıcity of circulating cell-free DNA methylation-
based biomarkers. SarahØ. Jensen,Mai-BrittW.Ørntoft, Jesper B. Bramsen, Tor-
ben F. Ørntoft, Claus L. Andersen.Aarhus University Hospital, Aarhus, Denmark.
Analysis of circulating cell-free DNA (cfDNA) is a promising approach for
non-invasive detection of human cancer. The approach has wide-spread appli-
cations including early detection of disease in asymptomatic individuals, resid-
ual disease detection and disease monitoring. A challenge for the clinical utili-
zation of cfDNA is the small fragment size of cfDNA and the limited amount of
cfDNA present in blood. For detection of circulating tumor DNA (ctDNA)
highly sensitive methods for cfDNA detection e.g. targeted sequencing and dig-
ital droplet PCR (ddPCR) target tumor specifıc mutations or DNAmethylation
alterations. Detection of methylation-based biomarkers requires that cfDNA is
bisulfıte converted prior to biomarker detection, which is known to be associ-
ated with some loss of cfDNA. Yet, surprisingly few efforts have focused on
ensuring high cfDNA bisulfıte conversion (BSC) effıciency and -recovery, and
few commercial kits are especially designed for this purpose. In this study we
aimed to fınd a BSCmethod suited for cfDNAmethylation biomarker research,
with high BS conversion effıciency and minimum loss of cfDNA, in order to
increase the amount of cfDNA template available for downstream analysis. We
studied 13 different methods for BSC and examined both the recovery and the
BSC effıciency using quantitative real-time PCR (qPCR), polyacrylamide gel
electrophoresis (PAGE) and ddPCR. A signifıcant variation in DNA recovery
was observed between the 13methods tested using both high and lowmolecular
weight DNA templates. Especially fıve kits performed consistently well on all
DNA templates tested, as evaluated by qPCR and PAGE. As the lengths of
cfDNA is 146-167 base pairs, only methods that are able to recover fragments of
this lengths is suitable for cfDNA pipelines. Results showed that few methods
enabled recovery of DNA fragments  150 base pairs. However, three kits
showed a higher amount of 150 base pair fragments compared to the other
methods tested. In a clinical setting it is expected that the target cfDNA compose
only a minor fraction of the total cfDNA in plasma. Thus, the fıve best perform-
ing kits were tested using ddPCR on serial dilutions of leucocyte DNA frag-
mented to 150bp to mimic cfDNA. The best performing kit had a recovery of
69% of the initial input compared to only 13% for the poorest performing kit.
Collectively, our comprehensive comparison hereby guide which BS conversion
methods are suited for cfDNA methylation-based biomarker pipelines.
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#3805 Pre-diagnostic statin use among breast cancer patients - the rela-
tion to HMG-CoA reductase expression and disease-free survival. Helga
Tryggvadottir, EmmaGustbée, AndreaMarkkula, Maria Simonsson, Björn No-
din, Karin Jirström, Carsten Rose, Christian Ingvar, Signe Borgquist, Helena
Jernström. Lund University, Lund, Sweden.
Background: The purpose of this study was to investigate whether pre-diag-
nostic statin use was associated with tumor expression of HMG-CoA reductase
(HMGCR) and disease-free survival (DFS) in breast cancer. Previous studies
have shown anti-carcinogenic properties of statins and a signifıcantly longer
survival among breast cancer patients using statins. We recently showed, that
the target of statins, HMGCR, was up-regulated in breast cancer among patients
preoperatively treatedwith statins in awindow-of-opportunity trial.Methods:A
population-based cohort of primary breast cancer patients in Lund, Swedenwas
assembled betweenOctober 2002 and June 2012. Patients completed a question-
naire including information onmedication use. Statin use in relation toDFSwas
analyzed in 985 patients. Tumor tissue microarrays were constructed and
stained with a polyclonal HMGCR antibody to assess HMGCR expression
(n848). Results: Patients were followed for up to 11 years (median follow-up
time 5.0 years). In the present study, pre-diagnostic statin use was neither asso-
ciated with HMGCR expression (P0.53) nor with DFS (P0.92), overall or
separately in any of the HMGCR expression groups (negative, weak, moderate/
strong). Moreover, statin use was not associated with clinical tumor character-
istics (tumor size, axillary lymph node involvement, histological grade, hor-
mone receptor status or HER-2 amplifıcation). Conclusion: In contrast to
previous studies, the present study did not show any signifıcant association
between pre-diagnostic statin use and DFS. It is possible that patients who al-
ready used statins have developed tumors that are less dependent on cholesterol
metabolism and consequently less influenced by statin treatment. The timing of
statin use in relation to breast cancer diagnosis and prognosis should be evalu-
ated in another cohort with preferably longer follow-up time.
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#3806 Integrative omics analysis in gastric cancer reveals SLC7A5 func-
tional related to DNA mismatch repair system as a potential therapeutic
biomarker in GC. Yunyun Zhou,1 Xuehua Chen,2 Zhenggang Zhu,3 Junqing
Wang2. 1University of Mississippi Medical Center, Oxford, MS; 2Department of
Surgery, Shanghai Ruijin Hospital, Shanghai Jiao TongUniversity School ofMed-
icine, Shanghai, China; 3Department of Surgery, Ruijin Hospital, Shanghai Jiao
Tong University School of Medicine, Shanghai, China.
Background: Metastasis is a major cause leading to high mortality rate and
poor prognosis in Gastric Cancer (GC) patients. Our previous studies showed
that SLC7A5 is an amino acid transporter gene meditated by a pivotal post-
transcriptional tumor suppressormir-126 and associated with tumormetastasis
in GC. Purpose: (a) to further determine the SLC7A5 functional mechanisms in
GC by involving more bio-omics data such as DNA methylation, copy number
variation (CNV) and mRNA expression; b) to study the association of SLC7A5
bio-omics data with the clinicopathologic features, prognosis and subtypes in
GC patients. Methods: We intensively performed the genome-wide association
study for bio-omics data of GC patients available from The Cancer Genome
Atlas (TCGA, n421) and Gene Expression Omnibus published studies (GEO,
GSE13911, n69, GSE15459, n209). We did Kaplan-Meier survival analysis
and univariate Cox regression model analyses in SLC7A5 mRNA expression
from curated database (http://www.kmplot.com)with 882GCpatients for over-
all survival and 646 GC patients for progression free survival analysis. Results:
CNV of SLC7A5 is positively correlated with mRNA expression (p3.18e-07),
which suggests that SLC7A5 is potentially a target driver gene for GC. Further
integrative analysis identifıed two important methylation probes in promotor
region (TSS200 position) negatively correlated with mRNA expression of
SLC7A5 (p1.03e-3). In addition, the aberrant high methylation and expres-
sion of SLC7A5, which were signifıcantly higher than the corresponding non-
malignant tissues, were identifıed in a subset of gastric cancer patients. Interest-
ingly, SLC7A5 showed statistically signifıcant correlation with the mismatch
repair-defıcient phenotype in sporadic microsatellite instability gastric cancer
(p2.12e-5). Data mining from two independent datasets of GEO validated
SLC7A5 is positively correlated with DNA mismatch repair genes MLH1,
BRCA1 and BRCA2. And further Gene Ontology (GO) pathway analysis sug-
gested that SLC7A5 and DNA mismatch repair genes (MMR) together shared
the same metabolic processes. Importantly, the overall survival from 882 GC
patients and progression free survival analysis from 646 GC patients showed
SLC7A5high expression is associatedwith poor prognosis tumorigenesis, which
demonstrated that SLC7A5 is a potential independent biomarker for GC. Con-
clusion: We found SLC7A5 has positive interaction with DNAmismatch genes
through databasemining, which result inmicrosatellite instability phenotype in
GC patients. We also found SLC7A5 over expression is associated with poor
prognosis and potentially an pivotal therapeutic target in GC.
#3807 ATMprotein loss and clinical outcomes with platinum chemother-
apy in patients with advanced solid tumors. Raghav Sundar, Susana Miranda,
Suzanne Carreira, Maxime Chénard-Poirier, Daniel Nava Rodrigues, Ines
Figueiredo, Claudia Bertan, Wei Yuan, Desamparados Roda Perez, Ana Fer-
reira, Nina Tunariu, Joaquin Mateo, Johann de Bono. Institute of Cancer Re-
search, London, United Kingdom.
Background: Loss of ataxia telangiectasia mutated (ATM), a key protein reg-
ulating DNA damage repair signaling, appears to sensitize tumors to platinum
chemotherapy in preclinical studies. In this study, the incidence of ATM loss in
patients with advanced solid tumors and clinical outcomes with platinum che-
motherapy was analyzed. Methods: Archival tumor and biopsy samples of pri-
mary or metastatic sites of patients treated in a phase I trial unit were retrieved
and ATM immunohistochemistry (IHC), as well as targeted next generation
sequencing (NGS)was performed.Analytic validation and assay optimization of
rabbit monoclonal antibody [Y170] to ATM (Abcam ab32420) was undertaken
using known positive (VCaP xenograft material and GM14680 cell pellet) and
negative (GM01526 cell pellet) controls. IHC slides were assessed by a trained
pathologist for nuclear staining intensity of ATM and semi-quantitatively
scored. ATM loss was defıned as a nuclear H score of 10. Clinical data were
collected retrospectively from case records. Duration on platinum therapy was
defıned as time from start of fırst platinum therapy to time to subsequent therapy
(adjuvant platinumexcluded). Results: Overall, 679 samples of 587 patientswere
tested for ATM IHC, of which 517 samples had NGS performed; 5% of patients
(n  31) had ATM IHC loss, and 5% (n  27) had somatic ATM mutations
detected by NGS (Table 1). In 70 matched primary/metastatic or different met-
astatic sites, concordance of ATM IHC loss occurred in 99% (n  69; 7 with
ATM IHC loss) of samples. Of the colorectal cancer cohort (n 223), duration
on platinum therapy was signifıcantly longer for the ATM loss group (11 vs 8
months, HR: 0.57, 95% CI: 0.35 to 0.93, p  0.04). Discussion: Loss of ATM
expression was detected among 5% of this cohort of advanced solid cancers,
primarily in breast and gastrointestinal tumors. Sensitivity to platinum therapy
is signifıcantly higher inATM loss colorectal cancer. Further prospective studies
with larger cohorts are required to validate these fındings.
ATM IHC and ATMmutation by NGS by tumor group
Tumor
types Total
ATM IHC
loss (%) ATMmutation (%)
Concomitant
ATM loss
and ATM
mutation
Concomitant
TP53 mutation
with ATM
IHC loss
or mutation
Total
Misense
n
Frameshift
n
Truncating
n
(as % of
those with
ATM IHC
loss)
(as % of
those with
ATM IHC
loss/mutation)
Colorectal 223 16 (7) 9 (4) 5 4 4 (25) 10 (48)
Gynaecological 105 1(1) 7 (7) 4 1 2 5 (63)
Thoracic 80 1(1) 3 (4) 2 1 1 (100) 2 (67)
Breast 44 8 (18) 4 (9) 2 2 3 (38) 4 (44)
Upper GI 37 2 (5) 1 (3) 1 2 (67)
Hepatobiliary 22 1(5) 1 (5) 1 1 (50)
Others 76 2 (3) 2 (3) 2 1 (50)
Total 587 31(5) 27(5) 14 (52) 3 (11) 10 (37) 9 (29) 24 (49)
#3808 TM4SF1 regulates cell cycle and ROS status in bladder cancer cells
by targeting FOXO3a via PPAR-SIRT1 negative feedback loop. Rui Cao,
GangWang, KaiyuQian, Liang Chen, QingxuanHu, Yu Xiao, XinghuanWang.
Zhongnan Hospital of Wuhan University, Wuhan, China.
Transmembrane 4 superfamily member 1 (TM4SF1) is a member of tetras-
panin family, which locates in the cell membrane, functions as signal transducer
to regulate cell development, growth andmotility. Currently, TM4SF1 has been
reported to be overexpressed in liver cancer, pancreatic cancer and colorectal
cancer, but its role in bladder cancer (BCa) has not been illustrated. We have
found that TM4SF1was strongly upregulated in humanbladder cancer tissues at
both transcription and translation levels, compared with the paracancerous tis-
sues and normal bladder tissues. This result was corroborated with our tran-
scriptome analysis. Moreover, the tissue array data showed that TM4SF1 closely
related with survival rate of BCa as the patients with high expression of TM4SF1
have a poorer prognosis. Furthermore, in vitro and in vivo studies suggested that
proliferation of BCa cells was signifıcantly suppressed by knockdown of
TM4SF1.Moreover, downregulation ofTM4SF1 inducedG0/G1phase cell cycle
arrest and apoptosis possibly via induced reactive oxygen species (ROS) status in
BCa cells. In addition, we observed that phosphorylated/total SIRT1 proteins
were considerably reduced in the BCa cells lacking TM4SF1. In contrast, PPAR
as well as its target phosphorylated/total FOXO3a were strongly increased, an
important downstream transcriptional factor of PPAR/SIRT1 negative feed-
back loop, regulating cell cycle, apoptosis and ROS metabolism. Therefore, we
treated the TM4SF1-silencing BCa cells with GW9662 (antagonist of PPAR)
and resveratrol (activator of SIRT1), showing a recovery of the G0/G1 phase cell
cycle arrest and scavenge of ROS status. Interestingly, the increase of phosphor-
ylated/total FOXO3a by knockdown of TM4SF1 could also be rescued by using
GW9662 and resveratrol. In conclusion, our results suggested that TM4SF1may
regulate cell cycle and ROS status of BCa cells by targeting FOXO3a via the
PPAR-SIRT1 negative feedback loop.
#3809 SWI/SNF aberrations sensitize pancreatic cancer cells to DNA
crosslinking agents. Zhewei Shen, Jean Davidson, Jonathan Pollack. Stanford
University, Stanford, CA.
While gemcitabine has been the mainstay therapy for advanced pancreatic
cancer, newer combination regimens (e.g. FOLFIRINOX)have extendedpatient
survival, though carry greater toxicity. Biomarkers are needed to better stratify
patients for appropriate therapy. Previously, we reported that one-third of pan-
creatic cancers harbor deletions or deleterious mutations in key subunits of the
SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex.
The SWI/SNF complex mobilizes nucleosomes on DNA, and plays a key role in
modulating DNA transcription and repair. Thus, we hypothesized that pancre-
atic cancers with SWI/SNF aberrations might exhibit compromised DNA re-
pair, and show increased sensitivity to DNA damaging agents. Here, we studied
pancreatic cancer cell lines with defıcient (or else exogenously reconstituted)
SWI/SNF subunits, as well as normal pancreatic epithelial cells (HPDE) follow-
ing SWI/SNF subunit knockdown. Cells were challenged with DNA damaging
agents, including those used in current combination regimens, and then cell
viability assayed. We found that pancreatic cells with SWI/SNF dysfunction
showed markedly increased sensitivity to DNA damaging agents, and in partic-
ular DNA crosslinking agents (cisplatin and oxaliplatin). Assaying clearance of
H2AX foci confırmed that SWI/SNF dysfunction impaired DNA damage re-
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sponse/repair. Finally, by analyzing pancreatic cancer patient data (TCGA), we
found that pancreatic cancers with SWI/SNF defıciency (subunit mutation
and/or decreased expression) showed a strong trend towards extended survival
with platinum containing chemo regimens. Thus, SWI/SNF dysfunction sensi-
tizes pancreatic cancer cells to DNA crosslinking agents, and SWI/SNF muta-
tion statusmay provide a useful biomarker to predict which patients are likely to
benefıt from platinum-containing chemotherapy regimens.
#3810 Validation of novel high-plex protein spatial profıling quantitation
based onNanoString’sDigital Spatial Profıling (DSP) technologywith quan-
titative fluorescence (QIF).Maria I. Toki,1 Chris Merritt,2 Giang Ong,2 Joseph
M. Beechem,2 Daniel E. Carvajal-Hausdorf,1 Yalai Bai,1 David Rimm1. 1Yale
University School of Medicine, New Haven, CT; 2NanoString Technologies, Seat-
tle, WA.
Background: Protein expression in formalin-fıxed, paraffın-embedded
(FFPE) tissue is routinely measured by Immunohistochemistry (IHC) on only
one protein, or with quantitative fluorescence (QIF) on a handful of proteins on
a single section. NanoString’s Digital Spatial Profıling (DSP)* technology can
detect and quantify proteins at signifıcantly higher multiplex (currently 30 plex,
potential for up to 800 plex) with spatial resolution using molecular digital
color-coded “barcodes”, within specifıc regions of interest on FFPE tissue. Here,
we compare Nanostring DSP technology to automated QIF (AQUA), for accu-
rate and reproduciblemeasurement of protein expression on a continuous scale.
Additionally, using themultiplexing potential of Nanostring technology, we did
a pilot study to assess cold ischemic time as a variable tomonitor tissue quality by
assessment of epitope degradation in Non-Small Cell Lung Cancer (NSCLC).
Methods: The DSP technology uses a cocktail of primary antibodies conjugated
to indexingDNAoligos with aUVPhotocleavable linker that can be counted on
the nCounter™ platform. Regions of interest (ROI) on the tissue are selectedwith
fluorescently labeled antibodies, and oligos from that region are released via UV
mediated linker cleavage. Free oligos are captured via microcapillary fluidics
into a microtiter plate and then quantitated on the nCounter. The comparator
for this technology was the AQUAmethod ofQIF.We examined a breast cancer
tissue microarray with a range of HER2 expression, and a NSCLC time to fıxa-
tion standardization array with timepoints from 20min to 48 hrs. Results: Mul-
tiple markers were assessed and a high correlation was found between Nanos-
tring DSP counts and QIF scores (R²0.7), when the measurements were
performed in the same region of interest (defıned by cytokeratin expression).
The dynamic range of DSP exceeded the quantifıcation range of QIF (nearly 4
logs vs about 2 logs).When the 28 proteinmarkers’ expression was compared at
different fıxation timepoints, most were found to be stable over different cold
ischemic timepoints. Two markers, including phospho-ERK (Extracellular Sig-
nal-Regulated Kinases) and phospho-GSK (Glycogen Synthase Kinase) showed
epitope loss as a function of delay to fıxation (R²0.0064 and R²0.05 respec-
tively). Conclusion: The Nanostring DSP is a reproducible method with the
capability of highly multiplexed measurements of protein expression on a fıeld
of view averaged basis. It shows high concordance with the AQUA method of
QIF, an extensively validated technique for protein quantifıcation. For the fırst
time, the high-plex capacity ofDSP allows inclusion ofmarkers that are sensitive
to time to fıxation as an intrinsic control for tissue quality. *FOR RESEARCH
USE ONLY. Not for use in diagnostic procedures.
#3811 Defıning the relevant genome in solid tumors. Habib R. Hamidi,
Santoshi Bandla,NickKhazanov, PaulWilliam,Nikki Bonevich, Chris Zurenko,
Sarah Anstead, Chris Taylor, Reuban Richmonds, David Galimberti, Ken Kopp,
Dinesh Cyanam, Michael Hogan, Vinay Mittal, Seth Sadis. Thermo Fisher Sci-
entifıc, Ann Arbor, MI.
Decades of cancer research including comprehensive molecular profıling
combined with the development of a broad array of targeted therapies have
created the opportunity to transform cancer care by implementing precision
oncology based approaches. An important element of this system is the wide-
spread availability of robust and cost-effective multi-variate profıling methods
to characterize relevant cancer associated molecular alterations in the future.
Current commercially available multi-variate profıling methods vary dramati-
cally with regard to the number of cancer genes that are interrogated. Given that
many large scale and detailed molecular profıling studies have been completed,
the landscape of somatic alterations in solid tumors is reasonably well-known.
Furthermore, the specifıc gene variants that are relevant to application of tar-
geted therapies are also a matter of record. Therefore, we set out to defıne the
number of relevant cancer genes for precision oncology research based on
the currently available empirical evidence. To defıne recurrent somatic al-
terations in solid tumors, we created a compendium of variant calls from 
15,000 exomes, defıned focal amplifıcations and deletions from  30,000
arrays, and defıned recurrent fusions from several thousand RNAseq pro-
fıles. Statistical approaches were implemented to defıne genes containing
recurrent missense mutations (i.e., hotspots), enriched in truncating muta-
tions or subject to recurrent copy number gain/loss or translocation. This
gene set was then used to comprehensively search approved cancer drug
labels, clinical practice guidelines, and clinical trials to identify records con-
taining published evidence that specifıc recurrent somatic gene variants were
used as part of the indication statement of an approved targeted therapy,
were recommended for testing as part of clinical practice for therapeutic
decisions, or were used as enrollment criteria in clinical trials. The relevant
cancer genome thus defıned consists of  100 genes. These results suggest
that targeted multi-variate profıling approaches may be suffıcient to support
precision oncology goals in the future.
#3812 JAK2 and PTPN11mutations as potential biomarkers for BCL-xL
inhibition as monotherapy and in combination therapy for acute myeloid
leukemia. Richard J. Bellin, Valerie Hilgenberg, Relja Popovic, Tamar Uziel,
Lloyd T. Lam. Abbvie, North Chicago, IL.
Acute Myeloid Leukemia (AML) is a heterogeneous disease where many dis-
tinct functional mutations have been identifıed. While mutations in FLT3,
NRAS, NPM1, and IDH genes have been well characterized in de novo AML, a
subset of AML associated with leukemic transformation of chronic myelopro-
liferative neoplasms (MPNs) are enriched inmutated JAK2 and PTPN11.MPNs
are a set of disorders characterized by the chronic and abnormal overproduction
of blood cells which can ultimately progress to AML. Targeted therapy against
mutated JAK2 and PTPN11 with small molecule inhibitors against the JAK-
STAT and RAS-ERK pathways, respectively, are being actively investigated in
AML. However, acquired resistance and non-durable responses are already be-
ing demonstrated in monotherapy treatment. Thus, AML that has arisen from
leukemic transformation ofMPNs remains an area of unmetmedical need. This
need is underscored by the fact that these patients suffer from poor outcomes
and low response rates to standard chemotherapy. Together, these results indi-
cate the need for rational combinations in this population. In this study, we
sought to better defıne the dependencies ofAML cells onBCL-2 familymembers
by screeningAMLcell lineswith selective smallmolecule inhibitors to theBCL-2
familymembers. The screen revealed that themajority of AML cell lines depend
on BCL-2, or BCL-2 together with MCL1 for survival. Intriguingly, a subset of
AML cell lines is exquisitely sensitive to BCL-xL inhibition. Treating these cell
lines with BCL-xL-selective inhibitor or with navitoclax, a dual BCL2/BCL-xL
inhibitor induces apoptosis. These BCL-xL inhibitor-sensitive cell lines express
high levels of BCL-xL, but not BCL-2 and MCL1. Genomic analysis of BCL-xL
inhibitor-sensitive AML cell lines revealed that this subset is also enriched in
JAK2V16F and PTPN11mutations. We further demonstrate positive combina-
tion effect between BCL-xL inhibitor or navitoclax with JAK inhibitor (ruxolit-
inb) and two MEK inhibitors (trametinib and AZD6244) in cell lines with
JAK2V16F and PTPN11 mutations, respectively. Together, these results dem-
onstrate the potential utility of a BCL-xL inhibition as a combination partner in
JAK2 and PTPN11mutated cancers. Importantly, JAK2 and PTPN11mutations
in addition to expression of BCL-xL, BCL-2, and MCL1 could also be further
tested as potential biomarkers for the utility of BCL-xL inhibition based treat-
ments for patients with these mutations.
#3813 MPF as amonitoring biomarker for a mesothelin-targeted therapy
against malignant mesothelioma and other cancer. Yunkai Yu, Raffıt Hassan,
Jingli Zhang, Masanori Onda, Ira Pastan, Liang Cao. National Cancer Institute,
Bethesda, MD.
Introduction: Tumor antigen mesothelin had been shown to be elevated in
mesothelioma, ovarian, pancreatic, and lung cancer. The mesothelin gene en-
codes a precursor protein of 69 kDa, which is cleaved into a 31 kDa soluble
megakaryocyte potential factor (MPF), and a cell membrane-bound 40 kDa
mesothelin. There is a high degree of interest in targeting mesothelin for meso-
thelioma and other cancers with various antibody-based agents, and some suc-
cesses in early stage clinical trials with some of the agents. For the development
of these targeted therapeutics, specifıc biomarkers would be needed for moni-
toring treatment responses, and detecting and evaluating tumor progression.
The current test that detects mesothelin is not suitable due to the antigen-bind-
ing from the therapeutic antibodies. There is an urgent need to develop and
validate an alternative test to support these clinical trials and for disease man-
agement.Methods:UsingECLIA technology andproprietary antibody reagents,
we developed a new test for the cleavedMPF polypeptide.We further conducted
comprehensive analytical and clinical validation of the test according to the
guidelines for tumor antigen tests. Using samples from a retrospective clinical
trial with an anti-mesothelin immunotoxin and the standard 1st line chemo-
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therapeutic agents for newly diagnosed malignant mesothelioma patients, we
examined the effectiveness of the test for treatment monitoring of the investiga-
tional therapy. Results: Our data gives a strong validation for the analytical and
clinical performances of MPF test. While no other current test has been proven
to be able to monitor response of mesothelioma to systemic therapies, our data
provides the proof of clinical effectiveness for MPF test. In the patients with the
elevated tumor antigen, there is a specifıc and highly signifıcant reduction of
MPF at the end of each treatment cycle for a total of 6 cycles in the patients with
objective response. Later, about half of these patients with objective response
andMPF reduction regained the levels ofMPF at the time of disease progression.
Conclusion: The study indicates that MPF test is effective in monitoring the
treatment response to systemic therapies for mesothelioma patients with ele-
vated MPF. It may also provide pivotal information on the expression of target
mesothelin protein when tumors progress.
#3814 A pan cancer analysis of the tumor inflammation signature. Patrick
Danaher, Sarah Warren, Alessandra Cesano. NanoString Technologies, Inc., Se-
attle, WA.
Introduction: The Tumor Inflammation Signature (TIS) is an 18 gene signa-
ture in development for the detection of adaptive immune response within tu-
mors by measuring expression of genes associated with cytotoxic cells, antigen
presentation, and IFN activity. The TIS has previously been shown to enrich
for a population of patients who respond to the anti-PD1 therapy pembroli-
zumab. We characterized the behavior of the TIS across a range of tumor gene
expression data downloaded from the TCGA in order to understand the distri-
bution of TIS within and between tumor types, with special emphasis on those
tumors for which anti-PD1 therapy is approved for use. Methods: The TIS was
trained to predict response to pembrolizumab using gene expression profıles
from 289 biopsies from 11 different tumor types. Its association with clinical
response was retrospectively assessed in an independent set of 200 samples from
14 additional tumor types. We calculated TIS scores in over 9000 samples from
31TCGARNASeq datasets.We contrasted TISwithmutational load, with over-
all survival, andwith other gene expression signatures. Results:While TIS scores
are higher in classically immunogenic tumor types, they display a signifıcant
amount of intersample variability within most tumor types, and a subset of
patients can be identifıed that possess elevated TIS scores consistent with re-
sponsiveness to pembrolizumab. TIS genes have highly conserved co-expression
patterns across tumor types, consistent with amodel inwhich the genesmeasure
immune-intrinsic transcriptomic activity with minimal contribution of tumor-
intrinsic gene expression. Notably, ranking tumors by median TIS score is su-
perior to mutational load ranking at predicting clinical response to anti-PD1.
TIS was minimally correlated with mutational load in most tumor types, except
in tumor types known for hypermutation-driven bymismatch repair defıciency.
TIS and mutation burden had their greatest variability in melanoma; in most
other tumors, TIS retains more variability than mutation burden, possibly re-
flecting patients with anti-tumor immune responses driven by one or a few
mutation-derived neoantigens. Average mutation burden and average TIS are
positively correlated within most tumor types. Notable exceptions to this trend
include two tumors for which anti-PD1 is currently approved. Bladder urothe-
lial carcinoma has lower average TIS than its mutation burden would predict,
and kidney renal clear cell carcinoma has much higher average TIS than its
mutation burdenwould predict. Conclusion: The TIS has the potential to enrich
for anti-PD1 responders independent of tumor type. It may identify rare poten-
tial responders in tumors with low average response rates. These results support
further research into the effıcacy of anti-PD1 in patients with high TIS scores,
regardless of tumor type.
#3815 The clinical impact of c-MET over-expression in advanced biliary
tract cancers. Mi Hwa Heo, Seung Tae Kim, Young Suk Park, Joon Oh Park,
Hansang Lee. Samsung Medical Center, Seoul, Republic of Korea.
Background: c-MET is a proto-oncogene that encodes the tyrosine kinase
receptor for hepatocyte growth factor (HGF). Activation of HGF-c-MET
signaling involves cell invasiveness and evokes metastasis through direct
involvement of tumor angiogenesis. However, the value of c-MET overex-
pression is still unknown in metastatic BTC. Methods: We analyzed the
incidence and clinicopathologic characteristics of c-MET overexpression in
advanced BTC. Moreover, we investigated the value of c-MET overexpres-
sion in predicting response to gemicitabine plus cisplatin (GC), a fırst line
standard regimen, and as a prognostic marker in metastatic BTC. Results:
The BTC subtype distribution (N44) was as follows: intrahepatic cholan-
giocarcinoma (IHCC, n7), extrahepatic cholangiocarcinoma (EHCC,
n25) and gallbladder cancer (GBC, n12). Liver (52.3%) was the predom-
inant metastatic site, followed by lymph nodes (36.4%) and bone (15.9%).
Among the 44 patients analyzed for c-MET expression, 15 (34.1%) exhibited
c-MET overexpression in tumor tissues. There was no signifıcant difference
in the prevalence of c-MET overexpression among primary sites in EHCC
(7/25, 28.0%), IHCC (3/7, 42.9%), and GBC (5/12, 41.7%). There was also no
signifıcant correlation between specifıc clinicopathological variables and c-
MET expression. Comparing the tumor-response to GC according to c-MET
expression (overexpression vs. non-overexpression), there was no signifı-
cant difference in either RR or DCR (p0.394 and 1.000, respectively). PFS
for all 44 patients was 9.00 months (95%CI, 7.47-10.53 months) and there
was no signifıcant difference for PFS between patients with c-MET overex-
pression and those without (p0.917). The median OS was 14.4 months
(95% CI, 12.8-19.2). There was a signifıcant difference in OS between pa-
tients with c-MET overexpression compared to those without (13.7 vs. 14.4
months, respectively; p0.708). Conclusions: c-MET overexpression was
detected in 34.1% of advanced BTC patients irrespective of tumor location.
c-MET overexpression did not predict response to GC or survival. Further
studies are needed to fully elucidate the value of c-MET overexpression as a
novel biomarker in these patients.
#3816 Mutations of the lim protein ajuba mediate sensitivity of head and
neck squamous cell carcinoma to treatment with cell cycle inhibitors. Ming
Zhang,1 Singh Ratnakar,2 Shaohua Peng,2 Mazumdar Tuhina,2 Shen Li,2 Pan
Tong,2 Curtis Pickering,2 Jeffrey N. Myers,2 Jing Wang,2 Faye M. Johnson2.
1Fudan Univ., Shanghai, China; 2MD Anderson Cancer Center, Houston, TX.
The genomic alterations identifıed in head and neck squamous cell carcinoma
(HNSCC) tumors have not resulted in any changes in clinical care, making the
development of biomarker-driven targeted therapy for HNSCC a major trans-
lational gap in knowledge. To fıll this gap, we used 59 molecularly characterized
HNSCC cell lines and found that mutations of AJUBA,SMAD4 and RAS pre-
dicted sensitivity and resistance to treatment with inhibitors of polo-like kinase
1 (PLK1), checkpoint kinases 1 and 2, and WEE1. Inhibition or knockdown of
PLK1 led to cell-cycle arrest at theG2/M transition and apoptosis in sensitive cell
lines and decreased tumor growth in an orthotopic AJUBA-mutant HNSCC
mouse model. AJUBA protein expression was undetectable in most AJUBA-
mutant HNSCC cell lines, and total PLK1 protein expression was increased in
cell lines wild-type for AJUBA. Exogenous expression of wild-type AJUBA in an
AJUBA-mutant cell line partially rescued the phenotype of PLK1 inhibitor-
induced apoptosis and decreased PLK1 substrate inhibition, suggesting a
threshold effect in which higher drug doses are required to affect PLK1 substrate
inhibition. PLK1 inhibition was an effective therapy for HNSCC in vitro and in
vivo. However, biomarkers to guide such therapy are lacking. We identifıed
AJUBA, SMAD4 and RAS mutations as potential candidate biomarkers of re-
sponse of HNSCC to treatment with these mitotic inhibitors.
#3817 Deciphering the immune system in small intestine:Multiplex strat-
egies for inflammatory bowel disease. David Altree-Tacha, Wei Wei Yuan,
George Yang. Biocare Medical, Concord, CA.
Introduction Inflammatory bowel disease (IBD) can affect the lower part of
the small intestine (ileum) and the colon. It can, however, occur in any part of the
large intestine, small intestine, or stomach. Recent evidence suggests that several
factors may tip the balance between homeostasis and intestinal inflammation,
presenting future challenges for the development of new therapies for IBD. In
this study, we use normal small intestine as amodel to identifymultiple immune
targets using mouse and rabbit monoclonal antibodies. Peyer Patches are lym-
phoid tissues in the wall of the small intestine that are involved in the develop-
ment of immunity to antigens presented in thatmilieu. Small intestine and cases
of IBDwere evaluated as a potential model using immunohistochemistry (IHC)
to identify categories of immune cells including cytotoxic T-cells, costimulatory
cells (agonists), T-regulatory cells (TREGs), T-cell effector cells (regulators) and
checkpoint inhibitors. cases of IBD were also examined for the utilization of
single and double/triple stains. Design Formalin-fıxed paraffın-embedded cases
of small intestine and IBDwere cut to 4micron thickness and stainedwithH&E.
Mouse and rabbit monoclonal antibodies including CD56 (natural killer cells),
CD163 (macrophages), CD8 and CD4 (cytotoxic T-cells and helper T- cells),
CD103, OX40 and CD137 (costimulatory), FOXP3 and LAG3 (TREGs), T-bet
andRORT (T-cell effectors), andPD-1 andPD-L1 (immune checkpoints)were
tittered for optimization and evaluated for IHC. Several IHC multiplex stains
(double and triple stains) were also developed and compared with the relevant
single stains. Results Single, double and triple stains utilizing CD56, CD163,
CD4, CD8, CD103, OX40, CD137, FOXP3, LAG3, T-Bet, RORT, PD-1 and
PD-L1 antibodies were successfully established using small intestine as staining
model for IBD cases. All single stains versus double and triple stains gave equiv-
alent results. Double stains and/or co-expression of CD8  CD103, CD8 
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PD-1, and triple stain CD8 PD-1 FOXP3 were easily visualized with blue,
brown, red or black chromogen staining. Conclusion Small intestine is a good
model to develop single or multiplex stains for a host of immune cell targets.
Enhanced visualization of these targets is possible with the use of double and
triple stains; thus, this technique may help facilitate acquisition of important
prognostic information and help support new strategies for inflammatory bowel
disease in targeted therapeutic treatment.
#3818 Identifıcation of a FGFR3-TACC3 fusion in esophageal cancer.
Takuro Mizukami,1 Kazuko Sakai,2 Saeko Naruki,1 Tomoko Taniyama,1 Yo-
shiki Horie,1 Naoki Izawa,1 Takashi Tsuda,1 Takashi Fujino,1 Narikazu Boku,1
Hiroshi Yasuda,1 Tetsu Fukunaga,3 Takako Eguchi Nakajima,1 Kazuto Nishio2.
1St. Marianna University School of Medicine, Kanagawa, Japan; 2Kinki Univer-
sity Faculty of Medicine, Osaka, Japan; 3Juntendo University School of Medicine,
Tokyo, Japan.
Aberrant activation of fıbroblast growth factor (FGF) signaling has been
found to contribute to carcinogenesis. Recently, activating FGFR fusions are
detected in several malignancy. However, limited information is available re-
garding the existence of FGFR fusions in esophageal squamous cell cancer
(ESCC) and gastric cancer (GC). In this report, we explored major FGFR1,
FGFR2, and FGFR3 fusion transcripts in ESCC and GC specimens (n 74 and
114, respectively) using a most comprehensive next-generation sequencing
panel.We detected a targetable fusion between exon 18 of FGFR3 and exon 11 of
TACC3 at a frequency of 1.4% (1/74) in ESCC,whereas other FGFR fusionswere
not detected in the ESCC or GC specimens analyzed. Furthermore, split FGFR3
signals were apparent in this specimen by fluorescence in situ hybridization
(FISH) with break-apart probes. The patient, a 64-year-old man with unresect-
able T4bN3M1 poorly differentiated ESCC of stage IV, was treated with pallia-
tive chemoradiotherapy followed by taxane chemotherapy. The patient died of
cancer progression, with his overall survival time having been 9.5 months. Our
results provide sequence information that should prove useful for development
of simple and cost-effective diagnostic assays as an alternative to FISH for pa-
tients with ESCC harboring the FGFR3-TACC3 fusion.
#3819 Identifıcation and quantifıcation of isoforms of eukaryotic initia-
tion factor 4E as biomarker in Mnk inhibitor-treated mouse model by capil-
lary-based immunoassay platform.ZhiyuanKe,1 SifangWang,1 VithyaMano-
haran,1 Susmitha Vuddagiri,1 Esther Ong,1 Sharon Lim,2 Sin Tiong Ong,2
Kanda Sangthongpitag,1 Nacro Kassoum,1 Jeffrey Hill,1 May Ann Lee1. 1Exper-
imental Therapeutics Centre, Agency for Science, Technology and Research, Sin-
gapore, Singapore; 2Duke-NUS Medical School, Singapore, Singapore.
Elevated levels of the phosphorylated m7G cap binding protein, eukaryotic
initiation factor 4E (eIF4E) are associated with neoplasia. An observed onco-
genic signaling effect upon activation of Erk1/2 or p38 MAPKs in cells is the
phosphorylation of eIF4E specifıcally at Serine 209 by downstream kinase MAP
kinase-interacting kinase 1 and 2 (Mnks). Therefore, inhibitingMnks could be a
potential therapeutic approach that selectively targets cancer cells without in-
troducing toxicity to normal cells. To measure the target engagement and effı-
cacy of Mnk inhibitors, we have established a sensitive method to quantitatively
detect phospho-eIF4E and non-phospho-eIF4E.Here, we report usingNanoPro
100 system, an automated capillary-based immunoassay platform that could
separate the phosphorylated and non-phosphorylated eIF4E isoforms based on
different isoelectric points. Primary antibodies against both non-phospho eIF4E
and Serine 209 phosphorylated eIF4E were used for identifıcation and verifıca-
tion of eIF4E isoforms in protein samples obtained from cell lysate, blood sam-
ples and tumor samples. Two major isoforms of eIF4E with isoelectric point at
5.38 for phospho-eIF4E and 5.88 for non-phospho-eIF4E were identifıed in
eIF4E-overexpressing K562 cells. siRNA knockdown of eIF4E expression re-
duced both isoforms, while treatment with Mnk inhibitor only reduced phos-
pho-eIF4E level. The measurement and quantifıcation of the relative changes of
phosphorylated eIF4E by this method can potentially be used in monitoring the
effıcacy of Mnk inhibitors in xenograft and future clinical trials.
#3820 Hepatitis B virus gene pre-S2 mutant as a high risk serum marker
for hepatoma recurrence after a hepatic resection. Wen-Ya Huang. Cheng
Kung University Hospital, Tainan, Taiwan.
Background: Chronic hepatitis B virus (HBV) infection is the major cause of
hepatocellular carcinoma (HCC). The pre-S2 mutant large HBV surface antigen
(LHBS) is highly associated with HCC. This study aimed to evaluate the serum
pre-S2 mutant LHBS as a high-risk recurrence marker in HCC patients after a
hepatic resection.Methods: The pre-S gene chipwas used to analyze 175 patients
with HBV-related HCC who underwent a hepatic resection between 2008 and
2012. Thirty independent pre-S clones in every patient were analyzed for a semi-
quantitative detection. Results: Multivariate regression analysis showed that the
serum pre-S2 mutant level ( 5%) and the American Joint Committee on
Cancer (AJCC) tumor stage were two independent high-risk factors for HCC
recurrence. A Cox proportional hazards analysis also showed that the com-
bined evaluations of the AJCC stage and serum pre-S2 mutant level provided
a reliable predictive marker for HCC recurrence after primary surgery. We
developed a Cox prediction model, which indicated the recurrence-free sur-
vival rates along with the time after surgery. This model was validated in an
independent HCC cohort. Receiver operating characteristic curve analysis
revealed that the model showed close sensitivities in the main and validation
cohorts (AUC values: 0.741 and 0.704, respectively). Conclusions: The rela-
tive level of pre-S2 mutant in serum is, independently of tumor stage, an
important predictive high-risk marker for HCC recurrence after a primary
hepatic resection. The combined evaluations of the AJCC tumor stage and
serum pre-S2 mutant level potentially serve as a convenient high-risk pre-
dictive marker for HCC prognosis.
#3822 Expression of androgen receptor and CD24 correlates with im-
proved 5-year survival in Pakistani patients with invasive breast cancer.Na-
zia Riaz,1 Romana Idress,2 Sadia Habib,3 Azhar Hussain,3 El-Nasir Lalani3.
1Centre of Regenerative Medicine and Department of Surgery Aga Khan Univer-
sity, Karachi, Pakistan; 2Department of Pathology and LaboratoryMedicine, Aga
KhanUniversity, Karachi, Pakistan; 3Centre of RegenerativeMedicine, AgaKhan
University, Karachi, Pakistan.
Introduction: Androgen receptor (AR) expression has been shown to corre-
late with improved survival in luminal A, B and triple negative (TN) breast
cancer (BCa). Cancer stem cells (CSC) with CD44/CD24- and ALDH1 phe-
notype is associated with pro-invasive gene signature in BCa. Aim of our study
was to evaluate prognostic signifıcance of AR expression in relation to CD44,
CD24 and ALDH1 in invasive BCa. Methodology: Immunohistochemical ex-
pression of AR, CD44, CD24 and ALDH1 was evaluated in 180 FFPE blocks of
BCa cases from one institution. Clinico-pathological details and follow-up data
were collected from medical charts. Data was analyzed on SPSS 19. Five-year
survival was estimated by Kaplan Meier. Results: Median age of patients was 55
years (range: 28-87). Fifteen percent of patients were diagnosed with stage I,
52.2% with stage II, 25% with stage III and 7.8% with stage IV disease. Mean
duration of follow-up was 4.5 years (SD 2.7) and 29% mortalities were attrib-
uted to BCa. ARwas expressed in 63.9%, ER in 61%, PR in 51%&HER-2/neu in
30%of tumors. CD44, CD24 andALDH1were expressed in 60%, 43.3%&28.3%
of tumors respectively. AR expression was associated (p-value0.001) with
grade II tumors expressing ER, PR andCD24 but lackingALDH1.Multivariable
analysis confırmed AR (adjusted HR 0.43, 95% CI 0.19-0.95) and PR (adjusted
HR: 0.20, 95% CI: 0.07-0.60) to be independently associated with better out-
come. Five year survival of patients with AR versus AR- expressing tumors,
showed that patients with AR tumors had signifıcantly better outcome (p-
value0.03) with survival advantage of 39.6 months. Survival advantage de-
creased by 9.6 months in tumors expressing CD44/CD24-/AR- (p-
value0.01) phenotype and by 12 months in patients whose tumors were
phenotypically ALDHI /AR- (p-value0.12). We stratifıed TN tumors
into 2 groups: A. TN/CD24/AR; B. TN/CD24-/AR- and found that
group A tumors had a trend towards better 5 survival (p-value0.09). Con-
clusions: Three individual markers (CD44, CD24, AR) may afford prognos-
tic information. Combinations of CD44, CD24 and AR permitted patient
stratifıcation into 3 risk categories: poor risk CD24-/AR-; intermediate risk
CD44/CD24-/AR- and good risk CD24/AR. Stratifıcation of TN group
showed that loss of AR and CD24 was associated with poorest outcome.
These results underscore the relevance and importance of AR and CD24 as
prognostic markers in invasive BCa.
#3823 High intrinsicDPD activitymatters too. Emmanuel Chamorey, Eric
Francois, Marie-Christine Etienne-Grimaldi, Julien Viotti, Frederic Peyrade,
Alexandre Bozec, Jean-Marc Ferrero, Renaud Schiappa, Gerard Milano. Centre
Antoine Lacassagne, Nice, France.
Introduction: Fluoropyrimidines (FP) are of major use in treating cancer.
Dihydropyrimidine dehydrogenase (DPD) is the main enzyme responsible for
FP catabolism. Low DPD activity screening has proven its predictive clinical
value in identifying patients at risk for toxicity. However, highDPD activitymay
translate to decreased FP activation and effıcacy. Patients and methods: One
hundred and forty-three patients (monocentric retrospective study) underwent
a pretreatment assessment of DPD activity in lymphocytes between 01/01/2004
and 20/04/2016. Included patients were male or female, 18 years, FP-treat-
ment-based. Cut-off for DPD activity was assessed using smoothing spline
curves. Results: Median patient follow-up was 30 months [CI95%: 27.3-36.2],
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mean age 63/-3 years, females accounted for 53%, 90% of patients had a good
performance status (0 or 1). Fifty-eight percent of FP indications (65% 5-FU and
35% capecitabine) were adjuvant or neoadjuvant and 42% were prescribed for
local or metastatic recurrences. Tolerance was poor for 43% of patients and 49%
needed dose reduction. Objective response (complete and partial) was observed
in 50% of patients, stable disease in 38% and progression in 12%. No signifıcant
correlation was observed between DPD activity and response to treatment.
Mean DPD activity (pmol min1 mg1 protein) was 0.21/-0.1 (quartile:
[0.001-0.14-0.20-0.28-0.48]). DPD activity analyzed as a continuous variable
was signifıcantly linked to overall survival (OS) (p0.042) but not with progres-
sion-free survival (PFS). The higher the DPD activity, the lower the OS. DPD
activity analyzed as a binary variable (cut-off at 0.30) was signifıcantly linked to
overall survival (p0.012) but alsowith PFS (p0.016). ACox regressionmodel
forOS andPFS adjusted for age, sex, type of cancer, type of administered FP, and
associated surgical or radiotherapy treatment was performed. After adjustment,
DPD activity remained signifıcantly linked to OS (p0.03) and PFS (p0.021).
Conclusions: DPD activity screening could lead to a two-pronged approach: FP
dose reduction in the event of low DPD and dose increase for high DPD. Such a
strategy needs to be prospectively validated under personalized DPD-based
treatment.
#3824 Analysis of TOPO II and p53 by immunohistochemistry and qPCR
in sarcoma patients with ChemFx assay to determine sensitivity against
Adriamycin and Etoposide.MaxHenry Jacobsen,1 LijunNi,2 Sandy Althouse,1
Nagendra Prasad,1 George Sandusky,1 Daniel Rushing1. 1Indiana Univ. School
of Medicine, Indianapolis, IN; 2Stanford University, Stanford, CA.
Sarcomas are a heterogeneous group of tumors that account for about 200,000
cancers diagnosed each year and represent 15% of all pediatric malignant tu-
mors. They comprise over fıfty subtypes that include bone and soft tissue sarco-
mas. Bone sarcomas represent about 20% of all sarcomas. It is estimated that
over 50% of human sarcomas have a TP53 mutation. Topoisomerase II (TOPO
II) is the target for doxorubicin which is the most effective chemotherapeutic
agent, although it is sometimes replaced with etoposide to decrease risk of car-
diac toxicity. In this study, 83 clinical sarcomas were evaluated from the IU
Medical Center. Of these 83 clinical cases, 34 were primary tumors, 46 were
metastatic tumors. Subtypes included in this study are: Liposarcoma, Leiomyo-
sarcoma, Fibrosarcoma, Malignant Fibrous Histiosarcoma (MFH), Synovial
Sarcoma, Osteosarcoma, and Ewings. Paraffın-embedded tissue blocks were ob-
tained from the Indiana University Heath Pathology Laboratory under IRB ap-
proved protocols. Immunostainings with TOPOII and P53 antibodies (DAKO)
were preformed using the DAKO platform with LSAB2 system at the IU Health
Pathology Laboratory. The stained tissues were scanned using Aperio Imaging
System and analyzed using the positive-pixel algorithm. In addition, qPCR
(TaqMan® assays) was performed using the RNA isolated from the same speci-
mens to analyze TOPO II by a second technique. Live tissue testing was also
employed using ChemFX assay was performed on fresh specimens to determine
Adriamycin and Etoposide (VP-16) sensitivity and/or resistance. Response to
Adriamycin and Etoposide were combined to form a composite precision value
and then compared with Clinical Response. This showed a 100% positive pre-
dictive value and 90% negative predictive value. We combined the two together
to create an overall “Combined Response” Variable. This variable was com-
parted to Immunohistochemistry for both TOPO II and P53, and the expression
levels of TOPOII RNA. The results showed that the lung metastases expressed a
higher level of TOPO II and P53 then did the primary tumors. qPCR and im-
munohistochemistry data did not correlate with each other. The positive pixel
data in the primary tumors were 5.238% for TOPO II and 2.4818% for P53,
compared to the metastatic lung lesions with 9.64% for TOPO II and 4.5692%
for P53. The combined response versus the categorized TOPO II IHC (into
categories of increasing intensity, 1,2,3) had a Chi-squared p-value of 0.656. The
combined response to versus the categorized P53 IHC (5% and5%) had a
Fisher-Exact test p-value of 0.082. There were approximately 40 resistant and 16
sensitive combined responses available for comparison.We conclude that P53 is
a negative predictor for clinical response, with 12 of 40 resistance cases stained
positive for P53, whereas 15 of the 16 sensitive cases were negative for P53.
#3825 Digital PCR-characterized, highly multiplexed, oncology RNA fu-
sion referencematerials: Performance onmultipleNGSplatforms.Catherine
Huang, Yves Konigshofer, Lequan Nguyen, Rajeswari Vemula, Praveena Kami-
neni, Deepika Philkana, Ekta Jaiswal, Bharathi Anekella. Seracare Life Sciences,
Gaithersburg, MD.
Introduction: Genomic structural alterations are increasingly actionable for
targeted therapeutics and personalizedmedicine.Molecular diagnostics are rap-
idly being introduced for detection of fusion RNAs by highly multiplexed next-
generation sequencing assays. However, reference materials to aid in the devel-
opment, optimization and validation of these assays are lacking. We developed
Seraseq FFPE Fusion RNA Reference Material to fıll this unmet need and show
that this material is compatible across a wide range of NGS assay platforms.
Methods: Biosynthetics were used for transcription of clinically actionable RNA
fusions, including fusions of ALK, RET, and ROS1, as well as rare fusion events
such as PAX-PPARGandETV6-NTRK3. Sixteen (16) in vitro transcribedRNAs
were introduced into GM24385 reference cell line (The 1000 Genomes Project,
Coriell). The cells were collected, fıxed in formalin, and total RNA was isolated.
Digital PCR with TaqMan® chemistry was used to determine the target Fusion
RNA copies per microliter. Use of fusion-specifıc digital PCR provides an or-
thogonal method of verifying transcript levels and serves as the “ground truth”
for the abundance of each RNA. NGS testing of the purifıed RNA used the
ArcherDx FusionPlex™ CTL Panel, QIAGENQIAseq Targeted RNAscan Panel,
and the Thermo Fisher Oncomine Focus Assay. Results: All sixteen (16) fusions
present in the prototype were detected as expected on each NGS platform. Re-
sults among the three different NGS platforms were generally concordant, al-
though the reads across the fusion junctions did vary slightly amongNGS assays
and with digital PCR results. However, all methods indicated that the reference
material gave low positive results, similar to a patient sample, and that the single
reference material could serve as a positive control for detection of sixteen dif-
ferent fusions, which represent a variety of different solid tumor types. Conclu-
sions: Seraseq FFPE RNA Fusion Reference Material allows simultaneous eval-
uation of detection for sixteen fusions observed in a variety of solid tumors, both
common and rare. It provides a consistent, unlimited supply of QC materials
particularly valuable for diffıcult to fınd rare fusions. The reference material
generates low positive results on three leading assays, and this is important to
truly challenge the assay system. This material is handled identically to a patient
sample from extraction through analysis, and verifıes performance at levels ex-
pected for patient samples.
#3826 Clinical validation of a serum protein panel (FLNA, FLNB and
KRT19) for diagnosis and prognosis of prostate cancer. Shobha Ravipaty,1
Wenfang Wu,1 Aditee Dalvi,1 Nikunj Tanna,1 Joe Andreazi,1 Tracey Friss,1 Al-
lison Klotz,1 Chenchen Liao,1 Jeonifer Garren,1 Sally Schofıeld,1 Eleftherios P.
Diamandis,2 Eric A. Klein,3 Albert Dobi,4 Shiv Srivastava,5 Poornima Tekum-
alla,1 Michael A. Kiebish,1 Vivek K. Vishnudas,1 Rangaprasad Sarangarajan,1
Niven R. Narain,1 Viatcheslav Akmaev1. 1BERG, LLC, Framingham, MA;
2Mount Sinai Hospital, Toronto, Ontario, Canada; 3Cleveland Clinic, Cleveland,
OH; 4Uniformed Services University of the Health Sciences and the Walter Reed
Military Medical Center, Framingham, MA; 5Uniformed Services University of
the Health Sciences and theWalter ReedMilitaryMedical Center, Bethesda, MD.
Background: Prostate cancer (PrCa) is a leading cause of cancer deaths in
males in the US. Current tests of prostate-specifıc antigen (PSA) screening and
the diagnostic prostate biopsy are often inconclusive. Many patients with a PSA
positive blood test often undergo invasive repeat biopsy procedures. Addition-
ally, there is a need for diagnostic tests that differentiate between low and high-
risk cancers. This study reports on the development of a novel serum protein
panel of three PrCa biomarkers, Filamin A, Filamin B and Keratin-19 (FLNA,
FLNB andKRT19) usingmultivariatemodels for disease screening and progno-
sis.Methods: ELISA and IPMRM(LC-MS/MS) based assayswere developed and
analytically validated by quantitativemeasurements of the biomarkers in serum.
Retrospectively collected and clinically annotated serum samples with PSA val-
ues and Gleason scores (GS) were analyzed from 503 subjects who underwent
prostate biopsy, and showed no evidence of cancer with or without indication of
prostatic hyperplasia, or had a defınitive pathology diagnosis of prostatic ade-
nocarcinoma. Probit linear regressionmodelswere used to combine the analytes
into score functions to address the following clinical questions: does the bio-
marker test augment PSA for population screening? Can aggressive disease be
differentiated from lower risk disease, and can the panel discriminate between
benign prostate hyperplasia (BPH) and PrCa? Results: Table 1: Berg PrCa Panel
AUC summary for the four clinical indications. Conclusion: As shown in Table
1,modelling of the data demonstrated that the newPrCa biomarkers and PSA in
combination were better than PSA alone in identifying PrCa, improved the
prediction of high and low risk disease, and improved prediction of BPH versus
PrCa.
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#3827 NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and
high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV
melanoma. Ahmad A. Tarhini,1 Paul H. Frankel,2 Christopher Ruel,2 Marc S.
Ernstoff,3 Timothy M. Kuzel,4 Theodore F. Logan,5 Nikhil I. Khushalani,6 Hus-
seinA. Tawbi,7 KimA.Margolin,2 SanjayAwasthi,2David F.McDermott,8 Alice
Chen,9 Primo N. Lara,10 John M. Kirkwood1. 1Univ. of Pittsburgh Cancer Inst.,
Pittsburgh, PA; 2City of Hope, Duarte, CA; 3Roswell Park Cancer Institute, Buf-
falo, NY; 4Northwestern Memorial Hospital, Chicago, IL; 5Indiana University,
Indianapolis, IN; 6Moffıtt Cancer Center, Tampa, FL; 7MD Anderson, Houston,
TX; 8Beth Israel Deaconess Medical Center, Boston, MA; 9NIH/NCI, Rockville,
MD; 10University of California Davis, Sacramento, CA.
Background: IL-2 plays a central role in antitumor immunity. VEGF plays a
critical role in angiogenesis and host innate and adaptive immunity. High base-
line serum VEGF was associated with non-response to IL-2. Z, a high-affınity
soluble decoy VEGF receptor, may deplete VEGF prior to IL-2 to reverse the
immunosuppressive impact of VEGF and enhance antitumor T cell response.
Methods: NCI8628 was a phase II trial of Z and IL-2 (A) versus IL-2 alone (B)
randomized 2:1. Eligible patients (pts): Stage III inoperable or Stage IV mela-
noma. Up to two prior regimens for metastatic melanoma and stable treated
brainmetastases were allowed. The primary endpoint was progression-free sur-
vival (PFS). Results: A total of 89 pts were enrolled, but 5whonever started study
treatment were excluded. Six pts (4 in A and 2 in B) who were treated but
withdrew early without a response assessment were considered non-responders
in this analysis. Pt and disease characteristics are summarized in Table 1.
Median number of IL2 cycles was 3 (A) and 2 (B) and of Z cycles in A was 3
(1 - 31). Median follow up for all alive patients was 19 months. Among 84
treated pts (55 in A and 29 in B), there was signifıcant improvement in PFS in
favor of A: median and 95% CI of 6.9 (4.2 - 8.8) months vs 2.1 (1.7 - 4.1),
logrank p 0.001. No signifıcant difference in OS: median and 95% CI of
23.1 (14.4 - 35.0) months (A) vs 22.3 (12.6 - NA). Response rate (RECIST)
was 22% in A (5CR, 7PR) and 17% in B (5PR). Stable disease or PR or CRwas
seen in 69% in A and 48% in B. Adverse events were consistent with the AE
profıles of monotherapy with IL2 and Z. Grade 4 events in A included de-
creased lymphocytes (41 pts) and platelets (6), renal (1), hypophosphatemia
(4), hypertension (2) and thromboembolism (1).
Table 1 Arm A (N55) Arm B (N29)
Age (median and range) 55 (26-73) 55 (31-74)
Gender
Female 22 11
Male 33 18
Cutaneous primary 36 16
Mucosal 5 4
Uveal Unknown 68 45
AJCC Stage
III (N3) M1a 910 35
M1b 11 6
M1c 25 15
Conclusions: The combination of Z and IL2 signifıcantly improved PFS over IL2 alone,
meeting the study’s primary endpoint. The regimen was relatively safe and manageable.
Correlative and mechanistic studies are ongoing
#3828 The role of CK2 for overcoming paclitaxel resistance in gastric can-
cer.Minkyu Jung. Yonsei Univ. College of Medicine, Seoul, Republic of Korea.
Despite advances in cancer treatment, gastric cancer is still one of the most
fatal cancers. This is because paclitaxel, the most widely used treatment for
gastric cancer, has limited clinical utility by the development of resistance. Ca-
sein kinase 2 (CK2) activation has been reported to be involved in proliferation
in various tumors and resistance form chemotherapy. Therefore, we investi-
gated the association between paclitaxel resistance and CK2 activation. CK2
expression was evaluated by immunohistochemistry (IHC) on formalin-fıxed,
paraffın-embedded tumors from 59 AGC patients who were treated with pacli-
taxel as second line therapy. Patients with high expression of CK2 (29/59, 39%)
showed lower disease control rate (DCR) (47.7 % vs. 72.3 %, p0.017) and
shorter progression free survival (PFS) (2.8 months vs. 4.8 months, p0.009)
compared to those who with low expression. Cell proliferation assay were car-
ried out by MTT assay after drug treatment with paclitaxel, CX-4945 (CK2
inhibitor) in 49 gastric cancer cell lines. CK2 protein expressionwas shown to be
associated with paclitaxel sensitivity. Of the gastric cancer cell lines, SNU-1 was
selected for paclitaxel resistance, high expression of CK2, and high sensitivity to
CX-4945. Combination therapy CX-4945 and paclitaxel showed synergistic an-
titumor effect in SNU-1 byMTT assay and showed inhibition of down signaling
of PI3K/AKT pathway on western blot. In conclusion, CK2 activation was
shown to be related to paclitaxel resistance. CX-4945 in combination with pac-
litaxel could be treatment of choice in gastric cancer with paclitaxel resistance.
#3829 TCIRG1, T-cell immune regulator 1, functions as a metastatic en-
hancing gene in liver tumorigenesis. Hee Doo Yang, Jung Woo Eun, Qingyu
Shen, Hyung Seok Kim, Sang Yean Kim, SukWoo Nam. Lab of Coding & Non-
coding Genomics, Department of Pathology, College of Medicine, The Catholic
University of Korea, Seoul, Republic of Korea.
Recurrence and metastasis are a major challenge in the management of hep-
atocellular carcinoma (HCC) patients after HCC resection. In order to identify
metastatic molecular signature, we performed comparative gene expression
profıling analysis with recurredHCC tissues fromHCCpatientswhounderwent
partial or total hepatectomy and non-metastatic primary HCC. From this, we
were able to recapitulate molecular signatures associate with HCC recurrence,
and found that TCIRG1 (T-Cell Immune Regulator 1) was one of the aberrantly
overexpressed gene elements in recurred HCC patients with total hepatectomy.
We then observed that TCIRG1 is signifıcantly overexpressed in TCGA-LIHC
(Liver Hepatocellular Carcinoma Dataset of The Cancer Genome Atlas), and
high expression of TCIRG1 was signifıcantly associated with poor prognosis of
HCCpatients in 5-year disease-free. TCIRG1 knockdown suppressed tumor cell
growth and proliferation inHuh7 and SNU475, liver cancer cell lines. From flow
cytometric analysis for cell cycle analysis and cell death, we observed that
TCIRG1 knockdown caused a signifıcant increase of G1/S phase, and also in-
duced programmed cell death processing in liver cancer cells. TCIRG1 knock-
down also reduced themetastatic potential ofHCC cells by selectively regulating
epithelial-mesenchymal transition (EMT) regulatory proteins, E-cadherin, N-
cadherin, Vimentin, Fibronectin, Snail and Slug, in liver cancer cells. In addi-
tion, sustained expression of TCIRG1 in liver cancer cell line reduced tumor
growth rate in mouse xenograft model. Moreover, targeted-disruption of
TCIRG1 signifıcantly attenuated the metastatic potential of ras-transformed
NIH-3T3 cells in vitro and in vivo. In conclusion, our fındings suggest that
TCIRG1 functions asmetastatic enhancing gene bymodulating cellular growth,
death, and EMT in liver cancer cells providing TCIRG1 as a therapeutic target
for the treatment of liver malignancy and metastasis.
#3830 Plucked anagen scalp hair: A reproducible surrogate tissue tomon-
itor drug induced transcriptional changes and provide pharmacodynamic
biomarker and target engagement information from cancer patients. Benja-
min J. Reed, TimothyMefo, ElliottHarrison, RossHaggart, EmmaGrimes, Alan
Murdoch, Gino Miele. Epistem Ltd., Manchester, United Kingdom.
Monitoring target engagement is crucial to informon early drug development
decisions, and development of a peripheral tissue-based gene expression signa-
ture indicative of pathway inhibition could facilitate the continued clinical de-
velopment of compounds. Plucked anagen scalp hair is an ideal source of epi-
thelial tissue to monitor drug induced transcriptional changes. High
vascularisation of the hair follicle, frequent epithelial origin of tumors, ease of
sampling and high degree of congruence of expression in hair of pathways dys-
regulated in cancers, make the cellular bulb of plucked human scalp hair an
excellent surrogate tissue for the non-invasivemonitoring of pharmacodynamic
(PD) andmechanism of action (MOA) effects in clinical trials. Using our ex vivo
plucked hair culture platform, hair bulbs from several healthy donors were ex-
posed to BEZ235, a dual pan-class PI3K and mTOR inhibitor at different con-
centrations and durations. Total RNA was isolated from the cellular bulb of
individual anagen hair post-culture and used for microarray analysis to assess
global transcriptional alterations and develop a gene expression signature indic-
ative of BEZ235 exposure. The results of the ex vivo plucked assessment gener-
ated a dose dependent appreciable and biologically relevant transcriptional sig-
nature following exposure to BEZ235. Transcriptional readouts from patients
also revealed strong correlations (0.97-0.99) in the genes expressed in anagen
scalp hair between donors and across samples taken from the same donor. In
addition, global gene expression data indicated that assessing three plucked
scalp hairs or less at each collection point was suffıcient to detect signifıcant
differential expression (p0.05 & 1.5 fold change) underpinning the low vari-
ance in the majority of target genes in plucked hair as a biomarker platform.
Gene signatures for compounds targeting the PI3K/mTOR pathway that were
established using the ex vivo plucked scalp hair platform were used to support
clinical trials and scalp hair taken from patients receiving treatment showed an
excellent post-exposure target signature modulation. In summary, our results
substantiate that plucked anagen scalp hair is an ideal non-invasive surrogate
tissue to obtain drug-induced pharmacodynamic biomarker and target engage-
ment information from oncology patients.
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#3831 The development of an immunohistochemical digoxigenin-labeled
mouse on mouse single and double stain methodology. Joseph Vargas, David
Tacha, Sara Figueroa. Biocare Medical, Concord, CA.
IntroductionWhen amouse or monoclonal antibody is desired for immuno-
histochemical detection on mouse tissues, the anti-mouse secondary antibody
will also bind to endogenous mouse IgG in the tissue and may produce un-
wanted background staining. In the past, mouse-on-mouse (MM) detection
utilized a biotinylated primary antibody or biotinylation kit. Tissues rich in
endogenous biotin such as kidney or livermade it diffıcult to use, as streptavidin-
horseradish peroxidase is required for detection. Attempts to completely negate
endogenous biotin are ineffective as avidin-biotin blocking steps are unlikely to
work acceptably in problematic tissues. Therefore, the design of a digoxigenin-
labeled detection system is advantageous forMMdetection as it would eliminate
these issues. This technology has broad application as it allows the use of a
variety ofmonoclonal antibodies reactive onmouse tissues.Materials andMeth-
ods Mouse tissues were formalin-fıxed for 24 hours and embedded in paraffın
(FFPE). Sections were cut and dried on slides before deparaffınizing and perox-
idase blocking in the usual manner. Slides were then HIER in a citrate-based
buffer prior to application of antibody. Mouse antibody concentrates were se-
lected andmixed with aDigoxigenin Anti-Mouse Linker and incubated at room
temperature (RT) for 1 hour. An Absorption Reagent is then added to the mix-
ture, and further incubated for 30 minutes. The mixture is then diluted in anti-
body diluent to the desired concentration and applied to themouse tissue for 60
minutes at RT, followed by a rabbit anti-digoxigenin antibody for 15 minutes.
Detection of anti-digoxigenin is performed with an incubation in either a goat
anti-rabbitHRPorAPPolymer for 30minutes.Visualization is accomplished by
using a DAB or Fast Red chromogen. For double stains, a sequential DSmethod
using twomonoclonal antibodies was employed using a heating step in retrieval
solution after the fırst chromogenic reaction followed by a second monoclonal
antibody and detection with either a rabbit-AP or HRP polymer. Visualization
of the second antibody target is accomplished by using Fast Red or a blue chro-
mogen. Slides were coverslippedwith a permanentmountingmedium and eval-
uated using brightfıeld microscopy. Results MM single stains with a variety of
antibodies were easily achieved with specifıc, clean and biotin-free staining.
Sequential DS techniques using monoclonal antibodies were also achieved and
visualizedwithDAB, Fast Red or blue chromogens. Bothmanual and automated
procedures were used. Conclusion The replacement of biotin-labeledMM tech-
nology with a digoxigenin MM technology is a superior method that not only
eliminates endogenous biotin, but allows utilization of HRP and AP polymers
for double stain technology.
#3832 Optimization strategy for fluorescent multiplex immunohisto-
chemistry tissue staining. Yi zheng, Carla Coltharp, Ryan Dilworth, Linying
Liu, DarrynUnfricht, Cliff Hoyt,Milind Rajopadhye, PeterMiller. PerkinElmer,
Hopkington, MA.
Introduction: Recent insights into the tumor microenvironment have fueled
the need for additional information beyond the one or two phenotypes provided
by traditional immunohistochemistry (IHC). As a response, manual and auto-
mated fluorescent multiplex immunohistochemistry (fIHC) techniques have
been recently developed and accepted by the immuno-oncology space. Fluores-
centmultiplex immunohistochemistry (fIHC) assays are designed to simultane-
ously measure multiple biomarkers in tissue sections with visual context that is
lost in other methods, such as flow cytometry. Here we describe a novel optimi-
zation strategy to achieve quantitative, robust, and specifıcmultiplex fIHC stain-
ing results with both manual and automated multiple-color Opal procedures.
Methods: Formalin-fıxed paraffın-embedded samples of primary tumors were
immunostained using Opal™ reagents both manually and on a fully automated
Leica BOND RX™ stainer. The impact of different reagent concentrations and
quantities were analyzed in respect to signal specifıcity and robustness, stripping
effıciency, signal co-localization, signal to noise, and color separation. Images
were acquired on a Vectra 3.0® automated imaging system, and analyzed with
inForm® software. Results: The goals of this study were two-fold: -to understand
the impact of Opal reagent concentrations/quantities on fluorescent signal in-
tensities acquired from cells within the context of tissue. -to develop an Opal
reagent optimization method that yields more consistent, quantitative results
from separated and co-localized fluorescent signals. We’ve applied this novel
fIHC experimental approach and optimization strategy to Opal monoplex and
multiplex assays and explored staining robustness, contextual specifıcity, stain-
ing order independence, and co-localized signal separation. Using the novel
optimization strategy, we have achieved optimal staining patterns with im-
proved confıdence in the quantitative characteristics of the assay. Tissue sections
stained after optimization have exhibited staining order independence and
closely alignwith traditional IHCpatterns. Conclusion: This novel optimization
strategy, developed for Opal fIHC assays, is more quantitative, improves stain-
ing results, and minimizes interference between co-localized biomarkers.
#3833 Systematic evaluation of transcriptome sequencing shows compa-
rable profıles for an exome-capturemethod for formalin-fıxed, paraffın-em-
bedded (FFPE) breast cancer tissues and the standard poly-A method for
matched fresh frozen (FF) tissues. Xi Zhao, Marianna Zavodovskaya, Luting
Zhuo, Kevin Kwei, Xin Guo, Zhaoshi Jiang, Scott D. Patterson, Carrie B. Brach-
mann. Gilead, Foster City, CA.
Background: Tissue samples are routinely preserved as FFPE blocks. This
abundant sample reservoir holds promises in clinical omics for disease diagnosis
and precision cancermedicine. However, due to extensive cross-linking, nucleic
acids are not effıciently extracted from FFPE samples and are heavily degraded,
posing challenges for molecular assays including next generation sequencing.
Our study aims to identify the RNA sequencing (RNA-seq) library prepmethod
for FFPE samples that provides comparable data to the established poly-A en-
richment method for FF tissue. Methods: RNA-seq data were collected on
matched FF and FFPE samples from triple negative breast cancer (TNBC; n7)
and normal breast tissues (n2). Tissues were sourced from a commercial ven-
dor. Three library preparation protocols from Illumina were tested: poly(A)
enrichment protocol (Poly-A; FF only), ribosomal RNA deletion protocol
(Ribo-ZeroGold), and exome-capture based protocol (RNA-Access). Data were
compared on absolute and differential gene expression, as well as molecular
subtyping for breast cancer (PAM50; Parker 2009). Results: Both absolute ex-
pression values and log fold changes between tumor and normal samples corre-
late strongly across different tissue preservation and library preparation meth-
ods. Among tested methods, RNA-Access had the highest yield of mappable
reads on coding region and provided uniform transcript coverage with less
rRNA contamination. Regardless of the protocol, all TNBC samples were clas-
sifıed as PAM50 basal-like subtype. As expected, FF with either Ribo-Zero or
RNA-Access had the strongest correlation with FF PolyA on the distance to
subtype centroids (r0.99). For FFPE methods, RNA-Access (r0.94) had the
strongest correlation with FF PolyA, followed by Ribo-Zero (r0.85). Principal
component analysis showed that sampleswere primarily segregated by technical
differences (library preparation or tissue preservation method) rather than bio-
logical differences (tumor/normal status or patient identifıcation), suggesting
strong technical bias in the data. Gene families and biological processes under-
lying the differentially expressed genes due to technical variations included ri-
bosomal, histone and metabolic pathways proteins. The aforementioned tech-
nical bias can be largely eliminated by a batch effect adjustment method
(COMBAT; Johnson 2007). Conclusion:As expected, RNA-seq data is primarily
impacted by technical differences. RNA-Access based transcriptome sequenc-
ing on breast FFPE samples generated highly concordant gene expression pro-
fıles when compared to data derived from FF samples. Our study supports the
use of RNA-Access based transcriptome sequencing on FFPE samples when FF
samples are not available.
#3834 Tracking CAD-ALK gene translocation in urine and plasma of a
colorectal cancer patient treated with ALK blockade. Giulia Siravegna,1 An-
drea Sartore-Bianchi,2 Benedetta Mussolin,1 Laura Palmieri,2 Federica Tosi,2
Andrea Cassingena,2 Luca Novara,1 Michela Buscarino,1 Giorgio Corti,1 Gio-
vanni Crisafulli,1 Alice Bartolini,1 Mark Erlander,3 Federica Di Nicolantonio,1
Salvatore Siena,2 Alberto Bardelli1. 1IRCC, Candiolo, Italy; 2Niguarda Cancer
Center, Milano, Italy; 3Trovagene Inc, San Diego, CA.
Ametastatic colorectal cancer (mCRC)patient carryingCAD-ALKtranslocation
achieved partial response to an experimental ALK inhibitor and then progressed
after 5 months. We studied whether urine cell-free, trans-renal DNA (tr-DNA)
could be used to monitor tumor burden and patient’s response. A NGS panel was
developed to interrogate52commoncancergene rearrangements and14 frequently
mutated genes in cancer patients. A TP53 p.R248W mutation and the CAD-ALK
genomic breakpoint (rearrangement) were identifıed in the tumor tissue and
matched plasma circulating tumor DNA (ctDNA) Urine samples were longitudi-
nally obtained from the patient during ALK inhibitor treatment in parallel with
blood. To detect the CAD-ALK translocation in urine tr-DNA we designed ultra-
short (51 bp amplicon) primer pairs spanning the genomic breakpoint as a unique
tumor marker. This approach allowed the non-invasive monitoring of the gene
fusion in urine with amounts paralleling tumor burden. Of note, CAD-ALK gene
fusion was apparent in urine tr-DNA before radiological confırmation of disease
progression. The same strategy was applied to plasma ctDNA and the results were
compared. To detect point mutations in urine tr-DNA, we exploited a peptide nu-
cleic acids (PNA)-CLAMPPCRcoupledwith droplet digital PCR (ddPCR) analysis
to specifıcally suppress amplifıcation of wild-type DNA fragments. Custom PNA
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probes were designed for TP53 codon 248, and a ddPCR assay was optimized to
detect the TP53 p.R248Wmutation, which was then identifıed in all urine tr-DNA
samples, with absolute copies correlating with tumor burden throughout ALK in-
hibitor treatment. In conclusion, we fınd that urine tr-DNA can be exploited to
non-invasively monitor tumor burden by detecting tumor-specifıc gene fusions as
well as point mutations.
TUMOR BIOLOGY: Cell Culture and Animal Models of Cancer 4
#3835 High-purity patient-derived cells: An advanced cell culture model
for precision cancer medicine. Seok-Young Kim,1 Hwan Kim,1 Sung-Moo
Kim,1 Hye Ryun Kim,2 Mi Ran Yun,1 Ji Min Lee,1 HunMi Choi,1 Byoung Chul
Cho2. 1Yonsei Cancer Research Institute, JE-UK Laboratory of Molecular Cancer
Therapeutics, Seoul, Republic of Korea; 2Division of Medical Oncology, Depart-
ment of InternalMedicine, Yonsei University College ofMedicine, Seoul, Republic
of Korea.
Purpose: Patient-derived cells (PDCs) established frommalignant effusions can
represent an excellent tool for the studyof non-small cell lung cancer (NSCLC)with
oncogenic driver mutations. However, because of cellular paucity and low tumor
purity, PDCs have a limited utility for in-depthmolecular analysis. In this study, we
developed ahigh-purity patient-derived cell (HP-PDC)method for primary culture
of malignant effusions. Experimental design: HP-PDCs were established by a mul-
tistep tumor cell isolation protocol as follows. 1) Initial cultures of malignant effu-
sions were observed under a lightmicroscope to identify spheroid-forming cells. 2)
Tumor purity of PDCswas analyzed by Immunofluorescence (IF) and flow cytom-
etry. 3) Mutation status of EGFR or ALK in PDCs was screened by direct or PCR-
based sequencing and RT-PCR and then was compared with driver mutations de-
tected in matching patient tumor samples. 4) HP-PDCs were tested for drug
effıcacies by a cell viability assay, a colony-forming assay, and western blot. 5) HP-
PDCs were screened with a panel of 84 kinase inhibitors to identify effective drugs.
Results:A consecutive series of 45malignant effusion sampleswas collected from36
patientswith advancedNSCLC. Spheroid-forming cellsweredetected in19 samples
(42.2%) which were cultured in AR5 media to establish PDCs. IF analysis revealed
that TTF-1 was upregulated in 9 PDCs. These 9 PDCs with high TTF-1 expression
also showed EpCAM-positive cell population in flow cytometry with high purity of
over 70%. Using Sanger sequencing, EGFR exon 19 deletion was detected 3 cases,
EGFR T790M with L858R in 2 cases, and ALK rearrangements in 4 cases. Two of
PDCs established from patients, who carried EGFR mutations and progressed on
gefıtinib, showed resistance to gefıtinib in vitro.One of gefıtinib-resistant PDCswas
sensitive to AZD9291 with IC50 value of 47 nM. Three of PDCs established from
patients, who carried ALK fusion genes and progressed on ALK inhibitors (crizo-
tinib, alectinib, and ceritinib respectively), also recapitulated patient’s response to
theALK inhibitors. In an alectinib-resistant PDC, crizotinib and ceritinib exhibited
potencywith IC50 valuesof321nMand215nM, respectively.Colony-formingassay
andwestern blot resultswere correlatedwith the cell viability assay data. Time spent
for establishment ofHP-PDCs ranged from26 days to 132 days. Conclusions: Nine
HP-PDCs established by multistep tumor cell isolation protocol had high tumor
purity, and recapitulatedpatient’s genomicprofıle anddrug responses.HP-PDCis a
powerful preclinical model which predicts responses to targeted drugs in a short
period of time andmay provide an excellent platform for personalized therapies in
patients with advanced NSCLC.
#3836 New type of drug resistant isogenic cancer cell model created by
CRISPRgenomeediting.Lysa-AnneVolpe,1MetewoSelase Enuameh,2 Luping
Chen,1 Michael Jackson,1 Catherine Nguyenngo,1 John Foulke,1 Fang Tian1.
1ATCC, Manassas, VA; 2ATCC, Gaithersburg, MD.
Mutant BRAF gene can lead to uncontrolled cell growth through overactivation
of RAS-RAF-MAPK signaling pathway. BRAFV600Emutation occurs in approxi-
mately 40% to 50% of melanomas. Although BRAF inhibitors have been used to
successfully treatmelanomas containing the BRAFV600Emutation, patients often
becomeresistant toBRAF inhibitorswithin a fewmonths.Anumberof studieshave
indicated that secondary mutations such as NRAS or NF1 are signifıcantly associ-
ated with BRAF resistance by sequencing patient samples. However, due to the
genetic heterogeneity commonlyobserved in tumors, it is unclear if those secondary
mutations already existed within low percentage subclones or if they were acquired
through drug treatment. It’s yet to be determinedwhether such genetic variants are
only associatedwith resistance, or theyactually cause the resistance. In this study,we
used genome editing CRISPR technology to generate a drug resistant mutation
NRAS Q61K within A375 melanoma cell line which naturally contains
BRAFV600E.When compared to the parental line, this isogenic cellmodel demon-
strated that geneticallymodifıedNRASgeneat theendogenous leveldirectly leads to
a signifıcant resistance to BRAF inhibitors. Method and results: Single guide RNAs
(sgRNAs) were designed and built to guide Cas9 to bind and cut desired regions in
the NRAS gene target. Melanoma cell line A375 was co-transfected with the single
guide and CRIPSR all-in-one plasmid alongside donor plasmid. Transfected cells
were sorted into single cells and expanded for subsequent screening of desired gene
mutation events. The introduction of NRAS Q61K mutation in the cells was then
confırmed via Sanger sequencing and NGS at the genetic level and transcriptional
level. Drug responses to BRAF specifıc inhibitors and non-specifıc chemotherapy
drugswere comparedbetweenA375NRASQ61K isogenic cell line andparental cell
line in 2D and 3D culture environment. Testing results demonstrated that the iso-
genic cell line createdbyCRISPR showed signifıcant resistance toBRAF inhibitor in
comparison to the parental control in both 2D and 3D culture environment. In
summary, we utilized the CRISPR/Cas9 genome editing platform to target endoge-
nous loci in human cells and create the intended genetic mutation event. This new
approach provides direct bio-functional evidence of acquiring a drug resistant gene
drives tumor cells survival under targeted therapeutic treatment. Furthermore, un-
like conventional drug resistant cell models that have been developed through drug
selection, the A375 NRAS Q61K isogenic cell line represents a new type of drug
resistantmodel that contains a defıned genetic resistancemechanism. It reserves the
permanent and genetically stable resistance characteristics without being main-
tained in drug selection culture environment. Therefore, it provides a valuable tool
for developingnext generation therapeutics that canovercomeBRAFdrug resistant
inmelanoma.
#3837 Primary tumor cell lines derived from gastric PDX tumors displays
differences in chemosensitivity.Xiaomei Ge,1 Fulin Qiang,2 Yixin Zhang,2 Jib-
ing Liu,2 Lei Yang,2 Yingying Qu,1 Fubo Xie,1 Xueting Li,1 Ying Gu,1 He Zhou1.
1Shanghai ChemPartner Co., Ltd., Shanghai, China; 2Nantong Cancer Hospital,
Nantong, China.
Gastric cancer is amultifactorial and fatal diseasewith limited effective therapeu-
tic options. Its overall mortality ranked third among cancer-related deaths world-
wide. Patient-derived-xenograft (PDX) models have been widely used in the bio-
medical research. They recapitulate the genomic diversity/heterogeneity of patient
tumors,maintaina lotof thecharacteristicsof theoriginal tumorsandshowedmuch
better correlation with clinical outcome comparing to traditional cell line derived
xenograft models. However, the relatively low throughput and time-consuming
nature of PDX studies prevent them from being used in large scale screening or
mechanistic studies. To facilitate drug development in gastric cancer, different can-
cer cell lines have been developed in our laboratory from gastric PDX tumors. We
performed STR analyses to validate their identity and RNAseq data also showed
high similarities to their parental PDX tumors. These primary gastric tumor cell
lines displayed differences from each other in their chemo-sensitivities in vitro and
in vivo. They also differ in their protein expression such as the HER-2 expression
level. Pharmacology studies using different compounds showed similar drug re-
sponses of these cell lines in tissue culture, xenografts using these cell lines and the
original PDXmodels. Our data demonstrated the high fıdelity of these cell lines to
their parental PDX tumors and serve as a bridge between the high-throughput drug
screeningandhighly clinical relevantPDXmodels andwill greatly facilitate thedrug
development in gastric cancer.
#3838 Drug sensitivity profıle of 5TGM1 murine multiple myeloma cell
line emphasizes the translational potential of the syngeneic in vivo model.
Jenni Mäki-Jouppila,1 Jenni Bernoulli,1 Mari I. Suominen,1 Tiina Kähkönen,1
JussiM. Halleen,1 Sanna Timonen,2 Elina Huovari,2 Katja Suomi,2 Swapnil Pot-
dar,2 Maria Nurmi,2 Päivi Östling,2 Jani Saarela,2 Katja M. Fagerlund1. 1Phar-
matest Services Ltd, Turku, Finland; 2Institute for Molecular Medicine Finland
FIMM, Helsinki, Finland.
Multiple myeloma (MM) is the second most common hematologic malig-
nancy that originates fromB-cells (plasma cells) and causes 2%of cancer-related
deaths. Symptoms of MM include bone pain caused by multiple osteolytic le-
sions, pathologic fractures, and hypercalcemia. Typically, MMhas a low growth
fraction and it is highly dependent on the microenvironment. These properties
have made it hard to target by conventional chemotherapy, but could now be
exploited by novel stroma-targeting drugs and immunotherapy. These new ap-
proaches underline the need for well characterized models with functional im-
mune system and appropriate tumor microenvironment. To gain additional
information supporting the use of the syngeneic 5TGM1 murine multiple my-
elomamodel in drug development, we tested drug sensitivity of 5TGM1 cells by
screening an extensive panel of drugs. The compound library consisting of 460
compounds included conventional chemotherapy, kinase inhibitors, metabolic
modifıers, rapalogs, differentiating/epigenetic modifıers, kinesin inhibitors, ap-
optotic modulators, NSAIDs, hormone therapy, immunomodulators and HSP
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inhibitors. The compoundswere tested in fıve concentrations covering a 10.000-
fold drug-relevant concentration range in 384-well format. Cells were seeded to
plates with a compound library, followed by cell viability measurements (Cell-
Titer-Glo) after 72 hours. Maximal and minimal responses to drugs were ana-
lyzed, and the EC50 values were calculated. Drug Sensitivity Score (DSS) was
calculated for each drug as a measure of reduced viability. According to DSS
analysis, 5TGM1 cells showed sensitivity to conventional chemotherapy, such as
antimitotic drugs, and kinase inhibitors, such asMEK1/2 inhibitors. In addition,
the cells showed particular sensitivity to several HSP90 inhibitors currently in
phase I/II clinical development for MM. Lenalidomide and pomalidomide, ef-
fıcient in treating multiple myeloma in humans, both gave low DSS value indi-
cating that 5TGM1 cells are not sensitive to these drugs, which is expected
because they do not bind to murine form of the target cereblon. In contrast,
5TGM1 cells were highly sensitive to the proteasome inhibitor bortezomib (DSS
32.2), which is currently in clinical use. In conclusion, the murine 5TGM1 cells
show sensitivity to variousMMdrugs used in the clinic and under development.
Evaluating the effects of the microenvironment on the growth and drug sensi-
tivity of 5TGM1 cells in vitro and in vivo will be essential. Furthermore, the
cell-based compound screening combined with DSS analysis provides a possi-
bility to profıle cellular responses to an extensive collection of anti-cancer com-
pounds enabling identifıcation of vulnerabilities in cancer cells and functional
investigation of cellular pathways behind drug sensitivity or resistance.
#3839 MLN8237 treatment in an orthoxenograft rodent model for malig-
nant peripheral nerve sheath tumors. Oliver Mrowczynski. Penn State Her-
shey, Hershey, PA.
Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas
that arise from peripheral nerves and often occur in the extremities. MPNSTs
arise sporadically or in the neurofıbromatosis type one (NF1). NF1 is an auto-
somal-dominant disorder characterized by neurofıbromas, cutaneous hyperpig-
mentation, and intellectual defıcits affecting 1 in 3000 births. The lifetime risk of
a person with NF1 developing MPNSTs ranges between 8-13%. MPNSTs have
increased expression of the oncogene Aurora kinase A. This leads to enhanced
cell proliferation,makingMPNSTs extremely aggressive, with high potential for
metastasis, and devastating prognosis, with fıve year survival estimates ranging
from a dismal 15-60%. MPNSTs are currently treated with surgical resection,
sometimes requiring limb amputation, as well as chemoradiation, all of which
demonstrate limited effectiveness, and highlight the necessity for novel thera-
pies. To evaluate the effectiveness of new treatments, a translationally accurate,
robust, and cost-effective model is crucial. A major goal of this study was to
produce an orthotopic xenograft murineMPNSTmodel for evaluation of novel
therapies, which we created by intra-neural injection of luciferase transfected
MPNST cells into the mice sciatic nerve. Our model circumvents drawbacks of
previous in vivo models by producing a robust tumor in the physiologically
relevant microenvironment of the nerve that allows for accurate tumor burden
quantifıcation through luciferin fluorescence. Another goal of this study was to
demonstrate the effectiveness of MLN8237 for MPNST treatment. MLN8237 is
an aurora kinase A inhibitor that we demonstrate to decrease MPNST burden
and increase survival signifıcantly. This study provides a robust and reproduc-
ible MPNST model, allowing for the advancement of MPNST therapy. This
study also demonstrates the effectiveness of MLN8237 for MPNST treatment.
Together, our data has major implications on the future of MPNST research by
providing a robustmurinemodel aswell providing evidence thatMLN8237 is an
effective treatment for MPNSTs.
#3840 The National Cancer Institute’s patient-derived models repository
(PDMR). Yvonne A. Evrard,1 Michelle Ahalt-Gottholm,2 Sergio Alcoser,2 Car-
rie Bonomi,1 Suzanne Borgel,1 JohnCarter,1 Biswajit Das,1 VivekanandaDatta,1
Cheryl Davis,1 Kelly Dougherty,1 Michelle Eugeni,2 Marion Gibson,1 Catherine
Karangwa,1 Jason Lih,1 Dianne Newton,1 Han Si,1 Shivaani Kummar,3 Larry
Rubinstein,4 Alice Chen,4 P. Mickey Williams,1 Melinda G. Hollingshead,2
JamesH. Doroshow2. 1Frederick National Laboratory for Cancer Research, Fred-
erick, MD; 2National Cancer Institute, Frederick, MD; 3Stanford School of Med-
icine, Stanford, CA; 4National Cancer Institute, Bethesda, MD.
The National Cancer Institute (NCI) is developing a Patient-Derived Models
Repository (PDMR) comprised of quality-controlled early-passage clinically-
annotated patient-derived xenografts (PDXs) and in vitro patient-derived cell
cultures (PDCs), including tumor cell and cancer-associated fıbroblast cell cul-
tures, to serve as a resource for public-private partnerships and for academic
drug discovery efforts. These PDMs will be clinically-annotated with molecular
information (whole exome sequence, RNASeq) available in a publicly accessible
database andwill be available to the extramural community for research use. The
PDMRwas established by NCI at the Frederick National Laboratory for Cancer
Research (FNLCR) in direct response to discussions with academia and indus-
try; the oncology community’s highest priority need is better preclinical models
that more faithfully reflect the patient’s tumor and are associated with the pa-
tient’s treatment history. NCI has focused on collecting specimens frompatients
with cancer that are under-represented in many other PDX collections such as
head and neck, pancreatic, bladder, ovarian and small cell lung cancers, mela-
nomas and sarcomas. In addition, NCI is increasing its focus on creating PDXs
from minority/underserved populations and will soon be expanding to include
pediatric cancers. The PDMR generates the majority of its PDXs by subcutane-
ous implantation; however certain histologies have better take-rates in either
orthotopic or alternate implant sites. All SOPs and quality-control standards
developed by the PDMRaswell as those shared by collaborators will be posted to
the public web site that houses the PDMRdatabase. The overall goal of NCI is to
create a long-term home for at least 1000 models such that suffıcient biological
and clinical diversity is represented to allow researchers to ask questions such as:
what is the impact of tumor heterogeneity on target qualifıcation or clinical
response; do PDXs more faithfully represent the human tumor for pharmaco-
dynamic assay and predictive marker development; or can an adequately pow-
ered preclinical PDX clinical trial lead to better evaluation of therapies for future
clinical use? Grant Support: This project has been funded in part with federal
funds from the National Cancer Institute, National Institutes of Health, under
Contract No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health andHuman
Services, nor does mention of trade names, commercial products, or organiza-
tions imply endorsement by the U.S. Government.
#3841 Ahybridmapping approach improves genomic and transcriptomic
analysis of patient derived orthotropic xenograft (PDOX) models of pediat-
ric CNS tumors. Oliver A. Hampton,1 Michael C. Gundry,1 Mari Kogiso,2 Lin
Qi,2 Yuchen Du,2 Yulun Huang,2 Frank K. Braun,2 Huiyuan Zhang,2 Sibo
Zhao,2 Holly Lindsay,2 Sarah G. Injac,2 David A. Wheeler,1 Xiao-Nan Li,2 D.
William Parsons1. 1Baylor College of Medicine, Houston, TX; 2Texas Children’s
Hospital Cancer Center, Houston, TX.
Background.Patientderivedorthotopicxenograft (PDOX)models are an impor-
tant tool for cancer research, including personalized preclinical testing of targeted
therapies. PDOX models of CNS tumors faithfully replicate the invasive nature of
patient tumors, resulting in variable contamination of the harvested xenograft tis-
sues by mouse brain cells. This presents technical challenges to genomic and tran-
scriptomic analyses, including correct alignment of sequencing reads to human or
mouse genomes, and can result in identifıcation of false positive tumor mutations.
Improved bioinformatic methods for systematic correction of such errors are
needed. Methods. Whole exome sequencing (WES) was performed on 32 diverse
childhoodCNStumors (meanof109Mreads/sample) andmatchingPDOXmodels
(mean of 62M reads/sample), including atypical teratoid rhabdoid tumor (ATRT),
glioblastoma (GBM), and medulloblastoma (MB). Patient-matched blood DNA
wasalso subjected toWES.Whole transcriptomesequencing (WTS)wasperformed
on a subset of tumors and PDOXmodels (mean of 94M reads/sample). Integrated
WES and WTS analysis pipelines were constructed to unequivocally identify each
sequencing reads’ species-of-origin prior to genomic and transcriptomic variant
calling, expression profıling, and fusion gene analysis. Xenograft NGS reads were
competitively mapped to a hybrid reference created by merging the human (hg19)
and mouse (mm10) genomes, with reads segregating to their respective genomes
based on mapping score. Reads that mapped exclusively to the human reference
were selected for analysis. Results. Mouse DNA contamination varied widely be-
tween PDOX tumors (1% to 94%;mean 40%).Hybridmapping resulted in 2.4-fold
higher combined sensitivity and specifıcity for identifıcation of somatic variants as
compared to direct human reference mapping followed by mouse polymorphism
subtraction.WES analysis confırmed themaintenance of somatic driver mutations
in PDOX models, including SMARCB1 in ATRT, TP53 and NF1 in GBM, and
DDX3X inMB. Interestingly, 37% of tumor and 55% of PDOX somatic mutations
exhibited signifıcant allele fraction changes between the primary tumor and PDOX
model. WTS analysis based on hybrid mapping resulted in an increase in positive
predicted value (PPV) for correlation of FPKM values between tumor and PDOX
model, with greater PPV in cases with high levels of mouse contamination, albeit
with lower sensitivity due to decreasing coverage. Conclusions. Hybrid mapping
basedWES andWTS analysis identifıes fewer false positives than direct hg19map-
ping and represents a more streamlined process of species-of-origin sequencing
read classifıcation and fıltering at the alignment stage.Thismethodhas thepotential
to improve molecular characterization of PDOXmodels and inform the design of
rational preclinical studies.
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#3842 Comprehensive genomic analysis demonstrates concordance of
PDX models and patient tumor cohorts. Xing Yi Woo,1 Vinod Yadav,1 Al
Simons,2 Anuj Srivastava,2 Guruprasad Ananda,1 Vishal Kumar Sarsani,2 Roger
Liu,1 Grace Stafford,2 Joel Graber,2 Krishna Karuturi,1 Susie Airhart,2 Joshy
George,1 Carol Bult2. 1The Jackson Laboratory for Genomic Medicine, Farming-
ton, CT; 2The Jackson Laboratory, Bar Harbor, ME.
The Jackson Laboratory has established more than 400 unique patient-de-
rived xenograft (PDX) cancer models from patient tumors in the immunocom-
promised NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (aka, NSGTM) mouse strain, span-
ning across more than 30 tumor types. At low passages, these engrafted models
are known to retain similar molecular characteristics and heterogeneity to the
originating human tumor. As such, PDX models offer an excellent preclinical
platform to test drug responses of novel cancer therapeutics and a powerful
resource for conducting preclinical cancer pharmacogenomic studies. To aid the
selection of suitable PDX models for preclinical studies and for the research
purpose to understand tumor biology and response or resistance to a given
treatment, we have characterized the PDXmodels for their transcriptomic, mu-
tational and copy number profıles using sequencing and array approaches. We
have established a compendium of PDX-tailored computational pipelines as the
analysis of genomic data from PDX models could be challenging due to a) the
contamination of PDX sample with mouse stroma, which complicates down-
stream bioinformatics analyses as mouse genome is almost 90% homologous to
the human genome, and b) the lack of matched normal material to call somatic
events. Our pipelines incorporate various fılters to identify tumor specifıc single
nucleotide variants, indels, copy number changes and expression profıle in the
PDXmodel. For the purpose of validating the accuracy of our analysis pipelines
and demonstrating that the JAX PDX models are indeed representative of pa-
tient tumors, we compared JAX’s PDX cohort with patient cohorts in TCGA for
mutations, copy number aberrations and RNA expression concordance. Using
gene sets representative of each tumor type, we found that the overall genomic
profıle of each PDX tumor type is more correlated to the same tumor type in
TCGA than other tumor types. In addition, an integrative analysis across all data
types reveals that there are more common affected pathways between the same
tumor type in PDX and TCGA. This comprehensive analysis revealed that the
PDX and patient cohorts exhibit similar molecular characteristics, hence estab-
lishing the suitability of JAX PDXmodels as in vivo models to study fundamen-
tal tumor biology as well as to carry out preclinical studies of cancer drugs,
including identifıcation of biomarkers of response or resistance.
#3843 Autologous resconstitution of human cancer and immune system
in vivo. Juan Fu,1 Rupashree Sen,1 David L Masica,1 Rachel Karchin,1 Drew
Pardoll,1 Young Kim2. 1Johns Hopkins University, Baltimore, MD; 2Vanderbilt
School of Medicine, Nashville, TN.
Correlative studies from checkpoint inhibitor trials have indcated that better
understanding of human leukocytic traffıcking into the human tumormicroen-
vironment can expedite the translation of future immune-oncologic agents. In
order to directly characterize signaling pathways that can regulate human leu-
kocytic traffıcking into the tumor, we have developed a completely autologous
xenotransplanation method to reconstitute the human tumor immune mi-
croenvironment in vivo.When we analyzed the TCGA database of human head
and neck squamous cell carcinoma(HNSCC), we found that STAT3 signaling
was associated with worse prognostic mesenchymal subtye.We silenced STAT3
signaling in the tumor compartment in these autologously reconstituted hu-
manized mice, and we noted increased tumor infıltrating lymphocytes and
slower tumor growth rate. We also used this novel agents that can alter endog-
enous leukocytic infıltration into the tumor. Taken together, we present a valu-
able method to study individialized human tumor microenvironments in vivo
without confound allgeneic responses.
#3844 Identifıcation and validation of novel therapeutic targets driving
clonal heterogeneity in treatment-refractory GBM. Chirayu Chokshi, Nick
Yelle, Parvez Vora, Chitra Venugopal, Maleeha Qazi, Mohini Singh, Minomi
Subapanditha, Avrilynn Ding, Sheila K. Singh. McMaster Stem Cell & Cancer
Research Institute, Hamilton, Ontario, Canada.
Glioblastoma (GBM) is themost commonprimary adult brain tumor, character-
ized by extensive cellular and genetic heterogeneity. Even with surgery, standard
chemotherapy with temozolomide (TMZ), and radiation, tumor re-growth (or re-
currence) and patient relapse are inevitable. Patients face a median survival of15
months, with uniformly fatal outcomes upon disease progression post-therapy. Re-
cent profıling of GBM-initiating genes has shown that evolution of cancer-driving
clones or cell populations within a solid tumormay progress through (and possibly
be driven by) cancer treatment, such that GBM recurrencemay no longer resemble
the genetic landscape of the original primary tumor. Understanding and mapping
clonal evolution of the primary GBM through therapy and at recurrence will allow
for the discovery of novel targets specifıc to treatment-refractory GBM. Here, we
havedevelopedearlypassagepatient-derivedbrain tumor initiatingcell (BTIC) lines
that have been annotated by genomic deep-sequencing technologies to systemati-
cally characterize and describe the extent of intratumoral heterogeneity. Tagged
with a red florescent protein, theseBTIC lineswere engrafted into immunocompro-
mised NOD SCIDmice. Following half-maximal tumor engraftment, tumor bear-
ing mice underwent a clinically relevant chemoradiotherapy regimen, with 2 Gy
gamma-irradiationon the fırst day and66mg/kg temozolomide for fıve consecutive
days. Following therapy, mice were kept alive until tumor recurrence. Engrafted
BTICs were harvested at initial tumor formation, minimal residual disease after
chemoradiotherapy, and tumor recurrence. Samples were analyzed by RNA and
genomic deep-sequencing technologies to map cancer progression and identify
novel therapeutic targets in treatment-refractoryGBM.Potential therapeutic targets
were validated by their effect on self-renewal and proliferation of patient-derived
BTIC lines of human GBM in vitro and in vivo. Using CRISPR Cas9, potential
targets were knocked out in patient-derived BTIC lines of humanGBM in order to
characterize the effect on sphere formation and proliferation in vitro, and tumor
formation in vivo. Following validation of new therapeutic targets of treatment-
refractor GBM, we aim to build novel biotherapeutics against highly validated cell
surface targets, and establish preclinical testing protocols using our novel patient-
derived and therapy-adapted xenograft model of treatment-resistant GBM.
#3845 Establishment and characterization of patient-derived xenografts
of clear cell carcinoma of the ovary. Hidemichi Watari,1 Daisuke Endo,1
Kouhei Honda,2 Mihoko Kunitomo,2 Toshiyuki Nomura,2 Noriaki Sakuragi1.
1Hokkaido University, Sapporo, Japan; 2Takeda Pharmaceutical Co. Ltd., Fu-
jisawa, Japan.
Background; The patient-derived xenograft (PDX)model is likely to reflect orig-
inal human cancer biology compared to cultured cell lines, since tumor tissues are
directly implanted into animals. PDX models of ovarian cancer have been devel-
oped, but were not fully characterized at themolecular level, especially for clear cell
carcinoma(CCC),which ismoreprevalent in Japan thanwesterncountries, exhibits
chemoresistant phenotype and poor survival. The development of new treatment
strategies and the better understanding of biology ofCCCboth depend on clinically
relevant animal models. In particular, molecular annotated PDXmodels are useful
for the preclinical investigation of anticancer drugs and individualized anticancer
therapy. Methods; We transplanted 19 parent (primary or metastatic) tumors di-
rectly intoNOGmice.Thehistologic characteristicswere comparedbetweenparen-
tal tumors and PDXones. AmongCCCpairs, gene expression analysis, genemuta-
tion analysis were conducted on parental tumors and corresponding PDX tumors.
Response to chemotherapeutic agentswas analyzedusingPDX tumors ofCCC, and
correlated with clinical outcome. Results; Six of nineteen (31.6%) transplanted tu-
mors could be passaged. Gene expression profıles revealed that engrafted tumors
expressed more proliferation-related genes than those of non-englafted ones.
Among six PDXmodels established, twowere found to be CCC. Two PDX tumors
of CCC maintained the histologic characteristics of parental CCC tumors. Gene
expression profıle revealed similar results between primary CCC and PDX tumors
of CCC except that PDXs lost expression of immune-related genes.. Gene muta-
tional analysis showed similar pattern between primary CCC and PDX of CCC.
Drug-sensitivity test showed resistance to carboplatin in two PDX tumors of CCC,
which is consistent with their clinical outcomes. Conclusions. PDXs of CCC were
established and found to retain histologic and clinical features of original tumors,
and can be utilized to screen new target drugs for platinum-resistant CCC.
#3846 Imodi initiative: A novel holistic and integrative approach with
patient-derived tumormodels against pancreatic cancer. Juan Iovanna,1 Nel-
son Dussetti,1 Florence Meyer-losic,2 Françoise Le Vacon,3 Loreley Calvet,4
Nico Forraz,5 Kevin Dhondt,6 Mariana Kuras,7 Christophe Lautrette,8 Séverine
Tabone-Eglinger,9 Philippe Vaglio,10 Olivier Duchamp11. 1INSERM, Marseille,
France; 2IPSEN Innovation, Les Ulis, France; 3BioFortis-Merieux NutriSciences,
Saint-Herblain, France; 4Sanofı, Vitry-sur-Seine, France; 5CTI-Biotech, Meyzieu,
France; 6Pierre-Fabre Research Institut, Saint-Julien-en-Genevois, France; 7Ari-
ana Pharmaceuticals, Paris, France; 8OncoMedics, Limoges, France; 9Centre Léon
Bérard, Lyon, France; 10Modul-Bio, Marseille, France; 11Oncodesign S.A., Dijon,
France.
Patient-derived xenografts (PDX) are appearing as a prime approach for pre-
clinical studies despite being insuffıciently characterized as a model of the hu-
mandisease and its diversity.Many reports support that xenografts fromPDX in
mice recapitulate well themolecular diversity, cellular heterogeneity, and histol-
ogy seen in patient tumors. However, several lacks such as the limited clinical
diversity of the PDXs, the absence of human drug metabolism and the reduced
immune system are limiting the predictive values of these PDX models. To
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set-up a holistic integration of these criticisms, we have associated efforts from
public hospitals, academic groups, biotechs and private pharmaceutical compa-
nies with the fınancial support of the French Ministry of Industry. First, to
improve the clinical diversity of the PDX collections, surgical specimens or
biopsies from patients with 9 different types of cancers (pancreas, lung, breast,
ovary, liver, prostate, AML, myeloma, lymphoma) are collected since 2013 to
establish large collections of PDXs inmice. In addition, primary cultures of cells
from these samples are established leading to a collection of cell lines from the
stroma and the tumoral compartment. Pancreatic PDX from primary tumors
and its metastasis were obtained from either surgery or by endoscopic ultra-
sound-guided fıne needle aspirate and therefore representing a bio-banking
with a unique diversity. The established pancreatic models are being evaluated
for histological, extensive molecular characteristics and in vitro and in vivo
sensitivities to relevant anticancer drugs. We found i/ a variable sensitivity on
PDX-derived cells when treated in vitro with increasing concentrations of clin-
ically relevant drugs; ii/ that sensitivity to one drug does not predict the sensi-
tivity to the another one; and iii/ sensitivity to drugs in vivo reproduce, but not
systematically, the results in vitro. To be noted, no correlation between sensitiv-
ity and genetic characteristics (mutations or CNV) or histological proprieties
was found. Allmodel characteristics are being compiled in aweb-based database
for effıcient features search and interconnection. Second,we are generatingmice
with humanized liver showing human drug pharmacokinetic and metabolism
profılesWewill present the fırst pancreatic cancermodels characterized andwill
discuss their usefulness and chance to bring benefıt to patients via this holistic
strategy developed within IMODI initiative.
#3847 Oral cavity squamous cell carcinoma xenografts display conserva-
tion of primary tumor genomic heterogeneity.KatieM. Campbell,1 Tianxiang
Lin,1 Ashley E. Winkler,1 Paul Zolkind,1 Zachary L. Skidmore,1 Erica K. Bar-
nell,1 Ian Hagemann,1 Elaine R. Mardis,2 Malachi Griffıth,1 Rebecca D. Cher-
nock,1 Obi L. Griffıth,1 RavindraUppaluri3. 1WashingtonUniversity in St. Louis,
Saint Louis, MO; 2Nationwide Children’s Hospital, Columbus, OH; 3Dana-Far-
ber Cancer Institute, Boston, MA.
Purpose: Patient derived xenograft (PDX) models represent a platform for
defıning therapeutic opportunities based on their ability to maintain the
genomic and molecular features of their respective tumors. We used a compre-
hensive genomics approach to analyze PDXs for oral squamous cell carcinoma
(OSCC), which had not been previously described. This involved confırming
that the PDXs conserve the heterogeneous somatic landscape of the primary
tumors fromwhich they were derived. Methods:We established a large panel of
OSCC PDXmodels by engrafting fresh, primary tumor samples into NOD scid
gamma (NSG) mice. We performed whole genome sequencing (WGS; n10),
whole exome sequencing (WES; n15), and transcriptome sequencing
(RNAseq; n15) on matched primary and fırst passage xenografts. Somatic
events, includingmutations, copynumber alterations (CNAs), loss-of-heterozy-
gosity (LOH) regions, and structural variation (SV), were detected indepen-
dently in tumors and PDXs. Conservation was defıned by the correlation of
variant allele frequency (VAF) distributions and gene expression patterns, pres-
ence of larger somatic events, and predictions made about the subclonal archi-
tecture of the tumor and xenograft. Results: PDXs were established with an
overall success rate of 47% (56/118). The somatic landscape of primary tumors
was representative of the published genomic data on OSCC, including amplifı-
cations of CCND1 and EGFR family members, inactivating mutations and loss
of TP53 and CDKN2A, and chromosome 3q amplifıcation. These somatic
events were also strongly conserved in matched xenograft samples. Mutations
that were detected in either the xenograft or primary tumor, but not its matched
sample, consisted primarily of low-frequency mutations. The predicted clonal
architecture, however, revealed correlative subclonal heterogeneity between
matched xenograft and primary tumor. This includes maintenance of founding
clone mutations and consistent VAF distributions, indicating that a heteroge-
neous tumor population engrafted. Conclusions: This comprehensive approach
establishes early-passage PDXs as high fıdelitymodels forOSCC. Their ability to
maintain the genomic heterogeneity detected in primaryOSCC tumors presents
a clinically relevant platform for understanding tumor biology and identifying
novel therapeutic strategies.
#3848 The clinical relevance of targeting IFITM1 in three distinct sub-
types of aggressive breast cancer. Asona Lui,1 Joshua Ogony,1 Jordan Mar-
quess,1 Eric Geanes,1 William Jewell,1 Ikbale El Ayachi,2 Gustav Miranda-Car-
boni,2 Ossama Tawfık,1 Joan Lewis-Wambi1. 1Univ. of Kansas Medical Ctr.,
Kansas City, KS; 2University of Tennessee Health Science Center, Memphis, TN.
Breast cancer canbe separated intoestrogen receptor/progesterone receptorpos-
itive (ER/PR), Her2/neu positive (HER2), and triple negative (ER-/PR-/
HER2-) subtypes. Additionally, breast cancermaymanifest clinically as either non-
inflammatoryor inflammatorydisease. Inflammatorybreast cancer is ahighly lethal
subtype of breast carcinoma that may express any of the three aforementioned re-
ceptors. Our laboratory has found that a novel marker, interferon-induced trans-
membrane protein 1 (IFITM1), is overexpressed inmultiple subtypes of breast can-
cerand itsoverexpression isassociatedwithpooroverall survival aswell as resistance
to endocrine therapy, chemotherapy, and radiation. IFITM1 is a type 1 interferon
(IFN) stimulated gene that is not expressed in normal breast tissue, and is only
induced upon IFN exposure. In this study, we conducted immunohistochemical
staining for IFITM1 in 94 ER human breast tumor samples and discovered that
high IFITM1 expression was associated with increased clinical stage and resistance
to endocrine therapy. Elevated expression of IFITM1 was also detected in human
triple negative breast cancer (TNBC) samples as compared to normal breast tissue.
Notably, this overexpression wasmost pronounced in TNBC tumors fromAfrican
American (AA) patients. We screened a panel of nine cell lines that represent all
major subtypes of breast cancer and found IFITM1 overexpression in ER aroma-
tase inhibitor-resistant MCF-7:5C, AA-derived triple negative MDA-MB-468 and
MDA-MB-157, and triple negative inflammatory SUM149 cells.We used inducible
shRNA and CRSPR/Cas9 respectively, to investigate the effect of IFITM1 knock-
downonMCF-7:5C and SUM149 xenograft tumors using two in vivo breast cancer
models. The orthotopic (mammary fat pad) model evaluated tumor proliferation,
and the mammary intraductal (MIND) model assessed tumor cell invasion out of
the milk duct. We found that loss of IFITM1 in MCF-7:5C and SUM149 cells sig-
nifıcantly inhibited their ability to form tumors in vivo and it completely blocked
their ability to invade out of themilk duct. Additional studies indicated that hyper-
activated JAK/STAT signaling was responsible for driving IFITM1 expression in
MCF-7:5C,MDA-MB-468, and SUM149 cells. Furthermore,we demonstrated that
JAK/STAT activation can be targeted in vivowith the FDA approved JAK inhibitor
ruxolitinib (Jakafı™). Oral treatment of mice with 50 g/g bodyweight ruxolitinib
reduced IFITM1expressionand inhibited thegrowthofbothMCF-7:5CandMDA-
MB-468 tumors by loss of STAT1/2 phosphorylation. The overexpression of IF-
ITM1 in three distinct breast cancer subtypes indicates that IFITM1 may be a tar-
getable marker of aggressive disease in general and may open the door for novel
therapies of treatment-refractory breast cancer.
#3849 HuPBL humanized models as a tool to evaluate the effıcacy and
immune regulation of immune checkpoint inhibitors. Xuzhen Tang, Xianzhi
Zhai, Hui Qi, Qin Hong, Qiyao Zhang, Lei Jin, Shaoyu Yan, Zhuozhi Wang,
Yong Zheng, QingyangGu,NormanZhang, Jing Li, Qunsheng Ji.WuXiAppTec
(Shanghai) Co., Ltd., Shanghai, China.
After the success of PD-1, PD-L1 and CTLA-4 antibodies, a number of im-
mune-checkpoint inhibitors are already in advanced stages. Meanwhile, tumor
infıltrating lymphocytes (TIL) are well recognized as features of tumor progres-
sion and keys to effective cancer immunotherapy. Therefore, there is an urgent
need to establish an effective pre-clinical platform for the evaluation of thera-
peutical outcomes in the human immune-system and the understanding of
TILs. Either traditional syngeneicmodels or human target knockinmodels have
their drawbacks: syngeneic models disable the development of antibodies that
do not recognize mouse receptors; neither of them can achieve a good clinical
prediction due to their inherent property as a murine system. To get a reconsti-
tution of the human immune system in murine models, we have established
several customizedHuman peripheral blood lymphocytes (hu-PBL) humanized
models in NOG (NOD/Shi-scid/IL-2Rnull) mice either systemically or focal-
ized in tumors. Those models were validated by immune-checkpoint inhibitors
for effıcacy and by conducting TIL analysis with the support of sophisticated
Flow Cytometry-Based Approach. Here we report that the engrafted human
cells can expand and infıltrate in tumors in response to xenogenic stimulation
with functional Th and Tc detected. The cell lineages are mainly CD3 T lym-
phocytes (90%) and to lesser extent NK/NKT cells; the redistribution in tumors
is unique not only compared to splenic and peripheral blood T cells, but also
varies among different cancer cell lines when the same donor was applied. In
addition, cell surface expression of immune checkpoint targets showed unique
redistributions.We further investigated the correlation between the effıcacy and
the immune-regulation in these models: Models with more dense infıltration at
the early phase usually grew more slowly than its NON-PBMC control, which
also are prone to be better responders to immunotherapy due to the higher
Effector cell: Target cell ratio (E:T ratio). When compared the effıcacy of 2
different hPD-1 test antibodies in A375 systemic humanized model, the one
with better effıcacy also achieved stronger inhibition on PD-1 expression in
TILs. Treatment with the clinically used Opdivo showed not only different re-
sponses in HCC827, A375 and A431 xenograft models but also unique profıles
in TILs subsets and related immune-checkpoint expression. These models can
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be used for the purpose of pre-clinical immune-checkpoint inhibitor and bi-
specifıc antibody screening under human background, as well as for further
investigations regarding distinct functions of TILs subsets and target expression.
#3850 Establishment of patient derived model of high-risk endometrial
cancer for pre-clinical combined carboplatin and decitabine therapy.Weiwei
Feng, Menghan Zhu, Yinhua Yu, Wei Jiang. Obstetric and Gynecology Hospital
of Fudan University, Shanghai, China.
Objective: The high risk endometrial cancers (EC), including high grade EC,
serous carcinoma (SC), clear cell carcinoma (CC) and carcinosarcoma, account
for 50% of death. Therapies for them are limited and patient derived tumor
xenograft (PDX) model become useful tools to predict response to treatment.
Here we compared the two methods of establishment of PDX models and eval-
uated the effıcacy of carboplatin and decitabine in two high grade EC PDX
models. Methods: Fresh tumor tissues collected from 11 primary high risk EC
patients (6 high grade ECs, 4 SCs, 1 CC and 1 carcinosarcoma) were engrafted
subcutaneously and in subrenal capsule in SCID mice. For those subcutaneous
models, tumors were then orthotopic transplanted into uterine cavity. Histol-
ogy, vimentin, cytokeratin, ER, PR, P53 expressionwere evaluated, togetherwith
mutation profıles by next generation sequencing for 500 cancer-panel genes.
The effıcacy of carboplatin and decitabine were evaluated in two high grade EC
models. Results: The total tumor take rate was 81.8% (9 /11), without regard to
engraft methods. The tumor take rate was higher in subrenal capsule models
than subcutaneous models (70% vs 54.5%, respectively). The time for tumor
formation (from transplantation to 1 cm in diameter) varies greatly from 4
weeks to 5 months. We observed good similarity between primary tumors and
corresponding different passage of xenografts. One high grade EC model was
sensitive to carboplatin and decitabine treatment whereas another was drug
resistant. Two models harbor different genetic mutation profıles. Conclusion:
The high tumor take rate ensures the establishment of the high risk EC biobank
which provides a powerful resource for pre-clinical drug-sensitive tests aswell as
identifıcation of biomarkers of response or resistance.
#3851 Targeting HER2 in gastric cancer: Hints from a gastric PDX plat-
form. Simona Corso,1 Cristina Migliore,1 Maria Apicella,1 Silvia Menegon,2
Eirini Pectasides,3 Tania Capeloa,1 Stefania Durando,4 Marilisa Cargnelutti,4
Paola Cassoni,1 Anna Sapino,1 Maurizio de Giuli,1 Adam Bass,5 Silvia Gior-
dano1. 1Universita’ di Torino, Italy; 2Candiolo Cancer Institute-FPO, IRCCS,
Italy; 3Beth Israel Deaconess Medical Center, boston, MA; 4Candiolo Cancer In-
stitute-FPO, IRCCS, Candiolo, Italy; 5Dana Farber cancer Institute, MA.
Introduction: Gastric cancer is the 3rd leading cause of cancer mortality
worldwide. Surgery is the only curative treatment strategy and conventional
chemotherapy has shown limited effıcacy. Trastuzumab (a HER2 mAb), is the
only therapy targeting molecular alterations approved so far in gastric cancer,
for HER2 patients with advanced disease. However only a fraction (20%) of
HER2 amplifıed patients benefıts from treatment. Methods: We have recently
generated a molecularly annotated colony of gastro-esophageal PDXs (at the
moment, 70 PDXs). The platform also comprises primary cell lines and 3D-
cultured organoids derived from gastric cancer PDXs. Results and Discussion:
At present, we have identifıed several HER2 PDXs and generated the corre-
sponding in vitro derivatives. Four HER2 PDXs, showing 3 HercepTest
score and HER2 amplifıcation  8 copies (thus theoretically sensitive to Tras-
tuzumab), were selected to undergo ’xenotrials’ with the following anti-HER2
drugs/combos: Trastuzumab (T); Pertuzumab (P, anti-HER2 mAb); Lapatinib
(L, a dual HER2-EGFR tyrosine kinase inhibitor). According to RECIST-like
criteria, T induced tumor regression in only 1 out of 4 HER2 PDXs. Interest-
ingly, in all the tumors but one the combos TP and TL were able to bypass
resistance to T monotherapy and to induce tumor regression. One tumor was
resistant to all the tested therapeutic approaches. Conclusion: We identifıed
PDXs displaying HER2 gene amplifıcation. Only a minor fraction of them ben-
efıted from the anti-HER2mono-therapy, despite the presence of a strongHER2
gene amplifıcation, while the association of two HER2 inhibiting drugs resulted
in intense and prolonged response. This suggests that monotherapy with T
might not be the most effective therapeutic approach in gastric cancer patients.
We are currently investigating the cause of resistance to anti-HER2 drugs to
identify mutations/CNV in tumors showing resistance to Trastuzumab.
#3852 Validation of synthetic lethality of PARP andNAMPT dual inhibi-
tion in a small cell lung cancer PDX model. Zhixiang Zhang, Dongfang Li,
ChenChen, BoZhang,XuzhenTang,HaoYe,QingyangGu,Qunsheng Ji.WuXi
AppTec (Shanghai) Co., Ltd., Shanghai, China.
Small cell lung cancer (SCLC) is a highly malignant cancer type with a 5-year
survival rate of less than 10%. Different from non-small cell lung cancer (NSCLC),
no effective target therapies have been approved to treat SCLC. Poly (ADP) ribose
polymerase (PARP) overexpression in SCLChas prompted great efforts to evaluate
the role ofPARP inhibitors in clinic.Tomaximize their therapeutic value it is urgent
in need to explore the best combination strategies between PARP inhibitors and
otherpathwaymodulators. In this studywe identifıed aSCLCpatient-derivedxeno-
graft (PDX) model with high PARP level and low nicotinamide phosphoribosyl-
transferase (NAMPT) level. Furthermore, synergistic effect of PARP and NAMPT
dual inhibitionwasdemonstrated, supporting translational researchofPARPinhib-
itors andNAMPT inhibitors in thismodel. ThemRNA expression of PARP as well
as its 30 most-studied synthetic lethality genes was compared between SCLC and
NSCLC inbothPDXsandcancer cell lines.We found thatNAMPT levels decreased
most signifıcantly in SCLC compared with NSCLC across the 30 synthetic lethality
genes of PARP. As NAMPT is the rate-limiting enzyme for the synthesis of the
PARP substrate -NAD, we hypothesized that low -NAD level due to low
NAMPT level might render SCLC sensitive to PARP inhibition. LU-01-0547, a
SCLC PDX model with high PARP and low NAMPT expression, was identifıed
here. To test our hypothesis, we investigated the preclinical effıcacy of ABT888, a
PARP inhibitor, with or without FK866, a NAMPT inhibitor, in this subcutaneous
xenograft model. The single-agent effıcacy of ABT888 was demonstrated
(TGI96%@100mg/kg,BID).At a sub-optimal dose (50mg/kg,BID), treatmentof
ABT888aloneproduced little activity in the samemodel,while its combinationwith
aNAMPTinhibitor,FK866, signifıcantlyboosted theantitumorresponse indicating
the synergistic effect (TGI117%,ORR6/6, CR4/6).When nicotinic acid (NA)
was administered to promote-NADbiosynthesis via the de novopathway other
than theNAMPT-mediated transformation, the PARP inhibitor’s effectiveness was
greatly antagonized (TGI70%vs. 13%), suggesting-NAD levelmight correlate
with PARP inhibitor sensitivity. In conclusion, this study identifıed a SCLC PDX
modelwithhighPARPand lowNAMPTexpression. Synergistic inhibitionofPARP
andNAMPT in this model was demonstrated superior to either treatment alone in
effıcacy, which warranted its future application in drug discovery. To our knowl-
edge, this was the fırst in vivo evidence of synthetic lethality in SCLCPDX, support-
ing future clinical test of combination of PARP and NAMPT inhibitors in SCLC
patients.
#3853 Patient-derived xenograft models from peritoneal metastasis of
colorectal carcinoma as novel platform for biomarker analysis and drug test-
ing. Wolfgang Walther,1 Eva Pachmayr,1 Bernadette Brzezicha,2 Britta Bütt-
ner,2 Beate Rau,3 Ulrike S. Stein1. 1Charité Universitätsmedizin Berlin and Max
Delbrück Ctr. forMolecularMedicine, Berlin, Germany; 2epo GmbH, Berlin, Ger-
many; 3Charité Universitätsmedizin Berlin, Berlin, Germany.
Colorectal carcinoma (CRC) is associatedwithhigh incidence andmortality rate,
particularly if metastasized to distant sites, such as the peritoneum. At time of fırst
diagnosis 4 to 7 percent of the patients suffer from peritoneal metastasis (PM) of
CRC. The PM is associated with poor prognosis and limited therapeutic options.
Therefore, availabilityof adequate invivomodels forPMwill promote the search for
novel prognostic or even predictive biomarkers as well as the evaluation of chemo-
sensitivity of PM towards standard, targeted and novel drugs. In this regard such
models could be employed for more individualized concepts to improve the thera-
peutic outcome of PM patients. During the last decade patient-derived xenograft
(PDX)mousemodels have gained importance, since they closely resemble themo-
lecular and biological features of the original primary tumors. However, until now
no PMPDXmodels have been established fromCRC.We therefore focused on the
establishment and characterization of a novel CRC PM panel of PDX as useful
platform for preclinical studies. For the PDXestablishment colorectal surgical spec-
imens were subcutaneously (s.c.) transplanted onto immunocompromized NOD
scid gamma (NSG) mice. The successfully engrafted tumors were transferred to
NMRI nu/nu mice for further passaging. Engrafted tumors were characterized by
histopathology, immunohistochemistry and gene expression analyses using real-
time RT-PCR. Chemosensitivity of PDX models was evaluated in vivo by applica-
tion of a panel of conventional chemotherapeutic and of targeted drugs. For PDX
establishment 68CRC surgical specimenswere transplanted ontoNSGmice. From
those, currently 22 PDX have engrafted and are stably growing on NMRI nu/nu
mice. From those, 13 models of 10 patients have been analyzed. Their tumor dou-
bling times ranged between 4 to 28 days. The histopathological evaluation revealed
maintenanceof theoriginalCRChistology in thePDX.Thechemosensitivity testing
of conventional and of targeted drugs in the 13 PM PDXmodels revealed the indi-
vidual, diverging response of the PDX, such as for 5-FU, irinotecan, oxaliplatin,
cetuximab, and erlotinib. For selected PDX, orthotopic transplantation into the
peritoneum revealed their potential to formdisseminated tumors in kidney, ovaries
and abdominal diaphragm. Our results demonstrate, that this novel panel of PDX
maintains the morphology of the patient tumor in early passages, reflect heteroge-
neous response rates, andcanbeusedaspreclinical invivoplatformfor translational
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studies of potential clinical use. In conclusion, this PDXpanel of PMof theCRCcan
be used for further studies to evaluate new biomarker and to test novel therapies or
combinations for PM of CRC.
#3854 Precisionmedicine approach: analysis of renal cancer patient-derived
cells with phenomics, genomics and drug sensitivity profıling. Vilja M. Pietiäi-
nen,1 Piia Mikkonen,1 Khalid Saeed,1 Lassi Paavolainen,1 Teijo Pellinen,1 Swapnil
Potdar,1 JohnMpindi,1HarryNisén,2Antti Rannikko,2 TuomasMirtti,3 PeterHor-
vath,1 Päivi Östling,1 Olli Kallioniemi4. 1Institute for Molecular Medicine Finland-
FIMM, Helsinki, Finland; 2Helsinki University Hospital, Helsinki, Finland;
3HUSLAB, Helsinki University Hospital and FIMM, Helsinki, Finland; 4Science for
Life Laboratory and Karolinska Insitutet, Stockholm, Sweden.
We have built up the precisionmedicine approach for solid tumors to under-
stand biological heterogeneity and driver signalling pathways in cancer, to de-
velop pharmacogenomic biomarkers and to ultimately tailor effective treat-
ments for patients. In addition to genetic profıling of original tumor tissues, we
have developed patient -derived tumor cell (PDC) models, and characterized
these models with genomics, image-based phenotyping (phenomics) and high
throughput drug profıling. Here, we describe our approach for a clear cell renal
cell carcinoma (ccRCC) patient. PDC cultures were initiated using conditional
reprogramming method from fresh primary tumor, protrusion to vena cava,
and the benign tissue samples. The exome-sequencing of tissues and PDCs
showed that several copy number variations and somatic driver mutations were
shared between the cancer tissue and corresponding cell models, including
TSC2 andVHLmutations. Using image-based phenotyping, the PDCs from the
benign tissue were observed to be strongly positive to cytokeratin 7 (CK7), while
original tumor tissue and PDCs from tumor tissue were predominantly CK7
negative. The PDCs expressed vimentin, amesenchymalmarker, but the epithe-
lial marker E-cadherin was downregulated, suggesting for epithelial-mesenchy-
mal transition. The PDCs from primary tumor were exposed to drug sensitivity
profıling with a library of 525 approved and investigational oncology com-
pounds in fıve different concentrations and imaged for proliferation with Ki-67.
PI3K/mTOR pathway inhibitors were found to be among the drugs inhibiting
the cell proliferation, in agreement with detected somatic mutations affecting
these pathways. In addition, our image-based drug sensitivity testing revealed
the intra-sample heterogeneity in drug responses and resistance, andwe are now
further investigating the mechanisms of most potent drugs and their combina-
tions in PDCs at single cell level. As a conclusion, our results implicate the
importance of comprehensive characterization of PDCs and their drug re-
sponses in translational research. We also foresee that these approaches may
potentially improve the translation of results back to clinic and support the
design of combination therapies in cancer.
#3855 Excavation of therapeutic targets based on themolecular signature
of patient-derived tumor xenografts in gastric cancer. Zuhua Chen, Jing Gao,
Lin Shen. Peking University Cancer Hospital & Institute, Beijing, China.
Objective: The optimal preclinical models in new targeted drug development
are patient-derived tumor xenografts (PDXs) models with defınite molecular
signatures, which will be excavated and validated in this study. Methods: The
genomic profıles of 50 PDXs fromadvanced gastric cancer (AGC)were analyzed
by targeted next-generation sequencing. The Epstein-Barr virus (EBV) infec-
tion, microsatellite instability (MSI) status, and expressions of EGFR, HER3,
c-Met, PTEN and c-Myc were determined by in situ hybridization and immu-
nohistochemisty, respectively. Results: A total of 581 non-synonymous single
nucleotide variations (SNV), 513 Indels, and 225 amplifıcations were identifıed
in 50 PDXs. Pathway analysis revealed recurrent alterations in the MAPK sig-
naling, ErbB signaling, VEGF signaling,mTOR signaling and cell cycle pathway.
The ErbB family amplifıed in 8% (EGFR), 10% (ERBB2), 2% (ERBB3) and 2%
(ERBB4) of the 50 PDXs respectively. Meanwhile, several activating mutations
in EGFR (L858R and G719S), ERBB3 (P1212S) and ERBB4 (R1174Q) were also
detected in our study. Moreover, we detected 7 PDXs harboring PIK3CA acti-
vating mutations (E545K, Q546K, H1047R) and 2 PDXs with PTEN loss.
Whether PI3K/Akt/mTOR inhibitors could turn over the primary or acquired
resistance of anti-HER2 therapies remains further researches. Genes in the cell
cycle pathway altered in 70% of the 50 PDXs. The mutation rates of TP53,
BRCA1 and BRCA2 were 28%, 8% and 14%. We also detected amplifıcations of
CCNE1, CCND1 andMYC in 16%, 6% and 20% of the xenografts. In this study,
9 PDXs (18%) were EBV positive, with frequent alterations of ARID1A but rare
mutations of TP53, and a robust expression of PD-L1. However, we didn’t ob-
serve any loss ofMMR protein expressions. Conclusions: Several potential ther-
apeutic targets were identifıed based on the molecular signature of PDXs in
advanced gastric cancer, which will provide evidences for drug development.
#3856 Identifıcation of circulating tumour cells in breast cancer patient-
derived xenograftmodels.Chiara Agnoletto,1 LindaMinotti,1Marco Galasso,1
Fabio Corrà,1 Federica Baldassari,1 Stefano Cairo,2 Jean-Gabriel Judde,2 Aurelie
Sauvage,2 Olivier Deas,2 Lorenzo Pasquali,3 Stefano Volinia1. 1University of Fer-
rara, Ferrara, Italy; 2XenTech, Evry, France; 3Karolinska University Hospital,
Stockholm, Sweden.
Metastases from primary tumours accounts for the great majority of can-
cer-related deaths. This process is thought to involve a series of sequential
steps, with the release of circulating tumour cells (CTCs) into the blood
stream. CTCs have been detected in the peripheral blood of patients with
advanced cancers of different origin and in some localized cancers. Recently,
liquid biopsy focusing on the analysis of CTCs has received enormous atten-
tion because of its obvious clinical implications for personalized medicine.
Clinical applications of CTCs detection include early detection of cancer,
prediction of the risk for metastatic relapse or progression, monitoring the
effects of systemic therapies, and stratifıcation of patients based on the de-
tection of therapeutic targets on resistance mechanisms. To date, only few
data are available about the numbers of these cells, their molecular and
biological heterogeneity, and their signifıcance. CTCs comprise a minute
fraction of mononucleated cells in the circulation, posing a serious challenge
for any analytical system. Multiple technologies have been developed for
CTC capture, but there is still a critical need for increased sensitivity in rare
tumour cell isolation within blood specimens. Most of the current CTC
detection techniques rely on antibody-based capture of cells, and epithelial
markers have been frequently used to distinguish cancer cells from normal
blood cells. However, the phenotypic changes that occur in CTCs, due pre-
dominantly to the epithelial-mesenchymal transition process, could be re-
sponsible for the failure to detect them in blood samples.We describe a novel
approach for the identifıcation of molecular markers to detect CTCs in pe-
ripheral blood of patient-derived xenograft (PDX) models. We analyzed the
transcriptome in more than 10,000 samples of primary and metastatic tu-
mours deposited in public databases, and identifıed a small set of cancer-
specifıc genes coding for membrane protein. Putative markers were assayed
by reverse transcription PCR with species-specifıc primers in blood samples
from breast cancer PDXs, testing their ability to detect human CTCs. Thus,
we identifıed human membrane proteins, which can be used for CTC mon-
itoring in peripheral blood. The use of multiple targets for CTC capture and
identifıcation increases the sensitivity of CTC detection, allowing the isola-
tion of all heterogeneous CTCs subpopulations.
#3857 Patient-derived tumor xenografts as pharmacologicalmodel of hu-
man pancreatic ductal adenocarcinoma. Alessia Anastasia,1 Andrea Resovi,1
Carmen Ghilardi,1 Roberta Avigni,1 Edoardo Micotti,2 Lucia Minoli,3 Eugenio
Scanziani,3 Carlo Corbellini,4 EugenioMorandi,4 Dorina Belotti,1 Raffaella Gia-
vazzi,1 MariaRosa Bani1. 1Department of Oncology, Mario Negri Institute for
Pharmacological Research, Milano, Italy; 2Department of Neuroscience, Mario
Negri Institute for Pharmacological Research, Milano, Italy; 3Department of Vet-
erinary Medicine, University of Milan, Milano, Italy; 4Ospedale di Rho, ASST-
Rhodense, Rho (MI), Italy.
INTRODUCTION and AIM: Pancreatic ductal adenocarcinoma is a lethal
disease with an overall survival rate of 5% and amedian survival time of less than
6 months. Current systemic treatments offer only a modest benefıt in symptom
control and survival, thus surgery remains the most effective treatment. The
exploitation of new therapeutics is an urgent need, but the research is braked by
the limited value of the current preclinical models as predictors of patients re-
sponse. The aim of our study is to develop patient-derived primary pancreatic
ductal adenocarcinoma xenografts (PDAC-PDX) growing into the pancreas of
recipient mice that retain features of the patient’s tumors andmimic the biolog-
ical heterogeneity of human pancreatic cancer. METHODS: Cancer specimens
from patients undergoing cephalic duodenopancreatectomy were transplanted
in NSG mice and orthotopically propagated by their re-implantation into the
pancreas of SCID mice. Tumor burden was measured by abdominal palpation
and by non invasive magnetic resonance imaging (MRI). PDAC-PDXs were
characterized histologically, for mutational status (KRAS, TP53 and SMAD4),
and responsiveness to gemcitabine. Gemcitabine was administered alone or
combined with nab-paclitaxel, to mice bearing tumor in their pancreas; drugs
were given intravenously on days 1 and 8 of each 21-day cycle to copy asmuch as
possible patient’s recommendations. To determine the antitumor effects of the
treatments, changes in tumor growth over time were evaluated by MRI and
plasma level of Ca19-9. RESULTS Surgically resectable pancreatic adenocarci-
noma (histologically confırmed) engrafted successfully in 5 cases (out of 11) and
retained the molecular, morphological and biological features of the original
patient tumors. Mutational landscape of the PDAC-PDXs reflect the clinical
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scenario: 80% are mutated in KRAS (G12D, G12R), 80% carry a TP53 mutation
(I162F, R213*, Y220C, R248Q) and 20% show the deletion of SMAD4. Histo-
logical features recapitulate the human disease, the PDAC-PDXs exhibit a ro-
bust amount of host derived stroma with collagen deposition, constant through
generations (up to fıve). Orthotopic growing PDAC-PDXs were marginal re-
sponsive to gemcitabine treatment, while signifıcant response (stable disease
and regression) was observed with the gemcitabine and nab-paclitaxel combi-
nation regimen, which was more effıcacious than paclitaxel (equimolar dose).
CONCLUSION: PDAC-PDXs growing orthotopically in the pancreas of mice
provide a valuable tool for the preclinical exploitation of novel therapeutics for
pancreatic cancer. . Supported byAssociazione Italiana per la Ricerca sul Cancro
(AIRC 5 per mille n. 12182) and Fondazione “EugenioMorandi” ONLUS per lo
studio e la cura dei tumori del pancreas.
#3858 Development and characterization of an extensive panel of patient-
derived tumor xenograft models of prostate and bladder cancers. Hervé
Lang,1 Claire Béraud,2 Isabelle Bernard-Pierrot,3 Clémentine Krucker,3 Audrey
Bethry,2 Imène Hamaidi,4 Sabrina Danilin,4 Véronique Lindner,1 Yves Allory,5
François Radvanyi,3 ThierryMassfelder4. 1StrasbourgUniversityHospital, Stras-
bourg, France; 2Urolead, Strasbourg, France; 3UMR144 CNRS – Institut Curie,
Paris, France; 4INSERM U1113 Team 3, Strasbourg, France; 5Hôpital Henri
Mondor, Paris, France.
We have recently published data obtained on the development and the charac-
terization of 30 patient-derived tumor xenografts (PDX) of kidney cancer by xeno-
grafting 336 tumor tissues (Lang et al. Oncotarget, 2016). Here we focused on blad-
der and prostate cancers. Taken together prostate and bladder cancers represent
around 1 700 000 cases and 450 000 deaths per year worldwide. Their incidence is
increasing each year by 1-10%. At early stages, surgery is generally curative, but no
therapies are effıcient at advanced and metastatic stages. PDX faithfully reproduce
the heterogeneity of patient tumors and thus became over the last decade essential
preclinical tools for drug testing and identifıcation of predictive biomarkers. We
obtained bladder and prostate primary tumors tissues from patients at surgery.
Fragments were subcutaneously xenografted in nudemice. After the fırst growth in
mice, they were serially passaged up to passage (P) 10. We also harvested normal
corresponding tissues. Informed consent and clinical history are available for all
patients. We analyzed the stability of the PDX by comparing primary tumors and
tumors grown in mice at different passages. Analysis included growth characteris-
tics, histopathology, molecular profıling, genetic stability (short tandem repeat fın-
gerprinting), and response to therapies. In addition, specifıc features were
also explored for each cancer type including the expression of the androgen
receptor, PSA and pan-cytokeratin for prostate PDXs and hotspot mutations
of FGFR3, PIK3CA, HRAS, KRAS, NRAS for bladder PDXs. We have col-
lected 230 prostate tumors and 130 bladder tumors at all stages and grade
since 7 years, and developed 5 and 25 models ( P3 in mice), i.e. 1 and 20 %
success rate, respectively. The take rate was not correlated to any tumor
features (stage, Gleason scoreÊ). Tumor growth was stable from passage to
passage. All histologic, molecular and genetic analysis confırmed the stabil-
ity of the PDX models compared to the original tumors. Molecular profıling
revealed that less than 5% of genes were differentially expressed between the
primary tumors and tumors grown inmice at various passages. Interestingly,
in bladder PDX, we were able to defıne several molecular subtypes, including
PDX models of the basal subtype as well as PDX with mutated-FGFR3.
Responses to current therapies recapitulated the clinical state. The establish-
ment of prostate and bladder PDX, together with our kidney cancer PDX
panel, constitute one of the largest collection of urological PDX. Since no
active therapies are yet available for these cancers at advanced stages, this
collection should be useful to develop effıcient therapies and for translational
research to reach personalized medicine.
#3859 Effıcacy of capecitabine in chemoresistant PDX established from
triple-negative breast cancerswith residual disease after neoadjuvant chemo-
therapy.ElisabettaMarangoni, Cécile Laurent, FlorenceCoussy, Rania El Botty,
Ludmilla de Plater, Franck Assayag, Sophie Vacher, Ivan Bièche, Fabien Reyal.
Inst. Curie, Paris, France.
Background: triple-negative breast cancer (TNBC) patients with residual disease
following neoadjuvant chemotherapy have a high risk of relapse and poor survival.
Conventional treatments for relapsed patients are limited, particularly, because
standard chemotherapeutic regimens containing anthracyclines and taxanes have
usually already been given in the neoadjuvant settings. Our objectives were 1) to
identify effıcient chemotherapies in patient-derived xenografts (PDX) established
from residual TNBC and 2) to determine feasibility of PDX establishment and drug
testing before tumor recurrence in patients.Methods: tumors from51 patients with
residual disease at surgerywere transplanted in nudemice. EstablishedTNBCPDX
were treated with different chemotherapies used in early stages and metastatic set-
tings: anthracyclines combined to cyclophosphamide (AC), taxanes, platins, cape-
citabine and gemcitabine. Drug responses in PDX were compared to responses in
patients who recurred after surgery and were treated in the metastatic setting. Re-
sults: overall tumor take of residual tumorswas 40%and 75% forTNBC,with 15/20
PDX established, more than twice the tumor take of treatment naïve TNBC (34%).
Median latency time,defınedas time fromimplantation till fırst tumourgrowth,was
only60daysandwas further reduced to3-4weeksduringsuccessive tumorpassages.
On the 8 TNBCPDX evaluated for chemosensitivity, 7 exhibited amultidrug-resis-
tance phenotype with resistance or limited response to AC, taxanes and platins.
Capecitabine, a chemotherapy given in the advanced stage as second or third line,
was effıcient in 5 out of 8 PDX tested with 3 models showing stable disease and 2
models durable tumor regressions. Interestingly, capecitabine effıcacy was de-
creased when xenografts were pre-treated with a fırst line containing platins, sug-
gesting that in some tumors capecitabinemighthave superior activitywhengiven in
the adjuvant setting or as a fırst line. In one third of TNBC patients, time to recur-
rence, comprisedbetween7and12monthsafter surgery,wascompatiblewithxeno-
graft establishment anddrug testing.Conclusions andperspectives:we established a
unique panel of PDXmodels from patients with residual disease after neoadjuvant
chemotherapy. These aggressive PDX recapitulate the resistance phenotype of pa-
tients’ tumors to treatments given inneo-adjuvant andmetastatic settings.We iden-
tifıed capecitabine as effıcient fırst line chemotherapy for residual chemoresistant
PDX. In 30%of cases, PDXmodels could have been used to evaluate chemotherapy
responses before tumor recurrence occur in patients. In order to identify predictive
biomarkers of capecitabine response, additional experiments are ongoing in 25 sup-
plementary TNBC PDX, established from treatment-naïve patients.
#3860 Magnetization transfer and T2-weightedMRI studies are useful for
visualizing phenotypic presentations of orthotopic, patient-derived xeno-
graft mouse models of glioblastoma. Tavarekere N. Nagaraja,1 Rasha
Elmghirbi,1 Susan Irtenkauf,1 Laura Hasselbach,1 Baruch Tawil,1 Stephen L.
Brown,1 Swayamprava Panda,1 Glauber Cabral,1 TomMikkelsen,2 James R. Ew-
ing,1 Ana deCarvalho1. 1Henry Ford Hospital, Detroit, MI; 2Ontario Brain Insti-
tute, Toronto, Ontario, Canada.
Introduction: Patient-derived xenograft (PDX) models for glioblastoma (GBM)
fromresected tumor tissues replicate several features of the original tumor.They are
considered to be representative models to study tumor progression, and to test
responses to putative therapies. Longitudinal noninvasive imaging can be useful in
such investigations. To that end, we employedmagnetic resonance imaging (MRI)
to visualize and measure tumor burden in four different PDX models of GBM.
Experimental procedures: Four orthotopic mouse PDXmodels, HF2587, HF2927,
HF3077andHF3253,developed fromneurosphere culturesof fourdifferenthuman
glioblastoma sampleswere used in the study. The neurosphere cells were implanted
into the right striatum in immunocompromised nudemice (n5-8 permodel) and
allowed to grow for 2-8 weeks, depending on their known growth rates from previ-
ous studies. They were imaged in a Varian 7T MRI system with the following
weightings: T2, T1, magnetization transfer (MT), and contrast enhancedMRI (CE-
MRI) with Magnevist as the contrast agent (CA). Following imaging, all the mice
were sacrifıced and their brains processed for hematoxylin and eosin (H&E) histol-
ogy andhumanmajorhistocompatibility complex (MHC) immunohistochemistry.
Results:Tumormasseswerevisible ashyperintense regionsonMTandT2-weighted
images. The extent of such masses matched the H&E and MHC staining patterns.
Ventricle enlargements seen onMRI in several mice were also confırmed by histol-
ogy. Necrotic cores, when present, were observed on both imaging and on histopa-
thology with good spatial correlations. Surprisingly, post-contrast T1 imaging did
notenhance in the tumormassorperitumorally, except inonemouse inwhichsome
intra-tumoral enhancementwas observed. In all other instances from the four PDX
models tested, enhancement was observed only when the tumor tissue or parts of it
were contiguous with pial or dural vasculature. Conclusions: At 7 Tesla, MT-MRI
and T2-weighted imaging, rather than CE-MRI, appear to be of better utility in
visualizing these PDX models of GBM if MRI is chosen as the imaging modality.
Since the parent tumors imaged at lower fıeld strengths showed contrast enhance-
ment, absenceof a similar feature in thesemodels needs additional studies tounder-
stand their vascular characteristics. Such properties may include low level of vascu-
larization and/or relatively less leaky tumor vasculature. Another possible reason
maybe that themodels tested represent the invasive features ofGBMbetter than the
vascular features, e.g. peritumoral ring enhancement, of larger clinical tumors with
increased exposure to hypoxia.
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#3861 Development of testicular cancer patient derived xenograft models
to test combination therapies targeting PI3K/Akt and MDM2. Gerda de Vr-
ies,1 Ximena Rosas-Plaza,1 Marcel A. van Vugt,1 Albert J.H. Suurmeijer,2 Jourik
A. Gietema,1 Steven de Jong1. 1Department of Medical Oncology, Cancer Re-
search Centre Groningen, University Medical Centre Groningen, Groningen,
Netherlands; 2Department of Pathology, University Medical Centre Groningen,
Groningen, Netherlands.
Metastatic testicular cancer (TC) is highly sensitive to cisplatin-based chemo-
therapy. However, patients with advanced disease in the poor prognosis group
only have a 50% 5-year survival resulting from chemoresistance. Previous data
showed that both the PI3K/Akt pathway and theMDM2/p53 axis are involved in
cisplatin resistance of TC cells. In this study we aim to establish and characterize
TC patient-derived xenografts (PDX) in order to investigate PI3K/Akt and/or
MDM2 inhibition as possible treatment options for TC. Excised and minced
(8mm3) primary TC tissue was implanted subcutaneously into male NSG mice
to obtain a fırst generation PDX model (F1). Animals were sacrifıced when
tumor volume exceeded 1500mm3. The tumorwas harvested andminced. Small
pieces (8mm3) were implanted in a second generation (F2), as well as stored in
FCS-5% DMSO to establish a biobank. In a panel of TC cell lines, combination
treatment of Akt inhibition with or without cisplatin or Nutlin-3a was per-
formed. Cleaved caspase-3 staining was assessed to measure apoptosis, and
western blot was used to determine the effect of different treatments on sub-
cellular localization and phosphorylation status of MDM2.We have established
3 TC PDX models. Histology of the primary tumors included the following
subtypes: mixed germ cell tumors with embryonal- and yolk sac carcinoma and
teratoma components. Engraftment effıcacy was 100% and tumor growth initi-
ated within 4-5 weeks after implantation. Interestingly, we successfully im-
planted a biopsy taken from a metastatic lesion of a patient presenting with
progressive refractory disease after receiving standard chemotherapy. Histology
of the different PDX generations was comparable to the patient material, al-
though a loss of the teratoma component was observed. In our cell line panel,
Akt inhibition usingMK2206 sensitized the acquired cisplatin resistant cell line
TeraCP towards cisplatin treatment, whereas an additive effect was observed in
other cell lines. Combination of Akt andMDM2 inhibition was highly synergis-
tic in apoptosis induction in all cell lines. No relation was observed between the
synergistic effect of Akt combined with MDM2 inhibition and sub-cellular lo-
calization or phosphorylation levels ofMDM2.Taken together, we have success-
fully established 3 TC PDX models, including a chemo-resistant model. The
biobank is currently being expanded. Combined Akt and MDM2 inhibition
resulted in synergistic induction of apoptosis, and these combinations or other
novel therapies will be tested in established TC PDX models. Supported by
Dutch Cancer Society grant RUG 2014-6691 and CONACYT grant 381543
#3862 In vivo chemopreventive of pseudosemiglabrin via inhibition of
tumor angiogenesis and manipulation of hormones in estrogen-responsive
breast cancer. Loiy E. Ahmed Hassan. Faculty of Science and Technology, Om-
durman, Sudan.
Breast cancer is the most frequently diagnosed form of malignancy and the sec-
ond leading cause of death in Western women. Mortality and most of the compli-
cations associated with breast cancer are due to metastasis developing in regional
lymph nodes and in distant organs, including bone, lung, liver and brain. Chemo-
preventive is administration of chemical agents to prevent the initiational and pro-
motional events associated with carcinogenesis. Some chemopreventive agents can
prevent reaction or attackingmolecules by differentways, these agents can suppress
growth factors or signaling pathway. On this study we examined (-)-Pseudosemi-
glabrin (SSG) a natural compound extracted from Tephrosia apollinea on breast
cancercells and tumorvascularization invitroand invivo.Hormonesensitivebreast
cancer cell MCF-7 was found subtitle susceptible to SSG, it showed profound anti-
tumorgeneis via inhibiting breast cancer cellmigration, invasion and colony forma-
tion invitro settings. In silico investigationofpotentialPARP inhibitor, SSGshowed
high binding affınity comparable toRucaparib (standardPARP inhibitor). The nat-
ural compound signifıcantly inhibited the sprouting of new blood vessels in ex vivo
rat aorta ring assay; the antiangiogenic effıcacy is perturbed by targeting VEGF
expression and VEGFR phosphorylation. SSG completely inhibited the onset of
breast cancer in animals pretreated with the compound. Molecular docking study
showed that SSGbinds to active site ofAromatase (the enzyme responsible for a key
step in the biosynthesis of estrogens) with binding affınity better than standard
aromatase inhibitor (Arimidex), moreover the compound has inhibitory activity
against estrogen receptor in the breast cancer cells comparable to Tamoxifen. Our
fındings reveal that (-)-Pseudosemiglabrin can potentially be benefıcial in prevent-
ing breast cancer in high-risk women or it can be adjuvant therapy with standard
chemotherapy or even can be used for the treatment of women who have been
diagnosed with breast cancer.
TUMOR BIOLOGY: Pediatric Cancer 2: Epigenetics and Stem
Cells
#3863 A subset of poorly prognostic pediatric posterior fossa ependymomas
exhibit lowered H3K27me3 and DNA hypomethylation and show epigenetic
similaritieswithH3K27Mmutantdiffuse intrinsicpontinegliomas.SriramVen-
neti,1 Jill Bayliss,1 PialiMukherjee,2 ChaoLu,3 Siddhant Jain,4ChanChung,1Daniel
Martinez,5 Benjamin Sabari,3 AshleyMargol,6 Pooja Panwalkar,1 Abhijit Paroloia,1
Melike Pekmezci,7 Richard Mc Eachin,1 Marcin Cieslik,1 Benita Tamrazi,6 Benja-
minGarcia,8GaspareLaRocca,9Mariarita Santi,5 Peter Lewis,4CynthiaHawkins,10
AriMelnick,2 CDavidAllis,3 Craig B. Thompson,9ArulChinnaiyan,1AlexanderR.
Judkins6. 1UniversityofMichiganMedical School,AnnArbor,MI; 2EpigenomicsCore
Facility,WeillMedical College of Cornell University, NewYork, NY; 3The Rockefeller
University, New York, NY; 4University ofWisconsin, Madison,WI; 5Children’s Hos-
pital of Philadelphia, University of Pennsylvania, Philadelphia, PA; 6Children’s Hos-
pital Los Angeles, Keck School of Medicine University of Southern California, Los
Angeles, CA; 7University of California, San Francisco, San Francisco, CA; 8Perelman
School of Medicine, University of Pennsylvania, Philadelphia, PA; 9Memorial Sloan
Kettering Cancer Center, New York, NY; 10Department of Laboratory Medicine and
Pathobiology, Faculty ofMedicine,University of Toronto, Toronto,Ontario, Canada.
Pediatric posterior fossa ependymomas are poorly understood childhood
brain tumors and have no effective treatments. The biology of these tumors is
obscure as recent sequencing efforts suggest that they lack recurrent genetic
alterations. A subset of these tumors termed PF-A ependymomas exhibits CpG-
island hypermethylation implicating epigenetic alterations in their pathogene-
sis. Through comprehensive analyses of histone modifıcation, we discovered
global H3K27me3 reduction in a subset of these tumors. Tumors with lowered
H3K27me3 showed many clinical and biologic similarities with PFA-
ependymomas. Global reduction inH3K27me3 is likewise observed in pediatric
gliomas that bear histone H3K27M mutations termed diffuse intrinsic pontine
gliomas (DIPG) that also arise in the posterior fossa of young children. Analyses
of ependymomas with reduced H3K27me3 and H3K27M mutant DIPGs
showedmany similarities inDNAmethylation and enrichment ofH3K27me3 in
many genomic loci important for neuroglial specifıcation. Combined integra-
tive analysis of both tumor types uncovered common epigenetic deregulation of
select factors that control radial glial biology and radial glia in the developing
posterior fossa showed reduced H3K27me3. Finally, PF ependymomas with
loweredH3K27me3weremore invasive radiologically and exhibited poor prog-
nosis in three independent cohorts (P0.001 in all three cohorts, collective
n300). These data have clinical implications for biomarker development and
to inform epigenetic approaches to treat PF ependymomas.
#3864 Combined targeting of the EWS/ETS transcriptional program by
blocking epigenetic readers and transcription initiation in Ewing sarcoma.
Tim Hensel,1 Chiara Giorgi,2 Fiona Becker-Dettling,1 Julia Calzada-Wack,3
Frauke Neff,3 Oxana Schmidt,1 Shudong Wang,4 Beat W. Schäfer,2 Stefan Bur-
dach,1 Günther HS Richter1. 1Laboratory for Functional Genomics and Trans-
plantation Biology, Children’s Cancer Research Centre and Department of Pedi-
atrics, Munich, Germany; 2Department of Oncology and Children’s Research
Center, University Children’sHospital, Zurich, Switzerland; 3Helmholtz Zentrum
München, - German Research Centre for Environmental Health (GmbH),
Neuherberg, Germany; 4School of Pharmacy and Medical Sciences, University of
South Australia, Adelaide, Australia.
Introduction: Previously, we reported blocking of BET bromodomain bind-
ing proteins (BRDs) by use of an inhibitor (JQ1) and the associated strong
down-regulation of the predominant EWS-ETS protein EWS-FLI1 in Ewing
sarcoma (ES). Here we analyzed in depth the mechanistic effects of this treat-
ment by EWS-FLI1 interaction studies and the evaluation of possible combined
targeting. Experimental procedures: Function of BRDs was analysed by applica-
tion of specifıc inhibitors (JQ1, I-BET151), RNA interference (RNAi) with the
generation of stable and inducible knockdowns or knockouts by the generation
of BRD4 CRISPR/Cas9 cell lines. To analyse the resulting changes Co-IP, ChIP-
qPCR, RT-PCR, western blotting, cell cycle analysis, proliferation and invasion
assays, whole transcriptome analysis via microarrays as well as xenograft mouse
models were utilized. Results: By use of JQ1 or iBET we strikingly observed a
strong down-regulation of the predominant EWS-ETS protein EWS-FLI1 and
subsequent microarray analysis revealed JQ1 treatment to block the typical ES
associated expression program. The effect on this expression program was par-
tiallymimicked by RNAi for BRD3 or BRD4 but not by BRD2.However, knock-
out studies of BRD4 by CRISPR/Cas9 as well as knockdowns of individual
BRD2, 3 or 4 did not recapitulate JQ1-mediated proliferation restrictions and
blockade and tumor development in xenograft mice as observed for JQ1. How-
ever, co-immunoprecipitation experiments revealed an DNA independent in-
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teraction of BRD4 with EWS/FLI1 and further interaction with CdK9. Treat-
ment of ES cells with a specifıc CDK9 inhibitor demonstrated a rapid down
regulation of EWS-FLI1 expression and block of contact dependent growth.
Furthermore, CDK9 inhibition induced apoptosis in ES as depicted by down
regulation of XIAP and CFLAR and consequently cleavage of Caspase 8, PARP
and increased CASP3 activity, similar to JQ1. Combined treatment of ES with
BRD and CdK9 inhibitors was more effective than individual drug application.
Conclusion: Translocation driven tumors such as ES are very susceptible to
combined treatment with epigenetic inhibitors. Here we demonstrate that treat-
ment with inhibitors targeting the p-TEFb complex could interrupt communi-
cation between EWS-FLI1, BRD4 and CDK9 further impeding EWS-ETS tran-
scriptional activity and its associated pathognomonic expression program.
#3865 Targeting the epigenetic modifıer HMGA2 in lethal adult and pe-
diatric gliomas inhibits invasion, growth and tumorigenicity. Harpreet
Kaur,1 Sabeen Z. Ali,1 Huizi Guo,1 Sepehr Akhtarkhavari,1 Fausto Rodriguez,2
Charles G. Eberhart,2 Eric H. Raabe1. 1Department of Oncology, Johns Hopkins
Univ. School of Medicine, Baltimore, MD; 2Department of Pathology, Johns Hop-
kins Univ. School of Medicine, Baltimore, MD.
Glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) are highly
infıltrative, incurable adult and pediatric brain tumors characterized by the pres-
ence of tumor stem-like cells. Although GBM and DIPG have different epige-
netic drivers, we found increased expression of an epigenetic modifıer and stem
cell factorHMGA2 in both tumors by immunohistochemistry andwestern blot-
ting. HMGA2 is a DNA-binding protein that regulates transcription during
normal embryogenesis and in cancer stem cells. We hypothesized that HMGA2
contributes to high grade glioma tumorigenicity through its ability to alter the
transcription of many genes. Lentiviral short hairpin RNA (shRNA)-mediated
reduction of HMGA2 in multiple patient-derived GBM cell lines signifıcantly
reduced invasion in transwell assay (shHMGA2 vs. shControl, P0.01). Simi-
larly, shRNAmediated suppression of HMGA2 in DIPG cell lines reduced pro-
liferation (BrdU incorporation), reduced invasion (transwell assay), inhibited
clonogenicity (soft agar assay) and increased apoptosis (cleaved caspase-3 im-
munofluorescence, shHMGA2 vs. shControl, P0.001). Pharmacological inhi-
bition ofHMGAproteins using theDNAminor-groove binding drugNetropsin
signifıcantly inhibited invasion (transwell assay), decreased proliferation (BrdU
incorporation) and increased apoptosis of DIPG neurospheres (P0.01). Mice
bearing orthotopic GBM xenografted cells transduced with HMGA2 shRNA
lived signifıcantly longer (108 days) compared to control shRNA (67.5 days,
P0.0001 by log-rank analysis). To investigate the mechanism of HMGA2-
mediated malignancy, we discovered high levels of CD44 (a knownmediator of
invasion and stemness) that correlated with high HMGA2 expression in DIPG
and GBM tumors. Suppression of HMGA2 led to decreased CD44 expression
while ectopic expression of HMGA2 increased CD44 expression in GBM cell
neurospheres. Knockdown of CD44 in HMGA2-high GBM neurospheres re-
duced invasion (P0.01). Our studies suggest an oncogenic role ofHMGA2 and
its downstream effectors in gliomas and identify this important pathway as a
potential therapeutic target. We conclude that minor groove binding agents
similar to Netropsin may be effective agents for HMGA2-expressing pediatric
and adult high grade gliomas.
#3866 Investigating the role of class I HDACs in Ewing sarcoma pathol-
ogy. Kristina von Heyking, Tim Hensel, Julia Singer, Oxana Schmidt, Stefan
Burdach, Günther H. Richter. Technische Universität München, Munich, Ger-
many.
Introduction: Recent evidence demonstrated that a lowmutation rate seems a
general feature of pediatric cancers. Ewing sarcoma (ES) is defıned by balanced
chromosomal EWS/ETS translocations, which give rise to oncogenic chimeric
proteins (EWS-ETS). Other contributing somatic mutations involved in disease
development have only been observed at low frequency. Thus, cancer in children
is not solely a genetic disease and can neither be understood nor cured presum-
ably without epigenetics. Previously, we identifıed the histone methyl-trans-
ferase enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), the
enzymatic subunit of the polycomb PRC2 complex, to be over-expressed in ES.
RNA interference of EZH2 suppressed tumor development and metastasis in
vivo and microarray analysis of EZH2 knock down revealed an EZH2-main-
tained, undifferentiated, reversible phenotype in ES. Experimental procedures:
The role of class I histone deacetylases (HDACs) was determined using different
potent inhibitors like Trichostatin A (TSA), Romidepsin (FK22), Entinostat
(MS-275) and PCI-34051 as well as a CRISPR/Cas9 approach to knock out
specifıcHDACs. To analyze resulting changes qRT-PCR,WesternBlotting, pro-
liferation, apoptosis and invasion assays as well as immunofluorescence exper-
iments were deployed. Results: Interestingly, the effects of gene silencing after
RNA interference of EZH2 could be mimicked by treatment of ES with TSA or
MS-275. Microarray analysis revealed that treatment with MS-275 or TSA re-
sulted in the induction of a similar pattern of differentiation genes as was previ-
ously observed after EZH2 blockade and seems to be dependent on histone
deacetylase (HDAC) activity. Furthermore, in proliferation assays ESweremore
susceptible to treatment with HDAC inhibitors than other small round blue cell
tumors such as neuroblastoma or pediatric cALL cells. Treatment of enzymatic
inhibitors blocking EZH2 activity could not mimic the results observed after
EZH2RNA interference indicating that EZH2-containingPRC2 complexesmay
serve as a building block of class I HDAC activity in ES. Conclusion: Class I
HDACs seem to be important mediators of the pathognomonic EWS-ETS-me-
diated transcription program in ES and thus interesting new treatment oppor-
tunities for this malignant disease.
#3867 Epigenetic siRNA and chemical screens identify SETD8 inhibition
as a therapeutic strategy to reactivate p53 in high-risk neuroblastoma. Ve-
ronica Veschi,1 Zhihui Liu,1 Ty C. Voss,1 Laurent Ozbun,1 Berkley Gryder,1
Chunhua Yan,1 Ying Hu,1 Anqi Ma,2 Jian Jin,2 Sharlyn J. Mazur,1 Norris Lam,1
Barbara K. Souza,1 Giuseppe Giannini,3 Gordon L. Hager,1 Cheryl H. Arrow-
smith,4 Javed Khan,1 Ettore Appella,1 Carol Thiele1. 1National Institutes of
Health, Bethesda,MD; 2Icahn School ofMedicine atMount Sinai, New York, NY;
3University la Sapienza, Rome, Italy; 4University of Toronto, Toronto, Ontario,
Canada.
Neuroblastoma (NB) is considered a failure of sympathoadrenal differentia-
tion. High-risk neuroblastoma (HR-NB) is an aggressive pediatric tumor ac-
counting for 15% of all pediatric oncology deaths. Less than 50% of HR-NB
patients have long-term survival, despite intense multimodality treatment.
Given the paucity of druggable mutations and fındings that epigenetic drivers
contribute to NB tumorigenesis, we undertook a chromatin-focused siRNA
screen to uncover epigenetic regulators critical for survival of high-risk NBs. Of
the 400 genes analyzed, high-content Opera imaging identifıed 53 genes whose
loss of expression led to signifıcant decreases in NB cell number with 16 also
inducing differentiation. A screen with 21 epigenetic compounds in 8 NB cell
lines and 2 non-transformed cell lines prioritized those siRNA hits with active
tool compounds in the drug development pipeline. This revealed UNC0379
(targets SETD8) inhibitedNB cell growth and identifıed SETD8 as an important
and druggable NB target. SETD8 is the H4K20me1 methyltransferase which
regulates DNA replication, chromosome condensation and gene expression.
Analysis of primary NB revealed that high expression of SETD8 is associated
with poor prognosis inNB (R2platformex.Kocak; p1.4e-07). Levels of SETD8
were not signifıcantly different between Stage 4 MYCN-amp compared to
MYCN-WT tumors but high SETD8 levels were only associatedwith poor prog-
nosis in the Stage 4MYCN-WT(p0.03). To understand SETD8-mechanism of
action, we performed RNA-seq transcriptome analyses after genetic or pharma-
cological inhibition of SETD8. Ingenuity PathwayAnalysis revealed that SETD8
ablation rescued p53 pro-apoptotic and cell-cycle arrest functions by activating
the canonical p53 pathway. Functional studies showed SETD8 methylates p53
(K382) leading to its inactivation. Levels of p53K382me1 are higher in
MYCN-WTNB cell lines compared to those with MYCN-amp. Less than 2% of
NB tumors have p53mutations butmultiplemechanisms have been identifıed in
MYCN-amp NB that functionally inactivate p53. This study identifıed that
SETD8 inactivates p53 in NB andmay be an importantmechanism to inactivate
p53 in MYCN-WT HR-NB. This subgroup represents 60-70% of HR-NB tu-
mors. SETD8 inhibition led to increases in caspase-dependent cell death only in
p53-WT but not -mutant or -null NB cells. Genetic rescue experiments con-
fırmed that SETD8-induced cell death is p53 dependent and p53K382 is impor-
tant for this activity. Our in vivo xenograft NB models, showed that genetic or
pharmacologic (UNC0379) inhibition of SETD8 confers a signifıcant survival
advantage. This work identifıes that SETD8 is a novel therapeutic target and its
inhibition may be especially relevant for the subset of high-risk NB tumors with
wildtypeMYCN. This is the fırst in vivo preclinical study showing that targeting
SETD8 inhibits tumor growth.
#3868 The stem cell factor LIN28B regulates proliferation and apoptosis
in diffuse intrinsic pontine glioma. Huizi Guo,1 Sepehr Akhtarkhavari,1
Charles G. Eberhart,2 Harpreet Kaur,1 Eric H. Raabe1. 1Department of Oncology,
JohnsHopkins University, Baltimore,MD; 2Department of Pathology, JohnsHop-
kins University, Baltimore, MD.
Diffuse Intrinsic PontineGlioma (DIPG) is an incurable, invasive and aggres-
sive pediatric brain tumor. Identifying molecular markers that regulate tumor
growth and invasion are needed for developing effıcient treatment strategies.
LIN28B is a stem cell factor expressed during normal fetal development and
re-expressed in cancer cells. We had previously shown that LIN28A, another
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family member of LIN28 proteins, regulates invasion and tumorigenicity in
adult high grade gliomas.We observed increased LIN28B expression in patient-
derived DIPG neurosphere cell lines using western blotting. We hypothesized
that LIN28B promotes proliferation and prevents apoptosis in DIPG. Using two
different lentiviral transduced short hairpin RNAs (shRNA), we suppressed
LIN28B protein levels in DIPG neurospheres, as confırmed by western blotting.
DIPG neurospheres that have been treated with LIN28B shRNA showed re-
duced proliferation asmeasured byBrdU incorporation (P0.01) and increased
apoptosis as measured by cleaved caspase-3 (CC-3) expression (P0.01). To
determine themolecularmechanism of LIN28B-mediated phenotypes inDIPG,
we studied the canonical downstream effector of LIN28B calledHMGA2, which
is a DNA-binding protein that functions as a transcriptional regulator. Using
western blotting, we found decreased HMGA2 protein levels in DIPG neuro-
spheres infected with LIN28B shRNA. Taken together, our results suggest that
LIN28B is important for promoting DIPG cell proliferation and preventing
apoptotic cell death. Additionally, we also found that LIN28B regulatesHMGA2
expression in DIPG neurospheres. Future studies will focus on expanding our
understanding of the molecular mechanisms of LIN28B-regulated malignancy
in DIPG.
#3869 Cell surface vimentin targeted mAb 86C increases sensitivity to
temozolomidemediated cell death in glioma stem cells.Hyangsoon Noh, Jun
Yan, Konrad Gabrusiewicz, Shulin Li.M.D. Anderson Cancer Center, Houston,
TX.
Glioblastomamultiforme (GBM) is one of themost aggressive brain tumor in
pediatric patients. The current standard of care including radiation and chemo-
therapy is not effective inmost patients due tomultiple factors such as resistance
and poor blood-brain barrier (BBB) penetration. The development of strategies
to reduce resistance and to increase sensitivity to chemotherapymay ameliorate
the problems. Glioma stem cells (GSCs) are considered the source of relapse and
chemoresistance. Sensitization of temozolomide TMZ resistance in GSC is
therefore integral for therapeutic effıcacy. Our lab has discovered that cell sur-
face vimentin (CSV) is presented on patient-derived GSCs. In this study, we
demonstrate that the treatment of GSCs with anti-CSV antibody (86C) sensi-
tizes them to TMZ. We found that the combination of 86C and TMZ induced
additional antitumor effects in 8 out of 12 GSCs. Mechanistic study of the four
resistance GSCs revealed slow re-surface rate of CSV from CSV- GSCs and low
CSV expression on GSCs as possible contributing factors. GSCs with rapid CSV
resurfacing fromCSV-GSCswasmore sensitive to combination treatment com-
pared to GSCs with a slow recovering from CSV- GSCs. Furthermore, the me-
tabolism study shows these four resistance cells have high intrinsic mitochon-
dria activity compared to sensitive cells. The combination of TMZwith 86Cmay
represent a valuable strategy to reverse GSC chemoresistance.
#3870 Clonal evolution of medulloblastoma BTICs in response to ther-
apy. David Bakhshinyan, Thusyanth Vijayakumar, Chitra Venugopal, Mohini
Singh, Maleeha Qazi, Sujeivan Mahendram, Sujeivan Mahendram, Branavan
Manoranjan, Nicole McFarlane, Ashley Adile, Sheila Singh. McMaster Univer-
sity, Hamilton, Ontario, Canada.
Medulloblastoma (MB) is the most common malignant pediatric brain tu-
mour. Global gene expression arrays performed on human MBs have divided
this tumour entity into 4 distinctmolecular subgroups. Out of all the subgroups,
Group 3 patients face the highest incidence of leptomeningeal spread and overall
patient survival of less than 50%.Current clinical trials for recurrentMBpatients
based on genomic profıles of primary, treatment-naïve tumours, provide limited
clinical benefıt since recurrent metastatic MBs are highly genetically divergent
from their primary tumors. By adapting the existing COG (Children’s Oncology
Group) Protocol for children with newly diagnosed high-risk MB for treatment
of immuno-defıcient mice intracranially engrafted with human MB brain tu-
mour initiating cells (BTICs), we aim to identify and characterize the rare treat-
ment-refractory cell population inGroup 3MBs.MB cell populations recovered
separately from brains and spines at (i) engraftment; (ii) post-radiation; (iii)
post-radiation and chemotherapy; and (iv) recurrence, during the course of
tumor development and therapy were comprehensively profıled for gene ex-
pression analysis, stem cell andmolecular features to generate a global, compar-
ative profıle of MB cells through therapy to relapse. One of the most intriguing
observations from our gene expression data was consistent over-expression of
proteins belonging to Inhibitor of DNA-binding/differentiation (ID) family,
transcription factors with a basic helix-loop-helix motif that act as suppressors
cellular differentiation and a longevity associated protein bactericidal/permea-
bility-increasing fold-containing-family-B-member-4 (BPIFB4) in our refrac-
tory population. The persistent upregulation of genes preserving undifferenti-
ated state and cellular longevity further strengthens the hypothesis of stem-cell
like cells driving tumor relapse in MB. We then set out to determine whether
genes upregulated at relapse correlated with patient outcome in our therapy-
adapted patient-derived xenograft model. Interestingly, the upregulation of the
top 90 genes in our relapse cohort was predictive of worse overall survival in
patients with group 3MB. In the next set of experiments, through application of
cellular barcoding technologywe determined howMBBTICs evolve in response
to therapy by tracking unique vector DNA sequences integrated at a single copy
level into individual cells. Our differential genomic profıle of the “treatment-
responsive” tumors against those that fail therapy will thus contribute to discov-
ery of novel therapeutic approaches for the most aggressive subgroup of MB.
#3871 Modeling the chromatin and transcriptional landscape ofMYCand
MYCN driven neuroblastoma in zebrafısh. Mark W. Zimmerman,1 Shuning
He,1 Shizhen Zhu,2 Song Yang,3 Yi Zhou,3 Leonard I. Zon,3 A Thomas Look1.
1Dana-Farber Cancer Institute, Boston, MA; 2Mayo Clinic, Rochester, MN; 3Bos-
ton Children’s Hospital, Boston, MA.
Elevated expression levels of MYC family genes are frequently observed in
human cancer cells and correlatewith tumor aggressiveness and poor prognosis.
In neuroblastoma 40% of all cases are high-risk, of which 20% harbor amplifı-
cation of the MYCN proto-oncogene. In high-risk cases lacking MYCN gene
amplifıcation, high expression levels of c-MYC (MYC) are often present and are
associated with unfavorable histology and a poor survival. Unlike MYCN am-
plifıcation, which is frequently observed in the presence of segmental chromo-
somal aberrations, MYC overexpression is not associated with genetic abnor-
malities or somaticmutations. In order to study this newly defıned subgroup, we
have created a novel transgenic zebrafısh model in which overexpression of
MYC alone in the peripheral sympathetic nervous system (PSNS) drives early-
onset neuroblastoma in nearly every fısh by seven weeks of age. The tumors
resulting from MYC overexpression arise in the interrenal gland, which is the
fısh counterpart of the adrenal medulla, and are histologically identical to hu-
man neuroblastoma. We next performed the Assay for Transposase Accessible
Chromatin (ATAC) sequencing and RNA-seq to identify open chromatin re-
gions that correlate with activation of gene transcription. Lineage specifıc genes
essential for neuronal precursor cell identity, such as PHOX2B, HAND2, and
TFAP2A are highly expressed in both MYC-expressing and MYCN-amplifıed
human neuroblastoma cell lines and are actively transcribed in zebrafıshmodels
of MYC and MYCN driven neuroblastoma. Furthermore, these studies reveal
shared and differential regulatory of effects ofMYC relative toMYCNactivity in
maintaining the malignant phenotype of neuroblastoma in vivo. Additional
insight into the mechanisms of aberrant transcriptional regulation will inform
the future design and use of therapeutic strategies targeting transcription in this
high-risk malignancy of childhood.
#3872 Retinoic acid (RA) relieves EZH2-mediated epigenetic suppression
in high-risk neuroblastoma (HR-NB). Deblina Banerjee, Zhihui Liu, Doo-Yi
Oh, Maggie Cam, Bong-Hyun Kim, Carol Thiele. National Cancer Institute,
Bethesda, MD.
High risk neuroblastoma tumors (HR-NB) are characterized by the presence
of undifferentiated histopathology, while tumors from low risk patients have
histologic evidence of differentiation and a transcriptome enriched in differen-
tiation genes. Determining the cellular and molecular underpinnings that con-
tribute to this undifferentiated state will lead to better understanding of the
disease pathogenesis. Retinoic acid (RA) is known toprime embryonic stemcells
for lineage specifıc differentiation. To elucidate the early events important for
reprogramming of NB cells leading to changes in the degree of cellular differen-
tiation, we treatedHR-NB cells (KCNR :MYCN amplifıed) with 5MRA for 24
hrs. RNA-Seq analysis, to assess early changes in the transcriptome, showed
signifıcant changes in gene expression [2fold-up-regulated-446, 2fold-down-
regulated-250, FDR0.01] which were enriched for biological functions like
neuron projection, neuron differentiation, indicating onset of neurogenesis as a
marker of differentiation. Gene set enrichment analysis identifıed signifıcant
positive enrichment of NB differentiation (p0.001) and PRC2 (Polycomb Re-
pressor Complex2) gene sets (p0.02) along with downregulation of MYCN
signature gene set (p0.001). PRC2 component EZH2 (Histone Methyltrans-
ferase) is highly expressed in NB and represses differentiation genes. Though,
EZH2 protein levels did not change after treatment, RA caused 40% reduction in
H3 bound EZH2. To gain insight into how this reduction affects subsequent
gene expression; we evaluated changes in genome wide binding of EZH2 and
H3K27me3 after treatment. Indeed, signifıcant correlation was observed be-
tween the changes in expression levels of genes after RA treatment and relative
binding of EZH2 (p3.88e-6) and H3K27me3 (p3.88e-6) at their promoter
regions. One-third (n147) of the upregulated genes (eg. HEY1, RARB) and
half (n117) of the downregulated genes (eg. INSM2, CAMK4) were EZH2
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targets. Upregulated genes were related to biological functions like negative
regulation of cell growth and transcription, nervous system development. To
probe the underlying mechanism, in-silico analysis indicated RA decreased
Wnt/ß-catenin, eNOS and PTEN pathways while stimulating cAMP, Integrin
linked kinase and G-coupled protein pathways. Evaluation of the cAMP path-
way candidates identifıed 13 genes as EZH2 targets. eg CNR1, DUSP6, PKIA,
RSG4. In primary NB tumors, microarray studies indicate that low levels of
CNR1 and DUSP6 are associated with poor prognosis. RA stimulates 10-fold
and 2-fold increases in CNR1 and DUSP6 levels, respectively. RA treatment
inhibits EZH2 binding to its target genes thereby activating pathways involved
in reprogramming of HR-NBs to a more differentiated state. Studies are under-
way to further evaluate the molecular mechanism leading to decreased EZH2
binding upon RA treatment.
#3873 Novel non-genetic mechanisms drive rhabdomyosarcoma tumori-
genesis. Justina McEvoy,1 Michael Dyer,2 Xiang Chen2. 1University of Arizona,
Tucson, AZ; 2St. Jude Children’s Research Hospital, Memphis, TN.
Most pediatric solid tumors originate from perturbations during develop-
ment, however themechanisms that drive these disruptions and promote tumor
progression are still poorly understood.We believe that epigenetic deregulation
of cancer genes and developmental pathways is a common driver in pediatric
cancers, especially those with a lowmutation rate. To test this novel idea, we are
focusing on rhabdomyosarcoma (RMS), a developing muscle tumor with strik-
ing genetic differences between two of the major subtypes. We hypothesize that
differential epigenetic deregulation of differentiation programs and cancer
genes between the major subtypes are essential for tumorigenesis. Indeed, our
preliminary integrative analysis reveal distinct epigenetic landscapes between
the two subtypes particularly at the loci of HOX cluster genes A-C, including an
oncogenic HOXC long non-coding RNA (lncRNA) called HOTAIR. Knock-
down of HOTAIR led to derepression of HOXD10, a candidate tumor suppres-
sor, and a decrease in RMS proliferation, migration, and invasion. Thus, we
believe HOX gene deregulation is required for tumorigenesis, and their impli-
cation in several adult cancers suggests this currently unappreciatedmechanism
is likely to be more broadly relevant. In addition, we identifıed a group of RMS
specifıc novel lncRNAs, of which one demonstrates an essential role in cell
survival. Our innovative approach to integrate epigenetic data sets from tumor
types with varying genetic differences shed light on the mechanisms that drive
tumorigenesis, which may lead to identifying previously unknown potential
therapeutic targets. Since current therapeutic options have not changed over the
last twenty-fıve years, these data will especially provide a strong translational
impact for children with RMS, whose survival outcomes are less than 20% in the
case of metastatic disease.
#3874 Epigenetic deregulation of SOCS5 expression in T cell lineage acute
lymphoblastic leukemia.Nitesh Sharma,1 Huining Kang,2 Christian C. Nickl,1
Scott A. Ness,2 Stuart S. Winter,1 Ksenia Matlawska-Wasowska1. 1University of
NewMexico Health Sciences Center, Albuquerque, NM; 2University of NewMex-
ico Comprehensive Cancer Center, Albuquerque, NM.
For children, adolescents and young adults with T-lineage acute lymphoblas-
tic leukemia, event free survival following relapse is10%. A variety of hema-
tologicmalignancies activate JAK-STAT signaling through activatingmutations
in JAK1-3, IL7R and downregulation of negative regulators. SOCS5 belongs to
the suppressor of the cytokine signaling (SOCS) family, which are known cyto-
kine-inducible negative regulators of JAK-STAT and other signaling pathways.
SOCS5 is involved in negative regulation of Th2 development. However, the
roles of SOCS5 in blood cancer, in particular T-ALL have not been elucidated so
far. Using Affymetrix U133 Plus 2.0 microarray we assessed SOCS5 expression
levels in a cohort of 100 T-ALL samples derived from AALL0434 COG study.
SOCS5 was deregulated in T-ALL cells, and its expression was lowered in cases
harboringMLL gene rearrangements (MLL-R) compared to the remaining cases
(P 0.0001). Because we did not identify any mutations in SOCS5 gene in the
cohort of 100 cases, we hypothesized that SOCS5 expression is regulated by
aberrant DNA methylation in T-ALL. Using methyl-specifıc PCR (MS-PCR)
and bisulfıte sequencing we found that SOCS5 expression is regulated by pro-
moter/1st exon CpG island methylation in T-ALL. CCRF-CEM and ALL-SIL
cells, and selected primary T-ALL samples showed hypermethylation in pro-
moter/1st exon region corresponding to lower levels of SOCS5 expression. In
contrary, Koptk1 and PF382 cells, and T-ALL samples with higher levels of
SOCS5 had hypomethylated SOCS5 promoter/1st region. SOCS5 transcript and
protein expression were induced by DNA demethylating agent, 5-azacitidine in
ALL-SIL and CCRF-CEM cells (P 0.0001). The increase in SOCS5 expression
was correlated with its promoter demethylation as shown by MS-PCR. SOCS5
mRNA and protein levels were also increased in ALL-SIL cells transduced with
DNMT1 shRNA compared to negative control (P  0.0001) indicating that
inhibition of DNA methyltransferase activity restores SOCS5 expression in T-
ALL. To assess whether histone deacetylation is involved in epigenetic regula-
tion of SOCS5 expression, we treated CCRF-CEM and ALL-SIL cells with
deacetylase inhibitor Trichostatin A (TSA). Treatment with TSA restored his-
tone acetylation and caused upregulation of SOCS5 (P  0.0001). We next
examined the effects of SOCS5 on leukemogenesis by shRNA-mediated knock
down of SOCS5 in KoptK1 and PF382 cells. Silencing of SOCS5 increased cel-
lular proliferation as shown by an increase in T-ALL cell number (P 0.0001).
Reduced expression of SOCS5 led to an increase in MYC, IL4, IL4R, IL7R
expression and STAT6 activation. These results indicate that SOCS5 is epige-
netically deregulated in T-ALL. Future studies are required to evaluate the tu-
mor suppressor roles of SOCS5 in a subset of T-ALL, in particular, in MLL-R
cases via the regulatory effect on cytokine and growth factor receptor signaling.
#3875 SSX drives gain-of-function BAF complex chromatin affınity and
genomic targeting in synovial sarcoma.Matthew J. McBride,1 John L. Pulice,1
Robert T. Nakayama,1 NazarMashtalir,1 Davis R. Ingram,2 Jack F. Shern,3 Javed
Khan,3 Jason L. Hornick,4 Alexander J. Lazar,2 Cigall Kadoch1. 1Dana Farber
Cancer Institute and Harvard Medical School, Boston, MA; 2The University of
Texas MD Anderson Cancer Center, Houston, TX; 3Genetics Branch, National
Institutes of Health, Bethesda, MD; 4Brigham and Women’s Hospital, Boston,
MA.
Synovial sarcoma (SS) is a soft-tissue malignancy driven by a recurrent chro-
mosomal translocation (t(X;18)) that uniformly produces the SS18-SSX onco-
genic fusion protein. SS18 is a core subunit of the mammalian SWI/SNF (BAF)
complexes, which remodel nucleosomes in an ATP-dependent manner and an-
tagonistically oppose gene-silencing activity of polycomb complexes to main-
tain transcriptional control throughout development and differentiation. We
previously discovered that in SS, incorporation of the oncogenic SS18-SSX fu-
sion into BAF complexes leads to eviction of the tumor-suppressor BAF47
(INI1/SMARCB1) subunit, and aberrant activation of polycomb target genes by
displacement ofH3K27me3-mediated repression.However, uncoupling the on-
cogenic consequences of two co-occurrent BAF complex perturbations, gain of
78- amino acids to SS18 and loss of BAF47 has remained a challenge for the fıeld;
understanding gain- versus loss-of-function properties of these molecular
events is critical to the identifıcation of effective targeted therapeutics for this
patient population. Here we show that synovial sarcoma primary tumors and
cell lines harbor a transcriptional signature markedly distinct from sarcomas
such as malignant rhabdoid tumors, which are driven solely by biallelic loss of
BAF47. Indeed, we show that SS18-SSX-containing BAF complexes exhibit dis-
tinct chromatin localization in that suppression of SS18-SSX results in a near
complete genome-wide retargeting of BAF complexes. We fınd that SS18-SSX
directs BAF complexes to polycomb-repressed sites to activate embryonic de-
velopment and neuronal gene pathways hallmark to SS primary tumors. Strik-
ingly, using biochemical affınity assays, we demonstrate that the SSX 78aa tail
dramatically increases the affınity of BAF complexes for chromatin as well as
their genomic footprint sizes uponChIP-seq analyses. This is in stark contrast to
the demonstrated decrease in chromatin affınity and genomic occupancy result-
ing from the loss of function of BAF47 inMRT.Moreover, using CRISPR/Cas9-
mediated KOof BAF47 in SS cell lines, we show that the proliferative arrest of SS
cell lines upon suppression of SS18-SSX is independent of the BAF47 reassembly
into BAF complexes, thereby demonstrating a unique SSX-driven oncogenic
mechanism distinct from BAF47 loss. Taken together, these studies uncover a
novel functionality of the SSX tail that is required for SS oncogenesis, and inform
the selection of appropriate targeted therapeutic agents for this gain-of-function
BAF complex-driven cancer.
#3876 Active enhancers delineate intra-tumor heterogeneity of develop-
mental states in neuroblastoma. Johan van Nes, Tim van Groningen, Linda J.
Valentijn, Danny Zwijnenburg, Jan J. Molenaar, Bart A. Westerman, Ellen M.
Westerhout, Mohamed Hamdi, Godelieve A. Tytgat, Jan Koster, Rogier Ver-
steeg. Academic Medical Center, Amsterdam, Netherlands.
Background: Cellular heterogeneity within tumors is increasingly recognized
as a source of therapeutic failure.However, the cis-regulatory landscapes driving
transcriptional states of intra-tumor heterogeneity, drug-resistance and relapse
remain elusive. Results: Here, using H3K27Ac chromatin immunoprecipitation
followed by sequencing (ChIP-seq) we characterized the active super-enhancer
(SE) landscape in neuroblastoma, a pediatric cancer of the sympathetic nervous
system. Analysis of differentially active SEs identifıed cis-regulatory modules
associated with distinct transcriptional states in material derived from individ-
ual patients. These transcriptional states associated with two phenotypically
divergent cellular subtypes. One subtype is referred to as adrenergic (ADN) and
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expresses classic neuroblastoma markers from the peripheral sympathetic ner-
vous system. In contrast, the other subtype referred to as mesenchymal (MES)
has similarity to neural crest cells, expresses mesenchymal genes, is motile and
lacks adrenergic markers. In contrast to ADN cells, MES-type cells are resistant
to a wide variety of chemotherapeutics used in clinical management of neuro-
blastoma. Computational reconstruction identifıed core transcription factor
modules associated with ADN- and MES-type cells. DNA binding profıles of
adrenergic TFs MAML3 and GATA3 suggest feed-forward activation of the
adrenergic SE-associatedTFs. Interconversion of FACS-sortedMES- andADN-
type cells is observed in vitro. Induction experiments with the mesenchymal TF
PRRX1 effıciently converted ADN-type cells to an induced-MES (iMES) state.
These iMES cells acquired many features of MES-cells including motility, mes-
enchymal gene expression and -histone modifıcations as well as chemo-resis-
tance. Primary neuroblastoma biopsies included a small fraction of PRRX1-
positiveMES-type cells, as determined by immunohistochemistry. Importantly,
the proportion of both cell types appears dynamic upon therapy and in relapse
development, suggesting selective pressure of treatment. Conclusions: Here we
establish that intra-tumor heterogeneity in neuroblastoma follows a bi-phasic
structure characterized by two different SE-associated TF programs that reflects
stages of the normal developmental programs. The detailed understanding of
core regulatory modules and pathways may redesign strategies for therapeutic
intervention.
#3877 Relationship of DNAmethylation tomutational changes and tran-
scriptional organization in fusion-positive and fusion-negative rhabdomyo-
sarcoma tumors. Wenyue Sun,1 Bishwanath Chatterjee,1 Jack F. Shern,2 Siva-
sish Sindiri,3 Yonghong Wang,3 Holly S. Stevenson,3 Daniel C. Edelman,3 Paul
S. Meltzer,3 Javed Khan,3 Frederic G. Barr1. 1NCI - Laboratory of Pathology,
Bethesda,MD; 2NCI - Pediatric Oncology Branch, Bethesda,MD; 3NCI - Genetics
Branch, Bethesda, MD.
Rhabdomyosarcoma (RMS) is themost common soft-tissue sarcomaof child-
hood and comprises two major subtypes: fusion-positive (FP, most commonly
PAX3-FOXO1 [P3F] or PAX7-FOXO1 [P7F] resulting from 2;13 and 1;13 chro-
mosomal translocations) and fusion-negative (FN). Our previous study demon-
strated that FP and FN RMS tumors exhibit distinct DNAmethylation profıles.
To further examine the signifıcance ofDNAmethylation,we generated genome-
wideDNAmethylation profıles for a new cohort of 48 RMS tumors forwhichwe
previously assessedmutation, copy number and expression status. Investigation
of the RMS subsets defıned by methylation clustering revealed a signifıcant as-
sociation of methylation with P3F versus P7F fusion status in the FP subset, and
an association of methylation with RASmutation status in the FN subset. Local-
ization studies of differentiallymethylated probes showed these probes were not
evenly distributed with respect to annotated genomic features. In particular,
hypomethylated probes were enriched in FP tumors in the promoter region and
in the intergenic region,whereas hypermethylated probeswere enriched in these
regions in FN tumors. In contrast, hypermethylated probes were enriched in FP
tumors in the 3= UTR region whereas hypomethylated probes were enriched in
FN tumors in these regions. In our new larger cohort of cases, there was a
signifıcant difference in the distribution of P3F binding sites between genes with
and without differential methylation. Integrative analysis of P3F binding sites,
promoter methylation and gene expression demonstrated that genes with P3F
binding sites tended to bemore highly expressed in FP tumors (compared to FN
tumors) than genes without P3F binding sites regardless of promoter methyl-
ation status. Though promoter hypomethylation is most highly associated with
enhanced expression among genes with P3F binding sites, the group of genes
with P3F binding sites and promoter hypomethylation is small in number com-
pared to the much larger group of genes with P3F binding sites but without
promoter hypomethylation. In conclusion, these results demonstrate the inter-
action of these epigenetic changes with mutational alterations and transcrip-
tional organization in RMS tumors and provide a direction for future studies of
these epigenetic events.
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#3878 Musashi-2 (MSI2) regulation of ERBB family proteins in non-small
cell lung cancer (NSCLC). Alexander Kudinov,1 Alexander Deneka,1 Anna N.
Nikonova,1 Emmanuelle Nicolas,1 Vladislav A. Korobeynikov,2 Ilya G. Serebri-
iskii,1 John Karanicolas,1 Erica A. Golemis,1 Yanis Boumber1. 1Fox Chase Can-
cer Center, Philadelphia, PA; 2Columbia University, New York, NY.
The purpose of this study is to establish whether a new signaling axis we
recently described can be targeted to improve patient survival in lung cancer,
one of the leading causes of death worldwide, with over 1.6 million deaths an-
nually. Non-small cell lung cancer (NSCLC) is the most common form of lung
cancer. A small number of targeted therapies have been shown to be useful in
lung cancer, including inhibitors of EGFR, but these are typically only active in
a subset of tumors thatmaintain epithelial characteristics.Musashi-2 (MSI2), an
RNA-binding protein that regulates mRNA translation, has been linked to
maintenance of a stem cell state inmultiple hematologic and solid tumormalig-
nancies. We recently established (Kudinov et al, PNAS 2016, PMID:27274057)
that MSI2 is elevated in a subset of NSCLC tumor upon progression and drives
NSCLC metastasis, in part based on activity supporting a TGF-beta/SMAD3/
claudin signaling cascade that enhances epithelial-mesenchymal transition
(EMT). Using reverse phase protein array (RPPA) analysis of MSI2-depleted
versus control KrasLA1/;P53R172H
G/murine NSCLC cell line models identi-
fıed a signifıcant 2.7-fold upregulation of HER3 uponMSI2 depletion. Negative
MSI2-dependent regulation of ERBB3 protein expression was confırmed in
multiple additional murine and human KRAS-dependent NSCLC models,
based on analysis of MSI2 depletion or overexpression. In contrast, MSI2 posi-
tively regulated expression of the EGFR/ERBB1 protein in the same models. In
detailed analysis, we have addressed the mechanism by which MSI2 regulates
expression of the ERBB group of receptor tyrosine kinases. In addition, these
data suggested the hypothesis that MSI2 expression might predict response to
EGFR-targeted inhibitors, and that dual targeting of MSI2 and EGFR might be
therapeutically valuable.We will present data on the activity of EGFR inhibitors
in the context of depleted or elevated MSI2 expression, and the effect of com-
bining inhibition of EGFR with recently developed MSI2 inhibitors. In sum-
mary, these results for the fırst time indicate a role of MSI2 in supporting EGFR
expression in NSCLC and suggest that MSI2 may drive NSCLC development
and progression in part via EGFR, and may modulate response to EGFR-tar-
geted agents.
#3879 Expression of sox2 and oct4 in human oral squamous cell carci-
noma and its relationship with clinical factors. Tetsuya Tamatani, Natsumi
Takamaru, Go Ohe, Keiko Kudo, Takaharu Kudo, Akira Takahashi, Yoshiko
Yamamura, Kenji Fujisawa, Hirokazu Nagai, Youji Miyamoto. Institute of Bio-
medical Sciences, Tokushim Univ Graduate School, Tokushima, Japan.
Background: A cancer stem cell (cancer initiating cell, CSC) is considered
capable of self -replication, self-differentiation, drug resistance, and immune
evasion. Recently, CSC has become increasingly important in the treatment of
malignant tumors. Cancer stem cells express specifıc molecules termed CSC
marker, including sex determining region Y-box2 (SOX2), and octamer-bind-
ing transcription factor 4 (Oct4), and their expression has been reported to be
the potential prognostic values. However, the prognostic values of SOX2 and
Oct4 expression in patients with oral cancer are less understood. [Purpose]The
aims of present study were to evaluate the expression of SOX2 and Oct4 in oral
squamous cell carcinoma (OSCC) and to elucidate the relationships among the
CSC marker expression, clinical stages, histological differentiation, the classifı-
cation of invasionmode, cerebral lymphnodemetastasis, distantmetastasis, and
disease-free survival rate. Materials and Methods: Tissue specimens were ob-
tains from 108 patients with OSCC after surgery or biopsy. Immunohistochem-
istry was used to assess SOX2 and Oct4 protein using at least 10% staining-
positive cells as the defınition of positive staining. Results:
Immunohistochemical analysis of 108 cases showed that 42 cases (39%) ex-
pressed SOX2. There was no signifıcant association between SOX2 expression
and tumor size, invasion mode or histological differentiation. However, there
was signifıcant association between SOX2 expression and distant metastasis or
disease-free survival rate at stage 1 and 2 patients (73 cases). Otherwise, seventy
cases (65%) cases of 108 OSCC patients expressed Oct4. There was signifıcant
association between Oct4 expression and histological differentiation. There was
no signifıcant association between Oct4 expression and tumor size, invasion
mode, metastasis, or disease-free survival rate. Conclusions: These fındings sug-
gested that the expression of SOX2 may be good marker indicating survival in
patients with OSCC.
#3880 Assessment of ALDH activity in neuroblastoma patient-derived
xenograft cells as a potential marker of neuroblastoma stem cells. Camilla
Persson, Kristoffer von Stedingk,Daniel Bexell,MyMerselius, Noémie Braekev-
eldt, Sven Påhlman, Caroline Wigerup. Lund University, Lund, Sweden.
Neuroblastoma is a tumor derived from immature neuroblasts predestined to
form the sympathetic nervous system. Children with aggressive neuroblastoma
are at high-risk of disease relapse despite their initial response to treatment. The
molecular mechanisms underlying these relapses are poorly understood, al-
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though clonal expansion and de novo mutations have been suggested as poten-
tial mechanisms. An alternative hypothesis is that neuroblastoma initiating ca-
pacity and resistance to chemotherapy reside in a subpopulation of tumor
initiating cells or cancer stem cells, which are not genetically different frommost
tumor bulk cells but through unknown mechanisms differ phenotypically and
functionally. Here we examine aldehyde dehydrogenase (ALDH) expression
and activity in neuroblastoma patient-derived xenograft (PDX) cells, cultured
under stem cell-promoting conditions, as a potential marker for neuroblastoma
stem cells. We found that neuroblastoma PDX cells in general expressed higher
levels of various ALDH isoforms as compared to an aggressive classical serum-
grown neuroblastoma cell line. Also, a distinct subgroup with high ALDH ac-
tivity was observed in PDX cells but not in the serum-grown cell line. Growing
the PDX cells in serum induced neuronal differentiation accompanied with
lower expression of ALDH1 isoforms and reduced ALDH activity. The change
in ALDH expression and activity was reversible, implying phenotypic plasticity.
Re-analyzing cells initially sorted on ALDH activity also confırmed an inter-
conversion of cells with low and high ALDH activity. Furthermore, in vitro
clonogenic capacity was signifıcantly higher in cells with high ALDH activity.
Serial in vivo passaging of PDXs allowed us to compare PDX cells isolated from
different in vivo generations. Interestingly, cells derived from later in vivo gen-
erations contained a higher frequency of cells with high ALDH activity. Finally,
orthotopic injection of cells with either low or high ALDH activity showed that
both subgroups led to tumor formation, however a higher tumor take was ob-
served when injecting cells with high ALDH activity. In conclusion, our results
suggest that ALDH activity is associated with an immature phenotype, which is
of clinical importance since less differentiated tumors are more aggressive and
associated with poor prognosis. Also, cells with high ALDH activity showed
higher in vivo tumor initiating capacity. We are currently pursuing a more
extensive characterization of neuroblastoma cells with high ALDH activity.
#3881 The expression of CD98hc might be a marker of radiation resis-
tance in HNSCC. Yohei Kawasaki, Yasufumi Omori. Akita University, Akita,
Japan.
Introduction: Head and Neck squamous cell carcinoma(HNSCC) represents an
aggressive malignancy. Although new advanced therapeutic strategies have been
applied to date, the 5-year survival rate have not been considerably improved. Gen-
erally speaking,highradio-sensitiveHNSCChasgoodprognosis, however, thereare
radio-resistant HNSCC. Recently, Sanne et al, have reported CD98 is one of the
marker of Cancer Stem Cell. Moreover, the over expression of CD98hc is high
associated with different cancers including the colon cancer, renal cancer. CD98 is
heterodimeric protein that comprises a heavy chain and a light chain. The CD98
heavy chain is type 2 linkage to one of 6 amino acid transporters. We hypothesize
that irradiationmay contribute tooverexpressionofCD98hc andexpansionCancer
Stem Cell population in HNSCC. Methods: Cell culture: Ho-1-u-1(Mouth floor),
Sa3(Gingiva),HSC2,HSC3,HSC4(tongue)wereused for this experiment.These cell
lines were exposed to 60Gy (2Gy/day) to establish stable cell lines to radiation.Flow
cytometry: For analysis of CD98-positive fraction, cell pellets were incubated with
FITC-conjugated anti-humanCD98hcmAb at the dilution of 1:11 at 4° for 15min-
.Sphere formation assay: Cells were cultured in a serum-free medium. 1x104 cells
were seeded in 80l of serum free RPMI1640 medium. The recipe of which was
mentioned above. Containing 1.0% agar on 100l of a solidifıed serum free
RPMI1640was poured on the top of eachwell. The cells were incubated for 20 days
in the same atomosphere as that for themonolayer culture.MigrationAssay: Radius
24 well Cell Migration (Cell Biolabs, INC.) were purchased. The experiment was
conducted according to the decided plotocol. Result: In radiation resistant cells,
spindle-shaped and large cytoplasmic cells were founded. After irradiation, the ex-
pression of CD98hc increased in all cell lines. In Ho-1-u-1, the population was
divided into twodistinct subpopulations showingahigher anda lower expressionof
CD98hc. Irradiated cancer cells exhibit an effıcient ability to developed numerous
large sphere. Irradiation had enhanced self-renewal of Cancer StemCells. Cell mo-
tility was higher in radio-resistant cells than their parental cells. Conclusion: Radio-
resistant cells overexpressed CD98hc. In other words, CD98hc may be a marker of
radiation resistance. Since incomplete radiation therapy can expand Cancer Stem
Cell population, so elucidation of mechanism of radiation resistance will improved
radiotherapy. CD98hcmight be the target for more effıcient treatment.
#3882 Identifıcation of targetable EMT markers in cancer stem-like cells
derived from therapeutic resistant melanoma.William P. Crosson, Elyse Ber-
linberg, Ramin Nazarian. UCLA David Geffen School of Medicine, Los Angeles,
CA.
Melanoma is the deadliest form of skin cancer, expected to claim approxi-
mately 10,000 lives in 2016. An activating mutation in BRAF(V600E) occurs in
50-60% of melanomas and 7% of all cancers. Despite an unprecedented initial
response, patients treated with a highly effective BRAF inhibitor, vemurafenib
(FDA approved 2011), acquire drug resistance within 6-9 months. Vemu-
rafenib-resistant sub-lines, derived from BRAFV600E isogenic parental mela-
noma cells, have altered cell morphology and upregulated PDGFR expression.
Epithelial-to-mesenchymal transition (EMT), a hallmark of cancer-stem-like
cells (CSC), is a potential mechanism that melanomas employ to evade targeted
therapy. Through immunocytochemical, immunoblot, and flow cytometric
analysis, we investigated the expression profıle of EMT biomarkers within pa-
rental and resistant melanoma cell lines. Our fındings indicate CSCs within
melanoma populations may serve as progenitor cells for therapy-resistant mel-
anoma sublines through differential expression of key EMT-related biomarkers.
Furthermore, resistant cell lines were signifıcantly more invasive in migration
assays. Our results implicate notable EMT biomarkers in CSCs that can be used
as novel targets for diagnosis and treatment of tumor resistance in melanoma
patients.
#3883 Transcriptome analysis reveals mitochondrial gene signature up-
regulation in gastric cancers expressing the stem cell marker CD133. Han
Hong Lee, Yoon Ho Ko, Tae-Min Kim, Won-Sang Park. Catholic University of
Korea, Seoul, Republic of Korea.
Gastric cancers expressing the stem cell marker CD133 are more aggressive
than those that do not express the marker, and are associated with more unfa-
vorable clinical outcomes. The CD133-associated aggressive behavior of gastric
cancer remains poorly understood at the molecular level. In the present study,
we performed gene expression profıling of bead-sorted CD133 and CD133-
KATO III cell lines to derive in vitro molecular signatures of CD133 expression
in gastric cancer. Three expression signatures associatedwithCD133 expression
(’Mitochondria’, ’Cell cycle’, and ’Lipid metabolism’) were inferred upon study
of a module association map of the key molecular signatures associated with
CD133 expression in gastric cancer. Using the public gene expression profıles,
we show that the patients with overexpression of CD133 show unfavorable clin-
ical outcomes compared to CD133- patients in the context of up-regulation of
’Mitochondria’ expression signature. We further showed that CD133 KATO
III cells had a higher mitochondrial function and were more susceptible to the
mitochondrial inhibitors rotenone, antimycin A, and NaN3, than were CD133-
cells. Together, our fındings suggest that transcriptional up-regulation of the
’Mitochondria’ gene signature may identify CD133 gastric cancers; such data
are of clinical and pharmacological relevance.
#3884 A tumor stem cell marker DCLK1 promotes hepatocellular carci-
noma by regulating -catenin, EMT and clonogenic properties of hepato-
cytes. Naushad Ali, Charles B. Nguyen, Parthasarathy Chandrakesan, Randal
May, Danny Dhanasekaran, Michael S. Bronze, CourtneyW. Houchen.Univer-
sity of Oklahoma Health Sciences Center, Oklahoma City, OK.
Introduction: Hepatocellular carcinoma (HCC) is the second most common
cause of cancer-related deaths worldwide with a 5-year survival rate of 15%.
Chronic viral hepatitis, NASH, and cirrhosis are major risk factors for the HCC
development. Thus, HCC represents a major public health issue worldwide.
Currently, sorafenib is the only FDA-approved drug used for HCC treatment.
Unfortunately, it increases patient’s survival by only 3months. Tumor stem cells
(TSCs) are likely responsible for resistance to chemotherapy, relapse, and me-
tastasis. We have demonstrated that a TSC marker, doublecortin-like kinase
(DCLK1), is induced during hepatic injury, cirrhosis and HCC and its overex-
pression in HCC patient’s liver signifıcantly reduces survival. Therefore, under-
standing of the mechanism(s) hepatic TSCs regulation is important for the de-
velopment of effective therapy against HCC. Methods: Hepatoma Huh7 cells
and primary human hepatocytes were infected with lentiviruses expressing re-
combinant RFP-DCLK1 fusion protein. The RFP-DCLK1-positive cells were
isolated using FACS and subjected to immunofluorescence confocal micros-
copy, clonogenic assay, Western blot and xenograft in mice. Results: DCLK1-
overexpressing human hepatocytes formed spheroids but not the control cells.
DCLK1 overexpression induced accumulation of active -catenin in the peri-
nuclear and nuclear regions in Huh7 cells with concomitant increase in c-Myc.
The DCLK1-negative cells lacked active -catenin and total -catenin was ob-
served only in their cell membranes. Hepatic -catenin mRNA levels were un-
affected during various stages of HCC. Analysis of HCC patients’ liver tissues
(n 369) suggested that elevated DCLK1 mRNAs expression signifıcantly cor-
relates with increased levels of MMP2, vimentin, Zeb2, Twist1 and VEGF-C
which are involved in epithelial-to-mesenchymal transition (EMT) and tumor
invasion. Huh7-derived tumors also exhibited high level expression of these
factors. Conclusions: These observations suggest that DCLK1 induces tumor/
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cancer stem cell-like properties and EMT in liver cells. DCLK1 appears to en-
hance active -catenin levels and its cellular localization to the nucleus. Thus,
the DCLK1 represents an important target for HCC therapy.
#3885 Establishment, characterization and drug response of primary and
metastatic prostate organoids. SofıaKarkampouna,1 Federico laManna,1 Eugenio
Zoni,1 LijkeleBeimers,2PeterKloen,3AntoinetteWetterwald,1 JoëlGrosjean,1 Irena
Klima,1 Marco Giovanni Cecchini,1 Martin Spahn,4 George Niklaus Thalmann,4
Marianna Kruithof- de Julio4. 1University of Bern, Bern, Switzerland; 2Slotervaart
Medical Centre, Amsterdam, Netherlands; 3Academic Medical Centre, Amsterdam,
Netherlands; 4University of Bern, Inselspital, Bern, Switzerland.
Introduction & objectives: Prostate cancer (PCa)-associated mortality results
from metastasis to bone and resistance to androgen deprivation or cytotoxic ther-
apy. Despite early detection of primary PCa, advanced castration resistant prostate
cancer (CRPC) and bonemetastases (BM) are detected in 10%of patients already at
the timeof initial diagnosis. Themajority of recurrencesmight bedue to cancer cells
with stem cell-like properties (cancer stem cell-like, CSC-like). These could be ther-
apy-resistant in a dormant state at the primary site or have metastasize prior to
diagnosis of the primary tumor. CSC-like cells are themost tumorigenic andmeta-
static, however, current treatments target thedifferentiated tumorbulkcells.Under-
standing themechanismsofPCa tumor initiationandmetastasis byCSC-like cells is
crucial for proper prognosis of high risk patient groups. Materials & methods: To
model CSC-like cells we generated organoids from patient-derived tissues (here
termed as “canceroids”) and established patient-derived xenografts (PDXs). Can-
ceroids were derived from bulk tumor tissues; primary PCa, bone metastasis from
PCa tissue (BM-PCa), established PDXmodels LAPC9 and BM18 and lymph node
(LN) metastasis from PCa (LAPC4) PDX models. Cytotoxic compounds and an-
drogen inhibitors are testedon the canceroids fromdifferentBMorLNtissuesusing
viability assays (CellTiter Glo assay) and 3D imaging by confocal and light sheet
microscopy. Results: We have generated several canceroid lines from human pri-
mary PCa and fromestablishedPDXmodels thatmaintain key features of theCSC-
like cells, previously characterized on the tumor itself (AR, PSA, Cytokeratins). The
luminal phenotype of BM18 is evidentlymaintained in the BM18 canceroids, based
on positive cytokeratin (CK)18 and absent CK5 expression. LAPC4 organoids con-
tain CK5 and CK18 cells, in line with the mixed basal and luminal phenotype. Im-
aging of PSA and cytokeratin distribution confırms the luminal phenotype of the
canceroids. BM18 and LAPC9 canceroids are maintained both in presence and
absenceofdihydrotestosterone indicating that androgen independentgrowthprop-
erties of the tumor are conserved in the canceroids. Viability assays indicate that
canceroids respond to chemotherapeutics (cabacitaxel, docetaxel) and partially to
hormone inhibitors (abiraterone, enzalutamide). Conclusions: Identifıcation of the
oncogenic properties of metastatic CSC-like (sub)populations has both prognostic
and therapeutic applications. Establishment of CSC-derived organoids is the fırst
step towardsroutinederivation frommetastasisorprimaryPCatissuesasapotential
platform for personalized drug compound evaluation.
#3887 GNA13 is a theranostic target that drives drug resistance and cancer
stem-like phenotypes in solid tumors. Suhail Ahmed Kabeer Rasheed,1 Hui
Sun Leong,2 Manikandan Lakshmanan,3 Anandhkumar Raju,3 Dhivya
Dadlani,1 Fui-Teen Chong,2 Ravisankar Rajarethinam,3 Thakshayeni Skantha-
kumar,2 Ern Yu Tan,4 Jacqueline Siok Gek Hwang,5 Kok Hing Lim,5 Daniel
Shao-Weng Tan,2 Paolo Ceppi,6 Mei Wang,1 Vinay Tergaonkar,3 Patrick J.
Casey,1 N. Gopalakrishna Iyer2. 1Duke-NUS Medical School, Singapore, Singa-
pore; 2National Cancer Centre, Singapore, Singapore; 3Institute of Molecular and
Cell Biology, Singapore, Singapore; 4Tan Tock Seng Hospital, Singapore, Singa-
pore; 5Singapore General Hospital, Singapore, Singapore; 6Friedrich-Alexander-
Universitaet Erlangen-Nuernberg, Germany, Germany.
Treatment failure in solid tumors occurs due to the survival of specifıc sub-
populations of cells that possess stem cell-like (CSC) phenotypes. Studies have
implicatedG protein-coupled-receptors (GPCRs) in cancer progression and the
acquisition of aggressive phenotypes. Many of the implicated GPCRs signal
through the G12 subfamily, comprised of GNA12 and GNA13. In this study, we
demonstrate that GNA13 is upregulated in many solid tumors and impacts
survival and metastases in these patients. Consistent with this, we show that
GNA13 expression modulates drug resistance through its effect on the CSC
sub-population in a panel of patient-derivedhead andneck (HNSCC) andbreast
cancer cells. These datawere validated in vivo, whereGNA13 over-expression in
patient-derived xenografts increased tumor initiating capacity, tumorigenicity
and drug resistance, with no effect on growth or proliferation. Signaling through
NFKB and MAPK pathways appear to be critical to the observed phenotype.
Importantly, blockade of GNA13 expression, or select downstream pathways
using small-molecule inhibitors, abrogates GNA13-induced CSCs, rendering
cells vulnerable to standard-of-care cytotoxic therapy for these cancers. Taken
together, these data indicate that GNA13 expression is a potential prognostic
biomarker, and interfering with GNA13-induced signaling provides a novel
strategy to block CSCs and drug resistance in solid tumors.
#3888 DCLK1 is part of an EMT feedback loop and promotes colorectal
cancer cell invasion and drug resistance.Dongfeng Qu,1 Nathaniel Weygant,1
William L. Berry,1 Randal May,1 Parthasarathy Chandrakesan,1 James J. To-
masek,1 Sripathi M. Sureban,1 Courtney Houchen,1 Yang Ge,2 Jiannan Yao,2
Guangyu An,2 Edwin Bannerman-Menson3. 1Univ. of Oklahoma Health Sci-
ences Ctr., Oklahoma City, OK; 2Beijing Chao-Yang Hospital, Beijing, China;
3COARE Biotechnology Inc., Oklahoma City, OK.
Colorectal cancer (CRC) is the third leading cause of cancer death in the U.S.,
with only a 6% 5-yr survival rate for stage IV disease. Its spread and acquisition
of resistance to chemotherapy, which are fueled by the epithelial-mesenchymal
transition (EMT) process and supported by tumor stem cells (TSCs), are major
challenges to improving patient outcomes. New therapies that target stemness
and EMT are desperately needed to prevent or delay metastasis and improve
patient survival. Recently doublecortin-like kinase 1 (DCLK1) has been defıni-
tively proven tomarkTSCs inCRCby two independent groups. Previous studies
have demonstrated that DCLK1 is a prognostic factor in CRC and that targeted
downregulation or inhibition of DCLK1 results in decreased CRC proliferation,
migration, invasion, and other anti-oncogenic effects. However, the effect of
overexpression of DCLK1 and its kinase active mutant on CRC has not been
assessed. In this study, we investigate the correlative role of EMT and DCLK1
expression in CRC progress. Human colon cancer cells (HCT116) were infected
with Lentivirus containing wild type DCLK1 or mutant DCLK1R326C cDNA
sequences to overexpress DCLK1, DCLK1R326C or green fluorescent protein
(GFP) cDNA sequence as control. The expressing levels of DCLK1 and EMT
factors were analyzed by western blotting. The proliferative and invasive poten-
tial of these cells were compared using a MTT assay for proliferation, wound
healing assay for migration, and Matrigel coated transwell assay for invasion.
Knockdown of either ZEB1 or DCLK1 by specifıc siRNA in HCT116 cells was
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performed. The effects of siDCLK1 on 5-FU were performed in both HCT116
and SW480 cells using a Caspase 3/7 activity assay. Analysis of human CRCwas
performed using TCGACOADREAD dataset. Here we report that compared to
GFP control cells, HCT116-DCLK1 andHCT116-DCLK1R326C cells exhibited
a more than 20% increase in proliferation, approximately 30% increase in mi-
gration, and a 2-fold increase (p 0.05) in invasion. DCLK1 expression level is
decreasedmore than 30%by knocking downZEB1 inHCT116 cells. In addition,
knockdown DCLK1 increased 5-FU induced cell apoptosis more than 50%
(P0.05). Evidence fromTCGACOADREADdemonstrated that EMTpredicts
survival in CRC patients, and increased expression level of DCLK1 in CRC
patients correlate to EMT andmesenchymal phenotype. These data suggest that
DCLK1 is a part of an EMT feedback-loop and may be exploited with DCLK1-
targeted therapeutics for CRC.
#3889 Novel drug candidates cep1430 and cep1507 for targeting pancre-
atic patient-derived xenograft cancer stem cell and circulating tumor cell
models. Michael Sharma,1 Maulik Jain,2 Cristian Sharma,1 Karina Amezcua,1
Natalee Amezcua,1 Reed Hasson,1 Miriam Navel,1 Donna Stanton,1 Satya
Narayan,3 Karl Kramberger,1 Rubio Punzalan,1 Jitesh Jani,1 Douglas Foster,1 Jay
P. Sharma1. 1Celprogen, Inc., Torrance, CA; 2Ross Medical School, Dominica,
Dominica; 3University of Florida, Florida, FL.
Pancreatic cancer is the fourth leadingcauseof cancermortality in theUS,despite
signifıcant improvements in diagnostic imaging and operative mortality rates. The
5-year survival rate remains less than 6%because ofmicroscopic or grossmetastatic
disease at time of diagnosis. Although the treatment of pancreatic cancer remains a
challenge, it is enteringnewerawithdevelopmentofnewstrategies and trial designs.
Because there is an increasing number of novel therapeutic agents and potential
combinations available to test in patients with pancreatic cancer and in their PDX
models, the identifıcation of robust prognostic and predictive markers for Cancer
StemCells (CSC)PDXandCirculatingTumorCells (CTC)PDXandof new targets
and relevant pathways is a top priority as well as the design of adequate trials incor-
poratingmolecular-driven hypothesis.Here, we examined the effıcacy of combined
treatments of CEP1430 and CEP1507 in human pancreatic patient-derived xeno-
graft (PDX) cancer cells, and pancreatic PDX CSCs models from the same donors.
CEP1430 inhibited the growth of CSCs and CEP1507 inhibited growth of CTCs,
whilegemcitabine suppressed theviabilityofnon-CSCs[70%](differentiated tumor
Cells). Consistently, in vivo studies showed that CEP1507 when combined with
gemcitabine could eliminate the engraftment of human pancreatic cancer CTCs
[85%(n50,p0.001) and CEP1430 with gemcitabine selectively inhibited [80%]
CSCs(n50,p0.001),more effectively than the individual agents. These data indi-
cated that administration of CEP1430, which targets CSCs and CEP1507 targets
CTCs, may constitute a potential therapeutic strategy for improving the effıcacy of
gemcitabine to eradicate advanced pancreatic cancer. This study has indicated the
potential molecular therapeutic targets to eradicate the tumor – and metastasis-
initiating cells (CTCs) and their progenies and development of new effective com-
bination therapies against locally advanced andmetastatic pancreatic cancer. Using
PDX models, we confırmed the effectiveness and selectivity of the identifıed treat-
ment responses with TGI at 97%with CEP1430.
#3890 Mitochondrial MCL1 maintains triple negative breast cancer stem
cells and contributes to chemotherapy resistance. Kyung-min Lee, Jennifer
Giltnane, Justin Balko, Luis Schwarz, Angel Guerrero, Katie Hutchinson, Mel-
lissa Hicks, Violeta Sanchez, Melinda Sanders, Taekyu Lee, Edward Olejniczak,
Stephen Fesik, Carlos Arteaga. Vanderbilt University, Nashville, TN.
Cytotoxic chemotherapy is the standard of care for patients with triple negative
breast cancer (TNBC). Most patients with advanced TNBC progress after chemo-
therapy and die from metastatic disease. MCL1 is an anti-apoptotic Bcl-2 family
memberknown to sequester and inactivatepro-apoptoticBcl-2 familyproteins and,
thus, contribute to chemotherapy resistance.We previously reported that45% of
residual TNBCs that remain in the breast after neoadjuvant chemotherapy harbor
MCL1 amplifıcation, suggesting a causal role forMCL1 in drug resistance. A recent
report (Goodwinet al. 2015) suggested that siRNA-mediatedablationofMCL1does
not induce apoptosis in claudin-lowTNBC cells with a cancer stem cell (CSC) gene
expression signature.CSCscomprise a rarepopulationof cellswith tumor-initiating
properties and refractoriness to chemotherapy. In this study,we showed thatMCL1
expression is elevated in claudin-low TNBC SUM159PT and MDA436 CSCs as
measured by ALDH by flow cytometry and ability to formmammospheres. RNA
interference ofMCL1 in SUM159PT cells reducedCSCs and attenuated tumor for-
mation in vivo. Mitochondrial oxidative phosphorylation (mtOXPHOS) plays a
crucial role inmaintenance of CSCs.MCL1 has been shown to localize in themito-
chondrial matrix and contribute to mitochondrial respiration. Thus, we hypothe-
sized that MCL1 contributes to enrichment of TNBC CSCs and chemotherapy re-
sistance via mitochondrial regulation. Stable transfection and overexpression of
MCL1 inMDA468 cells increased oxygen consumption ratio,mitochondrialmem-
brane potential, and production of reactive oxygen species (ROS), all features of
activated mtOXPHOS. Conversely, RNAi-mediated ablation of MCL1 in
SUM159PTandMDA436cells repressed thesemarkersof activatedmtOXPHOS.A
mutant of MCL1 lacking its mitochondrial target sequences (MTS) was unable to
localize in mitochondria and, when transfected into MDA468 cells, reduced the
CD44high/CD24low fraction and mammosphere formation. We next tested
VU0659158, a BH3mimetic in development at Vanderbilt that disrupts MCL1 in-
teractions with BH3 domain-containing proteins, such as BID, BIM, NOXA and
PUMA. Treatment of SUM159PT cells with VU0659158 increased caspase activity
but did not attenuate mammosphere formation. Analysis of mRNA expression in
TCGArevealed thatgenes inducedbymtOXPHOSinvolved in thehypoxiapathway
are signifıcantly up-regulated in MCL1 amplifıed breast cancers. Finally, pharma-
cological inhibition of HIF-1, a key regulator of hypoxia, with digoxin decreased
CSCs and attenuated tumor formation in vivo. These data suggest that 1) MCL1
confers resistance to chemotherapy by expanding CSCs via mtOXPHOS indepen-
dent of its BH3 domain-mediated, anti-apoptotic function, and 2) targeting mito-
chondrial respiration and the hypoxia pathwaymay delay or reverse chemotherapy
resistance inMCL1 amplifıed TNBC.
#3891 Chemoresistant cancer stem cells undergo gene changes that drive
tumor recurrence. Prithy C. Martis,1 Atira Dudley,1 Melissa A. Laramore,1
Hunter L. Gazda,1 Michael P. Markey,2 Barry H. Smith,3 Lawrence S. Gazda1.
1The Rogosin Institute, Xenia, OH; 2Wright State University, Dayton, OH; 3The
Rogosin Institute, New York, NY.
Despite the effıcacy of chemotherapy, resistant cells are thought to contribute to
tumor recurrence. In vitro models of recurrence must mimic the complexity and
heterogeneity of in vivo tumors and provide the longevity needed to capture tumor
dormancy following chemotherapy. We have previously described a 3D in vitro
model that simulates in vivo tumors containing cancer stem cell niches. Encapsula-
tion of murine renal adenocarcinoma (RENCA) cells in a double layer of agarose
that form spherical macrobeads allows for the development of 3D tumor colonies
comprised of tumor-initiating and tumor-amplifying cells within the inner agarose
matrix. In the current study, we used the RENCAmacrobead in combination with
chemotherapy toevaluategenetic regulation thatallows tumordormancyanddrives
recurrence. RENCAmacrobeads treatedwith docetaxel (5g/ml) undergo a signif-
icant loss of cell mass and a period of latency followed by tumor recurrence. RNA
isolated from docetaxel-resistant cells (Wk.6 post-treatment), recurrent tumors
(Wk.20 post-treatment) and paired vehicle controls were characterized using
whole-transcriptome profıling (GeneChip® WT Pico Kit with Transciptome Anal-
ysisConsole;Affymetrix).AtWk.6post-treatment, genes associatedwith a stemcell
phenotype (Car12, Arrb1,Nos2, Aldh1l2) andmembers of theABC1 family associ-
atedwithmultidrug resistancewere enriched indocetaxel-resistant cells.Genes reg-
ulating thecanonicalWntsignalingpathway, specifıcallyLRPfamilymembers,were
signifıcantly up regulated. Pathway analysis revealed dysregulated focal adhesion-
PI3K-Akt-mTor-signaling, including genes modulating integrin adhesion (Itga5,
Itga7), ECM receptor interaction (Lama5, Lamb2, Lamc1) and actin cytoskeletal
remodeling (Vcl). Supporting the quiescent nature of the docetaxel-resistant popu-
lation, genes implicated in DNA replication (Dbf4, Cdc6, Mcm5), transcriptional
initiation (Taf13, Gtf2h1, Polr2i) and tumor progression (Mmp3, Mmp13) were
signifıcantly down regulated. At Wk.20 post-treatment, up regulation of matrix
metalloproteinases (Mmp13) and partial retention of stem cell (Nos2, Car12) and
drug resistant (Abcb1) genes supports the evolution of regenerated tumors to a
metastatic phenotype.Genes involved in fatty acid-oxidation (Acsl5, Lipf), oxida-
tive phosphorylation (ND3, ND6) and the electron transport chain (COX2) were
down regulated in concert with up regulation of Me2 suggesting reduced flux
through the TCA cycle and use of aerobic glycolysis in rapidly growing cells. This
study further supports the RENCA macrobead as a model system to evaluate the
biology of chemotherapy-resistant cells and tumor recurrence in a 3D microenvi-
ronment. These data are in line with the notion that chemotherapy-resistant cells
exhibit a period of quiescence with a stem cell-like gene profıle and experience an
intrinsic transformation towards an invasive phenotype that drives tumor recur-
rence.
#3892 Delineating the role of ZEB1 loss in the chemo and radioresistance
of glioma stem cells.Mecca Madany,1 Lincoln Edwards,2 John S. Yu1. 1Cedars-
Sinai, Los Angeles, CA; 2Cornell, Ithaca, NY.
The most prevalent brain cancer, GlioblastomaMultiforme (GBM) has an aver-
age survival of less than 2 years. Despite advances in therapy there is still an overall
poor response to treatment which has been attributed to glioma stem cells (GSC’s),
a subsetof tumorcells that areable to self-renew, inhibitdifferentiationandareoften
chemo and radioresistant. The genetics and mechanisms underlying how glioma
stem cells are able to repopulate tumors and affect patient survival desperately need
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to be defıned.We are interested in delineating the role that ZEB1 (zinc fınger e-box
binding homeobox-1) loss has on GSC’s and what role this loss plays in the chemo
and radioresistance of GSC’s.Most insights into ZEB1 regard it as tumorigenic and
an initiator of EMT (epithelial mesenchymal transition). Surprisingly, in this study,
wehave shown that inTCGAdatasets ZEB1deletion frequently occurs and this loss
actually results in poorer glioma patient survival. Copy number analysis as well as
immunohistochemistry on patient samples shows that ZEB1 loss occurs both at the
gene and protein level. Stable ZEB1 knockdown in our patient derived glioma stem
cell lines results in increasedproliferationanda resistance todifferentiation. Follow-
ing chemotherapy aswell as radiotherapy, knockdown cell lines show increased cell
viability as well as higher levels of secondary neurosphere formation. Decreased
apoptosis and changes in cell cycle as well as the DNA damage response pathway
were also observed in the knockdown lines following chemo and radiotherapy.
Overall, this data indicates that loss of ZEB1 inGSC’s results in enhanced resistance
to standard therapy.With these results, we have reason to believe that ZEB1may be
usedasanovel therapeutic target tocombat thechemoandradioresistanceofglioma
stem cells.
#3894 A positive feedback loop prevents differentiation of endocrine re-
sistant luminal progenitor breast cancer cells.Brendan Ffrench,1 Sara Charm-
saz,1 Eamon Breen,2 Arnold Hill,1 Leonie Young1. 1Royal College of Surgeons in
Ireland, Dublin 2, Ireland; 2Trinity College Dublin, Dublin 8, Ireland.
Introduction: Treatment of breast cancer patients has advanced greatly with
the stratifıcation of ER, HER2 and triple negative cohorts. ER breast can-
cer is the most commonly diagnosed mammary malignancy and is managed
with anti-endocrine therapies. Therapy resistant disease emerges in approxi-
mately one in three women. Within the ER cohort, breast cancer remains a
heterogeneous disease, particularly at the cellular level. For example; ER breast
cancer can range from10% to90%ER cells within a tumor. This study set
out to defıne and target differences in cellular heterogeneity between endocrine
sensitive and resistant ER breast cancer.Methods: A flow cytometry based cell
surface protein (CSP) screen (37 proteins) identifıed changes in cellular hetero-
geneity between endocrine sensitive and resistant ERmodels. FACS isolation
and single cell plating characterized the self-renewal and differentiation poten-
tial of the identifıed sub-populations. Conditioned media experiments assayed
secretory activity of the endocrine resistant phenotype. Results: The CSP screen
identifıed FUT4MUC1- cells as central to the endocrine resistant phenotype.
The endocrine sensitive model (MCF7) was found to contain roughly equal
proportions of FUT4MUC1- (31.2 	 1.6 %), FUT4-MUC1- (38.5 	 7.1 %)
and FUT4-MUC1 (23.0 	 6.9 %) cells. While two independent models of
resistance were found to be dominated by FUT4MUC1- cells (LY2: 86.0	 5.5
%; TMR: 80.6 	 6.5 %). Conventional theory suggests that these resistant
FUT4MUC1- cells are the apex cancer stem cells (CSCs). To test this hypoth-
esis, single cell clonogenicity assays were carried out on FUT4MUC1- cells
isolated from the endocrine sensitive model. It was found that these
FUT4MUC1- cells were not apexCSCs, but rathermid-tier progenitor cells, as
they could not produce all the cell types of the sensitive model. Paired condi-
tioned media and clonogenicity studies demonstrated that the resistant secre-
tome is suffıcient to trap FUT4MUC1- cells isolated from the sensitive model
in a self-renewing, resistant-like state (p-value: 0.011; Chi-Squared test). More-
over, resistant cells which were removed from treatment conditions for 8
weeks maintained the resistant FUT4MUC1- phenotype. These data indicate
co-operation between cell- and treatment-driven mechanisms creating a
FUT4MUC1- resistant phenotype. Conclusions: Chronic tamoxifen therapy
drives heterogeneity towards a FUT4MUC1- phenotype. Single cell self-re-
newal and differentiation studies identify this cell type as a mid-tier progenitor
cell rather than an apex cancer stem cell. A positive feedback loop supplements
the treatment induced change, to maintain the resistant phenotype in the ab-
sence of further tamoxifen treatment. Targeting this feedback loop or its down-
stream effectors may allow for re-sensitization of endocrine resistant disease.
#3895 Verrucarin J targets both cancer cells and cancer stem cells. Kelsey
Carter,1 Seema Parte,2 Surinder K. Batra,3 Mariusz Z. Ratajczak,2 Sham S.
Kakar2. 1University of Louisville, Louisville, KY; 2Univ. of Louisville, Louisville,
KY; 3Univ. of Nebraska, Ohma, NE.
Ovarian cancer is the fıfth leading cause of death amongwomen in theUnited
States. The American Cancer Society estimates that approximately 22,280
women in the United States will be diagnosed with ovarian cancer and approx-
imately 14,240 women will die as a result of ovarian cancer in 2016. The most
common treatment for ovarian cancer is cytoreductive surgery, followed by
chemotherapy (combination of carboplatin and paclitaxel). Although this regi-
men is initially effective in a high percentage of cases, unfortunately, within few
months of initial treatment, tumor relapse occurs because of platinum-resis-
tance. The presence of cancer stem cells (CSCs) are the main cause of this phe-
nomenon. CSCs are a small population (2-5%) of cells in solid cancer which are
chemo-resistant, highly tumorigenic, possess a self-renewal capacity, and the
capability to differentiate into multiple lineage. Therefore, there is an urgent,
unmet need for amore effective therapy that targets cancer cells as well as cancer
stem cells. We screened for a novel drug that can target both cancer cells as well
cancer stem cells and came cross Verrucarin J, a metabolite of theMyrothecium
fungus family, which has not been tested for its antitumor activity. In our exper-
iments, we treated two cisplatin-sensitive ovarian cancer cell lines (A2780 and
OVCAR5) and one cisplatin-resistant cell line (A2780/CP70) with various con-
centrations of Verrucarin J. After treatment of cells, Verrucarin J showed: i) a
highly signifıcant inhibition of ovarian cancer cell proliferation in a dose- and
time-dependent manner, with an IC50 value of approximately 10 nM after 48 h
of treatment for all the three cell lines, ii) a signifıcant increase in cell apoptosis,
iii) a signifıcant increase in DNA damage and generation of reactive oxygen
species (ROS) compared to vehicle treated cells, iv) a signifıcant down regulation
of expression of cancer stem cells markers, and v) a signifıcant inhibition of
Notch1, Wnt1 and Shh signaling genes in a dose-dependent manner. Notch1,
Wnt1 and Shh are major regulatory pathways for self-renewal andmaintenance
of cancer stem cells. Additionally, our experiments revealed that Verrucarin J
inhibited the tumorigenic function (spheroid formation on ultra-low attach-
ment plates) of isolated ALDH1 positive CSCs from ovarian cancer cell line
A2780. Based on our results, we conclude that Verrucarin J is a highly potent
anti-tumor drug and targets both cancer cells and cancer stem cells. Therefore, it
may serve as a potential candidate for ovarian cancer treatment and replace
currently used chemo-therapy.
#3896 Exosomes derived from CD133 hepatocellular carcinoma (HCC)
cell promote the acquisition of stem cell-like properties of the targeted HCC
cell via the Akt/GSK 3/Snail and cyclin D1 pathways. Pengyi Guo,1 Haitao
Yu,1 Xiaozhai Xie,1 Yi Wang,2 Gang Chen1. 1The First Affıliated Hospital of
WenzhouMedical Univ., Wenzhou, China; 2Department of PreventiveMedicine,
Wenzhou Medical University, Wenzhou, China, Wenzhou, China.
Backgrounds and Aims: Liver cancer stem cells are closely related to the re-
currence and metastasis of hepatocellular carcinoma (HCC). However, the
mechanism underlying the reciprocity between liver cancer stem cells andHCC
cells in the tumor microenvironment remains unclear. Exosomes act as natural
shuttles to deliver bioactive molecules that alter the behavior of the recipient
cells, offering a new means of cell-cell communication for physiological and
pathological processes in the liver. This study aimed to clarify whether the exo-
somes derived from the liver stem cells could facilitate the acquisition of stem
cell-like properties of the adjacent HCC cells, thereby promoting the malignant
process ofHCC.Methods: CD133 liver cancer stemcellswere isolated from the
highly invasive HCC-LM3 cells or tumor tissues of HCC patients using flow
cytometry and were identifıed using qPCR and immunofluorescence. The exo-
somes from CD133 liver cancer stem cells were identifıed using CD133 and
other stem cell markers, and they were then used to treat HepG2 and Hep3B
cells. The cell viability, invasion ability, sphere formation and tumorigenesis
abilities of the treated HepG2 and Hep3B cells were analyzed to reveal the effect
of CD133 exosomes, and the underlying molecular mechanism was further
explored. Results: CD133 liver cancer stem cells were successfully isolated
from HCC-LM3 cells and HCC patients’ tumor tissues, which were able to
release CD133 exosomes. The intake of CD133 exosomes promoted the pu-
tative stem cell phenotype of Hep3B and HepG2 cells, as evidenced by signifı-
cantly enhanced cell proliferation, invasion and sphere formation abilities in
vitro and tumorigenesis in vivo. In additional, we found that CD133 exosomes
activated the PI3K/Akt/GSK3/Snail and cyclin D1 pathway, thereby reducing
the expression of E-Cadherin and promoting the epithelial-mesenchymal tran-
sition (EMT) of HCC cells. Conclusions: Our results suggest that exosomes
derived from CD133 HCC cells can change the malignant behavior and pro-
mote the acquisition of stem cell-like properties of targeted HCC cells via the
Akt/GSK 3/Snail and cyclin D1 pathways.
#3897 Novel inhibitor of GBM stem cells targets unique CREB & Myc-
mediated self-renewal pathways regulated by CDK5. Subhas Mukherjee,
Carol Tucker-Burden, Changming Zhang, Jun Kong, Monica Chau, Renee
Read, Daniel J. Brat. Emory University School of Medicine, Atlanta, GA.
Cancer stem cells exert enormous influence on neoplastic behavior, in part by
governing asymmetric cell division and the balance between self-renewal&mul-
tipotent differentiation. Growth is favored by deregulated stem cell division,
which enhances the self-renewing population & diminishes the differentiation
program. To uncover mechanisms relevant to deregulated cell division in hu-
man glioma stem cells, we fırst developed a novel adult Drosophila brain tumor
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model, 100% enriched with tumor stem cells. Using this model, we performed a
suppressor screen for kinases and found brain-specifıc dCdk5 partially reverses
the tumor phenotype. dCdk5 and its human ortholog CDK5 (79% identity) are
atypical protein kinases because they do not regulate cell cycle in normal cells,
but are critical for neurogenesis & survival of mature neurons. Interestingly,
many cancers show overactivation of CDK5 signaling, regulating cell cycle &
leading to uncontrolled proliferation. Our analysis of TCGA data shows that
IDH wt GBM has signifıcantly high level of CDK5 compared to the IDH wt
lower grade glioma. Additionally, we found a strong positive correlation be-
tween CDK5 & several stem cell markers in GBM. To date, not much is known
about the role of CDK5 in glioblastoma GBM) & glioma stem cell self-renewal.
Using patient-derived (GBM) neurosphere cultures & in vivo xenograft tumors
in mice, we further demonstrated that a novel pharmaceutical suppressor of
CDK5 signaling axis can suppress self-renewal properties through a new CDK5
phosphorylation site on CREB and Myc. Together, our results show that the
CDK5 signaling pathway is important for glioma stem cell survival & that sup-
pressing CDK5 could be a novel therapeutic approach to eliminate glioma stem
cells.
#3898 Emerging role of Fra-1 as a novel target for radiosensitization in
HPV-associated cancers. Abhishek Tyagi,1 Shilpi Gupta,1 Prabhat Kuamr,1
Alok C. Bharti,2 Bhudev C. Das1. 1Amity University Uttar Pradesh, Noida, India;
2University of Delhi, Delhi, Delhi, India.
Background: Activator protein-1 (AP-1) plays a central role in HPV-medi-
ated cervical and tongue cancer (subset of HNSCC). AP-1, a homo/heterodi-
meric protein composed of Jun and Fos family proteins, has been implicated in
chemoradioresistance but the mechanism(s) remained unexplored. In the pres-
ent study, AP-1 family protein Fra-1 has been shown to play a critical role in
promoting radiosensitization in enriched cervical cancer stem-like cells (CaCx-
SLCs) and can serve as a target for drug intervention in cervical and other HPV
associated cancers. Experimental Procedure: Cervical cancer stem-like cells
(CaCxSLCs) were isolated and enriched by sequential gating HPVve and
HPV-ve human cervical cancer cell lines, SiHa, and C33a using a set of func-
tional and phenotypic markers (ABCG2, CD49f, CD71, CD133) in defıned con-
ditioned media (DCM) with intermittent culturing. CaCxSLCs were also as-
sessed for their cervicosphere forming ability, exclusion of DCV dye for
generating SP cells, self renewability and quiescenceness. Both CaCxSLCs and
Non CaCxSLCs were exposed to different dose of UV irradiation and a herbal
compound curcumin, a potent inhibitor of AP-1 was used to examine the role of
AP-1 and its family proteins in the radiosensitization of cancer stem cells. Re-
sults: Upon UV irradiation, CaCxSLCs showed a dose-dependent higher prolif-
eration and highly increased AP-1 activity whereas it was completely abolished
in non-stem cancer cells. CaCxSLCs also showed differential overexpression of
c-Fos and c-Jun at transcript as well as in protein level. The loss of AP-1 activity
and expressionwas accompanied by decrease in cell viability and proliferation in
UV irradiated non-stem cancer cells. Interestingly, CaCxSLCs treated with cur-
cumin prior toUV irradiation abolishedAP-1 activity and a concomitant reduc-
tion in SP cells leading to abrogation of sphere forming ability, loss of prolifer-
ation, induction of apoptosis and the cells were poorly tumorigenic. The
curcumin pre-treatment abolished the expression of c-Fos and c-Jun but up-
regulated Fra-1 expression in irradiated CaCxSLCs. Conclusion: The study sug-
gests a critical role of AP-1 protein in the manifestation of radioresistance but
curcumin pretreatment helps in radiosensitizing CaCxSLCs through upregula-
tion of Fra-1 which may serve as a potential target for elimination of radioresis-
tant cancer stem cells in HPV-associated malignancies.
#3899 Synthetic small molecule targeting CD24-/CD44/ALDH cell
population inhibits cancer stem cell activities in breast cancer. Luxi Chen,
Chao Long, Kha A. Tran, Jiyong Lee. University of Texas at Dallas, Richardson,
TX.
Purpose of the study: Cancer stem cells (CSCs) have been described as the
“seed of tumor”, and have been suggested as the driving force of tumor relapses.
In this study we aimed to isolate small molecules via screening of the combina-
torial chemical library. The isolated molecules bind CD24-/CD44/ALDH
breast cancer cell subpopulation with high selectivity and specifıcity. Experi-
mental design and plan: Through the unbiased cell based chemical library
screening, we identifıed compound candidates that specifıcally bind the stem-
like cancer cell subpopulations in breast cancer cells and tissues. By performing
in vitro, tissue and in vivo-based assessments on ligand-binding specifıcity and
functional activities, we ensured that the isolated ligands target tumorigenic
stem-like breast cell or tissue preferentially. Summary of discoveries and fınd-
ings: The in vitro compound binding validations proved the specifıcity of the
isolated compound candidates toward breast cancer cells and tissues displaying
cancer stem cell properties. The compound-targeting cell populations display
signifıcantly-higher expressions of the well-known stem cell markers than the
unbound cell populations. On the other hand, a series of biological and bio-
chemical functional assays also confırmed the compound candidates exert tu-
mor-suppression activities on breast cancer cell lines, such as slow down prolif-
eration and reduce cell viability.More importantly, our study demonstrated that
both isolated compounds have preferential selectivity and higher binding affın-
ity to the TNBC cells and tissues, which have been reported for higher percent-
age of stem-like cancer cell population detected than in non-TNBC cells or
tissues. Through mouse xenograft study followed by histological analysis, we
further confırmed the binding specifıcity of the compound towards cell line
models could be retained in vivo in mouse xenograft model. Conclusion: We
demonstrated our ligand screening technique is able to identify synthetic com-
pounds targeting cell subgroups or sub-populations of defıned interest within
one particular type of tumor. High specifıcity of the isolated molecules could be
utilized to develop chemical probes for quantifıcation of percentage of CSC in
the tumor, which facilitates clinical evaluation of tumor relapse risk. The screen-
ing strategy also provides a new methodology in discovering novel drug target-
ingCSC subpopulations, not only in breast tumor, but also other types of human
cancers. Funding: This project is supported by the Cancer Prevention and Re-
search Institute of Texas (CPRIT) grant, award ID: RP150713.
#3900 STAT3 inhibition with Galiellalactone effectively targets the pros-
tate cancer stem-like cell population. Giacomo Canesin,1 Anne T. Collins,2
Rebecka Hellsten,1 Norman J. Maitland,2 Anders Bjartell1. 1Lund University,
Malmö, Sweden; 2University of York, York, United Kingdom.
Introduction and objectives Cancer stem-like cells (CSCs) represent a small
subpopulation of largely quiescent cells that reside within tumors. Several stud-
ies have demonstrated that this small population is more resistant to current
therapies and is therefore directly responsible for tumor recurrence. The tran-
scription factor STAT3has been recently related to the regulation of the stemcell
niche in prostate cancer (PCa), and inhibition of activated STAT3 (pSTAT3)
seems to be a valid strategy to selectively target PCa CSCs. We have previously
shown that pSTAT3 blockade by Galielallactone (GL) not only reduces prolif-
eration and induces apoptosis of prostate cancer cells in vitro, but also inhibits
the growth of prostate tumors and the metastatic spread to regional and distal
lymph nodes in vivo. Here we performed experiments aimed at studying the
effect of the inhibitor GL on PCa CSCs, in order to increase our understanding
on this compound as a promising therapeutic approach for prostate cancer
patients. Materials and methods The expression of stem, basal and luminal cell
surface markers (CD133/CD44/CD24) was analyzed by FACS on DU145 and
PC3 cells treated with GL. DU145 cells were sorted based on expression of the
above markers and then plated for further analysis, including expression of
pSTAT3 by IHC and cell proliferation by the WST1 assay. The effect of GL on
clonogenic recovery of PCa CSCs was studied by colony formation with sorted
cells. Results Our results show that the CSC populations (CD133/CD44)
express high levels of activated pSTAT3 compared to the CD44/CD24 cell
population. Treatment with GL decreased the number of CSCs in DU145 cells
after 48h, whilst the number of CD44/CD24 cells was less affected. Impor-
tantly, treatment with GL had no effect on CD133/CD44 or CD44/CD24
populations in PC3 cells, which don’t express pSTAT3. Of note, both CD133/
CD44 and CD44/CD24 cells responded to treatment with GL, as prolifera-
tion decreased in a dose-dependent manner. Treatment with GL signifıcantly
reduced the ability of CSCs to form colonies in a concentration-dependentman-
ner. Conclusion This study demonstrates that the STAT3 inhibitor Galiellalac-
tone can specifıcally target the prostate cancer stem-like cell population in vitro,
implying that pSTAT3 inhibition by GL could represent a valid therapeutic
strategy to antagonize CSCs in human prostate cancer. Future experiments will
be aimed at validating these data and relating the clonogenic inhibition to the
effects of pSTAT3 blockade by GL on tumor initiation by prostate cancer stem-
like cells in vivo.
#3901 Therapeutic targeting of C-terminal binding protein: a key depen-
dency for polyposis and cancer stem cell activity in APC mutant neoplasia.
Ayesha T. Chawla, Agnes Cororaton, Rashmi Seth, Barbara Szomju, Evan T.
Sumner, Steven R. Grossman. Virginia commonwealth University, Richmond,
VA.
TheC terminal binding proteins (CtBP) 1 and 2 are a family of transcriptional
co-repressors overexpressed in a variety of cancers, and are frequently associ-
ated with poor prognosis and chemoresistance. CtBP has also been character-
ized in cell culture models as drivers of migration/invasion and epithelial-mes-
enchymal transition. CtBP mediates its transcriptional corepressor activity via
its dehydrogenase domain, and inhibition of this domain interferes with CtBP
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oncogenic functions. The role of CtBP in APC mutant neoplasia remains ob-
scure even though APC is responsible for degradation of both -catenin and
CtBP in suppressing colorectal tumorigenesis. Our prior work demonstrates
that CtBP proteins can be effectively therapeutically targeted with substrate an-
alogues of their intrinsic dehydrogenase domains. We now observe that phar-
macologic inhibition of CtBP using either the 1st generation inhibitor 2-keto-4-
methylthiobutyrate (MTOB) or the 2nd generation inhibitor hydroxyimino-3-
phenylpropanoic acid (HIPP) signifıcantly reduces the burden of intestinal
polyps in the Apcmin mouse model of the human cancer predisposition syn-
drome Familial Adenomatous Polyposis. The number of intestinal polyps in
mice with CtBP2 inhibitors were signifıcantly lower (21 polyps/mouse for
MTOB, 15 polyps/mouse for HIPP) as compared with vehicle treated mice (45
polyps/mouse) with a P value0.0001. Pointing to the anti-neoplastic mecha-
nism of MTOB and HIPP, polyps that did grow inMTOB or HIPP treated mice
demonstrated robust downregulation of  catenin and Ctbp2 proteins. This
observation points to the role of Ctbp2 as a putative driver oncogene that can be
therapeutically targeted in vivo. In addition, CtBP2 has been reported to play an
important role in human colon cancer stem cells via its interaction with the
transcription factor TCF4 on chromatin. We now show that inhibiting CtBP
with HIPP or HIPP analogues attenuates CtBP2 protein levels in colon cancer
stem cells with resultant decreased expression of CtBP transcriptional target
genes, such as the motility/invasion regulator TIAM1, and c-MYC, a known
driver of the cancer stem cell phenotype. Moreover, colonospheres treated with
CtBP inhibitor showed downregulation of cancer stem cell markers CD133 and
c-MYC, as compared with vehicle treatment. Flow cytometry analysis of intes-
tinal epithelium from Apcmin mice treated with CtBP inhibitor vs. vehicle indi-
cated a signifıcant reduction in CD133/CXCR4 cells that are associated with
a tumor initiating cell phenotype. Our data demonstrate that CtBP inhibition
may reduce colon neoplasia via downregulation of c-MYC and the cancer stem
cell/tumor initiating cell compartment, and that CtBP is a promising and novel
target for therapy in colon cancer.
#3902 Interleukin-6 blockade, a novel cancer stem cell targeted therapy,
attenuates lung cancer tissue construction.Hiroyuki Ogawa, Michiyo Koyan-
agi-Aoi, Yoshimasa Maniwa, Takashi Aoi. Kobe University, Kobe City, Japan.
Background: Lung cancer stem cells are considered to be responsible for lung
cancer progression and metastasis. However, little is known about how they
actually promote aggressive behaviors of lung cancer. Methods: We transduced
OCT3/4, SOX2, and KLF4 (hereafter, OSK) into a KRAS-mutated (G12S) hu-
man lung adenocarcinoma cell line (A549) using retrovirus vectors. Dome-
shaped colonies appeared in the OSK transduced A549 cells from 10 to 15 days
after transduction. The colonies were picked up and sub-cultured. We named
them OSK-A549-Colony cells. We evaluated cancer stem cell properties in the
OSK-A549-Colony cells in terms of their chemo resistance, and sphere forma-
tion ability. We also assessed organoids constructing ability by co-culture with
mesenchymal stem cells (MSCs) and human umbilical vein epithelial cells (HU-
VECs) on low attachment plates. To clarify the molecular mechanisms that
determined the properties of the OSK-A549-Colony cells, we performed mi-
croarray analysis. We further analyzed the molecular mechanisms of organoids
construction by OSK-A549-Colony cells and searched for a method to destroy
them. Results: The induced OSK-A549-colony cells were signifıcantly more re-
sistant to cisplatin than the parental A549 cells. Sphere forming ability was
enhanced in the OSK-A549-Colony cells. Co-culture with MSCs and HUVECs
showed that only the OSK-A549-Colony cells were able to construct consoli-
dated organoids in vitro that mimicked bona-fıde human lung cancer tissues.
We named them “lung cancer organoids”. We found that interleukin-6 (IL-6),
which was the most differentially expressed gene in the OSK-A549-Colony cells
bymicroarray analysis, facilitated the formation of lung cancer organoids via the
conversion of MSCs into alpha-smooth muscle actin (SMA)-positive cells.
Surprisingly, the combination of anti-IL-6 antibody and cisplatin could destroy
the lung cancer organoids, while cisplatin alone could not. Conclusion: By trans-
ducing defıned factors, A549 cells acquired lung cancer stem cell like properties.
Analysis of chemosensitivity using the lung cancer organoids showed that the
combination of IL-6 blockade and cisplatin could be a novel therapy targeting
lung cancer stem cells.
#3903 Targeting oral cancer stem cells in the hypoxic niche by BCG in-
fected mesenchymal stem cells. Bidisha Pal,1 Seema Bhuyan,2 Jaishree Gar-
hyan,1 Hong Li,1 Rashmi Bhuyan,1 Herman Yeger,3 Bikul Das1. 1The Forsyth
Institute, Cambridge,MA; 2KaviKrishna Laboratory, Indian Institute of Technol-
ogy (IIT), Guwahati, India; 3Hospital for Sick Childern, Toronto, Ontario, Can-
ada.
Background: Tumor hypoxia is a major contributing factor in cancer thera-
peutic failure. The microenvironment of hypoxia/oxidative stress may repro-
gram cancer cells to highly tumorigenic, metastatic, angiogenic and stem cell-
like state.We have characterized in vitro and in vivomodels of hypoxia-induced
cancer cell reprogramming to cancer stem cell (CSCs) like cells including an
immunocompetent model of oral cancer. These CSCs exhibit ABCG2 cell sur-
face marker. Numerous approaches including targeted therapy using oncolytic
virus and bacteria have been attempted to target cancer cells in their hypoxic
niche without major therapeutic success. Major therapeutic challenges include
the inaccessibility of hypoxic niche by therapy-agents and the poor replication of
viruses or bacteria intracellular to hypoxic cancer cells. Furthermore, the im-
mune privilegedmicroenvironment of tumor hypoxia could pose a challenge to
viral/bacterial-induced immunity against the tumor. In this context, here we
have tested a novel stem cell-based approach to deliver BCG infected stem cells
to the hypoxic core of tumors. Methods: Human SCC-25 cell line-derived xeno-
graft in NOD/SCID mice exhibit hypoxic zones, where ABCG2 resides (1).
SCC-25 tumor-bearingmicewere injected i.v. withCD271 bonemarrowmes-
enchymal stem cells (BM-MSCs). We recently found that CD271 BM-MSCs
could be infected with M. tuberculosis. The BCG infected CD271 BM-MSCs
were injected to SCC-25 xenograft-bearing mice. The mice were sacrifıced on
day-20 of stem cell injection and then evaluated for the hypoxic CSCs. Next, we
have developed a 4-NQO induced oral cancer cell line, which was injected or-
thotropic to the tongue of congenic mice. The mice developed tumors, which
was hypoxic. In these tumor-bearing mice, BCG-infected murine CD271 BM-
MSCs were injected i.v., and animals were monitored for four weeks for tumor
growth. On day-20 of injection, mice were sacrifıced, and the tumors were col-
lected. In a control group, BCG alone was injected. Results: In both the SCC-25
and an immunocompetent mouse model, we found that BCG or CD271 BM-
MSCs injection alone did not result in marked anti-tumor activity and or elim-
ination of ABCG2 cells from their hypoxic niche. In contrast, the injection of
BCG infected CD271 BM-MSCs led to marked reduction of tumor growth.
Importantly, we observed marked replication of BCG intracellular to CSCs.
These results indicate that CD271BM-MSCs facilitated the transfer of BCG to
cancer cells residing in the hypoxic zone. Importantly, the transfer of BCG was
seen more in the immunocompetent model, suggesting potential role of im-
mune system. Conclusions: Our fındings indicate that hypoxic CSCs may be
targeted by a few BCG infected CD271 BM-MSCs. We propose this could be a
novel therapeutic approach to target drug resistance cancer stem cells residing in
the hypoxic niche of tumors.1. Bhuyan R et al, Cancer Research, 2016; Volume
76, Issue 14 Supplement, pp. 935.
#3904 Inhibition of the ERK5 pathway as a novel approach to target hu-
man chronic myeloid leukemia stem cells. Ignazia Tusa,1 Giulia Cheloni,1 Na-
thanael Gray,2 Antonella Gozzini,3 Persio Dello Sbarba,1 Elisabetta Rovida1.
1Univ. of Florence, Firenze, Italy; 2Dana Farber Cancer Institute, Harvard Med-
ical School, Boston, MA; 3Hematology Unit, AOU Careggi, Firenze, Italy.
Tyrosine kinase inhibitors (TKi) targeting BCR/ABL are very effective for the
treatment of Chronic Myeloid Leukaemia (CML). However, resistance mecha-
nisms or their ineffıcacy onCML leukaemia stem cells (LSC)may lead to relapse.
Therefore, there is urgent need to identify new molecular targets. The Extracel-
lular signal-Regulated Kinase 5 (ERK5) is a Mitogen-Activated Protein Kinase
involved in cancer. Our aim was to study a possible role of the ERK5 pathway in
CML LSC. Cells used were: human CML cell lines K562 and KCL22 that express
constitutively active ERK5; CML patient-derived cells and CD34 cells from
heathy donors (after informed consent had been obtained). Cells were incubated
in normoxic (routine) or hypoxic (0.2%O2) primary cultures (LC1) in the pres-
ence or the absence of drugs. Day-7 LC1 cells were transferred to drug-free,
non-selective normoxic secondary cultures (LC2), tomeasure LC2 repopulation
as a read-out of progenitor/stem cell potential (CRA assay). Compounds:
XMD8-92 (ERK5 inhibitor) and BIX02189 (MEK5 inhibitor); imatinib (BCR/
ABL inhibitor, IM). We previously showed that stem cell potential of CML LSC
is maintained in severe hypoxia. In K562 and KCL22 cells and in primary cells
derived from 9 CML patients, the treatment in hypoxic LC1 with XMD8-92 or
BIX02189, but not with IM, impaired progenitor/stem cell potential. The same
results were obtained by combined treatment of XMD892with IM. Importantly,
XMD8-92 did not affect progenitor/stem cell potential of CD34 cells from
heathy donors. In colony formation ability assays ERK5 inhibition decreased
colony formation by human primary CML cells to a higher extent than that by
normal humanCD34hematopoietic cells. Interestingly, in hypoxia, combined
treatment XMD8-92/IM decreased the expression of genes relevant for stem cell
maintenance such as p21, nanog and c-myc and the expression of CD26, a CML
LSCmarker.Moreover, combinedXMD8-92/IMmaintained low the expression
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of p27, another gene involved in stem cell maintenance, that is increased by
either drug when administered alone. This indicate that the ERK5 pathway
inhibitors impaired LSCmaintenance of CML cell lines and primary CML cells.
#3905 Development of anticancer aptamers targeting cancer stem cells.
Yuh-Ling Chen, I-Shan Hsieh, Keng-Fu Hsu, Tse-Ming Hong. National Cheng
Kung University, Tainan, Taiwan.
Background: Cancer stem cells (CSC), also called tumor initiating cells (TIC),
are a small population of cancer cells within a tumor that drive the tumor initi-
ation, metastasis, and resistance to chemotherapeutic drugs. An effective cancer
stem cell targeting strategy by oligonucleotide-based approaches such as aptam-
ers in diagnosis and treatment are urgently needed. In this study, we aimed to
develop an effective aptamer-based biomarker for CSCs in cancer detection and
therapy.Material andmethods: E-cadherin-null lung cancer cells, shEcad-A549,
was confırmed with stemness properties and used as targeting cells. The isola-
tion of DNA aptamers binding to CSCs was by using a Cell-SELEX (systematic
evolution of ligands by exponential enrichment). By combining the aptamer-
pull-down approach with proteomics, we identifıed the potential binding pro-
teins of CSC-aptamer. Flow cytometry, gene silencing and lung cancer xenograft
models were used to explore the functions of CSC-aptamer and its targeted
protein in lung cancer formation. Results: The aptamer AP-9R was identifıed to
bind lung CSCs with high affınity and specifıcity. AP-9R reduced lung cancer
cell stemness and migration but no apparent cytotoxicity. By using proteomic
approaches, the target protein of AP-9R in non-small cell lung cancer was fur-
ther identifıed and characterized its important role in cancer stemness. ForCSCs
detection, we developed AP-9R conjugated beads and confırmed their effective
captured rate of lung CSCs in vitro. Moreover, administration of AP-9R signif-
icantly reduced lung tumor growth in the xenograft model. Conclusions: Our
data aremoving closer to understand the signifıcance of cancer stem cells during
cancer progression and demonstrate that aptamer-based therapies will be useful
as therapeutic and diagnostic agents for lung cancer.
#3906 Targeting a novel G-protein coupled receptor (GPCR) for elimina-
tion of leukemia stem cells (LSC). Florida Voli, Hangyu Yi, Estrella Gonzales-
Aloy, Jenny Yingzi Wang. Cancer Stem Cell Biology Group - Children’s Cancer
Institute, Randwick, Australia.
Acutemyeloid leukemia (AML) is a lethal blood cancer. Clinical evidence has
highlighted the critical role for leukemic stem cells (LSCs) in the high relapse
rate of AML patients. Understanding the signaling pathways critical for LSC
function will facilitate the development of new therapies to target LSCs. G pro-
tein-coupled receptors (GPCRs) are the most successful drug targets with ap-
proximately 36% of currently marketed drugs targeting human GPCRs (Rask-
Andersen et al., Nat Rev Drug Discov 2011). Aberrant expression of GPCRs has
been observed in various cancers and the importance of GPCRs in cancer stem
cells has begun to be appreciated. In this study, our gene expression profıling
analysis identifıed a novel GPCR (hereafter named NG), which was suppressed
in LSCs compared to normal hematopoietic stem cells. Overexpression ofNG in
pre-LSCs severely impaired leukemia initiation and progression in mice,
whereas knockdown of NG signifıcantly accelerated the disease onset. Our data
also showed that NG overexpression substantially downregulated several well-
known Wnt/-catenin targets (e.g., Tcf7l2, c-Fos and Ccnd1). These data sup-
port a tumor suppressive role for NG in inhibiting leukemogenesis via down-
regulation of Wnt/-catenin signaling. Consistent with these observations,
treatment with an agonist that specifıcally activates the NG signaling pathway
induced a marked decrease in cell viability and growth in murine LSCs and in
human AML THP-1 cells, but had no effects on human AML MOLM-13 cells.
This agrees with our fınding that NG specifıcally targets the Wnt/-catenin
signaling, and the inhibitory effect of the agonist might largely depend on
-catenin expression levels in human AML cells, wherein THP-1 has been re-
ported to express endogenous -catenin but MOLM-13 exhibits no detectable
-catenin expression (Man CH. et al. Blood 2015). In summary, our data sup-
port a tumour suppressor role for NG in leukemogenesis and the forced expres-
sion of NG may provide a means to eradicate LSCs. Thus, restoring NG by the
agonist treatment represents a promising therapeutic strategy for AML treat-
ment.
#3907 Targeting cancer stem cells with microRNA therapeutics and par-
ticle radiation in challenging cancermodels.GuillaumeVares,1 Yannick Sain-
tigny,2 Sei Sai,3 Hirotaka Sugawara,1 Tetsuo Nakajima3. 1Okinawa Institute of
Science and Technology, Onna, Japan; 2CEA, Caen, France; 3QST, Chiba, Japan.
Remarkable progress has been made in the understanding and treatment of
human cancer, resulting in greatly improved survival for many patients. How-
ever, such achievements remain incomplete or out of reach for some hard-to-
treat cancers, such as pancreatic cancer or triple-negative breast cancer. Chon-
drosarcoma is resistant to conventional radiation therapy and to chemotherapy.
Innovative approaches focusing on those challenging cancer models are there-
fore highly expected. There is now wide acknowledgment that tumors are gen-
erally heterogeneous and that cancer treatment failure, relapse or metastasis
may be related a small population of stem-like cells that are capable of self-
renewing and of causing the different lineage of cancer cells comprising a tumor.
These cancer stem cells (CSCs) are more radio-resistant than their non-CSC
counterparts and have a distinct molecular signature. CSCs and differentiated
cancer cells seem to coexist in a dynamic equilibrium influenced by the micro-
environment and by specifıc micro-RNA expression patterns. The development
of new therapeutic strategies (such as micro-RNA modulating strategies) that
selectively target CSCs is currently receiving increasing attention. Particle radi-
ation therapy (such as carbon-ion therapy) is effective at treating various radio-
resistant tumors and has already achieved promising results. Approaches com-
bining high-LET radiation therapy and targeted-therapy have been suggested
for tumors with bad prognosis.We have described a new molecular pathway in
basal-like breast cells, resulting in the generation of breast CSCs.Maintenance of
the CSC phenotype required the downregulation of miR-29 expression and the
upregulation of Klf4 expression. Restoring miR-29 with mimic administration
might therefore improve breast cancer therapy effıciency by targeting CSCs. For
those reasons, we have evaluated the ability of several microRNA-modulating
treatments to reverse CSC phenotype in three experimental in vitro models
(pancreatic cancer, chondrosarcoma, triple-negative breast cancer), in combi-
nation with exposure spread-out Bragg peak (SOBP) carbon-ion beam (at the
HIMACmedical accelerator). In triple-negative breast cells, miR-29 mimic ad-
ministration increased radiation-induced cell death and decreased the propor-
tion of CSCs. We identifıed several other microRNAmimic treatments capable
of improving carbon-ion therapy effıciency by targeting radioresistant CSCs in
those experimental models.
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#3908 The mechanism of premetastatic niche formation through
FBXW7/NOTCH/CCL2 pathway and clinical trial using CCL2 inhibitor
“SK-818” for breast cancer patients. Miwa Noda,1 Takaaki Masuda,1 Naoki
Hayashi,1 Takahiro Kogawa,2 Shinji Ohno,3 Keiichi Nakayama,4 Yohsuke Ku-
roda,1 Hidetoshi Eguchi,1 Shuhei Ito,1 Masafumi Inomata,5 Koshi Mimori1.
1Kyushu University Beppu Hospital, Beppu-shi, Oita, Japan; 2National Cancer
Center Hospital East, Kashiwa-shi, Chiba, Japan; 3The Cancer Institute Hospital
Of JFCR, Tokyo, Japan; 4Medical Institute of Bioregulation, Kyushu University,
Fukuoka, Japan; 5Oita University, Yufu-shi, Oita, Japan.
Background: Metastasis is a major cause of death in cancer patients, & eluci-
dation of the mechanisms is expected to provide a basis for the development of
new cancer treatment. Premetastatic niche whereby tumors prepare defıned
organs for metastasized cells is considered to be crucial for the development of
metastasis, which consists of host cells such asmonocytes,macrophages,&other
inflammatory cells. However, the mechanism of how tumor cells communicate
with host cells to develop a premetastatic niche remains unclear. FBXW7 is the
F-box protein component of an SCF-type ubiquitin ligase, in which it functions
as a receptor responsible for substrate recognition followed by the degradation
of the substrate. Some part of the substrates of FBXW7 regulates the recruitment
of monocytes, macrophages, & other inflammatory cells. Therefore, we hypoth-
esized that expression of FBXW7 in the host cells is a key determinant of the
formation of premetastatic niches. Materials &Methods: To investigate the role
of FBXW7 in the formation of premetastatic niche, we developed bonemarrow-
specifıc FBXW7-defıcient mice. 1. We transferred B16F10 melanoma cells or
E0771 mouse breast cancer cells into the tail vein or mammary fat pad of the
mice & the wild type mice to evaluate the metastatic potential to lung. 2. We
examined the serum concentrations of various cytokines or chemokines in the
mice before & after E0771 cells transplantation using cytokine array. 3. To ex-
amine whether the enhanced metastasis apparent in FBXW7-defıcient mice is
dependent on the CCL2/CCR2 pathway, we treated FBXW7-defıcientmice with
SK-818, a CCR2 antagonist. 4. We measured the expression of FBXW7 mRNA
in peripheral blood of breast cancer patients by qRT-PCR & examined the rela-
tionship between FBXW7mRNA expression& prognosis. Results: 1. The extent
of lung metastasis of B16F10 or E0771 cell was markedly enhanced in FBXW7-
defıcient mice. 2. FBXW7-defıcient mice exhibited increased serum levels of
CCL2. Moreover, accumulation of NOTCH & consequent transcriptional acti-
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vation of CCL2 was observed in bone marrow-derived stromal cells of FBXW7-
defıcient mice. 3. Administration of SK-818 blocked the enhancement of lung
metastasis in FBXW7-defıcient mice. 4. In human breast cancer patients, low
FBXW7 mRNA expression in peripheral blood showed high concentration of
CCL2 in serum & poor prognosis. Conclusions: We found that the FBXW7/
NOTCH/CCL2 pathway play a key role in the regulation of cancer metastasis
through the formation of premetastatic niches, & that SK-818 inhibit cancer
metastasis in mice. SK-818 is currently administered clinically for the treatment
of patients with hepatitis B virus infection in Japan. Based on these fındings, we
have been conducting Phase I clinical trial to assess the safety of SK-818 for
breast cancer patients.
#3909 Investigating the role of ANXA2R in metastatic prostate cancer.
Gonzalo Torga, Kenneth J. Pienta. Johns Hopkins University, Baltimore, MD.
Skeletal metastasis is the most life-threatening complication in prostate can-
cer. Themolecularmechanisms behind the interactions between prostate cancer
and the bonemarrowpremetastatic niche remain unknown.Understanding and
preventing such interactions could lead to new promising therapeutic strategies
against lethal prostate cancer. Annexin 2 receptor (ANXA2R) was originally
identifıed as a cell surface receptor for Annexin 2 (ANXA2) that mediates the
stimulatory effects of ANXA2 during osteoclastic activation and osteoblastmin-
eralization. Moreover, ANXA2R is able to induce apoptosis independent of its
ligand, partially through activating caspases using non-conventional apoptotic
pathways. Osteoblasts and marrow endothelial cells express ANXA2 which
functions as a regulator of hematopoietic stemcell engraftment. Previous studies
demonstrated blocking ANXA2 or its receptor prevents prostate cancer cells
from establishing bonemetastases inmousemodels. It has been recently proven
that ANXA2R does not bind to ANXA2 directly but to S100A10 present in the
complex annexin A2 heterotetramer (AIIt), composed of 2 ANXA2 bound to a
S100A10 dimer. Higher levels of ANXA2 and S100A10 are associated with pro-
liferating and invasive cancers and correlate with poor prognosis. However, the
loss of ANXA2 expression appears to be specifıc for prostate cancer. Previous
work on prostate cancer has focused solely on ANXA2 as a ligand. In this study,
we demonstrate that S100A10 and ANXA2 are co-localized in prostate cancer,
and their expression and ANXA2R levels vary with grade in primary tumors as
well as within the different metastatic sites. Given prostate cancer cells as well as
bone marrow stroma can simultaneously express the ligand and receptor and
levels of AIIt decrease with tumor stage in the primary site, we hypothesize
prostate cancer cells require S100A10 and not only ANXA2 to spread to bone
and other tissues. ANXA2R could act as a dependence receptor,mediatingwith-
drawal-induced programed cell death in prostate cancer cells in the absence of
AIIt. Furthermore, AIIt-ANXA2R interactions between prostate cancer cells
and the premetastatic bone marrow niche might play an important role in the
development of skeletal metastasis by inducing selective pressures on prostate
cancer cells to metastasize to the bone marrow which is abundant of AIIt.
#3910 Analysis of metastatic potential by breast cancer type through a
microfluidic blood-brain niche. Christopher Ryan Oliver,1 Megan Altemus,1
Brendan Leung,2 Aki Morikawa,1 Michele Dziubinski,1 Maria Castro,1 Sofai
Merajver1. 1Univ. ofMichigan, AnnArbor,MI; 2Dalhousie, Halifax, Nova Scotia,
Canada.
Metastasis from the primary tumor site to the brain is the most lethal compli-
cation fromadvanced cancer. 15%of breast cancersmetastasize in the brainwith
a median survival of 5-14 months depending on the subtype. Therefore it is
critical to identify when a tumor has the clonal potential to metastasize to the
brain. Current detection methods and treatment therapies have continued to
improve but do not shed light on clonal metastatic potential. Models for char-
acterizingmetastatic potential of clonal populations currently used includemu-
rine in vivo and simple in vitro systems. Murine models are costly, time inten-
sive, slow to manifest metastasis and are not easy to analyze. On the other hand,
in vitro systems are faster and more cost effective but currently do not recapit-
ulate the complexity of the “live” micro-environment. We have developed a
microfluidic device that mimics the cellular and physical components of the
human blood-brain niche to study the brain metastatic process. The device is
composed of two chambers separate by a porous membrane. The top chamber
and apical side of the membrane is seeded with human brain endothelial cells
and uses flow to mimic shear stress encountered within the vasculature. Cancer
cells are introduced into this chamber in which they adhere to and migrate
through the endothelium into the bottom chamber. The bottom chamber con-
tains astrocytes suspended in a collagen gel to mimic the brain stroma and
provide room for invading cancer cells to colonize and grow. Barrier integrity is
monitoredusingTEER (trans-endothelial electrical resistance), and fluctuates as
the tight junctions of the endothelium are compromised by invading cancer
cells. This is characterized by IF and tight junction staining. Throughout all time
points, from introduction into the flow chamber, adherence to the endothelium,
extravasation through the barrier, migration into the stroma, and proliferation
the cancer cells can be monitored via both microscopy and TEER. We have
applied this microfluidic blood-brain niche model to compare brain-seeking
subclones of breast cancer cell lines of known whole exome sequence and nor-
mal-like cell lines (MCF10A) in terms of their ability to extravasate, migrate and
survive in the niche. We characterize their migratory behavior from live-cell
microscopy and correlate it to the TEERmeasurements to establish a metastatic
model. We then compare metastatic markers for BBN traversing and non-
traversing cells when appropriate.
#3911 Stromal platelet derived growth factor receptor-beta (PDGFRbeta)
promotes breast brain metastasis. Katie A. Thies, Anisha M. Hammer, An-
thony J. Trimboli, B. Eason Hildreth, Luke O. Russell, Chelsea M. Bolyard,
Raleigh D. Kladney, Steven T. Sizemore, Robert Pilarski, Lynn Schoenfıeld, Jose
Otero, ArnabChakravarti, BalveenKaur, Gustavo Leone,Michael C.Ostrowski,
Gina M. Sizemore. The Ohio State University, Columbus, OH.
The platelet derived growth factor (PDGF) pathway is a prime example of
tumor-stroma signaling in a number of cancer types. Others have shown that
PDGF receptors are expressed in breast fıbroblasts and pericytes while PDGF
ligands are often expressed in breast cancer cells and tumor-associated endothe-
lium; however, how PDGF signaling mediates breast cancer initiation, progres-
sion and metastasis remains unclear. Importantly, our evaluation of publicly
available datasets revealed that PDGFB expression correlates with breast cancer
patient metastatic recurrence leading to the hypothesis that PDGF-B to PDGFR
signaling promotes metastatic progression of breast cancer. Given that PDGF-B
preferentially activates PDGFR, we established an in vivo system to investigate
this pathway during breast cancer progression. We utilized a mesenchymal-
specifıc promoter to drive Cre recombinase and conditionally activate PDGFR
by way of the endogenous Pdgfrb promoter (hereafter “PDGFR mutant”). A
murine mammary tumor cell line which expresses high levels of PDGF-B was
injected either by tail vein or intracranially to evaluate metastatic seeding and
distant tumor growth. Following tail vein injection of tumor cells, we observed
50% incidence of brain metastases in the PDGFRmutant mice while no brain
lesions were seen in the controls. There was no difference in incidence of lung,
liver or bone metastases (other common sites of breast cancer metastasis). Not
surprisingly, larger tumors formed in the brains of PDGFRmutant mice when
cells were injected intracranially. Brains were stained for phospho-PLC as a
way to confırm activation of PDGFR. To our knowledge, this is the fırst exam-
ple where genetic manipulation of the stroma leads to an increased incidence of
breast brain metastases. Furthermore, this study highlights a role for stromal
activation of PDGFR in the brain microenvironment and during metastatic
progression. For the 20-30% of patients that develop breast cancer brain metas-
tases, the one-year survival rate is sadly less than 20%, and how the brain mi-
croenvironment contributes to metastatic seeding and subsequent growth of
tumor cells remains poorly understood. To confırm translational relevance, we
analyzed a small cohort of matched primary breast tumors and brainmetastases
for PDGFR expression observing strong stromal staining in fıbroblasts and
pericytes within and around all of the primary tumors similar to previous stud-
ies. Importantly, high PDGFR expression was found in the perivasculature of
all associated brain metastases suggesting a functional role in the establishment
or growth at this site. Combined, our fındings strongly suggest that high primary
tumor expression of PDGF-B/PDGFR might defıne a subset of breast cancer
patients predisposed to brain metastases. These patients may benefıt from ther-
apeutic targeting of PDGFR signaling as ameans to thwart metastatic seeding in
the brain.
#3912 Pancreatic cancer cell interaction with platelets impedes cell cycle
progression and increases viability. Andrew C. Cannon, Sushil Kumar, Brad-
ley Hall, Rakesh Bhatia, Rakesh Singh, Surinder Batra. University of Nebraska
Medical Center, Omaha, NE.
Background: Metastasizing cancer cells rapidly associate with platelets in cir-
culation, but the nature and functional consequences of this interaction have yet
to be fully elucidated. Here we investigated the physical interaction of platelets
with pancreatic cancer (PC) cells and the contribution of platelet-derived plate-
let factor 4 (PF4) mediated signaling in PC cells. Methods: Immunohistochem-
istry (IHC) andwestern blot analysis were performed to characterize the expres-
sion of PF4 receptor, CXCR3, in 42 Whipple samples and 8 PC cell lines
respectively. Physical interaction of human platelets with PC cell lines and its
impact on PC cell proliferation in low attachment conditions was analyzed by
flow cytometry. Cell viability was assayed by MTT analysis. Immunofluores-
cence analysis was performed to evaluate PF4 induced autophagy. Results: IHC
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and western blot analysis in Whipple samples showed CXCR3 expression in 86
percent of the pancreatic tumors and on all the tested PC cell lines respectively.
Flow cytometry demonstrated that 24 percent of Capan1 cells interacted with
platelets. Interestingly, incubation of platelets with cell-cycle-synchronized Ca-
pan1 cells under low attachment conditions inhibited the proliferation of PC
cells (10 percent) at 24 but not 48 hours. This effect was abrogated by phar-
macological inhibition of CXCR3 with AMG487. Concurrently, the viability of
Capan1 cells grown in low attachment conditions and treated with platelets for
72 hours was greater than that of control and AMG487 with platelets treated
groups as assessed by MTT assay. Mechanistic studies suggested that recombi-
nant PF4 augments autophagosome formation as an early event and increases
the expression of p21 as a late event. Of note, both LC3 punctation and p21
expression are abrogated by concomitant incubation with PF4 and AMG487.
Conclusion: Platelets appear to rapidly interact with cancer cells in suspension.
Additionally, in a PF4-CXCR3 signaling dependentmanner, platelets inhibit cell
cycle progression and increase PC cell viability in low attachment conditions.
Cumulatively, these data suggest that platelets aid in the metastatic dissemina-
tion of pancreatic cancer cells.
#3913 CXCL1 is critical for pre-metastatic niche formation and metasta-
sis in colorectal cancer. Dingzhi Wang,1 Haiyan Sun,2 Raymond N. DuBois1.
1Medical Univ. of South Carolina, Charleston, SC; 2Arizona State University,
Tempe, AZ.
Emerging evidence suggests that the primary tumor induces the formation of
pre-metastatic niches in certain distant organs. However, themechanisms underly-
ing the contributions of the primary tumor to pre-metastatic niche formation are
not fully understood. Here we demonstrate that colorectal carcinoma cells secrete
VEGF-A that stimulates tumor-associated macrophages to produce CXCL1 in the
primary tumor. Elevation of CXCL1 in pre-metastatic liver tissue recruits CXCR2-
positive myeloid-derived suppressor cells to form a pre-metastatic niche that ulti-
mately promotes liver metastases. Importantly, we found that pre-metastatic liver-
infıltrating MDSCs induce tumor cell survival without involvement of innate or
adaptive immune responses. Our work not only reveals a novel mechanism by
which the interactions of malignant cells with their stromal counterparts in the
primary tumor contribute to the formation of a pre-metastatic niche that favors
tumor cell survival, but also provides a rational for development of CXCR2 antago-
nists to inhibit or prevent metastatic spread of disease. Overall, our study provides
the fırst evidence we know of showing that primary malignant cell-secreted
VEGF-Astimulates tumor-associatedmacrophages toproduceCXCL1that recruits
CXCR2-positive MDSCs to form a pre-metastatic niche which promotes liver me-
tastases. Our fındings not only shed light on how the tumor microenvironment
contributes to pre-metastatic niche formation at distant sites, but also provide com-
prehensive insights into howMDSCs are recruited to other organs where they con-
tribute to metastatic spread of disease.
#3914 KLF4-dependent perivascular plasticity enhances pre-metastatic
niche formation and metastasis. Meera Murgai, Wei Ju, Matthew Eason, Jes-
sica Kline, Rosandra N. Kaplan.National Cancer Institute, National Institutes of
Health, Bethesda, MD.
Metastasis causes most cancer deaths, and new therapies that are based on a
deeper understanding of this process are required to improve patient survival.
Metastatic tumor cell colonization and growth is facilitated by a pre-metastatic
niche microenvironment composed of hematopoietic cells, stromal cells, and
extracellular matrix that support tumor survival and growth. Perivascular cells,
including vascular smooth muscle cells (vSMCs) and pericytes, are a key cell
population involved in new vessel formation critical to primary tumor develop-
ment. Given the well-described plasticity of perivascular cells, we sought to
determine whether perivascular cells regulate tumor cell survival and prolifera-
tion at metastatic sites. Using perivascular cell-specifıc and pericyte-specifıc lin-
eage tracing models, we demonstrated that perivascular cells lose traditional
vSMC/pericyte marker expression in response to tumor-secreted factors, and
exhibit increased proliferation, migration and extracellular matrix (ECM) syn-
thesis. Expression of the pluripotency gene Klf4 is increased and is critical for
this phenotypic transition to a less differentiated state characterized by increased
proliferation and ECM production. Genetic inactivation of Klf4 specifıcally in
perivascular cells decreases pre-metastatic perivascular cell proliferation and
consequently integrin-fıbronectin dependent tumor metastasis. Our data reveal
a previously unidentifıed role for perivascular cells in pre-metastatic niche for-
mation, and suggest that modulation of stromal cell plasticity may provide a
novel strategy for limiting metastasis.
#3915 Copper depletion as an approach for metastatic disruption in Tri-
ple Negative Breast Cancer.Divya Ramchandani, Vivek Mittal, Linda Vahdat.
Weill Cornell Medical College, New York, NY.
Triple-Negative Breast Cancer (TNBC) occurs in approximately 17-20%
of all breast cancer patients, and has an aggressive clinical course even in
patients with early disease stage, with peak of relapse at 3 years after diagno-
sis with (35%-40%) of TNBC patients relapsing within 5 years of diagnosis.
Targeted therapies do not exist for TNBC. Recently, copper (Cu) has
emerged as an essential factor in tumor growth and metastasis supporting
the notion that Cu-depletion may serve as an attractive therapeutic strategy.
Using historical controls, a promising single arm Phase II trial of Tetrathi-
omolybdate (TM) in breast cancer patients, who were at a high-risk of re-
lapse (Stage 3 and Stage 4 with no evidence of disease BC and Stage 2 if
triple-negative), was conducted at Weill Cornell. At a median follow-up of
5.9 years, the progression-free survival for all patients enrolled in this study
is 72% and the overall survival is 84%. Importantly, levels of circulating
LOXL2 and VEGFR2 endothelial progenitor cells were decreased with
Cu-depletion (Chan et al. 2016). With the knowledge about the effıcacy of
TM, it is currently unknown where the effectiveness of Cu-depletion lies,
whether it acts at the pre-metastatic site, on circulating tumor cells, or at the
primary tumor site. We utilized an immunodefıcient in vivo breast cancer
model that metastasizes to lungs (MDA231-LM2) in order to evaluate the
effect of Cu-depletion in metastasis, where the animals were either TM-
treated or untreated. To identify whether LOXL2 is a dominant factor down-
stream of TM-Cu axis in metastasis suppression, as observed in clinical trials
(Chan et al. 2016), we used “LOXL2-depletion, Cu-repletion” strategy. We
also examined the global functional changes between TM-treated and un-
treated groups for various Cu-dependent proteins and angiogenic factors at
the pre-metastatic site and primary tumors. We found that TM-treatment in
the in vivo model signifıcantly lowered disseminated tumor cell population
in animals that were successfully Cu-depleted. Cu-depletion also altered
pre-metastatic niche formation. We are currently exploring the effect of
Cu-depletion on primary tumor and its surrounding microenvironment that
might affect tumor cell shedding, leading to metastasis. In summary, this
study holds essential groundwork for the identifıcation of a strong mecha-
nistic arm for TM therapy in the suppression of metastasis/metastatic relapse
in TNBC patients. Thus, aiding in the development of additional therapeutic
options, which may be particularly useful for a subset of TNBC patients
impervious to Cu-depletion with single-agent therapy, or for whom Cu-
depletion is insuffıcient to prevent metastasis, and may also be extended to
other metastatic solid tumors that are responsive to Cu-depletion therapy.
#3916 Disease-specifıc markers may be used for the identifıcation of dis-
seminated tumor cells in the bone marrow of patients with prostate cancer.
Emma E. van der Toom, Stephanie A. Glavaris, Michael A. Gorin, James A.
Verdone, Kenneth J. Pienta, Heather J. Chalfın. The Johns Hopkins School of
Medicine, Baltimore, MD.
Introduction: The detection of microscopic disseminated disease in prostate
cancer has largely been attempted with the study of circulating tumor cells
(CTCs). Little is known about the character and clinical signifıcance of dissem-
inated tumor cells (DTCs) that have reached the bone marrow (BM) niche, and
prior studies has relied on epithelial markers. Yet, it is known that suchmarkers
are also expressed on normal erythroid precursor cells in the BM, thus we de-
veloped an assay for prostate-specifıc DTC identifıcation. Materials and Meth-
ods: BM aspirates from 18 men with localized and 2 men with metastatic pros-
tate cancer were collected at time of RP or clinic visit respectively, and processed
with the AccuCyte system (RareCyte, Inc., Seattle, WA). Slides were immuno-
stained with DAPI (nuclear), anti-pan-cytokeratin (epithelial), anti-CD45/
CD66b/CD11b/CD14/CD34 (white blood cell), and the prostate-specifıc mark-
ers HOXB13 and NKX3.1 (prostate). DTCs were detected using the CyteFinder
system. DTCs were required to have positive prostate channel staining and no
white blood cell signal. Results: DTCs were present in 89% (16/18) of patients at
time of RP,with range 0 to 3592 cells/4mL sample (average 270,median of 39.5).
Two patients with metastatic prostate cancer had 52 and 105 DTCs/4mL BM
(Table 1). Notably, only 5% of all DTCs were epithelial marker positive (CK),
and only 44% (8/18) of patients had anyCKDTCs.Conclusions: TheRareCyte
system is a promising selection-free system forDTCsdetection that does not rely
on epithelial markers. Here we report on a novel assay to distinguishDTCs from
other cells in the bone marrow using the presumed prostate-specifıc markers
HOXB13 and NKX3.1. Furthermore, we show that the majority of prostate-
specifıc marker positive DTCs did not express the epithelial marker CK. Analy-
ses of the association ofDTCcountwith clinicopathologic variables are ongoing.
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Table 1. Clinicopathologic Data and DTC Counts of the Cohort
Bx
Gleason
RP
Gleason
Metastatic/
Localized PSA
# of
DTCs
CK
DTCs
CK-
DTCs
% of
CK-DTCs
336 336 Localized 4.3 0 0 0 N/A
336 336 Localized 6.3 9 0 9 100%
336 437 Localized 3.9 48 12 36 75%
336 347 Localized 3.46 15 0 15 100%
347 347 Localized 5 25 0 25 100%
347 347 Localized 4.5 27 9 18 100%
347 347 Localized 8.1 12 0 12 100%
347 347 Localized 7.5 34 0 34 100%
347 347 Localized 6.7 81 21 60 74%
437 437 Localized 16.3 114 24 90 79%
437 437 Localized 5.9 135 27 108 80%
437 347 Localized 8.3 45 0 45 100%
437 347 Localized 3.1 225 48 177 79%
437 437 Localized 9 429 117 312 73%
437 347 Localized 4.3 3592 0 3592 100%
459 459 Localized 10.1 0 0 0 N/A
459 448 Localized 9.1 6 0 6 100%
459 459 Localized 9.4 60 9 51 85%
459 N/A Metastatic 5.79 105 15 90 86%
459 N/A Metastatic 65 52 8 44 85%
#3917 GenoCTC, a liquidbiopsydevice usingmicrofluidic enrichment for
affınity-based isolation of circulating tumor cells. Jiyeon Ryu,1 Do Hyung
Kim,1 Gyeong-Mi Kim,1 Jin Soo Kim,2 Youngkee Shin,3 Jaeku Lee,1 Hun Seok
Lee1. 1GenoBio. Corp, Seoul, Republic of Korea; 2Seoul National University Bora-
maeMedical Center, Seoul, Republic of Korea; 3Research Institute of Pharmaceu-
tical Science, Seoul National University, Seoul, Republic of Korea.
To achieve a complete remission of cancer is still challenging that most pa-
tients with solid cancer ultimately experience metastasis. Detection of circulat-
ing tumor cells (CTCs) from the peripheral blood is promising key to solve the
cancer cell dissemination and make accurate diagnosis, therefore, many efforts
have beenmade to isolate the CTCs. Here, we newly developed the liquid biopsy
device, GenoCTC, with microfluidic chips isolating CTCs from the patient
whole blood. To isolate CTCs, EpCAM CTCs in the whole blood are fırst
bound with magnetic beads conjugated with human-EpCAM antibody, and
GenoCTC and its chip can isolate the EpCAM CTCs through magnetic based
method. With 7.5 mL whole blood from lung cancer patient, we isolated Ep-
CAM CTCs, and these CTCs were validated by immunofluorescence assay
using anti-CK and anti-CD45.We also enumerated EpCAMCTCs in 17whole
blood samples from 10 lung cancer patients that various number, 2 to 114, of
CTCs were found from each patient. The number of CTCs is known to have a
correlationwith disease progression and chemo-resistance, so the clinicalmean-
ing of this result is needed to be investigated. Furthermore, some CTCs are also
found to be EpCAM independent which is regarded to have clinical utility in-
volved in EMT. We used plastin-3 as its marker, and it was confırmed with HS
578T breast cancer cell line which shows low expression of EpCAM but high
expression of plastin-3. The various molecules expressed on CTCs can be iso-
lated with GenoCTC for further study. The characterization of CTCs is not only
limited to EpCAM expression that it is important to be elucidated the complex
biology of CTCs to apply companion diagnosis for personalized medicine.
#3918 Identifıcation of disseminated prostate tumor cells in bonemarrow
during radical prostatectomy from patients with localized prostate cancer.
Stephanie A. Glavaris, Emma E. van der Toom, Michael Gorin, James Verdone,
Changxue Lu, Jun Luo, Kenneth Pienta, Heather Chalfın. JohnsHopkins Univer-
sity, Baltimore, MD.
INTRODUCTIONANDOBJECTIVES: In prostate cancer, disseminated tu-
mor cells (DTC) can escape the primary lesion and enter the bonemarrow (BM)
niche, representing an initial step towards conventionally detectable metastasis.
The frequency of occurrence is elusive in clinically localized prostate cancer.We
detected and characterized these cells bymeasuring gene expression of prostate-
specifıcmarkers fromBM samples collected at the time of radical prostatectomy
(RP). METHODS: 5 mL of BM were harvested at RP for 36 clinically localized
patients. A whole cell extract was assayed with the AdnaTest ProstateCancer-
Select kit (Qiagen). Reverse transcription (SensiScript RT kit, Qiagen) and real-
time qPCR quantifıed expression of RPL13A (control, ribosomal protein), EP-
CAM (epithelial), NKX3.1 andHOXB13 (prostate-specifıc), andAR-FL (andro-
gen receptor full length). Prostate markers known to be less sensitive or specifıc
were also assayed in a subset of patients (TMPRSS2-ERG, AR-V7, PSA, and
PSMA). DTC detection was defıned as prostate-specifıc marker expression in
the BM. Quality control was performed with Sanger sequencing. The associa-
tions of PSA and Gleason score (GS) with DTC detection were evaluated with
the Mann-Whitney U Test and Fisher’s exact test respectively. RESULTS: DTC
were detected via NKX3.1 expression in 30/36 patients (83%). 100% of patients
were EPCAM, consistent with the known non-specifıc expression of EPCAM
in the BM. HOXB13, AR-V7, and TMPRSS2-ERG were not detected in any
sample. AR-FLwas also non-specifıcally expressed in 67%ofNKX3.1 and 83%
of NKX3.1- patients. There was a pattern with DTC detection and higher PSA
and GS, with 100% of NKX3.1- patients having low-risk PSA less than 10, and
only one with primary GS greater than 3 (17%, 1/6). Conversely 47% (14/30) of
NKX3.1 patients had primary GS greater than or equal to 4, and 27% (8/30)
had PSA greater than 10. Yet, this was not statistically signifıcant (GS p0.367,
PSA p0.302), and DTC were detected across all Gleason scores. CONCLU-
SIONS DTC were detected based on NKX3.1 positivity in a large portion of
clinically localized prostate cancer patients at all Gleason scores. Ongoing inves-
tigation with healthy patient BM will clarify whether NKX3.1 is truly prostate-
specifıc, and if its expression associates with clinico-pathologic outcomes.
#3919 Isolation and characterization of viable pancreatic cancer circulat-
ing tumor cells using size-based fıltration system. Kenneth H. Yu,1 Benjamin
D. Krempley,2 BrianMcCarthy3. 1Memorial SloanKettering Cancer Center, New
York, NY; 2Charles E. Schmidt College of Medicine, Boca Raton, FL; 3Viatar CTC
Solutions Inc, Lowell, MA.
Introduction: Circulating tumor cells (CTCs) are important actors in metas-
tasis, a key feature of pancreatic ductal adenocarcinoma (PDAC). The ability to
isolate, characterize and culture viable CTCs holds promise for understanding
biology, treatment response and resistance. Methods: Peripheral blood samples
fromhealthy donors and patients with advanced PDACwere processed using an
innovative size fıltration system (Viatar LLC, LowellMA).Normal humanblood
samples were spiked with varying numbers of human PDACorganoid cells. The
impact of buffy coat separation was studied. Isolated CTCs were cultured in
Matrigel to generate organoids as previously described. Cells were imaged with
fluorescently labeled antibody to EpCAM. Data: Using spiked normal human
blood samples, viable CTCs can be isolated and expanded reliably in 3D or-
ganoid culture from as few as 10 CTCs/mL. Separation and processing of the
buffy coat enriched for the number of viable CTCs isolated. EpCAM positive
CTCswere isolated from6/6 blood samples frompatients with advanced PDAC.
Updated results will be presented. Conclusions: The current size-based fıltration
system allows for collection of viable CTCs from human PDAC blood samples.
Current work will use this system to grow, expand and characterize human
PDAC CTCs in organoid culture. Genetic, transcriptional, and epigenetic char-
acteristics will be compared with the primary tumor. CTC characteristics will be
studied as biomarker of treatment response and resistance.
#3920 Tumor volume as a predictor of lymph nodemetastases in prostate
cancer. Chidi N. Molokwu, Keith Yuen, Sanjay Addla, Rajindra Singh, Rohit
Chahal. Bradford Royal Infırmary, Bradford, United Kingdom.
Introduction: Pelvic lymph node dissection (PLND) is recommended during
radical prostatectomy (RP) in patients with high risk prostate cancer (PCa).
Guidelines recommend extended PLND in patients who have5% probability
of lymph node involvement, calculated from pre-operative parameters. PLND
increases procedure time and potential morbidity to patients. Tumour size has
been reported to be predictive of biochemical recurrence after RP. We analysed
the utility of several parameters including tumour size in predicting lymph node
metastases in order to further refıne the population who require PLND during
RP. Materials & Methods: We maintained a prospective database of Robotic
Assisted Radical Prostatectomy (RARP) from July 2012 to August 2016 consist-
ing of a cohort of 531 patients. Patients with 5% calculated probability of
lymph nodemetastasis had PLND during RARP.We performedmultiple linear
regression using age, PSA, D’Amico risk score, ISUP prognostic group, clinical
T-stage, radiological T-stage, tumour volume, tumour volume relative to pros-
tate size (relative tumour volume), and number of nodes excised during PLND
todetermine if any of these parameters could predict the presence of lymphnode
metastases. Results: Of the cohort of 531 patients, 154 had PLND during RARP.
Of the PLND cohort, 15 (10%) had pN1 disease. Tumour volume (r2 0.044, p
0.0098), relative tumour volume (r2 0.033, p0.026) and number of lymph
nodes excised (r2 0.046, p0.0075) were independent predictors of pN1 disease.
D’Amico risk score (r2 0.019, p0.089) approached but did not reach statistical
signifıcance. Patients with pN1 disease all had primary tumours6cc. Conclu-
sions: In our cohort of PLND patients, tumour volume was an independent risk
factor for pN1disease.With the increasing availability ofmulti-parametricMRI,
tumour volume can bemeasured pre-operatively as an adjunct to PIRADS scor-
ing. The role of tumour volume and relative tumour volume in predicting lymph
node metastasis in conjunction with other pre-operative parameters requires
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further investigation. The use of tumour volume in determining the need for
PLND in patients undergoing RP may help to further refıne the population at
highest risk for pN1 disease and avoid the additional morbidity of PLND in
those at low risk. In addition, our fındings support the recommendation of
performing an extended PLND to maximise regional lymph node clearance.
#3921 Detection of circulating tumor cells in osteosarcoma: A validation
study using a translational model. Marilia Takada,1 Ya-Ting Yang,1 Hunter
Piegols,1 Paulo Vilar Saavedra,1 Cha-Mei Tang,2 Pete Amstutz,2 Vilma Yuzbasi-
yan-Gurkan1. 1Michigan State University, East Lansing, MI; 2Creatv MicroTech,
Inc., Potomac, MD.
Osteosarcoma (OS) is themost commonprimary bone cancer in humans, and
most frequently seen in pediatric patients. Metastasis to distant organs via he-
matogenous route is the leading cause of mortality in OS. Current methods to
detect metastasis and to monitor response to treatment largely depend on im-
aging systems with low sensitivity to micrometastases. The value of circulating
tumor cells (CTCs) as prognosticmarker has been demonstrated in several types
of malignancies, including cancer of breast, prostate and colorectal. The objec-
tive of this study was to establish a protocol to quantify CTC in patients withOS,
as a biomarker for the presence ofmicrometastases and early detection of tumor
relapse.We used dogs with spontaneous OS as a unique translational model. OS
occurs in dogs with a 15-fold higher incidence than in humans. Our experimen-
tal method consisted of the isolation of CTCs using the microfıltration system
CellSieve™, and further enumeration of tumor cells by immunostaining. Normal
blood cells were spikedwith culturedOS cells and processed using theCellSieve™
systemwhere theCTCs are captured on amicrofılter and then incubatedwith an
antibody mixture consisting of fluorescent dye-conjugated antibodies against
Osteocalcin, Vimentin, and CD45R. We demonstrated that osteosarcoma tu-
mor cells could be recovered from the blood and characterized by 4-channel
immunofluorescence assay as Osteocalcin / Vimentin / DAPI  and
CD45R-, where CD45 serves as a differential marker of normal blood cells. In
addition,wewere able to demonstrate that the systemhas a 98%yield of recovery
of spiked tumor cells. When this protocol was applied to 7.5 ml of blood sample
from a naïve large breed dog diagnosedwithOS, wewere able to detect one CTC
with the predicted staining pattern. Ongoing studies evaluating CTC through-
out the clinical course of dogs with OS will determine the value for prognosis as
well as for evaluating response to therapy. In conclusion, the CellSieve™ micro-
fıltration platform applied with a set of 4 immunofluorescent antibodies is an
effective method for detection of CTCs in canine OS.
#3922 NR2F1 limits dissemination and stemness of early breast cancer
cells.Maria Soledad Sosa. Icahn School of Medicine at Mount Sinai, New York,
NY.
Tumor cells derived from MMTV-Neu mouse models or human ErBb2
primary tumors are known to be able to complete all steps of the metastatic
cascade.However, new evidence show thatNeu early cancer cells derived from
early stages of tumor progression (before detection of palpable tumors), can
disseminate and, as disseminated cancer cells (early DCCs), enter a non-prolif-
erative state for prolonged periods of time at secondary organs. We recently
showed that early DCCs contributed tometastasis formation together with late-
arriving DCCs (those coming from overt tumors). However, the mechanisms
that would allow these early cancer cells, considered sessile and with few genetic
alterations, to complete all steps of metastasis are unknown. Here we report that
downregulation of the orphan nuclear receptor NR2F1 in Neu early cancer
mammary epithelial cells (MECs) further activated a motile phenotype and this
was coincident with previously described detection of circulating cancer cells
(CCCs) and lung and bonemarrowDCCs inMMTV-Neumousemodel. Knock
down of basal NR2F1 levels inNeu early cancer cells induced cell motility, loss
of laminin-V deposition, -catenin delocalization from the membrane, dra-
matic loss of E-cadherin junctions and increased percentage of leader cells pos-
itive for CK14 and PRRX1 staining. Interestingly, TWIST and PRRX1 levels
became upregulated upon NR2F1 depletion in 3D structures. These results sug-
gest that NR2F1 expression maintains epithelial identity and suppresses epithe-
lial-mesenchymal transition (EMT). Knock down of NR2F1 in Neu early can-
cer cells enhanced mammosphere formation effıciency and this was
accompanied by upregulation of the pluripotency transcription factor NANOG
andEMTmaster regulator TWIST. Interestingly, early dormantDCCs (negative
for proliferation markers) showed re-expression of NR2F1 levels while micro-
metastases (cycling cells) had reduced levels of NR2F1. This result suggests that
downregulation of NR2F1 in early DCCs may contribute to the dormancy es-
cape of early DCCs and consequently metastatic relapse. Our fındings provide
for the fırst time evidence that NR2F1 functions as a suppressor of stemness and
dissemination during early stages of tumor progression. We propose that ther-
apies that restore expression of NR2F1 might limit early dissemination and the
progression of early and late-arriving DCCs toward metastatic outgrowth.
#3923 Oncogenic kinase-induced PKM2Y105 phosphorylation promotes
tumorigenesis and cancer stem cell-like property. Zhifen Zhou,1 Min Li,2 Lin
Zhang,1 Dihua Yu1. 1MD Anderson, Houston, TX; 2Baylor College of Medicine,
Houston, TX.
The role of pyruvate kinase M2 isoform (PKM2) in tumor progression is
controversial. Previously, it was reported that PKM2 has an oncogenic function
in promoting tumor growth in xenograftmodels; however, PKM2was indicated
non-oncogenic or even anti-oncogenic because depletion of PKM2 accelerates
mammary tumor growth in the Brca1 knockout mouse model of breast cancer.
Since tumors frequently harbor various abnormally activated oncogenic kinases,
we hypothesized that phosphorylation of PKM2 by oncogenic kinases in tumor
cells enables PKM2 to promote tumor growth, while unphosphorylated PKM2
in non-transformed cells cannot promote tumor growth. Here, we report that
PKM2 proteins were largely unphosphorylated and formed tetramers in normal
mammary epithelial cells (MCF10A, MCF12A). On the other hand, PKM2 pro-
teins were phosphorylated at Y105 and formed dimers in breast cancer cells
(MDA-MB-231, MDA-MB-435). Knocking down PKM2 didn’t affect normal
mammary epithelial cell (MCF10A) growth but signifıcantly decreased breast
cancer cell MDA-MB-231 proliferation. In addition, introducing the PKM2-
Y105D phosphomimetic mutant into MCF10A cells induced epithelial to mes-
enchymal transition, increased CD44Hi/CD24Neg stem cell-like cell population,
and induced colony formation in soft agar, promoted cell migration and inva-
sion. Interestingly, PKM2-Y105D increased YAP1 protein nuclear localization
in MCF10A cells, whereas inhibiting YAP1 by siRNA or a chemical inhibitor
(Verteporfın) decreased PKM2-Y105D-induced cancer stem cell-like popula-
tion and colony formation ability. The data indicate that YAP1 is a novel down-
stream target of pY105-PKM2 in promoting the stem-like property and trigger-
ing mammary tumor initiation. Next, we performed receptor tyrosine kinase
array and identifıed several oncogenic tyrosine kinases (AXL, EPHA2, FAK, Src,
JAK3 and so on) that effectively phosphorylates PKM2 at Y105. Currently, we
are testing the effıcacy of targeting these oncogenic tyrosine kinases in reversing
the phosphorylation of PKM2 and blocking its tumor-promoting function. To-
gether, our data indicate that oncogenic kinases-induced phospho-Y105-PKM2,
but not the unphosphorylated PKM2, promotes mammary tumor initiation by
increasing cancer stem cell populations.
#3924 Single-cell mechanical characteristics of human breast cell lines
analyzed by multi-constriction microfluidic channels. Xiang Ren, Parham
Ghassemi, Hesam Babahosseini, Jeannine S. Strobl, Masoud Agah. Virginia
Tech, Blacksburg, VA.
Studies of themechanical characteristics of single cancer cells have shown that
non-metastatic and metastatic cells have signifıcant differences in stiffness. We
used a microfluidic multi-constriction channel device to differentiate cancer
cells and normal cells based upon differences in theirmechanical properties.We
fabricated the multi-constriction channels on a silicon wafer with SU-8 photo-
lithography and polydimethylsiloxane (PDMS) soft-lithography, followed by
PDMS and glass bonding after plasma treatment. Themulti-constrictionmicro-
fluidic channel contains fıve constriction channels each 50 m in length sepa-
rated by relaxation sections of 50 m between every constriction channel. We
usedMDA-MB-231 as the cancer cell line andMCF-10A as the normal cell line,
and utilized a smart phone to record video via a microscope. Our measurement
by smart phone slow-motion video through microscope reliably collected the
velocities of over 200 cells. We focused on comparing the initial velocity change
due to cell deformation at the entrance of the fırst constriction channel and the
exiting velocity at the last segment of the fınal constriction channel, where the
cells have experienced sequential deformations. The multiple deformation par-
adigm tests cells’ resilience towards deformation and shape recovery. Cancer
cells recovered back to a round cell shape quickly, and therefore experienced
deformation at the entrance to each constriction channel, with a net result of a
decrease in velocity. The initial velocities of MDA-MB-231 cells were 1.1
mm/s, and exiting velocities were 2.2 mm/s. In contrast, normal cells de-
formed slower initially, but reached a higher velocity after two or three defor-
mations, because normal cells stay in a rod-like shape without fully recovering
back to an original spherical cell shape. The initial velocities of MCF-10A cells
were 0.5 mm/s, and exiting velocities were 3.8 mm/s. When normal cells
enter the fourth and fıfth constriction channels, the cells’ shapes were almost
fıxed. The entrance time of cancer cells into the fourth and fıfth channel was
longer than the normal cells. After calculating the velocity increments in the
fourth channel and fıfth channel compared to the initial velocity, the Matlab
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scatter plot of the velocity data of eachMDA-MB-231 (n 108 cells) andMCF-
10A (n 105 cells) cells showed clear separation of the two cell lines into distinct
regions. Algorithms based upon these criteria successfully differentiated
94.4%of the cancer cells fromnormal cells.Our experimental results indicated
that multi-constriction microfluidic channels can be used to differentiate meta-
static MDA-MB-231 and MCF-10A cells at the single cell level and may have
further applications in high-throughput cell sorting and analysis. The authors
would like to thank National Institute of Health (NIH) R21CA210126 for sup-
porting this research.
#3925 Integrative platform for the reconstruction and modeling of me-
chanically arrested single cells in the brain vasculature under spatial con-
straint and shear stress.Wendy V. Alvarez Barrios,1 Huijie Lu,1 Kyle R. Cow-
drick,1 Michelle Galarneau,1 Lan Jiang,1 Melinda Lake,2 Lin Yang,1 Danny
Chen,1 David Hoelzle,2 Zhangli Peng,1 Siyuan Zhang1. 1University of Notre
Dame, South Bend, IN; 2Ohio State University, OH.
During metastasis of breast cancer, tumor cells dissociate from the primary
tumor, disseminate through the vasculature, and colonize secondary organs
such as the brain, lungs, liver and bones. The mechanical arrest of circulating
tumor cells (CTCs) in capillary beds is an essential step in themetastatic cascade
for the successful early colonization of secondary organs. During mechanical
arrest, tumor cells are subjected to extreme physical stresses such as shear stress
and spatial constraint exerted by blood flow, as well as from compression by the
constricting capillary on the restricted cell. These mechanical stresses may crit-
ically impact metastatic success. However, the precise physical and mechanical
response of the disseminated tumor cells at the time of arrest in the vasculature
to the forces of spatial constraint and shear stress remain largely unknown.Here
we present an integrative platform that combines the use of amicrofluidic device
and computationalmodel as a tunable system to reliably reproduce themechan-
ical arrest of single cells and quantitatively determine their physical response to
precisely controlled mechanical forces of shear stress and spatial constraint.
Using confocal microscopy and computational modeling, we found that during
mechanical arrest, single tumor cells undergo extrememorphological deforma-
tions. Furthermore, the cellmorphology is dependent on themagnitude of shear
stress applied; with magnitudes above 60Pa inducing elongation, blebbing, and
rupture of the cell membrane. Our results demonstrate that our integrative plat-
form is a viable model system for the qualitative and quantitative study of phys-
ical cell behavior precisely at the metastatic stage of mechanical arrest. Particu-
larly, our results highlight the direct influence of physical forces on the restricted
tumor cell, and suggest the importance of these external cues as dynamic deter-
minants of cellular processes and ultimately ofmetastatic success.We anticipate
our platform to be a starting point for future studies seeking to understand the
reciprocal molecular and biophysical interplay imposed bymechanical forces at
the greatly understudied stage of mechanical arrest in metastasis.
#3926 Is FGD3 a potentially prognostic marker for breast cancer. Yuliang
Sun, ScooterWillis, Xiaoqian Lin, Justin Achua, CaseyWilliams, Brian Leyland-
Jones. Avera Center for Precision Oncology, Sioux Falls, SD.
Background: Prognostic factors are capable of providing information on clin-
ical outcomes at the time of diagnosis; they are usually indicators of growth,
invasion, and metastatic potential (Gasparini G. et al. 1993; Hayes DF. et al.
1998). Tissue marker is one of the prognostic factors; to date, only a small pro-
portion of markers are ultimately clinically useful, including Ki-67 and HER2.
Faciogenital dysplasia 3 protein (FGD3), a putative regulator of cell morphology
and motility, has been shown to regulate cell migration. In a study of 3,256
tumors, low expression of FGD3mRNA indicates poor outcome (HayakawaM.
et al. 2008; Scooter W. et al. 2014). However, an immunohistochemistry (IHC)
study to evaluate FGD3 protein expression has not been done. We hypothesize
that the expression levels of FGD3 protein by IHCmight improve the prediction
of patient outcomes, and FGD3 might be a potentially prognostic marker of
breast cancer.Materials andMethods: 322 cases of breast cancerTissueMicroar-
rays (TMA) (BR1504a, BR1505b, HBre-Duc068Bch-01, and BR20837) were
purchased from US Biomax, Inc (Rockville, MD). Rabbit polyclonal antibody
against FGD3 was purchased fromNovus Biologicals, LLC (Littleton, CO). Tis-
sue cores were stained for FGD3 with Dako’s EnVision  Dual Link System.
Image acquisition was performed using an Olympus camera and software.
FGD3 protein expression by IHC was quantitatively determined in the range of
0-4. Unpaired t-test was used for data analyses. Results: 1) Benign tumor and
breast adenocarcinomas in lower stages showed strong expression of FGD3,
whereas the breast adenocarcinomas in higher stages showed mild weak ex-
pression. 2) Invasive breast cancer in stage IIA showed strong FGD3 expression
compared to matched metastatic carcinoma which showed mild expression of
FGD3. 3) FGD3 protein levels for tumors (n135) with N0 indicating no re-
gional lymph node metastasis were compared with tumors with lymph node
metastasis (N1-3; n98) and corresponding matched metastatic tissue
(n103). An unpaired t-test comparing N0 vs. N1-3 showed lymph node me-
tastasis is associated with lower FGD3 protein levels (p0.0001). Conclusion:
FGD3protein expression levelswithin breast tumorswere different according to
metastatic status. Our IHC results suggest the possibility of FGD3 to be a prog-
nostic marker in patients with breast cancer.
#3927 Programmed cell death ligand 1 expression in resected colorectal
adenocarcinomas: association with micrometastasis. Ilseon Hwang,1 Keon
Uk Park,1 Jin Young Kim,1 Hun-Mo Ryoo,2 Yun-Han Lee1. 1Keimyung Univ.
Dongsan Medical Ctr., Daegu, Republic of Korea; 2Daegu Catholic University,
Daegu, Republic of Korea.
Background: Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key
suppressors of the cytotoxic immune response. PD-L1 expression on tumor cells
may be induced by the immunemicroenvironment, resulting in immune escape,
and an adverse prognosis in many malignancies. In colorectal carcinoma the
response to PD-1/PD-L1 inhibition is correlated with microsatellite instability.
However, little is known about the clinicopathologic, molecular, and prognostic
characteristics of colorectal carcinoma with PD-L1 expression. In surgically re-
sected colorectal adenocarcinoma, micrometastasis should be crucial for recur-
rence, and micrometastasis may be related to PD-L1. The aim of this study is to
assess the PD-L1 expression and its association with clinicopathologic manifes-
tations. Methods: PD-L1 expression was evaluated in 176 resected colorectal
adenocarcinomas using tissuemicroarrays. Immunohistochemical staining was
performed to evaluate the expression of PD-L1. The relationship of clinicopath-
ologic manifestations and PD-L1 expression in colorectal cancer were evaluated
by chi-squared test, Kaplan-Meier survival and Cox regression test. Results:
High PD-L1 expression was present in 52.8% colorectal adenocarcinoma and
was not related pathologic T or N stage. High PD-L1 expression was associated
with decreased recurrence rate (p  0.001), better disease-free survival (p 
0.001). Cox regression analysis revealed that pathologicN stage andHigh PD-L1
expression was an independent prognostic factors of disease-free survival (p
0.001). Conclusion:HighPD-L1 expression is an independent prognostic factor,
such as pathologic stage in colorectal adenocarcinoma. PD-L1 expression is
independent prognostic factor, relating immune response to micrometastasis
and immune suppression by PD-L1 may not be effective in micrometastasis of
colorectal adenocarcinoma. Keywords: PD-L1, colon, cancer, immunology,mi-
crometastasis
#3928 Association of calcium sensing receptor polymorphisms at
rs1801725 with circulating calcium in breast cancer patients. Diva Whalen,1
Li Wang,2 Sarrah Widatalla,1 Josiah Ochieng,1 Ann Richmond,2 Amos Sakwe1.
1Meharry Medical College, Nashville, TN; 2Vanderbilt University, Nashville, TN.
Patients with metastatic or end-stage breast cancer (BC) inevitably develop
hypercalcemia, while up to 30% of BC patients develop cancer-induced hyper-
calcemia (CIH) in the absence of metastases or bone diseases. The commonly
diagnosed mild increase in circulating calcium activates the calcium sensing
receptor (CaSR) and has been shown to be associated with larger and more
aggressive breast tumors in postmenopausal and premenopausal patients re-
spectively. Whether differences in circulating calcium and/or specifıc inactivat-
ing CaSR variants play any role in disparities in BC outcomes remains unclear.
DESIGN METHODS: We identifıed 199 BC cases and 384 age and genetic an-
cestry-matched controls with calcium assay and genotyping data from the Van-
derbilt University DNA biorepository (BioVU) linked to de-identifıed elec-
tronic medical records. The linear mixed effects and codominant models were
used to assess the relationship between inactivating CaSR mutations at
rs1801725 (codon 986) and rs1801726 (codon 1011) and either circulating cal-
cium levels or risk of high calcium-driven aggressive BC outcomes. RESULTS:
We observed that circulating calcium levels were signifıcantly higher in BC cases
compared to control subjects (p0.001) and interestingly, in subjects of African
ancestry compared to Caucasians (p0.001). The A986S mutant CaSR is com-
mon among Caucasians while the Q1011E mutant receptor is common among
African Americans. However, only inactivating mutations at rs1801725 locus
were signifıcantly associated with higher calcium levels (p0.006) and a higher
(69%) risk of high calcium-driven aggressive BC outcomes compared to thewild
type receptor. We also demonstrate that invasive BC cells are tolerant to sus-
tained high calcium and that their adaptation to high calcium occurs via up-
regulation of calcium-activated early response and malignancy-associated
genes. CONCLUSION: These data suggest that inactivating CaSR polymor-
phisms at rs1801725 predispose BC patients to hypercalcemia and that high
circulating calcium-driven aggressive disease outcomes occur via calciummod-
ulated malignancy-associated genes such as MAGEC2/CT10.
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#3929 Heterogeneity in circulating tumor cells in blood samples of meta-
static castration-resistant prostate cancer patient: comparison of isolation
technique. Gerit Theil, Christine Weiss, Kersten Fischer, Andre Schumann,
Paoloa Fornara. Martin Luther Univ. of Halle-Wittenberg, Halle/Saale, Ger-
many.
Introduction/Objectives: Metastatic castration-resistant prostate cancer
(mCRPC) is a heterogen disease. Since most prostate cancer patients have a
biopsy performed only at the time of diagnosis, representative tumor tissue
sample giving real time information about the disease status is generallymissing.
CTC enumeration is a biomarker associated with clinical outcomes in patients
with mCRPC. However, capturing these rare cells from whole blood is still a
major challenge because they are extreme rare. Futhermore CTCsmay exhibit a
feature of epithelial-mesenchymal transition. First we assessed the method is
best suited for the isolation of CTCs in mCRPC patients. Additionally was to
evaluate the association between CTCs counts and ERG rearrangement in tu-
mor samples. Materials & Methods A tumor sample from metastatic site, along
with blood samples were collected frommCRPC patients. Tumor samples were
characterized of ERG rearrangement by fluorescence in situ hybridization.
CTCs were detected using two methods. One was SreenCells system, CTC iso-
lation based on size exclusion. The second method was the CellCollector which
CTC captured using monoclonal specifıc antibody to EpCAM. This system can
be used for CTC isolation ex vivo and in vivo.We used it here ex vivo. Captured
CTCs were identifıed based on histological cell architecture by immunofluores-
cence staining using cytokeratin (8, 18, 19) and nuclear Hoechst staining posi-
tive as well as CD45 negative as criteria to exclude EpCam positive leucocytes
Results We obtained duplicate blood samples from 10 mCRPC patient using
SreenCells system andCellCollector isolationmethods. Bothemethods detected
CTCs in 8 of 10 blood samples, detection rate is 80 %. ScreenCells isolated in
average of 22.6 CTCs (range of 0-80CTCs). TheCellCollector capturedCTCs ex
vivo in average of 3 CTCs (range of 0-6 CTCs). In a direct comparison of the
ScreenCell system and the Cellcollector is signifıcant different (p 0.0156) in the
CTCcounts. TheCTCnumber of both systems ismoderate correlated (r 0.5). All
mCRPC tissue samples harbored an ERG rearrangement in range of 89 until 98
%. The CTC number of the ScreenCell system is good correlate with PSA level (r
0.776) and also with the ERG- rearrangement (r 0.5) of tissue samples. Conclu-
sion Our results demonstrate that CTC isolation based on the physical proper-
ties has a higher sensitivity as the CTC isolation technique based on the biolog-
ical cell properties in mCRPC patients. The size exclusion technique coupled
with characterization of specifıc stainingmorphologiesmight be used to identify
a heterogeneous CTC population which is always present in advanced cancer. It
should be decided in dependence of the advanced cancer stage which CTC
isolation technique can be used. The cost of the material and the hours of work
are equal in both systems.
#3930 ZEB1 is regulated by PKC in breast cancer cell lines.María Can-
delaria Llorens,1 Cynthia Lopez-Haber,2 Laura Barrio-Real,2 Maria V. Vagli-
enti,1 Marcelo G. Kazanietz,2 Ana M. Cabanillas1. 1School of Chemical Science,
National University of Córdoba, Córdoba, Argentina; 2University of Pennsylva-
nia, Philadelphia, PA.
Breast cancer is the second leading cause of cancer deaths inwomen.Cytokine
signals triggering kinase pathways play key roles in cancer progression which
regulate transcription factors such as ZEB1 or Snail. Our goal is to uncover the
role of PKC signaling pathway in the regulation of the biological action of ZEB1.
The protein expression of ZEB1, PKC isoforms, epithelial-tomesenchymal tran-
sition (EMT)markerswere determined byWestern Blotting (WB) in nine breast
cancer cell lines. PKC and ZEB1 had a signifıcant positive correlation
(p0.05), and both proteins were highly expressed inmammary cell lines with a
more aggressive phenotype (such as MDA-MB-231, BT-549 and MDA-MB-
453). Interestingly, silencing PKC using siRNAi signifıcantly reduced ZEB1
expression inMDA-MB-231,MDA-MB-453 andBT-549 cells, as determined by
Western blot. Likewise, the pan-PKC inhibitor (GF109203) and the cPKC in-
hibitor (Gö6976) reduced ZEB1 expression in breast cancer cells. However, the
EMT markers (E-cadherin, vimentin, ZO1 and N-cadherin) did not change
their expression. ZEB1 mRNA levels did not change signifıcantly in PKC
knockdown cells, suggesting that PKC possibly regulates ZEB1 expression by
affecting its protein stability. In addition, we found that the motile and invasive
capacity of MDA-MB-231 cells was markedly affected in both PKC and ZEB1
knockdown cells. Interestingly, depletion of PKC from MDA-MB-231 cells
markedly reduced the formation of ruffles and lamellipodia in response to se-
rum, whereas ZEB1 depletion did not. In summary, our results revealed that
PKC regulates the expression of the EMT marker ZEB1 in basal-like breast
cancer cell lines, and that in addition PKC is important for the control of cell
invasion and migration through regulation of ZEB1, thereby arguing that it
could be a potential target for breast cancer metastasis. Our results also suggest
that PKC may control important phenotypic responses both through ZEB1-
dependent and ZEB-independent mechanisms.
#3931 Sodium-calcium exchanger-1 regulates the epithelial phenotype
and is lost in renal cancers. Sona Lakshme Balasubramaniam,1 Anilkumar Go-
palakrishnapillai,1 Nicholas J. Petrelli,2 Sonali P. Barwe1. 1Nemours/A. I. duPont
Hospital for Children, Wilmington, DE; 2Christiana Care Health System, New-
ark, DE.
Epithelial cells that line the renal tubules possess apico-basal polarity and a de-
fıned cellular structure maintained by junctional proteins. The underlying mesen-
chymal cells are fıbroblastic with a non-uniform cell structure and secrete extracel-
lular matrix proteins. Mesenchymal to epithelial transition (MET) and epithelial to
mesenchymal transition (EMT) are required for renal tubule formation during kid-
ney development. Failure of renalmesenchymal cells to undergo epithelial transfor-
mation leads to the initiation ofWilms tumor, the most frequently occurring renal
cancer in children. Conversely, aberrant mesenchymal transformation of tubular
epithelial cells in the nephron contributes to the development of renal cell carci-
noma, which constitutes 85-90% of the adult tubular malignancies. The role of cal-
cium regulators in governing EMT andMET is becoming evident. Sodium calcium
exchanger 1 (NCX1), located on the basolateral surface of tubular epithelial cells, is
the principal calcium regulator that mediates calcium reabsorption in these cells.
NCX1mediates the extrusionofone calcium ionand the influxof three sodiumions
inoneexchangemovement.Wedemonstratedearlier thatNCX1regulatesepithelial
cell motility. However, the role of NCX1 in EMTwas undetermined.We observed
that knockdown of NCX1 in renal epithelial cells (MDCK) induced fıbroblastic
morphology, and increased permeability to rhodamine indicative of leaky cell-cell
junctions. Electron micrographs of these cells displayed increased inter-cellular
junctional distance also suggesting that NCX1 knockdown altered junctions be-
tween adjacent cells. CellswithNCX1knockdown showed loss of apico-basal polar-
ity in three-dimensional cultures accompanied by expression of mesenchymal
markers. Furthermore,NCX1knockdowncellswere capableof anchorage indepen-
dent growth suggesting that these cells had acquired tumorigenic potential. Inter-
estingly, we show for the fırst time that NCX1 mRNA and protein expression is
greatly reduced in both Wilms tumor and renal cell carcinoma demonstrating a
direct correlation between NCX1 expression and the epithelial phenotype. Mecha-
nistically, we provide evidence that NCX1 interacts with and anchors E-cadherin, a
classical adhesion molecule, to the cell surface independent of NCX1 ion transport
activity. MDCK cells with NCX1 knockdown exhibited -catenin nuclear localiza-
tion and enhanced transcriptional activity. Taken together, knockdownofNCX1 in
MDCK cells induces mesenchymal transition by destabilization of E-cadherin and
induction of -catenin transcriptional activity.
#3932 Dual role of p120ctn in cancer: epithelial vs mesenchymal. Pamali
Fonseka, SureshMathivanan,Michael Liem, IsharaAtukorala. LaTrobeUniver-
sity, Melbourne, Australia.
Neuroblastoma, a paediatric cancer, accounts for 15% of childhood cancer
mortality. Even though neuroblastoma is an aggressive cancer, the exact
mechanisms by which the cells resist treatment is poorly understood. Here,
we hypothesise that neuroblastoma cells have high expression of mesenchy-
mal markers and hence could attribute to the aggressive phenotype. P120ctn
is downregulated in epithelial cancers and is known to play a major role in
EMT and aggressiveness. In this study, immunohistochemical staining of
neuroblastoma patient tissues suggested that p120ctn is highly abundant.
Hence, the role of p120ctn and N-Myc in neuroblastoma aggressiveness was
investigated by using RNA interference. Amplifıcation of N-Myc oncogene
occurs in 20% of neuroblastoma patients and is considered high risk as it
correlates with aggressiveness and poor prognosis. Interestingly, knock-
down of p120ctn down regulated N-Myc both at mRNA and protein levels.
Upon knockdown of p120ctn and N-Myc, the proliferation, invasion and
migration of neuroblastoma cells were signifıcantly reduced. Quantitative
proteomic and qPCR analysis of the wild type and knockdown cells revealed
that p120ctn knockdown cells underwent mesenchymal-to-epithelial transi-
tion. Confocal microscopy andWestern blotting analysis of subcellular frac-
tionation showed nuclear accumulation of -catenin upon p120ctn knock-
down. Once in the nucleus, -catenin activated Wnt signalling pathway and
up regulated Wnt target genes including C-Myc. Interestingly, down regu-
lation of p120ctn sensitised the neuroblastoma cells to doxorubicin. Cur-
rently, there is no published study that explores the role of p120ctn in neu-
roblastoma. However, these fındings are contradictory to scientifıc literature
in the context of the functional role of p120ctn in epithelial cancer. Hence to
validate our fındings, we established knockdown of p120ctn in epithelial
colorectal cancer cells. Consistent with the literature, knockdown of p120ctn
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induced EMT, proliferation and migration. These results suggest that the
role of p120ctn is cell type dependent. Overall, the fındings from this study
suggest that p120ctn plays a pivotal role in progression of neuroblastoma.
#3933 Characterization of oncogenic activity of interferon-induced pro-
tein with tetratricopeptide repeats 1 and 3 in human oral squamous cell car-
cinoma progression.Vijaya Kumar Pidugu,1 Ai-Hsin Yen,2 Ying-Chen Chen,2
Mei-Maan Wu,3 Chung-Ji Liu,4 Te-Chang Lee1. 1Program in Molecular Medi-
cine, Taiwan International Graduate Program, National Yang-Ming University
and Institute of Biomedical sciences, Academia Sinica, Taipei, Taiwan; 2Institute
of Biomedical sciences, Academia Sinica, Taipei, Taiwan; 3School of Public
Health, Taipei Medical University, Taipei, Taiwan; 4Department of Oral and
Maxillofacial Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
Interferon-induced protein with tetratricopeptide repeats (IFITs) family
has multiple tetratricopeptide repeats with helix-turn-helix structural motifs
that mediate a variety of protein-protein interactions. There are four IFIT
genes that have been identifıed namely, ISG56/IFIT1, ISG54/IFIT2, ISG60/
IFIT3, and ISG58/IFIT5. IFIT proteins have been documented to involve in
a variety of cellular functions, such as cell proliferation, migration, virus-
induced translation initiation, replication and double-stranded RNA signal-
ing. Our previous study has demonstrated that IFIT2 inhibits oral squamous
cell carcinoma (OSCC) metastasis. However, little is known about IFIT1 and
IFIT3 in the progression of OSCC. In the present study, we are investigating
the functional role of IFIT1 and IFIT3 genes in OSCC tumor progression.
Immunohistochemical analysis of 147 patients derived tumor specimens
with OSCC revealed a strong correlation between IFIT1 and IFIT3 proteins
(p0.001). Clinicoplathological characteristics correlation of IFIT1 and
IFIT3 expression levels were positively associated with regional lymph node
invasion and nerve invasion. IFIT1 was also associated with venous invasion.
Ectopic expression of IFIT1 and IFIT3 proteins in Ca9-22 and SAS cells
inducing PKC, EGFR, and AKT activation, resulting in OSCC cells resistance
to cisplatin but highly susceptible to tyrosine kinase inhibitor gefıtinib,
whereas IFIT1 and IFIT3 knockdown SCC25 cells have shown opposite ef-
fect. Interestingly, IFIT1 and IFIT3 expression is associated with enhanced
cell invasion activity and altered expression of epithelial-mesenchymal tran-
sition markers. These data suggested that IFIT1 and IFIT3 may serve as
potential biomarkers for the OSCC treatment. The study on how IFIT1 and
IFIT3 cause PKC, EGFR, and AKT activation and resistance to DNA dam-
aging agents is ongoing. Our further investigations may explain the molec-
ular signaling mechanism of IFIT1 and IFIT3 in OSCC tumor progression.
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#3934 Bladder cancer tumor heterogeneity: development of a system-level
mutation assay. Katherin Patsch,1 Naim Matasci,1 Anjana Soundararajan,1
John Nicoll,1 Jonathan Katz,1 Antonio Sanchez,2 Erika Feierstein,2 Christina
Van Loy,2 Zhao Xu,2 David B. Agus,1 Mitchell E. Gross,1 Daniel Ruderman1.
1Lawrence J. Ellison Institute for Transformative Medicine of USC, Los Angeles,
CA; 2Thermo Fisher Scientifıc, CA.
Survival rates for patients with muscle-invasive bladder cancer have not im-
proved in the past 20 years, and new therapies are imperative. Intratumor het-
erogeneity can complicate molecular profıling attempts to optimize therapy for
cancers harboring several actionable tumor subclones. To develop personalized
treatment strategies, there is a need for assays to measure intratumor heteroge-
neity in bladder cancers. We conducted a pilot study of two muscle invasive
high-grade transitional cell carcinoma cases. We used a comprehensive cancer
panel (Thermo Fisher) covering 400 cancer genes to analyze distinct tumor
loci and matched normal tissues. Based on the identifıed somatic mutations, we
designed a bladder-specifıc panel to (1) validate our results with increased cov-
erage, and (2) analyze liquid biopsy samples. Using the comprehensive cancer
panel, we sequenced 6 tumor loci to an average sequencing depth of approxi-
mately 100x. We detected intratumor heterogeneity in both patients: By apply-
ing a combination of frequency-based (minor allele frequency10%) and prob-
abilistic (probability of difference between observed frequencies due to
sampling) fılters, we identifıed 44 credible somatic SNVs, including mutations
that were not shared among all three loci. We used these SNVs to design a
custom amplicon panel covering 42 SNVs across 38 genes that is suitable for
highly fragmentedDNA. The custom panel was used to validate the SNVs in the
same tumor regions and in liquid biopsy samples from plasma and urine (ap-
proximate coverage 6,000x). In both cases, we identifıed private mutations re-
ported in The Cancer Genome Atlas Urothelial Bladder Carcinoma (TCGA-
BLCA) data collection, reflecting tumor evolution. Liquid biopsy samples from
urine revealed all trunk mutations but only 1 out of 5 private mutations. We
conclude that tumor evolution can affect distinct loci within bladder tumors,
which may not be fully represented in liquid biopsy samples. These results sug-
gest the need for analyzing multiple tumor regions to identify all actionable
driver mutations. In the future, we plan to apply our assay to additional foci and
patients in order to identify optimal bladder tumor sampling strategies.
#3935 Dissecting small cell lung carcinomaheterogeneity and chemother-
apy resistance with mass cytometry. Jonathan M. Lehman,1 Nalin Leelatian,2
Bradford Harris,3 MeganHoeksema,1 Zou Yong,1 Deon B. Doxie,2 JonathanM.
Irish,2 Pierre P. Massion1. 1Vanderbilt Univ. Medical Ctr., Nashville, TN; 2Van-
derbilt University, Nashville, TN; 3Sarah Cannon, Nashville, TN.
Introduction: Small cell lung cancer (SCLC) is a high grade neuroendocrine car-
cinoma of the lung responsible for up to 25% of lung cancer deaths. Treatment in
SCLChas not changed signifıcantly in the last 20 years. SCLC initially respondswell
to chemotherapy, but inevitably recurs. Characterization of tumor heterogeneity
and changes in SCLC cell signaling and phenotypes after chemotherapy could yield
new insights and therapeutic options.Mass cytometry usesmetal labeled antibodies
to profıle expression and phosphorylation of more than 40 proteins in single cells
and offers the opportunity to identify new subpopulations including potential can-
cer stem cell populations as well as targets for novel therapies in SCLC. Methods:
Nude mice with SCLC patient derived xenografts (PDXs) were treated with one
cycle of carboplatin/etoposide or saline injection. Tumors were harvested at
2000mm3, disaggregated, and cryopreserved. PDXsampleswere stainedwith a22
marker panel and an intercalator dye to identify nucleated cells. This panel mea-
sured phospho-signaling, neuroendocrine, immune, and mesenchymal cell mark-
ers, and functional markers including ki67 and cleaved caspase 3. ViSNE analysis
and biaxial gating were used to identify major subpopulations of interest. Results:
PDX tumors released viable tumor and stromal cells suitable for cryopreservation
andmass cytometry.ACKbuffer andenzymaticdissociationyielded thebest quality
cells by depleting red blood cells. Mouse cells, including leukocytes, were excluded
using mouseMHC1 gating and iridium intercalator was used to identify nucleated
cells. Single cell protein expression and phosphorylation was analyzed using viSNE
andyieldedat least 9distinct subpopulationsbasedondensity islandswithneuroen-
docrine (CD56) and non-neuroendocrine (CD56-) populations. Chemotherapy
treated cells had dramatic changes in subpopulation distribution compared to
matched mock treated tumor. This included 2-3 fold expansion of SOX2,
CD117, and pSTAT3 populations with chemotherapy treatment. A small
CD44 tumor subpopulation identifıed in the chemotherapy treated cells was not
present in the matched mock treated tumor suggesting a potential chemotherapy
resistant/ stem- like subpopulation. Kinase activity showed stable p-AKT overall,
but increased p-S6 in the chemotherapy treated cells. Conclusions:Mass cytometry
was able to identifymultiple neuroendocrine and non-neuroendocrine cell popula-
tions from SCLC PDXs and characterize their signaling. Chemotherapy treated
PDXhaddifferential subpopulationdistributionwith enrichment ofmultiple stem-
like signaling factors. This work demonstrates the utility of mass cytometry and
viSNEasnovel techniques to identify subpopulationsassociatedwithchemotherapy
resistance for future targeting and demonstrates the feasibility of this technique for
characterizing signaling heterogeneity in human SCLC tumors.
#3936 A branching evolutionmodel at relapse characterizes multiple my-
eloma patients who responded to upfront combination therapy including
new drugs. Carolina Terragna,1 Marina Martello,1 Barbara Santacroce,1 Vin-
cenza Solli,1 Lucia Pantani,1 Elena Zamagni,1 Paola Tacchetti,1 Beatrice Zan-
netti,1 KatiaMancuso,1 GiuliaMarzocchi,1 Nicoletta Testoni,1 Gaia Ameli,1 Ro-
salinda Termini,1 Angela Flores Dico,1 Enrica Borsi,2 Giovanni Martinelli,1
Michele Cavo1. 1University of Bologna, Bologna, Italy; 2Fondazione Umberto
Veronesi, Milano, Italy.
Intro: Multiple Myeloma (MM) is a biologically complex disease, whose genetic
plasticity favors the coexistenceof genetically heterogeneous subclones, selected in a
Darwinian fashion throughout the disease course. Therapymight represent amajor
selective pressure over the different subclones, thus supporting an evolutionary
model of the disease. Aim: To explore the existence of different clonal evolution
patterns inMM,eventuallydrivenby therapeutic selectivepressure.P&MThestudy
included 33 pts with symptomatic MM, up-front treated either with combination
regimens including a proteasome inhibitor (28), or with cyclophosphamide. For
each pts, paired BM samples were collected both at diagnosis and at relapse. SNPs
array analyseswereperformedon theCD138 enriched cell fractions.Results: Two
approaches were applied: a) monitoring the variations of macro CNAs; b) focusing
on changes of CNAs frequencies, as observed in 27 genes of interest. Both ap-
proaches were consistent in highlighting three major evolution patterns: in 7/33
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(21%) pts, the genomic background at relapse was almost identical to that of diag-
nosis. In 13/33 (39%) pts, an overall increase in the frequencies of the sameCNAs as
observed at diagnosis was detected at relapse. Finally, in 13/33 (39%) pts, either
increased or decreased frequencies of several CNAs, as well as several differences in
the CNAs type’s prevalence were observed at relapse, as compared to diagnosis. Of
interest, even if an overall CNAsmedian number increase was observed from diag-
nosis to relapse (226 vs 507, respectively) - supported by acquisition of CNAs either
commonly described as secondary genomic events (i.e. del17p13, amp1q21,
del1p23), or associated to the resistance to bortezomib (i.e. del8p21) - any peculiar
CNAs resulted signifıcantly prevalent in the 3 identifıed subgroups of pts. A high
rate (92%) of achievement ofVGPRor better quality of response to upfront therapy
characterized the third subgroup of pts, whereas the rate of VGPR in the remaining
ptswasonly20%andPRorSDwereobserved in9and7pts, respectively. Finally, the
median time to fırst progression of this subgroup of pts was signifıcantly shorter as
compared to that of pts with branching evolution (24 vs 35months, range 4-41 and
7-123 months, respectively, p0,01). Conclusion: The genomic architecture of a
subgroupof relapsedMMpts,up-front responsive tonewdrugs-basedcombination
therapies, resulted overall different from that of diagnosis, suggesting a branching
evolution of the disease, sustained by the shrinking of the most prevalent clone
(therapy-sensitive), as well as by the expansion of subclones (therapy-resistant) not
already evident at diagnosis. This observation raises the question whether re-treat-
ment of relapsed pts should be appropriate in the case of branching evolution. Ac-
knowledgements: AIRC (MC), Fondazione Berlucchi (CT), FUV (EB).
#3937 Diversity index as a novel predictor of tumor progression in breast
cancer. Yul Ri Chung,1 Hyun Jeong Kim,2 Young A Kim,3 Mee Soo Chang,3
Ki-Tae Hwang,3 So Yeon Park1. 1Seoul National University College of Medicine,
Seoul National University Bundang Hospital, Seongnam, Republic of Korea;
2Seoul National University Bundang Hospital, Seongnam, Republic of Korea;
3Seoul National University Boramae Hospital, Seoul, Republic of Korea.
Intratumoral genetic heterogeneity leads to tumor progression and therapeu-
tic resistance. However, due to the diffıculty associated with its assessment, ap-
plication of intratumoral genetic heterogeneity as a prognostic or predictive
marker is limited.We investigated the signifıcance of Shannon diversity index as
a tool for measuring genetic heterogeneity by performing fluorescence in situ
hybridization of c-Myc gene in invasive breast cancers, and correlated the Shan-
non diversity index for c-Myc copy number variation with clinicopathologic
features of tumor including patient survival. Shannon index for c-Myc copy
number variation strongly correlated with average c-Myc copy number and was
signifıcantly higher in tumors with c-Myc genetic or regional heterogeneity than
in those without c-Myc amplifıcation. High Shannon index was associated with
high histologic grade, lymphovascular invasion, p53 overexpression, high Ki-67
proliferation index, hormone receptor negativity, and HER2 amplifıcation. In
survival analyses, c-Myc amplifıcation or c-Myc copy number gain was not
associated with patient survival. However, a high level of Shannon index was
associated with poor disease-free survival. In subgroup analyses, it was found to
be an adverse prognostic factor in hormone receptor-positive group, but not in
hormone receptor-negative group. In a validation set, high Shannon diversity
index for c-Myc copy number variation was also found to be associated with
poor survival of the patients. We further investigated the correlation with clin-
icopathologic features and predictive power of Shannon index using another
gene, fıbroblast growth factor receptor 1 (FGFR1) and observed that high Shan-
non index for FGFR1 gene copy number variationwas an independent prognos-
tic factor for poor clinical outcome in a whole group and in hormone receptor-
positive subgroup. In conclusion, this study demonstrated that higher diversity
index was associated with adverse pathologic parameters of breast cancer and
poor clinical outcome suggesting that Shannon diversity index, which repre-
sents intratumoral genetic heterogeneity, can be used as a potential biomarker
for tumor progression and prognostication in patients with breast cancer.
#3938 Dynamic interconversionof cancer cells: single-cell analysis of pop-
ulation-based equilibrium. Yuen San Chan,1 Edwin-Wai Kin Yu,1 William
Weimao Wang,1 Chi-Chun Fong,1 Timothy Tak-Chun Yip,2 Joseph Siu-Kie
Au,2 Mengsu Yang1. 1City University of Hong Kong, Hong Kong, Hong Kong;
2Queen Elizabeth Hospital, Hong Kong, SAR, Hong Kong, Hong Kong.
Background: Multiple subpopulations of cells with different phenotypes and
genotypes coexist within malignant tumours. Different subpopulations seem to
maintain themselves in an equilibrium position via stochastic interconversion.
Such plasticity plays an important role in cancer progression, such as transition
from epithelial states to mesenchymal state during metastasis, dedifferentiation
of non-CSCs to CSCs and rapid transition to MDR cells during drug exposure.
We attempt to explore this interconversion plasticity at both population and
single cell levels to better understand the dynamics of phenotypic transition.
Methods: We isolated CD90 and CD90- cells from A549 lung adenocarci-
noma cell line by flow cytometry and then characterized their phenotypic be-
haviors and interconversion dynamics at both population and single cells level.
Single cells were cultured in 96 well plate for 13 days. Viable cells were then
transferred into 6 well plate for further expansion until enough cells were col-
lected for measurement of CD90 expression in flow cytometry. Results: A549
maintains a stable expression of CD90 (50%) which is bimodal distributed.
The sorted subpopulations eventually achieved a new equilibrium (CD90 à
60% , CD90 - à 30%) and did not converge during the bulk cell interconversion.
Individual single cell clones showed large variation of CD90 expression. The
distribution of CD90 expressionwas signifıcantly different betweenCD90 and
CD90- single cell clones, while both groups of clones achieved a similar average
equilibrium as compared with the bulk cells. We noted two types of clones
defıned as transition clones and committed clones with differential interconver-
sion capacities. The later one showed no sign of interconversion and was com-
mitted to the original CD90/- expression level. Further experiments showed
that the committed CD90 cells were more mesenchymal with higher migra-
tion ability, while the committed CD90- cells were more epithelial and tumori-
genic. Conclusions: Interconversion plasticity varied from cell to cell and the
committed cells prohibited the return of sorted cell subpopulations returned
back to the original equilibrium. Phenotypic studies of CD90 and CD90- re-
vealed that the interconversion between them was EMT related.
#3939 Evolution and drug resistance of primary and relapse tumors in
diffuse large B-cell lymphoma. Rainer Lehtonen,1 Amjad Alkodsi,1 Kaiyang
Zhang,1 Mikko Kivikoski,1 Emilia Kozlowska,1 Alejandra Cervera,1 Annika
Pasanen,1HaraldHolte,2 Sirpa Leppä,1 SampsaHautaniemi1. 1University ofHel-
sinki, Helsinki, Finland; 2University of Oslo, Norway.
Our integrated multi-omics analysis of paired primary and relapse DLBCL
tumors provides comprehensive view to tumor evolution, drug resistance and
disease heterogeneity. DLBCL is an aggressive systemic disease in which tumors
can arise in virtually any part of the body. Activated B-cell (ABC) and germinal
center B-cell (GCB)-like subtypes differ molecularly and clinically. Three-year
progression-free survival (PFS) in ABC is around 40% vs over 80% in GCB.
Whole genome (WGS, 7 patients), transcriptome (total RNA, 7 patients) and
methylome sequencing data produced using the Illumina HiSeq platform was
complemented with Illumina TruSeq amplicon sequencing covering 102,571 bp
of the genome on 788 custom selected targets. Altogether 23 fresh frozen and 28
paraffın embedded tumor samples from 24 patients with an advanced disease
and at least one relapse event were included in the study. To investigate the
clonal hierarchy of the primary and relapsed tumors we employed dirichlet
process clustering using cancer cell fraction (CCF) estimates or variant allele
frequencies from somatic point mutations. Divergent evolution was prominent
in the GCB subtype whereas in ABC subtype subclonal mutations are rare and
only few genomic differences were detected between primary and relapse tu-
mors (p-value0.047, Pearson’s Chi-squared test on 7 patients withWGS data)
suggesting pre-treatment drug resistance which is probably triggered by global
hypo- or hypermethylation at relapse stage. In the GCB subtype primary and
relapse branches have diverged much before diagnosis and subsequently devel-
oped independently. Number of emerging primary or relapse specifıc clonal and
subclonal mutations correlate with PSF and overall survival (OS). Mutational
signatures were concordant with the inferred evolutionarymodels in four out of
fıve GCB cases. Contribution of the somatic hypermutation signature was
higher in resistant tumors and correlatedwith time to progression of the disease.
We identifıed 72 relapse tumor related genes including many known B-cell
lymphoma genes such as CD79B, IGLL5, PIM1, SGK1. These were used in
survival analysis in the CGCI RNA data set derived from 92 diagnostic DLBCL
tumors. Patients with subclonal mutations in these genes had shorter PSF and
OS (Kaplan-Meier p-values 0.0122 and 0.0071, respectively). To validate and
further defıne our hypothesis we are simulating DLBCL evolution as a discrete
time branching process model (Galton-Watson branching processes). The goal
is to reconstruct phylogenetic trees from a simulated tumor and explain differ-
ent types of evolutionary models inferred from the patient data. Despite of re-
markable heterogeneity in DLBCL we observed two main evolutionary models
which are concordant with disease subtype, patient’s survival, treatment re-
sponse at diagnosis and relapse, and molecular features of a tumor.
#3940 Transformation by ENO1 highlights the positive relationship be-
tween HIF1A’s and VEGFA’s RNA expression levels, putatively by counter-
acting heterogeneity in glioblastomas.Marie E. Beckner,1 Ian F. Pollack,2 Ron-
ald L. Hamilton3. 1Kent State University, OH; 2Children’s Hospital of Pittsburgh,
UPMC, PA; 3University of Pittsburgh School of Medicine, PA.
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Analysis of metabolic gene expression is compromised by tumor heterogene-
ity. Therefore, we investigated the use of RNA expression levels from ENO1,
which encodes enolase 1, to adjust for glycolytic heterogeneity within glioblas-
tomas attributed to irregular vascularity, necrosis, surgical removal, etc. Re-
cently, this approach revealed relationships between carbonic anhydrases and
amplifıed oncogenes (Beckner, et al. BBAClinical 5 (2016):1-15). Here in frozen
tissue samples from 22 glioblastomas, expressions of the metabolic gene encod-
ing hypoxia inducible factor - 1A (HIF1A) and its target, vascular endothelial
growth factor A (encoded by VEGFA), were contrasted with two non-metabolic
genes, i.e. those encoding platelet derived growth factor A (PDGFA) and epider-
mal growth factor (EGF) using RT-qPCR analysis. Genes of interest (GOI) were
initially normalized with delta-delta crossing threshold methodology using
housekeeping genes, ACTB and GAPDH. Then, concurrent expressions of
ENO1 (ave 0.83/- 0.18 CI (95%), range of 0.22 - 1.97 times normal) were used
to mathematically transform expressions of GOI to multiples of ENO1 to puta-
tively correct for glycolytic variation. Expressions of PDGFA (ave 1.90/- 0.69
CI (95%), 0.17 - 4.01 times normal) and EGF (ave 1.25/- 0.57 CI (95%), 0.07 -
5.14 times normal), had correlations, r  0.65 and 0.66, unranked (Pearson’s)
and ranked (Spearman’s) data, respectively, among the 22 tumors. After ENO1
transformation, r 0.68 for their unranked data & the difference in their ranges
rose to 1.31-fold. Prior to ENO1 transformation, expressions ofHIF1A (ave 1.33
/- 0.28 CI (95%), 0.25 - 2.55 times normal) and VEGFA (ave 2.89/- 1.36 CI
(95%), 0.17 - 9.94 times normal) had negative correlations, r - 0.15 and - 0.09,
unranked and ranked data, respectively. However, after transforming HIF1A
and VEGFA expressions to multiples of concurrent ENO1 expression, their
correlation became positive in both unranked and ranked data, with r 0.30 for
the ranked (Spearman) data. The difference in the ranges of the two metabolic
genes expanded to 6.76-fold. Whereas the Wilcoxon Rank Sum of VEGFA’s
untransformed values, with versus without 2.02-fold elevations of HIF1A ex-
pression, was insignifıcant, p 0.704, using ENO1 transformed values indicated
a signifıcant relationship, p 0.042. Therefore, ENO1 transformation revealed
the anticipated relationship between HIF1A and its target, VEGFA, at the RNA
expression level that was not initially apparent in this small group of tumors.
Transformation via expression levels of ENO1 compensates for glycolytic het-
erogeneity to reveal and highlight relationships among metabolic genes when
analyzing resected tumors. Support fromThePittsburgh Foundation’sWalter L.
Copeland Fund for Cranial Research (D2006-0379) and the Molecular Lab,
Dept. of Pathology, Univ. of Pittsburgh Medical Center.
#3941 Assessing heterogeneity in DCE-MRI data of breast cancer to pre-
dict treatment response. Anum Syed,1 Anna G. Sorace,1 Stephanie L. Barnes,1
Lori Arlinghaus,2 Xia Li,3 Thomas E. Yankeelov1. 1University of Texas at Austin,
Austin, TX; 2Vanderbilt University, Nashville, TN; 3GE Global Research, Nisk-
ayuna, NY.
Introduction: We investigate the ability of multi-parametric, voxel-based
characterizations of tumor heterogeneity from magnetic resonance imaging
(MRI) to predict the response of breast cancer patients to neoadjuvant therapy
(NAT). In particular, we use high-dimensional analysis of the longitudinal
changes in the vascular and cellular characteristics provided by quantitative
dynamic contrast enhanced MRI (DCE-MRI) to predict response. Methods:
DCE-MRI data was acquired from 34 patients with stage II/III breast cancer
before initiatingNAT (t1) and after one cycle ofNAT (t2). Pathological complete
response (pCR) and non-pCR was defıned at the time of surgery. Non-pCR
patients were further subdivided into partial response (30% decrease in tumor
volume), progressive disease (PD,20% increase in tumor volume), and stable
disease according to the Response Evaluation in Solid Tumors (i.e., RECIST)
criteria. For each tumor voxel, DCE-MRI data was modeled to extract the ex-
travascular, extracellular volume fraction, ve, the plasma volume fraction, vp,
and the volume transfer coeffıcients, Ktrans and kep, which correspond to the rate
ofwash-in andwash-out of contrast agent, respectively.Multi-parametric voxel-
based maps of physiological parameters Ktrans, kep, ve, and vp were used to iden-
tify different tumor subpopulations. Dimension reduction was completed using
t-distributed Stochastic Neighbor Embedding (t-SNE) and subpopulations were
identifıed using DBSCAN clustering. Using the t-SNE generated low-dimen-
sional maps, a subset subpopulations were analyzed based on cluster differences
between groups at t2. Based on MRI parameter values, the selected voxel sub-
populations fell into one of two categories: high vascularity-high cellularity
(HV-HC: high vp , Ktrans , kep values, low ve values) and low vascularity-low
cellularity (LV-LC: low vp , Ktrans , kep values, high ve values). The contribution of
each cluster to overall tumor volume was analyzed for each patient and quanti-
fıed as percent tumor volume. Results: No differences were observed between
patient groups at t1. At t2, patients with pCR revealed increased percent tumor
volumes containing LV-LC subpopulations, compared to PD patients (p 
0.03). Furthermore, PD patients demonstrated signifıcant increase in percent
tumor volumes with HV-HC subpopulations, compared to pCR patients
(p0.01). Compared to pCR patients, combined non-pCR patients showed de-
creased percent tumor volumes of LV-LC subpopulations, trending toward sig-
nifıcance (p0.06). Conclusion: The results indicate that analysis of high-di-
mensional parameter maps derived from quantitative MRI can be utilized to
characterize intratumoral heterogeneity and identify subpopulations of tumor
response within patients. These characterizations can potentially be used to
defıne and model tumor habitats and ultimately predict patient treatment re-
sponse.
#3942 Evolution of genomic alterations in breast tumors. Anu G. Gaba,1
Megan Landsverk,2 Jennifer L. Weiss,3 Paul Thompson,4 Chun-Hung Chan,2
Steven F. Powell,5 Lora J. Black,3 James M. Ford6. 1Roger Maris Cancer Center,
Sanford Health, Fargo, ND; 2Sanford Health, Sioux Falls, SD; 3Sanford Research,
Sioux Falls, SD; 4Sanford Research, Sanford Health, Sioux Falls, SD; 5Sanford
Cancer Center, Sanford Health, Sioux Falls, SD; 6Stanford University, Stanford,
CA.
Cancer therapy exerts a strong selection pressure that shapes tumor evolu-
tion. Recent studies have demonstrated high rates of concordance between pri-
mary tumor and recurrences. The main objective of our study was to demon-
strate the molecular evolution of breast cancer using next-generation
sequencing (NGS) across various time points during treatment. Methods: We
conducted a retrospective analysis of 3 patients with metastatic breast cancer.
Specimens from patients undergoing 1 or more lines of treatment in the meta-
static setting (met2) were tested using Foundation One, evaluating 343 genes
and select rearrangements by NGS. Archival tumor specimens from primary
and fırst metastases (met1) were subsequently obtained and tested using the
same assay. Each sample was analyzed independently at the time of submission
over a period of two years and results were compared across all time points.
Results: Functional variants in patient 1 were concordant at all time points.
Patient 2 was hormonal receptor positive andHer-2 negative at diagnosis and at
met1 and 2. A known variant in PIK3CA was detected at all three time points.
She developed an EGFR variant of unknown signifıcance (VUS) at met1 which
was retained in met2 where she also gained a variant in ESR1, coinciding with
development of resistance to hormonal therapy. Patient 3 was triple negative at
diagnosis and at repeat analysis. A known PIK3CA variant was also detected at
all time points. Her primary tumor sample was positive for an amplifıcation of
RUNX1T1 which was not detected at met1 or 2. At met1 she developed an
amplifıcation of CCNE1which persisted throughmet2 in which an ERBB3 vari-
ant also arose. Additional discordances in all three patients were due to technical
or interpretive differences at the time of analysis. All three patients had VUSs
reported in primary and met1 time points that were not present at met2. How-
ever, expanded gene bait set was implemented between the submission of met2
samples and the primary and met1 samples. Therefore, full concordance of all
genes across all samples could not be determined. Patient 2 had a variant in
CHD1 initially classifıed to have therapeutic implications based on literature
and databases at the time of analysis.More recent data indicated that it was likely
a benign germline variant and was downgraded to a VUS in subsequent reports.
Classifıcation of ROS1 amplifıcation as signifıcant or a VUS also varied. Con-
clusion: In our samples, the majority of genomic alterations showed concor-
dance throughout the course of breast cancer. There are key actionable genes
which make their presence later on in the metastatic setting. Repeat tumor as-
sessment bymethods such as biopsies or ctDNAshould be a part of breast cancer
management as it may lead to changes in therapy. However, since the method-
ology and classifıcation of variantsmay change over time, reanalysis of all data at
each time point is warranted.We have initiated a prospective larger trial to study
the spectrum of breast cancer evolution.
#3943 Determination of the molecular profıle of Chilean patients with
sporadic colorectal cancer.AnaMariaWielandt. Clinica Las Condes, Santiago,
Chile.
Introduction: Colorectal cancer (CRC) represents a major health problem
worldwide, ranking third among themost frequent cancers and fourth in cancer
mortality. In Chile CRC is the third leading cause of cancer death. CRC is a
heterogeneous disease, and three carcinogenic pathways have been described to
determine the molecular profıle: The microsatellite instability (MSI), chromo-
somal instability (CIN) andmethylator phenotype (CIMP). Several studies have
tried to propose CRCmolecular subgroups based on the 3ways described above
since CIN, MSI and CIMP are not mutually exclusive and overlapping of the 3
ways is still unclear. The most recent subtyping of CRC was in 2015, where four
molecular subtypes consensus (CMS 1 to 4) were established according to clin-
icopathological features, molecular pathways involved and mutational status of
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KRAS, BRAF and PI3KCA genes in order to encourage clinical translation. 21%
of tumors failed to be categorized into these subtypes. This classifıcation allows
us to understand and determine the clinical, pathological and biological charac-
teristics of CCR to provide customized therapies to patients. Aim: To describe
the molecular profıle of carcinogenic pathways CIN, MSI CIMP in Chilean
patients with sporadic CRC.Material andMethods: Prospective analytical study
of 56 patients operated between 2010-2016 at Clinica Las Condes, without neo-
adjuvant treatment. DNA was extracted from normal and tumor tissue of each
patient and using PCR amplifıcation of several markers CIN, MSI and CIMP
were defıned. By combining the 3 variables analyzed, tumors were classifıed in
Group-A (MSI-high), Group-B (MSI-low / CIMP-high / CIN-high), Group-C
(MSI-low / CIMP-high / CIN-low), Group-D (MSI-low / CIMP-low / CIN-
high) and Group-E (MSI- neg / CIMP-neg / CIN-neg). Results: In this study,
tumors in Group-A (17%) are located on the right side in patients older than 60
years and early stages. Tumors Group-B / C (18,9%) occur in patients older than
60 years and BMI25 kg / m2, with wall invasion pT3-T4 and late stages. Tu-
mors of Group-D / E (54,7%) are the most frequent, located on the left side,
without vascular invasion and moderately differentiated. Conclusions: This
study allowed to classify Chilean patients in 3 subgroups considering the 3main
routes described for carcinogenesis development: CIN, MSI and CIMP, which
are consistent with the percentages described by the global consortium. Studies
that analyze MSI and CIMP or MSI and CIN have consistently shown that
patients with MSI-high tumors have a better prognosis (in our case 17%). De-
spite therapeutic advances based on this molecular characterization, both the
heterogeneity of tumors and the different combinations of pathways involved
have shown that the response to therapy varies depending on the individual
profıle of each patient, therefore in clinical practice it would be important to
establish that profıle for each of them. Fondecyt 1140012.
#3944 Characterization of molecular heterogeneity in hepatocellular car-
cinoma: Trunk and branch drivers. Sara Torrecilla, Daniela Sia, Andrew N.
Harrington, Zhongyang Zhang, Genis Camprecios, Agrin Moeini, Toffanin
Sara, Isabel Fiel, Ke Hao, Monica Higuera, Laia Cabellos, Helena Cornella, Mil-
ind Mahajan, Yujin Hoshida, Augusto Villanueva, Sander Florman, Myron
Schwartz, Josep Llovet. Icahn School of Medicine at Mount Sinai, New York, NY.
Introduction: Molecular heterogeneity occurs in Hepatocellular carcinoma
(HCC), but its implications in clinical decision-making are unknown. The
clonal evolution model explains that trunk alterations arise at early stages and
are shared by all malignant cells, whereas branch alterations occur in subclonal
tumoral cells. We aim to characterize the genomic landscape of HCC through
the identifıcation of trunk driver alterations and the study of its distribution in
intra- and inter-tumor heterogeneity. Methods: 153 HCC samples representing
the multiple steps of hepatocarcinogenesis were analyzed by deep targeted-se-
quencing covering exonic and promoter regions of themost frequentlymutated
drivers in HCC. Genes mutated in early lesions [39 dysplastic nodules and 54
early HCCs (eHCC) defıned as 2cm, without satellites or vascular invasion]
were classifıed as candidate trunk genes. Candidate trunk genes were further
explored in two additional cohorts: a) intra-tumor heterogeneity cohort: 42
tumor regions of 21 tumors 4cm (2-3 regions/tumor); and 2) inter-tumor
heterogeneity cohort: 39 tumors from17 patients withmultinodular lesions (2-3
nodules/patient). Transcriptome and copy-number variations (CNVs) were an-
alyzed using expression and SNP arrays, respectively. Results: A total of 46 mu-
tations were identifıed in the cohort of early lesions. Average number of muta-
tions andCNVaberrationswere higher in eHCCs than in dysplastic nodules [1.1
vs 0.5, mutations/patient (p0.03), and 8% vs 0.6% of aberrant chromosomal
arms (p0.0003), respectively]. Overall, 72% (23/32) of the sequenced eHCCs
presented at least 1 trunk mutation, being TERT, TP53 and CTNNB1 the most
frequent (21/23, 91%). In the intra-tumor heterogeneity cohort, 81% (17/21)
tumors showed at least 1 shared mutation in TERT, TP53 and/or CTNNB1
between different tumor regions (trunk drivers). In the inter-tumor heteroge-
neity cohort, the similarity of the CNV-profıle of multinodular tumors was used
to classify them as clonal (intra-hepatic metastasis) or non-clonal (synchronic
tumors). 6/17 (35%) of patients harbored clonal tumors according to their CNV
profıles (Pearson p0.05). Clonality classifıcation was further confırmed by
gene expression-based hierarchical clustering. 82% (9/11) of the sequenced
clonal tumors shared TERT, TP53 and/or CTNNB1 as trunk alterations. In
contrast, no trunk mutations were shared across non-clonal tumors. Conclu-
sions: TERT, TP53 and CTNNB1 are trunk drivers mutated in early HCC tu-
mors that remained as trunk aberrations across different regions of the same
tumor and between primary and metastatic nodules. These mutations are early
trunk drivers that can be captured with single biopsies and could represent ideal
therapeutic targets in the future.
#3945 Precise copy-number profıling of single cells isolated from FFPE
tissues by low-pass whole-genome sequencing. Alberto Ferrarini, Genny
Buson, Chiara Bolognesi, Claudio Forcato, Paola Tononi, Valentina del Mo-
naco, Chiara Mangano, Francesca Fontana, Gianni Medoro, Nicolò Manaresi.
Menarini Silicon Biosystems, Castel Maggiore (BO), Italy.
Introduction: Chromosome instability (CIN) is a hallmark of cancer, acting
by boosting genetic alterations responsible of tumorigenesis, progression and
heterogeneity. Whole-genome sequencing (WGS) protocols are established
methods for studying copy-number alterations (CNA) in single-cells, following
a necessary whole-genome amplifıcation (WGA) step.We previously presented
a method for single-cell CNA profıling of CTCs based on shallowWGS of LM-
PCR based WGA products. Here for the fırst time, we show that the same
method may be employed even on single FFPE cells, overcoming the challenges
of DNA degradation and damage linked to this type of samples. Methods: Two
50m thick FFPE sections from pancreas ductal adenocarcinoma with 20%
tumor content were processed following DEPArray™ sample preparation proto-
col, including cell dissociation and staining with vimentin, keratin and DAPI,
andDNAquality was assessed using theDEPArray FFPEQCkit (QC0.7). Cell
pools (n15, range6-213 cells) and single-cells (n11) from pure tumor and
stromal populations were recovered in separate tubes and lysed. A pool of 86
tumor cells and a pool of 213 stromal cells were used for low-pass WGS on
MiSeq, obtaining 2M paired-end reads on average. By contrast, other cell
pools and single cells were fırstly whole-genome amplifıed using the Ampli1™
WGAkit and then sequenced at shallow coverage usingAmpli1 LowPass kit and
IonTorrent PGM, with500k single-end reads asmean throughput per library.
The genome integrity (GI) of WGA samples was evaluated by Ampli1 QC, a
PCR-assay based on 4 amplicons of different lengths. Results: The purity of
DEPArray sorting was confırmed by the large number of chromosome altera-
tions in sorted tumor and the parallel lack of gains and losses in sorted stromal
pools and single-cells. A titration test was conducted measuring the consistency
ofCNAprofıles of tumorWGAproducts starting fromdifferent number of cells,
ranging from 117 down to single cells. For the purpose, we employed a Receiver
Operating Characteristic (ROC) curve using the non-amplifıed tumor popula-
tion as reference. Results showed an excellent performance level with a mean
Area Under Curve (AUC) equals to 0.93. Interestingly, lower AUCs (0.87) were
observed for single-cells, due to some level of inter-cell heterogeneity.Moreover,
the proposed low-pass WGS method demonstrated a high resiliency to DNA
degradation as quality of CNA profıles, measured by Derivative Log Ratio
Spread (DLRS), only showed a weak correlation with GI level, with high-quality
CNA profıles obtained also with the lowest GI value. Conclusions: Presented
approach for copy-number profıling of tumor single-cells isolated byDEPArray
digital sorter and processed with Ampli1 workflow has proven to be a reliable
and valuable application for the molecular characterization of tumor clones in
degraded samples as FFPE tissues.
#3946 Chromosome instability drives phenotypic switching tometastasis.
Chong-Feng Gao,1 Yanli Su,1 Julie Koeman,1 Curt Essenberg,1 Karl Dykema,1
Eric Hudson,1 Sok Kean Khoo,2 George Vande Woude1. 1Van Andel Research
Inst., Grand Rapids, MI; 2Grand Valley State University, MI.
Chromosome instability (CIN) is themost striking feature of human cancers.
However, how CIN drives tumor progression to metastasis remains elusive.
Here we studied the role of chromosome content changes in generating the
phenotypic dynamics that is required for metastasis. We isolated epithelial (E)
andmesenchymal (M) clones fromhuman carcinoma cell lines and showed that
the E clones were able to generate mesenchymal variants, which had the poten-
tial to further produce epithelial revertants autonomously. The successive ac-
quisition of invasive mesenchymal and then epithelial phenotypes recapitulated
the steps in tumor progression to metastasis. Importantly, the generation of
mesenchymal variants from clonal epithelial populations was associated with
subtle changes in chromosome content, which altered the chromosome tran-
scriptome and influenced the expression of genes encoding intercellular junc-
tion (IJ) proteins, while the loss of chromosome 10p, which harbors the ZEB1
gene, was frequently detected in epithelial variants generated from M clones.
Knocking down these IJ genes in E cells induced a mesenchymal phenotype,
while knocking down the ZEB1 gene inM cells induced an epithelial phenotype,
demonstrating a causal role of chromosome content changes in phenotypic
determination. Thus, our studies suggest a novel paradigm of tumor metastasis:
primary epithelial carcinoma cells that lose chromosomes harboring IJ genes
acquire an invasive mesenchymal phenotype, and subsequent chromosome
content changes such as loss of 10p in disseminatedmesenchymal cells generate
epithelial variants, which can be selected for to generate epithelial tumors during
metastatic colonization.
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#3947 Intratumorheterogeneity impacts treatment response in rectal car-
cinoma. Rüdiger Meyer,1 Nicole E. McNeil,1 DarawaleeWangsa,1 Lena Anthu-
ber,1 Noam Auslander,2 Danny Wangsa,1 Zhongqiu Zhang,3 Daniel Rosen-
berg,4 Eytan Ruppin,2 Jens K. Habermann,5 Thomas Ried1. 1National Cancer
Institute/NIH, Bethesda, MD; 2University of Maryland, College Park, MD; 3Wa-
terbury Hospital/University of Conneticut School of Medicine, Waterbury, CT;
4University of Conneticut Health Center, Farmington, CT; 5University of Lübeck,
Lübeck, Germany.
Individual response to radiochemotherapy (RCT) in rectal cancer patients is
highly variable and the underlyingmechanisms of treatment resistance of cancer
cells are poorly understood. Recent studies revealed a considerable degree of
genomic tumor heterogeneity. We hypothesize that this heterogeneity has a
direct impact on treatment response as subpopulations of cancer cells are resis-
tant to currently used RCT and facilitate tumor growth under treatment. To
address this highly relevant clinical issue, patient-derived rectal cell lines were
established. The tissue was derived from a 59-year-old male presenting with an
adenocarcinoma of lower rectum (T3,N1,M0), who was treated by neoadjuvant
RCT (50.4Gy plus 5-FU) and low anterior resection. The neoadjuvant treatment
induced a shrinkage of the tumor (staging of the surgical specimen: ypT3,N0),
suggesting a partial response to RCT. A biopsy of the treatment naïve tumor was
implanted heterotopically into an immunodefıcient nude mouse. After in vivo
growth, the tumor was dissociated and introduced to an in vitro culture where
murine stromal cells were depleted using antibody-based columns. The cell line
proved to be of human origin by immunofluorescence for human Keratin 20 as
well as genotyping using short tandem repeat profıling. The characterization of
the genome by array CGH and spectral karyotyping (SKY) revealed a highly
complex near-triploid karyotype with numerous chromosomal imbalances,
which are specifıc for colorectal cancers, including gains in chromosomes 7, 13
and 20. We also observed other structural abnormalities including an isochro-
mosome 1q.Multiplex-FISH by consecutive hybridization of probes for 15 gene
loci, which are known to be relevant in colorectal cancer genesis, revealed a
signifıcant degree of clonal heterogeneity of the cell line. Single cell sorting was
then performed to establish single cell derived cell lines from the genomically
well characterized parental cell line. Exposure of the single cell derived cell lines
to irradiation in combinationwith 3 uM5-FU revealed substantial differences in
treatment response.Analyses of the genomeby arrayCGHand transcriptomeby
RNA-Seq of the respective single cell derived cell lines are currently underway.
This will allow the comparison of the respective sensitivities to RCT to the
identifıed aberration profıles. These data will facilitate the understanding of
therapy resistance and potentially allow a reliable prediction of the patient’s
response. A tailored therapy is an important step towards individualized treat-
ment in colorectal cancer patients to avoid therapy resistance.
#3948 Comprehensive characterization of genomic and transcriptomic
heterogeneity in advanced bladder cancer by multiregional analysis. Ma-
thilde B. Thomsen,1 Philippe Lamy,1 Iver Nordentoft,1 Søren Vang,1 Line Rein-
ert,2 Søren Høyer,3 Torben F. Ørntoft,1 Jørgen B. Jensen,4 Lars Dyrskjøt1. 1De-
partment of Molecular Medicine, Aarhus University Hospital, Aarhus N,
Denmark; 2Department of Biomedicine, Aarhus University, Aarhus, Denmark;
3Department of Pathology, Aarhus University Hospital, Aarhus, Denmark; 4De-
partment of Urology, Aarhus University Hospital, Aarhus N, Denmark.
Background: Bladder cancer is a highly heterogeneous disease - both clini-
cally, and at the genomic and the transcriptomic levels. Despite complete tumor
resections, recurrent tumors share a high number of mutations with the initial/
earlier tumors, indicating that new tumors arise from fıelds of transformed areas
of cells in the urothelium (i.e. fıeld disease). Furthermore, the high mutational
load found in bladder cancer and the assumed high degree of heterogeneitymay
have huge implications on therapy response. Thus, detailed knowledge on tu-
mor heterogeneity and mutational dynamics in adjacent normal urothelial cells
is needed in order to understand fıeld disease, disease development and disease
progression. To address this, we performed comprehensive genomic and tran-
scriptomic analysis of multiple samples of tumor and normal tissue procured
from four cystectomy specimens and associated metastases. Methods: Multiple
tumors, lymph node metastasis, relapse biopsies and adjacent normal tissue
from four patients with muscle invasive disease were analyzed. A targeted panel
(illumina TruSeq Custom Amplicon v1.5) was designed from whole exome se-
quencing of bulk tumorDNA and germline DNA. Targeted sequencing of DNA
from small cellular regions procured by laser-microdissection from tumor bi-
opsies and fromadjacent normal tissuewas used for generating a comprehensive
genomic map of the bladder. Transcriptomic profıling (Fluidigm GE) was car-
ried out using RNA from LMD procured tumor regions matching the regions
used for targeted sequencing. Results: In total, whole exome sequencing was
performed onDNA from 15 bulk tumors with an average coverage of 59.2X.We
identifıed a total of 331, 862, 685 and 1344 mutations, respectively, in the four
patients with 15-85% of the mutations being ancestral. Of all the mutations, 95,
380, 117 and 335, respectively, were estimated to have a functional impact. Tar-
geted sequencing of 207, 595, 538 and 483 mutations in the four patients was
performed on DNA from 137 small cellular regions, including DNA from 17
adjacent normal tissue areas. We observed low local heterogeneity while com-
paringmore distant regions revealed signifıcantly higher levels of heterogeneity.
This observation was in agreement with the heterogeneity observed at the tran-
scriptomic level, where some regions within the same bladder appeared to have
basal characteristics while others appeared to have luminal characteristics. Con-
clusion: Large intra-patient genomic and transcriptomic heterogeneity can be
observed in bladder cancer. However, even in multifocal tumors, all the regions
shared a substantial number of mutations, indicating a common origin. Ongo-
ing investigations indicate the presence of low frequency tumor associated mu-
tations in normal appearing tissue.
#3949 Deep immunophenotyping using flow cytometry of dissociated
cells from Barrett’s esophagus and matched adjacent squamous epithelium
defınes distinct phenotypic clusters. Friedrich G. Hahn,1 Eileen Snowden,1
Warren Porter,1 Mitchell Ferguson,1 William S. Dillmore,1 Stephanie S. Yee,2
Taylor Black,2 Maureen DeMarshall,2 Aaron Middlebrook,3 Smita Ghanekar,3
Anil Rustgi,2 Erica L. Carpenter,2 Rainer Blaesius1. 1Becton Dickinson Technol-
ogies, Research Triangle Park, NC; 2University of Pennsylvania, Philadelphia, PA;
3Becton Dickinson Life Sciences, San Jose, CA.
Barrett’s esophagus (BE) is defıned as metaplasia of the squamous epithelium
to a specialized columnar epitheliumwith risk factors of gastroesophageal reflux
and obesity and a predilection for middle-age and older white males. BE pro-
gresses through stages of dysplasia (low-grade and high-grade) before develop-
ing into esophageal adenocarcinoma. Challenges remain in early detection and
predicting which patients may progress to dysplasia. Here we describe amethod
by which we compare human clinical IRB-approved BE biopsies and adjacent
normal squamous epithelium using tissue dissociation and deep immunophe-
notyping by flow cytometric collection and analysis. A cassette of canonical
epithelial or tumor stem cell-associated targets (EpCAM, CD24, CD44, CD49f,
Her2/neu, CD133, CD90, CD166, and CD29), immune cell markers (CD3,
CD45, CD127, HLA-DR, CD16, CD56, CD4, CD8, CD25, and CD19), as well as
targets associated with myeloid derived suppressor cells (CD14, CD15, CD33,
CD11b, HLA-DR, CD31 and CD86) were used to discern differences across
subjects and between cellular compartments in normal and BE tissue. The Bar-
rett’s samples show a majority population with a characteristic phenotype
(EpCAMCD133lowCD49fhigh) when compared with normal squamous tissue
samples (EpCAM-CD133-CD49flow). The samples separate into two discrete
groups using hierarchical clustering based ondifferential surfacemarker expres-
sion of combined epithelial and immune cell markers, but also reveal unex-
pected, shared phenotypes for some normal and BE samples. Principal compo-
nent analysis supports this grouping and was used to identify more compelling
targets for categorization, such as CD133 and CD49f. The resulting expression
and distribution of targets offer a phenotypic fıngerprint characterizing both the
epithelial cell and immune cell compartment. Besides providing the potential for
revealing clinically relevant differences between BE and normal tissue, as well as
across subjects, the discovered surface immunophenotypes can be used to target
specifıc subpopulations from dysplastic tissue for further molecular investiga-
tion. A deeper understanding of the role of such specifıc subpopulations should
increase the prospects for more complete understanding of BE and its progres-
sion.
#3950 A novel combination therapy targeting BCL6 and phospho-STAT3
defeats intratumor heterogeneity in a subset of non-small cell lung cancers.
Dhruba Deb,1 Satwik Rajaram,2 Jill E. Larsen,1 Patrick P. Dospoy,1 Rossella
Marullo,3 Longshan Li,1 Kimberley Avila,1 Leandro Cerchietti,3 John D.
Minna,1 Lani F. Wu,2 Steven J. Altschuler2. 1UT Southwestern Medical Ctr.,
Dallas, TX; 2University of California San Francisco, San Francisco, CA; 3Weill
Cornell Medical College and New York Presbyterian Hospital, New York, NY.
Purpose: Lung cancer is a disease of great oncogenotype complexity (onco-
genes and tumor suppressor gene alterations). These alterations can appear in
different combinations even within histologically defıned lung cancer subtypes.
The success of targeted therapy has led to a search for oncogenotype-specifıc
therapies. But, no one therapy fıts all oncogenotypes. Here, we investigate
whether characterization of oncogene-specifıc alterations in cellular signaling at
single cell level indicate heterogeneity even within cells from the same patient
with defıned oncogenotype, and whether they can suggest new targets to deal
with this heterogeneity. Methods: We compared signaling alterations in single
cells for -CATENIN, SMAD2/3, phospho-STAT3, P65, FOXO1 and phospho-
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ERK1/2 among a collection of Human Bronchial Epithelial Cells (HBECs) that
have been oncogenically transformed with combinations of TP53, K-RAS, and
MYC, commonly found alterations in non-small cell lung cancer (NSCLC). We
studied 3000 cells/signaling marker/HBEC oncogenotype variant using im-
munofluorescence assays and single-cell image analysis (1M data points). For
downstream target identifıcation and validation we utilized gene expression,
Western blot and siRNAmediated knockdown assays. We utilized inhibitors to
STAT3 and BCL6 inMTTdrug sensitivity and colony formation assay in a panel
of NSCLC lines. We used xenografted subcutaneous tumors for the in vivo
validation of our results. Results:When all three oncogenic changeswere present
and the HBECs were tumorigenic, we observed STAT3 upregulation and
SMAD2/3 downregulation. Interestingly, these STAT3 and SMAD2/3 signaling
changes were found to be mutually exclusive in single cells within the trans-
formed HBEC strain. We targeted the STAT3 upregulated subpopulation with
the STAT3 inhibitor Stattic. But, Stattic treatment failed to eliminate the
SMAD2/3 downregulated subpopulation. To target the SMAD2/3 down-regu-
lated subpopulation, we identifıed BCL6, a downstream gene of SMAD2/3, as a
novel target in transformed HBECs. Next, to test the generality of BCL6 as a
target, we studied 5 NSCLC cell lines with various level of BCL6 expression:
H1693, H1819, H1993, HCC827 and H2009. Our data suggests that BCL6 can
also be a therapeutic target in a subset of NSCLC lines. Then we tested the
response of these NSCLC lines to a combination of BBI608 (potent STAT3
inhibitor) and FX1 (BCL6 inhibitor). The combination treatment eliminated
more cancer cells than the single treatments alone. Finally, we confırmed the
benefıt of the combination therapy in H1993 xenografted tumors. Conclusions:
We conclude that BCL6 is a new therapeutic target in NSCLC and combination
therapy that targetsmultiple vulnerabilities (Phospho-STAT3 andBCL6) down-
streamof commononcogenes and tumor suppressors (TP53,K-RAS, andMYC)
may provide a potent way to defeat intra-tumor heterogeneity.
#3951 Colony lysate arrays for proteomic profıling of drug-persistent can-
cer cell subpopulations. Kohei Kume, Satoshi S. Nishizuka. Inst. Biomed. Sci.,
Iwate Medical Univ., Japan.
Clonal heterogeneity of cancer cells is one of the key properties by which
to understand relapse after anticancer drug therapy. However, a very limited
number of technologies are available for individually profıling these hetero-
geneous drug-resistant subpopulations. Therefore, the development of tech-
niques to monitor molecular changes in the subpopulations responsible for
drug-resistance, namely, colony-forming drug-tolerant persisters (DTPs), is
needed in order to understand the occurrence of cancer relapse. To profıle
DTPs at the molecular level in relation to the colony-forming function, this
study aimed to develop colony lysate array (CoLA) for the quantitative mea-
surement of protein levels in individual colonies. To investigate multiple
parameters that may affect the emergence of DTP, DTPs derived from 5
cancer cell lines grown in the presence of 6 doses of 4 different drugs were
collected. A set of 2,000 colony lysates was printed onto a nitrocellulose-
coated glass slide using a microarrayer, which has been used for the produc-
tion of reverse-phase protein arrays (RPPAs). Each resulting CoLA slide was
stained with a specifıc antibody from the list of 44 functionally-diverse pro-
teins. Immunostained slides were then scanned using an ordinary optical
flatbed scanner for quantifying the spot intensity. To evaluate whether the
CoLA system produced biologically relevant data relating to the DTPs, the
epithelial/non-epithelial protein relationship between E-cadherin and vi-
mentin was examined. With the proteomic profıling of 2,000 DTPs, E-
cadherin was negatively correlated with vimentin (r -0.74, P 0.0001) and
positively correlated with CK-8 (r 0.86, P 0.0001), suggesting that DTPs
may flexibly transit their biological entity in response to drug administra-
tion. A set of hierarchical clustering of DTPs displays proteomic patterns in
each dose, allowing the comparison of proteomic changes in a dose-response
manner. For example, the “cisplatin-induced cluster” demonstrated similar
proteomic patterns regardless of the drug dose. In contrast to cisplatin, the
“gefıtinib-induced cluster” indicated that the proteomic patterns were sim-
ilar at drug concentrations from 0 to 0.1 M; however, those at 1 and 10 M
were distinct from those at lower concentrations. Individual protein analyses
of the DTPs revealed that the level of STAT3 decreased while that of OCT4A
increased according to the gefıtinib concentrations. An RPPA-modifıed
method, CoLA, for individual colony profıling has been successfully estab-
lished. The results of validation studies suggest that CoLA can be a tool for
understanding the emergence mechanism of DTPs. The molecular charac-
teristics of DTPs may reflect the entity of cancer cell subpopulations that
contribute primarily to post-chemotherapeutic cancer relapse. Further tech-
nical development will enhance understanding of the occurrence of cancer
relapse.
#3952 Rapid autopsy programs: A systematic review. Brian Li,1 Neesha
Dhani,1 WeiYang Yu,2 Shawn Khan,2 Elysia Grose2. 1Princess Margaret Cancer
Centre, Toronto, Ontario, Canada; 2McMaster University, Hamilton, Ontario,
Canada.
A Rapid Autopsy Program (RAP) is an advanced method of biospecimen
procurement whereby autopsies are conducted within 2-6 hours postmortem in
order to obtain substantial amounts of high-quality, fresh tissue in support of
current and future research. Rapid autopsies were fırst introduced in the late
1980’s and are still a relatively novel approach, but growing in popularity as a
viable alternative to traditional tissue sampling methods for cancer research. In
oncology, primary tumour, metastatic, and normal tissue from uninvolved or-
gan sites are sampled and can be subsequently snap frozen in liquid nitrogen or
preserved in formalin-fıxed paraffın-embedded blocks. Fresh tissue can also be
distributed immediately to cancer researchers allowing for analyses incompati-
ble with archival frozen or fıxed tissue. Tissue degradation has been found to be
minimized in different tissue types by decreasing the postmortem interval – the
time betweendeath and tissue preservation. Institutions capable of executing the
collection and maintenance of such a repository of biospecimens are a monu-
mental asset to clinicians and researchers who are interested in investigating
tumour biology, metastatic disease, and treatment response. In addition to the
clear scientifıc benefıts of RAPs, these programs offer a unique opportunity for
palliative cancer patients to donate their bodies to aid cancer research. This
systematic review was conducted to examine the scope of impact of RAPs thus
far on biomedical, translational, and clinical research in the fıeld of oncology, in
hopes to inform best practice for collection and use of biospecimen in oncology.
Medline, Embase, Cochrane Database of Systematic Reviews, Cochrane CEN-
TRAL, and Ovid MEDLINE will be searched with devised strategies and
screened from inception until present. In addition, grey literature will be re-
viewed. Two independent reviewers will be responsible for study selection and
data extraction. The results of the systematic review are pending.
#3953 Visualization of treatment resistant subclones in colorectal cancer
by mutation specifıc RNA in situ hybridization. Ann-Marie Baker,1 Mindy
Wang,2 Xiao-Jun Ma,2 Courtney Anderson,2 Weini Huang,1 Enric Domingo,3
Annabelle Lewis,3 John Bridgewater,4 Marnix Jansen,4 Nicholas A. Wright,1
Manuel Rodriguez-Justo,4 Emily Park,2 Ian Tomlinson,3 Trevor A. Graham1.
1Barts Cancer Institute, London, United Kingdom; 2Advanced Cell Diagnostics,
Hayward, CA; 3University of Oxford, Oxford, United Kingdom; 4University Col-
lege London Hospital, London, United Kingdom.
Introduction: Tumor heterogeneity is a major underlying cause of therapy
resistance and disease recurrence. Recent evidence shows that resistant clones
are nearly always pre-existing in a cancer, but are present at low frequencies.
Moreover, genetic analysis of clonal composition has been largely at the level of
’bulk’ sequencing, which does not inform of the arrangement of tumor sub-
clones in space. This spatial information contains crucial clues as to the mech-
anisms of subclone emergence. To address this gap in our knowledge, we have
used Basescope™, a novel RNA in situ hybridization (ISH) technology to detect
somatic single nucleotide variants (SNVs)within key treatment-resistance genes
in sections of archival formalin fıxed paraffın embedded (FFPE) colorectal can-
cer (CRC) and adenoma (CRA) samples. Experimental procedures: Basescope™
probes were designed against common CRC mutations in KRAS, BRAF and
PIK3CA, genes that are all implicated in modulating targeted therapy response,
and also for the corresponding wildtype genes. Publically available cell lines
containing the mutations of interest were used to confırm the sensitivity and
specifıcity of the Basescope™ probes.We then performedRNA-ISHon a series of
FFPE colorectal tumors (n24) using novel Basescope™ technology. The pres-
ence of detected mutations was confırmed by DNA sequencing. In additional
analyses wemultiplexed Basescope™ technology with conventional immunohis-
tochemistry and DNA ISH to study concurrent DNA- and protein-level altera-
tions. Stained sections containing subclonal mutations were digitized and used
to create 2D maps depicting the precise location of mutant and wild-type sub-
clones. These were then used to test and refınemathematicalmodels of subclone
expansion. Summary of novel results: Our data reports the application of Bas-
escope™ technology for the in situ detection of SNVs in human CRC. We have
used custom designed Basescope™ probes to visualize common mutations, and
mapped the spatial arrangement of these mutant subclones. We found mutant
subclones in 10 samples analyzed, and noted that these subclones appeared
generally contiguous in space. Mathematical modeling of these data reveals the
patterns of clonal selection and expansionwithinCRCs.Conclusions: This study
is the fırst to use RNA-ISH sensitive to specifıc somatic SNVs to visualize the
subclonal architecture of CRC, specifıcally of clones involved in treatment fail-
ure. Our results are suggestive of a complex clonal architecture within this com-
mon cancer type. Furthermore, we have confıdently detected mutant subclones
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comprising less than 5% of the total lesion - these would not be reliably detected
by standard methodology, and would likely be responsible for the failure of
targeted therapy. More generally, we envisage that Basescope™ technology will
be a useful tool in basic research, and furthermore is readily transferrable to
clinical applications.
#3954 Single-cell misregulation of NRF2 in basal-like breast cancer. Eliz-
abeth Pereira, Kevin Janes. University of Virginia, Charlottesville, VA.
Cancer is driven by a complex and heterogeneous combination of genes and
pathways, many of which are not explicitly oncogenic on their own. These so-
called non-oncogenes are required formaintenance of the tumorigenic state, but
they are notmutated themselves. Oneway to identify “non-oncogene” pathways
is to evaluate how proliferating cells adjust to variable and evolving environ-
ments. By examining heterogeneous transcriptional regulatory states of single
cells in a 3D culturemodel of breast epithelial organization, we uncoveredNRF2
as a candidate transcription factor upstream of an important regulatory state for
morphogenesis. NRF2 is a known oncogene in lung cancer, butmutations in the
transcription factor are uncommon in breast cancer. To examine the functional
impact of NRF2 signaling, we engineered several triple-negative breast cancer
cell lineswith inducible short hairpinRNA to knockdownNRF2. In claudin-low
MDA-MB-231 cells, knockdown of NRF2 caused dramatic reduction in stellate
invasion compared with shGFP control. In basal-like HCC-1806 cells, knock-
down of NRF2 caused a reduction in “ruptured” tumorspheres, in which cells
disseminate from their originating site. In a non-transformed breast epithelial
cell line, overexpression of a non-degradable form of NRF2 caused greater vari-
ation in the size of acini, while knockdown of NRF2 narrowed the size distribu-
tion of acini. Therefore, knockdown of NRF2 substantially normalizes the size
and shape of both non-transformed and cancerous 3D structures. We also ana-
lyzed expression levels of the genes in the provisional NRF2-regulated cluster
after NRF2 knockdown or overexpression. Upon NRF2 knockdown, the p53-
regulated transcripts CDKN1A (p21) and RPS27L were strongly induced, sug-
gesting that p53 may be activated after NRF2 loss. Our results suggest a func-
tional importance for NRF2 in multiple breast-epithelial and TNBC contexts,
and raise the possibility of interplay between NRF2 and p53. A detailed under-
standing of NRF2 regulation and dynamics could enable new strategies to dis-
rupt this non-oncogene addiction and re-sensitize cancer cells to their environ-
ment and to chemotherapy.
#3955 Spatially resolved, multiplexed digital characterization of protein
and mRNA distribution and abundance in formalin-fıxed, paraffın-embed-
ded (FFPE) tissue sections based on NanoString’s Digital Spatial Profıling
(DSP) technology: applications to immuno-oncology (IO) and tumor heter-
ogeneity. Chris Merritt,1 Jaemyeong Jung,1 Giang Ong,1 Yan Liang,1 Fiona Pa-
kiam,1 Dwayne Dunaway,1 Isaac Sprague,1 Sarah Warren,1 Gordon B. Mills,2
Joseph Beechem1. 1NanoString Technologies, Inc., Seattle, WA; 2MD Anderson
Cancer Center, Houston, TX.
Introduction: As intra-tumoral heterogeneity has emerged as a challenge in
development of targeted cancer therapeutics, the tissue context of biomarker
levels and colocalization of key immunoregulatory proteins has become an in-
creasingly important aspect for understanding tumor immune responses, pa-
tient classifıcation, and stratifıcation. Historically, immunohistochemistry and
in situ hybridization have been used to assess spatial heterogeneity of targets in
clinical samples. These approaches, however, have limitedmultiplexing capacity
and dynamic range. Here, we use DSP technology, a spatially resolved approach
for quantifying up to 800 protein or RNA targets with over 5 logs of dynamic
range in a single FFPE slide to overcome these limits. Methods: The technology
uses DNA oligo tags for either protein or RNA detection. For protein detection,
a cocktail of 30 primary antibodies (Abs), each with a unique, photocleavable
oligo tag, and 1-3 fluorescently (FL) labeled Abs was applied to a slide-mounted
FFPE tissue section. Regions of interest (ROI), selected based on a FL imaging
scan of the entire tissue, were illuminated sequentially with focused UV light to
release the oligos. Following each UV cycle, eluent was collected from the local
ROI, moved to a microtiter plate, hybridized to NanoString® barcodes, and then
analyzed with an nCounter® Analysis System. The resulting digital counts cor-
responded to the abundance of each targeted protein in the ROI. For RNA
detection, a cocktail of multiple UV-cleavable in situ hybridization probes were
used in a similar manner. Results: We demonstrate multiplexed detection from
discrete ROIs within a tumor and adjacent normal tissue, enabling systematic
interrogation of a heterogeneous tumormicroenvironment. In control samples,
we found expected levels of protein and RNA targets. We further demonstrate
that this approach enables analysis of target abundance from individually se-
lected cells, both contiguous and non-contiguous with the same phenotype, and
enables multiplexed detection of key IO targets. Finally, we demonstrate detec-
tion of key IO RNA targets using direct hybridization of oligo-labeled probes.
Conclusions:With further development, our novel DSP approach to capture the
spatial context of protein and RNA levels will have many applications in bio-
marker and translational research. The ability to digitally measure RNA and
protein at up to 800-plex from FFPE tissues could facilitate drugmechanism-of-
action and response studies within the tumor microenvironment. Quantitative,
high-plex data should also greatly accelerate the discovery of IO biomarkers in
tumors and the development of companion diagnostics for targeted therapies.
#3956 Intra-individual genomic heteroneity of ovarian cancer and clinical
utility of ascitic cancer cells for mutation profıling. Youn Jin Choi, Min Sung
Kim, Sug Hyung Lee. Catholic Univ. of Korea, Seoul, Republic of Korea.
Intra-individual tumoural heterogeneity (ITH) is a hallmark of solid tumours
and impedes accurate genomic diagnosis and selection of proper therapy. The
purpose of this study was to identify ITH of ovarian high-grade serous carcino-
mas (OSCs) and to determine the utility of ascitic cancer cells as a resource for
mutation profıling in spite of ITH. We performed whole-exome sequencing,
copy number profıling, and DNA methylation profıling of four OSC genomes
using multiregional biopsy from 13 intra-ovarian lesions, 12 extra-ovarian tu-
mour lesions (omentum/peritoneum), and ascitic cells.We observed substantial
levels of heterogeneity inmutations and copy number alterations (CNAs) of the
OSCs. We categorized the mutations into ’common’, ’shared’ and ’private’ ac-
cording to the regional distribution. Six common, 8 shared, and 24 private mu-
tations were observed in known cancer-related genes. Common mutations had
a higher mutant allele frequency and included TP53mutations in all four OSCs.
Region-specifıc chromosomal amplifıcations and deletions involving BRCA1,
PIK3CA, and RB1were also identifıed. Of note, themutations detected in ascitic
cancer cells represented 92.3-100% of overall somatic mutations in the given
case. Phylogenetic analyses of ascitic genomes predicted a poly-seeding origin of
somatic mutations in ascitic cells. Our results demonstrate that despite ITH,
somatic mutations, CNAs, and DNAmethylations in both “common” category
and cancer-related genes were highly conserved in ascitic cells of OSCs, high-
lighting the clinical relevance of genome analysis of ascitic cells. Ascitic tumour
cells may serve as a potential resource to discover somatic mutations of primary
OSC with diagnostic and therapeutic relevance.
#3957 Characterization of functional heterogeneity and in vivo dynamics
of clonal cell populations derived from the triple-negative breast cancer cell
line MDA-MB-468. Hendrik J. Kuiken,1 Sabin Dhakal,1 Laura M. Selfors,1 Jett
P. Crowdis,1 Hyo-eun C. Bhang,2 Frank Stegmeier,2 Gordon B. Mills,3 Joan S.
Brugge1. 1Harvard Medical School, Boston, MA; 2Novartis, Cambridge, MA;
3MD Anderson Cancer Center, Houston, TX.
Tumors evolve through progressive accumulation of (epi)genetic alterations,
favoring expansion of the fıttest cell populations as a result of stimuli and selec-
tive pressures in the microenvironment. Intratumor heterogeneity and the in-
terplay of tumor cells with the microenvironment present an order of complex-
ity that can have profound effects on tumor progression and drug sensitivity.
While tumor cell heterogeneity has been described atmany levels, there is a poor
understanding of the extent of functional heterogeneity within a single tumor,
and the dynamics and spatial organization of distinct cell populations over time.
The overall objective of this study is to characterize the functional heterogeneity
of breast tumor cells and evaluate the dynamics of clonal populations within
mixtures during tumor progression. We have generated and characterized 31
clonal cell populations (SCP) from the triple-negative breast cancer cell line
MDA-MB-468. These SCPs display considerable phenotypic heterogeneity with
respect tomorphology, proliferation rate, survival in suspension, colony forma-
tion in soft agar, and tumorigenicity. We have also performed whole-exome
sequencing for 7 SCPs, and RNA-seq and RPPA analysis for all SCPs and the
parental cell line. These analyses revealed SCP-unique single nucleotide vari-
ants, and differential expression of numerous genes. To study the dynamics of
SCPmixtures during the development of xenograft tumors, we have transduced
22 SCPswith uniqueDNAbarcodes derived from the ClonTracerDNAbarcode
library. The 22 barcoded SCPs were mixed in equal proportions and subse-
quently injected into the mammary fat pad of NOD/SCID mice. Tumors and
lungs were collected at different time points (3 weeks, 2 months and 4 months)
to determine the relative changes in clonal representation during tumor pro-
gression by next generation sequencing. We identifıed highly reproducible pat-
terns of clonal expansion,with SCP01 and SCP03being temporarily enriched for
in tumor samples collected at 3 weeks and 2 months respectively, and SCP32
becoming progressively enriched for in tumors over time. In addition, we found
recurrent enrichment for SCP01 inmost lung samples. Moreover, in contrast to
the tumor samples, we found a slight enrichment for SCP13, but not SCP32,
during in vitro propagation of the SCP mixture. Together these results suggest
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the existence of distinct competitive advantages of individual clonal populations
within certain spatial and temporal windows. In addition, the discordance in
SCP dynamics between the in vivo and in vitro arms suggests that enrichment
for SCP01, SCP03 and SCP32 is the result of stimuli or selective pressures that
are specifıc to the tumormicroenvironment. Guided by the RNA-seq and RPPA
analyses, we are currently testing several hypotheses that may explain the ob-
served enrichment patterns.
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#3958 The importance of co-localized resting CD8 T cells and prolifer-
ating tumor cells in gastric cancer. Mehmet Yigitsoy,1 Sophie Earle,2 Armin
Meier,1 Nathalie Harder,1 Matthew Hale,2 Aleksandra Zuraw,1 Takaki Yo-
shikawa,3 Günter Schmidt,1 Ralf Huss,1 Heike I. Grabsch4. 1Defıniens AG, Mu-
nich, Germany; 2University of Leeds, Leeds, United Kingdom; 3Kanagawa Cancer
Center, Yokohama, Japan; 4Maastricht UniversityMedical Center, Maastricht,
Netherlands.
Gastric cancer (GC) is the third leading cause of cancer-related death world-
wide. With the advent of immunotherapies, there is a need to characterize the
phenotype of tumor infıltrating immune cells and co-localized cancer cells. We
have shown previously that high density of CD45R0 T cells is related to better
prognosis in Japanese GC. However, the variation of T-cell infıltration in GC is
still not understood. We hypothesized that an increased CD8 T-cell infıltra-
tion is related to T-cell activation (highT cell Ki67 proliferation index). Purpose:
To establish the frequency of co-occurrence of Ki67 and CD8 in T cells and
their co-localization with tumor cells and evaluate the relationship with clinico-
pathological variables including survival. Patients andMethods: Immunohisto-
chemistry for T cells (CD8), proliferation (Ki67), and epithelial cells (CK) was
performed on tissue microarrays (TMAs) from 213 GC from the Kanagawa
Cancer Centre Hospital (Yokohama, Japan). Stained slides were scanned, qual-
ity controlled, and analyzed using Tissue Phenomics (Defıniens, Munich, Ger-
many) for cell/nuclei segmentation and automatic co-registration of consecu-
tive sections. The TMA cores were subdivided into tiles of size 64 m2 to count
co-localized positive cells. Average ratio of CD8 cells and Ki67 cells per
tile/patient was used for statistical analyses. The relationship with pT, pN and
histological tumor type was assessed using the Kruskal-Wallis test. Prognostic
features were determined by univariate stratifıcation which optimizes Kaplan-
Meier p-value using 50 independent pre-validations with 3 folds and ranked by
themedianpre-validationp-values. P-values 0.05were considered signifıcant.
Results: 60887 tiles were analyzed in total. Median (range) number of tiles ana-
lyzed per patient was 291 (81-345).Median (range) CD8/Ki67 ratio was 0.39
(0.01-0.92). Manual inspection of selected image tiles showed that CD8 cells
are rarely Ki67. Median (range) % of tiles/patient where CD8Ki67- cells
co-localized with Ki67 tumor cells was 17% (0%-93%). Signifıcant difference
of ratio was observed between histological subtypes (p0.0096). There was no
signifıcant relationship between CD8/Ki67 and pT or pN. A high CD8/
Ki67 ratio was related to better survival (p0.012). Conclusions: This is the
fırst study to suggest that themajority ofCD8Tcells inGCappear to be resting
(Ki67-) T cells rejecting our hypothesis that high numbers of intratumoral T
cells are due to high intratumoral T cell proliferation. The co-localization of
CD8 T cells and Ki67 tumor cells seems to be clinically relevant and char-
acterize certain histological phenotypes in GC. However, the potential underly-
ing biological mechanisms of interaction between T cells and tumor cells are
currently unknown. Further studies are needed to validate our fındings and
characterize the interface between tumor and immune cells.
#3959 CCL18-recruited naïve CD4 T cells are converted to tumor-infıl-
trating regulatory T cells in breast cancer and suppress antitumor immunity.
Shicheng Su, Jianyou Liao, Jiang Liu, Qiang Liu, Erwei Song. SunYat-Sen Me-
morial Hospital, SunYat-Sen University, Guangzhou, China.
Tumor-infıltrating regulatory T cells (Tregs) play a central role in tumor
immunosuppression. However, it remains unclear whether they are directly
recruited from peripheral blood or converted from infıltrating naïve T cells.
Here, full-length TCR / repertoire analysis of different T cell subsets from
peripheral blood, primary tumors and draining lymph nodes in patents suggests
that Tregs in human breast cancer aremainly converted from tumor-infıltrating
naïve CD4 T cells. Infıltration of naïve CD4 T cells and Tregs are closely
correlated, both indicating poor prognosis for breast cancer patients. Naïve
CD4

T cells in the tumors are recruited by tumor-associated macrophages
(TAMs) via CCL18. In addition, naïve T cells and memory T cells exhibit dis-
tinctive chemotactic response due to different expression of regulator of G-pro-
tein signaling 1(RGS1). Specifıc silencing CCL18 receptor-PITPNM3 in naïve
CD4 T cells using CD4 aptamer-siRNA blocks their chemotaxis, and thus
reduces infıltratingTregs and inhibits tumor progression in humanizedmice. By
comparison, silencing RGS1 in memory CD8 T cells using CD8 aptamer-
siRNA enhance their recruitment to tumors and anti-tumor immune response
in vivo. These fındings provide mechanistic insights for Treg enrichment in
breast cancer and suggest that modifıcation of the CCL18-PITPNM3-RGS1 sig-
naling pathway may be an attractive strategy for anticancer immunotherapy.
#3960 Tumor cell drug resistance induced by the programmed death li-
gand 1 (PD-L1) immune checkpoint is associated with autophagy. Lori M.
Minassian, Shannyn K. MacDonald-Goodfellow, Peter Truesdell, Daniel San-
walka, AndrewW.Craig,Madhuri Koti, D Robert Siemens, Charles H. Graham.
Queen’s University, Kingston, Ontario, Canada.
The interaction between the Programmed Death Ligand 1 (PD-L1) immune
checkpoint on the tumor cell surface with the Programmed Death-1 (PD-1)
receptor on cytotoxic T lymphocytes (CTLs) leads to CTL inactivation, thereby
promoting tumor cell escape from adaptive immunity. We previously demon-
strated that signaling by PD-L1/PD-1 is bidirectional and leads to activation of
oncogenic pathways as well as drug resistance in tumor cells. We also have
preliminary evidence that Immunity Related GTPaseM, an importantmediator
of autophagy, is up-regulated by PD-1/PD-L1 reverse signaling. Autophagy is a
well-established mechanism of drug resistance in cancer cells. This led us to
hypothesize that PD-1/PD-L1 signaling induces drug resistance in tumor cells
by up-regulating autophagy. The MEK/ERK and the PI3K/Akt signaling path-
ways are known to increase and decrease autophagy, respectively. Breast cancer
cells exposed to rPD-1 showed a time dependent increase in extracellular signal–
regulated kinase (ERK) activation and a decrease in protein kinase B (Akt) acti-
vation. Conversion of microtubule-associated protein light chain 3 (LC3)-I to
LC3-II is a requirement for autophagosome formation and is a robust marker of
autophagy. Exposure of humanbreast cancer cells to recombinant PD-1 (rPD-1)
showed a time-dependent increase in LC-3 II. We are currently conducting
additional studies to confırm that the activation of PD-L1 signaling in tumor
cells up-regulates autophagy. These results provide evidence that PD-1/PD-L1
reverse signaling activates autophagy as a potential mechanism of cancer cell
chemoresistance. (Supported by a grant from the Canadian Institutes of Health
Research.)
#3961 Increased CCR4-positive regulatory T cells in biopsy specimen of
poor prognosis prostate cancer. Masahito Watanabe, Kent Kanao, Susumu
Suzuki, Hiroyuki Muramatsu, Shingo Morinaga, Keishi Kajikawa, Ikuo Ko-
bayashi, Genya Nishikawa, Yoshiharu Kato, Kogenta Nakamura, Kazuhiro Yo-
shikawa, Ryuzo Ueda, Makoto Sumitomo. Aichi Medical University, Nagakute,
Aichi, Japan.
Introduction & Objective: Regulatory T cells (Treg) play important roles in
suppression of the immune response, including anti-tumor immunity. C-C
chemokine receptor 4 (CCR4) is highly expressed on effector Tregs, and the
anti-CCR4 antibody is attracting attention as a novel immunotherapeutic agent
for solid tumors. The purpose of this study was to evaluate the expression of
CCR4-positive Tregs in biopsy specimens of men with prostate cancer with a
poor prognosis and to estimate the clinical potential of CCR4-targeting therapy
for prostate cancer. Material &Methods: Data for 60 men diagnosed with pros-
tate cancer based on transrectal 12-core systemic biopsy were retrospectively
analyzed. They were divided into two groups, a good prognosis group compris-
ing men with no disease progression during the observation period and a poor
prognosis group comprising men with progression to castration resistant pros-
tate cancer. In the biopsy cores, the core with the highest tumor volume was
selected for immunohistochemical evaluation. Tregs were evaluated using im-
munohistochemistry with double staining using anti-forkhead box protein 3
(FOXP3) antibodies and anti-CCR4 antibodies. The number of CCR4/-
FOXP3 cells in the biopsy specimens were compared between the two groups.
Furthermore, the correlation between the number ofCCR4FOXP3 cells and
clinical stage, PSA at diagnosis, and Gleason score were evaluated. Results: The
good prognosis group included 29 men and the poor prognosis group included
31men. Approximately 70-80% of FOXP3 cells were positive for CCR4. There
was no signifıcant difference in the ratio of number of CCR4 FOXP3 cells to
the number of total FOXP3 cells between the poor and good prognosis groups.
However, the total number of FOXP3 cells signifıcantly increased in the poor
prognosis group than in the good prognosis group (200.1 	 174.8 vs. 38.1 	
38.1, p 0.01). Furthermore, the number ofCCR4FOXP3 cells signifıcantly
increased in the poor prognosis group than in the good prognosis group (123.6
	 99.1 vs. 58.88 	 26.4, p  0.01). The number of CCR4 FOXP3 cells
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positively correlatedwith clinical stage ( 0.558, p 0.001) andGleason score
(  0.458, p  0.006) in prostate cancer. However, there was no signifıcant
correlation between the number ofCCR4FOXP3 cells andPSA at diagnosis.
The men with a lower number of CCR4 FOXP3 cells had a signifıcantly
longer median survival time than those with high expression (not reached vs.
69.0 months; p 0.040). Conclusions: Our results suggest the clinical potential
of CCR4-targeted therapy for poor prognosis prostate cancer.
#3962 High-dimensional flow cytometric immune profıling of malignant
gliomas. Amber J. Giles,1 Caitlin M. Reid,1 Deric M. Park,1 Mario Roederer,2
Mark R. Gilbert1. 1NCI-NIH, Bethesda, MD; 2NIAID-NIH, Bethesda, MD.
INTRODUCTION: Immune therapy is emerging as a treatment modality for
patients with solid tumors including intracranial metastases. Similar immune
strategies are being tested in patients with malignant gliomas; diseases with
uniformly poor prognosis. Whereas, recent work has demonstrated a correla-
tion between the immune landscape of solid tumors and response to immune
therapy, the immunologic landscape of CNS tumors has not been thoroughly
defıned. To capture the phenotypic diversity of immune cells in CNS tumors, we
developed an 18-color flow cytometry panel and applied it to mononuclear cells
isolated from acutely resected brain tumor, matched patient blood, and healthy
donor blood specimens. METHODS: Linear discrimination analysis (LDA) and
T-distributed stochastic neighbor embedding (tSNE) dimensionality reduction
techniqueswere used to analyze flow cytometry data acquired frombrain tumor,
patient-matched peripheral blood, and healthy donor peripheral blood speci-
mens. RESULTS: LDA of 13 parameters collected by flow cytometry revealed
that CD8 tumor-infıltrating lymphocytes (TILs) differed notably from periph-
eral blood. CTLA-4 (TILs) and CD3 (peripheral blood) provided the greatest
degree of separation. Using the tSNE algorithm to analyze the same 13 param-
eters onCD8Tcells, we rapidly reduced 78potential parameter combinations by
creating a clustering pattern representing lymphocytes with similar staining
patterns. Lymphocyte clusters created fromTILs were easily distinguished from
clusters enriched in peripheral blood. Analysis of TIL clusters identifıedmarkers
consistent with activated/memory populations as well as elevated levels of
CTLA-4, LAG-3, and PD-1 relative to peripheral blood; due to a higher percent-
age of cells expressing these markers rather than increased expression on indi-
vidual cells. Identifying individual specimen points as well as clusters of speci-
mens (e.g. patients with the same tumor classifıcation), enabled comparisons
across individual patient specimens (intra-patient blood vs tumor), across tu-
mor type or grade, and across disease state (patient vs healthy donor). CON-
CLUSIONS: Dimensionality reduction techniques provided a rapid means to
identify markers that were differentially expressed in TILs relative to peripheral
blood. Importantly, these analyses were unrestricted by canonical gating strate-
gies. CD8 TILs express multiple markers of activation and maturation, suggest-
ing reactivity to tumor antigens and potential for immune therapy. Application
of these analyses to a broader patient population will reveal the immunologic
landscape of primary CNS tumors and provide insight into the immunologic
consequences of current therapies. Further, this may lead to identifıcation of
specifıc immune signatures that may predict therapeutic response to immune
therapy.
#3963 Neoadjuvant chemotherapy promotes prometastatic changes in the
primary breast tumor microenvironment in mice and humans. George S.
Karagiannis,1 Jessica Pastoriza,1 Jeanine Pignatelli,1 Yarong Wang,1 Allison S.
Harney,1 David Entenberg,1 Ved P. Sharma,1 Emily Xue,1 Esther Cheng,2 Tim-
othy M. D’Alfonso,2 Joan G. Jones,1 Jesus Anampa,1 Thomas E. Rohan,1 Joseph
A. Sparano,3 John S. Condeelis,1 Maja H. Oktay1. 1Albert Einstein College of
Medicine, Bronx, NY; 2Weill Cornell Medicine, New York, NY; 3Montefıore Med-
ical Center, Bronx, NY.
Chemotherapy induces influx of bone marrow-derived proangiogenic Tie2hi
monocytes in primary tumors. Tie2hi perivascular macrophages specifıcally induce
the prometastatic Mena isoforms in tumor cells and can assemble specialized mi-
croanatomical sites called “tumor microenvironment of metastasis” (TMEM),
structures thatmay serve as doorways for intravasation of tumor cells inmammary
tumors. Both TMEM and MenaINV are required for tumor cell intravasation and
dissemination. Thus, we hypothesized that chemotherapymay increase the density
of TMEM sites andMenaINV-expressing, intravasation-competent tumor cells, re-
sulting in increased tumor cell invasion and metastasis. We studied these potential
pro-metastatic effects of chemotherapy in a neoadjuvant setting (NAC) by either
administeringpaclitaxel or a combinationofdoxorubicin andcyclophosphamide in
severalmammary carcinomamouse andhumanbreast cancermodels.As expected,
chemotherapy delayed tumor growth, yet it signifıcantly increased the recruitment
of TMEM-forming, perivascular Tie2hi/Vegfhi macrophages and TMEM density.
Using high-resolution multiphoton intravital imaging in live tumor-bearing mice,
we observed that paclitaxel also increased the activity of TMEM sites, visualized as
endothelial cell tight-junctiondisruption aroundTMEMand subsequent intravasa-
tionof themigratorycancer cell subpopulation. Indeed,paclitaxel-treatedmicehave
higher numbers of circulating tumor cells, single cell seeding in lungs and incidence
andnumberofmicrometastatic foci, all associatedwith increasedTMEMactivity, as
demonstrated by high-resolution imaging techniques. Tie2 inhibitors reversed pa-
clitaxel-induced pro-metastatic phenotypes without affecting the assembly of
TMEM, indicating that Tie2-mediated signaling is required for paclitaxel-mediated
cancer cell dissemination via TMEM. Paclitaxel also caused a signifıcant increase in
the expression of MenaINV at both the gene and protein levels. Furthermore, pacli-
taxel treatment inMena-/- breast tumor-bearingmice resulted in failure to assemble
TMEMand to increase circulating-tumor cells andcancer cellmetastasis despite the
fact that Tie2hi macrophages are attracted to perivascular niches as a result of pacli-
taxel treatment. This indicated that Mena is involved in the paclitaxel-mediated
increase in cancer cell dissemination but not required for Tie2hi macrophage re-
cruitment. These pre-clinical data are further supported by fındings from a cohort
(N20) of breast cancer patients, who received pre-operative paclitaxel-based che-
motherapy and demonstrated signifıcant increases in TMEMdensity andMenaINV
expression. Together, our data provide solid evidence that NAC leads tometastasis
in rodents via TMEM/MenaINV-mediatedmechanisms, and to cancer cell dissem-
ination in certain clinical scenarios in humans.
#3964 Reducing systemic arginine with arginase (AEB1102) therapy does
not suppress the immune response induced by anti-PD-1 and anti-PD-L1,
and exerts an additive anti-tumor and synergistic survival benefıt.Giulia Ag-
nello, Susan E. Alters, DavidG. Lowe, ScottW. Rowlinson.Aeglea BioTherapeu-
tics Inc., Austin, TX.
Tumor dependence on specifıc amino acids for survival and proliferation is
well recognized and has been exploited effectively with the use of asparaginases
for the treatment of acute lymphoblastic leukemia. Sensitivity of tumors to L-
Arginine (L-Arg) deprivation results from an impaired ability to make L-Arg as
a result of decreased functional expression of one or more of the three enzymes
of the L-Arg biosynthetic pathway: ornithine transcarbamylase (OTC), argini-
nosuccinate synthase (ASS1) and argininosuccinate lyase (ASL). Native human
arginase I is not a viable drug candidate due to low activity and low stability in
serum. We have developed an alternative approach using a bioengineered hu-
man PEGylated arginase I (AEB1102) with enhanced pharmacological proper-
ties.We and others have successfully utilized arginase I to impart a direct tumor
cell killing effect through L-Arg starvation inmultiple tumor types e.g. AEB1102
single agent effıcacy in melanoma, small cell lung cancer (SCLC) and sarcoma
PDxmodels.However, the compatibility ofAEB1102with checkpoint inhibitors
is unclear as arginase I has been shown to be both immune suppressive and
immune neutral (PMID: 23717444), or immune promoting (PMID: 27043409).
Because of these conflicting reports we decided to investigate the impact of
systemic L-Arg removal on the anti-tumor effıcacy of check point inhibitors.
Murine syngeneicmodels (e.g. CT26,MC38 andLL2)were dosedwithAEB1102
alone and in combination with anti-PD-L1 and anti-PD-1monoclonal antibod-
ies (mAbs). Depending on the model, in vivo treatment with AEB1102 mono-
therapy resulted in tumor growth inhibition (TGI) ranging from 52% to 72%
compared to the untreated control group, whereas standardmonotherapy using
immunomodulatory mAbs that target PD-1 and PD-L1 resulted in TGI ranging
from 12% to 60%. Of signifıcance, combination therapy of AEB1102 with anti-
PD-1 or anti-PD-L1 resulted in additive anti-tumor effect with TGI ranging
from 60% to 86%. In the CT26 model, when AEB1102 was administered in
combination with anti-PD-L1 for at least 6 weeks, a 33% frequency of complete
tumor regression (non-palpable tumors) was observed, indicating that synergy
occurs with combination therapy. Collectively these results demonstrate that
disrupting the L-Arg physiological balance in the tumor microenvironment in-
hibits tumor growth and further sensitizes the tumor to immunotherapy when
AEB1102 is combined with anti-PD-1 and anti-PD-L1. These data open the
possibility of further improving outcomes in L-Arg dependent tumors through
combination of AEB1102 with anti-PD-1 and anti-PD-L1 inhibitors.
#3965 Epithelial membrane protein-2 is a novel regulator of immune ed-
iting in breast cancer. Jessica Tsui, Negin Ashki, Yuling Chang, Deven Patel,
Jasmine Sjarif, Madhuri Wadehra. UCLA David Geffen School of Medicine, Los
Angeles, CA.
Cancer immuno-editing is a process that describes the interaction between
immune cells and tumor cells. This interaction can result in elimination of a
developing tumor, tumor dormancy, or tumor cells that are capable of surviving
in an immune-competent host.We have recently uncovered a novelmechanism
of immunoediting by the tetraspan protein Epithelial membrane protein or
EMP2. We propose that EMP2 serves as a bridge between innate and adaptive
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immunity via tumor mediated type I interferon expression. Most tumor cells
evade the immune system through suppression or ignorance. EMP2 levels pro-
mote type I interferon expression which was found to correlate with PDL1 ex-
pression in a number of cell lines. Concordantly, in vivo, in multiple breast
cancer cell lines, EMP2promoted tumor growth. In contrast, reduction in EMP2
levels correlated with a reduction in tumor size and a corresponding increase in
tumor associated macrophages. Given that tumors with lower levels of EMP2
grow poorly, we hypothesized that targeting EMP2 may provide a therapeutic
benefıt. Recently, we have developed a panel of novel IgG1monoclonal antibod-
ies to EMP2 and tested their ability to treat both xenograft and syngeneic mouse
models. Our results show that anti-EMP2 IgG1 signifıcantly reduces tumor load
in both models in part through the recruitment of M1macrophages. To explore
this observation more fully, experiments using murine syngeneic models were
employed. Anti-EMP2 therapy elicits a robust ADCC response, producing an
immune infıltrate rich in macrophages, NK cells, and lymphocytes. In addition,
we show that CD8 cells show reduced exhaustion in the presence of anti-EMP2
antibodies. Conclusions: EMP2 is a protein upregulated in a number of cancers
in women including breast, ovarian, and endometrial tumors. Our work collec-
tively show that EMP2 is a novel immune regulator where its expression creates
an immunosuppressive tumor microenvironment. We thus predict that target-
ing EMP2 may improve therapeutic outcomes for cancers in women.
#3966 Targeting integrin v3-expressing cancer stem cells to manipu-
late tumor-associatedmacrophages.Hiromi I.Wettersten, ToshiyukiMinami,
Megan M. Kaneda, Laetitia Seguin, Judith A. Varner, Sara M. Weis, David A.
Cheresh. UC San Diego, La Jolla, CA.
Tumor associated macrophages are involved in regulation of cancer growth
and aggressiveness. Whereas M1 macrophages trigger an inflammatory re-
sponse and inhibit tumor growth,M2macrophages secrete pro-tumor cytokines
into the microenvironment to support tumor progression. A macrophage
switch from M1 to M2 has been associated with lung cancer progression, and
cancer stem cells have been implicated as a driver of this reprogramming. We
recently reported that integrin v3 expression is induced on lung adenocarci-
noma cells during drug resistance and is both necessary and suffıcient to repro-
gram these tumors to a stem-like state. Given the role that cancer stem cells play
in switching M1 to M2 macrophages, we asked whether v3 expression on
lung adenocarcinoma cells account for this macrophage conversion. The
M1/M2 macrophage ratio in v3-positive tumors was markedly decreased
relative to tumors lacking v3. We next treated mice bearing v3-positive
tumors with amonoclonal antibody (LM609) targeting this receptor to assess its
ability to alter the macrophage phenotype within these tumors. LM609 was able
to selectively eliminate the v3-positive cancer stem cells via antibody-depen-
dent cell-mediated cytotoxicity (ADCC), and this not only increased the M1
macrophage population, but also markedly enhanced the sensitivity of these
tumors to the effects of therapy. These fındings reveal that v3-expressing
cancer stem cells favor the pro-tumor M2 macrophage phenotype. Eliminating
v3-positive cancer stem cells via ADCC serves to both increase pro-inflam-
matory macrophages within the tumor microenvironment and prolong tumor
sensitivity to therapy.
#3967 High microsomal PGE2synthase-1 levels associate with low CD8 T
cells and poorer melanoma patient survival. Sun-Hee Kim, Jason Roszik,
Weiyi Peng, Suhendan Ekmekcioglu, Elizabeth A. Grimm. UT MD Anderson
Cancer Ctr., Houston, TX.
COX-2 and its product PGE2 are reported to enhance carcinogenesis and
tumor progression and to support immunosuppression, as reported by others in
melanoma and other cancers. Asmost COX-2 inhibitors result in cardiotoxicity,
the downstream microsomal PGE2 synthase-1 (mPGES1) is now also an alter-
native consideration for therapeutic targeting. Our previously published results
(Kim, et al., 2016) showed that mPGES1 protein increased with melanoma pa-
tient clinical stage and that its intense expression was associated with reduced
patient survival. We also reported that mPGES1 inhibition attenuated cell sur-
vival and increased apoptosis in human melanoma cells and signifıcantly sup-
pressed tumor growth inmelanoma xenografts. This current studywas designed
to evaluate whether expression of mPGES1 contributes to immune evasion.
Tumors in a Stage IIImelanomaTMAanalysis demonstrated that highmPGES1
expression (intensity 3) was signifıcantly associated with low CD8 levels (lower
than median CD8 percent value) (r-0.2722, p0.0128). Importantly, stage III
melanoma patients with this high mPGES1 and low CD8 signature had signifı-
cantly increased risk of death as determined by Kaplan-Meier method and Uni-
variate Cox proportional hazards regression models, and compared with pa-
tients with low mPGES1/low CD8 and low mPGES1/high CD8. Furthermore,
the differential levels of several chemokines including CXCL1 and CXCL2 to
regulate T cell migration were correlated the mPGES1 expression in the TCGA
melanomadata set. Collectively, our study continues to resolve the potential role
of mPGES1 in regulation of immune evasion and is designed as a preclinical
approach to develop a rational therapeutic strategy targeting PGE2-driven in-
flammatory mediators as useful adjuvants for immune-based therapy.
#3968 Canonical NFkB signaling in myeloid cells is required for the glio-
blastoma growth. Bhagelu R. Achyut, Jennifer Bradford, Kartik Angara, Mo-
hammad Rashid, Meenu Jain, Thaiz Borin, ASM Iskander, Roxan Ara, Ali
Arbab. Augusta University, Augusta, GA.
Glioblastoma (GBM) development and therapeutic resistance has been ac-
companying with the tumor-associated macrophages (TAMs) in the tumor mi-
croenvironment (TME). TAMs are heterogeneous cell populations of immune
regulatory myeloid-derived suppressor cells (MDSCs) and polarization of anti-
tumor macrophages (M1) into pro-tumor macrophages (M2). We investigated
the role of myeloid cell NF-B signaling in orthotopic GBM model using im-
mune defıcient and immune competent hosts. Interestingly, conditional dele-
tion of canonical NF-B signaling (p65) with Lysm-Cre (p65 KO) in myeloid
cells, signifıcantly inhibited syngeneic GL261 tumor growth in immune-compe-
tent mice compared to control mice. We studied the TAMs recruitment to the
tumor and their polarization under the influence of TME. P65 KO mice dis-
played decreasing trend of immune cell infıltration (CD45), which phenotyped
as decreased F4/80, CD68, CD206 (M2) and Gr1CD11b (MDSCs)
macrophages, compared to control mice. This was associated with the increased
CD80 (M1) macrophages, increasing trend of CD4 and CD8 cytotoxic T
cells, and decreasedCD44mesenchymal cancer stem cells (CSCs) populations
in theTME.Cytokine array data indicated that loss of canonicalNF-B signaling
within the TAMswas implicated in increased production of IFN, IGF1,MCP1,
MIP1, and TNF cytokines. Co-culture of T cells with p65 KO or control
MDSCs identifıed increased proliferation of T cells with p65 KO MDSCs com-
pared to control MDSCs. Conversely, GBM patient-derived xenografts and
U251 GBM cell line-derived tumors showed increasing trend of growth in im-
mune-defıcient mice, following the transplantation of p65 KO bone marrow
(BM) compared to control BM. Pro-tumor macrophages and CSCs were in-
creased and T cell populations were decreased in human tumors grown in im-
mune defıcientmice transplantedwith p65KOBM, comparedwith control BM.
In addition, analysis of humandata set revealed higher expression of p65 subunit
of NF-B complex in brain tumor stroma compared to the tumor cells. The
study suggests that canonical NF-B signaling in TAMs is required for the tu-
mor-promoting macrophage polarization and GBM growth in immunocompe-
tent host compared to immune defıcient host. Therefore, targeting myeloid-
specifıc NFB signaling in GBM could inhibit the immune suppressive TAMs
and improve the anti-tumor immunity.
#3969 AF1q/Mllt11 regulates the expression of intercellular adhesion
molecule-1 in breast cancer. Jino Park, Soojin Kim,William Tse.Univ. of Lou-
isville, Louisville, KY.
Intercellular adhesion molecule-1 (ICAM-1) is a cell surface glycoprotein in
the immunoglobulin superfamily. ICAM-1 expression is frequently observed on
many cell types including endothelial cells and different cancer cell entities.
Experimental data strongly indicate that ICAM-1 can activate intracellular sig-
naling pathways in cancer cells leading to enhanced cell motility, invasion and
metastasis. In clinical investigation, however, ICAM-1 expression was nega-
tively correlated to tumor size, lymph node metastasis, and tumor infıltration.
Also, there was improved relapse-free and overall survival in patients with
ICAM-1 positive tumors. Yet, the function of ICAM-1 expression during ma-
lignant progression in breast cancer patients is not understood clearly.However,
ICAM-1 is still considered as a breast cancer target and biomarker may lead to
the development of a new strategy and platform for breast cancer patients. We
observed AF1q, a metastasis enhancer, is only expressed in metastatic cells,
MDA-MB-231LN (invasive sub line from MDA-MB-231), not in the primary
tumor cells. To investigate whether AF1q has a responsibility in acquisition of
metastatic phenotype, we performed RNA-Seq and applied the Metacore net-
work building algorithm. Intriguingly, most genes were directly linked with
Intercellular Adhesion Molecule-1 (ICAM-1). Likewise, we identifıed that
ICAM-1 expression is attenuated inMDA-MB-231LN compared toMDA-MB-
231. Moreover, the expression of ICAM-1 was negatively regulated, when AF1q
was overexpressed in MDA-MD-231LN. Suppressed endogenous AF1q by
shRNA could effectively increase the ICAM-1 expression. Attenuation of
ICAM-1 by AF1q on tumor cells would disadvantage host anti-tumor defenses
by traffıcking of lymphocytes, which affect tumor progression and metastasis.
We observed that NF-B activity which regulates ICAM-1 expression is atten-
uated in response to AF1q expression in breast cancer cells. Published reports
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shown thatWnt/-catenin negatively regulatesNF-B activity through protein-
protein interaction in colon and breast cancer cells. Previously, we reported that
AF1q enhance the TCF7/LEF/-catenin complex binding affınity as a cofactor.
Structurally, AF1q has highly acidic peptide regions highly conserved between
species that fulfıll the criteria for an acidic blob, a typical feature for cofactors.
When we performed immunoprecipitation with NF-B antibody inMDA-MB-
231LN overexpressed AF1q, we observed that -catenin and AF1q were pulled
down together. However, it is not clear yet whether AF1q promote protein
interaction between -catenin and NF-B. These results suggest that activated
-catenin by AF1q would archive higher affınity to bind with NF-B and
thereby attenuate ICAM-1 expression.
#3970 Targeting the adenosine immunosuppressive pathway for cancer
immunotherapy with small molecule agents. Pierre Fons,1 Michael Esquerré,1
StéphanieVersluys,1GigliolaMambrini,1Michael Paillasse,1 AndyBell,2 Adrian
Schreyer,3 Richard Cox,3 Richard Bickerton,3 Joanna Lisztwan,1 Mark Whit-
taker,1 Françoise Bono,1 Craig Johnstone,1 Andrew Hopkins3. 1EVOTEC, Tou-
louse, France; 2Exscientia, Dundee, France; 3Exscientia, Dundee, United King-
dom.
Standard Immune Checkpoint Therapies, such as anti-CTLA-4 or anti-PD-
1/PD-L1 mAb, demonstrate long progression-free-survival for responding pa-
tients but with a low response rate. This can be due to additional immunosup-
pressive mechanisms developed by resistant tumors. The adenosine pathway is
one of themain drivers of tumor progression by acting on two key features of the
TME (TumorMicro-Environment); immunity and angiogenesis. Expression of
CD73 on tumor cells and on immunosuppressive cell subsets leads to the gen-
eration of adenosine fromAMP.Adenosine inhibits the biological functions of T
lymphocytes infıltrating the tumor by binding to the A2AR (receptor). Evotec
and Exscientia are collaborating to accelerate small molecule drug discovery in
the fıeld of Immuno-Oncology by integrating a unique biophysical screening
approach to the adenosine receptors and CD73 to drive automated medicinal
chemistry design with a translational-focused screening cascade, to discover
novel agents that target the adenosinergic pathway in immuno-oncology. We
have fırstly sought to generate novel A2AR antagonists and secondly to create
A2AR/CD73 bi-specifıc inhibitory molecules with a dual pharmacological pro-
fıle, from fragment screening and de novo design approaches. In vivo combina-
tion study demonstrate the advantages of targeting CD73 and A2AR. We have
obtained active molecules illustrated by in vitro data on primary human T lym-
phocytes. These results, have paved the way to an optimized process to identify
adenosinergic pathway inhibitors with properties optimized for immuno-on-
cology.
#3971 MTA-mediated inhibition of human T cells: Mechanism and
MTAP overexpression as putative overcoming strategy. Carolin D. Strobl,1
Frederik Henrich,1 Katrin Singer,2 Katrin Peter,2 Marina Kreutz,2 Anita Kre-
mer,1 Andreas Mackensen,1 Michael Aigner1. 1University Hospital Erlangen,
Erlangen, Germany; 2University Hospital Regensburg, Regensburg, Germany.
Metabolic changes of malignant cells lead to the secretion of tumor metabo-
lites which contribute to the shaping of a favorable milieu for tumor immune
escape facilitating cancer development and resistance to anti-tumor immuno-
therapy. Recently, disrupted methylthioadenosine metabolism drew interest as
further putative immunoinhibitory metabolic dysregulation. A broad spectrum
of tumor entities was reported to lack methylthioadenosine phosphorylase
(MTAP) expression leading to elevated levels of its substrate 5’-deoxy-5’-meth-
ylthioadenosine (MTA). MTAP defıciency is reported to correlate with worse
response to adjuvant interferon-alpha therapy and a higher risk for metastatic
disease in malignant melanoma providing evidence for immunobiological rele-
vance. We therefore examined the effect of the tumor metabolite MTA on hu-
man T cell responses. We could show that MTA has a strong inhibitory impact
on human T cell function regarding proliferation, viability, activation, differen-
tiation, tumor antigen-specifıc expansion and cytotoxicity. We therefore aimed
to overexpress MTAP in human T cells by retroviral transduction as a putative
strategy to overcomeMTA-mediated inhibition of T cells. In addition, we inves-
tigated the effect ofMTAonT cellmetabolism andmaturation of humanmono-
cyte derivedmDC.We successfully generated stableMTAP-overexpressing pri-
mary human T cells. First studies were performed to examine the resistance to
MTA after equipping the T cells with higher levels of its metabolizing enzyme
MTAP. MTAPhigh T cells revealed less sensitivity against inhibitory effects of
MTA on proliferation, viability or cytotoxicity compared to mock transduced
controls suggesting a promising approach to strengthen the performance of T
cells facing the MTA-rich milieu of MTAP-defıcient tumors. Mechanistically,
we found MTA to interfere with several signaling pathways. Of most impor-
tance,MTA impairedAkt phosphorylation as well as intracellular proteinmeth-
ylation, both crucial processes for proper T cell function. In addition, we studied
the combined effect ofMTAandPRMT5 inhibition onT cells. Severalmetabolic
studies focusing on glycolysis and fatty acidmetabolism could confırm our fınd-
ings that MTA keeps T cells in a rather inactive, naïve state. Finally, we found
MTA to interfere with DC maturation and their potential to induce cytokine
secretion of T cells. Our data emphasizes the crucial role of tumor metabolites
such as MTA in the tumor milieu for tumor immune escape. Additionally, the
identifıcation of potential molecular mechanisms of MTA-induced immuno-
suppression offer the opportunity to pharmacologically tackle MTA-mediated
immunoinhibition and will help to develop more effective immune-based ther-
apies against MTAP-defıcient tumors.
#3972 Ex vivo profıling of PD-1 blockade using organotypic tumor spher-
oids. David A. Barbie, Russell Jenkins, Kwok-Kin Wong. Dana-Farber Cancer
Inst., Boston, MA.
Despite the impressive activity of PD-1/PD-L1 immune checkpoint blockade
in melanoma, lung, and other cancers, the majority of patients are intrinsically
resistant to this therapy. Furthermore, despite years of effort few robust bio-
markers of response exist, and tumor PD-L1 expression andmutational load are
only partially predictive of activity. Nearly all attempts at biomarker develop-
ment have relied on fıxed tumor tissue or studies in plasma. Meanwhile, emerg-
ing functional approaches to study patient derived samples, such as organoid
development and circulating tumor cell culture, lack features of the native tumor
immune microenvironment and thus are limited in the ability to assess ex vivo
anti-PD-1 response.Wehave developed a novel approach to study short-term ex
vivo response to immune checkpoint blockade based upon short term culture of
murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS)
in a 3-dimensional microfluidic system. Spheroids derived from fresh mouse
and human tumor samples through partial collagenase digestion and fıltration
retain autologous tumor infıltrating immune cells, including PD-1 positive CD8
T lymphocytes. Using murine syngeneic mouse cancer models with known re-
sponsiveness or resistance to PD-1 blockade, we demonstrate the ability to re-
capitulate tumor killing ex vivo or lack thereof.Multiplexed cytokine profıling of
conditioned media in this system further enables characterization of the cyto-
kine and chemokine response to PD-1 and/or CTLA-4 blockade. We thus ana-
lyzed the secreted cytokine/chemokine response to PD-1 inhibition across a
large panel of PDOTS, and observed pronounced induction of CCL19/CXCL13,
which associated with% PD-1 positive CD8 T cells. This strategy further uncov-
ered production of a class of myeloid attracting chemokines and cytokines in
major proportion of samples, which clusteredwith the presence of plasmacytoid
dendritic cells and myeloid derived suppressor cells. Importantly, the presence
of this maladaptive cytokine/chemokine signature correlated with lack of re-
sponse in the subset of patients that had been treated with PD-1 blockade. To-
gether, these data demonstrate the ability to profıle the functional response to
tumor PD-1 blockade ex vivo and unveil a novel strategy to advance precision
immuno-oncology.
#3973 Role of thyroid tumor microenvironment secretome in cancer ini-
tiation and progression. Neha Yashpal Tuli, Ameet Kamat, Rachana Maniyar,
Ghada Ben Rahoma, Sanjukta Chakraborty, Sarnath Singh, Augustine Mosca-
tello, Jan Geliebter, Raj K. Tiwari. New York Medical College, Valhalla, NY.
The incidence of thyroid cancer in the United States is on a rise with an
appreciably high disease recurrence rate of 20-30%. Tumor associated macro-
phages (TAMs) release cytokines, chemokines and other secretory components
like exosomes which aid in thyroid tumor progression and metastasis. In our
previous study on thyroid tumor microenvironment, we established that M1
polarized pro-inflammatory macrophages modulate thyroid cancer phenotype.
TAMs secretome, consisting of pro-inflammatory cytokines such as TGF-, IL6,
TNF-, IL-1, amongst others, induce epithelial to mesechymal transition
(EMT) in thyroid cancer cells promoting tumor metastasis and propagation. In
our present study, we used an in vitro model system to assess the effects of
secretory molecules called exosomes, in the thyroid tumor microenvironment.
We used thyroid cancer cell lines: BCPAP (papillary), 8505C (anaplastic) and
CGTHW-1 (follicular) to represent the spectrum of clinically observed thyroid
cancers. THP-1 monocyte/macrophage cell line was used to denote the inflam-
matory component. Thyroid cancer cells treated with activated M1 polarized
THP-1 macrophage exosomes showed halt in proliferation, transformation to
mesenchymal phenotype as well as modulation in expression of EMT markers,
such as vimentin and NFk-B, indicative of induction of EMT in thyroid cancer
cells. Interestingly, secretory exosomes from anaplastic thyroid cancer cells led
to activation of THP-1monocytes. Since the exosomal cargo is the reflection and
fıngerprint of its originating parental cells, we profıled exosomalmiRNAderived
from thyroid cancer cells and THP1 cells. Modulation of various miRNA in
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follicular and anaplastic thyroid cancer exosomeswas observed,when compared
to papillary thyroid cancer exosomes. We detected a down regulation of miR-
138-5p, miR-146a-5p, miR-26a-5p, miR-26b-5p, miR-34a-5p andmiR-31-5p in
anaplastic and follicular cancer exosomes, which may play a role in promoting
cancer invasion and metastasis. In comparison to papillary thyroid cancer exo-
somes, an upregulation of miR-214-3p, miR-200a-3p, miR-298, miR-299-3p,
and miR-302a-3p was ascertained in follicular thyroid cancer exosomes. Con-
versely, we noted a down regulation of these miRNAs in anaplastic thyroid
cancer exosomes. These distinct miRNA expressions in cancer secretome will
provide new insights into the tumor development and dissemination. Our fınd-
ings suggest an important crosstalk between the secretome of thyroid cancer
cells and inflammatory cells in tumor microenvironment, defıning thyroid can-
cer phenotype. These exosomal miRNA serve as early diagnostic markers of
thyroid cancer differentiation as well as targets for novel therapies specifıcally
for anaplastic thyroid cancer.
#3974 Gender specifıc function of epithelial IL-6-STAT3pathway inK-ras
mutant lung cancer. Mauricio S. Caetano,1 Hieu Van,1 Emmanuel Bugarin,1
Amber Cumpian,1 Christina L. McDowell,1 Huiyuan Zhang,1 Scott E. Evans,1
Stephanie Watowich,1 Humam Kadara,2 Seyed J. Moghaddam1. 1UT MD An-
derson Cancer Center, Houston, TX; 2American University of Beirut, Beirut, Leb-
anon.
Activating mutations of K-ras are the most common oncogenic alterations
found in lung cancer, and are heavily associated with tobacco exposure and
poor prognosis. Using a conditional lung cancer mouse model (CC-LR), we
showed that K-ras mutant lung tumors have inflammatory characteristics
with activation of NF-kB pathway, release of IL-6 and activation of its down-
stream target, STAT3.We further demonstrated that IL-6 blockade results in
signifıcant tumor reduction as well as decreased pSTAT3 expression, tumor
cell proliferation, angiogenesis and a reduction in tumor-associated immu-
nosuppressive myeloid populations concomitant with induction of an anti-
tumor phenotype. These indicate essential autocrine and paracrine roles for
IL-6/STAT3 pathway in promotion of K-ras mutant lung cancer, largely via
perpetuating inflammation introducing it as a vulnerability factor for this
type of tumors. Here we generated a lung epithelial specifıc K-ras mutant/
STAT3 conditional knockout mouse (LR/STAT3
/
) to further study the
role of epithelial STAT3 activity in K-ras mutant lung cancer. We found that
in female mice, lack of epithelial STAT3 inhibited lung cancer, and signifı-
cantly decreased the lung inflammatory cell population, particularly macro-
phages, whereas in male mice, STAT3-defıciency surprisingly promoted
lung cancer and signifıcantly increased lung neutrophil population. To un-
derstand genome-wide mechanisms underlying this intriguing gender dis-
parity, we performed RNA-sequencing of whole lungs frommale and female
LR/STAT3
/
 and control CC-LR mice. Using a mixed effects model, we
found 339 transcripts that were signifıcantly modulated differently between
LR/STAT3
/
 and control CC-LR mice in males relative to females. Path-
ways and gene network analyses of the transcripts demonstrated that lungs of
male LR/STAT3
/
 mice exhibited markedly reduced Th1 immune T-cell
signatures.We corroborated these fındings and found signifıcant phenotypic
changes in the lung tumor microenvironment (TME) with males exhibiting
increased pro-tumor inflammatory markers. Markedly, we found opposing
IL-6 expression patterns with LR/STAT3
/
 females expressing low IL-6
while LR/STAT3
/
 males expressed high levels of IL-6. We then blocked
IL-6 in male LR/STAT3
/
 mice, which resulted in a signifıcantly reduced
lung tumorigenesis, and reformatted lung TME towards an anti-tumor phe-
notype with a Th1/CD8 T cell signature. By contrast, estrogen receptor
(ER) signaling blockade by tamoxifen in female LR/STAT3
/
 mice pro-
moted lung cancer, and reprogrammed lung TME toward a pro-tumor phe-
notype with an increase in Th17/Treg cell signature. Taken together, we
conclude that epithelial STAT3 signaling has an important gender-specifıc
role with autocrine and paracrine effects in K-ras induced lung tumorigen-
esis, which might be mediated by the interplay between ER signaling, and
NF-B mediated cytokine network.
#3975 Ovarian cancer cells release arginase-1-containing exosomes to
suppress antitumor immune response. Malgorzata Czystowska,1 Marta Sza-
jnik,2 Kavita Ramji,1 Slawomir Gruca,1 Artur Stefanowicz,3 Jakub Golab,1 Do-
minika Nowis4. 1Medical University of Warsaw, Warsaw, Poland; 2Military In-
stitute of Medicine, Warsaw, Poland; 3“Praski” Hospital, Warsaw, Poland;
4Medical University of Warsaw and Center of New Technologies, University of
Warsaw, Warsaw, Poland.
Aim/Background: Depletion of essential (L-tryptophan) or semi-essential
(L-arginine) amino acids has been shown to suppress antitumor immune
responses. Arginase-1 (Arg-1) is a cytosolic enzyme catalyzing degradation
of L-arginine to L-ornithine and urea. Several studies have shown the pres-
ence of abundant Arg-1 in either tumor cells or in tumor-infıltratingmyeloid
cells of neutrophilic or monocytic origin. This in turn, leads to downregula-
tion of CD3-zeta levels in T cells and correlates with suppressed antitumor
immunity. In patients with ovarian cancer (OvCa), exosomes released by
tumor cells (TEX) are detected in body fluids including plasma or ascites and
carry proteins that are expressed by OvCa cells. Here we report that OvCa
cells release Arg-1 in TEX and investigate the influence of OvCa TEX-de-
rived Arg-1 on the antitumor effector mechanisms of immune response.
Methods: TEX were isolated by ultracentrifugation or exclusion chromatog-
raphy and verifıed byWestern blotting, NanoSight and electron microscopy.
The presence of Arg-1 in TEX was determined by Western blotting and the
Arg-1 activity was assessed using an enzymatic assay that measured conver-
sion of arginine into urea. Immunohistochemical Arg-1 expression data in
primary OvCa lesions were correlated to clinico-pathological characteris-
tics. Effects of TEX Arg-1 on immune cells were analyzed by in vitro prolif-
eration assay and flow cytometry. Results: OvCa ascites contained higher
levels of exosomal Arg-1 as compared with the fluids obtained from benign
ovarian cysts. Enzymatically active Arg-1 was detected in TEX derived from
patients’ ascites as well as from ovarian cancer cell lines. High Arg-1 expres-
sion in correlated negatively with intratumoral T-cell infıltrates and CD3-
zeta expression and was associated with shorter time to recurrence (TTR). In
vitro, OvCa-derived Arg-1-positive TEX inhibited CD8 and CD4 T-cell
proliferation and decreased T-cell receptor expression. We also observed
that co-culture of bone-marrow-derived dendritic cells (DC) with TEX iso-
lated from OvCa cells results in the transfer of functionally active Arg-1 that
inhibits DCs-primed proliferation of OVA-antigen specifıc OT-I T cells. We
have used TEX isolated from OvCa cells transfected with V5-tagged Arg-1
for these experiments to ensure that this is OvCa-derived, but not endoge-
nous DC-derived arginase that suppresses T cell proliferation. All these in
vitro effects were reversed by a novel Arg-1 inhibitor (OAT-1746). Conclu-
sions: Our fındings provide the fırst evidence for the role of Arg-1 in the
formation of an immunosuppressive microenvironment in OvCa. We iden-
tify a novel mechanism of exosomal Arg-1 distribution from the tumor cells
to antigen presenting cells. Inhibition of Arg-1 activity may be an attractive
novel anti-cancer strategy. Funding: NCN - OPUS 6 Program 2013/11/B/
NZ6/02790, NCBIR – STRATEGMED2/265503/3/NCBIR/15
#3976 Resolving cellular complexity in renal cell carcinoma with droplet-
based single cell transcriptomics. Siva Vijayakumar, Mohan Bolisetty, Santosh
Sivajothi, Paul Robson. The Jackson Laboratory, Farmington, CT.
Purpose: The development, growth, invasion andmetastasis of cancer is sup-
ported and sustained by complex tissue microenvironments. Interactions be-
tween the stromal cells, cancer cells and immune cells through autocrine and
paracrine signaling, influencesmany stages of cancer progression. Furthermore,
understanding the identity of the tumor infıltrated immune cell populations is
known to predict survival outcomes. Kidney cancer is the 12th most prevalent
cancer in the world and is predicted to affect 62,700 new cases in 2016 in the
United States alone (American Cancer Society). Existing studies on renal cell
carcinoma utilizing bulk profılingmethods have been unable to deconvolute the
role of the various cell types in promoting the progression this cancer type.
Method: Single cell transcriptomics of primary tumors is a powerful approach to
study not only the cancer cells but also the cells of the microenvironment. We
profıled the various cell types that comprise primary renal cell carcinoma using
the Chromium Single Cell 3= system (10X Genomics). Results: With this single
cell approach, we have generated thousands of single cell transcriptomes leading
to the identifıcation of numerous cell types and cell states in renal cell carcinoma
and matched normal kidney. The microenvironment of renal cell carcinoma
tumors contains a heterogeneousmix of stromal, immune and kidney cell types.
Compared with the matched normal, the tumors are heavily infıltrated with
lymphocytes, mast cells and cells of themyeloid lineage.We identifıed pathways
enriched in specifıc cell types that illuminate potential mechanisms underlying
the cell-cell interactions between cancer cells, stromal cells, and the infıltrating
immune cells thus highlighting potentially new targeting strategies for the treat-
ment of this disease. In addition, the single cell data described here will be used
to deconvolute existing and new bulk analyses of renal cell carcinoma patients
and to establish targeted antibody panels for use in flow and imaging mass
cytometry. We anticipate both will lead to better patient stratifıcation to inform
patient-specifıc treatment regimes. Conclusion: Droplet-based single cell tran-
scriptomics can successfully identify the numerous cell types that comprise a
tumor, providing a foundation of knowledge to inform biomarker selection and
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provide insight into novel treatment strategies. This approach reflects a more
comprehensive view of renal tumors that is often masked by bulk profıling
analyses.
#3977 Neutrophils fertilize the pre-metastatic omental niche in ovarian
cancer. WonJae LEE, Honami Naora. MD Anderson Cancer Center, Houston,
TX.
More than 60% of ovarian cancer patients present with peritoneal carcinoma-
tosis that almost always involves the omentum, a fat pad that suspends from the
stomach. However, themechanisms that promote the tropism of ovarian cancer
cells for the omentum are poorly understood. Because the omentum is themajor
peritoneal conduit and reservoir for immune cells, we hypothesized that im-
mune cells control the propensity of ovarian cancer cells to implant on the
omentum. In this study, we evaluated changes in immune cell populations in the
omentum and in other visceral fat pads in the peritoneal cavity in mouse xeno-
graft models of ovarian cancer. Intriguingly, the proportion of neutrophils was
observed to dramatically increase in the omentum prior to tumor cell implan-
tation at this site. On the other hand, the proportion of neutrophils did not
substantially increase in other visceral fat pads. Furthermore, the proportion of
macrophages did not signifıcantly increase in any of the fat tissues prior to tumor
cell implantation. Collectively, these fındings raise the possibility that early re-
cruitment of neutrophils to the pre-metastatic omental niche promotes a mi-
croenvironment that is conducive to ovarian cancer cell implantation at this site.
#3978 B7-H1/PD-L1 soluble expression inmultiple cancer subtypes:High
sensitivity measurement by immunoassay. Justin Haworth, Rainer Grant,
Samuel Thayer, Melissa Floren, Nathan Steere, Isabel O’Brien, Paul Younge,
Michael Anderson, GretaWegner, Kathryn Brumbaugh. Bio-Techne, Minneap-
olis, MN.
Aberrant expression of the B7-H1/PD-L1 immunomodulatory molecule is
evident in many forms of cancer. The evidence for increased protein levels of
B7-H1/PD-L1 comes largely from immunohistochemistry analysis of surgical
and biopsy specimens. While several studies attempt to correlate B7-H1/PD-L1
expression with poor prognosis, there are studies that conclude no correlation
based on technical diffıculties associated with detecting B7-H1/PD-L1 protein
expression on the cell surface. We were able to quantifıably measure soluble
B7-H1/PD-L1 in conditioned medium from tumor cell cultures using two new
immunoassays, a Quantikine® ELISA and a Simple Plex™ Assay. We show that
breast, prostate, glioma, and non-Hodgkin’s lymphoma cells express various
levels of B7-H1/PD-L1 which correlate to their PTEN or proliferation status.
This is in agreement with previous fındings showing that increases in B7-H1/
PD-L1 expression levels are frequently coincident with loss of the PTEN tumor
suppressor or increased activation of the phosphoinositide 3-kinase (PI 3-K)
pathway. The androgen-responsive LNCaP prostate cancer cell line does not
exhibit measurable B7-H1/PD-L1 in any instance, while the androgen-indepen-
dent prostate cancer cell line PC-3 expresses measurable B7-H1/PD-L1 that is
further inducible with PMA treatment. In all cell lines included in our study,
incubation with PMA increases the level of B7-H1/PD-L1 released into the cul-
ture media, while pretreatment with the PI 3-K inhibitor, LY294002, abrogates
this increase. Importantly, the Simple Plex platform is able to quantify very low
levels of B7-H1/PD-L1 that are below detection by ELISA. Our data suggest that
combining the Quantikine ELISA and Simple Plex platforms is a powerful strat-
egy for reliably and quantitatively assessing soluble B7-H1/PD-L1 levels.
#3979 Immune correlates of pathologic response in bladder cancer pa-
tients undergoing neoadjuvant chemotherapy.PhilipH. Abbosh,1 David Liu,2
Woonyoung Choi,3 Wafık S. El-Deiry,1 Jonathan E. Rosenberg,4 David McCo-
nkey,5 Elizabeth R. Plimack,1 Eliezer M. Van Allen2. 1Fox Chase Cancer Ctr.,
Philadelphia, PA; 2Dana Farber Cancer Institute, Boston, MA; 3MD Anderson
Cancer Center, Houston, TX; 4Memorial Sloan Kettering Cancer Center, New
York, NY; 5Johns Hopkins Medical Institutes, Baltimore, MD.
Introduction andObjective: The immune system is increasingly recognized as
both a key player in cancer control and as druggable target. We hypothesized
that the immune system impacts pathologic response in patients undergoing
cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder
cancer though the immune system. Methods: Whole exome sequencing (WES)
was performed on tumor DNA from patients in two independent cohorts who
underwent cisplatin-based NAC. The Memorial Sloan Kettering/Dana Farber
Cancer Institute (n50; 25 responders) and Philadelphia cohorts (n48; 20
responders) were treated with gemcitabine /cisplatin or methotrexate / vinblas-
tine / doxorubicin / cisplatin. Mutation analysis was performed using standard
analytical pipelines. Macrohistocompatibility complex (MHC)-restricted neo-
antigens were identifıed with netMHCpan and PolySolver. High affınity neoan-
tigens were defıned to have500 nM binding affınity (Kd). Pathologic response
was defıned as ypTis cystectomy specimen. CIBERSORT was used to infer
immune cell infıltrate based on DASL Illumina microarray expression profıles
(n41; 17 responders). Results: Chemoresponders hadtwice asmanyputative
neoantigens as nonresponders (471 vs 207 neoantigens respectively; p110-6,
Wilcoxon). This relationship maintained signifıcance when neoantigens were
limited to Kd100 nM or 50 nM, and when chemoresponse was defıned as
ypT0-only, orypT1. ERCC2 loss-of-functionmutations were 36% sensitive in
identifying chemoresponders but 96% specifıc. Above-median neoantigen bur-
den was 81% sensitive in identifying chemoresponders and 78% specifıc. CD8
cells were enriched in responders (13.5% vs 8.4% of infıltrate; p0.008, t-test) as
were activatedNKcells (15.5%vs 12.7%; p0.05). In 28 sampleswhereWES and
CIBERSORT data was available, the neoantigen burden was correlated to the
CD8 infıltrate value (R20.33, Pearson). Conclusions:Neoantigen burden and
CD8 infıltrate correlate strongly with chemoresponse. Neoantigen burden and
CD8 infıltrate are directly proportional. NAC may therefore exert known
tumor cell autonomous effects and an extrinsic effect involving the immune
system via neoantigens. Anti-neoantigen responses have been shown to impact
immune checkpoint responses and a similar mechanismmaymediate cytotoxic
chemoresponse. Experiments are underway to directly and functionally charac-
terize the effect of the immune system in chemoresponse.
#3980 Ly6G neutrophils and polymorphonuclear myeloid derived sup-
pressor cells promote the survival of tumor cells. Sarah Herlihy,1 Cindy Lin,1
Maria Ozeriva,1 Alfred Garfall,2 Dan Vogl,2 Dmitry Gabrilovich,1 Yulia Nefe-
dova1. 1Wistar INST., Philadelphia, PA; 2University of Pennsylvania, Philadel-
phia, PA.
A heterogeneous group of immature myeloid cells which suppress the im-
mune system are termedmyeloid derived suppressor cells (MDSC). Collectively
aMDSC population is comprised of monocyte-likeMDSC and polymorphonu-
clearMDSC (PMN-MDSC).MDSC are increased in the presence of a number of
different tumors. We previously demonstrated that PMN-MDSC represent the
majority of MDSC in tumor-bearing mice. In a mouse model of multiple my-
eloma (MM) depletion of myeloid cells in vivo results in increased survival.
Direct co-culture of neutrophils (CD11bGr1 cells from tumor-free mice) or
PMN-MDSC (CD11bGr1 cells from tumor-bearing mice) and MM cells in-
creases the survival of the MM cells from chemotherapeutic-induced death.
Cell-cell contact is not necessary for the protective effect. Neutrophil and PMN-
MDSC supernatants protect MM cells from cell death, suggesting the factor
protecting tumor cells is soluble. Results in the mouse were confırmed using
humanMMcells and replicated on breast cancer cells with neutrophils or PMN-
MDSC. Several cytokines and growth factors, such as IL-6 and fıbroblast growth
factor, are implicated in chemoresistance. The role of these neutrophil and
PMN-MDSC soluble factors and the identifıcation of novel contributors to
chemoresistance are under investigation.
#3981 The Shc1 scaffold protein simultaneously balances Stat1 and Stat3
activity in breast cancer to promote immune suppression and resistance to
immunotherapy.RyuhjinAhn,1 Kévin Jacquet,2Marc Fabian,1 SidongHuang,3
Nicolas Bisson,2 Josie Ursini-Siegel1. 1Lady Davis Institute, Montreal, Quebec,
Canada; 2Centre de recherche du CHU de Québec, Quebec, Canada; 3Rosalind
and Morris Goodman Cancer Research Centre, Montreal, Quebec, Canada.
Receptor and cytoplasmic tyrosine kinases are key signal integrators in poor
outcome breast cancers that are central to the establishment of an immunosup-
pressivemicroenvironment. Immunotherapies represent an emerging approach
within the armament of anti-cancer agents. Although the effıcacy of tyrosine
kinase inhibitors relies, in part, on their ability to augment adaptive immunity,
the increased heterogeneity and functional redundancy of the tyrosine kinome
in poor outcome breast cancers represents a signifıcant hurdle to achieving
durable responses to immunotherapies. We previously identifıed the Shc1
(ShcA) scaffold protein, a central regulator of tyrosine kinase signaling, as es-
sential for promoting immune suppression. We recently showed that the ShcA
pathway simultaneously activates STAT3 immunosuppressive signals and im-
pairs STAT1-driven immune surveillance in breast cancer cells. Impaired phos-
phorylation of select tyrosine residues on ShcA potently and selectively reduces
STAT3 activation in breast tumors, profoundly sensitizing them to immune
checkpoint inhibitors and tumor vaccines. Meanwhile, impaired phosphoryla-
tion of other select tyrosine residues on ShcA potently increased antigen presen-
tation and sensitivity to tumor vaccines in preclinical mouse models. Based on
these results, we have set out to elucidate protein interactors dependent on
distinct ShcA phospho-tyrosines to regulate STAT1 and STAT3 signaling axis
that aid tumor driven immune suppression. We combined affınity-purifıcation
mass spectrometry (AP/MS) and proximity-dependent biotin identifıcation
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(BioID) followed bymass spectrometry (BioID/MS).Known interactors of ShcA
as well novel interactors have been identifıed. Promising candidates that could
be critical in immune suppression downstream of ShcA have been validated to
be true interactors by co-IP and BioID assays. They have been screened for
immune regulation in vitro for furthermodulation in vivo. Currently, inhibitors
of phospho-tyrosinemotifs of ShcAdonot exists. Therefore, the development of
pharmacological inhibitors to prevent phospho-tyrosine ShcA dependent
STAT3 signaling or relieve suppression of STAT1 signalingmay be an attractive
method to strategically sensitize breast tumors to multiple immunotherapies.
#3982 Tumor exosomes lead to positive feedback in tumor associated
macrophages leading to increased invasion and metastasis. Daniel C. Rabe,
Felicia D. Rustandy, Rebecca Sturey, Marsha R. Rosner. University of Chicago,
Chicago, IL.
Triple-negative breast cancer (TNBC) patients have the highest risk of recur-
rence and metastasis. This is in part due to the infıltration of macrophages into
the tumor that promote growth, survival, invasion, and therapy resistance
through secretion of growth factors and cytokines.We previously demonstrated
the metastasis suppressor Raf Kinase Inhibitory Protein (RKIP) regulates the
number and phenotype of tumor-associated macrophages (TAMs) by blocking
CCL5. Although CCL5 protein is suffıcient to recruit pro-invasive TAMs, alone
it does not robustly induce expression of pro-invasive genes, nor does it lead to
a pro-invasive macrophage phenotype. We therefore tested whether exosome
crosstalk within the tumor microenvironment was responsible for transmitting
a pro-invasive phenotype between tumor cells and TAMs. To determine the role
of exosomes in macrophage phenotype, we programmed naive M0 bone mar-
rowderivedmacrophages (BMDMs)with conditionedmedia (CM) fromTNBC
cells, CMdepleted of exosomes, or tumor exosomes alone. Only tumor exosome
treatment increased levels of pro-invasive genes MMP12, PGRN, and CCL7,
while CM or CM depleted of exosomes did not. This pro-invasive macrophage
phenotype was lost if exosomes from non-invasive (RKIP) tumor cells were
used or if tumor exosome secretion was inhibited. We determined that RKIP
regulated the pro-invasive phenotype of macrophages in part through cytokine
mRNA in exosomes. Levels of pro-invasive mRNAs like CCL5 were drastically
lower in exosomes from RKIP cells compared to control. Additionally, exo-
somes from CCL5 over-expressing cells further increased the pro-invasive na-
ture ofmacrophages while those from tumor cells with CCL5 knocked out using
CRISPR not drive a pro-invasive phenotype. For in vivo validation, mice were
injected with exosome-depleted tumor cells or co-injected with exosome-pro-
grammed BMDMs. These results indicate exosomes reprogram TAMs to reflect
increased invasiveness of the tumor cells, leading to positive feedback onto the
tumor cells to drive invasion and metastasis.
#3983 A cross comparison of technologies for the detection of immune
system related gene expression signatures in clinical FFPE samples of meta-
static prostate cancer patients.Kimberly Kruse,1 Fang Yin Lo,1 Ryan Fleming,1
Douglas Chung,1 Vickie Satele,1 Lindsey Maassel,1 Tuuli Saloranta,1 Inah
Golez,1 Saman Tahir,1 Sally Dow,1 Evan Anderson,1 Spencer Chee,1 Raghavee
Venkatramanan,1 Steve Anderson,2 Peter S. Nelson,3 Colm Morrissey,4 Anup
Madan,1 Sharon Austin,1 Kellie Howard1. 1Covance, Redmond, WA; 2Covance,
Durham, NC; 3Fred Hutchinson Cancer Research Center, Seattle, WA; 4Univer-
sity of Washington, Seattle, WA.
The success of immunotherapy for the treatment of metastatic cancers relies
on the prediction and identifıcation of potential neo-antigens. In recent years
expression levels of these neo-antigens along with other immune system related
genes have been evaluated in an effort to better understand response rates for
immunotherapy in various cancers. Gene expression levels can be assessed by
numerous techniques including hybridization-based or direct sequencing tech-
nologies. Two platforms-HTGMolecular and NanoString nCounter have been
utilized to profıle changes in gene expression and offer unique advantages for
analyzing challenging specimens such as formalin-fıxed paraffın embedded
(FFPE) tissues. The NanoString nCounter platform utilizes hybridized fluores-
cent probes targeted against genes of interest for a non-amplifıed measurement
of gene expression. Several studies have been shown that the NanoString plat-
form has good sensitivity, specifıcity, and reproducibility for the assessment of
gene expression levels from FFPE samples. The HTG platform is relatively new
and also uses a hybridization based method to enrich genes of interest without
fırst isolating RNA. To determine the robustness of the HTG platform, we pro-
fıled a set of 30 metastatic prostate cancer samples using the HTG Molecular
EdgeSeq Immuno-Oncology Assay. In these experiments, we found that expres-
sion data obtained by using both extracted RNA and lysate fromFFPE slides was
highly reproducible (Spearman coeffıcient 0.85). In addition, the expression
profıle of targeted genes obtained by using different slides from the same blocks
was also highly correlated (Spearman coeffıcient 0.90). Our experiments also
showed a high correlation between gene expressions profıles obtained by HTG,
the NanoString PanCancer Immune Profıling panel and RNA-Seq from the
same set of 30 metastatic prostate cancer samples. Further analysis to evaluate
and compare the sensitivity of different platforms is being performed and results
of these will be presented.
#3984 Neuropilin-1 mediates neutrophil elastase uptake and antigen
cross-presentation in breast cancer cells.Celine Kerros, Satyendra C. Tripathi,
Dongxing Zha, Sergeeva Anna, Haley L. Peters, Hiroyuki Katayama, Pariya
Sukhumalchandra, Kathryn R. Cox, Alexander A. Perakis, Lisa S. St John,
Gheath Alatrash, Elizabeth A. Mittendorf, Karen C. Dwyer, Samir M. Hanash,
Jeffrey J. Molldrem. UTMD Anderson Cancer Ctr., Houston, TX.
We previously showed that soluble neutrophil elastase (NE) is rapidly taken
up by tumor cells that lack endogenous NE expression, including breast cancer
(BrCa). NE uptake led to cross-presentation of PR1, an NE-derived HLA-A2-
restricted peptide that is an immunotherapeutic target in hematologic malig-
nancies. The mechanism of NE uptake, however, remains unknown. Here, we
demonstrated that NE internalization was temperature- and time-sensitive,
dose-saturation was observed, and uptake was partially blocked by chlorprom-
azine (CPZ) andwortmannin, supporting a receptor-mediated process and sug-
gesting a role for clathrin- and PI3K-dependent mechanisms. To identify a can-
didate NE receptor, we performed mass spectrometry (MS) of proteins after
anti-NE co-immunoprecipitation of NE-pulsed MDA-MB-231 BrCa cells and
we identifıed neuropilin-1 (NRP1) as an NE co-associated protein. Binding of
NE to NRP1 was confırmed by ELISA, and peptide epitope mapping studies
indicated NE bound via it consensus sequence RRXR, which is also known to
bind the b1b2 domain ofNRP1. NE bound toNRP1with high affınity (Kd38.7
nM) as measured with biolayer interferometry. To confırm the role of NRP1 in
cellular uptake of NE, we transfected MDA-MB-231 BrCa cells with siRNA or
shRNA against NRP1 and showed that NRP1 knockdown resulted in a 2-fold
decrease in NE uptake as determined with flow cytometry. Similarly, blocking
with an NRP1-neutralizing antibody decreased NE uptake by 60% vs. isotype
control antibody, an effect that was also observed in other breast cancer cell lines
that expressed NRP1. Conversely, transient expression of NRP1 in the NRP1-
defıcient T47DBrCa cell linewas suffıcient to induce uptake ofNE. Importantly,
knockdown of NRP1 expression in MDA-231 cells also prevented PR1 cross-
presentation as determined with the anti-PR1/HLA-A2 monoclonal antibody
8F4. This was confırmed by the loss of susceptibility of NE-pulsed MDA-MB-
231 cells to lysis by PR1-specifıc cytotoxic T cells following knockdown of NRP1
expression. Our data support a novel function of NRP1 in the uptake and cross-
presentation of neutrophil-derived proteins by non-hematopoietic cancer cells.
Because 8F4 mediates killing of PR1/HLA-A2 leukemia and NRP1 is broadly
expressed on many tumors, our results suggest a role for immunotherapy strat-
egies that target NE-derived peptides on NRP1 tumors.
#3985 NCoR2 regulates glioblastoma progression and treatment resis-
tance. Shelly Kaushik, Joanna J. Phillips, Valerie M. Weaver. University of Cal-
ifornia San Francisco, San Francisco, CA.
GlioblastomaMultiforme (GBM,WHOGrade IV glioma) is one of the dead-
liest adult CNS tumors with a median survival of less than two years. It is largely
resistant to aggressive therapeutic regimes, which combine radiation, chemo-
therapy and surgery. Thus, it is imperative to identify the molecular players and
pathways that facilitate GBM resistance and recurrence. Nuclear co-repressor
protein NCoR2 is upregulated in GBM and its increased expression correlates
with poor prognosis in GBMpatients (Alrfaei. Plos one. 2013). NCoR2, through
its binding to the histone deacetylase protein HDAC3, mediates transcriptional
repression (Zhu et al. Brain Res. 2013). NCoR2 is also involved in maintenance
of neural stem cells (Jepson et al. Nature. 2007), which contribute to treatment
resistance. Our study employs two distinct lineages of glioma - the less aggres-
sive proneural and the highly aggressive mesenchymal subtypes. We show that
NCoR2 is differentially expressed across these subtypes, suggesting a role for
NCoR2-mediated transcriptional reprogramming in GBM progression. More-
over, knockdown of NCoR2 leads to phenotypic changes both in vitro and in
vivo - including effects on neurosphere formation and proliferation, differential
expression of stem-like markers as well as regulation of tumor growth and pro-
gression inmice.We also demonstrate thatNCoR2 expression is increased upon
treatment with temozolomide (used for GBM therapy), indicating a protective
pro-tumor role for NCoR2. Finally, we explore the contribution of the GBM
microenvironment toGBMprogression by varying the three-dimensional prop-
erties as well as the rigidity of the extracellular matrix and investigating changes
inNCoR2 expression and its regulation of tumor progression.We conclude that
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NCoR2 regulates GBM progression and resistance to therapy potentially via
inducing a stem-like phenotype as well as responding to the tumor-promoting
mechanical cues within the GBMmicroenvironment.
#3986 Regulation mechanism and clinical signifıcance of KPNA2 pro-
motes MDSCs infıltrating in epithelial ovarian cancer. Shuting Huang, Min
Zheng, Yuanzhong Wu. Sun Yat-Sen University Cancer Center, Guangzhou,
China.
Myeloid-Derived Suppressor Cells (MDSCs) are a population of immune
cells that negatively regulate immune responses, which could promote tu-
mor invasion and metastasis. Recently research has revealed that tumor
could actively reshape the immune-microenvironment for its progression.
We recently demonstrated that KPNA2 is a candidate oncogene in ovarian
cancer that was closely related to MDSCs density, and found there was a
positive position feedback between KPNA2 expressed and MDSCs density,
which might contribute to the poor prognosis of patients. Based on these
results, we combined clinical sample analysis, animal model and experimen-
tal studies to do further molecular and genomic research. The conduction of
this project will help explain the molecular mechanisms of how KPNA2
regulates ovarian cancer through suppressing the immune system, and pro-
vide new strategies by molecular targeted therapy combining biological ther-
apy for ovarian cancer.
#3987 Solid stress and elastic energy as measures of tumor mechanopa-
thology. Hadi Nia,1 Hao Liu,1 Giorgio Seano,1 Meenal Datta,1 Dennis Jones,1
Nuh Rahbari,1 Joao Incio,1 Vikash Chauhan,1 Keehoon Jung,1 John Martin,1
Vasileios Askoxylakis,1 Tim Padera,1 Dai Fukumura,1 Yves Boucher,1 Francis
Hornicek,1 Alan Grodzinsky,2 James Baish,3 Lance Munn,1 Rakesh Jain1.
1MGH/Harvard Medical School, Boston, MA; 2MIT, Cambridge, MA; 3Bucknell
University, Lewisburg, PA.
Introduction: Increased tissue stiffness is a widely accepted and actively
studied biomechanical property of desmoplastic tumors, and has been linked
to several hallmarks of cancer, such as growth, invasion and metastasis. The
abnormal mechanics of tumors, however, are not limited to tissue stiffening.
We recently demonstrated that solid stress represents a newmechanopathol-
ogy that is consistently elevated in mouse and human tumors. The solid
stress, transmitted by solid elements of the extracellular matrix, is distinct
from interstitial fluid pressure. Therefore, tumors are not only more rigid
than many normal tissues, but cancer cells also produce and are exposed to
these physical forces. Composed of a combination of tension and compres-
sion, these forces are signifıcant in tumors, but negligible in most normal
tissues. Methods and Results: We developed the experimental and mathe-
matical frameworks to provide (i) two-dimensional spatial map of solid
stress in tumors (planar cut method), (ii) sensitive estimation of solid stress
in small tumors with small magnitudes of solid stress, e.g., metastatic lesions
(slicing method), and (iii) in situ quantifıcation of solid stress in tumors,
which retains the effects of the normal surrounding tissues (needle biopsy
method). All three methods are based on the physical concept of releasing
the solid stress in a controlled way with defıned geometry, and then quanti-
fying the stress-induced deformation by high-resolution ultrasonography or
optical microscopy. Given the specifıc topography of the stress relaxation
and the geometric and material properties of the tumour, the solid stress and
discharged elastic energy is estimated using mathematical modeling. Apply-
ing these novel methods to multiple mouse cancer models in primary and
metastatic settings has led to the following novel fındings: (i) solid stress and
elastic energy may be different between primary vs. metastatic settings, as
they depend on both cancer cells and their microenvironment; (ii) tumor
with higher elastic energy are not necessarily stiffer, and the stiffer tumors do
not necessarily have higher elastic energy; (iii) solid stress increases with
tumour size; and (iv) the normal tissue surrounding a tumour signifıcantly
contributes to the intratumoral solid stress. Conclusions: We developed
three distinct methods to perform in situ and sensitive measurement of solid
stress and obtain 2-D spatial map of solid stress in human andmouse tumors.
Application of these methods in models of primary tumors and metastasis
revealed that: (i) solid stress depends on both cancer cells and their microen-
vironment; it increases with tumour size; and mechanical confınement by
the surrounding tissue substantially contributes to intratumoral solid stress.
Further study of the genesis and consequences of solid stress, facilitated by
the engineering principles presented here, may lead to signifıcant discoveries
and new therapies.
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#3988 Antigen presentation by tumor-infıltrating B cells associates with
CD4 T-cell phenotype and function in NSCLC patients. Tullia C. Bruno.Uni-
versity of Pittsburgh, Pittsburgh, PA.
Despite improvements in surgical techniques and combined chemotherapies,
the 5-year survival rate for all stages of non-small cell lung cancer (NSCLC) is
only 18%. The focus of immunotherapy has been on subsets of CD8 and CD4
tumor infıltrating lymphocytes (TILs), however, tumor infıltrating B cells (TIL-
Bs) have been reported in tertiary lymphoid structures (TLS) with CD4 TILs,
and both TIL-Bs and TLS correlate with NSCLC patient survival. While TIL-Bs
have been identifıed in NSCLC patients, their function in the tumor microenvi-
ronment has beenunderstudiedwith no focus on their role as antigen presenting
cells (APCs) and their influence on CD8 and CD4 TILs. We hypothesize that
TIL-Bs help generate potent, long-term immune responses against cancer by
presenting tumor antigens to CD4 TILs. Using unmanipulated, primary human
B cells from fresh tumor, tumor adjacent and normal (cancer-free) lung tissue,
we observed that the total number of B cells at the site of the tumor versus the
tumor-adjacent tissue was increased compared to other immune subsets. We
generated a specifıc antigen presentation assay in vitro, and we observed three
types of CD4 TIL responses when TIL-Bs presented autologous tumor antigens.
There were activated CD4 TIL responses; CD4 TIL proliferated when combined
with TIL-Bs alone, which indicates stimulation with endogenous tumor anti-
gens. There were antigen-associated CD4 TIL responses that required exoge-
nous autologous tumor lysate to elicit a CD4 TIL response, and there were
patient CD4 TILs that did not respond to antigen presentation by TIL-Bs.
Within the activated and antigen-associated responders, the TIL-B phenotype
associated with the CD4 TIL phenotype; if the TIL-Bs were activated
(CD69CD27CD21), the CD4 TILs were T helper (antitumor) CD4 T cells
and if the TIL-Bs were exhausted (CD69-CD27-CD21-), the CD4 TILs were T
regulatory cells (pro-tumor). These data suggest that TIL-Bs influence the phe-
notype and function of CD4 TILs in NSCLC patient tumors. In conclusion,
TIL-Bs are increased in NSCLC primary tumors, they can present antigen to
CD4 TILs and influence their overall phenotype. Determining if TIL-Bs are
activated or exhausted in NSCLC patients will determine the extent of their
anti-tumor function in the cancer. Ultimately, results from this study will help
predict how to target TIL-B functions in futureTIL-B-specifıc immunotherapies
or in combination with current immunotherapies for NSCLC patients like
blockade of the inhibitory receptor, PD-1.
#3989 Different expression and prognostic effect of PD-L1/PD-1 in SCC
and non-SCC of non-small cell lung cancer. Yunpeng Liu, Shuo Wang, Xiu-
juan Qu, Zhi Liu, Xiaofang Che, Xu Ling, Kezuo Hou, Yibo Fan, Na Song, Ti
Wen, Ce Li. the First Hospital of China Medical University, Shenyang, China.
Although checkpoint inhibitors targeting PD-1/PD-L1 pathway have demon-
strated similar clinical activity in treatment of NSCLC both for squamous(SCC)
and non-squamous carcinoma (non-SCC) patients, the predictive role of PD-L1
expression is distinct between two histologies in clinical trials. In order to inves-
tigated the expression and prognostic roles of PD-1/PD-L1, data from TCGA
andGEOdatabase were analyzed and further validated with our original data by
IHC in 133 resected NSCLC tumor tissue(49 SCC and 84 non-SCC). Through
the analysis of online data, we concluded that PD-L1 expression in SCC was
signifıcantly higher than that of non-SCC. In addition, in non-SCC, PD-L1 was
associated with immune response and indicated worse prognosis while no such
results were observed in SCC. Further, our original data demonstrated PD-L1
expression in tumor cells(TC) and immune cells(IC) were signifıcantly more
often and more intense in SCC(P0.001). In survival analysis, PD-L1 expres-
sion in TC and IC were associated with shorter overall survival in non-SCC
(P0.019 and 0.003, respectively). However, in SCC, PD-L1 did not demon-
strate any signifıcant effect neither inTCor IC (P0.526 and 0.674, respectively)
which consistent with online data. Contrary to PD-L1, no signifıcant differences
of PD-1 expression in tumor infıltrating lymphocytes(TILs) were showed be-
tween two histologies. PD-1 in TILs of SCC correlated with worse prognosis
(P0.025) while in non-SCC there was no correlation(P0.986). Taken to-
gether, these fındings suggest distinct regulation mechanisms and clinical sig-
nifıcance of PD-L1/PD-1 pathway in NSCLC subgroups.
#3990 Use of 3D tumoroid systems to defıne immune and cytotoxic ther-
apeutic responses based on tumoroid and tissue slice culture molecular sig-
natures. Niklas K. Finnberg,1 Prashanth Gokare,1 Avital Lev,1 Alexander W.
MacFarlane,1 Kerry S. Campbell,1 KarenKaputa,1 Jeffrey Farma,1 Luigi Grasso,2
Nicholas C. Nicolaides,2 Wafık El-Deiry1. 1Fox Chase Cancer Center, Philadel-
phia, PA; 2Morphotek, Inc., Exton, PA.
TUMOR BIOLOGY: Tumor Microenvironment 5
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1019
Historically, the successful establishment of exponentially growing viable in
vitro tumor cell cultures has been found to occur from a minority of tumor
tissues following artifıcial selection of a sub-population of tumor cells. Such
limitations make it diffıcult to model patient variability in drug responses in
vitro. Moreover, the lack of stromal cells that play a critical role in tumor viabil-
ity, growth and drug response in vivo make the prediction of tumor response of
immune-based therapeutics challenging. Through recent advances in three-di-
mensional (3D) culture (“tumoroid”) methodologies some of these hurdles are
beginning to be addressed. However, it is currently unclear to what extent such
models can be engineered to retain important phenotypic properties of infıltrat-
ing immune cells from the tumor tissue of origin. To better understand these
limitations, we have developed 3D tumoroids and tumor slice in vitro cultures
from tumors derived from patients with colorectal cancer (CRC) to evaluate
immune cell populations infıltrating cultured CRC tissues. Furthermore, we
have developed a systemwhereby the patient’s immune cells are re-incorporated
into tumoroid in vitro cultures to evaluate the ability of the culture to mimic an
immunosuppressive tumormicroenvironment (ITM).Herewedemonstrate the
development of a propagating 3D epithelial tumoroid culture system from re-
sected CRC tissue where we assessed the response to standard FDA approved
therapy within weeks of surgical resection. Interestingly, tumoroid cultures
from a CRC patient were highly sensitive to the thymidylate synthase inhibitor
fluorouracil (adrucil) but less sensitive to the combination of the nucleoside
analog trifluridine and the thymidine phosphorylase inhibitor tipiracil (Lon-
surf). We isolated approximately four (4) million immune cells using Percoll
density gradient centrifugation and flow cytometry. Re-introduction of isolated
immune cells derived from surrounding and infıltrating tumor tissue and
CD45 tumor infıltrating hematopoietic cells displayed prolonged (10 days)
survival in co-culture. Moreover, established tumor slice cultures contained
both an outer epithelial and inner stromal cell compartment mimicking tumor
structure in vivo. Collectively, these data suggest that CRC tumoroid in vitro
assays can be used for the assessment of some therapeutic responses. While
further work is required to optimize this system, 3D tumoroid and slice culture
assays may represent a novel in vitro approach to assess therapeutic effıcacy of
novel therapeutics and evaluate mechanisms of therapy resistance in general as
well as for patient-specifıc response.
#3991 Profıling the immune tumor microenvironment in primary and
recurrent epithelial ovarian cancer. Laureen S. Ojalvo, Elizabeth D.
Thompson, Tian-Li Wang, Alan K. Meeker, Ie-Ming Shih, Amanda N.
Fader, Ashley Cimino-Mathews, Leisha A. Emens. Johns Hopkins Hospital,
Baltimore, MD.
Clinical trials targeting the immune tumor microenvironment (TME) in ep-
ithelial ovarian cancer (EOC) typically have included patients with heavily pre-
treated advanced disease and demonstrated only marginal effıcacy. A better
understanding of how the EOC TME evolves with progression from primary to
recurrent disease may inform future immunotherapy trials. Here, we evaluate
the immune TME in primary and recurrent EOC using tissue microarrays. Our
cohort included matched primary and recurrent tumors from 17 patients, and
additional non-matched primary tumors from 20 patients and recurrent tumors
from15 patients.We stained forCD8, FOXP3 (regulatory T cells (Tregs)), CD68
(tumor associated macrophages (TAMs)), programmed cell death protein 1
(PD-1) and programmed death ligand 1 (PD-L1) by immunohistochemistry to
interrogate the immune composition of the TME. Tregs increased in recurrent
tumors compared to primary tumors (8.0 vs 14.2/HPF, p0.0210).Higher TAM
density was associated with higher levels of Treg and CD8 T cell infıltrates in
recurrent tumors (p0.001 and p0.001, respectively), and with higher Treg
but not CD8 T cell infıltrates in primary tumors (p0.027 and p0.200).
TAM-dense recurrent tumors had increased PD-L1 on tumor cells and immune
cells, whereas TAM-dense primary tumors had increased PD-L1 only on im-
mune cells. IncreasedTregs in primary tumors correlatedwith decreased time to
fırst recurrence (17.0 vs 28.5 months, p0.022). Conversely, increased Tregs in
recurrent tumors correlated with longer overall survival (OS) from recurrence
(median not met vs 20.0m, p0.022). Although TAM density did not affect
patient survival, analysis ofmatched primary and recurrent tumors revealed that
patientswith increasedTAMs at recurrence (n5) had a longermedianOS from
recurrence than patients without increased TAMs at recurrence (n12). Tregs
increased at recurrence in the majority of matched tumor pairs (n12), but
there was no correlation with survival. In conclusion, the TME of EOC is im-
munologically active. TAM-dense recurrent disease had higher CD8 T cell
and Treg infıltrates and PD-L1 expression. In this study, patients with increased
cellular recruitment to the TME at recurrence had improved survival. Larger,
more detailed studies characterizing the evolution of the TMEwith progression
from primary EOC to recurrence are warranted.
#3992 Immune regulation of disseminated tumor cell clearance versus
metastatic growth. Hasan Korkaya, Eunmi Lee, Raziye Piranioglu, Maria Ou-
zounova, Abdeljabar El-Andaloussi, Iskander Asm, Ahmet K. Korkaya, Gang
Zhou, Ali Arbab, Paulo Rodriguez. Georgia Regents Univ., Augusta, GA.
Metastatic disease is the end stage of extremely ineffıcient processes that entail
overcoming multiple barriers including anti-tumor immunity. Although evi-
dences from preclinical and clinical settings suggest that dissemination of ma-
lignant cells is an early process, majority of disseminated cells either eliminated
or remain dormant in distant organs, while very few cells eventually develop
successful metastasis. Therefore, it is widely accepted that dynamic and revers-
ible tumor cell plasticity is required for metastasis, however, in vivo steps and
molecular mechanisms are poorly elucidated. We provide evidence that mono-
cytic and granulocytic subsets of myeloid derived suppressor cells (m-MDS,
g-MDSC) infıltrated in primary 4T1 tumor and distant organs with different
time kinetics regulate spatiotemporal tumor plasticity. Using co-culture exper-
iments and syngeneic mouse models of murine 4T1 (metastatic) tumor, we
demonstrated that tumor infıltrated m-MDSCs facilitate tumor cell dissemina-
tion from the primary site by inducing the EMT/CSC phenotype. In contrast,
g-MDSCs infıltrated in the lungs support metastatic growth by reverting the
EMT/CSC phenotype and thus promoting tumor cell proliferation. In contrast,
less invasive EMT6 tumors fail to induce effıcient pulmonary infıltration of
g-MDSCs and results in clearance of disseminated tumor cells in the lungs. Gene
expression analyses of tumors and MDCS subsets in primary tumor site and
distant organs at different time points reveal mechanistic temporal regulation of
in vivo tumor plasticity bym-MDSCandg-MDSC subsets in 4T1 tumor-bearing
mice. However, the lung microenvironment of EMT6 tumor-bearing mice dis-
play a gene expression signature of anti-tumor immunity which predict better
survival in breast cancer patients. In our functional studies, we demonstrate that
EMT6 tumor-bearing animals effıciently eliminate disseminated tumor cells in
the lungs. Furthermore, g-MDSCs isolated from 4T1-tumor bearing animals
signifıcantly enhance metastatic growth of already disseminated tumor cells.
Consistent with the “seed and soil” hypothesis, our studies provide a molecular
mechanism by which the immune system regulate spatiotemporal tumor plas-
ticity and generation of permissive or anti-tumorigenic microenvironment in
distant organs determining the fate of disseminated tumor cells.
#3993 A different spatiotemporal distribution of TIL subtypes is associ-
ated with response to neoadjuvant chemotherapy in locally advanced breast
cancer patients. Lisa Koenig,1 Fabian Dominik Mairinger,2 Oliver Hoffmann,1
Ann-Kathrin Bittner,1 KurtWerner Schmid,2 Rainer Kimmig,1 Sabine Kasimir-
Bauer,1AgnesBankfalvi2. 1Department forGynecology andObstetrics, University
Hospital of Essen, Essen, Germany; 2Institute for Pathology, UniversityHospital of
Essen, Essen, Germany.
Background: Tumor infıltrating lymphocytes (TILs) are described as an im-
portant immunemodulator in the tumormicroenvironment in cancer andwere
shown to be associated with breast cancer (BC) outcome. Besides the analysis of
total TILs, the discrimination into TIL subtypes is essential as they exhibit pro-
or anti-tumorigenic potential. The spatiotemporal TIL distribution at the inva-
sive tumor front (ITF) and the tumor center (TC) might provide insights into
tumor progression. Here we analyzed TIL infıltration in core biopsies of BC
patients (pts) prior to neoadjuvant chemotherapy (NACT) and correlated these
fındings with clinical parameters and tumor cell spread. Material and Methods:
Core biopsies from 87 pre-NACT BC pts were cut, deparaffınized and antigen
retrieval and automated immunohistochemistry were performed using the fol-
lowing primary antibodies: CD3 (clone: SP7; 1:400, DCS Innovative Diagnostik
Systeme,Hamburg, Germany), CD4 (clone: 1F6; 1:40, Zytomed Systems, Berlin,
Germany), CD8 (clone: C8/144B; 1:150), CD20 (clone: L26; rtu), CD68 (clone:
PG-M1; 1:500, all DAKOCytomation, Glostrup, Denmark). Binding of primary
antibodywas visualized using theOptiViewDABkit (VentanaMedical Systems,
Tucson,USA). The densities of total TILs (H&E staining) andTIL subtypeswere
evaluatedmicroscopically at the TC and ITF and classifıed into three categories:
Low 0-10%, Moderate 11-30%, High 31% infıltration. TIL results were
correlated with clinical parameters and disseminated tumor cells (DTCs) in the
bone marrow, determined by immunocytochemistry applying the pan cytoker-
atin antibody A45-B/B3. Results: TILs were differentially distributed at both
tumor areas. The ITF was mainly infıltrated by CD3 T- and CD20 B cells,
while low amounts of CD68 macrophages, CD4 and CD8 T cell subtypes
were present. Only CD3 T cells were present in a higher level at the TC. A high
total TIL amount and a high CD3 infıltration at the ITF was associated with
poorly differentiated tumors. Pre-NACT tumors T2 had a high CD4 T cell
infıltration at the TC, whereas in small post-NACT tumors a high infıltration of
total TILs and all TIL subtypes at the ITF, except CD68 cells, was observed. BC
pts responding to NACT exhibited signifıcantly more total TILs (p0.02) and
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CD3 T cells (p0.02) at the TC. A high CD4 T cell infıltration at the TC was
signifıcantly associated with the presence of DTCs post-NACT (p0.029).
CD68 macrophages located at TC or ITF were not related to any clinical pa-
rameter. Conclusion: The differential association of TIL subtypes with clinical
parameters andNACT response underlines the necessity of detailedTIL analysis
for gaining insights into immune modulatory processes in the tumor microen-
vironment. In this regard, BC patients not responding to standard NACTmight
be identifıed for application of additional immunotherapy.
#3994 Using NGS to characterize 40 NSCLC tumor with gene expression
and tumor infıltrating T cell repertoire profıling from FFPE and matched
Fresh Frozen samples. Ann Mongan,1 Geoffrey Lowman,2 Yuan-Chieh Ku,2
Timothy Looney,2 Lifeng Lin,2 Xinzhan Peng,2 Fiona Hyland2. 1Thermo Fisher
Scientifıc Inc, South San Francisco, CA; 2Thermo Fisher Scientifıc Inc, San Fran-
cisco, CA.
The tumor microenvironment (TME) is made up of stromal cells, immune
cells, signaling molecules, and blood vessels surrounding the tumor cells. It has
emerged as a key factor inmultiple stages of cancer progression, immune-escap-
ing, and disease progression. The composition and activity of TME co-evolve
with tumor cells andmay likely affect how the cancer responses to immunother-
apy. A clear understanding of the functional effect and evolution of the TME
necessitates a comprehensive approach to identify key immune cells as well as to
characterize signaling and inflammatory (immune-editing) activities at the tu-
mor site. Here we are describing the use of a targeted NGS panel to detect
aggregated gene expression and a novel AmpliSeqTM approach to profıle the
relative abundance of different T cell clones at the TME. Specifıcally, we mea-
sured the expression of 395 relevant genes that capture interferon and chemo-
kine signaling, T and B cell activation, checkpoint pathway, tumor proliferation,
and antigen presentation. By looking at the expression of markers specifıc to
different effector cell types, this gene panel offers a high-level view of the com-
position of different lymphocyte infıltrates. Complementarily, the TCR se-
quencing assay provides an estimate of T cell diversity and therefore offering a
different dimension of the immune response. We studied 40 NSCLC tumor
samples, of which we have matched FFPE and fresh frozen specimens. With a
targeted panel, we could detect expression of transcripts present as few as 50
copies in 10 ng of total RNA as input. Across 40NSCLC samples, wewere able to
measure expression of many low expressing cytokines such as IL2, IL21, IL23,
IFNG and TNF. We observed strong co-expression pattern among genes in-
volved in type II interferon signaling, indicating that they’re informative of T cell
activation. More specifıcally, we found strong correlation between CD8 expres-
sion and other T cell co-stimulatory receptors (CD28, CD80, CD86, CD40),
suggesting that expression of these genes can be reliable surrogates for the pro-
tein counterparts asmarkers for CD8T cells. TCRwas sequenced for each of
the matched fresh frozen sample in duplicates. Clonotype abundance of repli-
cateswas highly correlatedwith each other, indicating that the assaywas reliable,
and the samples were sequenced to appropriated depth. We identifıed 2000-
10,000 unique clones in each tumor sample; with the diversity indexmoderately
correlated with the percentage of tumor infıltrating lymphocytes provided by
pathology review. Together, these two assays provide a convenient means to
characterize T cells and their activities in combating tumor cells, thereby offer-
ing insights into how that tumor may respond to a particular immunotherapy.
#3995 Identifıcation of receptor tyrosine kinases (RTKs) expression in
tumor-infıltrating lymphocytes (TILs) and peripheral blood mononuclear
cells (PBMC). Dmitry Khochenkov,1 Maria Volkova,1 Ilya Tsimafeyeu2. 1N.N.
Blokhin Russian Cancer Research Center, Moscow, Russian Federation; 2Kidney
Cancer Research Bureau, Moscow, Russian Federation.
Aimof this study is to discover expression levels of RTKs (VEGFR1,VEGFR2,
PDGFRa, PDGFRb) in CD45 population of PMBC and TILs isolated from
patients with clear cell renal cell cancer (RCC). Here we present preliminary
data. Species of tumors and blood were prospective collected from 9 patients
with RCC after radical nephrectomy or tumor resection from July to October
2016. TILs isolation was performed under standard protocol with slight modi-
fıcation. Briefly, tumor was shredded with scissors on small pieces of 2-3 mm
and twicewashed inRPMI 1640media by centrifugation for 10min at 1500 rpm.
After centrifugation, pellet was diluted RPMI 1640 with enzyme mix (Collage-
nase andDispase II) on Petri dish and placed on shaker-thermostat andincubate
sample for 12h at 37C with continuous shaking. After incubation, cell suspen-
sion was passed thought a cell strainer, mesh size 70m, placed on a 50mL tube
and washed twice washed in RPMI 1640 media by centrifugation. For TILs
isolation cell suspension was placed on Ficoll-Paque Plus and isolated by cen-
trifugation for 25 min at 1500 rpm. Cell pellet was resuspended in RPMI 1640
media. PMBC was isolated from whole blood using the Ficoll-Paque method.
Isolated TIL and PMBC were prepared for flow cytometry at typical protocol
with or without permeabilization. Cells were stained with anti-CD45 FITC-
conjugated antibodies (Novus), primary anti-VEGFR1, anti-VEGFR2, anti-
PDGFRa, anti-PDGFRb (Abcam) mouse antibodies and Alexa-568 conjuated
secondary anti-mouse antibodies (Invitrogen) and analyzed onBDCanto II flow
cytometer. Expression of RTKs on CD45 cell population were evaluated.
Among PMBC 86	9% of cells was CD45-positive and expressed RTKs (10	1%
cells were positive for VEGFR1 and VEGFR2, and 6	2% cells were positive for
PDGRFa andPDGFRb). TILs contained 65	18%ofCD45-positive cells and did
not express RTKs on the cell surface (less than 1% of cells), but intracellular
staining showed presence of RTKs: 8	2% of cells were VEGFR1 or VEGFR2-
positive, 20	8% of cells were PDGFRa or PDGFRb-positive. Preliminary data
demonstrate extracellular expression of RTKs on PBMC and intracellular ex-
pression of RTKs in TILs. The study will be continued.
#3996 MDSC depletion combined with CTLA-4 blockade cause tumor
regression in a syngeneic model of oral cavity cancer. Paul Esteban Clavijo,
EllenMoore, Jianhong Chen, Ruth Davis, Carter VanWaes, Zhong Chen, Clint
Allen. NIH, Bethesda, MD.
Carcinogen-associated head and neck cancers are a heterogeneous group of
aggressive cancers with a high recurrence rate and poor 5-year survival.Many of
these cancers are T-cell inflamed but only a subset of patients respond to check-
point blocking immunotherapy. Local immunosuppression mediated by both
the tumor cells and other infıltrating immune cells are likely amajormechanism
of resistance to immunotherapy. Themouse oral cancer (MOC)model includes
genetically defıned cell lines derived from carcinogen-induced tumors that gen-
erate tumors with variable T-cell inflamed phenotypes when transplanted into
wild-type C57BL/6 mice. Mice bearing MOC1 tumors display a T-cell inflamed
phenotype but do not signifıcantly respond to PD-L1 checkpoint inhibition
alone, which models a signifıcant subset of human cancers from the oral cavity.
Conversely, MOC2 tumors are non-T-cell inflamed. Using these MOCmodels,
we have demonstrated an inverse relationship between accumulation of granu-
locytic MDSCs (gMDSCs) and effector immune cells (CD8/4 T-cells, and NK
cells) in the tumor microenvironment. Functionally, these gMDSCs suppressed
CD8 T-cell proliferation, IFN production, and antigen-specifıc killing. De-
pletion of these gMDSCs with a systemic anti-Ly6G antibody (1A8) did not
change CD8/4 T-cell or NK cell accumulation but restored tumor T-cell and
NK cell activation and draining lymph node antigen-specifıc T-lymphocyte ac-
tivation that was lost with tumor progression. Depletion of gMDSCs also signif-
icantly sensitized established MOC1 tumors to CTLA4-based checkpoint inhi-
bition. CTLA-4 blockade alone induced tumor regression in a subset ofmice and
a marked delay in others. However, gMDSC depletion plus CTLA-4 blockade
resulted in complete tumor rejection anddevelopment of immunologicmemory
in all treated mice. Peripheral gMDSCs were found to express the chemokine
receptor CXCR2 but no other myeloid chemokine receptors, and expression of
CXCR2 ligands CXCL1 and CXCL2 increased within the tumor microenviron-
ment during tumor progression. Macrophage chemotaxis components CSF1R
and CSF1 were not signifıcantly expressed in these models. TCGA data analysis
demonstrated anMDSC-rich gene expression profıle in60% of head and neck
cancers, along with signifıcant CTLA4, CXCR2, CXCL1, and CXCL8 (IL-8)
expression within both HPV-positive and negative head and neck cancers.
Functional inhibition or elimination of MDSCs from the tumor microenviron-
ment may signifıcantly reverse local immunosuppression and enhance re-
sponses to checkpoint inhibition in patients with head and neck cancer.
#3997 Interleukin-4 receptor-targeted cytotoxic T cells enhances the ther-
apeutic effıcacy of adoptive T cell therapy against melanoma.Gowri Rangas-
wamy Gunassekaran, Sri Murugan Poongkavithai Vadevoo, Guruprasath Pad-
manaban, Lianhua Chi, Ha-Jeong Kim, Byung Heon Lee. Kyungpook National
University, Daegu, Republic of Korea.
Melanoma, the deadliest form of skin cancer, has long been a major focus of
immunotherapy. Adoptive T cell therapy-based cancer immunotherapy has
been used to enhance the specifıcity and potential of host immune system to
treatmelanoma.However, the infıltration and antitumor function of cytotoxic T
cells (CTLs) are blocked or down-regulated by various signals derived from
tumor cells and cells in tumor microenvironment. A novel approach to specify
and enhance the homing ability of CTLs to tumor is of high demand. Interleu-
kin-4 receptor (IL-4R) is over-expressed onmany types of cancer cells, including
melanoma, and has been widely employed for targeted drug delivery. In this
work, we examined whether the tumor homing effıciency and anti-tumor ther-
apeutic effıcacy of CTLs could be heighten by labeling CTLs with IL4RPep-1, a
targeting peptide that binds to IL-4R. The labeling was empowered by conjugat-
ing IL4RPep-1 with Dioleylphosphatidylethanolamine-biological anchor for
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membrane (DOPE-BAM), an oleyl acid-derived membrane anchor that incor-
porates into lipid membrane of cells. Tumor-specifıc CTLs isolated from the
mice immunized by irradiated B16F10 melanoma cells were highly populated
with CD62LCD44 activated T cells. After labeling with IL4RPep-1 via
DOPE-BAM, CTLs were still functionally active, as determined by intracellular
interferon- and granzyme release assays.Moreover, such labeling did not affect
the proliferation of T cells. Adoptive transfer of IL4RPep-1-labeled, IL-4R-tar-
geted CD45.1CTLs into CD45.2 mice bearing B16F10 melanoma enhanced
their accumulation at tumor compared to that of unlabeled T cells. Tumor hom-
ing of IL4RPep-1-labeled T cells was further validated by in vivo fluorescence
imaging of mice bearing 4T1 tumor at mammary gland. Adoptive transfer of
IL-4R-targeted CTLs showed remarkable anti-tumor growth activity in mice
bearing B16F10 tumor compared to untargeted CTLs. After the transfer, flow
cytometric study of immune cells showed signifıcant increase of CD8 T cells
and F4/80CD86M1-polarized macrophages with noticeable decrease in tu-
mor-promoting immune cells, such as F4/80CD206M2-polarized macro-
phages, Gr1CD11b myeloid derived suppressor cells, and CD3CD4 T
cells. The CTLs accumulated at tumor weremostly exogenous CD45.1 T cells.
These results implicate that IL-4R-targetedCTLs, which is enabled by labeling of
with IL4RPep-1, can be a promising strategy in the fıeld of adoptive T cell ther-
apy against IL-4R-overexpressing tumor.
#3998 Alerting the immune system by removing epigenetic silencing of
Th1 chemokines. Heather M. Sonnemann, Amber J. Giles, Caitlin M. Reid,
Marsha-Kay N. Hutchinson, Deric M. Park, Mark R. Gilbert. NIH, Bethesda,
MD.
BACKGROUND: Solid tumors employ multiple mechanisms to evade an
immune response. However, the potential to enhance the immune response to
cancer has been proven in several malignancie and is under investigation in
many others, including primary CNS tumors. Brain tumors in particular lack
robust T-cell infıltration. Recent studies have found that certain tumors can be
induced to express T-cell attracting chemokines, CXCL9 and CXCL10, by inter-
feron gamma (IFNg). This response is further amplifıed usingmethyltransferase
inhibitors (Peng, et al. Nature 2015. Vol 527: 249-253.), resulting in increased
Tcell traffıcking to tumors both in vitro and in vivo.We hypothesized that T-cell
traffıcking to brain tumors could likewise be enhanced with DNA and histone
methyltransferase inhibitors to induce CXCL9 and CXCL10 transcription.
METHODS: Assays were performed on 7 human glioma brain tumor cell lines.
CXCL9 and CXCL10 expression were measured by real-time PCR. Two com-
mercially available methyltransferase inhibitors, 5-AZA-dC and GSK126, were
utilized to demethylate DNA and histone H3 (K9 and K27), respectively. His-
tone methylation status was examined usingWestern blot. T-cell migration was
measured using transwell migration assays. RESULTS: IFNg increased CXCL9
and CXCL10 transcription in brain tumor lines. GSK126 and 5-AZA-dC en-
hanced expression of CXCL9 and CXCL10 compared to IFNg alone. Migration
assays confırmedT-cell traffıcking towards chemokines produced by tumor cells
in response to methyltransferase inhibitors. CONCLUSIONS: These studies
demonstrate that brain tumors express T-cell attracting chemokinesCXCL9 and
CXCL10 in response to IFNg. Further, GSK126 and the combination of GSK126
and 5-AZA-dC enhanced expression of CXCL9 and CXCL10 transcription by
real-time PCR and T-cell traffıcking by migration assay. Together, these data
provide a potential means to increase T-cell traffıcking into tumors and poten-
tially enhances the effıcacy of immune therapies for brain tumors.
#3999 Cross talk between tumor cell derivedHMGB1 and adaptive B cells
in the tumor microenvironment of esophageal squamous cell carcinoma.
Ngar Woon Kam, Xin-Yuan Guan, Dora Lai-Wan Kwong. Clinical Oncology
and the Centre for Cancer Research, Hong Kong, Hong Kong.
Esophageal squamous cell carcinoma (ESCC) is the most aggressive type of
cancer among gastrointestinal cancers. The lack of effective anti-tumor immu-
nity strategy for ESCC patients imposes urgent demand for new treatment par-
adigm. Tumor microenvironment (TME) is characterized by diverse cell popu-
lations (cancerous, immune cells, and pleiotropic nature of cytokines and
inhibitory receptors) whose alternations are closely related with tumor progres-
sion. High mobility group box chromosomal protein 1 (HMGB1) has been rec-
ognized to be expressed in various tumor cells, and importantly it has also been
identifıed as one of the key factors regulating inflammatory reactions. By com-
paring differentially expressed genes between ESCC tumors (T) and their cor-
responding non-tumorous (NT) tissues high-throughput transcriptome se-
quencing system (RNA-Seq, Illumina HiSeq 2500), we found that the ligands of
TIM-3 (an inhibitory receptor), HMGB1 and galectin-9, but not, cell-surface
phosphatidylserine, were overexpressed in all ESCC samples when compared to
their NT counterparts. We further characterized HMGB1 and galectin-9 gene
expression changes in 37 matched primary ESCC T and NT control samples by
qRT-PCR. We found that HMGB-1 and galectin-9 mRNA is constitutively ex-
pressed in all samples, while ESCC T tissue signifıcantly expressed 2fold
higher of HMGB-1, but not galectin-9, mRNA as compared to paired NT tissue.
Histopathological characterization of ESCC tissue by sequential single staining
for B-cells (CD20) and plasma cells (CD138), demonstrating that B cell infıltrate
was dominated byCD20B cells lacking of terminal differentiation into plasma
cells. Additionally, CD20B cells infıltrateswere negative forCD27 (marker for
memory B cells) and IgD (marker for naïve B cells). Additionally, we isolated
CD20 B cells from healthy peripheral blood mononuclear cells (PBMC), and
stimulated with/without HMGB-1/IgM. Conditional medium (CM) were col-
lected for foci formation and we found that ESCC cell lines KYSE30 and
KYSE180 have better capacity for proliferation when culture with activated B
cells CM as compared to unstimulated B cells. Collectively, we believe that the
suboptimal clinical outcomes relies on CD20HMGB1 receptor B cells that
are exposed to high HMGB1 concentrations in the ESCC microenvironment
may eventually become pro-tumor B cells subset.
#4000 Establishing thenatural history of the immunosuppressivemyeloid
microenvironment in an inducible model of lung adenocarcinoma. Mouna
Lagraoui,1 Clifton L. Dalgard,1 Gauthaman Sukumar,1 Celeste Huaman,1
Thomas Summers,1 Corey A. Carter,2 Brian C. Schaefer1. 1Uniformed Services
University, Bethesda, MD; 2John Murtha Cancer Center, Bethesda, MD.
Tumorigenesis is accompanied by broad changes to the surrounding tissue
microenvironment in a tumor- and patient-specifıcmanner. Phenotype shifts in
tissue-resident immune cells promote cancer progression by establishing a pro-
liferative inflammatory environment, activating angiogenesis, stimulating tu-
mor cell invasion and suppressing anti-tumor immunity. While the former
mechanisms arewell appreciated and often targeted by current cancer therapeu-
tics, the nature of the mechanisms controlling establishment of the local immu-
nosuppressive state that contribute to a failure of anti-tumor immunity are less
clearly defıned. Blockade of tumor antigen-specifıc T cell killing is clearly a
major contributor to the failure to control tumorigenesis. However, evidence
suggests that phenotypic shifts in innate immune cell populations also contrib-
ute to the failure of anti-tumor immunity.We hypothesize that the emergence of
early lung adenocarcinomas is accompanied by a shift in myeloid phenotypes,
rapidly establishing a microenvironment favorable to tumor growth, survival
and vascularization, and hostile to cell-mediated anti-tumor immune responses.
Through the utilization of a Cre-inducible mouse model of p53-null, Kras-
G12D lung adenocarcinoma,wehave begun to defıne the natural history of the
myeloid component of the tumormicroenvironment, from tumor initiation to a
point equivalent to human stage I adenocarcinoma.Histological, flow cytometry
and real-time PCR approaches collectively demonstrate that tumor-associated
myeloid phenotypes emerge at a very early stage of disease. These data are con-
sistent with our hypothesis that the myeloid component of the tumor microen-
vironment plays a crucial role in establishing an immunosuppressive state dur-
ing early tumorigenesis. Implications of these fındings for current and emerging
immunotherapies will be discussed.
#4001 Infıltration of neutrophils in the tumor was associated with poor
prognosis of patients with gastric cancer. Hiroaki Tanaka, Soichiro Hira-
matsu, Tatsuro Tamura, Hisashi Nagahara, Kenjiro Kimura, Masatsune Shibu-
tani, Go Ohira, Takahiro Toyokawa, Sadaaki Yamazoe, Ryosuke Amano, Ka-
zuya Muguruma, Kiyoshi Maeda, Kosei Hirakawa, Masaichi Ohira. Osaka City
Univ. Grad. School of Medicine, Osaka, Japan.
Background: Recent evidence shows that neutrophils often migrate into the
tumor and are associated with tumor progression. These tumor associated neu-
trophils (TANs) neutrophils have potential to induce angiogenesis, lymphan-
giogensesis and immunosuppression by inhibiting cytotoxic T lymphocytes.
Immune status is one of the important prognostic factor of gastric cancer. We
previously reported that lymphangiogenesis was augmented in the primary tu-
mor of gastric carcinoma. Aim: The aim of this study was to investigate the
correlation between CD15 TANs and clinicopatological features of patients
with gastric cancer. Materials and Methods: We investigated the association of
the density of TANs in primary tumor with clinicopathological features by im-
munohistochemistry.Weused specimens froma total of 143 primary tumor and
497 lymph nodes from 120 patients underwent gastrectomy between 2007 and
2008 in our department. We examined prognostic value of TANs identifıed as
positive CD15 cells in both of the primary tumor and tumor draining lymph
nodes. Results: The median number of TANs in primary tumor and tumor
draining lymph nodes were 18.4 and 23 cells/HPF, respectively. High TANs in
both of the primary tumor and lymph nodes had correlation with depth of
invasion (primary tumor P0.001, lymph nodes P0.036) and lymph nodes
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metastasis (primary tumor P0.001, lymph nodes P0.002). Kaplan-Meier
analysis showed that patients with high TANs in both primary tumor and lymph
nodes had worse prognosis than patients with a low TANs (primary tumor
P0.031, lymphnodes P0.014).Multivariate analysis revealed that highTANs
in lymph nodes were independent prognostic factors. (P0.038) Conclusion:
Our results showed that patients with high CD15TANs infıltration in gastric
cancer tissues had poorer prognosis because of increasing lymph nodes metas-
tasis. These fındings suggested the TANs might have important role of tumor
lymphangiogenesis in microenvironment of gastric carcinoma.
#4002 Neutrophil extracellular traps (NETs) in abdominal cavity have
supportive roles on postoperative development of peritoneal metastasis.
Rihito Kanamaru, Hidenori Tsukui, Shin Saito, Kentaro Kurashina, Takashi Ui,
Shiro Matsumoto, Hironori Yamaguchi, Yasunaru Sakuma, Hisanaga Horie,
Yoshinori Hosoya, Naohiro Sata, Joji Kitayama. Jichi Medical University,
Tochigi, Japan.
Background: Peritoneal lavages just after abdominal surgery contain many
immune cells which consist mainly of granulocytes. Recent studies have dem-
onstrated that neutrophil extracellular traps(NETs) play important roles not
only on capture of pathogenic microbes but also on autoimmune disease,
thrombus formation and tumor metastasis. Here, in this study, examined the
NET forming capacity of granulocytes in postoperative peritoneal washings and
assessed the possible role of the NETs on metastasis formation on peritoneum.
Method: In patients who underwent laparotomy due to digestive malignancies,
abdominal cavity were washed with 1000 ml of normal saline at the timing of
laparotomy (Preoperative) and just before wound closure (Postoperative). Cells
recovered from the peritoneal washings were centrifuged on Ficoll-Hypaque
solution and cultured at 37c in 5 percentage CO2 condition for 24 hour. Then,
extracellular ds-DNA were stained with membrane impermeable dye, SYTOX.
Also, the granulocytes were immunostainedwithmAbs against CD66b, histone,
myeloperoxidase (MPO), neutrophil elastase (NE) and Matrix metalloprotei-
nase (MMP)-9, and NETs structures were observed under fluorescein micros-
copy. In adhesion experiments, human gastric cancer cells were stained by
PKH-26 and mixed with the granulocyte culture for 5 min and gently washed.
Results: 1. After Ficoll separation, CD66b () granulocytes were contained both
in polymorophonuclear (PMN) andmononuclear cell (PBMC) layers, which are
considered to be normo-density granulocytes (NDG) and low density granulo-
cytes (LDG), respectively. The percentage of LDG in PBMC layer was markedly
elevated in postoperative as compared preoperative lavages (Pre: M0.71%,
08.9% vs Post: M61.3%, 386.7% n39, p0.001) The LDG in postopera-
tive sample showed multinuclear morphology. 2. The short term culture of the
postoperative peritoneal LDG, but not preoperative or peripheral blood granu-
locytes, many SYTOX () fıbrous structures were observed, suggesting the vig-
orous NETs formation. The NETs appeared several min after the incubation,
peaked at 2 hour and gradually decreased thereafter. Immunostaining showed
that histone andMPOwere co-localized on theNETs, while NE orMMP-9were
less clear on NETs. 3. After 5 min co-incubation, human gastric cancer cell,
OCUM-1 andMKN45,were selectively attached on theNETs. 4. Similar SYTOX
() NETs-like structure were clearly detected on the surface of human omental
tissue resected by abdominal surgery. Conclusion: After laparotomy,many LDG
appear in human abdominal cavity which produce large amounts of NETs on
peritoneal surface. TheNETs effıciently trap the floating tumor cells, whichmay
have positive roles on peritoneal recurrence in advanced cancer.
#4003 Acral lentiginousmelanomaand infıltrating lymphocytes in aLatin
American population. Carlos Castaneda,1 Carlos Torres-Cabala,2 Sandro
Casavilca,1 Miluska Castillo,1 Valeria Villegas,1 Joselyn Sanchez,1 Claudio
Flores,3 HenryGomez,1 TatianaVidaurre1. 1InstitutoNacional de Enfermedades
Neoplasicas, Lima, Peru; 2University of Texas MD Anderson Cancer Center,
Houston, TX; 3Oncosalud, Lima, Peru.
Background: Acral lentiginousmelanoma (ALM) is unusual in Caucasian but
is themost common subtype inHispanic populations, andhas been associated to
poor prognosis. Herein we compare clinicopathological features associated to
ALM in a Latin-American population and prospectively evaluate its association
with tumor infıltrating lymphocytes (TIL). Patients and Methods: All patients
with melanoma presenting from 2005 to 2012 at Instituto Nacional de Enfer-
medades Neoplasicas in Lima, Peru, were retrospectively identifıed. Analysis of
association between clinicopathological features and ALMwas performed. Sur-
vival analysis compared the outcome of ALM to whole group and extremity
NALM. We performed prospective evaluation of TIL following Azimi et al re-
cently presented classifıcation. Results: A total of 537ALMand 287NALMcases
were identifıed.Older age (p 0.02), thicker Breslow (p 0.008), positive lymph
node (p 0.051) and ulceration (p0.001) were found to be more frequent in
ALM. Acral had worse OS compared with both whole group (p 0.04) and
extremityNALM (p0.001). Stage I-II patients had amedianOS of 5.3 (95%CI:
4.3-6.2) forALMand 9.2 (95%CI: 5.0 - 7.0) for extremityNALM(p0.016). TIL
was prospectively evaluated in 490 cases, and Grade 0-1, II and III of TIL repre-
sented 44.7%, 33.6% and 27.1%, respectively. Higher TIL gradewas associated to
less Breslow thickness (p 0.021), less mitosis index and NAM. Higher TIL
grade was also associated to better OS (p 0.001) Conclusion: ALM is highly
prevalent in Latin-America and carry poor outcome. Lower TIL levels was as-
sociated to poor outcome and ALM.
#4004 Rapamycin selectively targets obesity-polarized macrophages in
the prostate tumor microenvironment. Gloria C. Galván,1 Tommy Pham,1
Brittany Harlow,1 Christian Johnson,1 Riddhi Patodia,1 Duan Quach,1 Mi-
chael A. Liss,2 Linda A. deGraffenried1. 1The University of Texas at Austin,
Austin, TX; 2University of Texas Health Science Center San Antonio, San
Antonio, TX.
Background: Obesity is associated with prostate cancer progression andmor-
tality. Previous studies in our laboratory suggest that obesity drives prostate
cancer progression in part by increasing macrophage recruitment and by polar-
izing macrophages in the tumor microenvironment into a tumor promoting
M2/TAM phenotype. Rapamycin, a mammalian target of rapamycin (mTOR)
inhibitor, has been used for several decades in transplant patients, and in the last
several years has been shown to be an effective disease suppressor in certain
cancer types. Intriguingly, mTOR has been shown to be especially important for
M2 polarization and stabilization. Hypothesis: Based upon published data and
our preliminary studies, we hypothesize that rapamycin will selectively target
obesity-polarized macrophages and will provide a survival benefıt to the obese
prostate cancer patient. Methods: To address this hypothesis, we used our in
vitro model of obesity-induced macrophage polarization that includes two dif-
ferent prostate cancer cell lines, macrophages, and sera from obese and non-
obese men. qPCR was used to measure expression levels of markers associated
with an M2/TAM phenotype. MTT assays were conducted to measure cell via-
bility, and flow cytometry andWestern blot analyses were used to determine cell
cycle status and apoptosis. Results: Obese conditions increased expression of
M2/TAMmarkers in macrophages and rapamycin selectively decreased viabil-
ity of obesity-activated M2/TAMs compared to M1macrophages. Conclusions:
Our in vitro study suggests that obesity promotes a tumor-associated phenotype
in macrophages and that the mTOR pathway is involved in the survival of M2/
TAM macrophages. This study offers a novel mechanistic approach to treat
obese patients with prostate cancer.
#4005 HDAC inhibitors regulateM2 tumor-associatedmacrophage func-
tion through histone acetylation. Amber E. de Groot, Jelani C. Zarif, Kenneth
J. Pienta. The James Buchanan Brady Urological Institute; Johns Hopkins School
of Medicine, Baltimore, MD.
Macrophage tumor infıltration in metastatic prostate cancer is a predictor of
patient prognosis. Macrophages influence tumors in contrasting ways depend-
ing on their polarization:M1macrophages have anti-tumor functions whileM2
macrophages are pro-tumor. The external stimuli influencing macrophage dif-
ferentiation and M2 polarization have been largely elucidated but the resulting
downstream changes remain unknown. There are a number of epigenetic dif-
ferences between M1 and M2 macrophages that act as important functional
determinants. Recent work studying these epigenetic changes has implicated
histone deacetylases (HDACs), as critical regulators in macrophage differentia-
tion and inmaintainingM1 orM2 function. Pan-HDAC inhibitors (HDIs) such
as the clinically utilized suberanilohydroxamic acid (SAHA) target a wide range
of HDACs and provide a means for manipulating macrophage histone acetyla-
tion. ThoughHDIs have been found to attenuate inflammatory functions inM1
macrophages, the fıeld has yet to explore effects of histone acetylation in M2
macrophages. UsingM2macrophages derived from humanCD14monocytes,
we found that SAHA regulates M2 macrophage polarization and function
through alteration of histone acetylation. Work is ongoing to test expression
levels of canonical M2 markers such as the mannose receptor CD206 and scav-
enger receptor CD163 in M2 macrophages exposed to SAHA either during or
after M2 polarization. Additionally, investigation into the ability of these popu-
lations to secrete M2 cytokines such as IL-10 and VEG-FA and induce EMT in
prostate cancer cells is also being pursued. These results contribute to scientifıc
knowledge of epigenetic regulation inmacrophage function and elucidate strat-
egies to decrease the pro-tumor function of tumor-infıltratingM2macrophages.
This work lays the foundation for using epigenetic regulators to modulate the
tumor microenvironment and advance cancer medicine.
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#4006 Immune cell profıles and-catenin signaling inmelanoma. Jeremie
Nsengimana, SathyaMuralidhar, Joanna Pozniak, Jon P. Laye,DT. Bishop, Julia
A. Newton-Bishop. University of Leeds, Leeds, United Kingdom.
Introduction Immune profıling is a necessary step in understanding tumor
microenvironment and predicting the response to immunotherapies. Methods
We used the expression of genes exclusively expressed by immune cells in tu-
mors1, to classify 703 formalin-fıxed primary melanomas from the Leeds Mela-
nomaCohort. Transcriptomes were generated from tumor cores using Illumina
DASL HT 12.4 array. In the obtained tumor subgroups with differing immune
profıles, we tested the hypothesis that -catenin signaling controls immune
suppression in primary tumors as earlier reported in vitro and murine data2.
ResultsWe found and validated 6 tumor classes, which showed consistencywith
other published gene signatures, and predicted melanoma-specifıc survival
(HR1.8, P0.003, adjusted for AJCC stage, site, age, sex, ulceration, mitotic
rate, BRAF/NRAS mutation). Tumors of good prognosis expressed markedly a
large number ofmarkers of T cell cytotoxicity, dendritic cells, macrophages, NK
CD56 dim cells and genes coding for checkpoint co-inhibitor molecules (Table
1). They also had upregulation of -catenin suppressors3 and downregulated
-catenin itself (Table 1). By contrast, poor prognosis tumors (the largest group)
lacked both innate and adaptive immunity, and had activation of canonical
-catenin signaling (CTNNB1, its targets andWNT receptors) andWNT-inde-
pendent -catenin signaling (Table 1). Conclusion In a large subset of this pop-
ulation-based cohort of primary tumors, we report evidence of immune evasion
through -catenin signaling pathway. These results obtained from archival ma-
terial suggest that transcriptomic profıling is a viable alternative to flow cytom-
etry in understanding tumor biology and in determining the effectiveness of
immunotherapies.
Table 1. Immune scores and -catenin signaling in good/bad prognosis groups
Gene expression derived characteristic Good prognosis Bad prognosis
A. Immune scores from gene expression
Cytotoxic T cell (e.g. GZMA, GZMH, KLRB1, KILRD1) up down
Dendritic cells (e.g. CD1B, CCL13, CCL22, IDO1, IDO2) up down
NK CD56 dim (e.g. IL21R, GZMB, KIR2DS5, KIR3DL1) up down
Macrophages (e.g. PTGDS, GM2A, CD68, SC5, ATG7) up down
B. Checkpoint molecules
PDL1 up down
CTLA4 up down
VISTA up down
TIM3 up down
LAG3 up down
BTLA up down
C. -catenin inhibitors up down
DKK2 (secreted) up down
DKK3 (secreted) up down
SFRP2 (secreted) up down
AXIN2 (intracellular) up down
NKD2 (intracellular) up down
D. -catenin, its targets and WNT receptors
CTNNB1 (-catenin) down up
DVL1, DVL2, DVL3 down up
TCF12, TCF1 down up
APC2, APC,c-MyC down up
FZ5, FZ9 down up
E. WNT-independent -catenin signaling
FGFR4 down up
PYGO1 down up
BCL9 down up
FOXM1 down up
NUP98 down up
SMAD4 down up
References 1. Bindea et al. 2013. Immunity 39 (4): 782-95. 2. Spranger et al.
(2015). Nature 523:231-5. 3.MacDonald et al. (2009). Developmental Cell 17(1):
9-26.
#4007 Differential macrophage programming is associated with the ag-
gressiveness of gliomas. Nai-Wei Yao, Fang Liao, Chen Chang, Joanne Jeou-
Yuan Chen. Academia Sinica - Inst. of Biomedical Sci., Taipei, Taiwan.
Tumor-associated macrophages (TAMs), a major component of immune
cells in the tumor microenvironment, have been shown to be associated with
enhanced malignancy of gliomas. The polarization of macrophages toward a
pro-inflammatory phenotype M1 or an anti-inflammatory phenotype M2 gov-
erned by niche factors in the tumor microenvironment may dictate the malig-
nant outcome of gliomas. In this study, we examined the effects of differential
programming of TAMs on the development of C6 gliomas in different host
microenvironment using SDandWistar rats.Usingmulti-parametricMRImea-
surements, we show that C6 cells implanted into SD rats developed larger tu-
mors as compared to those inWistar rats (p 0.0199), which was accompanied
with a shorter survival of SD rats (p 1.0610-9). The increased tumor growth
in SD rats was associated with increased angiogenesis and higher levels of VEGF
and VEGFR2 expression. We also observed a signifıcantly increased ratio of
M2/M1 in the tumors of SD rats while a decreased ratio of M2/M1 in those of
Wistar rats, suggesting that the milieu of C6 gliomas in SD rats favors for the
polarization of macrophages toward the pro-tumorigenic M2 phenotype. Most
importantly, Induction of M1 polarization by IFN treatment greatly reduced
tumor burden in SD rats, and induction of M2 polarization by IL-4/IL-10 treat-
ment or blockade of M1 polarization by anti-IL12 treatment signifıcantly pro-
moted tumor growth in Wistar rats. These results demonstrate an important
role of TAMs in glioma pathogenesis and the crucial role of microenvironment
in dictating the polarization of TAMs into M1 or M2 phenotypes. We conclude
that macrophage programming plays an important role in glioma development
and that targeting glioma-associated macrophages may serve as a promising
therapeutic approach.
#4008 Human macrophage CM promotes EMT in human colon cancer.
Delphine R. Boulbes, Fan Fan, Rui Wang, Huiyuan Zhang, Stephanie S. Wato-
wich, Rajat Bhattacharya, Ling Xia, Xiang-Cang Ye, LeeM. Ellis.UTMDAnder-
son Cancer Ctr., Houston, TX.
Background: Although most studies support the observation that increased
macrophage infıltration is associated with better patient prognosis and overall
survival in patients with CRC (in contrast to other malignancies), others have
shown that macrophages have a pro-tumoral and pro-metastatic effect via epi-
thelial-mesenchymal transition and the secretion of growth factors and cyto-
kines. Therefore, we sought to determine the role of conditioned medium from
activated human macrophages on CRC cells. Methods: Human CRC cell lines
HCP-1 and HCT116 were treated with conditioned media (CM) from Phorbol
Myristate Acetate (PMA)-activated human macrophages cell lines THP-1 and
U937. Viability studies were performed using the MTT assay, the invasion and
migration were performed in Boyden chambers, coated with a collagen matrix
for the invasion assay. Results: The results showed that PMA-activated human
macrophages 1) dramatically increased both migration and invasion abilities of
HCP-1 and HCT116 CRC cell lines, 2) stimulated Epithelial-Mesenchymal
Transition (EMT) and 3) had no effect on the response of CRC cells to chemo-
therapy. Our PCR results also showed that PMA-activation greatly increased the
expression of growth factors and cytokines in humanmacrophages that could be
involved in the changes described above and are currently under investigation.
Conclusions: Our data show that PMA-activated human macrophages play an
active role in promoting EMT of human CRC cell lines.
#4009 Characterization ofM2macrophage subtype content in cancer and
normal tissues. Lisa M. Dauffenbach, Gela C. Sia, Jianping Zheng, Natalia Jun,
Eric P. Olsen, Christopher A. Kerfoot. Mosaic Laboratories, LLC, Lake Forest,
CA.
Tumor-associated macrophages play an important role in presenting tumor
antigens to T cells and are being investigated for their role in sensitivity to
immune checkpoint inhibitors such as PD-1 inhibitors. The M2 macrophage
subtype, characterized by CD163 expression, is immunosuppressive and asso-
ciated with poor prognosis. A multiplex CD68/CD163 immunohistochemical
assay was developed to characterize the density of cells expressing each marker
and determine the percentage of macrophages that are of the M2 subtype. The
assay was used to analyze 22 normal tissue types and 50 tumor tissues within 5
different indications. The results were analyzed by image analysis and results
were analyzed as percent positive anddensity permm2.Cancer tissues expressed
a greater percentage of CD163macrophages than normal tissues.
#4010 Tonggyu-tang, a traditional Korean medicine, suppresses inflam-
mation, potential implications in tumor microenvironment. Hyoin Kim,
Seong-GyuKo, YongCheol Shin, Ji Hye Kim,Hye-Sook Seo, Tai YoungKim, Se
Hyang Hong, Kangwook Lee, Jin Mo Ku, Myeong-Sun Kim, Yu-Jeong Choi,
Soo-yeon Kang, Chunhoo Cheon, Youme Ko, Huang Ching Wen, Yui Sasaki,
Sohyeon Kang. Kyung Hee University, Seoul, Republic of Korea.
The critical roles of inflammation in the development of cancer have long
been appreciated. A growing body of evidence supports the notion that infıl-
trates of inflammatory cells into tumor microenvironment influence the tumor
progression by providing bioactive molecules including pro-inflammatory cy-
tokines. Importantly, the increased number ofmast cells within tumormicroen-
vironment has been associated with a poor survival in cancer patients. More-
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over, keratinocyte inflammation is known to be crucial for skin tumor
development. The use of natural products to reduce inflammation in tumor
microenvironment is gaining an interest, because of their reduced toxicity to-
ward normal cells. In this study, we tested the effects of Tonggyu-tang (TGT)
which is composed of 14 different herbal extracts on the activity ofmast cells.We
found that TGT signifıcantly reduced the expression and production of inflam-
matory cytokines such as IL-4, IL-6, IL-8, and TNF- in PMA and ionomycin-
stimulatedHMC-1 (humanmast cell line-1). In an attempt to determinemolec-
ular mechanism underlying the inhibitory effects of TGT on cytokine expres-
sion, we revealed that TGT suppressed MAPK signaling pathway including
ERK, p38, and JNK as well as NF-B pathway, which are known to regulate
inflammatory cytokine expression. Similar results were obtained from the LPS-
stimulated HaCaT cells, immortalized human keratinocytes. Taken together,
our results demonstrate that TGT suppresses inflammation by inhibiting the
expression of pro-inflammatory cytokine in both mast cells and keratinocytes,
thereby potentially leading to inhibition of tumor progression.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Assay
Technology
#4011 Validation of novel continuous live-cell assays for immune cell ac-
tivation and killing of blood cell cancers. Nicola Bevan,1 Hinnah Campwala,1
Clare Szybut,1 Kalpana Patel,1 Dan Appledorn,2 Tim Dale,1 Derek Trezise1.
1Essen BioScience Ltd, Welwyn Garden City, United Kingdom; 2Essen BioScience
Inc, Ann Arbor, MI.
The blood cancers leukaemia, lymphoma andmyeloma are expected to cause
the deaths of 55,000 people in theUS in 2016.New immunological approaches
afford great promise for improved therapies. Here, we describe novel high
throughput live-cell image-based assays for immune cell activation andkilling of
target cells that are geared toward screening for new treatments for these malig-
nancies. Myeloid and lymphoid cells (Jurkats, Raji, Ramos, WIL2-NS, THP-1,
PBMCs) were plated on poly-L-ornithine (PLO) or fıbronectin coated 96-well
flat plates and monitored over time (h to days) using non-invasive live-cell
analysis (IncuCyte). The dynamics of proliferation were quantifıed via phase-
contrast image analysis (% confluence), and validated as a robustmeasure of cell
number by correlating to direct cell counts (Scepter, Millipore) and ATP assays
(PerkinElmer). Anti-CD3/IL-2 (0.1-100/10 ng/mL) or anti-CD28 activation (1-
100 ng/mL) of PBMCs evoked time-dependent proliferation (0-5d) that was
sensitive to the initial cell density and concentration of stimulus. L-Kynurenine
(4.69 - 300 M), a metabolite of the amino acid L-tryptophan caused concen-
tration and time-dependent inhibition of proliferation of PBMCs. To quantify
immune-cell killing in co-cultures, WIL2Ns and Ramos B-cell myelomas were
fırst transduced with nuclear-targeted RFP (NucLight Red) to enable direct cell
counting. PBMCs, either pre-activated or activated in situ (IL-2/CD3), were
then added and the time-course of killing quantifıed through live (RFP) and
dead/apoptotic (annexin-V) cell counting. Together, these protocol develop-
ments and validation data illustrate non-invasive continuous measurement of
proliferation, activation, clustering and immune-cell killing of non-adherent
tumour cells at industrial scale. Unlike flow cytometry, this approach follows the
full time-course of the biology without perturbing the cells and allows cell-cell
interactions to be visualised. These assays are amenable to testing new therapeu-
tic antibodies, small molecules and genetic T-cell modulation such as CAR-T.
#4012 Visualization of EPR effect and active targeting by using micro-
scopic mass spectrometry. Masahiro Yasunaga,1 Masaru Furuta,2 Koretsugu
Ogata,2 Yuki Fujiwara,1 Yoshikatsu Koga,1 Yasuhiro Matsumura1. 1National
Cancer Ctr. EPOC, Kashiwa, Japan; 2Shimadzu Corporation, Kyoto, Japan.
Microscopic mass spectrometry (MMS), in which a microscope is coupled
with an atmospheric pressure matrix-assisted laser desorption/ionization
(MALDI) and quadruple ion trap time-of-flight (TOF) analyzer has been devel-
oped for the investigation of the distribution of various molecules including
drugs. Thematrix-coated drug sample is ionized and then separated on the basis
of its mass-to-charge ratio (m/z). Images were acquired from imaging mass
spectrometry (IMS) or tandem mass spectrometry (MS/MS) data. Recently,
pharmacokinetic (PK) and pharmacodynamic (PD) studies have become im-
portant to evaluate the effıcacy and toxicity of the drugs. In these analyses, tissue
homogenates are generally used for the quantifıcation by high-performance liq-
uid chromatography (HPLC) or liquid chromatography mass spectrometry
(LC-MS). However, they lack the information regarding the drug distribution in
a specifıc anatomical area. The information of the drug distributionwould allow
us to optimize the drug design enabling more effıcient drug delivery. (1) We
studied the tissue distribution of paclitaxel (PTX) and its micellar formulation
(NK105) using a MMS. NK105 showed much stronger antitumor effects on a
human pancreatic cancer BxPC3 xenograft than PTX. In the drug imaging, we
demonstrated that NK105 deliveredmore PTX to the whole tumor tissue. In the
mouse model, PTX caused the peripheral neurotoxicity but NK105 did not.
Multiple high drug-signal areas surrounding and inside the caudal nerve were
observed in the case of PTX, whereas the signals after NK105 administration
were quite low. (2) The tissue distribution and controlled drug release of ADC
(antibody-drug conjugate) consisting of a tissue factor specifıc antibody (TF)
linked to the anticancer agent monomethyl auristatin E (MMAE) was evaluated
in comparison with control-ADC (control antibody-MMAE conjugation). TF-
ADC showed stronger antitumor effect on BxPC3 xenograft than control-ADC.
We then established the selective detectionmethod ofMMAE for distinguishing
free MMAE and its conjugated form. The released MMAE signal detected fol-
lowing the accumulation of TF-ADC was greatest 24 h after the administration,
compared with the control-ADC at the same time (P0.01). In summary, we
succeeded in visualizing (1) the EPR (Enhanced permeability and retention)
effect and (2) active targeting usingMMS. The data obtained will facilitate more
effıcient drug development in the preclinical setting.
#4013 A novel multifunctional protein tag enables simple and sensitive
bioluminescent quantifıcation of tagged proteins. Christopher Eggers,
Braeden Butler, Robin Hurst, Mary Hall, Brock Binkowski, Lance Encell, Marie
Schwinn, ThomasMachleidt, KeithWood, Frank Fan. Promega Corp.,Madison,
WI.
Dysregulation of protein expression is a key mechanism of tumorigenesis.
The most commonly used approach to monitor changes in expression is to
perform SDS-PAGE, followed by immunoblotting, a labor-intensive process
that requires high-quality antibodies to detect proteins at endogenous levels of
expression. We have developed a novel protein tag utilizing NanoLuc Binary
Technology (NanoBiT), a binary complementation system based on NanoLuc
luciferase. The tag, designated High BiT (HiBiT), is only 11 amino acids in
length, which minimizes potential interference with protein function. The
amount of HiBiT-tagged protein is measured using a lytic detection reagent
containing Large BiT (LgBiT), which binds with high affınity to HiBiT (KD1
nM) to reconstitute a bright, luminescent enzyme.HiBiT-tagged proteins can be
quantifıed in cell lysates over 7 orders ofmagnitude of linear dynamic rangewith
a limit of detection of less than 10-19 moles (3 fg of 30 kDa protein). The simple
add-mix-read assay protocol can be completed in minutes, providing an assay
that is compatible with high-throughput applications. The sensitivity of the as-
say allows quantifıcation of expression at endogenous levels, and the small tag
size is ideal for CRISPR-mediated genome editing. HiBiT-tagged proteins sep-
arated by SDS-PAGE can be detected on blots at sub-picogram levels with a
detection reagent containing LgBiT. By eliminating the multiple steps of block-
ing, binding, and washing of traditional blotting techniques, the protocol takes
minutes instead of hours. Additionally, the cell surface expression, internaliza-
tion, or secretion of HiBiT-tagged proteins can be measured in minutes using a
non-lytic detection reagent containing the cell-impermeable LgBiT protein.
HiBiT represents a next-generation protein tag that allows simple quantifıcation
of proteins of interest in their cellular context or following SDS-PAGE.
#4014 Blood-brain-barrier spheroids: Next-generation screening plat-
form for brain-penetrating agents. Choi-Fong Cho. Harvard Medical School,
Boston, MA.
The inability of most systemically delivered therapeutics to cross the blood-
brain-barrier (BBB) is considered amajor barrier to effective brain cancer treat-
ment. In malignant glioma the tumor neovasculature is known to be leaky,
however invasive cells remain protected behind an intact BBB, and continue to
thrive within the brain, ultimately leading to tumor regrowth and patient death.
This leaves us with an urgent unmet need for the development of next-genera-
tion therapeutics with improved brain delivery. For the fırst time, we describe
here the utility of 3D multicellular BBB spheroids made of human brain endo-
thelial cells (ECs), pericytes and astrocytes as a screening tool for brain-pene-
trating agents. We show that the outer surface of the spheroids, composed pri-
marily of ECs and pericytes, form a tight barrier which is permeabilized in the
presence of VEGF. The barrier is characterized by the presence of intact tight
junctions and efflux-pump activity (i.e., P-glycoprotein). Furthermore, we have
used this model to successfully demonstrate the transport of angiopep-2 (a well-
known brain delivery vector) and its conjugates (containing cargoes of various
sizes such as peptide, protein and affıbody), thereby displaying the versatility of
this model to screen and study a wide range of therapeutic agents. We demon-
strate that this model is superior to the conventional transwell model in main-
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taining essential BBB characteristics (i.e., tight/adherens junctions and P-glyco-
protein expression) and as a drug-screening tool. We have utilized the spheroid
model to screen a panel of cell-penetrating peptides (CPPs) to identify several
candidates with high brain-penetration potential. We then verifıed the ability of
the top 4 candidate CPPs to cross the BBB inmice. This high-throughput model
can lead to better design and analysis of fırst-in-class glioma therapeutics, and
improve prediction of drug penetration in a living model, paving the way for
breakthrough discoveries in brain cancer.
#4015 A comparative study of PD-L1 IHC 22C3 and 28-8 FDA-approved
diagnostic assays in cancer. Cory Batenchuk,1 Maher Albitar,2 Sucha Sudarsa-
nam,2 Vladislav Chizhevsky,2 Chelsea Jin,1 Virginia A. Burns1. 1Bristol-Myers
Squibb, Princeton, NJ; 2NeoGenomics Laboratories, Aliso Viejo, CA.
Background: Higher levels of PD-L1 expression at the surface of tumor cells
have been associated with increased response to anti-PD-1 therapies (Santabar-
bara G et al. Ann Transl Med. 2016;4:215; Borghaei H et al. N Engl J Med.
2015;373:1627-1639; Brahmer J et al. N Engl J Med. 2015;373:123-135). The
FDA has 2 approved tests associated with the use of these agents. The Dako
PD-L1 IHC 22C3 kit is approved as a companion diagnostic for the use of
pembrolizumab in the fırst- and second-line non-small-cell lung cancer
(NSCLC) settings, where diagnostic testing is required for its use. The Dako
PD-L1 IHC 28-8 kit is approved as a complementary diagnostic for nivolumab
therapy in second-line NSCLC, where testing is not required for its use. NeoG-
enomics Laboratories stained a subset of the samples received for PD-L1 testing
with both 22C3 and 28-8 on the same biopsy specimen. This dataset presents an
opportunity to explore real-world concordance testing for 22C3 and 28-8 anti-
bodies. Methods: The analysis was performed on a dataset obtained from Sym-
phony Health Solutions describing the PD-L1 biomarker test results and anno-
tations reported by NeoGenomics Laboratories between Oct 7, 2015, and Aug
31, 2016. A total of 5217 biomarker test results were available for 4528 patients
afflicted by diverse malignancies. Concordance testing was performed on 556
unique patients that had a single 22C3/28-8 pairing collected from the same
biopsy specimen. All staining was performed using the FDA-approved in vitro
diagnostic assay using the 22C3 antibody or the 28-8 antibody on the Dako Link
48. Cases were reviewed and scored randomly across multiple pathologists, who
received special training and certifıcation in scoring. All statistical analyses were
performed in SAS. Results: Paired biopsy specimens stainedwith both 22C3 and
28-8 displayed high degrees of correlation (Spearman’s correlation co-effı-
cient 0.97). In addition, Bland-Altman analysis revealed that the mean differ-
ence in the percentage of tumor cells positively stained for PD-L1 between the
paired 22C3 and 28-8 assay fındings was 0.48% [95% prediction limit (-12.41%
to 13.37%)]. Across expression levels both antibodies displayed a similar prob-
ability of being interpreted as greater than one another (43 of 556 where 28-
822C3 and 40 of 556 where 22C328-8), with no clear direction of a single
antibody displaying greater sensitivity. When analyzed at the  1%,  5%, 
10%, 25% and 50% thresholds, the overall rate of agreement was between
96.8% and 98.2% and associated with a level of agreement (Cohen’s kappa)
between 0.92 and 0.96. Conclusion: Both the 22C3 and 28-8 diagnostic assays
show strong agreement in a single central laboratory real-world setting. These
data, in conjunction with recent fındings from analytical comparability studies
reported elsewhere, support the potential interchangeability of these assays for
diagnostic interpretation.
#4016 Homogeneous BTK occupancy assay for pharmacodynamic assess-
ment ofGS-4059 target engagement.HelenYu,HoaTruong, Scott A.Mitchell,
John J. Gosink, Julie Lin, JoyY. Feng, JulianeM. Jürgensmeier, AndrewN. Billin,
Ren Xu, Siddhartha Mitra. Gilead Sciences, Foster City, CA.
Burton’s Tyrosine Kinase (BTK) plays an important role in B cell signaling,
cell proliferation and survival. Hence, it is an attractive target for therapeutic
intervention in B cellmalignancies and autoimmune disorders. GS-4059 (ONO-
4059) is a covalent, potent and selective inhibitor of BTK in clinical development
for CLL, NHL, and rheumatoid arthritis. Accurate measurement of target cov-
erage in early stage clinical studies is critical to informing dose selection for
GS-4059 in more advanced clinical studies. We developed a novel duplex ho-
mogeneous BTK occupancy assay to enable quantitative measurement of GS-
4059 binding to humanBTK for assessing target coverage in the clinic. The assay
is based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-
FRET) and simultaneously measures the levels of free BTK (BTK that is not
bound to GS-4059 in treated human PBMCs ex vivo or PBMCs from patients
treatedwithGS-4059 in clinical studies) as well as the levels of total BTKprotein.
We took advantage of the dualwavelength emission property of Terbium (Tb) to
serve as energy donor for 2 fluorescent energy acceptors with distinct excitation
and emission spectra. We designed and synthesized a GS-4059 analog with bi-
otin conjugate which showed equal potency to GS-4059, suggesting that it binds
in the same BTK pocket. To detect free BTK, a Tb-coupled anti-BTK antibody
was used as the FRET energy donor and G2-strepavidin-bound biotinylated
GS-4059 as the energy acceptor. Total BTK was detected in the same well with a
second D2-coupled anti-BTK antibody that binds to a different BTK epitope as
the FRET energy acceptor. The use of a common detection reagent in this mul-
tiplexed format allowsmeasurement of free and total BTK levels in the samewell
data. The assay was characterized and qualifıed using full length purifıed recom-
binant human BTK protein and PBMCs derived from healthy volunteers and
CLL patients. Preliminary data indicate the assay is also suitable for assessing
BTK occupancy in bonemarrow derived cells. Using this assay, we evaluated the
BTK synthesis rate following a 1 hour high dose (5M) treatment of GS-4059 in
BTK inhibitor resistant ABC-DLBCL andGCB-DLBCL tumor cells.While neg-
ligible new BTK synthesis was observed in BTK inhibitor sensitive DLBCL cells,
the free BTK level in the inhibitor resistant tumor cells recovered rapidly post-
treatment. In summary, we have established a homogeneous TR-FRET based
BTK occupancy assay that simultaneously measures free and total BTK levels in
the same well, yielding quantitative BTK occupancy data to support GS-4059
clinical development.
#4017 Development and application of an immunohistochemistry-based
assay for evaluating functional and accessible folate receptor expression in
vivo.Haiyan Chu, Jonathan M. Shillingford, Nikki Parker, Melissa Nelson, Jer-
emyF.Vaughn,Albert Felten, YingjuanLu, JosephA.Reddy, IontchoR.Vlahov,
Christopher P. Leamon. Endocyte, Inc., West Lafayette, IN.
With the development of molecularly-targeted therapeutics, it is critical to
have a reliablemethod for predicting response to therapy of patients with target-
expressing diseases. Folate receptor (FR) is overexpressed in a number of disease
states while it is low inmost healthy individuals with the exception of the kidney.
FR-targeted small molecule drug conjugates (SMDCs) are currently under de-
velopment and have shown promising pre-clinical and clinical results. Two
premises that a patient would respond to the folate-drug conjugates are: 1). FR
protein expressed in diseased tissues is functionally competent for folate binding
and 2). functional FR is accessible to intravenously-infused SMDCs. Although
anti-FR antibody-based immunohistochemical (IHC) assays are being devel-
oped as companion diagnostic strategies for antibody-drug conjugate (ADC)
therapies, it fails to address the functionality and accessibility of FR in an in vivo
context. To circumvent these limitations, we have developed an FR-targeted,
crosslinkable smallmolecule reporter conjugate (SMRC), FRRC,which contains
three modules: 1. a high-affınity folate ligand that binds with FR on diseased
cells; 2. a small hapten, FITC, which can be detected by anti-FITC antibodies;
and 3. an amino acid spacer in between these two modules that can crosslink
FRRC to FR in-situ during formalin fıxation. After intravenous (i.v.) injection,
FRRCwould dock to the accessible and functional receptors in vivo. By process-
ing biopsied tissues and performing anti-FITC IHC staining, we can evaluate the
cellular localization and relative abundance of functional FR in heterogeneous
tissues. To evaluate our design, we synthesized a compoundwe refer to as FRRC
and examined its properties both in vitro and in vivo. By testing FRRC in cell
lines, we found that it can bind to FR and is detected in formalin-fıxed cells by
anti-FITC immunostaining. To validate this assay in vivo, FRRCwas injected via
the tail vein into mice bearing FR-positive KB tumor xenografts and its specifıc
accumulation and kinetics in tumor and other tissues were evaluated by per-
forming anti-FITC IHC staining on formalin-fıxed paraffın embedded tissues.
Our resultswere shown to be in agreementwith previous folate-based functional
FR imaging and bio-distribution studies. In contrast, EC17, which lacks the
crosslinkable spacer module, showed signifıcantly reduced binding in in vitro
and in vivo assays. Owing to its modular design, additional SMRCs with differ-
ent ligands and small haptens (rhodamine, DNP) have also been designed to
assess the functional binding of other receptor and membrane-expressed pro-
teins. In conclusion, our assay is an effective tool for evaluating functional and
accessible receptor expression in vitro and in vivo, and has the potential to be
useful in patient or disease selection for our SMDC therapeutics.
#4018 Identifying allosteric modulators of KRas using second harmonic
generation. Elizabeth Donohue Vo,1 Gabriel Besserer Mercado,2 Patrick Alex-
ander,3 Ben Moree,2 Que Van,3 Andrew G. Stephen,3 Joshua Salafsky,2 Frank
McCormick1. 1UCSF, San Francisco, CA; 2Biodesy, Inc., South San Francisco,
CA; 3Frederick National Laboratory for Cancer Research, Frederick, MD.
The Ras protein family consists of small GTPases that are critical signaling
transducers regulating cellular processes including proliferation, differentia-
tion, and survival. As monomeric GTPases, Ras proteins cycle between an inac-
tive GDP-bound state and an active GTP-bound state. Oncogenic mutations in
one of the Ras isoforms, H-, N-, and K-Ras, impair GTP hydrolysis, thus de-
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regulating Ras signaling. Ras mutations are found in one-third of human can-
cers, and tumors bearing these mutations are notoriously diffıcult to treat. Con-
ventional approaches to inhibit Ras with small molecules have been largely
unsuccessful leading many to characterize the Ras family as an “undruggable”
target. However, there is renewed enthusiasm towards Ras drug discovery in
response to a recent surge of reports revealing structural complexities to Ras
proteins that provide opportunity for innovative drug discovery efforts. In light
of fındings suggesting KRas contains transient and dynamic binding pockets,
many of which are undetectable with traditional structural techniques, we used
a second harmonic generation (SHG) platform to screen a 2700 chemically
diverse fragment collection for allosteric modulators of KRas. This high
throughput SHGplatform enables real-timemeasurement of protein conforma-
tional change under physiological conditions. We selected 50 fragments for
validation by SPR, and positive binders will be selected for structural and bio-
chemical characterization. Another advantage of the SHG platform is that we
canmonitor the conformational dynamics of fully processed, farnesylated KRas
bound to a phosphatidylserine-enriched membrane that mimics KRas’ physio-
logical interaction with the plasma membrane. No other biophysical method is
suitable to monitor the real-time interactions of small molecules or proteins
withmembrane-boundKRas. This analysismay reveal surface contacts unavail-
able in solution-based assays.We have successfully implemented SHG as a drug
discovery platform against KRas, and we aim to utilize selected KRas conforma-
tional modulators towards the identifıcation of novel binding pockets and to-
wards the development of targeted KRas therapies.
#4019 A PCR-bias free capture-based library preparation platform per-
mitting highly accurate and sensitive CNA detection in tumor molecular
profıling and liquid biopsy. Anna Vilborg,1 Yosr Bouhlal,1 Ryan Koheler,1
Daniel Mendoza,1 Federico Goodsaid,1 Yannick Pouliot,1 Austin So,1 Francisco
De La Vega,2 Hanlee Ji3. 1TOMA Biosciences, Foster City, CA; 2TOMA Biosci-
ences, Stanford University, Foster City, Palo Alto, CA; 3Stanford University, Palo
Alto, CA.
Next Generation Sequencing is increasingly implemented as a diagnostic test
to identify actionablemutations in cancer patient samples. However, for routine
diagnostics, tumor DNA is extracted from formalin-fıxed, paraffın-embedded
(FFPE) samples, which yields low quantity of damaged DNA. Inability to accu-
rately repair the ends of these DNA fragments impairs adapter ligation by stan-
dard double stranded ligation methods. The resulting low yield of adapter-li-
gated DNA introduces the need for whole-genome PCR amplifıcation prior to
target capture. The drawback of such PCR amplifıcation is the introduction of
PCR biases, causing reduced sensitivity in the detection of copy number altera-
tions (CNAs), an important biomarker for targeted therapy. To address the need
for a library preparation platform that performs well with low quality and quan-
tity DNA, and without relying on massive PCR amplifıcation, we developed an
improved, in-solution, version the OS-Seq targeted enrichment assay. OS-Seq
circumvents the reliance on PCR amplifıcation by using a single-stranded
adapter ligation approach. Damaged bases induced by formalin fıxation are
removed by excision instead of attempting repair, and then DNA is denatured
prior to adapter ligation. This method of adapter ligation result in yields of
50% for low quality samples, eliminating the need for whole genome PCR.
OS-Seq directly uses the adapter-ligated DNA in a linear targeted primer-exten-
sion, followed by low-cycle post-capture PCR expansion with Illumina bridge-
PCR primers prior to library sequencing. We investigated the PCR duplication
rate of the OS-Seq libraries by including an 11-mer random barcode to track
unique molecules. We found that most input molecules were present in the
sequencing reads at only one copy. Further, we demonstrate a linear correlation
between the amount of DNA input (ranging from 1 to 600 ng) and the number
of unique molecules sequenced (R20.94). Importantly, we show that this low
PCR bias allows OS-Seq to detect CNAs in Coriell and Horizon Diagnostic cell
lines highly concordant to digital PCR detection (R20.96). Further, we present
CNAcalling on cell lineDNAsonicated to 200 bp fragments at 10 ngDNA input,
mimicking cell-free DNA. In addition to CNA detection, OS-Seq detects SNVs
with a sensitivity of 92-97% and a specifıcity of 100% down to 5% VAF. In
conclusion, the OS-Seq library preparation method relies on single stranded
adapter ligation and in-solution target capture, which generates uniform cover-
age with minimal PCR requirement, resulting in highly sensitive CNA calling.
#4020 Identifıcation and characterization of Novel MYC and p53 target
molecules frommedicinal plants of North East India. Sora Sandhya,1 Joyeeta
Talukdar,1 Bidisha Pal,2 Seema Bhuyan,1 Debabrat Baishya,3 Bikul Das2. 1Ka-
viKrishna Laboratory, Guwahati Biotech Park, IIT, Guwahati, India; 2Forsyth
Institute, Cambridge, MA; 3Gauhati University, Guwahati, India.
Background: Identifıcation and characterization of novel molecular inhibi-
tors that target key regulators of cancer stem cell (CSCs) self-renewal is prom-
ising in cancer therapeutics. MYC and p53, the two major cellular transcription
factors, acts as key molecular regulators in stem cells and cancer stem cells
self-renewal. While MYC enhances, p53 inhibits the self-renewal of stem cells.
Thus, developing novel molecules that could potentially target either MYC and
or p53 might potential therapeutic application. However, the search for small
molecules that could target the self-renewal aspect of these twoproteins has been
elusive. Previously; we demonstrated that isoprenoid molecule squalene could
enhance bone marrow hematopoietic and mesenchymal stem cells (MSCs) by
modulating MYC. Importantly, we found that ursolic acid, an isoprenoid mol-
ecule found inTulsi plant, inhibitedHIF-1alpha, a transcription factor regulated
by MYC and p53. Hence, having these prior experiences on isoprenoids, we
speculate that novel isoprenoid may exist that could modulate MYC’s role in
cancer self-renewal.We are especially interested in identifying novel isoprenoid
molecules (metabolites of mevalonate pathway) found in medicinal plants of
North East India, where KaviKrishna laboratory is located. Methods: For the
study, we proposed to develop an in vitro self-renewal based assay platform-
(henceforth known as STEM-TECH platform) to identify novel molecules that
act on self-renewal aspect of MYC and p53. In this assay, we subjected the oral
cancer cell line SCC-25 to 3-D tumoringeic growth using methylcellulose based
method. Using this assay, we have screened 20 herbal extracts of North East
India, and selected 3 herbal extracts for further evaluation. For the in vivo study,
we added these herbal extracts to drinking water of C57BL/6 mice treated with
4NQO (an oral carcinogen) and FVB/N mice with MYC-induced thymic lym-
phoma. The mice were observed for 10 weeks and subjected to evaluation of
tumor growth, and also evaluation of cancer stem cells using ABCG2, a cell
surface marker expressed by cancer stem cells. Results: We found that herbal
extracts from Tulsi and Soalu exhibited strong anti-tumor activity in the in vivo
mouse models. Importantly, these extracts exhibited the ability to inhibit the
self-renewal of MYC driven ABCG2 cancer cells (1). Also, these extracts were
then subjected to in vitro Stem-Tech assay and we found that one herbal extract
couldmodulate the transcriptional binding ofMYC. Importantly, we found that
squalene, an isoprenoid found in several herbal extracts in NE India couldmod-
ulate MYC activity by an unknown mechanism. Conclusion: Our results indi-
cate that the vast, untapped herbal plants available in India’s remote North East
contain valuable herbal medicinal plant having potential MYC inhibitor. 1. Das
B et al. MYC through HIF-2alpha regulates the self-renewal program in cancer
stem cells (under review).
#4021 Donor-specifıc primary monocyte-derived dendritic cell matura-
tionmodel for high-throughput screening of immunostimulatory adjuvants.
QinChen,1 Anthony Lawrenz,1 AlanWang,1 ErinKelly,1 ErinHarberts,2 Robert
K. Ernst,2 Jay Tong1. 1AllCells, Alameda, CA; 2University of Maryland-Balti-
more, Baltimore, MD.
Dendritic cell (DC) based immunotherapy is a promising treatment alterna-
tive for various solid tumor and hematological malignancies. DCs are capable of
initiating and propagating antigen-specifıc adaptive immune responses through
their intrinsic maturation process. Identifying novel, effective adjuvant drug
candidates that can stimulateDCmaturationwhile understanding and account-
ing for the variability of patient-specifıc DC cell responses to the immunostimu-
latory adjuvants is essential for development of such immunotherapies. Reliable,
high throughput assay platforms that characterize patient-specifıc modulatory
effects during the DC maturation process in vivo and in vitro are also highly
desirable. In this study, we present a high throughput in vitro primary cell assay
to evaluate dose-dependent DC maturation in a panel of human leukocyte an-
tigen (HLA) typed individual donors. CD14 monocytes from four healthy
donors were isolated from leukapheresis derived peripheral bloodmononuclear
cells (PBMC) and cultured for seven days with GM-CSF and IL-4 to achieve
differentiation to DC. Cells were then stimulated for 24 hours with lipopolysac-
charide (LPS), CpG oligonucleotides, or nine different novel toll-like receptor 4
(TLR4) ligands at three concentrations. To quantify the differentiation ofmono-
cytes into DC and subsequent maturation, flow cytometry was used to measure
the expression of biomarkers, MHC-II, CD40, CD80, CD83, and CD86. Greater
than 99% MHC-II expression was observed across all donors and confırmed
successful differentiation to DC. The TLR4 ligands showed reduced biomarker
expression, as compared to pathogenic E. coli LPS but similar to PHAD, a syn-
thetic TLR4 agonist currently used in adjuvants. While monocytes from all do-
nors responded to the ligands tested, the intensity of activation marker expres-
sion varied among donors with LPS/TLR4 ligand induced maturation process
showing 43-91%CD40 and 27-82%CD83 expression, highlighting the necessity
of multi-donor screening for drug development. In conclusion, a high through-
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put in vitro primary monocyte derived DC differentiation assay has been devel-
oped and is commercially available to assist researchers in characterizing donor-
specifıc DC responses to immunostimulatory adjuvants.
#4022 Validation of label-free impedance analysis as a versatile tool for
cancer molecular therapeutics screening. Fabio Cerignoli, Biao Xi, Brandon
Lamarche, Leyna Zhao, Yama Abassi. ACEA Biosciences Inc., San Diego, CA.
In vitro monitoring cancer cells response to treatment often involves labori-
ous sample processing and collects single data points that are against the dy-
namic nature of cancer cells. Here we present the adaptation of an impedance-
based methodology to dynamically monitor cancer cell behavior and
therapeutic response. The technology detects cell death, proliferation or migra-
tion by measuring changes in conductance of microelectrodes embedded in 96
and 384-wells cell culture plates. It avoids sample labeling and processing and
allows continuous monitoring of cell response. Our data shows validation with
cancer cell lines and primary cells monitored for cell invasion/migration, anti-
cancer drug response and receptor signaling activation, with similar results over
end point assays. Easy experiment set up and minimal sample processing make
the technology ideal for applications in large screening campaigns, while label-
free technology allows further analysis on the same samples through orthogonal
assays.
#4023 The SABRE platform: A novel, unbiased technology for drug dis-
covery and prioritization. Shelli M. Morris,1 Andrew J. Mhyre,1 Savanna S.
Carmack,1 Connor Burns,2Marc Ferrer,3Wenjuan Ye,3 JamesM. Olson,1 Rich-
ard A. Klinghoffer2. 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2Presage Biosciences, Seattle, WA; 3NIH/NCATS, Rockville, MD.
Targeted therapies designed to inhibit hyperactive oncogenic signaling have
demonstrated some encouraging clinical responses. However, most of the time
these responses are not durable as tumors “work around” pathway inhibition,
often reactivating the inhibited pathway, leading to drug resistance and disease
relapse. New technologies that enablemore effıcient discovery and development
of “suites” of drugs that comprehensively inhibit multiple pathway nodes are
needed. The SABRE (Splice Acceptor Brilliant Reporter) platform was devel-
oped to provide an unbiased method to screen large compound libraries and
dramatically improve the speed and effıciency of which novel targeted therapeu-
tics can be identifıed. SABRE is built off the premise that oncogenic output is
exerted through changes in gene transcription and that such changes can be
harnessed as powerful reporters of pathway activation status. SABRE utilizes the
power of gene trap technology coupled with a drug selection process to isolate
cells that generate a robust “off to on” signal in response to target or pathway
inhibition. Via massively parallel comparative analysis, multiple traps let nature
provide the best reporter for further analysis and drug discovery. In this proof-
of-concept study, we employed the SABRE technology to identify insertion sites
that are specifıcally regulated by the MAPK pathway. Experiments were per-
formed using the human BRAFV600Emutantmelanoma cell line A375. SABRE
lentiviral transduced A375 cells were treated with trametinib, a MEK inhibitor,
and clones were isolated that emitted a positive luciferase signal upon drug
treatment. To determine if these reporters were MAPK pathway specifıc, the
platform was miniaturized to a 1536 well format and used to screen a 6000
compound library. Results from the screen found that 70% (28/40) of the top
drug hits were known to directly modulate the MAPK pathway. Since drug
resistance is a common occurrence in melanoma, we generated a “resistant”
A375 SABRE reporter line to increasing concentrations of vemurafenib and
interrogated the top drug candidates identifıed in the screen. As expected, the
resistant SABRE line failed to respond to BRAFV600E specifıc inhibitors but
continued to respond to downstream MEK inhibitors, which is helping to de-
lineate the mechanism of resistance. We were also interested in the screening
hits that were not previously known to influence the MAPK pathway including
bafetinib and a Tie2 inhibitor. In follow-up testing, we found that these drugs
induced robust and titratable reporter signals in both the SABRE A375 vemu-
rafenib sensitive and resistant lines. In addition, treatment of either bafetinib or
the Tie2 inhibitor reduced ERK phosphorylation in the vemurafenib resistant
cells, suggesting that these drugs could be useful in the treatment of drug resis-
tant melanomas. Studies are currently underway to determine the in vivo effı-
cacy of these drugs in A375 SABRE reporter xenograft models.
#4024 Physiologically relevant target engagement using the cellular ther-
mal shift assay (CETSA). Jakob Karen, Catrine Sioberg, Nancy Dekki Shalaly,
Daniel Martinez Molina. Pelago Bioscience, Stockholm, Sweden.
Targeted therapies are dependent on adequate occupancy and target engage-
ment to reach their effıcacy measure. Yet, more than half of novel candidate
drugs entering clinical trial stage fail before proof of concept is achieved. Inad-
equate target engagement is often at the root cause of these failures. Therefore,
we have developed a versatile label-free method to quantify the target engage-
ment of drugs on their native physiological relevant targets. The method is
validated in multiple sample matrices, using different technical platforms to
allow studies of target engagement from bench to bedside: in living cells and
tissue from rodents and man. CETSA(®) is a patented biophysical method mea-
suring the thermal stability of drug target proteins and the shift induced by their
ligands. By quantifying the melting temperature and shift induced by the ligand
we can quantify the potency of target engagement. This potency determination
allows fıltering of candidate drugs by their ability to engage the target in its
physiologically relevant form, in relevant sample formats such as intact cells or
tissue. We present several applications of the method and the utility in preclin-
ical in vitro studies and translation to in vivo systems. In addition, new powerful
detection formats are being evaluated and will be presented. The utility and
value of the CETSA(®) method enabling preclinical development of novel drugs
is substantiated by the examples included here.We show the value of themethod
both for compound/drug profıling, for target profıling and for unbiased drug
profıling on whole proteomes in response to drug treatments. Such datasets can
be generated from in vitro systems to clinical samples and may reduce the high
attrition rate in proof of concept studies by facilitating the discovery, develop-
ment and evaluation of novel drugs.
#4025 Accelerating drug repurposing for cancer therapy using multi-
plexed viability assays. Steven M. Corsello,1 Christopher C. Mader,2 Jordan
Bryan,2 Jennifer Roth,2 David Peck,2 JohnDavis,2 Samantha Bender,2 LiWang,2
Alice Wang,2 Joshua Bittker,2 Francisca Vazquez,2 Aravind Subramanian,2
Aviad Tsherniak,2 Todd R. Golub2. 1Dana-Farber Cancer Institute, Boston, MA;
2Broad Institute, Cambridge, MA.
New therapies are desperately needed for patients with advanced cancer, but
making safe and effıcacious drugs remains expensive and time consuming.
Meanwhile,multiple non-oncology drugs have been successfully repurposed for
cancer, including thalidomide for multiple myeloma and aspirin for prevention
of colorectal cancer.While the benefıts of repurposing are clear, successes to date
have been largely serendipitous. We have created two foundational tools to
identify drug repurposing opportunities at a much greater scale: a new world-
class screening library of more than 4,000 drugs/clinical candidates and a mul-
tiplexed method to rapidly conduct cellular viability assays across hundreds of
cell lines. PRISM, a recently developed high-throughput assay, employs DNA-
barcoded cell lines to enable rapid testing of many drugs against pools of cancer
cell lines. We have tested 4,100 compounds against 578 genomically character-
ized cancer cell lines using PRISM. Our experiment is among the largest cell line
screens ever undertaken. Global analysis has revealedmultiple strong clusters of
active drugs, including vitamin D agonists, bromodomain inhibitors, and st-
atins. In addition, many novel and established drug-biomarker relationships
were identifıed, including alkylating agent response and lowMGMTexpression,
BRAF inhibitor response and BRAF mutation, and MDM2 inhibitor response
and TP53 wild-type status. Surprisingly, more than 100 non-oncology drugs
unexpectedly killedmultiple cancer cell lines, making them attractive repurpos-
ing candidates. For example, the FDA-approved phosphodiesterase inhibitor
anagrelide selectively kills PDE3A-high lung cancer and melanoma cell lines.
Confırmatory experiments are underway to validate screening results, evaluate
putative biomarkers, and test drug activity in preclinical models. Importantly,
this approach is expected to enable rapid initiation of clinical trials, dramatically
accelerating patient access to potential new therapies.
#4026 Bioluminescent metabolite assays enable easy measurement of
changes in tumor biology.Michael Valley, Mary Sobol, Donna Leippe, Jolanta
Vidugiriene. Promega Corp, Madison, WI.
Tumor cells rely on metabolic reprogramming to meet their increased de-
mands for energy and biomass. Such reprogramming is exemplifıed by in-
creased rates of glucose uptake, greater utilization of glycolysis, and a reliance on
glutaminolysis. Cancer cells also have a strong dependence on lipids and cho-
lesterol and thus feature enhanced rates of biosynthesis and uptake of these
molecules as well. We have developed a suite of bioluminescent assays that can
monitor metabolites in all of these important pathways. These assays share a
core technology that couples the production of NAD(P)H to the generation of
light through a variety of metabolite specifıc dehydrogenases. Changes in glyco-
lysis and glutaminolysis can be followed by measuring glucose, lactate, gluta-
mate, and/or glutamine through their respective dehydrogenases (and glutam-
inase). Glucose uptake is typically monitored through the accumulation and
phosphorylation of 2-deoxyglucose to produce 2-deoxyglucose-6-phosphate,
and this can be measured by employing glucose-6-phosphate dehydrogenase.
These bioluminescent assays are homogeneous and can be multiplexed with
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viability, cytotoxicity, and protein quantitation assays. Metabolites can be mea-
sured extracellularly (i.e. from media) or intracellularly and the assays can be
performed in 96- or 384-well plates. These assays are simple and sensitive and
can provide a greater understanding of how various treatments affect the meta-
bolic state of a tumor cell.
#4027 Developing biophysical platforms to study KRASmembrane inter-
action in artifıcial membranes. Frantz L. Jean-Francois, Andrew G. Stephen.
Frederick National Lab, Frederick, MD.
In our studies, we leverage the techniques that we believe will allow us to better
understand and tackle KRAS membrane interaction. RAS proteins are small GT-
Pases that oscillate between an activeGTP-bound and inactiveGDP-bound state to
function as plasma membrane localized molecular switches in growth factor regu-
lated signalingpathways.Mutation inHRAS,KRASandNRASarepresent innearly
30% of human tumors. In particular, KRAS ismutated in almost 90% of pancreatic
adenocarcinomas.Considering the requirementof theplasmamembrane forKRAS
activity, we are setting up ’screenable’ biophysical platforms to understand the im-
portance of lipids and fınd small molecules that could prevent KRAS membrane
association in reconstituted systems. The twomain techniques that are being devel-
oped are Surface Plasmon Resonance and Confocal Imaging inmodelmembranes.
Using these two techniques, we have been able to better understand themain lipids
thatdriveKRASmembraneassociationandsetupplatforms that canbe screenedby
small/large molecules. Biophysical techniques are frequently used by pharmaceuti-
cal companies as primary or secondary screening platforms. Developing such plat-
forms for KRAS membrane interaction could enable the discovery of anti-cancer
tool compounds.
#4028 Analysis and recovery of functionally defıned single immune cell
clones through opto-electro-positioning technology. Xiaohua Wang, Yelena
Bronevetsky, Kristin Beaumont, Guido Stadler, Xiaoyan R. Bao, Duane Smith,
Peter Beemiller, Kevin Chapman. Berkeleylights Inc, Emeryville, CA.
Cancer patientsmount protective innate and adaptive immune responses against
tumor cells. Such responses are able to control or even eliminate tumor burden if
harnessed properly. Identifying clonal adaptive immune cells targeting tumor cells
with designated function is extremely valuable as these cells are able to either fıght
the tumor directly or provide tumor targeting immune receptors to engineer other
effector cells like autologousCD8Tcells orNKcells. The process of isolating cancer
specifıc immune cells and their receptors, however, remains technically challenging
and labor intensive. Opto-Electro-Positioning (OEP) technology employs a light
actuated dielectrophoretic force tomaneuver live cells in their culture environment.
We have combined OEP with a nanofluidic cell culture system to produce an inte-
grated microfluidic platform that enables multi-dimensional investigation of lym-
phocyte specifıcity and function. The system is able to 1) deterministically capture
designated lymphocytes, 2) actively maintain and observe colony growth, and 3)
conduct cytokine release assays, all in a single enclosed microfluidic chip. The new
platform is suitable for high throughput screening to identify and harvest antigen
specifıc and/or functionally defınedT cells.Wehave successfully applied it to isolate
primary humanT cells targeting either EBV/Tetanus toxin antigens or tumor asso-
ciated antigens such asMART-1 through tetramer staining or a proliferation assay.
The systemisalsoexceptionally effıcient for investigating immunecells fromclinical
specimens typically of low cellularity. From tumor biopsies, we are able to capture
tumor infıltrating T cells, stimulate proliferation, investigate their TNF- secretion
on chip, and obtain full transcriptomic analysis after export. Overall, our data sug-
gest the OEP nano-fluidic environment provides a powerful high throughput
screening tool to identify rare lymphocytes against tumor associate antigens or neo-
antigens and to investigate precious clinical samples for biomarker discovery.
#4029 Robust Ras inhibition assay utilizing fully synthetic Ras-binding
domain. Lyuba Khavrutskii, Sergey G. Tarasov, Colin Fields, Karen Stefanisko,
Nadya Tarasova. NCI-Frederick, Frederick, MD.
Intensifying efforts to develop clinically useful inhibitors of Ras proteins re-
sulted in increasing need for quantitative, reliable and robust in vitro assays of
Ras activity. The vast majority of detection methods used in the assays require
fusion, chemical modifıcation or immobilization of the protein. We have found
that K-Ras modifıcations have signifıcant impact on its activity and function
because of the highly allosteric nature of the protein. We have attached three
different fluorescent moieties to two sites distant from the active site of the
protein in a site-selective manner. All six modifıcations resulted in signifıcant
drops in affınity towards Ras-binding domain of one of Ras’s major effectors
c-Raf as determinedbyMicroscaleThermophoresis (MST). Fluorescent labeling
of recombinant Raf1 RBD also resulted in inhibition of K-Ras binding. To pro-
duce a pair that interacted as unlabeled proteins, we have generated RBD with a
single-site attached fluorescent moiety utilizing microwave-assisted high effı-
ciency solid phase peptide synthesis. Optimization of coupling and deprotection
protocols and the type of the solid support allowed conducting the synthesis of
76 residues long protein in fully-automatedmanner in one run. Refolding of the
product yielded RBD that was indistinguishable from the recombinant one in
CD spectra, melting temperature and K-Ras binding affınity as determined by
isothermal calorimetry and microscale thermophoresis. Fluorescent RBD pro-
duced signifıcant changes in both thermophoretic signal and fluorescence an-
isotropy upon binding to K-Ras. BothMST and fluorescence polarization assays
have proven sensitive, reproducible and straightforward for determination of
Ras inhibition constant for Ras inhibitors identifıed by virtual screens and ra-
tional design. They can be easily adapted to high throughput screening formats.
Developed synthetic protocols allow for straightforward generation of proteins
with various natural and non-natural modifıcations.
#4030 Celsee™ SingleCell Chip can retrieve rare single cells with 100%
effıciency for genetic analysis. Kalyan Handique, Priya Gogoi, William Chow,
Kyle Gleason, Auston Payne, Vishal Premdev Sharma, Yixin Wang. Celsee Di-
agnostics, Inc, Plymouth, MI.
Tumors are comprised of heterogeneous cells. Only a specifıc or rare popula-
tion of tumor cells is capable of metastasizing through blood. While mapping
out the genome of cancer cells, gene expression variations indicative of more
aggressive cancer cells might be missed among the noise. Therefore, single cell
gene expression andmutation analysis provide amore comprehensive andmost
precise information about the heterogeneity of cancer progression and metas-
tasis. Although there has been a surge in technologies used for selection and
analysis of single cells, single cell analysis of rare cells such as circulating tumor
cells (CTCs) is fraught with technical challenges. Amongmany used techniques
to isolate single cells, the most common cell separationmethod is cell sorting by
flow cytometry, which requires cell labeling. The numerous steps involved in cell
labelling and centrifugation result in signifıcant cell loss and changes in gene
expression. In addition, centrifugation may also cause shear-induced gene ex-
pression changes in viable cells. For other single cell analysis platforms, there is
a minimum input of cells ranging from 200 - 1000 cells. Rare cells like CTCs are
found in the range of 1-10 per mL of blood. Another challenge is that the input
volume required for these systems is very low usually in microliters. Here, we
introduce a novel microfluidic chip with 250,000 microwells which captures
cells at 100% effıciency down to one cell with a dynamic range over 5 logs. The
underlying principle of this technology is that the geometric pattern of the mi-
crofluidic chip captures a single cell from an initial volume of up to 1mL of fluid
due to cell settling. The unique microwell structure promotes easy fluid ex-
change without perturbing the cells from their captured locations, thereby elim-
inating cell loss duringmultistep downstreamprocessing. Preliminary tests have
shown that single or cluster of spiked cancer cells in blood can be immuno-
stained, both live or fıxed and can also be retrieved very effıciently from this chip
using a micro capillary. The retrieved single cells can further be used for several
single cell genetic analysis. We will present data describing cancer gene expres-
sion and gene mutation analysis in isolated single cells.
#4030A S-PLEXSM Troponin I assay with fg/mL sensitivity. Anahit Agh-
vanyan, Louis Gardner, Animesh Shukla, Thomas Miller, Su Wang, Sheldon
Grove, Andrew Chow, Jessica Suschak, SarahWheeler, AnuMathew,Martin K.
Stengelin, Jacob N. Wohlstadter.Meso Scale Diagnostics, LLC, Rockville, MD.
Cardiovascular toxicity is a potential complication of multiple anticancer
therapies. Some drugs, such as anthracyclines, have been implicated in irrevers-
ible cardiac dysfunction. Cardiac troponin is a specifıc and sensitive marker of
myocardial injury. Serum and plasma concentrations of troponin are often be-
low the limits of detection in apparently healthy individuals. Sensitivity of tro-
ponin assays has improved by two orders of magnitude over the last several
years, but few assays can detect basal levels of serum troponin inmore than 50%
of apparently healthy individuals, limiting the utility of the assay for early detec-
tion of low levels of cardiac damage. S-PLEX is a novel ultrasensitive immuno-
assay platform based on MSD’s MULTI-ARRAY® electrochemiluminescence
technology. An S-PLEX cardiac troponin I assay was developed and analytically
characterized for research use. Serum and plasma samples from 24 apparently
healthy individuals, 90 individuals with cardiovascular complications, and 25
individuals receiving anthracycline chemotherapy were measured. The assay
required 25Lof sample permeasurement andwas run on theMESO® SECTOR
S 600 and MESO QuickPlex® SQ 120 instruments. The lower limit of detection
was determined to be 10 fg/mL and the limits of quantitation ranged from 31
fg/mL to 160,000 fg/mL. The assay was anchored to the NIST referencematerial
SRM 2921. Control samples run at 3 levels (n8 per plate, 8 plates, 2 days, 2
operators) had total CVs of 7% to 8% (n64). Spike recovery and dilution
linearity had recoveries between 80% and 120%. Specifıcity of the assay was
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demonstrated by analyte depletion using several commercially available anti-
troponin specifıc antibodies. There was no detectable cross-reactivity to skeletal
troponin. As expected, troponin I serum or plasma concentrations were high
(10,000 fg/mL to 160,000 fg/mL) for 90 individuals with cardiovascular
complications. Troponin I serum concentrations in 25 samples from individuals
receiving anthracycline chemotherapy had amedian concentration of 306 fg/mL
and a range of 10 to 5,820 fg/mL, comparable to a set of apparently healthy
specimens (n24) with a median concentration of 226 fg/mL and a range of
10 to 4,330 fg/mL. The S-PLEX troponin I assay was capable of detecting
troponin in 44 of the 49 samples from individuals with no known cardiovascular
disease. In conclusion, we have developed a highly specifıc and sensitive cardiac
troponin I assay that is capable of accurately measuring the cardiac troponin I
protein concentration in samples from individuals with known cardiovascular
disease, as well as 90% of the apparently healthy individuals tested. This assay
can be used to study low levels of cardiac troponin I in serum and plasma
samples and may provide a useful research tool for the detection of cardiac
troponin I, a biomarker linked to cardiac damage.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Combination Therapies and Approaches to Sensitize Cancer Cells
to Drugs
#4031 Mutant isocitrate dehydrogenase 1 (IDH1) inhibitor synergistically
prolongs animal survival with standard therapies in patient-derived IDH1
mutant glioma xenograft mouse models. Mari Kogiso,1 Lin Qi,1 Huiyuan
Zhang,1 Frank K. Braun,1 Yuchen Du,1 Yulun Huang,1 Holly Lindsay,1 Sibo
Zhao,1 Sarah G. G. Injac,1 Zhen Liu,1 Patricia A. Baxter,1 Jack M. Su,1 Laszlo
Perlaky,1 D. Williams Parsons,1 Murali Chintagumpala,1 Adekunle Adesina,1
Jialiang Wang,2 Yongcheng Song,1 Xiao-Nan Li1. 1Baylor College of Medicine,
Houston, TX; 2Vanderbilt University Medical Center, Nashville, TN.
Background:Mutation in isocitrate dehydrogenase 1 (IDH1) occurs in 70%of
WHO grades II and III astrocytomas and oligodendrogliomas and secondary glio-
blastoma (GBM). Themutant enzyme catalyze the reduction of-ketoglutaric acid
toD-2-hydroxyglutaric acid, leading to cancer initiation. In this study,we examined
the therapeutic effıcacy of SYC-435 (1-hydroxypyridin-2-one), a newly developed
mutant IDH1inhibitor, both in vitro and in vivo in IDH1mutant gliomas as com-
pared with IDH1 wild type GBMs. Methods: An established neurosphere line
(BT142) of anaplastic oligoastrocytoma (AOA), and a patient-derived orthotopic
xenograft (PDOX)model of recurrentAOA(IC-V0914AOA), and2PDOXmodels
ofGBM(IC-4687GBMandIC-3752GBM)were included. IDH1mutations (R132H
andR132C)were analyzed by pyrosequencing. To determine the in vitro antitumor
activities, tumor cells were exposed to SYC-435 (0.02 to 20M) and examining for
changes of cell proliferation every 3-4 days till day 13 by Cell Counting Kit-8 assay.
For in vivo effects, orthotopic xenograft mouse models of IC-BT142AOA and IC-
V0914AOAwere treatedwith vehicle (as control), SYC-435 (i.p., 15mg/kg/day x 28
days), temozolomide (TMZ, oral, 50 mg/kg/day x 5 days) fractionated radiation
(XRT, 2 Gy/day x 5 days) (as standard therapy), and combination of SYC-435 with
standard therapy starting 2 weeks after intracranial tumor implantation. Animal
survival times were analyzed by log rank analysis. Results: IDH1 R132H mutation
(homozygous) was detected in BT142AOA neurosphere line and R132Cmutation
(mutant allele frequency 39-42%) in IC-V0914AOA xenograft cells, while the two
GBMmodels (IC-4687GBM and IC-3752GBM) carried wild-type IDH1. Suppres-
sion of cell growthwas observed in time- and dose-dependentmanner by SYC-435,
particularly at the IDH1mutantmodels. At 0.5M, SYC-435 inhibited cell growth
by 90% inBT142 and60% in IC-V0914AOAcells, whereas in IDHwild-typeGBMs
onlyby17%in IC-4687GBMand19%in IC-3752GBMcells atday13, indicating the
high selectivity of SYC-435 ofmutant overwild type IDH1. Systematic in vivo treat-
mentwith SYC-435 alone did not alter survival times in neither IC-BT142AOAnor
IC-V0914AOAmodelswhen comparedwith the control group.Although standard
therapy signifıcantly prolonged animal survival times in both models (P0.0005),
combining SYC-435 with standard therapies further extended the median survival
times from 106 days (in the standard therapy group) to 124 days (P0.05) in IC-
V0914AOA and exhibited similar trend in IC-BT142AOA. Conclusion: SYC-435
possesses antitumor effects that are highly selective in IDH1 mutant gliomas, and
generated strong synergistic activities with standard therapies in vivo. Our data
support the clinical testing of SYC-435 in patients with IDH1mutant glioma.
#4032 Synergistic effects of Bortezomib and JQ1 for human and canine
osteosarcoma treatments. Ya-Ting Yang, Vilma Yuzbasiyan-Gurkan. Michi-
gan State Univ., East Lansing, MI.
Osteosarcoma (OS) is the most common primary malignant bone tumor of
both humans and dogs, with the incidence in dogs being nearly 15 times that
observed in humans. Despite advances in treatment of other cancers, the clinical
outcome of OS remains poor for the past several decades. Therefore, identifying
novel and effective treatments for osteosarcoma is an urgent need. Among the
small molecular compounds we tested in a drug screening study, we identifıed a
bromodomain inhibitor (JQ1) that targets bromodomains which modify chro-
matin and block transcription of key factors, and a proteasome inhibitor that
induces cell death through various mechanisms (bortezomib) as having good
growth inhibition effects on three canine OS cell lines (D17, Abrams, and Gra-
cie) and two human OS cell lines (SAOS2 and U2OS). We then determined the
IC50 values of these two drugs, the concentration capable of inhibiting prolifer-
ation by 50%. The IC50 values of bortezomib and JQ1 are both within achievable
plasma concentrations and tolerable levels. JQ1 inhibited OS cell proliferation
and survival by inducing G2 cell cycle arrest, while bortezomib induced G1 cell
cycle arrest. In addition, these two drugs decreased cell migration ability in
wound healing assay as well as invasion ability in aMatrigel assay. Furthermore,
in combination studies using both JQ1 and bortezomib, we identifıed synergistic
effects. With these promising results from in vitro studies, we further examined
JQ1 as therapeutic agent in an orthotopic tumor xenograft mouse model. Using
OS cells stably transfected with a lucerifase vector, we were able to track the
tumor progression during the treatment period. Mice treated with JQ1 did not
show any signs of adverse effect to the drug, indicating that JQ1was safe andwell
tolerated at a daily dosage of 50mg/kg (IP).While some of themice in treatment
group showed decreasing tumor growth compared to the control group, tumor
growth trends in the two groups were not consistent, suggesting that we have to
optimize the model and the treatment protocol as well as to evaluate combina-
tion treatments with bortezomib and JQ1 in in vivo models.
#4033 CombinedMEK and BCL-2/XL inhibition as a potential drug com-
bination for the treatment of high-grade serous ovarian cancer. Claudia Ia-
varone,1 Ioannis Zervantonakis,1 Laura M. Selfors,1 Sangeetha Palakurthi,2
Joyce F. Liu,3UrsulaA.Matulonis,3 Ronny I.Drapkin,4GordonB.Mills,5 JoelD.
Leverson,6 Deepak Sampath,7 Joan S. Brugge1. 1HarvardMedical School, Boston,
MA; 2Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute,
Boston, MA; 3Dana Farber Cancer Institute, Department of Medical Oncology,
Boston, MA; 4Obstetrics and Gynecology Department, University of Pennsylva-
nia, Philadelphia, PA; 5Department of Bioinformatics and Computational Biol-
ogy, The University of TexasMDAnderson Cancer Center, Houston, TX; 6Oncol-
ogy Development, AbbVie, Chicago, IL; 7Department of Translational Oncology,
Genentech, South San Francisco, CA.
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian
cancer deaths. Despite an initial response to platinum-based chemotherapy,
treatment resistance eventually occurs in most patients. The overall aim of our
studies is to identify synergistic drug combinations for the treatment of HGSOC
and biomarkers that predict sensitivity for future translation in clinical trials. In
particular, this study focuses on the vulnerabilities of patient-derived ovarian
cancer cells to combined inhibition of the MEK pathway and the anti-apoptotic
proteins BCL-2 and BCL-XL. The Ras/MAPK pathway is activated in a subset of
HGSOCby gene copy alterations. However,MEK inhibitors have not been eval-
uated in HGSOC. In this study, we used a collection of 14 primary samples
derived from ascites cells of platinum-resistant HGSOC patients (Liu JF et al.
2016). We investigated the sensitivity of these tumor cells to the MEK inhibitor
cobimetinib (GDC-0973). Treatment with GDC-0973 had no effects on cell
viability in vitro in any of the patient-derived models. To investigate the re-
sponse to MEK inhibition, we performed Reverse Phase Protein Array of the
tumor cells treated with 0.3M of GDC-0973 in vitro. We found that MEK
inhibition by GDC-0973 reduced cell cycle progression markers and upregu-
lated the pro-apoptotic protein BIM. Sincemore than half of themodels express
high levels of anti-apoptotic BCL-2 family proteins which neutralize BIM, we
examined the effects of antagonism of BCL-2 pro-survival proteins in combina-
tionwithGDC-0973. Treatmentwith a combination ofGDC-0973 and the BCL-
2/XL antagonist, navitoclax (ABT-263) signifıcantly reduced cell number and
increased cell death in 10 out of 14 patient-derivedmodels. Protein levels of BIM
following treatmentwithGDC-0973 correlatedwith sensitivity to the drug com-
bination (R20.8 p0.0001). Interestingly, the BIM levels afterMEK inhibition
correlate with BIM protein levels before the treatment, suggesting that baseline
BIM levels could be used as biomarker of sensitivity. Levels of the pro-survival
proteinMCL-1 also played a critical role in patient-derived cells that were resis-
tant to the drug combination. Indeed, treatmentwith a specifıcMCL-1 inhibitor,
A-1210477, in combination with GDC-0973 and ABT-263 led to dramatic tu-
mor cell killing in vitro compared to dual combination of GDC-0973 and ABT-
263. Finally, we tested the combination of GDC-0973 and ABT-263 in vivo and
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preliminary results indicate that the drug combination is well tolerated and is
able to signifıcantly reduce tumor growth in patient-derived xenograft models
(n4). Our studies provide signifıcant evidence that combined inhibition of
MEK and BCL-2/XL may be an effective drug combination for treatment of
HGSOC and that the pro-apoptotic protein BIM may serve as a predictive bio-
marker to stratify patients that can benefıt from these targeted therapies.
#4035 Anovel combi-molecule engineered to target the putative synthetic
lethal interactionsbetween the epidermal growth factor receptor (EGFR) and
poly(ADP-ribose)polymerase (PARP). Zhor Senhaji Mouhri, Martin Rupp,
Bertrand J. Jean-Claude. McGill University Health Centre, Montreal, Quebec,
Canada.
Over the past decade, PARP inhibition has been actively pursued as a novel
approach for the selective therapy of tumors with BRCA1/2 mutations. The
therapeutic benefıts of PARP inhibitors have now been proven in the clinic
against BRCA1/2 mutant ovarian cancers. This is hitherto limited to BRCA1/2
mutations, which only accounts for 5-10% of all cancers with hereditary muta-
tions in the homologous recombination pathway. Therefore, new strategies are
not only required to enhance the potency of PARP inhibitors but also to expand
their use beyond BRCA mutation. While several combination modalities have
been reported for PARP inhibitors, the concept of targeted PARP inhibitor has
not yet been explored. Here using our novel combi-targeting approach, we re-
port on the design of PARP inhibitors targeted to EGFR, a tyrosine kinase re-
ceptor overexpressed in several solid tumors. Recently, reports on the relation-
ship between EGFR, PARP and BRCA have begun to emerge, one of which
described a contextual synthetic lethality between EGFR and PARP (PloS one
7.10 (2012)). Here we report on the design and synthesis of novel PARP-EGFR
combi-molecule based on structural modifıcation of olaparib as a PARP inhib-
itorwarhead and the quinazolinemoiety for targetingEGFR.The results showed
that: (a) it is capable of inducing a dose-dependent inhibition of PARP in iso-
lated enzyme assay, (b) it induced a dose-dependent inhibition of EGFR in an
isolated kinase assay, (c) it showed a dose-dependent inhibition of EGFR phos-
phorylation and downstream signaling in whole-cell assay, (d) it was selectively
potent towards BRCA2 mutant and also EGFR-overexpressing cell lines, (d) it
was extremely potentwith activities superior to that of olaparib or gefıtinib alone
and their corresponding equimolar combination in three established triple neg-
ative breast cancer cell lines, (e) subcellular distribution analysis showed that it
was abundantly localized in the perinuclear region. These results in toto suggest
that this new combi-molecule could be developed as a single drug modality
emulating the combination of PARPandEGFR inhibitorswith the added benefıt
of being targeted to EGFR-expressing tumor cells.
#4036 Induction of detrimental aneuploidy in basal breast cancer cells
treated by MPS1 inhibitors in combination with paclitaxel. Simon J. Ander-
hub,1 Grace WY Mak,2 Amir Faisal,3 Katie Walsh,2 Mark Gurden,2 Liz Day,2
Paolo Innocenti,2 Hannah L. Woodward,2 Isaac M. Westwood,2 Kwai-Ming
J. Cheung,2 Sebastien Naud,2 Angela Hayes,2 Gary Box,2 Alexis de Haven Bran-
don,2 Melanie R. Valenti,2 Lisa O’Fee,2 Harry Saville,2 Rosemary Burke,2 Rob
LM van Montfort,2 Florence I. Raynaud,2 Suzanne A. Eccles,2 Julian Blagg,2
SwenHoelder,2 Spiros Linardopoulos2. 1Phenex Pharmaceuticals, Ludwigshafen
am Rhein, Germany; 2Institute of Cancer Research, London, United Kingdom;
3Lahore University of Management Sciences, Lahore, Pakistan.
Basal-like breast cancer has received considerable attention in recent years,
but despite all efforts, conventional chemotherapy remains themain therapeutic
option in the clinic with taxane therapy, the most frequently prescribed treat-
ment. A signifıcant reason for the lack of effective therapeutics may be related to
the high degree of heterogeneity and aneuploidy which is characteristic for bas-
al-like breast cancer. A new approach in this fıeld is the concept that cancer cells
may be targeted by the introduction of a detrimental level of aneuploidy. Inhi-
bition of one of the main spindle assembly checkpoint kinases, MPS1 is a ratio-
nal choice to achieve this goal. We report here the identifıcation of a synergistic
effect between the novel, oral, highly potent and selective MPS1 inhibitor
CCT289346 and paclitaxel.We demonstrate robust synergism inmultiple basal-
like breast cancer cell lines and provide mechanistic insights into how both
compounds’ individual properties work together to maximise mitotic defects
thereby increasing aneuploidy and cell death in a single round of mitosis. Addi-
tionally, in vivo studies in basal-like breast cancer xenograft models, including
patient derived xenografts and systemic metastatic models, using clinically rel-
evant doses of paclitaxel with well-tolerated doses of CCT289346, demonstrate
signifıcant benefıt of combination of the two agents in comparison to paclitaxel
alone.
#4037 High throughput kinase inhibitor screen reveals novel inhibitor
combinations acting in synergy with TUBB3/III-tubulin suppression in
non-small cell lung cancer.Wee Siang Teo, TanyaDwarte, TimW. Failes, Greg
M. Arndt, Joshua A. McCarroll, Maria Kavallaris. Children’s Cancer Institute,
Randwick, NSW, Australia.
Background: Non-Small Cell Lung Cancer (NSCLC) survival rates remain
dismal and this malignancy is poorly responsive to current therapy. The mech-
anisms contributing to this resistance phenotype and aggressive behavior of this
disease are not well defıned. TUBB3/III-tubulin is aberrantly expressed in
NSCLC and its expression correlates negatively with disease free survival of
patients. Our group has previously shown that III-tubulin plays a functional
role in chemotherapy resistance and tumorigenesis inNSCLC viamodulation of
the PTEN/AKT signaling pathway1, 2. This study aimed to identify kinase inhib-
itors that synergize with III-tubulin inhibition in NSCLC using a high-
throughput cell-based screen. Methods: A high-throughput cell-based screen of
a kinase inhibitor library was performed against our previously described1, 2
NSCLC H460 cells, expressing either III-tubulin shRNA or control non-tar-
geting shRNA. The primary screen consisted of a total of 210 kinase inhibitors
tested at a single, fıxed concentration and cell viability determined using the
Alamar blue assay. Secondary screens were performed using a fıve point dose
response. Further validation of the kinase inhibitors was performed against two
independent NSCLC, H460 and A549 expressing either III-tubulin shRNA or
control non-targeting shRNA.Results: A number of kinase inhibitors that act on
key signalling cascades were identifıed to act in synergy with TUBB3/III-tubu-
lin knockdown to inhibit NSCLC cell growth. Interestingly, several different
inhibitors which target mTOR were identifıed as top candidates for acting in
combination with III-tubulin knockdown to inhibit NSCLC cell growth.
Treatment of cells with clinically approvedmTOR inhibitors, Temsirolimus and
Rapamycin, resulted in a signifıcant decrease in cell viability in the III-tubulin
knockdown cells compared to control. Notably, mTOR acts downstream of
AKT signalling and further highlights a potential connection with III-tubulin
and theAKT signal transduction cascade.Other kinase inhibitors that act on key
signaling cascades includingAmuvatinib-Multi Kinase Inhibitor (Flt3,Met, Kit,
c-Ret & PDGFR); Mubritinib-HER-2 inhibitor; and Neratinib HER2, EGFR,
also acted in combination with III-tubulin knockdown to inhibit NSCLC cell
growth. Conclusions: Our results suggest that clinically approved therapies de-
signed to target mTOR combined with inhibition of TUBB3/III-tubulin may
offer a novel therapeutic strategy for the treatment of NSCLC patients. Refer-
ences: 1McCarroll et al. Cancer Research 2010; 70: 4995-5003. 2McCarroll et al.
Cancer Research 2015; 75: 415-425.
#4038 Exploring optimal targeted combination therapies with neratinib
for HER2 breast cancer. Ming Zhao,1 Stephen Scott,1 Kurt Evans,1 Erkan
Yuca,1 Rashmi Murthy,1 Francesca Avogadri-Connors,2 Richard Cutler,2 Al-
shad S. Lalani,2 Sarina Piha-Paul,1 Funda Meric-Bernstam1. 1The University of
Texas MD Anderson Cancer Center, Houston, TX; 2Puma Biotechnology, Inc.,
CA.
Activation by amplifıcation or overexpression of the proto-oncogene HER2
(also known as ERBB2) is associated with the development and progression of
breast cancer. Neratinib is a novel, irreversible, pan-HER tyrosine kinase inhib-
itor which selectively inhibits EGFR, HER2 and HER4. In this preclinical study,
we explored the effıcacy of neratinib in combination with other clinically rele-
vant targeted agents for optimal treatment of HER2-positive breast cancer in in
vitro and in vivo models. Western blot (WB) analysis of a panel of breast cancer
cell lines showed that BT-474, SKBR-3, and HCC-1954 cells displayed elevated
HER2 expression levels (here denoted as HER2), while MDA-MB-361, MDA-
MB-453, and CAMA-1 breast cancer cells expressed relatively lower HER2 ex-
pression levels. Interestingly, neratinib inhibition positively correlated with
HER2 expression levels as assessed by cell survival assays. The IC50 of neratinib
in theHER2 cell lines was in the 3.6 - 113nM range. Consistent with the in vitro
data, treatment of aHER2breast cancer PDXmodelwith neratinib single agent
(p.o. 5 days/week) led to a signifıcant dose-dependent tumor growth inhibition
with tumor regressions observed at a low dose of 10 mg/kg (p0.0001). The
activity of neratinib in combination with other targeted agents was then evalu-
ated in vitro in theHER2 breast tumor cell lines using a Chou-Talalaymethod.
Neratinib showed synergistic anti-proliferative activity in combination with the
PI3K inhibitor BYL719 in all the HER2 cell lines tested. By contrast, synergy
with mTOR inhibitors (everolimus and TAK228) and with the MEK inhibitor
trametinib was only observed in BT-474 and HCC-1954 cells. HCC-1954 cells
had the best response to neratinib combinations among all HER2 cell lines
tested, with combination index values 0.5. Immunoblot analysis demon-
strated that neratinib treatment displayed complete inhibition of HER2 phos-
phorylation in these cells. Substantial inhibition of downstream signaling path-
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ways following single agent neratinib treatment was evident by reduced
phosphorylation levels of AKT, S6K1, S6, 4EBP1, ERK1/2 andMEK1/2. Consis-
tently with the cell viability data, the combination of neratinib with PI3K/Akt/
mTOR and MAPK inhibitors showed a synergy on signaling blockage in these
two downstream pathways respectively. Taken together this data shows that
neratinib has effıcacy as single agent in preclinical models of HER2 breast
tumors and its anti-proliferative activity in vitro was enhanced when combined
with PI3K/Akt/mTOR and MAPK pathway inhibitors. Further studies of nera-
tinib-based combination treatments are underway in HER2 breast cancer
xenograft and PDX models to further corroborate these fındings.
#4039 Riluzole synergizes with paclitaxel to induce apoptosis and inhibit
cell growth in triple negative breast cancer. Miriam A. Bukhsh,1 Cecilia L.
Speyer,2Waris S. Jafry,2 Rachel E. Sexton,3David Thomas,1DavidGorki4. 1Oak-
land University William Beaumont School of Medicine, Rochester, MI; 2Wayne
State University School of Medicine, Detroit, MI; 3Michigan State University,
Lansing, MI; 4Barbara Ann Karmanos Cancer Institute, Detroit, MI.
Introduction: Systemic treatment for triple negative breast cancer (TNBC)
includes paclitaxel, which works by inhibiting the breakdown of microtubules.
We previously observed that riluzole, an FDA-approved drug for the treatment
of amyotrophic lateral sclerosis, can inhibit TNBC proliferation, invasion, and
colony formation. We now test whether riluzole can act synergistically with
paclitaxel to inhibit TNBC growth and induce apoptosis in TNBC. Methods:
After treatment of various TNBC cell lines with constant ratio concentrations of
riluzole and paclitaxel we conducted cell proliferation transformation assays
(MTT) to measure cell inhibition potential. Synergy or additivity was deter-
mined by the Chou-Talalay using Compusyn software. PARP cleavage normal-
ized to GAPDHwas alsomeasured byWestern blot to estimate apoptosis due to
the riluzole-paclitaxel combination. In vivo synergy was studied using a xeno-
graft study with MDA-MB-231, a human TNBC cell line sensitive to riluzole.
Results: MTT results show that riluzole and paclitaxel work synergistically to
inhibit cell proliferation in all TNBC cell lines tested, as determined by isobolo-
grams and CI values1. The strongest synergistic effect was observed in the cell
lines SUM159, SUM149, and SUM229,where synergismoccurred at Fa values as
low as 0.5 (50% inhibition of cell proliferation). Measuring PARP cleavage, we
demonstrated that the riluzole-paclitaxel drug combination induces greater ap-
optosis than does either drug alone. The signifıcant impact of the drug combi-
nation was best demonstrated in cell lines SUM159, SUM149 and SUM229, but
was observed in all cell lines tested. In the xenograft study, the highest non-toxic
dose of paclitaxel (7.2 mg/kg) combined with riluzole resulted in 8/9 tumor-free
mice, with a tumor growth inhibition ratio (T/C) of 0%, where10% is consid-
ered highly therapeutic. This result was better than riluzole monotherapy (0/9
tumor-free and T/C  99%) or paclitaxel monotherapy (4/8 tumor-free and
T/C 8%). Conclusions:Our results demonstrate that the addition of riluzole to
paclitaxel results in at least additive and inmany cases synergistic effects against
TNBC.Our observations thus suggest that repurposing riluzole, which is an oral
drug with an excellent safety profıle, to add to paclitaxel to treat TNBC repre-
sents a potential strategy to improve the effıcacy of adjuvant and neoadjuvant
treatments for TNBC and/or reduce chemotherapy doses and toxicity in pa-
tients. Our data support the need to proceed to clinical trials to test this approach
in patients.
#4040 Short-term romidepsin treatment combined with clotrimazole or
bifonazole leads to decreased mitochondrial hexokinase 2 and apoptosis in
cancer cells. RobertW. Robey,1 Andrew J. McDonald,1 Hanna Kozlowski,1 Mi-
chael M. Gottesman,1 Susan E. Bates2. 1NCI-CCR, Bethesda, MD; 2Columbia
Uniersity Medical Center, New York, NY.
In light of disappointing clinical trials in solid tumors, we have sought novel
combinations to increase the effıcacy of the histone deacetylase inhibitor (HDI)
romidepsin. Hexokinase 2 (HK2) expression is increased in cancer cells and is
postulated to prevent Bax-mediated cytochrome c release from mitochondria.
Since romidepsin treatment induces apoptosis via the mitochondrial pathway,
combining romidepsin with agents that detachmitochondrial HK2might result
in synergistic apoptotic effects. HCT-116 colon carcinoma cells were treated
with 25 ng/ml romidepsin alone for 6h, or with romidepsin in the presence of 25
M clotrimazole or bifonazole, compounds known to detach mitochondrial
HK2. The medium was removed and cells were treated for an additional 42 h
with or without clotrimazole or bifonazole. Cells were also treated with clotrim-
azole or bifonazole alone for 48 h. Apoptosis was then quantitated by annexin
staining. While short-term romidepsin treatment alone induced modest an-
nexin staining and 25 M clotrimazole or bifonazole had little effect, the com-
bination resulted in signifıcant apoptosis. Similar effects were observed forA549
lung cancer cells, MDA-MB-231 breast cancer cells and 786-0 renal carcinoma
cells. We also treated HCT-116 and A549 cells lacking Bak, Bax or both with the
clotrimazole/romidepsin combination. Apoptosis was slightly increased in
Bak-/- cells, reduced in Bax-/- cells and nearly completely abrogated in cells
lacking both proteins compared towild-type cells suggesting apoptosis occurred
through the intrinsic pathway. The clotrimazole analog TRAM-34 was similarly
active to clotrimazole. Protein expression was determined in cytoplasmic and
mitochondrial fractions of cells treated with romidepsin, clotrimazole or both
and we found a60% decrease in mitochondrial HK2 in cells treated with the
combination versus untreated cells. Our results suggest that combining ro-
midepsin with a compound that leads to decreased mitochondrial hexokinase,
such as clotrimazole or bifonazole, results in increased apoptosis. We postulate
that cell death following combined romidepsin and clotrimazole treatment re-
quires an intact intrinsic apoptotic pathway and that HK2 serves an anti-apo-
ptotic function at the mitochondria.
#4041 SUV39H2 inhibition enhances sensitivity of breast cancer cells to
doxorubicin through downregulation of -H2AX production. Theodore
Vougiouklakis,1 Vassiliki Saloura,1 Yo Matsuo,2 Yusuke Nakamura1. 1Univer-
sity of Chicago, Chicago, IL; 2Oncotherapy Science Inc., Kawasaki, Japan.
Accumulating evidence has demonstrated the biological importance of pro-
tein methyltransferases in human tumorigenesis, and several small molecular
inhibitors targeting these enzymes have been developed. Moreover, inhibiting
pathways involved inDNA repair has been shown to enhance the cytotoxicity of
DNA-damaging agents. Herein, we report the development of a potent
SUV39H2 inhibitor (OTS193320) that decreases global histone H3 lysine 9 tri-
methylation (H3K9me3) levels in cancer cells and attenuates cancer cell prolif-
eration, and suppresses the tumor growth in mouse xenograft models.
SUV39H2 (Suppressor of variegation 3-9 homolog 2), is a protein methyltrans-
ferase known to methylate histone H3 at lysine 9 (H3K9), and recently reported
to methylate histone H2AX at lysine 134, which enhances the accumulation of
phosphorylated H2AX (-H2AX) and regulates the DNA repair pathway in
human cancer. SUV39H2 is highly expressed in many cancer types, including
lung and breast cancers, while its expression levels are restricted to testis in
normal adult tissues. Exposure of OTS193320 to two triple negative breast can-
cer cell lines attenuated H3K9me3 levels in a dose-dependent manner and trig-
gered apoptotic cell death. Combination ofOTS193320 and doxorubicin (DOX)
resulted in reduction of -H2AX levels compared to single agent DOX, as visu-
alized on western blot and immunocytochemical analysis. Furthermore, combi-
nation therapy attenuated the levels of p53-binding protein 1, which is reported
to co-localize with -H2AX foci, compared to single agent DOX. Cell viability
assays demonstrated a signifıcant growth suppressive effect when OTS193320
was combined with DOX, compared to single agent treatment of either drug,
suggesting chemosensitization to DOX. Importantly, in a mouse xenograft
model of A549 lung cancer cells, we observed a tumor growth inhibition of
60.8% at day 14with 25mg/kg intravenous administration of the inhibitor, with-
out signifıcant body weight loss or toxicity. Immunohistochemical staining of
tumors treated with the inhibitor demonstrated a signifıcantly lower number of
Ki-67 positive cells and attenuated distribution patterns of H3K9me3 compared
to the control tumors. Collectively, our results demonstrate that SUV39H2 in-
hibition may be a promising approach to develop a novel class of anti-cancer
treatment.
#4042 N-121, a novel polypeptide conjugate of SN-38, demonstrated en-
hanced intratumoral accumulation and sustained release of free SN-38 with
potent antitumor activity. Haojun Wang,1 Wei Li,1 Xiaojian Zhou,2 Liuyi
Wan,1GuanghuiWen1. 1LabWorld Bio-Medicine TechnologyCorp. Ltd., Beijing,
China; 2Pharmeva LLC, Arlington, MA.
Introduction: SN-38 is a critical chemotherapeutic agent active against a va-
riety of solid tumors including advanced colorectal cancer. Clinical use of SN-38
is hampered by its poor solubility in pharmaceutically acceptable solvents. Al-
though irinotecan, the only approved prodrug of SN-38, is widely used, its effı-
cacy is limited by low conversion to the active SN-38 as well as hematologic and
gastrointestinal dose-limiting toxicities. In an attempt to improve the water
solubility, antitumor activity and safety profıles of SN-38, we synthesized awater
soluble polypeptide-SN-38 conjugate (N-121) and examined its antitumor ac-
tivity and pharmacokinetics (PK) in mouse models. Methods: Antitumor activ-
ity and PK of SN-38, administered as N-121 or irinotecan, was evaluated follow-
ing tail vein injection in male nude mice with subcutaneous orthotopic
xenografts of the HCT116 human colon cancer. Mice received N-121 400 mgk
(mg/kg) (32mkg of eq. SN-38) or irinotecan 80mgk once aweek for 2weeks and
were followed for up to 46 days. Results: N-121 drastically improved by over
1000 fold the water solubility of SN-38. At a SN-38 equivalent dose of less than
half of that of irinotecan, N-121 resulted in a much longer tumor growth delay
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(36 days) than irinotecan (14 days). The more durable tumor growth inhibition
with N-121 was consistent with its enhanced intratumoral accumulation: intra-
tumoral trough levels of SN-38 were about 250-fold higher than those observed
in plasma, compared with only 15-fold with irinotecan. With N-121, Intratu-
moral levels of SN-38 remained stable over the PK observation period (48 h),
contrasting to a marked decline in SN-38 levels with irinotecan; intratumoral
trough levels of SN-38 from N-121 were about 50-fold higher than those
achieved with irinotecan. N-121 was well tolerated with a slight weight loss of
7.2%. Conclusion: N-121, a novel water soluble polypeptide-SN-38 conjugate,
exhibited enhanced and sustained intratumoral exposure of SN-38 with high
antitumor activity in a mouse xenograft tumor model. These promising results
warrant further evaluation of N-121.
#4043 Design of a novel MGMT inhibitor targeted to EGFR overexpress-
ing tumor cells: a new approach to selectively potentiate temozolomide in
refractory tumors. Martin Rupp, Bertrand J. Jean-Claude. McGill University
Health Centre, Montreal, Quebec, Canada.
Temozolomide (TMZ) is an oral alkylating agent commonly used as a fırst-
line chemotherapeutic agent for the treatment of high-grade gliomas and mela-
noma. Alkylation of the O6-position of guanine in DNA is mainly responsible
for the antitumor effect of TMZ. The primarymechanism of chemoresistance to
TMZ has been shown to be the overexpression of the DNA repair enzyme O6-
methylguaninemethyltransferase (MGMT) that specifıcally removes themethyl
lesions from the O6-position of guanine. While O6-benzylguanine (O6-BG), a
potent inhibitor of MGMT, was shown to sensitize tumor cells to TMZ in vitro
and in vivo, the O6-BGTMZ combination failed in clinical trial due to acute
hematologic toxicity. To circumvent this problem, we wish to target O6-BG to
the epidermal growth factor receptor (EGFR), a receptor that is not generally
expressed in the hematological cells but overexpressed in many solid tumors.
We have now successfully designed and synthesized one such molecule termed
MR30 and showed that: 1) MR30 is capable of blocking EGFR and depleting
MGMT levels in whole cells; 2) MR30 is a unique molecule capable of inducing
stronger growth inhibition than the 2-drug combination involving clinical
EGFR andMGMT inhibitors in a panel ofmelanoma, lung, prostate and ovarian
cancer cell lines; 3) MR30 in vitro potentiated the effect of TMZ on MGMT
positive cell lines; 4) its kinase inhibitory profıling over 25 different kinases
demonstrated selectivity for EGFR, HER2 and EGFR mutant forms; 5) an iso-
genic model showed more than 70-fold selectivity towards EGFR expressing
cells in growth inhibitory assay; 6) MR30 showed good cell penetration with
distribution in the perinuclear region. The results in toto suggest that MR30 has
the potential to be developed as a tumor selective potentiator of TMZ.
#4044 LY3039579, a novel Notch inhibit, potentiates the anti-tumoral
effects of sorafenib in hepatocellular carcinoma (HCC). Annemilai Tijeras-
Raballand,1 Christian Hobeika,2 Elise Payen,3 Matthieu Martinet,1 Philippe
Bonnin,3 KarimA. Benhadji,4 Bharvin R. Patel,4 Clarisse Eveno,2Marc Pocard,2
Sandrine Faivre,5 Eric Raymond,6 Armand de Gramont1. 1AFR Oncology, Paris,
France; 2Inserm U965-Lariboisiere University Hospital, Paris, France; 3Inserm
U965- Lariboisiere University Hospital, Paris, France; 4Eli Lilly Company, News
Jersey, NJ; 5Beaujon University Hospital, Beaujon, France; 6Saint-Joseph Hospi-
tal, Paris, France.
Introduction:Notch pathwayhas been involved in cell fate determination, cell
differentiation, proliferation and death. Notch promotes cell survival, angiogen-
esis and treatment resistance in numerous cancers, making it a promising target
for cancer therapy. The role of the Notch pathways in HCC tumorigenesis has
shown some controversies over time and across studies, being endowed with
both oncogenic and tumor suppressive properties. Our study aimed at investi-
gating the anti-tumoral effects of combining LY3039478, a novel Notch inhibi-
tor, to sorafenib in an in vivo transgenic model of HCC. Methods: Transgenic
mice developing stage-defıned HCC were treated for 8 weeks (W) from W8 to
W16 with either vehicle, LY3039478 (8mg/kg, thrice weekly, oral gavage),
sorafenib (30mg/kg, daily, oral gavage) or LY3039478 plus sorafenib. Tumor
growth was evaluated by ultrasound (liver size), by the number of macronod-
ules, and the number ofmicronodules onHPS sections at sacrifıce. Angiogenesis
was evaluated by doppler (blood flow in the coeliac trunk) and byCD31 staining.
Results: Liver size and the number of liver tumor macronodules were signifı-
cantly lower in all treatment arms compared to control placebo at both theW12
intermediary sacrifıce and W16 fınal sacrifıce; the combination of LY3039478
and sorafenib showing increased tumor control at W16 (4,39	0,82 in mean
liver volumes (in mm3) in the combination arm vs 5,41	1,0, 5,84	0,47,
7,09	1,5 in the sorafenib, LY3039478 and placebo arms respectively). Angio-
genesis assessed by measuring the mean blood flow in the coeliac trunk (TCm),
decreased in all treatment arms, compared to placebo. At W16, LY3039478
potentiated the effect of sorafenib, with a TCm decrease of 36% compared to
23% and18% the sorafenib and LY3039478 arms, respectively. These results will
be confırmed by the assessment of micronodules number on HPS section for
tumor growth and CD31 staining for angiogenesis analysis (number of vessels
and the vessel lumen area). The effects of the combination versusmonotherapies
will be evaluated on the immune landscape. Conclusion: The combination of
LY3039478 and sorafenib showed promising anti-tumor activities that were
associated with decreased angiogenesis.
#4045 Decreased Fanconi anemia gene expression contributes to effıcacy
of PARP andDNMT inhibitor combination therapy in triple negative breast
cancer. Lena J. McLaughlin,1 Huili Li,2 Pratik Nagaria,1 Stephen B. Baylin,2
Cynthia A. Zahnow,2 Feyruz V. Rassool1. 1University of Maryland, Baltimore,
Baltimore, MD; 2Johns Hopkins University, Baltimore, MD.
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have effıcacy in a
sub-set of triple negative breast cancers (TNBCs) with inherited mutations in
DNA double strand break repair (DSBR) genes, such as the BRCA1/2 genes in
homologous recombination (HR), through synthetic lethality. However, PARP
inhibitors have failed for the majority of sporadic TNBCs with intact BRCA1
genes. Therefore, novel targeted therapies must be explored. We have recently
reported that PARPi Talazoparib in combination with DNAmethyl transferase
inhibitors (DNMTi)s azacytidine (AZA) or decitabine (DAC) have effıcacy in
sporadic TNBCs in vitro and in vivo. PARPi act not only to catalytically inhibit
PARP but also to trap PARP at DNA single strand breaks (SSB), leading to
suicidal DNA-protein crosslinks (DPC). We also showed that Talazoparib in
combination with AZA/DAC increases PARP trapping in DNA, leading to in-
creased and persistent levels of lethal DSBs, suggesting that DSBR may also be
impaired with this treatment. HR plays an important role in resolving DPC in
mammalian cells and Fanconi anemia (FA)-dependent HR has been previously
shown to resolve AZA-induced replication lesions. Herein, we determined
whether HR is impaired with combination drug treatment using a chromo-
somally integrated GFP-based reporter in the TNBC cell line, MDA-MB-231.
HR activitywas signifıcantly (p0.05) decreasedwithAZAorAZA/Talazoparib
combination treatment, suggesting that AZA mediates decreased HR activity.
We next questioned whether subsets of HR genes are indirectly down-regulated
by the epigenetic reprogramming effects of DNMTis, thereby contributing to
the effıcacy of DNMTi and PARPi combination therapy. Microarray analysis
was performed in multiple TNBC cell lines (including MDA-MB-231, MDA-
MB-468, and SUM159PT) post DNMTi treatment and showed signifıcant
(p0.05) decreases in expression of FANCD2, FANCC, and FANCE that could
potentially generate a synthetic lethality when combined with PARPi, as has
recently been reported. Decreased FA gene expression was validated by qPCR of
mRNA and western analysis of proteins. Moreover, treatment of TNBC with
DNA crosslinking agents, which require FA-dependent repair, have increased
sensitivity post DNMTi treatment. These data suggest that decreased FA gene
expression contributes to the effıcacy of PARPi/DNMTi treatment in TNBC.
Work is now underway to determine whether depletion of FA proteins can
increase PARP trapping in PARPis treated TNBCs, leading to increased levels of
cytotoxic DSBs.
#4046 Targeting jak/stat adaptivemechanismwith jak1 inhibitor azd4205
reduces residual disease and prolongs benefıt of osimertinib. Huawei (Ray)
Chen,1 Geraldine Bebernitz,1 Kirsten Bell,1 Erica Anderson,1 Nanhua Deng,1
Jason Kettle,2 Paul Lyne,1 Richard Woessner1. 1AstraZeneca R&D Boston,
Waltham, MA; 2AstraZeneca, Merside, United Kingdom.
EGFR kinase inhibitors have provided tremendous benefıt for non-small cell
lung cancer (NSCLC) patients with EGFR driver mutations. However, many
patients fail to respond or have responses of limited duration. Accumulating
evidence suggests that the JAK1/STAT3 axis plays a role in tumor escape, and
that combined inhibition of EGFR and JAK1 may drive more complete and
durable responses. Here we report AZD4205, a potent ATP-competitive inhib-
itor that inhibits JAK1 with a Ki of 2.8 nM and exhibits excellent selectivity vs.
other JAK family kinases and across the kinome. Combination of AZD4205
(dosed at 12.5, 25 or 50 mg/kg BID, PO) with Osimertinib (doses ranging from
1 to 25 mg/kg QD, PO) led to enhanced in vivo anti-tumor activity in several
NSCLC xenograft models driven by mutant EGFR: H1975 (L858R/T790M),
PC-9 (del19), and HCC827 (del19). In the H1975 model, after 18 days of treat-
ment beginningwith 189mm3 established tumors, treatmentwith osimertinib at
2.5 mg/kg led to tumor growth inhibition of 92% relative to vehicle. Addition of
AZD4205 at 12.5 and 50 mg/kg led to 30% and 69% tumor regression, respec-
tively. AZD4205 dosed at 12.5 and 50 mg/kg BID resulted in pSTAT3 (Y705)
knockdown of 72% and 91% at peak plasma concentration (2H) respectively,
and 42% and 86% at 8H. In the PC-9model, after 22 days of treatment beginning
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Combination Therapies and Approaches to Sensitize Cancer Cells to Drugs
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1033
with 234mm3 established tumors, osimertinib at 1 mg/kg induced an average
41% regression, and increased to 74% with the addition of 50 mg/kg BID
AZD4205. The volume of vehicle treated tumors increased by 3.7-fold over this
treatment period. In the HCC827 model, beginning with 127mm3 established
tumors, osimertinib at 25 mg/kg induced a complete response in 100% of mice
after 11 days of treatment, but tumors regrew to the average starting volume24
days after stopping treatment. When 50 mg/kg of AZD4205 was added to the
osimertinib treatment, regrowth was delayed by an additional7 days. Combi-
nation activity was also observed in the PDX (patient-derived xenograft) model
LG1049 (del19 and T790M EGFR mutations). Beginning with 189mm3 estab-
lished tumors, osimertinib at 25 mg/kg induced an average 39% regression after
28 days of treatment, which increased to 56% with the addition of 25 mg/kg
AZD4205 on a 4 days on / 3 days off / week schedule. AZD4205 treatment led to
67% knockdown of pSTAT3 after 4H of treatment in this model. Our experi-
ments establishAZD4205 as a potent and selective JAK1 inhibitorwith desirable
biophysical properties. While additional work is needed to build a patient en-
richment strategy, the data generated supports targeting the adaptive JAK1/
STAT3 axis with JAK1 inhibitor AZD4205 in clinic as a strategy to reduce resid-
ual disease and prolong the benefıt of Osimertinib in lung cancer patients with
EGFR activating mutations.
#4047 NF-kB inhibitor DMAPT enhances cisplatin effıcacy and reduces
its toxicity in a carcinogen-inducedmodel ofmuscle-invasive bladder cancer.
Rui M. Gil da Costa,1 Pedro Ferreirinha,1 Nazaré Pinto da Cunha,2 Carlos San-
tos,1 Tiago Neto,1 Ana I. Faustino-Rocha,3 Manuel Vilanova,1 Margarida M.
Bastos,1 Carlos Lopes,4 Paula A. Oliveira,3 Joaquim Gabriel,1 Peter Nelson,5
Christopher Sweeney6. 1University of Porto, Porto, Portugal; 2CEDIVET - Veter-
inary Diagnostic Center, Porto, Portugal; 3CITAB, University of Trás-os-Montes
and Alto Douro, Vila Real, Portugal; 4Portuguese Institute of Oncology, Porto,
Portugal; 5Fred Hutchinson Cancer Research Center, Seattle, WA; 6Dana-Farber
Cancer Institute, Boston, MA.
BACKGROUND: Nuclear factor kappaB (NF-B) blocks apoptosis and
promotes chemoresistance to drugs like cisplatin (CDDP). However, the
clinical use of NF-B inhibitors is restricted to hematological malignancies
and the benefıt of NF-B inhibition in solid tumors has yet to be realized. The
novel agent dimethylaminoparthenolide (DMAPT) blocks NF-B in bladder
cancer cell lines and can overcome chemoresistance as part of a combination
therapy. METHODS AND RESULTS: We tested DMAPT’s ability to en-
hance CDDP’s effıcacy against muscle-invasive bladder cancer. In vitro, 2.5
M DMAPT was shown to up-regulate death receptor 4 and 5 expression
and induce poly (ADP-ribose) polymerase (PARP) cleavage in UMUC-3
cells. Both 2.5 M DMAPT and 2.5 M CDDP reduced UMUC-3 cell via-
bility as single agents, and their effect was enhanced when combined. We
next tested CDDP (4.0 mg/kg/week i.p) and DMAPT (100.0 mg/kg/day oral)
in combination and as single agents for 6 weeks in an immune-competent
mouse model of muscle-invasive (T2) bladder cancer induced by the tobac-
co-related agent N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN). Proce-
dures followed the 2010/63/EU animal welfare directive. One DMAPT-
treated and 1 CDDP-treated mouse died during the experiments. The
cohorts were: negative control (no BBN exposure, n15), positive control
(BBN but no therapy, n19), BBN and DMAPT-treated (n17), BBN and
CDDP-treated (n18) and BBN and the combination of CDDP plus
DMAPT (n19). Negative control, positive control, DMAPT, CDDP and
combination-treated mice showed 0.0%, 42.1%, 35.3%, 11.1% and 0.0% blad-
der cancer incidence, respectively. T2 (muscle-invasive) lesions were present
in positive controls (15.8%), DMAPT (17.6%) and CDDP (5.6%), but not in
the combination group (0.0%). High-grade urothelial dysplasia, a pre-ma-
lignant lesion, was observed at rates of: 57.9% (positive controls), 29.4%
(DMAPT), 16.6% (CDDP) and 0.0% (combination). CDDP induced renal
tubular necrosis and interstitial nephritis seen on H&E with increased urea
(BUN) and creatinine. The combination therapy reduced interstitial nephri-
tis, BUN (p0.05, Student’s t test) and creatinine levels. CDDP reduced
gastrocnemius muscle mass, increased muscular fatigue (grip strength test)
and reduced body weight. These effects were ameliorated in combination-
treated mice. CDDP and the combination therapy induced anemia and at-
rophy of bone marrow, thymus and spleen at identical levels. CONCLU-
SION: The DMAPT-CDDP combination was more effective than CDDP as
single agent in vitro and in vivo, and totally eradicated malignant and pre-
malignant bladder lesions in an immune-competent mousemodel. The com-
bination ameliorated CDDP-induced nephrotoxicity and muscle wasting
presumably by blocking CDDP mediated injury from NF-B activation in
normal tissues, without imposing additional hematological toxicity.
#4048 In silico identifıcation and experimental validation of clinically ap-
proved drugs to treat molecular-targeted drug-resistant lung cancer cells.
Kenneth K. To, HongJian Li, Wing-Sum Tong, Mandy YM Lam, Kwong Sak
Leung. The Chinese University of Hong Kong, Hong Kong, Hong Kong.
The goal of this study is (i) to identify clinically used drug candidates for
repurposing to treat lung cancer cells resistant to the epidermal growth factor
receptor tyrosine kinase inhibitors (EGFRTKIs) by in silico docking simulation;
and (ii) to validate the chosen drug candidates in cancer cell models. Drug
repurposing is the application of clinically approved drugs, with optimized dos-
ing regimens andknown side effect profıles, to new indications. EGFRTKIs have
unprecedented clinical effıcacy in advanced lung cancer. However, their useful-
ness is severely compromised by drug resistance mediated by various mecha-
nisms, the most important of which is the secondary EGFR T790M mutation.
The mutation blocks the binding of EGFR TKIs to the receptor kinase domain
and thereby abolishing the therapeutic effıcacy. In this study, we have used our
in-house developed protein-ligand docking software “idock” (http://istar.c-
se.cuhk.edu.hk/idock/) to screen FDA-approved small molecule drugs against
EGFR bearing the resistance-causing mutations. The computationally selected
drug candidates were evaluated in vitro in non-small cell lung cancer (NSCLC)
cell lines resistant to EGFR TKIs. Mechanistic studies were performed to inves-
tigate the specifıcity of the compounds towards inhibiting the kinase activity of
the various EGFRmutants, and induction of apoptosis. Based on the simulation
score, thirty-six drug candidates were chosen from the in silico screening for in
vitro evaluation in NSCLC bearing wild-type EGFR, EGFR L858R (sensitizing
mutation), or EGFR L858R/T790M (resistance-causing mutation). Three drugs
were found to exhibit anticancer activity in the cancer cells and two of themwere
more potent in NSCLC harboring EGFR L858R/T790M than those with EGFR
L858R. Their specifıcity towards inhibiting EGFR L858R/T790M were further
confırmed by cell-free biochemical kinase assay andWestern blot analysis in the
NSCLC cell models. The positive hits were also showed to inhibit the EGFR-
PI3K-Akt signaling pathway and cause apoptosis. Interestingly, the drug candi-
dates identifıed also gave rise to pronounced synergistic anticancer activity spe-
cifıcally inNSCLCcells harboringEGFRT790Mwhenused in combinationwith
gefıtinib. The drug candidates identifıedmay be repurposed for treatingNSCLC
resistant to EGFR TKIs. The same in silico screening approach may be used to
hunt for other clinically used drugs for repurposing to treat cancer cells resistant
to other molecular targeted agents.
#4049 The synergistic effect ofmelphalan andXPO1 inhibition inpreclin-
ical models of multiple myeloma. Joel G. Turner. Moffıtt Cancer Center,
Tampa, FL.
Introduction: Signifıcant increases in response/survival have been seen over
the past several years; however, multiple myeloma (MM) remains incurable. In
this study we have demonstrated that the XPO1 inhibitors (XPO1i), selinexor
(SEL) and KPT-8602, sensitize both wild-type and drug-resistant MM cells to
melphalan (MEL) in preclinical models. Materials and Methods: We used the
XPO1i SEL (300nM), KPT-8602 (300nM), and KOS-2464 (10nM) /- MEL
(5-20 M) to treat human 8226, H929 and U266 MM cells, and MEL resistant
8226LR5 and U266LR6 cell lines and assayed for apoptosis. DNA damage was
assayed by comet assay and -H2AX in H929 human MM cells. XPO1i/MEL-
treated MM cells were assayed for P53, NFkB, IKK, and Fanconi Anemia
(FANC)/BRCA DNA repair proteins by Western blot and electrochemilumi-
nescent immunoassay(ECL-I). We also treated cells from patients with newly
diagnosed or relapsed/refractoryMMwith the XPO1i/- MEL and assayed for
apoptosis. NOD/SCID- (NSG) mice challenged with U226 or U266LR6 MM
tumors were treated with XPO1i/MEL and assayed for tumor growth, survival,
and toxicity. Results: The addition of the XPO1i’s SEL, KPT-8602 or KOS-2464
(P 0.03) sensitized drug-resistant 8226LR5 and U266LR6 cells to MEL when
compared to single-agent MEL. The XPO1i/MEL drug combination increased
DNA damage (Comet assay/-H2AX) more than single agent MEL or XPO1i
alone (P  0.005). Western blot and ECL-I showed that XPO1i treatment can
increase P53 and decrease NFkB, IKK, FANC/BRACpathway proteins includ-
ing FANCD2 in MM cells. CD138/light chain MM cells from newly diag-
nosed and relapsed/refractory MM patients were sensitized (20-fold and 5-10
fold respectively) by XPO1i to MEL. XPO1i/MEL combination treatment dem-
onstrated a strong synergistic antitumor effect when compared to single-agent
MEL (SEL/MEL, P  0.0024 and KPT-8602/MEL, P  0.0030) in NSG mice
challenged with U266, with little toxicity as assessed by weight loss. Similar
results were found with MEL resistant U266LR6 tumors in NSG mice. Conclu-
sions: XPO1i’s sensitized human MM cell lines, both parental and MEL resis-
tant, and patient MM cells toMEL both in vitro and ex vivo, and in in vivo NSG
mouse models. Our data show that the synergistic cell kill may be due to in-
creased XPO1i/MEL-induced DNA damage. The mechanism of this synergy
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may be due to increased nuclear P53, in combination with decreased NFkB and
IKK, and decreased DNA repair activity of the FANC/BRCA pathway. Thus,
combination therapies of XPO1i, especially the clinical compounds SEL and
KPT-8602/- MEL, may have potential to improve the treatment outcomes of
MM. The combination of XPO1i and melphalan are being investigated in the
context of high-dose chemotherapy and autologous transplant (NCT
02780609).
#4050 Multifaceted targeting of drug-resistant EGFR and HER2
breast tumors. Brian K. Law, Mary E. Law, Renan B. Ferreira, Mengxiong
Wang, Bradley J. Davis, Ronald K. Castellano, Coy D. Heldermon. Univ. of
Florida, Gainesville, FL.
Unmet needs in the breast cancer fıeld include the development of effective
treatments for 1) drug-resistant HER2 breast cancers, 2) Triple-Negative
(HER2-, ER-, PR-) Breast Cancers (TNBCs), and 3) Inflammatory Breast Can-
cers (IBCs). Treatment-refractoryHER2 tumors retainHER2 expression after
acquiring drug resistance, and large fractions of TNBCs and IBCs overexpress
either HER2 or EGFR. Thus, drugs that selectively kill breast tumors that over-
express EGFR or HER2 could benefıt patients suffering from these three classes
of treatment-refractory tumors. Our team has identifıed a class of compounds
termed Disulfıde bond Disrupting Agents (DDAs) that selectively kill cancer
cells that overexpress HER2 or EGFR. DDA-mediated cancer-selective cytotox-
icity results from A) downregulation of the EGFR/HER2/HER3 proteins, B)
inactivation of the Akt oncogene, and C) activation of the Unfolded Protein
Response (UPR). Importantly DDAs only elicit these responses in cancer cells
that overexpress EGFR or HER2. DDAs exhibit striking anticancer activity in
human HER2 xenograft tumors grown orthotopically in mice, with no evi-
dence of toxicity. DDAs function through mechanisms distinct from those of
HER2 specifıc monoclonal antibodies and tyrosine kinase inhibitors, and bio-
chemical studies indicate that DDAs are complementary with Lapatinib with
respect to blockade of HER2 driven proliferative and survival signaling. Current
efforts are directed toward identifying mechanism-based drugs that synergize
withDDAs to potentiateHER1-3 downregulation,Akt inhibition, andUPR, and
to kill HER2/EGFR patient-derived xenograft tumors that are refractory to
current therapies.
#4051 Combination effıcacy of HDAC inhibitor vorinostat and CDK-4/6
dual inhibitor palbociclib against therapy-resistant mantle cell lymphoma.
Nagendra K. Chaturvedi, Nathan D. Hatch, Garrett L. Sutton,Matthew J. Kling,
Julie M. Vose, Shantaram S. Joshi. University of Nebraska Medical Center,
Omaha, NE.
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma accounting
for about 7% of all non-Hodgkins lymphoma.While multiple therapy regimens
are available to treat MCL patients, ultimately relapse from therapy-resistant
MCL,makingMCL carry theworst prognosis of all B cell lymphomas. Emerging
evidence suggest that, dysregulated histone deacetylases (HDACs) and the key
molecules of cell cycle regulator cyclin-dependent kinases (CDKs) have been
shown to be commonly associated with many lymphomas including MCL, and
are considered as promising targets for relapsed lymphoma therapy. Several
inhibitors of these target pathways/molecules are in clinical trials asmonothera-
pies or in combination with other anticancer agents. Therefore, in this study, we
investigated the single agent and combination effıcacies of the HDACs inhibitor
vorinostat, andCDK-4/6 dual inhibitor palbociclib onMCLcell growth/survival
and underlying molecular mechanism(s) using different MCL cell lines (Granta
519, Jeko-1 and JVM-2) including therapy-resistantMCL cell lines derived from
Granta-519 (GRL, GRK and GRR).We usedMTT assay to measure the survival
and proliferation, agar colony formation assay to determine the effects of these
inhibitors on the anchorage independent growth, Annexin-V analyses to exam-
ine the cells undergoing apoptosis following treatments and western blot anal-
yses to determine the expression levels of target molecules including pRb, his-
tone acetylation, cyclin-D1 and Bcl-2. The concentration of these inhibitors
used in this study were similar to the published literature including sub-IC50
levels determined in our laboratory. Our results showed that both inhibitors as
single agents or combined, signifıcantly suppressed the cell growth, and induced
apoptosis in therapy-resistant and other MCL lines in vitro. The single agent
and combined anti-lymphoma effıcacies of these inhibitors were further con-
fırmed with the colony formation ability of the MCL cells grown in 0.3% agar
semisolid media. In addition, combination of vorinostat and palbociclib treat-
ment signifıcantly inhibited the activation of phosphorylated-retinoblastoma
(pRb) protein, a keymolecule of cell cycle and increased the expression of acety-
lated-Histone H3 (H3-Ac) as determined by western blot analyses. Subse-
quently, the expression of Cyclin D1 (proliferation, MCL hallmark) and anti-
apoptotic Bcl-2 proteins were also downregulated by these inhibitors. Together,
our fındings suggest that combination of vorinostat and palbociclib showed a
signifıcant synergistic anti-MCL activity by targeting associated pathways/mol-
ecules. This targeted approach warrants further preclinical evaluation for trans-
lation to the clinic.
#4052 Enhancing estrogen receptor beta mediated tumor suppression by
lysine specifıc demethylase 1A inhibitor for the treatment of ovarian cancer.
Gangadhara Reddy R. Sareddy,1 Jinyou Liu,1 LaurenGarcia,1 Suryavathi Viswa-
nadhapalli,1 Mei Zhou,1 Takayoshi Suzuki,2 Edward Kost,1 Ratna K. Vadla-
mudi1. 1UT Health Science Center at San Antonio, San Antonio, TX; 2Kyoto
Prefectural University of Medicine, Kyoto, Japan.
Ovarian cancer (OCa) is the deadliest of all gynecologic cancers in the United
States. Although patients with OCa respond initially to standard combinations
of surgical and cytotoxic therapy, nearly 90% will develop recurrence and inev-
itably succumb to chemotherapy-resistant disease. Estrogen mediates its effects
through the estrogen receptor  (ESR1) and estrogen receptor  (ESR2). Recent
studies suggest that OCa cells andOCa stem cells express ESR2, which functions
as a tumor suppressor and identifıed synthetic compound LY500307 as a potent
ESR2 specifıc agonist. However, ESR2 expression decreases during tumor pro-
gression and under the selection pressure of chemotherapy; this decrease occurs
via epigenetic mechanisms. The lysine-specifıc histone demethylase 1A
(KDM1A/LSD1) is overexpressed inOCa and plays a vital role inmetastasis and
cancer stemness. Our group recently developed a novel KDM1A-specifıc inhib-
itor (NCD-38) based on an innovative concept of direct delivery of phenylcyclo-
propylamine to the KDM1A active site. We reason that agents that restore the
expression and functions of ESR2 by increasing active histone marks may pro-
vide a novel therapeutic opportunity to reactivate ESR2 for suppression of OCa.
The objective of this study is to test whether KDM1A inhibitor could enhance
the expression and tumor suppressive functions of ESR2 and to test the combi-
nation of KDM1A inhibitor along with ESR2 agonist using in vitro and in vivo
preclinical models. Our results demonstrated that combination of ESR2 agonist
and KDM1A inhibitor reduces the cell viability of OCa cells synergistically.
Further caspase-3/7 activity andAnnexinV assays showed synergistic induction
of apoptosis upon combination therapy. Matrigel invasion assays revealed re-
duction in cell invasion of OCa cell lines following ESR2 agonist and KDM1A
inhibitor treatment. RT-qPCR analysis demonstrated that KDM1A inhibitor
treatment signifıcantly increases the expression of ESR2 and its target genes
leading to increased tumor suppression. Further, co-immunoprecipitation anal-
ysis revealed that KDM1A interacts with ESR2 and Chromatin immunoprecipi-
tation assays demonstrated that KDM1A inhibition increases the recruitment of
active histone methylation mark H3K4-me2 at ESR2 0N promoter. RNA-se-
quencing analysis demonstrated that ESR2 agonist treatment modulates the
several pathways related to cell cycle, apoptosis and DNA damage check point
regulation. Finally, ESR2 agonist and KDM1A inhibitor treatment signifıcantly
reduced the in vivo tumor growth in orthotopicmodels. Since ESR2 agonists and
KDM1A inhibitors are currently in clinical trials for other clinical indications
and are well tolerated, identifıcation of KDM1A inhibitor and ESR2 agonist
combination therapy as a novel therapeutic can be readily transferred to clinical
use for enhancing survival in OCa patients.
#4053 Disulfıram-copper combination induces cell death time- and
schedule-dependently in glioblastoma (GBM) and medulloblastoma cell
lines, and enhances temozolomide sensitivity of methylatorve GBM cells
in vitro and in vivo.MostafaGabr,1 StephenMarcus,2Hanumantha R.Madala,3
Kalkunte S. Srivenugopal,3 Francis Ali-Osman1. 1Duke University School of
Medicine, Durham,NC; 2Cantex Pharmaceuticals,Weston, FL; 3Texas TechUni-
versity Health Sciences Center, Amarillo, TX.
Background. Disulfıram (DSF), a carbamate derivative and a potent aldehyde
dehydrogenate inhibitor, is used clinically to treat alcoholism. Although, rela-
tively nontoxic, DSF exhibits signifıcant anticancer effects, when administered
with heavy metals (Cu and Zn). Because of this and the fact that DSF crosses the
blood-brain barrier, DSF is being investigated as a potential agent for brain
tumor therapy. In a previous study, we showed that, in glioblastoma (GBM)
cells, a copper-DSF complex inhibited activity of the DNA repair protein,
O6methyguanine-DNA methyltransferase, MGMT, involved in tumor resis-
tance to temozolomide. This study investigates, in greater detail, the anti-tumor
effıcacy of DSF and copper (as the gluconate), alone and in combination, in a
series of GBM cell lines (UW18, UW28, UW35, UW14 and MGR3) and one
medulloblastoma cell line (UW228). We examined the dose-, time- and sched-
ule-dependence of the anti-tumor activity (growth rates in a real-time cell, dou-
bling times and apoptotic induction) and correlated the results with cellular
levels of caspase activation, production of reactive oxygen species (ROS) and
activatedMAP kinases. The effects of DSF, copper and DSF-copper on temozo-
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lomide resistancewas examined in vitro and in vivo in twomethylatorveGBM
cell lines, UW18 andUW28. Results. DSF and copper, as single agents, up to 100
uM for 4-7 days, had little to no toxicity on any of theGBMcell lines. In contrast,
all the cell lines were highly sensitive to DSF, when combined with copper. The
effıcacy of the combination was highly dependent on the time (minimum 6 hrs)
and schedule (DSF prior to copper) of cellular exposure. The UW228 medullo-
blastoma cell line was approx. 4-fold more sensitive to DSF and to the DSF-
copper combination than GBM cells. We observed a direct correlation between
the levels of cellular ROS production andMAP activation, and the level of cyto-
toxicity of the DSF-copper combination. The temozolomide sensitivity of the
cell lines was signifıcantly enhanced by theDSF-copper combination and in vivo
xenograft growth of two temozolomide-resistant, methylatorve GBM cell
lines was signifıcantly inhibited and their temozolomide sensitivity enhanced by
the DSF-copper combination and was associated with signifıcant inhibition of
MGMT in the tumor cells. Conclusion: The results demonstrate signifıcant sen-
sitivity of GBM and, for the fırst time, medulloblastoma, cells to DSF-copper,
which is dependent on both the duration of cellular exposure to and the sched-
uling of DSF and copper. The DSF-copper combination increases the sensitivity
of temozolomide-resistant, methylatorve GBM cells to temozolomide. The
fındings support DSF-copper as a treatment strategy for GBM andmedulloblas-
toma.
#4054 Development of dual function small molecules as therapeutic
agents for cancer treatment. Scott Grindrod,1 Alfredo Velena,2 Mira Jung2.
1Shuttle Pharmaceuticals, Rockville, MD; 2Georgetown University, Washington,
DC.
Inhibitors of histone deactylases (HDACs) are emerging as potent anti-cancer
agents for treatment of patients with hematopoietic and solid tumors. However,
most of these compounds exhibit limitations, including off-targets and toxicity.
To improve the effıcacy and target specifıcity of drugs, we developed the com-
pound, SP-1-161 conferring HDAC inhibition activity and ataxia-telangiectasia
mutated (ATM) activation. The purpose of this study is to develop a therapy that
optimizes the protective effects of ATM activation in normal tissue with the
sensitizing effects ofHDAC inhibition in cancerous tissue into a singlemolecule.
The compound SP-1-161was rationally designed by optimizingATMactivation
by the cap domain of a hydroximic acid, screened against a panel of Class I and
Class II HDAC enzymes, and identifıed as a pan-HDAC inhibitor with nano-
molar potency (IC50  8 nM). Western analysis confırms that SP-1-161 in-
creases acetylated histone H3/H4 and -tubulin and ATM activation in MCF7
cells. Phosphorylated ATM was gradually increased within 1 - 4 hrs in a time-
dependent manner. SP-1-161 was then tested in normal breast epithelial
(184A1) and breast cancer (MCF7) cell lines to determine its cytotoxicity and
effect on radiation clonogenic survival in combination with graded radiation
exposure. The data showed that the cytotoxicity values (IC50) were low micro-
molar ranges. Furthermore, SP-1-161 protected 184A1 cells (fromD0 1 Gy to
D0 1.4 Gy) while increasing sensitivity of MCF7 cells to IR (from D01.6 Gy
to D01.12 Gy). Together, our results demonstrate that SP-1-161 is an unprec-
edented radio-chemo therapeutic agent for treatment of cancers while protect-
ing normal cells.
#4055 Enhancing anti-PD-1 immune blockade in melanoma through se-
lective inhibition of histone deacetylase 6. Tessa Knox,1 Eva Sahakian,2 Jaya-
kumar Nair,1 Jennifer Kim,1 Debarati Banik,1 Melissa Hadley,1 John Powers,2
FengdongCheng,1 Sida Shen,3 Javier Pinilla,2 JeffreyWeber,4 AlanKozikowski,3
Eduardo Sotomayor,1 Alejandro Villagra1. 1The George Washington University,
Washington, DC; 2H. Lee Moffıtt, Tampa, FL; 3University of Illinois at Chicago,
Chicago, IL; 4NYU Langone Medical Center, New York, NY.
Histone deacetylases (HDACs), were originally described in a limited context
as histone modifıers. New evidence has demonstrated that HDACs are also
involved in a diverse range of cellular processes that are not restricted to the
chromatin environment, such as the regulation of the cell cycle/apoptosis and,
more recently, a modulator of immune response. However, much remains un-
known about themechanismof action ofHDACs and their roles in the immune-
biology of cancer. The non-specifıc nature of pan-HDAC inhibitors results in a
narrow therapeutic window of use, limiting the dose and duration due to toxic-
ity. Our group has focused in one specifıc HDAC,HDAC6, and shown that both
the genetic abrogation and pharmacological inhibition of thisHDACmodulates
the expression of a variety of immune-regulatory proteins in the tumor mi-
croenvironment, including PD-L1, PD-L2, MHC class I, B7-H4 and TRAIL-R1.
In particular, we have previously demonstrated that both pharmacological inhi-
bition and/or genetic abrogation of HDAC6 plays a critical role in the immune
check point blockade by down-regulating the expression of PD-L1 and other
check-point modulators such as PD-L2, B7-H4, etc. Moreover, we have also
observed that in vivo inhibition of HDAC6 reduces tumor growth in B16 and
SM1murinemelanomamodels within syngeneic immunocompetent hosts. Ad-
ditionally, we have found that the combination of low doses of the HDAC6i
Nexturastat A and checkpoint immune blockade, including anti-PD-1 and anti-
CTLA4, results in an important improvement in anti-tumor immune responses
as evidenced by the reduction of tumor growth when compared to treatment
with individual stand-alone agents. In these studies we also evidenced an in-
creased production of IFN and IL-2 in the stand-alone check-point inhibitor
treatments, which leads to an upregulation of PD-L1 and PD-L2. Similar levels
of IFN and IL-2 were found in the combination groups. However, the expres-
sion level of PD-L1 and PD-L2 were comparable to the non-treated group. Tak-
ing all together, we have found that HDAC6i could be used as a potential adju-
vant in ongoing therapeutic options involving immune check-point blockade.
#4056 A modulator of multidrug resistance protein 1 selectively depletes
glutathione and synergizes with L-buthionine sulfoximine to sensitize
MRP1-expressing cancer cells to chemotherapy.ChristineC.Gana, Kimberley
Hanssen, Denise M. Yu, Claudia Flemming, Murray Norris, Michelle Haber,
Jamie Fletcher. Children’s Cancer Institute, Sydney, Australia.
Multidrug resistance protein 1 (MRP1) is frequently overexpressed in
tumors where it effluxes chemotherapeutic agents, protecting tumor cells
from chemotherapy. This is clearly illustrated in the pediatric solid tumor
neuroblastoma, where MRP1 expression is highly prognostic of clinical out-
come (1,2) and contributes to chemoresistance in mouse models (3). MRP1
also effluxes low levels of glutathione (GSH), a crucial intracellular antioxi-
dant necessary to avoid damage from the reactive oxygen species induced by
radiotherapy and chemotherapy and an important component of both Phase
II and Phase III drug metabolism. Depletion of GSH in cancer cells would be
of therapeutic value, however the GSH synthesis inhibitor L-buthionine sul-
foximine (BSO) has only limited selectivity for tumor over normal cells. We
have identifıed a novel MRP1 inhibitor, 7-methyl-5-phenyl-2-[(4-phenyl-1-
piperazinyl)carbonyl]pyrazolo[1,5-a]pyrimidine, that blocks MRP1-medi-
ated drug efflux while greatly enhancingMRP1-mediated GSH efflux and are
investigating the utility of this dual-function inhibitor for the treatment of
MRP1-overexpressing cancers. Methods: Cells expressing high levels of
MRP1 were treated with MRP1 drug substrates in combination with MRP1
inhibitors. Viability was assessed by short-term cytotoxicity or clonogenic
assays and GSH levels determined by glutathione recycling assay. Results:
Our MRP1 modulator depleted intracellular GSH in an MRP1-dependent
manner and sensitized MRP1-expressing human neuroblastoma, lung and
ovarian cancer cell to chemotherapeutics. This effect was highly synergistic
with BSO, both in depleting GSH (CI0.36, p0.05) and abolishing colony
formation (CI0.01, p0.05). Conclusion: Our MRP1 modulator blocks
MRP1- mediated drug efflux while greatly enhancing MRP1- mediated GSH
efflux inMRP1 expressing cells, potentially providing an increased therapeu-
tic window for chemotherapeutics in MRP1- overexpressing cancers. Syn-
ergy with BSO could widen the range of drugs and cancers that this could be
benefıcial for. References: 1. Haber, M., et al., (2006) J.Clin Oncol 24, 1546-
1553 2. Norris, M. D., et al., (1996) New Engl J Med 334, 231-238 3. Burkhart,
C. A., et al., (2009) Cancer Res 69, 6573-6580.
#4057 Inhibition of polyploidy and senescence induces intrinsic apoptosis
in double hit or double expresser DLBCL. Shariful Islam,1WenqingQi,2 Carla
Morales,3 LaurenceCooke,1 CatherineM. Spier,1DarukaMahadevan1. 1Univ. of
Arizona, Tucson, AZ; 2University of Tennessee Health Science Center, Memphis,
TN; 3St. Jude Children’s Research Hospital, Memphis, TN.
Introduction: Double Hit (DH) or Double Expresser (DE) DLBCL are
aggressive Non-Hodgkin’s Lymphomas (NHLs) with translocation or over-
expression of MYC and BCL-2 which are incurable with current therapies.
MYC is a critical driver of oncogenic phenotypes and regulates expression of
numerous genes including aurora kinases (AKs), which are validated drug
targets. AKs are over-expressed in DLBCL and AK inhibition in two Phase-II
trials of relapsed and refractory B/T-NHL resulted in 20%-30% overall re-
sponse rate. Bruton’s tyrosine kinase (BTK) plays a central role in B-cell
receptor (BCR) signaling and inhibitors of BTK have shown effıcacy in B-
NHL clinical trials. Targeting CD20 (rituximab) in DLBCL inhibits BCL-2
and induces apoptosis via caspase-3 activation. We hypothesized that DH/
DE-DLBCL are amenable to a novel therapeutic strategy of AK, BTK and
CD20 inhibition.Methods: Four DH/DEDLBCL cell lines were evaluated for
viability by MTS; polyploidy, senescence and apoptosis by flow cytometry;
DNA damage by TUNEL assay. Phospho-BCL-2, -AK and -BTK analysis by
western. Safety and effıcacy of drug combinations in a mouse xenograft
model. Analysis of patient samples and mouse tumors by IHC. Results: DH/
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DE-DLBCL cell lines and patient samples displayed over-expression of
MYC, BCL-2, BTK and AK-A proteins. Cell viability assays with alisertib
alone showed30% cell death, while majority of remaining70% cells were
polyploid and senescent at day-4 (a mechanism of treatment failure). These
polyploid and senescent cells (PASC) showed increased levels of phospho-
BTK indicating increased BCR signaling (a rationale for combination ther-
apy). We show that alisertib  ibrutinib  rituximab signifıcantly reduced
PASCs leading to intrinsic cell death compared to single/double combina-
tions. Dual inhibition of AK  BTK reduced phospho-ERK-1/2, -Bcl-6 and
-MYC with increased DNA breaks indicated by up regulation of phospho-
H2A-X, -Chk-2, and pro-apoptotic Noxa and Puma proteins. Triple therapy
reduced Bcl-2, Bcl-xL and increased Noxa and Puma compromising the
mitochondrial outer membrane potential, release of Cyt-C, activation of
caspase-3 and induction apoptosis by PARP cleavage. ADLBCL SCIDmouse
xenograft model showed ibrutinib alone is inactive while alisertib  ibruti-
nib was additive with a tumor growth inhibition (TGI) rate of25%. TGI for
ibrutinib rituximab was50-60%. However, triple therapy showed a TGI
of 90% and was well tolerated. Survival analysis: 67% of mice alive at
day-89 with triple therapy versus 20% with ibrutinib  rituximab. Other
treatments showed no survival past day-52. Conclusions: A novel triple ther-
apy consisting of alisertib  ibrutinib  rituximab inhibits PASCs induced
by AK inhibition in DH/DE-DLBCL leading to a signifıcant anti-prolifera-
tive signal and intrinsic apoptosis. Our work provides a rationale for explor-
ing these combinations in the clinic.
#4058 Preclinical and phase-2 clinical study of valproic acid adminis-
tered in combination with cisplatin and cetuximab in recurrent/meta-
static head and neck cancer. Alfredo Budillon, Andrea I. Zotti, Carlo Vita-
gliano, Elena Di Gennaro, Francesco Caponigro. Instituto Nazionale
Tumori, Napoli, Italy.
Recurrent metastatic (R/M) squamous cell carcinoma of the head and
neck (SCCHN) is a devastating malignancy with a poor prognosis and the
combination of cisplatin (CDDP) and cetuximab (CX) is one of the gold
standard for treatment. However, this therapy is often associated with high
toxicity and resistance, suggesting that the concomitant use of novel com-
pounds represents a critical strategy to improve treatment results. Histone
deacetylase inhibitors (HDACi) enhance the activity of several anticancer
drugs including CDDP and anti-Epidermal Growth Factor Receptor (EGFR)
compounds. EGFR overexpression is involved in chemotherapy resistance
and recently it has been demonstrated that EGFR nuclear localization rep-
resents one of the mechanism of resistance to both CDDP and CX. Our
group have demonstrated that HDACi synergize with anti-EGFR agents by
modulating ErbB receptors expression including EGFR. In this study we
evaluated the capability of Valproic acid (VPA), a generic low-cost anticon-
vulsivant drug with HDACi activity, to enhance the effıcacy of CDDP-CX
association in SCCHN cells with different EGFR basal expression and ge-
netic backgrounds. We showed, by the calculation of combination indexes,
an antiproliferative synergistic interaction between equipotent doses of VPA
and CDDP-CX in CAL27 and FaDu SCCHIN cells using either simultaneous
or sequential (with 24 h delay) schedule of administration. Notably, this
effect was not observed in immortalized human fıbroblasts BJ-hTERT, sug-
gesting a selective effect toward tumor cells. Next, we confırmed synergistic
interaction by testing clinically achievable concentrations of VPA/
CDDP-CX combination also on CAL27 and FaDu 3D spheroid cultures,
showing inhibition of fırst- and second-generation spheroids formation by
triple combination, compared to single agent treatments. Moreover we dem-
onstrated that VPA was able to down-regulate EGFR and to prevent EGFR
nuclear translocation induced by CDDP and CCDDP/CX combination, thus
preventing the activation of DNA repair and survival pathways. Indeed, we
showed that VPA was able to increase DNA damage and apoptosis induced
by CDDP-CX combination, evaluated by gamma H2AX foci and annexin
V-FITC assay, respectively. In vivo preclinical study is currently ongoing. All
together these data represent the rationale of the ongoing V-CHANCE
phase-2 clinical trial evaluating VPA/ CDDP-CX combination in R/M
SCCHN patients. We are also currently investigating pharmacodynamics/
predictive biomarkers of treatment effıcacy/resistance on patient’s samples.
#4059 KPC34: a co-drug that combines a DNA damaging agent with a
targeted therapy for the treatment of AML. Gregory L. Kucera, Peter Alexan-
der, Kristin Pladna, Timothy S. Pardee. Wake Forest School of Medicine, Win-
ston-Salem, NC.
AML occurs in the elderly with 18,000 new US cases in 2014. Mortality
is an estimated 10,050 US deaths in 2014. Elderly patient prognosis is a
dismal 6.6%, 5 year survival rate. AML treatment involves induction chemo-
therapy with Ara-C followed by consolidation therapy or stem cell trans-
plant. The major obstacle to long-term disease-free survival is relapse after
treatment due to chemoresistance. Chemoresistance occurs by several mech-
anisms including reduced activation of Ara-C via down-regulated deoxycy-
tidine kinase (dCK) levels or decreased uptake via lowered Equilibrative
Nucleoside Transporter 1 (ENT-1) levels. The low expression of both dCK
and ENT-1 correlates with a poor prognosis in patients with acute leukemias.
Recurrent disease is more diffıcult to treat successfully. Elderly patients often
have trouble tolerating repeated chemotherapy treatments. Activation of
NF- by protein kinase C (PKC) promotes proliferation and inhibits apo-
ptosis in AML. Increased expression of PKC isoforms has been detected in
AML. The activity of these isoforms promotes leukemic proliferation and
survival by ERK activation and BCL-2. KPC34 is a novel synthetic phospho-
lipid/deoxycytidine analog conjugate. KPC34=s novel properties result in
improved pharmacokinetics. It overcomes chemoresistance to Ara-C by by-
passing ENT-1 uptake and dCK activation. KPC34 is administered orally. It
crosses the blood-brain barrier, targeting CNS-infıltrating leukemias. Fi-
nally, KPC34=s lipid moiety inhibits PKC activity. The study’s hypothesis is
that KPC34 is active against AML in vivo. KPC34 is highly cytotoxic to a
variety of leukemic cell lines in vitro, with IC50s in the nM range. The mean
IC50 was 45.92 nM (range from 7.39-175.6 nM). In order to assess the activity
of KPC34 in vivo, we injected NSG mice with OCI-AML-3 cells expressing
luciferase. Following engraftment, mice were treated with KPC34, Ara-C, or
water on days 1, 4 and 7. A signifıcant prolongation of survival was observed
in the KCP34-treated mice (median survival 44.5 days vs. 25 days for Ara-
C-treated mice, p0.0033, by log-rank test). Retreatment of the mice with
additional KPC34 resulted in a median survival time of 78.5 days (p0.0028,
single KPC34 course vs. 2 additional treatment courses). KPC34  doxoru-
bicin is superior to the treatment of mice with Ara-C  doxorubicin. In a
PDX murine model, KPC 34 showed a reduction in leukemic burden in the
liver and spleen. KPC34 is well tolerated in vivo. KPC34 is effective against
multiple models of naïve and chemoresistant leukemia. It has two distinct
anti-neoplastic mechanisms. Oral administration improves effıcacy over i.v.
dosing. These data demonstrate KPC34 effıcacy in multiple preclinical mod-
els of leukemia, and support its continued translation to the clinic. This
co-drug has the potential to replace Ara-C-based therapies as a single agent/
combo in naïve AML, a single agent in relapsed leukemia, and it reduces the
CNS leukemic burden.
#4060 Pharmacological targeting of the Aurora A and Histone 3 lysine 9
methyltransferase pathways in pancreatic cancer induces mitotic catastro-
phe. Angela Mathison,1 Ann Salmonson,1 Mckenna Missfeldt,1 Thiago de As-
suncao,1 Jennifer Bintz,2 Trace Christensen,1 Sarah Kossak,1 Asha Nair,1 Juan
Iovanna,2 Robert Huebert,1 Gwen Lomberk1. 1Mayo Clinic, Rochester, MN;
2Cancerology Research Center of Marseille (CRCM); INSERM U1068, Marseille,
France.
By regulating gene expression networks that mediate neoplastic behavior,
epigenetic protein complexes are the ultimate effectors of oncogenic pathways.
This hierarchical position of epigenetic pathways within the mechanisms that
regulate cancermakes them ideal candidates for therapeutic targets. The current
work was designed to characterize the role of the K9H3 Histone Methyltrans-
ferase (HMT) pathway in mediating oncogenic signals downstream of Aurora
Kinase A (AurkA), with the goal of designing effıcient combinatorial therapies
against PDAC. Affınity protein purifıcation, combined withmass spectrometry,
demonstrates thatHP1 isolated frommitotic cells interactswithAurkAand the
HMTs, G9a and GLP. We also fınd that this complex is critical for mitotic
progression and cell proliferation. Congruently, treatment of PDAC cells with
individual drugs against AurkA or HP1-HMT inhibits cell growth by inducing
senescence, a cytostatic response. However, the combination of these agents has
a synergistic effect of reducing cell growth in both, monolayer and spheroid
cultures to result in a cytotoxic effect. Confocal and electron microscopy, along
with cell cycle analysis, demonstrate that the cytotoxic effect of this combination
is due to induction of mitotic catastrophe, a distinct form of cell death that
occurs during mitosis. Molecularly, the combination of AurkA and HP1-HMT
inhibition bypassesG2/Marrest with downregulation of theChk1-Cdc25c path-
way. In vivo treatment of PDAC orthotopic xenografts with the HP1-HMT
inhibitor alone demonstrated reduced PDAC growth, and increased effıcacy in
PDACgrowth reductionwas observed in combinationwith theAurkA inhibitor
over either individual treatment. Thus, our data demonstrate a novel AurkA-
HP1-HMT mitotic pathway that holds promise for potential pharmacological
targeting in combinatorial therapy for this malignancy.
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EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Mechanistic Understanding of Novel Anticancer Therapies
#4061 Computational exploration of mechanistic determinants of anti-
body drug-conjugate pharmacokinetics using quantitative systems pharma-
cology modeling strategies. A. Katharina Wilkins, Andrew Matteson, Lore
Gruenbaum, Jennifer Park, John M. Burke, Joshua Apgar. Applied BioMath,
LLC, Lincoln, MA.
The pharmacokinetics of antibody drug conjugate (ADC) therapeutics typi-
cally show a discrepancy between the PK of total antibody (conjugated and
unconjugated antibody) and that of conjugated antibody, carrying one or more
payload molecules. This discrepancy is often attributed to deconjugation (Ka-
math, 2014), however recent evidence suggests that the underlying mechanisms
may bemore complex. This work employs a computational quantitative systems
pharmacology (QSP), or mechabistic PK/PD approach to understand the im-
pact of drug antibody ratio (DAR) and the resulting changes in molecular prop-
erties on overall PK and relative payload disposition as observed in preclinical
and clinical studies. Our work establishes the benefıt of using computational
models to design novel ADCs and to optimize the discovery and development of
existing ADCs.
#4062 A computational driven protocol of metronomic oral vinorelbine
in metastatic non small cell lung cancer. Diane-Charlotte Imbs,1 Raouf El
Cheikh,1 Joseph Ciccolini,1 Raphaël Serre,1 Fabrice Barlesi,2 Dominique Barbo-
losi1. 1Aix-Marseille University, Marseille, France; 2Assistance Publique Hôpi-
taux de Marseille, Marseille, France.
Over the last decade, metronomic chemotherapy (MC) has emerged as an
alternative way to administrate chemotherapy. MC can be defıned as regular
administration of low/less-toxic doses without extended drug-free breaks. Be-
cause countless schedules are possible, testing them empirically looks like an
unachievable goal. Therefore, mathematical modeling can be an effective tool to
determine appropriate metronomic strategies. A phase Ia/Ib study based on a
mathematical model of oral vinorelbine in metastatic NSCLC and malignant
pleural mesothelioma was designed to confırm safety and evaluate effıcacy of a
new metronomic regimen (Elharrar et al. 2016). The optimized schedule pro-
viding weekly Day1 (D1), D2 and D4 with respective doses of 60, 30 and 60 mg
was suggested by in silico simulations using a Pharmacokinetic-Pharmacody-
namic (PKPD)model taking into account vinorelbine PK, PD toxicities and PD
effıcacy (Faivre et al. 2013). Trial recruitment will be two-staged, as 12 patients
have been enrolled to confırm safety and consolidate the calibration of model
parameters. An extension phase on 20-extra patients will be conducted to eval-
uate the effıcacy of the optimized protocol. Monolix 4.3.3 was used for popula-
tion PKPD analysis. A three-compartment model best described oral vinorel-
bine PK data. PK analysis revealed a high inter-individual variability on drug
exposure (CV73%). PD toxicity (neutropenia) was adequately described by a
modifıed Friberg model (Friberg et al. 2002), considering continuous adminis-
trations of metronomic dosing regimen. On the 12 recruited patients, 3 (25%)
presented either a stable disease (SD) or a partial response (PR). No direct link
has been established between toxicity (grade 4 neutropenia) and drug exposure.
However, responders to treatment were those presenting a higher vinorelbine
area under the curve (p0.02). Tumor assessments were used to adjust effıcacy
parameters. The model was used to simulate alternative metronomic scenarios
targeting higher effıcacy with similar toxicity. Simulations showed that the ini-
tial proposed schedule was the most appropriate in terms of effıcacy/toxicity
balance. Its effıcacy will be evaluated in the second part of the study. This trial
can be considered as a proof-of-concept study demonstrating the feasibility to
run a computational-driven protocol to ensure an optimal effıcacy/toxicity bal-
ance in cancer patients.
#4063 Design and synthesis of indole derivatives as ABCG2 mediated re-
sistance reversal agents. Chao-Yun Cai,1 Hong Zhai,2 Zi-Ning Lei,1 Bao-Li
Chen,2 Zhao-Yi Du,2 Yun-Kai Zhang,1 Yi-Jun Wang,1 Bo Wang,2 Zhe-Sheng
Chen1. 1St. John’s University, Queens, NY; 2Sun Yat-Sen University, Guangzhou,
China.
Multidrug resistance is a phenomenon that cancer cells become resistant to
anticancer drugs. Multidrug resistance has been shown to be related with the
overexpression of ATP-binding (ABC) transporters, including ABCG2. There-
fore, ABCG2 is a therapeutic target for the development of multidrug resistance
reversal agents. Fumitremorgin C, with an indole group which is an important
pharmacophore in many drugs, is a known ABCG2 inhibitor. Inspired by this,
we synthesized two series of indole derivatives as ABCG2 mediated resistance
reversal agents. With MTT assay, we found that two compounds from the two
series of indole derivatives respectively exhibited good reversal activity against
ABCG2. The two compounds did not signifıcantly alter the expression of
ABCG2 in ABCG2-overexpressing cell lines and they stimulated the basal ATP
hydrolysis of ABCG2.
#4064 Relating tumor drug concentrations to target effect with semi-
physiologic PK-PD modeling in drug development: an application using a
novel dCK inhibitor.MinaNikanjam,1 Soumya Poddar,1 Edmund Capparelli,2
Thuc Le,1 Liu Wei,1 Caius Radu1. 1University of California Los Angeles, Los
Angeles, CA; 2University of California San Diego, San Diego, CA.
Introduction:While plasma concentrations are commonly studied in preclin-
ical and clinical studies, drug concentrations in tumor and effects on molecular
targets may be more appropriate for determining drug dosing and predicting
response to therapy. The current study assessed tumor and plasma drug levels of
DI87, a novel deoxycytidine kinase (dCK) inhibitor, and determined the rela-
tionship to dCK activity using a PET biomarker and imaging. Methods: NSG
mice with CEM tumors were treated with DI87 (25 or 50 mg/kg) by oral gavage
for a single dose. Tumor and plasma concentrations were assessed over 24 hrs
(50 mg/kg dose, 5 times points, N4 separate mice per time point). Plasma and
tumor DI87 concentrations were quantifıed by LC-MS/MS. dCK activity was
determined by PET imaging of a biomarker for dCK activity over 27 hrs ([18F]-
clofarabine probe was injected 3 hrs prior to imaging) after a single dose of DI87
(50 mg/kg or 25 mg/kg, 5 time points, 4 mice per time point). Nonlinear mixed
effects modeling (NONMEM v. 7.2) was used to build a semi-physiologic phar-
macokinetic (PK) model to describe tumor and plasma concentrations (tumor
volume fıxed to observed median tumor size). The PK model was linked to an
inhibitory indirect response pharmacodynamic (PD) model of dCK activity in
the tumor using a pooled naïve approach to describe the relationship between
drug levels in the tumor and dCK inhibition. Results: Peak tumor DI87 concen-
trationswere lower (1.15	 0.64g/mLvs. 13.5	 4.5g/mL) andoccurred later
(9 vs. 3 hr) than peak plasma concentrations. Despite limited tumor sampling,
the semi-physiologic model described tumor concentrations well (R20.71).
The PK model had a plasma clearance of 0.52 L/hr/kg with a half-life of 3.7 hr.
DI87 exposure in the tumor (AUC) was 17% of that observed in plasma. Maxi-
mal and near complete dCK inhibition occurred at 9 hr for both the 50 mg/kg
and 25 mg/kg doses with recovery of dCK activity beginning at 27 hr post-dose.
The predicted tumor concentration at 12 hr of 0.36 g/mL was suffıcient to
maintain maximal dCK inhibition. The initiation of recovery of dCK activity
corresponded to the decline in tumor DI87 concentrations, but maintained sig-
nifıcant inhibition at 27 hr (25% of baseline). The relationship between dCK
activity and DI87 tumor concentrations was well characterized by a sigmoid
Emax PDmodel with a largeHill coeffıcient. This resulted in a dramatic increase
of effect over a small range of concentrations. The EC50 was within the range of
tumor concentrations observed in the study (0.21g/mL). Conclusions: The use
of semi-physiologic PK models that include tumor drug concentrations from
limited preclinical data can increase knowledge of the PK-PD for novel thera-
peutics. This approach enhances understanding of time-dependent effects on
molecular drugs targets and can improve selection of rational clinical dosing
regimens for phase I clinical trials.
#4065 Association study between iron and cholesterol for the treatment of
drug resistant neuroblastoma. Sang Y. Lee, Becky Slagle-Webb, Cara-Lynne
Schengrund, James Connor. Penn State Univ. College of Medicine, Hershey, PA.
Neuroblastoma is the most common childhood extracranial solid malig-
nancy. Although cancer cells need more iron and lipids for their active cell
metabolism, possible links between iron, mutations in genes involved in iron
metabolism (e.g., HFE) and lipid metabolism have not been studied well. We
determined the HFE genotype in human neuroblastoma cells as well as patients.
Neuroblastoma cells and patients have C282YHFEmutation rates (12%) that
are similar to those of the general Caucasian population. While cultured cells
derived from drug resistant neuroblastomas had less cholesterol, they expressed
more ferritin, and containedmore iron, than cells derived fromdrug susceptible
tumors. In drug resistant neuroblastoma CHLA-171 cells, siRNA induced alter-
ation of HFE expression had no effect on their iron levels but decreased their
cholesterol. Results of in vitro experiments indicated that simvastatin, an inhib-
itor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoAR), was
cytotoxic to drug resistant cells as was the iron chelator di-2-pyridylketone-4-
cyclohexyl-4-methyl-3-thiosemicarbazone (DpC). In vivo, the anti-tumor effect
of simvastatin administered orally was minimal. In summary, we found i) an
inverse association between ferritin and HMG-CoAR expression in neuroblas-
toma cells that was reflected in their iron and cholesterol levels, and ii) that the
most cytotoxic cholesterol inhibitor of neuroblastoma cells was simvastatin,
while themost cytotoxic iron chelation agent was DpC. Our results indicate that
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it may be possible to use HFE genotype to develop a precision medicine ap-
proach to use certain iron chelators and/or cholesterol decreasing agents in the
treatment of drug resistant neuroblastomas. Our results also indicate that alter-
ations in iron and cholesterol metabolism are part of the cell’s drug resistance
mechanism in neuroblastomas.
#4066 The dihydroartemisinin oxime dimer (NSC735847) displays a se-
lective toxicity in colon cancer cells which is potentially mediated by endo-
plasmic reticulum stress. Ahmed E. Elhassanny,1 Eman Soliman,2 Paul
McGuire,1 Mahmoud ElSohly,3 Waseem Gul,4 Rukiyah Van Dross5. 1Brody
School of Medicine, East Carolina University, Greenville, NC; 2Faculty of Phar-
macy, Zagazig University, Sharkia, Egypt; 3ElSohly Laboratories Inc. and Na-
tional Center for Natural Products Research, School of Pharmacy, The University
ofMississippi, Oxford,MS; 4ElSohly Laboratories Inc., Oxford,MS; 5Brody School
of Medicine and Center for Health Disparities East Carolina University, Green-
ville, NC.
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in
the United States. Common chemotherapeutic regimens for CRC include a
combination of chemotherapeutic agents to produce synergistic drug activity
and reduce adverse effects. However, adverse effects due to lack of selective
toxicity is still a major problem with many chemotherapeutic agents. Novel
drugs that display tumor selective toxicity are desperately needed. Several stud-
ies have shown that artemisininmonomers (Clinically used anti-malarial agent)
possess antineoplastic activity with minimal toxicity. Interestingly, artemisinin
dimers showedmore potent antineoplastic activity compared to themonomers.
However, few studies have fully characterized the activity of these molecules. In
this study, we tested the antitumor activity of fıve chemically-synthesized dihy-
droartemisinin (DHA) dimers using the human colon cancer cell lines, HT29
andHCT116 and the non-tumorigenic colon cell line, FHC. Compared to other
tested dimers, theDHAoxime dimer, NSC735847 showed pronounced selective
toxicity in HT29 and HCT116 cells. Using MTS cell viability assays,
NSC735847caused a preferential reduction in the viability ofHT29 andHCT116
colon cancer cells compared to the non-tumorigenic FHC cells. In addition,
NSC735847 signifıcantly increased caspase 3/7 activity in HT29 and HCT116
cells but not in FHC cells which suggests that this compound causes selective
apoptosis in these colon cancer cell lines. The combination of NSC735847 and
the topoisomerase I inhibitor, irinotecan (commonly used chemotherapeutic
agent for colorectal cancer) showed synergistic antitumor activity in HT29 cells.
The combination of the two drugs caused a signifıcant increase in cell death and
caspase 3/7 activity which were greater than those caused by the individual
drugs. Previous studies using other tumorigenic cell lines, suggested that
NSC735847 induces oxidative and endoplasmic reticulum (ER) stress. To gain
insight into the potential mechanisms of anti-colorectal cancer activity of
NSC735847, we tested if this compound causes ER stress and/ or oxidative stress
in HT29 cells and whether ER stress was required for NSC735847-induced ap-
optotic cell death. NSC735847 increased the expression of ER stress marker
C/EBP homologous protein 10 (CHOP10) inHT29 cells and the use of ER stress
inhibitor, salubrinal, signifıcantly decreasedNSC735847-induced cell death and
apoptosis. Additionally, NSC735847 caused oxidative stress inHT29 cells which
was inhibited by pretreatment of the cells with the antioxidant, trolox. The
crosstalk between oxidative stress and ER stress inNSC735847-induced apopto-
sis in colon cancer cells is still under investigation. Our results suggest that
NSC735847 causes ER stress in HT29 cells which plays a major role in drug-
induced cell death and apoptosis in these cells.
#4067 BPM31510, a clinical stage metabolic modulator demonstrates
therapeutic effıcacy in an in vivo C6 rat glioma model and synergizes with
temozolomide. Stephane Gesta,1 Semma Nagpal,2 Tulin Dadali,1 Milton Mer-
chant,2 Taichang Jan,2 Anne R. Diers,1 Michael Kiebish,1 Joaquin Jiminez,3
Vivek K. Vishnudas,1 Niven R. Narain,1 Rangaprasad Sarangarajan,1 Lawrence
Recht2. 1BERG, LLC, Framingham,MA; 2StanfordMedical, Palo Alto, CA; 3Uni-
versity of Miami, Miami, FL.
BPM31510, a parenteral nanodispersion of ubidecarenone that is in clinical
testing for solid tumors, effectuates an anti-cancer effect in highly metabolic
cancers by eliciting an anti-Warburg effect. Intraperitoneal (i.p.) administration
of BPM31510 reverses paraplegia in a rat CNS leukemia model demonstrating
the bioavailability of the drug to the central nervous system. The study describes
data demonstrating the therapeutic utility of BPM31510 in glioblastoma multi-
forme (GBM). BPM31510 decreased cell proliferation rates in patient derived
GBM cell lines compared to temozolamide (TMZ), pretreatment with
BPM31510 followed by TMZ challenge was associated with signifıcant synergy
in reducing cell proliferation compared to monotherapy. In a C6 glioma allo-
graft rat model treatment with BPM31510 alone (n30/group) (i.p., 50mg/kg,
b.i.d) increased overall survival compared to untreated control group.
BPM31510 in combination with procarbazine (oral, 60mg/kg; d 8, 21) and vin-
cristine (IV, 1.4mg/kg; d 8, 29) signifıcantly improved overall survival compared
to BPM31510 alone or chemotherapy. Furthermore, long term survival was
achieved in four of twenty rats with C6 gliomas receiving BPM31510 doses
between 10 and 50 mg/kg compared with none treated with either vehicle or
irradiation (P  0.02, Fisher exact test). Interestingly, the long term survival
persisted for over twomonths after all treatment was discontinued;MR imaging
confırmed the presence of static masses in these long term survivors. Collec-
tively, the data demonstrate that BPM31510 has a robust effect in a preclinical
model of GBM. Intravenous BPM31510 is currently in Phase 1/2 clinical trial for
TMZBEV refractory GBM patients.
#4068 HH-002, a derivative of Homoharringtonine, show promsing in
diverse cancer models in preclinical characterization. Hank Rui. Bensheng
Pharma Co. Ltd., Pudong, China.
Homoharringtonine (HHT) is an anti-cancer drug used to treat imatinib
resistant CML, and a reversible inhibitor of translation acting upon the early
steps in polypeptide chain elongation. BS-HH-002.SA is a derivative of HHT.
BS-HH-002.SA was shown to decrease the phosphorylation of Janus protein
tyrosine kinase 2 (JAK2) as well as downstream targets, such as signal transduc-
ers and activators of transcription 3 and 5 (STAT3 and STAT 5), it also reduced
Myeloid cell leukemia-1 (Mcl-1) protein level signifıcantly and resulted in apo-
ptosis. Evaluation of BS-HH-002.SA effıcacy. was test in HEL, an erthroleuke-
mia cell line carrying a JAK2V617F mutation which is seen in 90% of patients
with polycythemia vera (PCV) and half of thosewith essential thrombocythemia
or primary myelofıbrosis. HH-002.SA showed was highly potent (at low nM
concentration) to HEL. Effıcacy of BS-HH-002 was tested in a recombinant
human erythropoietin injection (rhEpo)-induced murine model of polycythe-
mia Vera, Treatment with BS-HH-002.SA BID for 4 days showed a signifıcant
inhibitory effect on rhEpo induced increase in reticulocytes, hematocrit and
splenomegaly, as well as in red blood cell, white blood cell and platelet counts.
Furthermore, histology evaluations revealed that BS-HH-002.SA exerted an in-
hibitory effect on rhEpo induced extramedullary hematopoiesis in spleen, and
decreased cellularity in bone marrow with more predominant effect on ery-
throid cells than onmyeloid cells. Also, BS-HH-002.SA also showpotent in vitro
and in vivo effıcacy in pancreatic cancer cell line KP-4 and non-small cell lung
cancer (NSCLC) NCI-H1975, BS-HH-002.S inhibited STAT3 Tyrosine 705
phosphorylation and reduced anti-apoptotic proteins expressionMcl-1 protein
levels in both two cancer cell lines.
#4069 Trimethylation and acetylation ofHistoneH3K27modulates 5-flu-
orouracil response by regulatingDPYDexpression.RentianWu.MayoClinic,
Rochester, MN.
The antimetabolite 5-fluorouracil (5-FU) is one of the most widely used che-
motherapy drugs. Dihydropyrimidine dehydrogenase (DPD) initiates the cata-
bolic degradation of 5-FU to inactive metabolites and is widely accepted as a
major determinant of 5-FU response and toxicity. While genetic variants in
DPYD have been shown to variants may affect 5-FU metabolism, they are rare
events anddonot completely explain the reported variability inDPD function or
the resultant differences in treatment response. Here, we report that DPYD
expression is epigenetically regulated by histone modifıcation at relevant pro-
moter and enhancer regions. Using both chemical inhibitors and genetic ap-
proaches, we show that that H3K27 tri-methylation (H3K27me3) at the DPYD
promoter is regulated by the epigenetic modifıers Ezh2 and UTX. Promoter
H3K27me3 suppresses DPYD expression by inhibiting the binding of the tran-
scription factor PU.1 bindingto the promoter and ,increases sensitivity leading
to increased resistance to 5-FU. In a cohort of healthy volunteers, H3K27me3
levels were inversely correlated with An enhancer that regulates DPYD expres-
sion was also identifıed. Modifying the H3K27 status of the DPYD promoter or
enhancer modulates DPYD gene expression. Deletions and mutations on the
DPYD promoter or enhancer abolish their transcription regulation function.
Enrichment of H3K27me3 at the DPYD promoter was negatively correlated
with both DPYD expression and DPD enzyme activity in peripheral blood
mononuclear cellsspecimens from healthy volunteers. Lastly, tumor expression
data suggests that DPYD repression by Ezh2 is a strong predictor ofs poor sur-
vival in 5-FU treated cancers. By using a combination of in silico prediction and
in vitro reporter assayswe also identifıed a functional enhancer region forDPYD
that is also likely to be clinically relevant to 5-FU treatment outcome. Collec-
tively, the presentthese fındings suggest that a previously uncharacterizedmech-
anisms regulates DPD expression andmay likely contribute to tumor resistance
to 5-FU.
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#4070 Salternamide A, a marine natural product, suppresses hypoxia-
induced accumulation ofHIF-1 and induces apoptosis in human colorectal
cancer cells. Duc-Hiep Bach, Woong Sub Byun, Seong-Hwan Kim, Ji-Young
Hong, Hyen Joo Park, Dong-Chan Oh, Sang Kook Lee. Seoul National Univ.
College of Pharmacy, Seoul, Republic of Korea.
Hypoxia inducible factor-1 (HIF-1) is an essential regulator of the cellular
response to low oxygen concentrations, activating a broad range of genes that
provide adaptive responses to oxygen deprivation. HIF-1 is overexpressed in
various cancers and therefore represents a considerable chemotherapeutic tar-
get. Salternamide A (SA), a novel small molecule that is isolated from a halo-
philic Streptomyces sp., is a potent cytotoxic agent against a variety of human
cancer cell lines. However, the mechanisms by which SA inhibits tumor growth
remain to be elucidated. In the present study, we demonstrate that SA effıciently
inhibits the hypoxia-induced accumulation of HIF-1 in a time- and concen-
tration-dependent manner in various human cancer cells. In addition, SA sup-
presses the upstream signaling of HIF-1, such as PI3K/Akt/mTOR, p42/p44
MAPK, and STAT3 signaling under hypoxic conditions. Furthermore, we found
that SA induces cell death by stimulating G2/M cell cycle arrest and apoptosis in
human colorectal cancer cells. Taken together, SAwas identifıed as a novel small
molecule HIF-1 inhibitor from marine natural products and is potentially a
leading candidate in the development of anticancer agents. Acknowledgment:
This work was supported by a National Research Foundation of Korea (NRF)
grant funded by the Korean Government (MEST) (MRC No. 2009-0083533).
#4071 FGFR1 inhibitor reverses Smoothened inhibition-induced epitheli-
al-to-mesenchymal transition in pancreatic ductal adenocarcinoma. Tista
Roy Chaudhuri,1 Qingxiang Lin,2 Ninfa L. Straubinger,1 WenWeeMa,3 Robert
M. Straubinger1. 1University at Buffalo, Buffalo, NY; 2Roswell Park Cancer Re-
search Institute, Buffalo, NY; 3Mayo Clinic, Rochester, MN.
The majority of Pancreatic cancer (PaCA) patients present with metastatic
disease and receive little benefıt from chemotherapy. Although nanoparticulate
carriers can potentially deposit sustained and high doses of chemotherapeutics
in tumors, PaCA tumors are poorly perfused, which limits drug deposition. Ten
days of oral dosing with NVP-LDE225 (40 mg/kg), an inhibitor of the sonic
hedgehog (SHH) pathway (sHHI), increased tumor deposition of blood-borne,
fluorescently labeled, sterically-stabilized lipidic (SSL) nanoparticles by enhanc-
ing the perfusion and permeability of the otherwise-impermeable microvascu-
lature of PaCA patient-derived xenograft (PDX) tumors. However, literature
indicates sHH ablation is associated with increased Epithelial-to-Mesenchymal
(EMT) transition and invasiveness in PaCA. Here we investigated the compen-
satory role of FGFR1 in sHHI-induced tumor progression. Four to 8 daily treat-
ments with the sHHI resulted in no signifıcant reduction of tumor volume, but
markedly increased the ratio of tumor cells (human mitochondria) to Colla-
gen1 in the stroma, in two s.c. low-passage PDX models of varying stromal
content. Immunostaining of sHHI-treated tumors revealed no alteration in total
FGFR1 expression, but showed a signifıcant elevation in the (1) percent of
FGFR1 pixels correlating with DAPI nuclei in tumor (human mitochon-
dria) cells and stromal cells, (2) number of vimentin (EMT) cells, and (3)
proliferative index marked by Ki67 nuclei, compared to controls, suggesting
accelerated tumor progression. Nuclear FGFR1 was associated with vimentin
cells, but was excluded from the nuclei of Ki67 cells in all groups, implicating
nuclear translocation of FGFR1 in EMT. NVP-BGJ398, a small-molecule pan-
FGFR inhibitor (FGFRI), administered p.o. for 3 days (15mg/kg/day) after 7d of
sHHI-pretreatment (1) signifıcantly reduced nuclear localization of FGFR1
compared to sHHI-treated animals, (2) reversed the ratio of human mitochon-
dria tumor cells to Collagen 1 stroma, (3) depleted vimentin structures by
2 fold, and (4) reduced Ki67 cells to control levels. FGFRI without sHHI-
pretreatment resulted in decreased nuclear FGFR1 relative to controls, but did
not impact proliferation, EMT, or tumor cell-to-stroma ratio. Finally, the sHHI/
FGFRI sequence increased functional (FITC-L. esculentum lectin) tumor ves-
sel density and area the perfused by vascular permeability probes (fluorescent
SSL) compared to both controls and sHHI-treated animals. FGFRI administra-
tion in vehicle-treated controls had no impact on vascular permeability or per-
fusion.We conclude that the combination of sHHI in sequencewith FGFRImay
reverse potentially deleterious effects of sHHI andmediate a transient enhance-
ment of tumor permeability, and increase deposition and penetration of nano-
particulate SSL drug formulations into pancreatic cancers.
#4072 FGFR inhibitors enhance gemcitabine sensitivity inpancreatic duc-
tal adenocarcinoma.Qingxiang Lin,1 Tista Roy Chaudhuri,2 Ninfa L. Straubin-
ger,2 Wen Wee Ma,3 Robert M. Straubinger2. 1Roswell Park Cancer Research
Institute, Buffalo, NY; 2University at Buffalo/State University of New York, Buf-
falo, NY; 3Mayo Clinic, Rochester, MN.
Pancreatic cancer (PaCA) is highly refractory to treatment, with a median
survival of 6months. Currently, gemcitabine (Gem), a difluoro analog of deoxy-
cytidine, is the standard care for PaCA, but it renders only a modest survival
benefıt. Combination therapy, integrating novel agents into standard-of-care
regimens, may maximize effıcacy of Gem-based therapy. Fibroblast growth fac-
tor receptor (FGFR) function is aberrant in pancreatic cancer, and suppression
of FGFRs inhibits pancreatic cancer growth and invasion. However, the mech-
anisms of FGFR action and their therapeutic utility in pancreatic cancer remain
to be elucidated. Here we tested the hypothesis that FGFRs can impact Gem
sensitivity of PaCA cells by employing pan-FGFR inhibitors and shRNAs
against FGFRs. NVP-BGJ398 and AZD4547 are novel FGFR inhibitors (FG-
FRIs) specifıc to FGFR1, FGFR2 and FGFR3, and are in various stages of clinical
trial. The FGFRIs modestly but signifıcantly inhibited proliferation, migration,
and invasion of PANC-1, MIAPaCa-2 cells in wound-healing and trans-well
assays. Treatment with low-concentration Gem (7.5nM) enhancedMIAPaCa-2
cell migration at 24hrs, but migration was reduced subsequently, suggesting a
sequence of delayed effects of Gemupon cell migration. After 72hrs of exposure,
Gemcombinedwith FGFRIs reducedMIAPaCa-2 cell proliferation signifıcantly
compared to controls or Gem- and FGFRI alone. Pharmacodynamic modeling
was employed to evaluate drug interaction, and the interaction coeffıcient Psi
was estimated by simultaneousmodeling of 16 different drug combinations over
a period of 0-96 hrs. The analysis estimated Psi0.78, which indicates syner-
gism. Compared to BGJ398 or Gem alone, the combination also increased the
percentage of cells arrested at S phase for a longer period of time. Western blots
revealed signifıcant downregulation of ribonucleoside-diphosphate reductase
large subunit (RRM1), DNA excision repair protein (ERCC1), and Epithelial-
to-Mesenchymal transition biomarkers (vimentin and snail) with FGFRI/Gem
treatment compared to Gem-treated cells, indicating that FGFRIs inhibit nu-
merous factors that may contribute to Gem resistance. Loss-of-function by
shRNA-mediated knockdown of FGFR1 in MIAPaCa-2 cells showed decreased
expression of RRM1, whereas knockdown of FGFR2 and FGFR3 mediated an
increase in RRM1 expression, implicating FGFR1 suppression in improving
Gem-sensitivity. These results suggest that inhibition of FGFR1 could poten-
tially enhance sensitivity of PaCA to Gem therapy, and that combining FGFRs
with gemcitabine is a promising treatment strategy in pancreatic cancer.
#4073 Antitumor activities of EGFR/HER2/HER4 kinase inhibitor
S-222611 in the experimental brain metastases of HER2-positive breast can-
cer. Michinari Hirata, Yukari Tanaka, Satomi Shinonome, Tomomi Yamada,
Mikinori Torii, Ken-ichi Nezasa, Hidekazu Tanaka. Shionogi &Co., Ltd., Osaka,
Japan.
S-222611 is an oral, reversible tyrosine kinase inhibitor of epidermal growth
factor receptor (EGFR), human EGFR2 (HER2) and human EGFR4 (HER4)
with antitumor activities in animal models expressing these proteins. In phase I
trials, S-222611 have shown to be well-tolerated with effıcacy against HER2-
positive tumors, including breast cancermetastatic to brain. The purpose of this
study is to evaluate the mode of action for S-222611 treatment in brain metas-
tasis using experimental mice models. At fırst, we examined the effect of
S-222611 on HER2-positive breast cancer cell “MDA-MB-361” intracranial im-
plantation model (ICM). Once daily oral administration of S-222611 signifı-
cantly reduced the tumor volume at doses ranging from 25 to 100mg/kg and the
ED50 value was 21.2 mg/kg. Furthermore, S-222611 showed the survival pro-
longing activity in the ICM and the activity was signifıcantly superior to that of
lapatinib. It is known that patients with breast cancers having brain metastases
display heterogeneous blood-tumor barrier (BTB) permeability that affects drug
delivery and effıcacy, also BTB integrities were reported to be disrupted in the
ICM. To understand the mode of action for S-222611 in patient whose BTB was
intact, we have developed the experimental brain metastases model by serial in
vivo passage (MDA-MB-361 intraventricular injection model; IVM). BTB in-
tegrities in IVM were confırmed to be largely remaining intact by fluorescently
labeled dextran incorporation study, and we examined the distribution of
S-222611 on this model after single oral administration at the clinical relevant
dose (50 mg/kg). By imaging mass spectrometry analysis, S-222611 concentra-
tion in the brain metastases of the IVM was signifıcantly higher than that of
lapatinib. The concentrations of S-222611 in the brain metastases of the IVM
showed 5.2 mol/L, which was remarkably higher than the in vitro IC50 value
(26.5 nmol/L) of S-222611 for growth inhibition of MDA-MB-361, indicating
that S-222611 could have potent antitumor activity in the brain metastases even
though the intact BTB was remained. In fact, once daily oral administration of
S-222611 signifıcantly reduced the tumor volume in the brain at 50mg/kg on the
IVM. Taken together, in vitro/in vivo antitumor studies forMDA-MB-361 sup-
ported that S-222611 could be effective against brainmetastaseswhich have both
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intact and permeable BTB. In conclusion, S-222611 is expected to be useful for
the treatment of patients with HER2-positive breast cancers, including those
with brain metastases.
#4074 Permeability changes and effect of chemotherapy in brain adjacent
to tumor in an experimental model of brain metastases of breast cancer.
Afroz Shareef Mohammad, Chris E. Adkins, Neal Shah, Rawaa Aljammal, Jes-
sica Griffıth, Paul R. Lockman.West Virginia Univ., Morgantown, WV.
Background: Brain metastases vasculature is compromised and more perme-
able than that of vasculature in normal brain. Unfortunately, little is known
about vascular permeability changes in brain adjacent to tumor (BAT). It is
critical to understand the potential changes as chemotherapy penetration and
accumulation brain tumors positively correlate with breakdown of the brain
vasculature. Herein, we evaluate quantitatively measure permeability, drug ac-
cumulation and cytotoxicity in normal brain that is adjacent (500microns) to
a tumor. Methods: The subclone population of brain seeking metastatic breast
cancer cells (MDA-MB-231Br) were injected into the left ventricle of female
NuNu mice. Mice were given a chemotherapeutic regimen of vinorelbine
(10mg/kg), erubilin (1.5mg/kg) or docetaxel (10mg/kg). Progression occurred
until neurological compromise was noted, at which time animals were injected
with texas red 625 Da(TR) and texas red dextran 3kDa (TRD). Dye concentra-
tions (measuring passive permeability changes) were determined in lesions and
the BAT using quantitative fluorescent microscopy. Chemotherapeutic induced
cytotoxicity was observed by staining for activated astrocytes and DNA damage
in neurons, glia and endothelia. Results: We observed permeability of TR is
highly heterogeneous both within and between the tumors (normal brain Kin
TR: 1.2 x10-5)with 2-40-fold increase in permeability over normal brain region.
TR concentrations in BAT (100m from tumor edge) is consistently 40% of the
tumor but signifıcantly higher than that of normal brain and TR permeability in
BAT increased 1-2.5-fold over normal brain. The permeability of TRD in tumor
increased 2.7- 8.4-fold over normal brain, whereas in BAT, the permeability
increased 1-1.6-fold over normal brain. We also observed animals treated with
chemotherapy showed activated astrocytes in BAT, along with some cellular
death. In vehicle treated animals there were little activated astrocytes and little
cell death in the BAT. Conclusions: Our data suggests that the tracer and drugs
accumulate in regions around tumors in the brain which result in neurotoxic
changes.
#4075 Effect of PEG chain length on antibody-drug conjugate tumor and
tissue distribution in tumor bearing xenograftmice.NagendraV. Chemuturi,
Martha Anderson, Julia Cochran, Thomas Pires, Josh Hunter, David Meyer,
Jason Neale, Alice Chin, Paul Pittman, Cindy Balasubramanian, Francisco
Zapata, Jessica Simmons, Robert Lyon, Steve Alley. Seattle Genetics, Bothell,
WA.
Antibody-drug conjugates (ADCs) are a promising new therapeuticmodality
having demonstrated clinical effıcacy in the treatment of cancer. While ADCs
have better exposures than their constitutive chemotypes, it is important that
theymaintain the favorable pharmacokinetics of their antibody backbones. Pre-
vious work incorporating PEG into the drug-linker as a sidechain helped to
mask the hydrophobicity of the chemotypes, resulting in improved ADC expo-
sures in rats compared to ADCs with non-PEGylated drug-linkers. The current
studies were aimed at understanding the effect of PEG chain length on ADC
effıcacy, tumor and tissue distribution in tumor bearing mice. Effıcacy and bio-
distribution of radiolabeled ADCs with 2, 4, 8, 12 and 24 PEG units in the
drug-linker as a side chain were investigated in SCIDmice bearing a subcutane-
ous xenograft of L540cy tumor cells. Anon-PEGylatedADCwas used as control.
Antibody based radioactivity in plasma, tumor, liver, lung, kidney, spleen and
brainweremeasured over 14 days.MMAE, the free drug released from theADC,
was measured by mass spectrometry. Reduction in tumor weight was deter-
mined as a measure of effıcacy. Compartmental analysis of the plasma exposure
data was conducted to understand the change in rate constants with change in
PEG chain length. ADCs with side chain PEGylated drug-linkers had greater
plasma and tumor exposures than the non-PEGylated control ADC. Increasing
PEGchain length in the linker led to increased plasma and tumor exposures, and
lower plasma clearances. Tumor distribution was binary with ADCs with 2 and
4 PEG units in the linker showing similar tumor exposures while the ADCs with
8, 12 and 24 PEG units providing similar but signifıcantly higher tumor expo-
sures. ADCs with 8, 12 and 24 PEG units in the linker had signifıcantly higher
tumor to plasma exposure ratios than ADCs with 2 and 4-PEG units in the
drug-linker. The reduction in tumor weights was also binary. ADCs with 2 and
4PEGunits provided a 35-45%decrease in tumorweightswhileADCswith 8, 12
and 24PEGunits in the linker provided 75-85% reduction in tumorweights. The
non-PEGylated control ADC decreased the tumor weights by 11%. In general,
PEGylated ADCs increased the extent of tissue distribution, but the tissue to
plasma ratios remained the same indicating that the increased tissue exposures
was a function of increased plasma exposures. However, PEGylated ADC tumor
exposure increased beyond that expected based solely on the increase in plasma
exposure. Incorporation of PEG as a side chain into the drug-linker improved
the tumor disposition of ADCs with little alteration in tissue disposition. ADCs
with 8, 12 and 24 PEG units in the drug-linker showed preferential uptake into
tumor, but not the tissues as evidenced by tumor (or tissue) to plasma exposure
ratios. Over all, the ADCs with 8, 12 and 24 PEG units in the linker provided the
optimal combination of tumor distribution, effıcacy and tissue distribution.
#4076 A novel prodrug of indoximod with enhanced pharmacokinetic
properties. Mario R. Mautino, Sanjeev Kumar, Hong Zhuang, Jesse Waldo,
Firoz Jaipuri, Hima Potturi, Erik Brincks, James Adams, Agnieszka Marcinow-
icz, Clarissa Van Allen, Nicholas Vahanian, Charles J. Link. NewLink Genetics
Corp., Ames, IA.
IDO1 catalyzes degradation of tryptophan (Trp) into kynurenines, which
plays an important role in the regulation of immune responses by triggering
anergy on reactive effector T cells and bymodulating differentiation and activa-
tion of regulatory T cells (Treg). Indoximod has been demonstrated to relieve
IDO-mediated immunosuppression in vitro and in vivo, by creation of an arti-
fıcial Trp-suffıciency signal that bypasses activation of GCN2 and inhibition of
mTOR in conditions of Trp deprivation. Inhibition of the IDO pathway by
indoximod in combination with immune-stimulatory treatments leads to in-
creased T cell proliferation, Treg reprogramming and antitumor effect. Indoxi-
mod has demonstrated an excellent safety profıle in human clinical trials and is
being dosed orally at 1200 mg bid. Increases in doses above this level do not
generally result in increased plasma concentration or drug exposure due to
limiting dose-dependent oral bioavailability. Animal models suggest that in-
creased therapeutic benefıt could be achieved at higher levels of exposure. For
this reason, we synthesized and tested the pharmacokinetic profıle of several
indoximod prodrugs in mice, rat and monkeys in both liquid and capsule for-
mulations. We selected clinical development drug candidate NLG802, which
increases indoximod exposure and plasma concentration 2-fold in rats and
5-fold in monkeys dosed with capsules of comparable formulation to that being
used in clinical trials. NLG802 is rapidly absorbed and metabolized in vivo to
indoximod. NLG802 DMPK profıle and GLP toxicology studies have been car-
ried out in rats and monkeys suggesting a safe toxicological profıle at predicted
therapeutic doses. In a preclinical tumor model of mice bearing established
B16F10 tumors, administration of NLG802 markedly enhanced the anti-tumor
responses of naïve, resting pmel-1 cells to vaccination with cognate hgp100
peptide plus CpG-1826 in IFA. In this tumor model, NLG802 plus pmel-1/
vaccine produced signifıcant tumor size reduction within 4 days of vaccination.
Moreover, the tumor response was achieved at lower doses than equivalent
molar doses of indoximod. In conclusion, NLG802 is a prodrug of indoximod
predicted to increase clinical drug exposure to indoximod above the current
achievable levels and will soon enter Phase 1 safety testing in oncology clinical
trials.
#4077 Application of drug sensitivity and resistance testing to identify
novel therapeutic agents for Down syndrome patients with AML. Apurvi R.
Patel, Justin J.Montoya,DanielH.Wai,DavidW. Lee, Robert J. Arceci, DavidO.
Azorsa. Phoenix Children’s Hospital, Phoenix, AZ.
Patients with Down’s syndrome who develop acute myeloid leukemia (AML)
are at increased risk of toxicity secondary to chemotherapy regimens. These
patients are harder to treat with conventional therapies at relapse. Overall, the
use of targeted drug therapy is rising in the pediatric oncology fıeld. Develop-
ment of drug sensitivity and resistance test allows identifıcation of specifıc tar-
geted therapies for patient’s with diffıcult to treat leukemia. Our laboratory is
working on the development of a drug sensitivity and resistance screening assay
that would provide functionally relevant drug response data of the patient’s
leukemia cells. Development of this assay included the preparation of pre-dosed
drug library plates allowing for rapid initiation of the assay. AML cells are then
added to the plate and treated for 72 hours after which cell viability was deter-
mined. Previous work in our laboratory tested a library of 56 anti-cancer and
targeted agents on a panel of 16 AML cell lines that included two Down’s syn-
drome AML cell lines CMK and CMY. Drug dose response data including IC50
values and Area Under the Curve (AUC) were calculated for each cell line.
Hierarchical clustering was performed to determine similar responses between
cell lines. Down’s syndrome cell lines, CMKandCMYwere found to be resistant
tomost conventional chemotherapeutic agents, but susceptible to targeted ther-
apies such as Navitoclax and 17-AAG. We further tested several cell lines with
the drug sensitivity and resistance assay under hypoxic conditions. Our screen-
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ing results showed improved sensitivity of the CMK and CMY cells to Navito-
clax and 17-AAG under normoxic and hypoxic conditions. Validation of the
screening results was done using a 10-concentration drug dose response assay.
Future studies will explore themechanismbywhich theDown’s syndromeAML
cells have increased sensitivity to these targeted agents under both normoxic and
hypoxic conditions. Furthermore, we will investigate the activity of combina-
tions of these targeted therapies with conventional therapies. The results from
these studies could lead to the establishment of improved therapeutic regimens
for Down’s syndrome patients with AML.
#4078 Tumorswith class 3BRAFmutants are sensitive to the inhibition of
activated RAS. Zhan Yao,1 Rona Yaeger,1 Vanessa S. Rodrik-Outmezguine,1
Anthony Tao,2 Neilawattie M. Torres,1 Matthew T. Chang,1 Matthias Drosten,3
Huiyong Zhao,1 Fabiola Cecchi,4 Todd Hembrough,4 Judith Michels,5 Hervé
Baumert,6 Linde Miles,1 Naomi M. Campbell,1 Elisa de Stanchina,1 David B.
Solit,1 Mariano Barbacid,3 Barry S. Taylor,1 Neal Rosen1. 1Mem. Sloan Kettering
Cancer Ctr., New York, NY; 2New York University, New York, NY; 3Centro Na-
cional de Investigaciones Oncológicas, Madrid, Spain; 4NantOmics, LLC, Rock-
ville,MD; 5Gustave RoussyCancerCampus, Paris, France; 6Saint JosephHospital,
Paris, France.
Approximately two hundred mutant BRAF alleles have been identifıed in
human tumors. Physiologic activation of RAF isoforms requires RAS-depen-
dent induction of their dimerization. Activating BRAF mutants cause ERK de-
pendent feedback inhibition of RAS.GTP and are RAS independent. As we have
shown previously, they signal either as active monomers or RAS-independent
constitutively active dimers. Here, we characterized a third class of BRAF mu-
tants—those that have impaired kinase activity or are kinase dead. These class 3
BRAF mutants are sensitive to ERK-mediated feedback and they function in a
RAS-dependent manner. In tumors, they bind more tightly to active RAS, thus
enhancing their heterodimerization with CRAF. This is associated with the am-
plifıcation of RAS-RAF-MEK-ERK signaling. Since these mutants are sensitive
to ERK-dependent feedback inhibition of RAS, their enhancement of ERK sig-
naling in tumors requires concurrent dysregulation of RAS activation. Thus,
melanomas with Class 3 mutations usually harbor coexistent RAS mutation or
NF1mutants/deletion, whereas receptor tyrosine kinase signaling is activated in
lung and colorectal cancers with these mutants. Our model suggests that these
tumors will be sensitive to the inhibition of RAS activation. Currently, no direct
inhibitors of RAS activation are available. However, in support of this idea,
inhibitors of activated RTK signaling in carcinomas with Class 3 BRAFmutants
and wild type RAS is suffıcient to markedly inhibit ERK signaling and their
growth in in vivo murine models and in patients. We have thus defıned a third
subset of BRAF mutants, which is RAS-dependent. Tumors harboring such
mutants are sensitive to tyrosine kinase inhibitors in tumors expressing wild
type RAS and NF1.
#4079 Pre-clinical toxicology and safety of SH7139: The fırst of a new class
of targeted therapeutics for non-Hodgkin’s lymphoma and other cancers.
Rod Balhorn, Monique Cosman Balhorn. SHAL Technologies, Inc., Livermore,
CA.
Selective High Affınity Ligands (SHALs) are small molecules that can be de-
signed to bind selectively and with high affınity to any protein target by linking
together several ligands that recognize and bind to different sites on the protein’s
surface. SH7139, our fırst SHAL therapeutic for treating advanced non-Hodg-
kin’s lymphoma, has shown remarkable effıcacy in B-cell lymphoma xenograft
models by providing permanent cures for up to two-thirds of the animals at a
human equivalent dose as low as 0.4g/kg. Functioning similar to an antibody-
drug conjugate and a pro-drug, SH7139 targets and binds to a unique structural
epitope within the antigen-binding pocket of HLA-DR10. HLA-DRs containing
this epitope are expressed in approximately 85% of B-cell lymphomas. Upon
binding to its HLA-DR target, SH7139 is carried into the cytoplasm where it is
concentrated and subsequently metabolized, releasing toxic metabolites (de-
rived from each of the linked ligands) that inhibit a series of cellular activities
required for tumor cell function. In preparation for an IND application submis-
sion and advancing SH7139 into clinical trials, acute dose range fınding (i.v.
bolus) and multiple dose (i.v. bolus on days 1, 8, and 15) toxicology and safety
studies have been conducted with SH7139 in rats and beagle dogs. In the rat
studies, doses up to 30 mg/kg (NOAEL 30 mg/kg, 11,854 fold higher than the
effıcacy dose), were well tolerated with no fındings associated with the drug.
Beagle dogs were found to be the most sensitive species (NOAEL  0.3mg/kg,
395 fold higher than the effıcacy dose), with doses at 1 and 10mg/kg producing a
reversible allergic-type reaction. A maximum tolerated dose (MTD) was
reached in rats (100 mg/kg). No attempt was made to identify theMDT in dogs.
In vitro assays conducted to evaluate potential cardiac safety showed SH7139
hadno effect onpotassium (hERG) and calcium (hCaV1.2) ion channel function
up to the highest concentration tested (25 M). A detectable effect above back-
groundwas only observedwith the sodium channel hNaV1.5 at 25M, a plasma
concentration that would only be achieved in patients administered a dose
2,000 fold higher than the effıcacy dose. SH7139 was found to be negative in
inducing gene mutation in fıve tester strains of Salmonella and E. coli (AMES
assay). In a CHO-K1 micronucleus assay, no genotoxicity was observed in the
presence of S9 over the entire concentration range tested. In the absence of S9, a
positive response (3.3 fold) just above the triggering threshold (3 fold) of the
assay was observed at the highest SH7139 concentration (500 M). Based on
these results and others derived from mouse xenograft effıcacy studies, a maxi-
mum recommended Phase I trial starting dose has been tentatively set at 0.5
g/kg with a safety factor of 324. This research was supported by the National
Cancer Institute Phase II SBIR Award R44CA159843.
#4080 Cytochrome P450 enzyme activity is enhanced in hepatocytes
grown using a perfused 3D cell culture drug screening system. James T. Shoe-
maker, Jelena Vukasinovic. Lena Biosciences, Atlanta, GA.
A critical requirement for assessing drug toxicity in vitro is cytochrome P450
(CYP) function that is physiologically representative. Due to low levels of CYP
enzyme activity, cell lines such as HepG2 hepatocytes have largely been sup-
planted with primary cells derived from human donor tissue. While these cells
retain CYP activity ex vivo, drug screening is limited to short-term assessments
due to de-differentiation. This limits their effıcacy in testing slow-clearing, large-
molecule compounds such as antibody-based therapies and low-turnover drugs.
Cell lines in monolayer cultures have been effective in assessing the safety of
small molecule drugs, but the disparity between cell lines and in vivo tissue
biology proves too substantial for current potential therapies. Three-dimen-
sional (3D) cultures have been shown to be more physiologically relevant mod-
els of in vivo tissue.However, even they fail to fullymimic living tissue and suffer
from the lack of active oxygen and nutrient transport. Lena Biosciences has
developed a groundbreaking in vitro system that facilitates long-term survival of
3D cultures. Cells seeded in 3D hydrogels supported by a rigid scaffold are
maintained in statistically independent wells in their own medium which floats
atop a high-density blood-substitute in which medium is immiscible. Infusion
and withdrawal of this blood-substitute introduces perfusion into a medium-
throughput multiwell system without the need for separate pumps for each
culture condition. Internal validation experiments using hepatocytes cultured in
a 12-well system showed a two-fold improvement in cellular respiration (mea-
sured by alamarBlue assay) over cultures maintained in a standard multiwell
plate when the blood-substitute was introduced, and a three-fold improvement
when the cultures were perfused. Cell viability (measured by LDH release) was
signifıcantly improved when perfusion was introduced. CYP activity (assessed
using both fluorescent and luminescent substrate-based assays) was also signif-
icantly higher in the perfused hepatocyte cultures. These data demonstrate the
substantial advantages to growing cells in this novel perfused cell culturemodel.
Scaling the system to include multiple cell types (primary or cell lines), would
allow for simultaneous testing of target andoff-target effects of potential small or
large molecule therapies. Thus, this system serves as a major improvement over
the current organ-on-a-chip solutions in the area of drug safety testing.
#4081 Superior SN-38 pharmacodynamic and tumor-accretion profıles of
labetuzumab govitecan (IMMU-130) versus irinotecan in experimental hu-
man colonic cancermodels.ThomasM. Cardillo, RobertM. Sharkey, Serengu-
lamV. Govindan, Jennifer Donnel, Maria Zalath, DavidM. Goldenberg. Immu-
nomedics, Inc., Morris Plains, NJ.
BACKGROUND: IMMU-130 is an antibody-drug conjugate (ADC) under-
going clinical investigation in patients with metastatic colorectal cancer (Clini-
calTrials.gov, NCT01605318). It is composed of a humanized anti-CEACAM5
IgG conjugated via a cleavable linker to SN-38, a topoisomerase-I inhibitor and
active formof irinotecan.We investigated the potential advantage of IMMU-130
versus irinotecan for SN-38 delivery in nude mice bearing CEA-expressing hu-
man colonic tumor xenografts (LS174T or GW-39). METHODS: Mice were
injected with irinotecan ( 900g; SN-38 equivalents500g) or 1.0 mg of
IMMU-130 (16g SN-38 equivalents). Irinotecan-treated animalswere necrop-
sied 5 min, 1, 2, 6-8 h post-injection, while IMMU-130-treated animals were
evaluated at 1, 6, 24, 48-72 h. Serumandhomogenates of tumors, liver, and small
intestinal contents were extracted, and SN-38, SN-38G, and irinotecan concen-
trations were determined by reversed-phase HPLC. For IMMU-130-treated
specimens, SN-38 concentrations were assessed in the extracted samples (Free
SN-38), as well as in acid-hydrolyzed samples to determine Total SN-38 (Free
bound). IgG was measured by ELISA. RESULTS: Irinotecan cleared quickly
from serum, with [SN-38]averaging 900 ng/mL to 200 ng/mL from 5 min to
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6 h. SN-38G and SN-38 levels were similar. With IMMU-130, Free SN-38 was
detected in serumover the entiremonitoring period, but levels were only a small
fraction of the Total SN-38 (10%). Importantly, Free SN-38G was very low,
being detected onlywithin the fırst 6 h. Total SN-38 levels droppedmore quickly
than the IgG, confırming in vitro studies showing gradual SN-38 release from
the ADC. In tumors, for irinotecan-treated animals, SN-38 peaked at 5 min,
representing 0.2%/g of the SN-38 equivalent given. In IMMU-130-treated
animals, no Free SN-38was detected in tumors, but levels of Total SN-38 peaked
at 6 h, with 5%/g of the injected SN-38 dose present at that time, and were
sustained longer than SN-38 delivered by irinotecan. Area under the curve anal-
ysis found SN-38 levels were 10- and 17-fold higher in LS174T and GW-39
tumors, respectively, from IMMU-130-dosed versus irinotecan-dosed animals.
This delivery advantage is amplifıed 30-foldwhennormalized to SN-38 equiv-
alents injected for each product, illustrating the improved bioavailability with
IMMU-130-targeted SN-38. Levels of SN-38 and SN-38G were appreciably
lower in the liver and small intestinal contents, which likely explains the lower
incidence of severe diarrhea reported in patients given IMMU-130. CONCLU-
SION: IMMU-130 delivers 300-fold more SN-38 to CEA-producing tumors
compared to irinotecan, while also reducing levels of potentially harmful SN-38
and SN-38G in normal tissues. These observations are consistent with preclini-
cal data showing improved effıcacy and safety.
#4082 Time- and exposure-dependent pharmacodynamic changes in-
duced by the BTK inhibitor GS-4059 in healthy subjects. Juliane M. Jürgens-
meier, Hoa Truong, Lianqing Zheng, Yuanyuan Xiao, Cara Nelson, Siddhartha
Mitra, Andrew N. Billin, Helen Yu. Gilead Sciences Inc, Foster City, CA.
Bruton’s Tyrosine Kinase (BTK) plays an important role in B-cell signaling,
cell proliferation and survival and is an established drug target in B-cell malig-
nancies. GS-4059 (ONO-4059) is an irreversible, small molecule inhibitor of
BTK, which is in development for hematological malignancies and rheumatoid
arthritis. A Phase 1 study to evaluate the effect of organic anion transporting
polypeptide (OATP) 1B1 and 1B3 inhibitors and inducers of cytochrome P450
3A (CYP3A) on GS-4059 Pharmacokinetics (PK) was performed in healthy
subjects (N15). Subjects were administered a single dose of 100 mg GS-4059
alone or in combinationwith a single ormultiple doses of rifampin (600mg) and
blood samples were collected up to 48 hours post dose to evaluate PK and Phar-
macodynamic (PD) markers in peripheral blood mononuclear cells (PBMCs).
PD biomarkers were exploratory endpoints and are reported here. PD was eval-
uated using the BTKoccupancy assay and the Basophil ActivationTest (BAT). A
novel duplex homogeneous BTK occupancy assay was used to quantitatively
measure GS-4059 binding to human BTK to assess target coverage. The assay is
based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET)
and simultaneouslymeasures the level of free BTKaswell as total BTKprotein in
PBMCs collected from subjects in the study. Free BTK levels in PBMCs de-
creased rapidly on treatment with GS-4059 with no detectable free BTK 3-24
hours post dose and no notable changes in total BTK. All subjects had free BTK
levels below the limit of detection (LOD6.8 ng/mL) 3-24 hours after dosing. Free
BTK levels started to increase after 48 hours. Free BTK levels on treatment with
multiple doses of rifampin plus GS-4059 followed a similar trend with no free
BTKdetectable 3-6 hours post dose but resulted in shorter duration of inhibition
andmore rapid recovery of free BTK levels. GS-4059 plasma exposure (Cmax and
AUC) was 70% lower after multiple doses of rifampin, due to a drug-drug
interaction. As a second PDmarker, inhibition of CD63 basophil activation in
the BATwasmeasured. In this functional assay themedian inhibition of CD63
basophil activation was between 90% and 100% at the time of maximum inhibi-
tion (3 hours post dose). At the peak of inhibition 13 of the 14 subjects had
inhibition of basophil activation higher than 97%. In line with the BTK occu-
pancy data, inhibition of CD63 basophil activationwas signifıcantly lowerwith
reducedGS-4059 plasma exposure. BTK occupancy as a directmeasure of target
binding and the functional assaymeasuring the inhibition of basophil activation
showed a similar time coursewithmaximumeffect in both assays achieved at 3-6
hours post dose. These data demonstrate that a single 100 mg dose of GS-4059
results in full BTK occupancy in healthy subject PBMCs as well as functional
changes measured in basophil activation as a surrogate for BTK signaling path-
way inhibition.
#4083 Basic mechanisms of Vernonia amygdalina exert antitumor activi-
ties in breast cancer cells. Clement G. Yedjou, Paul B. Tchounwou. Jackson
State Univ., Jackson, MS.
Breast cancer continues to represent the largest cause ofmortality in theworld
especially among women. It is estimated that cancer kills more women in the
USA than any other illness and it is also the leading cause of death among all
Americans. Traditional medicine represents the fırst-choice of healthcare treat-
ment for at least 80% of people living in developing countries. Preliminary stud-
ies from our laboratory have shown that a novel natural product, extracts of
Vernonia amygdalina (VA) leaf exerts DNA-damaging anticancer activities
against breast cancer. There is a need to develop targeted approaches for the
treatment of human breast cancer. Therefore, the goal of this research was to
determine the therapeutic mechanisms of V. amygdalina leaf extracts as anti-
cancer agent in the management of breast cancer. To achieve our goal, cell
viability, live and death cells were determined by trypan blue exclusion test. The
extent of oxidative cell/tissue damage was determined bymeasuring malondial-
dehydes (MDA) levels. Expression of p53 tumor suppressor gene was assessed
both by immunofluorescent and western blot analyses. Cell apoptosis was mea-
sured both by flow cytometry analysis and DNA laddering assay. Data obtained
from the Trypan blue indicated that V. amygdalina signifıcantly reduced the
viability ofMCF-7 cells in a dose-dependent response, showing gradual increase
in the loss of viability in V. amygdalina-treated cells due to membrane damage.
We observed an up-regulation of p53 tumor suppressor gene in V. amygdalina-
treated cells compared to the control. Flow cytometry data showed a strong
dose-response relationship betweenV. amygdalina exposure and caspase-3 pos-
itive cells. These resultswere confırmed by data ofDNA laddering assay showing
a clear evidence of nucleosomal DNA fragmentation in V. amygdalina-treated
cells. Collectively, data generated from the present study demonstrated that V.
amygdalina destroys breast cancer cells by reducing the percentage of cell via-
bility and inducing apoptosis through up-regulation of p53 tumor suppressor
gene, activation of caspase-3, and induction of nucleosomalDNA fragmentation
associated with the formation of MDA, a by-product of lipid peroxidation and
biomarker of oxidative stress. This result suggests that V. amygdalina treatment
may be a good anti-cancer candidate for the treatment of breast cancer. Research
supported by NIH Grant No. NIMHDG12MD007581).
#4085 Distribution analysis of S-222611 in brain metastases of HER2-
positive breast cancer by quantitative imaging mass spectrometry: prospect
for antitumor activity of EGFR/HER2/HER4 kinase inhibitor S-222611
against brain metastases. Yukari Tanaka, Michinari Hirata, Satomi Shinon-
ome,MitsunobuMatsumoto,WataruNogami,Mikinori Torii, Ken-ichiNezasa,
Hidekazu Tanaka. SHIONOGI & CO., LTD., Toyonaka, Osaka, Japan.
S-222611 isapotentandselective reversible tyrosinekinase inhibitorof epidermal
growth factor receptor (EGFR), human EGFR2 (HER2), and human EGFR4 devel-
oped in Shionogi.Greater potencyof anti-tumor activity than lapatinibwasdemon-
strated in vitro and in animal models. In the intracranial implantation mice model
implanted the HER2-positive cell line (MDA-MB-361-luc-2), S-222611 showed
morepotent anti-tumoractivity than lapatinib.On thebasis ofhigherpenetration in
brain of S-222611 than lapatinib indicated by the preclinical pharmacokinetic stud-
ies, we demonstrated the application of S-222611 to brain metastases with breast
cancer. Inorder to enhance the clinical predictability of S-222611 to the treatmentof
brain metastases, we have developed the experimental brain metastases models in
mice of HER2-positive breast cancer (MDA-MB-361-luc-2-BR2/BR3) or T790M-
EGFR expressing lung cancer (NCI-H1975-luc). After a single oral administration
of S-222611 or lapatinib, the concentrations of S-222611 and lapatinib in the brain
metastatic regionsof thesemicemodelswere analyzedbyquantitative imagingmass
spectrometry (IMS). In the NCI-H1975 lung cancer model (intraventricular injec-
tion model), the concentrations of S-222611 in brain metastases quantifıed by IMS
were comparable to those of lapatinib. In contrast, in the MDA-MB-361 breast
cancer model (intraventricular injectionmodel), the concentrations of S-222611 in
brain metastases were over 10 times higher than those of lapatinib, and the tumor-
to-normal brain ratio of S-222611 was approximately 4 times higher than that of
lapatinib. IMS revealed that the concentrations in brain metastases and tumor-to-
normal brain ratio of S-222611 were signifıcantly higher than those of lapatinib in
the breast cancer micemodel. In addition, the blood-tumor barrier (BTB) permea-
bility in each brainmetastatic region using thesemicemodels was assessed simulta-
neously. In the lung cancermodel, fluorescently labeleddextranwashighly detected
in the brainmetastatic regions than brain parenchyma.However, in the breast can-
cer models, fluorescence intensities for dextran in the brain metastatic regions and
brain parenchyma were comparable, indicating that the BTB was remained to be
largely intact inbrainmetastasesof thebreast cancermodelbutdisrupted in the lung
cancer model. These results show that S-222611 is expected to be useful for the
prevention and the prompt treatment of patients withHER2-positive breast cancer
having brainmetastases.
#4086 RNAseq hiPSC-cardiomyocytes reveals altered expression of DNA
damage and cell cycle genes in response to doxorubicin. Monica E. Reyes,1
JianzhongMa,2MeganL.Grove,2 JoannL.Ater,1 AlannaC.Morrison,2Michelle
A. Hildebrandt1. 1UT MD Anderson Cancer Ctr., Houston, TX; 2UT School of
Public Health, Houston, TX.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Mechanistic Understanding of Novel Anticancer Therapies
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1043
Introduction: Doxorubicin is a highly effective chemotherapeutic agent, but
its use is limited due to cumulative and dose-dependent effects that can lead to
irreversible heart damage. Despite efforts in understanding themechanisms, the
precise genes and pathways implicated in doxorubicin-induced cardiotoxicity
still remain elusive. We hypothesized that by exploring time- and dose-depen-
dent changes in gene expression in human induced pluripotent stem cell de-
rived-cardiomyocytes (hiPSC-CM), we can identify genes and signaling path-
ways related to doxorubicin-induced cardiotoxicity. Methods: hiPSC-CM were
treated with 0, 50, 150, or 450 nM of doxorubicin for 2, 7, or 12 days then
subjected to RNA sequencing for assessment of gene expression. Sequenced
reads were aligned to the human reference genome (GRCh37) with STAR, and a
read count matrix was then generated with the R package GenomicAlignments.
Global variation and differential gene expression analyses were performed using
DESeq2 software (P0.05). For time course analysis, log2 fold-changes in gene
expression for pairwise comparisons between any two time points or doses were
calculated using DESeq2 and a Time x Dosage interaction model. For Ingenuity
Pathway Analysis of time course genes, input genes were selected based on a
cutoff 2.0 and-2.0 average log2 fold-change in expression. Results: Hierar-
chical clustering of expression profıles of 40,861 genes produced by DESeq2
revealed 192 genes downregulated following doxorubicin exposure related to
mitotic roles of polo-like kinase, cell cycle control chromosomal replication, and
DNA damage checkpoint regulation pathways. This included a set of nine genes
with the highest variation in expression, MCM5, PRC1, NUSAP1, CENPF,
CCNB1, MELK, AURKB, RACGAP1, and TROAP, with functions in microtu-
bule stabilization and cell cycle regulation. Following a 2-day exposure to doxo-
rubicin, 242 genes, including the top nine genes, were differentially expressed
between untreated and treated with enrichment in ribosomal processes, DNA
repair and damage, and oxidation-reductase activity. Time course analysis re-
vealed 289 genes between 0 nMand 150 nMon days 2, 7 and 12with enrichment
in fatty acid oxidation, MIF-mediated glucocorticoid regulation, and relaxin
signaling pathways. Transcription regulator, SMARCA4, was identifıed as the
only upstream regulator with elevated expression following a later recovery time
(day 7 to day 12) compared to shorter or earlier time point comparisons at 150
nM dose. Conclusion: Overlapping genes and pathways identifıed in these anal-
yses provide additional support for a role of reactive oxygen species and mito-
chondrial dysfunction linked to DNA damage in doxorubicin-induced cardio-
toxicity. This study also warrants further investigation of SMARCA4 since it is a
direct regulator of genes with overlapping functions described for the top nine
genes.
#4087 Development of a potent, dual pan-PIM/FLT3 inhibitor for the
treatment of hememalignancies.Wojciech Czardybon,1 RenataWindak,1 An-
iela Gołas,1 Michał Gałe˛zowski,1 Aleksandra Sabiniarz,1 Izabela Dolata,1
Magdalena Salwin´ska,1 Paweł Guzik,1 Magdalena Zawadzka,1 Ewelina Gabor-
Worwa,1 Bożena Winnik,1 Małgorzata Z˙urawska,1 Ewa Kolasin´ska,1 Ewelina
Wincza,1 Marta Bugaj,1 Monika Danielewicz,1 Grzegorz Dubin,2 Ewa
Jabłon´ska,3 Maciej Szydłowski,3 Tomasz Sewastianik,3 Bartosz Puła,3 Anna
Szumera-Ciec´kiewicz,3 Monika Prochorec-Sobieszek,3 Elżbieta Mądro,3 Ewa
Lech-Maran´da,3 Krzysztof Warzocha,3 Jerome Tamburini,4 Przemysław
Juszczyn´ski,3 Krzysztof Brzózka1. 1Selvita S.A., Kraków, Poland; 2Uniwersytet
Jagiellon´ski, Kraków, Poland; 3InstytutHematologii i Transfuzjologii,Warszawa,
Poland; 4Inserm, France.
Despite huge effort spent on understanding the pathogenesis of acutemyeloid
leukemia (AML), current standards of care are still based on the same chemo-
therapy agents as two decades ago - combinational treatment of cytarabine with
an anthracycline. Fms-like tyrosine kinase 3 internal tandemduplication (FLT3-
ITD) is one of themost common genetic lesions in AML. Although FLT3 inhib-
itors initially exhibit clinical activity, resistance to treatment inevitably occurs
within months. PIM kinases are thought to be major drivers of the resistance
phenotype and their inhibition in relapsed samples restores cell sensitivity to
FLT3 inhibitors. Thus, simultaneous PIM and FLT3 inhibition represents a
promising strategy in AML therapy. Selvita has developed a potent and selective
fırst-in-class, dual PIM/FLT3 kinase inhibitor, the SEL24-B489 compound, and
profıled its activity for in vitro and in vivo AML models showing signifıcantly
broader anti-tumor activity of SEL24-B489 than selective FLT3-ITD or PIM
inhibitors. We compared SEL24-B489 head-to-head with a selective PIM inhib-
itor (AZD1208) and a selective FLT3-ITD inhibitor (AC220) in a panel of AML
cell lines with FLT3-ITD or unmutated kinase (FLT3-WT) as well as peripheral
AML cells and CD34 bone marrow blasts. SEL24-B489 exhibited a signifı-
cantly broader activity, irrespective of FLT3 status, than either of the selective
inhibitors. Since PIM kinases have emerged as important mediators of FLT3-
inhibitor resistance, we hypothesized that the dual specifıcity of SEL24-B489
might overcome the phenotype of resistance. We utilized previously developed
MOLM-14 cells transduced with either FLT3-WT or FLT3 alleles containing
TKD point mutations to show that neither of the these mutations decreased the
cellular sensitivity to SEL24-B489. Higher cellular activity and biomarker re-
sponse of SEL24-B489 than competitive inhibitors was shown by inhibition of
specifıc biomarkers such as S6 and STAT5 phosphorylation at nanomolar con-
centrations in both FLT3-ITDpositive and FLT3-WTcell lines in vitro.We have
also demonstrated SEL24-B489 superior potency of SEL24-B489 in xenograft
models in vivo. Consistent with the experiments in vitro showing marked syn-
ergy between SEL24-B489 and AraC, a combination of these agents resulted in
almost completely blocked tumor growth in vivo. Most importantly, SEL24-
B489 has been selected as a clinical candidate and is currently in phase I clinical
trials.
#4088 First-in-human dose selection for ALKS 4230, an investigational
immunotherapeutic agent. Lei Sun, Heather C. Losey, Juan Alvarez, Lisa von
Moltke, William J. Slichenmyer. Alkermes, Inc., Waltham, MA.
ALKS 4230 is an engineered fusion protein comprised of a circularly per-
muted interleukin-2 (IL-2) and the IL-2 receptor (IL-2R)  chain, CD25, de-
signed to selectively activate the intermediate-affınity IL2R, but not the high-
affınity IL-2R. Selective activation of the intermediate-affınity IL-2R by ALKS
4230 has the potential to provide enhanced tumor killing as well as improved
safety and tolerability. Various in vitro and in vivo studies were conducted to
characterize the primary and secondary pharmacodynamics (PD) of ALKS 4230
as well as its pharmacokinetics (PK). The results guided the selection of the
starting dose for the ALKS 4230 fırst-in-human (FIH) clinical study based upon
the Minimal Anticipated Biological Effect Level (MABEL) approach. The
PK-PD relationship for ALKS 4230 was evaluated in in vitro pharmacology
studies in target cells frommurine, non-humanprimate andhumandonors. The
mean EC10 values for activation of NK cells, memory CD8 T-cells and Tregs in
target cells from human donors were 0.09, 0.18 and 0.13 nM, respectively. Using
the lowest EC10 value of 0.09 nM (0.0031g/mL) as a surrogate for the MABEL,
assuming IV administration to a 70 kg humanwith 3 L plasma volume, a dose of
0.1 g/kg would be expected to result in an immediate post-dose concentration
of 0.0031g/mL. Themean EC50 values for activation ofNK cells, memoryCD8
T cells and Tregs in target cells from human donors were 0.46, 1.1 and 0.59 nM,
respectively. Using the EC50 value as surrogate for minimal effective ALKS 4230
concentration that induces activation of human IL-2R complex, the projected
minimal effıcacious dose (MED) in humans to achieve a concentration of 0.46
nM (0.016 g/mL) to 1.1 nM (0.038 g/mL) is 0.7- 1.6 g/kg. Based on a MA-
BEL dose of 0.1g/kg and projectedMED of 0.7- 1.6g/kg, the proposed doses
to be evaluated in the FIH Phase 1 study are 0.1, 0.3, 1, 3, 10, and 30 g/kg. In
comparison, the projected Cmax at the proposed starting dose of 0.1 g/kg is
750-fold lower than the Cmax at the no-observed adverse effect level (NOAEL) in
a repeat-dose toxicology study inmonkeys. It is also about 3-fold lower than the
lowest concentration of ALKS 4230 (0.01 g/mL) tested in the cytokine release
assays at which only slight elevations were observed for IL6, IL-8, and IFN- in
a small number of whole blood samples from healthy human donors, similar to
those in the low-response control across the concentration range evaluated.
Therefore, 0.1g/kg is considered a safe starting dose for the FIH study. The PK,
PD and toxicology assessments conducted to date support the FIH investigation
of ALKS 4230 at the proposed starting dose of 0.1 g/kg.
#4089 Quantitative prediction of human pharmacokinetics for duvor-
tuxizumab from cynomolgus monkey data: a translational pharmacokinetic
modeling approach. Xiling Jiang,1 Hua Li,2 Jeff Nordstrom,2 Jennifer Brown,2
Liqin Liu,2 Syd Johnson,2 Ralph Alderson,2 Pamela L. Clemens,1 Jacintha Shen-
ton,1 Imran Khan,3 Olivia Gardner,1 Yu-Nien Sun,1 Weirong Wang1. 1Janssen
Research & Development LLC, Spring House, PA; 2MacroGenics, Inc., Rockville,
MD; 3Janssen Research & Development LLC, Raritan, NJ.
Duvortuxizumab (also known as JNJ-64052781 and MGD011) is a bispecifıc
CD19 x CD3DART®molecule designed to simultaneously target CD19-positive
cells for recognition and elimination by CD3-expressing T-lymphocytes as ef-
fector cells. Duvortuxizumab is currently in clinical development for the poten-
tial treatment of B-cell malignancies. Here we report the results from a transla-
tional PKmodel that utilized duvortuxizumab pharmacokinetic (PK) data from
cynomolgus monkeys to predict duvortuxizumab PK in humans. The PK of
duvortuxizumab administered by intravenous infusion was evaluated in cyno-
molgus monkeys in two separate studies. Study 1 evaluated intra-animal esca-
lating doses from 0.5 to 100 g/kg or repeated doses from 0.005 to 0.5 g/kg
administered over a period of up to 4 weeks. Serum concentrations of duvor-
tuxizumab above the lower limit of quantifıcation were obtained at dose levels
0.5 g/kg. Study 2 evaluated duvortuxizumab doses of 0.2, 2, 5, or 10 g/kg
administered once weekly for 4 weeks. Dose-proportional increases in maxi-
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Mechanistic Understanding of Novel Anticancer Therapies
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171044
mum concentration (Cmax) were observed across the dose ranges evaluated, and
no signifıcant differences between male and female animals were observed. PK
modeling analysis, which integrated data from both study 1 and study 2 at 0.2 to
100 g/kg dose levels, was performed to further understand the PK behavior of
duvortuxizumab in cynomolgus monkeys. Duvortuxizumab PKwas reasonably
characterized using a two compartment model with linear clearance (CL) from
the central compartment. Model estimated parameters were CL 0.797 mL/h/
kg; volume of distribution for the central compartment (V1)  51.7 mL/kg;
intercompartmental clearance (Q) 2.29 mL/h/kg; and volume of distribution
for the peripheral compartment (V2) 88.8mL/kg. Assuming a body weight of
3 kg and 70 kg for a cynomolgus monkey and a human, respectively, human PK
parameters were estimated using an allometric scaling factor of 0.75 for CL and
1.0 for volume in the translational PK model. Observed duvortuxizumab PK
values obtained from an ongoing, fırst-in-human (FIH), phase 1 dose-escalation
trial in patients with relapsed or refractory B-cell malignancies (NCT02454270)
were used to validate the translational PK model. Comparison of the predicted
and observed duvortuxizumab PK profıles suggested that the translational PK
model using the allometric scaling method reasonably predicted duvortuxi-
zumab PK profıles in humans at multiple dose levels (15 to 100 ng/kg). In con-
clusion, the developed translational PKmodel successfully predicted duvortuxi-
zumab PK in humans and has been used to aid dose escalation of
duvortuxizumab in the ongoing FIH study. Thiswork showcases the potential of
translational PK modeling in supporting the selection of a FIH dose escalation
strategy utilizing preclinical PK information.
#4090 Preclinical pharmacokinetics of CASC-578, a novel, selective, po-
tent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor.
Dina Leviten,1 Teresa Sierra,1 AshleyDozier,1 Richard Boyce,2 Bob Boyle,2 Scott
Peterson,1 Alex C. Vo1. 1Cascadian Therapeutics, Seattle, WA; 2Sentinel Oncol-
ogy, Cambridge, United Kingdom.
Introduction: Checkpoint kinase 1 (Chk1) is a serine/threonine protein ki-
nase that regulates cell division in response to genotoxic stress by arresting cell
cycle progression in the S & G2 phases. Pharmacological inhibition of Chk1 is
proposed to selectively uncouple the completion ofDNAreplication fromG2/M
phase transition in tumor cells that have impaired DNA damage response net-
works, resulting inmitotic catastrophe and cell death. CASC-578 is a novel small
molecule inhibitor of Chk1 that is selective, highly potent and orally bioavailable
in multiple preclinical species. Methods: The in vitro ADME properties of
CASC-578 were evaluated, including in vitro intrinsic microsomal clearance,
Caco2 permeability, plasma protein binding and stability, blood to plasma par-
titioning, cytochrome P450 inhibition and induction, and transporter inhibi-
tion. Pharmacokinetic studies of CASC-578 were conducted in mice, rats, and
cynomolgus monkeys as either single dose (IV and/or PO) or repeat dose (PO
only). Multiple oral dose pharmacokinetic studies were conducted in mice, rats
and cynomolgus monkeys for 5-7 days. Results: CASC-578 is highly bound in
plasma protein across all species. The apparent permeability is high in Caco2
bi-directional transport study and correlatedwell with a rapid absorption profıle
observed in vivo. CASC-578 is not a substrate of P-glycoporotein (efflux 1).
There was no direct nor time dependent inhibition on humanCYP450 enzymes,
and only a slight induction of CYP3A4 was seen at 10 uM drug concentration in
a transporter cell-based induction assay. In all animal species, CASC-578 exhib-
ited species-dependent systemic clearance resulting fromboth phase I and phase
II metabolism, and a moderate to high volume of distribution. The elimination
kinetics appeared to be monophasic. Oral bioavailability was high in all species
studied (60% F). There was no signifıcant difference in the pharmacokinetics
of the drug between genders. Maximal plasma concentration and total drug
exposure (AUC) appeared to be proportional from repeat dose studies. Overall,
CASC-578 has very desirable drug-like properties and ideal pharmacokinetics
for an oral once daily drug, and represents a suitable candidate for clinical de-
velopment as a novel potential therapeutic approach for the treatment of solid
and hematological malignancies
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#4091 AKT canmodulate the in vitro response of HNSCC cell to irrevers-
ible EGFR inhibitors. Renato José Silva-Oliveira,1 Matias Melendez,1 Olga
Martinho,2 Maicon Fernando Zanon,1 Luciano de Souza Viana,1 André Lopes
Carvalho,1 Rui Manuel Reis1. 1Barretos Cancer Hospital, Barretos, Brazil; 2Life
and Health Sciences Research Institute, Braga, Portugal.
Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of head
and neck squamous cell carcinoma (HNSCC) tumors. Cetuximab is the fırst tar-
geted (anti-EGFR) therapy approved for the treatment of patients with locally ad-
vanced HNSCC. However, its effıcacy is limited due to primary and secondary re-
sistance, and there is no predict biomarkers of response. New generation of EGFR
inhibitors with pan HER targeting and irreversible action, such as afatinib and al-
litinib represents a signifıcant therapeutic promise in HNSCC treatment. In this
study,we intend to compare thepotential cytotoxicity of two irreversible anti-EGFR
inhibitors (afatinib and allitinib)with cetuximab and to identify potential predictive
biomarkers of response in a panel of HNSCC cell lines. The mutational analysis in
hotspot regions of EGFR, KRAS, NRAS, PIK3CA and PTEN in the eight HNSCC
cell lines revealed an EGFR mutation (p.H773Y) and gene amplifıcation in the
HN13 cells, and KRAS mutation in the JHU-28 cell line. According to the growth
inhibition score (GI), allitinibwas themost cytotoxic drug, followed by afatinib and
fınally cetuximab. The HN13 cell line exhibited a less responsive behavior to all
drugs assessed, and interestingly, also displayed the higher levels of AKTphosphor-
ylation. Therefore, we further performed drug combinations and found that with
anti-AKT agent (MK2206), afatinib and allitinib, but not cetuximab, sensitivity was
restored. Additionally, AKT1gene editing in afatinib and allitinib-treated cell lines
showed that AKT1 silencing-induced cell line decreased viability and increased cy-
totoxicity through caspases 3/7activation.Additionally, in silico analysis of TCGA
database showed that AKT1 overexpression was present in 14.7% (41/279) of HN-
SCC cases, and was associated with perineural invasion in advanced stage. In con-
clusion, allitinibpresentedagreater cytotoxicprofılewhencompared toafatiniband
cetuximab, and the AKT pathway constitutes a predictive marker of allitinib re-
sponse. Importantly, in allitinib and afatinib-resistant cases, the pharmacological
combination with AKT inhibitors could restore response and increase treatment
success.
#4092 Targeting compensatory mechanisms of resistance to phosphati-
dylinositol 3-kinase inhibitors in head and neck squamous cell carcinoma.
Nicole L. Michmerhuizen, Elizabeth Leonard, Susan K. Foltin, Aditi Kulkarni,
Thomas E. Carey, Carol R. Bradford, Hui Jiang, Chad Brenner. University of
Michigan, Ann Arbor, MI.
Recent sequencing studies of head and neck squamous cell carcinomas (HN-
SCCs)have identifıed thephosphatidylinositol 3-kinase (PI3K)pathwayas themost
frequentlymutated, oncogenicpathway in this cancer type.Despite the frequencyof
activating mutations or amplifıcation in PIK3CA (the gene encoding the catalytic
subunit of PI3K), targeted inhibitors of PI3K have not shown clinical effıcacy as
monotherapies.We tested a panel ofmore than 20 patient-derived oral cavity squa-
mous cell carcinoma (OCSCC) cell lines, which were profıled by Nimblegen V3
exomesequencing, andobservedresistance toPI3KinhibitorsdespitePIK3CAcopy
number amplifıcation and/ormutation.Of six inhibitors tested, only alpha-isoform
selective and pan-PI3K agents were somewhat effective; these inhibitors, despite
on-target and downstream activity, did not cause an appreciable reduction in cell
viability when administered at submicromolar concentrations. We hypothesized
that other oncogenic pathways might still be functional in the presence of PI3K
inhibitors and might serve as mediators of this resistance. For example, our group
and others have evaluated co-dependence on the Ras-MEK-ERK pathway in OC-
SCC, showing that this serves as a compensatory mechanism in some models. In
order tomore fully characterize other novelmechanisms of resistance, we have also
developed a high-throughput screening approach that utilizes a resazurin cell via-
bility assay. This screen serves as an unbiasedmeans of testing1400 inhibitors as
monotherapies and incombinationwithalpha-isoformselectivePI3K inhibitorHS-
173 and pan-PI3K inhibitor BKM120 in severalOCSCCmodels. Further validation
of “hits” from this screen, which are drugs that are effective in combination but not
asmonotherapies,may identify additional resistancemechanisms and lead to com-
bination therapies to improve HNSCC patient prognosis.
#4093 t-Darpp stimulates protein kinase A activity by interacting with its
RI regulatory subunit. Dirk Theile,1 Shuhui Geng,1 Erin Denny,1 Jamil Mo-
mand,2 Susan E. Kane1. 1City of Hope, Duarte, CA; 2California State University,
Los Angeles, Los Angeles, CA.
t-Darpp is the truncated form of the dopamine- and cAMP-regulated phos-
phoprotein of 32 kDa (Darpp-32) and has been demonstrated to confer resis-
tance to trastuzumab, a Her2-targeted anticancer agent, via sustained signaling
through the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt path-
way. t-Darpp over-expression results in enhanced activity of protein kinase A
(PKA), but the mechanism of t-Darpp-mediated PKA activation is poorly un-
derstood. In the PKA holoenzyme, when the catalytic subunits are bound to
regulatory subunits RI or RII, kinase activity is inhibited. We investigated PKA
activity and holoenzyme composition in cell lines that over-express t-Darpp
(SK.tDrp) or a T75A phosphorylation mutant (SK.tDrp.T75A), as well as an
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empty vector control cell line (SK.empty). We also evaluated protein-protein
interactions between t-Darpp and PKA catalytic (PKAc) or regulatory subunits
RI and RII in those cell lines. Whereas SK.tDrp cells had elevated PKA activity,
SK.tDrp.T75A cells did not. In agreement with the effects on activity, a proxim-
ity ligation assay showed that SK.tDrp cells, but not SK.tDrp.T75A cells, had
diminished association of RI with PKAc. Moreover, t-Darpp was seen to bind
directly to RI in co-immunoprecipitation studies. Cells that express both
Darpp-32 and t-Darpp had PKA activity levels and RI-PKAc association that
were similar to control SK.empty cells. This is consistent with our published
fındings that Darpp-32 reverses t-Darpp’s effects on trastuzumab resistance and
CREB DNA binding activity (downstream of PKA). Taken together, our data
suggest that T75 phosphorylation is crucial for t-Darpp-mediated PKA activa-
tion and this activation appears to occur through direct binding toRI and release
of RI from PKAc. The t-Darpp-RI interaction could be a druggable target to
reduce PKA activity in drug-resistant cancer.
#4094 Accumulation of hepatomaup-regulated protein in prostate cancer
cells inhibits bortezomib-induced apoptosis. Mohamed Hassan,1 Abdeloua-
hid Elkhattouti,2 Nasir Butt,2 Ingrid Espinoza,2 ChristianGomez2. 1Tulane Uni-
versity, New Orleans, LA; 2Univ. of Mississippi Medical Ctr., Jackson, MS.
The increased understanding of cellular signaling pathways in the regulation
of tumor progression and resistance, together with the identifıcation of key
molecular markers has allowed for considerable advances in the establishment
of therapies for therapy-resistant Prostate cancer (PCa). Hepatoma Up-Regu-
lated Protein (HURP), is overexpressed in several tumors, and has been identi-
fıed as a multifunctional protein with tumorigenic capacity. We previously re-
ported on HURP as an essential modulator of PCa resistance to radiation
therapy. Bortezomib, a proteasome inhibitor used clinically for multiple my-
eloma, has been shown to induce apoptosis in PCa cells. In the present study, we
evaluate HURP’s role in PCa resistance pathways by analyzing its effects on
bortezomib-induced apoptosis. LNCaP-TetOn-HURP, DU145-TetOn-HURP,
and PC3-TetOn-HURP clones were established for the expression of HURP.
HURP expression was induced with doxycycline (Dox) for 48 h. Next, cells were
treated with bortezomib (50 nM) for 24h. To assess the effect of HURP on
bortezomib-induced apoptosis, the cells were harvested and subjected to flow
cytometry (FC) analysis using annexinV/PI staining. Apoptosis was observed in
control cells (-Dox) following the treatment with bortezomib. Induction of
HURP expression (Dox), blocked bortezomib-induced apoptosis. This effect
was observed only in LNCaP- andDU145-TetOn-HURP cells with a 1.8 and 2.1
fold decrease in apoptosis, respectively; but not in PC3-TetOn-HURP cells. In
addition, we performed FC analysis of DHR123 to analyze the effects of HURP
on bortezomib-induced accumulation of reactive oxygen species (ROS). HURP
blocked bortezomib-induced ROS accumulation in LNCaP- and DU145-
TetOn-HURP cells with a 0.3 and 0.15 fold change, respectively. Bortezomib
also induced the expression of p53 and Noxa, and enhanced the cleavage of
PARP in LNCaP- and DU145-TetOn-HURP control cells (-Dox), but not in
(-Dox) PC3-TetOn-HURP cells. Induction of HURP, however blocked effects
on apoptosis effectors in LNCaP- andDU145-TetOn-HURP.Western blot anal-
ysis also demonstrated that inHURP-expressing cells, bortezomib-inhibited the
phosphorylation of ASK1, JNK or p38. Finally, we assessed the effects of HURP
expression on the cytoplasmic localization of Noxa, a mediator of bortezomib-
induced apoptotic signaling by immunocytochemistry. Noxa staining was
weakly detectable or absent in HURP expressing cells, suggesting the ability of
HURP overload to block bortezomib-induced Noxa expression.Overall, our re-
sults show that HURP-induced resistance of PCa cells to bortezomib is attrib-
uted to the effects of this protein on mechanisms related to a non-specifıc over-
load response leading to the activation of ubiquitin system. Funding: PCRP
W81XWH-14-1-0151 (CRG), UMMC Department of Pathology (MH)
#4095 c-Met activationmediates resistance to polo-like kinase 1 inhibitor-
induced apoptosis in non-small cell lung cancer.Ratnakar Singh, Li Shen, Pan
Tong, JingWang, FayeM. Johnson.MDAnderson Cancer Center, Houston, TX.
Background: Inhibiting polo-like kinase 1 PLK1may be an effective treatment
for non-small cell lung cancer (NSCLC). PLK1 is a key regulator of mitosis and
DNA damage checkpoints. PLK1 inhibitors are well tolerated, but only a few
unselected patients withNSCLC respond to single-agent therapy.However, pre-
dictive biomarkers have not been used to select patients who are likely to expe-
rience a response to PLK1 inhibitors, and themechanisms of resistance to PLK1
inhibitors have not been elucidated, making these unknowns a major gap in
knowledge. To address this gap, we compared basal gene and protein expression
in 63 NSCLC cell lines and discovered that mesenchymal NSCLC cell lines were
more sensitive to PLK1 inhibitors than epithelial cell lines in vitro and in vivo.
The induction of apoptosis in some NSCLC cell lines at very low drug concen-
trations and the need to fınd better therapy for mesenchymal NSCLCmotivated
us to further study PLK1 inhibition.Methods: To identify the pathways involved
in PLK1 inhibitor-induced apoptosis, we used 3 pairs of isogenic NSCLC cell
lines in which we had induced a mesenchymal phenotype using TGF-. These
isogenic lines were treated with the PLK1 inhibitor (volasertib) for 24 hours and
levels of 301 proteins and phosphoproteins were simultaneously measured be-
fore and after treatment with volasertib using reverse phase protein array
(RPPA). Results: The induction of a mesenchymal phenotype using TGF- in-
creased PLK1 inhibition-induced DNA damage and apoptosis in 3 NSCLC cell
lines. To further elucidate mechanisms of resistance to PLK1 inhibition, we
compared gene and protein expression in these isogenic cell lines, before and
after PLK1 inhibition. There were 35, 12 and 43 proteins differentially regulated
following PLK1 inhibition in epithelial vs. mesenchymal lines in HCC366,
H1975, and HCC4006 cell lines, respectively at False Discovery rate 0.1. Phos-
phorylated FAK (Y397) and c-Met (Y1234/1235) were consistently inhibited
following PLK1 inhibition in the mesenchymal lines but activated in the epithe-
lial lines. These changes were confırmed by Western blotting. Total FAK and
c-Met protein and mRNA levels were not affected, demonstrating post-transla-
tional changes. The inhibition of c-Met using EMD 1214063 led to FAK inhibi-
tion but FAK inhibition did not affect c-Met activation. The combination of
c-Met inhibitor and volasertib increases sensitivity in NSCLC cell lines tested.
The combinations led to more apoptosis than the single-agent inhibitors. Con-
clusions: NSCLC cell lines have diverse sensitivities to PLK1 inhibition, which is
consistent with the results of clinical trials of PLK1 inhibitors in solid tumors,
but no studies to date explain these diverse responses to PLK1 inhibition. We
have identifıed c-Met activation as a previously unknown pathway of resistance
to PLK1 inhibition in epithelial NSCLC.
#4096 Transglutaminase 2(TG2) induces the intrinsic EGFR-TKI resis-
tance in EGFR-mutant NSCLC. Junyoung Choi,1 Hannah Yang,2 Sang-We
Kim,3 Kyung Hae Jung,3 Kang-Seo Park,1 Dae Ho Lee3. 1Institute for Innovative
Cancer Reasearch, University of UlsanCollega ofMedicine, ASANmedical center,
SEOUL, Republic of Korea; 2Biomedical Science and Engineerinf Interdiscipli-
anary Program, Korea Advanced Institute of Science and Technology(KAIST),
DEAJEON, Republic of Korea; 3Department of Oncology, ASAN Medical center,
SEOUL, Republic of Korea.
The non-small cell lung cancer (NSCLC) patients with EGFR-sensitive mu-
tations can be therapeutically targeted by EGFR tyrosine kinase inhibitors
(EGFR-TKI), such as erlotinib. Unfortunately, even though the intrinsic EGFR-
TKI resistant patients harboring the EGFR-sensitizing mutation, a part of those
are still resistant to EGFR-TKI. And, it has been reported that both PTEN loss
and NF-kB activation contribute to intrinsic EGFR-TKI resistance in EGFR-
mutant lung cancer. Transglutaminse 2 (TG2) is post-translationalmodifıcation
enzyme and known to induce degradation of tumor suppressors including
PTENand IB-with peptide cross-linking activity. Because TG2was known as
a regulator of PTEN and IB- (NF-B inhibitor) level in cytosol, we have
explored if TG2 can be another key regulator to the intrinsic resistance of EGFR-
TKI in the intrinsic EGFR-TKI resistant NSCLC cell. In NSCLC with EGFR-
sensitive mutations, we fırst found that higher TG2 expression level and lower
PTEN and IB- expression levels in the intrinsic EGFR-TKI resistant NSCLC
compare with EGFR-TKI sensitive NSCLC. TG2 stably expressing EGFR-TKI
sensitive NSCLC cells harboring EGFR mutations showed reduction of both
PTEN and IB- and exhibited EGFR-TKI resistance. In reverse, TG2 stably
downregulated H1650, intrinsic EGFR-TKI resistant NSCLC cell harboring
EGFR sensitive mutation, restored EGFR-TKI sensitivity via PTEN and IB-
restoration by TG2 loss. Xenograft study using TG2 overexpressed and down-
regulated NSCLC cells also verifıed our in vitro results. Therefore, we have
demonstrated that TG2 elicits the intrinsic EGFR-TKI resistance via PTEN loss
and activation ofNF-Bpathway. These results suggest that TG2may be a useful
target for overcoming the intrinsic EGFR-TKI resistance of NSCLC harboring
EGFR sensitive mutations.
#4097 Src-met signaling confers apoptosis resistance to the combination
of BKM120 and erlotinib in head and neck cancer. A.R.M. Ruhul Amin, Abu
Anisuzzaman, Abedul Haque, Zhuo Chen, Dong Shin. Emory Univ. Winship
Cancer Inst., Atlanta, GA.
Purpose: Molecularly targeted agents will play a major role in the next gener-
ation of personalized cancer therapies. However, intrinsic and acquired resis-
tance to targeted agents poses challenges to the success of such treatments. The
purpose of the current study was to investigate the intrinsic resistance of head
and neck cancer (HNC) cell lines to apoptosis induced by the combination of
EGFR inhibitor erlotinib and PI3K inhibitor BKM120.Methods: In a panel of 10
malignant and 1 premalignantHN cell lines, we evaluated cell growth inhibition
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(by SRB assay), IC50, combination index, dose reduction index (by CalcuSyn
Software), and apoptosis (by Annexin-V staining). Protein expression levels
were measured by Western blotting. Small molecule chemical inhibitors and
siRNA-mediated knockdown strategies were used to inactivate and shut down
the expression of the relevant proteins, respectively. Results: Single targeting of
EGFR with erlotinib or PI3K with BKM120 (pan-PI3K inhibitor) suppressed
cellular growth without inducing signifıcant apoptosis. Co-targeting EGFR and
PI3K demonstrated in vitro synergy in all except one cell line (based on combi-
nation index and dose reduction index) and more effectively inhibited HNC
xenograft growth in vivo. The combination of erlotinib and BKM120 induced
variable apoptosis: some cell lines were very sensitive (Tu686, 686LN, 93-VU-
147T), some moderately (Fadu, SqCCy1, 1483, UMSSC90) and others were re-
sistant (UD-SCC2,MSK-LEUK1, JHU022) to apoptosis induction. JHU022 and
1483 cell lines expressed very high levels of p-cMet. Targeting cMet with the
small molecule inhibitor crizotinib or siRNA rendered these cell lines highly
sensitive to erlotinib and BKM120 induced apoptosis. Moreover, inhibition of
Src family kinases with the small molecule inhibitor dasatinib or with c-Src-
specifıc siRNA inhibited p-cMet. In addition, inhibition of SFK in these cell lines
conferred sensitivity to erlotinib and BKM120 induced apoptosis. Conclusions:
Our results strongly suggest that co-targeting of EGFR and PI3K has synergistic
activity, is effective in vivo, and induces apoptosis of some HNC cell lines. Two
of the resistant cell lines express a high level of p-cMet as a downstream target of
SFK, which confers resistance of these cells to the combination of erlotinib and
BKM120.
#4098 Tyrosine kinase inhibitor resistance were decreased in spheroid
culture platform. Toshihiro Suzuki,1 Risa Ito,1 Toshimitsu Yamaoka,2 Tohru
Ohmori,2 Kazuto Nishio,3 Yuki Ogasawara1. 1Meiji Pharmaceutical Univ., To-
kyo, Japan; 2Showa University, School of Medicine, Tokyo, Japan; 3Kinki Univer-
sity School of Medicine, Osaka, Japan.
Lung cancer is the leading cause of cancer related death in the world. Plati-
num-based combination regimen or molecular target drugs, such as EGFR ty-
rosine kinase inhibitors (EGFR-TKIs) are used for fırst line chemotherapy of
non small cell lung cancer (NSCLC). Somatic mutation in the tyrosine kinase
domain of epidermal growth factor receptor (EGFR) have been identifıed in
NSCLC and those mutations confer sensitivity to the EGFR-TKIs such as ge-
fıtinib. Unfortunately, it is already known that the almost cases are developed to
drug resistance after chemotherapy. Several EGFR-TKI resistant mechanisms
have been reported, including T790M gefıtinib/erlotinib resistance mutation,
C797S osimertinib resistant mutation, c-MET amplifıcation and ErbB3 activa-
tion. In the previous study, we revealed that the miRNA biosynthesis pathway
was critical for maintain the cisplatin resistant phenotype. Further, it was re-
ported that EGFRmodulated miRNAmaturation through the phosphorylation
ofAGO2. Protein phosphorylation is one ofmost important post transcriptional
modifıcation mechanisms and miRNA is also associated with fıne tuning of
mRNA expression. Thus, we focused on the relationship between miRNA ex-
pression and kinase signaling in gefıtinib resistance.Generally, developed resis-
tant cell lines and cell culture techniques were used in resistance research. How-
ever, some resistancemechanisms observed in cultured cells are not reflected the
in vivo. Recently, some three-dimensional (3D) cell culture techniques are de-
veloped and expected to bridge the gap between normal cell culture and in vivo
models. In this study, we attempted to analyze the resistant mechanism of ge-
fıtinib resistant cell lines in suspended spheroid culture using RPMI1640 me-
dium containing suspension polymer, FP001. We screened differences of rela-
tive resistance to anticancer compounds in 3D culture and normal culture
condition using chemical library and ATP assay. As results; we revealed that
ErbB3 and Akt phosphorylation levels were signifıcantly decreased in spheroid
formed from resistant cell lines in 3D culture condition compared to these levels
with normal culture condition. On the other hand, miR-205 levels remain high
in all resistant cell lines. Furthermore, some anticancer agents, including kinase
inhibitors showed higher sensitivity in resistant cell lines under 3D condition
than that under normal cell culture. We speculate that the decreased resistance
depends onnormal culture in plastic dish and remaining resistantmechanism in
3D culture is important and similar to in vivo. In conclusion, this approach with
3D culture is more close to in vivo, such as xenograft model, and promising
contribute to drug resistance research.
#4099 Targeting the paracaspase MALT1: A potential therapy to over-
come ibrutinib resistance in relapsed/refractory MCL patients. Changying
Jiang, Xin Lin,MichaelWang, LiangZhang.MDAndersonCancer Center,Hous-
ton, TX.
Mantle cell lymphoma (MCL) is an aggressive B cellmalignancy that is not yet
curable. Ibrutinib was FDA-approved in 2013 to treat relapsed/refractoryMCL;
however, ibrutinib resistance inevitably develops. Once patients relapse after
ibrutinib treatment, the 1-year survival rate is only 22%; therefore, there is an
urgent unmet need to overcome ibrutinib resistance and to study alternative
treatment options. Constitutive NF-B activation is the hallmark of MCL. In-
deed, next generation sequencing analysis of 110MCL patient samples revealed
that genes in the NF-B signaling pathway had the highest mutation rates
(28.8%), indicating the signifıcant contribution of NF-B signaling toMCLma-
lignancy. Mucosa-associated lymphoid tissue transformation protein (MALT1)
plays a crucial role in NF-B signaling. MALT1 is a unique paracaspase within
the human genome, and the proteolytic activity of MALT1 has been found to be
constitutively active inmanyMCL samples, suggestingMALT1may be a poten-
tial therapeutic target without signifıcant off-target side effects.MI-2 is a specifıc
inhibitor ofMALT1 and its effıcacy and safety are currently being evaluated in a
clinical trial with ABC-type diffuse large B cell lymphoma patients. Mice treated
with MI-2 did not have detectable physiological, histological or biochemical
signs of toxicity. However, whether MALT1 activity contributes to ibrutinib
resistance and whether targeting MALT1 can overcome ibrutinib resistance in
relapsed/refractory MCL patients remain unclear. In this study, we found that
both canonical and non-canonical NF-B signaling is activated in ibrutinib-
resistant MCL cells, which correlates with constitutive MALT1 activity. Inter-
estingly, we found that MALT1 is highly mutated in four clusters, including the
death domain, TRAF6-binding site, Caspase-like domain, and IKK-binding
site inMCL samples. Occurrence of L79P, K80R, E319D, L445P and N446S was
also highly correlated with ibrutinib resistance and disease progression, which
requiresmore detailed investigation. TreatmentwithMI-2 signifıcantly reduced
cell viability in several MCL cell lines with nanomolar activity. MI-2 treatment
inhibited NF-B activation, IL-6 production and its downstream STAT3 activa-
tion. CombiningMI-2with ibrutinib resulted in synergistic growth inhibition in
both ibrutinib-resistant MCL cell lines and primary MCL cells. These fındings
suggest that targetingMALT1 catalytic activity inMCL is a promising therapy to
overcome ibrutinib resistance in relapsed/refractoryMCL patients. The effect of
MI-2 in in vivo PDX models is currently under investigation. This work and
follow-up in vitro and in vivo studies will provide strong evidence that targeting
MALT1 withMI-2 may be an effective novel therapeutic approach to overcome
ibrutinib resistance.
#4100 Mechanisms of resistance to type I and type II MET inhibitors in
non-small cell lung cancer. Magda Bahcall, Yanan Kuang, Cloud P. Paweletz,
Pasi A. Jänne. Dana Farber Cancer Institute, Boston, MA.
Background:MET targeted therapies are clinically effective inMET amplifıed
and MET exon 14 deletion mutant non-small cell lung cancers (NSCLC). At
least 8MET tyrosine kinase inhibitors (TKIs), including both type I and II, have
been developed and are under clinical evaluation.We recently described a resis-
tancemechanism in a patient with a uniqueMET secondarymutation, D1228V,
refractory to all type I but sensitive to type II MET TKIs (Bahcall et al. Cancer
Discovery 2016). We examined whether the sensitivity and resistance of other
MET secondary mutations were similarly dependent on the mode of inhibitor
binding, and sought to determine the optimal sequence ofMET inhibitor use, so
as to achieve the longest combined latency before the emergence of resistance.
Methods: TPR-MET Ba/F3 cells were mutagenized with ENU and treated with
each of the type I TKIs - crizotinib; savolitinib; capmatinib, or type II TKIs -
cabozantinib; glesatinib; merestinib, until resistant clones emerged. Resistant
mutations were identifıed by sequencing, constructed in the TPR-MET back-
ground, and expressed in Ba/F3 and NIH-3T3 cells. Cross-resistance to the 6
MET TKIs was evaluated. Next, low frequency (0.1%) of mutant Ba/F3 cells was
spiked into parental TPR-MET Ba/F3 cells and sequentially exposed to different
METTKIs to identify the sequence associatedwith the longest combined time to
resistance. Clonal evolution was assessed by droplet digital PCR (ddPCR). Re-
sults: Of 300 plated wells per drug used at either 0.1M or 0.5M, crizotinib
yielded 210 and 2 clones; savolitinib 51 and 1 clone; capmatinib 9 and 3 clones;
cabozantinib 38 and 3 clones; glesatinib 300 and 300 clones; merestinib 18 and 3
clones, respectively. Of themutations, those at Y1230were common to all 3 type
I TKIs and themost frequently seenwith savolitinib and capmatinib; D1228was
shared by savolitinib and capmatinib; V1155L, themost commonmutationwith
crizotinib, was shared with savolitinib; M1211L emerged with capmatinib. Mu-
tated F1200 residue was shared by and exclusive to all type II TKIs and was the
single identifıedmutation for both glesatinib andmerestinib. Cabozantinib gave
rise to a broader array of uniquemutants - with F1200mutations being themost
common - and shared G1163R with crizotinib. We show D1228 and Y1230
mutations beingmoderately resistant to crizotinib and strongly resistant to both
savolitinib and capmatinib, while retaining sensitivity to all type II TKIs.
G1163R and L1195V were slightly to moderately resistant to crizotinib, cabo-
zantinib and glesatinib, but strongly sensitive to savolitinib and capmatinib. In
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this assay, merestinib had the broadest, while crizotinib most narrow activity
against the tested mutants. Conclusions: Here we highlight key differences be-
tween and within the 2 types of MET inhibitors that defıne their activity against
MET secondarymutants likely to emerge in patients, providing rationale for the
specifıc use of these inhibitors in the clinic.
#4101 Targeting theEGFR/STAT3axis inNSCLCwith resistance toEGFR
tyrosine kinase inhibitors using an oligonucleotide-based decoy. Christian
Njatcha,1 Mariya Farooqui,1 Jennifer R. Grandis,2 Jill M. Siegfried1. 1University
of Minnesota, Minneapolis, MN; 2UCSF School of Medicine, San Francisco, CA.
EGFR (EpidermalGrowth Factor Receptor) is amajor target for the treatment
of Non-Small Cell Lung Cancer (NSCLC), but patients lacking EGFR mutation
are insensitive to EGFR inhibition. Patients with EGFR mutations initially re-
spond to EGFR tyrosine kinase inhibitors (TKIs), but eventually develop ac-
quired resistance as a result of secondarymutations in the EGFR tyrosine kinase
domain. Upregulation of Signal Transducer and Activator of Transcription
(STAT3), a key oncogenic molecule in NSCLC that is downstream of EGFR
signaling, contributes to intrinsic and acquired resistance to EGFR TKIs. In the
clinic, agents targeting STAT3 have not been satisfactory to date. To address the
limitations of available STAT3 inhibitors, we are currently testing a cyclic oligo-
nucleotide molecule with a novel mechanism that acts as a STAT3 “decoy”
(Cyclic STAT3decoy, CS3D). CS3Dmimics theDNAconsensus sequence in the
promoter region of STAT3-responsive genes, causing the binding of STAT3
dimers and preventing transcriptional regulation of STAT3-target genes. The
effects of CS3D are compared to mutant cyclic STAT3 decoy (CS3M), which
differs from CS3D by one base-pair. We have tested the ability of CS3D to
produce anti-tumor effects in NSCLC cells that are EGFR WT (201T) and in
EGFRmutant cells that also carry the T790M resistantmutation (H1975). Initial
in vitro studies showed thatCS3D caused a 50% inhibition in cell proliferation in
201T and H1975 relative to CS3M using MTS assays. Flow cytometry studies
also demonstrated that CS3D caused a 2-fold increase in the percent of apoptotic
cells as compared toCS3M.CS3D also caused a 2-fold reduction in expression of
STAT3-target genes c-Myc, Bcl-xL and IL-6. Compared to CS3M, CS3D inhib-
ited colony formation by 70%. Using an in vivo mouse xenograft model of 201T
andH1975, CS3D caused a 96.5% reduction in tumor growth in 201T (P0.007)
compared to CS3M, while an 81.7% inhibition was seen in H1975 (P.0001).
Utilizing IHC, analysis of residual tumors also illustrated that CS3D induced
more caspase3 cleavage relative to CS3M. Additionally, western blot analysis
showed 70% reduction in c-Myc protein level in response toCS3D. These results
suggest CS3D can be effective as a single therapeutic agent. Combining CS3D
with EGFR inhibitors such as afatinib in vitro signifıcantly suppressed cell via-
bility by 85.2% and 80% in 201T and H1975 respectively, as compared to single
treatment (CS3D alone reduced cell viability by 53%, and 51.5%, and afatinib
alone reduced viability by 31.4% and 34.03% in 201T and H1975, respectively).
The combination of CS3D and afatinib warrants further testing in vivo. These
data suggest that CS3D alone or in combination with EGFR tyrosine kinase
inhibitors produces anti-tumor effects in NSCLC with intrinsic and acquired
resistance to EGFR TKIs. Supported by funding to the Masonic Cancer Center
from the Minnesota 5th Order of Eagles.
#4102 Overcoming intrinsic and acquired cetuximab resistance: an in
vitro study on the potential of afatinib inHNSCC cell lines. Ines De Pauw, An
Wouters, Jolien Van den Bossche, Vanessa Deschoolmeester, Patrick Pauwels,
Jan B. Vermorken, Marc Peeters, Filip Lardon. University of Antwerp, Wilrijk,
Belgium.
Aberrant signalling of the epidermal growth factor receptor (EGFR) plays an
integral role in the tumorigenesis ofmany cancer types, including head and neck
squamous cell carcinoma (HNSCC), making it a compelling drug target. After
the initial promising results of EGFR-targeted therapies, the problem of thera-
peutic resistance is emerging and new treatment options are necessary. In con-
trast to the fırst generation EGFR inhibitors, afatinib is an irreversible ErbB
family blocker that inhibits EGFR as well as HER2 and HER4. The objective of
this study was to investigate whether afatinib is able to overcome intrinsic and
acquired cetuximab resistance in human papillomavirus (HPV) positive and
negative HNSCC cell lines under normal and reduced oxygen conditions and to
identify the molecular mechanisms underlying afatinib’s cytotoxic effect. Sensi-
tivity to cetuximab treatment was investigated in a panel of HPV positive and
negative HNSCC cell lines using the colorimetric sulforhodamine B (SRB) assay
(168h, 0-2M). Cetuximab sensitive and intrinsically resistant cell lines were
identifıed. Acquired cetuximab resistant cell lines were generated by chronically
exposing initially sensitive cell lines to cetuximab. In parallel, control cell lines
were established by exposing these cells to the vehicle control (PBS). Cytotoxic-
ity of afatinib (72h, 0 - 5M)was assessed under normoxic and hypoxic (1%O2)
conditions. Cell cycle distribution and induction of apoptotic cell death were
assessed flow cytometrically using the Vindelov method and Annexin
V-FITC/PI assay, respectively. Data analysis was performed using WinNonlin
and FlowJo software. We identifıed intrinsic cetuximab resistance in 5 out of 7
HNSCC cell lines (i.e. LICR-HN1, Cal-27, SQD9, 93-VU-147T and UM-
SCC104) and generated acquired cetuximab resistant cell lines (i.e. SCC22b-R
and SC263-R). Afatinib showed a clear concentration-dependent cytotoxic ef-
fect in both cetuximab sensitive and resistant cell lines with IC50 values ranging
between 0.019 and 4.04 M. Furthermore, afatinib maintained its cytotoxic
effect under hypoxic conditions. Treatment with afatinib led to an increase of
the proportion of cells in the G0/G1 phase of the cell cycle. Afatinib also induced
an increase in the percentage of AnnV/PI- and AnnV/PI cells with a cor-
responding decrease of the percentage viable (AnnV-/PI-) cells. In conclusion,
our results suggest that afatinib has the potential to overcome cetuximab resis-
tance, as it was able to establish cytotoxicity in HPV positive and negative HN-
SCC cell lines that were intrinsically and acquired resistant to cetuximab. Fur-
thermore, treatment with afatinib caused a G0/G1 cell cycle arrest and induced
apoptotic cell death. These data support the hypothesis that afatinib might be a
promising novel therapeutic strategy to treat HNSCC patients experiencing in-
trinsic or acquired cetuximab resistance.
#4103 IL-6dynamics regulate neuroendocrine transformation in gefıtinib
acquired resistance EGFRmutant lung cancer cells. Shang-Yin Wu,1 Hsuan-
HengYeh,2 Chun-HuaHung,2 Chien-Chung Lin,2Wen-Pin Su,1Wu-Chou Su2.
1Graduate Institute of Clinical Medicine, Department of Internal Medicine, Na-
tional Cheng Kung University Hospital, College of Medicine, National Cheng
KungUniversity, TAINAN, Taiwan; 2Department of InternalMedicine, National
Cheng KungUniversity Hospital, College ofMedicine, National Cheng KungUni-
versity, TAINAN, Taiwan.
Transformation to small-cell lung cancer (SCLC, one of aggressive neuroen-
docrine [NE] tumor) is reported when activating epidermal growth factor re-
ceptor (EGFR) mutant non-small-cell lung cancer acquired resistance to ty-
rosine kinase inhibitors (TKI, such as gefıtinib). IL-6 activation confers to
acquire TKI resistance and associates with p53 and RB inactivation those are
SCLC hallmark changes. Whether NE transformation could phenocopy in iso-
genic acquired resistance cell line and the role of IL-6 in this process remain
unknown.We established 827GRs (including 827GR, 827GR and 827GR.M6)
acquired resistance to gefıtinib fromHCC827 cells by long term stepwise treated
with gefıtinib and they still hadEGFRexon19deletionwithout acquiredT790M.
827GRwas parental resistance linewith unstable gefıtinib resistance in drug-free
medium by passage. We maintained 827GR in medium with or without 1M
gefıtinib over 6 months to generate stable clones: 827GR and 827GR.M6.
827GRs had SCLC hallmark changes, i.e., inactivation of p53, RB and Notch by
western blot and gene set enrichment analysis. Compared to HCC827, 827GRs
were more sensitive to cisplatin and etoposide but not paclitaxel. IL-6 level was
positive correlated with gefıtinib resistance among 827GRs by cytokine array
and ELISA. Interestingly, among 827GRs, 827GR.M6 harbored low IL-6 secre-
tion had obviously NOTCH-ASCL1-DLL3 alteration, high NE marker expres-
sion and signifıcant inter-rater agreement with selected Byers’ SCLC gene sig-
nature than high IL-6 secretion 827GR, suggesting IL-6 dynamics might
regulate NE marker expression. IL-6 genetic manipulation in HCC827 and
827GR also demonstrated this phenomenon. Moreover, IL-6 dynamics corre-
late with NE expression also showed in patient derived lung cancer cell line in
published microarray dataset (GSE64322). In conclusion, our work demon-
strated activating EGFRmutant lung cancer acquired resistance to TKI with NE
transformation could phenocopy in isogenic cell line model and IL-6 dynamics
might regulate this process.
#4104 Intrinsic and acquired resistance to cetuximab in colorectal cancer
patients. StevenM. Bray,1 Jeeyun Lee,2 SeungTaeKim,2 Philip J. Ebert,1 JohnN.
Calley,1 Isabella H. Wulur,1 Thejaswini Gopalappa,1 Swee Seong Wong,1 Hui-
Rong Qian,1 Jason C. Ting,1 Jiangang Liu,1 Melinda D. Willard,1 Amit Aggar-
wal,1 Ruslan D. Novosiadly,3 Hee-Cheol Kim,2 Christoph Reinhard1. 1Eli Lilly
and Company, Indianapolis, IN; 2Samsung Medical Center, Seoul, Republic of
Korea; 3Eli Lilly and Company, New York, NY.
Anti-EGFR antibodies, such as cetuximab, are effective therapies for many
late-stage colorectal cancer (CRC) patients; unfortunately, many tumors are
initially unresponsive while others show initial effıcacy but eventually develop
acquired resistance. Genomic studies of patient tumors, cell lines, and xenograft
models have identifıed putative anti-EGFR resistance markers, including muta-
tions in KRAS, NRAS, BRAF, PIK3CA, and the EGFR extracellular domain, as
well as amplifıcations in ERBB2 and MET. In order to further confırm and
identify new resistance mechanisms to anti-EGFR treatment in CRC, we per-
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formed retrospective genomic profıling of 25 CRC patients treated at Samsung
Medical Center from 2006-2015. Patients received cetuximab containing chemo
regimens with varying duration of responses, including acquired resistance
cases. Our analysis identifıes mutations in receptor tyrosine kinases, such as
EGFR, NTRK1, and PDGFRA, as well as RAS/MAPK pathway genes that affect
cetuximab response. We also uncover genomic alterations in ERBB2 and c-KIT
as potential novel mechanisms regulating sensitivity to anti-EGFR antibodies.
Additional genomic analyses of acquired resistance tumors and in vitro studies
of a patient-derived cell line provide added insights into clonal selection and
signaling pathways that bypass the EGFRblockade.Overall, our study elucidates
important new facets in the landscape of anti-EGFR resistance mechanisms.
#4105 Diosgenin and temozolamide: A potential combinatorial chemo-
therapy to overcome temozolamide resistance in glioblastomamultiforme.Y
Rajesh, Angana Biswas, Subhayan Das, Mahitosh Mandal. Indian Institute of
Technology Kharagpur, Kharagpur, India.
Introduction: Glioblastomamultiforme (GBM) accounts for themost aggres-
sive form of tumor showing poor prognosis. Prevailing treatment modality in-
cludes chemotherapy with temozolomide (TMZ) concomitant with surgical re-
section and/or irradiation. However, it has been observed that a number of
patients are developing resistance to TMZowing to its high dosage regimen. The
aim of this study is to examine the effects of diosgenin (DSG), a natural steroidal
saponin obtained from fenugreek, in combination with TMZ in human GBM
cells and TMZ resistant GBM cells. Methodology: The potential of combinato-
rial chemotherapy for overcoming TMZ resistance was evaluated through de-
velopment of TMZ resistant GBM clones. These clones were generated by treat-
ment of GBM cells with sub-lethal dose of TMZ over several cycles. Cellular
effects were studied by viability assay, flow cytometry and wound healing assay
on both single and combined drug treated GBM cells and TMZ resistant cells,
respectively. The morphological study and cellular uptake in combined or indi-
vidual drug treated cells was assessed by microscopy and immunofluorescence
staining. The time dependant effect of drugs on invasive andmigratory potential
of GBM cells and TMZ resistant cells was analysed through zymography for
matrix metalloproteinases (MMPs) activity and western blot for apoptotic pro-
teins, epithelial and mesenchymal (EMT) markers, MMPs and VEGF expres-
sion. Further, the drug induced apoptosis was also assessed through chromatin
condensation and DNA laddering assay. Results: Our investigation shows that
co-administration of DSG and TMZ resulted in a substantial increase in GBM
cell apoptosis andmarked inhibition of cell growth in vitro. Anti-angiogenic and
anti-invasive potential of DSG and TMZwere assessed through in vitro studies.
At molecular level, DSG and TMZ synergistically lower XIAP expression and
cleavage of intracellular death substrates such as PARP thereby shifting the
balance from survival to apoptosis as indicated by the rise in the sub-G1 cell
population. This combination also alters EMT markers, downregulates the ex-
pression of Bcl-xL, Bcl-2, Mcl1, MMPs and VEGF and induces expression of
Bax, AIF, cytochrome C. Conclusion: The results suggested that DSG in combi-
nation with TMZ reduced the dose of TMZ, when administered singly, and also
inhibited themigration and invasion ofGBMandTMZresistant cells. It induced
apoptosis and altered the expression of EMT markers. These fındings reveal a
new therapeutic potential for overcomingTMZ resistance inGBM therapy. This
novel modality may be a promising tool for GBM treatment.
#4106 Mechanisms of secondary resistance to dual PI3K/mTOR inhibi-
tion in sarcomas with complex genetics. Benjamin Fourneaux, Aurélien Bour-
don, Vanessa Chaire, Carlo Lucchesi, Marie Karanian, Raphael Pineau, Audrey
Laroche, Antoine Italiano. Institut Bergonié, Bordeaux, France.
Background: Soft tissue sarcomas are a heterogeneous group of malignant
tumors includingmore than 70 histological subtypes.We have recently demon-
strated that dual targeting of PI3K/mTOR pathway is associated with signifıcant
anti-tumor activity in in vitro and in vivomodels of leiomyosarcoma (LMS), one
of themost frequent sarcoma subtype. Secondary resistance limits the effıcacy of
all targeted therapies.Wehave developed and characterized resistancemodels to
a dual PI3K/mTOR inhibitor in order to describe underlying resistance mecha-
nisms and develop alternative strategies. Methods: To develop in vitro BEZ-235
(dual PI3K/mTOR inhibitor) resistance models, 3 LMS and 1 myxofıbrosar-
coma cell lines were exposed to increasing doses of BEZ-235 several months. To
characterize the resistance models, sensitivity to BEZ-235 was assessed by MTT
assay andAnnexin V-PI staining. To test in vivo the resistancemodels, effects of
BEZ-235 treatment were observed in mice with subcutaneous cell line-derived
xenograft tumors for 3 weeks. The transcriptome profıle of sensitive and resis-
tant tumors to BEZ-235 was analyzed by using RNA-seq. Results: After pro-
longed exposure of cell lines to BEZ-235, we obtained secondary resistant cell
lines characterized by an IC50 value 5- to 21-fold higher than parental sensitive
cells. Resistant cells were also signifıcantly less sensitive to BEZ-235-induced
apoptosis than parental cells. We confırmed the resistance patterns in vivo with
a signifıcantly higher anti-tumor effect of BEZ235 in sensitive cell-line derived
xenograft group compared with resistant cell-line derived xenograft group.
Deep transcriptome profıling indicated overexpression of stem cells related
genes in resistant cells as well as a modifıcation of the cellular metabolism. By
using 1) RNAi-mediated suppression of pyruvate carboxylase (PC), a potential
key player in our resistance models and 2) hallmarks of CSC like CD133 and
enhanced aldehyde dehydrogenase (ALDH) activity, we confırmed that resistant
tumors were characterized by a signifıcantly higher proportion of cancer stem
cells and by a metabolic shift with a strong deregulation of glucose metabolism.
Conclusions: Selection of CSC subpopulation and metabolism shift play a cru-
cial role in secondary resistance to dual PI3K/mTOR inhibition in sarcoma.
Strategies assessing anti-CSC agents to suppress acquired resistance may have
major implications to improve effıcacy of dual PI3K/mTOR targeting in human
malignancies.
#4107 Acquired resistance to EGFR-TKI in an uncommon G719S EGFR
mutation.Atsushi Osoegawa, Tomonori Yamada, TakafumiHashimoto, Yohei
Takumi, Ryoji Kobayashi, Shuji Suehiro, Michiyo Miyawaki, Hideya Takeuchi,
TatsuroOkamoto,Kenji Sugio.OitaUniversity Faculty ofMedicine, Yufu, Japan.
Background: Acquired resistance (AR) to EGFR-TKI is a common event and
several underlying mechanisms, including T790M, MET amplifıcation and
PTEN downregulation have been reported for the common EGFR mutations:
Deletion 19 and L858R. An EGFR G719X mutation is an uncommon mutation
that was reported to show sensitivity to EGFR-TKIs in a series of clinical reports
and experiments using transformed cultured cells. However, no established lung
cancer or resistant cell lines harboring the EGFR G719X mutation have been
reported in the literature. We established a lung adenocarcinoma cell line
(G719S-GR) from the malignant pleural effusion of a patient whose tumor de-
veloped acquired resistance from initial treatment with gefıtinib. Materials and
methods: G719S-GR cells were established and maintained in RPMI1640 me-
dium supplemented with 10%FBS and 10 M ROCK inhibitor (Y-27632,
Wako). The ROCK inhibitor was removed from the medium for the following
experiments. Cell growth inhibition was examined with gefıtinib and afatinib
using CellTiter-Glo (Promega), and a comprehensive genomic analysis was per-
formed using hybrid capture-based NGS (NCC oncopanel, Agilent; MiSeq, Il-
lumina) for G719S-GR andMLPA (Salsa, MRC-holland) was used for the anal-
ysis of clinical tumor samples. Results: A cell growth inhibition test revealed
EGFR-TKI resistance in G719S-GR cells with an LC50 of more than 100M for
either gefıtinib or afatinib, indicating that the G719S-GR cells are also resistant
to EGFR-TKI in vitro. The NGS analysis showed that G719S-GR cells harbor
EGFRmutations (G719S and E709A) aswell as the amplifıcation of EGFR, IL7R,
MYC and the FGFR1 locus. The homozygous deletion of CDKN2A and the loss
of PTEN and TSC1 were also detected. In order to estimate the mechanism
underlying the development of EGFR-TKI resistance, copy number analyses of
several tumor suppressor genes were performed by an MLPA using genomic
DNA from G719S-GR and a tumor biopsy sample (obtained before gefıtinib
treatment). Losses of CDKN2A, PTEN and TSC1 were confırmed in G719S-GR
cells. Interestingly, the loss of PTEN was not observed in the gefıtinib-naïve
tumor sample. Discussion: Thus far, the mechanisms underlying the develop-
ment of EGFR-TKI resistance in uncommon mutations have not been investi-
gated. The newly established G719S-GR cell line could be a useful tool for inves-
tigating the mechanism underlying the development of AR in the G719X
mutation; the loss PTENcould be one suchmechanism. Further experiments are
warranted.
#4108 Targeting IL-6 signaling overcomes cetuximab resistance in head
and neck squamous cell carcinoma. Rachel A. O’Keefe, Neil Bhola, Toni M.
Brand, Yan Zeng, Daniel E. Johnson, Jennifer R. Grandis. University of Califor-
nia, San Francisco, San Francisco, CA.
Head and neck squamous cell carcinoma (HNSCC), the sixth most common
cancer worldwide, has a fıve-year survival rate of only 50%. The fırst targeted
agent FDA approved for treatment of HNSCC was cetuximab, a monoclonal
antibody targeting the epidermal growth factor receptor (EGFR). Despite EGFR
overexpression in up to 90% of HNSCC tumors and ample evidence supporting
EGFR as a therapeutic target in HNSCC, the response rate for single-agent
cetuximab is below 20%, and resistance to cetuximab-containing therapy re-
mains a major obstacle in the effective treatment of HNSCC. Identifıcation and
targeting of mediators of cetuximab resistance is needed to improve patient
outcomes. Secretion of the cytokine interleukin 6 (IL-6) has been proposed as a
mechanismof resistance to cetuximab inHNSCC, and inhibition of signal trans-
ducer and activator of transcription 3 (STAT3), a downstreammediator of IL-6
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signaling, has been shown to overcome cetuximab resistance in preclinical HN-
SCC models. Thus, we hypothesize that IL-6 signaling mediates resistance to
cetuximab and that co-treatment with agents targeting the IL-6 pathway will
enhance the therapeutic effıcacy of cetuximab in HNSCC. We have generated
cetuximab-resistant variants of the cetuximab-sensitive HNSCC cell lines Cal33
and PE/CA-PJ49. Quantitative reverse transcription polymerase chain reaction
(qRT-PCR) analysis indicated that IL6 expression is increased 3.5- to 8-fold in
cetuximab-resistant variants compared to the parental cells from which they
were derived. In addition, a colony formation assay revealed that, as expected,
cetuximab-treated parental cells formed fewer colonies than vehicle-treated
cells, while cetuximab treatment had no effect on the ability of cetuximab-resis-
tant PE/CA-PJ49 variants to form colonies. In contrast, treatment with tocili-
zumab, an IL-6 receptor-neutralizing monoclonal antibody, markedly reduced
the colony-forming ability of the cetuximab-resistant variants, but not parental
cells. These results suggest that targeted inhibition of IL-6 signaling may effec-
tively inhibit proliferation in cetuximab-refractory HNSCC cells.
#4109 HER3mediates acquired resistance to cetuximab in head and neck
squamous cell carcinoma.Yeon JuYang,1MinHeeCho,1 YooJungOh,1Hyung
KwonByeon,1DaHeeKim,1 JungMinKim,1 JiHoonKim,2Myung Jin Ban,3 Jae
Wook Kim,4 Eun Chang Choi,1 Yoon Woo Koh1. 1Yonsei University College of
Medicine, Seoul, Republic of Korea; 2Yonsei University College of Medicine,
Wonju, Republic of Korea; 3Soonchunhyang University College of Medicine, Cheo-
nan, Republic of Korea; 4Soonchunhyang University College of Medicine, Seoul, Re-
public of Korea.
Cetuximab, an EGFRmonocloanal antibody, is used to treat in head and neck
squamous cell carcinoma (HNSCC). Despite the clinical effıcacy of cetuximab,
the majority of patients who do initially respond suffered acquire resistance to
cetuximab as severe side effect. To understand mechanisms of acquired cetux-
imab resistance, we developed a model of acquired resistance to cetuximab by
exposing head and neck cancer cell line Cal27 to increasing concentration of
cetuximab and established recetuximab-resistant (Cr) clones derived from the
cetuximab sensitive (Cp). Cetuximab-resistant (Cr) clones showed robustly
overexpression on the HER family receptors HER3. Cr clones also expressed
upregulated EGFR, HER2, and HER3 activation resulting in activation of PI3K/
ATK and ERK signaling. We also showed that Cr clones exhibited increased
EGFR/HER3 dimerization. Treatment of cetuximab and siHER3 RNA reduced
EGFR activation in Cr clones and decreased robustly cell proliferation to resen-
sitize cells against cetuximab. Next, we examined lapatinib, a tyrosine kinase
inhibitor inhibiting HER3 on cetuximab-resistant clones. Combined treatment
of Cr clones with cetuximab and lapatinib lead to potent anti-proliferative ef-
fects. Co-treatment with cetuximab and lapatinib blocked EGFR, HER2 and
HER3 activities and inhibited downstream signaling pathways. Co-treatment
with cetuximab and lapatinib resulted in suppression of cell growth more effec-
tively than each drug alone and induced apoptotic cell death throughmitochon-
drial ROS. Furthermore, Co-treatment with cetuximab and lapatinib also leads
to decreased tumor growth in HNSCC tumor xenograft mouse model. These
results showed the upregulation of HER3 as one mechanism underlying resis-
tance to cetuximab inHNSCC, supporting further clinical treatment strategy for
tumors displaying acquired resistance to cetuximab.
#4110 Combinatory approaches targeting EGFR, HER2 and c-MET in
recurrent SCCHN. Dongsheng Wang, Kelly R. Magliocca, Sreenivas Nannap-
aneni, Coner Steuer, Mihir R. Patel, Mark W. El-Deiry, Xu Wang, Zhengjia
Chen, Dong M. Shin, Nabil F. Saba, Zhuo G. Chen. Emory Univ., Atlanta, GA.
Squamous cell carcinoma of the head and neck (SCCHN) cells that escape
cetuximab inhibition exhibit HER2, HER3, and/or c-Met activation. Simultane-
ous inhibition of EGFR, HER2, HER3 and c-Met presents an attractive clinical
strategy for treating SCCHN that has progresses despite EGFR-targeted therapy.
In an effort to develop new combination drug therapy options for recurrent
SCCHN, we evaluated three different c-Met inhibitors in combination with a
pan-HER inhibitor (afatinib/crizotinib, afatinib/tivantinib, afatinib/cabozan-
tinib) and investigated their anti-tumoral effects. SCCHN cell lines (JHU022
highly expresses c-Met, and SCC1-C is cetuximab resistant) as well as patient
derived xenograft (PDX) animal models from patients with recurrent SCCHN
were investigated. In our cell line study, western-blot assay indicated that acti-
vation of EGFR, HER2, and c-Met was blocked in all three combinations. In
addition the downstream PI3K/AKT and ERK signaling pathways were inhib-
ited. Sulforhodamin B colorimetric assay (SRB) revealed SCCHN cell growth
was more effectively inhibited by the combinations compared to any of the
single inhibitors in vitro. Furthermore, the combination was more potent in
inducing apoptosis when compared to each of the single treatments. Finally in
the PDX study, all treatment groups had signifıcantly greater effıcacy compared
to the non-treated control group (p0.005) and all combination treatments
exhibited better effıcacy in tumor growth inhibition than their respective single
inhibitors (p0.0l). In conclusion, our study demonstrates that targeting EGFR,
HER2, and c-Met with combination of their inhibitors is more effective than
each of the single inhibitors alone both in vitro and in SCCHN PDX models.
This study paves the way for further clinical investigation of this combination in
patients with SCCHN who have progressed after cetuximab-based therapy.
(This study is supported by NIH/NCI R21 CA182662-01A1 to NFS and ZGC)
#4111 EGFR wild type allele amplifıcation induces acquired resistance to
mutation-specifıc EGFR tyrosine kinase inhibitors in non-small cell lung
cancer cells. Keigo Kobayashi,1 Shigenari Nukaga,1 Hiroyuki Yasuda,1 Keita
Masuzawa,1 Jyunko Hamamoto,1 Ichiro Kawada,1 Katsuhiko Naoki,1 Sachiyo
Mimaki,2 Shingo Matsumoto,2 Koichi Goto,2 Katsuya Tsuchihara,2 Tomoko
Betsuyaku,1 Kenzo Soejima1. 1Keio University, Tokyo, Japan; 2Division of Trans-
lational Research, Exploratory Oncology Research and Clinical Trial Center, Na-
tional Cancer Center, Tokyo, Japan.
Purpose: Third-generation EGFR-tyrosine kinase inhibitors (TKIs) are mu-
tation-specifıc inhibitors that generally have minimal effects on wild type pro-
tein. The mechanisms underlying acquired resistance to third-generation
EGFR-TKIs remain relatively uncharacterized. The purpose of this study is to
clarify themechanisms of acquired resistance to third-generationEGFR-TKIs in
order to improve the prognosis of lung cancer patients harboring EGFR muta-
tions. Experimental design: We established third-generation EGFR-TKIs resis-
tant cells using a dose-escalation method. The PC9 (EGFR E746-A750del) and
H1975 (EGFR L858RT790M) human NSCLC cell lines were cultured with
rociletinib (CO-1686) or osimertinib (AZD9291) for several months. Their re-
sistance to a third-generation EGFR-TKIs was confırmed by the MTS cell pro-
liferation assay. To clarify the heterogeneity of potential resistancemechanisms,
those resistant cell lines were subcloned to isolate resistant clones. DNA isolated
from the parental and resistant cell clones was then subjected to whole exome
sequencing. Copy number alterations and several genetic alterations potentially
relevant to EGFR-TKIs sensitivity were detected. Results: We identifıed Src-
AKT pathway contribute to acquired resistance. In addition, we identifıed that
EGFR wild type allele, but not mutation allele, amplifıcation induced acquired
resistance. It mirrors the decreased inhibitory pressure for wild type EGFR by
mutation-specifıc EGFR-TKIs. Conclusion: We provide evidence of wild type
allele-mediated resistance, a novel concept of acquired resistance, occurring in
response to mutation-specifıc inhibitor therapy in cancer treatment. 1833
/2600characters
#4112 Overgrowth of competing resistance mechanisms, such as an ac-
quired KRAS mutation, underlies a poor prognosis subtype of acquired re-
sistance to osimertinib in T790M-positive NSCLC. Geoffrey R. Oxnard,1
YuebiHu,1 PhilipTracy,1Nora Feeney,1 CloudP. Paweletz,1 Kenneth S. Thress,2
Pasi A. Janne1. 1Dana-Farber Cancer Institute, Boston, MA; 2AstraZeneca,
Waltham, MA.
Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhib-
itor (TKI) which is highly active in EGFR-mutant NSCLC with resistance to
prior EGFR TKI. Acquired resistance to osimertinib had been observed clini-
cally; an improved understanding of the molecular mechanisms of resistance is
needed. Methods/Results: We initially studied an institutional cohort of 86 pa-
tients (pts) treated with osimertinib for advanced T790M-positive NSCLC. 50
pts hadprogressed on therapy, ofwhom25underwent a resistance biopsy and 17
hadNGS results available. 6 ptsmaintained theT790Mmutation at resistance, of
whom 3 also acquired an EGFR C797S mutation. The remaining 11 pts had loss
of T790M, ofwhom5had evidence of a competing resistancemechanism: 2with
histologic transformation to SCLC, one with BRAFV600E, one with an FGFR3-
TACC fusion, and one with KRAS Q61K. For the fınal case, we confırmed the
acquired KRASQ61K on therapy using serial plasma genotyping. Time to treat-
ment failure (TTF) on osimertinib was 3 months median in pts with loss of
T790M and 14 months median in pts with maintained T790M. To test the
hypothesis that loss of T790M is a poor prognosis subtype of resistance, we
analyzed 127 pts treated for T790M-positive NSCLC on the phase I AURA trial
of osimertinib. Plasma drawn after progression was submitted for genotyping
using droplet digital PCR. 88 pts had a detectable EGFR driver mutation and
were eligible for resistance analysis. 45 pts (51%) had detectable T790M at resis-
tance, 17 (19%) of whom also acquired a C797S mutation; the remaining 43 pts
(49%) had loss of T790M and no C797S. Median TTF on osimertinib was 6
months in pts with loss of T790Mand 11months in pts withmaintainedT790M;
among pts with TTF 5 months, 72% had loss of T790M. To study whether
baseline plasma genotyping could predict the eventual pattern of resistance on
osimertinib, we studied 30 pts from the AURA trial with pretreatment plasma
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genotyping positive for T790M and an EGFR driver. The relative allelic fraction
(AF) of T790Mwas calculated as the ratio of the T790MAF to the driver AF. In
9 pts with eventual loss of T790M, the relative T790M AF trended lower (25%
median) than in 21 pts with maintained T790M at resistance (38%median, P
0.086). Conclusion: Different molecular mechanisms of acquired resistance to
osimertinib have different clinical presentations, with early resistance being as-
sociated with loss of T790M and the potential for overgrowth of a competing
resistance mutation. These fındings have implications in steering pts towards
suitable trials for overcoming resistance - pts with early resistance to osimertinib
could favor trials targeting a competing resistance mechanisms (e.g. MET inhi-
bition) while pts with late resistance could favor trials targeting EGFR C797S.
#4113 Acquired resistance to cetuximab is mediated by HER3 activation
in head and neck squamous cell carcinoma. Yeon Ju Yang,1 Min Hee Cho,1
Yoo Jung Oh,1 Da Hee Kim,1 Jung Min Kim,1 Hyung Kwon Byeon,1 Myung Jin
Ban,2 Ji HoonKim,3 JaeWookKim,4MinHeeKu,1 JaeMoonYang,1 EunChang
Choi,1 Yoon Woo Koh,1 Jeong Yeon Lee5. 1Yonsei University College of Medi-
cine, Seoul, Republic of Korea; 2Soonchunhyang University College of Medicine,
Cheonan, Republic of Korea; 3Yonsei University College of Medicine, Wonju,
Republic of Korea; 4SoonchunhyangUniversity College ofMedicine, Seoul, Repub-
lic of Korea; 5Hanyang University, Seoul, Republic of Korea.
Cetuximab, an EGFR monocloanal antibody, is commonly known to be an
effective treatment agent in head and neck squamous cell carcinoma (HNSCC).
However, despite the clinical effıcacy of cetuximab, a majority of patients with
good initial response still suffer from side effects as the acquired resistance to
cetuximab. To understand themechanisms of acquired resistance to cetuximab,
we developed a model by exposing a head and neck cancer cell line Cal27 to
increasing concentrations of cetuximab and established cetuximab-resistant
clones (CETr) derived from the cetuximab sensitive (CETp).We examined how
the acquired resistance in the CETr influenced the signaling pathway compared
to the CETp. We investigated the effect of lapatinib, a tyrosine kinase inhibitor
inhibiting HER3, with or without cetuximab combination on CETr clones and
in a xenograft mouse model. Cetuximab-resistant(CETr) clones showed robust
overexpression on the HER family receptors HER3. CETr clones also expressed
upregulated EGFR, HER2, and HER3 activation resulting in activation of PI3K/
ATK and ERK signaling. We also showed that CETr clones exhibited increased
EGFR/HER3 dimerization. Treatment of cetuximab and siHER3 RNA together
reduced EGFR activation in CETr clones to re-sensitize cells against cetuximab
and robustly decreased cell proliferation. Combined treatment of CETr clones
with cetuximab and lapatinib led to potent anti-proliferative effects. Co-treat-
ment with cetuximab and lapatinib blocked EGFR, HER2 and HER3 activities
and inhibited downstream signaling pathways. Co-treatment resulted in sup-
pression of cell growth more effectively than each drug alone and induced apo-
ptotic cell death through mitochondrial ROS. Furthermore, Co-treatment with
cetuximab and lapatinib also led to suppression of tumor growth in orthotopic
xenograftmousemodel of oral tongue cancer. Our results suggested the upregu-
lation of HER3 as a mechanism underlying resistance to cetuximab in HNSCC,
supporting further clinical treatment strategy for tumors displaying acquired
resistance to cetuximab.
#4114 Polyclonal secondary FGFR2 mutations drive acquired resistance
to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients.
Lipika Goyal,1 Supriya K. Saha,2 Leah Y. Liu,1 Giulia Siravegna,3 Ignaty Lesh-
chiner,4 Leanne G. Ahronian,1 Jochen K. Lennerz,1 Phuong Vu,1 Benedetta
Mussolin,3 Stephanie Reyes,1 Pascal Furet,5 A. John Iafrate,1 Gad Getz,4 Diana
G. Porta,5 Ralph Tiedt,5 Alberto Bardelli,3 Dejan Juric,1 Ryan B. Corcoran,1
Nabeel Bardeesy,1 Andrew X. Zhu1. 1Massachusetts General Hospital, Boston,
MA; 2Fred Hutchinson Cancer Research Center, Boston, MA; 3Candiolo Cancer
Center-FPO, Italy; 4Broad Institute, Cambridge,MA; 5Novartis Institutes for Bio-
Medical Research, Switzerland.
Genetic alterations in the fıbroblast growth factor receptor (FGFR) pathway
are promising therapeutic targets in a broad range of cancers and occur in20%
of ICCs. As seen with other targeted therapies, however, acquired resistance has
limited the effıcacy of selective FGFR kinase inhibitors such as BGJ398. In a
phase II trial of patients with advanced refractory cholangiocarcinoma harbor-
ing an FGFR gene alteration, BGJ398 displayed an overall response rate of 22%,
but the durability of response was short in some patients. We report the molec-
ular basis of acquired resistance in 4 patients with advanced FGFR2-fusion pos-
itive ICC via integrative genomic characterization of cell-free circulating tumor
DNA (cfDNA), the primary tumor, and metastases. Each patient enjoyed an
initial response, but all subsequently progressed within 10 months. Serial anal-
ysis of cfDNA revealedmultiple pointmutations in the FGFR2 kinase domain at
progression (Table 1). The gatekeeper mutation, p. V564F, sterically hinders
drug binding and was identifıed in 3 of 4 patients. In patient #1, fıve different
FGFR2mutations were detected in the post-progression cfDNAbut only one, p.
K641R, was identifıed in the post-progression biopsy. A rapid autopsy was per-
formed, and genomic characterization of 12 metastatic lesions revealed marked
inter- and intra-lesional heterogeneity, with different FGFR2mutations in indi-
vidual resistant clones. Molecular modeling and in vitro studies indicated that
each mutation lead to BGJ398 resistance that was surmountable by structurally
distinct FGFR inhibitors. Thus, our report provides the fırst genetic evidence of
clinical acquired resistance to FGFR inhibitor therapy in patients and informs
future strategies for detecting mechanisms of resistance and promoting more
durable remissions.
Clinical and Molecular Data on Patients with Advanced Refractory
CCA treated with BGJ398
Patient
ID Sex
Age at
Diagnosis
(years)
FGFR2
Fusion
partner
Maximum
Response
Progression
Free
Survival
on BGJ398
(months)
Overall
Survival
since
Diagnosis
(months)
FGFR2
Mutations
on cfDNA
at progression
1 F 47 OPTN 28% 3.6 32 V564F, N549H,
K641R, E565A,
L617V
2 F 59 ZMYMY4 50% 5.6 31 V564F, N549H/K,
E565A, K659M
3 F 69 SORBS1 68% 12.6 50 K659M, K714R
4 M 43 BICC1 37% 7.4 18 V564F
#4115 Combination of FTY720 and tamoxifen inhibits drug-resistant
ovarian cancer cell proliferation.KellyMarie Kreitzburg,1 CharlesN. Landen,2
Tracy Gamblin,1 Rebecca Arend,1 Ronald Alvarez,3 Karina Yoon1. 1Univ. of
Alabama at Birmingham, Birmingham, AL; 2University of Virginia School of
Medicine, Charlottesville, VA; 3Vanderbilt University Medical Center, Nashville,
TN.
Despite satisfactory initial responses to frontline therapies that combine sur-
gical debulking with platinum based chemotherapy, virtually all women with
advanced ovarian cancer relapse with drug resistant disease. There is a critical
need to identify alternative, effective therapies. Previously, we used patient de-
rived xenograft (PDX) models of ovarian cancer in mice to identify the sphin-
gosine1 phosphate (S1P) pathway as one of the pathways most affected by two
agents frequently used to treat ovarian cancer, carboplatin and paclitaxel. The
S1P pathway contributes tomultiple biological processes recognized as essential
for tumor development, and aberrations in sphingolipid metabolism have been
directly correlated with advanced disease and with resistance to chemotherapy
and radiation. Further, recent studies indicate that tamoxifen may counteract
drug resistance mechanisms through modulation of sphingolipid metabolism,
specifıcally through inhibition of the ceramide converting enyzmes acid cerami-
dase and glucosylceramide synthase. Therefore, we evaluated the effıcacy of
modulating S1P metabolism using the sphingosine analog FTY720 and tamox-
ifen as an approach to inhibit the proliferation of drug-resistant ovarian tumor
cells. We used alamarBlue cell proliferation assays to compare the anti-prolifer-
ative effect of FTY720 and tamoxifen with the effect of each drug as a single
agent. FTY720  tamoxifen synergistically decreased the cell viability of 3/3
ovarian cancer cell lines: estrogen receptor alpha (ER) positive SKOV3.TR
(taxane resistant), ER negative A280.cp20 (platinum resistant) and
HeyA8.MDR (taxane-platinum resistant). The combination also increased lev-
els of apoptosis as reflected by Annexin V staining and cleaved caspase 3 levels.
Further, administration of 5mg/kg i.p. FTY720 20mg/kg p.o. tamoxifen daily
for 21 days to PDX-bearing mice demonstrated that FTY720 tamoxifen sup-
pressed tumor growth by60% compared to vehicle controls. Notably, immu-
nohistochemical staining of tumors harvested from treated mice showed that
the combination decreased expression of the proliferation marker Ki-67 and
increased expression of apoptosis indicators ceramide and cleaved caspase 3 to a
greater degree than in tumors exposed to either drug alone. We conclude that
FTY720 tamoxifen merit further investigation as potentially effective agents
for the treatment of drug-resistant ovarian cancer.
#4116 Acquired lapatinib resistant inducesEMT-phenotype inbreast can-
cer cells via Src and RUNX3. So Hyeon Kim,1 AhrumMin,1 Seongyeong Kim,1
Dong Hyeon Ha,1 Hyemin Jang,1 Yu Jin Kim,1 Kyung-Hun Lee,2 Tae-Yong
Kim,2 Seock-Ah Im2. 1Cancer Research Institute, Seoul National University Col-
lege of Medicine, Seoul, Republic of Korea; 2Seoul National University Hospital,
Seoul, Republic of Korea.
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Background: Lapatinib is an effective EGFR and HER2 targeting small mo-
lecular tyrosine kinase inhibitor which is widely used for HER2 positive breast
cancer patients. However, patients eventually acquire resistance, limiting its
long-term use. Overexpression of heregulin, a HER3 ligand, acquired stemness
were mechanism that confers resistance to the anti-HER2 lapatinib. However,
still, unknown mechanisms of developing lapatinib resistant remain as a ques-
tion to solve. Thus, we tried to fınd out there is a novelmechanismwhich related
to lapatinib resistant, and any specifıed molecules were involved in this process.
Methods: Acquired resistant SK-BR-3 cells were established by chronic expo-
sure to lapatinib or trastuzumab. Lapatinib or trastuzumab sensitivity were con-
fırmed by MTT assay. Western blotting was used to determine signal transduc-
tion molecule changes. Wound healing assay and Boyden chamber assay were
conducted for verifying invasive ability. Whole exome sequencing (WES) and
siRNA knock-down system were used for further analysis. Results: Lapatinib
resistant (LR) cell lines showed down-regulation of p-HER2, p-Akt, and p-Erk.
The activity of Src family kinase was increased in LR cells. Vimentin, famous
EMTmarker, is also increased in LR cells. Migration and invasion were signifı-
cantly increased in LR cells. Correlated with a missense mutation of RUNX3,
which identifıed byWES, expression ofRUNX3was decreased in LR cells.More-
over, siRNA knock-down parental cells showed more resistance to lapatinib.
Conclusion: The increase of Src activation, cell migration, and invasion was
observed in LR cells. RUNX3, which identifıed by WES, affected to lapatinib
sensitivity in SK-BR-3 cells. Therefore, RUNX3 might be a specifıed molecule,
which partially contributes resistance to lapatinib.
#4117 Mechanisms of acquired resistance to c-Src kinase inhibitor in tri-
ple negative breast cancer. Rabia A. Gilani, Eric J. Lachacz, Sameer Phadke, Li
Wei Bao, Xu Cheng, Evelyn M. Jiagge, Matthew B. Soellner, Sofıa D. Merajver.
Univ. of Michigan, Ann Arbor, MI.
Triple negative breast cancers (TNBCs) are especially lethal due to their high
metastatic potential and propensity to recur. TNBCs comprise the only subset of
breast cancer for which there are no FDA-approved targeted therapies. We have
developedamechanisticallynoveldual c-Src/p38 inhibitor,UM-164, thathaspotent
in vivo anti-TNBC activity. However, single-agent targeted therapies are prone to
resistance and rational drug combinations can overcome or prevent resistance.We
developed TNBC cells lines that are resistant to UM-164. Signifıcant morphology
andcell signalingchangesoccurred in thedrug-resistant cell lines.Most crucial is the
observation that in drug-resistant cell lines the activation of c-Src and/or p38 does
not return in thepresence ofUM-164, suggesting that resistance is not occurring via
constitutive activation enabling mutations of c-Src and/or p38 kinases. However,
compared to their drug-sensitive counterparts, theUM-164-resistant cells have sig-
nifıcantly hyperactivated MEK1/2 and ERK1/2 signaling when treated with UM-
164. Thus, we tested combinations of UM-164  MEK1/2 inhibitors in several
TNBC cell lines and patient derived xenografts. We found that trametinib (Me-
kinist®, an FDA-approved inhibitor of MEK1/2) is synergistic (Chou-Talalay CI at
ED90 0.4, CI 1 denotes synergy) with UM-164 to inhibit the growth of UM-
164-resistantMDA-MB-231 and SUM-149 cell lines. These results support our hy-
pothesis that activation ofMEK/ERK signaling can act as an escapemechanism that
leads to resistance to UM-164. Future research into rational combinations of tar-
geted therapies delivered in data driven schedules may hold the key to improving
survival in TNBC.
#4118 The EMT transcription factor TWIST1 mediates resistance to
EGFR inhibitors in EGFR-mutant non-small cell lung cancer. Zachary A.
Yochum,1HailunWang,2 JessicaA. Cades,2 Susheel Khetarpal,1 EricH.Huang,1
Phouc T. Tran,2 Timothy F. Burns1. 1University of Pittsburgh School ofMedicine,
Pittsburgh, PA; 2Johns Hopkins University School of Medicine, Baltimore, MD.
Recent advances in the treatment of non-small cell lung cancer (NSCLC) stem
from the paradigm shift of classifying patients into subtypes based upon the pres-
ence of distinct molecular drivers. Subsets of patients, such as those with EGFR
mutations and ALK translocations, have dramatic responses in their tumors to ty-
rosine kinase inhibitors (TKIs) that specifıcally inhibit these oncogenic drivers.
While many patients initially response to TKIs, therapeutic resistance is inevitable.
For EGFR-mutant NSCLC, there are multiple described mechanisms of resistance
to EGFRTKIs, including epithelial-mesenchymal transition (EMT). Previous stud-
ies have implicated the AXL kinase and ZEB1, an EMT transcription factor (EMT-
TF), in EMT-mediated EGFR TKI resistance. We have previously demonstrated
that theEMT-TF,TWIST1, is required foroncogene-drivenNSCLCtumorigenesis,
including those tumorswithEGFRmutations. In this study,we investigated the role
ofTWIST1 inEMT-mediated resistance toEGFRTKIs.Wehavedemonstrated that
genetic or pharmacologic inhibition of TWIST1 resulted in growth inhibition in a
panel of EGFR-mutant NSCLC cell lines and apoptosis in a subset of these lines.
Interestingly, TWIST1 overexpression in EGFR-mutant NSCLC cell lines led to
EGFR TKI resistance. Conversely, knockdown of TWIST1 in an erlotinib resistant
EGFR-mutant NSCLC cell line restored erlotinib sensitivity. We found that
TWIST1mediates resistance to EGFR TKIs through suppression of apoptosis pos-
sibly through decreasing the expression of the pro-apoptotic Bcl-2 member,
BCL2L11 (BIM). We observed that TWIST1 knockdown increased BIM levels,
while TWIST1 overexpression decreased BIM expression. Furthermore, TWIST1-
mediated resistancewas overcome by treatmentwith the BCL-2/BCL-XL inhibitor,
ABT-737. Knockdown of BIM recapitulated the resistance seen following TWIST1
overexpression, suggesting that TWIST1 suppression of BIM is a mechanism
through which TWIST1 leads to EGFR TKI resistance. To explore the role of
TWIST1 in modulating EGFR inhibitor sensitivity in vivo, we used an inducible
EGFR-mutant transgenic mouse model, CCSP-rtTA/tetO-EGFRL858R (CE), which
expresses EGFRL858R in the lung and a EGFR-mutant/Twist1 transgenic model,
CCSP-rtTA/tetO-EGFRL858R/ Twist1- tetO7-luc (CET), which expresses both
Twist1 and EGFRL858R in the lung. CET mice had a signifıcantly increased tumor
burden, decreased apoptosis and a decreased overall survival compared to CEmice
following erlotinib treatment. In summary, we found that TWIST1 overexpression
leads toEGFRTKI resistanceby suppressingEGFRTKI-inducedapoptosis through
suppressing BIM expression. Future studies aim to establish the mechanisms of
TWIST1 suppression of BIM expression and determine if our TWIST1 inhibitor,
harmine, is effective in overcoming EMT-mediated resistance.
#4119 The development of EGFR resistant mutation, T790M, in lung ad-
enocarcinoma is acquired through a specifıc cytosine deamination mecha-
nism. Khaled Hassan,1 Najwa El Kadi,1 April Davis,1 Gregory Kalemkerian,1
LuoWang,1 Hasan Korkaya2. 1University of Michigan, Ann Arbor, MI; 2Georgia
Cancer Center, Augusta, GA.
EGFR resistant mutation, T790M, in lung adenocarcinoma is acquired
through a specifıc cytosine deamination mechanism. Background: Epidermal
growth factor receptor (EGFR) activation mutations occur in 15% of lung ade-
nocarcinomas. This leads to constitutive activation of EGFR, which triggers
multiple downstream survival and proliferation pathways. Currently, EGFR ty-
rosine kinase inhibitors (TKIs) are fırst line therapy for stage IV non-small cell
lung cancer (NSCLC) patients with EGFR mutations. Despite initial signifıcant
response to TKIs, most tumors develop resistance. The main mechanism of
resistance detected in 50-60% of cases is a cytosine to thymine (CT) single
nucleotide transition mutation at position 2369. This causes a threonine to me-
thionine amino acid change at position 790 (i.e. T790M). Our data suggests that
the CT mutation is an acquired event secondary to cytosine deamination by
Activation Induced Cytosine Deamination enzyme (AICDA). Results: Single
cell clones of lung adenocarcinoma cell line, PC9, were treated with EGFR TKI.
At baseline, these clones have EGFR exon 19 deletion but no evidence of T790M
mutation by digital droplet PCR (ddPCR).However, after treatmentwith a serial
increasing dose of EGFRTKI, T790Mmutationwas detected by ddPCR. Assess-
ing whether cytosine deamination enzymes were altered by this treatment, a
signifıcant increase in AICDA expression was seen. Furthermore, recombinant
AICDA protein could deaminate cytosine at position 2369 in vitro. In addition,
using mass spectrometry and methylation specifıc primers, we determined that
cytosine at position 2369 is in factmethylated. This further supports our hypoth-
esis since 5-methyl cytosine is deaminated into thymine directly. Since in ger-
minal center B-lymphocytes, AICDA is activated through a non-canonical
NFkB mechanism, we assessed NFkB pathway in PC9 cell line. RelB and p52
expression were signifıcantly increased after TKI treatment. In addition direct
interaction between RelB and AICDA promoter was confırmed by ChIP Assay.
These fındingswere also seen in amouse PC9 xenograftmodel.Daily oral gavage
of EGFR TKI caused signifıcant increase in the expression of RelB as well as
AICDA. Adding NFkB inhibitor twice weekly inhibited the expression of RelB
and AICDA. Finally, knocking downAICDA by shRNA prevented the develop-
ment of T790Mmutation in PC9 cell lines after TKI exposure. Conclusion: Our
data suggest that the T790M mutation could be actively acquired after TKI
treatment through a cytosine deamination process by AICDA. This would have
signifıcant implications for treatment with targeted therapy. In fact, Imatinib
resistance in CML and GIST tumors have a similar CT single nucleotide tran-
sition mutation.
#4120 Acquisition of chemoresistance to mTORC1 inhibition due to ac-
tivation of the GSK-3 /4EBP1 pathway might predict poor prognosis of
mRCCpatients.Hiromi Ito,1 Sei Naito,1 Osamu Ichiyanagi,1 Hidenori Kanno,1
Yuta Kurota,1 Atushi Yamagishi,1 Vladimir Bilim,2 Yoshihiko Tomita,2 To-
moyuki Kato,1 Akira Nagaoka,1 Norihiko Tsuchiya1. 1Yamagata University,
Yamagata, Japan; 2Niigata graduate school of medical and dental science, Nii-
gata, Japan.
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Background: PI3K/Akt/mTORC1 signaling pathway is aberrantly acti-
vated in renal cell carcinoma (RCC). We previously demonstrated that gly-
cogen synthase kinase-3 (GSK-3) positively regulated RCC proliferation.
Herein, we aimed to investigate how the mTORC1 downstream substrate
4EBP1 is directly regulated by GSK-3 leading to acquisition of clinical
chemoresistance to mTORC1 inhibitor (mTORi). Methods: The expression
and phosphorylation of molecules in the subcellular pathways were exam-
ined by immunoblotting in surgically resected RCC tissues and human RCC
cell lines including ACHN. Rapamycin-resistant ACHN cells (ACHN/RR)
were generated by chronic exposure to an mTORi, rapamycin. Cell viability
was investigated by MTS assay. The direct role of GSK-3 in regulating
4EBP1 was evaluated by an in vitro kinase assay. Pharmacological inhibition
of GSK-3, PI3K/Akt/mTORC1 pathway, and mTORC1 was achieved by
treatment with AR-A014418, LY294002, and rapamycin, respectively. The
effects of drug combination were determined using CompuSyn software.
GSK-3 expression was evaluated in pathological RCC tissues obtained by
nephrectomy from patients with metastatic RCC (mRCC), nine of whom
were treated with mTORi as systemic therapies. GSK-3 expression was
immunohistochemically graded as high and low expression using a semi-
quantitative method based on positive staining intensity. Survival intervals
were evaluated using the Kaplan-Meier method and log-rank test. Signifı-
cance level was set as 0.05 in statistical analysis using a freeware R. Results:
Inhibition of PI3K/Akt/mTORC1 pathway and mTORi treatment suffı-
ciently decreased pS6RP, but only moderately decreased p4EBP1. In contrast
to the effect of rapamycin, AR- A014418 remarkably inhibited cell prolifer-
ation, and rapidly suppressed p4EBP1 in ACHN and ACHN/RR. In vitro
kinase assays showed that recombinant GSK-3 phosphorylated recombi-
nant 4EBP1 at Thr37, Thr46, Thr70 and Ser65, and these phosphorylations
were blocked by GSK-3 inhibitor. A combination of AR- A014418 and rapa-
mycin produced an additive effect at lower concentrations, and were antag-
onistic at higher concentrations. Immunoblotting demonstrated that 4EBP1
and p4EBP1 expression in RCC tissues was positively correlated with
GSK-3 expression. Overall survival was signifıcantly short in patients with
high GSK-3 expression, compared with those having low expression (n 
25 and 14, respectively, p  0.04). In addition, high GSK-3 expression in
tumors tended to shorten progression-free intervals in mRCC patients
treated with mTORi. Conclusions: High GSK-3 expression and direct
GSK-3/4EBP1 pathway can be a key mechanism for RCC acquiring clinical
chemoresistance to mTORCi. Activation of the direct pathway might be
predictive of poor prognosis of mRCC patients.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: New
Targets and New Drugs
#4121 Androgen receptor as a potential target in non-small cell lung can-
cer. Sean Brennan, Albert R. Wang, Hope Beyer, Dylan Wiese, Darya Buehler,
Anwaar Saeed,AndrewM.Baschnagel, Gopal Iyer.Univ. ofWisconsin-Madison,
Madison, WI.
The cancer genome atlas (TCGA) has identifıed androgen receptor (AR) to be
mutated, deleted and amplifıed across human lung squamous cell carcinoma
and adenocarcinoma. Expression of AR is critical for early lung development.
However, the intriguing expression of AR in non-small cell lung cancer
(NSCLC) opens up an alternative treatment paradigm in the event of onset of
clinical resistance to lung cancer drugs. To investigate this potential, a) 10
NSCLC cell lines and 3 control prostate cancer cell lines were stimulated with
synthetic AR agonist, R1881 at 24, 48 and 72 hours. 0.5-4-fold RNA and protein
expression was found across these lung cancer cell lines when compared to
unstimulated cells. b) droplet digital PCR revealed varying copies of AR DNA
when benchmarked to prostate AR. c) cell proliferation assays of these cell lines
with enzalutamide (MVD3100) treatment resulted in 50-65% cell survival at
concentrations ranging from 10 - 25 M. d) Immunohistochemical staining of
AR in a NSCLC human tissue microarray (TMA) revealed 10 out of 88 patients
(11%) to have AR positive staining in their tumor. This included 6 adenocarci-
nomas and 2 squamous cell carcinomas. 8 patients had focal while 2 had diffuse
staining. Validation of the TMA performed with whole mount slides confırmed
diffuse staining in these 11 samples. Taken together, these fındings suggest AR is
a potential therapeutic target in NSCLC and further work is underway to test
these observations in drug resistant lung cancer cell lines and pre-clinical mouse
models.
#4122 Tumor-specifıc PI3K inhibition via nanoparticle targeted delivery
in head and neck squamous cell carcinoma. Aviram Mizrachi, Yosi Shamay,
Janki Shah, Samuel I. Brook, Joanne Soong, Vinagolu K. Rajasekhar, John L.
Humm, Simon N. Powell, José Baselga, Daniel A. Heller, Adriana Haimovitz-
Friedman, Maurizio Scaltriti.Mem. Sloan Kettering Cancer Ctr., New York, NY.
Purpose: PI3K-pathway activation is the second most common genetic ab-
normality occurring in head and neck squamous cell carcinoma (HNSCC).Mu-
tation or amplifıcation of PIK3CA, the gene coding for the p110 subunit of
PI3K, occur in 34%-56% of HNSCC and there is evidence that targeting PI3K
in these tumors can be radiosensitizing. Small molecule kinase inhibitors of
PI3K are showing promising activity. However, the use of this molecule is
limited by serious side effects such as hyperglycemia, diarrhea and rush. In this
studywe aimed to apply novel nanotechnology for targeted drug delivery via the
cell adhesion molecule P-selectin, which was previously shown to be overex-
pressed in tumor microvasculature. Furthermore, P-selectin is up regulated fol-
lowing radiation therapy (RT), which could enhance drug delivery using tar-
geted nanoparticles. Experimental design: We explored the effıcacy and
specifıcity of targeted delivery of BYL719, a potent alpha-specifıc PI3K inhibitor,
using nanoparticles that selectively target P-selectin present in the tumormicro-
vasculature inPIK3CA-mutatedHNSCC.We compared the antitumor effects of
nanoparticle delivery versus standard oral gavage with free drug in PIK3CA
mutated HNSCC cell line- and patient-derived xenografts (PDXs). In addition,
we compared blood glucose and insulin levels between standardBYL719 admin-
istration and nanoparticle drug delivery at different time points after treatment.
Furthermore, we sought to evaluate the radiosensitizing properties of BYL719
when combined with fractionated RT of 5X4Gy. Results: P-selectin targeted
delivery of 50mg/kg/week BYL719 resulted in a signifıcant tumor growth delay,
which was comparable to the standard drug administration of 350 mg/kg/week
(50mg/kg/daily).While blood glucose and insulin levels were spiking after stan-
dard oral gavage of BYL719, these parameters were virtually unchanged upon
nanoparticle administration of the drug. The radiosensitizing abilities of low-
dose nanoparticle-linked BYL719 were comparable to the drug concentrations
used in standard daily BYL719 administration.When given concomitantly with
fractionated RT, both methods showed robust enhancement of radiotherapy
response in all the models tested resulting in durable control of tumor growth.
Conclusions: P-selectin targeted delivery of a PI3K inhibitor resulted in inhi-
bition of the PI3K/Akt/mTOR pathway without affecting glucose or insulin
levels. The magnitude of pathway inhibition was suffıcient to radiosensitize
several HNSCC animalmodels. This novel targeting strategy could be translated
to the clinic to treat patients with PIK3CA activated and radioresistant HNSCC
tumors sparing most of the systemic adverse effects of PI3K inhibition.
#4123 CRISPR-Cas9 and siRNA screening in primary human immune
cells.CristinaGhirelli, Thibault Laurent, Simon Scrace, KimHoenderdos, Chris
Lowe, Nicola McCarthy, Jonathan Moore. Horizon Discovery, Cambridge,
United Kingdom.
A major focus in immuno-oncology research is fınding new immuno-oncol-
ogy targets, including those that alter the character and frequency of T-cell-
mediated anti-tumour responses. Screens using CRISPR (Clustered Regularly
Interspaced Short Palindromic Repeats)-Cas9-mediated genome editing seem
well placed to identify new targets. However, although CRISPR-Cas9 gene edit-
ing works well in primary T cells using electroporation, use of a lentivirus one
vector system has proved challenging in primary T cells compared with cancer
cell lines. We have used several different approaches to identify the most useful
method for transduction of primary human T cells with CRISPR components.
Electroporation of sgRNAs and mRNA encoding Cas9 into proliferating T cells
effıciently generate T cells with specifıc gene knock-outs or knock-ins, with
targeting rates of around 37% for gene knockout. Thus, primary T cells are
amenable to CRISPR-Cas9 gene editing, and the capacity to rapidly modify loci
enables generation of primary T cell models suitable for comprehending the
function of modifıed receptor-ligand pairs involved in an immune checkpoint
response. Our pooled sgRNA-Cas9 screens in cancer cell lines have used our
in-house sgRNA libraries, which include a modifıed tracrRNA component im-
proving Cas9 affınity and subsequently the performance of a typical sgRNA for
promoting gene editing. However, use of the same approach in primary T cells
has not resulted in effıcient transduction of the library. Specifıcally, isolated
CD3T cells stimulated in vitro with anti-CD3 and anti-CD28 antibodies in the
presence of recombinant IL-2 resulted in no expression or low level expression
of GFP after cells were transduced with a one vector CRISPR-Cas9 sgRNA li-
brary. Our experiments indicate, in line with published data, that T cells can be
transduced effectively with lentivirus, thus we are examining the use of a two
vector CRISPR-Cas9 system and the use of CRISPRi to idealise CRISPR screen-
ing in primary T cells. We are also carrying out target identifıcation and valida-
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tion in myeloid derived suppressor cells (MDSCs). We are using an siRNA
approach in these cells, which are generated by PBMC co-culture with cancer
cell lines for 7 days, or by culture in the presence of recombinant GM-CSF and
IL-6 for 7 days. Our initial data indicate that these MDSCs can effectively sup-
press autologous, as well as allogeneic, CD8 T cell proliferation mediated by
anti-CD3 and anti-CD28 stimulation and that siRNA knockdown is effective in
MDSCs.We will use our druggable genome plus arrayed siRNA library to iden-
tify targets that when knocked down inhibit the capacity of MDSCs to suppress
T cell proliferation. We anticipate that these data will be useful in identifying
new targets that are involved in regulating an immune response to tumour
development and progression.
#4124 POPDC1 inhibits breast cancer cell migration and proliferation,
and is regulated by EGFR (ErbB1) and cAMP. Johanna N. Amunjela, Steven J.
Tucker. Univ. of Aberdeen, Aberdeen, United Kingdom.
Despite progress in the development of new treatments, breast cancer re-
mains the second leading cause of global cancer morbidity and mortality (1).
Identifıcation and validation of effective therapeutic targets is thus essential for
the development of better breast cancer treatments and improved prognoses.
This project seeks to develop POPDC proteins as potential therapeutic targets
for inhibiting breast cancer migration and proliferation. POPDC1 (also known
as blood vessel epicardial substance or BVES), is a cAMP-binding transmem-
brane protein encoded by the POPDC1 gene. Loss or suppression of POPDC1
has been correlated with enhanced aggressive cancer cell behaviour (2-6). Sup-
pression of POPDC1 promotes cell migration and invasion in hepatocellular
carcinoma and tumourigenesis in colorectal cancer (2,4,5,7). Furthermore, we
have previously shown that loss of POPDC1 promotes cell proliferation and
migration in breast cancer and glioblastoma cells (3,8). Using a cAMP-agarose
pulldown assay, we confırmed that POPDC1 interact with, and is upregulated by
cAMP in luminal A (MCF7) and triple-negative (MDA231) breast cancer cells.
Furthermore, immunocytochemistry and Western blotting has shown that
POPDC1 expression is abrogated in MCF7 and MDA231 breast cancer cells
compared to normal breast cells (HMepC). To confırm that POPDC1negatively
regulates migration and proliferation in breast cancer cells, we conducted
knock-in experiments where overexpression of POPDC1 signifıcantly inhibited
cell migration and proliferation in MCF7 andMDA231 cells. Interestingly, epi-
dermal growth factor receptor (EGFR/ErbB1) signalling negatively regulates
POPDC1 expression in MCF7 and MDA231 cells and reduces the capacity of
POPDC1 to inhibit cell migration. Epidermal growth factor reversed POPDC1-
mediated inhibition of cell migration, an effect blocked by the AG 1478 (an
EGFR inhibitor), suggesting EGFR-dependentmodulation of POPDC1 activity.
Furthermore, we have established for the fırst time using human breast tissue
sections that Her2- status correlates with low POPDC1 expression while Her2
status correlates with high POPDC1 expression. This suggests further interac-
tion between EGF and POPDC1 and that any links between these molecules
diverges at the level of the different EGFRs. Taken together, this strong dataset
shows that POPDC1 plays amajor role in breast cancer tumourigenesis that is at
least in part, modulated by EGFR and cAMP signalling pathways. Indeed, these
seem to demonstrate differential control of POPDC1 expression. This interplay
and the fact that POPDC1 downregulation may be a downstream molecular
target of the EGF cascade suggest that POPDC1 and its stabilisation may be a
therapeutic strategy in the future of breast cancer.
#4125 Comparison between knockdown of Pim-1, Pim-2 and Pim-3 iden-
tifıes Pim-2 as the most relevant Pim oncogene in hepatocellular carcinoma.
Ulrike Weirauch, Pia Kürz, Achim M. Aigner. Univ. of Leipzig, Leipzig, Ger-
many.
Introduction: Pim-Kinases (Pim - proviral integration site for moloney mu-
rine leukemia virus; Pim-1, -2, -3) are a family of serine/threonine kinases with
oncogenic potential. They are overexpressed in various solid tumors including
hepatocellular carcinoma (HCC) and have been found responsible for malig-
nant transformation, induction of cell proliferation and inhibition of apoptosis.
While the main focus has been on Pim-1 so far, the other Pim kinases, esp.
Pim-2, have not been explored in detail. Objectives: The aim of this study was to
compare the tumor-inhibitory effects of the single and combined of Pim family
members in HCC, for evaluating their individual contributions and potential as
therapeutic target. To this end, RNA interference (RNAi) for specifıc gene
knockdown was employed. Materials and methods: Different HCC cell lines
were transfected with small interfering RNAs (siRNAs) for inducing RNAi and
transient target gene downregulation. Various cellular and molecular effects
were analysed. Results: Transient siRNA transfection led to robust and specifıc
knockdown of the selected Pim kinase(s) on mRNA and protein level. This
resulted in anti-proliferative and pro-apoptotic effects. Most profound conse-
quences on cell growth, cell cycle and apoptosis were observed upon Pim-2
knockdown, with little additive effects upon combined inhibition. These cellular
changes were paralleled by alterations of various genes involved in cell cycle, cell
survival, EMT and other important cellular processes. Conclusion: In hepato-
cellular carcinoma, Pim-2 represents a functionally relevant oncogene.Wedem-
onstrate its higher potential as compared to the other Pim family members, and
analyze various consequences of its inhibition or knockdown on the cellular and
molecular level. Taken together, this identifıes Pim-2 as a potentially relevant
target gene for therapeutic intervention.
#4126 Validation of hypoglycosylated MUC1-CIN85 protein-protein in-
teraction as a new therapeutic target for prevention of cancer invasion and
metastasis. Sandra Cascio,1 Jacque Faylo,2 Raahul Sriram,3 Anda Vlad,4 Carlos
Camacho,2 Olivera J. Finn1. 1Univ. of Pittsburgh School of Medicine, Pittsburgh,
PA; 2University of Pittsburgh, Pittsburgh, PA; 3CarnegieMellon University, Pitts-
burgh, PA; 4Magee-Womens Research Institute,, Pittsburgh, PA.
Overexpression and abnormal glycosylation of the epithelial glycoprotein
MUC1 in cancer cells promotes metastasis. We have identifıed CIN85 (Cbl-
interacting protein 85 KDa), as a binding partner of MUC1 in tumors. MUC1/
CIN85 complex is found in early as well as advanced clinical stages of breast,
ovarian, colon and prostate cancers among others. Co-localization of MUC1
and CIN85 on invadopodia structures enhances invasion and migration of can-
cer cells. Our hypothesis is that preventing the formation or dissociating existing
CIN85/MUC1 complexes may result in a less aggressive tumor by decreasing
local invasion and preventing distant metastases. To test this hypothesis, we
have already identifıed and tested two novel compounds that signifıcantly re-
duce the association between hypoglycosylated form of MUC1 and CIN85, and
at 10M concentration drastically reduce the migratory activity of mouse and
human epithelial cancer cells. Our preliminary data also suggest that dissocia-
tion of theMUC1 andCIN85 complex decreases expression of hypoglycosylated
MUC1, restoring the expression of its normal, fully glycosylated form. We are
currently investigating the MUC1/CIN85-dependent signaling pathway with a
particular focus on the ability of CIN85 to modulate MUC1 glycosylation by
controlling its plasma membrane-Golgi traffıcking. Ongoing experiments in an
in vivo mouse model will confırm the ability of these drug compounds to de-
crease tumor growth and metastasis and validate CIN85/MUC1 complex as a
viable therapeutic target and support development and testing of more potent
antagonists.
#4127 Targeting MDM4 in hepatocellular carcinoma to reactivate p53
signaling. Sarah E.Woodfıeld, Yan Shi, Roma H. Patel, Zhenghu Chen, Aryana
M. Ibarra, Sanjeev A. Vasudevan. Baylor College of Medicine, Houston, TX.
Objective: New therapeutic strategies are desperately needed for hepatocellu-
lar carcinoma (HCC), the fourth most common cause of cancer-related deaths
worldwide.Most patientswithHCC lackmutations in the p53 tumor suppressor
gene. Therefore, we hypothesized that targeting MDM4 or MDM2 to reactivate
p53 signaling could be effective in this disease. Methods: HCC cell lines (SK-
Hep1, Huh-7, Hep3B) were profıled for gene and protein expression of MDM4
with qPCR and immunoblotting assays, respectively. The effects of MDM4 in-
hibitor NSC207895 on the same cell lines were analyzed with MTT assays for
cytotoxicity and qPCR experiments to look at changes in expression of p53
downstream targets, in comparison to the effects ofMDM2 inhibitor Nutlin-3a.
Effects of MDM4 on targets other than p53, including family members p63 and
p73, were examined in cells with mutant or null p53 for changes in expression
with qPCR experiments. Results: Three HCC cell lines showed expression of
MDM4. Inhibition of MDM4 showed cytotoxic (high dose, 0.16-15.0 M) and
anti-proliferative (low dose, 0.05-0.3M) effects in all three cell lines, including
p53 mutant Huh-7 and p53 null Hep3B cells. The same cell lines were strongly
resistant to Nutlin-3a. Gene expression analyses were conducted with cells ex-
posed toNSC207895 to examine effects ofMDM4 inhibition on p53 targets Bax,
Puma, and p21. In SK-Hep1 cells, NSC207895 treatment led to 2.5-fold overex-
pression of Bax, 27.4-fold of Puma, and 23.1-fold of p21. Huh-7 showed 11.8-
fold upregulation of Puma and 12.4-fold of p21, and Hep3B exhibited a very
strong 58.4-fold increase in p21 gene expression with the same treatment. Inter-
estingly, Hep3B showed 5.9-fold overexpression of p63 and 1.99-fold of p73
gene expression with NSC207895 exposure, suggesting novel interactions be-
tween MDM4 and p63/p73 in the absence of p53. Conclusions: Inhibition of
MDM4 shows effıcacy in in vitro models of HCC through upregulation of p53,
p63, and p73 to activate p53 tumor suppressive signaling. Thus, targeting
MDM4may be a viable option for all HCC patients, nomatter the p53mutation
status.
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#4128 Mechanismof action ofG-quadruplex forming oligonucleotide ho-
mologous to the telomere overhang inmelanoma.GaganChhabra,1 LukeWo-
jdyla,1 Ankita Sanjali,1 Mark Frakes,1 Marko Ivancich,1 Pooja Vinay,1 Zachary
Schrank,1 Benjamin E. Ramirez,2 Neelu Puri1. 1Univ. of Illinois at Chicago, Rock-
ford, IL; 2Univ. of Illinois at Chicago, Chicago, IL.
T-oligo, a guanine-rich oligonucleotide (GRO) homologous to the 3=-telo-
meric overhang of telomeres, elicits potent DNA-damage responses (DDRs) in
cancer cells. However, the detailedmolecular mechanism of action of T-oligo in
cancer cells is largely unknown. Recent studies suggest that GROs can form
G-quadruplexes (G4) which are stabilized by the hydrogen-bonding of guanine
residues. This study aims to examine the G4-forming capabilities of T-oligo in
vitro and investigates the molecular mechanism of single-stranded (SS) and
G4-T-oligo induced DDRs in melanoma cells (MM-AN). G4-formation by T-
oligo was confırmed using the SS-T-oligo and G4-T-oligo on a polyacrylamide
gel under non-denaturing conditions. NMR studies for T-oligo in KCl con-
fırmed that T-oligo forms G4 structures. Immunofluorescence studies con-
ducted with an anti-G-quadruplex antibody (BG4), a G4 detecting antibody,
showed 88.4% co-localization of T-oligo and BG4 in the nuclei of melanoma
cells confırming the ability of T-oligo to formG-quadruplexes insidemelanoma
cells. While G4-T-oligo was foundmore stable in nuclease degradation assay by
DNase I, it had a decreased anti-proliferative effects compared to SS-T-oligo.
However, G4-T-oligo had similar cellular uptake as SS-T-oligo. Further, two
shelterin complex proteins TRF2 and POT1 which are mainly found at the
telomere ends were found to be upregulated (2.0 fold) by T-oligo suggesting
TRF2 and POT1 mediated telomere overhang dissociation. We also found that
T-oligo can co-localize with telomere binding proteins TRF2 and POT1 by
88.4	4.5% (n12) and 84.5	8% (n10) respectively. Western blot analysis
results also showed upregulation of both p-JNK and total JNK by 4.0- and 2.0-
fold respectively. To further confırm the involvement of p-JNK in T-oligo me-
diated apoptosis we used a specifıc JNK inhibitor SP600125. Western blot anal-
ysis showed that T-oligo mediated upregulation of p-JNK was reversed in
presence of SP600125. Results from an MTT assay showed a 73.8% decrease in
cell viability after T-oligo treatment alone; however, cell viability was decreased
to 45.8%, and 25.3% when SP600125 was present at concentrations of 10 M,
and 12Mrespectively, in comparison to diluent. T-oligo also inhibitedmRNA
expression of hTERT; a catalytic subunit of telomerase by 50% .We further
investigated the effect of the JNK inhibitor SP600125 on hTERT expression and
found that treatmentwith SP600125 in presence of T-oligo partially reversed the
downregulation of hTERT. We found a 16% decrease in hTERT expression in
comparison to 50% reduction by T-oligo treatment alone. In conclusion, these
studies demonstrate that T-oligo can form G-quadruplexes and the anti-prolif-
erativemechanism of T-oligomay bemediated through POT1 and TRF2 as well
as via JNK-activation inducing hTERT-inhibition in melanoma cells.
#4129 Novel oncogenic BRAF fusions and impact on targeted therapies.
Sonia C. Dolfı, Ann Silk, Bhavna Paratala,Whitney Petrosky, Srilatha Simhadri,
Atul Kulkarni, Shridar Ganesan, KimM.Hirshfıeld. Rutgers Cancer Inst. of New
Jersey, New Brunswick, NJ.
BRAF mutations are driver events in a number of cancers including thyroid
cancer and melanoma. The most common, BRAF V600E, alters normal BRAF
protein activity in the mitogen-activated protein kinase (MAPK) pathway by
constitutively activating BRAF and inducing proliferative signaling and tumor
growth. Small molecule tyrosine kinase inhibitors targeting tumors with the
V600Emutation have been evaluated in clinical trials and are now approved for
melanoma. While BRAF missense mutations have been extensively character-
ized for oncogenic potential and actionability in genomically-guided therapy,
BRAF gene fusions have been underappreciated for not only their functional
role in cancer but also in differential drug response. More recently, data suggest
that alternative approaches may be needed for treatment of patients with BRAF
fusion-containing tumors. We have identifıed two novel BRAF fusions in tu-
mors from patients with papillary thyroid cancer and melanoma. Both fusions
result in an in-frame fusion of a novel gene partner at the 5’ end of the fusion, an
intact BRAF kinase domain at the 3= end, and loss of the BRAF auto-inhibitory
domain. We hypothesized that these novel BRAF fusions act as oncogenic driv-
ers, and the mechanism of BRAF activation differs from that caused by V600E
mutations and may be fusion partner-specifıc. These fusions have been engi-
neered in the laboratory and tested for tumorigenic potential and functional
activity. BRAF fusion expression in non-transformed cells induces colony for-
mation similar to the V600E mutation indicating tumorigenic potential. These
BRAF fusions also constitutively activate the MAPK pathway in the absence of
stimulation as demonstrated by phosphorylated ERK andMEK proteins. Addi-
tionally, BRAF fusion-expressing cells form tumors in vivo similarly to the
BRAF V600E-expressing cells. These tumors are highly proliferative as demon-
strated by strong Ki67 immunohistochemical staining and displayMAPK path-
way activation as evidenced by phosphorylated ERK. BRAF fusion-expressing
cells have differential sensitivity toMAPK pathway inhibitors compared to cells
with the V600E mutation as measured by reduced MAPK signaling. Inhibition
of the MAPK pathway is relevant in targeting BRAF fusion-containing cells but
may not follow the same paradigm as point mutations. Collectively, our data
suggest that BRAF fusions are functional and represent novel therapeutic tar-
gets, but may need an alternative approach as compared to tumors with BRAF
missense mutations.
#4130 Characterization of URST1 as a prognostic biomarker and thera-
peutic target for lung cancer. Atsushi Takano,1 Yohei Miyagi,2 Yataro Daigo3.
1Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 2Kanagawa
Cancer Center Research Institute, Yokohama, Japan; 3ShigaUniversity ofMedical
Science, Otsu, Japan.
Lung cancer is the most frequent cause of cancer deaths worldwide and its
overall prognosis remains poor. Therefore, next generation of biomarkers and
therapeutic strategies for lung cancer are eagerly awaited.We selected genes that
were overexpressed in the majority of lung cancer using our gene expression
profıle database. During this process, we identifıed URST1 (Up-regulated in
solid tumor 1) as a candidate. Immunohistochemical staining showed that
URST1 expression was observed in the majority of non-small cell lung cancer
(NSCLC) patients (P 0.0013 by log rank test). Multivariate analysis revealed
high level of URST1 expression was an independent prognostic factor for
NSCLC patients. Moreover, reduction of URST1 by siRNA or treatment with
URST1 inhibitor signifıcantly suppressed lung cancer cell growth probably
through cell cycle arrest at G2/M. Exposure of cancer cells to URST1 inhibitor
signifıcantly suppressed These data suggest that URST1 is a possible prognostic
biomarker and therapeutic target for lung cancer.
#4131 ERR: Validating a novel target for triple negative breast cancer.
Aileen I. Fernandez,1 Garrett Graham,1 Balázs Győrffy,2 Luciane Cavalli,1 Re-
becca B. Riggins1. 1GeorgetownUniversity,Washington, DC; 2MTATTK Lendü-
let Cancer Biomarker Research Group, Budapest, Hungary.
Triple negative breast cancer (TNBC) - defıned as estrogen receptor- (ER),
progesterone receptor- (PR), and human epidermal growth factor receptor 2-
(HER2) negative - is a highly aggressive form of breast cancer prevalent in
African-American (AA) women. Because ER- and HER2-targeted therapies are
ineffective in TNBC, current treatment strategies rely on cytotoxic chemother-
apy. There is a tremendous need for new approaches that can identify effective
therapies with less toxicity for this devastating form of breast cancer. Nuclear
receptors are highly druggable targets. Classical examples include ligand-regu-
lated receptors like ER, but orphan nuclear receptors are also emerging as targets
for cancer therapy. We recently published that increased mRNA expression of
estrogen-related receptor beta (ERR, gene symbol ESRRB) correlates with bet-
ter recurrence- and distant metastasis-free survival in women with TNBC, and
that a small molecule agonist ligand for ERR (DY131, DY) has growth inhibi-
tory and anti-mitotic activity in TNBC cell lines of multiple molecular subtypes.
The goal of our current work is to validate ERR as a novel therapeutic target for
TNBC in two distinct ways. First, we sought to determine whether ERR is
correlated with survival outcome specifıcally in African-American (AA)
women. Analysis of The Cancer Genome Atlas (TCGA) Breast Cancer RNAseq
data shows that low ERRmRNA expression is specifıcally associated with poor
overall survival in AA women with TNBC. This association is not observed in
AAwomenwith ER- orHER2-positive disease.We further fınd that while ERR
mRNA expression is decreased in tumor vs. normal breast tissue regardless of
race, this decrease is more pronounced in AA women. Ongoing studies in an
independent cohort of AA and white womenwill determine whether this is due,
in part, to copy number changes at the ERR locus (chromosome 14q24.3).
Second, we sought to determine whether ERR expression could predict re-
sponse to current treatment strategies commonly used in breast cancer, partic-
ularly TNBC.Usingmultiple combined datasets, we fınd that highERR expres-
sion is associated with improved recurrence-free survival (RFS) in women with
TNBC who received adjuvant or neoadjuvant therapy with anthracycline (e.g.
doxorubicin, Adriamycin). No association between ERR and RFS is observed
in patients treated with taxanes. Ongoing studies in TNBC cell lines seek to
determine if activating ERRwith its agonist ligand DY can enhance doxorubi-
cin-mediated growth inhibition and cell death.
#4132 Roles of the acetyltransferases CBP/p300 in breast cancer. Iqbal
Muhmud, Guimei Tian, Daiqing Liao.University of Florida College of Medicine,
Gainesville, FL.
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Intrinsic drug resistance renders certain breast cancer (BC) patients unre-
sponsive to standard-of-care therapies. For example, 50% of patients with
estrogen receptor-positive (ER) tumors do not respond to endocrine therapies
(ETs, e.g., tamoxifen). Acquired drug resistance is another cause for treatment
failure and deadly relapse. Therefore, new strategies that tackle both intrinsic
and acquired resistance are needed for improving clinical outcome for BC pa-
tients. ER-alpha, the defıning factor for ER tumors, is an estrogen-activated
transcription factor (TF) that drives tumor growth and progression. It critically
depends on the coactivators CBP/p300 for gene expression underpinning tumor
biology of ER subtypes that account for75%of all BC cases. Recent advances
revealed that another hormone receptor, the androgen receptor (AR), is ex-
pressed in the majority of ER BCs as well as in a subset of ER- BCs. Evidence
has shown that AR signaling is implicated in ET resistance. For the HER2-
enriched tumors, high levels of AR expression correlate with poor prognosis.
Similarly for ER-alpha, CBP/p300 act as key coactivators for AR-mediated gene
expression. Additionally, other oncogenic TFs (e.g., beta-catenin/TCF and
STAT3) also depend on CBP/p300 for gene activation. Importantly, these path-
ways are active in all BC subtypes, regardless of the hormone receptor status.
CBP/p300 overexpression and heightened acetyltransferase activity are detected
in clinical BC samples and correlate with disease progression. Thus, CBP/p300
represent attractive targets for developing novel therapies broadly applicable for
treating allmajor BC subtypes.We have discovered a novel class of highly potent
CBP/p300 inhibitors. Our previous studies indicated that this class of com-
pounds is highly effective to suppress tumor growth in vivo using a xenograft
mousemodel.We will present genomic features of CBP/p300 in different breast
cancer subtypes and experimental data underlying potential mechanisms by
which CBP/p300 regulate oncogenic phenotypes, as well as effects of pharma-
cologic inhibition of CBP/p300 on sensitivity of breast cancer cells to standard
anticancer therapeutics.
#4133 Amrubicin is effective for synovial sarcoma. Shinnosuke Take-
moto,1 Hiroshi Gyotoku,1 Hiroaki Senjuu,1 Takayuki Suyama,1 Noritaka
Honda,1 Kosuke Mizoguchi,2 Takaya Ikeda,1 Hiroyuki Yamaguchi,1 Katsumi
Nakatomi,1 Yoichi Nakamura,3 Minoru Fukuda,1 Hiroshi Mukae1. 1Nagasaki
University Hospital, Nagasaki City, Japan; 2Senju Hospital, Sasebo City, Japan;
3Tochigi Cancer Center, Utsunomiya City, Japan.
Background: Synovial sarcoma (SS) is representative sarcoma types, which is
account for 6%of sarcomas. Although the gold-standard of treatment is surgery,
SS is often diagnosed in an advanced clinical stage. Chemotherapy is the primary
treatment modality. Amrubicin (AMR), an anthracycline agent, is converted in
the body to amrubicinol (AMRol) by reduction of the 13-position ketone, which
has a higher antitumor activity than the parentmolecule. In this study, we eval-
uate the effectiveness in vitro and in vivo. Materials andMethods: Cell lines and
reagent. The SS cell lines, SW982, HSSYII and SS1. Cell viability assay. WST-1
mixture was used. Cell-cycle analysis. To evaluate the cell cycle, FITC BrdU Kit
Flow Kit was used. HSSY-II, SW982 were treated with AMRol for 4 hours and
analyzed by flow cytometry using BD FACSVerseTM. Animal experiments. Se-
vere Combined Immuno-Defıciency mice were used. SS cells were injected sub-
cutaneously or into right intrathoracic space. These mice were assigned ran-
domly to AMR group and normal saline group (NS). Micro-computed
tomography (CT). The R-mCT system was used to measure the diameter of
tumor in intrathoracic space. Statistical analysis: All of the results are expressed
as meanSEM. The Kaplan-Meier method was used to estimate survival. Treat-
ment groups were compared using a two-sided log-rank test. Results: Cell via-
bility assay. AMRwas highly metabolized into AMRol in tumor tissue and AM-
Rol was more toxic than AMR. AMRol was used to in vitro assay. AMRol was
equivalent to, or even more toxic than DXR in this experiments. Cell-cycle
analysis. After AMRol treatment, more cells were found in S-phase compared
with no treatment control. Subcutaneous SS model. AMR showed cytostatic
effect compared with normal saline (NS) in each of HSSYII and SW982. In-
trathoracic space SS model. SS-1 was established from primary pleural SS pa-
tient. In preliminary experiments, location of tumor was confırmed on CT.
Tumor growth was suppressed in AMR group compared with in NS group and
AMR showed cytostatic effect. In survival analysis, it was shown that AMR
group was tend to survive longer than NS group. Discussion: It was shown that
AMR is effective for SS in vitro and in vivo. Our results suggest an alternative
treatment of SS patients, including primary pleural SS. The effectiveness and
safety should be addressed in future studies.
#4134 Developmental pluripotency associated 4: A novel putative predic-
tor for prognosis of aggressive prolactin secreting tumors in the pituitary.
Shaima Jabbar,William Belden, OmkaramGangisetty, Dipak K. Sarkar. Rutgers
Univ., New Brunswick, NJ.
Prolactin-secreting pituitary tumors (prolactinomas) are the most common
pituitary tumors in humans. Majority of prolactinomas are adenomas and be-
nign and slow growing, but in some cases, they are locally aggressive and inva-
sive. In a rat animal model we found that fetal alcohol exposed female rats
develop aggressive prolactinomas following estrogen administration. Several
recent evidence suggest that human cancer is a stem cells disease because many
embryonic stem cell markers such as OCT4, SOX2, Nanog, and Klf4 are reex-
pressed in malignant tumor. The developmental pluripotency associated 4
(DPPA4) gene has an important role in self-renewal and pluripotency in embry-
onic stem cells. It is re-expressed in severalmalignant tumors and is identifıed as
a new pluripotency-related oncogene. We studied wither DPPA4 expresses and
function in aggressive prolactinomas induced by fetal alcohol exposures. Preg-
nant Fischer 344 rats were fed between gestational days 7 and 21 with a liquid
diet containing alcohol, pair-fed with isocaloric liquid diet, or fed ad libitum
with rat chow. At 60 days of age, female offspring rats were ovarictomized and
received a subcutaneous estradiol implant. These rats were sacrifıced at 3
months after the estradiol implants. Pituitary tumors were collected and pitu-
itary tumorspheres were prepared and maintained in cultures. Alcohol-fed pi-
tuitary tumorspheres, but not control-fed pituitary tumorspheres, expressed
DPPA4 and a panel of genes related to multipotency (OCT4, NANOG, KLF4,
and CD133) and showed increased invasiveness and marked growth in cultures
and in mice xenografts. The RNA sequence analyses identifıed selective expres-
sion of DPPA4 in the pituitary of fetal alcohol-exposed rats but not in control
rats. Ingenuity pathway analysis of the RNA sequence data showed interrela-
tionship of DPPA4 expression with the overexpression of pluropotent factors
SOX2 and NANOG and several growth promoting molecules such as Wnt5a,
TWIST1 and CTNNB1 and ESR1. Real-time PCR and western blot analysis
confırmed overexpression of DPPA4 and its network growth promoting factors
in pituitary tumors and in pituitary tumorspheres of fetal alcohol exposed rats.
Deletion of DPPA4 gene frompituitary tumorspheres using a CRIPRCas9 tech-
nique reduced the tumor cell ability to proliferate, migrate and form colony in
soft agar. These data suggest that DPP4 is selectively expressed in aggressive
prolactin-secreting tumors in the pituitary and controls the growth and migra-
tion of these tumors. (This work is supported by a National Institute of Health
grant R01 AA11591).
#4135 Inactivation/loss of PTPRS promotes ERK activation that sensi-
tizes colorectal cancer cells to ERK inhibitors. Thomas B. Davis,1 Mingli
Yang,1 Michael J. Schell,2 HeimanWang,1 LeMa,1W. Jack Pledger,1 Timothy J.
Yeatman1. 1Gibbs Cancer Ctr. and Research Inst., Spartanburg, SC; 2Moffıtt Can-
cer Center & Research Institute, Tampa, FL.
The RAS pathway is a driver of many cancers, and has been targeted for the
development of a variety of therapeutic inhibitors of BRAF, MEK, and more
recently ERK. One of challenging issues is to predict response to targeted ther-
apies. Here we report identifıcation of PTPRS, a receptor-type protein tyrosine
phosphatase, as a regulator/biomarker of ERK activation and inhibitor response
in colorectal cancer. To identify the genes with high frequency mutations that
might be predictive of RAS pathway dependence (“addiction”), we used a gene
expression signature score to stratify 468 colorectal cancer tumors that also
underwent targeted exome sequencing for 1321 cancer-associated genes. We
found that, when themasking effects caused bymutant KRAS, BRAF andNRAS
was iteratively removed, mutant PTPRS was strongly correlated with RAS path-
way activation, with a mutation rate of 10.4% (22 out of 211 remaining tumors).
This led us to inactivate PTPRS in vitro using a specifıc peptide inhibitor, siRNA
or CRISPR approaches in various colorectal cancer cell lines. Inhibition/loss of
PTPRS signifıcantly elevated phosphorylation of ERK and AKT and substan-
tially sensitized cancer cells to the treatment of ERK inhibitors, which was en-
hanced by an AKT inhibitor. Surprisingly, PTPRS did not modulate the activity
of EGFR and the ERK kinase, MEK. Our data indicate that PTPRS negatively
regulates ERK signaling downstream of the EGFR/RAS/RAF/MEKpathway in a
mechanism independent of AKT and DUSP6. As a result, inactivation/loss of
PTPRS promotes ERK activation and “addiction”, thereby contributing to in-
creased sensitivity to ERK inhibitors.
#4136 Effect of prorenin receptor PRR knock down and telmisartan on
endometrial cancer growth. Riazuddin Mohammed, Sarah J. Delforce, Yu
Wang, Nicole M. Verrills, Eugenie R. Lumbers, Kirsty G. Pringle. University of
Newcastle, Newcastle, Australia.
Endometrial cancer is the most common gynaecological malignancy and its
incidence is increasing. Tissue renin angiotensin systems (RAS) are known to
stimulate angiogenesis, cell proliferation and migration. All of these actions
potentiate cancer growth and spread. We have previously demonstrated that
endometrioid endometrial cancers express both prorenin and prorenin receptor
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((P)RR) mRNA and have signifıcantly greater levels of these proteins than nor-
mal adjacent endometrial tissue. Prorenin acting via the (P)RR can activate both
RAS dependent and independent signalling pathways. Therefore we hypothe-
sized that endometrial cancer growth can be inhibited by drugs that block Ang
II/AT1R interactions and prorenin/(P)RR mediated signaling pathways. To de-
termine the functional role of (P)RR in endometrial cancer growth, we used
siRNA transfection to knock down (P)RR expression in three endometrial can-
cer cell lines (Ishikawa, HEC-1A andAN3CA) at 24h, 48h, 72h& 96h. The effect
of RAS blockers on cell viability was also assessed by Resazurin assay at 48h in
the three endometrial cancer cell lines. All three of the endometrial cancer cell
lines examined (Ishikawa,HEC-1A andAN3CA) expressed (P)RR and prorenin
mRNA, however levels of (P)RR were much higher in Ishikawa cells. Transfec-
tion of the three cell lines with a (P)RR siRNA resulted in 90% knockdown of
(P)RR mRNA expression and reduced the cell viability of both Ishikawa and
AN3CA but not HEC-1A cells, as measured by a resazurin assay after 48h incu-
bation. Aliskiren (a renin inhibitor) inhibited Ishikawa cell growth by 20%.
There was no effect of Aliskiren on cell viability in HEC-1A and AN3CA cell
lines. Perindoprilat (an ACE inhibitor) and Losartan (an angiotensin II type 1
receptor (AT1R) inhibitor) had no effect on cell viability in any cell line. Another
AT1R antagonist, telmisartan, which also acts as a selective agonist of peroxi-
some proliferator-activated receptor gamma (PPAR-), did however signifı-
cantly reduce cell viability in all cell lines (Ishikawa 75%, HEC-1A 50% and
AN3CA 60%). Removal of the prorenin receptor inhibits the growth and devel-
opment of some endometrial cancer cell lines.Only telmisartan,whichhas prop-
erties additional to Ang II antagonism, was effective in inhibiting endometrial
cancer cell growth. (P)RR knockdown and telmisartan are therefore potential
therapeutic drugs for the treatment of endometrial cancer.
#4137 Second generation alpha-helical stapled peptides effıciently reduce
lymphoma cell viabilityby inhibiting LUBAC and NF-KB activity. Francisco
A. Aguilar-Alonso, Amanda L. Whiting, Erin Marshall, Federico Bernal. NCI/
NIH, Frederick, MD.
The linear ubiquitin chain assembly complex (LUBAC) is the only known
linear ubiquitin ligase whose function is dependent on the interaction of three
proteins: HOIL, HOIP and SHARPIN. The activity of this ubiquitin ligase has
been linked to amalignant phenotype associatedwith the activated B-cell (ABC)
subtype of diffuse large B-cell lymphoma (ABC-DLBCL) through constitutive
activation of theNF-KB pathway. A fırst generation of stapled peptides designed
to inhibit LUBACby intracellular disruption of the complex have been shown to
reduce cell viability andNF-KB activity inABC-DLBCL cellsmodestly.We have
developed a second generation of stapled peptides based on the alpha-helical
interaction interface of HOIP to enhance their ability to reduce LUBAC forma-
tion and, consequently,NF-KB activity aswell asABC-DLBCL cell viability. Live
cell imaging showed that some of the second generation HOIP stapled peptides
are cell permeable. Biochemical assays revealed that these peptides compro-
mised cell viability, disrupted LUBAC complex formation and inhibited the
NF-KB canonical pathway in ABC-DLBCL cell lines. Many of these new pep-
tides were farmore potent than any of the previously generated compounds that
target theHOIL-HOIP binding interface. These fındings support the hypothesis
that these second generation peptides may be a useful tool as coadjuvants or
therapeutic agents for the treatment of ABC-DLBCL.
#4138 In vitro and in vivo models for evaluation of inhibitors of trypto-
phan dioxygenases. Lai-Ming Ching, Petr Tomek, Brian D. Palmer, Sofıan Ti-
jono, Kimiora Henare, Lukas M. Braun. Univ. of Auckland Cancer Society Res.
Ctr., Auckland, New Zealand.
Cancers co-opt indoleamine 2,3-dioxygenase 1 (IDO1) as a mechanism for
evading the immune system, and IDO1 inhibitors have emerged as a promising
new approach for the treatment cancer through their potential to restore anti-
tumor immunity and to synergise with existing therapies. As part of our inves-
tigations into novel small molecule inhibitors of IDO1, we screened a number of
human and murine tumor lines for expression of tryptophan dioxygenases. All
the human and murine tumor lines that we tested were found not to express
tryptophan dioxygenases unless inducedwith IFN-gamma.Our screen included
testing 50 primary human melanoma lines developed from tumor samples ob-
tained New Zealand Melanoma patients (NZMel lines) for expression of IDO1
and IDO2. After co-culture with IFN-gamma, 84% of the NZMel lines were
IDO1 and IDO2; 4% were IDO1 only; 2 % were IDO2 only; whilst 10%
did not express either IDO1 or IDO2. Tryprophan dioxygenase (TDO) was not
detected in any of the NZMel lines before or after IFN-gamma exposure. To
overcome the need for IFN-gamma induction for our cell based assays of IDO1
inhibitory activity of our novel compounds, we transfected thewild-typemurine
Lewis Lung carcinoma line (LLTC) to constitutively express murine IDO1
(LLTC-mIDO1) or human IDO1 (LLTC-hIDO1), and used these engineered
lines to assay for potential species selectivity of our inhibitors. IDO1 expression
in the lines was consistent and stable, but when LLTC-hIDO1 cells were im-
planted subcutaneously into syngeneic mice for in vivo testing of inhibitors, we
found considerable heterogeneity in IDO1 expression between tumors. Approx-
imately half of the tumors from the same batch of implants were completely
negative for IDO1 expression byWestern blot analysis.More intriguingly, when
fragments of an IDO1 or an IDO1- donor tumor were implanted into new
recipients, the same degree of intertumoral heterogeneity in IDO1 expression
was seen in the subsequent generation of tumors. In contrast, subcutaneous
tumors developing from murine GL261 glioma cells similarly engineered to
over-express hIDO1 (GL261-hIDO1) were homogeneous in their expression of
hIDO1, and were used for subsequent in vivo studies of intratumoral
IDO1expression on its effects on immune cell infıltrates and tumor growth.
GL261-hIDO1 tumors had a signifıcantly faster growth rate than the wild-type
tumors, and 24 days after implantation, had reached a mean tumor volume of
3600 mm3 compared to a mean tumor volume of 500 mm3 of wild-type tumors.
Analysis of the immune cell infıltrates, showed that 14-day GL261 wild-type
tumors had a 3-fold higher percentage of CD3 T cells than that in GL261-
hIDO1 tumors. CD8 cells made up 55% and 25% of the CD3 cells in wild-
type andGL261-hIDO1 tumors, respectively. Percentage of Foxp3 (Treg) cells
was higher in GL261-hIDO1 tumors compared to that in wild-type tumors.
#4139 Role of zinc transporters in prostate cancer and a potential associ-
ation with racial disparity. Chandra K. Singh,1 KareemM. Malas,1 Caitlin Ty-
drick,1 Kenneth A. Iczkowski,2 Nihal Ahmad1. 1University of Wisconsin-Madi-
son, Madison, WI; 2Medical College of Wisconsin-Milwaukee, Milwaukee, WI.
Optimal intracellular zincconcentration is essential formanycellular functionsas
it serves as a catalytic and/or structural cofactor for a variety of proteins.Although, a
number of proteins are tangled in regulating cellular zinc homeostasis, the most
important are twoprotein families of zinc transporters, 14membersof solute carrier
family 39 (SLC39A) and 10 members of solute carrier family 30 (SLC30A). These
two families are known to transport zinc into- and out of- the cytoplasm, respec-
tively. Prostate cells accumulate a high amount of zinc to sustain ametabolic condi-
tion unique to the prostate which is characterized by a truncation of the Krebs cycle
andproductionofhighamountsof citrate.Zincdepletionhas frequentlybeennoted
in theprogressionofprostate cancer (PCa).Whether zinc transporters are a steering
cause of zinc depletion in PCa development and progression and/or are key deter-
minants in the racial disparity in PCa is not well studied. In this study, we deter-
mined the connectionof zinc transporters (SLC39A1-14 andSLC30A1-10) inPCa,
in the perspective of racial health disparity in human PCa samples taken fromAfri-
can-American (AA) and European-American (EA) patients and compared them
with respective adjacent benign samples. We also assessed the mRNA level of zinc
transporters in normal prostate epithelial cells (NrPEC and RWPE1) and among
PCa cells derived from AA (MDA PCa 2b, E006AA-PAR, E006AA-HT) and EA
patients (DU145, PC3, 22R1, LNCaP, C4-2B). In addition, we performed a dataset
analysis of the Oncomine database for differential expression profıle of zinc trans-
porters in PCa versus normal prostate.We found that SLC39AsmRNA levels were
differentially expressed in PCa with a signifıcant downregulation of SLC39A1,
SLC39A10, SLC39A11, SLC39A13 and SLC39A14, and upregulation of SLC39A3,
SLC39A5, SLC39A6 and SLC39A8. Further, SLC30As showed a signifıcant down-
regulation of SLC30A5 and SLC30A6 and upregulation of SLC30A1, SLC30A9 and
SLC30A10, in PCa. Further, compared to EA samples, the AA PCa showed an in-
creasing trend of SLC39A5, SLC39A6 and SLC30A9. In addition, compared to AA
samples, the EA PCa showed a trend of increasing SLC30A1 and SLC30A9 and
decreasing SLC39A10. These data provide evidence that the zinc transporters may
be linked to racial disparity of PCa in AA versus EA.Moreover, Ingenuity Pathway
Analysis revealed regulatory interactions between zinc transporters and tumor sup-
pressor/promoter genes proven to bemodulated in PCa. These genes areHOXB13,
ELAVL1, DIRAS3, ALPP, CSF2, CCL4, INSR, AKT, IL6, TGFBP1, CHI3L1, EGFR
andHNF4A.Overall, our study provides interesting data about the expression pro-
fıles of zinc transporters and their interactionwith tumor suppressor and promoter
genes in PCa, whichmay offer novel strategies for themanagement of PCa by phar-
macologically modulating zinc transporters.
#4140 Identifıcation of a selective MKLP2/KIF20A inhibitor with high
in-vivo antitumor activity. Yves Collette,1 Stephanie Miserey-Lenkei,2 Cathe-
rine Guillou,3 Denis Carniato,4 Bernard Pau,5 Bruno Goud,2 Norbert Vey,1 Ce-
cile E. Bougeret6. 1Institut Paoli-Calmettes, Marseille, France; 2Institut Curie,
Paris, France; 3ICSN-CNRS, Gif-sur-Yvette, France; 4DC2A Consulting, Paris,
France; 5BP CONSEIL, Saint-Gely-du-Fesc, France; 6BIOKINESIS, Paris, France.
Mitotic kinesins are essential regulators of cancer cell replication andmigration.
The mitotic kinesin MKLP2/KIF20A, a member of the kinesin-6 family, plays an
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essential role during cytokinesis and was identifıed as a potential new target for
cancer chemotherapy1. We have previously identifıed Paprotrain, a new synthetic
compound, as the fırst selective MKLP2 inhibitor2. Recently, we obtained Papro-
train analogueswith higher potency onMKLP23.Hereinwe describe the identifıca-
tion and characterization of BKS0349, a new potent analogue of Paprotrain.
BKS0349 compound is 10 timesmore potent than paprotain onMKLP2 inhibition
and has shown an evenmore restricted specifıcity profıle when tested on a large set
of kinases. In-vitro this compound is highly cytotoxic on a wide panel of human
cancer cell lines (IC50 ranged 10-70 nM, which corresponds to 1000 fold improve-
ment of paprotrain potency) while no toxicity is observed on human normal cells
suchasperipheralbloodmononuclear cells (PBMC)andprimaryhepatocytes (IC50
50M). BKS0349 compound is well tolerated inmice using repeated intravenous
administrations (200 mg/kg, twice a week for 4 weeks). In xenografted nude mice,
in-vivo treatmentwithBKS0349 compounddemonstrates a high antitumor activity
against various human cancer cellmodels, either sensitive or resistant to some stan-
dard-of-care treatments. In addition, human cancer cells treated in-vitro as well as
in-vivowith BSK0349 compound displayGolgi scattering and amitotic arrest lead-
ing to cell death, as hallmarks of BKS0349’modeof action. These fındings show that
MKLP2 is a potential new target for cancer chemotherapy and BKS0349 a good
candidate to be developed for cancer treatment. 1Paclitaxel targets FOXM1 to reg-
ulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. P.
Khongkow et al. Oncogene, 2015, 1-13. 2Relocation of Aurora B and Survivin from
centromeres to the central spindle impairedbyakinesin-specifıcMKLP-2 inhibitor.
S. Tcherniuk et al. Angew. Chem. Int. Ed., 2010, 49:8228-8231. 3NewMKLP-2 in-
hibitors in the paprotrain series: design, synthesis and biological evaluations. C.
Labrière et al. Bioorg andMed Chem, 2016, 24:731-734.
#4141 Phosphoproteome networks display consistent hyperactive kinase
activity in pancreatic cancer: evidence for new therapeutic options. Tessa Y.
Le Large,1Maarten F. Bijlsma,2 Btissame ElHassouni,1 Nicolla Funel,3 Nicole C.
van Grieken,1 Helene Damhofer,2 Jaco C. Knol,1 Sander R. Piersma,1 Thang V.
Pham,1HenkM.Verheul,1 HannekeW. van Laarhoven,2 Geert Kazemier,1 Elisa
Giovannetti,1 Connie R. Jimenez1. 1VU university Medical Center, Amsterdam,
Netherlands; 2AcademicMedical Center, Amsterdam,Netherlands; 3University of
Pisa, Pisa, Italy.
Introduction Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal
disease due to its aggressive nature. Patients typically present with distant me-
tastases, at which point cytotoxic agents can extend life expectancy by several
months at most. Large-scale phosphoproteomics complements our knowledge
obtained from genomics and transcriptomics as it provides information on
which proteins and kinases are phosphorylated, thereby implicating pathways
that are activated. This approach in cancer research may lead to improved pa-
tient selection for treatment with tyrosine kinase inhibitors (TKI). This study is
the fırst to employ phosphotyrosine-based phosphoproteomics on three differ-
ent preclinical PDACmodels as well as patient tumor tissues to understand the
aggressive nature of this disease and identify new drug targets. Approach We
performed phosphoproteomics on a panel of 11 PDAC cell lines, 7 primary cell
cultures, 10 patient-derived xenografts (PDX) and 16 fresh frozen human tumor
tissues. Tyrosine phosphopeptides were enriched via immunoprecipitation and
phosphopeptides were analyzed by high-resolution nano-LC mass spectrome-
try. Results Using phosphotyrosine-based phosphoproteomics, we identifıed a
total of 1723 tyrosine phosphorylated proteins and 138 phosphorylated kinases,
representing 27% of the kinome. The reproducibility of our workflow was very
high, with Pearson correlation coeffıcients of r 0.937 for technical replicates of
cell lines and r 0.876 for biological replicates of tumors. In our cell line panels,
multiple kinases were commonly highly phosphorylated (e.g. PTK2, EPHA2,
EGFR andMET). Functional testing of PTK2by usingTKI defactinib in primary
cell lines with high phosphorylation resulted in inhibition of proliferation and
migration in vitro. Inhibition of EPHA2 by shRNAs resulted in reduced prolif-
eration in vitro. To validate the relevance of these candidate target proteins in
vivo, the tyrosine phosphoproteome of PDXs and human tumors was analyzed.
In these tumors, kinase activity analysis based on kinase phosphorylation levels
and kinase-substrate networks validated these common active nodes in the ma-
jority of these tumors. Conclusion Our extensive tyrosine phosphoproteome
analysis spanning a wide range of PDACmodels revealed high phosphorylation
levels of multiple kinases. Interestingly, the phosphorylated kinase profıles of
tumors and cell lines did not show asmuch heterogeneity as expected, taken into
account the existence of biological subtypes in PDAC identifıed by others via
transcriptomics. The aggressive biology of this disease may be correlated with
the consistent activation of multiple pathways, some of which we have shown to
be targetable in vitro. This study prompts further validation and prognostic
evaluation of the identifıed active kinases to improve treatment of PDAC.
#4142 Regulation of tumor suppressor decorin by APE1 in head and neck
squamous cell carcinoma. Christina A. Wicker,1 Timothy L. Scott,1 Rangas-
wamy Suganya,2 Susan M. Arnold,1 Yolanda M. Brill,1 Craig M. Horbinski,3
Dana Napier,1 Joseph Valentino,1 Mahesh R. Kudrimoti,1 Guoqiang Yu,1 Tada-
hide Izumi1. 1University of Kentucky, Lexington, KY; 2Houston Methodist Re-
search Institute, Houston, TX; 3Northwestern University, Chicago, IL.
Oral cancers have a high rate of recurrence, and a tendency to develop treat-
ment resistance. From 2009 to 2013, Kentucky had a disproportionately higher
incidence of invasive oral cancers and resultant higher mortality compared to
the national average (SEER & NPCR, Kentucky Cancer Registry). Apurinic/
Apyrimidinic endonuclease (APE1) is a key protein in DNA repair, and an
important transcriptional regulator. Gene array analysis in pMEFs expressing
wild-type APE1 and extremely low levels of APE1 showed an eight-fold reduc-
tion of tumor suppressor decorin (DCN), with wild-type APE1. Decorin is a
known tumor suppressor and extracellular matrix protein, which can suppress
tumor proliferation, migration and angiogenesis. Tumors with decreased
decorin are associated with increased mortality. These studies aim to elucidate
APE1’s role in decorin regulation in oral cancer and identify biomarkers, which
may aid in diagnosis, treatment, or predicting prognosis. Immunohistochemis-
try studies of head and neck squamous cell carcinoma from Kentuckians were
analyzed aided by Aperio’s high resolution scanning capabilities, and software.
Analysis showed a signifıcant decrease in decorin in both tumor and carcinoma
in situ compared to benign tissue.Whereas, APE1 was signifıcantly increased in
tumors. Additionally there was a signifıcant negative correlation between APE1
and decorin total protein in carcinoma in situ. This data supports that increased
APE1 may deplete decorin. Superoxide Dismutase 3, which is important in
detoxifying extracellular ROS, was also signifıcantly decreased in tumor and in
carcinoma in situ. This along with previous research showing increased ROS in
the tumor microenvironment and APE1 activation by ROS may explain the
origination of decorin suppression. We hypothesize that the overexpression of
APE1 in early stages of oral cancer leads to diminished decorin translation,
which may drive cancer progression and increase mortality. Better understand-
ing howAPE1 influences tumor suppressorsmay eventually aid in development
of therapeutics that would increase patient survival.
#4143 Mastl, a novel therapeutic target in colon cancer. JayaPrakash Up-
pada,1 SaiPrasad Gowrikumar,1 Rizwan Ahmad,1 Steven Chen,2 J Joshua
Smith,3 Amar B. Singh,1 Punita Dhawan1. 1UNMC, Omaha, NE; 2University of
Miami Health System, Miami, FL; 3Memorial Sloan Kettering Cancer Center,
New York, NY.
Combining chemoradiation with agents that modulate tumor-specifıc path-
ways such as cell cycle checkpoints has shown immense promise in preclinical
and clinical studies. To ensure that only healthy cells proliferate, checkpoints
have evolved that induce cell-cycle arrest in response to the detection of defects
that may have arisen during DNA replication or other steps leading to mitosis.
The G2/M checkpoint Mastl in mammals (and Greatwall in Xenopus and Dro-
sophila) prevents cells from premature entry into mitosis, and thus minimizes
chromosomemis-segregation.Our preliminary data demonstrate thatMastl not
only plays a key role in regulating cell cycle and mitosis but also regulates key
oncogenic signaling pathways and assists therapy resistance in cancer cells. In-
terestingly, genetic elimination of Mastl expression in vivo compromised sur-
vival in young mice, however, only mild alterations were found when deleted in
adult mice. Here we show using two clinical and genomic databases using a total
of 265 patient samples that Mastl expression increases in colon cancer across all
cancer stages compared with the normal colon tissue (P  0.001). Moreover,
high Mastl expression associates with high-risk colorectal cancer patients and
poor prognosis. Silencing ofMastl expression using gene-specifıc shRNA, in two
different colon cancer cells with high endogenous expression of Mastl, induced
cell death/apoptosis supporting important role of Mastl in colon cancer cell
survival. To further determinemolecularmechanism/s bywhichMastl regulates
cell survival, we screened a panel of oncogenes. It was interesting that the knock-
down ofMastl expression sharply inhibited -catenin/c-myc signaling, key reg-
ulators of colon carcinogenesis, in both cell types. To further expand the breadth
of this investigation and to identify additional key players in Mastl dependent
regulation of colon cancer cell survival, we performed an oncogenic array anal-
ysis using above cell lines with or without stable inhibition of Mastl expression.
Here, we observed robust effects of inhibiting Mastl upon anti-apoptotic pro-
teins Bcl-xl and survivin. Notably, c-myc regulates survivin and Bcl-xl expres-
sions. Additional studies, where colon cancer cells were subjected to 5-FU treat-
ment sharply induced Mastl expression and combinational therapy using 5FU
and (targeting) Mastl resulted in signifıcantly increased death among these cells
(P0.0025; versus control). Taken together, we here report a novel and previ-
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ously undescribed role of Mastl in colon cancer progression, malignancy and
therapy resistance potentially by regulating cell survival in manners dependent
on -catenin/c-Myc/Survivin/Bcl-xl signaling.
#4144 Role of CTGF in hyperthermia resistance in ovarian and uterine
cancers. Hiroto Hatakeyama,1 Sherry Y. Wu,2 Yasmin A. Lyons,2 Sunila
Pradeep,2WanqinWang,2 QianHuang,2 KaremA. Court,3 Tao Liu,4 SongNie,4
Cristian Rodriguez-Aguayo,2 Fangrong Shen,2 Yan Huang,2 Takeshi Hisa-
matsu,2 TakashiMitamura,2 Piotr L. Dorniak,2 Lingegowda S.Mangala,2Marco
Petrillo,5 Madeline Torres-Lugo,3 Karin D. Rodland,4 Anna Fagotti,5 Gabriel
Lopez-Berestein,2 Chun Li,2 Anil K. Sood2. 1Chiba University, Chiba, Japan;
2The University of TexasMDAnderson Cancer Center, Houston, TX; 3University
of Puerto Rico-Mayaguez, Mayagüez, Puerto Rico; 4Pacifıc Northwest National
Laboratory, Richland,WA; 5Catholic University of the Sacred Heart, Rome, Italy.
Objective. Even though hyperthermia is a promising treatment for cancer,
multiple obstacles remain to be cleared. Among these, the tumor temperatures
that must be reached for obtaining clinical effıcacy are undefıned. The purpose
of our study was to identify the molecular predictors of response to hyperther-
mia in ovarian and uterine cancers. Methods. The temperature transition in
tumors during hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian
cancer patients was examined. To evaluate sensitivity to hyperthermia, 10 ovar-
ian and uterine cancer cells were treated with hyperthermia and determined
median lethal temperature 50 (LT50). An integrative analysis was performed to
identify molecules associated with hyperthermia resistance by comparison with
gene and protein expression between hyperthermia-resistant (HTR) and -sen-
sitive (HTS) cells. The effect of identifıed gene silencing on sensitization to
hyperthermia and tumor growth in orthotopic models of ovarian cancers by
using liposomal siRNA and local hyperthermia by NIR and CuS nanoparticles.
Results. The temperature during HIPEC in human tumors was  40°C even
though the perfusion temperature at the entrance was maintained at 42.5°C.
Based on LT50, we identifıed 5 cell lines as HTR (SKOV3, HeyA8, KLE, PEO4,
and ES2; LT50 47.5 	 0.3°C) and 5 as HTS (A2780, A2780CP20, Hec-1A, SK-
KUT-2, and ISHIKAWA; LT50 45.5	 0.2°C). Gene expression studies identi-
fıed 15 genes that were highly upregulated in HTR compared with HTS cells.
Proteomic analyses showed that glucose metabolism-related proteins were
down-regulated in SKOV3 cells after hyperthermia. Pathway analysis indicated
that FN1, SGK1, andCTGF among the 15 geneswere potentially connectedwith
glucose metabolism-related proteins. CTGF siRNA sensitized HTR cells to hy-
perthermia. The combination of CTGF silencing and local hyperthermia signif-
icantly inhibited tumor growth andmetastasis inHeyA8 and SKOV3 orthotopic
models. Conclusion. Collectively, we identifıedCTGF as a key target for enhanc-
ing response to hyperthermia in ovarian and uterine cancers.
#4145 Concurrent treatment with Pim kinase inhibitor decreases alterna-
tive non-homologous end-joining repair of DNA damage induced by topo-
isomerase 2 inhibitors in cells with FLT3-ITD. Kshama A. Doshi,1 Pratik K.
Nagaria,2 Adriana E. Tron,3 Feyruz V. Rassool,2 Maria R. Baer1. 1University of
Maryland Greenebaum Comprehensive Cancer Center and Veterans Affairs
Medical Center, Baltimore, MD; 2University of Maryland Greenebaum Compre-
hensive Cancer Center, Baltimore, MD; 3Oncology iMED, AstraZeneca,
Waltham, MA.
Purpose: Internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-
ITD) is a common (30%) molecular abnormality in acute myeloid leukemia
(AML), associated with a high relapse rate and short disease-free survival.
The oncogenic kinase Pim-1 is upregulated downstream of FLT3-ITD and
contributes to its proliferative and anti-apoptotic effects. We recently
showed that Pim kinase inhibition sensitizes AML cells with FLT3-ITD to
apoptosis induction by topoisomerase 2 (TOP-2) inhibitors by increasing
DNA double-strand breaks (DSBs) and oxidative stress. Here, we studied
whether altered DSB repair activity contributes to the increase in DNA dam-
age. Methods: Ba/F3 cells expressing FLT3-ITD (Ba/F3-ITD) or wild-type
FLT3 (Ba/F3-WT) were studied. The pan-Pim kinase inhibitor AZD1208
was provided by AstraZeneca. TOP-2 inhibitors included daunorubicin
(DNR), mitoxantrone (MXR) and etoposide (VP-16). Nuclear expression of
repair proteins was measured by immunoblotting. Functional changes in
DSB repair activities were measured in cell lines with stable chromosomal
integration of the green fluorescent protein (GFP)-based DSB repair report-
ers DR-GFP, EJ5-GFP and EJ2-GFP, measuring homologous recombination
(HR), classical non-homologous end-joining (C-NHEJ) and alternative
(Alt-) NHEJ, respectively. Results: Nuclear expression of the HR component
Rad51 decreased progressively (to 40%) in Ba/F3-ITD cells after 12 hours of
co-treatment with AZD1208 and DNR, compared to DNR alone. Progressive
decrease (to 60%) in nuclear expression of the Alt-NHEJ component DNA
ligase 3 and the C-NHEJ component Ku-70 was also seen with combination
treatment. Functionally, co-treatment with AZD1208 and DNR led to a 50%
decrease in Alt-NHEJ repair activity, compared to DNR alone, but no signif-
icant change in C-NHEJ or HR repair activity. Ba/F3-WT cells did not show
a signifıcant change in Alt-NHEJ, HR or C-NHEJ activity with combination
treatment. Decreased Alt-NHEJ activity was also seen in Ba/F3-ITD, but not
Ba/F3-WT, cells co-treated with AZD1208 andMXR or VP-16. Conclusions:
While nuclear expression of multiple DNA DSB repair proteins decreased,
only Alt-NHEJ repair activity decreased in FLT3-ITD cells co-treated with
Pim kinase and TOP-2 inhibitors. Alt-NHEJ, a highly error-prone DNADSB
repair pathway, is upregulated in cells with FLT3-ITD and contributes to
genomic instability in these cells. Decreasing Alt-NHEJ repair activity in
cells treated with TOP-2 inhibitors has the potential to decrease the genomic
instability that may contribute to disease progression in AML patients with
FLT3-ITD.
#4146 Selinexor synergizes with DNA damaging agents through down-
regulation of key DNA damage response genes. Trinayan Kashyap, Christian
Argueta, Boris Klebanov, Oscar Gonzalez, Erkan Baloglu, Yosef Landesman,
Margaret Lee, Humphrey Gardner, Sharon Shacham, William Senapedis.
Karyopharm Therapeutics, Newton, MA.
Background: Selinexor is a fırst-in-class, orally bioavailable SINE (Selec-
tive Inhibitor of Nuclear Export) compound currently in phase 1/2 clinical
trials of patients with solid and hematological malignancies. SINE com-
pounds bind exportin 1 (XPO1/CRM1) and inhibit nuclear export, resulting
in nuclear retention of major tumor suppressor proteins (TSPs). We previ-
ously found through Reverse Phase Protein Array analysis that selinexor
treatment alters the level of key DNA damage response (DDR) proteins. We
also observed enhanced anti-tumor activity when combining selinexor with
standard DNA damaging agents (DDA) in pre-clinical models and clinical
studies. We hypothesize that a reduction in DDR protein expression by
selinexor drives the synergy observed in combination with DDAs. Methods:
Solid and hematological cancer cell lysates treated with selinexor/- DDAs
(cisplatin, doxorubicin, docetaxel and gemcitabine) were analyzed by immu-
noblotting and qPCR. Comet assay and H2A.X staining were analyzed by
immunofluorescence to evaluate DNA damage. Mice bearing MDA-MB-231
(triple negative breast cancer) tumors were treated with sub-toxic doses of
selinexor (2.5 mg/kg), cisplatin (4 mg/kg) or docetaxel (4 mg/kg) alone or in
combination. Tumor growth and mouse weight were followed for 25 days.
Results: Selinexor reduced the expression of DDR mRNA and proteins in-
volved in single-stranded (SSB) and double-stranded break (DSB) repair as
early as 2 hours post treatment. We observed a dose-dependent correlation
between the degree of DDR protein reduction and selinexor cytotoxicity in
vitro. Selinexor prevented DDR activation following exposure to DDAs and
led to synergistic cell death. Treatment of cells with selinexor plus DDA
showed enhanced activity in comet assays and an increase in H2A.X stain-
ing when compared to treatment with the single agents. Exposure to se-
linexor 6 - 24 hours after DDA treatment inhibited the DDRmechanism and
was more synergistic than the opposite order (Sel ¡ DDA) or simultaneous
treatment. In aMDA-MB-231 xenograft, treatment with selinexor, docetaxel
(SSB) or cisplatin (DSB) alone resulted in 66.7%, 51.5% or 26.6% TGI, re-
spectively when compared to vehicle control whereas sequential treatment of
docetaxel or cisplatin followed by selinexor resulted in 93.9% TGI or 9.6%
tumor regression, respectively. No signifıcant weight loss was seen in any of
the groups by the end of the study. IHC staining and immunoblot analysis of
tumor tissue and sections showed a reduction of DDR proteins. Conclusion:
Selinexor synergizes with DDAs by increasing both SSB and DSB through
inhibition of relevant DDR proteins. This data supports clinical develop-
ment of selinexor in combination with standard chemotherapeutic agents in
patients with solid and hematological malignancies. The results also suggest
that sequential treatment of patients with DDAs followed by selinexor might
be more benefıcial.
#4147 DCLK1 a novel therapeutic target in non-small cell lung cancer.
Parthasarathy Chandrakesan, Dongfeng Qu, Randal May, Nathaniel Weygant,
William Berry, Naushad Ali, Sripathi Sureban, Eddie Bannerman-Menson, Mi-
chael Bronze, Courtney Houchen.University of Oklahoma Health Sciences Cen-
ter, Oklahoma City, OK.
Introduction: Lung cancers possess a rare population of cells that have the
capacity to self-renew, differentiation and ultimately promote tumorigene-
sis. These cells are often resistance to conventional therapies and are respon-
sible for tumor relapse andmetastatic spread, which contribute to the overall
mortality observed in non-small cell lung cancer (NSCLC). These cells are
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termed tumor stem cells (TSCs) and as such are highly desirable targets for
novel therapeutic strategies. Doublecortin-like Kinase 1 (DCLK1) has re-
cently been identifıed as a tumor stem cell marker in the intestine and pan-
creas and is dysregulated in many solid tumor cancers including lung cancer.
Increased expression has been demonstrated to correlate with poor survival
in several solid tumor cancers. Thus these data taken together provide the
rational for targeting DCLK1 expressing cells in NSCLC. Methods: Small
interfering RNA (siRNA) against DCLK1 was transfected into NSCLC cell
lines (A549 - wt-p53; H1299 –homozygous deletion of p53) of highly drug
resistant (A549) and metastatic (H1299). Cell proliferation, colony forma-
tion, self-renewal, cell migration and invasion and drug resistance assays
were performed to assess the tumor stem cell characteristics. A549 cells were
treated with siDCLK1 and cisplatin in order to assess the role of DCLK1 to
reverse the drug-resistance. A549 cells were utilized to generate tumor xeno-
graft in order to assess the role of DCLK1 knockdown on NSCLC tumori-
genesis in vivo. The data were generated utilizing experimental protocols for
clonogenic culture, immunohistochemistry, RT-qPCR and Western blot-
ting. Results: Silencing DCLK1 via RNA interference decreased the colony
formation (p0.001), and self-renewal ability (p0.0001) of the NSCLC cell
lines in vitro. Knocking down DCLK1 reduced (p0.001) NSCLC cells mi-
gration and invasion in vitro. Furthermore, DCLK1 knockdown decreased
the expression of EMT associated factors (Slug, Snail, Twist, Zeb1/2, Vimen-
tin) and pluripotency factors. Initial cisplatin treatment results in the isola-
tion of cisplatin resistant A549 cells. Retreatment of cisplatin resistant A549
cells results in greater resistance and survival ability. However, combination
therapy of these resistance cells with siDCLK1 and cisplatin overcame cis-
platin-induced resistance, resulting in greater cell death compared to cispla-
tin or siDCLK1 alone treatments. Nanoparticle encapsulated siDCLK1 treat-
ment in xenograft tumors resulted in tumor growth arrest in vivo.
Conclusions: NSCLC cells highly express DCLK1 display enhanced self-
renewal, increased migration and invasion. Combination therapy of siD-
CLKL1 with cisplatin overcame cisplatin induced drug resistance. Targeting
DCLK1 reduced tumor xenograft in vivo. Taken together these data suggest
that DCLK1 inhibition reduces TSC related properties, overcome drug re-
sistance and inhibits tumor growth, thus making DCLK1 targeted therapy an
attractive tool for combating NSCLC.
#4147A Potent anti-cancer activity of the imipridone ONC206: A selec-
tive dopamineD2-like receptor antagonist.VarunVijay Prabhu,1NeelMadhu-
kar,2 JessicaWagner,3 Rohinton Tarapore,1 Mathew Garnett,4 UltanMcDermott,4
Cyril Benes,5 Neil Charter,6 Sean Deacon,6 Alexander VanEngelenburg,7 Ol-
ivier Elemento,2 Wafık El-Deiry,3 Martin Stogniew,1 Wolfgang Oster,1
Joshua Allen1. 1Oncoceutics, Inc, Philadelphia, PA; 2Weill CornellMedicine, New
York, NY; 3Fox Chase Cancer Center, Philadelphia, PA; 4Wellcome Trust Sanger
Institute, Hinxton, United Kingdom; 5Massachusetts General Hospital, Boston,
MA; 6DiscoverX Corporation, Fremont, CA; 7HistoTox Labs, Inc, Boulder, CO.
DRD2 is a G protein-coupled receptor (GPCR) that is overexpressed in many
cancers, controls an array of pro-survival signaling pathways, and its antagonism
causes anti-cancer effects.ONC201, the foundingmemberof the imipridoneclassof
anti-cancer compounds, is a small molecule DRD2 antagonist that is in Phase I/II
advanced cancer clinical trials. In this study, we evaluated the binding target and
antitumor activity of ONC206, a chemical analogue of ONC201. An orphan small
molecule target prediction algorithm revealed that ONC206, likeONC201, antago-
nizesDRD2.ExperimentalGPCRprofılingusing thePathHunter®-Arrestinassay,
determined that ONC206 selectively antagonizes the D2-like (DRD2/3/4), but not
theD1-like (DRD1/5), subfamilyofdopaminereceptors.ONC206possesses a10-
fold increased affınity for DRD2 compared to ONC201 with a Ki of320nMwith
selectivity that was superior to approved antipsychotics. The increased association
rate for the ONC206-DRD2 interaction was responsible for the increased affınity,
whereas the dissociation rate was similar to ONC201 and atypical antipsychotics
that are well tolerated. TCGA analysis and immunohistochemistry of patient-de-
rived tissue microarrays revealed DRD2 was overexpressed in neuroblastoma, sar-
comaandpheochromocytomaspecimens relative tonormal tissues. Invitro effıcacy
profıling ofONC206 in theGenomic ofDrug Sensitivity inCancer collection of cell
lines revealed broad effıcacy across most tumor types (GI50 78-889nM). Bone
cancer and neuroblastoma were identifıed as the most ONC206-responsive solid
tumor types that were comparatively less responsive toONC201.Within bone can-
cer cell lines, Ewing’s sarcoma (n16) was the most sensitive to ONC206 with
nanomolar sensitivity (GI50 168-303nM) that was superior to ONC201. ONC206
was highly effıcacious in neuroblastoma (n35, GI50 87-589nM) including cell
lines derived from metastatic sites and with MYCN amplifıcation associated with
poor prognosis. In the PC12 rat pheochromocytoma cell line ONC206 (GI50
200nM)was superior toONC201.ONC206 time-course experiments revealed anti-
cancer effects occurring at 48-72post-treatment, similar toONC201. In support of a
wide therapeutic window, ONC206 reduced the viability of normal fıbroblasts
(HFF-1) at relatively high doses (GI50 5M). Effıcacy evaluations inMHH-ES-1
athymicnudemice xenografts demonstrated thatONC206 (100mg/kgPOevery 10
days) causes signifıcant tumorgrowth inhibition thatwascomparable tomethotrex-
ate (400mg/kg, IP)while being better tolerated. In summary,ONC206 is an imipri-
done that acts as a selective antagonist of DRD2 at nanomolar concentrations and
has broad-spectrum anti-tumor activity. ONC206 may address tumor types where
the properties of ONC201 do not permit for complete therapeutic engagement in
vivo.
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#4148 Novel ERX-11 and CDK4/6 inhibitor combination therapy for
treating therapy resistant breast cancer. Suryavathi Viswanadhapalli,1 Gan-
gadhara Reddy Sareddy,1 Shi-Hong Ma,2 Tae-Kyung Lee,3 Rajeshwar Rao Tek-
mal,1 Jung-Mo Ahn,3 Ganesh Raj,2 Ratna K. Vadlamudi1. 1UTHSCSA, San An-
tonio, TX; 2University of Texas Southwestern Medical Center at Dallas, Dallas,
TX; 3University of Texas at Dallas, Richardson, TX.
BACKGROUND: Themajority of the breast cancer is estrogen receptor alpha
(ESR1) positive. While tamoxifen and letrozole therapies are effective, therapy
resistance is common. Importantly, both therapy-sensitive and therapy-resis-
tant tumors retain ESR1 signaling, via interaction with critical oncogenic co-
regulator proteins. Further, resistant tumors commonly acquire cyclin D1:
CDK4/6 signaling via multiple mechanisms, cyclin D1 can independently
activate ESR1 and thus contribute to estrogen independence of ESR tumor.
Currently, CDK4/6 inhibitors in clinical trials for treating breast cancer, how-
ever, considering complex signaling interplay of estrogen and CDK axis, com-
bination therapy of CDK inhibitor with other potent ESR1 targeted agents may
have better utility and may prevent development of resistance to the CDK4/6
inhibitors. We recently developed a small organic molecule, ESR1 coregulator
binding inhibitor ERX-11 (EtiraRx-11). The objective of this study is to test the
utility of novel combination therapy of ERX-11 with CDK4/6 inhibitor palbo-
ciclib in treating therapy resistant cancer. METHODS: We have utilized multi-
ple therapy sensitive and therapy-resistant models with various genetic back
grounds.We tested effıcacy using both acquired resistance and engineeredmod-
els that express ESR1 mutations or oncogenes. Effıcacy of combination therapy
was tested using established in vitro assays including, MTT, colony formation,
apoptosis, and cell cycle progression.Mechanistic studies were conducted using
reporter gene assays, gene expression and signaling alterations. Xenograft stud-
ies were used to determine the in vivo effıcacy of the combination therapy.
RESULTS: ERX-11 effectively blocked ESR1-mediated oncogenic signaling and
has potent anti-proliferative activity against therapy-sensitive and therapy-re-
sistant breast cancer cells. Mechansistic studies showed that ERX-11 blocks the
interaction between a subset of coregulators with both native andmutant forms
of ESR1. ERX-11 showed potent activity in both preclinical xenograft models
and patient-derived breast tumor explantmodels. Co-treatment of ERX-11with
palbociclib synergistically reduced cell viability and induced apoptosis of ther-
apy sensitive and resistant breast cancer model cells. Importantly, combination
therapy of ERX-11 and the palbociclib synergistically reduced the growth and
induced apoptosis of tamoxifen and letrozole resistant xenograft tumors com-
pared to either drug alone. Mechanistic studies showed combination therapy
signifıcantly altered E2F1 and ESR1 signaling pathways and promoted apopto-
sis. CONCLUSIONS: Collectively our studies have discovered a novel combina-
tional treatmentwith ERX-11 and palbociclib for patientswith therapy-sensitive
and therapy-resistant breast cancers.
#4149 Increased migration ability of osimertinib-resistant EGFR-T790M
mutant non-small-cell lung cancer cells. Satoshi Kambayashi, Yasuhiro Koh,
Maiha Ohyama, Ayaka Tanaka, Hiroaki Akamatsu, Nahomi Tokudome, Hiroki
Ueda, Nobuyuki Yamamoto. Wakayama Medical University, Wakayama, Ja-
pan.
Background: A third generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) osimertinib is effective against gefıtinib/erlo-
tinib-resistant non-small-cell lung cancer (NSCLC) harboring EGFR T790M
mutation. Although the majority of these patients initially responds to
osimertinib, they eventually develop resistance. Acquired mutations such as
EGFR C797S mutation have been reported to confer resistance to osimertinib,
but mechanisms of resistance to osimertinib or biological behaviors of
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osimertinib-resistant NSCLC have not been fully elucidated. Materials and
methods: Osimertinib-resistant PC-9/ZD/OR1 and PC-9/ZD/OR3 cells were
generated after continuous exposure of gefıtinib-resistant PC-9/ZD cells har-
boring both EGFR exon 19 deletion and T790M mutations to increasing con-
centrations of osimertinib. Growth-inhibitory effect of inhibitors gefıtinib and
osimertinibwas evaluated byMTT assay. CommonEGFRmutational status was
examined by RainDrop Digital PCR System (RainDance Technologies). Immu-
noblot analysis was performed to investigate the modulation of molecules rele-
vant to EGFR signaling pathways. Cell-adhesion assay, wound closure assay and
transwell assay were performed to evaluate the ability of cell adhesion and mi-
gration. Results: Both PC-9/ZD/OR1 and PC-9/ZD/OR3 cells showed 50- to
120-fold more resistant to osimertinib than parental PC-9/ZD cells, and main-
tained resistance to gefıtinib as well. PC-9/ZD/OR cells maintain EGFR exon 19
deletion andT790Mmutations andC797Smutationwas not detected. Although
phosphorylation of EGFR and ERK1/2 were inhibited by osimertinib treatment
in PC-9/ZD/OR cells, phosphorylation of Akt was not inhibited. PC-9/ZD/OR
cells express the elevated level of c-METand its phosphorylated form, suggesting
that bypass signaling is activated to evade EGFR pathway blockade. PC-9/
ZD/OR cells also express marked level of E-cadherin which parental PC-9/ZD
cells do not express. PC-9/ZD/OR cells exhibited enhanced adherent activity,
cell motility and migration ability compared to PC-9/ZD cells. Notably,
osimertinib treatment signifıcantly reduced the number of migrated cells not
only in PC-9/ZD cells but also in PC-9/ZD/OR cells. These results suggest that
osimertinib-resistant PC-9/ZD/OR cells acquired enhanced migration ability
through c-MET pathway activation and/or induction of E-cadherin.
Osimertinib treatment may be still effective to inhibit cell migration, suggesting
that cell migration and cell growth are driven by different signaling pathways in
PC-9/ZD/OR cells. Conclusion: c-MET overexpression was suggested to confer
resistance to osimertinib and the resistant cells exhibited enhanced cell migra-
tion. Continuative osimertinib treatment may be benefıcial in preventing me-
tastasis even after the failure and involvement of c-MET and E-cadherin in
osimertinib resistance should be further investigated.
#4150 Anti-tumor activity of the PI3K/mTOR pathway inhibitors al-
pelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired
resistance to CDK-4/6 targeted therapy. Neil A. O’Brien,1 Dylan Conklin,1
Tong Luo,1 Raul Ayala,1 Shawnt Issakhanian,1Ondrej Kalous,1 ErikaVonEuw,1
Sara A. Hurvitz,1 Emmanuelle DiTomaso,2 Faye Su,2 Ronald Linnartz,3 Stefan
Scherer,2 SamitHirawat,2 Dennis J. Slamon1. 1UCLA, Los Angeles, CA; 2Novartis
Pharmaceuticals, Cambridge,MA; 3Novartis Pharmaceuticals, East Hanover, NJ.
The selective cyclin dependent kinases 4 and 6 (CDK-4/6) inhibitor, palboci-
clib, has recently been approved in combinationwith endocrine-based therapies
for the treatment of advanced ER/HER2- breast cancer (BC). Despite the
improvements in progression-free and overall survivals, a signifıcant number of
patients on CDK-4/6 therapy will go on to develop progressive disease. As such,
it is critical to identify the mechanisms by which tumor cells evade CDK-4/6
targeted therapy and to develop therapeutic strategies to overcome resistance. In
this study, we evaluated the effıcacy of a p110-selective PI3K inhibitor, alpelisib
(BYL719) and the mTORC1 specifıc inhibitor, everolimus (RAD001), in ER/
HER2- xenograft tumors conditioned in vitro and in vivo to acquire resistance to
combined palbociclib  endocrine-based therapy. The EFM19 (ER/HER2-,
PIK3CA mt), MDA134 (ER/HER2-, PIK3CA wt), and MDA361 (ER/
HER2, PIK3CA mt) BC cell lines were conditioned to acquire palbociclib
resistance through long-term culture in the presence of increasing concentra-
tions of drug. Baseline total/phosphoprotein levels of over 280 cancer-associated
analytes were measured in the parental and resistant cell lines by Reverse Phase
Protein Array (RPPA). In vivo resistantmodels were developed from xenografts
of the MCF7 and HCC1500 ER BC cell lines, treated until progression with
palbociclib (75 mg/kg)  fulvestrant (5 mg/mse). EFM19-PR cells maintained
palbociclib resistance in vivo and were included in the xenograft studies. Resis-
tance to palbociclib was confırmed in vitro by a shift in growth inhibitory IC50
from an average of less 50nM to over 1 M. Signifıcantly reduced Rb and ER
protein levels were detected in each of these palbociclib resistant cell lines by
RPPA. Cross-resistance to an alternative CDK-4/6 inhibitor (ribociclib) was
found in in vitro studies. In addition, switching treatment of the xenografts
progressing on palbociclib  fulvestrant to ribociclib (75mg/kg)  fulvestrant
did not impact tumor progression. However, when progressing tumors were
switched to BYL719 (30mg/kg) fulvestrant or RAD001 (10mg/kg) fulves-
trant, sustained tumor regression was observed for over 45 days of treatment in
every model tested. The triplet combination of ribociclib  fulvestrant 
BYL719 or RAD001 providedmarginal additional benefıt over the doublet com-
bination of BYL719 or RAD001 fulvestrant. RPPA analysis of xenograft tissue
collected from these studies will help to identify additionalmolecular alterations
involved in resistance to CDK-4/6 targeted therapy. These preclinical data indi-
cate that acquired resistance to CDK-4/6 inhibition occurs through a loss of
dependence on Rb-signaling. However, targeting an alternative pathway like
PI3K/mTOR with molecules such as BYL719 or RAD001 may be a viable strat-
egy for further clinical investigation.
#4151 Down regulation of ATP6V1B1 in HER2 breast cancer leads re-
sistance against trastuzumabmediated antibody dependent cellular cytotox-
icity and it might be associated with less effıcacy of trastuzumab clinically.
Mariko Nishie,1 Eiji Suzuki,1 Kosuke Kawaguchi,1 Ayane Yamaguchi,1 Moe
Tsuda,1 Takeshi Kotake,1 Masahiro Hirata,1 Fengling Pu,1 Keiko Sakamoto,1
Masakazu Hattori,1 Tomoharu Sugie,2 Masakazu Toi1. 1Kyoto Univ. Graduate
School of Medicine, Kyoto City, Japan; 2Kansai Medical University, Hirakata
City, Japan.
Among several resistant mechanisms of trastuzumab for HER2 breast can-
cer patients, little is clear on resistant mechanism of trastuzumab mediated
ADCC. In the current study, we investigated the role of Vacuolar-ATPase sub-
unit ATP6V1B1 on the resistantmechanism of trastuzumabmediated ADCC in
HER2 human breast cancer cell line SK-BR-3. To establish the trastuzumab
mediated ADCC resistant SK-BR-3, PBMCs are co-cultured with 1g/ml of
trastuzumab and SK-BR-3 for 4 hours. We removed CD45 positive PBMC by
usingMACS separation systemandobtainedADCCresistant SK-BR-3.Afterwe
expanded the resistant cells and repeated these processes several times, we es-
tablished the ADCC resistant SK-BR-3. The cytotoxicity of ADCC resistant
SK-BR-3, which was evaluated by LDH assay, was signifıcantly reduced as com-
pared with that of normal SK-BR-3 (38.7% and 67.4%, respectively). To sort
candidate genes for the resistance, we analyzed the gene expression profıle of
ADCC resistant SK-BR-3 by using DNA microarray and we focused on
ATP6V1B1 gene that was signifıcantly reduced on the resistant cells. We inves-
tigated ATP6V1B1mRNA level of SK-BR-3 and resistant cell by using real time
PCR and found the 50% reduction of ATP6V1B1 mRNA level in ADCC resis-
tant cells. To evaluate the role of ATP6V1B1 on the trastuzumab mediated
ADCC resistant mechanism, we established ATP6V1B1 knockout SKBR3 by
using CRISPR/Cas9 system. We cultured from small numbers of the knock out
cells and expand to obtain completely knock out cells. We confırmed that the
ATP6V1B1 knockout cell line was knocked out by western blotting and immu-
nohistochemistry. We found that ATP6V1B1-knockout SK-BR-3 were signifı-
cantly less ADCC activity as compared to control SK-BR-3(67.4% and 21.2%,
respectively). Furthermore, as the same as the result of ADCC activity, we found
that ATP6V1B1-knockout SK-BR-3 was less AICC (antibody-independent cel-
lular cytotoxicity) activity as compared to control SK-BR-3(41.2% and 12.5%,
respectively). Based on the in vitro fındings, we evaluated the role of ATP6V1B1
expression in HER2 positive breast cancer patients who are treated with neoad-
juvant chemotherapy (NAC) containing trastuzumab. Biopsy samples before
NACwere stained with ATP6V1B1 immunohistochemically. Four pathological
complete response (pCR) cases after NAC and 4 non pCR cases were included.
We found that non pCR cases showed signifıcantly week expression of the
ATP6V1B1 protein as compared to that of pCR cases. ATP6V1B1 gene is one of
the isoforms of the Vacuolar (V)-ATPase which is located in intracellular mem-
brane that regulate the cytosolic pH and membrane traffıcking. It is hypothe-
sized that ATP6V1B1 is involved in somewhere through the process of cytotox-
icity mediated by perforin and granzymes and now we are trying to explore the
mechanisms further.
#4152 The p90RSK-CDC25C signaling pathway leads to bypass of the
ganetespib induced G2/M arrest and mediates acquired resistance to
ganetespib in KRAS mutant NSCLC. Suman Chatterjee, Eric H. Huang, Ian
Christie, Timothy F. Burns. Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA.
Lung cancer is the leading cause of cancer death in the United States and
worldwide. A large fraction of non-small cell lung cancers (NSCLC) are depen-
dent upon oncogenic driver mutations of which the most commonly observed
driver is mutant KRAS. Unfortunately, NSCLC patients with oncogenic KRAS
mutations have no effective therapies and prognosis is poor. As direct RAS
targeting has been unsuccessful in the clinic to date, use ofHeat shock protein 90
(Hsp90) inhibitors inKRASmutantNSCLC appeared to be promising approach
for targeting KRASmutantNSCLC through its downstream effectors. However,
limited clinical effıcacy as monotherapy was observed due to rapid resistance.
Furthermore, the combination of ganetespib and docetaxel was recently tested
in a large phase III clinical trial (Galaxy-2) in advanced lung cancer and failed to
demonstrate benefıt. Here, we investigated themechanism(s) of resistance to the
Hsp90 inhibitor (Hsp90i), ganetespib by generating NSCLC cells with acquired
resistance to Hsp90i’s including ganetespib (GR cells). We have not only iden-
tifıed the mechanism of acquired resistance to ganetespib but have also found
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that thismechanism induces cross resistance to docetaxel. Finally, we have iden-
tifıed novel Hsp90i combinations that can overcome and prevent this resistance.
We report that hyperactivation of ERK and p90RSK and its downstream target,
CDC25C leads to acquired resistance to ganetespib and docetaxel. Moreover,
this resistance is mediated via bypass of a G2/M arrest. Overexpression of either
p90RSK or CDC25C in naïve cells was suffıcient to induce the bypass of this
G2/M arrest as well induced resistance to both ganetespib and docetaxel. Re-
markably, p90RSK or CDC25C overexpression also led to ganetespib resistance
in vivo. The observed resistancewas dependent on continued p90RSK/CDC25C
signaling, as synthetic lethality to specifıc ERK, p90RSK or CDC25C inhibitors
was observed. Importantly, we have found that the combination of ganetespib
with inhibitors of ERK1/2, p90RSK, or CDC25C was highly effıcacious. In sum-
mary, we propose that the hyperactivation of p90RSK induces CDC25C overex-
pression and activity which then induces G2/M progression via CyclinB1/cdc2
regulation resulting in ganetespib resistance. Despite two decades of testing in
the clinic, either as monotherapy or in combination with chemotherapy, Hsp90
inhibitors have been ineffective due to acquired resistance. Our preclinical anal-
yses provide a way forward for Hsp90 inhibitors through the development of
novel rationally designed Hsp90 inhibitor combinations that may prevent or
overcome resistance to Hsp90 inhibitors.
#4153 CRISPR/Cas9-based oncogene editing enables characterization of
rare mutations in cancer cells. Dennis Plenker, Martin L. Sos. University Hos-
pital Cologne, Cologne, Germany.
In the past decade new insights into key oncogenic pathways and the devel-
opment of targeted therapies enabled the success of precision medicine. How-
ever, only a small part of the cancer genome can be targeted effectively. This is in
part due to the fact that the number of cancer cell models for a given oncogenic
mutation is limited. We hypothesized that CRISPR/Cas9-mediated genome ed-
iting may enhance the ability to functionally study rare genomic lesions or re-
sistancemutations that arise in patients under therapy. As a proof of concept we
established, genetically modifıed PC9 lung cancer cells that harbor an activating
EGFR ex19 deletion (EGFRdel E746-A750) into double mutated (EGFRdel E746-
A750T790M) or triple mutated (EGFRdel E746-A750T790MC797S) EGFR in order
to induce resistance against known EGFR inhibitors. These cell lines fully reca-
pitulated the phenotypic response pattern to fırst and third generation EGFR
inhibitors that have been observed in patients harboring these clinically relevant
resistance mutations. In a next step we switched the dependency of PC9 cells
from the intrinsic oncogenic EGFR mutation into a rare ex20 SVDins mutation
(EGFRD770_N771insSVD) that is typically associated with resistance towards all
known EGFR inhibitors. Again, we observed a shift in the response to targeted
inhibition of EGFR when compared to parental cells. Since the methodological
principles can be applied to an array on known oncogenic mutations our ap-
proach may serve as a versatile platform for the functional study of oncogenic
mutations that are found in patients.We envision that such reprogrammed cells
may be of use for the screening of novel targeted therapeutics and thereforemay
enable the development of mutation specifıc drugs that are currently lacking for
the majority of patients.
#4154 Resistance to BET inhibitors involves the -catenin pathway in
uveal melanoma. Grazia Ambrosini, Benjamin Tycko, Chaterine Do, Gary K.
Schwartz. Columbia University, New York, NY.
Uveal melanoma (UM) is an aggressive intraocular malignancy with high
tendency to metastasize to the liver. Currently available drugs have shown lim-
ited clinical activity in patients with UM and there is an urgent need for new
effective therapies. Recent fındings from our laboratory demonstrated that UM
cells are sensitive to BET inhibitors (BETi) through the induction of cell cycle
arrest and apoptosis. However, despite the initial inhibitory effects, UM cells
acquire resistance to this class of drugs following chronic drug exposure. In
order to understand the mechanistic basis for BETi resistance in UM, we as-
sessed genome-wide CpG methylation patterns in UM cell lines that had been
rendered resistant to the clinical BET inhibitor PLX51107 (Plexxikon, Berkeley,
CA) following chronic drug exposure. The comparison between BET inhibitor-
resistant versus sensitive cell lines revealed differential methylation of 1700
genes, including several involved in Wnt/-catenin signaling, as well as other
signaling pathways. Immunoblotting analysis confırmed that -catenin protein
was induced and activated in the resistant cells, while depletion of -catenin by
siRNA re-sensitized the resistant cells to the BET inhibitor. We then explored
several combinations of PLX51107 with drugs that block -catenin transcrip-
tional activity through inhibition of its phosphorylation by PAK4 or through the
inhibition of binding partners like Cdk8 and CBP. All these combinations in-
creased the activity of the BET inhibitor in both sensitive and resistant cells, and
these effects were synergistic, with combination indexes (CI)1. These obser-
vations support the evidence that acquired resistant to BET inhibitors is medi-
ated, at least in part, by activation of theWnt/-catenin pathway, and inhibitors
of this pathwaymay provide ameans to overcome acquired BET inhibitor resis-
tance in UM patients treated with this class of drugs.
#4155 Crosstalk of SOX2 and epithelial-to-mesenchymal transition on
EGFR-TKI resistance. An-Chun Lee,1 Yu-Fan Chiu,1 Ming-Han Kuo,1 Yuan-
Hung Wang,2 Yu-Ting Chou1. 1National Tsing Hua University, HsinChu, Tai-
wan; 2Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.
EGFR-tyrosine kinase inhibitors (TKIs) have been shown to produce profound
therapeutic responses in lung adenocarcinomaharboringEGFRmutations.Despite
this initial response, patients with EGFR-mutated lung adenocarcinoma ultimately
developed resistance toEGFR-TKIs.Althoughboth SOX2and epithelial-to-mesen-
chymal (EMT) have been linked to the EGFR-TKI resistance in lung adenocarci-
noma, the interplaybetweenSOX2andEMTinEGFR-TKI resistance is not known.
Here, we report that cancer plasticity switched by SOX2 and EMT regulates EGFR-
TKI resistance. We found that the selection of EGFR-TKI resistant cells induced
EMT while attenuating SOX2 expression. We observed that EGFR-TKI treatment
induced SOX2 expression in EGFR-mutated lung cancer cells, and SOX2 silencing
encouraged EGFR-TKI resistance. Preselection of EGFR-mutated lung cancer cells
with the EMT feature endowed cells with EGFR-TKI resistance but suppressed
SOX2 expression. We found that TGF- induced EMT but attenuated SOX2 ex-
pression, resulting in increased EGFR-TKI resistance. Pharmacological inhibition
of HDACs in EGFR-mutated cells attenuated SOX2 expression but induced EMT,
causing increased EGFR-TKI resistance. Enriching SOX2 expression in EGFR-mu-
tated cells attenuated EMT and rendered cells more sensitive to EGFR-TKIs. Cor-
relationanalysis exhibitednegativecorrelationsbetweenSOX2andEMTmarkers in
primary non-small cell lung cancer. Kaplan-Meier analysis revealed that a SOX2
low/Vimentin high signature predicted a poor survival in EGFR-mutated lung ad-
enocarcinoma. Our fındings support the notion that the cancer plasticity regulated
by SOX2 and EMT plays a critical role in EGFR-TKI resistance, and SOX2 and
Vimentin can function as prognostic biomarkers in lung cancer progression.
#4156 Molecular and phenotypic characterization of breast and colorectal
cancer cells selected for resistance to antibody-dependent cell-mediated cy-
totoxicity (ADCC). Tanuka Biswas,1 Rebecca Fritzemeier,2 Adam Mark,3 To-
bias Meißner,3 Brandon Young,3 Brian-Leyland Jones,4 Mark Pegram1. 1Stan-
ford Univ. School of Medicine, Stanford, CA; 2University of Washington, Seattle,
WA; 3Avera Cancer Institute, La Jolla, CA; 4Avera Medical Group Precision On-
cology Sioux Falls, San Diego, CA.
Monoclonal antibody (mAb) therapy is limited by clinical resistance. For exam-
ple, alterations in PI3K/Akt /Ras-MAPK signaling, over activation/expression of
alternate receptor kinases (c-Met/ IGF-1R), or proteolysis of extracellular domains
harboring target epitopes are postulatedmechanisms of clinical resistance to trastu-
zumab.ADCCis amajormechanismof action formAbs.Most studies have focused
on cell models of resistance through in vitro selection, in presence of mAbs, in the
absence of immune effector cells. We developed a unique model of immune selec-
tion, where target cells (HER2 ve breast cancer cells SKBR3, BT474; and EGFR
ve colon cancer cells HT29, DLD1) were subjected to ADCC (90% cell death)
with saturating concentrations of trastuzumab or cetuximab (100 g/ml), respec-
tively, and human peripheral bloodmononuclear cells (PBMCs). Selection (in trip-
licate)was continued for 10 consecutivepassages and surviving cellswere allowed to
grow to confluence over a period of 8-10 weeks. Mock-treated parent cells, IgG1
isotypecontrol,mAb-aloneandPBMCsonlywereutilizedas controls.Compared to
parent controls, immune-selectedDLD1andSKBR3cells demonstrated statistically
signifıcant increase inproliferation (WSTviability assays,P0.01), andsignifıcantly
higher colony forming effıciency (soft agar assays, P0.001); immune-selected
HT29 and SKBR3 cells showed signifıcantly higher motility (trans-well migration
assays, P0.05, and P0.001 respectively). In vitro ADCC assays (calcein labeling)
suggested signifıcant reduction (max 20%, p0.005) in cell lysis in all the immune-
selected cell lines compared to parent. Immune-selectedHT29 cells demonstrated a
5-fold reduction ingene copynumberofEGFRby fluorescence in situhybridization
(FISH, p0.0001), 2-fold reduction in mRNA levels (qPCR, p 0.01) and 1.8-fold
reduction in protein levels of EGFR (densitometry scans, western blot analyses,
p0.01).Transcriptome-widenext-generationRNAsequencing (IlluminaNextSeq
500, 2 x 75 bp paired-end, with over 100million paired-end reads/sample), coupled
with bioinformatic analyses (Reactomepathwaydatabase) revealed gene expression
changes in ADCC-selected cells. These involve changes in key immune signaling
pathways such as class I/IIMHCantigen processing, cell chemotaxis, inflammatory
and immune regulatory pathways among others. Our data indicate immune-selec-
tion by effector cells contributes to ADCC resistance in vitro. Further investigation
will determinewhethermAb combinationwith an agonist antibody against CD137
(co-stimulatory NK cell receptor) or Fc-engineered MAbs (e.g. afucosylated) will
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sensitize the resistant cells. It is hoped that this investigationwill better informmAb
therapy by elucidating potentially targetable pathways/ markers that emerge from
immune-selection with therapeutic mAbs.
#4157 Co-blockade of mTORC1, ERBB and estrogen receptor signalling
pathways in endocrine resistance breast cancer: Combating tumor plasticity.
Ricardo Ribas,1 Sunil Pancholi,1 Stephanie K. Guest,1 Aradhana Rani,1 Joanna
Nikitorowicz-Buniak,1 Nikiana Simigdala,1 Allan Thornhill,2 Richard E. Cutler
Jr,3 Alshad S. Lalani,3 Francesca Avogadri-Connors,3 Mitch Dowsett,4 Stephen
R. Johnston,4 Lesley-Ann Martin1. 1Breast Cancer Now Toby Robins Research
Centre, Institute of Cancer Research, London, United Kingdom; 2Centre for Can-
cer Research, Institute of Cancer Research, London, United Kingdom; 3Puma
Biotechnology inc, CA; 4Royal Marsden Hospital, London, United Kingdom.
Introduction: The majority of breast cancers (BC) are estrogen (E) receptor
positive (ER). Endocrine therapies target E stimulation of tumour growth but
resistance remains problematic, often a result of enhanced crosstalk between ER
and growth factor pathways. Previously we reported the antiproliferative effı-
cacy of combining everolimus (RAD001, mTORC1 inhibitor) with endocrine
therapy in resistance models, but potential routes of escape from treatment via
ERBB2/3 signalling were observed.We hypothesised that combined targeting of
three cellular nodes (ER, ERBB andmTORC1) may target tumour rewiring and
provide enhanced long-termclinical utility in endocrine resistant BCs.Methods:
Several ER BC lines adapted to long term E deprivation (LTED), modelling
relapse to an aromatase inhibitor (AI), were treated in vitro with a combination
of RAD001 and neratinib (pan ERBB inhibitor) in the presence or absence of
estradiol (E2), tamoxifen or fulvestrant. Effects on proliferation, cell signalling,
cell cycle and transcription were assessed. Additionally, an in vivo model of AI
resistance was treated with monotherapies or combinations to evaluate effıcacy
in delaying tumour progression. Results All cell lines showed dose dependent
decreases in proliferation in response to RAD001 (IC50 0.6-50nM without E2;
1-10nM with E2). Neratinib showed a wide range of IC50 values in the presence
of E2 (300-1000nM). In the absence of E2, wild type (wt) cell lines showed IC50
values in excess of 1800nM with hormetic response curves, whilst in the LTED
IC50 values ranged between 400-900nM. Combination of either agent with en-
docrine therapy caused a concentration dependent decrease in proliferation in
both wt and LTED lines but the maximum effect was observed with a triple
combination of RAD001, neratinib and endocrine therapy. Expression of pS6
was suppressed by RAD001 in all cells tested, whilst neratinib caused a cell
specifıc reduction in expression of ERBB family proteins. Upregulation of pAKT
was observed in all cell lines upon treatment with RAD001. Combination of
RAD001 with neratinib suppressed the upregulation of pAKT and reduced cell
cycle progression. In the absence of E2, RAD001 reduced ER mediated tran-
scription and recruitment of ER and CREB binding protein to the TFF1 pro-
moter, contrastingwith neratinib,which caused amarked increase. In vivo study
using LTED tumour xenografts showed the triple combination of RAD001, ne-
ratinib and fulvestrant was the most effective at reducing tumour volume (89%,
p0.001). Antitumor effects persisted after therapy removal with exception of
RAD001 alone or in combination with neratinib where a slow increase in tu-
mour growth was observed. Conclusion: The combination of RAD001, nera-
tinib and endocrine agents may be effective in patients who have relapsed on
endocrine therapy but retain a functional ER by combating ERBB pathway up-
regulation.
#4158 Targeting the imatinib-resistant BCR-ABL T315I mutation in
chronic myeloid leukemia through a novel BCR-ABL inhibitor. Pranav
Gupta,1 Rishil Kathawala,1 Liuya Wei,2 Fang Wang,3 XiaoKun Wang,3 Brian J.
Druker,4 Li-Wu FU,3 Zhe-Sheng Chen1. 1St. John’s University, Fresh Meadows,
NY; 2Weifang Medical University, China; 3Sun Yat Sen University, China; 4Ore-
gon Health and Science University, OR.
Chronic Myeloid Leukemia (CML), a hematological malignancy, is largely
caused by the Philadelphia (Ph) chromosome carrying the Break point Cluster
Region-Abelson (BCR-ABL) oncogene. Imatinib is a BCR-ABL-targeted ther-
apy and considered the standard of care in CML management. Resistance to
imatinib therapy often develops because of mutations in the BCR-ABL kinase
domain. In this study, we evaluated PBA2, a novel BCR-ABL inhibitor, for its
anti-cancer activity against BCR-ABL expressing BaF3 cells. PBA2 shows potent
activity against wild-type and T315I mutated BaF3 cells as compared with ima-
tinib. PBA2 inhibited the phosphorylation of BCR-ABL and its downstream
signaling in BaF3/WT and BaF3/T315I cells. PBA2 inhibited themRNA expres-
sion of BCR-ABL in BaF3/WT and BaF3/T315I cells. Mechanistically, PBA2
increased the cell population in subG1 phase of the cell cycle, induced apoptosis
and elevated ROS production in both BaF3/WT and BaF3/T315I cells. Taken
together, our results indicate that PBA2 exhibits anti-proliferative effects and
inhibits the imatinib-resistant T315I BCR-ABLmutation. PBA2may be a novel
drug candidate for overcoming the resistance to imatinib in CML patients.
#4159 In vitro drug response (IVDR) and tumor-associated biomarker
(BM) expression profıles in lung carcinoma (LC).Ricardo J. Parker,1 PatricM.
Schiltz,1 Michael P. Myers2. 1National Univ., Costa Mesa, Costa Mesa, CA; 2Na-
tional Univ., Kearney Mesa, Kearney Mesa, CA.
Assessing IVDR to Chemo and BM expression in tumors of patients (Pts)
before treatment can stratify therapy and improve outcome. Historical IVDR
and BMdata were analyzed retrospectively on 582 human LC specimens includ-
ing 311 adenocarcinomas (ADCA), 131 non-small cell lung carcinomas
(NSCLC), and 140 squamous cell carcinomas (SQCC) resected from Pts diag-
nosedwith primary (PD), recurrent (RD) ormetastatic disease (MD), and tested
at a single clinical reference lab between March 2004 and July 2006. Pt and
specimen information were unlinked directly and anonymized. IVDR was de-
termined in prepared aliquots of Pts’ viable tumor cell suspensions after 5-day
exposures to single physiologic doses of Chemo (CARBO, CPLAT, GMCB,
NVBL, TAXOL, TXTR, VP16, TOPO). IVDRwas bifurcated into extreme resis-
tance (ER, non-response) or low resistance (LR, response). Standard immuno-
histochemistry (IHC) was performed on the same Pts’ paraffın-embedded LC
sections to detect BMsmutant-p53 (mp53; n322), EGFR (n250), and BCL-2
(n270), and results showed 57% overexpressed mp53, 91% overexpressed
EGFR, and 32% expressed BCL-2. IVDR profıles for ADAC and NSCLC were
similar, while SQCCwas comparatively less resistant. IVDR profıles for PD, RD
andMD of a given histology were relatively dissimilar. In ADCA, RD was more
resistant than PD and MD. In NSCLC and SQCC, MD was more resistant.
Signifıcant portions of LCs showed prevalent ER to CARBO, TAXOL, TXTR,
and VP16; and cross resistance to combinations, suggesting no clinical benefıt
from toxic ineffective Chemo. In such settings, disease progression may nega-
tively impact a Pt’s tolerance to further Chemo. Pre-assessment of IVDR and
BMsmay identify ER factors, stratify treatment, and potentially improve clinical
outcomes.
#4160 Impact of oral selective estrogen receptor degrader RAD1901 in
preclinical models of endocrine sensitive/resistant breast cancer. Sunil Pan-
choli,1 JoannaNikitorowicz-Buniak,1 RicardoRibas,1Nikiana Simigdala,1 Fiona
Garner,2 Teeru Bihani,2 Stephen R. Johnston,3 Mitch Dowsett,3 Lesley-Ann
Martin1. 1Breast Cancer Now Toby Robins Research Centre, Institute of Cancer
Research, London, United Kingdom; 2Radius Health Inc, London, MA; 3Royal
Marsden Hospital, London, United Kingdom.
Aromatase inhibitors (AI) are the mainstay for treatment of postmenopausal
estrogen receptor positive (ER) primary breast cancer (BC). However, many
patients relapse whilst retaining a functional ER. The selective ER degrader
(SERD) fulvestrant has been evaluated as a potential 2nd or 3rd line therapy for
patients who relapse on AI treatment. Although exhibiting promising potential,
its low bioavailability has limited its use to combination therapy in metastatic
patients. Here, we assessed the effıcacy of the orally available SERD, RAD1901,
in a panel of BC cells with varying genetic backgrounds modelling patients both
sensitive and resistant to AI therapy (LTED). Fulvestrant was used in parallel to
allow relative responses to be compared. Cell proliferation assays in 2D and
spheroids the presence of 0.01nM17-estradiol showed a concentration-depen-
dent decrease in proliferation in response to RAD1901 and fulvestrant. GI50
values for RAD1901 in general were 10-fold higher than fulvestrant but equated
to doses that are clinically achievable for RAD1901. Most importantly,
RAD1901 effectively suppressed proliferation of two LTED models harbouring
naturally occurring ESR1 mutations, MCF7 LTEDY537C (GI50 5nM) and
SUM44-LTEDY537S (GI50 100nM). GI50 values of RAD1901 and fulvestrant
showed similar reduction of ER, progesterone receptor (PGR) and cyclin D1
together with decreased phosphorylation of retinoblastoma (RB), concordant
with cell cycle arrest. Furthermore, chromatin immunoprecipitation (ChIP) for
ER in response to RAD1901 or fulvestrant showed a 70% reduction in recruit-
ment of ER to TFF1, GREB1 and PGR promoters and concomitant reduction in
mRNA expression of these genes. In MCF7-Arom cells, combination of letro-
zole with RAD1901 or fulvestrant showed enhanced antiproliferative effect
compared to letrozole alone. The addition of RAD1901 to CDK4/6 inhibitor
palbociclib or abemaciclib demonstrated additivity compared with mono-
therapy. In addition, RAD1901 effectively inhibited growth of palbociclib-resis-
tant MCF7 LTED cells.These preclinical fındings highlight the potential utility
of RAD1901 as a potent drug in the treatment of ER BC. Combined with its
bioavailability profıle, RAD1901warrants clinical testing versus fulvestrant after
relapse on an AI, either alone or in combination with a CDK4/6 inhibitor.
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#4161 Increased expression of ABCB1 could be associated with
osimertinib resistance in non-small cell lung cancer cell line PC9 cell.Takashi
Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Tomoko Funazo, Hi-
ronori Yoshida, Yuichi Sakamori, Hiroki Nagai, Young Hak Kim. Kyoto Uni-
versity, Kyoto, Japan.
Osimertinib, a third-generation EGFR Tyrosine kinase inhibitor, has shown
promising activity in EGFR mutation positive non-small cell lung cancer
(NSCLC) which harboring T790M mutation. The mechanisms of resistance to
osimertinib have been still unclear. To investigate the mechanisms of acquired
resistance to osimertinib, we established the osimertinib-resistant cell line (PC9/
osimertinib) from theNSCLC cell lines PC9, andmeasured the expression levels
of ATP-binding cassette (ABC) transporters using quantitative real-time poly-
merase chain reaction. Expression profıling of ABC transporters revealed that
the levels of ABCB1 gene expression were signifıcantly increased in the PC9/
osimertinib cells comparedwith the parental cells, but not other ABC transport-
ers. Knockdown of ABCB1 expression using short hairpin RNA enhanced
osimertinib cytotoxicity in PC9/osimertinib cells. These data suggest that in-
creased expression of ABCB1 may have an important role in the acquired resis-
tance to osimertinib.
#4162 Activation of aryl hydrocarbon receptor leads to resistance to tar-
geted therapy through contextual phosphorylation of Src by Jak2 kinase.
Mingxiang Ye, Jian Zhang. Xijing Hospital, Fourth Military Medical University,
Xi’an, China.
The discovery of epidermal growth factor receptor (EGFR) activating muta-
tion, anaplastic lymphoma kinase (ALK) and ROS1 kinase rearrangement serve
as predictive biomarkers for clinical response in non-small cell lung cancer
(NSCLC) patients who receiving tyrosine kinase inhibitors (TKIs). Unfortu-
nately, resistance to TKIs inevitably occurs within years of treatment. The emer-
gence of resistance mutations and bypass receptor tyrosine kinase tracks have
been implicated in targeted therapy resistance, however, a large proportion of
patients who relapsed on TKIs do not harbor resistance mutations or additional
receptor tyrosine kinase tracks. The aryl hydrocarbon receptor (AhR) is gener-
ally recognized as a transcriptional factorwhich encodesmetabolic enzymes and
mediates biochemical response to environmental xenobiotic pollutants. How-
ever, the association of AhR and sensitivity to targeted therapy has not been
reported and the molecular mechanism of resistance to targeted therapy re-
mains to be elucidated. By analyzing TCGA database and immunohistochemis-
try staining of relapsed biopsy samples, we identifıed that dysregulation of AhR
conferred resistance to TKIs. qPCR and Western blot screening of a panel of
NSCLC cell lines suggested that the AhRlow cells were sensitive to EGFR TKIs,
whereas the AhRhigh cells did not. Simultaneously inhibition of AhR and EGFR
signaling restored the sensitivity to EGFR TKIs in the AhRhigh cells. Moreover,
overexpression of AhR also led to resistance toALK andROS1TKIs by restoring
phosphorylation of Akt and Erk. Measurement of endogenous AhR ligand con-
tent by high performance liquid chromatography (HPLC) indicated that the
patients had more kynurenine (Kyn) in their serum after disease relapse and
progression. The AhR-associated targeted therapy resistance did not require its
transcriptional activity because the AhR
NLS truncated mutant also drives re-
sistance. By using large scale shRNAs screening, we showed that the non-recep-
tor tyrosine kinase Src phosphorylated Akt and Erk and mediates AhR-associ-
ated targeted therapy resistance. Bioinformatics analysis and
immunoprecipitation assay showed that Src immediately underwent phosphor-
ylationuponAhR ligands treatment through interactingwith the SH2domain of
AhR. The phospho-protein kinase array and in vitro kinase assay revealed that
Jak2 kinase directly phosphorylated Src, in which the liganded AhR provided
docking sites for Jak2 and Src interaction. Collectively, our study revealed an
uncovered, transcription-independent function of AhR. The liganded AhR re-
cruits Src and provides docking sites for Jak2-Src interaction, in which the phos-
phorylated Src acts as a resistance bypass track. Kyn content might be a bio-
marker to predict resistance to targeted therapy and targeting AhR helps to
overcome resistance.
#4163 Blockade of the interleukin-1 signaling pathway overcomes erlo-
tinib resistance in head and neck cancer cells. Andrean L. Simons, Aditya
Stanam, Katherine N. Gibson-Corley. University of Iowa, Iowa City, IA.
The EGFR tyrosine kinase inhibitor erlotinib has demonstrated poor clinical
response rates for head andneck squamous cell carcinoma (HNSCC) to date and
the majority of respondents acquire resistance to erlotinib relatively quickly.
Our previous data has shown that erlotinib activated interleukin-1 (IL-1) ex-
pression and signaling in HNSCC cells in vitro. We therefore investigated if
upregulation of IL-1 signaling is involved in erlotinib resistance inHNSCC cells.
We compared gene expression profıles of erlotinib-resistant (ER) and the paren-
tal erlotinib-sensitive (ES) HNSCC cell lines and observed a deregulation of the
IL-1 signaling pathway in ER versus ES-HNSCC cells using microarray enrich-
ment analysis. Secretion of IL-1 alpha (IL-1) and IL-1 beta (IL-1) were not
signifıcantly different in ER-SQ20B and ER-CAL 27 cells compared to their
respective ES-cells, however secretion of the IL-1 receptor antagonist (IL-1RA)
was signifıcantly reduced in ER-cells compared to ES-cells. Blockade of IL-1
signaling using a recombinant IL-1R antagonist (anakinra) was able to signifı-
cantly suppress the growth of ER-SQ20B but not ES-SQ20B xenografts as a
single agent and in combination with erlotinib. ER-SQ20B xenografts treated
with anakinra with or without erlotinib were found to be less vascularized (as
determined by CD31 staining) than ER-SQ20B xenografts treated with water or
erlotinib. Altogether, blockade of the IL-1 pathway using anakinra overcame
erlotinib resistance in HNSCC xenografts and may represent a novel strategy to
overcome EGFR inhibitor resistance for the treatment of HNSCC patients.
#4164 TRAIL resistance of glioblastoma cells is associated with DNA
damage signalling network. I´lknur Sur, Kerem Muslu, Ahmet Cingöz, Tuğba
Bağcı Önder. Koc University, I´stanbul, Turkey.
To reduce the risk of ageing associated dysfunctions and maintain the
genomic stability, cells need a complex DNA repair mechanisms. Defects in this
pathway or accumulation of DNA damage lead to genome instability, tumori-
genesis, and ageing. Chemotherapy and radiotherapy are designed to kill cancer
cells by inducing DNA damage and triggering cellular ageing. Surgery followed
by combined chemotherapy and radiotherapy is currently the standard therapy
for glioblastoma multiforme (GBM) which is the most common primary brain
tumor. TNF related apoptosis-inducing ligand (TRAIL) is promising anti-can-
cer agent for GBM therapy, as it induces apoptotic death in only cancerous cells,
but not in normal cells. However, themechanisms underlying TRAIL resistance
in GBM have remained elusive. To understand the role of DNA damage re-
sponse (DDR) mechanism and develop more effective therapeutic approaches,
TRAIL resistant and sensitive T98G cells were generated. The effect of DDR
proteins (H2AX (Ser319), ATM total, ATR total, CHK1 total, CHK2 total, ATM
(Ser1981), ATR (Ser428), CHK1 (Ser345), CHK2 (Ser19) and 53BP1) on TRAIL
resistance was detected in TRAIL resistant and sensitive T98G cells. These pro-
teins showed different level of protein expressions in TRAIL resistance and
sensitive T98G cells. Most remarkable difference was found in the level of phos-
phorylated kinaseCHK2 (Ser19)with higher expression level in TRAIL resistant
T98G cells than TRAIL sensitive T98G cells. Therapies that inhibit CHK2
(Ser19) levels in glioma may enhance the effıcacy of TRAIL treatment. In im-
munofluorescence analysis, increased number of H2AX foci was noted upon
TRAIL treatment. These fındings demonstrate that DNA damage signalling
pathways contribute to TRAIL resistance and targeted inhibition of DNA repair
factors can provide themost effective therapeutic strategies to overcome TRAIL
resistance of GBMs. Moreover, the information from this study may hold an-
swers for cancer research in future and serve as a potential suppressor for the
treatment of cancer.
#4165 SOX2 promotes lineage plasticity and antiandrogen resistance in
TP53 and RB1 defıcient prostate cancer. Ping Mu,1 Zeda Zhang,1 Matteo
Benelli,2WouterKarthaus,1 ElizebethHoover,1 Chi-ChaoChen,1 JohnWongvi-
pat,1 Sheng-Yu Ku,3 Dong Gao,1 Zhen Cao,1 Neel Shah,1 Elizabeth Adams,1
Wassim Abida,1 Philip Watson,1 Davide Prandi,2 Chun-Hao Huang,1 Elisa de
Stanchina,1 Scott Lowe,1 Leigh Ellis,3 Himisha Beltran,4 Mark Rubin,4 David
Goodrich,3 Francesca Demichelis,2 Charles L. Sawyers1. 1Memorial Sloan Ket-
tering Cancer Center, New York, NY; 2University of Trento, Trento, Italy; 3Ro-
swell Park Cancer Institute, Buffalo, NY; 4Weill Cornell Medicine, New York, NY.
Some cancers evade targeted therapies through a mechanism known as lin-
eage plasticity, whereby tumor cells acquire phenotypic characteristics of a cell
lineage whose survival no longer depends on the drug target. Here we show,
using in vitro and in vivo prostate cancer models, that these tumors can develop
resistance to the antiandrogen drug enzalutamide by a phenotypic shift from
androgen receptor (AR) dependent luminal epithelial cells to AR independent
basal-like cells. This lineage plasticity is enabled by loss of TP53 and RB1 func-
tion, is mediated by increased expression of the reprogramming transcription
factor SOX2 and can be reversed by restoring TP53 and RB1 function or by
inhibiting SOX2 expression. Thus, mutations in tumor suppressor genes can
create a state of increased cellular plasticity that, when challenged with antian-
drogen therapy, promotes resistance through lineage switching.
#4166 Role of CD44 as a regulator of adaptive plasticity in pancreatic
cancer cells. Chen Chen, Shujie Zhao, Xiangru Zhao, James W. Freeman. Uni-
versity of Texas Health Science Center, San Antonio, TX.
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Purpose: Patients with pancreatic ductal adenocarcinoma (PDAC)may show
an initial objective response to chemotherapy that is usually of short duration.
Our research goal is to understand the molecular mechanisms for this short
duration response and to more fully defıne differences between chemosensitive
and chemoresistant cells. Cancer cells that undergo an EMT and metastatic
tumors show an increase in CD44s expression. In this study, we use CD44 Low
and CD44 High isogenic cell models to identifying key molecular networks and
potential targets that could benefıt therapy. Experiments design: CFPAC1-
CD44Hi and Low cells were sorted by flowcytometry and single clone selection.
Isogenic model systems were generated by overexpression CD44s in CF-Low
cells. Western blot, MTT, migration and invasion assays had been used to char-
acterize cell growth, invasiveness and gemcitabine sensitivity. Receptor Ty-
rosine Kinase arrays were used to identify the CD44 regulated molecular net-
works in these isogenic cell models treated with/without CD44 ligand
hyaluronan acid (HA). Summary: CD44s high cells show an EMT phenotype
(increase of vimentin and loss of E-cadherin) and increase invasion. Expression
of CD44s in CD44 low cells was suffıcient to drive EMT partially and drive
invasion. By in vitro testing over expressing CD44s is not suffıcient to decrease
sensitivity to gemcitabine. By Receptor Tyrosine Kinase arrays, CD44 Hi clone
cells show increase in IGF-1R phosphorylation. Preliminary data had shown
that HA may stimulate ROR2, VEGFR1, and EphB2 phosphorylation in CD44
Hi clone cells. Conclusion: Our previous study suggested that CD44 could be a
therapeutic target in Gemcitabine resistant PDAC cells. The current study will
further identify the molecular targets that regulated by CD44 pathways. These
newly identifıed targets could be hopefully used for the optimizedmultimodality
therapy to sensitize the PDAC cells to therapy and to benefıt the pancreatic
cancer patients.
#4167 Co-targeting the stress survival proteins LEDGF/p75 and clusterin
to resensitize chemoresistant prostate cancer cells to docetaxel. Christina K.
Cajigas-DuRoss, Leslimar Rios-Colon, LeanneWoods-Burnham, Carlos A. Ca-
siano. Loma Linda University School of Medicine, Loma Linda, CA.
Prostate cancer (PCa) is the most commonly diagnosed male cancer and the
second leading cause of cancer deaths in U.S. men. Late-stage PCa is character-
ized by metastasis followed by castration resistant PCa (mCRPC), for which
there is no cure. Docetaxel (DTX) is the fırst-line chemotherapeutic drug for
late-stage PCa, and resistance to this drug is inevitable.Our grouphas previously
reported the elevated expression of the stress oncoprotein lens epithelium-de-
rived growth factor (LEDGF/p75) in PCa cells and tissues, and this upregulation
promotes resistance to DTX-induced non-apoptotic lysosomal cell death. An-
other stress oncoprotein, clusterin (CLU), is also upregulated in DTX-resistant
PCa, and protects cells from DTX-induced mitochondrial-triggered apoptosis.
In this study we observed that targeting LEDGF/75 with siRNAs partially resen-
sitized DTX-resistant (DR) mCRPC cell lines to DTX treatment in clonogenic
assays. Similarly, other groups have shown that knockdown of CLU in
mCRPC-DR cells resensitizes them to treatment with taxanes. However, recent
clinical trials targetingCLUhave not been effective, suggesting that blocking this
protein alone is insuffıcient to overcome DTX resistance. We hypothesized that
simultaneous knockdown or inhibition of both LEDGF/p75 and CLU could be
more effective in resensitizing chemoresisant PCa cells to taxane therapy than
targeting each protein alone. Because of LEDGF/p75’s role as a stress transcrip-
tion co-activator, we fırst sought to determine if this protein contributes to CLU
expression by performing siRNA-mediated knockdown of LEDGF/p75 on the
taxane-sensitive and -resistantmCRPCcell lines PC3 andDU145.Western blot-
ting revealed that CLU protein expression was not downregulated by LEDGF/
p75 knockdown, compared to treatment with scrambled siRNA control. Simi-
larly, CLU knockdown in these cell lines did not downregulate LEDGF/p75.
These results indicated that CLU expression is independent of LEDGF/p75,
consistent with previous observations that these two proteins promote
chemoresistance via distinct, possibly redundant, mechanisms. We then per-
formed siRNA-mediated knockdown of LEDGF/p75 and CLU, separately or
together, in PC3DR andDU145DR cells, in the presence and absence of varying
concentrations of DTX.MTT and clonogenic assays were used to determine cell
death viability and clonogenicity, respectively. Simultaneous knockdown of
LEDGF/p75 and CLU, in combination with DTX treatment, resulted in in-
creased sensitization to DTX than single knockdown of each protein. These
fındings suggest that co-targeting LEDGF/p75 and CLU could be an effective
strategy for ameliorating chemoresistance inmCRPC, and set the foundation for
combinatorial therapies targeting multiple stress pathways linked to taxane re-
sistance together with taxane chemotherapy for treatment of late-stage PCa.
#4168 Altering cisplatin sensitivity by manipulating the cellular metal-
lome. Lauren Amable, Eric Shide. NIH-NIMHD, Bethesda, MD.
The cellularmetallome serves as an important reservoir tomeet the biological
needs of the cell, serving as enzyme co-factors and ensuring proper protein
folding. Recent studies have suggested that cancer cells adapt their metallome in
order to accommodate rapid cellular growth and metabolism pathways. Thus,
altering the cancer metallome may yield new avenues to target cancer and
change the responsiveness to chemotherapy. Here, we aim to characterize and
understandhow changes in the ovarian cancermetallome affect sensitivity to the
chemotherapy drug cisplatin. Five ovarian cancer cell lines were used in exper-
iments: A2780, A2780/CP70, SKOV3, OVCAR3, and CAOV3. The metallome
wasmanipulated by treating cells with either zinc, copper, magnesium, calcium,
iron, manganese, or the metal chelator tetrathiomolybdate. Cisplatin sensitivity
after metal treatment was measured by WST-1 cell proliferation assays. Metal-
lomes were quantitated by Inductively Coupled Plasma-Mass Spectrometry
(ICP-MS) by measuring the following metals: zinc, copper, magnesium, cal-
cium, molybdenum, manganese, iron, phosphorous, and sulfur. Cellular metal
concentrations were normalized to sulfur levels. Changes in cisplatin sensitivity
were evaluated by measuring cellular cisplatin uptake by ICP-MS. Treatment of
ovarian cancer cells with various metals resulted in differences in cellular pro-
liferation and metallome composition. The changes in the metallome were not
singular in nature because altering one metal resulted in changes in multiple
metals. Cisplatin sensitivity was additionally affected under different metal
treatments. Preliminary data suggest that cisplatin uptakewas altered as amech-
anism to mediate the cellular response to cisplatin, however other mechanisms
such as DNA repair might also play a role. In conclusion, we demonstrate that
perturbations of the cancer metallome result in changes of various metals, cel-
lular proliferation, and sensitivity to the chemotherapy drug cisplatin. The data
lend further insight into howan individual’smetallomic status, a combination of
nutritional and harmful metal exposure, might result in the development and
progression of cancer and affect the response to chemotherapy.
#4169 A novel, short isoform of the Tip microtubule binding protein
CLIP170 confers taxane resistance in gastric cancer. Prashant V. Thakkar,1
Katsuhiro Kita,1 Giuseppe Galletti,1 Kyle Cleveland,1 Isabel Barasoain,2 Jose
Fernando Diaz,2 Manish A. Shah,1 Paraskevi Giannakakou1. 1Weill Cornell
Medicine, New York, NY; 2Centro de Investigaciones Biológicas, Madrid, Spain.
The microtubule (MT) cytoskeleton is one of the most validated therapeutic
targets in clinical oncology, as evidenced by the wide clinical activity of taxanes
and otherMT inhibitors.However, patientswith intrinsic drug resistance do not
benefıt from taxane chemotherapy, such as patients with diffuse gastric cancer
(GC). Currently, the molecular mechanisms underlying clinical taxane resis-
tance remain poorly elucidated. Using a panel of GC cell lines with intrinsic
sensitivity or resistance to taxanes, we showed lack of drug-target engagement in
the resistant lines, despite unimpaired intracellular accumulation of the drug
and in the absence of tubulin mutations or altered tubulin isotype expression.
Herein, we show for the fırst time that the resistant cells expressed a novel, short
isoform of the MT plus-end binding protein, CLIP170 (CLIP1). CLIP1 binds to
the plus-ends of microtubules (TIPs) and regulates dynein-mediated MT-
based traffıcking and the tubulin tyrosination cycle. We showed by both mass-
spec proteomics and 5’-RACE that the short CLIP1 isoform (CLIP1S) lacks the
fırst 150 amino acids, thus, missing the fırst Cap-Gly (Cytoskeleton-Associated
Protein-Glycine) domain, which is required for proper TIP localization. In-
deed, confocalmicroscopy experiments showed thatCLIP1Swasmislocalized to
the microtubule lattice in contrast to the canonical comet-like pattern of CLIP1
seen in taxane sensitive cell lines. CLIP1S expression was specifıcally correlated
with taxane resistance (docetaxel, cabazitaxel) as no correlation was observed
with other DNA-damaging agents. Since, CLIP1S expression has never been
reported before, to establish causation, we stably knocked down CLIP1 and
CLIP1S in taxane-sensitive and resistant cells, respectively. CLIP1SKD entirely
reversed taxane-resistance (300 fold) while CLIP1KD had no effect in the
taxane-sensitive cell lines. These data suggest a gain-of-function of CLIP1S that
leads to taxane resistance. To study the binding kinetics of taxanes toMTs in the
presence or absence of CLIP1S we performed live cell imaging of native cyto-
skeletons using fluorescently-labeled paclitaxel (Flutax). Our data revealed sig-
nifıcantly faster dissociation rates of Flutax from MTs in the resistant cells,
indicating transient interaction with MTs. Taxane binding to MTs is a two-step
process. First taxanes bind to the MT-pore low affınity surface site, which then
facilitates access to the high affınity luminal site. Using a small molecule that
binds only toMT-pore site, we showed that we showed that taxol binding to the
pore is signifıcantly slower in resistant cells expressing CLIP1S, which together
withmislocalization of this variant along theMT lattice suggests that it obstructs
access to the MT-pore thus restricting entry of taxane into the lumen of micro-
tubules. This fınding will have profound implications for taxane resistance as
well as microtubule biology broadly.
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#4170 Targeting androgen receptor overcomes resistance to tyrosine ki-
nase inhibitors in advanced clear cell renal cell carcinoma.RemiM. Adelaiye-
Ogala,1 Sreenivasulu Chintala,1 Ashley Orillion,1 May Elbanna,1 Ben Elzey,1
Nur Damayanti,1 Kiersten M. Miles,2 Chinghai Kao,1 Piergiorgio Pettazzoni,3
Giulio F. Draetta,3 Roberto Pili1. 1Indiana University School of Medicine, India-
napolis, IN; 2Roswell ParkCancer Institute, Buffalo, NY; 3TheUniversity of Texas,
MD Anderson Cancer Center, Houston, TX.
Background: Advanced renal cell carcinoma (RCC) responds initially to anti-
angiogenic therapies but eventually develop resistance which may be driven by
the expression of key intratumoral pro-survival protein and overall kinome
reprogramming. Androgen receptor (AR) expression has been reported in clear
cell renal cell carcinoma (ccRCC) but its biological role remains elusive and its
association with resistance to tyrosine kinase inhibitors (TKIs) has not been
studied. Here we report the role of AR and its associationwith resistance to TKIs
in advancedRCC.Methods:HumanRCCcell lines; 786-0, 786-0R (with induced
sunitinib resistance), ACHN, URMC2 (with intrinsic sunitinib resistance) were
used to assess the combination effect of sunitinib and the AR antagonist enzalu-
tamide in vitro. In vivo studies utilizing 786-0 tumors assessed the combination
effect of enzalutamide and sunitinib following acquired resistance to sunitinib.
AR expression was detected by qRT-PCR and Western blot analysis, and AR
localization by immunofluorescence in treated andnon-treated cells. Gene array
was used to assess 93 AR associated genes in sensitive and resistant cells. Results:
Quantitative RT-PCR data revealed a signifıcant increase in AR expression with
sunitinib resistance (100 folds; p0.001). In vitro and in vivo studies indicated
signifıcant increase in nuclear and cytoplasmic expression of AR with sunitinib
treatment in resistant cells which was abrogated with single agent enzalutamide
and combination treatment. More interestingly, combination treatment of en-
zalutamide and sunitinib signifıcantly decreased cell growth and induced tumor
regression in vitro and in vivo, respectively. Conclusion: Our data suggest the
role of AR both in intrinsic and acquired sunitinib resistance in ccRCC and
provide a rationale for combination strategies to restore TKI sensitivity that can
be tested in the clinical setting.
#4171 Combined AXL/FN14 inhibition sensitize drug-resistant NSCLC
in vitro and in vivo. Dhananjay Suresh,1 Ajit Zambre,1 Soumavo Mukherjee,1
Shreya Ghoshdastidar,1 Jennifer L. Schnabel,1 Sarah Chapman,2 W. Matthew
Leevy,2 Anandhi Upendran,1 Raghuraman Kannan1. 1University of Missouri,
Columbia, MO; 2University of Notre Dame, Notre Dame, IN.
Lung cancer is the number one cause of cancer-related deaths in both men and
womenwith amedian survival timeof 8-10months’ post treatment.NonSmallCell
LungCancer (NSCLC) accounts for 80%of the lung cancers and the treatment plan
is determined based on the activemutations (EGFR,ALK/ROS, andKRAS) present
in the tumor. Patients bearing EGFRmutation initially respond to targeted tyrosine
kinase inhibitor (TKI) therapy and after 10-14 months of treatment acquire TKI
resistance.Consequently, themedianPFS forNSCLCpatientswithEGFRmutation
is only 9.5 months. The reason for this acquired drug resistance is not yet fully
understood. Recent studies have reported oncogenes such as AXL could be respon-
sible forTKI resistance.Therefore, understanding themechanismofdrug resistance
is key in developing a solution to overcome the problem. For this study, we fırst
examined the resistancemechanism and developed a biodegradable targeted nano-
particle based solution to systematically investigate the role of AXL in resistant
NSCLC cell lines. In this study we (1) downregulated AXL using siRNA and sepa-
rately (2) knocked out the AXL gene using crRNA (CRISPR) and treated with TKI.
Our results show that AXL is responsible for activation of several EMT related pro-
teins and upregulation of mTOR pathway. We believe the upregulation of these
proteins is essential for cancer cells to switch pathways for proliferation and regu-
latingmiRNAs linked tomutations.Our results further confırm thatAXL is respon-
sible for regulatingMMP-2 that is associatedwith cell invasion. Based on data from
multiple cell lines such asH820 andA549,wedemonstrate thatAXLupregulation is
responsible for resistance independent of EGFR activating mutations. The eluci-
dated pathway for drug resistance was further confırmed in cell lines generated by
knocking-out theAXL gene. Interpretation forAXL signaling and drug resensitiza-
tionwas confırmed byWestern blotting, Zymography, Invasion&Migration assay,
Apoptosis assay andMTT toxicity assay. We performedmRNA andmiRNA anal-
ysis using qRT-PCR tounderstand gene expression post treatment.During the pro-
cess of our investigation, we found that NSCLC cells undergo further survival cross
talk with other biomarkers. Indeed, we report the fırst experimental evidence of a
survival cross talk betweenAXL and FN14, a wound healing gene, that enhance cell
survival post treatment. Down regulation of both AXL and FN14 dramatically re-
duced the IC50 of TKI. Based on themechanism,we designed a gelatin nanoparticle
that can carry bothAXLandFN14 to deliver it in the tumor cell. Thenanoparticle is
targeted to tumor using EGFR-antibody and releases the silencing RNAwithin cy-
toplasm.We further demonstrated that dual-inhibition of AXL and FN14 in A549
mice xenografts showed tumor reduction compared to controls. In conclusion, in-
hibitionofAXLandFN14canmaximize therapeutic responseofTKI,whereinAXL
is upregulated before or during drug treatment.
#4172 Activation of AR signaling by mifepristone enhances prostate can-
cer growth and impairs enzalutamide response.HaiyingZhou,Nadine Jachan,
Mallika Singh, Chris Tran, Dan McWeeney, Minna Balbas, Emily Schenkein,
Tatiana Zovorotinskaya, Erica L. Jackson, Julio Medina, Daqing Sun, Yosup
Rew, Xiaohui Du, John Eksterowicz, Xuelei Yan, Liusheng Zhu, Qiuping Ye,
Valeria Fantin. ORIC Pharmaceuticals, South San Francisco, CA.
Androgen receptor (AR) signaling is crucial for normal development and
homeostasis of the prostate, and is a key driver of prostate cancer initiation and
progression. Hormone therapies that deprive the cancer of androgen have long
been a mainstay of prostate cancer treatment. More recently, anti-androgens,
such as abiraterone and enzalutamide, have been approved for use in metastatic
castration resistant prostate cancer (mCRPC). Evidence also suggests that AR
may play an oncogenic role in certain breast cancers. Several recent publications
have demonstrated that activation of the Glucocorticoid Receptor (GR) can
confer resistance to enzalutamide, and GR has also been shown to provide pro-
tection from conventional chemotherapies in other solid tumor indications.
Mifepristone, is a synthetic steroidal antagonist of progesterone receptor, and to
a lesser extent of GR and AR. It is currently being tested in clinical trials in
combination with enzalutamide in mCRPC, and in combination with chemo-
therapy in triple negative breast cancer (TNBC). We sought to characterize the
effect of mifepristone in pre-clinical models of prostate and breast cancer. Here
we show that in the absence of androgen, mifepristone acts as a partial AR
agonist, and this agonism can only be partially overcome by enzalutamide. We
fınd that in low androgen conditions, mifepristone promotes the growth of
prostate cancer cells in vitro and accelerates the growth of prostate tumors in
xenograft models. Moreover, when given in combination, mifepristone signifı-
cantly reduces the effıcacy of enzalutamide in the LN-AR xenograft model. We
are currently assessing the effects of mifepristone treatment in TNBC. Our fınd-
ings suggest that partial AR agonist activity of mifepristone may have a negative
impact in prostate and other AR positive cancers. We have developed a GR
antagonist that is devoid of AR agonism to circumvent undesired effects on
proliferation and drug response.
#4173 Drug target mutations as a mechanism of acquired resistance to
small molecules activators of protein phosphatase 2a. Rita Tohme,1 Jaya San-
godkar,2 Janna Kiselar,1 Daniel Leonard,1 Caitlin O’Connor,1 Sai Gandhe,1
Wenqing Xu,3 David Brautigan,4Mark Chance,1 Michael Ohlmeyer,2 Goutham
Narla1. 1Case Western Reserve University, Cleveland, OH; 2Icahn School of Med-
icine at Mount Sinai, New York, NY; 3University of Washington, Seattle, WA;
4University of Virginia, Charlottesvilla, VA.
The sustainable activation of the RAS/MAPK and PI3K/AKT signaling path-
ways in cancer is promoted by a reduction in the activity of the tumor suppressor
protein phosphatase 2A (PP2A). Therefore, a novel therapeutic strategy consists
of directly activating PP2A, leading to the simultaneous inhibition of these on-
cogenic pathways. PP2A is a heterotrimeric complex, consisting of a scaffolding
A subunit, catalytic C subunit, and one of many regulatory B subunits respon-
sible for substrate specifıcity. Our lab has successfully developed fırst-in-class
Small Molecule Activators of PP2A (SMAPs), which induce tumor growth in-
hibition in both transgenic and patient derived xenograft mice models. How-
ever, alterations to the drug binding site is one of themost commonmechanisms
of acquired resistance, and we hypothesized that point mutations of the drug
binding amino acid residues of PP2A would lead to decreased sensitivity to
SMAP treatment. Determining potential mechanisms responsible for the devel-
opment of resistance to SMAPs would guide the development of novel thera-
peutic strategies to improve patients’ prognosis. In silico docking calculations,
photo affınity labeling, and hydroxyl radical footprinting studies were used to
identify K194, E197, and L198 as the putative residues of PP2A-A that were
interacting with SMAPs. K194R, E197K, and L198V mutations were generated
by site-directed mutagenesis. H358, a KRAS-driven lung adenocarcinoma cell
line, was used to create isogenic cell lines stably overexpressingmutated andwild
type PP2A-A. These mutations did not affect the phosphatase activity or its
ability to form holoenzymes in a cell-free system. SMAP response was investi-
gated in vivo using a xenograft model of H358 isogenic cell lines and it was
determined that tumors harboring mutant K194R and L198V PP2A-A were
resistant to SMAPs treatment. Together, our results suggest that residues K194
and L198 are required for drug binding and subsequent target engagement.
These fındings shed light on possible mechanisms of acquired resistance to
SMAPs in patients and have potential to guide the design of second-generation
drugs.
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#4174 The impact of catechol estrogen metabolism on the proliferation
rate and Docetaxel (DOC) resistance in hormone-responsive cancers.Mai F.
Tolba,1 Hany Omar,2 Ayman M. Noreddin,2. 1Ain Shams University, Cairo,
Egypt; 2University of Sharjah, Sharjah, United Arab Emirates..
Estrogen-responsive cancers such as breast cancer (BC) and prostate can-
cer (PC) are on the top of the most commonly diagnosed cancers in USA.
Docetaxel (DOC) is considered the fırst-line of therapy for both metastatic
BC and castration-resistant PC. However, its use in therapeutically effective
doses is associated with signifıcant toxic reactions and tumor resistance.
Estrogens (E2) play an important role in the development and progression of
both malignancies. Of special importance is that the catechol E2 metabolite,
4-hydroxyestradiol (4-OHE2) enhances the proliferation of both breast and
prostate normal epithelial cells. The goal of this work is to investigate the
relationship between catechol-E2 metabolism and cancer cells proliferation
and response to DOC. Methods: The cells were exposed to serial concentra-
tions of E2 and 4OHE2 (0.001-10 M) to assess their effect on cells’ growth
rate over 24-92 h. Cell proliferation assays were utilized to assess the density
of viable cells at different time points. Cytotoxicity assays were performed to
evaluate the median inhibitory concentration (IC50) of DOC alone or in the
presence of 4OHE2. Results: Exposure of the estrogen receptor (ER)-positive
BC cell line MCF-7 to 0.1 M of 17--hydroxyestradiol (E2) for 3 days
signifıcantly boosted the cell proliferation rate compared to control group by
about 27% (P0.05). Exposure of MCF-7 cells to the catechol estrogen me-
tabolite 4-hydroxyestradiol (4OHE2) at 0.1M for 3 days signifıcally en-
hanced cell growth by about 31% (P0.001). Similarly, exposure of the an-
drogen independent, ER-positive- advanced stage PC cells PC-3 to E2 (1M,
3 days) signifıcantly enhanced the growth rate by 37% (P0.05). Moreover,
our data showed that simultaneous exposure to 4OHE2 signifıcantly antag-
onized the cytotoxic activity of DOC with subsequent increase in the IC50 of
DOC by 18 folds (P0.006). Conclusion: these results indicate that altered
E2 metabolism with subsequent accumulation of 4-OHE2 can enhance the
proliferation rate of E2-responsive cancers in addition to hindering the cy-
totoxic activity of DOC with subsequent reduction in DOC potency. Further
research is in progress to assess the potential merit of modulating the clear-
ance of catechol E2 as a strategy to improve the cancer response to DOC.
(This project is supported by Fulbright Scholar grant FY15/16 and L’Oreal-
UNESCO for Women in Science-Levant and Egypt award for MFT).
#4175 Targeting of a mesenchymal profıle in order to sensitize multith-
erapy resistant glioblastoma clones. Mia Niklasson, Malin Jarvius, Caroline
Haglund, Efthymia Chantzi, Tobias Bergström, Frida Nyberg, Annika Her-
mansson, Mårten Fryknäs, Mats Gustafsson, Bo Segerman, Rolf Larsson, Bengt
Westermark, Anna Segerman. Uppsala Universitet, Uppsala, Sweden.
The overall aim of this study was to fınd ways to sensitize treatment resis-
tant glioma-initiating cell (GIC) clones to conventional therapy. Heteroge-
neity is substantial in glioblastoma multiforme (GBM) and through estab-
lishment of clonal GIC cultures from patient biopsies we have demonstrated
a wide variety in the responses to drugs and radiation. A multitherapy resis-
tance phenotype was linked to proneural-mesenchymal transition (PMT) in
the transcriptome. The variety in therapy response was observed as a con-
tinuum of phenotypes. The distribution of phenotypes resembled a normal
distribution and multitherapy resistance was associated with low DNA
methylation grade in promoter regions of mesenchymal master regulators
(FOSL2, RUNX1). Our data thus implied that the transition is bi-directional
and epigenetically regulated (Segerman et al, Cell Reports - accepted in prin-
ciple). To investigate if spontaneous changes in drug and radiation response
occur, we have derived subclones from a resistant clone. Both subclones with
higher and lower therapy resistance than the parental clone were generated.
Also molecularly the subclones largely reconstituted the original clonal vari-
ation. PMT shows similarities to epithelial-mesenchymal transition (EMT),
which is induced by extrinsic factors. We therefore specifıcally analyzed the
gene expression data for signaling receptors differentially expressed in resis-
tant vs. sensitive clones as well as cognate ligands. To estimate the impor-
tance of a particular signaling pathway, expression of co-receptors and li-
gands was taken into account. We found several cases of coherent
upregulation of receptor and ligand indicative of autocrine loops. Regarding
pathways that appeared to be overactive in resistant vs. sensitive clones, there
was a prominent overlap with EMT. It was also apparent that several path-
ways were activated concomitantly. We are currently focusing on identifying
combinations of drugs (and antibodies) that sensitize resistant clones to
conventional treatment throughmodulation of cell signaling patterns. In the
initial screen temozolomide (TMZ) response is used as an indicator of
achieved sensitization. The strategy is to iteratively combine primarily an-
tagonists of signaling receptors connected to resistance. We are also explor-
ing the effect of stimulating pathways with apparently higher activity in
sensitive clones (e.g. addition of ligands).The concept of sensitizing glioma
and other types of cancer cells by targeting the mesenchymal character
through usage of e.g. signaling receptor inhibitors is not new and has shown
promise. Indeed, our preliminary data look encouraging. In conclusion, our
data show that multitherapy resistance is connected to a plastic cell-state.
Also, receptors and ligands that are differentially expressed in resistant and
sensitive clones engage pathways regulating EMT.
#4176 Targeting TAM family members with antibody or small molecule
inhibitors enhances therapeutic modalities of HNSCC. Nellie K. Black, Mari
Iida, Tamara S. Rodems, Toni M. Brand, Randall J. Kimple, Deric L. Wheeler.
UW-Madison, Madison, WI.
Radiation, cisplatin, and cetuximab are clinical therapeutics used in the treat-
ment of head and neck squamous cell carcinoma (HNSCC). Despite clinical
success with these modalities, development of both intrinsic and acquired resis-
tance is an emerging problem in the management of HNSCC. Thus, identifying
and targeting molecules driving this drug resistance is essential for improving
effıcacy of treatment approaches. Recent studies have identifıed a role for the
TAM family of receptor tyrosine kinases (Tyro, Axl, andMer) in tumor biology,
especially the Axl receptor in promoting tumor growth and metastasis. Previ-
ously, we identifıed Axl as a logical molecular target in HNSCC and indicated
that itmay play a pivotal role in resistance to radiation, cisplatin, and cetuximab.
In the current study, we advanced these early fındings into pre-clinical models
using patient-derived xenografts (PDXs). We have shown that small molecules
targeting Axl can enhance therapy in PDXs that express high levels of Axl and
have been identifıed as resistant to radiation, cisplatin, and cetuximab. Current
studies are focusing on antibody-based targeting of Axl using PDXs and genet-
ically-modifıedmodels of resistance. Furthermore, studies focused on co-target-
ing of Axl and Mer in vitro and in vivo have shown striking results and denote
the importance of establishing logical approaches to target TAMs in the man-
agement of HNSCC. Finally, investigations into the molecular mechanisms of
how Axl signaling can lead to resistance have underscored the importance of
tyrosine 821 (Y821) of Axl. Overexpression of Axl rendered cetuximab sensitive
lines resistant, but cell lines overexpressing Axl-Y821F retained their sensitivity
to cetuximab.Advancing this line of study in vivo indicated that tumors express-
ing Axl were resistant to cetuximab whereas tumors harboring the Y821 muta-
tion were sensitive demonstrating that signals emanating from Y821 may be
critical for cetuximab resistant pathways. Collectively, the studies presented
herein identify the TAM family of receptors as key players in radiation, cisplatin,
and cetuximab resistance. These results provide rationale for the clinical target-
ing of TAM receptors to enhance the therapeutic modalities used in treating
HNSCC.
#4177 Anticancer agent Aminoflavone restores the expression of tumor
suppressor miRNA 26a and inhibits putative stemness biomarker 6-integ-
rin in Tamoxifen resistant cells. Petreena Campbell,1 Leah Rowland,1 Anna
Opoku-Agyeman,2 Nichole Mavingire,1 Ubaldo Soto,1 Gayathri Nagaraj,1
Yonghong Zhang,1 Sean (Xin) Chen,1 Charles Wang,1 Eileen Brantley1. 1Loma
Linda University, Loma Linda, CA; 2University of Maryland, Baltimore, MD.
Despite the effıcacy of anti-estrogen agent Tamoxifen, commonly used to
treat patients with estrogen receptor positive (ER) tumors, up to 40% of pa-
tients experience recurrence. Breast tumor-initiating cells (TICs), or breast can-
cer stem cells, exhibit Tamoxifen resistance and contribute substantially to re-
currence. We recently demonstrated that investigational anticancer agent
Aminoflavone (AF) disrupts mammospheres (in vitro clusters of cells enriched
with TICs) by thwarting the expression of 6-integrin. In the current study, we
found AF potently inhibited Tamoxifen resistant (TamR) cell growth and
blocked Tamoxifen-mediated stimulation of TamR cell proliferation using the
Alamar Blue assay. qPCR analyses revealed 6-integrin expression was signifı-
cantly elevated in ER breast cancer cell models of acquired and de novo Ta-
moxifen resistance relative to Tamoxifen sensitive cells. In particular, AF de-
creased the expression of both A and B variants of 6-integrin, the B variant
being essential for TIC function. Western blotting revealed AF reduced total
6-integrin expression in TamR cells. Furthermore, we found that an anti-6-
integrin blocking antibody sensitized TamR cells to the active Tamoxifen me-
tabolite, 4-hydroxy-Tamoxifen, and enhanced the effıcacy of AF in these cells.
AF also reduced the protein expression of p-Src, a downstream target of 6-
integrin that is linked to Tamoxifen resistance and decreased breast cancer sur-
vival. In addition, miRNA sequencing of Tamoxifen sensitive and TamRmam-
mospheres revealed differential expression of several miRNAs. Notably, miR-
26a expression was down-regulated 2-fold in TamR mammospheres compared
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to Tamoxifen sensitive mammospheres and AF restored miR-26a expression
5-fold in TamR mammospheres. Using miRNA target prediction algorithms
TargetScan and PicTar, we found miR-26a binding sites on the 6-integrin
promoter. Taken together, our data suggest that AF re-expresses tumor suppres-
sor miR-26a and inhibits the 6-integrin/Src signaling axis to reduce TIC ca-
pacity and counteract Tamoxifen resistance.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Targeting Protein Kinases and DNA Repair
#4178 The novel PLK1 inhibitor, CYC140: Identifıcation of pharmacody-
namicmarkers, sensitive target indications and potential combinations. Syl-
vie Moureau, CraigMacKay, Chiara Saladino, Elizabeth Pohler, Karin Kroboth,
Jonathan Hollick, Daniella Zheleva, Sheelagh Frame, David Blake. Cyclacel Ltd,
Dundee, United Kingdom.
Introduction: CYC140 is a selective and potent ATP-competitive inhibitor of
PLK1, which has completed IND-enabling studies. The aim of this translational
project was to inform the clinical development path of CYC140. Esophageal cancer
was investigated as a potential target indication based on unmet medical need and
the observation that PLK1 is frequently overexpressed in esophageal tumors and
carries a poor prognosis. Experimental procedures: The anticancer activity of
CYC140was examined acrossmultiple tumor types to identify sensitive target indi-
cations or tumor subsets. 6 h pulse exposure to CYC140 was used to determine
sensitivity in apanel of over 250 cancer cell lines, including15 esophageal cancer cell
lines, usingCellTiterGlo and resazurin-based assays. Candidate pharmacodynamic
markers were examined in malignant and non-malignant cells. Drug combination
testing was undertaken in several esophageal cell lines using approved and targeted
agents. Solid tumor and leukemia xenograft models were performed to assess
CYC140 dosing schedules and effıcacy. Summary: Inhibition of PLK1 by CYC140
perturbs the entry into and exit frommitosis. Inmalignant cells, CYC140 treatment
leads to the appearance of mitotic cells with monopolar spindles and a persistent
increase in the proportion of cells in G2 andMphase, resulting in complete growth
inhibition and induction of cell death. In non-malignant cells, the growth arrest is
transient, and cells resume cycling once compound is removed. Short (6 h) pulse
treatments of CYC140maximise the difference in cellular response betweenmalig-
nant esophageal cell lines and cells of a non-malignant origin. In the esophageal cell
line panel,CYC140 cellular IC50 correlateswith inductionof apoptosis. The effect of
CYC140 onpharmacodynamicmarkers of PLK-1 activity such as phospho-nucleo-
phosmin and phospho-histoneH3was characterized inmalignant and non-malig-
nant cells. Several promising combinations of CYC140 with targeted agents were
identifıed, including EGFR inhibitors, HDAC inhibitors and PI3K pathway inhibi-
tors, and CYC140 can also be combined with cytotoxic agents approved for use in
esophageal cancer, such as cisplatin or irinotecan. CYC140 anti-tumor effıcacy was
demonstrated in solid tumorand leukemicxenograftmodelswith responses includ-
ing tumor regression and tumor-free cures. Conclusions: CYC140 is a promising
anti-cancer agent with potent anti-proliferative activity and therapeutic potential in
a variety of cancers, including esophageal cancer and acute leukemia. The mode of
action of CYC140 is consistent with PLK1 inhibition and cell death is preferentially
triggered in sensitive malignant cells. Suitable pharmacodynamicmarkers and sev-
eral promising combinations have been identifıed that could assist clinical develop-
ment of CYC140.
#4179 Potent and selective TRK inhibitor CH7057288. Hiroshi Tanaka,1
Hitoshi Sase,1 Toshiyuki Tsukaguchi,2 Hiromi Tanimura,1 Masami Hasegawa,1
Kiyoshi Hasegawa,1 Yoshiyuki Ono,1 Nobuhiro Oikawa,1 Hiroshi Sakamoto,1
Toshiyuki Mio1. 1Chugai Pharmaceutical Co., Ltd., Kamakura, Japan; 2Chugai
Research Institute for Medical Science, Inc., Kamakura, Japan.
TRK receptor tyrosine kinases are expressed as fusion proteins encoded by vari-
ous fusion genes across awide variety of cancer types, including lung and colorectal
cancer. These fusion proteins have potent oncogenic activity and are thought to be
an attractive therapeutic target. In a kinase inhibitor screening we identifıed
CH7057288, a potent and selective TRK inhibitor belonging to a novel chemical
class. Our inhibitor showed selective inhibitory activity against TRKA, TRKB, and
TRKCincell-free kinase assays and suppressedproliferationofTRKfusion-positive
cell lines, butnot that ofTRK-negative cell lines. In subcutaneously implantedxeno-
graft models of TRK fusion-positive cells, strong tumor growth inhibition was ob-
served. Furthermore, CH7057288 induced regression of intracranial tumors and
greatly improved event-free survival in an intracranial implantationmodelmimick-
ing brain metastasis. Recently, resistant mutations in TRK have been reported in
patients showing disease progression after treatment with a TRK inhibitor under
clinical development. Our compound maintained similar levels of in vitro and in
vivo activity against some of the resistant mutants as it did to wildtype TRK. In
summary, CH7057288 could be a promising therapeutic agent for TRK fusion-
positive cancer.
#4180 RS-41, a multi-targeted kinase inhibitor, induces cell cycle arrest
and apoptosis in p53 mutant and wild type models of upper gastrointestinal
cancers. Tanvi Visal,1 Shraddha Patel,1 Priya Pancholi,1 Samhita Bapat,1 Am-
ruta Samant,1 Dhvanir Kansara,1 Sonali Kurup,2 Vikas Sehdev1. 1Long Island
Univ., Brooklyn, NY; 2Roosevelt University, Schaumburg, IL.
Introduction: Upper Gastrointestinal Cancers (UGCs) are a leading cause of
cancer-related mortality and account for approximately 1.1 million deaths
worldwide. UGCs respond poorly to conventional chemotherapy due to consti-
tutive over activity of multiple oncogenic signaling mechanisms, including the
epidermal growth factor receptor (EGFR), ERBB2/HER-2, Aurora kinases, and
JAK-STAT pathways. In addition, presence of mutant P53 further imparts re-
sistance to conventional chemotherapeutic agents. Therefore, novel small mol-
ecule inhibitors that target multiple kinases associated with oncogenic progres-
sion could pave the way for improved chemotherapy and better therapeutic
outcomes. In this study, we characterized the anticancer activity of RS-41, an
investigational 4-phenylbenzamidopyrrolo[2,3-d]-pyrimidin-4-amine multi-
kinase inhibitor, in P53 mutant and wild type models of UGC. Methods: Target
kinase inhibition and selectivity screening assays were performed to determine
potency and selectivity of kinase inhibition for RS-41. In addition, MTT-cell
viability assay, clonogenic cell survival assay, cell cycle analyses, andwestern blot
analyses were done to evaluated the effect of RS-41 treatment on cell viability,
survival, cell cycle progression, and expression of apoptotic markers in P53
mutant (FLO-1) and P53 wild type (AGS) UGC cells, respectively. Results: The
kinase selectivity screening assay characterized RS-41 for its selectivity against a
panel of 90 human kinases. The kinase screening analyses showed that RS-41
selectively inhibits AURKA (IC50-0.96	0.03M), JAK2 (IC50-1.21	0.17M),
and EGFR (IC50-5.92	0.75M) kinases, respectively. The cell viability data
indicate that treatment with RS-41 mediates signifıcant (P0.05) inhibition of
FLO-1 and AGS UGC cell viability. The clonogenic cell survival data showed
that treatment with RS-41 for 24 hrs. suppresses subsequent formation of colo-
nies in both FLO-1 and AGS UGC cells. The cell cycle data exhibited a marked
increase (P0.05) in the percentage of FLO-1 andAGS cells in the sub-G1-phase
(cell death) after treatment with RS-41 for 24 and 72 hrs., respectively. The
western blotting data further confırmed induction of apoptosis in FLO-1 and
AGS cells as evidenced by an increase in expression of various markers of apo-
ptosis (P73/P53, cleaved PARP, and/or cleaved caspase 3) following treatment
with RS-41 for 24 and 72 hrs. Conclusions: Our in vitro data indicate that inhi-
bition of various oncogenic kinases with RS-41 is an effective therapeutic strat-
egy for inducing apoptosis in both P53 mutant and wild type UGC cells. Our
study suggests that RS-41 is a promising multi-kinase inhibitor with a potential
to further enhance chemotherapeutic options for treatment of UGC.
#4181 Discovery of a selective small molecule inhibitor of Tankyrase by
structure-based screening. Hwani Ryu, Ah-young Kim, Jie-Young Song,
Sang-GuHwang, JiyeonAhn.Korea Institute of Radiological&Medical Sciences,
Seoul, Republic of Korea.
The Wnt/-catenin signaling pathway is critical for colorectal cancer (CRC)
development, progression and metastasis. Tankyrase enzymes (TNKS1 and
TANKS2), members of the PARP (Poly(ADP-ribose)polymerases) superfamily,
PARsylate and target Axin for degradation via ubiquitin-proteasome pathway,
leading to accumulation of -catenin into nucleus. In addition, aberrant YAP/
TAZ singling contributes to anticancer drug resistance, but inhibition of TNKS
suppresses YAP/TAZ signaling through stabilizing Angiomotin (AMOT).
Therefore, inhibition of TNKS has emerged as an attractive strategy for treat-
ment of cancers. To identify potent and selective small molecule inhibitors of
TNKS1, a TNKS1-ligand docking was used for computational-based virtual
screen of a chemical library containing 1.6 million compounds and 24 virtual
hits were further subjected to in vitro evaluation for TNKS1 inhibition. Using an
in vitro TNKS1 enzyme assay, we identifıed a novel pyridine derivative
(AZ236106) signifıcantly inhibited TNKS1 enzyme activity in a concentration-
dependent manner, but not PARP1/2. Treatment of AZ236106 stabilized Axin,
reduced -catenin in nucleus and downregulated -catenin target genes in
DLD-1 cells harboring adenomatous polyposis coli (APC)mutation. Moreover,
we observed that AZ236106 inhibited accumulation of YAP in the nucleus and
expression of YAP garget genes. Combination treatment of AZ236106 with ei-
ther radiation or PLX4032, a BRAF inhibitor, decreased cell proliferation and
increased apoptotic cell death in DLD-1 and SK-MEL28 cells, compare to
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AZ236106, radiation or PLX4032 alone. Our fındings suggest that AZ236106
may have therapeutic potential in cancers, and could be further refıned for
effıcacy and safety to develop a lead compound.
#4182 The two novel BTK-inhibitors M2951 and M7583 show in vivo
anti-tumor activity in pre-clinical models of B cell lymphoma. Eugenio Gau-
dio,1 Chiara Tarantelli,1 Emanuele Zucca,2 Davide Rossi,1 Anastasios Stathis,2
Francesco Bertoni1. 1Institute of Oncology Research - IOR, Bellinzona, Switzer-
land; 2Oncology Institute of Southern Switzerland - IOSI, Bellinzona, Switzerland.
Background. Diffuse large B cell lymphoma of the activated B cell like type
(ABC DLBCL) is an aggressive lymphoma in which the inhibition of the Bru-
ton’s tyrosine kinase (BTK) has shown biologic and clinical relevance. M7583
and M2951 are two novel highly selective irreversible BTK inhibitors (Fest C et
al, 2016). M7583 has shown activity in a mouse model of lupus erythematosus
(Bender et al, 2016). Here, we evaluated the anti-tumor activity of M2951 and
M7583 in an in vivo ABCDLBCLmodel. Methods. Xenografts were established
by s.c. injectingTMD8 lymphoma cells (100Lof PBS, 107 cells/mouse) into the
left flanks of female NOD-SCID mice (6 weeks of age and around 20g of body
weight). Treatments (QD, po) were started with an average tumor volume of
100mm3 on groups of 10 mice each. Results. NOD-SCID mice engrafted with
the ABC DLBCL TMD8 were treated with three different concentrations of
M7583 (1mg/Kg; 3mg/Kg; 10mg/Kg) orM2951 (5mg/Kg; 15mg/Kg; 25mg/Kg)
or vehicle, as control group. M2951 slowed tumor growth at all doses starting
after 10 days of treatment. M7583 at 3 and 10 mg/Kg showed stronger anti-
tumor activity than M2951, already evident after 5 days of treatment (P0.05)
and improving with time (after 10 days, P 0.005). Moreover, while most
groups had to be stopped after 2 weeks of treatment (D30 after engraftment)
because of the reaching of the maximum tumor volume, allowed by the ethical
veterinary committee, mice treated with M7583 at the two highest doses were
able to continue treatment for additional six (3 mg/Kg) or ten days (10mg/Kg),
when tumors became bigger than 2000 mm3, indicating a high activity of
M7583. No body weight losses and sign of toxicity were detected. Conclusion.
The two novel BTK inhibitors M2951 and M7583 showed promising in vivo
anti-tumor activity in an ABC-DLBCL model. These data provide the rational
for further investigating these compounds.
#4183 A novel selective DNA-PK inhibitor, M3814, as a potential combi-
nation partner of Etoposide and Cisplatin in the therapy of lung cancer.
Christian Sirrenberg,1 Astrid Zimmermann,1 Thomas Grombacher,1 Lyubomir
T. Vassilev,2 Lars Damstrup,1 Frank T. Zenke,1 Andree Blaukat1. 1Merck Biop-
harma, Darmstadt, Germany; 2EMD Serono, Billerica, MA.
M3814 is a potent and selective inhibitor of DNA-PK, one of the key
cellular regulators of DNA damage induced by ionizing radiation or certain
cytostatics used in the treatment malignant disease. One of these drugs,
Etoposide, induces double strand breaks (DSB) in cellular DNA. DSBs are
most diffıcult to repair and, if left unrepaired, can lead to induction of cell
cycle arrest and/or apoptosis and ultimately cell death. DNA-PK plays a
critical role in the repair of DSB via the non-homologous end-joining path-
way. M3814 was tested for activity in combination with Etoposide in a panel
of 98 cancer cell lines derived from lung cancer. A broad potentiation effect
of DNA-PK inhibitor was observed in most cancer cell lines. As a rule, cell
lines sensitive to Etoposide demonstrated increased sensitivity to the com-
bination. M3814 did not show signifıcant effect on cancer cell growth/via-
bility in combination with Cisplatin compared to Cisplatin alone at concen-
trations that effectively inhibit DNA-PK activity. At the same time, M3814
did not negatively affect the antitumor activity of Cisplatin. The therapeutic
effect of M3814 in combination with the standard of care (SoC) regimen of
Etoposide and Cisplatin was tested in the human small cell lung cancer
xenograft model, NCI-H520. Triple combination of M3814, Etoposide and
Cisplatin resulted in increased effıcacy compared to SoC treatment arm.
Since myeloid and lymphoid suppression is one of the dose limiting toxici-
ties of the SoC regimen in patients, the effect of the triple combination on
myeloid and lymphoid blood cells was investigated in immunocompetent
mice. Whereas the SoC treatment showed reduction of the myeloid and
lymphoid compartments, the addition of M3814 did not additionally reduce
these cells neither in the treatment nor the recovery phase. Our results war-
rant further investigations to explore the potential of the combination in the
clinical setting.
#4185 NTRC 1501-0, a TTK kinase inhibitor selected for its long target
residence time, completely inhibits tumorgrowth in theMDA-MB-231xeno-
graft model for triple-negative breast cancer. Joost C. Uitdehaag, Jos de Man,
Marion Libouban, Nicole Willemsen-Seegers, Jan Gerard Sterrenburg, Joeri J.
de Wit, Jeroen A.D de Roos, Martine B. Prinsen, Rogier C. Buijsman, Guido J.
Zaman. Netherlands Translational Research Center B.V., Oss, Netherlands.
The protein kinaseTTK is a critical component of the spindle assembly check-
point (SAC), which regulates the proper attachment of sister chromatids during
mitosis. TTK is essential for normal progression of the cell cycle and is upregu-
lated in various aggressive cancers such as triple negative breast cancer (TNBC).
Inhibition of TTK leads to an overriding of the SAC, premature progression of
the cell cycle and mitotic catastrophe. TTK inhibition therefore contrasts with
e.g. Aurora and PLK1 inhibition, which block the cell cycle [1]. Various studies
have shown the clinical utility of TTK inhibition, particularly in combination
therapy with paclitaxel [1,2]. In vivo, TTK inhibitor monotherapy has shown
partial tumor growth inhibition without weight loss [1,2]. We have developed a
novel class of TTK inhibitors based on a pyrimido-indolizine scaffold. These
bind selectively and with high affınity to the ATP pocket of TTK and potently
inhibit the proliferation of a variety of cell lines [1]. Previously we published a
representative of this class, NTRC 0066-0, which has an IC50 of 0.6 nM in a
biochemical assay for TTK activity and which is more than 200 times selective
over a panel of 276 kinases [1]. NTRC 0066-0 has an average IC50 of 98 nM in
proliferation assays in 66 different cell lines (Oncolines™ panel) [3]. To further
improve the potency of the pyrimido-indolizine series, we determined the X-ray
structures of a dozen of class representatives in complex with TTK. The results
were compared to 3D complexes of other chemical scaffolds such as BAY-
1161909,Mps-Bay2b,MPI-0479605, NMS-P715 andMps1-IN1. The pyrimido-
indolizine series uses an aromatic moiety to trap the catalytic lysine in the active
site, enforcing a catalytically incompetent conformation of TTK. Thermal melt-
ing and surface plasmon resonance experiments demonstrate that this leads to a
strong stabilization of the kinase domain and a slow dissociation rate for the
compounds, which is one of the key determinants for potent cellular activity.We
took advantage of these structure-activity relationships to develop analogs of
NTRC 0066-0 with increased residence time and cellular potency. One such
analog, NTRC 1501-0, inhibits the proliferation of 66 cancer cell lines with an
average IC50 of 18 nM, while retaining selectivity over the kinome. It has good
pharmacokinetic properties and shows no cross-reactivity with drug safety tar-
gets in vitro. In a xenograft model of the human TNBC cell line MDA-MB-231,
it completely inhibited tumor growth at a low oral dose, without effect on body
weight, indicating good tolerability. These data show, for the fırst time, that TTK
inhibition asmonotherapy can achieve complete inhibition of tumor growth. [1]
Maia et al. (2015) Annals of Oncology 26, 2180-2192; [2] Wengner et al (2016)
Mol. Canc. Therap. 15, 583-592; [3] Uitdehaag et al. (2016) Mol. Canc. Therap.,
in the press.
#4186 A biochemical approach to discriminate betweenATP-competitive
and non-ATP competitive protein kinase inhibitors. Daniel Mueller, Frank
Totzke, Thomas Weber, Carolin Heidemann-Dinger, Constance Ketterer, Di-
ane Krämer, Marcel Pathe, Michael H. Kubbutat. ProQinase GmbH, Freiburg,
Germany.
Protein kinases are central to cellular signal transduction and regulation of
cellular processes, and are one of the most attractive target classes in modern
drug discovery.Multiple kinase inhibitors have already been approved for treat-
ment of various diseases including such severe conditions as cancer. The fırst
and up to today largest group of drugs that effectively inhibits their respective
kinase targets belong to the class of ATP competitive compounds. They bind
into or near the ATP binding site of the enzymes and inhibit kinase activity by
blocking access of ATP to the active site. Although there are numerous examples
of highly specifıc ATP competitive compounds this mode of action is limited by
several factors: TheATPbinding pocket structures of kinases show ahigh degree
of similarity, whichmakes fınding highly selective compounds challenging. Fur-
thermore, competing with ATP for binding to the same target site, compounds
have to be of very high affınity due to the high intracellular ATP concentrations.
Therefore, the interest to develop non-ATP competitive inhibitors has risen
considerably over the last years. Such inhibitors bind to kinases at sites apart
from the ATP binding site, inhibiting their activity e.g. by stabilizing an inactive
conformation (like DFG-out state binders), displacing essential cofactors (like
cyclins for CDKs) or by blocking activatingmodifıcations (like phosphorylation
by upstream kinases).We present data of an in-vitro biochemical kinase activity
assay setup which is suited to discriminate between ATP-competitive and non-
ATP competitive inhibitors. The IC50 of an ATP-competitive inhibitor will in-
crease with increasing ATP concentrations and the IC50 value at a given ATP
concentration may be calculated using the equation of Cheng and Prussof:
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IC50Ki(Ki*[ATP]/KM[ATP] (Cheng Y., Prusoff W. H. (1973) Biochem.
Pharmacol. 22: 3099-3108). By determining IC50 values for an inhibitor of a
specifıc kinase at different ATP concentrations we examined whether the IC50
value changed according to the Cheng-Prusoff equation, indicating an ATP-
competitive mode of action, or if the IC50 values remained unchanged in pres-
ence of elevated ATP indicating a non-ATP competitive or mixed type mode of
action. In our assay setup we determined the IC50 values at ATP concentrations
in a range of 0.1 to 10 fold theATPKMof the kinase of interest. By comparing the
results obtained for the non-ATP competitive MEK1 inhibitor selumetinib and
theATP competitive inhibitor staurosporinewe could verify that our assay setup
is well suited to discriminate between these different types of kinase inhibitors.
#4187 Preclinical evaluation of sulfatinib, a novel angio-immuno kinase
inhibitor targeting VEGFR, FGFR1 and CSF1R kinases. jinghong Zhou, Jun
Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang,
qiaoling Sun, Fu Li, Jia Hu, Dongxia Shi, Hongbo Chen, Jingwen Long, Junen
Sun, Fang Yin, Xuelei Ge, Hong Jia, Feng Zhou, Yongxin ren, Weiguo Qing,
Weiguo Su. Hutchison MediPharma Limited, Shanghai, China.
Both vascular endothelial growth factor receptor (VEGFR) and fıbroblast
growth factor receptor (FGFR) singling pathways canmediate tumor angiogen-
esis. Colony stimulating factor 1 receptor (CSF1R) plays an important role on
functions of macrophages. Recently the roles of the VEGFR, FGFR and CSF1R
in regulation of T cells, tumor-associated macrophages (TAMs) and myeloid-
derived suppressor cells, thereby increasing tumor immune evasion, have been
demonstrated1
3
. Therefore, blockade of tumor angiogenesis and tumor immune
evasion by simultaneously targeting VEGFR, FGFR and CSF1R kinases may
represent a promising approach for anti-cancer therapy. We report here the
preclinical studies for sulfatinib (HMPL-012), a potent andhighly selective small
molecule tyrosine kinase inhibitor against VEGFR, FGFR1 and CSF1R. Sulfa-
tinib inhibited VEGFR1, 2, and 3, FGFR1 and CSF1R kinases with IC50s in a
range of 124 nM, and it strongly blocked VEGF induced VEGFR2 phosphor-
ylation in HEK293KDR cells and CSF1 stimulated CSF1R phosphorylation in
RAW264.7 cells with IC50 of 2 and 79 nM, respectively. Sulfatinib also attenu-
ated VEGF or FGF stimulatedHUVEC cells proliferation with IC50 50 nM. In
animal studies, a single oral dosing of sulfatinib inhibited VEGF stimulated
VEGFR2 phosphorylation in lung tissues of nude mice in an exposure-depen-
dent manner. Furthermore, elevation of FGF23 levels in plasma 24 hours post
dosing suggested suppression of FGFR signaling. Sulfatinib demonstrated po-
tent tumor growth inhibition in multiple human xenograft models and de-
creasedCD31 expression remarkably, suggesting strong inhibition on angiogen-
esis through VEGFR and FGFR signaling. In a syngeneic murine colon cancer
model CT-26, sulfatinib demonstrated moderate tumor growth inhibition after
single agent treatment. Flow cytometry and immunohistochemistry analysis
revealed an increase of CD8 T cells and a signifıcant reduction in TAMs,
(CD163 or F4/80CD11bCD45) and CSF1R TAMs in tumor tissue
indicating strong effect on CSF1R. Interestingly, combination of sulfatinib with
a PD-L1 antibody resulted in enhanced anti-tumor effect. These results sug-
gested that sulfatinib has a strong effect in modulating angiogenesis and cancer
immunity. In summary, sulfatinib is a novel angio-immuno kinase inhibitor
targeting VEGFR, FGFR1 and CSF1R kinases that could simultaneously block
tumor angiogenesis and immune evasion. This unique feature seems to support
sulfatinib as an attractive candidate for exploration of possible combinations
with checkpoint inhibitors against various cancers. Sulfatinib is currently in
multiple clinical trials including two Phase III trials against neuroendocrine
tumors. Reference: 1. VoronT, et al. J ExpMed. 2015; 212(2):139-48. 2. Ries CH,
et al. Cancer Cell. 2014; 25(6):846-59. 3. KatohM, et al. Int. J. of MolMed. 2016;
38: 3-15.
#4188 Multitargeted tyrosine kinase inhibitor identifıed as potential ther-
apeutic intervention for liposarcoma using high-throughput profıling.
Deepika Kanojia,1Manoj Garg,1 JakkiMartinez,2 AnandM.T.,1 Samuel B Luty,2
Ngan BDoan,3 JonathanWSaid,3 JeffreyWTyner,2 HPhillip Koeffler1. 1Cancer
Science Institute of Singapore, NUS, Singapore, Singapore; 2Knight Cancer Insti-
tute, Cell and Developmental Biology, Oregon Health and Science University,
Portland, OR; 3Department of Pathology and Laboratory Medicine, University of
California-Los Angeles Medical Center, Los Angeles, CA.
Liposarcoma is a rare fat cell adult tumor with high risk of recurrence and
metastasis, largely underserved by research community and till now limited
progress has been made in treatment of this aggressive disease. We used a strat-
egy to identify effective and potential therapeutic kinase inhibitors, irrespective
of the activated kinase pathway, using smallmolecule kinase inhibitor panel.We
screened liposarcoma cell lines of different histotypes to a panel of small mole-
cule kinase inhibitors and analyzed using cell proliferation assay. In vitro cell
proliferation assay, colony formation, cell cycle analysis, apoptosis assay and
western blotting analysis were performed to investigate the effect and mecha-
nism of inhibitor treatment on liposarcoma. Liposarcoma xenograft model sys-
tem was also employed to investigate anti-tumor in vivo effects of inhibitor
treatment. We observed that cell lines demonstrated diverse in vitro drug sen-
sitivity patterns to various kinase inhibitors. Most of the cell lines showed very
high sensitivity towards inhibitors targeting proteasome, protein kinase C,
Hsp90, PI3K,mTOR andCDKs. Among the receptor tyrosine kinase inhibitors;
Ponatinib, Dasatinib, and Sunitinib are the top most sensitive drugs affecting
liposarcoma cells lines’ viability irrespective of subtypes and all these are already
approved by the U.S. Food and Drug Administration to treat various cancers.
We studied multi-targeted tyrosine kinase inhibitor ponatinib as an effective
potential drug molecule in liposarcoma.We demonstrated that ponatinib treat-
ment in liposarcoma cell lines reduced the levels of phosphorylated KIT com-
pared to total KIT protein levels in dose dependent manner. Further, western
blotting experiments revealed effect of ponatinib treatment onKIT downstream
signalling by inhibiting the phosphorylation of AKT, ERK1/2, STAT3, mTOR,
P70S6K and RBwithout affecting their total protein levels. Signifıcant reduction
in cell number and colonies with ponatinib treatment implicates anti-neoplastic
effects in liposarcoma. Ponatinib treatment causes cell cycle arrest at G0/G1
phase by regulatingCDK4 and cyclinD1proteins levels. It also induces apoptosis
of treated cells by downregulating AKT and ERK signaling pathway leading to
dephosphorylation of BAD. Similar growth inhibiting effect of ponatinib was
demonstrated in in vivo liposarcoma xenograft model. In vitro drug sensitivity
profıling of liposarcoma highlighted Ponatinib, an oral FDA approved drug, as
potential therapeutic drug candidate for treatment and management of this
deadly tumor.
#4189 Homologous recombination pathway-based biomarkers for treat-
ment of non-small cell lung cancer with PARP inhibitors. Peter V. Deraska,
Hunter D. Reavis, Shelby Labe, Alan D. D’Andrea, David Kozono.Dana-Farber
Cancer Institute, Boston, MA.
Introduction: Clinical trials examining the addition of PARP inhibitors
(PARPi) to treatment regimens for non-small cell lung cancer (NSCLC) are
underway. Of note, these trials are not biomarker driven, and so any benefıt may
be obscured due to heterogeneity of tumor responses. The fırst FDA approved
PARPi, olaparib, was approved specifıcally for ovarian cancer patients with
germline mutations in BRCA1 or 2. These patients have tumors that show ho-
mologous recombination defıciency (HRD), a DNA damage repair pathway
defect that confers synthetic lethality in the setting of PARPi therapy. Whether
HRD may serve a biomarker for PARPi sensitivity in NSCLC, however, is un-
clear. Materials and Methods: Based on prior studies, NSCLC cell lines were
classifıed as 1) HR profıcient (A549, NCI-H23, NCI-H460, NCI-H522, NCI-
H1299), 2) HR defıcient due to early defects in the pathway as evidenced by
decreased cisplatin-inducedRAD51 focus formation (NCI-H1563, NCI-H1915,
NCI-H2087,NCI-H2126) or 3)HRdefıcient due to late defects in the pathway as
evidenced by impaired resolution of ionizing radiation (IR) inducedRAD51 and
-H2AX foci (Calu-1, Calu-6, HCC827, NCI-H520, SK-LU-1). NSCLC cells
expressing doxycycline-inducible BRCA1 or 2 shRNA were generated by Tet-
pLKO-puro lentiviral transduction. Cell viability assays to determine olaparib
IC50 values were performed using CellTiter-Glo and MTS. Gene expression
data were extracted from published datasets including CCLE, GSE32665 and
TCGA, and expression levels of select genes were assayed by RT-qPCR. Results:
BRCA1/2 shRNA knockdown inhibited IR-induced RAD51 focus formation in
HR profıcient NSCLC cells. This also induced PARPi sensitivity (A549 olaparib
IC50 63 M - 1.2 M with BRCA1 and 18 M - 3.4 M with BRCA2
knockdown). Because BRCA alterations are uncommon in NSCLC, however,
other HRD biomarkers were explored. There was no statistically signifıcant dif-
ference in PARPi sensitivity among cell lines grouped by cisplatin-induced
RAD51 focus formation or resolution of IR-induced RAD51 or -H2AX foci.
BRCA defıcient breast and ovarian cancers overexpress POLQ, which drives
DNA repair toward non-HR-dependent pathways including alternative end
joining. Like these cancers, NSCLC tumors overexpressed POLQ and RAD54L
compared to normal lung, p 0.001. Expression of these two genes correlated
highly in multiple datasets, e.g., r² 0.69 and p 0.001 in TCGA adenocarci-
nomas. High RAD54L expression tended to correlate with low olaparib IC50
values, r -0.56, p 0.059. NCI-H1299 and SK-LU-1, which showed the high-
est RAD54L expression, also showed the highest olaparib sensitivity. Conclu-
sion: Although certain HRD biomarkers including RAD51 focus formation and
impaired resolution did not predict NSCLC olaparib sensitivity, other potential
biomarkers, such as BRCA1/2 loss of function and elevated RAD54L expression,
may serve as potential HRD-related biomarkers.
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#4191 RXDX-106, a novel, selective and potent small molecule TAM
(TYRO3, AXL, MER) inhibitor, demonstrates effıcacy in TAM-driven tu-
mors. Erin D. Lew, Elizabeth A. Tindall, Joanne Oh, Colin Walsh, Maria Bar-
rera, Heather Ely, Amy Diliberto, Yumi Yokoyama, Gary Li, Amanda Albert.
Ignyta, Inc., San Diego, CA.
In recent years, the TAM (TYRO3, AXL, and MER) family of receptor ty-
rosine kinases (RTKs) has emerged as attractive targets for oncology therapeu-
tics. Under homeostatic conditions, the TAM RTKs are expressed by a number
of immune cells where they play key roles in the negative regulation of the
immune response. However, their expression on cancer cells has been specifı-
cally associated with epithelial-to-mesenchymal transition, an invasive pheno-
type, and more generally, with a poor prognostic outcome in human cancers.
Here, we sought (1) to establish whether expression of the TAMwas suffıcient to
drive cellular transformation, (2) to demonstrate that RXDX-106, a small mol-
ecule inhibitor of TAM RTKs, could inhibit tumors harboring activating TAM
gene fusions, and furthermore, (3) to decipher how pharmacological inhibition
of TAM signaling pathways both on cancer cells and immune cells would be
benefıcial, given their complex regulation and intimate relationship in the tumor
microenvironment. TAM expression on cancer cells has emerged as one of the
key mechanisms of resistance to targeted therapies, particularly to EGFR ty-
rosine kinase inhibitors (TKI). In addition, novel gene rearrangements (fusions)
have been identifıed in the TCGA database for both Mertk (TMEM87B-Mertk)
and Axl (Axl-MBIP) that retain the functionality of the tyrosine kinase domain,
but have fusion partners that alter the expression profıle or dimerization fre-
quency, respectively.Here, we demonstrate both in vitro and in vivo that expres-
sion of either wild type receptors or TMEM87B-MER and AXL-MBIP fusion
proteins is suffıcient to drive oncogenic transformation by both ligand depen-
dent and independent mechanisms. Treatment of these TAM-expressing cellu-
lar populations with RXDX-106 completely inhibits TAM phosphorylation and
downstream signaling and, consistent with our signaling data, RXDX-106 com-
pletely inhibits cellular proliferation and viability at sub-nanomolar concentra-
tions. Furthermore, we demonstrate that, in the co-culture of TAM-expressing
cancer cells with immune cells such as macrophages, TAM ligands such as Gas6
are secreted to drive liganddependent activation of TAMon cancer cells, leading
to their survival and proliferation. In summary, our data suggest that TAM
RTKs can act as traditional oncodrivers when activated either in a ligand depen-
dent or ligand independent manner. In addition, we demonstrate that TAM
fusions are tractable therapeutic targets and that patients with tumors harboring
such molecular alterations may derive clinical benefıt from RXDX-106. Finally,
we show that RXDX-106 not only has the potential to inhibit cellular prolifera-
tion and survival on the cancer cell itself, but also affect the TAM-expressing
tumor microenvironment to result in a global anti-cancer environment.
#4192 Targeting SHP-1/p-Lyn signaling shows therapeutic potential in
diffuse large B-cell lymphoma. Chun-Yu Liu,1 Man-Hsin Hung,1 Ming-Hsien
Tsai,2 Pei-Yi Chu,3 Tzu-Ting Huang,4 Chun-Teng Huang,5 Chung-Wai Shiau,6
Kuen-FengChen2. 1Taipei VeteransGeneralHospital, Taipei, Taiwan; 2National
Taiwan Univ. Hospital, Taipei, Taiwan; 3Show Chwan Memorial Hospital, Tai-
pei, Taiwan; 4National Taipei Veterans Hospital, Taipei, Taiwan; 5Yang-Ming
Branch of Taipei CityHospital, Taipei, Taiwan; 6National Yang-MingUniversity,
Taipei, Taiwan.
Background: Diffuse large B cell lymphoma (DLBCL) is one aggressive form
of non-Hodgkin’s lymphoma. Genetic analyses revealed molecular heterogene-
ity of DLBCL tumors, classifying the cell-of-origin into two distinct molecular
subtypes: germinal center B-cell (GCB) and activated B-cell (ABC). ABC-type
DLBCLhas aworse survival after upfront chemotherapy compared toGCB-type
DLBCL, thus ABC-type DLBCL patients have an unmet medical need that war-
rants additional research efforts and new therapeutic options. In current study
we explored the biological role and potential therapeutic implication of a protein
phosphatase SHP-1 in DLBCL. Methods: DLBCL cell lines including ABC-like
cell lines U2932, Ly-3 and GC-like cell lines DHL-6, Ly-7 and DB were used for
in vitro studies. Cell viability was examined by MTT assay. Apoptotic effects
were examined by flow cytometry and Western blot. Signal transduction path-
ways in cells were assessed byWestern blot. In vivo therapeutic testing of SHP-1
agonists were performed in nudemice withDLBCL xenografts. Results:We fırst
examined the protein expression of SHP-1 and its downstream p-STAT3 in a
panel of DLBCL cell lines, and identifıed in general SHP-1/p-STAT3 expression
was higher in ABC-like cells. Interestingly, the expressions of p-Lyn (Tyr396),
p-BTK (Tyr223), keymembers of B-cell receptor (BCR) signaling pathway, were
also higher in ABC-like cells. Knockdown or overexpression of SHP-1 protein
expression revealed a reciprocal change of p-Lyn, suggesting SHP-1 negatively
regulates phosphorylation of Lyn kinase. Immunoprecipitation experiments
confırmed SHP-1 interact with Lyn in DLBCL cells. We previously developed
direct SHP-1 agonists, namely SC-43 and SC-60, which could increase SHP-1
activities and induce apoptosis. Here we tested SC-43 and SC-60 in comparison
to ibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor. The SHP-1
agonists showed in general superior anti-proliferative and apoptotic effects,
comparing to ibrutinib.Mechanistically, SHP-1 agonists enhanced SHP-1 activ-
ity, decreased BCR signaling p-Lyn and p-BTK, which led to apoptosis. In addi-
tion, SHP-1 agonists also down-regulated p-STAT3 as previously reported,
which also contributes to anti-cancer effects. In vivo, SC-43 at doses of 10mg/
kg/day and 30mg/kg/day orally showed comparable anti-tumor effects with
ibrutinib at doses of 12.5 mg/kg/day and 25 mg/kg/day in mice bearing U2932
xenografts, respectively. Western blot confırmed SC-43 downregulation on p-
Lyn and p-BTK in vivo. Conclusions: SHP-1 negatively regulates phosphoryla-
tion of Lyn, and targeting SHP-1/p-Lyn with direct SHP-1 agonists shows ther-
apeutic potential in DLBCL.
#4193 A triple exon-skipping luciferase reporter assay identifıes a new
CLK inhibitor scaffold. Yihui Shi, Jaehyeon Park, Chandraiah Lagisetti, Wei
Zhou, Lidia C. Sambucetti, Thomas R. Webb. SRI International, Menlo Park,
CA.
The splicing of pre-mRNA is a critical process in normal cells and is deregu-
lated in cancer. Compounds that modulate this process have recently been
shown to target a specifıc vulnerability in tumors. We have developed a novel
cell-based assay that specifıcally activates luciferase in cells exposed to SF3B1
targeted compounds, such as sudemycin D6. This assay was used to screen a
combined collection of approved drugs and bioactive compounds. This screen-
ing approach identifıed several active hits, the most potent of which were CGP-
74514A and aminopurvalanol A, both have been reported to be cyclin-depen-
dent kinases (CDKs) inhibitors. We found that these compounds, and their
analogs, show signifıcant cdc2-like kinase (CLK) inhibition and clear structure-
activity relationships (SAR) at CLKs.We prepared a set of analogs andwere able
to ’dial out’ the CDK activity and simultaneously developedCLK inhibitors with
low nanomolar activity. Thus, we have demonstrated the utility of our exon-
skipping assay and identifıed newmolecules that exhibit potency and selectivity
for CLK, as well as some structurally related dual CLK/CDK inhibitors.
#4194 Antitumor activity ofmultikinase inhibitors inHER2-positive gas-
tric cancer cells. Takahiro Yoshioka, Kazuhiko Shien, Kei Namba, Hidejiro
Torigoe, Hiroki Sato, Hiromasa Yamamoto, Junichi Soh, Hiroaki Asano, Ka-
zunori Tsukuda, Toshiyoshi Fujiwara, Shinichi Toyooka. Okayama University
Graduate School, Okayama, Japan.
Background: The developments of novel anti-HER2 drugs includingmultiki-
nase inhibitors have achieved advancing evolution for past several years, and the
options in the treatment of HER2-positivemalignant tumors have been increas-
ing, especially in breast and lung cancers. On the other hand, regarding HER2-
positive gastric cancer, trastuzumab is still the only anti-HER2 drug with the
established clinical evidences. Afatinib, an irreversible human epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor, binds to the kinase domain of
HER2, and is one of the hopeful candidates as novel molecularly targeted drugs
for HER2-positive gastric cancer. In this study, we investigated the antitumor
effect of multikinase inhibitors including afatinib in gastric cancer cell lines.
Method: We examined the relation between molecular profıles and multikinase
inhibitors sensitivities in 12 gastric cancer cell lines: ECC10, GCIY, KATO-III,
MKN7, MKN74, N87, NUGC3, NUGC4, OCUM-1, SH-10-TC, SNU-16, and
SNU-216. In addition to multikinase inhibitors including afatinib, we also ex-
amined trastuzumab and gefıtinib sensitivity in 12 cell lines. HER2 copy number
alteration,HER2mutation, andprotein expression status ofHER2 and its down-
stream pathway molecules of these cell lines were analyzed by qPCR, direct
sequencing, and Western blotting, respectively. Cell proliferation was deter-
mined by a MTS assay. Result: Afatinib was effective in GCIY, N87, SNU-216,
NUGC3, and NUGC4 cells. The range of IC50 for these cell lines was 2.1 to 39.4
nM. All these cell lines except for NUGC3 were HER2 amplifıed. NUGC4, the
most afatinib sensitive cells, had also EGFR amplifıcation. Interestingly, among
the HER2 amplifıed cell lines, MKN7 cells were not sensitive to afatinib, never-
theless this cell line showed the activation of HER2 pathway with the expression
of phospho-HER2 by Western blotting. In addition, MKN7 cells were not sen-
sitive to other HER2-targeted drugs trastuzumab, and reported to be insensitive
to lapatinib either. On the other hand, ECC10 with HER2-L755S mutation was
not sensitive to afatinib. The range of IC50 in 7 insensitive cell lines was 0.80 to
more than 10 M. Three cell lines showed moderate sensitivity to gefıtinib of
which IC50 ranged from 100 to 1000uM. Inhibition rate of trastuzumab was
under 25% in all 12 cell lines. Conclusion: Afatinib, a multikinase inhibitor, is
highly effective to HER2 amplifıed gastric cancer cell lines, and may become a
novel treatment option inHER2-positive gastric cancer treatment. On the other
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hand, afatinib is not always effective even if cancer cells have HER2mutation or
amplifıcation. In this study, we report the detailed predictive biomarkers of
sensitivity to afatinib and other several multikinase inhibitors in HER2-positive
gastric cancer cells.
#4195 MIR002: a new POLA1 inhibitor endowed with a large spectrum of
antitumor activity. Claudio Pisano,1 Lucio Merlini,2 Sergio Penco,3 Raffaella
Cincinelli,2NadineDarwiche,4Mario B.Guglielmi,1 Antonietta Esposito,1 Ilaria
La Porta,1 Giacomo Signorino,1 Gabriele De Rubis,1 Fabiana Colelli,1 Francesco
Cardile,1 Alessandra Fucci,1 Egildo L. D’Andrea,1 Sabrina Dallavalle5. 1Biogem,
Centro Ricerche, Ariano Irpino (AV), Italy; 2University of Milan, Milan, Italy;
3Ronzoni Institute for Chemical and Biochem Research, Milan, Italy; 4American
University of Beirut, Beirut, Lebanon; 5Univesity of Milan, Milan, Italy.
A recent work fromHan et al. disclosedDNApolymerase 1 alpha (POLA1) as
the key target for the anti-cancer effects of CD437, a molecule belonging to the
class of Retinoid Related Molecules (RRMs). Before this evidence, this family of
compounds, of which CD437 and ST1926 represent the prototypes, has been
characterized for its antiproliferative, antitumor and pro-apoptotic activity.
With aim to identify a new RRMwith an improved pharmacological profıle, we
recently selected MIR002 as a novel compound endowed with a potent antitu-
mor activity and a peculiar pharmacological profıle. In vitro treatment with
MIR002 leads to a G1/S arrest and exerts a potent anti-tumor/proapoptotic
activity in a wide range of cancer cell lines, including H460-R9A cells, which are
cross resistant to ST1926 and CD437 (IC5070 fold of H460-R9A vs H460).
Moreover, in H460-R9A cells, we identifıed the L764F mutation in POLA1,
already described as a mutation conferring resistance to CD437. We also dem-
onstrated that POLA1 is the molecular target of both MIR002 and ST1926 and
that, interestingly, the expression of the L764Fmutant, although associated with
the resistance to RRM’s, only marginally reduces the cytotoxic effects of
MIR002. In order to investigate the activity ofMIR002 against tumor growth, we
examined a panel of in vivo xenograft tumormodels, including those originating
from human Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural
Mesothelioma (MPM). In these models, using a q2dx5x3w schedule in doses
ranging from 50 to 70 mg/Kg administered orally, we observed a strong tumor
growth inhibition (TGI70%). Interestingly, the combination of MIR002 with
Cisplatin (4mg/Kg; qd7x3w; i.v.) in MPM models showed a synergistic antitu-
mor effıcacy, reaching a TGI90%, and cured animals. Interestingly, we previ-
ously identifıed POLA1 as a key pro-proliferative player in 9 primary MPM
samples. The ex-vivo analyses indicated that POLA1 expression was strongly
modulated upon MIR002 treatment. Furthermore, in the same models, we also
observed that the expression/secretion of multiple circulating factors is affected
by MIR002 and we identifıed some of them as potential biomarkers of tumor
responsiveness to MIR002. Taken together, our results identify MIR002 as a
novel anti-cancer compound and suggest POLA1 as a target for new antitumor
strategies to be investigated in Clinical Trials.
#4196 Anti-tumor activity of aTAMkinase-targeting compound inCT-26
syngeneic mouse model. Shenshen Lai, Hong Zhang, Jun Yan, Zaihui Zhang.
SignalChem Lifesciences Corporation, Richmond, British Columbia, Canada.
Aberrant expression of TAM family receptor tyrosine kinases, comprising
Tyro3, Axl and Mer, is found in virtually every type of human cancer. The
expression levels correlate positively with disease staging and prognostic out-
come, attributing to metastasis and drug resistance. The TAM kinases have
recently emerged as a dual oncological therapeutic target, owing to their immu-
nosuppressive activity. Apart from targeting tumor-survival/growth pathways
their inhibition also unleash the anti-tumor immunity in the tumor microenvi-
ronment. In our efforts to develop small-molecule inhibitors targeting the TAM
kinases, we identifıed SLC-391 as one of the most promising preclinical candi-
dates with potent activity towards both Axl and Mer, which play roles in main-
taining tumor survival and immunosuppressive tumor microenvironment, re-
spectively. Pharmacodynamic studies of SLC-391 in CT26 syngeneic mouse
model revealed increase in the number of NK cells and the ratio of M1/M2-
polarized macrophages in the treatment group relative to the vehicle control,
followed by the rise of CD8T/Treg ratio and reduction in immunosuppressive
myeloid cells. This is indicative of sequential engagement and stimulation of
pro-inflammatory innate immune response and adaptive immune response. In
addition, a synergistic anti-tumor effect was observed when the anti-PD-1 in-
sensitive CT-26 model was treated with a combination of SLC-391 and an anti-
PD-1 antibody, suggesting that blocking the Axl/Mer-mediated immunosup-
pressive pathway may signifıcantly enhance the therapeutic effıcacy of immune
checkpoint inhibitors. In summary, the anti-tumor activity of SLC-391 is medi-
ated by directly inhibiting tumor cell growth as well as reversing the immuno-
suppressive tumor microenvironment.
#4197 Interaction ofB lymphoma cellswith themicroenvironment affects
ibrutinib sensitivity. Hsu-Ping Kuo, Sidney Hsieh, Mint Sirisawad, Chun-Te
Chen, Leo W. Cheung, Karl J. Schweighofer, Chia-Lin Hsu, Chi-Ling Fu, Jing
Liu, ShiquanWu,Karl Eckert, HughWang,MutiahApatira, KamaldeepDhami,
Kevin Kwei, Jeff Hsu, Betty Y. Chang. Pharmacyclics, LLC, anAbbVie Company,
Sunnyvale, CA.
Introduction: The cellular microenvironment plays a key role in the patho-
genesis of B-cell malignancies (Amé-Thomas, Blood 2007; Podar, Leukemia
2009). Bone marrow stromal cell interactions can provide survival signals to
CLL cells (Kurtova, Blood 2009), and stromal cell gene signatures and markers
can predict survival outcomes and add prognostic value, respectively, for pa-
tients with DLBCL (Lenz, NEJM 2008;Meyer, Am J Clin Pathol 2011). Ibrutinib
(ibr), a fırst-in-class, oral, once-daily inhibitor of Bruton’s tyrosine kinase, has
demonstrated single-agent activity in R/R DLBCL (Wilson, Nat Med 2015). In
this study, we established an in vitro coculture system and report the effects of
stromal cells on ABC-DLBCL cells and their sensitivity to ibr. Methods: The
effect of ibr on cell growthwas evaluated by luminescent cell viability assay. Flow
cytometry was used to evaluate the effect of ibr on cell death in different cell
populations. Live-cell imaging detected drug effects on apoptosis at different
time points. Gene expression levels in B lymphoma cells were examined by
quantitative PCR and NanoString panels. Human cytokines/chemokines were
quantifıed using MILLIPLEX® MAP Kit. Results: Reduced ibr sensitivity was
observed in TMD8 DLBCL cells cocultured with HS-5 bone marrow-derived
stromal cells. HS-5 cells protected TMD8 cells from ibr-induced apoptosis.
Treatment with ibr induced TNFSF10 expression only in TMD8 cells without
HS-5 coculture, providing a survival mechanism for escape of ibr-induced cell
death. In addition, coculturing withHS-5 decreased surface expression of CD20
but not CD19. Several cytokines/chemokines showed differential expression in
the coculture system (increased CCL22 and IL-10; decreased CCL4 and TNF).
Reduced expression of BCR signaling-related miR-155 was observed in ABC-
DLBCL and CLL cell lines with HS-5 coculture, suggesting downregulation of
BCR signaling in these cells. The adhesion molecule, SELL, showed decreased
expression in theABC-DLBCL cells culturedwithHS-5 aswell as in ibr-resistant
TMD8 cells, consistent with our observation that ABC-DLBCL patients with
poor responses (PDSD) to ibr have lower SELL expression in their tumor
samples. We further assessed expression levels of amino acid metabolism-re-
lated genes and demonstrated signifıcant increases of ASS1 and TDO2 in the
TMD8 cells cocultured with HS-5. Expression levels of amino acid metabolism-
related genes varied across patients with different responses to ibr, further sug-
gesting the importance of amino acid levels in the tumormicroenvironment and
ibr response. Conclusions: The changes in ABC-DLBCL cells cocultured with
stromal cells identifıed here may provide new insights into cellular cross-talk in
the microenvironment. Further investigation into cell-cell interactions and ibr
may help stratify patient populations and provide new therapeutic strategies.
#4198 Highly potent and selectiveDNA-PK inhibitorM3814with sustain-
able anti-tumor activity in combination with radiotherapy. Thomas Fuchss,1
Werner W. Mederski,1 Ulrich Emde,1 Hans-Peter Buchstallter,1 Frank Zenke,1
Astrid Zimmermann,1 Christian Sirrenberg,1 Lubo Vassilev,2 Lars Damstrup,1
Klaus Urbahns,1 Andree Blaukat1. 1Merck KGaA, Darmstadt, Germany; 2EMD
Serono, Billerica, MA.
Physical or chemical agents that damage DNA such as ionizing radiation are
among themost widely used classes of cancer therapeutics today. Double strand
breaks (dsb) generated in DNA by radiation induce a multitude of cellular re-
sponses, including DNA repair, cell cycle arrest or cell death once the damage is
left unrepaired. A complex set of molecular events are responsible for DNA
repair mediated by twomajor repair mechanisms - homologous recombination
(HR) or non-homologous end joining (NHEJ). DNA-PKcs together with its
regulatory protein subunits Ku70&Ku80, is an integral component of theNHEJ
process and considered an attractive intervention point to inhibit DNA dsb
repair. We have developed an orally bioavailable, highly potent & selective in-
hibitor of DNA-PK,M3814, for cancer therapy in combination with DNAdam-
aging modalities such as radiation & radio-chemotherapy. Here, we present the
optimization of initial hit matter & its structure-activity relationships leading to
M3814, its chemical structure (fırst-time disclosure) & preclinical characteriza-
tion using biochemical, cellular & human tumor xenograft models. M3814 sen-
sitized multiple tumor cell lines to radiation therapy in vitro and strongly en-
hanced the anti-tumor activity of ionizing radiation in vivowith complete tumor
regression by applying a clinically relevant fractionated radiation regimen.
These effects are due to inhibition of DNA-PK protein kinase activity as dem-
onstrated by the levels of DNA-PK autophosphorylation in human tumor cell
lines&xenograft tumors.M3814 is currently being investigated inPhI/II clinical
trials.
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#4199 Inhibition of NF-kB inducing kinase (NIK) selectively abrogates
NIK andTRAF3mutantmultiplemyeloma tumor growth.Matthias Versele,1
Lut Janssen,1 Tamara Geerts,1 Wim Floren,1 Boudewijn Janssens,1 Hillary Mil-
lar,1 Edgar Jacoby,1 Gerhard Gross,1 Yannick Ligny,2 Yvan Simonnet,2 Nathalie
Amblard,2 Olivier Querolle,2 Imre Csoka,2 Virginie Poncelet,2 Virginie Tronel,2
Sophie Nocquet-Thibault,2 Lieven Meerpoel,1 James Edwards,3 Marc Salvati,4
Sriram Balasubramanian,4 Laurie Lenox,4 Charles Theuer,5 Ricardo Attar,4 Ian
Stansfıeld2. 1Janssen R&D, Beerse, Belgium; 2Janssen R&D, Val-de-Reuil, France;
3Janssen R&D, San Diego, CA; 4Janssen R&D, Spring House, PA; 5Tracon Phar-
maceuticals, San Diego, CA.
Enhanced NF-kB signaling is a hallmark of aggressive lymphoid malignan-
cies, including multiple myeloma (MM), mantle cell lymphoma (MCL), and
diffuse large B-cell lymphoma (DLBCL). Non-canonical NF-kB signaling in-
volves NIK-dependent activation of IKK, which triggers nuclear accumulation
of p52/RelB heterodimers. NIK is a highly unstable protein and degradation is
mediated by a ubiquitin ligase complex consisting of TRAF2, TRAF3 and
c-IAP1/2 (encoded by BIRC2/3). In a subset of MM, NIK is stabilized by muta-
tions in NIK, TRAF2/3 or BIRC2/3 (Annunziata et al./Keats et al., Canc. Cell
2007). Similar activating mutations in the non-canonical NF-kB signaling path-
way were recently found in ibrutinib-refractoryMCL cell lines (Rahal et al., Nat.
Med. 2014), and in DLBCL (Zhang et al., Cell Rep. 2015). Inmany other cases of
B-cell malignancies, NIK is stabilized by high level expression of the upstream
TNF receptors (BAFFR, CD40, LTR) or high abundance of their ligands in the
bonemarrow or the lymph nodes. To date, bioavailable NIK inhibitors have not
been reported, and it has remained unclear whether NIK inhibitors are effective
and tolerated inmousemodels of B-cell malignancies associated with activation
of NIK. Here, we report for the fırst time on a potent orally bioavailable NIK
kinase inhibitor, TRC694. TRC694 selectively inhibits NIK enzymatic activity,
translating into inhibition of phospho-IKK in NIK and in TRAF3 mutant cell
lines with single digit nM IC50. TRC694 prevents nuclear accumulation of p52/
RelB (but not canonical NF-kB) and represses the associated NF-kB gene pro-
gram selectively in MM cell lines with genetic activation of the non-canonical
NF-kB pathway. Proliferation of NIK translocated, TRAF3 or BIRC3 mutant
MM cell lines is inhibited by low nM concentrations of TRC694, whereas MM
cell lines which lack genetic activation of non-canonical NF-kB are much less
sensitive to TRC694. Consistently, elevated expression of a previously described
11-geneNFkB signature inMM(Annunziata et al., Canc. Cell 2007) is predictive
of sensitivity to TRC694 in a 21-MMcell line panel. A single, oral dose of 10 to 40
mg/kg of TRC694 to mice bearing a NIK-translocated MM tumor (JJN-3), was
suffıcient to inhibit phospho-IKK and repress P52-mediated transcription of
NFkB regulated genes in the tumors. Consistently, once-daily, oral dosing of
TRC694 to mice bearing subcutaneous NIK translocated (JJN-3) or TRAF3
(RPMI-8226, MM.1S) mutant MM tumors, completely inhibits growth of these
tumors at doses of 10 to 40 mg/kg, with no signs of toxicities. In conclusion,
TRC694 is a fırst-in-class orally bioavailable NIK kinase inhibitor, and provides
the fırst opportunity to test the clinical relevance of non-canonical NF-kB inhi-
bition in aggressive lymphoid malignancies.
#4200 Targeting cancer stem cells in serous ovarian carcinoma using
RP6530, a dual PI3k 
/ inhibitor. Sneha S,1 Nivetha R,1 R P. Nagare,1 Srikant
Viswanadha,2 SwaroopVakkalanka,3 T S. Ganesan1. 1Cancer Institute, Chennai,
India; 2Incozen Therapeutics Pvt Ltd, Hyderabad, India; 3Rhizen Pharmaceuti-
cals SA, La Chaux-de-Fonds, Switzerland.
Ovarian cancer is one of the most lethal gynecological malignancies as most pa-
tients are diagnosed at an advanced stage andhave a poor prognosis. Several studies
have prospectively isolated cancer stem cells (CSCs) from samples of tumor from
patientswith serous adenocarcinomaof the ovary (SOC).This has been achievedby
using cell surface antigens or functional assays. Targeting this subpopulation could
be critical to overcome drug resistance, recurrence, and hence improve the survival
of patients. The PI3K pathway is deregulated in 37% of SOC with PI3K and 
amplifıed in 16% of tumors (TCGAdata).We have used a novel and selective PI3K
/ inhibitor (RP6530) with high potency against PI3K (IC5025 nM) and 
(IC5033 nM) enzymes and selectivity over  (300-fold) and  (100-fold) iso-
forms. RP6530, an orally active and sensitive small molecule inhibitor, is currently
being tested in Phase-1 trials in US and Europe to evaluate its safety and effıcacy in
patients with hematologicalmalignancies. The objective of this studywas to test the
effıcacy of RP6530 against CSCs of EOC. Spheroids, enriched for CSCs were em-
ployed as an approach to evaluate the specifıc potency of the drug. In the experi-
ments, Salinomycin was used as a control drug that targets CSCs. Initially, we have
analyzed 3 cell lines (PEO4,OVCAR-5 andCAOV-2)with andwithout addition of
5MRP6530. RP6530 signifıcantly inhibited spheroid formation in PEO4 (0.001)
andOVCAR-5 (p0.05) andCAOV-2 (p0.01) (mean of3 experiments in trip-
licate). In cell viability assay, RP6530 had no cytotoxic effect as compared to Cispla-
tin in any of the cell lines. To evaluate the effect of the compound on CSC, we
performed analysis of side population (SP) with Hoechst 33342 at 355 nm by flow
cytometry. RP6530 either caused a signifıcant reduction (50%) in the fraction of
SP cells (PEO4 and CAOV-2) or was neutral (OVCAR-5) indicating that the com-
pound preferentially targets CSC in ovarian cancer cell lines. Colony assay revealed
signifıcantly lesser number of colonies in RP6530 treated cells. Phosphorylation of
Akt that is downstream of PI3 kinase was inhibited in a dose dependent manner in
all three cell lines. Evaluation of drugs that are intended to target CSCs is different
from that of conventional cytotoxic drugs. Taken together, the results indicate that
RP6530 shows potent inhibitory effect on CSCs in ovarian cancer cell lines.
#4201 Combination of palbociclibwith enzalutamide shows in vitro activ-
ity in RB-profıcient and androgen receptor-positive triple-negative breast
cancer cells. Ling-Ming Tseng,1 Tzu-Ting Huang,1 Chun-Teng Huang,2 Ka-Yi
Lau,1 Chun-Yu Liu,1 Chung-Wai Shiau,3 Kuen-Feng Chen4. 1Taipei Veterans
General Hospital, Taipei, Taiwan; 2Yang-Ming Branch of Taipei City Hospital,
Taipei, Taiwan; 3National Yang-Ming University, Taipei, Taiwan; 4National
Taiwan University Hospital, Taipei, Taiwan.
Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have
in vitro synergistic effects and signifıcant clinical effıcacy in combination
with hormone therapy for estrogen receptor (ER)-positive advanced breast
cancer. However, the effects of CDK4/6 inhibitors in triple negative breast
cancer (TNBC) are not well-elucidated. Retinoblastoma (RB, a known sub-
strate of CDK4/6) protein pathway deregulation is a frequent occurrence in
TNBC and in vitro studies have revealed that pharmacological CDK4/6 in-
hibition yields a cooperative cytostatic effect with doxorubicin in RB-profı-
cient TNBC models, suggesting that RB may be a biomarker for selecting
patients receiving CDK4/6 inhibitors. In addition, anti-androgen therapy
have been shown preclinical effıcacy in androgen-receptor (AR) positive
TNBC cells. Here we tested the combination effect of a CDK4/6 inhibitor
palbociclib with an AR antagonist enzalutamide in TNBC cells. Methods:
MDA-MB-231, MDA-MB-468 and MDA-MB-453 TNBC cell lines were
used for in vitro studies. Cell viability was examined by MTT assay. Apopto-
tic effects were examined by flow cytometry. Signal transduction pathways in
cells were assessed byWestern blot. Results:We correlated the expressions of
AR and pRB status in these TNBC cells and identifıed that MDA-MB-453
were AR-positive/pRB-positive, MDA-MB-231 were AR-negative/pRB-pos-
itive, and MDA-MB-468 were AR-negative/pRB-negative cells. Since
CDK4/6 inhibition leads to dephosphorylation of pRB, we examined effects
of palbociclib and found that palbociclib signifıcantly inhibited the cell
growth of pRB-positive cell lines MDA-MB-453 and MDA-MB-231, but did
not affect pRB-negative MDA-MB-468 cells. Further combining palbociclib
with enzalutamide showed that the growth inhibitory effects of combination
therapy were additive in AR-positive/pRB-positive MDA-MB-453 cells, but
not in AR-negative/pRB-positive MDA-MB-231 cells, nor AR/pRB double
negative MDA-MB-468 cells. Moreover, palbociclib-induced G1/S arrest
only exhibited in pRB-profıcient MDA-MB-453 and MDA-MB-231 cells. In
contrast, enzalutamide did not affect the cell cycle on any of these TNBC cell
lines but inhibited phosphorylation of AR signaling in AR-positive MDA-
MB-453 cells. In addition, both palbociclib and enzalutamide induced little
apoptosis, suggesting cytostatic effects of these agents. Conclusions: In sum-
mary, both pRB and AR status are important for response of TNBC cells to
palbociclib. Combination of palbociclib with enzalutamide shows more
prominent cytostatic effects in RB profıcient and AR positive TNBC cells,
comparing to AR-negative/pRB-positive or AR/pRB double negative TNBC
cells. Our data provide a preclinical rationale in selecting patients whomight
have therapeutic benefıt from combining CDK4/6 inhibitors with AR antag-
onists.
#4202 Trametinib, a MEK inhibitor, augments nab-paclitaxel based che-
motherapy response in preclinical models of pancreatic cancer. Niranjan
Awasthi,1 SheenaMonahan,1 Alexis Stefaniak,2Margaret A. Schwarz,1 Roderich
E. Schwarz1. 1IndianaUniversity School ofMedicine, South Bend, IN; 2University
of Notre Dame, South Bend, IN.
Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading
cause of cancer related deaths in the USA with a 5-year survival less than 6%.
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, NPT) has demon-
strated 8.5 months median survival in combination with gemcitabine, and
now represents a standard of care for PDAC patients. Genetic alterations of
the RAS/RAF/MEK/ERK (MAPK) signaling pathway yielding constitutive
activation of the ERK cascade have been implicated in many human cancers.
In PDAC, activating K-ras mutations occur at a frequency of 90%, rendering
this a potential therapeutic target. Efforts to develop drugs that directly
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Targeting Protein Kinases and DNA Repair
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1073
target mutant KRAS protein remain challenging due to target specifıcity
issues. Alternative strategies therefore focus towards inhibition of down-
stream targets in the RAS-MAPK cascade such as MEK. Trametinib (Tra) is
a potent and highly selective small molecule inhibitor of MEK1/2 kinase
activity. We evaluated effıcacy of trametinib to enhance antitumor response
of nab-paclitaxel based chemotherapy regimens in preclinical models of
PDAC using K-ras mutant cell lines. In subcutaneous PDAC xenografts
using AsPC-1 cells, net tumor growth in different therapy groups was 432.6
mm3 in controls, 105.3 mm3 after NPT (p0.0023), 184 mm3 after Tra
(p0.0018), 81mm3 after NPTTra (p0.0003), 37.3mm3 after NPTGem
(p0.0025) and -8.1 mm3 (tumor regression) after NPTGemTra
(p0.0001). In another subcutaneous PDAC xenografts using Panc-1 cells,
net tumor growth in different therapy groups was: 274.1 mm3 in controls,
80.8 mm3 after NPT (p0.0002), 150.6 mm3 after Tra (p0.0047), 75.1 mm3
after NPTTra (p0.0002), 48.4 mm3 after NPTGem (p0.0004) and 3.8
mm3 after NPTGemTra (p0.0001). In PDAC peritoneal dissemination
model using AsPC-1 cells, median animal survival compared to controls (20
days) was increased after therapy with NPT (33 days, a 65% increase,
p0.0004), Tra (31 days, a 55% increase, p0.0004), NPTTra (37 days, a
85% increase, p0.0001), NPTGem (39 days, a 95% increase, p0.0001)
and NPTGemTra (49 days, a 145% increase, p0.0001). Effects of ther-
apy on intratumoral proliferation and apoptosis corresponded with tumor
growth inhibition data. In vitro studies demonstrated inhibition in PDAC
cell (AsPC-1, Panc-1, Mia PaCa-2, CFPAC) proliferation by NPTGem,
Tra, and combination. Immunoblot analysis revealed that trametinib effects
were specifıcally accompanied by decrease in phospho-ERK expression and
increase in the expression of apoptosis-related cleaved caspase-3 and cleaved
PARP-1 proteins. These fındings suggest that the effects of nab-paclitaxel
based chemotherapy regimens can be enhanced through specifıc inhibition
of MEK1/2 kinase activity, which clinically could lead to improved PDAC
therapy effects.
#4203 Kinase inhibitor demonstrates effıcacy in patient derived xenograft
model of fıbrolamellar hepatocellular carcinoma featuring DNAJB1-
PRKACA gene fusion. Jayant Thatte,1 Elvira C. Talaoc,1 Colleen Scott,1 Ken
Ren,2 Thomas Broudy1. 1Crown Bioscience San Diego, San Diego, CA; 2Casi
Pharmaceuticals Inc, Rockville, MD.
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare and distinct pri-
mary hepatic malignancy that has conventionally been considered to be a histo-
logic variant of hepatocellular carcinoma. However, it has more recently been
recognized as a distinct clinical entity with respect to its epidemiology and prog-
nosis. The etiology of FL-HCC is unclear and there is no clinical or histological
evidence for association with chronic liver disease. Recent genetic studies have
identifıed the fusion geneDNAJB1-PRKACA as a recurrent genetic lesion in the
disease. Molecular pathogenesis of FL-HCC; however, is not well understood
and has been reported to occur in association with focal nodular hyperplasia.
Overexpression of genes in PIK3, MAPK and RAS pathways is observed in
FL-HCC and in contrast to viral-associatedHCC, epigenetic instability is rare in
FL-HCC. Here we describe development of a novel FL-HCC Patient Derived
Xenograft (PDX) model LI5132. RNASeq analysis revealed presence of
DNAJB1-PRKACA gene fusion on chromosome 19, a molecular signature of
FL-HCC. Clinical diagnosis as HCC of fıbrolamellar type was confırmed by
H&E staining in the PDX tumor. The PDX tumor had a distinctive intratumoral
fıbrosis with a lamellar pattern. PDX model was established by inoculating pa-
tient tumor cells subcutaneously inNOD-SCIDmice. Robust tumor growthwas
observed with a 100% take rate in NOD-SCID mice. To evaluate the transla-
tional relevance of this model toward therapeutic development, the effıcacy of a
novel multi-target Aurora kinase A and angiokinase inhibitor, ENMD-2076,
was evaluated in a therapeutic mode in this model. ENMD-2076 showed signif-
icant effıcacy in suppressing tumor growth in NOD-SCID mice, at the 200
mg/kg dose evaluated in this study. Weight loss observed during the treatment
period could not be attributed to ENMD-2076 as it was similar to weight loss
observedwith vehicle treatment. ENMD-2076 has now progressed in to phase II
trials in the clinic for treatment of FL-HCC. This demonstrates the translational
utility of this FL-HCCmodel in development of anti-cancer therapeutic agents.
#4204 ASN002: A novel dual SYK/JAK inhibitor with strong antitumor
activity in both hematological and solid tumor xenograft models. Sanjeeva P.
Reddy,NiranjanRao,DavidZammit, ScottK. Thompson, RogerA. Smith, Louis
Denis. Asana BioSciences, Lawrenceville, NJ.
Spleen tyrosine kinase (SYK) and Janus kinase (JAK) play important roles in the
pathogenesis of various types of lymphomas, solid tumors, and myeloproliferative
and inflammation disorders. Inhibition of both SYK and JAK kinases has been
shown to suppress tumor growth in various preclinical and/or clinical studies.
ASN002 is a novel and potent dual inhibitor of SYK and JAK kinases with IC50
values of 4-46 nM in biochemical assays. Inmechanistic cell-based studies, ASN002
strongly suppressed theSYKand JAKfamily kinase signalingpathways asmeasured
in pLAT and pSTAT assays, respectively.When profıled in a panel of 178 cell lines,
the compound showed strong anti-proliferative activity in many lymphoid/leuke-
mia cell lines, including SU-DHL-6, SU-DHL-4,OCI-LY10,H929 andPfeiffer. The
proliferationofmanysolid tumorcell lines representingbladder, lungandcolorectal
cancer tumor types was also potently inhibited. Importantly, it also strongly inhib-
ited the growth of ibrutinib and idelalisib resistant cell lines. ASN002 was highly
effıcacious in inhibiting the tumor growth in several tumor xenograftmodelswhich
include Pfeiffer (diffuse large B-cell lymphoma, DLBCL), SU-DHL-6 (DLBCL),
H929 (myeloma), HEL (erythroleukemia), and RT112 (bladder). ASN002 shows
little to no inhibition of CYP450 isozymes suggesting low potential for drug-drug
interactions. ASN002 is currently being evaluated in a Phase I/II clinical study in
patients with lymphomas (DLBCL, mantle cell lymphoma and follicular lym-
phoma) and solid tumors.
CANCER CHEMISTRY: Drug Screening Innovation
#4205 Intracellular pharmacokinetics of 5FU and palbociclib: Uptake and
efflux in disaggregated cells and 3Dmodels.Maria Jove,1 Paul Loadman,1 Jade
Spencer,1 Lava Sulayman,2 JoWicks,1 Amanda Race,1 Chris Twelves3. 1Institute
Cancer Therapeutics, Bradford University, Bradford, United Kingdom; 2Utrecht
University, Utrecht, Netherlands; 3Leeds University, Leeds, United Kingdom.
Introduction: Pre-clinical drug development does not routinely assess drug pen-
etration beyond use of the human intestinal Caco-2 cell line as an in vitro model of
the intestinal barrier to evaluate potential drug absorption. Detailed in vivo tumour
pharmacokinetic (PK) studies areunusual.However, the ability of adrug to reach its
target plays a key role indrug effıcacy.Herewepresent amethodology to studydrug
PK in disaggregated cells and in a 3D cell culturemodel (spheroids) using 5FU and
palbociclib. The comparison of these 2 drugs is of interest taking into account their
different mechanisms and chemical properties, logP 0.58 and 2.12 respectively.
Knowledge of cellular uptake and efflux in disaggregated cells and 3D models to-
gether with intracellular binding characteristics is vital to optimise a better drug
delivery. Experimental procedures: MCF-7 and DLD-1 cells were used for cellular
and spheroid experiments. Spheroidgrowthwasoptimized toproducea spheroidof
300-400mdiameter at day 4. Drug uptake: 1x106 cells or 30 spheroids/time point
wereexposed to10M5FUor0.1Mofpalbociclib fordifferent timedurations.For
5FU, drug uptake at 100M was also monitored to detect 5FU metabolites. Drug
efflux: 1x106 cells were exposed fırst to 100M 5FU or 0.1M of palbociclib for
60min then, drugmedia removed, substituted by freshmedia and sample over a 4h
period. Drug concentration inside cells and in the freshmedia wasmeasured. Drug
concentrations weremeasured usingHPLC-TandemMass Spectrometry. Each ex-
perimentwascarriedout in triplicate.Results: 5FUachieves intracellular steady state
within 5-10min in cells and spheroids with equal concentrations inside and outside
the cell/spheroids. Intracellular metabolites of 5FU were only seen with 100M
treatment andhad a similar PK characteristics to 5FU. 5FUdrug efflux experiments
showed that efflux occurred rapidly within 5min achieving a new equilibriumwith
30% of 5FU remaining inside the cells. 5FUrdwas also detected extracellularly after
1h in the fresh media, showing that cells have both 5FU and metabolite efflux. In
contrast, palbociclib cellular uptake had an initial intracellular drug concentration
peak at 5-10min which then plateaued. Interestingly, total intracellular concentra-
tions of palbociclib were over 30 times higher compared to the externalmedia drug
at steady state. Spheroid and efflux experiments of palbociclib are on-going andwill
be presented. Conclusions: Our results suggest that both drugs penetrate quickly in
cancer cells. Palbociclib intracellular concentrations were 30 times higher than the
external media suggesting excessive intracellular binding while 5FU achieve equal
concentrations between the inside and outside of the cell. These data and method-
ology may be useful to allow generation of mathematical models to improve drug
delivery design.
#4206 A high-throughput 3D tumor spheroid screening method for drug
discovery using imaging cytometry. Leo Li-Ying Chan, Scott Cribbes, Sarah
Kessel, Scott McMenemy, Jean Qiu. Nexcelom Bioscience LLC, Lawrence, MA.
There have been 1600 FDA approved drugs since their inception in 1938.
Currently it costs approximately 883million dollars to bring a drug candidate to
the market, and often times the potential candidate fails at the beginning of the
clinical phase. Therefore, it is important to develop drug screeningmethods that
are more clinically relevant or predictable. The current 2D methods for cancer
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drug discovery have had some diffıculty in identifying potential drug candidates
that can be used for clinical testing. To overcome this challenge, there has been
an increase in research of 3D tissue culture that facilitated the development of
new in-vitro tumor model assays. Traditional 3D spheroid analysis method re-
lied heavily on visual observation using standard microscopy, which is time-
consuming and has high operator variations. In the recent years, high-through-
put image-based cytometers, such as Celigo, have demonstrated the ability to
perform bright-fıeld and fluorescence cell-based assays. Celigo imaging cytom-
eter can be employed to rapidly analyze and characterize 3D tumor spheroids,
which can be used to generate both quantitative and qualitative results. In this
work, we demonstrate a high-throughput 3D tumor spheroid screeningmethod
using the Celigo imaging cytometer to screen the effects of 14 drug compounds
(NIH/NCAT) on U87MG spheroid size, matrigel invasion, and tumor spheroid
viability. First, a dose response experiment is performed to screen the growth
inhibitory effects of the drug compounds. In addition to direct spheroid size
analysis, dose inhibitory responses of tumor invasion into the matrigel are also
examined. Finally, the use of specifıc fluorescent dyes such as Calcein AM, PI,
and Caspase 3/7 were used to screen drug induced cytotoxicity on the tumor
spheroids. The results showed that Celigo imaging cytometer can quickly gen-
erate accurate growth inhibitory data to identify potential drug candidates. Fur-
thermore, tumor invasion were clearly observed and quantifıed in the captured
images, as well as fluorescent analysis of tumor spheroid viability. By utilizing
the 3D spheroid screening method, researchers can rapidly characterize and
quantify drug effects on tumor spheroids in a high-throughput format, which
can improve the effıciency of identifyingmore qualifıed cancer drug candidates.
#4207 Selective drug sensitivity score (DSS) for indolent and aggressive
prostate cancer cell lines. Jenni Mäki-Jouppila,1 Jenni Bernoulli,1 Johanna
Tuomela,2 Mari I. Suominen,1 Jussi M. Halleen,1 Sanna Timonen,3 Elina Huo-
vari,3 Katja Suomi,3 Swapnil Potdar,3 Päivi Östling,3 Jani Saarela,3 Katja M.
Fagerlund1. 1Pharmatest Services Ltd, Turku, Finland; 2University of Turku,
Turku, Finland; 3Institute for Molecular Medicine Finland FIMM, Helsinki, Fin-
land.
Prostate cancer (PC) is the most commonmalignancy in men and the second
leading cause of cancer-related deaths. The majority of the PCs are classifıed as
adenocarcinomas characterized by the expression of androgen receptor (AR)
and prostate-specifıc antigen (PSA). Two of the most commonly used cell lines
are LNCaP and PC-3 cells, derived from lymph node and bone metastases,
respectively. AlsoVCaP cells, derived from vertebralmetastases, are widely used
in prostate cancer research. It has been well established that LNCaP and VCaP
cells represent the conventional indolent formof PC expressingARandPSAand
are androgen-dependent. PC-3 cells, on the other hand, do not express AR and
PSA, are androgen-independent, and represent the highly aggressive form. The
drug sensitivity of the cell lines was assessed by applying a large panel of drugs
covering cancer chemotherapeutics and clinically available and emerging drugs
including conventional chemotherapy, kinase inhibitors, metabolic modifıers,
rapalogs, differentiating/epigenetic modifıers, kinesin inhibitors, apoptotic
modulators, NSAIDs, hormone therapy, immunomodulators and HSP inhibi-
tors. A panel of 460 compounds was tested in fıve concentrations covering a
10.000-fold drug-relevant concentration range in 384-well format. Cells were
seeded to pre-drugged plates, followed by cell viability measurements (CellTi-
ter-Glo) after 72 hours.Maximal andminimal responses to drugswere analyzed,
the EC50 values were calculated andDrug Sensitivity Score (DSS)was calculated
for each drug as ameasure of reduced viability. A selectiveDrug Sensitivity Score
(sDSS) was calculated to identify the selective drug response pattern of each
three cancer cell lines. As expected, the results indicate that LNCaP and VCaP
cells in general were more sensitive to drugs of different categories than PC-3
cells. According toDSS analysis, all three cell lines showed sensitivity to conven-
tional chemotherapy and kinase inhibitors. However, PC-3 cells weremore sen-
sitive to kinase inhibitors than conventional chemotherapy. Determining sDSS
revealed specifıc sensitivities of each cell line. LNCaP cells were sensitive to
kinase inhibitors, such as mTOR and AKT inhibitors. Also VCaP cells showed
selective sensitivity to kinase inhibitors, especially Aurora kinase and IGF1R
inhibitors. In addition to kinase inhibitors, VCaP cells were selectively sensitive
to HDAC inhibitors. Furthermore, PC-3 cells were sensitive to e.g. CDK inhib-
itors.We conclude that the cell-based compound screening combined with DSS
and sDSS analysis provides a possibility to profıle cellular responses to an exten-
sive collection of anti-cancer compounds enabling repurposing of existing drugs
to new indications, identifıcation of vulnerabilities in different types of cancer
cells and functional investigation of cellular pathways behind drug sensitivity or
resistance.
#4208 Inhibition of proliferation and induction of apoptosis by a novel
phytobiological mixture against breast cancer cell lines. Afnan A. Alqarni,1
Aliaa A. Alamoudi,1 Ghada M. Ajabnoor,1 Ahmed M. Al-Abd,2 Aleksandra
Niedwiecki,3 Matthias Rath,3 Steve Harakeh4. 1King Abdulaziz University, Jed-
dah, Saudi Arabia; 2National Research Centre of Egypt, Giza, Egypt; 3Dr. Rath
Research Institute, Santa Clara, CA; 4King Fahd Center for Medical Research
King Abdulaziz University, Jeddah, Saudi Arabia.
Breast cancer remains a leading cause ofwomen’s deathworldwidewith progres-
sive emergence of resistance towards approved chemotherapies. For this reason,
new complementarytreatments have been sought. One of those includethe use of a
phytobiological mixture against different types of malignancies, including but not
limited to breast cancer. Herein, we investigated the anti-proliferative effects of a
novel phytobiological mixture (PB)against two breast cancer cell lines :MDA-MB-
231 and MCF-7.The PB mixture is composed of the following: quercetin, resvera-
trol, cruciferex, epigallocatechin-3-gallate and curcumin at different proportions.
Theanti-proliferative and pro-apoptotic effects of PB were evaluated at non-cyto-
toxic concentrations as determined usingthe Sulfa-Rhodamine B assay (SRB).The
effects of PBon the induction of apoptosiswere valuated usingAnnexin-V and flow
cytometry to measure the resultingDNA fragments. The results showed that at
72hrs, PB had cytotoxic effects against MDA-MB-231 and MCF-7 cells with an
IC50’s of 25.8	5.4g/mland56.9	4.2g/ml, respectively.ExposureofMDA-MB-
231 to PB for 72hrs resulted in the induction of apoptosis in a dose-dependent
manner. PB concentrations of 10 g/ml and 30 g/ml, resulted in early pro-
grammed cell death of 9.1	1.5% and 22.1	1.8% respectively. Exposure to PB (10
g/ml for 24 hrs) resulted in mild cell cycle arrest at the G2/M phase20.3	0.3%
;while higher dosesshowed a signifıcant cell cyclearrest at theS-phaseas compared to
the control untreated cells (p0.001). However, exposure to PB for 48 hrs at both
doses,10g/ml and30g/ml,resulted in a signifıcant cell cycle arrest at the S-phase
25.3	1.6% and 20.5	 0.4%respectivelyas compared to the control untreated cells
12.4	1.5% (p0.001). In conclusion, PB was found to have a promising anti-pro-
liferative and pro-apoptotic effect in breast cancer cell lines. Further studies are
needed to address the underlying mechanism of action of PB against breast cancer
cell lines.
#4209 Inhibitory activity of lichen secondary metabolite, physciosporin,
against lung cancer cell motility. Yi Yang,1 Young Hyun Yu,1 Hyung-Ho Ha,1
Kyung-Hwa Lee,2 Kyung-Sub Moon,2 Kyung Keun Kim,2 Hangun Kim1. 1Sun-
chon National Univ., Sunchon, Republic of Korea; 2Chonnam National Univer-
sity Medical School, Gwangju, Republic of Korea.
Lichens produce various unique chemicals that can be used for pharmaceu-
tical purposes. To screen for novel lichen secondary metabolites showing inhib-
itory activity against lung cancer cell motility, we tested acetone extracts of 13
lichen samples collected in Chile. Physciosporin, isolated from Pseudocyphel-
laria coriacea (Hook f. & Taylor) D.J. Galloway & P. James, was identifıed as an
effective compound and showed signifıcant inhibitory activity in migration and
invasion assays against human lung cancer cells. Physciosporin treatment re-
duced both protein andmRNA levels ofN-cadherinwith concomitant decreases
in the levels of epithelial-mesenchymal transition markers such as snail and
twist. Physciosporin also suppressed KITENIN (KAI1 C-terminal interacting
tetraspanin)-mediatedAP-1 activity in both the absence and presence of epider-
mal growth factor stimulation. Quantitative real-time PCR analysis showed that
the expression of themetastasis suppressor gene, KAI1, was increasedwhile that
of the metastasis enhancer gene, KITENIN, was dramatically decreased by
physciosporin. Particularly, the activity of 3=-untranslated region of KITENIN
was decreased by physciosporin. Moreover, Cdc42 and Rac1 activities were de-
creased by physciosporin. These results demonstrated that the lichen secondary
metabolite, physciosporin, inhibits lung cancer cell motility through novel
mechanisms of action.
#4210 Screening of kinase focused libraries for the identifıcation ofGreat-
wall inhibitors. Tristan D. Reuillon, SarahWalker, Darren Le Grand, Simon E.
Ward, Ben Wahab, Mohan B. Rajasekaran, Helfrid Hochegger, Antony W. Ol-
iver. University of Sussex, Brighton, United Kingdom.
MASTL (microtubule-associated serine/threonine kinase-like), commonly
known asGreatwall (GWL), is amember of theAGCkinase family andhas recently
emerged as a novel cancer therapy target. GWL regulatesmitotic division via phos-
phorylation of its known substrates ENSA andARPP19, which upon phosphoryla-
tion act as inhibitors of the PP2A-B55 phosphatase. Inactivation of PP2A-B55
induces sustained activity of the CDK1-cyclin B complex, triggering mitotic entry
and preventing mitotic collapse during cell division. Towards the end of mitosis,
GWL inactivation is required to initiate mitotic exit. Overexpression of GWL in
breast cancer cells drives oncogenic properties, such as transformation and inva-
sions. In particular, triple negative breast cancer tumors,which are associatedwith a
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poor prognosis, overexpress GWL and are highly sensitive to GWL depletion. In
addition, GWL expression has been found to be elevated in oral squamous cell
carcinoma and prostate cancer tissues. A number of studies have also indicated that
GWLmaycontributedirectly to tumorigenesis, suggesting thatmodulationofGWL
activity with small-molecule inhibitors could afford a potential new anti-cancer
therapy. The precise role of GWL in cells remaining largely unexplored, the identi-
fıcation of a pharmacological tool would be useful to further assess the tumor-asso-
ciated functions of this protein. To that end, we have recently developed and opti-
mized a robustHTRF assay, based on a specifıc ENSApeptide analogue, and used it
to screen kinase focused libraries, made available to us by GlaxoSmithKline and
Roche.A10.2%hit ratewasachieved fromthe screeningof the11,000compoundset
at a single concentration of 10 M.Molecules inducing over 50% inhibition in the
single point screen were subsequently tested in concentration-dependent experi-
ments. Analysis of the IC50 generated enabled to identify molecular clusters and
potential hits to initiate a medicinal chemistry campaign. A review of the literature
on the selectivity of the hits identifıed indicated that a signifıcant number of these
molecules also had affınity for other AGC kinases and that selectivity among the
AGCkinase family could be challenging to achieve.Computational studies using an
in-house co-crystal structure of GWL in complex with Staurosporine and the pub-
lished crystal structures of other AGC kinases will be used to design out selectivity
and guide the design of inhibitors to obtain a potent chemical probe.
#4211 Gene expression changes in Polyphenon E treated prostate cells. L.
Michael Carastro,1 RicardoA. Cordova,1 Daniel A. Barboto,1 RicardoA.Declet-
Bauzo,2 IrenaGushterova,1 Nicholas K. Lago,1 Nicholas E. Braganca,1 Joanna C.
Burr,1 Dara E. Hoffman,1 Jong Y. Park3. 1The University of Tampa, Tampa, FL;
2Universidad Central de Caribe, Bayamon, PR; 3Moffıtt Cancer Center & Re-
search Institute, Tampa, FL.
Prostate cancer (PCa) is themost commonmalignancy amongmen in the USA.
Polyphenon E (PolyE) is a standardized blend of polyphenols found in green tea
extract, which has been shown to have chemoprevention value in PCa models, but
themolecular mechanism(s) have not been elucidated. Polyphenols from green tea
are known to alter the expression levels of somegenes.Our experimental goalwas to
identify genes with expression level changes (up- or down-regulated by 2-fold or
more) in normal, primary prostate cells as well as two PCa cell lines, DU145 and
PC-3. Ultimately, we sought to identify genes whose expression level was differen-
tially altered by PolyE treatment in normal versus PCa cells. We hypothesized that
exposure to PolyE induces gene expression changes, which could provide rationales
for the molecular mechanism(s) and provide potential targets for therapeutics and
detection.Anon-cancerous, humanprimaryprostate cell line aswell as twoPCacell
lines (DU145 andPC-3)were cultured and treated themwith varied concentrations
of PolyE for 24 hours. Cellular RNAwas isolated and subjected tomicroarray anal-
yses (MA) at the Molecular Genomic Core facility of the Moffıtt Cancer Center. A
plethora of genes were identifıed byMA as having two-fold or higher gene expres-
sion level changes after PolyE exposure. Of these genes, fourteenwith were selected
for further analyses by TaqMan qRT-PCR. Cellular RNAs were converted into
cDNA used in validated TaqMan qRT-PCR assays (StepOneTM RT-PCR System).
RT-PCR data was analyzed using StepOneTM software and the 

Ct method.
ACTB served as the endogenous control gene for all TaqManqRT-PCRassays.Our
qRT-PCR data from PolyE-treated DU145, PC-3, and primary prostate cells were
consistent in the lack of expression changes greater than 2-fold for ATM, CASP8,
HDAC4 and RB1. For RGCC, MXD1, CCSER2/FAM190B, CBLB and BCL2L11,
gene expression levels increased by more than 2-fold in all three cell lines. For
CCNB1 and SEC62, primary cells experienced more than a 2-fold change in gene
expression, while the DU145 and PC-3 cell lines did not. Interestingly, ATM gene
expression levels decreased by more than 10-fold in primary prostate cells, but in
DU145andPC-3hadchanged less than3-fold.Mostnotably,RGS4geneexpression
levelswere differentially altered in primary prostate cells compared to the PCa lines.
In primary prostate cells, RGS4 decreased by more than 7-fold, but experienced a
greater than 10-fold increases in DU145 and PC-3. In summary, we have identifıed
RGS4asagenewhoseexpression levels aredifferentially affected inprimaryprostate
cells versus the PCa cell lines DU145 and PC-3.
#4212 Natural compounds alone and in combinationwith platinumdrugs
found to show signifıcant anti-tumour activity against ovarian cancer cell
lines.Md Sheikh Anwar,1 Jun Qing Yu,1 Philip Beale,2 Fazlul Huq1. 1The Uni-
versity of Sydney, Sydney, Australia; 2Concord Repatriation General Hospital,
Sydney, Australia.
Acquired drug resistance remains major problem in platinum based chemo-
therapy against ovarian cancer. It is believed that elevated expression of NF-kB
and AKT/PKB is one of the prime reasons for acquired drug resistance. Since
tumour active natural compounds can dampen NF-kB and AKT/PKB expres-
sion, it is thought that platinum drugs in combination with the natural com-
pounds may produce synergism in killing tumor cells. The present study aimed
to apply combinations of platinum drugs cisplatin, oxaliplatin, and carboplatin
with natural compounds mycophenolic acid, honokiol, cholecalciferol and
6-shogaol to four ovarian cancer cell lines: A2780, A2780CisR, A2780ZD0473R and
SKOV-3 towards overcoming drug resistance. IC50 values of single compounds
were determined followed by administration of binary combinations. Studies on
DNAdamage, cellular platinumaccumulation, and platinum-DNAbinding lev-
els were carried out. Proteomic studies will be done to explore the key proteins
involve with drug resistance. Mycophenolic acid (IC50: 1.34-7.83 M) from
Penicillium brevicompactum and 6-shogaol (IC50: 6.79-10.20 M) from Zin-
giber offıcinale showed signifıcant activity against ovarian cancer cell lines. Gin-
ger derived pure compound 6-shogaol showed prominent synergism in combi-
nation with platinums when administered as a bolus (0/0h) and with 0/4 h
sequence. Honokiol from Magnolia virginia alone and in combination with
cisplatin showed signifıcant DNA damage in A2780 cell line whereas cholecal-
ciferol did the same to A2780cisR cell line. Bolus combination of cisplatin and
6-shogoal produced increased cellular platinum accumulation and 3 timesmore
Pt-DNA binding than cisplatin alone treated A2780 cells. Though honokiol and
cisplatin (0/0 h) combination have half cellular platinum accumulation in com-
pare to cisplatin alone treated A2780 cells but showed 9 times higher Pt-DNA
binding. Cholecalciferol and 6-shogaol in combination with cisplatin also
showed promising Pt-DNA in A2780CisR cell line. In conclusion, 6-shogaol,
cholecalciferol and honokiol showed signifıcant activity alone and in combina-
tion with cisplatin and oxaliplatin against ovarian cancer tumour models.
#4213 A combined, affordable solution for the performance of automated
3D in vitro hepatotoxicity testing. Brad Larson,1 Kristina Klette,2 Michael
Mouradian2. 1Biotek Intruments, Inc., Winooski, VT; 2Hamilton Company,
Reno, NV.
Prescription medications, environmental toxins, and non-prescription herbal
remedies together form the major causes of hepatic injury. When looking at drugs
alone, induced hepatic injury is the most common reason cited for warnings or
withdrawal of an approved drug depending on the severity of the induced hepato-
toxicity. Due to this reality, a paradigm shift has taken place in the way toxicology
studies are beingperformed, includingdeterminationof hepatotoxicity. Early phase
assessment of potential hepatotoxic effects from a wider range of new and existing
drugs or chemicals is now the norm. Coupled with the change in the development
phase where testing takes place is the desire to use cell models that close the gap
between in vitro and in vivo systems. Hepatotoxicity studies historically have been
performedby repeatedly dosinghepatocytes cultured on the bottomof amicroplate
withmultiple concentrations of a test drug or compound. Because hepatocytes rap-
idly de-differentiate, losemetabolic activity, and lack the communication networks
found in vivo when cultured in this manner, results may be inaccurate and yield
misleading claims regarding the safety of the test agent. To combat this shortfall,
three-dimensional (3D) spheroidal models, incorporating hiPSC-hepatocytes, can
be incorporated that allow cells to aggregate and retain typical long-term viability,
functionality and communication found in vivo; allowing for the generation of re-
peatable, accurate data. To meet the demand for increased hepatotoxicity testing,
automationhas been incorporated to streamline the procedure and reduce the need
for large scale manual manipulations. Typically, included liquid handling systems
havebeen large, expensive, andmany times requiredplacement intocleanrooms for
sterile processing.While this type of solution is suitable for pharmaceutical, biotech,
and even larger core facilities, the size and cost can be prohibitive to the typical
academic research lab. Therefore, a smaller, less expensive instrumentation set,
which can still provide accurate and repeatable results, is necessary. Here we dem-
onstrate theability tocombine liquidhandlingwithanovel cell imagingmulti-mode
reader to perform 3D hepatotoxicity studies. hiPSC-hepatocytes were aggregated
into spheroids easily and effıciently using magnetic bioprinting technology. Multi-
ple known hepatotoxicants were tested with the automation and cell model to vali-
date the ability of the combined solution to be used to meet the need to perform
automated, walk-away hepatotoxicity studies in an academic setting.
#4214 Identifıcation of personalized active agents in pediatric gliomas
through high-throughput drug screening in matching pairs of patient de-
rived orthotopic xenograft (PDOX) neurosphere and monolayer cells. Lin
Qi,1 Yuchen Du,1 Mari Kogiso,1 Goeun Bae,2 Frank Braun,1 Holly Lindsay,1
Huiyuan Zhang,1 Sibo Zhao,1 Sarah Injac,1 Patricia Baxter,1 Jack Su,1 Michael
Mancini,3 Oliver Hampton,4 William Parsons,1 Murali Chintagumpala,1 Clif-
ford Stephan,2 Peter Davies,2 Xiao-Nan Li,1 Xiao-Nan Li1. 1Texas Children’s
Cancer Center, Houston, TX; 2Center for Translational Cancer Research, Hous-
ton, TX; 3Department of Molecular and Cellular Biology, Houston, TX; 4Human
Genome Center, Houston, TX.
CANCER CHEMISTRY: Drug Screening Innovation
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171076
Objective: Glioblastoma (GBM) is one of the deadliest brain tumors both in
adults and children. While next-generation sequencing rapidly identifıes whole
exome/genome gene mutations, the effıcacy of targeting mutated genes/path-
ways has not been systematically analyzed. Additionally, it remains unknown if
neurospheres (enriched with cancer stem cells) and non-stemmonolayer tumor
cells will respond equally to the same target therapies. Methods: Matching pairs
of neurosphere and monolayer cell cultures from 4 molecularly characterized
PDOX mouse models established from distinct clinical stages of pediatric gli-
oma (treatment-naïve, early recurrent, terminal, and radiation-induced) were
treated with 7,913 drugs (mostly in clinical use or trials) at 4 doses (0-10 uM) for
3 and 7 days. Dose-response curves and active area under the curve (AAUC)
were constructed to identify active drugs and correlate withmodel-specifıc gene
mutations. Results: Relatively long-term treatment (7 day screening) was
achieved for high-throughput drug screening and revealed time- and dose-de-
pendent effects in most of the 4,629 compounds that were active in at least one
culture at one time point. When gene mutations were druggable, not all inhibi-
tors of the same family were active. In IC-4687GBM (a treatment-naïve GBM),
high NF1 mutation (76-99% allele) frequency was found in patient tumor,
xenografts, and cultured cells, but only 3/17MEK inhibitors were active in neu-
rospheres and 2/17 in monolayer cells (GDC0980 and PI-103 were active in
both) on day 7. In IC-R0315GBM (from an autopsied terminal GBM) that car-
ried PI3KCA mutation (allele frequency 22-27%), 5/33 PI3K inhibitors were
active in neurospheres and 8/33 in monolayer cells (only Tremetinib was active
in both) after 7 days. In IC-3752GBM (recurrent GBM) and ICb-1127AA (radi-
ation-induced anaplastic astrocytoma), no druggable mutations were detected.
The number of active drugs on day 7 was 366 in IC-4768GBM, 406 in IC-
3752GBM, 284 in IC-R0315GBM, and 305 in ICb-1277AA. When the 4 match-
ing pairs of neurospheres and monolayers were compared, the agents active in
both cultures ranged from36% to 60%, active only in neurosphere from10.3% to
25%, and active only in monolayer cells from 14.8% to 53%. Subsequent in vivo
validation using MLN8327 in IC-4687GBM and IC-R0315GBM showed that
effective targeting of both neurosphere and monolayer was required for signif-
icantly-improved animal survival times. Conclusion:We showed that long-term
treatment is feasible for high-throughput drug screening. Targeting druggable
mutations can be achieved but only by a fraction of specifıc agents. Neuro-
spheres and monolayer cells do not always respond equally toward the same
drugs, and effective targeting of both subpopulations is needed to generate pro-
longed animal survival times.
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#4215 Cancer-related fatigue and physical activity vary by age for black
women with a history of breast cancer.Melody A. Swen,1 Amandeep Mann,2
Raheem Paxton,3 Lorraine T. Dean1. 1Johns Hopkins Bloomberg School of Public
Health, Baltimore,MD; 2Drexel UniversityDornsife School of PublicHealth, Phil-
adelphia, PA; 3University of North Texas Health Science Center, Fort Worth, TX.
Purpose: Cancer-related fatigue is the most discomforting symptom among
women with a history of breast cancer. Black women are more likely to experi-
ence risk factors for cancer-related fatigue, like physical inactivity and obesity,
yet cancer-related fatigue studies have not explicitly focused on Black women.
This cross-sectional analysis assesses cancer-related fatigue and physical activity
among Black female breast cancer survivors. Methods: InMay and July of 2012,
266 members of the Sisters Network, Inc completed an online survey on: demo-
graphics, cancer history and treatment, fatigue using the 13-item Function As-
sessment of Chronic Illness Therapy (FACIT) Fatigue Scale, and engagement in
150 minutes per week of physical activity (CDC guideline). Multiple linear
regression assessed relationships between fatigue and physical activity. Results:
The average participant was 54 (SD9) with a FACIT score of 13.63, indicating
“severe fatigue”. Fatigue was greater (p0.02) among the 56% of women meet-
ing physical activity guidelines. Multivariable analysis showed that meeting
physical activity guidelines (-3.01, p0.01) and higher age group (50-59:
-4.75, p0.001; 60: -4.38, p0.01) were associated with greater fatigue. An
interaction plot showed that differences in fatigue for those meeting or not
meeting physical activity guidelines is largest among Blackwomen under age 50.
Conclusions: Meeting physical activity guidelines was associated with greater
cancer-related fatigue, which was most pronounced for those under age 50.
Interventions for Black breast cancer survivors with cancer-related fatigue
should consider physical activities that can be integrated into existing tasks and
provide age-appropriate resources to address physical and emotional fatigue
domains.
#4216 Racial disparities in receipt of adjuvant hormonal therapy among
patients diagnosed with breast cancer in South Carolina. Oluwole A. Baba-
tunde, Swann Adams, Tisha Felder, Jan Eberth, Robert Moran, Erica Sercy,
James Hebert. Univ. of South Carolina, Columbia, SC.
Background: Women with hormone receptor-positive (HR) breast can-
cers (BC) have experienced signifıcant reductions in mortality as a result of
the use of adjuvant hormonal therapy (AHT). However, mortality rates re-
main higher among Blacks compared to Whites. This disparity has widened
despite overall improved BC survival rates over time. The widening gap in
Black-White mortality for BCmay be related to differences in tumor biology,
treatments received and access to care. The objective of this study was to
assess racial disparities in the receipt of AHT among patients diagnosed with
BC in South Carolina (SC). Methods: We derived data on all female BC cases
in 2002 to 2009 from the Central Cancer Registry linked with administrative
medical and pharmacy claims data for the Public Employee Benefıts Plan
(private insurance) and Medicaid. HR BC included three potential classi-
fıcations for estrogen (ER or ER-) and progesterone receptors (PR or
PR-): ER/PR, ER/PR-, ER-/PR. The main outcome variable was re-
ceipt of AHT (receipt vs non-receipt). The main exposure variable was pa-
tient race (White vs Black). Chi-square tests and logistic regression analyses
were conducted to compare patients who received AHT to those who did not
to identify important predictors of AHT receipt. Two-way interactions were
assessed between seven covariates hypothesized to modify the effect of race
(age at diagnosis, marital status, county of residence, year of diagnosis, re-
ceipt of surgery (early vs late), tumor stage and tumor grade). Results: Of the
1611 total breast cancer cases reported in the study period, 834 were HR
(641 white, 76.86%; 193 black, 23.14%). The crude odds of non-receipt of
AHT were 1.59 (95% CI: 1.14-2.21), and the adjusted odds was 1.23 (95% CI:
0.85-1.78) among Black compared to White patients. The adjusted odds of
non-receipt of AHT were 2.02 (95% CI: 1.36-2.99) and 5.15 (95% CI: 3.41-
7.77) among tumor grade II and III/IV compared to grade I respectively.
Stratifıed analysis showed that among patients who were married, the odds
of non-receipt of AHT were 2.19 (95% CI: 1.28-3.74) among Blacks com-
pared to Whites; among those that received late surgery, the odds of non-
receipt of AHT were 3.00 (95% CI: 1.34-6.71) among Blacks compared to
Whites; and among tumor stages II and III/IV, the odds of non-receipt of
AHT were 1.81 and 2.42 (95% CI: 1.14-2.87 and 1.29-4.55), respectively
among Blacks compared to Whites. Conclusions: To improve overall use of
AHT, efforts need to be directed at Black BC patients that received late
surgery (30 days after diagnosis).
#4217 Consumer credit, cancer treatment, and health amongwomenwith
a history of breast cancer. Lorraine T. Dean,1 Kathryn H. Schmitz,2 Kevin
Frick,3 Lauren Nicholas,1 Yuehan Zhang,4 SV Subramanian,5 Kala Visvana-
than1. 1JohnsHopkins Bloomberg School of Public Health, Baltimore,MD; 2Penn-
sylvania State University College ofMedicine, Hershey, PA; 3JohnsHopkins Carey
Business School, Baltimore, MD; 4University of Pennsylvania School of Medicine,
Philadelphia, PA; 5Harvard School of Public Health, Boston, MA.
Background: Breast cancer treatment may represent an economic shock that
may be influenced by, or may influence a cancer survivor’s socio-economic
position (SEP). Financial toxicity or economic burden due to cancer treatment
and treatment’s adverse effectsmay be reflected in one’s consumer credit ratings;
however, credit’s contribution to individual health for cancer survivors or those
managing long-term adverse effects of cancer treatment has not been evaluated.
This analysis examined associations between self-rated health outcomes of
womenwith a history of breast cancer, type of cancer treatment, and presence of
breast cancer-related lymphedema, a persistent adverse effect of treatment, and
consumer credit rating. Methods: From May to September 2015, 129 women
from Pennsylvania and New Jersey were enrolled in the PAL Social and Eco-
nomic Quality of Life cross-sectional study. All participants had a history of
breast cancer, and completed a survey of: demographics, SEP, co-morbidities,
SF-12 self-rated health, psychosocial stress, adjuvant cancer treatments (chemo-
therapy, hormone therapy, radiation), breast cancer-related lymphedema symp-
toms, and credit quality (5-point scale self-reported as poor to excellent). Mul-
tivariable linear regression measured the association between credit and health.
Results: Mean respondent age was 64, with 38.2% reporting excellent and 37.4%
reporting very good/good credit. Participants completed cancer treatment on
average 11.5 years ago. After adjusting for demographics and SEP, good credit
was associated with a 4.5 (p0.009) point increase in composite physical health
t-score and -1.13 (p0.02) decrease in psychosocial stress compared to women
with poor credit, but was not associated with type of cancer treatment or
lymphedema. Conclusion:While credit was associated with self-rated health for
women with an average 11.5 year history of breast cancer, current credit quality
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did not appear to be associatedwith type of cancer treatment previously received
or with the presence of lymphedema, a persistent adverse effect of cancer treat-
ment. It is still possible that cancer treatmentmay have influenced credit close to
time of treatment, and credit was able to rebound since that time. Future work
should test causal pathways between credit and health outcomes after cancer
diagnosis.
#4218 Racial similarities in the effects of depression on hospital cost of
breast cancer. Baqar A. Husaini,1 Oscar Miller,1 Meggan Novotny,1 Robert
Levine2. 1Tennessee State University, Nashville, TN; 2Baylor College of Medicine,
Houston, TX.
Objective: Breast cancer (BC) incidence is reported to have declined in the
nation. However, the role of depression on hospital costs for BC by race
remains unknown. In this presentation, we examine two issues: (i) preva-
lence of BC with comorbid depression among discharged hospital patients;
(ii) racial variation in the effect of co-morbid depression on hospital costs of
BC patients. Methods: We extracted data on depression and breast cancer
from the 2008 Tennessee Hospital Discharge Data System (HDDS). The BC
sample (n2,523) patients were mostly white (86%) with an average age of
63 years. We computed age-adjusted BC prevalence rates per CDC method-
ology, and compared the hospital costs for BC patients with vs. without
depression. Results: Age adjusted BC rates (per 100,000) were higher among
white than black patients (92.2 vs. 43.3, p.000). Nearly one-fourth (23%) of
BC patients had depression (no racial differences: (25% white vs. 24% black
BC patients). Hospital costs for BC patients were 17% higher compared to
non-BC patients, and cost was 55% higher among BC patients with co-
morbid depression compared to non-depressed BC patients ($64,439 vs.
$41,344). The higher cost for depressed BC patients was similar across both
white and black BC females. Conclusion: BC is higher among white females
compared to black females. BC patients cost with depression tended to be
signifıcantly higher compared to non-depressed patients regardless of race.
Since nearly one-fourth of BC patients were depressed with higher hospital
cost, these results point to possible signifıcant costs savings by treating de-
pression before the need for hospitalization among BC patients.
#4219 An exergaming intervention to reduce breast cancer risk in Black
women. Chiranjeev Dash,1 Jennifer Hicks,1 Vivian Watkins,1 Mary Mills,1
James Hagberg,2 Lucile L. Adams-Campbell1. 1Georgetown Lombardi Comp.
Cancer Ctr., Washington, DC; 2School of Public Health, University of Maryland,
College Park, MD.
Obesity and low physical activity rates contribute to high rates of postmeno-
pausal breast cancer in Black women. Use of new and exciting strategies to
increase physical activity should be tested in health disparity populations at high
risk of cancer.We tested the effect of a six-month exercise intervention using the
active videogaming systems (exergaming) on anthropometric markers, body
composition, and cardiovascular fıtness (VO2max) in overweight and obese
Black women. We conducted a six-month, two-arm randomized clinical trial
comparing an exergaming intervention group to a control group in 100 cancer-
free, overweight/obese, sedentary Black women who were 40-59 years of age.
Participants were randomized to a supervised facility-based exergaming group
(n50) or a usual care control group (n50). Participants in the exergaming
group followed an exercise program using the Nintendo Wii Fit and/or the
X-Box Kinect gaming systems under supervision of a clinical exercise physiolo-
gist. Control group participants were asked to maintain their normal daily ac-
tivities. Endpoints were assessed at baseline, 3 months, and 6 months. Assess-
ments included measurements of demographic variables, medical history,
physical activity, VO2max, anthropometric variables (height, weight, waist and
hip circumferences), and body composition. Distribution of baseline character-
istics between exergaming and control groups was comparable except for edu-
cation status and BMI. Data on 3 month and 6-month follow-up were available
for 66 participants. Follow-up rates were similar for exergaming and control
groups. Compared to control group participants whose waist circumference on
average remained unchanged, exergaming group participants had lower waist
circumference at 3-months and 6- months compared to baseline (mean change:
-2.54 cm, P0.05). Exergaming participants also had small changes in weight
(-1.4 lbs) at 6 months compared to control group in whom average weight
remained unchanged but this fınding was not statistically signifıcant. Fat mass
and lean mass as measured by DXA did not show any changes at 3-months or
6-months in either the exergaming or the control group. This pilot study of a
short-term exergaming in overweight/obese Black women was associated with
small changes in waist circumference in the intervention group. Given the chal-
lenges associated with traditional physical activity interventions to reduce can-
cer risk, new and non-traditional interventions like exergaming should be tested
in larger studies in health disparity populations.
#4220 Liverpool healthy lung project: a primary care initiative to identify
hard to reach individuals with a high risk of developing lung cancer. John K.
Field,1 Edward S. Gaynor,2 StephenW. Duffy,3 Katy Gardner,2 Cathy Hubbert,2
Dimitris Tsintzos,2MichaelW.Marcus,1 Lisa Jones,2 Rachel Avanitis,2Michelle
Timoney,2 Martin Ledson4. 1Univ. of Liverpool, Liverpool, United Kingdom;
2NHS Liverpool Clinical Commissioning Group, Liverpool, United Kingdom;
3Queen Mary University of London, London, United Kingdom; 4Liverpool Heart
& Chest Hospital, Liverpool, United Kingdom.
Introduction: TheUKLSCT screening trial has demonstrated that by utilizing
a population based approach, a risk prediction algorithm (LLPv2), volumetric
based CT nodule detection and a specifıcmanagement pathway, 80% of the lung
cancers detected were Stage I or II, 85% of which were suitable for surgical
resection. In the Liverpool region, 2.4% of the screened population were found
to have lung cancer at baseline. Methodology: Liverpool has one of the highest
lung cancer mortality rates in England, and double the national average of cases
diagnosed. It was decided to tackle this health inequality and the NHS Liverpool
Clinical Commissioning Group (CCG) introduced the Liverpool Healthy Lung
Programme (LHLP). LHLP, began in February 2016 and aims to increase knowl-
edge in communities, promoting positive messages around lung health, recog-
nizing and tackling fear and fatalism surrounding lung cancer. The LHLP is
undertaking coordinated, focused public engagement (Breathe Freely) events,
throughout the Liverpool region, starting in neighborhoods with the highest
incidence of lung cancer. These events are followed by patients between the ages
of 58-70 who have COPD, or have smoked, being invited to a local face to face
lung health check, conducted by a lung-health nurse working in local commu-
nity clinics and in partnershipwithGeneral Practice. Summary&Findings: This
assessment of lung health involved calculation of their risk of developing lung
cancer in the next 5 years (My Lung Risk). Those who triggered a 5% threshold
were offered low dose thoracic CT. In the Liverpool CCGRegion 34,000 patients
will be eligible: in the initial 12 weeks in the fırst neighborhood, 1014 of 2471
(41%) eligible individuals booked to attend the lung health check (865 attended),
351 (41%) triggered the offer of a CT appointment. 306 scans have been re-
ported; 31 (10%) had lung nodules. 59 (20%) had a noncancer signifıcant fınding
managed inGeneral Practice. To date, September, 4 have confırmed lung cancer
with surgical resection; 2 on follow-up. 406 patients (45%) were not previously
diagnosed with COPD, 225 (45%) had abnormal spirometry, and were referred.
238 (28%) accepted lifestyle referrals (e.g. smoking, exercise). Conclusion: The
project is over 3 years. Projections suggest 34,000 participants will be eligible.
We are aiming for an ambitious 70% uptake meaning 24,000 will have a face to
face lung health check. We estimate that 150 cases of lung cancer will be
diagnosed
#4221 Factors associatedwithHPVvaccination initiation and completion
among 18-26 year olds in the United States. Eric Adjei Boakye,1 Betelihem B.
Tobo,1 Daphne Lew,1 Meera Muthukrishnan,1 Vy T. Pham,1 Rebecca Rohde,2
Thomas Burroughs,1 Mark A. Varvares,3 Nosayaba Osazuwa-Peters4. 1St. Louis
Univ., Saint Louis, MO; 2St. Louis Univ. School of Medicine, Saint Louis, MO;
3Harvard Medical School, Boston, MA; 4St. Louis Univ. Cancer Center, Saint
Louis, MO.
Background: The HPV vaccine prevents HPV-associated cancers and genital
warts, which cause signifıcant morbidity and mortality in the US. While the
vaccine is targeted toward 11-12-year-old boys and girls, there is a catch-up
vaccination range up to 26 years.However, vaccination rates are very low among
eligible young adults, aged 18-26 years, and besides college-related studies, not a
lot is known about factors associated with the HPV vaccine uptake in this pop-
ulation. The aim of this study was to assess sociodemographic factors associated
with HPV vaccination uptake in a nationally representative sample of 18-26-
year-old adults. Methods: The National Health Interview Survey 2014-2015 was
examined for young adults, aged 18-26 years (n 7588). HPV vaccine initiation
was defıned as receipt of at least one dose of the vaccine and completion as
receipt of the three doses. Sociodemographic factors included age, gender, race,
marital status, education, health insurance, regular provider, number of doctor
visits, and geographic region. Survey-weighted multivariable logistic regression
models were used to examine the socio-demographic factors that were associ-
ated with HPV vaccine uptake. Results: Approximately 27% of respondents had
initiated the HPV vaccine and 16% had completed the HPV vaccine. After ad-
justing for covariates, compared to females, males were 81% less likely to initiate
HPV vaccine [(adjusted odds ratio) 0.19; (95 % confıdence interval) 0.16-0.23].
Other factors associated with HPV vaccine initiation included having health
PREVENTION RESEARCH: Population Science in Cancer Prevention Research
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171078
insurance (1.70; 1.32-2.18), visiting the doctor’s offıce 6 times (1.86; 1.48-2.34)
and 1-5 times (2.09; 1.56-2.81) vs. no doctor’s offıce within the last 12 months,
and having no high school diploma (0.46; 0.32-0.64) and having high school
diploma (0.40; 0.31-0.52) vs. college degree or higher. The same factors were
associated with HPV vaccine completion; but, being black (0.60; 0.44-0.83) vs.
white and having no usual place of care (0.74; 0.57-0.96) were also associated
with lower odds of completing the vaccine series. Conclusions: Our study shows
that there are sociodemographic factors associated with HPV vaccine uptake
among young adults in the United States, and males, individuals with a lower
education, and those without adequate healthcare access are less likely to initiate
and complete the HPV vaccination. Our fındings suggest it is necessary to de-
velop targeted interventions to promote HPV vaccination among those in the
catch-up age range.
#4222 Examining sociodemographic disparities in perceptions of cancer
risk from medical imaging radiation. Kekoa Taparra,1 Kay Pepin,2 Richard
Moser,3 Bradford Hesse,3 Alexandra Greenberg2. 1Mayo Clinic School of Medi-
cine, Rochester, MN; 2Mayo Clinic, Rochester, MN; 3National Cancer Institute,
Bethesda, MD.
In the United States, ionizing radiation frommedical imaging is estimated to
account for nearly half of the total radiation exposure among the general popu-
lation. While controversial, some estimates suggest thousands of future cancer
cases can be attributed to radiation from medical imaging. With the advance-
ment in medical technologies, understanding the health risks of radiation from
medical imaging has become increasingly complex for the average cancer pa-
tient. This complexitymay shape the public’s perceptions of the potential cancer
risks of medical imaging tests, including as x-rays, mammography, and radio-
active dyes. Due to the enumerable, often misleading, sources of information
available to the average consumer regarding the effect of radiation on general
health, trends in risk perception need to be assessed. To investigate the associa-
tion between perceptions of radiation exposure frommedical imaging and can-
cer risk, we analyzed data from the National Cancer Institute’s Health Informa-
tion National Trends Survey (HINTS 4, Cycle 2). HINTS is a probability-based
nationally-representative survey which collects data on the American public’s
knowledge, perception, and use of cancer- and health-related information since
2003. The data examined in the present study were collected between October
2012 and January 2013; (response rate  39.97%). Bivariate analyses reveal
individuals who perceive medical imaging radiation to be harmful to health are
largely female, Hispanic, non-Hispanic Black, or non-Hispanic Asian, with less
education and lower incomes. This perception is especially prevalent in individ-
uals who self-report having a poor or fair general health and less confıdence in
their ability to take care of their own health. After adjusting for sociodemo-
graphic and health care factors, a signifıcantly increased odds of believing radi-
ation frommedical imaging causes “some” or “a lot” of harm to healthwas found
among those who have had a previous cancer diagnosis compared to those who
did not (OR1.67, 95%CI1.18-2.35). Individuals who self-reported being
Hispanic (OR2.08, 95%CI1.29-3.34), non-Hispanic Black (OR1.54,
95%CI1.09-2.19), and non-Hispanic Asian (OR4.66, 95%CI2.05-10.62)
had signifıcantly higher odds of perceiving “some” or “a lot” of harm to health
frommedical imaging compared to non-Hispanic white counterparts. Our data
reveal existing populations that perceive radiation from medical imaging is
harmful to health. These perceptions, particularly among women and minori-
ties, may affect the personal decisions of cancer care from individual patients.
Future analyses may be useful to identify whether these perceptions alter health
outcomes, especially related to frequency of patients declining cancer radiation
therapy. Overall, understanding patient perceptions of radiation exposure and
cancer riskmay help guide conversation and education for physicians with their
patients.
#4223 Colorectal cancer knowledge and screening among Asian Ameri-
cans aged 50-75 years old. JennyGuo,1Hee-Soon Juon,1 Sunmin Lee2. 1Thomas
Jefferson University, Philadelphia, PA; 2University of Maryland, College Park,
MD.
Background: Chinese, Vietnamese, and Korean Americans, three of the larg-
est Asian American (AA) subgroups, have particularly high rates of colorectal
cancer (CRC) incidence and mortality. However, CRC screening rates among
these Asian Americans remain very low. Increased knowledge of CRC has been
shown to be positively correlated with a person’s inclination to undergo screen-
ing. Purpose: This study estimated the prevalence of up to date CRC screening
and examined the predictors of CRC knowledge and screening compliance
among Chinese, Korean, and Vietnamese Americans living in the Baltimore-
Washington metropolitan area. Methods: A cross-sectional sample was em-
ployed in this study and included 274 Chinese, Korean, and Vietnamese Amer-
icans between ages 50-75 years old. A questionnaire was given to participants in
either their preferred native language or in English.Datawas collected in person.
Results: Data from the 2009 California Health Interview Survey (CHIS) indi-
cates that Chinese Americans had higher rates of FOBT at 32.2% than Vietnam-
eseAmericans (27.3%) andKoreanAmericans (24.8%). Compared to these rates
from CHIS, we had signifıcantly lower rates of up to date FOBT: less than 10%
(9.1%) reported having FOBT in the past year. Vietnamese had the highest rate
(13.8%) followed byKorean (7.5%) andChinese (6.9%). For the prevalence of up
to date colonoscopy (10 years), CHIS data disaggregated by ethnicity among
AA shows that Vietnamese Americans (63.7%) had highest rates of having
colonoscopy followed by Korean Americans (51.1%) and Chinese Americans
(48.7%). In our study, Chinese had higher rates of up to date colonoscopy
(63.3%) than Vietnamese (47.5%) and Korean (43.0%). The average CRC
Knowledge Score was 6.10 out of 9 (SD2.91). In bivariate analysis, education,
marital status, and self-rated healthwere highly correlatedwithCRCknowledge.
Those with higher education levels, those married, and those rated with good
physical health had increased CRC knowledge. In multivariate analysis, educa-
tion, health insurance, and CRC knowledge were signifıcantly related to having
colonoscopy. Those with high CRC knowledge weremore likely to have colono-
scopy than those lowknowledge (aOR2.74, 95%CI, 1.13, 6.64). Thosewhohad
health insurance had higher likelihood of having colonoscopy than those with-
out health insurance (aOR4.40, 95% CI, 2.33, 8.32). Those more than high
school education were less likely to have colonoscopy than those with less than
high school education (aOR0.37, 95% CI, 0.16, 0.84). Conclusions: The fınd-
ings of this study suggest that CRC knowledge is a strong predictor of CRC
screening behavior in Asian Americans. Lack of CRC screening knowledge still
remains an important barrier to screening, and future strategies to increase
public awareness on CRC is necessary to achieve greater screening compliance
amongst AA populations.
#4225 Disparities in cervical cancer screeningparticipation: a comparison
of Russian, Somali and Kurdish immigrants with the Finnish general popu-
lation. Esther E. Idehen,1 Päivikki Koponen,2 Tommi Harkanen,2 Tellervo
Korhonen3. 1University of Eastern Finland, Kuopio, Finland; 2Finnish National
Institute for Health and Welfare (THL), Helsinki, Finland; 3University of Hel-
sinki, Helsinki, Finland.
Background: Cervical cancer screening throughPap test has been shown as an
effective preventive measure for early detection of precancerous in the cervix.
Finland offers mass Pap test screening to all eligible women. Knowledge about
disparities in the screening participation among immigrants compared with the
Finnish general population is limited. Objectives: (1) To compare Pap test
screening participation in the past fıve years among Russian, Somali and Kurd-
ish immigrants living in Finland with the Finnish general female population; (2)
to examine if the observed disparities remain similar when adjusted for socio-
demographic and health-related confounding factors. Methods: Data from the
Finnish Migrant Health andWell-being Study and Finnish Health 2011 Survey
were used. Random samples of persons living in six cities in Finlandwere drawn
from the national population registry. Data of self-reported cervical screening
participation (Pap test) among women aged 29-60 were available from the
women of Russian (n257), Somali (n113), Kurdish (n167) origin and the
general population (n 436). Logistic regressionwas used for statistical analysis.
Results: The age-adjusted Pap test participation rates were 79% among the Rus-
sian, 41% among the Kurdish, and 64% among the Somali, compared to 94%
among the Finnish general population. After adjusting for age, socio - demo-
graphic, and health-related confounders, the immigrants had signifıcantly lower
likelihood for screening compared with the Finnish reference group (Russian
Odds Ratio[OR] 0.33, 95% confıdence interval [CI] 0.19-0.58; Somali [OR]0.08,
[CI] 0.03-0.19; Kurdish [OR] 0.17 [CI]0.08-0.34). Conclusions: Initial results
demonstrate signifıcantly lower likelihood for Pap test screening among the
immigrant groups compared with the Finnish general population.
#4226 Challenges to breast cancer early detection in the developing, high
income country of Trinidad and Tobago.Kimberly Badal,1 Fidel Rampersad,2
Hamish Mohammed,3 Murrie Moosoodeen,4 Siva Konduru,5 Nalini Kokaram
Maharaj,6 Adaila Russel,2 Melissa Nathan,2 Marisa Nimrod,7 Wayne A. War-
ner,8 Rajini Haraksingh,2 Adetunji Toriola8. 1Caribbean Cancer Research Initia-
tive, San Fernando, Trinidad and Tobago; 2University of the West Indies, San
Fernando, Trinidad and Tobago; 3Public Health England, London, United King-
dom; 4San Fernando General Hospital, San Fernando, Trinidad and Tobago;
5Sangre Grande General Hospital, Sangre Grande, Trinidad and Tobago; 6Port of
Spain General Hospital, Port of Spain, Trinidad and Tobago; 7St James Medical
Complex, San Fernando, Trinidad and Tobago; 8Washington University in St.
Louis, St. Louis, MO.
PREVENTION RESEARCH: Population Science in Cancer Prevention Research
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1079
Trinidad and Tobago (T&T) has one of the highest breast cancer (BC)
mortality rates in the Americas. For the period 1995-2007, 5-year BC survival
rates in T&T were approximately 30%. One possible explanation for T&T’s
low BC survival rates could be late presentation and detection. Currently,
opportunistic BC screening programs exist in the public and private sectors
and some advocate for an organized national BC screening program. How-
ever, the World Health Organization (WHO) only recommends the imple-
mentation of organized BC screening in high resource settings. Thus, the
purpose of this study was to conduct a situational analysis of breast cancer
early detection services in the public and private sector to identify gaps in
service and determine if a national organized screening program is war-
ranted. The quality, availability, affordability and accessibility of BC screen-
ing services in the public and private sector was assessed with an online
survey using the Cancer Control WHO Guide for Effective Programs frame-
work. The inter-rater reliability and validity was assessed during a pilot
phase at two public institutions. All public and private facilities and NGOs
with BC early detection services were invited to participate in the survey. A
focus group with key radiologists in T&T was held to review the results of the
study, identify unaddressed challenges and make recommendations for im-
provement. Signifıcant challenges exist in service availability and access,
physical and human resources, program monitoring and evaluation, quality
control mechanisms, follow-up diagnostics and care. Specifıcally, services
are largely monopolized by the private sector at a cost to nationals. Public
services which are free, are restricted to major hospitals where wait times
extend to 3-6 months, thus contributing to a disparity in access. Both sectors
cite a lack of trained staff such as specialist breast radiographers and radiol-
ogists. There is also a lack of preventative maintenance and investment in
new machinery. No quality control guidelines or manuals for machinery use
exist in the public sector. Across both sectors, 70% of institutions have no
program evaluation. Other systemic problems such as long wait times for
pathology reports also undermine the effıcacy of current BC early detection
efforts. An organized national breast cancer screening program is not rec-
ommended for T&T at this time. More pressing concerns across the cancer
care continuum need to be fırst addressed particularly in strengthening hu-
man and physical resource capacity and service quality for detection, diag-
nosis, and follow-up care. Also, research into factors such as time-to-treat,
frequency of late stage presentation and misdiagnosis warrant further atten-
tion if T&T is to improve its BC survival rate.
#4227 The Family Life, Activity, Sun, Health and Eating Study: A public
use data resource for individual and dyadic analyses of cancer preventive
behaviors. Linda C. Nebeling,1 Laura Dwyer,1 April Oh,1 Erin Hennessy2. 1Na-
tional Cancer Institute, Rockville, MD; 2Tufts University, Rockville, MA.
The NCI’s Family Life, Activity, Sun, Health, and Eating (FLASHE) study
was designed to examine multilevel factors that relate to cancer preventive
behaviors within parent-adolescent dyads. The neighborhood, home and
school environments, parenting, psychosocial variables and demographics
were assessed. Outcomes were diet and physical activity behaviors, in addi-
tion to sleep, sun safety, and tobacco use. This presentation will describe the
FLASHE resources that are available to facilitate individual and dyad-level
analyses related to cancer preventive behaviors. The FLASHE study involved
two cross-sectional, web-based surveys of adolescents (12-17 years old) and
their parents that were administered between April -October 2014. One
survey focused on diet and another focused on physical activity and other
cancer-preventive behaviors. These surveys included constructs and items
that were informed by: existing literature, input from scientifıc experts, and
cognitive testing with 18 parent-adolescent pairs. A subset of adolescents
also wore an accelerometer for seven days to objectively assess physical ac-
tivity. A total of 1,573 parent-adolescent dyads completed all surveys. Of
these dyads, 38% were mother-daughter dyads, 36% mother-son, 13% fa-
ther-son, and 12% father-daughter. Parents were predominantly female
(75%), married (72%), and home-owners (72%), and 47% had a 4-year col-
lege degree. The majority of parents (70%) and adolescents (64%) were non-
Hispanic White. Approximately 16% of parents and adolescents were non-
Hispanic Black, and 7% of parents (10% of adolescents) were Hispanic.
Several resources are available for FLASHE data users. Survey datasets are
available for free download. Separate datasets for parents and adolescents
facilitate individual-level analyses on parents’ or adolescents’ health behav-
iors. Datasets can also be merged to conduct dyadic analyses, such as exam-
ining associations in health behavior constructs within dyad members. Ad-
ditional resources include: a methodology report, data users guide, list of
FLASHE constructs with references, sample statistical code for conducting a
dyadic analysis (Actor-Partner Interdependence Model), and an introduc-
tory webinar on dyadic data. These materials will be accompanied by a forth-
coming journal theme issue focused on the FLASHE study, including topics
such as: study development and methodology, physical activity and diet
assessment, and individual and dyadic approaches to examining FLASHE
data. Data on parent- and adolescent-reported constructs included in
FLASHE offer multiple opportunities to study research questions among
individuals and dyads and related cancer prevention behaviors. Researchers
interested in these areas can access FLASHE data and resources online to
examine their own research questions.
#4228 Interlaboratory concordance of genetic variant classifıcations in
BRCA1 and BRCA2. Stephen E. Lincoln,1 Shan Yang,1Melissa S. Cline,2 David
Haussler,2 Benedict Paten,2 Robert Nussbaum1. 1Invitae, San Francisco, CA;
2University of California, Santa Cruz, Santa Cruz, CA.
Background: Clinical laboratories use publicly available literature, data-
bases, and expertise to determine the pathogenicity of genetic variants in test
reports. Recently, discordances between public databases have been raised as
a concern, most prominently by those who use proprietary data in their
classifıcation processes. However, the clinical impact of these discordances is
unclear. In prior work, we observed 99.8% concordance of clinically signif-
icant variant classifıcations between two labs across 975 prospectively ac-
crued patients (Lincoln et al., J Mol Diag 2015). Here we evaluated
BRCA1/12 variant classifıcation concordance amongmultiple labs in a much
larger patient population. Methods: Over 5000 ClinVar submissions of clas-
sifıed BRCA1/2 variants from 7 established laboratories (Ambry, the Chil-
dren’s Hospital of Eastern Ontario, Counsyl, Emory, GeneDx, Invitae, and
Myriad) were available for comparison. Myriad data were submitted by the
Sharing Clinical Reports Project. Clinically signifıcant differences were those
that could substantially change clinical management: i.e. between patho-
genic (including likely pathogenic), versus VUS (variant of uncertain signif-
icance), benign or likely benign; otherwise results were considered concor-
dant. Approximately 22,000 patients were represented in this comparison.
Results: Counting each variant separately, concordance between labs was
high: 98.5% overall. However this calculation greatly underestimates the
much higher concordance calculated on a per-patient basis. All discordant
classifıcations were in rare variants that, by defınition, are present in very few
patients. Moreover, classifıcations of most rare variants are concordant
(sometimes, concordantly VUS). Based on clinical and population preva-
lence, we calculate that 99.8% of patients would receive net concordant
BRCA1/2 reports, similar to our previous study’s results. The dominant
sources of discordance were (a) date, where classifıcations that postdate a
critical piece of evidence disagree with those that predate it; and (b) expert
judgment differences evaluating the strength of certain evidence, usually
functional assays. Discussion: Classifıcation concordance needs to be mea-
sured carefully to avoid over-counting differences. While substantial differ-
ences are seen in few patients, it is important to resolve these collaboratively,
not competitively, as is done in other areas of oncology. Thorough and
ongoing peer review of classifıcations is enabled by public databases like
ClinVar which both enable laboratory quality control efforts and help im-
prove personalized medical care practices.
#4229 Metabolically active macrophages: A novel link between obesity
and TNBC. Payal Tiwari, Kelly Schoenfelt, Ariane Blank, Chang Cui, Marsha
Rich Rosner, Lev Becker. Univ. of Chicago, Chicago, IL.
Triple negative breast cancer (TNBC) patients have an extremely poor
prognosis due to their high metastatic potential and lack of targeted drug
therapies. Emerging epidemiological data suggest that obesity is strongly
linked to the incidence and severity of TNBC. However, mechanisms by
which obesity potentiates TNBC progression are unclear. Adipose tissue
macrophages (ATMs) are an attractive mechanistic link between obesity and
TNBC because they are the predominant type of macrophage in the breast
during early tumorigenesis and obesity causes accumulation of ATMs. How-
ever, during obesity, the macrophage phenotype was reported to switch from
an apparent pro-tumorigenic M2-like phenotype to an apparent anti-tumor-
igenic M1-like phenotype. This result raises a paradox: how does obesity
promote tumor progression if it activates an anti-tumorigenic macrophage
phenotype? Here we show that metabolic dysfunction promotes a mechanis-
tically distinct pro-inflammatory phenotype (metabolic activation; MMe) in
breast adipose tissue macrophages isolated from obese women. These ATMs
express cell surface markers of MMe (CD36, ABCA1) but not M1 (CD38,
CD319, CD274) macrophages. We further demonstrate that pretreating
TNBC cells with conditioned media derived from MMe but not M1 macro-
phages promotes mammosphere formation as well as invasion in vitro, and
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intravasation of cancer cells into the blood in vivo. Moreover, pre-treated
cancer cells showed a two-fold increase in the expression of stem-like cell
markers (OCT4, SOX2 and NANOG). Remarkably, we saw the same effect
on ’stemness’ of tumor cells in a spontaneous TNBC mouse model when fed
a 60% high fat diet and a signifıcant increase in tumor incidence in obese
mice compared to lean mice in a syngeneic mouse model. We further show
that blocking inflammatory cytokines expression in MMe(s) using genetic
knockouts inhibits the ability of MMe(s) to promote both mammosphere
formation and invasion. These fındings suggest that obesity-induced
changes to mammary adipose tissue reprogram macrophages to an MMe
phenotype that potentiates TNBC initiation andmetastasis via inflammatory
cytokines. A comprehensive understanding of the signaling mecha-
nism(s) involved in metabolic activation of mammary ATMs would enable
development of directed therapies towards this specifıc pro-tumorigenic
macrophage phenotype, thereby leaving the immune system of cancer pa-
tients intact.
#4230 Modulation of adiponectin and leptin levels in obese post-meno-
pausal women after 6 months of a structured weight loss intervention, ran-
domized to placebo or supplemental omega-3 fatty acids. Bruce F. Kimler,1
Jennifer L. Nydegger,1 Amy L. Kreutzjans,1 Teresa L. Phillips,1 Kandy R. Pow-
ers,1 Jennifer R. Klemp,1 Debra K. Sullivan,1 Christie A. Befort,1 Susan E. Carl-
son,1 Stephen D. Hursting,2 Carol J. Fabian1. 1Univ. of Kansas Medical Ctr.,
Kansas City, KS; 2Univ. of North Carolina at Chapel Hill, Chapel Hill, NC.
Background: Obesity is a modifıable risk factor for breast cancer in the
United States. While structured interventions can achieve short-term weight
loss, this does not necessarily correlate with favorable modulation of risk
biomarkers at the blood or breast tissue level. We combined a proven inter-
vention (calorie-controlled meals, moderate exercise, and weekly group be-
havioral session) with daily omega-3 fatty acid supplementation to examine
whether we could improve either weight loss and/or biomarker modulation
in women who are at high risk for development of breast cancer. Methods: 46
post-menopausal high-risk women with a BMI  27 kg/m2 (median 31 kg/
m2) had baseline blood collections and random periareolar fıne needle aspi-
ration (RPFNA) benign breast tissue sampling for biomarkers. Two weeks
after starting the weight loss intervention, subjects received study agent,
randomized 1:1 to placebo vs. supplementation with 2100 mg Eicosapenta-
enoic Acid (EPA)  1050 mg Docosahexaenoic Acid (DHA) daily. After 6
months, blood and tissue sampling were repeated. Results 42 women com-
pleted the 6 month weight loss intervention with all but one achieving a
weight loss (median relative weight loss 12%; range 0 to 23%). For the entire
cohort, there were substantial and favorable changes in levels in serum of
blood collected fasting for adiponectin (increase; p0.01) and leptin (de-
crease, p0.001), as well as the ratio of adiponectin to leptin (A:L, increase,
p0.001). The same effect for all three measures was observed in serum
collected 2 hours after a standard meal; and for leptin and the A:L ratio in
breast tissue also collected postprandial. When dichotomized to relative
weight losses of 10% vs 10%, women with 10% loss had greater favor-
able modulations for leptin and the A:L ratio for fasting and non-fasting
serum (0.0001 for all) as well as breast tissue (p0.004). There were no
signifıcant differences between groups of women dichotomized by whether
they exhibited (or not) an increase in the ratio of EPA:DHA to arachidonic
acid in erythrocyte phospholipids at 6 months. Conclusions: These results
demonstrate that the cytokines adiponectin and leptin, and the ratio of the
two, are robust biomarkers for modulation in serum and breast tissue of
women achieving a successful weight loss on a structured intervention trial.
Supported by a grant from the Breast Cancer Research Foundation and pilot
funds from National Cancer Institute Cancer Center Support Grant P30
CA168524.
#4231 Signifıcant reduction in workplace contamination of antineoplas-
tic hazardous drugs in 13U.S. hospitals following utilization of a new closed-
system drug transfer device. Timothy Tyler,1 Luci Power2. 1Desert Regional
Medical Center, Palm Springs, CA; 2UCSF (retired), San Francisco, CA.
Background: Adverse effects of worker exposure to antineoplastic hazard-
ous drugs (AHD) have been well documented with dermal absorption from
contaminated surfaces in the work environment being one of the most well
researched sources of exposure. Multiple studies have documented de-
creased surface contamination when using CSTDs for AHD handling. De-
creased surface contamination should result in decreased worker exposure
and decreased risk of adverse effects. Purpose: The purpose of this study was
to determine the effectiveness of a new CSTD in reducing surface contami-
nation of marker AHDs cyclophosphamide (CP) and 5-fluorouracil (5FU)
during compounding and administration in multiple cancer centers, using
surface wipe-sampling methodology. The results of the wipe sampling were
compared to existing contamination in the sites and to similar studies in
peer-reviewed literature to determine relative effectiveness. Methods: Wipe
samples of six predetermined surfaces were collected in designated com-
pounding and infusion areas of 13 cancer centers to establish the preexisting
level of surface contamination with two marker AHDs. Stainless steel tem-
plates of approximately 500 cm2 were placed over previously sampled sur-
faces, and a specifıc protocol of set doses of the AHDs were compounded and
infused, using all of the components of the new CSTD system, over the
templates. Wipe samples of the templates were collected following the com-
pletion of tasks and analyzed for both marker AHDs. Results: A total of 312
wipe samples were collected from the 13 centers, 156 at baseline and 156 with
the CSTD. All samples were reported as ng/cm2 with the analytical limit of
detection (LOD) for each drug being 0.002 ng/500 cm2. In the aggregate
results of 13 sites sampled for existing contamination, 67% of wipe samples
had detectable levels of the AHDs with a range of LOD to 19.880 ng/cm2 of
5FU and 0.648 ng/cm2 of CP. With the new CSTD the contaminated samples
were reduced to 5.8% with a range LOD to 0.004ng/cm2 of 5FU and 2.60ng/
cm2 of CP. Conclusions: The new CSTD signifıcantly reduced surface con-
tamination by the marker AHDs during both compounding and administra-
tion. Compared to published results of two multi-site studies of another
CSTD for compounding, the new CSTD is superior in reducing surface con-
tamination with marker AHDs, as determined by wipe sampling of similar
surfaces. Research reported in this study was supported by the National
Cancer Institute (NCI) of the National Institutes of Health (NIH) under
award number 5R44CA153636.
#4232 Gastrointestinal stromal tumor: Retrospective analysis of 44 cases
of center of reference in eastern Algeria. Soufyane Ali Boukhalfa, Tah Filali.
CHU de Constantine, Tadjenanet, Algeria.
Aim: To analyze the clinicopathologic characteristics, prognostic factors,
and treatment of gastrointestinal stromal tumors (GISTs). Methods: We
conducted a retrospective analysis of all cases of GISTs treated in theMedical
Oncology Unit from 2010 through 2015. Results: We analyzed 44 patients
with a median age of 49.43 years (17-76 years) with sex ratio 1:1. The main
symptom was abdominal pain. Thirty patients had limited-stage disease and
14 patients had metastatic disease. We observed 90% of the immunohisto-
chemistry exams were positive for CD117 (c-Kit). The most frequent lo-
cation was in the stomach (45%), the high-risk group was predominant
(50%) and the average tumor size is 12.84 cm. Surgery was considered R0
(extensive) in 75% of the cases and themain sites of metastases were liver and
peritoneum.25 patients received imatinib 400 mg qDay in adjuvant setting,5
patients in neoadjuvant, 13 patients in palliative and 1 patient had best
supportive care. A total of 44 patients were followed up for 1 to 78 months.6
patients (13 %) developed recurrence or metastasis during or after adjuvant
treatment. Two patients had surgery after neoadjuvant treatment(40%). 4
patients treated in second line with imatinib 800 mg qDay, 5 patients with
sunitinib and 2 patients rechallenged in third line with imatinib 800 mg
qDay. Conclusion: Our patients presented mainly in the form of high-risk
disease, Surgery is the mainstay treatment when GISTs are localized, Adju-
vant therapy is used depending their risk of relapse. In the advanced disease,
tyrosine kinase inhibitors have substantially improved the prognosis of
GISTs.
#4233 Linking education to action: A program to increase research par-
ticipation among African American women. Carmen Radecki Breitkopf,1
Karen P. Williams,2 Jennifer L. Ridgeway,1 Alice L. Strong Simmons,3 Monica
W. Parker,4 Michele Y. Halyard,5 Sharonne N. Hayes1. 1Mayo Clinic, Rochester,
MN; 2The Ohio State University, Columbus, OH; 3The Links, Incorporated, DC;
4Emory University, Atlanta, GA; 5Mayo Clinic, Scottsdale, AZ.
Addressing underrepresentation of minorities and women as research
participants has largely focused on clinical trials, while little is known about
attitudes and knowledge regarding other types of biomedical research, e.g.,
epidemiologic and genetic studies. These types of studies are essential for
advances in cancer research, including development of targeted therapies for
women and minorities. As part of an academic/community partnership be-
tweenMayo Clinic and The Links, Incorporated, a national volunteer service
organization of professional African American women, this study sought to:
(1) examine attitudes regarding participation in research involving access to
the medical record, genetic studies/biobanking, and clinical trials; and (2)
develop and evaluate a novel, targeted online educational program address-
ing these 3 types of biomedical research. Initial qualitative inquiry via 3 focus
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groups (n34) found that most women associated health-related research
with clinical trials; few women were familiar with other study types. Women
expressed more concerns about how information is collected, used, and
shared by investigators than with personal mistreatment in research regard-
less of study type (genetic research (GEN), chart review (CR), clinical trial
(CT)) or the kind of information (social, health, genetic) collected. The
importance of investigator transparency regarding the signifıcance of the
disease in African Americans, research funding source, the investigator’s
agenda, and commitment to the population being studied was emphasized.
Qualitative results informed development of the educational program. A
total of 244 Links members completed the program (77% response rate) and
answered pre- and post-assessments of intentions, attitudes and knowledge.
The percent of women indicating that they “defınitely” or “probably” intend
to participate in research increased from 9.4% to 19.5% and 27.1% to 49.8%,
respectively, after program completion. Agreement with the statement “re-
search in the U.S. is ethical” increased from 52.9% to 74.4%. Factual knowl-
edge related to each of the 3 study types also increased. Prior to completing
the program many women reported “little or no understanding” of the 3
types of studies (66% GEN, 62.9% CR, 40.7% CT) whereas after program
completion, these numbers decreased to 24.9%, 18.4%, and 15.5%, respec-
tively. While few women rated their opinion of the study types as “very
positive” prior to beginning the program (14.3%GEN, 15.0% CR, 28.6% CT),
upon completion these proportions increased and equalized (42.8% GEN,
43.0% CR, 42.5% CT). Two-month follow-up will evaluate longer-term im-
pact including knowledge dissemination, visiting clinicaltrials.gov, and en-
rolling in ResearchMatch. An online education-to-action program targeting
professional African American women improved knowledge, perceptions of
research ethics, and intent to participate in biomedical research.
#4234 A culturally competent, community driven, collaborative approach
to health care education conferences addressing the health disparities of Af-
rican Americans. Ricardo Parker,1 Patric Schiltz,1 Ernesta Wright,2 Jhenifa
Parker,3 Denise Tolbert,1 Lezlee Matthews,4 LaQuetta Shamblee2. 1National
Univ., Costa Mesa, CA; 2The GREEN Foundation, Orange, CA; 3Eastern Wash-
ingtonUniversity, Cheney,WA; 4LoyolaMarymountUniversity, LosAngeles, CA.
The ability to effectively deliver health care education that meets the social,
cultural, and linguistic needs of people with diverse cultures is an important
consideration, and is referred to as culturally or community competent ap-
proaches. Community and culturally competent health care education ap-
proaches are especially important in educational conferences designed to engage
residents in health care issues such as health screenings, lifestyle, and preventa-
tive approaches toward improved health, as well as examining the impact of
these and other factors on health disparities related to ethnicity. In this report,
we evaluated 15 ActNOW cancer education conferences over a 5-year period,
using a community driven, culturally competent conference model designed to
educate African Americans participants, with an emphasis on reducing health
disparities through understanding cancer, the importance of clinical trials par-
ticipation, screening, and preventative and healthy lifestyle choices. Qualitative
data on an aggregate of 380 participants were obtained through an anonymous
evaluation and feedback survey questionnaire distributed to participants at the
end of the conference. Participants’ pre- and post-conference perceived cancer
knowledge and intent to change lifestyle were evaluated. Conference attendees
voluntarily completed the self-administered questionnaire comprised of 8 ques-
tions. Each question had 4 possible responses: 1. non-existent; 2. minimal; 3.
moderate or 4. considerable. For statistical analysis, responses were separated
into two groups; low and high. Responses designated 1 or 2 were considered to
reflect minimal understanding of the subject material; and frequency counts for
responses 1 or 2 were aggregated and designated as ‘Low‘ understanding re-
sponses. Responses 3 or 4 reflected a higher understanding of the subject mate-
rial; and frequency counts for responses 3 or 4were aggregated anddesignated as
‘High‘ understanding responses. The groups were then analyzed statistically
using Fisher’s exact test, where a two-sided p0.05 is considered signifıcant. The
results demonstrated a signifıcant number (27%) of respondents indicating a
low understanding of the topics before the event. After the event, a signifıcantly
lesser number (2%) of low respondents reported a low understanding of the
topics, with a concomitant increase in high respondents reporting a greater
understanding (from 73% pre- to 98% post-conference); p0.0001. Similar sig-
nifıcant shifts in practice knowledge profıleswere also seen (p0.0001). Cultural
and/or community competent approaches for health care education are a
needed consideration
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#4235 Application of convolutional neural networks to breast biopsies to
uncover tissue correlates ofmammographic breast density.MaeveMullooly,1
Babak Ehteshami Bejnordi,2 Maya Palakal,1 Pamela M. Vacek,3 Donald L.
Weaver,3 John A. Shepherd,4 Bo Fan,4 Amir Pasha Mahmoudzadeh,4 Jeff
Wang,5 Jason M. Johnson,6 Sally D. Herschorn,3 Brian L. Sprague,3 Ruth M.
Pfeiffer,1 Louise A. Brinton,1 Mark E. Sherman,7 Andrew Beck,8 Gretchen L.
Gierach1. 1National Cancer Institute, Bethesda, MD; 2Radboud University Med-
ical Center, Nijmegen, Netherlands; 3University of Vermont, Burlington, VT;
4University of California, San Francisco, San Francisco, CA; 5Hokkaido Univer-
sity, Sapporo, Japan; 6MD Anderson Cancer Center, Houston, TX; 7Mayo Clinic,
Jacksonville, FL; 8Harvard Medical School, Boston, MA.
Background: High percent mammographic density (MD), which reflects the
relative fıbroglandular tissue content of the breast, is one of the strongest breast
cancer risk factors; however, the pathologic mediators of this risk are unknown.
We hypothesize that analysis of breast tissue sections using deep learning ap-
proachesmay characterize histologic features that underpin risk associated with
high MD. Methods: Non-targeted H&E stained breast tissue sections of diag-
nostic image-guided breast biopsies were evaluated among 588 women enrolled
following an abnormal mammogram in the Breast Radiology Evaluation and
Study of Tissues (BREAST) Stamp Project (2007-2010). Overall volumetric per-
centMD for the biopsied breast and localized volumetric percentMD surround-
ing the biopsy site were determined for each participant. A deep convolutional
neural network (CNN) model was trained to identify and quantitatively assess
breast epithelial, stroma and fat tissue and their organizational and spatial ar-
rangements. Least absolute shrinkage and selection operator (Lasso) regression
was used to determine relationships between MD measures and pathological
features. To ensure reliability of the model, a cross-validation strategy was em-
ployed to build and assess the performance of the fıtted model. Finally, Spear-
man correlation coeffıcients were estimated to test the association between the
predicted density values by eachmodel (predicting overall or localizedMD) and
the actual MD measurements. We report the average and standard deviation
(SD) of the correlation coeffıcients. Results: In an independent validation set, the
CNN model was 95.5% accurate in classifying epithelial, stromal and fat tissue.
The mean (SD) correlations between the predicted model and the actual mea-
surements for overall and localizedMDwere 0.70 (0.06) and 0.65 (0.06) respec-
tively. The amount of stroma identifıed (normalized to tissue area) had the
highest selection probability (P-value) by the Lassomodel and thus the strongest
positive relationship with MD (P-value 0.9 for each MD measurement). In
contrast, the amount of normalized epithelial tissue was not related to MD
(P-value0.01 for eachMDmeasurement). No associationwas observed for the
total normalized fat area with MD (P-value0.31 for each MDmeasurement).
In addition, the number of distributed epithelial regions was positively associ-
ated, whereas the distance between epithelial regions was inversely associated
with overall MD (P-value 0.87 and 0.62, respectively). Conclusions: These
results show that greater stromal tissue amount and spatial distribution patterns
of epithelial regions, rather than total epithelial amounts, had the strongest re-
lationships with elevated MD. Future work will determine the relationship of
these MD features with biopsy diagnosis.
#4236 Gene expression profıling of prostate tissue identifıes biological
pathways associated with TMPRSS2:ERG gene fusion. Ericka Ebot,1 Masis
Isikbay,2 Travis Gerke,3 Thomas U. Ahearn,4 Rachel S. Kelly,2 Svitlana
Tyekucheva,1 Andreas Pettersson,1 Kathryn L. Penney,5 Lorelei A. Mucci1.
1Harvard School of Public Health, Boston,MA; 2HarvardMedical School, Boston,
MA; 3University of Florida, Gainesville, FL; 4National Cancer Institute, Rockville,
MD; 5Brigham And Women’s Hospital, Boston, MA.
Background: TMPRSS2:ERG, a hormonally regulated gene fusion present in
about half of prostate tumors, is the most common somatic event in prostate
cancer. There is intriguing evidence to suggest that TMPRSS2:ERG-positive
tumors may defıne a distinct subgroup of prostate cancer. In this study we
compared gene expression profıles according to fusion status to identify genes
andbiological pathways differential expressed byTMPRSS2:ERG.Methods: The
study included men with prostate cancer in the Health Professionals Follow-up
Study and the Physicians’ Health Study diagnosed between 1982 and 2004 and
followed through 2012. Tumor biomarker data was available for archival tumor
tissue from 380 cases, 191 of whom also had gene expression data for adjacent
normal tissue. Whole genome mRNA expression profıling (20,254 genes) was
performed using the Affymetrix 1.0 ST array. TMPRSS2:ERG tumor status was
assessed by a genetically validated IHC assay for ERG. To relate expression of
individual genes to ERG we used linear regression. Gene Set Enrichment Anal-
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ysis (GSEA) was used to identify pathways of genes associated with ERG in both
tumor and adjacent normal tissue. Data from The Cancer Genome Atlas
(TCGA) was used to validate these fındings. Results: Among 380 cases, 186
(49%) of tumors were positive for the gene fusion. Genome-wide differential
expression analysis identifıed 492 genes upregulated and 369 genes downregu-
lated in tumor tissue comparing ERG to ERG- tumors (FDR p-value 0.05).
No genes were identifıed in the adjacent normal tissue at this signifıcance level.
772 of the 861 genes (90%) identifıed in the HPFS/PHS dataset were confırmed
in TCGA (448 upregulated and 324 downregulated). The top ten genes included
ERG, WNK2, CACNA1D, HES1, SEPT9, PLA2G7, TDRD1, ANTXR2,
SORBS2, and MYO6. Enrichment analysis identifıed a number of metabolic
pathways associated with ERG tumor status including pathways involved in
amino acid and fatty acid metabolism. Conclusions: We identifıed signifıcant
differences in gene expression profıles in prostate tumor tissue according to
TMPRSS2:ERG status, providing supportive evidence of this fusion as a unique
subtype.
#4237 Estrogenmetabolism in menopausal hormone users: Does it differ
between estrogen plus progestin and estrogen alone users in the Women’s
Health Initiative Observational Study. Roni T. Falk,1 Garnet L. Anderson,2
Vanessa M. Barnabei,3 Louise A. Brinton,1 Jane A. Cauley,4 Chu Chen,2 Rowan
T. Chlebowski,5 Sally B. Coburn,1 JoAnn E. Manson,6 RuthM. Pfeiffer,1 Kerryn
W. Reding,7 Thomas E. Rohan,8 Gloria E. Sarto,9 Nicolas Wentzensen,1 Britton
Trabert1. 1National Cancer Institute, Bethesda, MD; 2Fred Hutchinson Cancer
Research Center, WA; 3Jacobs School of Medicine and Biomedical Sciences Uni-
versity at Buffalo,NY; 4University of Pittsburgh Schools of theHealth Sciences, PA;
5David Geffen School of Medicine UCLA, CA; 6Harvard Medical School, MA;
7University of Washington School of Nursing, WA; 8Albert Einstein College of
Medicine, NY; 9University of Wisconsin School of Medicine and Public Health,
WI.
Background: The Women’s Health Initiative (WHI) provided divergent re-
sults regarding the effects of menopausal hormone therapy (MHT) on breast
cancer risk, with women in the conjugated equine estrogen plus medroxypro-
gesterone (CEEMPA) arm at elevated risk, and women in the CEE alone arm
at reduced risk. Although direct progestin-mediated effects may largely explain
the elevated risk, we hypothesize that in addition, these MHT treatments may
differentially influence patterns of estrogenmetabolism, with CEE alone prefer-
entially inducingmetabolism along the 2-hydroxylation pathway, a pattern pre-
viously linked to reduced breast cancer risk. Study methods/population:
Women in a case-control study of estrogen metabolites (EM) and ovarian and
endometrial cancer from the WHI Observational Study were identifıed for this
analysis. Unlike the WHI trial, no medication restrictions were applied. At en-
rollment, serum, anthropometric measures, and self-administered question-
naireswhich ascertained reproductive history, lifestyle factors and health behav-
iors including MHT use, were obtained. 615 women reported current use of
estrogen plus progestin formulations (EP), of whom 343 used CEEMPA;
266 used estrogens alone (E alone), with 148 using CEE. Fifteen EM were mea-
sured by liquid chromatography/mass spectrometry and analyses were con-
ducted separately for each EM. EM differences between E alone and EP users
were assessed using inverse probability weighted linear regression. Primary
analyses includedwomen using anyMHT formulation; secondary analyses were
restricted toCEEusers. Results: Compared to users of EP, concentrations of all
EM were higher in E alone users, and signifıcantly so for unconjugated estrone,
estradiol, 2-methoxyestrone, 4-methoxyestrone and unconjugated estriol. Rel-
ative to total EM, concentrations of 2- and 4-pathway EMdid not differ byMHT
group (for E alone and EP users, 2-pathway EM were14% of the total EM;
4-pathway EMwere2% of the total), but EP users had a signifıcantly higher
proportion of 16-pathway EM compared to E alone users (32% vs. 30%,
p0.025). Similar patterns were observed in analyses comparing users of CEE
alone to CEEMPA, albeit not signifıcant. Conclusion: Our data suggest that
women using E alone may preferentially metabolize estrogens along the 2- and
4-hydroxylation pathways, whereas in EP users, more extensive metabolism
occurs along the 16-pathway. However, we did not observe these effects in the
smaller groups of women using CEE alone or CEEMPA, the MHT formula-
tions administered in the treatment arms of the WHI trial. Our fındings in E
alone users are consistent with epidemiologic investigations demonstrating re-
duced breast cancer risk in postmenopausal womenwithmore extensive 2-path-
way estrogen metabolism, and may provide a clue to the breast cancer risk
reduction observed in these women.
#4238 COnsortium forMETabolomics Studies (COMETS): leveraging re-
sources to accelerate scientifıc discovery. Rachael Z. Stolzenberg-Solomon,1
Steven Moore,1 Crnelia Ulrich,2 Elizabeth Poole,3 Marinella Temprosa,4
MukeshVerma,1 Demetrius Albanes,1 Clara Barrios Barrera,5 Eric Boerwinkle,6
Juan P. Casas,7 Clary Clish,8 Robert Gerszten,3 Christian Gieger,9 Marc
Gunter,10 Sei Harada,11 Tamara Harris,12 David Herrington,13 Ann Hsing,14
Mattias Johannson,15 Claudia Langenberg,16 Jessica Lasky-Su,17 Loic LeMarch-
and,18 Charles Matthews,1 Cristina Menni,19 Matej Oresic,20 Eric Orwoll,21 Al-
exandre Pereira,22 Kathyrn Rexrode,23 Svati Shah,24 Xiao-ou Shu,25 Victoria
Stevens,26 Bing Yu,27 Hua Zhao,28 Krista Zanetti1. 1National Cancer Inst., Rock-
ville, MD; 2Huntsman Cancer Institute, Salt Lake City, UT; 3Harvard University,
Boston, MA; 4George Washington University, Washington, DC; 5Hospital del
Mar, Spain; 6University of TexasHealth Science Center at Houston, Houston, TX;
7Institute of Health Informatics/University College London, United Kingdom;
8Broad Institute of MIT and Harvard, Boston, MA; 9Helmholtz Zentrum
Munchen Institute, Germany; 10International Agency for Reseach on Cancer,
France; 11Keio University, Japan; 12NIA, Baltimore, MD; 13Wake Forest School of
Medicine, Winston-Salem, NC; 14Stanford University, Stanford, CA; 15Northern
Sweden Health and Disease Study, Norway; 16University of Cambridge School of
Clinical Medicine, United Kingdom; 17Brigham and Women’s Hospital, Boston,
MA; 18University of Hawaii Cancer Center, Honolulu, HI; 19King’s College Lon-
don, United Kingdom; 20University of Helsinki, Finland; 21Oregon Health and
Science University, Portland, OR; 22University of Sao Paulo, Brazil; 23Harvard
Medical School, Boston, MA; 24Duke Molecular Physiology Institute, Durham,
NC; 25Vanderbilt University, Nashville, TN; 26American Cancer Society, GA;
27University of Texas Health Science Center at Houston, TX; 28Fred Hutchinson
Cancer Research Center, Seattle, WA.
Metabolomics is a systems approach to the biology of health and disease and
an ‘-omics’ discipline that measures small metabolites representing end prod-
ucts of a variety of metabolic and cellular processes as reflected in available
biological specimens (e.g. blood, urine, saliva, feces and tissue). As an increas-
ingly more common approach used for epidemiologic and clinical studies,
metabolomics has the potential to improve disease risk assessment, screening,
diagnosis, prognosis and predictive response to therapy, as well as provide dis-
easemechanistic insight andhelp to establish criteria for causation. It is timely to
establish mechanisms for leveraging existing resources and data for novel bio-
marker discovery using metabolomics approaches. To this end, the National
Institutes of Health COnsortium of METabolomics Studies (COMETS) was
established in 2014 (http://epi.grants.cancer.gov/comets/), and currently in-
cludes 34 prospective cohorts and 2 consortia from the United States, Europe,
Asia and South America. The COMETS mission is to promote collaborations
among prospective cohort studies that follow participants for a range of out-
comes and perform metabolomic profıling of individuals. COMETS aims to
facilitate an open exchange of ideas, knowledge, and results to accelerate a
shared goal of identifying metabolomic profıles associated with chronic disease
phenotypes (e.g. heart disease, diabetes, cancer). The structure of COMETS
includes a steering committee with one representative from each participating
cohort/consortium and a number of working groups, including age analysis,
data harmonization, statistics, and trainee. In November 2016, COMETS held
their inaugural scientifıc meeting. As a result of this meeting, more working
groups are currently being established to support additional interests/projects
among the consortiummembers. Here we further describe the COMETS struc-
ture, including preliminary descriptive data, which aims to advance the use and
impact of metabolite profıling in population-based research.
#4239 The effects of long-term storage on commonly-measured serum
analyte levels. Cynthia Kleeberger,1 David Shore,2 Elaine Gunter,3 Dale P. San-
dler,4 Sandra Deming-Halverson,1 Clarice R. Weinberg4. 1Social & Scientifıc
Systems, Inc., Durham, NC; 2Westat, Durham, NC; 3Specimen Solutions, LLC,
Tucker, GA; 4NIEHS, RTP, NC.
Introduction: Cohort studies typically bank biospecimens for many years
prior to assay and the levels of analyte degradation is unknown. Long storage
times could cause degradation and producemeasurement errors that would bias
estimation of the analyte effects on health outcomes. Such effects could also
produce confounding with other factors under study. Methods: We collected
control samples from 22 non-study participants using the same enrollment cri-
teria and specimen collection, processing, and storage protocols as in The Sister
Study, a large cohort study conducted by the National Institute of Environmen-
tal Health Sciences. Samples were assayed for 21 analytes at collection and then
six years later. For each sample, the difference between the result at baseline and
at six years was calculated for each analyte. The difference, Yij  result6 year 
result
baseline,
was then modeled using a mixed-effects model, with random effects
for batch (bi) and a fıxed effect for the overall mean difference: Yij u bi eij ,
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where , biN(0, s2batch) , i1,2,3,5,6. Results: Some of the analytes experienced
a marked change in concentration after six years of frozen storage, compared to
their baseline value. There were no signifıcant changes in ten of the analytes.
Two of the analytes, lactate dehydrogenase (LDH) and sex hormone binding
globulin (SHBG), increased signifıcantly in concentration over time. Two ana-
lytes, HDL cholesterol and luteinizing hormone (LH), decreased signifıcantly
but within the limits of the internal laboratory control variance. Signifıcant
reductions in excess of the laboratory control variance were found for 7 of the 21
analytes tested (aspartate transaminase (AST), total cholesterol, estradiol, glu-
cose, protein, sodium, and triglycerides). Despite the evidence for systematic
changes over long-term storage, correlations between baseline and later mea-
sures were high and there was little relation between the size of the correlation
and the estimated mean difference across the two time points. Conclusion: We
conclude there are differences in assay results after long-term storage, although
for most analytes the correlation coeffıcients were high and percent change
small. Biobanks or cohort studies that bank samples should consider building in
QC experiments designed to assess the impact of long-term storage on antici-
pated analytes of interest, when possible. By doing so, degradation could be
corrected for to control bias due to the associated measurement error. Since not
all cohorts were able to conduct these QC experiments, those that have carried
out such assessment should share their results so others can use the data to
evaluate the potential impact of measurement error on their study fındings.
#4240 Determination of normative patterns of gene expression levels and
breast cancer risk biomarkers in humanbreastmilk.MariaOuzounova,Geor-
gina Lewis, Raziye Piranlioglu, Tiana Curry-McCoy,Wonsuk Yoo, NitaMaihle,
Sangmi Kim, Hasan Korkaya. Augusta University, Augusta, GA.
Parity and breastfeeding influence a woman’s risk of developing breast
cancer. Understanding the underlying molecular changes in the breast will
facilitate identifıcation of additional factors during pregnancy and postpar-
tum that modify breast cancer risk. Most prior studies in humans on this
topic, however, have been cross-sectional studies comparing breast tissue
samples from nulliparous versus post-pregnant women, and are limited in
their ability to characterize longitudinal changes and within-person varia-
tions. Breast milk contains cells of the mature gland, and may have a poten-
tial as a noninvasive source for studying molecular characteristics of the
pregnancy-associated changes in the breast and their impact on breast can-
cer risk. The objectives of this study were to (1) determine normative pat-
terns of gene expression levels in longitudinally collected breast milk sam-
ples and (2) correlate gene expression data in relation to self-reported
measures of psychosocial stress during pregnancy and postpartum period.
Our preliminary results showed that the post-pregnancy gene expression
levels in breast milk samples can be measured reproducibly over a short
period of time. Whole-genome transcriptome analysis revealed that expres-
sion levels of the post-pregnancy genes are different in early (less than 3
month postpartum) and late lactation period (more than 6 month postpar-
tum). Moreover cytokine expression profıling correlated expression of in-
flammatory cytokines with early versus late postpartum period. The unique
contribution of this study is to capture longitudinal gene expression data
from breast milk samples collected over the course of lactation, hence pro-
viding a valuable basis for future studies to identify differential dynamics
associated with breast cancer susceptibility.
#4241 Circulating microRNAs in plasma of men screened for prostate
cancer. Alicia C. Mcdonald,1 Jing Shen,2 Manish Vira,3 Martin Sanda,4 Jason
Liao,1 Martin L. Lesser,5 Dattatraya Patil,4 Jay D. Raman,6 Emanuela Taioli7.
1Pennsylvania StateUniversityCollege ofMedicine,Hershey, PA; 2ColumbiaUni-
versity, New York, NY; 3Hofstra Northwell School of Medicine, Hempstead, NY;
4Emory University School of Medicine, Atlanta, GA; 5The Feinstein Institute for
Medical Research, Manhasset, NY; 6Pennsylvania State Milton S. Hershey Medi-
cal Center, Hershey, PA; 7Ichan School of Medicine at Mount Sinai, New York,
NY.
Introduction: Although microRNAs (miRNAs) have been linked to prostate
cancer risk, their role as a screening biomarker for prostate cancer (PC) has yet
to be determined.We examinedwhether circulatingmiRNAs in plasma could be
potential biomarkers for the early detection of PC amongmen undergoing pros-
tate needle biopsy.Methods:Menwho had a prostate biopsy due to an abnormal
screening test were recruited. Demographics, medical history, clinical informa-
tion, and blood processed into plasma were collected. TaqMan Low Density
Arrays were used for the expression profıling of 733 miRNAs in plasma. Wil-
coxon test was used to compare expression levels betweenmenwith andwithout
a PC diagnosis. Logistic regression was used to examine the association between
miRNAs and PC status, after adjusting for age and Bonferroni-correction. Re-
sults: Therewere 131men, aged 46 to 86 years, included in the fınal analysis, with
66 men diagnosed with PC on prostate biopsy and 65 men without a PC diag-
nosis.Majority were white (72.5%) followed by black race (13.5%).Menwith PC
were older (median: 64 vs. 62 years; p-value 0.16) and had statistically signif-
icantly higher serumPSA (median: 5.8 vs. 5.1 ng/mL; p-value 0.01) compared
to men without a PC diagnosis. The most statistically signifıcant PC circulating
miRNAs in plasma were miR-381, miR-523, miR-450B-5p, miR-34a, miR-34b,
miR-639, and miR-365, after adjusting for age (p-values 0.05). The detection
rate of these miRNAs in plasma ranged from 23.7% to 83.2%. These miRNAs
were no longer statistically signifıcant with PC diagnosis, after adjusting for
multiple comparison (FDR q-value 1.00). Conclusion: Among the 733 miR-
NAs evaluated, there was no miRNA found to be associated with PC diagnosis
after adjusting formultiple comparison. Studies that examine a larger number of
miRNAs which include the discovery of new miRNAs and their relationship
with PC risk are warranted.
#4242 Mass spectroscopic analysis of MGMT tryptic peptides allows de-
tection ofO6-alkylguanine adducts in oligodeoxyribonucleotides, temozolo-
midemodifıed calf thymusDNAandhumancolorectal cancerDNA.RashaA.
Abdelhady,1 Perdita E. Barran,1 David M. Williams,2 Andrew C. Povey1. 1Uni-
versity of Manchester, Manchester, United Kingdom; 2University of Sheffıeld,
Sheffıeld, United Kingdom.
Background: Red andprocessedmeat consumption increases human colorec-
tal cancer (CRC) risk, potentially by heme-catalysed formation of carcinogenic
N-nitrosocompounds (NNOC) that form mutagenic O6-alkylguanine (O6-
alkG) DNA adducts. NNOC formation cannot be accurately estimated from
meat consumption alone due to in situ processing required for their formation.
We are thus developing a novel approach to assess NNOC exposure by quanti-
fying O6-alkylguanine DNA adducts that result from their exposure, using the
known action of the DNA repair protein, O6-alkylguanine O6-alkyltransferase
(MGMT), to irreversibly transfer theO6-alkyl to an active site cysteine residue in
MGMT. Methods: Oligodeoxyribonucleotides (ODNs) containing O6-methyl-
guanine (O6-MeG), O6-carboxymethylguanine (O6-CMG), O6-carboxyethyl-
guanine (O6-CEG) were synthesised by alcohol modifıcation of an ODN con-
taining the convertible base 2-amino-6-methylsulfonylpurine. O6-MeG
containing calf thymus (CT) DNA was prepared by incubation with temozolo-
mide (TMZ). Both maltose binding protein-MGMT (MBP-MGMT) and his-
tagged MGMT (his-MGMT) fusion proteins were expressed, purifıed, and
MGMT functional activity determined by tritium transfer usingCTDNAmeth-
ylated with [3H]-N-Nitrosomethylurea. Double stranded O6-alkG-containing
ODNs, unmodifıed ODN and methylated CT DNA were incubated with MBP-
MGMT and the resulting alkylated MGMT digested with trypsin and analysed
by mass spectrometry using MALDI-TOF. Human CRC DNA samples were
incubatedwith his-MGMTwhichwas then recovered usingNi-coatedmagnetic
beads.MGMTwas digested in situwith trypsin and the tryptic peptides analysed
by MALDI-TOF. Results: S-methylcysteine (m/z 1329.7), S-carboxymethylcys-
teine (m/z 1373.7) and S-carboxyethylcysteine,modifıedMGMTactive site pep-
tides were detected in tryptic digests of MBP-MGMT incubated with O6-MeG-,
O6-CMG- and O6-CEG-containing ODNs respectively. Only the unmodifıed
active site peptide (m/z 1315.7)was found after incubatingMGMTwith unmod-
ifıed ODN. Subsequent MS analysis of tryptic digests of MGMT incubated with
TMZmodifıed CTDNA also revealed the active site peptide containing S-meth-
ylcysteine. Using this approach, pilot studies revealed the presence of O6-MeG,
O6-CMG and O6-CEG in CRC DNA. Conclusions: These results demonstrate
proof of principle and confırm that this approach could be used to characterise
O6-alkylguanine adducts in human CRC DNA.
#4243 Epigenome-wide association study of metabolic syndrome in Afri-
can-Americans. Tomi Akinyemiju.University of Alabama at Birmingham, BIr-
mingham, AL.
Background: The epidemic of obesity among US adults has resulted in
signifıcant increases in associated metabolic disorders such as diabetes, dys-
lipidemia and high blood pressure. Together, these disorders constitute met-
abolic syndrome, a clinically defıned condition highly prevalent among Af-
rican-Americans. Identifying epigenetic alterations associated with
metabolic syndrome, including DNA methylation changes may provide in-
formation on biological pathways that are dysregulated and may potentially
act as early biomarkers in cancer. Methods: Data on cardio-metabolic risk
factors and DNA methylation was assessed on 606 African-Americans from
the Hypertension Genetic Epidemiology Network (HyperGEN) study. Met-
abolic syndrome was defıned using the joint harmonized criteria of at least
three of: elevated waist circumference, high triglycerides, low HDL-choles-
terol, high fasting blood glucose and high blood pressure. DNA methylation
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was assessed using the Illumina HumanMethylation 450K Bead Chip assay
on DNA extracted from buffy coat. Linear mixed effects regression models
were used to examine the association between CpG methylation and meta-
bolic syndrome in crude and adjusted (for age, alcohol, smoking, sex) anal-
yses. Replication using DNA from 76 African-Americans in the REason for
Geographic and Racial Disparities in Cancer (REGARDS) study, as well as
meta-analysis combining both cohorts was conducted. Results: Two differ-
entially methylated CpG sites in the IGF2BP1 gene on chromosome 17
(cg06638433;  0.01, p-value3.10x10-7) and the ABCG1 gene on chro-
mosome 21 (cg06500161; : 0.018, p-value2.60x10-8) were identifıed in
models adjusted for age, sex, alcohol and smoking. Methylation of CpG sites
on the TXNIP gene on chr 1 (p2.83 x 10-9), and CPT1A gene on chr 11
(p1.39 x 10-4) were also signifıcantly associated with metabolic syndrome
in unadjusted models. Results for the ABCG1 gene remained statistically
signifıcant in the replication set and meta-analysis. Conclusion: Metabolic
syndrome was consistently associated with focal DNA hypermethylation in
the ABCG1gene, a region of the chromosome that encodes proteins in the
ATP-binding cassette transporter family, and is involved intra- and extra-
cellular signaling. Alterations in the ABCG1 gene was observed in 40% of
invasive breast cancer tumors in the TCGA, providing a potential epigenetic
link between metabolic syndrome and breast cancer that deserves further
study.
#4244 Detection and characterizationof extrachromosomal circularDNA
in human plasma. Jing Zhu, Meijun Du, Peng Zhang, Liang Wang. Medical
College of Wisconsin, Milwaukee, WI.
Background: eccDNA (extrachromosomal circular DNA) has been re-
ported in most eukaryotes, including in human cells. However, little is
known about the eccDNA profıles in human circulating system such as
blood. Method: We extracted plasma cell free DNA (cfDNA) from three
patients with advanced stage cancers. For each patient, we tested 10ng, 1ng
and 0.1ng cfDNA, each with a technical replicate. The cfDNA samples were
subjected to ATP-dependent DNase digestion and whole genome amplifıca-
tion (WGA). An additional 2ng cfDNA from each patient skipped the DNase
digestion and went directly toWGA step.We sequenced the amplifıed DNAs
using the Illumina 100bp PE read protocol. We analyzed sequencing data
using a custom split reads-based strategy to retrieve circular DNAmolecules.
We further analyzed eccDNAs for their biofeatures using functional anno-
tation tools. Results: We received sequence reads at 14.8 million
(11.422.4) for each sample. When read depth 3 as a cutoff, we detected a
total number of 2542, 1578, and 57 unique eccDNAs in three patients while
negative controls showed5 eccDNAs. For non-DNase digested cfDNAs,
we detected only 3 eccDNAs. By comparing read numbers mapped to mito-
chondria and human genome, we found that mitochondrial sequence reads
increased signifıcantly from 0.34-1.1% before digestion to 24.1-50.1% after
digestion. Numbers of detected eccDNAs were similar between technical
replicates and proportional to initial input cfDNA. However, eccDNAs de-
tected also showed few overlaps between technical replicates. Size distribu-
tion ranged from 31bp to 19740bp (median 1801-1962bp). To test if eccD-
NAs were generated in specifıc genomic regions and if eccDNA-involved
genes were enriched in specifıc pathways, we performed enrichment analysis
and observed higher GC content in smaller eccDNAs (500 bp, 48%) than
larger ones (500bp, 41%) (p0.001). When compared to random distribu-
tion, eccDNAs were more likely located at CpG islands (1.36-1.53 fold en-
richment). The eccDNAs were also enriched in exons, 5’UTR, 3=UTR and
DNase hypersensitive sites (enrichment folds from 1.39 to 2.3). Using DA-
VID annotation tool, we observed signifıcant enrichment of the eccDNA-
related genes in several categories including the Coiled coil, phosphoprotein,
fıbronectin, suggesting a potential involvement in gene expression regula-
tion and cell adhesion events. Using GREAT (Genomic Regions Enrichment
of Annotations Tool), we found that the eccDNAs were involved in genes
associated with invasive cancer cell gene expression regulation (p0.001).
Conclusion: Human plasma contains an abundant number of eccDNAs.
Distribution of these eccDNAs is nonrandom event and is likely enriched in
genomic regions with known functional consequences and genes that play a
role in gene regulations. Further characterization of circulating eccDNAs in
peripheral blood will facilitate understanding of their molecular mecha-
nisms and potential clinical utilities.
#4245 Serologicmarkers of infection and risk of non-Hodgkin lymphoma
in a pooled prospective study of three Chinese cohorts. Bryan A. Bassig,1
Angelika Michel,2 Xiao-Ou Shu,3 Woon-Puay Koh,4 Yu-Tang Gao,5 Lesley M.
Butler,6 Mark Purdue,1 Yong-Bing Xiang,7 Jennifer Adams-Haduch,6 Renwei
Wang,6 Nicole Brenner,2 Tim Waterboer,2 Martina Willhauck-Fleckenstein,2
Bu-Tian Ji,1 H. Dean Hosgood,8 Charles S. Rabkin,1 Jason Y.Y.Wong,1 Jinming
Zhang,1 Wei Hu,1 Gong Yang,3 Wong-Ho Chow,9 Michael Pawlita,2 Wei
Zheng,3 Jian-Min Yuan,6 Qing Lan,1 Nathaniel Rothman1. 1NCI-DCEG, Rock-
ville, MD; 2German Cancer Research Center (DKFZ), Heidelberg, Germany;
3Vanderbilt University School of Medicine, Nashville, TN; 4Duke-NUS Graduate
Medical School, Singapore; 5Shanghai Cancer Institute, Shanghai, China; 6Uni-
versity of Pittsburgh Cancer Institute, Pittsburgh, PA; 7Shanghai Cancer Institute,
Shanghai Jiaotong University School of Medicine, Shanghai, China; 8Albert Ein-
stein College of Medicine, New York, NY; 9The University of Texas MDAnderson
Cancer Center, Houston, TX.
Background: Infections with some viruses, including HIV and Epstein-Barr Vi-
rus (EBV) in immunocompromised individuals, are known risk factors for specifıc
subtypes of non-Hodgkin lymphoma (NHL). Epidemiological studies have also
provided evidence that hepatitis viruses, and EBV in immunocompetent individu-
als, may also be associated with NHL. There are limited population-based prospec-
tive studieswith pre-diagnostic blood samples that have comprehensively evaluated
viral biomarkers andNHL risk in East Asians, in whom the descriptive characteris-
ticsofNHLandtheprevalenceofcertainviral infectionsdiffer compared toWestern
populations.Methods:We conducted a nested case-control study of 214NHL cases
and 214 controls from three population-based prospective cohorts in Shanghai and
Singapore. Cases and controls were individually matched by age, sex, date of blood
draw, and cohort. Antibodies to 21 antigens associated with the evaluated viruses
(herpesviruses, Hepatitis B (HBV) and C (HCV), and polyomaviruses) were mea-
sured in plasma/serum using fluorescent bead-based multiplex serology. Condi-
tional logistic regression was used to evaluate associations between viral antibody
levels measured as median fluorescence intensity and NHL. Results: For herpesvi-
ruses, an increased risk of NHL was observed for higher compared to lower early
antigen diffuse (EA-D) (OR 2.2, 95%CI 1.2-4.1) and BZLF1-encoded replica-
tion activator (ZEBRA) (OR  2.2, 95% CI  1.0-4.9) antibodies (rsp  0.5)
associated with EBV. An increased risk of NHL was also observed among those
seropositive for the intermediate-early 1A antigen (OR 1.9, 95%CI 1.0-3.3; rsp
with EBV antibodies0.2) associated with human herpesvirus-6 (HHV-6). For
hepatitis viruses, a signifıcant NHL risk was observed for higher compared to lower
antibodies to theHBV-associated core (HBc) antigen (OR1.8, 95%CI1.1-3.1),
and this riskwasparticularly apparent in thosewith thehighestHBcandEBVEA-D
antibody levels (OR 4.2, 95%CI 1.4-12.7) compared to the lowest. Seropositiv-
ity toHCVwas low (1.4%cases; 0.9%controls).NoassociationswithNHLriskwere
observed for individual polyomaviruses (BK, JC, TSV, MCV). Discussion: Our
study of serologic markers of infection and NHL risk in three prospective popula-
tion-based studies of Chinese individuals suggests a role of specifıc viral agents in
lymphomagenesis. The fındings for EBV are consistent with some data fromWest-
ern cohorts and indicate that EBV reactivationmay be associated with NHL risk in
the Chinese general population. HHV-6 is a lymphotropic virus that has been ob-
served in some retrospective studies to be associated with lymphoma, but to our
knowledgehasnotpreviouslybeenassociatedwithNHLprospectively in thegeneral
population. HBV is endemic to regions of East Asia, including China, and our data
suggest that high levels of antibodies to the HBc antigenmay be a marker for NHL
risk.
#4246 Associations of Epstein-Barr virus (EBV)-positive gastric cancer
with circulating mediators of inflammation and immune response.M. Con-
stanza Camargo,1 Armands Sivins,2 Sergejs Isajevs,2 Dace Rudzite,2 Margaret
Gulley,3 G. Johan Offerhaus,4 Marcis Leja,2 Charles S. Rabkin1. 1National Can-
cer Inst., Bethesda, MD; 2University of Latvia, Latvia; 3University of North Car-
olina, Chapel Hill, NC; 4University Medical Center, Utrecht, Netherlands.
Epstein-Barr virus (EBV) positivity defınes one of fourmajormolecular types
of gastric cancer in The Cancer Genome Atlas (TCGA). However, viral status is
not routinely determined in clinical practice and tumor samples are not gener-
ally collected in epidemiologic research. Histologically, EBV-positive gastric
cancer is characterized by prominent inflammatory infıltrate. Inmolecular anal-
yses from TCGA, EBV-positive gastric cancer had signifıcantly higher expres-
sion of several chemokines, chemokine receptors and programmed death-li-
gand 1 (PD-L1) as compared to other molecular types combined. We
hypothesized that EBV tumor status may also be reflected in profıles of circulat-
ing chemokines and other markers of immune response. We have therefore
evaluated pre-treatment EDTA plasma samples of gastric cancer patients from
Latvia, including 28 with EBV-positive (as assessed by EBV RNA in situ hybrid-
ization) and 34 with EBV-negative tumors, frequency-matched by age, sex, an-
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atomical subsite and Lauren histological type. We measured 92 markers using
the Proseek Inflammation Panel I (Olink Proteomics, Uppsala, Sweden). We
used logistic regression to model adjusted associations between tertiles of the
markers and tumor EBV positivity. P0.05 was considered statistically signifı-
cant. Nine markers had undetectable levels in all or almost all samples. Of 83
evaluable markers, 8 were signifıcantly higher in patients with EBV-positive
tumors vs. those with EBV-negative tumors, including Chemokine C-C motif
ligand (CCL) 20 (odds ratio per tertile [OR]: 3.6; p-trend0.001), Chemokine
C-X-C motif ligand 19 (OR3.6; p-trend0.003), PD-L1 (OR3.4;
p-trend0.004), interleukin (IL) 10 (OR2.4; p-trend0.019), CCL19
(OR2.3; p-trend0.019), CCL11 (OR2.2; p-trend0.026), IL-17A
(OR2.0; p-trend0.038) and CCL8 (OR1.9; p-trend0.049). These eight
markers were positively correlated with the 28 pair-wise Spearman correlations
ranging from 0.14 - 0.71, of which 24 were statistically signifıcant. A model
combining the top three markers, CCL20, CXCL19 and PD-L1, discriminated
tumorEBV statuswith an area under the receiver operating characteristics curve
of 0.82. These data indicate that the local alterations of specifıc chemokines and
PDL-1 characterizing EBV-positive gastric tumors are reflected in the systemic
circulation. Profıling of these molecules may enable non-invasive diagnosis of
EBV-positive gastric cancer and facilitate etiologic and translational studies in
large-scale prospective cohorts that lack tumor specimens. Our fındings provide
additional support for evaluating PD-1 blockade and other immunomodulatory
therapies for patients with EBV-positive gastric cancer.
#4247 Quantitativemeasurement of aflatoxin-serum albumin adducts re-
veals substantial exposure in Guatemala, a country with high rates of liver
cancer mortality in men and women. Joshua W. Smith,1 Patricia A. Egner,1
Mariana Lazo,1 Alvaro Rivera,2 Fernanda Kroker,2 Neal D. Freedman,3 Kather-
ine A. McGlynn,3 Manuel Ramirez-Zea,2 Eliseo Guallar,1 John D. Groopman1.
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; 2Institute of
Nutrition of Central America and Panama, Guatemala City, Guatemala; 3Na-
tional Cancer Institute, National Institutes of Health, Rockville, MD.
Low-income countries across theworld are increasingly burdenedwith grow-
ing rates of cancer incidence and mortality. Opportunities for prevention in
these populations may be realized most readily for cancer sites with known
etiologies that are amenable to intervention. Liver cancer is the sixth-most com-
monly occurring cancer worldwide and is the second-most common contribu-
tor to global cancermortality. AflatoxinB1 (AFB1) is a knownandpotent human
hepatocarcinogen, with exposure occurring via ingestion of grains - especially
maize - contaminated with Aspergillus flavus. Previous work in regions with
endemic levels of liver cancer has shown that reducing AFB1 exposure attenu-
ated liver cancer mortality - even in the presence of other known etiological
exposures, such as hepatitis B virus. Guatemala experiences high rates of liver
cancer - which is uniquely distributed equally between men and women - and
consumes maize as a dietary staple, making the assessment of AFB1 exposure a
high priority for cancer prevention efforts in this country. Therefore, we mea-
sured circulating levels of the AFB1-albumin adduct, an established biomarker
of AFB1 exposure, in adults residing in fıve geographically and ecologically
dispersed departments of Guatemala (Guatemala, Suchitepéquez, Sololá, Es-
cuintla, andQuiché). Healthymen andwomen aged 40 and older were recruited
for the study. Pregnant women or individuals with implanted cardiac devices
were excluded from participation. Subjects (n436) gave informed consent and
provided demographic information and a venipuncture blood sample during a
clinic visit. Serum was separated from whole blood, digested with protease,
subjected to solid-phase extraction, and analyzed with isotope dilution ultra-
high-performance liquid chromatography-triple quadrupole mass spectrome-
try. Serum albumin wasmeasured by ELISA. AFB1-albumin adducts (pg AFB1-
lysine adduct/mg albumin) were detectable in 100% of samples, with a mean	
SEM of 21.6 	 2.5 and range of 0.2 - 814.8. These levels are similar to those
observed in regions of China in the 1980s, prior to reductions in AFB1 exposure
and liver cancermortality. Stratifıcation by demographic factors revealed signif-
icant differences in aflatoxin levels in urban (9.6	 1.3) versus rural (28.8	 3.9)
subjects (p  0.001). Accordingly, AFB1-albumin adduct levels were lowest in
the urban municipality of Escuintla (5.8 	 1.1) and highest in rural Suchite-
péquez (36.4	 4.8). Exposure was signifıcantly different by sex, with men hav-
ing higher levels compared towomen (30.0	 5.4 vs. 15.3	 1.3, p 0.01). These
data show that AFB1 exposure in Guatemalan adults is similar to levels previ-
ously shown to increase liver cancer risk. Larger cohort and prospective studies
are warranted to assess the relationship between liver cancer incidence and
AFB1 exposure in this population.
#4248 Adiposity, change in adiposity during adulthood and mammo-
graphic density in premenopausal women.AliyaAlimujiang, GrahamColditz,
Catherine Appleton, Adetunji T. Toriola.Washington Univ. School of Medicine,
St. Louis, MO.
Background: Body mass index (BMI) is inversely associated with mammo-
graphic density among postmenopausal women, but few studies have evaluated
this in premenopausal women. Further, there is limited data on the associations
of weight change during adulthood with mammographic density. To address
these, we investigated the associations of current adiposity measures, BMI at
ages 18, 30, and changes in BMI at these age periods with volumetric mammo-
graphic densitymeasures in 314 premenopausal womenwhounderwent screen-
ing mammogram at the Breast Health Center, Washington University in St.
Louis, MO. Methods: Study participants completed a questionnaire with infor-
mation on breast cancer risk factors. Weight at ages 18 and 30 were self-re-
ported. Current weight, height, waist, and body fat percent (%), were assessed by
trained research personnel. BMIs were calculated as weight at each age/current
height squared (kg/m2). We calculated weight change from; (i) age 18 to 30, (ii)
age 18 to current age, (iii) age 30 to current age. Volpara was used to determine
volumetric mammographic density measures. We investigated age-adjusted
correlations between adiposity measures and mammographic density measures
using Pearson correlation coeffıcients. We used multivariable linear regression
models (adjusted for age, age at menarche, parity, age at each birth, family
history of breast cancer, race, and education) to evaluate the associations of
adiposity measures with mammographic density measures. Results: All adipos-
ity and weight changemeasures were signifıcantly inversely associated with per-
cent density (PD), and positively associatedwith breast volume (BV). The stron-
gest inverse correlations with PD were observed for body fat % (r -0.68,
P0.001), and waist (r -62, P0.001). For BV, the strongest positive correla-
tions were observed for waist r0.75, P0.001) and current BMI (r0.76,
P0.001). In multivariable regression models, body fat % had the strongest
association with PD (beta coeffıcient (ß) -0.50, P0.001). BMI during the
three time points were each inversely associated with PD, with BMI at age 18
having the largest beta coeffıcient (ß - 0.50, P0.001) compared with current
BMI (ß -0.45, P0.001) and BMI at age 30 (ß - 40, P0.001). After control-
ling for BMI at age 18, weight gain at all time periods was associated with a
decrease in PD and an increase in BV. The largest decrease in PD was observed
for weight gain from age 18 to current age (ß - 8.5, P0.001) comparing
women who gained 25kg to those who had stable weight (gained between
0-5kg) during this period. Conclusions: Weight gain in early adulthood is asso-
ciatedwith reductions in PDand increases inBV in premenopausalwomen.Our
fındings highlight the need for mechanistic studies focusing on early adulthood
to provide a better understanding of how adiposity relates to mammographic
density, and possibly breast cancer development in premenopausal women.
#4249 Evidence of APOBEC3 editing in the HPV16 genome. Yanzi Xiao,1
Bin Zhu,1 Meredith Yeager,1 Michael Cullen,2 Joseph Boland,2 Nicolas Went-
zensen,1 Tina Raine-Bennett,3 Zigui Chen,4 Kai Yu,1 Qi Yang,2 Mia Steinberg,2
David Roberson,2 Sara Bass,2 Laurie Burdette,2 Thomas Lorey,3 Philip Castle,5
Robert Burk,5 Mark Schiffman,1 Lisa Mirabello1. 1National Cancer Institute,
Rockville, MD; 2Leidos Biomedical Research, Inc., Frederick, MD; 3Kaiser Perma-
nente Northern California, Oakland, CA; 4The Chinese University of Hong Kong,
Hong Kong; 5Albert Einstein College of Medicine, Bronx, NY.
Human papillomavirus (HPV) is a very common sexually transmitted infec-
tion, however only a small proportion of women progress to cervical precancer
or cancer. HPV16 is the most carcinogenic type, causing more than half of the
cervical cancer globally. The HPV16 genome is 7,906base-pairs coding for 8
genes (E6, E7, E1, E2, E4, E5, L2, L1) and one upstream regulatory region (URR).
WithinHPV16 there are 4main lineages (A, B, C, D) that are strongly associated
with disease risk. Human APOBEC3A (hA3A) cytidine deaminases have been
shown to have antiviral effects. The APOBEC mutational process results in a C
to T base change at specifıc motifs (5’ [C/T]●CT●W 3=). Previous studies
established that there was evidence of APOBEC3 editing on a small number of
HPV16 samples. It’s unknown how these mutations are related to infection
clearance or the long-term accumulation of genomic mutations that contribute
toHPV-associated cancers.We conducted detailed analyses to comprehensively
evaluate APOBEC3 editing on HPV16 genomes using HPV16 whole-genome
sequencing data from 3,215 HPV16-infected women in the NCI-HPV Persis-
tence and Progression (PaP) cohort. Cases were defıned as women with cervical
precancer (CIN3, N  1,093) or cancer (N  109) and controls were women
with no histologic evidence of precancer or cancer (CIN2, N 1,107). HPV16
DNA was extracted from banked specimens and whole-genome sequenced us-
ing a high-throughput assay. We evaluated all rare variants, defıned as having a
minor allele frequency of1%, for matching an APOBEC3-associated variant.
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AnAPOBEC3-associated variantwas defıned as a variant having one of the eight
possible motifs (5’ [C/T]●CT●W3=) out of 96 potential motifs of 3 base-pairs.
Using logistic regression, we compared the number of APOBEC3-associated
variants in cases and controls, among HPV16 variant lineages, and among ge-
nome regions of the virus. We discovered that there is evidence of APOBEC3
editing throughout the HPV16 genome. Specifıcally, we observed that women
with precancer or cancer had less APOBEC3-associated variants compared to
the controls (OR 0.84, p-value 0.06). We further showed that women with
an HPV16 A lineage infection have more APOBEC3-associated variants com-
pared to those with a non-A lineage infection (OR 1.35, p-value 0.02). After
controlling for the number ofAPOBEC3 vulnerable loci, we observed that the L1
(OR 0.23, p-value 0.04) and E7 (OR 0.29, p-value 0.07) genes have less
APOBEC3 footprints overall, and particularly in the cases compared to the con-
trols in these regions, compared to the viral non-coding upstream regulatory
region (URR). Overall, we found that APOBEC3 is not affecting the HPV16
genome in a uniformway, and instead, it appears to be targeting specifıc regions
which could suggest antiviral activity. Importantly, we determined that APO-
BEC3-associated variants are less prevalent in cases which could be related to
disease progression in these individuals. Further evaluation is underway.
#4250 Molecular alterations in the breast associated with early menarche.
Mariah L. Johnson,1 Natascia Marino,2 Anna Maria V. Storniolo,2 Bradley A.
Hancock,2 Milan Radovich,2 George E. Sandusky2. 1Komen Tissue Bank at the
Indiana University Simon Cancer Center, Indianapolis, IN; 2Indiana University
School of Medicine, Indianapolis, IN.
Background: Menarche, the onset of the female menstruation, is a marker of
pubertal timing. Age at menarche varies widely between girls and is highly de-
pendent on nutritional status and body fat accumulation. The occurrence of
menarche at an early age is linked to an increased risk of several adverse health
conditions later in life, such as obesity, type-2 diabetes, breast and endometrial
cancer, and cardiovascular disease. Indeed, for every one year decrease in age at
menarche (from an average age at menarche of 12.5 years), breast cancer risk is
increased by 5%. Several genome wide association studies (GWAS) have identi-
fıed genetic variants (i.e. in the LIN28B gene) that are associatedwith early age at
menarche, however little is known about the changes occurring in the breast
tissue of women with early menarche. We hypothesize that early age at men-
arche results in permanent molecular alterations in the breast tissue and that
those abnormalities may contribute to the tissue’s susceptibility to carcinogens
and breast cancer development. Methods: To test our hypothesis we used the
resources available at the SusanG. KomenTissue Bank at the IndianaUniversity
Simon Cancer Center (KTB). We selected histologically normal breast tissue
from healthy, young women with either early (age 10 years) or late menarche
(age 15 years), and matched for age, race, BMI, and menstrual phase. Breast
tissue biopsies from these women were microdissected to isolate the breast epi-
thelium and next generation RNA-sequencing was used to generate a transcrip-
tome profıle for each sample. Differential expression was performed using
DESeq2 in R. The tissue samples were also evaluated using immunostaining.
Results/Conclusions: Preliminary data show signifıcant differences when com-
paring the transcriptome profıles of the microdissected breast epithelium from
the early and late menarche sample cohorts. The tissue from women with early
menarche had upregulation of genes associated with defense against oxidative
stress and/or infectious bacteria (lactotransferrin [LTF], ceruloplasmin [CP]),
cell adhesion, (ITG11, ITGX, ITGM, ITGL, ITG2), immune response
(CARD9, LAIR1), and had downregulation of ubiquitination pathways (USP40,
AMFR) and lipoprotein metabolism (OSBPL1A, LIPH, PIGN). Immunohisto-
chemical evaluation of markers of oxidative stress (LTF, CP), cell proliferation
(Ki67), and immune infıltrates (CD45, CD20, CD8, CD68) is underway. To-
gether, this information will give us the opportunity to better understand early
age at menarche as a breast cancer risk factor and advance research for women’s
health.
#4251 DNAmethylation of mitochondrial biogenesis regulating genes: A
possible link between telomeres, mitochondria, and cancer incidence. Jacob
K. Kresovich,1 Tao Gao,2 Brian T. Joyce,2 Pantel Vokonas,3 Joel Schwartz,4 An-
drea A. Baccarelli,5 Lifang Hou2. 1University of Illinois-Chicago, Chicago, IL;
2Northwestern University, Chicago, IL; 3Department of Veterans Affairs, Boston,
MA; 4Harvard University, Boston, MA; 5Columbia University, New York, NY.
Background: PGC1A and PGC1B encode transcriptional factors that regulate
mitochondrial biogenesis and have been implicated as a link between telomeric
andmitochondrial functions. Telomere dysfunction is associated with impaired
mitochondrial biogenesis and increased generation of reactive oxygen species.
Animal studies have also shown that loss of PGC1A protects against cancer as
mitochondrial function is required for transformation and tumor growth. No
human studies have examined the role of these genes in relation to cancer inci-
dence. Our objective was to examine associations between PGC1A and PGC1B
methylation in relation to cancer incidence. Methods: We studied 491 Norma-
tive Aging Study participants who had blood drawn 1-4 times from 1999
through 2012. After median 10.2-year follow-up, there were 125 incident can-
cers including 36 prostate. PGC1A and PGC1Bmethylation wasmeasured at 30
and 27 sites, respectively, using theHumanMethylation450k assay.WeusedCox
proportional hazardsmodels to examine associations betweenCpGmethylation
and cancer incidence measured at fırst blood draw as well as in time-dependent
associations. All models adjusted for age, race, smoking status and pack-years,
alcohol consumption, blood cell composition, and processing batch. Results: In
single-site adjusted time-dependent models, we identifıed 13 instances of 11
individual loci (10 from PGC1A and 1 from PGC1B) signifıcantly associated
with all-cancer and prostate cancer incidence. In multi-site adjustedmodels, we
showed cg0677257 from the 3= UTR of PGC1A was inversely associated with
fırst-visit (HR: 0.41; 95% CI: 0.21, 0.79) and time-dependent all-cancer inci-
dence (HR: 0.42; 95% CI: 0.22, 0.81). Similarly, we showed cg0942771 and
cg03281309 from the gene body of PGC1A were inversely associated with time-
dependent all-cancer incidence (HR: 0.51; 95% CI: 0.30, 0.88; HR: 0.74; 95% CI:
0.56, 0.98, respectively). Finally, we found that cg1521939 from the 5’ UTR
region of PGC1B was positively associated with time-dependent all-cancer in-
cidence (HR: 3.27; 95% CI: 1.55, 6.90). Conclusion: This is the fırst study in
humans to show site-specifıc PGC1A and PGC1B methylation is a signifıcant
predictor of cancer incidence. These fındings point to a possible interplay be-
tween telomere and mitochondrial dysfunction, and epigenetics in carcinogen-
esis. Additional studies should also examine these associations in larger cohorts
with greater racial/ethnic, gender, and socioeconomic diversity to validate these
fındings.
#4252 New molecular evidence associating exposure to aristolochic acid
with urothelial cancers in South Korean patients: Implications for global
public health risk linked to carcinogenic herbal medicines. Shuhan Wang,1
DaeeunChoi,2 Jaesung Lim,3 KathleenG. Dickman,1Magali Olivier,4 Stephanie
Villar,4 Viktoriya S. Sidorenko,1 Maude Ardin,4 Byeong H. Yun,5 Robert J.
Turesky,5 Minho Shong,6 Jiri Zavadil,4 Arthur P. Grollman1. 1Stony Brook Uni-
versity, Stony Brook, NY; 2Medicine, Chungnam National University Hospital,
Daejeon, Republic of Korea; 3Surgery, Chungnam National University Hospital,
Daejeon, Republic of Korea; 4International Agency for Research on Cancer, Lyon,
France; 5University of Minnesota, Minneapolis, MN; 6Medicine, Chungnam Na-
tional University Hospital, Jung-Gu, Daejeon, Republic of Korea.
Aristolochic acid (AA) is a potent nephrotoxin and carcinogen (IARCGroup
1) associated with urothelial, hepatobiliary, and renal carcinomas. Exposure to
AA from dietary intake of traditional herbal medicines containing Aristolochia
species poses a global health hazard, yet also an opportunity for disease preven-
tion.Molecular epidemiology studies employing sensitive and specifıc biomark-
ers for screening of populations at risk are thuswarranted.Genome-scale studies
established a characteristic mutational signature of AA. Exploiting its unique
features (predominant AT transversions), alongside the knowledge of key
affected cancer genes, we devised a cost-effective targeted resequencing (TRseq)
method to detect AA etiology in upper tract urothelial carcinoma (UTUC) sam-
ples from South Korean patients. Aristolochia species (e.g., A. contorta, Bunge)
are included in the Korean traditional pharmacopoeia although the local occur-
rence of AA-associated cancers remains unexplored. DNA from archived,
paired kidney andUTUC samples of 16Korean patients was used for adduct and
TRseq analyses. Thirty-one cancer genes, previously found recurrently mutated
in AA-induced UTUCs from Asia and Europe, were selectively captured using
SeqCap EZ enrichment kit (Nimblegen Roche) and sequenced using Illumina
MiSeq. Sets of UTUCs from Croatia (harboring AA signature) and from US
patients (unlikely to be exposed) were included as respective positive and nega-
tive controls. Somatic variants were called against the patient-matched non-
tumor DNA, using two distinct variant calling strategies. Three out of 16 kidney
cortex samples tested positive for aristolactam-dA (AL-dA) adducts, indicative
of past exposure to AA. One UTUC sample with AT-mutated TP53 harbored
32 AT mutations across the 31-gene panel, and another 8 cases, 3 of which
were adduct-positive, harbored lower counts of AT mutations (up to 3 per
gene panel per sample). The allelic frequencies of the considered AT muta-
tions ranged between 10-83%. The positive control samples exhibited a strong
AT signal while the US samples were all AT-negative, as expected. We pro-
pose that the TRseq approach can detect AA-driven mutagenesis in UTUC
tumors, providing a sensitive complement to the AL-dA adduct analysis, at low
per-sample cost. Importantly, the presence of adducts and AA signature muta-
tions in SouthKoreanUTUCcases highlights a previously uncharacterized pop-
ulation at risk. The future use of TRseq, either alone or in combination with
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adduct analysis, can address exposure to AA in extended UTUC case series,
thereby assisting in the design of preventive measures against this global public
health hazard. Funding: IARC; SW is Recipient of research support from the
Drs.Martin &Dorothy Spatz Charitable Foundation; Henry andMarsha Laufer
grant to KGD, VSS, APG.
#4253 Expression profıling of paired benign and breast cancer lesions in
African American women. Andreana Natalie Holowatyj,1 Julie J. Ruterbusch,1
Rouba Ali-Fehmi,1 Sudeshna Bandyopadhyay,1 Christine Mehner,2 Melody
Stallings Mann,2 Gregory Dyson,1 Derek Radisky,2 Michele L. Cote1. 1Wayne
State University School of Medicine, Detroit, MI; 2Mayo Clinic Cancer Center,
Jacksonville, FL.
Benign breast disease, a known risk factor for subsequent breast cancer, in-
cludes a histological spectrum of lesions that can be subdivided based on the
overall impression into non-proliferative lesions, proliferative lesions without
atypia, and atypical hyperplasia. Yet little is known about the molecular charac-
teristics of benign breast tissue fromAfricanAmericanwomen, who suffer from
disproportionately high breast cancer mortality rates. 72 breast samples from
African American women were obtained. RNA was extracted from archival
formalin-fıxed, paraffın-embedded (FFPE) blocks. Gene expression profıling
was performed on these samples using the Affymetrix HTA2.0 exon array chip.
A fıt linear model using generalized least squares identifıed probe sets with
differential expression in benign-in situ and benign-invasive breast cancer
paired lesions. 36 benign and 36 breast cancer paired lesionswere included in the
study. In the benign-in situ set (n20), 978 probe sets were differentially ex-
pressed (threshold: fold-change, 1.50; p 0.05). Probe sets mapped to 125 an-
notated genes, ofwhich 69 (55.2%)were involved in cancer. The benign-invasive
set (n52) identifıed 351 differentially expressed probe sets that mapped to 84
annotated genes, of which 61 (72.6%) had known cancer signifıcance. Genes
involved in cellular growth and proliferation were signifıcantly over-expressed
in both benign-in situ and benign-invasive lesions (p-values  0.0104). In the
population of 36 paired samples, differentially expressed genes were found to
regulate the estrogen receptor (ESR1) through distinct network associations.
Many genes are differentially expressed by benign and breast cancer lesions, and
in situ/invasive histology contribute to the distinctmolecular characteristics and
pathways of breast malignancy. Our fındings highlight the fırst study to assess
expression profıling of paired benign and breast cancer lesions among African
American women.
#4254 Improved understanding of the etiology of breast cancer in young
women through evaluation of the genomic landscape. Matthew D. Wilker-
son,1 Clifton L. Dalgard,1 Craig D. Shriver,2 Rachel E. Ellsworth3. 1Uniformed
Services University School of Medicine, Bethesda, MD; 2Murtha Cancer Center,
Bethesda, MD; 3Murtha Cancer Center, Windber, PA.
Background: Breast cancer is a disease where biological age and age at meno-
pause are established risk factors, thus diagnosis of breast cancer in young
women (40 years, YW) is not common, representing 6% of breast cancer
diagnoses annually. Germline mutations in cancer predisposition genes ac-
counts for 20% of breast cancer diagnoses in YW, thus the etiology of breast
tumors for the majority of YW is unknown. Methods: Frozen tumor specimens
andmatched genomicDNA samples from 31women diagnosed40 years were
available. Whole genome sequencing (WGS) was performed by generating se-
quencing libraries from 1 mg input using the TruSeq PCR-free library prepara-
tion workflow and sequencing on the HiSeq X Ten at triple lane depth with
150bp paired-end reads. WGS was analyzed using the Hiseq Analysis Software
Tumor Normal Workflow, Bioconductor: deconstructSigs and ad hoc inte-
grated analysis and hypothesis testing. Results: Luminal A tumors fromYWhad
signifıcantly lower somatic mutational loads, copy number alterations and
structural variants than other subtypes and structural variants on chromosome
17 were enriched in patients with the HER2-enriched subtype and HER2 sta-
tus 3. Aging was themost common signature (28/31) followed by APOBEC
activation (14/31). Signatures associated with defects in mismatch repair (9/31)
and polymerase  (10/31) were also detected in25% of patient tumors. Of the
six patients with BRCA defect signatures, three had germline mutations in
BRCA2 and one had a CHEK2 mutation. Mutational signatures could cluster
patients into two groups, with the youngest patients (35 years) less likely to
have signatures associated with aging but an enrichment in signatures of APO-
BEC, BRCAmutations and smoking; tumors within this group weremore likely
to be non-luminal A. Conclusions: Profıling the genome of tumors from YW
supports the idea that most tumors are not characterized by profıles associated
with genetic predisposition but rather processes such aging, APOBEC activa-
tion,mismatch repair, and defects inDNA replication. Of note, breast tumors in
the youngest patients (35) have a different pattern of mutational signatures
suggesting that even within YW, etiology differs by age.
#4255 Associations of coffee consumption and caffeine intake withmam-
mographic breast density. Lusine Yaghjyan,1 Graham Colditz,2 Bernard Ros-
ner,3 Aleksandra Gasparova,1 Rulla Tamimi3. 1Univ. of Florida, Gainesville, FL;
2Washington University in St. Louis, MO; 3Channing Division of Network Med-
icine, Department of Medicine, Brigham and Women’s Hospital and Harvard
Medical School, Boston, MA.
Purpose: Previous studies suggest that coffee consumption and caffeine intake
may be associated with reduced breast cancer risk which may result from stim-
ulating effect of coffee on estrogen metabolism enzymes and subsequent
changes in bioavailable estrogen. We investigated the association of coffee con-
sumption and caffeine intake with mammographic density by woman’s meno-
pausal status and, in postmenopausal women, by hormone therapy (HT).Meth-
ods: This study included 4,130 cancer-free women within the Nurses’ Health
Study andNurses’ Health Study II cohorts. Percent breast density (PD), absolute
dense and non-dense areas were measured from digitized fılm mammograms
using a computer-assisted thresholding technique; all measures were square-
root transformed for the analysis to improve normality. Diet was assessed with a
food frequency questionnaire; average cumulative coffee/caffeine consumption
was calculated using data available from all the questionnaires preceding the
mammogram date. Information regarding breast cancer risk factors was ob-
tained frombaseline or biennial questionnaires closest to themammogramdate.
We used generalized linear regression to quantify associations between expo-
sures and breast density measures, adjusted for potential confounders. Associ-
ations were examined separately for regular coffee, decaffeinated coffee, total
coffee, and energy-adjusted caffeine intake. Results: In multivariable analyses,
decaffeinated coffee was positively associated with PD in premenopausal
women (2 cups/day: 0.23, p-trend0.03). In postmenopausal women, de-
caffeinated and total coffee were inversely associated with PD (decaffeinated
coffee 2 cups/day: -0.24, p-trend0.04; total coffee 4 cups/day: -
0.17). These associations appeared to be driven by the inverse associations of
these exposures with absolute dense area. Among current HT users (n980),
regular coffee and caffeine intake were inversely associated with PD (regular
coffee 4 cups/day: -0.29, p-trend0.01; caffeine 4th vs. 1st quartile: -
0.32, p-trend0.01). Among past users (n430), decaffeinated coffee was in-
versely associatedwith PD (2 cups/day-0.70, p-trend0.02). Conclusions:
Our fındings suggest that among current HT users, regular coffee and caffeine
are inversely associated with mammographic percent breast density.
#4256 Impact of diesel engine exhaust exposure on the airway transcrip-
tome. Eduard I. Drizik,1 Sean Corbett,1 Roel Vermeulen,2 Yufei Dai,3 Wei Hu,4
Marc Lenburg,1 Dianzhi Ren,5 Huawei Duan,3 Yong Niu,3 Jun Xu,6 Wei Fu,5
Kees Meliefste,2 Baosen Zhou,3 JuFang Yang,5 Meng Ye,3 Xiaowei Jia,3 Tao
Meng,3 Ping Bin,3 Yuxin Zheng,3 Debra Silverman,4 Nathaniel Rothman,4
Avrum Spira,1 Qing Lan4. 1Boston University, Boston, MA; 2Utrecht University,
Utrecht, Netherlands; 3Chinese Center for Disease Control and Prevention, Bei-
jing, China; 4National Cancer Institute, Rockville, MD; 5Chaoyang Center for
Disease Control and Prevention, Chaoyang, China; 6HongKongUniversity, Hong
Kong, Hong Kong.
Rationale: Recent epidemiological studies show that Diesel Engine Exhaust
(DEE) exposure is associated with lung cancer, however the mechanism by
which this occurs is not well understood. The goal of this study was to assess the
transcriptomic alterations in the nasal epithelium ofDEE exposedworkers from
factories where diesel engines are utilized.Methods: Nasal epithelium brushings
were obtained from41 subjectswhowork in a factorywithDEEexposure, and 38
comparable control subjects who work in factories without any DEE exposure.
The median Elemental Carbon (EC) levels of exposed individuals was 60.7g/
m3, with a range of 17.2-105.4g/m3, respectively. RNAwas isolated from nasal
epithelial cells, and profıled for gene expression using Affymetrix microarrays.
Linear modeling was used to detect differential expression between DEE expo-
sure and controls. Pathway enrichment in differentially expressed genes was
assessed usingGOBiological Process andKEGG terms via EnrichR. Results:We
found 234 genes that were differentially expressed between samples derived
fromDEE exposed participants versus controls at FDR q 0.25.Within this set
of genes, we observed a higher expression of genes involved in oxidative stress
response, as well as cell proliferation, cellular transcription, and regulation of
apoptosis. In addition, we found that genes involved in ion transport, such as
CFTR, were expressed at lower levels in DEE exposed samples. Conclusions:
Chronic DEE exposure associates with changes in the airway transcriptome,
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with increased stress response as a major effect of DEE exposure. The transcrip-
tomic alterations we identifıed may help provide insight into the underlying
mechanisms of DEE carcinogenicity.
#4257 Dietary nutrient intake, ethnicity, and epigenetic silencing of lung
cancer genes detected in sputum in New Mexican smokers. Shuguang Leng,1
Maria Picchi,1 Piotr Filipczak,1 Frank Gilliland,2 Steven A. Belinsky1. 1Lovelace
Respiratory Research Inst., Albuquerque, NM; 2University of SouthernCalifornia,
CA.
Promoter hypermethylation of lung cancer (LC) genes detected in sputum
assesses fıeld cancerization and predicts LC risk. Hispanic smokers have greater
risk for methylation than non-Hispanic Whites (NHW). We aimed to identify
novel dietary nutrients affecting methylation of LC genes in sputum and deter-
mine the degree of ethnic disparity explained by diet. A cross-sectional popula-
tion-based study was conducted with dietary intake assessed using a validated
Harvard food frequency questionnaire in 327 Hispanics and 1502 NHWs from
the Lovelace Smokers cohort (LSC). Twelve LC genes with diverse cellular func-
tions whose concomitant methylation strongly predicted LC risk were studied.
A global association was identifıed between dietary intake and genemethylation
(Ppermutation0.003). Seventeen nutrient measurements were associated with
methylation with magnitude greater than seen for folate and these nutrients
together accounted for 36% of the variance in methylation. Six protective nutri-
ents were identifıed and their insuffıcient intake in Hispanics explained approx-
imately 42% of ethnic disparity in methylation. Functional validation of protec-
tive nutrients that also explained ethnic disparity was provided by showing an
enhanced DNA repair capacity towards double-strand DNA breaks, a mecha-
nistic biomarker strongly linked to acquisition of LC genemethylation in smok-
ers. Dietary intake is a major modifıable factor for preventing promoter meth-
ylation of LC genes in smokers’ lungs. Altering the diet in Hispanics may
alleviate ethnic disparity for methylation. Complex dietary supplements could
be developed based on these protective nutrients for LC chemoprevention in
smokers. This study was funded by NIH R01 CA097356, NIH/NCI P30
CA118100, and the State of New Mexico as a direct appropriation from the
Tobacco Settlement Fund.
#4258 Influence of lifestyle factors on adipocyte size in human breast tis-
sue.Kristin L. Campbell,1 NagarajanKannan,2 Sarah E.Neil-Sztramko,3 Connie
J. Eaves,4 Jonathan P. Little,5 Ilona Csizmadi,6 David Zhu,1 Sarah Sayyari,1 Kel-
cey Bland,1 James D. Johnson1. 1Univ. of British Columbia, Vancouver, British
Columbia, Canada; 2Mayo Clinic, Rochester, MN; 3McMaster University, Ham-
ilton, Ontario, Canada; 4Terry Fox Laboratory, Vancouver, British Columbia,
Canada; 5Univ. of British Columbia, Kelowna, British Columbia, Canada; 6Uni-
versity of Calgary, Calgary, Alberta, Canada.
Background: Accumulating epidemiological studies positively associate
healthy bodymass index (BMI) and higher physical activity with lowered risk of
postmenopausal breast cancer. Many of the proposed biomarkers underlying
these associations, such as insulin, inflammatory markers, steroid hormones,
and adipokines, are produced or regulated by adipose tissue. However, the bio-
logical impact of lifestyle factors at the level of the breast tissue, particularly
adipose tissue in the breast, is unclear andmayplay a role in the etiology of breast
cancer. Methods: Using a cross-sectional design, we examined the impact of
demographic and lifestyle factors on histological features of breast adipose tis-
sue.Women (age) undergoing reductionmammoplasty surgery were consented
to collection of their cancer-free breast tissue at the time of surgery. An adipose
rich section of the sample was dissected under sterile conditions and formalin
fıxed. Samples were sectioned at 7 m thickness and stained with hematoxylin
and eosin. The stained sections were imaged and mean adipocyte size was de-
termined as diameter (m) from3 randomly selected areas at 10Xmagnifıcation
and each sample was scored by two independent assessors using Image J soft-
ware. BMI status documented at the timeof surgerywas abstracted formmedical
records. A subset of women completed an additional visit where percent total
body fat wasmeasured by air displacement plethysmography and aerobic fıtness
(VO2peak) was measured by a maximal graded exercise test with expired gas
collection. The association between adipocyte size and demographic/lifestyle
factors was examined using multivariate linear regression adjusted for age and
menopausal status. Results: Participants (n42) were primarily Caucasian
(77%) and pre/peri-menopausal (62%), with a mean age of 44.6	12.9 years
(range 19-70) and mean BMI of 27.7	5.1 kg/m2 (range 19.1-37.4). Adipocyte
size was associated with BMI (per 5 kg/m2 increase,  5.6	2.15, p0.01) and
number of pregnancies (  6.04	2.34, p0.02), but not age (  0.1	0.3,
p0.81). In the subset of participants who completed an additional study visit
(n9), there was a trend towards an inverse association between adipocyte size
and aerobic fıtness (per 2 ml/kg/min of O2 consumption,   -3.54	1.52,
p0.07) and percent body fat (per 2% increase,   1.94	1.28, p0.17) in
unadjusted analyses. Conclusion: Higher BMI is associated with larger adi-
pocyte size in adipose tissue taken from the breast, suggesting a biological role
for body composition in influencing gross histological features of adipocytes and
its behavior that would impact the health of the mammary gland. A better un-
derstanding of the biological mechanisms underlying the observed epidemio-
logical associations are needed to guide the development of intervention strate-
gies and the most effective public health messages for breast cancer prevention.
#4259 The relation of childhood diet to the timing of puberty in boys:
Results from the Longitudinal Studies of Child Health and Development.
Aliya Alimujiang,1 Graham A. Colditz,1 Catherine S. Berkey,2 Siobhan Sut-
cliffe1. 1Washington University School of Medicine, Saint Louis, MO; 2Harvard
Medical School, Boston, MA.
Background: Although accumulating evidence from different disciplines sup-
ports an early-life contribution to prostate cancer (PCa) risk, few studies have fo-
cused on this life stage. Onemajor reason for this dearth of research is the decades-
long span of time between early-life exposures and PCa onset, making traditional
epidemiologic study designs challenging. To overcome this challenge, we took ad-
vantage of several well-supported or recently observed PCa risk factors - age at peak
height velocity (APHV), height at age 13, and adult height - to shorten the time
required to study early-life exposures and to improve exposure classifıcation by
using these risk factors as markers of future PCa risk. We focused our analysis on
childhooddiet because it influencedAPHVina similar studyof girls, andbecauseof
its strongly suspected role in PCa development. Methods: We analyzed data from
theLongitudinal StudiesofChildHealth andDevelopment,which followed67Cau-
casian boys from Boston from birth through adolescence in the 1930-40s. At each
biannual (or annual) visit, study staffmeasured participants’ height andweight, and
assessed their diet by dietary history interviews.We used these data to estimate age-
and energy-adjusted nutrient intake, diet scores (combining information on fat and
animal protein from ages 1-10 years into aWestern diet score, and information on
vegetable protein from ages 1-10 into a healthy diet score), age-specifıc height-z-
scores, body mass index, peak height velocity (PHV), and APHV.We investigated
crude associations between dietary and anthropometric measures by Pearson cor-
relation coeffıcients, and multivariable-adjusted associations by linear regression.
Results: Childhood consumption of aWestern diet (as measured by our fat-animal
protein score) was positively associated with height at age 13 (beta coeffıcient
(ß)0.08, P0.001) and adult height (ß0.05, P0.013), and inversely associated
with APHV (ß-0.06, P0.014). In contrast, childhood consumption of a healthy
diet (as measured by our vegetable protein score) was inversely associated with
height at age13 (ß -0.09,P0.008).Nonotable associationswereobserved fordiet
and PHV. After controlling for height at ages 1-2 as a marker of genetic growth
potential, only the association betweenWestern diet and height at age 13 remained
signifıcant (ß0.04, P0.001). Conclusions: Our fındings suggest that consump-
tionof aWesterndiet during childhood (1-10 years of age) is associatedwith greater
height at age13, apossiblemarkerofbothearlieronsetofpubertyandgreaterheight.
As this measure was recently associated with later PCa risk/mortality in a large
Danish cohort study, our fındings may point towards an early dietary contribution
to PCa risk. Future studies should explore this possible association further for its
potential to inform primary PCa prevention strategies.
#4260 Increased mutation burden in normal-appearing lung tissues with
high cancer risk. Emi Kubo,1 Hideyuki Takeshima,1 NorikoMotoi,2 Toshikazu
Ushijima1. 1National Cancer Center Resarch Institute, Tokyo, Japan; 2National
Cancer Center Hospital, Tokyo, Japan.
Background: Genetic alterations are considered to be accumulated in normal
tissues at extremely low levels by exposure to various carcinogenic factors, and the
degree of accumulated alterations, namely mutation burden, is likely to be associ-
ated with cancer risk. In lung tissues, smoking is a well-known carcinogenic factor,
and is considered tobe involved inaccumulationofmutationburden.However,due
to the limitation of detection methods of such extremely low frequency mutations,
thepresenceofmutationburden innormalhuman lung tissueshasbeenunclear.To
overcome this limitation, we recently developed a newmethod to detect mutations
with extremely low frequency by sequencing 100DNAmolecules using a next gen-
eration sequencer[Yamashita, submitted]. Aim:We aimed to reveal 1) the presence
of mutation burden in normal lung tissues, and 2) its association with cancer risk.
Methods and results: The presence of somaticmutationswas analyzed in 55 cancer-
related genes (totally 15,724 bp) in normal lung tissues (n  11) obtained from
background tissues of lung metastasis of cancer patients, without smoking history,
other than thosewith lung cancers (’’entirely normal lung tissues’’) andnon-cancer-
ous lung tissues (n 11) of lung cancer patients with smoking history (’’smoking-
exposed normal tissues’’). Themutation frequency in smoking-exposed normal tis-
sues (2.7 	 0.810-5/bases) was signifıcantly higher than that in entirely normal
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tissues (1.8	 0.510-5/bases) (p 0.0189). C to T transition was most frequent in
both smoking-exposed normal tissues (60% of detected base substitutions) and en-
tirely normal tissues (61%), but the fractions were not different between the two
groups. In contrast, C to A transversion, the signature mutation of smoking, was
more frequent in smoking-exposed normal tissues (4%) than in entirely normal
tissues (2%). Accumulation of somaticmutations tended to be associated with can-
cer risk [OR 3.75 (95%CI 0.54-26.046)]. Conclusion: Itwas shown, for the fırst
time, that somatic mutations were accumulated in normal lung tissues with high
cancer risk, possibly by exposure to tobacco smoking.
#4261 Cancer in childhood and molecular epidemiology - The KIKME
case-control study. Manuela Marron,1 Sebastian Zahnreich,2 Olesja Sinizyn,2
Heinz Schmidberger,2 Moritz Hess,3 Patricia Sadre Dadras,1 Iris Altebockwin-
kel,2 ThomasHankeln,4 SteffenRapp,4 Anne Ebersberger,2 ChristianGrad,2 Eva
Holzhäuser,2 Lukas Eckhard,5 Dirk Proschek,5 Maria Blettner,3 Peter Kaatsch,6
Claudia Spix,6 Danuta Galetzka,2 Harald Binder3. 1Leibniz Institute for Preven-
tion Research and Epidemiology - BIPS, Bremen, Germany; 2Department of Ra-
diation Oncology and Radiation Therapy, University Medical Center of the Jo-
hannes Gutenberg University, Mainz, Germany; 3Institute of Medical
Biostatistics, Epidemiology and Informatics, University Medical Center of the
Johannes Gutenberg University, Mainz, Germany; 4Institute of Molecular Genet-
ics, Johannes Gutenberg University, Mainz, Germany; 5Department of Orthopae-
dic Surgery, University Medical Center of the Johannes Gutenberg University,
Mainz, Germany; 6German Childhood Cancer Registry, Institute of Medical Bio-
statistics, Epidemiology and Informatics, University Medical Center of the Jo-
hannes Gutenberg University, Mainz, Germany.
Treatment of fırst primary neoplasms (PN) in childhood with radiotherapy or
chemotherapy is an established risk factor for second primary neoplasms (SN). In
addition, there is growing evidence for this association from observational studies
on ionizing radiation and cancer risk, in particular after radiation exposure in child-
hood. As only a subgroup of the treated children suffers from SN, other risk modi-
fying factors (e.g. genetics) must be involved. We are conducting a case-control
study with 600 anticipated participants to evaluate gene-radiation interactions and
risk of SN (leukemia, thyroid or skin cancer) as well as PN (leukemia, lymphoma or
CNS) with a new epidemiological design, in which we combine observational with
experimental elements by analyzing gene expression in irradiated cultured human
fıbroblasts from skin biopsies. In a fırst step, we examine the participation propor-
tionsof survivorsof childhoodcancerwith andwithout aSNandcancer free control
patients (CO) from the department of accident surgery and orthopaedics. In addi-
tion to a skin biopsy of 3mm and a saliva sample, we collect detailed questionnaire
information on lifetime exposure to medical radiation and chemotherapy, socio-
demographic factors, smoking, drinking, physical activity,medical history and fam-
ily history of cancer and other diseases. Cases and controls will be matched by sex
and age (1:1), and additionally among the former childhood cancer patients by type
of the PN and year of fırst diagnosis (1 SN:3 PN). In explorative pilot experiments,
we estimate gene expression differences by RNA-Seq in fıbroblasts after low (0.05
Gy) andhigh (2Gy) radiationdoses at different timepoints (0.25 h, 2 h, 24 h). In the
fırst recruitment drives of the ongoing study, we recruited 77 patients with SN and
95matched patients with only one PN from 1975 eligible former childhood cancer
patients at the GermanChildhoodCancer Registry, as well as 22 COpatients. Until
November2016, 33%of the contacted231SNpatients, 20%of the486 contactedPN
patients and 69% of the 32 contacted CO patients participated in our study. Two
hours after low and high in vitro radiation doses, the largest number of genes were
differentially expressed, some of them only after high doses, some only after low
doses and some after both. To our knowledge, the KIKME study is the fırst epide-
miological project analyzing differential gene expression in primary fıbroblasts be-
fore and after radiation with high and low doses to evaluate the potential genetic
basis for emergence of a SN and a PN. However, the biological importance of the
suggesteddifferential gene expression after high and lowdoses of radiationhas to be
confırmed with the full study population. In addition, the gene expression must be
analyzed in detail by group (SN, PN, CO) and will be combined with results from
whole genome sequencing in order to obtain a comprehensive view of the role of
radiation in the carcinogenesis of childhood cancer.
#4262 Inflammatory gene expression differences among prostate cancer pa-
tients exposed to the World Trade Center aftermath. Dana Hashim, Yixuan
Gong,MatthewGalsky,CharlesBaker, PaoloBoffetta,Michael J.Donovan,Emanu-
ela Taioli, WilliamK. Oh.Mt. Sinai Icahn School of Medicine, New York, NY.
Background:World Trade Center (WTC) rescue and recovery workers were ex-
posed to a complexmixture of dust anddebris after the collapse of theWTC towers.
Anexcess incidenceof prostate cancerwasobserved in theWTCworkers and,more
advanced prostate cancer cases have been associated with higher levels of WTC
exposure. As inflammation is known to promote tumor development and progres-
sion and the prostate cancer etiology remains uncertain,we comparedRNAexpres-
sion of inflammatory markers in prostate cancer tumors fromWTC patients with
matched prostate cancer patients not related toWTC.Methods: RNAwas prepared
from formalin-fıxed paraffın embedded tumors of 15WTC prostate cancer and 14
non-WTCprostate cancers, age, race, andGleason-scorematched.Gene expression
was quantifıed using Nanostring nCounter® PanCancer Immune Profıling Panel,
which combines markers for 24 immune cell types and populations, 30 common
cancer antigens and genes representing all immune response categories including
key checkpoint blockade genes. Data analysis was performed using the NanoString
nSolver 2.6 analysis software. Genes shown to be characteristic of innate and adap-
tive immune cell populations were used to derive cell-type scores indicating popu-
lation abundance of each immune cell type. Comparisons of cell type scores were
performed using Student’s t test. Results: WTC prostate cancers expressed high
levels of genes associated with chronic inflammation: NFATC2 (Fold change3.0,
P0.001),MRC1 (Fold change2.0, P0.001), CT8L (Fold change1.5, P0.01),
CSF1 (Fold change1.5, P0.001),NFKB1 (Fold change1.3, P0.005), CXCL13
(Fold change3.7, P0.04), IL6 (Fold change2.5, P0.04) and ITCH (Fold
change 0.3, P0.001) compared with non-WTC prostate cancers. Conversely,
non-WTC prostate cancers expressed higher levels of genes associated with innate
immunity: TIRAP (Fold Change0.05, P0.001), IRF3 (Fold change1,
P0.001), and FADD (Fold change0.5, P0.005), comparedwithWTCprostate
cancer. In cell type enrichment analysis, macrophage and CD45 cells scored
higher in non-WTC (8.83	0.75 SD and 9.09	0.78 SD) thanWTC (7.81	0.73 SD
and8.53	0.53SD)prostate cancer samples (t3.70,P0.001andt2.29,P0.02);
regulatory T cells scored higher in WTC (5.90	0.52 SD) than non-WTC
(5.42	0.67SD)prostate cancer samples (t2.15,P0.04).Conclusions:Compared
to non-WTC prostate cancers, tumors from WTC-exposed patients show overall
lower expressions of genes involved in local innate immune-system response and a
higher expression of adaptive immune-system response genes. Environmental fac-
tors, such as exposure during the 9/11 aftermath, may have played a role in the
development of advanced prostate cancer in these patients via high immune-toler-
ance. The results have implications for a role of environmental factors in prostate
carcinogenesis.
#4263 Smoking impacts endogenous estradiol and testosterone levels in
young healthy women. Carolina Ellberg, Håkan Olsson, Helena Jernstrom.
Lund University, Lund, Sweden.
Introduction: The purpose of the study was to elucidate the association between
smoking and estradiol (E2) and testosterone (T) levels in young healthy women
from high-risk families. Cigarette smoke containsmultiple carcinogens and is con-
sidered a risk factor for breast cancer. However, tobacco also contains aromatase
inhibiting substances, but the impact onhormonal levels in youngwomenat the age
whenbreast cancer is initiated isunclear andneeds further elucidation.Material and
methods: Between 1996 and 2002, 258 healthywomen fromhigh-risk breast cancer
families in Sweden were enrolled in a study on the impact of lifestyle factors in
women40 years. Blood samples and bodymeasurements were obtained in the
luteal phase (5-10 days before predicted onset of the next menstrual cycle) by a
trained research nurse. Participants fılled out questionnaires on lifestyle and repro-
ductive factors. Ongoing breastfeeding, use of hormonal contraceptives other than
combined EP oral contraceptives (OCs), as well as missing data on onset of next
menstrual cycle and smoking status led to exclusion of 28 women. Two hundred
thirtywomen including 33 knownBRCA1/2mutation carrierswere included in the
analyses.Weightandhormonal levelswerenotnormallydistributedandwere trans-
formed using the natural logarithm to obtain better distribution. Since OCs influ-
ence endogenous hormones, the women were stratifıed by current OC use. Multi-
variable linear regressionwere used to obtain P-values, adjusted for age, nulliparity,
menstrual cycle day, waist-to-hip ratio (WHR), and weight. Geometric means for
current smokers and non-smokers were standardized at age 29 years, nulliparity,
number of days until onset of next menstrual period (7 days), WHR 0.76, and LN-
weight (64kgs).Results: In allwomen, themedianagewas29yearsold, (IQR24-35),
and the median year of birth was 1969, the median weight was 64 kgs, and the
median WHR was 0.76. In total, 47% were parous, and 42% had ever smoked,
whereas 22% were current smokers, and 38% were current OC users (40% of the
smokers and 37% of the non-smokers). In non OC users, E2 levels were similar in
smokers and non-smokers (adjP0.26), while standardized total T levels were
higher in smokers (51.8 vs 45.1 ng/dL; adjP0.067). In contrast, among currentOC
users, smokers had higher standardized E2 levels (22.7 vs 17.7 pg/mL; adjP0.023)
comparedwith non-smokers, while total T levels were similar in smokers and non-
smokers (adjP0.56). Conclusion: In non-OC users, amore androgenic profıle was
observed in smokers compared with non-smokers.While in OC users endogenous
E2 levels were higher in smokers compared with non-smokers, which suggests that
cigarette smokemayreduce theeffıcacyof thepill.Differential impactof smokingon
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endogenous E2 and total T levels in current OC users and non-users was thus ob-
served. Therefore, history of OC use needs to be incorporated in studies on associ-
ations between smoking and breast cancer risk.
#4264 Smoking exposure and quantitative levels of estrogen-receptor ex-
pression in ER breast tumors. Eboneé N. Butler, John A. Baron, Jeannette T.
Bensen, Mengjie Chen, Kathleen Conway, Andrew F. Olshan, Melissa Troester.
University of North Carolina at Chapel Hill, Chapel Hill, NC.
Introduction: Smoking is a suspected risk factor for breast cancer and has been
linked to increased risk of estrogen-receptor positive (ER) disease in some epide-
miologic studies.Cigarette smokehasalsobeenshowntohaveantiestrogeniceffects,
leading to a potentially contradictory hypothesis that smoking would lead to de-
creased risk of breast tumors driven by estrogen-signaling. Binary classifıcation of
breast tumorswith respect toERmaymaskquantitativeassociationsbetweensmok-
ing andERexpression.Methods:Using data from theCarolinaBreastCancer Study
(CBCS), we examined relationships between smoking and quantitative levels of ER
expression from tumors of 1,297 women with ER disease (i.e., 10% of tumor
cells ERby immunohistochemical analysis).Weusedmultinomial logistic regres-
sion to estimate associations between categoricalmeasures of smoking andquartiles
of ERprotein or ESR1mRNAexpression, represented by odds ratios (OR) and 95%
confıdence intervals (95%CI).Wealsoexaminedassociationsbetweensmokingand
quantitative ER levels among women with ER breast tumors, stratifıed bymeno-
pausal status.Multivariate regressionmodels include adjustment for age, race, stage,
grade, and tumor size. Results:QuantitativeESR1waspositively associatedwith any
history of smoking (i.e., current at time of diagnosis or former smoking) (OR: 1.96
and 95% CI: 1.24 to 3.10). In addition, smoking more than 1 pack of cigarettes per
daywas associatedwithhighESR1 expression (OR: 3.19 and95%CI: 1.29 to 7.91) as
was smoking duration of 20 years (OR: 2.08 and 95% CI: 1.16 to 3.74). Among
former smokers, we observed higher ESR1 expression among those who quit 5-10
years prior todiagnosis. Themagnitudesof associationbetween smoking andquan-
titative levels of ESR1 expression were similar for both pre- and post-menopausal
women, but were not reflected in similar association on the protein level. Conclu-
sions: Among women with ER breast cancer, smoking dose and duration was
positively associated with elevated ESR1 mRNA levels, regardless of menopausal
status.Absenceof thisassociation forproteinsuggests thatESR1RNAmerits further
consideration, butmay suggest that ESR1RNAmore sensitively captures biological
differences than ER protein expression.
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#4265 Risks of familial breast cancer associatedwith known and proposed
breast cancer susceptibility genes. Kara N. Maxwell,1 Thomas Paul Slavin,2
Jenna M. Lilyquist,3 Joseph Vijai,4 Susan L. Neuhausen,2 Steven N. Hart,3 Vi-
gnesh Ravichandran,4 Tinu Thomas,4 Ann Maria,4 Kasmintan A. Schrader,5
Raymond Moore,3 Chunling Hu,3 Brad Wubbenhorst,1 Brandon M. Wenz,1
Kurt D’Andrea,1 Susan M. Domchek,1 Mark E. Robson,4 Paulo Peterlongo,6
Paolo Radice,7 James M. Ford,8 Judy E. Garber,9 Csilla Szabo,10 Kenneth Offıt,4
Katherine L. Nathanson,1 Fergus J. Couch,3 Jeffrey N. Weitzel2. 1University of
Pennsylvania, Philadelphia, PA; 2City of Hope, Duarte, CA; 3Mayo Clinic, Roch-
ester, MN; 4Memorial Sloan Kettering Cancer Center, New York, NY; 5British
ColumbiaCancer Agency, Vancouver, British Columbia, Canada; 6IFOM,Milan,
Italy; 7Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 8Stanford
University School of Medicine, Stanford, CA; 9Dana Farber Cancer Institute,
Philadelphia, PA; 10National Institutes of Health, Bethesda, MD.
A better understanding of gene-specifıc risks for development of breast cancer
will lead to improved screening, prevention, and therapeutic strategies for indi-
viduals identifıed to carry germlinemutations.We performed targetedmassive-
ly-parallel sequencing to identify mutations and large genomic rearrangements
in 26 known or proposed breast cancer susceptibility genes in 2134 BRCA-
negative women with familial breast cancer (FBC). A case-control analysis was
performed comparing the frequency of internally classifıedmutations identifıed
in FBC cases to that in non-Finnish European controls from the Exome Aggre-
gation Consortium (ExAC) excluding samples from The Cancer Genome Atlas.
Including large genomic rearrangements, mutations were identifıed in 8.2% of
FBC cases compared to 6.2% of ExAC controls, including mutations in high-
penetrance genes (0.6% in cases vs. 0.1% in controls), moderate-penetrance
genes (3.7% vs 1.7%), and seven cases with two mutations (0.3%). The re-
mainder of FBC cases and ExAC controls had mutations in proposed breast
cancer genes (1.6% of cases vs 2.4% of controls), Lynch syndrome genes
(0.5% vs. 0.5%) or were heterozygous MUTYH carriers (1.5% vs. 1.5%).
Case-control analysis demonstrated signifıcant associations with FBC for
ATM, PALB2, and TP53 mutations (OR3.0, p10-4), BARD1 mutations
(OR3.2, p0.012), and CHEK2 truncating mutations (OR1.6, p0.041).
Our results therefore demonstrate that only approximately 4% of BRCA1/2
negative FBC patients have mutations in genes defınitively associated with
breast cancer at this time. Large case-control studies are needed to fully
evaluate the breast cancer risks associated with moderate penetrance and
proposed breast cancer susceptibility genes.
#4266 Double somatic mutations as a cause of tumor mismatch repair-
defıciency in population-based colorectal and endometrial cancer with
Lynch-like syndrome. Daniel D. Buchanan,1 Mark Clendenning,1 Harindra
Jayasekara,2 Jihoon E. Joo,1 Ee M. Wong,1 Melissa C. Southey,1 Rhiannon J.
Walters,3 Bernard J. Pope,4 Aung K. Win,1 John L. Hopper,1 Mark A. Jenkins,1
Roger L. Milne,2 Graham G. Giles,2 Dallas R. English,1 Finlay A. Macrae,5
Amanda B. Spurdle,3 Ingrid M. Winship,5 Christophe Rosty1. 1University of
Melbourne, Parkville, Australia; 2Cancer Council Victoria, St. Kilda, Australia;
3Queensland Institute of Medical Research Berghofer, Herston, Australia; 4Uni-
versity of Melbourne, Carlton, Australia; 5Royal Melbourne Hospital, Parkville,
Australia.
Background: Tumour mismatch repair (MMR) defıciency, determined by
immunohistochemical (IHC) loss of MMR protein expression, is used diagnos-
tically to identify individuals with Lynch syndrome. A high proportion of colo-
rectal cancers (CRCs) and endometrial cancers (ECs) that demonstrate tumor
MMR-defıciency are categorised as having “Lynch-like syndrome” due to the
absence of tumor MLH1 methylation or germline MMR gene mutations after
standard screening approaches. The aim of this study was to investigate somatic
causes of tumor MMR-defıciency in patients with Lynch-like syndrome. Meth-
ods: Population-based participants with incident MMR-defıcient colorectal
(n193; ACCFR and MCCS) or endometrial cancer (n197; ANECS and
MCCS) were categorised as either Lynch syndrome, MLH1 methylated or
Lynch-like after screening for germline MMR gene mutations and for tumor
MLH1 gene promoter hypermethylation. Lynch-like tumors were tested for so-
matic MMR gene mutations (point mutations and loss of heterozygosity) using
AmpliSeq-Ion Proton custom capture sequencing and forMSH2 orMSH6 gene
promoter methylation. Overall survival for molecularly defıned subgroups of
Lynch-like CRCs were compared to Lynch syndrome related CRCs using cox
regression models to estimate hazard ratios (HR) and 95% confıdence intervals
adjusting for age at CRC diagnosis, sex, AJCC stage and grade. Results: Lynch-
like tumors comprised 32% (63/193) and 23% (45/197) of the MMR-defıcient
CRCs and ECs, respectively compared with 27% and 15% for Lynch syndrome
and 41% and 62% for MLH1 methylated CRCs and ECs, respectively. Two so-
matic mutations were identifıed in the MMR gene indicated by the pattern of
MMR IHC loss of expressionwere identifıed in 36.7% (18/49) and 47.8% (11/23)
of the Lynch-like CRCs and ECs tested. The proportion of tumors with double
somatic alterations was highest for both CRC and EC tumors showing MSH2-
defıciency (40% and 64.3%). Themean age at diagnosis for the Lynch-like CRCs
with double somaticmutations was 49.7	 15.8years whichwas not signifıcantly
different from the Lynch syndrome CRCs (n52; 45.4	 11.3years; p0.2) but
was signifıcantly different compared with the MLH1 methylated CRCs (n83;
70	 8.9years; p0.0001). The adjustedHR for double somatic Lynch-likeCRCs
was 2.58 (95% CI, 0.77-8.67) compared with Lynch syndrome CRCs (p0.1).
No evidence of tumor MSH2 or MSH6 gene promoter methylation was identi-
fıed in eitherMSH2-defıcient orMSH6-defıcient Lynch-like CRCs or ECs tested
(n34 and n12, respectively). Conclusions: Double somatic mutations in the
MMR genes represent a signifıcant proportion of the unexplained Lynch-like
MMR-defıcient subtype for both population-based CRC and EC. Triaging strat-
egies used to identify Lynch syndrome for both CRC and EC should include
tumor testing for somatic mutations in the MMR genes.
#4267 Association of polygenic risk scores and family historywith the risk
of chronic lymphocytic leukemia (CLL).Geffen Kleinstern,1 Silvia de Sanjosé,2
Nicola Camp,3 Claire M. Vajdic,4 Timothy G. Call,1 Mark Liebow,1 Dennis
Robinson,1 Neil E. Kay,1 Julie Cunningham,1 Yolanda Benavente,2 Alain Mon-
nereau,5 John Spinelli,6 James R. Cerhan,1 Susan L. Slager1. 1Mayo Clinic, Roch-
ester, MN; 2L’Hospitalet de Llobregat, Barcelona, Spain; 3University of Utah, Salt
Lake City, UT; 4University of NSW, Sydney, Australia; 5Sorbonne Paris Cité Cen-
tre, Paris, France; 6BC Cancer Research Center, Vancouver, British Columbia,
Canada.
Background: Thirty-four single nucleotide polymorphisms (SNPs) are asso-
ciated with CLL risk to-date. Moreover, family history (FH) of hematological
malignancy has been consistently found to be associated with CLL, with an
8.5-fold increased risk of CLL among fırst-degree relatives. However, there has
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not been an evaluation of the interactive effects among genetic factors and FH
with CLL risk.Methods:We pooled data from 8CLL case-control studies within
the InterLymphConsortium (1499CLL cases and 2601 controls).We computed
a polygenic risk score (PRS), a weighted average of the number of risk alleles
across the 34 SNPs, with the weights being the log of the previously reported
odds ratio (OR) for each SNP. We categorized the PRS by quintiles using the
cutoff points based on the distribution of all InterLymph controls (N8228).
Self-reported FHdatawas available for 60%of cases and 73%of controls. FHwas
defıned as any hematological malignancy in one or more fırst-degree relative.
Logistic regressionwas used to estimateORs and 95% confıdence intervals (CIs)
adjusted for age, sex, socioeconomic status and study. Results Themedian age at
diagnosis of CLL was 63 years and median age of consent was 60 years in the
controls. 67% were male in CLL cases and 57% in controls. As expected, FHwas
associated with CLL risk (OR 2.14, CI 1.60-2.86). The median PRS in the
cases was 0.40 and in the controls was -0.36 with the frequency of CLL cases in
the upper PRS quintile as 48%while in the lowest quintile only 6%. The PRS was
strongly associated with CLL risk (OR 2.90, CI 2.35-3.56 for upper versus
middle quintile). When jointly modeling FH with PRS, a signifıcant interaction
was observed (P0.03). When stratifying by FH, the upper quintile of the PRS
had an 11.8-fold (CI 3.97-34.8) increased risk relative to those in the middle
quintile in the FH strata, while a 3.11-fold (CI 2.35-4.10) increased risk was
observed in the FH- strata. Conclusions: Our data suggest that the PRS has a
strong association with CLL risk and this association varies with FH status.
Among those with FH-, the risk of CLLwas 3-fold for those withmany inherited
variants while the CLL risk was much higher than that in those with a FH.
Studies are needed to see whether this PRS stratifıes risk among those with
monoclonal B-cell lymphocytosis, theCLLprecursor condition that affects 5-7%
of the general population.
#4268 Familial lung cancer is signifıcantly linked to cancer-associated
genes on fıve chromosomes. Joan E. Bailey-Wilson,1 Anthony M. Musolf,1
Claire L. Simpson,2 Mariza de Andrade,3 Diptasri Mandal,4 Colette G. Gaba,5
Ping Yang,3 Ming You,6 Elena Y. Kupert,6 Marshall W. Anderson,6 Ann G.
Schwartz,7 Susan M. Pinney,8 Christopher I. Amos9. 1NIH-NHGRI, Baltimore,
MD; 2University of Tennessee Health Sciences Center, Memphis, TN; 3Mayo
Clinic, Rochester, MN; 4Louisiana State University Health Sciences Center, New
Orleans, LA; 5University of Toledo Dana Cancer Center, Toledo, OH; 6Medical
College of Wisconsin, Milwaukee, WI; 7Karmanos Cancer Center, Detroit, MI;
8University of Cincinnati, Cincinnati, OH; 9Geisel School of Medicine at Dart-
mouth, Lebanon, NH.
Lung cancer (LC) is the leading cancer killer of Americans; an estimated
158,000 people will die in the U.S. from LC in 2016. While it is well-known that
LC risk is affected by the environment, particularly tobacco smoking, there is a
substantial genetic risk to LC also. We examined genotype data from Illumina
HumanCore-12v1-0 array (297,000 SNPs) on 175 individuals in 25 extended
families with a strong history of LC recruited by the Genetic Epidemiology of
Lung Cancer Consortium. The purpose of this study is to determine which
families are segregating a high-penetrance genetic risk haplotype so that the
most informative families can be selected for DNA sequencing studies. Quality
control was performed to remove SNPs and individuals with greater than 1%
missingness as well as monomorphic SNPs. SNPs with Mendelian errors in
more than one family were dropped. Identity-by-descent values were calculated
to confırm correct familial relationships; 1 individual was dropped. After quality
control we were left with approximately 245,000 SNPs for analysis. We per-
formed three types of parametric linkage analyses using an autosomal dominant
model with 40% penetrance in carriers and 1% penetrance in non-carriers. A
disease allele frequency of 0.01 was used. Standard single variant two-point
analysis between the disease and each marker was performed using TwoPoint-
Lods. Multipoint linkage analysis was performed using SimWalk2.We also per-
formed regional-based linkage analyses using SEQLinkage and MERLIN. SE-
QLinkage builds a multiallelic regional marker (similar to a microsatellite) that
corresponds to a gene or a portion of a gene. Two-point linkage analyses were
then performed on the regional markers using MERLIN. We identifıed fıve loci
that were genome-wide signifıcant (HLOD score 3.3) from the regional-based
linkage analyses on 18p11.23 (HLOD 4.1), 2p22.2 (3.9), 14q13.1 (3.7), 16p13.1
(3.4), and 20q13.11 (3.4). It is particularly exciting that the scores centered on
prospective cancer genes. Our highest score was centered on PTPRM, a protein
tyrosine phosphatase on chromosome 18 that has been implicated as a LC on-
cogene. The signal on 20q13 also centered on another protein tyrosine phospha-
tase (PTPRT) that has been shown to be mutated in LC cells. The source of the
signal on 16p13was RNAbinding protein RBFOX1, which has been shown to be
deleted in LC cell lines and the source of the signal on 2p22 was LRP1B, a LDL
receptor-related protein that is often inactivated in LC cells. The source of the
fınal signal on 14q13 was NPAS3, a transcription factor that is a tumor suppres-
sor in brain tumors. It should be noted that all previous evidence linking these
genes to cancer was based on somaticmutations; this is the fırst time any of these
genes has been shown to be signifıcantly linked to germline disease risk in a
family-based study. We plan to perform targeted sequencing on the linked re-
gions to elucidate the exact causal variant.
#4269 Risk of different cancers among fırst-degree relatives of pancreatic
cancer patients and impact of probands’ germlinemutationon sibling cancer
risk. Samuel O. Antwi,1 Sarah E. Fagan,2 Kari G. Chaffee,3 William R. Bamlet,3
McWilliams R. Robert,4 Ann L. Oberg,3 Gloria M. Petersen1. 1Epidemiology,
Mayo Clinic, Rochester, MN; 2Epidemiology, Tulane University, New Orleans,
LA; 3Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN; 4Medi-
cal Oncology, Mayo Clinic, Rochester, MN.
Background: There have been varying reports on risk of different cancers, other
than pancreatic cancer (PC), among fırst-degree relatives (FDRs) of PC patients.
Because the pattern and scope of aggregation of PC with other malignancies in
families of PC patients are not entirely clear, we investigated risk of 15 common
malignancies among FDRs of unselected PC probands. Methods: The study in-
cluded 17,181 FDRs with more than 336,000 person-years at risk. The FDRs were
identifıed through sequentially enrolledPCprobands (n2,305) in theMayoClinic
prospective pancreatic cancer patient registry from 2000-2016. Data on family his-
toryof cancerwereprovidedby theprobands at the timeof enrollment in structured
risk factor questionnaires. Standardized incidence ratios (SIRs) and95%confıdence
intervals (CIs) were calculated by comparing cases of each cancer type observed
among the FDRs with those expected using data from the Surveillance Epidemiol-
ogy and End Results Program (SEER). Stratifıed analyses were performed among
siblings of the probands based on whether the related proband tested positive for a
mutation in ATM, BARD1, BRCA1, BRCA2, CDKN2A, CHEK2, MUTYH, NBN,
PALB2, or PMS2; or tested negative for mutation in a total of 25 sequenced cancer
susceptibility genes.Results:Compared to theSEERreferencepopulation, riskofPC
was two-fold higher than expected among the FDRs (SIR2.04, 95%CI: 1.78-2.31)
and 12-fold higher than expected among FDRs with history of PC in at least two
bloodrelatives (SIR11.99,95%CI:10.48-13.64).Siblingsofmutation-positivepro-
bands had higher risk of PC (SIR13.57, 95% CI: 6.19-25.76) than siblings of mu-
tation-negative probands (SIR8.91, 95% CI6.73-11.57). For other cancer types,
primary liver cancer was elevated among female FDRs (SIR2.10, 95% CI: 1.34-
3.12), whereas breast (SIR3.16, 95% CI: 1.63-5.52) and ovarian (SIR6.61, 95%
CI: 1.33-19.31) cancers were elevated only among siblings of the mutation-positive
probands. There also were suggestions of lower than expected risk of other malig-
nancies, such as bladder, colorectal and prostate cancers, among the FDRs as com-
pared with the SEER population. Conclusions: These fındings confırm familial ag-
gregation of PC with breast and ovarian cancers, and further suggest a potential
aggregation of PC and primary liver cancer among female FDRs of PC probands.
The elevated risks of breast cancer and ovarian cancer among siblings of the muta-
tion-positive probands suggests a strong influence of genetic susceptibility shared
with the related proband, possibly due to an inheritedmutation inBRCA1, BRCA2,
orPALB2.These fındings lend support to genetic counseling and targeted screening
of certain cancers in high-risk families.
#4270 Family history in fırst degree relatives and risk of gastric cancer in
the alpha-tocopherol, beta-carotene cancer prevention study. Minkyo Song,
Maria ConstanzaCamargo, Stephanie J.Weinstein, Demetrius Albanes, Charles
S. Rabkin. National Cancer Institute, Bethesda, MD.
Background: Studies of the familial associations of gastric cancer risk have largely
been limited to case-control approaches which are susceptible to recall bias and
cannotdistinguish temporality. Furthermore, associationswith familyhistory could
be explained by shared exposure to Helicobacter pylori infection, the most impor-
tant environmental risk factor for gastric cancer. Notably, the risks of early onset
disease and diffuse-type tumors are thought to have a greater genetic component.
We therefore examined in a prospective study the associations of gastric cancer risk
with history of gastric cancer in fırst degree relatives, controlling forH. pylori infec-
tion.Methods:We selected405 incident gastric cancer cases and4,129 controlswith
known H. pylori serology status from the Finnish Alpha-Tocopherol, Beta-Caro-
teneCancer Prevention (ATBC) Study amongmale smokers aged 50-69 at baseline.
Odds ratios (ORs) and 95% confıdence intervals (95% CIs) were calculated using
logistic regression with adjustment for H. pylori and other potential confounders.
All statistical tests were two-sided. Results: Family history of gastric cancer was
associated with increased risk (OR1.84, 95% CI1.32-2.58). The association ap-
peared stronger with gastric cancer in siblings (OR2.87, 95%CI1.64-5.03) than
with gastric cancer in parents (OR1.53, 95%CI1.05-2.24). Distinguishing cases
by anatomic subsite, the family history association was signifıcant for noncardia
gastric cancer (n305; OR2.15, 95% CI1.50-3.07), but not for cardia cancer
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(n100;OR1.25, 95%CI0.63-2.49).With regard to histological subtype, family
history was signifıcantly associated with both diffuse-type (n90; OR2.12, 95%
CI1.10-4.12) and intestinal-type (n153; OR1.70, 95% CI1.02-2.83) gastric
cancer. In age-specifıc analyses, the association with family history was strongest in
the youngest age-group at baseline 50-54 years (OR3.42, 95%CI1.85-6.30) and
absent in the oldest age group 65-69 years (OR0.85, 95%CI0.28-2.58). Conclu-
sion: The results suggest that certain subtypes of sporadic gastric cancer are strongly
associatedwith family history of gastric cancer. These associations do not appear to
be explained by the associations with H. pylori infection.
#4271 Population-wide vs. carrier-probability-based BRCA1/2 mutation
testing in theWashington Ashkenazi Study.Ana F. Best, Margaret A. Tucker,
Hormuzd A. Katki. National Cancer Institute, Division of Cancer Epidemiology
and Genetics, Bethesda, MD.
Background: Currently, women are referred for BRCA1/2 mutation testing if
their family history of breast and ovarian cancer indicates they have suffıcient
probability of carrying mutations. In contrast, calls have intensifıed for popula-
tion-wide testing for BRCA1/2 founder mutations among Ashkenazi Jews, due
to relatively high mutation prevalence (2.5%) and decreasing genotyping costs.
However, population-wide testing would strain genetic counseling resources
and incur costs from testing mostly mutation-negative women. We compared
the performance of population-wide vs. carrier-probability-based BRCA1/2
testing in the community-based Washington Ashkenazi Study (WAS). Meth-
ods: BRCA1/2 carrier-probabilities based on reported family histories were cal-
culated using BRCAPRO for 4589 probands (102 BRCA1/2 mutation-carriers)
in WAS. For each carrier-probability threshold, we compared the percent of
mutations found (sensitivity) vs. the percent of women requiringmutation test-
ing, overall and by proband age. At example carrier-probability thresholds, un-
detected and detected carriers’ attributes were compared using nonparametric
tests. Results: A 1.2% carrier-probability threshold identifıed 80% of BRCA1/2
mutations in the 35% of women with highest carrier-probability. For women
under age 40, 94% of BRCA1/2 mutations were identifıed in the 50% of women
with highest carrier-probability. Compared to identifıed mutation-carriers,
missed mutation-carriers had no personal cancer history, no affected fırst- and
second-degree relatives (p0.0001), more unaffected fırst-degree relatives
(p0.0002), and were older (p0.012; median age53). Conclusion: Carrier-
probability-based BRCA1/2 mutation testing identifıed large majorities of mu-
tation-carriers and would have avoided testing for many mutation-negative
women. Missed mutation-carriers were older and cancer-free and would gain
minimal benefıt from risk-reducing interventions. A cost-effective carrier-prob-
ability threshold could acceptably tradeoff identifying BRCA1/2 mutation car-
riers before they get cancer while testing as few women as possible.
#4272 Mutations inRABL3 alter RAS prenylation and are associated with
hereditary pancreatic cancer. Sahar Nissim,1 Ignaty Leshchiner,2 Joseph D.
Mancias,3 Matthew B. Greenblatt,4 Ophélia Maertens,1 Christopher A. Cassa,1
Jill A. Rosenfeld,5 Andrew G. Cox,1 John Hedgepeth,1 Julia Wücherpfennig,1
Andrew J. Kim,1 Jake E. Henderson,1 Patrick Gonyo,6 Anthony Brandt,6 Ellen
Lorimer,6 Bethany Unger,6 Jeremy W. Prokop,7 Jeremy W. Heidel,8 Xiao-Xu
Wang,3 Chinedu I. Ukaegbu,3 Gad Getz,2 Shamil R. Sunyaev,1 J. Wade Harper,9
Karen Cichowski,1 Alec C. Kimmelman,3 Yariv Houvras,4 Sapna Syngal,1 Carol
Williams,6 Wolfram Goessling1. 1Brigham and Women’s Hospital, Boston, MA;
2Broad Institute of MIT and Harvard, Cambridge, MA; 3Dana-Farber Cancer
Institute, Boston, MA; 4Weill Cornell Medical College, New York City, NY;
5Brigham andWomen’s Hospital, Brookline, MA; 6Medical College ofWisconsin,
Milwaukee, WI; 7HudsonAlpha Institute for Biotechnology, Huntsville, AL; 8Or-
egon State University, OR; 9Harvard Medical School, Boston, MA.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid cancers
with limited treatment options despite intensive research efforts. Familial predispo-
sition to PDAC is thought to occur in10% of cases, but causative genes have not
been identifıed in most of these families. Uncovering the genetic basis for PDAC
susceptibility has immediate prognostic implications for families and can provide
precious mechanistic clues to PDAC pathogenesis. Here, we perform whole-ge-
nome sequence analysis in a family with high incidence of PDAC and identify a
germline nonsense mutation in the member of RAS oncogene family-like 3
(RABL3) gene that has never before been directly associatedwith hereditary cancer.
The truncated mutant allele (RABL3_p.Ser36*) co-segregates with cancer occur-
rence.To evaluate the contributionof theRABL3mutant allele inhereditary cancer,
we generated rabl3 heterozygousmutant zebrafısh and found increased susceptibil-
ity to cancer formation in two independent cancer models. Complementary unbi-
ased approaches implicate RABL3 in RAS pathway regulation. RNA-Seq and ge-
nome-set enrichment analysis of juvenile rabl3 mutants reveals a KRAS
upregulation signature. Furthermore, affınity-purifıcation mass-spectrometry for
proteins associated with RABL3 or RABL3_p.Ser36* identifıes Rap1 GTPase-GDP
Dissociation Stimulator 1 (RAP1GDS1, SmgGDS), a chaperone that regulates pre-
nylation of RAS GTPases. Indeed, in vitro studies demonstrate that
RABL3_p.Ser36* accelerates KRAS prenylation, and this impact is lost in the ab-
senceofH/N/KRASproteins.Whereas heterozygous rabl3mutant zebrafısh exhibit
cancer predisposition, homozygous rabl3 mutant zebrafısh develop severe cranio-
facial, skeletal, and growth defects consistent with human RASopathies, and these
defects are partially rescued with the MEK inhibitor trametinib. Our fındings sup-
port a gain-of-function rather than a null function typically associated with prema-
ture protein truncations. The discovered causative RABL3 germline mutation pro-
vides new diagnostic opportunities for genetic testing in other cancer families and
uncovers an alternativemechanism for dysregulatedRAS signaling in development
and cancer.
#4273 Variant reclassifıcations in hereditary cancer genetics and their
implications for clinical care. Thomas P. Slavin,1 Stacy W. Gray,1 Lily R. Van
Tongeren,1 Ilana Solomon,1 Christina Rybak,1 Bita Nehoray,1 Lili Kuzmich,1
Mariana Niell-Swiller,1 Kathleen R. Blazer,1 Kai Yang,1 Julie Culver,2 Sharon
Sand,1 Danielle Castillo,1 Josef Herzog,1 Jeffrey N. Weitzel1. 1City of Hope, Du-
arte, CA; 2University of Southern California Norris Comprehensive Cancer Cen-
ter, Los Angeles, CA.
BACKGROUND: Clinicians who provide genetic cancer risk assessment
(GCRA) are dependent on laboratory reporting of germline results to inform
cancer screening and treatment recommendations. Efforts to enhance variant
classifıcation and harmonization, such as ClinVar, will lead to an increase in the
number of variants being reclassifıed. Given that the impact of variant reclassi-
fıcation on care is unknown, we evaluated the frequency and clinical impact of
variant reclassifıcation on individuals seen for GCRA. METHODS: We retro-
spectively evaluated data on 7,356 participants enrolled through the Clinical
Cancer Genomics Community Research Network (CCGCRN) at City of Hope
andOliveViewMedical Center fromSeptember 1996-October 2016. RESULTS:
4,969 commercial genetic tests yielded a total of 1,610 variants of any category, of
which 181 unique variants in 20 genes were reclassifıed. BRCA1 and BRCA2
(BRCA) and mismatch repair genes comprised 73.5% and 5.5% of the genes
reclassifıed, respectively. Reclassifıcation impacted 225 individuals (97%
women) from 217 families; 89% of these individuals (n201) had a personal
history of cancer. The interval between initial report and variant reclassifıcation
averaged 3 years (17 days- 13 years). Minorities had higher reclassifıcation rates
as compared to non-Hispanic white participants (P  0.0149). Of the 181
unique reclassifıcations, 164 (90.6%) of variants were downgraded. Sixteen re-
classifıcations led to changes in clinical care. Thirteen variants carried by 15
individuals were upgraded from a variant of uncertain signifıcance (VUS) to
likely pathogenic or pathogenic (10 BRCA, 3 MLH1 or MSH2). These reclassi-
fıcations prompted additional prophylactic surgical interventions (i.e., bilateral
salpingo-oophorectomy), specialist referrals, and surveillance recommenda-
tions for at risk patients and family members. Three variants (NBN
p.Arg215Trp, PTEN p.Ala79Thr, and MET c.12002TC) were downgraded
from likely pathogenic or pathogenic to VUS. Prior to downgrade to VUS, 2
cases had unnecessary surveillance procedures. CONCLUSIONS: Since many
genomic variants will be reclassifıed over time, it is critical that laboratories
deliver prompt notifıcation of reclassifıcations, and that providers involved in
GCRA discuss the possibility of variant reclassifıcation with patients and family
members and collect patient/proxy information during informed consent so
that re-contact is possible. Given the non-trivial effort required for variant re-
classifıcation and patient/participant re-contact, system-level interventions are
needed to facilitate genomic reinterpretation and the return of results to indi-
viduals over time.
#4274 The contributionof deleterious germ-linemutations of susceptibil-
ity genes to ovarian, fallopian tube, and peritoneal cancers in Japanese.Akira
Hirasawa,1 Issei Imoto,2 Takuya Naruto,2 Tomoko Akahane,1 Wataru
Yamagami,1 Nobuyuki Susumu,1 Hitoshi Tsuda,3 Daisuke Aoki1. 1Keio Univ.
School of Medicine, Tokyo, Japan; 2Graduate School of Biomedical Sciences,
Tokushima University, Tokushima, Japan; 3National Defense Medical College,
Saitama, Japan.
Different ethnic groups present specifıc morphological features in ovarian
cancer (OC). High-grade serous OC is more frequently found in Caucasian
women, in contrast clear cell OC ismore frequently found in East Asianwomen.
Although inheritedmutations of BRCA1 or BRCA2 (BRCA1/2) and other genes
are known to predispose to OC, the contributions of these inherited mutations
on disease burden is not well characterized in Japanese OC patients. Using a
comprehensive genetic testing panel, the aim of our study was to identify the
prevalence of pathogenic germ-line mutations of candidate genes associated
EPIDEMIOLOGY: Familial and Hereditary Cancers
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1093
with genetic predisposition to OC in Japanese patients with ovarian, fallopian
tube, or peritoneal cancer.Samples from 236 individuals with unselected ovar-
ian, fallopian tube, or peritoneal cancer, which were obtained from the Keio
Women’s Health Biobank (KWB) from the School of Medicine at Keio Univer-
sity (Tokyo, Japan), were used for this study. Germ-line DNA was enriched
using the SureSelect XT Target Enrichment System (Agilent Technologies) de-
signed for 75 or 79 genes as a custom OC panel, followed by sequencing using
MiSeq (Illumina). Detected variants, including point mutations, small indels,
and a gross deletion, were classifıed according to the American College of Med-
ical Genetics and Genomics (ACMG) recommendations. Furthermore,
BRCA1/2 variants were interpreted using resources fromMyriad Genetic Labo-
ratories.Forty-two (17.8%) OC patients had germ-line mutations of cancer pre-
disposition genes. BRCA1/2 pathological germ-line mutations were found in 27
cases (11.4%) while six cases (2.5%) had a mutation in a mismatch repair gene
(MLH1,MSH2,MSH6, or PMS2). Furthermore, ten cases (4.2%) had germ-line
mutations in the RAD51D, ATM, MRE11A, FANCC, or GABRA2 genes. Of
patients with a BRCA1/2 mutation (n27), we found that the most common
histological subtypewas high-grade serousOC, butwe also found two cases with
clear cell carcinoma. Of 42 cases with an inherited mutation, we found that 25%
(6/24) had no family history of cancer, and 78% (31/41) were under 60 years old
at diagnosis.We found that approximately 18% of unselected Japanese patients
with ovarian, fallopian tube, or peritoneal cancer were associated with inherited
mutations of cancer-predisposing genes. Our study demonstrates that compre-
hensive genetic testing is informative for all womenwith ovarian, fallopian tube,
and peritoneal cancers to establish personalized clinical management and ge-
netic counseling, irrespective of the patient’s histological subtypes, ages or fam-
ily histories.
#4275 Pathogenic germline variants in Mexican patients with hereditary
breast andovarian cancer syndrome.FelipeVaca-Paniagua,1 RosalíaQuezada-
Urban,1 Clara Díaz-Velásquez,2 Rina Gitler,3 Gabriela Torres-Mejia,4Maria Pa-
tricia Rojo-Castillo,3 Max Sirota-Toporek,3 Andrea Figueroa-Morales,3 Oscar
Moreno-Garci´a,3 Ivan Delgado-Enciso,5 Victor Hugo Garzo´n-Barrientos,6
Nayeli Lizbeth García-Esquivel,3 Ernesto Arturo Rojas-Jiménez,2 Héctor Gre-
gorio-Martínez,2 Luis Ignacio Terrazas2. 1Facultad de Estudios Superiores Izta-
cala-INCAN,México,Mexico; 2Facultad de Estudios Superiores Iztacala,México,
Mexico; 3FundacionAlma,México,Mexico; 4InstitutoNacional de Salud Pública,
México, Mexico; 5Instituto Estatal de Cancerología de Colima, México, Mexico;
6Hospital General deChilpancingo ‘RaymundoAbarcaAlarcón‘,México,Mexico.
Hereditary breast and ovarian cancer syndrome (HBOC) is an autosomal
dominant disease that represents approximately 5-10%of all patientswith breast
cancer. This syndrome is mainly associated to high risk pathogenic alleles in
BRCA1/2 genes, but only for 25% ofHBOC cases.More than 25 genes have been
associated with familial breast and/or ovarian cancer and still more are expected
to emerge. In the Mexican population there have been some efforts to analyze
this syndrome, but they are limited to BRCA genes. This work aims to fınd new
pathogenic alleles in exonic and splice sites in a panel of 143 cancer-predisposing
genes in 309 Mexican cancer patients with suspicion of HBOC and 27 non-
cancer patients with a severe family history of cancer, using massive parallel
sequencing technology. In the group of cancer patients 14.6% (45/309) had
pathogenic variants, 23.9% (74/309) harbored variants with unknown clinical
signifıcance (VUS) and 61.5% (109/309) were negative. The genes most fre-
quently affected with pathogenic variants were BRCA2 24.4% (11/45), BRCA1
8.9% (4/45), MSR1 4.4% (2/45), ATM 4.4% (2/45), PDE11A 4.4% (2/45) and
FANCI 4.4% (2/45). The non-cancer group had a 18.5% (5/27) of patients with
pathogenic variants and 81.5% (22/27) were negative. In this group pathogenic
variants were found in BRCA2, FANCF, PDE11A, POLH andWRN. Private or
ultra-rare variants defıned asVUS (ClinVar, deleterious in SIFT/Polyphen2, less
than 0.001% in ExAC/1KG/ESP6500) were found in 53 genes. This study dem-
onstrates that there is a higher contribution of pathogenic alleles in other sus-
ceptibility cancer genes (66.7%) than BRCA1/2 (33.3%), confırming that clinical
sequencing of expanded gene panels will identify new, rare and private, variants
and eventually will translate in better molecular diagnosis and personalized risk
assessment in carriers. Clinical impact of the VUS identifıed here must be fur-
ther evaluated. This work was supported by the National Autonomous Univer-
sity of Mexico, PAPIIT (IA204215).
#4276 Oral contraceptive use and breast cancer risk: a cohort study of
BRCA1 and BRCA2 mutation carriers. Lieske H. Schrijver,1 Hakan Olsson,2
Antonis Antoniou,3 Roger Milne,4 Kelly Phillips,5 Nadine Andrieu,6 Douglas
Easton,3 David Goldgar,7 Christoph Engel,8 Karin Kast,9 Marie-Jose Blom,1
Thea Mooij,1 John Hopper,10 Floor Van Leeuwen,1 Mary-Beth Terry,11 Matti
Rookus,1 IBCCS, kConFab, BCFR. 1Netherlands Cancer Institute, Amsterdam,
Netherlands; 2Lund University, Lund, Sweden; 3University of Cambridge, Cam-
bridge, United Kingdom; 4University of Melbourne, Cancer Council Victoria,
Melbourne, Australia; 5University of Melbourne, Peter MacCallum Cancer Cen-
tre, Melbourne, Australia; 6Institute Curie, PSL Research University, INSERM,
Paris, France; 7University of Utah, Salt Lake City, UT; 8University of Leipzig,
Leipzig, Germany; 9Department of Gynecology and Obstetrics, University Hospi-
tal Carl Gustav Carus, Dresden, Germany; 10University of Melbourne, Mel-
bourne, Australia; 11Columbia Universtiy, New York, NY.
Background: BRCA1 and BRCA2 mutation carriers are at high risk of breast
and ovarian cancer. Oral contraceptive preparations (OCPs) may reduce ovar-
ian cancer risk, but its effect on breast cancer risk remains unclear. Methods:
Combined data from three cohorts of 5705 BRCA1 and 3521 BRCA2 mutation
carriers (IBCCS, BCFR and kConFab) were analyzed using age-dependent Cox
regression models stratifıed for study and birth cohort. We conducted the fırst
prospective analyses on this topic. Our additional main retrospective analyses
were left-censored 5 years preceding date of baseline questionnaire to control for
survival bias. The full-cohort retrospective analyses, without left-censoring, was
performed to compare results with the literature. Prospective analyses were con-
sideredmost valid, while retrospective analysesweremost powerful. Results: For
BRCA1 mutation carriers we found no association between ever OCP use and
risk of breast cancer in the prospective analyses (HR1.08, 95% CI 0.75-1.56),
but 23% and 27% increased risks for ever OCP use in the left-censored and full
retrospective analyses, respectively. Retrospectively, an increasing trend for lon-
ger duration of use, especially before fırst full-termpregnancy (FFTP)was found
(left-censored analyses: &lt5 years HR 1.05 (95%CI 0.84-1.33), 5-9.9 years HR
1.15 (95%CI 0.92-1.44), &gt10 years HR 1.41 (95%CI 1.10-1.813),
p-trend0.001 for duration of use before FFTP). For BRCA2 mutation carriers
we found a positive association between ever OCP use and risk of breast cancer
prospectively (HR1.75, 95% CI 1.03-2.97), but retrospectively fındings were
inconsistent (HR1.06, 95% CI 0.85-1.33 and HR1.52, 95% CI 1.28-1.81 for
the left-censored and full analyses, respectively). Conclusion: For BRCA1 mu-
tation carriers the discrepancy between results of prospective and retrospective
analyses may be explained by time since last OCP use before FFTP. Thus, a
temporal increased risk of breast cancer following longer duration of OCP use
before FFTP cannot be ruled out. The discordant fındings between prospective
and retrospective analyses for BRCA2 carriers could not be explained. Because
of the lack of scientifıc clarity it is too early to give an unequivocal advice onOCP
use with respect to breast cancer risk to BRCA1 and BRCA2 mutation carriers.
#4277 Clinicopathological signifıcance of endometrial cancer withMSH2
defıciency. Junko Haraga, Takeshi Nagasaka, Keiichirou Nakamura, Tomoko
Haruma, Takeshi Nishida, Akihiro Nyuya, Kazuya Yasui, Hisashi Masuyama,
Toshiyoshi Fujiwara, Yuji Hiramatsu. Okayama University Graduate School of
Medicine Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Ja-
pan.
Background: Endometrial cancer accounts for the second percentage of
Lynch syndrome related tumors following colorectal cancer. Inactivation of
MSH2 was frequently observed in endometrial cancer with microsatellite insta-
bility (MSI) or mismatch repair complex defıciency (dMMR). With respect to
MSH2 defıciency (dMSH2), not like MLH1 defıciency, most of dMSH2 were
caused by germlinemutations in theMSH2 gene or germline EpCAMdeletions.
Meanwhile, heritable germline epimutations in MSH2 have been reported in a
few Lynch syndrome families that lacked germlinemutations in theMSH2 gene.
We previously provided evidence for frequent MSH2 hypermethylation in
Lynch syndrome colorectal tumors with dMSH2 and MSH2 methylation may
serve as the “second hit” at the wild-type allele. Materials and Methods: In this
study, we analyzed MSH2 promoter methylation status, as well as MLH1meth-
ylation status, and expression status of the mismatch repair proteins (MLH1,
MSH2, PMS2, and MSH6) by immunohistochemistry in a cohort of 138 endo-
metrial cancer tissues surgically resected at OkayamaUniversity Hospital. DNA
was extracted from formalin-fıxed, paraffın-embedded tissue, analyzedMSI sta-
tus by four mononucleotide markers and both MLH1 and MSH2 promoter
methylation status by a fluorescent quantitative bisulfıte PCR assay. Results:
Endometrial cancers displaying MSI or dMMR were observed in 40 (29.0%) or
41 cases (29.7%), respectively. Endometrial cancers with MSH2 defıciency were
observed in eight (5.8%) of 138 tumors (19.5% of dMMR). MSH2 promoter
methylation was present in 7 cases (5.1% in 138 tumors), and signifıcantly cor-
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related with dMSH2 (P0.0041, Fisher’s exact probability test). Then, we also
examined the family history of fırst-degree relatives retrospectively. In this co-
hort, although patients with MMR defıciency were signifıcantly associated with
family history of Lynch syndrome related tumor (P0.001), patients with this
family history of Lynch syndrome related tumor aremore frequently observed in
patients with dMSH2 (P0.0347). Interestingly, patients with MSH2 promoter
methylation were strongly associated with this family history of Lynch syn-
drome related tumor (P0.002), though patients with MLH1methylation were
not (P0.0878). Conclusions: In this study, we demonstrated thatMSH2meth-
ylation signifıcantly correlated with dMSH2 and may have strong relation with
family history of Lynch syndrome related tumor, taking a role as “second hit” to
the MSH2 gene.
#4278 Screening for BRCA1 foundermutation inMexican population: an
accessible approach. Rosa M. Alvarez,1 Jose Velazquez,2 Veronica Fragoso,1
Julieta Dominguez,1 Paulina Nuñez,1 Talia Wegman,1 Yuliana Sanchez,1 Silvia
Vidal,1 Enrique Bargallo,1 Dolores Gallardo,1 Abelardo Meneses,1 Luis A. Her-
rera1. 1National Cancer Institute, Mexico, Mexico City, Mexico; 2National Insti-
tute of Pediatrics, Mexico City, Mexico.
Aim: To implement an accessible strategy for detection of the Mexican
foundermutationNG_005905.2:g.118973_133629del, located in BRCA1, which
deletes exons 9-12 (BRCA1 ex9-12del), as part of the health care setting of pa-
tients with hereditary breast and ovarian cancer (HBOC), from the National
Cancer Institute (Mexico). Material and methods: We designed a polymerase
chain reaction (PCR) basedmethod, for the targeted detection of the deletion of
exons 9 through 12, of the BRCA1 gene. The method was validated with previ-
ously verifıed results of the deletion by multiplex ligation-dependent probe am-
plifıcation assay (MLPA), or deep sequencing of the region. Finally, the tech-
niquewas used for the detection of BRCA1 ex9-12delmutation in a group of 302
HBOC patients, in whom the existence of BRCA1 and BRCA2 point mutations
had been ruled by pyrosequencing. Results: The concordance of our method,
with previously reportedBRCA1 ex9-12delmutation results, was 100%.Also,we
provided a profıle of the clinical and familial characteristics of 302 Mexican
patients with clinical suspicion of HBOC, in whom the detection of BRCA1
ex9-12del mutation was performed. In this way, 21 patients (6.95%) were iden-
tifıed as BRCA1 ex9-12del mutation carriers. Among whom, a higher propor-
tion of triple negative breast cancer was found (73% versus 21%, p0.0005; two
sided Fisher’s exact test) . Conclusions: A feasible molecular diagnostic strategy
for the detection of BRCA1 ex9-12del mutation was established in Mexican
patients, with HBOC. In this way, we identifıed 21 (21/302) carriers of the dele-
tion, who represented the 6.95%. Related to the clinical features, triple negative
breast cancer carriers stood out. It had been reported that large genomic rear-
rangements in BRCA1 are associated with an increased frequency of high risk
features. These type of approach is appropriate in populations where a founder
effect is recognized. For its simplicity and effectiveness, it can be transferred to
other laboratories, for the benefıt of a greater number of Mexican patients and
with the aim of minimize costs of testing. Because of the frequency of BRCA1
ex9-12del mutation, this method has been implemented as the fırst line of
BRCA1 clinical genetic analysis in patients with suspected HBOC, at National
Cancer Institute (Mexico).
#4279 Germline BRCAmutations in Asian patients with locally advanced
unresectable ormetastatic pancreatic adenocarcinoma (PDAC): Risk catego-
ries for genetic testing inAsian population.Kyoungmin Lee, ChanghoonYoo,
Kyu-pyo Kim, Heung-Moon Chang, Hyerim Kwak, Tae Wom Kim, Jae Lyun
Lee, Baek-Yeol Ryoo. Asan Medical Center, Seoul, Republic of Korea.
Background: Familial PDAC constitutes of 5-10% of all PDAC, and germline
mutations in BRCA1 and BRCA2 are associated with increased risk of PDAC.
Although previous studies showed the prevalence of BRCA1 and BRCA2 germ-
line mutations in patients with PDAC ranged between 3% and 21%, these data
have been mostly based on theWestern patient population. Considering ethnic
differences in the prevalence of the mutations in these genes, we performed
prospective evaluation to analyze the prevalence of BRCA1 and BRCA2 muta-
tions in PDACpatients withAsian ethnicity.Methods: BetweenNovember 2015
and May 2016, all consecutive PDAC patients with locally advanced unresect-
able ormetastatic disease who were referred for systemic chemotherapy in Asan
Medical Center, Seoul, Korea were included. Mutation analysis for germline
BRCA1 and BRCA2 were performed for patient with one or more fırst- or sec-
ond-degree relatives with breast or ovarian cancers, or past medical history of
these diseases. Germline DNA was extracted from 10 cc of whole blood and
analyzed for 23 coding exons of BRCA1 and 26 coding exons of BRCA2 using
Sanger sequencing. Results: A total of 175 potential participants with locally
advanced unresectable or metastatic PDAC were identifıed during the study
period. Among them, 10 (5.7%) patients met the criteria for further analysis of
germline BRCA1 and BRCA2 mutations. Six (60%) patients had family history
of breast or ovarian cancers and four (40%) patients had previous medical his-
tory of breast cancer. The median age was 60 years (range 49-72) and 5 patients
(50%) were male. Pathogenic germline BRCA2mutation (7480CT) was iden-
tifıed in one male patient (10%) with family history of breast cancer. Two pa-
tients had germline BRCA2 mutations (68-7TA and 1744AC), which were
regarded as the variants of uncertain signifıcance (VUS). Conclusion: Germline
BRCA mutations, potentially clinically meaningful, were identifıed in 1.7% (3/
175) of overall patients with locally advanced or metastatic PDAC and 30%
(3/10) of patients with past or family history of breast or ovarian cancers. Our
results indicate that the prevalence of BRCA mutation in Asian PDAC popula-
tion is lower thanWestern patients. Risk category used in this study (past med-
ical history or one or more fırst- or second-degree relatives with breast or ovar-
ian cancers) may be the feasible criteria for germline BRCAmutation analysis in
PDAC patients with Asian ethnicity.
#4280 FH (rs367543046, chr1:241661227 A/ATTT) heterozygous carrier
status does not confer risk to hereditary leiomyomatosis and renal cell cancer
(HLRCC) and prostate cancer.Michael F. Walsh,1 Diana Mandelker,1 Joseph
Vijai,1 David Musheyev,1 Jennifer Kennedy,1 Zsofıa Stadler,1 Yelena Kemel,1
Sabine Topka,2 Karen Cadoo,1 Maria Carlo,1 Marc Ladanyi,1 Mark Robson,1
Kenneth Offıt,1 Liying Zhang1. 1Memorial Sloan-Kettering Cancer Center, New
York, NY; 2Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center,
New York, NY.
Fumarate Hydratase (FH) mutations underpin the autosomal recessive syn-
drome FumarateHydratase defıciency and the autosomal dominant syndromeHe-
reditary Leiomyomatous and Renal Cell Carcinoma (HLRCC). The variant
rs367543046, a duplication leading to p. Lys477_Asn478insLys in FH has strong
evidence for risk towards fumarate hydratase defıciency when occurring in trans to
another germline alteration in the FHgene. In addition, this variant in the heterozy-
gous state has been reported in ClinVar to predispose to the autosomal dominant
condition HLRCC, given other heterozygous mutations have shown to be patho-
genic. Population level data is sparse to determine the variant’s impact in the
heterozygous state.Here, we show in a series of 1375 cancer cases the (rs367543046,
chr1: 241661227 A/ATTT), variant detected in 7 (0.5%) individuals with cancer.
One patient with bladder cancer had a history of uterine leiomyomas, but the im-
munohistochemistry for2SCwasnegative, suggesting that the leiomyomaswerenot
associatedwithHLRCC.Noneof the other 6 carriers of this variant had any features
of HLRCC. Notably, this variant was not detected in any of the patients with renal
cancer (n178) participating in the study. Since 4/7 prostrate cancer patients of
Ashkenazi ethnicity harbored this variant, we performed a genetic epidemiology
study using 856 Ashkenazi Jewish prostate cancer patients. The allele frequencies
were comparedwith557Ashkenazi Jewishnon-cancer controls.A fısher’s twosided
exact test showedthat thevariant isnotassociatedwithprostatecancer in Jews(P1,
OR 1.12(CI 95% 0.21-7.25). Our fındings suggest that the variant, which is patho-
genic for autosomal recessive fumarate hydratase defıciency does not confer patho-
genicity in the heterozygous form for Hereditary Leiomyomatous and Renal Cell
Carcinoma or prostate cancer.
Ashkenazi Jewish Prostate Cancer Patients vs Ashkenazi JewishNon-Cancer Patients
Attribute
Ashkenazi Jewish
Prostate Cancer Patients
Ashkenazi Jewish
Non-Cancer patients
CT 5 3
CC 1707 1151
#4281 Identifıcationof putative cancer susceptibility genes throughwhole
exome sequencing of a family presenting hereditary colorectal cancer. Gio-
vana T. Torrezan,1 Anna Smirnova,1 Felipe C. Silva,1 Erika M. Santos,2 Renan
Valieris,1 Jorge E. de Souza,3 Samuel Aguiar,1 Benedito M. Rossi,2 Sandro J. de
Souza,4 Dirce M. Carraro1. 1A. C. Camargo Cancer Center, Sao Paulo, Brazil;
2Sírio-Libanês Hospital, Sao Paulo, Brazil; 3Instituto de Bioinformática e Biotec-
nologia – 2bio, Sao Paulo, Brazil; 4Universidade Federal do Rio Grande do Norte,
Sao Paulo, Brazil.
Germline mutations in known colorectal cancer (CRC) predisposing genes ac-
counts for less thanhalf of the genetic cause of hereditaryCRCcases. The absence of
mutations in the remaining patients suggests that other yet unknown CRC predis-
posing genes might exist. However, recently studies with large cohorts probably
discounts the existence of major unknown genes and it is thought that rare or even
family private variants and genes may contribute to familial CRC. Thus, the aim of
ourstudywas to identifynovelCRCsusceptibilitygenesbywholeexomesequencing
(WES) of a family presenting hereditary CRC. The studied family fulfılled Amster-
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damIcriteria andappears to segregate adominant cancer syndromewithahigh risk
of colon and rectal cancer, with four affected members in three generations. The
index patient’s tumor was microsatellite stable and positive for the four mismatch
repair proteins at immunohistochemistry. Genetic testing of the proband was neg-
ative for the following genes: MLH1, MSH2, MSH6, PMS2, PMS1, TP53, CHEK2.
We performedWES in three familymembers: two with rectal cancer (onset 26 and
56 years) and one with colon cancer (onset 63 years). Using a functional-based
variant prioritization, we identifıed six novel or very rare (MAF0.002) candidate
variants segregating with the phenotype. Two variants were loss-of-function stop
codon variants in LSG1 and RRH genes. Three variants were missense (ARID1A,
MC1R and SPEN), and three were synonymous (KIT, POLE andXAB2), all occur-
ring in cancer-related genes. The identifıed KIT variant (c.1983CA) is located 8
basepairs fromthe3= endof exon13, and is predicted it todisrupt an exonic splicing
enhancer by in silico tools (ESR fınder andHumanSplice Finder), possibly affecting
the splice of this gene. Pyrosequencing of the KIT variant in tumor cDNA revealed
an allelic imbalance between mutated and wild type alleles, with the mutated allele
being three timesmore expressed.Transcript analysis using a customizedheterodu-
plex enrichment-based method identifıed a novel KIT transcript in the index pa-
tient’s tumor, presenting an exon skipping event of exon12.The resulting transcript
(c.1775_1879del) is predicted to produce an in-frame deletion of 35 amino acids
(p.Gly592_Pro627delinsAla) at the beginning of the protein kinase domain. The
functional impact of this transcript and its relevance for CRCpredispositionwill be
further evaluated. Moreover, experiments evaluating allelic imbalance, loss of
heterozygosity andalternative spliced transcripts for theother identifıedvariants are
ongoing.Our resultsprovidea setofputativeCRCpredisposinggenesandunderpin
that WES of highly informative CRC families, ascertained on the basis of highly
selected phenotypes and followed by functional validation, are likely to continue to
prove an effective strategy for gene discovery.
#4282 Germline TP53 p.R337Hmutations and Li-Fraumeni syndrome: A
new variant form of the disease. Claire Freycon,1 Kelvin César De Andrade,2
Amina Yacouba,1 Maria Nirvana Formiga,3 Camila Bittar,4 Karina Miranda
Santiago,3 Sharon Savage,2 Patricia Ashton-Prolla,4 Pierre Hainaut,1 Maria Isa-
bel Achatz2. 1Institut Albert Bonniot, Grenoble, France; 2Clinical Genetics
Branch, Division of Cancer Epidemiology and Genetics, National Cancer Insti-
tute, National Institutes of Health, Department of Health and Human Services,
Bethesda, MD; 3A.C. Camargo Cancer Center, Sao Paulo, Brazil; 4Universidade
Federal do Rio Grande do Sul, Porto Alegre, Brazil.
The founder germline TP53 mutation, p.R337H, was detected in South and
SouthernBrazil in familieswithLi-Fraumeni Syndrome(LFS).Theaimof this study
was to estimate the burden and patterns of cancer in p.R337H carriers and other
germline TP53 mutations. We analyzed data on 539 individuals from the LFS/LFL
database from A.C. Camargo Cancer Center in São Paulo, Brazil and compared to
International Agency for Research on Cancer (IARC) germline TP53 mutations
database (R17). A total of 144 p.R337H carriers have developed 147 cancers (16.7%
multiple primaries). Themost frequentmalignancieswere soft tissue sarcoma (STS;
25.9%), breast cancer (24.5%) and adrenocortical carcinoma (ACC; 17.7%). Com-
pared to IARCdatabase, p.R337Hcarriershadahigher riskofACCandSTS, a lower
risk of brain tumors and osteosarcomas (P0.01). Patients with p.R337H were at
risk for developing thyroid and kidney cancers. Themedian age at diagnosis was 43
years in p.R337H carriers, 30 in other mutations carriers and 65 in the general
population. The overall penetrance was similar in both groups until age 12 years.
Penetrance was lower in p.R337H carriers (27% at 30 years, 55% at 60 years). The
lifetime penetrance was signifıcantly higher in females (79%) than in males (48%).
p.R337H-associated disease resembles LFS until age 12, and then diverges, with
differences in men and women and a predisposition to cancers that are not part of
the LFS spectrum. These observations suggest that p.R337H could predispose to a
variant form of LFS.
#4283 BRCA1 and BRCA 2mutation predictions using BRACAPRO and
MYRIAD models in patients with Korean ethnicity. Kyung Jin Eoh, Hyung
Seok Park, Ji Soo Park, Seung-Tae Lee, JeongwooHan, Jung-YunLee, Sunghoon
Kim, SangWun Kim, Young Tae Kim, Eun Ji Nam. Yonsei University College of
Medicine, Seoul, Republic of Korea.
Introduction: This study is aimed to compare the predictive effıcacy of
BRCAPRO and MYRIAD BRCA risk calculator in patients tested in Korean
ethnicity.Methods: Individuals, who received gene test onBRCAmutation from
November 2010 to August 2016, were recruited from database of department of
obstetrics and gynecology at a single institute in Korea. Observed BRCA1 and
BRCA2 mutation status was compared with predicted carrier probabilities un-
der the BRCAPRO, andMYRIAD BRCA risk calculator. Risk assessment for all
patients was calculated using the CancerGene assessment software. Results: To-
tal of 279 patients was recruited, and 99.3% (277 out of 279) had Korean ethnic-
ity. The mean age at presentation was 52 years. Out of the 279 individuals, 206
had ovarian cancer, 36 had breast cancer, 26 had double primary ovarian/breast
cancer, and 11 hadno cancer. Fifty fıve individuals had family history of ovarian/
breast cancer in fırst degree relatives. Sixty three patients (22.6%) tested positive
for a BRCAmutation (45 BRCA1, 18 BRCA2). Themean BRCAPRO andMYR-
IAD score for all patients was 6.4% and 7.7%, respectively. The BRCAPRO and
MYRIAD scores were signifıcantly higher for patients who tested positive for a
BRCA mutation (30.4% vs. 6.3%, P 0.001, 12.1% vs. 7.7%, P 0.001, respec-
tively). The area under the receiver operating characteristics curves were 0.762,
and 0.751 for all patients for the BRCAPRO and MYRIAD score to predict the
risk of carrying a BRCA mutation. Conclusion: BRCAPRO and MYRIAD ap-
pear to be valid risk assessment tools for determining the risk of carrying aBRCA
mutation in Korean ethnicity.
#4284 Gate keeping role for endometrial cancer about Lynch syndromeby
surgeon. Min Kyu Kim,1 Min Jung Kwon,2 Min Jeong Yun2. 1Sungkyunkwan
University of Medicine, Samsung Changwon Hospital, Changwon-Si, Republic of
Korea; 2Sungkyunkwan University of Medicine, Samsung Medical Center, Seoul,
Republic of Korea.
Background: It is well known that Lynch syndrome increases risk of endome-
trial and colorectal cancer. There is not much study about detecting Lynch
syndrome patient fast among Korean population by gynecologic oncology sur-
geon. We undertook this study to investigate this. Methods: A review of endo-
metrial cancer patients who was counseled about Lynch syndrome in Depart-
ment of Obstetrics and gynecology, Samsung Changwon Hospital by single
surgeon was done. Clinical information was extracted from the medical record
including age, family and personal history of cancer, immunohistochemis-
try(IHC), microsatellite instability test(MSI), and gene sequencing results. Risk
management and posttest education after result were offered about risk reduc-
ing options and cascade testing for affected individual Results: App patient was
16.There were two germline mutations (both MSH2) (c.23CT (p.Thr8Met),
c.187delG (p.Val63*).Both were negative for MSH2 IHC, But no patient
matched criteria of Amsterdam. Four variation of unknown signifıcance (VUS)
was found (Three MSH2 and One MLH1).Among those all were abnormal in
IHC and there was only one Amsterdam criteria matched patient. There were
two unstableMSI patients, one wasMSH2 germlinemutation and the other was
MSH2 VUS. Median age was 57(4176).Most cases were endometrioid type
(11/16, 69 %).Seventy fıve percent were stage I(12/16). Conclusion: Two MSH2
germline mutation patients among this population was found. Gynecologic on-
cology surgeon can be adapted to develop the ability to assess and evaluate
genetic risk among endometrial cancer.
#4285 Impact of subsidies on cancer genetic testing uptake in Singapore.
Shao Tzu Li, Jeanette Yuen, Ke Zhou, JOANNE NGEOW. National Cancer
Centre, SINGAPORE, Singapore.
Purpose: Previous reports cite high costs of clinical cancer genetic testing as
main barriers to patient’s willingness to test. We report fındings of a pilot study
that evaluates how different subsidy schemes impact genetic testing uptake and
total cost of cancer management. Methods:We included all patients who at-
tended the Cancer Genetics Service at the National Cancer Centre Singapore
(January 2014-May 2016). Two subsidy schemes, the blanket scheme (100%
subsidy to all eligible patients), and the varied scheme (patients received 50%-
100% subsidy dependent on fınancial status) were compared.We estimated total
spending on cancer management from government’s perspective using a deci-
sionmodel. Results: 445 patients were included. Contrasting against the blanket
scheme, the varied scheme observed a higher attendance of patients (34 vs 8
patients per month), of which a higher proportion underwent genetic testing
(5% vs 38%), while lowering subsidy spending per person (S$1098 vs S$1161).
The varied scheme may potentially save cost by reducing unnecessary cancer
surveillance when fırst-degree relatives uptake rate is above 36%. Findings :Pro-
vision of subsidy leads to a considerable increase in genetic testing uptake rate.
From the government’s perspective, subsidising genetic testing may potentially
reduce total costs on cancer management. Understanding and overcoming bar-
riers for cascade testing in fırst degree relatives can improve cost-savings.
#4286 What have we learned from pancreatic cancer patients undergoing
multigene panel testing. Holly LaDuca,1 Chunling Hu,2 Hermela Shimelis,2
Eric Polley,2 Jenna Lilyquist,2 Mary Helen Black,1 Brigette Tippin Davis,1 David
E. Goldgar,3 Jill Dolinsky,1 Fergus J. Couch2. 1Ambry Genetics, Aliso Viejo, CA;
2Mayo Clinic, Rochester, MN; 3University of Utah, Salt Lake, UT.
Purpose: The relevance of inherited pathogenic variants in cancer predispo-
sition genes to pancreatic cancer (PC) is not well understood. Several small
studies have identifıed pathogenic variants in 4% to 14% of unselected PC pa-
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tients using multigene panels of predisposition genes, but only BRCA2, ATM,
and PALB2 have been clearly implicated in this disease. We aimed to assess the
clinical andmolecular characteristics of PC patients referred for hereditary can-
cer genetic testing, and to estimate the risk of PC associated with pathogenic
variants in panel-based cancer predisposition genes. Methods: PC patients
(n1,819) were ascertained from a large cohort of over 140,000 patients under-
going multigene panel testing (MGPT) of predisposition genes between March
2012 and June 2016 at a single diagnostic laboratory. Clinical histories and mo-
lecular results were reviewed and summarized. Gene-level variant frequencies
among PC cases were compared to those from the Exome Aggregation Consor-
tium (ExAC) to calculate gene-specifıc pancreatic cancer risk ratios. Results: PC
patients were predominantly Caucasian (76.5%) and female (58.9%), with a
median age at diagnosis of 61 years (51.7). Of these, 33.5% reported additional
cancer primaries, and 44.8% reported a family history of PC. Overall, 15.4% of
PC patients were found to have at least one pathogenic/likely pathogenic variant
in panel-based predisposition genes. Genes with the highest frequencies of
pathogenic/likely pathogenic variants included BRCA2 (3.9%), ATM (3.6%),
CHEK2 (excluding p.Ile157Thr) (2.0%), PALB2 (1.5%), VHL (1.4%), CDKN2A
(1.2%), BRCA1 (0.8%), andMSH6 (0.8%). 21.8% of BRCA1 and BRCA2 carriers
did not meet BRCA1/2 testing criteria and 61.5% ofMSH6 carriers did not meet
Lynch syndrome testing criteria. No CDKN2A families met diagnostic criteria
for familial atypicalmultiplemolemelanoma syndrome, and 44%did not report
any personal or family history of melanoma. To estimate associations between
pathogenic variants and pancreatic cancer, Caucasian PC cases were compared
to non-Finnish European, non-TCGA ExAC reference controls. Pathogenic
variants in ATM, BRCA2, CDKN2A, MSH6, and PALB2 were signifıcantly as-
sociated with high PC risks. Pathogenic variants in BRCA1were associated with
a moderate risk of PC (RR2.7). Conclusions: These fındings shed light on the
spectrum of mutations that can be expected for PC patients referred for cancer
predisposition testing. The results confırm the associations of CDKN2A and
BRCA2 variants with PC, and expand on the phenotypic spectrum associated
with these variants. Furthermore, these results suggest that ATM, PALB2, and
MSH6 may be high-risk PC genes, warranting further investigation in case-
control and family-based studies.
#4287 HABP2 p.G534E variant in patients with family history of thyroid
and breast cancer.Maisa Pinheiro,1 SandraA.Drigo,1 FabioA.Marchi,2 Renata
Tonhosolo,2 Sonia C. Andrade,3 Igor Jurisica,4 Luiz P. Kowalski,2 Maria Isabel
W. Achatz,2 Silvia R. Rogatto5. 1Sao Paulo State University, Botucatu, Brazil;
2A. C. Camargo Cancer Center, Sao Paulo, Brazil; 3University of Sao Paulo, Pi-
racicaba, Brazil; 4Princess Margaret Hospital, Toronto, Ontario, Canada; 5Uni-
versity of Southern Denmark, Vejle, Denmark.
Background. Familial Papillary Thyroid Carcinoma (PTC) has been recently
associated with the HABP2 p.G534E mutation. In this study we evaluated the
putative association of the HABP2 p.G534E mutation and familial history of
PTC and Breast Carcinoma (BC) in the Brazilian population. Methods. Germ-
line mutations of twenty unrelated individuals with personal and/or family his-
tory of PTCand/or BCwere identifıed bywhole exome sequencing (WES), using
Nextera Exome Enrichment kit and HiSeq200 platform (Illumina). Two cases
were positive for p.G534E. Family members from both positive cases (seven
from Family 1 and three from Family 2) were recruited for segregation analysis.
An additional patient and three relatives (Family 3) with history of PTC and BC
were included for validation. Fifty frozen PTC tumor samples and 170 healthy
Brazilian individuals were also screened for the HABP2 variant. Confırmation
and validation were performed by Sanger sequencing. Results. Interestingly,
Family 1 reported a consanguineous history, reflected in two homozygous cases:
the proband (PTC) and his unaffected sister. Also, only one (BC) out of eight
tested members was negative for p.G534E. In the Family 2, the only patient
diagnosed with PTC was negative for the mutation, while three relatives were
positive for the same loci. The index case (PTC) fromFamily 3, was wild type for
HABP2 and three relatives tested were positive carriers. In PTC tumor samples
the Allele Frequency (AF) was 0.04: two heterozygous and one homozygous for
p.G534E.Among 170 healthy individuals, fıvewere heterozygous for the variant,
representing an AF of 0.0147. The two index patients evaluated by WES also
presented interesting pathogenic variants in genes potentially associated with
deregulation of the extracellular matrix organization pathway (CTSB, TNXB,
COL4A3, COL16A1, COL24A1, COL5A2, NID1, LOXL2, MMP11, TRIM24
and MUSK) and DNA repair function (NBN and MSH2). Conclusion. Our
fındings suggest that HABP2 is not a predisposition gene involved in familial
PTC andBC. Financial Support: FAPESP (2013/01867-8 and 2014/03983-8) and
CNPq (481132/2012-0).
#4288 Inherited mutations in BRCA1 and BRCA2 in an unselected multi-
ethnic cohort of Asian breast cancer patients and healthy controls fromMa-
laysia.WeiXiongWen,1KahNyin Lai,1 JamieAllen,2 Craig Luccarini,2 Shivaani
Mariapun,1 ChengHar Yip,1 Nur AishahMohd Taib,3 Alison Dunning,2 Doug-
las Easton,2 Soo Hwang Teo1. 1Cancer Research Malaysia, Subang Jaya, Malay-
sia; 2University of Cambridge, Cambridge, United Kingdom; 3University of Ma-
laya, Kuala Lumpur, Malaysia.
Background: BRCA1 and BRCA2 are signifıcant cancer predisposition genes
which have hitherto primarily been tested in breast cancer patients selected on the
basis of age of onset of breast cancer and family history of breast andovarian cancer.
Given that only 40% of breast cancer occur in post-menopausal women in many
Asian countries including Malaysia, compared to close to 80% in many Caucasian
countries, the proportion of risk attributable to genetic factors is likely to be corre-
spondingly higher in Asians. We sought to determine the prevalence of germline
mutations in BRCA1 and BRCA2 in an unselected cohort of Asian breast cancer
patients and healthy controls. Methods: Women diagnosed with invasive breast
cancer recruited fromUniversityMalayaMedicalCentrebetweenOctober2002and
April 2015, and Sime Darby Medical Centre between September 2012 and April
2015 [n2,592]. Eligible control subjects were recruited fromwomen attending an
opportunistic mammography screening programme at UniversityMalayaMedical
Centre between January 2014 and April 2015, and Sime Darby Medical Centre
between October 2011 and April 2015 [n2,851]. Amplicon-based targeted se-
quencing of exonic andproximal splice site junction regions of 31 knownandprob-
able breast cancer susceptibility genes were performed on Fluidigm Access Array
system, with sequencing conducted on the Illumina HiSeq2500 platform. Variant
calling was performed as per GATK recommended best practices with Unifıed-
Genotyper using the default parameters except -minIndelFrac 0.05. Variants were
annotatedwithANNOVARandvariantswithMAF1%as reported inpopulation
databaseswere fılteredout.Nonsense, frameshift indels, and splice site variantswere
presumed to bedeleterious. Results:Overall, 111distinctmutations (50BRCA1and
61BRCA2)were identifıed in143carriers (70BRCA1and73BRCA2)amongbreast
cancer patients, and 11 carriers (5 BRCA1 and 6 BRCA2) were identifıed among
healthy controls. Germline carriers were more likely to be younger, have family
history of breast and/or ovarian cancer, have higher grade tumours and for BRCA1
carriers, theyweremore likely tohavebreast cancerswhich arenegative for estrogen
receptor and ERBB2 receptor. Notably, 45% of breast cancer patients fulfılled the
NCCN guidelines for recommendation for genetic counseling and genetic testing,
andof these, 80%of carriers fulfıll theNCCNguidelines. Taken together, our results
show that 5% of Asian breast cancer patients have pathogenic mutations in
BRCA1 or BRCA2, and that germline testing can be cost-effectively delivered to
Asianwomenby focusing primarily onwomenwith early onset breast cancer in the
presence of family history of breast and ovarian cancers.
#4289 Whole-exome sequencing study of nevoid basal cell carcinoma syn-
drome (NBCCS) families to identify disease-causing exonic mutations.Mat-
thew Gianferante,1 Alisa Goldstein,1 Mingyi Wang,2 Bin Zhu,2 Belynda Hicks,2
NCI DCEG Cancer Genomics Research Laboratory, Lisa Mirabello1. 1National
Cancer Institute, Rockville, MD; 2Cancer Genomics Research Laboratory,
Fredrick, MD.
NBCCS is an autosomal dominant disorder with nearly complete penetrance
and variable expression. Clinical fındings includemultiple basal cell carcinomas,
keratocysts of the jaw, pits of the palms and/or soles, and more rarely medullo-
blastoma. The PTCH1 gene is the major NBCCS susceptibility gene; it regulates
the sonic hedgehog (SHH) pathway. Here, we are evaluating mutations in un-
known NBCCS families to identify potential disease-causing mutations. Our
study included specimens and clinical data from 21 NBCCS families. PTCH1
targeted sequencing and CGH array were previously performed. We subse-
quently whole-exome sequenced (WES) affected family members with no mu-
tation detected from prior targeted analyses (N9).We focused our analyses on
rare variants of PTCH1, genes that directly interact with PTCH1, SHH pathway
genes, and cancer predisposing genes. Variants were considered rare if minor
allele frequency (MAF) was less than 1% in publicly available databases (ESP,
ExAC, and 1000 genome), 1000 in-house population cancer-free controls, and
an in-house database of approximately 2,000 familial samples that underwent
WES in parallel with our NBCCS families. We used in-silico prediction models,
variant impact on the protein (i.e., nonsynonymous, nonsense, frameshift, splice
site), and public mutation databases to assess pathogenicity. Rare variants in
PTCH1 were considered pathogenic if they were (a) previously reported as dis-
ease-causing in NBCCS, or (b) predicted high impact (ie, frameshift, nonsense
mutation), or (c) predicted damaging by at least fıve of seven in-silico prediction
programs (CADD, PolyPhen 2, SIFT, Assessor, Mutation Taster, LRT,
FATHMM). Ten families (N 17 individuals) without a PTCH1mutation were
assessed with WES. WES identifıed PTCH1 mutations in six families. Overall,
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only one PTCH1 variant was previously reported (p.S732fs) in HGMD or Clin-
Var databases. Six novel variants were identifıed: three frameshifts, p.Y92fs,
p.S732fs and p.T212fs; one nonsense, p.W862*; one nonsynonymous variant,
p.E835K; and, one splice site variant, c.2716-2AC. The nonsynonymous vari-
antwas a heterozygousC toT transversion (chromosome 9, position 98 229 452)
and predicted damaging. In the four families without a PTCH1 mutation, two
separate families had a rare nonsynonymous variant in the same gene that di-
rectly interactswith PTCH1. Both variants had aMAFof less than 0.1%, but only
onewas predicted damaging.Another family had a rare nonsynonymous variant
in a known cancer predisposing gene that was deleterious in fıve of seven in-
silico prediction tools and found in both the proband and affected mother.
Overall, in our 21 NBCCS families, 81% had PTCH1 gene mutations detected
with targeted sequencing, aCGH, or WES. Additionally, WES detected two po-
tentially new disease-associated genes that we are currently evaluating further.
#4290 A study in locus heterogeneity: Targeted sequencing analysis of 6q
reveals multiple signifıcant loci as the source of a previous linkage peak in
familial lung cancer. Anthony M. Musolf,1 Claire L. Simpson,2 Bilal A. Moiz,1
CandaceMiddlebrooks,1Mariza deAndrade,3 DiptasriMandal,4 Colette Gaba,5
Ping Yang,3 Yafang Li,6 Ming You,7 Elena Y. Kupert,7 Marshall W. Anderson,7
Ann G. Schwartz,8 Susan M. Pinney,9 Christopher I. Amos,6 Joan E. Bailey-
Wilson1. 1NIH NHGRI, Baltimore, MD; 2University of Tennessee Health Science
Center, Memphis, TN; 3Mayo Clinic, Rochester, MN; 4Louisiana State University
Health Sciences Center, New Orleans, LA; 5University of Toledo Dana Cancer
Center, Toledo, OH; 6Dartmouth College, Lebanon, NH; 7Medical College ofWis-
consin, Milwaukee, WI; 8Karmanos Cancer Institute, Wayne State University,
Detroit, MI; 9University of Cincinnati College of Medicine, Cincinnati, OH.
Lung cancer is the leading cancer-related cause of death in the United States.
We had previously performed multipoint linkage analysis on families with a
strong family history of lung cancer and found signifıcant linkage to the 6q25
region. In order to fınd the source of that linkage signal, we performed targeted
sequencing 6q23-6q27 on 75 individuals from the 9most highly linked families.
We performed two types of parametric linkage analysis, using an autosomal
dominant mode of inheritance with 10% penetrance for carriers and a 1% phe-
nocopy rate using a disease allele frequency of 1%. The fırst type was a two-point
analysis using an Elston-Stewart algorithm. This approach did not lead to any
genome-wide signifıcant results but demonstrated signifıcant heterogeneity
throughout the nine families.In an effort to recover the power from the original
multipoint analysis, we performed a regional linkage analysis using SEQLinkage
and MERLIN. SEQLinkage built regional haplotypes that corresponded to a
gene or an intergenic region - the regionswere based on a customizedmapof our
design. The regional markers were multiallelic which allowed for greater infor-
mation content and were similar to the microsatellites that were used in the
original multipoint analysis. The regional markers were then analyzed in a two-
point linkage analysis via MERLIN. This allowed us to identify two genome-
wide signifıcant signals at PACRG-AS1 at 6q26 (HLOD  3.4) and SAMD5 at
6q24 (3.3). The PACRG-AS1 is novel, though it is associated with the known
lung cancer gene PARK2. SAMD5 may be involved in lung cancer cell prolifer-
ation. The heterogeneity of the two signals was particularly interesting. The
PACRG-AS1was driven primarily by two families. The SAMD5marker was not
being strongly driven by any of the families and appears to be a small cumulative
effect across the nine families. In addition, several families have large, but non-
signifıcant LOD scores at other loci across the region. This further reinforces the
locus heterogeneity within the region, and it is likely that our two signifıcant
signals here are not the only variants affecting the phenotype. We further at-
tempted to localize the signals by running SEQLinkage using a custom map
where genes are broken into exons and introns. Though this resulted in no
signifıcant markers, the highest signal was located in the intronic region of
SAMD5 (HLOD  3) and several other suggestive signals were localized to
intronic regions of good candidate genes like SASH1 andARID1B. Examination
of predicted effects of the candidate regulatory variants using eQTL databases is
ongoing. This is a region full of promising candidates, and it is likely that the two
signifıcant signals found here are just part of many that could be affecting lung
cancer risk. We plan to do further analysis within the individual families to
elucidate any more genes affecting this signal.
#4291 Body constitution in young healthy women from breast cancer
higher risk families in relation to smoking. Carolina Ellberg, Håkan Olsson,
Helena Jernström. Lund University, Lund, Sweden.
Introduction: The purpose of this study was to investigate potential associa-
tions between body composition and current smoking in young healthy women
from high-risk families. Cigarette smoke contains7000 chemicals of which 69
are established carcinogens and smoke also acts as an aromatase inhibitor.
Smoking is now recognized as a carcinogen for the breast and influences both
risk and prognosis. However, the underlying mechanisms need to be better
elucidated. One study showed that breast cancer patients who smoked were
younger, had a lower body mass index (BMI), smaller breast volumes, but a
higher waist-to-hip ratio (WHR) than non-smokers. However, smoking was
also associated with a higher frequency of prior oral contraceptive (OC) use.
Since breast cancer development starts long before the tumor is clinically detect-
able, we aimed to study the impact of cigarette smoke on anthropometric factors.
Material and methods: Between 1996 and 2006, 269 healthy women were in-
cluded in a study on the impact of lifestyle factors in women40 years from
high-risk breast cancer families. Thirty-six participants who had missing breast
measurements or who had undergone previous breast surgeries, who were cur-
rently breast-feeding or who were current users of hormonal contraceptives
other than combined EP OCs or had missing smoking status were excluded,
leaving 233 women of which 35 were known BRCA1/2 mutation carriers.
Height, weight, waist- and hip circumference, and total breast volume were
measured in a standardized way by a research nurse 5-10 days before predicted
onset of the next menstrual period. Weight, BMI, breast volume, and waist
circumference, were not normally distributed and were transformed using the
natural logarithm to obtain a better distribution.Multivariable linear regression
was used to obtain P-values, adjusted for age, nulliparity, and current OC use.
Means and geometricmeans for smokers andnon-smokerswere standardized at
age 29 years, nulliparity, and non-current OC use. Results: The median age was
29 years (IQR 24-35) and the median year of birth was 1970. Forty-two percent
had ever smoked, 23% were current smokers, 28% were current OC users, and
54% were nulliparous. Current smoking was not associated with height, weight,
BMI breast volume, or hip circumference (all adjPs0.18). However, current
smokers had signifıcantly larger standardized waist circumference (78 vs 74 cm;
adjP0.02), and higher standardizedWHR (0.79 vs 0.76; adjP0.003) compared
with non-smokers. Conclusion: Current smokers had signifıcantly larger waist
circumference and higher WHR, but similar BMI and breast volume compared
with non-smokers, althoughmost women had anthropometricmeasures within
WHO’s recommended limits. The difference in fat distribution towards more
abdominal fat, suggests that current smoking is associated with a more inflam-
matory and/or androgenic profıle at the age when breast cancer is initiated.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Cell
Death in Cancer
#4292 Indole-3-carbinol (I3C) enhances effıcacy of Gemcitabine in leio-
myosarcoma. Sujit Suwal, Alexandra Moran, Ana Paz-Mejia, Lorena Flor,
Omar Picado, Basem Azab, Jonathan Trent, Fiorella Pendola, Alan S. Living-
stone, Danny Yakoub. University of Miami-Miller School of Medicine, Miami,
FL.
Introduction: Adjuvant Gemcitabine have recently been shown to improve
progression free survival in some types of leiomyosarcoma. Adequate cellular
uptake of the drug remains a challenge. We aimed to evaluate the role of nucle-
oside transporter activator (I3C) in increasing the in vitro effıcacy of gemcit-
abine in the treatment of leimyosarcoma. Methods: Leiomyosarcoma cells
(SKLMS) were incubated with DMEM10% FBS  1% Antibiotics. Dose re-
sponse curves were generated for gemcitabine and I3C to identify the IC-50
values. Triplicates of cells were then plated in 96 well plates (3000 cells/well) and
allowed to adhere. The adherent cells were further treated with gemcitabine in
the presence or absence of I3C and compared with controls (DMSO treatment).
MTS cell viability assays were done and absorbance was monitored in a micro-
plate reader. Flow cytometry was performed with Propidium Iodide (PI) stain-
ing. Scratch assays were done to assess cell migration. Results: Viability assay
showed signifıcant increase in the cytotoxicity of gemcitabine in presence of I3C
compared to controls. Flow cytometry data showed gemcitabine alone treat-
ment has arrested the cell cycle atG0/G1phasewithout increase of cell death.On
the contrary, use of gemcitabine in combination with I3C increased the cell
death by at least three folds compared to control as well as gemcitabine alone
treated cell population. Scratch assay over a 16 hour period showed that the rate
of cellular migration signifıcantly dropped by 1.5 folds upon treatment with
gemcitabine combined with I3C compared to gemcitabine alone. Western blots
showed increased expression of membrane transporter hENT-1 with I3C treat-
ment. Conclusion: The use of I3C enhanced cellular uptake, transport and cy-
totoxicity of gemcitabine in SKLMS cells. Further studies are warranted and
underway to elaborate on intracellularmechanisms of action to optimize the use
of I3C as a potential adjunct in preclinical and clinical leiomyosarcoma treat-
ment.
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#4293 Siramesine and lapatinib induce ferroptosis in glioblastoma and
lung adenocarcinoma cells.Anna R. Blankstein,1 ShumeiMa,2 Spencer B. Gib-
son1. 1University ofManitoba,Winnipeg,Manitoba, Canada; 2Research Institute
in Oncology and Hematology, Winnipeg, Manitoba, Canada.
Ferroptosis, amorphologically and biochemically distinct cell death pathway,
is characterized by iron-dependent accumulation of reactive oxygen species
(ROS)within the cell. The combination of siramesine, a lysosome disruptor, and
lapatinib, a dual tyrosine kinase inhibitor, has been shown to synergistically
induce cell death in breast cancer cells. This cell death was blocked by the fer-
roptosis inhibitor ferrostatin-1 (Fer-1) and the iron chelator deferoxamine
(DFO). The objective of the present study was to determine whether lysosome
disruptors and tyrosine kinase inhibitors, in combination, induced synergic cell
death via the ferroptotic pathway in additional types of cancer. U87 (glioblas-
toma) and A549 (lung adenocarcinoma) cells were treated with various lyso-
some disruptors (siramesine or desipramine) in combination with tyrosine ki-
nase inhibitors (lapatinib or sorafenib), and the amount of cell death was
measured by trypan blue exclusion. We found that these combinations syner-
gistically induced cell death in U87 and A549 cells. To determine whether fer-
roptosis was themechanism of cell death, cells were pretreated with either Fer-1
or DFO (inhibitors of ferroptosis), or with exogenous iron chloride (an inducer
of ferroptosis) before treatment with the combination of siramesine and lapa-
tinib. Pretreatment with Fer-1 or DFO decreased cell death by approximately
35%. Pretreatment with iron chloride increased the effect of the drug combina-
tion by approximately 45%. Prussian Blue staining demonstrated that there was
an increase in intracellular iron accumulation following treatment with the
combination of siramesine and lapatinib. Collectively, these data show that in
U87 andA549 cells, the combination of lysosome disruptors and tyrosine kinase
inhibitors, specifıcally siramesine and lapatinib, induces ferroptotic cell death.
Therefore, inducing ferroptosis in tumor cells is a potential strategy for therapy
in these cancers with limited treatment options.
#4294 Preclinical evaluation of imipridone ONC201 in triple negative
breast cancer identifıes predictive biomarkers and combinatorial opportuni-
ties. Bora Lim, Jangsoon Lee, Huey Liu, Troy Pearson, Larry Coffer, Debu Tri-
pathy, Naoto T. Ueno. UTMD Anderson Cancer Ctr., Houston, TX.
Background: Triple negative breast cancer (TNBC) lacks effective targeted
therapy, leaving chemotherapy as the only therapeutic option. Metastatic TN-
BCs eventually develop resistance to chemotherapy via several mechanisms in-
cluding apoptosis evasion, hence representing an urgent unmet need for novel
therapies. ONC201 is a fırst-in-class imipridone that induces caspase-mediated
apoptosis in multiple cancers including TNBC, selectively antagonizing dopa-
mine D2-like receptors (DRD2) resulting in inhibition of Ras signaling and cell
death. Selective antagonism of D2-like receptors has been shown to induce cell
death in cancer cells via the same signaling pathways engaged by ONC201. To
translate these early fındings for breast cancers patients, more studies to prove
ONC201’s activity andmechanism of action in breast cancers are needed. In this
study, we tested the effıcacy of ONC201 in TNBC cell lines, and further con-
fırmed themechanismof action ofONC201 by studying the association between
DRD2/DRD5 andONC201 effıcacy. Additionally, we performed siRNAkinome
screening to identify combinatorial opportunities to further enhance ONC201
effıcacy in TNBC.Method:We determined the effıcacy of ONC201 in 20 TNBC
cell lines by determining the IC50. We then selected one cell line with low IC50
(CAL51) and high IC50 (HCC70) for siRNA synthetic lethality screening via 2D
and 3D culture systems. Additionally, we correlated the IC50 with the mRNA
expression of DRD2 measured by Affymetrix microarray on each TNBC cell
lines with IC50 of the ONC201. Result: IC50 ranged from 2.09 to 40M, with
median IC50 of 10M. No correlation between Vanderbilt TNBC molecular
subtype and IC50. 2D/3D siRNAkinome screening and Ingenuity pathway anal-
ysis showed PIK3, MAPK, and Ephrin receptor pathways as top three target
candidates correlating with tumor growth inhibition effıcacy of ONC201. The
long variant of DRD2 mRNA expression and ONC201 IC50 showed a correla-
tion. There was a negative correlation between mRNA expression of DRD5 and
IC50 (R20.3601, P0.018). Conclusion: Our preclinical results suggest that
ONC201 is active is TNBC cells within previously proven safe therapeutic dose
and provides potential combinatorial opportunities with PI3K/MAPK targeted
drugs. These results highlight the importance of targeting the dopamine recep-
tor pathway for ONC201 effıcacy and supports DRD5 as a potential predictive
marker. Targeting DRD2 and apoptosis induction could be one of therapeutic
strategy in triple negative breast cancers. Ongoing work involves further in vitro
and in vivo studies to determine the best synergistic therapeutic partner and
conducting a phase II single agent trial to study the pharmacodynamics changes
induced by ONC201 in TNBC.
#4295 AZ’5576, a selective CDK9 inhibitor, demonstrates in vitro and in
vivo activity in diverse preclinical models of non-Hodgkin lymphoma. Justin
Cidado,1 Theresa Proia,1 Gareth Gregory,2 Izabela Todorovski,2 Scott Boiko,1
Maryann San Martin,1 Ricky Johnstone,2 Lisa Drew1. 1AstraZeneca, Waltham,
MA; 2Peter MacCallum Cancer Centre, Victoria, Australia.
Cyclin-dependent kinase 9 (Cdk9) is a serine/threonine kinase that regulates
elongation of transcription through phosphorylation of RNA polymerase II at
serine 2 (pSer2-RNAPII). Transient inhibition of Cdk9 results in modulation of
genes with short-lived transcripts and labile proteins, thereby representing a
potential therapeutic opportunity in tumors dependent upon oncogenes fıtting
these criteria. Mcl1, an anti-apoptotic protein that has been linked to increased
survival and chemotherapy resistance in various cancers, and Myc, a proto-
oncogenic transcription factor that coordinates diverse transcription programs
and is over-expressed, amplifıed, or translocated in many cancers, are two such
oncogenes. AZ’5576 is a potent, highly selective, and orally bioavailable inhibi-
tor ofCdk9 that inhibitsCdk9 enzyme activitywith an IC505nManddecreases
phosphorylation of Ser2-RNAPII in cells with an IC50 of 96nM. In sensitive cell
lines, short-term treatment with AZ’5576 led to a rapid dose- and time-depen-
dent decrease in pSer2-RNAPII with concomitant loss of Mcl1 andMycmRNA
and protein, resulting in the cleavage and activation of caspase 3 and loss of cell
viability. Using cell potency and magnitute of caspase activation to defıne sen-
sitivity, we previously reported that AZ’5576 demonstrates broad in vitro and in
vivo activity across hematological malignancies. Initially focusing on acute my-
eloid leukemia (AML) andmultiplemyeloma (MM),we have now expanded our
scope to encompass non-Hodgkin lymphoma (NHL), which includes diffuse
large B-cell lymphoma (DLBCL), Burkitt’s lymphoma (BL), mantle cell lym-
phoma (MCL), andWaldenstrommacroglobulinemia (WM). In vitro screening
assays reveal about half (19/35) of NHL cell lines undergo cell death in response
to AZ’5576, demonstrating a potency520nM and a maximum caspase activa-
tion 55% after 6 hour treatment. Combining AZ’5576 with a BTK inhibitor
further enhances cell death compared to that observed with either single agent
alone in BTK inhibitor-sensitive ABC-DLBCL cell lines. Consistent with the in
vitro data, signifıcant anti-tumor activity was associated with short-term reduc-
tion of pSer2-RNAPII tumor levels after intermittent dosing of AZ’5576 in a
mouse xenograft model of ABC-DLBCL cell line OCILY10. Similarly, combin-
ing AZ’5576 with a BTK inhibitor in vivo drove tumors into regression (combi-
nation199% TGI) compared to the partial TGI from either single agent alone
(AZ’557679% TGI, Acalabrutinib58% TGI) in the OCILY10 xenograft
model. Finally, in an agressive E-Myc transgenic mouse model of B-cell lym-
phoma, AZ’5576 treatment results in potent induction of apoptosis in vitro and
a greater than 50 day increase inmedian overall survival in vivo. Together, these
results highlight the therapeutic potential for selective CDK9 inhibition in the
treatment of patients with non-Hodgkin lymphoma.
#4296 A real-time annexin V method for monitoring programmed cell
death. Kevin Kupcho,1 Andrew Niles,1 John Shultz,1 Jamison Grailer,1 Wenhui
Zhou,2 Robin Hurst,1 Jim Hartnett,1 Terry Riss,1 Dan Lazar,1 James Cali1. 1Pro-
mega Corporation, Madison, WI; 2Promega Biosciences LLC, San Luis Obispo,
CA.
Effıcacious and durable anti-cancer responses are driven by both the selective
death of malignant cells and the induction of immunostimulatory activities.
Limited but promising clinical evidence suggests that provocation of an un-
known balance of inflammatory- and non-inflammatory cell death may be key
for orchestrating these positive outcomes. Therefore, identifying and character-
izing new clinically useful small molecules and biologic inducers (or combina-
tions thereof) which promote a spectrum of programmed cell death in in vitro
screening environments remains critically important. Unfortunately, current
screeningmethods are either insuffıciently robust, cost- or resource-prohibitive,
or provide no means for initial characterization of the kinetics of programmed
cell death. To address this unmet need, we developed a real-time, live cell assay
method that utilizes a fully homogeneous, bioluminescent annexin V reagent.
The method does not require laborious washing and sample preparation steps
associated with traditional annexin methods and is fully compatible with plate-
based multimodal signal detection systems. The system contains two annexin
proteins which have been engineered to contain separate and distinct comple-
menting domains of a binary luciferase. Additionally, the system contains a
novel time-released luciferase substrate and a cell impermeable, fluorogenic
DNA dye for monitoring necrosis. Because the annexin-luciferase fusion pairs
have only modest affınity for each other, luminescence remains low until phos-
phatidylserine exposure, a hallmark of the programmed cell death phenotype,
brings annexin monomers into close proximity facilitating complementation of
the luciferase sensor. The assay reagent can be applied at dosing for real-time
measurement of the dose-dependency andmagnitude of programmed cell death
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progression. This work describes our efforts to characterize and validate the
performance of the bioluminescent annexin assay using relevant cell death in-
ductionmodels. First, the assay was shown to be functionally concordant with a
flow cytometry annexin method in a dose-response model with bortezomib at
exposure periods known to produce both early and late-apoptosis (with necro-
sis) phenotypes. Next, we assessed the performance of the assay using a limited
training set of small molecule and biologic inducers of programmed cell death
that utilize different mechanisms of action (i.e., apoptosis and necroptosis) and
by using a number of diverse but representative cancer cell lines. We conclude
that the bioluminescent annexin method provides a new kinetic approach to
effıcient and effective detection of programmed cell death mechanisms in real
time in a convenient homogeneous format.
#4297 ADCs inhibiting the all-powerful osmotic transducer. JamesR. Pru-
dent,1 David Marshall,1 Fabio Malavasi,2 Antonella Chillemi2. 1Centrose LLC,
Madison, WI; 2University of Torino Medical School, Torino, Italy.
Purpose: Extracellular drug conjugates (or EDCs) are a new type of ADC that
selectively inhibit the all-powerful Na,K-ATPase, an extracellular membrane
ion pump required for life. To determine if EDCs may be valuable clinical can-
didates, we further assessed their safety, effıcacy andmode of action. Experimen-
tal Design: Cynomolgus monkeys were infused with EDCs at various levels and
monitored by heart telemetry, blood cell levels and serum examination. Addi-
tionally, cultured cells were subjected to EDCs and monitored in real time and
by high resolution dual fluorescent labeling to better understand themechanism
of cell death. Results: We tested the effıcacy of the EDCs in a number of xeno-
grafts models and observed strong activity (regression and cures). Little to no
tumor reduction was observed for the free antibodies or with control-EDCs
where the antibody target was not expressed. To test for safety, each cynomolgus
monkey were infused with one of three EDCs to better understand the MTD of
each EDC. In all cases, MTD was determined to be between 5 and 10mgs/kg
where EDC serum levels reached between 100 and 200ugs/ml. At the maximum
safe dose tested (5mgs/kg), heart beat and other observed parameters were
found to be normal with the exception of the blood cells expressing the EDC
targets (EDC targeting CD20 at this high level was found to drop all B-cells to a
nondetectable level which rebounded to normal on day 58). To further under-
stand the EDCmechanism, cells exposed to the EDCs andmonitored visually in
real-time or by dual fluorescence microscopies. All cells exposed to the EDCs
showed membrane swelling and extracellular localization of the EDC. Conclu-
sion: These results show that targeted inhibitors of the Na,K-ATPase ion pump
have promise as future anticancer medicines. First, EDCs appear safe in nonhu-
man primates at effıcacious doses in rodent xenografts. In addition, an identifıed
mechanism of extracellular necrotic death is novel in the fıeld of oncology. Our
hope is that cancers that up-regulate MDR and/or anti-apoptotic mechanisms
will be sensitive to EDCs. Continuing efforts to identify the full death pathway of
this new type of ADC should lead to identifying patients most likely to respond
to EDC based therapies.
#4298 FTY720 induces necroptosis in lung cancer by modulating cer-
amide signaling at the plasmamembrane. Rose Nganga.Medical University of
South Carolina, Charleston, SC.
Sphingolipids are important signaling molecules in cells and have recently
been explored as cancer therapy targets. FTY720 (Fingolimod, Gilenya) is an
FDA approved sphingosine analogue drug used for the treatment of multiple
sclerosis (MS). FTY720 is phosphorylated by sphingosine kinase 2 (SK2), to
generate P- FTY720 to exert its immunosuppressive properties through binding
to sphingosine -1 phosphate receptors (S1PRs). FTY720 also exhibits anti-can-
cer properties. Our previous studies indicated that one of the mechanism by
which FTY720 induces cell death is through necroptosis. FTY720 directly binds
to I2PP2A/SET (Inhibitor 2 of PP2A), consequently activating the tumor sup-
pressor protein phosphatase 2A (PP2A). The activated PP2A then induces cell
death by stimulating the activity of Receptor-Interacting Protein kinase-1
(RIPK1), involved in necroptosis signaling. Previous studies have shown that
FTY720 can modulate sphingolipids metabolism in cells. However, little is
known about the roles of FTY720 in ceramide signaling and regulation of
necroptosis in lung cancer. We hereby seek to investigate the mechanisms of
FTY720 in inducing necroptosis with regard to ceramide signaling. Preliminary
data indicate that inhibitors of ceramide generation partially protect cells against
FTY720-induced cell death. Interestingly, FTY720 and non-phosphorylated
FTY720 analogues do not affect ceramide generation, but lead to the formation
of cancer specifıc ceramide-multi-protein complexes at the plasma membrane.
Our studies show a role of these complexes in inducing plasma membrane rup-
ture, a key phenomenon in necroptosis. Further elucidation of these novel struc-
tures will be helpful in improving cancer therapeutics that further promote the
formation these structures hence more cell death.
#4299 Chemosensitizing effect of telomerase-dependent oncolytic adeno-
virus through virally induced microRNA-29-mediated MCL1 downregula-
tion in osteosarcoma cells. Shuhei Osaki,1 Hiroshi Tazawa,2 Joe Hasei,2 Yasuo
Urata,3 ToshifumiOzaki,2 Toshiyoshi Fujiwara2. 1Japanese Red Cross KobeHos-
pital, Kobe, Japan; 2Okayama University, Japan; 3Oncolys BioPharma, Inc., Ja-
pan.
Osteosarcoma is a rare highly malignant tumor. It is generally refractory to
chemotherapy, which contributes to its poor prognosis. The enhancement of
chemosensitivity is a potential approach to improve the prognostic outcome of
osteosarcoma patients. We developed a telomerase-specifıc replication-compe-
tent oncolytic adenovirus, OBP-301. We recently confırmed the antitumor ef-
fect of OBP-301 monotherapy in human osteosarcoma cells. We also revealed
the synergistic chemosensitizing effect of OBP-301 in human epithelial malig-
nant tumor cells. In this study, we investigated the chemosensitizing effect of
OBP-301 and its underlyingmechanisms in humanosteosarcoma cells.We used
four human osteosarcoma cell lines, SaOS-2, MNNG/HOS, HOS and 143B.
OBP-301 is an attenuated adenovirus, in which the hTERT promoter drives the
expression of E1 gene, and causes tumor-selective lysis in a variety of human
malignant tumor cells with telomerase activity. OBP-301 infection enhanced the
cytotoxic effect of chemotherapeutic agents (cisplatin and doxorubicin). The
calculation of combination index revealed the synergistic effects in all four hu-
man osteosarcoma cell lines. Combination of OBP-301 increased chemothera-
py-induced apoptosis. To clarify the molecular mechanism underlying the che-
mosensitizing effect of OBP-301, we investigated whether OBP-301 affects the
expression of anti-apoptotic BCL2 family proteins. In SaOS-2 andMNNG/HOS
cells, the expression level of MCL1 was markedly decreased by OBP-301 infec-
tion. MCL1 knockdown by siRNA enhanced the chemotherapy-induced apo-
ptosis as well as OBP-301. We recently revealed that OBP-301 increase the ex-
pression of cellular miRNAs in human cancer cells. To investigate the
underlying mechanism of OBP-301-mediated MCL1 suppression, we deter-
mined whether OBP-301 upregulates MCL1-targeted miRNAs. OBP-301 dose-
dependently upregulated the expression of MCL1 targeted miR-29 in SaOS-2
and MNNG/HOS cells. Exogenously introduced miR-29 effıciently suppressed
MCL1 expression and enhanced the chemotherapy-induced apoptosis. More-
over, combination treatment signifıcantly inhibited tumor growth, as compared
to monotherapy, in a subcutaneous xenograft tumor model. MCL1 is overex-
pressed in various types of human tumor cells. Overexpression of anti-apoptotic
proteins is an important factor to prevent chemotherapy-induced apoptosis in
cancer. We demonstrated OBP-301 effıciently kills human osteosarcoma cells
and markedly sensitizes them to chemotherapy. MCL1 suppression via OBP-
301-induced miR-29 is critical as the underlying mechanism of the OBP-301
mediated chemosensitizing effect. These results suggest that replicative virus-
mediated tumor specifıc MCL1 ablation may be a promising strategy to attenu-
ate chemoresistance in osteosarcoma patients.
#4300 Thymoquinone Inhibits Proliferation and induces apoptosis in leu-
kemic cells. Steve Harakeh,1 Josiane Semaan,2 Marwan El Sabban,3 Soad K. Al
Jaouni,4 Mona Diab-Assaf,2 Rania Azar2. 1King Abdulaziz University,
00966559392266, Saudi Arabia; 2lebanese university, Lebanon; 3american uni-
versity of beirut, Lebanon; 4King Abdulaziz University, Jeddah, Kingdom of Saudi
Arabia, Saudi Arabia.
Introduction: Adult T-cell leukemia (ATL) is caused by human Tcell lym-
photropic virus 1 (HTLV1) and is an aggressive form of malignancy. So far,
there is no effective treatment for ATL. Thymoquinone has been reported to
exhibit many useful effects including anti-cancerous properties. Objective: The
aim of this study is to investigated the effects of TQ on proliferation, apoptosis
induction and the underlying mechanism of action in both HTLV-1 positive
(C91-PL and HuT-102) and HTLV-1 negative (CEM and Jurkat) malignant
T-lymphocytes.Materials andmethods: Cells were treated with various concen-
trations of thymoquinone for 24h. Cell cytotoxicity was assayed using the Cyto-
Tox 96® Non-Radioactive Cytotoxicity Assay Kit. Cell proliferation was deter-
minedusingCellTiter 96®Non-RadioactiveCell Proliferation.Cell cycle analysis
was performed using staining with propidium iodide. Apoptosis was assessed
using cell deathELISAkit. The effect of TQonp53, p21, Bcl-2 protein expression
was determined using Western blot analysis while TGF mRNA expression was
determined by RT-PCR. Results: At non-cytotoxic concentrations of TQ, it re-
sulted in inhibition of proliferation in a dose dependant manner. Flow cytomet-
ric analysis revealed a shift in the cell cycle distribution to the PreG1 phasewhich
is a marker of apoptosis. Also TQ increased DNA fragmentation. TQ mediated
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its anti-proliferative effect and apoptosis induction by an up-regulation of
TGF1, p53 and p21 and a down-regulation of TGF- and Bcl-2. Conclusion:
Thymoquinone showed antiproliferative and proapoptotic potentials in ATL
cells. For this reason, further research is required to investigate its possible ap-
plication in the treatment of ATL.
#4302 Disulfıram possesses antitumor activity and inhibits cancer stem-
like properties via inhibition of STAT3 activation in triple-negative breast
cancer cells.Yoon-JaeKim,NahyunLee, EunhyeOh,Daeil Sung, Tae-MinCho,
Ji Young Kim, Jae Hong Seo. Korea University, Seoul, Republic of Korea.
Disulfıram (DSF), a clinically used treatment for alcohol dependence, is con-
sidered as a potential anti-cancer agent due to its cytotoxicity inmany cancer cell
types on copper (Cu)-dependent processes. However, the molecular mecha-
nisms underlying DSF-induced antitumor activity in triple-negative breast can-
cer (TNBC) are still poorly understood.Here, we hypothesized thatDSF induces
antitumor effects by targeting cancer stem cells (CSCs) and STAT3 signaling in
TNBC.We then examined the effects of DSF in combination with Cu on the cell
viability and apoptosis, cell proliferation and survival, as well as CSC-like prop-
erties in MDA-MB-231 and 4T1 TNBC cell lines. DSF/Cu effectively induced
cytotoxicity and apoptotic cell death, concomitant with caspase-3 activation and
PARP cleavage. DSF/Cu also signifıcantly suppressed cell migration and mam-
mosphere formation, which are accompanied by a remarkable decrease in the
CD44/CD24- (or CD49f/CD24 in mouse 4T1 cells) stem-like population
and ALDH1 activity. These effects were functionally associated with the inhibi-
tion of STAT3 phosphorylation (Tyr705). Furthermore, DSF/Cu treatment re-
sulted in the downregulation of cyclin D1 and survivin expression, which are
downstream targets of STAT3 signaling. Interestingly, phosphorylated STAT3
and STAT3 downstream signaling were highly upregulated in the mammo-
spheres, and these upregulated molecules were signifıcantly decreased by
DSF/Cu treatment. In MDA-MB-231-derived xenograft model, DSF adminis-
tration elicited a signifıcant reduction in tumor growth with a noticeable down-
regulation of CD44, ALDH1 and phosphorylated STAT3 levels. Taken together,
our results suggest that therapeutic treatment to DSF can effectively manifest
antitumor activity by reducing CSC-like properties, and that STAT3 could be a
key molecule of aggressive TNBC that is targeted by DSF.
#4304 Feedback-phosphorylation ofMKK4 byMAPKs promotes apopto-
sis.HisashiMoriizumi.The Institute ofMedical Science, TheUniversity of Tokyo,
Tokyo, Japan.
Feedback-phosphorylation of MKK4 by MAPKs promotes apoptosis Morii-
zumi Hisashi, Takanori Nakamura and Mutsuhiro Takekawa Div. of Cell Sig-
naling andMol. Med., IMS, Tokyo Univ. Themitogen-activated protein (MAP)
kinase pathway is an important system for cellular responses to extracellular
stimuli. Each of the MAPK pathways is composed of MAPKKK, MAPKK and
MAPK. In mammalian cells, at least three subfamilies of MAPKs, namely ERK,
p38 and JNK, are present. The ERK pathway is activated in response to mito-
genic stimuli andplays a key role in proliferation anddifferentiation. In contrast,
the p38 and JNK pathways [collectively called stress-activated protein kinase
(SAPK) pathways] regulate cellular stress responses such as apoptosis and cell
cycle arrest. MKK4 is unique among the members of the mammalian SAPKK
family (i.e., MKK3/4/6/7) in its ability to phosphorylate and activate both p38
and JNK. Interestingly, inactivatingmutations of theMKK4 gene are frequently
found in many types of cancer. Although MKK4 has been suggested as a tumor
suppressor, the molecular mechanism by which MKK4 inhibits tumorigenesis
remains unclear. Here we demonstrate that MKK4 can be phosphorylated at
specifıc serine and/or threonine residues by downstream MAPKs(named the
“feedback-phosphorylation”) and thereby regulates stress-induced apoptotic
cell death. By generating antibodies specifıc to these phosphorylation sites, we
found that under stress conditions both Thr and Ser residues of MKK4 were
phosphorylated by JNK, while only the Ser residue was phosphorylated by ERK
in response tomitogenic stimuli. In order to clarify physiological signifıcance of
the feedback-phosphorylation, we then generated a phosphorylation-defıcient
mutant of MKK4 (MKK4-AA) by substituting both Thr and Ser residues with
Ala. Although the feedback-phosphorylation did not affect the enzymatic activ-
ity, stability and subcellular localization ofMKK4,we found that cells expressing
MKK4-AA mutant suppressed apoptosis induced by various stresses stimuli
such asUV irradiation and anticancer drug treatment. These results suggest that
feedback-phosphorylation of MKK4 regulates stress-induced apoptosis. More-
over, we are currently investigating the mechanism of how MKK4 affects apo-
ptotic cell death in response to feedback-phosphorylation.
#4305 Iron accumulation in clear cell renal cell renal cell carcinoma and
effects of iron deprivation on HIF2- expression and cell survival. Christo-
pher J. Greene, Nitika J. Sharma, Gary J. Smith, Kenneth W. Gross, Bo Xu, Eric
C. Kauffman. Roswell Park Cancer Inst., Buffalo, NY.
PURPOSE: The von Hippel Lindau (VHL)/hypoxia inducible factor-alpha
(HIF-) pathway is commonly dysregulated in clear cell renal cell carcinoma
(ccRCC) and potentially exacerbated by oxidative stress. Iron is the most abun-
dant heavymetal in the human body and is required for nephrogenesis in utero;
it is also a major source of intracellular oxidative stress capable of inducing
ccRCC in rodent models. Recently, iron was shown to stabilize HIF2- tran-
script by inhibiting iron regulatory protein 1. Still, a role for iron in human
ccRCC remains largely unexplored. We tested the hypotheses that intracellular
iron is accumulated in human ccRCC cells and that iron deprivation can sup-
press HIF2- expression and ccRCC cell growth. METHODS: Over 1500 core
sections from 587 tissues (272 primary tumors, 240 benign kidney, 75 metasta-
ses) of 288 RCC patients were stained and scored for levels of iron and the
primary iron uptake protein, transferrin receptor 1 (TfR1), using Prussian Blue
and immunohistochemistry, respectively. 178 cores from 14 different body tis-
sues of non-cancer patients were stained as controls. Staining levels were tested
for association with patient features and outcomes. TfR1 protein expression was
further evaluated in 4 ccRCC and 2 benign renal epithelial cell lines by flow
cytometry and western blot. Micromolar concentrations of 3 clinical iron che-
lator drugs, deferoxamine (DFO), deferiprone (DFP), and deferisirox (DFX),
were tested by MTT assay for effects on ccRCC versus benign renal cell prolif-
eration. DFO effects on cell viability/apoptosis and HIF2- levels were mea-
sured using annexin-V/7-AAD flow cytometry and western blot, respectively.
RESULTS: Intracellular iron was increased in ccRCC tumors compared to be-
nign renal tubule epithelium; although more advanced tumors had smaller in-
creases. Benign renal epithelium expressed higher TfR1 protein levels than any
other tissue site in the body tested, and expression in ccRCC tumors increased
during progression to metastasis and cancer-specifıc death. CcRCC cell lines
had elevated TfR1 expression relative to benign renal cell lines. Iron chelation
using DFO, DFP, or DFX uniformly achieved 80-90% growth reduction in
ccRCC cell lines at clinically utilized concentrations, while benign renal cell lines
were relatively resistant. The mechanism of ccRCC growth inhibition was pri-
marily cell death via apoptosis, whereas benign renal cells had no increased
death even after prolonged iron chelation treatment. Intriguingly, iron chelation
in ccRCC cell lines effectively downregulated HIF2- in a time- and concentra-
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tion-dependent manner. CONCLUSIONS: These data indicate that increases in
intracellular iron content occur during human ccRCC tumorigenesis and sup-
port further investigation of iron chelation as a novel therapeutic strategy for
targeting HIF2- and inducing cancer cell death in ccRCC patients.
#4306 Combined effects of chemotherapy to reduce metastasis caused by
insuffıcient hyperthermia. Tae Hee Lee,1 Jiyoon Bu,2 Byoung Hyuck Kim,3
Young Jun Kim,2 Yoon-Tae Kang,2 Jung Eun Moon,4 Young-Ho Cho2. 1Cell
Bench Research Center (SEMCELL), Daejeon, Republic of Korea; 2KAIST, Dae-
jeon, Republic of Korea; 3Seoul National University College of Medicine, Seoul,
Republic of Korea; 4Armed Forces Medical Research Institute, Daejeon, Republic
of Korea.
Hyperthermia therapy is one of the most widely studied non-surgical meth-
ods for breast tumors, which eliminates tumor by inducing acute stress on tumor
cells. However, it has been extensively known that the viability of the tumor cells
is highly influenced by the applied temperature. Insuffıcient thermal stress dur-
ing hyperthermia treatments may alter tumormicroenvironment by promoting
epithelial to mesenchymal-like transition (EMT) and as a result, enhancing the
outgrowth of residual tumor cells. Therefore, cells that have survived from sub-
lethal thermal stress and experienced EMTmay cause substantial clinical prob-
lems. In this case, hyperthermia requires additional therapy in order to promote
cell death ofmore invasive tumor cells that have resisted to the thermal stimulus.
In this study, we confırmed that the co-treatment of chemotherapy with hyper-
thermia may overcome the phenotypical transition caused by insuffıcient heat
treatment. After exposing breast cancer cells (MCF-7) into two different tem-
perature conditions (42°C and 47°C) for an hour, we have verifıed that 10.51	
1.71% and 18.27	 10.66% of cells experienced apoptosis or necrosis when the
cells were exposed to 42°C and 47°C, respectively. At the same time, cancer cells
showed higher invasiveness, spear-like morphology, and enhanced migratory
behaviors as the exposed temperature increases, which is mainly shown among
the cells that have experienced EMT. Furtherwestern blot assay and quantitative
real-time polymerase chain reaction (qRT-PCR) using mesenchymal marker
(vimentin) and epithelial marker (E-cadherin) also support that the mesenchy-
mal-like phenotype has been highly increased on the cells that have resisted to
the thermal stress. However, when chemotherapy was conducted after the heat
treatment, cell viability was highly reduced. Paclitaxel (11.7 nM), cisplatin (3.3
M), and combination of two anticancer drugs were treated for 24 hours on the
cells that have been exposed to different temperatures, respectively. As a result,
death rate of tumor cells has increased from 11.31 to 66.69%. Especially, when
paclitaxel and cisplatin were co-treated, the death rate was up to 73.75	 4.37%
after cells were exposed to 47°C. In conclusion, cancer cells that have survived
from insuffıcient hyperthermia showed high potential to promote metastasis or
recurrence but additional chemotherapy can successfully reduce the side effects
induced by insuffıcient hyperthermia treatment.
#4307 Characterizing the differential phosphorylation of Bim in plasma
cell disorders. Jason E. Conage-Pough, Vikas A. Gupta, Shannon M. Matulis,
Lawrence H. Boise. Emory University, Atlanta, GA.
The pro-apoptotic Bcl-2 family protein Bim is known to be phosphorylated in
response to many stimuli. These phosphorylation events have been linked to
proteasomal degradation, release from dynein light chain, and impacting the
ability of Bim to initiate apoptosis. We’ve recently shown that IL-6 stimulation
of myeloma cells results in phosphorylation of Bim at S69 and S77. IL-6 treat-
ment additionally led to increased association with Mcl-1 at the expense of
Bcl-2/xL. This data, coupled with our longstanding interest in factors that influ-
ence Bim binding to anti-apoptotic proteins, led us to study the baseline phos-
phorylation state of Bim in plasma cell malignancies. To study the global phos-
phorylation of Bim, we utilized PhosTag gel electrophoresis, which allows for
detection of phosphorylated forms of a protein. We’ve shown that Bim is con-
stitutively phosphorylated in myeloma cell lines and patient samples. Impor-
tantly, these cell lines and samples display differences in their distribution of Bim
binding to anti-apoptotic proteins. The pattern of Bim phosphorylation varies
signifıcantly across cell lines, with expression of anywhere from1 to 4 phosphor-
ylated forms. Using the Bax/Bak-defıcient Waldenström Macroglobulinemia
cell line RPCI-WM1, we were able to recapitulate constitutive phosphorylation
in stable cell lines overexpressing Bim. In order to identify and characterize
constitutive Bim phosphorylation sites, we created phospho-mimetic (E) and
unphosphorylateable (A) versions with individual and combination of muta-
tions of seven potential sites—S59, S77, S87, S94, S104, T116 and S118. PhosTag
allowed us to identify individual phosphorylation sites—bymutating individual
sites to A, we could determine if we eliminated phosphorylated Bim bands.
These experiments showed that S118 and S59 are constitutively phosphorylated
in RPCI-WM1. Lastly, we tested whether A and E mutations were affecting the
distribution of Bim among anti-apoptotic proteins and dynein light chain. We
observed thatmutation of the T116 residue to either A or E resulted in increased
binding to Mcl-1, suggesting this amino acid is critical for binding to dynein
light chain, regardless of phosphorylation status. Our results support the pres-
ence of multiple constitutive Bim phosphorylation events, differential signaling
and regulation of Bim across a spectrumof plasma cell disorders, and a potential
mechanism underlying the preferential binding of Bim. Characterization of the
signaling cascades regulating these events may provide novel insights into im-
proving therapies for cancer. The effıcacy of drugs such asNavitoclax andVene-
toclax can be improved by coupling them with kinase inhibitors that can either
mobilize Bim from dynein light chain or alter its affınity for anti-apoptotic
proteins.
#4308 Cordycepin induces apoptosis by caveolin-1-mediated JNK regula-
tion of Foxo3a in human lung adenocarcinoma cells. Eunbi Jo,1 Hyun Jin
Jang,2 Ik-Soon Jang1. 1Korea Basic Science Inst., Daejon, Republic of Korea; 2Ko-
rea Basic Science Inst., Daejeon, Republic of Korea.
Forkhead transcription factor (Foxo3a) is a critical effector of JNK-mediated
tumor suppression. However, it is not clear whether the caveolin-1 (CAV1)-
mediated JNK/Foxo3a pathway is involved in cancer cell apoptosis. We found
that cordycepin upregulates CAV1 expression, which was accompanied by JNK
phosphorylation (p-JNK), and, subsequently Foxo3a translocation into the nu-
cleus, resulting in the upregulation of Bax protein expression. Furthermore, we
found that CAV1 overexpression upregulated p-JNK whereas CAV1 siRNA
downregulated p-JNK. Additionally, SP600125, a specifıc JNK inhibitor, signif-
icantly increased Foxo3a phosphorylation, which attenuated Foxo3a transloca-
tion into the nucleus, indicating that CAV1mediates JNK regulation of Foxo3a.
Foxo3a siRNA downregulated Bax protein and attenuated A549 apoptosis, in-
dicating that theCAV1-mediated JNK/Foxo3a pathway induces the apoptosis of
A549 lung cancer cells. Cordycepin signifıcantly decreased tumor volume in
nude mice. Taken together, these results indicate that cordycepin promotes
CAV1 upregulation to enhance JNK/Foxo3a signaling pathway activation in-
ducing apoptosis in lung cancer cells and support its potential as a therapeutic
agent for lung cancer.
#4309 Modeof actionof LTX315-induced cell death.HENGZHOU,1Allan
Sauvat,1 Sylvère Durand,1 Sabrina Forveille,1 Takahiro Yamazaki,1 Sylvie Sou-
quere,1 Valentina Sica,1 Øystein Rekdal,2 Oliver Kepp,1 Guido Kroemer1. 1Insti-
tute Gustave Roussy, Villejuif, France; 2Lytix Biopharma, Norway.
The experimental anticancer agent LTX-315 is an amphipathic cationic pep-
tide that effıciently eradicates cancer cells in vitro and in vivo. Attracted by its
effıcacy we launched an in depth mechanistic study on LTX-315. First we fo-
cused on the mode of action of LTX-315 and found that the agent failed to
induce morphological signs of apoptosis but evoked necrotic phenotypes. Ac-
cordingly, LTX-315 failed to stimulate the activation of caspases, and the pan-
caspase inhibitor Z-VAD-fmkwas unable to reduce cell killing.We then studied
its subcellular localization by fractionation of LTX-315-treated cells, and re-
vealed that the agent was enriched in mitochondria and caused an immediate
arrest of mitochondrial respiration without any major uncoupling effect. LTX-
315 disrupted the mitochondrial network, dissipated the mitochondrial inner
transmembrane potential, and caused the release of mitochondrial intermem-
brane proteins into the cytosol. Cells lacking the two pro-death multidomain
proteins BAX and BAK, were less susceptible to LTX-315-mediated killing.
Moreover, cells engineered to lose their mitochondria were resistant against
LTX-315, underscoring the importance of this organelle for LTX-315-mediated
cytotoxicity. Further, we observed that LTX-315 induced all known character-
istics of immunogenic cell death, including calreticulin exposure, ATP secre-
tion, HMGB1 exodus and type-1 interferon induction. When injected into es-
tablished cancers, LTX-315 caused a transiently hemorrhagic focal necrosis that
was accompanied bymassive release of HMGB1 (from close-to-all cancer cells),
as well caspase-3 activation in a fraction of the cells. Collectively, these results
support the idea that LTX-315 triggers unregulated necrosis, and kills cancer
cells by virtue of its capacity to permeabilize mitochondrial membranes. In ad-
dition, LTX-315 can induce ICD, hence explaining its capacity to mediate im-
mune-dependent therapeutic effects.
#4310 SH003 induces apoptosis of DU145 prostate cancer cells by inhib-
iting ERK-involved pathway. Yu-Jeong Choi, Myeong-Sun Kim, Soo-Yeon
Kang, Kangwook Lee, Jin Mo Ku, Se Hyang Hong, Hyo In Kim, Chunhoo
Cheon, Youme Ko, Huang Ching Wen, Yui Sasaki, Sohyeon Kang, Tai Young
Kim, Ji HyeKim, YongCheol Shin, Seong-GyuKo.KyungHeeUniversity, Seoul,
Republic of Korea.
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Herbal medicines have been used in cancer treatment, with many exhibiting
favorable side effect and toxicity profıles compared with conventional chemo-
therapeutic agents. SH003 is a novel extract from Astragalus membranaceus,
Angelica gigas, and Trichosanthes Kirilowii Maximowicz combined at a 1:1:1
ratio that impairs the growth of breast cancer cells. Our data demonstrate that
SH003 induced apoptosis in DU145 prostate cancer cells by inhibiting ERK
signaling. SH003 induced apoptosis of prostate cancer cells in dose-dependent
manner, whichwas independent of androgendependency. SH003 also increased
intracellular ROS levels but this is not associated with its pro-apoptotic effects.
SH003 inhibited phosphorylation of Ras/Raf1/MEK/ERK/p90RSK in andro-
gen-independent DU145 cells, but not androgen-dependent LNCaP and PC-3
cells. Moreover, ERK2 overexpression rescued SH003-induced apoptosis in
DU145 cells. Thus, our data conclude that SH003 induces apoptotic cell death of
DU145 prostate cancer cells by inhibiting ERK-mediated pathway.
#4311 Targeting specifıc regulatory subunits of protein phosphatase 1
phenocopies estrogen-induced apoptosis. Catherine Sevigny, Surojeet Sen-
gupta, Kerrie B. Bouker, Robert Clarke. Georgetown Lombardi Comp. Cancer
Ctr., Washington, DC.
The growth of estrogen receptor positive (ER) breast cancers is considered
to be dependent on estrogen and its actions can be blocked by selective estrogen
receptor modulators (SERMS), like tamoxifen, or by inhibiting the synthesis of
estrogen, by aromatase inhibitors (AIs). Both of these classes of drug are used to
treat ER breast cancers in the clinic. Paradoxically, before the discovery of
SERMs and AIs, high dose estrogen was the choice of endocrine therapy to treat
post-menopausal breast cancers. Recent clinical trials have confırmed a 30%
clinical benefıt rate with high, as well as low, doses of estrogen therapy in AI-
resistant breast cancers. However, the underlyingmechanismbywhich estrogen
triggers the tumor regression remains unknown. Using an in vitro cell model
MCF7:5C cells, that undergo estrogen-induced apoptosis, we demonstrate that
sustained phosphorylation of eukaryotic initiation factor 2-alpha (eIF2-), a
downstream target of PERK activation, is crucial in estrogen-induced apoptosis.
Growth arrest and DNA damage inducible-34 (GADD34) and constitutive re-
pressor of eIF2 phosphorylation (CReP) are two regulatory subunits of protein
phosphatase 1 (PP1) complex, that provides substrate specifıcity towards eIF2,
and are responsible for its de-phosphorylation. Our results show that pharma-
cological inhibition of GADD34 and CReP, or their genetic depletion, can en-
hance the phospho-eIF2 (p-eIF2) levels and promote apoptosis. Elevated
levels of p-eIF2 attenuated global translation but preferentially allowed high
expression of activating transcription factor 4 (ATF4) and C/EBP homologous
protein (CHOP) that are involved in apoptosis. Both estrogen and inhibition of
GADD34 and CReP promote apoptosis by an identical mechanism. Impor-
tantly, inhibition of GADD34 andCReP induced apoptosis in another estrogen-
independent breast cancer cell line, LCC9, which is resistant to both tamoxifen
and fulvestrant but does not undergo estrogen mediated apoptosis. Overall, our
study provides crucial evidence that inhibiting specifıc regulatory subunits
(GADD34 and CReP) of PP1 complex, can mimic estrogen-induced apoptosis
in breast cancer cells that are not susceptible to estrogen mediated apoptosis.
Therefore, GADD34 and CReP can be targeted for potential therapeutic inter-
vention in endocrine therapy resistant breast cancers.
#4312 Targeting FoxM1 in inducing anticancer effects in triple-negative
breast cancer cells.Rong Bu, Abdul K. Siraj, Maqbool Ahmed, Fouad Al-Dayel,
Khawla S. Al-Kuraya. King Faisal Specialist Hospital & Res. Ctr., Riyadh, Saudi
Arabia.
Triple-negative breast cancer (TNBC) is highly aggressive and a major threat
to survival due to absence of molecular targets. Invasion, metastasis and
chemoresistance are the greatest obstacles to the successful tumor treatment in
breast cancer patients. In this study, over-expression of Forkhead box transcrip-
tion factor M1 (FoxM1) was observed in 79% (770/975) of breast cancers from
Saudi Arabia. FoxM1 over-expressionwas found to be an independent prognos-
tic marker in multivariate analysis in late stage (Stage 3 and 4) breast cancer
(p0.0110). Our in vitro results show that treatment with thiostrepton, a dual
FoxM1 and proteasome inhibitor caused cell viability loss and induce apoptosis
in a dose dependent manner in triple-negative breast cancer cell lines. Thio-
strepton treatment also inhibited colony formation and invasion/migration ca-
pabilities of triple-negative breast cancer cells. In vivo, thiostrepton treatment
regressed TNBC cells;MDA-MB-231 generated xenografts via down-regulation
of FoxM1 and its downstream targets. Altogether, our results suggest that
FoxM1 and its associated signaling pathway may be a potential target for ther-
apeutic intervention in the treatment of aggressive breast cancer. Key words:
Triple-negative breast cancer, FoxM1, Apoptosis and Invasion.
#4313 Protein synthesis modulates paraptotic death induced by inhibi-
tion of cyclophilins in glioblastoma (GBM) cells. LinWang, JustinGundelach,
Richard Bram.Mayo Clinic School of Medicine, Rochester, MN.
In this study, we investigated the mechanisms underlying cell death induced
by the small molecule cyclophilin inhibitor NIM811. NIM811 effectively killed
GBM cells through a non-apoptotic pathway, as there was no nuclear shrinkage
or caspase activation. Instead, death was preceded by dramatic cytosolic vacu-
olization, stemming from enlargement of the endoplasmic reticulum (ER).
RNA-seq revealed upregulation of genes pertinent to the unfolded protein re-
sponse (UPR) and autophagy. Western blotting for UPR and autophagy medi-
ators also supported a transient UPR signaling and compromised autophagy
during prolonged NIM811 treatment. By utilizing a bicistronic reporter plas-
mid, we independently quantitated Cap-dependent and Cap-independent
translation. We further assessed the long-term effects mediated by different
short-term paraptosis inhibitors via colony formation assay. We fınd that
NIM811 initiates paraptosis in GBM cells, due to an abnormal upregulation of
protein translation that caused accumulation of misfolded or unfolded proteins
in ER. Transient activation of pro-survival autophagy and UPR signals were
shutdown during prolonged treatment withNIM811, thus allowing cell death to
occur. Cycloheximide was previously reported by others to suppress paraptosis.
In our studies, we fınd instead that it temporarily delayed vacuole formation, but
actually enhanced paraptotic cell death in the long term. The mTOR inhibitors
rapamycin or torin-2 rescued cells fromNIM811 induced paraptosis by sustain-
ing autophagy and the UPR, and specifıcally restrained cap-dependent transla-
tion.We propose that ER vacuolization could be a protective response generated
by cells to isolate defective proteins within the ER in order to prevent misfolded
aggregates to interfere with cellular homeostasis. For that reason, simply inhib-
iting vacuole formation without clearing protein accumulation in the ER was
insuffıcient to prevent cell death. These fındings aid our understanding of cellu-
lar mechanisms that contribute to non-apopotic death. Moreover, this work
underlines the importance of evaluating cellular responses in cell death experi-
ments over multiple time frames to judge the true impact.
#4314 Exclusive delivery of mazF in cancer cells by Listeria monocyto-
genes.Maryam Saffarian, Jeremy Tzeng. Clemson University, Clemson, SC.
Programmed cell death (PCD), an active process that leads to cell suicide, is a
critical mechanism in every organism. MazF, a bacterial ribonuclease protein,
can trigger PCD in bacterial cells and also induce Bak-dependent apoptosis in
mammalian cells. This bacterial ribonuclease cleavesmRNAs at ACA sequences
leading to inhibition of protein synthesis in cells. Hence, we hypothesized that
the overexpression ofMazF proteins in cancer cells could result in the induction
of apoptosis. In the present study, the ACA-less mazF gene was inserted down-
stream of the Internal Ribosome Entry Site (IRES) and under the control of T7
promoter. The plasmidwas electroporated into Listeriamonocytogenes harbor-
ing pCSA1 that encodes T7 RNA polymerase under the control of the listeria
actA promoter. Subsequently, the bacteria were functionalized with Trastu-
zumab (Herceptin®) to deliver the mazF mRNA into HER2/neu breast cancer
cells. The results showed that MazF protein has an ability to induce apoptosis in
HER2/neu breast cancer cells. This fınding is the fırst report of the application
and delivery of MazF as an anti-cancer agent for the induction of apoptosis in
HER2/neu breast cancer cell line. This research suggests cancer therapy that
targets only cancer cells but not healthy cells and offers more advantages, e.g.,
inexpensiveness, target tissue specifıcity, easy and safe delivery, in comparison
to other gene therapy vectors or direct protein administration.
#4315 PTBP1modulation ofMCL1mRNA regulates sensitivity to antitu-
bulin chemotherapeutics.William J. Placzek, Jia Cui.Univ. of Alabama at Bir-
mingham, Birmingham, AL.
Background: Myeloid Cell Leukemia 1 (MCL1), an anti-apoptotic Bcl-2 fam-
ily protein, is a key regulator of intrinsic apoptosis. Normal cells require strict
control over MCL1 expression and aberrant MCL1 expression has been shown
linked to the emergence of various diseases and chemoresistance. Previous stud-
ies have detailed how MCL1 expression is regulated by multiple mechanisms
both transcriptionally and translationally. However, characterization of the
post-transcriptional regulators ofMCL1mRNA is limited. Polypyrimidine tract
binding protein 1 (PTBP1) is a known regulator of post-transcriptional gene
expression that can control mRNA splicing, translation, stability, and localiza-
tion. In the described studywe characterize the impact that PTBP1 has onMCL1
expression, its molecular mechanisms, and its roles on cellular apoptosis. Meth-
ods: Cross-linking Immunoprecipitation (CLIP)-seq data analysis andRNA im-
munoprecipitation (RIP) were performed to analyze protein interactions with
RNA andmap the RNAbinding sites on the genes of interests. RNAhalf-life was
measured by treating cells with Actinomycin D and extracting total RNA at
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different time point. Cell viability wasmeasured by theMTS assay and apoptosis
was assessed by Annexin V/Propidium Iodide (PI) staining followed by flow
cytometry analysis. Results: Our studies demonstrate that PTBP1 binds to
MCL1mRNA and that knockdown of PTBP1 up-regulates MCL1 expression in
cancer. Mechanistically, PTBP1 silencing stabilizes MCL1mRNA and increases
MCL1 mRNA accumulation in cytoplasm. We further identify that this post-
transcriptional regulation is mediated by microRNAs and Argonaute2 (Ago2).
Moreover, we show that PTBP1 down-regulation is anti-apoptotic to antitubu-
lin chemotherapeutics in a MCL1-dependent manner. Conclusions: Our fınd-
ings suggest that PTBP1 is a novel post-transcriptional regulator of MCL1
mRNA by which it controls apoptotic response to antitubulin chemotherapeu-
tics.
#4316 MCL-1 inhibition ameliorates the expansion of human leukemia in
a dose dependent fashion.Haley E. Ramsey,1 Melissa A. Fischer,1 Taekyu Lee,2
Agnieszka E. Gorska,1 Pia Arrate,1 John Sensintaffer,2 Leah Hogdal,2 Edward
Olejniczak,2 Stephen Fesik,2Michael R. Savona1. 1Vanderbilt UniversityMedical
Center, Nashville, TN; 2Vanderbilt University, Nashville, TN.
Myeloid cell leukemia-1 (MCL-1) is a prosurvival BCL-2 familymember pro-
tein commonly overexpressed in cancer, including hematologic malignancies.
The successful use of BH3 mimetics against other anti-apoptotic proteins has
validated the potential of this line of therapy in hematologicmalignancies. How-
ever, targeting BCL-2 family members, like MCL-1, with a small molecule in-
hibitor is challenging because these inhibitors mediate their effects through
protein-protein interactions. Recently, we discovered potent (sub nM), selective
small molecule MCL-1 inhibitors that exhibit cell-based activity and slow the
growth of tumors in multiple mouse models. To determine tumor cell depen-
dence on specifıc BCL2-familymembers, we employed BH3 profıling on a panel
of myeloid tumor cells to reveal mitochondrial outer membrane permeabliza-
tion (MOMP) in a cytochrome C release assay. Additionally, we determined
growth inhibition of these cell lines in the presence of the potent MCL-1 inhib-
itor. These assays indicatedMV-411 cells were dependent onMCL-1 and sensi-
tive toMCL-1 inhibitionwith aGI50100nM.After cell line profıling, we began
in vivo studies with the MCL-1 inhibitor in a systemic AML xenograft model.
NSGS mice were sublethally irradiated and administered MV-411 cells intrave-
nously. Engrafted mice received the MCL-1 inhibitor in 3 different doses (vehi-
cle vs 10, 25 and 75mg/kg) daily via intraperitoneal injection. During treatment,
the kinetics of MV-411 expansion was monitored via flow cytometry for the
detection of human AML in the blood. At approximately 4 weeks after trans-
plant, the vehicle mice became moribund, and all experimental groups were
sacrifıced for analysis of chimerism. Signifıcant decreases in leukemic expansion
were evident in the bone marrow (25 and 75mg/kg vs vehicle, P .01, P.001)
and spleen (vehicle vs. 75mg/kg, P.001) of treated mice in a dose-dependent
fashion. MCL-1 blockade also eliminated splenomegaly in MCL-1 inhibitor
treated mice. Successful use of the BCL-2 inhibitor, venetoclax, as a single agent
and in combination with DNA methyltransferase inhibitors or low dose ara-C
has proven the powerful role BH3mimeticsmay play inAML therapy.However,
mediation of resistance via alternative BCL-2 family antiapoptotic proteins re-
mains a concern, and development of suitable inhibitors ofMCL-1 and BCL-XL
is important. These data show that we have developed a potentMCL-1 inhibitor,
with in vivo effıcacy in anAMLmousemodel. Further studies can determine the
potential use of this drug to overcome resistance in the clinic. In addition,wewill
employ dynamic BH3profıling of patient samples to determine the combination
and sequencing of therapeutically applied BH3 mimetics.
#4317 EGLN1/c-Myc induced lymphoid-specifıc helicase inhibits ferrop-
tosis through lipid metabolic gene expression changes. Yongguang Tao, Sh-
uang Liu, Yiqun Jiang. Central South University, China, China.
Ferroptosis has emerged as a new formof non-apoptotic cell death inmultiple
human diseases. However, the epigenetic mechanisms of ferroptosis remain
poorly defıned.We demonstrate that Lymphoid-specifıc helicase (LSH), a DNA
methylationmodifıer, interacts withWDR76 to inhibit ferroptosis by activating
lipid metabolism-associated genes, including GLUT1, and ferroptosis related
genes SCD1 and FADS2. These effects are dependent on iron and lipid reactive
oxygen species. We further show that EGLN1 and c-Myc directly activate LSH
expression by inhibiting HIF-1. Finally, we demonstrate that LSH functions as
an oncogene in lung cancer in vitro and in vivo. Therefore, our study elucidates
the molecular basis for a c-Myc/EGLN1-mediated induction of LSH expression
to inhibit ferroptosis, which can be exploited for the development of therapeutic
agents to target ferroptosis in cancer.
#4318 Role of Bcl-2 in hematological cancer formation.Abigail V. Fortier,1
Ally Koh,1 Lisa Stanovski,1 Alisa Kepner,1 Supriya Jain,1 Misha Ul-Islam,1 Ellie
Walter,1 Lawrence Boise2. 1Walton High School, Marietta, GA; 2Emory Univer-
sity, GA.
B cell leukemia/lymphoma 2 (BCL-2) is a 26 kilodalton, amphipathic, anti-
apoptotic protein located on the outer mitochondrial membrane. BCL-2 inter-
acts with other anti-apoptotic and pro-apoptotic factors in order to regulate
apoptosis. If a structural change occurs on the BCL-2 gene, overexpression of the
BCL-2 protein can result. This causes a change in the ratio of BCL-2 to its BCL-2
Homologous 3 (BH3) ligands, preventing the release of the apoptotic signal. The
primary change associated with BCL-2 overexpression in lymphomas is a t(14;
18) chromosomal translocation, which causes an increase in BCL-2 transcrip-
tion. The upregulation of the oncogene allows for the survival of the mutated B
cells by raising the apoptotic threshold, which then dislodges regular lympho-
cytes in the bone marrow or lymph nodes. Lack of cell death due to overexpres-
sion of BCL-2 has been linked to hematological malignancies, specifıcally lym-
phomas andmyelomas. Both B-lymphocytic cancers can result from alterations
of the immunoglobulin heavy chain locus on chromosome 14. While BCL2
translocation can cause Follicular Lymphoma, BCL2 over-expression is ob-
served in many other tumor types and likely contributes to cancer progression
and drug resistance in these tumors. Treatments to inhibit BCL-2 include at-
tempts at activation and overexpression of the pro apoptotic BH3 proteins,
BCL-2AssociatedXProtein (BAX) andBCL-2AssociatedK protein (BAK), and
creation of BH3mimetics. Indeed, the FDA approved the BCL2 inhibitor Vene-
toclax (ABT-199) earlier this year for the treatment of Chronic Lymphocytic
Leukemia. These treatments could help cause cancer cell death by binding to
targeted anti-apoptotic proteins and causing the signal for apoptosis to be re-
leased. This could neutralize the cancerous effects of the BCL-2 oncogene up-
regulation.WaltonHigh School SMART (StudentsModelingAResearchTopic)
Team used the computer program JMOL to create a 3D printedmodel of BCL-2
and composed a review poster of our secondary research to investigate and
demonstrate the relationship between the structure and function of this mole-
cule.
#4319 Analysis of Bcl-2 familymembers and protein-protein interactions
using novel multiplex immunoassays. Reeti Maheshwari, Melissa Schluter,
Danielle Pepin, Joseph Hwang.Millipore Sigma, St Charles, MO.
Bcl-2 family members play a very important role in intrinsic apoptotic path-
ways. The family consists of more than 17 members that can be functionally
separated into pro-apoptotic and anti-apoptotic subfamilies. Interactions be-
tween these family members determine cell fate, and dysregulation can lead to
tumor growth and tumor cell survival. There are several investigational drugs for
cancer treatment targeting Bcl-2 family members in clinical trials, driving the
need for robust assays to measure Bcl-2 family members and their interactions.
Though existing assays measure Bcl-2 family members, there is a lack of reliable
assays to evaluate total proteins and protein-protein interactions simultane-
ously. To address this issue, we have developed two Luminex®-based multiplex
immunoassay panels that allow for the simultaneous detection of multiple com-
ponents of the Bcl-2 family in a single well, including Total Bcl-2, Bcl-xL,Mcl-1,
BAD, BIM, and BAX as well as protein interactions like NOXA/Mcl-1, Mcl-1/
BIM, and Bcl-xL/BAD. Using these panels, we analyzed changes in the expres-
sion and interactions of Bcl-2 family members in response to known apoptotic
drugs, including Camptothecin (topoisomerase inhibitor), Anisomycin (pro-
tein translation inhibitor), and AT101 (BH3 mimetic drug). Camptothecin and
Anisomycin each elicited a signifıcant decrease in the levels of Mcl-1. Addition-
ally, the Mcl-1/BIM interaction was disrupted by both Camptothecin and Ani-
somycin, perhaps a consequence of the reduced Mcl-1 levels. However, expres-
sion of the other anti-apoptotic proteins was unaffected by any of the three
drugs. Interestingly, all three treatments had different effects on the Mcl-1/
NOXA interaction. Mcl-1/NOXA signal was increased by AT101, decreased by
Anisomycin, and showed a dose dependent effect with Camptothecin. In con-
trast to their disparate effects on the Mcl-1/NOXA interaction, all three drugs
acted in a similar manner in blocking the Bcl-xL/BAD interaction without af-
fecting the total levels of either protein. Overall, these results illustrate the dy-
namic responses of the Bcl-2 family to apoptosis-inducing drugs. The novel
multiplex immunoassays describedhere provide a powerful tool for studying the
underlying mechanisms regulating the Bcl-2 family of proteins.
#4320 The Survivin-targeting miR-542-3p overcomes erbB3 signaling-
mediated chemo-resistance and enhances the antitumor activity of paclitaxel
against erbB2-positive breast cancer. Hui Lyu,1 Shuiliang Wang,2 Jingcao
Huang,3 Bolun Wang,1 Bolin Liu1. 1University of Colorado Denver/AMC, Au-
rora, CO; 2Fuzhou General Hospital, China; 3West China Hospital, China.
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Elevated expression of erbB3 interacts with erbB2 in breast cancer cells to
confer chemo-resistance via induction of Survivin. However, the underlying
mechanism of erbB3 signaling-induced upregulation of Survivin remains elu-
sive. Ectopic expression or downregulation of erbB3 in erbB2-positive breast
cancer cells did not alter Survivin mRNA levels and had no signifıcant effect on
Survivin protein stability. We thus hypothesize that the erbB3 signaling modu-
lates certain miRNAs that target Survivin to influence its protein translation.
Here we showed that overexpression of erbB3 decreased and specifıc knock-
down of erbB3 enhanced expression of two Survivin-targeting miRNAs, miR-
203 and miR-542-3p in breast cancer cells. While the specifıc inhibitor of either
miR-203 or miR-542-3p clearly attenuated an anti-erbB3 antibody (Ab)-medi-
ated reduction of Survivin, a more profound effect on Survivin expression was
observed with inhibition of miR-542-3p than miR-203 inhibition. Consistently,
miR-542-3p mimic was much more effective than miR-203 mimic not only to
downregulate Survivin, but also to enhance paclitaxel-induced apoptosis in the
otherwise paclitaxel-resistant breast cancer cells. Moreover, using a murine tu-
mor xenografts model established from a human breast cancer cell line express-
ing both erbB2 and erbB3, we discovered that the combinations of miR-542-3p
mimic and paclitaxel, as compared to either agent alone, signifıcantly inhibited
tumor growth in vivo. Collectively, these data demonstrate that the erbB3 sig-
naling upregulates Survivin via inhibition ofmiR-203 andmiR-542-3p in erbB2-
positive breast cancer cells. Since miR-542-3p has three binding sites on the
3=UTR of erbB3 mRNA, the miR-542-3p mimic serves as an excellent replace-
ment therapeutic agent to downregulate Survivin, and thereby signifıcantly en-
hances the antitumor activity of paclitaxel against erbB2-positive breast cancer.
#4321 TNF receptor 2 is essential for RIP1-dependent cell death in refrac-
tory leukemia. Julia Aguadé-Gorgorio,1 ScottMcComb,1 Cornelia Eckert,2Ma-
ria Pamela Dobay,3 Gunnar Cario,4 Caterina Mezzatesta,1 Arend Von Stackel-
berg,2 Martin Stanulla,5 Schrappe Martin,4 Jean-Pierre Bourquin,1 Beat C.
Bornhauser1. 1Univ. Children’s Hospital Zurich, Zurich, Switzerland; 2Charité
Medical University Berlin, Germany; 3Swiss Institute of Bioinformatics, Laus-
anne, Switzerland; 4University Hospital Schleswig-Holstein, Germany; 5Han-
nover Medical School, Germany.
The identifıcation of molecular determinants that regulate sensitivity to spe-
cifıc agents is essential for the development of new therapeutic approaches in
cancer. We have earlier shown that a subset of refractory acute lymphoblastic
leukaemia (ALL) samples respond to SMAC-mimetic (SM) induced IAP deple-
tion by concurrently inducing RIP1-dependent apoptosis and necroptosis.
Comparative gene expression profıling indicated a correlation of sensitivity to
SM with the expression of TNF receptor 2 (TNFR2) in primary ALL. Using an
independent cohort of primary chemotherapy-resistant ALL samples, we found
that presence of high TNFR2 expression identifıed by qPCR predicted ex vivo-
sensitivity to SM. High TNFR2 levels also correlated with higher expression of
TNFR1. Deletion of either TNFR1 or TNFR2 using CRISPR/Cas9 in primary
ALL conferred resistance to treatmentwith SM, indicating that TNFR1 and 2 are
both functionally required for cell death. Concomitant with an important role
for TNFR2 in the response to SM, the overexpression of TNFR2 leads to in-
creased sensitivity to TNF through increased activation of the TNFR1/RIP1
death axis.On themechanistic level, SM induced recruitment of RIP1 toTNFR1,
which was abolished in cells defıcient for TNFR2. Taken together, our data
reveal a novel function of TNFR2 in cell death signalling, as TNFR2 predicts
sensitivity to SMACmimetics and plays a key role in modulating a switch from
RIP1-controlled cell survival to cell death.
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#4322 Exosomal delivery of stroma-derived miR-145 inhibits pancreatic
cancer cell proliferation. Song Han, Sayali Belsare, DongYu Zhang, Mark Bev-
eridge, Carlos Rinaldi, Jose G. Trevino, Thomas D. Schmittgen, Steven J.
Hughes. University of Florida, Gainesville, FL.
We previously reported that within the pancreatic ductal adenocarcinoma
(PDAC) microenvironment, miR-145 and miR-199a are exclusively expressed
in tumor-associated stroma (TAS) cells, but thesemiRNAs are present in PDAC
cells following co-culture with TAS cells. We hypothesized that miRNAs func-
tion as paracrine signals via exosomal exchange between TAS cells and adjacent
PDAC cells. Primary cultures of human TAS and PDAC cells were employed.
Membrane-bound microparticles were isolated from TAS conditioned, serum-
free culture media by sequential ultracentrifugation followed by ultrafıltration.
Exosomes and microvesicles were then assayed for particle size distribution
using nanoparticle tracking analysis and electronicmicroscopy.miRNA expres-
sion levels were determined using quantitative PCR. miRNA transfection was
performedwithRNAiMax reagents. Cell viabilitywasmeasured byAlamarBlue.
Statistics were performed using Prism 6 software. Following transfection of hu-
man TAS cells with cel-miR-39, a nonhuman miRNA, we demonstrated that
miRNA exchanges occurred between TAS cells and neighboring PDAC cells via
a process that is not dependent upon cell-cell contact. We next confırmed the
presence and enrichment of miR-145-5p in TAS-cell-derived exosomes (8-fold
higher concentrations in exosomes than parental cells, p0.05). Feeding of
TAS-derived exosomes or transfection of miR-145-5p mimics into PDAC cells
led to dose-dependent decreases in PDAC cell viability (p0.05). Taken to-
gether, our data suggest that stroma derived exosomes deliver miRNAs to adja-
cent PDACcells andmay function as tumor-suppressing paracrine signals in the
case of miR-145. This fınding provides a potential explanation for the observa-
tion that stroma depletion paradoxically accelerates PDAC progression in mu-
rine models.
#4323 Metabolic reprogramming in acute myeloid leukemia cells by mes-
enchymal stromal cell-derived exosomes induces chemoresistance.Hongyun
Zhao,1 Abhinav Achreja,1 Ziwen Zhu,1 Ahmed N. Rawi,2 Marina Konopleva,2
Michael Andreeff,2 Deepak Nagrath1. 1University of Michigan, Ann Arbor, MI;
2The Univeristy of Texas MD Anderson Cancer Center, Houston, TX.
Mesenchymal stromal cells play an important role in acute myeloid leukemia
(AML) development. Altered cellular metabolism supports AML cells’ survival
in multiple aspects, such as drug resistance. Here, we demonstrate the role of
MSC-derived exosomes inmetabolic regulation of AML cells, and put forward a
combinatorial strategy to sensitize AML cells to chemodrugs. Exosomes se-
creted by MSCs can reprogram the metabolic machinery following their inter-
nalization by AML cells. Through 13C tracing experiments and flux analysis, we
elucidate that MSC-derived exosomes enhance oxidative phosphorylation and
glutamine’s entry into TCA cycle, which replenish the pool of carbon sources in
mitochondria. Further, our work shows that inhibiting the interactions between
MSCs and AML cells by targeting the metabolic regulation exerted by MSC-
derived exosomes sensitizes AML cells to chemodrugs. Taken together, our
work reveals a novel role of the TME in regulating the metabolic adaptation in
AML cells and uncovers the improved strategy for AML therapy.
#4324 Estrogen promotes proliferation and apoptosis of endometrial car-
cinoma cell lines Ishikawa and HEC1A via endometrial stromal cells. Xiang
Tao,1 Jian Wu,2 Yinhua Yu1. 1Ob/Gyn Hospital of Fudan University, Shanghai,
China; 2Shanghai Gongli Hospital, Shanghai, China.
Endometrial carcinoma is the leading malignancies of women in Western
countries and the second leading cancer of female in China. As endometrial
stromal cells (ESCs) are sharply decreased in endometrial carcinoma (EC) com-
pared to normal endometrium, it is interested to explore the roll of ESCs in the
tumorigenesis of endometrium. Unopposed estrogen is considered as the etiol-
ogy of endometrioid carcinoma, but the underlying mechanism is needed to
further explore. This study is to determine the biological effects of primary
cultured ESCs on two endometrial cancer cell lines-Ishikawa andHEC1A. ESCs
from normal, atypical hyperplastic and malignant endometrial specimens were
collected, validated by immunohistochemistry and cultured in vitro, whichwere
maintained in a medium containing 10 nM estradiol (E2) for three months to
simulate the unopposed estrogen stimulation of EC patients. Microarray were
performed to detect the alteration of gene expression, which were then con-
fırmed by real time RT-PCR. Co-culture of ESC and EC cell lines were per-
formed by Transwell plate. Cell proliferation was analyzed by CCK8 assay. Ap-
optosis was analyzed by flow cytometry based on PI/Anexin V staining. Our
results showed E2 promoted the proliferation of three types of ESCs. E2 has no
direct effect on cancer cell lines Ishikawa and HEC1A, but when they co-cul-
tured with ESCs, which were stimulated by E2, the proliferation of cancer cells
was promoted by all three type of ESCs. Moor interestedly, we found that the
much obvious promoted effects were occurred by the ESCs that extracted from
malignant samples. Estrogen could also reduce the apoptosis of both cancer cell
lineswhen co-culturingwith ESCs fromnormal specimen.Genemicroarray and
real time RT-PCR indicated that collagen 9 were up-regulated 2.3 times when
ESCs cells treated by E2. In conclusion, Estrogen altered the microenvironment
of stromal cells, which could lead to the proliferation of endometrial carcinoma
cells via paracrine function. The alteration of collagen synthesis by ESCs might
contribute to this communication between the epithelial andmesenchymal cells.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Cell Death in Cancer
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1105
#4325 The role of tumor cell heterogeneity in the targeted therapy ofALK-
positive neuroblastoma. Jing Li, Penelope M. Or, Andrew M. Chan. Chinese
Univ. of Hong Kong, Shatin, Hong Kong.
Neuroblastoma (NB) is the most common extracranial solid tumor of child-
hood. One of its hallmarks is high histological heterogeneity. The primary tu-
mors are composed of neuroblastic cancer cells, Schwannian stroma and some
infıltrating immune cells. The origin and functions of Schwannian stroma still
remain controversial. It is suggested that they are tumor-infıltrating normal
cells. Studies using Bone Marrow Stromal Cells (BMSCs) or Schwann cells to
mimic Schwannian stroma have shown both tumor promoting or suppression
effects. An alternative hypothesis is that Schwannian cells are derived from can-
cer stem-like cells since they shared the same genetic lesions with neuroblastic
tumor cells. Our laboratory had reported that in the SK-N-SH cell line, both
N-type cells (neuroblastic cells) and S-type cells (Schwann-like cells) shared
almost identical genetic background. These cell linesmay serve as relevantmod-
els to study NB tumor heterogeneity. Genome-wide sequencing for driver on-
cogenes in familial NB uncovered mutations in Anaplastic Lymphoma Kinase
(ALK) gene. ALK point mutations have been found in 8-12% of all NB patients,
and are restricted to the kinase domain. Aberrant activation of ALK signaling,
and its downstream target, PI3K/AKT, STAT3 and ERK1/2, can contribute to
NB tumorigenesis. Thus, ALK is an intensely studied therapeutic target. Sub-
lines of N-type and S-type cells were isolated from an early passage of SK-N-SH.
Surprisingly, over 90% have cell morphology that resembled S-type cells. Se-
quencing analysis revealed that all harbored the same ALK F1174L mutation,
indicating they were tumor-derived. Western blotting analysis showed that N-
type cells, but not S-type cells, expressed ALK protein. This may explain the
insensitivity of S-type cells towards ALK inhibitor, TAE684. Next, co-culture
experiments showed that S-type cells protected N-type cells from apoptosis in-
duced byTAE684.Western blotting analysis showed thatALK,AKTand STAT3
signaling were stimulated in the co-culture. Furthermore, conditioned medium
(CM) from Schwann-like cells activated these downstream signaling molecules
in N-type cells, indicating secreted factors from S-type cells contributed to the
pathway stimulations. As AKT and STAT3 were ALK downstream targets, ALK
ligand could be a potential factor. We further confırmed these results in two
additional ALK WT N-type cell lines, IMR 32 and BE (2)-M17. Co-cultivation
and CM experiments had demonstrated robust STAT3 activation even without
ALK stimulation. Overall, tumor-derived S-type cells could prevent N-type cells
from apoptosis via secreted factors. The signaling involved could be separated
into an ALK-independent STAT3 activation and a ligand-activated ALK-AKT
pathway. Future work will focus on identifying STAT3 stimulators and ALK
ligands in CM of S-type cells. This work was supported by a General Research
Fund grant (#14100514) from the Hong Kong University Grants Committee to
A.C.
#4326 Tissue density can create a carcinogenic microenvironment for
normalmammary epithelial cells. ShayanNazari, PinkuMukherjee.University
of North Carolina at Charlotte, Matthews, NC.
Background: Breast cancer is the most diagnosed cancer and the fourth lead-
ing cause of cancer related mortality among females. Mammographic density
(MD) is defıned by the amount of stromal and epithelial tissues present in the
breast tissue. Fifty percent ofwomenhave highMDand are 4-6 timesmore likely
to develop breast cancer in their lifetime compared to women with low MD.
Additionally, mammograms often miss abnormal lesions in high MD breast
leading to late-stage diagnosis. The stromal microenvironment is characterized
by extracellularmatrix (ECM) reorganization and stiffness, and increase inECM
proteins including collagen I and fıbronectin, which drives proliferation, tumor
cell survival and migration. Expression of fıbronectin and collagen are signifı-
cantly higher in women with high MD compared to women with low MD.
However, the mechanisms underlying the initiation and progression of breast
cancer associatedwithMD remains largely unknown. Therefore, understanding
themolecular pathways involved in the unique transformation of normal mam-
mary cells to cancer cells in a dense microenvironment is an important step in
fınding diagnostic tools and therapeutic targets for prevention and treatment of
breast cancer.We hypothesize that normalmammary epithelial cells behave like
cancer cells in an ECM protein-rich microenvironment by activating pathways
associatedwith tumor growth and survival and contributing to the initiation and
progression of breast cancer. Methods: We conducted an in vitro study, deter-
mining the effects of different concentrations of ECMproteins on the activation
of pro-carcinogenic pathways including theMAPK pathway and the PI3 Kinase
pathway usingWestern blotting analysis. This study helps us understand if there
is a difference in the expression of ERK1/2 signaling and/or PI3 Kinase signaling
in normal mammary cells (hTERT) seeded on culture dish coated with ECM-
proteins (collagen and fıbronectin), compared to a non-coated control. We also
examined morphological changes that can occur in a breast cancer cell line
(HCC1806) that are seeded on ECM-rich coating dishes compared to non-
coated dishes. Results We observed changes in the morphology of breast cancer
cell lines after cells were seeded on increasing concentration of extracellular
matrix coatings using light microscopy. We also observed an increase in the
expression of PI3 Kinase in normal mammary cell lines compared to control
after cells were stressed using hypoxia. Conclusion Collagen and fıbronectin-
rich microenvironment can induce desmoplastic-like phenotype and behavior
for normal mammary cells, which highlights the possible fırst steps in transfor-
mation of normal mammary cells to desmoplastic cells. Given that high MD is
one of the major risk factors for breast cancer development, it is critical to
decipher the molecular mechanisms associated with the high risk.
#4327 Bonemarrow adipocytes drive transcriptional changes in leukemic
blasts to enhance their capacity to derive energy from free fatty acid metab-
olism.Manar Shafat,1 ThomasOellerich,2 SebastianMohr,2 StephenRobinson,1
Dylan Edwards,1 Rachel Piddock,1 Amina Abdul-Aziz,1 Christopher Marlein,1
Matthew Fenech,1 Jeremy Turner,3 Matthew Lawes,3 Lyubov Zaitseva,1 Johna-
than Watkins,1 Kristian Bowles,1 Stuart Rushworth1. 1The University of East
Anglia, Norwich, United Kingdom; 2Goethe University, Frankfurt, Germany;
3Norfolk and Norwich University Hospitals NHS Trust, Norwich, United King-
dom.
Introduction: Most patients diagnosed with acute myeloid leukaemia [AML]
die of their disease and the average age of patients at diagnosis is 72 years. For
this reason, new therapeutic strategies with tolerability in the fragile, less fıt
population is necessary for reducing the mortality rate associated with this dis-
ease. The tumor microenvironment is an emerging target in the search for less
cytotoxic therapies.We have previously shown that the adipocyte component of
the bone marrow (BM) is a key player in blast survival, proliferation and che-
motherapy evasion. In this study, we draw focus onto the status of an adipocyte
rich environment in the context of leukemia and highlight the key players in
regulating leukemic cell metabolism through transport and metabolism of fatty
acids. Objective: We hypothesize that the presence of adipocytes within the
proximity of AML blasts creates a FA rich environment for increased  - oxida-
tion within the blasts. Methods: We used primary AML blasts and normal
CD34 hematopoietic stem cells (HSC) following informed consent
(LRCEref07/H0310/146). Adipocytes were derived from bone marrow stromal
cells (BMSC). Differential expression analysis of RNA sequencing data (GEO
ID: GSE49642, GSE48846) was used to compare respiratory gene signatures of
BM AML blasts, peripheral blood obtained AML and normal CD34 HSC.
Fatty acid binding protein 4 (FABP4) and carnitine palmitoyltransferase 1A
(CPT1A) were identifıed as one of the key genes involved in the lipolysis and
oxidation signature differential expression. Oxygen consumption rate (OCR) of
adipocyte co-cultured blasts and normal CD34 were analyzed using Seahorse
technology. Lentiviral-knockdown of FABP4 and CPT1A were performed on
blasts prior to in vivo xenograftmousemodel injection. Results: Leukemic blasts
showed increased adipocyte lipolysis stimulation compared with normal
CD34 cells. Moreover, adipocytes increased transcriptional activation of
FABP4 and CPT1A in malignant blasts compared to CD34 HSC. FABP4 in-
hibitor reduced AML blast survival when cells were cultured with adipocytes
which is in contrast to normal CD34 HSC. Moreover, AML had increased
oxygen consumption rate when grown on adipocytes which was inhibited by
etomoxir ( - oxidation inhibitor). Finally in-vivo lentiviral mediated knock-
down of FABP4 and CPT1A reveled an increased survival of AML xenografts.
Conclusion: Our results show that the stimulation of lipolysis and fatty acid
oxidative genes that contribute to the genetic signatures of these processes are a
malignant blast exclusive profıle. Interventions at a molecular level reveal sur-
vival favorable outcomes in xenograftmodels suggesting the need for enhancing
strategies which include targeting the FABP4 andCPT1A axis. Our data provide
a biologic rationale for exploring future therapies that target the adipocyte/AML
interactions.
#4328 Galectin-3 mediates tumor-stromal interaction by activating pan-
creatic stellate cell through integrin1/ILK/NF-B signaling.Wei Zhao, Yan
Xu, Guha Sushovan, Rosa Hwang, Nobuo Ochi, Margarete Hafley, Robert
Bresalier, Craig Logsdon, ZhenningWang, Jaffer Ajani, Shumei Song.UTM.D.
Anderson Cancer Ctr., Houston, TX.
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggres-
sive tumor with poor survival in PDAC patients. Proinflammatory cytokines/
chemokines play an essential role in tumor microenvironments associated with
its invasive and aggressive phenotype. Galectin-3 (Gal-3), a member of a family
of -galactoside-specifıc lectins, has been found to be involved in tumor pro-
gression and tissue fıbrosis. However, the precise molecular mechanisms of
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Gal-3 mediate tumor-stromal interaction and abundant cytokine production is
unknown. Methods: The effects of Gal-3 on secretion of cytokines/chemokines
from stromal cells (HPSC) were assessed by cytokine array. HPSC proliferation
and invasionwere assessed by theMTS andMatrigel invasion assays. Co-culture
and Conditional medium from PDAC tumor cells with genetic alterations of
Gal-3 levels were used to study the interaction between tumor cell and stromal
cells. IL-8 production in both tumor cells and stromal cells was confırmed by
ELISA. Transcriptional activities of NF-B and IL-8 were determined by tran-
sient transfection. An IKBmutant construct (IKBM), Mutation of the IL-8 pro-
moter at the NF-B site, and inhibitors of NF-B (Bay11), ILK and neutral
antibody of Integrin1 were used to determine the signaling pathways evoked
by Gal-3. Results: Gal-3 expression is in both tumor cells and stromal cells of
human and genetic mousemodel. Secretion of cytokines such as IL-8, GM-CSF,
CXCL1, CCL2 and IL6 were signifıcantly increased in HPSC cells treated with
rGal-3 which is concomitant with activation of HPSC. Conditioned medium or
co-culture from Panc-1 cells in which Gal-3 was down-regulated inhibited the
growth and invasion capacity of HPSC cells compared with the vector controls.
rGal-3 dramatically induced production and secretion of IL-8 in HPSCs. Mech-
anistically, Gal-3 stimulates IL-8 secretion at the level of transcription and
through Integrin1/ILK/NF-kB signaling. rGal-3 strongly stimulated integrin
1 expression and NF-B transcriptional activity; and inhibitors of ILK inhibi-
tor or NF-B or neutral antibody of integrin 1 blocked IL-8 transcriptional
activity and its secretion. NF-B mutant construct IKBM or mutation of the
NF-B site in the IL-8 promoter completely block the induction of IL-8 activity
by Gal-3. GEO data and our own patients’ cohort analysis of pancreatic tumor
samples demonstrated that the level of Gal-3, IL-8 and other cytokines is signif-
icantly higher in tumor tissues than those of normal and pancreatitis. Conclu-
sion: Collectively, these data suggest that Gal-3 secreted from tumor cells acti-
vate HPSC cells and induce many inflammatory cytokines including IL-8
production via Integrin1/ILK/NF-B signaling. Thus, Gal-3may play a critical
role in mediating tumor-stromal interaction and remodeling tumor associated
microenvironments.
#4329 Targetable nodes in fıbroblast-supportedmelanoma cells that show
resistance to BRAF inhibitors. Kotryna Seip,1 Marco V. Haselager,1 Kjetil Jør-
gensen,1 Marco Albrecht,2 Mads H. Haugen,1 Eivind Valen Egeland,1 Philippe
Lucarelli,2 Thomas Sauter,2 Olav Engebraaten,1 GunhildM.Mælandsmo,1 Lina
Prasmickaite1. 1Oslo University Hospital Radium Hospital, Oslo, Norway; 2Uni-
versity of Luxembourg, Luxembourg, Luxembourg.
Metastatic melanoma is notorious for the ability to change its phenotype in
response to signals from the microenvironment, which might influence how
melanoma responds to therapy. We have disclosed an association between fı-
broblast-induced phenotypic alterations inmelanoma and resistance to themu-
tated BRAF inhibitor vemurafenib (BRAFi). This signifıes the need to fınd other
targets than BRAF to eliminate stroma-influencedmelanoma cells. To approach
this challenge, we performed proteomic analysis and cancer drug sensitivity
screening, comparing fıbroblast-supported versus non-supported melanoma
cells.We showed that the effect of fıbroblastswas critically dependent on cell-cell
proximity, where melanoma cells get trapped in a fıbronectin network, pro-
duced by adjacent fıbroblasts. In such environment, melanoma cells down-reg-
ulate melanocytic programs (MITF-driven), gain mesenchymal features (AXL,
PDGFR, fıbronectin) and activate stress/inflammatory-response signaling path-
ways (JNK and STAT3). Altogether, this indicates fıbroblast-inducedmelanoma
transition to a de-differentiated, mesenchymal-like, pro-inflammatory pheno-
type.Melanoma cells with such phenotypewere less responsive to BRAF/MAPK
inhibitors and a number of other targeted drugs. However, they showed en-
hanced sensitivity to PI3K/mTOR inhibitors and, particularly, an inhibitor of
GSK3b, stimulating Wnt/b-catenin signaling. Further, we employed flow cy-
tometry to measure the levels of Ki67 and pS6 in single melanoma cells upon
different conditions/treatments. Such analysis allowed discrimination of cell
subpopulations representing a proliferative and a quiescent cellular state, and
nicely reflected the influence of the tested drugs in the presence or absence of
fıbroblasts. We observed a subpopulation of proliferative pS6high/Ki67high mel-
anoma cells, which remained after treatment with BRAFi if fıbroblasts were
present. This, fıbroblast-protected BRAFi-resistant cell subpopulation, could be
reduced/eliminated by PI3K or GSK3b inhibitors, verifying PI3K/GSK3 as po-
tential targets in fıbroblast-rich tumors. Currently, we are usingmass cytometry
(CyTOF) to further characterize cell subpopulations with respect to multiple
markers related to cell signaling and immune interactions. Preliminary results
indicate that not only signaling protein levels, but also levels of immunoregula-
tory proteins are altered inmelanoma cells that get support from the fıbroblasts.
In conclusion, we demonstrate fıbroblast-induced melanoma switching to a
mesenchymal-like pro-inflammatory phenotype, which favors melanoma resis-
tance to BRAF inhibitors, but sensitizes to inhibitors of PI3K/mTOR-associated
signaling. CyTOF-analysis of complex tumor-stroma cell systems is used to
search for additional strategies to target stroma-supported melanoma cells, ei-
ther at the level of signaling, or immune interactions.
#4330 Astrocytic S1P3 regulates blood-brain/tumor barrier permeability.
Anurag N. Paranjape,1 Brunilde Gril,1 Stephan Woditschka,2 Emily Hua,1 Jef-
frey C. Hanson,1 Xiaolin Wu,3 Renata Duchnowska,4 Priscilla K. Brastianos,5
David L. Liewehr,6 Seth M. Steinberg,1 Cody Peer,1 William D. Figg,1 Gary T.
Pauly,1 Christina Robinson,3 Joel P. Schneider,1 Patricia S. Steeg1. 1National
Cancer Institute, Bethesda, MD; 2University of North Carolina Wilmington, NC;
3Frederick National Laboratory for Cancer Research, Frederick, MD; 4Wojskowy
Instytut Medyczny, Warsaw, Poland; 5Massachusetts General Hospital, MA;
6NCI, Bethesda, MD.
Introduction: Incidence of breast cancer brain metastasis is increasing owing
to prolonged life-span and better detection techniques. Prognosis of patients
with brain metastases is extremely poor with median survival time of one year.
One of themajor impediments in treating brainmetastases is presence of blood-
brain/tumor barrier that limits the permeability of chemotherapeutic drugs into
the brain parenchyma. Understanding the mechanisms that regulate blood-
brain/tumor barrier permeability in context of brain metastases is imperative to
developing successful therapy. Methods: Mouse models with brain-tropic sub-
lines ofMDA-MB-231 (231), JIMT-1, and SUM190were used to generate breast
cancer brain metastases. Using laser capture microscopy, the permeable and
non-permeable lesions from mouse brains were isolated and profıled for gene
expression using microarray. Immortalized human brain endothelial cells, as-
trocytes, and pericytes were used for developing in vitro blood-brain/tumor
barrier model along with spheres generated with 231-BR6 or JIMT-1-BR3 cells.
Secreted cytokines were evaluated using human cytokine profıler. Transendo-
thelial electrical resistance (TEER) was measured using EVOM2 volt/ohm me-
ter. Results: Gene expression profıling and immunostaining of mouse brains,
harboring breast cancer metastases showed that astrocytes at permeable regions
express elevated S1P3. Pharmacological inhibition of S1P3 using antagonist TY-
52156 (10mg/kg) in mice bearing 231-BR6 brain metastases showed reduction
in 3KDa Texas red dextran (TRD) uptake. To investigate the role of S1P3 in
regulating barrier permeability, we established in vitro blood-brain/tumor bar-
rier models. Treatment of astrocytes with TY-52156 (2M) signifıcantly in-
creased mean TEER values (33.9 to 55.8 .cm2; p0.001, after 24 hrs), while
there was a decrease in permeability for TRD (1.9 fold; p0.0001) and doxoru-
bicin (1.3 folds; p0.05). Immunostaining on endothelial monolayer showed
increased membranous ZO-1 and VE-cadherin expression. The dynamics of
increase in TEERwas faster when 231-BR6 spheres were included.We observed
similar results when S1P3 was knocked down using shRNA. Astrocytes with
down-modulated S1P3 showed decreased secretion of various cytokines includ-
ing IL-6, IL-8, CCL2, CXCL1, and GM-CSF. Inhibition of these cytokines indi-
vidually using neutralizing antibodies recapitulated the effects of S1P3 inhibi-
tion, while treatment of endothelial monolayer with activated cytokines
increased the permeability. This study provides a proof of concept for role of
S1P3 and downstream cytokine signaling in regulating blood-brain/tumor bar-
rier permeability in breast cancer brain metastases. Conclusion: Our study
shows that astrocytic S1P3 regulates blood-brain/tumor barrier permeability in
breast cancer brain metastases by modulating cytokine secretion. This observa-
tion might lead to discovery of novel strategies for augmenting drug effıcacy.
#4331 Novel Wnt-SCD-LRP5/6 pathway linking liver fıbrosis to cancer.
Keane Lai,1 Soo-Mi Kweon,1 Feng Chi,1 Edward Hwang,1 Raymond Wu,1 Ya-
suaki Kabe,2 Ramachandran Murali,3 Lopa Mishra,4 James Ntambi,5 Hidekazu
Tsukamoto1. 1University of Southern California, Los Angeles, CA; 2Keio Univer-
sity School ofMedicine, Tokyo, Japan; 3Cedars SinaiMedical Center, Los Angeles,
CA; 4George Washington University, Washington DC; 5University of Wisconsin-
Madison, Madison, WI.
Activated hepatic stellate cells (HSCs) are primarily responsible for the gen-
esis of liver fıbrosis which promotes liver tumor development. Stearoyl-CoA
desaturase (SCD) which synthesizes monounsaturated fatty acid (MUFA such
as oleic acid or palmitoleic acid), is implicated in metabolic syndrome, tumori-
genesis and stemness. Indeed, we demonstrate SCD upregulation in both HSCs
and liver tumor cells in patients. Further, SCD correlates with the advancing
grade of HCC andmortality in patients. However, its causality in tumorigenesis
and mesenchyme-tumor crosstalk, and underlying mechanisms, are unknown.
The present study aimed to determine whether and how SCD promotes and
links liver fıbrosis and cancer. In both HSCs and liver tumor-initiating stem
cell-like cells (TIC), we reveal that the Wnt effector -catenin is a potent co-
activator for SREBP-1-dependent Scd transcription as demonstrated by pro-
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moter-reporter assay and re-ChIP analysis. We also discover -catenin which
drives SCD expression is in turn stabilized by SCD-derived MUFA. To identify
molecular targets of MUFA mediating this SCD--catenin positive loop, we
performed MUFA-nano-beads pull-down assay with TIC lysate, ESI-MS based
identifıcation of MUFA interacting proteins, computational docking analysis,
co-IP and ribonucleoprotein-IP. These analyses reveal that MUFA is essential
for LRP5/6 expression: MUFA interferes Transportin-1 and Ran-1 interaction,
resulting in suppressed nuclear import of themRNAbinding proteinHuR,HuR
cytoplasmic accumulation, and increased HuR binding to and stabilization of
Wnt co-receptor Lrp5/6 mRNA. As such, genetic or pharmacologic SCD inhi-
bition reduces cytosolic HuR, LRP5/6 expression, -catenin stabilization, HSC
activation and TIC self-renewal and attenuates liver fıbrosis and tumorigenesis
in mice. Moreover, conditional genetic ablation of Scd2 in HSCs not only abro-
gates HSC-mediated promotion of TIC-derived tumorigenesis in a xenograft
mouse model but also inhibits DEN-induced liver tumor development in
Col1a1-Cre; Scd2flox/flox mice (tumor volume reduced to 21.5 7.9 vs. 360.9
193 mm3 in Scd2flox/flox mice; tumor multiplicity decreased to 18 5.4 vs. 45
8.4 in Scd2flox/flox mice, both p0.05). Collectively, our fındings support that a
newly disclosed Wnt-SCD-LRP5/6 loop may serve as a novel therapeutic target
for liver cancer and underlies a known crosstalk between liver mesenchyme and
liver tumor development.
#4332 Interactome between vascular endothelial cells and Proneural gli-
oma stem cells protects seeds for GBM recurrence from radiation therapy.
Soniya Bastola,1 Marat S. Pavlyukov,1 Shinobu Yamaguchi,1 Jun Wang,1 Svet-
lana Komarova,1 Harley I. kornblum,2 Ichiro Nakano1. 1University of Alabama
at Birmingham, Birmingham, AL; 2University of California Los Angeles, Los An-
geles, CA.
Glioblastoma (GBM) is themost aggressive form of intracranial tumors. Despite
multimodal treatment strategies that include surgical resection, radiation and che-
motherapy, most patients survive for less than two years. GBM cells tend to invade
into adjacent normal brain tissues and therefore, cannot be completely resected by
surgery. These remaining tumor cells are the “seeds” to escape post-surgical thera-
pies, thereby giving rise to recurrent tumors during or after treatment. The exact
mechanisms by which these seeds contain pre-existing resistant cells, and/or gain
resistance to therapy remain elusive. Recent fındings demonstrated that communi-
cation between normal and GBM cells play physiological roles in tumor initiation
and progression. Here, we aim to determine how vascular endothelial (VE) cells
affectGBMrecurrence in response to radiotherapy.To this end,we fırst assessed the
effect of secreted factors from VE cells on patient-derived GBM neurospheres in
vitro byusing their conditionedmedium(CM).GBMneurospheres promoted their
growth with CM from VE cells. qPCR and FACS exhibited that the CM treatment
preferentially protected CD133 population in GBMneurospheres that otherwise
were depleted by irradiation treatment. Furthermore, RNA sequencing of VE cells
andA2B5-expressingGBMstem-like cells directly isolated fromGBMand epilepsy
patients demonstrated that only tumor-derived VE cells and GBM stem-like cells
express a high level of a secreted factor Endocan (ESM1) and its receptor CD11a,
respectively. Preferential expression of CD11a in perivascular GBM cells was also
confırmedby immunocytochemistry.Further,we found that recombinantEndocan
is able to promoteGBMneurosphere growth in vitro after irradiation andprotected
them from irradiation-induced aggressive mesenchymal transition of these cells.
Taken together, these results demonstrate a potential role of a crosstalk between
peri-vascular GBM stem-like cells and their adjacent VE cells, via the ligand-recep-
tor interaction mechanism. This interactome network may help Proneural GBM
stem cells to escape from radiation therapy, thereby reinitiating the tumor as recur-
rence via an Endocan-CD11a signaling. Hence, targeting Endocan in endothelial
cells or CD11a in GBM cells may have potential as a novel effıcacious strategy for
preventing recurrence.
#4333 The role of cancer-associated fıbroblast-induced chemokine ligand
11 in tumormicroenvironment contributes to the progression of oral cancer.
Shin Nieh. National Defense Medical Center, Taipei, Taiwan.
Oral squamous cell carcinoma (OSCC) is one of the leading causes of cancer-
related death in Taiwan and worldwide. The prognosis of OSCC is usually poor
because of its propensity of extensive invasion, local recurrence and frequent
regional lymph nodemetastasis, even at initial diagnosis. Recent studies showed
carcinoma-associated fıbroblasts (CAFs), a major type of tumor-surrounding
stromal cell, generate certain mediators through which CAFs interact with tu-
mors and contribute to cancer progression in numerous cancers. The orchestra-
tion between CAFs and cancer cells is complex and its underlying mechanism
needs to be explored. In the present study, we used organotypic culture to inves-
tigate CAFs that promote aggressive behavior of cancer cells. Using microarray
analysis, we detected abundant expression of chemokine (C-C motif) ligand
11(CCL11), also named Eotaxin, secreted by CAFs and further be identifıed as a
critical mediator in CAF-induced invasiveness. We planned to validate that
CCL11 played a major role in the crosstalk between fıbroblasts and OSCC cells
via the paracrinemanner. CCL11was foundupregulated inCAFs than in normal
fıbroblasts via Western blot analysis. Cells lines of OSCC, Fadu and TW204,
treated with recombinant CCL11 increased capabilities of sphere formation in
ten days. Administration of CCL11 promoted migration and invasion abilities
through induction of the epithelial-to-mesenchymal transdifferentiation with
corresponding morphological alterations of cancer cells. Counteracting CCL11
activity diminished the aggressive phenotype of cancer cells induced by CAFs.
We further studied the relationship between the expression of CCL11 in both
CAFs and OSCC cells and clinical outcome in the patients with OSCC. As a
result, a high CCL11 expression level was associated with poor prognosis in
terms of nodalmetastasis and survival. These results indicate thatCAFs promote
cancer invasiveness via a paracrine effect onmicroenvironmental CCL11 signal-
ing and suggest that CCL11 is a potential prognostic biomarker that may be
considered in therapeutic strategies for the treatment of patients with OSCC.
#4334 Interleukin-6 is a key player in stroma-induced resistance to che-
motherapy for gastric carcinomas. In-Hye Ham,1 Dakeun Lee,2 Hyejin Jin,1
Sang Yong Son,1 Yong Bae Kim,2 Sang-Uk Han,1 Hoon Hur1. 1Department of
Surgery, Ajou University School of Medicine, Suwon-si, Republic of Korea; 2De-
partment of Pathology, AjouUniversity School ofMedicine, Suwon-si, Republic of
Korea.
Introduction: Gastric carcinomas (GCs) are known to progress through the in-
teraction between cancer cells and the tumor stroma. Moreover, recent molecular
analysis revealed that the expression of stroma-related genes was signifıcantly asso-
ciatedwith poor response to chemotherapy inGCs.However, the specifıc targets to
inhibit the interaction between stroma and cancer cells and to reverse stroma-in-
duced chemoresistance have never been suggested in GCs. Experimental proce-
dures: The gene expression in the biopsied GCs tissues from 10 patients, who were
treated with preoperative chemotherapy, was analyzed using Nanostring analyzer.
We compared the expression pattern of genes involved in the cancer progression
panel between chemotherapy response and non-response groups. In addition, we
investigated the level of serum interleukin-6 (IL-6) in 39 GCs patients, who under-
went curative gastrectomy and postoperative adjuvant chemotherapy.GCs patients
were subclassifıed into recurrence and non-recurrence groups, and the level of IL-6
was compared between two groups. We performed cell proliferation assay, qRT-
PCR,ELISAandWesternblot to investigate the role of cancer-associated fıbroblast-
s(CAFs)-produced IL-6 on the chemoresistance. Summary of the new data: For
pretreated biopsied tissues of patients with preoperative chemotherapy, the expres-
sion of IL-6 gene in non-response group was signifıcantly higher than response
group. In addition, for patients with postoperative adjuvant chemotherapy, the se-
rum level of IL-6 in GCs patients with recurrence was higher than patients without
recurrence. Moreover, In vitro studies demonstrate that co-culture with CAFs in-
creased chemoresistance of various GCs cell lines to 5-fluouracil (5-FU) andCAFs-
derived IL-6 activated themembrane gp130 and the STAT3 signal pathway in GCs
cell lines. When anti-IL-6R monoclonal antibody was added to 5-FU for GCs cell
lines in co-culture with CAFs, activation of STAT3 was signifıcantly reduced and
apoptosismarkers effıciently induced. Conclusion: Our study showed that the stro-
ma-induced IL-6 is a key player in the resistance to chemotherapy in GCs. We
convinced that the interaction between stroma cells and cancer cells could be inhib-
ited by blockade of IL-6 signal pathway. We suggest the use of IL-6 inhibitor as
therapeutic agent to enhance the response to chemotherapy in GCs.
#4335 The role of fıbroblasts in prostate cancer cell invasion in tumor
microenvironments. Tariq Shah, Flonne Wildes, Dmitri Artemov, Zaver M.
Bhujwalla. Johns Hopkins Univ. School of Medicine, Baltimore, MD.
Cancer-associated fıbroblasts (CAFs) play a critical role in tumor aggressiveness.
We have started to investigate the role of CAFs in different tumor microenviron-
ments of hypoxia and acidic extracellular pH. To further understand interactions
betweenCAFsandcancer cells under carefully controlled conditionsofhypoxia and
acidic pH, we have used ourMR compatible cell perfusion system to determine, for
the fırst time, changes in the ability of prostate cancer cells to invade anddegrade the
extracellularmatrix (ECM) in the presence of prostatemyofıbroblasts. Experiments
were performed using the human prostate cancer cell lines PC-3 and prostatemyo-
fıbroblasts (WPMY-1,ATCC,Manassas,VA).BeforeeachMRexperiment, 2.5X106
PC-3 cells were seeded on 0.5 ml of Plastic Plus beads in fıve 100mm dishes and
grown for 4 days. Experiments were carried out with PC-3 cells plated on an ECM
chamberwith orwithout prostatemyofıbroblasts layered between the PC-3 and the
ECM. For experiments investigating prostate myofıbroblasts-cancer cell interac-
tion, 5X 104 prostatemyofıbroblasts were seeded onECMgel contained in a cham-
ber overnight before theMR experiment. This time interval allowedmyofıbroblasts
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to attach to theECMgel.Degradation of ECMby cancer cellswas determined at the
24h time point relative to the initial time point from the proton images. MR data
were acquired on a 9.4 T MR spectrometer every 12 h over a period of 2 days.
T1-weighted 1HMR imaging was performed to evaluate changes in ECM invasion
anddegradation.TheextentofECMdegradationwasestimatedbydrawinga region
of interest (ROI) around the ECM gel region using NIH ImageJ software. The deg-
radation indexwas defıned as (ROIt0-ROIt24)/ROIt0.One-dimensional 1HMR
profıles of intracellular water were acquired along the length (z-axis) of the sample
bydiffusion-weightedMRI. These profıleswere used to derive an invasion index by
quantifying thenumberof cells invading into theECM.Fibroblasts alonemarginally
degraded thematrigel. PC-3 cells, being invasive cells alsodegraded theECM.How-
ever, ECM degradation increased when prostate myofıbroblasts were layered be-
tween the ECMand the PC-3 prostate cancer cells. Consistent with the degradation
data, PC-3 cells showed a signifıcant increase in the invasive index in the presence of
myofıbroblasts under normoxia. The enhanced invasion and degradation of ECM
byPC-3 cells in thepresenceofmyofıbroblasts suggests that the interactionbetween
myofıbroblasts andPC-3 cells plays a role in prostate cancer invasion. Further stud-
ies with hypoxia and acidic pHmicroenvironment are currently ongoing.
#4336 Human mesodermal-derived CNS metastasis-associated stromal
cells induce a fıbrotic response to limit tumor growth.Christophe Legendre,1
Gerald C. Gooden,2 Kyle N. Johnson,1 Rae Anne Martinez,1 Mark Bernstein,3
Jennifer Glen,3 Jeffrey Kiefer,1 Aleksander Hinek,4 Steven A. Toms,5 Bodour
Salhia2. 1Translational Genomics Research Institute, Phoenix, AZ; 2University of
Southern California, Los Angeles, CA; 3University Health Network, Toronto, On-
tario, Canada; 4Hospital for Sick Kids, Toronto, Ontario, Canada; 5Lifespan
Health System, Providence, RI.
Metastasis to the central nervous system (CNS) remains a major cause of
mortality and morbidity in patients with systemic cancer. However, the mech-
anistic interactions of the neural niche with disseminated tumors cells in CNS
metastases (CM) are still poorly understood. To better understand the cross-talk
between the neural niche and metastatic tumors, we generated fıve different
patient-derived cell lines (PDCs) originating from surgically resected CM. To
assess the genetic and epigenetic characteristics of each PDC, DNA and RNA
sequencing, andDNAmethylation analysis was performed. Non-tumoral PDCs
revealed normal copy number profıles, and retention of germline mutations as
seen in patient-matched germline DNA. In contrast, one PDC (CM04) resem-
bled its patient tumor, showing numerous copy number and somatic alterations.
RNA-seq andDNAmethylation analysis demonstrated that non-tumoral PDCs
highly resembled each other, suggestive of a common cell of origin. Addition-
ally, PDCs revealed gene expression signatures associatedwith cancer associated
fıbroblasts, epithelial to mesenchymal transition, and mesenchymal stem cells.
Further in vivo studies demonstrated that CM04 cells were tumorigenic,
whereas non-tumoral PDC (CM08) cells were unable to form tumors in mice.
However, CM04:CM08 mixed tumors were signifıcantly smaller than CM04
only tumors and revealed induction of a fıbrotic response by immunohisto-
chemistry. These data offer the fırst evidence that CNS metastasis-associated
stromal cells (cMASCs) produce a collagen and fıbronectin-rich extracellular
matrix constituting a protective host response, which impedes growth of tumor
cells. The therapeutic potential of these cells merits further exploration.
#4337 PDGFR- induced stiffness abrogates mammary ductal develop-
ment and enhances tumorigenesis in vivo. Anisha Mathur Hammer, Gina M.
Sizemore, Vasudha Shukla, Steven T. Sizemore, Maria Cuitino, Cynthia J. Tim-
mers, Quinn Verfurth, Arnab Chakravarti, GustavoW. Leone, Samir N. Ghadi-
ali, Michael C. Ostrowski. The Ohio State University, Columbus, OH.
Breast cancer is a leading cause of mortality in women worldwide, in part due
to the tumormicroenvironment which increases tumor heterogeneity and abets
tumor growth. Fibroblasts are cells ofmesenchymal origin that are an important
component of normal and tumor stroma. Genetic alterations in these cells were
shown by several groups including our own to cause fıbroblast activation and
fuel tumor progression giving rise to more aggressive disease. Platelet-Derived
Growth Factor Receptor (PDGFR) alpha is a receptor tyrosine kinase that is
chiefly expressed in mesenchymal cells such as fıbroblasts. Ligand binding
(PDGFAA) activates this receptor. PDGFR signaling plays critical roles in de-
velopment and aberrant signaling is seen in several types of cancer, such as lung,
pancreas, GI and brain. The central goal of this study was to elucidate the role of
stromal PDGFR in breast cancer development and metastasis, where its role
remains largely unknown. To address this goal, we developed a genetic mouse
model of stromal activation of PDGFR in the mammary gland by crossing an
auto-activating Pdgfra mutant allele with a mesenchymal specifıc Cre recombi-
nase. We found that stromal PDGFR activation completely abrogated postna-
tal mammary gland ductal formation, with signifıcantly reduced terminal end
bud formation. PDGFR activation also led to progressive fıbrosis in the mouse
mammary fat pad. As early as four weeks of age, mammary collagen (trichrome
staining; secondharmonic generation) andhyaluronandeposition (AlcianBlue)
was greatly increased in vivo. In fact, this increase in collagen and hyaluronan
deposition in mutant animals is believed to be responsible for the observed
increased in stiffness of mutant mammary tissue (atomic force microscopy
{AFM}). pFAK, which can be activated due to mechanical stress, was increased
inmammary epithelia of themutantmice in vivo corroborating theAFMresults.
Further, when tumor cells were injected into the mammary glands of the
PDGFRmutants, tumors grew faster as compared to controls. Importantly, we
found that mRNA expression of PDGFRA correlates with worsened patient
outcomes in HER2 disease, while expression of both the ligand (PDGFA) and
the receptorwere found to correlatewith increased incidence of lungmetastases.
We further discovered that in HER2 patients, PDGFRA levels correlate with
breast density. Breast density is the third strongest risk factor for breast cancer,
and is directly related to collagen deposition and breast stiffness, thus suggesting
a novel predictive role of PDGFRA as a molecular readout of stiffness and den-
sity. Studies are underway to utilize mouse models of HER2 breast cancer to
study both primary tumor growth and metastases. Taken together, our mouse
studies and paralleling human data analyses suggest that the stromal PDGFR
signaling provides a novel theranostic window in breast cancer treatment and
prognosis.
#4338 The role of IMPACT in survival of cancer cells during tryptophan
deprivation by immunosuppressive enzyme indoleamine 2,3-dioxygenase
(IDO1). Petr Tomek,1 Ariane Hallermayr,2 Michael Kilian,3 Cristin Gregor
Print,1 Lai-Ming Ching1. 1University of Auckland, Auckland, New Zealand;
2Ludwig Maximilian University, Munich, Germany; 3German Cancer Research
Center (DKFZ), Heidelberg, Germany.
A broad range of human malignancies overexpress an enzyme called in-
doleamine 2,3-dioxygenase 1 (IDO1) to suppress antitumor immunity
which associates with poor patient prognosis. One mechanism whereby
IDO1 activity suppresses the host’s immune cells is mediated by deprivation
of the essential amino acid tryptophan (Trp) which raises an intriguing
question. How do the cancer cells overcome low levels of the essential amino
acid when the immune T-cells are triggered to self-destruct? A protein called
IMPACT (product of IMPrinted gene with AnCienT domain) was reported
to confer skin cells and neuronal cells increased survival in Trp-deprived
environments. Based on these reports, we hypothesise that cancer cells hijack
IMPACT to gain survival advantage in Trp-deprived environments. To ob-
tain evidence for this hypothesis, we analysed publicly available genomics
datasets and performed experimental assays. Murine GL261 glioblastoma
cells overexpressing a full-length mouse IMPACT gene (GL261-IMPACT)
were generated by lipofection. IMPACT overexpression was confırmed by
Western blot. Metabolic activity and survival of the GL261 cells in Trp de-
privation experiments were evaluated using MTT assay and staining with
live/dead indicators fluorescein diacetate and propidium iodide, respec-
tively. Meta-analysis of the publicly available RNA-sequencing datasets, The
Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx),
provided evidence that IMPACT was overexpressed in the majority of the 24
analysed human cancers compared to their non-malignant tissue counter-
parts. Consistent with the high IMPACT expression in prostate cancer pa-
tients, 12-25% prostate tumors show amplifıcation of the IMPACT gene
(source: cBioPortal for Cancer Genomics). In addition, we found an associ-
ation of high IMPACT expression with poorer survival for certain leukemia
and lung cancer patients in the Gene Expression Omnibus (GEO) portal. To
obtain experimental evidence that IMPACT protects cancer cells during Trp
deprivation, GL261-IMPACT cells were cultured in media containing 2.5 -
50 MTrp. Metabolic activity of GL261-IMPACT cells decreased at a slower
rate than that of GL261-wild-type cells after 3 to 5 days in media containing
limiting Trp concentration (2.5 - 10 M). On day 5, GL261-wild-type and
GL261-IMPACT cells cultivated in 10 M Trp showed 4.5% and 23% meta-
bolic activity (p 2.8x10-8), respectively, relative to the same cells grown in
50 M Trp. Fluorescence microscopy utilising live/dead staining showed
that after 5 days of incubation at limiting Trp concentrations (5 - 10M), the
majority of GL261-wild-type cells were non-viable whereas GL261-IMPACT
cells were predominantly viable. Our initial results support the hypothesis
that IMPACT aids cancer cells to overcome periods of tryptophan depriva-
tion.
#4339 Single cell RNA sequencing dissects cellular growth factor depen-
dencies and oncogenic driver effects in an organoid model of gastric cancer.
Jiamin Chen, Noemi Andor, Susan M. Grimes, Billy Lau, Hanlee P. Ji. Stanford
University Medical School, Stanford, CA.
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Gastric cancer is a lethal malignancy with few therapeutic options. Gastric
tumors rely on complex intercellular signaling “crosstalk” that enables tumor
development, metastasis, and therapeutic resistance. To recapitulate the inter-
cellular communications among various cell populations that exist in vivo, we
are using a three-dimensional culture system to grow and manipulate mouse
gastric tissue in vitro, otherwise referred to as organoids. Importantly, this or-
ganoidmodel contains epitheliumwith its endogenousmesenchymal niche and
does not require exogenousWnt stimulation. To systematically analyze the dis-
tinct cellular lineages and their interactions, we applied amassively-scaled single
cell RNA-Seq platform to sequence thousands of individual cells from organoid
cultures. With PCA and t-SNE analysis of the high-dimensional data generated
from single cell RNA-seq, we characterized two major cell types, i.e. epithelial
andmesenchymal cells. Leverage the information from single cell transcriptome
profıles, we identifıed specifıc niche factors of the Wnt signaling pathways that
are activated in different stomach cell lineages. These results suggest that the
mesenchymal cell populations provide a potential source of the R-spondin, a
Wnt agonist, that sustains the growth of epithelium. Furthermore, we compared
cell populations from Cdh1-/-/Trp53-/- and Trp53-/-organoids, and character-
ized changes on the transcriptome profıles due to the loss of Cdh1, an early
oncogenic event in diffuse gastric cancer development. Overall, using organoid
model and high-throughput single cell RNA-Seq provides a novel approach to
study early tumor transformation and critical cancer-stroma interactions.
#4340 RHBDF2 in stromal fıbroblasts mediates TGF- signaling and en-
hances gastric cancer cell invasion via intercellular crosstalk. Takatsugu
Ishimoto,1 Keisuke Miyake,1 Masakazu Yashiro,2 Tsugio Eto,1 Daisuke Izumi,1
Kota Arima,1 Yoshifumi Baba,1 Masayuki Watanabe,3 Kosei Hirakawa,2 Hideo
Baba,1 Patrick Tan4. 1Kumamoto University, Kumamoto, Japan; 2Osaka City
University, Osaka, Japan; 3The Cancer Institute Hospital of JCFR, Tokyo, Japan;
4Duke-NUS Medical School, Singapore, Singapore.
Background: Cancer-associated fıbroblasts (CAFs) have been reported to
promote various types of tumor through secretion of soluble factors. However,
there have been no systematic studies of CAFs in diffuse-type gastric cancers
(DGCs). We investigated the characteristics and functional roles of CAFs in
DGCs using comprehensive genomic approach. Methods: We established pri-
mary fıbroblasts, normal fıbroblasts (NFs) and CAFs frommore than 100 tissue
samples from GC patients. NFs/CAFs were subjected to Exome and RNA se-
quencing, and the possible candidates for functional assay were selected from
among the acquired comprehensive data. The candidate molecules were exam-
ined the functional roles for GC tumor progression by in vitro assays. Results:
CAFs exhibited an invasive molecular pattern and acquiredmotility in extracel-
lular matrix (ECM). We identifıed RHBDF2 as a mediator of TGF- signaling
and an enhancer of CAF motility. RHBDF2 silencing in CAFs signifıcantly de-
creased their motility stimulated by TGF-1 in ECM, whereas NFs transfected
with the RHBDF2 expression vector displayed a greater motility in ECM than
did control NFs. RHBDF2 silencing also decreased type I TGF- receptor
(TRI) cleavage through tumor necrosis factor (TNF)- converting enzyme
(TACE) activity and attenuated the invasive molecular pattern of CAFs. Conse-
quently, high-motility CAFs confer on DGC cells the ability to invade the ECM.
Furthermore, simultaneous treatment with interleukin (IL)-1, IL-1 and
TNF- resulted in a strong induction of RHBDF2 expression in NFs. The ex-
pression of these cytokines in GC tissues was associated with poor prognosis in
GC patients. Conclusion: These fındings highlight the underlying mechanism
whereby DGC cells take advantage of CAFs to acquire invasiveness.
#4341 Mesenchymal stem cells promote epithelial-mesenchymal transi-
tion of colon cancer cells via direct cell-to-cell contact. Hidehiko Takigawa,1
Yasuhiko Kitadai,2 Toshio Kuwai,3 Ryo Yuge,1 Shinji Tanaka,1 Kazuaki
Chayama1. 1Hiroshima University, Hiroshima, Japan; 2Prefectural University of
Hiroshima, Hiroshima, Japan; 3Kure Medical Ctr. & Chugoku Cancer Ctr., Hi-
roshima, Japan.
We previously reported that in an orthotopic nude mouse model of human
colon cancer, bone marrow-derived mesenchymal stem cells (MSCs) migrated
to tumor stroma and promoted tumor growth andmetastasis. We evaluated the
proliferation and migration ability in directly and indirectly co-culture assay to
clarify the mechanism of interaction between cancer cells and MSCs. Prolifera-
tion andmigration ability of cancer cellswere increased by direct co-culturewith
MSCs but not by indirect co-culture of MSCs. Thus, we thought that direct
contact between cancer cells and MSCs is important to their interaction. We
performed microarray analysis of gene expression in KM12SM colon cancer
cells directly co-cultured with MSCs. Expression of epithelial-mesenchymal
transition (EMT) related genes such as fıbronectin (FN), SPARC and Galectin 1
was increased by direct co-culture with MSCs. We also confırmed the upregu-
lation of these genes with real time PCR, and these genes were not increased in
cancer cells indirectly co-cultured with MSCs. Among these EMT related genes
upregulated by direct co-culture withMSCs, we examined immune localization
of FN, well-known EMTmarker. In co-culture assay in chamber slides, expres-
sion of FN in cancer cluster was seen only at the edge where cancer cells directly
contacted with MSCs. FN expression by cancer cells was increased at the tumor
periphery and invasive edge in orthotopic nude mice tumors and human colon
cancer tissues, respectively. These results suggest that mesenchymal stem cells
induce epithelial-mesenchymal transition of colon cancer cells via direct cell-to-
cell contact and may play an important role of colon cancer metastasis.
#4342 Loss of MSLN impairs pancreatic cancer growth in the peritoneal
cavity.MichaelW. Rudloff, Danielle Arons, Salma El-Behaedi, RakanAlbalawy,
Christine Alewine. National Cancer Institute, Bethesda, MD.
Mesothelin (MSLN) is a cell surface glycoprotein that is expressed in at least
85% of pancreatic adenocarcinoma but not on cells of the healthy pancreas nor
in the parenchyma of other vital organs. Due to this differential expression,
MSLN has been used as a target for various antibody based treatments and
cancer vaccines. The physiologic role of MSLN is unknown. Previous reports
have suggested that overexpression of MSLN may increase tumorigenicity and
metastatic potential of pancreatic adenocarcinoma. To further defıne the role of
MSLN in this disease, we deleted MSLN from the human pancreatic cancer cell
line, KLM1, using CRISPR/Cas9 gene editing. Successful deletion of MSLN was
confırmed via flow cytometry and immunoblotting. Furthermore, KLM
MSLN
cells were rendered invulnerable to theMSLN-targeted immunotoxin, RG7787,
which depends on the presence of surfaceMSLN for cytotoxicity. In cell culture,
KLM
MSLN cells grew at the same rate as control cells. KLM
MSLN formed
subcutaneous tumors in nudemice with the same frequency as control cells and
these tumors grew at the same rate. However, when nude mice were inoculated
withKLM
MSLNor control cells intraperitoneally, amarked decrease in tumor
burden was observed in cells lacking MSLN. In summary, we have engineered a
pancreatic cancer cell line that lacksMSLN and demonstrated that loss ofMSLN
impairs tumor growth and spread specifıcally within the peritoneal cavity. Fur-
ther experiments are in progress to identify the factors contributing to this phe-
notype.
#4343 Effects of the co-expression of RANTES and IL-6 on the trans-
formed phenotype of breast cancer cells. Marianna Gallo, Daniela Frezzetti,
Nicola Normanno, Antonella De Luca. National Cancer Inst., Naples, Naples,
Italy.
Introduction: Cells of the tumormicroenvironment play an important role in
the progression of breast cancer through their interaction with cancer cells. In
this regard, mesenchymal stem cells greatly increased themetastatic potential of
breast cancer cells through the secretion of the chemokine CCL5/RANTES. In
addition, we demonstrated that breast cancer cells migrate in response to either
recombinant RANTES or interleukin-6 (IL-6). Starting from this observation,
we analyzed whether the co-expression of RANTES and IL-6 induced a more
aggressive phenotype in breast cancer cells. Methods: MCF-7 and MDA-MB-
231 breast cancer cells were transfected with expression vectors coding for hu-
man RANTES and IL-6. XMAP Bio-Plex Cytokine arrays were employed to
measure the levels of secretedRANTES and IL-6. To evaluate the proliferation of
stable clones, anchorage-independent growth assays were used. Migration and
invasionwere analyzed using commercially available kits. Tumor growth in vivo
was determined after injection of transfected cells in the mammary fat pad of
nudemice. Results: MCF-7 andMDA-MB-231 clones that stably overexpressed
RANTES and/or IL-6 were isolated after selection with appropriate antibiotics.
Stable transfectants produced higher levels of secreted RANTES and IL-6 than
control cells trasfected with mock vectors. To evaluate whether RANTES and
IL-6 induced amore aggressive phenotype in breast cancer cells, we analyzed the
proliferation, migration and invasive ability of stable clones. MCF-7 cells co-
expressing RANTES and IL-6 had a greater ability to form colonies in soft agar,
compared to cells overexpressing RANTES or IL-6. In addition, both MCF-7
and MDA-MB-231 clones co-expressing RANTESIL6 showed a signifıcantly
higher ability to migrate through a fıbronectin-coated and to invade through a
matrigel-coated matrix. The analysis of phosphorylated ERK1/2, AKT and
STAT3 signal transduction proteins revealed that in cells overexpressing both
RANTES and IL-6 more signaling pathways are simultaneously activated as
compared with cells overexpressing a single factor. Finally, MCF-7 cells overex-
pressing RANTESIL6 showed a signifıcant increase in in vivo tumor growth
when clones were injected in the mammary fat pad of nude mice. Conclusions:
Taken together, our data suggest that the simultaneous expression of IL-6 and
RANTES produce a more aggressive phenotype in breast cancer cells. This ob-
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servation might be useful for the identifıcation of potential targets for novel
therapeutic strategies aimed to prevent breast cancer progression through the
blockade of the tumor-stroma interaction.
#4344 Cd146modulates themalignant phenotype in human prostate can-
cer. Eugenio Zoni,1 Letizia Astrologo,1 JanineMelsen,2 Irena Klima,1 Joël Gros-
jean,1 Peter C. Gray,3 Gabri van der Pluijm,2 Marco G. Cecchini,1 Marianna
Kruithof-de Julio,1 George N. Thalmann1. 1University of Bern, Bern, Switzer-
land; 2Leiden University Medical Center, Leiden, Netherlands; 3Salk Institute for
Biological Studies, La Jolla, CA.
Prostate Cancer (PCa) is the most frequent cancer in males and the second
leading cause of death from cancer inmen.When PCa progress from androgen-
responsive to castration resistance, the formation of incurable metastases,
mainly in the bone, is almost inevitable. Therefore, understanding the factors
that regulate homing and survival of metastatic cancer cells in the bone is im-
portant for the identifıcation of new therapeutic targets. HighCD146 expression
has beenmeasured in the stroma of lytic and blastic lesions in preclinicalmodels
of PCa bone metastasis. The objective of this study is to characterize the role of
CD146 in the maintenance of the aggressive and invasive phenotype in human
PCa. We used shRNAs to knockdown the expression of CD146 in the lytic
PC-3M-Pro4Luc2dTomato and in the blastic C4-2BdTomato PCa cell lines.We
validated the knockdown at protein level and tested the effect with functional
assays such asmigration, proliferation.We usedRT-qPCR to test CD146 knock-
down on EMTmarkers.Wemeasured the effect of the knockdown on themain-
tenance of cancer stem/progenitor-like cells by ALDEFLUOR assay. CD146
knockdown reduced proliferation in PC-3M-Pro4Luc2dTomato PCa cells and
resulted in increased E-Cadherin expression. Conversely, no effect on prolifer-
ation was measured on C4-2BdTomato cells. It has been described that meta-
static human PCa cells target the hematopoietic stem cell (HSC) niche in the
bone marrow at the level of an “endosteal/osteoblast” niche and a “vascular/
perivascular” niche. We optimized an in vitro model of “osteoblast niche” to
study the behavior of prostate cancer cells upon co-culture with osteoblasts and
to measure the resulting effects on cancer stem/progenitor-like markers. Our
results showed that CD146 is required for the osteoblast-mediated induction of
ALDH activity on PCa cells and CD146 knockdown prevented the increase in
the size of the ALDHhigh subpopulation in the tumor cells, mediated by human
osteoblasts. Additionally, CD146 knockdown in PCa cells co-cultured with os-
teoblast, reduced the amount of CD146 expressed by osteoblasts compared to
non-targeted control. Finally, we showed that CD146 is signifıcantly increased
in the highlymetastatic ALDHhigh cells and identifıed a new subset of ALDHhigh
/ CD146high cells which could be depleted upon CD146 knockdown. In Conclu-
sion, we detected a novel subset of ALDHhigh/CD146high cells and found that
CD146 influences themaintenance of an aggressive-mesenchymal phenotype in
human PCa. Therefore, CD146 represents a promising molecule to modulate
the behavior of aggressive PCa cells.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Epigenetics 4
#4345 Epigenetic dysregulation of transcriptional program in MLL-EEN
leukemia. Xianwen Yang, Yuk Man LAM,Wing Chi Lui, Ray Kit Ng. The Uni-
versity of Hong Kong, Hong Kong, Hong Kong.
Aberrant DNA methylation is a typical feature of cancers, which is usually
associated with deregulation of tumor suppressor genes and oncogenes. Mixed
lineage leukemia (MLL)-rearranged leukemia is characterized by the presence of
MLL fusion proteins resulting from chromosomal translocation between MLL
and its partner genes. TheMLL fusion proteins have lost theMLL histonemeth-
yltransferase SET domain, leading to alteration of epigenetic functions. Many
genome-wide DNA methylation profıling studies showed signifıcant global al-
teration inMLL-rearranged leukemia patients, suggesting thatMLL fusion pro-
teins mediate leukemia through dysregulation of DNAmethylation status. Our
previous work showed that MLL-EEN fusion protein can enhance the self-re-
newal capacity of murine hematopoietic progenitor cells through mediating
DNA hypomethylation at HoxA family gene promoters. Nevertheless, how the
aberrant DNAmethylation alters the transcriptional program inMLL-EEN leu-
kemia cells remains unclear. We performed RNA-seq to study the transcrip-
tional program associated with MLL-EEN in murine hematopoietic stem and
progenitor cells (HSPCs). We observed 1023 upregulated and 317 downregu-
lated protein coding genes (PCGs) upon MLL-EEN overexpression. Interest-
ingly, key regulators of DNAmethylation, including Dnmt3a, Dnmt3b and Tet
family genes, were downregulated, suggesting their involvement in the dysregu-
lation of DNAmethylation inMLL-EEN-driven leukemia. Gene ontology anal-
ysis showed that signaling pathways crucial to hematopoietic stem cell func-
tions, such as Wnt and NFb, were signifıcantly enriched. Motif enrichment
analysis also showed that the promoters of dysregulated genes were enriched
with the binding sites of hematopoietic specifıc transcriptional factors, such as
PU.1 and C/EBP family. In addition, we have identifıed 3016 upregulated and
1357 downregulated long non-coding RNAs (lncRNAs) in MLL-EEN HSPCs.
lncRNAs, Hotairm1 and linc-p21, which was previously reported playing im-
portant roles in hematopoiesis and leukemogenesis, were also found deregu-
lated. Notably, the deregulated lncRNAs showed positive correlation with the
expression of nearby PCGs (	5 kb to lncRNAs), further demonstrating the
transcriptional regulatory role of lncRNAs. MBD-seq analysis showed global
DNA hypermethylation in MLL-EEN HSPC. Promoters of genes involved in
myeloid differentiation and cell cycle regulation were hypermethylated, pre-
sumably associated with their downregulation mediated by MLL-EEN. We are
currently investigating how the aberrant DNA methylation mediated by MLL-
EEN can affect lncRNA transcription, which subsequently alters the expression
of PCGs and leads to leukemic transformation. Taken together, our study pro-
vides new insights into the epigenetic regulation of transcriptional program in
MLL-rearranged leukemia, which could facilitate the development of novel
therapeutic strategies.
#4346 S-Adenosyl methionine (SAM) blocks breast cancer growth, inva-
sion andmetastasis in vitro and in vivo.NiazMahmood, David Cheishvili, Ani
Arakelian,William J.Muller,Moshe Szyf, ShafaatA. Rabbani.McGill University,
Montreal, Quebec, Canada.
DNA hypomethylation has been implicated in the coordinated targeting of vari-
ous signaling pathways involved in tumor growth and metastasis. In the current
study through various in vitro and in vivo assays, we have examined the plausibility
ofusinguniversalmethyldonarS-adenosylmethionine (SAM)for its ability toblock
breast cancer development, growth andmetastasis in our xenograft and transgenic
models of breast cancer. Treatment of highly invasive human triple negative breast
cancer (TNBC) cell linesMDA-MB-231 andHs578Twith SAMresulted in a signif-
icant dose-dependent decrease in cell proliferation, invasion,migration, colony for-
mation and increased apoptosis in vitro. Affymetrix gene expression array and real
time PCR (qPCR) validated showed the ability of SAM to decrease the expression
several genes implicated in cancer progression in MDA-MB-231 cells. For the in
vivo studies, MDA-MB-231 cells expressing green fluorescent protein (MDA-MB-
231-GFP)were inoculated into femaleCD-1nudemice viamammary fat pad. From
day three post tumor cell inoculation, animals were treated with SAM (0.8-1.6 mg/
day) or vehicle alone as control via daily oral gavage and tumor volume was deter-
mined at weekly intervals for 10 weeks. SAM treatment caused a signifıcant dose
dependentdecrease in tumorvolumeandGFPpositivemetastasis to lungs, liver and
spleen in experimental animals compared to vehicle-treated controls. Analysis of
RNA from primary tumors by qPCR showed the ability of SAM to cause a marked
decrease in the expression of several pro-metastatic and EMTpathway genes. Pyro-
sequencing of tumoral DNA from control and experimental animals showed that
SAMtreatmentcausesa signifıcant increase in thepercentageofCpGmethylationat
the promoter region of several cancer-related genes which were seen to be down-
regulated in the qPCR assay. We next determined the effect of SAM in MMTV-
PyMT transgenicmousemodel of breast cancerwhere SAM treatment resulted in a
signifıcant delay in the development of mammary tumors and decreased tumor
growth in experimental animals as compared to vehicle treated controls. SAMwas
found to bioavailable in the serum of experimental animals as determined by mass
spectrometry and no notable adverse side effects were seen including any change in
animal behavior. Results from these studies provide compelling evidence for the
therapeutic potential of SAM in breast cancer to provide the rationale for initiating
clinical trialswith SAMinpatientswithbreast andother commoncancers asmono-
therapy or in combination setting with current therapeutic agents to reduce cancer
associatedmorbidity andmortality.
#4347 Epigenetic targeting of DNMT1 in adipocytes inhibits high-grade
serous ovarian cancer cell migration and invasion through TIMP3 upregula-
tion. Jessica Tang, Fang Fang, Aaron Buechlein, Pietro Taverna, Kenneth P.
Nephew. Indiana University, Bloomington, IN.
Ovarian cancer frequentlymetastasizes to the omentumand adipocytes play a
signifıcant role in tumor progression. As methylation levels in obese adipose
tissue are increased due to increased DNMT1 levels and activity, it was of inter-
est to test the hypothesis that inhibitingDNMT1would reverse adipocytemeth-
ylation, alter adipokine secretion, and decrease migration and invasion of ovar-
ian cancer cells towards adipocytes. Human adipocytes were seeded in a 24-well
plate and treatedwith low-dose guadecitabine (100nMdaily for 3 days). Ovarian
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cancer cells (SKOV3, Kuramochi, OVCAR4, OVCAR8) were seeded in the Boy-
den chamber and allowed tomigrate or invade toward adipocytes for 8 and 16h,
respectively. Expression of epithelial-mesenchymal transiton (EMT) markers
(SLUG, FN1, TWIST1) were assessed by qRT-PCR. Adipocyte-conditionedme-
dia was used to culture ovarian cancer cells in clonogenicity assay and a human
adipokine array (R&D Systems) was used to assess changes in cytokine secre-
tion. DNMT1 protein levels in adipocytes were determined by western blot. To
determine a possible mechanism, DNA and RNA from guadecitabine-treated
adipocytes were subjected to methylcapture-sequencing (MBD-seq) and RNA-
seq, respectively. Guadecitabine treatment of adipocytes decreased (P0.05)
migration of OVCAR4 and OVCAR8 (35% and 40%, respectively, compared to
control), and a 50% decrease (P0.05) in invasion towards adipocytes after
guadecitabine treatment was observed forOVCAR4, OVCAR8, andKuramochi
cells. Expression of EMTmarkers SLUG, FN1 and TWIST1 decreased (P0.05)
after guadecitabine treatment. Conditioned media from guadecitabine-treated
adipocytes decreased (P0.05) clonogenic survival by 18%compared to control.
Adipokine array results revealed increased secretion of LIF (lipoprotein lipase
inhibitor) and TIMP3 (metalloproteinase inhibitor) after guadecitabine treat-
ment (1.6- and 1.8-fold increase, respectively; verifıed by qRT-PCR). Treatment
with recombinant TIMP3 (50nM) decreased invasion of OVCAR8 (63%,
P0.001) and OVCAR4 cells (73%, P0.05). DNMT1 protein levels in adi-
pocytes decreased in the presence of guadecitabine, despite the presence of a
DNA synthesis inhibitor. Ingenuity Pathway Analysis (IPA) of MBD-seq data
showed signifıcant changes in cell-to-cell signaling and interaction pathways
(FC10; FDR0.05). RNA-seq demonstrated increased expression of matrix
metalloprotease inhibitors (THSB2, TFPI2, and NDRG4) and IPA analysis re-
vealed a signifıcant change in regulation of EMT pathway (FC  1.5; FDR
0.05).Guadecitabine treatment of adipocytes alters adipokine secretion result-
ing in decreased cancer cell migration and invasion. In addition to direct effects
on ovarian cancer cells, hypomethylating agents may impact the tumor mi-
croenvironment to alter adipokine secretion leading to decreased metastasis.
#4348 Methylation analysis of uveal melanoma reveals defınitive patterns
in tumors harboring BAP1 mutations.Michael Durante, Matthew Field, Ste-
fan Kurtenbach, Parker Bussies, Christina Decatur, J.WilliamHarbour.Univer-
sity of Miami Miller School of Medicine, Fort Myers, FL.
Introduction: Uveal melanoma (UM) is the most common primary intraoc-
ular malignancy and can be classifıed by gene expression profıling into two
distinct molecular classes that correspond to metastatic risk: Class 1 (low risk)
and Class 2 (high risk). The less aggressive Class 1 UMs express a more differ-
entiated phenotype and exhibit numerous characteristics of normal uveal mela-
nocytes, while the metastasizing Class 2 UMs display loss of melanocytic differ-
entiation and have acquired a primitive, stem-like phenotype. The majority of
Class 2 UMs harbor loss of chromosome 3 in addition to inactivating mutations
of the tumor suppressor BAP1, which also catalyzes ubiquitin removal from
histone H2A and modulates gene expression. Histone modifıcations have been
shown to be associated with DNA methylation and this study investigates the
globalmethylation and gene expression changes in BAP1mutant tumors.Meth-
ods: RNA-Sequencing data and Illumina HumanMethyl 450K BeadChip Array
data obtained from 92 primary uveal melanoma tumors was analyzed using
optimized pipelines. Results: This analysis revealed that the more aggressive
Class 2 tumors exhibit a distinct pattern of hypermethylation and silencing of
developmental genes involved in neural crest migration and differentiation.
Chromosomal regions that were signifıcantly enriched for hypermethylated
genes with decreased gene expression in Class 2 tumors included chromosome
3p14-26, 3q12-29 and 8p12-22, whereas the only signifıcantly enriched region
for genes that were hypomethylated with increased gene expression in Class 2
tumors was chromosome 8q22-24. Additionally, BAP1 itself was differentially
hypermethylated in Class 2 UMs, suggesting that it may regulate its own tran-
scription. Conclusions: Class 2 UMs harboring BAP1 mutations displayed dis-
tinct regions of differential hypermethylation in comparison to Class 1 UMs. In
these tumors, themost signifıcantly hypermethylated regions occurred on chro-
mosome 3 and in regions that were enriched for genes encoding neural crest
guidance cue proteins that regulate homing,migration and invasion. These fınd-
ings suggest that BAP1 mutations are associated with marked reorganization of
the DNA methylome, providing new insights into the pathophysiology of UM
and suggesting that methylation may serve as a diagnostic to further stratify
metastatic risk. Furthermore, these fındings may open new opportunities for
targeted therapy of Class 2 UMs.
#4349 Adverse & anticancer activities of 5-azaCdR & DNA methyltrans-
ferase (DNMT) isoform specifıc inhibitors: therapeutic implications. David
Cheishvili, Moshe Szyf.McGill, Montreal, Quebec, Canada.
Activation of methylated and silenced promoters of genes that suppress
tumorigenesis has been the rationale behind the clinical use of DNMT family
inhibitor 5aza for treating cancer. However, the adverse effects of general
DNA methylation inhibition on tumors through activation of tumor pro-
moting and prometastatic genes as well adverse effects on normal cells have
not been comprehensively assessed, nor is it known which particular DNMT
is responsible for regulating these adverse effects. A related critical question
is whether such potential toxicity could be reduced by targeting a specifıc
isoform of DNMT. We, therefore, performed a comprehensive molecular
characterization of the effects of the pan DNMT inhibitor 5aza and isoform-
specifıc inhibition of DNMT1, DNMT3a and DNMT3b by shRNA on cell
growth and invasiveness, the methylome and transcriptome of the breast,
liver and lung cancer cells as well as their normal primary cell counterparts.
Our results suggest that 5aza causes general DNA methylation inhibition
both as far as genomic features as well as the genes that are affected. This
results in activation of genes involved in promoting cancer and metastasis in
both cancer and normal cells. 5aza also induces rampant activation of retro-
viral elements and ectopic transcription initiation in gene bodies and inter-
genic regions. Second, isoform-specifıc exhibit a more limited and specifıc
profıle of activity on promoter methylation and gene expression. Third, the
adverse profıle of 5aza corresponds to the effects of specifıc inhibition of
DNMT3a suggesting that the adverse effects of 5aza are partly mediated
through inhibition of DNMT3a. Fourth, specifıc inhibition of DNMT1 re-
sults in an enriched inhibition of DNA methylation in promoters and inhi-
bition of growth without triggering activation of tumor suppressor genes
and a more favorable molecular footprint on cancer cells. Our data provide a
comprehensive assessment of the impact of DNA methylation inhibition on
normal and cancer cells and points to the potential adverse effects of such an
approach. However, since the different DNMTs have a different molecular
footprint, these adverse effects might be inhibited using isoform-specifıc
DNMT inhibitors. Our data needs to be considered for further clinical de-
velopment of DNMT inhibitors.
#4350 Cell-of-origin differentiation stages defınemethylation-based sub-
types of human colorectal cancer. Felix Bormann,1 Manuel Rodríguez-Pare-
des,1 Yehudit Bergman,2 Heinz G. Linhart,3 Frank Lyko1. 1German Cancer Re-
search Center, Heidelberg, Germany; 2Institute for Medical Research Israel-
Canada, Hebrew University Medical School, Jerusalem, Israel; 3Asklepios Klinik
Lindau, Lindau, Germany.
Introduction: Colorectal cancer accounts for a signifıcant fraction of cancer-
related mortalities, but has proven to be surprisingly refractory to consensus
pathological andmolecular subclassifıcation. Similarly, little is known about the
molecular profıles of colorectal cancer cells-of-origin. DNA methylation is an
important epigenomic marker of cellular identity and can therefore be used to
infer cancer cells-of-origin.Methods: Infınium 450k data from colorectal cancer
samples provided by “The Cancer Genome Atlas” was applied to a consensus
clustering algorithm. The identifıed epigenetic subgroups were tested for fea-
tures including well established clinical parameters or subgroup specifıc gene
expression. Additionally, the subgroups were compared with Infınium 450k
data of non-malignant colorectal adenomas. Finally, clinical signifıcance was
addressed by testing for subgroup specifıc overall survival rates. Results: Analy-
sis of the TCGA dataset defıned 5 distinct epigenetic subtypes of human colo-
rectal cancer. These subgroups showed an overlap to the microsatellite instabil-
ity phenotype and theCpG islandmethylator phenotype. Gene expression based
analysis revealed that the subtypes also form a continuum of epigenetic pro-
grams reflecting various intestinal crypt cell differentiation stages. Patient sur-
vival correlated with the differentiation stage, with a particular poor prognosis
for patients with stem cell-related signatures. Interestingly, its prognostic poten-
tial outperformed a recently established gene expression-based classifıer. Fi-
nally, non-malignant colorectal adenomas could be classifıed into the same
methylation subtypes, reflecting their shared cell-types of origin with carcino-
mas Conclusion: Our results establish a novel and clinically relevant approach
for colorectal cancer classifıcation and illustrate how differences in the cell-type
of origin shape the tumor methylome.
#4351 Effects of epigenetic agents on methylation of DNA in vitro and in
vivo, as measured with stable isotopically labeled methionine. Lawrence An-
derson,1 Eva Majerova,2 Kimberly D. Hill,2 John Carter,2 Jesse Stottlemyer,2
Howard Stotler,2 Melinda G. Hollingshead,1 Jerry M. Collins1. 1NCI, Frederick,
MD; 2FNLCR Leidos Biomedical Research Inc., Frederick, MD.
Background: Modulation of cytidine methylation in DNA continues to be
actively investigated as a target for chemotherapy. The primary source ofmethyl
groups is methionine, via S-adenosyl-methionine (SAM) as the direct methyl
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donor for DNA methyl transferases, e.g., DNMT1. Methods were developed
using stable isotopes and mass spec detection to examine the flux of the DNMT
reaction and modifıcation to this flux by cytidine analogs such as decitabine, an
established hypomethylation agent, and 5-aza-4=-thio-2=-deoxy-cytidine
(AzaTdC), currently under development at NCI. Methods: For in vitro studies;
A549, H23, HCT116, H522, and OVCAR3 cell lines grown in RPMI1640 media
supplemented with 10% FBSwere exposed to D3-methionine(20uM) and either
decitabine or AzaTdC (NSC77586) at 0 to 5uM in themedia for 0 to 48hr. For in
vivo studies; mice were maintained under standard ACUC protocols and prac-
tices. Tumors were grown SC in the flank area. Stable labeledmethionine, decit-
abine and AzaTdC were administered as an oral bolus. At set times, mice were
sacrifıced and tumors, tissues and plasma samples collected. DNAwas extracted
and purifıed from cells and tissues using PureLink Genomic DNA kits (Invitro-
gen) according tomanufacturer’s instruction. The purifıedDNAwas digested to
nucleosides for analysis. The isotopic enrichment in 5-methyl-deoxy-cytidine
(mdC)was determined by analysis usingHPLC coupled to aQEmass spectrom-
eter (Thermo Scientifıc). Results: D3-methionine was found to be an effıcient
precursor via SAM for themethylation of cytidine inDNA. Fortifıcation of basal
media (100uM methionine) with 20uM D3-methionine yielded D3-mdC en-
richment of 5-15% in 24 hr, depending on cell line. All cell lines were found to
have some enrichment. Treatment of cells with either decitabine or AzaTdC
caused a concentration dependent reduction of the enrichment for mdC in
DNA. In mice, after an oral dose of D3-methionine, enrichment of methionine
and SAM in plasma peaked within 1hr and fell to 5% of peak levels within 5hr.
Methionine and SAM enrichment in tissues followed similar time curves. At
50mg/kg of D3-methionine, no perturbation was observed for endogenous lev-
els of either methionine or SAM. Enrichment of mdC in DNAwas detectable in
1hr, maximal in 5hr, and remained constant for up to 48hr. When mice were
treated with 1-2 mg/kg of either decitabine or AzaTdC along with D3-methio-
nine, the level of enrichment ofmdC inDNAwas reduced by 20-70% in tumors,
bone marrow and intestine. Conclusions: Stable labeled methionine can be effı-
ciently used to monitor the flux of methyl groups into mdC in DNA, both in
vitro and in vivo. Changes in the flux of the methylation reaction can be used to
assess the extent and time course for inhibition caused by cytidine analogs.
These techniques may have relevance for improvement of doses and schedules
to produce epigenetic modulation. Funded by NCI Contract No.
HHSN261200800001E
#4352 Identifıcation of ZFP42/REX1 as a regulator of cancer stemness in
CD133 liver cancer stem cells by genome-wide DNA methylation analysis.
Steve Tin-Chi Luk,1 Man Tong,1 Kai Yu Ng,1 Kevin Yuk-Lap Yip,2 Xin Yuan
Guan,1 Stephanie Ma1. 1The University of Hong Kong, Hong Kong; 2The Chinese
University of Hong Kong, Hong Kong.
The existence of a cancer stem cell (CSCs) subset is well established in hepa-
tocellular carcinoma (HCC). This subset can be characterized by its CD133
expression. Since the discovery of thismarker, studies have revealed deregulated
pathways and epigenetic alterations associated with this subset, but few have
focused on changes inDNAmethylation. This study aims to fıll this research gap
by discovering aberrant DNA methylation patterns governing CD133 CSC-
driven HCC. Results from Infınium HumanMethylation450 BeadChip (Hu-
Met450 BeadChip) have led to the discovery of differential methylation patterns
between CD133 liver CSCs and matched CD133- differentiated samples.
ZFP42/REX1 is one of the top-ranking differentially methylated candidates.
Probes corresponding to its promoter are extensively hypermethylated in the
CD133 samples. To explore the hypothesis that promoter DNA hypermethyl-
ation modulates REX1 expression, REX1mRNA levels were fırst validated to be
down regulated in sorted CD133 HCC cell lines (n2) and HCC samples
(n46, p0.05) byRT-qPCR.Upon5-AZA treatment, only low-REX1-express-
ing cells re-expressed REX1. By in silico prediction, a CpG island of interest
located in the REX1 promoter region was selected for further investigation.
Results of pyrosequencing of this CpG island show that REX1 expression ap-
pears to be negatively correlated with the degree of DNA methylation in HCC
cell lines (n3); and that HCC samples (n13) exhibit a predominantly hyper-
methylated state compared to thematched non-tumor samples. To add onto the
clinical relevance of REX1, two HuMet450 BeadChip datasets of HCC sample
cohorts (GSE54503 and GSE60753) were obtained from Gene Expression Om-
nibus (GEO). In these cohorts, the CpG probes corresponding to the REX1
promoter region are signifıcantly hypermethylated (p0.01) in HCC samples
compared to the adjacent non-tumor tissues. Lentiviral-based approaches were
adopted to establish stable REX1 overexpressing and knockdown cells in HCC
cell lines. REX1 expression appears to be negatively correlated with the cells’
abilities to migrate, invade, and form foci in vitro; and tumorigenicity in vivo.
ChIP-seq has been adopted to study the DNA-binding property of REX1 in
HCC cells. These fındings suggest that REX1 may play a part in mediating var-
ious cancer properties in HCC.
#4353 Polyphenol-mediated epigenetic reactivation of tumor suppressor
gene SEMA3A in breast cancer cells.Megan Beetch,1 Katarzyna Lubecka,1 Lu-
cinda Kurzava,1 Kirsty Flower,2 James M. Flanagan,2 Barbara Stefanska1. 1Pur-
due University, West Lafayette, IN; 2Imperial College London, London, United
Kingdom.
Alterations in DNAmethylation occur in cancer, and may underlie silencing
of genes with tumor suppressor functions. Reversing DNA methylation, thus
potentially reactivating genes that combat cancer, constitutes a promising anti-
cancer strategy. Interestingly, studies have indicated that certain dietary poly-
phenols, such as resveratrol present in grapes, exert anti-cancer effects through
epigenetic regulation of gene expression. However, studies have been limited to
candidate genes, and comprehensive and mechanistic insights are missing. In
the present study, following genome-wide DNAmethylation analysis with Illu-
mina 450K BeadChip array, we identifıed CpG sites within regulatory regions of
tumor suppressor genes that are hypomethylated upon treatment of breast can-
cer cells with resveratrol. Non-invasiveMCF10CA1h and invasiveMCF10CA1a
human breast cancer cell lines were used as an experimental model. Pyrose-
quencing and QPCR were performed to assess respectively methylation and
expression of selected genes. Chromatin immunoprecipitation (ChIP) was ap-
plied to assess binding events. We identifıed 990 hypomethylated CpG sites in
MCF10CA1h and 1,146 hypomethylated CpG sites in MCF10CA1a cells upon
9-day treatmentwith 15Mresveratrol as comparedwith control untreated cells
(differential methylation -0.05, nominal p0.05, limma t-test). Those CpG
sites corresponded to approximately 650 genes that were predominantly associ-
ated with tumor suppressor function in cancer. We selected tumor suppressor
gene SEMA3A as resveratrol target for further investigation. As array data indi-
cated, resveratrol led to reduction in methylation of SEMA3A promoter region.
The 18%decrease inmethylation of SEMA3Awas confırmed by pyrosequencing
in MCF10CA1a breast cancer cells. This coincided with 23% up-regulation of
SEMA3A expression. In addition, analysis of the effects on DNA methyltrans-
ferases (DNMTs) demonstrated that resveratrol decreases expression of
DNMT3A. Furthermore, ChIP indicated decreased occupancy of DNMT3A at
the SEMA3A promoter, suggesting that down-regulation and lower affınity of
this de novo DNAmethylating enzyme to DNAmaymediate decrease in meth-
ylation within tumor suppressor genes upon resveratrol exposure. In support of
reactivation of SEMA3A, active histone mark, H3K9ac, was signifıcantly in-
creased and repressive histone mark, H3K27me3, was signifıcantly decreased
after resveratrol treatment, indicating an open, more transcriptionally active
chromatin state. These results demonstrate a role for polyphenol-mediated epi-
geneticmodifıcations in reactivation of tumor suppressor genes in breast cancer
and pave the way for further studies on the mechanism driving these changes.
This study was supported by the PCCR, Indiana CTSI (UL1TR001108), Wom-
en’s Global Health Institute, and USDANational Institute of Food and Agricul-
ture (Hatch project 1005656) granted to BS.
#4354 Methylation-mediated silencedPYCARD plays a key role in human
prostate cancer. Shinichi Fukushige, Toshiya Miyauchi, Teppei Okubo, Koji
Mitsuzuka, YoichiArai, AkiraHorii.TohokuUniv. Graduate School ofMedicine,
Sendai, Japan.
Epigenetic gene silencing by aberrant DNA methylation leads to loss of key
cellular pathways in tumorigenesis. In order to analyze effects of DNA methyl-
ation in prostate cancer, we constructed LNCaP-derived human prostate cancer
cells that can induce global reactivation of hypermethylated genes by themethyl-
CpG targeted transcriptional activation (MeTA) method. In MeTA, a cassette
construct of MBD2-derived methyl-CpG binding domain (MBD) with NFB-
derived transcriptional activation domain is transfected into cancer cells. Then
expressed MBD domain specifıcally binds to the hypermethylated promoter
regions, and NFB transcriptional activation domain recruits p300/CREB-
binding protein (CBP) and reactivates hypermethylation-mediated silenced
genes. A cell proliferation assay indicated that MeTA suppressed the growth of
LNCaP cells. Furthermore, both flow cytometry and TUNEL assays demon-
strated that MeTA induced apoptosis. In order to search genes responsible for
apoptosis, we performed gene expression microarray analysis of MeTA-unin-
duced and -induced LNCaP cells: Five genes encoding apoptosis-inducing fac-
tors upregulated two-fold or more in accordance with the induction of MeTA;
PYCARD (PYD and CARD domain containing), TNFRSF25 (tumor necrosis
factor receptor superfamily 25), HRK (harakiri, BCL2 interacting protein), BIK
(BCL2 interacting killer), and CIDEA (cell death-inducing DFFA-like effector
a). These genes also contained CpG islands (CGIs) within 	 1,000-bp of the
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transcription start site. We focused on PYCARD and TNFRSF25 because these
two genes upregulated 10-fold or more in accordance with the induction of
MeTA. We found that both genes were hypermethylated and showed low ex-
pression levels in LNCaP prostate cancer cells, whereas only PYCARD was un-
methylated in RWPE-1 normal prostate epithelial cells. We further analyzed
primary prostate cancer tissues and found tumor-specifıc promoter hypermeth-
ylation of PYCARD in 53.8% (7/13; P 0.01). These results suggest that meth-
ylation-mediated silencing of PYCARD contributes to escape from apoptosis in
human prostate cancer, and MeTA may provide important clues to analyze
changes in cancer cell phenotypes by DNA methylation alterations.
#4355 Altered DNA methylation in breast milk from women with breast
cancer. Lucas A. Salas,1 Sara N. Lundgren,1 Eva P. Browne,2 Elizabeth C. Pun-
ska,2 Douglas L. Anderton,3 Kathleen F. Arcaro,2 Brock C. Christensen1. 1The
Geisel School of Medicine at Dartmouth, Lebanon, NH; 2University of Massachu-
setts Amherst, Amherst, MA; 3University of South Carolina, Columbia, SC.
Prior candidate gene studies have shown that methylation-induced silencing
of tumor suppressor genes in breast milk is related with history of breast biopsy,
an established risk factor for breast cancer. To further establish the utility of
breast milk as a tissue-specifıc biospecimen for investigations of breast carcino-
genesis we measured genome-wide DNA methylation in breast milk from
women with and without a diagnosis of breast cancer. Breast milk provides a
source of cells without invasive procedure that is available during a window of
increased breast cancer risk. Actively lactating women were enrolled and con-
sented through the University of Massachusetts Amherst breast milk study tar-
geting high risk subjects. Participants completed a questionnaire to provide
demographic and breast cancer risk factor data. Genome-wide DNA methyl-
ation levels were quantifıed using the Illumina 450K HumanMethylation array.
Data was processed in R using RnBeads. Beta-values were normalized (FUN-
norm), low quality probes were fıltered and transformed to M-values. Linear
mixed effects models were fıt including a random effect for subject and adjusted
for history of breast biopsy, age, bodymass index, age of the baby, and estimated
cell type proportions, an interaction term for time of diagnosis was included.
DNA methylation in women with breast cancer (n9), was compared with
women without a history of breast cancer (n22). Among women with a diag-
nosis of breast cancer there were two groups: those diagnosed within one year of
donating breast milk, and those diagnosed more than one year before sample
collection. Four women in the control and fıve women in the cancer group
provided bilateral breast milk samples at recruitment and both samples were
included in the analyses. CpGs with signifıcant differential methylation were
tested for enrichment in gene pathways using the KEGGdatabase.We identifıed
215 differentially methylated CpG sites in women diagnosed within one year of
sample donation compared with women without a diagnosis of breast cancer
(Q0.10). The top sites were in ATF3 (an adaptive-response gene linked to
epithelial mesenchymal transition), and in COL5A3 (an extracellular matrix
gene related to metastasis potential). In addition, among women with a breast
cancer diagnosis more than one year before sample donation we identifıed 8148
differentially methylated CpG sites compared with women without a breast
cancer diagnosis (Q0.05). Five sites were in OTOF a calcium-sensing protein
in cancer. These differentially methylated sites were signifıcantly enriched in
relevant pathways such metabolic (Q 3.12E-116), and cancer pathways (Q
2.08E-58), PI3K-Akt signaling pathway (Q7.05E-40), and transcriptionalmis-
regulation in cancer (Q1.41E-29). Future studies are needed to validate our
fındings in independent subjects and to investigate the utility of breast milk as a
biospecimen for understanding the molecular basis of disease risk and prospec-
tive risk assessment.
#4356 Methylation and expression of androgen receptor in Papillary Thy-
roid Cancer. Anvita Gupta,1 Timmy O’Connell,1 Melanie Jones,1 Karnika
Singh,1Monica Schwarcz,1 JK Rasamny,1 Dorota Halicka,1 Jiangwei Li,1 Codrin
Iacob,2 Nina Suslina,2 Stimson Schantz,2 Edward Shin,2 Zbigniew Darzynkie-
wicz,1 Raj Tiwari,1 Jan Geliebter1. 1New York Medical College, Valhalla, NY;
2New York Eye and Ear Infırmary, New York, NY.
Papillary Thyroid Cancer (PTC) accounts for the vast majority of thyroid
cancers and comprises more than 90% of neoplasms in the endocrine system. In
the last 30 years, the incidence and prevalence of PTC has dramatically risen in
developed countries, with a three-fold higher incidence in women than in men.
With an overall fıve-year survival rate of 98.1%, early stage PTC has a favorable
prognosis. However, PTC exhibits increased aggressivenesswith poor prognosis
in men diagnosed with the disease. These striking observations led us to explore
the role of androgen and androgen receptor (AR) in this disease. We found an
approximately 70% decrease in median AR RNA expression (p0.0001) in 24
PTC patient tissue samples (from New York Eye and Ear Infırmary), compared
to matched, normal thyroid tissue. A similar trend was also observed in about
500 PTC samples in the TCGA database, compared with 60 normal thyroid
samples.Methylation was explored as a cause for the down-regulation of the AR
mRNA in disease pathogenesis, using in-silico methods such as Wanderer, a
Maplab tool for TCGA RNA data visualization, and MethylPlotter. A methyl-
ation pattern of the AR gene, spanning 7 exons, was generated with 30 methyl-
ation sites and, AR in PTC was found to be predominantly methylated at ten
sites, compared to matched normal thyroid tissue samples, in the TCGA. Pa-
tients with ten or more hypermethylated sites on the AR gene in tumor tissue
exhibited a signifıcant decrease in the AR RNA expression in the tumor, versus
matched normal thyroid tissue. Methylation of AR (10 or more sites) was ac-
companied by a nine-fold reduction in AR expression in male PTC, and a fıve-
fold decrease in female PTC. This reduction was not observed in hyper- or
equally-methylated normal thyroid tissue. We selected eleven methylation sites
in the CpG islands that we predict are essential for AR silencing, with four sites
in the AR promoter region. Additionally, we found AR gene-specifıc and global
transcription activators to be downregulated, and repressors up-regulated in the
PTC samples. The data adds importance to our previous studies showing induc-
tion of senescence inAR-transfected PTC cells in culture, whenAR is stimulated
with 5-dihydrotestosterone. In conclusion, our study demonstrates a fıne reg-
ulation and differential expression of AR associatedwithmethylation, and high-
lights the signifıcance of epigeneticmodifıcations in thyroid cancer progression.
#4357 ESRP1 overexpression and its role in ovarian cancer. Mi Jeong
Kwon. Kyungpook National Univ., Daegu, Republic of Korea.
Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2) areRNAbind-
ing proteins which are recently known to be involved in tumor progression via
regulation of alternative splicing of cancer-associated genes. However, their ex-
pression and clinical signifıcance in ovarian cancer remain unclear. Here, we
found that ESRP1 and ESRP2 gene expression is upregulated in ovarian cancer
cells compared with immortalized ovarian surface epithelial (IOSE) cells and
their overexpression at protein level was also confırmed in ovarian cancer tis-
sues. Consistent with TCGA data of ESRP1 gene amplifıcation, higher ESRP1
gene copy number was observed in ovarian cancer cells compared with IOSE
cells, whereas there was little correlation between gene copy number and gene
expression in ovarian cancer cells. Importantly, their gene expression was in-
versely correlated with DNA methylation in ovarian cancer cells and ESRP2
overexpression in ovarian cancerwas signifıcantly associatedwithDNAhypom-
ethylation (P 0.036). Of note, TCGA data analysis showed that high ESRP1
gene expression is signifıcantly associated with shorter 5-year survival of pa-
tients with ovarian cancer. Ectopic expression of ESRP1 in ESRP1 low-express-
ing mesenchymal type ovarian cancer cells increased cell proliferation, whereas
it suppresses cell migration. Furthermore, our results revealed that the effect of
ESRP1 overexpression on cell proliferation andmigration is related to activation
of the Akt/CyclinD pathway and increased of E-cadherin expression. In conclu-
sion, our fındings suggest that ESRP1 overexpression is associated with poor
outcome of patients and ESRP1 may play a cancer-promoting role in ovarian
cancer.
#4358 The immunomodulatory anticancer agent RRx-001 induces a vac-
cine-like interferon response through epigenetic induction of viral mimicry.
Susan J. Knox. Stanford University School of Medicine, Stanford, CA.
RRx-001, sourced from the aerospace industry and currently in phase II clin-
ical trials, is a novel anti-cancer agent thatmediates immunomodulatory effects,
either directly through polarization of tumor associated macrophages or indi-
rectly through vascular normalization and increased T-lymphocyte infıltration.
With multiple additional mechanisms of action including upregulation of oxi-
dative stress, depletion of GSH and NADPH, anti-angiogenesis and epigenetic
modulation, RRx-001 is being studied as a single chemotherapeutic agent to
resensitize tumors to prior therapy and to prime tumors to respond to radiation,
chemotherapy and immunotherapy in combination therapy studies. In this
study, we identifıed another mechanism, viral mimicry, which refers to the ’un-
silencing’ of epigenetically repressed viral genes present in the tumor that pro-
vokes an immune response and may contribute to the anti-cancer activity of
RRx-001. Specifıcally, RRx-001 inhibited the growth of human colon cancer cells
(HCT 116) and decreased levels of the DNA methyltransferases Dnmt1 and
Dnmt3a in a time and dose-dependent manner. Treatment of HCT 116 cells
with 0.5 M RRx-001 for 24 hours signifıcantly increased transcripts of inter-
feron (IFN)-responsive genes and this inductionwas sustained for up to 4 weeks
after transient exposure to RRx-001. ELISA assays showed that RRx-001 in-
creased secretion of type I and III IFNs by HCT 116 cells, and these IFNs were
confırmed to be bioactive. Transcription of endogenous retroviruses was in-
duced by RRx-001 through demethylation of the promoter of endogenous ret-
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rovirus genes as determined by methylation-specifıc polymerase chain reaction
and combined bisulfıte restriction analysis. Immunofluorescence staining with
J2 antibody confırmed induction of double-stranded RNA. In conclusion, tran-
sient exposure of HCT 116 cells to low-dose RRx-001 induced transcription of
silenced retroviral genes present in the cancer cell DNA with subsequent syn-
thesis of IFN in response to this “pseudo-pathogenic” stimulus, mimicking an
antiviral defense. RRx-001-mediated IFN induction may have the potential to
improve the effıcacy of immunotherapies as well as radiotherapy, standard che-
motherapies and molecularly targeted agents when used in combination.
#4359 Systematic approach to methylation biomarker development in
chronic lymphocytic leukemia, breast and lung cancers.TomaszK.Wojdacz,1
Iben Daugaard,2 Tina Kjeldsen,2 Henrik Hager,3 Thomasz Kristensen,4 Louise
Kristensen,4 Michael B. Møller,4 Lise Lotte Hansen2. 1Aarhus Institute of Ad-
vanced Studies, Aarhus, Denmark; 2Aarhus University, Aarhus, Denmark; 3Aar-
husUniversityHospital, Aarhus, Denmark; 4OdenseUniversityHospital, Odense,
Denmark.
There is no doubt that testing for disease specifıc methylation changes can
guide disease risk assessment, facilitate detection of the disease, support prog-
nostication and personalization of treatment as well as guide post treatment
patient care (1). Nevertheless, the use of methylation biomarkers in standard
patient care is still marginal. Diffıculties in implementation of methylation bio-
marker testing in standard in-vitro diagnostics are mainly attributed to chal-
lenges in establishment of the systematic approach allowing for effıcient discov-
ery and subsequent validation of clinical utility of potential disease specifıc
methylation biomarkers. We have combined state-of-the-art genome wide
methylation screening technologies (including: newest Illumina Methylation-
EPIC 850k BeadChip) enabling methylation biomarker discovery with the cost
and time effıcient locus specifıc technologies to streamline the development,
validation and implementation of methylation biomarkers for clinical disease
management. With the use of technologies that in an affordable fashion enable
screening for genome wide methylation changes in a substantial number of
clinical samples, we were able to discover clinically relevant disease specifıc
methylation signatures e.g. inCLL. The high technical complexity of the genome
wide screen technologies prevents them for being straightforward applicable
in diagnostic settings. Thus we used techniques such as Methylation-Sensi-
tive High Resolution Melting (MS-HRM) (2) to develop assays fulfılling the
requirements for diagnostic applications. Subsequently, we evaluated the
clinical relevance of the most promising biomarker candidates in chronic
lymphocytic leukaemia, breast and lung cancers, using these assays (3, 4).
Overall, our workflow allows fast and effıcient validation of not only already
existing biomarker candidates but also discovery of new disease specifıc
methylation changes that show promise for clinical implementation. Refer-
ences: (1) Wojdacz TK. Expert Rev Mol Diagn. 2012 Jan;12(1):39-47 (2) for
BLUEPRINT consortium, Nature Biotechnology, Vol. 34, Nr. 7, s. 726-737.
(3) Daugaard I et al., Sci Rep. 2016 Oct 26;6:35807. (4) Wojdacz TK et al..
Breast Cancer Res. 2014 Feb 3;16(1):R17
#4360 Epigenetic alteration at HBV integrants is associated with methyl-
ation at flanking human genome. Yoshiyuki Watanabe, Ritsuko Oikawa, Hi-
royuki Yamamoto, Fumio Itoh. St. Marianna Univ. School of Medicine, Kawa-
saki, Japan.
Integration of DNA viruses into the human genome plays an important role
in various types of tumors, including hepatitis B virus (HBV)-related hepatocel-
lular carcinoma. However, the molecular details and clinical impact of HBV
integration on either human or HBV epigenomes are unknown. Here, we show
thatmethylation of the integratedHBVDNA is related to themethylation status
of the flanking human genome. We developed a next-generation sequencing-
based method for structural methylation analysis of integrated viral genomes
(denoted G-NaVI). This method is a novel approach that enables enrichment of
viral fragments for sequencing using unique baits based on the sequence of the
HBV genome. We detected integrated HBV sequences in the genome of the
PLC/PRF/5 cell line and found variable levels of methylation within the inte-
grated HBV genomes. Allele-specifıc methylation analysis revealed that the
HBVgenomeoften became signifıcantlymethylatedwhen integrated into highly
methylated host sites. After integration into unmethylated human genome re-
gions such as promoters, however, the HBV DNA remains unmethylated and
may eventually play an important role in tumorigenesis. The observed dynamic
changes in DNA methylation of the host and viral genomes may functionally
affect the biological behavior of HBV. These fındings may impact public health
given thatmillions of people worldwide are carriers of HBV.We also believe our
assaywill be a powerful tool to increase our understanding of the various types of
DNA virus-associated tumorigenesis.
#4361 An integrated genome-widemethylation analysis with gene expres-
sion in normal breast tissues identifıes differentially methylated CpG loci
associatedwith obesity.Daniel Y.Weng,1Min-Ae Song,1 TheodoreM.Brasky,1
Catalin Marian,1 Renny S. Lan,1 Adana A. Llanos,2 Scott L. Spear,3 Bhaskar V.
Kallakury,3 Jo L. Freudenheim,4 Peter G. Shields1. 1The Ohio State University,
Columbus, OH; 2Rutgers School of Public Health and Rutgers Cancer Institute of
New Jersey, New Brunswick, NJ; 3Georgetown University, Washington DC, DC;
4School of Public Health and Health Professions, University at Buffalo, Buffalo,
NY.
Introduction: Obesity is a risk factor for breast cancer, but the underlying
mechanisms for this are only partially understood, and there has been only
limited study of breast tissues molecularly before cancer develops. Methods:
Breast tissues from healthy women undergoing reduction mammoplasty and
epidemiologic interviews (n121) were profıled for the whole genome tran-
scriptome (Affymetrix Human Transcriptome Arrays) and genome-wide DNA
methylation (InfıniumHumanMethylation 450 BeadChip array). Results: After
adjusting for confounding by age and race, 12,210 CpG dinucleotides with al-
teredmethylation levels correlatedwith bodymass index (BMI) (10,808 positive
correlations and1,402 negative correlations, FDR0.05). Among them 4,170
BMI-associated hypermethylated CpG dinucleotides (-1.5 kb from transcrip-
tion start site, 1st Exon, and 5’UTR) and 443 BMI-associated hypomethylated
CpGdinucleotideswere located in promoter regions. By integratingDNAmeth-
ylation and mRNA expression data, we identifıed 310 methylated genes that
correlated with gene expression (FDR0.05). Of these, 242 genes had higher
methylation status showing concurrent down-regulation in obese women, and
68 genes had lower methylation status showing concurrent up-regulation in
obese women. Among the affected genes involved in diseases and disorders for
inflammatory response, hereditary disorder, and immunological disease. Con-
clusions: This study provides evidence that obesity epigenetically deregulates
genes potentially involved in breast cancer that have functional relationships to
gene expression.
#4362 Coordinated regulation of several microRNAs in lung cancer pa-
tients. Irene Ferrer,1 Ana Salinas,2 AngelaMarrugal,1 Jon Zugazagoitia,1 Aman-
cio Carnero,2 Luis Paz-Ares,1 Sonia Molina-Pinelo1. 1Unidad de Investigación
Clínica de Cáncer de Pulmón Hospital 12 de Octubre-CNIO, Madrid, Spain;
2Instituto de Biomedicina de Sevilla (IBIS/HUVR/CSIC/Universidad de Sevilla),
Spain.
Background: Non-small cell lung cancer (NSCLC) accounts for approxi-
mately 85% of all lung cancers. NSCLCs are mainly classifıed adenocarcinoma
and squamous cell carcinoma. It seems more and more obvious that specifıc
molecular analyses are necessary to elucidate the complexity of clinically rele-
vant phenotypes which determine the lung carcinogenesis. This includes the
role of microRNAs (miRNAs) in the disease, involved in the complexity of gene
expression regulation. Differentmodulatormechanisms are involved in the bio-
genesis and function of miRNAs, one of them is DNAmethylation. Alterations
in these mechanisms may contribute to the tumor genesis and progression. The
purpose of this studywas to assessmiRNAmethylation patterns in patients with
NSCLC to study the potential of coordinate regulation of miRNAs as a relevant
mechanism involved in this pathogenesis. Materials and Methods: DNA meth-
ylation of gene clusters was analyzed by Illumina 70 subjects. The samples were
divided into two cohorts. A fırst cohort constituted from 47 patients who had
undergone surgical resection for clinical early stage NSCLC. A second group
from 23 subjects was used as health cohort. DNA was extracted using the
QIAampDNAMini Kit. For each assay, 500 ng ofDNAwas treatedwith sodium
bisulfate using EZ DNA Methylation™ Kit and cleaned with ZR-96 DNA
Clean-up Kit™, before standard Illumina amplifıcation, hybridization, and im-
aging steps. Methylation data were processed using the RnBeads R package.
Results: We identifıed two clusters clearly corregulated by methylation in lung
cancer, involving 49 miRNAs differentially hypomethylated in tumor samples
respect to control tissue. Some of these miRNAs have been implicated in several
pathways in cancer. Conclusions: Our results strongly imply hypomethylation
of two miRNA clusters, which represent key targets in unravelling of the mech-
anism of lung tumorigenesis.
#4363 Bisulfıte DNA sequencing analyses to detect methylation patterns
in the p73 gene promoter in prostate cancer cell lines.Nicholas E. Braganca,1
L. Michael Carastro,1 Johannes J. Schabort,1 Jong Y. Park2. 1The University of
Tampa, Tampa, FL; 2H. Lee Moffıtt Cancer Center & Research Institute, Tampa,
FL.
Transcription is regulated through a variety of different mechanisms. One
facet of transcriptional regulation is epigenetics, which is the regulation of
gene expression without altering the nucleotide sequence of the genome, but
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rather reversible modifıcations, e.g. CpG methylation. The CpG islands in
tumor suppressor gene promoters are often hypermethylated, thus down
regulating their expression. The p73 gene is a member of the p53 tumor
suppressor family of proteins, and like p53, has a bifurcated promoter. The
p73 P1 promoter transcribes a full-length mRNA, which then translates into
the transcriptionally active p73. The p73 P2 promoter transcribes a trun-
cated mRNA, which translated into transcriptionally inactive 
Np73. The

Np73 product lacks the N-terminal trans-activation domain that TAp73
possesses. This study sought to analyze the extent of DNAmethylation in the
CpG islands in the p73 P1 promoter of three prostate cancer (PCa) cell lines
(LNCaP, PC-3, and DU145), and primary prostate cells. We hypothesized
that the p73 P1 promoter would be hypermethylated in prostate cancer cell
lines and hypomethylated in primary prostate cells. The methylation status
of the p73 P1 promoter in all four prostate cell lines was analyzed by using
bisulfıte sequencing PCR (BSP). Our analyses revealed that a CpG island in
the p73 P1 was hypermethylated in LNCaP, PC-3, and DU145 cells com-
pared to primary prostate cells. Furthermore, among the three PCa cell lines
evaluated, the p73 P1 promoter was the most methylated in DU145 cells, and
the least methylated in LNCaP cells. The P1 region sequenced contained 28
CpG islands, and among them, only fıve were methylated in the primary
prostate cells (18% methylated), 23 were methylated in LNCaP cells (82%
methylated), 26 in PC-3 cells (93%methylated), and 28 in DU145 cells (100%
methylated). Furthermore, of the 28 CpG sites, 14 of them were differentially
methylated in the primary prostate cell line versus the three PCa cell lines
evaluated in this study. These data are consistent with the PCa tumor-de-
rived cell lines (LNCaP, PC-3, and DU145) having hypermethylated CpG
sites in the p73 P1 promoter compared to the primary prostate cell line.
#4364 Establishment and validation of a breast cancer panel using tar-
geted next generation bisulfıte sequencing (tNGBS). Matthew L. Poulin,1
Ryan Drennan,1 Andrew Miller,1 Andrew Miller,1 Ann Meyer,1 Garth H.
Rauscher,2 Liying Yan1. 1EpigenDx, Inc., Hopkinton, MA; 2University of Illinois
at Chicago, Chicago, IL.
Aberrant DNA methylation (e.g., global reduction in DNA methylation and
differential methylation of promoter regions) is a hallmark of cancer and may
function in various ways to influence transcription. We developed a panel of
bisulfıte specifıc methylation sequencing assays in order to assess the methyl-
ation status of large number of genes using pyrosequencing. By combining these
pyrosequencing assays into a targeted NextGen bisulfıte sequencing panel, we
can screen both a large number of genes and a large number of samples simul-
taneously. We fırst assembled the 40 pyrosequencing assays and sensitivity and
reproducibility were analyzed on pilot DNA samples isolated from FFPE tissue.
Assays were specifıcally designed to work in highly fragmented and cross-linked
DNA from formalin-fıxed, clinical samples. Initial pyrosequencing on these pi-
lot samples showed that 24 of the 40 assays gave quality validation and sample
results. Reasons that some assays were not successful may be due to the A/T or
G/C content within the amplicon, PCR Bias, low amplifıcation effıciency, or
strong cross-linking from fıxation within the assay to name a few. The initial 40
assays were next assembled in a combination of 7 multiplex PCRs in which
gradient PCRs were performed and analyzed for optimal multiplex amplifıca-
tion using a bioanalyzer. Final assay multiplexing combinations were estab-
lished andPCRbias testingwas performed by tNGBS on a sample set of high and
low methylated DNA mixed at different ratios. Assays with an R-square of less
than 0.9 between the expected and generatedmethylation from thismixingwere
removed, leaving us with 21 validated assays in our panel (9 of 24 assays that
were previously validated in pyrosequencing and 12 of 19 assays that could not
be validated in pyrosequencing). In the present study we looked at DNAmeth-
ylation changes in breast cancer development using paired adjacent normal,
invasive and in situ tissue from a 30 patients with breast cancer as well as 11
various normal tissues other than breast, and 12 cell lines for a total of 83 samples
in a panel of 21 genes. The results of the tNGBS were compared with the pyro-
sequencing results. This process of panel development, where small amounts of
bisulfıte treated DNA can be amplifıed in a target specifıc manner, prior to
sequencing, makes investigating a large number of samples on a large panel of
genes possible in a small amount of time. We observed a high correlation be-
tween the pyrosequencing and tNGBS sequencing results, andwe show that that
there are several genes that are either hypermethylated or hypomethylated in
tumor tissue when compared to adjacent normal tissue.
#4365 Epigenetic and biological effects of 5-azacytidine and RRX-001 on
DLD-1 colorectal cancer cell lines. Rory Kokelaar, Huw Jones, John Beynon,
Dean Harris, Gareth Jenkins. ABMU / Swansea University, Swansea, United
Kingdom.
Introduction. Extramural vascular invasion (EMVI) in rectal tumours is an
important risk factor for disease recurrence and death. Recent studies have dem-
onstrated CpG island hypermethylation phenotype (CIMP) to be an indepen-
dent risk factor for developing EMVI. This study investigates the cellular pro-
cesses linking hypermethylation with EMVI by an in vitro model of rectal
cancer, and assess the biological and epigenetic effects of known and putative
demethylating agents. Methods. Hypermethylated DLD-1 human colorectal
cancer cells were cultured for three days and treated daily with demethylating
agents 5-azacytidine (AZA) or RRx-001 across a dose range (0.5M to 5M).
Standard tests of population doubling (RPD) and cytotoxicity (trypan blue)
were performed across the dose range for each compound. Treated cells were
subjected to a 500m gel-insert scratch migration assay and video microscopy
was used to record time-to-convergence (TC). Methylation specifıc PCR was
performed on harvested cells across the dose range and compared to controls for
eight genes associated with CIMP (SOCS1, MINT-1, hMLH, NEUROG1,
THBD, HAND1, ADAMTS1, IGFBP3). Results. 5-azacytidine and RRx-001
both demonstrated 50% reduction in RPD at a dose of 2M, with a linear
dose-dependent retardation of population growth from 0.1M to 1.0M.
Trypan blue test also demonstrated linear increase in cytotoxicity for both
agents up to 1M. Mean TC was 38.6hrs/- 2.4hrs (1SD) for control, solvent
control (DMSO), and 0.5MAZA&RRx-001. Mean TC for 1.0Mand 2.0M
AZAwas 52.0hrs/- 3.0hrs and 91.0hrs/- 3.75hrs, respectively (p0.001).
Mean TC for 1.0M and 2.0M RRx-001 was 57.0hrs /- 2.0hrs and 96.0hrs
/- 6.0hrs, respectively (p0.005). BothAZA andRRx-001 demethylate 5 out
of 8 CpG islands across the dose spectrum. hMLH, SOCS, and IGFBP3 were
resistant to demethylation for both compounds at all doses. MINT, HAND, and
THBDwere partially demethylated by both agents, but ADAMTS1was demeth-
ylated by AZA only. In each of the genes that demonstrated CpG island demeth-
ylation the demethylation was incomplete, with strong methylated bands pres-
ent despite an additional demethylated band also being demonstrated. RRx-001
demonstrated a dose-dependent demethylation of NEUROG1 and THBD as
integrated density of demethylated bands decreased against increasing dose of
drug. Conclusions. This study demonstrates the demethylating ability of both
agents against themethylome of 5 out of 8 genes associated with CIMP, which is
a known to be associated with EMVI; an independent risk factor for poor prog-
nosis in rectal cancers. The biological and demethylating effects occur at doses
below those that may be considered cytotoxic, suggesting that demethylation its
self is reducing the rate of cell division and migration of cancer cells. Further
work is required to quantify the effects of both agents on the methylome of
DLD-1 cells, and to explore the mechanisms of action of both compounds.
#4366 CpG,CHGandCHHmethylation inRUNX3andMGMTgenes and
correlation with mRNA expression and serum concentration of various cy-
tokines in oesophageal cancer in Northeast Indian population. Snigdha Sai-
kia,1 Prajjalendra Barooah,1 Asad Ur Rehman,2 Preeti Sarmah,3 Mallika Bhat-
tacharyya,3 Bhabadev Goswami,3 Syed Akhtar Husain,2 Subhash Medhi1.
1Gauhati University Institute of Science and Technology, Gauhati University.,
Guwahati, India; 2Jamia Millia Islamia, New Delhi-110025, New Delhi, India;
3Gauhati Medical College Hospital, Guwahati, India.
Introduction: Oesophageal cancer (EC) has the highest prevalence in North-
eastern population of India. One step DNA repair is done by O6-methylguanine
methytransferase (MGMT) which is a ubiquitous repair protein that eliminates
DNA alkyl adducts. Runt-related transcription factor 3 (RUNX3), a transcrip-
tion factor of the transforming growth factor (TGF)- family and acts as a
tumour suppressor gene involved in the TGF–beta pathway. Objective: The
study was designed to evaluate the role of DNA repair gene (MGMT) and tu-
mour suppressor gene (RUNX3) through epigenetic modulation with mRNA
expression and its correlation with serum protein level correlation of cytokines
in EC cases. We also tried to evaluate the environmental and lifestyle factor’s
association with cytokines expression in EC cases. Methods: In this study a total
of 120 cases of EC cases and 100 normal controls were included in the study.
Promoter methylation is usually evaluated by methylation specifıc PCR (MSP),
a classical and semi-quantitative method. Searching for alternatives, we used
quantitative real time based methylation specifıc high resolution melting (MS-
HRM) analysis and next generation sequencing (NGS) methods. The quantita-
tive expression of inflammatory agents (IFN , IL4, IL6, IL10, IL2, TNF) in-
volved in tumerogenesis were analyzed by fluorescence based real time PCR and
by Luminex technology. Results: The CpG methylation of MGMT was signifı-
cantly correlated, while RUNX3 was not with EC. The non CpG methylation;
CHH and CHG were signifıcantly correlated for both MGMT and RUNX3
(p0.05). In addition, mRNA expression was signifıcantly correlated with pro-
moter methylation status of MGMT in CpG, CHG and CHH context but on the
contrary RUNX3 showed the negative association with CpG methylation
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whereas positive correlation was observed in CHG and CHH context. mRNA
and serum protein expressions of IFN , IL4, IL6, IL10, IL2, TNF were not
correlated with promoter methylation status of MGMT and RUNX3 genes.
Smoking habit was associated with IFN , IL6 and TNF for mRNA expression
and IL 2 for protein expression. Alcohol consumption was statistically associ-
ated with IL6 for for mRNA expression and IL 10 for protein expression. Betel
nut consumption was signifıcantly correlated with IL 4 and IL 6 for mRNA
expression and IFN , IL4, IL6, TNF were with protein expression. Tobacco
consumption was correlated with only protein expression of IL2 and IL6.
Smoked food consumption was statistically associated with IFN , IL4, TNF
for mRNA expression and IL6 and IL10 for protein expression. Conclusions:
Promoter methylation of MGMT was correlated with mRNA expression but
RUNX3 was not. Both RUNX3 and MGMT promoter methylation was not
found to be associated with alteration of cytokine expression whereas they were
associated with different life style factors in EC cases from North-East India.
#4367 LOX expression,LINE 1 DNA methylation and prognosis in oe-
sophageal cancer.Rebecca T. Kalikawe, Yoshifumi Baba, Yuki Kitano, Kensuke
Yamamura, Keisuke Miyake, Kenichi Nakamura, Hideo Baba. Kumamoto Uni-
versity, Kumamoto, Japan.
Background: In cancer cells, DNAmethylation may be altered in two princi-
ple ways; global DNA hypomethylation and site-specifıc CpG island promoter
hypermethylation. Since Long interspersed element-1 (LINE-1 or L1) consti-
tutes a substantial portion (approximately 17%) of the human genome, the ex-
tent of LINE-1 methylation is regarded as a surrogate marker of global DNA
methylation. In previous studies, we demonstrated that LINE-1 hypomethyla-
tion was strongly associated with a poor prognosis in oesophageal cancer, sup-
porting its potential role as a prognostic marker. Lysyl oxidase (LOX) is an
extracellular matrix remodelling enzyme and its upregulation has been associ-
ated with poor prognosis in various cancers since it has been reported to pro-
mote malignancy. We constructed this study to examine the correlations be-
tween LOX expression, LINE-1 methylation and the clinical pathological
features in patients with oesophageal cancer. Methods: We examined LOX ex-
pression in 8 oesophageal cancer cell lines by quantitative reverse-transcriptase
polymerase chain reaction (RT-PCR) andWestern blotting. The expression lev-
els of LOX in 150 oesophageal cancer tissues and adjacent normal mucosa was
measured by RT-PCR and immunostaining. Results: Our Gene Expression Mi-
croarray revealed that LINE-1 hypomethylated oesophageal tumours presented
higher expression level of LOX compared with LINE-1 hypermethylated tu-
mours. Similar resultswere observed in the comprehensive analyses using public
array data of oesophageal cancer cell lines. In cell lines, LOX mRNA was ex-
pressed at a high level inTE-6, TE-11, TE-14 and at a Low level inTE-1, TE-4 and
KYSE 30 and similar expression patterns for catalytically active LOX were ob-
served in Western blot analysis. In immunohistological study, LOX was pre-
dominantly identifıed in the cytoplasm of oesophageal cancer cells. LOX expres-
sion was signifıcantly associated with LINE-1 methylation levels (P0.034).
LOX expression was signifıcantly associated with invasion depth, tumour stage
and venous invasion. Overall and cancer-specifıc survival rates of high LOX
expression group were signifıcantly lower than those of low LOX expression
group (P 0.015 and P 0.008 respectively). Inmultivariate analysis high LOX
protein expressionwas an independent prognostic factor in oesophageal cancer.
Conclusions: The expression of LOX is up-regulated in oesophageal cancer cell
lines and resected tumour specimen and its controlled epigenetically. Our fınd-
ings suggest that LOX can serve as a useful prognostic biomarker in oesophageal
cancer patients and might be potential therapeutic target.
#4368 The clinicopathological signifıcance of glutathione S-transferase
P1 hypermethylation in breast cancer, a meta-analysis and literature review.
Mingli Liu.Morehouse School of Medicine, Atlanta, GA.
Background: Glutathione S-transferase P1 (GSTP1) has been reported to
function as a tumor suppressor gene in various types of human cancers includ-
ing breast cancer (BC). However, the association and clinicopathological signif-
icance betweenGSTP1 hypermethylation and BC remains unclear. The purpose
of this study is to conduct a meta-analysis and literature review to investigate
clinicopathological signifıcance of GSTP1 methylation in BC. Method: A de-
tailed literature search was made in PubMed, EMBASE, Web of Science and
Google Scholar databases. The data were extracted and assessed by two review-
ers independently. Odds Ratios (OR) with 95% corresponding confıdence inter-
vals (CIs) were calculated. A total of twenty four relevant articles were available
for meta-analysis. Results: The frequency of GSTP1 hypermethylation was sig-
nifıcantly increased in BC than in benign breast disease, the pooledORwas 7.09,
p0.00001. The rate of GSTP1 hypermethylation was signifıcantly different
between early stage I/II and later stage III/IV, OR was 2.05, p0.0001. In addi-
tion, the rate of GSTP1 hypermethylationwas also signifıcantly different regard-
ing the node involvement status. The rate of GSTP1 hypermethylation in node
positive BC was higher than that in node negative BC, OR was 1.77, p0.006.
However, GSTP1hypermethylationwas not signifıcantly associatedwith ER, PR
andHER2 status. Conclusion: In summary, ourmeta-analysis indicated that the
frequency of GSTP1 hypermethylation was signifıcantly increased in BC than in
benign breast disease. The rate of GSTP1 hypermethylation in late stages of BC
was higher than that in early stages. Our data suggested that GSTP1 hypermeth-
ylation could be a risk factor and a diagnostic biomarker of BC carcinogenesis.
GSTP1 hypermethylation may have a role in the progression of BC. GSTP1 is a
potential drug target for development of demethylation treatment for patients
with BC.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Genomic Landscape of Head and Neck and GI Cancers
#4370 ASNS and other signifıcant mutations in head and neck squamous
cell carcinomas: mutational landscape in a South Asian population. Sadiq
Rehmani,1 Safına Abdul Razzak,2 SaroshMadhani,3 M Kamran Azim,2 Rashdia
Ahmed,3 Mumtaz Khan,3 Kulsoom Ghias3. 1Mount Sinai St. Luke’s Hospital,
Icahn School of Medicine at Mount Sinai, New York, NY; 2University of Karachi,
Karachi, Pakistan; 3Aga Khan University, Karachi, Pakistan.
Head and neck cancers are the sixth most common cancer type globally and
contribute signifıcantly to the burden of disease in South Asia. Specifıcally in
Pakistan, they are themost commonly diagnosed cancer inmales and the second
most common in females. The increasing burden of head and neck squamous
cell carcinoma (HNSCC) in the region along with a unique set of risk factors
merited a deeper investigation of the disease at the genomic level. Whole exome
sequencing of HPV-negative HNSCC samples and matched normal genomic
DNA (n 7) was performed. Smoking, oral tobacco use and alcohol were iden-
tifıed risk factors in the study cohort. Signifıcant somatic single nucleotide vari-
ants (SNVs) were identifıed and pathway analysis performed to determinemost
frequently affected signaling pathways. Signifıcant, novel recurrent mutation in
ASNS (asparagine synthetase) and driver mutations in previously reported
genes, including TP53, PIK3CA, FGFR2, ARID2, MLL3, MYC and ALK, were
identifıed. Using the IntOGen platform, we identifıed MAP kinase, cell cycle,
actin cytoskeleton regulation, PI3K-Akt signaling and other pathways in cancer
as among the most commonly affected pathways in all the samples. This data is
the fırst of its kind from the Pakistani population. The results of this study can
guide a better mechanistic understanding of HNSCC in the population, ulti-
mately contributing new, rational therapeutic targets for the treatment of the
disease.
#4371 Genomic characterization of oropharyngeal squamous cell carci-
noma in Korean population. Jeesoo Chae,1Weon Seo Park,2 DongwanHong,2
Jong-Il Kim,1 Yuh-Seog Jung2. 1Seoul National University, Seoul, Republic of
Korea; 2National Cancer Center, Goyang, Republic of Korea.
Objective: Oropharyngeal squamous cell carcinoma (OPSCC) is a subtype of
head and neck squamous cell carcinoma (HNSCC). Environmental risk factors
such as tobacco, alcohol, and especially, human papillomavirus (HPV) are
known to be associated with HNSCC. Also, large-scale sequencing studies iden-
tifıed several HNSCC-associated genes such as TP53, EGFR and PIK3CA.How-
ever, still the initiation and progression of OPSCC and mutational profıles of
OPSCC inKoreanpopulation are unclear.Methods: Frozennon-tumormucosa,
tumor tissues and blood were collected from nine OPSCC patients; 6 HPV pos-
itive and 3 negative. Adjacent non-tumor tissueswere obtained about 1 cm apart
from the tumor tissue and were histologically confırmed as non-neoplastic. We
then performed whole exome sequencing with Agilent SureSelect Human All
Exon Kit v4UTR, yielding average on-target coverage of 100X. Results: First,
we compared somatic alterations of adjacent non-tumor and tumor tissue to
understand the genomic status of non-tumor mucosa. Comparison of genome-
wide copy number alterations (CNA) between non-tumor andOPSCCs showed
that majority of somatic CNA (SCNA) was occurred after tumor progression.
Also, non-tumor mucosa rarely harbored genomic changes, showing average
nonsilent mutations rate of 0.07 per Mb. In contrast, OPSCC showed 1.0 muta-
tions perMb with few sharedmutations with non-tumor. These results indicate
occurrence of new distinct subclones after tumor progression. Second, somatic
mutations and CNA analysis of 9 OPSCC identifıed two distinct groups divided
by the HPV status of tumor. HPV() tumors showed lower mutation burden
than HPV(-) tumors (0.63 and 1.73 mutations per Mb, respectively). And TP53
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and CDKN2A mutations were detected exclusively in HPV(-) group, account-
ing for 66.6% of HPV(-) tumors. Furthermore, HPV(-) tumors showed greater
degree of chromosomal alterations compared to HPV() tumors. Conclusions:
Although there are many studies to understand the relationships between pre-
malignant and malignant tissue, there is a lack of understanding for genetic
changes further fromnon-neoplasticmucosa. Our data show that genetic profıle
of normal crypt mucosa rarely changes and tumor develops in distinct sub-
clones. This would provide a glimpse into the fundamental cellular changes of
non-tumor cells of tonsillar crypts and oral cavity. Also, we provide amutational
landscape in HNSCC of Korean population. Although our OPSCC showed re-
currentmutations and copy number alterations of genes related to RTK/PI(3)K-
and differentiation-signaling pathways, similar as western, mutation burden in
tumors was relatively lower, and somatic mutations on well-known HNSCC-
associated genes such as PIK3CA, FAT1 and HRAS weren’t detected. Further
investigation and molecular experiments are required to understand the mech-
anism of carcinogenesis and to discover early driver mutations of HNSCC.
#4372 Genomic, RNAi screening, and functional validation reveal cross
activation of classical and alternativeNFBpathways in head and neck squa-
mous cell carcinoma of different HPV status.Xinping Yang,1 Hui Cheng,1 Ru
Wang,2 Jianhong Chen,1 Han Si,3 Anthony Saleh,1 Carter Van Waes,1 Zhong
Chen1. 1NIH-NIDCD, Bethesda,MD; 2Beijing TongrenHospital, CapitalMedical
University, Beijing, China; 3Frederick National Laboratory for Cancer Research,
Leidos Biomedical Research, Inc., Frederick, MD.
Aberrant activation of transcription factor NF-B promotes tumorigenesis of
head and neck squamous cell carcinoma (HNSCC), but the genomic alterations
and pathways affectingNF-B signaling have not been fully dissected. As part of
The Cancer Genome Atlas (TCGA) project for head and neck cancer, our labo-
ratory recently uncovered that HNSCC harbored frequent alterations affecting
gene expression of signal molecules in NF-B and cell death pathways. We
analyzed the transcriptome, integratedwith the genetic alterations of 279 TCGA
tumors with different HPV status in parallel with 15 HPV(-) and 11 HPV()
HNSCC cell lines sequenced in our laboratory through whole exome and tran-
scriptome sequencing. Using bioinformatics and pathway analyses, we identi-
fıed 61 genes interacting with the genetically altered components of the NF-B
pathway.We found expression for 38 of these 61 genes were signifıcantly higher
in tumors than in mucosa tissues. Differential expression affecting more com-
ponents of the canonical than the alternative NF-B pathways were found in the
HPV(-) group, while the alternativeNF-B pathway components were predom-
inantly affected in the HPV() group. The distribution of genomic DNA copy
number variation (CNV) between groups differing in HPV status support this
observation. The mRNA levels are signifıcantly correlated with their corre-
sponding CNV for more than 2/3 of top 30 genes in both TCGA cohort and the
cell lines. Supervised clustering analysis of mRNA expression of the TCGA and
cell lines revealed distinct gene expression patterns related to their genetic fea-
tures andHPV status. Functional genome-wide RNAi screening was performed
using HNSCC cell lines stably transfected with the -lactamase NF-B reporter
construct (Gene BLAzer). We identifıed 16 genes that signifıcantly modulated
TNF- or Lymphotoxin  (LT) induced NF-B activity and/or cell survival in
bothHPV(-) orHPV()HNSCC lines. Knocking downTNFR, LTR, or down-
stream signaling components demonstrated cross-activation of classical and
alternative NF-B pathways in response to TNF- or LT in HPV(-) or
HPV() cells. Our study uncovers the prominent contribution of keymolecules
involved in canonical and alternative NF-B activation, which modulate sur-
vival and migration of HNSCC. (Supported by NIDCD/NIH intramural proj-
ects ZIA-DC-000016, 73, and 74; and NCI/NIH, under contract number
HHSN261200800001E).
#4373 SOX2-related gene signature predicting the prognosis in head and
neck squamous cell cancer. Young-Gyu Eun,1 Young Chan Lee,1 Jun Eul
Hwang2. 1KyungHeeUniversity, Seoul, Republic of Korea; 2ChonnamUniversity,
Gwangju, Republic of Korea.
Purpose: Numerous studies have indicated that Sex-determining region Y-
box 2 (SOX2) is involved in many squamous cell carcinomas. However, the role
of SOX2 in head and neck squamous cell carcinoma (HNSCC) remains unclear.
Therefore, we investigatedwhether activation of SOX2 is signifıcantly associated
with prognosis inHNSCC.Methods: Gene expression signature reflecting SOX2
activation was identifıed inHNSCC cohort, and patients were stratifıed into two
groups according to this signature: SOX2-high group or SOX2-low group. Val-
idation of the signature was sought in two independent patient groups. The
association between the signature and prognosis of patients was assessed. Re-
sults: The SOX2-low group was associated with poor prognosis for HNSCC in
three independent patient cohorts. In a multivariate analysis, the impact of the
SOX2 signature on overall survival (OS) was independent of other clinical vari-
ables [hazard ratio (HR), 1.45; 95% confıdence interval (CI), 1.09 - 1.92;
P0.01]. In patients who received radiotherapy (RT), SOX2-low group had
signifıcantly poor OS than those in SOX2-high group. Conclusions: SOX2-low
signature is associated with poor prognosis in patients with HNSCC and could
be used to predict patients who would benefıt from RT.
#4374 Chromosome 3q22-29 amplifıcation is linked to increased expres-
sion of multiple genes in key pathways deregulated in head and neck cancer
tumors and cell lines. Hui Cheng,1 Xinping Yang,1 Han Si,1 Anthony Saleh,1
Jamie Coupar,1 Robert L. Ferris,2 Wendell G. Yarbrough,3 Mark E. Prince,4
Thomas E. Carey,4 Carter Van Waes,1 Zhong Chen1. 1National Institutes of
Health, Bethesda,MD; 2University of Pittsburgh Cancer Institute, Pittsburgh, PA;
3Yale School of Medicine, New Haven, CT; 4University of Michigan, Ann Arbor,
MI.
As part of the Cancer Genome Atlas (TCGA) Network, our comprehensive
genomic analysis of 279 head and neck squamous cell carcinomas (HNSCCs)
found frequent chromosomal copy number variation (CNV) and mutations of
potential biologic and therapeutic importance. This underscored an urgent need
to identify cell line models that harbor genomic alterations representative of
HNSCC. We performed whole exome-DNA and transcriptome RNA sequenc-
ing on 15 human papillomavirus HPV() and 11 HPV() HNSCC cell lines.
HNSCC lines harbored chromosome gains (3q, 5p, 7p, 8q, 11q) and losses (3p,
5q, 8p, 9p, 18q), consistent with those found in HNSCC tumors by TCGA and
previous karyotype studies. Integrative genome-wide analysis of CNVwith gene
expression uncovered over 1500 genes that display signifıcant correlation be-
tween CNV and gene expression in both TCGA tumors and cell lines. Ingenuity
Pathway Analysis revealed multiple genes that converge on key pathways and
functions deregulated in HNSCC, including PI3K/AKT/mTOR, NF-B, RAS/
MAPK, TP53, death receptor signaling, inflammation, and differentiation. In-
triguingly, 103 genes displaying signifıcant amplifıcation and increased expres-
sion were predominately located on chromosome 3q22-29. These genes encode
components involved in the PI3K/AKT/mTOR, Hippo, TGF-beta and Wnt/
beta-catenin pathways, cell cycle, translational and post-translational regula-
tion, and mitochondrial biosynthesis. Fisher’s exact test and survival analysis
showed signifıcant co-occurrence and worse overall survival of 3q26.3 amplifı-
cation and TP53 mutation in HNSCC patients from TCGA datasets; 3q26.3
encompasses 53 genes including PIK3CA, PLD1, ACTL6A and SOX2. HNSCC
cell lines also harbor common mutations found in TCGA, such as TP53, FAT1
andNOTCH1, and novel and rare tumor suppressor genes, such asMYH9. Our
fındings suggest that these cell lines could serve as models for mechanistic stud-
ies and pharmacologic screening, and investigation of genomic and expression
alterations as potential biomarkers for precision diagnosis and prognosis of
HNSCC. (Supported by NIDCD/NIH intramural projects ZIA-DC-000073,
ZIA-DC-000074. This study utilized the high-performance computational ca-
pabilities of the Biowulf Linux cluster at the National Institutes of Health,
Bethesda, MD. (http://biowulf.nih.gov).)
#4375 Complex interactions between genomic and epigenomic altera-
tions in esophageal adenocarcinomas. Dunfa Peng,1 Yan Guo,2 Heidi Chen,2
Shilin Zhao,2 Kay Washington,1 Tianling Hu,1 Yu Shyr,2 Wael El-Rafai1. 1Van-
derbilt University Medical Center, Nashville, TN; 2Vanderbilt University, Nash-
ville, TN.
Background: The incidence of Barrett’s-related esophageal adenocarcinoma
(EAC) is rapidly rising in the USA and the Western countries. However, the
interaction between genomic and epigenomic alterations in regulating gene ex-
pression networks in EAC is poorly understood. Results and Discussion: We
carried out an integrative analytical approach to identify DNA copy number,
promoter DNA methylation and gene expression in a panel of esophageal ade-
nocarcinomas, using chip-based technologies.Our analysis displayed signifıcant
differences between EAC and normal samples in DNA copy numbers, gene
expression, and DNA methylation profıles. Our results identifıed remarkable
incidence of DNA copy number (CN) alterations showing that 90% of probes
had a copy number aberration (gain or loss) in at least one tumor, suggesting a
vast chromosomal instability in EAC. Integrative analysis indicated that altered
expression of 1755 genes was associated with changes in CN ormethylation.We
found that expression alterations in 84 genes (56 overexpressed and 28 down
regulated)were associatedwith changes in bothCNandmethylation. These data
suggest a strong interaction between genetic and epigenetic events to modulate
gene expression in EAC. Of note, we detected a prominent K-RAS signature in
EAC. Network analysis predicted activation of several important transcription
factor networks in EAC, including -catenin, MYB, TWIST1, SOX7, GATA3
and GATA6. 56 genes were overexpressed in EAC with simultaneous promoter
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hypomethylation and gene amplifıcation, including CDH17 and GATA6. No-
tably, several genes associated with inflammation such as COX2, IL8 and IL23R
were overexpressed and hypomethylated in EAC, a reaffırmation of the under-
lying inflammatory process in Barrett’s tumorigenesis and a suggestion of an
epigenetic regulation of these genes. Conclusions: In summary, our integrative
analysis of genetic and epigenetic alterations in EAC demonstrates a complex
interaction between molecular mechanisms in EAC and provides several novel
insights for future studies.
#4376 Next-generation sequencing of gastric cancer samples from Rwan-
da: a feasibility study. Mary D. Chamberlin, Francine B. De Abreu, Torrey L.
Gallagher. Geisel School of Medicine at Dartmouth, Lebanon, NH.
Background: Gastric cancer is associated with high morbidity and mortality
around theworld. In developing countries, patients often present with advanced
disease creating a challenge for effective treatment. Next generation sequencing
is identifyingmutations inmore than 50% of gastric cancers in developed coun-
tries. Chronic infections and other geographic differencesmay lead to variations
in somaticmutations that could lead to different approaches to treatment. In this
pilot study we sought to determine if an overseas collaboration between the
University of Rwanda College of Medicine and Health Sciences and the Geisel
School of Medicine at Dartmouth was feasible and effective at determining mo-
lecular profıles of gastric cancer. Methods: Patients referred for endoscopy at
University Teaching Hospital of Kigali, Rwanda were consented to participate
prior to the procedure. Biopsy tissues were processed for routine pathologic
assessment and those confırmed as gastric adenocarcinoma were included. For-
malin-fıxed paraffın embedded tissues, H&E stained slides and tissue blocks
were transported from Rwanda to New Hampshire, USA by visiting professors
participating in the Human Resources for Health Program between May 2015
and July 2016. DNA and RNA from 39 samples were extracted using at least 7
FFPE unstained slides according to AllPrep RNA/DNA FFPE Kit Protocol. Li-
brary preparation was performed using 5 ng gDNA using the Pillar NGS SLI-
MampTM Lung and Colon Hot Spot Panel. Library quanitifıcation was per-
formed using Qubit, and samples with at least 4 nM were normalized, pooled
and sequenced on the v3 cartridge on the Illumina’s MiSeq system. For data
analysis, FASTq fıles were uploaded to Pillar Biosciences, where sequence align-
ment, annotation, and variant classifıcation were performed. Results: Eighteen
samples had insuffıcient tissue for nucleic acid extraction. Of the 39 samples
processed for sequencing, 17 had low library quantifıcation due to low DNA
concentration or poor quality. Mutations were detected in 9/22 samples (41%).
One sample contained 3 mutations while the majority of mutated cases had 1-2
mutations identifıed. A total of 12 mutations were identifıed: TP53 (4), SMAD4
(2), ERBB4 (2) (S341L and D228N), PTEN (2)(K267RfsTer9 and C136Y),
FBXW7 (1) and KRAS (1). Conclusions: Overseas collaboration for next gener-
ation sequencing of gastric cancer samples is feasible. Quality control is a com-
mon challenge and may improve with larger sized biopsies or tissue blocks.
Frequency of mutations is lower than expected. ERBB4mutations identifıed are
not known to be pathogenic. The PTEN mutations observed are considered
pathogenic and this may be a feasible target for therapy. A fusion panel and
amplifıcation profıling may be more effective in identifying potential targets for
therapeutic trials. Limitations: Small sample size. Panel limited to mutations.
#4377 EBV associated gastric cancer in Korean. Woochan Lee. Seoul Na-
tional University, Seoul, Republic of Korea.
Gastric cancer was the third leading cause of death worldwide andmost prev-
alent malignant cancer in Korea, comprising 20.8% of all cancers. The Cancer
Genome Atlas (TCGA) divided gastric cancer to four subgroups; EBV (Epstein-
Barr Virus infected, 9%),MSI (Microsatellite instability, 22%), GS (Genomically
stable, 20%), CIN (Chromosomal instability, 50%). We sequenced transcrip-
tomes of 11 gastric cancers associated with EBV infection (EBVaGC) tissues, 11
gastric cancers not associated with EBV infection (EBVnGC) tissues and 22
matched normal gastric mucosa for fınd unique features of Korean EBVaGC.
We compared RNA expression, EBV gene expression, germline mutations, and
somatic mutation between EBVaGC and EBVnGC. We found IKBKE gene,
which is taking an essential role in regulating antiviral signaling pathways, ex-
pressed higher on EBVaGC tumor than EBVnGC tumor (p-value1.73 x 10-4).
While most EBV genes appeared to be similar, BMRF1,2 genes made distinctive
patterns compared to previous TCGA report in expression of EBV which inte-
grated into human cells. The BMRF-2 gene is associated with cell-to-cell spread
of EBV, which is major infection mechanism of EBV.We found novel germline
mutations on PABPC3, PGA3, and C4A,B in almost every samples, which are
candidate for Korean specifıc mutations.
#4378 Gastric cancer organoid culture shows preserved genomic stability
in long-term passage. Sarah Siu Kuen Yue, Helen Hoi Ning Yan, Hoi Cheong
Siu, Siu LunHo,Wai Yin Tsui, Dessy Chan, Annie Shuk Yee Chan, Bernard Chi
Hang Lee, Anthony Kin Wang Chan, Suet Yi Leung. Department of Pathology,
The University of Hong Kong, Hong Kong.
With recent advances in 3D organoid culture techniques, normal epithelial
and tumor cells can be directly cultured from clinical specimens in vitro and
expanded long-term with a very high success rate. Thus, this constitutes a good
platform for various mechanistic functional studies and clinical applications. A
previous karyotyping and gene expression profıling study has indicated that
organoid culture of normal epithelial cells can be propagated for long periods of
time without genomic alterations. However, data on the genomic stability of
tumor organoids in long-term culture are not yet available.We have successfully
established organoid cultures derived from either primary tumor or lymphnode
metastasis from 4 gastric cancer patients. For each sample, we performed long-
term culture for at least 6 months. DNAwas extracted from blood, as well as the
early and late passages of these organoids, and submitted for whole-exome se-
quencing (WES), achieving a mean coverage approaching 50X. Somatic muta-
tions detected in early versus late passage gastric cancer organoids were com-
pared. Furthermore, we examined the organoids for copy number variations
based on the coverage and loss of heterozygosity (LOH) information derived
from exome sequencing. We detected between 80 to 228 somatic mutations in
the 4 early passage organoids, in which over 84-99% of them were retained
during long-term culture. We detected 16, 20, 31 and 98 newmutations in the 4
long-term cultures, respectively. The one case with a substantially large number
of new mutations (n98) appeared to have emerged from a subclone of TP53
wild-type cells in a TP53 mutant tumor. Notably, the CT mutation was the
most dominant mutation spectrum in this case, constituting 48%. Despite the
presence of frequent long segment LOH and chromosomal aberrations in early
passage organoids, indicating the presence of chromosomal instability, these
patterns of aberrations were stably maintained in long-term passage. Overall,
with the current organoid culture protocol, tumor genomes are mostly stably
maintained with the accumulation of only a small number of new mutations.
Our results indicate that this is a reliable and stable in vitro cell culturemodel for
various cancer-related and clinical studies.
#4379 Somatic exomic landscape of small intestinal adenocarcinomas.
Ulrika A. Hänninen,1 Riku Katainen,1 Jiri Hamberg,1 Jukka-Pekka Mecklin,2
Linda Forsström,1 Esa Pitkänen,1 Netta Mäkinen,1 Lauri A. Aaltonen1. 1Ge-
nome-Scale Biology Research Program, Research Programs Unit, University of
Helsinki &Department ofMedical and Clinical Genetics, Medicum, University of
Helsinki, Finland; 2Department of Surgery and Education & Science, Jyväskylä
Central Hospital and University of Eastern Finland, Jyväskylä, Finland.
The small intestine makes up 75% of the length of the alimentary tract, how-
ever, small intestinal tumors constitute less than 5% of gastrointestinal tumors.
Of small intestinal tumors, around one third are aggressive adenocarcinomas
with poor outcome (5-year survival rate is approximately 30%). Reasons for
their rarity are still unclear. Predisposing factors include Crohn´s disease, celiac
disease, hereditary genetic syndromes such as familial adenomatous polyposis
(FAP) and hereditary nonpolyposis colorectal cancer (HNPCC), and di-
etary factors. Due to the low incidence of small intestinal adenocarcinomas
(SIAs), the number of genetic studies remains insuffıcient. Since there are lim-
ited data available to guide the therapeutic decisions, our aim is to characterize
the somatic mutational landscape of SIAs in a population-based material using
exome sequencing. We collected information on all patients diagnosed with
SIA in Finland between the years 2004-2011 utilizing the Finnish Cancer Regis-
try. This registrymaintains a nation-wide database on all cancer cases diagnosed
in Finland since 1953. From these we selected all cases with 1) confırmed small
intestinal primary tumor, 2) available tumor material, and 3) the tumor content
of at least 50%. In order to focus solely on small intestinal tumors, we excluded
tumors of the papillary region since they might also have arisen from the pan-
creas or the biliary tract. Altogether 107 tumors representing all three parts of the
small intestine were selected for exome sequencing. The tumor data was fıltered
against the ExAC and SISU databases to remove germline variations. In addi-
tion, Sanger sequencing of the corresponding normal tissuewill be used to verify
the somatic origin of themost interesting observedmutations. The data analysis
is ongoing. The average number of mutations in a tumor was 358 (range 40 -
4,166). Preliminary results show that themost frequentlymutated known cancer
genes were TP53 (42%) and KRAS (31%). We will identify all the most fre-
quently mutated genes, compare the mutational patterns between the three dif-
ferent sections of the small intestine, and further characterize their similarities to
gastric and colorectal adenocarcinomas. We will also analyze the association
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between the discoveredmutations and patients’ survival time. This comprehen-
sive characterization of themolecular basis of SIAs will provide better insight on
how these tumors arise and possibly how they should be treated.
#4380 Integrative genomics analysis ofmetastatic colorectal cancer.Marla
Lipsyc, Walid Chatila, Jaclyn F. Hechtman, Francisco Sanchez-Vega, Sumit
Middha, Andrea Cercek, Zsofıa Stadler, Ritika Kundra, Aijazuddin Syed, David
M. Hyman, Ahmet Zehir, Armin Shahrokni, Anna Varghese, Diane Reidy, Neil
H. Segal, Efsevia Vakiani, David B. Solit, Marc Ladanyi, Michael F. Berger,
Nancy Kemeny, Leonard Saltz, Nikolaus Schultz, Rona Yaeger.Memorial Sloan
Kettering Cancer Center, New York, NY.
We performed an integrated clinical and bioinformatic analysis of colorectal
cancers (CRCs) genotyped at our institution from4/2014-7/2016 to comprehen-
sively characterize genomic alterations in metastatic CRC (mCRC). We ana-
lyzed 1008 samples (474 primaries, 534 metastases) from 985 mCRC patients
and 128 early stage CRCs sequenced with MSK-IMPACT, a hybridization cap-
ture next generation sequencing assay. Metastatic CRCs were divided into 3
groups by mutation burden and MSIsensor algorithm score: microsatellite sta-
ble (MSS) (n939; 95%), microsatellite-high (MSI-H) (n41; 4%), and ultra-
mutated (n5; 1%). Early stage CRC were enriched for MSI-H due to clinical
selection andwere 53%MSS, 44%MSI-H, and 4%ultra-mutated.Ultra-mutated
tumors exhibited100 mutations and harbored hotspot mutations in POLE in
8 cases and a potential novel POLE alteration in 1 case. We evaluated the fre-
quency of oncogenic alterations in MSI-H and MSS mCRCs. The frequency of
the resistance biomarkers KRAS and NRAS did not vary between MSI-H and
MSS mCRCs (46% v 41%, p0.6). Potentially actionable alterations were en-
riched in MSI-H tumors (78% v 33%, p0.001). Metastases did not have more
actionable alterations than primary tumors.We classifıed clinically relevant tar-
gets using the OncoKB classifıcation as level 2B (FDA-approved target in an-
other disease type), 3A (target with compelling early clinical evidence in CRC),
and 3B (target with compelling early clinical evidence in another disease type).
Twelve percent (109/939) of MSS mCRCs had a level 2B target: BRAF V600E
(5%), ERBB2 amplifıcation (AMP) (4%), MET AMP (1%), BRCA1/BRCA2 al-
teration (1%), TSC1/TSC2 mutation (1%), EGFR mutation (1%), RET fusion
(1%); there was signifıcant enrichment of BRAF V600E (24%) and BRCA1/
BRCA2 alterations (29%) in MSI-H versus MSS mCRC (p0.001). NTRK fu-
sions, themain 3A alteration identifıed, occurred in 7%ofMSI-H and1%MSS
CRC (p0.01). Level 3B alterations at  1% in MSS CRC included PIK3CA
(15%),NRAS (3%), AKT1 (1%),MAP2K1 (1%), andERBB2 (1%)mutations and
FGFR1 AMP (2%). PIK3CA and PTCH1 mutations were both enriched in
MSI-H versus MSS mCRC (32% v 15%, p0.01; 27%,v1%, p0.001, respec-
tively). Analysis of mutation frequencies in 3 MSS CRC disease states - early
stage resected primary (The Cancer Genome Atlas, TCGA), primary site of
mCRC, andmetastatic site - found signifıcant depletion of FBXW7mutations in
metastases. We also found signifıcant and progressive enrichment of TP53 al-
terations (58% TCGA, 73% primaries of mCRC, 79% metastases) and BRAF
mutations (4% TCGA, 9% primaries of mCRC, 10% metastases) in advanced
disease, suggesting a role of these genes in aggressive disease. One third of the
BRAF mutations in our cohorts were not V600 but known to be oncogenic. In
this large dataset, we identifıed markers of advanced CRC and found that while
MSI-H andMSSCRChave a similar frequency of resistance biomarkers,MSI-H
CRC more commonly harbor actionable alterations.
#4381 Themobile genome of colorectal cancer: Characterization of retro-
transposon insertions in 202 colorectal cancer whole genomes. Tatiana Ca-
juso, Päivi Sulo, Riku Katainen, Ulrika Hänninen, Tomas Tanskanen, Johanna
Kondelin, Jiri Hamberg, Niko Välimäki, Kimmo Palin, Outi Kilpivaara, Esa
Pitkänen, Lauri A. Aaltonen.Genome-Scale Biology Research Program, Research
ProgramsUnit andDepartment ofMedical andClinical Genetics,Medicum,Uni-
veristy of Helsinki, Helsinki, Finland.
The aim of this study is to characterize the landscape of retrotransposon
insertions in 202 colorectal cancer (CRC) patients to elucidate their role in
colorectal tumorigenesis. Retrotransposons are genetic sequences that can copy
themselves into an mRNA intermediate and insert elsewhere in the genome.
Germline retrotranspositions can contribute to genetic variation however, high
retrotransposon activity can also lead to genetic instability. Albeit retrotrans-
posons are usually repressed in normal adult tissues, they become highly active
in several cancer types, being most active in epithelial cancers such as CRC.
Moreover, retrotransposon insertions have been diffıcult to detect with previous
methodological approaches, which has resulted in very few genome-wide stud-
ies. Whole genome sequencing (WGS) was performed in 202 tumors and their
corresponding normal tissue on the Illumina HiSeq 2000 platform; with 100
base-pairs paired-end reads. Each sample was sequenced to a minimum of 40x
median coverage. To detect retrotransposon insertions we utilized TraFiC
(Transposome Finder in Cancer). To identify retrotransposon-mediated trans-
ductions that were not identifıable using TraFiC, we utilized DELLY and the
European database of L1-HS retrotransposon insertions in humans (euL1db).
To characterize somatic insertions and decrease the rate of false positives, all
insertions present in any of the normal genomes were fıltered. After careful
visual inspection of the paired-end read data, we estimated 80% of true somatic
calls. We detected high retrotransposon activity in CRC with remarkable varia-
tion among patients. Themean number of insertions per tumor was 25, ranging
from 0 to 197 insertions. In addition, we were able to identify few highly active
retrotransposons that accounted for 70% of the retrotransposon-mediated
transductions. We identifıed a total of 5065 somatic insertions, 2% of these
insertions were located in exons, whereas 45% were in introns. We identifıed
several genes with recurrent insertions, some of these loci being known fragile
sites. However, we identifıed 13 known cancer genes with two or more inser-
tions. Furthermore,we identifıed twopatientswith insertions in exon 16 ofAPC,
suggesting that these insertions could be initiating tumorigenic events. To con-
clude, we found retrotransposon insertions to be a common phenomenon in
CRC, contributing to genome instability and colorectal tumorigenesis.
#4382 Genomic events associated with metastasis of colorectal cancer by
whole-genome sequencing.Yi Pan, Joanna Tong, Johnny Kwan, KwokWai Lo,
Anthony Chan, Ka Fai To. Prince of Wales Hospital, The Chinese University of
Hong Kong, Hong Kong, Hong Kong.
Background: The diversity of the genomic landscape in colorectal cancer
(CRC) is under active investigation. Concordance in molecular events between
primary CRC and metastatic tumors is a subject of debate. Understanding the
genetic background of metastatic CRC facilitates personalized therapies that
target specifıc molecular events associated with the tumor. Methods: We per-
formed whole genome sequencing in matched primary, metastasis and normal
tissues from 3 patients with RAS/NRAS/BRAF wild types and microsatellite
stable CRC. We implemented an analysis pipeline that integrated the genetic
lesions to characterize somatic single nucleotide variations (SNVs), short inser-
tions and deletions (indels), structural variations including fusions and copy
number alterations. Results: Both primary andmetastatic tumors showed a pre-
dominant mutational signature of C: G ¡T: A transition. A total of 282 non-
silent mutations were identifıed in 3 pairs of CRC (median 63 per tumor, range
42 to 98). There were 148 (52.5%) variants shared in matched primary and
metastatic tumors, 63 (22.3%) were found unique to primary and 71 (25.2%)
were unique to the metastases. Only common well known genes (APC and
TP53) and TTN mutations were found to be recurrent in the 3 patients. A total
of 609 (range 33-171 per tumor) structural variants were discovered with 44.1%
concordance between primary and metastasis pairs. We also identifıed 6 novel
candidate fusions shared in primary andmetastases and 2 private to the primary
tumors. Consistent with the result of previous studies, copy loss at chromosome
17p and 18, and gain at chromosome 5, 8 and 13 were the common events both
in the primary and metastatic tumor. Discussion and conclusions: Our data
demonstrated a considerable difference in mutational landscape between pri-
mary CRCs and their matchingmetastatic tumors. The result suggested that the
metastasis might originate from a distinct subclone from a heterogeneous pri-
mary tumor, or additional gain or loss of function via mutation to permit tumor
invasion and spreading is necessary to facilitate metastasis. Each of the two
models is complicated by the possibility of tumor heterogeneity within the pri-
mary tumor. In conclusion, comprehensive analysis and assessment for the
genomic events is a powerful approach to delve deeper into the internal relations
and contradictions between primary and paired metastases, helping to identify
novel genomic events associated with metastasis of CRC.
#4383 Novel fusion transcripts in colorectal cancer patients revealed by
next-generation RNA sequencing.Yuri Choi,1 ChaeHwaKwon,2 Hye Ji Park,2
Yeo-Jin Won,2 Do Youn Park1. 1Pusan National University, Busan, Republic of
Korea; 2Pusan National University Hospital, Busan, Republic of Korea.
Although colorectal cancer (CRC) is the thirdmost common type of cancer in
the world, there is an insuffıcient research on molecular targets for prevention
and therapies of CRC. Gene fusions are associated with tumorigenesis and tu-
mor activation, and could be a standard to distinguish tumor heterogeneity for
personalized therapy. In the present study, we performed next-generation RNA
sequencing (150 tumor and 50 matched normal tissues) in order to discover
novel fusion transcripts in CRC. A total 25 transcript candidates were detected
by GFP, deFuse, and FusionMap algorithms. Among the candidates, 6 fusion
transcripts were selected (B4GALT1-BAG1, GTF3A-CDK8, NAGLU-IKZF3,
RNF121-FOLR2, STRN-ALK, and TAF4-NDRG3) after analyzing expression
and function of the acceptor genes. All of them were validated by sanger-se-
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quencing and were not found in another cohort. Overexpression of these fusion
genes, except B4GALT1-BAG1, increased proliferation of CRC cells. In addi-
tion, overexpression ofNAGLU-IKZF3 enhancedmigration of CRC cells. These
results reveal novel fusion transcripts and their tumorigenic effects in CRC.
Ultimately, it could illuminate a genomic-driven strategy to develop personal-
ized medicine. Key words: fusion transcript, colorectal cancer, RNA-seq
#4384 Targeted sequencing reveals distinct and rare pathogenic variants
in Caucasians with colorectal cancer. Pooneh Mokarram,1 Sudhir Varma,2
Hamed Azimi,3 Hasti Olumi,3 Ali reza Safarpour,1 Michael Nickerson,4 Hassan
Brim,3 Hassan Ashktorab3. 1Shiraz University, Shiraz, Islamic Republic of Iran;
2Hithru, Washington, MD; 3Howard Univ., Washington, DC; 4NIH, Bethesda,
MD.
PURPOSE: Next-generation sequencing (NGS) is currently used to establish
mutational profıles in manymultigene diseases such as colorectal cancer (CRC)
which is on the rise in many parts of the developing World including in the
Middle East. Little is known about its genetic hallmarks in these populations.
AIM: To identify variants in 15 CRC-associated genes in patients of Iranian
descent.METHODS:CRC specimens from63patientswere used to establish the
variants’ profıle on an Ion Torrent platform by targeted exome sequencing. To
rule out technical artifacts, the variants were validated in 13 of these samples
using an Illumina NGS platform. Validated variants were annotated and com-
pared to variants from publically available databases. An in-silico functional
analysis was performed. MSI status of the analyzed samples was established.
RESULTS: There were 51 validated variants distributed on 12 genes: 22%MSH3
(n11/51), 10%MSH6 (n5/51), 8% AMER1 (n4/51), 20% APC (n10/51),
2% BRAF (n1/51), 2% KRAS (n1/51), 12% PIK3CA (n6/51), 8%
TGFR2A (n4/51), 2% SMAD4 (n1/51), 4% SOX9 (n2/51), 6% TCF7L2
(n3/51), and 6% TP53 (n3/51). Most known and distinct variants were in
mismatch repair genes (MMR, 32%) and APC (20%). Among oncogenes,
PIK3CA was the top target (12%). MSH3 variants were more frequent and pre-
dominantly homozygous in the analyzed population. CONCLUSION: These
results illustrate for the fırst time CRC mutational profıle in Iranian patients.
MSH3, MSH6, APC and PIK3CA genes seem to play a bigger role in the path to
cancer in this population. This is especially true for MSH3 variants that were
very frequent and predominantly homozygous as these will associate with the
EMAST phenotype that has prognostic implications. These fındings will poten-
tially lead to informed genetic diagnosis protocol and targeted therapeutic strat-
egies.
#4385 Landscape of driver gene mutations in stage II and stage III colo-
rectal cancer. Yoshikage Inoue,1 Nobuyuki Kakiuchi,1 Kenichi Yoshida,1 Yu-
suke Shiozawa,1 Yuichi Shiraishi,2 Kenichi Chiba,3 Keisuke Kataoka,1 Hiroo
Ueno,1HirokoTanaka,3 SatoshiNagayama,4 SatoruMiyano,3 Yoshiharu Sakai,1
Seishi Ogawa1. 1Kyoto University, Sakyo-ku, Kyoto City, Kyoto, Japan; 2Univer-
sity of Tokyo, Minato-ku, Tokyo, Japan; 3University of Tokyo, Minato-ku, Tokyo,
Japan; 4The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.
Introduction: Colorectal cancer (CRC) is the second leading cause of cancer
death in Japan. The overall survival rate is approximately 85% and 70% for stage
II and stage III CRCs, respectively, where over 45,000 deaths were ascribed to
recurrence or metastasis. Survival benefıt of adjuvant therapy is well defıned
only among stage III CRC patients, whereas that for stage II CRC patients re-
mains modest, or according to recent reports, might be even deleterious among
those with microsatellite instability (MSI). In an attempt to reveal the landscape
of driver mutations in CRC and their association with clinical outcomes, we
conducted targeted-capture sequencing of known driver mutations in stage II
and III CRCs. Methods: A total of 248 patients with stage II (n 145) and stage
III (n 103) CRC, were enrolled. All patients were treated at a single institute
between 2004 and 2016 and clinically well-annotated. Targeted-capture se-
quencing was performed using RNA baits designed for detection of oncogenic
variants in 128 known driver genes in CRC. Additional baits for 1,605 SNPs, 7
introns and 18 microsatellites were also included to assess genome-wide copy
numbers, fusion genes and MSI, respectively. Results: The median age at diag-
nosis was 64 (32-95) with a median observation period of 1,460 days. Of the 101
patients with recurrence, 59 and 42 patients had stage II and III diseases, respec-
tively. Sixty percent of stage III patients received adjuvant chemotherapy,
whereas only 10% of stage II patients received adjuvant chemotherapy. The
average depth of the targeted-capture sequencing was 909. In total, 2,243 so-
matic mutations (median 5 per patient, range 0-106) were detected in 243 pa-
tients (97.9%). VTI1A-TCF7L2 translocation was identifıed in one sample. Ex-
cept for amodest overrepresentation of TP53mutations, frequency distribution
of mutations was similar to those reported in previous reports, where APC
(83%), TP53 (79%), KRAS (45%), and PIK3CA (18%) represented the most
frequent mutational targets. Although none of these mutations were signifı-
cantly associated with tumor recurrence or overall survival, we found that
FBXW7mutations had a positive correlation with tumor free survival. Twenty-
one patients had more than 20 mutations, suggesting the presence of defects in
DNA repair and/or replication. In fact, analysis of 18 microsatellites suggested
the presence of MSI in 12 of the 21 samples (4%). The remaining patients with
hypermutated cancer were explained by somatic mutations in POLE gene.
Conclusions:We revealed the landscape of drivermutations in Japanese patients
with stage II and III CRCwith their implication in clinical outcomes. Hypermu-
tated samples accounted for 8% of the whole cohort, which were explained by
MSI or replication errors due to somatic POLE mutations. Our fındings help to
understand the relationships between driver mutations and recurrence for
CRCs after curative resection.
#4386 Identifıcation of clinically relevant colon cancer genes predictve of
improved relapse free survival.Marie J. Parsons. TheWalter and Eliza Hall Of
Medical Research, Parkville, Australia.
Colorectal cancer (CRC) is the third most common cancer worldwide, affecting
over 15,000 individuals inAustralia eachyear.WhileCRC isoftendetectedat a stage
where resection of the primary tumour is possible, approximately 50% will relapse
and die from metastatic disease. Prognostication is mainly determined by tumour
depth (T), lymph node stage (N) and the extent of cancer spread (M). However,
clinical outcomes of patients with the same TNM stage can be heterogeneous.
Therefore, there is a need to identifymarkers to better predict prognosis and stratify
patients for treatment regimes. A panel of 113 candidate CRC genes were identifıed
as signifıcantly mutated in whole genome and whole exome sequencing studies
from 361 MSS colon cancers and 63 CRC cell lines. Custom amplicon panels for
target enrichment were designed for use with the HaloPlexTM target enrichment
system. Sample libraries were prepared for 274 patients with stage II/III CRC using
the automated Bravo liquid handling platform followed by next-generation se-
quencing (NGS) on the IlluminaNext-Seq 500. Analysis of the 113 candidate genes
identifıed 31 genes recurrently mutated above 10 percent in our discovery cohort.
We identifıed 4 genes previously reported as colon cancer genes (APC 68%, TP53
60%, KRAS 30% and PIK3CA 20%), confırmingAPC, TP53 andKRAS as themost
frequentlymutatedgenes inCRC.To identifynovel andclinically relevantgenes, the
31 genes in our discovery cohort were tested for associationwith clinical features of
CRC. In the discovery cohort, 24/31 genes were signifıcantly associated with right
sided CRC, 10/31 with mucinous CRC, 9/31 with stage II CRC and 7/31 with im-
proved relapse free survival (RFS). Of these signifıcantly associated genes, 10/24
genes were validated as signifıcantly associated with right sided colon cancer, 3/9
with stage II and 3/10 with mucinous CRC in the validation cohort. Five of these
genes were selected for further investigation as they were signifıcantly associated
with improved RFS, together with one or more clinical feature of CRC. Identifıca-
tion of novel recurrently mutated genes is key to a better understanding of the
molecular mechanisms of CRC and development of novel therapeutics.
#4387 The clonal composition of colorectal cancer cell lines is defıned by
the maintenance of specifıc genomic imbalances, not by ongoing chromo-
somal instability. Darawalee Wangsa,1 Madison Schiefer,1 Daniel Bronder,1
Hesed Padilla-Nash,1 Irianna Torres,1 Lidia Warner,1 Yue Hu,1 E Michael
Gertz,2 Russell Schwartz,3 Alejandro A. Schäffer,2 Daniela Hirsch,4 Timo
Gaiser,4 Rüdiger Meyer,1 Jordi Camps,5 Kerstin Heselmeyer-Haddad,1 Thomas
Ried1. 1National Cancer Inst., Bethesda, MD; 2National Center for Biotechnology
Information, Bethesda, MD; 3Carnegie Mellon University, Pittsburgh, PA; 4Uni-
versity Medical Center Mannheim, University of Heidelberg, Heidelberg, Ger-
many; 5Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Bar-
celona, Spain.
Tumor type specifıc genomic imbalances are the defıning feature of carcinomas.
It remains elusive to which extent intratumor heterogeneity and the clonal compo-
sitionof cancer cell populations influences thegeneticmakeupand thephenotypeof
tumors. Many studies aimed at understanding the idiosyncrasies of cancer rely on
the analysis of cell lines derived from primary tumors. In an attempt to decipher
patterns of chromosomal heterogeneitywe analyzed thewidely used colorectal can-
cer cell lines DLD-1, HCT116, H508, SW620, HT-29 and SW480 using FISH and
gene expression profıling. First, we applied a four color probe set that targets the
oncogenes EGFR, CCND1, CDX2 and TERC and enumerated 200 metaphase
spread, which included chromosome counts, and 5,000 interphase cells. Not sur-
prisingly, themismatch repairdefıcient cell linesDLD-1andHCT116were themost
stable,whereas the aneuploid cell linesdisplayedahigherdegreeof instability.These
results prompted us to apply our recently developed multiplex interphase FISH
approach that allows copy number analysis of 12 gene loci in individual cells to 11
single cell derived clones from both HT-29 and SW480. SW480 was considerably
more instable thanHT-29. The parental lines consisted ofmajor clones, whichwere
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propagated in the single cell derived lines. These analyses were complemented by
gene expression profıling of the single cell derived clones and the parental cell lines
using the Nanostring technology which measures expression levels of 770 cancer-
associated genes. The SW480 clones separated into two distinct clusters that reflect
discrete ploidy levels that were also present in the parental line. We then explored
whethermutations of theBRAF (HT-29) andKRAS (SW480) genes observed in the
parental lines were maintained in the derived clones; this was the case in all in-
stances. Finally, we reconstructed phylogenetic trees of tumor evolution using a
specifıcally developed algorithm, termedFISHTrees.Ourmeticulous analysis of the
clonal composition of these colorectal cancer models shows that, despite a certain
degree of chromosomal instability, specifıc genomic imbalances are maintained.
The results challenge the concept of ongoing chromosomal instability in cancer cell
populations. This suggests a karyotype evolution that is driven by the necessity to
arrive at a different plateau of chromosomal copy number as the driving force of
carcinogenesis.
#4388 Characterisation of molecular events across the colorectal cancer
progression axis. Joke Reumers,1 Liesbeth Van Wesenbeeck,1 Eric Ciamp-
orcero,1 Gerald Chu,2 Stan Gaj,3 Emanuele Palescandolo,1 Carl Van Hove,1
Karin Verstraeten,1 Gary Borzillo,2 Dianna Wu,2 Pieter Peeters,1 Janine Arts1.
1Janssen R&D, Beerse, Belgium; 2Janssen R&D, Spring House, PA; 3LabConnect
LLC, Seattle, WA.
Uniquely amongst the major tumor types, the premalignant state in colorectal
cancer (CRC) is readily detectable and diagnosed. Indeed, a multi-step process of
CRCgenesis was defıned by the seminal work ofVogelstein et al, who described the
mutational events leading fromadenoma to adenocarcinoma. In addition to genetic
aberrations, recent evidence has highlighted the importance of the gutmicrobiome
andassociated inflammation inpredictingCRCprogression.Todatehowever, these
insights have not led to signifıcant changes in the treatment paradigm because ef-
forts continue to be focused on the later stages of disease.We believe CRC presents
an exceptional opportunity for disease interception but to design effective interven-
tional strategies, the exact sequence of molecular events underlying progression
needs to be better defıned and understood. To address these needs, we have assem-
bled a clinically annotated sampledatabase encompassing all stages ofCRC(healthy
colon, adjacent mucosa, adenomas, high-grade dysplasia, primary CRC and liver
metastases), including samples from the conventional,microsatellite stable subtype,
as well as from the serrated, microsatellite instable pathway. The progression status
of each sample was characterized using standard pathology criteria. In addition,
molecular progression was determined by targetedmutation profıling and targeted
copy number profıling, as well as genome-wide expression profıling. This analysis
confırms previous observations of early mutational events at the adenoma
stage, including known tumor suppressor and oncogene driver mutations,
e.g. KRAS G12 and G13 are mutated in 15% of the conventional adenomas
but not in sessile serrated adenomas, as well as in 23% of the colorectal
tumors. Copy number aberrations were observed at the adenoma and carci-
noma stage, but with a lower prevalence then somatic mutations. Further-
more, genome wide expression analysis indicates that several pathways
known to be affected in colorectal cancer are already disregulated at the
adenoma stage. These pathways include Wnt signaling, mucosal barrier de-
fects, bile acid metabolism, and several immune respons genes, again fınger-
pointing at the interplay between local inflammation, the microbiome, and
epithelial events. In addition, we observed that while genetic events are very
dissimilar between the serrated/MSI and conventional/MSS pathway, the
transcriptional regulation has many similarities, indicating at a possibility at
targeting these disease subtypes using the same therapeutics. These initial
fındings provide rational avenues to intercept CRC at the adenoma stage and
efforts are now focused on exploring the added role of the colonic microbiota
and immune system modulation. A more comprehensive and integrated
view of the changes associated with disease initiation will lead to the identi-
fıcation of new paths for prevention, interception and cure.
#4389 TSC1/2mutations defıne a molecular subset of HCC with aggres-
sive behavior and treatment implication. Daniel Wai Ho,1 Lo Kong Chan,1
Yung Tuen Chiu,1 Iris Ming Xu,1 Ronnie Poon,1 Tan To Cheung,1 Chung Ngai
Tang,2 Victor Tang,2 Irene Lo,3 Polly Lam,3 Derek Yau,3 Miao Xin Li,1 Chun
Ming Wong,1 Irene O. L. Ng1. 1Univ. of Hong Kong, Pokfulam, Hong Kong;
2Pamela Youde Hospital, Hong Kong; 3Queen Elizabeth Hospital, Hong Kong.
We investigated themutational landscape ofmTOR signaling cascade in hep-
atocellular carcinomas (HCCs) with chronic hepatitis B (HBV) background,
aiming to evaluate and delineate mutation-dependent mechanism of mTOR
hyper-activation in hepatocarcinogenesis. We performed next-generation se-
quencing on human HCC samples and cell line panel. Systematic mutational
screening of mTOR pathway-related genes was undertaken and mutant genes
were evaluated based on their recurrence. Protein expressions of TSC1, TSC2
and pRPS6 were assessed by immunohistochemistry in human HCC samples.
Rapamycin sensitivity was estimated by colony formation assay in HCC cell
lines and the treatment was further tested using our patient derived tumor xeno-
graft (PDTX) models. Results: We identifıed and confırmed multiple mTOR
components as recurrently mutated in HBV-associated HCCs. Of signifıcance,
we detected frequent (16.2%, n 18/111)mutations of TSC1 and TSC2 genes in
theHCC samples. The spectrum of TSC1/2mutations likely disrupts the endog-
enous gene functions in suppressing the downstream mTOR activity through
different mechanisms and leading to more aggressive tumor behavior. Muta-
tional disruption of TSC1 and TSC2was also observed inHCC cell lines and our
PDTXmodels. TSC-mutant cells exhibited reduced colony forming ability upon
Rapamycin treatment. With the use of the biologically relevant TSC2-mutant
PDTXs, we demonstrated the therapeutic benefıts of the hyper-sensitivity to-
wards Rapamycin treatment. Taken together, our fındings suggest the signifı-
cance of previously undocumented mutation-dependent mTOR hyper-activa-
tion and frequent TSC1/2 mutations in HBV-associated HCCs. They defıne a
molecular subset of HCC having genetic aberrations in mTOR signaling, with
potential signifıcance of effective specifıc drug therapy.
#4390 The Thailand initiative in genomics and expression research in
liver cancer: Race related commonmolecular subtypes among Asian hepato-
cellular carcinoma and cholangiocarcinoma identifıed by integrated genom-
ics. Anuradha Budhu,1 Jittiporn Chaisaingmongkol,2 Hien Dang,1 Siritida
Rabibhadana,2 Benjarath Pupacdi,2 So Mee Kwon,1 Marshonna Forgues,1 Yot-
sawat Pomyen,1 Vajarabhongsa Bhudhisawasdi,3 Nirush Lertprasertsuke,4
AnonChotirosniramit,4 Chawalit Pairojkul,3 ChirayuU. Auewarakul,5 Thaniya
Sricharunrat,5 Kannika Phornphutkul,6 Suleeporn Sangrajrang,7 Maggie Cam,1
Ping He,8 Stephen M. Hewitt,1 Xiaolin Wu,1 Snorri S. Thorgeirsson,1 Joshua J.
Waterfall,1 Yuelin J. Zhu,1 Jennifer Walling,1 Holly S. Stevenson,1 Daniel Edel-
man,1 Paul S.Meltzer,1 Christopher A. Loffredo,9 RobertH.Wiltrout,1 Curtis C.
Harris,1 Chulabhorn Mahidol,2 Mathuros Ruchirawat,2 Xin W. Wang1. 1Na-
tional Institutes of Health, Bethesda, MD; 2Chulabhorn Research Institute, Thai-
land; 3Khon Kaen University, Thailand; 4Chiang Mai University, Thailand;
5Chulabhorn Hospital, Thailand; 6Rajavej hospital and Lampang Cancer Center,
Thailand; 7National Cancer Institute, Thailand; 8FDA, Silver Spring, MD;
9Georgetown University Medical Center, Washington, DC.
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma
(ICC) are two distinct histological liver cancers. They are clinically and biolog-
ically heterogeneous and highly resistant to treatment, making liver cancer the
secondmost lethalmalignancy in the world. In Thailand, liver cancer represents
the primary cause of cancer-related death and is a major health problem.While
HBV and HCV are major etiological factors for HCC globally, liver fluke infec-
tion (O. viverrini) is a major etiological factor for ICC in Thailand, especially in
north-easternThailandwhereO. viverrini is endemic and approximately 70%of
liver cancers are ICC. These unique risk factor patterns provide an opportunity
to study cancer heterogeneity and unique liver tumor biology. The Thailand
Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC)
consortiumwas established to identify genomic and expression factors thatmay
modify HCC and ICC susceptibility and progression. Here, we determinedmo-
lecular subtypes and features of HCC and ICC through systems integration of
genomic, transcriptomic and metabolic profıles. We performed genome wide
profıling of 398 surgical specimens derived from 199 Thai liver cancer patients.
We employed the Affymetrix Human Transcriptome Array 2.0, the Affymetrix
Genome-Wide Human SNP Array 6.0, Metabolon’s DiscoveryHD4 platform
and Exome Sequencing to examine transcriptome profıles, somatic copy num-
ber alterations (SCNA), cancer metabolic profıles and mutation patterns, re-
spectively. The results were validated in 847 independent Asian or Caucasian
HCCor ICCcases. Transcriptomic analyses revealed that ThaiHCCconsisted of
3 stable subgroups (C1-C3), while Thai ICC contained 4 stable subgroups (C1-
C4). Interestingly, HCC-C1 and ICC-C1 subtypes shared a similar gene expres-
sionmatrix, as didHCC-C2 and ICC-C2, which correlatedwith patient survival.
These prognostic subtypes were validated in independent Asian HCC and ICC
cohorts, but not in Caucasian patients, and were associated with tumor biology
rather than etiology. GSEA revealed that the C1 subtype is enriched for mitotic
checkpoint anomalies, while the C2 subtype is related to cytokine and chemo-
kine signaling. We found that the C1 subtype encompassed a higher degree of
SCNA when compared to the C2 subtype, suggesting an association with a
genomic instability phenotype. Further analysis showed that the C2 subtype is
linked to an increased body mass index, inflammatory responses and unique
tumor metabolic activities. HCC and ICC from Asian populations, while clini-
cally treated as separate entities, share common subtypes with similar actionable
drivers which can be targeted to improve precision therapy.
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#4391 Identifıcation of novel cancer driver genes in hepatocellular carci-
noma cells by RNAi screening method. Atsushi Takai,1 Hien Dang,2 Naoki
Oishi,3 XinWeiWang2. 1Graduate School of Medicine, Kyoto University, Kyoto,
Japan; 2Center of Cancer Research, National Cancer Institute, Bethesda, MD;
3Kanazawa University Hospital, Kanazawa, Japan.
Recent studies revealed that EpCAM is one of the molecular markers for
hepatic cancer initiating cells. However, the mechanism how the EpCAM ex-
pression in the liver cancer cell is regulated still remains to be delineated. In this
study, we identifıed candidate genes critical for the maintenance of EpCAM
positive hepatocellular carcinoma (HCC) cells using a global RNAi screening
method. HCC cells were infected with pools of 200,000 lentiviral shRNA li-
brary, then they were sorted to EpCAM positive or negative group. The abun-
dance of shRNA in each group was analyzed using a microarray hybridization
method. As a result, 76 candidate shRNAswith signifıcantly different expression
between EpCAM positive and negative populations were identifıed by class
comparison analysis. Unsupervised clustering analysis of these genes in 247
HCC samples clearly separated EpCAMpositiveHCCcases fromnegative cases.
Furthermore, we found that the EpCAM-dependent gene signature can predict
survival in epithelial-like HCC cases. We focused on shRNA for PMPCB gene,
which has an important role for processingmitochondrial protein, since it ranks
as the top differentially altered shRNA-targeted gene between EpCAM positive
and negative cells. PMPCB shRNA effıciently reduced EpCAM positive popu-
lation and effectively inhibited cell proliferation both in vitro and in vivo. Inter-
estingly, PMPCB shRNA specifıcally induced cell death in EpCAM positive
HCC cells, but not in EpCAM negative cells. These data suggest that EpCAM
positive cells functionally depend on PMPCB expression. On the other hand, we
confırmed that PMPCB shRNA induced physiological dysregulation of mito-
chondrial function, leading to the increase of reactive oxygen species (ROS)
production. We found that PMPCB shRNA signifıcantly reduced TCF4 activity
as well as the expression level of c-myc and cyclinD1, which are the downstream
molecules of Wnt/-catenin pathway. Although total -catenin levels in the
cytosol and nuclei fractions were not affected by PMPCB knockdown, overex-
pression of constitutively activated mutant -catenin partially rescued the cells
from PMPCB-induced apoptosis. Forkhead box O (FOXO) is known to be in-
duced by theROSproduction, bind-catenin anddecreaseTCF activity, leading
to the induction of apoptosis.We found that the nuclear translocation of FOXO
family molecules, such as FOXO1 and FOXO3, were facilitated by PMPCB
shRNA in EpCAM positive cells. These results suggest that the activation of
FOXOs induced by PMPCB knockdown-mediated ROS production suppressed
the activity of Wnt/-catenin pathway, leading to the death of EpCAM positive
HCC cells. In conclusion, we discovered a novel candidate target molecule of
EpCAM positive HCC cells using a genome-wide RNAi screening method. Our
study shed light on the mechanisms how EpCAM positive HCC cells are main-
tained and identifıed a new target molecule that has therapeutic vulnerability in
EpCAM positive HCC cells.
#4392 Genetic diagnosis of multiple hepatocellular carcinoma. Yutaka
Midorikawa,1 Shogo Yamamoto,2 Kenji Tatsuno,2 Hiroki Ueda,2 Shingo Tsuji,2
Genta Nagae,2 Tadatoshi Takayama,1 Hiroyuki Aburatani2. 1Nihon Univ., To-
kyo, Japan; 2Univ. of Tokyo, RCAST, Tokyo, Japan.
Multiple hepatocellular carcinoma (HCC) is categorized into two types; mul-
ticentric hepatocarcinogenesis (MC) and intrahepatic metastasis (IM). Al-
though discrimination of the types of multiple HCC is of clinical importance, it
is quite diffıcult to determine it correctly even after histological diagnosis. In
order to determine multiple HCC as MC or IM, we compared pairs of multiple
HCC samples from 40 patients with multiple HCC and 2 patients with pairs of
primary HCC and extrahepatic metastasis such as adrenal grand and lung me-
tastasis with regard to molecular aberrations. Exome sequence showed that
more than 70% of somatic mutations were common in the pairs of IM, which
were consistent with the result of a pair of primary HCC and extrahepatic me-
tastasis, while no common somatic mutations was detected in genomic-MC
(gMC) pairs. Notably, more than 60% of clinically metachronous-MC cases
were diagnosed as genomic-IM (gIM) due to the concordance of mutation and
shows signifıcantly frequent tumor thrombus, suggesting that gIM pairs devel-
oped from the common ancestor. In addition, cell-free DNAwas analyzed using
exome sequence in fıve patients with recurrent HCC, and found that somatic
mutations of cell freeDNAwere similar to the primaryHCConly in gIMbut not
in gMCcases. Taken together, comparison ofmutations in a pair ofHCCsmakes
it possible to classify multiple HCCs into MC and IM, which is diffıcult to be
correctly determined in clinical practice. Furthermore liquid biopsy for muta-
tion analysis is available to make treatment plans for multiple HCC patients.
#4393 Integrative molecular analysis of gene expression and methylation
reveals 116 putative key regulator genes of human hepatocarcinogenesis.
Amanda J. Craig, Seungyeul Yoo, Verónica Miguela, Delia D’Avola, Pedro Mo-
lina-Sánchez, Josep Llovet, Amaia Lujambio, Jun Zhu, Augusto Villanueva.
Icahn School Of Medicine At Mount Sinai, New York, NY.
Introduction: Liver cancer is the second cause of cancer-related mortality
worldwide. Currently, there are only two systemic agents able to increase sur-
vival in patients at advanced stages (i.e. sorafenib and regorafenib). Median
survival of these patients is still poor, which highlights the need for new thera-
pies. Our aim is to identify key regulatory gene networks with oncogenic prop-
erties amenable for therapeutic intervention through 1) integration of gene ex-
pression and DNAmethylation data from human HCC samples followed by 2)
functional validation inmice using shRNA screens.Methods: DNAmethylation
(Illumina HM450) and mRNA expression (Affymetrix human genome U219)
data of 215 human HCC samples (Villanueva, Hepatology 2015) were analyzed
to identify key gene regulatory networks. A causality test interrogated the impact
of cis and trans regulation of promoter methylation on gene expression (Yoo,
PLoS Genet 2015). A key regulator gene was defıned when it regulated a sub-
stantial number of downstreamgenes (more than 2 standard deviations from the
mean predicted trans-regulated downstream genes). Data analysis includes dif-
ferential gene expression, topological overlap clustering (hierarchical, non-neg-
ative factorization [NMF]), and gene annotation. The tumorigenic potential of
candidate tumor suppressors was experimentally validated through a positive
selection shRNA (short-hairpin RNA) screen in mice (6 shRNAs/gene, 48 shR-
NAs/pool, 5 mice/library). Results: We identifıed 116 potential HCC key regu-
lator genes, predicted to regulate expression of between 1,484 and 3,511 down-
stream genes for each one. Among the key regulators, 60 were classifıed as
potential tumormaintenance genes and 56 as potential tumor suppressors genes
based on differential expression with non-tumoral tissue (FDR0.05). Hierar-
chical clustering of downstream genes showed signifıcant overlap among mul-
tiple key regulators, suggesting their function in co-regulatory networks. Gene
annotation showed a majority of key regulators associated (FDR0.05) with
focal adhesion and matrix reorganization. Three clusters of patients emerged
upon NMF clustering of the key regulator’s gene expression, one of which
showed (n69/215, 32% of patients) signifıcant overlap with the previously
described CTNNB1 subclass of HCC (Chiang, Cancer Res 2008). In mice, 2/6
shRNA libraries showed signifıcant accelerated tumor growth when compared
to control [median time to 400 cc of tumor volume were 29 (library #2) and 30
(library #3) versus 39 days in control, P0.05], suggesting enrichment of bona
fıde tumor suppressors. Planned sequencing analysis will confırm the identity of
these candidates. Conclusions:We have identifıed 116 putative key regulators of
hepatocarcinogenesis by integrative analysis of gene expression andDNAmeth-
ylation. Functional validation indicates enrichment of bona fıde tumor suppres-
sors.
#4394 Whole-genome, virome, and immuno-genome of liver cancer indi-
cate its genomic feature associated with virus infection and inflammation.
Hidewaki Nakagawa. RIKEN Center for Integrative Medical Sciences, Tokyo, Ja-
pan.
Liver cancer is prevalent worldwide, mainly associated with virus infection
and chronic inflammation, but its underlying molecular mechanism is quite
heterogeneous. We performed virome and immuno-genomic analyses, in addi-
tion towhole-genome landscape of somatic alterations and transcriptome in 300
liver cancers. Our whole-genome analysis elucidated point mutations in non-
coding regions, structural variations, and virus integrations (HBV andAAV), in
addition to coding mutations. We discovered novel recurrently mutated coding
and non-coding regions, such as NEAT1/MALAT1 lincRNAs, promoters,
CTCF-binding sites, and novel regulatory regions, and known cancer genes
(CDKN2A, APC, TERT) and novel cancer genes (ASH1L, NCOR1, MAC-
ROD2) thatwere recurrently affected by SVs. For virome analysis, we performed
ultra-deep sequencing after capturing HBV sequences from DNAs of 100 liver
cancers or adjacent HBV-infected liver tissues, which demonstrated genome-
wideHBV-integrations (1794 sites) in liver cancers and infected liver tissues and
eliminated pathological mechanism of viral integration. We also generated im-
muno-genomic profıles of these liver cancers, including HLA genotypes and
mutations, neo-antigen presentation, immune signatures, and TCR repertories,
which suggested some distinct immunological features and underlying molec-
ular pathways of liver cancer associated with inflammation. These trans-omics
data demonstrated comprehensive and distinct immuno-genomic feature of
virus-related liver cancer, as well as its distinct whole-genome profıles, and can
help to understand the molecular and microenvironment pathways underlying
carcinogenesis and treatment response of liver cancer.
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#4395 Somatic genomic alteration of 412 cancer-targeted genes of peri-
ampullary and pancreatic ductal adenocarcinoma in Indian patient popula-
tion. Nilabja Sikdar,1 Gourab Saha,1 Richa Singh,1 Dhiraj Anchlia,2 Paromita
Roy,3 Supriyo Ghatak,4 Sudeep Banerjee,3 Sumit Gulati,4 Shibajyoti Ghosh2.
1Indian Statistical Institute, Kolkata, India; 2Calcutta Medical College, Kolkata,
India; 3Tata Medical Center, Kolkata, India; 4Calcutta Medical Research Insti-
tute, Kolkata, India.
Introduction: Pancreatic Ductal Adenocarcinoma (PDAC), the most com-
mon primary malignant disease of the pancreas and the periampullary region,
accounts for about 75%of all nonendocrine tumors arising in this region. It is 4th
most lethal malignancies. The 5 year survivability rate is below 5%. At the be-
ginning of the 21st century, the estimated number of PCworldwide was 110,000,
with an estimated global mortality rate of 98%. Incidence of periampullary ad-
enocarinoma (PACs) is low, approximately 0.5-2% of all gastrointestinal malig-
nancies and 20%of all tumors of the extrahepatic biliary tree. Aims&Objectives:
To identify the somatic single nucleotide variants (SNV’s) in 412 cancer related
genes in PDAC & PAC’s. To identify possible altered biological pathways en-
riched in these cancers. Methodology: DNA samples from Tissue and blood
were sequenced for exon sequencing of 412 cancer related genes (NIMBLGNE
panel, Custom). Raw fastq fıles processed using GATK tools and variants iden-
tifıed by Varscan2, & MuTect. Altered pathways identifıed by KEEG. Result: A
total 105 Somatic exonic Single Nucleotide Variants (SNV’s), 9 somatic exonic
Indels, 22 LOHmutations (both Indel and SNV’s) were identifıed in our sample
set. Among the candidate genes of PDAC somatic SNV’s were found in TP53,
SMAD4 in somepatientwhereas frequency ofKRASmutationwas less frequent.
Fourteen SNV’s were reported in cosmic database which includes 5 pathogenic
variants, whereas 91 SNV’s were novel. A total 75 non-synonymous, 6 stopgain,
and 24 synonymous SNV’s were observed among 105 SNV’s. Fifty eight percent
of transversion and 52% of transition observed from all SNVs. Among all trans-
version fıfty fıve percent SNV’s were CT, GT. PI3-Akt, Proteoglycans in
cancer, Transcription misregulation, Rap1, ErbB, Neurotrophin pathways were
found to be most commonly enriched in our patient population. Our data
strongly suggest PI3-Akt, Proteoglycans in cancer pathways play a critical role in
the disease. Conclusion: This study implicates a landscape of somatic SNV’s in
PDAC’s and PAC’s and alteration of biological pathways in our patient popula-
tion.We also observeed ERBB2 andKMT2C genes are predominantly alerted in
PDAC’s and PAC’s. P53, KRAS and SMAD4 are the known mutated genes
contributes very similar mutational pattern.
#4396 Multiomics assessment of the cancer and stromal compartments of
patient-derived pancreatic xenografts reveals clinically-relevant subtypes
and novel targeted therapies. Remy Nicolle,1 Yuna Blum,1 Laetitia Marisa,1
Celine Loncle,2 Odile Gayet,2 VincentMoutardier,3 Olivier Turrini,4 Marc Gio-
vannini,4 Benjamin Bian,2 Martin Bigonnet,2 Marion Rubis,2 Nabila Elarouci,1
Lucile Armenoult,1Mira Ayadi,1 Pauline Duconseil,2MohamedGasmi,3Mehdi
Ouaissi,5 Aurélie Maignan,2 Gwen Lomberk,6 Jean-Marie Boher,4 Jacques
Ewald,4 Erwan Bories,4 Jonathan Garnier,2 Anthony Goncalves,4 Flora Poizat,4
Jean-Luc Raoul,4 Veronique Secq,3 Stephane Garcia,3 Philippe Grandval,5 Ma-
rine Barraud-Blanc,5 Emmanuelle Norguet,5 Marine Gilabert,4 Jean-Robert
Delpero,4 Julie Roques,2 Ezequiel Calvo,7 Fabienne Guillaumond,2 Sophie Vas-
seur,2 Raul Urrutia,6 Aurélien de Reyniès,1 Nelson Dusetti,2 Juan Iovanna2.
1Ligue Nationale Contre le Cancer, Paris, France; 2Centre de Recherche en Can-
cérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Institut
Paoli-Calmettes, Aix Marseille Université, Marseille, France; 3Hôpital Nord,
Marseille, France; 4Institut Paoli-Calmettes, Marseille, France; 5Hôpital de la
Timone, Marseille, France; 6Mayo Clinic, Rochester, MN; 7CHUL Research Cen-
ter, Quebec, Canada.
Patient-derived xenografts (PDX) are appearing as a prime approach for pre-
clinical studies despite being insuffıciently characterized as a model of the hu-
man disease and its diversity. In this work, 29 PDX were obtained from either
surgery or endoscopic ultrasound-guided fıne needle aspirate of pancreatic ad-
enocarcinoma. The extensive genomic profıling of these pancreatic PDX, re-
vealed two clinically-relevant subtypes having broad similarities with human
primary tumors. These subtypes are defıned by highly specifıcDNAmethylation
and transcriptomic profıles (mRNA, miRNA or lncRNA) but are not distin-
guishable by exonic mutations or copy number aberrations. Moreover, by spe-
cifıcally analyzing the stroma transcriptome, as defıned by the expression of
murine transcripts, we found that it is able to stratify the patients with the same
effıciency than the analysis of grafted human tumor cells. This fınding suggest
that transformed pancreatic cells drive the composition of their own stroma.
Finally, the multiomics analysis pinpoints novel therapeutic targets, one of
which we demonstrate to be an effıcient method for treating pancreatic cancer.
Overall, we show that PDX are trustworthy pre-clinical models of pancreatic
adenocarcinoma including of unresectable tumors. Their multiomics profıling
allow the independent analysis of the uncontaminated cancer or stromal com-
partments and discloses several original therapeutics targets.
#4397 Deciphering the diversity of somatic alterations and Salmonella
infection in gallbladder cancer bywhole exome sequencing.Prajish Sundaram
Iyer,1 Nilesh laxman Gardi,1 Malika Ranjan,1 Bikram Sahoo,1 Pratik Chan-
drani,1 PawanUpadhyay,1Mukta R. Ramadwar,2 ShaileshV. Shrikhande,2 Amit
Dutt1. 1ACTREC, Mumbai, India; 2Tata memorial Centre, Mumbai, India.
Background: Gallbladder cancer is fıfth most common cancers among the
gastrointestinal cancers with the majority of patients presented at an advanced
state of the disease. In India, gallbladder cancer is a major problem in the north-
ern part of the country with its highest incidence of 22/1,00,000 women and risk
factors ranging from gallstones, female gender, ethnicity, Salmonella infections
and genetic alterations. Despite its high incidence in our country, there is only
few candidate gene based studies and systematic genome-wide studies are far in
dismal. Hence there is an unmet need to understand the genomic landscape of
Indian gallbladder cancer genome.Materials andmethods:We interrogated the
coding region of gallbladder cancer genome of 27 samples (10 paired and 7
unpaired tumors) usingwhole exome sequencing at an average coverage of 100X
and above. Further, we validated our fındings from whole exome sequencing in
an extended cohort of 27 FFPE (Formalin fıxed paraffın embedded) samples
using other sequencing technologies. In addition we used a computational sub-
traction tool to identify Salmonella DNA sequences in the whole exome se-
quencing data. Results: We identifıed 383 somatic alterations across 17 tumors,
which includes an average 112 synonymous, 245 missense, 8 nonsense, 8 indels
and 8 splice site changes. The average mutation rate considering the paired
tumors is about 14 mutations/Mb. We found recurrent alterations in TP53,
CTNNB1, SF3B1, ATM, AKAP11 and other genes by exome sequencing analy-
sis. In addition, we examined our exome sequencing data for identifying Salmo-
nella sequences as well as presence of 143 HPV types using computational sub-
traction based on HPVDetector. In our analysis we found association of
typhoidal Salmonella strains in 11 of 26 gall bladder cancer samples and non-
typhoidal Salmonella species in 12 of 26 sample, 6 samples were co-infectedwith
both. Moreover, we observed co-occurrence of TP53 alterations in 4 of 16 Sal-
monella positive samples while we did not observe TP53 alterations in Salmo-
nella negative samples. Conclusion: Taken together, we present the landscape of
somatic alterations in Indian gallbladder cancer genome and identifıcation of
non-typhoidal Salmonella species along with co- occurrence of TP53 alterations
could aid in the treatment of gallbladder cancer.
#4398 Identifıcation of bile duct cancer specifıc fusion genes in patient
tissues.KaheeKim,1DawoonEsther Jung,2Mi-kyoung Seo,2 SangWooKim,2 Si
Young Song2. 1Brain Korea 21 PLUS Project for Medical Science, Yonsei Univer-
sity College of Medicine, Seoul, Republic of Korea; 2Yonsei University College of
Medicine, Seoul, Republic of Korea.
Gene fusion occurs when a part of one gene fuses with or attaches to a part of
another gene by genome rearrangement and the result in gene fusion may pos-
sess oncogenic properties; fused gene may be translated into a unique protein
that may promotes cancer properties. Bile duct cancer are one of the most lethal
cancer types with low 5-year survival rates, but lack of proper diagnostic or
prognostic markers. Our aim was to investigate bile duct cancer specifıc fusion
genes found in patient’s specimens. We extracted total RNA from fıve bile duct
cancer tissues and normal tissues from the same patients. We performed RNA
sequencing and the result data was analyzed using ChimeraScan, Jaffa or Fu-
sionchacher softwares to detect gene fusion. To identify the cancer somatic
fusion gene, the fusion occurred in normal tissues and previously reported fu-
sion genes found in normal tissues were excluded and the fusion occurred in
coding region was included. As a result, we found 52 bile duct cancer tissue
specifıc- fusion genes.We analyzed the expression of selected fusion genes in 30
bile duct cancer patients and cancer cell lines by qRT-PCR. As a result we ob-
served two novel bile duct cancer specifıc fusion genes. We cloned one of the
fusion genes and transfected into the bile duct cancer cell lines SNU-1196 to
assess, and increase in cellmotility was observed in vitro. These fındings indicate
the presence of novel fusion genes as well as its possible application for the early
diagnosis or prognosis of bile duct cancer.
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#4399 MUC13 induced NFB activation regulates metabolic reprogram-
ing by promoting its crosstalk with GLUT-1 receptor. Sonam Kumari,1
Sheema Khan,1 Subash C. Gupta,2 Vivek K. Kashyap,1 Murali M. Yallapu,1 Sub-
hash C. Chauhan,1 Meena Jaggi1. 1Univ. of Tennessee Health Science Center,
Memphis, TN; 2Banaras Hindu University, Varanasi, India.
Objective: Pancreatic cancer (PanCa) is the fourth most common cause of
cancer-related deaths in the US. MUC13, mucin is aberrantly expressed in
PanCa and promotes tumor growth and progression. Herein, we investigate the
fundamental role ofMUC13 in glucosemetabolism and delineate themolecular
interplay of various molecules governing MUC13 mediated metabolic repro-
graming that may be involved in pancreatic tumor maintenance. Methods:
MUC13 expressing (Panc-1) and knockdown PanCa cells (HPAF-II) were gen-
erated for the study. Immunoblotting and qRT-PCR assays were performed to
assess the expression of protein and mRNA levels, respectively, of key signaling
molecules involved in glucose metabolism of PanCa. MUC13 and Glut-1 inter-
action was studied using reciprocal co-immunoprecipitation, immunofluores-
cence, proximity ligation, Western blotting, co-capping assays in cell lines. Lac-
tate and glucose assays were performed using commercially available kits. In
vitro functional assays using wound healing scratch assay (migration), and cell
Matrigel assay (invasion) were performed in presence or absence of Lactate and
2DG supplementation. Results: Our results demonstrate that MUC13 expres-
sion leads to the TNF-induced activation/nuclear translocation of NFB p-65
and phosphorylation of IkB which in turn upregulates additional key proteins,
Glut-1, c-Myc, Bcl-2. This recruits theGlut-1 toMUC13, whereinMUC13 func-
tionally interacts with Glut-1 and stabilizes it, initiating downstream events that
result in altered glucose metabolism. MUC13 expression in PanCa cells in-
creases glucose uptake, lactate secretion which is reduced uponMUC13 knock-
down. Additionally, MUC13 mediates increased cell migratory and invasion
potential which can be potentiated by supplementing the culture media with
lactate, an end product of aerobic glycolysis. However, treatment of cells with
NFB inhibitor, Sulfasalazine, inhibits the MUC13 and Glut-1 interaction and
abrogates all these events associated with glucose metabolism. Conclusion:
These outcomes from our study suggest that MUC13 plays an important role in
metabolic reprogramming of PanCa cells metabolism to induce cancer growth
and enhanced cellular invasion andmotility. NFB acts downstream ofMUC13
to coordinate the events leading to its interation with Glut-1 and metabolic
reprogramming.Overall, these fındings illustratemechanisms bywhichMUC13
coordinates the shift in metabolism to sustain cancer growth and invasion in
PanCa.
#4400 Targeting lactate dehydrogenase-Apromotes docetaxel induced cy-
totoxicity predominantly in castration-resistant prostate cancer cells. Hi-
royuki Muramatsu,1 Makoto Sumitomo,1 Shingo Morinaga,1 Hiroshi Saiki,1
Ikuo Kobayashi,1 Keishi Kajikawa,1 GenyaNishikawa,1 Yoshiharu Kato,1Masa-
hito Watanabe,1 Kent Kanao,1 Kogenta Nakamura,1 Kazuhiro Yoshikawa2.
1Urology, Nagakute, Japan; 2Advanced Research Promotion, Nagakute, Japan.
Introduction & objectives: It is well known as Warburg effect that anaerobic
glycolytic pathway is activated in various type of advanced cancers including
prostate cancer (PC). Lactate dehydrogenase-A (LDH-A) controls the conver-
sion of pyruvate to lactate and plays an important role in glucose metabolism.
Since LDH-A pathways have been implicated in chemoresistance in various
cancers, we investigated whether inhibition of LDH-A pathway could mediate
the sensitivity to docetaxel (DOC) in human PC cells. Materials and Method:
Four PC cell lines (PC3, DU145, LNCaP, LN-CSS ) were used. LN-CSS is one of
the LNCaP-derived castration-resistant PC (CRPC) cell lines established in our
laboratories. Sodium oxamate (SO) was used as a specifıc LDH-A inhibitor. The
protein expression was detected by western blot analysis using specifıc antibod-
ies. Cell growth and survival were evaluated by WST-1 assays. Cell cycle pro-
gression and apoptotic inducibility were evaluated by flow cytometry using pro-
pidium iodide andAnnexinV. The cytotoxicity of SO/DOC combination on PC
cells was evaluated using the Chou-Talalay combination index (CI) method
which offers quantitative defınition for additive effect (CI 1), synergism (CI
1), and antagonism (CI 1) in drug combinations. Result:Western blot analysis
showed that LDH-A protein was highly expressed in LN-CSS cells compared
with other PC cell lines including the parental LNCaP. WST-1 assays showed
that treatment with SO (50 mM) for 72 hours in PC cells resulted in growth
inhibition (PC3;30%, DU145;55%, LNCaP;20%,LN-CSS;55% ), while
SO has little growth inhibitory effects on normal lymphocytes in the concentra-
tions between 1-100 mM. IC50 to DOC in PC cells were showed to be 4 nM, 1
nM, 1nM, and 4.5 nM in PC3, DU145, LNCaP and LN-CSS, respectively, sug-
gesting that both PC3 and LN-CSS were relatively resistant to DOC compared
with DU145 and LNCaP. Synergistic cytotoxicity was observed after the combi-
nation therapy with DOC and SO in LN-CSS (CI: 0.5) but not in PC3 (CI: 1.9),
DU145 (CI: 2.0), or LNCaP (CI: 6.5). Cell cycle analyses revealed that the com-
bination with DOC and SO for 72 hours resulted in the accumulation of cells in
G2-M phase followed by sub-G1 accumulation in LN-CSS cells. Annexin V
assays showed that 43% apoptosis was induced by the combination therapy in
LN-CSS cells, while only 12% by DOC only in LN-CSS cells. Conclusion: Our
results strongly suggest that LDH-A plays an important role in DOC resistance
in advanced PC cells and inhibition of LDH-A promotes DOC-sensitivity espe-
cially in CRPC cells. Our study may provide valuable information for the future
development of targeted therapies in patients with CRPC.
#4401 Role of estrogen signaling in colonmicroenvironment during obe-
sity. Amena Archer,1 Linnea Pettersson,1 Marcela González-Granillo,2 Chris-
tina Savva,2 Marion Korach-André,2 CeciliaWilliams1. 1KTH SciLifeLab, Stock-
holm, Sweden; 2Karolinska Institutet, Stockholm, Sweden.
Recent epidemiological studies highlight the strong association between high
body mass index (BMI) and enhanced risk of colon cancer. This association
appears stronger in men than in women, indicating a possible protective role of
estrogens in this context. The biological action of the estrogens is mediated by
specifıc transcription factors, the estrogen receptors (ERs). ER is the main ER
in the intestine; and it is expressed in both epithelial cells and immune cells.
Anti-inflammatory and anti-tumorigenic effects of ER in colitis-associated
neoplasia have been demonstrated. Several rodent models for obesity show an
impaired intestinal epithelial barrier function and an increase of pro-inflamma-
tory markers in the colon. Moreover, in murine colitis models, high fat diet
(HFD) exacerbates colonic inflammation. However, the specifıc molecular
mechanisms linking obesity to increased colon cancer development, where es-
trogen signaling may be involved, is not clear. We hypothesize that ER-selec-
tive agonists can oppose the HFD-mediated inflammatory pro-tumorigenic co-
lonic signalling in a gender-specifıc manner during obesity, and thereby protect
against colorectal cancer. Our study is focused on the initiation of colon inflam-
mation during obesity and aims to investigate the impact of ER activation in
this context. To address this question, male and female mice were fed a HFD for
26 weeks and treated with a ER-selective agonist for 3 weeks prior sacrifıce.
Stool pellets were regularly collected. Animals were sacrifıced; colon samples
and caecal contents were collected for further analysis.We show that the expres-
sion pattern of inflammatory genes in colon is modifıed by the ER-selective
agonist in HFD fedmice. Moreover the ER-selective agonist appears to induce
gender-specifıc changes of the microbiota of HFD-fed mice. Our results show
that an ER-selective agonist canmodulate the colonmicroenvironment during
obesity inmice and will provide a better comprehension of themolecularmech-
anisms leading to obesity-associated colonic inflammation.
#4402 CHTM1, a novel protein linked to cellular metabolism and human
malignancy.Mansi Babbar, Ying Huang, M Saeed Sheikh. SUNY Upstate Med-
ical University, Syracuse, NY.
Several lines of emerging evidence indicate that alterations in metabolism are
linked to pathogenesis of human malignancies. However, more studies are
needed to completely understand the link between tumorigenesis and metabo-
lism. In this context, we have characterized a novel protein named CHTM1
(Coiled-coil Helix Tumor andMetabolism 1) that appears to be associated with
cancer and cellularmetabolism. Per our fındings, CHTM1was present in cytosol
as well as mitochondria. CHTM1 knockdown in human cancer cell lines caused
oxidative stress, and decrease in cellular oxygen consumption and mitochon-
drial ATP levels, suggesting mitochondrial dysfunction. In view of the impor-
tance of mitochondria to nutrient stress, the effect of CHTM1 defıciency on
human cancer cells in glucose-deprived conditions was also analyzed. The re-
sults indicated that CHTM1-defıcient cells became more sensitive to glucose
deprivation and exhibited altered cellular metabolism involving down regula-
tion of PKC-CREB-PGC1 alpha signaling events. CHTM1 expression was also
found to be increased in patient samples representing breast, colon and lung
cancers when compared to their respective matching normal tissues. Based on
our fındings, we propose CHTM1 to be a valuable tumormarker that can also be
developed as a target for novel therapeutics particularly those that exploit cellu-
lar metabolism to mediate their effects.
#4403 FDG uptake in human lung adenocarcinoma associated with inva-
sion through the hexosamine biosynthesis pathway. Weiruo Zhang,1 Gina
Bouchard,1 Alice Yu,1 Majid Shafıq,1 Mehran Jamali,1 Joseph Shrager,1 Kelsey
Ayers,1 ViswamS.Nair,1 AndrewGentles,1MaximilianDiehn,1AndrewQuon,2
Sandy Napel,1 Sylvia Plevritis1. 1Stanford University, Stanford, CA; 2UCLA, Los
Angeles, CA.
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Introduction: Metabolic reprogramming is a cancer hallmark that is not fully
understood. Moreover, increasing evidence suggests that metabolic dysregula-
tion is histology-specifıc, particularly in the case of non-small cell lung cancer
(NSCLC). In this study, we investigated the differences in glucose metabolism
between the two major histology subtypes of NSCLC, namely adenocarcinoma
(AD) and squamous cell carcinoma (SQ). We explored transcriptomics in asso-
ciation with FDG-PET SUVmax (maximum standardized uptake value), a com-
mon clinical marker of glucose uptake in cancer. Methods: We identifıed meta-
bolically-associated differentially expressed genes (DEGs) by histology subtypes
using RNAseq data from resected tumors in our study cohort of 127 NSCLC
patients (96 AD and 31 SQ) and validated the DEGs on The Cancer Genome
Atlas. We also identifıed gene-enriched cellular processes correlated with SUV-
max separately for AD and SQ. We validated our fındings in public domain cell
line microarray data. In a separate cohort of 40 NSCLC patients (20 patients
overlap with study cohort) whose tumors were sorted by cell type (cancer, en-
dothelial, fıbroblast and immune cells), we identifıed specifıc cell typeswhere the
genes of interest were expressed. Results: Metabolically-associated DEGs in AD
were enriched in the hexosamine biosynthesis pathway (HBP),which is involved
in glycosylating proteins related to invasion. SUVmax correlated genes in AD
were enriched for epithelial-mesenchymal transition (EMT) and extracellular
matrix remodeling. In particular, GFPT2 (the rate-limiting gene in HBP) and 4
EMT-related glycoprotein genes were highly correlated with SUVmax, suggest-
ing potency of HBP for EMT related glucose metabolic reprogramming. We
validated the fındings on cell line microarray data (GSE49644) before and after
TGF- induced EMT, showing that many genes in HBP increased after induced
EMT, while genes in the glycolysis pathway and the pentose phosphate pathway
(PPP) were unchanged or reduced. HBP genes and many SUVmax correlated
EMT genes were most highly expressed in tumor-associated fıbroblasts com-
pared to other cells in the tumor microenvironment. In SQ, metabolically-asso-
ciated DEGs were enriched in the glycolysis pathway and PPP. SUVmax corre-
lated genes were enriched for cell development. Conclusion: An integrative
analysis of PET-RNAseq showed that in AD glucose uptake was related to inva-
sion through metabolic reprogramming of HBP. In SQ, glucose uptake was
associatedwith glycolysis and higher proliferation potential. Our work confırms
that metabolic dysregulation in NSCLC is histology-specifıc and extends the
fınding to identify cellular processes associated with FDG uptake that differ by
histology as well. Understanding histology-specifıc differences of tumor metab-
olism provides new insights into tumor behavior that can have implications for
anti-cancer therapy.
#4404 Novel approach to circumvent cisplatin resistant lung cancer by
targeting metabolism. Medhi Wangpaichitr,1 Chunjing Wu,2 Ying Ying Li,1
Lynn G. Feun,3 Macus T. Kuo,4 Niramol Savaraj1. 1Univ. of Miami/VAMedical
Ctr., Miami, FL; 2VAMedical Ctr., Miami, FL; 3University of Miami, Miami, FL;
4MD Anderson, Houston, TN.
For the past three decades, there are no drugs which could reverse cisplatin
resistance or selectively kill these resistant cells. We have discovered that cispla-
tin resistant (CR) lung cancer shares one common factor which is increase in
reactive oxygen species (ROS). Decreased intracellular thioredoxin-1(TRX1)
due to excessive secretion was found in vitro and in vivo, as well as in patients’
serum which could be a primary contributory factor to higher mitochondria-
ROS levels. Furthermore, CR cells possess signifıcantly increased number of
mitochondria and consume higher rates of oxygen. Key glycolytic enzymes
(HKII and LDHA) and lactate production were decreased in CR cells which
suggests rewiring of tumor metabolic pathways. NAD, crucial co-factor of all
redox systems, is signifıcantly reduced in all CR cells. Importantly, treatment
with riluzole (the FDA approved drug that interferes with cystine/glutamate
pump and results in reduced intracellular glutathione (GSH) levels) led to fur-
ther decrease in NAD and LDHA, as well as heightened oxidative stress in CR
cells. ROS levels were increased (2-3X)more in resistant cells after riluzole treat-
ment while no signifıcant change occurred in parental cells. The ID50 dosage of
parental cells were 3-4 fold more than theirs CR cell counterparts and no cyto-
toxicity were found in normal lung fıbroblast (n8; p0.05). Addition of 200
M NAD re-stabilized LDHA, reduced ROS, and reversed riluzole induced
cell death. To further determine whether LDHA correlates with ROS levels and
sensitivity to riluzole, we inhibited LDHAexpressions in parental cell lines S and
H460 using siRNA. Lactate productions were decreased in knockdown cells and
further attenuated upon riluzole treatmentwhen comparedwith scrambled con-
trol. Higher basal levels of ROS were obtained from SsiLDHA and
H460siLDHAand further increased in ROS levels were observedwhen treated
with riluzole. We then evaluated the viability of these cells under riluzole treat-
ment. Both siLDHA clones were sensitive to riluzole particularly in SsiLDHA
which showed 4 foldmore sensitivity. Importantly, treatment of riluzole also led
to further decrease in LDHA expressions at both protein and mRNA levels.
Using riluzole in 2 mouse xenograft models (H460CR (KRAS mutant) and SC
(wt)) resulted in completely disappeared in wild type mice and were signifıcant
reduced inKRASmutantmice (n5 per treatment group; p0.002). Repurpose
of riluzole should be considered for future treatment of CR lung cancer patients.
Supported by Department of Veterans Affairs, CDA2 award (1K2BX001289)
and Woman Cancer Association Fund.
#4405 A new energy restriction mimetic decreases survival and FOXM1
expression in pancreatic cancer cells. Laura Scolaro, Susan Lanza-Jacoby.
Thomas Jefferson Univ., Philadelphia, PA.
Pancreatic cancer is a deadly disease with only 6% of the patients living longer
than 5 years. Even if the disease is diagnosed when it is localized, the 5-year
survival rate is approximately 19%. A characteristic of cancer cell metabolism is
a shift from oxidative phosphorylation to aerobic glycolysis known as the War-
burg effect. It is well known that calorie restriction (CR) is a powerful interven-
tion that suppresses tumorigenesis in animal models by targeting glycolysis and
oncogenic signaling pathways. Recent studies have shown that the metabolic
responses characteristic of CR can be obtained with the use of energy restriction
mimetics (ERM). The purpose of this study is to evaluate a newERM,OSU-CG5
in altering growth of pancreatic cancer cells and nutrient-sensitive signaling
pathways. Tumors including those of the pancreas have uncontrolled prolifera-
tion necessitating increased fuel demands by increasing glucose availability and
altering metabolic signaling pathways. Since ERM have been reported to target
glucose transport, we evaluated whether OSU-CG5 alters glucose transport
(Glut) proteins and glucose uptake. Glut1, but not Glut2, 3, 4, and 6, were
overexpressed in Panc-1 cells with a 6-fold higher expression compared to
HPNE cells. Glut proteins were not altered in MiaPaca cells. OSU-CG5 did not
alter Glut1 protein expression in either cell line. Silencing Glut1 also had no
effect on the cytoxicity of OSU-CG5. OSU-CG5 did not alter glucose uptake
when measured in different concentrations of glucose in the media. Cell sur-
vival, as measured with Pico green, was decreased after OSU-CG5 treatment
with an IC 50 of 3uM when cultured in physiological concentration of 5 and
10mMof glucose. FOXM1 is unregulated in pancreatic cancer and a promoter of
theWarburg effect.We found that OSU-CG5 signifıcantly decreased expression
of FOXM1 in Panc1 and MiaPaca cells. Our fındings indicate that OSU-CG5
does not inhibit the growth of Panc1 and MiaPaca pancreatic cancer cells by
decreasing glucose uptake but may target the FOXM1 signaling pathways.
#4406 Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to
inhibit lipid synthesis and tumor progression. Cen Zhang, Juan Liu, Yuhan
Zhao, Xuetian Yue, Hao Wu, Jun Li, Zhiyuan Shen, Bruce Haffty, Wenwei Hu,
Zhaohui Feng. Rutgers-The Cancer Inst. of New Jersey, New Brunswick, NJ.
Increased lipid synthesis is a key characteristic of many cancers, which is
critical for cancer progression. As a key enzyme in lipid synthesis, ACLY (ATP
citrate lyase) converts citrate in the cytosol to acetyl-CoA, which is a precursor
for lipid synthesis. ACLY is frequently overexpressed or activated in cancer,
which plays an important role in promoting lipid synthesis and cancer progres-
sion. Currently, themechanismunderlyingACLYoverexpression and increased
lipid synthesis in cancer is poorly understood. Cullin3 (CUL3) is a core protein
for CUL3-RING ubiquitin ligase complex. CUL3 has been recently reported to
be a tumor suppressor and its expression is frequently down-regulated in lung
cancer. The mechanism of CUL3 in tumor suppression is not well-understood.
In this study, we found that CUL3 interacted with ACLY through its adaptor
protein KLHL25 to ubiquitinate and degrade ACLY in cells. Ectopic CUL3 ex-
pression in lung cancer cells greatly inhibited lipid synthesis, cell proliferation
and tumor growth, whereas knockdown of endogenous CUL3 in lung cancer
cells greatly promoted lipid synthesis, cell proliferation and tumor growth. Fur-
thermore, negative regulation of ACLY contributes greatly to these functions of
CUL3. Supplementation of lipid metabolites in culture medium, such as oleic
acid,mevalonate and acetate, signifıcantly reduced the inhibitory effect of CUL3
on proliferation and colony formation of cancer cells. SB-204990, a small-mol-
ecule ACLY inhibitor greatly abolished the promoting effect of CUL3 down-
regulation on lipid synthesis, cell proliferation and tumor growth. In addition,
we identifıed K540, K546 and K554 of ALCY as major ubiquitination sites of
CUL3. Mutations of K540, K546 and K554 (K540R/K546R/K554R) greatly re-
duced CUL3-mediated ubiquitination and degradation of ACLY, and greatly
compromised the inhibitory effect of CUL3 on tumor growth as well. Impor-
tantly, low CUL3 expression is signifıcantly associated with high ACLY expres-
sion in clinical lung cancer specimens, and poor prognosis in lung cancer pa-
tients. In summary, our results identifıed CUL3-KLHL25 ubiquitin ligase as a
novel negative regulator for ACLY and lipid synthesis, and demonstrated that
decreased CUL3 expression is an important mechanism for increased ACLY
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expression and lipid synthesis in lung cancer. These results also revealed that
negative regulation of ACLY and lipid synthesis is a novel and critical mecha-
nism for CUL3 in tumor suppression.
#4407 Glucose transporter 1 is associated with proliferation and progno-
sis on esophageal squamous cell carcinoma.Hiroshi Sawayama,Masaaki Iwat-
suki, Naoya Yoshida, Yoshifumi Baba, Yasuo Sakamoto, Koichi Kinoshita,
Kenichi Nakamura, Daisuke Kuroda, Eto Tsugio, Tasuku Toihata, Tomoyuki
Uchihara, Eri Oda, Taisuke Yagi, Mayuko Ohuchi, Takatugu Ishimoto, Hideo
Baba. Kumamoto Univ., Kumamoto, Japan.
Purpose: Cancer cells exhibit altered glucose metabolism, termed glycolysis
which is described by the increased uptake of glucose and the conversion of glucose
to lactate in cancer cells under adequate oxygen tension. Alternating glucose trans-
porters (GLUTs) expressionwasdetected in the cancer specifıcmetabolism to adapt
to the rapid growth and tumormicroenvironment in diverse malignant tumors. In
this study,GLUTsprofılingofESCCpatients, the relationbetweenproliferationand
GLUT1 expression using siRNA forGLUT1were analyzed. Furthermore, the prog-
nostic features according to GLUT1 expression was evaluated on esophageal squa-
mous cell carcinoma (ESCC) patients. Methods: The ratio of the 11 GLUTs
(GLUT1- GLUT14) expression between tumor and normal tissue (T/N) were ana-
lyzed in silico (GDS3838). GLUT1 expression was down-regulated using 3 siRNAs
in vitro. Immunohistochemical staining of GLUT1 was performed using paraffın
sections of tissues obtained from145 resectableESCCpatientswithout preoperative
treatment. Results: Expression of GLUT1 (T/N 2.44; 95% confıdence interval (CI):
1.78-3.34, P0.001), GLUT3 (T/N 1.96; 95%CI: 1.23-3.13, P0.01) and GLUT6
(T/N 1.31; 95%CI: 1.12-1.54, P0.001) increased in tumor tissue compared with
normal tissue. TE-1 and TE-8 cells were treated with 3 siRNAs for GLUT1 and
control siRNA for 72 hours in vitro. The proliferation of TE-1 and TE-8 cells after
siRNAs for GLUT1 compared with control siRNA decreased 72.9-84.5% and 44.8-
53.3%, respectively. GLUT1 expression was evaluated with 145 ESCC patients.
Glut1 positivity was observed in 41 patients (28.2%) and associated with depth of
invasion (odds ratio (OR)2.984; 95%CI: 1.208-7.371, P0.018) and vascular in-
vasion (OR2.771; 95%CI: 1.118-6.871, P0.028) inmultivariate analysis.GLUT1
positivity was a signifıcant disadvantage to both relapse-free survival (hazard ratio
(HR)2.021; 95%CI: 1.100-3.712; P0.023) and esophageal cancer-specifıc sur-
vival (HR2.223; 95%CI: 1.121-4.411; P0.022) in univariate Cox hazard analysis.
Conclusions: GLUTs expression was altered in ESCC patients and GLUT1 expres-
sion was most up-regulated among the 11 GLUTs. Growth assay with siRNAs for
GLUT1 revealed that GLUT1 played a curial role of ESCC cells proliferation. High
expression of GLUT1 was associated with depth of invasion and poor prognosis of
ESCC patients. These fındings provide evidence of the signifıcance of GLUT1 ex-
pression as a biomarker and GLUT1may be therapeutic target in ESCC patient.
#4408 Metabolic alterations inducedby ibrutinib inCLL cells as a basis for
drug combinations to enhance ibrutinib therapeutic activity. Helene Peli-
cano, Li Feng, William G. Wierda, Michael J. Keating, Peng Huang. UT MD
Anderson Cancer Ctr., Houston, TX.
The use of ibrutinib, which targets the Bruton tyrosine kinase, has signifı-
cantly improved the therapeutic outcome for patients with chronic lymphocytic
leukemia (CLL), especially in cases with chromosome 17p deletion, which usu-
ally respond poorly to conventional chemotherapy. However, ibrutinib is not
completely curative, and a small portion of CLL patients exhibit resistance. The
main objectives of this study were to investigate the effect of ibrutinib on CLL
mitochondrial metabolism and to develop novel strategies to enhance the ther-
apeutic activity of ibrutinib. Ibrutinib-induced changes in mitochondrial func-
tions were analyzed by measuring oxygen consumption rate (OCR) as an indi-
cator ofmitochondrial respiration and extracellular acidifıcation rate (ECAR) as
a parameter of lactate production from glycolysis using an extracellular flux
analyzer. In a primary CLL cell-stromal cell co-culture system (whichmaintains
long-term CLL cell viability), ibrutinib induced little change in OCR and ECAR
during the fırst 48-72 h. However, prolonged drug exposure (up to 7 days) in
vitro caused a consistent and signifıcant decrease in OCR compared to that in
untreated co-cultured CLL cells. Importantly, CLL cells isolated from patients
treated with ibrutinib for 7 days also had signifıcantly decreasedOCR compared
to pre-treatment samples from the same patients, suggesting that the impact of
ibrutinib on mitochondrial functions occurred in vivo and was clinically rele-
vant. On western blot analysis, ibrutinib induced decreases in expression of
certain respiratory chain components associated with AMPK activation. On
electronmicroscopy,CLL cells treatedwith ibrutinib in vitro for 6 days exhibited
lower numbers of mitochondria than untreated cells, which was confırmed by
flow cytometry analysis of cells stained with Mitotracker Green. Functional
analysis showed that ibrutinib caused CLL cells to take up less glutamine but did
not affect glucose uptake, suggesting that ibrutinib has a preferential impact on
glutamine metabolism. On testing the possibility that the metabolic alterations
and mitochondrial dysfunction induced by ibrutinib render CLL cells vulnera-
ble to compounds that affect mitochondria or inhibit glutaminemetabolism, we
found that combinations of ibrutinib with metformin (inhibitor of mitochon-
drial OXPHOS) or with C968 (glutaminase inhibitor) resulted in synergistic
activity against CLL cells and induced massive leukemia cell death compared to
either drug alone. Notably, the combination of ibrutinib and C968 was syner-
gistic in killing CLL cells with 17p deletion. Overall, our results suggest that
ibrutinib induces metabolic alterations characterized by decreased mitochon-
drial respiration and attenuated glutamine metabolism. Such metabolic altera-
tions provide a biochemical basis for mechanism-based drug combination to
enhance the therapeutic activity of ibrutinib.
#4409 Cholesterol pathway determines ovarian cancer drug resistance
through transcription factor SREBP2. Galina Karashchuk, Nataliya Karash-
chuk, Signe Caksa, Tyler S. Smith, Alexander S. Brodsky. Alpert Medical School
of Brown University and Rhode Island Hospital, Providence, RI.
Ovarian cancer is the most common cause of gynecological cancer death in
women in United States. Up to 70% of all ovarian cancer cases are high-grade
serous carcinomas with 5-year survival rates less than 30%. Recent studies have
suggested the importance of the cholesterol pathway inmultiple cancers includ-
ing gynecological malignancies. Here we demonstrate that genetic or pharma-
cological disturbance of cholesterol pathway in high-grade serous ovarian car-
cinoma cell lines results in signifıcant changes in survival rate after drug
treatment, and in protein and RNA expression patterns. SREBP2 is a transcrip-
tion factor encoded by SREBF2 gene that regulates expression of sterol-regu-
lated genes and thus maintains cholesterol homeostasis. To assess the role of
SREBP2 in ovarian cancer we have created a stable OVCAR8 cell line with
SREBF2disrupted usingCRISPR technology. This SREBF2-KD line has reduced
SREBF2 mRNA and protein expression level that indicates an effective gene
knockdown. Activation of SREBF2 is dependent on the cholesterol status of the
cell. We observed that expression of the SREBP2 precursor form is signifıcantly
reduced in SREBF2-KD line when cells are maintained under low serum condi-
tions. Mutant cells treated with paclitaxel in low, but not high serum or in
presence of statin, revealed signifıcantly lower cell viability. SREBF2-KD cells do
not survive long-term, high concentrations of paclitaxel, nor do they grow back
as effıciently as control cells. RNA expression and proteomic analysis revealed
the critical regulators mediating SREBP2 activity in stressed cells. Together,
these observations suggest that the cholesterol pathway is critical for ovarian
cancer cells not only to resist stresses, such as chemotherapy, but also to return to
a high proliferation state upon recurrence. Further studies will provide impor-
tant targets for developing new drugs for treatment of ovarian cancer.
#4410 LSR promotes ovarian cancer cell growth following the activation
of-oxidation and its antibody inhibits lipid catabolism.KosukeHiramatsu,1
Satoshi Serada,1 Takayuki Enomoto,2 Takuhei Yokoyama,1 Yusuke Takahashi,1
Minoru Fujimoto,1 Kiyoshi Yoshino,3 Tadashi Kimura,3 Tetsuji Naka1. 1Na-
tional Institute of Biomedical Innovation, Health and Nutrition, Japan; 2Niigata
University, Japan; 3Osaka University, Japan.
Ovarian cancer is the most lethal gynecologic malignancy; thus developing new
treatment options is urgently required. Molecular targeted therapies for cancers,
which are generally more tolerable than widely used cytotoxic agents, have shown
highly specifıc inhibition of target molecules. In this study, we aimed to identify a
new ovarian cancer antigen and to develop a novel monoclonal antibody (mAb).
Furthermore we evaluated its preclinical effıcacy and analyzed the function of its
antigen in ovarian cancer.To identify a new ovarian cancer antigen, cell surface
membrane proteins of normal ovarian epithelial and ovarian cancer cell lines were
analyzed by iTRAQ-based proteomic technology. We identifıed lipolysis-stimu-
lated lipoprotein receptor (LSR) as the new therapeutic target for ovarian cancer. By
the immunohistochemical analysis, signifıcant poor prognosis was observed in
high-LSR expression patients with ovarian cancer compared to patients with low-
LSR expression by survival assay (p 0.05). Our newly developed anti-LSR mAb
showed signifıcant inhibition of tumor growth in vivo against xenograft model of
LSR-positive ovarian cancer cell line and patient derived LSR-positive ovarian can-
cer tissue (p 0.05). In LSR-positive ovarian cancer cells, high number and large
lipid droplets were observed compared to LSR-negative cells and anti-LSR mAb
decreased these droplets.Moreover addition of VLDL to LSR-positive ovarian can-
cer cells signifıcantly promoted the cell proliferation (p 0.05) and anti-LSRmAb
inhibited that in vitro (p 0.05). Supporting these data, addition of VLDL to LSR-
positive ovarian cancer cells signifıcantly promoted-oxidation-mediated lipid ca-
tabolism (p 0.05) and anti-LSR mAb also inhibited that (p 0.05). In addition,
this anti-LSRmAbwhich cross-reacted withmouse LSR did not show any cytotox-
icity on normal organs and lipidmetabolism inmice. In summary, high expression
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of LSR in ovarian cancer was the poor prognostic factor. Our newly developed
anti-LSR mAb showed signifıcant tumor growth inhibition against not only LSR-
positive ovarian cancer cell line but also patient derivedLSR-positive ovarian cancer
tissue. In LSR-positive ovarian cancer cells, high number and large lipid droplets
wereobservedandLSRpromotedcellproliferation following-oxidation-mediated
lipid catabolism. Anti-LSR mAb inhibited these processes. Our preclinical data
demonstrated that targeting LSR by mAb is a promising therapy for patients with
LSR-positive ovarian cancer.
#4411 Loss of fructose-1,6-bisphosphatase expression induces altering
glucosemetabolism and tumor progression in hepatocellular carcinoma.Hi-
roaki Wakiyama,1 Hidenari Hirata,2 Keishi Sugimachi,3 Takaaki Masuda,4
Naoki Hayashi,4 Yohsuke Kuroda,4 Shuhei Ito,4 Hidetoshi Eguchi,4 Kotaro
Terashima,1 Katsumi Sakamoto,1 Masakazu Hirakawa,1 Hiroshi Honda,2 Koshi
Mimori4. 1Department of Radiology, Kyushu University Beppu Hospital, Beppu,
Japan; 2Department of Clinical Radiology, Graduate School of Medical Sciences,
Kyushu University, Fukuoka, Japan; 3Department of Surgery, Fukuoka City Hos-
pital, Fukuoka, Japan; 4Department of Surgery, Kyushu University Beppu Hospi-
tal, Beppu, Japan.
Background: A recent study reported the loss of gluconeogenic capacity in hepa-
tocellular carcinoma (HCC). Fructose-1,6-bisphosphatase (FBP1), the rate-limiting
enzyme in gluconeogenesis, is reduced in expression in some cancers.However, the
role of FBP1 in altered glucose metabolism in HCC was unclear. Therefore, the
objective of this studywas to examine the function and clinical signifıcance of FBP1
expression inHCC.Materials andMethods: First, three independent cohorts total-
ing 594 cases ofHCC (118 real-timeRT-PCRdata fromour institution, 242 expres-
sion array data from GSE14520, and 234 RNA-sequencing data from The Cancer
Genome Atlas (TCGA)) were analyzed to address clinical signifıcance. Data from
methylation arrays, SNParrays, andwhole-exome sequencingwere also analyzed to
investigate the regulation of FBP1 expression in the TCGA cohort. Second, we an-
alyzed mRNA expression, promoter methylation, and DNA copy number profıles
of 967 human cancer cell lines, including 27 liver cancer, in the Cancer Cell Line
Encyclopedia.Third,we establishedHCCcell lines stably expressingFBP1or empty
vector control.Weperformed sphere formation assay and xenograft studies to eval-
uate the role of FBP1onHCCprogression. Furthermore, in order to assess the effect
of FBP1 on altered glucose metabolism, isotopomer distribution analysis was per-
formed using [U-13C] glucose. Finally, to validate the effects of FBP1 expression on
survival, risk of recurrence, and glucosemetabolism,we performed gene set enrich-
ment analysis (GSEA). Results: Lower FBP1 expression associated with advanced
tumor stage, poor overall survival (OS), and poor recurrence-free survival (RFS) in
three independentHCCcohorts. For eitherOSorRFS in each cohort, this prognos-
tic impact persisted, even after adjusting for tumor stage. In HCC cell lines, where
endogenous FBP1 expression is low, engineering its ectopic overexpression inhib-
ited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis.
In patient specimens, promoter methylation and copy-number loss of FBP1 were
independently associated with decreased FBP1 expression. Similarly, FBP1 down-
regulation inHCC cell lines was also associatedwith copy-number loss. HCC spec-
imens exhibiting lowexpressionof FBP1hadahighlymalignant phenotype, includ-
ing large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced
aerobic glycolysis. The effects of FBP1 expression on prognosis and glucosemetab-
olism were confırmed by GSEA. Conclusion: Our fındings established that FBP1
downregulation in HCC contributed to tumor progression and poor prognosis by
altering glucose metabolism, and they rationalize further study of FBP1 as a prog-
nostic biomarker and therapeutic target in HCC patients.
#4412 Metabolic reprogramming in EMT - targeting regulatory nodes in
mesenchymal cells. Bylgja Hilmarsdottir,1 SkarphedinnHalldorsson,2Maria T.
Grinde,3 Anna Barkovskaya,1 Solveig Pettersen,1 Thorarinn Gudjonsson,4 Siver
A. Moestue,3 Ottar Rolfsson,2 Gunhild M. Mælandsmo1. 1Institute for Cancer
Research, Oslo University Hospital, Oslo, Norway; 2University of Iceland, Reyk-
javik, Iceland; 3Norwegian University of Science and Technology, Trondheim,
Norway; 4University of Iceland, Landspitali - University Hospital, Reykjavik, Ice-
land.
To combat cancer we have to avoid development of resistant and metastatic
disease. Breast cancer cells can switch from an epithelial to mesenchymal phe-
notype through a process called epithelial to mesenchymal transition/EMT.
Emerging evidence suggests that this process is vital to avoid treatment pressure
and to gain metastatic capacity. Furthermore, recent literature shows that met-
abolic reprogramming is an essential attribute of cellular plasticity. Metabolic
targeting could therefore be an attractive possibility to prevent development of
resistance and metastatic dissemination. Here we tried to understand the meta-
bolic phenotype of EMT and themechanisms linking themetabolic programs to
cellular plasticity. We also aimed to unravel compensatory metabolic pathways
and use the metabolic inhibitors to sensitize breast cancer cells to conventional
therapy. To that end we have investigated the metabolic signature of the D492
EMT cell model. The D492 cell line, established from human breast epithelial
progenitor cells, has retained stem cell characteristics and has the ability to
undergo EMT upon stromal (endothelial) influence, forming the mesenchymal
D492M cells. Thus, D492 cell system has preserved the natural flexibility of
breast epithelial progenitor cells, and constitutes a unique platform to unravel
the factors responsible for stromal cell-induced cellular plasticity.We show that
metabolic reprogramming is essential for induction of themesenchymal pheno-
type using metabolomic profıling. Using Ultra performance liquid chromatog-
raphy Mass Spectrometry and gene expression profıling we have created ge-
nome-scale metabolic models of D492 and D492M. Our data show that
glycolytic flux and oxidative phosphorylation is higher in D492, however,
D492Mcells relymore on amino acid anaplerosis and fatty acid oxidation to fuel
the TCA cycle. Glutamine and glucose tracing using NMR will give further
insight into the difference in metabolism between the two cell lines. We have
used these data to fınd metabolic targets that lock the cells in the epithelial state
or identify the means to induce lethality in the mesenchymal cells. Using the
metabolic rewiring of EMT in theD492 cell model we can understand themech-
anisms responsible for treatment resistance, identify compensatory metabolic
pathways during treatment and fınd metabolic inhibitors that will sensitize BC
cells to conventional therapy.
#4413 Targeting glutamine metabolism in MUC1 expressing triple nega-
tive breast cancer. Gennifer D. Goode, Venugopal Gunda, Pankaj Singh. Uni-
versity of Nebraska Medical Center, Omaha, NE.
Breast cancer, the second leading cause of cancer deaths in women, accounts
for nearly 1 in 3 cancer cases diagnosed in theU.S. women. Triple negative breast
cancer (TNBC) accounts for approximately 15-25%of all breast cancer cases and
has an increased incidence of metastasis, high recurrence within 1-3 years and a
high mortality rate. Therefore, identifying factors that facilitate tumor growth
and metastasis have the potential to serve as novel molecular targets for breast
cancer therapy. Mucin1 (MUC1), a glycoprotein associated with chemoresis-
tance, is aberrantly overexpressed inTNBCand facilitates growth andmetastasis
of TNBC cells. Recent studies suggest a role forMUC1 inmodulating cancer cell
metabolism to support tumor growth. In the present studywe examined the role
that MUC1 plays in TNBC tumor metabolism; thus facilitating tumor growth.
Our results indicate that MUC1 expression facilitates glutamine metabolism. A
correlation betweenMUC1 expression, glutamine dependency, and amino-oxy-
acetate (AOA) sensitivity was established. These alterations can be attributed in
part to alterations in the expression of genes regulating glutamine metabolism.
Collectively, these fındings suggest thatMUC1 serves as ametabolic regulator in
TNBC, facilitating metabolic reprogramming of glutamine that influences
growth of TNBC. Additionally, the fındings with AOA’s effectiveness provide
evidence for potential therapeutic utility, particularly forMUC1 overexpressing
TNBC.
#4414 Arginine metabolism is modulated by androgen signalling and
prostate cancer progression. De-Xue Fu,1 Hubert Huang,1 Jee-Hoon Song,1
MinXu,1 Lucy Liu,1MohamadAfnanKhan,1 KrishChandrasekaran,1 ArifHus-
sain,1 Ganesh Sriram,2 MohummadM. Siddiqui1. 1University of Maryland, Bal-
timore, MD; 2University of Maryland College Park, College Park, MD.
Background:Metabolic reprogramming has been described as one of the hall-
marks of cancer. A pathway of promise in prostate cancer management is argi-
nine (Arg) metabolism. Phase 2 clinical trials are underway to study arginine
deprivation as a treatment of prostate cancer. However, heterogeneous response
has been noted and further studies are needed to better identify prostate tumors
most reliant on Arg metabolism. The aim of this study was to investigate if Arg
metabolism was associated with androgen signalling and prostate cancer pro-
gression from androgen dependent (AD) to androgen independent (AI) pheno-
type. Methods: The LNCaP prostate cancer cell line was used. Four sets of con-
ditions were tested: LNCaP control, LNCaP in the presence of
dihydrotestosterone (DHT), LNCaP with MDV3100 (an AR inhibitor), and a
subline of LNCaP (CSS90) which has become AI. MTT viability assay was used
to assess cell viability. The Seahorse XF bioenergetics analyzer was used to mea-
sure metabolic oxygen consumption. Gas Chromatography andMass Spectros-
copy (GC/MS) was used for metabolomics characterization. Results: LNCaP
cells at a baseline are Arg-dependent. Arg starvation led to a 63% decrease in
LNCaP cell viability (p0.0001) in 24hrs. By contrast, the AI CSS90 only dem-
onstrated a 23%decrease in cell viability when depleted of Arg (p0.01withArg
control, p0.001 between LNCaP and CSS90) demonstrating AD cells were
much more dependent on exogenous Arg. Enhanced AR signaling with DHT
further sensitized cells to arginine depletion with a 73% decrease, and low level
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AR inhibitiondecreased response to arginine depletionwith only a 21%decrease
in cell viability (p0.001 for all changes). Metabolic characterization by GC/MS
demonstrated a 33.8 fold increase in buildup of an arginine metabolism inter-
mediate, ornithine in the CSS90 cells vs LNCaP (p0.0001) reflecting compen-
satory ability of the CSS90 cells to endogenouslymanage Argmetabolism.Mod-
ulation of androgen signaling with DHT and MDV3100 demonstrated similar
increased reliance of exogenous Arg for AD cells with increased androgen sig-
nalingwith a 2.2 fold increase inArg dependent oxygen consumptionwithDHT
and 95% drop withMDV (p0.0001 for both). Conclusions: Arginine is poten-
tially an important aspect of prostate cancer metabolism. Arg targeted therapies
may best be suited towards earlier stage tumors and Arg metabolism character-
ization may have potential as a biomarker of progression to AI prostate cancer.
#4415 Fatty acid synthase-mediated palmitate production impacts epi-
dermal growth factor receptor signaling to regulate specifıcity protein 1 in
breast cancer cells. Lincoln J. Barlow, Jian-Ting Zhang. Indiana University
School of Medicine, Indianapolis, IN.
Fatty acid synthase (FASN), the sole cytosolic enzyme responsible for de novo
palmitate synthesis, is critical for cancer cell survival and is a marker of poor
prognosis. FASN overexpression has been shown to confer resistance to both
drug and radiation resistance by inhibiting drug-induced ceramide production
and by increasing DNA repair activities. Recently, it was found that FASN up-
regulation of non-homologous end joining (NHEJ) repair of double strand
DNAbreaks was due to FASNup-regulation of Poly (ADP-ribose) polymerase 1
(PARP1) by increasing expression of specifıcity protein 1 (SP1). However, how
FASN regulates the expression of SP1 remains unknown. In this study, we tested
the hypothesis that, palmitate, the end product of FASN catalysis, plays an im-
portant role in regulating SP1 expression by posttranslationally modifying epi-
dermal growth factor receptor (EGFR) and affecting its activity. Using paired
isogenic cell lines with FASN overexpression and FASN knockdown as well as
exogenous supplementation of palmitate, we found that depleting palmitate in
culture reduced SP1 expression while supplementing palmitate rescues this ef-
fect. Furthermore, FASN overexpression and knockdown increased and de-
creased, respectively, phosphorylation and activation of EGFR. Treatment with
EGFR inhibitor, Erlotinib, reduced SP1 expression. These fındings suggest that
FASN regulation of SP1 and NHEJ repair may be via regulating EGFR activity.
We are in the process of determining the potential effect of palmitoylation of
EGFR on its activation and regulation of SP1 expression.
#4416 Studies on role of acyl-CoA cholesterol acyltransferase (ACAT)
expression in ovarian/endometrial cancer progression - An invitro study.
Vijayalakshmi N. Ayyagari,1 Xinjia Wang,1 Laurent Brard2. 1Southern Illinois
Univ., Springfıeld, IL; 2Southern Illinois Univ. Simmons Cancer Inst., Springfıeld,
IL.
INTRODUCTION: Cancer progression and tumorigenesis have been linked
to alterations in cellular metabolic pathways of lipid and cholesterol synthesis in
many cancers. Increased levels of cholesterol esters (CE) have been reported in
breast cancer, leukemia, glioma and prostate cancer, but not exploited in detail
in ovarian and endometrial cancers. Inside cells, excess free cholesterol is ester-
ifıed by acyl-CoA cholesterol acyltransferase (ACAT) and stored as cholesteryl
ester (CE) in lipid droplets (LDs). Cholesteryl ester accumulation may be a
consequence of loss of tumor suppressor PTEN and subsequent activation of
PI3K/AKT pathway as observed in pancreatic cancer. In the present study, we
focused on the role of ACAT and cholesterol esters in altered cholesterol metab-
olism in ovarian/endometrial cancer cell lines. METHODS: We studied the ef-
fect of abrogation of cholesterol esterifıcation either by an ACAT-1 inhibitor/
shRNA knockdown or via inhibition of PI3K/AKT/mTOR pathways and
subsequent effect on ovarian/endometrial cancer cells proliferation, invasion,
cell migration and tumorigenesis. The expression of ACAT was studied at the
protein andmRNA levels in a panel of ovarian/ endometrial cancer cell lines and
also in normal and ovarian cancer clinical samples. ACAT expression was as-
sessed by western blotting, ELISA, quantitative RT-PCR and immunostaining
techniques. RESULTS: Our results reveal an elevated expression of ACAT-1 at
both protein and mRNA levels in ovarian and endometrial cancer cell lines as
compared to primary cells. Our results also provide preliminary data on involve-
ment of ACAT and cholesterol esters in the progression and metastasis of ovar-
ian cancer. CONCLUSION: These studies may aid in the development of new
biomarkers or treatment targets for ovarian/endometrial cancer.
#4417 The role of EBV infection in aerobic glycolysis in nasopharyngeal
carcinoma. George S. Tsao,1 Jun Zhang,1 Lin Xia,1 C Tsang,1 Weitao Lin,1 Y
Yip,1 W Deng,1 K Lo,2 M Lung1. 1Univ. of Hong Kong, Pokfulam, Hong Kong;
2Chinese University of Hong Kong, Shatin, Hong Kong.
Accumulating evidence indicates that oncogenic viral protein exerts a crucial
role in activating aerobic glycolysis during tumorigenesis, but the underlying
mechanisms are largely undefıned. The Epstein-Barr virus (EBV)-encoded la-
tent membrane protein 1 (LMP1) is a trans-membrane protein with potent cell
signaling properties and has tumorigenic transformation property. Activation
of NF-B is a major signaling pathway mediating many downstream transfor-
mation properties of LMP1. Here we report that activation of mTORC1 by
LMP1 is a key modulator for activation of NF-B signaling to mediate aerobic
glycolysis. NF-B activation is involved for LMP1-induced upregulation of glu-
cose transptor-1 (Glut-1) transcription and growth of nasopharyngeal carci-
noma (NPC) cells. Collectively, blocking the activity of mTORC1 signaling ef-
fectively suppressed LMP1-induced NF-B activation and Glut-1 transcription.
Interfering NF-B signaling has no effect on mTORC1 activity but effectively
alteredGlut-1 transcription. Luciferase promoter assay of Glut-1 also confırmed
that Glut-1 is a direct target gene of NF-B signaling. Furthermore, we demon-
strated that the LMP1 C-terminal activating region (CTAR) 2 is the key domain
involved inmTORC1 activation, mainly through IKK-mediated phosphoryla-
tion of TSC2 at Ser939. Depletion of Glut-1 effectively led to suppression of
aerobic glycolysis, inhibition of cell proliferation, colony formation, and atten-
uation of tumorigenic growth property of LMP1-expressing nasopharyngeal
epithelial (NPE) cells. These fındings suggest that targeting the signaling axis of
mTORC1/NF-B/Glut-1 represents a novel therapeutic target against NPC. Ac-
knowledgement: 96 800x600 This project was supported by the General Re-
search Fund (HKU 779810M, 17120814 and 17161116), CRF equipment grant
(1061402980, Health and Medical Research Fund of Hong Kong (12110782),
AoE grant (AoE/M-06/08) and TBRS grant (T12-401/13-R). We thank Prof.
Dongyan Jin (Department of Biochemistry, The University of Hong Kong) for
the kind gifts of IKK related plasmids and Prof. Zhenguo Wu (Division of Life
Science, The Hong Kong University of Science and Technology) for the discus-
sion and interpretation of the data. We also thank Mr. Tony Chan for his tech-
nical support.
#4418 Enhanced endocytosis as a metabolic detour for cancer cells. Yang
Liu, Yanxin Lu, Aiguo Li, Orieta Celiku, Mark R. Gilbert, Chunzhang Yang.
Center for Cancer Research, National Cancer Institute, Bethesda, MD.
INTRODUCTION: Metabolic defects impair physiology and life cycle of ev-
ery somatic cell. However, emerging evidence showed abnormalities in meta-
bolic pathways paradoxically serve as initial steps in many types of human can-
cers. Little is known about the molecular mechanisms that confer metabolic
adaptation and oncogenic predisposition for a transforming cell with intrinsic
metabolic defect. In the present study, we explore themolecularmechanism that
assists cellular adaptation when confrontingmetabolic defıciency, and its corre-
lation acquisition of aggressive phenotypes. METHOD: We took advantage of
clinical cases and in vitro cellular models with neomorphic IDH1 mutations, as
a paradigm of metabolic defıciency-associated cancer. We investigated whole
transcriptomic profıling based on RNA sequencing on IDH1-mutated cells and
seek for selective activated canonical pathways. As a validation, we investigated
the signature pathways in IDH1-mutated cells, with a focus on cytoskeleton
assembly, cellular migration and endocytosis. Moreover, we investigated
mTORC pathway and identifıed its pivotal role in the metabolic adaptation and
cellular motility changes in IDH1-mutated cells. RESULTS: Transcriptomic
profıling suggested profound activation in molecular pathways that govern cell
movement, endocytosis, chemotaxis and invasion in IDH1-mutated cells. Hier-
archical clustering analysis suggested that acquisition of R132C or R132H IDH1
mutant leads to consistent activation pattern for cellularmovement. In addition,
we confırmed that IDH1-mutated cells exhibit stronger capacity in cellular mi-
gration, endocytosis and cytoskeleton re-organization. Importantly, we demon-
strated remarkable enhancement in endocytosis pathways in IDH1-mutated
cells, suggesting cellular transformation eases metabolite uptake for metabolic
defıcient cell. Finally, we demonstrated that Rictor/mTORC2/Rac1 pathway is
selectively activated in IDH1-mutated glioma cells, which is essential to enable
cytoskeletonmobilization, endocytosis and acquisition of aggressive phenotype
in transforming cells. CONCLUSION:Our fındings demonstrate thatmetabolic
defıciency leads to enhancement in food seeking behavior in cellular level, high-
lighted with enhanced cell motility, chemotaxis, and endocytosis; suggesting
that this is an importantmolecularmechanism in cellular transformationduring
oncogenesis. This phenotypic transformation provides additional carbon
sources, compensating for IDH mutation related alterations and may help ex-
plain the enhanced cell migration and invasion characteristic of these cancers.
#4419 HER2 expression and 17-estradiol induce ACSL4 expression in
estrogen receptor positivemammary carcinoma cells.MarouaMbarik, Anissa
Belkaid,Marc E. Surette.Université deMoncton,Moncton, NewBrunswick, Can-
ada.
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Breast cancer is a multifactorial disease involving several molecular changes
and a high proliferation rate often under the activation of hormonal receptors.
Therefore, cancer cells require themetabolicmachinery formembrane synthesis
and to promote signaling pathways. Amongst biomolecules required for effı-
cient cell growth are polyunsaturated fatty acids, like arachidonic acid, that are
essential nutrients whose cellular uptake is partly governed by long chain acyl-
CoA synthetases (ACSL). In this study, we investigated the impact of 17-estra-
diol andHuman Epidermal growth factor Receptor 2 (HER2) on cellular uptake
of polyunsaturated fatty acids and on the expression of ACSLs. The administra-
tion of 17-estradiol in steroid-starvedMCF-7 and T47Dmammary carcinoma
cells induced a signifıcant increase in cellular uptake of arachidonic acid (AA)
and eicosapentaenoic acid (EPA), and in ACSL4 protein content (p0.05).
There was no change in the expression of the ACSL1, ACSL3 and ACSL6 iso-
forms. Increased ACSL4 protein expression was not accompanied by changes in
ACSL4 mRNA expression, but was associated with a signifıcant increase in the
protein half-life (T1/226	2h) compared to untreated cells (T1/28	0.5h).
Silencing of ER reversed the impact of 17-estradiol onACSL4 protein expres-
sion and half-life. Silencing of ACSL4 eliminated the 17-estradiol-induced in-
crease in cellular polyunsaturated fatty acid uptake, cell migration and invasion
capacities. ACSL4 silencing also prevented the 17-estradiol-induced increases
in p-Akt and p-GSK3, as well as the 17-estradiol-induced decrease in E-
cadherin expression, important events in epithelial to mesenchymal transition.
In addition, the forced expression ofHER2 inMCF7 cells induced an increase in
cellular uptake of AA and in the expression of ACSL4 measured by both qPCR
and western blots. This suggests that HER2-induces ACSL4 expression by a
mechanism that differs from that of 17-estradiol. Further investigations are
planned to study the implication of ACSL4 on cellular functions induced by
HER2. Overall, these results demonstrate that an induction of ACSL4 protein
expression in ER positive MCF-7 and T47D cells is implicated in 17-estradi-
ol-induced cellular migration and invasion capacities.
#4420 Elevated glycolytic gene signature in patient-derived neuroendo-
crine prostate cancer xenograft models and its clinical relevance. Stephen Y.
Choi,1 Susan L. Ettinger,1 Dong Lin,1 Hui Xue,2 Robert H. Bell,1 Fan Mo,1 Mi-
chael Pollak,3 Colin C. Collins,1 Yuzhuo Wang1. 1Vancouver Prostate Centre,
Vancouver, British Columbia, Canada; 2British Columbia Cancer Research Cen-
tre, Vancouver, British Columbia, Canada; 3McGill University, Montreal, Que-
bec, Canada.
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of
prostate cancer (PCa) that is becoming increasingly common in the clinic.While
the vast majority of PCa presents as androgen-dependent adenocarcinoma, re-
cent uses of increasingly potent therapeutics targeting the androgen receptor
signaling axis has resulted in the promotion of NEPC transdifferentiation as a
mechanism of treatment resistance. Unfortunately, there is currently no effec-
tive treatment option for NEPC. Altered cancer metabolism is now recognized
as a hallmark of cancer and a crucial factor for promoting tumour growth and
spread. In particular, altered glucose metabolism and the resultant acidifıcation
of the tumor microenvironment via increased lactic acid production has been
shown to play an important role in multiple cancer-promoting processes, in-
cluding tissue invasion/metastasis, angiogenesis, and suppression of local anti-
cancer immunity. While increased glycolysis is not generally considered a phe-
nomenon relevant to primary treatment-naive PCa, we have recently
demonstrated its relavance to castration-resistant prostate cancer (CRPC) and
thus suspect that it is also relevant to themore aggressive NEPC. Our laboratory
has also developed a number of unique serially transplantable patient-derived
xenograft (PDX) models of NEPC that are histologically highly similar to the
donor tissues and retain important genetic and epigenetic features. In particular,
we have developed the fırst spontaneousNEPC transdifferentiationmodel in the
fıeld (LTL331/331R). The gene expression profıles of these NEPC PDX models
were compared to that of PCa adenocarcinoma PDX models. To determine
whether certain metabolic pathway alterations were specifıc to NEPC, genes
from a number of key metabolic pathways were compiled and overall pathway
scores were generated using average expression z-scores. Furthermore, publi-
cally available gene expression data from NEPC patient tumors were used to
validate our fındings. From our analysis, we found that genes in the glycolysis
pathway were signfıciantlly upregulatied in both our PDX models and also in
patient NEPC samples. Of particular interest is the upregulation of genes in-
volved in the production and secretion of lactic acid, such as LDHA andMCT4.
As such, our results suggest that elevated glycolysis and production of lactic acid
could be a clinically importantNEPCphenotype. Furthermore, the inhibition of
glycolysis and particularly the inhibition of lactic acid secretion viaMCT4 could
be a potentially viable therapeutic strategy for NEPC.
#4421 IGF2 regulatesmitochondrial cell energy phenotype andbiogenesis
in TNBC cells. Maria L. Pagan,1 Vinodh Kumar Radhakrishnan,2 Daisy De
Leon2. 1University of Puerto Rico School of Medicine, San Juan, Puerto Rico;
2Loma Linda University, Loma Linda, CA.
Triple-negative breast cancer (TNBC) is very aggressive, resistant to chemo-
therapy and more likely to relapse, causing the worst prognosis. African Amer-
ican (AA) women suffer higher incidence and mortality of TNBC due to the
expression of high levels of Insulin Growth Factor 2 (IGF2) which promotes
tumor progression, metastasis, and chemoresistance. Also, it has been estab-
lished that functional mitochondria and mitochondrial DNA (mtDNA) are es-
sential for cancer cell growth. Mutations and/or reductions in mtDNA copy
number that alter the Oxidative Phosphorylation (OXPHOS) physiology are
common features of TNBC. We have demonstrated that mtDNA content is
lower in CRL-2335 AA TNBC cell line when compared to the CRL-2335 IGF2
knockout cell line. Thus, we propose that IGF2 regulates the mtDNA content.
This study was designed to demonstrate if IGF2 regulates mitochondrial genes
to determine the cell energy phenotype. An XFp analyzer was used to study the
mitochondrial function in terms of OCR (Oxygen Consumption Rate/Mito-
chondrial Respiration) and ECAR (Extracellular Acidifıcation Rate/ Glycolysis)
in the wild type and IGF2 stable knockout of CRL-2335 AA TNBC cells. Real
Time PCRwas performed to study the gene expression pattern of IGF2, PGC1
and PGC1. PGC1 and PGC1 are critical genes in the regulation of the mi-
tochondrial biogenesis, thus, they are important in the cellular metabolic phe-
notype. Utilizing the Seahorse metabolic system we assessed cell energy pheno-
type and alterations in terms of mitochondrial respiration rate (OCR) % and
Glycolysis (ECAR)%. Our preliminary results showed that the overall OCR and
ECAR of the stressed CRL-2335 AA TNBC cells was altered according to the
levels of IGF-II expressed. Furthermore, the results demonstrated that there was
a metabolic shift in the CRL-2335 AA TNBC cells towards the glycolytic path-
way when IGF2 was knockout in comparison to the wild type CRL-2335 cells.
Also, IGF2 knockout cells showed higher gene expression rate of PGC1 as
compared to the wild type. The above data confırms that IGF2 plays a critical
role in determining the cell energy phenotype.
#4422 Capsaicin suppresses pancreatic tumor growth by inhibiting tumor
cell metabolism. Sharavan Ramachandran, Sanjay K. Srivastava. Texas Tech
University, Amarillo, TX.
Tumor cell metabolism is considered to be a hallmark of tumorigenic pro-
gression. Pancreatic cancer cells are shown to develop addiction towards the
metabolic pathways like glycolysis andmitochondrial respiration tomeet energy
demands. Pancreatic tumor cells predominantly utilize cytosolic aerobic glyco-
lysis for energy production. In our previous studies, we have reported that cap-
saicin treatment inhibits the survival of AsPC-1 and BxPC-3 pancreatic cancer
cell lines. In this study, we evaluated the effect of capsaicin on glycolysis and
mitochondrial respiration in pancreatic cancer cells. Our results showed that
capsaicin treatment reduced the extra-cellular acidifıcation rate (glycolysis) and
oxygen consumption rate (mitochondrial respiration) in AsPC-1 and BxPC-3
cells in a concentration-dependent manner after 24h of treatment. Capsaicin
treatment caused 86% and 55% down-regulation of glycolysis process in AsPC-
1and BxPC-3 cells respectively. Our results also indicate the inhibition of glyco-
lytic capacity and glycolytic reserve by capsaicin treatment indicating the poten-
tial of capsaicin to inhibit glycolysis. In addition, capsaicin treatment reduced
98% of basal oxygen consumption rate and ATP production in AsPC-1 cells.
Furthermore, capsaicin treatment inhibited spare respiratory capacity & proton
leak in a concentration dependent manner in AsPC-1 cells. Treatment of
AsPC-1 and BxPC-3 with capsaicin for 48h also inhibited the expression of
LDH-A and its upstream regulators such as HIF-1, pSTAT3 (Y705) and EGFR
as evaluated by Western blot. Our study thus indicate that capsaicin suppresses
pancreatic tumor growth by down-regulating glycolysis and mitochondrial res-
piration. Further mechanistic studies are in progress. [Supported in part by R01
grant CA129038, awarded to (S.K.S.) by the National Cancer Institute].
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#4423 Deep sequencing of lung cancer samples using different library
preparation methods produces discordant short non-coding RNA profıles.
BridM.Ryan,1 Phillipe Loher,2 KhadijahMitchell,1 AdrianaZingone,1 Yongmei
Zhao,1 Jyoti Shetty,1 Bao Tran,1 Isidore Rigoutsos2. 1National Cancer Inst.,
Bethesda, MD; 2Thomas Jefferson University, Philadelphia, PA.
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Background: RNA-seq is the new standard for profıling coding and non-
coding RNAs in a cell. This study compared two methods for miRNA library
preparation from NEB and Qiagen. Our goal was to evaluate overall perfor-
mance in terms of coverage, knownmiRNA detection, novel miRNA detection,
isomiR detection, and tRNA fragment (tRF) detection.Methods:We performed
short RNA-seq on 4 lung cancer tumor-normal pairs.We used two library prep-
aration kits: NEB Next Small RNA kit and Qiagen Qiaseq. All 16 preparations
were sequenced on an Illumina NextSeq 550 using NextSeq High V2 chemistry
and 75 bp single-end reads were obtained. After adapter removal and quality
trimming reads were mapped to the hg19 human genome assembly using the
Bowtie2 and SHRiMP packages. Results: On average read yield was 46 million
reads. A signifıcantly higher portion of the sequenced reads survived adapter
removal and quality trimming in theNEBpreparations (96.5%) compared to the
Qiagen (72.9%). The portion that could be uniquely mapped to hg19 was lower
for the NEB kit (41.1%) than for the Qiagen (50.8%).NEB performed better
(39.6%) compared with Qiagen (36.9%). Qiagen preparations had lengths be-
tween 20 and 25 bp whereas more than half of the mapped reads in the NEB
preparation were 26 bp or longer. At the miRNA arm level the Qiagen kit de-
tected signifıcantly more known miRNAs (792) with 10 or more reads, com-
pared with NEB (576). The same 530 miRNA arms were identifıed by both kits.
There was no discernible pattern in the ID’s or the sequence composition of the
miRNAs that were identifıed by each kit. The detection of novel miRNAs was
also higher with Qiagen (102), compared with NEB (82). The same 79 novel
miRNAs were identifıed by both. The Qiagen kit detected nearly twice as many
isomiRs (5,316)with 10 ormore reads compared toNEB (2,958). The same 2,631
isomiRs were identifıed by both kits. However, isomiR detection across samples
was more consistent with the NEB kit. When we computed pairwise Pearson
correlations of normal samples, using the most highly expressed miRNAs in
each sample, the NEB kit exhibited higher consistency (0.98) compared with the
Qiagen kit (0.95). Pearson correlations of tumor samples showed even higher
consistency for NEB (0.96) than Qiagen (0.89). Unsurprisingly, Pearson corre-
lations of like samples across the NEB and Qiagen kits was very low: 0.42 for
normal and 0.56 for tumor samples. RIN value did not seem to affect the overall
performance of either kit. Lastly, we compared tRFs. Here, the differences were
very pronounced. For multiple choices of the support threshold the NEB and
Qiagen profıles agreed on approximately 33%of the reported tRFs. Conclusions:
Library preparation kits give rise to both consistent and divergent results. End
users interested in the detection of miRNAs, isomiRs or tRFsmay derive greater
utility by selecting one kit over another.
#4424 Cancer stem cells-relatedmicroRNAshave prognostic implications
in non-small cell lung cancer. Sandra Gallach Garcia,1 Alejandro Herreros-
Pomares,2 Silvia Calabuig-Fariñas,3 Eva Escorihuela,1 Atilio Navarro,4 Aminta
Isabel Martínez,5 Alberto Jacobo Cunquero,6 Eloisa Jantus-Lewintre,2 Carlos
Camps7. 1Molecular Oncology Laboratory, General University Hospital of Valen-
cia Research Fundation, Valencia, Spain; 2Molecular Oncology Laboratory, Gen-
eral University Hospital of Valencia Research Fundation. Department of Biotech-
nology. Universidad Politécnica de Valencia., Valencia, Spain; 3Molecular
Oncology Laboratory, General University Hospital of Valencia Research Funda-
tion. Department of Pathology. Universidad de Valencia., Valencia, Spain; 4De-
partment of Pathology, General University Hospital of Valencia, Valencia, Spain;
5Department of Thoracic Surgery, General University Hospital of Valencia, Va-
lencia, Spain; 6Department of Medical Oncology, General University Hospital of
Valencia, Valencia, Spain; 7Department ofMedical Oncology, General University
Hospital of Valencia. Department of Medicine. Universidad de Valencia. Molec-
ular Oncology Laboratory, General University Hospital of Valencia Research
Fundation., Valencia, Spain.
Background: Lung cancer stem cells (CSCs) are a small population of stem-
like cells that remains largely unknown. MicroRNAs (miRNAs) regulation of
CSCs gene expression has been reported, constituting a promising therapeutic
target. The aim of this study was to isolate and analyze differential expression of
a set of miRNAs in tumorspheres from lung cancer cell lines and tumor tissue
from resectable non-small cell lung cancer (NSCLC) patients and to determine
the prognostic implications of these miRNAs in a cohort of resected-NSCLC
patients.Methods: Lung CSC-relatedmiRNAs (miR-145-5p,miR-188-5p,miR-
218-5p, miR-34a-5p, miR-21-5p and miR-125a-5p) were analyzed in cells from
seven NSCLC tumor samples and six cell lines (H1650, H1993, H480, H358,
A549 and PC9) grown in monolayer and as spheroids by RTqPCR using Taq-
Man® microRNA assays. The expression levels of these six miRNAs were also
analyzed in paired fresh-frozen tumor and normal adjacent lung tissue samples
(N178) from resected-NSCLC patients. Statistical analyses were considered
signifıcant at p0.05. Results: miRNA expression analysis of cultured cells re-
vealed an increased expression of miR-125a (p0.04) andmiR-188 (p0.05) in
lung tumorspheres from tumor samples and cell lines compared to their paired-
adherent cells.Moreover, lungspheres frompatients showed elevated expression
levels of miR-21 when compared with their paired monolayer-cell cultures (p
0.028). Interestingly, miR-125a, miR-188 and miR-21 had prognostic value
when were analyzed in patients’ tissue samples. We found that those patients
with higher levels (above the median) of miR-188 and miR-21 had a signifıcant
reduction in relapse-free survival (RFS, 23.67 vs 66.97 months; p 0.009 and
24.03 vs 56.83 months, p 0.042, respectively) and overall survival (OS, 42.9 vs
NR months; p 0.002 and 42.6 vs 82.60 months; p 0.043, respectively),
whereas the group of patients with higher levels of miR-125a had a worse out-
come (OS 51.90 vs NR; p 0.014). A signature combining the expression of
miR-188 and miR-21 was able to give more signifıcant prognostic information
(RFS, 16.97 vs. 56.83 months; p 0.006 and OS, 29.90 vs. NR; p0.0001). The
multivariate analysis including clinico-pathological and analytical variables re-
vealed this miRNAs signature as an independent prognostic biomarker for RFS
(HR 2.170 [1.372-3.431]; p 0.001) and OS (HR 3.256 [1.907-5.561];
p0.0001). Conclusions: Lung tumorspheres had increased levels of the CSC-
related miRNAs miR-125a, miR-188 and miR-21, highlighting their role in the
CSC biology. The analyses performed in a large cohort of resectable NSCLC
patients show that a two miRNAs-signature (miR-188 and miR-21) was an in-
dependent prognosticmarker for RFS andOS. Supported by grants RD06/0020/
1024 and RD12/0036/0025 from RTICC-FEDER, PI12-02838 and PI15-00753
from ISCIII, TRACE (TRA09-0132) and Beca Roche Oncohematología.
#4425 Analysis of host-Epstein-Barr virus microRNA expression in naso-
pharyngeal carcinoma. Wen-Hui Su,1 Jia-Hao Zhang,1 Kai-Ping Chang2.
1Chang Gung University, Taoyuan, Taiwan; 2Chang GungMemorial Hospital at
Lin-Kou, Taoyuan, Taiwan.
In the tumorigenesis process, miRNAs could act as oncogenes or tumor sup-
pressor genes in the cancer cells by regulating miRNA target genes. Nasopha-
ryngeal carcinoma (NPC) associated Epstein-Barr virus (EBV) can also influ-
ence the occurrence of NPC through its miRNAs. In this study, we used the next
generation sequencing technology to analysis host-viral miRNA profıles in 24
NPC and 5 adjacent normal tissues. In average, 10.62% of mappable reads
mapped to EBV genome in NPC tissue. Most of the small RNAs in NPC tissues
which mapped to EBV genome were miRNAs (95.51%), rest of them were
EBERs (1.80%) and v-snoRNA1 (2.68%). The percentages of EBV miRNA in
total human and EBV mature miRNA reads were ranged from 4% to 51% (av-
erage 29.61%). For EBV miRNAs, the expression level of BART10-3p and
BART9-3p were the top two in NPC tumors. BART20-5p, BART19-3p and
BART21-5p were correlated to tumor stage. On the other hand, there were 11
and 34 human miRNAs differentially up- and down-regulated in NPC tissue,
respectively. The present research provides the fırst evidence obtained through
direct sequencing to systematically and comprehensively describe the expres-
sion of EBV and human miRNAs in NPC tissue.
#4426 Alcohol consumption and hepatitis B-associated microRNAs in
hepatocellular carcinoma. Pin Xue Li,1 Hao Zheng,1 Maarouf A. Saad,2 Angela
E. Zou,1 Xiaoqi Wang,3 James G. Kwok,1 Avinaash Korrapati,1 Yuanhao Qu,1
ThomasK.Honda,1 JessicaWang-Rodriguez,4WegM.Ongkeko1. 1University of
California San Diego, San Diego, CA; 2Yale School of Medicine, New Haven, CT;
3University of Hong Kong, Hong Kong, China; 4Veterans Affairs, San Diego, CA.
Hepatocellular carcinoma (HCC) affects more than 500,000 new patients
each year and is characterized by fast growing, heterogeneous tumors and low
fıve-year survival rates. Despite the identifıcation of HCC risk factors, including
alcohol consumption and chronic hepatitis B (HBV) infection, early diagnosis of
HCC andmolecular understanding of how these risk factors promoteHCCboth
individually and in combination remain elusive. microRNAs (miRNAs), non-
coding transcripts22 nt in length, have emerged as central mediators of post-
transcriptional and translational gene regulation, and have been increasingly
implicated in the initiation and progression of many cancers, including HCC.
However, the dysregulation profıle of miRNAs in HCCs of varying etiologies
remains largely unexplored. To identify dysregulated miRNAs specifıcally asso-
ciated with alcohol use or with HBV in HCC patients, we analyzed next-gener-
ation RNA-sequencing data from 234 HCCs in The Cancer Genome Atlas
(TCGA). Through differential expression analyses on cohorts stratifıed by alco-
hol consumption and HBV status, we discovered 10 miRNAs specifıcally dys-
regulated in alcohol-associatedHCCs and 251miRNAs specifıcally dysregulated
in HBV-associated HCCs (FDR 0.05). Among these, two miRNAs, miR-944
andmiR-223-3p, signifıcantly overexpressed inHCC alcohol consumers, exhib-
ited additional correlations with patient survival, tumor stage, andmutations in
CTNNB1,MUC16 and TNN (p 0.05).We subsequently validated the upregu-
lation of miR-944 and miR-223-3p in vitro following treatment of both normal
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liver and HCC cell lines with biologically relevant doses of alcohol and acetal-
dehyde, the fırst breakdownmetabolite of ethanol. Knockdown of miR-944 and
miR-223-3p signifıcantly reduced cellular proliferation in both acetaldehyde-
treated and untreated normal and HCC cell lines, and resulted in increased
sensitivity to cisplatin. Inhibition of both miRNAs in HCC cell lines also re-
stored the expression of several tumor suppressor genes targeted by miR-944
andmiR-223-3p. Taken together, our fındings enhance knowledge of the respec-
tive roles of miRNAs in alcohol- and HBV-mediated HCC, and highlight the
increased transcriptomic resolution afforded by etiology-specifıc studies of can-
cer pathogenesis and progression.
#4427 An integrated analysis package of miRNA and mRNA expression
dataAn integrated analysis package of miRNA and mRNA expression data.
Ti-Tai Wang. National Taiwan University, Taipei, Taiwan.
MicroRNAs(miRNAs) are small and non-coding RNAs that can regulate
gene expression by binding on the 3=UTR of target mRNAs and inhibiting mR-
NAs to translate protein, or even promoting mRNAs degradation. In various
complex disease and pathological conditions, we can identify dysregulated
which are the causative factors. Therefore, it is an essential approach to explore
the interactions between miRNA and gene in certain diseases, such as cancers.
However, challenge arises when we are trying to validate the interactions by
doing bench experiments. The numbers of miRNA-gene interactions are too
large to be validated. Currently,most prediction algorithms only provide its own
result and low consistency rates across independent methods have been re-
ported. Therefore, it is necessary to develop a systematic method to perform a
comprehensive analysis by using the expression profıles from genes and miR-
NAs concurrently. To address these issues, we developed anR package named as
anamiR.AnamiR is able to performan integrated analysis ofmRNAandmiRNA
with the phenotype information. The analysis procedures are briefly summa-
rized as the follows. Initially, differential expression analysis would be applied to
the raw data. Subsequently, the anamiR package can identify signifıcant pairs of
miRNAs and genes if their Pearson correlation coeffıcients are lower than the
pre-defıned threshold. Next, the signifıcant pairs were compared to the embed-
ded database in anamiR, which included two validated and several predicting
miRNA-gene databases. Lastly, functional analysis is also available in this pack-
age to characterize the biological functions and signaling pathways of dysregu-
latedmiRNAs and genes. A breast cancer dataset was analyzed by using anamiR,
which identifıed nine miRNA-gene interactions for deeper studying. Among
these interactions, there are two miRNAs and nine genes included. miR-497-5p
and miR-204-5p which both were mentioned in breast cancer frequently, are
found by anamiR. The anamiR package is freely available at Bioconductor.
#4428 A miRNA signature linked to human environmental risk defıned
from carcinogen-induced and genetically-driven colon carcinogenesis mod-
els. Ying-Shiuan Chen,1 Rong Wang,2 Wan-Mohaiza Dashwood,1 Christiane
Löhr,2 David E. Williams,2 Emily Ho,2 Susanne Mertens-Talcott,3 Roderick H.
Dashwood1. 1Texas A&MUniv. Health Science Ctr., Houston, TX; 2Oregon State
University, Corvallis, OR; 3Texas A&M University, College Station, TX.
Heterocyclic amines (HCAs) produced during high-temperature cooking
have been studied extensively in terms of their genetic effects, but recent work
has implicated epigenetic mechanisms involving non-coding RNAs. We re-
ported that colon tumors induced in the rat by 2-amino-1-methyl-6-phenylimi-
dazo[4,5-b]pyridine (PhIP) have alteredmicroRNA (miRNA) signatures linked
to dysregulated pluripotency factors, such as c-Myc and Krüppel-like factor 4
(Klf4). The corresponding miRNAs prioritized from PhIP-induced colon tu-
mors were examined in other target organs from a one-year carcinogenicity
bioassay, and compared with miRNAs dysregulated in the Apc-mutant polypo-
sis in rat colon (Pirc) genetic model. Multiple let-7 family members were down-
regulated in colon, skin, lung, small intestine, and Zymbal’s gland tumors, and
were associated withMyc andHmga2 upregulation. A “PhIPmiRNA signature”
with the profıle mir-21high mir-126low mir-29low mir-215low mir-145low
was linked to reduced expression of Klf4 inmultiple target organs of the rat, and
was predictive of poor prognosis in human pan-cancer and colorectal cancer
datasets (https://cancergenome.nih.gov/). Findings from The Cancer Genome
Atlas suggested that PhIP signature miRNAs might serve as an arbiter of HCA
exposure, defıning a subset of human tumors linked to environmental carcino-
gen exposure. We conclude that future studies should examine the miRNA
signatures of other HCAs, and determine their possible predictive value for
human risk assessment. This work was supported in part by NIH grants
CA090890, CA122959, ES00210, and ES023512, the John S. Dunn Foundation,
and aChancellor’s Research Initiative.We aremost thankful to RobertHawk for
providing a graduate student fellowship in aid of Y-S Chen.
#4429 An exhaled microRNA panel interrogation and validation as risk
biomarkers for lung cancer. Simon D. Spivack. Albert Einstein College of Med-
icine, Bronx, NY.
Background: There is a need for non-invasive airway-based biomarkers in
lung carcinogenesis for both risk assessment of the ex-smoker, and earlier diag-
nosis. Recent studies have revealed that microRNAs play important regulatory
roles in carcinogenesis. Exhaled breath condensate (EBC) contains airway lining
fluid molecules, including nucleic acids, presumably in part from epithelial cel-
lular origins. Here we further develop and begin validation of the detection of
microRNAs in EBC from lung cancer patients and controls. Methods: Exhaled
breath condensate (EBC) was collected non-invasively, using a handheld device
in ambulatory subjects.MicroRNAexpression profıling usingRNA-specifıc RT-
qPCR was performed in EBC in an initial batch (E) of 88 individuals (41 lung
cancer cases, 47 controls), and a second batch D of 88 individuals (41, cases and
47 controls). We generated a 39 miR panel based on literature-derived microR-
NAs, combined with a lung tissue-based discovery effort we have performed
using microRNA-seq on lung tumors and surrounding non-tumor tissue. The
qPCR primers were designed using our previously published RNA-specifıc re-
altimeRT-PCR technique. All sampleswere run twicewith positive andnegative
controls. Results: Qualitative analyses of the fırst donor batch E was performed
on 39 microRNAs measured in 41 cases and 47 controls. Chi-square analysis
(univariate) within the training set (batch E) revealed that exhaled miR-31, 33,
105, 200b, 944, 1269a were signifıcantly different between the initial set of cases
and controls; their absence marked the cases. In the validation batch (D) pre-
liminary analysis, exhaled miRs 200b (this time present in cases, p0.044) and
944 (again absent in cases, p0.052) were case-control discriminant. In addi-
tion, test set batch D showed case-control discrimination for additional miRs
130b-3p (present in cases, p0.035), 212 (absent in cases, p0.009), 1910a (ab-
sent in cases, p0.006) and other microRNAs that were not seen in the qualita-
tive training set (batch E). Importantly, multi-miR discriminant signatures,
quantitative analysis, and risk ROC/modelling analyses are pending as of this
AACR abstract deadline. Conclusion: This new exhaled biomarker platform can
yield case-control discriminant microRNA sets, including a subset of miRs that
can validate in test sets. Once further distilled and validated, our goal is to apply
this non-invasive biomarker approach to prospective cohorts for non-invasive
lung cancer risk assessment, in order to better select higher risk individuals who
should undergo CT screening.
#4430 Circulating microRNA expression profıles as a novel diagnostic
biomarker for esophageal squamous cell carcinoma.Yutaka Shimada,1 Yoshi-
nori Takei,1 TomoyukiOkumura,2 TakuyaNagata,2Haruka Fujinami,2Miwako
Arima,3 Tetsuya Abe,4 Yasumasa Niwa,4 Masahiro Tajika,4 Tetsuo Sudo,1 Ka-
zuharu Shimizu1. 1Kyoto Univ., Kyoto, Japan; 2University of Toyama, Toyama,
Japan; 3Saitama Cancer Center Hospital, Ohmiya, Japan; 4Aich Cancer Center
Hospital, Nagoya, Japan.
Background: The fındings of a recent analysis onmicroRNAs (miRNAs) sug-
gest that circulating miRNAs have potential as biomarkers of esophageal squa-
mous cell carcinoma (ESCC). In order to identify specifıc miRNAs of ESCC, we
analyzed the circulatingmiRNAs of patients who underwent endoscopic muco-
sal resection (EMR) and esophagectomy. Method: After obtaining written in-
formed consent, we collected paired (pre and post treatment) blood samples
from 60 superfıcial ESCC patients and 42 pretreatment advanced ESCC patients
between 2011 and 2015. Sampleswere divided into training (40 superfıcial ESCC
and 22 advanced ESCC) and test (15 superfıcial ESCC and 20 advanced ESCC)
cohorts according to the period at which they were obtained (between 2011 and
2013 and between 2014 and 2015). Fifty-fıve patients underwent EMR and were
confırmed as stage 0 or Stage 1a. Microarray analyses of blood samples were
performed using the 3D-Gene miRNA microarray platform (Toray). Normal-
ization was achieved using the Quantile method, and poor quality samples were
excluded from the analysis. Any two clinical groups were compared using a
two-sided Student’s t-test. miRNAs exhibiting signifıcant differences were sub-
sequently evaluated using a logistic regression analysis (LRA). Multivariate
LRA, Akaike’s InformationCriterion (AIC), and Receiver Operating Character-
istic (ROC) analyseswere performed in order to evaluate the diagnostic power of
miRNA combinations. In all series, we used post-EMR patients as control cases.
Results: Twelve miRNAs (miR-6722-5p, 489, 4525, 409-3p, 6088, 3678-5p, 197-
5p, 4281, 5090, 3173-3p, 762, and 1470) were selected as discriminant markers
(S-combination: AUC 1.00) of superfıcial ESCC, while 4 miRNAs (miR-4723-
3p, 4646-3p, 2392, and 1236-3p) were selected as discriminant markers (A-
combination: AUC 1.00) of advanced ESCC in the training cohort. There were
no overlap miRNAs between the two combinations. In the test cohort, the S-
combination discriminated superfıcial ESCC (AUC 1.00), while the A-combi-
nation discriminated advancedESCC (AUC1.00) frompost-EMRpatients. Fur-
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thermore, the S-combination discriminated advanced ESCC in the test cohort
(AUC 1.00). However, the A-combination did not clearly discriminate superfı-
cial ESCC (AUC 0.833). Conclusion: Our results suggest that selected miRNAs
are useful biomarkers for the discrimination of ESCC. However, biomarkers of
superfıcial ESCC and advanced ESCC may differ.
#4431 Urine microRNA profıling in bladder cancer by next-generation
sequencing. Barbara Pardini,1 Francesca Cordero,2 Alessio Naccarati,1 Giulio
Ferrero,3 Clara Viberti,1 Marco Oderda,4 Maddalena Arigoni,5 Raffaele Calog-
ero,5 Carlotta Sacerdote,6 Paolo Gontero,4 Paolo Vineis,7 Giuseppe Matullo1.
1HumanGenetics Foundation,Hugef Torino, Torino, Italy; 2University of Torino,
Torino, Italy; 3University of Turin, Torino, Italy; 4University of Torino and Città
della Salute e della Scienza, Torino, Italy; 5Molecular Biotechnology Center, Uni-
versity of Torino, Torino, Italy; 6Center for Cancer Prevention (CPO-Piemonte),
Torino, Italy; 7School of Public Health, Imperial College London, London, United
Kingdom.
Bladder cancer (BC) is one of the leading causes of cancer-related death
worldwide. BC is among the most expensive cancer per patient because it re-
quires frequent surveillance and repeated treatments overmany years. The iden-
tifıcation of new biomarkers for early BC detection, recurrence/progression is
urgently needed to both improve patient outcomes and decrease health care
costs. MicroRNAs (miRNAs) are aberrantly expressed in many cancers, includ-
ing BC, andmay be isolated from various biological specimens, including urine.
To investigatemiRNA signatures in surrogate tissuesmay be a useful alternative
to reduce invasiveness of biopsies, allowing repetitive samplings during fol-
low-up and reducing health care costs for detection, monitoring of progression
and treatment. We aim to identify specifıc miRNA signatures in urine samples
from 66 BC male patients (10 muscle invasive BC (MIBC) and 56 non-muscle
invasive BC (NMIBC)) and 48 healthy controls using a Next Generation Se-
quencing (NGS) approach able to accurately distinguish BCpatients and predict
disease outcome. The measurement of miRNA levels in urine could allow to
measure the levels of promising biomarkers in one of the best and closest sur-
rogate tissue for BC, since it is in direct contact with the tissue of tumor origin. A
specifıc miRNA signatures that could distinguish the different types of BC pa-
tients from healthy controls was found in urine. For MIBC, a 18-miRNAs sig-
nature had over 80% predictive power (PP) to recognize patients from controls
(data are under validation). For NMIBCwe were able to stratify cases according
to grade. In particular, 23 miRNAs resulted differentially expressed among
G1-G2 cases and controls (5 of them had PP0.70), while several miRNAs
resulted differentially expressed among G3 patients and controls (a 10-miRNAs
signature with PP0.97). Interestingly, we found several differentially ex-
pressed miRNAs in common among cases and some miRNAs that were differ-
entially expressed only in specifıc subcategories of BC cases. NGS data were also
used to search for the most constant miRNAs in the set of samples to be used as
reference genes in a validation step. Twenty-three miRNAs (21 target and 2
reference miRNAs) were validated by qPCR on 177 urine samples from 113 BC
case and 64 controls . Interestingly, miRNAs differentially expressed among
cases and controls were able to discriminate not only BC cases from controls, but
also its subcategories. This data provide evidences of the possibility to use miR-
NAs specifıcally within the urine of patients with BC as diagnostic, prognostic
and predictive biomarkers. Acknowledgements: Work supported by Fondazi-
one Umberto Veronesi (FUV) “Post-doctoral fellowship Year 2014, 2015 and
2016” (B.P. recipient), a FUV Grant 2013 (G.M. recipient), and by a HuGeF
grant.
#4432 Low miR-222 expression levels predict long-term survival of pa-
tients affected by glioblastoma. Laura Lattanzio,1 Marzia Borgognone,1 Ros-
sella Merli,2 M. Cristina Dechecchi,3 Gianluigi Dorelli,2 Cristina Mocellini,1
Andrea Talacchi,4 Daniela Vivenza,1 Federica Tonissi,1 Alessandra Santangelo,3
Fabrizio Giordano,1 Caludio Ghimenton,3 Albino Eccher,3 Sergio Pericotti,2
Luisa Zanolla,3 Claudio Bernucci,2MarcoMerlano,1 Cristiana LoNigro,1 Giulio
Cabrini3. 1S.Croce & Carle Teaching Hospital, Cuneo, Italy; 2Papa Giovanni
XXIII Hospital, Bergamo, Italy; 3University Hospital of Verona, Verona, Italy;
4Verona University, Verona, Italy.
Introduction MicroRNAs (miRNAs) are small non-coding RNAs which are
known to play an important role in proliferation, differentiation, invasion and
angiogenesis of different malignant tumors. The role of tissue and blood level of
miRNAs as useful bio-markers of gliomagenesis is also increasing. Interest is
growing on tissue and plasma miR-222 level as prognostic marker in fırst line
chemo- and radiotherapy treated patients with glioma, the mechanisms of ac-
tion and the target genes of this miRNA in gliomagenesis being under extensive
investigation. Furthermore, some evidence exist that miR-221 and miR-222 are
upregulated in glioblastoma (GBM) patients and that these paralogues target
O(6)-methylguanine-DNA methyltransferase (MGMT) mRNA. Here we fo-
cused on the prognostic role of tissue miR-222 in GBM patients. Experimental
procedures 63 GBMpatients were included in the analysis (overall survival (OS)
range: 8-122months). For each patient formalin-fıxed paraffın-embedded tissue
samples at fırst surgerywere collected.miR-222 expression level was analyzed by
qRT-PCRwith TaqMan probe, normalizing miR-222 level onmiR-U6 level. OS
was analyzed by Kaplan-Meyer (K-M) survival curves. MGMT methylation
analysis by pyrosequencing on tumoral DNA is on-going. Results In silico anal-
ysis of The Cancer GenomeAtlas (TCGA) for GBMdefıned amedianOS of 13.6
months in the whole sample population (n199). Comparison of median OS,
done stratifying two groups according to median tissue miR-222 expression
level (low 222 vs high 222), showed a signifıcant increasedOS in low 222 patients
(14.3 vs 13.1 months, p0.017). Interestingly, K-M curves overlapped for the
fırst 14 months and then diverged after. In particular, K-M analyses starting
from 14 months revealed a signifıcantly increased hazard ratio for high 222
patients (HR 1.96, 95%CI 1.25 - 3.09, p0.004) in respect to low 222 patients,
being the median OS prolonged of further 15.1 months in low 222 and of 6.6
months in high 222 patients. On this basis, we tested the hypothesis of a possible
role ofmiR-222 in a local sample population of 63GBMpatients with prolonged
survival. MiR-222 expression level wasmeasured as described above. Therefore,
patients were stratifıed in two groups according to median tissue miR-222 ex-
pression level (low 222 vs high 222) and OS analysed on a K-M curve. The
HazardRatio for high 222 patientswas signifıcantly higher (HR5.30, 95%CI
2.53-11.11, p0.0001), being the median OS of 55 month in low 222 vs 30
months in high 222 GBM patients, respectively. Conclusions Quantitative anal-
ysis of miR-222 expression in the tumor tissue obtained at fırst surgery might
provide a relevant prediction of prolonged survival in GBM patients. Further
conclusions will be presented on the relationship betweenmiR-222 andMGMT
which will shed light on a possible role of miR-222 on gene methylation and
GBM epigenetics.
#4433 Deregulated microRNAs in NF1 derived malignant peripheral
nerve sheath tumors (MPNST) and their role in carcinogenesis. Azadeh
Amirnasr, Patricia F. van Kuijk, Robert M. Verdijk, Walter Taal, Stefan Sleijfer,
Erik A. C. Wiemer. Erasmus Medical Ctr., Rotterdam, Netherlands.
Background and aim: MPNSTs are rare and highly aggressive soft tissue sar-
comas that can occur spontaneously (sporadic MPNST) or from pre-existing
plexiform neurofıbromas in neurofıbromatosis type 1 (NF1) patients. MPNSTs
are usually diagnosed relatively late,metastasize easily, are resistant to therapeu-
tic intervention and frequently fatal for the patient. Diagnostic biomarkers that
detect earlymalignant transformation in theNF1 setting as well identifıcation of
putative targets for treatment are urgently needed. In this context we investi-
gated the miRNA expression profıles in NF1-derived MPNST. Materials and
Methods: Total RNA was isolated from sections of formalin fıxed paraffın em-
bedded (FFPE) tumor samples. miRNA expression was determined using a RT-
PCRplatform (TaqMan® LowDensityArrayHumanMicroRNACards; Applied
Biosystems). The expression of selected miRNAs was transiently modulated in
neurofıbroma and MPNST cell lines by transfection with miRNA mimics
(Dharmacon) or LNA™ based anti-miRs (Exiqon) and effects on cell prolifera-
tion, invasion/migration andWnt/-catenin signaling were studied. Results: In
order to identify miRNAs that are specifıcally deregulated in MPNST we ana-
lyzed miRNA expression in a unique set paired tumor samples (n9) of plexi-
formneurofıbroma andMPNSTwhichwere derived from the sameNF1patient.
At least 90 miRNAs were found to be differentially expressed (FDR 10%;
p0.025) between neurofıbromas and MPNST; the vast majority (82/90) of
miRNAs being downregulated in MPNST. Interestingly, and in contrast to re-
ports in the literature, sporadicMPNST samples (n10) could be easily discrim-
inated from NF1-derived MPNST by their miRNA expression profıles. On the
basis of their statistical signifıcance, fold difference and expression level, we
selected miRNAs to examine their role in MPNST pathogenesis. MiRNA levels
were modulated in MPNST (ST88-14, sNF96.2, 90-8TL) and neurofıbroma
(Hs53.T) cell lines using miRNAmimics for let-7b, miR-16, miR-26a, miR-29a,
miR-139-5p, miR-146a and antisense inhibitors for miR-889, miR-135b. The
effects of miRNA expression levels on cellular proliferation, invasion and mi-
gration were determined. As Wnt/-catenin signaling is considered a cancer
related driver pathway in MPNST we also investigated whether differentially
expressed miRNAs could regulate this pathway focusing on miRNA previously
linked to Wnt regulation or predicted to target Wnt signaling components.
Using TOP/FOP luciferase reporter assays we analyzed the effects of miR-135b,
miR-30a, miR-139-5p and miR-146a. Conclusion: miRNAs specifıcally deregu-
lated inMPNSTmay fulfıl key oncogenic roles andmay be used as biomarker or
for therapeutic purposes.
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#4434 MicroRNA methylomes of normal breast tissue from ER negative
andERpositive breast cancer identify progressionmarkers specifıc for estro-
gen receptor status. Kang Mei Chen, Josena K. Stephen, Indrani Datta,
Dhananjay Chitale, George Divine, Maria J. Worsham. Henry Ford Health Sys-
tem, Detroit, MI.
The unique structure and function of normal tissues is known to be regulated
by epigenetic mechanisms. Understanding how normal cells in their respective
tumormilieusmight affect their susceptibility to become not onlymalignant but
acquire breast cancer (BC) subtype-specifıc phenotypes, may determine tumor
clinical behavior outcomes. The goal was to compare genome wide methylation
profıles of non-coding miRNAs of breast cancer tissue and normal breast epi-
thelium from estrogen receptor (ER) negative (-) and ER positive () tumors,
and assess their miRNA methylomes in the context of tumor ER phenotypes as
either ER- or ER. BC tissue from 79 patients (39 ER- and 40 ER) and normal
tissue from 39 of these patients (19 ER- and 20-ER) were assayed using the
Illumina 450K bead array. A sub analysis focused on 2249 miRNA CpGs as-
signed to 615 uniquemiRNAs.M-values were computed as a logit function [(log
(beta/ (1-beta))] of themethylation beta values. T-testswere used to compare the
means of the M-values for the ER and ER- groups. The t-test p-values were
used to generate adaptive FDR (aFDR) levels and aFDRs of 0.05 or lower were
considered to be statistically signifıcant (Tier 1). Tier 1 CpGs were subsequently
fıltered to select only those with a mean beta ratio between ER and ER- of
under 0.5 or over 2.0 (Tier 2). The Tier 2CpGswere further fıltered to select only
those with a mean beta difference of 0.2 or more (Tier 3). In the tumor cohort,
1224/2249 (54%) CpGs were differentially methylated between ER- and ER
BC at Tier 1. Of the 1224, 963 (78.7%) were hypermethylated, and 1035 (84.6%)
were in promoter regions. The 1224 CpGs at Tier 1, the 24 at Tier 2, and 2 CpGs
at Tier 3 were associated with 379, 22 and 2 genes respectively. When the same
analysis was performed on normal tissue only (19 ER- and 20-ER), 76 of the
2249 CpGs had signifıcant aFDR values and none of those met the Tier 2 or Tier
3 criteria. Seventy-one of the 76 (93.4%) were hypermethylated, and 65 (85.5%)
were in promoter regions. The 76 signifıcant Tier 1 (aFDR) differentially meth-
ylated CpGs were associated with 48 genes of which 43 were common to tumor
Tier 1 differentiallymethylatedmiRNA genes, 10 were common to tumor Tier 2
genes, and 5 were restricted to normal tissue only. Normal epithelial tissues
demonstrated similar differential methylation directionality as their respective
tumor counterparts, favoring promoter region localization. Accordingly, the
recognition of normal breast tissue-specifıc epigenetic propensities that align
with their tumor phenotypes, suggest the possibility of progression markers
specifıc for ER status as well as markers not associated with progression. This
provides insights into our view of possible links between epigenetic program-
ming, progression continuums, and how hormonal receptor subtypes may be
determined. Support: Komen Foundation: KG110218
#4435 Exosomal miR-3622a as prognostic marker in prostate cancer.
ThaoYang,Divya Bhagirath, Kirandeep Sekhon,NathanBucay, ShahanaMajid,
Varahram Shahryari, Marisa Shiina, Yutaka Hashimoto, Priyanka Kulkarni,
Pritha Dasgupta, Mitsuho Imai-Sumida, Soichiro Yamamura, Z Laura Taba-
tabai, KirstenGreene, Yuichiro Tanaka, Rajvir Dahiya, GuorenDeng, Sharanjot
Saini. UCSF and San Francisco VA Medical Ctr., San Francisco, CA.
Loss of chromosome (chr) 8p21 is a frequent genomic alteration in prostate
cancer (PCa). Genomic deletions of this region increase signifıcantly with tumor
grade and are associated with tumor progression and poor prognosis. A com-
mon region of loss of heterozygosity (LOH) has been mapped to the chr8p21
locus that primarily harbors prostate-specifıc NKX3.1 homeobox gene. We re-
cently demonstrated that this frequently deleted locus is associatedwith a cluster
of microRNA genes- miR-3622a/b- that are lost in prostate cancer and play an
important mechanistic role in PCa progression and metastasis. MicroRNA ex-
pression profıling in microdissected human PCa clinical tissues showed that
miR-3622a/b expression is widely downregulated and is correlated with poor
survival outcome in prostate cancer. Our analyses suggested thatmiR-3622a has
potential as a prognostic and diagnostic marker for prostate cancer. Extending
these fındings, we explored the prognostic potential of serum miR-3622a in
prostate cancer patients. Since exosomes provide an important source of non-
invasive, circulating biomarkers and represent an enriched source of microR-
NAs for biomarker profıling, we profıled the microRNA content of exosomes
derived from sera of prostate cancer patients. In a pilot study, we profıled exo-
somal miRNAs from a training cohort of individuals with benign prostate hy-
perplasia (BPH), an indolent form of PCa or aggressive metastatic PCa. Exo-
somes were isolated from sera of prostate cancer patients and integrity of
exosomal preparations was confırmed by nanoparticle tracking analysis and
Western blot analyses for exosomal markers. Expression analyses of exosomal
miR-3622a expression showed that thismiRNA is enriched in exosomes.Higher
levels of miR-3622a were signifıcantly associated with tumor stage and lymph
node metastasis in a cohort of prostate cancer clinical specimens. Further, ROC
(Receiver Operating Characteristic) analyses showed that exosomal miR-3622a
expression can be a single signifıcant parameter to discriminate between BPH
and prostate cancer. Overall, our data suggests that exosomal miR-3622a is a
promising prognostic biomarker for prostate cancer. patients.
#4436 Novel microRNA signature score to predict bone metastasis and
prognosis of breast cancer.TstutomuKawaguchi, Li Yan, QianyaQi, Song Liu,
Kazuaki Takabe. Roswell Park Cancer Institute, Buffalo, NY.
Backgrounds: 40,000 US women still die with breast cancer every year. Vast
majority of death occur after they develop metastasis, where bone is the most
frequent site for breast cancer. New measures to identify the patients who de-
velop metastasis allow us to intervene early, which is expected to prolong sur-
vival. The aim of this study is to establish a microRNA (miRNA) signature
scoring system that can predict bonemetastasis and survival utilizing integrated
transcriptomics analyses in breast cancer. Materials and Methods: Both clinical
and RNA expression data, including microRNA and mRNA, of 1051 patients
were retrieved from The Cancer Genome Atlas (TCGA). 1) Multivariate Cox
proportional hazard model and Kaplan-Meier for overall survival were per-
formed to construct and identify novelmodels ofmiRNAs signature for predict-
ing patient survival. 2) Competing risk analysis using themiRNAs signature was
conducted to clarify its association with metastatic distributions. 3) Gene Set
EnrichmentAnalysis (GSEA)was performed to identify the genome-epigenome
signifıcance of themiRNAs signature. Results: 1) Utilizing Coxmodel on TCGA
cohort, we established a novel risk scoring systemwith threemiRNAs signatures
(miR-19a, miR-93, and miR-106a) that identifıed the patients population with
extremely poor overall survival (p 0.0004; 5-y survival rate, 49.2%). This result
was reproduced in two other completely independent cohorts with microarray
datasets (GSE19536, p 0.0009; GSE22220, p 0.0003, respectively). 2) Utiliz-
ing competing risk analysis for each metastatic sites of breast cancer, we found
that the patients with bone metastasis demonstrated signifıcantly high scores
(p  0.0052). The evaluation also showed a statistical tendency of association
with lungmetastasis (p 0.0854). 3)We found that high score is associatedwith
several critical gene sets such as angiogenesis (p 0.0001) or epithelial mesen-
chymal transition (p 0.0155) by GSEA that suggests that high signature score
is associated with enhanced metastasis in breast cancer patients. Conclusions:
We established a miRNAs signature scoring system to predict bone metastasis
and poor overall survival in breast cancer using novel integrated transcriptomics
concept.
#4437 Small non-coding RNA profıling from prostate cancer plasma by
deep sequencing. Xianghua Liu, Andrew Hunter, Qing Zhang, Quanyuan He,
Annemarie Benton, Gerri Ortiz, Vaishali Pannu, Nick Xiao, Mark Miglarese,
David Spetzler. Caris Life Sciences, AZ.
Background: Prostate cancer (PCa) is the most common non-skin cancer
among American men. MicroRNAs (miRNAs) are critical post-transcriptional
regulators and involved in prostate cancer tumorigenesis. The aim of this study
is to identify a PCa-specifıc expression profıle of miRNAs from plasma to guide
prostate cancer diagnosis and therapeutic treatment. Methods: Plasma was col-
lected from 5 PCa patients and 5 normal men. Circulating RNA was extracted
from 1) 200ul plasma or 2) the pellets of anti-Ago2 immunoprecipitations from
500ul plasma using the miRNeasy Serum/Plasma kit (Qiagen), with addition of
glycogen as a carrier. Small RNA libraries were constructed using the NEBNext
Multiplex Small RNA Prep Set for Illumina® (New England. BioLabs). The
cDNA library fragments were purifıed by Blue Pippin (Sage Science) for extrac-
tion of 140-160 bp size fraction containing small RNA inserts. Equimolar
amounts of cDNA library samples were pooled and were sequenced in a single
flowcell on an IlluminaHiSeq2500 with 50 cycle kit and rapid runmodel. Bioin-
formatics analysis: Adaptor was fırstly removed from the raw reads, and the
sequences weremapped to several small RNA databases by using bowtie1 with 1
mismatch. Themultiple aligned reads were weighted to themapped small RNAs
based on their uniquemapped reads counts.We then calculated the RPM (reads
per million) as indicator of the expression levels of the small RNA. To get con-
fıdent analysis results, we discarded the small RNAs whose averages of the raw
reads counts in cancer and normal groups are smaller than 25 and only focus on
the mature microRNAs. The moderate t-test is applied to fınd the differently
expressed (DE) microRNAs between normal and cancer group. Results: Two
major small RNA classes identifıed from total plasma are miRNA (47.7%) and
yRNA (35.0%). The percentage of miRNA increased to 85.3% by Ago2-IP
method. The compositions of categories of small RNAs in cancer and normal
samples are similar. We identifıed 28 and 22 differential miRNAs (2 fold
change between cancer and normal group) by total plasma and Ago-2 IP meth-
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ods respectively. Conclusions: We discovered a unique expression profıle of
miRNA detectable in the plasma from prostate cancer patients. Extracted RNA
from the pellets of anti-Ago2 immunoprecipitations can enhance the detection
of miRNA. Expand study to confırm these fındings are needed.
#4438 MiRNA expression analysis in the tumor stroma predicts Tenascin
C to promote colorectal cancer liver metastasis. Tomohiro Murakami,1 Hisa-
hito Ishimatsu,1 Hirotoshi Kikuchi,1 Amane Hirotsu,1 Tomohiro Matsumoto,1
Yusuke Ozaki,1 Toshiki Kawabata,1 Yoshihiro Hiramatsu,1 Kinji Kamiya,1
Megumi Baba,1 Takanori Sakaguchi,1 Hiroyuki Konno2. 1Second Department of
Surgery Hamamatsu University School of Medicine, Hamamatsu, Japan;
2Hamamatsu University School of Medicine, Hamamatsu, Japan.
Background: Liver is the most common site for colorectal cancer (CRC) me-
tastasis, and mechanisms underlying colorectal liver metastasis need to be ex-
plored. The tumor microenvironment consists of many stromal cells which are
known to interact with cancer cells and to promote metastasis. Recently many
microRNAs (miRNAs) specifıcally expressed in the stroma is receiving atten-
tion. In this study, we analyzed the differences in miRNA expression profıles
between peritumoral stroma of CRCs with and without liver metastasis, and
sought to identify livermetastasis-promotingmolecules that can be regulated by
the altered expression of miRNAs in the peritumoral stroma. Materials and
methods: The formalin-fıxed paraffın-embedded (FFPE) specimens of primary
CRCs from 8 patients without metastasis, 4 patients with synchronous liver
metastasis and 4 patients with metachronous liver metastasis were used for
miRNA array analysis. None of the patients had received any treatment prior to
surgery. Tumor stroma was isolated from FFPE samples using laser capture
microdissection without contamination of cancer cells, and total RNAs were
extracted. The quality of total RNA was assessed, and miRNA expression was
analyzed using TaqMan miRNA arrays. Protein expression of Tenascin C
(TNC) was immunohistochemically analyzed in 139 primary CRCs. Results:
Unsupervised hierarchical clustering classifıed 16 samples analyzed into two
groups according to their miRNA expressions. CRCs with synchronous liver
metastasis showed differential miRNA expression profıles from those without
liver metastasis or with metachronous liver metastasis. Top10 miRNAs up-reg-
ulated in CRCs with synchronous liver metastasis vs. CRCs without liver metas-
tasis or with metachronous liver metastasis were hsa-miR-518b, 618, 186, 520f,
29c, 520e, 155, 30c, 518e and 106b, and those down-regulated in CRCs with
synchronous liver metastasis were hsa-miR-302a, 551b, 627, 628-5p, 19a, 372,
302b, 384, 198 and 636. The predictive targets of the top 10 down-regulated
miRNAs were analyzed in silico using on-line data base such as .miRDB. TNC
was identifıed as a candidate for metastasis-promoting molecule which can be
upregulated in the peritumoral stroma followed by the downregulation of miR-
NAs. Immunohistochemical analysis revealed that protein expression of TNC
was higher in the stroma of primary CRCs with synchronous liver metastasis
compared with those without liver metastasis or with metachronous liver me-
tastasis. Furthermore, high expression of TNC protein in the primary CRC
stroma was correlated with shorter overall survival and liver metastasis-free
survival. Conclusions: Alterations of miRNAs in the CRC stroma appear to
create a metastasis permissive environment in which TNC plays an important
role. Expression of TNC in primary CRC stroma has the potential to be a novel
biomarker to predict the risk of postoperative liver metastasis in CRC patients.
#4439 The urine miRNA transcriptome of prostate cancer is temporally
stable and predicts disease aggressivity. Jouhyun Jeon. Ontario Institute for
Cancer Research, Toronto, Ontario, Canada.
The clinical management of prostate cancer is the most common non-skin
male malignancy in the world is hindered by the limitations of current diagnos-
tic and prognostic tests, such as the low specifıcity of prostate-specifıc antigen
(PSA) testing, low sensitivity of digital rectal examination (DRE) and complica-
tions of biopsies. To try to resolve these issues, we evaluatedmiRNA abundance
in the urine of prostate cancer patients. Alterations in miRNA abundance levels
have been reported as playing essential roles in the pathogenesis of cancer and is
occurred in a tumor phenotype-specifıc manner (e.g. aggressive and non-ag-
gressive). miRNAs are stable under diverse analytical conditions and can be
detected in various types of body fluids including urine. These characteristics
make themas promisingnon-invasive biomarkers.Here,we examined the intra-
and inter-individual variance of urine miRNA abundance by investigating lon-
gitudinal changes over months to years in a cohort of patients with localized
prostate cancer.We observed a large dynamic range of intra-individual variance
in miRNA abundances and identifıed a set of miRNAs that is stable within
individuals, and is biased toward specifıc biological functions including regula-
tion of transmembrane channel activity. We combined this observation with
machine-learning techniques to create a predictive model that can identify ag-
gressive prostate cancer. This fourmiRNAs predictivemodel was validated in an
independent prostate cancer cohort to non-invasively predict high-risk disease.
Remarkably it showed comparable performance to the best existing tissue-based
prognostic markers. These results demonstrated that non-invasive biomarkers
can be developed to precede or supplement tissue-based tests by understanding
the intra- and inter-tumoural heterogeneity of the urinemiRNA transcriptome.
#4440 New predictive and preventive biomarkers for preclinical hepato-
cellular carcinoma in Egyptian population by detection of serum miRNAs.
Sara Salama Ghazy, Amira S. Fyala, Ahmed S. Sultan. Alexandria University,
Alexandria, Egypt.
The hepatocellular carcinoma (HCC) is one of the most common malignant
tumors and carries a poor survival rate. Prognosis, survival and management of
patients at risk for developingHCC remain challenging in Egypt andworldwide.
Furthermore, poor prognosis of patients with symptomatic (HCC) diagnosed
clinically at advanced stages suggests an urgent need for new biomarkers detec-
tion that can be used for pre-clinical screening for early detection of premalig-
nant lesions and tumors in high risk to hepatitis C infection. In the present study
we used novel formulated anticancer compound(s), combined with or without
Sorafenib treatment to exert their antiproliferative effects by eliciting concomi-
tant expression of known or novel biomarkers, including different serum miR-
NAs, which can be quantitatively analyzed for differences in the levels of metab-
olites and proteins in the blood and liver tissues of treated HCC xenografts and
liver cirrhosis animal models. In addition, circulating miRNAs levels were mea-
sured as promising markers in 12 month interval-serum samples that were col-
lected from normal, chronic hepatitis C virus infected patient cohorts at the
pre-malignant or pre-clinical stages and liver cirrhotic patients that did not
develop cancer. Different serum miRNAs, including miR-21, miR-142, let-7a,
let-7b, miR-429 and miR-34a were detected in pre-clinical HCC patients and
have the potential to screen for hepatitis C virus infected patients at high risk to
develop HCC 12 months after miRNAs detection. Our data of detected serum
miRNAs from animal models and patient samples can be used to confırm and
correlate histological and histochemical results at various time points with se-
rum or imaging biomarkers, which may have a great promise for the prediction
and prevention of HCC in high risk Egyptian populations.
#4441 Unveil the role of cell-free circulating microRNA in lung cancer.
Fabrizio Bianchi, Valentina Melocchi, Tommaso Colangelo, Roberto Cuttano,
Lucia Anna Muscarella, Elisa Dama. Casa Sollievo della Sofferenza-IRCCS, San
Giovanni Rotondo, Italy.
We previously reported the identifıcation of a signature composed by 34
serum circulating cell-free microRNAs (cf-miRNA) diagnostic for lung cancer.
Using this signature, we developed a blood test (miR-test) which was capable of
detecting asymptomatic lung cancer in a large cohort (N1000) of high-risk
individuals (50years and smokers). Interestingly, we now found that a fraction
(30%) of these cf-miRNAs were preferentially expressed in cells of epithelial
origin, while another 30% were more expressed in hematopoietic cells. We
reasoned that this cf-miRNA signature could result from the extracellular re-
lease of miRNAs from cancer epithelial cells as well as from immune/stromal
cells composing the tumor microenvironment. We developed an integrated
strategy for the identifıcation of the origin of cf-miRNAs through combined
analysis of published circulating and intracellular miRNAs expression datasets
(microarray and qRT-PCR based) and of NGS analysis of cf-miRNAs in lung
tumors. Our approach will contribute elucidating the biological role of cf-miR-
NAs in lung cancer and explore eventual therapeutic implications.
#4442 micoRNA in FA defective tumor. Shirley Tang,1 Li Gao,1 Kathleen
Kathleen,1 Andrew Fink,1 Arjun Kalvala,1 Brittany Aguila,1 Gregory Otterson,1
Miguel Villalona-Calero,2 Wenrui Duan3. 1Ohio State University, Columbus,
OH; 2Miami Cancer Institute, Miami, FL; 3Florida International University, Mi-
ami, FL.
The Fanconi Anemia (FA) pathway is essential for human cells to maintain
integrity following DNA damage. This pathway is involved in the endogenous
repair of double stranded DNA breaks and homologous recombination as well
as repair of DNA cross-linking caused by exogenous agents. Cancers with de-
fective FApathway are expected to bemore sensitive to cross-link based therapy,
or to treatments in which additional repair mechanisms are targeted. We have
recently reported the detection of up to 20% of NSCLC to be FA functionally
inactive (lack of FANCD2 foci formation in the nucleus of proliferating cells by
triple stain immunofluorescence, FATSI negative).MicroRNAs (miRs,miRNA)
are small, 19-25 nucleotide, single stranded, non-coding RNA molecules that
have regulatory roles in humans by targetingmRNAs via cleaved or translational
repressionwhich can affect the output of protein coding genes and cause various
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changes in developmental and physiological processes including cancer. It has
been published that somemiRNAs are tumor suppressors, and others are onco-
genes. However, microRNAs and the FA pathway in relationship to lung cancer
progression remain unknown. In order to elucidate the role of FA related miRs
in human lung cancer development or treatment, we analyzedmiR expression in
lung cancer cells and patient lung tumors. Several cell lines were generated using
RNAi technology with FANCD2 defıciency and confırmed via reduction in
FANCD2 protein expression. Using Nanostring counter technology, mi-
croRNA array analysis was performed on FANCD2 foci positive and foci nega-
tive tumors as well as matching normal lung tissues. A cluster of microRNAs
(mir-431, 377, 376c, 200c, 26a, 135a, and let-7e) were found to be up-regulated,
and miR-494,205, 630, 145,671 were found to be down-regulated in the foci
negative tumors samples compared to matching non-tumor lung tissue. The
same group of miRs were upregulated and its corresponding group were down-
regulated in the foci negative tumors as compared to foci positive tumors. These
fındings indicate that the FA pathway may regulate downstream genes through
regulation of microRNAs in lung cancer. In order to validate this hypothesis,
specifıc miRs were be analyzed with Real-Time Quantitative PCR via foci posi-
tive and foci negative samples (cell and patient tissue) in hopes of fınding signif-
icant and consistent regulation. This study contributes to further understanding
inmiRNA and cancer pathology that may be applicable to futuristic lung cancer
treatment.
#4443 SPARC overexpression alters microRNA expression profıles in-
volved in tumor progression. Bhavesh K. Ahir, Sajani Lakka. University of Illi-
nois at Chicago, Chicago, IL.
Medulloblastoma is the most common of malignant brain tumor in children.
SPARC (secreted protein acidic and rich in cysteine), amulticellular non-structural
glycoprotein is known to be involved inmultiple processes in various cancers. Pre-
viously, we reported that SPARC expression signifıcantly impairsmedulloblastoma
tumor growth in vivo and alters chemo sensitivity. MicroRNAs are a class of post-
transcriptional gene regulators with critical functions in tumor progression. In ad-
dition, they also play role in regulation of vital genes that control mechanisms of
chemo-resistance.Herein,weassessedmicroRNA(miRNA)profıling to identify the
functional network and biological pathways altered in SPARC-overexpressed me-
dulloblastoma cells. A total of 27 differentially expressed miRNAs were identifıed
between the control and SPARC-overexpressed samples. Potentialmessenger RNA
(mRNA) targets of the differentially expressed miRNA were identifıed using Inge-
nuity Pathway Analysis (IPA). Network-based functional analyses were performed
on the available human protein interaction and miRNA-gene association data to
highlight versatile miRNAs among the signifıcantly deregulatedmiRNAs using the
IPA, and the biological pathway analysis using the PANTHERweb-based tool.We
identifıed six miRNAs (miR-125b1*, miR-146a-5p, miR-181a-5p, miR-204-5p,
miR-219-5p and miR-509-3p) which are differentially regulated with SPARC ex-
pression inmedulloblastoma cells. Furthermore, pathway enrichment analysis out-
line that these sixmicroRNAsmainlybelong tobiologicalprocesses related tocancer
related signaling pathways. Collectively, these results suggest that a perturbed ex-
pression for these six miRNAs and their complex regulatory loops contribute to
tumor suppressive effects in SPARC overexpressedmedulloblastoma cells.
#4444 MicroRNA hsa-miR-145 expression in hepatocellular carcinoma
correlates with patient survival. Go Nakajima, Kazuhiko Hayashi. Tokyo
Women’s Medical Univ., Tokyo, Japan.
Aim: MicroRNAs (miRNAs) are known as one of the regulator of gene ex-
pression at a post-transcriptional level. Previous study fromour group identifıed
forty nine miRNAs that are expressed differentially by comparing 26 pair sam-
ples of hepatocellular carcinoma (HCC) tumor tissue andnon-tumor liver tissue
using next-generation sequencer system, and hsa-miR-145, one of the candidate
miRNA was chosen for this validation study. The expression of hsa-miR-145 in
validation set HCC samples were measured by real-time PCR, and were exam-
ined the correlation between the miRNA expression and clinical data. Patients
and Methods: Forty-four patients diagnosed as HCC had undergone surgical
removal from 1991 to 1997 at the Department of Surgery, Institute of Gastroen-
terology, TokyoWomen’s Medical University, Japan. The formalin-fıxed paraf-
fın embedded samples were prepared using the standard protocol. The paraffın
blocks were cut into 10 micrometer sections, and the tumor and its adjacent
non-tumor liver tissue were collected using laser-captured microdissection and
total RNA including miRNA fraction were isolated. After synthesized cDNA
using miRNA specifıc primer, real-time PCR was performed using miRNA spe-
cifıc primer/probe. Results: The expression level of hsa-miR-145 was down-
regulated in tumor compared to non-tumor liver tissue (P0.0004). The pa-
tients were divided into two groups, higher/lower expression, the group of the
higher hsa-miR-145 expression was signifıcantly longer overall survival time
compared to the lower expression group (P0.0378). Conclusion: The hsa-
miR-145 may be potential prognostic factor for HCC patients.
#4445 MiRNA profıle of excised cutaneous squamous cell carcinoma tis-
sues comparative to adjacent normal tissue. Christopher S. Pulford, Ellise M.
Loomis, McKale R. Montgomery, Chandana K. Uppalapati, Agnes S. Pascual,
Elizabeth E. Hull, Kathryn J. Leyva.Midwestern University, Glendale, AZ.
Cutaneous Squamous Cell Carcinoma (cSCC) is the second most common
form of skin cancer commonly arising from sun-induced mutations. As most
cases of cSCC are treated by tumor excision, research aimed at understanding
factors influencing the metastasis, and possible alternative treatments, of cSCC
is limited. Cancer metastasis is a multistep process, including epithelial-to-mes-
enchymal transition (EMT). During EMT, epithelial cells undergo a dedifferen-
tiation process whereby they transition to a highly mobile and invasive mesen-
chymal cell type with metastatic capacities. Although the factors influencing
EMT are varied, one importantmediator of intercellular communication shown
to be involved in oncogenesis is miRNA. Our work focuses on miRNAs, which
are small non-coding RNA species that may be one epigenetic factor contribut-
ing to the progression of cSCC. In this study, we compared the expression pat-
tern of seven miRNAs (miR-21, -31, -34a, -125b, -199a, -204, and -1246) be-
tween fresh primary tumor samples and fresh adjacent normal tissue (ANT)
collected frompatients diagnosedwith cSCC, SCC in situ, or invasive SCC. Total
RNA was isolated from each of the samples and qPCR on all samples was per-
formed to determine the expression level of each miRNA relative to control. Of
the sevenmiRNA tested, threewere signifıcantly upregulated (miR-31, -34a, and
-199a) and one was signifıcantly downregulated (miR-204) in the patient SCC
samples compared toANT.Asmany of thesemiRNAs are predicted to influence
proteins involved in the progression of EMT in other cancers, we have begun
examining the expression of known EMT markers via qPCR and/or Western
blot from RNA and protein isolated from both SCC and ANT tissues. Prelimi-
nary results indicate that expression of E-cadherin is signifıcantly reduced in
cSCC relative to normal tissue, indicative of a progression of EMT in the can-
cerous tissue. Other EMT markers are being examined as well. Further work
investigating the function of these differentially-expressed miRNAs will help to
begin elucidating the role miRNAs are playing in the progression of cSCC.
#4446 Molecular profıling and threshold expression of microRNAs in
mammary tissue of asymptomatic women. Andrew Y. Li,1 Kristin Knight,2
Margaret Kneifel,1 Mark Feldmann,3 Kurtis Moyer,3 Allan Dickerman,4 Carla
Finkielstein4. 1Virginia Tech Carilion School of Medicine, Roanoke, VA; 2Caril-
ion Clinic Research & Development, Roanoke, VA; 3Carilion Clinic Plastic Sur-
gery, Roanoke, VA; 4Biocomplexity Institute of Virginia Tech, Blacksburg, VA.
Night shift-work and circadian dysfunction have been linked to increased
incidence of breast cancer. Circadian modulation of gene expression is often
mediated by microRNAs (miRNAs), small 18-25 nucleotide noncoding RNA
molecules that regulate posttranscriptional gene expression viamRNA inactiva-
tion. Although miRNA dysregulation has been implicated in breast cancer de-
velopment, the relationship between breast cancer incidence in women exposed
to chronic circadian disruption and their miRNA profıles has not been exam-
ined due to the lack of existing normal profıles of expression. We fırst identifıed
miRNA expressed in asymptomatic breast tissue and defıned their baseline pro-
fıles in women exposed to a regular work schedule compared to those who
experienced chronic circadian disruption by night shift work. Normal mam-
mary tissue was obtained from women undergoing therapeutic breast reduc-
tions. Clinical metadata on work, stress, sleep, pregnancy, medical, medication,
family, and surgical history were obtained through survey and chart review.We
selected night shift work starting from 0700 to 0300 as a marker of circadian
disruption. Our studies focused on two major comparisons. First, we deter-
mined qualitative oscillatory differences in miRNA variants expressed during
day and night. Second, we determined statistically signifıcant expression levels
of those day and night miRNAs in shift workers. Mammary miRNA reads were
mapped against the reference human genome andmaturemiRNA set. One-way
ANOVAwas used to comparemiRNA expression levels between night shift and
non-night shift workers, as well as miRNA expression between other clinical
metadata. At present, twelve samples have undergone experimental and statis-
tical analyses. Three out of the twelve samples were from night shift workers.
One-way ANOVA was run on the top one hundred expressed miRNAs includ-
ing hsa-miR-143-3p, hsa-miR-99a-5p, hsa-miR-21-5p, hsa-miR-10b-5p, and
hsa-miR-148a-3p to exclude miRNAs with zero or extremely low counts. Anal-
ysis showed no signifıcant difference in miRNA expression of normal samples
between night shift and non-night-shift workers (p 0.06099), pregnant and nul-
liparous (p 0.2658), and women who breastfed and those who did not (p 0.111).
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: MicroRNA Profıling in Cancer
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171136
There was signifıcant difference in miRNA expression of normal samples be-
tween patients who had breast cancer in the opposite breast compared to those
who did not (p 0.03269) and patients with sleep problems and those who did not
(p 0.003448). It is interesting to note that night shift work and sleep problems
both represent forms of circadian disruption, yet only the latter showed signifı-
cant difference in miRNA expression between controls. It is expected that pa-
tients with cancer in the other breast may exhibit signifıcantly different reads
from patients who have never had breast cancer. Future analyses will be per-
formed using additional samples to build on these fındings.
#4447 Analysis of small RNA-seq data for differential expression of small
noncoding RNAs in human colorectal cancer. Srinivas V. Koduru,1 Amit K.
Tiwari,2 Sprague W. Hazard,1 Milind K. Mahajan,3 Dino J. Ravnic1. 1PennState
University, Hershey, PA; 2University of Toledo, Toledo, OH; 3Icahn School of
Medicine, Mount Sinai, New York, NY.
Background: Cancer is a major cause of deaths worldwide, despite improved
healthcare and technologies. Recent advancements in genome sequencing have led
to the rapid study of the whole transcriptome and small RNAs with their biological
functions. Non-coding RNAs (ncRNAs) play an important role in biological pro-
cesses that greatly impact biomarker development for diagnosis, prognosis, and
therapy. Non-coding RNAs such asmicroRNAs (miRNA), Piwi-interacting-RNAs
(piRNAs), small nuclear/nucleolar RNAs (sn/snoRNAs) have recently been studied
to understand their biology and pathology. Results: In the present study, we used
eight matched colorectal patient tissue samples (benign, tumor, and metastasis)
small RNAsequencingdata remapped for various small RNAannotation.We iden-
tifıed aberrant expression of 13miRs in tumor andmetastasis specimens [tumor vs
benign group (19 miRs) and metastasis vs benign group (38 miRs)] of which fıve
were upregulated, and eight were downregulated, during disease progression. We
also investigated pathway analysis on abbarent expression of miRNAs, which
showedmajority ofmiRs involved in the colon other types of cancers. Further anal-
ysis of piRNAs revealed that six piRNAs in tumor vs benign and 24 inmetastasis vs
benign samples (commonly in both groups, only two piRNAs). Additionally, we
examined other types of small RNAs [sn/snoRNAs, mt_rRNA, misc_RNA, non-
sensemediated decay (NMD) and rRNA], we identifıed 15 in tumor vs benign and
104 metastasis vs benign and only four in commonly expressed. Conclusion: In
summary, our results identifıed multiple sncRNAs during colorectal cancer pro-
gressionwhich needs to be further validated and can be used for prognosis, diagno-
sis, and therapeutic potentials.
#4448 Elevated levels of circulating miR-34a-5p and miR-181c-3p during
cancer initiation by aflatoxin B1. Merricka C. Livingstone,1 Bill D. Roebuck,2
NatalieM. Johnson,3 ThomasW.Kensler,4 JohnD.Groopman1. 1JohnsHopkins
University School of Public Health, Baltimore, MD; 2Dartmouth Medical School,
Hanover, NH; 3Texas A&M School of Public Health, College Station, TX; 4Uni-
versity of Pittsburgh School of Medicine, Pittsburgh, PA.
MicroRNAs are small non-coding RNAs that affect gene expression. They are
essential innormal physiological processes andhavebeen implicated in carcinogen-
esis. Hepatocellular carcinoma (HCC) is the second leading cause of cancer death
globally, with the risk factor aflatoxin (AFB1) estimated to play a causal role in up to
28% of all HCC cases. In this study, we analyzed circulatingmiRNAs in a quantita-
tive rat cancer model that were previously found to be associated with AFB1 expo-
sure in liver. Sera were examined from 3 groups of animals: rats dosed with AFB1
(200g) for 28 consecutive days receiving vehicle only orAFB1 plus the chemopre-
ventive agent CDDO-Im (30 mol), and controls (Johnson et al., CaPR, 2014).
Small RNAswere isolated from these serum samples at the end of the dosing period
and analyzed by RT-qPCR. Quantitative PCR results at the end of the carcinogenic
28-day dosing regimen revealed notable increased expression of miR-34a-5p and
miR-181c-3p (13 fold and 170 fold, respectively) in the AFB1 treated samples com-
pared to controls. This expression was reduced in animals that received complete
protection fromdevelopingHCCby concurrent interventionwith CDDO-Im. Ad-
ditionally,miR-122-5pdisplayed increased expression (5 fold) andmiR-541-5pwas
downregulated (0.08 fold) in the sera of AFB1-treated animals. Overall, the data
suggest that serum expression ofmiR-34a-5p and 181c-3p during liver cancer initi-
ation could give insight into increased risk of developing HCC. Supported by
T32ES007141-31A1 and CA197222.
#4448A MicroRNA profıling of prostate cancer tissue identifıes a prog-
nostic 4-miRNAmodel and implicates one novel microRNA in prostate can-
cer cell viability. Linnea Schmidt1, Jacob Fredsøe1, Helle Kristensen2, Anne
Rasmussen2, Peter Mouritzen2, Søren Høyer1, Michael Borre1, Torben Øyrn-
toft1, Karina Dalsgaard Sørensen1. 1Clinical Medicine, Aarhus, Denmark; 2Ex-
iqon, Vedbaek, Denmark.
Purpose: New prognostic biomarkers for prostate cancer (PC) risk stratifıcation
are urgently needed.Here, we identify and validate a novel 4-microRNAprognostic
ratio model for prostate cancer. We also identify a new microRNA with tumor
suppressive characteristics in prostate cancer cell lines.Methods: PC tissue samples
from123 radical prostatectomy (RP)patients, 58 ofwhomexperiencedbiochemical
recurrence, were profıled for genome-wide miRNA expression using RT-qPCR
(training cohort). Initially,we identifıed 11 top candidate prognosticmicroRNAs (P
0.05, univariate Cox regression). Based on these, all possible 2-4microRNA ratio
models were systematically tested for their potential to predict time to biochemical
recurrence (BCR), as assessed by Kaplan-Meier, uni- and multivariate Cox regres-
sion analyses. The fındings were validated in two independent RP cohorts. A novel
microRNA, included in the fınal ratiomodel andwithpreviouslyunknownfunction
inprostate cancer,wasover expressedusing amicroRNAmimic inPC3andDU145
cells to evaluate its effect on prostate cancer cell viability and proliferation. Results:
We identifıed a new prognostic 4-microRNA ratio model ((miR-23a-3p*miR-10b-
5p)/(miR-133a*miR-374b-5p)) that signifıcantly predicted time to BCR indepen-
dently of established clinicopathological variables in a training RP cohort (n123).
The ratiomodelwas successfully validated in two independentRPcohorts including
112 and 476 patients, respectively. Ectopic expression of one of these microRNAs
(miR-374b-5p) signifıcantly inhibited viability and proliferation in two prostate
cancer cell lines, suggesting it has a tumor suppressor function in PC. Conclusions:
Here,we describe the identifıcation and independent validation of a 4-miRNAratio
model that allows risk stratifıcations of prostate cancer patients undergoingRP into
different prognostic groups. Furthermore, we identify and functionally characterize
a novel possible tumor suppressor miRNA in prostate cancer.
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#4449 Thrombospondin-1 regulation by MDM2 in aggressive cancers.
Priya Dondapati,1 Jason Maragh,1 Karna Mangrola,1 Ali Alaseem,1 Khadija
Cheema,2 ThiagarajanVenkatesan,2 SivanesanDhandayuthapani,2AppuRathi-
navelu1. 1Nova Southeastern Univ, Fort Lauderdale, FL; 2Rambaugh Goodwin
Institute for Cancer Reserach, Fort Lauderdale, FL.
MDM2 amplifıcation, which is often seen in different cancer types, indicates
that its plays an important role in tumorigenesis and also in cancer metastasis.
Amplifıcation of the MDM2 gene correlates with poor prognosis, aggressive
growth, and reoccurrence. Thrombospondin-1 (TSP-1) that is expressed by
THBS1 gene is a matricellular protein, and is known to have differential expres-
sion in cancers. When TSP-1 activates Transforming Growth Factor-1 (TGF-
1) through latent cytokine complexation, the activated TGF-1 contributes to
the Epithelial to Mesenchymal Transition (EMT) which is known to impart
stem-cell like characteristics and drug resistance to the cancer cells. However, no
studies regarding MDM2=s role in THBS1 regulation have been carried out so
far. Therefore, the objective of this study was to determine the correlation be-
tween MDM2 and THBS1 expression in MDM2 overexpressing cancers. For
this purpose the SJSA-1 osteosarcoma cells were cultured at 37 oC under humid-
ifıed air/CO2 (19:1) in RPMI-1640 complete medium supplemented with 10%
FBS, 10,000U/mL penicillin, 10,000g/mL streptomycin, 1% ()-L-glutamine,
and 1% amphotericin B. The cells were incubated in the presence of 20 M of
Nutlin-3 for 24 hrs, following which, RNA and protein were extracted and sub-
sequently purity and concentration were determined. Reverse Transcriptase
Polymerase Chain Reaction (RT-PCR) and western blotting were performed
using specifıc primers, primary and the secondary antibodies respectively. In-
terestingly elevated levels of TSP-1 and TGF1 were observed in these SJSA-1
cells. However, after treatment with Nutlin-3, anMDM2-p53 interaction inhib-
itor, a signifıcant increase in p53 was noted. However, contrary to the existing
literature, where studies have shown p53 to positively regulate TSP-1 levels, we
observed an opposite outcome. Despite the Nutlin-3 induced elevation in p53
levels, a signifıcant decrease in TSP-1 level was observed indicating that MDM2
may be regulating THBS1 gene expression in a p53 independent manner, in
MDM2 overexpressing SJSA-1 cells. The fındings of this study suggest a novel,
p53 independent role for MDM2 in THBS1 regulation. SinceMDM2 amplifıca-
tion can positively induce TSP-1 levels, which is one of the natural activators of
TGF-1, it is anticipated that stimulatory signal flowing throughMDM2 -TSP-1
- TGF-1 axis may induce the cancer cells to undergo EMT, thereby increasing
their metastatic ability and promote cancer stem cell characteristics. This novel
MDM2-regulated pathway can very well serve as a drug target and might play a
biologically relevant role in the treatment of cancer metastasis. Our future stud-
ies will include validation of this correlation in multiple cancer cell lines, to
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further elucidate the mechanism through which MDM2 is regulating THBS1
gene expression. (This project was supported by The Royal Dames of Cancer
Research Inc., Ft. Lauderdale, Florida).
#4450 The role of paired-like homeodomain 2B in non-small cell lung
cancer progression. Sheng-Yi Lin,1 Yu-Han Huang,1 Yi-Hua Lai,1 Sung-Liang
Yu,2 Sheng-Fang Su,3 Tse-Ming Hong,4 Gee-Chen Chang,5 Chi-ChungWang,6
Jeremy J.W. Chen1. 1National Chung Hsing Univ., Taichung, Taiwan; 2National
Taiwan University College of Medicine, Taipei, Taiwan; 3National Taiwan Uni-
versity, Taipei, Taiwan; 4National Cheng Kung University, Tainan, Taiwan;
5Taichung Veterans General Hospital, Taichung, Taiwan; 6Fu Jen Catholic Uni-
versity, New Taipei,, Taiwan.
The transcription factor PITX2 (paired-like homeodomain 2) is well known
to play an essential role in normal embryonic development. Emerging evidence
suggests that PITX2 may be involved in human tumorigenesis. However, the
functional role that PITX2 plays in tumor progression remain unclear. In this
study, we investigated its function in human non-small cell lung carcinoma
(NSCLC). Using real-time quantitative RT-PCR, we demonstrated that PITX2B
is the most abundant isoform in lung cancer cells. Enforced expression of
PITX2B could promote lung cancer cell morphological change, migration, in-
vasion, anchorage-dependent growth ability and tumorigenesis in xenograft
model mice. In addition, nuclear PITX2B localization was correlated with its
oncogenic functions and two important nuclear localization signals (NLSs)were
identifıed.Moreover, high expression of PITX2Bwas associated with poor over-
all survival (P0.05) in NSCLC patients. Importantly, silencing of PITX2B by
siRNA caused a marked increase in autophagy based on LC3-II, Beclin-1, and
p62 protein expression, acridine orange fluorescence of acidic vacuoles and elec-
tronmicroscopic detection of autophagosomes. Furthermore, we found that the
autophagy induced by PITX2B knockdown preceded apoptosis in lung cancer
cells. Treatment of lysosome inhibitor, NH4Cl, could provide a protective effect
that increases cell viability. In conclusion, our studies not only provide new
insights into how PITX2B may contribute to the tumor progression in lung
cancer but also the autophagy induced by PITX2B knockdown that may be
developed as an effective therapeutic strategy for the treatment of lung cancer.
#4451 Elevated USP22 is a potential therapeutic target for human non-
small cell lung cancer. Keqiang Zhang, Tommy R Tong, Xinwei Yun, Rebecca
Nelson, Nardi Isaac, Ravi Salgia, DanRaz.City of HopeNationalMedical Center,
Duarte, CA.
Elevated ubiquitin-specifıc protease 22 (USP22) is associated with enhanced
malignancy, therapeutic resistance, and poor prognosis of various human can-
cers. In this study, the clinicopathological signifıcance of USP22, therapeutic
implication of targeting USP22, and underlying molecules of USP22 knock-
down were investigated in human non-small cell lung cancer (NSCLC). Immu-
nohistochemistry analysis revealed that USP22 protein was dramatically ele-
vated in  67% of 197 NSCLC tissues compared with adjacent normal lung
tissues. Importantly, statistical analysis demonstrated that elevated USP22 was
positively associated with advanced cancer stage and a trend to poor prognosis
of NSCLC patients. Moreover, siRNA-mediated knockdown of USP22 induced
a cell cycle arrest in G1/S phase and signifıcantly suppressed cell proliferation
and soft agar colony formations in NSCLC cell lines. In addition, knockdown of
USP22 signifıcantly enhanced cisplatin-induced genotoxic effects inNSCLC cell
lines. Furthermore, USP22 silencing substantially down-regulated SIRT1 and
upregulated p53 tumor suppressor in NSCLC cells, indicating downregulation
of USP22 may boost p53-mediated tumor suppression and DNA damage re-
sponse inNSCLC cells. Knockdown ofUSP22 also increased global histoneH2B
monoubiquitylation, H3K4 and H3K79 trimethylation leading to global gene
expression profıle changes in these NSCLC cells. These results suggest that tar-
geting USP22 will have broad anti-cancer effects via altering multiple cancer
signaling pathways. Taken together, data of this study further indicate that the
elevated USP22 may potentially represent a prognostic factor and therapeutic
target for NSCLC patients.
#4452 Study of themechanisms of emetine dihydrochloride on inhibiting
NSCLC tumorprogression andattenuatingEGFRsignalingpathway.Yi-Hua
Lai,1 Wan-Ting Huang,1 Sheng-Yi Lin,1 Yao-Ting Huang,2 Yuh-Ling Chen,3
Hsuan-YuChen,4Huei-WenChen,5 Jeremy J.W.Chen1. 1Institute of Biomedical
Sciences, National Chung Hsing University, Taichung, Taiwan; 2Department of
Computer Science and Information Engineering, National Chung Cheng Univer-
sity, Chia-yi, Taiwan; 3Institute of Oral Medicine, National Cheng Kung Univer-
sity Hospital, College of Medicine, National Cheng Kung University, Tainan,
Taiwan; 4Institute of Statistical Science, Academia Sinica, Taipei, Taiwan; 5Grad-
uate Institute of Toxicology, National Taiwan University, Taipei, Taiwan.
Epidermal growth factor receptor (EGFR) is a transmembrane receptor pro-
tein and can mediate the cellular biological responses including regulation of
cellular proliferation, differentiation, migration and survival. More than 60% of
non-small cell Lung cancers (NSCLCs) express relatively high level of EGFR.
Therefore, EGFR has become an important therapeutic target for the treatment
of NSCLC. However, almost all NSCLC patients ultimately develop drug resis-
tance to targeted therapy agents. The most common secondary mutation is
found to harbor EGFR mutation in T790M, which is acquired resistance to
EGFR TKIs. In order to overcome the resistance of T790M mutation in lung
cancer, we used EGFR pY1068 ELISA as drug-screening platform to screen the
candidate compounds with the capacity to suppress EGFR activity from the
compound library of more than 300 plant active ingredients. Among the com-
pounds identifıed, the emetine could most signifıcantly restrain EGFR pY1068
activity and reduce cancer cell viability. Moreover, the Western blotting results
showed that emetine treatment can repress EGFR phosphorylation and expres-
sion in a dose-dependent manner as well as inhibit its downstream substrates
including PI3K, STAT3 and Src in three different Iressa-resistant cell lines. In
addition, emetine also could inhibit cell proliferation, migration, invasion, and
clonogenicity in vitro and xenograft tumor growth in vivo. Taken together, our
data suggest that emetine might be a novel inhibitory modulator of EGFR activ-
ity and might be through suppressing the phosphorylation and expression of
PI3K, STAT3, and Src to inhibit lung cancer progression. These fındings will
help us to develop the anti-cancer drugs for lung cancer in the future.
#4453 Identifıcation and characterization of oncogenic kinase LASK2 as a
diagnostic and therapeutic target for lung cancer. Yataro Daigo,1 Atsushi Ta-
kano,1 Yusuke Nakamura2. 1Institute of Medical Science, The University of To-
kyo, Tokyo, Japan; 2University of Chicago, Chicago, IL.
Lung cancer is the leading cause of cancer deaths worldwide. Since the num-
ber of patients responding well to standard therapies is still limited, further
development of new anti-cancer agents with minimum risk of adverse event is
urgently awaited. To screen oncoantigens which could be used for the develop-
ment of new diagnostic biomarkers and molecular targeted drugs, we have es-
tablished a screening system as follows; i) To identify overexpressed genes in 120
lung cancers by genome-wide screening using the microarray representing
27,648 genes and pure populations of tumor cells taken from cancer tissues by
laser microdissection, ii) To verify the genes for their very low or absent expres-
sion in normal tissues by northern-blotting, iii) To validate the clinicopatholog-
ical signifıcance of their expression with tissuemicroarray covering hundreds of
archived lung cancers, iv) To verify whether the target genes are essential for the
growth or survival of lung cancer cells by RNAi and cell growth assays. During
this process, we selected dozens of druggable oncogenes with various enzymatic
activities, and identifıed overexpression of protein kinase LASK2 (lung cancer-
associated kinase 2) in the majority of lung cancers, but not in normal tissues
except testis. Immunocytochemical analysis foundLASK2 to bemainly localized
in the cytoplasm and nucleus of lung cancer cells. Immunohistochemical anal-
ysis revealed that strong LASK2 expression was an independent prognostic fac-
tor for non-small cell lung cancer (NSCLC) (P0.0001). Suppression of LASK2
expressionwith its specifıc siRNAs caused growth inhibition of lung cancer cells.
The enhanced cellular proliferation by introduction of LASK2 in mammalian
cells also supported its oncogenic function. Since LASK2 plays a signifıcant role
in the cell proliferation andmalignant nature of lung cancers, LASK2 is likely to
be a prognostic biomarker and a potential therapeutic target for developing new
anti-cancer drugs.
#4454 MED12 is recurrentlymutated inMiddle Eastern colorectal cancer.
Abdul K. Siraj, TariqMasoodi, Rong Bu, Fouad Al-Dayel, Khawla S. Al-Kuraya.
King Faisal Specialist Hospital & Res. Ctr., Riyadh, Saudi Arabia.
Colorectal cancer (CRC) is a common cancer and a leading cause of cancer
deaths. Previous studies have identifıed a number of key steps in the evolution of
CRC but our knowledge of driver mutations in CRC remains incomplete. Rec-
ognizing the potential of studying different human populations to reveal novel
insights in disease pathogenesis, we conducted genomic analysis of CRC in
Saudi patients. In the discovery phase of the study, we conductedwhole-genome
sequencing of tumor and corresponding germline DNA in 27 CRC patients. In
addition to known driver mutations, we identifıed three MED12 somatic muta-
tions. In the replication phase, we employed a next-generation sequencing ap-
proach to capture and sequence MED12 and other candidate genes in a larger
sample of 400 CRC patients and confırmed the enrichment for recurrent
MED12 mutations. In order to gain insight into a plausible biological mecha-
nism for the potential role of MED12 mutations in CRC, we studied CRC cell
lines that differ substantially in the expression level of MED12, and found the
latter to be correlated inversely with TGF-beta signaling and directly with apo-
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ptosis in response to chemotherapeutic agents. Importantly, these correlations
were replicated whenMED12 expression was experimentally manipulated. Our
data expand the recently described role of MED12 as a tumor suppressor in
other cancers to include CRC, and suggest TGF-beta signaling as a potential
mediator of this effect.
#4455 Identifıcation of novel oncogene, copine-7 (CPNE7), in colorectal
cancer.Dongjun Jeong,1 SeonaBan,1HyungjooKim,1 SeunghyunOh,1 Sanghee
Ji,1 Han Jo Kim,1 Sang Byung Bae,1 Tae Sung Ahn,1 Chang-Jin Kim,2 Moon Soo
Lee,1 Moo-Jun Baek1. 1College of Medicine, Soonchunhyang Univ., Cheonan-si,
Republic of Korea; 2NTL Clinic, Yongin-si, Republic of Korea.
Background: CPNE7, a member of copine family, is composed of calcium-
dependentmembrane-binding proteins. The encoded proteinmay play a role in
calcium-mediated intracellular processes andmembrane traffıckingmainly. Al-
though this protein was known as tumor suppressor in breast cancer, we iden-
tifıed the possibility as an oncogene in colorectal cancer. In this study, we per-
formed to evaluate the oncogenic functions of CPNE7 in the colorectal cancer
cell line and the clinical signifıcance of CPNE7 expression in colorectal cancer
patients.Method: The colorectal cancer cell lines (SW480, SW620, HCT116 and
HT29) were transfected with siRNA for knockdown CPNE7. The oncogenic
functions were identifıed in the transfected cell lines and compared them with
CPNE7 highly expressing control cell lines. In vitro functional studies included
cell proliferation assay, migration assay, invasion assay and semisolid agar col-
ony forming assay. The clinical signifıcance of CPNE7 expression was evaluated
in 250 cases of colorectal cancer tissue by immunohistochemistry. Results: The
knockdowned cell lines signifıcantly showed lower oncogenic function (prolif-
eration, migration, invasion and colony forming) compared to the CPNE7
highly expressing control cell lines (p0.05). The overall survival rate was de-
creased in patients of CPNE7 high expression (p0.03). Multivariate and uni-
variate Cox-regression analysis showed that CPNE7 high expression was an
independent prognostic factor in colorectal cancer (HR1. 54, 95% CI1. 00-
2.38: p0. 048 / HR1. 58, 95% CI1. 03-2.41: p0. 032). Conclusion: This
study announces that CPNE7 is a novel oncogene, an independent prognostic
factor and therapeutic target in colorectal cancer. In the future, studies on in vivo
assay and identifying oncogenic signal pathways of CPNE7 in colorectal cancer
are necessary.
#4456 Novel oncogenic function of Notch4 in Hispanic lung cancer. Edna
Gordian,1 Nicholas Gimbrone,1 Antonio Pannuti,2 Lucio Miele,2 W. Douglas
Cress,1 Teresita Muñoz-Antonia1. 1Moffıtt Cancer Center, Tampa, FL; 2LSU
Stanley S. Scott Cancer Center, New Orleans, LA.
Background: Molecular drivers of 40% of lung adenocarcinomas are still
unknown.We reasoned that since the frequencies of drivermutations have been
shown to be different between ethnic groups, comparison of targeted exome
sequencing data would identify genes with signifıcant alteration frequencies
between White Non-Hispanics (WNH) and other racial/ethnic groups. Notch
signaling in cancer is context- and tissue-specifıc and may be both oncogenic
and tumor suppressive. The mechanisms of action and genetic alterations in-
volved in Notch oncogenesis have been studied for Notch1 and Notch3; specif-
ically in Non-Small Cell Carcinoma (NSCLC), translocations in Notch3, and
gain of function Notch1 mutations have been found in 1 in 10 patients. Notch4
is amammary oncogene, but little is known about its role in NSCLC tumorigen-
esis. Truncations in Notch4 have been reported in lung cancer cell lines, and in
public databases the frequency of Notch4 alterations in WNH adenocarcinoma
is5.5%. However, little is known about the mechanisms by which Notch4 acts
in lung oncogenesis. Methods: Using data from the TCCTM protocol, we ana-
lyzed targeted sequencing of 1,321 genes of interest to determine the mutations
driving lung cancer in Hispanic (H/L) patients. The functional relevance of the
Notch4 mutations was tested by cloning the intracellular domain (ICD) of
Notch4 containing one of the mutations identifıed in the ANK domain
(P1663Q) into pcDNA3.1. Plasmids expressing either the WT or a mutated
Notch 4 (P1663Q) were transfected into A549 cells and the effect of this muta-
tion tested on the ability to induce the expression of Notch4 expression genes.
Results: In our H/L cohort we see Notch4 altered in about 20% of our samples,
and 7/12 of the Notch4 single amino acid substitutions are in the Negative
Regulatory Region (NRR). PROVEANprotein analysis of theNotch4mutations
shows that more than half of the mutations would disrupt the NRR. Introduc-
tion of the P1663Q mutation in the ANK repeats of the Notch4 ICD, which
mediates binding to CSL and is essential for Notch transcriptional activity, re-
sulted in a shift in the amount of transcript of known Notch4 target genes, such
as Hes1 and Snai1. This effect is specifıc, as it is not observed with other genes,
previously reported to be targets for other Notch paralogs such as Smad3 and
Zeb1. A similar effect of the P1663QNotch4 mutation on Hes1 transcript levels
was observed in breast cancer cells, suggesting that this is not lung cancer spe-
cifıc. Transcriptional activity of the Notch-responsive luciferase construct
(pHESLuc) was increased in the presence of Wt Notch4, and reduced in the
presence of the P1663Q Notch4 Mu. Conclusion: The nature and high number
of genetic alterations in Notch4 in H/L lung cancer patients, suggests that
Notch4may play a critical role in NSCLC tumorigenesis. Our data suggests that
mutations in the ANK domain of Notch4 can interfere with its transcriptional
activity and function, and should be further characterized.
#4457 Inverse relationship between exon 8 single nucleotide polymor-
phism (c.1293C>T) of gigaxonin andhuman tumor cell growth.Eri S. Srivat-
san,1 Kimberly J. Hwang,1 Albert Ko,1 Jenna R. Chatoff,1 Saroj K. Basak,1 Nat-
arajan Venkatesan,1 Fernando Palma-Diaz,2 Michael S. Lewis,1 Pascale
Bomont,3 Marilene B. Wang2. 1VA Greater Los Angeles UCLA David Geffen
School ofMedicine, LosAngeles, CA; 2UCLADavidGeffen School ofMedicine, Los
Angeles, CA; 34INM-INSERM U1051, Hospital St Eloi, Paris, France.
Gigaxonin, a product of theGiantAxonalNeuropathy (GAN) gene located on
chromosome 16, is involved in intermediate fılament processing of neural cells
and vimentin fıbers in fıbroblasts. Previous studies have shown an interaction
between p16 and gigaxonin in cisplatin mediated ubiquitination of NFkB.
Genomic studies have indicated higher frequency (44.25%) of exon 8 single
nucleotide polymorphism (SNP) (c.1293 CT) of gigaxonin in the individuals
of Caucasian population compared to normal population (22%). The polymor-
phism frequency is much lower in individuals of other ethnicities. To determine
the relationship to tumors, we analyzed exon 8 polymorphism in HPV positive
and negative cervical and head and tumors. Our studies showed a 47.25% poly-
morphic frequency in these tumors. There was no relationship between the
presence of polypmorphism and HPV status. However, there was an inverse
relationship between polymorphism and tumor recurrence. Our studies have
further shown higher expression of gigaxonin protein in cancer cell lines con-
taining the polymorphic T allele. Growth assays in vitro and in soft agar have
shown a direct relationship between the presence of the T allele and slower cell
line growth. Our results therefore indicate that in addition to p16 expression,
exon 8 SNP could also serve as a diagnostic marker of chemo sensitivity in
human tumors.
#4458 Regulation ofMYCprotein stability bymutantKRAS in pancreatic
ductal adenocarcinoma. Angelina V. Vaseva,1 Devon R. Blake,1 Salma H.
Azam,1 Karim T. Gilbert,1 Chad V. Pecot,1 Kenneth H. Pearce,1 Laura E. Her-
ring,1 LeeM. Graves,1 Peter J. Houghton,2 Channing J. Der1. 1UNC-Chapel Hill,
ChapelHill, NC; 2GreeheyChildren’s Cancer Research Institute, SanAntonio, TX.
With the nearly 100% mutation frequency of KRAS in pancreatic ductal ad-
enocarcinoma (PDAC), the development of therapeutic strategies to target
KRAS is a high priority for the pancreatic cancer fıeld. In the current study, we
aimed to identify signaling changes caused by the acute suppression of mutant
KRAS in PDAC cell lines. Strikingly, acute suppression of mutant KRAS in
PDAC cell lines caused potent and rapid proteasome-dependent degradation of
MYCprotein. Ablation ofMYC also suppressed PDACgrowth both in vitro and
in vivo, indicating a critical driver role for MYC in KRAS-dependent PDAC
maintenance. A mechanism by which RAS effector signaling regulates MYC
protein stability has been described, however we determined that this mecha-
nism cannot fully account for how endogenous mutant KRAS stabilizes MYC
protein in PDAC cells. We verifıed a role for the Raf-MEK-ERK but not the
PI3K-AKT-GSK3 effector signaling pathway. Unexpectedly, we also excluded
a role for MYC protein phosphorylation at MYC residue T58, and determined
that ubiquitin ligases other than FBW7 are involved. These fındings prompted
us to search for additional KRAS-dependent protein kinases that facilitateMYC
protein stability. We applied multiple screening strategies. First, we developed a
novel fluorescence-based system tomonitor real-timeMYCprotein degradation
in PDAC cells and we adapted this system for use in a high-throughput flow-
cytometry based assay. Second, we applied amass spectrometry-based approach
to profıle the human kinome for KRAS-dependent changes in protein kinases.
Finally, we applied gain-of-function (Cancer Toolkit) and loss-of-function
(CRISPR/Cas9) genetic screens to identify signaling regulators of MYC protein
stability. The results of these screens will be presented.
#4459 Glycine decarboxylase inhibits proliferation of ovarian cancer cells
via SIRT1-mediated apoptosis. So-Jin Shin,1 Jin-Young Kim,2 Eun-Young
Ha,2 Chi-Heum Cho2. 1Keimyung University, Daegu, Republic of Korea;
2Keimyung University School of Medicine, Daegu, Republic of Korea.
Glycine decarboxylase (GLDC) is a very recently identifıed metabolic onco-
gene that links glycine metabolism with tumorigenesis. We designed this study
to determine the mechanistic role of GLDC in in ovarian cancer cells. First, we
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confırmed the expressions of GLDC in eight different ovarian cancer cell lines.
And colony formation assay revealed decreased proliferation of OVCAR3 ovar-
ian cancer cells transfectedwith siGLDC comparedwith that of control. Intrigu-
ingly, we found that knockdown of GLDC induced decreased S-adenosylme-
thionine (SAM)/ S-adenosylhomocysteine (SAH) ratio, which implicates
methyl donor defıcient state in OVCAR3 cells. Expressions of sirtuin 1 (SIRT1),
heat shock protein (HSP) 90 and heat-shock factor protein 1 (HSF1) decreased
while that of p53 increased in GLDC knock-downed cells, suggesting heat shock
response. Addition of SAM into siGLDC knock-downed cell restored the ex-
pression of SIRT1. Inhibition of SIRT1 decreased Bcl2 and increased cyto-
chrome c expressions. In summary, these results suggest GLDC induces methyl
donor defıcient state in OVCAR3 ovarian cancer cells, which in turn leads to
apoptosis via SIRT1-mediated pathway.
#4460 TET1 over expression contributes to lung cancer malignancy. Piotr
Teodor Filipczak, Shuguang Leng, Carmen S. Tellez, Steven A. Belinsky.
Lovelace Respiratory Research Inst., Albuquerque, NM.
Epigenetic alterations are a leading cause of lung carcinogenesis and malig-
nancy. While the role of enzymes catalyzing cytosine-guanine (CpG) island
methylation and chromatin modifıcations has been extensively studied, the role
of the recently discovered demethylating enzymes represented by ten-eleven
translocation methylcytosine dioxygenases (TETs) remains unknown. The goal
of this study was to investigate the expression and functional signifıcance of the
TET1 gene in non-small cell lung cancer (NSCLC). QRT-PCR revealed 2- to
30-fold over expression of TET1 in 52% of squamous cell carcinoma (SCC) and
40% of adenocarcinoma (AdC) tumors compared to paired normal lung tissue.
This result was validated using The Cancer Genome Atlas (TCGA) database
with TET1 over expressed in 72% of SCCs and 53% of AdCs. Elevated levels of
TET1 transcript were associated with increased protein levels in NSCLC cell
lines compared to normal human bronchial epithelial cells (HBECs). A reporter
assay analysis defıned the promoter region critical for elevated transcription of
the TET1 gene using lung cancer cell lines, and studies to identify the transcrip-
tion factors underlying the increase in expression are underway. Transient
knock down of TET1 expression in NSCLC cell lines caused global changes in
the transcriptome, reduced cell proliferation, colony formation, and inhibited
growth of tumor xenografts in nude mice. Cellular senescence mediated by p21
signaling and associated with -galactosidase activation was identifıed as one
mechanism underlying growth inhibition. This study suggests that TET1 may
function as an oncogene contributing to the lung cancer malignant phenotype
and thus, could serve as a potential new target for treatment. (Supported by R01
CA183296)
#4461 Detection of somaticmutations in exosomalRNA fromhumanoral
squamous cell carcinoma cells. Norihiko Tokuzen, Koh-ichi Nakashiro, Hi-
royuki Hamakawa. Ehime Univ. Graduate School of Medicine, Toon, Ehiem,
Japan.
Exosomes are small vesicles, ranging from 30 to 100 nm in size, secreted from
most types of cells. They contain proteins, lipids, and nucleic acids (e.g. DNA,
mRNA, and microRNA) and are thought to play an important role in cell pro-
liferation, invasion, and metastasis in human malignancies. Recently, circulat-
ing exosomes have also been of interest as a source for liquid biopsies. In this
study, we examined the usefulness of exosomal RNA as a biomarker and at-
tempted to detect the tumor-specifıc gene mutations from exosomal RNA de-
rived from human oral squamous cell carcinoma (OSCC) cells. We used 3 hu-
man OSCC cells (HSC2, KT-T, KT-N). KT-T and KT-N cells were established
from the lower gingival tumor and lymphnodemetastasis, respectively. First, we
detected the somatic mutations in genomic DNA extracted from these cells by
next-generation sequencing (NGS) with the use of HaloPlex Cancer Research
Panel (Agilent Technologies). PIK3CA H1047R mutation was identifıed in all
OSCC cells, and KT-N cells had the additional HRAS Q61Rmutation. We con-
fırmed these mutations of PIK3CA and HRAS in OSCC cells by TaqMan® SNP
Genotyping Assays (Thermo Fisher Scientifıc). Subsequently, we evaluated the
gene mutations in exosomal RNA from these OSCC cells. Exosomal RNA was
isolated from the conditioned medium using exoRNeasy Serum/Plasma Maxi
Kit (Qiagen) according to the manufacture’s protocol. In exosomal RNA, we
found the PIK3CA H1047R mutation from all OSCC cells and HRAS Q61R
mutation from KT-N cells by genotyping assays. Furthermore, we assessed the
detection of thesemutations in tumor xenograftmousemodels. KT-T andKT-N
cells (5 x 106) complexed with Matrigel® (BD) in 100-l aliquots were injected
subcutaneously space in the flank of male athymic nude mice. Exosomal RNA
was isolated from the serum of tumor-bearing nude mice using exoRNeasy
Serum/Plasma Midi Kit (Qiagen). By genotyping assays using serum exosomal
RNA, PIK3CA H1047R mutation was observed in both types of xenograft mice
and HRAS Q61R mutation was positive in KT-N xenograft mice. Cancer cell-
derived exosomal RNAhad the same genemutations in those cells, and could be
detected in the serum of tumor-bearing nude mice. These results suggest that
exosomal RNA is useful for detecting somatic mutations in OSCC cells.
#4462 ACTN4 stabilises RIPK1 to function as an oncogenic driver inmel-
anoma. Lei Jin, Hessam Tabatabaeehatambakhsh, Chen Chen Jiang, Xu Guang
Yan, Jia Yu Wang, Yuan Yuan Zhang, Hamed Yari, Chun Yan Wang, Ting La,
Fu Xi Lei, Yu Chen Feng, Su Tang Guo, Xu Dong Zhang. The University of
Newcastle, Callaghan, Australia.
We have recently reported that receptor-interacting protein kinase 1 (RIPK1)
is commonly up-regulated through cellular inhibitor apoptosis protein (cIAP)-
mediated stabilization and functions as an oncogenic driver via activation of
NF-B inmelanoma cells. Here we show that -actinin-4 (ACTN4), an isoform
of -actinins of spectrin superfamily proteins that is emerging as an oncogenic
regulator, is required for cIAP-mediated stabilization of RIPK1 and plays a pro-
oncogenic role in melanoma. Similar to RIPK1, ACTN4 was found to be com-
monly increased in melanoma cells. While knockdown of ACTN4 inhibited
melanoma cell proliferation that was associated with down-regulation of RIPK1
and reduction in the basal levels of NF-B activation, overexpression of ACTN4
resulted in enhanced proliferation of melanocytes that was associated with ele-
vation in RIPK1 expression and increased NF-B activation. The inhibitory
effect of ACTN4 knockdown on melanoma cell proliferation and activation of
NF-B was due to decreased expression of RIPK1, as it was abolished by over-
expression of RIPK1. On the other hand, knockdown of RIPK1 diminished
ACTN4overexpression-triggered enhancement in proliferation inmelanocytes.
Strikingly, knockdownofACTN4 attenuated the association between cIAPs and
RIPK1 and reduced K63-linked ubiquitination of the protein, leading to RIPK1
protein degradation. Mechanistic studies showed that ACTN4 bound to RIPK1
through itsN-terminus, whereas it was associatedwith cIAPs via its C-terminus,
and that dimerization of ACTN4 in an anti-parallel manner is required for the
interaction between cIAPs and RIPK1. Collectively, ACTN4 is necessary for
stabilization of RIPK1 by cIAPs and functions as an oncogenic driver in mela-
noma.
#4463 The coactivator oncogene AF1Q associates with STAT3 activation
downstream ofMET action in gastro-esophageal cancer patients. Elisabeth S.
Gruber,1 Peter Birner,2 Olaf Merkel,2 Michael M. Bergmann,1 Sebastian F.
Schoppmann,1 Jino Park,3 Richard Moriggl,4 William Tse,3 Lukas Kenner5.
1University Clinic for Surgery, Medical University of Vienna, Vienna, Austria;
2Institute of Pathology,Medical University Vienna, Vienna, Austria; 3James Gra-
hamBrownCancer Center, University of Louisville School ofMedicine, Louisville,
KY; 4University Vienna, Ludwig Boltzmann Institute, Vienna, Austria; 5Institute
of Laboratory Animal Pathology, University of Veterinary Medicine, Vienna,
Austria.
AF1Q was initially identifıed as an oncogene in acute myeloid leukemia. In
breast cancer, AF1qmediates tumor progression by boosting STAT3-signalling.
In addition, AF1q enhances wnt-signalling resulting in transcriptional activa-
tion of CD44 and promotes tumor cell proliferation, migration and chemo-
resistance. In gastrointestinal malignancies both pathways are linked to en-
hanced MET tyrosine kinase receptor action, accelerating tumor progression
and metastases. We showed that Af1q overexpression in the gastro-esophageal
cancer cell lines SK-GT-4, FLO-1 and OE33 led to increased sphere formation
and increased invasive capacity in the case of FLO-1 andOE33.We investigated
the role of AF1q in a retrospective collective of 460 resected gastro-esophageal
cancer specimens (74.3% adenocarcinomas (AC), 25.7% esophageal squamous
cell cancers (SCC)).With respect to topographic location, 40.4% of tumors were
esophageal (EC), 20% gastro-esophageal (GEC) and 39.6% gastric cancers (GC).
Immunohistochemistry revealed overexpression ofAF1q in 205, and of CD44 in
114 patient tumor samples. AF1q overexpression was found more often in EC/
GEC as compared to GC (p0.007) and associated with HER2 (p0.035), pyS-
TAT3 (p0.001) and MET (p0.004) expression as well as neoadjuvant che-
motherapy (p0.001). AF1q and CD44 overexpression correlated in the overall
group (p0.001) and in AC (p0.001). In SCC CD44 was expressed more
frequently compared to AC (p0.001). Analysis of the matched primary and
metastatic tumors revealed that primary AF1q-positive tumor samples were
largely overlapping with AF1q-positive tumors lymph node metastases (23/32)
and distant metastases (6/7). AF1q overexpression correlated with shorter dis-
ease free survival (DFS) (p0.003) and shorter disease specifıc survival (DSS)
(p0.036), but overall survival (OS) was similar (p0.117). In a subgroup anal-
ysis a shorter OS was observed in EC/GEC (p0.03, log rank test). In a Cox
regression model AF1q and CD44 expression was associated with shorter DFS
(p0.001 and p0.025) and DSS (p0.005 and p0.035), but OS remained
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Oncogenes and Tumor Suppressors 2
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171140
unchanged. Prognostic signifıcance was limited to AF1q (p0.003 and p0.04,
respectively). We conclude, that AF1q overexpression is associated with pro-
gression and metastases in GEC. AF1q and downstream pathway markers such
as pySTAT3- as well as CD44 andMET are linked with AF1q expression. There-
fore we propose AF1q as a novel prognostic marker for GECs.
#4464 Biological functions ofLSAMP, a gene frequently deleted inAfrican
American prostate cancers. Shyh-Han Tan, Kevin Babcock, Indu Kohaar,
Ahmed A. Mohamed, Denise Young, Shiv Srivastava, Albert Dobi. Center for
Prostate Disease Research, Uniformed Services University, Rockville, MD.
Introduction: Most genomic studies of prostate cancer (CaP) have been
performed primarily on men of European ancestry, including Caucasian
Americans. African Americans (AA)men, however, bear the burden of high-
est CaP incidence and mortality rates in the US. Cumulative data from other
groups and from us have shown signifıcantly lower rate of alterations of the
two common CaP driver genes (PTEN and ERG) in AA CaP as compared to
CA CaP. Using a combination of whole genome sequencing, IHC and FISH
based validations on tissue microarrays, and analysis of the TCGA data from
a total of 438 CaPs, we recently reported a higher frequency of a genomic
deletion on 3q13.31 locus in AA CaP which also associated with rapid bio-
chemical recurrence. This deletion is centered at the LSAMP (Limbic System
Associated Membrane Protein) gene. The LSAMP protein functions as a cell
adhesion molecule affecting cell differentiation and migration during devel-
opment. We hypothesize that the loss of LSAMP contributes to CaP progres-
sion. Here, we report the biological consequence of LSAMP modulation in
CaP cells. Methods: LSAMP status in CaP cell lines (LNCaP, MDAPCa2b,
CWR22rv1, LAPC4, NCI-H660, and PC3) was assessed by FISH, immuno-
blot, qRT-PCR and immuno-fluorescence (IF), assays using MC-IXC neu-
roepithelioma cell line as the positive control. We established doxycycline
inducible LSAMP in LNCaP and in MDAPCa2b (an AA patient derived cell
line with monoallelic LSAMP deletion) cells, and constitutive expression in
DU145 cells. The effect of LSAMP loss and over-expression on cell growth,
proliferation apoptosis and cell migration was monitored byMTT, soft-agar,
and Boyden chamber assays. Results: Of the CaP cell lines analyzed, LSAMP
RNA and protein expression was detected in PC3 and NCI-H660. IF assay
showed that endogenously expressed LSAMP is predominanty localized to
the cell surface. Exogenous expression of LSAMP, either constitutively in
DU145, or by inducible means in LNCaP and MDAPCa2b cells, showed
similar localization to the plasma membrane. Both inducible and constitu-
tive overexpression of LSAMP resulted in reduced cell growth. LSAMP ex-
pression in DU145 resulted in enhanced formation of fılamentous extracel-
lular extensions. Analysis of published TCGA (The Cancer Genome Atlas)
data showed a correlation of high LSAMP promoter methylation and low
LSAMP expression in CaP tumors compared to normal prostate tissues.
Conclusion: The cell biology features of LSAMP reported here, together with
observations of genomic deletion and methylation of LSAMP promoter in
CaP, support its role in CaP development or progression. These data support
the function of LSAMP as a tumor suppressor gene, as previously reported in
other cancers.
#4465 Glypican-1: A tumor suppressor or an oncogene in human bone
metastatic prostate cancer cells. Nhat D. Quach,1 Matthew Eggert,2 Deepraj
Ghosh,3Michelle R.Dawson,3 RobertArnold,2 Brian S. Cummings1. 1University
of Georgia, Athens, GA; 2Auburn University, Auburn, AL; 3Brown University,
Providence, RI.
Glypican-1 (GPC-1) is a cell surface heparan sulfate proteoglycan that medi-
ates cell proliferation, differentiation and migration. It also possess oncogenic
functions in breast, pancreatic and lung cancer cells, and is a proposed bio-
marker for prostate cancer. Despite these data the function of GPC-1 in prostate
cancer is not fully known. We addressed this gap-in-knowledge using in vitro
and in vivo mouse models. We fırst showed that GPC-1 was overexpressed in
bonemetastatic prostate cancer cells (PC-3) but was not detected in lymph node
metastatic cancer cells (LNCaP) and non-cancerous prostate cells (RWPE-1).
Next, we inhibited GPC-1 expression using shRNA in bone metastatic cancer
cells (PC-3), and verifıed inhibition using western blot analysis and qRT-PCR.
Crystal violet staining, trans-well assays, matrigel colony cultures and adhesion
assays were used to determine the effect of GPC-1 inhibition on cancer cell
growth, migration, spheroid formation and cell adhesion. Inhibition of GPC-1
reduced prostate cancer cell growth, migration and spheroid formation; how-
ever, there were no changes in cell adhesion. These in vitro data suggested that
GPC-1 played a role in prostate cancer progression by acting as an oncogene.We
further investigated this possibility in vivo using athymic (NCr)mice xenografts.
Interestingly, inhibition of GPC-1 in PC-3 cells appeared to increase tumor size
as compared to scrambled controls. Further analysis showed that that inhibition
of GPC-1 increased the tumor expression of MMP-9 and N-cadherin, but not
E-cadherin. We hypothesized that the discrepancy between the in vitro and in
vivo results may be mediated by interaction of PC-3 cells with the tumor mi-
croenvironment. We addressed this hypothesis by testing the effect of tumor
conditionedmedia (TCM) from control andGPC-1 knockdown cells on human
bone marrow derived mesenchymal stem cells (hMSC) and fıbroblast (HS-27).
Treatment of both hMSC and HS-27 cells with TCM from GPC-1 knockdown
PC-3 cells increasedMMP-9 and interestinglyMMP-2 expression and activity as
compared to control cells. We also detected increases in the expression of N-
Cadherin in a co-culture model. Collectively, these data suggest that GPC-1 acts
as an oncogene to enhance prostate cancer cell growth in vitro; however, these
data also suggest the GPC-1may act as a tumor suppressor in vivo. This discrep-
ancy may be due to the interaction off GPC-1 with the tumor microenviron-
ment, which would not be detected in single-cell culture models.
#4466 The key role of Abi1 loss in dysregulating cell-cell adhesion during
prostate cancer tumorigenesis. Disharee Das, Anita Hryniewicz-Jankowska,
HeidiHehnly,DawnPost, GennadyBratslavsky, LeszekKotula.UpstateMedical
University, Syracuse, NY.
Prostate cancer accounts for 20-25% of cancer cases every year and is
predicted at over 180,000 new cases in 2016. However, the mechanisms of
prostate cancer initiation and castration resistance still remains poorly un-
derstood. Our previous research shows mutations and deletions in Abelson
interactor 1 (Abi1), an integral part of WAVE complex, in prostate tumor
samples. Moreover, WAVE complex levels are inversely correlated to pros-
tate cancer recurrence and castration resistance, outlining their clinical sig-
nifıcance. A common phenomenon found early on in most cancers, includ-
ing prostate cancer, is dysregulated cell-cell adhesion. This points towards a
possible tumor suppressor mechanism, since Abi1 and the WAVE complex
are in fact the primary regulators of branched actin polymerization via the
Arp2/3 complex, and are critical for the formation and maintenance of cell-
cell adhesion complexes. Hence, to study Abi1 in prostate cancer, we gener-
ated a prostate-specifıc conditional Abi1 knock-out (KO) mouse. In these
mice, we observed evidence of prostatic intraepithelial neoplasia (PIN), a
precursor of invasive carcinoma, with changes in proliferation and cell-cell
adhesion markers. The goal of this study is to elucidate the mechanism by
which the loss of Abi1 leads to the development of PIN in these mice. We are
leading this analysis by primary 3D cultures with cells from our Abi1 KO
prostates, and 2D cultures withmouse embryonic fıbroblasts (MEFs). Loss of
Abi1 leads to increase in size of the cultured spheroids, which indicates
increased proliferation and dysregulated cell-cell adhesion. Also, adherens
junction (AJ) markers E-cadherin and -catenin levels are lower in western
blots and immunostaining, suggesting defects in cell-cell adhesion. In MEFs,
we observe loss of membrane localization of AJ proteins in Abi1 KO cells.
Loss of Abi1 is often associated with upregulation of Abi2, which may be a
contributing factor to the phenotype. To validate our fındings in a human
system, we have recently developed a CRISPR-mediated KO of Abi1 in the
RWPE-1 non-tumor prostate cell line. We will use this KO cell line to deter-
mine cell-cell adhesion formation and maintenance in 2D and 3D cultures.
In conclusion, loss of Abi1 leads to dysregulation of cell-cell adhesion in
prostate epithelial cells, which may be a key mechanism for tumor develop-
ment and progression in prostate cancer. Supported by NCI R01 CA161018
(LK).
#4467 ETV6 is a tumor suppressor regulated by EGFR-miR-96 pathway in
prostate cancer.Yen-NienLiu,1 Yuan-ChinTsai,1Wei-YuChen,1ManKit Siu,1
Hsiu-Lien Yeh2. 1Taipei Medical University, Taipei, Taiwan; 2National Tsing
Hua University, Hsinchu, Taiwan.
ETV6 is an ETS transcription factor and a putative tumor suppressor in pros-
tate cancer according to several genomic analyses. However, its cellular func-
tions and upstream regulating signaling remain unclear. We demonstrated that
ETV6 suppresses the prostate cancer progression and that ETV6 levels are neg-
atively associated with advanced prostate cancer, supporting the idea that ETV6
acts as a tumor suppressor. Furthermore, ETV6 can be regulated by epidermal
growth factor receptor (EGFR) signaling through microRNA (miR)-mediated
downregulation. One of themiRs,miR-96, can be transcriptionally-regulated by
nuclear EGFR. The association patterns connecting miR-96, EGFR activation,
and ETV6 were further validated in the clinical tissue samples. We proposed an
EGFR-miR-96-ETV6 signaling pathway in promoting prostate cancer.
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#4468 Oncogenic activation of the RNA binding protein AGO2 in hepa-
tocellular carcinoma.Hien T. Dang, Lucy Knight, Yotsawat Pomyen, Xin Wei
Wang. NIH/NCI, Bethesda, MD.
Global transcriptomic alterations of coding and non-codingRNAs are a ubiq-
uitous feature of cancers including Hepatocellular carcinoma (HCC). Dysregu-
lation of RNA-binding proteins (RBPs), key regulators of RNA processing such
as RNA maturation and degradation, is one mechanism in which cancer cells
select to promote tumorigenesis. RBPs are highly expressed in solid tumors and
have been demonstrated to be drivers of carcinogenesis, however, the underly-
ing mechanisms in which RBPs regulate the HCC transcriptome is unknown.
We analysed genomic alterations amongst a family of more than 800 mRNA
RBPs (mRBPs) in 1,225 clinical specimens from HCC patients and found that
RBPs are signifıcantly activated through gene amplifıcation in a subset of tumors
with poor prognosis, suggesting their potential oncogenic roles inHCCprogres-
sion. Amongst the top candidates, Argonaute 2 (AGO2) was further character-
ized for its oncogenic role and effects on the HCC transcriptome. Elevated
AGO2 mRNA expression was highly correlated with elevated somatic copy
number alterations across fıve different cancer types including HCC.Moreover,
AGO2 expression was associated with overall survival in two independent data
sets (TCGA and the Liver Initiative Cancer), suggesting that AGO2 activation is
oncogenic. While the activation of AGO2 induced an oncogenic phenotype, the
abrogation of AGO2 inHCC cells signifıcantly decreased cancer associated phe-
notypes such as cell proliferation, migration/invasion and tumorigenicity in
vivo. Further analyses revealed thatAGO2-associated geneswere tumor-related,
including c-Myc. Notably, c-Myc amplifıcation was also found in AGO2 high
HCC cells, suggesting an interplay between AGO2 and c-Myc. Our results dem-
onstrate that oncogenic activation of AGO2 is a novel mechanism that may
contribute to global transcriptome selective for the activation of c-Myc onco-
genic. Our current work suggests that therapies focused on targetingAGO2may
be valuable for clinical treatment ofmany different tumors with activated c-Myc
signalling, including HCC
#4469 Targeting the tri-snRNP complex for triple-negative breast cancer
therapy. Stefanie Chan, Praveen Sridhar, Ying-Jie Lock, Fabio Petrocca. Boston
University School of Medicine, Boston, MA.
Triple negative breast cancers (TNBC) account for15% of all breast cancers
and the majority of breast cancers in women carrying a BRCA1 germline muta-
tion. Due to the inadequacy of existing treatment, here we sought to identify
shared genetic dependencies across different TNBC cell lines with the ultimate
goal of uncovering novel therapeutic targets. To this end, we performed a tar-
geted siRNA lethality screen across 11 human breast cell lines focusing on 154
genes, which we previously identifıed as selectively essential to a genetically-
defıned TNBC progenitor cell line (BPLER) relative to a myoepithelial-like iso-
genic cell line (HMLER). Thirty genes scored as recurrently and selectively re-
quired for survival of progenitor-like (or basal-A) TNBC lines compared to
differentiated cell lines. Genes for proteins involved inRNA splicingwere prom-
inent shared dependencies among basal-A TNBC cell lines. Of particular note
were those associated with the U4/U6.U5 tri-snRNP complex, including PRPF8
and PRPF38A. Transcriptome-wide RNA-seq analysis of the knockdown of ei-
ther led to widespread intronic retention, expression of immune system genes
and aberrant splicing of transcripts involved in protein translation, proteasome
function, mitosis and apoptosis, including the TNBC dependency gene MCL1.
As the proteasome and mitosis are also established TNBC vulnerabilities, we
have identifıed specifıc classes of transcripts that are both particularly suscepti-
ble to perturbation of tri-snRNP activity and selectively essential for TNBC,
making the tri-snRNP complex an attractive target for downstream drug devel-
opment.
#4470 RNA m5C methyltransferases and hnRNPK mediate disease-asso-
ciated chromatin structure and drug resistance in leukemia. Jason X. Cheng,
Li Cheng, Adam Cloe, Yuan Li, Ming Yue, Michelle M. Le Beau, Richard A.
Larson, James W. Vardiman. University of Chicago, Chicago, IL.
The mechanisms governing disease-associated chromatin organization and
drug selectivity are poorly understood. Our epigenetic drug screening experi-
ments identify two distinct lineage-specifıc drug-responsive patterns inmyeloid
leukemia (MDS/AML) cells. We have established multiple MDS/AML cell lines
resistant to nucleic acid analogues with different chemical backbones and have
demonstrated a clear relationship betweendrug-resistance and sugar-phosphate
backbone. Based on these results, we used various experimental approaches to
elucidate leukemia-associated, drug-responsive chromatin structural changes
and their underlying mechanisms. Our data demonstrate that hnRNPK, a con-
served factor in heterogeneous nuclear RNA-binding protein (hnRNP) com-
plexes, directly interacts with RNA m5C methyltransferases NSUNs/DMNT2
and RNA-polymerase II (pol-II)/CTD9 as well as erythroid vs myeloid lineage-
determining transcription factors (TFs) GATA1 and SPI1/PU.1 to form distinct
drug-responsive chromatin structures inMDS/AMLcells. hnRNPpreferentially
binds to methylated polypyrimidine RNA sequences to facilitate transcription
elongation. Compared to azacitidine-sensitive MDS/AML cells, there is a
marked increase in azacitidine-resistant MDS/AML cells in RNA m5C and
NUSNs/ DNMT2 associated with a marked increase in the interaction between
hnRNPK and active pol-II/CDK9. By employing a newly-developed nascent
RNA capturing technology coupled with super-resolution stimulated-emission
depletion confocal microscopy, we demonstrate co-localization of hnRNPK
with the TFs and active pol-II at nascent RNA sites in MDS/AML cells, further
supporting the existence of hnRNPK-mediated drug-responsive transcription
and lineage-specifıc chromatin structures in MDS/AML cells. Our experiments
using clinical specimens demonstrate a positive correlation betweenMDS/AML
progression and increase in expression of hnRNPK and RNAm5Cmethyltrans-
ferases, supporting their importance and clinical relevance. Furthermore,
knockdown of hnRNPK and RNA 5mCmethyltransferases effectively inhibited
the growth of MDS/AML cells. In conclusion, our data demonstrate distinct
RNA m5C methyltransferases/hnRNPK-mediated chromatin structures that
control the growth and drug sensitivity of MDS/AML cells. Based on our data,
we propose a novel working model of RNA m5C methyltransferase/hnRNPK-
mediated drug-responsive chromatin structure in MDS/AML cells, in which
RNA m5C methyltransferases function as the writers of m5C on nascent RNA,
and hnRNPK functions as a reader of the RNAm5C and an operator to regulate
transcription elongation and gene activation. Such novel chromatin structure-
based drug action models and mechanisms may identify new diagnostic and
prognostic biomarkers and therapeutic approaches.
#4471 Novel SF3B1 deletionmutations result in aberrant RNA splicing in
CLL patients.Anant A. Agrawal,1Michael Seiler,1 Lindsey Brinton,2 RoseMan-
tel,2 Rosa Lapalombella,2 Jennifer A. Woyach,2 Amy J. Johnson,2 Lihua Yu,1
John C. Byrd,2 Peter G. Smith,1 James S. Blachly*,2 Silvia Buonamici*1. 1H3
Biomedicine, Inc., Cambridge, MA; 2The Ohio State University Comprehensive
Cancer Center, Columbus, OH.
Recurrent heterozygous mutations in SF3B1, a component of the U2snRNP
complex involved in branchsite recognition during the fırst step of splicing ca-
talysis, are found in various solid tumors and hematologic cancers including
myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia (CLL).
To provide broader insight into the effects of SF3B1mutations on RNA splicing
in CLL, RNAseq was performed on 215 CLL patient samples with unknown
SF3B1 mutation status. 37 patients (17%) demonstrated cryptic 3= splice site
usage we and others have previously reported in patients with known SF3B1
hotspot mutations. Interestingly, 3 patient samples harbored previously unre-
ported in-frame deletions in SF3B1 aroundK700, themost common amino acid
mutated in hematologic cancers with SF3B1 mutations. In particular, 2 patient
sequences contained 6 nucleotide (nt) deletions (c.2186 to c.2191) resulting in
replacement of Q698, Q699 and K700 with Q (p.Q698_K700delinsQ:
“p.Q698del”) and 1 patient sequence had a 3 nt deletion (c.2192 to c.2194)
resulting in replacement of K700 and V701 with N (p.K700_V701delinsN:
“p.K700del”) in SF3B1. The variant allele fraction (VAF) of these deletions was
20-40%. Targeted resequencing of DNA confırmed presence of these mutations
at similar VAFs. Differential splicing analysis across patients with wild-type
SF3B1, mutant SF3B1 and our novel deletions revealed similar alternative 3=
splice site patterns. To study themechanism of alternative 3= splice site selection
induced by these novel p.Q698del and p.K700del in-frame deletionswe used our
ZDHHC16 minigene system with modifıcations in the canonical and cryptic 3=
splice sites and respective branchsites. After confırming expression of these de-
letion mutants and their incorporation in the SF3b complex by qPCR and co-
immunoprecipitation, we demonstrated that recognition of both canonical 3=
splice site and alternate branchsite are important for aberrant splicing. This
observation is identical to the intronic features required for aberrant splicing
that we previously reported for the p.K700E SF3B1 hotspotmutation inCLL and
MDS. By comparing the recent cryo-electron microscopy and X-ray crystal
structures of SF3b complexes (PDB: 5GM6 and 5IFE, respectively), it is evident
that the K700 present at the edge of heat repeat domain 6 is important for
pre-mRNA interactions. Both the in-frame deletions and substitution muta-
tions at K700 perturb SF3B1 charge, likely affecting a side-chain interactionwith
pre-mRNA, thus altering splice-site recognition through a mechanism that is
still not well understood. Together, these data indicate that small in-frame de-
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letions in SF3B1 aroundK700 offer a novel mechanism to induce aberrant splic-
ing in patients with CLL. The commonmechanism of action of these mutations
and deletions suggest that they should also be sensitive to splicing modulators.
#4472 A subunit of splicing factor 3b, SF3B4, functions as driver of liver
cancer via aberrant splicing activity on tumor suppressor KLF4. Suk Woo
Nam, Qingyu Shen, Jung WOo Eun, Hyung Seok Kim, Hee Doo Yang, Sang
Yean Kim. The Catholic University of Korea, Seoul, Republic of Korea.
Alternative splicing is one of the crucial mechanism that contribute to pro-
teome diversity and, as reported, up to 90% of genes are alternatively spliced in
human. In the last few years, a large number of mRNA isoforms revealed to
contribute many cellular development and disease, including cancer. SF3B4 is
one of six subunits of the splicing factor 3b (SF3b) complex which is an impor-
tant protein complex in U2 snRNP super complex. In this study, we show that
SF3B4 expression was overexpressed in a large cohort of human hepatocellular
carcinoma (HCC) patients. SF3B4 knockdown caused G1/S cell cycle arrest by
recovering p27 expression and simultaneously suppressing cyclins, andCDKs in
liver cancer cell. Consistently, Spliceostatin A, a SF3b complex inhibitor, also
suppressed liver cancer cell growthwith similar effect on cell cycle regulation. In
addition, sustained suppression of SF3B4 reduced the in vivo tumor growth rate
in mouse xenograft models. Furthermore, SF3B4 knockdown repressed in vitro
tumor cell motility and invasion of liver cancer cells. Notably, we observed that
SF3B4 knockdown increased alternative transcript splicing event of a large num-
ber of genes in liver cancer cells. From this, we found that SF3B4 knockdown
caused induction of wildtype KLF4 transcript expression, and thereby exerted
anti-tumor growth effect on liver cancer cells. Indeed, ectopic expression of
KLF4mimicked SF3B4 knockdown effect on same cells. Our results suggest that
aberrant regulation of SF3B4 contribute to malignant transformation and
growth of liver cancer cells by repression of tumor suppressor via unmodulated
alternative splicing activity during liver tumorigenesis.
#4473 SRRM4 drives treatment-induced neuroendocrine transdifferen-
tiation of prostate adenocarcinoma under androgen receptor pathway inhi-
bition.Yinan Li.Vancouver Prostate Centre, Vancouver, British Columbia, Can-
ada.
Treatment-induced neuroendocrine prostate cancer (t-NEPC) is an aggres-
sive subtype of castration-resistant prostate cancer that typically does not re-
spond to AR pathway inhibition (ARPI) and its diagnosis is increasing. To un-
derstand its development, we analyzed transcriptomes of prostate tumors to
identify t-NEPC-specifıc RNA splicing. Interestingly, more than 66% of the
splice events are predicted to be regulated by the RNA splicing factor, Serine/
Arginine Repetitive Matrix 4 (SRRM4). We confırmed in vitro and in vivo that
one SRRM4 target gene is the RE1-Silencer Factor (REST), a master regulator of
neurogenesis. SRRM4 strongly stimulates adenocarcinoma cells to express t-
NEPC biomarkers and this is exacerbated byARPI. ARPI combinedwith gain of
SRRM4 results in adenocarcinoma cells to assume multicellular spheroid mor-
phology and establishes progressiveNEPCxenografts. These SRRM4actions are
further enhanced by loss-of-function of TP53. We conclude that SRRM4 drives
t-NEPC progression. This knowledgemay guide the development of novel ther-
apeutics aimed at t-NEPC.
#4474 Functional characterization of alternatively spliced GSN in head
and neck cancer. Dylan Z. Kelley,1 Emily L. Flam,1 Theresa Guo,1 Craig
Bohrson,1 Michael Considine,1 Ludmila V. Danilova,1 Justin A. Bishop,2 Chi
Zhang,1WayneM.Koch,1 David Sidransky,1WilliamWestra,2 SarahWheelan,1
Liliana Florea,1 Elana J. Fertig,1 JosephA.Califano,3DariaA.Gaykalova1. 1Johns
Hopkins School of Medicine, Baltimore, MD; 2Johns Hopkins Medical Institu-
tions, Baltimore, MD; 3University of California, San Diego, La Jolla, CA.
PURPOSE: Analyze the functional role of alternative splicing in HPV-related
(HPV) Head and Neck Squamous Cell Carcinoma (HNSCC) biology and
oncogenesis. HPV HNSCC incidence is rapidly increasing, while its onco-
genic mechanisms, demographic, and clinico-pathological characteristics are
largely uncharacterized and discrete from those of HPV-HNSCC. Investigation
into the molecular biology of HPV pathogenesis in HNSCC may help with
creation of more specifıc clinical tools for diagnosis and treatment, which are
limited and lack accuracy. Alternative Splicing Events (ASEs), post-transcrip-
tional modifıcations resulting in variant transcripts leading to alternative pro-
tein isoforms, have been under-investigated as putative causes of gene expres-
sion dysregulation in HPV HNSCC. Using RNA-Seq data, a genome-wide
ASE discovery analysis was performed on a JHUHPVHNSCC cohort, which
has expanded HPV HNSCC transcriptional characterization by identifying
novel ASE biomarkers implicated in carcinogenic progression. Outlier Gene Set
Analysis (OGSA) was used to identify genes with high rates of ASE and results
were validated in TCGA samples from seven different cancer types. To verify the
functional implications of differential isoform expression, vectors for knock-in
and knock-down of WT-GSN and ASE-GSN isoforms were developed to eval-
uate changes in cell proliferation and invasion. ASE-GSN/WT-GSN ratio outli-
ers were identifıed by OGSA in tumor samples from discovery JHU HPV
HNSCC cohort, as well as in TCGA public domain data from HNSCC, Lung
Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma and Endocervi-
cal Adenocarcinoma, Bladder Urothelial Carcinoma, Breast Invasive Carci-
noma, and Colon Adenocarcinoma. The increased ASE-GSN/WT-GSN ratio
was also observed in a cohort ofHPVHead andNeckCancerCell lines. SCC61
and UM-SCC-22B HNSCC cell lines were used to evaluate the function GSN
ASEs in vitro. Overall expression levels of both GSN isoforms inversely corre-
lated with cell proliferation whereas the high ratio of ASE-GSN to WT-GSN
correlated with increased cellular invasion of stroma in vitro. Additionally, a
decrease or increase in expression of one isoform is seen to cause a compensa-
tory increase or decrease in the other isoform respectively. ASE-GSN outliers
correlated with HPV cancers indicate that expression ratio between GSN iso-
forms is related to tumor behavior, which is reinforced in vitro whereWT-GSN
is inversely correlated and ASE-GSN is directly correlated to with cell invasion.
These relationships suggest that both overall expression and balance between
the two GSN isoforms are mediating factors in cell death or proliferation, while
shorter ASE-GSN is more likely to indicate progression to cancer. Finally, we
propose a mechanism for the role of GSN isoforms in apoptosis and metastasis,
in which trends in expression between WT- and ASE-GSN isoforms can alter-
natively affect rates of apoptosis or metastatic ability.
#4475 Delineating translocation renal cell carcinoma oncogenesis in cells
harboring TFE3 fusion with spliceosomemachinery associated genes.Nur P.
Damayanti,1 Sreenivasulu Chintala,1 Ashley Orillion,1 Remi Adelaiye-Ogala,1
May F. Elbanna,1 Pete Hollenhorst,2 Roberto Pili3. 1Indiana University, india-
napolis, IN; 2Indiana University, Bloomington, IN; 3Indiana University, India-
napolis, IN.
Background: Translocation Renal Cell Carcinoma (tRCC) represents an ag-
gressive subtype of kidney cancer associated with various gene fusions involving
translocation of one of two members of micropthalmia transcription factor
(MiT) family, TFE3 or TFEB. Despite identifıcation of multiple TFE3 gene fu-
sions in tRCC, heterogeneous phenotype and various dysregulated signaling
pathway resulting from variety of gene fusion partners pose a challenge to es-
tablish effective treatments for these patients. In this work, we sought to study
the biology underlying oncogenesis in tRCC involving TFE3 fusion with genes
associated with pre-mRNA splicing factor machinery; NONO, SFPQ and
PRCC. Methods: To investigate the biology of different TFE3 fusion proteins,
oncogenic phenotypes and oncogenic signaling were compared among cells
with distinct endogenous expression of TFE3 fusions such as SFPQ-TFE3,
NONO-TFE3, PRCC-TFE3. Endogenous SFPQ-TFE3 expressing cells, RP-
RO7, were generated from patient derived xenograft. UOK-109 and UOK-146
(kindly provided by Dr. Marston Lenehan, NCI) were used as endogenous
NONO-TFE3 and PRCC-TFE3 expressing cells, respectively. TFE3 fusion tran-
scriptswere identifıedwithRT-PCR.TFE3 fusion preferentialDNAbindingwas
assessed with ChIP-sequencing. Oncogenic phenotype assessment was done in
2D culture and two different 3Dmodels; 1) Solid tumor model, in which cancer
cell interaction with extracellular matrix and stromal cells, were represented in
multiculture-spheroid system, 2) Invasion model, in which cell ability to invade
basement membrane barrier was modeled with matrix restricted spheroid. Re-
sults: Dissimilar oncogenic phenotypes were seen among RP-R07, UOK-109
and UOK-146 in 2D and 3D culture. The presence of nuclear E-Cadherin was
observed in all three cells model, with increasing level of nuclear expression in
fusion partner dependent manner (P0.05). Distinctive profıles of global phos-
photyrosine and global phosphoserine were observed in cells model harboring
different TFE3 fusions, despite commonnuclear signal of TFE3.Nuclear expres-
sion of selected kinases and phosphokinases such as AKT, FAK, mTOR,
VGEFR-2were identifıed amongTFE3 fusion cells with different level of expres-
sion (P0.05). These results suggest distinct alteration of kinases nucleocyto-
plasmic shuttling regulation in tRCC cells (P0.05), as compared to non TFE3
fusion cells. TFE3ChIP-seq data in RP-R07 indicate novelDNA target involving
metabolism and TGF- signaling related genes. Conclusions: Our results indi-
cate a distinct biology underlying tRCC oncogenesis in different TFE3 fusion
models involving kinase reprograming and nucleocytoplasmic shuttling regula-
tion. These differences also suggest the possibility of generating personalized
treatments targeting specifıc TFE3 fusion genes associated with the spliceosome
machinery.
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#4476 Anovel nonsensemutation in androgen receptor confers resistance
to CYP17 inhibitor treatment in prostate cancer. Dong Han, Jude Owiredu,
Kevin Valencia, Changmeng Cai. University of Massachusetts Boston, Boston,
MA.
Background: The standard treatment for prostate cancer (PCa) is androgen
deprivation therapy (ADT) that blocks AR transcriptional activity, which is
responsible to the initiation and progression of PCa. However, ADT invariably
leads to the castration-resistant PCa (CRPC) with restored activity of AR. CRPC
can be further treatedwithmore intensiveADTs, includingCYP17-inhibitors to
block intratumoral androgen synthesis and more potent AR antagonist. By an-
alyzing the tumormRNA from aCRPCpatient biopsywho developed resistance
to CYP17-inhibitor treatment, we identifıed a novel nonsense AR mutation on
ligand binding domain (Q784*), which produces aC-terminal truncated formof
AR protein containing only a fraction of ligand binding domain (LBD) andmay
mimic the function of someAR splice variants.We hypothesized thatAR-Q784*
may gain the androgen-independent activity, or may enhance the transcrip-
tional activity of full-length AR (AR-FL) under low androgen environment
through dimerization with AR-FL. Method: Luciferase reporter assays were ap-
plied to assess the transcriptional activity of AR-Q784* in absence or presence of
androgens, and with or without AR-FL. Immunoblotting and immunofluores-
cence assays were used to examine the protein stability and cellular localization
of AR-Q784*. Chromatin immunoprecipitation assays were also used to assess
the chromatin binding ability of AR-Q784*. Moreover, the stable cell line that
expresses endogenous AR-FL and tetracycline-inducible AR-Q784* was gener-
ated to determine the transcription activity on AR target genes and assess the
effects on cell proliferation, particularly under low dose androgen condition.
Result: Although it was constitutively expressed in nucleus, AR-Q784* does not
elicit transcriptional activity despite the conditions of ligands. However, when it
was co-expressed with AR-FL, AR-Q784* can enhance AR-mediated transcrip-
tional activity and thus increased PCa cell proliferation particularly under low
androgen conditions.Mechanistically, AR-Q784* can dimerize with AR-FL, en-
hance DNA binding ability of AR-FL, and strengthen AR recruitment of p300
coactivator. Conclusion:We show thatCYP17 inhibitor treatment inCRPCmay
select for a distinct class of AR mutations/variations, including nonsense (AR-
Q784*) or point-deletion mutations within LBD and certain splice variants that
only lose a fraction of LBD domain. This class of AR mutants/variants is tran-
scriptionally inactive but can enhance the activity of AR-FL due to their abilities
of constitutive DNA binding and dimerization with AR-FL. However, this en-
hancing activity of those AR mutants/variants can be prevented by antagonist
treatments such as enzalutamide. Therefore, this study provides an additional
rationale for treating PCa patients with combination therapy of abiraterone and
enzalutamide, which may prevent the selection for such AR mutations/varia-
tions in CRPC.
#4477 HnRNP Q1 translationally increases the expression of Aurora-A
and promotes tumorigenesis in colorectal cancer. Liang-Yi Hung. National
Cheng Kung Univ., Tainan, Taiwan.
Abnormally elevated Aurora-A can causemitotic defects and aneuploidy, which
might lead to genomic instability and tumorigenesis. According to the literatures,
overexpressed Aurora-A may result from gene amplifıcation, RNA transcriptional
activation, or increased protein stability. Our previous study has demonstrated that
Aurora-Acanbe translational upregulated in colorectal cancer.Bybiotinpull-down
assay and in vivo translational assay, we found that Aurora-AmRNA can be trans-
lational upregulated by heterogeneous nuclear ribonucleoprotein (hnRNP) Q1, a
RNAbindingprotein.HnRNPQ1hasbeen implicated inmanyposttranscriptional
regulatory processes including mRNA splicing, RNA metabolism and translation.
In this study, we further clarifıed the regulatorymechanism of hnRNPQ1 in trans-
lational regulating Aurora-A mRNA, as well as investigated the clinical role of hn-
RNPQ1 incolorectal carcinogenesis.Our results indicated thathnRNPQ1canbind
to the Aurora-AmRNA 5’-untranslated region (5’-UTR). Ribosomal protein S6-IP
assay further indicated that hnRNP Q1 can enhance the translational effıcacy of
Aurora-A mRNA. Ribosomal profıling assay further confırmed the translational
regulation of Aurora-AmRNA by hnRNPQ1. Overexpression of hnRNPQ1 pro-
motes cell proliferation and tumor growth. The expression level of hnRNP Q1 is
positively correlated with Aurora-A in colorectal cancer. Taken together, our data
indicate hnRNP Q1 is a novel trans-acting factor that binds to Aurora-A mRNA
5’-UTRs and regulates its translation,which increases cell proliferation and contrib-
utes to tumorigenesis in colorectal cancer.
#4478 Characterization of the biochemical interaction of hnRNP A18 to
thioredoxin transcript. Elizabeth Tsuying Chang, Palak Parekh, Eun Yong
Choi, Ruiqing Yang, France Carrier. Univ. of Maryland Greenebaum Cancer
Center, Baltimore, MD.
Introduction: The RNA-binding protein heterogenous ribonucleoprotein
A18 (hnRNPA18) is a protein translation regulator found to be elevated inmany
cancers. Previous work from our lab has shown that under stress conditions,
hnRNP A18 is able to bind and regulate the translation of a group of mRNAs,
including thioredoxin (TRX), a redox-regulating protein implicated in promot-
ing tumor progression. Additionally, the formation of functional hnRNP A18:
TRX complexes increases de novo protein synthesis of TRX through the stabi-
lization of itsmRNA transcript. It has been reported that likemost RNA-binding
proteins, hnRNPA18 is a modular protein and is uniquely composed of a single
N-terminal RNAbinding domain (RBD) and aC-terminal arginine-glycine rich
(RGG) domain. The RBD is able to dictate specifıcity and affınity of substrate
binding, whilemethylation of the arginine residues in the RGGdomain contrib-
utes to its RNAbinding capability. The observed translational regulation of TRX
by hnRNP A18 merits further studies into understanding the physical interac-
tion between the two molecules. Methods/Results: To determine the region
which hnRNP A18 interacts with thioredoxin, stable cell lines overexpressing
the RBD, RGG or full length (FL) domains of hnRNP A18 were generated in
human melanoma cells. Ribonucleoprotein immunoprecipitation assays were
performed using specifıc antibodies to either the RBD or RGG domain epitope.
Reverse transcription PCR data reveals the presence of TRX mRNA in the re-
sultant immunoprecipitated materials, indicating that both the RBD and RGG
domain of hnRNPA18 protein is able to independently bind TRXmRNA.Max-
imum binding was observed when both RBD and RGG regions were present.
Furthermore, hnRNP A18-GST recombinant proteins were engineered to de-
termine the exact region which hnRNP A18 binds to on its target mRNAs. TRX
mRNA was systematically deleted and increasing amounts of hnRNP A18-GST
protein was added to determine binding capability. Northwestern analysis re-
veals that hnRNP A18 binds to its consensus motif in the TRX 3=UTR and to a
new 19 nucleotide motif downstream of the consensus site. Conclusion: Heter-
ogenous ribonucleoprotein A18 is a stress-activated RNA-binding protein that
functions in the translational regulation of TRX. Although the RBD and RGG
domains are each independently able to physically interact with TRX, both re-
gions are necessary for maximal binding. Furthermore, a new 19 nucleotide
motif located downstream of the hnRNPA18 consensusmotif was also found to
be suffıcient for binding. The binding interface between RNA-binding proteins
and their target mRNAs hold signifıcant importance in understanding how the
two molecules interact and will offer new insights into developing novel drug
therapeutics that disrupt ribonucleoprotein formation.
#4479 Cancer cell ribogenesis: MYC and the integrity of the RNA poly-
merase I-rRNA machinery. Stefano Rossetti, Andrzej J. Wierzbicki, Nicoletta
Sacchi. Roswell Park Cancer Institute, Buffalo, NY.
Upregulation of RNA Polymerase (Pol I)-mediated transcription of ribo-
somal RNA (rRNA) and increased ribogenesis, which are necessary to sustain
the increased metabolic demand of highly proliferating cancer cells, are hall-
marks of cancer. Increased rRNA transcription can be due deregulation of tu-
mor suppressors and oncogenes that affect Pol I activity. Overexpression of the
MYC oncogene, a potent Pol I activators, is particularly frequent in cancer. In
addition, based on our analysis of the Cancer Genome Atlas (TCGA), amplifı-
cation/upregulation of genes encoding for basal components of the Pol I tran-
scriptionalmachinery is also frequent in cancers of various histotype (Rossetti et
al., Cell Cycle, 2016). By using breast and ovarian epithelial cells, we mechanis-
tically found that: 1) ectopic expression of either MYC or RRN3 (TIF-IA), a key
Pol I basal component, by increasing rRNA synthesis, is suffıcient to induce in
vitro transformation phenotypes and to promote cell proliferation; 2) there is a
causal link between MYC overexpression and RRN3 upregulation; 3) MYC- or
RRN3-induced rRNA upregulation sensitizes cells to the anti-proliferative ac-
tion of drugs inhibiting rRNA transcription.Our fındings provide a rationale for
using drugs targeting rRNA transcription to curb proliferation of cancers cells
due to rRNA upregulation by MYC. Funding for this study was provided by an
RPCI-UPCI Ovarian Cancer Spore DRP award (NS), the NCI R01 CA127614
grant (NS), the Terri Brodeur Breast Cancer Foundation (SR), the SusanKomen
Foundation (SR), and the NCI P30 CA016056 institutional grant.
#4480 SerRS is a key inhibitor of VEGFA through both transcriptional
and translational controls. Ze Liu, Yi Shi, Qian Zhang, Xianglei Yang. The
Scripps Research Institute, La Jolla, CA.
Vascularendothelial growth factorA(VEGFA) is themost importantmediatorof
angiogenesis and a major target for cancer therapy. Recent studies from our lab
revealed that seryl-tRNA synthetase (SerRS), by counteracting transcription factor
c-Myc in thenucleus, is the crucial transcriptional repressor ofVEGFAandapotent
inhibitor of angiogenesis (1,2).Herewe report that SerRS controls the expression of
VEGFA not only in the nucleus but also in the cytoplasm through mediating its
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translational readthrough. Translational read-through of the VEGFAmRNA gen-
erates a novel isoform called VEGF-Ax that, compared with the non-readthrough
isoform VEGF165, has a 22-amino acid C-terminal extension and much weakened
angiogenic activity (3,4). Interestingly, serine was identifıed as the amino acid in-
serted in the place of the UGA stop codon during the read-through (3). In unpub-
lishedwork,wWe fındound that SerRS canbind to the 3=UTRregionof theVEGFA
mRNA.ThebindinganchorsSerRS tocharge serineonto tRNASec (the tRNAfor the
21st amino acid selenocysteine that decodes theUGAstop codon), while preventing
the charged serine from being modifıed into selenocysteine. SerRS binding also
blocks the release factors (eRFs) from terminating translation at the stop codon.
Therefore, SerRS is the keymediator of the translational readthrough that generates
VEGF-Ax. Collectively, we have established that amember of the aminoacyl-tRNA
synthetase family plays a critical role in regulating VEGF and angiogenesis through
both transcriptional and translational controls. References: 1. Xu X, Shi Y, Zhang
HM, Swindell EC, Marshall AG, Guo M, Kishi S, Yang XL*. Unique domain ap-
pended to vertebrate tRNA synthetase is essential for vascular development. Nat
Commun. 2012 Feb 21;3:681. 2. Shi Y, XuX, ZhangQ, FuG,MoZ,WangGS,Kishi
S, YangXL*. tRNAsynthetase counteracts c-Myc to develop functional vasculature.
Elife. 2014 Jun 17;3:e02349. 3. Eswarappa SM, PotdarAA,KochWJ, FanY,VasuK,
Lindner D, Willard B, Graham LM, DiCorleto PE, Fox PL. Programmed transla-
tional readthrough generates antiangiogenic VEGF-Ax. Cell. 2014 Jun 19;157(7):
1605-18. 4. Xin H, Zhong C, Nudleman E, Ferrara N. Evidence for Pro-angiogenic
Functions of VEGF-Ax. Cell. 2016 Sep 22;167(1):275-284.
#4481 Translation initiation factor DAP5 plays an essential role in trans-
lational control of breast cancer metastasis. Columba de la Parra, Amandine
Alard, Amanda Ernlund, Robert J. Schneider. NYU School of Medicine, New
York, NY.
Metastasis is the cause of 90%of cancer-related deaths. SelectivemRNA trans-
lation has been found to be crucial for breast cancer development, progression
andmetastasis; however, there is a poor biological andmechanistic understand-
ing of the role of translation in these processes. Our work and others have
pioneered an understanding of translational regulation in breast cancer. We
have previously shown that overexpression of initiation factor eIF4GI in ad-
vanced breast cancer cells selectively increases the translation ofmRNAs encod-
ing survival, cell cycle inhibition, and DNA damage and repair proteins, among
other DNA damage-protective mRNAs. eIF4G consists of three family mem-
bers: eIF4GI, eIF4GII, and the poorly studied eIF4Ghomolog,DAP5, the subject
of this study. DAP5 lacks the N-terminal domain for eIF4E and PABP binding.
DAP5 is therefore suspected to promote eIF4E-independent or IRES-driven
translation of mRNAs involved in cell stress and oncogenesis, but its role in
metastasis hasn’t been investigated.We analyzed the NCI human tissue genome
cancer atlas (TCGA) and found that higher DAP5mRNA expression is strongly
associated with estrogen receptor negative breast cancer metastasis with lower
overall survival. We then engineered a highly metastatic breast cancer cell line
MDA-MB-231TR to express dox-inducible shRNA to DAP5 or a non-silencing
(NS) control. Tumors were developed in clinically relevant orthotopic mouse
models, with and without DAP5 silencing by addition of dox to the drinking
water. Remarkably, reduction of DAP5 expression by70% had no impact on
primary tumor growth but fully eliminatedmetastasis to the lung.Genome-wide
transcriptome and translatome analysis of DAP5 and in vivo ultraviolet-cross-
linking and high-throughput sequencing (HITS-CLIP) identifıed specifıc mR-
NAs that interact directly with DAP5. A signifıcant fraction of DAP5 mRNA
targets are involved in cell death and survival, cell proliferation, cell mobility,
DNA repair and translation initiation and do not have IRESs, suggesting a novel
role for DAP5 in a non-classical translation initiation process upon cellular
stress and metastasis. Our results suggest that the translation initiation factor
DAP5 likely plays a critical role in breast cancer metastasis by a unique mecha-
nism formetastasis-specifıc translation initiation and provides new concepts for
therapeutic strategies involving translational regulation.
#4482 Osteopontin, p53 and PTEN isoforms expression patterns in endo-
metrium carcinoma cell lines. Vanessa F. Franco,1 Nataly dos Santos Melo,2
Iaci N. Soares,3 Ya-Ting Hsu, Ya-Ting,4 Tim H. Huang,4 Wallace M. Araujo,1
José A.Morgado-Diaz,1 Jerson L. Silva,3 Etel Rodrigues Pereira Gimba5. 1INCA,
Rio de Janeiro, Brazil; 2UFF, Rio de Janeiro, Brazil; 3UFRJ, Rio de Janeiro, Brazil;
4University of Texas Health Science Center at San Antonio, San Antonio, TX;
5UFF/INCA, Rio de Janeiro, Brazil.
Total osteopontin (OPN) is overexpressed in endometrium carcinoma (EC) and
modifıcations at TP53 and PTEN genes correspond to major genetic alterations in
these tumors.Althought totalOPNexpressionhasbeencorrelated top53andPTEN
expression, no data is available regarding OPN splice variants and their association
to p53 and PTEN isoforms expression. OPN has three splicing isoforms (OPN-SI),
namedOPNa,OPNb andOPNc, while p53 has at least 12 variants, such as p53 (full
lenght), p53, p53, 
40p53, 
133p53 and 
160p53. Moreover, PTEN splicing
isoforms (PTEN-SI) are named vs-fl (full lenght variant), vs-3a-3c, vs-5a-5d, and
vs-D6.Weaimed toevaluate the expressionprofıleofOPN,p53andPTENisoforms
as a fırst approach to establish their presumptive associations and functional inter-
actions inendometrial tumoralandnontumoral cells.TotalRNAhasbeenextracted
from endometrial non-tumoral (E6/E7 andEM42) and tumoral (Ishikawa, RL95-2,
AN3CA andKLE) cell lines, followed by cDNA synthesis. Transcriptional and pro-
tein expressionpatternshavebeen evaluated forOPN,p53orPTEN isoforms, using
quantitative real time PCR, immunoblot or immunofluorescence. OPNa is overex-
pressed in tumoral and non-tumoral cell lines in relation to OPNb and OPNc.
Regarding p53, the full lengh isoform is overexpressed, followed by 
40p53, in
relation to other variants in EC cells. Conversely, 
40p53 it is the major expressed
transcript in both EM42 and E6/E7 non-tumoral cells. Otherwise, in EC and endo-
metrial non-tumoral cells, PTEN vs-fl isoform is overexpressed in relation to the
other splice variants. Specifıcally in E6/E7 cells, all PTEN-SI, except vs-3b e vs-D6,
are overexpressed in relation to EC cell lines. At the protein level, both p53 and
PTEN isoforms are overexpressed in E6/E7 cells, when compared to EC cells. Of
note, distinct isoforms formost of these variant transcriptshavenotbeendetected at
the protein level. Our data demonstrate that full lenghtOPN, p53 andPTENare the
major expressed variants in EC tumor cell lines. However, most of these transcript
variants display differential expression between endometrial tumor and non-tu-
moral cells and also among distinct EC cell lines. These data provide early evidence
that these variants can differently modulate the expression and functional roles of
their full length couterparts. Further work should investigate the impact of OPNa
overerexpression on p53 and PTEN isoforms and their putative cellular andmolec-
ular roles onmodulating p53 and PTEN tumor supressive roles.
#4483 TGF- downregulates osteopontin isoforms and induce and epi-
thelial plasticity in PC3 metastatic prostate cancer cells. Durval Marques,1
Rodrigo A. Peres,2 Paula P. de Freitas,3 Abigail C. Resende,4 Nataly dos Santos
Melo,5 Waldemir Fernandes de Souza,3 José A. Morgado-Diaz,3 Etel Rodrigues
Pereira Gimba4. 1UF, Niterói, Brazil; 2UFF, Rio das Ostras, Brazil; 3INCA, Rio de
Janeiro, Brazil; 4UFF/INCA, Rio de Janeiro, Brazil; 5UFF, Niterói, Brazil.
Total osteopontin (OPN) has been described as a master regulator of epithe-
lial-mesenchymal transition (EMT), including in prostate cancer (PCa). How-
ever, the contribution of each OPN splicing isoform (OPN-SI), named OPNa,
OPNb, and OPNc in the epithelial plasticity dynamic process is currently un-
known. Besides, the contribution of alternative splicing regulation in this sce-
nario is poorly understood. Here we aimed to investigate the expression of
OPN-SI and the associated splicing pattern regulation in response to metastatic
prostate cancer (PCa) cells treatment with TGF- . Further, we aimed to inves-
tigate the resulting cell phenotypic features. To achieve this, we treated PC3 cells
with TGF- 10ng/ml for 48 h as a model to induce epithelial plasticity in these
cells. Total RNA was extracted and the corresponding cDNA was tested for
transcriptional levels of OPN-SI, SR and HnRNP splicing regulators as well as
classical (EMT) markers by using real time PCR. EMT markers and cell mor-
phology have also been analyzed by immunofluoresce. PC3 cell phenotype has
also been evaluated by using cell migration and viabilitity assays in response to
-lapachone cytotoxic reagent. PC3 cells treated with TGF- displayed an in-
termediate EMT phenotype, as evidenced by a signifıcant downregulation of
both epithelial (E-cadherin, claudin-3 andcytokeratin 18) and mesenchymal
markers (vimentin, N-cadherin, snailandslug). These cells presented a higher
cytoplasmic E-cadherin expression, as well as a lower vimentin cytoplasmic
staining. A major cortical distribution of actin fılaments beneath the cell cortex
has been observed. Further, a signifıcant downregulation of OPNa and mainly,
OPNb and OPNc isoforms, as well as most tested splicing regulators has been
shown. TGF- treatment also promoted a signifıcant inhibition on cell migra-
tion as well as higher sensitivity to -lapachone treatment, as compared to con-
trol cells. Altogether, our data evidence that in our in vitro experimental model,
TGF- promoted a an intermediate EMT phenotype, with a predominance of
epithelial features, associated to downregulation of OPN-SI and most tested
splicing regulators. We then hypothesize that TGF-may also be an EMT-like
inducer, in which metastatic PCa cells could acquire major epithelial features
that facilitate cell anchorage and adhesion in distant tumor sites. OPN-SI dow-
regulation in this process could favour epithelial-like features, as apposed to
OPN-SI overexpression during tumor progression towards metastic circulating
cells typically displaying mesechymal phenotypes.
#4484 KRAS regulates eIF4E Binding Proteins (4EBPs) via MAPK-Inter-
acting Kinases (MNKs) in a PI3K-dependent, AKT-independent manner.
Jillian M. Silva,1 Rachel K. Bagni,2 Davide Ruggero,1 Frank McCormick1. 1Uni-
versity of California, San Francisco, San Francisco, CA; 2Frederick National Lab-
oratory for Cancer Research, Frederick, MD.
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Oncogenic RAS mutations are present at high frequencies in human cancer
leading to the sustained activation of the ERK1/2 mitogen-activated protein
kinase (MAPK) signaling pathway. Of the three major RAS isoforms (HRAS,
KRAS, and NRAS), KRAS is the most commonly mutated isoform, in which a
substitution of glycine for cysteine (G12C), aspartic acid (G12D), or valine
(G12V) is typically altered at codon 12. However, the unique dependencies on
upstream or downstream oncogenic signaling amongst the KRAS mutants re-
mains elusive and often masked by the remaining wild-type allele, other RAS
isoforms, or additional secondary genetic alterations. Moreover, mutational ac-
tivation of RAS can also enhance the assembly and activity of the cap-binding
complex, eukaryotic initiation factor 4F (eIF4F). It has been demonstrated that
RAS signaling via ERK promotes MAPK-interacting serine/threonine kinases
(MNKs) to interact with eIF4G and the phosphorylation of eIF4E at serine 209,
which is a critical site for oncogenic function. Thus, we employed an isogenic
mouse embryonic fıbroblast (MEF) system, devoid of H-, N-, and KRAS alleles
and reconstituted with a single KRAS mutant isoform, to examine the depen-
dencies of growth factor and PI3=-lipid activities on KRAS-mediated control of
translational regulation. Although oncogenic KRAS G12C, G12D, and G12V
mutant cells proliferated at twice the rate of KRAS4b wild-type MEF cells,
growth factor deprivation or inhibition of PI3K ormTORC1/2 displayed potent
anti-proliferative effects on all MEF cell lines. Analysis of signaling downstream
of KRAS revealed that phosphorylation of 4E-BP1, MNK, and eIF4E occurred
independent of growth factor activity, which stood in contrast to the substantial
inhibitory effects of growth factor deprivation on AKT, p70S6K, and ribosomal
protein S6 phosphorylation. Interestingly, AKT inhibition largely had no effect
on 4E-BP1 phosphorylation, whereas inhibition of PI3KormTORC1/2 potently
suppressed p70S6K, ribosomal protein S6, and 4E-BP1 phosphorylation. More-
over, growth factor deprivation resulted in amarginal decrease of global protein
synthesis with negligible effects on cap-dependent translation initiation in all
MEF cell lines. Taken together, these data suggest that KRAS regulates 4EBPs
and MNKs in a manner that is dependent on PI3K-mTORC1 signaling, but
independent of AKT or growth factor activities.
#4485 Identifıcation and characterization of novel RACK1 binding part-
ners that may modulate the elongation phase of protein synthesis. Beatrice
Malacrida,1 Rasmus K. Flygaard,2 CatríonaM. Dowling,1 John C. Coffey,1 Lasse
B. Jenner,2 Patrick A. Kiely1. 1Univeristy of Limerick, Limerick, Ireland; 2Aarhus
University, Aarhus, Denmark.
RACK1 (Receptor for Activated C Kinase 1) is a member of the tryptophan-
aspartate (WD-repeat) family of proteins. By functioning as a scaffold protein,
RACK1 is involved in regulating many different signalling pathways in cells,
including cell proliferation and cell migration. Interestingly, RACK1 has been
identifıed as a central component of the ribosomal machinery, specifıcally lo-
cated on the 40S ribosomal subunit close to the mRNA exit channel where it
makes contact with other ribosomal proteins. Importantly, it is believed that in
this position, RACK1 can recruit a series of kinases and phosphatases as well as
functioning to regulate the translation and the synthesis of particular cohorts of
proteins.Moreover, RACK1plays a central role in influencing the location of the
translation machinery. Using 2D and 3D models of colon cancer cell lines, to-
gether with Click-IT chemistry andMass Spectrometry analysis, we were able to
identify a series of proteins, including newly synthesized proteins, that interact
with RACK1. We identifıed proteins involved in cell cycle control, metabolism
and protein synthesis. As expected, we have found a number of proteins that are
involved in cellmigration and a number of proteins that aremediators of the cell
adhesion process. Interestingly, some of the most highly scored interacting pro-
teins were those involved in protein synthesis. Of those, we identifıed several
elongation factors as being novel RACK1 binding partners. Elongation factors
are a class of proteins directly involved in the elongation phase of protein syn-
thesis. Along with this primary function, these factors have different important
roles in cells, such as influencing cytoskeleton remodelling and activation of
growth and proliferation pathways. Elongation factors have been found to be
upregulated in many different types of cancer. We have confırmed the interac-
tion between RACK1 and several of these elongation factors and we have deter-
mined that many of these are dysregulated in colon cancer.We have established
that the activity of these elongation factors is regulated by a combination of stress
conditions and growth factor stimulations. We have determined that RACK1
plays a central role in scaffolding these proteins to promote proliferation and
migration in our colon cancer cell models. Collectively, these results provide a
novel and interesting role for RACK1 in themodulation of the elongation phase
of protein synthesis. We are now investigating the subcellular location of these
factors in response to different stimuli and asking how is RACK1 involved in
their localization downstream of IGF-I and integrin signalling. Characterizing
and mapping the interaction between these proteins and RACK1, both in cells
and tissue, may lead to the design of novel therapeutic approaches in colon
cancer.
#4486 Redox regulation of the biosynthesis ofmitronic tsmiRmiR6855 in
the basal like breast cancer cells. Smita Misra, Gautam Chaudhuri. Meharry
Medical College, Nashville, TN.
Radiation and chemotherapeutic agents eradicate tumors by inducing irrep-
arable DNA damage. However, cancer cells often develop resistance to therapy
by manipulating the DNA repair machinery. Conversely, a dividing cell con-
stantly exposed to environmental and endogenous DNA damaging agents can
transform into a tumor due to incorrect repair. Therefore the expression level of
DNA repair proteins is critical both for cancer therapy and tumorigenesis. Our
preliminary studies implied a unique mechanism involving an miRNA miR-
6855-3p that promotes the biosynthesis of the transcriptional regulator protein
SPRDX5 which enhances the expression of the tumor suppressor protein
BRCA2 leading to the genotoxin and radiation-resistance of aggressive SLUG-
high basal-like breast cancer (BLBC) cells. ThemiRNAmiR-6855-3p thus acts as
a tumor suppressor miRNA (tsmiR). Interestingly, the gene for the miRNA
miR-6855-3p is mitronic and is nested within the intron#13 of the USP20 gene
which is a deubiquitinase. Thus, the transcription of miR-6855-3p gene is regu-
lated through the USP20 gene promoter. We present evidence here that USP20
and miR-6855 gene transcriptions are up regulated by oxidative stress. Tert-
butylhydroperoxide was used for oxidative stress. Under the oxidative stress
conditions tested, NRF2 level and the levels of several NRF2-regulated proteins
are increased, indicating activation of NRF2 in the stressed BLBC cells. Under
the stress conditions the levels of USP20 and miR-6855-3p are increased signif-
icantly. Knockdown of NRF2 prevented stress-induced elevation of USP20 and
miR-6855-3p RNA level in the BLBC cells indicating the involvement of NRF2
in this process. The binding of NRF2 to the USP20 gene promoter and its func-
tion were characterized by ChIP analysis, site-directed mutagenesis and using
the promoter-luciferase reporter constructs. We conclude that the biosynthesis
of the tsmiR miR-6855-3p in the BLBC cells is regulated by oxidative stress and
involves NRF2. Since oxidative stress is a hallmark in the etiology and progres-
sion of metastatic breast cancer, understanding the redox regulation of a tsmiR
that positively influences BRCA2 gene expression in the BLBC cells could be
clinically signifıcant. Supported in part by DOD-CDMRP IDEA Expansion
Grant# BC103645 and NIH/NCI grant 1R21CA181920-01 to GC and
1U54RR026140 to SM.
#4487 A critical role of PARylation in regulating the functions ofOVOL2.
Rui Zhang,1 Boan Li,2 Yih-Cherng Liou1. 1National University of Singapore,
Singapore, Singapore; 2State Key Laboratory of Cellular Stress Biology, Xiamen
University, Xiamen, China.
Poly(ADP-ribosyl)ation (PARylation) is one of the post-translational modi-
fıcations, by which the ADP-ribose (PAR) polymers are added to the specifıc
protein by a PARpolymerase (PARP). In the about 50 years’ studies, this specifıc
modifıcation has been verifıed to be related to multiple important biological
functions including cell death, cell differentiation, histone modifıcation, tran-
scriptional regulation, DNA repair and genome stability. Ovo-like 2 (OVOL2), a
novel zinc fınger transcriptional factor, contains a Snail/Gli (SNAG)motif at the
N-terminal to possess a transcriptional regulatory activity and four DNA-bind-
ing Cys2-His2 (C2H2) zinc fınger domains at the C-terminal to bind with DNA.
OVOL2 is demonstrated to be involved in the cranial neural tube, angiogenesis,
heart and placental development. In addition, OVOL2 can also suppress cell
cycle and terminate differentiation of keratinocyte by directly inhibiting of c-
Myc andNotch1.However, the regulation andbiological function ofOVOL2 are
still largely unknown. In this study, we identify the binding targets, PARP1 and
NPM1, of OVOL2. In addition, we report that the function of OVOL2 is regu-
lated by PARP1 through PARylation, which modifıes on C2H2 zinc fınger do-
mains and plays an important role in the regulation ofOVOL2 functions. PARy-
lated OVOL2, but not the 3K mutant, alters focal adhesion and cell cycle,
resulting in the formation of polyploidy in cells. Our fındings not only have
signifıcant implications for the cellular functions of OVOL2, but also provide a
better understanding on the multiple biological functions of the PARylation.
#4488 Tumor suppressor phosphatase PHLPP1 regulates transcription
factor activity and gene expression in inflammation.Ksenya Cohen Katsenel-
son, Joshua D. Stender, Christopher K. Glass, Alexandra C. Newton. University
of California, San Diego, La Jolla, CA.
Epigenetic mechanisms play a key role in cancer and are a major contributor
in driving the aberrantly high levels of oncogenic receptor tyrosine kinases
(RTK) in cancer. Understandingmechanisms leading to altered transcription of
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oncogenes and tumor suppressors has the potential to provide new therapeutic
targets. Here we show that the PH domain leucine-rich repeat protein phospha-
tase 1 (PHLPP1), a tumor suppressor that directly dephosphorylates and inac-
tivates Akt, has an additional function of regulating approximately 10% of the
transcriptome. Specifıcally, we used non-biased high-throughput RNA-se-
quencing and chromatin immunoprecipitation-sequencing techniques to ana-
lyze genome-wide mRNA levels and acetylation patterns of genes in cells from
wild-type and PHLPP1 knockout mice. De novo motif analysis of the promoter
for the genes regulated by PHLPP1 identifıed enrichment in the recognition
motifs for a number of transcription factors, including ones involved in inflam-
matory signaling. Biochemical analysis revealed that PHLPP1 regulates the
phosphorylation and activation of these transcription factors, such that loss of
PHLPP1 leads to enhanced inflammatory signaling.Our data support amodel in
which PHLPP1 dephosphorylates specifıc transcription factors to act as the
brakes to inflammatory signaling, a hallmark of cancer.
#4489 Knockdown ARID5A suppresses proliferation of LNCaP prostate
cancer cell through the inhibition of global protein synthesis.Chao Sun, Vik-
tor Chesnokov, Keiichi Itakura. Beckman Research Institute of City of Hope Na-
tional Medical Center, Duarte, CA.
AT-Rich InteractionDomain-containing protein 5a (ARID5A; also known as
Modulator Recognition Factor 1(MRF1) ) was fırst cloned in our laboratory by
screening a cDNA library of Tera-2 mRNAwith an oligonucleotide probe from
themajor immediate early gene of human cytomegalo virus. It has been reported
that ARID5A forms a complex with androgen receptor (AR) in yeast two hybrid
assays and is a cosuppressor of AR in transient transfection assays. In this study,
we report that the knockdown of ARID5a expression inhibits proliferation of
LNCaP cells on the contrary to the expectation from the transient transfection
assay. We found that proliferation of cells stimulated by the treatment with
dihydro-testosterone (DHT) was suppressed when ARID5a expression was
down-regulated by siRNA technology. Androgen stimulates cell proliferation
through activation of mammalian target of rapamycin complex 1 (mTORC1).
However, the suppression of ARID5a does not affect androgen-activatedmTOR
activity. Furthermore, the expression of androgen-inducible and androgen-sup-
pressive genes were not affected by suppression of ARID5a. We concluded that
ARID5a is not a cosuppressor of AR. Meanwhile, flow cytometer analysis
showed thatDHT-stimulated cell cycle was arrested atG1 phase after the knock-
down of ARID5a expression. Oil Red O staining assays showed that the inhibi-
tion of ARID5a expression led to decreased DHT-induced lipid accumulation.
Our data further proved that the knockdown of ARID5a expression inhibited
the protein expression of DHT-induced sterol regulatory element binding tran-
scription factor 1 (SREBP-1). In addition,Western blot analysis revealed that the
down-regulation of ARID5a decreased the expression of cell survival / prolifer-
ation and cell cycle regulation proteins, such as hypoxia inducible factor 1 alpha
(HIF1a), cyclin D1 and cyclin D3. Real time PCR data revealed that the knock-
down of ARID5a expression did not affect the steady level of HIF1a, cyclin D1
and cyclin D3 mRNA. These suggested that knockdown of ARID5a expression
affected protein expression at translational and/or post-translational level. Our
data suggested that knockdown of ARID5a expression increased the phosphor-
ylation of eukaryotic translation initiation factor 2a (eIF2a) which inhibited
translation initiation. S35 labeling assay confırmed that the knockdown of
ARID5a expression suppressed the global protein synthesis. We showed that
one of the four eIF2a kinases, general control non-derepressible 2 (GCN2) was
activated by the suppression of ARID5a expression. We are currently studying
on the mechanisms by which ARID5A regulates GCN2 kinase.
#4490 Post-transcriptional regulation on PIAS3 expression in malignant
mesothelioma. Tian He, Karen McColl, Nneha Sakre, Gary Wildey, Afshin
Dowlati. Case Western Reserve University, Cleveland, OH.
Protein Inhibitor of Activated STAT3 (PIAS3) was originally identifıed as an
endogenous suppressor of STAT3 activity which can specifıcally interact with
activated STAT3 and block its downstream oncogenic effects. Previous studies
from our lab have shown that low PIAS3 protein expression in mesothelioma
tumors was associated with poor patient survival. Furthermore, low PIAS3 ex-
pression inmesothelioma cell lines correlatedwith higher STAT3 activity. Over-
expression of PIAS3 decreased STAT3 activity and cell growth. These fındings
suggest that low PIAS3 expression may play an important role in mesothelioma
tumorigenesis, thus understanding the regulatory mechanism(s) of PIAS3 ex-
pression may provide new therapeutic strategies in mesothelioma treatment.
Initially, we examined PIAS3 expression by western blotting and RT-qPCR
among sixmesothelioma cell lines (H28, 211H,H2052, H2452, HAY, YOU) and
found that while PIAS3 mRNA levels were relatively constant, PIAS3 protein
expressionwas highly variable. This fınding indicated a potential post-transcrip-
tional regulation of PIAS3 expression in mesothelioma. To investigate this fur-
ther, we fırst examined PIAS3 protein stability in the presence of proteasome
inhibitors and cycloheximide (CHX).We observed no increase in PIAS3 protein
levels during proteasome inhibition using eitherMG132 (10M)or bortezemib
(1 M) for up to 8 h in 211H, H2052 and H2452 cells, whereas TP53 protein
expression was increased. Blocking translational protein synthesis with 50 or
100 g/ml CHX for up to 24 h also produced little change in PIAS3 protein
expression in mesothelioma cells, indicating that PIAS3 is a very stable protein.
We next explored the PIAS3 3=UTR as a potential site for translational regula-
tion. We initially utilized a miR microarray and computational analysis, fol-
lowed by a PIAS3 3=UTR luciferase reporter assay, to screen miRNAs that are
both increased in cells with low PIAS3 and have seed sequences targeting the
PIAS3 3=UTR and identifıedmiR-18a as our fırst candidate. Taken together, our
study suggests that variable expression of PIAS3 protein in mesothelioma is
regulated by translational control and not by protein stability.
#4491 Modulation of p63 expression by phosphorylation of RBM38 at
S195 via miR-203. Yanhong Zhang, Wensheng Yan, Jin Zhang, Xinbin Chen.
UC Davis, Davis, CA.
p63, a p53 family protein, acts as a sequence-specifıc DNA-binding transcrip-
tional factor to regulate the expression of target genes involving in various cel-
lular processes, including growth suppression and epithelial development.
RBM38, a RNA-binding protein, is a target of p53 family and is known to inter-
act with its target mRNAs and regulate their expression via mRNA stability.
Previously, we found that RBM38 negatively regulates p63 mRNA stability
through binding to the AU/U-rich element in 3= untranslated region (3=-UTR).
We also found that phosphorylation of RBM38 at Ser195 alters the conforma-
tion and function of RBM38 protein. However, it is unclear whether phosphor-
ylation of RBM38 ormiR-203 alters the ability of RBM38 to regulate p63 expres-
sion. In this study, we found that in both MCF7 and HaCaT cells, wild-type
RBM38 and S195Amutant, but not phosphor-mimic S195Dmutant, inhibit p63
mRNA stability, suggesting that Ser195 phosphorylation abrogates the ability of
RBM38 to repress the expression of p63. Importantly, we found that phosphor-
ylation of RBM38 disrupts the binding of RBM38 to the U-rich element in p63
3=-UTR. Additionally, we found that miR-203 inhibitor increases, whereas
miR203 mimic decreases p63 expression through binding to p63 3=-UTR, con-
sistent with a previous report. Interestingly, we found that the ability of RBM38
to repress p63 expression is disrupted by miR-203 inhibitor but enhanced by
miR-203mimic. Furthermore, we found that wild-type RBM38 protein, but not
phosphor-mimic S195Dmutant, physically interacts with Ago2, indicating that
RBM38may inhibit p63mRNA stability bymodulatingAgo2-miR-203 complex
to bind to the U-rich element in p63 3=-UTR. Together, we uncovered a novel
mechanism by which RBM38 modulates p63 expression via miR-203.
#4492 Androgen receptor affects GLI activity by promoting transcrip-
tionally active states of GLI upon androgen stimulation. Sarah Truong,1 Na
Li,2 Mannan Nouri,1 Ralph Buttyan1. 1University of British Columbia, Vancou-
ver, British Columbia, Canada; 2Vancouver Prostate Centre, Vancouver, British
Columbia, Canada.
Introduction: While “castration” therapies benefıt metastatic prostate cancer
(PCa) patients, their effects are transient and progression to castration resistant
disease (CRPC) remains a vexing clinical problem. Despite low levels of circu-
lating androgens in treated patients, CRPC typically remains dependent on an-
drogen/androgen receptor (AR) signaling for further growth. Previously we
showed that Gli protein binding to AR co-activates AR transcriptional activity
and supports androgen-independent growth. Here we show evidence that the
interaction of AR with Gli proteins, particularly Gli3, allows for a “non-canon-
ical” activation of Hedgehog signaling that contributes to PCa cell growth and
progression to CRPC. Methods: Androgen growth-dependent (LNCaP) or -in-
dependent (LNCaP-AI, LN95) PCa cells were transfected with a Gli-luciferase
(Gli-luc) reporter and were treated with R1881, enzalutamide (Enz), or a com-
bination. Luciferase activity was measured. R1-D567 (harboring a genomic de-
letion of AR) served as a negative control. Knockdown of AR-FL with siRNA or
overexpression of a small decoy peptide from the Gli2 AR-binding domain
(Gli-DP) was also performed in above cells. Western blot and real-time PCR
confırmed both AR and Gli target gene/protein expressions in LNCaP and LN-
CaP-AI cells (-/R1881). Sonic hedgehog (Shh) ligand-responsive 3T3-E1 cells
were transiently expressed with AR-FL to confırm the involvement of canonical
Shh-Gli activation pathway in AR co-activation of Gli transcription. Co-immu-
noprecipitation (co-IP) was performed to verify the blocking effıciency of
Gli-DP in AR-Gli3 interaction in LN95 cells and AR-overexpressing 293FT.
Results: Androgen (R1881) treatment strongly inducedGli transcription activity
in AR PCa cells while Enz reversed this effect; AR-FL-specifıc knockdown or
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exogenous Gli-DP expression suppressed androgen-induced Gli reporter ex-
pression as well as expression of endogenous Gli-responsive genes. R1881 treat-
ment promoted Gli2/3 protein processing to transcriptionally active states
(Gli3-FullLength and Gli2-Active) and enhanced the expression of Gli-target
genes, Gli1/Ptch1, at protein and/or mRNA levels. Co-IP revealed that exoge-
nous Gli-DP blocked the interaction between AR and transcriptionally active
Gli3-FL in PCa cells. Overexpression of AR in 3T3-E1 cells confırmed that AR
interaction with Gli stabilizes the active Gli3-FL form by suppressing degrada-
tion of Gli3 in a manner independent of the canonical Shh-Gli activation path-
way. Conclusions: Our fındings further identify the importance of AR-Gli inter-
action in progression of PCa to CRPC and shows that cooperative binding of AR
to Gli proteins enhances both AR and Hedgehog signaling in PCa cells. Inter-
ference with the AR-Gli interaction using a decoy peptide provides a means to
suppress AR activation of Hedgehog in PCa cells.
#4493 The co-chaperone UNC45A controls cancer cell proliferation
through Nek7 and centrosomal separation. Yasmeen Jilani,1 Nada H. Eisa,1
Kashish Kainth,1 Sumin Lu,2 Nehal M. Elsherbiny,3 Laila A. Eissa,3 Mamdouh
M. Elshishtawy,3 Hasan Korkaya,1 Abdeljabar El Andaloussi,2 Ahmed Chadli1.
1Augusta University, Georgia Cancer Center, Augusta, GA; 2Augusta University,
Augusta, GA; 3Mansoura University, Mansoura, Egypt.
Recent fındings have shown that the Heat Shock Protein 90 (Hsp90) co-
chaperone UNC45A is overexpressed in ovarian and breast cancers. Previously,
we have shown that UNC45A is a centrosomal protein essential for cervical
tumor cell growth through activation of the checkpoint kinase 1 (ChK1). In this
report, we further examined the role of UNC45A in breast tumorigenesis using
a variety of biochemical and cell biology techniques and animal models. We
confırmed that UNC45A is highly overexpressed in human breast-infıltrating
ductal carcinomas as compared to adjacent normal tissues. Silencing UNC45A
in vitro blocked the proliferation of all breast cancer subtypes and drastically
reduced tumor growth of the triple negative MDA-MB-231 cell line implanted
in mammary fat pads of NOD/SCID mice. However, loss of UNC45A did not
affect the proliferation of normal mammary cells. Remarkably, UNC45A be-
comes more nuclear in human cancer tissues and cancer cell lines as compared
to normal tissues and non-transformed Hs578Bst and HME mammary cell
lines, respectively. This suggests an important nuclear function for UNC45A
during tumorigenesis.Microarray analysis ofmRNA fromHs578T cells showed
that loss of UNC45A alters the expression of 121 genes, involved in cancer and
cellular development and growth networks. Relevant to cell proliferation, we
found that Nek7 gene was signifıcantly repressed upon silencing UNC45A,
which was validated by RTqPCR and Western blot analyses in multiple breast
cancer cell lines. Nek7 is a member of the NIMA (never in mitosis, gene A)
family of serine/threonine kinases. It plays a key role in centrosomal separation
duringmitosis. This correlates neatly with our observation that loss of UNC45A
causes a centrosomal separation defect, cell proliferation arrest and death of
breast cancer cell lines. ChIP experiments showed that UNC45A binds to the
promoter of the Nek7 gene, suggesting direct transcriptional regulation. Inter-
estingly, the UNC45A sequence contains four LxxLL motifs, which are thought
to be signatures for co-activator binding to nuclear receptors. Furthermore,
computational analysis identifıed two glucocorticoid response elements (GRE)
consensus sequences in the Nek7 promoter, suggesting its transcriptional regu-
lation by the glucocorticoid receptor (GR). This hypothesis was further
strengthened by a signifıcant decrease in the mRNA and protein levels of Nek7
upon silencing GR. Thus, our data suggest that UNC45A functions as a GR
co-activator to control Nek7 gene transcription. Consistent with this, immuno-
precipitation experiments confırmed that UNC45A and GR form endogenous
complexes, and treatment of Hs578T and MCF7 cell lines with dexamethasone
upregulates Nek7 mRNA and protein levels. In conclusion our data strongly
support the premise that UNC45A promotes Nek7 transcription through acti-
vation of GR, and thus controls centrosomal separation and cancer cell prolif-
eration.
#4494 Tumor suppressive role of ZFP36L1 by suppressing HIF1 and
CyclinD1 in bladder and breast cancer.Xin Yi Loh, LingWenDing, H. Phillip
Koeffler. Cancer Science Institute, Singapore, Singapore.
AU-rich mRNAs are a class of mRNAs that contains AU-rich elements
(AREs)motifs in their 3=UTR.The half-life and turnover ofAU-richmRNAs are
tightly regulated by AREs-binding proteins, such as Zinc fınger protein 36 C3H
type-like 1 (ZFP36L1). ZFP36L1 is one of the RNA-binding proteins (RBPs),
which consists of two tandemly repeated zinc fınger motifs that specifıcally rec-
ognize AREs motifs and mediate mRNAs decay. However, our knowledge on
role of ZFP36L1 in breast and bladder cancers and its downstream targets re-
mains poorly elucidated. Here, we hypothesized that ZFP36L1 might degrade
oncogenic mRNAs transcripts, thus leading to suppression of tumorigenesis.
Our analysis of in silico data revealed that ZFP36L1 is signifıcantly mutated or
downregulated in a variety of cancers. The high proportion of inactivation mu-
tation pattern as well as the Mutsig result suggest that it may act as an unappre-
ciated tumor suppressor. Lower ZFP36L1 expression correlated with reduced
survival in patients. Forced expression of ZFP36L1 markedly reduced cellular
proliferation, invasiveness and migration in vitro, as well as tumor growth in
vivo. In addition, microarray and RNA-seq data analysis showed that several
important cancer-related candidates such as IL8 and HIF1 were signifıcantly
downregulated.Overexpression of ZFP36L1 reducedHIF1mRNAandprotein
expression. Similarly, HIF1 forced expression also inhibited ZFP36L1 mRNA
and protein, suggesting a feedback loop of HIF1 and ZFP36L1. Dual luciferase
reporter assays and RNA Electro-mobility Shift Assay (REMSA) showed that
only wild type ZFP36L1, but not different mutants of ZFP36L1, was able to bind
directly and to degrade aHIF1 3=UTRconstruct that containsAU-rich regions.
Meanwhile, mRNA pull down assay demonstrated that ZFP36L1 protein recog-
nized cell-cycle related transcripts. Overexpression of ZFP36L1 led to reduction
of Cyclin D1 and phospho-Rb in protein expression. Furthermore, SILAC data
unveiled interesting binding partners of ZFP36L1. Collectively, our fındings
propose that ZFP36L1might have a critical tumor suppressive role in breast and
bladder cancer by negatively regulatingmRNAwhose protein products cooper-
atively promote hypoxia and transition into S phase of cell cycle. Augmenting
ZFP36L1 function might disable the cell cycle and proliferation of aggressive
bladder tumors.
#4495 Elucidating BCL11A’s function in triple negative breast cancer.
Nicholas O. Stevers, Samantha L. Tinsley, Rebecca Moody, Chang-Ching Lin,
Jennifer Meagher, Jeanne A. Stuckey, Miao-Chia Lo, Duxin Sun.Univ. of Mich-
igan, Ann Arbor, MI.
It has been recently shown that the B-cell CLL/lymphoma 11A (BCL11A)
transcription factor is highly expressed in triple-negative breast cancer (TNBC)
and has critical functions in promoting tumor growth and mammary stem cell
maintenance. Studies in our group have found that the fırst twelve amino acids
(aa 1-12) of BCL11A are a conserved sequence that allows binding to retinoblas-
toma binding protein 4 (RBBP4). RBBP4, a histone binding protein, is involved
in many epigenetic complexes, including the Polycomb repressive complex 2
(PRC2), the nucleosome remodeling and deacetylase (NuRD) complex, and
SIN3A complex. Through these interactions BCL11Amay exert transcriptional
and epigenetic regulation. Herein we investigate the importance of BCL11A’s
interaction with RBBP4 and its function in TNBC. BCL11A-complex interac-
tions were observed through pull-down experiments of TNBC cell lysate utiliz-
ing aa 2-16 of BCL11A and a scramble control sequence. Our results demon-
strate that this 16-amino acid sequence is suffıcient to bind to RBBP4 and pull
down the PRC2, NuRD, and SIN3A complexes. Furthermore, the NuRD and
Sin3a complexes pulled down by BCL11A aa 2-16 retained their functionality as
observed through post pull-down histone deacetylase (HDAC) activity assays.
These results indicate signifıcantly higher HDAC activity in the wildtype se-
quence as compared to the scrambled sequence. To further investigate this in-
teraction, protein crystallizationwas conducted, the results of which validate the
binding betweenBCL11AandRBBP4.Additionally, a BCL11Apeptide (aa 2-12)
and a scramble control were transfected into the TNBC cell line SUM149. Anal-
ysis via flow cytometry shows a reduction of the ALDH cell population in the
BCL11A peptide transfected cells versus scramble control. We are currently
investigating the necessity of this 12-amino acid sequence in interactions with
RBBP4, PRC2, NuRD and SIN3A via co-Immunoprecipitation experiments us-
ing an N-terminal truncated BCL11A protein (del 2-12). The effects of full-
length BCL11A and del 2-12 on the ALDH cell population are also being
examined. These experiments will further delineate this sequence’s importance
in BCL11A-RBBP4 interactions.
#4496 Dissecting cellular heterogeneity using single cell RNA sequencing
in human lung tumors. Elise T. Courtois,1 Huipeng Li,2 Yuliana Tan,2 Daniel
Tan,3 Shyam Prabhakar,2 Paul Robson1. 1Jackson Laboratory, Farmington, CT;
2Genome Institute of Singapore, A-STAR, Singapore; 3National Cancer Center of
Singapore, Singapore.
Intra-tumor heterogeneity is a key determinant of tumor biology, treatment
response and patient survival. It is therefore essential to comprehensively char-
acterize the phenotypes and interactions of the diverse cells within the tumor
ecosystem. However, traditional molecular profıling studies have largely relied
on bulk-tissue analysis, which obscures the signatures of distinct cell popula-
tions. We present here an unbiased analysis of functional heterogeneity in
NSCLC (Non Small Cell Lung Cancer) cancers (Lung Adenocarcinoma and
Squamous Cell Carcinoma) and their microenvironment using RNA-seq pro-
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fıling of unsorted single cells from 20 primary tumors andmatched normal lung
tissue (NL). Using a new clustering algorithm RCA (Reference Component
Analysis), we identifıed themajor cell types composing the normal lung tissue as
well as the tumor ecosystem such as epithelial, fıbroblast, endothelial and im-
mune cells. Notably, we were able to identify resident alveolar macrophages, in
tumor and normal tissue and their single-cell differential expression analysis
revealed substantial differences in their gene expression. Similarly, we identifıed
blood-vessel endothelial cells in matched normal and tumor tissue, and identi-
fıed the differentially expressed genes in both cell types. Our unbiased approach
allowed us to study the diversity of the epithelial malignant cells present in
different tumors, highlighting the tumor and patient specifıc variability. To-
gether, the unbiased study of the NSCLC at the single cell level by sc-RNAseq
offers a powerful tool to provide insights into the transcriptomic variability
within the key cellular players of the tumorigenesis.
#4497 Single-cell protein-mRNA co-detection to reveals subpopulation-
specifıc correlation patterns. Haibiao Gong, Xiaohui Wang, Benjamin Liu,
Ilona Holcomb, Gajalakshmi Dakshinamoorthy, Aik Ooi, Gang Sun, Ramesh
Ramakrishnan. Fluidigm inc, Foster City, CA.
We have developed a streamlined workflow for multiplexed co-detection of
proteins andmRNAs in single reactions at single-cell resolution. This workflow
couples OER for protein detection with reverse transcription (RT) for mRNA
detection. In this study, we examined 31 overlapping targets, from a panel of 84
protein and 40mRNA assays, across three different cell lines (A549, SKBR3 and
K562). Unsupervised gene expression profıling analysis, including principal
component analysis and hierarchical clustering revealed different aspects of the
protein-mRNA relationship. The top 10 genes contributing to cell differentia-
tion were identifıed for both proteins and mRNAs, and eight of them overlap.
This result implies an overall concordance of certain protein andmRNAexpres-
sion in different cell lines.Our results also demonstrate that cells can be classifıed
into subpopulations based on protein-mRNA expression profıles, and different
subpopulations have distinct correlation coeffıcient values. The correlation be-
tween CCNB1 protein and mRNA was low (R  0.2884) in the whole popula-
tion. However, there was a subpopulation in which CCNB1 protein correlated
stronglywith itsmRNA.When this subpopulationwas analyzed, the R valuewas
0.8350, while therest of the cells had an R value of 0.0233. More interestingly, in
subpopulation I CCNB1 protein level correlated positively with CCNA2 protein
(R 0.9102) but negatively with CCNE1 protein(R 0.5249). The observed
correlation patterns of these genes match their known expression profıling at
cell-cycle phases of S, G2 and M, suggesting that this subpopulation may repre-
sent actively dividing cells. This study further indicated that systematic compar-
isons of protein and mRNA expression data in single cells can reveal additional
layers of complexity which are not attainable at bulk levels.
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#4498 Targeting IRE1a-XBP1 signaling in lung cancer.Michael J. Crowley,
Shira Yomtoubian, Geoffrey Markowitz, Nasser K. Altorki, Dingcheng Gao,
Juan Cubillos-Ruiz, Vivek Mittal.Weill Cornell Medical College, New York, NY.
Every year 1.5million people die from lung cancerworldwide. Approximately
15-30%of non small cell lung cancers (NSCLC) are driven byKRASmutations
and currently possess no viable therapeutic options. As such the discovery of
effective therapeutic alternatives for the treatment of KRAS driven NSCLC are
sorely needed. One prospect being explored in other solid tumors, but currently
unexplored in NSCLC, is targeting the endoplasmic reticulum (ER) stress re-
sponse. Adverse conditions in tumors such as hypoxia, nutrient starvation and
reactive oxygen species disrupt protein folding, and induce ER stress. The most
evolutionarily conserved pathway by which this insult is alleviated is the IRE1-
XBP1 axis, which responds by increasing the expression of a broad range of
protein folding and quality control genes. Previous work has demonstrated that
several cancers utilize this pathway to promote tumorigenesis, progression, ep-
ithelial to mesenchymal transition and metastasis. A preliminary analysis of a
tissue microarray containing 304 human NSCLC samples, 254 demonstrated at
least some positivity and50% were strongly positive for the active isoform of
XBP1. Given these preliminary fındings we investigated the status of IRE1a-XB1
in our murine orthotopic model and confırmed the activation of IRE1a-XBP1
signaling in tumor cells in the context of the tumormicroenvironment. Further-
more, in both cell types we can see the activation of canonical downstream
targets of XBP1. Utilizing the CRISPR-CAS9 system, we knocked out IRE1a in
the orthotopic tumor cell line. IRE1a abrogation was confırmed by western blot,
evaluating the fraction of active XBP1 after induced ER stress in vitro, and qPCR
of canonical downstream targets. Additionally, this knockout did not alter pro-
liferation or morphology in vitro. However, when tumors were grown orthoto-
pically, Cas9-IRE1a knockouts failed to growpast 10 days, whereas Cas9-Scram-
ble controls and the parental tumor line grew comparably until end stage. Given
these preliminary fındings and data from prior studies, we hypothesize that the
abnormal activation of the IRE1-XBP1 axis may influence KRAS NSCLC pro-
gression and aggressiveness and serve as a potential novel avenue for the treat-
ment of NSCLC. After probing the impact of the underlying mechanism on
tumor growth we will fınally evaluate the translational utility of targeting the ER
stress pathway with a small molecule inhibitor against IRE1a.
#4499 The oncometabolite fumarate prevents hypoxia-induced ER stress
by enhancing the pentose phosphate pathway. Luana Schito, Sergio Rey,
Bradly G. Wouters, Marianne Koritzinsky. Princess Margaret Cancer Centre,
Toronto, Ontario, Canada.
Cancer cells co-optmechanisms of adaptation to hypoxia tominimize energy
expenditure and halt proliferation thereby increasing hypoxic tolerance, amajor
factor contributing to chemo- and radioresistance in patients. The endoplasmic
reticulum (ER) kinase PERK is one of the three signaling transducers of the
unfolded protein response (UPR) that inhibits mRNA translation via eIF2
phosphorylation to alleviate hypoxia-induced ER stress. We have previously
shown that accumulation of fumarate, resulting from loss-of-function (LOF) of
the mitochondrial enzyme fumarate hydratase (FH), augments the antioxidant
capacity of hypoxic cancer cells through upregulation of the pentose phosphate
pathway (PPP). Here, we report for the fırst time that the fumarate-dependent
increase of antioxidants generated by the PPP prevents hypoxic activation of the
PERK¡eIF2 axis enabling protein synthesis and proliferation leading to an
impairment of hypoxic tolerance. HeLa (cervix), HCT-116 and LS174T (colon)
adenocarcinoma cells were transfected with lentiviral vectors encoding for shR-
NAs targeting FH. Immunoblot assays showed that FH LOF impaired PERK
activity under hypoxia thus inactivating eIF2. Moreover, the ability of fumar-
ate to prevent PERK activation was specifıc to hypoxia since fumarate did not
affect the pharmacological activation of the UPR by thapsigargin, DTT or tuni-
camycin. A comprehensive analysis utilizing a RT-qPCR array to profıle the
mRNA expression of 84 UPR genes, showed that FH LOF inhibited the UPR in
HCT-116 cells. A similar response was observed in patient-derived UOK262
kidney cancer cells whereby bi-allelic FHmutations resulted in downregulation
of 72% of the UPR genes whereas FH re-introduction restored UPR signaling.
We employed LS174T mucinous adenocarcinoma cells as a model to assess
protein synthesis.Mucin synthesis was not affected in hypoxic FH defıcient cells
whereas it was abrogated in wild-type cells. Consistent with these results, FH
LOF increased 3D spheroid growth and decreased clonogenic potential inHCT-
116 and HeLa cells. Pharmacological inhibition of the PPP by 6-aminonicotin-
amide activated the PERK¡eIF2 axis in FH silenced cells thereby suggesting
that PPP activation by fumarate is implicated in PERK inhibition. RNAseq data
analysis in melanoma, prostate, colon, breast, lung and renal cancers from
TCGAcohorts shows a negative correlation between PERK and the PPP enzyme
PGLS suggesting that the mechanism hereby delineated occurs in cancer pa-
tients. In conclusion, we show that fumarate impairs PERK¡eIF2UPR signal-
ing in hypoxic cancer cells. Clinical and molecular data show that UPR activa-
tion is one of the mechanisms responsible for chemo- and radioresistance in
hypoxic tumors. This study suggests that fumarate accumulation (either
through extrinsic or FH LOF) represents a novel approach to target hypoxic
cancer cells and improve patient prognosis.
#4500 Inhibition of PERK by small molecule inhibitors enhances the re-
sponse to ionizing radiation in vitro and animal tumor models. Ioannis Ver-
ginadis, Joel Encarnación, Souvik Dey, Constantinos Koumenis. Univ. of Penn-
sylvania School of Medicine, Philadelphia, PA.
Endoplasmic reticulum (ER) is a well organized membranous network, re-
sponsible for synthesis and folding of secretory and membrane proteins, lipid
and sterol biosynthesis and intracellular calcium storage. Perturbations in ER
lumen caused by depletion of Ca2 levels, hypoxia, nutrient deprivation, affect
the ERhomeostasis, a condition known as anER stress. In order to copewith this
stress, cells have developed an orchestrated biochemical response, termed Un-
folded Protein Response (UPR). Hypoxia, an ER stress inducer, is an important
and unique characteristic of the solid tumor microenvironment, promotes re-
sistance to radiotherapy and contributes to poor patient prognosis. Cancer cells
overcome these stress conditions through activation the PERK-eIF2 armof the
UPR, leading to inhibition of global protein synthesis and cell survival. We
hypothesize that the use of small molecule PERK inhibitors will decrease the
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survival of hypoxic cells and eventually sensitize them to irradiation. In this
studywe used highly radioresistantmelanoma and head and neck squamous cell
carcinoma cell lines B16F10-ova and SQ20B, under nomroxia and hypoxia,
respectively. We used two specifıc PERK inhibitors (PERKi) and tested for their
effıcacy both in vitro and in vivo. Induction of ER stress in both cell lines, either
by treatmentwith the pharmacologic agents thapsigargin (TG) and tunicamycin
(TN), or by exposure to hypoxic conditions (0.2%), was evaluated by activation
of PERK and its downstream targets. Pre-treatment of stressed B16F10-ova and
SQ20B cells for 2h with PERKi (1M), caused complete inhibition of PERK-
eIF2a-ATF4-CHOP arm of the UPR. Moreover, both cell lines pre-treated with
PERKi presented a signifıcant decrease in survival fraction under ER-stress in-
duced by TG (0.5M) as well as under hypoxia (0.2%) along with increasing
doses of irradiation (IR). For the in vivo experiments, nude and C57BL/6 mice
were treated with either 100mg/kg of PERKi by oral gavage, twice a day for
3weeks, or IR or a combination of PERKi and IR. Mice treated with PERKi
showed a small but not signifıcant delay of tumor growth in both backgrounds of
mice. However, combined treatment with IR (12 and 15Gy) caused a signifıcant
reduction of tumor volume as well as a delayed tumor growth which was signif-
icantly more pronounced in the immunocompetent mice. Data from flow cy-
tometry analysis of one of the the PERKiIR treated tumors fromC57BL/6mice
showed that there is a signifıcant infıltration of CD3 cells as well as signifıcant
higher number of CD3CD8 cells compared to the untreated mice or mice
treated with either PERKi or IR alone. Collectively, our results show that PERKi
effectively reduces the survival of hypoxic B16F10-ova and SQ20B cells and
sensitize them to IR in vitro and in tumors. Further experiments will clarify
whether PERKi have a dual role on reducing the hypoxic fraction and direct
recruitment of the cytotoxic T-cells.
#4501 CEBPD is an early endoplasmic reticulum stress response gene im-
plicated in breast cancer cell survival. Namratha Sheshadri, Shikha Sharan,
Esta Sterneck. National Cancer Institute, Frederick, MD.
CEBPD (C/EBP delta) is a member of the CCAAT-enhancer binding protein
(C/EBP) family of transcription factors characterized by a b-Zip domain that
mediates dimerization and DNA binding. CEBPD is induced in response to
acute stressors such as cytokine stimulation, bacterial lipopolysaccharide (LPS),
corticosteroids, radiation and hypoxia. We have previously reported that
CEBPD has dual functions in breast cancer by both attenuating or enhancing
oncogenic pathways depending on context (Balamurugan and Sterneck, 2013,
Mendoza-Villanueva et al., 2016). Recent studies reveal that elevated Endoplas-
mic Reticulum (ER) stress is associated with the pathology of several diseases
including cancer. Limiting supply of nutrients and oxygen in growing tumor
cells disrupts the protein folding homeostasis resulting in activation of the un-
folded protein response (UPR). The UPR includes pathways that support adap-
tation to stress, and that are also implicated in promotingmalignant features and
therapy resistance in breast cancer. Hence, we investigated a possible role for
CEBPD in this stress response pathway. Using breast cancer cell lines as model
systems, we found that CEBPD is dynamically regulated in response to chemical
and physiological inducers of ER stress. Kinetic analyses indicate that CEBPD
induction is concurrent with the activation of the UPR effectors XBP1s and
ATF4 suggesting a potential role in stress adaptation. Examination of the global
transcriptional prolife of the Thapsigargin-induced stress response in MDA
MB-231 cells indicated that CEBPD activates genes involved in cytokine and
chemokine production/signaling, immune cell recruitment as well as angiogen-
esis pathways. While XBP1s has been previously ascribed to activating these
pathways, the levels of activated XBP1 were not affected by CEBPD silencing.
This is the fırst report of a similar role for CEBPD in the ER stress response and
warrants the investigation of possible co-operation of CEBPD and XBP1 in the
UPR pathway. Further, we show that knock down of CEBPD in cancer cells
increased PARP cleavage and susceptibility to ER stress induced cell death.
CEBPD defıcient cells also displayed reduced LC3II accumulation, suggesting
impaired autophagy induction in response to ER stress. Taken together, our data
suggests that CEBPD is a novel proximal effector of the ER stress response in
breast cancer cells. Activation of this transcription factor regulates tumor pro-
moting inflammatory and angiogenic signaling pathways. Additionally, CEBPD
expression confers a survival advantage to cancer cells encountering ER stress.
Therefore, we propose that targeting CEBPD may sensitize cancer cells to ER
stress inducing therapeutics.
#4502 Heat shock protein 47 maintains cancer cell survival through its
inhibitory effect on ER stress sensor IRE1alpha activity. Akihiro Yoneda,1
Norio Takei,1 Kaori Sawada,1 Marina Kosaka,1 Kenjiro Minomi,2 Yasuaki Ta-
mura1. 1Hokkaido University, Sapporo, Japan; 2Nitto Denko Corporation, Sap-
poro, Japan.
Background and aims: Heat shock protein 47 (HSP47) is a collagen-specifıc
chaperone and is expressed in fıbroblasts and stromal cells that constitutively
produce and secrete several types of collagens. In a tumor microenvironment,
HSP47 is also highly expressed in cancer-associated fıbroblasts, involving in the
tumorigenesis through construction of the extracellular matrix. Intriguingly,
HSP47 is expressed in cancer cells in which almost no collagen is synthesized,
and its expression has been reported to be associated with malignant grade of
gliomas and poor prognosis of breast cancer. However, the functional signifı-
cance ofHSP47 in cancer cells remains unclear. Thus, the purpose of the present
studywas to clarify themolecularmechanismbywhichHSP47maintains cancer
cell survival and to explore the possibility of HSP47 becoming a therapeutic
target for tumors. Methods: Expression of HSP47, collagen type I and collagen
type IV mRNAs and proteins was examined in 13 human cancer cell lines by
real-time PCR and western blotting. After transfection of colorectal cancer cells
with HSP47 siRNA, cell proliferation, morphological features and apoptosis
were examined by flow cytometric analysis, transmission electron microscopy
andwestern blotting. To determine whether silencing of HSP47 expression sup-
presses tumorigenicity, anHSP47 siRNA-liposome complex was intratumorally
injected in colorectal tumor-bearing Balb/c nu/numice. Results: HSP47mRNA
and protein, but not collagen type I and collagen type IV, were expressed in 13
human cancer cell lines. Silencing of HSP47 in colorectal cancer cells markedly
caused apoptosis. Electron microscopic analysis revealed that dilation of the
endoplasmic reticulum (ER) in colorectal cancer cells was induced by silencing
of HSP47, similar to that evoked by ER stress. Furthermore, activation of the ER
stress sensor inositol-requiring protein 1alpha (IRE1alpha)/apoptosis signal-
regulating kinase 1/Jun-N-terminal kinase signaling pathway was responsible
for apoptosis of colorectal cancer cells by silencing of HSP47. Immunoprecipi-
tation of HSP47 and IRE1alpha showed that HSP47 forms a complex with
IRE1alpha in colorectal cancer cells under a basal condition. Persistent activa-
tion of IRE1alpha by silencing ofHSP47 triggered an increase in reactive oxygen
species in colorectal cancer cells followed by activation of the other ER stress
sensors PKR-like ER kinase and activating transcription factor 6alpha, resulting
in activation of the subsequent apoptosis-associated signaling pathway. Finally,
treatment of colorectal cancer cell-bearing mice with HSP47 siRNA resulted in
complete regression of colorectal tumors. Conclusion: These results suggest that
HSP47 sustains cancer cell survival through its inhibitory effect on IRE1alpha
activity and that targeted disruption of HSP47 might become a therapeutic mo-
dality for tumors.
#4503 Role of ER-associated degradation in rhabdomyosarcoma. Sara
Sannino, Christopher J. Guerriero, Jeffrey L. Brodsky. University of Pittsburgh,
Pittsburgh, PA.
Due to their higher proliferation rate, most cancers experience impaired
ATP generation, hypoxia, hypoglycemia, and increased genetic mutations
that may perturb cellular and protein homeostasis. Persistent stress condi-
tions induce the unfolded protein response (UPR) as well as increased ex-
pression of molecular chaperones, such as Hsp70, to modulate cell fate. Our
recent studies demonstrate how perturbing cytosolic Hsp70 activity with a
small molecule modulator, MAL3-101, induces rhabdomyosarcoma cell
(RMS13) death, patient-derived cells of one of the most common soft-tissue
cancers in children. MAL3-101 addition activates PERK- and CHOP-depen-
dent RMS13 cell death in a dose dependent manner (Sabnis et al., PNAS,
2016). To identify the mechanism that links UPR-triggered cell death and
cytosolic Hsp70 inhibition, an isogenic MAL3-101-resistant cell line was
generated (MAR4C). Even though both RMS13 and MAR4C cells were
equally sensitive to a diverse panel of therapeutic compounds, we now fınd
that they have different effıciencies of ER-associated degradation (ERAD), a
quality control pathway that degrades misfolded proteins in the secretory
pathway and that lessens proteotioxic stress. Specifıcally, MAR4C cells re-
move both soluble and membrane associated ERAD substrates faster than
RMS13 cells and possess increased levels of ubiquitinated proteins upon
proteasomal inhibition. These data suggest that higher ERAD effıciency is
required for MAR4C cell survival upon Hsp70 inhibition and highlight an
unexpected link between cytosolic Hsp70 inhibition and the ERAD pathway
in cancer cells. Moreover, RNAseq analysis suggests that select redox-related
ER quality control chaperones are differentially expressed between MAR4C
and RMS13 cells, and lower levels of the BiP and PDI chaperones and Per-
oxiredoxin 4 are found in MAR4C cells. Because new therapeutic agents as
well as reliable biomarkers are critically needed in rhabdomyosarcoma and
other cancers, this study sheds light on one mechanism of cancer pathogen-
esis and suggests that different cancer subtypes modulate ER quality protein
quality uniquely.
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#4504 Androgen receptor aggregation is a key regulator of endoplasmic
reticulum stress and cell survival in ETS-related gene driven prostate carci-
nogenesis. Taduru L. Sreenath,1 Natallia Mikhalkevich,1 Shashwat Sharad,1
Rishita Gupta,1 Oluwatosin Diaro,1 Kevin Babcock,1 Charles Xavier,1 Ahmed
Mohamed,1Muhammad Jamal,1 Shyh-Han Tan,1 Albert Dobi,1 Gyorgy Petrov-
ics,1 Isabell A. Sesterhenn,2 David G. McLeod,1 Inger L. Rosner,3 Shiv Srivas-
tava1. 1USUHS, Rockville,MD; 2Joint Pathology Center, Silver Spring,MD; 3Urol-
ogy Services, WRNMMC, Bethesda, MD.
Introduction and Objectives: Deregulated androgen receptor (AR) signaling
due to either mutations or altered expression of the AR and its cofactors (acti-
vators or suppressors) has been identifıed as critical in prostate cancer develop-
ment and progression. AR regulated oncogenic activation of Ets Related Gene
(ERG) represents one of the most common and validated prostate cancer driver
gene. In our recent studies using prostate specifıc ERG transgenic mouse pros-
tate glands, we observed novel morphological phenotypes of endoplasmic retic-
ulum (ER) stress. Since ARwas the critical regulator of ERG expression through
TMPRSS2 promoter in human prostate cancer, the present study was aimed
towards understanding the post-translational interactions betweenERGandAR
in ER stress and subsequent cell survival mechanisms in mouse and cell culture
models. Understanding such mechanistic insights will potentially have major
therapeutic implications. Methods: Histological phenotype in the mouse pros-
tate glandswere examined by light and electronmicroscopy. Cell culturemodels
of LNCaP, HEK293 and COS7 cells were utilized to examine the AR aggrega-
tions, Co-IP and Proximal Ligation Assay in the presence and absence of ERG.
Various domain deletions of AR were utilized to identify specifıc AR domain
interactions with ERG and its contribution in AR aggregation. Luminal cell
surface markers on the isolated mouse prostate glands and spontaneously im-
mortalized mouse prostate epithelial cells from ERG transgenic mouse (MoE1)
were analyzed by FACS analysis. Results: Co-expression of ERG and AR in
LNCaP and COS-7 cells showed signifıcant aggregation of AR in fılter assays.
Co-IP experiments and PLA assays in VCaP, LNCaP and HEK 293 cell revealed
that ERG physically interacts with AR. Epithelial cells of ERG-Tg mouse pros-
tates showed 70% increase in CD49f (low) and Sca-1 (med) population with
increased sphere formation capability and resistance to radiation induced cell
death. Both epithelial cells grown into spheres and established MoE1 cells dis-
played increased CD49f (low) and signifıcant increase in the EpCAM negative
population. Conclusions: Overall, our experiments demonstrate the mechanis-
tic link that the physical interactions between ERG and AR initiate the ER stress
in prostate epithelium through AR misfolding/aggregation. Our observation of
ERG induced AR aggregation is one of the initial events that lead to ER stress to
cell survival indicate a critical function for ERG in the etiology of prostate cancer
initiation and progression. Funding: This research in part was supported by the
National Cancer Institute R01CA162383 (S. S.) and HU0001-10-2-0002 funds.
#4505 Activating transcription factor-6 dependent regulation of Rheb-
mTORandNotch signaling contributes to chemoresistance in osteosarcoma.
Suma Yarapureddy,1 Pooja Hingorani,2 Saravana Kumar,1 Omar Asad,1
Jazmine Abril,1 Veena Sharath,1 Paul Dickman,2 Aparna C. Sertil1. 1University
of Arizona College of Medicine-Phoenix, Phoenix, AZ; 2Phoenix Children’s Hos-
pital, Phoenix, AZ.
The standard treatment for patients with newly diagnosed osteosarcoma (OS)
consists of surgery in combination with multi-agent chemotherapy. However,
the optimal treatment strategy for patients with refractory and/or metastatic
disease is yet to be defıned and continues to be a persistent challenge in osteo-
sarcoma treatment. The high degree of genetic aberrations and tumor heteroge-
neity has impeded the identifıcation and testing of new and effective therapeutic
targets. Therefore, fınding and characterizing cellular mechanisms, which con-
tribute to OS chemoresistance could be one promising strategy for designing
therapies that can change the outlook for patients with this disease. Due to the
well-known role of unfolded protein response (UPR) in promoting chemoresis-
tance in solid tumors our objective here is to examine how this promotes
chemoresistance in patients with OS. Using in silico pathway analysis of gene
expression datasets from patients with OS we found that protein processing in
the ER was one of the pathways that was signifıcantly enriched in OS tumors
compared to normal tissue. We then examined whether the UPR sensors
ATF6, PERK and IRE-1were also activated inOS cells in vitro. Usingwestern
blotting, qPCR and immunofluorescence we confırmed that all three UPR path-
ways were activated in humanOS cell lines. However we found that only ATF6
activation signifıcantly enhanced chemoresistance to cisplatin, irinotecan and
combinatorial treatment with cisplatin and the mTOR inhibitor rapamycin.
This occurred via inhibition of Bax activation, suppression of RHEB-mTORand
NOTCH signaling. Our fındings highlight a novel mechanism of chemo–resis-
tance in OS. Furthermore, retrospective analysis of banked OS patient samples
for ATF6 expression followed by a preliminarymultivariate analysis usingCox
regressionmodel showed that high levels of nuclearATF6, was an independent
prognostic indicator while also taking into account the presence of metastases
and tumor site. Moreover, we found that while 50% patients with high nuclear
ATF6 levels had a poor histologic response to treatment only 32%patientswith
low nuclear ATF6 expression suggesting that ATF6 activation could be asso-
ciated with resistance to chemotherapy and poor outcome for OS patients. Our
fındings emphasize a role forATF6 as the nexus of a versatile signaling network
that regulates pathways that are crucial for the pathogenesis and therapy resis-
tance of osteosarcoma.Hence therapeutic targeting of theATF6pathway holds
promise as an innovative and effective treatment strategy for OS.
#4506 UPR biomarker expression correlates with inhibition of migration
of TNBC cells treated with low doses of chemotherapy. Annat Raiter,1 Julia
Lipovetsky,1 Britta Hardy,1 Rinat Yerushalmi2. 1Tel Aviv University Medical
School, Petach Tikva, Israel; 2RabinMedical center and Tel Aviv UniversityMed-
ical School, Petach Tikva, Israel.
Much attention has been directed to the study of triple-negative breast cancer
(TNBC) because of its short disease-free interval from diagnosis and more ag-
gressive course in the metastatic setting. TNBC also lacks specifıc target recep-
tors for treatment. Third-generationmetronomic chemotherapy using available
agents that target DNA repair complexes (i.e., taxanes), and cell proliferation
(i.e., anthracycline) have shown promise results. However, specifıc regimens for
TNBC at the different disease stages have not been clearly defıned. Therefore,
researchers are seeking molecular biomarkers to predict response to current
chemotherapeutic agents. In a previous study of TNBC, we demonstrated that
low doses of anthracyclines and taxanes, which are known to increase endoplas-
mic reticulum stress, increased tumor cell expression of glucose-regulated pro-
tein 78 (GRP78), a key regulator of the unfolding protein response (UPR), re-
sulting in tumor cell apoptosis. GRP78 gene expression is upregulated via
CREB2L1, an endoplasmic reticulum transmembrane transcription factor and
member of the CREB/ATF family of transcription factors. CREB3L1 is a meta-
static suppressor and functions as a transducer of UPR. The aim of the present
study was to investigate the effect of low doses of doxorubicin and paclitaxel on
UPR activation in metastatic TNBC cells by determining CREB3L1 protein ex-
pression in correlation to cell-surface GRP78 expression. Furthermore, we re-
lated CREB3L1 and cell-surface GRP78 expression with the migration potential
of the cells in response to treatment. We found that metronomic doses of doxo-
rubicin signifıcantly induced CREB3L1 and cell surface GRP78 expression in
TNBC cells. CREB3L1 increased by 2.5-fold in MDAMB231 and by 3-fold in
MDAMB468 (p0.04); GRP78 increased by 3.7-fold and 6.1-fold, respectively
(p0.01). Similar results were obtained with low doses of paclitaxel. A strong
correlation was observed between CREB3L1 and cell-surface GRP78 protein
expression. The increased expression of both proteins in MDAMB231 (highly
metastatic) and MDAMB468 (moderated metastatic) was associated with sig-
nifıcant inhibition of the migration capacity of the treated TNBC cells. In con-
trast, the migration capacity of treated estrogen-positive MCF7 cells (non-met-
astatic) and Her2- positive BT474 cells (highly metastatic) was poorly inhibited,
coinciding with a non-signifıcant increase in CREB3L1 and GRP78 expression.
The results demonstrated that the drug effect via theUPRwas specifıc for TNBC
and unrelated to the metastatic profıle of the cells. This study is the fırst stage in
the identifıcation of UPR-related biomarkers of benefıcial outcome of metro-
nomic chemotherapy for TNBC. Futuremechanistic studies should focus on the
possible use of cell surface GRP78 and CREB3L1 as targets for combination
therapies.
#4507 Upregulation of unfolded protein response (UPR): A novel activity
of the tumor suppressor klotho in colorectal cancer. Tal Etan, Tammi Rubin-
stein, Tami Rubinek, Shiri Shahmoon, ChenVarol, Ehud Zigmond, Rina Rosin-
Arbesfeld, Iris Barshack, Ido Wolf. Tel Aviv Medical Center, Tel-Aviv, Israel.
Klotho is a transmembrane protein, which can be shed and act as a circulating
hormone.Klotho-defıcientmicemanifest a syndromeresemblingacceleratedaging,
while klotho overexpression extends life span.We previously identifıed klotho as a
breast and pancreatic tumor suppressor and as an inhibitor of the IGF-1 pathway.
Recent data indicate klotho as a tumor suppressor in an array of malignancies,
including colorectal cancer (CRC). We aimed to decipher the role of klotho as a
tumor suppressor in CRC. Analysis of a public database (Oncomine) indicated re-
duced expression of klotho in CRC. Twomodels were employed to study the effect
of klotho in vivo.Using the azoxymethane inflammationmodel, we discovered that
klotho inhibited colon polyp formation. Using an orthotopic model consisting of
direct injection of MC38 cells to the mice colons, we found that klotho inhibited
colonicobstructionand tumor formation. Similarly, klotho inhibited colony forma-
tion and proliferation of CRC cell lines. Aberrant activation of the canonical Wnt
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pathway is implicated in CRC development and progression. -catenin, the key
effector of this pathway, functions with T-cell factor/lymphoid-enhancer-factor
(TCF/LEF) to activate expressionofWnt target genes.Whilewedidnot see an effect
ofklothoon the IGF-1pathway, it reducedWnt3Aand-catenin levels asmeasured
byWestern blotting, and inhibited TFC/LEF transcriptional activation in luciferase
assay. As transcriptional inhibition was abrogated by a constitutively active
-catenin, we suspected that klotho inhibited the pathway upstream of -catenin.
Indeed, co-immunoprecipitation analyses indicated direct interaction between
klothoandWnt3A.Yet, the inhibitoryeffectofklothoonCRCcell colony formation
wasonlypartially rescuedbyaconstitutivelyactive-catenin.Thesedata indicateon
additionalmechanisms involved in theTS activity of klotho.Thus,we conducted an
RNA expression array and observed involvement of klotho in endoplasmic reticu-
lum (ER) stress and unfolded protein response (UPR). Further studies showed that
klotho induced elevation in XBP1 RNA levels, GRP78 protein levels, and eIF2
phosphorylation, all indicative of UPR regulation. Importantly, pharmacologic in-
hibition of ER stress and UPR overcame the growth suppression effect of klotho in
CRC cells. Our data indicate klotho as a potent tumor suppressor in CRC, and
suggest its role at very early stages of tumor formation, already at polyp formation.
Our data also indicate, for the fırst time, klotho as a regulator of ER stress andUPR
incancer.These fındingsmaypave theway for thedevelopmentofnovel therapeutic
strategies based on enhancement of UPR.
#4508 Penfluridol-induced endoplasmic reticulum stress leads to au-
tophagy-mediated pancreatic tumor growth suppression. Alok Ranjan,
Sharavan Ramachandran, Nehal Gupta, Sanjay Srivastava. Texas Tech Uni.
Health Science Center, Amarillo, TX.
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the
United States. Experimental and clinical evidences suggested that high basal
state autophagy in pancreatic tumors could induce resistance to chemothera-
pies. Recently, we have demonstrated that penfluridol suppresses pancreatic
tumor growth by autophagy-mediated apoptosis both in vitro and in vivo. (Ran-
jan and Srivastava, Scientifıc Reports: 2016;6:26165; PMID: 27189859), however
the mechanism of autophagy induction by penfluridol was not clear. Several
studies have established that endoplasmic reticulum (ER) stress could lead to
autophagy and inhibit tumor progression. In the current study, we demon-
strated that penfluridol induced ER stress in BxPC-3, AsPC-1 and Panc-1, pan-
creatic cancer cell lines as indicated by up regulation of ER stressmarkers such as
BIP, CHOP and IRE1 after treatment with penfluridol in a concentration-
dependentmanner. Inhibiting ER stress by pre-treatment with pharmacological
inhibitors such as sodium phenylbutyrate and mithramycin or by silencing
CHOP using CHOPsiRNA, blocked penfluridol-induced autophagy. These re-
sults clearly indicated that penfluridol induced ER stress lead to autophagy in
our model. Western blot analysis of subcutaneously implanted AsPC-1 and
BxPC-3 tumors as well as orthotopically implanted Panc-1 tumors demon-
strated upregulation of BIP, CHOP and IRE1 expression in the tumors lysates
from penfluridol treated mice as compared to tumors from control mice. Alto-
gether, our study established that penfluridol induced ER stress mediated au-
tophagy in pancreatic tumor. Our study opened a new therapeutic target for
advanced chemotherapies against pancreatic cancer. (Supported in part by RO1
grant CA129038, awarded by National Cancer Institute, NIH).
#4509 GRP78 is neither expressed on ER-/PR-/Her2- human breast cancer
cell surface nor secreted in the culture media. Jesus E. Serrano,1 Eva C. Ro-
mero-Nutz,1 Neysharie Sanchez,1 Aditi Banerjee,1 Krishna Baksi,2 Dipak K. Ba-
nerjee1. 1Univ. of Puerto Rico, San Juan, PR; 2Universidad Central del Caribe,
Bayamon, PR.
GRP78 (Mr78 kDa) is a glucose regulated protein. It is a member of the heat-
shock protein (HSP) family but located in the lumen of the endoplasmic reticu-
lum (ER). Its function as ER chaperone translocating protein across the ER
membrane that needs to be glycosylated at the asparagine residue present in the
sequeon Asn-X-Ser/Thr (N-linked glycosylation) is well recognized. This im-
portant biochemical event is essential for glycoprotein folding and function. For
example, when the protein N-glycosylation is impaired with tunicamycin a pro-
tein N-glycosylation inhibitor, angiogenesis, a hallmark for tumor progression
and metastasis is inhibited due to an induction of ER stress. Under such condi-
tion, GRP78 is overexpressed inmicrovasculature and in tumor tissue, conclud-
ing that GRP78 is a master regulator in ER stress induced unfolded protein
response (upr)-mediated apoptosis in tumor microvasculature (J. Biol. Chem.
286, 29127-29138, 2011; Pure Appl. Chem. 84, 1907-1918, 2012). This contra-
dicts the current dogma that supports GRP78 expression on the tumor cell
surface interferingwith the therapeutic(s) andmaking themas tumor promoters
instead. To evaluate the GRP78 localization, we have used ER-/PR-/Her2- (i.e.,
triple negative) human breast cancer cell line MDA-MB-231 (Caucasian) cul-
tured normally orwithout serumaswell as before or after inducing the ER stress.
After establishing the expression of GRP78 mRNA by qPCR and protein by
western blotting, we focused on its cell surface expression. Unfıxed cells were
stained with Concanavalin A (Con A; Specifıcity  -D-Mannose, -D-Glu-
cose, branched mannose), wheat germ agglutinin (WGA; Specifıcity  (Gl-
cNAc--(1,4)-GlcNAc)1-4-GlcNAc-NeuAc) as well as with anti-GRP78 an-
tibody followed by their detection by immunofluorescence microscopy using
either Rhodamin or Alexa-conjugated secondary antibody. The fluorescence
images were captured in a Zeiss microscope with Axiocam camera. Con A and
WGA staining provided images of N-glycans on the cell surface and supported
the intactness of the cellmembrane.On the other hand, GRP78 fluorescencewas
absent from the surface of these cancer cells. Similar results were also obtained
irrespective of cells cultured in the absence of serum and/or in the presence of
1g/mL of tunicamycin. GRP78 fluorescence however was detected in cells after
either fıxing them with ice-cold methanol or after permeabilization with digi-
tonin. In addition, western blotting also failed to detect GRP78 in the culture
media of MDA-MB-231 cells. We, therefore, conclude that GRP78 is neither
expressed on the outer-leaflet of the cell surface of ER-/PR-/Her2- human breast
cancer cells MDA-MB-231 nor secreted in the culture media. Supported in part
by Susan G. Komen for the Cure BCTR0600582 and NIH/NIMHD
G12MD007583 (KB).
#4510 ADP- dependent glucokinase controls hypoxic gradients, ex vivo
avascular and in vivo tumor growth through modulation of HIF-1/mTOR
signaling. Sergio Rey, Luana Schito, Marianne Koritzinsky, Bradly G.Wouters.
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
ADP- dependent glucokinase (ADPGK) is an evolutionarily conserved ar-
chaeal glycolytic enzyme frequently upregulated in human cancers whose role
remains elusive. We have recently discovered that ADPGK contributes to ROS-
dependent stabilization of hypoxia- inducible factor (HIF)-1 (and -2) and
hypoxic target gene transactivation in cancer cells. Hereby, we deconvolute the
effect of ADPGK loss-of-function (LoF) upon the 3D hypoxic tumor microen-
vironment, a crucial pathobiological aspect determining therapeutic responses
in cancer patients. ADPGK, HIF-1 and HIF-2 LoF was attained through
shRNA- mediated knockdown (75%) in HCT-116 colon cancer cells. HIF-1
(and -2) transcriptional activity was measured through RT-qPCR arrays
whereas protein levels were assessed by immunoblot. O2 and glucose consump-
tionweremeasured in 2Dwith a real-time bioanalyzer (Seahorse). Avascular 3D
spheroids and xenografts were used to measure the effect of ADPGK LoF upon
tumor growth. Hypoxic gradients in 3D tumor spheroids were quantifıed using
the O2- sensitive nitroimidazole probe EF5 in combination with confocal mi-
croscopy and 3D image reconstruction. RT-qPCR arrays identifıed a core group
of 11 hypoxia- inducible transcripts dependent upon ADPGK expression (CA9,
DDIT4, ERO1L, Igfbp3, Scl2a3, Bhlhe40, Bnip3L, Egln1, Fam162a, Pgk1 and
PKM), henceforth referred to as ’ADPGK- dependent HIF- target signature’
(ADHTS). Comparison of ADHTS transcriptional profıles with HIF-1 or -2
defıcient cells showed that ADPGKLoF is not selective for eitherHIF- paralog.
Since ADHTS contained genes critical for mTOR signaling, glycolytic activity
andmitochondrial autophagy, we performedmetabolic profıling and found that
ADPGK LoF increased O2 consumption in a rapamycin- sensitive manner
whilst increasing mitochondrial mass. Moreover, ADPGK LoF enhanced xeno-
graft growth and vascularization associated with decreased protein levels of
HIF-2 and the negative mTOR regulator DDIT4. In avascular 3D spheroids,
ADPGK LoF increased growth, intra-spheroidal hypoxia and caused steeper
hypoxic gradients in parallel to enhanced mTOR¡pS6K¡p4EBP1 signaling.
RNAseq data from colon adenocarcinoma patients (TCGA; n 382) confırmed
that ADPGK expression correlates with ADHTS, HIF- target gene expression,
hypoxia scores and decreased overall survival. Consistent with our preclinical
fındings, the ADHTS gene signature inversely correlated with an mTOR gene
signature in the same dataset. Our results uncover a hitherto unknown function
of ADPGK as a crucial determinant of the degree and distribution of hypoxia
within the tumor microenvironment through modulation of HIF-1¡mTOR
signaling. Our analysis of TCGAdata supports these preclinical fındings thereby
suggesting that ADPGK is a suitable therapeutic target in patients bearing hy-
poxic cancers.
#4511 HIF-1-dependent regulation of creatine kinase metabolism pro-
motes breast cancer invasion and metastasis. Hilaire Barch, Danielle L.
Brooks, RayaKrutilina, Luciana P. Schwab,Deanna Parke, TiffanyN. Seagroves.
Univ. of Tennessee Health Science Ctr., Memphis, TN.
Dysregulated tumor cell metabolism is a hallmark of cancer progression and
therapeutic resistance. In a screen for Hypoxia-Inducible Factor (HIF)-depen-
dent genes regulating metabolism, we identifıed creatine kinase, brain isoform
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(CKB) as down-regulated in HIF-1 knockout mammary tumor cells. Creatine
kinases (CKs) reversibly catalyze the transfer of a high-energy phosphoryl group
from ATP to creatine, generating phosphocreatine in the forward reaction, and
ATP in the reverse reaction. CKs are up-regulated in a variety of solid tumors,
including ovarian, breast, colon, lung and brain. Knockdown of CKB in the
polyoma middle T (PyMT) transgenic mouse model of metastatic breast cancer
suppressed the production of intracellular ATP and invasion in vitro, and inhib-
ited metastasis from the mammary gland to the lung in vivo. CK activity is
known to be inhibited by cyclocreatine, a creatine kinase substrate that represses
CK-dependent generation of ATP fromphosphocreatine.When female FVB/Nj
mice were injected with wild type PyMT cells in a tail vein assay and then treated
with cCr (1g/kg/day, IP), lung metastasis was repressed to the same extent as
Ckb gene knockdown. Moreover, when cCr therapy was administered 7 days
after tail vein injection, cCr was effective in preventing the transition of lung
micrometastases to macrometastases. To explore the role of CK activity in reg-
ulating cell proliferation, survival in suspension, cellular metabolism and inva-
sion, we next created CKB loss- and gain-of-function models using human
breast cancer cell lines, and compared phenotypes to cCr treatment. Whereas
deletion of CKB had no effect on cell proliferation or survival in adherent con-
ditions or in suspension, either deletion of CKB or cCr therapy potently reduced
ATP levels and invasive potential in vitro. Preliminary data also indicate that
pre-treatment of triple negative breast cancer cell lineswith cCr sensitizes cells to
doxorubicin. Together, these data suggest that inhibition of CK activity may be
effective in treating stage IV breast cancer.We are currently testing whether cCr
has anti-metastatic effıcacy as a monotherapy, or in combination with conven-
tional chemotherapies, using luciferase-labeled patient-derived xenograft
(PDX) models. This work was sponsored by the NIH (CA138488), the Dept. of
Defense (BC150640), the METAvivor foundation, and the West Cancer Center
in Memphis, TN.
#4512 The landscape of hypoxia-driven alternative splicing in breast can-
cer. Hani Choudhry,1 Spyridon Oikonomopoulos,2 Peng Yu,3 Cristina Ivan,4
Mircea Ivan,5 Adrian L. Harris,6 Jiannis Ragoussis2. 1Cancer Metabolism and
Epigenetics Unit, King Abdulaziz University, Jeddah, Saudi Arabia; 2McGill Uni-
versity, Quebec, Canada; 3Texas A&M University, TX; 4MD Anderson Cancer
Center, TX; 5Indiana University, IN; 6University of Oxford, United Kingdom.
Tumor hypoxia is generally associated with poor patient outcome and resis-
tance to therapy.Hypoxia has an impact onmultiple pathways inside the cell and
awidespread effect on phenotype. Here we determined the changes in transcript
architecture that arise as result of alternative splicing in hypoxic cells. A panel of
breast cancer cell lines that include the Luminal A and B, HER2, Triple-Neg-
ative subcategories grown in hypoxic and normoxic conditions were subjected
for deep RNA-sequencing. Depending on the cell lines we found between 23-
927 splicing events with 3-45% of them also present in the differentially ex-
pressed fraction of genes. This points to an extensive isoform switching control
independently of the transcriptional control of the genes themselves. The splic-
ing events appear on genes responsible for mRNA processing (splicing, nuclear
export and catabolism) as well as initiation of translation. Members of the SR
family of proteins involved in RNA splicing, appear to be potential regulators of
the biogenesis of the hypoxia specifıc splicing events. The differentially spliced
exons are frequently part of both the coding and noncoding isoforms of a given
gene potentially indicating a switch between these two types under hypoxia. Ten
of the hypoxia specifıc splicing events were also found to be associated with the
hypoxia status of primary breast cancer samples taken from The Cancer Ge-
nomeAtlas (TCGA) database. Altogether, these data demonstrate the important
role of hypoxia in driving alternative splicing events in breast cancer.
#4513 Investigation of bystander effects of hypoxia activated prodrugs
using three dimensional cell cultures. Cho Rong Hong, Gib Bogle, William R.
Wilson, Kevin O. Hicks. University of Auckland, New Zealand.
Background: Hypoxia in solid tumors acts as the major barrier to anti-
cancer therapies and promotes tumor progression. Hypoxia-activated pro-
drugs (HAPs) are designed to not only eliminate these resistant cells, but also
to exploit hypoxia as a basis of tumor selectivity. A key concept in exploiting
hypoxia with HAPs is that active drug metabolite should be able to diffuse
from hypoxic zones to maximize effect in surrounding aerobic tumor tissue.
There is some evidence that these ’bystander effects’ contribute to the anti-
tumor activity of HAPs, but currently there is a lack of robust methods for
their detection. Objectives: To investigate bystander effects from HAPs in a
novel spheroid co-culture system using PR104A which releases a diffusible
DNA crosslinkingmustard and the tirapazamine analogue SN30000 which is
converted to a short lived radical that is not expected to diffuse out of cells.
Methods: A new method for measuring the bystander effect with multicel-
lular spheroids under hypoxic conditions was developed using co-cultures of
HCT116 colon cancer cells with high metabolic capacity for HAP metabo-
lism (activators, transfected to overexpress cytochrome P450 reductase
[POR]) and cells that cannot activate HAPs effıciently (targets, with POR
knocked out by zinc fınger nuclease gene targeting) along with differential
antibiotic resistance and fluorescent protein markers to enable their quanti-
tation in mixed cultures. Sensitivity of activators and targets to PR104A and
SN30000 was determined in spheroid co-cultures by dissociation and clono-
genic cell survival assay. Results were compared to output of a novel agent-
based mathematical model (ABM) of spheroid co-cultures. Results: In
monolayer cultures, activator cells showedmarkedly higher sensitivity to the
HAPs than did targets. Tagging of activators and targets with fluorescent
proteins allowed visualization of their spatial distribution in spheroid co-
cultures. When spheroids were treated with PR104A, killing of targets mark-
edly increased with increasing proportion of activators, confırming a by-
stander effect. However, increasing proportions of activators reduced cell
killing of targets after SN30000 treatment, suggesting that rapid metabolism
by activators inhibits its penetration, which was confırmed by flux experi-
ments in multicellular layer co-cultures. ABM simulations of cell killing by
PR104A and SN30000 in spheroids using our published transport parame-
ters agreed with experimental results indicating diffusion of active metabo-
lites of PR104A but not SN30000. Discussion: Using this novel spheroid
co-culture model, a bystander effect of PR104A was demonstrated while
SN30000 showed no bystander effect. This is the most direct demonstration
of a hypoxic bystander effect for PR104A to date, and demonstrates the
utility of the novel spheroid ABM in simulating active metabolite diffusion
in 3D co-cultures.
#4514 Low release of exosomal miR-663a from hypoxic tumor cells and
poor tumor response to neoadjuvant radiotherapy in rectal cancer patients.
Tonje Bjørnetrø,1 Karianne R. Handeland,1 Sebastian Meltzer,1 Rampradeep
Samiappan,2 Lars G. Lyckander,1 Caroline Jegerschöld,2 Linda Sønstevold,1
Nirujah S. Thusyanthan,1 Kathrine R. Redalen,1 Anne H. Ree1. 1Akershus Uni-
versity Hospital, Oslo, Norway; 2Karolinska Institute, Stockholm, Sweden.
Introduction: Hypoxia is an important hallmark of the tumor microenviron-
ment and contributes signifıcantly to radiotherapy resistance in solid tumors.
Exosomes are nanosized vesicles actively released from tumor cells, and recent
studies support their central role in the aggravated biology caused by tumor
hypoxia through their miRNA cargo. In this study, we aimed to characterize
miRNAs of exosomes from hypoxic colorectal cancer (CRC) cell lines and in-
vestigate thesemiRNAs in circulating exosomes from rectal cancer patients with
poor response to neoadjuvant radiotherapy. Methods: Five CRC cell lines were
cultured in RPMI-1640 medium supplemented with 1% bovine serum albumin
under normoxia (21% O2) or hypoxia (0.2% O2) for 24 hours. Exosomes were
isolated from conditioned media by differential ultracentrifugation, and integ-
rity and size were determined by cryo-electron microscopy and NanoSight
tracking analysis and further characterized byWestern blot and flow cytometry
analyses. In a prospective biomarker study, plasma samples were collected from
29 patients with rectal cancer at the time of diagnosis, and histologic tumor
response (tumor regression grade, TRG) to neoadjuvant radiotherapy was eval-
uated. Exosomes were isolated from plasma using the miRCURY™ Exosome
Isolation Kit (Exiqon). Expression profıling of exosomal miRNAs of the CRC
cell lines and the patients’ plasma samples was conducted using the miRCURY
LNA™Universal RTmicroRNA PCRHuman panel I (Exiqon). Data normaliza-
tionwas performed based on global arraymean. Results: Normoxic and hypoxic
CRC cells released vesicles, 30-150 nm in size, that expressed proteins known to
be enriched in exosomes (CD9, CD63, CD81, Alix) and with absence ofmarkers
of the endoplasmic reticulum (GRP78, Calnexin) and the Golgi apparatus
(GM130). Exosomes from the CRC cell lines harbored strong cell line-specifıc
miRNA profıles; however, when comparing the hypoxic cell lines collectively
with the normoxic counterparts, four exosomal miRNAs (miR-195-5p, miR-
423-3p, miR-622, miR-663a) were signifıcantly down-regulated by hypoxia. Of
these, circulating exosomal miR-663a was lower (p  0.033) in rectal cancer
patients with poor tumor response (TRG 2-3) to neoadjuvant radiotherapy.
Conclusion: Vesicles released from CRC cell lines were characterized as exo-
somes carrying miRNAs that were retrieved in the circulation of rectal cancer
patients, where low level of exosomal miR-663a at the time of diagnosis was
associated with poor tumor response to neoadjuvant radiotherapy. These fınd-
ings suggest that repressed release of miR-663a from tumor cells into the circu-
lationmay be amarker of radiotherapy resistance caused by tumor hypoxia. The
results are currently under validation in an independent patient cohort. Trial
registration: NCT01816607
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#4515 Metabolic stress sensorMondoAmediates in vivo aggressiveness of
common ALL by induction of HIF1. Alexandra A. Sipol,1 Thomas G.
Grunewald,2 Juliane Schmaeh,3 Monique L. den Boer,4 Rebeca Alba Rubío,2
Michaela Baldauf,2 Caroline Wernicke,1 Martin Horstmann,5 Gunnar Cario,3
Günther Richter,1 Stefan Burdach1. 1Technische Universität München, Munich,
Germany; 2Ludwig-Maximilians-Universität München, Munich, Germany;
3Schleswig-HolsteinUniversityMedical Center, Kiel, Germany; 4ErasmusUniver-
sity Medical Center, Rotterdam, Netherlands; 5University of Hamburg Medical
Center, Hamburg, Germany.
Tumor cells evolve adaptive mechanisms to survive hypoxia, nutrient depri-
vation, oxidative or genotoxic stress to ultimately drive tumor progression (So-
rensen et al. 2015). We previously described MondoA (also known as MLXIP,
MAX like protein X interacting protein) as a metabolic stress sensor, required
for leukemogenesis. Lymphocytes, in particular B Lymphocytes are adapted to
hypoxic environments from their very beginning. They are destined to travel
from the hypoxic bonemarrow via normoxic peripheral blood to hypoxic lymph
nodes. They thus are specialized in glycolysis to compensate the lack of oxidative
phosphorylation under hypoxic conditions. Leukemic counterparts of B-lym-
phocytes exploit these features for their survival. Glucose-derived metabolites
control the nuclear activity of the transcription factor MondoA. Here we report
on the expression of MondoA in common B-cell acute lymphoblastic leukemia
(cALL) compared to other malignancies, its role in malignancy of cALL in vivo,
downstream pathways and correlation with relapse risk. Methods. Our human/
murine xenotransplantation model with immunodefıcient RAG2-/-gc-/- mice
was used (Richter et al. 2009). NALM6 and 697 cALL lines were lentivirally
transduced withMondoA short hairpin RNA. Upon successful MondoA knock
down (KD), KD and control lines were injected into the mice; CD10 blasts in
blood, spleen andmarrowwere assessed. Results.We foundMondoA to bemost
strongly expressed in pediatric cALL and AML. Moreover MondoA expression
was high in gastrointestinal stromal tumors and alveolar rhabdomyosarcoma.
MondoA KD in cALL cell lines and their subsequent analysis in xenograft mice
resulted in a reduced number of leukemic blasts in blood, marrow and spleen.
Spleen size and weight normalized inmice afterMondoAKD. Further microar-
ray analysis revealed an enrichment of glycolytic and hypoxia response gene sets
byMondoA.Moreover, HIF1a induction under hypoxia requiredMondoA.We
demonstrate that hypoxia facilitates vincristine resistance of cALL. MondoA is
induced under hypoxia and confers cALL cells chemotherapeutic resistance.
Tied to these results, MondoA overexpression correlated with relapse risk; its
expression was 63% higher in the very high-risk group as compared to the non-
high-risk group of cALL. In conclusion, our fındings demonstrate thatMondoA
maintains leukemic burden and aggressiveness of cALL in vivo possibly bymod-
ulating metabolic and hypoxia stress response, in particular by induction of
HIF1a.
#4516 Dual inhibition of CDK1 and HSP90 destabilizes HIF1 and syn-
ergistically induces cancer cell death. Shuai Zhao, David T. Dicker, Wafık S.
El-Deiry. Fox Chase Cancer Ctr., Philadelphia, PA.
Solid tumors are often characterized by intratumoral hypoxia. Hypoxia-in-
ducible factor 1 (HIF1) has been implicated in cell proliferation, survival,
angiogenesis, invasion and migration. The expression of HIF-1 is increased in
a variety of cancers but this is not restricted to hypoxic regions. We have previ-
ously shown that cyclin-dependent kinase 1 (CDK1) stabilizes HIF1 through
direct phosphorylation of its Ser668 residue in a Von Hippel-Lindau (VHL)-
independentmanner both under hypoxia and at G2/Munder normoxia (Warfel
et al., Cell Cycle, 2013). Heat shock protein 90 (HSP90) is also an acknowledged
VHL-independent HIF1 stabilizer. We sought to explore the link between
CDK1-mediated and HSP90-mediated HIF1 stabilization. Administration of
the CDK1 inhibitor, Ro-3306, reverses the heat shock (40°C)-increased level of
HIF1 in normoxia suggesting that CDK1 activity may contribute to HSP90-
mediated HIF1 stabilization. Under hypoxia, combination treatment with
HSP90 inhibitor geldanamycin and CDK1 inhibition/knockdown decreases
HIF1 levels more robustly than either treatment alone. This led us to investi-
gate whether combined CDK1 and HSP90 inhibition results in synergistic anti-
cancer effects. Indeed, dual inhibition of CDK1 and HSP90 synergistically de-
creases HCT116 colon cancer cell viability. PARP cleavage and sub-G1 analysis
indicate the combinational treatment triggers cancer cell death through apopto-
sis. Consistent with these fındings, we observed that inhibition of cell viability by
the combination is impaired in HCT116 Bax-/- cells. Furthermore, the dual in-
hibition also suppresses cell migration in vitro. We further validated our results
with CDK1 and HSP90 inhibitors that have entered clinical trials. Second-gen-
eration HSP90 inhibitor ganetespib and Ro3306 synergistically inhibit cell via-
bility in HCT116 cells. We have previously demonstrated that CDK4 also con-
tributes to the stabilization of HIF1 under hypoxia (Warfel et al., Cell Cycle,
2013). Interestingly, the combination of CDK4 andHSP90 inhibitors is also able
to improve downregulation of HIF1 as compared to either agent alone in
various cancer cell lines (eg. colon cancer, gliobastoma, etc). The FDA-approved
CDK4 inhibitor palbociclib along with ganetespib synergistically inhibits cell
viability in HCT116 cells under hypoxia. Such effect is not observed in WI38
normal cells under normoxia at similar concentrations. Our fındings demon-
strate that CDK1 inhibition disrupts the interaction betweenHSP90 andHIF1
providing a rationale for therapeutic targeting of HIF1 through the combina-
tion of CDK1/4 andHSP90 inhibitors in cancer. Ongoing studies are examining
the effects of CDK1/4 plus HSP90 dual inhibition in other tumor types and in
vivo.
#4517 A CRISPR approach to monitoring hypoxia-inducible proteins in
real-time.Marie K. Schwinn, Thomas Machleidt, Brock F. Binkowski, Christo-
pher T. Eggers, Keith V. Wood. Promega Corporation, Madison, WI.
Hypoxia-inducible factor 1A (HIF1A) regulates expression of genes impli-
cated in various aspects of oncogenesis, including angiogenesis, cell survival,
metastasis, and glucose metabolism. Overexpression or hypoxia-induced stabi-
lization of HIF1A has been associated with poor prognosis in cancer patients,
making HIF1A and its associated pathway a high-profıle target for anticancer
therapies. We sought to develop a live-cell assay to monitor abundance of en-
dogenous HIF1A and HIF1A-inducible proteins that could be used to identify
potent and specifıc inhibitors of the hypoxia signaling pathway. To accomplish
this goal, mammalian cell lines were edited by CRISPR using a Cas9:crRNA
ribonucleoprotein complex with a single-stranded oligonucleotide donor DNA
to introduce the HiBiT tag at the C-terminus of HIF1A and a number of known
hypoxia-inducible proteins, including BNIP3, ANKRD37,HILDPA andKLF10.
The 11 amino acid HiBiT peptide and its complementing 18 kDa polypeptide,
known as LgBiT, spontaneously reconstitute into an active luciferase derived
from the NanoLuc enzyme. Co-expression of LgBiT in edited cells, followed by
addition of the cell-permeable luciferase substrate, leads to generation of a
bright, steady luminescent signal that directly correlates with abundance of the
HiBiT fusion. The edited cells were treated with several known modulators of
the HIF1A signaling pathway, and changes in the abundance of the protein
fusions were followed in real-time by monitoring luminescence. The HiBiT tag
was also used to validate size and subcellular localization of the fusion proteins
using bioluminescence imaging and antibody-free blotting. As expected, all
tested compounds induced HIF1A accumulation. However, the downstream
targets of HIF1A generated differing response to the chemical modulators, war-
ranting further investigation into the modes by which these compounds act. By
coupling the speed and effıciency of CRISPR-mediated editing with the small
size and brightness of HiBiT, it was possible to generate a live-cell assay to
monitor abundance of proteins along the HIF1A pathway. This assay could
easily be adapted to screen for compound-induced effects on protein levels of
HIF1A, as well as HIF1A- induced changes in expression patterns.
#4518 Impact of hypoxia on SFK activities in prostate cancer cells. Yao
Dai, Dietmar W. Siemann. Univ. of Florida College of Medicine, Gainesville, FL.
Background: Metastasis is the major reason of disease progression and poor
prognosis in prostate cancer. Src family kinases (SFKs), including c-Src, Lyn and
Fyn, are non-receptor tyrosine kinases that have been shown to play an essential
role in local invasion, castration resistance, and metastasis in prostate cancer.
Hypoxia is able to promotemetastasis-associated functions by activating various
signaling molecules, including SFKs. However, whether all SFK members are
upregulated by hypoxia is unclear. In the current study, the effects of hypoxia on
cell functions and SFK activities are determined. Further, genetic approaches are
applied to identify the typical SFK member that is mostly activated by hypoxia.
Methods: For hypoxic exposure, prostate cancer cells were exposed to low oxy-
gen tensions (1%O2) for varied durations (0, 2, 6, 24 h). For drug treatment, cells
were treated with saracatinib (0, 100, 500, 1000 nM) for indicated time periods.
To test cell migration, “wound-healing” assay was used by making a scratch on
confluent monolayers. Cells that have migrated to the denuded area were im-
aged. Cell invasion was detected by seeding cells into Matrigel-coated transwell
chamber and cells on the bottom membranes were counted after treatment.
Clonogenic assay was performed to test cell survival. At the molecular level,
SFKs phosphorylation was detected by Western blotting, and gene knockdown
was accomplished by siRNA transfection. To investigate expression of p-SFK
andHIF-1 in patients, tumor tissues fromprostate cancer patientswere probed
with desired antibody by immunohistochemical staining. Results: Both p-SFK
and HIF-1 were highly expressed in patient tissues with advanced stage, with
HIF-1 expression signifıcantly associated with tumor grade and Gleason score.
At the cellular level, while short term hypoxic exposure (2-6 h) induced greater
cell migration, invasion and survival than prolonged hypoxia (24 h) in PC-3ML
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and C4-2B, these behaviors were increased under hypoxia with a period of 24 h
in TRAMP-C1 cells. Further, hypoxia enhanced SFK phosphorylation in the
pattern that was consistent with cell functions. Knockdown SRC, but not LYN,
abolished hypoxia-induced invasion and p-SFK expression. Lastly, SFK inhibi-
tor saracatinib showed stronger inhibition on functional behaviors facilitated
under hypoxia than normal conditions. Conclusions: Our data show that hyp-
oxia, particularly short-term exposure, is able to enhancemetastatic phenotypes
by activating SFKs, predominantly c-Src, in prostate cancer cells, suggesting
c-Src may be the most important signaling molecule of hypoxia-mediated be-
haviors. These fındings have clarifıed the exact SFK member that is typically
activated under hypoxia at least in prostate cancer model in vitro. More impor-
tantly, SFK inhibitors are able to impair cell functions driven by hypoxia, sug-
gesting their therapeutic potential by suppressing tumor metastasis that is
driven by hypoxia in prostate cancer.
#4519 ATM/ATR-SerRS pathway dominates hypoxic angiogenesis in tu-
mor.Yi Shi,1 Ze Liu,2 Xiang-Lei Yang2. 1NankaiUniversity, Tianjin, China; 2The
Scripps Research Institute, La Jolla, CA.
Hypoxia-induced angiogenesis is a critical response in multicellular organ-
isms to maintain oxygen homeostasis. It is also an important mechanism to
support tumor progression. Hypoxia activates hypoxia-inducible factor (HIF)
and HIF-independent pathways to transcriptionally induce the expression of
pro-angiogenic genes. However, our knowledge on transcriptional repressors of
angiogenesis and how they are regulated during hypoxia are limited. Here we
report that seryl-tRNA synthetase (SerRS), a newly identifıed transcriptional
repressor of vascular endothelial growth factor (VEGFA), is a major inhibitor of
angiogenesis that is inactivated during hypoxia1-4. Inactivation of SerRS is
achieved through its phosphorylation at serine 101 and serine 241 by ataxia
telangiectasiamutated (ATM) and the related kinaseATR.KnockdownofHIF is
not suffıcient to completely block hypoxia-induced VEGFA expression in hu-
man cells unless a phosphorylation-defıcient form of SerRS (SerRSS101A/S241A) is
simultaneously expressed to escape ATM/ATR inactivation. Consistently, in
mice, SerRSS101A/S241A can bypass hypoxia response despite HIF activation to
strongly inhibit angiogenesis in a matrigel assay and a xenograft model of hu-
man breast cancer. These fındings reveal ATM/ATR-SerRS pathway as a key
negative regulator of angiogenesis related to hypoxia and a new target for cancer
therapy. References: 1. Fukui, H., Hanaoka, R., and Kawahara, A. (2009). Non-
canonical activity of seryl-tRNA synthetase is involved in vascular development.
Circ Res 104, 1253-1259. 2. Herzog, W., Muller, K., Huisken, J., and Stainier,
D. Y. (2009). Genetic evidence for a noncanonical function of seryl-tRNA syn-
thetase in vascular development. Circ Res 104, 1260-1266. 3. Shi, Y., Xu, X.,
Zhang, Q., Fu, G., Mo, Z., Wang, G. S., Kishi, S., and Yang, X. L. (2014). tRNA
synthetase counteracts c-Myc to develop functional vasculature. Elife 3, e02349.
4. Xu, X., Shi, Y., Zhang, H. M., Swindell, E. C., Marshall, A. G., Guo, M., Kishi,
S., and Yang, X. L. (2012). Unique domain appended to vertebrate tRNA syn-
thetase is essential for vascular development. Nat Commun 3, 681.
#4520 Hepatitis B virus X protein regulates hypoxia-inducible factor-1al-
pha (HIF-1 alpha) and lysyl oxidase like 2 (LOXL2)pathway inhepatocellular
carcinoma. Cerise Yuen-Ki Chan, Aki Pui-Wah Tse, Elley Yong-Tuen Chiu,
Karen Man-Fong Sze, Hui-Yu Koh, Irene Oi-Lin Ng, Carmen Chak-Lui Wong.
The University of Hong Kong, Hong Kong, Hong Kong.
Hepatocellular carcinoma (HCC), the most common form of primary liver
cancer, is a fatal malignancy and is prevalent in HBV-endemic geographical
areas. Hepatitis B virus (HBV) infection is amajor etiologic factor ofHCC.HBV
is a double-stranded DNA virus and encodes for a viral onco-protein called
transactivator proteinX (HBx)which interactswith the host proteins to enhance
proliferative potential of the host cells. Here, using Tet-ON and Tet-OFF HBx
inducible systems in HBV-negative HCC cell lines, we showed that induced
expression of HBx stabilizes hypoxia-inducible factor-1 (HIF-1) protein un-
der hypoxia. Reversely, knockdown of HBx in HBV-positive HCC cell lines
reduced HIF-1 protein stabilization under hypoxia. More intriguingly, we
found that induced HBx expression up-regulated the mRNA and protein ex-
pression a knownHIF-1 transcriptional target, lysyl oxidase like 2 (LOXL2) in
HCC. Our previous study showed that LOXL2 cross-linked collagen in the ex-
tracellular matrix to promote HCC metastasis. Scanning electron microscopy
demonstrated that knockdown of HBx in HCC cell lines markedly reduced
formation of collagen fıbers in vitro. Transwell invasion assay showed that
knockdown of HBx reduced HCC invasive ability. Picrosirius red staining fur-
ther showed that knockdown of HBx reduced collagen cross-linking in vivo and
repressed HCC growth andmetastasis. Taken together, our study unprecedent-
edly show the HBx remodels the ECM through HIF-1/LOXL2 pathway to
promote HCC metastasis.
#4521 Long term hypoxia induces stable overexpression of JUNB and the
TGF pathway in colon cancer. Colin Flinders, Norah Alwash, Shannon Mu-
menthaler. USC, Los Angeles, CA.
Introduction: Metastasis is responsible for over 90% of cancer related
mortality, however mutations unique to themetastatic phenotype have yet to
be identifıed. This raises the possibility that the metastatic phenotype is the
result of a transcriptional profıle adopted by cells of the primary tumor
enabling them to spread to distal regions of the body. The tumor microen-
vironment (TME) is capable of influencing gene expression and cellular
behavior. Hypoxia, low oxygen tension, is a component of the TME that
arises due to improper tissue architecture and correlates with poor survival
outcome. Stabilization of the transcription factor HIF-1 during hypoxia
induces the expression of genes involved in metastasis through direct acti-
vation and through the alteration of the epigenome. However, upon re-
oxygenation HIF-1 is degraded and can no longer induce expression of
hypoxic responsive genes. During the metastatic process, cells that have
adopted hypoxia induced metastatic behavior such as increased motility and
invasiveness must transit through regions of normoxia on their way to met-
astatic colonization. Hypothesis: As hypoxic cell migrate away from regions
of low oxygen towards oxygen rich environments, such venous blood, genes
induced by hypoxia would be expected to return to basal levels of expression.
Those genes whose expression does not return to levels associated with nor-
moxia, but instead remain elevated following re-oxygenation, may be crucial
for maintaining the hypoxia induced metastatic phenotype. Experimental
Design: To study the stability of hypoxia induced gene expression alterations
following re-oxygenation, colon cancer cell lines were grown under hypoxic
conditions (1% O2) for up to 3 weeks and then transitioned to normoxic
conditions (21% O2). RNA sequencing was used to assess changes in gene
expression during hypoxia adaptation and for 3 more weeks following re-
oxygenation. Results: While the majority of genes whose expression was
induced by hypoxia returned to basal levels following re-oxygenation, a sub-
set of genes clustered in the TGF- pathway remained at elevated levels. In
particular the expression of JunB, a component of the AP-1 transcription
factor, was induced by hypoxia and continued to remain overexpressed after
return to normoxic growth conditions. Conclusion: Long term culturing of
colon cancer cells in hypoxic conditions induces changes in gene expression
that remain stable following return to normoxic growth conditions. We
hypothesis that genes whose expression follows this pattern may be involved
in the hypoxia induced metastatic phenotype. RNA-seq profıling of cells
grown in hypoxic conditions for three weeks and then returned to normoxic
growth conditions for an additional three weeks identifıed genes involved in
the TGF- pathway and in particular JunB that were induced by hypoxia and
remained stable following return to normoxia.
#4522 Hypoxia-induced alteration ofmitochondrial dynamics is linked to
chemoresistance in ovarian cancer. Youngjin Han, Boyun Kim, Yong Sang
Song. Seoul National University, Seoul, Republic of Korea.
Hypoxia, commonly observed in the tumor microenvironment, has been
shown to be related to the cancer hallmarks. Hypoxia generates reactive
oxygen species (ROS), inducing changes in mitochondrial function and
structure in various diseases. Mitochondria, dynamic intracellular organ-
elles, go through incessant processes of fıssion and fusion for effıcient gen-
eration of energy. We investigated alterations in mitochondrial networks
under hypoxic conditions ( 1 % O2) and subsequent effects of the mito-
chondrial alteration on drug response in ovarian cancer cells. Mitochondrial
fıssion was prevalent in cancer cells under hypoxic conditions. Translocation
of phospho-Drp1 (Ser616), a biochemically active mitochondrial fıssion pro-
tein, to mitochondria was enhanced under hypoxic conditions. An increase
in ROS production was accompanied under hypoxic conditions. ROS scav-
enging reversed the hypoxia-elicited mitochondrial fıssion, while exogenous
H2O2 treatment promoted mitochondrial fıssion. These results strongly im-
plicate that ROS are important modulators of mitochondrial dynamics un-
der hypoxia. Interestingly, hypoxia-induced mitochondrial fıssion altered
the response of cancer cells to cisplatin (CDDP). Ovarian cancer cells in
hypoxic and normoxic conditions were differentially affected by CDDP
when mitochondrial fıssion was inhibited. Taken together, the alteration of
mitochondrial dynamics, a cellular adaptation to hypoxia, is associated with
chemoresistance. Mitochondria adapted to the hypoxic tumor microenvi-
ronment could be a potential target for anti-cancer therapy.
#4523 Agent-based models for prediction of tumor spheroid response to
radiation and the hypoxia-activated prodrug SN30000. Xinjian Mao, Gib
Bogle, Sarah McManaway, William Wilson, Kevin Hicks. University of Auck-
land, Auckland, New Zealand.
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Introduction: Hypoxia-activated prodrugs (HAPs) are a promising strat-
egy to specifıcally target radioresistant hypoxic cells in tumors.We have used
multicellular layers (MCLs) and steady state Green’s function pharmacoki-
netic/pharmacodynamic (PK/PD) modelling in microvascular networks to
select SN30000 as a tirapazamine analogue with optimal spatial complemen-
tarity with radiation. However these models have several limitations such as
lack of time dependent PK. Multicellular tumor spheroids are a more trac-
table model than MCLs for investigating PD parameters. However, the chal-
lenges of interpreting spheroid experiments in terms of spatial complemen-
tarity limits their application. We have developed an in silico agent-based
(AB) tumor spheroid model, in which cell fate can be tracked as a function of
time and is determined by spatially-varying concentrations of oxygen, glu-
cose and therapeutic agents (radiation and HAP). The hypothesis is that our
AB model can predict tumor spheroid response to radiation and SN30000,
both alone and in combination. Methods: In the AB model, spheroid growth
is simulated as a function of oxygen, glucose and drug concentrations deter-
mined by solving diffusion equations using oxygen consumption measured
in HCT116 monolayers and glucose and SN30000 diffusion and metabolism
measured in HCT116 MCLs and stirred cell suspensions, linked with intra-
cellular reaction equations. Cell fate is determined by oxygen, glucose and
drug concentrations. Spheroid diameter, cell survival and hypoxic fraction
of HCT116 spheroids grown at a range of oxygen and initial glucose concen-
trations were compared to model predictions, as was glucose depletion from
the culture medium. Radiation (cobalt-60) and SN30000 induced clonogenic
cell killing under oxia and anoxia was determined using HCT116 monolay-
ers. Model simulations of HCT116 spheroid response to radiation and
SN30000 were compared to experimental results. Results: The model repro-
duced known features of spheroids including oxygen and glucose gradients,
rapid cell proliferation at the periphery and central hypoxia and necrosis.
Measured HCT116 spheroid diameters increased linearly with time, at rates
that decreased at lower ambient O2 concentrations. Spheroid growth and
glucose depletion was well-fıtted by the AB model. Good agreement was
found between simulated and measured clonogenic cell killing by radiation
and SN30000, while the model underestimated spheroid growth delay by
radiation and SN30000 than experimental observation. Discussion: An oxy-
gen and glucose dependent AB model for growth and PD response (cell
killing and growth delay) of HCT116 spheroids has been developed and
calibrated using experimentally determined parameters. Further develop-
ment of this model will link cell fates (including cell cycle arrest) explicitly to
DNA damage responses and O2 and glucose-dependence of cell prolifera-
tion and survival.
#4524 The effect of acute intraoperative hypoxia in breast cancer.Dimple
R. Bhatia, Shalaka Joshi, Rohan Chaubal, Prajakta Kalkar, Farheen Naeem, Ni-
santh Mathew Raju, Nilesh Gardi, Nita Nair, Vaibhav Vanmali, Rohini W. Ha-
waldar, Amit Dutt, Rajendra A. Badwe, Sudeep Gupta. Tata Memorial Centre,
Mumbai, India.
Background:Hypoxia is defıned as oxygen levels in tumormicroenvironment
of less than that in blood (90-100 mm Hg) and influences many aspects of
tumour biology. During surgery tumour vasculature is cut off gradually leading
to induction of acute hypoxia.The present study aims to experimentally test the
genotypic and phenotypic effects of surgically induced acute hypoxia in breast
cancer tumor samples and cell lines. Methodology: Core biopsy samples were
collected from breast tumors (N8 patients) at three time points during their
curative surgery: prior (pre), mid-way (intra) and at the end (post). The samples
were subjected to RNA-Seq and a list of differentially expressed genes (DEG)
was prepared.A set of 26DEG (’pre’Vs ’intra’ Vs ’post’) obtained fromRNA-Seq
analysis and additional 17 genes involved in inflammation, EMT and hypoxia
pathways were chosen for validation in tumor samples. These genes were vali-
dated using a customized qPCR Array (Qiagen). A gene was considered vali-
dated if it was signifıcantly deregulated in at least 4 out of 8 patients. In another
experiment, MCF-7 cells were exposed to varying levels of oxygen concentra-
tions (0.1-20%) for varying time periods ranging from30minutes to 72 hours, to
study time and dose dependent effects of hypoxia on following functional char-
acteristics: proliferation, invasion and cell cycle changes. Results: Concordant,
statistically signifıcant up-regulation of FOS, DUSP1, JUNB, FOSB, ZFP36,
RGS1, S100A4, CXCL8 and CCL2 were observed in RNA-Seq and qPCR exper-
iments while MMP13, HIF1A and VEGFA were up-regulated only in qPCR.
However, 7 protein markers of inflammation, EMT and hypoxia did not show
any signifıcant change between pre, intra and post-operative samples. InMCF-7
cells, a dose and time dependent decrease in cell viability was observed with
increasing severity of hypoxia as well as decrease in invasiveness, but there was
no signifıcant impact on cell cycle phases.When hypoxic cells were re-incubated
under normoxic conditions an increase in cell proliferation and accumulation of
cells in S phase (with a reduction in G2-M fraction) were observed, compared to
cells grown under only normoxic conditions. Conclusion: Acute intra-operative
hypoxia up-regulates expression of genes related to cell survival, chemoresis-
tance, invasiveness, inflammation and angiogenesis in breast tumors. Breast
cancer cells exposed to acute severe hypoxia followed by normoxia show in-
creased proliferation. These effects may have implications for tumor cells that
disseminate during surgery.
#4525 Hypoxia signaling pathway plays a role in ovarian cancer chemore-
sistance.Noelle L. Cutter, TylerWalther, Kimberly H. Doyle, Ryan Frank.Mol-
loy College, Rockville Centre, NY.
Hypoxia-inducible factor 1 (HIF-1) is a basic helix-loop-helix transcrip-
tion factor that when induced regulates the expression of many genes in-
volved in cytoprotective stimuli, which attenuates apoptosis and improves
survival.. Increased expression of HIF-1 gene (HIF1A) has been found in
several carcinomas, including ovarian cancer. Ovarian cancers are generally
refractory to platinum-based chemotherapy. Despite the large number of
studies, molecular events that govern the emergence of aggressive therapy-
resistant cells after chemotherapy are poorly defıned. Genomic instabilities,
such as copy number variation(CNV), may play an important role in
chemoresistance and have been implicated in many complex diseases, like
cancer.. We analyzed CNV data that is publically available through the Can-
cer Genome Atlas and others. Of particular interest was the transcription
factor HIF1A which plays an integral role in oxidative stress response such as
those induced by chemotherapy reagents. The present study provides evi-
dence for the rare escape of tumor cells from drug-induced cell death by
entering a non-cycling senescent state. We report the adaptive response of
human ovarian surface epithelium cells to CoCl2, a chemical hypoxia-mim-
icking agent resulting in a senescent-like state of chemoresistant cells. The
effect of the treatment was evaluated on CNV of HIF-1 gene expression, cell
proliferation, survival, and tumor invasiveness. We show here that CNV
duplication events of HIF1 results in an oxidative stress response in cells
leading to chemoresistance through the induction of cellular senescence.
Understanding the molecular events associated with chemoresistance will
ultimately lead to better patient treatment and outcomes.
#4526 Attenuation of hypoxia in solid tumorwithmultifunctional upcon-
version nanoparticles to enhance photodynamic therapy.Yan Zhang, Jingqiu
Li, Jun Hu, Xiangliang Yang. Huazhong University of Science and Technology,
Wuhan, China.
As a non-invasive therapeutic technique, photodynamic therapy (PDT) re-
quires suffıcient oxygen in order to generate adequate singlet oxygen upon the
excitation of photosensitizer using an appropriate light wavelength. It has lim-
ited effıcacy in preexisting hypoxia in tumor and PDT-induced hypoxia, owing
to the limit oxygen level in the tissue and the consumption of the oxygen during
the PDT treatment.Herein, taking advantage of hyperbaric oxygen (HBO),mul-
tifunctional upconversion nanovehicle is constructed to overcome the above-
mentionedproblems.HBOprovides timely oxygen supply during the treatment,
which greatly enhances the photodynamic effect of the loaded nanoparticles, as
demonstrated by the accelerated generation of 1O2 and elevated cytotoxicity.
Tumor growth is greatly regressed in the HBO-PDT treated mice. Our fınding
provides new insights into the modulation of unfavourable tumor microenvi-
ronment with the perfect marriage between HBO and NIR-light sensitized up-
conversion nanoparticles to overcome the current limitation of cancer photo-
dynamic therapies.
BIOINFORMATICS AND SYSTEMS BIOLOGY: Modeling and
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#4527 Estimating tumor cell dissemination rates through lymph and
blood via computational modeling. Anne Marie Barrette, Benedicte Lenoir,
Mihaela Skobe,MarcR. Birtwistle. Icahn School ofMedicine atMount Sinai, New
York, NY.
Metastasis is the primary cause of death from most cancer types, but the
relative rates of tumor cell migration through lymphatic versus blood routes
remains an open question. Here we combine data from a xenograft model of
metastatic breast cancer with a computational model of tumor cell growth
and dissemination to help answer this question. Orthotopic mouse xeno-
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grafts using the triple negative breast cancer cell line MDA-MB-231 allowed
for monitoring of metastatic cells within the primary tumor, bloodstream,
lymph nodes, and lungs. Experiments resembling a pulse-chase method
helped inform and parameterize the model to the rate of dissemination to the
lymph nodes and lungs. Our ordinary differential equation model describes
primary tumor growth as the balance between proliferation and death, with
the proliferative fraction decreasing with tumor size, and the apoptotic or
necrotic fraction increasing with tumor size. Intravasation to both lymph
and blood rapidly increases early in tumor growth, followed by a decay to a
low rate of tumor cell release well before the primary tumor grows to its
saturating size. The mouse data guided our parameter estimations based on
the assumptions that disseminated tumor cell death rate is greatest in the
harsh environment of the blood and lowest in the more accommodating
lymph node, and that metastatic cells seeding in the lymph nodes and lungs
follow similar growth dynamics as the primary tumor only with far fewer
total cells. We are currently performing sensitivity analysis to explore the
range of relative rates of tumor cell dissemination that fıt the in vivo data,
and thus gain insight into tumor cell dynamics within the different compart-
ments. These analyses will allow us to estimate what the relative contribu-
tions of blood versus lymphatic tumor cell dissemination are to overall met-
astatic burden, as well as suggest experiments that further constrain these
estimates. Such combined experimental and modeling analysis lend insight
into where one might detect pre-metastatic cells early in disease progression
or suggest new targets for anti-metastasis drugs based on the dominant mode
of dissemination.
#4528 A novel transducer array design optimizing TTFields delivery to
the thorax. Hadas S. Hershkovich,1 Sholi Strauss,1 Uri Weinberg,2 Eilon D.
Kirson,1 Ze’ev Bomzon1. 1Novocure ltd, Haifa, Israel; 2Novocure GmbH, Lu-
cerne, Swaziland.
Objective: The purpose of this study was to design transducer arrays for the
delivery of Tumor Treating Fields (TTFields) to the thorax, generating high
intensity in the upper torso while potentially improving patient comfort. Back-
ground: TTFields are low intensity, intermediate frequency, alternating electri-
cal fıelds that disrupt cell division. The ongoing Phase II STELLAR trial
[NCT02397928] is investigating the effıcacy and safety of TTFields in combina-
tion with chemotherapy for the treatment of mesothelioma. A pivotal study to
evaluate the effıcacy of TTFields in treating NSCLC is planned for 2017. TT-
Fields are delivered via capacitive transducer arrays, comprising ceramic disks
covered with a thin layer of conductivemedical-grade gel, which are arranged in
an almost rectangular order. Two orthogonal pairs of arrays are placed on the
skin in the vicinity of the treated region. One pair is placed on the anterior and
posterior sides of the thorax. The other pair is placed on the lateral and contralat-
eral sides of the thorax. This confıguration has limitations: (a) Sub-optimal elec-
tric contact may be caused by poor attachment of the arrays on the chest due to
body curvature; (b) TTFields intensity generated by anterior-posterior arrays
may be attenuated in the thorax of females and obese individuals, due to high
resistivity of the thick adipose layers in the breast; (c) the current lateral-con-
tralateral arrays generate lower fıeld intensities in the lung’s apex. This study
presents novel array designs to overcome these limitations. Methods: Various
concepts for array designs that avoid placement over regions of thick sub-cuta-
neous fat were designed. To evaluate the fıeld distribution generated by these
arrays and optimize their design, numerical simulations using realistic compu-
tational phantoms were used. Results: Novel array designs were developed for
the delivery of TTFields to the lungs. These arrays consist of sets of intercon-
nected small patches that adhere to the natural contours of the human body.
Simulations showed that the proposed arrays deliver uniformly distributed, high
electrical fıeld to the lungs. One notable design is a pair of arrays shaped as
circular rings, in which one array is placed around the neck and shoulders,
whereas the second array is placed on the lower torso. This design yielded a
highly uniform fıeld directed longitudinally throughout the torso. Conclusion:
The array designs presented in this study are expected to maintain patient com-
fort and will ensure high fıeld intensity delivered to the thorax. Compliance and
TTFields treatment delivery could both be improved by using these designs.
#4529 Optimization of the sequence for the administration of bevaci-
zumab in combination with pemetrexed and cisplatin in NSCLC : a pharma-
cology based in vivo study. Arnaud Boyer,1 Diane-Charlotte Imbs,2 Raouf El
Cheikh,2 Celine Mascaux,1 Fabrice Barlesi,1 Dominique Barbolosi,2 Sebastien
Benzekry,3 Joseph Ciccolini2. 1Assistance Publique Hôpitaux de Marseille. Mul-
tidisciplinary Oncology & Therapeutic Innovations, marseille, France; 2Aix mar-
seille University, marseille, France; 3Inria, Bordeaux, France.
Introduction: Bevacizumab is active in advanced non-small cell lung can-
cer (NSCLC) and is administred in combination with chemotherapy in fırst
line for non squamous NSCLC. However the best sequence of administration
has not been defıned. Previously published data suggest that before acting as
an antiangiogenic drug, Bevacizumab would initially and transitory normal-
ized the vascularization of the tumor. This initial phase could be thus be
optimal to administrate chemotherapy. By using mathematic modeling, we
showed that sequential administration of chemotherapy 3 days after Bevaci-
zumab may be more benefıcial than concomitant administration. Herein we
tested and compared concomitant versus different schema of sequential ad-
ministration of Bevacizumb with chemotherapy in NSCLC. Methods: H460
Luc  cells were transfected with dTomato allowing to measure tumor
growth by fluorescence. Nude mice were engrafted subcutaneously with
around 120,000 cells. Fluorescence was used to monitor tumor growth twice
a week and treated with Bevacizumab, Cisplatin and Pemetrexed with vari-
ous sequences of administration. A total of 15-16 replicates were included in
each therapeutic group. Results Five therapeutic schema were compared : 1)
Cisplatine-Pemetrexed only ; 2) concomitant administration of Bevaci-
zumab with Cisplatine-Pemetrexed ; 3) chemotherapy 3 days after Bevaci-
zumab predicted to be the optimal sequence by mathematic modeling; 4)
chemotherapy 8 days after Bevacizumab predicted to be the worse sequence
by mathematic modeling; 5) control group receiving placebo. Tumor growth
was reduced of 38% in group 3 as compared with group 2, but this difference
remains non signifıcant (p0.13), but was signifıcantly reduced compared to
groups 1, 4 and 5. The median survival was the longest in group 3 (74 days),
as compared with group 2 (70 days), group 4 (67 days), group 1 (54 days) and
control group (40 days). Conclusion: This in vivo study indicate that the
sequential administration of Bevacizumab three days before chemotherapy
in NSCLC may be the optimal schema as compared with concomitant ad-
ministration or longer delay as predicted by mathematic modeling. Mecha-
nistic and pharmacokinetic analyses as well as biomarker studies are cur-
rently ongoing and should be shortly available.
#4530 A biophysical model for necrosis development in glioblastoma in-
formed by subject-specifıc MRI measurements. David A. Hormuth, Thomas
E. Yankeelov. University of Texas at Austin, Austin, TX.
Introduction: We have previously developed the means to use quantitative
magnetic resonance imaging (MRI) data to initialize a biophysical model
(Model 1) of tumor growth which accurately predicts future tumor volume but
fails to capture the development of low-cellularity (or necrotic) regions in a
murine model of glioblastoma. In this work, we expand upon this biophysical
model (Model 2) to characterize necrosis by relating tissue perfusion to cell
death. We evaluate the accuracy of both models to in vivo measurements of
tumor growth. Methods: To evaluate this model, rats (n  4) with C6 gliomas
were imaged with dynamic contrast enhanced MRI (DCE-MRI) and diffusion-
weighted MRI (DW-MRI) seven times over 10 days. DCE-MRI was used to
identify tumor regions and estimate tissue perfusion (as estimated by the param-
eter Ktrans), while DW-MRI was used to estimate cell number. For both Models
1 and 2, parameters describing tumor proliferation, diffusion, and carrying ca-
pacity were optimized from the fırst three imaging time points. For Model 1,
these parameters were then used in a forward evaluation of the model to predict
future tumor growth at the later days. For Model 2, additional parameters de-
scribing cell death and sensitivity toKtranswere estimated from the all timepoints
and used to simulate tumor growth over the fınal four time points. Error was
assessed between the model and observed tumor growth by calculating the per-
cent error in tumor volume, percent error in voxel cell number, and the concor-
dance correlation coeffıcient (CCC) over the fınal four days. Results No statisti-
cally signifıcant differences for percent error in tumor volume were observed
betweenModel 1 (6.49	 4.70%, mean and 95% confıdence interval) andModel
2 (6.77 	 4.77%). Model 1 had 12.0 	 0.3% error in voxel cell number in low
cellularity regions (where cellularity was between 60-80% of carrying capacity).
Model 2, however, exhibited a statistically signifıcant decrease (P  0.05) in
error at the voxel level (8.3 	 0.2%) in the same low cellularity regions. No
signifıcant differences for percent error in voxel cell number were observed
between the models at high cellularity regions (greater than 80% of carrying
capacity).Model 2 had stronger agreement (CCC 0.69) between themeasured
and model described cell number in low cellularity regions compared to model
1 (CCC 0.57). Bothmodel 1 and 2 had CCC 0.90 in high cellularity regions.
Conclusion Incorporating a model of cell death informed by tissue perfusion
improves the overall tumor growth characterization by decreasing the error in
predicted cell number at the voxel level in the low cellularity (or hypoxic) re-
gions. The lack of a model for Ktrans in the current implementation, however,
BIOINFORMATICS AND SYSTEMS BIOLOGY: Modeling and Algorithms
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1157
requires a posteriori measurements to update tissue perfusion. Further work is
needed to develop a predictive model for the spatial-temporal evolution of
Ktrans.
#4531 Systems pharmacology to predict cellular biomarkers and optimize
mono- and combination-therapy regimens: Focusing on immune checkpoint
targets PD-1, PD-L1 and CTLA-4.Oleg Milberg,1 Chang Gong,1 Bing Wang,2
Paolo Vicini,3 Rajesh Narwal,4 Lorin Roskos,4 Aleksander Popel1. 1Johns Hop-
kins University, Baltimore, MD; 2MedImmune, Mountain View, CA; 3MedIm-
mune, Cambridge, United Kingdom; 4MedImmune, Gaithersburg, MD.
Cancer immunotherapy focuses on stimulating and promoting the immune
system to recognize and eliminate cancer cells, with several FDA approvals in
recent years. However, identifying patients best suited for specifıc immune ther-
apies, and determining optimal treatment regimens continue to be a clinical
challenge. Using a molecular-detailed computational systems pharmacology
model to identify cellular biomarkers and optimize regimens, we may be able to
predict the effıcacy of regimens in specifıc patient populations, and expedite
drug development for cancer treatment. We developed a cell/receptor-based
multi-compartment systems pharmacology model focusing on the immune re-
sponse against a growing tumor, with the intent to test the effects of immune
checkpoint inhibitors against PD-1, PD-L1 andCTLA-4 administered asmono-
and combination therapies. Additionally, the model also allows for testing of
other immuno-therapies, such as adoptive cell therapies, which can be com-
bined with the checkpoint inhibitors. The model was designed and developed
using the SimBiology plug-in in MATLAB. Simulations were performed with
parameters that defıne the immune response at particular tumor stages of mel-
anoma and NSCLC. All results were qualitatively and quantitatively compared
to experimental pre-clinical and clinical data for model validation, or used for
the generation of predictions suitable for further experimental testing. In silico,
we have identifıed that administrations of the prescribed doses of 1-10 mg/kg of
anti-CLTA-4 (based on binding kinetics) effectively saturates the receptors on
the T cells, and promotes both an extended life span of the antigen presenting
cells (APCs), and themaximumattainable activation levels of the effector T cells.
The model further predicts that the effectiveness of anti-CTLA-4 therapy is
limited by the immunogenicity of the system (i.e., the antigen intensity level and
number of APCs presenting the antigens) in amonotonic fashion. Furthermore,
injecting activated APCs without therapy would show a temporary tumor re-
sponse and a subsequent recovery by the tumor to its original growth trajectory,
while raising the antigen intensity had a sustained effect on tumor response.
Other simulations indicate that, despite the lack of apparent tumor response, a
sustained immune attack may be ongoing in the body; however, the immune
activity is proportionally limited by the tumor and regulatory cells. Lastly, sev-
eral dose-responses and clinical trials were simulated for both combination and
monotherapies, and correlated with published clinical trial data. Future work
will focus on uncovering the cellular biomarkers responsible for such results,
experimentally validating them, as well as simulating optimal combination
treatment regimens for future evaluation.
#4532 Adrenalmetastases in lung cancer: Clinical implications of amath-
ematical model. Jeremy M. Mason,1 AnneMarie Ciccarella,2 Lori Marx-Ru-
biner,3 Lyudmila Bazhenova,4 Paul K. Newton,1 Kelly Bethel,5 Jorge J. Nieva,1
Peter Kuhn1. 1University of Southern California, Los Angeles, CA; 2Independent
Research Advocate and Breast Cancer Patient, New York, NY; 3Independent Re-
search Advocate andMetastatic Breast Cancer Patient, Los Angeles, CA; 4Univer-
sity of California San Diego, San Diego, CA; 5Scripps Clinic, San Diego, CA.
Adrenal gland metastases are common in lung cancer. It is well recognized
that aggressive treatment of solitary adrenal metastases leads to improved out-
comes but the exact nature of adrenal deposits is not well understood. Contro-
versy exists as to the routing of cancer cells to the adrenal gland with some
believing that this transmission is lymphatic, in contrast to the more generally
accepted theory of hematogenous spread. Using an autopsy dataset of 3827
untreated cancer patients, we use the metastatic distribution of common pri-
mary cancer types to createMarkovmodels of progression. The anatomical sites
of spread in the body represent states in the model, while the transition proba-
bility between states represents the probability ofmetastatic spread fromone site
to another. We then use the Markov models to run Monte Carlo simulations of
random walkers representing circulating tumor cells traveling within the body
to simulate metastatic spread. We calculate mean fırst passage times (MFPT) to
each site as a representative of time to metastasis formation. Analysis of 6 com-
mon cancer types (bladder [n120 autopsies; 289 metastases], breast [n432;
2235], colorectal [n161; 420], lung [n560; 859], ovarian [n418; 806], and
prostate [n62; 212]) from the dataset showed distinct metastatic distributions
across the populations. MFPT calculations to anatomical sites in the 6 analyzed
primary cancer types indicated model progression times to the adrenal gland
similar to the regional and distal lymph nodes in only lung cancer. The times
associated with adrenal gland in the other primary cancers were similar to other
metastatic sites of hematogenous spread. The Markov models created strongly
support the lymphatic theory for metastatic spread to the adrenal glands. After
performing a literature review to look for the biological plausibility of the sim-
ulated results, we believe evidence supports this theory and validates themodels.
This could explain improved survival for patients in whom solitary adrenal
metastases are managed aggressively with surgical or radiation modalities. In
order to further validate this theory, we are calling for clinical trials prospectively
testing this hypothesis.
#4533 In silico analysis of enhanced radiosensitivity in radiation treat-
ment combined with androgen deprivation therapy for prostate cancer.
Mengdi Qian,1 Alexandru Almasan,2 EvrenGürkan-Çavusoglu1. 1CaseWestern
Reserve Univ., Cleveland, OH; 2Cleveland Clinic, Cleveland, OH.
The purpose of this study is to quantitatively analyze the improved radiosen-
sitivity of prostate cancer cells to ionizing radiation (IR) when radiation treat-
ment is combinedwith androgen deprivation therapy (ADT). The double strand
breaks (DSBs) induced by ionizing radiation are repaired primarily by non-
homologous end joining (NHEJ). It is reported in the literature that NHEJ is
impaired after ADT, which then results in increased radiosensitivity and better
IR treatment outcomes in prostate cancer. In this study, we have used our mod-
els for NHEJ repair of DSBs under IR treatment and IR  ADT combination
treatment conditions to determine how the combination treatment results in
better outcomes. We have modeled the effect of multiple doses of IR that are
delivered 24 hours apart tomimic the conventional, fractionated radiation treat-
ment. The analysis results showed that the DSBs accumulate more in the case of
combined treatment with ADT compared to faster and more effıcient repair
when only IR is applied. We have used the experimental data on relative cell
numbers and relative sub-G1 cell numbers from the literature to determine the
difference in the levels ofDSBs that lead to cell death differences between the two
treatment strategies. The literature data also shows that there is patient response
variability toADT in terms of the reduction in the levels of Ku70/80, which is the
fırst NHEJ protein complex that is recruited to DSBs. We have modeled this
patient variability in our models by introducing variability to Ku70/80 protein
concentrations used in the simulations. Our simulation results agree with the
observation from clinical data that lower concentration levels of Ku70/80 lead to
better radiosensitization. The amount of IR can be adjusted with respect to the
level of radiosensitization after ADT on a patient specifıc level to achieve a
desired level of DSBs that will lead to maximum cell death; this dose optimiza-
tion effort will be the next step in our quantitative analysis.
#4534 Theory andmethodology for the design and analysis of PDXmouse
clinical trials. Sheng Guo,1 Binchen Mao,1 Henry Q. Li2. 1Crown Bioscience,
Taicang, China; 2Crown Bioscience, Santa Clara, CA.
Patient-derived xenograft (PDX) is a well-accepted experimental cancer
model mimicking original patients in histo- & molecular pathology, as well as
drug response. Mouse clinical trials (MCT) using PDX becomes increasingly
prevalent in oncology research, yet the theory and methodology for trial design
and analysis is underdeveloped. By analyzing tumor growths of 34081 PDX
mice, we showed that majority of them can be satisfactorily modeled by expo-
nential growth kinetics, based onwhichwe derived a new drug response readout
called the AUC ratio that is superior to the tumor growth inhibition (TGI) and
its variants. We outlined a bootstrap algorithm to calculate its confıdence inter-
val, and showed that a 4:4 (4mice in both treatment groups) or up design sharply
increasesmeasurement accuracy over the lesser design.Next, we introduce three
approaches for drug evaluation and biomarker discovery in MCTs. In the end-
point based analysis, we used a cohort of gastric PDXs to show a positive corre-
lation between EGFR mRNA expression and cetuximab effıcacy, in agreement
with clinical trial results.We then used linearmixedmodels (LMMs) to describe
MCTs as clustered longitudinal studies that capture the growth and drug re-
sponse heterogeneities across PDXs and among mice within a PDX. Further,
LMMs can separate prognostic and predictive biomarker effects, quantify re-
sponse difference to a drug for multiple cancers, or effıcacy difference of multi-
ple drugs to a cohort of PDXs. Thirdly, we used additive frailty models to per-
form survival analysis on MCTs. We defıned survival endpoints of PFS and OS
in PDXs, and showed that hazard ratios can be more accurately estimated. We
revealed an inherent connection between frailty and growth rate for PDXs. We
performed computational simulations for the last two methods to show that
statistical power improves tremendously with a 3:3 or up design. This work lays
the foundation for rational design and analysis of PDX mouse clinical trials.
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#4535 Tumor cell division rate heterogeneity explains in vitro clonal dom-
inance.MargrietM. Palm,Marjet Elemans, Joost B. Beltman. Leiden University,
Leiden, Netherlands.
The cells that make up a tumor exhibit large phenotypic and genotypic vari-
ation, which strongly influences the effectiveness of cancer therapy. A typical
manifestation of intratumor heterogeneity is the presence of a few clones that
represent most of the tumor population, i.e. clonal dominance. Such heteroge-
neity could potentially be caused by the occurrence of different ratios of cancer
stem cells and differentiated cells per clone, or, alternatively, clonal dominance
may be caused by heterogeneity of division rates between clones. Previously
published work, applying lineage tracing with genetic barcodes to in vitro iter-
ated growth and passage experiments demonstrated that clonal dominance was
accompanied by clone loss and partial overlap in dominant clones between
biological replicates [1]. To identify the source of these observations, we build a
computational model that simulates the iterated growth and passage experi-
ments. By varying the ’division rules’ in themodel, we can quantitatively predict
the evolution of the clone distribution for the aforementioned hypotheses. In
this manner, we show that clonal dominance does not appear in simulations
where all cells divide at a uniform rate, even when the population is subdivided
in cancer stem cells and differentiated cells. However, when the division rates
vary between clones and are inherited from parent cells, dominant clones ap-
pear. These simulations also closely match the in vitro evolution of clone loss
and clonal overlap between biological replicates. Altogether, our fındings sug-
gest that tumor cells exhibit a heritable variability in the division rates of indi-
vidual cells. References: [1] Porter, S. et al. (2014). Lentiviral and targeted cellu-
lar barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo.
Genome Biology, 15(5), R75.
#4536 Using diffusionweighted imaging (DWI) data to accurately predict
electric fıeld delivery to the tumor during TTFields treatment. Cornelia
Wenger,1 Ze’ev Bomzon,1 Pedro Cavaleiro Miranda2. 1Novocure, Haifa, Israel;
2Faculty of Science, University of Lisbon, Lisbon, Portugal.
Tumor Treating Fields (TTFields) are low intensity (1-3 V/cm) alternating
electric fıelds in the intermediate frequency range, delivered through two
pairs of transducer arrays placed on the patient’s scalp. TTFields are an
anti-mitotic modality approved for the treatment of glioblastoma multi-
forme (GBM). Simulation-based studies show that TTFields distribution
within the brain depends on the location of the arrays on the scalp as well as
the anatomy of the patient. Therefore, to study how fıeld distribution influ-
ences disease progression requires the creation of patient-specifıc computa-
tional models. To date the creation of such models is based on accurate
segmentation of MRI images into various tissues, and further of volume
mesh assembly. These tasks are performed using semi-automatic, labor-
intensive algorithms, making this approach impractical for studies which
require the creation of a large number of patient models. We recently out-
lined that diffusion tensor imaging (DTI) could be used to construct realistic
head models for simulating TTFields distribution without the need for com-
plex segmentation of the brain. This is possible because the diffusion tensors
evaluated fromDTI can be scaled into anisotropic conductivity tensors using
simple relationships. However, the approach is limited because the acquisi-
tion of high-quality DTI data is not widely practiced for GBM patients. Yet,
shorter diffusion weighted imaging (DWI) sequences, such as an apparent
diffusion coeffıcient (ADC) map or trace image, are common diagnostic
techniques. The aim of this study was to test whether DWI data could po-
tentially be used to create realistic head models. We used a previously devel-
oped head model created from structural and DTI data of a healthy individ-
ual. To test pathological scenarios, virtual lesions were placed. To simulate
data acquired with DWI, we substituted the diffusion tensor at each point
within the model with the mean diffusion (MD), which is the value that can
be measured using DWI. The computational model was then completed by
scaling the MD into a voxel-wise isotropic conductivity map using the same
relationship as applied to convert anisotropic diffusion into conductivity
tensors. TTFields distributions within the model were then evaluated for
various array layouts and tumor locations. The fıeld distribution within the
DWI-derived models did not vary signifıcantly from those found in the
DTI-derived models. The highest deviation between models was a difference
of 5% in the average electric fıeld intensity in the tumor. The study shows that
DWI data can be used to develop realistic head models for simulating TT-
Fields, opening a new avenue for creating patient-specifıc computational
models on a large scale. These models could be benefıcial for retrospective
studies investigating possible connections between fıeld distribution and
disease outcome.
#4537 Computational modeling and characterization of Diedel proteins
that regulate highly-conserved immune signaling. Aulon Jerliu,1 Mary Ellen
Heavner,2 Shubha Govind,2 Shaneen Singh1. 1CUNY Brooklyn College, Brook-
lyn, NY; 2CUNY City College, New York, NY.
TheNF-kB and JAK/STAT pathways are well-established signal transduction
pathways, conserved from insects to mammals. They regulate several key bio-
logical processes such as cellular proliferation, stem cell maintenance, hemato-
poiesis and innate immunity responses. Consequently, their dysregulation re-
sults in aberrant conditions, often with deleterious consequences. It is well
documented that a variety of human diseases, especially cancer and immune-
related conditions are associated with various components of these pathways.
The focus of this study is the protein Diedel, which was identifıed as one of the
novel genes involved in the regulation of the JAK/STAT pathway in a genome-
wide RNA interference screen in Drosophila cells. Drosophila Diedel and its
viral homolog also suppress the conserved Imd-mediated NF-kB pathway in
flies. Diedel is a small cysteine-rich protein: It is comprised of only 115 amino
acids out of which 10 are cysteines. A recent crystal structure has revealed that
Diedel is composed of two sub-domains and incorporates two special structural
features, i.e. a hydrophobic surface patch suggesting a putative interaction site,
and a cis/trans conformation for a proline residue that may be relevant to its
physiological mechanism. However, its precise molecular function and mecha-
nism of action still remains unclear. Based on current sequence information in
the databases, Diedel seems to be conserved in drosophilids, the aphid Acyrto-
siphon pisum, and insect DNA viruses of the Baculoviridae and Ascoviridae
families.While investigating themechanism of infection of Drosophilamelano-
gaster larvae by the parasitic wasp, Leptopilina heterotoma, we have uncovered
two wasp venom sequences that are putative Diedel homologs. This study ex-
plores the detailed characterization of various Diedel homologs with an end to
establishing structure-function correlations in this family of novel proteins, us-
ing a combined tool-kit of template based modeling, sequence and structure
analyses algorithms. Our results confırm a conserved structural fold but there
are signifıcant sequence differences among the homologs. We present a com-
parative analysis of the theoretical models of Diedel homologs and their bio-
physical characterization. This study will help elucidate the molecular function
of the parasite Diedel proteins in suppressing the fly’s immune response. Our
fındings will also point to new ways by which dysregulated immune signaling
can be turned down and these fındings will potentially have implications in
treating inflammation and cancer in humans.
#4538 UniConSig: A new algorithm for genome wide quantifıcation of
gene functions and disease associations. Xu Chi,1 Meenakshi Anurag,2 Sartor
A.Maureen,3XiaosongWang1. 1University of Pittsburgh, Pittsburgh, PA; 2Baylor
College of Medicine, Houston, TX; 3University of Michigan, Ann Arbor, MI.
One of the greatest hurdles for cancer biologists is to identify the cancer-
causal genes from thousands of candidate genes suggested by large-scale genom-
ics or deep sequencing studies. In our previous study, we discovered that cancer
genes possess a complicated yet distinct “gene concept signature.” Concept Sig-
natures include cancer-related signaling pathways,molecular interactions, tran-
scriptional motifs, protein domains, and gene ontologies. We developed a Con-
cept Signature (or ConSig) analysis that prioritizes the biological importance of
candidate genes underlying cancer by computing their strength of association
with those cancer-related signature concepts. TheConSig analysis has facilitated
the discovery of a recurrent ESR1-CCDC170 gene fusion in more aggressive
Luminal B breast cancers (Nat. Commun. 2014) as well as TLK2, MAP3K3, and
MYST3 amplifıcations in aggressive luminal breast cancer (Nat. Commun. 2016,
J. Pathol. 2014, Oncogene In press). Nevertheless, current candidate gene prior-
itization methods, including ConSig, are subject to bias from redundancy in the
compiled knowledgebase (also known as gene concept database). This leads to
variation of the gene ranking and jeopardizes the reliability of the prioritymeth-
ods. In light of these problems, we developed an innovative, universal algorithm
called uniConSig. By penalizing overlapping concepts with a stable parameter,
“effective concept number”, we reduced the fluctuation in uniConSig scores, and
stabilized the ranking of the genes even with the randomly duplicated gene
concept databases. We tested the uniConSig algorithm by identifying known
cancer genes based on a cancer gene list, and found that the uniConSig algorithm
demonstrated signifıcantly enhanced prioritization of known cancer genes com-
pared to the ConSig algorithm, and the results are stable even in the presence of
randomly duplicated gene concept databases. In addition, we used calculations
based on the dominant/recessive cancer gene lists, and were able to provide a
quantitative measure of the potential dominant/recessive functions of human
genes underlying cancer. As an example application of this algorithm, we show
that the uniConSig scores can directly reveal the primary oncogene targets from
genomic amplicons in breast cancer.To our knowledge, UniConSig is the fırst
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tool for genome-wide quantifıcation of gene functions and disease associations.
UniConSig has broad applications on gene prioritization for genomic-based
studies to discover new disease causal genes or new gene functions.
#4539 Novel feature selection strategies for enhanced predictivemodeling
and deep learning in the biosciences. Pengwei Yang,1 Ryan Abo,1 Chang Liu,1
Zehua Chen,1 Haiguo Wu,1 Jike Cui,1 Chandri Yandava,1 Shannon T. Bailey,1
Curt Balch,2 Jeffery R. Gulcher,1 Thomas W. Chittenden1. 1Wuxi NextCODE,
Cambridge, MA; 2Bioscience Advising, Ypsilanti, MI.
Artifıcial Intelligence (AI) is the single most transformative technology in
human history. Advancements in personalized medicine depend upon signifı-
cantly furthering our current understanding of how genetic variation and so-
matic mutation regulate aberrant gene activity and subsequent disease biology,
including the myriad of dysregulated molecular mechanisms of cancer. To this
end, we have built a robust AI method to precisely assess pathogenicity for all
genomic missense variants. Coupled with our advanced deepCODE feature se-
lection strategy for constructing deep learning models, we can quantitatively
integrate a priori pathway-based biological knowledge with multiple types of
high-throughput omics data. This approach signifıcantly improves performance
of established classifıcation methods via enhanced semantic interoperability for
mapping between multiple biomedical ontologies and the subsequent identifı-
cation of genes and molecular pathways more highly predictive of cancer type
etiology. Specifıcally, our deepCODE AI methods greatly improve tumor sub-
type and drug-response classifıcation accuracies by combining tumor DNA-
and RNA-seq data. Our results indicate classifıcation of human breast and lung
cancer subtypes with 96% and greater than 99% accuracy, respectively. Our
novel multinomial statistical-learning method, which was validated with 6 can-
cer type patient-derived tumor xenograft (PDTX) mouse models, achieved
greater than 95% accuracy across 10,000 human tumors within the collection of
28 TCGA cancer types. Finally, our stepwise deepCODE drug target discovery
approach systematically integrates our deep learning classifıcation strategy with
advanced Bayesian Network modeling to identify causative driver genes, repre-
senting probable novel drug targets. This stepwise machine learning approach
also serves as a unique means to assess drug effıcacy. Taken together, our ad-
vanced deepCODE AI tools greatly expand the means to fully understand the
underlying molecular determinants of human cancer. We have developed user-
friendly decision support and research tools for in-depth tumor analysis and
large-scale case-control methods that afford investigators access to our deep-
CODE variant annotation algorithms.
#4540 MiVax: an innovative cancer neoantigen prediction system. Lenny
Moise, Guilhem Richard, Frances Terry, William Martin, Ann De Groot.
EpiVax Inc, Providence, RI.
T cell epitopes bearing tumor-specifıc mutations discovered using next gen-
eration sequencing stimulate T cell-mediated processes that lead to tumor re-
gression. Althoughneoantigen prediction using computationalmethods rapidly
identifıes epitope candidates in the mutanome, a large proportion prove to be
non-immunogenic. Innovative computational tools validated for infectious dis-
ease can be applied to enhance design of personalized cancer immunotherapies
by classifıcation of predicted epitopes according to potential for mounting a
tumor-specifıc response. We developed the JanusMatrix algorithm that parses
query sequences into MHC-facing and T cell receptor (TCR)-facing sequences
and screens sequence databases to identify MHC ligands that share TCR faces
with host-related proteins. A database of human protein sequences is available
to identify tumor-specifıc epitopes that may reduce anti-tumor activity by se-
quences that activate regulatory T cells (Tregs) trained in the thymus on self-
antigens. Similarly, tumor-specifıc epitope candidates are screened using data-
bases composed of human commensal- or pathogen-derived sequences to
identify epitopes that, respectively, may detrimentally or benefıcially cross-react
with T cells raised over the course of an individual’s immune history. We con-
ducted retrospective analyses of cancer vaccine effıcacy studies performed in
mice [Kreiter et al. 2015Nature 520, 692-696] showing thatmutanome-directed
vaccines effective at preventing tumor growth containedhigher numbers of class
I and II MHC neo-epitopes and had lower potential to cross-react with other
murine proteins, as identifıed by theMiVax platform. Likewise, an evaluation of
mutanomes derived from non-small cell lung cancer patients [Rizvi et al. 2014
Science 348, 124-128] revealed that improved clinical outcomes were observed
in patients with mutanomes enriched in class I MHC neo-epitopes with TCR
faces distinct from other self-epitopes.While retrospective in nature, the suite of
tools used for these analyses have been extensively validated in prospective vac-
cine studies for infectious disease. Removal of Treg epitopes identifıed by Janus-
Matrix has led to the development of a novel H7N9 influenza vaccine scheduled
for Phase I clinical trial. These results highlight the benefıts of using in silico tools
for the selection of high-value neoantigen candidates and how they can improve
the design and effıcacy of cancer vaccines. Neoantigens with low Treg activation
potential may then be used to support development of personalized therapies
including vaccination and in vitro expansion of tumor infıltrating lymphocytes
for adoptive cell transfer.
#4541 Understanding thedose and schedule dependence of effıcacy for the
Wee1 inhibitorAZD1775 in xenograft andpatient derived explantmodels by
mathematical modelling. James W. Yates, Elaine Cadogan, Jennifer Hare,
Adina Hughes, Urszula M. Polanska, Mark O’Connor, Susan E. Critchlow. As-
traZeneca, Cambridge, United Kingdom.
AZD1775 is a highly selective, small-molecule inhibitor of WEE1 being de-
veloped to treat patients with advanced solid tumors, as monotherapy and in
combination with olaparib. Experimental Procedures Patient-derived explant
(PDX) and xenografted models with a range of sensitivities to AZD1775 were
tested for response to different doses and schedules of AZD1775. WEE1 inhibi-
tion was assessed by pCDK1 as a direct substrate of Wee1 and RRM2 as a
surrogate ofCDK2 activity. Concentration ofAZD1775 in plasmawasmeasured
in the same animals. Mathematical models were developed to describe the rela-
tionship between drug exposure, biomarker modulation and resulting tumour
growth inhibition. Results The PKPD relationship of both pCDK1 and RRM2
could be described by the mathematical model with signifıcant delay between
PK and RRM2 reduction due to this being a protein degradation event. Three
factors influenced anti-tumour activity in the A427 xenograft and three TNBC
PDX models, namely the AZD1775 dose, the number of consecutive days of
dosing and the number of days between AZD1775 doses. The minimally effec-
tive preclinical dose with anti-tumour activity was 60mg/kg od. TGI was seen to
increase with increased days of consecutive AZD1775 dosing from 3 days on,
such that a 5 days on/9 days off schedule was more effıcacious than 3 days on/4
days off schedule for two weeks. A mathematical model successfully described
this effıcacy by using the predicted dose and schedule dependent reduction in
pCDK1. Conclusions The insights from this predictive modelling informed the
starting dose of 125mg BIDAZD1775 on a 5 day on/9 day off schedule; with the
clinical goal to optimize the days of consecutive AZD1775 dosing as well as the
maximum tolerated dose.
#4542 A mathematical model for immuno-chemotherapy. Raphael Serre,
Dominique Barbolosi. Aix Marseille Universite, marseille, France.
Chemotherapy and immunotherapy have sometimes been considered two
mutually exclusive approaches. On the one hand, chemotherapy has long been
considered as amodestly effective treatment (outside pediatric oncology), with a
short-lived effect caused by drug resistance, a poor tolerance profıle and a det-
rimental effect on the immune system. On the other hand, the oncologist con-
tinues using chemotherapies for many reasons: if the control of a large tumor
mass has to be obtained urgently irrespective of the side effects on the immune
system, if immunotherapy has failed or has not been validated as a fırst line of
treatment, when no targeted therapy can apply, etc. However, the issue of mod-
ifying the long-validated chemotherapy protocols tomake them a good fıt for an
adjuvant (or concomitant) immunotherapy has not been addressed yet. The
practice of gluing together an old Maximum Tolerated Dose (MTD) protocol
with a new immunotherapy protocol is often the standard practice, even though
some re-design would be needed to mitigate the massive and prolonged immu-
nosuppression caused by chemotherapy protocols. This lack of flexibility in the
chemotherapy regimen could seriously jeopardize the effects of adjuvant or
concomitant immunotherapy. Fortunately, chemotherapy and immunotherapy
may not be incompatible per se: there are accumulating evidence that low-dose
chemotherapies with little or no break-period (the so-called metronomic regi-
men) might have an immunological mode of action (in addition to the classical
explanation of its anti-angiogenic effect and cytotoxicity). Furthermore, even
withMTD protocols, experienced oncologists can improve the clinical outcome
with the rationale use of pro-immunogenic drugs. Nevertheless, the best way to
combine chemotherapywith immunotherapy is unknown and to fınd it in a trial
and error manner is unrealistic (high number of possibilities). This is why we
present a pharmacodynamic model of chemotherapy in combination with im-
mune checkpoint blockers, in order to provide a practical tool for the design and
the management of clinical trials. Based on simple equations, this model does
not predict a priori the best protocol, but helps the analysis of clinical data and
the subsequent identifıcation of optimal combinations. The mathematical
model is based on discrete-time equations of the tumor mass dynamics, under
the retro-control of a specifıc immune response partly antagonized by chemo-
therapy, but also stimulated by the release of tumor antigens. An original dy-
namic model of lymphopenia is introduced to describe the immunosuppressive
consequences of chemotherapy. The effects of immune checkpoint blockers are
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described in coherence with a previous publication in Cancer Research by the
same authors. Acquired drug resistance and tumor angiogenesis are also mod-
eled. Examples of practical applications are provided by showing how themodel
can describe various pre-clinical and clinical data.
#4543 Local and systemic tumor-immune dynamics in metastatic cancer.
Rachel Walker,1 Jan Poleszczuk,2 Heiko Enderling1. 1Moffıtt Cancer Center,
Tampa, FL; 2Polish Academy of Sciences, Warsaw, Poland.
Despite decades of effort, most disseminated cancers remain incurable, and
progression from localized tometastatic disease is largely responsible for cancer-
related mortality. In metastatic disease, an ongoing battle between tumor and
host occurs at each site; tumor-associated antigens, stress proteins, and danger-
associated molecular patterns can both initiate and continually stimulate an
immune response against a tumor. Adding an additional layer of complexity,
locally activated cytotoxic T cells traffıc through the host circulatory system to
also surveil metastasis elsewhere in the body. Thus, metastatic tumors are highly
interdependent; changes in the nonlinear tumor-immune interactions in one
tumor can perturb the systemic antitumor immune response, potentially facili-
tating spontaneous regression or aggressive outgrowth in distant sites. This can
additionally influence the clinical outcome of therapeutic intervention, which
depends on therapy-induced changes in tumor-immune dynamics both locally
and systemically, as well as patient-specifıc initial conditions of the global dis-
ease. Using the tools of mathematical oncology we gain insights into this com-
plex interconnectivity between metastatic sites. ODE models have been devel-
oped which incorporate both local tumor-immune interactions in each tumor
site and the traffıcking of activatedT cells systemically, and canbe parameterized
by experimental and clinical investigations. Using four primary tumor sites
(lung, liver, breast, kidney) we simulate the growth behavior of a primary site
upon both seeding, growth, and treatment of a secondary (or several) metastatic
site(s). In the presence of several metastatic sites, the dissemination of activated
T cells is not necessarily intuitive and depends on many factors including the
blood flow fraction to each organ and the tumor volume to organ size ratio.
Certain sites may experience inhibition of growth, and other sites may be pro-
moted upon seeding of an additional site. We computationally analyze all com-
binations of metastatic sites, and predict which sites are likely to benefıt (tumor
growth) andwhich to suffer (tumor shrinkage) in each combination based upon
known properties of physiological blood flow and tumor volume at initial pre-
sentation. This allows the identifıcation of which sites in each combination
would be the optimal target for surgical therapy in order to induce themaximum
reduction in overall tumor burden. Furthermore,we can simulate local radiation
at each respective site, quantifying the difference inmodel-predicted decrease in
overall tumor burden between individual targets. The results facilitate an im-
proved understanding of general disease kinetics in the metastatic setting, em-
phasize that ‘local‘ therapy is highly likely to have systemic effects, and support
the case for a paradigm shift in treatment target selection for metastatic disease.
#4544 Computational modeling to suggest patient-specifıc screening
schedules for early detection of gastric cancer. Heiko Enderling,1 Rachel
Walker,1 Jose Pimiento,1 Jaime Mejia,2 Domenico Coppola1. 1Moffıtt Cancer
Center, Tampa, FL; 2Instituto de Patologia Mejia Jimenez, Cali, Colombia.
Gastric cancer (GC) is often diagnosed at an advanced stage and consequently
remains the thirdmost common cause of cancer-related death worldwide. Early
detection and surgical intervention has been found to reduce GC-associated
mortality, yet an effıcient and cost-effective screening program still does not
exist. Several proteins including Lgr5, CD44 and CD133 have been found to be
upregulated during the H. pylori-associated Correa pathway of carcinogenesis,
and have the potential to act as biomarkers for early detection. The tools of
mathematical oncology facilitate the development of models capable of both
reproducing andpredicting the increase in expression of thesemarkers, and thus
the patient-specifıc progression of disease. These predictions can allow the iden-
tifıcation of optimal screening times to minimize the risk of undetected malig-
nant transformation. Here, we present a combined mathematical-statistical ap-
proach to identifying such optimal screening times in a manner which is both
biomarker-independent and H.pylori status-independent, thus allowing im-
proved generalizability and the potential for broader application in the clinical
setting. Logistic regression models are developed for each biomarker of interest
(Lgr5, CD133, CD44) to determine the likelihood of a patient being either early
in the Correa pathway (gastritis or metaplasia) or late in the pathway (dysplasia
or carcinoma) based on current age, sex and biomarker-positive cell fraction
obtained from immunohistochemical staining of biopsy tissue samples. Cali-
brated models for all three biomarkers were able to accurately classify disease
stage as determined by pathology report inmore than 85% of an initial cohort of
59 patients. Mathematical models describing the temporal evolution of the ex-
pression of each marker of interest are then defıned based on clinical data.
Coupled with the statistical tool for identifying the likelihood of being at each
stage of disease for all combination of input parameters, this framework can
forecast time to a clinically-signifıcant endpoint such as the development of
dysplasia or adenocarcinoma for future patients, allowing the suggestion of
screening times at which the likelihood of progression reaches a certain thresh-
old. The results suggest that for 13 out of 16 patients in our initial test cohort
(81%), models independently developed using three different markers all rec-
ommend similar follow-up screening times, showing promise for the general
applicability and robustness of such a tool.
#4545 A computational biology method to predict HMA or lenalidomide
treatment response in non-Del(5q) MDS. Leylah Drusbosky,1 Neeraj Kumar
Singh,2 Shireen Vali,2 Taher Abbasi,2 Christopher R. Cogle1. 1Univ. of Florida,
Gainesville, FL; 2Cellworks Group Inc, CA.
60% of myelodysplastic syndromes (MDS) patients fail to achieve clinical
improvement with hypomethylating agents (HMAs). 26% of patients with non-
del5q MDS respond to lenalidomide (LEN), but the mechanism of response is
unknown. Treatment of non-del5q patients who fail HMA is challenging and
predicting response to LENwould address this unmet clinical need.Methods: A
retrospective analysis was performed on non-del5q MDS patient cytogenetics,
gene mutations, treatments, and clinical response data. Using Cellworks Group
software, genomic data was used to generate disease-specifıc protein network
maps. Digital drug simulations were done by quantitatively measuring drug
effect and calculating a MDS inhibition score. Each patient-specifıc map was
digitally screened for the extent by which LEN and HMAs inhibited MDS in a
dose-dependent manner and compared to the patient’s clinical outcome. Re-
sults: Patient 1 is a non-del5q patient with trisomy 8 (8) and an ASXL1 frame-
shift mutation. Simulation modeling revealed overexpression (OE) of MYC
leading to IRF4 and IKZF expression, key pathways for LEN sensitivity. MYC
OE also leads to CCND1 expression, aiding proliferation of MDS cells. Simu-
lated LEN treatment targets MYC-induced upregulation of IKZF1, STUB1,
CRBN, and CSNK1A1 to reduce MDS cell survival. Upregulated TP53 inhibits
MYC expression, augmenting the patient’s response to LEN. To compare re-
sponse to other SOC drugs, azacitidine (AZA), was screened. The ASXL1 mu-
tation led to loss of PRC2-mediatedDNMT1 function.8 results inOEofGGH,
reducingmethylation of CpG regions. Given loss of DNMT1 function, patient 1
was predicted be a non-responder to AZA. Patient 2 is a non-del5q patient with
8, add(14q)(11.1-11.2), add(8)(p23.3-q24.3), and an ASXL1 mutation. Mod-
eling revealed the samedysregulated pathways as patient 1, predicting sensitivity
to LEN and resistance to AZA. Patient 3 is a non-del5q patient with complex
karyotype and mutations in IDH2, TET2, and SRSF2. Modeling revealed OE of
CARD11 yielding sensitivity to LEN. OE of CDH1 and AXIN1 decreased beta-
catenin activity, a known resistance mechanism to LEN. OE of apoptotic TP53,
BAX, and BBC3 sensitize this patient’s MDS cells to LEN. Modeling revealed
reduced EZH2 mRNA levels due to the SRSF2 mutation, directly impacting the
PRC2 complex needed for DNMT1-mediated CpG methylation. EZH2 is fur-
ther down regulated by L3MBTL2OE. TET2 is functionally challenged from the
lack of CpGmethylation, diminishing IDH activity, resulting in AZA resistance.
Conclusions: Computer modeling of non-del5q MDS patient biology can de-
duce the abnormal protein networks and consequent drug effects. This method
could be used to understand drug failure and highlight resistance pathways that
can be targeted to recover chemosensitivity. This technology can also be used to
predict MDS patient response prior to treatment, increasing drug effectiveness
and reducing side effects and treatment costs.
#4546 Structural evaluation of mutations identifıed on Cue domain of
FANCD2. Mohd Quadir Siddiqui, Ashok K. Varma. TMC-ACTREC, Navi
Mumbai, India.
Fanconi anemia complementation groupD2 (FANCD2) protein plays pivotal
role in DNA interstrand crosslink (ICL) repair and genome stability. FANCD2
comprises conserved CUE domain at N terminus, which is important for DNA
ICL repair and protein stability. However, molecular mechanism associated to
genetic alteration has not well characterized. Here, we have carried out multi-
modal approaches to explore folding pattern of FANCD2Cue domain and func-
tionally relevant mutations. Dynamic Light Scattering and Mass Spectrometry
data of purifıed proteins could revealed that wild- type protein is predominantly
monomeric, but mutated counterparts are exhibiting oligomeric properties.
Secondary, tertiary structure assessment and their thermal stability ofwild- type,
mutants were studied by Circular Dichroism (CD) and Fluorescence spectros-
copy. Furthermore, binding affınity and kinetics of Cue domain and mutants
withmonoubiquitin was evaluated by surface plasmon resonance (SPR).Molec-
ular modelling, simulation, normal mode analysis, principal component analy-
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sis and docking studies were carried out to understand in-depth conformational
dynamics and interactions. References:- 1. Regulation of the Fanconi anemia
pathway by a CUE ubiquitin-binding domain in the FANCD2 protein. Rego,
M. A. et al, Blood 120: 2109-2117,(2012). 2. Hypomorphicmutations in the gene
encoding a key Fanconi anemia protein, FANCD2, sustain a signifıcant group of
FA-D2 patients with severe phenotype. Kalb et al, Am JHumGenet 80: 895-910,
(2007)
#4547 Structural, thermodynamics and kinetics role of novel hot-spot
mutations of BCR-ABL1 in resistance towards ‘Ibs‘ inhibitors. Erik Laurini,
DomenicoMarson, Silvia Boccardo, Maurizio Fermeglia, Sabrina Pricl.Univer-
sity of Trieste, Trieste, Italy.
The present contribution integrates structural, computational, andmolecular
biology techniques to understand the eventual role of our newly reported hot-
spot mutations of the BCR-ABL1 KD in TKI resistance observed in CML pa-
tients (1) using a ‘two-tier level‘ investigation: isolated KDs and SH2-liker-
SH3-KD BCR-ABL1 constructs. Specifıcally, in silico experiments will disclose
the effects exerted by the “hot-spot” BCR-ABL1mutations on the protein struc-
ture, thermodynamic stability, and ability to interfere with BCR-ABL1 binding
to specifıc TKIs (e.g., imatinib, dasatinib, and ponatinib). Structural biology
(e.g., SAXS) evidences of wild type and mutant isolated KDs and SH2-linker-
SH3-KD (SSK) constructs (per se and in complexwith TKIs) will be discussed to
support in silico predictions. Direct drug binding thermodynamics and kinetics
to both KD and SSK constructs will be measured using isothermal titration
calorimetry and surface plasmon resonance. In vitro kinase assays will monitor
the ability of thesemutant isoforms to auto-phosphorylate and to phosphorylate
a substrate peptide. (1) Gibbons DL, Pricl S, Posocco P, et al., Molecular dynam-
ics reveal BCR-ABL1 polymutants as a uniquemechanism of resistance to PAN-
BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A. 2014 Mar
4;111(9):3550-5. doi: 10.1073/pnas.1321173111
#4548 Uncovering the membrane targetingmechanism of human uncon-
ventional class I myosins: a computational study. Daniel Gruffat, Shaneen
Singh. CUNY Brooklyn College, Brooklyn, NY.
The class 1 myosins (Myo1) are a widely expressed family of single-headed,
non-fılament-forming, membrane-binding myosins that comprise several sub-
classes and are characterized by their ability to cross-link the plasmamembrane
to the underlying actin cytoskeleton by the presence of a lipid-binding region in
the tail domain and an actin-binding region in the motor domain. Conse-
quently, these motor proteins are drivers of numerous cellular processes that
link themembranes to the actin cytoskeleton, including but not limited to vesicle
traffıcking, phagocytosis, cell migration, and intracellular membrane traffıck-
ing. Their importance in regulating these processes is underscored by studies
that link pathogenesis and cancer with this class ofmotor proteins. For example,
it has been recently shown that aberrant expression of Myo1b is linked to the
lymph node metastasis of human head and neck squamous cell carcinoma
through enhanced cancer cell motility and therefore, an interesting target for
new diagnostic and therapeutic strategies for patients with this type of cancer,
the sixth most common malignancy worldwide. Our focus in this study is the
little studied aspect ofmembrane targeting in the different sub-classes forMyo1,
even though it is critical part of the functionality of these proteins. Biological
membranes are an intricate system consisting of many structurally discrete pro-
teins and lipids that serve as interaction sites with lipid binding domains of
soluble proteins. The pleckstrin homology (PH) domain is one of the most
common structural folds that serve as a perfect scaffold for cytosolic proteins to
bind and target membranes. Although conventional sequence analysis doesn’t
identify any membrane binding domains in the tails of Myo1 proteins, recent
studies of Myo1c and Myo1g implicate the presence of a PH domain and attri-
bute this domain to their membrane targeting function. A preliminary analysis
based on a combination of sequence analysis and secondary structure prediction
tools, suggested that Myo1b and several other sub-classes also contain a PH
domain. We hypothesize that the membrane targeting function of all Myo1
sub-classes is driven by the presence of a PH domain within their tails. To
address this hypothesis, we have carried out a comprehensive investigation of
the Myo1 tails from all human unconventional class I myosin isoforms sub-
classes to identify, model, and analyze the membrane binding mechanism of
their PH domains. This study details the membrane binding mechanisms of
unconventional class I myosins and lays the foundation for the role of mem-
brane targeting of Myo1 proteins in cancer and disease.
#4549 Identifıcation of clinically relevant patterns in complex genomic
interactions of glioblastoma multiforme. Nevenka Dimitrova,1 Konstantin
Volyanskyy,1 Vlado Menkovski,2 Yee Him Cheung,3 Minghao Zhong,4 John T.
Fallon,4 Eric Vail4. 1Philips Intellispace Genomics, Valhalla, NY; 2Technishe Uni-
versiteit Eindhoven, Eindhoven, Netherlands; 3Philips Research North America,
Cambridge, MA; 4New York Medical College, Valhalla, NY.
Background: In clinical practice of complex diseases such as cancer it is a
challenging task to correctly identify driving factors and specifıc interactions
between multitudes of genomic and clinical variables. In cancer where patterns
are heterogeneous and involve highly complex interactions of biological path-
ways, this is by far a non-trivial task. Using novel approaches in machine learn-
ing, we demonstrate the ability to quantitatively and accurately reveal and de-
scribe patterns in genomic and clinical data. Method: We developed a
computational framework based on a number of interacting learners perform-
ing extensive pattern search and data characterization. This framework is mul-
tilevel and involves steps of relevant data transformations. We formulate and
apply contextually relevant criteria to distinguish and rank iteratively obtained
fındings and identify hidden relations between features and characteristic con-
nections to the clinical outcome. Summary: We successfully tested our method
on the public data of Glioblastoma Multiforme (GBM) from The Cancer Ge-
nome Atlas (TCGA).We identify interacting sets of genomic variables to repre-
sent clinically relevant subgroups of samples. We observe a dense presence of
interacting known cellular processes in GBM such as EGFR, FGFR, ERK, RAS,
MAPK, P53, as well as novel such as calcium signaling, kinesin motor and pro-
tein kinase pathways, tubulin and microtubule binding, phorbol esters/diacyl-
glycerol binding domain (C1 domain), purine ribonucleoside triphosphate
binding, positive regulation of phospholipase activity and others. The top rank-
ing pathways recap the well-known and new biology. In addition, compared to
known genes in the literature, we also observe involvement of novel genes in
GBM subtype characterization. Finally, we propose two-fold solution: identifı-
cation of distinctive patterns in the input genomic and output clinical data, and
specifıc format of their interactions.
#4550 IODNE: an integrated optimizationmethod for identifying the de-
regulated sub-network for precision medicine in cancer. Lijun Cheng, Sai
Mounika Inavolu, Milan Radovich, Varshini Vasudevaraja. Indiana University,
Indianapolis, IN.
Background and Purpose: Sub-network analysis can explore complex pat-
terns of the entire molecular pathways and networks for the drug target identi-
fıcation, and therefore drug selection. Computational algorithms are needed to
optimize the sub-network search for molecular pathways and networks under
certain conditions. Materials and Methods: In the paper, the gene expression
profıle of a cohort breast cancer patients and protein-protein interaction (PPI)
network are integrated with edge score and node score simultaneously. A novel
optimization algorithm, IODNE, is developed to search for the optimal de-
regulated subnetwork of merging gene and protein network. The application of
IODNE is demonstrated for a sub-network of drug target selection in breast
cancer subtypes Luminal-A/Luminal-B data from Cancer Genome Atlas
(TCGA). Where, the PPI networks data selected from Pathway Commons. Re-
sults: IODNE selects sub-networks, which contain ER1/PR and HER2, the well-
known targets in clinic Luminal-A/Luminal-B breast cancer subtypes. This val-
idates the utility of IODNE.When applying IODNE to the triple-negative breast
cancer subtype data, we identify sub-networks that contain genes such as
ERBB2, HRAS, PGR, CAD, POLE and SLC2A1. Conclusion: Using the known
drug targets in breast cancer subtypes, we demonstrate that IODNE is a robust
and powerful algorithm to identify sub-networks for drug target identifıcation.
Based on the gene expression profıles and protein interaction networks, it de-
tects the optimum deregulated subnetwork for the candidate drug target selec-
tion. The IODNE is promising tool for the precision medicine.
#4551 Divergence analysis with coarse coding of omics data across cancer
phenotypes. Wikum Dinalankara,1 Qian Qe,2 Lanlan Ji,2 Yiran Xu,2 Nicole
Pagane,2 Francisco Lobo,3 Laurent Younes,2 Donald Geman,2 Luigi Mar-
chionni1. 1Johns Hopkins Univ. School of Medicine, Baltimore, MD; 2Johns Hop-
kins University, Baltimore, MD; 3Federal University of Minas Gerais, Belo Hori-
zonte, Brazil.
Motivation: Complex cancer omics data can be diffıcult to interpret and an-
alyze with standard statistical methods. We thereby propose an innovative data
representation that drastically reduces complexity while improving usability
and interpretability for complex cancer phenotype analysis. Method: Despite
recent advances in omics technologies, the robustness of predictive biomarkers
in cancer remains severely limited. We hypothesize that this is primarily due to
an overemphasis on applying statistical learning methods without taking into
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consideration the underlying biological processes driving cancer. We therefore
propose a new approach based on representing data based on the comparison to
a baseline group. This results in a data format that encodes biologically mean-
ingful information and can be easily analyzed. We apply this transformation to
publicly available datasets obtained across multiple tumor types using different
omics technologies. For each cancer phenotype considered, we cross-validate
the learned decision rules using SVMs and random forests and demonstrate that
there is no drop in performance despite the use of a simplifıed data representa-
tion.We also apply the Chi-squared test to our simplifıed data to select genomic
features differentially associated with relevant cancer phenotypes. To this end
we compare our method to traditional class comparison approaches. Overall,
this analysis shows that omics features selected by ourmethod provides equal or
better classifıcation performance than standardmethods. Further, we show that
our simplifıed data representation fılters out much of the biologically irrelevant
variation and that the resulting data can be successfully applied to gene set
analysis applications, ultimately improving inference on disease phenotypes.
For instance, by applying our method to signaling pathways and cancer hall-
marks gene sets, we show that our approach can be used to detect dysregulated
pathways more effıciently than with traditional methods. Conclusion: By com-
paring cancer omics data to a baseline status, we obtain a much simpler data
representation that preserves biologically relevant information while eliminat-
ing much of the unwanted variance that is often confounding in the analysis of
high-dimensional data. Furthermore, data represented using our approach can
be easily stored and analyzed, and it is equivalent or superior to traditional data
representationmethods for predicting clinically relevant cancer phenotypes and
detecting biologically relevant cancer pathways.
#4552 ssCOPA: a novel method with improved sensitivity to assess statis-
tical signifıcance for cancer outlier profıle analysis of gene expression.Hong
Gao, Sam Ng, Hinco J. Gierman. Illumina, San Diego, CA.
To understand the genetic mechanism of disease, fınding biomarkers and
drug targets are a major focus of academic and pharmaceutical research. How-
ever, it has become clear thatmany important genes driving diseases like cancer,
are deregulated in a relatively small group of outliers, e.g. amplifıed and fusion
genes. Cancer outlier profıle analysis (COPA), introduced by Tomlins et al, has
raised interest in detecting genes with outlier expression within a group, partic-
ularly in cancer patients. However, the magnitudes of the COPA scores are not
directly comparable across different studies or with different input parameters.
Also, integrating COPA scores across multiple studies in a meta-analysis is
problematic. Current solutions to performing meta-analyses, including rank-
based methods and binomial test, require large study numbers without adjust-
ment for the differences in study size. Also, within a single study COPA scores
alone do not provide a P-value, and it is impossible to know which outlier genes
are statistically signifıcant. Here we developed three novel methods to address
these problems by computing a signifıcance for COPA scores, including Boot-
strap resampling, Bootstrap generalized Pareto distribution (GPD) and Bino-
mial method for statistical signifıcance of COPA (ssCOPA), to enable the com-
parison of COPA score across studies or parameters. We fırst evaluated our
methods using two breast cancer studies. The P-values generated by Binomial
method match closely to Bootstrap resampling using 10,000 randomizations,
better than Bootstrap  GPD. In addition, the Binomial method requires sig-
nifıcantly less computing time than the othermethods.We further validated our
methods with a meta-analysis of fıve breast cancer studies and compared the
results with the top-ranking genes of a large-scale meta-analysis of 31 breast
cancer studies by ONCOMINE. We show that our P-value-based approaches
(P 10-1710-24) achieves signifıcantly better concordance than the Binomial
test (P  10-14). Data and methods are available for use on the Illumina Bas-
eSpace® CohortAnalyzer platform (formerly known as NextBio Clinical).
#4553 Development of a 4-sample version of the Kolmogorov-Smirnov
test for evaluating the temporal physiology of cells treated with test com-
pounds in a label-free, high content, platform for quantitative analysis of
adherent cell-culture models. Ed Luther,1 Livia Mendes,1 Jiayi Pan,1 Elena
Holden,2 Vladimir Torchilin1. 1Northeastern University, Boston, MA; 2SeeCyte
Biotechnology, Boston, MA.
Our objective is to develop multi-functional nanotechnology-based anti-tu-
mor drug delivery systems for improving the effıcacy of treatments and reducing
undesirable side effects. The essential part of this process is the development and
validation of un-biased, quantitative analytical techniques. We employed a
newly developed holographic imaging cytometry system HoloMonitor® M4 for
label-free time-lapse cellular analysis (Phase Holographic Imaging, Sweden).In
previous work we have demonstrated our ability to obtain quantitative, high
content cellular feature data congruent to data obtained from traditional label-
based systems. We applied a modifıed version of the Kolmogorov-Smirnov
2-sample test. The classic test takes control and test frequency distributions
(histograms), and converts them to probability functions. The maximum verti-
cal displacement between the two is reported as the D-value, to determine if the
two distributions are signifıcantly different. In modifıed versions of the test, it is
a comparator; instead of a single value, we obtain histograms of the difference
between the control and test normalized probability functions. These histo-
grams are termed Brownian Bridges, where the end points are fıxed at a value of
zero, and the function is free to vary in between, in either up-going, down-going
or mixed. Now, we report the development of a 4-sample Kolmogorov based
method. TwomodifıedK.S. tests are performed to compare distributionsA toAc
and B to Bc. It is assumed that all the distributions have the same time basis, and
each time point is processed sequentially. The resulting time point pairs are
plotted as a vector in a two parameter scattergram, tracing the outlines of the
probability distribution of the cell populations through time.Unlike, the Brown-
ian Bridge histograms, here, the starting and the ending points are both at the
same location (0,0), within the two dimensional scattergram, but are free to
move in both positive andnegative directions away from the origin.HeLa cells in
a 12-well MatTek plate were adhered and treated with Paclitaxel (PCT) in con-
centrations from 0 to 40 nM in 5-fold increments, either pulsed for 4 hrs. fol-
lowed by 48 hours of imaging or with continuous exposure for 48 hours of
imaging. We obtained a variety of different plot types, including continuous vs.
pulsed comparisons, inter dosage comparisons, as well as the ability to compare
multiple features to each other. Of particular signifıcance is the fact that in
comparative dosage experiments over 10 nM, the pulsed and continuous prob-
ability zones are completely separated, reflecting live and dead cells, and allow-
ing complex pharmacodynamic tracking.
#4554 Unifıed theoretical algorithms for graphics dynamic multiple
transformations of dose-effect relationships with computer simulation.
Ting-Chao Chou.Memorial Sloan-Kettering Cancer Center, New York, NY.
Based on physico-chemical principle of themass-action law, bio-system anal-
ysis (arrangement & combinatorial) several hundred rate equations have been
derived and published. Mathematical induction allows the deduction of them
into the unifıed general median-effect equation (MEE) that makes dose & effect
“interchangeable” for the 1st order and higher order dynamics. Based on the
MEEplot, all dose-effect curves can be “linealized”which allows the quantitative
determination of x-intercept (log Dm which signifıes potency) and slope (m
which signifıes shape or dynamic order). Extension of MEE to multi-drug com-
binations resulted the combination index (CI) theorem which quantifıes syner-
gism (CI1), additive effect (CI1), and antagonism (CI1). This unprece-
dented approach and multi-step logics have been summarized in [Chou TC.
Pharmacol Rev 58: 621-681, 2006] which has been cited 1,261 times in 485
bio-medical journals (http://www.researcherid.com/rid/B4111-2009 as of
10.19.2016). Dose-effect curves (single & multi-drugs) can be quantitatively
transformed into the MEE plot, Fa-CI plot, isobologram, Fa-DRI Plot for dose-
reduction index, and when n2, the polygonogram. This presentation will il-
lustrate of combinations (1:5) of docetaxel (TXT) with T-compound against
HCT-116 colon carcinoma xenograft in nude mice. In all, only 66 nude mice
have been used, i.e. TXT 3 doses, T 3 doses and TXTT 4 doses, plus a control
group, each N6. The MEE “Linearization” allows the “Econo-Green Bio-re-
search”, with small experimental size and small number of data points, using
small number of animals. The algorithms based computer simulation using
CompuSyn software can be completed within one second after the dose and
effect data entries. The CompuSyn has been offered for free download upon
registration via www.combosyn.com.
#4554A Simple, effıcient, and quantitative approach for determination of
synergism, additive effect, and antagonism of drugs in vivo using combina-
tion index method: a proposition for clinical protocol design and regulatory
synergy claims. Jianing Fu,1 Ting-Chao Chou2. 1Columbia University Medical
Center, NewYork,NY; 2Memorial Sloan-KetteringCancerCenter, NewYork,NY.
Based on the systematic dynamic rate derivations with the mass-action prin-
ciple and mathematical induction-deduction, the median-effect equation of
Chou, and the combination index (CI) equation and their algorithmallowquan-
titative determination of synergism (CI1), additive effect (CI1) and antago-
nism (CI1) (Pharmacol Rev 58:621-681, 2006). Based on Google Scholar Ci-
tations, the CI simulation has been cited 7,712 times in 800 bio-medical
journals as of 10.19.2016.However,most citing papers were with experiments in
vitro, relative few in vivo and rarely in clinical trials. This is despite the fact that
the CI method equation, algorithm, and the CompuSyn software are the same
for in vitro and in vivo, although the practical aspects such as sample size, time
and cost, the readiness of the end-point measurement, and the ethical consider-
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ations are different. Our recent publication (in Fu J et al. Synergy 3: 15-30, 2016)
of two-drug combination (docetaxel and T-607 compound, 1:2) against HCT-
116 colon carcinoma xenograft in nude mice has demonstrated very desirable
synergy. We now illustrate the experimental and data-analytical details of the
experimental planning and design, execution, measurements, for docetaxel and
T-Compound combination against MX-1 mammary carcinoma xenograft in
nudemice. Treatment Q3Dx4 i.v. starting Day 7, and the tumor sizes and body-
weight changes measured on Days 16, 19, and 22. A total of 50 nude mice were
used (each drug and combinations, 3 doses each (n5) plus a control group of
5). Full spectrum of synergism (CI0.79 to 0.93) were observed on Days 19 and
22. Automated simulationwere carried out for dose-effect curve,MEplot, Fa-CI
plot, isobologram, and Fa-DRI (Dose-Reduction Index) plot with CompuSyn
software (Free download available upon registration via www.combosyn.com).
This simple, effıcient, “econo-green” bio-research paves the way for drug com-
bination clinical trial design and regulatory synergy claims.
IMMUNOLOGY: Clinical Immunotherapy, Viruses, and Bacteria
#4556 MEDI5395: An armed oncolytic Newcastle disease virus. Danielle
Carroll, James Harper, Travers Jon, Shannon Burke, Ruth Franks, Christel Na-
varro, Xing Cheng, RobertWilkinson, Hong Jin.MedImmune, LLC, Cambridge,
United Kingdom.
Oncolytic viruses are live, replication-competent viruses that infect and/or
replicate selectively in tumour cells leading to the destruction of the infected cell.
Cell lysis occurs as a natural consequence of the viral life cycle and released
virions can infect and kill neighbouring tumour cells leading to an amplifıed
therapeutic effect. Oncolysis has the added benefıt of releasing multiple tumour
antigens that may further induce an immune-mediated therapeutic response.
Newcastle Disease Virus (NDV) is an avian paramyxovirus, which has proven
safety and demonstrated effıcacy against a variety of preclinical cancer models
and in PhI clinical studies as an oncolytic agent, oncolysate orwhole cell vaccine.
Using reverse genetics, we have generated a recombinant strain of NDV that
overcomes environmental and regulatory concerns uncoupling oncolytic po-
tency and avian pathogenicity. Furthermore we have enhanced the immune
modulatory properties of NDV by engineering the virus to express granulocyte/
macrophage colony-stimulating factor (GM-CSF). We have evaluated the bio-
logical characteristics of recNDVGM-CSF (MEDI5395) in vivo and in vitro.
MEDI5395 selectively replicates in and kills a wide variety of human andmouse
tumour cell lines. Additionally infection of cancer cells with MEDI5395 results
in the increased production and secretion of pro-inflammatory cytokines and
chemokines which are able to recruit mediators of both the innate and adaptive
immune responses. MEDI5395 is a potent activator of the type I interferon
response. In vivo, using a range of syngeneic and xenograft models we have
demonstrated thatNDV treatment has robust anti-tumour activity. In aHT1080
fıbrosarcoma xenograft model a single administration (intra-tumoural or sys-
temic) was able to cure 80% of tumour bearing mice. In syngeneic mouse tu-
mour models, which support minimal viral replication MEDI5395 treatment
causes signifıcant changes in the local immune suppressive microenvironment
and results in long-lasting anti-tumour immune responses. These responses are
further enhanced in models that permit greater replication and also when com-
binedwith immune checkpoint blockade. The inherent properties ofNDV (self-
propagation, tumour-selective replication, and immunostimulatory properties)
coupled with the ability to genetically engineer NDV to express therapeutic
transgenes may provide a multi-modal attack on the tumour, delivering greater
benefıt to patients.
#4557 Tumor immune profıling identifıes multiple unique therapeutic
targets that improve vaccination oncolytic virotherapy against metastatic
ovarian cancer.AJ Robert Mcgray,1 Cheryl Eppolito,1 AnthonyMiliotto,1 Raya
Huang,1 Kelly Singel,1 Jonathan Pol,2 Kyle Stephenson,2 BrahmH. Segal,1 Brian
Lichty,2 Kunle Odunsi1. 1Roswell Park Cancer Institute, Buffalo, NY; 2McMaster
University, Hamilton, Ontario, Canada.
While spectacular responses to cancer immunotherapy have been observed in
some patients, the majority of responses are short-lived with ultimate tumor
relapse. Therefore, it is crucial to identify strategies that will effectively synergize
with immunotherapy to improve treatment outcome. Using a pre-clinical
mousemodel, we explored the use of a potent heterologous prime/boost vaccine
strategy for the treatment of metastatic intraperitoneal ovarian cancer. Priming
with an adjuvant based vaccine followed by boosting with a novel oncolytic
Maraba viral vector elicited robust tumor-specifıc CD8 T cell responses, with
high numbers of therapy-induced CD8 T cells effectively traffıcking to the
tumormicroenvironment.While this approach greatly improved tumor control
and long-term survival compared to treatment with the priming vaccine alone,
the combination therapy was not curative and cellular analysis suggested that T
cells within the tumor microenvironment were functionally suppressed/ex-
hausted. Transcriptional profıling of tumors following therapy revealed that
prime/boost vaccination led to induction of numerous inflammatory processes,
with gene signatures consistent with not only CD8 T cell infıltration, but also
upregulation of multiple co-stimulatory and immune checkpoint receptors, in-
duction of chemokine networks associatedwith both lymphoid andmyeloid cell
traffıcking, as well as infıltration of immunosuppressive myeloid cell popula-
tions. We reasoned that these gene signatures could be used to design rational
combination therapies that would have the potential to further enhance tumor
attack following prime/boost vaccination. Using this strategy, we observed that
checkpoint blockade usingPD-1 in combinationwith prime/boost vaccination
resulted in a dramatic improvement in tumor control, as did transient depletion
of granulocyticmyeloid cells (but notmonocytes/macrophages) following treat-
ment. Current studies are underway that combine prime/boost vaccinationwith
relevant co-stimulatory agonist antibodies, as well as inhibitors of candidate
chemokine networks identifıed through tumor profıling. These fındings under-
score the importance of designing treatment strategies that not only elicit robust
anti-tumor T cell responses, but also improve the duration and/ormagnitude of
immune attack within the tumor microenvironment. Additionally, our data
suggest that interrogating the tumor microenvironment during treatment can
identify unique therapeutic targets that have the potential to further improve
therapeutic impact.
#4558 Immunogenicity and antitumor effıcacy of live attenuated Salmo-
nella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and
VXM06m. Sébastien Wieckowski,1 Lilli Podola,2 Marco Springer,3 Iris Kobl,3
Zina Koob,4 Caroline Mignard,4 Amine Adda Berkane,5 Ming Wei,5 Albrecht
Meichle,3 Klaus Breiner,1 Matthias Schroff,1 Philipp Beckhove,2 Heinz
Lubenau3. 1VAXIMM AG, Basel, Switzerland; 2University Hospital Regensburg,
Regensburg, Germany; 3VAXIMM GmbH, Mannheim, Germany; 4Oncodesign
S.A., Dijon, France; 5CellVax S.A.S., Romainville, France.
Signifıcant progresses have been recently accomplished in immuno-oncology
and in the development of cancer immunotherapies. However, novel solutions
are necessary to overcome the peripheral tolerance and the immunosuppressive
tumor microenvironment that prevent the eradication of cancer. VAXIMM is
developing fırst-in-kind Salmonella typhi Ty21a-based oral T-cell vaccination
platform for the initiation of anti-tumor cellular immune responses via a unique
mode-of-action. This study summarizes the immunogenicity and preclinical
anti-cancer effıcacy for Salmonella typhimurium murine vaccines VXM01m,
VXM04m and VXM06m which encode murine vascular endothelial growth
factor receptor 2 (VEGFR2), mesothelin (MSLN) and Wilm’s tumor 1 (WT1)
protein antigens, respectively. Immunokinetic studies were performed in
healthy animals treated with 1010 CFU/dose of either the control Salmonella
typhimurium empty vector VXM0m_empty, or Salmonella typhimurium
VXM01m, VXM06m or VXM04m, and antigen-specifıc T cells were detected
with MHC class I pentamers by flow cytometry in the spleen. The anti-tumor
effıcacy of VXM01m and VXM04m was evaluated in the Panc02 syngeneic
model of pancreatic adenocarcinoma overexpressing MSLN, and the anti-can-
cer activity of VXM06m was evaluated in the FBL-3 disseminated model of
erythroleukemia expressingWT1, in a prime-boost setting. Treatmentwith each
of the vaccines VXM01m, VXM04m and VXM06m induce a peak antigen-spe-
cifıc systemic immune response 7 to 10 days after the last vaccination. Treatment
of Panc02 tumor-bearing mice with VXM01m and VXM04m single agents re-
sulted in a signifıcant reduction in the tumor growth rate, compared to the
control group, with amedian T/C of 37.6% and 19.4% respectively, 35 days after
tumor challenge. Treatment of mice bearing FBL-3 leukemia with VXM06m
generated a rapid and sustained anti-tumor effect with 100% (10 out of 10) of
surviving animals 175 days after leukemia challenge. In contrast, treatment with
VXM0_empty did not show any anti-cancer effect, with a median survival of 45
days and 0% (0 out of 10) of cancer regression. VXM01m, VXM04m and
VMX06m were tolerated at the effective doses and have demonstrated consis-
tent anti-cancer activities with substantial T cell responses in different animal
tumor models. This study provides further evidence that VAXIMM’s versatile
oral T-cell vaccination platform can be used to stimulate anti-tumor immunity
against various tumor-associated antigens. Further studies of VAXIMM’s can-
cer vaccine candidates, as monotherapy as well as in combination, are war-
ranted.
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#4559 Novel T-cell targets for HPV16-associated oropharyngeal cancer
immune therapy. Sri Krishna,1 Falguni Parikh,2 Peaches Ulrich,1 Shanshan
Yang,1 Amelia Clark,3 Seunghee Kim-Schulze,3 Marshall Posner,3 Jin Park,1
Andrew Sikora,2 Karen S. Anderson1. 1The Biodesign Institute, Arizona State
University, Tempe, AZ; 2Baylor College of Medicine, Houston, TX; 3Mount Sinai
School of Medicine, New York, NY.
Background: Human papillomavirus subtype 16 (HPV16) is the primary
cause of an increasing number of oropharyngeal cancers (HPVOPC)worldwide.
Despite effective prophylactic vaccines, low vaccine uptake and high incidence
of HPV16 infections provides a strong rationale for the development of novel
targeted immune therapies against HPVOPC. We sought to 1) Identify novel
CD8T-cell (CTL) epitopes fromHPV16 antigens; 2)Understandmechanisms
of immune resistance in HPVOPC to enhance T-cell based immune therapies.
Methods: We developed a comprehensive bioinformatic strategy to predict po-
tential CTL epitopes for 10 HLA class I alleles representing common HLA-
supertypes (with90% global coverage) against HPV16 antigens E2, E6 and E7.
T-cell reactivity against candidate epitopes was assessed by short term ex vivo
T-cell cultures from healthy donors (n15) andHPVOPC patients (n18).We
data mined publicly available OPC transcriptomes (University of Michigan
(UM-OPC) cohort, n36) for gene expression analysis. Results: IFN-gamma
Elispot assays using 58 candidate epitopes from HPV16 E2, E6 and E7 revealed
that 70% of HPVOPC patients had either E2 or E6-specifıc CTL reactivity.
E2-CTL reactivity was 2-fold higher in HPVOPC patients than in healthy
controls (mean 68.75 vs. 24.6 SFUs/106 cells, P 0.027), while no difference
in E6- CTL responses were observed between patients and controls. In contrast,
E7-specifıc CTL responses were low to undetectable. We have further identifıed
7 novel E2 and 3 novel E6 CTL-epitopes, and confırmed immunogenicity of
previously described E2, E6 and E7 epitopes. RNAseq analysis of the UM-OPC
dataset indicated that 78% of HPV16 OPCs expressed E2 (P0.05), while E6
and E7 was expressed in all HPVOPCs (P0.01) demonstrating tumor antigen
expression. Unsupervised hierarchical clustering of immune transcriptomes re-
vealed that HPVOPCs have higher expression of immune-regulatory ligands
than HPV-negative OPC tumors, indicating high immune infıltration and pos-
sible immune-editing. We identifıed high expression of several key immune
exhaustion genes such as IDO-1, TIM-3 and LAG-3, previously undescribed in
HPVOPC. Conclusion: HPV16-E2 represents a novel antigen target for
HPVOPC immune therapy, as demonstrated by T-cell reactivity and tumor
antigen expression. Several novel and previously defıned E2, E6 and E7 CTL
have been confırmed for T-cell reactivity in HPVOPC patients. Transcriptomic
analysis of OPCs indicate extensive immune dysfunction in HPVOPCs that are
distinct from non-HPV OPCs. The T-cell epitopes identifıed in this study in
combination with blockade of HPVOPC-specifıc checkpoints may be useful for
targeted immunotherapy.
#4560 Fusobacterium nucleatum and tumor immunity status according
to microsatellite instability in colorectal cancer. Kosuke Mima,1 Tsuyoshi
Hamada,2 Reiko Nishihara,2 Jonathan Nowak,3 Zhi Rong Qian,2 Keisuke Ko-
sumi,2Marios Giannakis,2 Susan Bullman,2 Hideo Baba,1 Curtis Huttenhower,4
Wendy Garrett,2 Andrew Chan,5 Matthew Meyerson,2 Charles Fuchs,2 Shuji
Ogino2. 1Graduate School of Medical Sciences, Kumamoto University, Ku-
mamoto, Japan; 2Dana-Farber Cancer Institute, Boston, MA; 3Brigham and
Women’s Hospital, Boston, MA; 4Harvard T.H. Chan School of Public Health,
Boston, MA; 5Massachusetts General Hospital, Boston, MA.
Objective: Fusobacterium nucleatum (F. nucleatum) is a microbial pathogen
that contributes to the initiation and progression of colorectal cancer. Although
evidence points to its immunosuppressive effects in colorectal cancer, F. nuclea-
tum has been associated with high-level microsatellite instability (MSI) which is
characterized by intense immune response. We hypothesized that the associa-
tion of F. nucleatumwith local immunosuppressionmight be stronger in tumors
with high-level MSI or a high neoantigen load, which is a direct consequence of
MSI that influences tumor-immune interactions. Design:We utilizedmolecular
pathological epidemiology database of 1,027 colon and rectal cancer cases in the
Nurses’ Health Study and the Health Professionals Follow-up Study. We as-
sessed the association of F. nucleatum (negative, low, or high) with tumor im-
munity status in strata ofMSl status.Wemeasured F. nucleatumDNA in tumor
tissue using quantitative PCR. As immunity status, we evaluated hystopatho-
logical lymphocytic reaction (tumor-infıltrating lymphocytes [TIL], intratu-
moral periglandular reaction, peritumoral lymphocytic reaction, or Crohn’s-
like lymphoid reaction) and measured T cell densities (CD3, CD8, CD45RO
[PTPRC] or FOXP3 cells) using immunohistochemistry and computer-as-
sisted image analysis. Logistic regression model was used to adjust for potential
confounders, including CpG islandmethylator phenotype, LINE-1methylation
level, and KRAS, BRAF, and PIK3CA mutations. Using whole-exome sequenc-
ing data (N 586), we conducted secondary analyses to assess the interaction of
F. nucleatum with a neoantigen load. Results: The association between F. nu-
cleatum and TIL differed by MSI status (P for interaction  0.0017; with the
adjusted  level of 0.006). Compared with F. nucleaum-negative cases, F. nu-
cleatum-positive cases were associated with low-level TIL in MSI-high tumors
(odds ratio, 0.40 [95% confıdence interval, 0.14-1.08] and 0.40 [95% confıdence
interval, 0.17-0.97] for F. nucleaum low and high cases, respectively), but not in
microsatellite stable/MSI-low tumors. We did not fınd any interaction between
F. nucleatum and MSI status in T cell subsets. The association between F. nu-
cleatum and TIL did not differ signifıcantly by levels of a neoantigen load (P for
interaction  0.015). Conclusions: The association of F. nucleatum with the
immunosuppressive microenvironment may be stronger in colorectal cancer
with high-level MSI. Our fındings suggest the interplay between F. nucleatum
and MSI status in host immune response to the tumor.
#4561 Non-integrative lentiviral particles for immunotherapy: RNA de-
livery to drive tumoral antigen presentation in a safe and effıcient way. Pas-
cale Bouillé,1 Christine Duthoit,2 Nicolas Martin,2 Lucille Lamouroux,2 Jean-
Christophe Pages3. 1VECTALYS and FLASHCELL, Toulouse, France;
2VECTALYS, Toulouse, France; 3INSERM U966 Faculté de Médecine, Tours,
France.
Safe and effıcient cancer therapies using adoptive transfer of engineered cells
are very promising but very challenging approaches. Opportunities to improve
gene transfer into primary cells involve a better design of the vectors used. Such
improvements must lead to an increase of the effıciency of gene expression, the
cell phenotype preservation and the increase of the gene number delivered. The
use of lentiviral vectors has largely increased in clinical protocols over the past
few years but safety concerns have slowed down this progression. Actually, the
permanent genetic modifıcation remains a focus of signifıcant regulatory over-
sight. On another side, mRNA delivery is a versatile, flexible, and safe mean for
protein therapies, but existing techniques, such as chemical or electroporation-
based transfection protocols, are known to induce cell toxicity and phenotype
modifıcations of the target cells. Here, we present an innovative tool, named
LentiFlash, allowing RNA delivery into target cells without any genomic scar.
This tool combines RNA delivery, providing the best expression system to get
effıcient and transient expression, and lentiviral delivery which exhibits the best
effıciency of entry into primary and stem cells. The RNA encapsidation is me-
diated via an RNA/protein interaction using properties of the MS2 bacterio-
phage. This new vector breaks with all existing systems. The resulting lentiviral
particle is able to effıciently deliver non-viral coding or non-coding RNA into
the cytoplasm of any cell type. These LentiFlash particles, are able to transduce
delicate primary cells, such as dendritic cells, T cells and hematopoietic stem
cells. They show an effıcient, fast and transient expression of protein and RNA,
such as antigenic peptides or genome editing tools, with no cell phenotypemod-
ifıcation. Here we show a proof of concept on primary murine dendritic cells
transduction with LentiFlash particles, successfully used to deliver several tu-
moral antigens. As a result, these dendritic cells are able to present the antigens
to the immune system which in turn can effıciently fıght a tumor development
into wild typemice. This new delivery system gives the opportunity for multiple
antigens co-expression to enhance immune responses, avoiding tumor relapse.
Such multiple co-expressions into immune cells are expected to mimic the in-
nate and adaptive immune responses. This transient RNA delivery mediated by
LentiFlash is a powerful tool to induce an effıcient gene delivery. The possibility
to express multiple genes at once in the target cells is an attractive therapeutic
perspective. The absence of any viral sequence avoids any integration event, an
important safety consideration for human use. Finally, another advantage of the
LentiFlash system is its ability to utilize lentiviral production platforms already
validated in clinical settings.
#4562 Exploring the immune stimulatory properties of oncolytic New-
castle Disease Virus. Shannon Burke, Ruth Franks, James Harper, Jon Travers,
Christel Navarro, Xing Cheng, Robert Wilkinson, Hong Jin, Danielle Carroll.
MedImmune, LLC, Cambridge, United Kingdom.
Newcastle Disease Virus (NDV) is an avian paramyxovirus, which has signif-
icant oncolytic activity against mammalian cancers. It is multi-modal in its anti-
tumour activity and offers a tumour selective, self-propagating therapeutic with
oncolytic activity and immunostimulatory properties. Within the tumour itself,
NDV infection is able to modulate the immune suppressive microenvironment
and induce positive anti-tumour inflammatory responses. Additionally, we have
enhanced the immune modulatory properties of NDV by engineering the virus
to express granulocyte/macrophage colony-stimulating factor (GM-CSF). To
better understand the immune modulatory mechanisms by which NDV infec-
tion is able to alter the tumourmicroenvironment we investigated the responses
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of normal human PBMCs and isolated immune cell populations followingNDV
exposure. Using flow cytometry, cytokine and gene expression analysis we dem-
onstrated activation of the innate immune cells and a robust type I IFN and
pro-inflammatory response. 24 hours post infection, innate immune cells (mac-
rophages, natural killer cells and dendritic cells) had upregulated cell surface
activation markers and secreted high levels of cytokines in a dose-dependent
fashion. Furthermore, by using NDV constructs encoding fluorescent proteins
we showed, in a specifıc subset of myeloid cells, the preferential uptake of virus
and subsequent self-limiting viral replication. In a co-culture system, these in-
fectedmyeloid cells were able to function as ’virus cellular carriers’ andwere able
to mediate the effıcient transfer of infectious NDV to tumour cells resulting in
their oncolytic death. To further investigate the ability of NDV to infect, spread
and kill tumour cells in vivo, we utilised tissue slice cultures of fresh patient
samples. These studies demonstrated virus replication and transgene expression
in tumour slices, as well as the uptake of virus in a small fraction of specifıc cells
in slices of normal liver. Moreover, evidence that NDV was able to alter the
tumourmicroenvironment could be demonstrated in such cultures by sampling
the culture supernatants over time. By investigating the immune modulatory
properties of NDV in vitro and in vivo we will gain greater insight and under-
standing of the anti-cancer properties ofNDV.Thisworkwill also help guide the
selection of transgenes for next generation approaches to augment the inherent
immunostimulatory properties ofNDV, and help inform clinical dosing options
such as intravenous infusion or cell-based delivery.
#4563 Local and abscopal effects in oncolytic virotherapy are boosted by
immune checkpoint blockade, immunogenic chemotherapy, or IFNAR
blockade. Laetitia Fend,1 Takahiro Yamazaki,2 Xavier Préville,1 Eric Quémé-
neur,1 Oliver Kepp,3 Julien Adam,2 Aurélien Marabelle,2 Jonathan Pitt,2 Guido
Kroemer,3 Laurence Zitvogel2. 1TRANSGENE S.A., Illkirch Graffenstaden,
France; 2Institut Gustave Roussy, Villejuif, France; 3Centre de recherche des Cord-
eliers, Paris, France.
Athough the clinical effıcacy of oncolytic viruses has been demonstrated for
local treatment, the ability to induce immune-mediated regression of distant
metastases is still poorly documented. We here report that an engineered onco-
lytic Vaccinia Virus, VVWR-TK-RR--Fcu1, is able to induce an immunogenic
cell death and thus to generate a systemic immune response. Effect on tumor
growth and survival is largely driven by CD8 T-cells, and we could demon-
strate that the immune cell infıltrate in the tumor could be reprogrammed to-
wards a higher ratio of effector T-cells to regulatory CD4 T-cells. The key role
of the type 1-IFN pathway in oncolytic virotherapy was also highlighted, and we
could show a strong abscopal response in Ifnar-/- tumors. In this model, the
single administration of the virus directly into the tumors, on one flank, led to
regression in the contralateral flank (i.e. opposite to the virus injection site).
Moreover, we observed that these effects are further enhanced when the onco-
lytic treatment is combined with either immunogenic chemotherapy such as
oxaliplatin, or with immune checkpoint blockers such as anti-PD-1 or anti-
CTLA-4. Altogether, these data suggest that local oncolytic virotherapy in pa-
tients with tumors altered in IFNAR signaling could increase immune-mediated
abscopal regression of distant metastases.
#4564 Synergistic anti-tumor effıcacy of combination therapy with
APS001F, a cytosine deaminase (CD) expressing Bifıdobacterium, 5-fluoro-
cytosine (5-FC) and anti-mPD-1 antibody in syngeneicmicemodel.Koichiro
Shioya,1 Yuji Seki,1 TomioMatsumura,1 Yuko Shimatani,1 Shun’ichiro Tanigu-
chi,2 Minoru Fujimori3. 1Anaeropharma Science, Inc., matsumoto, Japan; 2De-
partment of Comprehensive Cancer Therapy, Shinshu University School of Med-
icine, matsumoto, Japan; 3Department of Breast Surgery, Tokyo Medical
University Ibaraki Medical Center, Ibaraki, Japan.
Immune checkpoint blockers like anti-PD-1 antibody are leading the new
generation in anti-cancer drug development. A lot of scientifıc evidences have
demonstrated that immune checkpoint antibodies have promising clinical re-
sponse in patients with multiple cancer types. Nevertheless, limited fraction of
patients responds to the antibody immunotherapy, and moreover, immune re-
lated serious adverse events caused by nonspecifıc reaction with immune check-
point blockers result in treatment discontinuation. Many approaches have been
attempted to improve therapeutic outcomes of antibody immunotherapy, par-
ticularly a combination of antibody treatment and other therapies is one of
worth-trying ideas. APS001F is a live recombinant Bifıdobacterium longum ex-
pressing cytosine deaminase (CD), which is an enzyme to catalyze the hydrolytic
deamination of cytosine to uracil. Bifıdobacterium is a non-pathogenic anaero-
bic bacterium derived from normal human intestinal flora. It can only survive
and grow at low oxygen environment such as solid tumor. Intravenous admin-
istration of APS001F to patients leads to colonization of the B.longum and pro-
duction of CD enzyme only inside the solid tumor. Locally expressed CD en-
zyme converts orally taken prodrug, 5-FC, into anti-tumor drug 5-FU, which
increases 5-FU concentration specifıcally inside tumor and results in alleviation
of side effects caused by attacking normal organs. The phase 1 clinical trial for
APS001F is conducted in the US sponsored by us. 5-FU has been shown to
alleviate Myeloid Derived Suppressor Cells (MDSC) in the tumor site and re-
lease immune suppression in tumor [1]. Furthermore,VanDerKraak et. al. have
reported that 5-FU upregulated PD-L1 expression on the surface of tumor cells
[2]. These fındings drove us to combine anti-PD-1 antibody with the APS001F
therapy. At this present study, systemic administration of APS001F and 5-FC
signifıcantly suppressed tumor growth in CT26 bearing syngeneic mice model,
which is consistent with our previous fınding. Additionally, anti-murine PD-1
antibody combined with APS001F and 5-FC further suppressed tumor progres-
sion and some of individual samples achieved complete regression of CT26
tumors. The combination treatment effect of anti-murine PD-1 antibody and
APS001F with 5-FC showed statistical signifıcance in comparison with either
treatment group, which encourages us to expect much effective results and less
side effects in clinic. Reference: 1. Vincent J. et. al., Cancer Res. 2010 Apr 15;
70(8):3052-61, 5-Fluorouracil selectively kills tumor-associated myeloid-de-
rived suppressor cells resulting in enhanced T cell-dependent antitumor immu-
nity. 2. Van Der Kraak et. al., J Immunother Cancer., 2016 Oct 18;4:65.
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastroin-
testinal cancers.
#4565 Forced expression of GITRL in cancer cells enhances adenovirus-
mediated in situ vaccination. Yisel A. Rivera-Molina, Francisco Puerta Marti-
nez, Teresa Nguyen, Hong Jiang, Xuejun Fan, Rehnuma Shifat, Mohammad
Belayat Hossain, Verlene K. Henry, Caroline C. Carrillo, Candelaria Gomez-
Manzano, Juan Fueyo.MD Anderson Cancer Center, Houston, TX.
Our approach involves a platform of killing cancer using more potent onco-
lytic viruses-based immunotherapy strategies. These replication competent ad-
enoviruses are targeted to the Rb pathway to generate tumor-selectivity. The
second generation of these therapeutic agents, Delta-24-RGD, was successfully
translated to the clinical setting and is currently been tested in Phase I studies in
several institutions in the USA and in Europe for the treatment of patients
suffering from recurrent gliomas. Preliminary data from these clinical trials
showed that 10 to 15% of Delta-24-RGD-treated tumors undergo complete re-
gression. Agonistic treatments targeting co-stimulatory tumor necrosis factor
receptor superfamily (TNFRSF), such as GITR (CD357), have been shown to
enhance the proliferation and activation of T cells. Moreover, in preclinical
tumor effıcacy studies, these agonistic signals have shown potent tumoricidal
activity. Different from antibodies, co-stimulatory ligands can be easily incor-
porated into replication competent oncolytic adenoviruses. Infection of cancer
cells with these armed viruses will lead to the expression in their cell membranes
of the co-stimulatory molecule that will directly interact with the tumor infıl-
trating lymphocytes to amplify and enhance the anti-tumor T-cell activity. In
this study,we have developed an armedDelta-24-RGDcarrying the cDNAof the
mouseGITRL,Delta-24-GREAT. Treatment of glioma-bearingmicewith intra-
cranial injection of Delta-24-GREAT increasedmice survival (P 0.0001, long-
rank test) and inhibited lung cancer growth in subcutaneous models. Infection
of the tumor elicited an inflammatory response increasing the populations of
CD4 and CD8 T cells versus treated controls. Importantly, 2 weeks after the
adenovirus treatment a subset of brain hemispheric cells were positive for
GITRL. In addition, co-culture experiments with tumor cells infected with vi-
ruses and splenocytes isolated from treated glioma-bearing mice demonstrated
a response against the cancer cells as assessed by ELISA analyses of IFN-.
Demonstrating the generation of anti-tumormemory, the surviving animals did
not show evidence of tumor growth after re-challenging with GL261 glioma cell
implantation in the contralateral hemisphere. However, survivors of GL261 tu-
mors did not survive after the re-challenge was performed by intracranial im-
plantation of B16/F10 melanoma cells, strongly indicating that the immune
response was specifıc for GL261 glioma antigens. This is the fırst study with an
oncolytic adenovirus expressing GITRL and our results strongly indicate that
oncolytic adenoviruses armed with molecules of the TNFRSF may be of future
clinical interest for the treatment of patients with cancer.
#4566 OncoVEXmGM-CSF (HSV-1 modifıed similarly to Talimogene La-
herparepvec) in combination with CTLA-4 blockade leads to both local and
systemic effıcacy in amurine syngeneic model of metastatic melanoma.Kee-
gan Cooke, Juan Estrada, Jinghui Zhan, David Hill, Andrea Boden, JonWerner,
Pedro J. Beltran. Amgen, Thousand Oaks, CA.
Talimogene laherparepvec is an oncolytic immunotherapy based on a modi-
fıed herpes simplex virus type 1 (HSV-1) designed to kill cancer cells through
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two mechanisms: a) direct viral-mediated lysis and b) stimulation of a tumor
antigen-specifıc adaptive immune response. We developed a mouse model of
metastatic melanoma using the B16F10 cell line to study local and systemic
responses following treatment with talimogene laherparepvec alone or in com-
bination with CTLA-4 blockade. OncoVEXmGM-CSF, an HSV-1 modifıed simi-
larly to talimogene laherparepvec (murine GM-CSF is expressed instead of hu-
man GM-CSF) was used in these studies. B16F10 cells have been reported to be
resistant to HSV-1 infection due to a lack of requisite entry receptors. To over-
come resistance, we transduced B16F10 cells with a lentiviral vector expressing
mouse nectin1 (mNectin1) or eGFP as a control. Expression was confırmed by
ddPCR and sensitivity to OncoVEXmGM-CSF evaluated in an in vitro viability
assay. B16F10-mNectin1 cells were highly sensitive to OncoVEXmGM-CSF with a
multiplicity of infection (MOI) IC50 of 0.001 (B16F10-eGFP were insensitive at
MOI of 100). In vivo, B16F10-mNectin1 and B16F10-eGFP cells showed similar
growthwhen injected subcutaneously. OncoVEXmGM-CSF treatment of B16F10-
mNectin1 tumors (intratumoral, 5x106 PFU/dose, 3X) caused a signifıcant
(p0.0001) inhibition of tumor growth and prolonged median overall survival
compared to control animals. To assess the local and systemic effect of OncoV-
EXmGM-CSF in combination with CTLA-4 blockade, we developed a model of
experimental metastatic melanoma by delivering the B16F10-eGFP cells intra-
venously (systemic, non-injectable tumors) on day 0 and implanting the
B16F10-mNectin1 cells SC (local, injectable tumors) on day 2. Mice were dosed
with OncoVEXmGM-CSF and anti-CTLA-4 antibody 9D9 (100ug/dose) every 3
days between days 12 and 19. Subcutaneous tumor growth inhibition was as-
sessed and lung metastasis were quantifıed on day 28. Both OncoVEXmGM-CSF
and CTLA-4 treatment signifıcantly inhibited subcutaneous tumor growth and
lung metastasis. The combination of both therapeutics resulted in signifıcantly
greater local and systemic effıcacy than either agent alone. The strong local and
systemic anti-tumor activity of the combination resulted in a signifıcant increase
in median overall survival (p0.0001) compared to control mice that received
intravenous B16F10-eGFP cells only. In conclusion, OncoVEXmGM-CSF in com-
bination with CTLA-4 blockade signifıcantly reduced systemic tumor burden
and prolonged median overall survival in a B16F10 mouse model of metastatic
melanoma. These data support the proposedMOAbywhichOncoVEXmGM-CSF
treatment can cause direct tumor lysis along with potentiation of an adaptive,
systemic anti-tumor immune response.
#4567 Immunoclassifıcation of gastric cancer in the context of clinical
outcome.Weili Wang,1 Ping Liao,1 Shangchen Xie,1 Dongya Shen,1 Chengfang
Zhou,1 Howard Mcleod,2 Yijing He1. 1Institute of Clinical Pharmacology, Cen-
tral South University, Changsha, China; 2Moffıtt Cancer Center, DeBartolo Fam-
ily Personalized Medicine Institute, Tampa, FL.
Background: Gastric cancer (GC) plays a leading role in all cancer deaths
especially in Eastern Asia. Current classifıcations including WHO, Lauren, and
TCGA defınedmolecular classifıcation have illuminated the clinicopathological
characteristics or genetic profıle of GC. However, these classifıcations were lack
of association with clinical outcome and guidance for medication selection.
Objective: We aimed to identify a new immunoclassifıcation for GC to predict
patient’s prognosis and provide evidence for choosing proper medication.
Methods: Formalin-fıxed and paraffın-embedded (FFPE) samples of GC were
obtained along with the clinical outcome of the patient. Epstein-Barr virus
(EBV) infection was measured by RT-PCR. Immune markers including CD3,
CD8 and PD-L1 were measured by immunohistochemistry (IHC) at tumor
infıltration area (TI) and invasivemargin area (IM). The expression of PD-L1 in
tumor microenvironment (TME) was assessed by immune reactive score (IRS)
system. For immunoclassifıcation, patients were classifıed into two subgroups:
strong immunoreaction (SIR) and weak immunoreaction (WIR) defıned by the
number ofCD8Tcells andPD-L1 expression at TI. Results: EBV infectionwas
associated with the number of CD3T cells and PD-L1 expression in TME.
EBV patients also showed a poor overall survival (OS) compared with EBV-
patients. Importantly,WIR patients lived signifıcantly shorter than SIR patients.
Moreover, patients who were treated by taxanes inWIR group had a shorter OS
compared with those not using taxanes. Conclusion: In this study, we suggest a
new immunoclassifıcation for gastric cancer which is associated with patients’
outcome and may provide a way to guide chemotherapy.
#4568 Anovel TGF-beta receptor I kinase inhibitor demonstrated to be an
effective immuno-therapy for cancer. Zusheng Xu,1 Yangtong Lou,1 Li Chen,1
Kun Zeng,1 Qingrui Sun,1 Yingying Qu,2 Wei Wang,2 XiaodongWu,2 Xiaomei
Ge,2 Ying Gu,2 Yingjia Zhang,2 He Zhou2. 1Shanghai Yingli Pharmaceutical Co.
Ltd, Shanghai, China; 2Shanghai ChemPartner Co., Ltd., Shanghai, China.
TGF-beta (TGF-) pathways, despite serving as tumor suppressor in early
stage of carcinogenesis, have shown be one of the key tumor-promoting factors
in later-stage tumor progression. TGF- receptor I kinase (TGF-R1) inhibitors
have shown great potentials in their anti-tumor and anti-metastasis effıcacy in
preclinical studies and some of them are being tested in the clinical settings. A
specifıc TGF-R1 inhibitor YL-13027 was developed at Yingli Pharmaceutical.
YL-13027 possesses goodADMEandPKproperties and shows potent inhibition
of the TGF- and receptor interaction both in cell-free and cell-based assays.
Functionally, in vitro Treg differentiation assay demonstrated the signifıcant
inhibition of the induction of FoxP3 expressing cells as well as inhibiting the
secretion of IL-10 by YL-13027. In murine colon cancer CT26model, YL-13027
was well tolerated and signifıcantly inhibited tumor progression with dose de-
pendency. More mechanistic studies are on-going. These data suggest that YL-
13027, a novel TGF-R1 inhibitor, represents a promising and safe immune
modulator and shows great potential as a cancer immuno-therapeutics.
#4569 Effect of smoking on tumor-infıltrating immune cell composition
and prognosis in non-small cell lung cancer.Menno Tamminga, T. Jeroen N.
Hiltermann, Ed Schuuring, Rudolf S. Fehrmann, Harry J. Groen. University
Medical Centre Groningen, Netherlands.
Introduction: The immune system plays an important role in tumor progres-
sion and treatment response such as with new immunemodulating therapies. It
is unclear in lung cancer what the effect of smoking is upon intratumoral im-
mune cell composition and their function. In our study publicly available ex-
pression data were used to fınd evidence for the influence of smoking on the
composition of intratumoral immune cell fractions and their prognostic impact.
Methods: We searched the Gene Expression Omnibus (GEO) for human non-
small cell lung cancer (NSCLC) samples. Analysis was confıned to samples hy-
bridized to the Affymetrix HG-U133 Plus 2.0 (GEO accession number GPL570)
platforms. Expression profıles were downloaded and curated for duplicates and
corrupt fıles. Different immune cell fractions were estimated usingCIBERSORT
and the LM22 leukocyte signature matrix. We combined this information with
available clinical data.We usedCox regression analyses to evaluate the prognos-
tic impact of the different immune fractions and Mann-Whitney U tests to test
signifıcant differences. Results: Smokers with NSCLC had a signifıcantly
(p0.05) higher percentage of plasma cells, CD8T-cells, active CD4T-cells,
follicular helper cells, monocytes, M0 macrophages, resting dendritic cells, ac-
tive mast cells and neutrophils compared to non-smokers. Smokers had a lower
percentage of naïve B-cells, memory B-cells, resting CD4 T-cells and resting
mast cells. Non-smokers signifıcantly benefıt from a higher percentage of intra-
tumoral memory B-cells in the immune infıltrate as compared to normal tissue
(HR 0.92, 95% CI 0.85-1.00, p0,049), while the smokers signifıcantly benefıt
from higher intratumoral immune factions of resting CD4 T-cells (HR 0.93,
95% CI 0.89-0.98, p0.001). Higher percentages of regulatory T-cells (HR 1.23,
95% CI 1.03-1.47, p0.025), neutrophils (HR 1.11, 95% CI 1.02-1.21, p0.014)
and follicular helper cells (HR 1.12, 95% CI 1.01-1.24, p0.03) had a signifıcant
detrimental effect on survival of smokers. There was a borderline benefıcial
effect for smokers of the intratumoral NK cell faction (HR 0.61, 95% CI 0.36-
1.02, p0.057). For non-smokers, a detrimental effect was observed for the
intratumoral plasma cell fraction (HR 1.04, 95% CI 1.00-1.09, p0.073) and the
naïve B-cell fraction (HR 1.17, 95%CI 0.99-1.39, p0.075). Conclusion: In
NSCLC signifıcant different composition of intratumoral immune cells were
observed between a smoking and non-smoking population. These differences
were associated with differences in overall survival.
#4570 Intratumoral IFN- gene transfer reduces traffıcking of Tregs into
tumor by inhibition of CCL17 expression. Kazunori Aoki, Chihiro Shibasaki,
Hisayoshi Hashimoto, Kenta Narumi, Chie Kudo. National Cancer Ctr. Re-
search Inst., Tokyo, Japan.
Type I interferon (IFN) is a pleiotropic cytokine regulating the cancer cell
death and immune response. IFN- can effectively induce an antitumor immu-
nity by the activation of tumor-specifıc T cells and maturation of dendritic cells
in various animal models. It is widely known that an induction of tolerance by
the tumor is one of the critical mechanisms involved in tumor progression and
resistance for immune therapy. Extensive studies have shown that
CD4Foxp3 regulatory T cells (Tregs) are critical in controlling antitumor
immune responses in the tumor microenvironment. Since the effect of type I
IFN on an immunotolerant microenvironment is unknown, we investigated the
immunological effects of intratumoral IFN- gene transfer on tumor-infıltrat-
ing Tregs in a mouse model. Here, to examine whether the expression of IFN-
affects the immunotolerant microenvironment in tumors, CT26 murine colon
cancer tumors were directly injected once with 1 x 108 PFU of IFN--expressing
adenovirus (Ad-mIFN). The injection of Ad-mIFN signifıcantly suppressed the
tumor growth. We found that intratumoral IFN- gene transfer signifıcantly
decreased the frequency of Tregs per CD4 T cells in tumors compared with
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control vector injection. We hypothesized that Treg-homing cytokines such as
CCL17 and CCL22 cytokines are involved in the reduction of tumor-infıltrating
Tregs by theAd-mIFN injection. The IFN- expression signifıcantly suppressed
of CCL17 and CCL22 expression of tumors, and the expression of CCR4 and
CCR5 expression on Tregs was not changed. IFN- protein signifıcantly sup-
pressed CCL17 of CT26 cells in vitro in a dose-dependent manner. Then, we
constructed CCL17 shRNA-transduced CT26 cells (CT26shCCL17) to examine
the immunological role of CCL17 in vivo. The frequency of Tregs per CD4 T
cells was signifıcantly reduced in subcutaneous tumors of CT26shCCL17 cells
(25.9 %), and tumor growth was inhibited compared with that of control
shRNA-transducedCT26 cells (39.4%), suggestingCCL17 has an important role
tomigrate Tregs into tumors. The study demonstrated that IFN- gene delivery
creates an environment strongly supporting the enhancement of antitumor im-
munity through the suppression of Tregs.
#4571 Advantage of dendritic cells for the therapeutic cancer vaccine.Koji
Nagaoka, Akihiro Hosoi, Tamaki Iino, HirokazuMatsushita, Kazuhiro Kakimi.
The University of Tokyo Hospital, Tokyo, Japan.
Background: To develop effective cancer vaccine, we examinedCTLs induced
by peptide vaccination (CTLpep) and DC vaccination (CTLDC) in terms of their
antitumor effects. Methods: For preparation of peptide vaccine, 50 g hgp100
peptide (KVPRNQDWL) and 20 g CpG were emulsifıed with 50 l CFA or
IFA. Bonemarrow-derivedDCswerematuredwith LPS and pulsedwith hgp100
peptide at 1 g/ml and used as DC vaccine. To induce CTLpep and CTLDC,
C57BL/6micewere fırst injectedwith 1 x 107 naive spleen cells fromPmel-1TCR
transgenic mice to increase hgp100-specifıc CTL precursors. Then mice were
vaccinated twice with 2 weeks interval. The induction of CTLs were evaluated 2
weeks after the second vaccination. To evaluate their antitumor activity, 1 x 106
B16F10 were inoculated into vaccinated mice (prophylactic model). For thera-
peutic model, 1 x 106 B16F10 were inoculated intomice on day 0. Five days later
1 x 107 Pmel-1 splenocyteswere transferred. Then,micewere vaccinated ondays
5 and 12, followed by the measurement of tumor growth. Results: DC vaccine
induced 5-times more CTLs than peptide vaccine. The numbers of CTLpep and
CTLDC obtained in the spleen were 2.4	0.2x105 and 1.2	0.4x106, respectively.
CTLpep expressed PD-1 and Tim-3 at higher level than CTLDC. Most of CTLpep
showed effectormemory phenotype (CD44hiCD62L-), whileCTLDC contained a
considerable fraction of central memory cells (CD44hiCD62L). Although both
CTLpep and CTLDC produce IFN- and TNF- at similar level, more CD107a
were detected on CTLDC than CTLpep upon re-stimulation. CTLDC displayed
better proliferation potential than CTLpep. These phenotypic differences were
confırmed by the comprehensive gene expression analysis. Transcriptome anal-
ysis revealed that considerable portion of CTLpep and CTLDC were comparable
and different from that of naïve CTLs. However, several genes were expressed
differentially. CTLpep expressed higher amount of inhibitory receptors, such as
Pdcd1, Lag3, Ctla4 and Tigit than CTLDC. CTLDC expressed Fbp1, which inhib-
its glycolysis, and Cpt1a, which is the rate-limiting enzyme of mitochondrial
fatty acid oxidation, suggesting that their metabolic statuses were shifted from
glycolysis to fatty acid oxidation. DC vaccine completely inhibited the tumor
growth in prophylactic vaccine setting, while peptide vaccine delayed tumor
growth compared to control mice. In therapeutic protocol, peptide vaccine
showed no antitumor effect, while DC vaccine signifıcantly suppressed tumor
growth. The numbers of intratumoral CTLpep and CTLDC on day 19 were
5.2	2.8 x 104/g and 5.0	1.4 x 105/g, respectively. Intratumoral CTLDC
expressed lower levels of PD-1, Tim-3 and LAG-3 and more Ki67 than CTLpep.
Furthermore, Intratumoral CTLDC producemore IFN- and TNF- than CTLpep.
Conclusion: DC vaccine induced intratumoral CTLs with multi-functionality and
high proliferation potential. Therefore, DC vaccine is our choice for the therapeutic
cancer vaccine.
#4572 Characterizationof thepotent and selectiveA2aRantagonistAB928
for the treatment of cancer. Matt J. Walters, Joanne B. Tan, Annette Becker,
Fangfang Yi, Tim Park, Manmohan R. Leleti, Brandon Rosen, Ehesan Sharif,
Laurent Debien, Steve Young, Wan Hsin Lim, Stefan Garrido-Shaqfeh, Juan C.
Jaen, Jay P. Powers. Arcus Biosciences Inc., Hayward, CA.
Introduction: In the tumor micro-environment, extracellular ATP is sequen-
tially hydrolyzed to adenosine by the ecto-nucleotidases CD39 (ATP¡AMP)
and CD73 (AMP¡adenosine). Adenosine, through activation of the A2a recep-
tor (A2aR), is a potent inhibitor of T-cell activation, resulting in an immunosup-
pressed phenotype. Thus, inhibition of A2aR has recently generated great inter-
est in immuno-oncology. We present the characterization of a novel, selective,
and highly potent small molecule antagonist of A2aR which is slated to enter the
clinic in 2017.Methods: The cellular potency ofA2aR antagonists was assessed as
a function of decreased cAMP levels in CHO cells stably over-expressing hA2aR,
a Gs coupled receptor, following stimulation with the agonist NECA. Experi-
ments were conducted in the presence and absence of human serum. Selectivity
against the Gi-coupled receptor A1R was assessed similarly as a function of
cAMP elevation in CHO cells stably expressing hA1R, following pretreatment
with forskolin and stimulation with NECA. The ability of AB928 to reverse
adenosine-mediated immune suppression (25 M) of human or mouse CD8
T-cells was determined using standard CD3/CD28 activation conditions. CD25
expression and cytokine release were measured by flow cytometry and ELISA,
respectively. The pharmacokinetic characteristics of AB928 were assessed in
rodent and non-rodent species to facilitate calculation of a projected human
dose. Results: AB928 represents a novel series of potent and selective com-
pounds designed to inhibit adenosine-mediated A2aR activation. This molecule
is different frommost knownA2aR antagonists in that it does not cross the blood
brain barrier. AB928 inhibited NECA-mediated A2aR activation with a potency
of10 nM andmaintained its potency in the presence of human serum. AB928
did not signifıcantly inhibit any of the major CYP450 isozymes and did not
signifıcantly inhibit the potassium ion channel hERG. AB928 fully reversed the
ability of adenosine to suppress CD8 T cell activation as indicated by CD25
expression and increased levels of cytokines such as IFN- and IL-2 in the su-
pernatants (p0.01 vs 25Madenosine only). AB928 inhibitedmouse A2aR, as
indicted by reversal of adenosine-mediated immune suppression in the CD8
T-cell activation assay. Pharmacokinetic characterization of AB928 showed it to
be orally bioavailable with characteristics suitable for human dosing that will
allow  90% target inhibition over 24 hrs. Conclusions: AB928 is a potent,
selective and peripherally restricted antagonist of the A2aR receptor which is
slated to enter clinical development in 2017.
#4573 Characteristics and outcomes of patients with advanced sarcoma
enrolled in early phase immunotherapy trials. Roman Groisberg, Vivek Sub-
biah, DavidHong, Filip Janku, Sarina Piha-Paul, AungNaing, Robert Benjamin,
Shreyas Kumar Putal, Neeta Somaiah, Anthony Conley.UTMDAnderson Can-
cer Center, Houston, TX.
Background: Immunotherapies, specifıcally those based on immune
checkpoint inhibitors, have shown promising activity in multiple tumor
types. Other than the drug mifamurtide for osteosarcoma, there are cur-
rently no approved immunotherapies for sarcomas. We analyzed the out-
come of patients with advanced sarcomas treated in immunotherapy phase 1
trials. Methods: We analyzed the medical records of patients with advanced
sarcoma who were referred to Phase 1 trials and had received at least one
dose of an immunotherapy including checkpoint inhibitors, vaccines, or
cytokine based therapies. Clinical parameters reviewed were age, histology,
lactate dehydrogenase, albumin, metastatic sites, performance status, prior
therapies, toxicity and response on imaging. Progression free survival (PFS)
was measured from the date of the fırst dose to the date of progression on
imaging. Results: Among 50 patients enrolled in immunotherapy trials we
found 14 different subtypes of sarcomas (Bone 10; Soft tissue 40). Patients
were 42% male and 58% female. The median age was 53.5 years (18-84) and
Royal Marsden Hospital (RMH) prognostic score was 2 (86%). The Per-
formance status (PS) was ECOG 0-1 in 48 patients (96%); the median num-
ber of prior therapies was 3 (range: 0-12). Immunotherapy consisted of
checkpoint inhibitors in the majority of trials (82%: PD1 8, PD-L110,
CTLA422, other1), as well as vaccines (14%), and cytokines (4%). The
median overall survival (OS) was 13.4 months, 95% [CI]  (11.2 months to
not reached). Median PFS was 2.4 months (95% CI  1.9-3.2 months). Best
response was partial response (PR) in 2 patients with alveolar soft part sar-
coma (ASPS) and stable disease in 11 patients (3 GIST, 3 lipo (2 dedifferen-
tiated, 1 well-differentiated), 2 ASPS, 2 leiomyo, 1 osteo). Patients were
treated past progression per iRECIST criteria (32%). Pseudo-progression
followed by response was observed in 3 patients (6%). Median OS was 24
months for patients (40%) with 0-2 prior therapies and for patients (60%)
with &gt2 prior therapies was 8 months (P0.001). Median OS was 24
months for RMH score 0 and was 12 months for patients with score 1-2
(P0.08). Grade 3/4 adverse events included rash (10%), fever (6%), fatigue
(6%), and nausea/vomiting (6%). Other toxicities included hypothyroidism,
transaminitis, pancreatitis, pituitary apophysitis, pneumonitis and mucosi-
tis. Conclusions: Immunotherapies were well tolerated in advanced sarcoma
patients enrolled in trials. These patients had been heavily pretreated and
had good performance status and favorable RMH prognostic scores. All
ASPS patients had clinical benefıt with checkpoint inhibitors and this was
the only subtype with a partial response. Further evaluation of checkpoint
inhibitors in sarcomas, especially ASPS, is warranted.
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#4574 Combinatorial strategies of folate receptor-targeted chemotherapy
guided by improved understanding of tumormicroenvironment and immu-
nomodulation. Yingjuan Lu, Leroy W. Wheeler, Vicky A. Cross, Elaine M.
Westrick, Alex M. Lloyd, Theresa P. Johnson, Nikki L. Parker, Christopher P.
Leamon. Endocyte, West Lafayette, IN.
Inflammation disorder is a major component of cancer progression and drug
resistance. Tumor microenvironment due to its complex nature presents phys-
ical and physiological barriers to both chemotherapy and immunotherapy. On
the other hand, the folate receptor (FR) family includes two cysteine-rich GPI-
anchored membrane glycoproteins (FR/) that are capable of bringing folate-
linked small-molecule drugs (SMDCs) into the cell cytosol via endocytosis. Con-
sequently, both receptor isoforms have been considered promising therapeutic
targets due to frequent overexpression of FR by cancer cells of epithelial origins
and FR by tumor-associatedmacrophages (TAMs). TAMs are strongly immu-
nosuppressive and high TAM frequency has been correlated with poor patient
prognosis and treatment outcome.While a folate-targeted chemotherapy can be
very powerful for sensitive tumor types, resistance does regularly occur in FR-
positive tumors for reasons that are largely unknown. Moreover, there seems to
be considerable disconnect between a drug candidate’s in-vitro activity and in-
vivo effıcacy. Using syngeneic mouse models that represent different tumor
immune microenvironments (M109, Renca, 4T1-Cl2), we investigated the im-
munomodulatory properties of SMDCs and devised combinatorial strategies
with standard-of-care (SOC) agents to break the tumor-induced immune toler-
ance. Our results indicated that a successful treatment goes beyond targeting the
cancer cells themselves; instead, it requires a good match between our com-
pound and a “sensitive” tumor microenvironment. We found that within
“TAM-rich” solid tumors, an effective SMDCmay be onewith dualmechanisms
of action that affect both FR-positive tumor cells and FR-positive TAMs.
Moreover, the process of choosing partner drugs, such as immune checkpoint
inhibitors and inhibitors of myeloid-derived suppressor cells, should be guided
by the immunomodulatory properties of both SMDCs and SOC agents to over-
come the frequently observed chemo- and immuno-resistance.
#4575 Chimeric antigen receptor macrophages (CARMA) for adoptive
cellular immunotherapy of solid tumors.Michael Klichinsky,1 Marco Ruella,1
Olga Shestova,1 Saad S. Kenderian,2 Miriam Y. Kim,1 Roddy O’Connor,1 John
Scholler,1 Carl June,1 Saar Gill1. 1University of Pennsylvania, Philadelphia, PA;
2Mayo Clinic, Rochester, MN.
Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated
profound results in hematologic malignancies but clinical effıcacy in the solid
tumor setting has not been observed. Barriers to T cell entry and function may
partially explain this observation. As solid tumors actively recruit myeloid cells,
we hypothesized that macrophages have the potential to be a powerful cellular
immunotherapeutic agent in this setting if properly activated and redirected.We
here describe the development of CARmacrophages (CARMA), demonstrating
the feasibility, mechanism, and effıcacy of this platform. To examine the func-
tion of CARs in macrophages, fırst generation anti-CD19, anti-mesothelin, or
anti-HER2 CARs with a CD3	 intracellular domain were introduced into the
THP1macrophagemodel. In vitro functionwas assessed via quantitative phago-
cytosis and luciferase-based specifıc killing assays. CARMA selectively phago-
cytosed and cleared cognate antigen-bearing tumor cells. To demonstrate the
requirement for CAR-mediated intracellular signaling for activity, a CD3	-null
CAR construct was tested in vitro. The deletion of CD3	 signifıcantly reduced
the phagocytic and killing capacity (p0.01) of CARMA.We identifıed Ad5f35,
a chimeric adenovirus, as a novel and highly effıcient viral vector for the trans-
duction of normal donor and cancer patient macrophages (70% CAR expres-
sion). Ad5f35 transduction polarized human macrophages toward a durable
immunostimulatory M1 phenotype and rendered CARMA resistant to subver-
sion toward the immunosuppressiveM2 phenotype, as defıned by surfacemark-
ers andmetabolomics. CARMA enhanced the proliferative capacity of CD8 T
cells in phytohemagglutinin activation assays and secreted factors that activated
by-stander macrophages. Primary human anti-HER2 CARMA demonstrated
targeted phagocytosis and killing of HER2 expressing ovarian and breast cancer
cell lines, and exhibited a six-fold higher luciferase-based killing capacity of
SKOV3 cells compared to trastuzumab in vitro (p0.002). Anti-HER2CARMA
was evaluated in vivo in an intraperitoneal (IP) SKOV3ovarian cancer xenograft
model. Mice that received IP CARMA had a decrease in tumor burden of ap-
proximately two orders of magnitude and had a 30-day survival benefıt relative
to untreated or control macrophage treated mice (p0.018). In a systemically
disseminated SKOV3 model, a single dose of IV CARMA led to a durable anti-
tumor response (38-fold reduction relative to control on day 31 post-treatment;
p0.016) Lastly, we demonstrated that the blockade of the anti-phagocytic
CD47/SIRP axis enhanced the phagocytic capacity of CARMA. In summary,
we here demonstrate that human macrophages engineered with a CAR exhibit
targeted anti-tumor function in both in vitro and in vivo preclinicalmodels. This
novel cellular immunotherapeutic approach has a clear translational potential
for the treatment of solid tumors.
#4576 Targeted human cytolytic fusion proteins: an update. Stefan Barth.
University of Cape Town, Observatory, South Africa.
Targeted immunotherapeutics, such as antibody drug conjugates (ADCs) or
immunotoxins (ITs) represent promising agents for treatment of cancer. De-
spite their encouraging performance in clinical trials, both ADCs and ITs suffer
from disadvantages like stoichiometrically undefıned chemical linkage of the
cytotoxic payload and potential immunogenicity of bacteria- or plant-derived
toxins in humans, respectively. Therefore, in contrast to depletingB cell epitopes
from bacterial toxins, we designed a number of targeted recombinant cytolytic
fusion proteins, replacing bacterial toxins like Pseudomonas exotoxin A by hu-
man enzymes like proteases, kinases, RNases or microtubuli-associated pro-
teins. Binding and biological activities were shown in vitro, ex vivo and in dif-
ferent in vivo models. This presentation will summarize the latest results on the
hCFPs generated and demonstrate the effıcacy of treatment of CD64-, CSPG4-,
and EpCAM-targeting constructs in direct comparison to the corresponding
Pseudomonas exotoxin-based immunotoxins. The presentation will conclude
with an outlook on future perspective and applications of the next generation of
targeted fully human recombinant cytolytic fusion proteins.
#4577 Appropriately delivered curcumin causes recruitment of natural
killer cells into glioblastoma brain, stabilizing M1 polarization of tumor-
associated microglia. Sumit Mukherjee,1 Angela Fried,2 Rahman Hussaini,2
Richard White,3 Aheli Chatterjee,2 Probal Banerjee2. 1City University of New
York Graduate Center, New York, NY; 2City University of New York College of
Staten Island, Staten Island, NY; 3City University of NewYork at The City College
of New York, New York, NY.
Glioblastoma (GBM) is themost insidious form of primary adult brain tumor
with a mean life expectancy of 12-24 months. Previously, we have used the
non-invasive strategies of (1) intranasal delivery of a glioblastoma-directed cur-
cumin (CC) adduct (CC-CD68Ab) and (2) the intraperitoneal (i.p.) infusion of
a lipid-encapsulated formulation of CC-phytosome to rescue orthotopically
GL261-implantedGBMmice and study the effect of CC on the phenotype of the
tumor-associated microglial cells (TAMs). Both treatment regimens not only
caused tumor remission in 50-60% of GL261-implanted GBM mice, but also
induced a dramatic change in the tumor-associated Iba1 TAMs, suppressing
the tumor-promoting Arginase1high, IL10high, iNOSlow, IL12lowM2-type TAMs,
while simultaneously inducing the Arginase1low, IL10low, iNOShigh, IL12high
M1-type TAMs. Concurrently, we observed a marked induction and phospho-
rylation-mediated activation of microglial p65 NF-kB and STAT1, with con-
comitant suppression and inactivation of STAT3. p-STAT1high, p-STAT3lowM1
microglia are known to cause IL12-dependent recruitment/activation of tu-
moricidal NKp46high natural killer (NK) cells. In determining the kinetics of
CC-inducedM1 repolarization ofM2-TAMs, we observed that fıve days of CCP
treatment (i.p.) was suffıcient to induce a dramatic change in the tumor-associ-
ated Iba1 TAMs, inhibiting the tumor-promoting M2-type TAM population,
while activating M1-type microglia. As expected, we observed a concomitant
recruitment of NKp46high NK cells into the GBM tumor. Cognizant of the fact
that NK cells activate and stabilize theM1-microglia, we eliminated theNK cells
in these GBMmice using the NK cell-targeted antibody NK1.1 Ab to observe a
signifıcant reduction in CC-evoked repolarization of TAMs. Our results dem-
onstrate a unique oncoimmunotherapeutic function of CC, which when appro-
priately delivered, not only eliminates GBM directly, but also indirectly elicits
recruitment and activation of tumoricidal NK cells and M1-TAMs. Further-
more, maintenance of this CC-evoked M1 phenotype is contingent upon CC-
induced recruitment and activation of NK cells. Thus, when delivered appropri-
ately, CC functions on GBM both directly as well as by stimulating and
recruiting an army of immune cells that eliminate both GBM and GBM-initiat-
ing cells.
#4578 Does poor prognosis in African Americans with MSI-H colorectal
cancer associate with altered immune markers. Umamaheshwari Golconda,1
Lena Sokol,2 Babak Shokrani,1 Edward Lee,1 Donna Hansel,3 Oluwole Fadare,4
Sandip Patel,4 Mehdi Nouraie,5 Hooman Soleimani,1 Zaki Sharif,1 Ali Afsari,1
Fareed Daremipouran,1 Hassan Brim,1 Hassan Ashktorab1. 1Howard Univ.,
Washington, DC; 2University of Bern, Bern, Switzerland; 3UCSD, San Diego, CA;
4UC San Diego Moores Cancer Center, La Jolla, CA; 5Univ. of Pittsburgh, Pitts-
burgh, PA.
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BACKGROUND: Microsatellite instability high (MSI-H) of sporadic colo-
rectal carcinomas (CRC) is usually associated with improved prognosis and a
high density of tumor-infıltrating lymphocytes. However, African Americans
with MSI-H have poor prognosis. AIM: To evaluate whether or not expression
of different immune and tumor markers individually or in combination in Af-
rican American MSI-H CRC associate with the prognosis status. METHODS:
Tissues Microarray (TMA) were prepared by microdissection from FFPE (For-
malin Fixed Paraffın Embedded) blocks of 15MSI-H patients. Immunemarkers
(CD8, Granzymes, Perforins, CD4, STAT1, IRF1 and IRF5) and PD-L1
status were analyzed by immunohistochemistry (IHC). Demography and clini-
cal data including TNM, tumor grading (WHO standard), histological type of
the tumor, date of diagnosis, date of the last follow-up examination, treatment,
comorbidities, metastasis, recurrence, 5-year disease-free survival and death
were collected. RESULTS: Therewere 4 patients with improved prognosis (27%)
with relatively high CD4 density (2 with50% and 2with 11-50%) regardless of
PD-L1 status (3/1-), stage (II,III), and other immune markers (CD8, CD4,
Granzymes, Perforins, IRF1, IRF5 and STAT1). One of the improved prognosis
patients with KRASmutation has elevated expression of all considered immune
markers besides CD4. There were 9 patients (6 dead, 3 alive) with poor progno-
sis, with different immune and tumormarkers level (3 were PD-L1 and 5 have
relatively high CD4 count; but with low level of STAT1. There were also 2
patients with expected improved prognosis based on their immune markers
level (stage II), however, they diedwithin the 5 year periodpost-diagnosis, due to
their age (98 and 87 years old). Conclusion: MSI-H Colorectal cancer from
African American patients has poor prognosis which may correlate with the
nature of tumor-associated immune response. Other factors such as MSH3 de-
fects might cancel the positive prognosis of MSI-H status. Nonetheless, low
STAT1 and low CD4 may be indicators of poorer prognosis.
#4579 Improving the effıcacy of radioimmunotherapy by controlling the
tumor microenvironment of gastric cancer. Hae Young Ko,1 Jin Su Kim,1
HyeonGi Kim,1 Seonhwa Lee,1 Chae-Ok Yun,2 SangMoo Lim1. 1Korea Institute
of Radiological & Medical Sciences, Seoul, Republic of Korea; 2Hanyang Univer-
sity, Seoul, Republic of Korea.
Purpose: Radioimmunotherapy(RIT) of solid tumor is limited to poor anti-
body distribution due to extracellular matrix (ECM) of tumor microenviron-
ments. In this study, we investigated the effect of the protein X, which is known
to degrade ECM, on the accumulation and the microdistribution of trastu-
zumab. Methods: Tumor xenografts were established by subcutaneous inocula-
tion of 5 x 106 NCI-N87 cells (human gastric cancer) into each flank of nude
mice (n5 / group). When the tumor size reached 200 mm2, the mice was
intravenously injected with 150 g of Alexa 488-labeled trastuzumab under the
treatment of protein X. As a control, we used the same dose of antibody under
the non-treatment of protein X. For investigating antibody penetration, we cal-
culated the intensity per area, vascular density and the intensity from the tumor
edge (500 m) and blood vessel (150 m) by analyzing fluorescence image
of whole tumor using In Cell analyzer. For in vivo PET image, trastuzumab was
labeledwith 64Cu usingDOTA chelator and themice was intravenously injected
with 150 g (400 Ci) of 64Cu-DOTA-trastuzumab under the treatment of
protein X. We acquired PET image at 2, 15, 40 and 64 hours after injection.
Results: In mouse model, protein X decreased ECM protein in tumor microen-
vironments and that resulted in the change of intensity compared with non-
treatment of protein X; 1) the intensity per area: 2.5 times increase, 2) vascular
density: not changed, 3) the intensity from the tumor edge: 5 times increase, and
4) the intensity from blood vessel: 3.7 times increase. As analyzed result of in
vivoPET image, the proteinX-treatedmice showed 3.9%ID/g tumor uptake; the
non-treated mice showed 2.3 %ID/g tumor uptake 2 hours after injection and
the protein X-treated mice showed 4.6 %ID/g tumor uptake; the non-treated
mice showed 3.8 %ID/g tumor uptake 15 hours after injection. In addition sig-
nifıcantly increased anti-tumor effect of RIT were observed in the combined
treatment group. Conclusion: This study demonstrates that the treatment of
proteinXwas signifıcantly enhances the uptake of trastuzumabwithout vascular
change in implanted tumor tissue of nude mice. This fınding implies that ECM
degraded function of proteinX improves antibody accumulation of tumor tissue
and that can enhance the effect of RIT.
#4580 Improved quality of life and tumor regression in a patient with
stage IV non-small cell lung cancer with brain metastasis 10 months after
daily treatment with single agent mifepristone. Jerome H. Check,1 Diane
Check,1 Mahmoud Aly,2 Patricia Lofberg,1 Rachael Cohen,1 Dwight McKee1.
1CooperMedical School of RowanUniversity, Melrose Park, PA; 2RichmondUni-
versity Medical Center, Staten Island, NY.
The FDA granted an IND for a 40 patient study entitled “A phase II study of
treatment with oralmifepristone as salvage therapy in patients with advanced or
metastatic non-small cell lung cancer who have failed 2 or more previous che-
motherapy or immunotherapy regimens”. Presented herein is a description of
the effect of treatingCase 1who is a 68 year oldmalewhopresentedwith stage IV
non-small cell lung cancer with brain metastasis causing seizures following 10
months of treatment with single agent oral mifepristone (Korlym from Corcept
Inc) 300mg qd. He had shown tumor progression despite treatment with carbo-
platin, docetaxel, premetrexed, and gemcitabine. He was not considered a can-
didate for nivolumab or pembrolizumab because his tumor was negative for the
programmed cell death factor ligand 1 (PD-L-1) marker. His preclinical perfor-
mance status was ECOG 1. After 2 months of daily 300mg mifepristone treat-
ment he showed a considerable improvement in energy and stamina and less
shortness of breath. There have been no new lung or brain lesions. In fact, there
has been shrinkage of the lung lesions and no growth of the brain lesion and no
more seizures. His ECOG was “0” after 10 months of single agent mifepristone
treatment. The mechanism of action is believed to be by suppressing intracyto-
plasmic production of an immunomodulatory protein known as the progester-
one induced blocking factor (PIBF). One of the functions of PIBF is to stabilize
perforin granules in natural killer cells thus inhibiting their cytotoxic activity.
This protein seems to be unique to rapidly growing cells, e.g., trophoblast cells or
cancer cells. Thus, in general, in low dosages, as used in this patient, the drug is
very well tolerated. PIBF does not seem to be needed for cells growing at normal
speed. In humans, mifepristone has been found to either cause complete tumor
regression, ormore commonly, stabilization of the cancerwith improved quality
of life. Previously, mifepristone allowed long-term complete remission from a
terminal small cell lung cancer with associated hyponaotremia. The case re-
ported here is believed the fırst involving palliative benefıt of treating advanced
non-small cell lung cancer with mifepristone. Stabilization of the brain metas-
tasis in this report supports evidence from a previous case of advanced glioblas-
tomamultiformewith a clear though transient response tomifepristone, that the
drug can cross the blood-brain barrier, and thus be effective for brain lesions.
This is the fırst case treated with 300mg daily mifepristone (200mg used previ-
ously). Similar to the lower dosage, this patient reported no adverse side effects.
Mifepristone was also found to improve longevity and body conditioning scores
in a placebo controlled study of spontaneous murine lung cancer.
#4581 Primate pharmacology of TYG100, a vaccine employing a novel,
antigen-specifıc checkpoint control mechanism (S-TIR) for pancreatic and
gastroesophageal cancers. Jorge Sepulveda,1 Christopher Taus,1 Liesbeth C.
Mudde-Boer,1 Robert L. Wardle,2 Paul Broome,3 Geert C. Mudde4. 1OncoQR
ML GmbH, Vienna, Austria; 2East Carolina University, Greenville, NC; 3TYG
Oncology, Nottingham, United Kingdom; 4Tyg Oncology & OncoQRML GmbH,
Vienna, Austria.
Gastrin neutralization by active immunization with a DT-conjugated gastrin
peptide construct (G17DT) in a water-in-oil emulsion adjuvant has been shown
in several clinical trials to extend median survival for pancreatic cancer patients
declining or ineligible for chemotherapy1, as well as those receiving standard
gemcitabine therapy2. Survival benefıt was highly signifıcant (P  0.003) for
immunological responders to the vaccine and correlated with the gastrin neu-
tralizing capacity of the induced immune response. However, the negative con-
tribution of low-level and non-immunoresponders has constrained overall
(ITT) effıcacy of the progenitor vaccine, G17DT. As there is no means of pre-
dicting or selecting for antibody responders, the effıcacy of a gastrin vaccine
would be improved by increasing the immune response. TYG100 is a novel,
rationally designed, recombinant vaccine using the S-TIRTM- platform to gen-
erate high levels of antibodies to gastrin 17 and glycine-extended gastrin 17,
proven growth hormones for several gastro-intestinal cancers. Vaccines based
on the S-TIRTM platform target CD32-expressing antigen presenting cells,
whilst activating plasmacytoid dendritic cells through its intrinsic adjuvant ac-
tivity. To confırm the fırst study3 and prepare for a human trial, doses of 6.2, 30.8
and 154mcg given as an alum-adsorbed aqueous formulation at 0, 2, 4 and 6
weeks have been investigated in cynomolgus macaques. The highest dose pro-
duced a rapid rise in titre to yield 150mcg/ml of IgG within 14 days of adminis-
tration of the fırst immunization; the lowest dose was slower in onset but
achieved clinically relevant titres by day 43. Pre- and concurrent treatment of
another group with gemcitabine at 50 mg/kg showed no attenuation of titre.
Peak titre levels of the highest dose were 3 logs higher than those previously
shown to be associated with extended survival in pancreatic cancer patients1,2.
Despite these rapid onset, high titres, no adverse effects were seen except for a
minor and transient injection site reaction in 2 of the high dose group. Func-
tional competence of the resulting primate antibodies was confırmed by growth
inhibition of (gastrin-dependent) HT-29 cells. Cancer Research UK is planning
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to sponsor andmanage a fırst-in-human phase I study in patients with advanced
solid tumours, evaluating safety, tolerance and immunogenicity. The study will
be undertaken by the Experimental CancerMedicines Centres network with the
University of Leeds as lead centre. 1 Pancreas 2012 Apr;41(3):374-9 2 Abstract
no 4012, ASCO 2005 meeting publication. 3 Poster presentation, AACR 2014
annual meeting 7 Apr 2014
#4582 Evaluating benefıts of PD-L1 image analysis for the clinical setting.
Staci Kearney, Joshua Black, Famke Aeffner, Joshua Black, Luke Pratte, Joseph
Krueger. Flagship Biosciences, Westminster, CO.
Tissue-based investigations can prove challenging due to complex tissue archi-
tecture and heterogeneous biomarker expression, visual and cognitive “traps” that
affect interpretiveprecision, andsubjectiveassessments thataffect reproducibility.A
major concern is that these challenges could increase the risk of failure for therapeu-
tic/diagnostic co-development and clinical use, as the biomarker measurements
continue to increase in complexity and require increasingly precise diagnostic cut-
points. Image analysis tools have been developed to overcome some of the chal-
lenges for conventional anatomicpathologypractices, capitalizingon theobjectivity
and computational power of a digital platform. A computer, however, lacks the
cognitive ability and experience of a human to interpret tissue architecture and
context. FlagshipBiosciences’ computational TissueAnalysis (cTA™) platform inte-
grates the power of our tissue ImageAnalysis (tIA™) technologywith the contextual
experience of an anatomic pathologist to produce robust, precise, quantitative re-
sults that demonstrate biomarker content in the tissue context. FlagshipBiosciences
envisions the integration of our cTA™ technology into a computer-aided clinical
pathology workflow as amethod to improve the precision of scoring for even some
of the most challenging tissue-based biomarker measurements. In a proof-of-con-
cept study, we evaluated the performance of manual versus digital scoring ap-
proaches in a cohort of non-small cell lung carcinoma (NSCLC) samples stained
with the IHC protocol for the PD-L1 PharmDx 28-8 complementary diagnostic. A
comparison of the 2 modalities demonstrated that in nearly all cases, the within
sample standard deviation of the cTA™digital score resultswas less than themanual
score (median inter-pathologist%CVswerereduced from124.9%to7.8%andintra-
pathologists from 65.4% to 7.6% for manual and digital scores, respectively). As an
additional exploratory examination, the effect of heterogeneity on PD-L1 interpre-
tation was also investigated. Pathologists evaluated the same whole tissue slides
within 5 high powered fıelds (HPFs) using bothmanual and cTA™ -derived scoring.
Results demonstrated that the use of cTA™ provides improves agreement between
HPF and whole slide assessments (absolute difference between the manual scores
from HPF to whole slide were larger than the absolute differences for the digitally
derivedscores, at3.14%and8.27%, respectively).Taken together, these studiesdem-
onstrate that theuseof cTA™can signifıcantly reducevariability inPD-L1 scoring, as
compared to amanual scoring approach.
#4583 Heterogeneity in immune biomarker expression: Detailed anal-
ysis of a case with SCLC transformation after EGFR-TKI treatment.Keni-
chi Suda,1 Isao Murakami,2 Hui Yu,1 Jihye Kim,1 Kim Ellison,1 Christopher
J. Rivard,1 Tetsuya Mitsudomi,3 Fred R. Hirsch1. 1University of Colorado
AnschutzMedical Campus, Aurora, CO; 2Higashi-HiroshimaMedical Center,
Higashi Hiroshima City, Japan; 3Kindai University Faculty of Medicine,
Osaka, Japan.
Introduction: The expression status of immune markers are of current re-
search interest due to their potential roles as predictive biomarkers for immu-
notherapy in cancers. Currently there is little information on how the microen-
vironment of tumors and/or therapy-inducible histological transformationmay
affect the expression of these immune markers. Methods: A 76-year-old never-
smoking female with epidermal growth factor receptor (EGFR) mutated lung
adenocarcinoma (AC) acquired resistance to gefıtinib. After her death, autopsy
revealed small-cell lung cancer (SCLC) transformation and EGFR T790M sec-
ondary mutation as mutually exclusive resistance mechanisms. Two liver me-
tastases (SCLC vs. AC with T790M) and two lymph node metastases (SCLC vs.
AC with T790M) were analyzed to compare the expression status of immune
markers by immunohistochemistry (IHC) and an immune-oncology gene ex-
pression panel (HTGEdgeSeq Immuno-OncologyAssay). Results: IHC analysis
revealed that PD-L1 was expressed in 5% of tumor cells with AC histology
(T790M) but not in tumor cells with SCLC transformation (Table 1). The liver
metastasis with SCLC transformation showed negative stromal PD-L1 expres-
sion and scant tumor infıltrating lymphocytes, while the other lesions demon-
strated stromal PD-L1 staining and infıltration of CD8-positive T cells. PD-1
was positive in lymphocytes from lymph nodemetastases, but not in those from
liver metastases. Data generated using an IO panel indicated higher expression
of galectin 9 and higher level of T cell stimulatory checkpoints in lesions with
SCLC transformation. Bioinformatic analysis also demonstrated lower expres-
sion of type I interferon regulated genes in lesions with SCLC transformation.
Conclusion: These data highlight the heterogeneity of expression of immune
markers depending on the metastatic sites and histological transformation, and
indicate that a biopsy from one lesion may not be representative of immune
marker status for all lesions.
Summary of immune marker IHC staining in all specimens
Specimens
PD-L1
(tumor)
PD-L1
(stroma) TILs
CD8
(T cells)
PD-1
(T cells)
Liver metastasis (AC/T790M) 5% 5%   negative
Liver metastasis (SCLC) negative negative scant n.a. n.a.
Lymph node metastasis (AC / T790M) 5% 5%   
Lymph node metastasis (SCLC) negative 10%   
#4584 High PD-1 expression on regulatory and effector T cells in lung
cancer draining lymph nodes.Rieneke VanDeVen,1 Anna-Larissa N. Niemei-
jer,1 Anita G. Stam,1 Sayed M. Hashemi,1 Christian G. Slockers,1 Johannes M.
Daniels,1 Erik Thunnissen,1 Egbert F. Smit,2 Tanja D. de Gruijl,1 Adrianus J. de
Langen1. 1VU University Medical Center, Amsterdam, Netherlands; 2Nether-
lands Cancer Institute, Amsterdam, Netherlands.
The treatment of advanced non-small cell lung cancer (NSCLC) with PD-1 im-
mune checkpoint inhibitors has improved clinical outcome for a proportion of pa-
tients. The current challenge is to fınd biomarkers thatwill identify patients likely to
benefıt from this therapy. In this study we assessed the difference of T cell subsets
and PD-1 expression levels on T cells in tumor-draining lymph nodes (TDLN),
non-TDLN (NTDLN) and peripheral bloodmononuclear cells (PBMC). To evalu-
ate this, flow cytometric analyses were performed on endobronchial ultrasound-
guided (EBUS) fıne-needle aspirates (FNA) from TDLN and NTDLN of patients
withNSCLC and compared to PBMC.Our data show that the frequency of PD-1
CD4 and CD8 T cells, as well as the PD-1 expression level on activated regula-
tory T (aTreg) and CD4 and CD8 T cells, are higher in TDLNs as compared to
NTDLNs or PBMC. These elevated PD-1 expression levels in TDLN may reflect
tumor-specifıc T cell priming and may serve as a predictive or early response bio-
marker during PD-1 checkpoint blockade.
#4585 Radiation combined with checkpoint blockades enhanced antitumor
effıcacy for osteosarcoma. Yutaka Takahashi, Tomohiro Yasui, Keisuke Tamari,
Kazumasa Minami, Masahiko Koizumi, Yuji Seo, Fumiaki Isohashi, Keisuke
Ohtani, Ryosuke Kambe, Kazuhiko Ogawa.Osaka University, Osaka, Japan.
Osteosarcoama is one of the commonmalignancies at bone in children and ad-
olescent. Recent study demonstrated that combination of anti-PD-L1 and anti-
CTLA-4 antibodies provided grate control of metastatic osteosarcoma. However, a
strong local treatment strategy including surgeryorhighprecision radiation therapy
is necessary to elucidate osteosarcoma.Radiation therapy plays an important role in
local control formalignant tumorsbutprevious studiesdemonstrated that radiation
enhanced immune response in which not only local tumor regression at irradiated
sites but also regression of metastatic tumor outside the radiation fıeld were ob-
served. Although this phenomenon, so called the abscopal effect, is rarely seen,
recent studies demonstrated that combination of X-ray irradiationwith checkpoint
blockades provided higher probability of the abscopal effect for some kind of tu-
mors. However, the effect of x-ray irradiation combined with checkpoint blockade
on the abscopal effect for osteosarcoma has been totally unknown.We investigated
whether local X-ray irradiation combined with the anti-PD-L1 and anti-CTLA-4
antibodies enhances local and distant antitumor effıcacy for osteosarcoma. LM8
mouse osteosarcoma cells were inoculated into both legs of C3H mice. Mice were
treated by 10 Gy X-ray irradiation alone to the tumor in the one side leg (RAD
group)atday12, 150ugof anti-PD-L1andanti-CTLA-4antibodies (P1C4group)at
days 9, 12, and 15, or those combination (COMB group). Administration of anti-
PD-L1 and anti-CTLA-4 antibodies provided tumor growth delay or complete re-
sponse at day 37 for about 20% of the mice. X-ray irradiation strongly inhibited
tumorgrowthat irradiated tumorbutnot inunirradiated tumor.On theotherhand,
thecombination therapyprovided the strongest tumorgrowth inhibitionnotonlyat
irradiated tumor but also at unirradiated tumor for about 89%of themice. Accord-
ingly, lungmetastasis inmice inCOMBgroupwas strongly reducedby97%with the
signifıcant survival benefıt comparedwith themice inP1C4group. Flowcytometric
analysis revealed that mice in COMB group signifıcantly recruited CD8 tumor in-
fıltrating lymphocytes withmoderate reduction of regularly T cells (Tregs), thereby
increasing the CD8/Treg ratio. Furthermore, quantitative real time PCR showed
signifıcant induction of PD-L1 on irradiated LM8 cells in vitro. The radiation-in-
duced upregulations of PD-L1, B7-1, and B7-2, the ligands of CTLA-4, were also
confırmed by flow cytometry, indicating that the enhanced effıcacy anti-PDL1 and
CTLA-4 antibodies may associate with these upregulations by radiation. These re-
sults suggest thatX-ray irradiationcontributes to theenhancementof theeffıcacy for
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the distant metastasis as well as local control in the treatment of anti-PD-L1 and
anti-CTLA-4 antibodies for osteosarcoma.Ourdata provide a rational to establish a
new therapeutic strategy and start up a clinical trial for osteosarcoma.
IMMUNOLOGY: Immunoconjugates and Antibodies
#4586 Intratumoral Treg cell depletion by local administration of IL-2-
Diphteria toxin fusion protein E7777 induces a therapeutic and memory
anti-tumor immune response in preclinical models. Diana I. Albu,1 Christy
Ingersoll,1 Kuan-Chun Huang,1 Mary Woodall-Jappe,2 Xingfeng Bao1. 1Eisai
Andover Innovative Medicines Institute, Andover, MA; 2Eisai Oncology Business
Group, Eisai Inc., Andover, MA.
T regulatory (Treg) cells play an important role in maintaining immuno-
logical tolerance to self-antigens, thus limiting immune responses to tumor
antigens. Therefore, depleting or suppressing Tregs is one strategy by which
anti-tumor immunity can be restored. The immunotoxin ONTAK® is an
IL-2-diphteria toxin fusion protein that has been shown to diminish Tregs in
patients and animal models of cancer in peripheral blood using a systemic
intravenous (i.v.) administration route. E7777 is a new version of ONTAK®.
In this study we tested the hypothesis that locally-diminished Tregs by in-
tratumoral (i.t.) administration of E7777 generate effective anti-tumor im-
mune response at both local and systemic levels. First, we showed superior
anti-tumor activity and safety of E7777 i.t. over E7777 i.v., where i.t. admin-
istration resulted in complete tumor regressions in both moderately immu-
nogenic CT26 and non-immunogenic B16F10 tumors with minimal animal
body weight loss. In contrast, only tumor growth delay was observed for
E7777 i.v. with dose-limiting animal body weight reduction in the same
models. Immune phenotyping showed a 4 fold reduction of intratumoral
Tregs in treated CT-26 tumors without signifıcant change of Tregs in the
spleens of treated animals, confırming a local Treg-depleting effect of E7777
i.t. In contrast, intratumoral CD8 T cells were not reduced. Second, E7777
i.t. enhanced overall anti-tumor immune response, manifested by signifı-
cantly increased numbers of CD45 hematopoietic cells, Granzyme B
CD8 cytotoxic T cells, and ratios of cytotoxic T cells/Tregs in the treated
tumors. Importantly, E7777 i.t. also resulted in distant effects in the spleen
characterized by increased ratio of T lymphocytes to myeloid cells and in-
creased frequencies of both effector memory CD8 T cells (CD8CD62L-
CD44) and central memory CD8 T cells (CD8CD62LCD44) indica-
tive of systemic immune activation. Consistent with the generation of
immunological memory, 60% of the tumor-free animals treated with E7777
i.t. rejected completely and 40% displayed delayed tumor growth of B16F10
cell challenge while all naïve control animals grew tumors. Taken together,
our results demonstrate that intratumoral Treg depletion by local adminis-
tration of E7777 leads to an effective local and memory anti-tumor response
in preclinical models and support further evaluation of local E7777 delivery
as a cancer immunotherapy.
#4587 A human hybrid immuno-oncology construct targeting the
TWEAK receptor Fn14 and containing the serine protease granzyme B. Ana
Alvarez de Cienfuegos,1 Lawrence H. Cheung,1 Khalid A. A. Mohamedali,1 Jef-
frey A.Winkles,2 Michael G. Rosenblum1. 1MDAnderson Cancer Center, Hous-
ton, TX; 2University of Maryland School of Medicine, Baltimore, MD.
Targeting immune effector cells to tumors has recently emerged as a clinical-
ly-relevant approach for therapy. The underlyingmechanism for immune effec-
tor killing involves T or B-cell-mediated delivery of the serine protease gran-
zyme B to the target cells. The cell-surface receptor Fn14 for the TNF-related
cytokineTWEAKhas emerged as a potentially valuable target for cancer therapy
because its expression is low in most normal tissues but signifıcantly elevated in
a variety of solid tumor types. The serine protease Granzyme B (GrB) is a highly
cytotoxic component of human immune effector cells and induces multiple,
intense pro-apoptotic signals when delivered to the cytoplasm of target cells.
This protein has been well-studied, operating through multimodal pathways
which are both caspase-dependent and caspase-independent. Our laboratory
has designed series of new Fn14-targeted fusion constructs containing an engi-
neered GrB payload. The GrB-Fc-IT4 construct is a completely human ho-
modimer (200kDa) containing an IgG Fc domain for prolonged serum half-
life. This construct displays high-level protein production in an HEK293E
expression system. It exhibits high affınity and selective cytotoxicity within the
nanomolar range (IC50 ranged from 4 to 284 nM) when tested against a panel of
25 Fn14-positive human cancer cell lines. We are currently assessing a panel of
100 annotatedNSCLC cell lines to try to defıne amolecular fıngerprint related to
cellular sensitivity or resistance to the GrB payload. Pharmacokinetic studies in
mice revealed that GrB-Fc-IT4 exhibited a bi-exponential clearance from
plasmawith a rapid initial clearance (t½ 0.36 hours) followed by a prolonged
terminal-phase plasma half-life (t 1/2 35 hours).Mice bearingMDA-MB-231
orthotopic tumor xenografts were intravenously treated with saline, or GrB-Fc-
IT4 construct (QODX5). On average, tumors from saline-treated mice grew
about 10-fold over 40 days. In contrast, tumors frommice treated with GrB-FC-
IT4 did not growduring this period and remained the same size as at the onset of
treatment. Moreover, 3/5 mice treated with GrB-Fc-IT4 showed complete tu-
mor regression lasting beyond day 80 (end of the study). Overall, treatment with
GrB-FC-IT4 was well-tolerated bymice (no loss of body weight) and resulted in
signifıcant anti-tumor effıcacy. Toxicology and bio-distribution studies are on-
going and will be presented. Research conducted, in part, by the Clayton Foun-
dation for Research.
#4588 Novel anti-Trop-2 monoclonal antibodies with unique binding
specifıcities show therapeutic synergy against most human cancers. Emanu-
ela Guerra,1 Marco Trerotola,1 Valeria Relli,1 Chiara Pedicone,1 Antonella D’
Amore,1 Francesca Dini,1 Silvia Fratarcangeli,1 Saverio Alberti2. 1“G. d’ Annun-
zio” University of Chieti-Pescara, Chieti Scalo, Chieti, Italy; 2‘G. d’ Annunzio‘
University of Chieti-Pescara, Chieti Scalo, Chieti, Italy.
Trop-2 is an epithelial transmembrane glycoprotein that transduces a calcium
signal and activates a growth-signaling network that converges on AKT. Trop-2
is overexpressed in the majority of carcinomas, where it drives tumor cell pro-
liferation, and in its mature, glycosylated/functionally-competent form associ-
ates with worse prognosis. Trop-2 extracellular domain contains an N-terminal
cysteine-rich globular region followed by a cysteine-less region as a connecting
“stem” to the transmembrane domain. Trop-2molecules engage in homophylic
interactions between adjacent cells and establish multimeric complexes with
tight junction proteins, which may hinder accessibility by therapeutic antibod-
ies. Up to now, Trop-2-targeted approaches have employed anti-Trop-2 mono-
clonal antibodies (mAb) which essentially recognize a single immunodominant
epitope poised between the globular and stem regions. Such mAb have limited
or no therapeutic effıcacy. In order to untap the potential of anti-Trop-2 immu-
notherapy we generated novel anti-Trop-2 mAb with tailored specifıcity to-
wards the globular versus stem regions. Hybridoma diversity wasmaximized by
immunization with soluble human Trop-2 extracellular region produced in dif-
ferent transformed mammalian cell lines (human 293 and murine L) and in
insect cells/baculovirus expressing system. These were expected to provide na-
tive folding of Trop-2 together with a broad spectrum of differential glycosyla-
tion. Trop-2-binding hybridomas were further selected by multiple rounds of
flow cytometry analysis using live 293 cells expressing different Trop-2 extracel-
lular portions. Two classes of mAb were identifıed, that bound the stem versus
the globular region. ThesemAb effıciently boundTrop-2 expressing cancer cells
and were able to inhibit cell growth in vitro. In vivo the naked anti-globular
OX-G64 and anti-stem OX-S55 mAb were most effective in inhibiting the
growth of distinct tumors, including colon, ovary and prostate cancers. Notably,
they showed differential effıcacy for established tumors versus isolated-cell
models of metastatic dissemination, consistent with our strategy of maximizing
differential accessibility of Trop-2 according to growthmode.Most remarkably,
we demonstrated in vivo synergy of these anti-Trop-2 mAb, paving the way for
game-changing anti-cancer mAb therapy. The differential effıcacy of the OX-
G64 and OX-S55 anti-Trop2 mAb against different tumor histotypes and
growth stages further allows to exploit their cancer-killing potential in patho-
logical stage-tailored therapeutic approaches.
#4589 Preclinical investigation of SGN-CD70A antibody-drug conjugate
in T cell lymphomas. Chen-Yen Yang, Linlin Wang, Laura Pincus, Frank Mc-
Cormick, Ryan Gill, Wei Ai. UCSF, San Francisco, CA.
CD70 is a member of the tumor necrosis factor (TNF) superfamily and aber-
rantly expressed in several solid tumors and a variety of hematologic malignan-
cies. The CD70 protein is expressed on highly activated lymphocytes (like in T
and B cell lymphomas). Since normal lymphocytes do not express much CD70,
it is suggested that anti-CD70 antibodies could be a potential treatment for
CD70 positive lymphomas. SGN-CD70A is a novel antibody-drug conjugate
that combines an anti-CD70monoclonal antibody with a synthetic DNA cross-
linking molecule, pyrrolobenzodiazepine (PBD) dimer. It is currently under
phase I clinical trials for renal cell carcinoma, mantle-cell, diffuse large B-cell,
and follicular lymphoma. The aim of this study is to investigate the anti-tumor
activity of SGN-CD70A in T cell lymphomas. We fırst examined CD70 expres-
sion in 36 cases ofmature T orNK cell lymphomas using immunohistochemical
(IHC) staining of patient biopsy specimens. The IHC results were reviewed and
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scored by 2 independent pathologists.We further investigated CD70 expression
in Sezary syndrome (SS), mycosis fungoides (MF), and T cell acute lymphoblas-
tic leukemia (T-ALL) cell lines, along with patient-derived T cell lymphoma
primary cells and healthy donors’ peripheral blood mononuclear cells (PBMC)
by flow cytometry.We next evaluated the anti-tumor activity of SGN-CD70A in
cutaneous T cell lymphoma (CTCL) cell lines and patient-derived T cell lym-
phoma primary cells. Cell lines or primary cells were treated with SGN-CD70A
at various concentrations, after which growth inhibition and apoptosis were
assessed by CellTiter-Glo Assay, flow cytometry or Caspase-Glo 3/7 Assay, re-
spectively. CD70 negative T-ALL cell lines were treated in parallel as negative
controls for CD70 positive CTCL cell lines. Additionally, h00d-1910, an isotype
control of the anti-CD70 antibody conjugated to PBD, was used as the negative
control for SGN-CD70A. CD70 expressionwas observed across all subtypes of T
cell lymphomas and all CTCL cell lines. In contrast, CD70 is not expressed in
PBMC from healthy subjects. We demonstrated that SGN-CD70A potently in-
hibited cell growth in CD70-positive CTCL lines, but had no signifıcant activity
inCD70-negative T-ALL lines. In addition, SGN-CD70A inducedmore apopto-
sis and cell death inCTCL cell lines comparedwithmedia andh00d-1910 treated
controls. Furthermore, we showed that SGN-CD70A inhibited cell proliferation
and induced higher caspase 3/7 activity in CD70-expressing patient-derived T
cell lymphoma primary cells in a dose-dependent manner, while h00d-1910
treated in parallel had no signifıcant effects. In summary, CD70 is expressed in
both nodal and cutaneous T cell lymphomas but not in healthy donors. SGN-
CD70A not only shows anti-tumor activity in CTCL cell lines expressing CD70,
but also inhibits proliferation and induces apoptosis in patient-derived T cell
lymphoma primary cells, indicating it is a promising treatment for T cell lym-
phomas.
#4590 Abviximab manifests striking anti-tumor effects in sensitive and
chemoresistant ovarian cancer cells. Ghassan M. Saed, Nicole M. Fletcher, Ira
Memaj.Wayne State University, Detroit, MI.
Introduction: We have recently reported myeloperoxidase (MPO) to be ex-
pressed in epithelial ovarian cancer (EOC) cells and tissues. This fınding was
surprising, as MPO is known to be expressed only in cells of myeloid origin.We
have also found that targeting 2 integrin (CD11b/CD18), a known ligand for
MPO, resulted in signifıcant anti-tumor effects. The objective of this study was
to determine if targetingCD11bwith a clinically approved drug that cross-reacts
with CD11b will have anti-tumor effıcacy for the treatment of sensitive and
chemoresistant ovarian cancer. Methods: Human EOC cell lines MDAH-2774,
SKOV-3, andA2780 and their chemoresistant counterpartswere utilized for this
study. Cells were treated for 24 hrs with increasing doses of docetaxel (0.0075,
0.01, and 0.025 M) or cisplatin (0.1, 0.5 and 1.0 M) with our without abcix-
imab (5 or 10 g/ml), an existing clinically approved anticoagulant drug. Ab-
ciximab is a human-murine chimeric antibody Fab fragment against platelet
integrin glycoprotein IIb/IIIa (GP IIb/IIIa). Cytotoxicity was determined by the
TACS MTT Cell Proliferation Assay. Data was analyzed using SPSS and signif-
icant cytotoxic effects were determined by one-way analysis of variance within
groups (sensitive, resistant to docetaxel or cisplatin) followed by Tukey’s post
hoc tests, and independent t-tests for comparison between groups. For the syn-
ergistic effect of abciximab and chemotherapy, the automated calculation of
combination index values was conducted by CompuSyn software. A combina-
tion indexmethod provides qualitative information on the nature of compound
interaction (antagonistic, additive or synergistic effect) and was used to analyze
the results. Statistical signifıcance of p0.05 was considered signifıcant for all
analyses. Results: Abciximabhad signifıcant cytotoxic effects in sensitive (40.8	
10.3 and 56.7	 5.3%), docetaxel resistant (30.0	 11.6 and 46.6	 10.0%), and
cisplatin resistant (27.3	 7.9 and 41.9	7.0%) EOC cells at the 5 and 10 g/ml
dose, respectively, as compared to untreated controls (p0.01). Abciximab is
signifıcantly more cytotoxic to sensitive as compared to cisplatin resistant cells
(p0.01), with no signifıcant difference in killing as compared to docetaxel
resistant cells (p0.057). Treatment with chemotherapy combined with abcix-
imab resulted in a synergist cytotoxic effect in all sensitive EOC cell lines, and in
chemoresistant MDAH-2774 and SKOV-3 cell lines. For the cisplatin resistant
A2780 cell line, synergist effects were only observedwhen combining abciximab
with 1.0 M cisplatin. Conclusions: The observed intriguing anti-tumor effects
of abcixiamb in ovarian cancer cells indicates the potential for abciximab to be
repurposed as a novel therapy for ovarian cancer.
#4591 Specifıc elimination of invasive and multidrug-resistant cancer
cells by an antibody-drug conjugate targeting AXL. Julia Boshuizen,1 Louise
A. Koopman,2 Esther C. Breij,2 David Satijn,2 Daniel Peeper,1 Paul W. Parren2.
1Netherlands Cancer Institute, Amsterdam, Netherlands; 2Genmab, Utrecht,
Netherlands.
Upon therapeutic pressure, cancers commonly select for drug-resistant, inva-
sive subpopulations with elevated expression of the receptor tyrosine kinase
AXL. Besides the correlation between high AXL expression and induction of
epithelial-to-mesenchymal transition, a process known to support metastasis,
ample evidence also links AXL to resistance against a variety of targeted thera-
pies, including inhibitors of theMAPKpathway inmalignantmelanoma and the
EGFR pathway in lung cancer. AXL-107-MMAE (HuMax-AXL-ADC) is a ther-
apeutic antibody-drug conjugate specifıc for AXL, containing the microtubule
disrupting agent monomethyl auristatin E as the cytotoxic payload. AXL-107-
MMAEwas previously shown to induce potent cytotoxicity in vitro and in vivo,
which was dependent expression of AXL on the cell surface. We evaluated the
capacity of AXL-107-MMAE to target AXL-positive MAPK pathway inhibitor
resistant tumor cells, using malignant melanoma as a clinically relevant exam-
ple. First, AXL-107-MMAE was shown to induce cytotoxicity in BRAF-mutant
tumor cell lines that showedAXL expression upon acquired resistance to BRAF-
inhibitors. In contrast, no cytotoxicity was observed in the BRAF-inhibitor-
sensitive, AXL-negative parental cell lines. In heterogeneous tumor cell cultures,
treatment with a BRAF-inhibitor selected for AXL-high, MAPK pathway inhib-
itor-insensitive melanoma cells, which was prevented by combined BRAF-in-
hibitor and AXL-107-MMAE treatment. Interestingly, we observed marked
AXL upregulation in biopsies obtained from patients after they developed resis-
tance to MAPK pathway inhibitors compared to paired pre-treatment biopsies.
The in vivo potential of AXL-107-MMAE in malignant melanoma was demon-
strated using BRAFV600E-mutated xenograft model derived from a patient who
developed resistance to the BRAF inhibitor vemurafenib in the clinic. This in-
dicates that AXL expression levels in treatment-resistant malignant melanoma
are suffıcient to induce tumor regression with AXL-107-MMAE, at least in this
model system. These fındings merit clinical validation of the targeting of both
treatment-naïve and drug-resistant cancers with AXL-107-MMAE, either alone
or in combination with other targeted therapies.
#4592 Complement regulatory protein expression in solid tumors: impli-
cations for resistance to antibody-mediated immunotherapy. Pankita He-
mant Pandya, M. R. Saadatzadeh, Jixin Ding, Barbara Bailey, Sydney Ross,
Khadijeh Bijangi-Vishehsaraei, Mary E. Murray, Karen E. Pollok, Jamie L. Ren-
barger. Indiana University School of Medicine, Indianapolis, IN.
Background: Resistance to anti-cancer therapies results in relapsed/refractory
disease of Glioblastoma (GBM) and Ewing’s Sarcoma. Up-regulation of mem-
brane-bound complement regulatory proteins (mCRPs) CD46, CD55, and
CD59 can enable solid tumors to confer resistance to antibody-mediated immu-
notherapy by preventing complement and antibody-dependent cytotoxicity.
mCRPs’ inhibitory role in monoclonal antibody treatments for liquid tumors
have been reported, but their role and regulation in solid tumors has not been
explored. In the context of refractory tumors, others have reported that vascular
endothelial growth factor-A (VEGF-A) can induce mCRP expression in endo-
thelial cells. Notably, p53 mutational status induces VEGF-A and its receptor
(VEGFR2) in breast cancer cell lines. To investigate potential links among p53
status, VEGF-A, and mCRP, we screened wildtype (wt-p53) and mutant p53
solid tumor cell lines for mCRP expression and VEGF-A secretion. Our data
suggest that p53 mutational status is associated with expression of CD55 and
VEGF-A secretion. These studies provide foundation for potentially recogniz-
ing mCRPs as immune biomarkers in solid tumors, ultimately, resulting in de-
velopment of novel immunotherapies for improved clinical outcomes.Methods:
Pediatric Ewing’s sarcoma (CHLA9 andCHLA10) and adult GBM (GBM10 and
GBM43) cell lines differing in p53 status were selected for in vitro studies.
GBM43 originates from a primaryGBM,whileGBM10 is from a recurrentGBM
patient. Ewing’s Sarcoma cell lines, CHLA9 and CHLA10, were generated from
the same patient at primary diagnosis and at relapse respectively. Western blot,
and sequencing confırmed the expression and p53 mutational status. mCRP
expression was evaluated using RT-PCR and flow cytometry. Milliplex platform
assessed VEGF-A expression in cell supernatants. Results: Whole genome se-
quencing data confırmed p53 mutations in all cell lines. CHLA9 and GBM10
harbor wt-p53. CHLA10 cells have p53 deletion and GBM43 cells have a F270C
p53 mutation in both alleles CD55 transcripts were undetected in wt-p53 lines
(CHLA9 and GBM10), but CD55 transcripts were increased in mutant/deleted
p53 lines (CHLA10 and GBM43). Flow cytometry data show increased CD55
expression in mutant p53 glioblastoma (GBM43) versus wt-p53 (GBM10) cells
(p0.001). Transcript and flow cytometric analysis of CD46 and CD59 in Ew-
ing’s sarcoma and GBM cell lines are in progress. Mutant p53 Ewing’s sarcoma
and GBM cell lines secreted more VEGF-A compared to wt-p53 cell lines
(p0.05 and p0.001, respectively). Conclusion: These fındings highlight the
importance of further investigating role of VEGF-A in regulating mCRPs in
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wt-p53 versus mutant p53 solid tumor cell lines. Elucidating mechanisms for
mCRP regulation is critical for immune biomarker development and in facili-
tating the use of antibody-based therapeutic approaches for solid tumors.
#4593 Glycoengineered antibodies for click chemistry applications.
Drishti Sehgal, Stephen Kalscheuer, Tanmoy Sadhukha, Jayanth Panyam. Uni-
versity of Minnesota, Minneapolis, MN.
Antibody-drug conjugates (ADC) hold considerable promise as anticancer
agents. A critical determinant of the effectiveness of ADCs is the chemistry that
is used to conjugate the payload. Currently used approaches include primarily
conjugation to either side-chain amine or carboxylic acid groups or conjugation
to thiols. Because these reactions are not site specifıc and not easily controlled,
these chemistries can result in reduced affınity for the target antigen. Further,
these conjugation reactions lack selectivity and can result in heterogeneousmix-
tures of products that differ in the sites and stoichiometry of modifıcation. We
investigated a glycoengineering strategy that enables the introduction of artifı-
cial azide groups in the antibody without affecting their antigen affınity. This is
based on the observation that glycosyltransferases can incorporate non-natural
sugars (e.g., azido mannose) at different sites on an IgG molecule. The azide
groups inthese artifıcial sugars are then available to react with alkynes through
copper-catalyzed ’click’ chemistry or with strained alkynes such as dibenzyl
cyclooctyne (DBCO) allowing for biorthogonal, copper-free ’click’ chemistry.
Because the sugars are added reproducibly and at asite that does not affect anti-
gen binding, the glycoengineering technology would overcome problems asso-
ciated with traditional conjugation strategies. Using this approach, azide groups
were introduced in anti-CD133 and anti-perlecan antibodies. Further, the azide
groups were available to react with various DBCO conjugates including fluoro-
phores, drugmolecules and nanoparticles. Importantly, the addition of artifıcial
sugar and subsequent azide-alkyne reactiondid not affect the affınity of the an-
tibody for the target antigen. Conjugation of nanoparticles to antibodies using
this approach resulted in enhanced cellular uptake of the nanoparticles. Simi-
larly, conjugation of a cytotoxin to the antibody resulted in enhanced cell kill in
vitro. Weexpect that this glycoengineering strategy will prove to be a unique
platform technology that will have a signifıcant impact on antibody-based ther-
apeutics.
#4594 Inductionof apoptosis by anti-CD20 antibodies requires the induc-
tion of EGR-1 and calcium influx. Ivana Spasevska, Jade Villé, Kamel Chettab,
Eva-Laure Matera, Charles Dumontet. INSERM 1052/CNRS 5286/University of
Lyon Cancer Research Center of Lyon, Lyon, France.
Background: Anti-CD20 monoclonal antibodies (mAbs) are an essential
component of the treatment of patients with CD20-positive non-Hodgkin’s
lymphoma and chronic lymphocytic leukemia (CLL). Anti-CD20 mAbs medi-
ate their antitumor effects by activating the immune system or by direct apopto-
tic signaling in target cells. In a previous preclinical study, we have shown that
treatment of B-lymphoma cell lines with anti-CD20 mAbs, rituximab and obi-
nutuzumab, resulted in upregulated expression of the transcription factor early
growth factor -1 (EGR-1) (Dalle et al. 2011). However, the role of EGR-1 in
response to passive immunotherapies has not been explored so far. Further-
more, EGR-1 has been described as a calcium (Ca2) regulated transcription
factor and CD20 is hypothesized to regulate transmembrane Ca2 flux. In this
study we aim to assess the role of EGR-1 and Ca2 flux in the cytotoxic activity
of anti-CD20 mAbs. Methods: EGR-1 modulation and cell death induction by
anti-CD20 mAbs rituximab and obinutuzumab were investigated in cells ex-
pressing endogenous and exogenous CD20. The cytotoxic effect of anti-CD20
mAbs was evaluated in SCIDmice and in B-lymphoma cell lines overexpressing
EGR-1 or knocked down for EGR-1. The impact of anti-CD20 mAbs on Ca2
flux was investigated by flow cytometry using Indo-1 AM stained cells. Ca2
channel blocker agent nifedipine was used to investigate the role of Ca2 flux on
obinutuzumab effıcacy. Results: EGR1 expression is rapidly upregulated in
CD20 cells following rituximab and obinutuzumab exposure. Decreasing
EGR-1 expression by shRNA abolished the direct cytotoxic effect of obinutu-
zumab both in vitro and in vivo, indicating that EGR-1 is required for CD20-
mediated apoptosis. Additionally, the overexpression of EGR-1 resulted in en-
hanced cytotoxic activity of obinutuzumab both in vitro and in vivo. Rescuing
EGR-1 expression in EGR-1 knocked-down cells restored sensitivity to obinu-
tuzumab.Moreover, our results indicate that both rituximab and obinutuzumab
could induce calcium influx in the presence of suboptimal concentrations of
ionomycin. Blocking Ca2 flux with the calcium channel blocker nifedipine or
the Ca2 chelating agent EGTA abolished EGR-1 induction by anti-CD20
mAbs. In vivo, nifedipine treatment interfered with obinutuzumab antitumor
activity against established Granta (a human mantle cell lymphoma line) xeno-
grafts in SCIDmice. Conclusion: EGR-1 plays amajor role in the direct cytotoxic
activity of anti-CD20 monoclonal antibodies and should be evaluated as a new
biomarker to predict response to anti-CD20 treatment. Our data also show that
calcium channel blockers interfere with the antitumor activity of obinutuzumab
in preclinical models.
#4595 Moxetumomab pasudotox spares CD4 and CD8 lymphocytes in
multiply relapsed hairy cell leukemia patients, while prospective trials of
fırst, second, and later lines of purine analogs show increasing toxicity. Rob-
ert J. Kreitman,Maryalice Stetler-Stevenson, EvgenyArons, Ira Pastan.National
Cancer Institute, Bethesda, MD.
The purine nucleoside analogs cladribine and pentostatin damage DNA and
cause long-term suppression of CD4 and CD8 lymphocytes in patients with
hairy cell leukemia (HCL). There is increasing concern that these reductions,
particularly in CD4 T-cells, may be associated with opportunistic infections
and secondary malignancies. The anti-CD22 recombinant immunotoxin mox-
etumomab pasudotox targets HCL without damaging DNA, and spares T-cells.
In a phase 1 trial, 20 patients treatedwith 50 ug/Kg every other day for 3 doses for
2-8 (median 4) cycleswere evaluated for T-cell subsets. CD4 cells increased -56%
to 152% (median 46%) after end of treatment, decreasing in only 1 of the 20
patients. Because there is very little prospective data on the effect of purine
analogs on T-cells, we analyzed data from 80 consecutively enrolled patients
receiving cladribine in fırst line, 40 receiving cladribine in second line, and 52
receiving either pentostatin or bendamustine in third or later lines. The latter
group was most appropriate to compare with moxetumomab pasudotox, which
was also used in third or later-line treatment of HCL. CD4 counts after moxetu-
momab pasudotox were 85-600 (median 424), compared to 22-618 (median 73)
after third or later line purine analog (p0.0001). These CD4 counts after mox-
etumomab pasudotox were even higher than those after fırst line (86-954, me-
dian 259, p0.0037) or second line (53-724, median 185, p0.0001) cladribine.
CD4 counts after fırst line cladribine were higher than those after second line
cladribine (p0004), which in turn were higher than those after third or later
line purine analogs (p0.0001). Even after 2 years, CD4 counts after third or
later line purine analogs, 41-1004 (median 264), n43, remained suppressed
compared to 1st line cladribine, 191-1044 (median 392, n68, p0.0013). The
percent decreases in CD4 counts after fırst line cladribine were signifıcantly
greater compared to those after moxetumomab pasudotox (median 63% de-
crease vs 46% increase, p0.0001). CD8 counts were also preserved after mox-
etumomab pasudotox, increasing by -32% to 198% (median 46%). Similar dif-
ferences between moxetumomab pasudotox and purine analog groups were
observed with respect to CD8-cell suppression. Opportunistic infections, neu-
tropenic fevers, and other infectious complications were much more common
after purine analogs than after moxetumomab pasudotox, particularly in later
lines of therapy. These data provide a rationale for avoiding repeated cycles of
purine analog for relapsed HCL, and support the use of non-chemotherapy
approaches like moxetumomab pasudotox before repeated courses of purine
analog are tried. (Supported in part by MedImmune and NCI, Intramural Pro-
gram).
#4596 Antibody-drug conjugates bearing pyrrolobenzodiazepine or tu-
bulysin payloads alter the tumor immune microenvironment and synergize
with multiple immunotherapies. Jonathan Rios-Doria,1 Jay Harper,1 Ray-
mond Rothstein,1 Leslie Wetzel,1 Jon Chesebrough,1 Allison Marrero,1 Cui
Chen,1 Patrick Strout,1 Kathy Mulgrew,1 Kelly McGlinchey,1 Ryan Fleming,1
Binyam Bezabeh,1 John Meekin,1 David Stewart,1 Maureen Kennedy,1 Philip
Martin,1 Andrew Buchanan,2 Nazzareno Dimasi,1 Emil Michelotti,1 Robert
Hollingsworth1. 1MedImmune, LLC, Gaithersburg, MD; 2MedImmune, LLC,
United Kingdom.
Immunogenic cell death (ICD) is the process bywhich certain cytotoxic drugs
induce apoptosis of tumor cells in amanner that stimulates the immune system.
In this study, we investigated whether ADCs conjugated with pyrrolobenzodi-
azepine dimer (PBD) or tubulysin payloads induced ICD, modulated the im-
mune microenvironment, and could combine with IO drugs to enhance antitu-
mor activity. We show that these payloads on their own induced an immune
response that prevented the growth of tumors following subsequent tumor cell
challenge. ADCs had greater antitumor activity in immunocompetent vs. im-
munodefıcientmice, demonstrating a contribution of the immune system to the
antitumor activity of these ADCs. These ADCs also induced immunological
memory. In the CT26model, depletion of CD8T cells abrogated the activity of
these ADCs when used alone or in combination with a PD-L1 antibody, con-
fırming a role for T cells in the antitumor activity. Combinations of ADCs in
different tumor models with IO drugs including PD-1 or PD-L1 antibodies, or
OX40 ligand or GITR ligand fusion proteins produced synergistic antitumor
responses. Importantly, synergy was observed in some cases with suboptimal
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doses of ADCs, potentially providing an approach to achieve potent antitumor
responses whileminimizing ADC-induced toxicity. Immunophenotyping stud-
ies in different tumor models revealed broad immunomodulation of lymphoid
and myeloid cells by ADCs and ADC/IO combinations. These results suggest
that it may be possible to develop novel combinatorial therapies with PBD- and
tubulysin-based ADCs and IO drugs that may increase clinical responses.
#4597 A novel immuno-oncology approach: targeting cell-surface meso-
thelin with a fusion construct containing human granzyme B. Lawrence H.
Cheung,1 Rasheed Tijani,2 Nasir Khan,2 Claire Thuning-Roberson,2 Michael G.
Rosenblum1. 1MD Anderson Cancer Center, Houston, TX; 2H2Biologics Inc,
Shrewsbury, MA.
Immunological approaches to target tumors have gained considerable trac-
tion recently because of excellent clinical results. In addition, targeted treatment
with antibody-drug conjugates (ADCs) can also be effective in achieving regres-
sion of solid tumors. The challenge forADCs continues to be effıcacy, stability of
the construct anddevelopment of resistance.Wehave developed a unique fusion
protein composed of 1) a novel human single-domain antibody (SD1) that
uniquely targets Region III of the mesothelin glycoprotein and 2) an engineered
version of the human serine protease Granzyme B (GrB). Mesothelin is highly
expressed in aggressive cancers such asmalignantmesothelioma, pancreatic and
ovarian cancers, and NSCLC. Granzyme B generates an intense, irreversible
pro-apoptotic effect throughdirect cleavage of caspases, release of cytochromeC
from mitochrondria, and cleavage of nuclear matrix. Previous ADCs targeting
mesothelin have faced the drawbacks of toxic payloads, formation of neutraliz-
ing antibodies, and competition with the serum protein MUC16/CA125. SD1-
GrB represents a new class of completely human immunotoxins containing a
payload with a unique mechanism of action. Additionally, because of its unique
binding properties, SD1 does not compete with circulating CA125 and is not
subject to cleavage. The SD1-GrB construct was designed as a homodimer
(200kDa) containing an IgG Fc domain and was expressed using transient-
transfection of HEK293E cells. The soluble SD1-GrB was isolated from condi-
tionedmedia and purifıed to homogeneity as assessed by SDS-PAGE andWest-
ern. Enzymatic activity of the GrB component was assessed by IEPD and found
to be similar to authentic, native GrB. Binding to mesothelin was confırmed by
surface plasmon resonance. Additionally, binding to the human lung adenocar-
cinoma cell lines H460 and HCC1703 was demonstrated by ELISA. Initial cyto-
toxicity (IC50) of SD1-GrB against H460 and HCC1703 was in the 30 nM range.
Assessment against a larger panel of cell lines is ongoing followed by in vivo
effıcacy in a human tumor xenograftmodel. Our preliminary evaluation of SD1-
GrBADCsuggests this construct has a uniquemechanismof action and is highly
cytotoxic against target cells. This molecule appears to be an excellent candidate
for further pre-clinical development as a therapeutic agent. Research conducted,
in part, by the Clayton Foundation for Research.
#4598 Triggering of OX40 on T cells by a novel monoclonal antibody
elicits robust antitumor immunity<!–EndFragment–>. Hua Long,1 Ann
White,2 Jie Wei,1 Brittany Jiang,3 Reid Feldman,1 Danielle Pappas,1 Aymen Al-
Shamkhani,4 John Lin5. 1Pfızer Inc, South San Francisco, CA; 2UCB Pharma,
South San Francisco,UnitedKingdom; 3Abbvie, RedwoodCity, CA; 4University of
Southampton, United Kingdom; 5None, CA.
T cell costimulation is an attractive strategy for cancer treatment in addition
to check point inhibitors. CostimulatorymoleculeOX40 is amember of theTNF
receptor superfamily that is transiently expressed on activatedT cells. Activation
of OX40 leads to enhanced T cell proliferation and cytokine secretion and in
turn results in better anti-tumor effıcacy as shown bymultiple mouse syngeneic
tumor models. PF-04518600 (PF-8600) is a fully human IgG2 agonist antibody
to human OX40 with high affınity and specifıcity. We used in vitro and in vivo
methods to evaluate the co-stimulatory functions of PF-8600. PF-8600 demon-
strated better agonist activity in a luciferase reporter cell line expressing OX40
and NFB as compared to a human IgG1 antibody. In human primary T cells,
PF-8600 dose dependently increased T cell proliferation and cytokine secretion
in vitro. Furthermore in a mouse line expressing human OX40, PF-8600 in a
mouse IgG1 framework increased the proliferation of OT1 cells and inhibited
EG7 tumor growth as compared to isotype control antibody, further confırming
the mechanism of action as an OX40 agonist. As regulatory T cells are a major
inhibitory population in the tumor microenvironment, their specifıc depletion
in the tumor is highly desirable. In an in vitro assay using monocyte derived
macrophages as effector cells, PF-8600mediated the depletion of OX40 express-
ing cells similar to a human IgG1 antibody, and this activity is dependent on the
binding to hFcRIIA. In humanFcRknock-inmice, anti-OX40-hIgG1 showed
increased Treg reduction in the tumor comparing to anti-OX40-hIgG2, but less
T cell proliferation and activation in the periphery. In combination with an
anti-PD-L1 antibody, both anti-OX40-hIgG1 and hIgG2 showed similar en-
hanced anti-tumor activity in the MC38 colon carcinoma model as comparing
to anti-PD-L1 alone. Both in vitro and in vivo results demonstrated PF-8600
enhanced T cells functions and inhibited tumor growth in a mouse syngeneic
tumormodel. The activity of the hIgG2 antibody is similar to that of an hIgG1 in
both phagocytosis assays and hFcR KI in vivo assays. Based on the mechanism
of action and robust anti-tumor effıcacy in preclinical models, PF-8600 is cur-
rently in clinical development in a broad spectrum of malignancies.
#4599 Antibody targeting PDZ domain of TIP-1 induces proliferation
arrest throughAKT/mTOR signaling inhibition in lung cancer and glioblas-
toma. Vaishali Kapoor, David Dadey, Kelly Hoye, Andrea Collins, Dinesh
Thotala, Dennis Hallahan. Washington University in St. Louis School of Medi-
cine, st. louis, MO.
Antigens that are over-expressed in cancer in response to radiation are being
used as novel targets. We showed tax interacting protein 1 (TIP-1) to be radia-
tion-inducible that translocated to the surface of the cancer cell following irra-
diation. TIP-1, which consists of a single PDZdomain plays an important role in
cell signaling, cancer development, and progression. TIP-1’s involvement in
various survival pathways makes it an attractive target for anticancer therapeu-
tics. We used antibodies specifıc to this PDZ domain to determine its role in
cancer cell survival. We monitored proliferation in lung cancer (A549 and
H460) and glioblastoma (D54 andU251) cells after 24, 48, 72 and 96h treatment
with the anti-PDZ antibody.We observed a time-dependent proliferation arrest
with anti-PDZ antibody treatment which was associated with increased apopto-
sis. The anti-PDZ antibody when combined with radiation (3Gy) led to reduced
proliferation and colony formation. Anti-PDZ antibody had no effect on the
proliferation of normal lung (MRC-5) and endothelial (HUVEC) cells. Cells
treated with anti-PDZ antibody showed decreased levels of the phosphorylated
forms ofAKT,mTOR, and a downstream substrate ofmTOR, 4EBP1.Anti-PDZ
antibody treatment also led to an overall reduction in basal levels of AKT,
mTOR, and 4EBP1. Further, we evaluated the effect of the anti-PDZ antibody on
tumor growth in heterotopic mouse models of lung cancer (A549) and glioma
(U251). We observed signifıcant growth delay in mice treated with anti-PDZ
antibody treatment when compared to mice treated with the isotype control.
The combination of the anti-PDZ antibody with radiation showed an additive
effect. Immunoblot analysis of tumor tissues also showed downregulation of
phosphorylated and total levels of AKT,mTORand 4EBP1 in the tumors treated
with anti-PDZ antibody. Overall, our results suggest that TIP-1 is a promising
therapeutic target for treatment of lung cancer and glioblastoma. Antibodies
specifıc to the PDZ domain of TIP-1 enhance the effıcacy of radiotherapy. The
anti-PDZ antibodies need to be optimized further before translating it into the
clinic.
#4600 Potent and selective C-C chemokine receptor (CCR4) antagonists
potentiate anti-tumor immune responses by inhibiting regulatory T cells
(Treg). Oezcan Talay, Lisa Marshall, Cesar Meleza, Maureen K. Reilly, Omar
Robles, Mikhail Zibisky, Abood Okal, Lisa Seitz, Jenny McKinnell, Scott Jacob-
son, ErinRiegler, EmilyKarbaz,DavidChian,AngelaWadsworth, PaulKassner,
David Wustrow, Jordan S. Fridman. FLX Bio, Inc., South San Francisco, CA.
Naturally suppressive CD4 Foxp3 Treg are essential for immune tolerance.
Although Treg-mediated suppression of effector cells is important to control
inflammation and prevent autoimmune diseases, the presence of Treg in the
tumor microenvironment (TME) has been shown to dampen anti-tumor im-
mune responses. Human Treg express CCR4, the receptor for the chemokines
CCL17 and CCL22. These chemokines are produced by tumor cells, tumor-
associated macrophages and dendritic cells, as well as by effector T cells (Teff).
Preclinical and clinical data supports a role for CCR4-mediated recruitment and
accumulation of Treg in the TME which can be associated with poor prognosis.
Further, recent longitudinal studies in patients receiving IO agents demonstrate
an influx of Treg in responding patients which may dampen optimal anti-tumor
responses. Therefore, CCR4 is an ideal target to selectively block Treg recruit-
ment into the TME.We have developed structurally unique series of small mol-
ecule antagonists of CCR4. These antagonists have cellular potencies inmultiple
assays (e.g. chemotaxis of primary human Treg in 100% serum) in the low dou-
ble-digit nM range. Representative compounds are selective against other
chemokine receptors, GPCRs and ion channels, including the hERG channel,
and lack inhibition of common human CYP450 enzymes. Moreover, com-
pounds have excellent in vitro and in vivo ADME properties, consistent with
convenient oral dosing. In preclinical syngeneic tumor models, these CCR4
antagonists block Treg migration and support expansion of activated Teff. In
contrast to the non-selective approach of depleting anti-CCR4 antibodies, our
compounds reduce Treg in the tumor, but not in peripheral tissues such as blood,
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spleen or skin. In preclinical effıcacy studies, CCR4 antagonists potentiate the
anti-tumor effects of various checkpoint inhibitors and immune stimulators
such as anti-PD-L1 and anti-CD137 antibodies. We observe enhanced tumor
growth inhibition and increased tumor regressions when these agents are com-
bined with CCR4 antagonists, without any gross toxicity. Further characteriza-
tion of these CCR4 antagonists and their anti-tumor effects will be described.
#4601 Mechanisms of action for therapeutic antibody variants of human
IgG3 isotype: Enhancing the CDC activity of cetuximab and rituximab. Ralf
Schwanbeck,1 Anna Skof,1 Thies Rösner,1 Marco Jansen,2 Anina Räuchle,1
Anna Kretschmer,1 Axel Scheidig,1 Jeanette Leusen,2 Stefanie Derer,3 Thomas
Valerius1. 1Christian-Albrechts-University, Kiel, Germany; 2University Medical
Center, Utrecht, Netherlands; 3University Hospital Schleswig-Holstein, Lübeck,
Germany.
Objectives. Human IgG3 differs from other antibody isotypes by its extended
hinge region and by its higher affınity for C1q. The ability of complement to
promote lysis of antibody-opsonized cells is well-established andmay represent
amainmechanism in antibodymediated tumor therapy. The aim of this project
was to investigate effector mechanisms of tumor- directed IgG3 antibodies in
more detail. Experimental procedures. Therapeutic antibodies against EGFR
(cetuximab, 225) andCD20 (rituximab, C2B8) were produced as IgG1 and IgG3
isotype variants by co-transfecting CHO cells with the respective de novo syn-
thesized VH and VL domains fused to the respective heavy chain containing
vectors. A Fab fragment of C2B8-IgG3 was crystallized and analyzed by X-ray
structure analysis at PETRA III (DESY, Hamburg, Germany). Based on the
resolved structure selected mutations were introduced into the CH1 domain of
IgG3 aiming to improve or abolish CDC. Purifıed antibodies were assessed for
complement fıxation in ELISA and on tumor cells. Complement- and antibody-
dependent cellular cytotoxicity (CDC and ADCC) activities were measured us-
ing 51chromium release assays. The signifıcance of complement regulatory fac-
tors on target cells was investigated by siRNA mediated knock-down. A
peritoneal tumor model was used to investigate the in vivo effıcacy of IgG3 in
comparison to IgG1 antibodies. Results. Switching isotypes from IgG1 to IgG3
did neither affect target antigen binding nor the proliferation inhibition by
EGFR antibodies. Unexpectedly, the IgG3 antibodies were not very active in
ADCC, in spite of their strong FcRIII (CD16) binding affınity. However, for
target cells expressing low antigen levels, the IgG3 isotype improved CDC
against CD20 and enabled CDC against EGFR expressing tumor cells. The com-
plement-regulatory factor CD55 in particular mitigated the IgG3 induced CDC
activity. Structural comparison of Fab fragments of IgG1 and IgG3 demon-
strated signifıcant differences in the CH1 domains of the respective heavy
chains, which contain the disulfıde bond to the light chain and also harbor the
docking interface for the complement factors C3b and C4b. Preliminary results
from an peritoneal tumor model demonstrated that 225-IgG3 was effective in
killing EGFR- expressing cells. This in vivo activity was abolished by cobra
venom factor treatment. Conclusion. Switching the isotype of a therapeutic
IgG1 antibody to IgG3 represents a promising approach to enable complement-
mediated killing of tumor cells. Protein engineering of the C3b/C4b interaction
interface in the CH1 domain may constitute a novel strategy to modulate the
CDC activity against tumor target cells. Together, these approaches may en-
hance the CDC effıcacy of CD20- and EGFR- directed antibodies.
#4602 The dissociation constant rate of ADC would be an important fac-
tor for antitumor activity in vivo. Ryo Tsumura,1 Shino Manabe,2 Yoshikatsu
Koga,1 Masahiro Yasunaga,1 Yasuhiro Matsumura1. 1National Cancer Center
East, Kashiwa, Chiba, Japan; 2RIKEN, Wako, Saitama, Japan.
Introduction: Antibody-drug conjugates (ADCs), consisting of amonoclonal
antibody, a potent cytotoxic agent and a linker, are currently considered as
promising potent agents for cancer therapy.However, especially in solid tumors,
the tumor stroma would hinder ADCs from accessing to cancer cells, leading to
decline the effıcacy of ADCs in clinical study. In order to overcome these diffı-
culties and to maximize the ADC potential, the optimization of ADC compo-
nents is needed. And it’s well-known that antitumor activity of ADCs depends
on PK properties, binding affınity, internalization effıciency and other func-
tions. In present study, therefore, we focused on the characteristics of antibody
for ADC design, and investigated what characteristics could affect anti-tumor
effects in vivo. Material and Method: First, we prepared 4 types of monoclonal
antibodies against tissue factor (TF) which is known as a 47-kDa transmem-
brane glycoprotein and an initiation factor of the extrinsic blood coagulation.
And then, anti-TF antibodies were conjugated with maleimidocaproyl-valine-
citrulline-p-amino-benzoyloxycarbonyl linker and monomethyl auristatin E.
Both of them were well-known liker system and drug for current ADC design.
After conjugation, we investigated the characteristics, including binding param-
eters, internalization effıciencies, drug release rates, cytotoxicity against human
pancreatic cancer cell lines in vitro, half-life in vivo, anti-tumor effects using
xenograft model, and distribution in tumor tissues. Results: In SPR analysis,
anti-TFADCs showed the signifıcant differences of binding kinetics parameters.
However, in other assays, anti-TF ADCs showed almost same internalization
effıciencies, drug release rates, cytotoxicity against cancer cell lines in vitro,
half-life in vivo. The effıcacy of anti-TFADCswas examined in BxPC3 xenograft
model when the average tumor size reached 200 mm3. Although anti-TF ADCs
signifıcantly inhibited BxPC3 tumor growth compared with control groups,
there was no difference of anti-tumor effects among anti-TF ADCs. We further
examined the anti-tumor effects when the average tumor size reached 600mm3.
Interestingly, the antitumor effect of ADCusing the clonewith high dissociation
constant was superior to that with low dissociation constant against large size
tumor, especially in the early phase. Furthermore, the distribution of ADC in
BxPC3 tumor demonstrated that the former clone showed higher penetration
ability than the latter clone. Conclusion: We concluded that binding kinetics
parameters, in particular, the dissociation constant rate contributed to the tu-
mor penetration ability of anti-TFADCs and the different distribution inBxPC3
tumor. The distribution changes would affect the differences of anti-tumor ef-
fects in large size BxPC3 tumor. Therefore we suggested that the dissociation
constant rate would be an important factor for ADCs design.
#4603 Protocol optimization combining activatable nanodelivery with
immunotherapy in a murine breast cancer model. Azadeh Kheirolomoom,
Matthew Silvestrini, Lisa Mahakian, Elizabeth Ingham, Josquin Foiret, Spencer
Tumbale, Sarah Tam, Neil Hubbard, Alexander Borowsky, Katherine Ferrara.
UC Davis, Davis, CA.
Activatable nanotherapeutics provide the opportunity to deliver anthracyclines
to a well-controlled region of interest and therefore to locally stimulate immuno-
genic cell death. Such a strategy can be combined with immunotherapy for both
local tumor control and creation of an abscopal effect. Our group previously re-
ported that combining local administration of a CpG oligonucleotide with local
release of doxorubicin from a temperature-sensitive liposomal nanoparticle (TSL)
led to the elimination of directly treated lesions in a syngeneic murine model of
mammary adenocarcinoma.1 While this therapeutic approach increased the num-
bers of tumor infıltrating CD8 T lymphocytes in distant lesions and extended
survival, distant tumors returnedwith a growth delay of approximately 14 days and
T-regulatorycellswerenot reducedby treatment.Therefore, checkpointblockadeof
the programmeddeath-1 (PD-1) pathway (anti-PD-1)was incorporated in the pro-
tocol. CuDox-TSLwere prepared fromDPPC:MPPC:DSPE-PEG2k (86:10:4) in the
presence of copper (II) gluconate and triethanolamine at 0.2 mg-drug/mg-lipid. A
complex between doxorubicin and copper was created to enhance the circulation
and stability of TSL and to reduce systemic toxicity. On day 21, mice with bilateral
invasive neu deletion (NDL) tumors (4mm)were treatedwith i.v. administration
ofCuDox-TSLat6mgdoxorubicin/kgbodyweight.Ultrasound(US)hyperthermia
(1.1MPa, 1.5MHz, achieving42°C for5minbefore and20minafterdrug injection)
triggereddrugrelease. Immediately afterUS,100gofCpG-ODN1826wasadmin-
istered intratumorally to the insonifıed tumor; anti-PD-1 (200g, i.p.) was admin-
istrated three days later. Flow cytometry and immunohistochemistry were per-
formed on day 28 after one treatment with each component and survival was
assessed after treatment was repeated for three weeks.While control mice survived
35days, 50%of treatedmicewere tumor-free after 100days.All primary tumors and
50% of the contralateral tumors regressed and were eliminated by day 63.With the
incorporation of immunotherapy, three doses of chemotherapy were suffıcient to
eliminate all directly treated tumors, as compared with 8 doses without immuno-
therapy. After a single treatment with each component, a substantial change was
observed in systemic immune cells, including a signifıcant increase in natural killer
anddendritic cells indistant lymphnodes, inCD8Tcells in tumorsandassociated
lymph nodes and in IFNγ-secreting CD4T cells in the treated tumor and distant
lymph nodes. The results demonstrate that activatable chemotherapy can be paired
with an immune adjuvant and PD-1 blockade to generate a curative response in
primary anddistant tumors. Further, local chemotherapy, as potentiated by activat-
able liposomes does not impede a systemic CD8 T cell response. [1] Journal of
Controlled Release (2015); 220: 253-264.
#4604 MEDI1873, a GITR ligand fusion protein (GITRL FP), induces
effector T-cell proliferation, modulates T-regulatory cell function and has
the potential to combine with checkpoint inhibitors.Michelle Morrow,1 Re-
becca Leyland,1 James Hair,1 Ross Stewart,1 Natalie Tigue,1 Lisa Bamber,1 Sa-
mantha Ireland,1 Nicholas Holoweckyi,2 Michael Oberst,2 Amanda Watkins,1
Emily Offer,1 David Perez-Martinez,1 Ching Ching Leow,2 Lesley Young,1
Tristan Vaughan,1 Philip Mallinder,1 Robert Wilkinson1. 1Medimmune, Cam-
bridge, United Kingdom; 2Medimmune, Gaithersburg, MD.
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Glucocorticoid-induced tumor necrosis factor receptor-related protein
(GITR) is part of a system of signals involved in controlling T-cell activation.
MEDI1873 is a novel hexameric human GITR agonist comprising an IgG1 Fc
domain, a coronin 1A trimerisation domain and the humanGITRL extracellular
domain (ECD) that is currently being assessed in a Phase 1 clinical study
(NCT02583165) in patients with solid tumors. MEDI1873 exhibits in vitro su-
periority to an anti-GITR antibody with respect to evoking robust GITR ago-
nism, T-cell activation and clustering of Fc gamma receptors. Using in vitro
assay systems, MEDI1873 recapitulates aspects of GITR targeting previously
described inmice, includingmodulation of regulatory T-cell (Treg) suppression
and the ability to increase the CD8:CD4 T-cell ratio via antibody-dependent
T-cell cytotoxicity. Pharmacodynamic assessment of an agonisticmouseGITRL
FP (mGITRL FP) in the CT26 model of colorectal cancer demonstrated activa-
tion and proliferation of peripheral CD4 andCD8T cells coincident with an
increased depletion of intratumoral Tregs, likely through Fc mediated effector
functions. Furthermore, CT26 tumor growth studies indicated the mGITRL FP
could result in signifıcant antitumor activity. These data provide evidence that
MEDI1873 is a novel, potent GITR agonist with the potential tomodulate T-cell
responses and enhance anti-tumor immunity. Combinations of immunothera-
pies are generating exciting results in the clinic, therefore, we sought to assess the
potential for GITRL FPs to combinewith antibodies targeting either anti-PD-L1
(durvalumab) or anti-CTLA-4 (tremelimumab) using both in vitro and in vivo
systems. In vitro studies where MEDI1873 was combined with either dur-
valumab or tremelimumab showed that both combinations have the potential to
enhance interleukin-2 release in a superantigen-stimulation of human periph-
eral bloodmononuclear cells (PBMCs) compared to checkpoint blockade alone.
Further evidence to support the potential for combinatorial antitumor activity
was generated in the CT26 model where either 0.2mg/kg mGITRL combined
with 10mg/kg anti-mouse PD-L1 or 0.1mg/kg mGITRL combined with 5mg/kg
anti-mouse CTLA-4 antibodies resulted in enhanced antitumor activity versus
monotherapies alone. Overall, our data suggest that therapeutically targeting
GITR with a multimeric fusion protein, GITRL FP, may provide increased ago-
nistic potential versus an antibody, and have the ability to both activate effector
T-cells andmodulate Tregs through suppression and/or depletion. Finally, com-
bination studies provide preclinical evidence to support the rationale for com-
bination of MEDI1873 with anti-PD-L1 or anti-CTLA-4 antibodies further re-
inforcing the potential of targeting the GITR pathway as a therapeutic approach
to treating patients with cancer.
#4605 Effıcient targeting of BCMA-positive multiple myeloma cells by
antibody-coupled T-cell receptor (ACTR) engineered autologous T cells in
combination with an anti-BCMA antibody. Tooba Cheema,1 Taylor Hick-
man,1 Katie O’Callaghan,1 Lori Westendorf,2 Luke Manlove,2 Shyra Gardai,2
Allison Nelson,1 Ryan Boomer,1 Kathleen McGinness,1 Birgit Schultes,1 Seth
Ettenberg,1 Django Sussman,2HeatherHuet1. 1UnumTherapeutics, Cambridge,
MA; 2Seattle Genetics, Bothell, WA.
B cell maturation antigen (BCMA) has recently emerged as an attractive ther-
apeutic target in multiple myeloma. BCMA has restricted expression on plasma
cells with little to no expression on other normal tissues, but is upregulated on
the surface of multiple myeloma cells. BCMA can regulate proliferation and
survival of myeloma cells via binding to its ligands APRIL and BAFF and induce
downstream signaling pathways. Thus, several approaches to target BCMA are
currently under clinical investigation, including chimeric antigen receptor
(CAR) T cell therapies, bispecifıc antibodies and antibody drug conjugates. The
Antibody-Coupled T cell Receptor (ACTR) technology is a universal, engi-
neered T cell therapy consisting of the extracellular domain of humanCD16 and
the intracellular T cell co-stimulatory and signaling domains. ACTR is designed
to engage the Fc domain of therapeutic antibodies opsonized to target cells to
mediate anti-tumor activity. Previous work has demonstrated ACTR T cell ac-
tivity in combination with rituximab, trastuzumab, and hu14.18 K322A against
CD20, Her2, and GD2 expressing cell lines, respectively (Kudo et al. Cancer Res
2014; 74:93-103). Currently ACTR is being evaluated in Phase I clinical trials
with rituximab to treat relapsed refractory B cell lymphoma. Here we demon-
strate a humanized afucosylated anti-BCMA antibody, SEA-BCMA, binds to
ACTR expressing T cells with high affınity andmediates T cell activation, potent
cytotoxicity, cytokine release and proliferation across a wide range of BCMA
expressing myeloma cells. ACTR activity was specifıc to SEA-BCMA - op-
sonized target cells, dose dependent and had no activity on BCMA negative
tumor lines. Furthermore, the SEA-BCMA antibody has additional properties
that might contribute to a therapeutic effect, including blocking the binding of
ligands to BCMA and driving natural killer cell mediated ADCC effects. These
preclinical studies demonstrate a promising multi-faceted activity of ACTR T
cells in combination with the anti-BCMA antibody, SEA-BCMA, for clinical
consideration in multiple myeloma patients.
#4606 Preclinical characterization of a novel fully human IgG1 anti-
PD-L1 mAb CK-301. Leonid Gorelik,1 George Avgerinos,1 Yune Kunes,2
Wayne A. Marasco3. 1Checkpoint Therapeutics, New York, NY; 2TG Therapeu-
tics, New York, NY; 3Dana-Farber Cancer Institute, Boston, MA.
Antibodies targeting ProgrammedDeath-1 (PD-1), or its ligand, PD-L1, have
demonstrated remarkable effıcacy in subsets of cancer patients, with inhibition
of the interaction between PD-1 on T-cells and PD-L1 on tumor cells leading to
the recovery of anti-tumor immune response and immune-mediated eradica-
tion of tumors. However, not all patients respond to existing PD-1 and PD-L1
targeting agents and relapses to therapy still occur. Therefore, there exists a need
to identify additional therapeutics and approaches to engage the immune system
to enhance the effıcacy of current anticancer therapies. Using phage and yeast
display approaches, we have discovered and optimized a novel, fully human,
PD-L1 specifıc IgG1 antibody, CK-301, which exhibits subnanomolar binding
affınity for PD-L1. CK-301 blocks binding of PD-L1 to both PD-1 and B7-1 in
enzyme-linked immunosorbent assays (ELISA) and cell-based competition as-
says. Using an assay measuring inhibition of a nuclear factor of activated T-cells
(NFAT) reporter caused by PD-L1 binding to PD-1, we demonstrate that CK-
301 completely reverses reporter inhibition at concentration of less than 1 g/
ml, IC50 of the dose response curve is 80ng/ml. CK-301 enhances IFN-gamma
secretion in allogeneicmixed lymphocyte reaction (MLR) using primary human
T-cells and immature dendritic cells. CK-301 can also trigger antibody-depen-
dent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotox-
icity (CDC) mediated killing of PD-L1 cell lines, including lymphoma cells.
CK-301 has similar subnanomolar affınity for cynomolgusmonkey PD-L1 as for
human PD-L1, hence we chose Macaca fascicularis for pre-clinical toxicology
and safety pharmacology studies. Single-dose administration ofCK-301 tomon-
keys up to the highest tested dose of 100 mg/kg was shown to be safe and dem-
onstrated linear dose-dependent pharmacokinetic (PK) properties over the dose
range from 1 to 100 mg/kg with a half-life of 15 days at 100 mg/kg. A fırst-in-
human Phase 1 study of CK-301 is planned to commence in mid-2017.
#4607 Specifıc inhibition of PGE2-EP4 signaling by E7046 promotes anti-
tumor activity of checkpoint blockade agents through boosting cytotoxic T
cell activity. Diana I. Albu,1 David Verbel,1 Yuan Huang,1 Donna Kolber-Si-
monds,1 Zichun Wang,1 Xulong Wang,1 Zoltan Dezso,2 Christy Ingersoll,1
Kuan-ChunHuang,1 Janna Hutz,1 MaryWoodall-Jappe,3 Xingfeng Bao1. 1Eisai
Andover Innovative Medicines Institute, Andover, MA; 2Nurix Inc., San Fran-
cisco, CA; 3Eisai Oncology Business Group, Eisai Inc., Andover, MA.
Purpose: Immunotherapies targeting immune checkpoint receptors have
shown great promise for a subset of cancer patients; however, robust and safe
combination therapies are still needed. In the tumor microenvironment, pros-
taglandin E2 receptor type 4 (EP4) signaling has been implicated in both protu-
moralmyeloid cell differentiation and cytotoxic T cell exhaustion.We evaluated
the combination of the EP4 antagonist E7046 (clinical trial NCT02540291) with
anti-PD1 or anti-CTLA4 in preclinical tumor models, and also interrogated the
relationship between PGE2 pathway activation and cancer patient survival. Ma-
terials/Methods: Mouse syngeneic tumor models CT-26 and 4T1 were used for
pharmacological investigation. GMP grade E7046 was administered to tumor-
bearing animals by oral gavage. Co-culture of EG7-OVA and OT1 cells in an
antigen-specifıc cytotoxic T cell (CTL) activation assay provided mechanistic
insights. For translational validation, transcripts of fıve major genes involved in
PGE2 synthesis, transport and degradation were compared between malignant
and normal tissues across all TCGA tumor types, and correlation of their ex-
pression with overall survival was assessed. Results: In the CT26 tumor model,
the combination of E7046 and anti-PD1 resulted in signifıcantly more tumor-
free animals compared with either agent alone. In the 4T1 tumor model, the
combination of E7046 and anti-CTLA4 was also more effective in suppressing
tumor growth and tumor rejection compared with anti-CTLA4 alone, and was
accompanied by a markedly increased accumulation of GZMBCD8T CTLs
in the treated tumors. Consistent with those fındings, addition of anti-PD1 an-
tibody promoted OVA-specifıc CTL activation in vitro while addition of PGE2
strongly inhibited it, as measured by IFN secretion. Inclusion of E7046 dose-
dependently reversed the PGE2-induced suppressive activity in the presence of
anti-PD1 antibody. Among major human PGE2 pathway genes, TCGA analysis
showed that PTGES1was upregulated andHPGDdownregulated across a broad
range of tumor types. In contrast, COX1, COX2 and PGT showed less difference
between malignant and normal tissues. Importantly, these differences of one or
multiple PGE2 pathway genes were strongly associated with patient survival in
IMMUNOLOGY: Immunoconjugates and Antibodies
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1177
certain cancer types. Conclusions: A subset of human cancer types displays
upregulated PGE2 pathway that is associatedwith a poorer prognosis. PGE2-EP4
signaling potently suppresses antigen-specifıc CTL activation in the presence of
PD1 signaling blockade. The combination of EP4 antagonist E7046 with either
anti-PD1 or anti-CTLA4 demonstrated superior anti-tumor activity compared
with anti-PD1or anti-CTLA4 alone. This increased activitywas accompanied by
increased CTL activation.
#4608 A 5T4 x CD3 bispecifıc DART®molecule with extended half-life for
T-cell immunotherapy of cancers. Ling Huang,1 Gurunadh Chichili,1 Ralph
Alderson,1 Francine Chen,2 Jennifer Brown,1 Hua Li,1 Valentina Ciccarone,1
Jim Tamura,1 Daorong Liu,1 Liqin Liu,1 Syd Johnson,1 Ezio Bonvini,1 Paul
Moore1. 1MacroGenics, Inc., Rockville, MD; 2MacroGenics, Inc., South San Fran-
cisco, MD.
Introduction: 5T4 (trophoblast glycoprotein), an oncofetal antigen involved
in embryo development, is expressed on the cell surface of multiple cancers.
Several 5T4-directed interventions have been reported, including a cancer vac-
cine and an antibody-drug conjugate. A superantigen-driven redirected cell kill-
ingmodality was also developed, but obstacles, such as immunogenicity, remain
to a successful 5T4 therapeutic molecule.We have developed an Fc-bearing 5T4
x CD3 DART® bispecifıc protein designed to redirect T cells to target 5T4-
expressing tumors. Methods: 5T4 x CD3, a humanized Fc-bearing DART mol-
ecule, was stably expressed in CHO cells and purifıed to homogeneity via a
standard antibody-purifıcation platform. In vitro characterization and func-
tional studies were performed with 5T4-positive tumor cell lines and human T
cells. In vivo studies were performed in immune-defıcient tumor-bearing mice
co-implantedwith activated humanT cells or reconstitutedwith human periph-
eral blood mononuclear cells (PBMCs). Pharmacokinetic studies were per-
formed in both human FcRn transgenic mice and cynomolgus monkeys. Re-
sults: 5T4 x CD3 demonstrated bispecifıc binding properties to both human and
cynomolgus monkey antigens. In redirected cytolysis studies, 5T4 x CD3medi-
ated lysis of 5T4-positive pancreatic, lung, renal, triple-negative breast, and
ovarian cancer cell lines with EC50 values ranging between 0.03 and 0.08 ng/mL.
5T4 x CD3 displayed favorable pharmacokinetics with a prolonged circulating
half-life in human FcRn transgenic mice and cynomolgus monkeys. Tumor
clearance studies in NOD/SCID mice implanted subcutaneously with activated
human T cells and tumor cells demonstrated robust inhibition of tumor growth
upon intravenous administration of 5T4 x CD3 at doses as low as 0.8g/kg, but
not with a CD3-binding control DART protein. In addition, human PBMC-
reconstituted NOD/SCID/IL2 gamma-chain null mice were implanted intrad-
ermally with renal and pancreatic tumor cell lines or orthotopically with a triple-
negative breast cancer line and, after tumor establishment,were treatedwith 5T4
x CD3. Anti-tumor activity was observed at doses as low as 4 g/kg. Immuno-
histochemical analysis of tumor xenografts confırmed tumor clearance was as-
sociatedwithT-cell recruitment into the tumormass. Conclusions: In summary,
5T4 x CD3 displays robust antitumor activity against several cancer cell lines in
vitro and in vivo together with a favorable pharmacokinetic profıle and merits
further consideration as a potential treatment for 5T4-positive cancers.
#4609 Agenus’ next generation cancer vaccine platforms.Mohamed Udu-
man,1 Mithun Khattar,1 Bishnu Joshi,1 Antoine Tanne,1 Benjamin Morin,1 Ar-
men Karapetyan,1 Elise Drouin,1 Sandra Craig,1 Paisley Myers,1 Erin Jeffery,1
Nicholas Wilson,1 Amy Yang,1 Victor H. Engelhard,2 Mark Cobbold,3 Donald
F. Hunt,4 Dennis Underwood,1 Shiwen Lin,1 Mark Findeis,1 Jeffrey Raizer,1
John Goldberg,1 Jennifer S. Buell,1 Robert Stein,1 Daniel L. Levey,1 John Castle1.
1Agenus Inc., Lexington, MA; 2University of Virginia School of Medicine, Char-
lottesville, VA; 3Massachusetts General Hospital Cancer Center, Charlestown,
MA; 4University of Virginia, Lexington, MA.
Most cancer cells carry mutations unique to the patient’s individual tumor
and shared biochemical signatures that are not present in healthy cells. Agenus
has three vaccine platforms designed to treat cancers based on the unique needs
of a given patient. Our vaccine platforms are designed to educate the patient’s
immune system to recognize tumor-specifıc aberrations, or neo-antigens, and
mount an anti-tumor immune response. Agenus’ Prophage™ vaccine platform is
an individualized vaccinemade from the patient’s own tumor tissue. Heat shock
proteins (gp-96) that naturally chaperone and bind tumor-derived peptides are
extracted from the patient’s tumor and constitute the vaccine. Some of these
peptides are neo-antigens. Agenus has completed Phase 2 clinical trials with
Prophage™ vaccine in newly diagnosed glioblastoma (ndGBM), and has previ-
ously reported that there was improved progression-free and overall survival
with Prophage™ vaccine compared to standard of care. Agenus’ AutoSynVax™
vaccines are uniquely designed and manufactured for each patient based on
NGS profıling of the patient’s tumor from a biopsy. Leveraging the Agenus
Immunogenic Mutation (AIM™) workflow, we are able to generate a synthesis-
ready blueprint for an optimal immunogenic and personalized neo-antigen vac-
cine. The AIM™ platform provides a robust and effıcient approach to computa-
tional vaccinology designed to deliver a set of likely immunogenic peptides,
agnostic to vaccine format, followed by generation of a format-specifıc blueprint
ready for vaccine synthesis and manufacture. The synthesized neo-epitopes are
complexed to recombinant heat shock protein 70 (HSC70) and are administered
along with our QS-21 Stimulon® adjuvant. HSC70 is known to transport
epitopes and play a role in displaying them to T cells. While the fırst two of
Agenus’ vaccine platforms are highly individualized, our PhosphoSynVax™ vac-
cine is an off-the-shelf vaccine format targeting a novel class of tumor neo-
antigens arising from post translational modifıcations (PTMs). Due to dysregu-
lated cell signaling pathways in cancer, self-peptides can be aberrantly
phosphorylated, a number of which are subsequently presented on HLA mole-
cules. Using mass-spectrometry, we have identifıed a library of over a thousand
HLA phospholigands. Many of these are tumor specifıc and found in multiple
patients across multiple indications, enabling pre-manufacture of PhosphoSyn-
Vax™ vaccines for ready use. Upon testing the HSP plus synthetic peptide vac-
cine format inmurinemodels, we have demonstrated effective tumor control in
a therapeutic setting and also effective immunememory in a long-term prophy-
lactic setting. Given Agenus’ diverse portfolio we have the opportunity to com-
bine our immune education strategies with immunomodulatory antibodies to
increase therapeutic effıcacy.
#4610 Towards understanding the cellular uptake patterns of nano-parti-
cles among different immune cell lines. Noha Ismail,1 Ashish Kulkarni,2 Siva
Kumar,2 Vineeth krishna,2 Shiladitya Sengupta2. 1The American Univ. in Cairo
/ Brigham and Women’s Hospital – Harvard Medical School / Harvard-MIT
Health Sciences andTechnology, Cairo, Egypt; 2BrighamandWomen’sHospital –
Harvard Medical School / Harvard-MIT Health Sciences and Technology, Cam-
bridge, MA.
Today with the privilege of being able to synthesize extremely small particles in
the nano-range and make use of nanoscience and nanotechnology, we can reach
superior properties than the bulk scale.Nanoparticles have their ownphysicochem-
ical properties that make them promising in the fıeld of cancer immunotherapy in
form of drug delivery, diagnostic and theranostic modalities. Manipulation of the
immune responseby therapeutic intervention is becomingof great interest owing to
the signifıcant role of immunity in the general health and disease control. APCs like
Dendritic cells and macrophages are important targets for the particulate delivery
system due to their ability to trigger cascade of events on both levels cellular and
humoral immune response specially DCs. Successful targeting of DCs and macro-
phages will have a great impact on T-cell activation and priming. The design of
successful particulate system that can elicit preferential targeting towards specifıc
immune cell in the tumor microenvironment is becoming crucial. This might rep-
resent a novel avenue for enhancing the antitumor immunity. Liposomes aremade
of phospholipid bilayer with a composite nature. Their properties are highly linked
to their physicochemical characteristics such as size, surface charge and composi-
tion. These physicochemical properties can trigger certain immune response.The
hypothesis herewhetherpassive targetingviaparticulate systemcanoffer aplatform
for preferential targeting for critical immune cells residing in spleen and tumor.
Moreover, test whether therewill be differences in uptake according to certain pref-
erence towards surface charge in specifıc time frame. In the current study, three sets
of fluorescently labelled nano-liposomes were engineered as a model for different
surface charges, the cationic DOTAP NP, anionic DOPG NP and near neutral
DOPC NP with mean diameter of  200 nm. Physical stability of the NPs was
evaluated bymonitoring the changes in size and zeta potential. B16melanoma can-
cer model was induced subcutaneously in C57BL/6 black mice, divided into four
groups each of fıve mice. CD11c Dendritic Cells (DCs), CD11b macrophages,
CD90.2 T-cells and CD49bNatural Killer (NK) cells were isolated from the tumors
and spleens of each group. The three sets of NPswere tested against the isolated cell
lines. The cellular uptake (internalization) was assessed by normalizing the fluores-
cence of the cells against their protein concentration, then all sampleswere acquired
to flow cytometry, and shifts in fluorescence histograms on horizontal axis were
monitored against PE channel on the vertical axis. Results reveal the presence of
preferential internalizationof specifıc surface chargeover others in somecell lines in
different time frames. For the fırst time differences in the internalization pattern are
reported in the same immune cell line isolated from two different contexts tumor
and spleen.
#4611 A3D in vitro culture-basedmethod to visualize and quantify effects
of immuno-modulatory drugs. Lidia Daszkiewicz, Kuan Yan, Maarten Klop,
Leo Price. OcellO, Leiden, Netherlands.
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BACKGROUND: Unleashing the full potential of cancer immunotherapy is
hampered by a lack of effective in vitro testingmethods. 2D cultured cells poorly
reflect the in vivo situation and lack the tumour microenvironment whereas
humanized animal models are slow, have low throughput and are expensive. 3D
cultures, on the other hand, more faithfully reproduce the organization of a
tissue, recapitulating the cell-cell connections and cellular heterogeneity found
in the tumour and allow for a cost-effıcient testing of drug candidates. To ad-
dress the unmet need of immunotherapy cancer drug developers for robust
assays that incorporate the human immune system, with functional read-outs in
a high throughput (384well plate) format, we developed an in vitro platform
based on 3D co-cultures of cancer tumoroids and immune cells. This assay is
designed to test the capacity of small molecules, bi-specifıc antibodies, check-
point modulators, vaccines and combinations of thereof to enhance anti-cancer
immune responses.METHODS: Cancer cells of different sources were grown in
a hydrogel to form tumoroids and then HLA-matched PBMCs pre-conditioned
via different protocols to achieve activated or exhausted T cells, were added in
the presence or absence of immune-modulatory drugs. T cell infıltration and
subsequent tumoroid killing was quantifıed using 3D high-content imaging.
After ’optical sectioning’ 3D image stacks were reconstituted andmorphometric
analysis was performed with OMiner software. RESULTS AND CONCLU-
SIONS: Addition of immune checkpoint inhibitors, pembrolizumab and ipili-
mumab, led to enhanced T cell infıltration and cytotoxicity of exhausted T cells.
These results showed that automated 3D image and data analysis enables dis-
crimination of immune-tumour cell interactions depending on activation status
of T cells and permits the visualization of T cell re-gain of function in the pres-
ence of checkpointmodulators. A 3D environment allows the different cell types
to engage in amore realistic setting thanwhen cells are grow in amonolayer and
enables the quantifıcation of spatially resolved information, which is of an ut-
most importance when studying tumor-immune cell relationships. This new
and innovative platform empowers immunotherapy drug developers with a
powerful tool to evaluate drug performance. Furthermore, drug combinations
can be studied to determine synergistic effects with other checkpoint inhibitors
of standard of care compounds in an effıcient manner.
#4612 Development and validation of a screening platform for the iden-
tifıcation of novel immuno-oncology targets. Ariane Scoumanne,1 Virginie
Rabolli,2 Lea Legrand,3 Murielle Martini,4 marie-claire Letellier,5 Stefano Cro-
signani,6 Christophe Quéva,3 Michel Detheux,7 Sandra Cauwenberghs,8 Jakub
Swiercz9. 1Ariane Scoumanne, Gosselies, Belgium; 2Virginie Rabolli, Gosselies,
Belgium; 3iTeos Therapeutics, Gosselies, Belgium; 4Murielle Martini, Gosselies,
Belgium; 5Marie-Claire Letellier, Gosselies, Belgium; 6Stefano Crosignani, Gosse-
lies, Belgium; 7Michel Detheux, Gosselies, Belgium; 8Sandra Cauwenberghs, Gos-
selies, Belgium; 9Jakub Swiercz, Gosselies, Belgium.
Although immune therapy of cancer, including immune-checkpoint block-
ade have demonstrated therapeutic benefıt in patients with various advanced
cancers, further understanding of human immune pathology triggered by the
tumormicroenvironment, is essential to improve these therapeutic approaches.
In order to shed light onnovel immune suppressivemechanisms in tumor, iTeos
Therapeutics developed a target discovery and drug repurposing platform based
on phenotypic screening assays. We established a co-culture assay combining
tumor immune suppressive cells and T-cells. This assay is flexible to allow the
screening of chemicogenomics, shRNA and cDNA libraries. Multi-parameter
readouts are combined to assess bothT cell activation and proliferation, through
high content imaging of T cell clusters formation, complementedwith detection
of IFN secretion and tumor cell death, as assessed using a cytotoxicity assay.
The 96-well format of the assay allowsmedium-throughput testing of up to 3000
samples/screen. From the technical point of viewwewere able to adapt the assay
to low level of automation, making it affordable to the biotech start-ups and
academic laboratories. As a proof-of-concept we evaluated the assay for its abil-
ity to detect metabolic immune-oncology targets in A549 cells, a lung cancer
immune suppressive cell line. A549 express indoleamine-2,3-dioxygenase 1
(IDO1), an enzyme expressed in many cancers that mediates local T-cell sup-
pression through depleting the essential amino acid tryptophan. The assay con-
ditions were validated with an IDO1 inhibitor as positive control and subse-
quently scaled up for automation. A commercially available small molecule
library of 1900 compounds, with a high percentage of clinically tested drugs was
screened. The library was tested at two different concentrations (0.3M and
3M), with two independent T-cell donors and spiked with IDO1 inhibitor as
control. Combined analysis of T-cell activity and tumor killing led to the iden-
tifıcation of 42 compoundswith activity onmultiple, potential immune suppres-
sive pathways, including metabolism, epigenetics, autophagy, TGF, Wnt/-
catenin and TNF/NF-B signaling.
#4613 Cytotoxicity of selenium trastuzumab and bevacizumab immuno-
conjugates against triple negative breast cancer cells. Soni Khandelwal, Lau-
ren Gollahon, Julian Spallholz, Mallory Boylan, Maria Del Mar Garcia-Hernan-
dez. Texas Tech University, Lubbock, TX.
Breast cancer (BC) is the second leading cause of death among women with an
estimated 246,660 new cases of invasive breast cancer expected to be diagnosed this
year. Of the different subtypes, 15-20% are classifıed as triple negative breast cancer
(TNBC) because they lack three key receptors; progesterone, estrogen and HER2.
These receptors are considered essential for “targeted therapies”. Thus, systemic
chemotherapy is the only TNBC drug treatment option. In this study, two clinical
monoclonal antibodies;Herceptin® andAvastin®were covalently labeledwith redox
seleniumandused to treat twoTNBCcell lines (MDA-MB-231andMDA-MB-468)
in culture. TNBC cell lines were treated with vehicle control, increasing concentra-
tionsof seleniumasSelenite (ranging from2 to20g); Se-Herceptin®orSe-Avastin®
andcompared tonative antibodieswith equal concentrationsof protein.Cell counts
and viability were analyzed using BeckmanViCell Counter and Trypan Blue exclu-
sionover a sevendayperiod. Selenite, Se-Avastin® and Se-Herceptin®were observed
to be more cytotoxic over dose and time to both TNBC cell lines in comparison to
control cells and cells treated with native antibodies alone. Morphological changes
were observed under phase contrastmicroscopy in all selenium treated cell lines. In
contrast, visible alterations in morphology were absent in native Herceptin® and
Avastin® treated cells compared to control cells.We believe this is the fırst report of
selenium Antibody-Drug Conjugates (ADCs) being demonstrated as cytotoxic to
these TNBC cell lines, suggesting a potential strategy to designmore effective treat-
ments of TNBC resistant to chemotherapy.
#4614 Upregulation of memory T cell population and enhancement of
Th1 response by lenvatinib potentiate antitumor activity of PD-1 signaling
blockade. Yu Kato. Eisai.Co.,Ltd., Tsukuba-Shi, Ibaraki, Japan.
Introduction: Lenvatinib (LEN) selectively inhibits the kinase activity of
VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, which are involved in tumor
angiogenesis and tumor cell proliferation in several cancer types. Currently,
Phase 1b/2 clinical trials of the combination of LEN and pembrolizumab (a
monoclonal antibody [mAb] that blocks the interaction between PD-1 and its
ligands) are ongoing for selected types of cancer including renal cell carcinoma,
melanoma and non-small cell lung carcinoma. We have reported that tumor
associatedmacrophage and regulatory T cell populationwere downregulated by
treatment of LEN. In this study,mechanismof LENandPD-1mAbcombination
was investigated by flow cytometory and RNA-seq analyses. Experimental Pro-
cedure: We examined antitumor activity of combination treatment of LEN
(10mg/kg, qd) and anti-mouse PD-1mAb (500g/mouse, twice weekly) in Ct26
and B16F10 syngeneic mouse models. In order to investigate tumor-specifıc
memory T cell response, re-inoculation of fresh CT26 cells into tumor-freemice
was conducted. For immune cell population analyses, tumor or spleen samples
were analyzed by flow cytometry. Changes of molecular immune response in
tumors were examined by RNAseq followed by weighted gene co-expression
network analysis (WGCNA). Summary of data: Combination of LENwith PD-1
mAb showed more potent anti-tumor growth activity in CT26 and B16F10
models compared with either treatment alone. Notably, complete tumor regres-
sionwas detected in a portion ofmice that received combination treatment only.
Re-inoculation of fresh CT26 cells into these tumor-free mice did not grow
tumor; in contrast, all naïve animals grew tumor aggressively in the same exper-
imental condition. RNAseq analysis of treatedCT26 tumors indicated that com-
bination of LEN with PD-1 mAb synergistically up-regulates IFN signaling-
related genes. Flow cytometory analysis revealed that LEN increased memory T
cell population compared with vehicle treatment. Conclusions: The results in-
dicate that the combination of LEN with PD-1 mAb was more effective than
either single agent alone in multiple syngeneic tumor models and was accom-
panied with a potent antitumor immune response, especially the up-regulation
of memory T cell and Th1 activation by LEN.
#4615 Development of an antibody-drug conjugate with broad anticancer
activity. Siang-Yo Lin,1 Zoltan Szekely,1 Chen-Yong Lin,2 Joseph R. Bertino,1
Gulam Mohmad Rather1. 1Rutgers Cancer Instutute of NJ, New Brunswick, NJ;
2Georgetown Medical School, Georgetown, MD.
Treatment for patients with advanced solid tumors that include triple nega-
tive breast cancer (TNBC), non-small cell lung cancer (NSCLC), and castrate
resistant prostate cancer (CRPC), as well as Mantle Cell Lymphoma (MCL),
while increasing survival is not curative.We have identifıed a membrane bound
protease, “activated” matriptase, as an attractive target antigen for highly selec-
tive antibody delivery of cytotoxins as activated matriptase expression is re-
stricted to epithelial tumors and some B-cell lymphomas. We generated a novel
ADC by linking M69, a mouse antibody specifıc to activated matriptase, to
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monomethyl auristatin E (MMAE) via a PEGylated, releasable di-peptide linker
as a proof-of-principle prototype. Both in cell lines and in human xenograft
models of TNBC, NSCLC, CRPC and MCL, the conjugate was found to exhibit
potent anticancer activity against all of these tumor types without toxicity. En-
couraged by these results, we are also exploring the use of this ADC against
gastric and pancreatic cancer, and in combination with chemotherapy and im-
munotherapy. As this is a mouse antibody, we are also generating a chimeric
antibody for toxicity studies in primates.
IMMUNOLOGY: Innate Immune Response to Cancer
#4616 Exploring the role of interferon and innate immune regulators in
outlier cancer cell line survival. Hugh S. Gannon,1 Michael Kiessling,2 Fran-
cisca Vazquez,3 William Hahn,1 MatthewMeyerson1. 1Dana-Farber Cancer In-
stitute, Boston, MA; 2Zürich University Hospital, Switzerland; 3Broad Institute,
Cambridge, MA.
We conducted an outlier dependence analysis using functional genomic
screening data generated by groups at the Dana-Farber Cancer Institute and
Broad Institute. These genome-wide knockdown (shRNA) and knockout
(CRISPR-Cas9) screens seek to discover genetic vulnerabilities, or “Achilles’
heels“, across hundreds of cancer cell lines. The most recent version of the gene
knockdown screen includes over 500 total cell lines, allowing overall and lin-
eage-specifıc outliers to be assessed. Taking advantage of the relatively large
number of cell lines in this data set, our study parallels “exceptional responder”
patient studies derived from clinical trials, with the goal of fınding a small num-
ber of cell lines that are acutely dependent on certain genes for survival. These
outlier cell lines could then be profıled to search for a common genetic factor or
gene expression signature that can be used to predict sensitivity to the knock-
down of the gene(s) in question. Strong, specifıc genetic dependencies have the
potential to generate novel, hypothesis-driven therapeutic strategies that can be
further tested experimentally. Initially, we focused on the lung cancer cell lines
profıled in the knockdown screen.We used an unbiased approach to investigate
genes with the most pronounced outlier patterns across these lung lines. One of
the top genes in our analysis encodes the RNA-editing enzyme ADAR1, which
has a role in epigenetically altering double-strand RNA sequences. ADAR1 en-
codes a protein that catalyzes adenosine-to-inosine editing in RNA. This RNA
editing function has been studied in the context of suppressing innate immune
sensing, as endogenous RNA is edited to avoid detection by intracellular sensors
that activate the type I interferon pathway after encountering unedited RNA
from infecting viruses. ADAR1homozygousmutant patients andmousemodels
each display greatly increased interferon levels and activation of downstream
interferon-induced gene expression, further supporting the role of ADAR1 to
suppress interferon activation and autoimmunity. Importantly, outlier cell lines
sensitive to ADAR1 knockdown are also sensitive to knockdown of ISG15,
which similarly suppresses interferon signaling, and show greatly increased sur-
vival after IFNAR1 knockdown, a positive regulator of interferon signaling. We
next mined genome-wide CRISPR-Cas9 knockout screens and found a pancre-
atic cell line that is also dependent on ADAR1 and ISG15 for survival. Likewise,
knockout of IFNAR1 or any gene along the IFNAR1-JAK-STAT pathway en-
hances survival in this cell line. These converging data suggest a link between the
interferon pathway and vulnerability to knockdown of ADAR1 or ISG15.While
no common mutations or genomic changes were found in the outlier cell lines,
we have uncovered a shared gene expression signature. We are continuing to
study the mechanisms that cause these cell lines to be acutely dependent on
ADAR1 and ISG15.
#4617 Daratumumab combined with CD38(-) natural killer cells armed
with a CS1 chimeric antigen receptor for the treatment of relapsed multiple
myeloma. Yufeng Wang, Yibo Zhang, Don Bnson, Michael Caligiuri, Jianhua
Yu. Ohio State Univ., Columbus, OH.
Multiple myeloma (MM) is the second most frequent hematological can-
cer in developed countries. The recent development of monoclonal antibod-
ies, including Daratumumab (Dara) approved by the FDA, is changing the
treatment algorithm of MM. However, MM still relapses and remains incur-
able. Recently, chimeric antigen receptor (CAR) T cell immunotherapy has
been successful in the clinic for the treatment of leukemia and lymphoma.
We previously show that both CS1-CAR T cells and CS1-CAR NK cells are
effective in eradicating MM cells in vitro and in vivo (Chu et al., 2014,
Leukemia and Chu et al., 2014, Clin. Cancer Res.). Both CS1 and CD38 are
tumor-associated antigens expressed on the surface of MM cancer stem-like
cells, suggesting that dual targeting of CS1 and CD38 may prevent relapse.
Thus, we investigated the combination therapy with Dara and CS1-CAR NK
cells for the treatment of relapsed MM. Our data showed that CD38 is highly
expressed on the surface of both NK and MM cells. Dara induces NK cell
activation, as Dara-treated NK cells display a higher capacity to produce
IFN-gamma and increased cytotoxicity against MM, the latter of which cor-
related with augmented expression of the cytolytic gene, granzyme B. Mech-
anistically, we found that activation of NK cells by Dara is CD16-dependent.
This is further evidenced by that Dara also signifıcantly induces phosphor-
ylation of NF-kB and STAT1, the two downstream mediators of CD16. Fur-
thermore, Dara mediated cytotoxicity of NK cells against MM cells through
antibody-dependent cell-mediated cytotoxicity (ADCC) against CD38-pos-
itive (e.g., MM1.S), but not CD38-negative (e.g., U266), which can be
blocked by a CD16 blocking Ab. Dara-induced NK cell ADCC against
CD38() MM MM1.S cells also leads to increased T cell proliferation and
activation in a co-culture system including dendritic cells. However, Dara
also induces apoptosis and fratricide in NK cells. This is evidenced by the
data in vitro as well as our clinic data showing that Dara depletes NK cells in
MM patients. Cleaved Caspase-3 and cleaved PARP-1were found increased
in NK cells treated with Dara. Dara-induced apoptosis in NK cells is most
likely also through an ADCC mechanism and Dara induces apoptosis in
CD16() NK cells but not CD16(-) NK cells. Our data further show that
Dara activates but does not induce apoptosis in CD38(-) NK cells. Thus, we
hypothesize that the combination of Dara and CD38(-) CS1-CAR NK cells
can show a synergistic effect on tumor eradication and prevention of MM
relapse. Our data indeed demonstrated that the combination of CS1 CARNK
cells with CD38(-) NK cells but not with CD38NK cells shows a synergistic
effect to eradicate MM cells. Interestingly, we also found that when com-
pared to expanded CD38() NK cells, expanded CD38(-) NK cells have
more cells, a better capacity of proliferation and survival, a higher potential
of cytokine production, and higher cytotoxicity against MM cells.
#4618 TGF-BupregulatesGSK3BandmediatesNKdysfunction in cancer.
Evelyn Ojo, Folashade Otegbeye, Stephen Moreton, David Wald. Case Western
Reserve University, Cleveland, OH.
Transforming growth factor-B (TGF-) is an important regulator of tumor-
igenesis. Initially, it was discovered to have anti-cancer activities by promoting
apoptosis and preventing hyperproliferation of cells. However, abundant pres-
ence of TGF- in the tumor microenvironment is known to hinder cancer
eradication by suppressing anti-tumor activities of immune cells. Themolecular
switches that regulate the role of TGF- are not fully understood. One main
target of TGF--mediated immune cell dysfunction are natural killer (NK) cells.
NK cells are innate immune cells that lyse virally-infected and cancer cells.
Recently, we have discovered that glycogen synthase kinase 3-beta (GSK3)
upregulation in NK cells leads to NK dysfunction. Another study has indicated
that GSK3 phosphorylates SMAD3 to inhibit TGF-B-mediated growth dysfunc-
tion in AML12 cells. In addition, GSK3 inhibition has been linked to increased
sensitivity of cancer cells to NK killing but the role of GSK3 in NK function is
understudied. This study examines how the role that GSK3 has on TGF-B-
mediatedNK cell dysfunction.Methods: NK cells were isolated from the periph-
eral blood of healthy donors and expanded in vitro for 14 days. NK cells were
either treated with or without 5ng/mL TGF- for 72 hours, and GSK3 expres-
sion, and the expression of NK activating receptors was measured via flow cy-
tometry. In addition, GSK3B expression is abrogated using a siRNA in NK cells.
The NK cells were treated with or without TGF-, and NK cell cytotoxicity is
measured with a fluorometric cytotoxicity assay. Results: TGF- pretreatment
of NK cells led to 2-fold GSK3 expression inNK cells. TGF- pretreatment led
to decreased expression of NK activating receptors NKp46 and NKG2D. Also,
TGF- led to decreased expression of lymphocyte function-associated anti-
gen-1 (LFA-1), an adhesion molecule necessary for NK cells to adhere to target
cells prior to lysis of the target cells. TGF-B pretreatment ofNK cells led to 33.3%
reduced killing of both leukemic and solid tumor targets. Pharmacologic and
genetic abrogation of GSK3 minimized TGF-B-mediated NK dysfunction as
measured by calcein-AM based cytotoxicity assays. Importantly, inhibiting
GSK3B activity with TGF-B treatment rescued NK cell cytotoxic function. Dis-
cussion: Our data suggests that TGF- leads to upregulated GSK3 expression,
and downregulation ofNKactivating receptors. In addition, TGF-B reducedNK
killing of cancer cells. We believe that TGF--mediated NK dysfunction is fa-
cilitated by GSK3 upregulation. Further studies are underway to determine
how TGF- affects the expression of other NK receptors, and to elucidate the
mechanism by which TGF- directs GSK3 upregulation.
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#4619 CD47 promotes ovarian cancer progression by inhibiting macro-
phage phagocytosis. Yuting Huang,1 Peng Gao,2 Yifeng He,3 Yuchi Ma,4 Shan-
gwen Dong,5 Zhijun Li5. 1Tianjin Medical University Cancer Hospital and Insti-
tute, Tianjin, China; 2University of the District of Columbia, Washington, DC;
3Shanghai Jiao Tong University, Shanghai, China; 4National Heart Lung and
Blood Institute, Bethesda, MD; 5Tianjin Medical University General Hospital,
Tianjin, China.
CD47 is highly expressed in many malignant diseases including ovarian can-
cer, and rendersmalignant cells resistant to phagocytosis bymacrophages. Anti-
CD47 mAbs have shown anti-cancer effects in several types of cancers. How-
ever, it remains controversial whether anti-CD47 mAbs promote phagocytosis
by the inhibition of CD47 function or by CD47-SIRP independent opsoniza-
tion. We tried to provide more evidence in our study by knocking down CD47.
CD47 expression of 93 patients was tested by flow-cytometry. We confırmed a
positive correlation between high CD47 levels and poor clinical characteristics,
such as poorly differentiated and advanced FIGO stages. A cohort of 29 FIGO
stage III-IV patients with poorly differentiated serous adenocarcinoma were
followed up for 50 months. Median survival for CD47 high patients was 19
months, while for CD47 low patients was 43months, p0.0435. To further eval-
uate themechanismofCD47 in phagocytosis, CD47 expression on SK-OV-3 cell
was knocked down using shRNA. No change in tumor cell viability, prolifera-
tion, and migration was observed. Macrophage phagocytosis index increased
from10.2% to 43.9% in vitro. In xenograph experiments, average tumor number
decreased from75.6 to 50.4 and the animals also experienced signifıcantly longer
survival (p0.0017). Similar sets of experiments were done using an anti-CD47
mAb B6H12 clone while adopting both control IgG and anti-HLA ABC as con-
trol antibodies. Consistent with the results from the knockdown experiments,
anti-CD47mAb treatment led to an increase inmacrophage phagocytosis index
in vitro of both SK-OV-3 cells (from 8% and 9.4% to 37.1%) and primary cancer
cells (from 5.6% and 7.4% to 35.1%). In vivo xenograft experiments also showed
increasedmacrophage infıltration (6.5% compared to 1.5% in control group). In
fıve different ovarian cancer cell lines, we found that CD113 tumor initiating
cells (TICs) expressed higher levels of CD47 compared to CD133- cancer cells.
Tumorigenic capabilities of TICs were confırmed by colony-forming assay and
ALDEFLUOR assay. Upon anti-CD47mAb treatment, macrophage phagocyto-
sis of TICs was enhanced signifıcantly in vitro (phagocytosis index increased
from 10% and 12.7% to 47.3%). In conclusion, CD47 inhibits macrophage
phagocytosis of both ovarian cancer cells and TICs. Downregulation of CD47 or
inhibition bymAbwas able to reverse this effect, and it may involve Fc indepen-
dent mechanism. Thus, CD47 antibody therapymay be a promising strategy for
not only eliminating tumor cells but also preventing cancer relapse triggered by
TICs, benefıting the patients’ short-term and long-term prognoses.
#4620 Signaling cascade of metastasis-associated macrophages deter-
mines breast cancer distal metastasis. Bin-Zhi Qian. University of Edinburgh,
Edinburgh, United Kingdom.
Macrophages are abundantly found in the tumor microenvironment and en-
hance malignancy. At distal metastatic sites, our previous studies identifıed a
distinct population of metastasis-associated macrophages (MAMs) that pro-
mote tumor cell extravasation, seeding and persistent growth. These macro-
phages were derived from inflammatory monocytes recruited by CCL2/CCR2
chemokine signaling and directly promote tumour cell extravasation through
VEGF production. Our recent studies identifıed two subsequent signaling path-
ways that mediate the retention and function of MAMs after recruitment that
are critical for tumour cell survival and persistent growth. Specifıcally, activation
of CCR2 signaling turns on CCL3 expression in MAMs. Genetic deletion of
CCL3 or its receptor CCR1 in macrophages reduces lung metastasis, andMAM
accumulation in tumor-challenged lung. Adoptive transfer of wild type mono-
cytes restores lung metastasis in Ccl3 defıcient mice. Mechanistically, Ccr1 de-
fıciency prevents MAM retention in the lung by reducing direct MAM-tumour
cell interactions. On the other hand, MAMs turn on cell surface expression of
FMS-like tyrosine kinase 1 (FLT1) upon differentiation frommonocytes. Using
several genetic models of Flt1 defıciency, we show that macrophage specifıc
FLT1 signaling is critical for breast tumor distal metastatic potential. FLT1 spe-
cifıc inhibitory antibody signifıcantly inhibits the metastatic seeding and persis-
tent growth but does not affect the recruitment or retention of MAMs. Further-
more, we identifıed that FLT1 signaling regulates a set of downstream
inflammatory response genes including Colony Stimulating Factor 1 (CSF1) a
central regulator of macrophage biology. Using a genetic gain-of-function ap-
proach we show that CSF1 mediated autocrine signaling in MAMs is down-
stream of FLT1 and can restore the tumor-promoting activity in MAMs even
when FLT1 is inhibited. Together, our data indicates CCL3/CCR1 and FLT1
signaling pathways are critical in regulatingMAMs andpromoting breast cancer
distal metastasis, and suggests the therapeutic potential of targeting these path-
ways in treating metastatic disease.
#4621 Metabolic activation of macrophages by CpG stimulates anti-tu-
mor activity and overcomes CD47-independent inhibition by tumor cells in
pancreatic ductal adenocarcinoma.Mingen Liu, Gregory Beatty. University of
Pennsylvania, Philadelphia, PA.
Macrophages dominate the immune infıltrate present in pancreatic ductal
adenocarcinoma (PDAC). Although tumor-infıltrating macrophages have the
potential to mediate anti-tumor activity, they most commonly acquire an im-
munosuppressive role in cancer. We have found that CpG oligonucleotides -
containing unmethylated cytosine-guanine motifs - potently induce macro-
phages to phagocytose PDAC cells andmediate anti-tumor effects.When deliv-
ered in vivo, in a fully immunocompetent murine model of PDAC, CpG in-
creased the presence of macrophages within PDAC tumors and suppressed
tumor outgrowth in a macrophage-dependent manner. Though CpG did not
polarize macrophages toward classical anti-tumor (M1) or pro-tumor (M2)
phenotypes, CpG treatment increased the basal rate of oxygen consumption in
macrophages. Reversing this metabolic shift by inhibiting fatty acid oxidation
abolished pro-phagocytic and anti-tumor effects bymacrophages in vitro and in
vivo. We investigated the impact of CpG in overcoming anti-phagocytic signals
from CD47, a membrane protein overexpressed in multiple malignancies, in-
cluding PDAC. While targeted knockout of CD47 in PDAC cells was not suffı-
cient to activate in vitro phagocytosis by macrophages or anti-tumor effects in
vivo, delivery of CpG potentiated anti-tumor and phagocytic activity that was
independent of CD47 expression by tumor cells. However, the combination of
CD47 loss in tumor cells and systemic CpG treatment enhanced the survival of
tumor-bearingmice, indicating that disruption of CD47 can sensitize tumors to
macrophage-directed immunotherapy. Together, our fındings demonstrate a
key role for cellular metabolism in directing the anti-tumor functions of macro-
phages and overcoming negative regulatory signals imposed by malignant cells.
#4622 Characterization of sulfatide reactive type IINKT cells frommouse
lung. Lise Pasquet,1 Shingo Kato,2 Tony Adams,1 Susan Sharrow,1 Theresa Da-
vies-Hill,1 Elaine Jaffe,1 Xia Zheng,1 Motoshi Suzuki,3 Damian Kovalovsky,1 Jay
Berzofsky,1 Masaki Terabe1. 1NIH-NCI, Bethesda, MD; 2Yokohama city Univer-
sity, Yokohama, Japan; 3NIH- NHLBI, Bethesda, MD.
The immune system plays a major role in the elimination of tumors. CD8 T
cell infıltration is known to be a good prognostic indicator. The development of
therapies based on checkpoint inhibitor antibodies was an important break-
through in increasing survival by limiting the exhaustion of cytotoxic cells and
increasing tumor cell eradication. However, the immune system also contains
regulatory cells that protect the organism from inappropriate activation of im-
mune cells against self-antigens. Thus, the fact that tumor cells are autologous
leads regulatory cells to inhibit the activation of anti-tumor cytotoxic cells and
thus increase tumor escape. Therefore, understanding the function and the ac-
tivation of regulatory cellsmight help to develop therapies to limit the activation
of regulatory cells in order to increase tumor clearance. Natural killer T (NKT)
cells are lymphocytes with features of natural killer (NK) and of T cells placing
them at the interface of innate and adaptive immunity. Like NK cells, they
rapidly produce cytokines after stimulation, orienting the immune response. As
T cells, they express aT cell receptor (TCR) that allows the recognition of specifıc
lipids presented by the non-classicalMHC-Imolecule CD1d. According to their
TCR usage, two populations of NKT cells are described: type I and type II. All
type I NKT cells express a semi-invariant TCR (Valpha24Jalpha18 in humans,
Valpha14Jalpah18 in mice) that recognizes -galactosylceramide (GalCer).
They can be identifıed with the GalCer-loaded CD1d tetramer. In contrast,
type II NKT cells express a more diverse TCR repertoire. There is no currently
identifıed lipid antigen recognized by all type II NKT cells, making their identi-
fıcationmore diffıcult. A fraction of them recognize sulfatide. By using sulfatide-
loaded CD1d-tetramers, we observed for the fırst time that sulfatide-reactive
type II NKT cells were enriched in the lung, a major site of tumor metastasis.
Moreover, we previously showed that in vivo stimulation of type II NKT cells
with sulfatide increased the number of tumor nodules in the lung. An in-depth
phenotype analysis revealed that they were CD4 or CD8 single positive cells, like
conventional T cells, whereas type I NKT cells are either CD4CD8- or double
negative. Type II NKT cells do not express PLZF, the master regulator of NKT
cell development and exist in PLZF-/- mice contrary to type I NKT cells. We
showed that type II NKT cells also expressed markers of myeloid cells, c-Kit,
CD11b and Ly6C even though histological analysis revealed lymphocytic mor-
phology. Interestingly, at steady state, type II NKT cells expressed granzyme A
but not granzyme B or perforin. The in vivo injection of sulfatide increased the
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expression of the activation markers CD69 and CD44 as well as granzyme A.
Since the regulatory functions of type IINKT cells have been shown to be critical
in tumor immunity, the detailed characterization of these cells could help to
develop a new immunotherapy for cancer.
#4623 Transcriptional analysis of the functional differences between M1
and M2 macrophages to identify new targets for myeloid cell modulation in
pancreatic tumors. Kimberline R. Yang, Todd D. Armstrong, Elizabeth M.
Jaffee.The Sidney Kimmel Comprehensive Cancer Center, JohnsHopkins Univer-
sity School of Medicine, Baltimore, MD.
Macrophages exhibit dynamic plasticity in their function in response to the
accumulating genetic alterations that occur during tumorigenesis, resulting in
the establishment of an immune tolerized tumor microenvironment. However,
depending on their environmental cues, they can switch between two functional
phenotypes: pro-inflammatory/anti-tumorigenic (M1) or anti-inflammatory/
pro-tumorigenic (M2). The importance of these twomacrophage subsets iswell-
recognized; however, identifying and distinguishingM1 fromM2macrophages
in patient tumors still remains a challenge. Prior studies have utilized transcrip-
tome profıling of artifıcially skewed M1 and M2 macrophages from healthy
donors to identify individual genes or gene clusters unique to each macrophage
subset.However, these studies are limited to surfacemarker expression and gene
expression profıles alone to distinguish subsets and lack functional validation of
M1 and M2 macrophages. Surface marker and gene expression profıling of hu-
manM1 andM2macrophages provide an incomplete characterization, as func-
tionality is an important feature distinguishing these macrophage subsets. To
improve the characterization ofM1 andM2macrophages, we performed a thor-
ough three-step validation of artifıcially skewedM1 andM2macrophages from
healthy donormonocytes using surfacemarker expression, gene expression pro-
fıling, and multi-analyte ELISA analyses. Using our validation assays, we tested
previously published protocols for their effıcacy in generatingM1 andM2mac-
rophages. While M1 macrophages using these protocols generated as expected
M1 characteristics, M2 macrophages lacked hallmark functional features, par-
ticularly IL-10 secretion. This necessitated the generation of an optimized pro-
tocol to skewM1 andM2macrophages that exhibited distinctive surfacemarker
expression, gene expression profıles, and cytokine and chemokine production
for their respective subset. We then performed RNA-sequencing to interrogate
the transcriptional landscape of functional M1 and M2 macrophages and have
found 1,472 transcripts that have at least a two-fold change in differential ex-
pression between M1 and M2 macrophages across 4 different donors. These
results represent themost in-depth characterization of humanM1 andM2mac-
rophages and provide insights into better biomarkers and targets for novel im-
munotherapy approaches.
#4624 Natural killer cell licensing contributes to clearance of lung cancer.
Shi Lei,1 Kang Li,1 Saeed Arefanian,2 Alexander S. Krupnick1. 1University of
Virginia, Charlottesville, VA; 2Washington University in St. Louis, St Louis, MO.
a) Natural Killer (NK) cell Inhibitory receptors function in a dichotomous
role. Their engagement byMHCClass I upon encountering a target results in the
inhibition of cytotoxicity. During NK development, however, their interaction
with MHC Class I mediates the process of licensing or education, leading to an
increase in responsiveness and cytotoxicity. For this reason the role of inhibitory
receptors in controlling the clearance of MHC Class I solid tumors such as
lung cancer is poorly defıned. Since NK cells comprise the primary cytotoxic
lymphocyte responsible for clearance of lung cancer, we set out to determine
whether the licensing status ofNK cells contributes to lung cancer susceptibility.
b) Growth ofMHCClass Imurine lung cancer was evaluated inMHCClass I-
mice, with unlicensedNKcells in direct comparison toMHCClass Imicewith
licensed NK cells. IFN- production was evaluated after plate bound antibody
stimulation through theNKp46 andNKG2Dpathways both flow cytometrically
and by quantitative RT-PCR. Bone marrow transplantation was performed by
injection of 10x106 unfractionated bone marrow cells after 500cGy irradiation
and NK and CD4 T cell depletion of recipient host. c) Injection of Lewis Lung
Carcinoma (LLC) revealed a signifıcant decrease in pulmonary tumor burden in
mice with licensed NK cells (230.4	21.6 vs. 442.7	53.8 mg) that disappeared
after NK depletion (421.4	36.8 vs. 421.9	66.3 mg). Freshly isolated licensed
NK cells lysed LLC more robustly than unlicensed NK cells (28.7	.16% vs.
4.9	.2% specifıc lysis at 100:1 ratio respectively). Lung cancer expresses stress
ligands recognized by NKG2D and NKp46 activating receptors. Licensed NK
cells produced signifıcantlymore IFN- than their unlicensed counterparts after
plate-bound stimulation with anti-NKp46 and anti-NKG2D (17.9	2.8% vs.
5.4	.8% respectively for dual NKp46 and NKG2D stimulation). No differences
were evident between licensed and unlicensedNK cells in ribosomalmass, mak-
ing it unlikely that translational defects were responsible for altered cytokine
production. Licensing status also did not affect stability of IFN- but did affect
mRNA levels. This suggests transcriptional control of licensing-mediated NK
activity. IFN- production could be signifıcantly increased in unlicensed NK
cells by reintroduction of MHC Class I through non-myeloablative bone mar-
row transplantation fromMHCClass I-suffıcient congenic donors. Blockade of
H2Kb-Ly49c (MHC Class I-inhibitory receptor) interaction during NK devel-
opment in C57BL/6 mice using a non-depleting anti-Ly49c antibody (clone
4LO) decreased IFN- production in NK cells. d) The role of NK cell licensing
and tumor-specifıc cytotoxicity is highly controversial. We now demonstrate
that licensed NK cells mediate a superior lung cancer-specifıc immune response
in amurinemodel.Our data suggests that altering the licensing status ofNKcells
may be an avenue of lung cancer-specifıc immunotherapy.
#4625 Natural killer T cells regulate tumor immunity inmouse pancreatic
cancer organoid orthotropic model. Shingo Kato,1 Tetsuya Matsuura,1 Yoshi-
taka Hippo,2 Atsushi Nakajima1. 1Yokohama City Univ. Hospital, Yokohama,
Japan; 2Chiba Cancer Center Research Institute, Chiba, Japan.
Natural killer T (NKT) cells are lymphocytes with features of natural killer
(NK) and of T cells placing them at the interface of innate and adaptive immu-
nity. Like NK cells, they rapidly produce cytokines after stimulation, orienting
the immune response. As T cells, they express a T cell receptor (TCR) that allows
the recognition of specifıc lipids presented by the non-classicalMHC-Imolecule
CD1d. There are two subsets of NKT cells, type I and type II, distinguished by
their T-cell receptors. All type I NKT cells express a semi-invariant TCR
(V2418 in humans, V14J18 inmice) that recognizes-galactosylceramide
(-GalCer). In contrast, type II NKT cells express a more diverse TCR reper-
toire. The biological activity of these two subsets of NKT cells is assessed com-
paring J18-/- mice that specifıcally lack type I NKT cells and in CD1d-/- mice
which lack all populations ofNKT cells. In tumor immunity, these two subsets of
NKT cells have opposite functions. Type I NKT cells enhance and type II NKT
cells suppress anti-tumor responses. It has been also reported that these two
types of NKT cells cross-regulate each other. Although there is no currently
identifıed lipid antigen recognized by all type IINKTcells, sulfatide is a relatively
well-defıned self-antigen recognized by a fraction of type IINKT cells. In human
organs, sulfatide is rich in myelin sheath of nerve tissue and pancreas. Thus,
sulfatide may release from pancreatic tissue during the invasive growth of the
pancreatic cancer, and activate a fraction of type II NKT cells. To test this hy-
pothesis, we analyzed the involvement of NKT cells in the regulation of tumor
immunity in pancreatic cancer, using mouse pancreatic cancer organoid ortho-
tropic model. The pancreatic organoids derived from KrasG12D mice were
transduced with Cre and shRNA against p16, to activate Kras and repress p16,
respectively. These transduced organoids were then subcutaneously injected to
C57BL/6J wild type mice, and tumors were harvested after two weeks. The tu-
mors were cut into small pieces, and the weight of each piece wasmeasured. The
piece of tumor was sewn to the pancreas of wild type, J18-/- mice and CD1d-/-
mice. After two weeks, tumors were harvested, and the weight of tumor was
measured. The tumor weight was signifıcantly heavier in CD1d-/- mice than
wild type mice (p0.0416). Although it was not statistically signifıcant, the tu-
mor weight was slightly heavier in J18-/- mice than wild type mice. We also
analyzed the population of T cell subsets in peripheral bloods, however, there
were no differences among the three strains of mice. Considering these results,
NKT cells may regulate tumor immunity in the microenvironment of the pan-
creatic cancer. Moreover, since sulfatide is rich in pancreas, sulfatide-reactive
type II NKT cells may be involved in this local immune response. The detailed
analysis of the regulatory functions of NKT cells in pancreas could help to de-
velop a new immunotherapy for pancreatic cancer.
#4626 Macrophages alter heparan sulfate-modifying enzyme levels,
growth factor activity and cancer cell growth in 3Dhydrogels.FabioHenrique
Brasil daCosta,1NoraM.Navone,2MaryC. Farach-Carson,3DanielD. Carson1.
1RiceUniversity,Houston, TX; 2University of TexasMDAndersonCancerCenter,
Houston, TX; 3University of Texas Health Science Center, Houston, TX.
Tumor progression in both primary and metastatic niches often involves the
activation of associated or “reactive” stroma similar to that seen in a wound
healing response. The stromal participants include fıbroblasts, endothelial and
immune cells, including macrophages. Cancer-associated fıbroblasts (CAFs)
and tumor-associatedmacrophages communicatewith local cells including can-
cer cells and the surrounding stroma to induce epithelial-to-mesenchymal tran-
sition, immunosuppression and increased production of extracellular matrix
(ECM) components, growth factors, and ECM-remodeling enzymes. Heparan
sulfate (HS)-modifying enzymes produced by tumor-associated stroma play key
roles in the delivery of heparin-binding growth factors (HBGFs) and cytokines,
serving to enhance tumorigenesis, foster growth and recruit other bystander
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cells to sites of metastasis. Through the use of a novel, biomimetic, 3D collagen/
hyaluronic acid hydrogel system developed in our labs, this study focused on
interactions between primary humanmacrophages and cancer cells, specifıcally
on how this dialogue impacts the production of the secreted HS-modifying
enzymes, heparanase (HPSE) and endosulfatase 1 (SULF1). We studied the im-
pact of co-cultures containingmacrophages and endometrial or prostate cancer
cell lines, aswell as patient-derived xenografts, on the levels ofHPSE and SULF1.
We also assessed cancer growth characteristics in the presence of macrophages.
Taken together, our observations indicate cancer cell responses to macrophages
are cell type specifıc, and we demonstrated signifıcant functional consequences
of interactions between macrophages and HS-mediated signaling. We are cur-
rently determining if macrophage polarization to classically activated (M1) or
alternatively activated (M2) phenotypes alters cancer cell responses in 3D. This
system is being used to determine novel approaches to intervene in HBGF de-
livery to limit cancer growth in a more physiologically relevant in vitro system.
#4627 Prognostic signifıcance and population shift of peripheral mono-
cytes in patients with oropharyngeal squamous cell carcinoma. Hideyuki
Takahashi, Koichi Sakakura, Kazuaki Chikamatsu.GunmaUniversity Graduate
School of Medicine, Maebashi, Gunma, Japan.
Evidence has accumulated that chronic inflammation plays a critical role in
carcinogenesis, tumor growth, and metastasis. To date, several inflammatory
biomarkers are considered as potential prognostic factors in various cancers.
The aim of the present study was to investigate the prognostic signifıcance of the
pretreatment levels of inflammatory biomarkers in patients with oropharyngeal
squamous cell carcinoma (OPSCC). A total of 67 patients newly diagnosed as
OPSCC was fınally included. The neutrophil, lymphocyte, monocyte and plate-
let counts recorded before treatment was initiated, then lymphocyte-to-mono-
cyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lym-
phocyte ratio (PLR) were calculated. These inflammatory biomarkers and
clinical parameters including age, differentiation, T-stage, N-stage, TNM-stage,
smoking, and drinkingwere comparedwith progression-free survival (PFS) and
overall survival (OS) using cox regression. Elevated monocyte count and ad-
vanced T-stage were signifıcantly associated with poor PFS; in addition, these
were independent prognostic factors for PFS. Elevatedmonocyte count and low
LMR were signifıcantly associated with poor OS; moreover, low LMR was an
independent prognostic factor for OS. Of note, monocyte count and LMR were
associated with prognosis more intensively in patients with p16-negative OP-
SCC. Following these results, we evaluated the peripheral blood mononuclear
cells of 14 patients with OPSCC collected before treatments. CD14 CD86
HLR-DR cells were gated as monocytes, then divided into three subsets ac-
cording to the expression of CD14 and CD16. The proportion of intermediate
monocytes was lower and that of classical monocytes was higher in OPSCC
patients than in healthy donors, especially in patients with elevated monocyte
count. Furthermore, the expression level of PD-L1was higher in patients than in
healthy donors on all subsets. In conclusion, our data suggests that elevated
monocyte count and low LMR seem to be useful biomarkers for predicting
prognosis of OPSCC; furthermore, the population shift ofmonocytesmay relate
to poor prognosis of OPSCC.
#4628 Selectionof Smad2 forTGF- to suppress dendritic cells by STAT3/
c-Ski-induced repression of Smad3. Jeong-Hwan Yoon,1 Eunjin Bae,1 Katsuko
Sudo,2 Masakatsu Takanashi,2 Jin Soo Han,3 Seok Hee Park,4 Michael Wein-
stein,5 Susumu Nakae,6 Tadashi Yamashita,7 In-Kyu Lee,1 Ji Hyeon Ju,8 Tak-
ayuki Sumida,9Masahiko Kuroda,2 KeijiMiyazawa,10Mitsuyasu Kato,9Mizuko
Mamura1. 1Kyungpook National University, Daegu, Republic of Korea; 2Tokyo
Medical University, Tokyo, Japan; 3Konkuk University, Seoul, Republic of Korea;
4Sungkyunkwan University, Suwon, Republic of Korea; 5The Ohio University,
Columbus, OH; 6University of Tokyo, Tokyo, Japan; 7Azabu University, Kana-
gawa, Japan; 8Catholic University of Korea, Seoul, Republic of Korea; 9University
of Tsukuba, Tsukuba, Japan; 10University of Yamanashi, Yamanashi, Japan.
The mechanisms how Smad-mediated transforming growth factor-
(TGF-) signalling regulates dendritic cells (DCs) remain largely unknown,
despite its crucial regulatory roles in the differentiation and activation of DCs.
Here, we show that STAT3/c-Ski-induced downregulation of Smad3 during
differentiation selects Smad2 as the specifıc TGF- receptor-regulated Smad
(R-Smad) to suppress the immunogenicity of DCs. Smad3 transcribed by un-
phosphorylated Smad2/3 prevented the progenitor cells from DC differentia-
tion with repression of Flt3, IRF4 and STAT3. Repression of Smad3 by synergy
of phosphorylated STAT3 and c-Ski was essential for DCdifferentiation. TGF-
suppressed DC activation via Smad2, hence DC-specifıc Smad2 deletion en-
hanced anti-lymphoma effector functions of cytotoxic T lymphocytes (CTLs)
and type 1 helper T (Th1) cells in a mouse EL4 lymphoma model. Our fındings
reveal stepwise regulatory roles of R-Smads in DC regulation: Smad3 inhibits
differentiation and Smad2 suppresses immunogenicity.
#4629 Macrophage number correlates with tumor stage in cutaneousmel-
anoma. Satu Salmi,1 Hanna Siiskonen,2 Reijo Sironen,2 Kristiina Tyynelä-
Korhonen,2 Päivi Auvinen,2 Sanna M. Pasonen-Seppänen1. 1University of East-
ern Finland, Kuopio, Finland; 2Kuopio University Hospital, Kuopio, Finland.
Tumor associatedmacrophages and regulatory T cells (Tregs) have an impor-
tant role in tumor progression as a part of the immunosuppressive tumor mi-
croenvironment. By means of immunosuppression, melanoma, as well as many
other cancers, is able to resist anti-cancer immune reactions. To understand the
mechanisms how tumor cells escape from the anti-tumor immune response is
the key for effıcient treatment strategies. In several cancers, programmed cell
death ligand-1 (PD-L1) -mediated pathways have been shown to suppress anti-
tumor immune responses. Our aim was to investigate the number of tumor
associated macrophages (TAMs) and Tregs in benign, premalign and malign
melanocytic lesions to fınd out if the density of these cells is associated with the
tumor stage or survival in melanoma. Moreover, the expression of PD-L1 was
studied. Altogether 187 tissue samples, including 29 benign and 27 dysplastic
nevi, 16 in situ melanomas, 38 superfıcial (Breslow  1 mm) and 43 deep
(Breslow  4 mm) melanomas and 34 lymph node metastases, were stained
immunohistochemically for CD68 and CD163 representing all TAMs and M2-
like macrophages, respectively and for FoxP3, a marker for Tregs. In addition, a
part of the FFPE -samples was dual stained for CD68 and PD-L1. Macrophages
and Tregs were counted using a hot spot -method. In the statistical analyses, the
cell numbers were graded as either low or high according to the median. Non-
parametric Kruskal-Wallis test was used to compare the macrophage numbers
in different groups andPearson chi-square test to study the correlations between
the numbers of CD163 and CD68 -positive cells and clinicopathological param-
eters. CD68 and CD163 macrophage numbers were signifıcantly higher in
malign melanocytic lesions and lymph node metastasis compared to in situ
melanomas and benign nevi. In deep melanomas and lymph node metastases
macrophages located mainly inside the tumor nests whereas in thin melanomas
they were mostly scattered around the tumor. High CD68macrophage num-
ber correlated with the presence of ulceration (p0.011) and with both local
recurrence (p0.008) and recurrence with distal metastases (p0.002). PD-L1
immunoreactivity was relatively scanty inmelanoma samples being restricted to
certain areas only; both membraneous and cytoplasmic staining was observed.
Overall, the staining was higher in deepmelanomas and lymph nodemetastases
compared to superfıcial melanomas. Dual stainings indicated that in addition to
tumor cells, a part of the tumor infıltrating CD68 macrophages were PD-L1
-positive. The density of FoxP3 cells did not correlate with the tumor stage.
However, the number of these cells was signifıcantly lower in benign nevi com-
pared to other groups. Our observations highlight that TAMs are involved in
melanoma progression and have an important role in the formation of an im-
munosuppressive tumor microenvironment.
#4630 Development of selective and potent CDK8 inhibitors that increase
NK cell activity, which translates in tumor surveillance.Marco H. Hofmann,
Harald Engelhardt, Sebastian Carotta, Heribert Arnhof, Dirk Scharn, Marc
Kerenyi, Moritz Mayer, Gerhard Gmaschitz, Georg Egger, Christian Engel-
hardt, Michael Sanderson, Maria A. Impagnatiello, Renate Schnitzer, Mark
Pearson, Darryl McConnell, Norbert Kraut, Jürgen Moll. Boehringer Ingelheim
RCV GmbH & Co KG, Vienna, Austria.
Background: Cyclin-dependent kinase 8 (CDK8) is part of themediator com-
plex that can either positively or negatively influence transcription. CDK8 is
known to phosphorylate signal transducer and activator of transcription 1
(STAT1) at the position Ser727. STAT1 activity is regulated by JAK-mediated
phosphorylation of tyrosine701 which leads to dimerization, nuclear transloca-
tion and IFN- induced phosphorylation mediated by CDK8. Introduction of
an alanine mutation at the phosphorylation site STAT1-S727 results in en-
hanced NK cell cytotoxicity accompanied by increased levels of perforin and
granzyme B (Putz et al. 2013). Method: Here we present the discovery and
development of potent and selectiveCDK8 inhibitors guided by crystallography.
The inhibitory effect of optimized compounds BI 9811 and BI 1347 on STAT1
phosphorylation and perforin release was investigated in the humanNK cell line
NK-92MI. Direct effects on cancer cells were furthermore analyzed in a broad
panel of cell lines. The compound BI 1347 was profıled in vivo in the orthotopic
B16-F10 melanoma mouse model. Results: Highly potent and selective CDK8
inhibitors were identifıed with an IC50 of below 10 nM in a biochemical kinase
assay, which translated in a potent down regulation of the STAT1- Ser727 signal
and in increased perforin and granzyme B secretion. BI 9811 and BI 1347 were
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highly selective for CDK8, as tested in a broad kinase panel and showed no
cytotoxic activity onNK cells andmost cancer cell lines, which distinguishes this
compound class from published CDK8 inhibitors. A representative molecule
out of this compound class demonstrated in vivo biomarker modulation and
survival increase in the murine B16-F10 melanoma mouse model. Conclusion:
We developed potent CDK8 inhibitors that show activation of NK cells that
translates into biomarker modulation (pSTAT1Ser727) and in vivo effıcacy.
#4631 Enhanced glycolysis promotes function of tumor associated mac-
rophages in mouse breast cancer model. Yan Liu,1 Wei Zhou,2 Wei Wang,1
Lipeng Bai,1 Huiwen He,1 Jian Guo,1 Yunping Luo1. 1Chinese Academy of Med-
ical Sciences, Beijing, China; 2Nankai University, Tianjin, China.
Tumor associated macrophages(TAMs) represent a major part of immune
cells in tumor microenvironment(TME) and play crucial roles in promoting
tumor progression by secreting cytokines or enzymes that could remodel TME
or enhance envision or migration capabilities of tumor cells. Given their indis-
pensable effect on tumor, themechanisms underlying TAMs’ tumor-promoting
phenotype and function remain unclear. Glucose metabolism in tumor cells has
been intensively studied; however, the status of glucose metabolism of TAMs is
still unclear. In this study, we aim to identify glucose metabolism status in
TAMs, and explore how glucose metabolism regulates phenotype and function
of TAMs. In the begining, we isolated TAMs from 4T1 mouse breast tumor,
spleen macrophages from normal mouse as a control, and performed RNA
sequencing to analyze the expression pattern in glucose metabolism related
genes. The results from transcriptomics showed that TAM shown up regulation
of glycolysis genes pattern. Then we analyzed and found that HK’s activity was
increased while IDH’s activity was decreased in mouse breast cancer moel. Fur-
thermore, In vitro, we found that up regulation of impotent glycolysis genes
including HK2, PFK-L and LDHA in mouse peritoneal macrophages (CMPM)
andmouse bone marrow derived macrophages (CMBMDM) conditionally cul-
turedwith 4T1 supernatants. Glucose consumption or production of lactate and
ATP were also increased in CMPM or CMBMDM. Then we monitored lactate
producing rate with seahorse energymetabolism detector, and found that either
CMPM or CMBMDM produced lactate faster than that of control. Moreover,
inhibition of LDHA activity by oxamate ( inhibitor) also decreased glucose con-
sumption and lactate production. Importantly, the expression of Arg1 and
CD206, positively correlated with glycolysis and function of TAMs. Finally, we
search the underneathmechanism and found PI3K/AKT pathway was activated
in CMPM or CMBMDM. In detail it was found that p-p85 and p-AKT was
upregulated at 8 hour after 4T1 supernatants stimulation. Inhibition of PI3K/
AKTpathway by LY294002 (PI3K inhibitor), notably inhibited the expression of
glycolysis genes andmarkers of TAMs,which indicated that PI3K/AKTpathway
maybe involved in glycolysis of TAMs. Together, we identifıed that TAMs ad-
opted glycolysis as a major way to consume glucose and glycolysis was directly
contributed to the phenotype and function of TAMs, which was regulated by
PI3K/AKT signaling pathway.
#4632 Exosome-mediated transfer of miR-183-5p from tumor cells to
macrophages contributes to regulate TAMs phenotypes and promote tumor
progression and metastasis. Jian Guo, Wei Wang, Yan Liu, Huiwen He, Chen
Zhang, Chong Chen, Yunping Luo. Chinese Academy of Medical Sciences, Bei-
jing, China.
Tumor-associated macrophages (TAMs) perform supportive roles in pro-
moting tumor progression and metastasis. In tumor microenvironment, the
phenotypes of TAMs are regulated by a variety of factors, such as cytokines,
ligends and products of metabolism. Recently, Exosome-mediated transfer of
miRNAs is proved to be a signifıcant way for intercellular communications.
Whether exosomalmiRNAs derived from tumor cells contribute to TAMs’ phe-
notypes remains unclear. In this study, we aim to identify the miRNAs in exo-
somes transferred from tumor cells tomacrophages and explore how thesemiR-
NAs regulate theTAMsphenotypes. In the beginningwe transferredCY3-labled
miRNA NC to 4T1 mouse breast cancer cells and then co-cultured with bone
marrow-derived macrophages (BMDMs). The CY3 fluorescence could be ob-
served in BMDMs after 48 hour, suggesting that miRNAs could be transferred
from tumor cells to macrophages. Next, we performed miRNAs sequencing in
either BMDM or exosomes derived from 4T1 cancer cells. We analyzed and
compared the miRNAseq data by bio- informatics and found that there were 30
of the most abundant miRNAs in 4T1 exosomes, and nearly all of which were
rich in BMDMs. However, it was found interestingly that miR-183-5p was ex-
tremely low in BMDMs. Furthermore, we treated BMDMs with exosomes iso-
lated form 4T1 cell conditioned medium, and then we found importantly the
miR-183-5p in BMDMs was increased signifıcantly, while cultured with exo-
some-depleted 4T1 conditionedmedium, the expression of miR-183-5p in BM-
DMs was not changed. Meanwhile, we isolated TAMs from 4T1 mouse breast
tumor while spleen macrophages from normal mouse as a control. The expres-
sion ofmiR-183-5p in TAMswasmuch higher than that in spleenmacrophages.
Moreover, it was determined that expression of pro-inflammatory cytokineTNF
and IL-6 in BMDM were increased signifıcantly in BMDMs treated with 4T1-
derived exosomes. Correspondingly, transferred miR-183-5p mimic into BM-
DMs, the expression ofTNFand IL-6were also increased. Finallywe co-cultured
4T1 cells with BMDMs transferred with miR-183-5p, and the migration and
invasion of 4T1 cells were signifıcantly enhanced. Taken together, our study
demonstrate that miR-183-5p that high expression in 4T1 exosomes can trans-
ferred intomacrophages to regulated their phenotypes and promote tumor pro-
gression and metastasis in breast tumor microenvironment.
#4633 Crosstalk between MDSCs and Th17. Brijendra Singh. University of
Pittusburgh Cancer Institute, Pittsburgh, PA.
Expansion of myeloid-derived suppressor cells (MDSCs) within the tumor is
a known barrier to successful cancer immunotherapy. MDSCs are heteroge-
neous population of immature myeloid cells with potent immunosuppressive
activity. Emerging evidences in the recent years defıne the role of immunosup-
pressive activity of MDSCs on different subsets of CD4 T cells, however the
exact effect of MDSCs on inflammatory Th17 cells during tumor progression is
not clear. Here we demonstrate the immunosuppressive effect of MDSCs on
Th17 cells. We further show that the interaction between MDSCs and Th17 is
not unilateral and reveal that Th17 cells can promote the immunosuppressive
effect of MDSCs. MDSCs, either isolated from tumor bearingmice or generated
in vitro from bone marrow (BM-derived MDSCs), can both suppress IL-17A
expression. Our data also demonstrate that IFNg, produced by Th17 cells is
essential for the immunosuppressive activity of BM-derived MDSCs on IL-17A
expression and further that the IFNgR1-driven signaling is important for Nos2-
mediated immunosuppressive effect of BM-derived MDSCs on IL-17A expres-
sion.Understanding themolecularmechanismof the interplay betweenMDSCs
and Th17 cells may help to develop more specifıc targeted therapy for cancer
immunotherapy and improve therapeutic effıcacy of the existing therapies
against cancer.
#4634 Role of surgical stress in altering host immunity in breast cancer
patients. Madhuri Taranikanti, Aswin Kumar Mudunuru, Rohit Kumar Gun-
tuka. ESIC Medical College & Hospital, Hyderabad, India.
Background: Stress of any kind can alter the immune system. Surgery is a form
of stress that can have signifıcant effects on immune system. There occurs a
reduction in the ability to fıght the disease progression and also metastatic
spread. Cell mediated immunity plays an important role in the control of ma-
lignancy. A reduction in cellular immunity can have adverse effects on the body.
The objective of the study was to understand the effects of surgical stress on cell
mediated immunity in breast cancer patients.Methods: 31womenwith operable
early stage breast cancer, who underwent surgery and were also receiving adju-
vant chemotherapy were included in the study. Blood samples were collected
from the patients during the pre-operative period and twice during the post-
operative period, after 72 hours and after 21 days. Peripheral Blood mononu-
clear cells were subjected to flow cytometry analysis. The mean values of lym-
phocyte sub-populations as percentage were calculated. A questionnaire was
also given to all study participants to assess the levels of stress of having breast
cancer. An informed consent was taken from all the participants involved in the
study. Results: Themean values of lymphocyte sub-population were found to be
signifıcantly lower (p0.5) in the early post-operative period in breast cancer
patients. However, the values returned to near pre-operative levels after 21 days.
A positive correlation existed between psychological stress of having the disease
and low host immunity. This indicates that any intervention that further sup-
presses immunity in breast cancer patients following surgery should not be used
for at least 3 weeks after surgery.
#4635 The LSD1 Specifıc Inhibitor INCB059872 enhances the activity of
immune checkpoint blockade by reshaping the myeloid compartment in the
syngeneic 4T1 mouse mammary tumor model. Thomas Condamine, Steve
Wang, Melody Diamond, Leslie Hall, Huiqing Liu, Antony Chadderton, Jin Lu,
Chunhong He, Liangxing Wu, Timothy Burn, Wenqing Yao, Gregory Hollis,
ReidHuber, Bruce Ruggeri, Peggy Scherle, Holly Koblish, SangHyunLee. Incyte
Corporation, Wilmington, DE.
Immune checkpoint blockade has shown considerable therapeutic promise in
the clinic. However, single agent activity is compromised by the presence of
suppressive myeloid cells, including myeloid derived suppressor cells (MDSC),
tumor associatedmacrophages (TAM) and polymorphonuclear (PMN) cells, in
the tumor microenvironment. Epigenetic alterations can signifıcantly contrib-
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ute to the development of the immunosuppressive tumor microenvironment
and recent data have suggested that combining epigenetic-based therapies with
immunotherapeutic agents can lead to improved effıcacy in preclinical models.
Since Lysine SpecifıcDemethylase 1 (LSD1) has been shown to play a critical role
in hematopoiesis, we hypothesized that inhibition of LSD1 could have a direct
effect on myeloid cell differentiation and potentially restore normal myelopoi-
esis in cancer patients. To test this hypothesis, we evaluated INCB059872, a
potent, selective and orally available FAD-directed covalent inhibitor of LSD1 in
several experimental models. In an in vitro differentiation assay, the majority of
CD34progenitor cells were driven to amonocytic phenotype in the presence of
INCB059872, while control treated cells differentiated toward granulocytic
PMN cells. Similar results were observed in vivo. Using the orthotopic 4T1
mammary cancer model, the myeloid compartment was characterized in tumor
tissues following treatmentwith INCB059872.Notably, the population of PMN-
MDSC was signifıcantly decreased in tumor tissues following oral administra-
tion of INCB059872, whereas the macrophage population was increased. These
data suggest that INCB059872 can redirect myeloid differentiation toward
monocyte/macrophages and inhibit the differentiation of PMN-MDSC in this
syngeneic tumor microenvironment. Consistently, intratumoral T lymphocyte
infıltration was increased following INCB059872 treatment. The combination
of INCB059872 and-PD-L1 antibody enhanced anti-tumor effıcacy in the 4T1
orthotopic tumormodel. Collectively, these data suggest that inhibition of LSD1
with INCB059872 can directly affect myeloid differentiation to reduce the accu-
mulation of myeloid suppressive cells, restoring the tumor microenvironment
to be more responsive to PD-1/PD-L1 axis blockade. This study supports the
therapeutic potential for the combination of an LSD1 inhibitor with immuno-
therapeutic agents to improve overall clinical response in cancer patients.
#4636 p53 governs the tumoricidal activity of M1 macrophages in lung
cancer.Yi-JingHsiao,1Hsuan-YuChen,2 Kang-Yi Su,1 Bing-ChingHo,1 Jeremy
J.W. Chen,3 Pan-Chyr Yang,1 Sung-Liang Yu1. 1National Taiwan University,
Taipei, Taiwan; 2Academia Sinica, Taipei, Taiwan; 3National Chung-Hsing Uni-
versity, Taichang, Taiwan.
Macrophages in a tumor microenvironment have been characterized as M1-
andM2-polarized subtypes.M1macrophage is associatedwith favorable clinical
outcome of lung cancer patients, but the detail molecular mechanism is not
thoroughly understood. Herein, we elucidate the anti-tumor mechanism of M1
macrophages by in vitro and in vivo assays. M1 conditionedmedia (CM) signif-
icantly reduced the tumor size in the xenograft mouse model via intratumoral
administration. TheM1-altered differential expressionwas profıled bymicroar-
ray and the pathway analysis indicated that p53 was a critical regulator. Lung
cancer cells harboring wild-type p53 (wt-p53) went apoptosis after M1 CM
culture, but cells with mutant p53 did not. Additionally, M1 CM enhanced
wt-p53 accumulation through reducing p53 ubiquitination and increasing pro-
tein stability. Moreover, we identifıed a p53 interacting protein STAT1 involved
inM1-induced apoptosis andp53 accumulation. TheM1CMnot only enhanced
the interaction between STAT1 and p53 but also up-regulated and activated
STAT1. We found that STAT1-Y701 phosphorylation is required for the p53
stability. The interaction of STAT1-Y701F and p53 was reduced compared to
wild-type STAT1. To reveal the upstream signaling, we found that knockdown
of IFNAR2, JAK1 and TYK2 attenuates M1-induced apoptosis. Taken together,
STAT1 signaling is essential for M1 CM-induced apoptosis and p53 accumula-
tion. Our fındings imply that p53 and M1 macrophages play important roles in
the immune surveillance in lung cancers.
#4637 Activation of toll-like receptor-2 promotes proliferation in human
lung adenocarcinoma cells. Patrick Kohtz. University of Colorado - School of
Medicine, Denver, CO.
Objective: Toll-like receptors (TLR) have been implicated in tumor progres-
sion by affecting the immune response in the tumor microenvironment. Toll
like receptors have been described to be present in human cancer cells but the
presence and the role of these receptors in the growth and proliferation of hu-
man lung cancer cells is not known.We analyzed human lung cancer cells for the
presence of TLR-2 receptors and evaluated the proliferation response to a spe-
cifıc TLR-2 agonist. Methods: Human non-small cell cancer cell (NSCLC) lines
A549, (adenocarcinoma) H125 adenosquamous, and H1650 adenocarcinoma
(American Type Culture Collection), were cultured using standard techniques.
Cells were treated with Pam3CSK4, a specifıc agonist of TLR2, at doses of 0ug/
ml, 5ug/ml, and 10ug/ml for 72 hours. Baseline protein levels of TLR2 were
assessed using standard western blotting techniques. Proliferation assays were
completed using the MTS assay in response to treatment with the agonist Re-
sults: Protein analysis demonstrated varying but consistently detectable levels of
TLR2 protein in each cell line. After treatment with Pam3CSK4 we found that
proliferation was signifıcantly promoted in the human lung adenocarcinoma
cell lines (p.03), but not in the adenosquamous cell line (p0.001). Conclu-
sion: Toll-like receptor -2 is consistently present and detectable on human lung
adenocarcinoma cells. Toll Like receptor -2 activation results in increased pro-
liferation in human lung adenocarcinoma cells and this effect appears to be
specifıc to adenocarcinoma cells. Further study is necessary to elucidate the
downstreampathways responsible for the increased proliferationwe see in these
human lung adenocarcinoma cells, however these fındings may suggest TLR-2
to be a possible therapeutic target in human lung cancer.
#4638 The p53 suppression on tumor cells may recruit macrophages and
modulate their expression of the indoleamine 2, 3-dioxygenase. Takafumi
Nakamura. Kawasaki Medical School, Kurashiki, Japan.
We had found that expression of indoleamine 2,3-dioxygenase (IDO) on cer-
vical cancer cells increased as it progressed from carcinoma in situ (CIS) to
microinvasive cancer, and that tumor-associatedmacrophages (TAM) recruited
at the invasive front also expressed IDO in cervical cancer patients (Cancer Sci
98:874-881 2007). We previously produced homozygous T3 transgenic mice
carrying two copies of A-SV40Tag transgene (A denotes murine A-crystal-
lin promoter) in order to study DNA virus-induced carcinogenesis. The T3
mice developed undifferentiated cancer of lens epithelium, which tumors
showedmulti-step carcinogenesis whichwas similar to cervical cancer (J Cancer
Res Clin Oncol 135:1521-1532 2009). We found that homozygous T3 mice
carrying two copies of SV40Tag transgene progressed faster and died earlier
than hemizygous T3mice carrying one copy of Tag transgene. In this study, in
order to examine the relationship between p53 function and tumor progression,
T3 mice were mated with M1 mice expressing mutant p53 in lens cells (Proc.
Natl. Acad. Sci. USA, 92:6142-6146, 1995) producing T3M1 mice, and also
were mated with p53-defıcient mice to produce p53-defıcient T3
(T3p53(-/-))mice(Cancer Letters 179:165-173,2002,OncologyReport 12:253-
258, 2004). At 20 weeks of age, the proportion of progression from CIS to inva-
sive cancerwas analyzed byH&E staining and the number of recruitedTAMand
IDO-expressing TAM were determined by immunohistochemical staining and
FACS analysis. Pathologically, both T3M1 and T3p53(-/-) lens tumors sig-
nifıcantly progressed to invasive cancer more than T3 tumors. There were a
few macrophages in wild-type lens, but more TAMwere recruited in both T3,
T3M1 and T3p53(-/-) lens tumors. However, no signifıcant difference of the
number of IDO-expressing macrophages in peritoneal cavity was detected in
each mice of wild-type, T3, T3M1 and T3p53(-/-). It suggested that p53
suppression on tumor cells might modulate IDO-expression for macrophages.
Moreover, we established the tumor cell lines from each T3, T3M1 and
T3p53(-/-) lens tumors. The peritoneal macrophages were analyzed for IDO-
expression in 4 days after i.p. injection of these cells. Signifıcantly, IDO-express-
ing macrophages in peritoneal cavity were more detected after i.p. injection of
each T3M1 and T3p53(-/-) cells than i.p. injection of T3 cells. And the
co-culture of peritonealmacrophages with eachT3M1 andT3p53(-/-) tumor
cells also induced the IDO-expression ofmacrophagesmore than the co-culture
with T3 cells. These results suggested that the amount of p53 suppression on
tumor cells would be related to the number of recruited TAM and their expres-
sion of IDO.The p53 suppression on tumor cellsmay recruit TAMand affect the
macrophage function and, suppress an innate immunity possibly through the
expression of IDO, which may enhance invasion and progression of tumors.
#4639 HLA and NKG2D ligand abnormalities and IFN- unnresponsive-
ness in human colorectal carcinoma cell lines. Yi-Hsin Liang,1 Yen-Cheng
Lin,2 Kuo-Hsin Chen,1 Chiu-Hwa Kao,1 Ann-Lii Cheng,1 Kun-Huei Yeh,1
Chien-Chung Chang2. 1Graduate Institute of Oncology, College ofMedicine, Na-
tional Taiwan University, Taipei, Taiwan; 2Institute of Molecular and Cellular
Biology, National Tsing Hua University, Hsinchu, Taiwan.
Background: Cetuximab, an anti-epidermal growth factor receptor (EGFR)
monoclonal antibody, has shown promising effıcacy on wild-type RAS meta-
static colorectal cancer (CRC) patients. Cetuximab demonstrates anti-cancer
effect via NK cells and subsequent immunogenic cell death. Chemotherapy or
targeted therapymay change immune surfacemarkers.Methods:We character-
ized a panel of 6 CRC cell lines with different genetic features. The impacts of
interferon- (IFN-) on cell surface expressions of major histocompatibility
complex (MHC) class I (including subtypes),MHCclass II (including subtypes),
MHC class 1 related molecule A (MICA, the NK cell ligand), Intercellular Ad-
hesion Molecule 1 (ICAM-1, the immunoglobulin superfamily), EGFR, and
Chondroitin Sulfate Proteoglycan 4 (CSPG-4, pericyte attachingmarker) before
and after treatment with IFN- (100 U/ml, 48 h) were explored in selected cell
lines Results: Among six human colon cancer cell lines analyzed, DLD-1,
HCT15, and LoVo exhibited no expression of HLA-A and HLA-B,C. Colo-320
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demonstrated both low HLA-A and HLA-B,C expression and irresponsive to
IFN- stimulation. In contrast, both HT-29 and SW-480 showed low HLA-A
and HLA-B,C expression, but the expression of both HLA-A and HLA-B,C was
corrected after IFN- stimulation. All six cell lines possessed low MHC class II
expression and irresponsive to IFN- stimulation. All six cell lines possessed low
MIC expression and irresponsive to IFN- stimulation. All six cell lines showed
low ICAM-1 expression, but only HT-29 and SW-480 were responsive to IFN-
stimulation. LOVO and SW-480 demonstrated high EGFR expression and irre-
sponsive to IFN- stimulation. Only HT-29 possessed high CSPG-4 expression.
Conclusion: These fındings reveal that regardless of their genetic features, all six
CRC cell lines possess a phenotype that may allow them to escape cytotoxic T
and NK cell attack.
Table
Cell Line MSI CIMP KRAS BRAF PI3KCA TP53
DLD-1 MSI  G13D WT E545K S241F
HCT-15 MSI  G13D WT E545K S241F
LOVO MSI - G13D WT WT WT
COLO-320 MSS - WT WT WT R248W
HT-29 MSS  WT V600E P449T R273H
SW-480 MSS - G12V WT WT R273H
CLINICAL RESEARCH: Diagnostic Biomarkers
#4640 Proteomic differentiation of pulmonary cancer with squamous cell
histology. Hanibal Bohnenberger,1 Diego Yepes,2 Sabine Merkelbach-Bruse,3
Alexander Emmert,4 Anna-Maria Lois,1 Sha Yao,1 Maren Sitte,5 Kuan-Ting
Pan,6 Leif Hendrik Dröge,7 Felix Bremmer,1 Jasmin Strecker,1 Stefan Küffer,1
Martin Sebastian,8 Martin Hinterthaner,4 Julia Kitz,1 Lorenz Biggemann,9
Joachim Lotz,9 Hans-Ulrich Schildhaus,1 Hendrik Wolff,7 Martin Canis,10
Bernd Danner,4 Tim Beißbarth,5 Reinhard Büttner,3 Philipp Ströbel,1 Hubert
Serve,8 Henning Urlaub,6 Thomas Oellerich8. 1Institute of Pathology, University
Medical Center Goettingen, Goettingen, Germany; 2German Cancer Research
Center, Frankfurt, Germany; 3Institute of Pathology, University medical Center
Cologne, Cologne, Germany; 4Department of Thoraxic Surgery, University Med-
ical Center Goettingen, Goettingen, Germany; 5Institute ofMedical Statistic, Uni-
versity Medical Center Goettingen, Goettingen, Germany; 6Bioanalytical Mass
Spectrometry, Max Planck Institute Goettingen, Goettingen, Germany; 7Depart-
ment of Radiooncology, University Medical Center Goettingen, Goettingen, Ger-
many; 8Department of Hematology/Oncology, University Hospital Frankfurt,
Frankfurt, Germany; 9Institute of Radiology, University Medical Center Goettin-
gen, Goettingen, Germany; 10Department Of Otorhinolaryngology, University
Medical Center Goettingen, Goettingen, Germany.
Histologic classifıcation of pulmonary cancer with squamous cell histology is
challenging as reliable immunohistochemical biomarkers are lacking. In partic-
ular smokers with head and neck cancer can develop both lung metastases and
primary lung cancer. However, their differentiation is clinically important for
therapy and risk stratifıcation.Moreover, molecular targeted therapies for squa-
mous cell carcinoma of the lung are largely lacking. To identify proteomic diag-
nostic biomarkers, signaling patterns and potential novel drug targets we char-
acterized a broad panel of primary patient-derived formalin-fıxed squamous cell
carcinomas from lung and head and neck cancer by quantitativemass spectrom-
etry Proteins were isolated from formalin-fıxed paraffın-embedded (FFPE) pa-
tient-derived genetically characterized cancer tissues by using a “fılter-aided
sample preparation (FASP)” method. The resulting proteins were analyzed by a
Super-SILAC-based mass spectrometry approach and data was analyzed using
the software suitesMaxQuant and Perseus to determine the tumor-type-specifıc
protein expression and signaling patterns. In this study we quantitatively ana-
lyzed the protein-expression-profıles of 50 primary patient-derived non-small
cell lung cancer specimens with squamous cell histology and 30 squamous cell
carcinomas from the head-neck-region derived from patients that developed
lung tumors with similar histology in the course of their disease. Using themass
spectrometric approach we were able to quantify in average around 2500 pro-
teins per sample. Unsupervised clustering- and principal component analyses
revealed that the detected protein expression patterns show a strong correlation
with the cellular origin of the analyzed carcinomas. Furthermore, secondary
lesions with similar histological morphology in the lung in patients with squa-
mous cell carcinoma of the head-neck-region could be classifıed as primary or
metastatic cancer according to their protein expression profıles. Collectively,
this study provides a large set of potential proteomic biomarkers that might be
useful to improve diagnostics in the context of lung tumors with squamous cell
histology in the future. In particular the differentiation of squamous cell carci-
noma and head and neck cancer-derived metastases in the lung - that is still a
challenge for diagnostics - will be improved by the presented biomarker panel.
Moreover, the expression of kinases and activation patterns of signaling path-
ways discovered in our study are of interest regarding potential novel lung can-
cer therapies as overexpression or hyperactivation of certain kinases can poten-
tially contribute to the malignant phenotype of lung cancer cells.
#4641 Wild type APC is an independent marker of poor prognosis in late
stage colorectal cancer. Abdul K. Siraj, Rong Bu, Shaham Beg, Tariq Masoodi,
Khawla S. Al-Kuraya. King Faisal Specialist Hospital & Res. Ctr., Riyadh, Saudi
Arabia.
Background: Colorectal cancer (CRC) is one of the commonest cancer world-
wide and ranks as the most common cancer in males and the third most com-
mon among females in Saudi Arabia. Wnt pathway alteration is well known in
colorectal cancer. In this study we aimed to comprehensively study Wnt path-
way alterations in a large cohort of Middle Eastern colorectal patients and to
know its role in this unique ethnic group. Methods: 426 CRC cases were ana-
lyzed for APC, AXIN2 and CTNNB1 somatic mutations by targeted capture
sequencing and protein expression status by immunohistochemistry in tissue
microarray format. Results were analyzed for association with any clinicopath-
ological parameters and for prognostic signifıcance. Results: The incidence of
APC, AXIN2 and CTNNB1 mutations in our patient cohort were 58.2%, 4.2%
and 3.8% respectively. APC mutation was associated with grade 2 tumors
(p0.0494) and male sex (p0.0349). AXIN2 mutation were associated with
grade 3 tumors (p0.0231), MSI-high tumors (p0.0001) and AXIN2 protein
expression loss (p0.0056). CTNNB1mutationswere associatedwithMSI-high
tumors (p0.0076). AXIN2 and CTNNB1 mutation were signifıcantly associ-
ated with each other (p0.0263). Wild type APC was associated with poor
overall survival and was an independent marker of poor prognosis in late stage
CRC (p0.0200). Conclusion: We reported the incidence of Wnt pathway al-
terations in this unique ethnic group on which such data is lacking. APCmuta-
tion plays major and other genes minor role in Wnt pathway activation. Inci-
dence of APC mutation in this group is comparatively high compared to
reported incidence worldwide. Wild type APC independently predicts poor
prognosis in Middle Eastern late stage colorectal patients.
#4642 Ionmobility separation of N-Glycans directly from ffpe colon can-
cer tissue section in a MALDI imaging experiment. Emmanuelle Claude,1
Peggi M. Angel,2 Richard R. Drake,2 Hernando Olivos,3 James I. Langridge1.
1Waters Corporation, Wilmslow, United Kingdom; 2Medical University of South
Carolina, Charleston, SC; 3Waters Corporation, Beverly, MA.
Colon cancer is currently the third most common cancer in both men and
women. Research studies have reported extensive alterations in protein glyco-
sylation patterns in cancer tissues. However during these studies, the tissues are
homogenized and the spatial information showing the localization of the glycans
is lost. Mass spectrometry imaging (MSI) is an established analytical tool for
biomolecular research which can accurately determine the spatial location of
molecules in a tissue section. Recently, methods have been developed to deter-
mine releasedN-Glycans directly from tissues. Amajor challenge in the analysis
ofN-glycans is the large number of isobaric glycans resulting from their complex
structureswith branched chains andmultiple additions residues.Herewe report
the advantage of ion mobility separation to differentiate these glycans in a
MALDI MSI workflow used in the analysis of human FFPE colon cancer tissue.
5m FFPE tissue were were deparaffınized in xylene, rehydrated in different
composition of ethanol/water solutions, transferred in citraconic anhydride
buffer for antigen retrieval and water washed. To release the glycans from their
proteins, a PNGaseF solution was sprayed on the tissue. A solution of MALDI
was sprayed onto the tissue. Experiments were carried out on a SYNAPT G2-Si
HDMS system(Waters) where the tri-wave separated ions according to their ion
mobility in the gas phase. The overall MALDI spectrum shows strong signal for
N-glycan molecules, demonstrating the effıcacy of the digestion step of the
methodology. Using prior knowledge of the type of glycans, 76 glycans were
identifıed and mapped directly from the FFPE tissue section, from a mass to
charge ratio (m/z) of 771.5 up to 2905.03 using accurate mass information.
MALDI MSI was able to distinguish the tissue morphology and determine the
tumor region based on specifıc ions, especially sodiated N-Glycans
Hex7HexNAc2 (m/z 1581.5) which was highly abundant in the tumor tissue.
When the IMS was explored using the DriftScope software, it could clearly been
observed that two nested trendlines in m/z vs. DriftTime existed. The faster
trendline corresponding to more compact conformation of the ions in the gas
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phase was identifıed to be the N-Glycan class of molecules. Using IMS the MS
data showed a clear picture of the N-Glycans compare to the MS data alone. In
several cases, the IMS peaks were broader than the expected resolution or there
were shoulder peaks, indicating that isobaric species were present. For example,
m/z 1444.6 ( Hex4dHex1HexNAc3,Na) displayed two IMS distinct peaks
whichwhile not baseline separated were suffıciently separated to obtain individ-
ual ion images which showed signifıcantly different distributions. The isobaric
species with the faster drift time was evenly distributed across the tissue type of
the section, whereas the isobaric species that had the slower drift time was less
abundant in the cancer tissue.
#4643 Plasma thioredoxin reductase 1 as a diagnostic marker for non-
small cell lung cancer. Xiaozheng Kang,1 Chaoran Dong,2 Bocun Shen,1
Wanpu Yan,1 Liang Dai,1 Yongbo Yang,1 Hanwei Yin,3 Guobing Xu,1 Huihui
Zeng,2 Ke-Neng Chen1. 1Peking University Cancer Hospital and Institute, Bei-
jing, China; 2Peking University Health Science Center, Beijing, China; 3Keaise
Center for Clinical Laboratory, Wuhan, China.
Non-invasive diagnostic markers for patients with suspicious non-small cell
lung cancer (NSCLC) may provide needed guidance on invasive diagnostic and
therapeutic decisions. Thioredoxin reductase 1 (TrxR1) is a pivotal intracellular
redox sensor and antioxidant enzyme, and plays an important part in tumor
growth, progression, metastasis, and chemotherapy resistance. The goal of this
study is to test the feasibility of developing plasma TrxR1 as a novel diagnostic
marker for NSCLC. The plasma TrxR1 activity was determined spectrophoto-
metrically bymonitoring theNADPH-dependent production of 2-nitro-5-thio-
benzoate at 412nm and at 37°C. All detection kits and automatic analyzer pos-
sess independent intellectual property rights, and have been widely used in
breast cancer screening. In this study, the plasma levels of TrxR1 weremeasured
in 45 treatment-naïve NSCLC patients and 10 individuals with benign tumor-
like pulmonary diseases. Taking plasma TrxR1 activity of 4 as reference, the
overall concordance rate was 73.3%, while those of CEA, CA199, CA125, NSE,
CYFRA21-1 and SCC were 19.0%, 7.1%, 16.7%, 35.7%, 24.4% and 2.5%, respec-
tively. Furthermore, using TNM staging (AJCC 7th ed.) as classifıer, the concor-
dance rates of TrxR1 in local, local regional and advanced stage subgroups were
66.7% (20/30), 77.8% (7/9) and 100% (4/4), respectively. A multipoint linear
fıtting correlation model was created, and the equation was TrxR1  5.821 
0.396*Stage. Besides, the concordance rates of TrxR1 in benign tumor-like pul-
monary diseases was 60% (6/10). Our data suggest that plasma TrxR1 activity is
a useful non-invasive diagnostic marker for NSCLC, and there may be a linear
correlation between TrxR1 activity and pathological stage.
#4644 A cell-line based TP53 expression pattern control panel with inter-
observer variability and next-generation sequencing analysis. Yaling Zhou,1
Sorana Raiciulescu,1 Viqar Syed,2 Patrick Malafronte,1 Justin Wells,1 Mica
Grantham,3 Michael Allgaeuer,4 Heping Gong,5 Joel Moncur,1 Deyin Xing,6
John D. Andersen1. 1Walter Reed National Military Medical Center, Bethesda,
MD; 2Uniformed Services University and Health Sciences, Bethesda, MD; 3Fort
Belvoir Community Hospital, Bethesda, MD; 4National Institutes of Health,
Bethesda, MD; 5Joint Pathology Center, Bethesda, MD; 6Johns Hopkins Univer-
sity, Baltimore, MD.
Introduction: TP53 gene mutation status is known to be manifested through
distinct p53 immunohistochemical staining patterns; diffuse, wild-type and
null. This stratifıed staining pattern is routinely utilized in subtyping ovarian
and endometrial cancer subtypes and distinguishing low- and high-grade serous
carcinoma. Experimental Procedure: Three ovarian cancer cell lines were used
in the construction of an immunohistochemical control panel slide that high-
lights each respective TP53 expression pattern. Cell lines were expanded, har-
vested and resuspended in agarose gel and subsequently sectioned onto amicro-
scope slide. Procured tissue specimens were submitted along with either
standard control tissue or the TP53 cell line control panel to pathologists of
varying experience. Next-generation sequencing analysis was performed on
cases in which there was discordance in expression pattern interpretation. Re-
sults: Interobserver variability was assessed on 44 samples between fıve raters of
varying experience. The results were similar with the use of the TP53 expression
panel (Fleiss kappa 0.6 vs 0.53). Next-generation sequencing analysis demon-
strated low-frequency variant mutations in cases in which there was reviewer
discordance. Conclusion: This study suggests the addition of a TP53 cell line
expression pattern control panel could potentially increase diagnostic accuracy
for ovarian and endometrial cancer subtypes and distinguishing ovarian low-
grade and high-grade serous carcinoma. The cell line control has refıned quality
assurance potential for antibody optimization.This cell line control panel has the
potential to be utilized in routine immunohistochemical staining with diffıcult
to interpret p53 expression patterns directed to submission for next-generation
sequencing.
#4645 A serummultiomics signature for enhancing prostate cancer diag-
nosis and prognosis. Michael A. Kiebish,1 Jennifer Cullen,2 Albert Dobi,2
Amina Ali,2 Leonardo O. Rodrigues,1 Yezhou Sun,1 Aniruddha Pawar,1 Aditee
Dalvi,1 Denise Young,2 Vivek K. Vishnudas,1 Jason Sedarsky,2 Gyorgy Petrov-
ics,2 Emily Chen,1 Viatcheslav Akmaev,1 Inger L. Rosner,2 DavidMcLeod,2 Isa-
bell A. Sesterhenn,3 Rangaprasad Sarangarajan,1 Alagarsamy Srinivasan,2 Elder
Grainger,1 Niven R. Narain,1 Shiv Srivastava2. 1BERG, LLC, Framingham, MA;
2Uniformed Services University and the Walter Reed National Military Medical
Center, Center for Prostate Disease Research, Bethesda, MD; 3Joint Pathology
Center, Silver Spring, MD.
Introduction and Objective: Diagnosis of prostate cancer (CaP) has relied on
prostate specifıc antigen (PSA) level and digital rectal examination (DRE) fol-
lowed by prostate biopsies. These modalities have the potential to yield false-
positive and false-negative results for CaP. These challenges prompted efforts to
develop more specifıc body fluid based assays including PCA3, TMPRSS2:ERG,
K4csore andPHI tests. Further, emerging data on signifıcant racial differences of
common CaP driver genes, e.g., PTEN and ERG in CaP can lead to signifıcant
limitations in biomarker performance. Thus, the goal of our study was to dis-
cover CaP serum markers with equal performance among African American
(AA) and Caucasian American (CA) men. We employed proteomics, signal-
and structural lipidomics and metabolomics platforms to discover serum bio-
markers and evaluate their utility for diagnosis and prognosis of CaP in AA and
CAmen.Methods: Sera from700 individuals were analyzed, which includedAA
and CA CaP patients stratifıed for ERG oncoprotein expression by immunohis-
tochemistry (N495). Sera from age-matched healthy control men were also
included (N205) in this study. Quantitative global profıles of lipidome, pro-
teome and metabolome were analyzed by high resolution MS-based technolo-
gies. Random forest and Interrogative Biology® analytical platformswere used to
identify analytes differentiating healthy from CaP cases including clinical-
pathologic data. Results: The unbiased global profıling and integration of the
data and clinical-pathologic features have led to the identifıcation of molecular
fıngerprints differentiating cancer patients from healthy controls. Specifıcally,
three analytes in serum metabolome showed robust separation between both
AA and CA CaP and control groups. Elevated levels of nicotinamide and ei-
cosenoic acid and decreased levels of a decanoylcarnitate alone have indicated
strong separation between cases and controls. Further inclusion of additional 9
analytes provided an optimal multi-omics panel for distinguishing the com-
bined cohort of AA andCA cases vs. healthy controls. Conclusions: The fındings
presented here support that an integratedmultiomics approach has the potential
to defıne serum marker panels for diagnosis of CaP in the context of racial
diversity andmolecular annotation (e.g., ERG) of CaP. These promising data are
undergoing validation in additional patient cohorts.
#4646 A novel truncated variant of the hematopoietic H-1 tubulin iso-
type with implications for stem cell biology. Yang Bai, Paul Basciano, Xi Li,
Jason Matakas, Silvana Di Giandomenico, Siddhartha Sen, Todd Evans, Joseph
Scandura, Monica Guzman, Paraskevi Giannakakou. Weill Cornell Medicine,
New York, NY.
The -tubulin dimer is the building block of the microtubule cytoskeleton,
which is important formany cellular functions. Several and tubulin isotypes
have been identifıed so far; H-1 tubulin (human  tubulin Class VI) is a hema-
topoietic-specifıc tubulin isotype whose expression is restricted to megakaryo-
cytes and platelets. TCGA analysis showed that -1 is highly and specifıcally
expressed in acute myeloid leukemia (AML). -1 may therefore be an attractive
target for the development of novel therapeutics for AML. We developed a
highly-specifıc polyclonal antibody against the last 8 C-terminal amino acids
and analyzed a panel of AML cell lines and primary samples by western blot.We
identifıed the presence of a novel truncated 35kD band, distinct from the canon-
ical 50kD tubulin. This 35kD band, which we have named as Acute Leukemia
Isoform 1 (ALIBI), was present in 10 of the 19 AML cell lines tested as well as
in a large number of AML clinical samples, as evidenced by immunoblotting,
and corroborated by RNA-sequencing. We determined that ALIBI was a splice
variant ofHb1 tubulin, lacking exons 1 and 2with partial retention of exon 3 and
intron 3. Mass array methylation analysis revealed differential promoter and
intragenicmethylation pattern in canonical b1 tubulin versus ALIBI, suggesting
that there is an epigenetic switch that determines the expression of each tubulin
isoform. Immunofluorescence analysis revealed that ALIBI, unlike all tubulin
isotypes, does not incorporate into microtubules but instead accumulates in the
nucleus and in distinct puncta in the cytoplasm. Exogenous expression ofALIBI,
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also resulted in a similar cellular distribution. Using a murine leukemia mouse
model we found signifıcant enrichment of ALIBI in the leukemic stem cell frac-
tion, while in normal mouse development ALIBI was present in fetal liver and
hematopoietic progenitor cells. Based on this observation, aswell as the relation-
ship between leukemic stem cells and embryonic stem cells, we probed for the
presence of ALIBI within murine embryonic stem cells (mESCs) and found
ALIBI to be present in cultured mESCs, and down-regulated upon differentia-
tion when full length b1 tubulin was expressed. Taken together, these data sug-
gest that ALIBI has an important, heretofore unrecognized, role in stem cell
biology. However, much remains unknown regarding the function of ALIBI
within the nucleus, the factors that regulate its expression over the canonical
H1 isoform, and most importantly its precise role in progenitor or stem cells.
Understanding the function and regulation of ALIBI will allow us to understand
a novel role of tubulin in stem cell biology and open multiple avenues for appli-
cation of this knowledge.
#4647 Mass spectrometric analysis of oncometabolite 2-hydroxyglutarate
in clinical gliomas with the isocitrate dehydrogenase-1 mutation.Mitsuhiro
Hayashi,1 Hiroaki Aikawa,2 Makoto Ohno,3 Koichi Ichimura,1 Yuko Matsu-
shita,1 Mayu Ohuchi,1 Mariko Mizui,1 Akihiko Yoshida,3 Yoshitaka Narita,3
Akinobu Hamada1. 1National Cancer Center Research Institute, Tokyo, Japan;
2Exploratory Oncology Research and Clinical Trial Center, National Cancer Cen-
ter, Tokyo, Japan; 3National Cancer Center Hospital, Tokyo, Japan.
Introduction:Mutations of the isocitrate dehydrogenase (IDH)-1/2 genes fre-
quently occur in certainmalignancies, including gliomas. Mutant IDH-1/2 pro-
teins gain a new ability to produce oncometabolite 2-hydroxiglutarate (2HG),
which results in a different clinical impact on gliomas in comparison to those
with a wild-type IDH. The status of IDH mutations has been determined by
immunohistochemistry (IHC) using the IDH1-R132H antibody or through the
DNA sequencing of IDH1-R132C/R132S; however, its practical applications are
still under discussion, and the signifıcance of the oncometabolite 2HG evalua-
tion is not clear. In this study, we analyzed the serum and tissue levels of 2HG in
clinical gliomas using liquid chromatography-tandem mass spectrometry (LC-
MS/MS) and thematrix assisted laser desorption and ionizationmass spectrom-
etry imaging (MALDI-MSI) system.Method: Glioma samples (n 78,matched
pairs of serum and flash frozen tissue) were obtained between October 2007 to
January 2015 at the National Cancer Center Hospital, Japan. High performance
liquid chromatography (Nexera X2, Shimadzu) and triple quadmass spectrom-
etry (QTRAP4500, AB SCIEX) were used for LC-MS/MS analysis. The two
MALDI-MSI systems, quadrupole ion trap time-to-flight mass spectrometry
imaging (iMScope, Shimadzu), and high-resolution atmospheric pressure mass
spectrometry imaging (AP-SMALDI, TransMIT; Q-Exactive, Thermo Fisher
Scientifıc) were used for analyzing the 2HG tissue distribution after coatingwith
9-aminoacridine or 2,5-dihydroxybenzoic acid. The IDH mutation was deter-
mined by direct sequencing and IHC. Results: The median 2HG concentration
in serumwas 21.43 ng/mL (range: 9.58 to 62.51) in this study, and no signifıcant
correlation was observed between the IDH mutation and the wild type status
(mutation, n 28, median 20.2 ng/mL, range 9.58 to 62.51 vs. wild type, n 50,
median 22.88 ng/mL, range 11.51 to 40.32; Wilcoxon test p  0.1597). The
median of the 2HG tissue concentration in the entire group was 0.16 ng/g, and
a signifıcant difference was seen between the IDHmutant and wild type groups
(mutation, median 4.86 ng/g, range 0.51 to 49.86 vs. wild type, median 0.09
ng/g, range 0.02 to 0.45; Wilcoxon test p  0.0001). In the MALDI-MSI
analysis, the average 2HG ion intensities were 381.62/mm2 in the IDHmutation
and 8.25/mm2 in the wild-type IDH tissues (Wilcoxon test p  0.016), which
showed a positive correlation with the 2HG tissue concentration by LC-MSMS
analyses (Spearman   0.87, p  0.0003). The MSI results indicate a possible
link between the 2HG tissue distributions and the histology of IDH mutant
sections. Conclusion: Tissue 2HGmeasurement usingmass spectrometric anal-
ysesmay be a useful alternative in determining IDHmutations. Further research
may provide a biological perspective and help gain some insights on the clinical
signifıcance of 2HG.
#4648 Development of a rapid, precise, and sensitive molecular assay for
ALK fusion detection. Mona D. Shahbazian, Yulei Shang, Maidar Jamba, Mi-
chael J. Powell. DiaCarta, Richmond, CA.
Introduction: In non-small cell lung cancer (NSCLC), chromosomal translo-
cation events that result in overactivation of the anaplastic lymphoma kinase
(ALK) have been identifıed and shown to play a key role in tumorigenesis.
Inhibitors of the ALK kinase, such as the FDA-approved crizotinib, are effective
in treating ALK-fusion-positive non-small cell lung cancer. Molecular studies
have identifıedmanyALK fusion variants in various cancer types, encompassing
a combination of 22 different gene partners as well as various break points
within the partner genes. Themost common fusion events in non-small cell lung
cancer are between the echinoderm microtubule associated protein like 4
(EML4) gene and the ALK gene. Fusion events between the Kinesin Family
Member 5B (KIF5B) gene andALK have also been identifıed. Existing assays for
ALK fusion detection include the time-consuming, costly, and challenging flu-
orescence in situ hybridization (FISH) method, which is the current gold stan-
dard. Next generation sequencing approaches are also available, which are also
costly to implement, diffıcult to interpret, and have lengthy workflows. Reverse-
transcriptase PCR methods are ideal, as they are cost-effective, sensitive, rapid,
and require little interpretation expertise. Methodology: We designed a multi-
plexed real-time RT-PCR method to enable indiscriminate detection of ten
EML4-ALK and three KIF5B-ALK fusion variants (encompassing approxi-
mately 95% of EML4-ALK and 90% of KIF5B-ALK characterized fusion vari-
ants, based on the Catalogue of Somatic Mutations in Cancer (COSMIC) data-
base). The assay uses standard real-time PCR instrumentation and was
characterized using the Bio-Rad CFX384™, Roche LightCycler® 96, and Roche
LightCycler® 480 II instruments. Assay preparation and run time requires 2
hours or less. Sensitivity testing showed that for the Roche LightCycler® 480 II
and Bio-Rad CFX384™, 100% detection was achieved for 50 copies of fusion
template for each of the 13 targeted variants. The Roche LightCycler® 96 showed
slightly poorer sensitivity, with 100%detection observed at 50 copies for 9 fusion
variants and 100 copies for the remaining four variants. Inter- and intra-run
precision testing demonstrated good reproducibility and repeatability, with a
coeffıcient of variation of less than 10% for all targeted fusion variants. Using
ALK-positive and ALK-negative FFPE reference materials, it was demonstrated
that 50 ng of total FFPE RNA was suffıcient and up to approximately 200 ng
showed good performance. Conclusion In summary, we have developed a rapid,
precise, and sensitive assay for the detection of thirteen EML4-ALK and KIF5B-
ALK fusion events to enable molecular characterization of non-small cell lung
cancer tumors.
#4649 Development of an ethnicity informed gene expression panel with
potential to improve prostate cancer diagnosis. Indu Kohaar,1 Lakshmi Ra-
vindranath,1 Sreedatta Banerjee,1 Yongmei Chen,1 Amina Ali,1 Yingjie Song,1
Jacob Kagan,2 Sudhir Srivastava,2 Albert Dobi,1 David McLeod,1 Inger L. Ros-
ner,3 Shiv Srivastava,1 Gyorgy Petrovics1. 1CPDR/USUHS, Rockville, MD; 2NCI/
NIH, Bethesda, MD; 3WRNMMC/USUHS, Bethesda, MD.
Introduction and Objectives: Prostate cancer (CaP) affects 1 in 7 men
throughout their life time. One of the major risk factors for the development of
CaP is race/ethnicity. African American (AA) men have signifıcantly higher
incidence andmortality fromCaP compared to CaucasianAmerican (CA)men.
Emerging data including ours have described signifıcantly lower frequencies of
alterations in the common CaP driver genes (ERG and PTEN) in AA men as
compared to CAmen. We have also noted that genes commonly overexpressed
in CaP (ERG, AMACR and PCA3), and currently used as diagnostic markers,
exhibit much lower frequency and more heterogeneity in AA men. The goal of
this studywas to defıne a broaderCaPmarker panel that is overexpressed equally
well in AA and CA CaP. Methods: Three platforms (RNASeq, NanoString and
QRT-PCR) were used for evaluation of CaP associated gene expression in CA
and AA patients (N144). Candidate genes with robust tumor overexpression
(over 4-fold) in CaP in comparison of paired normal and tumor specimens from
AA and CA patients were selected from the Nanostring and RNASeq data for
validation by QRT-PCR (TaqMan) in laser microdissected (LCM) tumor and
benign cells of frozen tissue sections (50CAand 35AA).An assay protocol (gene
specifıc pooled RT and pre-amplifıcation followed by TaqMan PCR) was set up
for the noninvasive early detection of candidate genes in regular patient urine
(non-DRE) using RNA derived from urinary exosomes. Results: As expected
tumor transcriptomes of CA patients revealed consistently elevated expression
of PCA3 and AMACR genes. However, these genes had variable overexpression
in AA cohort. The top genes that were similarly over expressed in tumors of AA
and CA patients were validated by real time QRT-PCR (TaqMan) analysis in
LCM dissected tumor and normal epithelial cells (N85). At least one gene of a
six gene signature (DLX1, HOXC4, NKX2-3, COL10A1, HOXC6 and PSGR)
was overexpressed in tumor cells of all AA and CA cases, providing a consistent
ethnicity informed tumor expression signature, which was further validated in
silico in TCGA RNASeq data. Urinary exosome based assay was developed and
optimized for PSGR, DLX1, HOXC4, NKX2-3, as well as PCA3 and ERG. Sen-
sitivity and specifıcity with optimal cutoff for the urine marker panel was 71%
and 61% respectively (N40). Evaluation of the assay performance in CA and
AA patients in a prospective independent cohort of 100 patients addressing race
specifıc performance is in progress. Conclusions: A CaP tissue based gene ex-
pressionmarker panel has been defınedwith potential diagnostic utility for both
CA and AA men in the context of urinary exosomes.
CLINICAL RESEARCH: Diagnostic Biomarkers
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171188
#4650 Mutation detection by target sequence analyses using tissue-spe-
cifıc panels in esophageal squamous cell carcinoma.Takeshi Iwaya,1 Fumitaka
Endo,1 Kohei Kume,1 Yasushi Sasaki,2 Takashi Tokino,2 Satoshi Nishizuka1.
1Iwate Medical Univ. School of Medicine, Morioka, Japan; 2Research Institute for
Frontier Medicine, Sapporo Medical University, Sapporo, Japan.
Whole-exome sequencing (WES) studies on esophageal squamous cell carci-
noma (ESCC) have revealed that only a small number of frequently mutated
genes, such as TP53, NOTCH1, NRF2, and ZNF750, are present in individual
tumors, whereas hundreds of others less frequently mutated genes are accumu-
lated. The mutation detection rate by target sequence analyses is an important
factor for clinical sequence in the course of ESCC treatment. This study aimed to
evaluate the mutation detection rates of several target sequence analyses for
ESCC. Ten pairs of surgically or endoscopically acquired tumor tissues and
corresponding peripheral blood mononuclear cells were obtained from ESCC
patients.Weused three types of target sequence panels formutation screening in
10 ESCC patients as follows: 1) Cancer Hotspot Panel (CHPv2), targeting mu-
tation hotspot regions in the most common 50 human cancer genes that are
frequently mutated (panel size: 22,027 bp), for fıve patients; 2) TP53 Panel,
covering all exons of TP53 (panel size: 2,359 bp), for fıve patients; and 3) ESCC
Panel, originally designed to target 31 frequently mutated genes in ESCC (panel
size: 210,570 bp), for seven patients. Fourmissense and two nonsensemutations
in TP53 were detected in CHPv2 and the TP53 Panel. Furthermore, one mis-
sensemutation in FBXW7 and one intronicmutation in the vicinity of exon 8 in
TP53 were also observed in CHPv2 and the TP53 Panel, respectively. In the
ESCC Panel, 47 mutations in 17 genes were detected in seven patients. The
mutation detection rates by the TP53 Panel, CHPv2, and ESCC Panel were
593.0/Mb, 63.5/Mb, and 30.4/Mb, respectively. These mutation detection rates
were more than 20-fold higher than that ofWES, which has been reported to be
3.1/Mb for ESCC. These results suggest that tissue-specifıc cancer-related gene
panels are a highly effective approach for mutation detection in ESCC.
#4651 Multiple platform evaluation of KRAS codon 12/13 reference ma-
terial.Russell Garlick, Yves Konigshofer, Farol L. Tomson, Dale Yuzuki, Bhara-
thi Anekella. SeraCare, Gaithersburg, MD.
An assay’s ability to detect the presence of a KRAS driver mutation is critical
when attempting to determine whether a tumor may respond to anti-EGFR
therapy. Currently, there are two FDA approved companion diagnostics that
can be used to assess whether there are mutations in KRAS codons 12 and 13,
and both include their own internal controls. However, there is a need for ex-
ternal reference materials that allow laboratories to validate such assays - espe-
cially, at levels near their limits of detection (LODs). We describe the design of
the Seraseq™ FFPE Tumor KRAS Reference Material. This reference material is
composed of 7 different 5-micron FFPE curls that contain the 7 different KRAS
mutations detected by the companion diagnostics: G12A, G12C, G12D, G12R,
G12S, G12V and G13D. Each curl contains a mixture of KRAS wildtype
GM24385 cells and a KRAS mutant cell line in suffıcient quantity for most
assays. KRAS mutant frequencies of about 5% were targeted and subsequently
verifıed by digital PCR. A 5% mutant frequency was selected because it is near
the LOD for the existing companion diagnostics, and is close to the minimum
reported frequency of many next generation sequencing (NGS)-based assays
that test for somatic variants. The reference material was evaluated using differ-
entmethods, which include digital PCR, the Roche cobas® KRASMutation Test,
the QIAGEN therascreen® KRAS RGQ PCR Kit and several NGS-based assays.
Testing revealed general compatibility with these assays in that suffıcient DNA
could be extracted, and concordance of the results with the expected calls was
high. For example, apparent DNA yields by Nanodrop with the cobas assay
exceeded the required amount by more than 3-fold and all 7 curls led to a
“mutation detected” result in duplicate testing. Interestingly, not all variants
were detected with the therascreen assay, which may be due to some variants
being present at slightly below the claimed LODs, however DNA yields were
suffıcient and the correct variants were identifıed. Finally, variant frequencies
obtained by NGS were consistent with those observed by digital PCR. We con-
clude that the Seraseq FFPE Tumor KRAS Reference Material may be useful as
part of KRAS codon 12/13 assay validation.
#4652 Profıling of immunity biomarkers in whole blood. Alex Chenchik,
Andrei Komarov, Michael Makhanov, Costa Frangou. Cellecta, Inc., Mountain
View, CA.
Cancer immunotherapies are rapidly changing traditional treatment para-
digms and expanding the therapeutic landscape for cancer patients. However,
despite the current success of these therapies, signifıcant number of patients do
not respond to immunotherapy and responders often experience signifıcant
toxicities. Therefore, there is a growing need to identify predictive and prognos-
tic biomarkers that enhance our understanding of dynamic immunity mecha-
nisms involved in cancer development. The genome-wide expression profıling
of whole blood is an attractive method for the discovery of biomarkers due to its
non-invasiveness, possibility for retrospective simple clinical site processing,
and rich biological content. To this end, we have developedGeneNet, a genome-
wide targeted RNA expression assay that profıles 19,000 genes based on multi-
plex RT-PCR followed by NGS in whole blood samples stabilized in PAXgene.
The GeneNet 19K assay provides comprehensive and unbiased profıling of im-
mune cell activation and canonical immune pathway genes for both innate
adaptive and humoral immune responses. In this study, we present the perfor-
mance of the assay for immunophenotyping of immune cells in blood samples
from TNBC patients and assess the immune responses to complex immuno-
modulatory stimuli in ex vivo model system. Preliminary studies demonstrate
the assay’s unparalleled specifıcity and sensitivity resulting in better detection of
low abundance mRNA transcripts as well as an improved cost-effectiveness for
high-throughput clinical applications.
#4653 Genomics of regulatory crosstalk between PPAR gamma & 14-3-3
genes in breast cancer cells. Ashraf A. Khalil,1 Nihal F. Kabapy,1 Fouad N.
Sharabi2. 1City of Scientifıc Research, Alexandria, Egypt; 2Alexandria University,
Alexandria, Egypt.
PPAR, a ligand-stimulated transcription factor with differentiation promot-
ing activity is overexpressed in a variety of cancers. Perturbation of PPAR-
signaling is nowbelieved to be a strategy for treatment of several cancers, includ-
ing breast cancer. A set of genes regulated by PPAR- ligands is expected to
mediate the antiproliferative and prodifferentiation effects in cancer cells. Be-
cause 14-3-3 family of proteins shows a debatable activity and varying expres-
sion levels in different tumors, in the studies presented here we explored the
transcriptional regulatory role of Pioglitazone on the seven 14-3-3 isoforms
presenting in MCF-7 breast cancer cells. This study demonstrated that the po-
tent PPAR- agonist, Pioglitazone exerted a regulatory role on expression of
14-3-3 genes where it upregulated 14-3-3 gamma, epsilon, zeta and tau by 3.8,
5.2, 2.7 and 739 folds, respectively. However, it had a negative regulatory effect
on 14-3-3 beta, sigma and Eta by 16.94, 4.58 and 2.12 folds, respectively com-
pared with control cells. These results correlated with growth arrest and a great
increase in BRCA1 gene expression by 1076 folds. In summary, these fındings
are the fırst time showing that PPAR- regulates 14-3-3 genes and raises ques-
tion whether PPAR- ligands mediate their anticancer effects via regulation of
14-3-3 proteins. Selected References: 1. Bridges, D. and G.B. Moorhead. 2005.
14-3-3 proteins: a number of functions for a numbered protein. Sci. STKE
2005(296):re10. 2. Chearwae, W. and J. Bright. 2008. PPAR agonists inhibit
growth and expansion of CD133; brain tumour stem cells. Brit. J. Cancer
99(12): 2044-2053
#4654 The primary study of the correlation between mRNA expression
and protein phosphorylation of epidermal growth factor receptor EGFR in
colorectal and breast cancer cell lines. Hongwei Wang, Catherine Ma, Yuan
Zhou. AbboMax, Inc., San Jose, CA.
The EGFR family is a group of receptor tyrosine kinases that mediates cell
proliferation, migration, and differentiation. Activation of EGFR signaling is
triggered by ligand-binding induced receptor dimerization. The dimerization
activates the intracellular kinase domains of the receptor, resulting in autophos-
phorylation of C-terminal tail and the initiation of downstream signaling. EGFR
overexpression is correlated with more aggressive clinical indications in multi-
ple types of cancer, including colon, breast, lung, and head and neck carcinoma.
Clinical studies show that EGFR-directed therapeutic approaches improved bet-
ter outcomes of metastatic lung, colorectal, and head and neck cancers. Predic-
tive biomarkers are being developed to deliver personalized therapies. There-
fore, it is important to determine the protein as well as molecular biomarker
expression for selecting targeted therapies. Here we present a panel cancer cell
lines to examine EGFR expressions at a molecular biomarker level (mRNA) as
well as a protein level of phosphorylated EGFR(pS1060). Colon cancer cell lines
HT29, HCT116, SW620, as well as the breast cancer cell line SKBR3, were cul-
tured and processed onto formalin-fıxed paraffın-embedded (FFPE) CellMax
pellets. Expression levels of EGFRmRNA in the FFPE slideswere examinedwith
RNAScope technology to visualize single RNA molecules per cell by using
probes specifıcally against EGFR. Expression of phosphorylated EGFR was ex-
amined by the phosphospecifıc EGFR (pS1070) antibodies by using immuno-
histochemistry (IHC). EGFRmRNA expressionwas detected inHT29 andHCT
116 cells showing strong punctuated signals in the cytoplasm. However, no
EGFR mRNA signals were detected in SW620 cells. Breast cancer cell line
SKBR3 showed abundant EGFRmRNAexpression. Phosphorylated EGFRwere
found in the cell HT29, HCT 116 and SKBR3 cells with membrane staining
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pattern. No phosphorylated EGFRwas observed in SW620 cells using Immuno-
chemistry staining. Together, our results demonstrated that the EGFR mRNA
expression is correlated to the phosphorylation of EGFR in these cancer cell
lines. We concluded that the EGFR mRNA probes, phosphorylated EGFR anti-
bodies, and/or the cell lines can be served as the control-references for clinical
biomarker screening.
#4655 Elevated level of serummiR-99a is correlated with serous epithelial
ovarian cancer and can be a potential biomarker.AkihikoYoshimura, Kenjiro
Sawada, Koji Nakamura, Yasuto Kinose, Erika Nakatsuka, Seiji Mabuchi, Ta-
dashi Kimura. Osaka Univ. Hospital, Suita, Osaka, Japan.
Objective: There is a critical need for improved diagnostic markers to detect
ovarian high grade serous cancer (HGSC).microRNAs (miRNAs) stably exist in
circulating blood, reflecting tissue or organ conditions and present in circulating
microvesicles such as exosomes.We aimed to identify whichmiRNAs are highly
produced from HGSCs and analyze whether serum miRNA can discriminate
patients with HGSC from healthy controls. Methods: Secreted exosomes from
ovarian cancer cell lines were collected and exosomal miRNAs extracted.
miRNA microarray was performed and several elevated miRNAs specifıc to
ovarian cancer cells were picked up. Among these, we focused onmiR-99a. Sera
were collected from 15 patients with HGSC (stage III and IV) and 10 healthy
controls. Expression level of miR-99a was determined by miRNA RT-qPCR.
Results: miRNA microarray revealed several miRNAs were highly expressed in
exosomes in patients with HGSC. In patients, serummiR-99a levels were signif-
icantly increased (4.8 fold) compared with those of healthy controls. ROC anal-
ysis showed that at the cut-off of 1.4, the sensitivity and specifıcity were 73% and
80 % respectively for detecting HGSC (AUC  0.85). Conclusion: Exosomal
miRNAs can be detected in sera of patients withHGSC and have the potential to
predict ovarian cancer.
#4656 Assessment of BCL-2, BCL-xL and MCL-1 in bone marrow biopsy
samples using VENTANA BenchMark XT automated slide stainer. Ashley
Streator, Eneida C. Villanueva, Burton F. Holmes, Liping Zhang.Roche, Tucson,
AZ.
Immunophenotyping is essential for diagnosis and classifıcation of most he-
matopoieticmalignancies, and often followed by ancillary studies to understand
the predictive and prognostic value of biomarkers. Immunohistochemistry
(IHC) provides in-situ coupling of antigen expression with morphology of pre-
cursor B- fromprecursor T-lymphoblastic leukemia/lymphoma. The number of
different IHC antibodies that can be applied to bone marrow (BM) biopsies is
increasing concurrently with development of flow cytometry and molecular
diagnosticmethods. IHCdetects scattered tumor cells inHodgkin’s Lymphoma,
MultipleMyeloma (MM) and AcuteMyelogenous Leukemia (AML), where key
biomarkers may not be detectable by current flow cytometry methods. The goal
of this study was to detect BCL-2, Bcl-xL and MCL-1 that are able to predict
pre-clinical sensitivity to the drug Venetoclax. We examined the expression of
these biomarkers inMMbone samples decalcifıed using commercially available
reagents to determine whether decalcifıcation methods impact BCL-2 family
IHC Staining. Results:MMbone samples (n59) decalcifıed inDecal STAT® for
20 min, stained for BCL-2 (124) and Bcl-xL (54H6). MM bone samples (n7)
decalcifıed in Decal STAT® for 60 min stained for BCL-2 and Bcl-xL. Finally,
eleven MM bone samples decalcifıed in Richard Allan Decal Solution® stained
for BCL-2 and Bcl-xL.MCL-1 stained poorly with commercially available decal-
cifıcation solutions. For MCL-1 to be used, additional staining optimization is
required. Conclusion: BCL-2 and BCL-xL proteins can be detected inMMbone
samples decalcifıed with commercially available solutions. With these prelimi-
nary results, future studies will pursue the potential for sensitivity to ‘Venetoclax
(ABT-199/GDC-0199)‘.
#4657 LOX and ZFPM2 as novel diagnostic biomarkers for malignant
pleural mesothelioma. Minkyu Kim, Hyun-Won Kim, Soon-Hee Jung, Sung
Soo Oh, Yangsik Jeong, Jong-Whan Choi. Yonsei University Wonju College of
Medicine, Wonju, Republic of Korea.
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer being
developed on outlayer of lung tissues and caused by mostly occupational expo-
sure to asbestos. Poor prognosis needs to develop therapeutic drug as well as
early diagnostic biomarker. Currently, mesothelin (MSLN), osteopontin
(OPN), and fıbulin 3 (FBLN3) have been reported as potential diagnostic bio-
markers for MPM. In this study, we fırst performed bioinformatics analysis for
public database to fınd diagnostic biomarkers forMPM. From the analysis using
Cancer Cell Line Encyclopedia (CCLE) and Gene Expression Omnibus (GEO)
databases, included were 7 genes involving LOX, LOXL1, LOXL2, ZFPM2,
THBS2, SULF1, CDH11 identifıed as potential diagnostic biomarkers. These
genes showed a similar diagnostic ability to FBLN3orMSLNasMPMbiomarker
candidates. Further molecular approach using quantitative real-time polymer-
ase chain reaction (QPCR) confırmed the higher mRNA expression of these
candidates in MPM cell lines and patient samples. Moreover, two particular
genes, LOX and ZFPM, showed MPM specifıc patterns of mRNA expression
that were further confırmed in protein level by western blot assay. Together with
biological approach, biostatistical analysis of receiver operating characteristic
(ROC) analysis using the GEO database revealed signifıcantly higher diagnostic
potential of LOX and ZFPM2 genes compared to the FBLN3, one of the best
diagnostic biomarkers currently reported. From this study, we believe these
genes togetherwith FBLN3 andMSLNwould becomenovel potential biomarker
candidates for MPM diagnosis.
#4658 Inflammatory based diagnostic markers of lung cancer in African
Americans.Claire L.Meaney,1 KhadijahA.Mitchell,1 Adriana Zingone,1 Derek
Brown,1 Wei Tang,1 Yunkai Yu,1 Liang Cao,1 Angela S. Wenzlaff,2 Ann G.
Schwartz,2 Brid M. Ryan1. 1National Cancer Institute, Bethesda, MD; 2Wayne
State University, Detroit, MI.
African Americans have a higher risk of developing lung cancer compared
with all other ethnic groups in the USA. Previous studies based on a small panel
ofmarkers suggested that certain circulating cytokineswere associatedwith lung
cancer. Given the complexity of the immune response in lung cancer and the
multitude of cell types involved, we reasoned that examining a broad panel of
inflammatory markers—including cytokines, chemokines, angiogenic and
other pro-inflammatory factors—might identify a diagnostic signature of lung
cancer for African American patients. Differences in 30 inflammatory marker
serum levels were measured in 316 African-American cases and 508 African
American controls from the National Cancer Institute-Maryland (NCI-MD)
case-control study using aMesoscale (MSD)multiplex platform. The panel of 30
serum inflammatorymarkers included chemokines, cytokines and other inflam-
matory related proteins. Logistic regression analyses were conducted to investi-
gate the association between levels of inflammatorymarker expression and lung
cancer risk. Expression levels above the median threshold defıned within the
control samples were considered high. Statistical models were also adjusted for
potential confounding factors such as age, gender, pack-years and smoking sta-
tus. Nineteen inflammatory markers (CRP, IFN-ϒ, IL-10, IL-15, IL-17A, IL-1,
IL-1, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-4, MIP-1, TARC, TNF-,
TNF- and VEGF) were signifıcantly different among African American cases
compared with African American controls (P0.05). In agreement with our
previous observations, levels of IL-10, IL-1, IL-6, IL-8, and TNF- were asso-
ciated with lung cancer risk. In addition, we found that CRP, IFN-ϒ, IL-15, IL-7,
IP-10, MCP-4, MIP-1 , TARC, TNF- and VEGF were associated with lung
cancer in African Americans. The associations between CRP, IFN-ϒ, IL-10,
IL-15, IL-1, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-4, MDC, MIP-1, TNF- and
TNF- levels and lung cancer among African Americans was signifıcant after
adjustment for additional potential confounding factors. Serum cytokine levels
vary by race and might contribute to lung cancer differently in African Ameri-
cans and European Americans. The fındings presented here build upon recent
work that identifıed associations between elevated levels of IL-10, IL-1, IL-6,
IL-8, TNF- and lung cancer specifıcally among African Americans. By analyz-
ing a broader spectrumof inflammatorymeasures, we have identifıed additional
markers of lung cancer for African American patients. Further to this, we have
integrated GWAS andMSD data for 137 cases and 203 controls that allows us to
examine the genetic basis to the relationship between risk of lung cancer and
modulated inflammatory marker expression. Markers identifıed here as signif-
icant for lung cancer risk will be further analyzed using case-control samples
from an independent African American validation cohort.
#4659 Detection of autoantibodies against tumor-associated antigens
(TAAs) improving immunodiagnosis in human osteosarcoma by serological
proteome analysis. Jitian Li,1 Manyu Huang,2 Manli Luo,2 Liping Dai,1 Wen
Xie,2 Xiaofei Qin,2 Zongchang Han,2 Wuyin Li,2 Jianying Zhang1. 1The Univer-
sity of Texas at El Paso, El Paso, TX; 2Henan Luoyang Orthopedic-Traumatologi-
cal Hospital, Luoyang Institute of Orthopedic and Traumatology, Luoyang,
China.
Osteosarcoma (OS) is the most common malignant primary solid bone-tu-
mor. Despite its relatively low incidence rate among overall cancers, it remains
one of the most harmful primary malignant tumors in childhood and adoles-
cence. Thus, a critical need in the diagnosis and management of OS is to deter-
mine an optimal combination of clinical biomarkers that could detect tumors
early with high specifıcity/sensitivity and with limited invasiveness. The objec-
tive of this study is to identify and characterize the targeted tumor-associated
antigens (TAAs) as biomarkers inOS by serological proteome analysis (SERPA)
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approach, and further to analyze the frequency and specifıcity of anti-TAA an-
tibodies in OS patients. In this initial study, autoantibodies to 29 TAAs were
detected by ELISA and Western blotting in 90 sera from patients with OS, Os-
teochondroma (OC), and age matched normal individuals. Only 8 protein an-
tigens includingDSF70, HMGB1, HCC1, RalA, c-myc, AnnexinA1, IMP1, PBP,
can induce signifıcantly higher antibody responses in OS patients compared to
normal individuals, achieving the highest sensitivity and specifıcity, 66% and
95%, respectively. The cumulative positive rate of autoantibodies against these
eight selected TAAs in OS reached 70.7% with an observed AUC of 0.972 (95%
CI: 0.867-0.988), signifıcantly higher than that in normal control sera. Positive
results were also confırmed byWestern blotting. These preliminary data exten-
sively evidence that not all proteins identifıed in cancer can be used as TAA
biomarkers in OS, and only some of these proteins can induce immune re-
sponses, which could be potential TAAs in OS immunodiagnosis or prognosis,
and further studies of novel targeted proteins in OS are currently in progress by
SERPA approach. In addition, it supports the hypothesis that a customized TAA
array can be used for enhancing anti-TAA antibodies detection, and it may
constitute a promising and powerful tool for immunodiagnosis of OS.
#4660 HPRT as a biomarker for tumor classifıcation and its variability of
expression in breast cancer.Michelle H. Townsend, Abigail M. Felsted, Jacob
Clarke, Richard A. Robison, Kim L. O’Neill. Brigham Young University, Provo,
UT.
The purpose of this study is to investigate the differential expression of HRPT
between various breast cancer tissues in comparison to healthy breast tissue in
order to evaluate its potential use as a diagnostic tool. Breast cancer is the most
common malignancy diagnosed in women and remains incurable in the meta-
static setting requiring accurate and reliable tools for early diagnosis. We ana-
lyzedHPRT, a purine salvage pathway enzyme responsible for synthesizing 90%
of the available GMP and IMP in cellular maintenance. Due to its critical role in
maintaining necessary nucleotides for cell proliferation, we hypothesized an
increase in the expression of HPRT in cancer. Tissues from 48 patients with
breast carcinoma were stained using standard immunohistochemistry (IHC)
techniques. We examined infıltrating ductal carcinoma, margin of carcinoma,
hyperplasia, atypical hyperplasia, adenosis, collagen fıbers tissues, and normal
breast tissue in order to determine expression between various breast cancers.
Briefly, tissues were treated with a polyclonal anti-HPRT antibody along with a
GADPH positive control and a universal negative control. Tissues were incu-
bated with an HRP-polymer conjugated antibody, and DAP substrate which
reacts to antibody-antigen binding sites and results in a color change. Adenosis
and hyperplasia are benign breast conditions and are early signs of breast carci-
noma development. Hyperplasia tissues, which are in a state of rapid prolifera-
tion, showed signifıcant upregulation of HPRT and adenosis tissues showed
approximately 42%upregulation. ThisHPRTupregulation in pre-stage 1 tissues
indicates that it may be used as a biomarker to detect early stages of breast
cancer. Expression of HPRT was also found to be upregulated in 65% of infıl-
trating duct carcinoma showing high expression in active malignant areas. In
marginal tissue located on the perimeter of primary tumors only 31% of tissues
show upregulation of the protein. Because the levels of HPRT inmarginal tissue
is signifıcantly lower than those found in primary tumors, HPRTmay serve as a
useful diagnostic tool when evaluating successful tumor removal. These data
suggests HPRT as a useful diagnostic tool when identifying tissue with a high
proliferation rate indicative of potential cancer development. Additionally,
HPRTmay also be used as a tool for pathologists to evaluate the success of tumor
removal.
#4661 Omentin as an adjunct to CA-125 in detecting recurrent ovarian
cancer. Kelsey Lewis, Chi Lam Au Yeung, Samuel Mok, Karen Lu.University of
Texas MD Anderson Cancer Center, Houston, TX.
Omentin (Intestinal Lactoferrin Receptor ITLN1) is an adipokine that is
mainly secreted by the mesothelial cells lining visceral adipose tissues. It has
been shown in previous studies that ovarian cancer cells down-regulate omentin
which allows increased proclivity to spread to the omentum. Levels of serum
omentin are decreased in patients with high-grade serous ovarian cancer (HG-
SOC) compared with patients with benign gynecologic diseases. Moreover, sur-
vival correlation studies showed that patients with lower serum omentin level at
the time of fırst treatment experienced signifıcantly shorter survival times than
those with higher levels of omentin. CA-125 is currently the only biomarker
used to monitor progression and re-occurrence of ovarian cancer. To our best
knowledge, the relationship between omentin and CA-125 has not been inves-
tigated previously. We hypothesize that omentin may be a clinically useful ad-
junct to CA-125 in detecting recurrent ovarian cancer. 92 serum samples were
collected prospectively from 27 HGSOC patients during the postoperative pe-
riod until recurrence was detected. Patients had an average of 3.37 follow up
visits and CA-125 levels were concurrently established. Recurrence was deter-
mined by imaging or an increase from baseline in CA-125 level. Samples were
stored frozen at -80 degrees Celsius until use for this study. Circulating omentin
levels were quantifıed using commercially available enzyme-linked immunosor-
bent assay (ELISA) kits. The results showed that 24 patients experienced a rise in
CA-125 level during the postoperative period and 12 of these patients had an
associated decrease in serum omentin level (average 127.8 ng/mL). A signif-
icant negative correlation between omentin and CA-125 levels was observed
(p 0.02). This study provides the fırst evidence that omentinmaybe a clinically
useful adjunct to CA-125 in detecting recurrent ovarian cancer and warrants
further investigation.
#4662 Expression of PLAG1 in salivary duct carcinomas: its effıcacy of the
distinction of carcinoma ex pleomorphic adenoma type and de novo type.
Takayoshi Suzuki, Satoshi Kano, Kanako Hatanaka, Yutaka Hatanaka, Tomo-
hiro Sakashita, Takatsugu Mizumachi, Hiromitsu Hatakeyama, Akihiro
Homma, Yoshihiro Matsuno, Satoshi Fukuda. Hokkaido University, Sapporo,
Hokkaido, Japan.
Salivary gland duct carcinoma (SDC) is one of the high-grade salivary gland
carcinoma, classifıed into two patterns; i) carcinoma ex pleomorphic adenoma
(Ca-ex-PA) type, which is derived from benign pleomorphic adenoma (PA), ii)
de novo type,which is generated fromnormal salivary gland tissue.According to
current WHO classifıcation, Ca-ex-PA is diagnosed when pathological exami-
nation proves as follows, a) themixture of the component of cancer cells and that
of pre-existing PA cells, b) the existence of malignant cells after the resection of
PA. However, current criteria cannot entirely be accurate from the viewpoint of
disease onset. For example, i) if a benign component of PA is replaced com-
pletely by Ca-ex-PA, the Ca-ex-PA type can be misdiagnosed as de novo type
because histopathological examination cannot clarify the existence of PA in its
surgery specimen. Moreover, ii) if a de novo type SDC, arising from normal
salivary tissue, is growing and infıltrate to the preexisting PA, the de novo type
can be misdiagnosed as Ca-ex-PA type. Recently, Pleomorphic adenoma gene 1
(PLAG1) has been identifıed as the gene associated with tumorigenesis of PA.
Subsequently, the overexpression of PLAG1 protein has been reported to be
observed in both PAs and Ca-ex-PAs and useful for diagnosis of them. Thus, we
considered that PLAG1 immunohistochemistry can enable us to distinguish
Ca-ex-PA type anddenovo type in SDCsmore defınitively. In this study, 23 SDC
patients who underwent primary surgery for cancer at our institution were en-
rolled, including 14 Ca-ex-PA types and 9 de novo types. In each case, we had its
formalin-fıxed-paraffın-embedded tissue sample stained for PLAG1-antibodies
(clone 3B7, Mouse mAb, 1:100, Abnova) and evaluated PLAG1 protein expres-
sion in the component of glandular-epithelial component and that of non-glan-
dular-epithelial, respectively. PLAG1 immunostaining was scored as positive
when the more than 10% nuclear staining of tumor cells are observed. In all 23
SDCs, there was no PLAG1 protein overexpression in glandular-epithelial com-
ponent, irrespective of benign or malignant. In all 14 Ca-ex-PA types, positive
fındings of PLAG1 overexpression were observed in non-glandular-epithelial
component. In all 9 de novo types, no non-glandular-epithelial component
showed any signs of PLAG1 protein overexpression. There was no discrepancy
of conventional criteria and the status of PLAG1, which are the cases; i) Ca-
ex-PA which is misdiagnosed as de novo type, ii) de novo type which is misdi-
agnosed as Ca-ex-PA type. Conclusions : There is no difference between con-
ventional criteria and PLAG1-based criteria in our cases. However, in the cases
with obscure characteristics of PA morphologically, such as mucoid/myxoid or
cartilaginous-like materials, fındings of PLAG1-positive cells can help us to dis-
tinguish Ca-ex-PA type from de novo type more defınitively.
#4663 Exploratory serum biomarker analysis in gastric cancer patients
treated with GS-5745, an MMP9 Inhibitor, in combination with mFOL-
FOX6. Marianna Zavodovskaya, Yafeng Zhang, Yuanyuan Xiao, Julie Maltz-
man, Victoria Smith, Carrie Baker Brachmann, Scott D. Patterson. Gilead Sci-
ences Inc., Foster City, CA.
In the tumormicroenvironment,matrixmetalloproteinase 9 (MMP9) cleaves
and activates substrates such as VEGF, IL8 and TGF that promote tumor
growth through angiogenesis and immune suppression. Data from preclinical
models supports the hypothesis that inhibition of MMP9 reduces local immune
suppression, resulting in increased anti-tumor immunity. GS-5745 is a mono-
clonal antibody in clinical development that is a selective inhibitor of MMP9.
The effect of GS-5745  mFOLFOX6 (GSchemo) on systemic biomarkers
related toMMP9 activity, and immune suppression and activation,was explored
in samples from patients in the gastric cancer cohort of the phase 1b study,
NCT01803282. Immunoassay analysis of a set of serum proteins based on
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MMP9 biology and preclinical data (including 10 MMP9 substrates, 5 MMP/
TIMPs and 25 inflammatory markers) are reported; exploratory analyses of a
larger set will be presented. Total and GS-5745-free MMP9 was measured using
a proprietary validated assay. Serum was collected at baseline and the start of
every 28-day cycle from40 gastric cancer patients treatedwithGSchemo every
2 weeks. Biomarker area under the curve (AUC) of fold change over time was
tested using the Wilcoxon signed rank test. Multiple testing adjustment was
based on false discovery rate. GSchemo treatment resulted in a signifıcant
decrease of 3 MMP9 substrates in serum (TGF, VEGF and CXCL5), with
non-signifıcant trends observed for 3 others (Kit-L, IL8 and CXCL1). MMP3,
associated with MMP9 activation, was signifıcantly increased by the combina-
tion treatment. MMP2 (an MMP9 homolog) and its binding partner, TIMP2,
also showed an increased trend over time. All MMP9 was bound by GS-5745
after one cycle of GSchemo treatment, but total MMP9 was unchanged. Anal-
ysis of biomarkers in the inflammatory set primarily identifıed trends; factors
(10) related to immunosuppressivemonocyte chemoattraction or activation de-
creased, whereas a fewmarkers (3) of immune activation increased. TIMP-2 and
TPO were identifıed by random forests as key markers of a potential baseline
biomarker signature to distinguish responders from non-responders (best over-
all response: n20 and 9, respectively) with 82.8% accuracy (AUC of
ROC0.83). This exploratory analysis of serum proteins in gastric cancer pa-
tients treated with GSchemo identifıed pharmacodynamic changes in bio-
markers related to MMP9 biology, immune suppression and innate inflamma-
tion, consistent with the hypothesis ofMMP9-inhibition based upon preclinical
models. Modulation of these systemic biomarkers may reflect inhibition of
MMP9 activity in the tumor consequent with reduced suppression of anti-tu-
mor immunity; however, conclusions from this study are limited by the fact that
all patients were treated with GSchemo. Confırmation of these fındings will
require a controlled prospective study. First two authors contributed equally.
#4664 CXCL14 and CXCR7 expression are upregulated in human squa-
mous lung cancers. YoonHee Choi,1 Soo Young Chung,2 Yoo Sang Yoon,3 Jae
Hyun Kim,3 Ha-young Lee,1 Kyung A Kwon,1 Bong-Gun Seo,1 Hee Sam Na,4
Sung Sook Lee5. 1Department of Hemato-oncology, Dongnam Institute of Radio-
logical andMedical Sciences, Busan, Republic of Korea; 2Department of Pathology
, Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of
Korea; 3Department of Thoracic Surgery, Dongnam Institute of Radiological and
Medical Sciences, Busan, Republic of Korea; 4Department of Oral Microbiology,
School of Dentistry, Pusan National University, Yangsan, Republic of Korea; 5De-
partment of Hemato-oncology, Haeundae Paik Hospital, Inje University College
of Medicine, Busan, Republic of Korea.
Purposes: Lung squamous cell carcinoma (SQCC) is the second-largest his-
tological subtype of non-small cell lung cancer, but relatively few biomarkers are
available compared to adenocarcinoma. Recently, chemokines and their recep-
tors have been suggested to play important roles in the initiation or progression
of cancers. In this study we examined the expression of chemokines and their
receptors in human lung SQCC.Methods: FormRNAexpression of chemokines
their receptors study, tumors and their matched normal lung specimens were
collected from fresh frozen samples of 10 patients. For immunohistochemistry
(IHC) study, formalin-fıxed paraffıne-embedded samples of 35 patients with
primary lung SQCC were collected. All samples were from patients who were
subjected to curative surgical resection at Dongnam Institute of Radiological
andMedical Sciences. ThemRNAwas extracted by Quiagen RNeasy kit and the
humanRT2ProfılerPCR arrays for Chemokines/Receptors (SA Biosciences) was
employed to determine the mRNA expression. Also, IHC was used to demon-
strate their protein expression. Results: The expression profıles of 84 chemo-
kines and their related genes were compared across the tumors and their
matched normal lung tissues. Among them, mRNA expression levels of
CXCL14 (p0.000) and CXCR7 (p0.025) were signifıcantly upregulated in
tumor. CXCL14 and CXCR7 protein expression by IHC were detected in 25
(71%, p0.000) and 21 (60%, p0.000) of 35 cases for tumor, respectively.
However, normal lung tissues showed no protein expression for CXCL14 and
CXCR7. We also analyzed the correlation between clinicopathologic features
(age, stage, tumor size, lymph node involvement, lymphovascular and perineu-
ral invasion and differentiation of tumor) and protein expression of CXCL14
and CXCR7. Although not signifıcant, CXCL14 protein expression was more
detected in the advanced stage (stage I/II, 60% vs III/IV, 90%) (p0.120), lym-
phatic invasion (Yes, 82% vs No, 41%) (p0.146) and perineural invasion (Yes,
100% vs No, 57%) (p0.067). CXCR7 protein expression was signifıcantly
higher in advanced stage (stage I/II, 11/24, 46% vs III/IV, 10/10, 100%)
(p0.005) and lymphatic invasion (Yes, 13/16, 81% vs No, 8/18, 44%)
(p0.039). Conclusions: This study demonstrated that mRNA expression level
of CXCL14 andCXCR7were signifıcantly higher in SQCC compared to those in
normal tissue. CXCR7 protein expression was detected signifıcantly higher in
advanced stage and lymphatic invasion. Our results indicated that CXCL14 and
CXCR7 might play important roles in carcinogenesis and further study to elu-
cidate their role in SQCC is required.
#4665 Induction of receptor tyrosine kinase signaling by sera from pa-
tients with lung adenocarcinoma. Gabriela C. Lobato, Jared D. Fialkoff, Imad
Tarhoni,Nicholas Lund,VineelaChukkapalli, Selina Sayidine, Cristina L. Fhied,
Sanjib Basu,Wen-Rong Lie, Michael J. Liptay, Philip Bonomi, Jeffrey A. Borgia.
Rush Univ. Medical Ctr., Chicago, IL.
Background: The objective of this study was to evaluate disease stage-associ-
ated differences in receptor tyrosine kinase (RTK) signaling in A549 cells using
pretreatment sera from cases of pathologically-confırmed lung adenocarcinoma
or control cases derived from a lung cancer screening study. This was accom-
plished as a means to explore the hypothesis that circulating concentrations of
decoy receptors and/or ligands, as well as disease-specifıc ligand degradation all
regulate RTK signaling in vivo. Methods: Pretreatment peripheral blood were
prepared from either from non-cancer control patients (n30) or those with
lung adenocarcinoma, consisting of stage I (T1-2N0M0, n25); locoregionally
progressed (T1-2N1-2M0, n36) or disseminated, stage IV disease (n43). All
patients were enrolled with written informed consent to our IRB-approved,
institutional biorepository. Confluent cultures of A549 cells were stimulated for
10 minutes with patient sera diluted 1:1 in RPMI-1640 followed by immediate
whole cell lysate preparation. After protein determinations by BCA, 8.5 g of
each sample was interrogated using theHumanRTK (phosphoprotein) kit from
MilliporeSigma according to manufacturer’s instructions. After being normal-
ized to the kit-supplied (stimulated) HeLa cell lysates, all resulting data were
evaluated by one-way ANOVA (LSD and Tukey post-hoc) for categorical com-
parisons. Results: The most commonly observed differences in RTK signaling
was noted upon comparing cohorts with locoregional (T1-2N1-2M0) progression
and disseminated (stage IV) disease. Levels of in c-Met and insulin receptor (IR)
signaling were higher in patients with stage IV disease relative to those with
locoregional disease by 24% and 10%, respectively (both p0.01); whereas in-
duction of c-Kit, VEGFR3, and Tie-1 were reduced by 12.8%, 6.67%, and 17.3%,
respectively (all p0.05). Circulating levels of HGFwere previously observed by
our group to be 25% higher in stage IV patients relative to those with locore-
gional progression (p0.005) - agreeing with our observation in direction of
change, though not scale. This is in contrast to levels of VEGF-C and VEGF-D
previously being observed elevated 51% and 452% (both p0.001) in these same
cohorts. Also of note was the 1.9 fold decrease in ability of sera from stage I
patients to stimulate IGF-1R signaling relative to control patients (p0.002).
We have previously reported a 12% increase in IGF-1 levels between these
groups (p0.002), though we observed no changes in IGF binding proteins that
could account for the observed differences in IGF-1R signaling. Conclusions:
We observed an apparent discoupling of certain circulating ligands in patient
sera to stimulate their respectiveRTKs in a disease stage-specifıcmanner.We are
currently evaluating levels of circulating ligands, potential disease stage-associ-
ated (partial) proteolytic degradation, and decoy receptors to help explain these
observations.
#4666 DREAMing as a simple and low cost alternative for the assessment
ofmethylation inultra rareDNA.ThomasR. Pisanic,1 PornpatAthamanolap,1
Brendan F.Miller,2 VincentWu,1 Laura Elnitski,2 Tza-HueiWang1. 1JohnsHop-
kins University, Baltimore, MD; 2National Institutes of Health, Rockville, MD.
Background: Current approaches for the assessment of methylation, such as
methylation-specifıc PCR (MSP) and next-generation bisulfıte sequencing (BS-
Seq) are fundamentally limited in their ability to detect and assess heterogeneous
methylation patterns (epialleles) in ultra-rare (0.1%) DNA. These limitations
critically compromise diagnostic utility and render them ill suited for many
emerging applications in cancer diagnostics, such as the analysis of methylation
heterogeneity in cell-free DNA (cfDNA) and rare cell populations. We recently
addressed the need for a low cost alternative to the assessment of methylation of
ultra-rare DNA with the development of DREAMing (Discrimination of Rare
EpiAlleles by Melt), which uses semi-limiting dilution and precise melt curve
analysis to distinguish and enumerate individual copies of DNA at single copy
sensitivity and single-CpG-site resolution. Here, we seek to demonstrate the
advantages of the DREAMing method over conventional approaches to meth-
ylation assessment. Methods: We expand upon the underlying theory of
DREAMing and provide guidelines for the development of single-copy sensitive
DREAMing assays. We further elucidate methods for tailoring DREAMing as-
says to samples of interest and compare the performance of these assays to
commonly employed techniques including quantitative MSP (qMSP) and BS-
Seq. Results: Development of single-copy sensitive DREAMing assays for a
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number of loci associatedwith classic tumor-specifıcmethylation such as CHFR
and RASSF1A as well as a candidate pan-cancer locus are reported. These assays
are then used to analyze methylation in cfDNA derived from the plasma of
cancer-positive and healthy patients. DREAM analysis reveals that DREAMing
can readily detect over an order of magnitude more epialleles when directly
compared to qMSP and BS-Seq assays of the same locus. Some of the challenges
associated with distinguishing potential tumor-specifıc aberrant methylation
from background methylation are then discussed and proposed solutions are
demonstrated. Lastly, methods for optimizing DREAMing assays for specifıc
sample types are discussed. Conclusions: DREAMing is a recently introduced
method for the assessment of locus-specifıc methylation in samples containing
ultra rare target DNA. Its low cost and simplicity coupled with the ability to
provide enhanced, single-copy detection of heterogeneous methylation make
DREAMing an attractive option over traditional techniques for demanding
specimens such as cfDNA and rare cell populations. DREAMing has potential
utility in the evaluation of DNAmethylation dynamics in cell populations, pre-
natal testing, as well as clear use in early cancer diagnostic, companion diagnos-
tic and predictive applications.
#4667 mtDNA sequencing in HNSCC as a measurer of intratumoral het-
erogeneity and lymph node metastasis. Adrian D. Schubert,1 Evgeny Izum-
chenko,1WilliamH.Westra,1 Aditi Chatterjee,2 WayneM. Koch,1 Mohammad
O. Hoque,1 David Sidransky1. 1Johns Hopkins University, School of Medicine,
Baltimore, MD; 2International Technology Park, Bangalore, India.
Head andneck squamous cell carcinoma (HNSCC), accounts for 650,000 new
cases worldwide. It is notorious for poor prognosis, which reflects its propensity
to present as metastatic disease upon diagnosis. The prognosis and treatment
regiments vary dramatically upon themanifestation of lymph node (LN)metas-
tasis. Detection of regional LN metastasis is usually based on the clinical exam-
ination and imaging, followed by post-operational histological analysis. Unfor-
tunately, current tools for detection of tumor cells in surgically resected LNmay,
in some cases, miss the presence of micrometastasis. Novel strategies for detec-
tion of micrometastasis based on the analysis of tumor-derived genetic aberra-
tions by next generation sequencing (NGS) offer new hope for improved risk
assessment and better selection of the treatment regimen. However, detection of
mutations inminusculemetastatic lesions comprised of only fewneoplastic cells
may still fall below the detection threshold of these highly sensitive techniques.
By virtue of their clonal nature, higher mutation rate and copy number, assess-
ing tumor-specifıc mitochondrial DNA (mtDNA) mutations in histologically
clean LNmay provide amore sensitive diagnostic tool and eventually reduce the
false negative rate in patients. Additionally, due to its circular confıguration,
mtDNA thought to bemore stable than genomic DNA, andmay also be suitable
for sequencing formalin-fıxed paraffın-embedded (FFPE) -derived genomic
material, an invaluable resource for clinical research.However, currentmethods
for library preparation are still imperfect for detection of lowprevalence variants
and heteroplasmy with high depth of coverage, especially in highly degraded
samples. To this end, we aimed to set up a novel NGS assay for mtDNA analysis
in primary and metastatic samples. Amplicon-based NGS library preparation
approach, consisting of 148 primers pairs that cover the entire mitochondrial
genome (with a dual coverage of 86.18%) was designed in collaboration with
Fluidigm to be used on Access Array™ platform. To enhance the coverage of
degradedmaterial the amplicon size was limited to170 base pairs. Primers for
three nuclear housekeeping genes were added to the panel to allow quantitative
copy number analysis. To address mitochondrial mutational patterns, hetero-
plasmy and heterogeneity, we have used this novel high-throughput enrichment
technology to sequence mtDNA from different areas of 16 primary HNSCC
tumors (fresh frozen and FFPE), and multiple matched metastatic or histologi-
cally clean lymph-nodes.We obtained over 99% coveragewith amedian average
depth of 3000X and no difference between fresh frozen and FFPE samples. This
method allows obtaining a snapshot on the extent of mitochondrial heterogene-
ity of these lesions and may be used for detection of low frequency tumor-
associated mtDNA mutations as a measurer of possible metastatic processes in
histologically clean LN.
#4668 Analysis of c-Met protein expression by immunohistochemistry
and MET gene copy number in hepatocellular carcinoma. Christian Ihling,1
Sienna Yoast,2 Matthew DeNicola,3 Josef Straub,1 Klaus Dücker,1 Karsten Niel-
son,4 Russell A. Baldocchi,2 Aaron R. Ellison,2 Holly Yamada5. 1Merck KGaA,
Darmstadt, Germany; 2Dako North America, an Agilent Technologies company,
Carpinteria, CA; 3Mission Pathology Consultants, Santa Barbara, CA; 4Dako
Denmark A/S, an Agilent Technologies company, Denmark; 5Hemediagnostics,
San Marino, CA.
Background: Hepatocellular carcinoma (HCC) typically occurs in patients
with chronic liver disease. Such diseases create a demand for liver regeneration
due to injury, which in turn promotes upregulation of c-Met, a receptor for
hepatocyte growth factor (HGF) involved in wound healing, leading to in-
creased cellular proliferation, survival, andmobilization. c-Met is the product of
the proto-oncogene MET, so increased c-Met activity not only effects wound
healing but can also contribute to the development and progression of HCC.
Aberrant c-Met signaling is associatedwith rapid tumor growth and aggressively
invasive disease in HCC, resulting in poor patient prognosis. We examined
c-Met expression andMETgene amplifıcation in 69 procuredHCC samples and
c-Met expression in adjacent non-tumor tissue. Methods: c-Met expression was
assessed using MET IHC MSC2156119J pharmDx anti-c-MET (clone D1C2)
rabbit mAb. c-Met expression was scored semiquantitatively on a scale of 0-3
based on the staining intensity in 50% of cells [Koeppen et al. Proc USCAP
2012 (abstract 2001)]; tumors scoring 2 or 3were judged positive.MET gene
copy number (GCN) was assessed using the MET IQFISH Kit-111480 with a
probe covering a 269 kb segment on chromosome 7q31.2 containing the MET
gene. Tumors were considered to be FISH positive if scored cells had a mean
MET/CEN7 ratio2.0 or50% of cells contained5MET signals. Results: All
cases showed typical HCCmorphology and were classifıed as low to high grade
trabecular, pseudoglandular, or solid with common cytoplasmic features. The
tumor cells and cells of the adjacent cirrhotic/non-cirrhotic liver tissue (bile duct
epithelia, hepatocytes endothelial cells) showed cytoplasmic and membrane
staining of varying extent and intensity. c-Met staining in tumor was heteroge-
neous and present in 68/68 cases. Semiquantitative analysis showed that 11/67
(16%) tumorswere c-Met-positive (3, 3 cases; 2, 8 cases). Six out of 69 (8.7%)
were amplifıed by ratio and 3 (4.3%) others had5 MET gene copies in50 %
of cells, giving an overall frequency of FISHpositivity of 13%.Most interestingly,
amplifıcation and/or increased gene copy number was homogeneous through-
out the tumor in all cases, in contrast to heterogeneous c-Met staining observed
in some of the same tumors with IHC. Five of the 11 c-Met-positive (IHC 2/
3) tumors were MET amplifıed, and all 3 of the IHC 3 tumors were ampli-
fıed. Conversely, 4 of the 9 FISH-positive tumors were c-Met-negative. Conclu-
sion: These data provide insight into the frequency of c-Met/MET abnormalities
in HCC and show there is discordance between c-Met protein expression and
MET GCN alterations. This may be of importance for selection of patients with
HCC for clinical trials of c-Met inhibitors.
#4669 Circulating cytokines as biomarkers of BEP toxicity in TGCTs pa-
tients. Daniela Svetlovska,1 Viera Miskovska,2 Dana Cholujova,3 Paulina
Gronesova,3 Silvia Cingelova,4 Michal Chovanec,1 Zuzana Sycova-Mila,4 Jana
Obertova,1 Patrik Palacka,1 Vanda Usakova,5 Katarina Kalavska,6 Jan Luha,6
Dalibor Ondrus,2 Stanislav Spanik,7 JozefMardiak,1MichalMego1. 1NCI Slova-
kia; Commenius University, Bratislava, Slovakia; 2Comenius University and St.
Elisabeth Cancer Institute, Bratislava, Slovakia; 3Biomedical Research Center,
Slovak Academy of Siences, Bratislava, Slovakia; 4NCI Slovakia, Bratislava, Slo-
vakia; 5St. Elisabeth University of Health and Social Sciences and St. Elisabeth
Cancer Institute, Bratislava, Slovakia; 6Comenius University, Bratislava, Slova-
kia; 7St. Elisabeth University of Health and Social Sciences and St. Elisabeth Can-
cer Institute; Comenius University, Bratislava, Slovakia.
Background: Cytokines are key components in process of inflammation and
immune response, what are important processes in many toxicities. Bleomycin,
etoposide, cisplatinum (BEP) is a standard treatment in patients with testicular
germ cell tumors (TGCTs). Grade 3/4 toxicity can be dose limiting and can
highly influence patient’s quality of life. Our aim was to investigate correlation
between circulating cytokines and BEP toxicity in TGCTs patients. Methods:
The study population consisted of chemonaive TGCTs patients treated by BEP
chemotherapy. Grade 3 and 4 toxicities were assessed according to the Common
TerminologyCriteria forAdverse Events (CTCAE) version 4.0 after fırst cycle of
chemotherapy. G-CSFwas administered to all patients after chemotherapy. Cir-
culating 51 plasma cytokines were analyzed at baseline before chemotherapy
administration (94 patients) and on cycle 1 day 22 (57 patients) using multiplex
bead arrays. Toxicities were correlated to pretreatment and also postreatment
levels of circulating cytokines. Spearman’s correlation test was used to analyze
the association between cytokines and toxicity. Results: Signifıcant correlations
between grade 3/4 toxicity and cytokines were observed. Neutropenia was asso-
ciated with elevated pretreatment levels of TGF-beta 2, IL-2R alpha, HGF,MIG,
NGF-beta, SDF-1 alpha, IL-1beta, IL-4, IL-5, IL-17, FGF-basic, G-CSF, MIP-1
alpha and postreatment elevated levels of GRO-alpha, TNF-beta. Thrombocy-
topenia related with higher pretreatment levels of IL-2R alpha, IL-18, M-CSF
and higher postreatment IL-3, IL-12p40, GRO-alpha, MCP-3, M-CSF, MIF,
NGF -beta. Anemia correlated with elevated pretreatment IL-16, GRO-alpha,
HGF, MIF, NGF-beta, SCF, SCGF-beta, MCP-1-MCAF and elevated postreat-
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ment levels of IL-16, HGF, M-CSF, SCGF-beta. There were many positive asso-
ciations between pyelonephritis and pretreatment IL-2R alpha, IL-18, M-CSF,
NGF-beta and postreatment IL-2R alpha, IL-3, IL12p40, CTACK,HGF,MCP-3,
M-CSF, NGF-beta, SCGF-beta, IL-6. Diarrhea related with higher pretreatment
levels of IL-15 and also higher postreatment IL-15, GM-CSF and lower postreat-
ment levels of IFN-alpha, CTACK. Several other associations were detected
between elevated postreatment levels of cytokines and toxicities: nausea and
SCGF-beta, febrile neutropenia and GRO-alpha, TNF-beta, SIRS and GRO-
alpha, PDGF-BB. All correlations were signifıcant P0.05. Conclusions: Circu-
lating cytokines are promising and easily detectable biomarker for predicting
BEP toxicity in TGCTs patients. This work was supported by the Slovak Re-
search and Development Agency under the contracts No. APVV-0016-11 and
APVV-15-0086.
CLINICAL RESEARCH: Epigenetics and DNA Repair
#4670 Identifıcation of a possible therapeutic candidate for multiple my-
eloma based on dual inhibition of EZH1/EZH2. Makoto Nakagawa,1 Shuhei
Fujita,1 Daisuke Honma,2 Kazushi Araki,2 Issay Kitabayashi1. 1National Cancer
Center Research Institute, Tokyo, Japan; 2Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Multiplemyeloma (MM) is largely incurable as the disease eventually relapses
despite the recent development of novel therapies. Previous reports show that
side population (SP) cells comprise myeloma stem cells. Therefore, targeting SP
cells may be a promising strategy for preventing and treatingMM relapse. Poly-
comb repressive complexes 1 (PRC1) and 2 (PRC2) are important epigenetic
regulators thatmaintain the “stemness” of ES cells and other hematopoietic stem
cells. Enhancer of zeste homolog 1 and 2 (EZH1/2) are catalytic components of
PRC2, which trimethylate histone H3 at lysine 27 to repress transcription of
target genes. Mutation and overexpression of EZH2 are associated with many
cancers, including MM. Here, we found that SP cells expressed signifıcantly
higher levels of EZH1/2 thannon-SP cells. These results suggest that overexpres-
sion of EZH1/2 is important for maintaining the stemness of MM cells and that
EZH1/2 could be a potential therapeutic target. We developed a novel EZH1/2
dual inhibitor, OR-S1, and used it to investigate the effect of pharmacologic
inhibition of EZH1/2 on MM. OR-S1 suppressed the proliferation of almost all
MM cell lines tested, with an IC50 signifıcantly lower than that of the specifıc
EZH2 inhibitor, GSK126. Furthermore, flow cytometry analysis revealed that
OR-S1 signifıcantly depleted the SP cell population. RNA-seq analysis revealed
that the transcriptional profıles of MM cell lines treated with OR-S1 were char-
acterized by up-regulation of genes related to theWnt pathway. qRT-PCR con-
fırmed that expression of Wnt, Frizzled, and Protein kinase C family members
increased markedly after exposure to OR-S1. Previous studies show that in-
creased activation of the canonicalWnt signaling pathway down-regulates HSC
self-renewal and differentiation. Therefore, we generated -catenin-overex-
pressing MM cells to examine the effects of increased Wnt signaling on MM
cells. Surprisingly, proliferation of these cells was signifıcantly lower than that of
control cells. These results suggested that PRC2 directly targets Wnt signaling,
and that over-activation induced by EZH1/2 dual inhibition was responsible for
the reduced proliferation of MM cells. Oral administration of OR-S1 to mice
bearing MM xenografts led to signifıcant impairment of subcutaneous tumors.
Interestingly, long-term administration of the drug at lower doses to mice bear-
ing orthotopic xenografts resulted in complete eradication of minimal residual
disease from the bone marrow and complete cure of MM without any serious
side effects. Furthermore,OR-S1 treatment of an orthotopic PDXmodel derived
from a relapsed and heavily pretreated MM patient led to a reduction in the
levels of human immunoglobulins in the serum. Taken together, these results
strongly suggest that dual inhibition of EZH1/2 is a promising therapeutic ap-
proach to eradicating myeloma stem cells and could lead to important advances
in the treatment of MM.
#4671 Co-occurrence of alterations in the DNA damage repair genes syn-
ergize with uncontrolled proliferation and associate with very-poor progno-
sis in acutemyeloid leukemia patients.Antonella Padella,1 Giorgia Simonetti,1
Maria Chiara Fontana,1 Marco Manfrini,1 Giovanni Marconi,1 Anna Ferrari,1
Italo Faria do Valle,1 Marianna Garonzi,2 Cristina Papayannidis,1 Eugenia
Franchini,1 Elisa Zuffa,1 Viviana Guadagnuolo,3 Samantha Bruno,1 Andrea
Ghelli Luserna di Rorà,1 Emanuela Ottaviani,1 Daniel Remondini,1 Massimo
Delledonne,2 Giovanni Martinelli1. 1Univeristy of Bologna, Bologna, Italy; 2Uni-
veristy of Verona, Italy; 3CellPly, Bologna, Italy.
Partner and localizer of BRCA2 (PALB2) plays a key role in the DNA damage
repair (DDR) by recruiting BRCA1, BRCA2 and RAD51. Alterations in PALB2
were described in hereditary breast cancer and Fanconi Anemia (FA). Little is
known in Acute Myeloid Leukemia (AML). Aim of the study is to defıne the
frequency and interplay of PALB2 alterations with patterns of somatic muta-
tions and copy number variants (CNVs) in AML. We genotyped 233 AML
samples by Single Nucleotide Polymorphism array (SNP 6.0 and Cytoscan HD,
Affymetrix) to detect CNVs. We also performed Whole Exome Sequencing
(WES, Illumina) of 56 cases to detect single nucleotide variants and small indels
(MuTect and Varscan 2.0). Differences in survival were assessed by Kaplan-
Meier survival analysis and Breslow test. We detected PALB2 loss in 12/233
patients (5%), with a minimal common region of deletion of 6.6 Kb including
exon 12, which encodes for the domain of interaction with RAD51, BRCA2 and
POLH. PALB2 deletion were correlated with CN loss of MYH11, CREBBP,
PLK1 and FANCA on chromosome (chr) 16 (p.005), deletions of TP53, NF1
and BRCA1 on chr 17 (p.004), 5q deletions (p.001) and loss of XPO1 on chr
2 (p.006). PALB2-loss patients were enriched for alterations in genes involved
in the protein kinase pathway (p510-4), JUN kinase activity (p.0006) and,
notably, in genes belonging to the chromosome breakage pathway (p.001;
TP53, BRCA1 and BRCA2). To identify mutations that co-operates with CN
alterations, we integratedWESdata of 56AMLpatients.Nomutations in PALB2
were detected. However, we identifıedmutations in other DDR genes, including
FANCE, BRCA2, TP53 and BRCA1. Of note, alterations in the DDR genes
frequently co-occurred with both mutations and CN loss of TP53, leading to
homozygous loss of function of TP53. In addition, KRAS, IDH1, TET2 and
BCOR mutations were mutually exclusive with PALB2 loss. Preliminary gene
expression profıling data revealed a 2-fold upregulation of FANCA in samples
withDDRgenes alterations comparedwith patients with no alterations (p.04),
while the other genes of the pathway were not affected. Finally, patients harbor-
ing PALB2 loss had a poorer prognosis compared complex karyotype cases
(p.021). We here defıne a new subset of AML patients, characterized by the
synergistic loss of key DDR genes, which may in turn result in FANCA over-
expression as a mechanism to overcome the DDR defıcit. Our data suggest that
the leukemogenic process associated PALB2 loss integrates defects in the DDR
together with enforced proliferative stimuli leading to uncontrolled prolifera-
tion of cells, which potentially accumulate genetic lesions. These results may
help improve patient stratifıcation and defıne ad hoc therapeutic strategies for
this aggressive leukemia type. Supported by: ELN,AIL,AIRC, progettoRegione-
Università 2010-12 (L. Bolondi), FP7 NGS-PTL project.
#4672 Novel epigenetic approach to relapsedmantle cell lymphoma based
on dual inhibition of EZH1/EZH2. Shuhei Fujita,1 Yuki Kagiyama,1 Daisuke
Honma,2 Nobuaki Adachi,2 Kazushi Araki,2 Issay Kitabayashi1. 1National Can-
cer Center Research Institute, Tokyo, Japan; 2Daiichi Sankyo Co., Ltd., Tokyo,
Japan.
Mantle cell lymphoma (MCL) is a well-defıned and aggressive type of B cell
non-Hodgkin’s lymphoma that is genetically characterized by the t(11;14)(q13;
q32) chromosomal translocation, which results in constitutive overexpression
of CYCLIN D1. Although newly developed drugs such as ibrutinib show prom-
ising clinical outcomes, relapsedMCL often acquires drug resistance, which is a
critical obstacle to treatment. Alternative approaches to overcoming the drug
resistance of relapsed MCL are urgently needed. PRC1 and 2 are important
epigenetic regulators that maintain the stemness of embryonic and hematopoi-
etic stem cells. EZH1 and 2 are catalytic components of PRC2, which trimethy-
lates histone H3 at lysine 27 (H3K27) to repress transcription of target genes.
Mutation and overexpression of EZH1/2 are associated with cancers, including
hematopoietic malignancies. Here, we used a novel dual inhibitor of EZH1/2 to
show that inhibiting EZH1/2 is a promising therapeutic strategy for MCL. First,
we developed a xenograft (PDX) mouse model using cells from a heavily pre-
treated and relapsed MCL patient, and then orally administered an inhibitor of
EZH1/2, called OR-S1. OR-S1 strongly impaired proliferation of the patient-
derived tumors and did not cause any serious side effects. Additionally, an in
vitro assay usingMCL cell lines showed thatOR-S1 inhibited the growth ofMCL
cells, and that the effect was much more signifıcant than that using the single
EZH2 inhibitor (GSK126). The IC50 of OR-S1 was about one tenth that of
GSK126. These results strongly suggest that dual inhibition of EZH1/2 could be
a promising therapeutic strategy for relapsedMCL.Next, to investigate the effect
induced by dual inhibition of EZH1/2, we conducted further analyses of the
MCL cell lines. Cells exposed toOR-S1 showed cell cycle arrest (G1 arrest) along
with a dose-dependent reduction in phospho-Rb and cell differentiation, cou-
pled with increased cell surface expression of hCD138. We then used RNA-seq
analysis of MCL cell lines to compare OR-S1-treated cells with vehicle-treated
cells and found that cell cycle-related signaling was signifıcantly affected and
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that a cyclin-dependent kinase inhibitor, CDKN1C (TP57), was one of the genes
mostmarkedly upregulated byOR-S1.ChIP qPCRofMCLcell lines showed that
the CDKN1C locus was strongly marked by H3K27 trimethylation, and that
OR-S1 induced a signifıcant reduction in the level of this histone marker. Fur-
thermore, administration of OR-S1 alone to PDX mice induced increased ex-
pression of CDKN1C (as in the in vitro assay). Thus, dual inhibition of EZH1/2
in MCL induces expression of CDKN1C, which in turn causes cell cycle arrest
and reduced growth of MCL. Taken together, these results strongly suggested
that dual inhibition of EZH1 and EZH2 is a promising therapeutic strategy for
MCL, illustrating the potential of novel epigenetic approaches to overcoming
drug resistance of relapsed MCL.
#4673 EZH2 as a therapeutic target in glioblastoma: a cellular andmolec-
ular study. Javier de la Rosa,1 Marta Iraburu,1 Gabriel Gallo-Oller,1 Alejandro
Urdiciain,1 Xing Fan,2 Mehdi H. Shahi,3 Bárbara Meléndez,4 Juan A. Rey,5
Miguel A. Idoate,6 Javier S. Castresana1. 1Univ. of Navarra, Pamplona, Spain;
2University of Michigan, Ann Arbor, MI; 3Aligarh Muslim University, Aligarh,
India; 4Virgen de la Salud Hospital, Toledo, Spain; 5La Paz University Hospital,
Madrid, Spain; 6Univ. of Navarra Clinic, Pamplona, Spain.
Glioblastoma is the most common and deadliest malignant brain tumor in
adults. It is currently treated with a combination of surgery, radiotherapy and
chemotherapy with temozolomide (TMZ). Resistance to TMZ is a challenge in
the treatment of this type of brain cancer. Epigenetic modulation is a new pos-
sibility to be tested against glioblastoma. Inhibition of EZH2, a histone methyl-
transferase (H3K27met3) which is overexpressed in cancer cells, leading to an-
giogenesis and metastasis, might be a new strategy to treat this tumor. In this
work, the EZH2 inhibitor DZNeP was tested in A172 glioblastoma cells and in
A172-TMZ-resistant glioblastoma cells. Inhibition of cell proliferation, cell ad-
hesion, colony formation, and cell migration was noted in A172 and A172-
TMZ-resistant glioblastoma cells after DZNeP treatment. DZNeP also de-
creased EZH2 expression, and increased the expression of its target genes (E-
cadherin and TIMP3), which might probably contribute to inhibiting the
development of a cancer metastatic phenotype. Finally, DZNeP negatively reg-
ulated the TGF pathway: the expression of receptors involved in this pathway
(TGFR1 and TGFR2) was decreased, and the expression of inhibitors of this
pathway (BAMBI, SMAD6 and SMAD7) was increased. In order to support the
results obtained by qRT-PCR about the TGF1 pathway, protein expression of
SMAD2 and PSMAD2 was analyzed by Western blot. The ratio between PS-
MAD2/SMAD2 decreased in cells treated with DZNeP, which supports the pos-
sible therapeutic effect of this drug against the TGF pathway, as PSMAD2 is a
negative prognostic marker in glioblastoma. In conclusion, we propose that
inhibition of EZH2 might be considered as a therapeutic strategy against glio-
blastoma.
#4674 Epigenetic modulators for the treatment of invasive lobular carci-
noma breast cancer. LouiseWalsh,1 Bruce Moran,2 Sudipto Das,1 Finbarr Tar-
rant,2 Philip Schouten,3 Suet-FeungChin,4 ReneBernards,3CarlosCaldas,4Wil-
liamGallagher,2 Tríona Ní Chonghaile*,1 DarranO’Connor*1. 1Royal College of
Surgeons in Ireland, Dublin, Ireland; 2University College Dublin, Dublin, Ireland;
3The Netherlands Cancer Institute, Amsterdam, Netherlands; 4University of
Cambridge, Cambridge, United Kingdom.
Invasive lobular carcinoma (ILC) is a breast cancer subtype comprising 10%
of breast tumors. Themajority of ILC (90%) are estrogen receptor (ER)-positive
and therefore candidates for endocrine therapy. Unfortunately, de novo resis-
tant to endocrine therapies occurs in 33% of women and a further 40% will
relapse on treatment. Therefore, novel therapeutic targets are required for ILC.
Deregulated transcription is a recurring theme in cancer, which can be due to
epigenetic events. The bromdomain & extra-terminal domain (BET) family of
proteins (BRD2, BRD3, BRD4, BRDT) function as chromatin readers that bind
acetylated lysine residues on histones and regulate transcription.We performed
RNA-Sequencing analysis on 61 primary ILC samples and found that high ex-
pression of BRD3 is associated with poor survival in ILC (log rank test,
p0.037). We validated this fınding, that high expression of BRD3 is associated
with poor survival, in a second cohort of 99 ILC primary samples from the
METABRIC dataset (log rank test, p0.0157). Next, we tested if ILC cell lines
were sensitive to BET inhibition using the small molecule inhibitor JQ1, which
inhibits all BET family proteins. JQ1downregulates growth and survival genes in
ILC cell lines includingMYC, ER andBCL-XL. Pathway analysis following RNA
sequencing revealed that JQ1 targets the apoptotic andWnt signalling pathways
in ILC cell lines. Interestingly, JQ1 inhibited the cell growth in all ILC cell lines
tested, however apoptosis was only induced in two ILC cell lines. Furthermore,
ILC cell lines whichwere relatively resistant to JQ1-induced apoptosis expressed
both the BCL-2 and BCL-XL anti-apoptotic proteins. This led us to assess the
combination of JQ1 and the BH3mimetics, ABT-199 and ABT-263. ABT-199 is
a selective small molecule inhibitor of BCL-2, whereas ABT-263 is an inhibitor
of BCL-2, BCL-XL and BCL-W proteins.We found the combination of JQ1 and
ABT-263, but not the combination of JQ1 & ABT-199, to be synergistic and
enhance apoptosis in ILC cell lines. This is in accordance with BH3 profıling of
ILC cell lines which indicated that ILC cell lines are dependent on BCL-2/
BCL-XL proteins for cell survival. As JQ1 is a pan-BET family inhibitor, we also
wish to determine which BET protein is responsible for sensitivity to JQ1. Fol-
lowing knockdown of each BET protein in the CAMA-1 cell line we found that
BRD3 and BRD4 were responsible for loss of cell viability. Future work will
include determining the specifıc role of BRD3 in ILC and the effectiveness of the
JQ1 and ABT-263 combination in vivo. Our work suggests that inhibition of
BET proteins in combination with BH3 mimetics may be a rational therapeutic
combination for ILC.
#4675 Novel combination therapy of DNA methyltransferase inhibitor
guadecitabine (SGI-110) and PARP inhibitor talazoparib (BMN-673) for
BRCA-profıcient high-grade serous ovarian cancer.Nicholas Pulliam,1 Pietro
Taverna,2 John Lyons,3 Kenneth P. Nephew1. 1IndianaUniversity, Bloomington,
IN; 2Astex Pharmaceutical, Inc., Pleasanton, CA; 3Astex Pharmaceutical, Inc.,
Cambridge, United Kingdom.
Ovarian cancer recurrence has been shown to be associated with increased
DNA damage response (DDR) mediated by poly-(ADP)-ribose polymerase 1/2
(PARP1/2), which can be therapeutically targeted by PARP inhibitors (PARPi).
PARPi are indicated for platinum-responsive, BRCA-mutated high-grade se-
rous ovarian cancer, but most ovarian cancer patients have BRCA-profıcient
disease. Our previous studies support a role for DNA methylation in chemore-
sistant ovarian cancer mediated by the enzyme DNA methyltransferase 1
(DNMT1), and report on a functional role for DNMT1 in DNA damage repair.
We therefore hypothesized that combining a DNMTi and PARPi will impair
BRCA-mediated DDR, resulting in cytotoxicity in ovarian cancer cells. A panel
of ovarian cancer cell lines (A2780, platinum sensitive, BRCA1/2-wild type;
A2780-cp and HeyC2, platinum resistant, BRCA1/2-wild type; high-grade se-
rous Kuramochi, platinum resistant, BRCA2 mutant) was examined for cell
growth using colony formation assays after treatment with DNMTi guadecit-
abine (low dose, 20-100nm) and PARPi talazoparib (1-10nm), alone or in com-
bination. While talazoparib alone only marginally reduced colony formation in
all cell lines (dose-dependent effect), combining guadecitabine with talazoparib
further decreased (P0.05) survival at all doses examined. To focus more spe-
cifıcally on BRCA status, we utilized two high-grade serous ovarian cancer cell
lines (“PEO”) derived from the same patient but harboring a mutant (PEO1) or
wild type (PEO4) BRCA2 gene (Langdon et al, 1988; Sakai et al, 2009). Treat-
ment with low-dose guadecitabine (20 nm, 3 days) increased (P0.05) PARP
levels (western blot analysis) as well as enzymatic activity (P0.05; ELISA anal-
ysis), while talazoparib treatment alone increased (P0.05) DNMT1 levels and
decreased (P0.05) PARP enzymatic activity. Treatment with guadecitabine or
talazoparib alone had no effect on cell proliferation; however, combining the
two drugs inhibited (80%; P0.05) PEO1 and PEO4 proliferation and in-
creased (3-fold; P0.05) apoptosis (caspase 3 cleavage) in both cell lines. Fur-
thermore, co-administration guadecitabine (0.5mg/kg) and talazoparib
(0.25mg/kg) to mice harboring BRCA2-wild type ovarian tumor xenografts de-
creased (p0.05) tumor volume (60%) and tumor weight (70%) compared
to control, respectively. In summary, combining a hypomethylating agent with a
PARP inhibitor results in enhanced cytotoxicity in high-grade serous ovarian
cancer cell lines harboring either wild type- or mutant-BRCA, indicating that
the talazoparib-guadecitabine drug combination is effective regardless of
BRCA-mediated DDR and may represent an effective treatment regimen for
BRCA-related cancers.
#4676 DNA repair protein expression and response of homologous re-
combination defıcient ovarian cancer to the poly(ADP-ribose) polymerase
(PARP) inhibitor rucaparib in the ARIEL2 Part 1 study. Andrea E. Wahner
Hendrickson,1 Kevin K. Lin,2 Daniel W. Visscher,1 Rachel M. Hurley,1 Mitch
Raponi,2 Thomas C. Harding,2 LindaM.Murphy,1 Jill M.Wagner,1 Heidi Gior-
dano,2 Iain McNeish,3 Elizabeth M. Swisher,4 Scott Kaufmann1. 1Mayo Clinic,
Rochester, MN; 2Clovis Oncology, San Francisco, CA; 3University of Glasgow,
Glasgow, United Kingdom; 4University of Washington, Seattle, WA.
Background: PARP inhibitors (PARPis) are active in cancers with homolo-
gous recombination (HR) defects. Preclinical studies have shown that secondary
mutations or alterations in gene expression (e.g., downregulation of 53BP1,
Ku70, Ku80 or DNA-PKcs) restore HR and confer PARPi resistance. In addi-
tion, low PARP1 expression can diminish PARP trapping and cause PARPi
resistance. ARIEL2 Part 1 is a phase 2 study of the PARPi rucaparib in platinum
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sensitive, relapsed high grade serous or endometrioid ovarian cancer (OC). Pre-
treatment OC biopsies were previously assayed for HR gene mutations and loss
of heterozygosity (LOH), a genomic scar that reflects HR defıciency. Two tumor
groups (BRCA wildtype [wt]/LOH high and BRCA1 or BRCA2 mutant) have
objective response rates of 29.3% and 80%, respectively, as well as progression
free survival (PFS) of 5.7 and 12.8months, respectively, on rucaparib (E. Swisher
et al., Lancet Oncol., in press). Common AEs included nausea (80%), asthenia/
fatigue (78%), constipation (46%), and vomiting (44%). The present studies
tested the hypotheses that i) lower PARP1 expression and/or ii) lower expression
of NHEJ components 53BP1, DNA-PKcs, Ku80, Ku70, or LIG4, may correlate
with diminished response rate as well as PFS in pts treated with rucaparib on
ARIEL2. Methods: Immunohistochemical assays were developed for 53BP1,
DNA-PKcs, Ku80, Ku70, LIG4, and PARP1 and validated in formalin fıxed,
paraffın embedded cell lines differing in analyte expression. Available pretreat-
ment OC biopsies from ARIEL2 Part 1 were stained and scored for % of tumor
nuclei that were negative (0), weak (1), moderate (2) or strong (3). Mod-
ifıed H-scores were correlated with clinical characteristics and outcome mea-
sures. Results: Pretreatment biopsies from 62-68 pts were successfully stained
for each repair protein. Across the samples, PARP1 H-scores varied from 0 to
300 (median 160). Focusing on the BRCA wt/LOH high group (n  38), there
was no signifıcant difference in PFS of pts with low (100), intermediate (100-
200) or high (200) PARP1 H-score (p  0.57). Expression of DNA-PKcs,
Ku70, Ku80, and LIG4was generally lower (medianH-scores 20-60) and did not
individually correlate with response or PFS. In contrast, there was a trend to-
ward improved PFS in BRCA wt/LOH high OC pts expressing intermediate or
high 53BP1 (H-score 100, n 10) compared to pts with low 53BP1 (H-score
100, n 25), with median PFS 20.7 vs. 5.5 months (p 0.073), respectively.
Staining of additional pretreatment biopsies is planned. Conclusions: In the
BRCA wt/LOH high group, pretreatment PARP1 expression does not correlate
with rucaparib response. In contrast, BRCA wt/LOH high OC pts with low
53BP1 have a trend toward shorter PFS with rucaparib, suggesting that 53BP1
downregulation might correlate with clinical PARPi resistance in BRCA wt/
LOH high OC.
#4677 Integrated molecular profıles and guadecitabine response in re-
lapsed/refractory acute myeloid leukemia. Woonbok Chung,1 Andrew D.
Kelly,1 PatriciaKropf,2 PietroTaverna,3 SueNaim,3MohammadAzab,3 Jaroslav
Jelinek,1 Hagop M. Kantarjian,4 Jean-Pierre J. Issa1. 1Fels Inst. for Cancer Re-
search &Molecular Biology, Philadelphia, PA; 2Fox Chase Cancer Center, Phila-
delphia, PA; 3Astex Pharmaceuticals Inc, Pleasanton, CA; 4The University of
Texas MD Anderson Cancer Center, Houston, TX.
Epigenetic patterns of DNA methylation are frequently altered in acute my-
eloid leukemia (AML). Guadecitabine is a novel next generation hypomethylat-
ing drug with a demonstrated clinical activity in elderly AML. In our previous
study of guadecitabine, we identifıed in relapsed/refractory (r/r) AML patients a
gene expression signature (high DNMT3B, low P15, and low CDA) associated
with reduced LINE-1 demethylation and resistance to the drug. Since pharma-
codynamics only explains a small portion of the variability in response to gua-
decitabine, we suggest that intrinsic genetic and epigenetic characteristics can
distinguish responders fromnon-responders.We analyzed genome-widemeth-
ylation patterns and screened 54 genes frequently mutated in leukemia in DNA
from pre-treatment blood or bone marrow from 119 patients with r/r AML
enrolled in guadecitabine phase I/II trials. Blood samples from 49 healthy do-
nors were used as controls. We also examined expression of a panel of genes
(CDA, P15, P21, DNMT3B, DNMT3A, DNMT1, and CTCF) at baseline by
quantitative RT-PCR. Global DNA methylation at pre/post treatment was esti-
mated by bisulfıte-pyrosequencing of the LINE-1 repetitive sequence. For com-
paring methylation profıles at CpG islands (CGI), we performed hierarchical
clustering analysis of differentially methylated 2794 CGI sites in 119 r/r AML
and 49 healthy controls. Hierarchical clustering split them into 3main groups of
normal-like cluster (n36), intermediate (n41) and CpG island methylator
phenotype (CIMP) like cluster (n42). Normal-like cluster had a higher re-
sponse rate (39 %) compared to intermediate (17%) and CIMP- like cluster
(15%) (p0.025, Fisher’s exact test). Demethylation rate of LINE-1 was lower in
CIMP-like cluster than in normal-like and intermediate cluster (average de-
methylation -19	 2 % in CIMP-like cluster vs. -31	 2 % in normal-like vs. -23
	 2 % in intermediate cluster, p0.0007, One-way ANOVA).Mutation screen-
ing revealed frequent alterations affecting signaling pathways (CSF3R, KIT,
KRAS, NRAS and FLT3) in the CIMP-like cluster (62%) compared to normal-
like (11%) and intermediate cluster (13%) (p0.0001, Fisher’s exact test). High
number of hypermethylated sites per patient was prominent in the CIMP-like
cluster and associated with a four gene expression classifıer z-score (low CDA,
low P15, low CTCF and high DNMT3B) (R-0.637, p0.0001) as well as resis-
tance to guadecitabine (meanof 4 gene z-score 0.54 in non-responders vs. 2.31 in
responders, p0.001).We propose that DNAhypermethylation at CpG islands,
mutations in signaling pathways and unfavorable gene expression signature can
be developed as biomarkers predicting resistance to guadecitabine in r/r AML.
This trials were registered at www.clinicaltrials.gov as NCT02293993 (Phase I)
and NCT02197676 (Phase II).
#4678 Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in
patients with advanced solid tumors carrying deleterious BRCA mutations.
Robert S. Meehan,1 Alice P. Chen,1 Geraldine O’Sullivan Coyne,1 Shivaani
Kummar,1 Jiuping Ji,2 Rasa Vilimas,2 Lamin Juwara,2 Robert J. Kinders,2 Kath-
erine Ferry-Galow,2 Deborah Wilsker,2 Yiping Zhang,2 Angie B. Dull,2 Tony
Navas,2 Lihua Wang,2 Ralph E. Parchment,2 James H. Doroshow1. 1NCI/NIH
DCTD, Bethesda, MD; 2Frederick National Laboratory for Cancer Research,
Frederick, MD.
Inhibition of poly (ADP-ribose) polymerase (PARP) sensitizes tumor cells to
DNA damage that would normally be repaired through the base excision repair
pathway. PARP inhibitors are active clinically against BRCA-defıcient ovarian
cancers. The PARP inhibitor talazoparib produces cytotoxicity in human cancer
cell lines and animal models of tumors that harbor mutations that compromise
DNA repair pathways. In this study, single agent talazoparib (1000g/day) was
administered to patients with deleterious BRCA1 or BRCA2 mutations and
advanced solid tumors in 28 day cycles. The primary objective of the trial was to
examine pharmacodynamic (PD) effects of talazoparib; the secondary objective
was to determine response rate in patientswhose tumors carryBRCAmutations.
Mandatory paired tumor biopsies were obtained pre-treatment and 3-6 hrs
post-treatment on cycle 1 day 8. Optional biopsies were collected at the time of
progression. One core from each time point was analyzed for PARP inhibition
by a validated ELISA assay while the other core was used for IFA analysis of
H2AX. A total of 9 patients (pts) were enrolled and treated before this trial was
closed due to lack of drug availability: [prostate (3), ovarian (2), breast (2),
uterine sarcoma (1), pancreatic (1)]. Median age was 63 (range: 33-73 yrs);
male-to-female ratio was 4:5; and the median number of prior treatments was 6
(range: 1-12). All 9 pts were evaluable for PD endpoints. One pt progressed
during the fırst cycle of treatment; 8 pts were evaluable for clinical response.
Mean time on study for evaluable pts was 8 cycles (range: 2-18); 5 of 8 (62%) pts
experienced a documented partial responses [ovarian (2), prostate (2), breast
(1)] lasting between 4 and12 cycles (median: 6 cycles). Twopts had stable disease
for 4 to 6 cycles, and one progressed after 2 cycles. The agent was well tolerated;
the most frequent adverse events were hematologic including grade (gr) 4 ane-
mia (1) and thrombocytopenia (1), and gr 3 anemia (2), neutropenia (1), lym-
phopenia (1). Decreases in PAR levels (75%) were observed in all cycle 1 day 8
biopsy pairs, documenting a primary PD effect. Increased H2AX expression
was observed for 4/6 pts in post-dose biopsies; pre-treatment H2AX levels,
measured as %Nuclear Associated Protein (NAP), increased from amean	 SD
of 1.33 	 1.08 to a post-treatment %NAP mean of 5.60 	 0.78; (p0.018),
supporting a role for drug-enhanced DNA double strand breaks in the mecha-
nismof action of talazoparib for BRCAmutant tumors. In summary, talazoparib
demonstrated signifıcant clinical activity as a single agent in patients with
BRCA-defıcient tumors and produced substantial reductions in tumor PAR
levels in matched pre and post-treatment tumor biopsies.
#4679 Mismatch repair defects in lethal prostate cancer. Pasquale
Rescigno, Daniel Nava Rodrigues, Wei Yuan, Suzanne Carreira, Maryou Lam-
bros, George Seed, Ruth Riisnaes, Susana Miranda, David Dolling, Matthew
Clarke, Mateus Crespo, Claudia Bertan, Gunther Boysen, Joaquin Mateo, Ana
Ferreira, Adam Sharp, Ines Figueiredo, Semini Sumanasuriya, Mariane Sousa
Fontes, Diletta Bianchini, Zafeiris Zafeiriou, Johann Sebastian de Bono. The
Institute of Cancer Research, London, United Kingdom.
INTRODUCTION: A subset of prostate cancers (PCs) has a hypermutated
phenotype. We hypothesized that lethal PCs with a high mutational load (ML)
have DNA repair defects including mismatch-repair (MMR) aberrations and
that such aberrations may impact outcome. METHODS: Diagnostic and meta-
static castration resistant prostate cancer (mCRPC) tissues were tested by A)
immunohistochemistry (IHC) for MSH2, MSH6, MLH1, and PMS2; B) micro-
satellite instability (MSI) (Promega v1.2 assay); C) targeted next generation se-
quencing (NGS) of the coding regions of 113 genes, a panel enriched for DNA-
repair genes that includesMMRgenes. UtilizingNGS data we also evaluatedML
andMSI byNGS (MSINGS; Pritchard et al, 2014). IHCwas used as reference for
sensitivity (SE) and specifıcity (SP) of methods B) and C).Youden’s index was
used to determine the optimal cut off for the ROC for IHC in relation to
MSINGS andML.Demographics and clinical datawere retrospectively collected
from electronic records. Relationship between ML in diagnostic and mCRPC
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samples was evaluated by paired t-test. The relationship betweenML andMMR
defıcient tumors on IHC (MMRd) and/or MSI tumors by PCR (MMRd/MSI)
was analyzed by negative binomial regression model. The relationship between
MMRd/MSI tumors and overall survival (OS)was analyzed using univariate and
multivariate Cox regression, adjusting for radical treatment (prostatectomy or
radiotherapy), Gleason score, age, PSA and stage and presence of metastatic
disease at diagnosis. RESULTS: We analyzed 306 PC biopsies (180 hormone-
sensitive [HS] and 126 castration resistant [CR]) from 208 patients. Overall 16
patients (7.7%) had either MMRd or MSI. Matched, same-patient, HSPC and
mCRPC tumor biopsies were available for 82 patients. Only one case with
MMRd status in HS was not confırmed in matched mCRPC. This patient was
consideredMMR profıcient for the survival analysis. MSI had a SE of 80% and a
SP of 97%. An MSI by NGS cut-off of 0.096 had SE of 60% and SP of 99%, with
an area under ROC curve of 0.83. AML cut-off of 11mutations per panel had SE
of 60% and SP of 99%, with an area under ROC curve of 0.79. Although ML in
diagnostic samples correlates with ML in mCRPC, ML was signifıcantly higher
inmCRPCMMRd/MSI cases (p0.001; predictedML of 14 versus 4mutations
per panel). MMRd/MSI andMMR profıcient patients were balanced for type of
radical treatments, Gleason score, presence of metastatic disease, PSA, age and
stage at diagnosis. Despite this, median OS from start of LHRH for the MMRd/
MSI group was signifıcantly shorter than in the MMR profıcient group in uni-
variable and multivariable analysis (3.84 vs 6.81 years; aHR: 2.44; 95% CI 1.27
-4.70; p 0.008). CONCLUSION:We provide evidence thatMMRd/MSI status
represents a negative prognostic factor for survival for metastatic CRPC.
MMRd/MSI status in diagnostic biopsies accurately identifıes MMRd/MSI in
mCRPC. MSINGS and ML can detect MMRd/MSI tumors.
#4680 H3K9 methyltransferase G9a epigenetically regulates breast cancer cell
ironhomeostasisvia repressing ferroxidasehephaestinexpression,promotesbreast
cancergrowth.Ya-fangWang,JieZhang,YiSu,Yan-yanShen,Mei-yuGeng,JianDing,
YiChen. Shanghai Institute ofMateriaMedica, Shanghai, China.
G9a is a H3K9 methyltransferase with elevated expression observed in
many types of human cancers, seems to be required for the maintenance of
the malignant phenotype. However, the tumorigenic role of G9a in breast
cancer is still far from clear. In addition, growing evidence revealed that the
disruption of iron homeostasis may contribute to the development of breast
cancer (BC). Pathways of iron acquisition, efflux, storage and regulation are
all perturbed in BC, suggesting that reprogramming of iron metabolism is a
central aspect of tumor cells survival. Hephaestin (HEPH) is a ceruloplasmin
homologue that converts iron (II) to iron (III), and mediates iron efflux in
concert with ferroportin to transport iron across the basolateral membrane.
It retains unclear whether HEPH concentration has any impact on the iron
status of breast tissue, and breast cancer growth. In this study, we demon-
strate that G9a exerts its oncogenic function by destruction cellular iron
homeostasis. We revealed that G9a knockdown, and G9a specifıc inhibitors
signifıcantly up-regulated HEPH expression, decreased intracellular labile
iron content, and then suppressed BC cells proliferation both in vitro and in
vivo. This idea is further validated by the fınding that the enhanced iron
content and decreased HEPH expression are required for the increased pro-
liferation of G9a-overexpressed breast cancer cells. Further, our CHIP and
co-IP data demonstrate a traditional role of G9a as a transcriptional repres-
sor that co-existed with YY1 and HDAC1, contribute to the reduction of
HEPH transcription. In addition, depletion of HEPH with an increase in
labile iron reversed cells growth in G9a silencing BC cells. These observa-
tions prompted us to investigate the relevance of G9a-HEPH pathway to
human disease. The immunohistochemistry analysis of 75 breast cancer
specimens revealed inverse staining patterns between G9a and HEPH ex-
pression in breast cancer tissues independent of BC type (Spearman’s non-
parametric correlation test, correlation coeffıcient: -0.678, p0.05). Patients
who owned a G9ahigh tumor had an even worse prognosis in this retrospec-
tive analysis, with a median overall survival of 56.9 months compared to
103.4 months in the G9alow tumors. And we revealed for the fırst time that
low level of HEPH also correlated with overall lower disease-free survival.
Finally, expression of high G9a and low HEPH correlated a worse prognosis.
In summary, we propose that G9a has an upstream regulatory role in HEPH-
mediated cellular iron hemostasis, leads to iron accumulation and stimulates
breast cancer progression through its epigenetic silencing machinery. Our
observations raise exciting possibilities regarding G9a and HEPH might be
potential prognostic markers of breast cancer progression and targets for
therapeutic intervention.
#4681 Histone deacetylase 3 inhibition overcomesBIM deletion polymor-
phism-mediated osimertinib resistance in EGFR-mutant lung cancer. Azusa
Tanimoto. Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Purpose:The BIM deletion polymorphism is associated with apoptosis resis-
tance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs), such as gefıtinib and erlotinib, in non-small cell lung cancer (NSCLC)
harboring EGFR mutations. Here, we investigated whether the BIM deletion
polymorphism contributes to resistance against osimertinib, a third-generation
EGFR-TKI. In addition, we determined the effıcacy of a histone deacetylase
(HDAC) inhibitor, vorinostat, against this form of resistance and elucidated the
underlying mechanism. Experimental Design:We used EGFR-mutated NSCLC
cell lines which were either heterozygous or homozygous for the BIM deletion
polymorphism to evaluate the effect of osimertinib in vitro and in vivo. Protein
expression was examined by western blotting. Alternative splicing of BIM
mRNAwas analyzed by RT-PCR. Results:EGFR-mutated NSCLC cell lines with
the BIMdeletion polymorphism exhibited apoptosis resistance to osimertinib in
a polymorphism dosage-dependent manner, and this resistance was overcome
by combined use with vorinostat. Experiments with homozygous BIM deletion-
positive cells revealed that vorinostat affected the alternative splicing of BIM
mRNA in the deletion allele, increased the expression of active BIMprotein, and
thereby induced apoptosis in osimertinib-treated cells. These effects were me-
diated predominantly by HDAC3 inhibition. In xenograft models, combined
use of vorinostat with osimertinib could regress tumors in EGFR-mutated
NSCLC cells homozygous for the BIM deletion polymorphism. Moreover, this
combination could induce apoptosis even when tumor cells acquired EGFR-
T790M mutations. Conclusions:These fındings indicate the importance of de-
velopingHDAC3-selective inhibitors, and their combined use with osimertinib,
for treating EGFR-mutated lung cancers carrying the BIM deletion polymor-
phism.
#4682 Genomic profıles in gene expression and methylation help defıne
the molecular characteristics of hairy cell leukemia subtypes.Daniel C. Edel-
man, Holly S. Stevenson, Yonghong Wang, Evgeny Arons, Joshua J. Waterfall,
David Petersen, Hong Zhou, Paul S. Meltzer, Robert J. Kreitman. NIH/NCI,
Bethesda, MD.
Hairy cell leukemia (HCL) until recently was characterized as a single
blood and bone marrow malignancy, even though clinically at least two
pathologies seemed to be at work. This study sought to confırm the clinical
observations using genomic evidence. HCL is a chronic mature B-cell ma-
lignancy with distinctive immunophenotype, typically expressing CD20,
CD22, CD25, CD11c, CD103, CD123, annexin A1 (ANXA1), and tartrate-
resistant acid phosphatase (TRAP). Purine analog therapy is highly effective,
with most patients achieving durable remissions. HCL- variant (HCLv) was
fırst identifıed by Cawley et al. (1980) and recently recognized by the World
Health Organization as a separate cancer. HCLv lacks CD25, ANXA1, TRAP,
and BRAF V600E expression, and patients respond poorly to purine analogs.
In order to fınd detailed biological information involving these two diseases,
we studied the genome-wide gene expression and methylation profıles of 75
HCL patient samples; 67 were tested by both methods. Our study results
indicate that HCL and HCLv show very distinct gene expression and meth-
ylation patterns. Many genes that are differentially expressed are involved in
immunological and inflammatory response pathways. Several cancer associ-
ated genes such as ANXA1 and FLT3 are down-regulated in HCLv compared
to HCL. Correlation patterns between methylation and gene expression for
many genes such as ANXA1 suggest that methylation plays an import role in
gene expression regulation for these malignancies. This study has begun the
process of identifying better biomarkers for disease discrimination between
HCL and HCLv and providing potential new targets for strongly needed
therapies for HCLv.
#4683 Co-existence of SRSF2 andEZH2 genemutations inmyeloidmalig-
nancies. Durga P. Cherukuri, Brian Kwok, Jacqueline Lekostaj, Paris Petersen,
Peter Bui, Farzad Nooraie, Li Cheng, Francesca Fike, David A. Taylor, Bashar
Dabbas, Matthew J. Mcginniss. Genoptix Medical Laboratory, Carlsbad, CA.
SRSF2 is recurrently mutated in a variety of myeloid malignancies, including
chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome
(MDS), myeloproliferative neoplasm (MPN), and acute myeloid leukemia
(AML); andmost alterations involve the codon proline-95 (P95). In vitro studies
have shown that the SRSF2-P95H mutation affects splicing of EZH2 and func-
tionally reduces its protein expression. Inactivating mutations of EZH2, located
at 7q36.1, have also been reported in a variety of myeloid malignancies. Studies
have shown that SRSF2 andEZH2 genemutations aremutually exclusive events.
In this study, we retrospectively analyzed next-generation sequencing results of
16,767 patient cases with a clinical indication of a possible myeloid malignancy.
All exons of the EZH2 gene and exon 1 of SRSF2 gene were sequenced. A total of
33 cases (0.2%) had mutations in both SRSF2 and EZH2 genes; 70% were male
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(age: 58-89 years) and 30% were female (age: 64-89 years). Of the 20 cases
with suffıcient material for rendering a pathologic diagnosis, 40% were CMML;
10%wereMDS/MPN, unclassifıable; 10%wereAMLwithMDS-related changes
and monocytic differentiation; 10% were AML with MDS-related changes and
no monocytic differentiation; 10% were MDS; 10% were AML, not otherwise
specifıed, with monocytic differentiation; 5% were AML, not otherwise speci-
fıed, without monocytic differentiation; and 5% were primary myelofıbrosis. In
total, 60% (12/20) of the cases with co-existing SRSF2 and EZH2 mutations
displayed monocytic differentiation. In 97% (32/33) of the cases, SRSF2 muta-
tions occurred in the hot spot codon, proline-95 [P95H (13 cases), P95R (8),
P95L (6), P95T (3), P95V (1), and P95 deletion (1)]. In regards to EZH2, a single
mutation was detected in 88% (29/33) of the cases. Double mutations were
found in four cases with both mutations detected simultaneously in three cases
and, acquisition of a second frameshift mutation noted in one case. EZH2 loss-
of-functionmutations including frameshift, nonsense, and splice-sitemutations
were detected in 40% (13/33) of the cases. Missense mutations were detected in
48% (16/33) of the cases, and 56% of these mutations were located in the con-
served catalytic SET domain of the EZH2 protein. The othermutations included
an in-frame insertion involving the SET domain and splice-region mutations.
Cytogenetic information was available for 16 cases with 56% showing a normal
karyotype. Trisomy 8 was the predominant chromosomal abnormality ob-
served, especially in cases of AML. One case with AML with MDS-related
changes showed monosomy 7 and an EZH2-R690H mutation. In conclusion,
our data demonstrate that mutations in SRSF2 and EZH2 can infrequently co-
exist in different subtypes of myeloid malignancies, and are associated with
monocytic differentiation in most cases.
#4684 MYC inhibition in human malignancy by BET-Bromodomain in-
hibitor JQ1, using a 3-D human tumor primary culturemicro-spheroid plat-
form to explore clinically relevant observations. Robert Alan Nagourney,1
Steven S. Evans,1 Alexander J. Nagourney,1 Paula J. Bernard,1 Federico R. Fran-
cisco,1 Milan Sheth,2 Nilesh Vora,2 Eknath Deo2. 1Rational Therapeutics, Inc.,
Long Beach, CA; 2Todd Cancer Institute, Long Beach, CA.
The transcription factorMYC is associated with the regulation of over 15% of
human gene expression. Deregulation of MYC is found in up to 70% of human
cancers. As MYC is responsible for the reprogramming of cell metabolism,
growth and survival, it is an attractive therapeutic target, yet effective drug de-
velopment has been slow. As the Bromodomain/BET proteins epigenetically
regulate MYC, BET inhibitors like JQ1 have been developed as MYC therapeu-
tics. We used the Ex Vivo Analysis of Programmed Cell Death (EVA/PCD)
previously shown to correlatewith response, time to progression and survival, to
examine JQ1 activity in 46 human tumor specimens isolated from surgical bi-
opsies. Methods: Surgical biopsies were mechanically and enzymatically disag-
gregated, withmicro spheroids of desired size isolated by density centrifugation.
Five-Point dose response curves were interpolated to provide LC50 values for
comparison by Z-score. Synergy was conducted by median-effect. Results: JQ1
revealed activity in hematologic, breast, glial & gastrointestinal (GI) tumors. By
rank order, JQ1 activity favored hematologic (AML & NHL) & breast tumors
over Lung, Ovary and GI with inter-patient differences observed within tumor
types. MYC association with histone acetylation and aurora kinase (AURK)
activity, led to an exploration of JQ1 synergy with SAHA (HDACi), MLN 8054
& Tozasertib (both AURKi). JQ1 synergy analysis revealed SAHA  Tozaser-
tib  MLN 8054. Conclusions: Based upon JQ1 activity, several tumor types
appear to be candidates for agents that target MYC-mediated cell survival, of-
fering potential treatment options for patients with advancedmalignancies. JQ1
synergy with HDACi & AURKi suggests novel drug combinations for future
development. As MYC signaling influences thousands of gene targets, pheno-
typic analyses like the EVA/PCD platform can offer insights into cellular cell
death events that serve as surrogate markers for clinical response to MYC inhi-
bition. Supported in part by the Vanguard Cancer Foundation, the Nagourney
Institute and the Malcolm C. Todd Cancer Institute.
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#4685 Immune checkpoint protein VISTA is a critical regulator of the
IL-23/IL-17 inflammatory axis. Na Li,1 Wenwen Xu,1 Ying Yuan,1 Natarajan
Ayithan,1 Yasutomo Imai,1 Xuesong Wu,2 Halli Miller,1 Michael Olson,1 Sam-
uel T. Hwang,1 Subramaniam Malarkannan,3 Li Wang1. 1Medical College of
Wisconsin, Milwaukee, WI; 2Medical College of Wisconsin, Dermatology, Mil-
waukee, WI; 3Blood Research Institute, Milwaukee, WI.
V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) is an
inhibitory immune-checkpoint molecule that suppresses CD4 and CD8 T
cell activation when expressed on antigen-presenting cells. Vsir-/- mice devel-
oped loss of peripheral tolerance andmulti-organ chronic inflammatory pheno-
types. Vsir-/- CD4 and CD8 T cells were hyper-responsive towards self- and
foreign antigens.Whether or notVISTA regulates innate immunity has not been
demonstrated. Our current study shows that VISTA-blocking monoclonal an-
tibody (mAb) enhanced anti-tumor T cell response, and synergized with a pep-
tide vaccine andTLR7 agonist imiquimod as adjuvant to suppress tumor growth
in the B16 melanoma model. Surprisingly, the therapeutic effect of this combi-
nation therapy was abolished in the IL17R knockout hosts, indicating that the
IL-17-mediated inflammation is regulated by VISTA and is required for anti-
tumor immunity in the context of VISTA blockade. To better defıne the regula-
tory role of VISTA in inflammation, we employed a murine model of psoriasis
induced by topical treatment of IMQ. Our data show that VISTA defıciency
exacerbated the psoriasiform inflammation. Enhanced TLR7 signaling in Vsir-/-
dendritic cells (DCs) led to the hyper-activation of Erk1/2 signaling and aug-
mented the production of IL-23. IL-23, in turn, promoted the expression of
IL-17A in both TCRgd T cells and CD4 Th17 cells. Furthermore, VISTA
regulates the peripheral homeostasis of CD27- gd T cells, and their activation
upon TCR-mediated or cytokine-mediated stimulation. IL-17A-producing
CD27- gd T cells were expanded in the Vsir-/- mice and amplifıed the inflamma-
tory cascade. Together, these results indicate that VISTA is a critical regulator of
the IL-23/IL-17-mediated inflammatory axis. Ongoing studies will defıne how
IL-17 regulates tumor-reactive immunity in the context of VISTA blockade and
TLR vaccine adjuvant.
#4686 Omx a hypoxia modulator reverses the immunosuppressive glio-
blastomamicroenvironment by stimulating T cell infıltration and activation
that results in increased number of long-term survivors. Natacha Le Moan,1
Philberta Leung,2 Sarah Ng,2 Tina Davis,2 Carol Liang,2 Jonathan W. Winger,2
Stephen P. Cary,2 Nicolas Butowski,3 Ana Krtolica2. 1Omniox, Inc., San Carlos,
CA; 2Omniox, Inc., San Francisco, CA; 3University of California San Francisco,
San Francisco, CA.
Oxygen is one of the key modulators of tumor microenvironment whereby
low oxygen or hypoxia is associated with resistance to chemo- and radio- ther-
apies and poor patient outcomes. Hypoxia favors an immunosuppressive tumor
microenvironment by promoting Treg recruitment and activation and sup-
pressing T cell and NK cell proliferation and effector function and pro-inflam-
matory cytokine secretion. Therefore, reversing tumor hypoxia could create an
immunopermissive microenvironment and improve the effıcacy of several im-
munotherapies. Omniox has developed an oxygen carrier OMX that can specif-
ically deliver oxygen to hypoxic tumor regions without affecting oxygenation of
tissueswithin physiologic oxygen levels. Due to its biochemical features, OMX is
well tolerated in small (rats and mice) and large (sheep and dogs) animals.
Following intravenous administration, OMX extravasates through leaky tumor
vasculature and accumulates within immunocompetent rodent orthotopic gli-
oblastoma models as well as spontaneous canine brain tumors. Consequently,
OMX decreases hypoxia levels in the tumor tissue measured directly using ox-
ygen sensor probes and indirectly with exogenous hypoxia markers using
ELISA, immunohistochemistry and flow cytometrymethods.Herewe evaluated
OMX’ activity in reversing the immunosupressive tumor microenvironment
using a combination of immunohistochemistry, flow cytometry and Luminex
methods. Moreover, we investigated the effıcacy of OMX in improving mouse
survival and effectiveness of checkpoint inhibitors (CPI). Similar to previously
published fındings, we demonstrated that T lymphocytes are mostly excluded
from hypoxic tumor areas in the GL261 model. A single OMX treatment in
GL261 tumor-bearingmice reduces tumor hypoxia, enhances T cell localization
in previously hypoxic tumor areas, and increasesCD8 accumulation by4-fold.
Specifıcally, OMX treatment increased the activated cytotoxic T lymphocytes
(CTLs) fraction by2 fold and reduced the immunosuppressive Treg fraction
by 2-fold, resulting in a 3-fold increase of Teff/Treg ratio, which indicates a
switch from an immunosupressive to an immunopermissive microenviron-
ment.When combined with CPI, OMX reverses the immunosuppressive tumor
microenvironment by increasing CD8 T cell infıltration, proliferation and cyto-
toxic activity, and modulating IFNg and IFNg-inducible cytokines that may
polarize T cells towards a Th1 phenotype. Furthermore, treatment of late-stage
GL261 tumor-bearingmicewith the combination ofOMX-CPI increasesmouse
survival by 80%. By delivering oxygen specifıcally to the hypoxic tumor mi-
croenvironment, OMX may restore anti-cancer immune responses in glioblas-
toma patients and synergize with radiotherapy and immunotherapy to enhance
tumor control and improve patient outcomes.
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#4687 Characterization of the cryoablation-induced immune response in
kidney cancer patients. Taigo Kato,1 Tomoyuki Iwasaki,2 Motohide Uemura,3
Akira Nagahara,3 Hiroki Higashihara,3 Keigo Osuga,3 Yuji Ikeda,4 Kazuma Ki-
yotani,1 Jae-Hyun Park,1 Norio Nonomura,3 Yusuke Nakamura1. 1Univ. of Chi-
cago, Chicago, IL; 2Tohoku Univeristy, Sendai, Japan; 3Osaka University Gradu-
ate School of Medicine, Osaka, Japan; 4SaitamaMedical University International
Medical Center, Hidaka, Japan.
Cryoablation is one of promising treatment modalities for kidney cancer and
expected to inducestrong local immuneresponseaswell as systemicTcell-mediated
immune reaction that may lead to regression of distant metastatic lesions. In this
study, we collected tumor tissues from 14 kidney cancer patients, at the time points
of pre-cryoablation and 3 months after cryoablation. In addition, blood samples
were collected from 8 kidney cancer patients at the same time points.We applied a
next generation sequencing approach to characterize T cell receptor beta (TCRB)
repertoires using mRNA isolated from tumor tissues and peripheral blood mono-
nuclearcells.Toassess clonalityofTcells, thediversity indexofTCRBwascalculated
according to complementarity-determining region 3 sequences. Through TCRB
repertoire analysis, we demonstrated expansion of certain T cell clones in tumor
tissues by cryoablation. In addition, we found that proportions of abundant TCRB
clonotypes ( 1% frequency among total TCRB reads) were signifıcantly increased
in the post-cryoablation tissue samples than those of pre-cryoablation tumor sam-
ples, suggesting that cryoablation could induce strong immune reactions in tumors
with oligoclonal expansion of anti-tumorT cells. Interestingly, some of these TCRB
clonotypes were also increased in peripheral blood, indicating that certain numbers
of T cell clonesmay also circulate systemically and then attack tumor cells in distant
regions.WealsomeasuredmRNAexpression levels of immune-related genes in the
tissue samples of pre- and post- cryoablation and found signifıcantly elevated ex-
pression levelsofCD8,CD4,GranzymeA,andCD11calongwithhighCD8/FOXP3
ratio in the post-cryoablation tissue samples. Furthermore, immunohistochemical
analysis confırmed infıltration of a large number of CD11c-positive cells, probably
representing macrophages and dendritic cells into the post-cryoablation tissues.
Collectively, our fındings revealed that cryoablation could induce both local and
systemic immune responses associated with CD11c-positive cells infıltration and
oligoclonal expansion of anti-tumor T cells. For the translation into clinics, unique
TCR sequences identifıed in post-cryoablation tissues in individual patients can be
applied to personalized TCR-engineered T cell therapy.
#4688 AVID200: a novel computationally-designed TGF beta trap pro-
moting anti-tumor T cell activity.Maureen D. O’Connor-McCourt,1 Anne E.
Lenferink,2 John Zwaagstra,2 Traian Sulea,2 Catherine Collins,2 Renu Singh,2
Yves Durocher,2 Christiane Cantin,2 James Koropatnick3. 1Formation Biologics,
Inc., Montreal, Quebec, Canada; 2National Research Council of Canada, Mon-
treal, Quebec, Canada; 3Univ. of Western Ontario, London, Ontario, Canada.
AVID200 is a computationally-designed, avidity-enhanced, receptor ectodo-
main-based trap that binds and neutralizes TGF-beta 1 and 3 with low pM
potency. Of the three TGF-beta isoforms, blockade of TGF-beta 2 has been
shown to promote cancermetastasis. Therefore, AVID200 is designed to inhibit
TGF-beta 1 and 3 only. TGF-beta is a strongly immunosuppressive molecule
that, when expressed by cancers, mediates escape from immune surveillance.
Increased TGF-beta ligand promotes cancer progression by suppressing anti-
tumor immunity, predominantly by suppressing recruitment and activation of
anti-tumor T cells. Consequently, TGF-beta is an important therapeutic target
in cancer.AVID200 immunotherapy blocks the capacity of TGF-beta 1 and 3
ligands to interact with their receptors. That blockage induces T cell infıltration
into tumors, thereby promoting a ‘T cell-inflamed‘ tumor state. Multiple trap
formats with differing in vitro blocking potency, biophysical traits, and circulat-
ing half-lives in rodents have been designed, synthesized, and tested. On the
basis of favorable characteristics, the AVID200molecule was selected for in vivo
assessment of effıcacy in inhibiting growth of syngeneic 4T1 triple negative
breast cancer (TNBC) homografts in immunocompetent hostmice. In addition,
CD4 and CD8 T cells isolated from draining lymph nodes of 4T1 tumor-
bearing mice, treated and untreated with AVID200 and other candidate TGF-
beta traps, were assessed for activities important in anti-tumor immune activity.
We report that AVID200 immunotherapy decreased T-cell apoptosis, stimu-
lated T-cell proliferation in response to tumor cell lysate-loaded dendritic cells,
and enhanced the capacity of T-cells to specifıcally recognize and kill 4T1 tumor
cells in ex vivo 2D cultures. The effect of combining AVID200 with immune
checkpoint inhibitors in the treatment of syngeneic homografts in immune-
competentmice is being assessed. AVID200 is a promising new immunotherapy
to selectively inhibit the TGF-beta 1 and 3 isoforms, thereby enhancing desirable
anti-tumor immunity while avoiding the tumor-promoting effects resulting
from TGF-beta 2 neutralization.
#4689 Anti-proliferative effect and tumor targeting properties of Sur-
VaxM-derived monoclonal antibodies. Michael J. Ciesielski, Sheila Figel,
Laura Wiltsie, Phillip Galbo, Cheryl Frank, Robert A. Fenstermaker. Roswell
Park Cancer Inst., Buffalo, NY.
Background: Survivin is an inhibitor of apoptosis protein (IAP) which is up-
regulated in many cancers. SurVaxM (active anti-survivin immunotherapy) is
currently being evaluated in a multi-center phase II clinical trial. Circulating
anti-survivin antibodies were recently detected in recurrent glioblastoma pa-
tients who received SurVaxM immunizations in a previous phase I study.
Though primarily functioning as an intracellular molecule, survivin has also
been identifıed in patient serum, and, recently, in tumor-derived exosomes.
Methods: Patients in the completed SurVaxM phase I clinical trial produced
both antibody and CD8 T cell responses against survivin. In order to gauge
whether antibodies to the vaccine provided any therapeutic benefıt, or might
serve as potential biomarkers for SurVaxM responsiveness, we tested these an-
tibodies in pre-clinical tumor models. Murine hybridomas derived from the
SurVaxM peptide were established and purifıed yielding several high-affınity
IgG antibodies. These antibodies were characterized for target recognition and
therapeutic potential. Results: Two of the clones with the highest affınities, 2C2
(IgG2a) and H30 (IgG1), recognized both SurVaxM peptide and the wild type
survivin counterpart (ELISA assay), as well as endogenous, full-length survivin
(western blotting). Survivin was detected on cells with these antibodies using
both immunofluorescence and flow cytometry. Following s.c. implantation of
glioblastoma (GL261) and melanoma (B16) tumors in immuno-competent
C57BL/6 mice, administration of 2C2 and H30 antibodies (i.p. injection) re-
duced tumor growth in both models compared to an irrelevant IgG. An ortho-
topic intracranial glioma study showed similar anti-tumor effects when treated
with SurVaxM-derived antibodies. Tumor growth was also inhibited in im-
muno-compromised (nude) animals treated with 2C2 or H30 antibodies, al-
though to a lesser extent. Conclusions: Antibodies generated in response to the
SurVaxM vaccination are highly cross-reactive to survivin and provide thera-
peutic benefıt in immuno-competent mouse tumor models. These antibodies
retain some effıcacy in immuno-compromised models, indicative of a direct
T-cell independent effect. An anti-tumor response through anti-survivin tar-
geted antibodies is unexpected as surface-accessible survivin expression has not
yet been well described in the literature. Data presented here highlight possible
avenues for investigation of mechanism(s) of action.
#4690 Hexavalent CD27 agonists show single agent anti-tumor activity
and enhanced memory formation in mouse syngeneic tumor models. Chris-
tian Gieffers, David Richards, Jaromir Sykora, Mauricio Redondo-Müller,
Meinolf Thiemann, ChristianMerz, Karl HeinonenHeinonen, ViolaMarschall,
Harald Fricke, Oliver Hill. Apogenix AG, Heidelberg, Germany.
Tumor necrosis factor receptor superfamily (TNFRSF) proteins are widely
expressed by immune and tumor cells highlighting their importance inmultiple
locations and phases of the anti-tumor immune response. Apogenix has devel-
oped a proprietary technology platform for the construction of novel hexavalent
TNFRSF agonists (HERA) for the treatment of cancer. HERA fusion proteins
comprise a perfect molecular mimic of the TNFSF cytokine structure and are
based on dimerization of trivalent single-chain TNFSF receptor-binding do-
mains (scTNFSF-RBD) via a Fc- receptor (FcR) binding defıcient immuno-
globulin Fc domain. As a result of this molecular design, HERA proteins are
capable of clustering six receptors in a spatially well-defıned manner. Signaling
following treatment with the Apogenix HERA “scTNFSF-RBD-Fc fusion pro-
teins” is entirely independent of secondary crosslinking through FcRs that is
required for many agonistic anti-TNFRSF antibodies. The HERA engineering
concept has been successfully translated to TRAIL, GITRL, CD40L, LIGHT and
CD27L resulting in agonists that are currently in development. CD27L is a po-
tent co-stimulatory molecule that drives T cell activation and survival through
interaction with its receptor (CD27). HERA-CD27L is expressed in CHO sus-
pension cells followed by a lab-scale purifıcation process that results in homog-
enous aggregate-free protein lots. The purifıed protein binds its respective tar-
get-receptor with high affınity. In vitro, HERA-CD27L was able to bind CD27
expressed on primary human CD4 and CD8 T cells. Binding signifıcantly
increased T cell expansion following CD3/CD28 stimulation and leads to
increased expression of OX40 on CD4 T cells and 41BB on CD8 T cells,
respectively. In vivo, a single dose of 10mg/kg HERA-CD27L increases clonal
expansion of antigen-specifıc CD8 T cells upon immunization with Ovalbu-
min (Ova) in the mouse OT-1 model with a kinetics leading to peak levels of
25% Ova-specifıc CD8 T cells at day 6 after treatment. Anti-tumor effıcacy
of HERA-CD27 was evaluated in MC38-CEA and CT26 colorectal syngeneic
murine tumormodels. In both models treatment with HERACD27L resulted in
a dose dependent inhibition of tumor growth. CT26 tumor bearingmice treated
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with 1mg/kg HERA-CD27L, twice weekly showed an 85% tumor-growth inhi-
bition (TGI) compared to the control group. A signifıcant TGI of 48% could be
observed in theMC38-CEAmodel upon treatment with 10mg/kg, twice weekly.
Analysis of peripheral lymphoid tissues in the MC38-CEA bearing mice could
furthermore show that HERA-CD27L treatment is accompanied with enhanced
memory formation in both CD4&CD8T cells. In summary, the data on the
hexavalent HERA-CD27L indicate a potent immune cell driven anti tumor ef-
fıcacy. Therefore, HERA-CD27 agonists could be applied for the treatment of
cancer as a single agent or in combination with check-point Inhibitors.
#4691 Polarization of macrophages with STING agonists. Kimiora L.
Henare, Sofıan M. Tijono, Lai-Ming Ching. The University of Auckland, Auck-
land, New Zealand.
The functional plasticity of macrophages and their ability to support tumour
growth or promote potent antitumor immunity make them an attractive target
cancer therapy. Macrophages have been implicated in the complex antitumor
activity of murine STING agonist, DMXAA, including disruption of tumor vas-
culature, induction of cytokine production, and promotion of durable antitu-
mor immune responses. Many of these activities are lost in STING/ mice, and
DMXAAdoes not bind to human STING, providing a pertinent explanation for
why the anti-tumour effects ofDMXAAobserved inmicewere not recapitulated
human clinical trials. Using PMA-differentiated THP-1 macrophages, we
sought to identify human active analogues of DMXAA in vitro, comparing their
capacity to induce cytokines indicative of a classically activated antitumour phe-
notype; the non-canonical STINGagonist 2=3=-cGAMPwas also included in our
investigation. IP-10 (CXCL10) production, measured by ELISA, was used as an
initial marker for activity, followed by multiplex cytokine analysis for broader
characterisation compared to M(IFN-/LPS), M(IL-4/IL-13), and ’resting’
M(media alone) macrophage phenotypes. Parallel experiments were also con-
ducted with RAW264.7murinemacrophages to compare theDMXAA-induced
cytokine profıle directly with that of 2=3=-cGAMP. 2=3=-cGAMP induced 22-
fold and 18-fold increases in IP-10 production in resting and M(IL-4/IL-13)
THP-1 macrophages, respectively. By comparison, THP-1 macrophages were
much less responsive to DMXAA and analogues tested to date. Furthermore,
2=3=-cGAMP induced a spectrum of cytokines similar to that observed in
M(IFN-/LPS) macrophages, and markedly different to that of M(IL-4/IL-13)
THP-1 macrophages. DMXAA, and analogues previously shown to have cyto-
kine-inducing activity in human leukocytes did not produce cytokine spectra
indicative of a classic M(IFN-/LPS) phenotype. Unlike human cells, however,
cytokine spectra produced by RAW264.7 murine macrophages were compara-
ble between DMXAA- and 2=3=-cGAMP-treated cells. These fındings support
previous data that suggest that STING agonists can promote macrophage po-
larisation towards an antitumour phenotype.WhileDMXAA is active inmurine
macrophages, only 2=3=-cGAMP can induce in human THP-1 cells, an M(IFN-
/LPS)-like spectrum of cytokines often attributed to an antitumour macro-
phage phenotype.
#4692 Local adjuvant treatment of clinical stage I-II melanoma with low
doseCpG-Band/orGM-CSF: Long-term follow-upof three randomized con-
trolled phase II trials. Bas D. Koster, Mari F. van den Hout, Berbel J. Sluijter,
Barbara G. Molenkamp, Ronald J. Vuylsteke, Arnold Baars, Paul A. van Leeu-
wen, Rik J. Scheper, Monique P. van den Tol, Alfons J. van den Eertwegh, Tanja
D. de Gruijl. VU University Medical Center, Amsterdam, Netherlands.
Introduction: Currently, there is no widely used adjuvant treatment available
to improve survival after surgical excision of localized melanoma. Here, we
present the clinical outcome of patients who participated in three randomized
phase-II trials and received low-dose local immunotherapy, whichwas shown to
be safe and to boost loco-regional and systemic anti-melanomaT cell immunity.
Patients and Methods: In three single-center, single-blinded, randomized and
placebo (saline) controlled phase-II clinical trials, patients with early stage mel-
anoma were treated with 1) Granulocyte/Macrophage-Colony Stimulating Fac-
tor (GM-CSF), 2) unmethylated CpG type-B oligodeoxynucleotide CpG7909
(CpG-B), and 3) CpG-B, alone or combined with GM-CSF, through 1-4 intra-
dermal injections at the site of the primary melanoma excision scar, within 7
days preceding re-excision and sentinel lymph node (SLN) biopsy. For clinical
follow-up analysis, all treated patients were grouped together (treated group
n36) as were the patients who received saline (saline group n28). Results:
10-year recurrence-free survival rate in the treated group was 94% (95% CI
78-98) versus 48% (95% CI 21-71) in the saline group (P0.005), hazard ratio
(HR) for recurrence was 0.15 (95% CI 0.06-0.60) for the treated group. This
apparent antitumor effıcacy was in line with the observation upon pathological
examination of less tumor positive SLN in the treated group (P0.05). The
10-year distant recurrence-free survival rate in treated patients was also higher
(94%, 78-98 versus 59%, 28-81, HR 0.22, 0.07-0.93; P0.04). Conclusion: Local
low-dose immunotherapy in patients with early-stage melanoma may offer du-
rable protection against distant recurrences. These fındingswarrant further clin-
ical exploration of this local non-toxic immune potentiating regimen.
#4693 Fc effector bioassays enable faster andquantitativemeasurement of
ADCC and ADCP mechanisms of action. Zhi-Jie Jey Cheng, Rich Moravec,
Aileen Paguio, Denise Garvin, Gopal B. Krishnan, Frank Fan, Mei Cong. Pro-
mega Corp., Madison, WI.
Antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-de-
pendent cell-mediated phagocytosis (ADCP) are recognized as important
mechanisms of action (MOA) of therapeutic antibodies. Primary peripheral
blood mononuclear cells (PBMCs) are routinely used in traditional bioassays to
measure potency, stability of antibody drugs in ADCC and ADCP. However
these methods are labor intensive and highly variable. Here we report the devel-
opment of a luciferase-based reporter assay that measures activation of effector
cells via cross-linking of Fc receptors with target cell-bound antibodies. We will
discuss functional cell-based Fc effector reporter bioassays developed to mea-
sure Human FcgRIIIa (V158 and F158 variants), Human FcgRIIa (H131 and
R131 variants), Human FcgRI as well asMouse FcgRIV and FcgRIII. Compared
to primary cell-based assays these reporter bioassays are less variable, easier to
use andprovidemore consistent analysis of the importantMOAs that are critical
to for drug development programs. In qualifıcation studies, performed in accor-
dance with ICH guidelines for antibody screening and characterization, we
tested the bioassays for specifıcity, accuracy, precision and linearity.
#4694 The humanized anti-CD47monclonal antibody, CC-90002, has an-
titumor activity in vitro and in vivo.RamaKrishnaNarla,1 HardikModi,1 Lilly
Wong,1 Mahan Abassian,1 Daniel Bauer,1 Pragnya Desai,1 Bonny Gaffney,1 Pil-
grim Jackson,1 Jim Leisten,1 Jing Liu,1 Antonia Lopez-Girona,1 Maria Romero,1
WenQing Yang,1 Brendan P. Eckelman,2 Quinn Deveraux,2 Laurie Phillips,1
Heather K. Raymon,1 Laure Escoubet,1 John Boylan,1 Kandasamy Hariharan1.
1Celgene Corp., San Diego, CA; 2Inhibrix, San Diego, CA.
Cluster of differentiation 47 (CD47) is a transmembrane protein ubiquitously
expressed on human cells but overexpressed onmany different tumor cells. The
interaction of CD47 with signal-regulatory protein alpha (SIRP) expressed on
macrophages results in the inhibition of phagocytosis. Thus, tumor cell overex-
pression of CD47 enables escape from immune surveillance via the blockade of
phagocytic mechanisms. We report here the characterization of CC-90002, a
humanized anti-CD47monoclonal antibody (mAb) that is being developed as a
potential therapeutic for hematologicmalignancies and solid tumors. CC-90002
has a high affınity for binding to CD47 with a subnanomolar dissociation con-
stant (Kd) value. The IC50 required for the blockade of the CD47-SIRP inter-
action was also in the subnanomolar range. CC90002 is unique among previ-
ously reported anti-CD47 antibodies for its inability to promote
hemagglutination while maintaining high affınity binding to CD47 and inhibi-
tion of the CD47-SIRP interaction. CC-90002 enabled antibody-mediated
phagocytosis of a panel of hematological cancer cell lines in vitro, includingALL,
multiple myeloma (MM) and acute myeloid leukemia (AML) cells, and primary
AMLpatient samples. The phagocytosis index for this panel (at 1g/mL) ranged
from approximately 20% to 60% for all the cell lines tested. Antibody concen-
tration-response studies indicated that the CC90002 effect was concentration-
dependent in the ALL and AML cell lines. CC90002 treatment signifıcantly
enabled the phagocytosis of two lenalidomide-resistant MM cell lines and pri-
mary AML cells from three patients. Additionally, CC-90002 treatment elicited
the phagocytosis of solid tumor lines, including those from ovarian, breast, head
and neck, lung, and pancreatic cancers. The in vivo effıcacy of CC-90002 was
evaluated across cell line-derived and patient-derived xenograft models. Signif-
icant dose-dependent antitumor activity was observed with CC-90002 treat-
ment in theMMcell line-derived xenograftmodels, RPMI 8226 and the parental
NCI-H929 and lenalidomide-resistant NCI-H929 (H929/R1). Treatment with
CC-90002 demonstrated signifıcant tumor regression in solid tumor xenografts
including a cell linederived model of triple negative breast cancer (TNBC),
MDA-MB-231, and a patientderived TNBC model, AA1126 and signifıcantly
prolonged survival in the HL60disseminated AML tumor model. Mechanistic
studies in the RPMI 8226 xenograft model confırmed binding of CC-90002 to
tumor cells and recruitment of F4-80-positive macrophages into the tumor.
RPMI 8226 tumor lysates from CC-90002-treated animals demonstrated an in-
crease in select chemokines and cytokines of murine origin. Taken together, the
in vitro and in vivo data demonstrate the potential for activity of CC90002 across
both hematological malignancies and solid tumors. CC-90002 is currently in
early clinical development.
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#4695 Targeting the LGR5 complex with BNC101 to improve checkpoint
inhibitor therapy in colorectal cancer. Daniel J. Inglis, Donna M. Beaumont,
Tina C. Lavranos. Bionomics Ltd., Thebarton, Australia.
LGR5 is a well characterised marker of intestinal stem cells found at the base
of intestinal crypts and a receptor for R-spondins, potent Wnt signalling mod-
ulators and stem cell growth factors. Overexpression of LGR5 in colorectal tu-
mor cells has been shown to be a predicative marker of higher relapse rates in
CRC patients. BNC101 is a fırst-in-class high affınity anti-LGR5 humanized
monoclonal antibody currently in a Phase I clinical trial in patients with recur-
rent metastatic CRC. BNC101 has been shown pre-clinically to have anti-tumor
activity in multiple CRC patient derived xenografts and limiting dilution re-
implantation assays consistent with the hypothesis that LGR5 is a functional
cancer stem cell (CSC) target in CRC. Recent evidence suggests that CSCs or
treatment resistant cells, due to distinct gene and antigen expression profıles,
may share the same immune privilege that is afforded to normal stem cells.
Immunologic therapies with checkpoint inhibitors directed against whole tu-
mors are largely biased toward differentiated tumor cells which form the bulk of
the tumor. CSCs may also have an immunosuppressive phenotype, allowing
them to evade and dampen the anti-tumor host immune response. The synge-
neic murine MC38 colorectal cancer model was used to explore the potential
synergies of BNC101 and anti-PD-1 treatments. The combination of murine
versions of both antibodies drove a reduction (35%) in tumoral Tregs (FoxP3)
when BNC101 and anti-PD-1 were used compared to anti-PD-1 treatment
alone. This is a signifıcant fınding and shows early effıcacy in keeping with the
notion that CSCs create an immunosuppressive environment which can be tar-
geted in combination for a better immunotherapeutic response. The activation
of antibody-dependent cell-mediated cytotoxicity (ADCC) was demonstrated
using BNC101 treatment of cells. Membrane dye tracked U-937 monocytes
(which express FcR) were able to specifıcally cross bind with CHO-LGR5 cells
but only in the presence of BNC101 (an IgG1). This potentially indicates a
further adaptive immune priming mechanism with the ability to complement
the action of checkpoint inhibitors. Understanding the role of CSCs in tumor
immunity will help guide future clinical applications of immune checkpoint
inhibitors in CSC-driven solid tumors. In addition, combination of immune
checkpoint therapies with CSC targeting agents may improve the clinical utility
of each approach. These fındings support clinical evaluation of BNC101 in com-
bination with checkpoint inhibitors. Releasing the immunosuppressive capabil-
ities of CSCwith BNC101 driven targeting of the tumormay extend the reach of
the immune system, whereby checkpoint inhibitors are able to leverage greater
therapeutic benefıt to a larger patient population and extend duration of re-
sponse.
#4696 Development of an inhaled TLR9 agonist for the immunotherapy
of lung cancer. Marilena Gallotta, Hikmat Assi, Robert L. Coffman, Cristiana
Guiducci. Dynavax Technologies, Berkeley, CA.
CpG-oligonucleotides (CpG-ODN) stimulate innate immune responses
through Toll-like receptor-9 (TLR9). Intratumoral (IT) administration of CpG-
ODN has been shown to be safe and clinically effective in humans and in mul-
tiple animal species. An important feature of local administration of a CpG-
ODN is the ability to stimulate immune responses that control the growth of
distant, uninjected tumors. Such treatment is especially effective when com-
bined with a complementary mode of immunotherapy, such as anti-PD-1 or
radiation. However, repeated IT injection is not practical for many tumor types,
including most lung cancers. In mild asthmatic patients and healthy subjects,
CpG-ODN have demonstrated safety and pharmacologic activity when deliv-
ered by inhalation directly to the lungs. Thus, inhaled CpG presents an alterna-
tive to IT injection for primary lung cancers and for other tumor types with
prominent lungmetastases. In the 4T1mousemodel ofmetastatic breast cancer,
treatment of mice with a CpG-ODN administered intranasally led to a marked
reduction in the number of lungmetastases. This reductionwas accompanied by
infıltration of tumorswith activatedCD8 andCD4T cells and the formation
of highly organized tertiary lymphoid structures. These changes are similar to
those observed after IT injection of solid tumors growing subcutaneously, and
are consistent with changes observed in human tumors responsive to immuno-
therapy. In the 4T1 model, intranasal CpG-ODN strongly synergized with sys-
temic anti-PD-1 treatment and induced complete clearance of lung tumors, as
well as metastases in tissues not exposed to the CpG-ODN, including liver,
pancreas and bone. This generation of systemic immunity resulted in long-term
survival in the majority of mice. Immune cell subset depletion studies implicate
both CD8 and CD4 T cells in the rejection of lung tumors treated with inhaled
CpG-ODN plus anti-PD1. Dynavax has developed a CpG-ODN, DV281, that is
optimized for aerosol delivery and plans to initiate clinical studies in NSCLC
patients in 2017.
#4697 Intratumoral immunotherapy with TLR7/8 agonist MEDI9197
modulates the tumor microenvironment and holds potential for combina-
tion with immune checkpoint inhibitors. Stefanie R. Mullins,1 Katharina Vo-
gel,1 John Vasilakos,2 Iwen Grigsby,2 Simon Dovedi,1 Ryan Patricia,3 Zachary
Cooper,3 Ronald Herbst,3 Rakesh Kumar,3 Mark Tomai,2 Robert W. Wilkin-
son1. 1MedImmune, Cambridge, United Kingdom; 23M Drug Delivery Systems
Division, St Paul, MN; 3MedImmune, Gaitherburg, MD.
Recent successes in immuno-oncology have focussed primarily on the T-cell
synapse, targeting co-activatory /inhibitory pathways to modulate T cell func-
tion. However, strategies that target tumor-resident myeloid cells may be re-
quired to fully exploit the therapeutic potential of the anti-cancer immune re-
sponse. TOLL-like receptors (TLRs) are expressed on a broad range of myeloid
cells and function to recognise highly evolutionarily conserved pathogen-asso-
ciated molecular patterns. Signalling through TLRs leads to the activation of
antigen-presenting cells (APCs) and to expression of inflammatory cytokines.
However, whilst topical application of TLR agonists have proved successful in
the treatment of dermatological tumors, systemic administration have proved to
be poorly tolerated. MEDI9197 (formerly 3M-052), is a novel lipophilic TLR7/8
agonist designed with a lipid tail to facilitate retention at the site of injection,
limiting systemic exposure. These properties makeMEDI9197 ideal for intratu-
moral (IT) administration. We have demonstrated that MEDI9197 is a potent
TLR7 and TLR8 agonist and induces pro-inflammatory cytokines through acti-
vation of a diverse range of myeloid and lymphoid cells. In mice bearing estab-
lished tumors, IT injection ofMEDI9197 induces a local inflammatory response,
characterized by upregulation of genes associated with the activation of innate
and adaptive immunity in the injected tumor and tumor draining lymph nodes.
Moreover, treatment leads to an increase in the frequency of tumor infıltrating
lymphocytes (TILs), such as CD8 cytotoxic T cells and increased expression of
activationmarkers, such as CD69. Cellular depletion studies reveal that CD8T
cells are required for therapeutic activity. Furthermore, using in vitro co-cul-
tures we demonstrate thatMEDI9197 is able to enhance cytotoxic activity of NK
cell and T cells. Importantly, in models that respond poorly to mAbs targeting
either PD-L1 or CTLA-4, combination with MEDI9197 signifıcantly improved
anti-tumor activitywhen compared to eithermonotherapy alone. These preclin-
ical data demonstrate that MEDI9197 can modulate both the myeloid and lym-
phoid immune compartments to mediate anti-tumor activity and combines
productively with immune checkpoint blockade. MEDI9197 is currently being
evaluated as a monotherapy for safety and effıcacy in human clinical trials
(NCT02556463).
#4698 Immuno-oncological effıcacy of RXDX-106, a novel, selective and
potent small molecule TAM (TYRO3, AXL, MER) inhibitor. Yumi
Yokoyama,1 Erin D. Lew,1 Ruth Seelige,2 Colin Walsh,1 Maria Barrera,1 Eliza-
beth Tindall,1 Joanne Oh,1 Heather Ely,1 Amy Diliberto,1 Amanda Albert,1 Jack
Bui,2 Gary Li1. 1Ignyta, Inc., San Diego, CA; 2University of California, San Diego,
San Diego, CA.
The TAM family of receptor tyrosine kinases (RTKs), TYRO3, AXL, and
MER, has been implicated in the pathogenesis and progression of many cancer
types. In cancer cells, overexpression of TAMRTKs is associated with resistance
and mesenchymal phenotype. In immune cells, TAM RTKs play a key homeo-
static role as negative regulators of immune responses, contributing to the eva-
sion of cancer cells from immune surveillance. Here we studied expression as
well as functional modulation of TAM RTKs on immune cells in the tumor
microenvironment and evaluated whether RXDX-106, a selective and potent,
pseudo-irreversible small molecule inhibitor of TAM RTKs could restore and
enhance host immunity against cancer. We fırst evaluated the expression of
TAM RTKs on immune cells in non-tumor bearing mice and tumor bearing
mice. Tumor bearing animals showed increased expression of TAM RTKs in
subsets of immune cells such as lymph nodemacrophages andT cells, compared
to non-tumor bearing mice. Particularly, TAM expression was upregulated in
CD8 T cells in tumors, suggesting that the increased expression could restrain
T cell activation and mediate exhaustion. RXDX-106 reduced TAM phosphor-
ylation onmacrophages at concentrations as low as 2.5 nM, and inhibited AXL-
and MER-dependent in vitro phagocytosis with an IC50 of 10.8 and 9.1 nM,
respectively. In syngeneic mouse models, including 4T-1 breast cancer model
and CT26 colon cancer model, RXDX-106 dose-dependently inhibited tumor
growth and demonstrated further tumor growth inhibition in combinationwith
anti-CTLA-4 or anti-PD-1 antibodies. The tumor growth inhibition was asso-
ciated with increased total T cells, decreased T-regulatory cells, and increased
IFN- production by NK cells in the tumor. RXDX-106 also increased IFN-
levels in the blood when combined with anti-PD-1 antibody. Although RXDX-
106 had no effect on T cell proliferation in vitro, it could increase the prolifera-
tion of T cells in lymph nodes in vivo. In conclusion, we demonstrated that
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tumors could induce TAMexpression on subsets of T cells and that inhibition of
TAM RTK activity by the small molecule inhibitor, RXDX-106, could poten-
tially remove the molecular “brake” on immune activation in macrophages, NK
cells and T cells, resulting in repolarization of the immune response towards an
anti-tumor environment. The unique mechanism of activating both innate and
acquired immunity by RXDX-106, and the compelling preclinical data in cell
line and syngeneic models, support the clinical development of RXDX-106 in a
wide variety of cancers.
#4699 Single domain antibody (sdAb) localizes in cancer cells to inhibit
signal transducer and activator of transcription 3 (STAT3) resulting in ther-
apeutic inhibition of multiple cancers. Sunanda Singh,1 Genoveva Murillo,2
AmandaRom,2Avani Singh,1 Samara Singh,1Meenakshi Parihar,1DongChen,3
Rajendra Mehta,2 Robert Baker,2 Anjali Singh,1 Ashutosh S. Parihar1. 1Singh
Biotechnology, Tampa, FL; 2IITResearch Institute, Chicago, IL; 3Creative Biolabs,
Shirley, NY.
STAT3 is involved in the pathogenesis ofmanymalignancies, sowedeveloped
an anti-STAT3 VHH (variable region of the heavy chain), SBT-100, that inter-
nalizes in cancer cells and binds unphosphorylated STAT3 (U-STAT3) and
phosphorylated STAT3 (P-STAT3) and results in signifıcant inhibition of mul-
tiple cancers. ATCC cell lines for triple negative breast cancers (MDA-MB-231,
MDA-MB-468, MDA-MB-453), ER/PR breast cancer (MCF-7), HER2
breast cancer (BT474), pancreatic cancers (PANC-1, BX-PC3), murine mam-
mary cancer (4T1), STAT3 null cells (PC-3), and castrate-resistant prostate can-
cer (DU145) were tested. Athymic nude mice were obtained from Envigo. The
IL-6 Reporter Cell Assay was obtained from Promega. VEGF inhibition ELISA
was done using retinal epithelial cells (ATCC). In vitro growth inhibition was
done using a MTT assay. Immunoprecipitation (IP) and western blot studies in
MDA-MB-231, PANC-1, HeLa, DU145, 4T1 and PC-3 showed that SBT-100
binds U-STAT3 and P-STAT3. No STAT3 binding was seen in PC-3. Binding to
P-STAT3 was seen in lysates from the 4T1 cells, which have constitutively acti-
vated STAT3. Since rodent and human STAT3 have a 99% homology, rodents
are excellent models for extrapolating to human disease for over production of
P-STAT3. Within 24 hrs IL-6 assay showed that SBT-100 blocked the produc-
tion of IL-6 (p0.0001) compared to control. The degree of IL-6 suppression
was comparable to the negative control, BB1608 (STAT3 inhibitor). VEGF
ELISA showed signifıcant (p0.0001) inhibition of VEGF production within 12
hrs and was maintained for up to 48 hrs. After 3 days with SBT-100 the MTT
assay showed growth inhibition (p0.001) in BT474 (93%), MCF-7 (93%),
MDA-MB-231 (77%), MDA-MB-468 (85%), MDA-MB-453 (64%), PANC-1
(79%), BX-PC3 (90%), and DU145 (92%). MDA-MB-231 tumors grown in
xenograft athymic mice showed suppression (p0.001), IHC staining in the
cytoplasm, and nucleus after 7 days of SBT-100 treatment. U-STAT3 and P-
STAT3 activate genes that promote growth, proliferation, angiogenesis, im-
mune suppression, cancer stem cells, metastasis, and apoptosis inhibition. SBT-
100 enters the cancers cells, binds STAT3 and P-STAT3 causing growth
inhibition (p0.001) in MCF-7, BT474, MDA-MB-231, MDA-MB-468, MDA-
MB-453, PANC-1, BX-PC3, andDU145. These results suggest that SBT-100 can
be developed as a therapeutic for cancers expressing either STAT3 or P-STAT3.
#4700 Poly G oligonucleotide enhances anti-tumor immune response
among the patients with primary lung cancer.Nobuaki Kobayashi,1 Yuji Shi-
bata,2 Masaki Yamamoto,2 Takashi Sato,2 Masaharu Shinkai,2 Harumi Koi-
zumi,3 Kenichi Takahashi,3 Makoto Kudo,1 Hidekazu Shirota,4 Takeshi
Kaneko2. 1Yokohama City University Medical Center, Yokohama, Japan; 2Yoko-
hama City University, Yokohama, Japan; 3YokohamaMinami Kyousai Hospital,
Yokohama, Japan; 4Tohoku University Hospital, Yokohama, Japan.
Synthetic oligonucleotides (ODNs) containing specifıc sequences have an im-
munomodulatory effect. It is highly expected that such ODNs can be developed
into a novel anti-cancer immunotherapy with these effects. Our past data re-
vealed that a novel poly-GODNhas an anti-tumor immune effect in the tumor-
bearing murine model. This effect of poly-G ODN was mediated by T cells in a
TLR9 independent manner. Poly-GODN directly induced the phosphorylation
of Lck, thereby enhancing the production of IL-2 and T cell proliferation.Mean-
while, our recent data suggested that the immune effect by poly-G ODN against
cancer was different in human. We identifıed poly-G ODN induced T cell pro-
liferation and production of IFN-gamma through the enhancement of mono-
cyte maturation in human mononuclear cells isolated from peripheral blood or
malignant pleural effusion of lung cancer patients. Further studies are continued
for the establishment of a novel anti-cancer immune therapy with poly-GODN.
#4701 Blocking FSTL1 ameliorates immunity against osteosarcoma.Chie
Kudo-Saito, Yamato Ogiwara, Kazunori Aoki.National Cancer Center Research
Institute, Tokyo, Japan.
Purposes: Osteosarcoma is a rare malignant tumor of bone in children and
young adults, and it is very hard to successfully control the systemic metastases
and life-threatening health problemsmore than a decade after the completion of
the care due to the intensiveness of the conventional treatments including sur-
gical resection of the primary tumor and chemotherapy. Therefore, non/low-
toxic but advanced treatments have been expected for a long while. We recently
found that a BMP family FSTL1 is highly and functionally expressed in murine
and human osteosarcoma cell lines, and systemically expands pluripotent mes-
enchymal stem/stromal cells (MSCs), which play a central role in amplifıcation
of tumor heterogeneity that is consequence of reciprocal evolution togetherwith
the tumor microenvironment, including induction of immune suppression and
dysfunction, desmoplasia, and angiogenesis. FSTL1 and its induced MSCs also
directly confer higher invasive and metastatic properties on tumor cells leading
to further cancer progression. In this study, we evaluated antitumor effıcacy
induced by anti-FSTL1 mAb on murine osteosarcoma models, and also com-
pared the therapeutic effıcacy with those induced by immune checkpoint inhib-
itory mAbs (ICIs). Results: We used two syngeneic tumor models that were
subcutaneously implanted with murine osteosarcoma NHOS cells in BALB/c
mice, or LM3 cells in C3Hmice. Thesemice were intraperitoneally injectedwith
anti-FSTL1mAbs (10mg/kg) twice on day 5 and day 8 after tumor implantation,
andwere sacrifıced for immunological analysis of tumor-infıltrating cells, spleen
cells and bone marrow cells on day 15. In both osteosarcoma models, CD45-
MSCs as well as other immunosuppressive CD4Foxp3 Tregs and
CD11bGr1MDSCs systemically increased, indicating impairment of anti-
tumor immunity in the mice. Treatment with the anti-FSTL1mAb signifıcantly
induced potent tumor-specifıc CTLs through reduction of MSCs, resulting in
tumor-free in some of the treated mice. Although the antitumor effıcacy was
similar to those induced by ICIs, the mode of action was totally distinct because
MSCs and the MSC-inducible exhausted CD8PD1Tim3 T cells were re-
duced only in the anti-FSTL1-treated mice, but not in the ICI-treated mice.
Conclusions: These results suggest that blocking FSTL1 properly reprograms
immunity toward elimination of osteosarcoma by reducing the tumor-support-
iveMSCs. Anti-FSTL1mAbmay be a promising drug for treating osteosarcoma
more moderately but effectively in clinical settings.
#4702 PD-L1 blockade in preclinical models of PTEN-defıcient prostate
cancer. Marco A. De Velasco,1 Yurie Kura,1 Naomi Ando,1 Noriko Sato,1 Ka-
zuko Sakai ,1 Barry R. Davies,2 Koichi Sugimoto,1 Masahiro Nozawa,1 Kazuhiro
Yoshimura,1 Kazuhiro Yoshikawa,3 KazutoNishio ,1 HirotsuguUemura1. 1Kin-
dai University Faculty of Medicine, Osaka-Sayama, Japan; 2AstraZeneca,
Macclesfıeld, United Kingdom; 3Aichi Medical University, Nagakute, Japan.
Immune checkpoint blockade with antibodies aimed at enhancing antitumor
immunity have become an attractive therapeutic option. Establishing immuno-
competent and clinically relevant models that predict treatment response is
essential for the development of novel immunotherapies. To gain better insights
into the preclinical evaluation of novel immunotherapeutic strategies, we used
genetically engineered mouse models of PTEN-defıcient prostate cancer. We
fırst analyzed the transcriptome in castration-naïve prostate tumors and the
progression to castration-resistant disease. Comparative analyses were per-
formed between age-matched normal prostate and PTEN-/- prostate tumor
samples from castration-naïvemice and, at 4weeks (castration-sensitive) and 10
weeks (castration-resistant) post-surgical castration. Pathway and gene-set en-
richment analysis indicated that abnormal tumor immunity was strongly asso-
ciated with the progression to castration resistance. Chemokine signaling, B cell
receptor and T cell receptor signaling pathways were among the top dysregu-
lated pathways, and gene signatures of suppressed tumor immunity were en-
riched in castration-resistant tumors. Higher expression patterns of the pro-
grammed cell death protein 1(PD-1) and its ligand (PD-L1) were observed in
castration-resistant tumors compared to castration-naïve tumors.We also char-
acterized immune expression profıles in more aggressive tumors from PTEN/
P53 double knockout (DKO) mice. PD-L1 was strongly expressed cancer cells,
but a higher presence of PD-1, CD45 and F4/80 stromal infıltrating im-
mune cells in was observed in castration-resistant tumors. PD-1/PD-L1 block-
ade with antibodies against mouse PD-L1 increased CD45 tumor infıltrating
lymphocytes (TILs) in an early model of PTEN/P53-defıcient castration-resis-
tant prostate cancer. PTEN/P53-DKO mice with advanced castration-naïve
prostate cancer tended to experienced longer overall survival after treatment
with PD-1/PD-L1 blockade compared to vehicle and isotype controls, median
survival 23, 14 and 11 days, respectively, P0.458. A higher number of CD45
TILs was observed in tumors of mice receiving the anti-PD-L1 treatment. In-
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terim analysis of PD-1/PD-L1 blockade on a model of advanced PTEN/P53-
defıcient castration resistant prostate cancer (CRPC) has thus far shown that
mice receiving treatment experience signifıcantly longer survival (P0.017,me-
dian survival not yet reached). Our fındings show that castration-resistance
promotes tumor immune suppression inmouse PTEN-defıcient prostate cancer
and suggest that this phenomenon can be reversed pharmacologically with anti-
PD-L1 blockade. Thus, we provide preclinical evidence for immune checkpoint
blockade as a potentially promising prostate cancer therapy.
#4703 INCAGN1949, an anti-OX40 antibodywith an optimal agonistic pro-
fıle and the ability to selectively deplete intratumoral regulatory T cells.AnaM.
Gonzalez,1 Mariana L. Manrique,1 Lukasz Swiech,1 Thomas Horn,1 Ekaterina Bre-
ous,2 Jeremy Waight,1 David Savitsky,1 Yuqi Liu,1 Shiwen Lin,1 Christopher
Clarke,1 Taha Merghoub,3 Daniel Hirschhorn-Cymerman,3 David Schaer,3 Gerd
Ritter,4 Jennifer Pulini,5 Kevin Heller,5 Peggy Scherle,5 Gregory Hollis,5 Reid Hu-
ber,5Marc vanDijk,5 Jennifer Buell,1 Robert Stein,1 NicholasWilson1. 1Agenus Inc,
Lexington, MA; 2Agenus Inc/ 4-Antibody, Basel, Switzerland; 3Memorial Sloan Ket-
teringCancerCenter,NewYork,NY; 4TheLudwig Institute forCancerResearch,New
York, NY; 5Incyte Corporation,Wilmington, DE.
OX40 is a T cell co-stimulatory receptor that can enhance the magnitude and
durability of T cell immune responses. Anti-OX40 agonist antibodies have
shown signifıcant single agent tumoricidal activity in preclinical models, and
can combine effectively with other immunomodulatory antibodies, targeted
therapies and vaccines. OX40 agonists are able to counteract the immunosup-
pressive tumor microenvironment and promote tumor-specifıc cellular immu-
nity via at least two distinct mechanisms: 1) promoting OX40 forward signaling
in tumor-specifıc T cells; and 2) co-engaging Fc receptors expressed by tumor-
associated effector cells, and facilitating the selective elimination of OX40high
intratumoral regulatory T cells. INCAGN1949, an anti-OX40 human IgG1 an-
tibody, was selected based on its ability to optimally enhance T cell responsive-
ness under conditions of suboptimal T cell receptor stimulation. INCAGN1949
was shown to mediate effective apical OX40 clustering that is translated into
effective downstream activation of the NFB pathway. Notably, INCAGN1949
was shown to maintain a sigmoidal dose response curve across a broad range of
antibody concentrations. This suggests a wide therapeutic window and may be
advantageous for dosing considerations. By contrast, evaluation of reference
OX40 antibodies indicated an inverted U-shaped dose response curve, leading
to impaired T cell responses at high concentrations. INCAGN1949 was selected
for clinical development based on its optimal agonist profıle, further reinforced
by its ability to combine with other co-inhibitory and co-stimulatory antibodies
to augment T cell responsiveness. Prior to human testing, the pharmacology and
tolerability of INCAGN1949 was evaluated in non-human primates (NHPs).
Pharmacokinetic (PK) and pharmacodynamic (PD) parameters were evaluated
including longitudinal measurements of serum cytokines, immune cell popula-
tions, activation state and T cell-mediated immune responses to reporter vac-
cine antigens. INCAGN1949 exhibited a linear PK profıle andwas well tolerated
at all doses tested, with nomaximum tolerated dose established. Co-administra-
tion of INCAGN1949 and vaccines in NHPs showed an immune-based PD
signature across a broad exposure range. These studies were in line with in vitro
fındings and support a wide PD range for INCAGN1949 in patients. An impor-
tant secondarymechanismof INCAGN1949 is the ability of its IgG1 Fc region to
mediate selective depletion ofOX40high intratumoral regulatory T cells. Immu-
nohistochemistry and flow cytometry analyses support the validity of this regu-
latory T cell depletion mechanism in a range of tumors. The functional in vitro
and in vivo attributes of INCAGN1949make it suitable for clinical development.
It is currently under evaluation in a Phase 1/2 study in subjects with advanced or
metastatic tumors (NCT02923349).
#4704 Long-lived de novo DNA methylation programming enforces ter-
minal T-cell exhaustion. Hazem E. Ghoneim, Yiping Fan, Hossam A. Abdel-
samed, Pradyot Dash, Robert Carter, Walid Awad, Pranay Dogra, Paul G.
Thomas, Ben Youngblood. St. Jude Children’s Research Hospital, Memphis, TN.
Immune-checkpoint blockade (ICB)-mediated rejuvenationof exhaustedCD8T
cells has emerged as one of the most promising frontiers for treating cancer and
chronic infections. However, antigen-specifıc T cells that have differentiated to a
terminal state of exhaustion remain refractory to ICB-mediated rejuvenation and
currently have limited potential for contributing to this promising therapeutic ap-
proach.Given thatmanyof the impairedeffector-propertiesof terminally exhausted
CD8 T cells appear to be heritably maintained even in the absence of antigen, we
investigated the role of de novo DNA-methylation programming as a cell-intrinsic
mechanismforestablishing the ICB-nonresponsive stateofT-cell exhaustion.Using
a TCR-inducible system to delete the de novo DNAmethyltransferase, Dnmt3a, in
CD8 T cells (cKO) responding to a chronic LCMV infection, we observed that
antigen-specifıc CD8 T cells lacking the capacity to acquire new DNAmethylation
programs retained their effector function despite exposure to high antigen loads for
severalmonths. Longitudinal whole-genome bisulfıte sequencingmethylation pro-
fıling and gene expression analysis of wild-type and Dnmt3a cKO antigen-specifıc
CD8 T cells during persistent antigen exposure revealed that de novo DNAmeth-
ylation was progressively targeted to the loci of effector cytokines, transcription
factors, and regulators of cellular proliferation (e.g., IFN, T-bet, Tcf7, and Myc)
enforcing their repressed gene expression. Dnmt3a-defıcient CD8 T cells resisted
terminal T-cell exhaustion and maintained high proliferation potential in a cell-
intrinsic manner. These data reveal Dnmt3a as a critical regulator in the develop-
ment of T-cell exhaustion and identify exhaustion-specifıc de novo methylation
programs as a potential cell-intrinsic barrier of ICB therapy. Our fındings provide
mechanistic insights for identifyingnovel epigenetic targets in exhaustedTcells that
can be exploited to overcome the ICB-nonresponsive state of severely exhausted T
cells. Moreover, our study provides a rationale for developing new combinatorial
strategies of targeted epigenetic therapies and T cell-based immunotherapy to treat
cancer.
#4705 CTLA4 blockade with HER2-directed therapy (H) yields clinical
benefıt in women undergoing radiation therapy (RT) for HER2-positive
(HER2) breast cancer brainmetastases (BCBM).HeatherMcArthur,1 Kath-
ryn Beal,2 Darragh Halpenny,2 Micaela Henrich,2 Shanu Modi,2 Sujata Patil,2
Robert Young,2 Thomas Kaley,2 Taha Merghoub,2 Christopher Barker,2 Phillip
Wong,2NicolaHamilton,2 CliffordHudis,2 JeddWolchok,2 LarryNorton2. 1Ce-
dars-Sinai Medical Center, Los Angeles, CA; 2Memorial Sloan Kettering Cancer
Center, New York, NY.
Introduction: BCBM is a devastating complication of breast cancer and
women with specifıc subtypes (i.e. HER2 disease) are at increased risk. Con-
ventional systemic and local therapies have demonstrated limited effectiveness
in preventing and treating BCBM. However, preclinical and clinical data indi-
cate that the local effects of RT may be augmented by immune therapy and that
abscopal effects (distant benefıts outside of the RT fıeld) may be achieved when
combined with CTLA4-blockade. Thus, a pilot study of standard-of-care brain
RT with tremelimumab, a CTLA4-directed monoclonal antibody, was under-
taken to evaluate the impact on distant (non-CNS) disease control in women
with HER2-normal (HER2-) disease and to confırm safety when administered
with H in women with HER2 disease. Methods: Eligible women were age
18y, ECOG 0-2, with radiologically confırmed BCBM of any histology requir-
ing whole brain RT (WBRT) or stereotactic radiosurgery (SRS), and non-CNS
progression of disease (PD). Twenty women with HER2- disease were enrolled
in an effıcacy cohort with a primary endpoint of 12-week non-CNS disease
control by RECIST v1.1. Six women with HER2 disease were enrolled in a
safety cohort and received concurrent H every 3 weeks. Tremelimumab (10mg/
kg)was administeredwithin 5 days prior to or 3 days after the fırst fraction ofRT,
then monthly for 6 months, and then every 3 months. Radiographic responses
by irRC criteria were explored. Results: Of the 6 women with HER2 disease: 6
(100%) received WBRT, 1 had a non-CNS partial response (PR) at 12 weeks
(-56.9% by RECIST, -86.2% by irRC) after 5 lines of palliative H-chemotherapy
that was durable at 6months; 1 had non-CNS stable disease at 12 weeks that was
durable at 6 months; 2 had non-CNS PD at 12 weeks; 1 came off study for
non-CNS PD prior to 12 weeks; and 1 died at 5 weeks. Among the 20 women
with HER2- disease the best response was non-CNS SD (2 had SD, 9 had PD, 9
came off study due to PD and/or died prior to 12 weeks). The regimen was well
tolerated with 15 grade 3 and no grade 4 attributable toxicity events reported.
Themost common treatment related AEs were diarrhea (12.9%), fatigue (9.7%),
and colitis (6.5%). Conclusions: BCBM RT plus tremelimumab with or without
H was generally well tolerated. This is a poor prognosis population with 11/26
(42%) women coming off study due to death or rapid PD within 12 weeks of
initiating brain RT. Although only modest activity was observed at 12 weeks in
the HER2- cohort, durable clinical benefıt was observed with concurrent H in 2
women with HER2 disease. This is the fırst report of clinical responses to
checkpoint blockade with H in breast cancer. The contribution of an abscopal
effect due to RT is not known and thus, studies of immune therapy with H/-
RT are underway.
#4706 Spherical nucleic acids targeting toll-like receptor 9 enhance anti-
tumor activity in combination with anti-PD-1 antibody in mouse tumor
models. SubbaRao Nallagatla, Bart R. Anderson, Sagar Anantatmula, Ekambar
R. Kandimalla. Exicure, Inc., Skokie, IL.
Of the several immunotherapy approaches being developed, checkpoint in-
hibitors (CPI) represent a breakthrough for the treatment of cancer. A T cell-
inflamed tumor microenvironment (TME) is required for antitumor effıcacy of
CPI. However, the evidence suggests that 70% of tumors do not possess T cell-
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inflamed TME limiting the potential of CPI treatments to a smaller population
of cancer patients. Immunotherapies that enable CPI effectiveness in patients
with non-T cell-inflamed phenotype are being studied. Oligonucleotide-based
TLR9 agonists induce potent CD8 T cell and plasmacytoid dendritic cell acti-
vation and limit immune suppressor cell phenotypes in TME. Therefore, the
combination ofTLR9 agonistswithCPIwould be a rational approach for achiev-
ing higher rates of success in cancer treatment. However, TLR9 agonists were
unsuccessful in previous cancer clinical trials. Spherical Nucleic Acids (SNAs)
are a novel class of agents with oligonucleotides densely packed and radially
oriented around spherical liposomal nanoparticles. SNAs overcome limitations
of therapeutic oligonucleotides through increased uptake and nuclease stability.
We have evaluated a TLR9 targeted SNA for anticancer activity as a mono-
therapy and in combination with an anti-PD-1 (a-PD-1) antibody in both a-
PD-1 sensitive and insensitive mouse tumor models. Mice bearing a-PD-1 sen-
sitive MC38 tumors were treated with intratumoral dosing of TLR9 agonist
SNA, intraperitoneal (IP) dosing of a-PD-1 or the combination of both agents
when average tumor volume was 100 mm3, with twice weekly dosing for a total
of 5 doses. SNA alone showed dose-dependent tumor growth inhibition (TGI)
of up to 87% and increased survival of mice. The combination of SNA and
a-PD-1 greatly enhanced TGI (92% vs SNA, 74% or a-PD-1, 77%) and mice
survival compared with either monotherapy. Moreover, once weekly dosing of
SNA showed similar TGI compared with twice weekly dosing. In a-PD-1 insen-
sitive EMT-6model, mice were treatedwith intravenous dosing of TLR9 agonist
SNA, IP dosing of a-PD-1 or the combination of both agents starting on day 3
following subcutaneous tumor cell inoculation. SNA alone showed potent dose-
dependent TGI of up to 80% and increased mice survival. The combination of
SNA and a-PD-1 showed a synergistic TGI (86% vs SNA, 64% or a-PD-1, no
effect) and increased mice survival. Further, no tumor growth was observed in
surviving mice after subsequent challenge with EMT-6 cells, suggesting devel-
opment of tumor-specifıc memory responses in SNA treated animals. These
data demonstrate that the TLR9 agonist SNA studied herein induces innate and
adaptive immune responses in tumor-bearing mice and shows synergistic TGI
with a-PD-1 in both a-PD-1 sensitive and insensitive tumor models. A TLR9
agonist SNA, AST-008, is currently in clinical development.
#4707 Evaluation of effıcacy and immune response to PD1 checkpoint
inhibition in human immune-reconstituted mice using patient-derived
xenograft models. Hooman Izadi, Tommy Broudy, Deborah Yan, Jayant
Thatte. Crown Bioscience, San Diego, CA.
Background: Human Immune-reconstituted Mice, generated by transplant-
ing pre-validated humanCD34 hematopoietic stem cells (HSC) into immune-
compromised mice, are extremely useful in basic and applied human disease
research. Many cancer therapies, including immune checkpoint inhibitors such
as the anti-PD-1 monoclonal antibody, rely on an intact immune system to
release immunosuppression and destroy cancer cells.Material andmethods:We
evaluated the effects of anti-PD-1 in humanized mice in donor cohorts utilizing
the cancer matrix of 5 HSC donor cohorts of humanized animals with PDX
models from7 small cell lung cancer (SCLC).We also tested anti-PD-1 in 1 triple
negative breast cancer (TNBC) model and in 1 MDA-MB-231 study. Results:
Here, we show thatHSCderived human immune cell engraftment does not have
signifıcant effects on patient derived xenograft (PDX) tumor growth. However,
humanization is required for anti-tumor response to anti-PD-1. In MDA-MB-
231 study, tumors showed complete regression after the fırst round of treatment.
Re-engraftment of same animals withMDA-MB-231 cells showedminor tumor
growth before complete regression again. Aged match control naïve animals
engrafted with same cells showed normal tumor growth. In SCLC studies anti-
PD-1 effıcacy varied between themodels, which clearly underscores the inherent
donor to donor variability in this humanized model system. Tumors from these
studies were then analyzed to determine target engagement of anti-PD-1, tumor
infıltrating lymphocytes (TILs) characterization and histology comparing anti-
PD-1 responders vs non-responders. As expected, in this study, we demonstrate
humanization of the animals is necessary to evaluate the effıcacy of anti-PD-1
therapy and can elicit an immunotherapy mediated anti-tumor effect. Conclu-
sion: Here we demonstrate the development of humanized mouse studies with
ability to run multi point analysis to determine the outcome of treatment.
#4708 A novel anti-MUC1 CART cell drives immunity to pancreatic can-
cer. Mahboubeh Yazdanifar, Ru Zhou, Shu-ta Wu, Priyanka Grover, Pinku
Mukherjee. Univ. of North Carolina at Charlotte, Charlotte, NC.
Background: Pancreatic cancer is the 4th leading cause of cancer deaths in
the US with very poor prognosis. Treatment options are limited to surgery
and chemo/radiation that often times do not increase survival and are asso-
ciated with high toxicity. Targeted immune-based therapies have shown
some promise but needs further exploration. Mucin 1 (MUC1), a glycopro-
tein expressed on the apical surface of epithelial cells of most epithelial
organs, undergoes hypoglycozylation in tumors. This tumor-form of MUC1
(tMUC1) is over-expressed in 80% of pancreatic ductal adenocarcinomas
(PDAC). tMUC1 therefore remains a promising target for therapeutic inter-
vention. We have developed a patented antibody (TAB004) which specifı-
cally detects tMUC1 and spares normal MUC1. Using a novel technology,
functional fragments of TAB004 antibody (scFv) were incorporated into the
chimeric antigen receptor (CAR) construct and used to genetically modify
primary human T cells. ScFv domain which recognizes tMUC1 is linked to
the co-stimulatory molecules of T cells (CD28 and CD3	). When the engi-
neered T cells come in contact with tMUC1 expressing tumor cells, multiple
T cell signaling pathways are initiated leading to fully activated cytotoxic T
cells that lyse the tumor cells. Methods: Retroviral based technique was used
to deliver the CAR gene into human PBMC derived primary T cells. A fluo-
rescent tag (mKate) was fused to the C-terminus of CAR molecules, in order
to visualize CAR expression on T cell membrane by fluorescent microscopy
and potentially for in vivo tracking. Cytotoxicity was evaluated using co-
culture method with varying T cell to target cell ratios followed by MTT
assay. Intracellular IFN was measured by flow cytometry. Results: tMUC1-
CAR-T cells show increased activation and proliferation compared to nor-
mal T cells. These cells bind strongly to tMUC1 expressing human pancreatic
cancer cells forming immunologic synapse. Minimal binding of the tMUC1-
CAR T cells was observed to normal or low MUC1 expressing tumors cells
suggesting high specifıcity of these CAR T cells to tMUC1. CAR expression
was distributed evenly on the cell surface of the T cells. Engineered tMUC1-
CAR T cells exhibit robust cytotoxicity against a panel of PDA cell lines,
associated with high IFN release. Fortunately, the same CAR T cells display
minimum toxicity against normal epithelial cells. CAR T cell function will be
evaluated in the preclinical mouse model of PDA, as single treatment and
also in combination with checkpoint inhibitors and chemotherapy drugs.
Conclusion: Despite the remarkable successes reported using CAR T cells in
clinic, particularly CD19 CAR T for leukemia; some adverse effects have
been attributed to this treatment. This highlights the urgent need for devel-
oping tumor-specifıc CAR T cells. This study demonstrates the specifıcity
and effectiveness of tMUC1-CAR T cells against pancreatic cancer cells.
Thus, tMUC1 CAR T cells have the potential to be further developed for
future clinical use.
#4709 Induction of enhanced tumor-specifıc immunity byHsp90 targeted
photodynamic therapy (Hsp90-PDT) combinedwith immune checkpoint in-
hibition. Kensuke Kaneko, Takuya Osada, Timothy A. Haystead, Michael A.
Morse, Herbert K. Lyerly. Duke University, Durham, NC.
Background: Immunotherapy has become an emerging anti-cancer therapy,
as immune checkpoint blockadewithPD-1 or PD-L1 inhibitionhave been active
against multiple cancer types. Nonetheless, there remainmany non-responders,
suggesting that combinations may improve activity, particularly combinations
which can target tumors and have low toxicity. Methods & Results: We have
developed a novel Hsp90 targeted photodynamic therapy (Hsp90-PDT), which
causes local anti-tumor responses. Hsp90-PDT can be combined with immune
checkpoint blockade to generate potent anti-tumor effects. We synthesized well
characterized PDT agent, verteporfın (VP) tethered to a HSP90 small molecule
inhibitor, to create a Hsp90-PDT agent (Hsp90i-VP). We fırst compared the
uptake of VP and Hsp90i-VP into the breast cancer cell lines (E0771-OVA) in
vitro. Hsp90i-VP showed stronger incorporation thanVPwhen the compounds
were added 3M or less in concentration. We next performed in vitro and vivo
PDTwithHsp90i-VP and laser exposure (690nmwavelength). Killing effıciency
of VP and Hsp90i-VP was analyzed by MTT assay, which showed increased
killing in a dose dependent manner for both photosensitizers (0-30M) and
laser (0-120J/cm2). Next, we treated E0771-OVA tumor-bearing C57BL/6 mice
with Hsp90i-VP (25nmol/mouse) administration alone, laser irradiation (240J/
cm2) alone, or the combination of Hsp90i-VP and laser. Suppression of the
tumor growth was confırmed only in Hsp90i-VP and laser group. In addition,
induction of tumor-specifıc immune response by PDTwas confırmed by ELISA,
where the elevation of anti-OVAantibodywas seen only in PDTgroup. Further-
more, combination treatment of Hsp90-PDT and anti-PD-L1mAbs was able to
enhance cytotoxic T-cell response and suppress tumor growth signifıcantly even
with relatively PDT-resistant cell line. Conclusions: Hsp90-PDT showed a sig-
nifıcant ability to induce antigen-specifıc immune response in both in vitro and
in vivo. These results suggest that Hsp90-PDT can play an important role in
anti-cancer immune therapy. Our future plan is to investigate the effect of local
photodynamic therapy combined with various types of checkpoint inhibitor in
breast cancer models.
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#4710 Tumor-infıltrating immune cells in gastrointestinal stromal tu-
mors (GIST) related to the response to tyrosine kinase inhibitor therapy.
Peter Hohenberger,1 Wenyi Zhao,2 Maria Deligianni,3 Katia Simon-Keller,3
Alina Diel,1 Andrea Homburger,3 Hui Cao,2 Alexander Marx3. 1Div. of Surgical
Oncology & Thoracic Surgery, Mannheim, Germany; 2Dept. of Gastrointestinal
Surgery, Shanghai, China; 3Institue of Pathology, Mannheim, Germany.
Purpose: The prognostic predictors for neoadjuvant and palliative tyrosine
kinase inhibitor (TKI) effect in GIST patients are few beyondmutational status.
We analyzed the extent and composition of tumor-infıltrating immune cells in
GIST after different TKI therapeutic regimens and response. Methods: From 60
GIST patients, surgical specimens were available and divided into six different
groups of 10 cases each, with the primary tumors graded for malignant behav-
iour acc. to Miettinen&Lasota 2006. In the neoadjuvant groups all tumors were
biopsy proven andhad documented IM-sensitivemutations in theKIT receptor.
- low risk gastric GIST - high risk GIST of the small bowel - locally advanced
GIST after neoadjuvant imatinib (IM) with 10% - or 30% of viable cells
remaining - progressive liver metastases resistant to 2 TKI inhibitors - pro-
gressive peritoneal mets. resistant to2 TKI inhibitors.We used 2-m sections
of formalin-fıxed, paraffın-embedded tissue samples for immunohistochemis-
try with the used Dako REAL EnVision Detection System (K5007, Dako) and
Anti-CD68 (Dako); Anti-CD11c (Abcam); Anti-CD163 (Leica); Anti-CD11b
(Abcam); Anti-CD4 (Leica); Anti-CD8(Leica); Anti-FOXP3 (Abcam) antibod-
ies. The phenotypes of immune cells were compared in the defınedGIST groups.
Recurrence-free survival (RFS) was evaluated in neoadjuvant and overall-sur-
vivals (OS) after TKI failure wasmeasured in TKI resistantM1 patients . Results:
The rate of CD11cM1macrophages is higher in low-risk GISTs compared to
high risk GISTs, but CD11b myeloid cells are exactly the opposite. Foxp3
Tregs, CD163M2 macrophages and CD11b myeloid cells are signifıcantly
higher in TKI resistance or neoadjuvant (viable cells30%) tissues compared
with neoadjuvant (viable cells10%) cases. Kaplan-Meier curves show high
CD163M2 macrophages or CD11b myeloid cells to correlate signifıcantly
with worse RFS in after neoadjuvant IM (p 0.01). In the TKI resistant condition,
patients with high CD11cM1macrophages show better medianOS (p0.07).
Conclusions: Our study reveals dynamic changes of tumor-infıltrating immune
cell protagonists in GISTs after different TKI therapeutic regimen and response.
This may help to understand the response to TKI-therapy beyond mutational
status and open an option for immunotherapy in patients resistant to standard
TKIs.
#4711 Immunomodulatory effects of an EphA2-targeted docetaxel anti-
body-directed nanotherapeutic and synergistic combination with PD-1 in-
hibitor. Andrew J. Sawyer, Anne-Sophie Dugast, Lia Luus, Zhaohua Richard
Huang, Suresh K. Tipparaju, Dmitri B. Kirpotin, Daryl C. Drummond,Walid S.
Kamoun.Merrimack, Cambridge, MA.
The effıcacy of the current class of PD-1/PD-L1 antagonists can be limited by
the immunogenicity of the tumormicroenvironment. Studies showed that some
chemotherapeutic agents including taxanes and anthracyclines can increase im-
munogenicity, resulting in therapeutic synergy with immune checkpoint inhib-
itors. In particular, treatment with a taxane has been shown to increase the
recruitment of CTLs and decrease immunosuppressive cells such asMDSCs and
T-regs. Additionally, the immune-modulatory activity of paclitaxel has been
shown to increase with prolonged exposure of the taxane at the tumor level,
achieved through metronomic dosing. MM-310 is an Ephrin Receptor A2
(EphA2)-targeted antibody-directed nanotherapeutic (ADN) that encapsulates
a docetaxel prodrug. Preclinically, MM-310 leads to prolonged exposure of do-
cetaxel at the tumor level, while lowering systemic exposure to bioavailable
docetaxel, and thus decreasing not only dose-limiting neutropenia but also the
killing of circulating lymphocytes potentially critical to anti-PD1/PDL1 activity
relative to free docetaxel. Taken together, we hypothesize that MM-310 can
synergistically combine with anti-PD-1 therapy. In this study, we evaluated the
potential combination of MM-310 and a murine anti-PD-1 Ab in the treatment
of several syngeneic mouse tumor models. The tumor lines EMT-6, CT-26, and
LLC were selected to provide a range of sensitivity to both docetaxel and anti-
PD-1. In vivo activity studies and immune-phenotype studies were performed
comparing MM-310anti-PD-1 combination to the monotherapies. MM-310
administration was initiated two days prior to anti-PD-1 therapy and consisted
of four weekly doses, while anti-PD-1 was dosed twice weekly for four weeks.
The response to MM-310 or anti-PD-1 as monotherapies varied between the
models. LLC was unresponsive to anti-PD-1 and poorly responsive toMM-310,
CT-26 was poorly responsive to both anti-PD-1 and MM-310, while EMT-6
responded moderately to anti-PD-1 with tumor stasis and well to MM-310,
achieving tumor regression. In all models, however, MM-310 given in combi-
nation with anti-PD-1 outperformed controls and both monotherapy arms in
terms of growth inhibition and tumor regression rate. In the EMT-6 model,
combination treatment resulted in durable complete regressions in 6/10 mice
when compared to 2/10 and 0/10 for MM-310 and anti-PD-1 monotherapies
respectively. InMM-310 andMM-310anti-PD-1 groups, re-challenge of mice
with the same tumor cells, at 10 weeks post treatment interruption, did not lead
to tumor growth, suggesting that treatment with anti-PD1MM-310 promotes
the development of a memory response against the tumor antigen. In conclu-
sion, the novel combination of MM-310, an EphA2-targeted docetaxel ADN
with an anti-PD-1 antibody, is highly active in syngeneic tumor models, and
represents a promising strategy for the treatment of cancer.
#4712 Image-guided focal irradiation in syngeneic preclinical oncology
mouse models. Sarah Krueger, Thomas Dailey, Kevin Guley, Maryland Frank-
lin.MI Bioresearch, Ann Arbor, MI.
Use of image-guided focal irradiation is a mainstay of human cancer treat-
ment. Image guidance allows for highly conformal treatment plans that mini-
mize normal tissue toxicity and systemic response. With the advent of image-
guided small animal irradiators such as the Small Animal Radiation Research
Platform (SARRP), targeted focal irradiation can now be utilized in a broad
range of preclinical oncologymodels. Of particular interest is the possible use of
focal irradiation to broaden the effıcacy and response duration of immuno-
oncology therapy. The work presented here evaluates tumor response in a num-
ber of syngeneic tumor models following focal irradiation alone and in combi-
nation with immune regulation. Image-guided irradiation was performed using
a SARRP system (Xstrahl Inc., Suwanee, GA). Animals were imaged with an
open fıeld at 60 kV and 0.5 mA for a computed tomography (CT) image which
was used for treatment planning. Treatment was delivered at 220 kV and 13.0
mA using an appropriately sized collimator to the total indicated dose (in Gray;
Gy) in 2 equally weighted beams. For daily treatments, the same treatment plan
was applied and adjusted for changes in animal positioning or target alteration
over time. Bilateral subcutaneous (SC) mouse tumormodels tested were A20 (B
cell lymphoma; Balb/Cmice) andRIF1 (sarcoma;C3Hmice) and an intracranial
(IC) GL261-luc (glioblastoma; C57BL/6 mice) model. In the SC models, focal
irradiation was delivered only to the right side tumors and tumor growth
changes tracked for both right and left side implants. A20 was sensitive to both
fractionated low doses (2.5Gy) of radiation, which resulted in tumor stasis, and
single bolus 20Gy, which resulted in tumor regressions. Effects on the non-
irradiated left sideswere dependent uponwhich dose regimenwas utilized. RIF1
is a more radiation resistant model and a single bolus dose of 10Gy only mod-
erately reduced tumor burden on the right side tumors but had no effect on the
contralateral tumors. In theGL261-luc ICmodel a single bolus dose of 15Gywas
curative whereas 10Gy resulted in 60-75%mortality over the study duration. In
a follow on study we determined that combination of 10Gy focal radiation with
systemic anti-PD-1 antibody therapy could improve overall survival over either
monotherapy. Inmousemodels, radiation treatment has been shown to increase
the level of tumor antigen presentation and the variety of peptides available for
cross-presentation. Current work in the fıeld focuses on using radiation as a tool
to bridge the gap from tumor equilibrium to tumor elimination, which could
improve the response rate of immuno-oncology agents. The models presented
here highlight the importance in choosing appropriate focal irradiation targets,
dose regimens and timing for each model. Tools such as the SARRP greatly
enhance the ability of preclinical models to provide a fırst line assessment for
advanced immuno-oncology therapy combinations.
#4713 Deubiquitination and stabilization of programmed cell death-li-
gand 1 by CSN5. Seung-Oe Lim, Chia-Wei Li, Mien-Chie Hung. UT MD An-
derson Cancer Center, Houston, TX.
Chronic inflammation in cancer is often associated with disease aggressive-
ness. Pro-inflammatory cytokines produced in the tumor microenvironment
lead to eradication of antitumor immunity and enhanced tumor cell survival. In
the current study, we identifıed TNF as a major factor triggering cancer cell
immunosuppression against T cell surveillance via stabilization of programmed
cell death-ligand 1 (PD-L1). We demonstrated that COP9 signalosome 5
(CSN5), induced by NF-B p65, is required for TNF-mediated PD-L1 stabili-
zation in cancer cells. CSN5 inhibits the ubiquitination and degradation of PD-
L1. The role of CSN5 in modulating PD-L1 stabilization prompted us to use
CSN5 inhibitor, curcumin, to show that it could destabilize PD-L1. Curcumin
reduced CSN5 activity to attenuate TNF-mediated PD-L1 stabilization and
enhanced anti-tumor immunity. Preclinical data demonstrated inhibition of
CSN5 sensitized cancer cells to anti-CTLA4 therapy, suggesting CSN5 inhibitor
may be a useful adjuvant to enhance immune-based therapies.
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#4714 Blockade of LAG-3 amplifıes immune activation signatures and
augments curative antitumor responses to anti-PD-1 therapy in immune
competentmousemodels of cancer.BrianB.Haines,1 Sarah Javaid,1 LongCui,1
Heather Hirsch,1 Saso Cemerski,1 Terri McClanahan,2 Manjiri Sathe,2 Shuli
Zhang,2 Michael Rosenzweig,1 Brian Long,1 Rene de Waal Malefyt2. 1Merck
Research Laboratories, Boston, MA; 2Merck Research Laboratories, Palo Alto,
CA.
MK-4280 is a humanized IgG4monoclonal antibody (mAb) that binds to the
immune checkpoint receptor Lymphocyte Activation Gene-3 (LAG-3) to block
the interactionwith its ligand,MajorHistocompatibility Complex (MHC)Class
II. LAG-3 is frequently co-expressed with other immune checkpoint receptors,
most notably programmed cell death protein-1 (PD-1), on T cells with an ex-
hausted phenotype. LAG-3 and PD-1 cooperate to regulate peripheral immune
tolerance in healthy individuals, and, conversely, play critical roles in several
diseases, including autoimmunity, graft rejection, viral infections, and cancer.
Co-blockade of LAG-3 and PD-1 in immunocompetent mouse tumor models
have demonstrated augmented anti-tumor activity over single agents. However,
themolecularmechanisms behind these combination effects have not been fully
investigated. Here, preclinical proof-of-biology studies are presented for co-
targeting LAG-3 and PD-1 in cancer. c28G10-mG1-[D265A] (abbreviated
28G10-mG1) is a rat:mouse chimera that mimics MK-4280 by its ability to
directly block the mouse LAG-3:MHC Class II interaction without initiating
Fc-mediated effector functions. As a single agent, 28G10-mG1 demonstrated
modest anti-tumor activity across several syngeneic mouse tumor models, de-
spite evidence of systemic drug exposure and target engagement (as assessed by
sLAG-3-mAb complex accumulation). The combination of 28G10-mG1 and
the anti-mouse PD-1 blocking antibody mDX400 resulted in greater tumor
growth inhibition and increased numbers of complete responses (CR) over
mDX400 alone in the MBT-2 tumor model. Furthermore, animals that had
achieved CR to combination therapy were subsequently protected fromMBT-2
re-challenge, suggesting the establishment of immunememory. RT-qPCR anal-
yses revealed up-regulation of immune-related genes, primarily at Day 4 in the
blood and Day 8 in the tumor with mDX400, but not 28G10-mG1, treatment.
However, when combined with mDX400, 28G10-mG1 further altered the ex-
pression of many immune-related genes that were perturbed bymDX400 single
agent therapy. Genes unique to combination treatment were also observed. Sig-
nifıcantly, immune pathway signatures associated with clinical effıcacy to
Keytruda were upregulated with combination therapy. Tumor transcriptome
and network analysis by RNAseq revealed enrichment in several immune- and
cytokine-related pathways with combination therapy compared to mDX400
single agent therapy. Taken together, these preclinical oncology studies support
the concept of co-targeting LAG-3 to increase the therapeutic effıcacy of PD-1
blockade. Clinical investigation of MK-4280 in combination with anti-PD-1
therapy (pembrolizumab/Keytruda) is ongoing.
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#4715 Protective anti-tumor immune responses in breast cancer depend
on tumor mutation rate. Lance D. Miller, Eric D. Routh, Jeff W. Chou, Alex-
andra Thomas.Wake Forest School of Medicine, Winston Salem, NC.
The relationship between tumor antigenicity and anti-tumor immune re-
sponses in breast cancer are poorly understood. Metrics that can accurately
predict tumor immunogenic potential could guide therapeutic decisions for
breast cancer patients. We examined the relationship between tumor immune
subclasses and patient overall survival in the context of the rate of nonsynony-
mous mutations in breast cancers. These analyses were conducted using
RNAseq and exome sequencing data from the Cancer Genome Atlas (TCGA)
breast cancer cohort (n1,098 patients). A previously described tumor-im-
mune classifıcation system, based on the relative abundance of infıltrating effec-
tor immune cells, was employed for assigning patients to favorable, weak or poor
immunogenic dispositions (FID, WID or PID, respectively). In breast tumors
exhibiting low mutation rates (LMR), no signifıcant survival differences were
observed among patients comprising the immune subclasses. By contrast, in the
context of tumors with high mutation rates (HMR), the immune subclasses
exhibited highly signifıcant survival differences (p0.001). Patients with FID
tumors achieved 100% survival at 10 years as compared to those with PID tu-
mors who displayed a 10-year survival rate of 44%. These survival differences
were independent of molecular subtype composition, with the majority of the
excellent-outcome FID subclass comprising predominantly of Basal-like,
HER2-enriched and Luminal B breast tumors. In the smaller subset of HMR
Luminal A breast tumors, the immune subclasses also exhibited signifıcantly
different survival outcomes (p0.01), with patients of the poor-outcome Lumi-
nal A PID subclass experiencing a 10-year survival rate of 22%. By Cox propor-
tional hazards regression analysis, the immune subclasses contributed signifı-
cant additive prognostic information in the presence of AJCC stage (p0.003).
A mutation rate of 1.63 mutations per megabase of sequenced DNA was found
to be an optimal threshold for distinguishing immune-relevant low and high
mutational load. These fındings fıt a model where mutational burden, reflective
of tumor antigenicity, is a major determinant of clinically-relevant breast tumor
immunogenicity. This relationship between immunogenic tumor subclasses,
overall survival and mutational burden may offer opportunities for therapeutic
stratifıcation of breast cancer patients.
#4716 Stemness markers in colorectal cancer: Analysis in a racially-di-
verse population. Ingrid C. Espinoza, Amit Reddy, Xu Zhang, Eldrin Bhanat,
Logan Fair, Joy King, Elizabeth Tarsi, Tara Craft, Jesus Monico, Charulochana
Subramony, Xinchun Zhou, Roy Duhe, Christopher Lahr, Christian Gomez.
Univ. of Mississippi Medical Ctr., Jackson, MS.
The diagnosis of colorectal cancer (CRC) is based on tumor-node-metastasis
staging, a weak staging system due to different genetic and epigenetic back-
grounds. Biological markers improve early detection and guide clinicians in
subsequent therapies. Stemnessmolecules have the potential to identify patients
at high risk of developing aggressive cancers. Herein, Zinc fınger E-box binding
homeobox 1 (ZEB1), Trefoil factor 3 (TFF3), Hepatoma Up-Regulate Protein
(HURP), Mucin 2 (MUC2), and Cystic fıbrosis transmembrane regulator
(CFTR) are assessed as potential prognostic biomarkers in CRC. There were a
total of (N56) cases included in this study which were assessed by a patholo-
gist, out of them 32 were African Americans (AA) and 24 Caucasian Americans
(CA). Themedian follow-up for 42 surviving patients were noted to be 4.5 years
(range 2.5 - 7.5 years). A tissue tumor microarray (TMA) was created using
tumor stage-matched CRC tissues fromAA andCA. The TMAwas stained with
each biomarker using immunohistochemistry (IHC) and consisted of 132 cores
including both controls and tumors. The individual staining score ranged from
(0-3) for both area and intensity. The product of area and intensity was used as
the fınal score which ranged from (0-9) with 0 defıning no expression and 9 as
high expression. We evaluated the association for expression of all the fıve bio-
markers with disease-free survival (DFS) inAA andCA separately. Stratifıcation
of the cohort by race revealed that in CA, high ZEB1 expression (nuclear and
cytoplasmic) was associated with poor DFS (p 0.015 for cytoplasm, p 0.116
for nucleus). ZEB1 expression was not found to be a signifıcant predictor of DFS
in AA who are usually known to have worse CRC outcomes. These fındings
suggest that expression of ZEB1 may represent a marker for CRC prognosis,
particularly in CA. High nuclear TFF3 expression in AA was found to be mar-
ginally associated with poorer DFS (p0.089). However, the cytoplasmic ex-
pression of TFF3 was not signifıcantly associated with DFS. Both the cytoplas-
mic and nuclear expression ofHURP,MUC2, andCFTR among the AA andCA
did not signifıcantly correlate with DFS. Overall, we have identifıed two stem-
ness molecules, ZEB1 and TFF3, with potential as markers for aggressiveness in
CRC. Our fındings also provide evidence of a possible biological basis for eth-
nicity-related differences with regards to stemness and regulatory factors of
CRC aggressiveness. ZEB1 can contribute to be a novel biomarker to predict the
prognosis of CRC in CA, and TFF3 will be a prognostic marker for AA. Future
goals include collecting additional samples and follow-up of the patients to
accurately estimate the prognosis. In addition, we will expand the project to the
cellular and molecular basis underlining our fındings. Funding sources: PCRP
W81XWH-14-1-0151, UMMC Medical Student Research Program, and
UMMC Offıce of Research.
#4717 Combination of PD-L1 expression and microsatellite instability
status is a useful prognostic factor in gastric cancer.ToshiakiMorihiro, Shinji
Kuroda, Nobuhiko Kanaya, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fu-
jiwara. Okayama University, Okayama, Japan.
Interaction of programmed death-1 (PD-1) and programmed death-ligand 1
(PD-L1) induces functional impairment of antigen-specifıc T cells, which leads to
immune evasion of tumors. Immune checkpoint therapy including PD-1/PD-L1
blockade is an emerging treatment strategy which brings great improvement in
patient’s prognosis. Microsatellite instability (MSI) is a condition of genomic insta-
bility caused by the loss of DNA mismatch repair activity, which has recently re-
ceived a lot of attention from the standpoint of cancer immunotherapy. While the
TNMclassifıcation system is commonly used on variousmalignant tumors for pre-
dictionofprognosis andplanningof treatment strategy, establishmentofprognostic
factors related to cancer immune system is considered important as cancer immu-
notherapy has recently becomemore and more popular. Thus, we investigated the
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usefulness of PD-L1 expression and MSI status in addition to histological type as
prognostic factors in gastric cancer. In this study, 255 gastric cancer caseswhichhad
curative surgical resection at OkayamaUniversity Hospital between 2002 and 2009
were analyzed retrospectively. PD-L1 expression level was classifıed into 4 groups
according toPD-L1positive rateontumorson immunohistochemical staining(0:
1%, 1: 1-5%, 2: 5-10%, 3: 10%), and 2 and 3 were defıned as PD-L1
positive.MSI statuswasanalyzedbyPCRandclassifıed intoMSI-high (MSI-H), and
MSI-low andMicrosatellite stability (non-MSI). Histological type was divided into
intestinal and diffuse according to the Lauren classifıcation.PD-L1 positive rate was
15%, and PD-L1 positivewas signifıcantly correlatedwith advanced stage and inva-
sive status. Overall survival (p0.0109) and disease-free survival (p0.0052) were
signifıcantly poor in PD-L1 positive group, and amultivariate analysis revealed that
PD-L1 expression was an independent risk factor for recurrence after surgery
(p0.0160, odds ratio: 3.19). MSI-H was detected in 7.5%, and more observed in
PD-L1 positive cases (p0.0068). Although non-MSI, as a single factor, showed
only a weak tendency to have poor prognosis compared to MSI-H (p0.1965),
combination of PD-L1 positive and non-MSI (PD-L1/non-MSI) showed signifı-
cantly poor prognosis (p0.0010). Although other combinations also showed the
usefulness in detection of patients with poor prognosis, such as PD-L1 positive and
diffuse type, and non-MSI and diffuse type, a multivariate analysis revealed that
PD-L1/non-MSI was the most useful combination among them to predict poor
prognosis (p0.0009, hazard ratio: 3.88). In conclusion, while PD-L1 expression is
a useful prognostic factor and predictive factor for recurrence after surgery as a
single factor, combination withMSI status can be more useful and attractive prog-
nostic factor in gastric cancer.
#4718 Filamin A interacting protein 1-like is a marker of prognosis, pro-
gression and chemosensitivity in ovarian cancer. Mijung Kwon,1 Jae-Hoon
Kim,2 Chel Hun Choi,3 Joon-Yong Chung,4 Stephen Hewitt,4 Steven Libutti1.
1Albert Einstein College of Medicine, Bronx, NY; 2Yonsei University College of
Medicine, Seoul, Republic of Korea; 3Sungkyunkwan University School of Medi-
cine, Seoul, Republic of Korea; 4National Cancer Institute, Bethesda, MD.
Purpose: The WNT/-catenin pathway and the resulting epithelial-to-mes-
enchymal transition (EMT) play a key role in ovarian cancer progression and
chemoresistance. Filamin A interacting protein 1-like (FILIP1L) enhances
-catenin degradation, thereby inhibiting canonical WNT signaling and EMT.
FILIP1L is a tumor suppressorwhose expression is down-regulated by promoter
hyper-methylation in ovarian cancer. FILIP1L down-regulation is inversely cor-
related with the invasive potential of ovarian cancer cells. However, the clinical
relevance of FILIP1L down-regulation in ovarian cancer progression has yet to
be addressed. Experimental design: To study the clinical implications of FILIP1L
in regulating theWNT/-catenin pathway and chemoresistance, the expression
of FILIP1L, -catenin, SNAIL and SLUG was analyzed by immunohistochem-
istry on tissue microarrays of 369 ovarian samples ranging from normal to met-
astatic. Their expression was evaluated with clinicopathological characteristics
including FIGO stage and chemosensitivity, and correlated with overall and
disease-free survival by Kaplan-Meier plots and Cox proportional hazards
model. Results: We demonstrated that FILIP1L expression decreased with tu-
mor progression, resulting in a signifıcant difference between primary andmet-
astatic ovarian cancer samples. In contrast, levels of -catenin and SLUG in-
creased with tumor progression. Furthermore, tumors that were resistant to
platinum/paclitaxel combination therapy showed a signifıcant reduction in
FILIP1L expression when compared to sensitive tumors, contrary to SLUG ex-
pression, which was signifıcantly higher. The expression of FILIP1L was nega-
tively correlated with the expression of -catenin and SLUG, whereas -catenin
expression was positively correlated with SLUG expression, suggesting a link
between FILIP1L and the WNT/-catenin pathway in ovarian cancer. More-
over, patients with low FILIP1L expression showed a median overall survival
and disease-free survival of 60 and 19 months, respectively, whereas patients
with high FILIP1L expression had not yet reached median overall and disease-
free survival at their 120month follow-up. Notably, low FILIP1L expressionwas
independent negative prognostic factor with respect to overall and disease-free
survival. Conclusions: Our study provides the fırst clinical relevance of FILIP1L
in human cancer, and suggests that FILIP1Lmay be a novel biomarker for good
prognosis and lower probability of recurrence in ovarian cancer patients.
#4719 MYCexpression correlateswithPD-L1 expression and related poor
clinical outcome innon-small cell lung cancer.EunYoungKim,ArumKim, Se
Kyu Kim, Yoon Soo Chang. Yonsei Univ. College of Medicine, Seoul, Republic of
Korea.
Background: Programmed death-ligand 1 (PD-L1) is widely used biomarker
for the response prediction of immune checkpoint inhibitors, but its usefulness
has been challenged. MYC, a transcriptional factor which is overexpressed in
various cancers, plays critical roles in preventing immune cells from attacking
tumor cells by inducing PD-L1 expression. We evaluated that MYC expression
is positively related that of PD-L1 in non-small cell lung cancer (NSCLC) clinical
specimens and that it has potential as a predictor of response to immune check-
point inhibitors in NSCLC. Methods: Eighty-four cases who were diagnosed as
NSCLC and underwent surgical resection were evaluated by immunohisto-
chemistry (IHC). PD-L1 expression was evaluated by FDA-approved PD-L1,
22C3 PharmDxTM protocol using the Dako Automated Link 48 platform at
Clarient Diagnostic Services, Inc (Aliso Viejo, CA, USA). Its expression was
determined by using Tumor Proportion Score (TPS), which is the percentage of
viable tumor cells showing partial or complete membrane staining. If TPS
50% of the viable tumor cells exhibit membrane staining at any intensity, it was
considered positive. IHC of MYC was performed using anti-c-MYC antibody
[Y69] (ab32072, Abcam, USA) and its expression was evaluated by scoring sys-
tem using product of nuclear staining intensity and percentage of positive cells.
Results: When MYC cDNA was transfected into KRAS-dependent lung cancer
cell lines that did not express bothMYC and PD-L1, the protein expression and
mRNA of PD-L1 were induced in a dose-dependent manner. On the other
hands, knockdown of MYC with siRNA inhibited protein expression and
mRNA indicating MYC regulates PD-L1 at transcriptional level. Of 84 NSCLC
tumor tissues, PD-L1 was expressed in 14 (16.7%) andMYC in 30 (35.7%) cases.
Dual positive patients were 9 (10.7%) and dual negative patients were 49
(58.3%). When the relationship between PD-L1 and MYC expression was eval-
uated, signifıcant positive correlation was observed between PD-L1 and MYC
expression (0.267, P0.014). Dual positive patients showed signifıcantly
shorter disease free survival (16.1 vs. 62.5months, P0.004) and overall survival
(24.9 vs. 70.9 months, P0.002) than dual negative patients. Conclusion: MYC
expression correlateswith PD-L1 expression in theNSCLCand the patientswith
overexpression of both MYC and PD-L1 showed signifıcantly poor survival.
This suggest that it is worth of investigation of MYC expression as a surrogate
predictive marker for treatment of immune checkpoint inhibitors in NSCLC.
#4720 Novel fındings for the clinical signifıcance of RNA editing status of
AZIN1 andADAR 1 and 2 expression levels in gastric cancer patients.Yoshi-
naga Okugawa,1 Yuji Toiyama,1 Kunitoshi Shigeyasu,2 Takashi Ichikawa,3 Sa-
toshi Oki,3 Koichiro Mori,3 Yuka Nagano,3 Hiromi Yasuda,3 Shigeyuki Yo-
shiyama,3 Masaki Ohi,3 Koji Tanaka,3 Yasuhiro Inoue,3 Toshimitsu Araki,3
Yasuhiko Mohri,3 Motoyoshi Tanaka,4 Chikao Miki,4 Ajay Goel,1 Masato Ku-
sunoki3. 1Baylor Univ. Medical Ctr., Dallas, TX; 2Okayama University,
Okayama, Japan; 3Mie University, Tsu, Mie, Japan; 4Iga City General Hospital,
Iga, Mie, Japan.
Background. Despite recent advances in surgical techniques and treatment
options, gastric cancer (GC) remains the third most common cause of cancer-
related deaths worldwide. Besides DNA sequence mutations, epigenetic altera-
tions have emerged as signifıcantly major players in cancer development. A-to-I
RNA editing is a post-transcriptional modifıcation that converts adenosines to
inosines in both coding and noncoding RNA transcripts, and has recently been
recognized has a novel epigenetic mechanism in GC pathogenesis. More specif-
ically, A-to-I editing of AZIN1 transcripts was shown to be regulated by an
adenosine deaminase acting on RNA-1 (ADAR1), and edited AZIN1 resulted in
an aggressive phenotype during disease progression in some human cancers.
The aim of this study was to clarify the clinical consequences of RNA editing
status of AZIN1 and the RNA editing enzymes (ADAR1 and 2) in GC patients.
Methods. Two hundred eighty-eight gastric specimens from one hundred forty-
four patients who underwent surgery for GC were evaluated. We analyzed the
RNA editing status of AZIN1 by RNA editing site-specifıc quantitative PCR
(RESSqPCR). RESSqPCR allows quantitation of RNA editing levels using wild-
type or edited AZIN1-specifıc primers, and RNA editing levels are calculated by
determining the ratios of Ct values between edited vs. wild-type transcript ex-
pression levels. Furthermore, expression levels of ADAR1 and ADAR2 were
evaluated by qPCR inGC tissues. Results.We observed a higher frequency of the
AZIN1 RNA editing in tumors compared with normal mucosa in GC. RNA
editing status of AZIN1 was signifıcantly increased in a stage-dependent man-
ner, and high frequency of RNA editing in AZIN1 signifıcantly correlated with
advanced T stage and presence of lymph node metastasis in GC patients. Mul-
tivariate analysis revealed that high frequency of RNAediting in theAZIN1 gene
was an independent prognostic factor for poor disease free survival and overall
survival. Furthermore, signifıcant upregulation of ADAR1 and downregulation
of ADAR2 was also observed in GC tissues compared with matched normal
mucosa, and these alterations also signifıcantly correlated with disease progres-
sion factors and poor prognosis in GC patients. Interestingly, ADAR1 expres-
sion level was positively correlated with RNA editing status of AZIN1 in GC
tissues. Conclusions. Our fındings revealed that altered gene-specifıc A-to-I ed-
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iting events mediated by ADAR1 promote disease progression in GC. We con-
clude that assessment of RNA editing status of the AZIN1 gene might offer a
novel and superior biomarker for a more accurate diagnosis of disease staging
and may help predict clinical outcomes in GC patients.
#4721 Novel lincRNA SLINKY is a prognostic biomarker in kidney can-
cer. Xue Gong,1 Zurab Siprashvili,1 Okyaz Eminaga,1 Zhewei Shen,1 Yusuke
Sato,2 Haruki Kume,2 Yukio Homma,2 Seishi Ogawa,3 Paul A. Khavari,1 Jona-
than R. Pollack,1 James D. Brooks1. 1Stanford Univ. Medical Ctr., Stanford, CA;
2Graduate School of Medicine, The University of Tokyo, Japan; 3Graduate School
of Medicine, Kyoto University, Japan.
Clear cell renal cell carcinomas (ccRCC) show a broad range of clinical be-
havior, andprognostic biomarkers are needed to stratify patients for appropriate
management. We sought to determine whether long intergenic non-coding
RNAs (lincRNAs) might predict patient survival. Candidate prognostic lin-
cRNAswere identifıed bymining The Cancer GenomeAtlas (TCGA) transcrip-
tome (RNA-seq) data on 466 ccRCC cases (randomized into discovery and val-
idation sets) annotated for 21,000 lncRNAs. A previously uncharacterized
lincRNA, SLINKY (Survival-predictive LINcRNA in KidneY cancer), was the
top-ranked prognostic lincRNA, and validated in an independent University of
Tokyo cohort (P0.004). In multivariable analysis, SLINKY expression pre-
dicted overall survival independent of tumor stage and grade [TCGA HR3.4
(CI, 2.1-5.4), P 0.001; TokyoHR9.2 (CI, 2.2-43), P 0.003], and by decision
tree, ROC and decision curve analysis, added independent prognostic value. In
ccRCC cell lines, SLINKY knockdown reduced cancer cell proliferation (with
cell-cycle G1 arrest) and induced transcriptome changes enriched for cell pro-
liferation and survival processes. Notably, the genes affected by SLINKY knock-
down in cell lines were themselves prognostic and correlated with SLINKY ex-
pression in the ccRCC patient samples. From a screen for binding partners, we
identifıed direct binding of SLINKY to Heterogeneous Nuclear Ribonucleopro-
tein K (HNRNPK), whose knockdown recapitulated SLINKY knockdown phe-
notypes. Thus, SLINKY is a robust prognostic biomarker in ccRCC, where it
functions possibly together with HNRNPK in cancer cell proliferation.
#4722 Evaluation of the prognostic value of ATG4B expression in differ-
ent breast cancer subtypes. Svetlana Bortnik,1 Basile Tessier Cloutier,1 Jamie
Magrill,1 Samuel Leung,2 Aline Talhouk,2 Karen Gelmon,1 Stephen Yip,1 Tony
NG,1 Torsten Nielsen,2 Sharon Gorski1. 1BC Cancer Agency, Vancouver, British
Columbia, Canada; 2University of British Columbia, Vancouver, British Colum-
bia, Canada.
Introduction: Autophagy, a lysosome-mediated degradation and recycling
process, functions as an adaptive survival response during various stressful con-
ditions including hypoxia and chemotherapy. The cysteine protease ATG4B, an
important component of the autophagy pathway, is becoming a promising ther-
apeutic target, but its value as a prognostic marker in breast cancer has not been
investigated yet. Our recent studies established a novel association between
ATG4B andHER2 positive breast cancer. Objective: The aimof this studywas to
investigate the prognostic value of ATG4B in different breast cancer subtypes
using a large population-based cohort.Methods/Experimental Design:We eval-
uated ATG4B cytoplasmic expression by immunohistochemistry on tissue mi-
croarrays constructed from a cohort of 2003 breast cancer patients seen at the
British Columbia Cancer Agency. For this large, well-characterized cohort de-
tailed clinical information was available, including age, histology, tumor grade,
tumor size, lymph node status, type of local and adjuvant systemic therapy, and
dates of fırst recurrence and death. Median follow-up time was 12.4 years.
ATG4B expression was scored by two independent observers using a catego-
rizedH-score system. Survival analyses were performed using the Kaplan-Meier
function and Cox proportional hazards regression models to evaluate the asso-
ciation of ATG4B expression with breast cancer-specifıc survival, stratifıed by
intrinsic subtype. Results: ATG4B expression was signifıcantly lower in basal-
like vs. non-basal (p0.001), basal vs. HER2 overexpressed (p0.0029), and
triple-negative vs. non-triple-negative (p0.001) breast cancer subtypes. In
HER2 positive breast cancers, high (H-score 200) ATG4B expression was
signifıcantly associated with poor overall survival (hazard ratio (HR) 1.90,
95% confıdence interval (CI)1.10 to 3.27, p0.033), disease specifıc survival
(HR2.23, CI 1.23 to 4.04, p0.016), and relapse-free survival (HR1.92,
CI1.09 to 3.39, p0.037). However, in Luminal A breast cancers, high (H-
score150) ATG4B expression was strongly associated with improved overall
survival (HR0.71, CI0.55 to 0.93, p0.012) and disease-specifıc survival
(HR0.43, CI0.26 to 0.67, p0.00009). Conclusion: High ATG4B expression
is a poor prognostic marker in HER2 positive breast cancer, but a favorable
prognostic factor in the Luminal A subtype. Validation analyses are planned on
a further set of 1989 cases.
#4723 Improving prognosis or promoting progression? Double sword of
S100A8 in colorectal cancer. Si Li, Fangying Xu, Lili Wang, Hui Li, Maode Lai.
Department of Pathology andPathophysiology, School ofMedicine, ZhejiangUni-
versity, Hanzghou, China.
Tumor tissues are heterogeneous, including cancer cells, cancer stemcells and
immune cells. The immune states are involved in malignancy and prognosis in
colorectal carcinomas (CRC). S100A8, which represented granulocytes and
monocytes, was identifıed as a favorable indicator for survival by previous work.
Cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) play
critical roles on tumor cell malignancy andmetastasis. The immune states, CSC
and EMT should be regarded as integrity, which is important for clinical efforts
and the mechanism investigation. For better understanding the associations
among immune cells, CSC and EMT in CRC, S100A8 as along with CSC (Lgr5,
Nanog, ALDH1 and CD44v6) and EMT (E-cadherin and Snail) markers were
detected in the tumor invasive front (TF) and tumor center (TC) respectively by
immunohistochemistry in 419 CRCs and survival analysis was done. Further-
more, functions of S100A8 in EMTwere verifıed in vitro. S100A8TF count was
positively correlated with Lgr5TC (r0.162, p0.004) and cytoplasmic SnailTF
expression (r0.116, p0.043), while it was not correlated with other stem cell
markers wherever they were located, and not associated with E-cadherinTC or
E-cadherinTF, or cytoplasmic snailTC or nucleic SnailTC and SnailTF expression
(p0.005). After combining S100A8TF and Lgr5TC, three groups were got. It
showed S100A8TFhigh Lgr5TChigh had the best 5-year survival, while
S100A8

TF
low Lgr5TClow had the worst 5-year survival. After joining with cyto-
plasmic snailTF into S100A8TF and Lgr5TC, six groups were got. Finally, three
groups with similar outcome were merged as A, B, and C, called SLS (S100A8,
Lgr5 and snail). Kaplan-Meier survival curve analysis showed group C, with
S100A8
low
Lgr5lowsnailhigh had the worst 5-year survival. SLS was also an inde-
pendent predictor for 5-year survival. S100A8 was not only stained in granulo-
cytes andmonocytes but also in tumor cells. Then S100A8was overexpressed by
lentiviral vector in DLD1 and sw620 CRC cell lines to further investigate its
intracellular functions. On the contrary, overexpression of S100A8 in tumor
cells not only facilitated tumor cell proliferation,migration and invasion but also
converted cells to EMT phenotype.Western blot showed E-cadherin was down-
regulated and Vimentin, MMP9 and snail were up-regulated in S100A8 overex-
pressed cells. The transcription factor USF2was verifıed to interact with S100A8
by luciferase reporter gene. Western blot showed overexpression of USF2 in-
creased S100A8 expression, while overexpression of S100A8 had no effect on
USF2. In conclusion, S100A8 from immune cells or tumor cells has opposing
effects on cancer progression. S100A8 in immune cells predicts good prognosis.
However, S100A8 in tumor cells, which could be regulated by USF2, promotes
proliferation, migration and invasion, along with EMT transformation.
#4724 Combined clinical and biological risk stratifıcation in pediatric
hepatoblastoma. Stefano Cairo,1 Carolina Armengol,2 Beate Häberle,3 Marina
Simon-Coma,2 Catherine Guettier,4 Ivo Leuschner,5 Marie-Annick Buendia,6
Dietrich von Schweinitz,3 Roland Kappler3. 1XenTech, Evry, France; 2Germans
Trias i Pujol Research Institute, Badalona, Spain; 3University ofMunich,Munich,
Germany; 4Paris Sud University, Le Kremlin Bicetre, France; 5Kiel Pediatric Tu-
mor Registry, Kiel, Germany; 6INSERM U1193, Villejuif, France.
Introduction: Advances in chemotherapy and surgery have greatly improved
overall survival rates of children with hepatoblastoma (HB). However, progno-
sis still remains quite poor for HB patients with high risk characteristics such as
portal/hepatic venous macrovascular involvement, extrahepatic growth, high
extent of the disease, and metastasis, as shown by studies of the International
Childhood Liver Tumours Strategy Group (SIOPEL). The aim of our trinational
study was to validate recently identifıed genetic and transcriptional characteris-
tics of HB as prognostic biomarkers to aid development of a new risk stratifıca-
tion system based on clinical and biological factors. Experimental procedures:
Tumor tissue of a cohort of 171 hepatoblastoma patients fromGermany, France
and Spainwas analyzed formutations in CTNNB1,NFE2L2 andTERT (Eichen-
müller et al., J Hepatol 2014; 61:1312-1320) by Sanger sequencing and the 16-
gene signature (Cairo et al., Cancer Cell 2008; 14:471-84) by real-time PCR.
Kaplan-Meier estimates of specifıc survival time in the various groups were
compared using the log-rank Mantel-Cox test. Results: Mutations of CTNNB1,
NFE2L2, and TERT were found in 133 (78%), 10 (6%), and 10 (6%) patients,
respectively. The adverse C2 subtype of the 16-gene signature was detected in 60
(35%) patients. Kaplan-Meier analyses depicted a signifıcant association of the
16-gene signature (P0.0001) and NFE2L2 mutations (P0.0166) with poor
outcome. Stratifying the patients of our cohort into a standard and high risk
group based on the commonly used clinical SIOPEL criteria (Zsiros et al., J Clin
Oncol 2010; 28:2584-2590) also revealed a strong association (P0.0001) of the
high risk group with poor outcome. When added to the SIOPEL risk groups,
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presence of at least one biomarker could discriminate the SIOPEL high risk
patients into an intermediate and a very high risk group (P0.0001), whereas
biomarker positive and negative standard risk patients showed no difference in
outcome. Conclusions: We have validated the 16-gene signature and NFE2L2
mutations as highly prognostic biomarkers in HB and propose a new stratifıca-
tion system that is based on the combination of clinical and biological factors,
which might facilitate more tailored and risk-adapted therapies and thus better
outcome of high risk patients in the future.
#4725 Multiple Myeloma DREAM Challenge: a crowd-sourced challenge
to improve identifıcation of high-risk patients.MichaelMason,1 Fadi Towfıc,2
Brian S. White,1 Dan Rozelle,3 Erin Flynt,2 Anjan Thakurta,4 Thomas Yu,1
Frank Schmitz,4 Andrew Dervan,4 Doug Bassett,4 Justin Guinney1. 1Sage Bio-
networks, Seattle, WA; 2Celgene, Summit, NJ; 3Rancho Biosciences, Boston, MA;
4Celgene, Seattle, WA.
Introduction: Multiple myeloma (MM) is a cancer of the plasma cells in the
bone marrow, and its clinical course depends on a complex interplay of traits
including age, performance status, as well as genetic and molecular aberrations,
and other molecular states of the plasma cells. Since risk-adapted therapy is
becoming standard of care, there is an urgent need for a precise risk stratifıcation
model to assist in therapeutic decision-making. While progress has been made,
there remains a signifıcant opportunity to improve patient stratifıcation to op-
timize treatment and to develop new therapies for high-risk patients. To accel-
erate the development and evaluation of such risk models in MM, we formed a
DREAM Challenge, a crowd-sourced competition that engages large cross-dis-
ciplinary teams of experts to address complex problems in biomedicine. Meth-
ods and Data: Clinical variables, patient outcomes, genetic, and gene expression
data fromover 2100 sampleswere curated and harmonized frommultiple public
and private studies. A subset of the data (N913) was used to evaluate previ-
ously published high-risk signatures against progression-free survival (PFS), the
clinical endpoint of the challenge. We also developed and assessed de novo and
ensemble methods. All models were evaluated using area under the receiver
operating characteristic curve (AUC). Results: The international staging system
(ISS) for Myeloma was used as a baseline for high-risk classifıcation (PFS 
18mo, AUC  0.57). We evaluated published high-risk signatures - UAMS-5,
UAMS-17, UAMS-70, EMC92 - and observed AUCs of 0.62, 0.62, 0.61, 0.59,
respectively. The average correlation of high-risk scores was 0.73 [min: 0.52
(UAMS-5 vs EMC92); max: 0.90 (UAMS-17 vs UAMS-70)], suggesting pub-
lished classifıers capture non-overlapping determinants of risk. As such, we
developed a RandomForest classifıer that combined expression of genes utilized
in the published classifıers with gender and age, trained on 70% of the data set,
and validated on the remaining 30%. This de novo classifıer achieved anAUC of
0.66 for PFS based risk classifıcation. Incorporation of ISS lead to a modest
improvement of accuracy (AUC0.67). Conclusion: Preliminary analysis of the
Challenge data suggests there is an opportunity to signifıcantly improve risk
stratifıcationmodels inMM. In addition to the robust benchmarking of existing
classifıers, we anticipate new, more accurate models will be proposed through a
MMChallenge given the scale of the combined data sets. Additionally, we hope
to uncover novel clinical and molecular traits that may yield insight into the
pathology of MM and provide direction for follow-up studies. Importantly, this
Challenge will illustrate the advantages of leveraging public data and crowd-
sourcing to address therapeutically relevant questions in oncology.
#4726 TonEBP promotes hepatocellular carcinoma and is associated with
poor prognosis. Jun Ho Lee,1 Jae hee Suh,2 Soo Youn Choi,1 Hyun Je Kang,1
Gap Ryol Lee,3 Whaseon Lee-Kwon,1 Neung Hwa Park,2 Hyug Moo Kwon1.
1UNIST, Ulsan, Republic of Korea; 2UlsanUniversity Hospital, Ulsan, Republic of
Korea; 3Sogang University, Seoul, Republic of Korea.
Carcinogenesis is initiated by genetic changes due to aberrant processing of
genetic information. Tumor microenvironment, however, should not be over-
looked as cancer risk because they influence the development and progression.
Indeed, the role of inflammation has received a lot of attention lately. Specifı-
cally, hepatocellular carcinoma (HCC) has been considered as an inflammation-
associated tumor like colorectal cancer and lung cancer. In addition, high rate of
recurrence is the major feature of HCC, and there is a need to identify novel
biomarkers for post-operative prognosis of HCC patients Tonicity-responsive
enhancer binding protein (TonEBP), also known as nuclear factor of activated T
cell 5 (NFAT5), is a key transcriptional cofactor for the expression of pro-in-
flammatory genes such as TNF-, IL-1, and cyclooxygenase 2 (COX-2). Since
chronic hepatic inflammation is essential for hepatocellular carcinogenesis, we
asked whether TonEBP plays a role in HCC. To investigate the relevance of
TonEBP in HCC development, TonEBP expression in hepatic tumors and their
adjacent normal tissues were analyzed from of HCC patients. TonEBP expres-
sion was higher in tumors than adjacent normal hepatic tissues in 94% of HCC
patients (n  104). In a mouse model of diethylnitrosamine (DEN)-induced
HCC, TonEBP expression was also higher in 100% of the tumors. Downregula-
tion of miR-223 was responsible for the elevated TonEBP expression. miR-223
targeted the 3=-UTR of TonEBP gene and suppressed TonEBP translation. In-
terestingly, univariate analyses revealed that TonEBP expression in normal tis-
sues adjacent to HCCwas signifıcantly associated with tumor size, tumor grade,
vascular invasion, viral DNA replication, -fetoprotein, PIVKA-II, recurrence,
metastasis, and death. In addition, Kaplan-Meier estimation and multivariate
analyses showed that the TonEBP expression was an independent prognostic
marker for recurrence and death in HCC patients. In mice, TonEBP haplo-
defıciency reduced both DEN- and DEN/high-fat diet (HFD)-induced HCC in
association with lower COX-2 transcription and milder hepatic inflammation.
Acute hepatic inflammation induced by DEN or lipopolysaccharide was also
reduced in hepatocyte- or myeloid-specifıc TonEBP knockout mice. TonEBP-
mediated activation of hepatic COX-2 promoter was dependent on the tran-
scription factor Yin Yang 1 (YY1). TonEBP interacted with YY1 through the
Rel-homology domain of TonEBP and spacer domain of YY1. In aggregate, our
data demonstrate that TonEBP-mediated hepatic inflammation is a critical reg-
ulator of hepatocarcinogenesis. The miR-223-YY1/TonEBP-COX-2 pathway
drives hepatic inflammation and commits the stressed hepatocytes tomalignant
fate. Thus, TonEBP promotes HCC via COX-2 expression and is a strong post-
operative prognosticator of poor outcome in HCC patients.
#4727 Analysis of PIK3CA mutations and PI3K signaling proteins as
prognostic biomarkers for advanced gastric cancer. Satoshi S. Nishizuka,1
Chie Ito,2 Kohei Kume,1 Takeshi Iwaya,2 Keisuke Koeda,2 Akira Sasaki2. 1Iwate
Medical University Institute of Biomedical Sciences,Morioka, Japan; 2IwateMed-
ical University School of Medicine, Morioka, Japan.
Although surgery and chemotherapy has extended the survival of patients
with advanced gastric cancer, some patients experience relapse. In cases of po-
tentially curative gastrectomy, no visible tumor mass should be present at the
time of post-operative chemotherapy. Therefore, relapse may be attributed to
very small cancer cell populations that survive and develop drug resistance.
Previously, we found that changes in the phosphatidylinositide 3-phosphate
kinase (PI3K) pathway protein levels were responsible for the growth of drug-
resistant cancer cells. In the present study, we postulated that the oncogenic
mutations in PIK3CA and PI3K pathway proteins could be prognostic biomark-
ers for patients with advanced gastric cancer. A retrospective cohort of 160
patients with advanced gastric cancer, receiving potentially curative surgery
with/without chemotherapy was investigated for PIK3CA mutations and PI3K
pathway protein levels in the context of 5-year overall survival (OS) and relapse-
free survival (RFS). Mutations were screened by direct sequencing followed by
validation through allele-specifıc quantitative real-time PCR, digital PCR, and
ultra-deep sequencing. Tissue microarrays were produced from tumor-rich ar-
eas of surgically removed specimens. Protein levels were assessed by incubation
with specifıc primary antibodies against total and phosphorylated proteins in-
cluding PI3K (p85), AKT, mTOR, and PTEN, followed by colorimetric detec-
tion. Samples were deemed to have positive staining when more than 5% of the
cancer cells were stained. OS and RFS periods were estimated using the Kaplan-
Meiermethod. A log-rank test and Cox proportional hazardsmodel was used to
compare the survival and hazards ratio, respectively. Subgroup analysis was also
performed. Thirteen patients (13/111 11.7%) had PIK3CA mutations in codon
545, whereas one patient (1/94 1.1%) had amutation in the PIK3CAcodon 1047.
Phosphorylated-AKT positive (p-AKT()) patients in the surgery-only group
showed good prognosis in terms of OS and RFS. Both OS and RFS of PTEN()
patients were higher than those of PTEN(-) patients in both surgery-only and
chemotherapy groups although statistical signifıcance was not confırmed.
PTEN() patients showed similar survival curves for up to 2 years post-opera-
tion, and separated thereafter. No signifıcant association was observed between
PIK3CA mutations and PI3K pathway protein levels. Subgroup analysis dem-
onstrated that both p-AKT() and PTEN() were better prognostic factors for
survival. There was no interaction between the protein levels and any clinico-
pathological/mutational factors. This study revealed that: (i) PIK3CA hotspot
mutations occurred with low frequency in gastric cancer; (ii) PIK3CA hotspot
mutations were not directly associated with PI3K pathway activation; and (iii)
p-AKT() may be a biomarker for better outcomes in gastric cancer patients
undergoing gastrectomy.
#4728 Plasma interleukin-6 level predicts prognosis of patients who re-
ceived sorafenib for advanced hepatocellular carcinoma.Yu-Yun Shao, Hang
Lin, Yong-Shi Li, Ying-Hui Lee, Ho-Min Chen, Ann-Lii Cheng, Chih-Hung
Hsu. National Taiwan University Hospital, Taipei City, Taiwan.
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Background: No biomarker has been proven to predict the treatment out-
comes of sorafenib, the only approved fırst-line therapy for advanced hepatocel-
lular carcinoma (HCC).We explored predictive and prognostic values of plasma
interleukin (IL)-6 levels for patients who received sorafenib as fırst-line therapy
for advanced HCC. Methods: This study had 2 patient cohorts. The exploration
cohort consisted of patients who were previously enrolled in a phase 2 clinical
trial that examined sorafenib with tegafur/uracil as fırst-line therapy for ad-
vancedHCC. The validation cohort consisted of patients who received sorafenib
alone as fırst-line therapy for advanced HCC under reimbursement of National
Health Insurance of Taiwan. Pretreatment plasma IL-6 levels were determined.
We used the receiver operating characteristic (ROC) curve in the exploration
cohort to determine the best cut point for IL-6 levels to predict overall survival
(OS). We then confırmed the cut point in the validation cohort. Results: There
were 55 and 73 patients in the exploration and validation cohort, respectively. In
the exploration cohort, there was no complete response but 3 (6%) partial re-
sponse. The median OS was 8.1 months. In the validation cohort, there was no
complete response but 7 (10%) partial response. The median OS was 10.3
months. In the exploration cohort, we found 4.28 pg/ml was the best cut point in
defıning high and low IL-6 levels because it could differentiate OS (p  0.042)
with the best sensitivity and specifıcity. Applying the cut point on the validation
cohort, patients with high pretreatment plasma IL-6 levels, compared with pa-
tientswith low IL-6 levels, exhibited signifıcantly poorerOS (median, 8.0 vs. 13.9
months, p  0.031). After adjusting for age, gender, hepatitis etiology, tumor
characteristics, -fetoprotein level, performance status, and prior treatment, a
high plasma IL-6 level remained an independent predictor for poor OS (hazard
ratio 2.594, p 0.005). By contrast, the plasma IL-6 level was not associatedwith
progression-free survival, treatment response, disease control, or other patient
characteristics. Conclusion: High pretreatment plasma IL-6 level predicted
prognosis of patients who received sorafenib as fırst-line therapy for advanced
HCC.
#4729 Association of mitochondrial DNA copy number variation in pe-
ripheral blood leucocytes with risk and prognosis of gallbladder cancer. Ab-
hijit Chandra,1 Hasan R. Kazmi,2 Leena K. Satyam,3 Saket Kumar1. 1King
George’s Medical University, Lucknow, India; 2Banaras Hindu University, Vara-
nasi, India; 3Aurigene Discovery Technologies Ltd., Bangalore, India.
Gallbladder Cancer (GBC) is the most common malignancy of the biliary
tract with very high incidence in Northern India, especially around Gangetic
belt. Late diagnosis and poor prognosis are the important features of this disease.
For improving treatment strategies and outcomes, novel non invasive prognos-
tic biomarkers are needed. Variations in peripheral blood mitochondrial DNA
(mtDNA) copy number in various cancers arewidely studied but information in
relation to gallbladder malignancy is unknown. In this pilot study, we investi-
gated leucocytes mtDNA copy number variation in relation to risk and progno-
sis of GBC. A total of 300 histologically confırmed or fıne needle aspiration
cytology proven GBC patients were recruited along with equal number of age
and sexmatched controls. ThemtDNAcopy numberwasmeasured by real-time
polymerase chain reaction through absolute quantifıcation using SYBR green
chemistry. We also explore prognostic utility of mtDNA content in relation to
overall survival of GBC patients. Statistical analysis was done by Student’s test
and survival data was compared using KaplanMeiermethod. Two tailed p value
less than 0.05 was considered to be signifıcant. We observed high mtDNA con-
tent in cases as compared with controls (mean	standard deviation, 1.21	0.88
vs. 1.02	0.76). Higher mtDNA copy number was signifıcantly associated with
increased gallbladder cancer risk (p0.005). In this study, we compared overall
survival (OS) for gallbladder cancer patients in relation tomtDNA copy number
median value (median, 1.12). KaplanMeir survival curve predicts decrease inOS
(p0.03, Hazard ratio2.54; 95% CI 1.79-5.86) for GBC patients in relation
to high mtDNA content (median) as compared with low mtDNA copy num-
ber (median). This study supports an association between increased mtDNA
copy number with susceptibility to gallbladder cancer in this endemic belt. Fu-
ture studies are warranted to confırm these fındings and to elucidate the biolog-
ical role of mtDNA copy number in relation to gallbladder cancer.
#4730 Fluorescence in situ hybridization panels for prediction of disease
progression in prostate cancer patients on active surveillance.Adam J. Koch,1
Ying Zhang,2 Beth Blondin,1 Svetlana Sitailo,1 Huixin Fei,1 Stephen Van Den
Eeden,3 Ekaterina Pestova1. 1Abbott Molecular, Des Plaines, IL; 2Abbott Labora-
tories, Beijing, China; 3Kaiser Permanente, Oakland, CA.
Background: Overdiagnosis and overtreatment of men with lower-risk Pros-
tate Cancer (PCa) is a concern due to co-morbidities and healthcare costs. Max-
imizing patient quality of life while recognizing early signs of aggressive disease
is essential. There is a need to stratify patients according to the risk of disease
progression, identifying with high sensitivity and specifıcity patients to biopsy,
re-biopsy andmonitor. Within the high risk population, there is a need to iden-
tify when to proceed with treatment. Methods: We performed a retrospective
study to evaluate FISH biomarkers on PCa specimens with histologically con-
fırmed, clinically localized disease (T1c-T2c) enrolled in Active Surveillance
(AS). AS patients were classifıed into two categories: Progressive (clinical inter-
vention within 10 years), and non-progressive (did not progress to intervention
in 10 years). Cohorts were matched by clinical characteristics (Gleason score,
disease stage and grade, PSA level, age, race) as possible. The study objective was
to establish a FISH biomarker panel to differentiate non-progressive from pro-
gressive prostate cancer in the low and intermediate risk groups. Receiver Op-
erating Characteristics (ROC) curve analysis was performed to obtain the best
single parameters based upon Area Under the Curve (AUC). For each FISH
parameter cutoffs were determined based on Sensitivity, Specifıcity and Dis-
tance from Ideal (DFI). Further ROC analysis was used to identify the best 3-5
probe combinations. FISH parameters were combined with clinical parameters
in the fınal model. Results: Five combinations of FISH parameters with the
highest AUC and sensitivity in discriminating case and control groups were
selected based on ROC curve analysis. Combinations were superior in perfor-
mance to single probes. The best individual parameter, MYC gain, had an AUC
of 0.6998. The two best combinations of parameters, MYC Gain/NKX3.1 Gain/
NMYC Gain/PTEN Homozygous and MYC Gain/ETV1 Break Apart/NKX3.1
Gain/PTEN Homozygous had AUC of 0.7363 and 0.7236, respectively. In the
logistic regression analysis, these combinations contributed signifıcantly to the
prediction of PCa outcome (progressive vs non-progressive, odds ratios of 5.522
and 6.118, respectively). The combination of clinical parameters and FISH out-
performed clinical parameters or FISH alone, with odds ratios of 5.955 and 6.787
in the fınalmodel. Conclusions: Combinations of FISH parameters discriminat-
ing cases (progressive) from controls (non-progressive) were selected based on
ROC curve analysis. The combination of clinical parameters and FISH outper-
formed clinical parameters alone, andwas complimentary to clinical parameters
(NCCN Risk Groups) in the fınal model, demonstrating potential utility of
multi-color FISH panels as an auxiliary tool for PCa risk stratifıcation. Further
studies with larger cohorts are planned to confırm these fındings.
#4731 Phospho-akt: a potential resistance marker to chemotherapy and a
therapy-target to restore sensitivity in pancreatic cancer.DanielaMassihnia,1
Amir Avan,2 Niccola Funel,3 Carlotta Granchi,3 Filippo Minutolo,3 Leticia
Leon,3 Godefridus Peters,1 Elisa Giovannetti1. 1University of Amsterdam, Am-
sterdam, Netherlands; 2University of Mashhad, Mashhad, Islamic Republic of
Iran; 3University of Pisa, Pisa, Italy.
Oncogenic KRAS signaling is themain driving force behind pancreatic ductal
adenocarcinoma (PDAC); however, targeting this pathway has proven to be
diffıcult. Conversely, the PI3K/Akt pathway represents an exciting new target,
because it has been associated with poor prognosis and chemoresistance, and
several inhibitors are under development. In particular, perifosine prevents Akt
translocation to the cell membrane, whileMK-2206 is anAkt allosteric inhibitor
and BEZ-235 is a dual PI3K/mTOR inhibitor. Therefore, we investigated the
prognostic role of phospho (p)-Akt in PDAC tissues, as well as the molecular
mechanisms underlying the interaction of Akt inhibitors with gemcitabine, us-
ing PDAC cells, primary cultures and spheroids. Immunohistochemistry of tis-
sue microarrays with specimens from radically-resected patients (n100) re-
vealed a correlation between high p-Akt1 expression and worse outcome.
Patients with low p-Akt expression (as detected by digital scoring) had amedian
overall survival (OS) of 16.2 months (95% CI, 14.8-20.1), while patients with
high expression had a median OS of 12.0 months (95% CI, 9.0-14.9, P0.03).
Parallel immunocytochemistry studies revealed high expression levels in
LPC028 primary cells, while LPC006 were characterized by low p-Akt1. Akt
inhibitors reduced cancer cell growth in monolayers and spheroids, and syner-
gistically enhanced the antiproliferative activity of gemcitabine in LPC028 (e.g.,
combination indexCI of 0.2, in the gemcitabine-perifosine combination for 72h,
at fıxed IC50 ratio), while this combination was antagonistic in LPC006 cells.
The synergistic effect was paralleled by a 5-fold reduction in the expression of
the main gemcitabine target ribonucleotide reductase. Inhibition of Akt de-
creased cell migration and invasion, which was additionally reduced by the
combination with gemcitabine. However, the combination of Akt inhibitors
with gemcitabine increased apoptosis, associated with induction of caspase-3/6/
8/9, PARP and BAD, and inhibition of Bcl-2 and NF-kB in LPC028, but not in
LPC006 cells. The Akt signaling is involved in the expression/localization of the
key glucose transporter Glut1, and increased glucosemetabolismwas associated
to resistance to axitinib (Hudson et al, Cell Death Dis 2014). Remarkably, the
resistant LPC006 cells were characterized by overexpression ofGlut1, whichwas
not reduced after exposure toAkt inhibitors. However, the novel Glut1 inhibitor
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PGL13 enhanced perifosine and perifosine/gemcitabine-induced cell death. In
conclusion, our fındings support the analysis of phospho-Akt1 expression as
both a prognostic and a predictive biomarker, for the rational development of
new combination therapies targeting the Akt pathway in PDAC. Finally, inhi-
bition of Glut1 might overcome resistance to these therapies and warrants fur-
ther studies.
#4732 Analysis of KRAS variant in a cohort of resected HPV negative
HNSCC. Jeffrey Mufson,1 Elizabeth Handorf,2 Joanne Weidhaas,3 Miriam
Lango,2 Barbara Burtness,1 EricaGolemis,2 JohnA. Ridge,2 RaneeMehra4. 1Yale
University, New Haven, CT; 2Fox Chase Cancer Center, Philadelphia, PA;
3UCLA, Los Angeles, CT; 4Johns Hopkins University, Baltimore, MD.
Background:A single nucleotide polymorphism in let-7 complementary site 6
(LCS-6) of the KRAS 3=UTR reduces KRAS inhibition by the let-7 family of
miRNA. It is associated with increased risk and greater proliferation of NSCLC
tumors, and poor outcomes in ovarian cancers. It is also associated with plati-
num resistance in head and neck squamous cell carcinoma (HNSCC). The ex-
cision repair cross-complementing group 1 enzyme (ERCC1) plays an impor-
tant role in nucleotide excision repair and double strand break repair, also
affecting platinum resistance. We measured ERCC1 expression and KRAS
LCS-6 variant status as prognostic markers for HNSCC outcome in a series of
p16 negative tumors. Methods: KRAS variant status was determined by PCR
(MiraDx) from DNA extracted from 99 available cases of p16 negative HNSCC
in the Fox Chase Cancer Center Biosample Repository. Pearson’s Chi-squared
tests and Wilcoxon tests were used to compare patient/tumor characteristics,
including ERCC1 (HPA029773, Sigma) expression which was analyzed previ-
ously, by KRAS variant status. Overall survival was examined using Kaplan-
Meier curves with log-rank tests for signifıcance, and Cox proportional hazards
regressions controlling for stage, grade, and tumor site. Results: A set of 99 p16
negative tumors (1990-2002) were analyzed: 62%male, 92% white, 53%moder-
ately differentiated, 29% poorly differentiated. 72% stage III/IV disease. Smok-
ing statuswas: 32% current, 15%never, 32%past smoker. Primary site of disease:
13% glottis, 44% oral cavity, 14% oropharynx, 20% oral tongue. The KRAS
variant was identifıed in 27/99 (27%) of tissue samples, and in 21/62 (33%) of
male patients versus 6/37 (16%) of female patients (P0.06). Comparing by
histologic grade the KRAS-variant was identifıed in 2/11 (18%) well differenti-
ated tumors, 15/37 (40%) moderately differentiated and 9/29 (31%) poorly dif-
ferentiated tumors (P0.81). On univariate analysis, therewas a non-signifıcant
increase inOS among all KRAS-variant patients (p0.09) and those treatedwith
surgery and adjuvant radiation (p0.08).Onmultivariate analysis, the direction
of the effect was maintained (all patients: HR0.65, P0.23; radiation sub-
group:HR0.41, P0.06). Therewas no association betweenKRAS variant and
ERCC 1 expression analyzed as a continuous variable (p 0.70). Conclusions:
In this small series, there was no association between the KRAS-variant and
ERCC1 expression. Trends suggesting improved outcomes among KRAS-vari-
ant HPV negative patients treated with adjuvant radiation warrant further
study.
#4733 Dysregulation of CUL4A and CUL4B ubiquitin ligases in lung can-
cer. Hui Li,1 Lei Jia,1 Fan Yan,1 Pengbo Zhou2. 1Tianjin Medical University
Cancer Institute &Hospital, Tianjin, China; 2Weill CornellMedical College, New
York, NY.
Background: The Cullin-RING ubiquitin ligases 4 (CRL4) is implicated in
controlling cell cycle, DNA damage repair and checkpoint response based on
studies employing cell lines and mouse models. CRL4 proteins, including
CUL4A and CUL4B are often highly accumulated in human malignancies. Ele-
vated CRL4 attenuates DNA damage repair and increases genome instability
that is believed to facilitate tumorigenesis. However, this has yet to be evaluated
in human cancer patients. Methods: 352 lung cancer and 62 benign lung speci-
mens of Asian origin were constructed into tissue microarrays (TMAs) of four
distinct lung cancer subtypes. Expression of CUL4A, CUL4B and their sub-
strates was detected by immunohistochemistry (IHC), and analyzed statistically
for their prognostic value and association with DNA damage response and
genomic instability. Results: Both CUL4A and CUL4B are overexpressed in the
majority of lung carcinomas (PCUL4A0.001, PCUL4B0.001), and signifı-
cantly associated with tumor size (PCUL4A0.001, PCUL4B0.002), lym-
phatic invasion (PCUL4A0.004, PCUL4B0.001), metastasis
(PCUL4A0.019, PCUL4B0.006), and advanced TNM stage
(PCUL4A0.001, PCUL4B0.001), which parallels gene amplifıcation and ab-
normal activation of the canonical Wnt signaling. Moreover, overexpression of
CUL4A, but not CUL4B, is signifıcantly associated with tobacco smoking
(P0.01), and inversely correlated with XPC and p21, both of which are sub-
strates of CUL4A (PCUL4A0.019, PCUL4B0.006). Higher levels of CUL4A
or CUL4B are signifıcantly associated with patients’ OS (PCUL4A0.001,
PCUL4B0.001) and PFS (PCUL4A0.001, PCUL4B0.001). Conclusion:
Our fındings revealed that CUL4A and CUL4B are differentially associated with
etiological factors for pulmonary malignancies and are independent prognostic
markers for survival of distinct lung cancer subtypes.
#4734 miR-9-5p expression in breast cancer correlates with hormone re-
ceptor status and affects patients survival. Raffaela Barbano,1 Barbara Pas-
culli,1 Michelina Rendina,1 Andrea Fontana,1 Caterina Fusilli,1 Massimiliano
Copetti,1 Stefamo Castellana,1 Vanna Maria Valori,1 Maria Morritti,1 Paolo
Graziano,1 Luigi Ciuffreda,1 Michelina Coco,1 Francesco Picardo,2 Tommaso
Mazza,1 Ella Evron,3 Roberto Murgo,1 Evaristo Maiello,1 Manel Esteller,4 Vito
Michele Fazio,1 Paola Parrella1. 1IRCCS Casa Sollievo della Sofferenza, San Gio-
vanni Rotondo, Italy; 2Campus Bio-Medico University, Rome, Italy; 3Assaf
Harofeh Medical Center, Zerefın, Israel; 4Bellvitge Biomedical Research Institute
(IDIBELL), Barcelona, Spain.
miR-9 (hsa-miR-9-5p, miR-9-5p) is a highly conserved microRNA (miRNA)
primarily expressed in the central nervous system. The three promoters of
miR-9 (miR-9-1 at 1q22, miR-9-2 at 5q14.3 andmiR-9-3 at 15q26.1) are embed-
ded within CpG islands, and hypermethylation in at least one of these regions
has been reported in several tumor types, thus miR-9-5p has been designated as
an epigenetically regulatedmiRNA. However, only a partial or none correlation
between methylation status of miR-9 loci and miR-9-5p expression has been
demonstrated so far. Furthermore, the expression levels of miR-9-5p resulted
highly variable across different carcinomas and conflicting evidences also exist
about its functional role within the tumor context. In light of this, we took the
effort of clarifying the role of miR-9-5p in primary breast cancer tissues and of
evaluating its potential as clinical relevant prognostic biomarker. We analysed
miR-9-5p expression and miR-9 promoters methylation status in 129 breast
cancer cases and 12 normal breast tissues (NBTs), by qRT-PCR andMSP respec-
tively. Overall, miR-9-5p was increased in tumors compared to NBTs
(P0.001). No signifıcant correlation between promoter methylation and miR-
9-5p expression was found either in tumors or in NBTs. Interestingly, miR-9-5p
expression was inversely correlated with ER and PgR positivity (P0.004 and
P0.003, respectively). Consistently, triple negative breast cancer (TNBC)
showed the highest miR-9-5p levels and luminal subtype the lowest (P0.04).
The analysis of the TCGA Breast Cancer dataset (n256) confırmed our results
and further demonstrated that miR-9-5p was differentially expressed between
the two luminal subtypes (P0.009) and HER2-amplifıed compared to TNBCs
(P0.0001). In Univariable Cox regression analysis miR-9-5p expression was
signifıcantly associated with higher risk of death (P0.023). Ingenuity Pathway
Analysis exploring the putative interactions among miR-9-5p, ER and PgR up-
stream and downstream regulators suggested a regulatory loop by which miR-
9-5p is induced by steroid hormone receptor and acts within hormone-receptor
regulated pathways. Our data suggest miR-9-5p may help refıne the molecular
classifıcation of breast cancer subtypes and provide additional prognostic infor-
mation.
#4735 Expression of Notch1 and Numb in small cell lung cancer. Hajime
Kikuchi,1 Jun Sakakibara-Konishi,1 Megumi Furuta,1 Hiroshi Yokouchi,2 Hiro-
shi Nishihara,3 Shigeo Yamazaki,3 Uramoto Hidetaka,4 Fumihiro Tanala,5
Masao Harada,3 Kenji Akie,3 Fumiko Sugaya,3 Yuka Fujita,3 Kei Takamura,3
Tetsuya Kojima,3 Toshiyuki Harada,3 Mitsunori Higuchi,2 Osamu Honjo,3 Yo-
shinori Minami,3 Naomi Watanabe,3 Satoshi Oizumi,3 Hiroyuki Suzuki,2
Takashi Ishida,2 Hiotoshi Dosaka-Akita,3 Hiroshi Isobe,3 Mitsuru Munakata,2
Masaharu Nishimura1. 1Hokkaido University School of Medicine, Sapporo, Ja-
pan; 2Fukushima Investigative Group for Healing Thoracic Malignancy, Japan;
3Hokkaido Lung Cancer Clinical Study Group Trial, Japan; 4Kanazawa Medical
University, Uchinada, Japan; 5University of Occupational and Environmental
Health, Kita-kyushu, Japan.
Background: Notch signaling plays an important role in tumorigenesis.
Numb represses intracellular Notch signaling. Previous studies have demon-
strated thatNotch signaling suppresses the proliferation of small cell lung cancer
(SCLC) cell lines. However, in SCLC, the association between Notch1 and
Numb expression and clinicopathological factors or prognosis has remained
unclear. In this study, we evaluated the expression of Notch1 and Numb in
SCLC. Methods: We immunohistochemically assessed 125 SCLCs that were
surgically resected at 16 institutions participating in either the Hokkaido Lung
Cancer Clinical Study Group Trial (HOT) or the Fukushima Investigative
Group forHealing ThoracicMalignancy (FIGHT) between 2003 and 2013. Cor-
relations between Notch1 or Numb expression and various clinicopathological
features were evaluated. Results: Notch1 expression was associated with ECOG
performance status. Numb expression was associated with age, sex, and patho-
CLINICAL RESEARCH: Prognostic Biomarkers 1
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1211
logical histology (SCLC or Combined SCLC). Analysis of cellular biological
expression did not demonstrate a signifıcant correlation between the expression
of Notch1 and of Numb. Multivariate Cox regression analysis showed that high
Notch1 expression was an independent favorable prognostic factor for SCLC
(hazard ratio  0.503, P  0.023). Conclusions: We demonstrate that Notch1
expression, but not Numb, is associated with prognosis in SCLC and may pro-
vide a novel prognostic marker of SCLC.
#4736 ADAMs: potential biomarkers and oncotargets in breast cancer.
Shuying Liu, Michael Z. Gilcrease, Huiqin Chen,Wenbin Liu, Fan Zhang, Kim-
Anh Do, Gordon B. Mills, William F. Symmans, Naoto T. Ueno, Ana M. Gon-
zales-Angulo, Gabriel N. Hortobagyi, Debasish Tripathy. UT MD Anderson
Cancer Ctr., Houston, TX.
Background: There is growing evidence that ADAM (a disintegrin and met-
alloproteinase) family proteins are involved in multiple types of cancer, includ-
ing breast cancer. More than 50 members of the ADAM family have been iden-
tifıed thus far. Previous studies have focused on one or two ADAMs but
comparative research among the members of the family is lacking. This study
was undertaken to identify the most important ADAMs associated with breast
cancer. Methods: We analyzed mRNA expression of ADAMs in tumor bed
stroma and paired normal adjacent stroma from 31 breast cancer patients. The
original raw data was adapted from a breast dataset (Finak et al, 2008). We next
analyzed RNA expression of 35 ADAMs in different subtypes of breast cancers
[dataset from Affymetrix U133A arrays using methods available in the R statis-
tical software package (http://cran.r-project.org)].We further evaluated protein
expression of ADAMs and related signaling molecules in 187 breast cancers,
including 110 untreated primary tumors and 77 residual tumors after neoadju-
vant chemotherapy, and 167 matched ’normal’ mammary tissues using reverse
phase protein arrays (RPPA). The association between ADAMs expression and
survival was analyzed using Kaplan–Meier analysis. Results: The microarray
analysis of tumor bed stroma revealed signifıcantly elevated mRNA levels of 12
ADAMs, including ADAM8, ADAM 12, ADAM 19, ADAM 21, ADAM 17,
ADAM 10, ADAM 28, ADAM 7, ADAM 33, ADAM 22, ADAM 6 and AD-
AMTS20, compared to their normal adjacent stroma. We evaluated the expres-
sion of 35 ADAMs in total 369 breast cancers, including 201 hormone receptor
positive (HR), 60 HER2 amplifıed (HER2) and 108 triple negative (TN)
patients using RNA array and demonstrated that 24 of 35 ADAMs were signif-
icantly upregulated in TNBC compared to that in HR and HER2 subtypes.
We further analyzed protein expression of ADAMs in 189 breast cancers and
172 matched “normal” breast tissues with RPPA. Compared to “normal” breast
tissues, ADAM17, ADAM10, ADAM15, ADAM8 and ADAM9 were signifı-
cantly increased in tumors (P  0.0001, respectively), while ADAM20,
ADAM23, ADAM29, and ADAM30 exhibited lower level. Kaplan–Meier anal-
ysis showed that 13-year overall survival rate in high expression of ADAM 17,
ADAM 15 or ADAM10 group was signifıcantly decreased compared to that in
the low expression group (40% vs. 12%, P  0.0026; 50% vs. 11%, P  0.0104;
53% vs. 9%, P 0.0001, respectively), suggesting that upregulation ofADAM17,
ADAM15, or ADAM10 was signifıcantly associated with poor outcome.
ADAM17, ADAM9 or ADAM10 expression was tightly associated with eleva-
tion of anti-apoptotic molecule Bcl-X, cyclins (E1, E2, B1), PTPN12, and phos-
phorylation of 4-EBP1. Conclusion: Several ADAM proteins have elevated ex-
pression in breast cancer and are associated with decreased patient survival.
ADAMs may, therefore, serve as potential biomarkers for predicting outcomes
and oncotargets in breast cancer.
#4737 A lung cancer risk classifıer comprising genomemaintenance genes
measured in normal bronchial epithelial cells. Jiyoun Yeo,1 Erin Crawford,1
Xiaolu Zhang,2 Sadik Khuder,1 Tian Chen,1 Albert Levin,3 Thomas Blomquist,1
James Willey1. 1Univ. of Toledo, Toledo, OH; 2National Institutes of Health
(NIH), MD; 3Henry Ford Health System, Detroit, MI.
Background: Annual low dose CT (LDCT) screening of individuals at high
demographic risk reduces lung cancer mortality by more than 20%. However,
subjects selected for screening based on demographic criteria typically have less
than a 10% lifetime risk for lung cancer. Thus, there is need for a biomarker that
better stratifıes subjects for LDCT screening. Toward this goal, we previously
reported a lung cancer risk test (LCRT) biomarker comprising 14 genome-
maintenance (GM) pathway genesmeasured in normal bronchial epithelial cells
(NBEC) that accurately classifıed cancer (CA) from non-cancer (NC) subjects.
The primary goal of the studies reported here was to optimize the LCRT bio-
marker for high specifıcity and ease of clinical implementation. Methods: Tar-
geted competitive multiplex PCR amplicon libraries were prepared for next
generation sequencing (NGS) analysis of transcript abundance at 68 sites
among 33 GM target genes in NBEC specimens collected from a retrospec-
tive cohort of 120 subjects, including 60 CA cases and 60 NC controls. Genes
were selected for analysis based on contribution to the previously reported
LCRT biomarker and/or prior evidence for association with lung cancer risk.
Linear discriminant analysis was used to identify the most accurate classifıer
suitable to stratify subjects for screening. Results: The best classifıer com-
prised 11 features including age and 10 transcript abundance assays repre-
senting nine genes; specifıcally, CDKN1A, E2F1, ERCC5, GPX1, GSTP1,
KEAP1, TP63, XPA, and XRCC1. After cross-validation, the Receiver Oper-
ator Characteristic area under the curve was 0.94 (95% CI: 0.92-0.96) and
overall classifıcation accuracy was 88.3% (95% CI 82.4%-94.1%). Using a
threshold set at 95% sensitivity, specifıcity was  70%. Conclusions: The
LCRT biomarker reported here displayed high specifıcity and ease of imple-
mentation on a high throughput, quality-controlled targeted NGS platform.
As such, it is optimized for clinical validation in specimens from the ongoing
LCRT blinded prospective cohort study. Following validation, the bio-
marker is expected to have clinical utility by better stratifying subjects for
annual lung cancer screening compared to current demographic criteria
alone.
#4738 Risk of ipsilateral invasive breast cancer after DCIS: a comparison
of primary DCIS and subsequent invasive disease by morphological and im-
munohistochemical analysis. Lindy L. Visser, Lotte L. Elshof, Koen van de
Vijver, Emma J. Groen,Mathilde Almekinders, Marjanka K. Schmidt, Flora van
Leeuwen, Emiel J. Rutgers, Michael Schaapveld, Esther H. Lips, Jelle Wesseling.
Netherlands Cancer Institute, Amsterdam, Netherlands.
INTRODUCTION. The wide spread adoption of population-based breast
cancer screening has led to a substantial increase in diagnosis of ductal
carcinoma in situ (DCIS). When detected, almost all DCIS is treated to
prevent progression to invasive disease, even though the majority of DCIS
will never progress. Yet, we are unable to discriminate harmless from poten-
tially hazardous DCIS. Hence, there is an urgent need to fınd characteristics
of DCIS and biomarkers that predict subsequent invasive tumor develop-
ment. In this study, we compared primary DCIS lesions with their subse-
quent ipsilateral invasive breast cancer (iIBC), to explore how the initial
DCIS lesion and its subsequent iIBC are related. PATIENTS AND METH-
ODS. We used a population-based, nation-wide cohort consisting of 2,654
women who were treated for primary DCIS by breast conserving surgery
(BCS) only. Within a median follow-up time of 10.7 years, 316 women de-
veloped a subsequent iIBC (12%). FFPE tissue blocks of both DCIS and
subsequent iIBC could be collected for 158 of these 316 women. We assessed
histology characteristics, tumor location, estrogen and progesterone recep-
tor status, p16 expression, and HER2 and p53 overexpression. Additionally,
DNA and RNA were simultaneously isolated from 100 DCIS and 100
matched subsequent iIBC specimens for extensive molecular profıling. RE-
SULTS. More than 95% of the invasive recurrences were located at or near
the site of the primary DCIS. Concordant histological grade was found in
94% of the matched pairs and identical immunohistochemical (IHC) marker
expression in 58%. Of the 44 patients with HER2 positive DCIS, 36% devel-
oped HER2 negative iIBC. Furthermore, this change in HER2 status was also
a main cause of a change in surrogate intrinsic subtype (based on ER, PR,
HER2) between DCIS and iIBC, which was observed in 16% of the patients.
These dissimilarities were not found when we compared invasive disease
with synchronous DCIS (present in 83 of 158 patients). Molecular analyses is
still ongoing. CONCLUSION. This is the fırst time that an unbiased com-
parison could be made between primary DCIS and its subsequent iIBC
within such a large patient group, integrating clinical, histological and IHC
data. Our results suggest that the majority of invasive breast cancers in our
cohort reflect outgrowth of residual disease based on tumor location and
histological grade. DCIS and iIBC are very similar when comparing histo-
logical grade, but frequently show differences on the IHC level. Remarkably,
the dissimilarities in HER2 status and surrogate intrinsic subtype as seen in
primary DCIS vs. iIBC are missing when comparing IBC with synchronous
DCIS. As a next step, we will analyse the lesions on the molecular level, to
verify these fındings and to look for molecular characteristics of DCIS that
could be associated with progression to invasive disease.
#4739 Prognostic impact of abnormal DNA damage response protein ex-
pression in breast cancer. Koung Jin Suh,1 Han Suk Ryu,1 Kyung-Hun Lee,1
Hyojin Kim,1 Ahrum Min,2 Tae-Yong Kim,1 Hyeong-Gon Moon,1 Sae-Won
Han,1 Do-Youn Oh,1 Wonshik Han,1 In Ae Park,1 Dong-Young Noh,1
Seock-Ah Im1. 1Seoul National University Hospital, Seoul, Republic of Korea;
2Seoul National University Cancer Research Institute, Seoul, Republic of Korea.
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Purpose: Defects of DNA damage repair are known to be associated with the
effıcacy of anthracycline or platinum-based chemotherapy as well as poly[ADP-
ribose] polymerase (PARP) inhibitors (PARPi) and PD-1/PD-L1 checkpoint
inhibitors. Since multiple proteins are involved in DNA-damage response
(DDR) and operate collectively, our main aim was to better understand the
expression of proteins in DDRmachinery and their integrated prognostic value
in the different subtypes of breast cancer. Methods: A total of 419 consecutive
breast cancer patients who underwent curative resection in 2008 were enrolled
in the study. Tissue microarray has been constructed, and NBS1, BRCA1,
BRCA2, ATM and p53 expression were determined by immunohistochemistry.
Results: All patients were female, with a median age of 47 years; 280 (67%) had
luminal A, 36 (9%) had luminal B, 37 (9%) had HER2-enriched, and 56 (13%)
had triple-negative breast cancer (TNBC). Loss of NBS1, BRCA1, BRCA2, and
ATMexpressionwas observed in 6.7%, 33.7%, 89.9%, and 30.8%of breast cancer
patients, respectively, and abnormal p53 expression was observed in 39.3% of
patients. Loss of NBS1, BRCA1, ATM and abnormal p53 expression was asso-
ciated with signifıcantly lower disease-free survival (DFS) rates, respectively.
“Abnormal DDR protein expression”, defıned as loss of any one of NBS1,
BRCA1, ATM and/or abnormal p53 expression, was observed in 258 of 399
evaluable cases (64.7%) and was signifıcantly associated with higher tumor
grade, larger tumor size, and ER- and/or PR-negative status.Majority of patients
with luminal B (31/36, 86.1%), HER2-enriched (34/35, 94.4%), and TNBC (46/
53, 86.8%) subtype showed abnormal DDR protein expression. In comparison,
136/264 patients (53.8%) with luminal A subtype had abnormal DDR protein
expression. AbnormalDDRprotein expressionwas associatedwith signifıcantly
lower 5-year DFS rate than those in patients with normal DDR protein expres-
sion in all patients (95.6% vs. 84.8%, p 0.001), as well as in luminal A subgroup
(97.4% vs. 89.0%, p  0.011). In multivariate analysis, abnormal DDR protein
expression remained as an independent predictor of shorter DFS for luminal A
subtype tumors (hazard ratio 3.14; 95% confıdence interval, 1.16 – 8.47, p 
0.024). Conclusion: We demonstrated differential expression of proteins in
DDR machinery according to breast cancer subtypes and its prognostic impli-
cation. Most of luminal B and HER2-enriched tumors has abnormal DDR ex-
pression as frequently as triple negative tumors. Less but signifıcant proportion
of luminal A tumors also shows abnormal DDR protein expression, which is an
independent poor prognostic factor.
#4740 Loss of the tumor suppressor zinc fınger protein-36 and risk of
lethal prostate cancer. Travis Gerke,1 Daniela Börnigen,2 Himisha Beltran,3
Svitlana Tyekucheva,4 Curtis Huttenhower,5 Gwo-Shu Lee,4 Bruce Trock,6 Lo-
relei Mucci,5 Christopher Sweeney4. 1Moffıtt Cancer Center, Tampa, FL; 2Uni-
versity Heart Center Hamburg-Eppendorf, Hamburg, Germany; 3Weill Cornell
Medical College, New York, NY; 4Dana-Farber Cancer Institute, Boston, MA;
5Harvard T.H. Chan School of Public Health, Boston, MA; 6Johns Hopkins Uni-
versity, Baltimore, MD.
Background. Biomarkers are needed to complement current clinicopatho-
logic variables towards distinguishing prostate tumors that are likely to be met-
astatic from those that are indolent. We previously used a bioinformatic analyt-
ical approach to identify ZFP36, also known as Tristetraprolin (TTP), as a tumor
suppressor in the NFB pathway. The current study aims to evaluate the prog-
nostic potential of tumor mRNA expression of ZFP36. Methods. Our primary
analysis leveraged data from a case-control study nested in the Health Profes-
sionals Follow-up Study and Physicians’ Health Study. Gene expression for
ZFP36 was quantifıed from archival surgical tumor tissue using Affymetrix Hu-
man Gene 1.0 ST microarrays. Cases (n113) were men who died of prostate
cancer or developed metastatic disease, and controls (n291) were men who
lived at least 8 years after diagnosis and remained metastasis free. A genetically
validated PTEN immunohistochemistry (IHC) assay was performed on tissue
microarrays (TMAs) for a subset of the men (n257). Results. Mean ZFP36
expression was signifıcantly lower in the cases compared to the controls
(p0.001), and the crude odds ratio (OR) for lethal disease comparing those
with low ZFP36 expression (below the lower quartile) to those with high ZFP36
expression (greater than or equal to the lower quartile) was 3.52 (95% CI: 2.18-
5.69; p0.001). The association persisted with adjustment for Gleason category,
age at diagnosis, and clinical stage, with an adjusted OR of 1.93 (95% CI: 1.07-
3.49; p0.03). When modeled as a continuous variable in a logistic regression
for prognosis, ZFP36 improved the AUC of the clinical factor model (Gleason,
age, and clinical stage) from 0.83 (95% CI: 0.79-0.88) to 0.85 (95% CI: 0.81-0.89;
p0.10 for improvement). Among the patients with available PTEN staining,
independent effects of ZFP36 and PTEN loss were observed. In the logistic
regression on lethal disease with both variables included, PTEN negativity con-
ferred an OR of 2.10 (95% CI: 1.11-3.93; p0.02) and low ZFP36 produced an
OR of 2.34 (95% CI: 1.24-4.36; p0.01). Taken together, we observed an OR of
4.90 (95% CI: 2.05-11.72) comparing patients with PTEN negativity and low
ZFP36 to those with PTEN staining present and high ZFP36. Conclusions. Loss
of the tumor suppressor ZFP36 is prognostic for metastatic or lethal prostate
cancer. Combining information on ZFP36 with measurements from other
mechanistic pathways, such as PTEN, may lead to highly accurate models.
#4741 Biomarker signifıcance of plasmaand tumormiR-21,miR-221, and
miR-106a in pediatric osteosarcoma. Manjula Nakka,1 Wendy Allen-
Rhoades,1 Yiting Li,1 Aaron Kelly,1 Jianhe Shen,1 Aaron Taylor,1 Donald A.
Barkauskas,2 Jason Yustein,1 Irene Andrulis,3 Jay Wunder,3 Richard Gorlick,4
PaulMeltzer,5 Ching Lau,1 Tsz-KwongMan1. 1Baylor College ofMedicine,Hous-
ton, TX; 2Children’s Oncology Group, Monrovia, CA; 3University of Toronto,
Toronto, Ontario, Canada; 4Albert Einstein College of Medicine, NY; 5National
Cancer Institute, Bethesda, MD.
Osteosarcoma is the most common malignant bone tumor in children and
young adults. Despite the use of surgery and multi-agent chemotherapy, osteo-
sarcoma patients who respond poorly towards chemotherapy or develop re-
lapses have a dismal outcome. Identifıcation of biomarkers for active disease
may help to monitor tumor burden, detect early relapses, and predict prognosis
in these patients, so that they can be treated as early as possible to improve their
survival. In this study, we examined if circulating microRNAs (miRNAs) can be
used as biomarkers in osteosarcoma patients. We performed genome-wide
miRNA profıling on a discovery cohort of OS plasma samples (n32) collected
from the Texas Children’s Hospital. A total of 56miRNAswere upregulated and
164 miRNAs were downregulated in osteosarcoma samples when compared to
normal plasma samples (n8). miRNA-21, miR-221 and miRNA-106a were
selected for further validation based on their known biological importance. We
showed that all three circulating miRNAs were expressed signifıcantly higher in
OS samples (n29) than normal samples (n17) in an independent cohort
obtained from the Children’s Oncology Group. Furthermore, we demonstrated
that miR-21 was expressed signifıcantly higher in osteosarcoma tumors (n89)
compared with normal bone controls. More importantly, lower expressions of
miR-21 and miR-221, but not miR-106a, signifıcantly correlated with a poor
outcome. In conclusion, our results indicate that miR-21, miR-221 and miR-
106a are elevated in the circulation of osteosarcoma patients, whereas tumor
expressions of miR-21 and miR-221 are prognostically signifıcant. Further in-
vestigation of themiRNAsmay lead to a better prognosticmethod and potential
miRNA therapeutics for osteosarcoma.
#4742 APCWT/RASWT/BRAFWT tumors represent an under recognized
poor prognostic group of right sided colorectal cancer. Jonathan M. Loree,
Krittiya K. Korphaisarn, Michael Lam, Van K. Morris, Kanwal P. Raghav, Mi-
chael J. Overman, Cathy Eng, Arvind Dasari, Bryan K. Kee, David Fogelman,
Robert A. Wolff, Kenna Shaw, Russell Broaddus, Mark J. Routbort, Rajyalak-
shmi Luthra, Dipen M. Maru, David G. Menter, Funda Meric-Bernstam, Scott
Kopetz. The University of Texas MD Anderson Cancer Center, Houston, TX.
Background: Side of primary tumor has prognostic and predictive signifı-
cance in metastatic colorectal cancer (mCRC). RAS/BRAF wild type (WT) left
(L) sided tumors have improved outcomes with anti-EGFR therapy while right
(R) sided tumors do worse. We aimed to identify mutations (MTS) in RAS/
BRAF WT patients (pts) which may explain the differing response. Methods:
Using a 46 gene panel, we comparedMT frequencies by side in 1880mCRC pts.
Overall survival (OS) was summarized with Kaplan-Meier curves, the log rank
test, and Coxmodels. Microsatellite unstable pts were excluded from univariate
OS analysis. Results: RASmutant (MT) pts were more likely to be APCMT (OR
1.64, P0.0001) than RAS WT pts. Presence of APC MTS was associated with
improved OS in WT RAS/BRAF (HR 0.58, P0.0003) and MT RAS/BRAF pts
(HR 0.69, P0.0004). Multivariate analysis confırmed APC MTS were associ-
ated with improved OS (HR 0.67, P0.001) after controlling for RAS/BRAF,
side, and MSI. Given the association of tumor location and OS, we stratifıed pts
by side and compared APC MT/WT pts. Improved OS with APC MTS was
independent of side (L-HR 0.70, P0.0011; R-HR 0.62, P0.0012), but pts with
R APCWT tumors stood out as an extreme risk group with the worst OS of all
L/R and APC MT/WT combinations even in RAS/BRAF WT pts (P0.0001).
This group of R sided RAS/BRAF/APC WT pts represents a novel poor prog-
nostic group and its baseline characteristics are summarized below.When strat-
ifying APC MT by genomic location, only MTS in the mutation cluster region
(n686) that contains axin and -catenin binding sites remained prognostic in
multivariate models (HR 0.63, P0.0001), while other APCMTS (n163) were
no longer signifıcant (HR 0.82, P0.27). Conclusion: APC WT R sided pts
represents a group with poor prognosis regardless of RAS/BRAF MT status.
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Given the difference in CTNNB1 MT rate and importance of MTS in axin/
-catenin binding sites, WNT signaling differences between L and R sided tu-
mors may be important to explore further.
Baseline Characteristics of Patients with APC/RAS/BRAFWild Type Right Sided Tu-
mors
Baseline
Characteristic
Right Sided
APC/RAS/BRAFWT
(N88, 15.2%)
Other Right
Sided Tumors
(N492, 84.8%) P-Value
Median Age (IQR) 56 (47-61) 56 (48-64) 0.23
Gender
Female 46 (52.3%) 241 (49.0%) 0.56
Male 42 (47.7%) 251 (51.0%)
MSI-H 8 (10.5%) 25 (6.5%) 0.22
Histology
Adenocarcinoma 50 (56.8%) 366 (74.4%) 0.0018
Mucinous / Signet 38 (43.2%) 123 (25.0%)
Other 0 3 (0.6%)
Average # of Mutations
Per Patient (/- SD)
1.38/-2.01 3.10/-1.79 0.0001
Synchronous Metastasis 76 (86.4%) 401 (81.5%) 0.36
TP53 MT 47 (53.4%) 275 (55.9%) 0.67
PIK3CAMT 6 (6.8%) 111 (22.6%) 0.001
CTNNB1 MT 7 (8.0%) 11 (2.2%) 0.004
#4743 Identifıcation of metastasis-associated biomarker PLEC1 by
iTRAQ-based proteomic approach and prognostic role of PLEC1 in patients
with hepatocellular carcinoma. Lin-lan Song, Yu Chen, Di Mu, Xiao-Yan Ji-
ang, Yu-Nong Li, Ling-Yu Jiang, Zhen-Fang Zhang, Liang Yan, Min Yang, Yi-
xuan Yang, Hong Ren, Yong Liao. Key Laboratory of Molecular Biology for In-
fectious Diseases (Ministry of Education), Institute for Viral Hepatitis,
Department of Infectious Diseases, The Second Affıliated Hospital, Chongqing
Medical University, Chongqing, China.
Purpose: Hepatocellular Carcinoma(HCC)is the fıfth most prevalent can-
cer and the second most frequent cause of cancer-related death in men
worldwide because of high incidence of recurrence and widespread metas-
tasis. However, to date, there have been no direct metastesis-associated bio-
marker which is critical for the effective treatment of patients with HCC, we
thus aimed to identify novel HCC metastasis-associated biomarkers with
prognostic signifıcance.E xperimental Design: Two human HCC cell lines,
MHCC97-L and MHCC97-H with similar genetic background and stepwise
increasing metastatic potentials, were used to explore potential metastasis-
associated biomarkers for HCC by isobaric tag for relative and absolute
quantitation (iTRAQ) combination with 2D-LC-MS/MS. Ninety-fıve HCC
cancerous and paracancerous tissues were further analyzed by immunohis-
tochemistry to validate the correlations between the expression levels of
PLEC1 with various clinicopathologic factors and patient survival. Results:
Using iTRAQ combination with 2D-LC-MS/MS, a total of 47 differentially
expressed proteins were found in MHCC97-L and MHCC97-H cells, of
which 26 proteins were up regulated and 21 proteins were down regulated.
Plectin-1 (PLEC1) was identifıed and re-confırmed as a potential biomarker
for HCC that was highly up-regulated in tumor tissues, in comparison with
that of para-cancerous tissues. Over-expression of PLEC1 was also strongly
correlated with tumor size (P  0.05) and TMN stages (P  0.05). In addi-
tion, both univariate and multivariate analyses demonstrate that PLEC1 ex-
pression is an independent prognostic factor for patients with
HCC(p0.05). Conclusions: In this study, iTRAQ-based proteomic technol-
ogy was explored to uncover novel metastasis-associated biomarkers in
HCC. We identifıed and validated metastasis-associated protein PLEC1 as a
potential prognostic marker in patients with HCC.
#4744 Clinical validation of a prognosticmodel integratingBreast Cancer
Index (BCI) with tumor size and grade for prediction of late distant recur-
rence in hormone receptor-positive (HR) breast cancer with 1-3 positive
nodes. Yi Zhang,1 Piiha-Lotta Jerevall,2 Brock E. Schroeder,1 Amy Ly,2 Hannah
Nolan,2 Catherine A. Schnabel,1 Dennis C. Sgroi2. 1Biotheranostics, San Diego,
CA; 2Massachusetts General Hospital, Boston, MA.
Background: The Breast Cancer Index (BCI) 11-gene expression signature
has been previously demonstrated to signifıcantly predict risk of overall
(10y), early (0-5y), and late (5y) distant recurrence in patients with HR,
node negative breast cancer. A distinct BCI model that integrated tumor size
and grade (BCIN) was developed and validated for prediction of distant
recurrence in HR women with 1-3 positive nodes (N1) (Sestak et al.,
SABCS 2015, P2-08-12; Zhang et al, ASCO 2016, abstract no. 541). The
objective of this analysis was to evaluate BCIN performance in the subset
of patients that were treated with nomore than 5 years of adjuvant endocrine
therapy. Methods: The validation study included 402 HR N1 patients di-
agnosed between 1993 to 2007 with 5y follow-up and available tumor
blocks. Patients treated with 5y of endocrine therapy 	 chemotherapy
(n276) were included in this analysis. BCIN risk scores and categories
(low vs high, using a pre-defıned cutpoint) were determined blinded to clin-
ical outcome. Kaplan-Meier estimates of overall (015y) and late (5y) dis-
tant recurrence, hazard ratios and 95% CIs were estimated. Multivariate
analysis adjusting for standard prognostic factors (age, tumor type, surgery
type, PR and HER2 status) was performed using Cox proportional hazards
model. Results: Mean age was 53y. 99% were ER, 89% PR, and 14%
HER2. The majority of tumors were T1 (61%) or T2 (34%), and 16%, 53%,
and 31% were grade 1, 2, and 3, respectively. 79% of patients were treated
with adjuvant chemotherapy. BCIN signifıcantly separated patients into
low and high risk groups for both overall (P0.0001) and late (P0.0067)
distant recurrence. For overall distant recurrence, BCIN classifıed 18% of
patients into the low risk group. The 15y risk of distant recurrence was 2.1%
(95% CI: 0.0-6.0%) in the BCIN low risk group vs 36.8% (95% CI: 29.3-
43.4%) in the high risk group (HR: 21.88; 95% CI: 3.04-157.32). Of patients
that were distant recurrence-free for at least 5y, 22% were classifıed as
BCIN low risk. The risk of distant recurrence at year 15 was 2.1% (95% CI:
0.0-6.0%) in the BCIN low risk group vs 19.0% (11.6-25.8%) in the high
risk group (HR: 9.49; 95% CI: 1.29-69.7). Conclusions: In this subset analysis
from an independent validation study, BCIN identifıed a signifıcant pro-
portion of N1 patients that were associated with a considerably low 15y risk
of distant recurrence after 5 years of endocrine therapy 	 chemotherapy.
BCIN may provide additional prognostic information to facilitate selec-
tion of N patients for extended endocrine treatment wherein patients iden-
tifıed as BCIN low may be considered adequately treated with adjuvant
therapy alone.
CLINICAL RESEARCH: Radiobiology and Radiotherapy
#4745 Circulating cytokine levels predictive of Grade>3 radiation pneu-
monitis: Preliminary secondary analysis of a randomized controlled trial of
defınitive chemoradiation in locally advancedNSCLC.Matthew S. Ning, Ting
Xu, Daniel Gomez, Hai T. Tran, Ritsuko Komaki, Xiong Wei, Steven H. Lin,
Stephen Hahn, Eric Prado, Jianjun Zhang, John V. Heymach, Zhongxing Liao.
University of Texas MD Anderson Cancer Center, Houston, TX.
PURPOSE: Host immune activation is believed to be a major player of
radiation pneumonitis (RP). Several cytokine and angiogenic factors (CAFs)
have been studied as correlative markers and therapeutic targets for RP;
however, studies are sparse in the setting of prospective trials and high-grade
toxicity (Grade3) endpoints. We examined the predictive value of several
CAFs in combination with clinical factors for RP in the context of a Phase II,
prospective randomized study of intensity modulated RT (IMRT) versus
proton therapy for locally advanced NSCLC (n178) as well as a prospective
laboratory cohort (n43). METHODS: From July 2009 to April 2014, 221
patients were treated with proton therapy or IMRT to doses of 60-74 Gy
equivalents with concurrent platinum-doublet chemotherapy. Primary end-
points were symptomatic RP (Grade2) and RP requiring intervention
(Grade3). Plasma circulating levels of IL-6, IL-10, IL-8, IL-17, IL-2, IL-1,
and IL-1 were measured at baseline and post-treatment (median time 48
days post-RT) by multiplex electrochemiluminescence immunoassay. Clin-
ical characteristics were evaluated for associations with Grade3 RP: histol-
ogy, age, smoking status, mean lung dose (MLD), chemotherapy, stage, per-
formance status, and RT technique. CAFs with 50% undetectable samples
were removed from analysis, and samples below the lower limit of quantita-
tion (LLQ) were transformed to the mean of zero and the LLQ. Predictive
values of clinical and cytokine factors were evaluated in univariate and mul-
tivariate analyses via Cox proportional hazards modeling. RESULTS: Of the
221 patients, 42 (19.0%) developed Grade 2 RP, and 22 (9.95%) developed
Grade3 RP. Both IL-1 and IL-1 had50% of undetectable samples and
were removed from analysis. Pre-treatment level of IL-6 4.00 pg/mL was
associated with Grade3 RP (HR 2.487; p.048), as was post-treatment
level of IL-10 0.50 pg/mL (HR 2.931; p.020). On multivariate analysis,
the factors associated with Grade3 RP development were post-treatment
level of IL-100.50 pg/mL (HR 3.332; p.015) andMLD20 Gy (HR 5.864;
p.001). CONCLUSIONS: In this preliminary analysis of prospectively col-
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lected CAFs, post-radiation IL-10 level was signifıcantly associated with
Grade3 RP and, if validated, may serve as a predictor of this toxicity in
combination with MLD. IL-10 plays an important role in the inflammatory
response and is potentially targetable, warranting further investigation.
#4746 Early clinical support for 4-demethyl-4-cholesteryloxycarbonyl-
penclomedine (DM-CHOC-PEN) as a radiosensitizer in cancers involving
the CNS. Lee Roy Morgan,1 R S. Weiner,2 T Mahmood,3 R. Kawauchi,3 K De-
visetty,4 J Herman,5 M Bhandari,6 R Summe,6 E Benes,1 AH Rodgers,1 ML
Ware,7 JS Hayman,8 JWeber,9 Jay J. Zou10. 1DEKK-TEC, Inc., New Orleans, LA;
2TulaneUniversity, NewOrleans, LA; 3Detroit Clinical Research Center, Lansing,
MI; 4Karmanos Cancer Center Institute at McLaren Flint, Flint, MI; 5Sparrow
Hospital, Lansing, MI; 6The Christ Hospital, Cincinnati, OH; 7Ochsner Medical
Center, New Orleans, LA; 8Johns Hopkins Medical Center, Baltimore, MD;
9Gamma Radiosurgery Center of New Orleans, New Orleans, LA; 10University of
Texas Health Science Center/Hermann Hopsital, Houston, TX.
Background: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-
CHOC-PEN) is a poly-chlorinated pyridine cholesteryl carbonate with a MOA
via bis-alkylation of DNA @ N7-guanine and N4-cytosine that has completed
Phase I/II studies [AACR #CT129, 2016] in subjects with cancers involving the
CNS. The current presentation reviews clinical and in vitro data that support
radiosensitizing properties for DM-CHOC-PEN in cancers involving the CNS.
Patients & Methods: DM-CHOC-PEN was administered as a 3-hr IV infusion
once every 21 days to subjects with advanced cancer involving the CNS. The
dose schedule was 2-tiered: 85.8 mg/m2 for subjects with liver involvement and
98.7 mg/m2 for subjects with normal livers. All subjects with resistant or new
CNS lesions that did not respond to DM-CHOC-PEN were given the option of
surgery, stereotaxic radio-surgery (SRS) or whole brain irradiation (WBRT). As
preclinical support, human NSCLC adenocarcinoma cells (H-2086) growing in
culture (106 cells/mL) were pretreated with DM-CHOC-PEN (0.1 -1.0 g/mL)
for 24 hrs, drug washed, re-fed freshmedium and then 48 h later irradiated (SRS
with 6, 9 or 12 Gy). Results: Fifty-three (53) subjects with/without CNS involve-
ment have been treated to date with DM-CHOC-PEN. Five (5) subjects (4-
NSCLC & 1-sarcomas) in the Phase I/II trials required surgery for persistent
CNS lesions following DM-CHOC-PEN therapy. DM-CHOC-PEN was identi-
fıed in samples from all subjects - 90-212 ng/g tumor [subjects had been treated
with 39-98.8 mg/m2 of drug]. Five subjects (1-sarcoma & 4-NSCLC) who had
been treated with DM-CHOC-PEN for 6-wks - 8-mos had persistent NSCLC
lesions involving the CNS were treated with SRS orWBRT. All fıve subjects had
excellent objective results (OS 8 - 29mos) with no CNS toxicity. Preclinical
in vitro studies supported the clinical data: NSCLC cells treated with DM-
CHOC-PEN (0.1 -1.0g/mL) demonstrated 50 & 100% cytotoxicity @ 0.4 & 1.0
g/mL; for SRS alone (6, 9 &12 Gy) - cell kill was 20 & 65% @ 6 & 12 Gy [100%
kill was not observed at this dose range]; for DM-CHOC-PEN (0.25 g/mL)
SRS (6-12 Gy) - cell kill was 80 & 100%@ 6& 12 Gy. Thus, in combination - less
drug (0.25 g/mL) and 12 Gy - produced a 100% cell kill, as compared to either
SRS or drug, alone. Photon induced charge transfer reactions with DM-CHOC-
PEN will be discussed. Conclusion: Preliminary data is presented that supports
DM-CHOC-PEN’s cytotoxicity and radiosensitizing properties in cancers in-
volving the CNS. Observations during clinical trials support the drug’s persis-
tent presence in human tumors after systemic administration and notable pos-
itive effect on response to subsequent radiation. Complete data on patient
responses and observed toxicities will be presented. Supported by - NCI/SBIR
grants - R43/44CA132257 and NIHNIGMS 1 U54 GM104940 - the latter funds
the Louisiana Clinical and Translational Science Center.
#4747 Subcutaneous fat predict outcome in head and neck cancer. Ngan
M. Tsang. Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Background: Previous studies have shown that body mass index (BMI) is
linked to survival in cancer patients. Our objective was to analyze whether body
composition before treatment can predict outcomes in patients with head-and
neck cancer. Methods: All 881 patients with loco-regional head-and -neck can-
cer treated with curative-intent RT during 2005 to 2012 were retrospectively
studied. Body composition analyses by using pre-RTCT images acquired for RT
simulation.We compared subcutaneous adipose tissue (SAT) index andmuscle
index by measuring cross-sectional area of tissues at level of the third thoracic
vertebrae (T3) in both genders. Overall survival (OS), loco-regional control
(LRC), and distant metastasis-free survival (DFS) were analyzed by body com-
position index that divided into two groups based on values higher and lower
than the median. The median follow-up was 4.68 years. Results: SAT index in
female patients was signifıcantly higher than that in male (p0.001). The me-
dian SAT index and muscle index for female were 15.25 cm2/m2 (range, 0.93-
88.09 cm2/m2) and 34.3 cm2/m2 (range, 14.78-73.05 cm2/m2), and formale were
6.19 cm2/m2 (range, 0.21-40.48 cm2/m2) and 51.74 cm2/m2 (range, 8.03-89.06
cm2/m2). The 5-year and 10-year OS, LRC and DFS were 66.3%, 57.6%, 73.4%,
71.4%, 83%, and 82.1%. Higher pre-treatment SAT index was associated with
longer OS (HR  0.616; P  0.001) and DFS (HR  0.649; P  0.015) and a
trend towards longer LRC (HR 0.772; P 0.066). Pre-treatmentmuscle index
was also a signifıcant predictor of OS (HR 0.662; P 0.006) and LRC (HR
0.684; P 0.029). Conclusion: SAT index andmuscle index of T3 level obtained
fromCT images appear to predict outcomes in patients with curative head-and-
neck cancers.
#4748 Novel predictive biomarker for monitoring adverse reactions to
radiation therapy. Paul OKunieff,1 Steven Swarts,1 Elena Peletskya,2 Anne Val-
lerga,2 Rachel Chuang,2 Michael J. Powell,2 Aiguo Zhang2. 1University of Flor-
ida, Gainesville, FL; 2DiaCarta, Richmond, CA.
Introduction: Radiation treatment is required by 70%of cancer patients, how-
ever there is currently no clinical method for determining the therapeutic re-
sponse or radiation induced toxicity that can be used during a course of radia-
tion therapy to personalize the dose for individual patients. The only standard
method is CT/PET and/or MRI. This is a major clinical concern for radiation
oncologists with so many new agents being approved in combination with radi-
ation therapy. Methodology: Herein we describe a highly sensitive clinically
validated assay that measures the extent of normal tissue damage induced by
radiation by quantitation of circulating freeDNA (cfDNA) derived fromcellular
apoptosis detected in plasma of patients undergoing radiation therapy. The as-
say employs DNA capture probes and SuperbDNATM signal amplifıcation tech-
nology with alkaline phosphatase labelled signaling probes coupled with diox-
etane phosphate chemiluminescence detection. The assay can be performed
directly on patient plasma samples and can be readily automated. Conclusion:
RadTox TM can be used both for research and clinical testing of plasma samples
for patients undergoing radiation therapy for optimization and personalization
of treatment.
#4749 Aphase II study using cardiacMRI to assess cardiac injury in breast
cancer patients receiving three-dimensional conformal regional nodal radio-
therapy (3DCRT) with heart dose constraints. Carmen Bergom,1 Jason
Rubenstein,1 AimeeWelsh,1 Philip Prior,1 Daniel Eastwood,1Mei-Jie Zhang,1 J.
FrankWilson,1 Julia White,2 Julie Bradley3. 1Medical College of Wisconsin, Mil-
waukee, WI; 2The Ohio State University Comprehensive Cancer Center, Milwau-
kee, WI; 3University of Florida, College of Medicine, Jacksonville, FL.
Purpose/Objectives: Regional nodal radiotherapy (RNR) can improve sur-
vival for node positive breast cancer (NPBC) patients, yet this benefıt is offset by
potential late cardiac toxicity.Most cardiac toxicity reports fromRNRhave been
in eras where no specifıc dose or volume heart constraint was used. CardiacMRI
(CMR) is ideal to assess ventricular function and volumes. We report a phase II
trial designed to assess cardiac injury by CMR in NPBC patients who received
chemotherapy (CT) and RNR planned with 3DCRT using heart constraints.
Materials/Methods: 244 NPBC patients treated with 3DCRT RNR following
surgery planned with heart constraints between 2000-2008 were screened. Eli-
gibility included prior anthracycline CT, no cardiac disease pre-NPBC, and no
recurrent disease. Patients with active atrial fıbrillation were excluded. The car-
diac dose constraint utilized was V2510% of the heart. Mean heart dose was
not constrained. Eligible women were invited via letter to enroll in the IRB-
approved trial. CMR parameters to be evaluated included indicators of left ven-
tricular (LV) function: ejection fraction (EF), LV mass (LVMI), and LV dimen-
sions, as well as late gadolinium enhancement (LGE) and total heart
extracellular volume fraction (ECV) as measures of cardiac injury and/or early
cardiac fıbrosis. Planned analysis included correlation of CMR parameters with
cardiac dose-volume constraints using Spearman and Pearson correlations. Re-
sults: The fırst 15 L-sided and 5 R-sided patients consented underwent CMR.
Median age at diagnosis was 50 (32-77); median age at CMR was 60 (40-83).
Median time after 3DCRTwas 8.3 yr (5.7-14.4). Themedian L-sidedmean heart
dose was 4.8 Gy (1.1-11.2) and V25 was 5.7% (0-12%). No patient had clinical
cardiac disease at time of CMR.Median LVEF was 63%. No LGE and no abnor-
mal total heart ECV values (25%) were obtained. Values mildly outside nor-
mal limits were seen for LVMI or LV dimensions in 4/15 (27%) L-sided and 2/5
(40%) right-sided patients. No correlations were seen between heart mean and
max doses, V5, V10, V25, and V45 and the CMR variables of LVEF, LV mass,
and LV dimensions. Two patients had valvular abnormalities found on CMR
(L-sided with aortic regurgitation and R-sided with mitral regurgitation). Con-
clusions: CMR fındings were largely within normal limits at a median follow of
8.3 years in this cohort of NPBC patients who received prior cardiotoxic chemo-
therapy and RNR planned with heart constraints. A subset of patients had sub-
clinical mildly abnormal LV measurements, but these did not correlate with
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heart dose or laterality, and the signifıcance remains unknown. In this cohort, no
signifıcant cardiac injury from RNR as measured with CMR was seen. Con-
versely, CMRmay not be a sensitive tool for subclinical partial heart injury from
RNR. Larger corroborating studies are warranted.
#4750 Predicting severe hematologic toxicity from extended-fıeld chemo-
radiation of para-aortic nodal metastases from cervical cancer. Kevin Yan,
Ezequiel Ramirez, Xuejun Gu, Kevin Albuquerque. UT Southwestern, Dallas,
TX.
Background and Purpose: To determine signifıcant factors predictive for se-
vere hematologic toxicity (HT) in cervical cancer patients with para-aortic
lymph node (PALN) metastasis treated with concurrent chemoradiation with a
specifıc focus on radiation dose to total bone marrow (BMTOT) and active bone
marrow (BMACT). To create a nomogramusing signifıcant factors to predict HT
in these patients. Material and Methods: 38 Patients with cervical cancer and
PALN metastasis who underwent 18F-FDG-PET / CT before treatment with
extended fıeld radiation therapy (EFRT) and concurrent cisplatinwere analyzed.
BMACT was defıned as the region within BMTOT with a standardized uptake
value (SUV) greater than or equal to the mean for the individual. Blood counts
were collected weekly from the beginning of radiation treatment to the end of
radiation treatment. HT was graded based on the guidelines set by the National
Cancer Institute Common Terminology Criteria for Adverse Events Version
4.0. Results: 19 patients (50%) had Grade 3 or higher hematologic toxicity
(HT3), not including lymphocyte toxicity. Patients who were obese (n12)
were less likely to get HT3 compared to patients whowere not obese (p0.03)
despite getting the same weight related dose of chemotherapy. Volume of BM-
TOT receiving 20 Gy, 30 Gy, and 45 Gy were signifıcant predictors for HT3 at
78.56% (p0.01), 47.14% (p0.00), and 20.36% (p0.01) respectively. Volume
of BMACT receiving 10 Gy, 20 Gy, 30 Gy, and 45 Gy were signifıcant predictors
for HT3 at 95.50% (p0.03), 80.52% (p0.05), 59.64% (p0.03), and 31.74%
(p0.01) respectively. Through logistic regression, the probability of develop-
ing HT3 is given by the equation: Prob(HT3)  1 / (1  exp(7.34 
0.22*BMI - 0.44*Mean Dose to BMTOT)). Patients who had HT3 received an
average of 4 cycles of chemotherapy and 62 days of treatment time, signifıcantly
different than the 4.74 chemotherapy cycles and 53 days of treatment in patients
without HT3 (p0.05, 0.00 respectively). Conclusions: Both higher patient
BMI and bone marrow irradiation were associated with HT3. A simplifıed
nomogram has been created to predict HT3 in these patients. Radiation pa-
rameters have been identifıed for cervical cancer patients with PALN involve-
ment receiving EFRT concurrently with chemotherapy. Bone marrow sparing
approaches for EFRT need to be addressed to improve patient care.
#4751 Correlating the genomic and transcriptomic profıles of pre-treat-
ment cervical tumor biopsies with patient recurrence after defınitive chemo-
radiation. Fiona J. Ruiz, Julie K. Schwarz.WashingtonUniversity in St. Louis, St.
Louis, MO.
Purpose: The purpose of this study was to identify genomic mutations that
correlatewith patient recurrence after curative intent chemoradiation therapy in
advanced stage cervical cancer patients. Methods: Pre-treatment cervical tumor
biopsies and normal blood were prospectively collected from patients treated at
Washington University in St. Louis. DNA and RNA was isolated from the fresh
frozen tumor biopsies and sent for next-generation sequencing and RNAseq
respectively. Targeted exome sequencing was done using a panel of 127 known
cancer associated genes, and an additional 8 genes previously reported to be
mutated in cervical cancer. Gene tiling was done to probe for 30 different HPV
subtypes. Results: The mutational signatures of single nucleotide polymor-
phisms were an APOBEC cytidine deaminase and CpG site cytidine deamina-
tion mutagenesis pattern. The non-silent somatic mutations were analyzed by
online prediction algorithms to assess the mutation’s putative effect on protein
function. Univariate COX regression was used to correlate patient recurrence
with non-silent putatively functional mutations. In our patient cohort 88% of
samples were HPV positive, with 74% being the high-risk HPV 16 and 18 sub-
types. Patient’s with HPV positive tumors had increased progression-free sur-
vival when compared to theHPVnegative patient tumors; and theHPVpositive
patients with HPV 16 had increased progression-free survival over the other
HPV subtypes. Complete gene tiling of the HPV 16 and 18 subtypes allowed us
to determine whether the HPV DNA was integrated in the host genome or
retained episomally. In our patient cohort less than 30% of samples had inte-
grated HPV DNA, and there was no signifıcant difference in progression-free
survival between patients with integrated or episomal HPV. Conclusions: The
genomic analysis of our advanced staged cervical cancer patient cohort found
that epigenetic modifıers were frequently mutated and that cytidine deamina-
tion mutagenesis was primarily responsible for the generation of the SNP mu-
tations. Our study identifıed NSD1 mutations as being correlated with tumor
recurrence, indicating that histone modifıcations and chromatin structure may
play an important role in tumor response to ionizing radiation therapy. Gene
expression analysis is currently ongoing.
#4752 Inflammatory cytokines and hematopoietic stem cells are associ-
ated with fatigue and insomnia in breast cancer patients undergoing adju-
vant radiation therapy. Wei Shi, Kathy Han, Madeline Li, Justin Williams,
Megan McCusker, Jie Su, Wei Xu, Scott Bratman, Kenneth Yip, Fei-Fei Liu.
Princess Margaret Cancer Center, University Health Network, Toronto, Ontario,
Canada.
Introduction: Breast cancer patients undergoing adjuvant radiation therapy
(RT) commonly experience fatigue and insomnia. We previously reported that
this fatigue is associated with a reduction in circulating hematopoetic stem cells
(HSCs; CD34); the role of inflammatory cytokines in mediating this process
however, has not been clearly elucidated. Materials and Methods: Breast cancer
patients (n147) undergoing adjuvant RTunderwent phlebotomies for analysis
of CD34, CD45, CBC, as well as 17 inflammatory cytokines using a multi-
plexed ELISA platform, during 5 time points: prior to RT (D1); after Days 2, 5,
during fınal week of RT (D2, D5, andDf, respectively); as well as onemonth post
RT-completion (M1). At the same time, patients also completed questionnaires
for the multidimensional fatigue inventory (MFI-20), hospital anxiety and de-
pression scale (HADS), and insomnia severity index (ISI). Results: General fa-
tigueworsened over the course of RT fromD1 toDf, beingmost severe at the end
of treatment (Df), but returned to baseline at M1. This trend was statistically
signifıcant (p0.001), after adjusting for anxiety, depression, and insomnia. The
levels of CD34, CD45, white blood cell, as well as lymphocyte counts de-
creased over time, with the lowest levels observed at Df (p0.001 for all). Gen-
eral fatigue correlated inversely with CD34 counts (adjusted for anxiety, de-
pression, and ISI), and was also negatively associated with hemoglobin, RBC,
and lymphocyte counts (p0.001 for all). There was also a signifıcant correla-
tion between increasing insomnia with lower CD34, CD45, white blood cell
and lymphocyte counts (all p0.05). Serum concentrations of TGF-1,MCP-1,
MMP-2, IL-1ra and IFN-2a changed signifıcantly during RT (p0.01 for all),
with either the highest or lowest levels observed at Df. Increasing levels of
MCP-1, TNF-RII and TNF-a were associated with worsening general physical
fatigue, reduced activity, decreased motivation, as well as increased insomnia
(p0.001 for all). Furthermore, there appeared a trend between increasing
MMP-2, as well as decreasing IL-1ra and TGF-1, with reduced CD34,
CD45,WBC and lymphocyte counts (p0.001). The 52 patients who received
prior adjuvant chemotherapy demonstrated signifıcantly higher fatigue, anxi-
ety, and insomnia scores. Conclusions: This study represents one of the most
comprehensive longitudinal evaluations of the effects of RT on fatigue and in-
somnia, demonstrating that this process was associated with increased levels of
the pro-inflammatory cytokinesMCP-1, TNF-RII andTNF-a, and reductions in
circulating HSCs and other hematologic parameters. Further understanding of
the roles of these cytokines would provide important insights into both quality
of life for patients undergoing cancer therapies, as well as the interactions be-
tween RT with immunotherapy.
#4753 Prognostic signifıcance of galectin-1 expression in patients with
glioblastomamultiforme following radiotherapy. Eng-YenHuang, Shang-Yu
Chou. Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Purpose: Galectin-1 is a radioresistant marker and prognostic factor in our
previous study for cervical cancer. The aim of current study is to determine the
prognostic signifıcance of galectin-1 expression level in patients with glioblas-
toma multiforme (GBM) undergoing adjuvant radiotherapy (RT). Materials
andMethods:We included 45 patientswithGBMwho treatedwithmaximal safe
surgical resection or biopsy only, followed by adjuvant RT of EQD2 60 Gy
(equivalent doses as 2-Gy fractions) for homogeneous treatment. Paraffın-em-
bedded tissues acquired from the Department of Pathology were analyzed using
immunohistochemistry staining for galectin-1 expression. Overall survival (OS)
and cancer-specifıc survival were compared between strong and weak expres-
sion of galectin-1. Results: According to univariate analysis for optimal cutoff of
galectin-1 expression level, better median survival (27.9 months) in patients
with weak level than that (10.7 months) in patients with strong level (p 0.009)
was revealed. We compared characteristics between weak and strong galectin-1
expression level, and only galectin-3 expression level was correlated. The weak
galectin-1 expression group displayed a 3-year survival rate of 27.3% and 3-year
cancer-specifıc survival (CSS) rate of 27.3%, but which are only 5.9% and 7.6%
respectively in strong galectin-1 expression group (p 0.009 and 0.020, respec-
tively). Cox regression was used to confırm that the role of galectin-1 expression
level (weak vs. strong) is a signifıcant factor of OS (p  0.020) and CSS (p 
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0.022). Other parameters such as galectin-3 expression level, ECOG perfor-
mance, gender, operation method, age  50 years, or radiation fıeld were not
signifıcant factors. Conclusion:Galectin-1 expression level affectsOS andCSS in
patient with GBM treated with adjuvant RT.
#4754 Fractionated whole brain radiation-induced behavioral changes
in athymic nude mice is associated with sustained neuroinflammation
and microglial M1-phenotype. Suman Kanji, Benjamin Johnson, Kristina
Witcher, Pooja Gulati Gulati, Shannon Chen, Jonathan Godbout, Randy J.
Nelson, Saikh Haque, Arnab Chakravarti. The Ohio State University, Colum-
bus, OH.
The objective of this study is to study the late-chronic effects of fraction-
ated whole brain irradiation (fWBI) on cognitive impairment and associated
cellular and molecular neuro-inflammatory mechanisms using clinically rel-
evant and reliable mouse models. Microglia are recognized as the primary
innate immune component of neuroinflammation. However, microglial
contributions to radiation-induced cognitive impairment are poorly under-
stood. Here, an athymic nude (Nu/Nu) mouse model was employed to ad-
dress this issue. Mice were divided into two groups: radiation treatment
(XRT) and no-treatment control (CTL). The whole brain of each XRTmouse
received 30 Gy (3 Gy/fraction) of radiation over two weeks. XRT and CTL
mice were assessed for cognitive and behavioral changes at 1, 4, and 6
months posttreatment using the novel object recognition test (for long-term,
non-spatial memory), the free running Y-Maze (for short-term, spatial
memory) and Barnes Maze (for spatial learning and memory). A signifıcant
decline in novel object recognition in the XRT group (P0.05) was seen at
the 4 month time point and continued to persist at 6 months (P0.05). No
signifıcant changes in the Barnes maze or Y-maze were seen at these time
points. Expression of neuroinflammatory mediator genes, from both whole
brain and isolated microglia, were measured by RT-PCR. We found that
markers of the M1-phenotype, which include TNF-, and MHC II, were
signifıcantly upregulated (P0.05) and markers of the general M2 Pheno-
type, which include IL-4ra, IL-10ra, and TGF-, were downregulated
(P0.05) at 1 and 6 month time points. These results indicate that sustained
neuroinflammation and microglial M1-polarization are associated with
long-term cognitive impairment induced by fWBI. Radiotherapy is the most
prevalent treatment for primary and metastatic brain tumors. Whereas pre-
vious studies that identifıed important mechanisms underlying XRT-in-
duced cognitive decline had used treatment regimens that were not clinically
relevant ones, we have employed a clinically relevant fractionation scheme to
address the cellular and molecular deregulations in association with cogni-
tive impairment.
#4755 Calpastatin phosphorylation regulates radiation response in gli-
oblastoma. Emily A. Bassett, Mitchell Pearson, Kamalakannan Palani-
chamy, Saikh J. Haque, Arnab Chakravarti.Ohio State University, Columbus,
OH.
Glioblastoma (GBM) is themost prevalent and aggressive primarymalignant
brain tumor in adults. Patients diagnosed with GBMhave a very poor prognosis
and quality of life, with amedian survival time of 12-15months despite receiving
the standard of care treatment. GBMs are highly heterogeneous, invasive, and
resistant to both chemo- and radio-therapy. The overall goal of this study is to
identify novel mechanisms of radioresistance in GBM, so that more effective
therapies can be developed in the future.We performed quantitative mass spec-
trometry-based phosphoproteomic profıling of GBM cell lines before and after
radiation treatment, and determined post-radiation fold-changes in phosphor-
ylation for each phosphopeptide. Results show calpastatin as one of the statisti-
cally signifıcant differentially regulated phosphopeptides following radiation
treatment. Calpastatin is an endogenous inhibitor of calpains, which are calci-
um-dependent cysteine proteases that control a wide range of cellular processes
including cell survival and apoptosis. We hypothesized that phosphorylation
inactivates calpastatin resulting in increased calpain activity. Western blot anal-
yses with phospho-specifıc calpastatin antibodies validated the mass spectrom-
etry results. In order to test the functional signifıcance of phosphorylated cal-
pastatin, we utilized site-directed mutagenesis to generate non-
phosphorylatable and phospho-mimetic calpastatin proteins. Western blot
analyses of U87 cells stably expressing CAST-S633A or -S633E supported the
hypothesis that calpastatin phosphorylation leads to increased calpain activity.
In conclusion, we identifıed increased levels of calpastatin phosphorylation in
multiple GBM cell lines following radiation treatment, and shown that this cor-
relates with increased calpain activity. Modulation of calpastatin activity is a
potential strategy to increase radiosensitivity of glioblastomas. Targeting cal-
pastatin is advantageous over targeting calpain itself, since many calpain inhib-
itors exhibit limited selectivity. Results of this study will contribute to our un-
derstanding of how GBM tumors become resistant to radiation therapy.
Funding: R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01
(NCI), Brain Tumor Funders Collaborative Grant, and The Ohio State Univer-
sity CCC (all to AC).
#4756 A SPP1-EGFR pathway links stem-like properties of KRAS-mu-
tated lung cancer to radiation resistance. Meng Wang,1 Jing Han,2 Lynnette
Marcar,1 Josh Black,3 Qi Liu,1 Xiangyong Li,1 Kshithija Nagulapalli,4 Lecia V.
Sequist,1 Raymond H. Mak,4 Cyril H. Benes,1 Theodore S. Hong,1 Kristin Gur-
tner,5 Mechthild Krause,5 Michael Baumann,5 Jing X. Kang,1 Johnathan R.
Whetstine,1HenningWillers1. 1Mass. GeneralHospital, Boston,MA; 2JinanMu-
nicipal Center for Disease Control and Prevention, Jinan, China; 3University of
Colorado School of Medicine, Aurora, CO; 4Dana-Farber Cancer Institute, Bos-
ton, MA; 5University Hospital Carl Gustav Carus, Technische Universität, Dres-
den, Germany.
Lung cancers with activating mutations in the KRAS oncogene present a
major clinical challenge due to poor prognosis and frequent treatment resis-
tance, particularly to agents targeting the epidermal growth factor receptor
(EGFR). For many years, it has been known that mutations in KRAS enhance
cellular resistance to ionizing radiation (IR). Clinical data are emerging suggest-
ing that the radioresistance of KRASmut cancer cells that is observed in the
laboratory is also seen in patients. However, the underlying mechanisms of
mutant KRAS-associated radioresistance is understudied and poorly under-
stood. Cancer stem cells (CSC), also referred to as tumor-initiating cells, may
promote metastases development and recurrence after therapy. Generally, can-
cer cells with CSC-like phenotypes or markers have been found to be radiore-
sistant. Enhanced DNA damage response and repair pathways have been dis-
cussed as one underlying mechanism. Interestingly, mutant KRAS has been
recently linked to CSC-like phenotypes such as tumor initiation, anchorage
independence, and self-renewal. Here, we characterized a radioresistant pheno-
type associated with KRAS mutated lung cancer cells, xenografts, and patients.
CSC-like cells were defıned as tumor-initiating cells. Genomic, biochemical, and
cell-based assays were used to identify candidates for targeting KRASmutation-
mediated radiation resistance. Radiation resistance is conferred by a CSC-like
subpopulation that is characterized by condensed chromatin, high CD133 ex-
pression, invasive potential, and tumor-initiating properties. Osteopontin, the
gene product of SPP1, promotes aspects of this phenotype including radiation
resistance and acts in the same pathway as the EGFR. SPP1/EGFR-dependent
chromatin condensation not only protects cells against radiation-induced DNA
damage but also downregulates putative negative regulators of CSC-like prop-
erties, including CRMP1 and BIM. This phenotype defınes a subset of KRAS
mutated lung cancers that is enriched for co-occurring TP53mutations. In con-
clusions,markers andmechanisms of resistance to radiation therapy in lung and
other cancers are poorly characterized. Our data provide novel insight into the
aggressive biology of KRAS mutant cancers and have major implications for
strategies to overcome the radiation resistance associated with this genotype.
#4757 Radioresistance is linkedwith stem-like properties via activation of
aryl hydrocarbon receptor. SHuang Liu, Bin Yan, Yongguang Tao. Central
South University, China.
Most cancer patients receive radiotherapy in the course of their disease and
the occurrence of radioresistance is associated with a poor prognosis for cancer
patients. Themolecular pathways that drive the enhanced tumorigenic potential
during the development of radioresistance are poorly understood. Here, we
demonstrate that the aryl hydrocarbon receptor (AhR) plays a vital and previ-
ously unrecognized role in the maintenance of stem-like cells that are isolated
from radioresistant epithelial lung cancer and nasopharyngeal carcinoma. AhR
promotes the stem-like phenotype anddrivesmetastasis by directly targeting the
promoters of ’stemness’ genes, such as the ATP-binding cassette sub-family G
member 2 (ABCG2) gene. Cancer cell populations enriched for ABCG2 expres-
sion (CD338) show an elevated ’stemness’ signature and are more prone to
cancer progression in vitro and in vivo. Ubiquitin C-terminal hydrolase-L3
(UCHL3), a deubiquitinating enzyme,may counteract AhR, while IKK, a bone
fıde chromatin modifıer, may directly activate stemness related genes. The ra-
dioresistant cancer cell sublines are associated with a hybrid state in epithelial-
mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET),
and elevated tumor associated macrophages and proinflammatory factors.
Moreover, the radioresistant sublines display high levels of oncometabolites,
including -ketoglutarate, and treatment of cancer cells with -ketoglutarate
enhances their stem-like properties through activation of the AhR. Thus AhR is
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functionally linked with radioresistance in lung cancer and nasopharyngeal car-
cinoma, and it drives tumorigenesis by an epithelial and mesenchymal compo-
sition, tumor associated macrophages and oncometabolites.
#4758 Sensitization of nasopharyngeal carcinoma to radiotherapy by tar-
geting GFPT1/TGF-1 signaling pathways. Siqi Chen, Wei Gao, Jimmy Yu-
Wai Chan, Thian-Sze Wong. The University of Hong Kong, Hong Kong SAR,
China.
Background: Nasopharyngeal carcinoma (NPC) is a unique cancer with high
susceptibility to radiation and mainstay treatment is radiotherapy. Effectiveness of
NPC treatment is therefore dependent on the sensitivity of cancer cells to ionizing
radiation treatment. Further, development of radio-resistant phenotype is a risk
factor fordistantmetastasis anddisease recurrence.Therefore, enhancing thedegree
of radiation sensitivity could improve prognosis and reduce the toxicity of radio-
therapy with the use of lower radiation dose. Transforming growth factor1(TGF-
1) expression is responsive to radiation treatment and the increase is important in
the post-irradiationDNA repair. Tumor with lowTGF-1 level is more responsive
to radiation treatment. Therefore, inhibiting TGF-1 production can enhance the
radiationdamage to cancer cellDNAandalso intensify the sensitivity of cancer cells
to radiation. Our preliminary results indicate that TGF-1 production in NPC is
mediated by hexosamine pathway. Of which, GFPT1 (glucosamine-fructose-6-
phosphate aminotransferase) is the rate-limiting enzyme. Purpose of the study: To
enhance radiation sensitivity by targetingGFPT1/ TGF-1 cascade inNPC. Exper-
imentalprocedures:RadiationprotectiveeffectsofTGF-1wasexaminedbycolony
formation assay and Danio rerio (zebrafısh) embryonic system. Production of
TGF-1 by activated hexosamine pathway in NPC was revealed by glucose and
glucosamine treatment. Effects of GFPT1 silencing on radiosensitization are re-
vealedbyGFPT1siRNAtreatment followedbycolony formationassayandgamma-
H2AX formation assays. Results: Pretreatment of HONE1 cells with recombinant
TGF-1 protein enhanced the clonogenic ability of irradiated cells. TGF-1 signif-
icantly increased the survival of zebrafısh embryos after irradiation. Glucose and
glucosamine treatment increased theexpressionofTGF-1protein inHONE1cells.
Silence ofGFPT1 reducedTGF-1mRNAand protein expression inHONE1 cells.
SilencingGFPT1reduced the clonogenic capacityofheadandneckcancer cells after
radiotherapy and enhanced the degree of radiation-induced DNA double-strand
breaks.Conclusions: TargetingGFPT1enhances head andneck cancer cell sensitiv-
ity to radiation. GFPT1 inhibition can enhance the radiation sensitivity of head and
neck cancer cells by inhibiting the expression of TGF-1.
#4759 TP53 control of the survivin-mediated radio-adaptive response in
human tumors. Jeffrey S.Murley,1 RichardC.Miller,1 RalphR.Weichselbaum,1
David J. Grdina2. 1Univ. of Chicago, Chicago, IL; 2Univ. of Chicago, Naperville,
IL.
Doses of ionizing radiation100mGy induce changes in radiation sensitivity
expressed by cells exposed to subsequent higher doses. This is referred to as an
adaptive effect. We describe a unique survivin-associated adaptive response in
which increased radiation resistance or sensitization of cells can be induced by
exposure to doses as low as 5 mGy and is controlled by p53 expression. Experi-
ments were performed using ten human cancer cell lines: HCT116 TP53 wild
type (WT) colorectal carcinoma and its isogenic TP53 null mutant (Mut); RKO
colorectal carcinoma TP53 WT and associated isogenic TP53 null Mut; breast
adenocarcinomas MCF7 (TP53WT) andMDA-MB-231 (TP53Mut); lung car-
cinomas A549 (TP53 WT) and NCI-H1975 (TP53 Mut); and pancreatic carci-
nomas Hs766T (TP53WT) and Panc-1 (TP53Mut). Doses of 5 mGy were used
to induce changes in the response of these tumor cells to higher therapy doses
using a multi-dosing paradigm. Effects on radiation sensitivity were associated
with changes in both survivin concentration and its translocation to the cyto-
plasm (TP53WT) and nucleus (TP53 null or point mutant). In vitro survival (2
Gy per fraction, two once daily fractions) studies were performed on all tumor
cell lines. Intracellular localization of survivin was determined by ELISA and
correlated to survival response. 2 Gy alone had no signifıcant effect on intracel-
lular translocation of survivin. When preceded 15 min earlier by a 5 mGy expo-
sure, survivin increased in the cytoplasm of all TP53 WT tumor cell lines as
compared to the nuclei of their counterpart isogenic TP53 null lines (HCT116
and RKO) or those carrying TP53 point mutations (MDA-MB-231, NCI-
H1975, Panc-1). All TP53 WT tumor lines were signifıcantly protected P 
0.001 by the addition of a 5 mGy dose while TP53 Mut lines, isogenic null or
point mutated, were sensitized P  0.001. HCT116 and RKO TP53 WT cells
were admixed and grownwith their respective isogenic TP53 null counterpart at
ratios of 1:3, 1:1, and 3:1. Under each of these growth conditions, the mixed
cultures expressed an enhanced sensitization (P  0.035) characteristic of that
expressed by cultures of 100% TP53 Mut tumor cells suggesting cell to cell
communication and/or a diffusible factor(s) affected by TP53 Mut cells is play-
ing an important role in the expression of this survivin-mediated radio-adaptive
response. We have identifıed a very low radiation dose-induced survivin-medi-
ated radio-adaptive response whose expression is linked to TP53 mutational
status that could affect therapeutic outcomes associated with the routine usage
of imaging procedures in conventional radiation therapy. This work was sup-
ported in part by NIH/NCI grant R01 CA132998 and DOE LowDose Program/
Project Grant DE-SC0001271 (D.J.G.)
#4760 Wnt/-catenin signaling mediates resistance of colorectal cancer
cell lines to chemoradiotherapy. Georg Emons,1 Melanie Spitzner,2 Sebastian
Reineke,2 Noam Auslander,1 Frank Kramer,2 Margret Rave-Fraenk,2 Jochen
Gaedcke,2 Michael Ghadimi,2 Thomas Ried,1 Marian Grade2. 1NIH, Bethesda,
MD; 2University Medical Center, Goettingen, Germany.
Background: Activation ofWnt/-catenin signaling plays a central role in the
development and progression of colorectal cancer (CRC). Previously, we dem-
onstrated that the Wnt transcription factor TCF7L2 was overexpressed in pri-
mary rectal cancers that were resistant to chemoradiotherapy (CRT), and that
TCF7L2 functionally mediates resistance of CRC to clinically relevant doses of
CRT. However, it remained unclear whether the resistance was mediated by a
TCF7L2 inherent mechanism or Wnt/-catenin signaling in general. Methods:
We silenced another key-component of canonicalWnt-signaling, CTNNB1 (-
catenin) in rectal cancer cell lines LS1034, SW480, and SW837 by RNAi. After-
wards cells were exposed to varying doses of irradiation (/- 5 FU) to assess the
influence of -catenin on radiation response. Activation of Wnt-signaling in
“normal” epithelial cells (retina pigment epithelial cells RPE) was achieved ei-
ther by stimulation with Wnt-3A, or stable overexpression of non-degradable
-catenin (S33Y-mutated) and confırmed by a dual luciferase reporter assay.
Changes in radio-(chemo-) sensitivity were analyzed again by a colony forma-
tion assay. SW1463 were repeatedly irradiated (68Gy) to establish an isogenic
radio-resistant cell line. Gene-expression profıles, without or 6h after a single
dose of 4Gy, of RPE cells expressing a control vector or overexpressing-catenin
and radioresistant or wildtype SW1463 cells were established using micro Ar-
rays. Results: Silencing of CTNNB1 resulted in (chemo-) radiation-sensitization
of all three CRC-cell lines. To further investigate the potential role of Wnt/-
catenin signaling in controlling therapeutic responsiveness, non-tumorigenic
RPE cells were stimulatedwithWnt-3A, which signifıcantly increased resistance
toCRT.This effect could be recapitulated by overexpression of-catenin (S33Y-
mut.), resulting in a signifıcantly increased resistance to CRT. The effect could
be rescued by siRNA mediated knockdown of -catenin. Consistent with these
fındings, we observed higher expression levels of active (unphosphorylated)
-catenin as well as increased TCF reporter activity in SW1463 cells that were
rendered radiation-resistant due to repeated IR treatment. Gene expression pro-
fıling of radioresistant and wildtype SW1463 as well as RPE cells overexpressing
-catenin or a control vector revealed signifıcant transcriptomal changes. Most
interestingly the resistant cells (radioresistant SW1463 and RPE overexpressing
-catenin) reacted with differential activation of metabolic, inflammatory, cell
survival and cell cycle pathways to irradiation. Conclusion: Together, these fınd-
ings strongly support the interpretation that Wnt/-catenin signaling plays a
central role in mediating resistance of CRC cells to CRT by deregulating essen-
tial pathways. Hence, pathway inhibition may represent a promising strategy to
increase therapeutic responsiveness to CRT.
#4761 BCL2 induced by LAMTOR3-MAPK is a druggable target of
chemoradioresistance in mesenchymal lung cancer.Ok-Seon Kwon, Soon-Ki
Hong, Hyuk-Jin Cha. Sogang University, Seoul, Republic of Korea.
Metastasis and chemoresistance, which aremain causes of lung cancer related
death, have been major interest in cancer research. Recently, Epithelial-Mesen-
chymalTransition (EMT) a foremost process for acquiringmetastatic properties
has been demonstrated to be strongly link to chemoresistance. Due to limited
understanding of mechanism for EMT mediated chemoresistance, druggable
targets for chemoresistance remained unidentifıed yet. In this study, we estab-
lished the mesenchymal like cancer cells (MLCCs) from A549 lung cancer cells
with chronic exposure of TGF. With clinicogenomics database analysis and
following validation with MLCC model, we determined that BCL2, of which
expressionwas clearly induced and indicated a poor prognosis in themesenchy-
mal cancer patients, was responsible for high chemoresistance in MLCCs.
Therefore combined treatment of chemotherapeutic drug and BH3 mimetic
such as ABT-263 or ABT-737, remarkably sensitized MLCCs to chemo and
radio therapy. Furthermore, BCL2 expression was governed by sustained ERK1
activity in MLCCs, which resulted from high level of MEK partner-1 (MP1)
protein expression. Therefore, combined chemotherapy with small molecules
(approved by FDA or clinically tested) targeting for MEK1 or BCL2 would be a
clinically feasible approach to overcome EMT related chemoresistance.
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#4762 New device for radiation delivery in breast cancer patients - double
balloon applicator for optimal dose distribution. Manny R. Subramanian,
Mike Cutrer, Rohit Mehta. BEST Medical International, Springfıeld, VA.
Currently available applicators for delivery of accelerated partial breast irra-
diation using a high dose afterloader, have treatment catheters close to the center
of the balloon in fıxed positions, restricting one’s ability to modify the dose to
critical organs. Recently we developed a novel, dual balloon brachytherapy ap-
plicator using which one could optimize radiation dose by shaping the resection
cavitywith an outer balloon and allowing an inner balloon to selectively position
the treatment catheters away from the central axis of the balloon based on cavity
size. TheDouble BalloonBreast Brachytherapy applicator offers a unique design
with adjustable treatment catheters, allowing for both optimized dose delivery
and conformal avoidance of critical structures. This applicator is a single entry (1
cm incision), multi-channel high dose rate afterloader (HDR) accessory device.
The treatment catheters can be expanded to an optimal location greater than or
equal to 50% of the outer balloon diameter( 1 cm diameter) - thereby optimiz-
ing dose delivery to the patient. The Conformal Double Balloon Breast Brachy-
therapy Device has the ability to optimize either conformality or homogeneity
by allowing expansion of an inner polyurethane balloon to selectively position
multiple treatment catheters signifıcantly away from the central axis of an ex-
panded outer polyurethane balloon. Amodel study of theDouble BalloonBreast
Brachytherapy Device was performed with a wide range of volumes of the
lumpectomy cavity. Each case is scanned in a CT scanner and the data trans-
ported to a treatment planning system. Dosimetric parameters such as dose
delivered to treatment site, different organs such as skin, ribs, etc are evaluated
and compared against existing breast brachytherapy applicator devices. Both
ultrasound andCT images clearly indicate that the quality of theDouble Balloon
Device images are comparable to other commercial devices. All catheters are
distinguishable and can be reconstructed for treatment planning, and the bal-
loon volume can be clearly delineated. Planning Treatment Volume (PTV)
based on balloon volume can be easily generated and optimized dosimetry per-
formed. Initial patient studies also indicate that using the double balloon appli-
cator optimized dosimetry can be obtained thereby reducing the dose to critical
structures such as skin and rib while maintaining the dose to the target.
TUMOR BIOLOGY: Cancer Stem Cells
#4763 Metronomic chemotherapy prevents therapy-induced stromal ac-
tivation and induction of cancer stem cells. Kelvin K. Tsai,1 Tze-Sian Chan,1
Chung-Chi Hsu,1 Vincent C. Pai,1 Shenq-Shyang Huang,1 Valerie M. Weaver2.
1Taipei Medical University, Taipei City, Taiwan; 2University of California, San
Francisco, San Francisco, CA.
Whilst traditional chemotherapy kills a fraction of tumor cells, it also activates
the stroma and can promote the growth and survival of residual cancer cells to
foster tumor recurrence and metastasis. Accordingly, overcoming the host re-
sponse induced by chemotherapy could substantially improve therapeutic out-
come and patient survival. Treatment resistance and metastasis have been at-
tributed to expansion of cancer stem-like cells (CSCs). Molecular analysis of the
tumor stroma in neoadjuvant chemotherapy-treated human desmoplastic can-
cers and orthotopic tumor xenografts revealed that traditional maximal toler-
ated dose chemotherapy, regardless of the agents used, induces persistent
STAT-1 andNF-B activity in carcinoma-associated fıbroblasts that induces the
expression and secretion of ELR-motif-positive (ELR) chemokines, which sig-
nal through CXCR-2 on carcinoma cells to trigger their phenotypic conversion
into CSCs and promote their invasive behaviors, leading to paradoxical tumor
aggression following the therapy. By contrast, the same total accumulated dose
administered as a low-dose-metronomic chemotherapy regimen largely pre-
vented the therapy-induced stromal ELR-chemokine paracrine signaling for
CSCs, thereby substantially enhancing treatment response and extending sur-
vival of mice carrying desmoplastic cancers (Chan et al, J. Exp. Med. 2016).
These studies illustrate the importance of stroma in cancer therapy and how its
impact on treatment resistance could be tempered by altering the dosing sched-
ule of systemic chemotherapy.
#4764 Activation of estrogen receptor beta signaling reduces stemness
and promotes differentiation of glioma stem cells. Gangadhara Reddy Sare-
ddy, Jinyou Liu, Suryavathi Viswanadhapalli, Rajeshwar R. Tekmal, Andrew
Brenner, Ratna K. Vadlamudi. UT Health Science Center at San Antonio, San
Antonio, TX.
Glioblastoma (GBM) are the most common and deadliest tumors of the cen-
tral nervous system. GBM have poor prognosis due to tumor recurrence and
resistance to current therapies. Glioma Stem Cells (GSCs) are implicated in the
tumor initiation and therapy resistance of GBM. Agents that can specifıcally
reduce stemness of GSCs are urgently needed for the effective treatment of
GBM.Estrogen play a crucial role during brain development, differentiation and
in neuroprotection. However, its role in promoting differentiation of GSCs re-
main unknown. Estrogen effects are mediated by two estrogen receptors (ESR1
and ESR2) and ESR2 functions as a tissue-specifıc tumor suppressor. Our recent
studies discovered that GSCs preferably express ESR2 with low or undetectable
levels of ESR1. The objective of this study is to test whether ESR2 agonists
modulate stemness of GSCs and to determine their mechanism(s) of action.We
have tested the hypothesis using GSCs isolated from established and patient
derivedGBMcells using stem cellmarkers CD133 andCD15. Knockout of ESR2
using CRISPR/Cas9 system increased the CD133 positive GSCs and overexpres-
sion of ESR2 reduces theCD133-positive population inGBMcells. Treatment of
GSCs with ESR2 agonists (Liquiritigenin and LY500307) signifıcantly inhibited
the neurosphere formation, self-renewal ability and proliferation. Further ESR2
agonist treatment resulted in the loss of stemness and induction of differentia-
tion and apoptosis of GSCs. Western blot analysis and RT-qPCR analysis re-
vealed reduced expression of stemness markers such as Nestin and Sox-2 and
increased expression of differentiation markers GFAP and tuj-1 in GSCs. RNA
sequencing analysis of ESR2 agonist treated and untreated GSCs revealed mod-
ulation of pathways related to apoptosis, cell cycle, stemness and differentiation.
Further, ESR2 agonists treatment signifıcantly reduced the GSCs mediated tu-
mor growth in orthotopic models and improved the mice overall survival. Im-
munohistochemical studies demonstrated that ESR2 agonists reduces the ex-
pression of proliferation of marker Ki67 and induced the apoptosis in tumors.
Together, our results established ESR2 agonists liquiritigenin and LY500307 as
novel therapeutic agents for elimination of GSCs. Since ESR2 agonists has good
blood-brain barrier permeability and less neuronal toxicity, they can be readily
transferred to clinical use with current radiation and chemotherapies, thereby
providing an additional tool for enhancing survival in GBM patients.
#4765 Targeting glioblastoma cancer stem cells with a novel Connexin43
mimetic peptide. Samy Lamouille,1 JamesW. Smyth,1 Laurie O’Rourke,1 Pratik
Kanabur,2 Sujuan Guo,1 Jane Jourdan,1 Zhi Sheng,1 Robert G. Gourdie1. 1Vir-
ginia Tech Carilion Research Institute, Roanoke, VA; 2Virginia Tech Carilion
School of Medicine, Roanoke, VA.
Glioblastoma (GBM) is a highly malignant and lethal cancer of the central
nervous system. Despite intensive research efforts, there has been limited prog-
ress in improving patient outcome. The current therapy for GBM patients in-
cludes surgical resection, radiotherapy and cytotoxic chemotherapy with temo-
zolomide (TMZ), conferring amedian survival time of only 14.6months. Failure
to generate more effective treatment strategies is due in part to the cellular
heterogeneity within GBM tumors, which comprise a sub-population of GBM
cancer stem cells (GSCs) characterized by self-renewal characteristics and resis-
tance to TMZ. Recent work, including our own, has demonstrated that levels of
the gap junction protein Connexin43 (Cx43) correlate with GBM TMZ resis-
tance. IncreasedCx43 levels occur inGSCs compared to parentalGBMcells, and
patients with high levels of Cx43 mRNA and low levels of MGMT, an enzyme
that repairs TMZ-inducedDNA lesions, have a signifıcantly shorter life span. In
contrast, Cx43 has also been associated with anti-proliferative effects in glioma
and reduced levels of Cx43 protein are reported in high-grade gliomas. In addi-
tion to forming gap junctions, Cx43 can regulate cell proliferation, migration,
and apoptosis, through distinct channel-independent mechanisms. Therefore,
altering the localization and/or activity of Cx43 rather than Cx43 expression
alone may represent a more targeted strategy in GBM treatment. Using super-
resolution microscopy, we fınd intracellular Cx43 decorating microtubules in
GSCs demonstrating for the fırst time such clustering in situ. Regulation of Cx43
function is primarily associated with multiple sites for post-translational modi-
fıcation andprotein-protein interactionwithin theCx43 carboxy-terminus (CT)
which includes a tubulin binding domain. We have developed a peptide named
JM2 (juxtamembrane 2) composed of the Cx43 CT amino acids encompassing
the microtubule-binding sequence fused to an antennapedia cell penetration
domain for cellular uptake. Super-resolutionmicroscopy and biochemical anal-
ysis confırm JM2 specifıc interaction with microtubules concomitantly with a
loss of Cx43 interaction with microtubules in GSCs derived from patient tu-
mors. In addition, we observe that JM2 decreases Cx43 gap junction plaque
formation and cell-cell communication inGSCs and limitsmicrotubule dynam-
ics. Importantly, JM2 decreases cell survival in TMZ-resistant GSCs and GSC
neurosphere formation in vitro, and GSC-derived tumor growth in vivo. Our
current research includes the development of JM2-loaded biodegradable nano-
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particles for sustained JM2 delivery in preparation for future clinical trials. In
conclusion, we have developed a Cx43 mimetic peptide that signifıcantly de-
creases the tumorigenic potential of GSCs and represents a novel and potent
therapeutic opportunity to alter Cx43 activity in targeting chemoresistant GSCs
for GBM treatment.
#4766 Translation from unconventional 5’ start sites drives tumor initia-
tion. Ataman Sendoel. Rockefeller University, New York, NY.
How translational control impacts tumor-initiation and malignancy is just
beginning to unfold. Here, we devise an epidermis-specifıc, in vivo ribosome
profıling strategy to interrogate the translational landscape during the transition
from normal homeostasis to malignancy. Inducing SOX2, broadly expressed in
oncogenic RAS-associated cancers, we fınd that despite widespread reductions
in translation and protein synthesis, certain oncogenicmRNAs are spared. Seek-
ing mechanism, we fınd that during tumor-initiation, the translational appara-
tus is redirected towards unconventional upstream initiation sites, enhancing
translational effıciency of oncogenic mRNAs. An in vivo RNAi screen of trans-
lational regulators revealed that dampening conventional EIF2 complexes has
dire consequences for normal but not oncogenic growth. Conversely, we iden-
tify alternative initiation factors essential for cancer progression, where they
mediate initiation at these upstream sites, differentially skewing translation and
protein expression. Our fındings unveil a hitherto unappreciated role of 5’UTR
translation in cancer, and expose new targets for therapeutic intervention.
#4767 Identifying CDCA7 as a novel regulator of tumor-initiating cells in
triple-negative breast cancer. Chang-Ching Lin,1 Miao-Chia Lo,1 Rebecca
Moody,1 Nicholas Stevers,1 Samantha Tinsley,1 MaxWicha,2 Duxin Sun1. 1Col-
lege of Pharmacy, University of Michigan, Ann Arbor, MI; 2Comprehensive Can-
cer Center, University of Michigan, Ann Arbor, MI.
Tumor-initiating cells (TICs) are a small fraction of cancer cells that stands at
the apex of the tumor hierarchy. Given their tumor-initiating ability and resis-
tance to conventional chemotherapies, TICs are considered potential therapeu-
tic targets for preventing the relapse and metastasis of malignancies. Our group
has identifıed a novel gene, Cell division cycle associated 7 (CDCA7), as an
important regulator of TICs in triple-negative breast cancer (TNBC). CDCA7 is
a target gene of MYC and NOTCH. Ectopic expression of CDCA7 has been
demonstrated to induce neoplastic transformation in vitro and tumorigenesis in
vivo. Despite its potential tumor-initiating ability, CDCA7 has not yet been
well-studied in breast cancer. We found that CDCA7 was highly expressed in
TNBC compared to other subtypes of breast cancer according to the RNA-
sequencing data from The Cancer Genome Atlas. Furthermore, our Kaplan-
Meier analysis of multiple datasets demonstrated that higher expression of
CDCA7was associated with poor prognosis in breast cancer.Whenwe knocked
down CDCA7 by siRNA in TNBC cell lines including SUM149, HCC1937,
MDA-MB-231, and MDA-MB-436, CD44/CD24- stem-like cell population
and primary and secondary mammosphere formation were signifıcantly de-
creased. In addition to suppressing the stem-like properties, knockdown of
CDCA7 also inhibited the invasion and migration of breast cancer cells. These
phenotypes indicated the inhibition of epithelial-to-mesenchymal transition
(EMT), which was in accordance with the up-regulation of E-Cadherin and
down-regulation of Vimentin after CDCA7 knockdown in TNBC cell lines. In
conclusion, our results have demonstrated that CDCA7 is an important regula-
tor of TICs in TNBC. Loss-of-function of CDCA7 leads to the inhibition of EMT
and stemness in TNBC cells.
#4768 ASHARP /Xist complex regulates breast cancer stemcells.Yongyou
Zhu, Li Shang, Justin Colacino, Michael Brooks, Ramdane Harouaka, Chang-
Ching Lin, Ming Luo, Max S. Wicha. Univ. of Michigan, Ann Arbor, MI.
Many cancers including breast cancer display hieratical organization and are
driven by a cellular sub-population that displays stem cell properties. These
cancer stem cells (CSC’s) mediate metastasis and contribute to treatment resis-
tance highlighting the importance of elucidating CSC regulatory pathways. Nu-
clear proteins and lncRNAs involved in themaintenance of chromatin structure
have been shown to play roles in CSC regulation. Among them the polycomb
proteins bmi-1 and EZH2 are involved in epigenetic regulation of CSC’s in
breast and other cancers. SHARP/SPEN, an RNA binding protein, has been
previously been found to bind the lncRNA Xist which, by recruiting the PRC2
polycomb complex mediates transcriptional repression of the X chromosome.
We utilized breast cancer cell lines and xenograft models to examine the role of
the SHARP/Xist complex in the regulation of breast CSC’s. In a series of breast
cancer cell lines including MCF7 (luminal )and SUM 159 (basal/claudin low)
cells, SHARP mRNA and protein as well as the lncRNA Xist were more highly
expressed in cells expressing aldehyde dehydrogenase as accessed by the Alde-
fluor assay than in ALDH -cells . Conditional knockdown of SHARP or Xist in
SUM159 signifıcantly decreased the ALDHCSC population without affecting
cell growth in vitro. Furthermore, SHARP or Xist knockdown signifıcantly re-
duced tumor initiating capacity and growth of SUM 159 cells in NOD/SCID
mice. To determine the mechanism of breast CSC regulation by the SHARP
complex we compared mRNA expression patterns of control and SHARP
knockdown SUM 159 cells using RNAseq. There was signifıcant overlap be-
tween the genes regulated by SHARP with genes regulated by the PCR1 and
PRC2 polycomb complexes in addition to many histone genes. These studies
suggest that the SHARP/Xist complex my regulate breast CSC’s through epige-
netic regulatory histone and polycomb genes. Since SHARP expression is ele-
vated in a number of cancers including breast cancer this pathwaymay represent
a novel therapeutic target.
#4769 Targeting HER2 enriches Jagged1 high cancer stem cells in breast
cancer. Deep S. Shah,1 Debra Wyatt,1 Andrew Baker,1 Andrew Green,2 Alek-
sandra Filipovic,3 LucioMiele,4 ClodiaOsipo1. 1LoyolaUniv. Cardinal Bernadin
Cancer Ctr.,Maywood, IL; 2University of Nottingham,Nottingham,UnitedKing-
dom; 3Imperial College of London, London, United Kingdom; 4Louisiana State
University, New Orleans, LA.
The human epidermal growth factor receptor 2 (HER2) positive subtype of
breast cancer is characterized by gene amplifıcation and/or protein overexpres-
sion of HER2. It is driven by a subpopulation of cells possessing stem cell prop-
erties of self-renewal and differentiation, known as Cancer Stem cells (CSCs).
CSCs are implicated in tumor growth as well as radiotherapy and chemotherapy
associated resistance. Notch receptors promote breast CSCs survival and self-
renewal, and overexpression of a Notch ligand Jagged1 mRNA predicts poor
prognosis in women with breast cancer. Our lab has published that Jagged1 or
Notch1 is a critical target in trastuzumab/lapatinib (LAP) resistant HER2
breast cancer. The study aimed to determine whether anti-HER2 therapy selects
for Jagged-1/Notch-dependent CSCs that are responsible for tumor initiation.
Surface expression of Notch1 and Jagged1 upon HER2 blockade using LAP was
measured in HER2 breast cancer cell lines (MDA-MB-453 and HCC1954)
using flow cytometry. LAP treatment increased the Jagged1-positive subpopu-
lation compared to vehicle. Cells were sorted based on Jagged1 cell surface ex-
pression and assessed for CSC-like properties (i.e. mammosphere forming effı-
ciency, Aldefluor activity, expression of CD44high /CD24low, Notch target
transcripts expression, and limiting dilution tumor initiating potential in athy-
mic, nude mice). In addition, immunohistochemistry was performed on 145
HER2 breast tumor microarray to detect cytoplasmic, membrane, or nuclear
Jagged1 protein expression. Kaplan-Meier analysis was performed to determine
overall survival. The results showed that upon HER2 inhibition, Jagged1 cell
surface expression increased andNotch1 cell surface expressionwas unchanged.
The Jagged1high subpopulation of cells showed elevated levels of Aldehyde de-
hydrogenase activity, Notch target gene transcripts, and mammosphere forma-
tion effıciency compared to vehicle treated cells. The MRK-003 -secretase in-
hibitor (GSI) prevented mammosphere formation in the Jagged1high cells
indicating that Notch activation drives Jagged1high CSC survival. Also, we con-
fırmed that Jagged1 expression is required for the enrichment of CSCs using a
Jagged1 siRNA. Combined knockdown of Notch1 and Notch3 receptors was
necessary to reduce LAP-enriched mammospheres suggesting that targeting
HER2 enriches for a Jagged1-Notch1Notch3 driven CSC phenotype. Impor-
tantly, higher membrane expression of Jagged1 protein in 145 HER2 breast
tumor specimens correlatedwith signifıcantly lower overall cumulative survival.
These results reveal that HER2 blockade in breast cancer cells enriches for a
Jagged1high subpopulation that has higher CSC potential and is resistant to
HER2 inhibitors. The implications of this work are that dual blockade of Jagged-
1/Notch1/Notch3 and HER2 could be more effective than either therapy alone
to eliminate both HER2 and Jagged-1-dependent cancer cells.
#4770 Novel CXCR3 allostericmodulators inhibit breast cancer stem cells
and metastasis. Namita Kundu,1 Regine Brox,2 Xinrong Ma,1 Jocelyn Reader,1
Nuska Tschammer,3 Amy M. Fulton1. 1Univ. of Maryland Greenebaum Cancer
Ctr., Baltimore, MD; 2Friedrich Alexander University, Erlangen, Germany;
3NanoTemper Technologies, Munich, Germany.
There is an urgent need to identify molecular targets that are relevant to
metastatic and/or stem-like cancer cells (CSC). Theoretically, surface-expressed
G-protein coupled receptors on CSC are attractive therapeutic targets. There is
considerable evidence that the inflammatorymilieu of the tumormicroenviron-
ment drives CSC andwe now show that two isoforms of the chemokine receptor
CXCR3 play important but distinct roles in cancer behavior. In the bulk tumor
cell population, CXCR3, isoform A is highly expressed relative to CXCR3B.
CXCR3A is critical to metastatic success. CXCR3, isoform B, is highly upregu-
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lated in breast cancer CSC.When CXCR3B is gene-silenced in amodel of basal-
type,metastatic breast cancer, tumorsphere-forming capacity is reduced and the
aldehyde dehydrogenase-positive (ALDH1) population is correspondingly
decreased. Conversely, overexpression of CXCR3B enhances these CSC proper-
ties. Thus, CXCR3B is critical to maintenance of the phenotype and function of
breast CSC. CXCR3 ligands CXCL9, CXCL10 and CXCL11 all bind with high
affınity to CXCR3, however, each ligand is coupled to different intracellular
signaling pathways. For example, others have reported that, in HEK cells,
CXCL10 strongly induces ERK activation, but CXCL11 does not. In our hands,
CXCL11more potently induces anALDH1 population inMDA-MB-231 cells
compared to CXCL10. We have developed novel allosteric modulators of
CXCR3 that demonstrate probe (ligand)-dependence. BD64 preferentially in-
hibits CXCL11-mediated -arrestin 2 recruitment relative to inhibition of
GPCR signaling; BD103 is signifıcantly more effective at blocking CXCL11 ver-
sus CXCL10-mediated GPCR signaling. Neither BD64 nor BD103 affects the
proliferation of non-CSC, however both compounds inhibit the ability ofCSC to
form tumorspheres. Furthermore, both CXCR3 antagonists reverse ligand-me-
diated induction of the ALDH1 fraction. Most interesting is that both BD64
and BD103 effectively inhibit tumor cell colonization of the lung. These data
suggest that optimal tumor control will be achieved when both metastatic,
CXCR3Ahigh as well as CXCR3Bhigh CSC populations are inhibited by highly
specifıc CXCR3 modulators.
#4771 The role ofHes1 in thenormal and tumor stemcells of the intestine.
Norihiro Goto, Akihisa Fukuda, Tsutomu Chiba, Hiroshi Seno. Kyoto Univer-
sity Graduate School of Medicine, Kyoto, Japan.
Notch-Hes pathway plays a crucial role in the differentiation, proliferation,
and tumorigenesis of the intestine. We previously reported that prenatal dele-
tion of Hes1 reduces intestinal tumor proliferation; however, postnatal deletion
of Hes1, which recapitulates Hes1-targeted tumor therapy, has not been thor-
oughly investigated. Here, we elucidated the novel role of Hes1 in normal stem
cells (NSCs) and tumor stem cells (TSCs) of the adult intestine. First, we deleted
Hes1 in Lgr5-expressing or Bmi1-expressing NSCs and performed lineage trac-
ing using Lgr5CreERT2/; Hes1flox/flox; Rosa26LacZ/ and Bmi1CreER/; Hes1flox/
flox; Rosa26LacZ/mice. After Hes1 deletion, Lgr5-expressing or Bmi1-express-
ing NSCs gave rise to progeny cells, but could not self-renew. However, Hes1
deletion in NSCs did not disrupt intestinal homeostasis, because Hes1-positive
NSCs were newly generated soon after Hes1-deleted NSCs were depleted. Next,
we stabilized beta-catenin for intestinal tumor formation and deleted Hes1 in
Lgr5-expressing cells using Lgr5CreERT2/; Ctnnb1lox(ex3)/; Hes1flox/flox mice.
Tumor formation was dramatically suppressed, and the animal survival was
signifıcantly improved, suggesting that Hes1 is required for the initiation of
intestinal tumor formation. Finally, we deletedHes1 in Lgr5-expressing TSCs of
established intestinal tumors using Lgr5CreERT2/; Hes1flox/flox; ApcMin/ mice.
Of note, Hes1 deletion in TSCs of established intestinal tumors induced imme-
diate apoptosis of TSCs and signifıcantly reduced the number of tumors. qRT-
PCRanalysis of sorted Lgr5-expressing cells one day afterHes1 deletion revealed
upregulation of pro-apoptotic genes and downregulation of anti-apoptotic
genes in Hes1-deleted TSCs, but not in Hes1-deleted NSCs. We also deleted
Hes1 in Dclk1-expressing TSCs of established intestinal tumors, and confırmed
that, irrespective of stem cell markers analyzed, Hes1 deletion in TSCs leads to
tumor regression by inducing immediate apoptosis in TSCs. Taken together,
Hes1 is required in different ways for the maintenance of NSCs and TSCs: Hes1
deletion in NSCs does not perturb homeostasis, whereas Hes1 deletion in TSCs
leads to tumor regression. Furthermore, Hes1 is necessary for the initiation of
intestinal tumor formation. Therefore, we propose Hes1 is a novel tumor-spe-
cifıc therapeutic target.
#4772 Stearoyl-CoA Desaturase (SCD1) regulates liver tumor initiating
cells throughmodulating ER stress.Kin FaiMa,1 Eunice YuenTing Lau,2 Irene
Oi Lin Ng,1 Kin Wah Lee2. 1University of Hong Kong, Hong Kong; 2The Hong
Kong Polytechnic University, Hong Kong.
Sorafenib is the FDAapproveddrug for patientswith advancedhepatocellular
carcinoma (HCC), but the survival benefıt is only modest, partly due to drug
resistance. Increasing evidence shows that tumor-initiating cells (T-ICs) are
intrinsically resistant to conventional treatments, and targeting signaling path-
ways in T-ICs provides potential therapeutic targets for HCC. In our established
enriched T-IC population, we identifıed the activation of a lipogenesis pathway
in which expression of stearoyl-CoA desaturase-1 (SCD1), an enzyme involved
in the conversion of saturated into monounsaturated fatty acids, was most sig-
nifıcant. SCD1 overexpression is frequently found in HCC samples and is sig-
nifıcantly associated with poorer patient survival. Using overexpression and
knockdown approaches, SCD1 was found to regulate the traits of T-ICs, includ-
ing tumorigenicity, self-renewal, differentiation, drug resistance and the expres-
sion of liver T-ICmarkers. Interestingly, SCD1wasmarkedly upregulated in our
established sorafenib-resistant cell lines as well as patient-derived xenografts
(PDTXs), and its overexpression predicts the clinical response of HCC patients
to sorafenib treatment. Consistently, pharmacological inhibition of SCD1 sup-
pressedT-ICphenotypes and enhanced sensitivity to sorafenib treatment.Using
a patient-derived xenograftmodel, we found that a novel SCD1 inhibitor (SSI-4)
in combination with sorafenib demonstrated a maximal tumor suppressive ef-
fect. Induction of endoplasmic reticulum (ER) stress-mediated T-IC differenti-
ation can account for the enhanced sensitivity towards sorafenib treatment upon
SCD1 suppression. In conclusion, SCD1-induced ER stress may specifıcally in-
crease the sensitivity of liver T-ICs to the effects of sorafenib treatment. Target-
ing SCD1 in combination with sorafenib therapy may be a novel therapeutic
regimen against HCC.
#4773 Dysregulated expression of pentraxin-3 in glioblastoma (GBM)
stemcells: Implications forGBMinvasion andprogression.UmadeviV.Wes-
ley, Paul Clark, John S. Kuo, Robert J. Dempsey. University of Wisconsin, Mad-
ison, Madison, WI.
Glioblastoma multiforme (GBM) is highly invasive and resistant to current
therapies. The aggressiveness of brain tumor is attributed to GBM stem cells
(GSC) that release inflammatory cytokines, and exacerbate inflammation in tu-
mormicroenvironment, critically affecting GBM survival and invasiveness. The
glycoprotein pentraxin-3 (PTX3), a modulator of tumor-associated inflamma-
tion, is known to be correlated with tumor grade and severity of malignancies of
some cancers. However, little is known about the role of PTX3 in GBM growth
and invasion. In this study, we examined the role of PTX3 in GSCs exhibiting
various degree of invasiveness. Frompatient brain tumors, our teamhas isolated
the small subsets of glioblastoma stem cells (GSCs) and are validated for their
self-renewal and multi-lineage potential. Our studies have shown that these
GSCs effıciently form orthotopic brain tumors in immune-defıcient mice. Our
results show that conditioned media from GSCs promote pro-angiogenic tube
formation from endothelial cells. GSCs that are grown in the absence of growth
factors EGF and bFGF, formed effıcient xenografts in immune-defıcient mice
and showed increased dispersal in the mice brain. Interestingly, polymerase
chain reaction (RT-PCR) and immunofluorescence staining showed upregu-
lated expression of PTX3 in these GSCs, and correlated with the degree of inva-
siveness. Differentiation of GSC into astrocytes in vitro, lead to decreased ex-
pression of PTX3. In support of this, recent histochemical study has shown that
PTX3 levels correlate with GBM grade and is a candidate biomarker for cancer
progression. Thus, PTX3 may represent a new target and marker of inflamma-
tion for glioma malignancy.
#4774 Polyamines are rich and induces epigenetic change by inhibition of
LSD1 in cancer stem-like cells. Keisuke Tamari, Hideshi Ishii, Masamitsu
Konno, Naohiro Nishida, Jun Koseki, Koichi Kawamoto, Fumiaki Isohashi,
Yuichiro Doki, Masaki Mori, Kazuhiko Ogawa.Osaka University, Suita, Osaka,
Japan.
Cancer stem cells (CSC) are highly tumorigenic and resistant to chemother-
apy and radiotherapy. We have previously reported that a small fraction of
cancer cells with low proteasome activity had CSC-like properties. Ornithine
decarboxylase (ODC) is an enzyme which converts ornithine to polyamines
including putrescine, spermidine, and spermine. Proteasomal degradation of
ODC is known to be ubiquitin-independent. The aimof this studywas to explain
how low proteasome activity gave CSC-like properties. Western blot showed
high ODC protein level in CSC-like cells in cervical cancer and osteosarcoma
cell lines, although ODC mRNA level is not high. These fındings suggest that
ODC protein level is high in CSC-like cells because ODC protein degradation is
inactive. To investigate polyamine metabolism in CSC-like cells, we performed
GC-MS analysis and found that putrescine, spermidine, and spermine were
enriched in CSC-like cells. Furthermore, flux analysis showed conversion from
ornithine to polyamines was more rapid in CSC-like cells. We performed a
computational structure analysis and found that polyamines bind and inhibit
demethylase site of LSD1 which is known to be a demethylase of histone H3K4
and a nuclear homolog of amine oxidases. Spermine was the strongest binding
energy. An enzyme assay showed that LSD1 activity was dose-dependently in-
hibited by polyamines and spermine was the strong inhibitor. Finally, we ana-
lyzed performed ChIP sequencing analysis by using HeLa CSC-like cells and
found that more global enrichment of H3K4me3 and less global enrichment of
H3K4me1 than non-CSC-like cells. In conclusion, polyamines are rich in CSC,
and be able to inhibit LSD1 activty and induce epigenetic alterations especially in
H3K4 methylation in CSC.
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#4775 PTHrP regulate CSC and promote EMT in the PyMT model of
breast cancer progression.Rui Zhang,1 Jiarong Li,1 AndrewC. Karaplis,2 Rich-
ard Kremer1. 1Research Institute McGill University Health Center, Montreal,
Quebec, Canada; 2Lady Davis Institute for Medical Research, Montreal, Quebec,
Canada.
PTH-related peptide (PTHrP) was fırst discovered in cancer patients as the
primary cause of humoral hypercalcemia of malignancy (HHM).We previously
showed that PTHrP ablation in theMMTV-PyMTmurine model of breast can-
cer progression can dramatically prolongs tumor latency, slows tumor growth&
metastases suggesting that PTHrP may regulate cancer stem cells (CSCs). CSCs
& epithelial-mesenchymal transition (EMT) have been recognized as driving
forces in tumor initiation & progression, & have been characterized previously
using ALDH & CD49/EpCAM markers. Here, we aim to determine the role of
PTHrP in CSCs & EMT regulation. For this purpose, we analyzed tumor cells
derived from Pthrpflox/flox;Cre- (Control) & Pthrpflox/flox;Cre (KO) tumors. Cells
were incubated with ALDH reagent followed by CD49f/EpCAMantibody label-
ling & subjected to FACS analysis. Using CD49f/EpCAM labelling, cells sepa-
rated into twodistinct populations, luminal progenitor cells (CD49fEpCAM)
& EMT cells (CD49fEpCAM-). In control tumors,85% of cells were charac-
terized as luminal progenitor and 15% as EMT. In contrast, in KO tumors,
97% of cells were characterized as luminal progenitor whereas only2%were
EMT.Using ALDH staining alone,8%&10% of the cells from the control &
KO tumorwereALDH, respectively. Furthermore, themajority of theALDH
cells were predominately containedwithin the luminal progenitor population in
both the control & KO tumors cells. Next, we confırmed the dividing capacity of
the two cell populations using a lipophilic fluorescent dye, PKH26. As expected,
luminal progenitor cells exhibited a fast-dividing phenotype, whereas EMT cells
displayed a slow dividing phenotype. However, using mammosphere assay, we
did not see any signifıcant difference in mammosphere forming effıciency be-
tween control & KO tumor. In summary, PTHrP ablation signifıcantly dimin-
ishes the EMT population in KO compared to the control tumor. In conclusion,
PTHrP may shift the tumor cell phenotype towards EMT, which suggests a
mechanism underlying PTHrP - driven metastases.
#4776 Circulating clusters in breast cancer express cancer stem cell phe-
notypes. Ramdane Harouaka,1 Gabrielle Hodges,1 Allison David,2 Rishika Po-
lasani,1 Spencer Freeman,3 Katherine Sanchez,1 KaitlinHarvey,1Max S.Wicha1.
1University of Michigan, Ann Arbor, MI; 2Thomas Jefferson University, Philadel-
phia, PA; 3Kalamazoo College, Kalamazoo, MI.
Breast cancer is a leading cause of death inwomen and itsmetastatic spread to
distant organs is responsible for over 90% of these deaths. Circulating tumor
cells (CTCs) implicated in the metastatic process occur when cancer cells un-
dergo cytoskeletal and phenotypic transitions that enhance motility, then pen-
etrate into the blood circulation. While CTC dissemination has typically been
considered as the spread of single cells, recent evidence suggests that collective
migration results in polyclonal circulating clusters that are the main drivers of
metastasis. To study circulating clusters we have developed a dual microfıltra-
tion system employing two stages of antigen-independent mechanical cell iso-
lation. As whole blood is passed through the system, circulating clusters are
trapped by the fırst stage while single CTCs are retained by the second stage.
Characterization experiments using cell lines demonstrated a capture effıciency
of 87.1% for clusters and 85.7% for single cells on their respective microfılters.
This system was used to investigate circulating cells in the metastatic MMTV-
PyMT syngeneic mouse breast cancer model. Both clusters and single CTCs
were detected inmicewith histological evidence of lungmetastases (14-16weeks
old), but not in mice that had not yet developed metastatic tumors (12 weeks
old). Immunofluorescence assays were established to determine expression of
CD24, CD90, cytokeratins, CD45 and DAPI. Tumor cells were identifıed as
nucleated cells that expressed epithelial cytokeratins, but not the leukocyte an-
tigen CD45. While PyMT cells with a CD90/CD24 stem cell phenotype
comprise only 1.5% of tumors, they were observed in  50% of circulating
clusters. The presence of cancer stem cells was correlated to cluster size, with
smaller clusters containing a greater percentage of CD90/CD24 cells. Iso-
lated clusterswill be further analyzed to quantify expression levels of cancer stem
cell markers in each individual constituent cell. The analysis of circulating clus-
ters may provide crucial insight into the mechanisms of metastatic disease and
provide the means to discover novel targets for therapeutic intervention.
#4777 Cancer stemness and resistance: Napabucasin (BBI-608) sensitizes
stemness-high cancer cells to Paclitaxel by inhibiting the STAT3-MUC1
pathway. Harry A. Rogoff, Juying Li, Chiang Li. Boston Biomedical, Inc., Cam-
bridge, MA.
Stemness-high cancer cells, or cancer stem cells (CSC) represent a subpopu-
lation of cancer cells with enhanced tumorigenic capacity, metastasis-forming
potential, and resistance to conventional chemotherapy and radiation.One such
key CSC pathway is regulated by STAT3, a transcription factor that is down-
stream of several cytokines and growth factor receptors which controls the ex-
pression of a broad range of target genes and plays essential roles in CSC biology
in many tumor types. Cancer stemness inhibitor Napabucasin (BBI-608), a
small molecule that inhibits gene transcription driven by STAT3, can inhibit
stemness gene expression, block spherogenesis, and kill CSCs. In vivo, BBI-608
effectively blocks cancer relapse and metastasis in xenograft models while spar-
ing normal hematopoietic stem cells, suggesting that targeting stemness-high
cancer cells is a feasible approach for developing next-generation cancer thera-
peutics to combat cancer recurrence. SOX2 (sex-determining region Y-box pro-
tein 2), a transcription factor that is essential for self-renewal and pluripotency,
is amplifıed in various cancer types and has been shown to be required for CSC
self-renewal and maintenance. Mucin 1 (MUC1), a glycoprotein normally ex-
pressed at the apical surface of epithelial cells, is overexpressed in most human
epithelial cancers.MUC1 has been implicated in regulating tumor proliferation,
metabolism, invasion, angiogenesis, chemoresistance, and inflammation. Here,
we generated a stemness-high culture system based on the reporter activity of a
SOX2-regulatory region construct in MKN28 gastric cancer cells (MKN28
SOX2-reporter GFP cells). BBI-608 treatment inhibited the STAT3-MUC1
pathway in stemness-high cells. High MUC1 status in stemness-high cells was
associated with Paclitaxel resistance. Down-regulation of MUC1 sensitized
stemness-high cells to Paclitaxel. Moreover, BBI-608 synergized with Paclitaxel
in inhibiting spherogenesis of stemness-high cells. This study provides a new
mechanism for the association of cancer stemness with drug resistance. Our
fındings support this combination therapy, which pairs a conventional chemo-
therapy (Paclitaxel) with a cancer stemness inhibitor (BBI-608), as a promising
strategy to combat cancer.
#4778 Telomere DNA damage promotes mammary gland fıbrosis and
estrogen receptor-positive breast cancer. JianchunWu, David L. Crowe.Univ.
of Illinois Cancer Ctr., Chicago, IL.
Human breast luminal progenitor cells exhibit telomere DNAdamage, which
is associated with mammographic density and increased cancer risk. Telomeric
repeat factor 2 (TRF2) protects telomeres from DNA damage response and its
expression is reduced in human ductal carcinoma in situ and breast cancers. To
determine the relationships between telomere DNA damage, mammary gland
biology, and cancer risk we genetically deleted TRF2 expression in the mouse
mammary gland. TRF2 conditional null mutantmice also were bred with tumor
proneMMTV-Wnt1 animals. TelomereDNAdamage responsewas determined
by localization of 53BP1 at telomeres and activation of ATM/Chk2/p53 signal-
ing by western blot. Mammary gland and tumor histopathology were deter-
mined by hematoxylin and eosin staining. Cell proliferation and ER differen-
tiation was determined by immunohistochemistry. Tumor derived CD24/
CD49f mammary stem cells and CD61 luminal progenitor cells were
transplanted to mammary fat pads of immunodefıcient mice. Alternative
lengthening of telomeres was determined by PML localization at telomeres,
chromosome orientation-fluorescence in situ hybridization, and telomere cir-
cular DNA amplifıcation. Tumor bearing mice were injected with 15 mg ralox-
ifene to determinemammary tumor anti-estrogen sensitivity. Mammary glands
lacking TRF2 expression exhibited increased telomere DNA damage response,
histopathological and functional degeneration, and prominent ductal fıbrosis.
TRF2 defıcient mammary tumors exhibited rapid onset and increased prolifer-
ation. Tumor derived LP cells failed to form tumors following transplantation.
The MSC population was highly tumorigenic and maintained telomeres via the
ALT mechanism. Telomere DNA damage response in mammary tumors re-
sulted in p53 dependent ER cellular differentiation and sensitivity to anti-
estrogen therapy. Telomere DNA damage correlated with estrogen receptor
expression in human breast cancer. We concluded that telomere DNA damage
resulted in mammary gland fıbrosis, reduced tumor latency, ER differentia-
tion, and sensitivity to anti-estrogen therapy.
#4779 Targeting the CCL20-CCR6 axis as a novel opportunity to stimula-
taneously modulate cancer stem cells and the tumor-immune infıltrate by a
dual anti-cancermechanism. Lilian E. van Vlerken-Ysla, Jonathan Rios-Doria,
James Moynihan, Lu Shan, Robert E. Hollingsworth, Ronald Herbst, Elaine M.
Hurt.Medimmune, Gaithersburg, MD.
Drugs that target cancer stem cells (CSCs) are thought to be a critical compo-
nent of any successful therapy against cancer. CSCs are responsible for chemore-
sistance, metastasis, and ultimately relapse of the cancer, even after an initial
successful therapeutic intervention.While it is well known that CSCs are driven
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by some of the same major self-renewal pathways that drive embryonic stem
cells, knowledge of other cellular pathways that drive CSC activity is still limited.
In this work, we uncover a novel role for chemokine (C-C motif) ligand 20
(CCL20) in CSC growth and activity, expanding the role for this chemoattrac-
tant protein.We discovered that CSCs ofmany tumor types overexpress CCL20,
which we show drives CSC self-renewal and proliferation by autocrine signaling
through its receptor CCR6. Targeting this axis with a neutralizing monoclonal
antibody against CCL20 signifıcantly reduces CSC frequency and tumor initia-
tion and growth, supporting the novel therapeutic potential of targeting the
CCL20-CCR6 axis as a strategy to eliminate CSCs. Furthermore, we found that
CCL20 secreted by tumor cells also strongly influences the frequencies not only
of T-cells, particularly immune-suppressive regulatory T-cells (Treg) and Th17
populations, but also dendritic and neutrophil/gMDSCpopulations, to promote
anti-tumor immunity that leads to immune-mediated inhibition of tumor
growth. Strikingly, we discovered that tumor-specifıc CCL20 impacted not just
the immune cell balancewithin the tumormicroenvironment, but had far reach-
ing effects into the peripheral immune system as well. Thus, our overall fındings
propose that CCL20 plays a dual role in the tumor environment: 1) by driving
activity and tumorigenic ability of CSCs, and 2) by promoting an immunosup-
pressive phenotype. In this work we show that therapeutic neutralization of
CCL20 can deliver a one-two punch against cancer, by directly inhibiting CSCs,
and by relieving immunosuppression, thereby opening this target up as an ex-
citing novel strategy to treat cancer.
#4780 Crucial role of S100A14 in blocking cancer stem cells and sensitiz-
ing to chemotherapy through STAT3 destabilization in human colorectal
cancer. Jaebeom Cho, Hye-Young Min, Ji-Sun Lee, Ho-Young Lee. Seoul Na-
tional University, Seoul, Republic of Korea.
Colorectal cancer (CRC) is a major type of human cancers in terms of inci-
dence andmortality worldwide. Chemotherapy is one of the standard protocols
for the treatment of CRC but drug resistance is recognized as the main cause of
treatment failure. Resistance to anticancer therapy is a multifactorial event in-
volving a number of interrelated or independent mechanisms. Growing evi-
dence supports a critical role of cancer stem cell (CSC) in development, progres-
sion, and resistance to anticancer therapies in CRCs. However, the molecular
and cellular mechanisms underlying the CSC’s chemoresistance are not com-
pletely defıned, and a comprehensive understanding of the biology of the CSCs
is urgently needed. We have investigated mechanisms of chemoresistance, fo-
cusing on those mediated by CSCs, through the employment of CRC stem-like
cell populations that are: 1) sorted out by using well-characterized stemness
markers; ii) established via serial passage through increasing doses of oxaliplatin
or 5-FU; or iii) enriched by culturing in sphere forming condition. We then
assessed changes involved in CSC maintenance and found a novel role of
S100A14 in CSCs of CRC. We found that transcriptional down-regulations of
S100A14 expression conferred phenotypes of CSCs in the stem-like cell popu-
lations of CRC. Consistently, elevation of S100A14 expression sensitized the
stem-like cell populations to the treatmentwith 5-FU in vitro and in vivo.Mech-
anistically, S100A14 directly interacted with STAT3 and promoted its degrada-
tion via the ubiquitin-proteasomepathway, leading to decreases in STAT3 target
gene expression and colony forming capacity of the stem-like cell populations.
Further, S100A14 expression was markedly downregulated in human CRC tis-
sue specimens compared with their normal counterparts. Moreover, the expres-
sion level of S100A14was inversely correlated with clinical outcomes in patients
withCRC.These results collectively suggest that S100A14 is a novel target for the
treatment of colorectal cancer by targeting CSCs.
#4781 Epigenetic regulation of neuroblastoma tumorigenicity through
MLL1 and JMJD3modulation in cancer stem cells. Saurabh Agarwal, Zaowen
Chen, Julie A. Tomolonis, Sanjeev A. Vasudevan, Jason M. Shohet. Baylor Col-
lege of Medicine, Houston, TX.
Introduction: Increasing evidence suggest that epigenetic regulators play a
critical role in cancer cell heterogeneity and in maintaining tumor sub-popula-
tionswith enhanced tumor-initiating anddrug-resistant capacities. Recently, we
discovered a drug-resistant, highly tumorigenic, self-renewing cell sub-popula-
tion with features of cancer stem cells (CSCs) in pediatric neuroblastoma (NB).
This sub-population, characterized by surface expression of G-CSF receptor
(CD114), can escape initial therapy and cause refractory and aggressively inva-
sive relapsed disease. Recently, we found that the CSF3R gene that code for
CD114 is expressed specifıcally in CD114 sub-population (1% of total cells)
but not in CD114- bulk tumor cells. We hypothesize that this differential gene
expression is epigenetically regulated andmaintain heterogeneousNB sub-pop-
ulations. Methods: Chromatin immunoprecipitation (ChIP)-qPCR for the his-
tone marks H3K4me3 and H3K27me3 was performed in sorted NB sub-popu-
lations. Pathway qPCR arrays and orthotopic xenografts mouse model were
used to determine the effects of epigenetic inhibitors in vitro and in vivo. Results:
We found that the epigenetic regulators mixed-lineage leukemia-1 (MLL1;
KMT2A; a H3K4me3 methyltransferase) and Jumonji D3 (JMJD3; KDM6B; a
H3K27me3 demethylase) are overexpressed in CD114 NB cells. These regu-
lators maintain a reversible epigenetic switch of high H3K4me3 and low
H3K27me3 histone marks at the CSF3R locus in CD114 cells for active tran-
scription. Targeting these epigenetic regulators with specifıc small-molecule in-
hibitors MM-102 (inhibit MLL1) and GSK-J4 (inhibit JMJD3) in NB, reverses
the histone patterns at CSF3R promoter locus and block gene expression, in-
duces apoptosis selectively in CD114 cells, and inhibits overall NB prolifera-
tion in vitro. These inhibitors also inhibit the expression of cancer stem cell
specifıc genes as determined by pathway arrays. Inhibiting MLL1 and JMJD3 in
NBorthotopic xenografts signifıcantly decreases tumor size (p0.001) andmet-
astatic burden (p0.001) compared to controls. As expected, reduction in tu-
mor size was signifıcantly correlated with the reduction in tumor CD114 cells.
We also found that MM-102 and GSK-J4 sensitize NB tumors to genotoxic
chemotherapy etoposide and further reduce tumor growth (p0.01) in compar-
ison to either drug alone. Interestingly, we do not observe any metastatic inci-
dences inmice treated withMM-102etoposide. Conclusion: Overall, we dem-
onstrate that epigenetic regulators MLL1 and JMJD3 regulate the expression of
critical genes and maintain NB CSC sub-population. Targeting these epigenetic
regulators reduce NB tumorigenicity, metastasis and increase drug sensitivity.
Further developing these strategies will pave the way for incorporating epige-
netic inhibitors in current therapies for effectivity improving long-term cure
rates.
#4782 Transforming growth factor-beta regulation of cancer stem cell
dynamics at different stages of breast cancer progression. Binwu Tang,
George Baker, Joshua Zent, Yuval Raviv, Lalage Wakefıeld. National Cancer
Inst., Bethesda, MD.
Cancer stem cells (CSCs) are a subpopulation of tumor cells that are uniquely
capable of initiating and sustaining tumorigenesis, and they have also been im-
plicated in driving disease recurrence after cancer therapy. We have previously
developed anovel lentiviral-based reporter system for direct visualization, quan-
titation and isolation of cells with CSC properties. The construct consists of a
tandemly-repeated composite SOX2-OCT4 response element (“SORE6”) driv-
ing expression of a destabilized fluorescent protein reporter (Tang et al. Stem
Cell Reports, 2015). TGF-s are pleiotropic regulatory factors with complex
roles in tumorigenesis. We and others have hypothesized that TGF- can regu-
late the CSC population in breast cancer with stimulatory or inhibitory effects
depending the model and stage of cancer development. Using the MCF10Ca1h
and MCF7 breast cancer models, which retain tumor suppressor responses to
TGF-, here we show that TGF- treatment signifıcantly reduces the size of the
CSC population in vitro. Although TGF- had relatively little effect on invasion
andmigration of the bulk population in thesemodels, it clearly inhibitedmigra-
tion and invasion of theCSCs, suggesting that biological responses toTGF- can
vary depending on the position of the cell in the differentiation hierarchy. Com-
bining our stem cell reporter with a TGF- pathway reporter, we further show
that CSCs in the MCF10Ca1h model have higher endogenous activation of the
TGF- pathway than does the bulk tumor cell population, and by time-lapse
video microscopy we fınd that CSCs with active TGF- signaling are relatively
quiescent. Furthermore, neutralization of TGF- in vivo leads to an increased
representation of CSCs in MCF10Ca1h and MCF7 tumors. Thus our prelimi-
nary results suggest that in breast cancer models where TGF- acts as a tumor
suppressor, TGF- signaling is preferentially activated in the CSC compartment
and keeps a subpopulation of CSCs in a quiescent and stationary state. These
fındings have important implications for the clinical use of TGF- pathway
antagonists. In contrast, in the metastatic breast cancer MDA-MB231model, in
which TGF- acts as a pro-progression factor, we show that TGF- can increase
the size of theCSCpopulation and enhance invasion. In thismodel, theCSCs are
enriched for the ability to form macroscopic lung metastases when compared
with non-CSCs, and we show that this effect is due in part to a selective survival
advantage of the CSCs in the fırst 24 hours after arrival at themetastatic site. The
role of TGF- in this process is currently under investigation.
#4783 Regulation of GBM stemness and mesenchymal transition. Kin-
Hoe Chow,1 Hee Jung Park,1 Joshy George,2 Yuanxin Chen,3 Andrew Gallup,4
Wen Jiang,5 Betty Y. Kim,3 Kyuson Yun6. 1The Jackson Laboratory, Bar Harbor,
ME; 2The Jackson Laboratory, Farmington, CT; 3Mayo Clinic, Jacksonville, FL;
4The Jackson Laboratory, ME; 5UT MD Anderson Cancer Center, Houston, TX;
6Houston Methodist Research Institute, Houston, TX.
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While growing evidence suggests that tumor microenvironment can modulate
stemness and the mesenchymal phenotype, little is known about how these cell
states are coordinately regulated.Wereport thatS100A4controlsboth stemnessand
mesenchymal transition inGBMcells. Ina spontaneousmousegliomamodel and in
primary human GBM tumorspheres, S100A4 expression is enriched in tumor-ini-
tiating cells and is required for self-renewal and tumor growth in vivo. In addition,
greater than 80 percent of S100A4 cells are associatedwith the tumor vasculature,
a known niche for glioma stem cells, and S100A4 promotes pro-angiogenic factor
expression. Interestingly, acidosis induces expression of S100A4 and the EMT reg-
ulators SNAIL1/2 and acidosis-inducedEMTregulator expression requires S100A4
function. Importantly, S100A4 functions as amolecular switchbetween theproneu-
ral and mesenchymal states in GBM as S100A4 knockdown results in down-regu-
lation of the mesenchymal signature genes, including the “master transcriptional
regulators of mesenchymal transition”, and concurrent up-regulation of proneural
signature genes. Together, these results indicate that S100A4 sits in a critical node in
the molecular network that controls both glioma stem cells and the mesenchymal
phenotype.
#4784 Regulation of ovarian cancer stem cell population by DDB2. Tian-
tianCui,1 Amit Kumar Srivastava,1 ChunhuaHan,1 ZhiqinGao,2 Xiaoli Zhang,1
Altaf A.Wani,1 Qi-EnWang1. 1Ohio State Univ., Columbus, OH; 2WeifangMed-
ical University, Weifang, China.
Cancer stem cells (CSCs), representing the root of many solid tumors includ-
ing ovarian cancer, have been implicated in disease recurrence, metastasis, and
therapeutic resistance.Our previous study has demonstrated thatDNAdamage-
binding protein 2 (DDB2) is able to reduce the abundance of CSCs in the bulk
ovarian cancer cells, providing a novel mechanism to explain the DDB2-medi-
ated suppression of tumorigenicity and metastasis, and also suggesting that low
expression of DDB2 is required for the maintenance of CSCs. However, the
underlying mechanisms still remain unclear. By using the Tet-On DDB2 mod-
ulation system, we have confırmed our previous fınding that downregulation of
DDB2 expands the CSC population in the 2008 ovarian cancer cell line.We also
found that DDB2 is able to suppress non-CSC-to-CSC conversions in this can-
cer cell line. DDB2 has been recognized as a transcriptional regulator. Our mi-
croarray analysis has identifıed ALDH1A1 to be targeted and regulated by
DDB2. The downregulation of ALDH1A1 expression by DDB2 at both mRNA
and protein levels has been validated in various ovarian cancer cell lines. The
mechanistic investigation demonstrated that DDB2 can bind to the promoter
region of the ALDH1A1 gene, facilitating the enrichment of histoneH3K27me3
by recruiting EZH2 to the promoter region, eventually inhibiting the promoter
activity of the ALDH1A1 gene. In addition, we also found that DDB2 competes
with transcription factor C/EBP for binding to the ALDH1A1 promoter, indi-
rectly inhibiting theALDH1A1promoter activity. Finally, we knocked down the
expression of DDB2 and ALDH1A1 individually or simultaneously in the 2008
ovarian cancer cell line, and analyzed their tumorigenicity. We found that
downregulation of ALDH1A1 is able to block DDB2 silencing-induced expan-
sion of the CSC population, indicating that ALDH1A1 plays a critical role in
DDB2-mediated suppression of the CSC population in ovarian cancer cells. In
summary, our data demonstrated that DDB2, functioning as a transcription
repressor, is able to abrogate ovarian CSC properties by downregulating
ALDH1A1 expression. This study provides a novel mechanism underlying the
regulation of the CSC population, and would facilitate the development of effı-
cient strategies for eliminating CSCs to prevent tumor relapse and metastasis in
ovarian cancers. (Supported by NIH R01CA151248)
#4785 Disrupting redox regulated cancer stem cell state equilibrium by
co-inhibition of glycolysis and thioredoxin/glutathione antioxidant path-
ways. Ming Luo,1 Li Shang,1 Michael Brooks,1 Evelyn Jiagge,1 Sarah Conley,1
RamdaneHarouaka,1 YongyouZhu,1 SofıaD.Merajver,1Douglas R. Spitz,2Max
S. Wicha1. 1Univ. of Michigan Medical School, Ann Arbor, MI; 2University of
Iowa, Iowa City, IA.
Breast cancer stemcells (BCSCs) exist inadynamicequilibriumofmesenchymal-
(M) and epithelial-like (E) states that coordinately drive tumorigenesis, metastasis,
and treatment resistance. Here, we show that BCSCs in both states display hyperac-
tive aerobic glycolysis or oxidative phosphorylation (OXPHOS), depending on the
availability of glucose. This metabolic plasticity is enabled by activation of genes
regulating glycolysis and OXPHOS, as well as increasedmitochondrial mass/activ-
ity. Despite their metabolic plasticity, E- and M-BCSCs exhibit markedly different
vulnerabilities to inhibitors of glycolysis and redox metabolism. Glycolysis inhibi-
tionorhypoxia,by inducingoxidative stress, facilitates invasiveM-BCSCs transition
to their proliferative E state. This process is reversible by addition of the antioxidant
N-acetyl-cysteine (NAC) and mediated by AMPK-dependent HIF1 stabilization,
providing a molecular link between hypoxic/oxidant stress and BCSC phenotypic
plasticity. Moreover, E-BCSCs are endowed with heightened thioredoxin (TXN)
and glutathione (GSH) mediated antioxidant defenses, which are twomajor meta-
bolic pathways to detoxify cellular hydrogen peroxide.We demonstrated that inhi-
bition of the TXN pathway by Auranofın (AUR, an inhibitor of thioredoxin reduc-
tase) in SUM149 and human breast cancer xenograft tumor cells is suffıcient to
abrogate their tumorsphere forming activity and selectively deplete E-BCSCs by
inducing their terminal differentiation and subsequent apoptosis. We also found
that, although the inhibition of the GSH pathway by BSO (an inhibitor of GSH
synthesis) was not suffıcient to abrogate tumorsphere formation and E-BCSCs, co-
inhibition of TXN and GSH pathways with low doses of AUR and BSO had a syn-
ergistic effect in suppressing tumorsphere forming activity, which could be rescued
by NAC. Using patient-derived xenograft models of human triple negative breast
cancer, we further validated that co-inhibition of glycolysis and TXN/GSH antiox-
idant pathways delivers synergistic antitumor effects to suppress tumor growth and
regenerativepotential by eliminatingbothM-andE-BCSCs.Hence, exploitingmet-
abolic vulnerabilities of distinct BCSC states provides a potential therapeutic ap-
proach. As the CSC state equilibriummay be similarly regulated across a spectrum
of tissuemalignancieswithdiverse oncogenic drivers, the conceptual frameworkwe
build in this work to target metabolic vulnerabilities of distinct BCSC phenotypic
states may have broad therapeutic applicability.
#4786 Integrated eoxme and transcriptome sequencing identifıes a novel
candidate for breast cancer. Kyung-Min Lee,1 Dong-Young Noh,2 Wonshik
Han2. 1Seoul National University, Seoul, Republic of Korea; 2Seoul National Uni-
versity College of Medicine, Seoul, Republic of Korea.
Many somatic mutations, structural alterations, and gene expression changes
are causally implicated in oncogenesis and tumor progression, and as a result,
affect clinical outcome. Although majority of breast cancer patients have bene-
fıts from therapeutics targeting tumor biology still many patients suffer from
disease recurrence and metastasis. To fınd novel therapeutic target in breast
cancer, here we examine the both whole exome and whole transcriptome of
fresh-frozen primary breast cancer tissues from 120 patients whose clinical,
pathological, and survival data are available. We identifıed 11,684 putative so-
matic mutations in 7,373 genes. We hypothesized that therapeutic target has to
have recurrent mutation and gene expression at least more than average expres-
sion. With a cut-off of 3 or more mutations in each gene, 1,116 genes were
selected. After the fıltering of Volume0.3, 696 genes were selected. Finally, 55
genes were selected which are druggable or potentially druggable using drug
database. Interestingly, 18 of the 55 were genes involved in metabolism. Among
them we further focused PSMD2 and interrogated their oncogenic roles, a sub-
unit of the 19S regulatory complex of proteasomes, as a constituent of a signature
is a candidate driven factor in breast cancer. PSMD2 is required for proliferation
both in vitro and in vivo, as shRNA-mediated PSMD2 silencing attenuated
tumor growth. Further, PMSD2 is suffıcient to induce stem cell characteristics,
as forced PSMD2 expression facilitatedmammosphere formation and increased
the CD44 breast CSC-like population. Mechanistically, PSMD2 inhibition
were associated with changes in epithelial-mesenchymal transition (EMT) phe-
notype. Knockdown of PSMD2 induced dramatic morphological changes, the
typical spindle-like appearance cells were replaced with the round shape, like
epithelial morphology. Moreover, treatment of TGF-1, the main inducer of
EMT, lead to increased expression of PSMD2. PSMD2 silencing up-regulated
E-cadherin and down-regulated expression of vimentin, N-cadherin and snail,
mesenchymal markers. Clinically, PSMD2 expression was elevated in basal-like
TNBC (triple negative breast cancer), correlated with poor prognosis, insilico
analysis on a dataset comprising over 2413 microarrays of the web application
bc-GenExMiner. Altogether, our fındings suggest that PSMD2 may be a good
molecular target candidate and PSMD2 inhibitor may kills breast cancer stem
cells and ameliorates poor prognosis of breast cancer.
#4787 The role of CaMK2A in reactive oxygen species homeostasis in lung
adenocarcinoma. Siqi Wang, Zhijie Xiao, Vicky Tin, Ian K. Lam, Xuyuan Gao,
Maria Wong. The University of Hong Kong, Hong Kong.
The role of Calcium/calmodulin-dependent protein kinase II alpha
(CaMK2A) in reactive oxygen species homeostasis in lung adenocarcinoma
Lung cancer is the most common cancer worldwide and patients have poor
prognosis and low survival rate. The unsatisfactory outcomes of lung cancer
treatment are related tomultiple factors including tumor recrudescence, metas-
tasis, cancer drug resistance, etc. Cancer stem cells are cell subsets within a
cancer that excel in tumor properties, especially survival, renewal and resistance
to treatment. Reactive oxygen species (ROS) are high energy molecules pro-
duced during cellular hyperproliferation and cell death. Studies have shown
though a low level of ROS is required to support stem cell functions but excessive
ROS damages DNA and predisposes to cell death. Therefore, the ability to at-
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tenuate oxidative damage from ROS and maintain redox homeostasis is an im-
portant property of aggressive and resilient cancer cells. The multifunctional
serine/threonine kinase calcium/calmodulin- dependent protein kinase II alpha
(CaMK2A) is a calcium signaling molecule involved in cell growth and stress
signals integration. It has been reported to play a tumor-supportive role in os-
teosarcoma, prostate cancer and leukemia. However, little is known about the
impact and mechanisms of CaMK2A on lung cancer and cancer redox homeo-
stasis. This study aims to investigate the role of CaMK2A in ROS regulation in
lung cancer stem cells. We measured ROS levels using H2DCFDA probes in
cancer stem cells isolated from two lung cancer cell lines by the known lung
cancer stem cell marker CD44 and CD166. Compared to CD44- and CD166-
non-stem cells, ROS levels were lower in both CD44 and CD166 cancer stem
cells. In cancer cells with stable CaMK2A knockdown by shRNA (CaMK2A-
KD), ROS was suppressed while CaMK2A overexpression led to ROS elevation,
suggesting a potential role of CaMK2A on ROS regulation in lung cancer stem
cells. To understand the mechanism, activated NRF2 levels, the master tran-
scription factor mediating ROS regulation, were measured in total nuclear pro-
tein extracts. By Western blot, nuclear NRF2 protein showed upregulation in
CaMK2A overexpression cells and decreased levels in CaMK2A-KD cells, im-
plying NRF2 might be a mediator of CaMK2A in ROS regulation. To further
identify downstream regulators, mRNA expression analysis of fıve ROS-regula-
tory NRF2 target genes (GSTP1, NQO1, GCLC, HMOX1, TRXR1) was per-
formed. Quantitative PCR results showed signifıcant corresponding changes of
some these gene expressions in cell lines, which upregulated in CaMK2A over-
expression and downregulated in both CaMK2A-KD cells and CaMK2A phar-
macological inhibition cells. Together, the results indicate CaMK2Amight reg-
ulate ROS status through mediating downstream target genes of NRF2.
#4788 Abraxane eliminates cancer stem cells in triple-negative breast can-
cers. Hebao Yuan, Hongwei Guo, Feng Li, Joseph Burnett, Miao He, Nathan
Truchan, Ila Myers, Duxin Sun. Univ. of Michigan, College of Pharmacy, Ann
Arbor, MI.
Triple-negative breast cancer (TNBC) represents about 20 percent of all
breast cancers, with a poorer survival rate and being associated with high-grade
tumors and the least favorable prognosis. Due to the absence of hormone recep-
tors andHer2 receptor, no targeted therapy is available and chemotherapy is the
standard treatment for TNBC patient. Paclitaxel is a widely used chemotherapy
drug for various cancerswith severe side effects due to its solvent. Abraxane is an
albumin-bound nanoparticle of paclitaxel with less severe side effects. Here we
investigated whether cancer stem cells (CSCs) in TNBC response differentially
to abraxane and paclitaxel both in cell culture and xenograft mouse models.
Using a series of human TNBC cell lines, we showed that there is no difference
between solvent-based paclitaxel and abraxane in vitro in term of effıcacy and
eliminating cancer stem cells usingMTS assay, mammosphere formation assay,
and flow analysis of cancer stemcells. Interestingly, we demonstrated that abrax-
ane shows superior effıcacy than solvent-based paclitaxel in human SUM149
xenograft NOD SCIDmouse model in adjuvant treatment. More important, we
demonstrated that abraxane eliminates cancer stem cells in xenograft NOD
SCID mouse model in advanced treatment, while solvent-based paclitaxel in-
creases cancer stem cells. Cell uptake assay indicated that TNBC cells take more
abraxane than solvent-based paclitaxel, which partially attributes to its superior
effıcacy in xenograft mouse models. Taken together, our data confırmed that
abraxane is superior to solvent-based paclitaxel and may be a better option for
TNBC patients in adjuvant or metastatic treatment.
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#4789 A novel MIF signaling pathway drives the malignant character of
pancreatic cancer by targeting NR3C2. Shouhui Yang,1 Peijun He,1 Liming
Wang,1 Jian Wang,1 Aaron Schetter,2 Wei Tang,1 Naotake Funamizu,3 Kat-
suhiko Yanaga,3 Tadashi Uwagawa,3 Abhay R. Satoskar,4 Jochen Gaedcke,5
Markus Bernhardt,5 B. Michael Ghadimi,5 Matthias M Gaida,6 Frank Berg-
mann,6 JensWerner,7 Thomas Ried,1 Nader Hanna,8 H. Richard Alexander,8 S.
Perwez Hussain1. 1National Cancer Inst., Bethesda, MD; 2U.S. Food and Drug
Administration, Silver Spring, MD; 3The Jikei University School of Medicine,
Japan; 4Dept. Pathology and Microbiology, Ohio State University, OH; 5Univer-
sity Medical Center Göttingen, Germany; 6University Hospital Heidelberg, Ger-
many; 77Department of Surgery, Ludwig-Maximillians University, Munich, Ger-
many; 8University of Maryland School of Medicine, MD.
Pancreatic cancers with aberrant expression of macrophage migration inhib-
itory factor (MIF) are particularly aggressive. To identify key signaling pathways
that drive disease aggressiveness in tumors with high MIF expression, we ana-
lyzed the expression of coding and noncoding genes in high and low MIF-
expressing tumors in multiple cohorts of pancreatic ductal adenocarcinoma
(PDAC) patients. The key genes and pathways identifıed were linked to patient
survival and were mechanistically, functionally, and clinically characterized us-
ing cell lines, a genetically engineeredmousemodel, and PDAC patient cohorts.
Here, we report evidence of a novel MIF-driven signaling pathway that inhibits
the orphan nuclear receptor NR3C2, a previously undescribed tumor suppres-
sor that impacts aggressiveness and survival in PDAC. Mechanistically, MIF
upregulated miR-301b that targeted NR3C2 and suppressed its expression.
PDAC tumors expressing high levels of MIF displayed elevated levels of miR-
301b and reduced levels ofNR3C2. In addition, reduced levels ofNR3C2 expres-
sion correlated with poorer survival in multiple independent cohorts of PDAC
patients. Functional analysis showed that NR3C2 inhibited epithelial-to-mesen-
chymal transition and enhanced sensitivity to the gemcitabine, a chemothera-
peutic drug used in PDAC standard of care. Furthermore, genetic deletion of
MIF disrupted a MIF-mir-301b-NR3C2 signaling axis, reducing metastasis and
prolonging survival in a genetically engineered mouse model of PDAC. Taken
together, our results offer a preclinical proof of principle for candidate therapies
to target a newly described MIF-miR-301b-NR3C2 signaling axis for PDAC
management.
#4790 Let-7 mediates sulindac inhibition of tumor cell transformation.
Zhipin Liang, Bin Yi, Hongyou Zhao, Ruixia Ma, Yaguang Xi. Louisiana State
University Health Sciences Center, New Orleans, LA.
Cell transformation is the process inwhich normal cells acquire the properties
of cancer. Sulindac Sulfıde (SS) is one of non-steroidal anti-inflammatory drugs
(NSAIDs), and its anticancer activity in prevention of tumor occurrence and
progression has been documented in various human cancers. In this study, we
observed the anti-transformative activity of SS in NIH/3T3 cells by using a two-
stage transformation assay induced by the carcinogens, 3-methylcholanthrene
(MCA) and 2-O-tetradecanoylphorbol-13-acetate (TPA) in which foci forma-
tion is used to characterize the transformed cells.We found that SS could inhibit
foci formation by attenuation of TPA’s promotive effect. K-Ras was upregulated
in the transformed cells, while SS treatment could selectively inhibit the growth
of transformed cell in which K-Ras was suppressed signifıcantly. Loss-of-func-
tion study demonstrated that knockdown of K-Ras in NIH/3T3 cells could sig-
nifıcantly reduce foci formation, which support that K-Ras might be one of the
key targets involved in SS inhibiting tumor cell transformation. When studying
the mechanism by which SS regulates K-Ras, we triggered tumor suppressor
miRNA, let-7b, which was previously reported to target K-Ras and repress its
expression through the post-transcriptional or translational modulation. We
found that let-7b could be upregulated in the transformed cells by SS treatment.
However, the inhibitory effect of SS on foci formation was signifıcantly attenu-
ated when let-7b was knocked down by CRISPR/Cas9. In parallel, K-Ras main-
tained static expression in the transformed cells, regardless of SS treatment.
Meanwhile, the overexpression of endogenous let-7b can signifıcantly inhibit
tumor transformation. In addition, we demonstrated that SS could suppress the
expression of Lin28 that interacts with let-7 through a documented feedback
loop. Given our previous studies reporting that SS was able to inhibit the tran-
scriptional activity of NF-B that is involved in regulation of Lin28 expression,
our study demonstrates that theNF-B/Lin28/Let-7/K-Ras axis addresses a new
mechanism responsible for anti-transformative activity of SS. These results will
provide novel insights into understanding the mechanisms involved in tumor-
igenesis and benefıting identifıcation of new targets for drug development in
prevention of tumor progression.
#4791 Cystathionine--Synthase (CBS) and the progression of colorectal
carcinogenesis. John R. Zatarain, Ketan Thanki, Michael E. Nicholls, Manjit
Maskey, Muhammad U. Jawad, Ches’Nique Phillips, Katalin Modis, Csaba
Szabo, Celia Chao, Mark R. Hellmich. University of Texas Medical Branch,
Galveston, TX.
Introduction: We recently demonstrated that cystathionine--synthase
(CBS) stimulates colon cancer bioenergetics, migration, invasion and angiogen-
esis and is increased in colorectal cancer compared to normal colonic mucosa.
The role of CBS in carcinogenesis is still, however, unknown. Here we compare
CBS protein levels and immunohistochemistry in human colonic biopsies at
different stages of colorectal carcinogenesis. In addition,we usedAzoxymethane
(AOM) inCBS knockdownmice to study the development of aberrant crypt foci
(ACF), a model of sporadic colorectal carcinogenesis. Methods: CBS protein
expression was assessed in human biopsies of normal mucosa, tubular adenoma
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and carcinoma in situ byWestern blotting. Immunohistochemical (IHC) stain-
ing was used to assess CBS levels in formalin-fıxed/paraffın-embedded speci-
mens of normal colonic mucosa, adenomatous polyps and colon adenocarci-
noma. To assess the effect of CBS gene dosage on azoxymethane (AOM)-
induced aberrant crypt foci (ACF) formation CBS heterozygous mice (CBS/-)
and wild-type (CBS/) controls were treated with the mutagen AOM at
10mg/kg via intraperitoneal injection once perweek for 5weeks. At the end of 16
weeks, the colons were harvested andACF visualized withmethylene blue stain-
ing by 3 independently blinded observers. Signifıcance (p  0.05) was deter-
mined using GraphPad Prism 7 software. Results: Consistent with our previ-
ously reported fındings CBS levels were relatively low in biopsies of normal
mucosa. By comparison, it was elevated in polyps exhibiting both low- and
high-grade dysplasia. IHC staining of normal mucosa and hyperplastic polyps
revealed CBS immunoreactivity in a small number of cells located along the
basal lamina aspect of the colonic crypts in both normal and hyperplastic polyps.
A sight increase in cytoplasmic CBS staining also was noted in the epithelial cells
of hyperplastic polyps. In contrast, the epithelial cells of tubular adenoma spec-
imens exhibited higher levels of diffuse cytoplasmic CBS staining with frequent
focal areas of intense staining adjacent tomucin-containing vesicles. Sections of
adenocarcinoma exhibited diffuseCBS staining throughout the cytoplasmof the
cancer cells. AOM treatment induced signifıcantly less ACF in the colons of
CBS(/-) mice compared to wild-type controls. The loss of one allele of CBS
reduced the number of AOM-induced ACF by half. The mean number of ACF
	 SD for CBS(/) and CBS(/-) were 10.9 	 5.2 and 5.6 	 2.5, respectively
(p 0.05). Conclusion:CBSprotein levels increase and the pattern of expression
changes with progression from benign hyperplastic polyps to invasive adeno-
carcinoma, suggesting the enzyme may play a functional role in colorectal car-
cinogenesis. In addition, CBS single allele knockdown signifıcantly reduces ACF
formation. CBS, and its product H2S, may, therefore, be a driver of carcinogen-
esis.
#4792 Prmt6 promotes lung tumor growth via modulation of Ilf2 expres-
sion. Sreedevi Avasarala, Pei-YingWu,Michelle Van Scoyk, Abinaya Baskaran,
Yanlin Su,OdileDavid, RobertA.Winn,KameshBikkavilli.University of Illinois
at Chicago, Chicago, IL.
Lung cancer kills more people in the US than any other malignancy. High
mortalities are in part due to the diagnosis at an advanced inoperable stage
where the 5-year survival is only 4%. Therefore improving survival will require
increased knowledge of genes that drive the complexmechanisms of lung cancer
initiation and progression. Emerging data implicate novel roles for protein ar-
ginine methylation in lung cancers. In protein arginine methylation, nitrogen/s
of arginine can be post-translationally modifıed via the addition of a methyl
group, catalyzed by a class of enzymes, protein arginine methyl transferases
(PRMTs). Protein argininemethyl transferase 6 (PRMT6) is amethyl transferase
that modifıes histone tails, and its expression is upregulated in lung cancers,
correlating with a worse overall patient survival. However, the in vivo role of
PRMT6 has never been examined. In this study, we show that targeted over-
expression of PRMT6 in the mouse lungs (PRMT6 gain-of-function mouse
model) results in an increased chemical carcinogen-induced lung tumorigene-
sis. We also performed proteomics on PRMT6-associated proteins from the
mouse lung and identifıed Interleukin-enhancer binding protein 2 (ILF2) a.k.a.
nuclear factor 45 (NF45) as a novel PRMT6 interacting protein. By using a
battery of cell-based assays, we show that PRMT6 plays an essential role in the
regulation of the pro-proliferative functions of ILF2. Therefore, targeting
PRMT6/ILF2 axis might open new possibilities for the therapeutic intervention
of lung cancer.
#4793 TRAF2 is required for the survival of ErbB2-transfored mammary
tumor cells. Hasem Habelhah, Yumei Fan, Laiqun Zhang. Univ. of Iowa, Iowa
City, IA.
TRAF2 regulates signaling pathways downstream of many members of the
TNF receptor superfamily, such as TNFR1 and CD40. Recently, we found that
TRAF2 also plays an important role in breast cancer cell survival under condi-
tions of endoplasmic reticulum (ER) stress. It is known that TRAF2 knockout
(KO) mice die within a week of birth and this lethality can be rescued by KO of
TNF or TNFR1. In order to determine the role of TRAF2 in mammary tumor
development and progression, we crossed MMTV-ErbB2 mice (FVB) with
TNF-/-/TRAF2-/ mice (B6), and generated MMTV-ErbB2 (ErbB2), MMTV-
ErbB2-TNF-/- (ErbB2/T-KO) and MMTV-ErbB2-TNF-/-/TRAF2-/- (ErbB2/T/
T2-DKO) mice all in FVB/B6 mixed background. In 43 weeks, only 1 of 10
ErbB2/T/T2-DKOmice developed a mammary tumor, while 50% of ErbB2 and
ErbB2/T-KOmice developed multiple and larger tumors in 30-32 weeks. Inter-
estingly, the tumor derived from the ErbB2/T/T2-DKO mice did not show de-
creased cyclin D1 expression, nor the tumor cells cultured in vitro show de-
creased NF-B activation in response to RANKL. In addition, ErbB2/T/T2-
DKOcells formedmammospheres of similar appearancewith that of ErbB2 cells
in HEMA-coated plates. However, after dispersion of the mammospheres into
single cells, ErbB2/T/T2-DKO cells formed dead cell aggregates, while ErbB2
and ErbB2/T-KO cells formed secondary mammospheres, suggesting that the
self-renewal capacity of ErbB2/T/T2-DKOcells is impaired.Mechanistic studies
reveal that ErbB2/T/T2-DKO cells are sensitive to death caused by ER stress but
not by TRAIL or DNA damage, and that this sensitivity is signifıcantly inhibited
by knockdown of RIP1. Collectively, these fındings suggest that TRAF2 plays a
critical role in mammary tumor development and progression by suppressing
the pro-death activity of RIP1, and that TRAF2 andRIP1 interaction could be an
attractive target for development of new anti-breast cancer drugs.
#4794 Reduced Epstein-Barr virus replication in human papillomavirus-
immortalized keratinocyte organotypic raft culture. Joseph T. Guidry, Wil-
liam K. Songock, Xiaohui Ma, Cherie-Ann O. Nathan, JasonM. Bodily, Rona S.
Scott. LSU Health Sciences Center - Shreveport, Shreveport, LA.
An epidemic rise in oropharyngeal squamous cell carcinoma (OSCC) infected
with human papillomavirus has been observed over the past decade. Themajor-
ity of HPVOSCC arise from the tonsils and base of tongue (BOT), which are
lymphoid-rich regions that are known to harbor Epstein-Barr virus (EBV). In-
deed,we previously reportedHPV/EBVco-infection in 25%of tonsillar and 70%
of BOT tumors. HPV is a DNA tumor virus that specifıcally infects proliferating
basal cells in stratifıed squamous epithelia. HPV replication is facilitated by viral
oncoproteins E6 and E7, which create an S-phase-like environment via degra-
dation of cell cycle regulators p53 andRb, respectively. EBV is also an established
DNA tumor virus that replicates in differentiated epithelia in its normal life-
cycle. However, EBV exhibits a latent infection characterized by oncogene ex-
pression and lack of viral replication in EBV-associated carcinomas. E6/E7-
mediated alteration of the cell cycle results in an interruption in epithelial
differentiation, which is required for EBV replication in epithelial cells. Thus, we
hypothesize that HPV immortalization of keratinocytes shifts the EBV life cycle
from replication to latency. To test our hypothesis, we developed an EBV/HPV
co-infection model utilizing organotypic raft culture to produce stratifıed epi-
thelia in vitro. Tonsillar keratinocytes immortalized byHPVwere EBV-infected
by co-culture with IgG-induced EBV-positive Akata Burkitt’s lymphoma cells
four days after differentiation induction. Raft tissues were harvested 6 days post-
EBV infection for analysis of viral life cycles. EBV infection did not alter HPV
replication or gene expression. In HPV-negative tonsillar keratinocytes, robust
EBV replication was observed that was blocked by treatment with acyclovir, a
nucleoside analog that inhibits EBV lytic replication. In contrast, a dramatic
decrease in EBVDNA levels was observed inHPV-positive keratinocytes, which
was not further reduced by acyclovir. Human telomerase-immortalized normal
oral keratinocytes supported robust EBV replication in organotypic raft culture
suggesting a specifıc effect of HPV rather than immortalization on EBV replica-
tion. Expression of E7 alone was suffıcient to decrease EBVDNA levels. Prelim-
inary data suggest no change in EBV infectivity between HPV-negative and
HPV-positive rafts, and an increase in EBV latency-associated gene expression
in HPV-positive cells. The ability of EBV to establish persistent latent infection
in HPV-infected epithelial cells would contribute additional viral oncogene ex-
pression to explain the rapid development and progression of HPVOSCC.
#4795 Nrf2 protects against chemotherapy-induced steatohepatitis and
peripheral neurotoxicity.LiuHe,1 LinlingQue,1WenchenYin,2 BaoshanCao,2
Siwang Yu1. 1Peking University, Beijing, China; 2Peking University Third Hospi-
tal, Beijing, China.
The indiscriminating protection of either normal or cancerous cells against
electrophilic stresses by nuclear factor E2-related factor 2 (Nrf2) has evoked
continuous controversy over its Janus face in cancer. However, both normal and
cancerous cells co-exist in cancer patients, and the outcome of therapy is deter-
mined by responses of both. Here we systemically analyzed the correlation be-
tween Nrf2 expression in normal cells and chemotherapy-associatedmyelosup-
pression, steatohepatitis and peripheral neurotoxicity, and explored the
possibility to predict and prevent these adverse effects by targeting Nrf2 signal-
ing. Firstly, the toxicities of 22 clinically-used chemotherapeutic drugs were
tested in bone marrow cells, liver cells and embryonic fıbroblasts derived from
either Nrf2 (-/-) or wild type mice, and the toxicities of drugs with IC50 in wild
type cells  2 folds higher than their Nrf2(-/-) counterparts are considered as
signifıcantly dependent on Nrf2. The dependency of taxol-induced myelosup-
pression on Nrf2 was confırmed in vivo, and the mRNA level of Nrf2 in periph-
eral blood mononuclear cells from cancer patients was reversely correlated to
taxol-associated myelosuppression. Then steatohepatitis induced by irinotecan
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(CPT-11) and peripheral neurotoxicity induced by oxaliplatin were further in-
vestigated. CPT-11 induced intestinal toxicity in wild type mice but no signifı-
cant steatohepatitis/liver toxicity was observed; however, CPT-11 treatment in
Nrf2 (-/-) mice caused severer intestinal toxicity and pronounced steatohepati-
tis, associated with dramatically elevated serum biomarkers, accumulation of fat
in liver cells, and altered liver histology. Similar results were observed for oxalip-
latin-induced hepatotoxicity. Furthermore, Nrf2 defıciency signifıcantly exag-
gerated oxaliplatin-induced peripheral neurotoxicity, as indicated by Von Frey
test and cold plate assay. Interestingly, CDDO-Me was found to activate Nrf2
signaling in both normal tissues and xenograft tumors, while sulforaphane se-
lectively activated Nrf2 in liver, bone marrow and peripheral nerves but not in
tumors. As expected, sulforaphane signifıcantly alleviated CPT-11-induced in-
testinal toxicity and oxaliplatin-induced peripheral neurotoxicity, while did not
impact the therapeutic effıcacy of drugs. Taken together, our results demon-
strate that the toxicities of some of chemotherapeutic drugs currently in clinic
usage are signifıcantly affected by Nrf2, therefore it is possible to personalize
therapeutic regimens according to Nrf2 expression in tumors and normal tis-
sues. Specifıcally, CPT-11-induced steatohepatitis and intestinal toxicity and
oxaliplatin-induced peripheral neurotoxicity are signifıcantly determined by
Nrf2, and Nrf2 could be selectively targeted to prevent or treat chemotherapy-
induced toxicities. The present works were supported by the NSFC (No.
81272468, 91429305 and 81372266).
#4796 Chronic exposure to nitric oxide drives human breast epithelial
cells tomalignant-like features.Yuk Sing Robert Cheng, StephenK. Anderson,
Daniel W. McVicar, Daivd A. Wink, Lisa A. Ridnour. National Cancer Inst.,
Frederick, MD.
The small endogenous signaling molecule, nitric oxide (NO) influences nu-
merous physiological conditions including cancers. We have previously shown
that different steady state NO levels activate pro-tumor signaling cascades. In
this study, we explored the effect(s) of chronic NO exposure on breast epithelial
cells as defıned by changes in genomic stability, RNA and protein expression,
and mostly importantly altered cell phenotype. Human breast epithelial cells
(MCF10A)were chronically exposed to various concentrations of theNOdonor
DETA/NO for a three weeks. Distinct patterns of genomic alteration in the
target genes (TP53, KRAS & PIK3CA) of exposed cells as compared to the
background mutations were observed. In addition, quantitative real time PCR
revealed increased expression of cancer stem cell (CSC) markers including
NANOG, CD44, CXCR4 and OCT4 at 300 M DETA/NO exposure. While
altered cell morphology was observed in cells chronically exposed to 300-500
MDETA/NO, increasedmotility occurred in cells cultured in 100MDETA/
NO. Strikingly, these 100 M NO-exposed cells grew in serum-free media; se-
lected clonal populations as well as pooled cells formed colonies in soft agar that
were disorganized and resembled cancer-like-clusters. In conclusion, these re-
sults implicate a precise tuning ofmicroenvironmental NO levels that shift non-
transformed breast epithelial cells toward cancerous phenotypes. The elucida-
tion of underlying mechanisms may lend a new perspective regarding
therapeutic approaches that redirect the cellular response(s) of tumor cells.
#4797 Continuous hepatocyte apoptosis accelerates diethylnitrosamine-
induced liver tumor development. Yasutoshi Nozaki, Hayato Hikita, Satoshi
Tanaka, Yuta Myojin, Sadatsugu Sakane, Kazuhiro Murai, Yuto Shiode, Yugo
Kai, Yuki Makino, Tasuku Nakabori, Yoshinobu Saito, Takahiro Kodama,
Ryotaro Sakamori, Tomohide Tatsumi, Eiji Miyoshi, Tetsuo Takehara. Osaka
University Graduate School of Medicine, Suita Osaka, Japan.
Background and Aim: Apoptosis serves as an important mechanism for re-
moving DNA damaged-cells and is considered to inhibit carcinogenesis. Hepa-
tocyte apoptosis is a key feature of chronic liver disease, as established precan-
cerous condition for liver cancer. The present study examined the impact of
continuous hepatocyte apoptosis on liver tumor development. Methods: We
used male hepatocyte-specifıc knockout (KO) mice of Mcl-1, one of anti-apo-
ptotic proteins, as a model of continuous hepatocyte apoptosis, and hepatocyte-
specifıc single or double KO mice of Bak and Bax, proapoptotic proteins, as a
model of apoptosis-resistant liver. To induce liver carcinogenesis those mice
were intraperitoneally administered 20 mg/kg diethylnitrosamine (DEN) at 2
weeks. Results: Among control group treated with PBS, neither Mcl-1 KO nor
wild-type (WT) mice developed macroscopically and microscopically any liver
tumors at age of 6 months. On the other hand, while only 8% (2/26) of DEN-
treated WT mice developed macroscopic liver tumors, 100% (15/15) of Mcl-1
KO mice developed (p0.05). Microscopically, 57% (15/26) of DEN-treated
WT mice developed liver tumors, 100% (15/15) of Mcl-1 KO mice developed
(p0.05). These tumors were histologically classifıed as well-differentiated
HCC. The average of maximum tumor size (12.4 vs. 6.5 mm), tumor numbers
(21.4 vs. 4.0) and liver weight to body weight ratio (12.3 vs. 4.2 %) in Mcl-1 KO
mice were signifıcantly higher than those in WT mice. At 6 weeks, serum ALT
levels and caspase 3/7 activity of DEN-treatedMcl-1 KOmice were signifıcantly
higher than those of DEN-treated WT mice. Immunohistochemistry revealed
that PCNA, Ki67, phospho-H2AX and 8-OHdG positive cells signifıcantly in-
creased in DEN-treatedMcl-1 KOmice compared with DEN-treatedWTmice.
ThemRNA expression levels of TNF-alfa andMcp-1 in DEN-treatedMcl-1 KO
mice were signifıcantly higher than those of DEN-treatedWTmice.In contrast,
macroscopic liver tumor incidence rate in WT, Bak KO, Bax KO and Bak/Bax
double KO mice treated with DEN at 9 months was 46 (6/13), 40 (6/15), 35
(7/20) and 52% (11/21), respectively. Microscopic liver tumor incidence rate in
WT, BakKO, BaxKO and Bak/Bax double KOmice was 100 (13/13), 80 (12/15),
70 (14/20) and 81% (17/21), respectively. There was no statistically signifıcant
difference in incidence rate of both macroscopic and microscopic tumors
among 4 groups. At age of 6 weeks, there was no signifıcant difference in serum
ALT levels and caspase 3/7 activity among 4 groups. Conclusion: Continuous
hepatocyte apoptosis is suggested to promote DEN-induced liver tumor devel-
opment. Increased liver damage, compensative hepatocyte proliferation,
genomic instability and inflammation may accelerate the incidence of DEN-
induced liver tumorigenesis. In contrast, inhibition of apoptosis does not make
much impact on DEN-induced liver tumor development.
#4798 Genetically engineered mouse models of proliferative C5 high
grade serous ovarian cancer. Clare L. Scott,1 Gwo Y. Ho,1 Elizabeth E. Li-
eschke,1 Olga Kondrashova,1 Ronny Drapkin,2 David Bowtell,3 Matthew J.
Wakefıeld1. 1Walter & Eliza Hall Inst. of Med. Research, Parkville, Australia;
2University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; 3Pe-
ter MacCallum Cancer Centre, Parkville, Australia.
Introduction: High-grade serous ovarian cancer (HGSOC) can be divided
into four subgroups based on molecular characteristics1,2. The proliferative/C5
subgroup is defıned by MYCN-pathway activation and may be associated with
stem cell-like behavior3. The majority of HGSOC originate from the secretory
cells of the fallopian tube (FT), with both tumours and secretory cells character-
ised by PAX8 expression4. We have developed pre-malignant C5 sub-type Ge-
netically Engineered Mouse Models (GEMM) to characterise key molecular
events in the initiation of this sub-type and to provide an immune-competent
model for testing therapeutics. Methods: We have generated independent
GEMM with p53 dysfunction (p53lsl-R172H knock-in5) and over-expression of
the MYCN-pathway, using either lsl-MYCN or lsl-lin28b transgenes6 directed
by the doxycycline-inducible PAX8 promoter. Murine FT were harvested fol-
lowing two-weeks of transgene activation. One FT was harvested en bloc and
paraffın embedded for analysis by H&E and immunohistochemistry for the
presence of pre-malignant tubal lesions. The contralateral FT was macro-dis-
sected into distal/mid-FT, which were snap frozen for analysis of gene expres-
sion by qRT-PCR and RNAseq. As mice with PAX8-directed expression of on-
cogenes (	MYCN/lin28b overexpression) developed enlarged kidneys due to
renal tubular adenomata, for alternate mice, the mid/distal FT tissue was im-
planted into the bursae of wild-type CBA/nu mice for observation and later
analysis. Results: FTwere harvested from twelve p53lsl-R172H/lsl-lin28bmice and
from ten p53lsl-R172H/lsl-MYCN mice (including relevant control mice). Dys-
plastic lesions were observed in a subset of p53lsl-R172H/lsl-MYCN or lsl-lin28b
FT and not in controls. MYCN pathway activation was demonstrated by qRT-
PCR analysis. Conclusion:Over-expression of theMYCN-pathway can drive FT
epithelial dysplasia in the presence of p53 dysfunction. RNASeq analysis is being
performed to elucidate early genetic events in dysplastic FT.Mice are now being
harvested after eight-weeks of doxycycline activation to determine whether
more advanced pre-malignant change occurs. CRISPR guides deleting relevant
genes including p53, PTEN, Nf1 or Rb1 were generated to delete additional
genes in MYCN pathway-transgenic FT, followed by implantation for observa-
tion of tumourigenesis.
#4799 Fibroblast growth factor receptor (FGFR) promotes progression of
cutaneous squamous cell carcinoma. Alok R. Khandelwal,1 Xiaohua Rong,1
Tara Moore-Medlin,1 Xiaohua Ma,1 Amelia Warner,1 John DiGiovanni,2 Che-
rie-Ann O. Nathan1. 1LSU Health-SHV, Shreveport, LA; 2University of Texas at
Austin, Austin, TX.
Cutaneous squamous cell carcinoma (cSCC) is a keratinocyte-derived inva-
sive and metastatic tumor of the skin. It is the second-most commonly diag-
nosed formof skin cancer (16%) striking 200,000Americans annually. Increased
understanding of themechanisms involved in pathogeneses of cSCC could iden-
tify means to prevent, inhibit and reverse this process. In our previous studies,
inhibition of Fibroblast growth factor receptor (FGFR) signifıcantly decreased
Ultraviolet B-induced (UVB) epidermal hyperplasia and hyperproliferation in
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SKH-1 mice suggesting an important role of FGFR signaling in skin cancer
prevention. However, the role of FGFR signaling in the progression of cSCC is
not yet elucidated.Analysis of the expression of FGFR2 in cSCCcells andnormal
epidermal keratinocytes revealed overexpression and increased FGFR2 activity
in cSCC cells. Tumor cell-specifıc overexpression of FGFR2 was detected in
human cSCCs and in UVB-induced mouse cSCCs, whereas the expression of
FGFR2 was low in premalignant lesions and normal skin. Further, treatment
with a selective FGFR inhibitor; AZD4547 signifıcantly decreased proliferation,
migration, and invasion of cSCC cells in culture. The decrease in FGFR activa-
tion was associated with an inhibition of mTORC1 and mTORC2 signaling
markers. Our studies provide mechanistic evidence for the role of FGFR2 in
early progression of cSCC and identify FGFR as a putative therapeutic target in
the treatment of skin cancer.
#4800 A next-gen animal model to Study PIK3CA-mTOR driven HPV-
related oral malignancies. Juan Luis Callejas-Valera,1 Ramiro Iglesias-Bar-
tolome,2 Panomwat Amornphimoltham,1 Julia Palacios-Garcia,3 Daniel Mar-
tin,4 Joseph A. Califano,1 Alfredo A. Molinolo,1 J.Silvio Gutkind1. 1Moores
Cancer Center, UCSD, La Jolla, CA; 2NIH/NIAMS, Bethesda, MD; 3Centro de
Biología Molecular Severo Ochoa (CSIC-UAM), Madrid, Spain; 4NIH/NIDCR,
Bethesda, MD.
The rising incidence of HPV-associatedmalignancies, especially for head and
neck squamous cell carcinoma (HNSCC), has highlighted the urgent need to
understand the role of HPV-16 E6/E7 oncogenes in cancer initiation and pro-
gression. For that propose we decided to generate a doxycycline inducible E6/E7
transgenic mouse targeting E6/E7 onco-proteins to the basal epithelia layer,
including the stem cell compartment, through a doxycycline inducible cytoker-
atin 5 promoter (cK5-rtTA). This system allows to turn on the expression of
HPVgenes after birth,minimizing the negative effect that viral E6/E7 expression
may have during embryonic development, and mimicking the natural infection
process that usually happens in adults after initiation of sexual activities. Inter-
estingly, we found that after doxycycline induction, both E6 and E7 were highly
expressed, resulting in a clear increase in the number of proliferative cells even in
the suprabasal layers, which results in rapid epidermal hyperplasia. However, in
our animal mouse model HPV-16 E6/E7 expression alone was not suffıcient to
induce spontaneous squamous carcinomas (SCC). Due that we decided to chal-
lenge the oncogenic role of HPV using a classical chemical carcinogenesis pro-
tocol (DMBA-TPA). These mice develop SCC rapidly after a single exposure to
a skin carcinogen, DMBA, which was increased by the prolonged exposure to a
tumor promoter, TPA. These data suggest that only few oncogenic hits may be
suffıcient to induce cancer in humans already infected with HPV-16 E6/E7.
Then, we decided to elucidate whether or not a few genomic alterations in com-
bination withHPV-16 expressionmay be suffıcient to induce cancer. One of the
most frequent mutations in HNSCC, including HPV-associated cancers, are
those affecting the PI3K-mTOR pathway. Based on that, we engineered a genet-
ically defıned mouse model combining HPV-16 E6/E7 and PIk3CAH1047R ex-
pression under the control of a cytokeratin 14 promoter driven tamoxifen-reg-
ulated Cre recombinase (cK14-CreERTM). Surprisingly, we found that upon
tamoxifen activation mice develop oral cancer in only few weeks. Furthermore,
our HPV-related cancer mouse models exhibited a marker increase of mTOR
activation which is a key oncogenic driver in malignant progression to SCC.
Remarkably, rapamycin, an mTOR inhibitor, was able to block tumor develop-
ment, supporting the potential clinical use of direct and indirect mTOR inhibi-
tors as a molecular targeted approach for prevention of HPV-associated malig-
nancies.
#4801 Collection of lung cancer patient-derived xenograft (PDX) models
to evaluate precision therapeutic strategies. Sonia Molina-Pinelo,1 Ricardo
Melendez,2 Rocío Suarez,1 Laura García,1 Laura Ojeda,1 Nicolas Moreno,1
María V Guijarro,3 Luis Paz-Ares,1 Irene Ferrer1. 1Unidad de Investigación
Clínica de Cáncer de Pulmón Hospital 12 de Octubre-CNIO, Madrid, Spain;
2Instituto de Biomedicina de Sevilla (IBIS/HUVR/CSIC/Universidad de Sevilla),
Sevilla, Spain; 3Musculoeskeletal and Oncology Lab, Orthopaedics and Rehabili-
tation, University of Florida, Gainesville, FL, USA, Gainesville, FL.
Background: Translational cancer research needs appropriated preclinical
models to discover predictive biomarkers and evaluate precision therapeutic
strategies. Conventional available preclinical models have proven not been op-
timal to this end, since cell lines based xenografts do not reconstitute the com-
plexity of human cancer and carry acquired mutations not found in the original
tumor. For these reasons our aim was generate and completely characterize a
collection of non-small cell lung cancer (NSCLC) PDXmodels useful for trans-
lational lung cancer research. Materials and methods: Resected primary tumors
fromNSCLCpatientswere subcutaneous xenografted in athymic nudemice and
expanded in successive groups ofmice to get a perpetual live bank of each tumor.
Every tumor, which successfully grew in mice, was analyzed by histologic and
molecular techniques (NGS gene panel, exome and RNA Seq). Furthermore, a
bank of frozen pieces of tumor was expanded and stored in order to generate
later cohorts of tumor-bearing mice suitable for preclinical drug evaluation.
Results: Our collection consists on 42 PDXmodels (26 SCC, 12ADC, 3LCC).We
have characterized all of them histologically and molecularly with a 22 genes
NGS panel. Furthermore, we have analyzed the exome and transcriptome of 33
models (20 SCC, 10 ADC and 3 LCC). All PDX models mostly retain the prin-
cipal histologic and molecular characteristics of their donors and recapitulate
the heterogeneity of human lung tumors. In our PDX collection we have suffı-
ciently represented all the NSCLC histology and the most relevant molecular
alterations in lung cancer in order to perform precision medicine evaluation
studies. Conclusions: We have generated a collection of 42 PDX models of
NSCLC characterized at the histological, genomic and transcriptomic level,
which represents the most frequent histological and molecular subtypes of this
type of lung cancer. This collection will be really useful to integrate drug screen-
ing with biomarker discovery and to evaluate precision therapeutic strategies.
Our future aim will be to use this collection for biomarkers identifıcation and
preclinical evaluation of new therapeutic strategies targeted to bad prognostic
lung tumors with suboptimal therapeutic approaches.
#4802 Immunedysfunction and fungal infection contribute to esophageal
carcinogenesis. Feng Zhu,1 Jami Willette-Brown,1 Na-young Song,1 Peilin
Zhang,2 Yinling Hu1. 1NCI, NIH, Frederick, MD; 2PZM Diagnostic, Charleston,
WV.
Human esophageal cancer is the sixth leading cause of cancer death world-
wide. More than 90% of esophageal cancer is esophageal squamous cell carci-
noma (ESCC).While the etiological causes remain unclear, esophageal mucosal
fungal infection is very common in esophageal cancer patients, including pa-
tients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy
(APECED) who have more than 20-fold risk of ESCC when compared to the
healthy population. Here, we report that kinase-dead Ikka knock-inmice (here-
after referred to as mutant mice) develop APECED-like autoimmune disease
due to developmental defects in thymus and lack of central tolerance. Similar to
human APECED patients who develop esophageal mucosal fungal infection on
average at the age of fıve,mutantmice develop fungal infection in oral cavity and
esophagus as early as sevenweeks old. About 20% ofmutantmice develop ESCC
during aging, which exhibits specifıc molecular signatures observed in human
ESCC, such as p16 gene silencing, elevated EGFR phosphorylation and PD-L1
expression, etc. Autoreactive T cell depletion, or central tolerance reconstitution
and/or normal T cell transfer prevents fungal infection and ESCC development
in mutant mice. Importantly, antifungal drug treatment inhibits inflammation
and ESCC development in mutant mice. However, oral inoculation of Clas-
dosporium, one of themajor fungal species isolated frommutantmice, increases
the tumor incidence from 20% to 63% in mutant mice. These results reveal that
immunedysfunction and fungal infection is associatedwithESCCdevelopment,
which sheds new light on ESCC etiological factors, prevention and treatment.
#4803 Over-production of thrombopoietin in the liver of transgenic mice
with liver-specifıc human BrafV600E expression. Hiroki Tanaka,1 Kie Ho-
rioka,1 Masahiro Yamamoto,1 Katsuhiro Okuda,1 Masaru Asari,1 Katsuhiro
Okuda,1 Seiji Ohtani,1 Kosuke Yamazaki,2 Keiko Shimizu,1 Katsuhiro Ogawa1.
1Asahikawa Medical Univ., Asahikawa, Japan; 2Japanese Red Cross Hokkaido
College of Nursing, Kitami, Japan.
TheBrafV637Emutation,which corresponds to the humanBRAFV600Emu-
tation, plays a pivotal role in mouse hepatic carcinogenesis induced by neonatal
treatment with diethylnitrosamine in B6C3F1 mice. We previously established
the transgenic mice that express the human BRAFV600E mutation in the liver
(Mol Carcinog 2016. doi:10.1002/mc22510). The transgenic mice showed 5
folds increase in liver/body weight as compared to normal mice, and their liver
was entirely consisted of small basophilic hepatocytes resemblingDEN-induced
preneoplastic hepatocytes. The transgenicmicewere normally born, butmost of
them spontaneously died during 2-3 months after birth. In this study, we inves-
tigated the reason for spontaneous death in the liver-specifıc BRAFV600E trans-
genic mice. The numbers of platelets and megakaryocytes were remarkably in-
creased respectively in peripheral blood and bone marrow in the transgenic
mice. Furthermore, fragmented red blood cells and activated platelets with en-
larged size were frequently observed in the peripheral blood smear of the trans-
genic mice. Thrombopoietin mRNA was abundantly expressed in the liver of
transgenic mice, and the conditioned-medium of the cultured hepatocytes from
the transgenic mice contained increased amount of thrombopoietin as com-
pared with that of normal mouse hepatocytes. Histopathological analysis re-
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vealed that many platelets were adhered to the sinusoidal walls in the liver of the
transgenic mice. Furthermore, glomerulonephritis associating with platelet de-
position in glomerular capillaries and interstitial pneumonia accompanyingmi-
crothrombosis in alveolar capillaries were also observed. Because platelets have
been shown to promote liver regeneration through interaction with various
hepatic cell components such as hepatocytes, endothelial cells and Kupffer cells,
the platelet accumulation in the liver of the transgenic mice may represent the
stimulation for growth and proliferation of hepatocytes by platelets. On the
other hand, the platelets might cause the renal and pulmonary diseases which
might cause spontaneous death in these mice. Our results indicate that over-
production of thrombopoietin by the BRAF-mutated hepatocytes may create
the macroenvironment that may favor the growth and proliferation of neoplas-
tic hepatocytes.(Supported by the grant from Japanese Ministry of Education,
Culture, Sports, Science and Technology.)
#4804 Sex-specifıc differences in Benzo(a)Pyrene [B(a)P]-induced colon
carcinogenesis. Kenneth J. Harris,1 Kelly L. Harris,1 Mary K. Washington,2
James Amos-Landgraf,3 Aramandla Ramesh1. 1Meharry Medical College, Nash-
ville, TN; 2Vanderbilt University, Nashville, TN; 3University of Missouri, Colum-
bia, MO.
Colorectal cancer (CRC) is the third most common diagnosed cancer and the
third leading cause of cancer-related deaths in the United States. It has also been
reported that colon cancer incidence and mortality rates are higher in men than
woman, but there is yet a determined mechanistic link to show the factors that
underlie the sex-specifıc differences in CRC initiation and progression. Benzo-
(a)pyrene [B(a)P], amember of the polycyclic aromatic hydrocarbon (PAH) family
of compounds is a well-characterized environmental toxicant that has been proven
to be a major contributor to the development of sporadic colon cancer. Published
studies indicate thatArylHydrocarbonReceptor (AhR), a receptor for [B(a)P], bind
to estrogen receptor (ER) and negatively affect AhR-target gene transcription. This
study aims to elucidate the sex-specifıc differences inB(a)P-induced colon cancer in
adult Polyposis In the Rat Colon (PIRC) model. We hypothesize that sex-specifıc
differences in B(a)P biotransformationmodulates the formation of colon tumors in
PIRC rats. Groups of female and male PIRC rats (n  8) received sub-chronic
exposure to 25, 50 and 100gB(a)P/kg bodywt. via oral gavage for 60 days. Female
and male rats that received no [B(a)P] treatment served as controls. [B(a)P] was
showntohavenosignifıcant effectonbodyweightof these rats and femalePIRCrats
that received 25, 50 and 100 g B(a)P/kg body wt. showed signifıcant decrease in
total polyp countwhencompared tomaleswith respective treatments. Polyp sizesof
female PIRC rats receiving 25, 50 and 100 g B(a)P/kg body wt. were increased
when compared to males respectively. Histopathological analysis of colon polyps
revealed that female animals exhibited low-grade to no dysplasia while high-grade
dysplasia was recorded in male animals treated with corresponding doses. Phase 1
enzyme, Cytochrome P450 isoform 1A1 (CYP1A1), and phase 2 enzyme, Sulfo-
transferaseFamily1AMember1 (SULT1A1),weredownregulated incolon tissueof
female PIRC rats receiving 25, 50 and 100g B(a)P/kg bodywt. when compared to
male counterparts. In future studies, by measuring the expression of other phase 1
and phase 2 drug metabolizing enzymes (DME), along with measuring circulating
estrogen levels, analyzing [B(a)P]metabolite profıle, andprobingB(a)P-DNAinter-
actions, we will provide insight into if and how estrogen receptor protects females
from developing colon cancer. This research was funded by NIH grants
5RO1CA142845-04, 5R25GM059994-3, and G12MD007586-29.
#4805 The role of exosomes in fıbrosarcoma progression. Miho Naka-
jima,1 Stephen C. Searles,2 Ayuko Hoshino,1 Katherine M. Offer,1 Candia M.
Kenifıc,1 Jack D. Bui,2 David C. Lyden1. 1Weill Cornell Medical Center, New
York, NY; 2University of California, San Diego, La Jolla, CA.
Among pediatric cancers, sarcomas, especially those with large tumor bur-
dens andmetastatic disease, often result in poor outcome. Thus, new treatments
are urgently needed to inhibit tumor progression, prevent metastasis, and im-
prove overall survival. To understand themechanisms driving sarcoma progres-
sion, we employed two mouse fıbrosarcoma cell lines that display different
growth phenotypes when transplanted into syngeneic immune competentmice.
Progressor fıbrosarcomas evade detection by the immune system and develop
large tumor burdens,while regressor fıbrosarcomas regress shortly after a period
of limited tumor growth. This difference in the growth phenotype ismediated in
part by immune cells, but the mechanisms by which progressor and regressor
cells influence immune cell activity are not fully elucidated. Our research has
focused on exosomes, 50-100 nm secreted nanovesicles, that contain bioactive
cargoes and have emerged asmediators of intercellular communication between
various cells. Here, we hypothesize that fıbrosarcoma exosomes determine the
aggressiveness of the disease by either educating tumor cells themselves or alter-
ing interactions with host cells. To investigate the role of fıbrosarcoma exo-
somes, we fırst educated regressor tumor cells with progressor exosomes for 3
weeks in vitro, and vice versa. Upon in vivo inoculation, progressor cells condi-
tionedwith regressor cell-derived exosomes grew signifıcantly slower compared
to untreated progressor cells. In contrast, regressor cells educated with progres-
sor exosomes did not regress and overgrew signifıcantly compared to untreated
regressor cells. These results indicate that exosomes have an ability to reprogram
a tumor phenotype. To determine if fıbrosarcoma exosomes specifıcally impact
the host, we evaluated whether conditioning naïve mice with progressor exo-
somes alters in vivo growth of regressor tumor cells injected after three weeks of
education. Twenty percent of regressor tumors continued to grow following
progressor exosome education, while all tumors regressed in the control PBS
group. These data suggest that exosomes also play an important role in the
interaction with the host cells influencing tumor growth and disease progres-
sion. Next, to determine which exosomal cargo may mediate these effects, we
sought to characterize the proteome of exosomes from progressor and regressor
cells usingmass spectrometry.We found basigin, also known as CD147, a trans-
membrane embryonic glycoprotein reported to regulate cell proliferation, tu-
mor migration and metastasis as one of the candidate proteins highly expressed
in progressor-derived exosomes. We conclude that exosomes derived from fı-
brosarcoma progresssors and regressors can alter the tumor phenotype both
directly and indirectly. Exosomal cargo, such as basigin, may mediate the ag-
gressive behavior of tumor cells, making it a potential therapeutic target to in-
hibit fıbrosarcoma progression.
#4806 Strategies to overcome the heterogeneity of tumor cells in breast
cancer therapy. Gloria M. Calaf,1 Marcela Gallardo,1 Debasish Roy,2 Richard
Ponce-Cusi1. 1Universidad De Tarapaca, Arica, Chile; 2The City University of
New York, United States, NY.
Breast carcinogenesis is a multistage process that involves mutations and altera-
tions attributed to exposure to exogenous environmental substances and endoge-
nous agents as female hormones. To overcome the heterogeneity of tumor cells in
breast cancer therapy several strategies must be considered from the bench to clin-
ical settings. It is proposed four strategies: Analysis to determine 1) Apoptosis, 2)
Epithelial-mesenchymal transition (EMT), 3) CD44/CD24 gene and protein ex-
pression in cells derived from mammospheres and 4) MicroRNAs as miR34a and
others by the effects of chemotherapeutic drugs (as pamidronate (Pam), 5-Fluorou-
racil (5-FU) and antioxidants asCurcumin (Cur) (diferuloylmethane) derived from
Curcuma longa. Pam, a bisphosphonate is used in the treatment of breast cancer.
5-FU is a chemotherapeutic agent for the treatment of a variety of solid cancers that
arrest cell cycle and induce apoptosis in cancer cells. We evaluated genes and pro-
teins targeted by these drugs and antioxidants in a triple positive cell line, as MCF7
and a negative, MDA-MB-231 for hormonal receptors, respectively and in an in
vitro breast cancer model induced by radiation and estrogen that was developed
with a normal immortalized breast epithelial cell line, MCF-10F exposed to low
dosesofhighLET(linear energy transfer) alphaparticles (150keV/m)of radiation,
and cultured in presence of 17-estradiol. We used: i) MCF-10F, ii) Alpha3, a ma-
lignant non-tumorigenic, iii) Alpha5, a tumorigenic one and iv) Tumor2 cell line
derived fromAlpha5 injected into thenudemice. Previous results showed increased
cell proliferation, anchorage independency, invasive capabilities and tumor forma-
tion in nude mice, microsatellite instability and loss of heterozygosity in chromo-
somes 6, 8, 11 and 17 andmutations of c-Ha-ras andRho-A inAlpha5 andTumor2
compared to the control MCF-10F and their counterparts. Pam, 5-FU and Cur
inhibited migration and invasion in both cell lines, and also decreased c-Ha-ras,
Rho-A, p53, and Cav-1 gene expression by RT-qPCR. These compounds also in-
duced1) apoptotic effect onBcl-xLandBaxgeneandproteinexpressionandby flow
cytometry; 2) changes in EMT markers such as Snail, Slug, Axl, 3) CD44/CD24
alterations and 4) targetMicroRNAs asmiR34a on different process. It can be con-
cluded that strategies to overcome the heterogeneity of tumor cells can be used to
interfere with genes involved in critical steps in breast carcinogenesis. Grant: Tara-
pacáUniversity, Arica, Chile (GMC). Short tittle: Strategies in breast cancer therapy
#4807 Brafmutations initiate the development of rat gliomas induced by
postnatal exposure to N-ethyl-N-nitrosourea (ENU). Kaishi Satomi,1 Qi
Wang,2 Ji Eun Oh,1 Barbara Hutter,2 Benedikt Brors,2 Nicolle Diessl,3 Hai-Kun
Liu,2 StephanWolf,2 Otmar Wiestler,4 Paul Kleihues,5 Bernd Koelsch,6 Andrea
Kindler-Rohrborn,6 Hiroko Ohgaki1. 1International Agency for Res. on Cancer,
Lyon, France; 2German Cancer Research Center (DKFZ), Heidelberg, Germany;
3High Throughput Sequencing, DKFZ, Heidelberg, Germany; 4Helmholtz-
Gemeinschaft Deutscher Forschungszentren, Berlin, Germany; 5University of Zu-
rich, Zurich, Switzerland; 6University Hospital Essen, Essen, Germany.
Purpose: A single dose of N-ethyl-N-nitrosourea (ENU) during late prenatal or
early postnatal development induces a high incidence of malignant schwannomas
and gliomas in rats. Although T -Amutations in the transmembrane domain of
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the neu (c-ErbB-2) gene are the driver mutations in ENU-induced malignant
schwannomas, the molecular basis of ENU-induced gliomas was unknown. The
objectives of this study were to identify driver mutations in ENU-induced rat glio-
mas.Methods:Weperformedwhole-genome sequencingof gliomas that developed
in three BDIV and two BDIX rats exposed to a single dose of 80 mg ENU/kg body
weight on postnatal day one. Results: T:A-A:T and T:A-C:Gmutations, which
are typical forENU-inducedmutagenesis,werepredominant (41-55%ofall somatic
single nucleotide mutations). T-Amutations were detected in all 5 rat gliomas at
Braf codon 545 (V545E), which corresponds to the human BRAF V600E. Addi-
tional screening revealed that 33 gliomas in BDIV rats and 12 gliomas in BDIX rats
all carried a Braf V545E mutation, while peritumoral brain tissue of either strain
(n16) had the wild-type sequence. The gliomas were immunoreactive to BRAF
V600E antibody. Conclusions Braf mutation is a frequent early event in the devel-
opment of rat gliomas caused by a single dose of ENU.
#4808 Effect ofMerkel cell polyomavirus large and small T-antigen on the
thrombospondin and the periostin promoter. Aelita Konstantinell, Ida Sofıe
Furuholmen, Baldur Sveinbjørnsson, UgoMoens. The Arctic University of Nor-
way, Tromsø, Norway.
Merkel cell carcinoma (MCC) is a rare, but aggressive form of skin cancer
with rising incidence and high mortality rate. Approximately 80% of MCC
tumors are positive for Merkel cell polyomavirus (MCPyV), suggesting a
causative relationship between MCPyV and MCC. Exosomes are 30-150 nm
vesicles that contain proteins, lipids, mRNAs, lncRNAs, and miRNAs. Exo-
somes from virus-infected cells comprise also viral nucleic sequences and
proteins. Because tumor cell-derived exosomes may contribute to cancer, we
hypothesized that MCPyV may affect the composition of exosomes and play
a role in tumorigenesis. Therefore, we compared the proteins in exosomes
produced by MCPyV-positive MKL1 and MKL2 and MCPyV-negative
MCC13 and MCC26 MCC cell lines. Our proteomic analysis of exosomes
originating from polyomavirus-negative and polyomavirus-positive MCC
cell lines revealed the presence of the oncogenic proteins periostin and
thrombospondin. Western blot analysis of exosomes and lysates of these
MCC cells confırmed the presence of these proteins in exosomes from all cell
lines. Thrombospondin, but not periostin was detectable in cell lysates, and
an enrichment of both proteins was detected in exosomes of all cell lines. The
effect of MCPyV large T-antigen (LT-ag) and small t-antigen (st-ag) on the
periostin and thrombospondin promoters was examined by transient trans-
fection studies with luciferase reporter plasmids. Transfection experiments
in MCC13 revealed that LT-ag, but not st-ag signifıcantly increased the ac-
tivity of the thrombospondin and periostin promoters. In MCC26 cells, nei-
ther LT-ag nor st-ag had a signifıcant effect on the thrombospondin pro-
moter activity, while both proteins alone or in combination signifıcantly
stimulated the periostin promoter strength. Our results suggest that MCPyV
proteins may contribute to tumorigenesis by enhancing the expression of the
oncoproteins thrombospondin and periostin and promote their secretion
via exosomes.
#4809 Development ofmouse brain tumormodel using in vivo electropo-
ration and piggyBac system. Nobuyuki Onishi, Sampetrean Oltea, Hideyuki
Saya. Keio University School of Medicine, Tokyo, Japan.
Glioblastomamultiforme (GBM), is one of themost malignant brain tumors,
has highly-proliferative and invasive characters. There is no established effective
therapy for GBM possess radio- and chemo-resistance. To comprehend these
malignant characters of GBM, an appropriate model of brain tumor is required.
INK4A/ARF loss of function and activation of RAS-related signaling pathways
are frequently ovserved in GBM. Neural stem cells (NSCs), having self-renewal
and multipotent abilities, are considered one of the cells-of-origin of GBM.
Previously, we have established a stable mouse models of brain tumors, trans-
planting the genetically modifıed NSCs. The NSCs derived from Ink4a/Arf KO
mice, transduced activated-RAS, rapidly formed highly proliferative and inva-
sive brain tumors. Recently, for the purpose of reproducing the clinical tumor
initiating process, we are developing the in vivo carcinogenesis model of mouse
brain tumors by having the genetic engineering in mouse brain directly. Using
the combination of in vivo electroporation and piggyBac system, activated-RAS
and shInk4a/Arf are introduced into NSCs genome in mouse brain, leading to
formed brain tumors having an equally malignant behavior as the transplanta-
tionmodel. Histological characteristics of these tumors resembled humanGBM
phenotype demonstrating necrosis, perivascular cuffıng and giant cell forma-
tion. Immunohistochemical analysis displayed that tumors were proliferation
markerKi-67 highly positive andhadheterogeneity, expressing stem cellmarker
Nestin or astrocyte marker Gfap. On the basis of these fındings, we propose this
in vivo carcinogenesis technique is effıcient method to generate appropriate
mouse brain tumor models.
#4810 Loss of Cav-1 is associated with manifestation of stem cell-like
properties via Src-mediated phosphorylation in human breast MDA-MB-
231 cancer cells.Hyo-JinYoon,1Do-HeeKim,1 Young-NamCha,2 Young-Joon
Surh1. 1College of Pharmacy, Seoul National University, Seoul, Republic of Korea;
2College of Medicine, Inha University, Incheon, Republic of Korea.
A subpopulation of cancer cells, termed cancer stem cells (CSCs), has self-
renewal and differentiation potential, which contributes to cancer recurrence
and tumor resistance. Caveolin-1 (Cav-1), the major structural protein of flask-
shaped plasma membrane invaginations called caveolae, functions as a tumor
suppressor or an oncogene depending on the tumor type and the grade. Cave-
olae participate in various cellular functions, such as vesicle traffıcking, choles-
terol homeostasis, signal transduction, and tumor progression. In the present
study, we investigated the role of Cav-1 on the stemness of human breast cancer
(MDA-MB-231) cells. A sphere formation assay has been widely used to enrich
for CSCs through serial passaging. A level of Cav-1 protein expression decreased
in third-generationmammospheres as compared to parentMDA-MB-231 cells.
Under the same experimental conditions, however, there was no concurrent
decrease in the Cav-1 mRNA level. Therefore, it is likely that stability of Cav-1
protein is decreased during mammosphere formation. Recently, it has been
reported that sustained phosphorylation of Cav-1 promotes its ubiquitination
and degradation by the proteasomes. We observed that PP2, an inhibitor of Src,
suppressed phosphorylation of Cav-1 inMDA-MB-231-derivedmammosphere
cells, which in turn increases its protein stability. Breast CSCs are enriched in
cells with enhanced expression of phenotypic markers, such as CD44/CD24-.
We found that Cav-1 gene silencing using siRNA enhanced the proportion of
CD44/CD24- MDA-MB-231 cells. In addition, Cav-1 knockdown increased
the number and the size of secondary mammospheres, and this was accompa-
nied by enhanced expression of Bmi-1 and Sox-2, which are representative self-
renewal markers. Moreover, epithelial-mesenchymal transition (EMT) was de-
creased by knockdown of Cav-1 in MDA-MB-231 cells. Taken together, these
fındings suggest that loss of Cav-1 protein stability facilitates the formation of
mammospheres through upregulation of self-renewal and EMT markers in
breast CSCs.
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#4811 XenoSarc: Patient-derived xenograft (PDX) models of soft tissue
sarcoma (STS), an update on a preclinical platform for early drug testing.
Agnieszka Wozniak,1 Jasmien Cornillie,1 Yemarshet K. Gebreyohannes,1 Jas-
mien Wellens,1 Lise Vreys,1 Daphne Hompes,2 Marguerite Stas,2 Friedl Sin-
naeve,2 Maria Debiec-Rychter,1 Raf Sciot,1 Patrick Schöffski1. 1KU Leuven and
University Hospitals Leuven, Leuven, Belgium; 2University Hospitals Leuven,
Leuven, Belgium.
Background: STS constitutes a rare and very heterogeneous family of mesen-
chymal tumors. The limited treatment options available for advanced STS un-
derline the need for reliable preclinical models to test novel therapeutic strate-
gies. Methods: A panel of patient-derived xenografts (PDX) was established by
subcutaneous implantation of fresh, surgically resected or biopsied tumor spec-
imens in immunodefıcient, athymic nude NMRI mice. Once tumor growth was
observed, pieces of tumor were re-transplanted to next generations of mice. At
each passage tumor fragments were collected for histopathological and molec-
ular characterization. Amodel was considered established after observing stable
histological and molecular features for at least two passages. Results: Until now
171 STS samples from consenting patients treated at the University Hospitals,
Leuven, Belgium, have been transplanted. Twenty-eight well-characterized, sta-
ble PDXmodels of STS have been established,maintaining the histopathological
and molecular features of the original tumor. The detailed clinical information
about a donor patient, including sensitivity to standard and experimental drugs,
is linked to everymodel. At this point the XenoSarc platform includesmodels of
gastrointestinal stromal tumor (6 models), myxofıbrosarcoma (6), dedifferenti-
ated liposarcoma (3), malignant peripheral nerve sheath tumor (3), synovial
sarcoma (1), leiomyosarcoma (4), epithelioid haemangioendothelioma (1),
mesenchymal chondrosarcoma (1), pleomorphic rhabdomyosarcoma (1) and
high-grade undifferentiated pleomorphic sarcoma (2). From these models we
have also available tissue microarray (TMA) as well as data on genomic and/or
expression profıle including mutations (by RNA-Seq). Some of these models
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have already been successfully used for in vivo testing of novel agents, including
both targeted and cytotoxic (pro-)drugs, and results served as a rationale for
several prospective clinical trials. In addition, 24 other xenografts are still in early
stages of engraftment, not yet fulfılling our criteria of an “established model”.
Conclusion: Our XenoSarc platform contains a number of well-annotatedmod-
els, characterized by stable histological and molecular features. This platform is
a reliable tool for the evaluation of new anticancer treatments for STS and for
studying the biology of these rare diseases. The platform is made available to
collaborators from academia and industry.
#4812 A novel set of patient-derived orthotopic xenograft (PDOX) mod-
els of primary and recurrent intracranial meningioma.Huiyuan Zhang,1 Lin
Qi,1 YuchenDu,1 FrankK. Braun,1Mari Kogiso,1 Sibo Zhao,1 Holly B. Lindsay,1
Sarah G. Injac,1 Patricia A. Baxter,1 Jack M. Su,1 Akash J. Patel,2 Xiao-nan Li,1
Baylor College ofMedicine. 1Texas Children’s Cancer Center, Houston, TX; 2Jan
and Duncan Neurological Research Institute, Houston, TX.
Background: Meningioma is the most common brain tumors in adults. De-
spite the overall benign nature of meningioma, cranial-base tumors are diffıcult
to achieve complete resection while others exhibit progression and aggressive
profıles characterized by high recurrence rates, pleomorphic histology, and re-
sistance to standard treatment. The lack of clinically relevant animal models is
blocking the development of novel therapies. Here, we report our establishment
of orthotopic xenograftmousemodels and in vitro culture systems from surgical
specimens of primary and recurrent meningiomas. Material and Methods: 6
primary surgical samples (3 WHO grade I and 3 atypical), and 4 recurrent
samples (1 WHO grade I, 2 atypical and 1 anaplastic meningiomas) were ob-
tained from meningioma patients. Tumor tissues were dissociated into single
cells and directly implanted into right cranial base of NOD/SCID mice (1x105
cells/mouse). Primary cultures were initiated in serum-free and traditional FBS-
based media. Tumor growth was monitored by small animal MRI. Pathologic
features of the PDOX models and the matched patient tumors were compared
with standard H&E and immunohistochemical staining. Molecular fıdelity of
PDOX tumorwas examined through genomic analysis and comparisonwith the
parental tumors. Results: Three of the 10 tumors were not tumorigenic, and
xenograft tumor formation from 5 additional samples is pending. Growth of
intracranial (cranial base) xenograft was confırmed in two samples derived from
the samepatient diagnosed as atypicalmeningioma (K029MEN) andprogressed
as anaplastic meningioma at recurrence (K037MEN). These patient derived or-
thotopic xenografts (PDOX) have since been serially subtransplanted in mouse
brains for generation 2 and can be cryopreserved for long-termmaintenance of
tumorigenicity. The xenograft tumors replicated histopathological features (in-
vasion, high proliferation and increased microvessel density) of their parental
tumors. Genomic analysis is being performed to examine the similarities be-
tween parental tumors and the corresponding orthotopic xenograft tumors and
the discrepancies between the primary and the recurrent tumor-derivedmodels.
In vitro growth of K029MEN and K037MEN as neurospheres and monolayer
weremaintained for 2months and passage for 10 times. Additionally, cells from
K030MEN, a WHO grade I meningioma, has been passaged as monolayer for
more than 30 times. Conclusion: A novel set of meningioma PDOX models
derived frommatching primary and recurrent tumorwas established. The xeno-
graft tumors replicated the histopathological and key molecular features of the
original patient tumors, providing a unique opportunity to understand the bi-
ology of malignant meningiomas and to conduct preclinical drug testing.
#4813 In vivo modeling of high grade glioma for oncology drug develop-
ment. Cecilia Krona, Soumi Kundu, Karl Holmberg-Olausson, Riasat Islam,
Rashmi Ramachandra, Ludmila Elfıneh, Sven Nelander. Uppsala Univ., Upp-
sala, Sweden.
In a multi-disciplinary project, patient derived glioblastoma stem-cell cul-
tures (GSCs) have been established and characterized extensively with the goal
of applying computational efforts to integrate results from high-throughput
screens of drugs andRNAiwith genomic and transcriptional profıling to predict
themost successful therapy for individual glioma patients. Themain goal of this
studywas to develop a platform for testing the tumor-initiating capacity ofGSCs
in mouse brain and to label the cells with GFP-luciferase to enable non-invasive
quantifıcation of tumor growth by in vivo bioluminescence imaging. Adherently
grown GFP-luciferase labeled glioblastoma stem-cell cultures were dissociated
and injected stereotactically into immunodefıcient mice. Tumor growth was
monitored by IVIS imaging for up to 40 weeks and brains were collected for
histopathological and immunohistochemical stainings. Automatic quantifıca-
tion and growth pattern analysis of tumor cells in brain sectionswas set up based
on human cell specifıc staining and a CellProfıler Analyst’s machine learning
classifıer with amanual observer correlation of 0.86. GSC xenograft tumors with
a wide range of histopathological features and biological behaviors recapitulat-
ing high grade astrocytoma was confırmed in mice injected with 14 of the 29
glioblastoma cell cultures (48%). Glial lineagemarkers, such as Sox2, GFAP, and
Olig2, were expressed both in patient tumors and patient derived xenografts.
Individual glioblastoma cell cultures were either characterized by formation of
condensed tumors (8/14, 57%) or diffuse infıltrative growth through the brain
parenchyma (6/14, 43%). In summary, we present a valuable mouse model for
preclinical studies of glioma. Integrative analysis of molecular profıles with
growth pattern data has the potential to unravel genes that distinguish tumors
with more infıltrative growth. Our biobank of luciferase labeled GSCs may be
useful for longitudinal monitoring of tumor growth dynamics in the setting of
therapies and provides a foundation for testing the effect of predicted drug
vulnerabilites in orthotopic xenografts mouse models.
#4814 Testing personalized therapies for ovarian cancer using mate pair
genomic analysis and patient-derived xenografts. Konstantinos Leventakos,
Faye R.Harris, Lin Yang, XiaonanHou, SaravutWeroha, IrinaV. Kovtun.Mayo
Clinic, Rochester, MN.
Purpose: The treatment of ovarian cancer poses a challenge since 70% of
patients will relapse with incurable platinum resistant disease. Although ovarian
cancers lack frequently-occurring driver mutations or amplifıcations, the study
presented herein examines the concept of individualized therapy based onmate
pair sequencing and protein expression in ovarian cancer patient-derived xeno-
grafts. Experimental Procedure: Macrodissection of patient tumor was followed
by genomic DNA isolation and next-generation sequencing using an Illumina
Mate Pair protocol to identify structural genomic changes and copy number
variations. Secondary analyses were carried out to select potential therapeutic
targets among those. The tumors were also propagated intraperitoneally in im-
munocompromised mice and treated with standard chemotherapy or/and tar-
geted therapy chosen based on genomic analyses. Results: Mate pair analysis
revealed that, in general, copy number changes (amplifıcations, gains and losses)
were common in ovarian tumors and included genes potentially targetable. Tu-
mors from early generation patient- derived xenografts showed a landscape of
genomic aberrations identical to that of original patient tumor. One PDXmodel
in which high expression of HER2 and copy number gains at RICTOR andAKT
genetic loci were revealed, was treated with either chemotherapy and Pertu-
zumab/trastuzumab (HER2 inhibitors), MK-8669 (mTOR inhibitor) or MK-
2206 (AKT inhibitor) or chemotherapy alone. Tumor size was measured by
serial abdominal ultrasound and after 28 days, the fınal tumor size ratio com-
pared to baseline was 0.23, 0.36, 0.55 and 0.56, respectively, indicating that the
best response was seen in the combined chemotherapy and Pertuzumab/trastu-
zumab cohort and that was better than in the chemotherapy only cohort. Con-
clusions: Patient-derived xenografts models in conjunction with genomic and
protein analyses of patient tumors are valuable for testing of combination ther-
apies including specifıc targeting drugs. This approach also provides actionable
information for more tailored treatment of ovarian cancer patients.
#4815 Humanized single mouse trial: A preclinical platform feasible for
immune-oncology drug screening and translational biomarker develop-
ment.Daniel Bug,1 Eva Oswald,2 Anne Grote,3 Anne-Lise Peille,2 Gabriele Nie-
dermann,4 Dorit Merhof,1 Friedrich Feuerhake,3 Julia B. Schüler2. 1RWTH
Aachen University, Aachen, Germany; 2Oncotest GmbH, Freiburg, Germany;
3Hannover Medical School, Hannover, Germany; 4Medical Center Freiburg,
Freiburg, Germany.
The fıeld of cancer immunology is rapidly moving towards innovative thera-
peutic strategies. As a consequence the need for robust and predictive preclinical
platforms arises just as well. The current project aims to establish a drug screen-
ing workflow bridging between innovative mouse models and clinical bio-
marker development. A total of 69NOG (NOD/Shi-scid/IL-2Rnull)mice were
engrafted with CD34 hematopoietic stem cells. Thereafter, tumor material
from 11 different lung cancer patient derived xenograft models (NSCLC PDX)
was implanted subcutaneously. Individual mice were treated with -CTLA-4,
-PD-1 or the combination thereof.With n1 per treatment armandmodel the
study design followed the screening approach of the single mouse trial (SMT).
Infıltration of human immune cells was detected by flow cytometry (FC) and
immunohistochemistry (IHC) in hematopoietic organs and tumor tissue. A
computerized analysis for digitized whole-slide images of the samples was used
to quantify the lymphocyte infıltration using color classifıcation and morpho-
logical image processing techniques. All 3 treatment arms displayed a discrete
activity pattern throughout the PDX panel. Tumor models with high tumor
infıltrating lymphocyte (TIL) rates in the donor patient material tended to be
more sensitive towards checkpoint inhibitor treatment asmodels with low rates.
Numbers of TILs in the PDX detected by FC and IHC were signifıcantly in-
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creased in the treatment groups as compared to control vehicle. In parallel,
hematopoietic organs showed high (25%) amounts of huCD45 cells in all
groups and models. PDX models being sensitive towards checkpoint inhibitor
treatment (responders) displayed a higher percentage of DAB nuclei in
huCD45 IHC stains than non-responder models as determined by image anal-
ysis. Irrespective thereof, in responders as well as non-responders the treatment
with checkpoint inhibitors enhanced the percentage of DAB nuclei. Whole-
slide image analysis of the H&E stains revealed an increase of the stromal com-
partment proportion in the tumor tissue under treatment with checkpoint in-
hibitors in respondermodels. In non-respondermodels the ratio between tumor
and stroma was not influenced by drug treatment. The use of PDX based hu-
manized mouse models in a SMT format allows screening approaches in com-
plexmousemodels. The combination with a comprehensive image analysis tool
enables additional read-outs to quantify antitumoral activity of immune mod-
ulatory compounds. The latter can be used to identify possible biomarkers in the
preclinical setting. Moreover, the translation and validation of these biomarker
candidates in a clinical setting is self-evident as primary material needed for
these types of analyses is easily accessible.
#4816 Circulating tumor cell monitoring, isolation, and culture from a
patient with metastatic triple-negative breast cancer for drug screening and
creation of a patient-derived xenograftmodel.ArturoB. Ramirez,1 CAnthony
Blau,2 Timothy J. Martins,2 ElisabethMahen,2 Lacey E. Dobrolecki,3 Michael T.
Lewis,3 Jackie L. Stilwell,1 Eric P. Kaldjian1. 1RareCyte, Inc., Seattle, WA; 2Uni-
versity of Washington, Seattle, WA; 3Baylor College of Medicine, Houston, TX.
Background. Enumeration, phenotyping and single cell genomics of circu-
lating tumor cells (CTCs) provide three types of information to guide cancer
therapy. In some instances, a fourth type is possible: functional analysis in vitro,
or in in vivo patient-derived xenografts (PDXs). We used a density-based rare
cell separation and analysis system to collect CTCs from the blood of a patient
with metastatic triple-negative breast cancer (TNBC) for in vitro culture and
high-throughput drug screening and to generate a PDX model. Methods: The
patient was enrolled in the ITOMIC-001 study (University of Washington) and
after informed consent, CTCs were evaluated prior to initial cisplatin treatment
and tracked longitudinally using the AccuCyte – CyteFinder system (RareCyte).
Samples containing high numbers of CTCs were placed into 3 different culture
media. Cells grown in culture were tested against a panel of anti-cancer drugs
and injected into mice to form a PDX model. Results: Nine CTC evaluations
were performed over 9.5 months. CTCs were verifıed by expression of epithelial
(cytokeratin and/or EpCAM) and nuclear stains without CD45 expression. Af-
ter initial treatment with cisplatin, the CTC count per 7.5 mL rose from 4 to 19
cells at 3 months, consistent with the lack of a clinical response, and decreased
after LE 011 (CDK4/6 inhibitor) and then glembatumumab vedotin (anti-
gpNMB) to 8 and 4 cells at 5 and 7 months respectively. At 9 months the CTC
count rose to 13,000 and 5 days later to 80,000 shortly before her death. At
autopsy there wasmassive infıltration of the liver and pulmonary vasculature by
tumor cells. Cultures in all media showed initial growth, but only one (RPMI
10% serum) was sustained, forming semi-adherent 3D tumor clusters. 6 million
cells were harvested and a drug screen using 160 anti-cancer agents was per-
formed. The CTC line showed sensitivity to several agents. Cells were also in-
jected into the mammary fat pad of immunodefıcient mice. In at least one
mouse, macroscopic tumors were observed. The CTC cell line has grown con-
tinually in culture for over a year. Aliquots of this cell line have been frozen and
thawed with no noticeable effect on cell growth. Conclusions: Using a density-
based rare cell collection system, we have established a CTC cell line from a
TNBC patient with extremely high CTC counts. The line was used to perform a
screen for agents active against the tumor cells and to create a PDXmodel. As in
vitro techniques advance, smaller number of CTCs may be effectively cultured
and thus allow this approach to be used in real time to fınd effective drug regi-
ments for individualized cancer therapy.
#4817 Regression of malignant ascites via PAPP-A inhibition in ovarian
cancer patient-derived xenograft model. Valentina Zanfagnin, Laurie K. Bale,
Marc A. Becker, Xiaonan Hou, Diogo Torres, Cheryl A. Conover, Saravut J.
Weroha.Mayo Clinic, Rochester, MN.
Malignant ascites is one of themost common causes ofmorbidity in end stage
ovarian cancer patients with negative impact on quality of life. Novel non-inva-
sive palliative therapeutic options are lacking for such patients. The zinc metal-
loprotease, pregnancy-associated plasma protein-A (PAPP-A), plays a key role
in the insulin-like growth factor (IGF) pathway, promoting ovarian cancer cel-
lular transformation, growth and invasiveness. Furthermore, patient primary
malignant ascites is known to contain high levels of PAPP-A by ELISA. Prelim-
inary data shows that inhibition of PAPP-A through a neutralizing monoclonal
PAPP-Aantibody (mAb-PA) inhibits the accumulation andpromote the regres-
sion of ascites in an ovarian cancer patient-derived xenograft (PDX) models. In
the current study, we investigated whethermAb-PA can promote ascites regres-
sion in an additional ovarian PDX model with measurable ascites. Patient de-
rived ascites xenograft (PDAX) models were defıned as SCID mice that devel-
oped ascites after intraperitoneal heterotransplantation of patient solid tumor
collected at the time of primary cytoreduction. Ascites from these models
(n51) was screened for human PAPP-A protein by ELISA and models were
divided into two groups by the relative concentration of PAPPA-A: high (n18)
and low (n33). PAPP-A High PDAX model PH438 was re-established intra-
peritoneal in 20 SCIDmice by ascites injection (0.1ml permouse).When ascites
area reached a threshold of 0.60 cm2 by ultrasound, mice were treated with
60mg/KgofmAb-PA (n10) or IgG2a control (n10) onday one and three.On
day four, a second ultrasound measurement was obtained and the mice were
euthanized. Ascites burden was measured at necropsy. Personnel involved with
the acquisition of ultrasounds measurements, subsequent ascites harvests, and
post hoc analyses were blinded to the treatments. The ratio of mean ascites
(mAb-PA/IgG2a in grams) collected at necropsy was 2.04/2.51, indicating that
the mAb-PA arm had less ascites compared to control. These data were consis-
tent with pre- and post-treatment ultrasoundmeasurements of ascites burden; a
statistically signifıcant (p0.0283 by paired t test) reduction of ascites burden of
52.3%was observed, compared to the starting baseline, indicating that mAb-PA
treatment causes ascites regression. Ascites weight at necropsy was compared to
the area of greatest fluid echogenicity by ultrasound and the Pearson correlation
R value achieved was of 0.859 (p0.0001). These PDAX data implicate PAPP-A
attenuation as a potential strategy to treat malignant ascites in OC. Additional
PDAXmodels are under examination to confırm these fındings and support the
translational development of PAPP-A as a new therapeutic target for women
with refractory ascites.
#4818 Neratinib/fulvestrant but not fulvestrant alone maintain complete
responses after treatmentwith trastuzumab/paclitaxel ofmice bearing ER/
HER2 xenografts. Luis J. Schwarz,1 Sarah E. Croessmann,1 Francesca
Avogadri-Connors,2 Richard E. Cutler,2 Alshad S. Lalani,2 Carlos L. Arteaga1.
1Vanderbilt University Medical Center, Nashville, TN; 2Puma Biotechnology,
Inc., CA.
Background: Neratinib is a potent, irreversible pan-HER tyrosine kinase in-
hibitor. The phase III trial ExteNET showed improved disease-free survival of
neratinib vs placebo in early-stage HER2 breast cancer patients (pts) after
trastuzumab-based adjuvant therapy. This benefıt from neratinib was greater in
ptswith hormone receptor (HR) tumors. Based on these fındings, we sought to
establish a human-in-mouse model that would simulate this clinical trial and
outcome, thus providing a platform for mechanistic investigation. Methods:
ER/HER2-amplifıed MDA-361 cells were injected subcutaneously (SC) into
5-week-old female athymic mice without estradiol supplementation. Mice with
tumors 250 mm3 were treated with trastuzumab (tz) 20 mg/kg  paclitaxel
(pac) 15 mg/kg IP twice weekly for 4 weeks, and then randomized to fulvestrant
(fulv) SC 5mg/week	 neratinib 20mg/kg/day by orogastric gavage for 4 weeks.
Results: Xenografts in all 20 mice showed a prompt and marked reduction in
volume after tz/pac treatment; 10 mice achieved a complete response (CR) be-
fore receiving ’extended adjuvant’ therapy with fulv (n5) or neratinib/fulv
(n5). A CR was maintained with neratinib/fulv following tz/pac, whereas tu-
mors rapidly recurred inmice treated with fulv alone (p0.05 at week 8; Table).
Immunoblot analysis of MDA-361 tumors recurring on fulv showed almost
complete downregulation of ER levels.
Timepoint Treatment
Mean ( SD) tumor volume, mm3
(% change from baseline)
Trastuzumab
paclitaxel ¡
fulvestrant(n5)
Trastuzumab
paclitaxel ¡
fulvestrant
neratinib(n5)
Baseline Treatment start 163.4	 52.9 (–) 187.1	 73.1 (–)
Week 4 Trastuzumab paclitaxel 8.6	 12.0 (–96.1) 9.8	 10.5 (–93.9)
Week 8 Fulvestrant	 neratinib 814.0	 435.1 (401.5) 2.0	 4.5 (–98.8)*
*p0.05 between groups (Student’s t-test). SD, standard deviation
Conclusions: Neratinib/fulvestrant but not fulvestrant alone maintained com-
plete tumor responses following initial treatment with tz/pac; recapitulating the
design and outcomes observed in the HR subgroup of the ExteNET trial. The
experimental model used herein provides a platform for investigation of the
underlying mechanisms for the fındings in ExteNET. Experiments evaluating
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ER gene signatures and expression levels, as well as the effects of neratinib 	
fulvestrant following initial adjuvant pertuzumab/trastuzumab/paclitaxel are
underway.
#4819 Insights from engraftable immunodefıcient mouse models of hy-
perinsulinaemia. Michelle L. Maugham,1 Patrick B. Thomas,1 Gabrielle J.
Crisp,1 Lisa K. Philp,1 Esha T. Shah,1 Adrian C. Herington,1 Chen Chen,2 Laura
S. Gregory,1 Colleen C. Nelson,1 Inge Seim,1 Penny L. Jeffery,1 Lisa K. Chopin1.
1Queensland University of Technology, Brisbane, Australia; 2University of
Queensland, Brisbane, Australia.
Hyperinsulinemia, obesity and dyslipidemia are independent and collective risk
factors formany cancers, however, there is a lack of suitablemousemodels available
to study this association. We examined the long-term effects of a “Western style”
23% high fat diet (HFD, 46% of total calculated energy from lipids) in two immu-
nodefıcient mouse strains (NOD/SCID and Rag1 -/-) suitable for engraftment with
human-derived cell lines and tissue xenografts.HFD-fedmice of both strains exhib-
ited diet-induced impairments in glucose tolerance at 16 and 23 weeks post initia-
tion of HFD feeding. Only Rag1 -/- mice developed higher fasting insulin levels
(2.16	 1.01ng/ml versus 0.71	 0.12ng/ml, P 0.01) and increased insulin resis-
tance (6.70 	 1.68 HOMA-IR, versus 2.91 	 0.42, P  0.01) when fed a HFD.
Similarly, hepatic steatosis was more extensive, and intramyocellular lipid storage
was increased in HFD-fed Rag1 -/- mice. Conversely, NOD/SCID mice exhibited
relatively low levels of steatosis and no intramyocellular lipid was observed. These
data suggest that Rag1 -/- mice are amore suitable pre-clinical model for examining
the interactions between hyperinsulinemia, obesity and hyperlipidemia and cancer
than themore commonly usedNOD/SCIDmousemodel.Wenext investigated the
growth of human prostate cancer cell lines (PC3 and LNCaP) subcutaneously in-
jected into hyperinsulinemic Rag1 -/- mice. Compared to normal chow-fed mice,
tumor growth velocity was greater in HFD-fed mice with PC3 and LNCaP xeno-
grafts, andmice reached humane endpoints (cancer-associated cachexia and tumor
burden) signifıcantly earlier (P 0.0078 and P 0.031). Strikingly, HFD-fedmice
bearing PC3 xenografts presented with signifıcantly greater normalized wet tumor
weight (485.16 	 143.80% vs. 1562.69 	 338.20%, P  0.032), tumor volume
(485.16	 143.80% vs.1562.69	 338.20%, P 0.032) and number of Ki67 positive
(proliferating) tumor cells (36.08	 2.53% vs. 66.14	 8.514, P 0.032), compared
to mice fed a normal chow diet. In summary, this is the fırst study of the metabolic
effects of a long-term “Western style” HFD in two immunodefıcient mouse strains
suitable for xenograft studies.We demonstrate that the Rag1 -/- mouse is an appro-
priate and novel model for studying the interactions between hyperinsulinaemia
and cancer.
#4820 Developing a xenograft human tumormodel in immunocompetent
mice. Matthew T. Basel, Sanjeev Narayanan, Chanran Ganta, Tej B. Shrestha,
Marla Pyle, Stefan H. Bossmann, Deryl L. Troyer. Kansas State Univ., Manhat-
tan, KS.
Animalmodels are essential to preclinical cancer research and are used clinically
to determine optimal treatment regimens, but current xenograftmodels are limited
in their utility, especially due to the lack of a competent immune system. Here we
demonstrate that a xenograft tumormodel can be developed in immunocompetent
mice by tolerizing murine fetuses to human tumor cells. A375 human melanoma
cells were injected into day E14 fetuses and, after birth, mice were challenged again
with A375 cells to determine their ability to develop tumors. Intravenous injections
of A375 cells after tolerization resulted in metastatic-like lung tumors, which were
verifıed to be human in origin by immunohistochemistry and PCR. The develop-
ment of lungneoplasmswas dependent on fetal tolerization; non-tolerizedmice did
notdevelop tumors after injection. Interestingly, subcutaneous injected cells didnot
form tumors, but this was shown to be due to an innate, non-adaptive immune
response and did not create lasting rejection of tumor cells. This procedure was
repeatedwith several different tumor lines to show theuniversal nature of themeth-
od: BxPC3 (human pancreatic cancer), M21 (human melanoma), HeLa (human
cervical cancer), andMDA231 (human breast carcinoma).
#4821 Influence of the injection site on the dissemination pattern and
drug sensitivity of patient derived leukemia cells in vivo. Julia B. Schüler,1 Eva
Oswald,1 Gabriele Greve,2 Dorothee Lenhard,1 Kerstin Klingner,1 Milena
Pantic,2Michael Luebbert2. 1Oncotest GmbH, Freiburg, Germany; 2Medical Cen-
ter Freiburg, Freiburg, Germany.
Theaimof this studywas todetermine the influenceof theengraftment siteon the
tumorbiology anddrug sensitivity of a panel of hematological patient derivedxeno-
grafts (PDX). PDX cells (3x10e6 cells/mouse) were injected intratibialy (i.t.), intras-
plenal (i.s.) or subcutaneously (s.c.) into NOG (NOD/Shi-scid/IL-2Rnull) mice.
Tumor engraftmentwasdeterminedby flowcytometry (FC) inbonemarrow (BM),
peripheral blood (PB) and spleenduring the course of engraftment and at the endof
a study.Overall survival (OS) served as an additional read-out. In 3models sensitiv-
ity towards cytarabine (Cy) was evaluated. Our group has established 18 PDX of
acute leukemia (16 AML, 1 ALL, 1 APL). 16/17 lines engrafted when injected i.t.,
10/12developedtumorsafter i.s. implantationand13/14established tumorspost s.c.
cell injection. Thus, the overall engraftment capacitywas formost of themodels not
depending on the injection site. Nevertheless, some models could only be propa-
gated in a specifıc setting: LEXFAM 2713, grew exclusively i.t. or i.s., whereas LEX-
FAM 2824 could be propagated solely when injected s.c.. The implantation site did
influence tumor growth rate: Mean OS ranged from 151.4 (	25.21) days for i.t. to
89.2 (	16.82) days for s.c. propagation. I.s. transplanted mice had to be sacrifıced
after 91.9 (	17.33) days. The dissemination pattern of individual lines was affected
by the injection site. In general, infıltration of the hematopoietic organs was higher
when cells were engrafted i.t. or i.s.. Nevertheless, also s.c. implanted, AML cells
infıltrated murine PB, spleen and BM, although not consistently and to a much
lowerextent. Interestingly, theexpressionpatternof the6 investigatedsurfacemark-
ers (CD45, CD3, CD34, CD33, CD38 & HLA-ABC) was not influences by the ap-
plication route. Every model depicted its distinct expression pattern irrespective of
the application route. Cy was highly active in 1 AML (LEXFAM 2531) and 1 ALL
(LEXFAL 2665) model. OS was signifıcantly prolonged in the s.c. as well as in the
disseminated setting (p 0.003, Log-rank (Mantel-Cox) test). Another AML line
(LEXFAM2734) depicted a less pronounced sensitivity towardsCy (p 0.007, Log-
rank (Mantel-Cox) test) both growing s.c. or i.t.. Thus, drug sensitivity was not
influenced by the injection site of the leukemic cells. Of note, the PDX drug re-
sponses mimicked the responsiveness of the respective donor patient. Taken to-
gether the leukemiaPDXpanel represents themolecular diversity of the disease and
mirrors sensitivity towards standard of care. Our recent careful investigation of the
subcutaneous approach in these models highlights their suitability for this type of
studies. This enhances the value of the platform as it combines the possibilities of a
mid-throughput screening enabled by the subcutaneous approach with the general
advantages of a patient-derived leukemiamodel.
#4822 Detection of EBVBamHIW region in surgical cancer specimen is a
useful method to evaluate the risk of lymphomagenesis in patient-derived
tumor xenografts. Junko Mukohyama,1 Dai Iwakiri,2 Yoh Zen,1 Toru Muko-
hara,1 Hironobu Minami,1 Yoshihiro Kakeji,1 Yohei Shimono1. 1Kobe Univer-
sity Graduate School of Medicine, Kobe, Japan; 2University of Human Arts and
Sciences, Saitama, Japan.
Patient-derived tumor xenografts (PDXs) established by xenotransplantation of
surgically-resected human cancer specimens are an attractive model to analyze the
characterof cancer cellswithin thepatient cancer tissues.However, establishmentof
PDXisoccasionallyhamperedby lymphomagenesis.Lymphomagenesis in thePDX
has been observed in the xenotransplantation of several types of cancers, such as
lung, liver, gastric, bladder, breast, prostate, and colorectal cancers. Lymphomagen-
esis in the PDX is caused by the proliferation of the EBV-infected lymphocytes
under insuffıcient immunosurveillance in the immunodefıcientmice.However, it is
still diffıcult to predict lymphomagenesis before xenotransplantation. In this study,
we analyzed the expression of EBV-related genes in the 15 surgical specimens of the
consented colorectal cancer (CRC) patients and the PDXs established by their xe-
notransplantation. The CRC specimens and the established PDX tumors were his-
tologically examined. Then, the specimens were immunohistochemically stained
with anti-CD3 and CD20 antibodies. The presence of EBV was histologically eval-
uated by EBER in situ. The expression levels of EBV-related genes, such as EBNAs,
LMP1, EBER, BamHI W region and EBV-associated microRNAs, were evaluated
using the genomic DNA and mRNAs prepared from the CRC specimens and the
established PDX tumors. Nine PDXs were established by the xenotransplantation.
Histological examination showed that 7 of 9 (78%) PDX recapitulated histopatho-
logical characteristics of the patient CRC tissues. However, 2 of 9 (22%) PDXs ex-
hibited the morphological characteristics of EBV-associated human diffuse large B
cell lymphoma(DLBCL).Then,weconfırmed that lymphomawas formedbyclonal
proliferation of human B-cell lymphocytes, and strongly positive for EBER. We
investigatedwhether the expression of EBV-related genes in the patient specimen is
associatedwith lymphomagenesis in thePDXs. Expressionof EBVgenes andRNAs
in patient CRC tissues were not clearly associated with lymphomagenesis in the
PDXs. BamHI W region is a major internal repeat in EBV genome and the PCR
amplifıcation of this region is useful to evaluate the presence and amount of EBV.
When theEBVBamHIWregionwas detectable in the patient specimens, the trans-
plantation of the samples resulted in lymphomagenesis in 2 out of 3 patient cancer
specimens. In contrast, when this region was undetectable, no patient cancer speci-
mens resulted in lymphomagenesis (0 out of 7 patient cancer specimens). These
results suggest that the amount and/or presence of EBV itself in the patient cancer
specimens is one of the factors that are associated with lymphomagenesis in the
PDXs. Therefore, the PCR amplifıcation of EBV BamHI W region is an attractive
method to evaluate the risk of lymphomagenesis before xenotransplantation.
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#4823 Characterization of newly establishedWM-1-SNU cell line harboring
negative forMYD88L265Pderived fromWaldenstrommacroglobulinemia pa-
tient’s peripheral blood using xenograft model. Hyejoo Park,1 Youngil Koh,2
Kwang-Sung Ahn,3 Hyo Jung Kim,4 Sung-Soo Yoon2. 1Cancer Research Institute,
SeoulNationalUniversityCollege ofMedicine, Seoul,Republic ofKorea; 2Department
of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;
3Functional Genome Institute, PDXen Biosystem Inc., Seoul, Republic of Korea; 4De-
partment of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym
University College of Medicine, Anyang, Republic of Korea.
Waldenstrom macroglobulinemia (WM) is a rare hematologic malignancy
that is a lymphoplasmacytic lymphoma a type of B-cell disease. The common
characteristics of WM cells are expression of B cell markers, CD19 and CD20
and secretion of monoclonal immunoglobulin (Ig) M. The other critical feature
of WM is MYD88 L265P that is found almost 90% patients. MYD88 gene is
relatedwith immune response and inflammatory signaling.Many researches are
underway about MYD88 L265P role in WM. However, there is a lack of func-
tional studies in the negative forMYD88 L265P inWMdue to the absence of the
MYD88 L265P negative cell line. Each cell lines represent the heterogeneity and
molecular diversity by genetic features, it is important to establish the MYD88
L265P negative WM cell line for elucidating the biological characteristics of
WM. Mononuclear cells obtained from patient’s peripheral blood by fıcoll sep-
aration and were injected to NRG (JAX, USA)mouse via tail vein. After 24 days,
mouse sacrifıced and extracted bone marrow (BM) cells from mouse tibia by
syringe flushing. Mouse BM cells were cultured in Iscove’s Modifıed Dulbecco’s
Medium (IMDM) supplemented with 20% heat-inactivated FBS, Penicillin-
Streptomycin (10,000 U/mL) (Gibco, USA). G-banding was used to confırm the
human chromosomes. Sanger sequencing conducted for detecting the MYD88
L265P mutation. Flow cytometry was used for screening cell surface markers
and ELISA was used for the detection of immunoglobulin level. For confırm the
tumorigenicity of the cell line, we re-injected the cell line to NSG (JAX, USA)
mouse by subcutaneously. After 3 weeks, tumor mass and metastatic tissues
were cultured in conditioned medium. Tumor cells have had adherent pheno-
type and human chromosomes were identifıed by G-banding. MYD88 L265P
mutation that genetic signature of WM was not detected both patient’s periph-
eral blood and established cell line. CD19 and CD20 expressions were not de-
tected, but CD138 highly expression was confırmed about 90%. Lambda and
Kappa secretionwere not detected in cell culture supernatant.We confırmed the
tumorigenicity through re-injection the cell line by subcutaneously. Tumor
mass was formed with a 100% probability and metastasis to lung and bone
marrow occurred in about 66%. Tumor mass and metastatic tissues were cul-
tured in in vitro and confırmed the reproducibility. In this study, we describe the
newly established human WM cell line derived from peripheral blood of the
WM patient who negative for MYD88 L265P using xenograft model having
unique biological characteristics comparing toMYD88 L265P positive cells that
high tumor formation ability and high expression of CD138 and does not secrete
IgM.
#4824 The “gatekeeper” function of Drosophila Seven-IN-Absentia
(SINA) E3 ligase and its human homologs, SIAH1 and SIAH2, is highly con-
served for proper RAS signal transduction inDrosophila development. Rob-
ert E. Van Sciver,1 Yajun Cao,1 Atique U. Ahmed,2 Amy H. Tang1. 1Eastern
Virginia Medical School, Norfolk, VA; 2Mayo Clinic, Rochester, MN.
Seven-IN-Absentia (SINA) is an evolutionarily conserved E3 ubiquitin ligase
that is themost downstream signalingmodule identifıed in the RAS signal trans-
duction cascade. Underscoring the importance of SINA is its high evolutionary
conservation with over 83% amino acid identity shared between Drosophila
SINA and its human SINA homologs (SIAHs). As a major signaling “gate-
keeper” in the RAS pathway, we have shown that SIAH is required for oncogenic
K-RAS-driven tumorigenesis and metastasis in human pancreatic, lung and
breast cancer. Since SIAHs appear to be the ideal drug target to inhibit “undrug-
gable” K-RAS activation, it is important to precisely characterize the activity,
regulation, and substrate targetingmechanism(s) of this highly conserved family
of SINA/SIAH E3 ligases. By deploying the elegant and well-established Dro-
sophila development system, we are able to study RAS activation and SINA
function under normal physiological conditions. In the developing Drosophila
eye, photoreceptor cells are recruited sequentially and acquire their distinctive
cell fates through a series of local inductive events. The 800x cell arrays allowed
us to dissect the role of SINA/SIAH downstream of RAS activation in photore-
ceptor cell development. To delineate SINA function, we performed an F1mod-
ifıer screen using ethyl methanesulfonate (EMS) and X-ray radiation, isolating
28 novel sinamutant alleles. Thesemutant alleles exhibit much strongermutant
phenotypes than those of the previously published sina2 and sina3 alleles, sug-
gesting that the sina2 and sina3 alleles are hypomorphic alleles. Sequencing anal-
ysis of these sinamutant alleles reveals the functional roles ofmutated residues and
protein domains. To defıne SINA/SIAH functional conservation, we have gen-
erated a complete panel of transgenic fly models that express either wild-type
(WT) or dominant negative (DN) SINA/SIAH. The corresponding UAS-sina/
siahGOF/LOF phenotypes have been characterized using sev-, GMR-, dpp- and
salivary gland-GAL4 drivers to elucidate the developmental outcomes of altered
SINA/SIAH expression upon RAS activation. Ectopic expression of sinaWT/DN/
siahWT/DN in neurons resulted in dramatic changes in neuronal cell fate in the
developing eye and notum, causing PNS neurodegenerative phenotypes. Our
results show that the biological functions of fly SINA and human SIAH1/SIAH2
are evolutionarily conserved and functionally interchangeable. Mechanistic in-
sights and regulatory principles learned fromDrosophila can be directly applied
to cancer biology to develop and validate next-generation anti-SIAH-based anti-
K-RAS and anticancer therapy in the future.
#4825 Functional role of Ring Finger Protein 43 in intestinal stem cell
during colorectal tumorigenesis. Tsugio Eto, Takatsugu Ishimoto, Eri Oda,
Daisuke Kuroda, Kota Arima, Mayuko Ohuchi, Kenichi Nakamura, Hiroshi
Sawayama, Koichi Kinoshita, Masaaki Iwatsuki, Yoshifumi Baba, Yasuo Saka-
moto, Naoya Yoshida, Hideo Baba. Graduate School of Medical Science, Ku-
mamoto University, Kumamoto, Japan.
Background: Colorectal cancer is one of the most general causes of cancer
related death. Ring Finger Protein 43(RNF43) is an E3 ubiquitin ligase that
suppresses the Wint signaling pathway and is known as a tumor suppressor
gene. Previous studies reported RNF43mutation leads to inactivation of RNF43
in pancreatic, ovarian, colorectal cancer and so on. Subsequently,Wnt signaling
activation is associtated with tumor progression in these types of cancers. How-
ever, functional role of RNF43 for tumor formation is not clear in colorectal
cancer. Aim: To investigate the functional role of RNF43 in colorectal cancer by
using RNF43 knockout mice. Method: We prepared RNF43 knockout mice by
usingCRISPR/Cas9 system.To induce colorectal tumor inmice,weusedAzoxy-
methane-Dextran sulfate sodium (AOM-DSS) model. First, we injected AOM
10mg/kg into the peritoneal cavity. After 7days from injection, drunk 2% DSS
water to mice for 7days. We sacrifıced the mice and evaluated the tumor inci-
dence and tumor size after 8, 10, 12, and 16 weeks from injection. Next, we
prepared the small intestine organoid from RNF43 wild and knockout mice.
Then we compared the organoid size and formation rate. In vitro analysis, we
prepared colon cancer cell lines (COLO205, SW620,HCT116) and evaluated the
effect on cell proliferation in suppression of RNF43 and normal condition. Re-
sult: Therewas no signifıcant difference in the tumor incidence and tumor size at
8, 10, and 12weeks after AOM injection. However, at 16 weeks, the tumor size of
RNF43 knockout mice was signifıcantly bigger than that of RNF43 wild type
mice. (p0.001) Further examination of the intestinal organoid revealed that
the organoids derived from RNF43 knockout mice tended to get bigger than
those from wild type mice. In vitro analysis, cell proliferation of RNF43 mutant
cell line (HCT116) was signifıcantly increased compared with RNF43 wild type
cell lines (COLO205, SW620). RNF43 silencing signifıcantly increased cell pro-
liferation in RNF43 wild type cell lines (p0.001), whereas did not affected in
RNF43mutant cell line. Conclusion: Our results suggest that RNF43 expression
suppresses epithelial cell growth in the intestine, and the dysregulation of Wint
signaling viaRNF43disruption promote intestinal stemcell expansion and colo-
rectal tumorigenesis.
#4826 Maternal high butter fat intake heightens mammary cancer risk in
offsprings gestationally exposed to bisphenol A at environmentally relevant
dose. Yuet-Kin Leung, Vinothini Govindarajah, Ana Cheong, Dan Song, Xue-
gong Zhu, Jun Ying, Ady Kendler, Mario Medvedovic, Scott Belcher, Shuk-Mei
Ho. Univ. of Cincinnati, Cincinnati, OH.
In utero exposure to bisphenol A (BPA) at 250ug/kg BW was shown to aug-
ment mammary cancer risk in rodent models. High fat diet is widely believed to
be a major risk of breast cancer (BCa). It is therefore important to investigate
whether maternal high fat intake could potentially heighten mammary cancer
risk associated to gestational BPA exposure. In this study, we exposed Sprague
Dawley rats with different doses of BPA (2.5-2500ug/kg BW) mixed with high
butter-based diet (HBF) in the period from preconception to birth. DMBA-
PND50 protocol was followed. In the presence of HBF, we observed non-mono-
tonic effects of BPA in cancer incidence as well as in the number of terminal end
buds of PND21 mammary glands. Both results were peaked at a dosage of
25ug/kg BW BPA and the effects were signifıcant when compared with HBF
alone group.We further analyzed transcriptomic data of microdissected epithe-
lia of PND21 mammary glands from BPA (25ug/kg BW) group as well as HBF
group and revealed that two specifıc cancer networks involving ERK and andro-
gen receptor signaling were dysregulated. DNA methylation is one of the key
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mechanisms to dysregulate and impair the transcription of two selected top
genes, Car7 and Kcnv2, as supported by our bisulfıte-sequencing data. These
data suggest that in utero BPA exposure could epigenetically modify gene ex-
pression and predispose cancer risk during early development. More impor-
tantly, someBPAgenes are of high human relevance because seven selected BPA
genes could dichotomize patients into two groups with signifıcant difference in
overall survival in aTCGAcancer cohort. The prognostic power of the geneswas
further enhanced in the survival analysis of Caucasian with ER positive patients.
In conclusion, our data strongly suggest that BPApredisposes higher cancer risk
by dysregulating gene expression during early mammary gland development in
the presence of HBF, which could facilitate cancer development later in life.
#4827 Establishing a platform for the generation of organoids from di-
verse tumor types as part of the NCI patient-derivedmodels (PDM) initiave.
Luke H. Stockwin,1 JennaMoyer,1 AnnaWade,1 Carrie Bonomi,1 Kelly Dough-
erty,1 John Carter,1 Jesse Stottlemeyer,1 Kaitlyn Arthur,1 Vivekananda Datta,1
Lindsay Dutko,1 Michael Mullendore,1 James H. Doroshow,2 Melinda G. Hol-
lingshead,3 Dianne L. Newton1. 1Leidos Biomedical Research, Inc, Frederick Na-
tional Laboratory for Cancer Research, Frederick, MD; 2National Cancer Insti-
tute, NIH, Bethesda, MD; 3Frederick National Laboratory for Cancer Research,
Frederick, MD.
Cancer Organoids are discrete multicellular structures that recapitulate tu-
mor microanatomy (1). These reagents can be generated by extended culture of
partially or fully dissociated tumor samples in three-dimensional matrices. By
maintaining tumor and accessory cells in an appropriate context, they provide a
biosimilar platform for studying disease pathogenesis and cellular pharmacol-
ogy (2). Similarly, cancer organoid culture is useful for propagating slow grow-
ing tumors or those requiring heterotypic cell-cell interactions. Here, prelimi-
nary data will be presented regarding generation of organoids from diverse
tumor types as part of the NCI patient-derived models (PDM) initiative. This
initiative aims to develop a national repository of patient-derived cancermodels
(PDMs) consisting of clinically annotated patient-derived xenografts (PDXs)
and patient-derived tumor cell cultures (PDCs) prepared from primary and
metastatic tumors (3). A standardized panel of different organoidmedia formu-
lationswas constructed to optimize culture conditions for disease subsets. Using
this approach, organoids were generated for colon, prostate, pancreatic, breast,
melanoma, NSCLC, and bladder tumors. Although some samples were refrac-
tory to organoid generation, in several instances, samples that failed to generate
2D cultures thrived as organoids. A further fınding was that direct implantation
of organoid cultures was an effıcient means of generating xenografts. Indeed,
work will be presented detailing the exact number of organoids required to
establish xenograft tumors. Protocols were developed for routine culture, pas-
saging and long-term storage in liquid nitrogen. Similarly, organoids were ame-
nable to characterization by FACS analysis, ICC/IHC and qRT-PCR to evaluate
metrics such as tumor type, histological similarity with patient tumor, cell via-
bility, percentage stroma and whether mouse cells persist in PDX-derived or-
ganoids. In summary, growth, expansion, analysis and storage of tumor or-
ganoids is feasible for a wide range of tumor types. Importantly, for certain
samples, generation of cancer organoids appears to be a useful intermediary step
for subsequent PDXmodel and 2D culture generation. Funded byNCIContract
No. HHSN261200800001E. References: 1. Baker LA, Tiriac H, Clevers H, Tuve-
son DA. Modeling pancreatic cancer with organoids. Trends Cancer. 2016;2:
176-90. 2. Cantrell MA, Kuo CJ. Organoid modeling for cancer precision med-
icine. GenomeMed. 2015;7. 3. Doroshow J,HollingsheadM, EvrardY,Williams
M, Datta V, Das B, et al. NCI patient derived models repository. [abstract]. In:
Proceedings of the AACR-NCI-EORTC International Conference: Molecular
Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia
(PA). Mol Cancer Ther. 2015;14(12 Suppl 2).
#4828 Recapitulating mammary ductal carcinoma microenvironment in
vitro using sacrifıcial bioprinting. Y. Shrike Zhang,1 Margaux Duchamp,1 Leif
W. Ellisen,2MarshaMoses,3 Ali Khademhosseini1. 1BrighamandWomen’sHos-
pital, Harvard Medical School, Cambridge, MA; 2Massachusetts General Hospi-
tal, Harvard Medical School, Cambridge, MA; 3Boston Children’s Hospital, Har-
vard Medical School, Cambridge, MA.
American Cancer Society projects that 1,685,210 new cancer cases will be
diagnosed and 595,690 death will occur in 2016, corresponding to about 1,600
deaths per day. In 2016, an estimated 246,660 and 2,600 new cases of invasive
breast cancer (e.g. invasive ductal carcinoma) are expected to be diagnosed in
women and men in the U.S., respectively, along with 61,000 new cases of non-
invasive (i.e., in situ) breast cancer for women. Although tremendous improve-
ments in breast cancer survival have been achieved, current drug administration
procedures relying on chemotherapy followed by radiographic scans often lead
to disparity in cancer care, necessitating the development of predictive models
that can achieve personalized drug administration regimes. While patient-de-
rived tumor graft models have achieved some success, the genetic difference
between animal species and the human remains a critical barrier for accurate
prediction of patient responses, in addition to their overly high cost. During the
past few years, the organs-on-a-chip technologies have made tremendous prog-
ress thanks to their capability in modeling the physiology of the sophisticated
human systems. Such capability has been further enhanced by advancements in
tissue engineering and bioprinting, making it possible to recapitulate the archi-
tecture and functionality of tissues in vitro. Here we have utilized a sacrifıcial
bioprinting strategy to generate biomimetic mammary duct-like structures
within a hydrogel matrix, to model the genesis and of ductal carcinoma and its
invasion. Sacrifıcial bioprinting has proved its utility in fabricating hydrogel
constructs containing hollow microchannels mimicking the tubular structures
in the human body. In a typical process we fırst deposit a mold consisting of
sacrifıcial microfıbrous structures using Pluronic from a computerized model
and allow it to dry overnight; we subsequently fıll the mold with a mixture of
gelatin methacryloyl (GelMA)/collagen I solution and induce gelation using
photocrosslinking; afterwards, the Pluronic fıllers are removed by immersing
the entire construct in a cold phosphate buffered saline to achieve hydrogel
microchannels. These bioprinted microchannels could then be populated with
mammary ductal carcinoma cells on their interior walls. The cells were able to
proliferate andpopulate the surface of themicrochannels in 3weeks, followed by
initiation of invasion from themicrochannels into the surroundingmatrix in the
4thweek of culture. In themeantime the cells were observed to deposit basement
membranemolecules such as collagen type IV.This bioprintedmammary ductal
carcinomamodel provides a proof-of-concept demonstration of using bioprint-
ing technologies for engineering biologically relevant cancer models, which can
be readily extended to other cancer types where duct-like structures are in-
volved.
#4829 Development of rapid 3-dimensional culture conditions that
support the in vitro differentiation of conditionally reprogrammed pri-
mary prostate cells for the study of prostate cancer. Lucas James Tricoli,1
Deborah Berry,1 Erika Parasido,1 Aisha Naeem,1 Olga Rodriguez,1 Iman
Abdelgawad,2 Richard Lee,3 Adam Feldman,3 Chris Albanese1. 1Georgetown
Lombardi Comprehensive Cancer Center, Washington, DC; 2National Cancer
Institute of Egypt, Cairo, Egypt; 3Massachusetts General Hospital Cancer Cen-
ter, Boston, MA.
Despite decades of research into the causes and possible cures, prostate
cancer (PCa) remains the second leading cause of cancer related death in
men with over 26,000 deaths each year in the United States alone. While
many of the studies performed over the years have identifıed important
genes and signaling pathways that are involved in prostate carcinogenesis,
the fact remains that due to the limited and suboptimal prostate cell lines
available for correlative analyses, signifıcant unmet needs exist in validating
clinical fındings. With this realization, many agencies such as the DOD and
the NIH are funding more rapid and clinically relevant patient derived mod-
els to fıll a void in our understanding of, and our ability to treat, cancer. Our
research has been on the forefront in development of a novel approach to use
patient samples for basic, preclinical and clinical applications, signifıcantly
advancing personalized medicine with a revolutionary new primary cell cul-
ture technique termed conditionally reprogrammed cells (CRCs). In fact, the
CRC approach is a major focus area of NIH U01/PAR 16-344. We have
pioneered the CRC technology for the rapid establishment and expansion of
patient-derived normal and cancerous prostate cell lines in typical tissue
culture conditions. We hypothesize that improved in vitro and in vivo plat-
forms using patient-derived prostate cells (e.g. CRCs) are required for the
elucidation and subsequent experimental verifıcation of key molecular and
genetic drivers for PCa as well as better curative approaches. While prostate
CRCs retain their lineage commitment, they fail to express many of the
differentiation markers associated with luminal prostate cells when grown
under normal two dimensional (2D) culture conditions. We have therefore
established three dimensional (3D) non-spheroid based platforms for differ-
entiation of both normal and malignant prostate CRCs. These include both
transwell-based systems and decellularized tissue matrices that use defıned
differentiation medias to enable AR activation and a luminal cell phenotype.
We have now demonstrated the in vitro re-engagement of key determinates
in the AR pathway and differentiation to luminal prostate cells. Documen-
tation of the proper engagement of AR signaling is a signifıcant step in
developing a more accurate and tractable model for prostate cancer research
and distinguishing between indolent and aggressive disease.
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#4830 Precision cut cancer tissues slices as humanmodel for the testing of
immuno-modulatory compounds. Kristina Bernoth, Florian T. Unger,
Moiken Petersen, Mirja Piller, Jana Krüger, Nicole Grabinski, Hartmut Juhl,
Kerstin A. David. Indivumed, Hamburg, Germany.
The goal of personalized medicine is to stratify individual patients to the
appropriate treatment. This approach depends on extensive characterization of
individual tumors and their sensitivity to therapeutics. In the context of the
immunotherapy of cancer, information on the localization, abundance and ac-
tivation of immune cells within individual tumors gained in importance. In this
study, we showed that viable tumors from colorectal cancer patients used within
our drug testing platform, exhibit different populations of infıltrating immune
cells. Analysis of immune cellswas conducted ondisaggregated, cells fromviable
tumor slices. Disaggregation of precision cut cancer tissue slices was performed
using the GentleMACS from Miltenyi. Immune cell subsets were analyzed by
flow cytometric multiplexing of CD3, CD4, CD8 and CD45. Furthermore, we
identifıed PD1 positive cells among the CD45/CD3 lymphocyte population,
indicating relevance for anti-PD1 targeted therapy in colorectal cancer. As a
proof of principle, precision cut cancer tissue slices were incubated for 24 hours
with different concentrations of Nivolumab (anti-PD1). The read out of treat-
ment effects was conducted in regard to cytokine secretions upon compound
treatment as well as immune cell composition. Cytokines were analyzed in su-
pernatants of tissue cultures using the proinflammatory panel from Mesoscale
Discovery. The results demonstrated that immune cell compositions were stable
and uniform within our precision cut cancer tissue slices both pre- and post-
cultivation, and pre- and post-treatment with Nivolumab. In contrast, cytokine
secretion had changed after treatment. This has been observed for different
cytokines, such as INFgamma, IL-2, IL-10 andTNFalpha.A correlation toPD-1
expression onT-cells in different patients has not been seen. In order to optimize
preclinical testing of immune-modulatory compounds, preclinical models,
which reflect the individual tumor, as well as the individual immune compo-
nents of the tumor, are mandatory. We have shown here that effects of treat-
ments with an immune-modulatory compound (Nivolumab) were detectable in
this system. Therefore, this drug testing platform represents a unique opportu-
nity to test immune-modulatory compounds in a fully human, patient derived
model that is close to in vivo situation. In the future, other immune-modulatory
classes of compounds have to be tested within the system to more comprehen-
sively elucidate the possibilities and limits of this drug testing platform in regard
to immunotherapy.
#4831 Small cell lung carcinoma (SCLC) cell line screenof standardof care
(etoposide/carboplatin) plus a third agent. Beverly A. Teicher,1 Michael
Selby,2 Thomas Silvers,2 Julie Laudeman,2 Russell Reinhart,2 Rene Delosh,2
Chad Ogle,2 Ralph Parchment,2 Julia Krushkal,1 Dmitriy Sonkin,1 Joel Morris,1
Mark Kunkel,1 David Evans2. 1National Cancer Inst., Bethesda, MD; 2Leidos
Biomedical Research, Inc., Frederick, MD.
The standard-of-care for limited stage and extensive stage SCLC has re-
mained etoposide and a platinum complex for more than 30 years because 60-
80% of patients respond; however, SCLC inevitably recurs. Recurrent SCLC has
proven to be resistant to many therapeutics administered as second- or third-
line treatments; therefore, combining therapies in the fırst instance may be a
critically useful strategy. A high throughput screen was performed where 62
SCLC lines were exposed to etoposide (0.3uM)/carboplatin (3.7 uM) (E/C) with
or without simultaneous exposure to a third agent (n  220). Viability of the
cells was measured using CellTiter-Glo after 96 hr exposure to 9 concentrations
of each individual compound or combination with E/C. The test concentrations
encompassed the clinical Cmax for each third agent, and the concentrations of
E/C selected for the screen were systematically determined to produce SCLC kill
that would allow observation of additivity/synergy upon addition of a third
agent. IC50s were determined from the concentration response data and showed
that the predominant effect of adding a third agent to E/Cwas additive. Less than
additive effects occurred more frequently in SCLC lines that were sensitive to
etoposide/carboplatin. Antagonismwith E/C occurred in combinationwith tax-
anes and tubulin fragmenters such as vinorelbine. Effective single agents such as
the nuclear kinase inhibitors (aurora kinase inhibitors, KSP/EG5 inhibitors and
polo-like kinase inhibitors) were antagonistic in combination with E/C but
were effective single agents. Greater than additive SCLC killing occurred
with E/C in combination with several classes of agents. The combination of
the Chk1 inhibitor rabusertib with E/C resulted in an IC50 that was 1 log
lower than that of rabusertib alone in several SCLC lines. The GSK-3 in-
hibitor LY-2090314 produced greater than additive SCLC killing in combi-
nation with E/C. LY-2090314 had little effect on the SCLC lines alone but the
simultaneous combination with E/C resulted in multi-log killing in selected
SCLC lines. The BET bromodomain inhibitor MK-8628 was highly effective
when combined with E/C as was the PARP1 inhibitor talazoparib in a small
subset of the SCLC lines. While many agents have been tested in combina-
tion with E/C in SCLC and failed to improve patients’ survival, the fındings
of this study identifıed third agents that may represent new leads for the
treatment of this recalcitrant disease. Distinct patterns of response in select
subsets of the 62 SCLC lines tested may allow identifıcation of biomarkers
predictive of the responders to certain 3-drug regimens. This project has
been funded in whole or in part with federal funds from the National Cancer
Institute, NIH, under contract no. HHSN261200800001E.
#4832 Establishment of lung cancer organoid lines as a new preclinical
model for lung cancer. Minsuh Kim,1 Sung-Min Chun,2 Hyemin Mun,1
Young-Ah Suh,1 Se jin Jang2. 1Asan Inst. For Life Sciences, Seoul, Republic of
Korea; 2Department of Pathology, AsanMedical Center, Seoul, Republic of Korea.
Human cancers are composed of genetically and phenotypically heteroge-
neous subpopulations organized into a hierarchy of tumor initiating stem cells
and various differentiated tumor cell. Cancer organoids seem to be more suit-
able in vitro models for targeting tumor heterogeneity than cell lines. We estab-
lished cancer organoid lines from lung cancer patient tissues, recapitulating
histology of human cancers in three dimensional culture conditions. Thirteen
organoid lines from various lung cancer subtypes including adenocarcinoma,
squamous cell carcinoma and small cell carcinoma were compared with their
original human tumors in histologic features and genetic profıles. In the IHC
staining, it revealed that organoids of adenocarcinomas have typical glandulo-
papillary structures or mucin-containing tumor cells. Organoids of squamous
cell carcinomas showed keratinization and intercellular bridges. Organoids of
small cell carcinoma displayed typical neuroendocrinemorphology. UsingNGS
cancer panel sequencing, the organoid lines maintained genetic characteristics
of the original human tumors in major driver genes including EGFR, TP53, and
RB mutation. In xenograft experiments, the organoid lines revealed stronger
tumorigenesity than direct graft of human tumor tissues. Cancer organoids
showed resistance to various anticancer drug treatments. In conclusion, our
lung cancer organoid lines are alternative cancer model for preclinical re-
searches recapitulating genotypic and phenotypic heterogeneity of original hu-
man tumors.
#4833 Perfusion-based bioreactor culture of primary cancer tissue main-
tains tumor microenvironment complexity and allow in-vitro testing of im-
mune blockade therapy.Manuele GiuseppeMuraro,1 SimoneMuenst,1 Celeste
Manfredonia,1 Valentina Mele,2 Silvio Daester,1 Alexandar Tzankov,1 Luigi
Terracciano,1 Walter Weber,1 Giulio C. Spagnoli,1 Giandomenica Iezzi,2 Ivan
Martin,1 SavasD. Soysal1. 1UniversityHospital of Basel, Basel, Switzerland; 2Uni-
versity of Basel, Basel, Switzerland.
In vitro culture of primary cancer tissue is still very limited and the gen-
eration of patient derived xenograft determine the loss of human-cancer
associated stroma. In this context, the use of 3D in vitro systems based on
human tissue may be an innovative system to be exploited for keeping the
tumor microenvironment (TME) complexity of the tissue in vitro. Freshly
excised colorectal (CRC) and breast cancer (BrCa) specimens were frag-
mented and cultured in 3D “sandwich-like format” between porous collagen
scaffolds under perfusion flow (U-CUP, Cellec Biotek AG). The mainte-
nance of tumor and immune-infıltrating cells, survival and phenotypic char-
acterization were histologically assessed. In a second step cancer treatment
were tested. U-CUP culture allowed the preservation, viability and expan-
sion of tumor tissue with concomitant stromal and immune cells. Expanding
cancer cells were viable after 10 and 21 days (CRC and BrCa, respectively).
Administration of anti-ER treatment to Lumina A ER BrCa was associated
with decreased expansion of cancer tissue into the scaffold after 21 days. The
maintenance of immune-infıltrating cells allowed testing of immune block-
ade therapy. Administration of anti-PDL1 antibody, alone or in combination
with anti-CTLA4, to the culture medium was associated with increased ex-
pression of markers of immune-activation (i.e. IFN) and decreased expres-
sion of immunosuppressive cytokine IL10. Preserving malignant, interstitial
and immunocompetent cells comprised in surgically excised tumor speci-
mens might allow a direct evaluation of the effects of various treatments on
the complex TME. This engineered in vitro model could allow animal-free
testing and it could be extended as a platform allowing the testing of inno-
vative approaches for the treatment of human malignancies. Our fındings
shed the light on a promising system for selecting personalized treatment
based on a patient’s tumor specifıc microenvironment.
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#4834 3Dmodeling of immune cell interactions in breast cancer and pre-
diction of immunotherapy response. Qi Guo,1 Stephen Shuford,1 Brian
McKinley,2 Mary Rippon,2 Wendy Cornett,2 Mark O’Rourke,2 David Scham-
mel,3 Jeff Edenfıeld,2 David L. Kaplan,4 Hal E. Crosswell,1 Teresa Desrochers1.
1KIYATEC, Inc., Greenville, SC; 2GHS, Greenville, SC; 3Upstate Pathology,
Greenville, SC; 4Tufts University, Boston, MA.
While breast cancer has an overall 5-year survival rate of 89%, the rate for
patients with stage 4 metastatic disease is only 26%. Immunotherapies have the
potential to improve the prognosis for these patients while also providing better
treatment options for all breast cancer patients since they have fewer side effects
enabling longer treatment times and the use of combination therapies and re-
duced chances of developing resistance. Currently these treatments are tested in
standard 2D cell cultures that are inaccurate inmimicking in vivo drug response
or animal models where the immune system differs from humans in numerous
ways including T-cell subsets, cytokine receptors, and costimulatory molecule
expression.We have developed 3Dmodels of human breast cancer that span the
subtypes, ER, HER2, and triple negative, incorporate numerous stromal cell
types, fıbroblasts and adipocytes, and include different immune cells, macro-
phages and T-cells under either static or perfusion culture systems. These mod-
els have been used to examine how tumor cells influence macrophage differen-
tiation using undifferentiated peripheral blood mononuclear cells (PBMCs),
how M1 and M2 macrophages influence tumor cell survival and proliferation,
how the combination of these cell types influence cytokine secretion, and how
the microenvironment affects macrophage invasion. We have also used these
complex models to examine response of tumor cells and T-cells to checkpoint
inhibitors through standard viability assays and flow cytometry. These models
have several potential uses which include the ability to quickly answer whether a
particular immunotherapy agent is effective for that particular patient-specifıc
manner and to screen potential novel immunotherapeutic candidates and/or
combinations prior to clinical use.
#4835 A robust, non-destructive image analysis method for the quantita-
tion and characterization of patient derived organoids. Erin Spiller, Roy Lau,
Colin Flinders, Shannon Mumenthaler. Lawrence J. Ellison Institute for Trans-
formative Medicine of USC, Los Angeles, CA.
Patient-derived organoids are an emerging 3D model system that more
closely recapitulate the organ functionality of the tissue of origin compared to
traditional 2D cell lines. Further advantages to the organoid system include
tunability i.e. adding additional cell types, adjusting matrix stiffness, and estab-
lishing nutrient gradients, in a physiologically relevant setting, as well as the
ability to quickly scale up from a small initial sample. We have established an
actively expanding biobank of primary and metastatic colorectal cancer (CRC)
tumor organoids under normoxic (21% O2) and physioxic (5% O2) conditions,
from a diverse patient population. Concurrently, we isolated and cultured
matched cancer-associated fıbroblasts (CAFs).With these sampleswe are able to
generate data from a cohort that mimics the CRC population at large, including
different ethnic groups, and mutational status. Here we detail a quantitative
imaging platform that captures 3D morphometric information in addition to
traditional live/dead readouts. Organoids from each patient are heterogeneous
in size, shape, symmetry, and various other phenotypic features. Furthermore,
the perturbation of microenviromental factors i.e. drugs, CAFs, etc. cause phe-
notypic changes over time. Common population-based viability assays used in
drug screens, such as ATP or MTT, may be inappropriate to capture the com-
plexities of drug response since they are often single end point measurements of
an entire population of cells, anddonot account for phenotypic variations. Short
term quantitative live cell imaging incorporates phenotypic information, and
can extend the lifetime of samples, yet still require manipulating samples by
using dyes. However, these dyes are phototoxic, making them less than ideal for
long term live cell imaging. By restricting image acquisition to brightfıeld we are
able to minimize manipulation of patient samples, leaving them intact and via-
ble. The additional benefıt of imaging organoids in 3D enables us to get spatial
information not available from assays with a single readout. Using our non-
destructive imaging technique we can track 3D morphometric changes in the
same organoid population over time. By using a flexible analysis method, and
unbiased machine learning algorithms to determine relevant features we can
account for these differences yet still get comparable data. Our organoid repos-
itory combined with long term image analysis andmachine learning techniques
provide a robust platform that is flexible enough to handle the heterogeneity
seen across the patient population. This platform could be used to advance
personalizedmedicine allowing clinicians to quickly andmore accurately deter-
mine the appropriate treatment for a patient by screening their tumor prior to
determining a course of treatment.
#4836 A colorectal cancer organoid library provides a promising screen-
ing tool for assessment of chemosensitivity. Naoya Sakamoto,1 Akira
Ishikawa,1 Ririno Honma,1 Takao Hinoi,2 Naohide Oue,1 Kazuhiro Sentani,1
Shoichiro Mukai,1 Tomohiro Adachi,1 Hiroyuki Egi,1 Hideki Ohdan,1 Wataru
Yasui1. 1Hiroshima University, Hiroshima, Japan; 2Institute for Clinical Re-
search, National Hospital Organization Kure Medical Center and Chugoku Can-
cer Center, Kure, Japan.
Colorectal cancer (CRC) is a leading cause of cancer mortality and the third
most common cancer worldwide. Annually, there are more than 900,000 cases
occur worldwide, nearly 500,000 of which are fatal. CRC have accumulated
defects in oncogenes and tumor suppressor genes. Many CRCs likely arise
through clonal outgrowth and evolution of an epithelial cell or cells in an adeno-
matous precursor lesion via so-called adenoma-carcinoma sequence. Intensive
studies have uncovered that the spectra of these geneticmodifıcations are highly
variable across the tumors. While genetic changes in tumors of individual pa-
tients can be assessed in several stratifıed methods, these data still need to be
properly interpreted for necessitating model systems for analysis of chemosen-
sitivity of CRC patients, which could enable us to organically coordinate among
genotype-to-phenotype correlations, clinicopathological features and clinical
outcomes. One of the most plausible models for implementing this magnifıcent
scheme is most likely to be “organoid”, which is a novel 3D intestinal stem cell
culture system and has successfully reconstitute normal and cancerous colonic
crypts in in vitro through using the specifıc niche factors in a dish, such as EGF,
Wnt3a, Rspondin-1 and Noggin, together with a TGF-b inhibitor and a p38
inhibitor. Two groups, Van der Wetering et.al and Fujii et.al, have previously
reported the establishment of organoid biobank of colorectal cancer patients,
and both of them proved the usefulness of this platform for underpinning the
signifıcance of genotype-phenotype analysis in every single patient and provid-
ing insights into tailor-made therapy inCRC. In this present study, we generated
a pairs of cancerous and normal adjacent organoids from a number of CRC
patients and aimed to fıgure out sustainability and reproducibility of CRC or-
ganoids especially in terms of phenotypic and genotypic features even after
several times of passage. We compared growth activity and histopathological
features of the CRC organoids among several time points after the passage by
evaluating ki-67 labeling index and morphology of the organoids. In order to
confırm the stability of genetic status of representative cancer-related genes, we
focused on TP53, KRAS, BRAF, and MSI status. We then tried to elucidate the
difference of chemosensitivity betweenMSI-high andMSI-low/MSS CRC cases
with similar genetic background in most of the representative cancer-related
genes. Although further in-depth studies on CRC organoids are needed, our
approach would be instrumental in accurately predicting the drug sensitivity of
CRC patients, which could possibly lead to the establishment of personalized
medicine in CRC.
#4837 Development of an in vitro 3D glioblastoma model system for pa-
tient-specifıc drug response profıling. Teresa DesRochers,1 Ashley Clark,1
Lauren O’Donnell,1 Qi Guo,1 Lillia Holmes,1 Lacey Dobrolecki,2 Michael
Lewis,2 David Schammel,3 Jeff Edenfıeld,4 Charles Kanos,4 Fred Nelson,4 Steve
Gardner,4Michael Lynn,4 PhilipHodge,4 ChristopherCorless,5 Paul Clark,6Hal
E. Crosswell,1 John Kuo6. 1KIYATEC, Inc., Greenville, SC; 2StemMed Inc, Hous-
ton, TX; 3Upstate Pathology, Greenville, SC; 4GHS, Greenville, SC; 5OHSU, Port-
land, OR; 6U. Wisonsin, Madison, WI.
Glioblastoma (GBM) has a median survival of less than 2 years due to intra-
tumoral and inter-patient heterogeneity, diffuse infıltration of adjacent brain
tissue, and absence of effective therapies. Development ofmore effıcacious ther-
apies will require better GBMmodels for the testing and identifıcation of novel
agents; traditional 2D cell culture lacks biologic and clinical fıdelity and ortho-
topic xenograft models are costly, low throughput, and time consuming. We
have developed a complex, patient-specifıc 3D cultured GBM model to assay
drug response that combines high-throughput drug response determination
with neurosphere formation and next-generation sequencing (NGS). Neuro-
sphere formation and the presence/quality of glioblastoma stem cells (GSCs) has
been validate through limited dilution growth in vivo. Our 3Dmodel system has
been validated against the primary patient GBM tissue and/or patient-derived
xenografts (PDX) and consists of histology, epigenetic and mRNA expression
analysis, and comparison of in vivo drug response. This strategy enabled exam-
ination of MGMTmethylation in relation to temozolomide response, and pos-
sible actionable genetic mutations with candidate targeted therapies. Using our
3D model, we have observed EGFR-amplifıed GBM sensitivity to the EGFR
inhibitor afatanib, and PTEN mutant GBM sensitivity to dual PI3K/mTOR in-
hibitor dactolisib. These data suggest validation of clinical andmolecular corre-
lation with this new in vitro, patient-derived 3D GBMmodel for drug response
profıling. Our data supports the further development and use of complex 3D
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models, neurosphere formation, and NGS profıling for patient-specifıc GBM
analysis. This model system is currently being considered for preclinical assess-
ment of novel therapies andmay be a useful adjunct in future precisionmedicine
applications to improve patient outcomes.
#4838 Optimization of prostate cancer organoid culturemethods to grow
PDX and human biopsy tissue.Mike L. Beshiri,1 Crystal Tran,1 AdamG. Sow-
alsky,1HollyM.Nguyen,2 SupreetAgarwal,1 CaitlinM.Tice,1 EvaCorey,2 Kathy
Kelly1. 1NCI, Bethesda, MD; 2University of Washington, Seattle, WA.
Amajor obstacle in the fıeld of prostate cancer research is the limited capacity
to culture prostate cancer-derived cells in vitro. There are relatively few estab-
lished prostate cancer cell lines in use today. Those that are available are ame-
nable to in vitro drug assays and mechanistic studies, but do not well-represent
the genetic diversity of the disease, nor do they accurately predict in vivo re-
sponse. Recently, organoid culture techniques have been developed for prostate
cancer by the laboratories of Hans Clevers and Charles Sawyers that have in-
creased our ability to grow metastatic tumor-derived prostate cancer cells in
vitro. This represents a great step forward, but we are still restricted by the
limited availability of biopsy tissue and the relatively low success rate (20%) in
establishing new organoid lines. The LuCaP series of patient-derived xenografts
(PDXs) represents a well-characterized set of prostate cancer specimens that is
genetically diverse, reflective of a range of treatment histories, and available to
the research community. We have modifıed the organoid culture technique
based upon systematic comparisons and analysis for organoid growth of the
LuCaP PDXs. Our modifıed conditions represent an improvement upon the
original growth conditions. We have successfully cultured 21 out of 24 LuCaPs
attempted, for at least one generation, and 16 out of 24 are able to grow long-
term over several generations. This includes 3 of the newest LuCaPs (167, 170.2,
and 189.3) that we have genomically characterized. Comparison of the PDX and
various organoid generations showed signifıcant conservation of genomic
changes ranging from 75-90% for nonsynonymous point mutations. The mod-
ifıed organoid culturemethod immediately and signifıcantly increases the num-
ber of prostate cancer lines that are available by making the LuCaP PDXs acces-
sible to in vitro culture. In addition to the PDXs, our method has improved the
success for culturing metastatic samples grown from biopsies. We show here
that 2 out of 3 patient-derived organoid lines that we have established, growwell
in the modifıed conditions but poorly in the original culture conditions, the
third grows equally well in both conditions.
TUMOR BIOLOGY: Metastasis Suppressors and Promoters
#4839 Ephrin-A ligands regulate cutaneous tumor etiology andmetastasis
through cell autonomous and non-autonomous mechanisms. Ji Zheng,1
Bethany PerezWhite,2 Nihal Kaplan,2 Zhe Zhao,1 Miroslav Blumenberg,3 Spiro
Getsios,2 Bingcheng Wang1. 1Case Western Reserve Univ., Cleveland, OH;
2Northwestern University, Chicago, IL; 3Uew York Univeristy, New York, NY.
Glycophosphatidylinositol-anchored ephrin-A ligands target EphA receptor
tyrosine kinases (RTKs) to promote keratinocyte differentiation. Accordingly,
genetic ablation of the major epidermal EphA subtype, EphA2, increases sus-
ceptibility to DMBA/TPA-induced cutaneous chemical carcinogenesis. Defın-
ing the corresponding role of ligands for EphA2 in skin cancer has been more
cumbersome as the three ephrin-A genes (Efna1, Efna3, Efna4) are all promi-
nently expressed in skin. We met this challenge by utilizing a triple Efna1/3/4
knockout (TKO) mice that reflects the pattern of reduced Efna gene expression
found inmouse and human cutaneous SCCs. Skin tumors developed earlier and
grew faster inmice lacking EphA2 or these three ephrin-A ligands. Interestingly
TKO mice displayed accelerated malignant progression toward invasive SCC
that metastasized to the lymph nodes and lungs by 25 weeks following DMBA-
TPA treatment. Using keratinocyte culture models, we found that ephrin-A
ligands act within the epidermis to limit keratinocytemigration in amanner that
depends on their targeting of EphA2.We also illustrated a key role for ephrin-A
ligands in the surrounding tumormicroenvironment by re-introducing isogenic
SCC cell lines into the skin of wild-type or TKO mice on congenic FVB back-
ground; tumor growth and metastasis was facilitated in mice lacking ephrin-A
ligands. Importantly, the invasive phenotype of TKOmouse tumor cell lines was
normalized by genetic reintroduction of either Efna1 or Efna3. Integrating our
fındings fromhuman tumors,mousemodels, primary cell cultures, and allograft
models provides strong support for the notion that ephrins operate within tu-
mor cells and also in the microenvironment to suppress skin tumor initiation
and metastasis.
#4840 SNP rs1052566 (Ala273Val) in BRMS1 variant2 promotes metas-
tasis in lung adenocarcinoma. Neel P. Chudgar,1 Yuan Liu,1 Joseph Monte-
calvo,1 Marty W. Mayo,2 Prasad S. Adusumilli,1 David R. Jones1. 1Memorial
Sloan Kettering Cancer Center, New York, NY; 2University of Virginia School of
Medicine, Charlottesville, VA.
Background: Metastatic lung cancer kills over 180,000 people in the United
States annually. Family history is one risk factor for lung adenocarcinoma
(LUAD), suggesting a putative genetic predisposition to the development of
LUAD. Single nucleotide polymorphisms (SNPs) are the most common genetic
variations in the human genome andmajor determinants of variations in disease
susceptibility, prognosis, response to medication, and toxicity. Recent studies
indicate that SNPs play important roles in the progression of LUAD. We have
previously shown that breast cancer metastasis suppressor-1 (BRMS1) plays a
critical role in inhibiting the progression of lung cancer. We observed that SNP
rs1052566 homo-variant in breast cancer metastasis suppressor-1 (BRMS1)
variant 2 (v2) causes an A273V mutation. However, the role of this SNP in the
progression of lung cancer remains to be determined. Methods: We utilized
next-generation DNA sequencing and Taqman SNP assays to detect the preva-
lence of rs1052566 in 40 surgically resected LUAD specimens. Next, we gener-
ated a retroviral expressional system (pBabe puro) encoding V5-tagged
BRMS1v2 wild-type (WT) and A273V mutant and created NSCLC H1299 and
A549 cell lines that stably express V5-tagged BRMS1v2 WT, A273V, or vector
control. The metastatic capabilities of these stable cells were evaluated by inva-
sion chamber assays in vitro and a tail-vein injection metastasis model in vivo.
To explore the mechanism(s) through which BRMS1v2 A273V promotes me-
tastasis, we performed RT profıler PCR assay. Results: We determined that SNP
rs1052566 is present in 45% of LUAD patients. Of these, the homo-variant
occurs in 7.5% of patients (3 of 40). Importantly, BRMS1v2 A273V signifıcantly
promotes metastasis of NSCLC cells in vitro and in vivo. Additionally, in our
mouse model, A273V was associated with decreased survival, compared with
BRMS1v2WTor control. OnRTprofıler PCR array, 7 genes, including L1CAM,
were found to be signifıcantly differentially regulated by BRMS1v2 WT and
A273V.Confırmatory RT-PCR and immunoblots proved that BRMS1v2A273V
increases both the transcript and protein levels of L1CAM. Furthermore, we
found that either c-Jun or c-Fos promotes the transcription of L1CAM. How-
ever, BRMS1v2 A273V specifıcally enhances c-Fos-, but not c-Jun-, induced
L1CAM transcription. Conclusion: We observed that BRMS1v2 A273V abol-
ishes the metastasis suppressor function of BRMS1 and promotes metastasis.
Up-regulation of c-Fos-induced L1CAM transcription is a putative mechanism
of BRMS1v2 A273V-induced metastasis. Our data suggest that SNP rs1052566,
especially its homo-variant, is associated with an increased risk of metastasis in
LUAD.
#4841 Suppression of metastasis by KP54 and non-KP54 kisspeptins.
Kelsey Rebecca Hampton, Keke M. Pounds, Andrew P. Trembath, Danny R.
Welch. Univ. of Kansas Medical Ctr., Kansas City, KS.
KISS1 is a secreted neuropeptide which can act as a metastasis suppressor
protein. Expression of KISS1 inhibits metastatic colonization at secondary sites,
rendering disseminated cells dormant. In order for KISS1 to suppress metasta-
sis, it must be secreted outside of the cell, where furin cleaves KISS1 into kiss-
peptins. This cleavage liberates an internal kisspeptin, Kisspeptin-54 (KP54, K67
to F121), which is amidated and has the ability to bind a Gq/11-coupled protein
receptor KISS1R. The mechanism of action for KISS1 metastasis suppression
has long been assumed to be KP54 interacting with KISS1R. However, expres-
sion of KISS1R is not necessary for KISS1metastasis suppression, and the extra-
cellular processing of KISS1 hints at an alternative hypothesis: a different kiss-
peptinmay be responsible for suppressingmetastasis. To test this hypothesis, all
possible kisspeptins were generated based on known dibasic cleavage sites (M1-
Q145; M1-R56; M1-R67; M1-R124; R56-R66; R67-F121; R56-F121; R56-Q145; R67-Q145;
R124-Q145) and were cloned to include the same secretion sequence as nascent
KISS1. These kisspeptins (KISS1 Manufactured Peptides, or KMP) were inde-
pendently expressed in B16-F10murinemelanoma cells. To test for experimen-
tal metastasis, B16-F10 cells expressing KMP were injected intravenously into
the lateral tail vein of syngeneicmice and the lungswere examined formetastatic
load. While KP54 suppressed metastasis, additional KMP lacking the KISS1R
binding site (LRF-NH2) were able to completely suppress metastasis (p0.05).
When assessing metastasis-associated traits in vitro, suppressor KMP sup-
pressed motility, increased mitochondrial biomass, and increased oxidative
phosphorylation (phenotypes previously reported with KISS1 expression). In
particular, one kisspeptin (KMP2,M1 - R56) suppressedmetastatic traits in vitro
as well as completely suppressing metastasis in vivo. As a whole, these data
suggest that metastasis suppression by KISS1 is not necessarily contingent on
KISS1R activation, and also supports investigation into additional receptors.
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#4842 TP53INP1 negatively regulates ERK1/2 via p73-dependent
DUSP10 expression to promote metastasis in hepatocellular carcinoma. Kai
YuNg,1 LokHei Chan,1 Stella Chai,1ManTong,1 XinYuanGuan,1Nikki P Lee,1
Yun Fei Yuan,2 Dan Xie,2 Terence K Lee,3 Alice Carrier,4 Nelson J Dusetti,4
Stephanie Ma1. 1The University of Hong Kong, Hong Kong, Hong Kong; 2Sun
Yat-Sen University Cancer Center, Guangzhou, China; 3The Hong Kong Poly-
technic University, Hong Kong, Hong Kong; 4Institut Paoli-Calmettes, CRCM,
Marseille, France.
The recurrence andmetastasis of hepatocellular carcinoma (HCC) portends a
poor prognosis and represents important clinical challenges. There is a great
need to identify critical factors involved inHCCmetastasis that will facilitate the
development of new therapeutic strategies. We have previously found that the
initiation, growth and self-renewal of CD133 liver tumors to be fıne-tuned by
a balance of miR-130b overexpression and tumor protein 53 inducible nuclear
protein 1 (TP53INP1) down-regulation, suggesting that TP53INP1 is a critical
effector driving hepatocarcinogenesis. In this study, we aimed to further inves-
tigate the role of TP53INP1 in HCC metastasis. We showed TP53INP1 to be
frequently down-regulated in advanced stage IV and metastatic human HCC
tumors as compared with early stage (I-III) and primary tumors. Functional
studies in immortalized normal liver cell line MIHA and HCC cell line MHCC-
97L found TP53INP1 suppression inHCC to promotemetastasis in vitro and in
vivo. To elucidate the downstream signaling mechanism by which TP53INP1
regulates HCC metastasis, a Proteome Profıler Human Phospho-Kinase Array
was utilized. Phospho-ERK was found to be consistently up-regulated in HCC
cell lines with TP53INP1 knocked down, with its involvement in TP53INP1-
mediated metastasis subsequently validated by rescue experiments using an
ERK inhibitor U0126 or shERK1/2 knockdown approach. ERK1/2 is known to
be negatively regulated by a family of dual-specifıcityMAPK phosphatase called
DUSP/MKP. Screening of a panel of DUSP/MKP family members by qPCR
identifıedDUSP10 to be commonly down-regulated in bothMIHAandMHCC-
97L cells with TP53INP1 suppressed as compared to controls. The importance
ofDUSP10 inactivation onERK inTP53INP1-mediatedHCCwas substantiated
by rescue experiments whereby DUSP10 ectopic expression in TP53INP1 sup-
pressed cells reversed up-regulated phospho-ERK expression and enhanced
HCC aggressiveness. Subsequent analysis of the DUSP10 promoter region by
open-access database revealed four putative binding sites for p73, of which tran-
scriptional activity has previously been found to be modulated by TP53INP1.
Chromatin immunoprecipitation and luciferase reporter assays collectively
demonstrated that TP53INP1 is vital for p73 transcriptional activity of DUSP10.
Taken together, TP53INP1 down-regulation promotesHCCmetastasis through
a p73-dependent DUSP10/ERK signaling pathway.
#4843 ANKRD52 inhibited tumormetastasis through dephosphorylation
of PAK1 in lung adenocarcinoma. Yen-Fan Lin,1 Ying-Pu Liu,1 Ting-Fang
Lee,1 Cheng-WenWu2. 1National Yang-Ming University, Taiwan, Taiwan; 2In-
stitute of Biomedical Sciences, Academia Sinica, National Yang-Ming University,
Taiwan, Taiwan.
As a leading cause of cancer-related deaths, metastasis is the ultimate chal-
lenge in our effort to fıght cancer as a life-threatening disease. A member of
ankyrin repeat proteins, ankyrin repeat domain 52 (ANKRD52), is studied here
to be involved in the regulation of lung adenocarcinoma metastasis. Ankyrin
repeat proteins are known to function as a platform for protein-protein interac-
tions, and ANKRD52 was shown to interact with protein phosphatase 6 (PP6).
This study aimed to investigate the anti-metastatic roles of ANKRD52 in lung
adenocarcinoma. Immunohistochemistry staining in lung cancer tissue re-
vealed prolonged disease-free survival in high ANKRD52 expressing cases. Us-
ing lung cancer cell lines, ANKRD52 knockdowns showed signifıcantly in-
creased cell mobility while forced expressed ANKRD52 decreased cell mobility.
Using mass spectrometry analysis, p21-activated kinases (PAK1) was identifıed
to interact withANKRD52.Upregulated PAK1phosphorylationwas detected in
ANKRD52 or PP6 knockdowns. Our model demonstrated a novel anti-meta-
static protein, ANKRD52, that regulates cell mobility through interactions with
PP6 and dephosphorylation of PAK1.
#4844 CRISPR-generated BAP1 knockdown in uveal melanoma cell lines
affects organotropism.KatharinaMahal, Kelly Brooks, AmitMandal,Matthew
Smith, Nathalie Dhomen, RichardMarais.CRUKMI,Manchester, United King-
dom.
Uveal melanoma (UM), a genetically distinct subtype of melanoma, arises
frommelanocytes located in the uveal tract of the eye, and is the most common
intraocular cancer in adults. Clinically evidentmetastasis occurs in about 50%of
patients, often several years after successful treatment of the primary tumour,
with secondary disease occurring predominantly in the liver. In most cases sur-
gical resection is not possible, and there are currently no effective chemothera-
peutic treatments available once themetastatic disease has developed. Loss of the
tumor suppressor and chromatinmodifıer BAP1 (BRCA1-associated protein 1)
is linked with poor prognosis and high risk for developing liver metastasis.
However, our knowledge about the processes involved inUMmetastasis and the
mechanisms that enable metastatic growth preferentially in the liver is limited.
We recently described a panel of isogenic BAP1 knockout/knockdown UM cell
lines generated by CRISPR technology, which allowed us to study the cellular
effects of BAP1 loss in comparison to parental UMcell lines. Inmouse xenograft
studies we were able to show that BAP1-loss of function (LOF) promoted met-
astatic growth preferentially in the liver, while the parental cells metastasized
mainly to lymph nodes and lung. A possible explanation for the observed liver
tropism could lie in the alteration of protein secretion or receptor expression
patterns upon BAP1 knockout that may result in an increased sensitivity to liver
specifıc growth factors or cytokines.We are currently investigating gene expres-
sion andprotein alterations resulting fromBAP1knockdown, and the reciprocal
signaling between the CRISPR cell line pairs and liver cells such as hepatocytes
and hepatic stellate cells in co-culture experiments. These studies will reveal a
potential mechanism by which loss of BAP1 function mediates liver tropism in
vivo and potentially provide new therapeutic avenues for patients at high risk of
metastatic UM disease.
#4845 Induction of aldolase C expression by NME1 may mediate metas-
tasis suppressor activity inmalignantmelanoma.Nidhi Pamidimukkala,1 Ka-
tie Leonard,1 Joseph McCorkle,2 Qingbei Zhang,2 Anup Mahurkar,1 Amol
Shetty,1 David Kaetzel1. 1Univ. of Marlyand School of Medicine, Baltimore, MD;
2University of Kentucky, Lexington, KY.
Although the metastasis suppressor activity of NME1 has been demonstrated
in a number of settings of human cancer, the underlyingmolecularmechanisms
are not well understood. NME1 has two known enzymatic activities, nucleoside
diphosphate kinase (NDPK) and a 3= to 5’ exonuclease. Todetermine the relative
contribution either of these activities has on the metastasis suppressor function
of NME1, our lab previously generated site directed mutants to abrogate one or
both of the enzymatic activities (Ma et al., 2004). These studies showed that
disrupting the 3= to 5’ exonuclease activity with the point substitutions gluta-
mate5-to-alanine (E5A) and lysine12-to-glutamine (K12Q) also signifıcantly
compromised the metastasis suppressor function of NME1 (Zhang et al., 2011).
To identify genes that are regulated by NME1 and potentially modulate its me-
tastasis suppressor activity, we compared the gene expression profıle induced by
forced expression of wild-type NME to those obtained with the E5A and K12Q
mutants. Using the human Exon 1.0 Affymetrix microarray , we identifıed 13
genes whose expression was modulated by wild-type NME1 expression, but not
by the suppressor-defıcient mutants, which were designated as metastasis sup-
pressor signature (MSS) genes. We are currently refıning the list to genes that
have the highest clinical relevance through observing expression profıles of the
MSS genes in clinical datasets. Preliminary results of unsupervised hierarchal
clustering of GEO melanoma dataset GSE8401 showed that expression of the
MSS gene, aldolase C (ALDOC), was signifıcantly lower in a subset ofmetastatic
melanoma lesions compared to primary melanomas. Western blot and qPCR
analysis confırm that NME1 induces expression of ALDOC in bothWM793 and
M14 melanoma cell lines, and that induction of ALDOC is dose-responsive to
NME1 expression as observed in the WM1158 metastatic melanoma cell line.
Further, NME1 induction of ALDOC is specifıc compared to the ALDOA and
ALDOB isoforms. Recent studies have indicated aldolase isoforms canmodulate
motile and invasive phenotypes of cancer cells (Li et al., 2015 & Hu et al., 2016),
suggesting regulation of ALDOC expression may represent a key mechanism
underlying the metastasis suppressor function of NME1. Current work is fo-
cused onmeasuring the impact of NME1-induced expression of ALDOC on the
metastatic potential of melanoma cells in culture and in vivo.
#4846 The metastasis suppressor NME1 is recruited to DNA double
strand breaks.Gemma S. Puts,1 Stuart G. Jarrett,2 Devin Snyder,1 Richard Vin-
cent,1 YingWang,1 Katie Leonard,1 Ben Portney,1 Feyruz Rassool,1 Michal Zal-
zman,1 David M. Kaetzel1. 1Univ. of Maryland School of Medicine, Baltimore,
MD; 2University of Kentucky, College of Medicine, Lexington, KY.
NME1 is a potent suppressor of metastasis, and reduced expression has been
associated with aggressive melanoma. The nucleoside diphosphate kinase and
3=-5’ exonuclease (3=-5’ EXO) activities of NME1 protein both contribute to its
metastasis suppressor activity. 3=-5’ exonucleases are important for proofread-
ing during DNA repair and synthesis, suggesting a potential role for NME1 in
maintenance of genomic stability in melanoma. Although impairment of DNA
repair activity has been implicated in melanoma risk, its contribution to mela-
noma initiation and progression is not well understood. We have shown previ-
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ously that both enzymatic activities of NME1 are critical for repair of UV-in-
duced DNA damage via nucleotide excision repair. In the current study,
chromatin immunoprecipitation was used to demonstrate recruitment of
NME1 to DNA double-strand breaks (DSBs), representing the fırst evidence of
direct recruitment of NME1 to sites of DNA damage. Induction of DSBs with
gamma irradiation (-IR) or bleomycin promoted rapid physical association of
NME1 with H2AX, ATM, NBS1 and RAD50. In addition, treatment of mela-
noma cells with -IR triggered a physical association of NME1 with XRCC4, an
effector of the non-homologous end-joining (NHEJ) pathway.We are currently
investigating whether knockout of NME1 induces a switch from NHEJ to the
homologous recombination (HR) pathway, a slower but higher fıdelity form of
DSB repair, using plasmid repair assays. We are also using plasmid rescue to
study the role of NME1 on the fıdelity of NHEJ repair. Overall, our study indi-
cates for the fırst time direct participation ofNME1 in amolecularmechanismof
DSB repair in both normal and transformed cells. In addition, these data suggest
a novel mechanism of metastasis suppressor function for NME1, with loss of
NMEexpression in tumor cells conferring genetic instability and enhancedmet-
astatic potential.
#4847 NME1 mediates a switch in beta integrin subunits that correlates
with prolonged patient survival.M. Kathryn Leonard,1 Grace Snow,1 Marián
Novak,1 Joseph R.McCorkle,2 Xiuwei H. Yang,3 Alexey Belkin,1 DavidM. Kaet-
zel1. 1University of Maryland, Baltimore, Baltimore, MD; 2St. Jude Children’s
Research Hospital, Memphis, TN; 3University of Kentucky, Lexington, KY.
Expression of the metastasis suppressor NME1 in melanoma is associated
with reduced cellular motility, invasion, and metastasis, but the molecular
mechanisms underlying this activity are not completely understood. Herein we
report a novel mechanism through which NME1 modulates focal adhesion dy-
namics via regulation of integrins 1 and 3. Stable expression of NME1 signif-
icantly altered focal adhesion turnover at the cell periphery. Interestingly, over-
expression of NME1 resulted in a switch from predominantly fast recycling
41 integrins to slower recycling v3 integrins. Contrary to its regulation of
other cell surface receptors, the inhibition of integrin 1 and induction of integ-
rin 3 by NME1 was found to occur at the transcriptional level rather than
through dynaminmediated endocytosis. Induction of integrin3 required both
the 3-5’ exonuclease and nucleoside diphosphate kinase (NDPK) activities of
NME1, which are also required for its metastasis suppressor activities in vivo.
Further suggesting that the induction of integrin3 is involved in themetastasis
suppression function of NME1, knockdown of integrin 3 signifıcantly in-
creased the invasion capability of cells expressing NME1 in vitro compared to
control cells. Analysis of metastatic melanoma patients in the TCGA showed
individuals with a 1.5x or greater increase in integrin 3 mRNA had a signifı-
cantly longer overall survival times. Additionally, an inverse correlation was
observed between NME1 and integrin 1mRNA in an independent microarray
of primary melanomas. The inverse correlation of NME1 and integrin 1 RNA
was also a strong predictor of prolonged distant disease free and overall survival
in patients with the basal-like subtype of breast carcinoma. Together, these data
strongly suggest NME1 prevents metastasis of human melanoma and some
types of breast cancers by altering beta integrin expression to reduce recycling of
focal adhesions and, ultimately suppress of cell motility.
#4848 The functional synergism and pro-metastatic role of FOXM1 and
CENPF in hepatocellular carcinoma.Wai Ling Macrina Lam, Lo Kong Chan,
Daniel Wai-Hung Ho, Charles Shing Kam, Irene Oi-Lin Ng. The University of
Hong Kong, Hong Kong, Hong Kong.
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death
worldwide and metastasis is regarded as the major cause of HCC-associated
lethality. In this study, we have analysed the TCGA whole-transcriptome se-
quencing data of paired human HCC samples (n50), and identifıed Forkhead
Box M1 (FOXM1) and Centromere Protein F (CENPF) to be the top-listing
upregulated genes. Interestingly, both of them are the essential components in
cell-cycle progression. FOXM1 encodes for the cell-cycle-dependent transcrip-
tion factor that regulates genes for DNA replication and mitosis, while CENPF
encodes for the centromere protein that is required for kinetochore function and
chromosome segregation in mitosis. We hypothesized that the upregulation of
FOXM1-CENPF signaling axis may drive hepatocarcinogenesis. In our human
HCC cohort (n34), FOXM1 and CENPF were shown to be upregulated com-
pared with the non-tumorous liver tissues, and their mRNA expressions were
positively correlated (p0.0001). Co-upregulation of FOXM1 and CENPF in
patient samples was demonstrated to be positively correlatedwith the absence of
tumor encapsulation (p0.035) in our clinico-pathological correlation analysis,
whereas the samples without their co-upregulation was less likely to be corre-
lated with venous invasion (p0.045). This indicated that FOXM1 and CENPF
are likely to be associated with HCCmetastasis synergistically. Stable single and
co-knockdown clones of FOXM1 and CENPF in four HCC cell lines (BEL7402,
SMMC-7721, MHCC-97L, Huh7) were established using short-hairpin (sh)
RNA approach for subsequent functional characterization. Both single and co-
knockdown of FOXM1 and CENPF cells have shown reduced proliferation rate
(p0.05) in cell proliferation assay. Moreover, all single and co-knockdown of
FOXM1 and CENPF cell lines were found to have a at least 2-fold reduction in
migration and invasion rate (p0.0001) in transwell cellmigration and invasion
assay. These suggested that FOXM1 and CENPF are critical for HCC cell pro-
liferation, migration and invasion. To assess the translational signifıcance of
targeting FOXM1 and CENPF, seven HCC cell lines (BEL7402, SMMC-7721,
MHCC-97L, Huh7, Hep3B, HepG2, PLC/PRF/5) were challenged with thio-
strepton and zoledronic acid, which are inhibitors against FOXM1 and CENPF,
respectively. Intriguingly, both individual and combined treatments of these
inhibitors effectively inhibited HCC cell growth. It was also demonstrated that
such inhibition acts via suppressing the respective endogenous transcript and
protein expression of FOXM1 and CENPF. Taken together, our study has dem-
onstrated that FOXM1 and CENPF play a critical oncogenic role in HCC and
they may function as an attractive molecular therapeutic target. This study is
supported in part by Health and Medical Research Fund (03142836).
#4849 ELMO1 promotes metastasis in colorectal cancer cells via activa-
tionofMAPK/ERKsignalingpathway.Xiao-binZheng,1ChiZhou,1Hai-chun
Cheng,2 Tuo Hu,1 Hua-shan Liu,1 Xuan-hui Liu,1 Xian-rui Wu,1 Feng-wei
Wang,3 Yu-feng Chen,1 Jian-ping Wang,1 Xiao-sheng He,1 Ping Lan1. 1Depart-
ment of Colorectal Surgery, the Sixth Affıliated Hospital of Sun Yat-sen Univer-
sity, Guangzhou, China; 2Department of General Surgery, the Affıliated Shenzhen
Shajing Hospital, Guangzhou Medical University, Shenzhen, China; 3State Key
Laboratory of Oncology in South China, Collaborative Innovation Center for
Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Background and Aim: Engulfment and cell motility 1 (ELMO1) has been
linked to the invasive phenotype of various types of cancer cells such as glioma
cells, rhabdomyosarcoma cells, ovarian cancer cells and so on. However, the
biological functions of ELMO1 in colorectal cancer (CRC) cells remains unclear.
The aim of this study is to evaluate the role of ELMO1 in the metastasis in CRC.
Methods: The expression level of ELMO1 was detected using quantitative RT-
PCR and western blot in 9 CRC cell lines and 1 human colon epithelial cell line
NCM460. ELMO1 was overexpressed via lentiviral vector system and silenced
using specifıc small interference RNA (si-ELMO1) in HCT116 and SW620.
Then wound-healing, migration assay and invasion assay were carried out to
investigate the function of ELMO1 in CRC cells.Western blot was performed to
detect the change of signalingmolecule extracellular signal-regulated kinase 1/2
(ERK1/2) following the down-regulated or up-regulated expression of ELMO1.
Results: ELMO1 expression was inhibited by si-ELMO1 and was overexpressed
by ELMO1-cDNA in HCT116 and SW620. Ectopic expression of ELMO1 in
HCT116 and SW620 was shown to promote migration and invasion, while in-
hibited ELMO1 expression suppressed the capacity of cell migration and inva-
sion. Furthermore, ELMO1 induced migration and invasion in CRC cells was
found to be associatedwith the activation ofMAPK/ERKpathway. Conclusions:
High expression of ELMO1 was found to be associated with the metastasis via
the activation ofMAPK/ERK signaling pathway. This fınding provides a molec-
ular basis for the role of ELMO1 in the progression of CRC, which may suggest
a novel target for the treatment of CRC.
#4850 Overexpression of P62/IMP2 promotes metastasis in hepatocellu-
lar carcinoma via inhibition of E-cadherin expression.Mengtao Xing, Pei Li,
Jitian Li, Jianxiang shi, Liping Dai, Giulio Francia, Jianying Zhang. UT El Paso,
El Paso, TX.
Hepatocellular carcinoma (HCC) is one of the most common type of cancer
and the third leading cause of cancer related death in worldwide. Insulin-like
growth factor 2 mRNA binding protein 2 (p62/IMP2/IGF2BP2) was originally
reported as an autoantigen in HCC which belongs to IMPs family. The IMPs
family contains three members: IMP1, IMP2 and IMP3, which share similar
protein structure. IMPs are oncofetal proteins, which are expressed during em-
bryogenesis and lost in most tissues in adults. Therefore, p62/IMP2 can be used
as a potential biomarker for early diagnosis of HCC. We have evaluated the
expression of p62/IMP2 protein both in human tissues and HCC cell lines by
immunohistochemistry andwestern blotting analysis, and found that p62/IMP2
protein is overexpressed in human HCC tissues compared with normal human
liver tissues (score 10.30, n40 vs. score5.23, n30, p0.05). The expres-
sion of p62/IMP2 was scored by immune-staining intensity and positively im-
mune-staining cell numbers. At the same time,we found that p62/IMP2was also
overexpressed in several HCC cell lines. Stable p62/IMP2 overexpression and
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depletion SNU449 human HCC cell line was made by using p62/IMP2 cDNA
transfection and lentivirus mediated knockdown approaches, and it was further
confırmed by western blotting analysis. Wound healing assay has shown that
overexpression of p62/IMP2 can signifıcantly enhance the cell migration ability
in SNU449 cells. On the contrary, the depletion of p62/IMP2 can reduce the
migration ability in SNU449 cells (p0.05). Moreover,MTT assay has also
shown p62/IMP2 overexpressed cells may have a higher rate of proliferation at
72h(p0.05). In addition, we have observed that overexpression of p62/IMP2
can signifıcant inhibit the expression of E-cadherin in western blotting analysis.
In summary, our data would suggest that overexpression p62/IMP2 may pro-
mote metastasis via inhibition of E-cadherin expression in HCC.
#4851 NOTCH signaling promotes metastatic seeding and growth of hu-
man breast cancer cells. Alexey Leontovich, Jeffrey Salisbury, Tufıa Haddad,
Matthew Goetz, James Ingle, Evanthia Galanis, Antonino B. D’Assoro. Mayo
Clinic College Of Medicine, Rochester, MN.
Background: NOTCH oncogenic signaling induces epithelial-to-mesenchy-
mal transition (EMT) and tumor stemness that play a critical role in driving
tumor progression. Following interaction ofNOTCHreceptors (NOTCH1, 2, 3,
and 4) with their ligands (DELTA-LIKE 1, 3, 4 and JAGGED 1, 2), -secretase
complex performs an intra-membrane cleavage releasing the NOTCH intracel-
lular domain (NNICD). NNICD translocates to the nucleus and induces the
expression of HEY1 and HES1 transcription factors that in turn orchestrate
NOTCH-mediated EMT and stemness reprogramming. Materials and Meth-
ods: Parental MCF-7 and unique metastatic MCF-7RAF-1 xenografts with con-
stitutively active MAPK signaling (D’Assoro et al., Oncogene 2014: 33:599-610)
were used to defıne the extent to which increased expression of NOTCH signal-
ing was linked to distant metastases. SKY analysis was performed to assess the
grade of chromosomal instability (CIN) in tumor xenografts. Stemness activity
was assessed by culturing breast cancer cells under non-adherent conditions to
generate mammospheres. Expression of CD24 luminal marker was character-
ized by FACS analysis and immunofluorescence. Global transcriptome analysis
was performed using Affymetrix® microarray. Highly invasive MDA-MB 231
breast cancer cells were used to perform a tail vein cancer cell-seeding assay. The
LY411575 -secretase inhibitor (Pan-NOTCH inhibitor) was used to block
NOTCH signaling in MDA-MB 231 cells. Results: Metastasis Initiating Cells
(MICs) isolated from the lungs of nude mice carrying MCF-7RAF-1 xenografts
exhibited a higher degree of genomic stability than primary tumor xenografts
that was characterized by the absence of centrosome amplifıcation and non-
clonal chromosomal abnormalities. MICs also showed higher mammosphere
forming capacity that was linked to lower expression of luminal marker CD24.
Signifıcantly, global transcriptome analysis showed that expression ofNOTCH3
and HES1 stemness genes was increased in MICs. To corroborate the role of
NOTCH signaling in inducing metastatic seeding, MDA-MB 231 breast cancer
cells were pre-treated with 1 M of LY411575 After 72 hours viable cells were
injected into the tail vein of immune-compromised mice to develop lung me-
tastases. While animals injected with untreated MDA-MB 231 cells developed
lung metastases, those injected with the LY411575-treated MDA-MB 231 cells
failed to develop lung metastatic lesions. Conclusions: These preliminary fınd-
ings demonstrate the role of NOTCH stemness signaling in promoting meta-
static seeding of breast cancer cells. Since NOTCH signaling is a “druggable
target”, these results also provide the rationale to develop novel NOTCH-tar-
geted therapies to inhibit tumor stemness and early onset of distant metastases.
#4852 Targeting cancer progression genes upregulated in CREB3L1-defı-
cient breast cancer cells. Deborah Anderson,1 Shari Smith,2 Farah Goubran,2
PaulMellor2. 1SaskatchewanCancer Agency, Saskatoon, Saskatchewan, Canada;
2University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Introduction:Our laboratory is interested in determiningways to block breast
cancer metastasis. We discovered that CREB3L1 (cAMP responsive element
binding protein 3-like protein), a stress-activated transcription factor, acts as a
metastasis suppressor in breast cancer. CREB3L1 is expressed ubiquitously in
noncancerous human breast cells and restricts expression of genes that promote
cell growth, angiogenesis, and migration. Loss of CREB3L1 expression is a fre-
quent event in high-grade metastatic human breast tumors and can result in
enhanced metastatic properties. Experimental Procedures: To establish the
mechanisms by which CREB3L1 exerts its tumor suppressive effects, a gene
expression microarray analysis was performed to determine which genes are
upregulated in CREB3L1-defıcient breast cancer cells. Six hundred and eighty
genes were statistically signifıcantly upregulated at least 2-fold in all 4 of the
CREB3L1-defıcient cell lines assessed. To focus our analysis, 4 genes were iden-
tifıed as potential targets for this study, given that they have previously been
shown to have a role in cancer progression. Knockdowns were generated for
each of the 4 genes in a CREB3L1-defıcient breast cancer cell line (HCC1806)
andmatchedCREB3L1-expressing cells (HCC1806HA-CREB3L1), as well as
a nontumorigenic control breast cell line (MCF10A). To knockdown expression
of each of the 4 targets, shRNAdirected at the gene of interest was transduced via
a lentiviral system into the cells. Cell-based assays were performed to character-
ize the properties of these cell lines, which included the Boyden chamber assay to
measure migration, soft agar assay to assess anchorage-independent growth,
and theMTT assay to evaluate cell proliferation. Results: Successful knockdown
at both the mRNA and protein level for each target gene was validated using
quantitative real time PCR and immunoblotting. Results from the MTT assay
verifıed that knockdown of each of the 4 gene targets did not affect cell survival
inMCF10A cells, confırming that these test genes are not essential for survival in
noncancerous breast cells (p  0.05). Similarly, knockdown of each of the test
genes did not affect cell proliferation inHCC1806 (	CREB3L1) cells, except for
a signifıcant decrease in proliferation inHCC1806CREB3L1-defıcient cells with
Gene 1 knockdown (p0.02). Preliminary results indicate that knockdown of
Genes 1, 2, and 4 inHCC1806CREB3L1-defıcient cells reduces cancer cell prop-
erties, including cell migration and anchorage-independent growth (p 0.05).
Conclusions: Promising candidates will be tested in follow-up mouse xenograft
studies. Encouraging results in these pre-clinical models would provide a strong
rationale for the development and testing of inhibitors to one or more of these
potential targets as a new therapeutic for the 30% of breast cancers that are
CREB3L1-defıcient.
#4853 NRP2b, a unique isoform of NRP2, promotes aggressive lung can-
cer phenotypes. Anastasios Dimou,1 Patrick Nasarre,1 Joyce Nair-Menon,1
Federico Cappuzzo,2 Lorenza Landi,2 Armida D’Incecco,2 Hidetaka Uramato,3
Takeshi Yoshida,4 Eric Haura,5 Monica Gooz,1 Kent Armeson,1 Robert Gem-
mill,1 Harry Drabkin1. 1Medical University of South Carolina, Charleston, SC;
2Istituto Toscano Tumori, Leghorn, Italy; 3Kanazawa Medical University, Uchi-
nada, Japan; 4KinkiUniversity Faculty ofMedicine, Charleston, SC; 5Moffıtt Can-
cer Center, Tampa, FL.
Neuropilins (NRPs) 1 and 2 are highly-related receptors for class 3 sema-
phorins, and interact with heparin-binding growth factors and their receptors
(e.g. HGF-MET, VEGF-VEGFR2 etc.). We previously reported that NRP2 is
upregulated by TGF and is required for its pro-tumorigenic activity. Here, we
show that this upregulation preferentially involves NRP2b, a largely uninvesti-
gated isoform encoding a divergent, yet highly-conserved C-terminus. Impor-
tantly, using a panel of lung cancer cell lines and orthotopic metastasis model,
NRP2b promoted migration, invasion, metastasis and tumorsphere formation,
whereas the prototype receptor, NRP2a had opposite effects. TGF-mediated
resistance to gefıtinib in EGFR mutated tumors also was dependent on NRP2b
expression. In addition, NRP2b, but not NRP2a, linkedMET activation byHGF
to AKT phosphorylation. Mechanistically, in co-immunoprecipitation assays,
we found that NRP2a robustly interacted with PTEN, while the interaction with
NRP2b was weak. At the clinical level, NRP2b expression was commonly up-
regulated in patient lung cancer samples and this upregulation was a signifıcant
poor-prognostic factor. Collectively, these data indicate that NRP2b plays an
important role in lung cancer invasion, metastasis and EGFR inhibitor resis-
tance. Furthermore, isoform-specifıc interactions between NRP2 and PTEN
may be responsible for the observed differences inMET signaling in response to
HGF.
#4854 Evaluating HDAC6 as a causal factor inmetastatic breast cancer to
develop immunotherapy. Debarati Banik,1 Melissa Hadley,1 Jennifer Kim,1
Tessa Knox,1 Jayakumar Nair,1 Alan Kozikowski,2 Sida Shen,2 Charu Vyas,1
Ashleyn Donohue,1 Eduardo Sotomayor,1 Alejandro Villagra1. 1The George
Washington University, Washington, DC; 2University of Illinois at Chicago, Chi-
cago, IL.
Histone deacetylases (HDACs), originally described as histone modifıers,
have recently been demonstrated to modify a variety of other proteins involved
in diverse cellular processes unrelated to the chromatin environment, including
the modulation of proteins related to cell cycle/apoptosis and immune regula-
tion. In contrast to the well-documented effects of HDAC inhibitors (HDACi)
in the control of cell cycle and apoptosis, their role in immune-biology is incom-
pletely understood.We have found that the pharmacological or genetic abroga-
tion of a single HDAC, i.e. HDAC6, inactivates the STAT3 pathway and modu-
lates the expression of immuno-regulatory proteins, including the down-
regulation of PD-L1, PD-L2 and B7-H4, important negative regulators of
immune function, often over-expressed in cancer cells; including breast cancer.
HDAC6 has been also involved in a number of structural functions related to
cellular motility, shape and intracellular transport through the regulation of the
acetylation of numerous targets, including tubulin and cortactin. This function
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is strongly suggestive ofHDAC6being a key player inmetastatic cancer progres-
sion. In our initial studies we observed that the selective HDAC6 inhibitor Nex-
turastat A is capable of reducing the tumor growth in a highly aggressivemurine
mammary carcinoma that mimics human triple negative breast cancer (TNBC),
under both orthotopic and subcutaneous conditions of implantation. Addition-
ally, we observed that the size and number of secondary tumor nodules in lungs
were signifıcantly diminished after theHDAC6i treatment. In order to boost the
anti-tumor T-cell response, we also tested check-point inhibitors against the
tumor (such as anti PD-1 and CTLA4 antibodies). While each of the standalone
treatments showed a certain degree of success in reducing tumor growth and
enhancing intra-tumoral IFN, we demonstrated that HDAC6i improves anti-
tumor immune responses when combined with immune check-point blockade.
#4855 Loss of USP18 represses invasion andmetastasis of lung cancer. Lin
Zheng, Lisa Mustachio, Yulong Chen, Xi Liu, Jason Roszik, Jonathan Kurie,
Ethan Dmitrovsky. UTMD Anderson Cancer Center, Houston, TX.
Metastasis is amajor cause of human lung cancermortality.Uncovering novel
targets andmechanisms involved in regulatingmetastasis is critical for develop-
ing effective ways to improve lung cancer survival. It is reported that ubiquitin
and ubiquitin-like pathways can regulate invasion and metastasis. We previ-
ously found that USP18 (Ubiquitin Specifıc Peptidase 18) is substantially up-
regulated in several cancers, including lung cancer. Engineered repression of the
deubiquitinase USP18 decreased growth, increased apoptosis and augmented
chemotherapeutic agent response of lung cancer cells. Our prior work showed
that loss of USP18 can destabilize specifıc oncogenic proteins and this results in
the marked reduction of lung cancer cell growth and in vivo tumorigenicity.
This study sought to explore the precise role of USP18 expression in invasion,
migration and metastasis of lung cancer. In murine (KC2 and 344SQ) and hu-
man (A549 and H1299) lung cancer cells with varying degrees of metastatic
potential, knock-down of USP18 by different short hairpin RNAs (shRNAs)
decreased cell growth and increased cell death as compared to vector control
transfectants. The fındings from wound-healing migration and Transwell inva-
sion assays established that USP18 knock-down in all studied lung cancer cell
lines conferred substantial reduction of migration and invasion versus vector
control transfected cell lines (p 0.001). Inmousemodels, USP18 knock-down
of lung cancer cell lines displayed a lower number of lung cancer metastasis in
vivo. To discern engaged mechanisms, Reverse Phase Protein Arrays (RPPAs)
were performed to interrogate over 300 growth-regulatory proteins in murine
(344SQ and KC2) and human (A549 and H1299) lung cancer cells following
USP18 knock-down. Using RPPAs, potential targets identifıed were differen-
tially expressed between USP18 knock-down and vector control transfected
lung cancer cells. Highlighted species included Myc, eEF2K (Eukaryotic Elon-
gation Factor 2Kinase), ProgrammedCellDeath 4 (PDCD4),Hes Family BHLH
Transcription Factor 1 (Hes) and Polo Like Kinase 1 (PLK1), among other spe-
cies. In addition, phosphorylated Acetyl-CoA Carboxylase (ACC), a key com-
ponent of the 5’-adenosine monophosphate-activated protein kinase (AMPK)
pathway, was signifıcantly affected in lung cancer cell lines following USP18
knock-down (p 0.05). Ingenuity Pathway Analysis and functional validation
are now underway to uncover specifıc pathways directly involved in the ob-
served reduction of lung cancer metastases. Taken together, this study impli-
cates the deubiquitinase USP18 as a molecular target to combat lung cancer
metastases.
#4856 HighmRNA expression of splice variant SYK short correlates with
poor hepaticmetastasis free survival in untreated lymphnode negative colon
cancer patients.Robert R. Coebergh van den Braak, Anieta S. Sieuwerts, Zarina
S. Lalmahomed, Sandra Bril, Annemieke M. Timmermans, Vanja de Weerd,
Michelle van der Vlugt - Daane, Anne van Galen, Shanshan Xiang, Katharina
Biermann, John A. Foekens, JohnW. Martens, Jan N. IJzermans. Erasmus Uni-
versity Medical Center, Rotterdam, Netherlands.
Introduction: In lymphnode negative (LNN) colon cancer 20%of the patients
will develop recurrence of disease. Identifıcation of these patients is an unmet
need. SYK, a protein kinase, has been ascribed both a tumor promoter and
suppressor role in epithelial cancers. The prognostic value of SYK and its splice
variants, largely uknown in colorectal cancer however, was explored in a clini-
cally well-defıned cohort of colon cancer patients. Methods: Total mRNA ex-
pression of SYK [SYK(T)] and of its two splice variants SYK short(S) and SYK
long(L)weremeasured usingRT-qPCR in a clinically well-defıned prospectively
collected cohort of 240 colon cancer patients (n160 untreated lymph node
negative [LNN] andn80 adjuvant treated lymphnode positive [LNP] patients)
selected from the MATCH-cohort. mRNA expression levels were related to
microsatellite instability (MSI), mRNA expression of epithelial (EPCAM), stro-
mal (BGN, FAP, INHBA) and infıltrate markers (VEGFA, CD45), known CRC
mutations (n238), and disease free (DFS), hepatic metastasis free (HFS) and
overall survival (OS). Results: Overall increased SYK levels were associated with
stage I/II, a left-sided located primary tumor andMicroSatellite Stability (MSS).
However, these associations and their interrelation differed signifıcantly be-
tween SYK(T), SYK(S) and SYK(L) expression implicating an added value for
measuring mRNA expression of the splice variants next to SYK(T). SYK(T),
SYK(S) and SYK(L) levels all showed a signifıcant positive correlation with the
expression of EPCAM, FAP was weakly negatively associated with SYK(S) and
VEGFAwasweakly positively correlatedwith SYK(T) and SYK(S). This suggests
a higher expression of SYK in epithelial-rich, stromal-poor tumors. SYK(T) and
SYK(S) expression was signifıcantly lower in tumors with a BRAF or PTEN
mutation (mt) compared to wild type (wt) tumors. Although others reported
differential expression of SYK between KRAS-dependent and KRAS-indepen-
dent cell lines andKRASmt versus wt tumors in 221 TCGA-samples (p0.008),
we observed no signifıcant differences for expression of SYK(T), SYK(S) and
SYK(L) between KRAS-mutant (mt) and KRAS-wild type (wt) tumors. In the
LNN group, using univariate Cox regression analysis increasing mRNA expres-
sion of SYK(T) (HR2.05 95%CI1.01-4.17 p0.047) and SYK(S) (HR1.83
95%CI1.09-3.05 p0.021) was associated with worse HFS, which remained
signifıcant for SYK(S) when correcting for the number of assessed lymph nodes
(HR1.83; 95% CI1.08-3.12; p0.026 and HR1.27; 95%CI1.009-1.60;
p0.042). No other signifıcant associations between SYK(T), SYK(S) and
SYK(L), and DFS, HFS and OS were observed. Conclusion: In our untreated
LNN colon cancer cohort SYK(S) is a pure prognostic marker for HFS. These
results may help to identify LNN patients at overall low risk to develop liver
metastases.
#4857 TAK1 mediated IL1 expression as autocrine signaling to promote
breast cancer metastasis. Oihana Iriondo, Mostafa Elhodaky, Yarong Liu,
Grace Lee, Julie E. Lang, Pin Wang, Min Yu. Univ. of Southern California, Los
Angeles, CA.
TGF-activated kinase 1 (TAK1), a serine/threonine kinase from the MAP-
KKK family, is regulated by different cytokines such as IL1, TGF, TNF and
BMPs, and it is therefore a key player in the cellular responses induced by
changes in the microenvironment. TAK1 regulates cell survival, differentiation
and inflammatory responses by activating other intracellular kinases such as
p38, JNK or IKK. TAK1 activation is thought to influence the progression of
several types of cancer, including lymphomas and pancreatic, colon, liver and
breast cancer. In this study, we aimed to investigate the mechanisms by which
TAK1 regulates breast cancer progression. (5Z)-7-Oxozeanol is a compound
that inhibits the kinase activity of TAK1. Treatment ofmice injectedwithMDA-
MB-231 cells with (5Z)-7-Oxozeanol containing nanoparticles reduced metas-
tasis formation, while growth of the primary tumor was not affected. TAK1
involvement in metastasis was confırmed by xenotransplantation experiments
done with MDA-MB-231 cells overexpressing wild type or dominant negative
forms of TAK1.Using these stable cell lines, we confırmed that TAK1 is required
for p38 activation induced by several cytokines. Interestingly, cells cocultured
with macrophages showed a TAK1-dependent increase in the expression levels
of IL1 and IL1, which can lead to TAK1 activation themselves. These cyto-
kines were also detected in cancer cells that colonized the mouse lung, suggest-
ing that the lung microenvironment could promote the initiation of a positive
feedback loop by cancer cells, promoting the growth of metastatic lesions. Dis-
ruption of this positive autocrine feedback loop may be a potential therapeutic
approach to suppress breast cancer metastasis to the lung.
#4858 AK4 promotes colorectal cancer progression and metastasis. Yau
Hei Yu, Joanna HungMan Tong, Yi Pan, RaymondWai Ming Lung, Ka Fai To,
Anthony Wing Hung Chan. The Chinese University of Hong Kong, Hong Kong.
Metastatic colorectal cancer (CRC) is a fatal disease with a poor prognosis. It
is crucial to understanding the underlying pathogenesis to battle this dismal
condition. We previously identifıed that AK4, a gene on chromosome 1p31.3
encoding a member of adenylate kinase family enzymes, was progressively up-
regulated from normal colon, primary CRC to metastasis by mRNA gene ex-
pression microarray of paired CRC samples. This study was aimed to validate
the overexpression of AK4 and explore in-vitro effects in CRC.We fırstly exam-
ined themRNAexpression level of AK4 in a panel of CRC cell lines. AK4mRNA
expression was higher in CRC cell lines (n8) than normal colon cell line, and
signifıcantly higher in advanced stage cell lines (n4,Dukes’ C andD) than early
stage ones (n4, Dukes’ A and B) (P0.03). We further evaluated expression
level of AK4 in two different cohorts of clinical samples. The fırst cohort con-
sisted of 18 paired primary CRCs and its corresponding normal colonicmucosa,
and 27metastaticCRC (including 15 caseswith paired primaryCRCandnormal
colonic mucosa). AK4 mRNA level was signifıcantly higher in metastatic CRC
TUMOR BIOLOGY: Metastasis Suppressors and Promoters
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171242
than normal colon (P0.001), and metastatic CRC than primary CRC
(P0.001). Among 15 cases with paired primary and metastatic tumors, 14
(93.3%) demonstrated higher AK4 in metastatic tumors than their primary
counterparts(P0.05). The second cohort composed of 190 consecutive pri-
mary CRCs. Upregulation of AK4 protein expression evaluated by immunohis-
tochemistry was found in 68.4% of CRC, and associated with advanced AJCC
stage (P0.001), poorer overall survival (P0.002) and worse disease-free sur-
vival (P0.001). To evaluate functional properties of AK4 in CRC, we knocked
down AK4 on a CRC cell lines with high endogenous AK4 expression (DLD1,
HCT116 and SW620) by siRNA. knockdown of AK4 signifıcantly reduced an-
chorage-dependent colony forming ability (P0.05) and eliminated migratory
(P0.05) and invasive (P0.05) abilities. In conclusion, AK4 is a potential on-
cogene upregulated in metastatic CRC and exhibiting in-vitro oncogenic prop-
erties. AK4 may play an important role in tumor progression and metastasis.
#4859 The role of LPAR1 and fıbrosis in breast cancermetastasis.Danielle
L. Brooks, LalageWakefıeld, Patricia Steeg.National Cancer Institute, Bethesda,
MD.
Tumormetastasis is a complex process inwhich tumor cells disseminate from
the primary tumor to colonize distant organ sites. The majority of breast cancer
related deaths are from metastatic disease, in part due to acquired resistance to
chemotherapies. Aberrant tumor microenvironment often resembles fıbrotic
lesions where dysregulated cell signaling pathways alter tissue architecture and
promote chronic inflammation. In fact, multiple studies have demonstrated a
positive link between cancer metastasis and fıbrosis, a condition characterized
by increased activated fıbroblasts (defıned as SMA positive) and extracellular
matrix (EMC) such as collagen 1 secretion. Lysophosphatidic acid (LPA) is a
signaling molecule that activates a family of G-protein coupled LPA receptors
(LPARs) in both metastasis and fıbrosis. Specifıcally, LPAR1 is highly expressed
in metastatic breast cancer cell lines, and its activation is involved in the coloni-
zation and proliferation of cancer cells during the metastatic process. Our pre-
vious data have shown that inhibition of LPAR1 reduced themetastatic potential
of breast cancer cells in vitro and in vivo. We sought to further study the rela-
tionship between metastasis, fıbrosis and LPA signaling using mouse models of
metastatic breast cancer. First, we investigated the extent to which metastasis is
accompanied by fıbrosis by utilizing 11 spontaneous mouse tumor models of
metastatic breast cancer. Mouse lung sections were stained with either SMA,
collagen 1, orMasson’s trichrome (pan collagen fıber stain) followedbyAshcroft
scoring. To evaluate whether targeting the observed fıbrosis therapeutically
could prevent metastasis, mice were injected intravenously with the breast can-
cer cell lineMDA-MB-231T followed by randomization to treatmentwith either
Nintedanib or Pirfenidone (two FDA approved drugs for idiopathic pulmonary
fıbrosis, IPF). Separately, mice were also treated with doxorubicin or paclitaxel,
both of which are used clinically in treating metastatic disease. We found that
fıbrosis occurred in themajority of themouse tumormodels examined (9 out of
11), although the extent of fıbrosis was heterogeneous acrossmodels. Treatment
of lung metastases with IPF drugs alone, however, did not show effıcacy in
reducing metastatic burden. Interestingly, we observed that while treatment of
lung metastases with chemotherapy reduced metastasis, it signifıcantly in-
creased the amount of fıbrosis observed compared to vehicle treated mice. This
fınding is signifıcant asmost patients diagnosedwith breast cancerwill receive at
least one round of chemotherapy in the course of treatment. Therefore, further
studies will look to evaluate whether targeting fıbrosis with LPAR1 or LPA
inhibitors is more effective when given concurrently or post chemotherapy
treatment as a means to decrease overall metastatic burden.
#4860 The role of VE-cadherin in small cell lung cancer progression. Stu-
art C. Williamson,1 Sarah Pearsall,1 Francesca Trapani,1 Benjamin Abbott,1
Melanie Galvin,1 Fiona Blackhall,2 Kristopher Frese,1 Kathryn Simpson,1 Caro-
line Dive1. 1Cancer Research UKManchester Institute,Manchester, United King-
dom; 2Department of Medical Oncology, Manchester, United Kingdom.
Background: Small cell lung cancer (SCLC) accounts for 12% of lung can-
cers worldwide. Although the majority of patients initially respond well to che-
motherapy, responses are short lived and the disease is characterized by rapid
progression, earlymetastasis and an overall poor prognosis.Wehave shown that
a subset of aggressive SCLC tumor cells can undergo vasculogenic mimicry
(VM), an epithelial to endothelial-like transition, leading to the formation of
blood-perfusing channels independent of host vasculature.We have shown that
VE-Cadherin (VE-Cad) is necessary for VM in a SCLC xenograft model and is
present in VM channels in CTC explant tumors (CDX). Additionally, a rare
subset of SCLC circulating tumor cells (CTCs) co-express cytokeratin and VE-
Cad. We sought to explore the impact of VE-Cad on SCLC biology; specifıcally
regarding aggressive nature of this disease. Methods: NCI-H446 (H446) cells
were depleted for VE-Cad with shRNA knockdown (KD) or CRISPR-Cas9
knockout via VE-Cad targeted guide RNAs. VM was assessed in vitro via a
channel forming assay on Matrigel. Cells were implanted subcutaneously into
immunocompromised mice and assessed for chemotherapy response and met-
astatic capacity. VMwas assessed in vivo with Periodic Acid Schiff (PAS)/CD31
immunohistochemistry (IHC). Metastases were assessed in H446 xenografts in
vivo by IHC for human VE-Cad and human mitochondria. Results: H446 pa-
rental cells grew rapidly in vivo and formed extensive lung metastases. Loss of
VE-Cad expression resulted in tumors that took longer to establish, had fewer
VM structures and had reduced ability to form metastases in vivo and reduced
migration and invasion capacity in vitro. In mice bearing VE-Cad KD tumors
with reduced VM, treatment with cisplatin, the standard of care for SCLC, re-
sulted in reduced intratumoral drug delivery. This was in keeping with reduced
vascularity in VM low tumors, but conversely, these mice exhibited increased
chemosensitivity. Chemosensitization was also observed in vitro, suggesting
drug sensitivity is independent of both VM vessel formation and drug delivery.
VE-Cad depletion in tumors also led to the expression of CD56, a classic neu-
roendocrine SCLC marker, suggesting the adoption of a more differentiated
phenotype. This was confırmed by assessment of a signature of ’stem-like’ and
VM associated genes by qPCR. VM competent cells clustered together, while
VE-CadKD caused loss of this signature and clusteringwithmore differentiated
SCLC cells which are incapable ofVM.Conclusions: VE-Cad has a broad impact
on SCLC biology. Depletion of VE-Cad directly inhibits VM vessel formation,
leads to increased drug sensitivity, and decreases the metastatic potential of
these cells, which also become more differentiated. Future work will investigate
the targeting of VE-Cad signaling for therapeutic benefıt, and determine
whether this recapitulates the drug sensitivity and metastasis data observed in
our model.
#4861 The role of PRAME inpromotinguvealmelanomametastasis.Mar-
garet I. Sanchez, Matthew G. Field, Jeffım N. Kuznetsov, Stefan Kurtenbach,
Dien Pham, James W. Harbour. University of Miami, Miami, FL.
Uveal melanoma (UM) is the most common primary eye cancer and has a
predisposition for fatal metastasis. Our group has shown that UMs can be cate-
gorized by gene expression profıling (GEP) into twomolecular classes associated
with metastatic risk: Class 1 (low metastatic risk) and Class 2 (high metastatic
risk). While the majority of Class 2 UMs (71%) metastasize, only 38% of Class 1
UMs metastasize. Our group was the fırst to identify the cancer-testis antigen
PRAME as a biomarker for increased metastatic risk in Class 1 UMs, and sub-
categorized these tumors into Class1 PRAME (intermediate metastatic risk)
and Class1 PRAME- (low metastatic risk) subgroups. Further we identifıed
PRAMEwas associatedwith shorter time tometastasis andworse prognosis in
class 2 patients. We have now shown that this PRAME expression is correlated
with hypomethylation in the promoter region of the gene, suggesting a mecha-
nism for its expression. Since we have previously shown that PRAME is associ-
ated with early metastasis in Class 1 and Class 2 UMs, we hypothesized that
PRAME plays a direct role in UM metastasis. To better understand the role of
PRAME in UM, we used Class1PRAME (F41) and Class1PRAME– (Mel290)
UM cell lines to develop in vitro models to study the role of PRAME. Since F41
cells are PRAME and highly metastatic, we constitutively silenced PRAME
with a V5 tag (F41 shPRAME-V5). For Mel290 cells, we overexpressed PRAME
to see whether this cell line, which does not induce metastatic death, became
more malignant. We confırmed the silencing and overexpression of PRAME in
our transformed cells with western blot. For cell proliferation, we found a slight
increase in the Mel290 PRAME cells compared to non-transformed Mel290.
Strikingly, in F41 cells, knockdown of PRAME led to complete cell death. In a
xenograft animal model, NSG male mice were injected with either Mel290
PRAME-V5, Mel290, F41 shPRAME-V5 or F41 TET-empty vector cells. We
found that PRAMEoverexpressing cell lines (Mel290 PRAME-V5 andF41TET-
empty vector) induced rapid, multiple and aggressive livermetastases that led to
death, whereas the non-expressing PRAME cells (Mel290 and F41 shPRAME-
V5) did not present macro or micrometastasis in any cases. This data highly
suggests that PRAME overexpression is involved in UM metastasis. Thus,
PRAMEmRNA expression is not only a prognostic biomarker but also could be
an important target for treatment.
#4862 SORBS1-AHNAK complex regulates metastatic properties of can-
cer.Woo-Cheol Cho, Ji-Eun Jang, Ja-Lok Ku. Seoul National University, Seoul,
Republic of Korea.
Purpose: CAP encoded by SORBS1,Vinexin andArgBP2 is participated in the
SoHo family of proteins. The SoHo protein interacts with different signaling
molecules and involves with cell migration, and has been implicated in a variety
of cellular processes including insulin-stimulated glucose transport. CAP has
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specifıc role in the stabilization of adhesion complexes and the consequent effect
of cell migration. It is possible that CAP or complex between CAP and other
proteins induces change of cancer cell characters.We assumed that SORBS1 has
substantial role of cell proliferation, migration and interaction with other sub-
cellular proteins. Methods and materials: To elucidate endogenous role of
SORBS1, colorectal cancer cell lines were manipulated by pcDNA, siRNA and
shRNA in some colorectal cancer cell lines. Function of SORBS1 as regulator of
cancer proliferation was demonstrated by cell cycle assay. And several methods
including western blotting, cell migration assay and immunoprecipitation assay
were performed for determining role of SORBS1 related other metastatic prop-
erties. Conclusion: Colony formation ability and proliferation were induced by
SORBS1-overexpression in HT29 cell line. In contrast, transient suppression of
SORBS1 inhibits cell proliferation. Moreover, when SORBS1 was constantly
suppressed in HCT-116 and SNU-C4 cell line, cell migration was impeded.
According to immunoprecipitation data, we chose the AHNAK protein as the
convincing candidate protein related with SORBS1. An interaction of SORBS1
and AHNAK was observed in both cytoplasm and nucleus. Expression level of
SORBS1 and AHNAK was also negative correlation in extraction of cytoplasm
and nucleus. SORBS1 and AHNAK bind each other as form of protein complex,
however, AHNAK known as nucleoprotein is abundant in both cytoplasm and
nucleus when SORBS1 is suppressed. Consequently, these results indicate that
SORBS1 has a key role of cancer cell growth and invasiveness through regulation
of AHNAK expression and degradation.
#4863 Aurora-A kinase: a nuclear driver of metastasis. Kristina Marinak,1
Anna Kiseleva,2 Yuriy Loskutov,1 Matthew Smolkin,1 Elena Pugacheva1. 1West
Virginia University, Morgantown,WV; 2Fox Chase Cancer Center, Philadelphia,
PA.
Aurora-A Kinase (AURKA) is a serine/threonine kinase that is critical for
mitosis. AURKA is overexpressed in 96% of human cancers, including breast
cancer. It has been previously shown that AURKA localizes to the nucleus in
breast cancer metastases and especially in metastases of Triple Negative
Breast Cancer (TNBC). Our objective is to defıne the role of nuclear AURKA
in breast cancer metastasis in TNBC. Here we report that TNBC cells vary in
amount of nuclear AURKA and this potentially correlates with their meta-
static capabilities. Based on our preliminary fındings we hypothesized that
nuclear AURKA promotes cell survival and resistance to apoptosis in the
metastatic niche. To test this hypothesis we created TNBC cell lines with
CRISPR/Cas9 based deletion of endogenous AURKA. We also constructed
exogenous AURKA specifıcally targeted to the nucleus by addition of a nu-
clear localization signal (NLS) or cytoplasm via addition of a nuclear exclu-
sion signal (NES), respectively. To allow for in vitro and in vivo rescue
experiments with exogenous NES or NLS AURKA in sgAURKA expressing
TNBC cells, we introduced several silent mutations to avoid sgAURKA tar-
geting. In our pilot orthotopic xenograft study with MDA-MB-231-luc2-
Cas9 (TNBC) cells expressing sgAURKAwithWTAURKA, NLS-AURKA or
AURKA-NES shows a trend of increased metastatic colonization in the AU-
RKA-NLS group. Overall, our results indicate that the amount of nuclear
AURKA is increased in metastatic breast cancer cell lines and metastases of
TNBC, but the mechanism of this translocation is currently unknown. Elu-
cidation of this mechanism is critical for development of new therapeutical
strategies for control and eradication of metastatic disease.
#4864 Role of AIB1 -4 inmalignant progression of breast cancer.Ghada
M. Sharif, Virginie Ory, Anton Wellstein, Anna Riegel. Georgetown University,
Washington, DC.
The nuclear co activator AIB1 is amplifıed and/or overexpressed in up to 60%
of breast cancers. We have previously described a splice variant of AIB1 (
4)
missing exon 4 that results in an N-terminally truncated protein. Full length
AIB1 transcriptional function can be repressed by the tumor supressorANCO1/
ANKRD11. However, 
4 is missing the ANCO1 binding domain and is not
transcriptionally suppressed. More metastatic variants of isogenic breast or co-
lon cancer cell lines have signifıcantly increased levels of
4 relative to full length
protein. 
4 levels also increase in breast tissue samples as they transition in
malignant progression.We conjectured that small increases in
4 protein in the
cell could have potent effects onmalignant progression. To determine the func-
tional signifıcance of 
4 in malignant progression we developed DCIS (ductal
carcinoma in situ) cell lines that only express this isoform and not the full length
protein. We engineered these lines by using CRISPR technology targeted at the
exon 3/4 splice junction. The resulting lines were signifıcantly more invasive in
ECIS endothelial invasion assays. In vivo, intracardiac zebrafısh injections of the

4-DCIS lines showed higher extravasation from the tail vasculature compared
to the parental line. Subcutaneous xenografts in athymic nude mice grew larger
tumors, presentedmore invasive lesions andmetastases. Also,
4-DCIS spheres
growing in matrigel, showed disorganization and enhanced invasion into the
matrix. In conclusion these data suggest a model where the increased splicing of
AIB1 to the 
4 variant alters transcription at specifıc target genes and contrib-
utes to the metastatic phenotype.
#4865 The functional and clinicopathological analysis of hypoxia induc-
ible factor-1 (HIF1-) in head and neck squamous cell carcinoma. Yuichi
Ikari,1 Hiroyuki Ozawa,1 Yorihisa Imanishi,2 Toshiki Tomita,1 Mariko Seki-
mizu,1 Yoshihiro Watanabe,3 Fumihiro Ito,1 Shin Saito,1 Kaoru Ogawa1. 1Keio
University School of Medicine, Tokyo, Japan; 2Kawasaki Municipal Hospital,
Kawasaki, Japan; 3Saiseikai Central Hospital, Tokyo, Japan.
Introduction: Tumor hypoxia is considered to be associated with progres-
sion in various cancers. Hypoxia inducible factor-1 (HIF-1) is one of the
molecules which play a key role in tumor hypoxia. High HIF-1 expression
is reported to have an impact on poor prognosis and resistance to chemo-
therapy or radiotherapy in head and neck squamous cell carcinoma (HN-
SCC). However, the effect and mechanism of HIF-1 on tumor metastasis in
HNSCC is still unclear. The aim of the present study was to investigate the
molecular targets of HIF1- relevant to metastasis, and to reveal the impact
of HIF1- on HNSCC metastasis by using clinicopathological assays. Meth-
ods: The cell proliferation rate with or without HIF-1 inhibitor (KC7F2) in
HNSCC cell lines (FaDu, Detroit512) was evaluated by MTS assay. Gene
expression levels related to epithelial-mesenchymal transition (EMT), can-
cer stem cell (CSC) and HIF-1 in each HNSCC cell lines were measured by
quantitative real-time PCR. Immunohistochemical expressions of HIF-1
and clinicopathological factors were analyzed using surgical specimens from
33 patients with hypopharyngeal carcinoma who had undergone trans-oral
tumor resection without previous chemotherapy nor radiotherapy. Results:
HIF-1 inhibitor suppressed the cell growth of HNSCC cell lines in a dose
dependent manner. HIF-1 inhibitor downregulated the expression of HIF-
1, twist, Oct3/4 and Nanog. In immunohistochemical study, the HIF-1
expression was higher in cancer cells than in normal cells of the adjacent
normal mucosa. Univariate analysis revealed that high expression of HIF-1
was signifıcantly correlated with T-classifıcation (P0.012), lymph node
metastasis (P0.002) and lymphatic invasion (P0.03). Conclusion: These
results suggest that HIF-1 plays a key role in tumor progression of HNSCC
through EMT and CSC properties. From the present study, HIF-1 inhibi-
tion may have the possibility to suppress tumor metastasis, making HIF-1
an attractive target for the treatment of HNSCC.
#4866 CD47 promotes metastasis and proliferation of colorectal cancer
via MAPK/ERK pathway. Tuo Hu, Yu-feng Chen, Chi Zhou, Jia Ke, Hua-shan
Liu, Xiao-bin Zheng, Jian-pingWang, Xiao-jianWu, Xian-rui Wu, Ping Lan. 1.
Department of Colorectal Surgery, the Sixth Affıliated Hospital of Sun Yat-sen
University, Guangz, Guangzhou, China.
Background and Aim: A number of studies demonstrated that CD47 was
overexpressed in several kinds of tumors including colorectal cancer (CRC).
Furthermore, the level of CD47 was positively correlated with tumor prolif-
eration, stemness and metastasis. The aim of this study is to evaluate the role
of CD47 in the metastasis and proliferation in CRC. Methods: We used the
data from GEO database GSE8671 to analyze the expression level of CD47
and its relationship with prognosis in CRC. The expression levels of CD47 in
normal and CRC tissues from our hospital were detected using quantitative
RT-PCR and western blot. CD47 was downregulated or overexpressed via
lentiviral vector system. Then the RTCA assay and migration assay were
carried out to investigate the function of CD47 in cell proliferation and
migration. Western blot for cancer related pathways was performed to fınd
out the downstream signaling pathways of CD47. Results: Increased expres-
sion of CD47 was found in CRC tissues. Inhibition of CD47 expression in
HCT116 by ShRNA attenuated the capacity of cell proliferation and migra-
tion. On the other hand, overexpression of CD47 in DLD1 increased the
capacity for cell proliferation andmigration. CD47 induced cell proliferation
and migration was found to be associated with the activation of MAPK/ERK
pathway. Conclusions: High expression of CD47 was found to be associated
with the proliferation and metastasis in CRC via the activation of MAPK/
ERK signaling pathway. These fındings provide an SIRP-independent
mechanism for CD47 in the progression of CRC, which may fınd a novel
therapy target for the precise treatment of CRC.
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#4867 Exome- and whole genome sequencing for clinical evaluation and
precision medicine in neuroblastoma. Angela Martinez Monleon,1 Susanne
Reinsbach,1 Niloufar Javanmardi,1 Anna Djos,1 Rose-Marie Sjoberg,1 Per
Kogner,2 Tommy Martinsson,1 Susanne Fransson1. 1University of Gothenburg,
Gothenburg, Sweden; 2Karolinska Institutet, Stockholm, Sweden.
Background. Despite major progress in treatment of pediatric cancer, aggres-
sive neuroblastoma (NB) still constitutes a major clinical problem. Currently,
the event free survival of high-risk NB is about 40% implicating that 60% either
don’t go into full remission or falls into relapse. Most relapses have an acquired
drug resistance meaning that conventional treatment options may not work.
Therefore, further studies of this group are of great importance.Massive parallel
sequencing has now become a valuable tool in both cancer research and in
clinical evaluation as it provides valuable information regarding patient specifıc
alterations that might be used in targeted therapy. Material and Methods. DNA
from 54 patients in total have been subjects for massive parallel sequencing; 16
tumor/normal pairs and 27 single tumors have been analyzed using exome se-
quencing, 8 tumor/normal pairs withwhole genome sequencing and three using
both exome and whole genome sequencing. Exome sequences were mapped
using BWAwithGATK realignment followed by variant calling through SNPeff
and copy number analysis trough ControlFreec. Whole genome data were ana-
lyzed using the CLCGenomicWorkbenchwith annotation and fıltering done in
Ingenuity variant analysis software. Results. On average, 14 somatic protein
changing single nucleotide variants were detected per patient (range 2-71) with
recurrent alterations mainly detected mainly in ALK. Predicted deleterious
germ line alterations in well-established cancer genes were detected in three
patients. Structural variants included genes such as ATRX and TERT, as de-
scribed by others previously, but also novel homozygous focal deletions at chro-
mosome 19. Shortest regions of overlapping deletions of this chr19 region in-
clude seven gens whereof CIC (Capicua) might be the most interesting in a
cancer context. Copy number analysis of both exome- and whole genome se-
quencing gives genomic profıles that are comparable to the genome profıles
generated from the SNP-microarrays that current are in clinical use. Specifıc
breakpoints for structural variants could be detected in all sample subjects for
whole genome sequencing as well as for all for all MYCN amplifıed neuroblas-
tomas that subjects for exome sequencing. Conclusions. Exome- and whole
genome sequencing can be used for clinical evaluation of NB providing infor-
mation regarding both constitutional and tumor specifıc alterations. The infor-
mation can be used for clinical decision of patient specifıc therapeutic options
such as ALK- or CDK4/6 inhibitors, but can also in rare cases give information
regarding which treatments not to use. Furthermore, whole genome sequencing
also gives the possibility to identify tumor specifıc structural alterations such as
translocation breakpoints that can be used to monitor tumor burden in liquid
biopsies.
#4868 RD3 reprogramming in N-MYC non-amplifıed neuroblastoma
evolution. Dinesh Babu Somasundaram, Karthikeyan Subramanian, Sheeja
Aravindan, Terence Herman, Aravindan Natarajan. University of Oklahoma
Health Sciences, Oklahoma City, OK.
N-MYC amplifıcation is restricted to 30% of the high-risk neuroblastoma
(NB), while the remaining 70% isN-MYCnon-amplifıed (N-MYC-NA), yet still
has a poor outcome with only 37% 5 Year OS and a miserable 9% 10Y OS.
Recently, we demonstrated, Retinal Degeneration Protein 3 (RD3) regulates
metastatic state of NB cells and its loss associates with poor prognosis. Herein,
utilizing bed-to-bench approach coupled with in vitro, in vivo and ex vivo NB
models, we investigated the role of RD3 reprogramming in the evolution of
N-MYC-NA-NB. Assessing 15 different human derived stage-4 N-MYC-
NA-NB cell lines demonstrated: transcriptional/translational loss of RD3 com-
pared to neural crest cells; cell specifıc loss and; association ofRD3 loss to cellular
progressive disease, cellular therapy resistance and disease relapse. Further, in
silico analysis demonstrated that RD3-loss was intrinsically associated with re-
duced OS and abridged relapse-free survival in N-MYC-NA-NB patient co-
horts.We also demonstrated the complete loss of RD3 inmetastatic site-derived
aggressive cells (regardless of CSC status) ex vivo and in reproducible aggressive
disease models in vivo. RD3-loss correlated with the heightenedmetastatic state
(tumor cell migration, invasion and tumorosphere formation) of the N-MYC-
NA-NB cells. Further, re-expressing RD3 in aggressive cells reverted their met-
astatic potential both in vitro and in vivo. These results demonstrate the loss of
RD3 in high-risk N-MYC-NA-NB, its novel tumor evolution stabilization func-
tion and further imply that continuous ongoing acquisition of RD3-loss in ther-
apy resistant cells may directly relate to tumor progression and poor clinical
outcomes.
#4869 The Signature Study: Molecular analysis of pediatric tumors with
establishment of tumormodels in a biology study. Elizabeth VanSickle,1 Ping
Zhao,1 DeannaMitchell,1 Jessica Foley,1 Julie Steinbrecher,1 Maria Rich,1 Abhi-
nav Nagulapally,1 Jeff Bond,1 William Hendricks,2 Giselle Saulnier Sholler1.
1Helen DeVos Children’s Hospital, Grand Rapids, MI; 2Translational Genomics
Institute, Phoenix, AZ.
Background: Pediatric cancer is the leading cause of death by disease in chil-
dren in the US. Signifıcant advances have been made in survival in the past 30
years and genomic understanding of tumors is underway. Gains in the identifı-
cation of biomarkers, drug targets, and themolecular characterization of cancer
are due to improved technology including gene sequencing, proteomics, and
epigenetics. Still, this remains limited primarily to large academic centers and
patients with high risk/metastatic disease experience 30% survival. Phase 1/2
trials not based on precision medicine result in poor response rates (10%).
Therefore, genomic understanding of tumors and molecular targeted therapies
with aims of reaching all children and reducing toxicitywhile improving effıcacy
is needed. Methods: The Signature Study is an IRB-approved biology study that
seeks to perform genomic analysis, high throughput (HTP) drug testing, and
creation of patient derived xenograft (PDX) models of all pediatric cancer pa-
tients diagnosed/relapsed atHelenDeVosChildren’sHospital. Patients are con-
sented, clinical history is collected in RedCap, and tumors are collected flash
frozen and in cell culturemedia. Blood is collected for germline analysis. Tumors
are analyzed through gene expression arrays, DNApanels and exomes and RNA
sequencing. Tumors in cell culture are used for generation of primary patient
cell lines (confırmed by IHC and STR) and immediate injection into NSG mice
for PDX models. Cell lines undergo HTP drug testing using the Prestwick and
NCI drug libraries, novel therapeutics and combinations. Results: Enrollment
has increased since inception in 2011 with now50 patients/year; a total of 284
pediatric tumors collected representing over 30 tumor types. Themost common
diagnosis is neuroblastoma, followed by medulloblastoma, osteosarcoma, and
rhabdomyosarcoma. Sequencing for genomic analysis has been performed on
166 tumors to identifymutations, fusions, CNV, and deletions. To date 184 have
been grown as primary patient cell lines and 75 as PDXmodels. Over 60 samples
have been evaluated in HTP drug testing. Genomic analysis of cultured tumor
cells has been correlated with response to drug libraries to establish correlative
predictive markers for therapeutic decisionmaking to be tested in clinical trials.
The study stores remaining tissue, cell lines, and PDX models for additional
future research. Conclusion: This study shows it is feasible for a mid-sized hos-
pital system to coordinate and collect tumors for genomic analysis in real time
for clinical decision making in the future. This resource is an integrated
TransMed database system which is a powerful resource which correlates clini-
cal outcomes, therapies, genomic sequencing, PDX models and HTP drug test-
ing used to answer research questions of biomarkers, biological characteriza-
tion, drug sensitivity, and driver pathwayswithin and between pediatric cancers.
#4870 Mutational landscape and timing of resistant clone emergence in
104 Chinese pediatric patients with relapsed acute lymphoblastic leukemia.
Benshang Li,1 Yongjin Li,2 Shuhong Shen,1 Xiaofan Zhu,3 XiaotuMa,2 Ningling
Wang,4 Yanling Liu,2 Yu Liu,2 Hui Zhang,5 Ting-Nien Lin,5 Michael Rusch,2
Michael Edmonson,2 John Easton,2 Yingchi Zhang,3 Jingliao Zhang,3 Cheng
Cheng,6 Jingyan Tang,1 James R. Downing,7 Ching-Hon Pui,8 Jun J. Yang,5
Jinghui Zhang2. 1Key Laboratory of Pediatric Hematology & Oncology Ministry
of Health, Department of Hematology & Oncology, Shanghai Children’s Medical
Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China;
2Computational Biology, St Jude Children’s Research Hospital, Memphis, TN;
3State Key Laboratory of Experimental Hematology, Institute of Hematology and
Blood Diseases Hospital and Center for Stem Cell Medicine, Chinese Academy of
Medical Sciences and Peking Union Medical College, Tianjin, China; 4Depart-
ment of Pediatrics, The Second Hospital of Anhui Medical University, Hefei, Chi-
na; 5Department of Pharmaceutical Sciences, St Jude Children’s Research Hospi-
tal, Memphis, TN; 6Department of Biostatistics, St Jude Children’s Research
Hospital, Memphis, TN; 7Department of Pathology, St Jude Children’s Re-
search Hospital, Memphis, TN; 8Department of Oncology, St Jude Children’s Re-
search Hospital, Memphis, TN.
Relapsed pediatric acute lympoblastic leukemia (ALL), occurring in 15-20%
of cases, is one of the leading causes of cancer-related death in children, confer-
ring a dismal survival rate of less than 40% primarily due to drug resistance. We
performed whole-genome sequencing (WGS) and RNA-seq of matched diag-
nosis and relapse tumors as well as WGS of remission DNA from 104 pediatric
ALL patients treated at Shanghai Children’sMedical Center (n89), Institute of
Hematology & Blood Disease Hospital in Tianjin (n14) and the Second Hos-
pital of Anhui Medical University (n1) between 2003 and 2014. The median
age at diagnosis was 6.29 (range, 0.23-16.05) years. Relapse occurred during
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chemotherapy in 85 patients and after completion of therapy in 19 patients.
Somaticmutation rate inALL increased signifıcantly from an average of 0.23 per
Mb at diagnosis to 0.65 perMb at relapse.We identifıed 34 potential driver genes
at diagnosis and 45 at relapse based on signifıcance of mutation recurrence and
pathogenicity. The four most signifıcant relapse-specifıc driver genes harbor
known point mutations on purine metabolism genes NT5C2 (n13) and
PRPS1/PRPS2 (n7), novel alterations affecting glucocorticoids receptor
NR3C1 (n13) and folylpolyglutamate synthetase FPGS (n8). Functional
characterization showed that all NR3C1mutations resulted in signifıcant loss of
transcription activator function and subcellularmislocalization. Ectopic expres-
sion ofmutantNR3C1 inALL cell lines consistently led to prednisone resistance.
Five driver genes (TP53, CREBBP, SMARCA4,WHSC1 andNIPBL) showed the
highest increase (2-5 fold) of mutation frequency from diagnosis to relapse with
mutations collectively present in 28% of relapsed ALL. Truncationmutations in
DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 occurred exclu-
sively at relapse in four ALL with the highest mutation burden. Targeted ultra-
deep sequencing at 5,000X of 268 somatic alterations was performed on 214
serial bone-marrow samples collected during ALL therapy for 17 cases. The
resulting mutant allele fraction (MAF) values showed high concordance with
minimum residual disease (MRD)measured by flow cytometry, indicating suit-
ability for quantifying leukemia burden. Temporal change of MAF in the serial
samples also allows us to track clonal identity and emergence of drug-resistant
clones during and after therapy. For example, one case had deep sequencing
performed on 11 somatic lesions from 10 bone barrow samples collected during
the 15 months between diagnosis and relapse. We found that a minor clone
present in 0.5-1% of ALL blasts at diagnosis emerged fıve months prior to re-
lapse, from which two new subclones arose harboring NT5C2 mutations
L406SSF and D407DRD. Preliminary data generated from serial bone mar-
row samples provides the fırst insight into the use of somatic alterations for
monitoring leukemia progress during relapse.
#4871 Whole-exome sequencing identifıes a high frequency of germline
deleterious variants in cancer predisposition genes in individuals with osteo-
sarcoma.Roelof Koster,1 Bin Zhu,1Meredith Yeager,1Michael Dean,1Matthew
Gianferante,1 Lei Song,1 Joshua Sampson,1 NCI DCEG Cancer Genomics Re-
search Laboratory, Julie Gastier-Foster,2 Richard Gorlick,3 Silvia Regina Cami-
nada de Toledo,4 Antonio Petrilli,4 Ana Patiño-Garcia,5 Fernando Lecanda,5
Massimo Serra,6 Claudia Hattinger,6 Piero Picci,6 Katia Scotlandi,6 Adrienne
Flanagan,7 Roberto Tirabosco,7 Maria Amary,7 Nilgün Kurucu,8 Inci Ergurhan
Ilhan,8 Neriman Sari,8 Mandy Ballinger,9 David Thomas,9 Donald Barkaus-
kas,10 Belynda Hicks,1 Margaret Tucker,1 Neil Caporaso,1 Robert Hoover,1 Ste-
phen Chanock,1 Sharon Savage,1 Lisa Mirabello1. 1Division of Cancer Epidemi-
ology and Genetics, National Cancer Institute, National Institutes of Health,
Bethesda, MD; 2Nationwide Children’s Hospital, and The Ohio State University
Department of Pathology and Pediatrics, Columbus, OH; 3Albert Einstein College
of Medicine, Bronx, NY; 4Pediatric Oncology Institute, GRAACC/UNIFESP, Sao
Paulo, Brazil; 5Department Of Pediatrics, University Clinic of Navarra, Univer-
sidad de Navarra, Madrid, Spain; 6Laboratory of Experimental Oncology, Ortho-
paedic Rizzoli Institute, Bologna, Italy; 7Royal National Orthopaedic Hospital
NHS Trust, London, United Kingdom; 8A.Y. Ankara Oncology Training and Re-
search Hospital, Department of Pediatric Oncology, Ankara, Turkey; 9The King-
horn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW,
Australia; 10Department of Preventive Medicine, Keck School of Medicine of the
University of Southern California, Los Angeles, CA.
In children and adolescents, osteosarcoma (OS) is the most common malig-
nant bone tumor. OS occurs in certain cancer predisposition syndromes at a
higher than expected frequency. However, outside of these rare syndromes, OS
is signifıcantly more common and its genetic etiology remains poorly under-
stood.We conducted an evaluation of rare exonic variants in 545 unselected OS
cases compared with 1061 cancer-free controls using whole-exome sequencing
of blood or buccal cell DNA to estimate the prevalence and burden of rare
deleterious germline variants. We assessed potentially pathogenic rare variants
in 126 established cancer predisposing genes (CPG) and known somatically
mutated genes. We also surveyed the exome for genes with a higher burden of
rare variants in 342 EUR cases with 994 EUR controls sequenced at the same
time. Rare genetic variants, defıned by a MAF 0.01 in 1000G, ESP or ExAC,
that passed quality control fılters were classifıed based on well-annotated data-
bases (IARC-TP53, Telomerase Database, ARUP, BIC, Insight and COSMIC-
hotspots), variant databases (e.g. Clinvar, HGMD and LOVD), and in silico
predictions (Sift, Polyphen, Mutation assessor, MutationTaster, FATHMMand
LTR). Rare variants matching known pathogenic variants, or inexact matches at
the same residue, in selected well-annotated databases were labeled as putative
pathogenic variants. High impact variants (frameshift, stop gain/loss, or known
splice sites) not matching a previously identifıed pathogenic variant in the se-
lected databases were categorized as probably pathogenic. Predictions based
solely on in silico predictions were categorized as possibly pathogenic, uncertain
or likely benign. A total of 14.5% of cases had a predicted pathogenic or high
impact variant in an autosomal dominant CPG. A signifıcantly higher patho-
genic rare variant burden was present in EUR cases compared with EUR con-
trols (Pburden3.7x10-05). TP53 had the highest prevalence of pathogenic muta-
tions (5% of EUR cases; Pburden1.05x10-09). CDKN2A, MEN1, MLH1,
MUTYH, PALB2 and VHL had a signifıcantly higher rare variant burden in the
EUR cases. 7.5% of cases had a predicted pathogenic or probably pathogenic
variant in an autosomal recessive CPG (Pburden5.4x10-03). Additionally, two
males had a pathogenic variant in the X-linked genes, DKC1 andGPC3. In total,
21% of cases had a predicted pathogenic or high impact variant in a CPG
(Pburden2.4x10-07). Exome-wide analysis identifıed two novel genes with sig-
nifıcantly higher rare variant burdens in the cases compared to controls. In
conclusion, several CPGs and two novel genes, not previously associated with
OS, had an enrichment of rare variants inOS andwarrant further follow-up.Our
results indicate that a clinically signifıcant fraction of OS cases may harbor one
ormoremutations worthy of consideration for further investigation and genetic
counseling.
#4872 Gene fusion detection in pediatric tumor samples utilizing multi-
caller fusion detection approach and integrative data analysis. Alma Imam-
ovic,1 Marian Harris,2 Alanna Church,2 Brian Crompton,1 Eliezer Van Allen,1
Katherine Janeway1. 1Dana-Farber Cancer Institute, Boston, MA; 2Boston Chil-
dren’s Hospital, Boston, MA.
Gene fusions are an important mechanism of oncogenesis in pediatric can-
cers. Fusion detection from RNA sequencing data is challenging for several
reasons including a high false positive rate by individual fusion callers. We
developed a new pipeline for gene fusion detection utilizing amulti-caller fusion
detection approach and focusing on improved specifıcity, annotation and visual
presentation.Multiple fusion detection algorithms, integrative data analysis and
known fusions and cancer genes annotation databases are integral parts of our
new pipeline. The following fusion callers were included in the pipeline: Chime-
rascan, TopHat Fusion and STAR-Fusion. Fusions called by at least two fusion
callers were included in the fınal results and annotated by utilizing the TARGET
database (Tumor Alterations Relevant for Genomics-driven Therapy) and
TICdb (Translocation breakpoints In Cancer database). A Venn diagram was
produced for visual presentation of candidate fusions detected by multiple fu-
sion callers. IGV (Integrative Genomics Viewer) was used to visualize the align-
ment of reads at fusion break points. The fusion detection pipeline was tested
with RNA sequencing data from 11 pediatric tumor samples either suspected to
harbor fusions based on diagnosis (n7; renal cell carcinoma, osteosarcoma,
synovial sarcoma, glomus tumor, undifferentiated sarcoma) or known to have
fusions based on standard methods (n4; Ewing-like sarcoma, EWSR1 FISH
sarcoma, clear cell sarcoma). In most cases, fusions previously known to be
present were identifıed with our pipeline. For the diffıcult to detect fusion CIC-
DUX4, optimization by adding another fusion caller (FusionCatcher) and ad-
justing the fıltering and annotation parameters was required to increase sensi-
tivity. Novel fusions were identifıed in cases suspected to harbor fusions and in
some cases these novel fusions have been validated to be present with other
methods. In one case (synovial sarcoma) the expected fusion, which was not
detected with standard testing (FISH), was identifıed with our pipeline. The
pipelinewas also successfully utilized to analyze prostate cancer samples (PMID:
27167109).Our newmulti-caller fusion detection pipeline has been successful in
increasing specifıcity anddecreasing the false positive rate for gene fusion calling
in transcriptomic data, while being sensitive enough to detect themore challeng-
ing gene fusions. Additional updates to the pipeline are anticipated like the
realignment against a modifıed reference sequence including the gene rear-
rangement for improved sensitivity.
#4873 Shedding light on the unknown of Ewing sarcoma: Single cell study
shows a co-expression pattern between TAPA-1 and EWSR1-FLI1. Roxane
Khoogar, Doris Phelps, Peter Houghton.UTHealth Science Ctr. at San Antonio,
San Antonio, TX.
Introduction: Ewing Sarcoma (ES) is the second most frequent bone cancer
found in children, and has the highest rate of recurrence among all childhood
cancers. This suggests the need for a better understanding of heterogeneous
cancer populations and rare cells that survive intensive cytotoxic therapy and
cause recurrence in patients. It is widely accepted that ’EWSR1-FLI1’ has amajor
role in determining ES survival and proliferation, but the mechanism is un-
known.Most studies inwhich expression of ’EWSR1-FLI1’ is correlatedwith the
level of expression of ’EWSR1-FLI1’ regulated genes have been conducted on
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bulk populations that ignore potential heterogeneity of ’EWSR1-FLI1’ in the cell
population. To address this we have used single cell RNA-Seq approaches.
Methods: The WaferGen iCell8 system was used to perform SMART whole
transcriptome amplifıcation using EW-8 ES cells.We sequenced single-cell
RNA-Seq libraries prepared from over 1260 ES parental cells. We combined
computational analysis with stringent quality control fılters to profıle candidate
ES cells.We used EWSR1 expression profıle to partition the entire population
into two clusters. A population of cells with TAPA-1 expression was distin-
guished and studied for their co-expression patterns with EWSR1. Results: Re-
sults revealed that ES cells show considerable heterogeneity at the transcriptome
level between seemingly identical EW-8 cells. We identifıed a subpopulation of
EW-8 ES cells with a positive correlation between the expression of EWSR1 and
Target of the antiproliferative antibody 1 and tetraspanin-28 (TAPA-1/CD81).
Our preliminary data from 200 cells indicate that EWSR1 (0-18 unique tran-
scripts, median 1) and TAPA-1/Cd81 (0-8 unique transcripts, median 0) were
correlated (r 0.32, P0.10). TAPA-1, a surface membrane protein, most fre-
quently associated with hematopoetic cells, that regulates cell development, ac-
tivation, growth and motility and has been implicated in proliferation of many
cancers. Conclusions: Taken together, our results suggest that there are two
classes of cells with respect to the expression of TAPA-1 in EW-8 cells. We also
show the relationship betweenTAPA-1with EWSR1-FLI1 expression in a single
cell level. This type of classifıcationmay lead us to identify a rare populationwith
a poor response rate to cytotoxic treatments. Future studies will determine if
EW-8 ES cells having elevated TAPA-1 have differential sensitivity to cytotoxic
agents compared with populations with low level expression.
#4874 Application of quantitative analysis of mouse cell contamination
and purifıcation of human tumor cells in patient derived orthotopic xeno-
graft mouse models of pediatric brain tumors. Frank K. Braun, Mari Kogiso,
LinQi,HuiyuanZhang, YuchenDu,Holly B. Lindsay, SiboZhao, SarahG. Injac,
Xiao-Nan Li. Baylor College of Medicine/Texas Children’s Cancer Center, Hous-
ton, TX.
Background: Pediatric brain tumors continue to be among the most diffıcult
to cure and are the leading cause of cancer-related deaths in children. Research
investigating pediatric brain cancer is still impaired by the lack of cancermodels.
We established a large panel of orthotopic xenograft models as well as several
paired permanent cell lines using in vivo and in vitro culture techniques. How-
ever an inherent risk of xenograft models is the contamination of isolates of
human tumors with host (mouse) cells. Therefor strategies to correctly and
timely identify the human/mouse ratio are essential. In this study we investi-
gated Prostaglandin Receptor EP2 (PTGER2) as a useful target to identifying
mouse cell contamination in PDOX models. Method: Species specifıc primers
based on Alcoster et al., 2011 were used to detect PTGER2 in genomic DNA
extracts of xenograft and cultured cells. Real-time qPCR was carried out using a
StepOnePlus™ Real-Time PCR System. Reaction mix contained SYBR Green
select master mix, respective primers and 5 ng of total genomic DNA in a total
reaction volume of 10 L. The qPCR conditions were as follows: 50°C-2 min,
95°C-10 min, 40 cycles of (95°C-15 sec, 61°C-1 min). Primer specifıcity was
controlled in addition by analysis of amplifıed products on a 1.2% agarose gel.
FACS was used to isolate human cells according to anti-Human HLA-ABC Ab
andmouse-specifıc Ab cocktail surface staining and subjected to qPCR. Results:
Various models of pediatric brain cancer (PXA, MB, GBM, EPN, ATRT, DIPG,
PNET) established in our groupwere investigated formouse cell contamination.
Cells from xenograft isolates as well as from cultured xenografts were routinely
analyzed. Our study confırms PTGER2 as a useful target for accurately estimate
mouse cell contamination in brain cancer xenograft models. This further en-
abled us to improve detection and characterization of HLA-ABC/mouse-cock-
tail double negative population as seen in FACS. Conclusion: In conclusion we
have successfully implemented an easy qRT-PCR approach to determine the
human/mouse cell ration in any mixed cell population. Particular for PDOX
models it is paramount to have reliable information on mouse cell contamina-
tion.
#4875 Identifıcation of the cellular origin and ‘stemness‘ phenotype of
Malignant Rhabdoid Tumors (MRT) may represent a new therapeutic ap-
proach in paediatric oncology. Ras A. Ramli, Martina A. Finetti, Matthew P.
Selby, Yura Grabovska, Stephen Crosier, Amanda J. Smith, Steven C. Clifford,
Daniel Williamson. Northern Institute for Cancer Research, Newcastle Univer-
sity, Newcastle Upon Tyne, United Kingdom.
Malignant Rhabdoid Tumors (MRT) are highly aggressive childhood malig-
nancies characterized by a singlemutation; biallelic inactivation of SMARCB1, a
component of the SWI/SNF chromatin remodeling complex. These tumorsmay
occur anywhere, most frequently in the brain (Atypical Teratoid/Rhabdoid Tu-
mor, ATRT) and in the kidneys and soft tissues (Extra Cranial Rhabdoid tumor,
ECRT). MRT presents immune markers from multiple lineages exhibiting a
teratoid phenotype, characterized by cells with heterogeneous morphology
within the same tumor leading to speculation that theMRTcell of origin is a type
of multipotent stem cell. Despite recent advances in treating other solid tumors,
treatment for MRT still remains ineffective and we hypothesized that MRT
“stemness” characteristics are key to its aggressive clinical course and resistance
to treatment. Here we analyze the expression profıles of primaryMRT (n 134)
and catalog the expression of a program of “stemness” genes capable of driving
aberrant self-renewal. Further, we show by re-expression of SMARCB1 inMRT
cells that several of these key “stemness” genes are aberrantly activated by
SMARCB1 mutation. One such gene, BMI1 was further demonstrated to be
critical toMRT tumorigenesis by shRNAknockout, and a novel anti-BMI1drug,
PTC209 was tested to show effıcacy inMRT. Knockdown of BMI1 inMRT cells
reduced the self-renewal capability of cells as seen from the number of tumors-
pheres formed in limiting dilution assay (LDA). Interestingly, BMI1 loss triggers
upregulation of p16(INK4a) expression and this mimics the expression profıle
when SMARCB1 was re-expressed into MRT cells. To identify a putative MRT
cell of originwe performed ameta-analysis cross-referencing expression profıles
from primary MRT (n 20), and functional models in which SMARCB1 was
re-expressed (n5 lines) with expression profıles from multiple stem cell types
including epithelial, embryonic, neuralmesenchymal andneural crest (n 446).
Analysis by t-SNE and NMF consensus clustering suggested that MRT bore the
closest resemblance to either early neural progenitors (ATRT) or early neural
crest cells (ECRT). In MRT cells in which SMARCB1 was forcibly re-expressed,
cells became gradually more differentiated and their expression profıle altered
from that of an early neural crest to a more differentiatedmesenchymal pattern.
For the fırst time, we show evidence that ECRTs and ATRTs appear to have
different cells of origin, despite having the same mutation and tumor appear-
ance. We further demonstrate that SMARCB1 expression is necessary for MRT
cells to maintain a de-differentiated “stem-like” state and fınally that the
SMARCB1-dependent stemness gene BMI1 shows potential as a novel thera-
peutic target in MRT.
#4876 Low frequent ALK hotspot mutations in neuroblastoma tumors
detected by ultra deep sequencing: Implications for ALK inhibitor treat-
ment. Susanne M. Fransson,1 Niloufar Javanmardi,1 Rose-Marie Sjoberg,1 Per
Kogner,2 Tommy Martinsson1. 1Sahlgrenska academy at University of Gothen-
burg, Gothenburg, Sweden; 2Karolinska Institutet, Stockholm, Sweden.
Background: The pediatric cancer neuroblastoma (NB) is heterogeneous in
terms of both genotype and clinical behavior. NB patients show complex pat-
terns of genetic abnormalities, which may include amplifıcation, translocation
or oncogenic mutations of ALK kinase in sporadic and familial cases. Three hot
spot residues (F1174, F1245, and R1275) localized within the kinase domain of
ALK, accounts for 85% of mutant ALK in NB. In this study we used ultra deep
sequencing for sensitive detection of ALK mutations. Methods: To detect the
sub-clonal ALKmutations in 105 neuroblastoma tumors that can remain unde-
tected using Sanger chemistry, we used two different approaches; hybridization-
based Haloplex kit (Agilent) and PCR-based amplicon sequencing, both se-
quenced on the MiSeq Illumina platform. Coverage, uniformity and variant
calling ability showed similar performance between both methods. Findings:
ALK mutations were detected in 14/105 patients (13%) whereof six with allele
frequency below 20%. At the I1171 locus an ALK mutation was detected in one
case with variant allele frequency as low as 2.6%, the lowest level detected in our
cohort. Mutations at the F1174 hotspot were observed in nine cases: six cases
with F1174L, while the remaining three showed F1174C, F1174S and F1174I
substitutions, with mutated allele fractions ranging from 14% to 60%. Interest-
ingly the patient harboring F1174S mutation with 58% frequency, in parallel
contained a small sub-clone of F1174I mutation with 8% frequency of the mu-
tated allele. F1245-codon alterations were detected in three cases: two F1245I
mutations and one F1245C mutation, with frequencies of 14%, 51% and 52%,
respectively. A single case showed a L1240V variant with a mutated allele frac-
tion at 57%. Sanger sequencing of all ALKmutated samples could confırm ALK
status for all samples with variant allele fraction above 15%. Because of the limits
of detection, 4 out of 6 samples with a mutated allele fraction below 15% would
have gone undetected relying on Sanger sequencing. Our results fail to reveal a
distinct mutation spectrum in relation to neuroblastoma genomic subtypes.
Moreover, a variety of neuroblastic tumours, from benign ganglioneuroma to
very aggressive metastatic neuroblastoma, could be observed in the context of
ALK mutation. Interpretation: These results indicate that, in neuroblastoma,
ALK mutations can be present at sub-clonal level with the possibility of subse-
quent clonal expansion at the time of progression. Tyrosine kinase inhibitors
have become the gold standard therapy in treating ALK positive NBs, making
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diagnostic high sensitive detection of ALK mutations a necessary step in iden-
tifying optimal treatment modalities. This study is of utmost importance in
clinical practice, highlighting the potential of NGS and the importance of serial
samplings for therapeutic decisions.
#4877 Transcriptome sequencing of pediatric hepatocellular carcinoma
reveals genomic events involving APC and TERT. Katherine Haines,1 Ang-
shumoy Roy,2 Stephen Sarabia,2 LinghuaWang,1 Pavel Sumazin,2 Kyle Coving-
ton,1 Harsha Doddapaneni,1 Oliver Hampton,1 Donna M. Muzny,1 Dolores
Lopez-Terrada,2 David A. Wheeler,1 Sharon E. Plon,1 D. Williams Parsons1.
1Baylor College of Medicine, Houston, TX; 2Texas Children’s Hospital, Houston,
TX.
Background: The goal of this project is tomolecularly characterize a cohort of
pediatric HCCs in order to understand the spectrum of genetic drivers for this
disease. Hepatocellular carcinoma (HCC) is a rare pediatric liver tumor with a
poor prognosis. The fıbrolamellar variant ofHCC (FL-HCC) has a characteristic
DNAJB1-PRKACA gene fusion. In non-FL-HCC a genetic cause has not been
identifıed. We hypothesize that alterations in known cancer genes play a role in
non-FL-HCC tumorigenesis. Methods: We have used RNA sequencing (RNA-
seq) on fresh frozen tissue to survey a cohort of 8 FL-HCCs, 4 pediatric HCCs,
and 6 normal liver samples for chimeric transcripts. Fusion transcripts in the
tumor samples were detected using deFuse on FASTQ fıles followed by subtrac-
tion of fusions called in the normal liver dataset. Fusions were verifıed using
BLAST and validated by RT-PCR. On average the deFuse algorithm predicted
150 fusion transcripts per tumor; fıltering bynormal liver reduced the number of
calls in the tumors by 60%. As expected, DNAJB1-PRKACA fusions were
identifıed in the FL-HCC cohort with no additional fusions. Filtering by the
COSMIC Cancer Gene Census list reduced the total number of fusion calls to 5
for the HCC dataset (3 unique events, 2 of which were confırmed by RT-PCR).
Results: The fırst event is an inversion disruptingAPC, resulting in two in-frame
fusion transcripts between APC and AP3B1. This fusion was confırmed and the
intronic breakpoints were mapped in tumor and germline DNA through WGS
by 10XGenomics®. Variant calling by Platypus on tumor RNA-seq reads did not
identify additional variants in APC. Reports of inversion of APC are rare, how-
ever we have identifıed an additional published case of APC inversion in a
patient with pediatric HCC.We will performWGS on germline DNA from this
patient to determine if the APC inversion breakpoint is recurrent. The second
event is a deletion encompassing the TERT promoter and results in an in-frame
fusion between TERT and LPCAT1. An increase in TERT expression is seen in
this tumor as compared to both normal liver and other pediatric HCCs. Con-
clusions: The detection of chimeric transcripts by RNA-seq has allowed us to
identify two structural variants involving known cancer genes in two tumors,
including an inversion of APC which have been historically diffıcult to detect.
These events present a possible genetic cause for these tumors and provide genes
for further analysis in the remaining cases with no identifıed fusions. These
results will inform future studies as we expand this cohort to include 18 addi-
tional pediatric HCCs which we plan to characterize through NGS and targeted
sequencing.
#4878 Sensitive and specifıc DNA and RNA sequencing techniques for
detecting minimal residual disease. Erin L. Crowgey,1 Nitin Mahajan,2 Wing
H.Wong,2 Edward A. Kolb,1 ToddDruley2. 1Nemours Alfred I. duPont Hospital
for Children, Wilmington, DE; 2Washtington University, St. Louis, MO.
The goal of this study was to assess the clinical applicability of molecular
genetic techniques in the study of minimal residual disease (MRD) in pediatric
acute myeloid leukemia (AML) via DNA and RNA-based methods. Currently,
multi-parametric flow cytometry (MPFC) for surface immunophenotypes is the
gold standard forMRDwith a limit of detection between 0.001-0.002. However,
approximately one-third of children with no detectable MRD by MPFC after
fırst induction still relapse and suffer inferior outcomes. One potential reason is
that a majority of refractory or recurrent AML clones will present with altered
immunophenotypes compared to diagnostic specimens. In contrast, DNAmu-
tations present at diagnosis will remain in refractory disease and therefore, a
gene-based MRD platform surveying many genes could enable targeted, gene-
specifıc therapy. Recently, the heterogeneous and unique genomic landscape of
pediatric AML was characterized in the TARGET project and highlights the
potential for leveraging companion molecular screens in the analysis of AML
MRD. Contrary to adult AML, pediatric AML is not primarily characterized by
single nucleotide variants (SNVs), but rather by complex structural variants
(SV) that are diffıcult to detect using standard next generation sequencing tech-
niques and analysis pipelines. The need to detect these complex SV and SNVs, all
of which are at low allelic ratios (AR) at the remission state, demands assays that
are capable of analyzing both DNA and RNA molecules at levels of detection
comparable to MPFC. As proof of principal, we leveraged a unique capture
technique (ArcherDx; CoreAML) to detect an important SV in pediatric AML,
the internal tandemduplication in Fms related tyrosineKinase (FLT3-ITD). Via
a serial dilution of cells with known FLT3-ITD allelic ratio (MV4-11 cells), to
determine a limit of detection, we were able to detect the mutation as low as
0.001. Next, we bench-marked the technique using diagnostic and relapse sam-
ples, and successfully detected FLT3-ITD at AR 0.01. To complement the
DNA-based approach, we compared two error-corrected (EC) RNA assays (a
Druley lab developed protocol and the ArcherDx; HemeV2 panel) to further
assay SVs that cause novel gene fusions and aberrant exon usage, which are not
detectable viaDNAassays. Compared to existing cytogenetic andRNA-seq data,
this new platform was capable of detecting known and novel cryptic transloca-
tions. Finally, we integrated the results from the FLT3-ITD assay and the RNA
assay with our custom error-corrected sequencing data to create a novel bioin-
formatics workflow for assessing the biological implications of MRD clones
detected. Collectively, our data support that EC sequencing, at both the DNA
and RNA level, enable accurate detection of low allelic variants that could be
used for improved clinical MRD diagnostics, prognostication and therapeutic
selection.
#4879 Genomic and epigenomic profıling of high-stage neuroblastoma.
Miki Ohira,1 Yasutoshi Tatsumi,2 Yohko Nakamura,2 Kenji Tatsuno,3 Shuichi
Tsutsumi,3 Shogo Yamamoto,3 Genta Nagae,3 Claire Renard-Guillet,3 Ryuichi
Sugino,1 Hiroki Nagase,2 Takehiko Kamijo,1 Hiroyuki Aburatani,3 Akira Naka-
gawara4. 1Saitama Cancer Center, Saitama, Japan; 2Chiba Cancer Center Re-
search Institute, Chiba, Japan; 3RCAST, University of Tokyo, Tokyo, Japan; 4Saga
Medical Center Koseikan, Saga, Japan.
Neuroblastoma (NB) is the most common pediatric extracranial solid tumor
with a wide range of clinical phenotypes from spontaneous regression to highly
resistant to chemotherapy. Despite intense multi-modal therapy, NB remains
the second most common cause of cancer deaths among children. MYCN am-
plifıcation is themost prominent poor prognosis factor forNB, however, certain
subgroup of high stage tumor without MYCN amplifıcation also shows low
survival rate in terms of long-term follow-up (10 years survival rate was 51%,
n161). To elucidate themolecular basis ofmalignant subtype ofNB, integrated
genomic and epigenomic analyses were performed. Array CGH of 537 tumors
indicated that genomic subgroups of 17q gain, with 1p loss and/or 11q loss,
exhibited aggressive characteristics even without MYCN amplifıcation. Whole
exome sequencing of 92 high stage, MYCN-non-amplifıed primary tumors
(SureSelect XT Human All Exon V4, mean depth CDS:138, x20 coverage:96%)
identifıed 1,735 non-silent somatic mutations, among which 53 were signifıcant
mutations observed more than once in the sample set. Aggressive tumors (died
of disease, n48) had several notable features, with mutations in chromatin
remodeling/modulating genes (27%, cf. ATRX), in DNA-damage response
(30%), in TP53 (28%) and RB (22%)-related gene networks, as well as with high
TERT expression (38%). By hierarchical clustering of methylome signature (In-
fınium HumanMethylation450 BeadChip), the 92 tumors were subdivided into
four clusters. Unfavorable cluster-2 and -4 exhibited hyper-methylation pheno-
types in CpG islands and the former was enriched byMYCN-amplifıed tumors.
These two clusters (53%) showed strong correlation with patient prognosis
(p0.0055). Thus, these prognosis-related genomic features could be useful
markers for risk classifıcation and help understandingmolecularmechanism for
aggressive phenotypes of MYCN-non-amplifıed NBs.
#4880 MAGE gene family expression in pediatric medulloblastoma: fre-
quency and possible therapeutic target. Rebecca R. Collins,1 Klementina Fon
Tacer,2 Dinesh Rakheja,1 Patrick Ryan Potts2. 1University of Texas Southwestern
Medical Center and Children’s Health, Dallas, TX; 2St. Jude Children’s Research
Hospital, Memphis, TN.
Background: The melanoma antigen gene family (MAGE) is a group of re-
lated genes that were fırst discovered in malignant melanoma. Among the ap-
proximately 40 MAGE genes in the human genome, two thirds are classifıed as
Type I (MAGE-A, MAGE-B, and MAGE-C), referred to also as cancer testis
antigens (CTAs), proteins that are restricted to testis but often aberrantly ex-
pressed in many adult cancers. Despite their common expression in adult can-
cers and their oncogenic potential, little is knownabout their expression and role
in pediatric cancers. To determine the frequency of MAGE expression in pedi-
atric medulloblastoma, we measured expression levels of Type I MAGEs in
patient tumors. In addition, we examined how MAGE expression in medullo-
blastoma cells affects their growth and oncogenic potential. Methods: We
searched the Children’s Health pathology database for pediatric medulloblas-
toma between 2008 - 2015 andwere able to recover an adequate amount of RNA
from formalin-fıxed paraffın-embedded tissue samples of 34 patients. The RNA
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was converted to cDNA using reverse transcriptase, and the relative expression
of 23 Type I MAGE genes was measured by qRT-PCR. To determine if MAGE
expression is critical formedulloblastoma cell survival we knocked down several
MAGEs using siRNAs in two MAGE-expressing medulloblastoma cell lines
(D283 and DAOY) and evaluated the effect by cell viability (Alamar Blue and
Cell titer Glo), apoptosis assays (Annexin V), and colony formation in soft agar.
Results: In 34 medulloblastoma patient samples we found that 10 (29.4%) ex-
pressed at least oneMAGE gene, and one case had high levels of expression of 10
of the 23 Type IMAGEs. MAGE expression was associated with the non-WNT/
SHH (G3/G4) molecular subgroup of tumors in our study. There was no corre-
lation between MAGE expression and histologic subtype. Furthermore, using
MAGE-A/-B2 positivemedulloblastoma cell lines, we showed that siRNAknock
down of multiple MAGE-As and -B2 decreased cell viability by 15 - 80%, in-
creased apoptosis (-B2), and decreased growth of cells in soft agar. Conclusion:
Type I MAGE genes are expressed in 30% of pediatric medulloblastoma in our
study. InMAGEpositivemedulloblastoma cells,MAGE genes are important for
cell survival and clonogenic growth. The decreased cell survival after MAGE
knockdown appears to be related, at least in part, to increased apoptosis. Our
results indicate that targeting ofMAGEs inmedulloblastomamay be a potential
therapeutic option.
#4881 Dissecting telomere maintenance mechanisms in neuroblastoma.
Gonzalo Lopez, Karina Conkrite, Kendra Hong, Jo Lynne Harenza, John M.
Maris, Sharon Diskin. Children’s Hospital of Philadelphia, Philadelphia, PA.
Background. Telomere maintenance is a major cancer hallmark and has re-
cently attracted attention as an oncogenic mechanism in the pediatric malig-
nancy, neuroblastoma (NBL), due to detection of frequent structural rearrange-
ments near the telomerase (TERT) gene. NBLs display substantial clinical and
molecular heterogeneity; tumors with MYCN amplifıcation and TERT-associ-
ated rearrangements defıne separate groups of high-risk patients with active
TERT. ATRX mutations are frequent in non-TERT active high-risk tumors,
indicating use of alternative lengthening of telomeres (ALT) as a maintenance
mechanism. Furthermore, the 4S low-riskNBLs display an elevated rate of spon-
taneous regression and overall good prognosis; it has been hypothesized that
lacking a telomere maintenance mechanism (“telomere crisis”) may be behind
this phenomenon.Methods. To gainmechanistic insight behind these phenom-
ena, we introduce an integrative analysis of a cohort comprising 104 high-risk
(32 MYCN-amplifıed) and 23 4S tumors with matched blood/tumor whole ge-
nome sequencing, CpG methylation, and RNA-seq data from the TARGET
consortium. Here, we preformed structural variant (SV), allelic specifıc expres-
sion (ASE), and differential CpG methylation analyses. Additionally, we intro-
duce a novel approach to measure relative telomere DNA abundance from
short-readWGSmeasured as the ratio between tumor andblood telomeric reads
(containing canonical repeats TTAGGG/CCCTAA) per million (TBrpm). Re-
sults.We identifıed 26 tumors harboring TERT rearrangements (25% of all high
risk tumors) and 3 tumors with ATRX mutations. We defıne 4 groups of high-
risk NBL with different telomere maintenance mechanisms: 1) Tumors with
MYCN amplifıcation or elevated MYC/N activity, TERT gene body hyper-
methylation (-value0.8), and expression of biallelic TERT; 2) Tumors har-
boring TERT associated SVs, hemi-methylation (-value0.5), and expression
of mono-allelic TERT, 3) Tumors without TERT expression, including ATRX
mutants with hypo-methylated TERT (-value0.3), 4) tumors with abnor-
mally high telomeric DNA abundance (TBrpm  1.5), hypo-methylation (-
value0.3), and no expression of TERT. Intriguingly, while groups 1-3 show
telomeric loss (TBrpm  0.7-0.9), 4S tumors show conservation of telomere
abundance between tumor and blood (TBrpm  1); hence no indication of
telomere crisis, perhaps due to early timing of biopsy at diagnosis. Conclusion.
We have used ASE status and gene body methylation of TERT in order to un-
derstand and validate mechanisms underlying TERT activation; we extend
MYCN-driven TERT activation to tumors with high MYC/MYCN activity in
the absence of MYCN amplifıcation. Our telomere analysis suggests that differ-
ent ALT mechanisms might take place in NBLs. Defıning the mechanism of 4S
NBL spontaneous regression requires further investigation.
#4882 Genomic mechanisms of disease progression in pediatric medul-
lary thyroid cancer (MTC). Ira L. Kraft,1 Srivandana Akshintala,2 Keith J. Kil-
lian,1 Robert B. Hufnagel,3 John W. Glod,1 Claudia Derse-Anthony,4 Yuelin
Zhu,1 Holly S. Stevenson,1 Diana Bradford,1 Maria J. Merino,1 Frank M. Balis,5
Elizabeth Fox,5 Brigitte C. Widemann,1 Jack F. Shern,1 Paul S. Meltzer1. 1Na-
tional Cancer Institute, Center for Cancer Research, Bethesda, MD; 2New York
University, Langone Medical Center, New York, NY; 3National Eye Institute,
Bethesda, MD; 4Clinical Research Directorate/Clinical Monitoring Research Pro-
gram, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick,
MD; 5Children’s Hospital of Philadelphia, Philadelphia, PA.
Background: Multiple Endocrine Neoplasia (MEN) 2B is a rare hereditary
disorder characterized by medullary thyroid cancer (MTC) in early childhood,
pheochromocytoma, and mucosal neuromas. Patients with advanced MTC are
treated with rearranged during transfection (RET) targeting tyrosine kinase in-
hibitors (TKIs) such as vandetanib. Despite initial responses, many patients
progress on TKI therapy and mechanisms of resistance are yet to be elucidated.
We analyzed tumor samples from seven children with MEN2B and MTC en-
rolled in a natural history study (NCT01660984). Methods: DNA samples from
tumor and adjacent normal tissue from paraffın embedded blocks or unstained
slides were analyzed by a custom capture next-generation sequencing panel.
Bioinformatics analyses identifıed point mutations, insertions, deletions and
copy number variations. Results: Seven patients (median age at study enroll-
ment 14 years, range 11-17 years) with theRETp.Met918Thr germlinemutation
were included in analysis. Tumor samples were available for three patients pre-
TKI (four samples), two patients at progression onTKI (three samples), and two
patients both, pre-TKI and at progression (fıve samples). Pre-TKI samples ex-
hibited few tumor specifıcmutations or copy number variations and 4/5 patients
had loss of chromosome 1p. Progression for one patient was associated with
acquisition of a previously unidentifıed p.Leu790Phemutationwithin the kinase
domain of the RET gene. Loss of heterozygosity and increase in copy number
variations were noted in 4/5 samples at tumor progression. Two patients had
copy number loss of chromosome 14 and three had copy number gain of chro-
mosome 1q. Recurrent, somatic, non-synonymous mutations were not identi-
fıed in the sample set. Conclusion: In children with MEN2B and MTC, we
identifıed increase in copy number variations and a somaticmutationwithin the
RET gene as potential mechanisms of drug resistance. Our data imply that a
common genetic mechanism for progression on TKI may not exist within this
small sample set and highlight the need for serial collection of tumor tissue.
Further, whole genome aneuploidy may provide rationale for the evaluation of
cytotoxic chemotherapy in patients who experience progressive disease on TKI
therapy. Analysis of additional samples and whole exome DNA and RNA se-
quencing are ongoing.
#4883 Targeting tumor-amplifıed ODC1 with difluoromethylornithine
(DFMO) inhibits global protein translation and has antitumor activity in
neuroblastoma. Andrea T. Flynn,1 Annette Vu,1 Kangning Liu,1 Elizabeth
Scadden,1 Edward Attiyeh,1 Murray Norris,2 Michelle Haber,2 Michael Hog-
arty1. 1Children’s Hospital of Philadelphia, Philadelphia, PA; 2Children’s Cancer
Institute, Sydney, Australia.
MYC genes are predominant oncogenic drivers in neuroblastoma, a lethal
pediatric tumor, often via amplifıcation of MYCN. MYC genes coordinately
deregulate programs that link cell cycle entry with requisite biomass and energy
creation. Polyamine synthesis is one such deregulated program that supports
protein synthesis. Ornithine decarboxylase (Odc, encoded byODC1) is the rate-
limiting enzyme in polyamine synthesis, a direct MYC target, and a bonafıde
oncogene. In addition to hyperactivated MYCN driving polyamine signaling,
ODC1 itself is co-amplifıed in a subset of high-risk tumors. We studied 30
neuroblastoma cell lines and 916 primary tumors via SNP-array. ODC1 ampli-
fıcation (confırmed by qPCR) was found exclusively in tumors with MYCN
amplifıcation, though amplifıcation peaks were distinct (ODC1 maps 5.5 Mb
telomeric to MYCN). ODC1 amplifıcation was identifıed in 33 of 256 (13%)
MYCN amplifıed primary tumors and 4 of 13 (31%)MYCN-amplifıed cell lines.
Difluoromethylornithine (DFMO) is an FDA-approved irreversible inhibitor of
the oncogenic Odc enzyme, and we have shownDFMO inhibits tumor progres-
sion and synergizes with chemotherapy in complementary murine models of
neuroblastoma. We postulated DFMO inhibits protein translation as its princi-
pal mechanism of anti-tumor activity. Polyamines support protein translation
via effects on both eIF5A and eIF4F-complex activities, yet their relative contri-
butions remain poorly defıned. Using the puromycin-incorporation assay we
show amarked decrease in global protein translation followingDFMOexposure
(up to 95% reduction), with translation inhibition largely correlated with
MYCN amplifıcation status in the tumor cells. Studies to defıne the dose-re-
sponse and kinetics of DFMO-mediated inhibition in tumors with distinct
MYCN andODC1 genotypes are ongoing, as are studies of eIF5A-hypusination
(by IEF) and eIF4F-complex status (polyamine-dependent 4E-BP phosphoryla-
tion). Moreover, eIF5A is required to resolve ribosome stalling at polyproline
stretches, so we characterized the human proteome for polyproline motifs (PPP
of 3) to defıne an eIF5A-dependent translatome. Candidate genes of diverse
polyproline content are being assessed for sensitivity to DFMO to defıne
whether ribosome pausing and selective translation inhibition contributes to
DFMO effects. Elucidating mechanisms of DFMO activity and correlating this
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with genomic status (MYCN and/or ODC1 amplifıed) will identify opportuni-
ties for drug synergy and provide a responder hypothesis to test in pivotal Phase
2 and 3 clinical trial of DFMO for neuroblastoma.
#4884 Focal 22q11.22 deletions combined with IKZF1 alterations are as-
sociated with worse clinical outcome in acute lymphoblastic leukemia. Julia
A. Meyer,1 Clint C. Mason,1 Luke Maese,1 Deqing Pei,2 Cheng Cheng,2 Ching-
Hon Pui,2 Mel Greaves,3 Richard Aplenc,4 Charles G. Mulligan,2 Elizabeth
Raetz,1 Rodney R. Miles,1 Karen R. Rabin,5 Joshua D. Schiffman1. 1University of
Utah, Salt Lake City, UT; 2St. Jude Children’s Research Hospital, Memphis, TN;
3Institute of Cancer Research, London, United Kingdom; 4Children’s Hospital of
Philadelphia, Philadelphia, PA; 5Baylor College of Medicine, Houston, TX.
Introduction: Prognostic biomarkers in childhood acute lymphoblastic leu-
kemia (ALL) are vital for risk-stratifıcation and intensifying therapy for children
at high risk for remission induction failure or relapse. Copy number alterations
in genes such as IKZF1 and VPREB1 have been shown to correlate with poor
outcome in ALL, highlighting genetic alterations as prognostic markers (NEJM
360:470, 2009, Leukemia 28(1):216-20, 2014). A second focal deletion in chro-
mosome 22q11.22, 200 kilobases (Kb) in length, occurs more frequently and in
the same IGLL region as VPREB1 and is distinct from deletions associated with
physiologic IGLL rearrangement. We further investigated this novel genomic
lesion, 22q11.22, and the prevalence of co-occurrence with IKZF1. Methods:
22q11.22 deletions were characterized in a compiled childhood ALL cohort
(N832) and correlated with available clinical outcome using multiple previ-
ously published studies (Clinical outcome total N730; Utah Cohort [N56],
TARGET P9906 cohort [N215], St. Jude Children’s Research Hospital cohort
[SJCRH, N236], Children’s Hospital of Philadelphia cohort [CHOP, N160],
and Down Syndrome cohort [DS, N63]). Microarray data was analyzed
(UtahMolecular Inversion Probe 330K [Affymetrix]; TARGET SNP 500K
[Affymetrix]; SJCRH SNP 500K/6.0 [Affymetrix], CHOP 850K, 610K, and
Omni Quadv1 [Illumina], DS SNP 500K, MIP 330K [Affymetrix]) by Nexus
Copy Number (BioDiscovery, Inc.). Results: ALL patients that harbored copy
number deletion 22q11.22 were present in about 30-45% of each cohort: Utah
42.8%, TARGET  29%, SJCRH  40%, CHOP  34%, DS  46.7%. The
majority of deletions, 93%, had a common recurring region just under 12 Kb in
length. The 12 Kb deleted segment encodes no known genes. Patients that har-
bored a combined deletion in both IKZF1 and 22q11.22 (IKZF122q) were
present in about 10-15% of each cohort: Utah  12.5%, TARGET  18%,
SJCRH  8.4%, CHOP  6.3%, DS  14.4%. IKZF122q conferred worse
event-free survival (N730, P0.0062) compared to those with only IKZF1
deletions and worse overall survival (N507, P0.0365). Additionally, those
patients with IKZF122q losses had a median decrease in event-free survival
compared to those patientswith neither deletion (normal cases): TARGET (high
risk cohort) 0.63 years, P0.0001, SJCRH (standard, low risk cohort) 10
years, P0.0001, DS  2.3 years, P0.0001. Conclusion: We present fur-
ther evidence that non-physiological deletions within the IGLL locus is associ-
ated with worse outcome in pediatric ALL and combined with IKZF1, these
double deletions identify a population of patients with very poor outcomes.
These combined alterations may be useful to identify patients in the future for
high risk stratifıcation and further work is now needed to understand themech-
anism and biological consequence of this common loss at 22q11.22 in childhood
ALL.
#4885 Identifıcation of actionable targets for refractory/relapsed child-
hood cancer leading to personalized targeted therapy (TRICEPS Study). Fida
Khater, Stephanie Vairy, Sylvie Langlois, JasmineHealy, SophieDumoucel,Ma-
thieu Lajoie, Thomas Sontag, Pascal St-Onge, Henrique Bittencourt, Dorothée
Dal Soglio, Anne-Sophie Carret, Sonia Cellot, Josette Champagne, Michel Du-
val, Maja Krajinovic, Jean-Marie Leclerc, Valerie Larouche, Natalie Patey,
Sébastien Perreault, Nelson Piché, Yvan Samson, Pierre Teira,MoniaMarzouki,
Daniel Sinnett. CHU St-Justine, Montréal, Quebec, Canada.
Childhood cancer is a group of heterogeneous complex diseases. Although
80% of these children are cured with conventional therapies, it remains the fırst
cause of death among children in Western countries. A signifıcant number of
refractory/relapse patients will eventually succumb to their disease and the lack
of therapeutic advances for these patients is even more worrisome. Indeed, no
signifıcant progress has been noted over the last decade for these patients, urging
the need for new andmore effective therapeutic approaches. Precisionmedicine
and more effective personalized targeted therapies (PTT) are a major break-
through leading to increased cure rates and decreased treatment-related mor-
bidity and mortality for the patients with refractory or relapsed tumors. To
address this challenge, the TRICEPS study was initiated on April 2014 at the
Sainte-Justine UHC (Montreal, Canada) with an overreaching goal to explore
the feasibility of performing genomic-driven targeted therapy in pediatric and
adolescent (aged 0-21 years) patients with relapsed or refractory childhood can-
cer. This study offers in-depth genomic and transcriptomic investigation of
patient’s tumoral material to identify patient-specifıc alterations and actionable
driver mutation(s) that can be targeted with approved targeted drug and within
a reasonable clinically relevant timeframe to assess the feasibility of going from
biopsy to a detailed tumor analysis report. Over a period of 30 months, 44
relapsed/refractory cancer patients were recruited. Twenty-two of them under-
went extensive genomic investigation (exomic and transcriptomic sequencing)
within a median timeframe of 9.7 weeks from patient enrolment to return of
results. Patient screen failures occurred due to benign/necrotic tumor biopsies
or low tumor purity resulting in suboptimal DNA/RNA quantity or quality for
genomic analysis. In all 22 patients, we have identifıed clinically relevant
genomic alterations (SNVs, indels, fusions, CNAs) and relapse-specifıc muta-
tions influencing patient management and providing options for personalized
interventions. We assessed the functional impact of some of these cancer-spe-
cifıc alterations. This was the case of a novel relapse-specifıc rearrangement,
identifıed on relapsed childhoodETP-ALL, and leading to asparagine synthetase
(ASNS) up-regulation through a promoter exchange. The expression of this
fusion was associated with reduced apoptosis following l-asparaginase treat-
ment. This study shows that PPT based on next generation sequencing technol-
ogy is a powerful approach that could be implemented in the clinic within a
foreseeable future to guide treatment of hard-to-treat childhood cancers and to
further improve patient care and outcomes.
#4886 The BRIP1 DNA helicase is a 17q dosage sensitive cooperative
driver in neuroblastoma. Suzanne Vanhauwaert,1 Kaat Durinck,1 Els Jans-
sens,1 Givani Dewyn,1 Bram De Wilde,1 Genevieve Laureys,1 Daniel Carter,2
Chueng Belamy,2 Katleen De Preter,1 Christophe Vanneste,1 Frank Speleman1.
1Ghent University, Ghent, Belgium; 2Children’s Cancer Institute, Sydney, Austra-
lia.
Neuroblastoma (NB) is an aggressive pediatric tumor arising from sympa-
thetic neuronal progenitors. NBs have a low mutation burden while copy num-
ber alterations are highly recurrent: MYCN amplifıcation is present in half of
high risk tumors often accompanied by 1p deletions while MYCN non-ampli-
fıed aggressive NB frequently exhibit 11q deletions. Remarkably, both high risk
groups show almost invariably chromosome 17q gain and we also reported that
the mouse syntenic chromosome 11 region was gained during MYCN driven
tumor formation. We propose that one or more dosage sensitive genes on 17q
act as cooperative drivers during NB development. Using an integrated bioin-
formatics analysis, we identifıed several candidate drivers implicated in DNA
repair including BRIP1, also known as FANCJ and located on 17q23.2. BRIP1
acts as a DNA helicase in unwinding of stable G-quadruplex (G4) structures in
single stranded DNA during replication ensuring timely progression through
S-phase. We show that BRIP1 knock down causes increased replicative stress in
MYCN overexpressing NB cells as evidenced as shown by increased RPA32
levels and reduced replication fork velocity. Overexpression of BRIP1 in dh-
MYCN-eGFP transgenic zebrafısh caused accelerated tumor formation sup-
porting its role as cooperative driver gene.Gene expression profıling after BRIP1
knock down confırmed enrichment for gene sets implicated in DNA replication
and repair and are indicative for perturbation of G4 enriched genes. We also
identifıed further additional 17q dosage sensitive genes implicated in replication
fork dynamics including BRCA1, BRCA2, EME1 and TOP2A.We propose that
17q gain acts as an amplifıer for expression of multiple genes implicated in
control of replicative stress and replication fork dynamics. Finally, we explored
whether this replicative stress resistance phenotype could represent a novel ther-
apeutic vulnerability for NB cells or other MYC(N) driven tumor entities. To
this end, we tested several compounds for synergistic interaction with G4 stabi-
lizing ligands such as TMPYP4, pyridostatin and BRACO-19 with promising
results. In conclusion, we identifıed BRIP1 as 17q cooperative driver in NB
through relief from G4 induced replication fork stalling in rapidly dividing tu-
mor cells. Further, NB cells exhibit replicative stress resistance through upregu-
lation of multiple critical regulators of replication fork dynamics, offering a new
venue for therapeutic interventions.
#4887 Comprehensive molecular analysis of pediatric thalamic tumors.
HeloisaH.Moser,1 Susanne Yoon,1Madhuri Kambhampati,1 Sridevi Yadavilli,1
Angela J. Waanders,2 Adam Resnick,2 Roger J. Packer,1 Javad Nazarian1. 1Chil-
drens National Health System,Washington, DC; 2Children’s Hospital of Philadel-
phia, Philadelphia, PA.
Childhood thalamic tumors are relatively rare cancers, accounting for 5% of
all pediatric brain tumors and categorized as midline gliomas such as diffuse
intrinsic pontine gliomas (DIPGs).We and others have shown thatmutations in
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genes encoding for histone 3.3 (H3F3A), histone 3.2 (HIST2H3C) and histone
3.1 (HIST1H3B) along with their obligate partner mutations are the major
driver mutations in DIPGs. Where recent studies have identifıed major histone
partner mutations associated with DIPGs, more research is required to provide
a clear landscape of genomic aberrations associated with thalamic tumors. We
hypothesize that comprehensive whole genome sequence, methylation and pro-
teome analysis of a large cohort of thalamic tumors will map differentially reg-
ulated pathways and identify potential novel driver and obligate partner muta-
tions associated with thalamic gliomas. We have established a cohort (CNHS
and CBTTC) of 128 thalamic specimens, including 56 pediatric and adolescent
primary thalamic tumors with median age at diagnosis of 5.6 years (range 0-20
years); 40 normal controls withmatched age and gender; and 32midline tumors
with potential thalamic involvement with median age at diagnosis of 7.6 years
(range 0-19 years).Our cohort of primary thalamic tumors contained 31 (55.3%)
and 19 (33.9%) tumors reviewed as high and low grade gliomas, respectively.
From ourmidline tumors with potential thalamic involvement, 22 (68.7%) were
classifıed as primary DIPG and 10 (31.2%) were other midline gliomas. Where
available, MRI reviews and histopathological analysis were performed. Prelim-
inary results showed that 7 of the extended tumors presented hypercellularity
and positive histone 3 K27M staining, confırming that these tumors in fact
extended to the thalamus asMRI showed. Additionally,Whole Exome Sequenc-
ing (WES) from one DIPG sample extending to the thalamus showed the same
mutations found on the primary pons tumor: H3.1 K27M; ACVR1 G328V;
PIK3CA H1047R; MAX R51Q and PTEN A126S. The remaining primary and
extended thalamic tumors will be analyzed byWES to understand themolecular
changes associated with this disease. In addition to our results, we analyzed the
genomic landscape from pediatric thalamic tumors previously published (188),
showing H3.3/H3.1 K27M (51%); BRAF (10.6%) and TP53 (8%) as the most
frequent mutations among thalamic high and low grade astrocytomas. Further
studies will allow us to compare comprehensive molecular analysis of thalamic
tumors (primary and metastatic) and non-thalamic midline tumors (specimen
and data already in hand) and identify similarities and differences in genomic,
epigenomic and proteomic expression pattern which may guide a better char-
acterization of thalamic tumor as a separate entity.
#4888 HumanPGBD5DNAtransposase promotes site-specifıc oncogenic
mutations in rhabdoid tumors. Anton G. Henssen,1 Richard Koche,1 Jiali
Zhuang,2 Eileen Jiang,1 Casie Reed,1 Amy Eisenberg,1 Eric Still,1 Elias Rodrí-
guez-Fos,3 Santiago Gonzalez,3 Montserrat Puiggròs,3 Andrew N. Blackford,4
Christopher E. Mason,5 Elisa de Stanchina,1 Mithat Gönen,1 Anne-Katrin
Emde,6 Minita Shah,6 Kanika Arora,6 Catherine Reeves,6 Nicholas D. Socci,1
Elizabeth Perlman,7 Cristina R. Antonescu,1 Charles W. Roberts,8 Hanno
Steen,9 Elizabeth Mullen,10 Stephen P. Jackson,4 David Torrents,3 Zhiping
Weng,2 Scott A. Armstrong,1 Alex Kentsis1. 1Mem. Sloan Kettering Cancer Ctr.,
New York, NY; 2University of Massachusetts Medical School, Worcester, MA;
3Barcelona Supercomputing Center, Barcelona, Spain; 4University of Cambridge,
Cambridge, United Kingdom; 5Weill Cornell Medical College, New York, NY;
6New York Genome Center, New York, NY; 7Ann & Robert H. Lurie Children’s
Hospital of Chicago, Chicago, IL; 8St. Jude Children’s Research Hospital, Mem-
phis, TN; 9Boston Children’s Hospital, Boston, MA; 10Dana-Farber Cancer Insti-
tute, Boston, MA.
Genomic rearrangements are a hallmark of childhood solid tumors, but their
mutational causes remain poorly understood. Here, we identify the piggyBac
transposable element derived 5 (PGBD5) gene as an enzymatically active human
DNA transposase expressed in the majority of rhabdoid tumors, a lethal child-
hood cancer. Using assembly-based whole-genome DNA sequencing, we ob-
served previously unknown somatic genomic rearrangements in primary hu-
man rhabdoid tumors. These rearrangements were characterized by deletions
and inversions involving PGBD5-specifıc signal (PSS) sequences at their break-
points, with some recurrently targeting tumor suppressor genes, leading to their
inactivation. PGBD5was found to be physically associatedwith human genomic
PSS sequences that were also suffıcient to mediate PGBD5-induced DNA rear-
rangements in rhabdoid tumor cells. We found that ectopic expression of
PGBD5 in primary human cells was suffıcient to promote penetrant cell trans-
formation in vitro and in immunodefıcient mice in vivo. This activity required
specifıc catalytic residues in the PGBD5 transposase domain, as well as end-
joining DNA repair, and induced distinct structural rearrangements, involving
PSS-associated breakpoints, similar to those found in primary human rhabdoid
tumors. Thus, PGBD5defınes a distinct class of oncogenicmutators and induces
site-specifıc somatic DNA rearrangements in human cancer.
#4889 Characterizing the viromes in pediatric cancers through whole ge-
nome sequencing. Ti-Cheng Chang, John Easton, Emilia M. Pinto, Jinghui
Zhang, Gang Wu. St. Jude Children’s Research Hospital, Memphis, TN.
Viral infections have been associated with the development of adult cancers
such as cervical carcinomas and head/neck cancers. However, there is lack of
clear understanding of the composition of virome in pediatric cancers. Here, we
made the fırst attempt to identify differentially enriched viral communities in
biological material from pediatric cancer patients, and to predict virus integra-
tion sites that may be associated with etiology or tumor progression of pediatric
cancers. ThePediatricCancerGenomeproject (PCGP)has previously generated
whole-genome sequencing (WGS) data of matched cancer-normal samples for
over 600 pediatric patients from three classes of cancers: leukemia, solid tumors,
and central nervous system (CNS) cancers. We re-constructed the virome com-
position profıles in each sample based on the unmapped and partially mapped
Illumina reads extracted from the PCGPWGS data. Taxonomic assignments of
the extracted read data were conducted using the Krakenmetagenomic pipeline
and virus integration siteswere predicted by theVyPERpipeline. Custom scripts
were used for downstream comparative analyses. A comparison of the alpha
diversity of each virome indicated that the tumor samples in general have a lower
diversity compared to the normal samples across all tumor types. This trend
holds true in leukemia, where both tumor and normal samples were blood de-
rived, suggesting that this is not due to different origins of the tumor samples.
Ordination analyses based on the viral composition identifıed distinct clusters in
the three classes of cancers. These clusters were formed mainly by samples of
medulloblastoma for CNS, T-ALL and hypodiploid B-ALL for leukemia, retino-
blastoma and rhabdomyosarcoma for solid tumors. Viruses, such as phages,
herpesviraidae and several sarcoma viruses, were differentially enriched in these
clusters. Potential integration with retroviruses or herpesviruses was predicted
at a high frequency. Less frequent integration events were also detected with
known oncogenic viruses, such as simian virus 40 and human adenovirus C,
which were under deep sequencing validation. In summary, our comprehensive
characterization of the virome in a wide spectrum of pediatric cancers revealed
a potential connection between specifıc viral communities and integration sites
in certain distinct types of pediatric cancers. Our fındings highlight a possible
mechanism underlying the tumor progression in pediatric patients.
#4890 A pan-cancer analysis framework for incorporating gene expres-
sion information into clinical interpretation of pediatric cancer genomic
data. Olena Morozova,1 Yulia Newton,1 Avanthi Tayi Shah,2 Holly Beale,1 Du
Linh Lam,1 JohnVivian,1 Isabel Bjork,1 Theodore Goldstein,1 Josh Stuart,1 Sofıe
Salama,1 E. Alejandro Sweet-Cordero,2 DavidHaussler1. 1UC Santa Cruz, Santa
Cruz, CA; 2UC San Francisco, San Francisco, CA.
Genomic characterization used in pediatric cancer clinical trials is limited to
the detection of somatic mutations and gene fusions in well-characterized can-
cer genes. However, these approaches do not reveal actionable therapeutic tar-
gets for the majority of pediatric cancer patients. Incorporation of gene expres-
sion information into clinical genomic analysis is hindered by the lack of
appropriate computational methods, designed for single patients rather than
patient cohorts. UC Santa Cruz Treehouse Childhood Cancer Initiative (tree-
housegenomics.soe.ucsc.edu) enables the incorporation of gene expression in-
formation into the genomic evaluation of pediatric cancer patients.We leverage
large cancer RNA sequencing datasets, including The Cancer Genome Atlas,
Therapeutically Applicable Research to Generate Effective Treatments, Medul-
loblastoma Advanced Genomics International Consortium, International Can-
cer Genome Consortium, and published research and clinical studies. Through
our “pan-cancer analysis”, we compare each prospective tumor’s RNA sequenc-
ing and/or mutational profıle to over 11,000 uniformly analyzed tumor profıles
using our Tumor Map method. Tumor Map visualizes single tumors together
with the reference compendium and identifıes samples that are most similar to
the given tumor based on the gene expression profıles.We also developed a gene
expression outlier analysis to identify transcripts that are over expressed in the
given tumor. These pan-cancer gene expression analyses are used in conjunction
with mutation data to nominate molecular pathways that may be driving the
disease in each child, providing useful information to themedical teams.We aim
to evaluate this approach in partnership with pediatric cancer clinical genomic
trials at Stanford University, UC San Francisco, Children’s Hospital of Orange
County,University ofMichigan, Children’sMercyHospital, andBritishColum-
bia Children’s Hospital. The analysis of the fırst 27 patients at Stanford, most
with refractory solid tumors, provided evidence of the potential clinical utility of
incorporating gene expression information into the genomic evaluation of pe-
diatric cancer patients. In all cases, we identifıed candidate driver molecular
pathways that could be targeted by existing FDA-approved therapies or thera-
pies available through a clinical trial. The most frequently identifıed molecular
targets were receptor tyrosine kinases and cyclin-dependent kinases. For 3 pa-
tients with no treatment options prior to our work, the analysis contributed to
treatment decisions. This study provides a framework for incorporating gene
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expression information into the clinical interpretation of pediatric cancer
genomic data. We underscore the importance of releasing the data to the com-
munity immediately following generation, so that theymay benefıt newpatients.
#4891 Identifıcationof recurrent high-affınityMHCclass I restrictedneo-
epitopes in neuroblastoma using ProTECT. Arjun A. Rao, Jugmohit Toor,
Sarvind Tripathi, Jacob Pfeil, Nikolaos Sgourakis, Sofıe Salama, David Haussler.
UC Santa Cruz, Santa Cruz, CA.
Introduction: T-cells are trained to differentiate between cell-surface MHC-
displayed peptide sequences from self- and non-self proteins and act on the
latter. The numerous mutations often associated with cancers can occur in cod-
ing regions of the genome and modify the sequence of wild-type proteins, po-
tentially creating targets for immunotherapies. We have developed an analysis
pipeline ProTECT (Prediction ofT-cell Epitopes forCancerTherapy) to identify
and rank neo-epitopes in terms of immunogenicity. Running ProTECT on a set
of Neuroblastomas patients predicted hotspot mutations that bind well to high-
frequency MHC alleles – combinations that would potentially benefıt a large
subset of NBL patients. Methods: ProTECT accepts paired tumor and normal
DNA sequencing fastq fıles, and tumor RNA sequencing fastqs. Mutations are
called using a panel of callers 1
4
, and are annotated[5] to identify coding muta-
tions. Prediction of self-MHC:mutated-peptides is carried out[6] and the fınal
binding predictions are ranked using an in-house algorithm. Summary: Run-
ning ProTECT on 6 Neuroblastoma samples (NBL) from the TARGET (Thera-
peutically Applicable Research to Generate Effective Treatments) project re-
vealed 2 well-known hotspot mutations in NBL (NRAS Q61K and ALK
R1275Q) that bind to commonMHC alleles (A*01:01 and B*15:01 respectively).
We also found 2 closely related mutations in ALK F1174L and F1174I that are
predicted to C*04:01 and C*07:02. We carried out in-vitro refolding and crys-
tallization assays [7] for the fıve highest-ranking mutant NRAS and ALK
R1275Q predictions. Properly conformed MHC trimers were verifıed by a
monodisperse peak after anion exchange chromatography. SDS gel electropho-
resis andMass-spec confırmed bound peptide for 4/5 tested predictions and 3 of
these were used to set up hanging-drop crystallization trials in various condi-
tions. Positive hits were obtained for one (AQDIYRASY::HLA-B*15:01) and the
structure was obtained at 1.7A. The structure suggested the binding of the 10-
mer (AQDIYRASYY) to the MHC and this was shown to bind better than the
9-mer usingDifferential Scanning Fluorimetry[9].Wewill run ProTECT on the
remaining 100 TARGET NBL trios, and on relevant cohorts within The Can-
cer Genome Atlas (TCGA). We aim to reveal clinically relevant hotspot-muta-
tion:MHC pairs. Conclusion: We have described a pipeline for identifıcation
and ranking of therapeutically relevant neo-epitopes.We have predicted poten-
tial targets for NBL that have been validated in-vitro. References: 1. Cibulskis, K.
et al. Nat Biotech 31, 213-219 (2013) 2. Radenbaugh, A. J. et al. PLoS ONE 9,
e111516 (2014) 3. Larson,D. E, et.al. Bioinformatics 28 (3) (2012) 4. Saunders, C.
T, et.al Bioinformatics 28 (14) (2012) 5. Cingolani, P. et al. Fly 6, 80-92 (2012) 6.
Vita, R. et al. Nucl. Acids Res. (2014) 7. Garboczi, D. N. et.al. PNAS 89 (8) (1992)
9. Lance M. Hellman et.al. J ImmMeth 432:95-101 (2016)
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#4892 MOSPD2, a newly characterized protein, promotes breast cancer
metastasis. ItzhakMendel, Yaniv Salem, Niva Yacov, Oshrat Propheta-Meiran,
Eyal Breitbart. VBL Therapeutics, Or Yehuda, Israel.
Introduction: We have previously described motile sperm domain-contain-
ing protein 2 (MOSPD2), a protein which up until recently no function was
ascribed to, as a key regulator of monocyte migration in-vitro. In this study, the
role of MOSPD2 in promoting breast cancer migration and metastasis in-vitro
and in-vivo was assessed. Experimental procedure: The prevalence of MOSPD2
was evaluated by IHC in tissue microarray layered with cores, representing dif-
ferent stages of invasiveness in breast cancer. MOSPD2 abundance was scored
according to the staining intensity on a scale from 0 to 3. MOSPD2 expression
was silenced in MDA-231 breast cancer cell line using lentiviral particles for
sh-RNAorCRISPR-CAS9 (CRISPR).Cellswere then tested by a trans-well assay
for migration towards EGF in vitro as well as for lung dissemination following
orthotopic or systemic inoculation in vivo. For mechanism studies, EGF-in-
duced signaling events were analyzed. Results: Within normal adjacent tissue
(NAT), 82% of the samples had no staining and the remaining 18% percent
displayed an intensity of 1. In the tissue cores with in-situ carcinoma pathology,
79% of the samples had no staining intensity while the remaining 21% only
scored 1 or 2. However, analysis of invasive andmetastatic cancer demonstrated
higher frequency in score of 2 and increased staining intensity up to score of 3
compared with NAT and in-situ carcinoma. Thus, the percent of combined
scores 2 and 3 for invasive lobular carcinoma, invasive ductal carcinoma and
metastatic invasive ductal carcinoma were 63%, 77% and 81%, respectively.
MOSPD2-silenced cells, either by sh-RNA or by CRISPR, were severely im-
paired in their ability tomigrate in-vitro towards EGF. FollowingEGF activation
of CRISPR-Control MDA-231 cells, all tested proteins down-stream to the
EGFR pathway, including AKT and p38, became phosphorylated. However, in
CRISPR-MOSPD2 silenced cells, phosphorylation of all tested proteins exclud-
ing p38 were markedly inhibited. Moreover, activation with IGF of CRISPR-
MOSPD2 MDA-231 cells did not hinder AKT phosphorylation. In vivo, SCID
mice injected orthotopically or systemically with CRISPR-MOSPD2 silenced
MDA-231 cells displayed signifıcantly reduced number of metastases in the
lungs relatively to mice injected with CRISPR-Control treated cells. Conclu-
sions: We suggest that MOSPD2 promotes metastasis of breast cancer cells and
is a potential target for the treatment of metastatic breast cancer.
#4893 AKT1 signaling negatively regulates invasion and metastasis of
non-small cell lung cancer cells carrying mutations in KRAS or EGFR. Gua-
nhua Rao,1 Mariaelena Pierobon,2 In-Kyu Kim,1 Wei-Hsun Hsu,1 Jianghong
Deng,2 Yong-Wha Moon,1 Emanuel F. Petricoin,2 Yu-Wen Zhang,1 Yisong
Wang,1 Giuseppe Giaccone1. 1Georgetown Univ. Medical Ctr., Washington, DC;
2George Mason University, Institute for Advanced Biomedical Research, Manas-
sas, VA.
Signaling driven by the phosphoinositide-3 kinase (PI3K) and AKT/protein
kinase B (PKB) pathway plays an important role in cancer development and
progression, and thus this pathway is an attractive therapeutic target. Although
manydifferent inhibitors targeting either PI3KorAKThave beendeveloped, the
therapeutic benefıt of these inhibitors in the clinic remains elusive, in part be-
cause of the perplexing role of AKT signaling in the regulation of cell motility,
invasion and metastasis. AKT activation is known to promote migration, inva-
sion andmetastasis; however under certain circumstances and different cellular
systems, it also exhibits an inhibitory activity on these cellular processes and the
underlying cause of these conflicting results is unclear. Through analysis of the
Reverse Phase Protein Array (RPPA) performed on a series of non-small cell
lung cancer (NSCLC) brain metastasis models generated via intracardiac injec-
tion inmice, we identifıedAKT1 (one of threeAKT familymembers) as a critical
negative regulator of A549 tumor metastasis. AKT1 tyrosine phosphorylation
(but not AKT2 or AKT3) inversely correlated with the metastatic potential of
A549 cells which carry a KRAS mutation. Using AKT1 siRNAs, we demon-
strated that inhibition of AKT1 signifıcantly enhanced migration and invasion
of KRAS- or EGFR-mutant NSCLC cells, but not wild type KRAS and EGFR
cells. Similarly, the AKT inhibitor MK-2206 also enhanced the migration and
invasion of KRAS- or EGFR-mutant NSCLC cells in vitro, and promoted me-
tastasis of KRAS-mutant A549 cells in vivo. The PI3K-AKT pathway is down-
stream of both EGFR and KRAS, whose constitutive activation caused by muta-
tions likely alter the signal output of PI3K-AKTpathway and thus the activity on
cell invasiveness. Therefore, our results provide a sound explanation that under
certain genetic backgrounds (as we demonstrated here with KRAS or EGFR
mutations) the AKT signalingmay switch frombeing a promoter to an inhibitor
of cell migration, invasion and metastasis. This observation may have strong
clinical implications for the development of inhibitors of this pathway for cancer
treatment. Furthermore, we found that AKT1 blockade induced phosphoryla-
tion of Myristoylated alanine-rich C-kinase substrate (MARCKS) and elevation
of Laminin subunit gamma-2 (LAMC2), which in turn inhibited AKT phos-
phorylation and promoted cell invasiveness. In contrast, MARCKS or LAMC2
knockdown abrogated the activities ofmigration and invasion induced byAKT1
inhibition. This study unravels an anti-metastatic role of AKT1 in NSCLC cells
with KRAS or EGFRmutation, and providesmechanistic insights for the under-
standing of the potentially contrasting roles ofAKT signaling in the regulation of
cell invasiveness.
#4894 Identifıcation of small molecules for the prevention and treatment
of colon cancer.Deeksha Pal,1 Becca Von Baby,1 Balaji Chandrasekaran,1 Arun
Sharma,2 Chendil Damodaran1. 1University of Louisville, Louisville, KY; 2Penn
State University, PA.
Metastatic colon cancer or colorectal cancer (CRC) is associated with poor
survival rate which is less than 5% due to chemo resistance. We previously
showed that overexpression of AKT and Notch1 are key players for progression
of metastasis of colon cancer cells. Withaferin-A (WA) is a potent herbal mole-
cule that inhibited CRC growth by down regulating AKT and Notch1 signaling
in both in vitro and in vivo colon cancer models. We found that WA binds to
TUMOR BIOLOGY: Pediatric Cancer 3: Genetics and Genomics
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171252
AKTwith a predicted binding affınity of -10.6 kcal/mol and inhibited its activa-
tion. So, we designed and developed several analogs of WA, that exhibits a
stronger AKT binding (binding energy higher than -10 kcal/mole) and more
potent than the parental WA. UL16 is one such compound which inhibited the
growth of colon cancer cells (HCT-116 and SW-620: IC50-300nM) at nanomolar
concentration. Western blot analysis revealed that UL16 inhibits AKT/NF-/
Bcl2- signaling axis in colon cancer cells. In addition, UL16 concurrently inhib-
ited Notch1 signaling pathway in colon cancer cells. Then we systematically
investigated the anti-migratory and anti-invasive effect of UL16by cell migra-
tion and invasion assays. Inhibition of both migration and invasion of colon
cancer cells correspondswith downregulation ofmesenchymalmarkers of Snail,
Slug and-catenin expression.We also examined the in vivo effıcacy of UL16 in
ApcMin/ mouse model. Treatment of ApcMin/ with UL16 (0.5 mg/kg/IP/
twice a week) over 12 weeks signifıcantly reduced the number of intestinal pol-
yps (distal 84%; Middle 63% and Proximal 2%) as compared vehicle treated
mice. In addition, we also observed 50% reduction in number of colon tumors in
UL16 treated mice. Our ongoing immunohistochemistry studies may confırm
the in vitro mechanistic results. In conclusion, our studies suggest that UL16
inhibits both AKT andNotch1 signaling and suppresses intestinal polyp forma-
tion in ApcMin/ mice. Hence UL16could be a viable therapeutic agent for
treating patients with metastatic colon cancer.
#4895 CT20p as a therapeutic for lung cancer with elevated chaperoning
containing TCP1 (CCT) expression levels. Ana C. Carr,1 Amr S. Khaled,2 Ra-
nia Bassiouni,1 Annette R. Khaled1. 1University of Central Florida, Orlando, FL;
2Orlando VA Medical Center, Orlando, FL.
Lung cancer is the leading cause of cancer related fatalities worldwide and
although there is a substantial effort in the development of improved, more
specifıc, and less debilitating therapies, very little progress has been made ac-
complishing this goal. We propose the use of CT20p, a therapeutic peptide
developed by our laboratory, as novel therapy for lung cancer. We have previ-
ously demonstrated that CT20p has tumor specifıc cytotoxicity in breast cancer
cells and it induces tumor regression in xenograft models of breast cancer. We
have also determined Chaperonin containing T-complex (CCT) to be the intra-
cellular target of CT20p and that susceptibility to CT20p correlates with its
expression levels, with tumor cells expressing high levels of CCT being the most
susceptible. CCT is a large macromolecular complex composed of 8 subunits
(CCT, CCT, CCT, CCT, CCT, CCT	, CCT, CCT). Immunoblot prob-
ing against four relevant CCT subunits (CCT, CCT, CCT, CCT) was used
to determine their relative expression level in fıve small cell lung cancer (SCLC)
cell lines when compared to normal lung cells. We determined that the expres-
sion levels of the four probed CCT subunits varied amongst the fıve SCLC cell
lines, however, the four CCT subunits were always expressed at higher levels
when compared to normal lung cells. Immunohistochemistry staining for
CCTwas used on tissuemicroarray (TMA) of lung cancer progression. Results
were interpreted on a scale of 1 to 4 (with 4 being the strongest staining). We
determined that CCT levels increase with cancer severity and identifıed a sig-
nifıcant correlation between CCT levels and cancer progression in both small
cell lung carcinoma (SCLC) and Squamous cell lung carcinoma (SqCLC). Using
The Cancer Genome Atlas (TCGA) database, we have found CCT gene altera-
tions in clinical lung cancer cases range from 10% to 43%, however, only CCT4
gene amplifıcation in SqCLC cases correlated with decreased survival. Alto-
gether, these results suggest that CT20p has the potential for being a therapeutic
for multiple types of lung cancer due to increased target expression.
#4896 Role of CDK8 in colon cancer hepatic metastasis. Jiaxin Liang,
Mengqian Chen, Mythreye Karthikeyan, M. Marjorette Pena, Daniel Hughes,
Vimala Kaza, Chang-Uk Lim, Eugenia Broude, Igor B. Roninson. University of
South Carolina, Columbia, SC.
About half of all colon cancer patients will develop liver metastases and the
5-year survival for these patients is less than 13%, making colon cancer the
secondmost lethal cancerworldwide. Cyclin dependent kinase 8 (CDK8), which
regulates transcription but not cell cycle progression, has been identifıed as an
oncogene amplifıed in many colon cancers. CDK8 acts as a positive mediator of
oncogenic transcription pathways regulated by Wnt/beta-catenin and TGF-
beta, both of which are strongly associated with tumor metastasis. In a colon
cancer liver metastasis model based on splenic injection of CT26 murine colon
carcinoma cells, treatment with Senexin B, a highly selective small-molecule
inhibitor of CDK8 and its paralog CDK19, strongly inhibited metastatic growth
in the liver and prolonged the survival of mice with hepatic metastases. In con-
trast to the effect on liver metastasis, CDK8 inhibition had little or no effect on
cell growth in culture or at primary tumor sites.Hepaticmetastasis was inhibited
to the same extent when Senexin B was administered starting from the time of
tumor injection or only during a later part of the study, suggesting that the drug
affected metastatic growth in the liver rather than just initial colonization. Liver
metastasis was similarly decreased by CDK8 knockdown in CT26 cells, suggest-
ing that the anti-metastatic activity of Senexin B was due at least in part to its
effect on tumor cells. Transcription profıling indicated that CDK8 inhibition by
shRNA or Senexin B strongly decreased the expression of metastasis-associated
metalloproteinases MMP 13, MMP10, and MMP3 and at the same time drasti-
cally increased the expression of TIMP3, a metalloproteinase inhibitor. TIMP3
overexpression in CT26 cells, like CDK8 inhibition, decreased hepatic metasta-
sis. CDK8 inhibition also blocked TGF-beta or Wnt3a-stimulated transwell
Matrigel invasion of CT26 cells in vitro. Knockdown of beta-catenin in CT26
cells decreased the expression of MMP3 and MMP13, while knockdown of
SMAD4 (transcriptional mediator of TGF-beta pathway) induced TIMP3 ex-
pression. Beta-catenin knockdown decreased both the primary tumor growth in
the spleen and metastatic growth in the liver, whereas SMAD4 knockdown, like
that of CDK8, selectively inhibited liver metastasis. Senexin B also suppressed
hepatic metastasis after splenic injection of human HCT116 colon carcinoma
cells. In summary, our data identifıed CDK8 as a key transcriptional regulator of
colon cancermetastatic growth in the liver, interactingwith TGF-beta andWnt/
beta-catenin pathways and regulating the expression of MMPs and Timp3.
CDK8/19 inhibitors, which are now entering clinical trials, may be effective for
the treatment of hepatic metastasis of colon cancer.
#4897 Circadian/melatonindisruptionbydim light at night drives human
epithelial breast cancer to a metastatic phenotype. Steven M. Hill, Shulin
Xiang, Robert T. Dauchy, MelissaWren-Dail, Murali Anbalagan, Brian Rowan,
Tripp Frasch, David E. Blask.TulaneUniv. School ofMedicine, NewOrleans, LA.
Cancer patientswith disrupted 24-hour (circadian) rhythms are reported to have
poorer survival as compared to those with normal rhythms. Severe alterations in
circadian rhythms predict an increased risk of death in patients with colorectal and
breast cancer, suggesting that circadian disruption may impact tumor progression
andmetastasis.Werecently reported that circadian/melatonin (MLT)disruptionby
exposure todimlight atnight (dLAN)resulted inconstitutivephospho-activationof
ERK1/2, CREB, NF-kB, and STAT3 in breast tumor xenografts promoting resis-
tance to Tamoxifen and Doxorubicin therapy. Given that chemoresistant breast
cancer is frequently metastatic, this study examined if dLAN-induced circadian/
MLT disruption can promote epithelial-to-mesenchymal transition (EMT) of epi-
thelialMCF-7breast tumorxenografts leading to thedevelopmentofmetastatic foci
in the lungs, livers, and brains of circadian complete (MLT-producing) athymic
nude female rats and mice. Female nude rats with ERMCF-7 or T47D human
epithelial breast cancer xenografts were housed in LD,12:12 and LD,12:12dLAN
(dLAN)photoperiods or indLANsupplementedwithnighttimeMLT (0.05g/ml)
in the drinking water, with lights on at 0600 hrs and off at 1800 hrs. Blood samples
collected during themid-dark phase (2400 hrs) showed elevated nocturnal melato-
nin (118.4 pg/ml) in the LD,12:12 group, but signifıcantly suppressed melatonin
(10.0 pg/ml) in the dLAN group. Tumor xenografts from rats housed in dLAN
showed a3-fold decrease in latency-to-onset and a2.8-fold increase in growth
rates vs. those from rats in dLANMLT.Tumor cAMP levels, aswell as numerous
signaling pathways involved in promotingEMT(Vimentin,-catenin, and SNAIL)
and metastasis (HER2/HER3, pCREB, pERK1/2, pRSK2, and pSTAT3), showed
increased expression/phospho-activation at 2400 hrs in response to dLAN but re-
pressed expression in tumors from rats in dLANMLT. Follow-up studies with
Foxn1nude female mice implanted with non-metastatic luciferase expressing
MCF-7 breast cancer cells showed that exposure to dLAN suppressed the nighttime
serum levels ofMLT by 93% in thesemice compared to those in a LD,12:12 photo-
period. Exposure of mice to dLAN induced the rapid growth of MCF-7luc tumor
xenografts and, after 5 weeks, induced the metastatic outgrowth of MCF-7 xeno-
grafts to form luciferase identifıablemetastatic foci in the lungs, livers, and brains of
all mice, as measured by IVIS small animal imaging system. Conversely,MCF-7luc
tumor xenografts from mice exposed to dLAN and supplemented with nighttime
MLT showed a reduced tumor development, 3-fold slower tumor growth, and a
small metastatic lesion in one lung of a single mouse. This study is the fırst to show
that circadian/MLT disruption by host exposure to dLAN is able to drive EMT in
human epithelial breast cancer xenografts to generate metastatic foci in lung, liver,
and brain of mice.
#4898 eIF4E reshapes the surface ofmigratingAML cells through regulat-
ing Hyaluronic Acid synthesis & CD44 expression.Hiba Zahreddine,1 Biljana
Kraljacic-Culjkovic,1 Valbona Cali,2 Mark Lauer,2 Lucy Skrabanek,3 Nabilah
Khan,4 Ronald Midura,2 Leandro Cerchietti,3 Vincent Hascall,2 Craig Jordan5.
1Institute for Research in Immunology and Cancer, University of Montreal, Mon-
treal, Quebec, Canada; 2Cleveland Clinic, Cleveland, OH; 3Cornell University,
New York, NY; 4University of Denver, Colorado, CO; 5University of Denver, Den-
ver, CO.
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Formation of cell surface protrusions has long been associatedwith tumor cell
migration, metastasis & bone marrow homing & retention. It was shown that
increased expression of endogenous or exogenous hyaluronic acid synthesizing
enzyme 3 (HAS3) induces growth of microvillus-like cell surface protrusions.
Some of the biological signals triggered by HA are dependent on its recognition
by the cell surface receptor CD44. In our studies we observe that overexpression
of the eukaryotic translation initiation factor 4E (eIF4E) increases formation of
cell surface protrusions resembling those produced by HAS3 upregulation.
eIF4E regulates mRNA export & translation through binding to the m7G cap of
mRNA in the nucleus & the cytoplasm, respectively. Strikingly, analysis of our
two complimentary screens (immunoprecipitation of mRNAs bound to eIF4E
in the nucleus, and mRNA export assay with ribavirin, an established inhibitor
of eIF4E) that we carried out to identify candidate eIF4E mRNA export targets,
showed that nearly all the enzymes involved in HA synthesis as well as CD44.
Here, we hypothesize that eIF4E regulatesHA synthesis &CD44 overexpression
to reshape the surface of cancer cells producing HA-rich microvillus-like pseu-
dopods. Following validation of the positive hits, we used immunofluorescence
stainingwith biotinylatedHAbinding protein (HABP) to determine the effect of
eIF4E expression on protrusion formation. Our data revealed that eIF4E over-
expression increased formation of HA-rich cell surface protrusions & was cor-
related with increased invasiveness of eIF4E overexpressing cells in in vitro
matrigel assay, compared to respective controls. Colocalization studies using
confocal microscopy indicated that protrusions positively stained for CD44.
Further, pharmacological inhibition with ribavirin and genetic knockdown of
eIF4E (or HAS3/CD44 in the context of eIF4E overexpression) abrogated pro-
trusion formation and decreased the invasion capacity of eIF4E overexpressing
cells. Together, these data indicate that eIF4Emodulates protrusion formation&
tumor invasion through coordinately regulating the export of RNAs in the
CD44-HA regulon. To establish the clinical relevance of our fındings in AML,
we examined primary AML specimens with high eIF4E levels for expression of
HA synthesizing enzymes, CD44 & we directly measured HA using confocal
methods. This comparison showed that these pathways are dysregulated inAML
patients & that their inhibition correlates with response to eIF4E inhibition by
ribavirin. While HA has long been considered as a component of the tumor
microenvironment required for themigration of cancer cells though interaction
with surface CD44, our results provide a novel role for eIF4E in the motility &
bone marrow homing. These fındings offer a rationale for potentially inhibiting
tumor cell metastasis through the combinatorial inhibition of eIF4E and CD44
or HAS3.
#4899 The small molecule cathepsin L and K inhibitor KGP-94 impairs
the metastatic phenotype of osteosarcoma cells. Henrietta Fasanya, Dietmar
Siemann. University of Florida, Gainesville, FL.
Osteosarcoma (OS) is the most common primarymalignant bone cancer and
primarily affects adolescents between the ages 10-20 years old. Today, OS re-
mains the second leading cause of cancer-related death for patients in this age
group.With current therapy, the 5-year survival for patients with clinicallymet-
astatic disease has remained unchanged at 20% since the early 1970s. There is a
signifıcant need for novel therapies that will increase overall survival for patients
with metastatic OS. Proteases secreted within the tumor microenvironment en-
able primary tumor development and potentiate the ability of OS cells to metas-
tasize. Typically, cysteine proteases under normal physiologic conditions func-
tion primarily within the lysosome to facilitate protein cell turnover. During
tumorigenesis, Cathepsin L (CTSL) is secreted into the tumor environment by
the tumor. CTSL secretion potentiates metastasis through its regulation of cell
motility, extracellular matrix degradation, angiogenesis, and bone remodeling.
Cathepsin K (CTSK) is overexpressed inOS and is secreted during bone remod-
eling by osteoclast to degrade the bonematrix. The bone environment is hypoxic
which induces proteomic changes that enable OS cells to survive in a nutrient
deprived environment and increase CTSL/CTSK secretion by the tumor cells.
The goal of these studies was to determine if CTSL/CTSK inhibition via KPG-94
(3-bromophenyl-3-hydroxyphenyl-ketone thiosemicarbazone) could decrease
the metastatic phenotype of human osteosarcoma cells under normoxic and
hypoxic conditions. The Hu09 cell line has been characterized as an osteoblastic
cell linewith the potential to groworthotopically in vivo.Hu09 and itsmetastatic
sublines Hu09-L6 and Hu09-M112 have been characterized to low and high
metastatic capacity, respectively. Treatment with KGP-94 at 10 and 25 uM ef-
fectively decreases cell motility and invasion of Hu09 and its metastatic sublines
under normoxic and hypoxic conditions. Our results demonstrate that dual
CTSL/CTSK inhibition is effective at decreasing two signature methods of mea-
suring metastasis: 1) cell motility and 2) invasiveness. Targeting CTSL/CTSK
may provide a novel therapeutic approach for patients with metastatic OS.
#4900 Cysteamine suppresses tumor metastasis by inhibiting activity of
matrix metalloproteases without inducing toxicity in mouse models of hu-
man ovarian cancer. Akiko Suzuki, Rukmini Bhardwaj, Pamela Leland, Bharat
H. Joshi, Raj K. Puri. FDA-CBER, Sivler Spring, MD.
Previously, we demonstrated that cysteamine, a small molecule inhibitor of
matrixmetalloproteases (MMPs), inhibited tumor invasion in vitro and metas-
tasis in vivo inmousemodels of human pancreatic and ovarian cancer.We have
also shown that subcutaneous cysteamine administration improved the survival
of mice with orthotopically transplanted pancreatic tumors. Herein, we exam-
ined the effect of cysteamine on total MMP activity, MMP isoforms and activity
by substrate gel zymography in tumors obtained from orthotopic mouse model
of human ovarian cancer.We also investigated any gastro-intestinal and general
toxicity in vital organs of mice treated with the highest dose of cysteamine (250
mg/kg). We developed orthotopic tumors by injecting two human ovarian can-
cer cell lines in the ovary of female athymic nude mice. After 4 days of tumor
implant, the mice were treated with different doses of cysteamine and followed
for 5 weeks. Total MMP activity by fluorogenic substrate, MMP-2, 9 and 14 by
ELISA andMMP activity by substrate gel zymography were measured in tumor
lysates and compared with untreated tumors. We performed H&E staining in
vital organs such as heart, lung, liver, kidney, spleen and brain for evaluating
general toxicity of cysteamine. In addition, we examined stomach and duode-
num from cysteamine treated and vehicle treated mice if they developed any
ulcerations. In two orthotopic murine models of human ovarian cancer, consis-
tent with our previous observations, tumor metastasis was signifıcantly de-
creased compared to controls in cysteamine treated mice. Similarly, total MMP
activitywas also signifıcantly decreased in primary tumors treatedwith cysteam-
ine in a dose dependent manner (P0.05). ZymographicMMP activity was also
decreased signifıcantly in cysteamine treated tumors compared to control cor-
roboratingwith totalMMP activity (P0.05). Interestingly, ELISA did not show
any changes in MMP expression in cysteamine treated and untreated tumors.
Furthermore, we did not observe any symptoms of general toxicity in animals
treated at the highest dose of cysteamine and major vital organs and gastro-
intestinal organs from treated animals showed no evidence of histological
changes as evident by H&E staining. In conclusion, our results suggest that
cysteamine is a potent inhibitor of MMP activity without affecting expression.
Cysteamine does not cause any gastro-intestinal or vital organ toxicity and may
be useful therapeutic agent for ovarian cancer either alone or in combination
therapy with known anti-cancer agents.
#4901 Urokinase-derived peptide UP-7 effectively inhibits metastatic
growth of breast cancer through suppression of FAK activation. Young Ae
Joe,1 Hyun-Kyung Kim,1 Purevjargal Naidansuren,1 Seung Woo Lee,1 Rae-
Kwon Kim,2 Su-Jae Lee,2 Suk Keun Lee,3 Yong-Kil Hong1. 1Catholic Univ. of
Korea, Seoul, Republic of Korea; 2Hanyang University, Seoul, Republic of Korea;
3Kangnung National University, Kangnung, Republic of Korea.
The recombinant kringle domain of urokinase-type plasminogen activator
(UK1) has been shown to inhibit angiogenesis in vitro and in vivo and suppress
brain tumor in vivo. To avoid limitations in application due to mass production
of recombinant proteins, we dissected UK1 sequences to seven peptides based
on structure and amino acid characteristics, and examined the anti-angiogenic
activities for the constructed peptides. UP-7 peptide derived from ß-sheets re-
gion of UK1 was the most potent inhibitor of the proliferation andmigration of
endothelial cells (ECs) in vitro, and it also inhibited in vivo angiogenesis in the
mouse matrigel plug assay. Such anti-angiogenic activities were not exerted by
the scrambled peptide. At molecular level, UP-7 inhibited the VEGF or bFGF-
induced phosphorylation of FAK and ERK1/2 and suppressed formation of
stress fıbers and focal adhesions. It also inhibited the attachment and spreading
of ECs onto immobilized fıbronectin. In a lung cancer animal model xeno-
grafted with UP-7-non-sensitive NCI H460, systemic treatment of UP-7 effec-
tively suppressed tumor growth through inhibition of angiogenesis. Interest-
ingly, breast cancer cells such as MDA-MB231 were sensitive to UP-7 in
proliferation differently from other cancer cells. It inhibited the migration and
invasion of LM-2-MDA-MD231 and suppressed the phosphorylation of FAK.
Accordingly, UP-7 potently inhibited lung metastatic growth of LM2-MDA-
MB-231 in experimental metastasis model. Taken together, these results suggest
that novel UK1-derived peptide, UP-7 can be effectively used for treatment of
the metastatic growth of breast cancer. (NRF-2012R1A1A2007175, NRF-
2012R1A5A2051476)
#4902 Celecoxib fıxed-dose combination: antitumor activity on tumor
growth and metastasis. Cynthia Lee,1 Osmond J. D’Cruz,1 Kevin Ng,1 Vuong
Trieu2. 1Autotelic Inc, Costa Mesa, CA; 2Marina Biotech, Agoura Hills, CA.
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Background: Breast cancer and melanoma are associated with a high rate
of lymphatic and hematogenous metastasis which results in high rate of
cancer mortality. Inflammation and hypertension (HTN) have recently
emerged as causal factors for tumor progression and anti-hypertensive
agents have been shown to reduce inflammation and suppress tumor growth
and metastasis. Cyclooxygenase-2 (COX-2) is upregulated in most human
tumors and is a potent inducer of cancer-associated inflammation that pro-
motes tumor angiogenesis and lymphangiogenesis. This study evaluated a
novel combination of a selective COX-2 inhibitor with three antihyperten-
sive drugs to suppress tumor growth and metastasis in preclinical xenograft
models. Methods: Three anti-hypertensive drugs were evaluated in this
study: i) Lisinopril [LIS], an inhibitor of angiotensin-1 converting enzyme
(ACE); ii) Olmesartan medoxomil (OLM), an angiotensin II receptor
blocker (ARB); and iii) Hydrochlorothiazide (HCTZ), a thiazide diuretic
along with Celecoxib [CEL], a selective COX-2 inhibitor. CEL, LIS, OLM,
and HCTZ were evaluated either alone or in combination for tumor growth
suppression and metastatic spread in an orthotopic xenograft model of tri-
ple-negative inflammatory breast cancer/SUM149 and subcutaneous xeno-
graft models of melanoma/MDA-MB-435, glioblastoma/U87-MG, and tri-
ple-negative SUM159. Luciferase-tagged SUM149 and MDA-MB-435 cell
lines were used to determine the incidence and the burden of locoregional
and systemic spread. Mice were monitored twice a week for 9-16 weeks for
percent weight loss, tumor volume and survival outcome. Metastatic tumor
burden and incidence was measured as luciferase expression in lymph nodes
and lungs and normalized to total protein. Results: In the SUM149 model,
the saline treated control had an average tumor burden of 17.6 	 8.6 x104
RLU per mg of protein in the ipsilateral lymph nodes (ILN). Two groups,
OLM alone and CEL  OLM, had a statistically signifıcant decrease in ILN
burden. Olmesartan alone had a 7.1-fold decrease in tumor burden with an
average of 2.4 	 0.6 x104 RLU per mg of protein (p-value  0.01 by Mann-
Whitney test). Similar trend was observed for LIS, but not for HCTZ. In the
subcutaneous model, synergistic antitumor activity was observed with OLM
(p 0.026) at low dose but not with LIS and CEL (p ns). At high dose, LIS,
OLM, and CEL showed signifıcant inhibition of tumor growth but no syn-
ergy. When these agents were combined with Paclitaxel in the SUM159
model, there was only additive effect. HCTZ, an antihypertensive diuretic
which has no direct impact on the vascular wall had no effect on tumor
growth. Conclusion: These preclinical data strongly suggest a hitherto un-
appreciated role of ACE/ARB in tumor growth control and support the
further exploration of fıxed-dose combinations of CEL with ACE/ARB in
cancer, especially inflammatory breast cancer.
#4903 Cationic polymer inhibits pancreatic cancer invasion in vitro and
metastasis in vivo. Ibtehaj A. Naqvi,1 Ruwan Gunaratne,1 Jessica McDade,1
Douglas Rouse,2 Jen Jen Yeh,3 David Pisetsky,2 Jaewoo Lee,2 Rebekah White,4
Bruce Sullenger2. 1Duke UniversityMedical School, Durham, NC; 2Duke Univer-
sity Medical Center, Durham, NC; 3UNC School of Medicine, Durham, NC; 4Un-
versity of California San Diego, San Diego, CA.
Pancreatic cancer has the poorest prognosis of all major cancers with a 5-year
survival of less than 5%. Cell-free DNA (cfDNA) has been well-validated as a
biomarker that correlateswith tumor burden.More recently, a role for cfDNA in
facilitating tumor progression has also been identifıed. The latter occurs through
activation of nucleic acid sensing receptors such as toll-like receptors (TLRs) in
both tumor cells and the host environment, which can upregulate pro-meta-
static signaling pathways. In addition, tumor-derived extracellular vesicles such
as microparticles and exosomes have also been implicated in promoting metas-
tasis by activating pro-invasive pathways in tumor cells and pre-conditioning
secondary sites for metastatic establishment. Our laboratory has previously
shown that cationic polymers can scavenge negatively charged nucleic acids like
cfDNA and abrogate aberrant inflammation in diseasemodels of autoimmunity
and infection. Herein, we investigated the ability of the cationic polymer,
PAMAM-G3, to bind and inhibit cfDNA as well as anionic tumor-derived ex-
tracellular vesicles using in vitro models of pancreatic cancer cell line invasion.
We also evaluated the effect of PAMAM-G3 treatment in a bioluminescent
syngeneic murine model of pancreatic cancer metastasis. PAMAM-G3 signifı-
cantly inhibited in vitro invasion of pancreatic cancer cell lines in response to
both cfDNA and tumor-derived extracellular vesicles. Moreover, biweekly in-
traperitoneal treatment with PAMAM-G3 (20 mg/kg) starting 48 hours after
pancreatic tumor cell implantation led to a signifıcant reduction in liver metas-
tasis without affecting primary tumor growth. Thus, cationic polymers such as
PAMAM-G3 may represent a novel class of therapeutics to combat pancreatic
cancer metastasis.
#4904 GLUT4 exhibits a non-canonical role of regulating lung cancerme-
tastasis. Changyong Wei,1 Abhinav Achreja,2 Jessica Konen,1 Gabriel Sica,1
Melissa Gilbert-Ross,1 Deepak Nagrath,2 Adam Marcus,1 Mala Shanmugam1.
1Emory University, Atlanta, GA; 2Rice University, Houston, TX.
Lung cancer continues to be fatal, in part due to the inability to prevent and treat
metastases. Highly metastatic cancers exhibit enhanced glucose uptake to sustain
proliferation and importantly, tumor invasion. Among the SLC2A family of facili-
tative glucose transporters, GLUT1 is largely attributed to be responsible for in-
creased glucose uptake of cancer cells. GLUT1 is however responsible for glucose
transport across the blood-brain barrier, expressed in many normal cell types and
therefore a less desirable therapeutic target. We previously reported that multiple
myeloma cells rely on overexpression and constitutive plasma membrane localiza-
tionof insulin-responsive glucose transporter,GLUT4. In this studywe investigated
a role for GLUT4 in lung cancer. To interrogate contributions of GLUT1 and
GLUT4 in proliferation, invasion and migration we generated H1299 and A549
GLUT1 orGLUT4 knockdowns. Knockdown (KD) ofGLUT4 did not inhibit pro-
liferation but suppressedmigration and invasion assessed through scratch andBoy-
den chamber assays, respectively. On the contrary, knockdown of GLUT1 reduced
proliferationof these lines.TreatmentofH1299andA549withournewlydeveloped
GLUT4-selective inhibitors also reduced invasion, phenocopying the effects de-
tectedwithGLUT4KD.GLUT4 inhibition also reducedH1299 invasion in a spher-
oid invasionmodel.We utilizedH1299 cells to isolate highly invasive less prolifera-
tive “leader cells” and less invasive but highly proliferative “follower cells”.
Interestingly, examination of these two cell types exhibited a differential expression
pattern of GLUT1/GLUT4. Leader cells have elevated expression of GLUT4 and
decreased GLUT1. On the contrary, follower cells have high GLUT1 and low
GLUT4 expression. Leader cells are more sensitive to GLUT4 inhibitors indicating
they aremore dependent onGLUT4 than follower cells. In addition, leader cells are
more sensitive to mitochondrial complex I inhibitors compared to follower cells,
suggesting they rely more on oxidative phosphorylation. A differential reliance on
glycolysis/OXPHOSwas further supported by evaluation of glucose uptake/oxygen
consumption. Isotope tracer and bioenergetics analyses further support altered nu-
trient dependencies of leader and follower cells. Lastly, we found that GLUT4 is
expressed in patient lung adenocarcinoma specimens including more aggressive
micropapillary lung adenocarcinoma. Examination of collective invasion packs in
human adenocarcinoma demonstrated patchy GLUT1 expression suggestive of a
subset of more proliferative “follower” cells. These results suggest that in a lung
cancerpopulationa subset ofmore invasive cells are reliantonGLUT4with reduced
GLUT1 expression while more proliferative cells rely on high GLUT1 expression,
making GLUT4 a promising candidate for targetingmetastasis in lung cancer.
#4905 Metastasis promoting long non-coding RNA, FEZF1-AS1, is an
important therapeutic target forEwing sarcoma. SheetalA.Mitra,1AnirbanP.
Mitra,2 Jon O. Nagy,3 Jonathan D. Buckley,2 Timothy J. Triche1. 1Children’s
Hospital Los Angeles, Los Angeles, CA; 2University of Southern California, Los
Angeles, CA; 3NanoValent Pharmaceuticals, MT.
Ewing sarcoma (ES) is a universally metastatic tumor of bone and soft tissue.
Five-year survival in patients with metastases at diagnosis is about 20% despite in-
tense treatment strategies. 85%of these tumorsharborachromosomal translocation
resulting in a fusion gene, EWS-FLI1. EWS-FLI1 imparts an oncogenic phenotype
bymodifying critical genes in signaling pathways, thus allowing for uninhibited cell
growth, invasion, andmetastasiswhile evadingdifferentiation. EWS-FLI1 is thus an
ideal therapeutic candidate, but targeting this fusion protein has proven diffıcult. In
an attempt to better understand ES biology and identify candidate therapeutic tar-
gets downstream of EWS-FLI1, we profıled RNA transcription in over 140 ES cases
andcompared thedata tootherpediatric cancers.Among themosthighly expressed
wasa recentlydiscovered longnon-codingRNA(lncRNA),FEZF1-AS1, inaddition
to protein-coding genes such as NR0B1, and CD99, which are known to be impor-
tant targets of the EWS-FLI1 chimeric protein. FEZF1-AS1 expression was specifıc
for ES and was increased more than a hundred fold in ES when compared to other
pediatric tumors. Chromatin immunoprecipitation (ChIP) studies along with lu-
ciferase promoter assays showed that EWS-FLI1 induces FEZF1-AS1 expression by
binding topromoterGGAArepeats. shRNA-mediated lncRNAknockdowndidnot
affect cell growth or survival. Instead, metastatic potential was markedly reduced,
based on Matrigel assays. Conversely, ES cells transfected to overexpress FEZF1-
AS1 engrafted better in mice and metastasized faster than control cells. Expression
profıling of lncRNA-knockdown cells showed that the lncRNA upregulated genes
were involved in cell movement and cell organization. ChIP-seq documented sig-
nifıcant reduction inH3K4me3and theH3K27achistonemarks in thepromotersof
genes that were downregulated as a result of lncRNA-knockdown. In order to doc-
ument FEZF1-AS1 function, we delivered FEZF1-AS1-specifıc antisense oligonu-
cleotide (ASO) and GFP-ASO in anti-CD99-targeted-nanoparticles to ES cells. An
effıcient uptake of nanoparticles and lncRNA-ASO delivery to ES cells led to a 70%
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decrease in lncRNA expression in cells within four hours of initiating treatment.
LncRNA-ASO-targeted ES cells maintained low lncRNA expression for 72 hours
and showed decrease invasion onmatrigel assays. The cells tolerated the treatment
well with no adverse effect on cell survival and proliferation. These results suggest
that FEZF1-AS1 is a highly functional and ES-specifıc lncRNA that can be an im-
portant therapeutic target, reduced expression of whichmarkedly decreasesmetas-
tasis of ES tumors. The primarymechanism of action appears to be histone acetyla-
tion that activates genes involved in cell migration. The nanoparticle data indicates
that FEZF1-AS1 is also a potential therapeutic target, via targeted delivery of inhib-
itory ASOs.
#4906 Sphingolipid regulates pro-inflammatory cytokines to subdue the
neoplastic lesions in hepatocellular carcinoma.Nabanita Chatterjee,1 Krishna
Das Saha2. 1Cancer Care Manitoba, Manitoba, Canada; 2CSIR-Indian Institute
of Chemical Biology, India.
Hepatocellular carcinoma (HCC), is the most leading cause of cancer-related
death in all over the world (seems to more than 80% of death cases). It is fre-
quently linked with continuous hepatocytes death, inflammatory cell infıltra-
tion, and compensatory liver regeneration with higher angiogenic rate. Consid-
ering the different signalling process during this tumorogenesis with the
involvement of new ’lead’ identifıcation of different sources, desire to be less
toxic and higher bioavailability. The use of live, attenuated or genetically com-
pensated microbes or its cellular component(s) or metabolites has begun to
emerge as a potential new approach in medicinal research to deliver bioactive
entities. Thus, advancing our knowledge of such microbes-mediated therapy
may suggest new avenues for therapeutic intervention in many fatal diseases.
Lipid (LSPL-1) isolated from Leishmania donovani could induce apoptosis in
human HepG2 (Hepatocellular carcinoma cell, human) cells, as characterized
by phosphatydylserine serine exposure, DNA fragmentation, alteration of BaX/
Bcl2 ratio with loss of mitochondrial membrane potential and cytochrome C
release, activation of series of caspases and cleaved PARP. LSPL-1 also modu-
lates the various transcription factors like NF-kb65, p53 through regulation of
cell proliferation exerted the death cause. Moreover this study also focused that
the LSPL-1 effectively suppressed diethylnitrosamine (DEN) induced liver in-
flammation and hyperplasia in murine also decline in lipid peroxidation and
increase in enzymic antioxidants (SOD, CAT, GPx, GR and GST) status with
improvement of their survival rate. It reduced the elevated level of cytokines
including tumor necrosis factors, interleukins, interferon (alpha and gamma),
and transforming growth factors in hepatocytes from liver fıbrosis bearingmice.
As evident from immunochemical analysis, inflamed hepatocytes and liver tis-
sue may up regulated the various growth factors including EGF, HGF, endoth-
line-1 regulation with promoting angiogenic activity via modulation of CD34,
VEGF, HIF-1 expression and alteration of these changes were balanced by
LSPL-1. So taken together, these fınding indicated that, LSPL-1 may induce
apoptosis and in hyper proliferating cancer cells via altering cytokines level with
tumour growth regulation in carcinogen exposed rodent system.
#4907 Elucidating the inhibitory role of plant alkaloids in breast cancer
metastasis.Waqas Iqbal, SalehAlkarim, Jamal S. Sabir, Roop S. Bora, Kulvinder
S. Saini. King Abdulaziz University, Jeddah, Saudi Arabia.
Despite extremely high morbidity and mortality of90% frommetastasis, it
remains one of the most challenging process for targeted therapeutic interven-
tions. Identifıcation and characterization of chemically active and bioavailable
compounds frommedicinal plants targeting the cell-signaling pathways of Can-
cer StemCells (CSCs), tumor cells and theirmicroenvironment that abetmetas-
tasis is of great clinical signifıcance. Hence, MCF-7; a breast cancer cell line, was
treated with fractionated alkaloidal extracts from Rhazya stricta with previously
documented anti-cancer activity in lung and pancreatic cancer cell lines. RNA-
seq. analysis was performed for samples treated with compounds that actively
inhibited cell migration in scratch assay to further substantiate their anti-meta-
static role at the cellular and molecular level. Genomic data corroborated the
presence of anti-metastatic compounds that actively down-regulated genes in-
volved in promoting metastasis (CDC6), cell migration (KIF23, DLGAP5), in-
vasion andCSCs’ expansion (PTTG1).We also found down-regulation of GAS1
expression, an enhancer ofHedgehog signaling pathway. To our knowledge, this
study, fırst of its kind, sets precedence in exploiting the anti-metastatic potential
of these compounds. Further proof of concept studies inmousemodels of breast
cancer to establish precise mechanism-of-action(s), would certainly open up
avenues for the development of new chemical entities (NCEs), targeting metas-
tasis regulating gene(s) with precision.
#4908 Neuropilin-1 is up-regulated in the adaptive response of prostate
tumors to androgen targeted therapies and is prognostic of metastatic pro-
gression and patient mortality.Marianna Volpert,1 Brian Tse,2 Ellca Ratther,1
Nataly Stylianou,1 Mannan Nouri,3 Melanie Lehman,1 Stephen McPherson,1
Mani Roshan-Moniri,3 Mandeep Takhar,4 Nicholas Erho,4 Mohamed
Alshalafa,4 Elai Davicioni,4 Robert Jenkins,5 Ashley Ross,6 Jeffrey Karnes,5 Rob-
ert Den,7 Ladan Fazli,3 Martin Gleave,3 Elizabeth Williams,1 Paul Rennie,3
Ralph Buttyan,3 Pamela Russell,1 Colleen Nelson,1 Brett Hollier1. 1Queensland
University of Technology, Brisbane, Australia; 2Translational Research Institute,
Brisbane, Australia; 3University of British Columbia, Vancouver, British Colum-
bia, Canada; 4GenomeDx Biosciences, Vancouver, British Columbia, Canada;
5Mayo Clinic, Rochester, MN; 6Johns Hopkins Medical Institutions, Baltimore,
MD; 7Thomas Jefferson University, Philadelphia, PA.
Aims: Androgen-targeted therapies (ATTs) are the mainstay treatment for
metastatic prostate cancer (PCa). However, ATTs promote adaptation of tu-
mour cells and lead to castration resistant disease (CRPC). We have recently
identifıed the cell surface receptor, Neuropilin-1 (NRP1) as increased during
EMT and in CRPC. However, the role of NRP1 in the prostate epithelium is
poorly understood. This study aims to determine whether the inhibition of
NRP1 will be a feasible therapeutic strategy for blocking PCa metastasis and
therapy resistance. Methods: qPCR and western blotting were used to assess
NRP1 expression in PCa cell lines. NRP1 expression inCRPCwas assessed using
a murine LNCaP xenograft model of castration. NRP1 was knocked down with
shRNA sequences from the pLKO.1 lentiviral construct. For metastasis assays,
PC3 cells were microinjected into the zebrafısh yolk sac and metastatic dissem-
ination imaged 5 days later. NRP1 expression in radical prostatectomy (RP)
samples from Mayo Clinic (545 patients) and Johns Hopkins Medical Institu-
tions (JHMI; 188 patients) cohorts was quantifıed byAffymetrix exon arrays and
multivariable analysis performed.Wound scratchmigration and invasion assays
were performed with the WoundMaker™ tool and IncuCyte™ FLR imaging sys-
tems. Results: NRP1 levels were elevated in humanCRPC xenografts, metastatic
and castrate resistant clinical PCa samples (p0.0001), andPCa cell lines.NRP1
suppression signifıcantly reduced metastasis of human xenografts in zebrafısh
and the migratory and invasive behaviour of metastatic PCa cells (p0.0002).
Multivariable analysis identifıed NRP1 as a signifıcant independent prognostic
indicator ofmetastasis and prostate cancer specifıcmortality in two large clinical
cohorts (Mayo Clinic and JHMI; p0.008/0.048 and 0.013/0,034 respectively).
We show that NRP1 knockdown promotes E-Cadherin expression and loss of
vimentin in mesenchymal PCa cells. Conclusion: These results will provide the
preclinical data necessary to rationalise the use of anti-NRP1 directed adjuvant
therapies for clinical use in PCa patients receiving ATTs, and will pave the way
for larger scale preclinical and clinical trials in the PCa setting.
#4909 Androgen targeted therapy induces ZEB1 expression and is associ-
ated with suppression of androgen signalling and therapy resistance.Katrina
G. Sweeney,1 Nataly Stylianou,1 Gregor Tevz,1 Atefeh Taherianfard,1 Katrina
Pirlo,1 Akanksha Upadhyaya,1 Ellca Ratther,1 Melanie Lehman,1 Martin
Gleave,2 Jennifer Gunter,1 Elizabeth D. Williams,1 Colleen C. Nelson,1 Brett
Hollier1. 1Australian Prostate Cancer Research Centre-Queensland, Institute of
Health and Biomedical Innovation, QueenslandUniversity of Technology, Trans-
lational Research Institute, Brisbane, Australia; 2Vancouver Prostate Centre,
British Columbia, Canada.
Reactivation of the embryonic developmental pathway, epithelial-to-mesen-
chymal transition (EMT) is associatedwith prostate cancer (PCa)metastasis and
therapy resistance. Recent evidence has demonstrated EMT is stimulated fol-
lowing androgen targeted therapy (ATT). In the present study we investigated
the role of EMT transcription factor ZEB1 in ATT-driven EMT, PCa metastasis
and drug resistance. Immunohistochemistry (IHC) staining of ZEB1 on tissue
microarrays of primary tumors from clinical samples demonstrated ZEB1 ex-
pression correlated with increased tumor aggressiveness and Gleason score.
Upon stratifıcation of patient data (n198), high ZEB1 protein expression cor-
related with a shorter time to biochemical recurrence (BCR). Furthermore, IHC
staining of primary tumours from 148 treatment-naïve patients with and with-
out metastasis demonstrated high ZEB1 levels and correlated to a reduced time
to metastasis. To delineate the role of ZEB1 as a molecular driver of late-stage
PCa, microarray analysis of an in vivo LNCaP progressionmodel demonstrated
ZEB1 levels increased following castration. Signifıcantly, high ZEB1 levels were
associated with patients who had undergone neoadjuvant hormone therapy
with or without docetaxel and high ZEB1 levels were associated with a shorter
time to BCR andmetastasis. Inhibition of the androgen/androgen receptor (AR)
axis in LNCaP cells using antiandrogen treatment or shRNA targeting AR re-
sulted in upregulation of ZEB1 in LNCaP cells suggesting enhanced levels of
ZEB1 may drive the early adaptive response of PCa after hormone therapy.
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Interestingly, in models where ZEB1 expression was elevated this was accompa-
nied with repression of classical androgen-regulated genes suggesting ZEB1 is
able to regulate the AR transcriptional pathway.We also investigated the role of
ZEB1 in cancer invasion and chemoresistance. An inducible model of ZEB1
overexpression in LNCaP cells produced a robust EMT upon ZEB1 expression
and was accompanied by an invasive phenotype in 3D cultures. ZEB1 overex-
pression also conferred resistance to docetaxel (IC50 of 8.17	2.45nM in ZEB1-
expressing cells vs. 3.35	0.23nM in control cells) potentially as a result of a
reduced apoptotic cell death responsemediated byZEB1.At suboptimal doses of
docetaxel, the percentage of apoptotic cells (annexin-V/propidium iodide-)
decreased 4-fold when ZEB1was expressed comparedwith control cells andwas
accompanied by a reduction in PARP cleavage and cleaved caspase-7 expres-
sion. In summary, we provide evidence that ZEB1 expression is increased in
response to ATTs and correlates with disease progression, metastasis and ther-
apy resistance.We also showZEB1 is a transcriptional regulator of AR signalling
in PCa, Together this provides the rationale to target ZEB1 for the development
of novel therapies for the treatment of CRPC.
#4910 Eribulin rapidly impairs TGF- signaling. Roma Kaul, April L. Ris-
inger, Susan L. Mooberry. University of Texas Health Science Center at San
Antonio, San Antonio, TX.
Microtubule targeting agents (MTAs) continue to be valuable in treating
breast cancer. While decades of research have shown that these drugs cause
mitotic arrest in cells by suppressing the dynamic instability of microtubules,
recent evidence demonstrates that the ability of MTAs to disrupt the microtu-
bule-dependent transport of key signaling components in interphase cells likely
contributes to their anticancer actions. Cell signaling messages are relayed by
proteins that organize or scaffold signaling hubs. These signaling nodes facilitate
the complex organization and coordination of multiple signaling partners.
NEDD9 is a member of the CAS scaffold family and it has been shown to coor-
dinate TGF- signaling, a driver of oncogenesis and epithelial-to-mesenchymal
transition (EMT). Ligand-mediated stimulation of TGF- receptors leads to the
activation of downstream canonical and non-canonical signaling pathways.
These pathways collectively induce the expression of Snail and Slug, key tran-
scriptional-repressors that promote EMT.We tested the hypothesis that a short-
term treatment of breast cancer cells with eribulin or 3 other clinically relevant
MTAs would differentially disrupt interphase microtubules and alter TGF--
dependent signaling. BT-549 cells were treated for 2 h with concentrations of
MTAs that are clinically relevant and cause maximum disruption of the inter-
phase microtubule network; 100 nMwas used for the destabilizers, eribulin and
vinorelbine and 1 M was used for the stabilizers, paclitaxel and ixabepilone.
The results showed that eribulin and vinorelbine signifıcantly inhibited TGF--
induced expression of Snail and Slug. The microtubule stabilizers had no effect
on Snail and Slug expression following TGF- stimulation. Further studies eval-
uated whether NEDD9 contributes to the downregulation of Snail and Slug.
Co-immunoprecipitation and knockdown studies suggest that eribulin impairs
the ability of NEDD9 to scaffold TGF- signaling partners, thus inhibiting
downstream transcriptional signaling. Consistent with the ability of eribulin to
reverse EMT in experimental models within 7 days, this study begins to shed
light on the mechanisms underlying its action. Funding for this work was pro-
vided by Eisai Inc.
#4911 Allosteric inhibition of the Receptor Tyrosine Kinases c-MET,
RON and VEGFR-2 via the co-receptor CD44v6 by the novel compound
AMC303.VanessaAl-Rawi, Thorsten Laeufer, KatrinGlocker, YvonneHeneka,
Alexandra Matzke-Ogi. amcure GmbH, Eggenstein-Leopoldshafen, Germany.
Introduction: The receptor tyrosine kinases (RTKs) c-MET and RON and
more importantly their crosstalk, play a crucial role in mediating local invasion,
systemic dissemination and resistance in different types of cancer. Both RTKs
are activated by the ligands HGF and MSP respectively and homo- or het-
erodimerize with each other. The RTKVEGFR-2 is themost important receptor
for angiogenesis in solid epithelial tumors. CD44v6, a member of the CD44
family of transmembrane glycoproteins, was identifıed as an essential co-recep-
tor for activation of c-MET, RON and VEGFR-2. AMC303, a peptide based
allosteric and selective inhibitor of CD44v6, was investigated for its inhibitory
effects on c-MET, RON and VEGFR-2 pathways in vitro and its effect on tumor
growth and metastases in vivo. Methods: Affınity was determined using Mi-
croscale Thermophoresis. For in vitro blocking assays AMC303 was added 30
min prior to induction with the ligands. Analysis of RTK activation was carried
out by western blot. Analysis of cell migration and invasion was performed with
Boyden Chamber assays. VEGF-A induced tube formation was microscopically
analyzed. For in vivo studies nude mice were orthotopically implanted with
human tumor cells (L3.6pl). Animals were treated with AMC303 i.v. at 0.1, 1, 10
mg/kg QOD or QWK for 3 weeks. Regression of metastases was investigated at
1 mg/kg QOD. HPLCwas used to detect the amount of AMC303 in the primary
tumor lysates. Results: AMC303 binds to the ectodomain of CD44v6 with high
affınity. In various pancreatic, breast, colon, lung and HNSCC tumor cell lines
activation of c-METandRONby their ligandswas inhibited byAMC303 in vitro
and consequently ligand induced cell scattering, migration and invasion was
signifıcantly reduced. In endothelial cells, activation of VEGFR-2 and VEGF-A
induced formation of a tubular network was blocked by AMC303 treatment. In
vivo treatment withAMC303 inhibited tumor growth in a dose dependentman-
ner. Themetastatic spreading of the primary tumorwas preventedwhen animals
were treated at early disease stage.Most strikingly, amarked regression of estab-
lished liver metastases was observed at progressed disease state when animals
were treated with AMC303 at 1mg/kgQOD for 3 weeks. Conclusions: AMC303
inhibits activation of the RTKs c-MET and RON allosterically in different epi-
thelial tumor cells and VEGFR-2 in endothelial cells by extracellular binding to
CD44v6. This unique and novel mode of action results in a strong anti-tumor
and anti-metastatic effect in vivo which together with its wide safety and toler-
ability window in preclinical toxicity studies is strongly supporting the clinical
investigation. AMC303 is currently tested in a Phase I study in patients with
solid epithelial tumors.
#4912 Effect of the combined treatment with mifepristone and chemo-
therapy on breast cancer brain metastases. Ayelen Rubin,1 Veronica de la
Fuente,2 Edgardo Salvatierra,3 Silvia Vanzulli,4 Osvaldo Podhajcer,3 Claudia
Lanari,1 Paola Rojas1. 1IBYME-CONICET, Buenos Aires, Argentina; 2Facultad
de Ciencias Exactas y Naturales (UBA), Buenos Aires, Argentina; 3Instituto
Leloir, Buenos Aires, Argentina; 4Academia Nacional deMedicina, Buenos Aires,
Argentina.
The treatment of brainmetastasis is limited due to the drug’s inability to cross
the blood brain barrier, because of the presence of endothelial cells’ multidrug
resistance efflux transporters, such as the P-glycoprotein (P-gp). The antipro-
gestinMifepristone (MFP) is known to inhibit the P-gp activity.We hypothesize
that a combination of MFP and Pegylated doxorubicin liposomes (doxo) im-
proves the drug effıcacy on breast tumors that do not express progesterone
receptors. Using the metastatic triple negative MDA-231-BrM2 breast cancer
cell line, transfected with GFP and luciferase, we explored different protocols to
generate tumors growing in the brain of NSG mice. Spontaneous metastases
were obtained by subcutaneous injection (sc) of 2 x 106 cells, and experimental
metastases by intracardiac injection (ic) of 1 x 106 cells or by intracranial injec-
tion of 2 x 105 cells. In the ic and sc models small and scattered brain metastases
as well as liver, lung and kidney metastases were observed. The intracranial
model enabled us to obtain measurable brain tumors in a short time. Thus we
selected this method to evaluate the effect ofMFP (6mg pellets, sc) and /or doxo
(4,5 mg/kg, iv) on tumors growing in the brain. Treatment was initiated 10 days
after cell inoculation. The amount of tumor cells after brain excision was mea-
sured by flow cytometry (GFP) and by luminometry (luciferase activity). A de-
creased luminescence signal was observed in brains frommice treated with both
agents as compared with the control mice (p0.05), whereas no effects were
observed between the single treatment groups and the controls. Moreover, the
flow cytometry analysis showed that the combined treatment, MFPdoxo, re-
duced the number of tumor cells further than the single chemotherapeutic agent
(p0.05). Our data suggest that MFP may be a promising agent to treat brain
metastasis of breast cancers, which do not necessarily express progesterone re-
ceptors, to increase the effectiveness of chemotherapeutic agents. The participa-
tion of the P-gp mediating this effect needs to be confırmed.
#4913 Invasive melanoma cells commandeer p53 activity to promote the
survival of a therapy resistant subpopulation.Marie R. Webster,1 Amanpreet
Kaur,1 Abibatou Ndoye,1 Curtis Kugel,1 Subhasree Basu,1 Alexander Valiga,1
Jessica Appleton,1 Ying-Jie Wang,2 Maureen Murphy,1 Ashani T. Weeraratna1.
1Wistar Institute, Philadelphia, PA; 2Zhejiang University, Hangzhou, China.
Metastatic melanoma is highly aggressively and often therapy resistant. Sig-
naling pathways which promote invasion ofmetastaticmelanoma, also promote
therapy resistance. Therapy resistantmelanomas are characterized byhigh levels
of the pro-invasive non-canonical Wnt molecule, Wnt5A. Previously, we de-
scribed an adaptive stress response in highly invasive melanoma cells, which is
characterized by a growth arrest and an increase in senescencemarkers, yet these
cells retain the ability to invade and form colonies. These highly invasive cells do
not undergo apoptosis following treatment with DNA damaging agents such as
doxorubicin and are resistant to BRAFV600E targeted therapy. Recently, Lukin et
al. have shown that p53 expression promotes survival of colorectal cancer cells
via p21 expression and a reversible cell cycle arrest, allowing for repair of dam-
aged DNA. Here, we show that highly invasive and therapy resistant melanoma
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cells expressWnt5A, p53 and p21, which regulate proliferation and slow cycling
in invasivemelanoma cells. The expression of p53 is promoted byWnt5A, knock
down of Wnt5A decreases p53 and p21 expression in these cells and decreases
the number of cells arrested in G2/M followingDNAdamage. The cell cycle and
apoptotic functions of p53 are highly regulated. iASPP, MDMX, and MDM2
have been shown to regulate the function of wild type p53 in melanoma cells.
MDM2, an E4 ubiquitin ligase, regulates p53 by shuttling it out of the nucleus
and targeting it for proteasomal degradation.We found that MDM2 expression
increases in invasive melanoma cells following DNA damage, however, in these
cells it is phosphorylated at serine 395. Phosphorylation of MDM2 at ser395
blocks its ability to export p53 from the nucleus, leading to increased p53 ex-
pression. Even with increased p53 expression, invasive melanoma cells undergo
a cell cycle arrest following stress instead of apoptosis. The apoptotic function of
p53 has been shown to be inhibited by nuclear iASPP, which is enriched in
metastatic melanoma. We found that knocking downWnt5A in invasive mela-
noma cells decreases the expression of iASPP. These data suggest that Wnt5A
promotes MDM2 Ser395 phosphorylation and iASPP expression, blocking
down regulation of p53 and its apoptotic function, while promoting cell cycle
arrest and survival following stress. These data may reveal a mechanism by
which highly invasive melanoma cells evade therapy to form therapy resistant
sub-colonies at distant sites.
#4914 Luteolin inhibits metastasis of triple-negative breast cancer cells to
the lungs.Matthew T. Cook,1 Yayun Liang,2 Cynthia Besch-Williford,3 Salman
Hyder2. 1Washburn University, Topeka, KS; 2University of Missouri, Columbia,
MO; 3IDEXX BioResearch, Columbia, MO.
Triple-negative breast cancers (TNBC) are basal-like tumors which lack the tra-
ditional pharmaceutical targets ER, PR and Her2neu. Most TNBC related deaths
occur followingmetastasis of cancer cells, and development of tumors at secondary
sites such as the lungs and bones. Since TNBC lacks ER, PR and Her2neu, toxic
non-specifıc chemotherapeutic agents are administered to these women, who gen-
erally present with early metastatic lesions that originate from drug-resistant resid-
ual cells, and have poor prognosis. Consequently, novel therapeutic strategies are
sought. Luteolin (LU) is a naturally occurring, non-toxic plant compound that has
proven effective against several types of cancer, though its effects against cancers of
the breast remain unknown.With this in mind we conducted studies, both in vivo
and in vitro, to determine whether LUmight suppress metastasis of TNBC. In vivo
studies were performed usingMDA-MB-231 (4175) LM2 cells, a subpopulation of
clinically relevantcells (kindlyprovidedbyDr. J.Massagué;Minnetal.Nature.2005,
436:518-24). MDA-MB-231 (4175) LM2 is a particularly aggressive TNBC breast
cancer cell line with a molecular signature preferential for lung metastasis. Herein
we report that LU effectively suppressed metastasis of MDA-MB-231 (4175) LM2
cells to lung. Compared with animals givenMDA-MB-231 (4175) LM2 cells alone,
which developed 67.6	 27.1metastatic lung colonies, treatmentwith 40mg/kg LU
reduced colony formation to 22.8 	 3.6 (P  0.035). Confırmation of the anti-
metastatic effect of LUwas achieved by inoculating animals with an alternative, less
aggressive TNBC cell line, MDA-MB-435. Administration of 20 mg/kg LU to ani-
mals treated with MDA-MB-435 cells reduced the number of lung colonies from
14.1	 1.6 to 5.3	 0.5; P 0.05. When tumor cells were incubated in vitro with
different concentrations (0-50 M) of LU, we observed a signifıcant dose-depen-
dent reduction in cell viability, induction of apoptosis (P0.001), and decreased
tumor cell migration. These data suggest that LU suppresses several steps of the
metastatic process. Furthermore, relatively low levels (10 M) of LU signifıcantly
inhibited VEGF secretion from tumor cells (P0.001), suggesting that the fla-
vonoid has the ability to suppress a potent angiogenic and cell survival factor. In
addition, when tumor cells were exposed to either LU or VEGF receptor (KDR)
antibody, a similar reduction in TNBCmigration potential was observed. This sug-
gests that the anti-tumor actions of LU may, in part, be due to its ability to reduce
VEGF levels and block KDR receptor-mediated activity, thereby inhibiting tumor
cell migration. These studies demonstrate that the use of LU, a non-toxic, plant
derived compound, deserves further investigation as a treatment option forwomen
with TNBC.Supported by a COR award from the College of Veterinary Medicine,
and in part by funds from generous donors to the Ellis Fischel Cancer Center, Uni-
versity ofMissouri.
#4915 Alcohol-induced reprogramming of tumor plasticity is mediated
via suppression of CCN5 signaling in breast cancer cells. Inamul Haque,1
Arvind Subramanian,2 Vijayalaxmi Gupta,1 Sandipto Sarkar,1 Snigdha Baner-
jee,1 Sushanta K. Banerjee1. 1University of Kansas Medical Center/Kansas City
VA Medical Center, Kansas City, MO; 2Kansas City VA Medical Center, Kansas
City, MO.
Background and Objective: The epidemiological and experimental studies sug-
gest that alcohol consumption is associated with increased risk for breast cancer
development and metastasis. However, the mechanisms of alcohol-induced breast
cancer progression andmetastasis remainunknown. In this study,we examined the
roles of CCN5, a tumor suppressor gene in alcohol induced breast cancer cell mi-
gration/invasion, epithelial tomesenchymal transition (EMT) and stemness.Meth-
ods: Estrogen receptor-positive (ER) human breast cancer cell line MCF-7 and
immortalized normal human epithelial breast cell lineMCF-12Awere treated with
ethanol at various concentrations in the presence and absence of human recombi-
nant human CCN5 protein (hrCCN5) . Invasive/migratory ability of treated and
untreated cells was measured by Boyden chamber assays. The mRNA and protein
expression level ofCCN5was determined by real-time qRT-PCRandWestern blot.
EMTandstemnessmarkerswere evaluatedbyWesternblot. Single-cell suspensions
from pre-treated cells were re-suspended at a density of 500 cells/ml mammocult
media in ultralow attachment dishes. Number as well as the size of the mammo-
sphere in specifıed experimental set-up was monitored and recorded alternate day
for 8-10days. Results: The studies demonstrated that alcohol promotes signifıcantly
the invasive/migratory ability and EMT phenotypes of breast cancer cells through
the suppression of CCN5. Interestingly, hrCCN5 protein treatment suppresses the
effect of alcohol and reprograms MET (mesenchymal to epithelial transition). In
addition, alcohol-inducedmammosphere formationeffıciency is also suppressedby
hrCCN5 protein-treatment. Conclusions: Our fındings suggest that the CCN5 sig-
nalingplaysapreventive role inalcohol-inducedreprogrammingof tumorplasticity
in breast cancer cells.
#4916 E3 ubiquitin ligase Cbl-b prevents tumor metastasis by maintain-
ing the epithelial phenotype in multiple drug-resistant gastric and breast
cancer cells. Ling Xu, XiujuanQu, Ye Zhang, Xiaofang Che, Tianshu Guo, Ying
Cai, Aodi Li, Danni Li, Ce Li, TiWen, Yibo Fan, Kezuo Hou, YanjuMa, Xuejun
Hu, Yunpeng Liu. China Medical University, Shenyang, China.
Background: Multiple drug resistance (MDR) and metastasis are two major un-
favorable factors causing failure of cancer treatment. However, the relationship be-
tween MDR and metastasis is not characterized. Additionally, the role of the E3
ubiquitin ligaseCbl-b inmetastasis ofMDRgastric andbreast cancer is little known.
Methods: The effect of Cbl-b on tumor invasion and metastasis was analyzed in
P-gp-positive gastric adenocarcinoma tissues. Transfections of Cbl-bWT and epi-
dermal growth factor receptor (EGFR)WT plasmid were used to assess Cbl-b and
EGFR involvement in epithelial-mesenchymal transition (EMT) and tumormetas-
tasis. Results: MDR gastric and breast cancer cells possess a typical mesenchymal
phenotype and an enhanced cell migration capacity. Additionally, Cbl-b is poorly
expressed in MDR gastric and breast cancer cells. We performed immunohisto-
chemical analysis on P-gp-positive gastric adenocarcinoma tissues and identifıed
associations betweenCbl-b expression and clinical pathological parameters.Gastric
cancer patients with lowCbl-b expression weremore likely to have tumor invasion
(P0.016) and lymph node metastasis (P0.007). Moreover, over-expression of
Cbl-b reduced cell migration in MDR cell cultures both in vitro and in vivo. Cbl-b
over-expressionalsopreventedEMTby inducingubiquitinationanddegradationof
EGFR, leading to inhibitionof theEGFR-ERK/Akt-miR-200c-ZEB1axis.However,
further over-expression of EGFR on a background of Cbl-b over-expression re-
stored both the mesenchymal phenotype and the cell migration capacity of MDR
gastric and breast cancer cells. Conclusions: These results suggest that Cbl-b is an
important factor for maintenance of the epithelial phenotype and inhibition of cell
migration inMDR gastric and breast cancer cells.
#4917 Therapeutic inhibition of Notch1 in metastatic prostate cancer.
MeghanA. Rice, En-ChiHsu, Tanya Stoyanova. StanfordUniversity, Palo Alto, CA.
Metastatic castration-resistant prostate cancer (CRPC) is the primary cause of
prostate cancer specifıc mortality, and is currently incurable. Defıning new
mechanisms that can predict progression and drive lethal CRPC is critical.
Notch1 receptor, a cell surface-signaling molecule dysregulated in many can-
cers, is highly expressed in CRPC. Chronic activation of Notch1 synergizes with
multiple oncogenic pathways altered in early disease to promote the develop-
ment of poorly differentiated prostate carcinoma. Consistent with its activation
in clinical CRPC, tumors driven by NICD1 in combination with alternative
pathways altered in prostate cancer are metastatic and resistant to androgen
deprivation. Genetic and pharmacological inhibition of Notch1 activity de-
creases cell proliferation and colony formation of 22RV1 prostate cancer cells in
vitro. 22RV1 subcutaneous xenograft growth was signifıcantly impaired by
treatment with pharmacological inhibitors of Notch1 activation over the course
of 20-day treatment. Further,Notch1 inhibition in combinationwith other stan-
dard prostate cancer treatments compounded effıcacy of individual treatments
to attenuate colony formation potential of prostate cancer cells in vitro. The
Notch1 signaling axis, confırmed to synergize with multiple pathways to pro-
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mote metastatic CRPC already provides a novel pathway for diagnostic stratifı-
cation of prostate cancer patients. Our studies additionally implicate Notch1 as
a therapeutically relevant target for aggressive prostate cancer.
#4918 Is Livin a protagonist of mucinous adenocarcinoma histology in
colorectal cancer.Mohammed Faruk,1 Abdulmumini Hassan Rafındadi,1 Sani
Ibrahim,1 Surajo Mohammed Aminu,1 Surajo Mohammed Aminu,1 Ahmed
Adamu,1 Ahmed Adamu,1 Yawale Iliyasu,1 Adamu Abdullahi,1 Mohammed
Sani Shehu,1 Abdullahi Mohammed,1 John Idoko,1 Abdullahi Jibril Randawa,1
Abdullahi Jibril Randawa,1 Atara Ntekim,2 Saad Aliyu Ahmed,1 Aishatu
Suleiman Maude,1 Almustapha Aliyu Liman,1 Abubakar Sani,3 Khalid Zahir
Shah,4 Yahaya Ukwenya,1 Yahaya Ukwenya,1 Cheh Augustine Awasum,1
Kasimu Umar Adoke,1 James Olowu Enemari,1 James Olowu Enemari,1 James
Olowu Enemari,1 Andrew Jonathan Nok1. 1Ahmadu Bello University, Zaria,
Nigeria; 2University of Ibadan, Ibadan, Nigeria; 3Bayero University, Kano, Nige-
ria; 4University of Wolverhampton, Wolverhampton, United Kingdom.
The mechanism of cancer resistance to chemotherapy regimen remains
uncertain. Colorectal mucinous adenocarcinoma is one of the distinct his-
tological subtypes of the disease implicated in chemotherapeutic resistance
associated with nodal and peritoneal metastases and worse disease-free sur-
vival as an index of poor prognosis. One of the important acquired capabil-
ities used by the cancer cells to resist anticancer therapies is evasion of
apoptosis possibly via inhibitor of apoptosis proteins for which Livin is one.
This protein contains baculoviral IAP repeat domains in addition to a RING
fınger, a protein-proteinmotif important for binding and inhibition of active
caspases that interfere with intrinsic and/or extrinsic pathway and the ensu-
ing blockade of apoptosis. Thus, understanding the molecular events on how
cancer cells of mucinous histology evade apoptotic death may provide a
novel paradigm for a molecular targeted therapy in the management of colo-
rectal mucinous adenocarcinoma. In this study, the expression pattern and
prognostic value of IAP family protein, Livin, in colorectal cancer patients
with mucinous histology pre and post-chemotherapy regimen was investi-
gated. Tissue sections from advanced stage colorectal cancer patients who
were treated or untreated with neo-adjuvant FOLFOX chemotherapy before
curative resection were included in this study. The tissue sections were
grouped according to colorectal adenocarcinomas showing mucinous his-
tology and non-mucinous component. Histological study including Haema-
toxylin and Eosin, and immunohistochemistry for Anti-Livin and DNAmis-
matched repair proteins were carried out. Immunofluorescence study was
performed to clarify the expression pattern of the protein using Anti-Livin
antibody. Protein expression quantifıcation study was also used. Results
show signifıcant cytoplasmic localisation and expression of Livin protein in
the colorectal cancer cells. The Livin protein expression was found to be
increased by more than a one-fold post-chemotherapy treatment when com-
pared with pre-chemotherapy treated patients with mucinous histology of
colorectal cancer. Younger patients were found to have a greater probability
of colorectal mucinous adenocarcinoma diagnosis and worse prognosis. Our
fındings show that Livin-induced inhibition of apoptosis activity can be a
target for novel approaches to treatment and prevention of chemotherapy
associated drug resistance in mucinous histology colorectal cancer since
Livin overexpression has been associated with metastases and worse disease-
free survival. More study is needed
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#4919 Ablation of neuropilin 1 from glioma-associated microglia and
macrophages slows tumor progression. Jeremy T. Miyauchi,1 Danling Chen,1
Matthew K. Choi,1 Kenneth Shroyer,1 David Selwood,2 Stella E. Tsirka1. 1Stony
Brook University, Stony Brook, NY; 2University College London, London, United
Kingdom.
Gliomas are the most commonly diagnosed primary tumors of the central
nervous system (CNS). Median times of survival are dismal regardless of the
treatment approach, underlying the need to develop more effective therapies.
Modulation of the immune system is a promising strategy as innate and adaptive
immunity play important roles in cancer progression. Glioma associatedmicro-
glia and macrophages (GAMs) can comprise over 30% of the cells in glioma
biopsies. Gliomas secrete cytokines that suppress the anti-tumorigenic proper-
ties of GAMs, causing them to secrete factors that support the tumor’s spread
and growth. Neuropilin 1 (Nrp1) is a transmembrane receptor that inmice both
amplifıes pro-angiogenic signaling in the tumor microenvironment and affects
behavior of innate immune cells. Using aCre-lox system,we generatedmice that
lack expression of Nrp1 in GAMs.We demonstrate, using an in vivo orthotopic
glioma model, that tumors in mice with Nrp1-defıcient GAMs exhibit less vas-
cularity, grow at a slower pace, and are populated by increased numbers of
anti-tumorigenic GAMs. Moreover, glioma survival times in mice with Nrp1-
defıcient GAMs were signifıcantly longer. Treating wild-type mice with a small
molecule inhibitor of Nrp1’s b1 domain, EG00229, which we show here is selec-
tive for Nrp1 over Nrp2, yielded an identical outcome. Moreover, transplanting
bonemarrow frommicewithNrp1-defıcientmacrophages towild type recipient
mice led to reductions in tumor growth, al-be-it not to the extent seen in knock-
out mice. Nrp1-defıcient or EG00229-treated wild-type microglia exhibited a
shift towards anti-tumorigenicity as evident by altered inflammatory marker
profıles in vivo and decreased SMAD2/3 activation when conditioned in the
presence of glioma-derived factors. These results provide support for the pro-
posal that pharmacological inhibition ofNrp1 constitutes a potential strategy for
suppressing glioma progression.
#4920 Inflammation and estrogen receptor betamodulate bacterial diver-
sity of the gut. Ahmed F. Ibrahim,1 Quentin Thomas,2 Ashish Saxena,3 Cecilia
Williams1. 1The Royal Institute of Technology, KTH, Solna, Sweden; 2KTH,
Solna, Sweden; 3University of Houston, Houston, TX.
Background: Chronic inflammation is a risk factor of colorectal cancer
(CRC), and the microbiota of the gut is important in both colitis and carcino-
genesis. Estrogen receptor beta (ER) is the predominant nuclear receptor in the
colon, and is downregulated inCRC.Here, we explore the role of colitis and ER
signaling with respect to the microbiota diversity. Methods: Intestinal ER-/-
mice were generated using the Cre-loxP system. WT and knockout mice were
treated with AOM/DSS inducing colitis (at 9 weeks) and CRC (at 16 weeks).
After 9 and 16 weeks, stool pellets were collected from treated and untreated
mice (n39), and DNA was extracted. Library preparation and 16S rRNA-
sequencing was performed using the illumina Miseq platform with specifıc
primers targeting the V3-V4 regions, and QIIME software was used to analyze
microbiota diversity. Sequencing results were validated by qPCR Results: High-
throughput 16S rRNA gene sequencing demonstrated that treatment induced
signifıcant differentiation of both alpha (p0.01) and beta (p0.01) microbiota
diversity. Alpha diversity indicators implied a signifıcant reduction of microbi-
ota richness and evenness after treatment. qPCR confırmed that 9-weeks treat-
ment increased OTUs affıliated with Bifıdobacteria (p0.03), Bacteroidetes
(p0.04), Lactobacilli (p0.0014), Cyanobacteria (p0.0023) andGammapro-
teobacteria (p0.05) inWTmice. After 16weeks treatment, 16s rRNA sequenc-
ing show enrichment of Tenercutes, Proteobacteria and Cyanobacteria in all
tumor-bearingmice (treatedWT and ER-/-), while Verrucomicrobia increased
in untreated mice (No tumors). Further treated ER-/- but not WT mice dis-
played signifıcant reduction of Gammaproteobaceria (p0.0083). Conclusion:
Our data demonstrate a clear effect of colitis-induced treatment on the micro-
biota, and that ER attenuates this response. Lactobacilli and Bifıdobacteria has,
for example, been shown to attenuate inflammatory response. We note an in-
crease in Lactobacilli and Bifıdobacteia after treatment in WT mice, but not in
ER
-/-
mice. This can result in increased colitis in ER-/- mice and help explain
the increased expression of pro-inflammatory cytokines we note in treated
ER-/- mice.
#4921 The adhesion protein JAM-A is important for maintenance of tu-
mor dormancy in breast cancer cells, and JAM-A high-dormant cells have
stem cell characteristics. Sri Harikrishna Vellanki, Rodrigo G. Cruz, Ann M.
Hopkins. RCSI, Dublin, Ireland.
Breast cancer cells which metastasize to bone marrow can remain dormant
and survive multiple rounds of adjuvant chemotherapy. The re-awakening of
dormant populations, particularly in estrogen receptor (ER)-positive patients,
has been associated with tumor cell proliferation and poor patient outcomes.
Tumor dormancy can bemodelled in vitro by exposing cancer cells on fıbronec-
tin-coated plates to bFGF-2, a mammary differentiation factor abundant in the
bonemarrow stroma, which causes partial re-differentiation, cell spreading and
re-expression of integrin-51. Ligation of integrin-51 by fıbronectin and
activation of the PI3K pathway both contribute to dormant cell survival. Our
study has uncovered a novel potential role for the adhesion protein Junctional
AdhesionMolecule-A (JAM-A) in tumor dormancy. JAM-Aoverexpressionhas
previously been linked to increased risk of metastasis in breast cancer patients,
and its expression regulates the angiogenic functions of bFGF-2. Furthermore,
since loss of JAM-A causes down-regulation of the 51 downstream effector
FAK, we hypothesized that JAM-A is required for maintenance of breast cancer
cell dormancy. To investigate this, JAM-Awas transiently silenced using siRNA
inMCF-7 breast cancer cells grown on fıbronectin-coated plates and exposed to
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FGF-2. JAM-silenced cells exhibited downregulations in the protein expression
of integrin-51 and FAK in this model, and failed to exhibit the cortical actin
redistribution and morphological spreading which characterize dormant cells.
We next investigated a potential relationship between JAM-A expression and
pro-inflammatory cytokines which have been linked with the re-awakening of
dormant cells in post-menopausal women. Exposure of MCF-7 cells to the pro-
inflammatory cytokines IL-1, TNF-, IL-6 and IL-8 decreased JAM-A expres-
sion in in a concentration-dependent fashion, suggesting that the loss of JAM-A
could be associated with re-awakening from tumor dormancy.We are currently
probing alterations in JAM-A expression and that of integrin-51 in matched
human primary breast tumor specimens and bone marrow metastases. Since
JAM-high dormant cells express high mRNA levels of the stemness factors
(Sox2, Oct3/4, Nanog) and have high Aldefluor activity, our data also suggest
that JAM-A may be required for a stem-like phenotype. To conclude, our data
support amodel whereby JAM-A is important for themaintenance of dormancy
in breast cancer cells in a simulated bone marrow microenvironment, and rep-
resents a novel therapeutic target worthy of investigation in breast cancer.
#4922 Microscale engineering of the tumor microenvironment for thera-
peutic targeting of tumor-associated macrophages in prostate cancer.David
Kosoff, Jiaquan Yu, Jennifer L. Schehr, David J. Beebe, Joshua M. Lang.Univer-
sity of Wisconsin, Madison, WI.
Background: The tumor microenvironment (TME) plays integral roles in
prostate cancer progression and therapeutic resistance. The development of
effective TME-targeted therapies is limited by current technologies which are
insuffıcient to replicate or analyze this complex environment. To address these
challenges, we have developed a microfluidic cell culture platform known as
STACKS,which permits co-culture of up to 6 patient-derived cell populations as
well as compartmentalized, multiplexed analysis of gene expression, cell signal-
ing, andmatrix remodeling. We have focused on investigation of tumor-associ-
ated macrophages (TAMs), which are traditionally classifıed as M2 (tumor-
supportive) or M1 (tumor-destructive) and are high value therapeutic targets
with roles in prostate cancer growth, metastasis, survival, and therapeutic resis-
tance. Methods: Cell line (THP-1) and patient-derived monocytes were differ-
entiated into macrophages within the STACKs device and polarized to either a
M1 or M2 state or left unpolarized. Unpolarized macrophages were cultured
with androgen dependent (LNCaP) and independent (DU145,C4-2B) prostate
tumor lines and cancer-associated fıbroblasts (CAFs) derived from patient bi-
opsies. Cells were cultured on 2D surfaces as well as within 3D matrix environ-
ments. Individual cell populations were isolated and analyzed for RNA, protein,
and secretory factor expression. Results: We report that M2 (CCL18, MRC1) as
well as M1 (CXCL10, CXCL11) associated genes were more highly upregulated
in THP-1s cultured with C4-2Bs than with LNCaPs. Select M1 and M2 genes
(CXCL10 andCCL18) were alsomore highly expressed in THP-1s culturedwith
CAFs than with DU145s. While IL-10 expression was higher in THP-1s in co-
culture with LNCaPs than with C4-2Bs on a 2D surface, the opposite was true
when THP-1s were cultured within a 3D collagen Imatrix. Conclusions:Within
a microscale co-culture environment, we have demonstrated that macrophage
gene expression is influenced by androgen dependent and independent tumor
cells, stromal cells, and the structural microenvironment. Expression of certain
genes, such as IL-10, was strongly dependent on the integration ofmultiple TME
signals, such as paracrine tumor factors and cell-matrix interactions. Addition-
ally, whilemacrophages are traditionally thought to polarize either towards aM1
or a M2 state, there was concomitant elevation of both M1 and M2 genes with
C4-2B and CAF co-culture. These fındings highlight the complexity of macro-
phage polarization within the TME and represent potential therapeutic targets.
We will continue to build on this data through 2D and 3D multi-culture of
macrophages with tumor, stromal, and immune cells to target pathways in-
volved in TAM polarization, tumor promotion, and therapeutic resistance.
#4923 MyD88 and IL-17 have essential local and systemic functions in
promoting tumors on mouse skin. Mary Klosterman, Christophe Cataisson,
Rosalba Salcedo, Kelly Shibuya, Jennifer Waters, Giorgio Trinchieri, Stuart H.
Yuspa. National Cancer Institute, Bethesda, MD.
NF-kB has been causally implicated with cancer-associated inflammation. In
the skin, ligands of the Toll-like receptor/IL-1 receptor superfamily induce the
recruitment of MyD88 (Myeloid differentiation primary response gene 88), ul-
timately leading to NF-kB activation. We previously reported that MyD88 is
required for two stage chemical carcinogenesis on mouse skin, and that MyD88
exerts a cell-intrinsic function inRAS-mediated transformation of keratinocytes
(Ras-keratinocytes). Now, we explore the role of MyD88 during tumor promo-
tion with 12-O-tetradecanoyl-phorbol-13-acetate (TPA). Epidermal hyperpla-
sia is reduced in MyD88 defıcient mice relative to controls after multiple appli-
cations of TPA. Furthermore, the upregulation of the chemokines Cxcl1 and
S100a8 in response to TPA was defıcient in MyD88 null cultured keratinocytes
revealing a necessary role forMyD88 in the intrinsic response of keratinocytes to
phorbol ester. We also uncovered a systemic requirement for MyD88 in carci-
nogenesis since lineage specifıc ablation of MyD88 in T cells conferred signifı-
cant resistance to skin tumorigenesis and reduced infıltration of IL-17 positive T
cells in TPA treatedMyD88 nullmouse skin. IL-17 treatment of normal primary
keratinocytes increased their proliferation while reducing their response to cal-
cium-induced differentiation but had no effect on the proliferation of RAS-
keratinocytes. The atypical nuclear IkBzeta protein can act as an activator of
so-called secondary NF-kB response genes. IkBzeta defıciency blocked the ker-
atinocyte proliferative response to IL-17 but had no effect on altered differenti-
ation. Finally, both IL-17 and oncogenic RAS required IkBzeta to upregulate the
expression of S100a8, lipocalin2 and Steap4 mRNAs. Collectively, these results
demonstrate that MyD88 plays a pro-tumorigenic function during tumor pro-
motion in both epithelial andT-cell compartments and that IL-17/IkBzeta could
play a facilitating role on keratinocytes during tumor promotion beyond its
pro-inflammatory activity.
#4924 Adh1blow/Cyp26b1high activity ofCD90 (myo)fıbroblasts supports
tumor-promoting inflammation in colorectal cancer. Romain Villeger,1 Ga-
briella Uribe,1 Judy A. Trieu,1 Paul Johnson,1 Suimmin Qiu,1 Don W. Powell,1
Ellen J. Beswick,2 Iryna V. Pinchuk1. 1University of Texas Medical Branch,
Galveston, TX; 2University of New Mexico, Albuquerque, NM.
Introduction. Retinol (RO) and its active metabolite, all-trans retinoic acid
(atRA), have been widely studied as cancer chemotherapeutic agents. atRA is a
critical immunoregulatory molecule reported to decrease cancer cell prolifera-
tion and inhibit tumor-promoting inflammation. However, recent studies re-
port a loss of effıcacy of atRA treatment to counteract colorectal cancer (CRC)
progress, and the mechanisms underlying this failure are not fully understood.
Alcohol dehydrogenase 1B (ADH1B), a major isoform of alcohol dehydroge-
nase expressed in normal colon, is responsible for the conversion of RO to atRA.
We recently reported that stromal (myo)fıbroblasts are major ADH1B express-
ers in normal colonicmucosa and that this expression is lost during the neoplas-
tic transformation process ofCRC.Thus, we hypothesized that aberrant retinoid
signaling in cancer-associated fıbroblasts (CAFs) is among key processes sup-
porting tumor-promoting inflammation inCRC.Methods. Real-timePCR, con-
focal microscopy and cytokine luminex arrays were used to evaluate alterations
in retinoid pathway gene expression and activity to defıne its relevance to the
tumor-associated inflammation in human normal and CRC colonic tissues, and
in normal primary (myo)fıbroblasts (N-CMFs) andCAFs. Results.We observed
a strong downregulation of ADH1B expression in CAFs in situ and in culture
along with an increased expression of the tumor growth promoting inflamma-
tory cytokine IL-6. Addition of the ADH1B substrate, RO, or its metabolite,
atRA, to N-CMF cultures decreased the LPS-inducible IL-6 expression by N-
CMFs. No downregulation of LPS-inducible IL-6 expression by RO was ob-
served in CAFs, while atRA treatment partially inhibits IL-6 expression. Silenc-
ing of adh1b gene in N-CMFs led to the increased production of the LPS-
inducible IL-6. This suggests that lack of ADH1B expression in CAFs prevents
conversion of RO into atRA, resulting in the disruption of the negative regula-
tion of IL-6. A decrease in downstream enzyme ALDH1A expression, which
converts ADH1B’s byproduct retinaldehyde, to atRA, was also observed in
CAFs. Finally, only a partial inhibition of IL-6 production by exogenous atRA
was observed in CAFs. When compared to N-CMFs, CAFs expressed higher
levels of CYP26B1, a cytochrome that is responsible for atRA degradation.
Treatment of CAFs with atRA resulted in an eight fold higher upregulation of
CYP26B1 expression than in N-CMFs. Conclusions. Taken together, our data
suggests that CYP26B1 overexpression in CAFs along with ADH1B downregu-
lation support aberrant retinoic acid metabolism in CRC. Adh1blow/
Cyp26b1high activity of CAFs leads to a decrease of atRA availability in the tumor
microenvironment, supporting IL-6-driven tumor growth promoting inflam-
mation and resistance to exogenous atRA as a chemotherapeutic agent in CRC.
#4925 Microbiome-TP53 gene interaction in human lung cancer. Leigh
Greathouse,1 James White,2 Valery Bliskovsky,3 Ashley Vargas,3 Eric Polley,4
Elise Bowman,3MohammedKhan,3AnaRobles,3 BridRyan,3AmiranDzutsev,3
Giorgio Trinchieri,3 Marbin Pineda,3 Sven Bilke,3 Paul Meltzer,3 Marina
Walther-Antonio,4 Garth Ehrlich,5 Joshua Mell,5 Joshua Earl,5 Sergey
Balashov,5 Archana Bhat,5 Alex Valm,6 Clayton Deming,6 Sean Conlan,6 Julia
Oh,7 Julie Segre,6 Curtis Harris3. 1Baylor Univ., Waco, TX; 2Resphera Biosci-
ences, Inc., MD; 3National Cancer Institute, Bethesda, MD; 4Mayo Clinic, Roch-
ester, MN; 5Drexel University, Philadelphia, PA; 6National Human Genome Re-
search Institute, Bethesda, MD; 7Jackson Laboratory, Framingham, CT.
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Lung cancer is the leading cancer diagnosis worldwide and the number one
cause of cancer deaths. Exposure to cigarette smoke, the primary risk factor in
lung cancer, reduces epithelial barrier function and increases susceptibility to
infections. Herein, we hypothesized that somatic mutations together with ciga-
rette smoke create a dysbiotic microbiota that is associated with lung carcino-
genesis. Using lung tissue from controls (n33) or cancer cases (n143), we
conducted 16S rRNA gene sequencing (MiSeq), with RNA-seq data from lung
cancer cases in The Cancer Genome Atlas (n1112) serving as the validation
cohort. We demonstrate a lower alpha diversity in normal lung as compared to
non-tumor adjacent or tumor tissue, indicating a shift in the overall microbial
community in lung cancer patients as compared to those without cancer. Lung
cancer cases were classifıed by the relative abundance of two taxa, Variovorax
and Streptococcus, with an increase inVariovorax abundance in tumors as com-
pared to non-tumor adjacent paired lung tissue (FDR corrected P0.013). The
species of Variovorax was identifıed histologically, and also by two additional
16S rRNA strategies (Resphera Insight analysis and PacBio sequencing). A
group of taxa were associated with squamous cell carcinoma (SCC), of which
Acidovorax were enriched in smokers (P0.0013). Further, these taxa, includ-
ing Acidovorax, exhibited higher abundance among the subset of SCC cases
with TP53mutations, an association not seen in adenocarcinomas (AD). There-
fore, we observed a microbiome-gene and a microbiome-exposure interaction
in SCC lung cancer tissue. Together, these results open the door for future
biomarker research that could be used to improve screening and direct mecha-
nistic studies of lung cancer therapy.
#4926 Gut microbiota regulates cisplatin mediated cachexia and systemic
toxicity. Soumen Roy,1 Rodrigo Das Neves,1 Amiran Dzutsev,1 Carolyne Smith,1
Bathai Edwards,1 Miranda Dawson,1 Simone Difılippantonio,2 Loretta Smith,2
April Huang,1 Young Kim,3 Giorgio Trinchieri1. 1NCI, CIP, Bethesda, MD; 2LASP,
NCI, Bethesda, MD; 3Division of Cancer Prevention, NCI, Bethesda, MD.
Chemotherapy induced toxicity severely affect the cancer survivors and low-
ers the quality of life. By 2020, there will be more than 18 million of cancer
survivors all over the world. Majority of themmight develop long term nephro-
toxicity, ototoxicity and gut toxicity. In addition, chemotherapy may also facil-
itate the initiation and progression of cachexia. Recent studies have shown that
gut microbiota modulates the effıcacy of anti-cancer chemotherapy, however
very limited knowledge is available regarding the role of gut microbiota in reg-
ulating systemic toxicity and cachexia. We hypothesized that gut microbiota
modulates cisplatin induced systemic toxicity as well as cachexia. Four groups
(n10 in each group) of 6-8 weeks old C57B/6 mice were treated with cisplatin,
cisplatinantibiotics cocktails (ABX), ABXonly and control. ABX cocktail con-
tained primaxin, vancomycin and neomycin. This experiment was validated
using C57B/6 germ free mice. We performed anti-p--H2AX based toxicity
assay for DNA damage. In addition, we performed immunohistochemistry for
studying cachexia. H&E staining and DNA damage were assessed by light and
super resolution confocal microscopy (Zeiss 880) and quantifıed by 3-D recon-
struction using IMARIS. We also performed high content imaging to evaluate
DNA damage in bone marrow and spleen. Body weight and kidney blood con-
tent were also analyzed to determine the degree of toxicity. Depletion of gut
microbiota signifıcantly reducednephrotoxicity and gut toxicity. In addition,we
found that depletion of gut microbiota prevents muscle and adipose tissue loss
by down-regulating UCP-1and PGC-1 in adipose tissue and MURF-1 and
Atrogin-1 in muscle. Experiments are confırmed by using Germ free mice. Our
data suggest that modulation of gut microbiota may be utilized to reduce che-
motherapy associated cachexia and systemic toxicity.
#4927 Presence of genotoxic and/or pro-inflammatory bacterial genes in
stool is associated with colorectal neoplasia.María González-Pons,1 Michelle
Cruz-Badia,2 Ramon Gomez-Moreno,2 Abel Baerga-Ortiz,2 Marcia Cruz-Cor-
rea1. 1University of Puerto Rico Comprehensive Cancer Center, San Juan, PR;
2University of Puerto Rico Medical Sciences Campus, San Juan, PR.
Despite increasing adherence to routine screening and advances in therapeutic
strategies,CRC is the 1st and3rd leading causeof cancer-relateddeath inPuertoRico
and the United States (US), respectively. Currently, CRC screening is the primary
means for prevention; however, 60% of CRC patients are diagnosed at more ad-
vanced, less treatable stages, which emphasize the need for novel CRC prevention
and risk stratifıcation strategies. The etiology of CRC is complex and still incom-
pletely understood. However, environmental factors including diet, the gut micro-
biota, and inflammation are accepted as major contributors to colorectal carcino-
genesis. It has been shown that individualswithCRChave a distinct gutmicrobiota,
but the mechanisms by which gut bacteria exert their CRC-promoting effects re-
mains elusive. Certain pathogenic bacterial strains carry genes encoding toxins that
promote DNA damage and perpetuate inflammation, yet the association of these
toxins toCRC remains poorly understood. The aimof this studywas to gain insight
into the association and possiblemechanisms bywhich a subset of the gutmicrobi-
ota contribute to colorectal carcinogenesis byprofıling sixgenes encodinggenotoxic
and/or pro-inflammatory bacterial toxins in stool from individuals with and with-
out colorectal neoplasia (adenoma and CRC). The association between the genes
encoding toxinsandCRCwasexaminedbycharacterizing the toxiccolonicbacterial
gene profıle in stool samples from healthy individuals (controls) and individuals
with colorectal neoplasia (cases). Stool samples fromindividuals in themainlandUS
(n 20) and Caribbean Hispanics (n33) living in Puerto Rico were provided by
theNCIEarlyDetectionResearchNetwork and the PuertoRico Familial Colorectal
Cancer Registry, respectively. Detection pks, TcPC, GelE, cnf-1, murB, and usp in
stool was performed by qPCR using gene-specifıc primers. Associations were as-
sessedusingodds ratios. Fourof the six toxic genesweredetectedmore frequently in
stool samples from individuals from theUSwith colorectal neoplasia (controls10;
adenoma10). Results showborderline statistical signifıcant associations (p0.07)
with the presence of usp and 2 genes and a higher odds of colorectal neoplasia
(OR5.44 andOR9.33, respectively). In the cohort fromourCaribbeanHispanic
subjects (controls13;adenomas12;CRC8), individualswith thepresenceGelE
weres 8.6-timesore likely tohave adenomas (p.07) and individualswith2of the
geneswere 11.3-timesmore likely tohaveCRCthan individualswithout these genes
(p0.04).Analysiswith a larger number of sampleswill be necessary to determine a
more defınite association between the presence of the toxic genes in this panel in
stool and colorectal neoplasia. Additional mechanistic analysis will be required to
fully understand how these bacterial toxins contribute to colorectal carcinogenesis.
#4928 Impact ofE. hiraeon the tumoricidal activity of cyclophosphamide.
Romain Daillere, Marie Vetizou, Laurence Zitvogel. Gustave Roussy, Villejuif,
France.
The tumor microenvironment is influenced by anticancer therapies, and even
more so by those affecting the gut homeostasis.We previously reported that a devi-
ated repertoire of the intestinal microbiome called « dysbiosis », caused by broad
spectrum antibiotics compromised the effıcacy of cyclophosphamide (CTX), an
immunomodulatory alkylating agent exerting cytotoxic effects against cancer, high-
lighting the importance of the gut microbiota in this mechanism (Viaud, Science,
2013). CTX is responsible for disrupting the gut barrier integrity aswell as intestinal
homeostasis, allowing a NOD2-dependent translocation of several Gram-positive
bacteria into secondary lymphoid organs. CTX breaks the intestinal tolerance to-
wards the intestinalmicrobiota and leads to immunization of the host against some
bacterial strains. Here, we identifıed a Gram positive bacteria, Enterococcus hirae,
whichmarkedlymodulates the intestinal and systemic immunity through the elici-
tation of bacterial-specifıc Th1 and pathogenic Th17 cells. Moreover, we have
shown that E. hirae is capable of enhancing tumor-specifıc CD4 and CD8 T cell
responses against candidate tumor antigens. In parallel, we have demonstrated that
intestinal epithelial cells NOD2 receptors represent ’’gut immune checkpoints’’ re-
stricting the immunogenicity of E. hirae. Finally, E. hirae specifıc-memory Th1 im-
mune responses selectively predicted longer progression-free survival in advanced
lung or ovarian cancer patients treated with immunotherapy and chemotherapy
(platinum salts- or CTX-based chemotherapy) (Daillère, Immunity, 2016). Alto-
gether, E. hirae represents a valuable probiotic against cancer, an oncomicrobiotic
ameliorating the effıcacy of themost commonalkylating immunomodulatory com-
pound.
#4929 Cooperation between the microbiota and oncogenic mutations
leading to the development of colon cancer. Dana Van De Hey, Susan Payne,
Cheri Pasch, Linda Clipson, KristinaMatkowskyj, DustinDeming.University of
Wisconsin Carbone Cancer Center, Madison, WI.
Background: The microbiome of the colon has been shown to play a role in
colon cancer tumorigenesis. Inflammation is a key step in the formation of
tumors, and it is possible that microbiota induce this inflammation, further
stimulating tumor growth. The interaction between mutant cells in the colon
and themicrobiota has been understudied.We hypothesized that eradication of
the intestinal microbiota could prevent tumorigenesis in the colon despite the
presence of oncogeneic mutations. Methods: We have previously generated a
transgenic murine model in which a constitutively active PI3K is expressed in
the distal small intestine and colon (FC3K). These mice develop aggressive can-
cers in the proximal colon via a non-canonical mechanismwithout loss of APC.
In addition, we developed a murine model possessing both PIK3CA mutations
and loss of APC (FCAK3K). These mice were treated with vancomycin in their
drinking water. Necropsy was performed at specifıc time-points or at moribund
to determine tumor counts and size. Spheroid cultures were also utilized to
determine the potential for cytotoxic effects of vancomycin treatment. Results:
Treatment with vancomycin in FC3Kmice at weaning resulted in a reduction in
tumor incidence and growth and prolonged survival, indicated by a 42% tumor
TUMOR BIOLOGY: Tumor Microenvironment 7
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1261
frequency and median lifespan of 101 days, compared to 100% frequency and
86.5-day lifespan of control mice (p0.001). In the tumors that formed there
was no difference in the epithelial mesenchymal transition (EMT), Ki67 index,
nuclear localization of CTNNB1, or activation of the PI3K/AKT/mTOR signal-
ing pathway. FCAK3K spheroid andmouse models portrayed ineffectiveness of
vancomycin through an absent change in spheroid diameter and also 100%
frequency of both treated and control mice. Conclusion: The above results in-
dicate that colon cancers induced by PIK3CA mutations are at least partially
dependent on the microbiota for tumorigenesis. This dependence appears to be
overcome in the setting of both APC and PIK3CA mutations.
#4930 Genetic and epigenetic characteristics of esophageal cancer tissues
withmicrobiome fusobacteriumnucleatum.Yoshifumi Baba, KensukeYama-
mura, Shigeki Nakagawa, Kosuke Mima, Takatsugu Ishimoto, Masaaki Iwat-
suki, Yasuo Sakamoto, Naoya Yoshida, Hideo Baba. Kumamoto Univ., Ku-
mamoto, Japan.
Background: Research into the microbiome is a rapidly advancing fıeld in
human cancers. The gutmicrobiome has recently been shown to play an impor-
tant role in health, as well as in diseases such as obesity, inflammatory bowel
disease, diabetes, non-alcoholic fatty liver disease, and several types of cancers.
Fusobacterium nucleatum is a component of the human microbiome that pri-
marily inhabits the oral cavity. It causes periodontal disease and has also been
implicated in the development of human cancers. We have recently reported
that Fusobacterium nucleatum in esophageal cancer tissues was associated with
shorter survival, suggesting a potential role as a prognostic biomarker. In addi-
tion, our KEGG enrichment analysis using microarray data showed that Fuso-
bacterium nucleatum might also contribute to aggressive tumor behavior
through activation of chemokines such as CCL20. Nonetheless, molecular fea-
tures of Fusobacterium nucleatum-positive esophageal cancers have been still
unknown. Methods: Using 325 esophageal cancers, we detected Fusobacterium
nucleatum DNA in 74 tumors (23%). We assessed other genetic and epigenetic
events including mutations in KRAS, BRAF, PIK3CA gene, p53 expression,
phosphorylated-AKT expression, LINE-1methylation level (global DNAmeth-
ylation level), IGF2DMR0methylation,MGMTmethylation, andMLH1meth-
ylation. Results: The LINE-1 methylation levels of Fusobacterium nucleatum-
positive tumors was signifıcantly lower compared with that of Fusobacterium
nucleatum-negative tumors (P0.0001). In addition, Fusobacterium nuclea-
tum was signifıcantly associated with PIK3CA wild type (P0.010). There was
no relationship of Fusobacterium nucleatum with KRAS, BRAF mutation, p53
expression, p-AKT expression, IGF2 DMR0 methylation, MGMTmethylation,
or MLH1 methylation. Conclusion: Fusobacterium nucleatum was related with
LINE-1 hypomethylation and PIK3CA wild type. Our fındings may shed lights
on understanding the mechanism by which Fusobacterium nucleatum affects
aggressive tumor behavior. .
#4931 Prospective study of oral microbiome and colorectal cancer risk in
low-income and African American populations. Yaohua Yang, Qiuyin Cai,
Xiao Ou Shu, William J Blot, Wei Zheng, Jirong Long. Vanderbilt University
School of Medicine, USA, TN.
Colorectal cancer (CRC) is the third most common cancer in both men and
women worldwide, and the third leading cause of cancer death in the USA.
Recent research suggests that oral microbiome may play important roles in the
pathogenesis of colorectal cancer and other chronic diseases. We conducted a
nested case-control study within the Southern Community Cohort Study to
investigate the association of oral microbiome with subsequent risk of develop-
ing CRC. This study included 231 incident CRC cases and 462 controls individ-
ually matched on age, race, smoking, alcohol drinking, season-of-study enroll-
ment and recruitment method, with74% subjects of African descent. The V4
region of 16S rRNA gene of the pre-diagnostic mouth rinse samples was deeply
sequenced. Sequencing data were processed using QIIME and sequence reads
were clustered into Operational Taxonomic Units (OTUs). In total, 11 phyla, 73
families and 134 genera were observed from study samples, and only 5 phyla, 12
families and 11 genera showed relative abundance1%. Multiple bacteria taxa
showed signifıcant associations with CRC risk at P 0.05. Notably, within the
phylum Firmicutes, four genera were associated with increased risk of CRC,
including Peptococcus, Ruminococcaceae_ [G-1], Clostridiales_[F-1][G-1],
and Mollicutes_[G-2], with ORs (95% CIs) being 1.34(1.11-1.63), 1.20(1.01-
1.44), 1.44(1.07-1.92), and 2.24(1.38-3.63), respectively. Multiple taxa within
other phyla were also associated with increased risk of CRC, such as the family
Bifıdobacteriaceae within phylum Actinobacteria with OR (95% CI) being
1.31(1.08-1.61), and genus Lautropia within phylum Proteobacteria with OR
(95% CI) being 1.23(1.02-1.48), and phylum SR1 with OR (95% CI) being
1.27(1.07-1.52). We also found that the phylum Firmicutes and the species sp.
Oral taxon 070, which belongs to the genus Streptococcus, were associated with
decreased risk of CRC, withORs (95%CIs) being 0.79(0.65-0.96) and 0.77(0.63-
0.93), respectively. Most of these associations were observed among both Afri-
can- and European- Americans. None of the associations remained signifıcant
after Bonferroni correction formultiple testing, whichmay be conservative. The
tests were not independent because the higher-level taxa is an aggregate of low-
er-level taxa. In addition, most taxa showed low relative abundance and preva-
lence and we have low statistical power to investigate them. Conclusion: Our
study suggested that multiple bacteria taxa may be associated with risk of CRC,
and raised the possibility that the oralmicrobiomemay play an important role in
CRC etiology.
#4932 Oxygen sensing byT cells establishes an immunologically favorable
metastatic niche. David Clever,1 Nicholas Restifo2. 1The Ohio State University
College of Medicine, Columbus, OH; 2National Institutes of Health, Washington,
DC.
Cancer cells must evade immune responses at distant sites to establish metas-
tases. The lung is a frequent site for metastasis. We hypothesized that lung-
specifıc immunoregulatory mechanisms create an immunologically permissive
environment for tumor colonization. We found that T-cell-intrinsic expression
of the oxygen-sensing prolyl-hydroxylase (PHD) proteins is required to main-
tain local tolerance against innocuous antigens in the lung but powerfully li-
censes colonization by circulating tumor cells. PHD proteins limit pulmonary
type helper (Th)-1 responses, promote CD4()-regulatory T (Treg) cell induc-
tion, and restrain CD8() T cell effector function. Tumor colonization is ac-
companied by PHD-protein-dependent induction of pulmonary Treg cells and
suppression of IFN--dependent tumor clearance. T-cell-intrinsic deletion or
pharmacological inhibition of PHD proteins limits tumor colonization of the
lung and improves the effıcacy of adoptive cell transfer immunotherapy. Collec-
tively, PHD proteins function in T cells to coordinate distinct immunoregula-
tory programs within the lung that are permissive to cancer metastasis.
#4933 Desminpericyte subpopulations correlated with blood-tumor
barrier permeability in brain metastases of breast cancer. Brunilde Gril,1 L.
Tiffany Lyle,2 Paul R. Lockman,3 Chris E. Adkins,3 Afroz Shareef Mohammad,3
Emily Sechrest,3 Emily Hua,1 Diane Palmieri,4 David J. Liewehr,1 SethM. Stein-
berg,1WojciechKloc,5 Ewa Izycka-Swieszewska,6 RenataDuchnowska,7Nayyar
Naema,8 Priscilla K. Brastianos,8 Patricia S. Steeg1. 1NCI-CCR, Bethesda, MD; 2
Purdue University College of Veterinary Medicine, West Lafayette, IN; 3West
Virginia University Health Sciences Center, Morgantown, WV; 4NCI, Bethesda,
MD; 5University of Varmia & Masuria University, Olsztyn, Poland; 6Medical
University of Gdan´sk, Gdan´sk, Poland; 7Institute of Medicine, Warsaw,Warsaw,
Poland; 8Massachusetts General Hospital Cancer CenterHarvardMedical School,
Boston, MA.
Breast cancer brain metastases remain incurable. The blood-brain barrier
(BBB) is a multicellular dynamic structure regulating exchanges between the
blood and the central nervous system.As cancer cells colonize the brain, the BBB
evolves into a blood-tumor barrier (BTB). The BTB limits compound penetra-
tion and therefore contributes to poor effıcacy of chemotherapy.While the BBB
has been well characterized in developmental and neurodegenerative disease
studies, the BTB composition remains unknown. We have characterized the
BTB in threemodel systems of brainmetastasis of breast cancer developed in the
laboratory: a triple negative (231-BR6), and two HER2 overexpressing
(SUM190-BR3, JIMT-1-BR3) subtypes. Using Texas Red dextran (TRD) as a
marker of permeability and quantitative immunofluorescence staining, we ana-
lyzed the cellular and molecular composition of: 1) unaltered BBB vs. BTB, and
2) BTB in highly permeable metastases vs. BTB in poorly permeable metastases.
The BTB developed from the BBB in a series of alterations, including a neuro-
inflammatory reaction with astrogliosis, endothelial cell dilation, increased
VEGF, reduced astrocyte endfoot polarity, and decrease in PDGFR pericytes.
Only 10% of the metastatic lesions harbored a profound TRD exudation, which
correlated with paclitaxel effıcacy. We hypothesized that specifıc cellular and
molecular changes account for the heterogeneity and increase in TRD diffusion.
When metastases with relatively low- and high-TRD diffusion were compared,
highly permeable metastases correlated with an increased expression of
desmin pericytes in three models (231-BR6 p0.0002; JIMT-1-BR3 p0.004;
SUM190-BR3 p0.008) and a decrease in CD13 pericytes in two model sys-
tems (231-BR6 p0.014; JIMT-1-BR3 p0.002). Decreased expression of
laminin 2 in the parenchymal basement membrane (231-BR6 p0.001; JIMT-
1-BR3 p0.049; SUM190-BR3 p0.023) were associated with higher permea-
bility. Desmin pericytes have been associated with pathological conditions
such as fıbrosis and spinal cord injury. Seven over nine human craniotomy
specimens were positive for Desmin staining, validating clinically the relevance
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of our fındings. We subsequently hypothesized that the desmin pericyte sub-
population functionally contributes to increased permeability. Desmin peri-
cytes were produced in vitro by co-culturing primary mouse pericytes with
astrocytes. When desmin or CD13 pericytes were added to in vitro transen-
dothelial electrical resistance (TEER) models of the BBB, the desmin pericytes
exhibited less resistance, indicative of higher permeability. The data suggest that
desmin pericytes may facilitate the permeability of the BTB. These studies
show that the BTB in brain metastasis model systems involves consistent mo-
lecular changes. These datamay identify new strategies to selectively permeabil-
ize the BTB and enhance chemotherapeutic effıcacy.
#4934 Brain metastatic microenvironment reshapes cancer cell metabo-
lism through epigenetic up-regulation of glutamate decarboxylase 1. Patricia
M. Schnepp, Dennis D. Lee, Ian H. Guldner, Treasa O’Tighearnaigh, Bhavana
Palakurthi, Kaitlyn E. Eckert, Tiffany A. Toni, Brandon L. Ashfeld, Siyuan
Zhang. Univ. of Notre Dame, Notre Dame, IN.
Cancer metabolism has been well documented to influence primary tumor
development. Yet, the role of deregulated metabolism in metastasis progression
is not well understood. Based on a distinct metabolic transcriptome profıle in
brain metastases compared to their primary tumor counterparts, we hypothe-
sized that metabolic transcriptome shifting during metastatic evolution is cru-
cial for metastatic success to the brain. Here we show that, despite a global
down-regulation ofmultiplemetabolic pathways in the brainmetastatic tumors,
the expression of the GABA metabolic pathway mediator glutamate decarbox-
ylase 1 (GAD1) is signifıcantly up-regulated. Using cell based co-culturemodels
for different primary and brainmetastaticmicroenvironments and in vivo brain
metastasis models, we demonstrate that down-regulation of DNAmethyltrans-
ferase 1 (DNMT1) induced by the brain microenvironment results in decreased
GAD1 promoter methylation and subsequent up-regulation of GAD1 expres-
sion in tumor cells. To dynamically visualize the cellular metabolic responses
mediated by GAD1, we utilized the Peredox biosensor to monitor the cytosolic
NADH:NAD equilibrium in tumor cells using time-lapse imaging. By knock-
ing down of GAD1 induced by primary glia cell co-culture, we abolished the
capability of tumor cells to utilize extracellular glutamine, leading to an NADH
accumulation in the cytosol and a more oxidative cellular status. Lastly, either
loss of GAD1 genetically or targeting GABA metabolic pathway by the repur-
posing of a neurological drug, vigabatrin, results in a signifıcant decrease in
brain metastasis incidence. Taken together, our results demonstrated that brain
microenvironment-specifıc metabolic shifting through GAD1 promoter de-
methylation drives brain metastasis outgrowth.
#4935 Development of a humanpancreatic tumormicroenvironment sys-
tem (TMeS) for evaluation of novel therapeutics. Daniel G. Gioeli,1 Chelsi
Snow,2 Michael Simmers,2 Robert Figler,2 J. Thomase Parsons,1 Stephen Ho-
ang,2 Todd Bauer,1 Brian Wamhoff2. 1Univ. of Virginia, Charlottesville, VA;
2HemoShear Therapeutics, Charlottesville, VA.
The development of drugs to treat cancer is severely hampered by the ineffı-
ciency of translating pre-clinical in vitro andmouse studies into clinical benefıt.
Over 90%of drugs that progress through pre-clinical studies fail in human trials.
Therefore, there is a critical need to improve the accuracy of evaluating pre-
clinical drug effıcacy through the development of more physiologically relevant
human models. This is especially the case for pancreatic cancer, the 4th leading
cause of cancer deaths with a 5-year survival rate of6%, where new therapies
are desperately needed. The tumor microenvironment (TME) of PDAC con-
tains numerous cell types including vascular endothelial cells, stellate cells and
fıbroblasts, as well as a complex extracellular matrix (ECM), all of which con-
tribute to the growth and survival of cancer cells, as well as posing potential
targets for therapeutic intervention. Thus, amore complete and nuanced under-
standing of the PDACTME is required for the rational development of effective
therapies. To address this problem, an in vitro tumormicroenvironment system
(TMeS) was engineered to incorporate tumor capillary hemodynamics and bi-
ological transport with co-cultured human microvascular endothelial cells,
along with pancreatic tumor and stellate cells. We demonstrate that signifıcant
tumor cell transcriptomic changes occur in the TMeS that correlate with the in
vivo xenograft transcriptome, including alterations in cell cycle regulation, on-
cogene signaling, and metabolism. PDAC tumor cells from two patients were
inhibited by the human Cmax dose of gemcitabine to levels paralleling the pa-
tients’ clinical responses. Previous work demonstrated that the FAK inhibitor,
PF-562,271, worked only on in vivo xenografts and not on 2D in vitro PDAC
cultures andherewe show that PF-562,271 effectively inhibitedPDACgrowth in
the TMeS indicating in vivo-like drug responses. In sum, the TMeS recapitulates
the in vivo xenograft transcriptional program and responds to both established
and experimental small molecule inhibitor chemotherapeutics at concentra-
tions that correspond to human therapeutic plasma levels. Therefore, thismodel
provides a unique platform to rigorously test the contributions of the cellular
and molecular components of the TME through manipulating individual con-
stituents in a controlled fashion that is not possible in vivo.Moreover, the TMeS
can be used for the rapid evaluation of novel precision therapies. Finally, this
system is amenable to using patient tumormaterial directly, enabling the poten-
tial use of the TMeS for patient avatars.
#4936 Modelling clinical issues by using patient-derived xenografts: Eval-
uation of partial hepatectomy on hepatoblastoma intrahepatic and distant
growth. Marianna Cornet,1 Anais Delaitre Delattre,2 Laura Brulle Soumare,2
Victorine Boissay,2 Thierry Tordjmann,3 Antoinette Lemoine,4 Olivier Deas,2
Jean-Gabriel Judde,2 Sophie Branchereau,1 Stefano Cairo2. 1Hôpital Bicêtre,
Université Paris Sud, LeKremlinBicêtre, France; 2XenTech, Evry, France; 3French
Institute of Health andMedical Research, Orsay, France; 4Hôpital Paul Brousse -
Hôpitaux Universitaires Paris-Sud, Villejuif, France.
Hepatoblastoma (HB) is a rare disease that represents the most frequent liver
malignancy during childhood. HB incidence is approximately 1.5 cases per mil-
lion children less than 15-years old in Western countries. HB is histologically
classifıed as epithelial or mixed depending on the presence of mesenchymal
component. The most common epithelial components are the embryonal and
fetal phenotype, reminiscent of at early or late stages of liver development. The
improvement of the clinical management in the last 30 years has allowed 5-year
survival rate to pass from 35 to 80%,due to the introduction of cisplatin-based
chemotherapy.More than 50% of tumors are either inoperable or aremetastatic
at diagnosis.Neoadjuvant chemotherapy allows tumor size reduction and some-
times leads to complete regression of pulmonary metastasis. In Europe, the
SIOPEL (International Childhood Liver Tumors Strategy Group) protocols rec-
ommend the use of cisplatinum-based neoadjuvant chemotherapy followed by
surgery and adjuvant chemotherapy. All international studies recommend re-
secting all the metastases remaining after neoadjuvant chemotherapy, however,
to date no indication is provided that defınes whether metatases removal must
take place before or after primary tumor resection by partial or total hepatec-
tomy.As liver regeneration is a complex process that involves the expression and
release of numerous factors that induce cell hypertrophy and proliferation, the
risk that hepatectomy-induced release of regenerating factors might help the
survival and proliferation of microscopic intrahepatic or distant tumor cells
leads several clinicians to perform hepatectomy only after the removal of all
detectable metastases. To challenge this paradigm, we used a panel of HB pa-
tient-derived xenograft and evaluated the impact of partial hepatectomy on
intrahepatic and extrahepatic tumor growth. Partial hepatectomy performed
either concomitantly with interscapular implantation of HB-217 xenograft, a
model established from a patient with intrahepatic recurrence, or at the time of
tumor appearance in mice failed to increase tumor growth. When hepatectomy
was realized on several HBmodels concomitantly with either intrahepatic injec-
tion of bioluminescent HB cells derived fromHB PDXs or by tumor fragments’
direct implantation, one of thesemodels, HB-243, also amodel established from
a patient with intrahepatic recurrence, showed increased tumor growth in mice
concomitantly subjected to partial hepatectomy. These results suggest that in-
creased tumor growth induced by hepatectomy can occur in HB, albeit hetero-
geneously. We are now evaluating the molecular features of this hepatectomy-
sensitive model and the impact of different cytokines on HB-243 PDX-derived
tumor cells. The aim of this study will be to identify molecular markers and
drivers of tumor sensitivity to hepatectomy.
#4937 Comparison of orthotopic and subcutaneous implantation of pan-
creatic cancer patient-derived xenograftmodels for drug development. Sarah
L. Fong, Marybeth A. Pysz, Kristen D. McKnight, Nicole Taylor, Regina Nieu,
Emily Janke, Erica Anderson, Holger Karsunky, Scott Dylla.Abbvie Stemcentrx,
South San Francisco, CA.
Patient derived xenograft (PDX) models of pancreatic cancer provide an ex-
cellent platform for understanding human disease, characterizing tumor-initi-
ating cells, and testing of novel therapeutics. Herein, we compared the natural
pancreatic microenvironment via orthotopic implantation and the traditional
approach of subcutaneous implantation for effects on PDX tumor growth, tu-
mor morphology, cell population diversity, tumorigenic potential, metastatic
potential, and response to therapeutics. Two approaches were used: (1) primary
human cancer tissue fragments were implanted in orthotopic and subcutaneous
environments; and, (2) PDX previously established by subcutaneous engraft-
ment were reimplanted into either an orthotopic or a subcutaneous environ-
ment.We report that orthotopically-engrafted primary PDXmore closely reflect
the gross tumor morphology of the original patient than subcutaneously-de-
rived tumors. In models derived from subcutaneous engraftment, variation of
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tumor morphology, tumor growth, cell population diversity, and tumorigenic
potential between tumors grown in orthotopic and subcutaneous environments
were dependent on PDX line; and, stromal infıltration and mucin production
were more prominent in the orthotopic background for some PDX models. In
addition, we observe increasedmetastatic potential in orthotopic tumor-bearing
mice compared with their subcutaneous counterparts. Tumor metastasis oc-
curred in distal fıltering organs, including the lung, liver, lymph nodes, and
peritoneal cavity, among others. This result is consistent with the observation of
increased circulating tumor cells in the blood of orthotopic tumor bearingmice.
Comparison of therapeutic effıcacy with gemcitabine chemotherapy and anti-
body-drug conjugate (ADC) therapy in orthotopic and subcutaneous tumors
showed therapeutic response was dependent on PDX line. Interestingly, for
PDX lines that exhibited morphological differences between orthotopic and
subcutaneous backgrounds, treatment was less effective in the orthotopic mi-
croenvironment suggesting themicroenvironment alters the ability of therapeu-
tics to impede tumor growth. Reduced therapeutic responsewas also found to be
consistent with reduced ADC uptake and vascularity in orthotopic tumors.
Taken together, the orthotopic PDX model serves as a more accurate represen-
tation of human pancreatic cancer by displaying stromal-rich morphology, ex-
hibiting metastatic cell behavior, and recapitulating therapeutic response chal-
lenges observed in patients.
#4938 Avicious cycle between osteoblasts-derivedWISP-1 andmesenchy-
mal-like cancer cells is essential to prostate cancer metastasis. An-Chen
Chang,1 Show-Mei Chuang,1 Chih-Hsin Tang2. 1National Chung Hsing Univer-
sity, Taichung, Taiwan; 2China Medical University, Taichung, Taiwan.
Prostate cancer (PCa) is the most commonly diagnosed malignancy in the
United States and other Western countries. It is well established that tumor
microenvironment plays an important role in cancer progression and metasta-
sis. Wnt-induced secreted protein-1 (WISP-1) belongs to the CCN family
(CTGF/CYR61/NOV) that plays a key role in osteogenesis and tumor growth.
We found that osteoblast-conditioned media (OBCM) stimulated migration
and invasion in humanPCa cells. Furthermore, themediumwas collected 2 days
after treatment of osteoblasts with PCa conditionedmedia which were designed
as PCa-OBCM. The results showed that treatment of PCa cells with PCa-OBCM
further increased the migration and invasion activity, as well as epithelial-mes-
enchymal transition (EMT), including the epithelialmarker (E-cadherin) down-
regulation and mesenchymal marker (N-cadherin and twist) up-regulation.
Moreover, human cytokine array was used to measure the secretion of 32 Cyto-
kines into PCa-OBCM. The data showed that WISP-1 is highly up-regulated
with PCa-OBCM treatment compared to OBCM. Stimulation of osteoblasts
with PCa conditioned media induced WISP-1 expression. In contrast, knock-
downWISP-1 in osteoblasts impacted PCa-OBCM-mediated cancer migration,
invasion, and EMT. In addition, conditioned media from PCa cells was incu-
bated with another cytokine array membranes. The data showed that ADAM-9
and cathepsinL were overexpressed in PCa conditioned media but only AD-
AM-9 could regulate WISP-1 expression in osteoblasts. Taken together, these
results demonstrated that primary PCa-secreted ADAM-9 promotes osteo-
blasts-derivedWISP-1 up-regulation, which in turn enhances primary PCa cells
migration, invasion, and EMT, resulting in cancer metastasis. Our study sug-
gests that inhibition of osteoblasts-derived WISP-1 is a new therapeutic target
for treating metastasis in human PCa patients.
#4939 Activation of GSK3/-catenin pathway promotes organ-specifıc
metastasis in prostate cancer. Siyuan Qin,1 Qiong Song,1 Jinlu Dai,2 Haibo
Tong,1 Evan Keller,2 Jian Zhang,1 Yi Lu1. 1Guangxi Medical Univ., Nanning,
China; 2University of Michigan, Ann Arbor, MI.
Metastasis is the major cause of treatment failure in various malignancies,
including prostate cancer (PCa). Accumulating data has suggested that primary
cancer cells prefer to spread to certain distant organs. To explore the mecha-
nisms of different cancer cells preferentially metastasizing to certain organs, we
established a prostate cancer lung metastasis model. Murine prostate cancer
cells (RM1), which labeled with luciferase, were used in this study. RM1 cells
were injected into left tibia of mouse (C57BL/6J), and monitored the tumor
growth and metastasis every week by Bioluminescence Imaging. The mice
would be sacrifıced when metastatic tumor appeared in multi-organs. We iso-
lated the lung metastatic tumor, made single cell suspension and amplifıed. The
lung metastatic tumor cells were specifıcally metastasized to lung when the tu-
mor cells were injected intratibially again. After several cycles we obtained
highly lung metastatic tumor cells, named RM1-LM cells. Further, we investi-
gated property and function changes in RM1-LM cells compared to parental
cells (RM1) using in vitro assays. We fırstly found the highly lung metastatic
tumor cells showedmoremesenchymal properties.Western blot results showed
that hallmarks of EMT including E-cadherin, vimentin, snail, and ZO-1 were
altered signifıcantly in RM1-LM cells. Then, we observed that the highly lung
metastatic tumor cells exhibited increased proliferative, colony formation, mi-
gratory and invasive abilities. Mechanistic analyses indicated that prostate can-
cer organ-specifıc metastasis mediated by the activation of GSK-3/-catenin
pathway. The current study may provide potential therapeutic targets and diag-
nostic biomarkers of PCa metastasis. This work was supported by Natural Sci-
ence Foundation of China (NSFC) Key Project (81130046); NSFC (81171993;
81272415); Guangxi Projects of China (2013GXNSFEA053004; 2012GXNS-
FCB053004).
#4940 Exosomal miR-19a: a novel communicator between cancer cell and
osteoclast in osteolytic bone metastasis of breast cancer. Kerui Wu,1 Jiamei
Feng,2 Fei Xing,1 Yin Liu,1 Sambad Sharma,1 KounosukeWatabe1. 1Wake Forest
University School of Medicine, Winston-Salem, NC; 2Shuguang Hospital Affıli-
ated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Bone is the most common site for breast cancer (BC) metastasis and relapse.
Bone metastasis (BM) causes considerable complications due to osteoclast-me-
diated bone resorption. Current treatment for osteolysis in BM is limited due to
their side effects and inability to extend the patients’ survival. Thus, there is an
urgent need for developing early predictivemarkers and alternative therapies for
BC-BM. Recently, circulating miRNAs have been found to harbor great poten-
tial for diagnostic and prognostic purposes. Due to the low stability of cell-free
RNA in serum, these circulating miRNAs exist mostly in a form of membrane-
wrapped extracellular vesicles (EVs) and they play important roles in cancer
progression. In this study, we aim to identify EVs derived-miRNA from serum
of BC patients as biomarkers for diagnosis and prognosis of BC-BM. To fınd the
circulating miRNAs that are associated with BC-BM, we applied a four-layer
screening system combining bioinformatic analyses and experimental verifıca-
tion. Firstly, 85 BC associated circulating miRNAs were identifıed to be up-
regulated in the serum of 32 BC patients compared to 22 healthy donors. Next,
we performed Kaplan-Meier survival analysis for these 85 miRNAs and found
that 10 miRNAs were positively correlated with metastases. To select the miR-
NAs specifıcally involved in BM, we compared the EVs derived miRNA profıles
between bone metastatic cell lines and the parental cell lines (231BoM-1833 vs
MDA-MB-231, MCF7-BoM2d vs MCF7). Among the 10 miRNAs, only miR-
19a was signifıcantly up-regulated in EVs derived from bone metastatic cell
lines. MiR-19a was also found to be highly enriched in exosomes compared to
microvesicles and apoptotic bodies. Lastly, we verifıed the high expression of
miR-19a in the serum of BC-BM patients compared to the BC patients without
BM. To study the role of miR19a in BC-BM, we applied the CRISPR/Cas9 tech-
nology to knockout the miR-19a in 231BoM-1833 andMCF7-BoM2d cells. The
knockout of miR-19a didn’t alter the proliferation or migration of BC cells.
However, it signifıcantly decreased bone metastasis in our xenograft mouse
models. We also found that the knockout of miR-19a decreased osteolytic le-
sions in the tumor-bearing bones, indicating the possible role of exosomal miR-
19a in osteoclast cells. To test this hypothesis, we treated osteoclast cells with
miR-19a-enriched exosomes and miR-19a-knockout exosomes. The results of
tartrate-resistant acid phosphatase assay and bone resorption assay indicated
that miR19a-enriched exosomes signifıcantly promoted osteoclast differentia-
tion and activity.Our study identifıed exosomederivedmiR-19a as amediator of
cell-cell communication between breast cancer and osteoclast cell, warranting
further investigation on exosomal miR-19a as a novel biomarker and a thera-
peutic target for breast cancer bone metastasis.
#4941 Lysophosphatidic acid receptor signaling and pancreatic adenocar-
cinoma tumor microenvironment. Nicholas J. Skill, Mary A. Maluccio. Indi-
ana University, Indianapolis, IN.
Introduction: Changes in lipid biosynthesis has attracted signifıcant attention
in the study of cancer. Its value in our understanding of pancreatic cancer has
not yet been realized. This study examined lysophosphatidic acid (LPA) variant
biosynthesis in patients with stage II-III pancreatic ductal adenocarcinoma
(PDAC), evaluating serum, bile, and tissue levels of LPA, its receptors, and
downstream metabolites. LPA, a product of phospholipase D activity of the
enzyme autotaxin (ATX) is a potentmitogenic agent. Data suggests that changes
in lipid biosynthesis contribute to the tumor microenvironment in PDAC.
Methods: PDAC,matched adjacent non-malignant tissues, gall bladder bile and
serum sampleswere collected frompatientswith Stage II-III pancreatic cancer at
the time of surgery. Control bile and serumwere collected from patients under-
going cholecystectomy for benign disease and living renal donors respectively.
Results: Serum and biliary LPA levels were increased in patients with PDAC
when compared to controls. ATX activity, and LPA receptors, LPAR1, LPAR2,
and LPAR5 were greater in PDAC adjacent pancreatic tissue when compared to
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PDAC tissue. In contrast, TNF receptors TNF1 and TNF2 and LPA recep-
tor LPAR3 receptor expression was greater in PDAC lesions when compared to
adjacent tissue. Conclusion: PDACpatients display amodifıed LPAbiosynthesis
profıle, when compared to non-PDAC patients, potentially providing a para-
crine-signaling cascade to promote pancreatic tumorigenesis through increased
expression of mitogenic cytokines and growth factors.
#4942 Small molecule inhibition of CXCR4 mobilizes prostate dissemi-
nated tumor cells (DTCs) from the chemoprotective bone marrow niche,
thereby sensitizing them to chemotherapy.Kenneth C. Valkenburg, Emma E.
van der Toom, Kenneth J. Pienta. Johns Hopkins School of Medicine, Baltimore,
MD.
Bone metastasis results in the deaths of approximately 28,000 prostate cancer
patients each year in the United States. Disseminated tumor cells (DTCs) go
from the primary tumor site to the bone marrow, which provides a chemopro-
tective environment. C-X-C chemokine receptor 4 (CXCR4), highly overex-
pressed in prostate cancer, is at least partially responsible for bone homing.
CXCR4 is also expressed in hematopoietic stem cells (HSCs), which occupy the
same niche within the bone marrow as DTCs. HSCs can be mobilized from the
bone marrow niche via CXCR4 antagonism. We have previously shown that
human tumor cells can be similarly mobilized from the bone marrow niche via
smallmolecule inhibition of CXCR4.We believe this represents an ideal strategy
for treating bone metastasis and hypothesize that mobilized DTCs will prolifer-
ate in the vascular niche, causing them to become chemosensitive. Several out-
standing questions still exist that we are in the process of answering. First is the
percentage of DTCs that aremobilized with CXCR4 antagonism. Previously, we
used a qPCR strategy to quantify tumor cells in the bone marrow and blood of
mice. This was imperfect because we could not reliably count cells, nor could we
query the cells further. Therefore, we developed a novel immunofluorescence
protocol to detect, quantify, and query tumor cells residing in the bone marrow
or blood ofmice.Wewill use this technique to determine the percentage of bone
marrow DTCs that are mobilized. The second outstanding question is whether
or not mobilized DTCs proliferate once mobilized. This is crucial to know,
considering most chemotherapy relies on tumor cell proliferation. Using our
novel protocol, we will determine the percentage of bone marrow DTCs and
mobilized DTCs that are proliferating. Finally, while there is evidence that com-
bining CXCR4 antagonism with chemotherapy kills more tumor cells than che-
motherapy alone, no one has shown defınitively that it works specifıcally for
prostate bonemarrowDTCs or bonemetastasis. Not only will we do this, but we
will also be able to quantify how effective each therapy strategy is by quantifying
the tumor cells present in each scenario. The data from these in vivo murine
experiments, which would be impossible to get from humans, will go hand in
hand with a fırst-in-prostate cancer clinical trial we are running that tests the
same hypothesis. Combined, these data will be critically important in deciding
whethermobilization therapy combinedwith chemotherapy is an effective strat-
egy for treating metastatic prostate cancer.
#4943 Orthotopic transplantation of pancreatic cancer PDX models in-
creases murine stroma content, but does not influence therapeutic response
to standard of care.Ulrike Pfohl,1 Diana Behrens,1 Iduna Fichtner,1 Jens Hoff-
mann,1 Britta Büttner,1 Wolfgang Walther2. 1EPO GmbH, Berlin, Germany;
2Charité University Medicine Berlin and Max-Delbrueck-Center for Molecular
Medicine, Berlin, Germany.
Background: Reasons for the poor prognosis of pancreatic cancer are ad-
vanced and inoperable tumor stages at time of diagnosis and resistance to con-
ventional therapies. Patient-derived xenografts (PDX) represent a valuable tool
for the prediction of therapy response, the identifıcation of new biomarkers and
therapeutic targets or pancreatic cancer specifıc activated pathways (MAPK,
hedgehog).However, PDX tumors differ frompatient tumors as their surround-
ing tissue is replaced by murine stroma within 3 to 9 weeks after primary trans-
plantation. Since the desmoplastic stroma has an impact on the progression and
treatment of pancreatic cancer, we investigated the characteristics and function
of murine stroma components in PDXmodels of pancreatic ductal adenocarci-
noma (PDAC). Methods: We analyzed the relevance of murine cancer-associ-
ated fıbroblasts (CAFs) for therapeutic response by comparing orthotopic with
s.c. transplantation in PDX.We selected a cohort of 3 PDACPDXwith different
growth rates (slow, median and fast growth). Human pancreatic tumormaterial
was implanted s.c. or orthotopically into immunodefıcient mice. After success-
ful engraftment, the chemosensitivity to standard of care (SoC) drugs (focus on
2 to 3 drugs) was determined according to clinically relevant and optimized
schedules. Growth of orthotopic PDX models was monitored via high-resolu-
tion ultrasound. Cryo- and formalin-preserved tumor tissues from the chemo-
sensitivity studies were collected and analyzed for specifıc stroma markers (col-
lagen I andSMA). Results: In general, the response profıles in our experiments
have closely reflected patient’s response in the clinic for the drug combination
gemcitabine and nab-paclitaxel. There were no differences in response when
comparing s.c. with orthotopic growing tumors. Semi-quantitative analysis of
tumor sections showed that orthotopic tumors contain more murine stroma
compared to s.c. tumors. Comparison of treated and untreated tumors revealed
a strong reduction of the tumor cell content by the SoC treatment, whereasCAFs
(collagen I and SMA positive fraction) were not affected. Conclusion: In sum-
mary, this study revealed that orthotopic transplantation results in the growth of
tumors with an improved and functional tumor microenvironment. Therapy is
effective on the pancreatic cancer cells, however, tumor stroma seems appar-
ently to be inherent resistant towards conventional therapy. The remaining tu-
mor stroma might provide a survival nice for some tumor cells - leading to the
frequently observed disease relapse. Therefore, orthotopic PDX are considered
to be the more clinical relevant models in comparison to s.c. PDX because they
mimic closely the human pancreatic cancer microenvironment and also favor
the development of metastasis. Further, targeting the tumor stroma should be
implicated into clinical treatment strategies.
#4944 Modeling tumor dormancy by using EMT lineage tracing under
chemotherapy. Jay Lopez, Robert Bednarczyk, Nasser Altorki, Vivek Mittal,
Dingcheng Gao.Weill Cornell Medical College, New York, NY.
Tumor dormancy and recurrence after initial effective treatment arose as one
of most challenging questions in cancer research. Up to now, there is still no
established animal model of tumor dormancy, which signifıcantly hurdles our
exploration in this fıeld. In an effort to trace the phenotypic changes of meta-
static tumor cells in vivo, we found that the dormant tumor cells were derived
through a mechanism of epithelial to mesenchymal transition (EMT). We es-
tablished an EMT lineage tracing model in triple transgenic mice (Tri-MMTV)
carrying Fsp1-cre, Rosa26-RFP-GFP and MMTV-PyMT alleles. Tumor cells
from thesemice are able to switch their fluorescentmarker fromRFP toGFPdue
to the specifıc activation of CRE recombinase during the EMT process. Using
this EMT lineage tracing model, we confırmed that within a predominantly
epithelial primary tumor, a small portion of tumor cells undergo EMT. Strik-
ingly, lung metastases were mainly derived from non-EMT tumor cells main-
taining their epithelial phenotype. However, under chemotherapy condition,
EMT cells signifıcantly contributed to recurrent lung metastasis. The EMT tu-
mor cells survived the chemotherapy due to reduced proliferation and apoptotic
tolerance, which are common characters of dormant tumor cells. More interest-
ingly, theGFPEMT tumor cells reversed back to epithelial phenotype through
mesenchymal to epithelial transition (MET) and formed recurrent metastatic
lesions in the lung. These results suggest that our EMT lineage tracing model
may provide a unique tool to study tumor dormancy and recurrence. The EMT
process may represent a major mechanism for tumor dormancy under chemo-
therapy condition, while MET is a driving mechanism for tumor recurrence.
#4945 Axl–hiDTCs in the bonemarrowof a genetically engineeredmouse
model of prostate cancer exhibit decreased proliferation. Haley D. Axelrod,
Kenneth C. Valkenburg, Brian W. Simons, Kenneth J. Pienta. Johns Hopkins
School of Medicine, Baltimore, MD.
The majority of prostate cancer (PCa) deaths are attributed to bone metasta-
ses, which may not arise until years after the primary tumor has been removed.
Disseminated tumor cells (DTCs) have been shown to already be present in the
bonemarrow of patients at the time of prostatectomy, and it is thought that they
undergo a period of dormancy, allowing them to remain undetected for years
before manifesting into clinically detectable metastases. It is not known what
allows PCaDTCs to undergo and persist in this dormant state, but it is likely that
factors in the bonemarrowniche play an essential role. Previously our group has
shown that one of these niche factors, Gas6, can regulate growth of PCa cells.
The growth restraining effects of Gas6 on PCa cells is likely mediated through
the tyrosine kinase receptor Axl, whose expression was found to be increased on
dormant DTCs compared to proliferating metastases in a xenograft mouse
model. Here, we utilized the TRAMP model, a genetically engineered mouse
model of spontaneous PCa progression, to compare the frequency of Axl-hi and
Axl-low bone marrow DTCs that are proliferating versus non-proliferating.
Further, we also comparedAxl expression and proliferation inmatched primary
tumors. To investigate the functional signifıcance of Gas6/Axl signaling in me-
diating PCa dormancy, we have generated Axl knockout PCa cells to test the
requirement of Axl in maintaining dormancy, and Axl overexpressing PCa cells
to test the suffıciency of Axl inmediating dormancy.Determining the role of Axl
and any other regulatory mechanisms of PCa DTC dormancy will be crucial in
efforts to prevent lethal and incurable metastasis.
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#4946 Host tissue stiffness regulates chemotherapy-induced cancer cell
dormancy.Alisya Anlas, CelesteM.Nelson. PrincetonUniversity, Princeton, NJ.
This study investigates how the tumormicroenvironment, namely host tissue
stiffness, affects the propensity of disseminated tumor cells to become dormant
at secondary sites. Approximately 90% of cancer-related deaths result fromme-
tastasis. In breast cancer, disseminated cancer cells cannot be detected at the
time of diagnosis of the primary tumor because they form “dormant” microme-
tastases that are not clinically detectable. Thus, metastases in secondary sites
such as the lungs, bonemarrow, liver and brain are usually discoveredmonths or
years after the initial diagnosis and/or treatment of the primary tumor. A 2D
polyacrylamide gel-based tissue culturemodel was used to investigate the effects
of host tissue stiffness on the proliferative behavior of breast cancer cells. To
assess the dormant phenotype, Ki67 and RNA staining were used to quantify
proliferation and RNA content, respectively. Additionally, changes in levels of
cell-cycle regulators were determined by quantitative RT-PCR. Dormant cells
have decreased levels of transcription and proliferation. We found that both
tamoxifen and 5-fluorouracil induce dormancy in estrogen receptor-positive
breast cancer cells cultured on soft and stiff substrata. After repeated rounds of
5-fluorouracil treatment and recovery, cells cultured on soft substratum, me-
chanical properties of which represent common metastatic sites, had a higher
tendency to recover. This suggests that cell growth at secondary sites favors a soft
microenvironment, characteristic of organs where breast cancer metastases of-
ten become clinically overt. Dormant cancer cells, or minimal residual disease,
cannot be detected with current diagnostic tools and cannot be targeted by
conventional therapies. Therefore, current clinical practices rely on estimating
the probability of recurrence from various prognostic factors including the
grade and the stage of the disease. Elucidating the mechanisms that regulate the
switch from dormancy to proliferation at metastatic sites will pave the way for
new treatments to control this incurable disease.
#4947 Her2 inhibition and dormant cell metabolism. Douglas B. Fox,
James V. Alvarez. Duke University, Durham, NC.
Breast cancer is themost diagnosed cancer inwomen in theUnited States, and
despite improved prognosis resulting from targeted therapies, tumors com-
monly re-emerge upon development of therapeutic resistance. In order to over-
come this, it is critical to explore the cellular pathways that change in tumors
following treatment.Whilemanymechanisms of resistance to targeted therapies
have been identifıed, themetabolic changes that occur following treatment have
not been well defıned. We believe that these changes may offer a general thera-
peutic target. Using a doxycycline-inducible Her2 mouse model of breast can-
cer, we are exploring the molecular and cellular consequences Her2 inhibition.
Using in vitro mammosphere cultures derived from these mice, we showed that
Her2 loss quickly downregulates ERK and Akt signaling. There is a correspond-
ing decrease in proliferation, and apoptosis is induced in 25-50% of cells. How-
ever, a population of cells survives Her2 withdrawal and remains dormant for
upwards of one month. We are using these models to study how metabolic
pathways are rewired following Her2 inhibition, and we believe that the meta-
bolic pathways adapted upon Her2 inhibition may represent targetable vulner-
abilities.
#4948 Characterization of hTERT-immortalized prostate-derived stro-
mal and epithelial cells: An authentic in vitromodel for tumormicroenviron-
ment studies. Luis G. Rodriguez, Russell E. McDaniel, Xiangshan Zhao, Eliza-
beth Turner, Christopher Annesi, Chaozhong Zou. ATCC Cell Systems,
Gaithersburg, MD.
Tumor development begins with mutational changes to the genetic makeup
of a cell, but its progression is not solely determined by themutated cell, but also
by the tumor’s microenvironment. Prostate cancer, a leading cancer diagnosed
in men, has been shown to be highly influenced by its surrounding stroma,
particularly fıbroblasts. It has been demonstrated that cancer-associated pros-
tate fıbroblast (CAFs) differ from normal-associated prostate fıbroblast (NAFs).
However, human prostate cancer model systems have focused largely on pros-
tate cancer epithelial cells. Currently, a need exists for a more physiologically
relevant human cell model system to study prostate cancer progression within
the context of its tumormicroenvironment. In this study, we characterized three
prostate-derived cells: prostate cancer-associated fıbroblast (CAFs), prostate
normal-associated fıbroblast (NAFs) and prostate cancer epithelial (PrE) cells;
all three lines were immortalized by hTERT (human telomerase reverse tran-
scriptase) alone, and have been continuously passaged for more than 40 PDL in
our hands.Our data shows that the hTERT immortalizedCAFs proliferate faster
than the NAFs; in addition, both CAFs and NAFs express fıbroblast markers
such as TE7 and alpha smooth muscle actin (-SMA), while neither cell line
expresses epithelial marker such as CK14. Both CAFs and NAFs also express
elevated levels of -SMA upon TGF- stimulation. All three prostate-derived
cells express the prostate specifıc marker AR, and show similar markers staining
after long time passaging. Importantly, conditionedmedia collected fromCAFs
promotes tumor cell growth better thanNAF conditionedmedia. In conclusion,
CAFs, NAFs, and immortalized prostate cancer epithelium may provide a very
valuable model system for the study of prostate cancer cell progression and
tumor microenvironment studies.
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#4949 Longitudinal monitoring of cell-free DNA in patients with small
cell lung cancer reveals dynamic insights into treatment effıcacy and disease
relapse.ChristineM. Lovly,1 KarinnaAlmodovar,1WadeT. Iams,2 Catherine B.
Meador,1 Sally York,1 Leora Horn,1 Christopher K. Raymond,3 Jennifer Her-
nandez,3 Lee P. Lim3. 1Vanderbilt University School of Medicine, Nashville, TN;
2NorthwesternUniversity School ofMedicine, Chicago, IL; 3ResolutionBioscience,
Bellevue, WA.
Introduction: Small cell lung cancer (SCLC) is a highly lethal neuroendocrine
malignancy that accounts for approximately 10-15% of all lung cancers and is
responsible for approximately 30,000 deaths annually in the United States and
200,000 deaths worldwide every year1. There is an urgent need to develop novel
treatment strategies for patients with this disease. We sought to improve the
quality of patient care by establishing a liquid biopsy assay for rapid, noninvasive
monitoring of disease burden. Design: The SCLC assay relies on targeted next-
generation DNA sequencing of cell-free DNA (cfDNA) collected from patient
plasma. The assay targets a panel of 14 genes that are frequently mutated in
SCLC2.We examined a total of 141 plasma samples from a cohort of 27 patients.
11 patients had limited stage SCLC and 16 patients had extensive stage SCLC.
The analyzed plasma samples were collected during the course of patient treat-
ment and included time points before and after chemotherapy or immunother-
apy. Results:Wedetected somatic, disease-associatedmutations in the cfDNAof
78% of patient samples (21/27). The allele frequency of cfDNA ranged from
0.5% to 85%. The most commonly mutated genes were TP53 and RB1,
which were found in 17/27 and 10/27 samples, respectively. We also detected
single nucleotide variants in PIK3CA (3/27) and PTEN (1/27) as well as copy
number variants in MYC and MYCL1 (2/27). The observed mutant allele fre-
quencies in longitudinal samples tracked closely with treatment responses.
Strikingly, we found instances where the assay detected the reappearance of
tumor-associated markers several weeks before clinical evidence of relapse was
detected. Conclusions: cfDNA sequencing allows for improved monitoring of
disease burden, depth of responses to treatment, and timely warning of disease
relapse in patients with SCLC. References: 1. Society, A.C., Cancer Facts and
Figures 2015. American Cancer Society, Atlanta, Ga, 2015. 2. George, J. et al.,
Comprehensive genomic profıles of small cell lung cancer, Nature 524:47
#4950 The emergence of ESR1 mutations is associated with aromatase
inhibitor and fulvestrant therapy. Yanan Kuang,1 Bilal Siddiqui,2 Jiani Hu,1
William T. Barry,1 Nancy U. Lin,1 Nikhil Wagle,1 Paul Kirschmeier,1 Pasi A.
Jänne,1 Cloud Paweletz,1 Ian Krop,1 Eric P. Winer,1 Myles Brown,1 Rinath Je-
selsohn1. 1Dana-Farber Cancer Institute, Boston, MA; 2Beth Israel Deaconess
Medical Center, Boston, MA.
Introduction: In recent studies, constitutively active recurrent ESR1 ligand bind-
ing mutations (LBD) were found in about 20% of metastatic (met) HR breast
cancers ( BRCAs) and rarely in primary HR cancers. In our previous work, we
analyzed clinical tissue samples and detected an association between the number of
prior endocrine treatments and the prevalence of these mutations, suggesting the
emergence of the ESR1 mutations under the selective pressure of endocrine treat-
ment.More recently, the LBDESR1mutationswere successfully detected in plasma
cell free (cf)DNA in patients with met HR disease. The presence of mutant ESR1
cfDNAwas found tobeprognostic.Herewesought to study theassociationbetween
endocrine treatments in the adjuvant (adj) and met settings and the prevalence of
cfDNA ESR1 and PIK3CAmutations in patients with met HR BRCA. Methods:
Plasma samples and detailed clinical data were collected from patients with met
BRCAthrough theCollectionof Specimens andClinicalDataprogramof theBreast
OncologyCenter at theDanaFarberCancer Institute.DropletDigital PCRwasused
for the detection of the most common ESR1 LBD mutations (E380Q, Y537C,
Y537N, Y537S and D538G) and the 3 most common PIK3CA mutations (E542K,
E545K andH1047R) in cfDNA. Fisher’s Exact Test was used for statistical analysis.
Results: Plasma samples were collected from 155 patients with met BRCA. ESR1
mutations were found in 30.1% of the patients with HR/HER2- negative disease
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(34/113). PIK3CAmutations were detected in 31.8% of patients withHR/HER2-
disease. The majority of the patients had either newly diagnosed met disease or
progressive met disease at the time of the blood draw. 14 patients had stable met
disease andamong thesepatients, only1of thesepatientswas found tohaveanESR1
mutation and no PIK3CA mutations were detected. The majority of patients with
ESR1 mutations (88%) and PIK3CAmutations (75%) had progressive disease. Pa-
tients that received an aromatase inhibitor (AI) either in the adj ormet setting had a
higher prevalence of ESR1 mutations compared to patients that had no AI treat-
ment, regardless of whether or not they received tamoxifen (TAM) (prevalencewas
32% for adj AI only, 40.4%AI inmet only, NoAI and no TAM7.1% and TAMbut
no AI 6.7%). In addition fulvestrant treatment in the met setting was signifıcantly
associatedwithESR1mutations (odds ratio3.38, p-value0.01).Conversely,wedid
not detect any signifıcant associations between endocrine treatments in the adj or
met settings and PIK3CAmutations. Conclusions: Analysis of cfDNA can success-
fully detect ESR1 and PIK3CA mutations in newly diagnosed or progressive met
BRCA patients and the emergence of the ESR1mutations is associated with AI and
fulvestrant treatment. These results support the serial monitoring of ESR1 muta-
tions in cfDNA inmet disease and highlight the need to study new agents to target
these mutations.
#4951 Dynamics of KIT exon 11 mutations in cell free plasma DNA of
patients treated for advanced gastrointestinal stromal tumors: Results from
the Dutch GIST bio-databank. Pieter A. Boonstra,1 Arja ter Elst,1 Marco Tib-
besma,1 Ron H. Mathijssen,2 Florence Atrafı,2 Frits van Coevorden,3 Sheima
Farag,3 Neeltje Steeghs,3 Ingrid M. Desar,4 Winette T. van der Graaf,4 Hans
Gelderblom,5 Boudewijn van Etten,1 Jelle Overbosch,1 Albert J. Suurmeijer,1
Jourik A. Gietema,1 Ed Schuuring,1 Anna K. Reyners1. 1UMCG, Groningen,
Netherlands; 2ErasmusMC, Rotterdam, Netherlands; 3Netherlands Cancer Insti-
tute - Antoni van Leeuwenhoek, Amsterdam, Netherlands; 4Radboud UMC, Ni-
jmegen, Netherlands; 5LUMC, Leiden, Netherlands.
Introduction: Gastrointestinal stromal tumors (GISTs) are rare malignancies of
the gastrointestinal tract. In theNetherlands,most patientswithGIST are treated in
fıve sarcoma expertise centers. GIST is known to have driver mutations in the ty-
rosine kinase receptors KIT and PDGFR in respectively 80% and 10% of the pa-
tients. Mutations (single nucleotide variations, insertions and deletions) are mostly
found in KIT exon 9 and 11. GIST patients with a primary KIT exon 11 mutation
respondgenerallywell to tyrosinekinase inhibitors (TKIs).Theaimof this studywas
to evaluate treatment responseby thedetectionofKITexon11mutations in cell free
DNA (cfDNA) of patients with GIST at multiple time points. Materials and meth-
ods: SinceDec2014, plasmasamplesofpatientshavebeencollectedat everyhospital
visit and were put in a bio-databank for analysis of mutation detection in cfDNA.
Eligibility criteria were histological diagnosis of GIST and treatment with a TKI.
PatientswithaknownKITexon11mutation, ofwhichabaseline (before start of any
TKI) sample or a recurrence/progression sample was available, were analyzed. A
custom single-tube digital droplet PCR (ddPCR) drop-off assay, designed at the
UMCG, was used. This assay detects 80% of the known KIT exon 11 mutations.
ResultsUntil Nov 2016,620 samples of 175 patients have been collected. From43
patientswith aKITexon11mutations in thepretreatment tumorbiopsy, a baseline/
progression sample was available. Mutations in exon 11 were detected in cfDNA
from baseline plasma of 22/43 patients, 20 with metastasized and 2 with localized
disease. Of the 21 patients without detectable mutations, 11 had localized and 10
metastaticdisease.Threeof thesepatientswithmetastaticdiseasehadmutations that
could not be detected by our probe. Two weeks after start of TKI, an increase in
mutant allelic frequencywas seen in 5 (of 9 available 2week samples) patients, while
4weeks later themutant allelic frequency had decreased, in parallel with decrease in
tumor load on radiological imaging. Eight patients developed radiological disease
recurrence (2 patients, after 4 and 20months) or progression (6 patients,median 10
(6-24) months). This was paralleled by an increase in mutant allelic frequency in
cfDNA in 6 of them (baseline median 0% (0-0.9%); at progression median 3.5%
(0-30%); p 0.028; related samplesWilcoxon signed rank test). Summary and con-
clusion: KIT exon 11mutations in cfDNA could be detected in 74% of the patients
with metastatic disease. Disease progression or recurrence, coincides with a rise of
mutant alleles detected in the plasma. In conclusion, mutation detection in cfDNA
of GIST patients with metastatic disease is feasible. Our study will be extended to
include themonitoringof earlyprogressionbasedoncfDNA,whichmayguideearly
treatment adaptations.
#4952 Whole exome sequencing of circulating tumorDNAhighlights spa-
tial and temporal tumor heterogeneity in neuroblastoma.Mathieu Chicard,1
Leo Colmet Daage,1 Nathalie Clement,1 Angela Bellini,1 Sylvain Baulande,1 Vir-
ginie Bernard,1 Gaelle Pierron,1 Eve Lapouble,1 Isabelle Janoueix-Lerosey,1 Jean
Michon,1 Valérie Combaret,2 Olivier Delattre,1 Gudrun Schleiermacher1. 1In-
stitut Curie, Paris, France; 2Centre Léon Bérard, Lyon, France.
Background: Liquid biopsies are revolutionary tools to monitor tumour-spe-
cifıc genetic alterations in sequential samples. In neuroblastoma (NB), signifı-
cant levels of circulating tumor DNA (ctDNA) in the bloodstream enable the
detection of tumour cell-specifıc markers including MYCN amplifıcation or
activating ALK mutations. As clonal evolution plays a role in NB progression,
analysis of a single genetic marker will be insuffıcient for ctDNA-based disease
follow-up. Methods: To gain further insights into mechanisms of clonal evolu-
tion in NB, we isolated ctDNA from plasma at diagnosis (n19) and during
follow-up (fınal time-point: partial or complete remission (PR/CR), n7; pro-
gressive disease (PD), n9) for 19 NB patients for whom primary NB and
matched germline DNA whole exome/whole genome sequencing data (WES/
WGS) was available. CtDNA (7-100ng) was subjected to Illumina 100PE WES
following modifıed library construction and capture approaches to account for
small ctDNAmolecules (target depth 100x). SNVs/mutations were called using
GATK-UnifıedGenotyper, GATK-HaplotypeCaller and Samtools. Copy-num-
ber profıles were generated using Varscan andDNAcopy. Results: CtDNAWES
yielded satisfactory depth in all cases. At diagnosis, a majority of observed SNVs
were common to the primary NB and corresponding diagnostic ctDNA of a
given patient (mean number of SNVs: 19; range 9-69) withMAF (mutated allele
fractions) corresponding to the estimated ctDNA content in the total cell free
DNA.At diagnosis, few SNVs specifıc to theNB (mean: 6; range 0-18) or specifıc
to ctDNA (mean:22; range 9-69)were observed, suggesting spatial heterogeneity
with different ctDNA amounts released by different clones. In PR or CR ctDNA
samples, lower numbers of SNVs with lower MAFs were detected (mean: 11,
range 0-12). Interestingly, PD ctDNA samples harboured an increase in MAFs
and a higher numbers of SNVs, with additional relapse-specifıc SNVs (mean: 22;
range 0-55) targeting, amongst others, the protein kinase A signaling pathway.
Analysis of additional ctDNA samples obtained between diagnosis and relapse
(2-6 samples/patient) using deep sequencing techniques demonstrated a disap-
pearance of SNVs coinciding with response to therapy, and re-appearance of
SNVs at the time of tumor progression. Discussion and Conclusion: CtDNA
WES proves to be an extremely powerful tool to study spatial and temporal
heterogeneity in NB, providing further proof of the importance of clonal evolu-
tion in NB progression. Full characterization of ctDNA, which might represent
more aggressive clones, might orient targeted treatment approaches.
#4953 Single cell signaling analysis reveals circulating tumor cell markers
of drug susceptibility and tumor heterogeneity. N. Murat Karabacak, Yu
Zheng, Erin Emmons, Michael Koulopoulos, Daniel A. Haber, Mehmet Toner,
Shyamala Maheswaran.MGH, Charlestown, MA.
Complexity of cancer requires advancements of tools for intervention and diag-
nostics. Rare circulating tumor cells (CTCs) from patient blood could be used for
real-time monitoring of solid cancer. We recently developed a microfluidic device,
theCTC-iChip,whichenricheswell-preservedCTCs insolutionthroughremovalof
the cellular components (red and white blood cells) and platelets of whole blood.
Protein expression analysis in CTCs has been limited to immunofluorescent stain-
ing for a fewwell-characterized tumormarkers (includingEpCAM,HER2,PSAand
Keratins) due to the limitations inherent to immunofluorescence labels and their
precise resolution through microscopy. The scarcity of cells precludes large-scale
proteomic analysis such as mass spectrometry of CTCs to effectively evaluate
changes in total as well as phospho-proteins, which serve as excellent surrogate
markers to monitor in real time the rapid alterations in signaling pathways within
cells. This approach would be particularly important since the PI3K, mTOR, Akt,
MAPK signaling pathways are aberrantly activated inmany cancers and are prom-
ising therapeutic targets. In this work, we applied inductively-coupled plasmamass
spectrometry (ICP-MS)measurementofcells (masscytometry) thatcanmeasureup
to40proteins inmillions of single cells due to quantitative, non-overlappingmass
signals acquired from antibodies taggedwith purifıed lanthanides. Sample prepara-
tion formass cytometrywasmodifıed tominimize the loss of cells using ourmicro-
fluidic platform in lieu ofwashing via centrifugation.Mass cytometry allowed iden-
tifıcation of tumor cells simultaneous analysis of markers that are associated with
proliferation, responseor resistance topathway inhibitiondue toadministered ther-
apeutic agent.We quantifıed the expression of twelve phospho-proteins tomonitor
changes multiple signaling nodes within single tumor cells. This approach allowed
assay and compare the target proteome within single CTCs as well as individual
tumor cells derived fromprimary andmetastatic tumors.We found that some pro-
tein levels of CTCs represent primary tumor protein levels well. When targeted
therapeutic was administered two of these epitopes were found to be signifıcantly
changed in both CTCs and primary tumor cells.We also found a portion of cancer
cells in primary tumor were more susceptible to the targeted therapeutic than the
rest of the tumor, showing a heterogeneity in response within the tumor. Overall,
single cell multiplexed molecular analysis revealed tumor molecular heterogeneity
and circulatingmarkers of drug susceptibility.
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#4954 Clinical validation of a cell-free DNA liquid biopsy approach for
non-invasive molecular profıling.Monica Nesselbush, Samuel Angiuoli, Luis
A. Diaz, Andrew Georgiadis, Shannon Glynn, Siân Jones, Laurel Keefer, Peter
LoVerso, Derek Murphy, Sonya Parpart-Li, David Riley, Naomi Sengamalay,
Manish Shukla, John Simmons, Snehal Talati, Rebecca Steinberg, Laura Tucker,
Victor E. Velculescu, Ellen Verner, Angela Villarta, Mark Sausen. Personal Ge-
nome Diagnostics, Baltimore, MD.
Clinical molecular profıling of advanced cancers enables the identifıcation of
actionable genomic alterations to guide therapeutic decisions. Although profıl-
ing of tissue samples is considered the gold standard, specimensmay be unavail-
able or unsuitable for testing due to limited tumor purity or specimen quality.
Further, genetically informed treatment decisions are increasingly necessary
after disease progression and re-biopsy in this setting may not be feasible. Cir-
culating tumor DNA (ctDNA) approaches for identifıcation of genetic altera-
tions in cancer patients may be more informative as the alterations reflect the
current status of the tumor. ctDNA is representative of multiple tumor sites
within a patient and may aid in the detection of alterations throughout the
course of therapy. However, the fraction of ctDNA obtained from a blood sam-
ple is often very low (1.0%) anddiffıcult to detect. Additionally,manymethods
to evaluate ctDNA interrogate single hotspot or a few mutations. The next gen-
eration of ctDNA assays must identify clinically actionable genetic alterations
and novel biomarkers with high precision and accuracy. To address these issues,
we have developed and validated PlasmaSelect64, a ctDNA approach to com-
prehensively detect genetic alterations at low allele frequencies in the circulation
of cancer patients. Utilizing digital genomic approaches, we demonstrated ro-
bust sensitivity and specifıcity in our CLIA laboratory in 64 well-established
cancer genes that were identifıed based on clinical actionability. In addition to
the evaluation of exons in 58 genes that are frequently mutated in cancer for
sequence mutations, we performed a comprehensive genomic analysis of trans-
locations in 18 genes and copy number analyses in 19 genes. We have also
developed a novel approach for identifıcation of microsatellite instability (MSI)
using these error correction methodologies. To evaluate the PlasmaSelect64 ap-
proach, we developed and optimized the pre-analytical conditions for sample
collection and processing with K2EDTA and Streck blood collection tubes. An-
alytical validation studies were performed with clinical samples and contrived
cell-line mixtures containing known alterations determined by orthogonal
methods. We robustly identifıed sequence mutations at 0.50% mutant allele
frequency (MAF) with a limit of detection of 0.05% MAF, corresponding to a
per-base specifıcity of 99.9997% and a sensitivity of 99.4%. For detection of focal
amplifıcations and translocations, analytical method validation studies demon-
strated sensitivity of 97.2% and 94.4% and specifıcity of99% atMAFs of20%
and 0.50%, respectively. PlasmaSelect64 provides a non-invasive platform to
enable detection of clinically relevant genetic alterations across a large number
of genomic regions to aid in the therapeutic management of cancer patients.
#4955 PD-L1 expression on circulating epithelial tumor cells (CETCs)
correlateswith thepresenceofmetastasis inbreast cancerpatients anddiffers
from PD-L2 expression. Monika Pizon, Dorothea Schott, Ulrich Pachmann,
Katharina Pachmann. Transfusion Center Bayreuth, Bayreuth, Germany.
Background: Strategies to improve the effıcacy of the immune system against
malignant tumors represent a major innovation focusing on the programmed cell
death-1 receptor (PD-1), with its two ligands PD-L1 and PD-L2. The expression of
PD-L1has been evaluated in a number of different tumor types and can be used as a
predictive biomarker for PD-1/PD-L1 checkpoint inhibitor treatment response.
PD-L2 has not received asmuch attention and its role inmodulating tumor immu-
nity is less clear. We used a non-invasive, real-time liquid biopsy to better charac-
terize PD-L1/-L2 expression on circulating epithelial tumor cells (CETCs) in breast
cancer patients. Methods: CETCs were determined from blood of 72 patients suf-
fering frombreast cancer.ThenumberofvitalCETCsandtheir expressionofPD-L1
and PD-L2 were investigated using the maintrac® method. Results: PD-L1 express-
ing CETCs were detected in 94.5 % of breast cancer patients whereas only 82%
patients had PD-L2 positive CETCs. Breast cancer patients with metastatic disease
had signifıcantlymore PD-L1 positive CETCs as compared to patients withoutme-
tastasis (median75%vs. 61.1%;p0.05).The fractionofPD-L1positiveCETCswas
signifıcantly higher than the fraction of PD-L2 positive CETCs (54.6% vs. 28.7%;
p0.001). Moreover, we observed a signifıcant heterogeneity in PD-L1 and PD-L2
immunostaining intensityacrossCETCs fromthesamepatients.Conclusion:Breast
cancer patients have detectable CETCs with a high frequency of PD-L1 which cor-
relates with progression of cancer disease. PD-L1 seems to be a major factor in
immune evasion andmaybe apromising target of anticancer therapies.Monitoring
the frequencyofPD-L1positiveCETCscould reflect individualpatient’s response to
an anti-PD-1/PD-L1 therapy.
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#4956 Transcriptome-wide association study identifıes new prostate can-
cer susceptibility genes in the OncoArray data. Nicholas Mancuso,1 Wei
Zheng,2 Kathryn Penney,3 The PRACTICAL Consortium, Zsofıa Kote-Jarai,4
Christopher Haiman,5 Simon Gayther,6 Matthew Freedman,7 Bogdan Pasa-
niuc1. 1Geffen School of Medicine, University of California, Los Angeles, Los An-
geles, CA; 2Division of Epidemiology, Department of Medicine, Vanderbilt Epide-
miology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School
of Medicine, Nashville, TN; 3Department of Epidemiology, Harvard T.H. Chan
School of Public Health, Boston, Massachusetts. Channing Division of Network
Medicine, Department of Medicine, Brigham and Women’s Hospital/Harvard
Medical School, Boston, MA; 4Division of Genetics and Epidemiology, The Insti-
tute of Cancer Research & Royal Marsden NHS Foundation Trust, London,
United Kingdom; 5Department of Preventive Medicine, Norris Comprehensive
Cancer Center, Keck School of Medicine, University of Southern California, Los
Angeles, CA; 6The Center for Bioinformatics and Functional Genomics, Cedars-
SinaiMedical Center, Los Angeles, CA; 7Department ofMedical Oncology, Dana-
Farber Cancer Institute and Harvard Medical School, Boston, MA.
Genome-wide association studies (GWAS) have identifıed over 150 genomic
regions harboring risk variants for prostate cancer which explain one third of all
familial risk. However, with some notable exceptions, the causal variants and
target susceptibility genes at these risk loci have yet to be identifıed. Recent work
has shown a strong overlap between loci associated with gene expression levels
(eQTLs) in prostate tissue andGWAS loci, which suggests that the causal mech-
anism at a signifıcant proportion of risk loci includes causal alleles that regulate
expression levels of nearby susceptibility genes. While overlapping eQTLs with
GWAS is a powerful method to prioritize susceptibility genes, it is often the case
that multiple eQTLs co-localize at the GWAS risk region (due to linkage dis-
equilibrium (LD) and correlations across transcript levels). This prohibits the
identifıcation of the true susceptibility gene as opposed to spurious co-localiza-
tion at the same locus. We recently leveraged gene expression imputation to
perform transcriptome-wide association studies (TWAS) as a principled ap-
proach to measure the strength of association between gene expression and
disease status. Here, we use imputed expression to identify new susceptibility
genes for prostate cancer in the OncoArray GWAS data. We integrate gene
expression data from more than 44 tissues across 4,000 individuals with
GWAS of prostate cancer from the OncoArray in 140,000 individuals. Our
approach identifıed 118 susceptibility genes for prostate cancer that reside in 90
independent loci across the genome. Of these, we report 7 genes located more
than 0.5 Megabases away from any previously reported GWAS loci for prostate
cancer, thus providing new risk loci. Second, we use TWAS to investigate genes
previously reported as susceptibility genes for prostate cancer through overlaps
of eQTL and GWAS. We fınd 36 (out of 86 previously reported genes) to be
signifıcant in TWAS. Overall, our fındings highlight the power of integrating
gene expression data with GWAS and provide testable hypotheses for future
functional validation of prostate cancer risk.
#4957 Gene expression signature of Gleason score is associated with pros-
tate cancer outcomes in a radical prostatectomy cohort.MinA Jhun,1Milan S.
Geybels,2 Jonathan L. Wright,3 Suzanne Kolb,1 Craig April,4 Marina Bibikova,4
Elaine A. Ostrander,5 Jian-Bing Fan,4 Ziding Feng,6 Janet L. Stanford1. 1Fred
Hutchinson Cancer Research Center, Seattle,WA; 2Maastricht University, Maas-
tricht, Netherlands; 3University of Washington School of Medicine, Seattle, WA;
4Illumina, Inc., San Diego, CA; 5National Human Genome Research Institute,
National Institutes of Health, Bethesda, MD; 6University of Texas MD Anderson
Cancer Center, Houston, TX.
Background: Prostate cancer (PCa) is a leading cause of cancer-related mor-
tality worldwide. Many men treated for clinically localized PCa will be cured,
however, 20 to 30% of men will relapse and some will experience metastatic-
lethal (ML) progression. Gleason score (GS) is one of the best predictors of PCa
aggressiveness, but additional tumor biomarkers may improve its prognostic
accuracy.Wedeveloped a gene expression signature ofGS to enhance prediction
of PCa outcomes. Methods: Elastic Net regularization was used to construct a
gene expression signature by contrasting tumors with GS 8-10 (high) vs. 6
(low) in The Cancer Genome Atlas (TCGA). Tumor tissue samples obtained at
radical prostatectomy for a Fred Hutchinson (FH) patient cohort of men with
localized PCa were used to generate genome-wide gene expression data. The
gene expression signature was then evaluated for its ability to predict recurrence
and ML progression in the FH patient cohort (N503; NRecurrence106; NML
progression27; mean follow-up for recurrence8 years). Results: The expression
signature includes transcripts representing 49 genes. In the FH cohort, the sig-
nature was associated with recurrence and ML progression with hazard ratios
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(HRs) for a 25% increase in the signature of 1.51 (95% CI: 1.24-1.82;
P2.710-5) and 2.41 (95% CI: 1.51-3.85; P0.0002), respectively. Among pa-
tients with GS 7 tumors, the signature was also signifıcantly associated with PCa
recurrence (HR1.38, 95% CI: 1.09-1.76; P0.008) and ML progression
(HR2.42, 95% CI: 1.30-4.52; P0.006). The signature’s area under the curve
(AUC) for predicting recurrence andML progression was 0.68 and 0.76, respec-
tively. Compared to a model with pathological stage and GS only, the gene
expression signature signifıcantly improved theAUC for overall recurrence (3%,
P0.0003) and ML progression (7%, P0.0004), particularly among patients
with GS 7 tumors (recurrence: 5%, P0.01; ML progression: 13%, P0.009).
Higher levels of the signature were associatedwith increased expression of genes
in cell cycle-related pathways including G2M checkpoint, epithelial mesenchy-
mal transition, and E2F targets pathways, and decreased expression of genes in
several pathways including androgen response, estrogen response, oxidative
phosphorylation, and apoptosis. Conclusion: The gene expression signature
based on GS may improve the prediction of overall recurrence as well as ML
progression in PCa patients after radical prostatectomy, in particular among
men with GS 7 tumors.
#4958 Pre-diagnostic peripheral bloodDNAmethylation and lung cancer
survival. Jennifer A. Doherty,1 Xuan Zhang,2 Devin C. Koestler,2 Matt J. Bar-
nett,3 Mark D. Thornquist,3 Gary E. Goodman,3 Carmen J. Marsit4. 1Huntsman
Cancer Institute, Salt Lake City, UT; 2Kansas University Medical Center, Kansas
City, MO; 3Fred Hutchinson Cancer Research Center, Seattle, WA; 4Emory Uni-
versity, Atlanta, GA.
Epigenetic regulation plays a critical role in cell and tissue development and
differentiation, is a known mechanism of carcinogenesis, and is altered by var-
ious exposures including cigarette smoking and age. Peripheral blood methyl-
ation represents a combination of these factors as well as blood cell type distri-
butions that reflect underlying immunophenotypes. Hematopoiesis is
programmed through epigenetic changes, and blood cell type-specifıc methyl-
ation markers can be leveraged to “fıngerprint” cell type distributions. We ex-
amined associations between pre-diagnostic methylation markers in peripheral
blood with overall lung cancer survival in very heavy smokers from the Beta
Carotene and Retinol Effıcacy Trial (CARET). CARET was a randomized, dou-
ble-blinded, placebo-controlled chemoprevention trial of daily -carotene and
retinyl palmitate in smokers with20 pack-years, and smokers who were occu-
pationally exposed to asbestos.Methylationwas successfullymeasured using the
Illumina 850K EPIC BeadArray on average 5 years prior to diagnosis for 331
lung cancer cases, of whom 253 died during follow up (median survival 329
days). Cox proportional hazards regression models were used to examine the
relationship between CpG-specifıc methylation and survival. Models were ad-
justed for age at blood draw, sex, race, enrollment year, placebo/active interven-
tion, asbestos exposure, current/former smoking and time since quit, pack years,
average number of cigarettes per day and histologic type, and were fıt separately
depending on the time between blood draw and lung cancer diagnosis: 0-3 years
(n  107), 3-5 years (n  77), and 5 years (n  147). After adjusting for
multiple comparisons by computing the false discovery rate (FDR) q-value,
there were 1,028, 296, and 4 CpGs that were statistically signifıcantly associated
with survival (q0.010) for samples collected 0-3 years, 3-5 years, and 5 years
before diagnosis, respectively. After controlling for blood cell type distributions,
much larger numbers of CpGs were statistically signifıcantly associated with
survival: 10,481, 456, and 257, respectively. The top canonical pathways of CpGs
identifıed in samples drawn 0-3 years prior to diagnosis included PTEN signal-
ing (p  1.1E-5) and PI3K signaling in B lymphoctyes (p  3.7E-5). We ob-
served that the number of methylated CpGs in peripheral blood that are associ-
ated with subsequent survival increases dramatically when measured closer to
lung cancer diagnosis. As well, we observed that the number of methylated
markers is increased by controlling for immunophenotype. Our study provides
evidence that peripheral bloodmethylationmarkersmeasuredmany years prior
to diagnosis may be associated with poor lung cancer survival, and that increas-
ing changes in methylation over time may also be associated. This points to the
critical role of the immune system, even prior to diagnosis, in influencing cancer
outcomes.
#4959 The RANK-axis and breast cancer risk by hormone receptor sub-
type: Results from the EPIC cohort. Danja Sarink, Helena Schock, Theron
Johnson, EPIC cohort collaborators, Rudolf Kaaks, Renée T. Fortner. German
Cancer Research Ctr., Heidelberg, Germany.
Background: Activation of the receptor activator of nuclear factor kappa-B
(RANK)-axis promotesmammary tumor development in experimentalmodels.
Circulating concentrations of soluble RANK ligand (sRANKL) may influence
breast cancer risk via RANK activation; this may be modulated by circulating
concentrations of osteoprotegerin (OPG), the decoy receptor forRANKL. sRANKL
andbreast cancer risk inhumanshavenot previously been investigated.Methods:A
case-control study was nested in the European Prospective Investigation into Can-
cerandNutrition(EPIC)cohort.Atotalof1976 incident invasivebreast cancercases
(estrogenreceptorpositive (ER),n1598),matched1:1 tocontrols,were included
in the analysis. Women were both pre- and postmenopausal at blood collection.
Serum sRANKL was quantifıed using an enzyme-linked immunosorbent assay
(ELISA). SerumOPGwasquantifıedusinganelectrochemiluminescent assay.Odds
ratios (ORs) and 95% confıdence intervals (95%CIs) were calculated using condi-
tional logistic regression. Results: Associations between sRANKL and breast cancer
riskdifferedby tumorhormone receptor status (phet 0.05).Higher concentrationsof
sRANKL were suggestively associated with risk of ER breast cancer (top vs. bot-
tom quintile OR 1.36 [0.99-1.87]; ptrend 0.31). While results considering the
sRANKL/OPG ratiowere similar to those for sRANKL alone for hormone receptor
positive breast cancer, we saw a suggestive inverse association between the ratio and
ER-PR- disease (5th vs. 1st quintile OR 0.60 [0.31-1.16]; ptrend 0.04). Conclusions:
This study provides the fırst prospective data on sRANKL and breast cancer risk,
providing suggestive evidence of a possible association between sRANKL concen-
trations and breast cancer. High circulating levels sRANKL in the context of low
OPGmay representnovel riskmarkers forhormone receptorpositive breast cancer.
Table 1. Circulating concentrations of sRANKL and breast cancer risk by
hormone-receptor subtype: EPIC nested case-control study
Quintiles
1 2 3 4 5 ptrend* phet*
sRANKL
ER/PR
Cases/Controls 167/198 203/183 176/192 160/157 214/190
OR (95% CI) ref. 1.32
(0.97-1.81)
1.12
(0.81-1.54)
1.19
(0.85-1.65)
1.36
(0.99-1.87)
0.31 0.05
ER-/PR-
Cases/Controls 52/51 57/40 47/53 49/56 46/51
OR (95% CI) ref. 1.58
(0.82-3.04)
0.97
(0.51-1.84)
0.83
(0.44-1.58)
0.74
(0.39-1.40)
0.08
sRANKL/OPG Ratio
ER/PR
Cases/Controls 146/177 175/181 186/178 184/180 224/199
OR (95% CI) ref. 1.19
(0.85-1.65)
1.25
(0.90-1.75)
1.22
(0.87-1.70)
1.42
(1.01-1.98)
0.22 0.02
ER-/PR-
Cases/Controls 45/41 46/42 53/47 60/60 46/60
OR (95% CI) ref. 1.11
(0.56-2.17)
1.09
(0.57-2.09)
0.87
(0.45-1.68)
0.60
(0.31-1.16)
0.04
* based on continuous log2-transformed values; Conditional logistic regression models
adjusted for: ages at menarche (12, 13, 14,15, missing), menopause (44, 44-47, 48-50,
51-52, 53-54, 55, missing), and fırst full-term pregnancy (no FTP, 25, 25-30, 30,
missing), and number of full-term pregnancies (0, 1, 2, 3, missing) and BMI (kg/m2,
continuous)
#4960 Recent ultraviolet radiation exposure and circulating immunosup-
pressive T-regulatory cells. Dana E. Rollison,1 Shalaka S. Hampras,1 Jane L.
Messina,1 Neil A. Fenske,2 Basil S. Cherpelis,2Michael J. Schell,1 Rhianna Reed,1
Juliana Balliu,1 Rebecca Hesterberg,1 Afua A. Akuffo,1 Pearlie K. Burnette1.
1Moffıtt Cancer Center, Tampa, FL; 2University of South Florida, Tampa, FL.
Background: Ultraviolet radiation exposure (UVR) is a risk factor for several
different cancer types.While the mutagenicity of UVR is well-documented, UVR’s
effects on human systemic immune function are not well understood. Several lines
of evidence suggest that UVR may have immunosuppressive effects, however, no
epidemiologic studies have investigated the association between quantitative mea-
sures of UVR and a biomarker of immune function. Objective: To evaluate the
association between UVR and systemic immune function, we conducted a cross-
sectional analysis of recentUVRandcirculating regulatoryT- cells (“Tregs”) among
acohortof skincancer screeningpatients.Methods:350patientsundergoingregular
skin cancer screenings with no prevalent skin cancer at the time of enrollment were
recruited from the University of South Florida Dermatology clinic. At the baseline
visit, blood was obtained, and a spectrophotometer was used to measure skin pig-
mentation at a sun-unexposed site (the axilla) and two sun-exposed sites: the fore-
headand theupper forearm.Recent sunexposurewasquantifıed as thedifference in
readings between the sun-exposed and sun-unexposed sites. Using flow cytometry
assays, lymphocyte samples were examined for Tregs (CD4CD25
CD127lowFoxp3), and proportions of Tregs with enhanced immunosuppressive
function (CD27-, CD45RA- Treg) and skin tissue affınity (CLA, CCR4high) were
EPIDEMIOLOGY: Molecular and Genetic Epidemiology
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1269
determined. Associations between UVR exposure and Tregs were described using
Spearman correlation coeffıcients. Linear regression using log-transformed values
ofUVR andTregswas used to adjust for age and sex. Results: Among all 350 partic-
ipants, UVRwas positively correlated with circulating immunosuppressive CD27-,
CD45RA- Tregs (r0.127, p0.020 for UVR measured at the forehead and
r0.197, p0.0002 for UVRmeasured at the forearm). UVRmeasured at the fore-
arm was also positively correlated with skin-homing Tregs expressing CLA
(r0.167, p0.002) and CCR4 (r0.19, p0.0004). When participants were cate-
gorized into light versus dark constitutive pigmentation based on themedian value
of spectrophotometer readings for the sun-unexposed axilla, the correlation be-
tweenUVRaveraged across the forehead and forearmwasmore strongly correlated
with immunosuppressiveTregs among lighter-skin participants (r0.30, p0.001)
thandarker-skin participants (r0.065, p0.400). Conclusion: RecentUVR is pos-
itively associated with increased levels of circulating immunosuppressive Tregs, in-
cluding Tregs with skin tissue affınity, with the association being stronger among
naturally lighter-skinned individuals. UVR-associated immunosuppressive effects
among otherwise immunocompetent individuals may play a role in skin cancer
carcinogenesis.
#4961 The oral microbiome and prospective risk for esophageal cancer: a
population-based nested case-control study. Brandilyn A. Peters,1 Jing Wu,1
Zhiheng Pei,1 Liying Yang,1 Mark P. Purdue,2 Neal D. Freedman,2 Eric J. Ja-
cobs,3 SusanM. Gapstur,3 Richard B. Hayes,1 Jiyoung Ahn1. 1New York Univer-
sity School ofMedicine,NewYork,NY; 2National Cancer Institute, Rockville,MD;
3American Cancer Society, Atlanta, GA.
Background: The two most common types of esophageal cancer, esophageal
adenocarcinoma (EAC) and squamous cell carcinoma (ESCC), are highly fatal.
The human microbiota have been suggested to play a role in esophageal cancer
etiology, although the evidence is limited to small, cross-sectional studies. We
hypothesized that the oral microbiota, which shape the esophageal microbiota,
may be causative agents in esophageal carcinogenesis. Methods: We conducted
a prospective study nested in two large U.S. cohorts: ACS CPS-II and NCI-
PLCO. Oral bacteria were assessed in pre-diagnostic mouth-wash samples col-
lected from cases and controls (n81/160 EAC and n25/50 ESCC cases/
matched controls), using 16S rRNA gene sequencing. We compared overall
microbial composition between cases and controls using permutational multi-
variate analysis of variance (PERMANOVA) of UniFrac distances, and we ex-
amined associations between centered log-ratio transformed taxon abundances
and cancer risk using conditional logistic regression. Metagenome functional
content was predicted from taxonomic composition using PiCRUST. Results:
Overall microbial composition did not differ between EAC cases and matched
controls or ESCC cases and matched controls, adjusting for matching factors
(age, sex, race, cohort, time to diagnosis/selection), BMI, smoking, and alcohol
intake (all p0.40). The periodontal pathogens Tannerella forsythia and Por-
phyromonas gingivalis were nominally associated with increased risk for EAC
(OR [95%CI] 1.21 [1.01, 1.46], p0.04) and ESCC (OR [95%CI] 1.3 [0.96,
1.77], p0.09), respectively. Conversely, genus Neisseria, previously shown to
be depleted by cigarette smoking, was associated with protection against EAC
(OR [95% CI]  0.88 [0.8, 0.97], p0.01). Other species associated with EAC
risk (p0.05) included Corynebacterium durum, Prevotella nanceiensis, and
Streptococcus pneumoniae (inversely associated with EAC), and Actinomyces
cardiffensis, Selenomonas oral taxon 134, and Veillonella oral taxon 917 (posi-
tively associated with EAC). Other species associated with ESCC risk (p0.05)
included Aggregatibacter paraphrophilus (inversely associated with ESCC) and
Prevotella nanceiensis, Bergeyella oral taxon 322, and Neisseria weaveri (posi-
tively associated with ESCC). Analysis of inferred metagenomes revealed that
bacterial carotenoid biosynthesis was associated with protection against EAC
(OR [95% CI]  0.84 [0.7, 1.0], p0.05). Conclusions: Our fındings from this
prospective study suggest that specifıc bacterial pathogensmay play a causal role
in esophageal cancer, whilemembers of the healthy oral microbiotamay protect
against carcinogenesis. Unique microbial profıles may contribute to each of the
distinct esophageal cancer types, EAC andESCC.Oralmicrobiotamanipulation
may be a future strategy for preventing this highly fatal disease.
#4962 Geographic disparities in prevalence of baseline prostate inflam-
mation and prostate cancer risk: results from amultinational trial. EmmaH.
Allott,1 Sarah Markt,2 Lauren E. Howard,3 Adriana C. Vidal,4 Daniel M.
Moreira,5 Ramiro Castro-Santamaria,6 Gerald L. Andriole,7 Lorelei A. Mucci,8
Stephen J. Freedland9. 1University of North Carolina at Chapel Hill, Chapel Hill,
NC; 2Harvard University, Boston, MA; 3Duke University, Durham, NC; 4Cedars
SinaiMedical Center, Los Angeles, CA; 5University of Illinois at Chicago, Chicago,
IL; 6GlaxoSmithKline, King of Prussia, PA; 7Washington University, St. Louis,
MO; 8Harvard University, MA; 9Cedars Sinai Medical Center, CA.
Introduction: Prostate cancer incidence rates vary 25-fold worldwide. The
distribution of lifestyle factors also varies by geographic region and these factors
may impact prostate inflammation, which is inversely associated with prostate
cancer risk in the REduction by DUtasteride of prostate Cancer Events (RE-
DUCE) trial. Herein, we examined geographic differences in the prevalence of
histological prostate inflammation and geographic differences in prostate can-
cer risk using REDUCE, a multinational trial of men with a negative baseline
prostate biopsy. Methods: We conducted a retrospective analysis of data from
7,213 men with a negative baseline prostate biopsy in REDUCE from Europe
(n4,802), North America (n1,796), South America (n467), and Australia/
New Zealand (n148). Histological inflammation was classifıed as chronic
(lymphocytes,macrophages) or acute (neutrophils) by central reviewof negative
baseline prostate biopsies. Logistic regression was used to calculate odds ratios
(OR) and 95% confıdence intervals (95% CI) for associations between geo-
graphic region and prostate inflammation, and between geographic region and
prostate cancer risk at trial-mandated repeat biopsy, adjusting for potential con-
founders. To avoid confounding by race, analyses were restricted to white men.
Results: Chronic and acute prostate inflammation was detected in 77% and 15%
of men, respectively. Relative to Europeans, North Americans and Australians/
New Zealanders were more likely to have acute prostate inflammation in the
negative biopsy (OR 1.74; 95% CI 1.48-2.05 and OR 2.04; 95% CI 1.38-3.02,
respectively), while SouthAmericanswere less likely to have acute inflammation
(OR 0.42; 95% CI 0.28-0.61). Among North Americans, Canadians were more
likely to have acute prostate inflammation thanmen from theUnited States (OR
1.40; 95% CI 1.07-1.83). Among Europeans, the prevalence of acute inflamma-
tion was lower in Northern, Southern and Eastern Europe, relative to Western
Europe (OR0.79; 95%CI 0.65-0.97,OR0.84; 95%CI 0.66-1.07 andOR0.62; 95%
CI 0.45-0.87, respectively), with similar results for chronic inflammation. Re-
gionswith higher prevalence of prostate inflammationhad lower prostate cancer
risk at 2-year biopsy, including North America (OR 0.87; 95%CI 0.71-1.07) and
Australia/New Zealand (OR 0.48; 95% CI 0.24-0.95), relative to Europe. Con-
versely, regions with lower prevalence of prostate inflammation had higher
prostate cancer risk at 2-year biopsy, including Northern and Eastern Europe
(OR1.30; 95%CI 1.05-1.62 andOR1.74; 95%CI 1.29-2.35, respectively), relative
to Western Europe. Conclusions: Geographic disparities in the prevalence of
prostate inflammation is a potential biologic mechanism contributing to global
differences in prostate cancer incidence rates.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Novel
Approaches for Experimental Therapeutics
#4963 Novel hexavalent GITR agonists stimulate T cells and enhance
memory formation.Meinolf Thiemann, ChristianGieffers, DavidM. Richards,
Christian Merz, Karl Heinonen, Mauricio Redondo Mueller, Viola Marschall,
Jaromir Sykora, Harald Fricke, Oliver Hill. Apogenix AG, Heidelberg, Germany.
Introduction: The co-stimulatory receptor GITR plays an important role in ini-
tiating the immune response in the lymph nodes and in maintaining the immune
response in the tumor tissue. Binding of GITR to its natural ligand directly leads to
increased anti-tumorTcell activation and their survival. It also reduces the suppres-
sive abilities of Treg cells, further increasing the anti-tumor immune response. The
HERA-technology developed by Apogenix targets the TNF-receptor superfamily
and generates fully human hexavalent fusion proteins with high clustering capacity
for the cognate receptor.HexavalentHERA-ligands are pure agonistswhose signal-
ing capacity is independent of secondary Fc-receptor crosslinking.Herewe report
in vitro and in vivoproperties of novel hexavalentHERA-GITRLconstructs. Exper-
imentalprocedures: For theassessmentof invivo stability, serumsamples fromaPK
studywith threeHERA-GITRL constructs inCD1-micewere analyzedwith respect
to theirdrug levels employingaspecifıcELISAassay.For functional characterization
of HERA-GITRL in vitro, immune cells were isolated from healthy-donor blood
samples and profıled by multicolor flow cytometry (MC-FC). Subsequently, im-
mune cells were cultured in growthmedia containing differentHERA-GITRL con-
structs and anti-CD3. Changes in activation and memory markers on T cells (e.g.
CD25, CD69, CD45RA, CD45RO), their proliferation rate (CFSE assay) and the
intracellular staining of cytokines (e.g. TNF- and IFN-) was assessed byMC-FC.
Results: Minor modifıcations led to three HERA-GITRL drug candidates with
unique pharmacokinetic properties / in vivo stability as explored inmice. Terminal
half-lifewasbetween61.7 and200.6hours. StimulationofpanTcells aswell asnaïve
CD4 T-lymphocytes by anti-CD3 was further augmented by HERA-GITRL as
demonstrated by CD69 and CD25 expression. This effect was accompanied by an
increased proliferation and an increased memory formation. Furthermore, we ob-
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served an increased level of intracellular TNF- and IFN- in naïve CD4 T-lym-
phocytes incubated with anti-CD3 that could be further raised by the addition of
HERA-GITRL. Conclusion: HERA-GITRL demonstrate excellent in vivo stability.
Their ability to enhance proliferation and activation of naïve CD4 T cells and to
induce memory formation render them as attractive candidates for immunothera-
peutic treatments of cancer.
#4964 Structure, in vitro biology and in vivo pharmacodynamic charac-
terization of a novel clinical IDO1 inhibitor. John T. Hunt, Aaron Balog,
Christine Huang, Tai-An Lin, Tai-An Lin, DerrickMaley, Johnni Gullo-Brown,
Jesse Swanson, Jennifer Brown. Bristol-Myers Squibb Co., Princeton, NJ.
The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the degradation
of tryptophan along the kynurenine pathway, and is frequently expressed in
human malignancies. The activity of IDO1 induces an immunosuppressive mi-
croenvironment in tissues by inhibiting T-cell function through local depletion
of tryptophan and through generation of kynurenine pathway metabolites. In-
hibition of IDO1 is expected to diminish the immunosuppressive tumor mi-
croenvironment and improve cancer patient outcomes, particularly when used
in combination with cancer immunotherapy agents such as nivolumab and ip-
ilimumab. In this presentation, we will disclose the chemical structure, enzyme
inhibitory mechanism, in vitro potency and in vivo pharmacodynamic (PD)
activity of BMS’ IDO1 inhibitor currently in Phase I clinical trials. The com-
pound is a potent and selective IDO1 inhibitor with no activity against another
tryptophan degrading enzyme, tryptophan 2,3-dioxygenase (TDO). It exhibited
potent cellular activity, suppressing kynurenine production in HEK293 cells
overexpressing human IDO1 (IC50 1.1 nM) and inHeLa cells stimulated with
IFN (IC50 1.7 nM). The compound also potently restoredT-cell proliferation
in a co-culture of T cells and human cancer cells and in a mixed lymphocyte
reaction where T cells were co-cultured with allogeneic IDO1-expressing den-
dritic cells (EC50  1.2 nM). In vivo, when given once a day orally, the com-
pound exhibited signifıcant PD activity inmouse tumors grown subcutaneously
in syngeneic hosts and in human tumors grown as xenografts in nude mice.
#4965 Sustained tumor regressions and signifıcant improvements in ther-
apeutic index for a lead monomethyl auristatin E nanoparticle-drug conju-
gate, CRLX701, with the potential for improved anticancer effects. Liang
Zhao, Roy I. Case, Donna Brown, Lata Jayaraman, Doug Lazarus, Christian
Peters, Derek Van Der Poll, Ellen Rohde, Scott Eliasof, Chester A. Metcalf.
Cerulean Pharma, Waltham, MA.
Cerulean Pharma Inc. creates nanoparticle-drug conjugates (NDCs) designed to
signifıcantlymitigate a payload’s limitations byproviding sustaineddrugdelivery to
the tumor and superior therapeutic index through controlled release kinetics. By
conjugating drug payloads to our novel -cyclodextrin-PEG (CDP) copolymer
through linker strategies that allow modulation of release and pharmacokinetics
(PK), we provide advantages over entrapped nanoparticle strategies, e.g., polymeric
nanoparticles and liposomes. Cerulean has two NDCs in the clinic, CRLX101 and
CRLX301, evidencing the translatability of our technology. CRLX101 has been
dosed inover 400patients andCRLX301 is in anongoingPhase 1/2a trial.Akey and
differentiating feature of our NDC platform is our linker technology, which is tai-
lored for an optimal fıt with the active pharmaceutical ingredient (API) conjugation
functionality of the drug payloads we incorporate into NDCs and customizable to
achieve desired drug release profıles. This linker technology works for most conju-
gatable APIs that can be linked through alcohol, carboxylic acid, amine, amide and
urea functionality to our CDP polymer. To illustrate the capabilities of our NDC
platformwewill present thebiological impact of a series ofmonomethyl auristatinE
(MMAE)-containing NDCs.MMAE belongs to the dolastatin family of natural cy-
totoxicpseudopeptides, demonstratingpotentdisruptionof tubulinpolymerization
and excellent in vitro anti-cancer properties. However, because of its toxicity
MMAEcannot be used as a drug on its own.Our novel linkers provided the synthe-
sized MMAE NDCs with sustained and controlled release kinetics, targeting low
release rates (0.4-13%) tominimize toxicityof theMMAEdrugpayload. Subsequent
PKstudies revealed that ouroptimizedNDC,CRLX701, demonstrateda superior in
vivo release profıle compared to our other testedMMAENDCs, with high released
drug tumor levels (31% of total drug in tumor) and low released drug plasma levels
(0.16% of total drug in plasma). CRLX701 demonstrated greater tolerability com-
pared toMMAEwith an 8-fold increase inmousemaximum tolerated dose (MTD)
for the NDC. At this MTD, CRLX701 was projected to have a 4-fold increase in
released drug tumor levels over MMAE. Indeed, this improved tumor PK for
CRLX701 translated into improved effıcacy in a human prostate DU-145 xenograft
model, in which sustained tumor regressions (6 of 8 cures) were observed for
CRLX701 (4mpk, qwx2) compared to reduced andunsustained effıcacy forMMAE
(0.5mpk, qwx2) atMTDdoses. Cerulean continues to expand its platform through
the development of new and emerging capabilities, including the conjugation of
multiple payloads to a single NDC and the development of antibody-conjugated
NDCs, to treat patients living with cancer.
#4966 Phospho-proteome analyses confırm the uniqueMode of Action of
MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin® drug
candidate. Vikram Mitra,1 Ulrike Fiedler,2 Dan Snell,2 Keith M. Dawson,2
Stephan Jung,3 Ian Pike,1 Elmar vomBaur2. 1Proteome Sciences, London, United
Kingdom; 2Molecular Partners AG, Schlieren-Zurich, Switzerland; 3Proteome
Sciences, Frankfurt a. M., Germany.
Background: HER2 is an important target for antitumor therapy in several can-
cers, and while currently available HER2-targeting drugs provide a great treatment
improvement they rarely achieve full disease control. We have developed a new
HER2-targeting molecule with a unique pro-apoptotic mode of action that may
provide additional benefıt to patients. The DARPin® molecule MP0274 shows po-
tency in several HER2-expressing PDXmodels and has been shown to directly in-
duce apoptosis in cells that are addicted toHER2.Here we show through phospho-
proteome analyses that MP0274 not only potently inhibits HER2/HER3
downstream signaling, but also shows a very distinct changes in the phospho-pro-
teome pattern compared to approved HER2-targeting drugs. This provides mech-
anistic support to the uniquemode of action ofMP0274 that results in direct tumor
cell killingwithout theneedof effector-functions likeADCC.Methods:The effect of
MP0274onHER2signalingwas compared to trastuzumab, pertuzumabandacom-
bination of both in theHER2-addicted cancer cell lines. Briefly, cellswere incubated
withdrugs for18hours and then lysed.Lysateswereanalyzed for changes in the total
proteome and phospho-proteome by Proteome Sciences’ proprietary SysQuant®
Global Phosphoproteomics workflow. Results: Heat-maps of genes of interest indi-
cate that MP0274 has a differential mode of action compared to trastuzumab, per-
tuzumab or a combination of both.On the total peptide and phospho-peptide level,
the samples cluster specifıcally, based on the cancer cells used as well as drug treat-
ment. Twenty nine unique global phosphorylation sites specifıc toHER2, including
C-terminal tyrosines which are reported to recruit adaptor proteins starting signal-
ing processes after auto-phosphorylation, were identifıed forMP0274. Several pro-
teins were identifıed which were differentially expressed and phosphorylated after
MP0274 treatment andwhich are involved in three keydownstreamsignalingpath-
ways activated by HER2/HER3 heterodimers: RAF/MAP kinase cascade, PI3K-in-
duced AKT signaling, and signaling by PLCG1. Conclusions: MP0274 shows a
unique and distinct inhibition of theHER2 signaling cascade, different from trastu-
zumab, pertuzumab and a combination of both. It induces amore profound inhibi-
tion of downstream signaling which provides mechanistic support to the fınding
that MP0274 direct cell killing by induction of apoptosis in HER2-addicted tumor
cells. *DARPins are small repeat proteins, designed tobind targetswithhighaffınity
and specifıcity, andwhich can be combined in amodular fashion to producemulti-
functional agents.
#4967 RAF kinase inhibition synergizes with MEK inhibitors in KRAS
mutant tumors. Ivana Yen, Christiaan Klijn, Frances Shanahan, Mark Mer-
chant, Christine Orr, Thomas Hunsaker, Matthew Durk, Hank La, Xiaolin
Zhang, Scott Martin, Eva Lin, John Chan, Yihong Yu, Amy Gustafson, Joachim
Rudolph, Shiva Malek. Genentech, Inc., CA.
While activating mutations in the KRAS oncogene frequently drive tumori-
genesis in human cancers (40% CRC, 20%NSCLC) through constitutive activa-
tion of the MAPK pathway, there are currently no targeted treatments available
for KRASmutant cancers. Inhibitors of the individual nodes of theMAPKpath-
way have been developed, but these molecules have been largely ineffective
against KRASmutant tumors in the clinic. Multiple studies have shown rational
combinations of MAPK inhibitors may have anti-tumor activity in KRAS mu-
tant models. In order to understand the versatility of combining RAF inhibitors
in this context, we conducted a library screen consisting of 430 small molecule
tool compounds in combination with RAF inhibitor AZ-628. Here we show:
RAF inhibitors combine especially well with otherMAPK pathway inhibitors in
KRAS mutant tumor cells. In particular, Type II RAF inhibitors are synergistic
with the MEK inhibitor Cobimetinib in vitro and exhibit tumor regressing effı-
cacy in xenograft mouse model studies in vivo. Mechanistically, we have found
theMEK inhibitor disables ERK induced negative feedback on theMAPK path-
way resulting in activation of CRAF in a KRAS dependent manner. The combi-
nation of RAF with MEK inhibition blunts KRAS-dependent activation of
CRAF kinase activity and robustly inhibits MAPK signaling, thereby driving
effıcacy in KRASmutant tumors. Broad cell line profıling with the combination
of RAF andMEK inhibitors demonstrates that a majority of KRASmutant lung
and colorectal tumor lines exhibit synergy with the combination. Therefore,
combining a Type II pan-RAF inhibitor with a MEK inhibitor has the potential
to improve the therapeutic outcome in KRAS mutant cancers.
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#4968 Importance of tumormicroenvironment in the preclinical estrogen
receptor positive breast cancer- Primary tumor and bonemetastasis models.
Jenni Bernoulli,1 Mari I. Suominen,1 Tiina Kähkönen,1 Jenni Mäki-Jouppila,1
Jussi M. Halleen,1 Riikka Oksala2. 1Pharmatest Services Ltd, Turku, Finland;
2Orion Corporation Orion Pharma, Espoo, Finland.
Estrogen receptor positive (ER) breast cancer has ability to metastasize to
bone in high frequency. Bone is known to be fertile soil for metastasized cancer
cells to survive and in turn, metastasized tumor cells alter normally balanced
bone environment. Prevention and treatment of bone metastasis is challenging
and better understanding why bonemetastasis are resistant to current therapies
is needed. Aim of the present study was to explore the role of tumor microenvi-
ronment and estrogen supplementation on growth of primary breast cancer
tumor and bonemetastasis to establish predictive ER breast cancermodels for
drug development. ER human breast cancerMCF-7 cells were inoculated into
mammary fat pad and in the tibia of female athymic nude mice. Mice received
either hormonal supplementation (17-beta estradiol pellet, E2) or placebo. Tu-
mor growth was followed for 5 and 9 weeks. From one group, E2 supplementa-
tion was removed on study week 5 and tumor growth was followed for 4 weeks.
During the study, blood samples were collected for serum steroid concentration
measurements and at the end, histopathological evaluation and immunohisto-
chemical (IHC) stainings were performed to examine tumor steroid hormone
receptor expression. Orthotopic MCF-7 tumor growth was clearly hormone
dependent. E2 supplementation, that increased serum estradiol for app. 3-fold,
supported tumor growth and when E2 was removed, tumor size decreased and
no tumor growth was observed thereafter. In the full absence of E2 supplement,
no orthotopic tumor growth was observed. In contrast, when MCF-7 cells were
inoculated into tibia, tumor growth was observed both with and without E2
supplement. IHC stainings confırmed orthotopic tumor to express ER, PR and
AR when animals received E2. After E2 removal, orthotopic tumors expressed
still ER and AR but no longer PR. Also intratibial tumors expressed ER and PR
in the presence of E2, but no PR in the absence of E2 supplement. E2 is needed to
support MCF-7 tumor growth when cancer cells are inoculated orthotopically
into mammary fat pad. No orthotopic tumor growth is observed in the absence
of E2 supplement. In contrast, in the bonemicroenvironment,MCF-7 cells form
tumor even in the absence of E2 supplement. Results highlight importance of
tumor microenvironment in the breast cancer progression and also refer why
tumor in the different sites may be resistant to therapy. Taking together, when
developing new therapies against breast cancer, focus should be addressed not
only on primary tumor growth but also on bone metastasis where cancer cells
are under influence of bone environment.
#4969 Impaired PARP1 DNA repair defınes chemosensitivity in IDH1
mutant cell. Yanxin Lu, Yang Liu, Yu-Ting Su, Wendy Bautista, Mark R. Gil-
bert, Jing Wu, Chunzhang Yang. Center for Cancer Research, National Cancer
Institute, Bethesda, MD.
INTRODUCTION: Mutations in isocitrate dehydrogenase (IDH1/2) are the
most prevalent genetic abnormalities in lower grade gliomas. The presence of
IDHmutations in glioma are prognostic for better clinical outcomeswith longer
patient survival, and greater sensitivity to chemotherapy. In the present study,
we explore the molecular mechanisms that determine the chemosensitivity in
IDH1-mutated glioma cells, and seek a potential therapeutic strategy by target-
ing DNA repair pathway in IDH1-mutated cells. METHODS: We established
IDH1-mutated cell lines by introducing pathogenic IDH1 mutations into gli-
oma cells via lentivirus. We confırmed the metabolic defıciency and enhanced
chemosensitivity in cells expressing IDH1 mutant enzyme. Further, we mea-
sured the intracellular level of nicotinamide adenine dinucleotide (NAD),
Poly (ADP-ribose) polymerase (PARP)-associated DNA repair and DNA dam-
age level in these cells when treated with temozolomide (TMZ). Moreover, we
evaluated a PARP inhibitor Olaparib and its synergic effect on TMZ-associated
cytotoxicity. RESULTS: Our results show that the IDH1-mutated cells are more
vulnerable to chemotherapy. TMZ treatment resulted in over 20-fold increase of
cell death in IDH1-mutated cells compared with their wild type counterpart.
IDH1-mutated cells exhibited an over 1.3-fold increase in DNA damage and
over 1.42-fold increase in cellular apoptosis under TMZ treatment. Accordingly,
IDH1-mutated cells produced 83.8% less poly (ADP-ribose) polymer (pADPR),
an important substrate for PARP-associated DNA repair, during TMZ treat-
ment; suggesting their incompetence to maintain genomic integrity due to de-
creased availability ofNAD. Targeting the PARP-associatedDNArepair path-
way using Olaparib remarkably potentiated TMZ-induced cytotoxic effects by
2.16 fold in IDH1mutated cells. CONCLUSION:Our fındings demonstrate that
metabolic defects in IDH1-mutated cells affect PARP-associated DNA repair
pathway via NAD depletion, and therefore prompt the sensitivity to chemo-
therapies. Targeting PARP-associated DNA repair pathway may represent a
novel therapeutic avenue for IDH1-mutated gliomas.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Novel
Small Molecular Targets and Approaches
#4970 Oxidative phosphorylation as a target in triple negative breast can-
cer therapy. Funda Meric-Bernstam,1 Kurt Evans,1 Xiaofeng Zheng,1 Xiaoping
Su,1 Erkan Yuca,1 Stephen Scott,1 Argun Akcakanat,1 Naoto Ueno,1 Bora Lim,1
Jennifer Litton,1 Vicente Valero,1 Fraser Symmans,1 Gabriel Hortobagyi,1
Charles Perou,2 Debu Tripathy,1 Guilio Draetta,1 Joe Marszalek,1 Ana Maria
Gonzalez-Angulo,1 Stacy Moulder1. 1The University of Texas MD Anderson
Cancer Center, Houston, TX; 2TheUniversity of North Carolina, Chapel Hill, NC.
Altered cellular metabolism is a hallmark of cancer. It is increasingly recog-
nized that selected tumors are dependent on oxidative phosphorylation (OX-
PHOS). However, the role of OXPHOS in TNBC is not well understood. We
performed RNA sequencing in pre-treatment biopsies from 43 patients with
operable triple negative breast cancer (TNBC) who received sequential taxane-
and anthracycline-based neoadjuvant chemotherapy. At a median follow-up of
63months, 14 patients recurred and 12 patients died. At a false discovery rate of
0.05, 33 geneswere differentially expressed between the patientswhodid anddid
not have a subsequent recurrence. Ingenuity pathway analysis demonstrated
that one of the top canonical pathways that differed was higher expression of
oxidative phosphorylation signature (p5.89E-0.7). The patients who recurred
had signifıcantly higher levels of mitochondrial genes: MT-ND1 (adjusted p or
FDR-BH; q0.007); MT-ND5 (q0.03) and MT-ND4 (q0.04). Further, 21
genes were differentially expressed between patients based on survival, includ-
ingMT-ND5 (q0.001);MT-ND4 (q0.005),MT-ND4L (q0.015),MT-ND6
(q0.018), and MT-ATP6 (P0.03). Top canonical pathway that was differen-
tially expressed based on survival was oxidative phosphorylation (p9.98E-10).
We therefore sought to determine the effıcacy of IACS-10759, a novel inhibitor
of OXPHOS, in 10 different TNBC patient-derived xenografts representing dif-
ferent gene expression based Lehmann TNBC subtypes. Growth inhibition was
observed inmultiple subtypes, with regression in one basal-like 1(BL1) 1model,
and stabilization of growth inmultiple BL1 and immunomodulatory expression
subtypes. Taken together, our data suggests that high OXPHOS is associated
with higher recurrence and lower survival. OXPHOS is a promising target in
several TNBC subtypes. A Phase I trial of IACS-10759, a potent inhibitor of
complex I of oxidative phosphorylation, in leukemia is ongoing and planned in
TNBC and other solid tumors.
#4971 IACS-010759, a novel inhibitor of complex I in Phase I clinical
development to target OXPHOS dependent tumors. Jennifer Molina,1 Mad-
havi Bandi,1 Jennifer Bardenhagen,1 Christopher Bristow,1 Christopher Car-
roll,1 Edward Chang,1 Jason Cross,1 Naval Daver,1 Ningping Feng,1 Jason Gay,1
Mary Geck Do,1 Jennifer Greer,1 Jing Han,1 Judy Hirst,2 Sha Huang,1 Yongying
Jiang,1 ZhijunKang,1MarinaKonopleva,1GangLiu,1HelenMa,1 PolinaMatre,1
Timothy McAfoos,1 Funda Meric-Bernstam,1 Pietro Morlacchi,1 Florian
Muller,1 Marina Protopopova,1 Melinda Smith,1 Sonal Sonal,1 Yuting Sun,1 Jay
Theroff,1 Andrea Viale,1 Quanyun Xu,1 Carlo Toniatti,1 Giulio Draetta,1 Philip
Jones,1 M. Emilia Di Francesco,1 Joseph R.Marszalek1. 1UTMDAnderson Can-
cer Center, Houston, TX; 2MRCMitochondrial Biology Unit, Cambridge, United
Kingdom.
Tumor cells depend on both glycolysis and oxidative phosphorylation (OX-
PHOS) for energy and biomass production to support cell proliferation. Recent
data has demonstrated a dependence of various tumor types on mitochondrial
OXPHOS, which represents an exciting therapeutic opportunity. Through an
extensive medicinal chemistry campaign, IACS-010759 was identifıed as a po-
tent, selective inhibitor of complex I of the electron transport chain, which is
orally bioavailable and has excellent PK and physicochemical properties in pre-
clinical species. Our group and others have demonstrated that AML, plus sub-
sets of glioblastoma, neuroblastoma, lymphoma, melanoma, triple negative
breast cancer (TNBC) and pancreatic cancer (PDAC) are highly dependent on
OXPHOS tomeet energy and biomass demands. Treatment ofmultiple cell lines
and patient derived xenograft (PDX) models in several cancer types with IACS-
010759 led to a robust decrease in cell viability and often an increase in apoptosis
with EC50 values between 1 nM - 50 nM across multiple lines. Through a series
of mechanistic studies we established that IACS-10759 blocks complex I of the
electron transport at the quinone binding site. Mechanistically, response to
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IACS-010759 was associated with induction of ametabolic imbalances that neg-
atively impacted energy homeostasis, aspartate biosynthesis, and NTP produc-
tion due to reduced conversion of NADH to NAD by complex I, decreased
ATP production, TCA cycle flux and nucleotide biosynthesis. Tumor growth
inhibition and regression have been observed in molecularly defıned subsets of
TNBC and PDAC PDX xenograft models treated with IACS-010759, indicating
that subsets of these indications are dependent on OXPHOS. Furthermore,
treating TNBC or PDAC PDX models post-chemotherapy with IACS-010759
extends progression free survival, consistent with IACS-010759 targeting re-
cently describedmetabolically adapted residual tumor cells. In orthotopic xeno-
graft models of primary AML cells, daily oral treatment with 1-7.5 mg/kg IACS-
010759 extended the median survival. Effıcacy was paralleled by robust
modulation of OCR, aspartate, and a gene signature levels. Therefore, these
readouts (OCR, aspartate and a nanostring geneset) have been validated for use
as exploratory clinical biology of response endpoints. In parallel, completion of
preclinical chemistry, manufacturing and control (CMC) as well as GLP safety
and tolerability studies with IACS-010759 in multiple species have enabled the
selection of a clinical entry dose. As a result of the robust response in multiple
cell lines, primary patient samples, and effıcacy in PDXmodels, a Phase I clinical
trial in relapsed, refractory AML was initiated in October 2016, with a parallel
trial in solid tumors expected to initiate in early 2017. Initial results from the
on-going AML trial will be disclosed.
#4972 Novel Ras inhibitorDC070-547 potently and selectively blocksRas-
RBD binding, EGFR binding to Ras signaling complex, EGFR activation of
Ras signaling, and growth of Ras-driven lung tumor cells. Bing Zhu,1 Xi
Chen,1 Jacob Valiyaveettil,1 Joshua Canzoneri,2 Kevin Lee,1 Kate Saville,1 Kristy
Berry,1 Luciana Barnes,1 Tyler Maddox,1 Ashley Lindsey,1 AntonioWard,1 Ve-
ronicaRamirez-Alcantara,1AdamKeeton,1Michael Boyd,2GaryPiazza1. 1Univ.
of South AlabamaMitchell Cancer Inst., Mobile, AL; 2ADT Pharmaceuticals Inc.,
Gulf Shores, AL.
A novel series of compounds that potently and selectively inhibits the growth of
tumor cells harboring constitutively activated Ras relative to cells lacking activated
Ras were identifıed by screening a proprietary library of indene derivatives in a
phenotypic, cell-basedassay. Lead-optimizationproducedadrugdevelopment can-
didate, DC070-547, which showed strong antitumor activity at doses not causing
any discernible toxicity in preclinical mouse models. Here we characterize the un-
derlyingmechanism of growth inhibition in lung tumor cells. A panel of non-small
cell lung cancer lines with constitutively activated Ras were highly sensitive to
DC070-547 with IC50 values as low as 2 nM, while normal airway epithelial cells
were essentially insensitive. Transfection of wild-type ras H322 bronchioalveolar
tumor cells withmutant ras (G12V) confırmed that activatedRas is required for the
selective growth inhibitory activity ofDC070-547. Ras-RBDbinding assays showed
that DC070-547 disrupts Ras-RBD binding at low nanomolar concentrations that
parallel those required to inhibit the growth of lung tumor cells with activated Ras.
Similar concentrations of DC070-547 were found to inhibit the binding of phos-
phorylated EGFR (Y1068) to Ras immunoprecipitates in mutant ras transfected
H322 cells, but not in control H322 cells. DC070-547 also inhibited the binding of
SOS, Grb2, Gab1, S338 phosphorylated c-Raf (pc-Raf), S473 phosphorylated Akt-1
(pAkt-1) andT202/Y204phosphorylatedErk1/2 (pERK1/2) toRasorEGFR immu-
noprecipitates. To determine if DC070-547 can inhibit EGF-stimulated Ras signal-
ing, serum-starved mutant ras transfected H322 cells were treated with EGF and
probed for effects on Ras signaling components. DC070-547 caused a concentra-
tion-dependent inhibition of EGF-induced Y1068-EGFR as measured in Ras im-
munoprecipitates, and also reduced pc-Raf, pAkt-1, pErk1/2 and pGab1 (Y627)
levels in Ras or EGFR immunoprecipitates. In addition, DC070-547 caused a con-
centration-dependent decrease in Erk1/2 and Akt-1-mediated phosphorylation of
Bad proteins (S112, S136 and S155) to induce apoptosis. These results show that
DC070-547 prevents Ras-RBD binding to block EGF-induced Raf/MAPK and Akt
signaling topotently and selectively inhibit the growthof lung tumor cells harboring
constitutively activated Ras. Support provided by NCI grants 1R01CA197147 and
1R21CA182941.
#4973 Discovery of LY3214996, a selective and novel ERK1/2 inhibitor
with potent anti-tumor activities in cancer models with MAPK pathway al-
terations. Shripad V. Bhagwat,1 William T. McMillen,1 Shufen Cai,1 Baohui
Zhao,1 Matthew Whitesell,1 Lisa Kindler,1 Robert S. Flack,1 Wenjuan Wu,1
KarenHuss,1 BryanAnderson,1 Xiu-JuanYuan,1 Susan Jaken,1DenisMcCann,1
Brian Mathes,1 Andrew J. Dropsey,1 Jason Manro,1 Jennie Walgren,1 Eunice
Yuen,1 Xueqian Gong,1 Michael J. Rodriguez,1 Jianping Huang,1 Ramon V.
Tiu,2 Sajan Joseph,1 Sheng-Bin Peng1. 1Lilly Research Laboratories, Eli Lilly and
Company, Indianapolis, IN; 2Early Phase Oncology, Oncology Business Unit, Eli
Lilly and Company, Indianapolis, IN.
The RAS/MAPK pathway is dysregulated in approximately 30% of human can-
cers, and the extracellular-signal-regulated kinases (ERK1 and ERK2) serves as key
central nodeswithin this pathway.The feasibility andclinical impact of targeting the
RAS/MAPK pathway has been demonstrated by the therapeutic success of BRAF
andMEK inhibitors in BRAFV600E/Kmetastatic melanoma. However, resistance
develops frequently through reactivation of the pathway. Therefore, simultaneous
targeting ofmultiple effectors such as RAF,MEK and ERK in this pathway, offers a
potential for enhanced effıcacy while delaying and overcoming resistance.
LY3214996 is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for
both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in
BRAF andRASmutant cancer cell lines. In an unbiased tumor cell panel sensitivity
profıling for inhibition of cell proliferation, tumor cells withMAPK pathway alter-
ations including BRAF, NRAS or KRAS mutation are generally sensitivity to
LY3214996. In tumor xenograft models, LY3214996 inhibits PD biomarker phos-
pho-p90RSK1 in tumors and the PD effects are correlated with compound expo-
sures and anti-tumor activities. LY3214996 shows either similar or superior anti-
tumor activity as compared to other published ERK inhibitors in BRAF or RAS
mutant cell lines and xenograft models. Oral administration of single-agent
LY3214996 signifıcantly inhibits tumorgrowth invivo and iswell tolerated inBRAF
orNRASmutantmelanoma,BRAForKRASmutant colorectal, lungandpancreatic
cancer xenografts or PDXmodels. Therefore, LY3214996 can be tailored for treat-
ment of cancers with MAPK pathway alteration. In addition, LY3214996 has anti-
tumor activity in a vemurafenib-resistant A375 melanoma xenograft model due to
MAPK reactivation, may have potential for treatment of melanoma patients who
have failed BRAF therapies. More importantly, LY3214996 can be combined with
investigational and approved agents in preclinical models, particularly KRAS mu-
tantmodels.Combination treatmentofLY3214996andCDK4/6 inhibitorabemaci-
clibwaswell toleratedand results inpotent tumorgrowth inhibitionor regression in
multiple in vivo cancer models, including KRAS mutant colorectal and non-small
cell lungcancers.Here,we fırst report thepreclinical characterizationofLY3214996,
a novel small molecule ERK1/2 inhibitor currently in Phase I clinical trials in pa-
tients with advanced andmetastatic cancers (NCT02857270).
#4974 Pharmacogenomic interactions in glioblastoma cell line models.
Ruben Ferrer-Luna,1 Shakti H. Ramkissoon,1 Karl H. Olausson,1 Lori A. Ram-
kissoon,1 Steven Schumacher,1 Rebecca Lamothe,1 Jaime H. Cheah,2 Kristine
Pellton,1 SamHaidar,1 Yun J. Kang,1 BrentonR. Paolella,1 CecileMaire,1Wenyu
Song,1 Alice Meng,1 Ahmed Idbaih,1 Mikael L. Rinne,1 David A. Reardon,1
Patrick Y. Wen,1 Paul A. Clemons,2 Stuart L. Schreiber,2 Alykhan F. Shamji,2
Rameen Beroukhim,1 Keith L. Ligon1. 1Dana-Farber Cancer Institute, Boston,
MA; 2Broad Institute, Cambridge, MA.
Glioblastoma (GBM) is the most common and malignant brain tumor. These
tumors display a uniform and very short survival time even with treatment, but are
highly heterogeneous at the histological and genomic level. To identify effective
treatmentsanddependencies,weprofıled thesensitivityofapanelof cancercell lines
to a small molecules and integrated this with systematic analysis of genetic and
non-geneticdeterminants associatedwithchemical response.Methods.Weprofıled
381 drugs described in the Cancer Therapeutics Response Portal (CTRP) at 16 dif-
ferentduplicated concentrations across 78GBMcell lines belonging to twodifferent
models: Patient-Derived GBM Cell Lines (PDGCL) and Long-Term GBM Cell
Lines (LTGCL) previously included in the Cancer Cell Line Encyclopedia (CCLE).
Cell linesweredeeply characterized as to genotype andphenotype.Asnon-genomic
determinants we considered:model, growth rate, behavior, stem cell and differenti-
ationmarkers. Genomic determinants includedmutations and somatic copy num-
ber alterations (SCNA) computed from whole exome sequencing. Each of these
were integrated todetermineoncogeneand tumor suppressorgenepathwaydisrup-
tion (p53,RBandRTKsignaling).At transcriptomic levelwe considered expression
of 20.647 genes and patters described inGBMs (proneural, neural, classical,mesen-
chymal). Overall we correlated 10,859,643 pharmacogenomic features to discover
associations with drug sensitivity. Summary. We developed a brain tumor living
tissuebankasplatformforpreclinical pharmacogenomics analysis. Large-scalephe-
notypic characterization of GBMmodels showed increased cellular and molecular
heterogeneity amongPDGCLs compared toLTGCLs. PDGCLsbetter recapitulated
patient GBM copy-number profıles. GBM cell lines exhibited all major driver mu-
tations in humanGBMs, except IDH1. PDGCLs andLTGCLs enriched for proneu-
ral andmesenchymal phenotypes, respectively.We identifıedNAMPT inhibitors as
among the compounds with highest activity across cell lines. Integrative pharma-
cogenomic analyses showed MDM2/4 inhibitors were able to effectively suppress
TP53wild typeGBMmodels,beingCDKN1A(p21)expressionarobustpredictorof
drug response in vitro and in vivo. Overall drug resistance across the screen in lines
washighlyassociatedwithTP53mutation,howevera specifıc subsetofTP53mutant
cell lines bearing simultaneous CDKN2A/B deletions were sensitive to CHK1/2
inhibitors, revealing a potential synthetic lethal interaction of clinical signifıcance in
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these highly refractory cells. Analysis identifıed genetic alterations associated with
vulnerabilities targeted by smallmolecules.About 85%ofGBMpatients display p53
pathway disruption, our results suggest independent pharmacological strategies for
two genetic subtypes of GBMdetermined by TP53 and CDKN1A status. Our anal-
ysesprovidemolecular insights todrive targeted therapies in theneweraofprecision
medicine.
#4975 A small molecule pan Id protein antagonist shows strong antitu-
mor activity. Paulina M. Wojnarowicz,1 Bina Desai,1 Yvette Chin,1 Sang Bae
Lee,2 Marta Garcia-Cao,1 Ouathek Ouerfelli,1 Guangli Yang,1 Sijia Xu,1 Yehuda
Goldgur,1 Meredith A. Miller,1 Jaideep Chaudhary,3 William A. Garland,4 Ste-
ven K. Albanese,1 Rajesh Soni,1 John Philip,1 Larry Norton,1 Neal Rosen,1 Ron-
ald C. Hendrickson,1 Xi Kathy Zhou,5 Antonio Iavarone,2 Andrew J. Dannen-
berg,6 John D. Chodera,1 Nikola Pavletich,1 Anna Lasorella,2 Robert Benezra1.
1Memorial Sloan Kettering Cancer Center, New York, NY; 2Columbia University
Medical Center, New York, NY; 3Clark Atlanta University, Atlanta, GA; 4Tosk
Inc., Mountain View, CA; 5Weill Cornell Medical College, New York, NY; 6Weill
Cornell Medical College, Cornell University, New York, NY.
The Id family of helix-loop-helix (HLH) proteins, Id1, Id2, Id3 and Id4, play a
critical role in inhibiting differentiation during mammalian embryogenesis. They
function in part by sequestering ubiquitously expressed E protein bHLH transcrip-
tion factors via direct protein-protein interactions. Various Id proteins are re-ex-
pressed in adults in a number of pathologic states including cancer and diseases of
the vasculature, where their activity has been shown to be essential for disease pro-
gression. The present study describes the solving of the Id1-E47 dimer crystal struc-
ture and subsequent development and characterization of a smallmolecule antago-
nist of the Id protein family, AGX51.AGX51was identifıed in an in silico screen for
compounds thatcouldbindahydrophobiccreviceadjacent to the loopregionof Id1,
highly conserved in the Id family. AGX51 inhibits the endogenous Id1-E protein
interaction leading to thedegradationof Id1viaubiquitin-mediatedproteolysis.The
stability of all fourmembers of the Id family are antagonized byAGX51 leading to a
G0-G1 arrest and profound inhibition of viability with no acquired resistance ob-
served in multiple cell lines after continuous exposure to the compound. Adminis-
trationofAGX51 iswell tolerated inmice andphenocopies genetic loss of Id expres-
sion analyses: suppression of breast cancer metastases to the lung associated with a
reduced mesenchymal-to-epithelial transition, perturbation of the vasculature
within the primary tumor, and growth regression of paclitaxel resistant breast tu-
mors in combinationwithpaclitaxel therapy. These studies identify a novel, fırst-in-
class compound capable of antagonizing the activity of a protein family formerly
considered undruggable and point to the possible utility of AGX51 in the manage-
ment of multiple disease processes in patients.
#4976 Ricolinostat, a selective HDAC6 inhibitor with immunomodula-
tory properties, has signifıcant anti-melanoma activity in vitro and in vivo.
Fengdong Cheng,1 Sodre Andressa,2 Jie Chen,1 Alejandro Villagra,1 David
Woods,2 Jeffrey Weber,2 Steven Quayle,3 Jones Simon,3 Eduardo Sotomayor1.
1The George Washington University, Washington, DC; 2Perlmutter Cancer Cen-
ter, NYU Langone Medical Center, New York, NY; 3Acetylon Pharmaceuticals3,
Boston, MA.
Melanoma is a less common but the most aggressive type of skin cancer and the
rates of melanoma have been rising for the last 30 years. Immunotherapymay rep-
resent a new treatment paradigm to benefıt melanoma patients. Previous studies
have identifıedHDAC6playing a central role in the regulatingmelanoma immuno-
genicity. We have shown that genetic knockdown (KD) of HDAC6 in murine and
human melanoma cells resulted in an increased the expression of MHCI and co-
stimulatorymolecules aswell asmelanomaassociatedantigens. Invivo studiesdem-
onstrated that the growth of melanoma cells lacking HDAC6 was signifıcantly de-
layed as compared to wild-type cells. This growth was further delayed when
HDAC6KD melanoma bearing mice were treated with anti-PD-1 antibodies. Re-
cently, we have shown that in vitro treatment of murinemelanoma cells with Rico-
linostat decreases PD-L1 expression and increases the expression of acetyl tubulin.
Surprisingly, in vivo treatment of B16 melanoma bearing animals with increasing
concentrations of ricolinostat resulted in a dose-dependent inhibition ofmelanoma
growth (p0.05). No toxicities were observed at the doses studied; however, the
antitumor effect exerted by ricolinostat was not observed whenmelanoma bearing
SCIDmicewere treatedwith this compound, indicating that an intact host immune
system is required for the observed antitumor activity. In lieu of these previously
unknown immunomodulatory properties of ricolinostat, we next assessed the ef-
fects of this compound upon T-cells and whether ricolinostat could augment the
effıcacy of checkpoint blockade in vivo. Murine T-cells were activated with anti-
CD3 plus anti-CD28 in the presence or absence of ricolinostat. Then, those T-cells
wereadoptively transferred intoB16melanomabearingmice.T-cell subpopulations
from the lymph nodes were analyzed ex vivo.We show here that treatment of mu-
rine T-cells with ricolinostat resulted in a signifıcant increase in central memory
T-cells endowed with a strong anti-melanoma activity in vivo as compared to con-
trol group (p0.05). Finally, the addition of ricolinostat treatment to either anti-
CTLA4 or anti-PD1 treatment was associated with an enhanced inhibition of mel-
anoma tumor growth. In summary, our results have identifıed HDAC6 as a novel
target for melanoma immunotherapy and point out ricolinostat as an attractive
agent to add to the immuno-oncology armamentarium.
IMMUNOLOGY: Adoptive Cellular Therapy for Cancer
#4977 Isolation and characterization of a PRAME-specifıc TCRwith high
avidity, potent anti-tumor effıcacy and a favorable preclinical safety profıle.
Manon Weis, Carina Wehner, Christian Ellinger, Susanne Wilde, Dolores J.
Schendel.Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany.
Some of the challenges regarding adoptive T cell transfer as an immunother-
apeutic approach for the treatment of cancer patients include the initial induc-
tion, isolation and later characterization of suitable TCR candidates. In addition,
the selection of appropriate target antigens is important and complex as such
antigens need to meet some critical demands. Published data as well as in depth
in silico analyses revealed the tumor associated antigen PRAME a suitable can-
didate. Classifıed as cancer/testis antigen, PRAME is highly expressed in tumors
with only limited or no expression in normal tissues, other than testis. Here we
describe the induction of PRAME-specifıc, HLA-A*02:01-restricted CD8-posi-
tive T cells by using an in vitro priming approach. Mature dendritic cells trans-
fected with ivtRNA encoding full-length PRAME were cocultured with autolo-
gous CD8-enriched PBL from a healthy, HLA-A*02:01-positive blood donor.
Initially primed T cells were expanded for 2 weeks and T cells bearing TCRs
specifıc for PRAME-derived epitopes were identifıed by multimer staining and
FACS analysis. Single cells were sorted into 96 well plates and after an expansion
period of another 2 weeks, growing clones were screened for specifıcity. TCR
sequences of specifıc clones were identifıed by usingNGS and reconstructed in a
retroviral vector system enabling stable transduction of effector cells. The result-
ing TCR-modifıed T cells were thoroughly analyzed and characterized using a
dedicated set of assays to evaluate multiple parameters concerning safety and
effıcacy. This characterization revealed TCRT4.8-1-29 to be highly specifıc for a
PRAME-derived epitope presented onHLA-A*02:01.Only epitope-positive tar-
get cells expressing the appropriate HLA-restriction element induced cytokine
secretion by T4.8-1-29 expressing effector cells, leading to recognition as well as
specifıc lysis of these target cells. Recognition and lysis, not just of peptide-
loaded T2 cells, but also of PRAME-transfected APC, transfected tumor cells as
well as endogenously PRAME-positive tumor cells was mediated by this TCR.
T4.8-1-29-expressing effectors show a high natural avidity for the target epitope
without the need of further manipulation, e.g. functional effıcacy enhancement
by affınitymaturation. In addition, the toxicity assessment using various in vitro
and in silico tools revealed a favorable preclinical safety profıle for this TCR. In
summary, by using an in vitro priming approach utilizing cells from healthy
donors, it was possible to generate a TCR recognizing a PRAME-derived epitope
with high natural avidity and specifıcity. The TCR shows a favorable safety
profıle, demonstrating that this approach is useful to generate TCRs potentially
qualifying for evaluation in clinical trials.
#4978 Adoptively transferred CMV-Specifıc T-cells recognizing domi-
nant and sub-dominant pp65 epitopes demonstrate improved in vivo inhibi-
tion of tumor xenografts in combination with PD-1 inhibition. Aisha N.
Hasan,1 Annamalai Selvakumar,1 Tzu-Yun Kuo,2 Richard J. O’Reilly1. 1Memo-
rial Sloan-Kettering Cancer Center, New York, NY; 2Weill-Cornell Graduate
School of Biomedical Sciences, New York, NY.
Adoptive transfer of transplant donor or third party donor derived CMV-
specifıc T cells (CMV-CTL) can effectively treat CMV infections in HSCT re-
cipients. In clinical trials, infusion of partially matched third party CMV-CTLs,
has demonstrated high response rates against persistent CMV infection. T-cells
(TC) generated in vitro or directly selected in vivo demonstrate a striking pre-
ponderance of specifıcity for 1-2 immunodominant (ID) epitopes presented by
specifıc HLA alleles. ID epitopes elicit higher TC functional activity in vivo,
compared to sub-dominant (SD) epitopes. The relative clinical effıcacy of TC
directed against ID versus SD epitopes in vivo remains undefıned. Agents aug-
menting activity of TC responsive to SD epitopes are unexplored. When these
alleles are co-inherited in humans, epitopes of CMVpp65 presented by HLA
A*02:01 are ID over HLA A*24:02 presented epitopes. We describe an in vivo
model to assess effıcacy of CMV-CTLs using colon carcinoma cells (coca)trans-
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duced to express CMVpp65, as a surrogate system.HLAA*02:01 andA*24:02
 human coca cells were transduced to express CMVpp65 and GFP-fırefly lu-
ciferase (cocapp65). CMV-CTLs responding to either the A*0201 presented ID
NLV epitope (A2-NLV) or the A*24:02 presented SDQYD epitope (A24-QYD)
were generated fromdonors co-inheritingHLAA*02:01 andA*24:02 by in vitro
stimulation using NIH 3T3 artifıcial antigen presenting cells, expressing HLA
A*02:01 or A*24:02, B7.1, LFA-3, and ICAM1. Tumor cells (105 cells) were
injected subcutaneously into groups of 5-6 NSG mice on the R flank, and 105
cells from a pp65 expressing melanoma cell line (melpp65), lacking expression
ofHLAA*02:01 or A*24:02 were injected on the L shoulder as control. 2 Groups
each received 106 of tetramerA2-NLVorA24-QYDCMV-CTLs i.v permouse;
one of each CMV-CTL treated group also received 2 i.v doses ( 200g /dose) of
anti-PD1 antibody (Nivolumab-BMS) at day 2 and 7 post CTL infusion. Control
groups received IL-2, with or without anti-PD1, or HLA mismatched CMV-
CTLs. Tumor growth was monitored by bioluminescent imaging. CMV-CTLs
responsive to SD A24-QYD epitope induced signifıcant cocapp65 growth sup-
pression compared to controls, but did not eradicate tumors in any animal.
Combined treatment of A24-QYD CMV-CTLs with anti-PD-1 Ab induced
complete cocapp65 eradication in 2 of 5 mice, with minute residual tumors in 3
mice. Treatment with ID A2-NLV CMV-CTLs induced complete cocapp65
eradication in 2 of 5 mice, and smaller residual tumors compared to SD A24-
QYDCTL treatment. Combined treatment with anti-PD-1 and A2-NLVCMV-
CTLs led to complete cocapp65 eradication in 3 of 5mice, withminute tumors in
2 mice. Taken together, these data provide evidence that blocking the PD-1/
PD-L1 interaction may signifıcantly augment the antiviral activity of both ID
and SD CMV-CTLs.
#4979 Development of KITE-585: a fully human BCMACAR T-cell ther-
apy for the treatment of multiple myeloma. Gregor B. Adams, Jun Feng, Ate-
fah Ghogha, Armen Mardiros, Jodi Murakami, Tammy Phung, Ruben Rodri-
guez, Stuart Sievers, Tassja J. Spindler, JedWiltzius, Clare Yarka, Sean C. Yoder,
Tony Polverino. Kite Pharma, Santa Monica, CA.
Background: Multiple myeloma (MM) is a usually fatal malignancy of
plasma cells, with no current therapy considered curative. About 15% of
patients diagnosed with MM are stratifıed as high risk with poor treatment
outcomes and short (2-3 years) survival from diagnosis. Standard risk pa-
tients tend to live longer but undergo chronic and/or high intensity therapy
and likely experience a relapsing and remitting disease pattern. Therefore,
there is still a considerable unmet need for innovative therapies that improve
outcomes in MM. One such approach is to use adoptive transfer of engi-
neered autologous T cells expressing a chimeric antigen receptor (CAR)
directed against malignant cells. The effıcacy of CAR T cells directed against
hematological malignancies, particularly CD19-expressing B cell leukemia
and lymphomas, has been demonstrated in multiple clinical studies. KITE-
585 was developed as a CAR T cell immunotherapy product candidate di-
rected against B cell maturation antigen (BCMA). BCMA is nearly ubiqui-
tously expressed on MM cells, plasma cells and subsets of mature B cells, but
with limited or absent expression on other tissues. Methods: We generated
50 fully human IgGs directed against BCMA using the BCMA protein as
antigen and selection criteria including affınity, cross-reactivity and poly-
specifıcity. Following assessment of the binding of the IgGs to a MM cell line
known to express BCMA, 10 IgGs were identifıed that met the criteria for
affınity and selectivity and had a 50-fold binding over background. The 8
IgGs that demonstrated the highest specifıc binding were then sequence-
converted to single-chain variable fragments (scFvs) and incorporated into
CARs. Results: In all but one case, human T cells engineered to express these
CAR constructs exhibited specifıc cytolytic activity against MM cell lines
(NCI-H929 andMM.1s). These CART cells demonstrated killing effıciencies
of 95% at effector:target ratios of 1:1 over a 24-hour period. Similarly
antigen-specifıc production of inflammatory cytokines was observed in re-
sponse to target cell lines in vitro. Assessment of antigen-dependent prolif-
eration over a 5 day period revealed 80% proliferation in the 7 constructs
that showed cytolytic activity in vitro. Multiple different anti-BCMA CAR
constructs representing distinct epitope binding bins of BCMA were then
selected for in vivo evaluation. In two disseminated tumor models of lu-
ciferase labeled NCI-H929 or MM.1s cells injected intravenously (i.v.), a
single i.v. injection of anti-BCMA CAR T-cells delayed the progression of
disease and signifıcantly increased survival when compared to control treat-
ment. Conclusions: The results of these studies highlight the potential of
targeting BCMA with adoptive transfer of engineered T cells for the treat-
ment of MM. Given these positive fındings, progress towards Phase 1 clinical
studies in MM patients with KITE-585 is continuing.
#4980 Engineering adoptive T cell therapy for effıcacy in ovarian cancer.
Kristin G. Anderson,1 Breanna M. Bates,2 Edison Y. Chiu,1 Philip D. Green-
berg1. 1Univ. of Washington, Seattle, WA; 2Fred Hutchinson Cancer Research
Center, Seattle, WA.
Over 20,000 women are diagnosed with ovarian cancer annually - more than
half will diewithin 5 years and this rate has changed very little in the last 20 years,
highlighting the need for innovative therapies. One promising new treatment
strategy has the potential to control tumor growth without toxicity to healthy
tissues, by employing immune T cells engineered to target proteins uniquely
overexpressed in tumors. Recent technological advances have helped identify
and validate Wilms’ Tumor Antigen 1 (WT1) and mesothelin (MSLN) as valid
antigen targets for ovarian cancer, as these proteins contribute tomalignant and
invasive phenotypes and have limited expression in healthy cells. In preclinical
studies using either patient-derived cell lines or the mouse ID8 ovarian tumor
model, we found that T cells engineered to express either a WT1- or MSLN-
specifıc high-affınity T cell receptor (TCR) can kill human and murine ovarian
tumor cells in vitro. Moreover, in a disseminated in vivo murine model, adop-
tively transferred TCR-engineered T cells preferentially accumulated within es-
tablished ID8 tumors, delayed ovarian tumor growth and prolonged mouse
survival. However, our data also revealed that the tumor microenvironment
(TME) can limit engineered T cell persistence and killing capacity. Cellular and
molecular analyses showed human therapy will face similar TME-mediated ob-
stacles. The ovarian cancer TME is a nutrient- and oxygen-deprivedmilieu, and
adaptivemetabolic responses by infıltrating T cells have protean effects on T cell
function. Thus, strategies that modulate T cell metabolic pathways, and thereby
influence activity in the TME, might enhance T cell function and improve anti-
tumor effıcacy by overcoming a critical component of immune evasion by solid
tumors. Ongoing studies will be discussed that are exploring strategies to over-
come elements common to the human andmurine TME, including direct mod-
ulation of the environment and T cell engineering to promote T cell survival and
function.
#4981 Extracellular spacer and co-stimulatory domains defıne target sen-
sitivity and persistence of CAR T cells for the treatment of PSCA bone
metastatic prostate cancer. Kelly Kennewick, Dileshni Tilakawardane, Ethan
Gerdts, JohnMurad,AnthonyPark, Brook Jeang, YukikoYamaguchi, Stephen J.
Forman, Saul Priceman. City of Hope, Duarte, CA.
Advancing chimeric antigen receptor (CAR)-engineered adoptive T cells for
the treatment of solid cancers is a major focus in the fıeld of immunotherapy,
given impressive recent clinical responses in hematological malignancies. Pros-
tate cancer should be amenable to CAR-based immunotherapy given that sev-
eral tumor antigens, including prostate stem-cell antigen (PSCA), are widely
over-expressed in metastatic disease. The selectivity of CARs for solid cancers is
crucial, however, due to the absence of truly restricted tumor antigen expression
and potential safety concernswith “on-target off-tumor” activity. Here, we show
that optimized co-stimulatory signaling and extracellular spacer domains are
essential in defıning a CAR’s selectivity towards tumor cells that over-express
the target antigen. The 4-1BB co-stimulatory domain in PSCA-CARs confers
enhanced tumor selectivity with dampened yet dose-responsive cytokine pro-
duction, reduced T cell exhaustion phenotype, and equivalent tumor killing
ability compared to PSCA-CARs containing the CD28 co-stimulatory domain.
CARs containing a short extracellular spacer demonstrate the most selective
killing of high PSCA-expressing tumors but are unable to produce the inflam-
matory cytokines important for a complete anti-tumor response. We show that
longer extracellular spacers in PSCA-CARs are necessary for both tumor killing
and cytokine production. PSCA-CARs exhibit robust in vivo anti-tumor activity
in subcutaneous and orthotopic bone-metastatic patient-derived prostate can-
cer xenograft models, and 4-1BB-containing CARs show superior persistence in
controlling metastatic disease compared with CD28-containing CARs. Our
study demonstrates the critical impact of CAR components in defıning an opti-
mized tumor-selective CAR T cell, and also highlights the importance of clini-
cally relevant animal models in developing effective solid cancer CAR T cell
therapies.
#4982 Regressionofmetastatic breast cancer after adoptive cell transfer of
tumor infıltrating lymphocytes and checkpoint blockade. Nikolaos Zachara-
kis,1 Katarzyna Trebska-McGowan,2 Robert Somerville,1 Yong-Chen Lu,1 Anna
Pasetto,1 Mary Black,1 Harshini Chinnasamy,1 Hui Xu,1 Jared J. Gartner,1 Todd
D. Prickett,1 Paul F. Robbins,1 Steven A. Rosenberg,1 Stephanie L. Goff,1 Steven
A. Feldman1. 1National Cancer Institute, Bethesda, MD; 2Virginia Common-
wealth University, Richmond, VA.
Background: Adoptive transfer of tumor infıltrating lymphocytes (TIL)
can effect long-term durable regression in patients with metastatic mela-
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noma but has not been widely tested in common epithelial cancers. Similar
to metastatic melanoma, recent studies on epithelial GI cancers report that
tumor regressions can be mediated by adoptively transferred TIL recogniz-
ing non-synonymous somatic mutations. Breast cancer metastatic tumors
are infıltrated by TIL and reactivity against autologous somatic mutations
can be identifıed. Methods: TIL were grown from a metastatic soft tissue
tumor of a patient with hormone and chemotherapy-refractory ER, HER2-
breast cancer. DNA was extracted from tumor and matched normal periph-
eral blood samples for whole exome sequencing (WES) and RNAseq. Non-
synonymous somatic mutations were identifıed and tested for potential rec-
ognition by autologous TIL using previously described tandem mini-gene
and long peptide approaches. Recognition was assessed by IFN- release on
ELISPOT and/or CD137 (4-1BB) upregulation with appropriate controls.
Mutation reactive TIL were rapidly expanded in culture and transferred back
to the patient. Adoptive cell transfer was preceded by a lymphodepleting
preparative regimen and one dose of pembrolizumab. Cells were supported
post-transfer with intravenous IL-2 administration, and pembrolizumab was
administered for three additional doses. Deep sequencing of TCR rearrange-
ment sequences was performed on the TIL and the pre- and post-infusion
peripheral blood. Results: The resected subcutaneous tumor no longer ex-
pressed ER and was negative for PD-L1 staining. WES/RNASeq identifıed 96
non-synonymous mutations for testing. Multiple CD4 clones specifıcally
recognizing a mutation expressed in the solute carrier SLC3A2 (p.K94T) and
a single CD8 clone recognizing a mutation in the proteasome-associated
protein KIAA0368 (p.S186F) were identifıed with no recognition of wild-
type peptides. These eight T cell clones constituted 23% of the infusion bag
TIL. Nine months after transfer of 82x109 cells, the patient has an ongoing
partial response, with target lesions down 96% from baseline, including mul-
tiple hepatic metastases and disabling brachial plexus adenopathy. Seven of
the eight T cell clones with known reactivity persisted in the peripheral blood
comprising 2.4% of all CDR3 sequences at 7 months. Only two of these TCR
clones were detectable, with frequencies totaling 0.005%, in the pre-treat-
ment circulation. Conclusions: Tumor-infıltrating lymphocytes derived
from a patient with metastatic breast cancer recognized tumor-specifıc non-
synonymous somatic mutations, expanded in vitro and were used for adop-
tive cell transfer. TIL, co-administered with IL-2 and a short course of pem-
brolizumab, persisted in vivo and mediated regression of soft tissue, nodal
and visceral metastases of breast cancer.
#4983 T cells expressing chimeric PD1 receptors that contain a Dap10
costimulatory domain are a potential treatment formultiple types of cancer.
Kelsey Deal, Emily Nylen, Amorette E. Barber. Longwood Univ., Farmville, VA.
Adoptive transfer of tumor-reactive T cells is a promising anti-tumor therapy
for many cancers. To enhance tumor recognition by T cells, chimeric antigen
receptors (CAR) consisting of signaling domains fused to receptors that recog-
nize tumor antigens can be created and expressed in T cells. One receptor that is
a prospective target for a new chimeric antigen receptor is PD1 because the
ligands for the PD1 receptor are expressed on many cancer types. Therefore we
developed a murine chimeric PD1 receptor (chPD1) consisting of the PD1 re-
ceptor extracellular ligand recognition domain and the activation domain of
CD3 zeta. In addition, current chimeric antigen receptor therapies utilize vari-
ous costimulatory domains to enhance anti-tumor effıcacy. Therefore, we also
compared the inclusion of CD28, Dap10, 41BB, GITR, ICOS, or OX40 costimu-
latory domains in our chPD1 receptor to determine which costimulatory do-
main induced optimal anti-tumor immunity. To determine if this novel CAR
could potentially target a wide variety of tumors, the anti-tumor effıcacy of
chPD1 T cells against murine lymphoma, melanoma, kidney, pancreatic, liver,
and colon cancer cell lines was measured. Of the ten cell lines tested, all ex-
pressed PD1 ligands on their cell surface, making them potential targets for
chPD1 T cells. Regardless of the costimulatory domain in the CAR, all of the
chPD1 T cells induced similar levels of T cell proliferation and tumor cell lysis.
However, differenceswere observed in the cytokine secretion profıles depending
on which costimulatory receptor was included in the CAR. While most of the
chPD1 T cell receptor combinations secreted both pro-inflammatory (IFN,
TNF, IL-2, GM-CSF, IL-17, and IL-21) and anti-inflammatory cytokines
(IL-10 and IL-5) as determined by ELISA and LegendPlex analysis, chPD1 T
cells containing a Dap10 costimulatory domain secreted high levels of proin-
flammatory cytokines, but did not secrete a signifıcant amount of anti-inflam-
matory cytokines. Therefore, adoptive transfer of chPD1T cells could be a novel
therapeutic strategy to treat multiple types of cancer and inclusion of the Dap10
costimulatory domain in chimeric antigen receptors may induce a preferential
cytokine profıle for anti-tumor therapies.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Exploiting Metabolic Vulnerabilities to Treat Cancer
#4984 BNip3 suppresses hepatocellular carcinoma (HCC) growth by lim-
iting lipogenesis. Kay F. Macleod. Univ. of Chicago Ben May Dept. for Cancer
Res., Chicago, IL.
BNip3 is amitochondrial protein that promotes the turnover ofmitochondria
at the autophagolysosome when nutrient supplies are low. BNip3-null livers
exhibit lipid accumulation and develop a phenotype mimicking non-alcoholic
steatohepatitis, a knownprecursor for development of hepatocellular carcinoma
(HCC). Additionally, BNip3 is silenced in human HCC and other malignancies
and this loss often correlates with more aggressive tumors and worse outcomes.
However, the functional signifıcance of BNIP3 loss for growth and progression
of HCC has not been determined. We utilized the diethylnitrosamine (DEN)-
induced mouse model of HCC to determine how loss of BNip3 affected HCC
development in the mouse. Wild type and BNip3-null mice were treated with
DEN, and tumor burden (size and number) was assessed at 6, 8, and 10 months
of age. We also generated primary HCC cell lines from the tumors arising in
BNip3-null mice for in vitro analysis of tumor cell growth and metabolism. We
observed that BNip3-null mice had reduced tumor latency and enhanced tumor
growth rate in the liver following DEN treatment compared to wild type mice
consistent with BNip3 functioning as a tumor suppressor of HCC. Interestingly,
tumors arising in BNip3-null mice accumulated increased lipid and qPCR anal-
ysis of primary tumors and cell lines revealed increased expression of lipogenesis
genes compared to wild type. Treatment with a novel fatty acid synthase inhib-
itor or re-expression of BNip3 in the BNip3-null HCC cell lines reduced tumor
cell growth and lipogenesis, and promoted oxidative metabolism. These results
indicate that BNip3 acts as a tumor suppressor in HCC by limiting de novo
lipogenesis and suggest that fatty acid synthase inhibitors could be effective
therapeutically against BNIP3 defıcient HCC in patients.
#4985 Understanding the vulnerabilities in cancer cells upon inhibition of
glutathione synthesis. Isaac S. Harris, Jennifer E. Endress, Joan S. Brugge.Har-
vard Medical School, Boston, MA.
A hallmark of cancer is the rewiring of cellularmetabolic pathways, including
those that mediate oxidative stress. Cancer initiation and progression, which
demands increased production of ATP and synthesis of proteins, also results in
elevated generation of toxic by-products such as reactive oxygen species (ROS).
Cancer cells counteract ROS by increasing the production of antioxidants,
which convert ROS into benign species. It has been shown that production of
glutathione (GSH), themost abundant intracellular antioxidant, is necessary for
many cancers to initiate malignant transformation. Whether inhibition of GSH
synthesis can impact the survival of established malignant tumors remains
poorly understood. In this study we investigated the extent to which GSH is
required in cancer cells and across different subtypes of breast cancer. Profıling
of an extensive panel of breast cancer cell lines demonstrated that themajority of
cells are resistant to death after acute GSH depletion, while only luminal breast
cancer cells are sensitive to chronic GSH depletion. To understand how most
tumor cells are resistant to GSH depletion and oxidative stress, we conducted a
small-molecule high-throughput screen interrogating more than 500 com-
pounds in a 10-point dilution format. Importantly, screening plates were im-
aged and cell numbers quantifıed to avoid any false positives/negatives poten-
tially associated with interrogating cellular metabolism using classical high
throughput techniques, such as CellTiter-Glo. This screen revealed that deple-
tion of glutathione sensitized breast cancer cells to inhibition of deubiquitinases,
resulting in a drastic induction of a proteotoxic stress response. Furthermore,
this sensitivity was found to be specifıc to malignant cells, as non-transformed
cells were resistant to the combined treatments. It has been hypothesized that
GSH, acting as an abundant thiol group, non-enzymatically reacts with ubiqui-
tin and limits ubiquitination of proteins. Loss of glutathione, in combination
with deubiquitinase inhibitors, leads to deregulation of ubiquitinated protein
pools, and cancer cells undergo proteotoxic stress and cell death. These fındings
elucidate a novel vulnerability in cancers cells and shed light on an unexpected
relationship between cancer metabolism and protein homeostasis.
#4986 Pancreatic cancers develop metabolic resistance pathways to glu-
taminase inhibition. Joseph D. Mancias,1 Douglas E. Biancur,1 Joao A. Paulo,2
Maria Quiles Del Rey,1 Cristovão M. Sousa,1 Xiaoxu Wang,1 Gerald C. Chu,3
Steven P. Gygi,2 J. Wade Harper,2 Alec C. Kimmelman4. 1Dana-Farber Cancer
Institute, Boston, MA; 2Harvard Medical School, Boston, MA; 3Brigham and
Women’s Hospital, Boston, MA; 4New York University Medical School, New
York, NY.
IMMUNOLOGY: Adoptive Cellular Therapy for Cancer
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171276
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive disease
with poor prognosis. Therefore, novel treatment options are essential to combat
this highly refractory disease. Oncogenic Kras can promote ametabolic rewiring
of pancreatic cancers, including the non-canonical use of glutamine to support
growth and proliferation through redox homeostasis. Indeed, inhibition of
downstream components of glutamine metabolism leads to a decrease in tumor
growth. The fırst step in glutamine metabolism is mediated by the enzyme glu-
taminase (GLS) which catalyzes the conversion of glutamine to glutamate in the
mitochondria where, in PDAC, glutamine-derived glutamate is metabolized
ultimately resulting in increased reducing potential in the form of increased
NADPH and GSH. An outstanding question in pancreatic cancer is whether
GLS inhibition is a viable therapeutic strategy given it is the most proximal
enzyme in the PDAC-specifıc glutaminemetabolismpathway, andhow thismay
differ from targeting distal parts of the pathway. Using a combination of in vitro
and in vivo models of pancreatic cancer, we tested whether recently developed
highly potent inhibitors of GLS are an effective therapy for PDAC. We demon-
strate that despite dramatic early effects on in vitro proliferation caused by GLS
inhibition, pancreatic cancer cells have adaptive metabolic networks that allow
them to sustain proliferation in vitro and in vivo. Through an integrated pro-
teomic andmetabolomic analysis, we identify multiple compensatory pathways
that may explain the resistance to GLS inhibition and show as proof of concept
that combining inhibitors to these pathways with GLS inhibitorsmay have ther-
apeutic utility.
#4987 ASS1 downregulation facilitates cancer cell survival in acidic envi-
ronment. Ayelet Erez,1 Alon Silberman,1 Adi Jacob,1 Shiran Limanovich,1
Odeya Boukobza1,1 Erez Persi,2 Rom Keshet,1 Alona Sarver,1 Joo Sang Lee,2
Alexander Brandis,1 Keren Bahar Halpern,1 Raya Eilam,1 Ben Pode,3 Yair An-
ikster,3 Igor Ulitsky,1 Sandesh Nagamani,4 Eytan Ruppin2. 1WEIZMANN IN-
STITUTE, Rehovot, Israel; 2University of Maryland, College Park, MD; 3Sheba
Hospital, Ramat Gan, Israel; 4Baylor college of Medicine, Houston, TX.
”pH gradient reversal”, namely the alkalinization of intracellular pH (pHi)
and acidifıcation of extracellular pH (pHe), is a unique phenotype of cancer cells
which enable cancer survival, migration and invasion. Hence, not surprisingly,
pH gradient reversal is emerging as a newhallmark of cancer. Argininosuccinate
synthase, ASS1, is a urea cycle enzyme found to be downregulated by methyl-
ation in multiple different types of cancers in correlation with increased metas-
tasis and poor prognosis. We recently showed that ASS1 downregulation in-
creases proliferation by channeling aspartate towards pyrimidine synthesis by
CAD. We now show that under hypoxia and acidic environments, ASS1 is
downregulated together with CAD by HIF1 as part of an essential network
necessary for cancer cells’ survival, invasion and migration. Similar to germline
defıciency of ASS1 which increases the levels of glutamine and ammonia, ASS1
downregulation by HIF1enables the cancer cells to increase glutamine levels
allowing its utilization for glutathione and importantly, for preservation of alkali
pHi by elevating ammonia levels and buffering the acidity caused by cancers’
enhanced glycolysis and the consequent increase in lactic acid.Moreover, cancer
cells which express ASS1 when grown in culture, downregulate its expression in
hypoxic regions when grown in vivo, suggesting that these cancersmight also be
sensitive to drugs previously utilized only in ASS1 defıcient cancers. Finally, we
show that treating cancers with ASS1 defıciency with ammonia scavengers as
given toASS1 defıcient patients, increases apoptosis and restrictsmigration, and
is hence benefıcial therapeutically. In summary, ASS1 downregulation is regu-
lated differently at altered carcinogenic states, promoting proliferation as well as
cancer survival and metastasis.
#4988 Genome-wideCRISPR screen andmetabolite profıling reveal a new
mechanism of methotrexate sensitivity. Naama Kanarek, Elizaveta Freink-
man, Jason Cantor, Monther Abu-Remaileh, Tim Wang, David M. Sabatini.
MITWhitehead Inst. for Biomed. Research, Cambridge, MA.
The chemotherapeutic drugmethotrexate (MTX) inhibits nucleotide biosyn-
thesis and causes cell death by blockingDNA andRNAproduction.WhileMTX
has had tremendous success as an anti-cancer treatment and is the subject of
nearly a thousand ongoing clinical trials, we do not fully understandwhy certain
cancers are more sensitive to it and why resistance emerges. To study these
questions, we used a CRISPR-based genetic screen to identify genes that confer
sensitivity toMTX.We identifıed an enzyme that plays a key role in a metabolic
pathway that was not known to be associatedwithMTX sensitivity. Inhibition of
the pathway, either by genetic loss of several genes in the pathway or through
nutritional modulations, causes dramatic resistance to MTX in cultured cancer
cells. Our results improved our understanding of the cellular response to MTX,
and suggest that expression levels of enzymes in the pathway may serve as clin-
ical predictor for MTX response in patients.
#4989 3D spheroid screen yields SCD1 pathway inhibitors for the treat-
ment of cancer. Sylvia Gruenewald, Carolyn Sperl, Patrick Steigemann, Alex-
ander Walter, Sylvia Zacharias, Uwe Eberspaecher, Roland Neuhaus, Ludwig
Zorn,Wolfgang Schwede, Kai Thede, Sven Christian. Bayer Pharma AG, Berlin,
Germany.
With three-dimensional growth conditions, multicellular tumor spheroids
reproduce several parameters of the tumor microenvironment, including oxy-
gen and nutrient gradients, characteristic of poorly vascularized tumor regions.
3D high content screening (HCS) identifıed compounds that selectively kill tu-
mor cells in the inner core of tumor cell spheroids by targeting the Stearoyl CoA
Desaturase 1 (SCD1) pathway. SCD1 catalyzes the rate-limiting step in the pro-
duction of mono-unsaturated fatty acids (MUFAs). Cancer cells are dependent
on higher levels of MUFAs compared to normal cells and SCD1 is highly ex-
pressed in multiple tumor types. Changes in the MUFA / SFA (saturated fatty
acid) ratio alters lipid biosynthesis and thus triggers cellular (ER) stress and
induces the Unfolded Protein Response. Although the lead compound was very
effective in vitro, it had unfavorable PK and physical chemistry properties, in-
cluding low permeability and solubility and very high lipophilicity. This led to
insuffıcient oral bioavailability, which could be overcome by optimization of PK
and physical chemistry properties. Here, we report on the in vitro/in vivo effects
of our 3D HCS compounds which showed high potency in the 3D spheroid
inner core death assay with T47D breast cancer cells. In this in vitro model
compound-induced inner core cell death is enhanced by SCD1 substrates
palmitic or stearic acid and rescued by the SCD1 products palmitoleic or oleic
acid. Furthermore, the effects can be reproduced in 2D cultures, which become
increasingly sensitive to inhibition by our 3D HCS compounds with decreasing
FBS concentration in the culture medium and this effect can also be rescued by
addition ofMUFAsbut not of palmitic acid.Mode of action analysis showed that
our compounds reduced palmitoleoyl- or oleoyl-CoA levels and simultaneously
increased saturated fatty acyl-CoAs of palmitate or stearate in several cell lines as
well as in vivo. In the sensitive T47D cells, the compounds induced expression of
stress response genes and genes related to lipid metabolism. While these results
support the SCD1 pathway as target for our 3D HCS compounds, we also ob-
served striking differences to published SCD1 inhibitors suggesting a new can-
cer target beyond SCD1. Thus, further validation of our inhibitors in vitro and in
vivo will be required, but these results suggest that 3D spheroid cultures may be
a valuable tool for elucidation of new drug targets for cancer therapy.
#4990 High-throughput drug combination screening in tumor spheroids
identifıes context-dependent synthetic lethalities.Wojciech Senkowski,1 Ma-
diha Nazir,1 Malin Jarvius,1 Jenny Rubin,1 Johan Lengqvist,2 Mats G. Gustafs-
son,1 Peter Nygren,1 Kim Kultima,1 Rolf Larsson,1 Mårten Fryknäs1. 1Uppsala
University, Uppsala, Sweden; 2Karolinska University Hospital, Solna, Sweden.
Monolayer, two-dimensional (2D) cell cultures have been a predominant in
vitromodel in anticancer drug discovery and high-throughput screening (HTS).
However, 2D cultures of cancer cells lack numerous properties of in vivo tumors,
such as tissue-like structure, cell-cell interactions and nutrient/oxygen gradi-
ents. Thus, in recent years there has been an increased interest in 3D cell cul-
tures, such as multicellular tumors spheroids (MCTS), to address some of these
limitations. Recently, we and others have applied MCTS for HTS and identifıed
oxidative phosphorylation (OXPHOS) as a selective vulnerability of quiescent
cancer cells persisting in hypoxic and nutrient-deprived milieu. However, pro-
longed continuous exposure to OXPHOS inhibitors is necessary for the cyto-
toxic effect. Thus, there is a need to identify processes that could be co-targeted
for enhanced anticancer activity. Here, we present two distinct HTS approaches
to identify combination partner molecules for OXPHOS inhibitors. Since we
were interested in targeting non-dividing nutrient-deprived cancer cells, we
used quiescent MCTS (Q-MCTS), as an in vitro model. Cells in Q-MCTS expe-
rience glucose concentrations and pH similar to those observed in deep tumor
parenchyma in vivo. In our fırst screening approach, we have applied high-
throughput gene-expression profıling to study drug effects in MCTS at a large
scale. Using L1000 Gene Expression Profılingmethod, we generated a dataset of
over 1000 drug-induced gene-expression profıles and found that co-targeting of
OXPHOS and themevalonate pathway results in selective synergistic toxicity in
quiescent cancer cells. In the other approach, we screened a library of 1650
biologically active compounds, with or without addition of the FDA-approved
anthelmintic agent nitazoxanide (an OXPHOS inhibitor with high drug repur-
posing potential). After the screen, we selected molecules that demonstrated
pronounced synergy when combined with nitazoxanide, but not when used
alone. Then, we validated the hits in an extensive dose-response combination
experiments in Q-MCTS and chose 14 compounds that demonstrated strong
synergistic interaction with nitazoxanide at broad range of concentrations.
These included antifungal agents, kinase inhibitors and others. In summary, we
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here report on novel approaches, utilizing 3D cell cultures, to identify drug
combinations targeting quiescent cancer cells. By high-throughput gene-ex-
pression profıling and large-scale combinatorial drug screens, we were able to
identify drug combinations preferentially toxic to quiescent cells. This work also
demonstrates how 3D cell cultures yield functional insights that are not acces-
sible through standard 2D cultures.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Transcriptional Regulation in Cancer Cells
#4991 Dynamic reprogramming of the chromatin landscape in cancer:
studies in real time. Ville Paakinaho, Diego M. Presman, Erin E. Swinstead,
Tina B. Miranda, David A. Ball, Tatiana S. Karpova, Gordon L. Hager.National
Cancer Institute, Bethesda, MD.
Reprogramming of the chromatin landscape by sequence-specifıc transcrip-
tion factors (TF) can influence in the prevalence and progression of several
diseases, including cancers. Steroid receptors are a class of hormone-regulated
TF that have amajor impact on the progression of cancers. The link between the
androgen receptor (AR) action in prostate cancer and the glucocorticoid (GR)
and estrogen receptor (ER) action in breast cancer is well-known. Furthermore,
other TFs such as the pioneer factor FoxA1 has been extensively linked to AR
andER action in these cancers. Although the action of these TF have beenwidely
studied, the knowledge is almost exclusively based on population-based assays
such as ChIP-seq and DHS-seq. Hence, the dynamic binding behavior of these
factors in living cell remains unclear. For example, the classical pioneer factor
model suggests long term static binding events between pioneer TFs, such as
FoxA1, and chromatin. However, little is known on the dynamic action of
FoxA1 in living cells. We have examined the behavior of steroid receptors and
cofactors, including FoxA1, at the single-molecule level in living cells. These
factors were fused with HaloTag, and labeled with the bright and stable fluoro-
phore JF549. Single-molecule tracking (SMT) of these proteins (using HILO
microscopy) revealed a highly dynamic binding behavior of TFs. This supports
transient rather than stable TF chromatin interactions. Specifıcally, two distinct
binding populations have been observed for all factors tested; fast or slow stops.
Fast stops represent genomic scanning of TF, while slow stops, with residence
time of 6-14 sec, represent functional binding events at specifıc response ele-
ments. The vast majority of molecules at any given time are either diffusing or
exhibit fast stops, while only a small percentage exhibit slow stops. However,
hormone activation of AR, GR or ER results in an increase in the percentage of
molecules with slow stops compared to the unstimulated state. Thus, our results
indicate that on a single-molecule level, only a small proportion TFs are func-
tionally bound at any given time. In addition to affırming the general model that
many TFs are highly dynamic in their chromatin binding activity, SMT experi-
ments in live cells revealed a highly dynamic interaction of FoxA1 with chroma-
tin in vivo. Unexpectedly, we also observed by ChIP-seq and DHS-seq analysis
that at subset of genomic sites, the role of pioneer can be reversed, with the
steroid receptors serving to enhance binding of FoxA1. We propose a general
model, dynamic assisted loading, wherein interactions between TFs and pioneer
factors are highly dynamic. Our fındings show that the action of key TFs in
cancer development aremore complex and dynamic in real time than previously
reported.
#4992 Miswired super enhancer logic driving childhood sarcoma. Berkley
E. Gryder,1 Marco Wachtel,2 Hsien-Chao Chou,1 Young Song,1 Joana
Marques,2 Beat Schaefer,2 Javed Khan1. 1National Cancer Institute, Bethesda,
MD; 2University Children’s Hospital, Zurich, Switzerland.
Super enhancers (SEs) are regulatory regions with unusually large deposits of
active histone marks, chromatin regulators and transcriptional coactivators.
Chromosomal rearrangements allowing SEs to drive oncogene expression is an
emerging mechanism in tumor biology. An aggressive myoblastic cancer of
childhood, alveolar (fusion-positive) rhabdomyosarcoma (FP-RMS), univer-
sally possesses a chromosomal translocation, involving most commonly PAX3
and FOXO1, more rarely PAX7-FOXO1, and in exceptional cases novel PAX3-
INO80D and PAX3-NCOA1 fusions. Patients with a PAX3-fusion frequently
relapse and have low survival rates. PAX3 initiates specifıcation of the muscle
lineage, but is shut off during myogenic differentiation, which is in turn domi-
nated by master regulators MYOD and fınally MYOG. FP-RMS has the master
regulators needed to trigger muscle differentiation, but are halted in an early
myoblastic and thus more proliferative epigenetic state. We hypothesized that
the translocations miswires regulation of the fusion oncoprotein in FP-RMS by
hijacking SEs and creating new topologically associated domains (TADs) which
allow for continued expression of PAX fusions, thus circumventing normal
myogenic enhancer logic. Thus, we recently completed the fırst epigenetic land-
scape of FP-RMS and uncovered a strong dependence on SEs for tumor survival,
with PAX3-FOXO1 being a chief determinant of SE formation in collaboration
with MYOD and MYOG, and oncogene MYCN. Importantly, we discovered a
key SE 300 kb distal of FOXO1 which was occupied by all four of these master
regulators. Further, we found that PAX3-FOXO1 is driven by this novel trans-
located SE forming a key TAD structure which was necessary to directly influ-
ence PAX3 upon translocation, with CTCF analysis in FP-RMS cells confırming
the predicted boundaries. The CTCF motif orientation was found to be antipa-
rallel after the translocation event, permitting chromatin loop extrusion. We
demonstrate these elements to physically interact only in the presence of the
translocation by chromatin conformation followed by sequencing (4C-seq).
Exon-level expression via RNAseq in primary tumors revealed that the fınal
exon of PAX3, not involved in the translocation, was unexpressed, indicating
that only the allele influenced by the FOXO1 SE is activated in patients. Finally,
CRISPR/Cas9 technologies were employed to functionally interrogate the rela-
tive contributions of the enhancer elements and CTCF looping sites at TAD
boundaries. Together these data suggest that these newly juxtaposed enhancer
elements initiate and continually drive PAX3-FOXO1 expression, implicating
that enhancer miswiring is at the heart of the oncogenic process in FP-RMS.
Thus, late myogenic factors (MYOG/MYOD) are contributing to drive an early
factor (PAX3), changing a “progressive” enhancer logic into an “infınite loop”
enhancer logic.
#4993 The role of super-enhancers and genetic boundaries in gene regu-
lation. Michaela Willi, Tyler M. Kuhns, Kyung Hyun Yoo, Fabian Reinisch,
Christian Reinbold, Teresa Mohr, Chaochen Wang, Lothar Hennighausen. NI-
DDK/NIH, Bethesda, MD.
The purpose of this study was to investigate the role of the Zn fınger protein
CTCF in the establishment of genetic borders and in controlling spatially-re-
stricted activity of a mammary-specifıc super-enhancer (SE) known to selec-
tively activate gene expression during pregnancy. CRISPR/Cas9 gene editing
was used to generate mice with deletions in CTCF binding sites (CBSs) separat-
ing the Wap SE from the Ramp3 gene. ChIP-seq and qRT-PCR were used to
investigate protein-DNA interactions and changes in gene expression, respec-
tively. RNA-seq data demonstrated that expression of the mammary-specifıc
Wap and widely-expressed Ramp3 gene was activated inmammary tissue at the
onset of lactation. To investigate the possibility that the Wap SE can regulate
both genes, mice carrying deletions in the SE were established. In these mice,
both Wap and downstream Ramp3 were downregulated to the same extent,
supporting the notion that the SE regulates both genes. Given these results, we
investigated the contributions of several intervening CBSs in dampening SE
activity on Ramp3. Mice harboring individual and combinatorial deletions of
three CBSs (A, B and C) between theWap SE and Ramp3were generated.While
loss of CTCF at site B (
B) had no apparent effect, loss of site A (
A) led to an
expansion of H3K27ac from the adjacent SE in mammary tissue. The site C
mutation (
C) resulted in a two-fold induction of Ramp3 in mammary tissue.
Mice lacking all three binding sites demonstrated a marked increase in Ramp3
expression, which indicates that the CBSs block expression in an additive man-
ner. To test the possible insulator function of these in a tissuewith opposing gene
expression, cerebellum was chosen as Ramp3 is actively transcribed while Wap
is silent. The 
A and 
B mice showed no phenotype, but surprisingly 
Cmice
demonstrated an 80% reduction in Ramp3 expression. Analysis of ChIP-seq and
DNAse-seq demonstrated that site C coincides with a cerebellum-specifıc en-
hancer, which appears to regulate Ramp3 expression. These data demonstrate
that a SE can activate two genes, albeit to different degrees. Furthermore, we
demonstrate that CBSs do not serve as tight genetic boundaries encapsulating
transcriptional enhancers and their associated genes, but are porous borders
that allow for fıne tuning of transcriptional activity. Individual CBSs have a
modest ability to insulate genes, but a cluster of CTCF proteins is required to
adjust the enhancer activity on genes and prevent deregulation. In addition, we
show that CBSs are not restricted to a unique function and can act in a tissue-
specifıc manner to contribute to gene regulation. These data help us to develop
a more nuanced understanding of SE function as well as the roles of CTCF in
regulating gene expression. Previous studies have shown that SEs and CBSs are
mutational hotspots in cancer, implicating them in tumorigenesis. Amore com-
plete understanding of their biology will allow a better understanding of their
role in cancer.
#4994 Understanding the MYC andWDR5 interaction at chromatin. Al-
issa D. Guarnaccia, April M.Weissmiller, Lance R. Thomas,William P. Tansey.
Vanderbilt University, Nashville, TN.
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MYC is an oncoprotein that is overexpressed in the majority of malignancies
and contributes to an estimated 70,000-100,000 cancer deaths in the United
States every year. The broad pro-tumorigenic functions of MYC stem from its
role as a sequence-specifıc transcriptional regulator, controlling the expression
of thousands of genes linked to cell cycle control, growth, and metabolism. Key
to understanding how MYC causes cancer, therefore, is understanding the
mechanisms through which it selects its target genes. Histone modifıcations,
DNA sequence, and interactions with other transcription factors have all been
suggested to influence where MYC binds chromatin, but a consistent signature
has not been defıned. Our laboratory recently discovered that the chromatin
regulatory protein WDR5—a core component of histone modifying complex-
es—interacts directly with MYC and co-localizes with MYC at a majority of its
target genes in human cells (Thomas et al., Mol. Cell, 58: 440-452, 2015). Point
mutations inMYC that disable interactionwithWDR5 do not impact the ability
of MYC to bind naked DNA, but they do prevent MYC from recognizing target
genes in the context of chromatin and from driving tumorigenesis in mice.
These studies led us to propose that the MYC-WDR5 interaction is a critical
determinant in MYC target gene recognition, in a process we refer to as “facili-
tated recruitment.” In the facilitated recruitment model, the presence of WDR5
at chromatin promotes MYC binding at certain genomic loci over others. The
role ofWDR5 in target gene selection byMYC can explainmuch of the plasticity
in genome-wide binding patterns of MYC that have been reported, and may
provide a new avenue for therapeutically targeting MYC in cancer. Two impor-
tant questions are raised by these studies, however. How does WDR5 recognize
and select its target genes? And what other functions, if any, doesWDR5 play in
regulating MYC target genes? To answer these questions, we are employing
traditional and quantitative proteomics, together with biochemical approaches,
to characterize the composition and stoichiometry of the WDR5-containing
complex that associates with MYC. These studies, still ongoing, have demon-
strated that this complex is devoid of canonicalWDR5-interactionpartners such
as RBBP5 and HCF-1, revealing that the function of WDR5 in this setting is
distinct from its well-characterized roles in histone modifıcations. We propose
that the WDR5 complex that associates with MYC on chromatin is either en-
tirely novel, or is a ’ghost’ complex in which select protein components have
been excluded by the direct interaction of MYC with WDR5. We continue to
defıne the biochemical constituents of the MYC-WDR5 complex, and will in-
terrogate their role in facilitated recruitment using a combination of genetic,
biochemical, and genomic, approaches.
#4995 Premature polyadenylation causes oncogenic truncations of the
tumor suppressor genes BRCA1, LATS1 and MAGI3 in breast cancer.
Thomas K. Ni, Charlotte Kuperwasser. Tufts University, Boston, MA.
Cleavage and polyadenylation is a fundamental process in the control of gene
expression, yet how cancer cells deregulate this process to generate cancer-caus-
ing alterations is only beginning to be appreciated.Wepreviously showed that in
human breast cancer, premature polyadenylation of the tumor suppressor gene
MAGI3 causes the expression of a truncated protein that dominantly promotes
malignant growth via the Hippo pathway. This established a precedent for pre-
mature polyadenylation as an aberrant process causing transformation in vitro
and in vivo. However, little is known about the molecular mechanism that
causes premature polyadenylation, or what types of genes it affects in cancer.
Despite the absence of cis-acting mutations, premature polyadenylation of
MAGI3 occurs specifıcally following the gene’s large internal exon.We therefore
asked whether an epigenetic mechanism might underlie the phenomenon of
premature polyadenylation in cancer. Here, we report that genes with large
internal exons are susceptible to truncation by premature polyadenylation. In
addition to MAGI3, premature polyadenylation truncates the gene products of
two tumor suppressor genes with large internal exons, BRCA1 and LATS1.
These truncated proteins are upregulated in breast cancer cells compared to
non-transformed mammary epithelial cells and enable downstream oncogenic
events instead of providing tumor suppressive functions. Large internal exons
are infrequently found in the genome as the mechanics of effıcient splice site
recognition favor small exons. Interestingly in transcripts, large internal exons
are conspicuously enriched in N6-methyladenosine (m6A), though the func-
tional signifıcance of these epitranscriptomic marks remains unknown. Molec-
ularly, we fınd that methylated levels of N6-adenosine in the large internal exons
of BRCA1, LATS1 and MAGI3 transcripts are signifıcantly reduced in breast
cancer cells that upregulate the truncated gene products compared to non-trans-
formed mammary epithelial cells. These results raise the intriguing possibility
that m6A marks in large internal exons are mechanistically involved in repress-
ing premature polyadenylation. We are currently investigating this hypothesis
by perturbing N6-adenosine methylation in cells and examining the functional
consequences. In summary, our study suggests that premature polyadenylation
may be a more pervasive alteration mechanism than previously appreciated in
cancer and begins to illuminate a gene region-specifıc mechanism responsible
for repressing premature polyadenylation.
#4996 The m6A hallmark of cancer: RNA demethylase ALKBH5 main-
tains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1
expression and cell proliferation. Sicong Zhang, Aidong Zhou, Oliver Bo-
gler, Sadhan Majumder, Suyun Huang.MD Anderson Cancer Ctr., Houston,
TX.
N6-methyladenosine (m6A) is the most prevalent internal modifıcation on
mRNA, but its functions in humandiseases are poorly understood. The dynamic
and reversible m6A modifıcation installed and erased by N6-methyltransferases
and demethylases regulates cell fate and gene expression.We show that them6A
demethylase ALKBH5 is highly expressed in patient-derived glioblastoma stem-
like cells (GSCs) and informs poor survival of patients with glioblastoma. Silenc-
ingALKBH5 suppresses the proliferation of GSCs in vitro and in vivo. Results of
integrated transcriptome and m6A-seq analyses reveal a global change of gene
expression enriched in cell cycle and altered expression of select ALKBH5 tar-
gets. Among these targets, Ingenuity’s upstream regulator analysis identifıed
FOXM1, an essential transcription factor for GSC proliferation, as a key medi-
ator responsible for the disrupted proliferation program. Usingmultiple molec-
ular and biochemical approaches, we demonstrate that ALKBH5 binds to and
demethylates FOXM1 nascent transcripts. This promotes the interaction of
FOXM1 pre-mRNA with HuR, thereby maintaining FOXM1 expression. Fur-
ther, a long noncoding RNA antisense to the FOXM1 (FOXM1-AS) interacts
with ALKBH5 as well as FOXM1 pre-mRNA and promotes their interaction.
Depleting ALKBH5 and FOXM1-AS abolishes GSC tumorigenesis through the
FOXM1 axis. The vulnerability of GSCs to disruptions in ALKBH5-dependent
gene expression suggests that m6A has a central role in tumor development and
provides a rationale for therapeutically targeting epitranscriptomic modulators
in patients with glioblastoma.
#4997 Specialized microRNP and translation mechanisms in quiescent
cancer cells. Syed I. Bukhari,1 Samuel S. Truesdell,1 Sooncheol Lee,1 Swapna
Kollu,1 Anthony Classon,1 Myriam Boukhali,1 Esha Jain,2 Richard D.
Mortensen,1 Akiko Yanagiya,3 Ruslan Sadreyev,2 Wilhelm Haas,1 Shobha Va-
sudevan1. 1Massachusetts General Hosp. Cancer Ctr., Boston, MA; 2Massachu-
setts General Hosp., Boston,MA; 3McGill University,Montreal, Qc, Quebec, Can-
ada.
Quiescence (G0) represents an assortment of reversible, cell cycle-arrested
states that are resistant to unfavorable conditions and associated with cancer
persistence. G0 involves regulated gene expressionwith selectivemRNAexpres-
sion and decreased canonical translation. LowmTORactivity inG0 activates the
cap complex inhibitor, eIF4EBP, and impairs canonical translation. The alter-
native translation mechanisms in G0 remain to be uncovered. Our data show
that microRNAs, regulatory, non-coding RNAs that target distinct mRNAs to
alter gene expression, can associate with alternative complexes and translation
factors to regulate specifıc mRNA translation in G0. One subset of transcripts
expressed in G0 includes specifıc mRNAs recruited by an FXR1a-associated
microRNP (microRNA-protein complex) for translation activation inG0mam-
malian cells. MicroRNPs predominantly mediate repression and downregula-
tion; however, FXR1a-microRNP lacks conventional microRNP repressors, and
instead, contains a specifıc RNA binding protein isoform, FXR1a. FXR1a pro-
motes translation and is overexpressed and associated with poor prognosis in
several cancers. Our data reveal that microRNA-mediated activation requires
target mRNAs with unadenylated/ shortened poly(A) tails to avoid the roles of
PABP in enhancing microRNA-mediated downregulation and in canonical
translation that is impaired in G0. Instead of canonical translation factors that
are inhibited by eIF4EBP in G0, we fınd alternative translation factors—a non-
canonical 5’cap binding factor and an eIF4G homolog that interacts with the
ribosome—are recruited by the 3=-UTR binding FXR1a-microRNP, and pro-
mote specifıc mRNA translation. Our data show that G0 leukemic cells are
chemoresistant and their translation profıle is similar to surviving leukemic cells
that are isolated after clinical therapy. We fınd expression of critical cytokines
and immune regulators in G0. Signifıcantly, inhibiting these immune regulators
in resistant G0 cancer cells reduces their survival and chemoresistance. These
data reveal a specialized translationmechanism inG0 cancer cells that promotes
specifıc mRNA translation in these conditions of reduced canonical translation,
and is important for chemoresistance.
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PREVENTION RESEARCH: Biomarkers and Intervention Studies
#4998 Breast tumor FOXA1 protein expression and reproductive charac-
teristics among African-American and European-American women. Ting-
Yuan David Cheng,1 Rochelle Payne Ondracek,2 Song Yao,2 Wiam Bshara,2
Thaer Khoury,2 Gary R. Zirpoli,3 Warren Davis,2 Elisa V. Bandera,4 Michael
Higgins,2 Christine B. Ambrosone2. 1University of Florida, Gainesville, FL; 2Ro-
swell Park Cancer Institute, Buffalo, NY; 3Massachusetts General Hospital, Bos-
ton, MA; 4Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
Background: Forkhead box proteinA1 (FOXA1) plays a key role in determin-
ing estrogen receptor (ER) function andmammary ductal development andmay
repress the basal cell phenotype during differentiation of breast epithelium.
While reproductive factors are known to influence breast cancer risk depending
on the subtypes, data on the association of tumor FOXA1protein expression and
reproductive characteristics are very limited.Methods: Tissuemicroarrays com-
prising surgical tumors from 638 women (466 African-American [AA] and 172
European-American [EA], aged 20-75 years) with primary breast cancer in the
Women’s Circle of Health Study (WCHS) were analyzed for FOXA1 expression
by immunohistochemistry and automated image analysis. In-person interviews
were conducted to obtain data on demographics, medical and family histories,
and reproductive andmenstrual histories. Logistic regressionwas performed for
FOXA1positivity (10% cells with strong staining)withmenopausal status, age
at menarche, age at fırst live birth, parity, and breastfeeding, adjusting for age at
diagnosis, family history of breast cancer, and history of benign breast disease.
Results: FOXA1 expression was higher in tumors from EA compared to those
from AA women (80% vs. 70% positivity, P0.011). FOXA1 expression was
highly correlatedwith ER positivity (88%positive in ER and 26% in ER- breast
cancer among AA women; 90% and 29% respectively among EA women; both
P0.001). Among AA women, a higher number of live births was associated
with lower FOXA1 expression (odds ratio [OR]0.45, 95% confıdence interval
[CI]0.22-0.91 for 2 live births and OR0.44, 95% CI0.20-0.91 for 3 live
births, versus nulliparous). However, the inverse association was not observed
among EA women, potentially due to the small sample size. Conclusion: In AA
women, a higher number of live births, which has been related to greater risk of
ER- breast cancer, is associated with lower FOXA1 expression. Because FOXA1
promotes luminal and represses the basal differentiation, respectively, the effects
of parity on expression of FOXA1 may be the link whereby it increases risk of
ER- breast cancer. (Funding: NIH P01CA151135, R01CA100598,
R01CA185623, P30CA072720, K07CA201334; US ArmyMedical Research and
Material Command DAMD-17-01-1-0334; the Breast Cancer Research Foun-
dation; and the Philip L. Hubbell family)
#4999 Stress, spiritual wellbeing and cancer risk among diverse racial
faith-based communities: elevated levels of stress proteomic biomarkers in
breast cancer patients. Padma P. Tadi Uppala,1 Gretchen Krivak,1 Sherine
Brown-Fraser,1 Dixon Anjejo,1 Alfredo Mejia,1 Dominique wakefıeld,1 Kumar
Kolli2. 1Andrews University, Berrien Springs, MI; 2Windber Research Institute,
Windber, PA.
Spiritual wellbeing is associated with decreased risk for cancer. Stress and
depression are common among cancer patients andmay be inversely associated
with spiritual wellbeing. The purpose of the study is to examine if stress and
depression as indicators of cancer risk are lower in a racially diverse faith-based
community. Methods: 752 individuals from a faith-based community com-
pleted a behavioral assessment survey that mapped the current patterns of be-
havior in key categories that include: stress, depression, exercise and nutrition
using the E-wellness platformFitThumb.To identify stress biomarkers in cancer
patients we examined levels of stress serum proteomic biomarkers that were
previously identifıed in our study by proteomic profıling using 2D-DIGEMS
analysis and a subset of samples by shotgun LCMS technology. The serum pro-
teomic study included serum samples from 15 African American breast cancer
patients and 12 healthy controls who were from a faith-based community. Re-
sults: The behavioral assessment surveys that included 752 individuals whowere
racially diverse showed a low stress risk of 47.74% vs 8.24%of high stress risk for
chronic disease; and lowdepression risk of 85.11%vs 1.99%high risk for chronic
disease. Elevated levels of stress and inflammatory serum proteomic biomarkers
such as ceruloplasmin known to increase in stressed animals and humans; hep-
taglobin, apolipoproteins, and heat shock proteins were signifıcantly elevated in
breast cancer patients compared to healthy controls. Conclusions: Our results
indicate that spiritual well-being is associated with signifıcantly low stress and
depression in a faith-based community regardless of race or ethnicity, posing a
low risk for cancer as shown inpreviousAdventistHealthCohort studies. Future
efforts will focus on validating and identifying panel of biomarkers from this
cohort to gain insight into their role(s) in the mechanisms of stress hormones
and cancer risk. Funded by Susan G Komen for the cure.
#5000 Astromal liver gene signature predictive ofHCCrisk across all liver
disease etiologies. Shigeki Nakagawa,1 Naoki Umesaki,1 Takanobu Yamao,1
Yuki Kitano,1 Kensuke Yamamura,1 Kota Arima,1 Tatsunori Miyata,1 Takayo-
shi Kaida,1 Yujin Hoshida,2 Katsunori Imai,1 Daisuke Hashimoto,1 Yo-ichi Ya-
mashita,1 Akira Chikamoto,1 Hideo Baba1. 1Graduate School of Medical Sci-
ences, Kumamoto University, Kumamoto City, Japan; 2Icahn School of Medicine
at Mount Sinai, New York, NY.
Background & Aims: HCC risk-predictive biomarkers will enable identifıca-
tion of patients who most need close monitoring and cancer preventive inter-
vention. We previously reported a stromal liver gene signature predictive of
HCC risk in multiple independent patient cohorts mainly affected with HCV
(Hoshida 2008, Hoshida 2013, King 2014). We aimed to determine whether the
gene signature is similarly prognostic in HBV, alcohol abuse, and NAFLD/
NASH patients. Methods: The liver gene signature was analyzed using an FDA-
approved diagnostic platform (NanoString), and an independent cohort of cu-
ratively resected early-stage HCC patients (n223, median follow up 4.5 years,
HCV [n67, 30%], HBV [n39, 17%], alcohol [n51, 23%], NAFLD [n66,
30%], and NASH [n52, 23%, a subset of 66 NAFLD patients]) were analyzed.
Complete surgical resection was radiologically and histologically confırmed,
and HCC recurrence in the cohort was confırmed to be mainly late recurrence,
i.e., de novo carcinogenesis, based on a recurrence hazard plot. Prognostic pre-
diction was performed by using a previously developed model without making
anymodifıcation, and evaluated for associationwith de novoHCC recurrence in
multivariable modeling and subgroup analyses. Results: The gene signature as-
say classifıed the patients into high- (n49, 22%), intermediate- (n127, 57%),
and low- (n47, 21%) risk groups. The high-risk prediction was associated with
higher HCC recurrence (HR4.8, p&lt0.001) as well as overall death (HR4.8,
p&lt0.001) in multivariable modeling. The association with HCC risk remained
signifıcant in subgroups of patients with HCV (HR3.0, p0.028), HBV
(HR6.1, p&lt0.001), alcohol (HR6.1, p0.023), and NASH (HR10.9,
p0.03) in multivariable models including cirrhosis and AJCC stage 2/3. The
association was diminished in NAFLD patients (HR3.02, p0.16), suggesting
that presence of active inflammation and/or fıbrosis is critical for the signature to
predict HCC risk in NAFLD. Established cirrhosis was less frequent in NAFLD/
NASH (23%/21%) compared to other etiologies (50%). Conclusions: The prog-
nostic liver gene signature was implemented in a clinically applicable assay, and
successfully validated for de novo HCC recurrence after curative resection of
early-stage HCC in all major etiologies of chronic liver disease and HCC. The
assay will enable prioritization of patients for HCC surveillance and enrichment
of high risk patients for more cost-effective clinical trials of new HCC chemo-
preventive therapies.
#5001 Functional biomarker discovery from cancer patient serum with
PEP technology. David L. Wang, Guofeng Fu, Michael Davies, Xing Wang.
Array Bridge Inc, St. Louis, MO.
Proteins play essential roles in numerous biological processes and being able
to pinpoint functional differences between cell or tissue samples can greatly aid
in understanding disease processes andmetabolic changes. The PEP technology
allows systematic analysis of protein functions within a proteome. Hundreds of
functional proteins can be separated and functionally assayed to generate a com-
prehensive three-dimensional landscape of protein families such as protein ki-
nases, phosphatases, proteinases and oxido-reductases. This information can
then be integrated into other genomic and proteomic knowledge bases to pro-
vide further insight of important biological processes such as cancer develop-
ment and aging. In the PEP technology, complex protein mixtures are fırst
separated by a modifıed two-dimensional gel electrophoresis process, giving
enhanced resolutionwhile stillmaintaining protein function. This is followed by
an effıcient protein transfer to a specially designed 1536-well Protein Elution
Plate. After further transfer of the samples from the PEP plate to multiple 384-
well microplates, functional assays can be performed on eachwell to generate an
enzyme activity profıle displayed in 3-D. Protein components of eachwell can be
further characterized by mass spectrometry if desired. Using the PEP technol-
ogy, functional biomarker candidates have been identifıed from lung and breast
cancer patient serum. Both qualitative and quantitative differences of metabolic
enzymes andproteaseswere observedwhen comparing the cancer patient serum
and normal serum. Some of the active enzymes were identifıed by mass spec-
trometry and validated in selected bioassays. It is believed that this functional
proteomics technology provides a unique approach in the discovery of potential
cancer biomarkers for diagnostic and prognostic applications.
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#5002 Premalignant squamous cell lung carcinoma lesions have distinct
molecular subtypes associatedwithhistologic progression. Jennifer E. Beane,1
Sarah Mazzilli,1 Joshua Campbell,1 Christopher Moy,2 Michael Schaffer,2
Catalina Perdomo,1 David Jenkins,1 Gang Liu,1 Sherry Zhang,1 Hanqiao Liu,1
JessicaVick,1 Evan Johnson,1 Suso Platero,2Marc Lenburg,1Mary Reid,3 Samjot
S. Dhillon,3 Avrum Spira1. 1Boston Univ. School of Medicine, Boston, MA; 2Jans-
sen Pharmaceuticals, Philadelphia, PA; 3Roswell Park Cancer Institute, Buffalo,
NY.
Background: Squamous cell carcinoma (SCC) of the lung is a leading cause of
cancer mortality in the US due to late stage diagnosis and lack of effective treat-
ments. Lung SCC arises in the epithelial layer of the bronchial airways and is
often preceded by the development of premalignant lesions (PMLs). Themolec-
ular events involved in the progression of PMLs to lung SCC are not clearly
understood, and not all PMLs go on to form carcinoma. By molecularly charac-
terizing PMLs and non-lesion areas in the airway of individuals with PMLs, we
hypothesize that we will be able to identify subgroups of PMLs that are more
likely to progress. Methods: We used mRNA sequencing to profıle biopsies
obtained from high-risk smokers undergoing lung cancer screening by auto-
fluorescence bronchoscopy and CT at the Roswell Park Cancer Institute in Buf-
falo, NY. For each subject (n30), we sampled bronchial biopsies repeatedly
over time (394 /- 170 days) with serial bronchoscopies (6 /- 5 biopsies/
subject) as the biopsied area progressed towards or regressed away from frank
malignancy.mRNA-Seq (n197 biopsies) datawas aligned to hg19using STAR,
and gene/transcript levels were summarized using RNA-Seq using RSEM and
Ensembl 74 annotation. Immune, stromal, and epithelial cells content were in-
ferred using the ESTIMATE algorithm and pathway activity of in vitro derived
oncogenic signatures was estimated using GSVA for each sample. Molecular
subtypes were derived using non-negativematrix factorization (NMF) and con-
sensus clustering. Linear modeling was used to associate PML outcome metrics
and pathway activity scoreswith subtypemembership. Results:We identifıed six
distinct molecular subtypes of bronchial biopsies using NMF across the 10%
most variable genes (n2,322 gene). One subtype contained samples with stable
high-grade histology (p0.01). This subtype was also enriched for basal epithe-
lial cell content and oncogenic pathway activity including AKT and EGFR
(p0.01). Another subtype was enriched for immune cell content and had ele-
vated expression of immune-related pathways including chemokine, cytokine,
and T-cell receptor signaling. Increased immune infıltrate was also observed in
H&E stains from biopsies taken adjacent to the sequenced biopsy. Conclusions:
Molecular classifıcation of premalignant lesions may lead to biomarkers of dis-
ease progression that could be used to stratify patients into prevention trials and
to monitor effıcacy of the treatment. Additionally, the results suggest that per-
sonalized interventions targeting specifıc cancer-related pathways or the im-
mune system may be have potential therapeutic benefıts.
#5003 Serum parathyroid hormone and risks of colorectal adenoma, ad-
enoma recurrence and colorectal cancer, results from the Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial. Xiangzhu Zhu,1 Martha J.
Shrubsole,1 Edward Giovannucci,2 Todd L. Edwards,1 Qi Dai1. 1Division of Ep-
idemiology, Department of Medicine, Vanderbilt University, Nashville, TN; 2De-
partments of Nutrition and Epidemiology, Harvard University, Boston, MA.
Background: Serum parathyroid hormone (PTH) may be related to risk of
incident colorectal cancer. However, no study has prospectively examined
whether serum PTH is differentially related to risks of different stages of colo-
rectal carcinogenesis (incident adenoma andmetachronous adenoma). Further,
it is unclear if PTH is associated with risk of incident colorectal neoplasia in
individuals receiving endoscopic screenings. To address these important scien-
tifıc inquiries, we have conducted three nested case-control studies within the
Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Meth-
ods: The PLCO is a large, multicenter, population-based randomized trial de-
signed to determine the effects of screening on cancer-related mortality with a
median of 12.5 years of follow up.We evaluated the associations between serum
PTH and the risks of incident colorectal adenoma (755 cases and 514 controls),
metachronous adenoma (755 cases and 755 controls) and incident colorectal
cancer (755 cases and 514 controls) within PLCO participants aged 55 to 74
years. Odds ratios (OR) and 95% confıdence intervals (95%CIs) were estimated
using unconditional logistic regressionmodels after adjusting for potential con-
founding factors. Results: Compared to low serum PTH (30 ng/L), higher
concentrations of serum PTH were associated with signifıcantly reduced risk of
incident colorectal cancer with the ORs (95% CIs) being 0.65(0.48-0.88) and
0.52(0.35-0.76) for PTH30 ng/L and PTH65 ng/L (p for trend, 0.001). The
inverse associations appeared signifıcant for both women and men. However,
overall, serum PTH was not related to risk of incident adenoma and metachro-
nous adenoma. Conclusion: In conclusion, compared to the lowest PTH levels,
higher serum PTH were related to reduced risks of incident colorectal cancer
among an US population who received endoscopy, but not incident colorectal
adenoma and metachronous adenoma.
#5004 Chemopreventive potential of Lactobacillus kefıri P-IF, a novel ke-
fır product, on Ehrlich ascites carcinoma cells. Nariman K. Badr El-Din,1
Sameh Shabana,1 Bashar A. Abdulmajeed,1 Mamdooh Ghoneum2. 1Mansoura
Univ., Mansoura, Egypt; 2Drew Univ. of Medicine and Science, Los Angeles, CA.
Purpose: Lactic acid bacteria are advantageous microorganisms that exert
benefıcial effects for maintaining health. Our previous studies have shown that
Lactobacillus kefıri P-IF, a novel kefır product, has the ability to activate den-
dritic cells, and to induce apoptosis in human gastric cancer cells and MDR
myeloid leukemia cells in vitro. In this study,we aimed to evaluate the anticancer
effect of L. kefıri P-IF against animal bearing Ehrlich Ascites Carcinoma (EAC)
and investigate the mechanisms of action. Materials and Methods: Mice were
inoculated intramuscularly with EAC cells to develop solid tumors. L. kefıri P-IF
was administered orally (2mg/kg/day) to mice 6 days/week, either two days
before tumor cell inoculation or nine days after inoculation tomice bearing solid
tumors. Tumor growth, blood lymphocyte levels, cell cycle progression, apopto-
sis, apoptotic regulators expression, TNF- expression, changes in mitochon-
drialmembrane potential (MMP), PCNA, andCD4 andCD8T cells in tumor
cells were quantitatively evaluated by flow cytometry or RT-PCR. Further stud-
ies in vitro were carried out where EAC cells were cultured in the presence of L.
kefıri P-IF at different concentrations (0, 0.6, 1.25, 2.5, and 5 mg/mL) for 1, 24,
and 48 hrs. % cell viability and IC50 was estimated by MTT assay. Results: 100%
of mice that were inoculated with EAC cells alone developed tumors. Mice
pretreated with L. kefıri P-IF showed tumor incidence in 76.5% of the animals.
Treatment with L. kefıri P-IF markedly reduced tumor weight: 64.6% for pre-
treatment and 48.6% for post treatment. Mice treated with L. kefıri P-IF showed
profound suppression of tumormarker PCNAexpression and cell cycle arrest in
the sub-G0/G1 phase, as indicated by elevation in the apoptotic cell population by
2.7 and 2.3 fold of control for pretreatment and post treatment, respectively.
Pretreatment or post treatment with L. kefıri P-IF in EAC mice increased the
Apoptosis index/ Proliferation index ratio by 3.4 and 2.4 fold, respectively versus
control. L. kefıri P-IF treatment modulated apoptotic regulators, including up-
regulation of p53 expression, increased Bax/Bcl-2 ratio, decreasedMMP of can-
cer cells, and activation of caspase-3 expression. L. kefıri P-IF intakemaintained
blood lymphocyteswithin the normal levels, increased the number of infıltrating
CD4 and CD8 T cells within the tumor, and enhanced TNF- expression.
Finally, L. kefıri P-IF enhanced cytotoxicity against EAC cells in vitro, as shown
by IC50 of 3.30mg/ml, 1.56 mg/ml, and 1.11mg/ml for 1, 24, and 48 hrs, respec-
tively. Conclusion: In conclusion, L. kefıri P-IF, a novel symbiotic microbe, may
have chemopreventive potential to reduce tumor incidence and tumor growth
by inducing apoptosis in EAC cells via mitochondrial dependent pathway, sup-
pressing cell proliferation, and stimulating the immune system. L. kefıri P-IF
was provided by Paitos Co., Ltd. Yokohama, Kanagawa, Japan. .
TUMOR BIOLOGY: Microenvironmental Cues in Immune Escape
and Therapy Resistance
#5005 Inhibition of E-selectin or E-selectin together with CXCR4 resen-
sitizes multiple myeloma to treatment. Barbara Muz,1 Henna Y. Bazai,1 Anita
Sekula,1 William E. Fogler,2 Ted Smith,2 John L. Magnani,2 Abdel Kareem
Azab1. 1WashingtonUniversity in St Louis, Saint Louis,MO; 2GlycoMimetics Inc,
Rockville, MD.
INTRODUCTION: Multiple myeloma (MM) is a plasma cell malignancy
localized in the bone marrow. Selectins and CXCR4 play a pivotal role in hom-
ing, adhesion, and proliferation of MM. Herein, we tested the role of E-selectin
in the pathophysiology of MM by using a specifıc E-selectin antagonist (GMI-
1271) and a dual E-selectin/CXCR4 antagonist (GMI-1359) on the proliferation
and cell traffıcking ofMM in vitro and in vivo. PROCEDURES: Endothelial cells
(HUVECs), stromal cells (HS5), MM patient-derived stromal cells (MSP1), and
MMcell lines (MM1s,H929, U266 andRPMI8226) were tested for expression of
E-selectin, CLA (E-selectin ligand) and CXCR4 by flow cytometry. The effect of
GMI-1271 and GMI-1359 was studied on MM cell adhesion to stroma; che-
motaxis to stromal media or SDF1; and MM cell survival by MTT assay, where
MM cells were treated with lenalidomide or carfılzomib; in the presence, or
absence of GMI-1271 or -1359. In a xenograft mouse model, the sensitivity of
MMwas tested inmice treated with vehicle, lenalidomide, GMI-1271, or a com-
bination ofGMI-1271 and lenalidomide (n10mice/group); and tumor growth
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was monitored weekly using bioluminescence imaging. SUMMARY: Expres-
sion of E-selectin was high in HUVECs, MSP1 and HS5; CLA was high only in
RPMI8226; and CXCR4was high in all MM cells. MM1s cell adhesion to stroma
was decreased byGMI-1271 and evenmore profoundly decreased byGMI-1359
in a dose-dependent manner. Chemotaxis of MM1s cells towards conditioned
media or SDF1 was modestly affected by GMI-1271, but greatly reduced by
GMI-1359.MM cell proliferation was signifıcantly inhibited by GMI-1359, only
when MM cells were co-cultured with stroma, but not alone. Stroma-induced
drug resistance of MM cells to carfılzomib and lenalidomide was reduced in the
presence of the GMI compounds, while the effect of GMI-1359 was stronger
than GMI-1271. In vivo, GMI-1271 and lenalidomide as single agents delayed
tumor growth compared to vehicle by 40% and 35%, respectively; however, a
combination treatment delayed tumor growthmore profoundly than vehicle by
64% (p0.04). CONCLUSIONS: GMI-1271 and GMI-1359 disrupt the interac-
tion between MM cells and bone marrow microenvironment as determined by
reduction of adhesion, chemotaxis and microenvironment-induced drug resis-
tance in vitro. However, the dual inhibition of E-selectin and CXCR4 produced
more profound effects compared to E-selectin alone. Moreover, GMI-1271 sen-
sitized MM cells to lenalidomide by alleviating chemoresistance and delayed
tumor growth in vivo.
#5006 Correlation between PD-L1 expression and tumor clinicopatho-
logic characteristics in early stage breast cancer. Hadeel Assad, Juan Cattoni,
Subramanyeswara Arekapudi, Nancy Jackson, Hugo Macchi Cattoni, Sherri
Motahari, Hema Govil, Anibal Drelichman. Providence Hospital and Medical
Center, Southfıeld, MI.
Background: Upregulation of Programmed Death-Ligand 1 (PD-L1) in tu-
mor cells results in the deactivation of cytotoxic T cells in the tumor microenvi-
ronment and development of tolerance to the malignant cells. We aimed to
investigate the role of PD-L1 expression in early stage breast cancer and its
correlation with tumor characteristics as well as assess the relationship between
PD-L1membrane protein and gene expression. Methods: For this single center,
retrospective study, women (age18 years) with early stage breast cancer diag-
nosed between January 2005 and December 2005 were enrolled. Key inclusion
criteria for enrollment were pathologic diagnosis of DCIS or invasive ductal/
lobular carcinoma, stage 0-2, with local resection done in 2005. Patients had to
have adequate formalin-fıxed paraffın-embedded tumor specimens for PD-L1
testing. We hypothesized that higher levels of PD-L1 expression correlates with
more aggressive disease and worse prognosis. We used histopathological analy-
sis, medical chart review, and PD-L1 expression via immunohistochemistry
(IHC) and reverse transcription polymerase chain reaction (RT-PCR) for data
analysis. Chi Square and one way ANOVA analyses were used to compare clin-
ical and pathological characteristics of patients with high and lowPD-L1 expres-
sion. Results In 2005, 368 women were diagnosed with breast cancer at Provi-
dence-Providence Park Hospital of which 31 pathological specimens were
obtained for exploratory analysis. PD-L1 protein expression was determined to
be positive if more than 1% of the tumor cells showed partial or complete mem-
brane staining for PD-L1 by IHC. All patients with DCIS (n7) were negative
for PDL-1 expression although 3 showed gene expression by PCR. After exclud-
ing the DCIS specimens, 17% (4/24) of early stage breast cancer was found to
express PD-L1 protein. Seven of 24 specimens (excluding DCIS) were positive
for PD-L1 RNA by RT-PCR. There was no relationship between PD-L1 protein
andmRNA expression (p0.552). 75% of the PD-L1 positive specimens by IHC
were also ER positive although this was not statistically signifıcant (p0.312).
There was a trend toward larger tumors for those expressing PD-L1 on the cell
surface (mean size of 2.7 cm vs 1.7 cm, p 0.07). All the PD-L1 positive speci-
mens had increased lymphocyte infıltration, although no statistical signifıcance
was observed. At 10 years from initial diagnosis, all-causemortality ratewas 29%
(7/24). The rate of death in PD-L1 positive patients was 2/4 (50%) compared to
5/20 (25%) in PD-L1 negative group. Conclusion: Expression of PD-L1 in early
stage breast cancer could be an important indicator for more aggressive disease
and supports investigating checkpoint inhibitors in this population. Further
investigation is needed to determine its applicability in clinical decisions and
effects on treatment.
#5007 Role of the interferon-gamma response pathway in immune escape
of colorectal carcinoma. Nathalie Britzen-Laurent, Julia Straube, Philipp Tri-
pal,MaximilianWaldner, ChristophBecker, SusanneMerkel, Roland S. Croner,
Michael Stürzl. University of Erlangen Nuremberg, Germany.
The presence of an interferon-dominated Th1 immune response in colorectal
carcinoma (CRC) has been associated with improved clinical outcome.We have
previously identifıed the guanylate-binding protein 1 (GBP-1), one of the major
IFN--induced proteins, as a marker for the Th1 immune response and an
independent positive prognostic factor in CRC. We also found that GBP-1 is a
necessary mediator of the anti-tumorigenic effects of IFN. Interestingly, the
expression of GBP-1 in CRC was observed more frequently in the desmoplastic
stroma than in the directly adjacent tumor cells, suggesting that CRC tumor cells
might become resistant to IFN- in the course of tumorigenesis. Indeed, we
found that several colorectal carcinoma cell lines failed to express GBP-1 or
other interferon-stimulated genes after treatment with IFN-, and were resis-
tant to IFN--induced apoptosis or proliferation inhibition. In these cell lines,
the loss of IFN-responsiveness correlated either with the down-regulation of
the IFN- receptor alpha chain (IFNR) or with the presence of a mis-glyco-
sylated form of IFNR, which displayed an aberrant intracellular localization.
We further validated these fındings at the clinical level by showing that the
expression of IFNR is decreased in CRC compared to normal tissue. In addi-
tion, the down-regulation of IFNR expression in CRC correlated with a re-
duced cancer-related survival togetherwith a higher rate of distantmetastasis. In
addition, in-vivo colon tumorigenesismodels using conditional knock-outmice
revealed that the absence of IFNR expression by intestinal epithelial cells
fosters tumor growth. Altogether, our data suggest that the loss of IFN- respon-
siveness is a common event in CRC and protects tumor cells against the anti-
tumorigenic effects of IFN-.
#5008 The brainmicroenvironmentmediates resistance in luminal breast
cancer to PI3K inhibition through HER3 activation. Gino B. Ferraro,1 David
P. Kodack,1 Vasileios Askoxylakis,1 Qing Sheng,2 Mark Badeaux,1 Shom Goel,3
Xiaolong Qi,1 Ram Shankaraiah,1 Alexander Z. Cao,2 Rakesh R. Ramjiawan,1
Divya Bezwada,1 Bhushankumar Patel,1 Youngchul Song,1 Carlotta Costa,1 Ka-
mila Naxerova,1 Christina Wong,1 Jonas Kloepper,1 Rita Das,2 Angela Tam,2
Jantima Tanboon,1 Dan G. Duda,1 Ryan C. Miller,4 Marni B. Siegel,4 Carey K.
Anders,4 Melinda Sanders,5 Valeria M. Estrada,5 Robert Schlegel,2 Carlos L.
Arteaga,5 Elena Brachtel,1 Alan Huang,2 Dai Fukumura,1 Jeffrey A. Engelman,1
Rakesh K. Jain1. 1Massachusetts General Hospital / Harvard Medical School,
Boston, MA; 2Novartis, Cambridge, MA; 3Massachusetts General Hospital / Har-
vard Medical School / Dana Farber Cancer Institute, Boston, MA; 4Lineberger
Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC;
5Vanderbilt-Ingram Cancer Center, Nashville, TN.
Brainmetastases represent a devastating progression of luminal breast cancer.
While targeted therapies are often effective systemically, they fail to adequately
control brain metastases. In preclinical models that faithfully recapitulate the
disparate clinical responses in thesemicroenvironments, we observed that brain
metastases evade PI3K inhibition despite effıcient drug delivery. In comparison
to extracranial disease, there is increasedHER3 expression and phosphorylation
in the brain lesions. HER3 blockade overcomes the resistance of both HER2-
amplifıed and/or PIK3CA-mutant breast cancer brainmetastases to PI3K inhib-
itors, leading to striking tumor growth delay and signifıcant improvement of
mouse survival. Collectively, these data provide a mechanistic basis underlying
therapeutic resistance in the brainmicroenvironment and identify rapidly trans-
latable treatment strategiesfor HER2-amplifıed and/or PIK3CA-mutant breast
cancer brain metastases.
#5009 Self-renewal of hypoxic glioma stem-like cells is facilitated by secre-
tion-mediated STAT3 activation. Damian A. Almiron Bonnin,1 Matthew C.
Havrda,2HuanLiu,1MyungChangLee,1MatthewH.Ung,1ChaoCheng,2Mark
A. Israel2. 1Dartmouth Geisel School of Medicine, Lebanon, NH; 2Geisel School of
Medicine at Dartmouth, Lebanon, NH.
Glioblastoma, a type of high-grade glioma, is the most common and themost
aggressive primary brain tumor of adults. Themedian survival is 12-15months.
Despitemultimodality treatment,most high-grade gliomas eventually recur and
are ultimately incurable. Several studies suggest that the initiation, progression,
and recurrence of gliomas are driven at least partly by cancer stem-like cells. A
defıning characteristic of these cancer stem-like cells is their capacity to self-
renew. We have identifıed a pathway dependent upon tumor hypoxia, a com-
monly found pathologic feature of GBM, that promotes self-renewal through
the HIF1-JAK1/2-STAT3 axis. Under hypoxic conditions, the expression of
HIF1 is greatly increased in GBM stem-like cells leading to the activation of
JAK1/2-STAT3 which mediates enhanced tumor stem-like cell self-renewal.
Our data further demonstrate the importance of VEGF secretion for this path-
way of hypoxia-mediated self-renewal.Using tumor stem-like cells derived from
the S100-v-erbB/p53-/- mouse model of spontaneous high-grade glioma, we
have discovered that the activation of STAT3 through hypoxia-mediated VEGF
secretion is required for self-renewal of glioma stem-like cells. Media condi-
tioned by these S100-v-erbB/p53-/- tumor sphere cells cultured under hypoxic
conditions promoted self-renewal in S100-v-erbB/p53-/- glioma stem-like cells
and depletion of VEGF from this media was suffıcient to inhibit STAT3 phos-
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phorylation.Moreover, we have been able to identify two drugs: Brefeldin A and
EHT-1864, that signifıcantly inhibit VEGF secretion, decrease stem cell self-
renewal, inhibit tumor growth, and increase the survival ofmice allograftedwith
S100-v-erbB/p53-/- glioma stem-like cells. Cells treated with these drugs ex-
pressmolecular signatures that correlated stronglywith the increased survival of
GBM patients. These fındings suggest a novel treatment strategy to inhibit hy-
poxia-mediated self-renewal of glioma stem-like cells in high-grade gliomas by
targeting the secretion of extracellular, paracrine mediators of self-renewal.
#5010 Activation of the notch signaling pathway confers a tumor-sup-
pressive phenotype on melanoma-associated fıbroblasts. Hongwei Shao,
Mecker G. Moller, Long Cai, Leiming Zhang, Zhao-Jun Liu. Univ. of Miami,
Miami, FL.
Objectives. The tumormicroenvironment (TME) is an emerging therapeutic tar-
get for cancer treatment. Cancer-associated fıbroblasts (CAF) play a crucial role in
cancer progression.We aim to target TME by altering intracellular signaling which
determines the biological functionofCAF.Wehave recently showed that theNotch
signaling pathway likely functions as a molecular switch in controlling the tumor
regulatory role of CAF in animal models and experimentally created “CAF”. Here,
we investigated the status ofNotch signaling in humanmelanoma-associated fıbro-
blasts (MAF) versus their normal counterparts and tested whethermanipulation of
theNotch pathway activity inMAFalter their tumor-regulating function.Methods.
We examined levels ofHes1, a canonicalNotch target, inMAFof humanmalignant
melanoma at different stages (I-IV) and fıbroblasts in either adjacent or non-adja-
cent normal skin tissues using tissue microarray. MAF were isolated from human
metastatic melanoma tissues. Notch pathway RT2-PCRArray and immunoblot
were used to assess Notch pathway activity in MAF versus normal human dermal
fıbroblasts. Activation of Notch signaling pathway inMAFwas achieved by lentivi-
ral vector encoding active form of Notch1 (NIC). The effect of Notch1-engineered
MAF on melanoma growth was tested by in vitro co-cultures and in a mouse co-
xenograft model (n6/group). Tumor angiogenesis was analyzed by immuno-
chemistry.Results.MAFexpresseddecreased levelsofHes1comparedwithadjacent
skin fıbroblasts. IsolatedMAF also exhibited lower Notch activity than normal hu-
mandermal fıbroblasts.Notch1-engineeredMAFsignifıcantly inhibitedmelanoma
cell growth in vitro (p0.01) and suppressed melanoma growth and tumor angio-
genesis inmice (p0.05).Conclusions.Notchpathwayactivity isdown-regulated in
MAF. IncreaseofNotchpathwayactivity confersMAFwith inhibition tomelanoma
growth and tumor angiogenesis. Our study demonstrates that Notch signaling is a
critical molecular switch in determining the tumor regulatory role of MAF and
provides potential targets for cancer therapeutic interventions on the TME.
#5011 Tumor associated macrophages promote malignant phenotypes of
disseminated human gastric cancer cells in intraperitoneal cancer immune
microenvironment. Shuichi Sakamoto, Shunsuke Kagawa, Kazuya Kuwada,
Atene Ito, Tetsuya Kagawa, Satoru Kikuchi, Shinji Kuroda, Ryuichi Yoshida,
Hiroshi Tazawa, Toshiyoshi Fujiwara. Okayama UNIV., Okayama, Japan.
Gastric cancer is the third leading cause of cancer-related death, and peritoneal
dissemination is one of the most frequent site of recurrence. Although the role of
tumor microenvironment is recognized, it is still unclear how intraperitoneal can-
cer-immune microenvironment contributes to peritoneal metastasis. Thus, we in-
vestigated the interaction between intraperitoneal cancer and immune cells, espe-
cially focusing on tumor-associated macrophages (TAM) in the peritoneal cavity.
The peritoneal wash from gastric cancer patients was subjected to conventional
cytology, flow cytometry, and immuno-fluorescent assay using antibodies against
CD45 (leukocytes), CD14 (monocytes), CD80/163 (M1/M2 macrophages, respec-
tively), in combination with genetically engineered cancer-imaging viral agent ’Te-
lomeScan’whichspecifıcally expressesGFPin telomerase-positivecells. Incytology-
positive samples, CD163-positivemacrophages could be detected in approximately
70% of intraperitoneal macrophages with TelomeScan-positive cancer cells, while
cytologynegative samples contained fewCD163-positivemacrophages. Inaddition,
peripheralbloodmononuclearcells (PBMCs) fromhealthyvolunteerswere induced
to differentiate into CD163-positive M2 macrophages (TAM-like macrophages),
and co-cultured with gastric cancer cells to examine the effect on their malignant
phenotype such asmigration and invasion.We found that PBMCs-derivedCD163-
positive M2 macrophages signifıcantly potentiated the ability of migration and in-
vasion in gastric cancer cells. In case of existence of free cancer cells in peritoneal
cavity, intraperitoneal macrophages appeared to differentiate into TAM and they
potentially accelerate malignant phenotypes of gastric cancer cells. These results
suggested that intraperitoneal cancer-immunemicroenvironmentmay play an im-
portant role to promote peritoneal disseminations in gastric cancer.
TUMOR BIOLOGY: Models for Treatment Resistance and Drug
Discovery
#5012 Mouse-Human co-clinical trials demonstrate superior effıcacywith
combinational approach of BKM120 and erbitux over BKM120 mono-
therapy in patients with recurrent and/or metastatic squamous cell carci-
noma of head and neck (R/M-SCCHN).HanNa Kang,1 Mi Ran Yun,1 Kyoung
Ho Pyo,1 Myung-Ju Ahn,2 Jong-Mu Sun,3 Sun Min Lim,4 Soonmyung Paik,5
ByoungChul Cho,6Hye RyunKim6. 1JE-UK Institute for Cancer Research, JEUK
Co., Ltd, Seoul, Republic of Korea; 2Division ofHematology&Oncology, Samsung
Medical Center, SungkyunkwanUniversity School ofMedicine,, Seoul, Republic of
Korea; 3Yonsei Cancer CenterDivision of Hematology & Oncology, Samsung
Medical Center, Seoul, Republic of Korea; 4CHA Cancer Inst, Seoul, Republic of
Korea; 5Division of Pathology NSABP, Pittsburgh, USA, Seoul, PA; 6Yonsei Can-
cer Center, Seoul, Republic of Korea.
Background: To investigate clinical activity, safety and biomarkers of a pan-PI3K
inhibitor BKM120 in R/M-SCCHN and identify optimal combinational strategies
by conducting mouse co-clinical trials mirroring the ongoing clinical study. Meth-
ods: Patients with R/M-SCCHN were eligible if they had progressed on platinum-
basedchemotherapy, andwere treatedwithBKM120100mg/day.Theprimary end-
point was disease control rate (DCR) at 8 weeks. Secondary endpoints included
response rate (RR), progression-free survival rate (PFS), overall survival (OS) and
safety. Patient-derived xenografts (PDXs) with genomic annotations were estab-
lished directly from patients for evaluation of novel drug combinations and bio-
markers. Based on the integrated clinical and preclinical data, study protocol had
been revised to combine BKM120 and erbitux to explore whether erbitux increases
the effıcacy of BKM120 in R/M-SCCHN. Results: A total of 52 patients were en-
rolled. Patient characteristics included median age (55 years; range, 31-82); male
(84.6%); ECOG performance status 0/1/2 (13.5%/73%/13.5%); locoregional/meta-
static/both (30.8%/30.8%/38.4%); oral cavity/oropharynx/larynx primary (36.5%/
30.8%/13.5%); prior chemotherapy regimens 1/2 (40%/60%). Sevenpatientswere
not evaluable due to rapid progression or withdrawal. DCR at 8 weeks was 60%
(27/45) and RR was 2.2% (1/45) in BKM120 monotherapy. Median PFS and OS
were 8.0 (95% CI, 5.3-9.5) and 30.7 weeks (95% CI, 11.8-26.6). After protocol revi-
sion, 11 patients were treated with BKM120 and erbitux after progression to
BKM120. Incombinationphase,PRwasobserved in18.1%(2/11)andSDwas45.5%
(5/11) in patients who failed to BKM120. Toxicities were not increased in combina-
tion phase. In seven established PDXs, we tested BKM120 alone or in combination
with erbitux. All PDXs showed strong resistance to single-agent BKM120, whereas
three PDXs (3/7, 42.8%) demonstrated strong synergistic inhibition of tumor
growth to combined BKM120 and erbitux, compared with single agent (vs.
BKM120, P0.01; vs. Erbitux, P0.01), which resembled the responses of corre-
sponding patients. We found several genetic alterations in F2 tumors including
EGFR fusion, HRAS mutation (G12D), MYC amplifıcation, KRAS mutation
(G13D), and EGFR amplifıcation. Interestingly, two PDXs with RAS mutations
demonstrated synergistic effect of BKM120 and erbitux. Conclusions: Combining
BKM120 and Erbitux would be effective treatment strategies withmanageable tox-
icity in R/M-SCCHN based on strong rationale of co-clinical trial with PDXs
(NCT01527877).
#5013 A 3D culture system identifıes a newmode of cetuximab resistance
and disease-relevant genes in colorectal cancer. Bhuminder Singh,1 Cunxi Li,1
Ramona Graves-Deal,1 Haiting Ma,1 Alina Starchenko,1 William H. Fry,1 Yu-
anyuan Lu,1 Yang Wang,1 Galina Bogatcheva,1 Mohseen P. Khan,1 Ginger L.
Milne,1 Shilin Zhao,1 Gregory D. Ayers,1 Nenggan Li,2 Mary K. Washington,1
Timothy J. Yeatman,3 Oliver G. McDonald,1 Qi Liu,1 Robert J. Coffey1. 1Van-
derbilt University Medical Center, Nashville, TN; 2Jiaen Genetics Laboratory,
Beijing, China; 3Gibbs Cancer Center & Research Institute, Spartanburg, SC.
We previously reported that single cells from a human colorectal cancer
(CRC) cell line (HCA-7) formed either hollow single-layered polarized cysts or
solid spiky masses when plated within type-I collagen in 3D. To begin in-depth
analyses into whether clonal cysts and spiky masses possessed divergent malig-
nant properties, individual colonies of each morphology were isolated and ex-
panded. The lines thus derived faithfully retained the parental cystic and spiky
morphologies and were termed CC (cystic) and SC (spiky), respectively. Al-
though both CC and SC expressed EGF receptor (EGFR), cetuximab strongly
inhibited growth of CC, whereas SC was resistant to growth inhibition and this
was coupled to increased tyrosine phosphorylation ofMET and RON. Addition
of the dual MET/RON tyrosine kinase inhibitor, crizotinib, to cetuximab in SC
restored cetuximab sensitivity. To characterize genome-wide divergence be-
tween CC and SC, we performed comprehensive genomic and transcriptomic
analysis of CC and SC in 3D. One of the most upregulated genes in CC was the
tumor suppressor 15-PGDH/HPGD and the most upregulated gene in SC was
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versican (VCAN) in 3D and xenografts. Analysis of a human CRC tissue mi-
croarray showed that epithelial, but not stromal, VCAN staining strongly cor-
related with reduced survival, and combined epithelial VCAN and absent
HPGD staining portended a poorer prognosis. Thus, with this 3D system, we
have identifıed a new mode of cetuximab resistance and a potential prognostic
marker inCRC.As such, this represents a potentially powerful system to identify
additional therapeutic sensitivities and disease-relevant genes for CRC.
#5014 Drug discovery for NF1-associated malignant peripheral nerve
sheath tumors using the zebrafısh model. Dong Hyuk Ki, Shuning He, A.
Thomas Look. Dana-Farber Cancer Institute, Boston, MA.
Children and young adults with type 1 neurofıbromatosis (NF1) are at risk to
develop plexiformneurofıbromas, which canundergomalignant transformation to
malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are among the
most frequently occurring sarcomas in children and young adults and are especially
problematic inNF1 patients. Currently, complete surgical excision is the only cura-
tive therapy forNF1-associatedMPNST, but these tumors are often not completely
resectable. Therefore, it is very important to identify promising drugs that can be
rapidly moved into clinical trials to improve the therapy of patients withMPNSTs.
We have developed a faithful zebrafısh model of NF1-associated MPNST by using
genome engineering to develop zebrafısh lines harboring loss-of-function muta-
tions of the duplicated nf1a and nf1b genes and p53. Our nf1 and p53 defıcient
zebrafısh models develop MPNSTs that are very similar to human NF1-associated
MPNST, and thus are ideal for experiments to test the effıcacy of FDA-approved
small molecule drugs in vivo. To test the FDA-approved drugs for activity against
MPNST tumor cells, about 100 Sox10:mCherry expressedMPNST primary tumor
cells were transplanted into dechorionized 2 day-post-fertilization (dpf) larval fısh
using amicro-injector.MPNST-implanted embryoswere exposed to individual test
compounds added to the fısh water at a range of concentrations and to the vehicle
control. After 4-days of treatment, quantitative assessment of the remaining
mCherry-labeled tumor cell numbers weremeasured using the ImageJ software for
each treated embryo.Currently, trametinib and sunitinib causedmarked antitumor
effects indicated by reduced numbers of mCherry-labeled nf1-defıcient MPNST
cells compared to the DMSO control in this study. We are now applying this em-
bryonic implantation assay to identify combinations of FDA-approved drugs that
have a high degree of effıcacy against MPNST and can be rapidly “repurposed” to
improve the treatment of this disease.
#5015 Innovative and predictivemodels against breast cancer.Olivier Du-
champ,1 Séverine Tabone-Eglinger,2 Caroline Mignard,1 Isabelle Goddard,3
Alain Bruno,4 Maia Chanrion,4 Loreley Calvet,5 Olivier Degoul,6 Kevin
Dhondt,7 Liliane Goetsch,7 Julie Miralves,8 Christophe Lautrette,9 Cindy
Pensec,10 Françoise LeVacon,10 Isabelle Treilleux,2 LaurentArnould,11 Philippe
Vaglio,12 Grégoire Prevost,13 Olivier Tredan2. 1Oncodesign S.A., Dijon Cedex,
France; 2Centre Léon Bérard, Lyon, France; 3Synergie Lyon Cancer, Lyon, France;
4Servier Research Institut, Suresnes, France; 5Sanofı, Vitry-sur-Seine, France;
6CTI-Biotech, Meyzieu, France; 7Pierre-Fabre Research Institut, Saint-Julien-en-
Genevois, France; 8Ariana Pharmaceuticals, Paris, France; 9OncoMedics, Limo-
ges, France; 10BioFortis-Merieux NutriSciences, Saint-Herblain, France; 11Centre
Georges François Leclerc, Dijon Cedex, France; 12Modul-Bio, Marseille, France;
13CIPREVO, Antony, France.
Many reports support that xenografts frompatient-derived xenografts (PDXs) in
mice or rats well recapitulate the molecular diversity, cellular heterogeneity, and
histology seen in patient tumors. However, shortcomings including limited clinical
diversity of the PDXs, absence of influence of humanmicrobiome, absence of drug
human metabolism and reduced immune system restrain the predictive values of
these PDXmodels. To set-up a holistic integration of these criticisms, we have asso-
ciated efforts frompublic hospitals, academic groups, biotechs and private pharma-
ceutical companies with the fınancial support of the French Ministry of Industry.
Patient surgical specimens from different breast tumor subtypes, among 9 other
cancer pathologies, are collected to establish large collections of PDXs in mice. In
addition, in vitro primary cultures of cells from these samples are conducted to
establish a collection of cell lines from the stromal and the tumoral compartments.
The 40 established breast PDX models represent the 4 major molecular clinical
subtypes amongwhich 37% are triple negative, 33% are Luminal BHER2-, 22% are
Luminal BHer2 and 8%Her2. Themodels are evaluated for ex vivo and in vivo
sensitivities to 4 clinically relevant anticancer drugs, for histology, immune infıl-
trates, and molecular characteristics including the analysis of gene polymorphism,
RNAseq gene expression and NGS exome sequencing of 112 genes. The metag-
enomic sequencing of the gutmicrobiota from stools collected in both patients and
tumor-bearing mice before and after chemotherapeutic treatments improves our
knowledgeon the role ofmicrobiota in cancerprogressionand treatment. Secondly,
to increase the predictability of themodels, we are generatingmicewith humanized
liver showing distinct drug pharmacokinetic profıles as compared with parental
mice. Finally, the humanization of the immune system in mice is developed by
several approaches including the use of induced pluripotent stem cells from cancer
patients. These tumor collection andmodel characterizationwere performedunder
harmonized procedures within the consortium, allowing high quality material and
results. All model characteristics are being compiled in a web-based database for
effıcient features search and data mining. We will present the fırst characterized
breast cancermodels andwill discuss their usefulness and chance to bring benefıt to
patients via this holistic strategy developed within the IMODI initiative.
#5016 High-throughput patient-derived 3-dimensional organoid cultures
as personalized models to assess drug response and post-treatment residual
disease. Eugen Dhimolea,1 Ricardo De Matos Simoes,1 Yoko DeRose,2 Pallavi
Awate,1 XiangWeng,1 Huihui Tang,1 Aedin Culhane,1 AlanaWelm,2 Constan-
tine Mitsiades1. 1Dana Farber Cancer Institute, Boston, MA; 2Huntsman Cancer
Institute, Salt Lake City, UT.
Cell lines grown in 2-dimensional (2D) plastic surfaces have historically been
the main models to identify cancer cell vulnerabilities. In contrast, malignant
tumors in vivo grow as 3-dimensional (3D) cellular masses and manifest re-
markably different drug-response patterns compared to cell lines. We have
shown that breast cancer (BrCa) cells in 3D extracellular matrices acquire dis-
tinct phenotypic properties, compared to the 2D counterparts. Notably, serum-
free culture medium supplemented with defıned cocktails of developmental
morphogenswas suffıcient to support the growth of BrCa cell lines in 3D, but not
in 2D conditions; indicating a key role of 3D architecture in in vivo growth
regulation. CRISPR/Cas9-based gene editing screens in BrCa cells indicated that
distinct gene subset govern the growth in 3D vs. 2D conditions. Using similar
culture conditions, we expanded several molecularly annotated BrCa patient-
derived 3D Organoids (3D PDOs), adapted them into a high-throughput min-
iaturized drug screening platform, and interrogated them against a panel of
500 target-annotated kinase inhibitors and FDA-approved anti-cancer agents.
This pharmacological screen revealed high sensitivity to distinct classes of agents
(eg. PI3K inhibitors), but also variable responses to others (eg. EGFR inhibitors);
and provided insight into potentially driver vs. passenger mutations in the re-
spective patients. Co-culture of PDOs with non-malignant stromal cells from
bone metastatic niche reduced sensitivity to some classes of drugs (eg. PLK
inhibitors). Importantly, long-term (up to 3-4weeks) treatment of 3Dorganoids
did not eradicate the cells in culture (in contrast to conventional 2D assays), but
generated a cell subpopulation which remained viable for the duration of the
experiment, reminiscent of the residual disease after initial clinical partial re-
sponses to a drug. This residual disease phenotype was also confırmed in vivo,
when the respective PD-Xenografts were treated with the same agents. The ma-
jority of transcriptswith differential expression in residual PDX tumor cellswere
also concordantly up- or down-regulated in the respective 3D PDO model.
These transcripts included canonical regulators of cell cycle, chromatin signal-
ing and epigenetic mechanisms, cytoskeletal function and metabolic pathways;
as well as other transcripts not previously linked to drug resistance in conven-
tional 2D models. To our knowledge this is the fırst description of an in vitro
personalized cancer model that simulates both molecularly and phenotypically
the post-treatment residual disease in vivo. Our high-throughput functional
platformcanpotentially complement genomic approaches in personalizedmed-
icine and help discover novel drugs that overcome tumor drug resistance.
#5017 Visualization of themechanisms ofmetastasis within a biomimetic
engineered tumormicroenvironment encompassing a perfusable cylindrical
3D microvessel. Andrew D. Wong,1 Vanesa Silvestri,2 Anderw J. Ewald,2 Peter
C. Searson1. 1Johns Hopkins University, Baltimore, MD; 2Johns Hopkins Univer-
sity School of Medicine, Baltimore, MD.
Metastasis is responsible for themajority of cancer relateddeaths; however,many
of the biological andphysical details surrounding the critical steps (e.g. invasion and
intravasation) are largelyunknown, inpartdue to thediffıculty in recapitulatingand
visualizing these dynamicprocesses. To elucidate thesemechanisms,wehavedevel-
oped an in vitro model of invasion and intravasation that comprises tumor cells
embedded within an extracellular matrix (ECM) surrounding an engineered mi-
crovessel. Themicrovessel is cylindrical, 150m in diameter, and lined with endo-
thelial cells forminga functional barrier that ismaintainedunder constantperfusion
at a shear stress of 2-8 dyne cm-2. Using this biomimetic tumor-microvessel plat-
form,wehave previously visualized invasion and intravasation of singleMDA-MB-
231 breast cancer cells into the microvessel and escape into flow. Here, we present
mechanistic details of intravasation from both single tumor cells (MDA-MB-231)
and mouse mammary tumor organoids (MMTV-PyMT). For single cells, we ob-
serve a mitosis-mediated mechanism of intravasation where tumor cell entry into
flow is prefaced by cell division at the ECM-vessel interface. For tumor organoids,
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we see vascular deformation anddestabilization fromgrowing tumors that impinge
upon proximal vessels, and that bulk intravasation is mediated by shear stress and
tumor cell adhesion. As we characterize the various ways in which tumor cells in-
teract with the vessel endotheliumand intravasate, we can explore strategies involv-
ing the tumor vasculature and clinically relevant drugs to inhibit critical steps in the
metastatic cascade.
#5018 Dissecting antigen-specifıc T-cell response in a novel mousemodel
of colon cancer. Mary C. Beytagh, Peter M. Westcott, Olivia C. Smith, Jatin
Roper, Omer Yilmaz, Tyler E. Jacks. David H. Koch Institute for Integrative
Cancer Research at MIT, Cambridge, MA.
Immune checkpoint blockade therapies, which unleash the immune system’s
ability to recognize and eliminate cancer cells, are currently among the most
promising treatments for cancer. Antibodies that block the immune inhibitory
receptors CTLA4 and PD1 have shown clinical success, with objective response
rates over 20% and some durable responses exceeding 10 years. However, some
cancers, such as colorectal cancer (CRC), have proven particularly refractory to
immunotherapy. Although it is appreciated that the colon is an immunosup-
pressive environment, the mechanism and extent of immune suppression re-
mains unclear. Studies of humanCRC tumors have shown that T cell infıltration
is an important predictor of clinical outcome, yet currentmousemodels of CRC
are not particularly well suited to the mechanistic study of T cell responses
against tumor-specifıc antigens. Syngeneic cell line transplants, by far the most
widely used models to study adaptive immune response in CRC, are character-
ized by a highly complex tumor antigen landscape, and have not employed
orthotopic transplant into the colon. In order to track highly specifıc T cell
responses in CRC, we have employed a novel colon organoid-based system, in
which transformed organoids expressing model antigens are orthotopically
transplanted into the wall of the colon via colonscopy-guided injection, a
method pioneered in the lab of Omer Yilmaz. Organoids were harvested from
VillinCreER; Apcfl/fl mice and grown in the presence of Wnt ligand; addition of
tamoxifen and removal of Wnt from the media facilitated expression of the
colon-specifc Cre, deletion of Apc, and selection of transformed organoids ca-
pable of growing in the absence ofWnt. To induce expression ofmodel antigens,
organoids were infected with a lentiviral vector that, in addition to the fluores-
cent reporter FusionRed, expressed the T cell antigens SIYRYYGL and two
antigens from ovalbumin - SIINFEKL and OVA323-339 - fused to the C-termi-
nus of luciferase (FRLucOS), enabling us to monitor antigen expression in vivo.
Organoids were then sorted and injected into the wall of the colon. Previous
work by Michael DuPage, in which he expressed the LucOS construct in an
autochthonous lung cancer and sarcoma mouse model, provided key insights
into the dynamic nature of T cell response against cancer cells. The novel model
system described here provides a powerful new tool to dissect antitumor T cell
responses in the poorly understood context of CRC.
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#5019 HMGA1 amplifıes Wnt signaling and expands the intestinal stem
cell compartment to drive premalignant polyposis in transgenic mice. Lin-
gling Xian, Dan Georgess, Li Luo, Lionel Chia, Qihua Gu, Tait Huso, Amy
Belton, David Huso, Andrew Ewald, LindaM.S. Resar. JHUMedical Institution,
Baltimore, MD.
Emerging evidence suggests that cancer cells undergo chromatin remodeling and
epigenetic reprogramming to co-opt stem cell properties and drive tumor progres-
sion. The HMGA1 chromatin remodeling protein is an architectural transcription
factor that binds toDNAatAT-rich sequenceswhere it “opens” chromatin, recruits
transcriptional complexes, and modulates gene expression. The HMGA1 gene is
highly expressed during embryogenesis and in adult stem cells, but silenced postna-
tally in differentiated tissues. HMGA1 becomes re-expressed in most high-grade
cancers andhigh levelsportendadverse clinical outcomes. Incoloncancer,HMGA1
is among the genes most highly overexpressed compared to normal intestinal epi-
thelium. We previously reported that HMGA1 drives tumor progression in colon
cancer by inducing stem cell genes involved in an epithelial-mesenchymal transi-
tion.We also discovered that Hmga1 transgenicmice developmarked proliferative
changes and pre-malignant polyposis in the intestinal epithelium. To determine
how Hmga1 functions in the intestines during tissue homeostasis and carcinogen-
esis, we examined in transgenic mice and organoid models. Here, we uncover a
novel role for Hmga1 inmaintaining the intestinal stem cell (ISC) pool and Paneth
cell niche.Hmga1 is required by ISCs to organize into three-dimensional organoids
in vitro; silencingHmga1 disrupts organoid formation and buddevelopment. Con-
versely, overexpression ofHmga1 increases organoid formation, bud development,
and replating effıciency, suggesting that Hmga1 enhances ISC function and/or
number. We therefore crossed the Hmga1 transgenic mice onto the Lgr5-EGFP
background to enumerate ISCs and found that Hmga1 expands the ISC compart-
ment. To determine how this occurs, we performed in vivo imaging and discovered
that Hmga1 enhances self-renewal of ISCs. Mechanistically, we found that Hmga1
amplifıes Wnt/-catenin signaling by inducing genes encoding both Wnt agonist
receptors and downstreamWnt target genes. Surprisingly,Hmga1 also expands the
Paneth cell niche, which is comprised of terminally differentiated crypt cells that
secreteWnt to support ISCs. BecausePaneth cells require Sox9 for development,we
determined whether Hmga1 regulates its expression. Hmga1 binds directly to the
Sox9 promoter at 2 AT-rich sites to activate its expression. In human colonic epi-
thelium, HMGA1 and SOX9 are positively correlated, and both become markedly
up-regulated in colon carcinogenesis. Thisworknot onlyprovidesnew insights into
the role of Hmga1 in intestinal homeostasis by maintaining both the stem cell pool
and epithelial niche compartment, but also suggests that deregulated Hmga1 per-
turbs this equilibrium during polyposis and carcinogenesis. Our results also high-
light theHMGA1-WNT-SOX9 pathway as rational therapeutic target in colon car-
cinogenesis.
#5020 A genome-scale ORF screen reveals an alternative splicing program
that regulatesmesenchymal and stem-like cell states in breast cancer. Ji Li,1 Peter
Choi,1 Christine Chaffer,2 Katherine Labella,1 Jong Wook Kim,1 John Doench,3
Chao Dai,1 Andrew Giacomelli,1 Seav Huong Ly,1 Justin Hwang,1 AndrewHong,1
Nina Ilic,1 Ole Gjoerup,1 MatthewMeyerson,1 Angela Brooks,4 RobertWeinberg,2
WilliamHahn1. 1Dana-Farber Cancer Institute, HarvardMedical School, Broad In-
stitute of MIT and Harvard, Boston, MA; 2Whitehead Institute for Biomedical Re-
search andMIT, Cambridge,MA; 3Broad Institute ofMIT andHarvard, Cambridge,
MA; 4University of California, Santa Cruz, Santa Cruz, CA.
Cells residing in mesenchymal state are often associated with stem cell prop-
erties. The phenotypic changes from epithelial to mesenchymal cell state, or
fromnon-stem-like to stem-like cell state contribute to tumor heterogeneity and
play important roles in tumor initiation, progression andmetastasis. To system-
atically interrogate the modulators of epithelial-to-mesenchymal transition, we
performed a genome-scale ORF screen to identify regulators of mesenchymal
and stem-like cell states using a barcoded humanORFome expression library in
humanmammary epithelial cells. In the screen, we used flow cytometric analysis
of theCD44 cell surfacemarker and identifıed 68ORFs that can switch cells from
CD44 low state to CD44 high state in 7 days. Among these genes, the RNA
splicing factors were highly enriched as analyzed by GO terms and Gene set
enrichment analysis (GSEA).We employed six different assays for candidate
validation: 1) Induction of CD44 cell surface markers; 2) Evaluation of the ex-
pression of EMT markers; 3) Test of the ability to form mammospheres; 4)
Investigation of the expression during EMT induction; 5) Test of the necessity of
these splicing factors for EMT and stem-like states; 6) Examination of the ability
to promote tumor formation in vivo.Wediscovered thatQKI andRBFOX1were
both necessary and suffıcient to promote EMT and stem-like states. MBNL1,
MBNL2 and CELF4 were suffıcient to induce some mesenchymal markers. We
further investigated the downstream targets of these splicing factors by RNA-
sequencing analysis. We found that QKI and RBFOX1 regulated the alternative
splicing of genes in 5 functionalmodules: 1)Cellmotility andECM/cytoskeleton
organization; 2) Stem cell fate determination; 3) Oncogenic signaling; 4) Epige-
netic targets; 5) cell polarity. Strikingly, usingmolecular and biochemical assays,
we found that QKI and RBFOX1/2 interacted and cooperatively regulated the
alternative splicing of a large number of overlapping transcripts, including Fil-
amin B (FLNB). QKI and RBFOX1 induced a shorter isoform via exon skipping.
which plays a key functional role in the regulation of EMT. Importantly, the
expression of QKI, RBFOX1/2 and the short isoform of FLNB are elevated in
basal B type of breast cancer cell lines and in basal-like breast cancer patient
samples, the subtype of breast cancer that displays higher degree of mesenchy-
mal and stem-like traits. In conclusion, alternative RNA splicing plays a key role
in the regulation of EMT and stem-like cell states. QKI and RBFOX1/2 are both
necessary and suffıcient to promote EMT and stem-like traits. Alternative splic-
ing of FLNB controlled by QKI and RBFOX1/2 is one of the key downstream
targets that regulates EMT. Thus, the molecular targets and mechanism identi-
fıed in this study may aid in the development of new diagnostic and therapeutic
approaches for breast tumors, especially for basal-like breast cancer.
#5021 Semaphorin signal via MICAL3 induces symmetrical cell division
of cancer stem-like cells to confer aggressiveness in breast cancer. Kana To-
minaga,1 Masao Yano,2 Kei-ichiro Tada,3 Arinobu Tojo,1 Noriko Gotoh4. 1In-
stitute of Medical Science, The University of Tokyo, Japan; 2Minamimachida
Hospital, Japan; 3The University of Tokyo, Japan; 4Kanazawa Univ. Cancer Re-
search Inst., Kanazawa, Japan.
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Breast cancer stem cells (BCSCs) are thought to be maintained in cancerous
tissues by increased frequency of symmetric cell division at the expense of asym-
metric cell divisionin the cancer tissues, although how this occurs it remain
largely unknown.Here, we discovered thatmolecules interactingingwithCasL 3
(MICAL3) contributed to tumor sphere formation in patient-derived breast
cancer cells and tumor initiating activity in a patient-derived xenograft (PDX)
model. Semaphorin (Sema)-stimulation induced complex formation involving
MICAL3 and collapsin response mediator protein 2 (CRMP2), leading to stabi-
lization of Numb in breast cancer cells. Neuropillin-1 (NP1), a receptor for
Sema, and Numb were specifıcally expressed and colocalized at high levels in a
BCSC-enriched population that induce tumor sphere formation. MICAL3
knockdown decreased symmetric cell division and increased asymmetric divi-
sion of in NP1-high cancer stem-like cells that express high level of Numb at
high levels. Thus, MICAL3/CRMP2/Numb pathway appears to play a critical
role in the symmetric division of NP1-high cancer stem-like cells to expand the
pool of BCSCs. Finally, we showed that breast cancer patients with higher ex-
pression levels of NP1 and Numb in cancer tissues show poor prognosis com-
pared with those with lower expression levels of NP1 and Numb by using tissue
microarray of breast cancer tissues.We provide a rationale for eradicating BCSC
by blocking the symmetric division of BCSC by targeting molecules in Sema/
NP1/MICAL3 pathway.
#5022 Keratin15 (Krt15) are radio resistant and tumor-initiating cells
in the mouse small intestine. Véronique Giroux,1 Julien Stephan,1 Kathryn E.
Hamilton,1 Priya Chatterjee,1 Sarah Andres,1 Andres J. Klein-Szanto,2 Christo-
pher J. Lengner,1 Anil K. Rustgi1. 1University of Pennsylvania, Philadelphia, PA;
2Fox Chase Cancer Center, Philadelphia, PA.
Background: Intestinal stem cells regulate the emergence of different cell lin-
eages across the crypt-villus axis and orchestrate cellular renewal and replenish-
ment following injury (e.g. radiation). Two major ISC have been identifıed to
date: a rapidly cycling crypt base columnar (CBC) stemcell and amore quiescent
reserve stem cell located at the4 position above the crypt base. CBCs marked
by the Wnt target gene Lgr5 are dispensable for homeostasis and are quantita-
tively ablated by radiation injury. In contrast, quiescent ISCs are indispensable
for homeostasis, regenerate CBCs, and are radioresistant. Keratins (Krt) are
intermediate fılaments required for architectural and mechanical support, but
also contribute to cell migration and intracellular signaling. Interestingly, Krt15
has been characterized as a stem cell marker in the hair follicle. Here we de-
scribed a radio-resistant Krt15 stem cell population in the small intestine and
demonstrate that cells within this population are capable of tumor initiation.
Methods: Krt15-CrePR1 mice were crossed with Rosa26 reporter mice to per-
form lineage-tracing experiments in the mouse small intestine. High-dose radi-
ation was used to investigate the role of Krt15 in tissue regeneration. Finally,
Krt15-CrePR1 mice were crossed with Apcfl/fl mice to characterize the tumor-
initiating properties of Krt15 cells. Results: We observed that Krt15 marks a
subpopulation of long-lived small intestinal crypt cells that are able to give rise to
all differentiated lineages supporting their self-renewing andmultipotent capac-
ities. Interestingly, we observed that Krt15 cells are able to form 3D organoids
when seeded in Matrigel as a single cell suspension. Irradiation of Krt15-
CrePR1;R26mTomato/mGFP mice with 12 Gy revealed that Krt15 cells are radio-
resistant and participate in tissue regeneration. Interestingly, Krt15 defıciency
impairs tissue regeneration following high-dose radiation. Indeed, irradiated
Krt15-/- mice display reduced crypt regeneration, crypt length, microcolonies
and BrdU incorporation when compared to irradiated Krt15/ mice. Finally,
we induced Apc loss in Krt15 cells and observed formation of adenomas as
well as adenocarcinomas in all Krt15-CrePR1;Apcfl/fl mice. Metastases were de-
tected in some Krt15-CrePR1;Apcfl/fl mice. Conclusion: We have identifıed a
long-lived Krt15 subpopulation of intestinal crypt cells displaying stem cell-
like properties that are radio-resistant and tumor initiating. This new stem cell
population may open new avenues for therapeutic targeting in colon cancer.
#5023 Disruption of Monocarboxylate transporter-4 Basigin interaction
as an effective strategy to inhibit hypoxic response, tumor growth and vascu-
larization, and stem cell phenotype in human glioblastoma in vitro and in
vivo.Raffaella Spina,1 DillonM. Voss,1 Kah Suan Lim,2 Constance J. Jeffery,3 Eli
E. Bar1. 1Case Western Reserve Univ., Cleveland, OH; 2Dana-Farber Cancer In-
stitute, Boston, MA; 3The University of Illinois at Chicago, Chicago, IL.
Monocarboxylate transporters, constitute a family (SLC16) of proton-linked
plasmamembrane transporters that carrymolecules containing a single carbox-
ylate group across biological membranes. Basigin (CD147), is involved in many
physiological functions during early stages of development and in cancer. Basi-
gin has been shown to be required for functional plasma membrane expression
ofMonocarboxylate transporter-1 andMonocarboxylate transporter-4. Using a
cell-based screening assay, we identifıed acriflavine, a small molecule that inhib-
its the binding between Basigin and Monocarboxylate transporters in vitro and
in vivo. Surface Plasmon Resonance analysis confırmed direct binding of acri-
flavine to Basigin’s immunoglobulin extracellular domain with a low binding
constant (kD) of 0.16M. Acriflavine inhibits normoxic growth of glioma stem
cells in vitro and this activity is augmented by hypoxia or by expression of
oxygen-stable mutant forms of HIF-1 or HIF-2. Treatment of mice bearing
established glioma stem cell-derived xenografts resulted in inhibition of tumor
growth. Acriflavine treatment inhibited intratumoral expression of the angio-
genic cytokine vascular endothelial growth factor and tumor vascularization.
Our work shows that disruption of monocarboxylate transporter binding to
Basigin is an effective approach to target glioma stem cells.
#5024 Unmasking heterogeneity within the adult mammary stem cell
compartment. Nai Yang Fu, Anne Rios, Bhupinder Pal, Charity Law, Paul Ja-
mieson, Francois Vaillant, Gordon K. Smyth, Matthew E. Ritchie, Geoffrey J.
Lindeman, Jane E. Visvader. Walter & Eliza Hall Inst. of Med. Research,
Parkville, Australia.
Breast cancer is a highly heterogeneous disease at both themolecular and patho-
logical levels. To understand this heterogeneity and ’cells of origin’ of breast cancer,
it is important to dissect the normal mammary epithelial hierarchy. Despite accu-
mulatingevidence for amammarydifferentiationhierarchy, thebasal compartment
comprising stem cells remains poorly characterized. Through gene expression pro-
fıling of Lgr5 versus Lgr5– basal epithelial cells, we identify a novelmarker that led
to the fractionationof threedistinctmammary stemcell (MaSC) subsets in the adult
gland. These exist in a largely quiescent state but differ in their repopulating ability,
spatial localisation, and their molecular signatures. Interestingly, the dormant MaSC
subset localises to theproximal regionof thegland throughout life.These cells appear to
originate fromtheembryonicmammaryprimordiabeforeswitchingtoaquiescentstate
post-natally but can be recruited into the cell cycle in response to hormones. Single cell
geneexpressionanalyseshavealso revealedunexpectedcomplexitywithin thebasal and
luminalcompartments.Moreover, analysesatdifferent stagesofdevelopmenthavepro-
vided insights into the earliest ’lineage priming’ events.
#5025 EZH2 reprogramming confers intrinsic stem cell properties and
developmental plasticity driving neuroendocrine prostate cancer. Alastair
Davies,1 Musa Ahmed,2 Chiara Bostock,1 Anna Gleave,1 Kirsi Ketola,1 Fraser
Johnson,1 Jennifer Bishop,1 Ladan Fazli,1 Haojie Huang,3 Hansen He,2 Amina
Zoubeidi1. 1Vancouver Prostate Centre, Vancouver, British Columbia, Canada;
2PrincessMargaret Cancer Centre, Toronto,Ontario, Canada; 3MayoClinic Can-
cer Center, Rochester, MN.
Introduction: Potent targeting of the androgen receptor (AR) in
castration-resistant prostate cancer (CRPC) has altered the archetypal
course of the disease, fueling the emergence of aggressive and incurable
neuroendocrine prostate cancer (NEPC). Alarmingly, no targeted therapies
exist for NEPC, which stems from our poor molecular understanding of the
disease. What regulates the plasticity that allows cells to shed their depen-
dence on the AR and re-emerge as “AR-indifferent” NEPC, especially under
the pressure of modern AR pathway inhibitors (ARPIs) such as enzalutamide
(ENZ)? Recent data suggest that neuroendocrine transdifferentiation is
aligned with dynamic reprogramming of the epigenome by developmental
regulators, like EZH2, making them attractive therapeutic targets. Method:
To uncover reprogramming factors that are activated in response to AR
pathway inhibition, we interrogated a panel of cell lines derived from ENZ-
resistant prostate tumors by RNA-seq. Mirroring what is observed in a sub-
set of patients who progress on ENZ, 25% of ENZ-resistant tumors and
matched cell lines displayed reduction in canonical AR pathway activity and
a NEPC phenotype. Gene set enrichment analysis revealed that these cells are
enriched for a Polycomb/EZH2 signature and share a conserved transcrip-
tional program with embryonic stem cells. In particular, we identifıed a
distinct phosphorylated form of EZH2 (EZH2-T350), upregulated in AR-
indifferent/NEPC cell lines and patient tumors, that was found to be indis-
pensable for the emergence and maintenance of a stem-like state. Results:
Blocking EZH2-T350 phosphorylation in AR-indifferent/NEPC cell lines
yielded a marked reduction in expression of pluripotency transcription fac-
tors and stem-like features, including ALDH activity and spheroid forma-
tion capacity. Notably, EZH2-T350 was found to be suffıcient and required
for cells to enter a transient stem-like state, a pre-requisite for neuroendo-
crine transdifferentiation under the pressure of ARPIs both in vitro and in
patient-derived prostate tumor xenografts. As our data revealed a strong
association between EZH2 and AR in response to ENZ we performed ChIP-
seq and observed extensive reprogramming of the AR cistrome, specifıcally
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at a core set of genes governing stem cell identity. EZH2 colocalized at the
reprogrammed AR binding sites. Accordingly, treating AR-indifferent/
NEPC cell lines with the EZH2 inhibitor GSK126 yielded a molecular sub-
type shift from PCS1 to AR-driven PCS2, and re-sensitized cells to ARPIs.
Conclusion: Our fındings establish the centrality of epigenetic reprogram-
ming in driving the insurgence of a clinically aggressive neuroendocrine
phenotype in response to AR pathway inhibition. Drugging the epigenome
via EZH2 inhibition to reverse the NEPC state and re-sensitize tumors to our
powerful arsenal of ARPIs has the potential to transform the treatment of
prostate cancer.
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EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Anticancer Precision Clinical Pharmacology
#5026 Association to drug-induced leukopenia using whole-exome se-
quencing of non-small cell lung cancer patients on gemcitabine/carboplatin
regimen. Anna Svedberg,1 Benjamín Sigurgeirsson,2 Niclas Björn,1 Sailendra
Pradhananga,2 Eva Brandén,3 Hirsh Koyi,3 Rolf Lewensohn,4 Luigi De Petris,4
Cristina Rodríguez-Antona,5 María Apellániz-Ruiz,5 Joakim Lundeberg,2 Hen-
rik Gréen1. 1Clinical Pharmacology, Division of Drug Research, Linköping, Swe-
den; 2Science for Life Laboratory, Solna, Sweden; 3Department of Respiratory
Medicine, Gävle, Sweden; 4Karolinska Biomics Center, Stockholm, Sweden; 5He-
reditary Endocrine Cancer Group, Madrid, Spain.
A classical non-small cell lung cancer (NSCLC) chemotherapy treatment is
gemcitabine in combination with carboplatin. The treatment is known to cause
severe hematological toxicity such as leukopenia, which can lead to chemother-
apy cessation or even death. It would therefore a priori be of advantage to iden-
tify patients at risk of severe leukopenia to allow for a personalized treatment
approach. In this study we aim to identify genetic markers for chemotherapy
induced leukopenia in non-small cell lung cancer. In total, 212 non-small cell
lung cancer patients treated with gemcitabine and carboplatin regimen were
included in the study. Whole blood extracted DNA was prepared with Nextera
Rapid Capture kit and whole exome sequenced using Illumina HiSeq 2500.
Leukopenia was assessed from leukocyte particle count at baseline and the fırst
cycle nadir values. The statistical approach was to study association of single
common variants (MAF 0.01) to leukopenia using linear regression in PLINK
and association of genes (common and rare variants) to leukopenia using
SKATO in the R-package SKAT. An enrichment analysis, with input from the
association results (p 0.001), was performed using the online tool Consensus-
PathDB-human to identify overrepresented pathways. A prediction model was
created from the single variant analysis results (n10 causal and n10 protec-
tive) using weighted genetic risk score from the R-package PredictABEL. The
single variant analysis of common variants identifıed 133 variants (p  0.001)
and the gene based analysis identifıed 54 genes (p 0.001). The pathway anal-
ysis identifıed 20 enriched pathways (p 0.05). A predictionmodel was created
to assess the risk of leukopenia. The top pathway, HIF-1-alpha transcription
factor network, overlaps with four genes (HDAC7, NDRG1, HK2 and CP). It
can be of interest to leukopenia as regulation of HIF-1 alpha is essential for
maintenance of hematopoietic stem cells in the bone marrow hypoxic niche. It
has also been shown that HIF-1 alpha knocked mice are more sensitive to my-
elosuppressive treatment compared to unknockedmice, supporting the involve-
ment of the pathway in chemotherapy induced myelosuppression. We have
identifıed variants located in genes and pathways likely to be involved in leuko-
cyte sensitivity after exposure of gemcitabine and carboplatin. A prediction
model has been created to estimate the risk that patients will suffer from severe
leukopenia. The biological connection of the pathway HIF-1-alpha transcrip-
tion factor network to leukopenia supports the relevance of these results. Further
studies on this are of interest to improve identifıcation of patients at high risk of
severe leukopenia after gemcitabine and carboplatin treatment.
#5027 Exome sequencing of cancer-related genes to identify geneticmark-
ers for sensitivity to cytotoxic anticancer drugs. Chihiro Udagawa,1 Yasushi
Sasaki,2 Hiroshi Suemizu,3 Yasuyuki Ohnishi,3 Hiroshi Ohnishi,1 Takashi
Tokino,2 Hitoshi Zembutsu1. 1National Cancer Center, Tokyo, Japan; 2Research
Institute for Frontier Medicine, Sapporo Medical University, School of Medicine,
Sapporo, Japan; 3Central Institute for Experimental Animals, Kawasaki, Japan.
Although the progress in moving from a one-size-fıts-all cytotoxic approach
to personalizedmolecularmedicine, majority of the patients with cancer receive
chemotherapywith cytotoxic anticancer drugs. Exome sequencing of 409 cancer
related geneswas conducted using 59DNAs extracted fromhuman tumor xeno-
grafts implanted into nude mice, of which sensitivity to nine cytotoxic antican-
cer drugs (5-fluorouracil (5FU), Nimustine (ACNU), adriamycin (ADR), cyclo-
phosphamide (CPM), cisplatin (DDP), mitomycin C (MMC), methotrexate
(MTX), vincristine (VCR), and vinblastine (VLB)) had been examined. We in-
vestigated the relationship between the sensitivities of the xenografts to the nine
anticancer drugs and single nucleotide variants (SNVs) by classifying them into
three groups according to the allele frequency (10%, 10-90%, 90%). We
further carried out replication study using additional set of 20 xenografts. We
also estimated the correlation between the expression levels of the 409 genes and
sensitivities to the nine drugs in the above xenografts. In the screening stage
using 59 xenografts, three SNVs, which were associated with sensitivity to VCR
or MMC, showed P  0.001. We further carried out a replication study of 596
SNVs showing P 0.05 in the screening stage using independent samples of 20
xenografts. A combined result of the screening and replication studies suggested
possible associations of 35 SNVs with sensitivities to the nine anticancer drugs
(Pcombined 0.0011 - 0.035). A total of 35 SNVs showedpossible associationwith
sensitivity to at least one of the nine drugs. Of the 35 SNVs, SNV-1 and SNV-2 in
a tumor suppressor gene and a oncogene were commonly associated with sen-
sitivity to two or four anticancer drugs, respectively. These fındings provide new
insights into precision anticancer therapy for the patients with cancer.
#5028 Whole exome sequencing and genetic association of gemcitabine/
carboplatin induced thrombocytopenia in non-small cell lung cancer pa-
tients. Niclas Björn,1 Anna Svedberg,1 Benjamín Sigurgeirsson,2 Sailendra
Pradhananga,2 Eva Brandén,3 Hirsh Koyi,3 Rolf Lewensohn,4 Luigi De Petris,4
Cristina Rodríguez-Antona,5 María Apellániz-Ruiz,5 Joakim Lundeberg,2 Hen-
rik Gréen1. 1Linköping University, Linköping, Sweden; 2Science for Life Labora-
tory, Solna, Sweden; 3Gävle Hospital, Gävle, Sweden; 4Karolinska Institutet,
Stockholm, Sweden; 5Spanish National Cancer Research Centre (CNIO), Madrid,
Spain.
Introduction: Chemotherapy induced myelosuppression is a clinically relevant
problem for cancer treatments, affecting both quality of life and response to treat-
ment. Severe hematological toxicities such as thrombocytopenia can lead to dose
reductions, postponement or cessation of treatment and there is a need to identify
patients at risk before the start of treatment to allow for personalizedmedicine. The
aimof this studywas to usewhole exome sequencing to identify geneticmarkers for
gemcitabine and carboplatin induced thrombocytopenia that can be used to guide
future treatments. Methods: 212 non-small cell lung cancer patients treated with
gemcitabine and carboplatin were included. Blood samples were whole exome se-
quencedusingNexteraRapidCaptureExomekit andIlluminaHiSeq2500.Patients’
thrombocyte counts weremeasured at baseline and during the fırst treatment cycle.
The thrombocyte nadir value and the relative decrease of the nadir value frombase-
line were used as thrombocytopenia toxicity parameters. Coding SNVs as well as
whole gene-regions and complete pathways were investigated using the following
statistical methods: A) Association of common SNVs/INDELs with thrombocyto-
penia using linear regression in PLINK. B) Association of the combined effect of
common and rare variants within a gene-region with thrombocytopenia using the
region based association test SKATO, in the R-package SKAT. C) All genes includ-
ingSNVs/INDELs inA)or agene-regions inB)withp0.001wereusedas input for
the online toolConsensusPathDB-human to fındoverrepresentedpredefınedpath-
ways.Results:The studyassociatedA)103SNVs/INDELsandB)21genes to throm-
bocytopenia (p0.001). The pathway analysis C) identifıed 28 enriched pathways
(p0.05). Potentially important pathways for gemcitabine/carboplatin induced
thrombocytopenia identifıed were: Hemostasis (ITGB1, SERPINA5, SERPINC1,
JMJD1C,DOCK8 andCAPZA2), Factors involved inmegakaryocyte development
and platelet production (JMJD1C, DOCK8 and CAPZA2) and Vitamin B9 (folate)
metabolism (FOLR3 and MTHFD1L). Single SNVs, INDELs and genes can be of
importance for induced toxicity. However, special interest should be given to the
variants and genes in the pathways above. Two of the pathways link back to throm-
bocytopenia via platelet production and hemostasis and include, JMJD1C and
DOCK8, previously associated with thrombocyte formation andmean platelet vol-
ume. The pathway concerning folate metabolism links back to gemcitabine’s and
carboplatin’smode of action via the involvement of folate in thymidylate andDNA
synthesis. Further, folate isnecessary for the rapid synthesisofbloodcells in thebone
marrow. Conclusion: The identifıed genetic markers and pathways are associated
withchemotherapy induced thrombocytopeniaandprovidea strong foundation for
further investigation.
#5029 Pharmacogenetics of doxorubicin, gemcitabine and docetaxel in
theGeDDiS soft tissue sarcoma trial.David Jamieson,1 Beatrice Seddon,2Katja
Kuever,1 Hakim-Moulay Dehbi,3 Sandra Strauss,2 Sandy Beare,3 Gareth Veal1.
1Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom;
2University College Hospital, United Kingdom; 3Cancer Research UK & UCL
Cancer Trials Centre, United Kingdom.
Introduction: The treatment of locally advancedormetastatic soft tissue sarcoma
remains a signifıcant clinical challenge, with overall survival rates of approximately
12months observedwith current fırst linepalliative chemotherapy.A recently com-
pleted randomised phase III clinical trial entitledGeDDiS (ISRCTN07742377), was
designed to compare fırst line treatment with gemcitabine in combination with
docetaxel (GemDoc) versus current standard treatment with doxorubicin. A phar-
macogenetic sub-study was incorporated into the trial to assess potential impact of
singlenucleotidepolymorphisms(SNPs) ingenesassociatedwith thepharmacology
of the three drugs. Methods: A total of 240 patients were recruited to the sub-study
with119on thedoxorubicin armand121on theGemDocarm.A4mlblood sample
was taken fromeach participant and genomicDNAextracted. Individual candidate
SNPs were assessed by Taqman PCR in 7 genes associated with doxorubicin phar-
macology, 7 genes associated with gemcitabine and 5 genes associated with the
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pharmacology of docetaxel. Association between the SNPs and effıcacy and toxicity
wasassessed.Results: SNPswithin the solute transporter SLC22A16, associatedwith
the intracellular influx of doxorubicin, were associatedwithworse PFS (HR 1.72,
p0.04) anddecreased frequencyof grade 3/4 adverse events (71%vs 48%,p0.04)
in the doxorubicin arm of the study but not in the GemDoc arm. Conclusions: The
association of genetic variants of SLC22A16 with decreased effıcacy and decreased
incidence of toxicity is consistent with a loss of function in the transporter and
previous observation of increased AUC in pharmacokinetic studies assuming that
distribution of the drug into target and collateral tissues is restricted.
#5030 The impact ofABCB1 single nucleotide polymorphisms on the out-
come in lenalidomide treated multiple myeloma patients. Ingrid Jakobsen
Falk,1 JohanLund,2HenrikGréen,1AstridGruber,2 EvrenAlici,2 Birgitta Lauri,3
Cecilie Blimark,4 Ulf-Henrik Mellqvist,4 Agneta Swedin,5 Karin Forsberg,6
Conny Carlsson,7 Mats Hardling,8 Lucia Ahlberg,9 Hareth Nahi,2 Kourosh
Lotfı1. 1Division of drug research, LinköpingUniversity, Linköping, Sweden; 2Unit
for hematology, Karolinska Institute, Huddinge, Sweden; 3Sunderby Hospital,
Luleå, Sweden; 4Hematology department, Sahlgrenska University hospital, Göte-
borg, Sweden; 5Hematology department, Skåne University hospital, Lund, Swe-
den; 6Department of hematology, Norrland University hospital, Umeå, Sweden;
7Department of Internal medicine, Halland Hospital, Halmstad, Sweden; 8De-
partment of hematology, Uddevalla hospital, Uddevalla, Sweden; 9Department of
hematology, Linköping University hospital, Linköping, Sweden.
Introduction: Multiple myeloma (MM) is an incurable plasma cell malig-
nancy with high mortality rate. Treatment outcomes have improved since the
introduction of new drugs such as the IMiD lenalidomide, but relapse rates and
resistance is still a problem. The gene ABCB1 encodes the drug transporter
p-glycoprotein (p-gp) which confers resistance through extrusion of drugs over
the cell membrane. Lenalidomide is subject to limited metabolism and excreted
mainly via the kidneys. In vitro studies have shown lenalidomide to be an
ABCB1 substrate, and single nucleotide polymorphisms (SNPs) affecting gene
expression, transporter function and/or activity may affect drug distribution
and the subsequent outcome and risk of adverse events.However, in vivo studies
of the effect of ABCB1 on lenalidomide pharmacokinetics are contradictory.
Our aim was to investigate the influence of ABCB1 SNPs on lenalidomide treat-
ment outcome and adverse events (AE). Materials & Methods: In the observa-
tional part of two connected studies, 133 Lenalidomide naïve patients at 1st
relapse/refractory MM were treated with lenalidomide and dexamethasone for
up to 9 cycles of 4 weeks. In the prospective 2nd part, 62 patients that had
achieved at least partial response according to IMWG-criteria followed by at
least two additional treatment cycles were randomized to either lenalidomide/
dexamethasone or lenalidomide as a single drug. 90 patients (of which 47 was
further randomized to the 2nd part) had samples available for genotyping of the
ABCB1 SNPs 1199GA (Ser400Asn, rs2229109), 1236CT (rs1128503),
2677GT/A (Ala893Ser, rs2032582) and 3435CT (rs1045642) using Pyrose-
quencing. Correlations to overall survival, time to progression (TTP), response
parameters and AE were investigated, and a p-value of 0.05 was considered
signifıcant. Results: No signifıcant correlations to hematological AE or response
rates were found, and no impact on survival for 1236CT, 2677GT/A or
3435CT, neither in thewhole populationnor in patients randomized to the 2nd
part. The results were similar also when risk (according to FISH) was consid-
ered. There was a trend towards improved TTP for patients carrying the 1199A
variant; mean TTP 3.2 years (95%CI 2.3-4.1) vs 2.2 years (95%CI 1.8-2.6) for
G/A and G/G, respectively (p0.076). This trend was confırmed in the multi-
variable cox regression analysis; HR0.280 (95%CI 0.74-1.054), p0.06. The
difference in TTP was signifıcant in the non-high risk subgroup; mean TTP 4.3
years (95%CI 3.7-4.9) vs 2.3 years (95%CI 1.8-2.8), p0.034, for G/A and G/G,
respectively. Conclusion:No evidencewas found for a large impact of 1236CT,
2677GT/A or 3435CT on lenalidomide treatment outcome or risk of hema-
tological AE. 1199GAmay be a potential marker of TTP in non-high riskMM
but further studies in a larger cohort is needed to clarify the relationship and
whether this is due to altered drug transport or efflux independentmechanisms.
#5031 Distribution of single nucleotide polymorphisms related to pacli-
taxel and carboplatin toxicity in ovarian cancer patients. Miguel Cordova,1
Maria L. Bravo,2 Isidora Arriagada,3 Elisa Cumsille,3 Luis Quiñones,4 Erasmo
Bravo,5 Raimundo Correa,6 Juan E. Leiva,6 Cesar Paredes,6 Mauricio Cuello,3
Carolina Ibañez,3 Marcelo Garrido,3 Gareth I. Owen2. 1Pontifıcia Universidad
Catolica de Chile, Universidad de Chile, Biomedical Research Consortium Chile,
Santiago, Chile; 2Pontifıcia Universidad Catolica de Chile, Biomedical Research
Consortium Chile, Santiago, Chile; 3Pontifıcia Universidad Catolica de Chile,
Santiago, Chile; 4Universidad de Chile, Santiago, Chile; 5Hospital Gustavo Fricke,
Viña del mar, Chile; 6Hospital Regional de Talca, Talca, Chile.
Introduction: Standard fırst-line treatment for ovarian cancer consists in the
combined use of taxanes and platinum, with neuropathies and neutropenia the
most frequent and complex adverse drug reactions (ADRs) requiring clinical
management. These adverse effects may be related to differing levels of drug
transport and metabolism brought about by intrinsic genetic characteristics of
the patients. Single nucleotide polymorphisms (SNPs) are now recognized as
key factors in the variability of drug response. In a cohort of Chilean ovarian
cancer patients we analyzed the frequencies of several SNPs previously reported
to be associated with paclitaxel and carboplatin ADRs. Methods: Blood samples
were obtained with informed consent from adult ovarian cancer patients (n 
120). DNA was extracted and SNPs within the ABC transporter and CYP P450
gene families were genotyped. High specifıcity Taqman probes were used. Re-
sults: Four SNPs associated with risk of ADRwithin the ABC transporter family
showed genotypic frequencies ranging between 0 - 23%. Frequencies for the
ADR-associated variants in the CYP P450 family were 4 - 90%. Finally, for the
CYP2C8 enzyme, whose function is essential in paclitaxel metabolism, the fre-
quencies of risk-associated SNPs ranged from 2.10% to 13.6%. Conclusions:
SNPs associated with paclitaxel and carboplatin ADRs are highly prevalent in
the Chilean population of ovarian cancer patients studied. The identifıcation of
these variants may help avoid severe ADRs associated with chemotherapy re-
gimes. Funding: CORFO 13CTI21526-P6 & 13IDL2-18608.
#5032 The relationship between the UGT1A1*27 and UGT1A1*7 genetic
polymorphisms and irinotecan-related toxicities in patients with lung can-
cer. Minoru Fukuda,1 Manabu Okumura,2 Tomomi Iwakiri,2 Arimori Ka-
zuhiko,2 Shinnosuke Takemoto,1 Takaya Ikeda,1 Takuya Honda,1 Hiroyuki
Yamaguchi,1 Katsumi Nakatomi,1 Kazuma Kobayashi,1 Mitsuko Masutani,3
MikioOka,4 KazutoAshizawa,1HiroshiMukae1. 1Nagasaki UniversityHospital,
Nagasaki, Japan; 2University of Miyazaki Hospital, Miyazaki, Japan; 3Nagasaki
University, Nagasaki, Japan; 4Kawasaki Medical School, Kurashiki, Japan.
Background: Genetic polymorphisms in the UDP-glucuronosyltransferase
1A1 (UGT1A1), UGT1A7, and UGT1A9 genes are associated with interindi-
vidual differences in irinotecan toxicities. The UGT1A1*7, *27, and *29 gene
polymorphisms occur within the common exons of UGT1A1 isoforms and
cause substantial reductions in their functional activity; however, few clinical
studies have examined the effects of these polymorphisms. Purpose: To evaluate
the effects of gene polymorphisms, including UGT1A1*7, *27, and *29, on the
safety of irinotecan therapy. Patients andmethods: The eligibility criteriawere as
follows: lung cancer patientswhowere scheduled to undergo irinotecan therapy,
aged 20 years, and had a performance status of 0-2. After informed consent
had been obtained, patients were enrolled, and their blood was collected and
used to examine the frequency of the UGT1A1*6, *7, *27, *28, and *29 polymor-
phisms and the drug concentrations of irinotecan, SN-38, and SN-38G after
irinotecan therapy. Results: Thirty-one patients were enrolled. The patients’
characteristics were as follows: male/female  25/6, median age (range)  71
(55-84), stage IIB/IIIA/IIIB/IV  2/6/11/12, and Ad/Sq/Sm/Oth  14/10/3/4.
The -/-, *6/-, *7/-, *27/-, *28/-, and *29/- UGT1A1 gene polymorphisms were
observed in 10 (32%), 10 (32%), 2 (6%), 2 (6%), 7 (23%), and 0 (0%) cases,
respectively. There were no homozygous or complex heterozygous polymor-
phisms. The UGT1A1*27 polymorphism occurred separately from the
UGT1A1*28 polymorphism. The lowest leukocyte counts of the patients with
the UGT1A1*27 and UGT1A1*6 gene polymorphisms were lower than those
seen in the wild-type patients. SN-38 tended to remain in the blood for a pro-
longedperiod after the infusion of irinotecan in patientswith theUGT1A1*27 or
UGT1A1*28 polymorphism. No severe myelotoxicity was seen in the patients
with UGT1A1*7. Conclusions: UGT1A1*27 and UGT1A1*7 are both rare gene
polymorphisms. UGT1A1*27 can occur separately from UGT1A1*28 in some
circumstances and is related to leukopenia during irinotecan treatment.
UGT1A1*7 is less relevant to irinotecan-induced toxicities, and UGT1A1*29
seems to have little clinical impact.
#5033 Optimized CYP2D6 phenotype assignment for plasma endoxifen
prediction in breast cancer patients treatedwith tamoxifen.Werner Schroth,1
Stefan Winter,1 Michel Eichelbaum,1 Thomas Muerdter,1 Matthias Schwab,2
Hiltrud Brauch3. 1Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacol-
ogy, Stuttgart, and University of Tuebingen, Tuebingen, Germany; 2Dr. Marga-
rete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Department of
Clinical Pharmacology, University Hospital Tuebingen, Cancer Consortium
(DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany;
3Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Uni-
versity of Tuebingen, Tuebingen, and German Cancer Consortium (DKTK) and
German Cancer Research Center (DKFZ), Heidelberg, Germany.
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Tamoxifen (Tam), a standard therapy for estrogen receptor (ER)-positive
breast cancer, is bioactivated to its active metabolite endoxifen by the cyto-
chromeP450 enzymeCYP2D6. CYP2D6polymorphisms constituting extensive
(EM), intermediate (IM) and poor (PM) metabolizer phenotypes are main de-
terminants of variable endoxifen plasma concentrations and supposed to influ-
ence therapeutic effıcacy. Genotype-guided prediction of TAMmetabolizer sta-
tus has long been debated to be useful for clinical dose adjustment in patients
with impaired metabolism. As this requires accurate genotype-phenotype as-
signments, we tested several CYP2D6 phenotype classifıcations including the
codeine metabolism-based scoring implemented by the ’Clinical Pharmacoge-
netics ImplementationConsortium’ (Crews et al. 2014, CPT) for their predictive
value of active metabolite concentrations. We applied linear modelling of
square-root transformed plasma endoxifen or log-transformed metabolic ratio
(MR) endoxifen/desmethyl-TAM depending on CYP2D6 phenotype classifıca-
tion in a cohort of 936 pre- and postmenopausal TAM treated breast cancer
patients of European, Middle Eastern Arabic, and Asian descent (Muerdter et al
CPT 2011; Saladores et al. TPJ 2015). CYP2D6 diplotypes were defıned by PM
(*3, *4, *5, *6, *7), IM (*9, *10, *41), EM (*1, *2, *35) or UM (duplicated EM)
alleles. CYP2D6phenotypeswere defıned by various diplotype groupings and an
adapted activity score regarding the *10 allele. Models were adjusted for
CYP2C9 and CYP3A5 genotypes, and robust coeffıcients of determination (R2)
with 95% confıdence intervals from 10.000 bootstrap replicates were calculated
using R package lmrob. Our analyses indicate, that the commonly used codeine-
based CYP2D6 phenotype assignment poorly predicts CYP2D6 mediated en-
doxifen formation. This is evident from a low predictability (20%) for both
metabolite endpoints particularly in Asians, most likely due to a misclassifıca-
tion of abundant IM/IM (*10) diplotypes as EM. Importantly, the active metab-
olite-to-precursor MR appears to be the endpoint that is more closely linked to
CYP2D6 enzyme activity, as it explains up to 68-82% of MR variability. In con-
trast, absolute endoxifen concentrations were only modestly predictable (38-
57%) byCYP2D6 diplotype or other phenotype groupings.Moreover, a reduced
activity for the *10 compared to other IM alleles appears to improve endoxifen
predictabilty by phenotype. Personalized TAM treatment decisions based on
plasma endoxifen prediction should rely on TAM specifıc CYP2D6 genotype-
guided phenotype assignments that quantitatively capture the allele-dosage ef-
fects and that include endoxifen-to-precursorMR as the endpoint most directly
linked to CYP2D6.
#5035 IDWAS: Imputingdrug response in large cohorts of cancer patients
to discover novel predictive biomarkers. Paul Geeleher, Zhenyu Zhang, Fan
Wang, Aritro Nath, Steven Bhutra, Robert Grossman, R. Stephanie Huang.
Univ. of Chicago, Chicago, IL.
There are currently only 10 cancer genes with FDA approved drug treatment
options (source: OncoKB). Here, we present a conceptually novel analytical
method that can rapidly expand this small list of clinically effective cancer drug
treatment biomarkers. Large sequencing studies, such as The Cancer Genome
Atlas (TCGA), have greatly accelerated our understanding of the molecular
basis of cancer. However, because of the diffıculty in collecting drug response
data in large cohorts of cancer patients, these studies have not been effectively
used for fınding new biomarkers of drug response (i.e. pharmacogenomics dis-
covery). Thus, much cancer pharmacogenomics research is conducted in pre-
clinical diseasemodels such as cell lines (e.g. theGenomics ofDrug Sensitivity in
Cancer (GDSC) project); but these studies are (among other limitations) always
restricted by comparatively smaller sample sizes. Here, we present an analytical
method that integrates data from large clinical studies (e.g. TCGA) with data
from pre-clinical disease models (e.g. GDSC) and overcomes these critical ob-
stacles, allowing studies such as TCGA to now be effectively used for pharma-
cogenomics discovery. We refer to this approach as an “Imputed drug-wide
association study” (IDWAS). The method works by fıtting a statistical model
relating gene expression and drug response in pre-clinical data (here we use the
GDSC cancer cell lines), then using this model to impute drug response from
tumor gene expression data in a clinical cohort (here we use TCGA). Next, we
compare these imputed drug response data to measured variants (e.g. somatic
mutations, copy number changes) in TCGA, thus fınding new biomarkers of
drug response. We show that we can recapitulate known clinically effective
biomarkers and we have validated new clinically relevant biomarkers, which
remarkably could not have been identifıed using conventional approaches. Our
method will set the stage for many future studies. Crucially, this approach could
easily be applied to any of the vast number of clinical cancer sequencing studies
now undertaken, meaning that it will be possible to use all of these datasets for
pharmacogenomics research. We have included a set of computational tools to
allow easy application of our method and replication of our results. Given that
this is a conceptually novel methodology, it is also likely that many other studies
will attempt to improve upon our proposed implementation. Furthermore,
members of our group are currently leading the development of the new
Genomic Data Commons (GDC; https://gdc.cancer.gov/), which is the NCI’s
new access portal for TCGAdata.We are currently working towardsmaking the
imputed drug response data directly accessible on GDC, along with all other
TCGA data. This means that our imputed drug response data will be easily
accessible to the thousands of researchers already accessing TCGA via the GDC.
#5036 Correlation of preclinical antitumor activity of regorafenib in
CRC-PDX xenografts with gene expression and clinical parameters of the
primary tumor. Henrik Seidel,1 Jens Hoffmann,2 Ralf Lesche,1 Sylvia
Grünewald,1 David Henderson,1 Dieter Zopf1. 1Bayer Pharma AG, Berlin, Ger-
many; 2EPO GmbH, Berlin, Germany.
Regorafenib is a small molecule inhibitor of multiple transmembrane and
intracellular kinases involved in normal cellular functions and in pathologic
processes such as oncogenesis, tumor angiogenesis, metastasis, and tumor im-
munity. Regorafenib is approved for the treatment of patients with metastatic
colorectal cancer (CRC) who have been previously treated with fluoropyrimi-
dine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy,
and, if RASwild-type, an anti-EGFR therapy or with locally advanced, unresect-
able or metastatic gastrointestinal stromal tumor (GIST) who have been previ-
ously treated with imatinib mesylate and sunitinib malate. Recently an overall
survival benefıt has been shown in patients with hepatocellular carcinoma
(HCC) who had previously been treated with sorafenib (RESORCE). On-
coTrack is an Innovative Medicines Initiative (IMI) sponsored project with the
goal to improve the basis for identifıcation of biomarkers based on the mecha-
nisms of action of therapies approved for this indication. For this purpose, a
panel of CRC-PDX xenografts was generated by the OncoTrack project. At the
time of the analysis reported here fıfty xenografts had been treated with rego-
rafenib at a dose of 10mg/kg/d or with vehicle for 24 days. The analysis of tumor
growth rates (TGR) showed pronounced differences between different tumors
and between vehicle and regorafenib treated models. The relative antitumor
activity (relative TGR) of regorafenib varied between -0,13 (good response) and
0.0 (no response). Investigations of relative TGR in relationship to (non-) clin-
ical parameters of the primary tumor such as age, gender, sidedness and tumor
histology identifıed amarginally signifıcant (p 0.04) better response in tumors
from younger patients. No other correlations were detected to this end, which
may be due to the small sample number. To correlate antitumor activity of
regorafenib with gene expression, RNA was isolated from sections of selected
vehicle and regorafenib treated xenografts and hybrized on Affymetrix
HuGene-2.1_st human transcriptome arrays. Expression profıles were subse-
quently analyzed using the Random Forests algorithm to identify gene expres-
sion signatures predicting response to regorafenib. The best signatures did not
perform better than signatures derived after randomizing responses, i.e. no pre-
dictive signature could be identifıed. Further studies with larger samples sizes
are necessary to improve the outcome of such an approach; however one should
acknowledge that to date no predictive gene signatures could be identifıed for
multikinase inhibitors, which may be intrinsic to their complex mechanism of
action. The research reported here received support from the Innovative Medi-
cines Initiative Joint Undertaking under grant agreement 115234 (OncoTrack).
#5037 New concepts for quantifying the benefıts of mono and combina-
tion therapy in an era of big data. Peter K. Sorger, Marc Hafner, Mario Niepel,
Caitlin Mills, Adam Palmer, Mohammed Fallahi Sichani. Harvard Medical
School, Boston, MA.
I will describe new (unpublished) approaches to quantifying drug response at
two points in the drug development pipeline: pre-clinical studies in cell lines and
clinical trials of combination therapies in patient populations. Drug sensitivity
and resistance in cell lines is conventionally quantifıed by IC50 or Emax values,
but these measures suffer from a fundamental flaw when applied to growing
cells: they are highly sensitive to cell division number, which varies with cell line,
experimental condition, seeding density etc. The dependency of IC50 and Emax
on division rate creates artefactual correlations between genotype and drug sen-
sitivity while obscuring important biological insights and interfering with bio-
marker discovery. I will describe alternative growth rate inhibition (GR)metrics
that are insensitive to division number and can directly measure both endpoint
sensitivity and adaptive drug resistance. Theory and experiments show that
GR50 and GRmax are superior to IC50 and Emax for assessing the effects of
drugs in dividing cells. GRmetrics promise to improve our ability to score drug
sensitivity in specifıc-derived tumor cells, improves data reproducibility, and
increase the translational potential of pharmacogenomics data. In patients,
combination therapy improves tumor control compared to monotherapy and
the development of combinations is motivated inmost cases by pre-clinical data
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on synergism in cell lines. However I will describe a different way in which
combinations can provide clinical benefıt. Based on analysis of between-patient
variability in existing trial data and a large set patient derived tumor xenograft
(PDX) mice published by Gao H, Korn JM, Ferretti S, et al. (Nature medicine
2015;21:1318-25), I will argue for a simple principle: in nearly two-thirds of cases
analyzed, effıcacious combinations work simply by improving the likelihood
that a tumor will experience an outlier response to a single drug. Thus, even in
the absence of additive or synergistic tumor inhibition, combinations are gen-
erally superior to monotherapies. Superiority by “independent action” provides
a principle on which to design new combinations and a scientifıc rationale for
the use of combination therapies in poorly understood cancers whenever toxic-
ity is acceptable.— These studies, at two different points of the drug discovery
pipeline, illustrate the value of combining new fırst-principles theories about
drug mechanism of action with “big data” that is increasingly available on pre-
clinical and clinical drug response. Conversely, in the absence of conceptual
innovation, wemiss importantmechanistic insights hidden in existing data. The
purpose of such insights, when obtained, is drive new laboratory and real-world
experiments. I will discuss how the process of coupling computation and exper-
imentation works in practice.
#5038 Comparison of the dose response of malignant peripheral nerve
sheath tumor in vitro growth inhibition of 30 drugs to reportedCmax values.
Karlyne M. Reilly, Robert G. Tuskan, Brigitte C. Widemann. NCI, NIH,
Bethesda, MD.
In this study we aim to identify drugs that can be repurposed to inhibit ma-
lignant peripheral nerve sheath tumor (MPNST), a rare and deadly sarcoma
associated with Neurofıbromatosis type 1 (NF1). Inhibition of MPNST cell
growth in vitrowas tested for 30 drugs that have previously been throughhuman
clinical trials such that the maximum concentration of compound in human
serum (Cmax) at the maximum tolerated dose has been determined. Drugs were
compared to the chemotherapeutic doxorubicin. Six MPNST cell lines from
human andmousewere tested and dose response curves were compared to Cmax
for each drug. For most compounds tested, inhibition of MPNST viability oc-
curred at drug concentrations higher thanCmax.Doxorubicinwas one of the best
compounds tested. Several compounds with less specifıc molecular targets ap-
pear promising, however, currently available inhibitors of receptor tyrosine ki-
nase signaling pathways required concentrations above Cmax to inhibit MPNST
viability. These data suggest that diffıculty in developing therapy for MPNST
may be due to the requirement for high concentrations of drugs to inhibit
MPNST cells.
#5039 Adata driven approach to predicting tissue-specifıc adverse events.
Kaitlyn M. Gayvert, Neel Madhukar, Coryandar Gilvary, Olivier Elemento.
Weill Cornell Medicine, New York, NY.
Adverse events are currently one of the main causes of failure in drug devel-
opment andwithdrawal after approval. As a result, predicting drug side effects is
an incredibly important part of drug discovery and development. With the
emergence of precision medicine there has been a surge in interest on creating
drugs for specifıc protein targets, howeverwe lack accurateways to connect drug
targets and mechanisms to specifıc side effects. Here we take a target-centric
approach to in-silico drug side effect prediction.We havemined drug side effect
databases and grouped sets of side effects to the originating human tissue. For
each of 30 tissues, we defıned a set of “toxic targets”- proteins that are only
targeted by drugs with toxicity in that tissue - and “safe targets” - proteins only
targeted by drugswith no related tissue toxicities.We found that toxic targets are
consistently more highly expressed than safe targets, indicating that their mech-
anisms may be more crucial in their respective tissue. Furthermore we found
that toxic targets have higher network connectivity. Using published gene
knockdown screens, we also found that toxic targets for each tissue are signifı-
cantly more likely to be essential than safe targets and are more likely to be
enriched for GO terms related to cell death. These pieces of information all
reinforce the proposed relationship between the identifıed toxic targets and drug
induced tissue toxicities. We next leveraged this information to draw insights
into unexpected drug toxicity events. We applied the BANDIT drug target pre-
diction tool to drugs misclassifıed by the PrOCTOR toxicity prediction method
and drugs with a specifıc type of tissue toxicity that were not known to hit any of
our identifıed toxic targets. We found that new drug-target predictions ex-
plained a large number of these toxicities, correctly classifying approximately
fıve times as many side effects as would have been expected by random chance.
These results all supported our target-centric hypothesis of drug side effect pre-
diction. Therefore we built a set of machine-learning models that would inte-
grate drug targets with tissue-wide expression patterns and gene-specifıc fea-
tures to predict specifıc side effects for a given drug. We found that these
methods could signifıcantly outperform other prediction techniques and ran-
dom chance. For instance, our method for predicting drug induced liver injury
(DILI) had 70% accuracy at pinpointing specifıc drugs known to cause DILI
and its likelihood score correlated with the FDA’s reported DILI severity score.
Overall these fındings show how a target-centric approach to drug development
can not only help us understand the relation between targets and specifıc phe-
notypic effects, but can help drug developers predict side-effects before costly
and time-consuming clinical studies. Our hope is that adoption of these meth-
ods will lead to overall increase in drug development effıciency and bring safer
drugs to the market quicker.
#5040 The plasma and cerebrospinal fluid pharmacokinetics of pegylated
liposomal doxorubicin after intravenous administration in non-human pri-
mates. Christine Higham, Robert Murphy, Cynthia McCully, Katherine War-
ren, Brigitte Widemann. National Institute of Health, Washington, DC.
Background: Pegylated liposomal doxorubicin (PLD) exhibits altered plasma
pharmacokinetics (PK) compared to doxorubicin, with a longer half-life (55
hours), large area under the concentration-time curve (AUC), lower rate of
clearance, andmarkedly smaller volume of distribution. The cerebrospinal fluid
(CSF) PK of PLD are unknown.We evaluated the plasma and CSF PK of PLD in
a non-human primate (NHP) model. Methods: PLD was given as single dose (1
mg/kg  low adult recommended dose of 20 mg/m2) intravenously over 60
minutes to 3 NHPwith indwelling central venous catheters and central nervous
system ventricular reservoirs or lumbar ports. Serial blood and CSF samples
were obtained for 96 hours after completion of the infusion. The total doxoru-
bicin concentration (liposome bound  protein bound  free) was quantifıed
with a validated liquid chromatography/tandemmass spectrometry assay (lower
limit of quantifıcation plasma0.29 ng/mL, and CSF0.06 ng/mL). PK param-
eters were estimated using non-compartmental methods. CSF penetration was
calculated from the AUCCSF:AUCplasma. Results: PLD was well tolerated. Total
doxorubicin plasma concentration time curves were characterized by sustained
PLD exposure, comparable to the exposure observed in humans at a similar
dose. The terminal elimination phasewas not captured. InCSF, doxorubicinwas
measurable and still present at the last time point in all animals, but the CSF
penetration was limited (Table). Conclusions: Using a sensitive assay, we could
quantify doxorubicin in CSF. However, the CSF penetration is limited in NHP
with intact blood brain barrier. Our assay analyzed the total doxorubicin con-
centration in plasma. It is unknown if PLD can penetrate into the CSF, therefore
we could not determine if the CSF penetration represents total versus free.
Plasma and CSF PK of pegylated liposomal doxorubicin in NHP
Animal
Cmax
Plasma
(ng/mL)
Tmax
Plasma(h)
AUC0-96h
Plasma
(ng*h/mL)
Cmax
CSF
(ng/mL)
Tmax
CSF
(h)
AUC0-96h
CSF
(ng*h/mL)
CSF
Penetration
(%)
1 9396 48 7.24E05 1.84 5 24.21 0.33
2 30449 0 1.76E06 0.71 6 18.75 0.11
3 37467 0.08 1.91E06 3.25 10 36.41 0.2
Mean 25770 16 1.46E06 1.93 7 26.46 0.21
#5041 Translational pharmacokinetic-pharmacodynamic xenograft
model for TAK-931, a small molecule cell division cycle 7 (CDC7) kinase
inhibitor. Charles Locuson,1 Mayank Patel,1 Akihiro Ohashi,2 Kenichi Iwai,2
Tadahiro Nambu,2 Toshiyuki Takeuchi,2 Akifumi Kogame,2 Douglas Bow-
man,1 Stephen Tirrell,1 Huifeng Niu,1 Cindy Xia1. 1Takeda Pharmaceuticals
International, Cambridge,MA; 2Takeda Pharmaceuticals International, Shonan,
Japan.
TAK-931 is a small molecule inhibitor of the cell division cycle 7 (CDC7)
kinase. As a serine/threonine kinase that contributes toDNA replication and the
DNA damage response, CDC7 is hypothesized to be a promising cancer drug
target. CDC7 inhibition with TAK-931 has demonstrated antiproliferative ac-
tivitywith cancer cell lines and tumor growth inhibition (TGI) inmurine ectopic
xenograft models. Herein, the analysis of multiple models to characterize phar-
macokinetic (PK) and pharmacodynamic (PD) relationships with xenograft
TGI is described. TAK-931 treatment-induced TGIwas dose schedule-indepen-
dent and could be described using plasma drug concentrations or tumor PD
inhibition. However, the effıcacious doses were at least 10-fold higher for the
PK-TGI relationship than for the PD-TGI relationship. This discrepancy was
used to select a dynamic PK-PD-TGImodeling approach to project theminimal
effıcacious dose (MED) and minimal biological active dose (MBAD) for TAK-
931 due to the large differences in time-concentration profıles predicted for
humans versus mice. The Phase I human trial is on-going and will be used to
verify the dynamic PK-PD-driven modeling approach for the CDC7 inhibitor.
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#5042 Defıning an optimal single time point sampling strategy represen-
tative of overall capecitabine pharmacokinetics. Stephen Welch,1 Wendy
Teft,1 John Lenehan,1 Rommel Tirona,1 Karen Lumsden,2 EricWinquist,1 Rich-
ard B. Kim1. 1Univ. ofWestern Ontario, London, Ontario, Canada; 2Grand River
Regional Cancer Centre, Kitchener, Ontario, Canada.
Background: Capecitabine is an oral chemotherapy pro-drug used to treat
advanced colorectal cancer. Patients may experience hand-foot syndrome and
diarrhea, among other side effects, that affect quality of life and may necessitate
dose modifıcation or discontinuation. There is signifıcant regional variation in
capecitabine tolerability, related to a myriad of factors including pharmacog-
enomics, dietary and cultural differences. Capecitabine dosemodifıcation, when
necessary, is empirical based on toxicity suggesting a personalized dosing ap-
proach might better optimize therapy. Objective: In phase I of a personalized
dosing approach, our objective was to defıne an optimal time point for blood
sampling that best represented overall exposure of capecitabine and its metab-
olites. Methods: A single-arm prospective pharmacokinetic cohort study of pa-
tients with advanced or metastatic colorectal cancer prescribed capecitabine
monotherapy was done. Blood samples were collected pre-dose and at timed
intervals between 0 and 8hours post-dose. Plasma concentration of capecitabine
and its major metabolites, 5=-deoxy-5-fluorocytidine (5=-DFCR) and 5=-deoxy-
5-fluorouracil (5=-DFUR), weremeasured by ultra-performance liquid chroma-
tography-tandemmass spectrometry (UPLC-MS/MS). Results: 26 patients were
enrolled; 65% were male and 42.3% had metastatic disease. Mean capecitabine
dose was 2854 944 mg. Hand-foot symptoms (60%), fatigue (53%) and diar-
rhea (30%) were the most common adverse drug reactions. Dose normalized
mean (SD) AUC0-8h for capecitabine, 5=-DFCR and 5=-DFUR were 6.74 (3.0),
4.19 (1.5) and 6.33 (2.8) ng/ml*h, respectively. Spearman correlation between
dose normalized concentrations and AUC at each blood draw was performed.
The best estimated time points for capecitabine, 5=-DFCR and 5=-DFUR were
1.5, 2 and 2 hours with r2 values of 0.6 (p 0.01), 0.64 (p 0.001) and 0.51 (p
0.01), respectively. There was a signifıcant correlation seen between capecit-
abine AUC and need for subsequent dose reduction (p0.05). Conclusions:
Blood samples obtained between 1.5 and 2 hours post-dose provide the best
estimate of capecitabine exposure. Further pharmacokinetic analysis in this co-
hort is ongoing. This blood draw strategywill be used in a larger trial intended to
develop a personalized capecitabine dosing algorithm.
#5043 Population pharmacokinetic model for OT-101 - A TGF-2-spe-
cifıc antisense oligonucleotide in cancer patients. Wen Wang,1 Kevin Ng,2
David Nam,2 Vuong Trieu,1 Larn Hwang1. 1Oncotelic Inc, Agoura Hills, CA;
2Autotelic Inc, Costa Mesa, CA.
Background: OT-101 (Trabedersen) is a phosphorothioate antisense oligode-
oxynucleotide specifıcally inhibiting the expression of transforming growth fac-
tor-beta 2 (TGF-2), whose overexpression is a pivotal factor for malignant
progression in solid tumors. In the clinical Phase I/II study, plasma pharmaco-
kinetic (PK) profıle of OT-101 administered intravenously was evaluated in
patients with advanced tumors. A population PK model was built to further
understand the factors contributing to the variability in PKofOT-101.Methods:
A total of 61 patients with pancreatic cancer (n37), malignant melanoma
(n19), or colorectal carcinoma (n5) were treated with OT-101 with escalat-
ing doses in 2 treatment schedules (1st schedule: 7-days on, 7-days off; 2nd sched-
ule: 4-days on, 10-days off; up to 10 cycles). The PK analysis was only performed
on Cycle 1 and, when applicable, Cycle 2. Blood samples were collected from
patients at planned time points from before start of infusion to 7 days (1st sched-
ule) or 10 days (2nd schedule) after stop of infusion. The plasma concentration
data of OT-101 were used to build a population PKmodel using Phoenix NLME
software. The influence of age, gender, body mass index (BMI), body weight
(BW), height, cancer type, and treatment schedule as covariates on PK was
evaluated. Results: With exclusion of protocol deviations, a total of 1444 plasma
sample concentration data from 100 patient cycles were examined. The concen-
tration time course of OT-101was best described by a two-compartmentmodel.
The model estimated the PK parameters as follows: total body clearance, 0.17
mL/h; distribution volume of the central compartment, 4.69 L; inter-compart-
mental clearance, 3.31 L/h; distribution volume of the peripheral compartment,
5046.44 L. BW was identifıed as a covariate on OT-101 inter-compartmental
clearance, withKBW as -ve 1.48. Conclusion: The PKparameters ofOT-101were
best described by a two-compartment model. OT-101 was largely distributed in
the peripheral tissues. The influence of age, gender, BMI, height, cancer type and
treatment schedule on the PK of OT-101 was not identifıed. The model will be
used for a sparse population PK study during the planned phase III trial of
OT-101 in pancreatic cancer.
#5044 Pharmacokinetic study of RCHOPprotocol in elderly patients with
non-Hodgkin lymphoma. Elodie BAUDRY,1 Anne Laure COUDREC,2 Pascal
CHAIBI,3 Fanny BRET,4 Sara DJEBNOUN,4 Sophie WEILL,4 Samuel HU-
GUET,4 Alexandre BOYAULT,4 Francois LOKIEC,4 Keyvan REZAI4. 1CHU
Bicetre, Kremlin Bicetre, France; 2Assistance publique hopitaux de Marseille,
Marseille, France; 3Hopital Charles Foix, Ivry sur seine, France; 4Inst. Curie, Saint
Cloud, France.
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common
lymphoma in elderly patients and R-CHOP chemotherapy is the standard treat-
ment protocol for DLBCL. Elderly patients (often defıned as 75 years of age) are
treated with anticancer drugs with precaution; however, the pharmacokinetics
and pharmacodynamics (PK and PD) of these agents have not been thoroughly
investigated in this population. In this study we investigated the PK of cyclo-
phosphamide (CP) and doxorubicin (DOX) in elderly patients in order to verify
if there is an influence of age on the PK of these anticancer drugs. Methods:
Non-Hodgkin lymphoma elderly patients were treated with a R-miniCHOP
chemotherapy regimen. Dose levels were 25 mg/m², 0.7-1.4 mg/m², 750 mg/m²
and 375mg/m² for DOX, Vincristin (VCR), CP and Rituximab respectively. For
PK analysis, 7 time point samples were collected over 48 h post administraion on
cycle 3. CP andVINplasma concentrationsweremeasured usingUPLC-MS/MS
validated method. DOX plasma concentrations were measured using UPLC
coupled with fluorescence detection validated method. PK-POP modeling has
been performedwith a non linearmixed effectmodel program (Monolix version
4.3.2). Results: 31 patients (15 males and 16 females), 75 to 96 years old, were
treated with DOX and CYP. Among them, 19 patients have received VCR. A
total of 134 and 120 concentrations for DOX and CP were used respectively for
PK-POP modeling. A 2-compartment open model adequately described DOX
concentration versus time courses. A 1-compartment open model adequately
described CP concentration versus time courses. The interindividual variabili-
ties (ISV) could be well estimated for both drugs and for all structural parame-
ters (clearances: CL, Q, volumes of distribution: Vc, Vp) except V for CP. The
population PK parameters for DOX obtained for the structural model were:
CL54.5 L/h, Q54.7 L/h, Vc30.6 L , Vp 1140 L. The population PK pa-
rameters for CP were: CL3.49 L/h, Vc29.2 L. VCR increases DOX Vc from
30.6 L to 56.9L L/h (p 0.0012). The main covariate effects were related to
gender, age, BW and to albumin. Conclusions: In this study we have estimated
with very good precision PK parameters of DOX and CP in very elderly patients
with DLBCL. Our data revealed the effect of gender, BW and VCR administra-
tion onDOXPK parameters.We have demonstrated the effect of increasing age
on PK of CP. A PK-PD modeling will be performed in order to verify there are
biological factors explaining the variation in the PK parameters of DOX and CP
in elderly patients.
#5045 Pharmacokinetics and pharmacodynamics of MEDI0680, a fully
human anti-PD1monoclonal antibody, in patients with advancedmalignan-
cies. Xuyang Song, Xizhe Gao, Bo Zheng, Chelsea Black, Matthew Gribbin,
Joyson Karakunnel, Lorin Roskos, Rajesh Narwal. MedImmune, Gaithersburg,
MD.
Background: MEDI0680 (AMP-514) is a humanized immunoglobulin
gamma 4, kappa (IgG4) monoclonal antibody (mAb) specifıc for human pro-
grammed cell death-1 (PD-1), developed for the treatment of cancer. The pri-
mary objectives of this analysis were to (a) describe the pharmacokinetics (PK)
ofMEDI0680 and quantitate the impact of patient/disease characteristics on PK
variability (b) to compare bodyweight (WT)-based and fıxed dosing regimens of
MEDI0680 and (c) to characterize PK-pharmacodynamic (receptor occupancy)
relationship. Methods: A total of 905 serum concentration records from 58
patients in Phase 1 study (D6020C00002) designed to evaluate safety, tolerability
and PK following 0.1, 0.5, 2.5, 10, and 20 mg/kg every 3 weeks (Q3W), every 2
weeks (Q2W) or weekly doses (QW) as intravenous (IV) infusion ofMEDI0680
were included in this analysis. The population PK analysis was performed using
a non-linear mixed effects modeling approach in NONMEM (version 7.2) soft-
ware. Impact of patient demographics, clinical indices and biomarkers on PK
parameters were explored. The appropriateness of the fınal model was tested
using visual predictive check (VPC). A sequential PK-PD analysis was per-
formed using receptor occupancy (RO) data from 35 subjects. Results:
MEDI0680 PK profıles were best described using a 2-compartment model with
linear clearance. The clearance (CL), volume of distribution (Vc) were 0.27
L/day, 5.07 L with amodest between-subject variability of 30% and 19%, respec-
tively. None of the evaluated covariates showed any impact on PK parameters
except a minor (not clinically relevant) impact of body weight on volume of
distribution. VPC results demonstrated good predictability of the fınal popula-
tion PK model. A direct Emax model described the PK-PD relationship of
MEDI0680. The estimate of EC50 was approximately 9.3 g/mL. PK/PD simu-
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lations indicate that following 20 mg/kg Q2W dose,90% receptor occupancy
can bemaintained in all subjects. Based onpreclinical/clinical PK, PD, and safety
data, a dose of 20 mg/kg Q2W was selected for phase 2 studies. Conclusions: A
population PK model of MEDI0680 was developed and validated. Modeling
results indicate no need for dose adjustment based on patient/disease character-
istics. Similar PK is expected following both WT-based and fıxed dosing regi-
mens. PK/PD fındings support the dose of 20 mg/kg Q2W. Clinical studies are
ongoing in various tumor types.
#5046 Exposure-effıcacy (OS) analysis of tremelimumab in unresectable
malignant mesothelioma. Paul Baverel,1 Lorin Roskos,2 Manasa Tatipalli,2
Nancy Lee,2 Paul Stockman,3 Maria Taboada,3 Paolo Vicini,1 Kevin Horgan,4
Rajesh Narwal2. 1MedImmune, Cambridge, United Kingdom; 2MedImmune,
Gaithersburg, MD; 3AstraZeneca, Macclesfıeld, United Kingdom; 4AstraZeneca,
Gaithersburg, MD.
Purpose: Tremelimumab is a fully human anti-CTLA-4 IgG2 monoclonal
antibody that enhances human T-cell activation. Tremelimumab was evaluated
in a Phase IIb (DETERMINE), randomised, double-blind, placebo-controlled
study in patients with unresectable pleural or peritoneal malignant mesotheli-
oma, randomised (2:1) to receive either tremelimumab (10 mg/kg, seven doses
Q4W followed by Q12W) or placebo. The study demonstrated no clinically
meaningful differences in overall survival (OS). The primary objectives of this
analysis were to evaluate the relationship of exposure withOS, and the impact of
potential confounders. Methods: A population PK model was developed to es-
timate and derive PK exposure metrics (area under the curve at steady state
[AUCss] or clearance [CL]) for exposure-OS analysis. Impact of potential con-
founders was evaluated using graphical and exploratory approaches. Factors
including body weight, age, gender, race, ECOG status, anatomical site (pleural
or peritoneal), line of therapy, EORTC status, tumour histology, baseline tu-
mour size, LDH, and CRP were evaluated. The analyses were performed using
NONMEM 7.2 and R software. Results: The population PK included 376 pa-
tients and 1328 post-fırst dose PK concentrations. PK was consistent with pre-
vious knowledge and low incidence of anti-drug antibodies was observed. A
2-compartment linear PKmodel adequately described the data. Tremelimumab
CL and volume of distribution (V1) were 310mL/day and 3.85 L, withmoderate
variability of 38% and 32%, respectively. There was an apparent expo-
sure-OS relation when stratifıed by AUCss. However, at least 3 factors (gender,
CRP, and baseline tumour size) were statistically signifıcant PK predictors
(p0.05 on CL) indicatingmulti-dimensional confounding effect. Higher base-
line tumor size, higher CRP levels and males were associated with lower PK
exposure of tremelimumab. Conclusions: The observed apparent exposure-OS
relationship is the result of imbalance in prognostic factors impacting OS rather
than a true association of exposure with effıcacy.
#5047 Celecoxib fıxed dose combination - therapeutic drug monitoring.
Cynthia Lee,1 Dongwon Lee,1 Sam Khateri,1 Wen Wang,2 Vuong Trieu2. 1Au-
totelic Inc, Costa Mesa, CA; 2Marina Biotech, Agoura Hills, CA.
Background: The anticancer properties of Celecoxib (CEL) have been dem-
onstrated in different cancer indications, including colorectal, breast and non-
small cell lung cancers. However, its use is associated with dose related cardio-
vascular adverse events including edema and hypertension.We have shown that
combination of CEL andOLM (Olmesartan) would negate drug induced edema
caused byCEL. To further improve on the safety of this combination,we are now
exploring therapeutic drug monitoring (TDM) guided dosing on CEL. This
study demonstrated that TDMvia lateral flowplatformwould be able to quantify
plasma drug concentration and guide the optimal dosing for CEL. Methods:
Pharmacokinetic (PK) data (Cmax and AUC) to oral formulations of CEL as
single dose to healthy adults were collected from published clinical trials. PK
data were analyzed against dose and demographic factors to evaluate the vari-
ability. To develop the lateral flow methods for quantifıcation, mAbs against
CEL were generated by synthesizing BSA-CEL immunogen and hybridoma
technology. The best clones demonstrating a dose response toCELwere selected
and tested. The assay requires the confıguration of immobilizing BSA-CEL onto
the membrane followed by flowing the colloidal-gold labeled mAb against CEL
through in presence of test analyte. This resulted in a competitive assay where
the signal decreased as the concentration of CEL in blood increased. Results: For
CEL, the AUC and Cmax across multiple doses were signifıcantly overlapped.
With 200 mg CEL, we used meta-analysis to show that older subjects have a
signifıcantly higher AUC than young subjects (p0.001). These results indi-
cated that different individualsmay have very different drug exposurewith same
dose ofCEL, depending on their age andother factors, resulting in over exposure
and toxicity. Using a cutoff of 6,741 ng*hr/mL, we were able to separate out
almost all of the elderly subjects from the young subjects. Therefore, to avoid
toxicity, we will use TDM guided dosing to maintain AUC at the target AUC of
6,741 ng*hr/mL. To make possible TDM guided dosing, we developed a quan-
titative point of care lateral flow assay for CEL. mAb against CEL were selected
based on good sensitivity and binding ability to CEL. Coupled with the lateral
flow reader by Qiagen, the assay exhibited a dynamic range of 7.5ng/ml to
30mg/ml of CEL, from a drop of blood with read time of less than 20 min.
Conclusion: A quantitative lateral flow platform coupled to a reader was devel-
oped to easily detect the CEL concentrations in fınger-prick blood samples,
allowing for in-home personal PK testing. The individual PK profıles built from
the concentration data will be used to guide the optimal dosing of CEL, to
maximize treatment effıcacy andminimize toxicity. This should allow for higher
dosing of CELwithout hitting the toxic exposure limit. This additional enhance-
ment on top of combination with OLM in the fıxed dose combination should
insure the safety of our patients on these drugs.
#5048 Residual concentrations of cetuximab predict clinical response in
head and neck cancer patients. Joseph Ciccolini,1 François Becher,2 Diane-
Charlotte Imbs,1 Claire Fournel,3 Florence Duffaud,3 Bruno Lacarelle,1 Se-
bastien Salas3. 1Aix-Marseille Univ., Marseille, France; 2CEA, Saclay, France;
3Assistance Publique Hôpitaux de Marseille, Marseille, France.
Cetuximab administration is contingent upon the upfront determination of
Ras mutational status, because mutated patients are unlikely to respond to this
therapy. In addition to tumor genomics, drug exposure levels could be a critical
yet largely underestimated issue, because several reports have already demon-
strated that cetuximab pharmacokinetic parameters (i.e., clearance values)
could be associated with survival in patients. Here, we have developed an origi-
nal bioanalytical method based upon the use of LC-MS/MS technology and a
highly simplifıed sample preparation procedure to assay cetuximab in patients
while meeting the requirements of standard therapeutic drug monitoring in
routine clinical practice. We used this method prospectively to evaluate the
inter-patient variability in drug exposure, and to search whether those exposure
levels could be associated with clinical endpoints. A total of 25 adult patients (22
M, 3F, mean age: 69 years) hospitalized for head and neck cancer and scheduled
for a cetuximab-containing regimen (250mg/m²QW)were included to perform
this pilot study. Seven patients received concomitant radiotherapy and 14 pa-
tients received concomitant chemotherapy. 28% of patients displayed severe
toxicities (CTC grading). Following RECIST assessment, 10 out of 25 patients
(40%) had progressive disease and 60%were categorized as patients with clinical
benefıt (stable disease: 5 patients (20%), partial response: 7 patients (28%), com-
plete response: 3 patients (12%)). A large inter-patient variability was observed
among individuals. Mean cetuximab residual concentrations were 40.3  20.3
g/ml (CV: 51%, range 0-74.6 g/ml) and mean cetuximab maximal concen-
trations were 126.9  39.6 g/ml (CV: 31%, range 65.1-210.6 g/ml). No sta-
tistical difference was observed in cetuximab residual concentrations between
patients with and without severe toxicities (36.7  21.2 g/ml VS. 41.8  20
g/ml, p0.05, t test), nor in maximal cetuximab concentrations (117.1 31.3
g/ml VS. 130.3  39.70 g/ml, p0.05, t test). Conversely, when comparing
exposure levels in patients with clinical benefıt to non-responding patients, a
statistical difference was found in both cetuximab residual concentrations (49
16.3 g/ml VS. 25.8 17 g/ml, p0.01, t test) and to a lesser extent in cetux-
imab maximal concentrations (143.7  37.9 g/ml VS. 100.9  24.6 g/ml,
p0.05, t test). Further ROCanalysis showed that 33.8g/mlwas theCmin level
associatedwith a probability of clinical benefıt with 86%of sensitivity and 75%of
specifıcity. These results advocate for the development of mass spec-based ther-
apeutic drug monitoring of cetuximab in head and neck cancer patients. In
addition to tumor molecular biology, drug exposure could be indeed a valuable
actionable item to improve effıcacy of cetuximab at bedside.
#5049 Application of population pharmacokinetic and exposure-re-
sponsemodeling forDS-8201a, aHER2-targetingADC,predicts 50%ORR in
patients with heavily pretreated breast cancer. Kazutaka Yoshihara,1 Seiko
Endo,1 Kenji Tamura,2 Toshihiko Doi,3 Taro Tokui1. 1Daiichi-Sankyo Co., Ltd,
Tokyo, Japan; 2National Cancer CenterHospital, Tokyo, Japan; 3National Cancer
Center Hospital East, Chiba, Japan.
Background: Antibody-drug conjugates (ADC) provide a wider therapeutic
index by allowing specifıc targeting of cytotoxic agents to tumor cells. DS-8201a
is a novel HER2-targeting ADC which contains a high average drug-to-anti-
body-ratio (DAR) of 7-8 molecules of a topoisomerase I inhibitor (exatecan
derivative, DXd) per antibody. Preclinical data demonstrated a broader antitu-
mor activity of DS-8201a than T-DM1 (the only FDA approvedHER2-targeting
ADC), including effıcacy against T-DM1 resistant and HER2 low-expressing
tumors. The fırst-in-human (FIH) study, comprising a dose escalation (Part 1)
and expansion (Part 2), is being conducted in patients with HER2 breast can-
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cer (BC), gastric cancer (GC), and other HER2 expressing tumors. This analysis
was aimed to assess DS-8201a population pharmacokinetics (POPPK) and ex-
posure-response (E-R) relationships for effıcacy and key safety endpoints using
data available so far, and to support Phase 2 dose selection. Methods: Prelimi-
nary data were obtained from Part 1 portion of the FIH study, in which a total of
23 patients with BC or GC received intravenous DS-8201a doses ranging from
0.8 to 8.0 mg/kg tri-weekly. Firstly, the POPPKmodel of DS-8201a and DXd in
serum was developed and the individual-predicted exposures were derived. An
exposure-driven, tumor growth inhibition (TGI) model was then fıt to the lon-
gitudinal tumor sum of longest diameter (SLD) data. Additionally, the E-R re-
lationships for thrombocytopenia (TCP) and gastrointestinal (GI) toxicity were
assessed using a cell lifespanmodel and a logistic regressionmodel, respectively.
Results: A 2-compartment PK model with parallel linear and nonlinear elimi-
nation and a 1-compartment model with linear release and elimination best
characterized the serum concentration-time profıles for DS-8201a and DXd,
respectively. The TGI model for tumor SLD indicated a DS-8201a-exposure-
dependent drug effıcacy across the dose range tested. Model-based simulations
showed that predicted % of patients exceeding pre-clinical effıcacious DS-8201a
concentration (4260 ng/mL) at trough was 86.7 to 95.9% during 6.4 mg/kg
tri-weekly dosing, and predicted objective response rate (ORR) was approxi-
mately 50.5% in the Part 1 patient population with BC or GC. The cell lifespan
modelling for TCP indicated that increased DS-8201a exposure was associated
with a greater risk of grade 3 or 4 TCP but the predicted probability was low for
doses of 6.4 mg/kg or below. No to minimal relationships with exposures of
DS-8201a or DXd were observed for the GI toxicity. Conclusion: A series of
model-based simulations demonstrated that 50% ORR was expected at 6.4
mg/kg DS-8201a tri-weekly, with limited increases in the risk of TCP and GI
toxicity relative to lower doses, which supports the selection of this dose for
Phase 2.
#5050 Pharmacodynamic and pharmacokinetic relationship of single
agent E7449 in patients with advanced solid tumors or B-cell malignancies.
Pallavi Sachdev,1 Shannon McGrath,2 Robert Shumaker,1 Jagadeesh Aluri,1
Claudio Savulsky3. 1Eisai, Inc., Woodcliff Lake, NJ; 2Eisai, Inc., Andover, MA;
3Eisai, Inc., Hatfıeld, United Kingdom.
E7449 is a small-molecule inhibitor of poly (ADP-ribose) polymerase
(PARP). Preclinical studies reported antitumor activity of single-agent E7449 in
BRCA-defıcient in vivo models. An open-label, multicenter, phase 1 study was
completed to determine the maximum tolerated dose (MTD), safety, pharma-
cokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity
of single-agent E7449. The MTD was determined to be 600 mg/day (n  8).
Treatment-emergent adverse events led to drugwithdrawal in 1 patient anddose
interruption in 2 patients at this dose level. E7449 treatment at the MTD was
associatedwith substantial and sustained dose-dependent PARP inhibition. The
overall response rate was 7.1% (2 confırmed partial responses [PR]) and durable
stable disease (23 weeks) was observed in 21.4% of patients. Here we report
additional PD and PK results from this trial. Patients in this study (N28) were
 18 years and had measurable, confırmed, advanced solid tumors or B-cell
lymphoma that had progressed after approved treatment. Patients received
E7449 at 50, 100, 200, 600, or 800mg/day. Food effect was examined in anMTD
expansion cohort. PD assessments included measurement of PARP activity and
comet assay to determine the extent of DNA damage. In the food-effect cohort
(n13), PARP inhibition (up to 90%) was sustained during treatment with the
MTD of E7449 600 mg/day up to 24 hours post-dose. Peak E7449 plasma con-
centrations were delayed by 2 hours in fed patients compared with fasted pa-
tients. In the PK/PD analysis set, peak plasma concentrations of E7449 were
observed at 2 hours following a single dose, and coincided with the lowest levels
of poly (ADP-ribose) (PAR; up to 90% inhibition). Of note, while E7449 expo-
sure was highest at the 800 mg dose, the lowest PAR levels were observed at the
600 mg dose. At the time of observed responses, the 2 patients with confırmed
PR demonstrated greater than 90%PAR inhibition from baseline. E7449 did not
cause a change in the level of DNA damage that could be detected by the comet
assay. DNA damage levels remained similar to the damage seen in healthy do-
nors. No signifıcant changes in percentDNA in the electrophoresis comet tail by
dose or E7449 plasma concentration were observed. In conclusion, continuous
E7449 dosing at 600 mg/day was associated with sustained PARP inhibition.
Dose-dependent PARP inhibition was observed and the greatest PARP inhibi-
tion occurred at the 600mg dose. Peak E7449 plasma concentration appeared to
coincide with maximal PARP inhibition. These results support E7449 dosing at
600 mg/day.
#5051 Comparison of microbeam versus conventional broadbeam radia-
tion therapy on tumor delivery enhancement of PEGylated liposomal doxo-
rubicin in a triple negative breast cancer mouse model. Sha X. Chang, Judith
N. Rivera, Leah B. Herity, Lauren S. Price, Andrew J. Madden, Jose R. Roques,
Charlene Santos, David Darr, William C. Zamboni. University of North Caro-
lina, Chapel Hill, NC.
Background: Recent meta-analyses have reported that the tumor delivery of
nanoparticles (NPs) is lower than expected and ineffıcient. Thus, there is a
strong need to develop new methods to enhance the tumor delivery of NPs
without increasing toxicity. Microbeam radiation therapy (MRT) is an experi-
mental therapy utilizing an array of parallel microplaner X-ray beams to deliver
periodically oscillating high and lowdose regions in the treatment volume.MRT
has been shown to eradicate tumors and causes signifıcantly less toxicity com-
pared to equivalent radiation doses delivered by conventional broadbeam radi-
ation therapy (BRT). Our prior studies reported that MRT signifıcantly altered
tumor microvasculature and enhanced the tumor delivery of PEGylated lipo-
somal doxorubicin (PLD) compared to PLD alone in mice (Chang et al. AACR
2015). In this study we compared MRT and the clinically widely used BRT in
their ability to enhance the tumor delivery of PLD in a preclinical murine tumor
model. Methods: Plasma and tumor PK studies of PLD were performed in a
genetically engineered mouse model of claudin-low triple-negative breast can-
cer (T11) in 4 treatment regimens: 1) PLD alone, 2) BRT 28 Gy PLD, 3) MRT
28GyPLD, 4)MRT100GyPLD.Mice received a single radiation treatment
24 h prior to administration of PLD at 6 mg/kg IVP x 1 via a tail vein. Following
administration of PLD,micewere harvested at 5min and 24 h. Encapsulated and
released doxorubicin concentrations (conc) in plasma and sum total (encapsu-
lated  released) doxorubicin conc in tumor were measured by HPLC with
fluorescence. Results: Themean SD conc of sum total doxorubicin in tumor at
24 h after administration of PLD alone, BRT 28 Gy PLD,MRT 28 Gy PLD,
and MRT 100 Gy PLD were 2,575 459, 8,601 1,552*, 7,579 4,428, and
12,911  3,445* ng/mL, respectively (*P0.05 vs PLD alone). In addition, the
ratio of tumor sum total conc to plasma encapsulated conc at 24 h for PLD alone,
BRT 28 Gy PLD, MRT 28 Gy PLD, and MRT 100 Gy PLD were 0.21
0.04, 0.51 0.17*, 0.39 0.22, and 1.45 0.70*, respectively (*P0.05 vs PLD
alone). The exposures of sum total doxorubicin in tumor at 5minwere similar in
all groups. The plasma PK of PLD was also similar in all groups. Conclusions:
MRT and BRT administered 24 h prior to PLD increased the tumor exposure of
sum total doxorubicin compared to PLD alone with 100Gy MRT having the
greatest increase in tumor delivery of PLD. In addition, MRT exhibits signifı-
cantly lower toxicity to normal tissues in comparison to BRT allowing for en-
hanced PLD tumor delivery with low toxicity. Studies are ongoing to evaluate
the mechanism(s) for the enhanced tumor uptake of PLD induced by MRT.
Future studies include investigating dose dependence of MRT-induced tumor
delivery enhancement and effects on other NP agents and tumor models.
#5052 Mechanistic pharmacodynamic analysis on safety profıles of eribu-
lin in patients with breast cancer using data obtained by post-marketing
observational study. Takahisa Kawamura,1 Valentina Fermanelli,2 Toshiaki
Takahashi,1 Yukinori Sakata,3 Toshiyuki Matsuoka,3 Mika Ishii,3 Yusuke Tani-
gawara2. 1Shizuoka Cancer Center, NA, Japan; 2Keio University School of Medi-
cine, Tokyo, Japan; 3Eisai Co., Ltd., Tokyo, Japan.
Background: Japanese regulation imposes a mandatory post-marketing ob-
servational cohort study for new chemical entities and biological products. The
primary purpose is collection of safety data in actual clinical settings by an active
surveillance approach. In this study, we utilized the observational safety data of
eribulin for model-based pharmacodynamic analysis to investigate more de-
tailed safety profıle of eribulin in patients with recurrent or metastatic breast
cancer (RBC/MBC).Methods: The demographics and safety data were collected
from RBC/MBC patients who were treated with eribulin by an active surveil-
lance method. Since dose-limiting toxicity of eribulin is neutropenia, we ana-
lyzed the time course of neutrophil counts using a mechanistic pharmacody-
namicmodel. Plasma concentrations of eribulin were simulated by a population
pharmacokinetic model developed byMajid et al. (J. Clin. Pharmacol. 2014). All
analyses were performed by Phoenix64NLME1.3 (Certara). Estimated pharma-
codynamic parameters were mean transit time (MTT [h]), proliferation rate
constant of neutrophils (Kprol [1/h]), elimination rate constant of neutrophils
(Kout [1/h]), feedback constant (Gamma) and linear coeffıcient of drug effect
(Slope [mL/ng]). Results: Clinical and laboratory data of 607 patients who were
not given granulocyte colony stimulating factor were collected from July
throughDecember 2011. Among them, 406 patients with a total of 5204 neutro-
phil countmeasurements were eligible formechanistic pharmacodynamic anal-
ysis. The estimated mean parameters for eribulin were: MTT45.4 [h],
Kprol0.1111 [1/h], Kout0.2074 [1/h], Gamma0.317 and Slope0.0254
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[mL/ng]. Pathophysiological factors (age, ECOG performance status, serum al-
bumin level, and previous treatment history of cytotoxic agents) that can affect
severity of neutropenia were investigated by Chi-squared test, and albumin level
was supposed to influence the proliferation of progenitor cells. Conclusions: The
present study reports the fırst example that observational data collected by a
post-marketing cohort study can be successfully applied to amodel-based safety
analysis. Different from pre-marketing clinical trials which strictly limit the
eligible population, the use of post-marketing data is useful to investigate exten-
sive safety profıles of eribulin in patients with broader backgrounds. The ob-
tained safety profıle of real-world clinical settings will provide clinically useful
information for the treatment of breast cancer using eribulin.
#5053 Arsenic trioxide metabolism in patients with acute promyelocytic
leukemia. Mohammad T. Khan,1 Sara Tariq,1 Cristina M. Ghiuzeli,1 Miroslav
Styblo,2 Jesse Saunders,2 Anthony Calabro,3 Nina Kohn,4 Daniel Budman,1 Ste-
ven Allen,1 Craig Devoe1. 1Hofstra Northwell School of Medicine, New Hyde
Park, NY; 2University of North Carolina at Chapel Hill, Chapel Hill, NC; 3New
York Genome Center, New York, NY; 4Feinstein Institute for Medical Research,
Manhasset, NY.
BACKGROUND: Arsenic trioxide (ATO) is a mainstay of therapy for Acute
Promyelocytic Leukemia (APL). Its long term effects and pharmacokinetics have
not been well -described. ATO is metabolized by a series of reactions involving
inorganic arsenic (iAs)methylation and reduction steps resulting inmono- (MAs),
di- (DMAs) and trimethylated arsenic (TMAs)metabolites which are subsequently
excreted mainly in the urine: iAsIII ¡MAsV¡MAsIII¡DMAsV¡DMAsIII¡
TMAsVO¡TMAsIII Individual polymorphisms in arsenic methyltransferase,
a key enzyme in this reaction, contribute to differences in the metabolism of
ATO. iAsIII, MAsIII and DMAsIII are more biologically active and more toxic
than pentavalent forms. In this study, we measured the total iAs, MA’s and
DMA’s in plasma and urine. METHODS: Blood and urine samples from 10
control patients and 26 APL patients treated with ATO were collected. The
treated patients had blood drawn immediately prior to and at 1, 2, 4, 6, and 24
hours, days 4, 8 and 15, and 4 weeks after the administration of ATO. Total
iAs (iAsIIIiAsV), MAs (MAsIIIMAsV) and DMAs (DMAsIIIDMAsV)
were measured in plasma using hydride generation-cryotrapping-atomic-
absorption spectrometry. The same arsenic species were measured in spot
urine at several time points. For statistical analysis, repeated measures anal-
ysis of variance (RMANOVA) were done to compare subject groups over
time. Two subjects were missing iAs urine values at 24 hours and so were
excluded from this analysis. RESULTS: iAs levels differed over time
(p0.0001), with a rapid increase noted after ATO administration followed
by a linear decline, reaching minimum levels by 4-6 hours. Between 6 hours
and 24 hours, two distinct groups of iAs metabolizers became apparent: 15
subjects had stable or decreased iAs levels at 24 hours (Group A) versus 9
subjects with at least a 5% increase in iAs at 24 hours (Group B). Methylated
metabolites in the urine were also higher at all measured time points in
Group A versus Group B; however, the difference between the two groups
was statistically signifıcant only for urine DMAs (p0.0390). CONCLU-
SIONS: Chronic iAs exposure has been associated with increased risk of
diabetes and lung, bladder and skin cancer. In patients treated with thera-
peutic dose ATO, we identifıed 2 distinct groups of arsenic metabolizers:
Group A patients who rapidly converted iAs toMMA andDMA and excreted
the metabolites in the urine, and Group B patients who metabolized arsenic
slowly and had a lower rate of excretion of metabolites in the urine. These
results suggest that Group B patients had a longer exposure time to iAs and
its metabolites and may be more susceptible to ATO toxicity. Prospective
clinical trials are needed to determine long term ATO toxicity in these pa-
tients. Note: 2 fırst co-authors: MK and ST.
#5054 Nanoformulation of talazoparib to increase effıcacy when com-
bined with temozolomide for the treatment of Ewing sarcoma xenografts.
Nabeela Baig, Rostislav Likhotvorik, Paige Baldwin, Srinivas Sridhar, Raushan
Kurmasheva. Greehey Children’s Cancer Research Inst., San Antonio, TX.
Ewing Family of tumors (EFT) comprises the fourth most common highly
malignant childhood cancer. Although sustained event-free survival (EFS)
can be achieved with intensive chemo-radiation therapy for patients with
local-regional disease, this therapy is relatively ineffective in the treatment of
metastatic disease with EFS of 12% at 5 years. Ewing sarcoma is characterized
by a reciprocal translocation between chromosomes 11 and 22 that encodes
a chimeric oncoprotein resulting from the fusion of EWSR1 to the FLI1
transcription factor in85% of tumors. Therapy for patients with EFT com-
prises surgery, intensive use of cytotoxic agents and radiation therapy. Dose
intensifıcation and dose compression has resulted in some improvement in
outcome, but patents with advanced or metastatic disease at diagnosis still
represent a challenge. Further, patients alive at 5 years from diagnosis still
have a high probability of subsequent relapse. Further, long-term conse-
quences of treatment included cardiac dysfunction, and secondary malig-
nancies. Thus, more effective and less toxic therapies are required to treat
patients with advanced disease. Our studies, as part of the Pediatric Preclin-
ical Testing Program (PPTP), identifıed the combination of the PARP inhib-
itor, talazoparib, with the DNA damaging agent temozolomide, as being
highly synergistic in xenograft models of Ewing sarcoma, but not against
other tumor types. In this study 5 of 10 Ewing tumor xenografts models
showed dramatic regressions to the combination, while administered as sin-
gle agents neither talazoparib or temozolomide were active. We have studied
the talazoparib-temozolomide synergy in vitro, and results indicate that in
models where there is no synergy as xenografts, the cell lines have either
intrinsic resistance to talazoparib, temozolomide or both drugs. In mice, and
in the clinical trial (NCT02116777), the talazoparib-temozolomide combi-
nation is toxic requiring a reduction in temozolomide dose to 15% of its
single maximum-tolerated dose. We are exploring the use of nanoparticle-
formulated talazoparib (npTLZ) developed by Nanomaterials Synthesis Lab-
oratory at Northeastern University without tumor targeting or with anti-
body-mediated targeting to increase the tumor-drug delivery, reduce normal
tissue toxicity (mainly thrombocytopenia), and potentially allow escalation
of temozolomide dose. In the PPTP study, the MTD for temozolomide com-
bined with free talazoparib (0.25 mg/kg PO BID daily x 5) was 12 mg/kg. Our
recent data showed no toxicity of temozolomide at 66mg/kg (PO daily x 5) in
mice treated with npTLZ (0.5 mg/kg IV daily x 5), suggesting that npTLZ
does not potentiate TMZ toxicity to normal mouse tissues. We anticipate
that nanoparticle delivery of talazoparib combined with temozolomide will
allow reduced toxicity while increasing the response rate for this combina-
tion in preclinical models of Ewing sarcoma.
#5055 Multiplatform metabolomics analysis of growth arrest in pancre-
atic tumor xenografts. Irving W. Wainer,1 Danuta Dudzik,2 Michel Bernier,3
Coral Barbas2. 1Mitchell Woods Pharmaceuticals, Washington, DC; 2Universi-
dad San Pablo CEU, Madrid, Spain; 3National Institute on Aging-NIH, Balti-
more, MD.
R,S-4-Methoxy-1-naphthylfenoterol, MNF, inhibits the G protein-cou-
pled receptor GPR55. In this study, we determine the effect of MNF on
human PANC-1 pancreatic tumor growth in mice and apply multiplatform
metabolomics analysis to identify pathways associated with growth arrest.
Methods: Female Balb/c nude mice, 6-8 weeks old, 18-20g, were inoculated
subcutaneously with 5 x 106 PANC-1 cells. On Day 8, mice were placed in
groups of 10 using random block design based upon tumor volume. Mice
received daily ip injections of vehicle or 40mgxkg-1 MNF 5 days/week for 3
treatment cycles. Mice were monitored daily and tumor volumes measured
at beginning and end of each dosing cycle. On Day 33, mice were euthanized,
and plasma samples and tumors collected. Tumor tissue was homogenized,
extracted and analyzed using liquid chromatography-QTOF-MS, capillary
electrophoresis-TOF-MS and gas chromatography-EI-Q-MS. Differences
between groups were evaluated by unpaired t-test or MannWhitney test
with post hoc Benjamini-Hochberg correction. Statistical signifıcance was
set at P0.05. Compound identifıcation was accomplished using online da-
tabases and in-house standards Results Tumor volume increased in vehicle-
treated mice by700%, 142 8 mm3 to 957 79 mm3 and only250% in
MNF-treated mice, 143 8 mm3 to 259 27 mm3. On Day 33, MNF was not
detected in plasma but accumulated in tumor tissues, 43.9  32.7 ng/g.
Plasma L-lactate levels were reduced from 3.29  0.66 mmol/L  2.81 
0.60 mmol/L, P0.001. Differences in tumor tissue metabolome were ob-
served with MNF compared to vehicle, which was reflected by signifıcant,
P0.05, changes in relative metabolite signals. MNF treatment was accom-
panied by the disruption of pyrimidine nucleotide biosynthesis at uridine
5=-monophosphate, UMP, and increased UMP degradation. Moreover, the
237% increase in ophthalmic acid and 95% increase in its precursor
2-aminobutyrate indicate higher oxidative stress and the 51% increase in
2-hydroxyproline suggest greater HFI-1	 proteolysis upon MNF treatment.
Conclusions These results are consistent with our previous observations in
PANC-1 cells showing that GPR55 inhibition attenuates activation of the
EGFR-MEK-ERK, Wnt--catenin and PI3K/AKT pathways resulting in
lower cyclin D1 expression and halting the cell cycle in G1. The reduction in
HIF-1	 expression and glycolytic flux in MNF-treated PANC-1 cells is in
line with the decline in L-lactate plasma levels in MNF-treated mice. The
data from this study indicate that MNF may be useful in the treatment of
pancreatic cancer.
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EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Epigenetic Agents
#5056 The bromodomain inhibitor JQ1 sensitizes homologous recombi-
nation profıcient ovarian cancer cells to the PARP inhibitor olaparib. An-
drew J. Wilson, Janese Thompson, Abdirahman Osman, Jeanette Saskowski,
Dineo Khabele. Vanderbilt Univ. Medical Ctr., Nashville, TN.
Introduction: Lack of effective treatment options for high-grade serous ovar-
ian cancers (HGSOC) retaining functional homologous recombination (HR)
DNA repair pathways is a signifıcant clinical problem. HR-profıcient HGSOC
tumors, for example those harboring cyclin E amplifıcations, have poorer clini-
cal outcomes and show relative resistance to DNA-damaging platinum agents
and newer poly ADP ribose polymerase inhibitors (PARPi).We and others have
shown that using epigenetic drugs to reduce HR effıciency in HR-profıcient
HGSOC sensitizes these cancer cells to DNA damaging agents. Onemechanism
bywhich these drugs reduceHR effıciency is by transcriptional down-regulation
of HR pathway components. An emerging class of epigenetic mediators of pro-
tumorigenic transcription is the bromodomain (BRD) family of proteins, and
BRD inhibitors (BRDi) have shown promising preclinical anti-tumor effıcacy.
However, it is unknownwhether BRDi sensitizeHR-profıcientHGSOC toDNA
damaging agents. Aims: To test the hypothesis that BRDi decrease effıciency of
HR DNA repair in HR-profıcient ovarian cancer cells, thereby sensitizing them
to PARPi. Methods: The HR-profıcient ovarian cancer cell lines, OVCAR-3
(cyclin E-amplifıed) and SKOV3, were treated with 0.01% DMSO vehicle, the
PARPi olaparib (Astra Zeneca), the BRDi JQ1 or with the olaparib/JQ1 combi-
nation. Sulforhodamine B (SRB) assays assessed cell growth and viability (72
hours treatment). Immunofluorescence (IF) assays assessed markers of DNA
damage (pH2AX), apoptosis (cleaved caspase-3), and HR effıciency (RAD51
foci, and GFP expression in cells co-transfected with I-Sce1 endonuclease and
DRGFP HR reporter plasmids) (24 hours treatment). Steady state levels of the
HR protein BRCA1, pH2AX and cleaved caspase-3 were assessed by western
blot (24 hours treatment). Results: The combination of JQ1 and olaparib syner-
gistically reduced cancer cell viability following isobologram analyses of SRB
experiments. Compared to either drug alone, the JQ1/olaparib combination also
signifıcantly reduced BRCA1 expression and increased protein levels of cleaved
caspase-3 and pH2AX in western blots, and also increased the number of cells
displaying DNA damage and apoptosis in IF assays. Finally, JQ1 and olaparib
combined to signifıcantly reduce HR effıciency in our RAD51 foci formation
and DRGFP assays compared to olaparib alone. Conclusions: Our results sug-
gest that BRDi sensitize HR-profıcient cells to DNA damaging drugs, in part by
reducing effıciency of HR DNA repair. These fındings have important implica-
tions for expanding the use of PARPi inHR-profıcientHGSOC through rational
combinations with epigenetic drugs such as BRDi that target the HR pathway.
#5058 Lysine specifıc demethylase-1 (LSD-1) Inhibitor SYC-836 in com-
bination with radiation prolongs animal survival in patient-derived poste-
rior fossa ependymoma xenograftmousemodels. Sibo Zhao, Huiyuan Zhang,
Lin Qi, Holly Lindsay, Yuchen Du, Mari Kogiso, Frank Braun, Sarah Injac,
Laszlo Perlaky, DonaldW. Parsons, Murali Chintagumpala, Adekunle Adesina,
Yongcheng Song, Xiao-Nan Li. Baylor College of Medicine, Houston, TX.
Background: Ependymoma (EPN) is the third most common malignant pe-
diatric brain tumor. Current standard therapy include maximally safe surgical
resection followed by radiation and lead to a 5-year overall survival of 50-71%.
Recent molecular subgrouping of EPN has identifıed one group, posterior fossa
A (PFA), which accounts for 45% of all EPN cases, to have one of the worst
prognosis and it is driven by epigenetic changes, suggesting targeting epigenetic
changes in PFA EPN can potentially be effective. In this study, we examined the
therapeutic effıcacy of SYC-836, a novel LSD-1 inhibitor compound developed
at Baylor College of Medicine, both in vitro and in vivo in PDOX models of
posterior fossa EPN.Methods: To examine in vitro anti-tumor activities, paired
primary cultured cells (both as attached cells and neurospheres) from an estab-
lished PDOX model of posterior fossa EPN (ICb-4423EPN) were subjected to
SYC-836 at various concentrations (0-25uM). Cell viability and proliferation
weremeasured usingCell CountingKit-8 assay at 5 different time points over 14
days. To validate the drug’s in vivo effıcacy, two established posterior fossa EPN
PDOX models, ICb-4423EPN and ICb-2002EPN, were utilized. 40 eight weeks
old SCID mice per model were implanted with tumor cells. They were divided
into 4 treatment groups (10 mice/group) each: 1) control (DPBS, 10uL/kg IP
daily x 28 days), 2) radiation/standard therapy (2Gy focal XRTdaily x 5 days), 3)
SYC-836 only (15mg/kg IP daily x 28 days), and 4) combination (radiation 
SYC-836 per regimen above). Animal survival times were analyzed using log
rank analysis. Changes of histone lysine methylation were examined through
western hybridization. Results: SYC-836 demonstrated effective cell killing in
vitro against both attached and neurosphere cultured cells in both time- and
dose-dependent manner. IC50 was7.5uM. In vivo experiment was completed
in 1 of the 2 EPN PDOX models (ICb-2002EPN) with the second model ongo-
ing. Median survival times for each group is as followed: control 136 days, radi-
ation 148 days, SYC-836 only 136 days, combination 180 days. There were no
survival benefıt with either XRT only (P0.205) or SYC-836 only (P0.186)
when compared to the control group; however, when used in combination, the
treatment strategy lead to signifıcant improvement in animal survival
(P0.004). SYC-836 was well tolerated in mice. Conclusion: Our data showed
that combining SYC-836 with current standard therapy of radiation synergisti-
cally prolongs animal survival signifıcantly, although as a single agent SYC-836
was not effective against posterior fossa ependymoma. Our data suggest that
SYC-836 may have a role in the clinical setting by either reducing radiation
dosages, or be a potential adjuvant agent to other chemotherapy drugs in our
treatment approach for ependymoma.
#5059 Preclinical study on the effıcacy of Panobinostat in hepatocellular
carcinoma. Chi Tung Choy, Wing Yu Man, Chi Hang Wong, Stephen Lam
Chan. The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Background: Aberrant regulation of histone deacetylases (HDACs) is known
to play a pivotal role in HCC pathogenesis as well as other humanmalignancies.
Panobinostat (LBH589) is a pan-HDAC inhibitor covering a wide range of
HDACs (Class I, II and IV) with high inhibitory activity at nanomolar concen-
tration. It has been approved by FDA for treating multiple myeloma and has
demonstrated promising anti-proliferative and cytotoxic activity in breast, pros-
tate, colon andpancreatic cancer cell lines. This study investigated in vitro and in
vivo effect of Panobinostat in HCC cell lines. Methods: Basal expressions of
HR23B and HDACs of 7 HCC cell lines (HepG2, PLC/PRF/5, Huh-7, Hep3B,
SNU-182, SNU-398 and SNU-449) were determined by western blotting. Their
corresponding IC50 for 24, 48 and 72 hours towards Panobinostat were deter-
mined by cell viability assay. Huh-7, Hep3B and SNU-449 were selected for
further in vitro experiments. Their cell cycle distribution after Panobinostat
treatment was evaluated by flow cytometry. Apoptosis was detected by Cell
Death Detection ELISA. Huh-7 and Hep3B xenograft model were used for in
vivo investigation. Cells were inoculated subcutaneously into the flanks of 3-4
week oldmale athymic nudemice.When tumorswere established, Panobinostat
was administrated intraperitoneally at 7.5mg/kg and 15mg/kg fıve days perweek
for 2 weeks. Results: All cell lines were able to achieve nearly 100% growth
inhibition and had displayed a dose- and time-dependent manner towards
Panobinostat. Maximum growth inhibition was 20-70% at 24hr compared to
over 90% at 72hr. There was signifıcant reduction in cell viability at low nano-
molar concentrations (IC50 at 48hr: HepG28.810.72nM, PLC/PRF/
518.90.74nM, Huh-714.011.12nM, Hep3B25.003.69nM, SNU-
18273.3315.52nM, SNU-39812.863.25nM, SNU-44973.019.09nM).
Flow cytometry analysis showed Panobinostat induced accumulation of cells at
G0/G1 phase in Huh-7 and SNU-449. Meanwhile, an increase in sub G1 popu-
lation was detected in Hep3B after exposure to 25nM Panobinostat for 48h.
Apoptotic induction was further confırmed by cell death detection ELISA and
western blotting. Panobinostat promoted apoptosis more remarkable in Hep3B
than other 2 cell lines as evidenced by a stronger cleaved PARP expression level.
Panobinostat treatment delayed tumor growth in Hep3B (p0.0005) and
Huh-7 (p0.0005) xenografts compared to vehicle control. The overall weight
loss was less than 20% despite of greater drop during middle of the treatment.
Conclusion: Panobinostat has been demonstrated to inhibit in vitro and in vivo
HCC cell growth. Further study on the mechanism behind Panobinostat sensi-
tivity is warranted. The study was supported by Novartis.
#5060 Activity of the EZH2 inhibitor tazemetostat as a monotherapy and
in combination withmultiple myeloma therapies in preclinical models.Alli-
son E. Drew, Vinny Motwani, John E. Campbell, Cuyue Tang, Jesse J. Smith,
Richard Chesworth, Robert A. Copeland, Alejandra Raimondi, Scott Ribich.
Epizyme, Cambridge, MA.
The EZH2 inhibitor tazemetostat (EPZ-6438) is currently being evaluated in
phase 2 clinical trials for the treatment of non-Hodgkin’s Lymphoma (NHL).
EZH2 inhibitors have shown anti-proliferative effects in multiple preclinical
models of NHL and objective clinical responses have been reported in patients
with B-cell lymphomas in phase 1 and phase 2 studies of tazemetostat.Mounting
evidence suggests that EZH2 is an important regulator of B cell differentiation,
both in normal B-cells and in B-cell lymphoma, and may be an important me-
diator of cell fate in B-cellmalignancies in the clinic. Consistent with its essential
role in regulating B cell differentiation, recent studies have also shown a depen-
dence on EZH2 activity in multiple myeloma (MM), a disease arising from
terminally-differentiated B-cell lymphocyte plasmablasts. Frequent genetic al-
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terations of epigenetic modulators are observed in MM, pointing towards an
important role in the initiation and maintenance of this disease. Dysregulation
of the H3K27 methyltransferase EZH2, its corresponding histone demethylase
UTX and the H3K36 methyltransferaseWHSC1 inMM suggest that disruption
of the balance of histone methylation may be fundamental to MM pathogenesis
in a subset of cases. Indeed, inhibition of EZH2 alone has shown potent anti-
proliferative effects both in in vitro and in vivo preclinical models of MM. Here,
we describe the effects of small molecule EZH2 inhibitors as monotherapy and
in combination with standard of care agents in preclinical models of MM.
Tazemetostat selectively inhibits intracellular H3K27 methylation in MM cell
lines and elicits a robust anti-proliferative effect in 14-day assays. Following
demonstration of single agent activity, we then investigated potential for com-
binatorial activity of tazemetostat with fırst and second line therapies for multi-
ple myeloma as well as other non-approved but emerging therapies. Synergistic
anti-proliferative activity was observed when tazemetostat was combined with
glucocorticoid receptor agonists (dexamethasone, prednisolone), small mole-
cule immune system modulators (lenalidomide, pomalidomide) and protea-
some inhibitors (bortezomib, ixazomib) when cells were primed with tazeme-
tostat for seven days prior to the addition of the standard of care drugs.
Combination activity was also observed with an alternate treatment schedule
where cells were co-treated with tazemetostat along with the combination part-
ner for seven days. Studies with selected therapeutic modalities were expanded
into in vivo xenograftmodels to further evaluatemonotherapy and combination
activity of EZH2 inhibitors in MM.
#5061 TET inhibits prostate cancer tumor growth, progression and me-
tastasis inTRAMPmice.Hari K. Koul, Prakash SrinivasanTimiri Shanmugam,
Praveen K. Jaiswal, Sweaty Koul. LSU Health Sciences Ctr. - Shreveport, Shreve-
port, LA.
Introduction: Prostate cancer (PCa) is the 2nd most common malignancy in
USA. Novel agents for treatment of advanced PCa are warranted. Transgenic
adenocarcinoma of the mouse prostate (TRAMP) is an autochthonous mouse
model exhibits both histological andmorphological features that mimic human
prostate carcinogenesis.Herein, for the fırst time,we evaluated the in vivo effects
of TET, a derivative of Tetrandrine in TRAMP model. Methods: Beginning 12
weeks of age, male TRAMP mice were administrated with TET (30 mgm/kg
body weight, orally, alternative days) in PBS or PBS alone (Control) till 30 weeks
of age. Body weight (B) of animals was recorded weekly. At various time points
animals were euthanized, genitourinary tract (G) were weighed. Prostate tissue
was subjected to immunohistochemical analyses for SV40-TAg, epithelial-mes-
enchymal transition (EMT), proliferation, neuroendocrine differentiation
(NED) and apoptosis. Multiple organs were examined for drug toxicity and
lungs were analyzed for metastasis. Results: TRAMPmice exhibit to high-grade
prostatic intraepithelial neoplasia (PIN) by 12 weeks and progresses to poorly
differentiated adeno-carcinoma by 30 weeks with distant metastasis to lungs.
TET feeding did not show any considerable difference body weight loss profıles
during the entire treatment regimen. At the time of necropsy, there was no
evidence of edema, abnormal organ size or appearance in non-target organs.
TET gavage group showed (p0.005) lower G/B ratio compared to the PBS
treated group. These fındings clearly indicate that TET dosing is non-toxic and
restricts the abnormal growth of the prostate in TRAMP mice. TET repress the
EMT as well as NED transition and inhibits cell proliferation (p0.005) by
Ki-67 staining.Oral administration of TET inhibits PCa growth and progression
by increases (p0.005) apoptosis in tumor tissues. Further, TET inhibited me-
tastasis as there was signifıcant (p0.005) decrease inmetastasis to lungs in TET
treated animals. Conclusion: Human achievable dose of TET treatment to
TRAMP mice bearing prostate tumor, exhibited no-observed-adverse-effect-
level in toxicology evaluations and also signifıcantly inhibited tumor growth,
progression, local invasion and distant metastasis involving suppression of tu-
mor, and thus could have potential against human PCa.
#5062 Development of a fırst in class inhibitor of BETbromodomains and
dopamine receptor 2.Makoto Yoshioka,1 Jay Chauhan,2 Steven Fletcher,2 Jef-
frey W. Strovel1. 1ConverGene, Cambridge, MD; 2University of Maryland, Balti-
more, MD.
ConverGene has developed a fırst-in-class dual-active small molecule inhib-
itor that i) inhibits BET family of bromodomain-containing proteins, and ii)
antagonizes dopamine receptorD2 (DRD2). BETprotein family includes BRD4,
an epigenetic reader protein that mediates expression of MYC oncogene. Thus,
BRD4 is considered as a cancer therapeutic target to indirectly suppress MYC
expression. In addition to being a therapeutic target for psychiatric diseases,
DRD2 is emerging as a potential therapeutic target in neuroendocrine tumors,
subsets of pancreatic ductal adenocarcinoma and small cell lung cancer. Our
lead compound showed high activity in a binding test against BRD4 (Ki  34
nM); exhibited high bioavailability upon oral administration; profoundly sup-
pressedMYC expression both in vitro and in vivo; inhibited growth of AML and
solid tumor cells in xenograftmodels; potently inhibited both isoforms ofDRD2
(IC50 0.1 M); and interfered with DRD2/-arrestin/Akt pathway in vitro.
Therefore, our BRD4/DRD2 dual-active compounds may hold promise as a
novel class of therapeutics that interferes with both cancer growth and mainte-
nance by simultaneously interfering with MYC and DRD2 pathways. We cur-
rently are investigating these dual-active compounds in multiple in vitro and in
vivo models and expect to report the outcomes at the AACRAnnual Meeting in
2017.
#5063 Epigeneticmodulators show differential activity on lung adenocar-
cinoma cells with loss-of-function mutations of SWI/SNF protein
SMARCA4. Tomasz Rzymski,1 Anna Wrobel,1 Michal Mikula,2 Karolina Py-
ziak,1 Anna Bartosik,1 Agnieszka Sroka,1 Agnieszka Paziewska,2 Aleksandra
Grochowska,2 Malgorzata Statkiewicz,2 Katarzyna Paczkowska,2 Michalina Da-
browska,2 Jerzy Ostrowski,2 Krzysztof Brzozka1. 1Selvita S.A., Krakow, Poland;
2Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.
SWI/SNF is a multiprotein chromatin remodeler with ATP-dependent activ-
ities leading to selective gene expression, DNA repair, recombination and rep-
lication. Various sequencing efforts indicated that nearly 20% of cancers bear
mutations in at least one subunit of the complex. One of the crucial regulators of
the complex is SMARCA4, a member of SWI/SNF family of helicases with AT-
Pase activities, which are thought to regulate transcription of certain genes by
altering the chromatin structure. SMARCA4 is mutated in virtually all cases of
small cell carcinoma of the ovary and SMARCA4 is fourth the most frequently
mutated gene in lung adenocarcinoma. High occurrence of inactivating muta-
tions prompted several screenings projects focused on synthetic lethality inter-
actions with other proteins, which led to the identifıcation of SMARCA2 as an
essential gene in SMARCA4 mutated cancers. This vulnerability could be po-
tentially exploited therapeutically and several groupsmanaged to identify potent
ligands of SMARCA2bromodomain. Surprisingly thesemoleculeswere inactive
in SMARCA4 mutant cells, however additional studies indicated that ATPase
rather than bromodomain is a target for novel compounds with anticancer ac-
tivities. Overall, these results revealed functional complexity of SMARCA2 and
SMARCA4 in cancer cells. In order to characterize molecular consequences of
SMARCA2 silencing in SMARCA4mutant lung adenocarcinoma cells, we have
carried out a series of gene knockdown experiments, followed by transcriptional
profıling by RNAseq and analysis of posttranslational histone modifıcations.
These studies indicated rapid and irreversible loss of viability in SMARCA4
mutant cells after SMARCA2 gene silencing. Interestingly double SMARCA2/
SMARCA4 knockdown in SMARCA4 WT cells has not resulted in lowered
viability. Transcriptional profıling of SMARCA2knockdown in SMARCA4mu-
tated cells revealed broad, predominantly repressory effects on gene expression
levels. Gene set enrichment analysis showed signifıcant inhibitory effects of
SMARCA2 knockdown, particularly on transcripts which could be induced af-
ter reintroduction of SMARCA4. FurthermoreMS/MS analysis indicated global
rearrangements in histone epigenetic marks. These results prompted us to test
activity of small-molecule epigenetic modulators, including DNAMethyltrans-
ferases (DNMTs), Histone Acetyltransferases (HATs), Histone Deacetylases
(HDACs), Histone Methyltransferases (HMTs), Histone Demethylases
(HDMs) and a distinct set of chromatin readers, bromodomains. Differential
activity of these compounds provides a strong basis for novel strategies for the
treatment of cancers with loss-of-function mutations of SMARCA4.
#5064 Identifying novel potential epigenetic anti-cancer drugs from nat-
ural compoundsusing aphenotypic-based screening.HanghangZhang,1Noël
J.-M Raynal,1 Takahiro Sato,1 Yasuyuki Okamoto,1 Judith Garriga,1 Benjamin
Garcia,2 George Morton,3 Wayne Childers,3 Marlene A. Jacobson,3 Stephen B.
Baylin,4 Xavier Graña,1 Magid Abou-Gharbia,3 Jean-Pierre J. Issa1. 1Fels Insti-
tute for Cancer Research, Philadelphia, PA; 2Perelman School of Medicine, Uni-
versity of Pennsylvania Philadelphia, Philadelphia, PA; 3Moulder Center for Drug
Discovery Research, Temple University School of Pharmacy, Philadelphia, PA;
4The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore,
MD.
Epigenetic aberrations such as DNA hypermethylation and repressive chro-
matin are validated targets for cancer chemotherapy. Since epigenetic modifıca-
tions are reversible, the goal of epigenetic therapy is to reverse the abnormal
alternations in cancer cells and induce tumor suppressor gene reactivation, lead-
ing to cancer cell differentiation and cell death. Many known anti-cancer drugs
are derived from natural compounds and there have been reports of natural
compounds modulating epigenetic activity. To explore this idea, our lab devel-
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Epigenetic Agents
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1297
oped a phenotypic-based system (YB5) by stably transfecting SW48 cells with a
vector containing GFP driven by a methylated and silenced CMV promoter.
GFP re-expression can be achieved by known epigenetic drugs that lead to de-
methylation or induce active chromatinmarks in theCMVpromoter. By screen-
ing an NDL-3040 natural compounds library and grouping the compounds
based on chemical structures, we identifıed two main drug classes. We then
synthesized 77 new analogs based on class #1’s lead’s structure and 23 were
positive in the YB5 system. The most potent analog (HH2) can induce 60%
GFP cells upon 500nM treatment after 96hr. All the positive hits can also be
validated in two other cancer cell lines (MCF7 and HCT116). Consistent with
GFP reactivation, endogenous hypermethylated genes (MGMT, RAR, etc) can
also be re-expressed upon drug treatment. We then performed RNA-seq analy-
sis to identify global gene expression changes following drug treatment. We
observed that most genes (2964 genes) were upregulated upon HH1 treatment
(10uM) and that many of the upregulated genes were expressed in normal tis-
sues but repressed in cancer, indicating that they might be potential tumor
suppressor genes (TSGs). Consistent with this, 94 TSGs could be reactivated
upon 10uM drug treatment. These drug target upregulated genes were also en-
riched for hypermethylation. By performing connectivity mapping using RNA-
seq, we identifıed X as the class #1 drug target. The on-target effect could be
further validated by using other selective X inhibitors as well as a dominant
negative X construct. Consistent with drug inhibition, dominant-negative X can
also reactivate drug targeted hypermethylated genes. Additionally, when we
overexpressed wild-type X, we saw that GFP induction as well as endogenous
gene reactivations can be inhibited. Strikingly, by using GFP induction as read-
out to optimize drugs, we found that the in vitro IC50 against X for our top lead
compound (HH2) is only 5nM and it is at least 22-fold selective for X over other
X family members. Thus, a novel epigenetic drug class derived from natural
compounds was identifıed and can be developed by targeting silenced gene
expression.
#5065 Harnessing epigenetic reprogramming by histone deacetylase in-
hibitor MS275 for pancreatic cancer therapy. Gaoyang Liang,1 Ruth Yu,1
Christopher Liddle,2 Morgan Truitt,1 Corina Antal,1 Annette Atkins,1 Ester Ba-
nayo,1MichaelDownes,1 Ronald Evans1. 1Salk Institute for Biological Studies, La
Jolla, CA; 2WestmeadMillennium Institute andUniversity of Sydney,Westmead,
Australia.
Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 85% of
pancreatic cancer and is one of the most lethal malignancies with limited ther-
apeutic options. Chromatin-modulating small molecules, or epigenetic drugs,
have the ability to reprogramcell fate and alter disease phenotypes. The potential
of these drugs for PDAC therapy remains to be fully investigated. Screening a
panel of epigenetic drugs identifıedMS275 (MS, also called entinostat), a histone
deacetylase inhibitor, as capable of suppressing PDAC cell proliferation and
inhibiting stromal fıbrosis. Genome-wide expression analysis revealed that MS
extensively reprograms the transcriptomes of tumor cells and cancer-associated
fıbroblasts (CAFs). In tumor cells, MS downregulates genes important for cell
cycle progression inducing cytostasis. In CAFs, MS specifıcally represses the
profıbrotic transcription program responsive to TGF-beta, effectively inhibiting
the fıbrotic response. Consistent with this, MS blocks the activation of pancre-
atic stellate cells, the primary source forCAFs in PDAC, to repress the fıbroblast-
like phenotypes in these cells. Using an orthotopic transplantation model, we
confırmed that MS treatment reduces tumor cell proliferation and decreases
intratumoral fıbrotic content. Importantly, we showed that MS substantially
enhances chemocytotoxicity, synergizing with gemcitabine to reduce tumor
burden in PDACmousemodels. Our study establishes a novel therapeutic strat-
egy for PDAC based on epigenetic reprogramming induced by HDAC inhibi-
tion.
#5066 Combination treatment with SAHA and 5-Azacytidine (Decit-
abine) induces apoptosis and suppresses tumor growth in preclinical models
of chondrosarcoma. Tahir Sheikh, Parag Patwardhan, Gary K. Schwartz. Co-
lumbia Univ. Medical Ctr, New York, NY.
Chondrosarcomas are the second most frequently occurring type of bone
malignancy, and account for approximately 25% of all bone sarcomas. They
are often highly aggressive neoplasms that rapidly progress and eventually
recur and give distant metastases. They are largely considered to be resistant
to conventional chemotherapy and radiotherapy. Several studies have re-
ported that targeting epigenetic mechanisms including DNAmethylation or
histone acetylation are novel approaches for the treatment of some human
cancers. Previous reports have shown that the interaction of DNA methyl-
ation and histone modifıcation regulates gene expression. In the present
study, we hypothesized that concurrent inhibition of histone acetylation and
DNA methylation could result in decreased viability of chondrosarcoma
cells both in vitro and in vivo. To test this, we used a panel of chondrosar-
coma cell lines including IDHwild type (CH2879), IDH1mutant (JJ012) and
IDH2 mutant (CS1) cell line. Results from our in vitro proliferation assay
showed that combination of sub-IC50 concentrations of the DNA methyl-
transferase (DNMT) inhibitor Decitabine (5-AZA-dC) and histone deacety-
lase (HDAC) inhibitor (SAHA) resulted in decreased cell viability of all the
three chondrosarcoma cell lines tested when compared to either drug alone.
Western blot analysis showed induction of cleaved Poly-ADP Ribose Poly-
merase (PARP), a known marker of apoptosis. Consistent with augmented
DNA damage, combination of Decitabine and SAHAmarkedly increased the
levels of phospho-H2AX, a DNA damage marker, and pro-apoptotic BH3-
only proteins such as Bim. Combination treatment also resulted in increased
induction of histone acetylation (AcH3) and increased expression of E-Cad-
herin. Previous reports have shown that E-cadherin is critical for apoptosis
and depletion and inhibition of E-Cadherin impairs apoptosis induction via
DR4 and DR5 death receptors. To this end, we showed that induction of
cleaved PARP by Apo2L/TRAIL stimulation decreased over time when E-
Cadherin was knocked down by siRNA. Xenograft studies using IDH2 mu-
tant (CS1) tumor model showed a signifıcant suppression of tumor volume
when animals were treated in combination with SAHA and Decitabine com-
pared to single agent treatments. Taken together, our data strongly suggests
that combination treatment with SAHA and Decitabine is a novel treatment
approach and merits evaluation in the treatment of chondrosarcoma.
#5067 BET protein proteolysis targeting chimera (BETP-PROTACs) ex-
ert more potent activity than BETP bromodomain inhibitor (BETi) against
post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.Dyana T.
Saenz,1 Warren C. Fiskus,1 Kanak Raina,2 Taghi Manshouri,1 Kevin G. Cole-
man,2 YiminQian,2 Andrew P. Crew,2 Angela Shen,2 Christopher P.Mill,1 Bao-
hua Sun,1 Misun Kim,1 Agnieszka J. Nowak,1 Srdan Verstovsek,1 Craig M.
Crews,3 Kapil N. Bhalla1. 1MDAnderson Cancer Center, Houston, TX; 2Arvinas,
LLC, New Haven, CT; 3Yale University, New Haven, CT.
In BCR-ABL1-negative myeloproliferative neoplasms with myelofıbrosis
(MPN-MF) transformation to AML (sAML) occurs in up to 20% of patients.
Ruxolitinib (R) is a type I, ATP-competitive, JAK1& 2 inhibitor (JAKi), which is
effective in the therapy ofMPN-MFbut does not signifıcantly impact the clinical
outcome in post-MPN sAML.We have previously reported that treatment with
BETi, e.g. JQ1 or OTX015 inhibits growth and induces apoptosis of cultured
sAML cells, including those that express JAK2 V617F and mutant TP53, e.g.
HEL92.1.7 and SET2, as well as patient-derived (PD) CD34 sAML cells. BETi
treatment attenuated the protein expressions of c-MYC, p-STAT5, Bcl-xL,
CDK4/6, PIM1 and IL-7R, while concomitantly inducing the levels of HEXIM1,
p21, NOXA and BIM in the sAML cells. However, treatment with BETi leads to
the accumulation of BETP, e.g. BRD4,whichmay reduceBETi-mediated repres-
sion of c-MYC, NFB and BETP-regulated oncoproteins. In contrast, BETP-
PROTACs (proteolysis targeting chimera) ARV-825 and ARV-771 (Arvinas
Inc.) degrade BETPs (including BRD4) in the cultured and PD CD34 sAML
cells. At equimolar concentrations, BETP-PROTACs were signifıcantly more
potent than the BETi in inducing apoptosis of cultured and PD sAML cells (p
0.05), while sparing the CD34 normal hematopoietic progenitor cells. Nota-
bly, BETP-PROTACs caused effıcient and prolonged depletion of the levels of
BETPs, including BRD4 ( 90%) in the sAML cells. BETP-PROTAC treatment
caused more up and down regulation of mRNA and protein expressions than
BETi, as determined by RNA-Seq and reversed phase protein array (RPPA)
analyses, respectively. As compared to treatment with BETi, BETP-PROTAC
caused greater depletion of c-MYC, JAK2, p-STAT5, STAT5, p-STAT3, STAT3,
PIM1 and Bcl-xL, whereas the protein levels of p21 and p27 were upregulated.
CyTOF or mass-cytometry also showed that BETP-PROTAC, more than
OTX015 treatment, reduced BRD4, c-MYC and p-Rb, while inducing p21 levels
in the CD34 sAML stem/progenitor cells expressing CD90, CD244, CD123
and TIM3-Fc. Compared to treatment with each agent alone, co-treatment with
BETP-PROTAC and R was synergistically lethal against the cultured and PD
CD34 sAML cells. Additionally, co-treatment with BETP-PROTAC and
HSP90 inhibitor AUY922 or BCL2/BcL-xL antagonist ABT263 was synergisti-
cally lethal against R-sensitive andR-resistant sAML cells. As compared to treat-
ment with vehicle control, R treatment alone, treatment with BETP-PROTAC
ARV-771 alone or in combinationwithR signifıcantly reduced the in vivo sAML
burden and improved the median survival of the immune-depleted mice en-
grafted with luciferase-transducedHEL92.1.7 cells. These fındings strongly sup-
port further in vivo development of the novel BETP-PROTACs-based combi-
nations against post-MPN sAML.
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#5068 A novel dual action inhibitor of histone deacetylase and demethyl-
ase in melanoma. Muzhou WU,1 Jay Kalin,2 Byungwoo Ryu,1 Philip Cole,2
Rhoda Alani1. 1Boston University, Boston, MA; 2Johns Hopkins University, Bal-
timore, MD.
Epigenetic agents have drawn great attention as anti-cancer therapies, with
several HDAC inhibitors approved for a subset of hematologic malignancies.
One of the biggest challenges in targeting epigenetic mechanisms of tumorigen-
esis is the wide spectrum of effects which restrict the therapeutic window for
these compounds. We have developed a series of potent small molecule inhibi-
tors with specifıcity towards the CoREST epigenetic corepressor complex
through a dual-action mechanism targeting LSD1 and HDAC1. These com-
pounds show a unique profıle of pharmacologic action with an improved ther-
apeutic window in a variety of cell types. Screening of tumor cell lines for growth
inhibitory effects revealed variable effıcacy in a broad spectrum of cancers with
themost consistent and potent effects seen in humanmelanomas. The growth of
a number of melanoma cell lines was found to be potently inhibited by one of
these compounds, Corin 2; however, primary human melanocytes were rela-
tively resistant to this agent. Transcriptomic analysis revealed that Corin2 was a
more potent inducer of tumor suppressor genes compared to the parent HDAC
and LSD1 compounds. Genetic knockdown of CoREST or LSD1 in cancer cell
lines abolished the differences in potency of Corin2 vs. the parent HDAC inhib-
itor, Entinostat, suggesting that Corin2’s favorable pharmacologic effects rely on
an intact CoREST complex. Corin2 was also effective in slowing tumor growth
in a melanoma mouse xenograft model. These dual action inhibitors demon-
strate a novel, potent, and specifıc therapeutic approach to targeting epigenetic
pathways in human melanomas which may lead to improved therapeutic bene-
fıts in patients with advanced disease.
#5069 Inhibition of BET bromodomain, epigenetic regulator, as an effec-
tive therapeutic approach for gastric cancer. Sun Kyoung Kang,1 Tae Soo
Kim,1 Woo Sun Kwon,1 Jae Kyung Roh,1 Ho-Yeong Lim,2 Hyun Cheol Chun,3
Sun Young Rha3. 1Song-Dang Institute for Cancer Research, Yonsei University
College ofMedicine, Seoul, Republic of Korea; 2Division of Hematology-Oncology,
Department of Medicine, Sungkyunkwan University School of Medicine, Seoul,
Republic of Korea; 3Song-Dang Institute for Cancer Research, Brain Korea 21
PLUS Project for Medical Science, Department of Internal Medicine, Yonsei Uni-
versity College of Medicine, Seoul, Republic of Korea.
Epigenetic dysregulation is a common characteristic of cancer, including gas-
tric cancer(GC), which ultimately contributes to the development and progres-
sion of GC. Sequencing of cancer genomes has revealed frequent mutations in
epigenetic regulators, particularly chromatin remodelers and histonemodifıers,
and disordered chromatin regulation has emerged as a distinct mechanism con-
tributing to tumor development. As a highly conserved class of epigenome read-
ers, BRD4 is a member of the BET (bromodomain and extra-terminal domain)
family that recognizes and binds acetylated histones H3 and H4 and influences
gene regulation. Smallmolecule BET inhibitors prevent binding of BETproteins
to acetylated histones and inhibit transcriptional activation of BET target genes.
BET inhibitors attenuate cell growth and survival in several hematologic cancer
models, partially through the down-regulation of the critical oncogene, c-Myc.
We would like to elucidate the sensitivity to I-BET151 and its relationship with
genetic/epigenetic alterations to identify predictive biomarkers in 49 gastric can-
cer cell lines. Anticancer effect of small molecular inhibitor of the BET family,
GSK1210151A (I-BET151, GSK, PA, USA), was treated for 6 days and assessed
using CCK-8 assay. For exploring predictive biomarkers, we analyzed genetic
and molecular characterization of BRD4-related genes using whole exome se-
quencing (WES), RNA sequencing and western blots. As a result, ARID1A de-
letion (SNU-5 and YCC-6) and single nucleotide variant (14/49, 28.5%) were cor-
related with decreased protein expression (p0.0001). However, these ARID1A
variants were not related to sensitivity of I-BET151.While, BRD4 was expressed in
almost cell lines with no mutations. When we screened 49 cell lines for growth
inhibition by I-BET151 and 73%(36) of cells showedmodest activity to I-BET-151.
Wedivided into twogroupsaccording to the sensitivity: extremely sensitive (IC50
1 uM: 13 cell lines) and extremely resistant (IC50 5 uM: 13 cell lines). Then, we
analyzedDifferentiallyExpressedGene (DEG) in eachgroupand selected about 600
genes (FDR 0.05, p 0.001 and 1.5 fold) including CXCL5, HRK, BMPER and
IGDCC4. BRD4 mRNA expression was lower in extremely sensitive group com-
pared to extremely resistant group (p 0.0163), but BRD4 protein expression was
not. In addition, no association has been observed between other genes expression,
such asMYC, BCL2,HEXIM1/2, SRC, TXNIP, CCND1 andMLKL, and sensitivity
to I-BET151. Our data indicates that I-BET151 is a potent inhibitor of GC and
showed the possibility of development a predictive biomarker based on genetic and
molecular profıling.
#5070 Structure-function studies and drug design on the human histone
lysine methyltransferases NSD1, NSD2 and NSD3. Eric Di Luccio, Damiaan
E.H.F Mevius, Yunpeng Shen, Yeon Jeong Noh, Jihyeon Kim, Masayo Mor-
ishita. Kyungpook National University, Daegu, Republic of Korea.
Chromatin dynamics are plastic processes controlled by epigenetic modifıca-
tions on the DNA and histone tails that play a critical role in gene expression.
Interestingly, DNA and histones modifıcations are also under the influence of
exogenous factors such as pollutants, smoking, sun exposure, daily diet, alcohol
consumption and environmental stress. Departure from “normal” cellular ho-
meostatic conditions is influenced by aberrant accumulation of specifıc epige-
netic patterns, which may contribute to the onset of diseases ranging from dia-
betes to cancers and neurological disorders.Moreover, epigeneticmodifıcations
appear to be inheritable to some extend and affect gene expression in the off-
spring. One of the key epigenetic modifıcations is histone methylation, which is
catalyzed by histonemethyl transferases (HMTases). The nuclear receptor bind-
ing SET domain proteins (NSDs) consist of a family of three HMTases, NSD1,
NSD2 andNSD3 all of which are bona fıde oncoproteins. TheNSDHMTases are
primarily responsible for methylation of H3K36 and H4K20 in vivo. However,
the outlines of the NSDs biological roles in normal and pathological conditions
remain unclear. Mutation, alteration or overexpression of the NSD HMTases
results in growth defects and is linked to an increasing number of pathologies,
carcinogenesis and is a maker for tumor progression and prognosis. However,
inhibition of HMTases and especially NSDs by small molecules may offer ther-
apeutic opportunities, especially in cases with poor prognoses, such as multiple
myeloma. To date, fewHMTase inhibitors exist and no inhibitors specifıc to the
NSD family have been identifıed. Therefore, a better understanding of the struc-
ture-function relationship and the design of specifıc, selective and bioavailable
HMTase inhibitors is essential for novel cancer therapy. In this study, we fırst we
focused on understanding the substrate specifıcity of the NSDs in vitro to get
insight into the druggability of the NSDs. Next, we performed virtual ligand
screening and identifıed the hit molecule LEM-07/14 with an IC50 value of 11.5
M inhibition against NSD2. LEM-07/14 derivatives resulted in a 45% methyl-
ation activity reduction in vitro. Furthermore, we identifıed BIX-01294 as an
NSD inhibitor that differentially inhibits H3K36 methylation by NSD1, NSD2,
and NSD3 with IC50 values of 40112 M and investigated the molecular basis
of inhibition using docking studies on the NSD homology models. Next, we
present our X-ray crystallographic efforts on the NSDs and their applications to
selective and specifıc drug-design.
#5071 Preclinical characterization of the potent and selective BET inhib-
itor INCB057643 inmodels of hematologicmalignancies.MatthewC. Stubbs,
Thomas Maduskuie, Timothy Burn, Sharon Diamond-Fosbenner, Nikoo Fala-
hatpisheh, Alla Volgina, Nina Zolotarjova, Xiaoming Wen, Patricia Feldman,
Mark Rupar, Robert Collins, Cindy Marando, Bruce Ruggeri, Maryanne Cov-
ington, Xuesong Mike Liu, Richard Wynn, Swamy Yeleswaram, Wenqing Yao,
Reid Huber, Gregory Hollis, Peggy Scherle, Andrew P. Combs, Phillip C. Liu.
Incyte Corp., Wilmington, DE.
Inhibitors of the Bromodomain and Extra-Terminal (BET) family of bromodo-
main containing proteins regulate expression of key cell fate, cell cycle, and survival
genes including c-myc. In preclinical models, BET inhibitors have demonstrated
signifıcant effıcacy in a variety of different oncology indications, including hemato-
logical malignancies. Here we describe the preclinical profıle of the novel, orally
bioavailable BET inhibitor INCB057643 in preclinical models of hematologic ma-
lignancies. INCB057643 inhibited binding of BRD2/BRD3/BRD4 to an acetylated
histone H4 peptide in the low nM range, and was selective against other bromodo-
main containingproteins. In vitro analyses showed that INCB057643 inhibitedpro-
liferation of human AML, DLBCL, and multiple myeloma cell lines, with a corre-
spondingdecrease inMYCprotein levels.Cell cycle analyses indicated thatG1 arrest
and a concentration-dependent increase in apoptosis were seen within 48 hours of
treatment with INCB057643. BRD proteins also regulate the expression of many
pro-inflammatory genes. Production of several cytokines, including IL-6, IL-10 and
MIP-1	, was repressed by INCB057643 in human and mouse whole blood stimu-
lated ex vivo with LPS. Consistent with these effects, analyses of gene expression in
cells treatedwith INCB057643 revealed that pathways involved in cell cycle progres-
sion, apoptosis, and IL-6 were among the most signifıcantly altered in vitro. Oral
administration of INCB057643 resulted in signifıcant anti-tumor effıcacy in xeno-
graftmodelsofAML,myeloma,andDLBCL.Additionally, combiningINCB057643
with standard of care agents used for the treatment of DLBCL including rituximab
andbendamustine resulted inenhancedanti-tumoreffıcacy relative to that achieved
with single agent therapies at doses thatwerewell tolerated. In addition,manyB cell
malignancies are reliant on the PI3K
 pathway for proliferation and survival, sug-
gesting that the combination of INCB057643 with the clinical stage PI3K
 specifıc
inhibitor INCB050465maybearational therapeutic strategy forDLBCL.Compared
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with single agent BETi or PI3K
i therapy, the combination signifıcantly potentiated
tumor growth inhibition in DLBCL models representative of the ABC subtype
(HBL-1), and the double hit GCB subtype (WILL2). These data suggest that clinical
exploration of INCB057643 as a monotherapy or in combination in hematologic
malignancies is warranted.
#5072 Inhibition of EZH2 as a therapeutic strategy for osteosarcoma. Es-
waran Devarajan, Wei-lin Wang, Jen-Wei Tsai, Andrew Futreal, Valerae O.
Lewis. UTMD Anderson Cancer Ctr., Houston, TX.
Introduction: Osteosarcoma is the most common primary malignant bone
tumor. About 30% of osteosarcoma patients experience relapse and die of their
disease. We previously demonstrated that IL-11R	 is overexpressed in primary
and metastatic osteosarcoma and plays a role in the development of metastases.
Our recent microarray data from KRIB, SJSA1, and LM7 IL-11R	 shRNA cells
show decreased expression of several components of polycomb repressive com-
plex 2 (PRC2). EZH2 is the catalytic subunit of PRC2 and blocks transcription of
numerous tumor suppressors’ genes. EZH2 has been widely implicated in can-
cer and inhibition of its catalytic activity has recently emerged as a novel ap-
proach to treat cancers. Purpose: To explore the effects and mechanisms of
inhibition of EZH2 on osteosarcoma metastasis. Inhibition was tested using
GSK126, a novel small-molecule EZH2 inhibitor that competes with methyl
groupdonor S-adenosyl-methionine in a highly selective fashion.Methods: Pro-
liferation assays were performed on a panel of osteosarcoma cell lines subjected
to increasing concentrations (0.0625 m to 20 m) of GSK126 for 3 days. The
effects of IL-11 in PRC1 complex histoneH3methylation (H3K27) were studied
byWestern blotting. For in vivo experiments, we used an orthotopic metastatic
model. Luciferase-labeled SJSA1 osteosarcoma cells were injected into the tibias
of 4- to 5-week-old nude mice. After 2 weeks, mice were treated with vehicle or
GSK126 three times per week intraperitoneally at 0.1 ml per 20 g of body weight
in 20% captisol for 48 days. The tumor-containing legs were amputated when
tumor volume reached 2 cm. Primary tumors were measured with calipers, and
tumorigenesis andmetastasis were evaluated by luciferase imaging.After 4more
weeks of treatment, all the mice were killed and their lungs collected. Immuno-
histochemical study for EZH2 (1:200, D2C9, Cell Signaling) was performed on
tissue microarrays composed of 200 formalin-fıxed decalcifıed human OS spec-
imens: 141 primary and 59 metastatic. Intensity and extent of tumoral labeling
were evaluated. Results: EZH2 expression was seen in 79/200 OS specimens
(40%)with 54 specimens (27%)withmoderate to strong labeling. In themajority
of cases, when staining was present, more than 50% of labeling was seen. More
metastatic specimens (24/59, 41%) had moderate to strong labeling than pri-
mary resection specimens (30/141, 21%). In vitro, SJSA1, HOS and CCH-OS-D
osteosarcoma cell lines were sensitive to EZH2 inhibition (IC50 3.576-
6.450uM). In vivo, mice treated with GSK126 developed signifıcantly fewer os-
teosarcoma lung metastases than control mice injected with vehicle alone
(P0.01). Conclusion:GSK126, a potent small-molecule EZH2 inhibitor, inhib-
its the development of osteosarcoma lungmetastases in vivo. Thus,GSK126may
be considered as a novel anticancer drug candidate for osteosarcoma.
#5073 Determination of sensitivity to BET and HDAC inhibitors in lung
cancer cell lines. Sara Verdura, Manuel Torres-Diz, Montserrat Sanchez-Ces-
pedes. IDIBELL, Barcelona, Spain.
Purpose: To determine the sensitivity of lung cancer cell lines to different
combinations of BET andHDAC inhibitors and to inquire possible associations
with the genetic and molecular profıles. Methods: A panel of lung cancer cell
lineswere treated in vitrowithBET andHDAC inhibitors. The capability of each
compound, administered individually or in combination (IC50), to inhibit cell
proliferation was assessed by MTT assays. Drug interaction analysis was per-
formed using Compusyn software. The protein and gene expression levels were
determined using western blot and real time PCR, respectively. Results: We
found that about 70% of the cell lines tested were sensitive to BET inhibitors and
about 60% responded to HDAC inhibitors. In both cases, increased sensitivity
was accompanied by changes in cell morphology, a reduction of the MYC pro-
tein levels and an increase in the levels of apoptotic-related markers. We also
determined the effects of the combination of these epigenetic treatments in cell
growth. Our results showed a synergic effect in about 75% of the cell lines which
was also correlated with dramatic changes in cell morphology, in apoptosis and
in decreasing the levels of theMYC protein. Finally, we determined the possible
correlation of the sensitivity to these epigenetic drugs and the expression levels
of some genes implicated in lung carcinogenesis. Conclusions: Our data showed
that lung cancer cells responded to BET and HDAC inhibitors and that the
combination of both drugs has a synergistic effect in cell growth inhibition,
suggesting that this could be an effective treatment in lung cancer. Our data also
point out to certain genes as potential biomarkers to determine sensitivity to
these compounds.
#5074 Therapeutic targeting of bromodomain and extra-terminal pro-
teins degradation in triple-negative breast cancer. Longchuan Bai, Bing Zhou,
Chao-Yie Yang, Jiao Ji, Donna McEachern, Sally Przybranowski, Shaomeng
Wang. University of Michigan, Ann Arbor, MI.
Triple negative breast cancer represents the most clinically challenging sub-
types of breast cancer for which targeted therapeutics are still lacking. BET
proteins have emerged as new therapeutic targets for human cancer and other
diseases.We have developed a highly potent BET degrader, BETd-246, with an
exceptional selectivity based upon a new class of BET inhibitor, BETi-211, and
investigated its therapeutic potential andmechanisms of action inTNBC.BETd-
246 induces degradation of BET proteins at low nanomolar concentrations
within 1 hour, leading to potent anti-proliferative activity and strong apoptosis
induction in themajority of TNBCcell lines, and ismuchmore effective than the
BETi-211 treatment. RNA-seq analysis reveals that degradation of BET proteins
by BETd-246 elicits distinct transcriptional response than BET BD inhibition in
TNBC cell lines. Transcriptomic analysis also shows a number of proliferation
and survival-related genes were differentially regulated by BETd-246 and BETi-
211 which were confırmed by quantitative RT-PCR. Mechanistically, down-
regulation ofMCL1 by BETd-246 plays a key role in the robust apoptosis induc-
tion in TNBC cell lines. In in vivo models, BETd-246 effectively degrades BET
proteins and suppressesMCL1 expression in xenograft tumor tissues and exhib-
its a strong antitumor activity at well-tolerated dose-schedules inmice. Our data
strongly suggest that targeting BET protein degradation is an exciting therapeu-
tic strategy for TNBC.
#5075 Phenotypic human tumor cell line profıling and predictive bio-
marker analysis for epigenetic inhibitors.UshaWarrior, Jesse J. Parry, Saman-
thaC. Burkart, Lee R. Cavedine, AlyssaM.Cracchiolo, BroganA. Epkins, Steven
M. Garner, Timothy J. Sindelar, Charles R. Wageman, Alastair J. King. Eurofıns
Panlabs Inc., St. Charles, MO.
In recent years, epigenetic target inhibitors have emerged as viable therapeu-
tics for treating various types of cancers. Testing of the epigenetic inhibitors in
cell proliferation assays revealed that inhibition of many epigenetic targets re-
sulted in a signifıcantly delayed drug response that is not revealed by conven-
tional, 72-hour cell growth assays. OncoPanel LT™ from Eurofıns Pharma Dis-
covery Services is developed specifıcally for evaluation of compounds with a
protracted mechanism of action, and consists of a large collection of cell lines
with broad cancer type and subtype representation, and extensive genomic char-
acterization. We have tested decitabine, a DNA methyltransferase inhibitor,
panobinostat, a histone deacteylase inhibitor, GSK-343, an EZH2 inhibitor,
GSK-J4, a JMJD3/UTX inhibitor, and JQ1, a BRD2/3/4 inhibitor in OncoPanel
LT™. These epigenetic inhibitors were incubated for 10 days with more than 200
human tumor cell lines and the inhibition data were analyzed to determine IC50,
EC50, and GI50 values. These inhibition data, as well as the genomic features of
the cell lines, were utilized to perform univariate genomic analysis to identify
predictive biomarkers of response. We will discuss the activity of compounds
against this cell line panel, as well as statistically signifıcant biomarkers of re-
sponse, based on the univariate genomic analysis.
#5076 IHCand flow cytometry quantifıes BRD4 levels in surrogate tissues
after ex-vivo and in-vivo dosing with a BRD4 degrading PROTAC. Sheryl M.
Gough, Kanak Raina, Debbie Gordon, Ryan Willard, Martha Altieri, Angela
Shen, Yimin Qian, Taavi Neklesa, Kevin Coleman, Ian Taylor. Arvinas LLC.,
New Haven, CT.
The Bromodomain and Extra-Terminal (BET) protein BRD4 has been iden-
tifıed as a key transcriptional regulator of various oncogenes, most notably
MYC, in numerous human malignancies. Efforts have been extensive over re-
cent years to inhibit the gene regulatory action of BRD4 andBET inhibitors have
entered clinical trials. In a new approach to cancer therapeutics, we have devel-
oped a proteolysis-targeting chimera (PROTAC) molecule, ARCC-29, which
induces degradation of BET (BRD4/3/2) proteins via the proteasome. ARCC-29
degrades BRD4 in several human malignant cell lines and in in-vivo rodent
xenograft tumors. In mice xenograft models of prostate (22Rv1), DLBCL (SU-
DHL-6) and ovarian (A2780) tumors, this molecule demonstrates a strong PK/
PD/effıcacy relationship. Obtaining tumor tissue from patients often requires
invasive procedures and may be unavailable. We have developed two assays
using surrogate tissues to evaluate PROTAC mechanism of action which could
be applied in the clinical setting.Wehave developed a flow cytometry protocol to
quantitatively assess intra-cellular BRD4 levels in peripheral blood mononu-
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clear cells (PBMCs). Frozen or fresh human PBMCs were cultured for six hours
ex-vivo with ARCC-29, fıxed and permeabilized for intra-cellular BRD4 stain-
ing, and BRD4 levels quantifıed in gated lymphocytes. ARCC-29 reduced BRD4
levels to 13, 10, 16, and 9 percent of vehicle in four fresh PBMC samples, and to
10, 9, 11, 6, 8 and 35 percent in six frozen PBMC samples. Treatment of PBMCs
with the BRD4 inhibitor OTX-015, showed similar or increased levels of BRD4
compared to vehicle control. Inactive stereoisomers of ARCC-29 also showed
BRD4 levels increased or similar to vehicle control. Duplicates of selected exper-
iments were analyzed bywestern blot, corroborating the depletion of BRD4. The
second assay uses immunohistochemistry (IHC) to evaluate BRD4 degradation
in skin biopsies of Sprague Dawley and nude male rats dosed with 2mg/kg
intravenous (i.v.) BRD4 PROTAC ARCC-29. IHC analysis of rat skin eight
hours after in-vivo dosing with ARCC-29 demonstrated a dose-dependent re-
duction in BRD4 protein. Rats dosed once a week with ARCC-29 [2 mg/kg]
showed a 60-90% reduction inBRD4 levels compared to vehicle, while 0.3mg/kg
twice per week showed a 10-30% decrease in BRD4 levels. These experiments
demonstrate that BRD4 degradation can be evaluated in surrogate tissue. Flow
cytometry using PBMCs and skin IHCprovide potential alternativemethods for
confırming thePROTACmechanism-of-action in the clinic using pre- andpost-
treatment patient samples. DISCLOSURES All authors are employed by Arvi-
nas, LLC.
#5077 A novel small molecule menin-MLL inhibitor for potential treat-
ment of MLL-rearranged leukemias. TaoWu,1 Linda Kessler,1 Shuangwei Li,1
Trupta Purohit,2 Shisheng Li,1 Hongzhi Miao,2 Brian Linhares,2 Rasmus Han-
sen,1 Jeff Kucharski,1 YiWang,1 Ke Yu,1 Katarzyna Kempinska,2 Tess Ely,1 Szy-
mon Klossowski,2 Ata Zarieh,1 Ulf Peters,1 Jun Feng,1 Yvonne Yao,1 Yuan Liu,1
Bo Wen,2 Francis Burrows,3 Duxin Sun,2 Jingchuan Zhang,1 Levan Darjania,1
Dana Hu-Lowe,1 Patrick Zarrinkar,1 Liansheng Li,1 Tomasz Cierpicki,2 Jolanta
Grembecka,2 Pingda Ren,3 Yi Liu3. 1Wellspring Biosciences, La Jolla, CA; 2Uni-
versity of Michigan, Ann Arbor, MI; 3Kura Oncology, La Jolla, CA.
Patients with MLL-rearranged leukemia typically have a poor prognosis.
With chemotherapy and stem cell transplantation as current standard of care,
the 5-year survival rate is estimated to be only about 35%. As the leukemogenic
activity of MLL fusion proteins has been shown to be dependent on their direct
interaction with menin, development of small molecules that block the menin-
MLL interaction is a promising therapeutic strategy for the treatment of this
disease. Although small molecule menin-MLL inhibitors have been reported,
previously published compounds exhibited modest cellular potency and/or
poor pharmacokinetic properties. We now describe a novel, potent, and selec-
tive small molecule menin-MLL inhibitor that effectively treats MLL leukemias
in in vivo models and demonstrate its potential clinical utility. The compound
selectively inhibits the growth of a panel of MLL-rearranged cell lines relative to
non MLL-rearranged cell lines, displays favorable pharmacokinetic properties,
and induces tumor regression in an MV4;11 subcutaneous xenograft mouse
model, with durable tumor suppression even after dosing is discontinued. In
both the MV4;11 andMOLM13 disseminated leukemia models, the compound
confers a prolonged survival benefıt compared to an untreated group when
dosed orally once daily at doses that are well-tolerated in the animals. We have
used this potent and selective menin inhibitor to investigate the functional cel-
lular response of MLL-rearranged cell lines to menin inhibition, assessing cell
growth, cell cycle and gene expression responses over time, and compared that
response to other epigenetic inhibitors and demonstrate signifıcantly increased
apoptosis which correlates with tumor regression measured both in early and
long term readouts in xenograft and systemic leukemia models. We describe a
menin-MLL inhibitor with optimized drug-like properties that demonstrates
potential clinical utility in preclinical models ofMLL leukemias. The compound
is currently under further preclinical evaluation.
#5078 EZH2 methyltransferase regulates disseminating tumor cells in
breast cancer metastasis. Shira Yomtoubian,1 Seongho Ryu,2 Sharrell Lee,1
Geoff Markowitz,1 Dingcheng Gao,1 Vivek Mittal1. 1Weill Cornell Medicine,
New York, NY; 2Soonchunhyang University, China.
Triple negative breast cancer (TNBC, ER-, PR-, HER2-) exhibits the worst
outcome due to higher rates of metastasis compared to non TNBC subtypes.
Despite this clinical signifıcance, there is a conspicuous lack of FDA approved
molecularly targeted anti-metastatic therapies for TNBC. The enhancer of zeste
homolog 2 (EZH2), a catalytic core subunit of the Polycomb repressive complex
2 (PRC2) with histone methyltransferase (HMT) activity is associated with the
worst clinical outcome in breast cancer patients. Using a combination of genetic
and pharmacological approaches, we show that EZH2 HMT blockade did not
impact primary tumor growth, but signifıcantly reduced distal metastases. Me-
tastasis suppression was associated with amarked reduction of tumor-initiating
cells (TICs) in primary tumor, circulating tumor cells (CTCs) in the blood and
impaired lung colonization. Using a SOX2/OCT4 promoter reporter system, we
identifıed EZH2-sensitive metastatic cells with GATA3 low luminal progenitor
phenotypes in the primary tumor, and EZH2 HMT blockade restored GATA3
expression, promoted differentiation of luminal progenitors and impaired me-
tastasis. These key preliminary fındings have led to the hypothesis that EZH2
promotes metastasis, and that inhibition of EZH2 HMTmay constitute a viable
anti-metastatic approach. We will also discuss the potential of EZH2 inhibition
in combination with chemotherapy as an effective strategy against TNBC me-
tastasis.
#5079 Inhibition of HDAC2, but not HDAC1, abrogates triple negative
breast cancer progression andmetastasis.Hope E. Burks,1 Steven Elliott,1 Van
T. Hoang,1 Margarite D. Matossian,1 Bridgette Collins Burow,1 Matthew E. Bu-
row2. 1Tulane University, New orleans, LA; 2Tulane University, new orleans, LA.
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast
cancer, with higher rates of metastasis and recurrence than other classifıed sub-
types. The decreased survival rates seen in TNBC can be attributed in part to the
lack of targeted therapeutics. HDAC inhibitors (HDACi) have emerged as a
potential adjuvant therapy for patients with triple negative disease. Previously,
our lab has identifıed Panobinostat, a pan-DAC inhibitor, as a successful therapy
for the reversal of the metastatic phenotype in TNBC. However, this therapy
lacks specifıcity and may have increased side effects as a result. In this study, we
aim to dissect the necessaryHDACs responsible for driving andmaintaining the
metastatic phenotype of TNBC, with the goal of informing specifıc HDAC tar-
geted therapies. Here we show that Romidepsin, an HDAC 1 and 2 specifıc
inhibitor, is capable of recapitulating aspects of Panobinostat treatment in
TNBC both in vitro and in a patient derived xenograft model in vivo. To parse
the necessity and role of HDAC1 and HDAC2 individually, we created knock-
down cell lines and analyzed them for changes in gene expression changes and
their respective associated biological processes, including proliferation, migra-
tion, mammosphere formation, tumor growth and metastasis. We found that
HDAC2 knockdown was able to signifıcantly repress migration and prolifera-
tion in TNBC cells and their associated gene expression signatures in vitro.
Furthermore, HDAC2 knockdown resulted in decreased tumor growth andme-
tastasis an in vivomousemodel. These results illustrate the effıcacy of Romidep-
sin in inhibition of oncogenic processes and implicate HDAC2 as a potential
target for therapeutic intervention in TNBC.
#5080 BET inhibitors INCB054329 and INCB057643 display signifıcant
activity in androgen-independent prostate cancer models. Ramiro Vázquez,1
Gianluca Civenni,1MartinaMarchetti,1 Sabrina Zadic,1 Phillip Liu,2 Bruce Rug-
geri,2 Giuseppina M. Carbone,1 Carlo V. Catapano1. 1Institute of Oncology Re-
search-IOR, Bellinzona, Switzerland; 2Incyte Corporation, Wilmington, DE.
Prostate cancer is a leading cause of cancer death worldwide. Deregulated
transcriptional factors and epigenetic effectors contribute to prostate cancer
progression and castration resistance providing ideal targets for developing new
therapeutic strategies. Bromodomain and extra-terminal (BET) proteins act
transcriptional co-activators interacting with multiple co-regulatory molecules
at gene promoters and enhancers. BET inhibitors (BETi) disrupt transcriptional
regulatory complexes and have broad anticancer activity. INCB054329 and
INCB057643 are BETi with proven pre-clinical activity in hematological and
solid tumors. Both compounds are currently in clinical trials (NCT02431260
and NCT02711137) in advanced cancer patients. In this study we explored for
the fırst time the activity of these two BETi in prostate cancer, comparing their
effects in androgen-dependent and independentmodels in vitro and in vivo.We
assessed the effect of INCB054329 and INCB057643 on cell proliferation, colony
formation and tumor-sphere assays in androgen-dependent (LNCaP and
VCaP) and androgen-independent (DU145, PC3, 22Rv1) cells. The in vivo an-
titumor activity was evaluated in mice with 22Rv1 derived subcutaneous xeno-
grafts with drugs administered orally (BID, daily for 3 weeks). INCB054329 and
INCB057643 inhibited proliferation of prostate cancer cell lines. In short-term
cell proliferation assays the BETi appeared more effective against androgen-
dependent (VCaP and LNCaP) than androgen-independent (DU145 and PC3)
cells (GI50 of100 nM and500 nM, respectively). 22Rv1 cells, which express
androgen-independent AR splice variants, exhibited an intermediate level of
sensitivity to both compounds (GI50: 150-250 nM). Interestingly, in colony and
tumor-sphere forming assays all the cell lines showed substantially greater sen-
sitivity to the BETi than in short-term assays. Notably, androgen-independent
22Rv1 cells were highly responsive with GI50 values 100 nM similar to those
seen in androgen-sensitive LNCaP cells. Treatment of mice bearing 22Rv1 tu-
mor xenografts with INCB054329 (50mg/kg) and INCB057643 (3mg/kg) led to
signifıcant inhibition of tumor growth (T/C%: 42 and 45%, respectively) and
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consistent reduction of tumor weight relative to vehicle-treated mice. These
results provide evidence of activity of INCB054329 and INCB057643 in prostate
cancer cell lines. Although short term assays suggest a preferential anti-prolif-
erative effect in androgen sensitive prostate cancer cells, both compounds also
exhibit signifıcant activity in an androgen-independent model both in vitro and
in vivo suggesting that they might represent a valid therapeutic option for treat-
ment of castration-resistant prostate cancer.
#5081 Disruption of DNA methyltransferase (DNMT) 1 confers resis-
tance to DNMT inhibitors in human colorectal cancer cells.Angelo B. Laran-
jeira, Dat Nguyen, Erich Huang, James H. Doroshow, Sherry X. Yang. Division
of Cancer Treatment and Diagnosis, National Cancer Inst., Bethesda, MD.
DNA methyltransferase (DNMT) 1 is responsible for the maintenance and
propagation of DNA methylation pattern, and plays an important role in cell
survival and proliferation. Thus, targeting DNMT represents a promising ap-
proach for cancer treatment. However, the role of DNMT1 in treatment effıcacy
with DNMT inhibitors remains controversial. The aim of this study was to
investigate potential alterations of DNMT inhibitor-induced cytotoxicity and
cellular survival after disruption/knockout of DNMT1 in cancer cells. The hu-
man colorectal cancer cell line HCT116 and its isogenic DNMT1 knockout pair
were treated with increasing concentrations of 4’-thio-5-aza-2’-deoxycytidine
(aza-TdCyd), a novel DNMT inhibitor, and 5-aza-2’-deoxycytidine (aza-dCyd).
Cytotoxic effects and cell survivalwere evaluated byMTTand clonogenic assays.
Apoptosiswasmeasured by annexin-V/propidium iodide test, and expression of
DNMT1, DNMT3A and DNMT3B was detected by western blot. After 96h of
drug exposure, IC50s of aza-TdCyd and aza-dCyd were 0.031M and 0.28 M,
respectively, inHCT116 cells. In contrast, DNMT1 knockout cells were remark-
ably resistant to both drugs with IC50s all higher than 10 M. The treatments
resulted in a signifıcant increase in apoptosis in the parental line versus its
knockout counterpart. As for the cell survival, IC50s were 0.12 M for aza-
TdCyd and4.62 M for aza-dCyd in HCT116 cells, compared to43.77 M
and 62.09 M in DNMT1 knockout cells. As such, disruption of DNMT1
caused over 300-fold and 10-fold increase in resistance to aza-TdCyd and aza-
dCyd. Moreover, we observed a G2/M arrest produced by aza-TdCyd versus
aza-dCyd in the parental cells, and no apparent alteration in cell cycle phase
distribution in DNMT1 knockout cells. Notably, aza-TdCyd was more potent
than aza-dCyd in depleting DNMT3A and/or DNMT1 in both cell lines after
48h of treatment. Our fındings demonstrate that disruption of DNMT1 leads to
a signifıcantly increased resistance to aza-TdCyd and aza-dCyd, suggesting that
DNMT1 is critical to the antitumor activity of DNMT inhibitors. Aza-TdCyd is
muchmore potent than aza-dCyd for both inhibition of DNMTs and growth of
cancer cells.
#5082 The selective bromodomain inhibitor, INCB054329 targets both
cancer cells and the tumor microenvironment in the KC inflammatory pre-
clinical model of ductal pancreatic cancer. Ana Sofıa Leal,1 Karen T. Liby,1
Phillip Liu,2 Bruce Ruggeri2. 1Michigan State University, East Lansing, MI; 2In-
cyte Corporation, Wilmington, DE.
Pancreatic cancer is expected to become the second most deadly cancer by
2030, with few effective therapeutic options available to improve patient sur-
vival. The Kras gene is mutated in over 90% of pancreatic cancers, but the Kras
protein is considered to be an undruggable target. p-Erk is a downstream effec-
tor of Kras and has been shown to be essential for the progression and mainte-
nance of pancreatic cancer. The LSL-KrasG12D/; Pdx-1-Cre (KC)mousemodel
is used to study pancreatic cancer, especially cancer progression, after stimula-
tion with an inflammatory agent, such as caerulein or LPS. Bromodomain in-
hibitors are a new generation of drugs that target BET (bromodomain and extra-
terminal) proteins, impairing their ability to bind to acetylated lysines and
therefore interfering with transcriptional initiation and elongation. BET pro-
teins regulate several genes responsible for cell growth, apoptosis and inflam-
mation. INCB54329 is a novel, orally bioavailable BET inhibitor that is currently
being investigated in Phase 1 clinical trials.INCB054329 inhibits cell growth in
murine pancreatic cancer cells harboring Kras mutations, derived from a
KrasG12D/; Trp53R172H/; Pdx-1-Cre (KPC) mouse with an IC50 values less
than 100 nM. Moreover, INCB054329 reduces the levels of p-ERK 1/2 in these
cells lines. When KC mice are injected with LPS to induce inflammation and
pancreatitis, p-Stat3 protein levels are signifıcantly increased, but this pro-sur-
vival protein is reduced by more than 50%, in mice that were pre-treated with
INCB054329. Tumor cells can use epigenetic modulation to evade immune rec-
ognition and to shape the TME (tumor microenvironment) toward an immu-
nosuppressive phenotype. Since epigenetic modulation is a mechanism used by
tumors to regulate the TME, using small molecules as epigenetic modulators to
activate immune recognition is a therapeutically desirable approach.Within the
TME, several cytokines and chemokines play crucial roles, recruiting and regu-
lating inflammatory cells [macrophages, T cells andMyeloid derived suppressor
cells]. KC mice stimulated with LPS have higher levels of CCL2 (1947  591
ng/mL) and IL-6 (2459 577 pg/mL) than unstimulated mice; these increased
levels of inflammatory cytokines and the subsequent immune cell infıltration
can be modulated by treatment with INCB054329, with INCB054329 demon-
strating50% inhibition of both cytokines (IL-6: 1063 502 pg/mL; CCL2: 713
 134 ng/mL). These data suggest that INCB054329 has a dual activity, targeting
cancer cells and modulating the TME; both activities may prove benefıcial for
the treatment of pancreatic cancer.Moreover, this work suggests that additional
mechanisms may underlie the benefıcial effects of bromodomain inhibitors.
#5083 A novel and highly effıcacious small-molecule degrader of BET-
BRD proteins for the treatment of acute leukemia. Ester Fernandez-Salas,1
Zhuo Chen,1 Mei Lin,1 Bing Zhou,2 Donna McEachern,1 Sally Przybranowski,1
Karson Kump,1 Luke F. Peterson,1 Malathi Kandarpa,1 Jiantao Hu,1 Fuming
Xu,1 Liu Liu,1 Longchuan Bai,1 Bo Wen,1 Duxin Sun,1 Moshe Talpaz,1 Sha-
omeng Wang1. 1Univ. of Michigan, Ann Arbor, MI; 2Shanghai Institute of Ma-
terica Medica, Shanghai, China.
The bromodomain and extra-terminal domain (BET-BRD) family of lysine
acetylation readers comprises BRD2, BRD3, BRD4, and BRDT that contain two
conserved N-terminal bromodomains (BD1 and BD2) and a long C-terminal
region containing the extraterminal (ET) protein-protein interaction domain.
These proteins have key roles in the assembly of transcriptional regulatory com-
plexes containing RNA polymerase II. BET-BRDs are new therapeutic targets
for cancer treatment and several small-molecule BET-BRD inhibitors are cur-
rently in clinical development for a diverse set of cancers including leukemia.
Based on the proteolysis targeting chimera (PROTAC) concept, we have devel-
oped novel and highly potent BET degraders, ZBC246 and ZBC260, with excep-
tional selectivity based upon a new class of BET inhibitor, ZBC11. ZBC260
effectively degrades all BET-BRD proteins at concentrations as low as 30 pM
within a few hours of treatment in the RS4;11 leukemia cell line and achieves
IC50 values of 50 pM in inhibition of RS4;11 cell growth. ZBC260 was tested in
a panel of 10 acute leukemia cell lines generating IC50s ranging from 20 pM to 1
nM in 4-days cell growth inhibition assays. In contrast to the cytostatic effect
observed with BET-BRD inhibition, degradation of BET-BRDs by ZBC246 and
ZBC260 induced robust apoptosis demonstrating a differential biology between
BET-BRD inhibitors and BET-BRD degraders. Signifıcantly, ZBC260 induces
rapid regression of RS4;11 xenograft tumors without overt signs of toxicity in
mice. More importantly, treatment of leukemia cells obtained from 10 patients
with ZBC260 demonstrated effıcient degradation of BET-BRDs within 5 h at 0.3
nM,while treatment with the inhibitor (300 nM) induced up-regulation of BET-
BRDs. Treatment of patients’ peripheral blasts with ZBC260 at 1 to 10 nM
induced remarkable levels of apoptosis within 24 h, even in relapsed and refrac-
tory patient samples. In conclusion, ZBC260 represents a highly potent and
effıcacious BET-BRD degrader undergoing extensive preclinical evaluation for
the treatment of acute leukemias.
#5084 Potent and isoform-selective ATAD2bromodomain inhibitor with
unprecedented chemical structure andmodeof action.AmauryE. Fernández-
Montalván,1 Markus Berger,1 Benno Kuropka,1 Seong Joo Koo,1 Volker Ba-
dock,1 Joerg Weiske,1 Simon J. Holton,1 Apirat Chaikuad,2 Laura Díaz-Sáez,2
James Bennett,2 Oleg Federov,2 Kilian Huber,2 Paolo Centrella,3 Matthew A.
Clark,3 Christoph E. Dumelin,3 Eric A. Sigel,3 Holly S. Soutter,3 Dawn M.
Troast,3 Ying Zhang,3 John W. Cuozzo,3 Anthony D. Keefe,3 Didier Roche,4
Vincent Rodeschini,4 Jan Hübner,1 Hilmar Weinmann,1 Ingo V. Hartung,1
Matyas Gorjanacz1. 1Bayer Pharma AG, Berlin, Germany; 2Structural Genomics
Consortium, Oxford, United Kingdom; 3X-Chem Pharmaceuticals, Waltham,
MA; 4Edelris, Lyon, France.
ATAD2 (ATPase family AAA-domain containing protein 2, also called AN-
CCA) is an epigenetic regulator that binds to chromatin through its bromodo-
main (BD), a motif specialized for acetyl-lysine recognition. ATAD2 directly
associates with multiple transcription factors such as ER	, AR, E2F, and Myc;
hence, ATAD2 has been proposed to act as a co-factor for oncogenic transcrip-
tion factors. Furthermore, we have recently reported a novel role for ATAD2
during DNA replication, uncovering interactions between ATAD2 and histone
acetylationmarks on newly synthesized histoneH4. High expression of ATAD2
strongly correlates with poor patient prognosis in multiple tumor types, includ-
ing gastric, endometrial, hepatocellular, ovarian, breast and lung cancers. How-
ever, the exact function ofATAD2 in these tumor types remains unclear. Amore
thorough validation of ATAD2 as a therapeutic target is hampered by the lack of
isoform-selective, potent and cellularly active ATAD2 inhibitors. A systematic
assessment of crystal structures of BD-containing protein family predicted that
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development of selective inhibitors ofATAD2would be challenging. In linewith
this prediction, only limited progress in developing lead compounds targeting
ATAD2 has been reported so far. A few notable exceptions relied on fragments
as starting points, however, their weak potency, insuffıcient selectivity against
other BDs, permeability limitations ormodest cellular activity have curbed their
further development towards drug candidates. Here we embarked on a novel
strategy to identify ATAD2 inhibitors: 11 different DNA-encoded libraries add-
ing up to 67 billion unique encoded compounds were combined and incubated
with ATAD2 BD followed by two rounds of affınity-mediated selection. This
approach provided with several series of binders, for which specifıc target en-
gagement of their SMOL moiety upon off-DNA synthesis was confırmed in
biochemical and biophysical assays. Several rounds of potency optimization led
to the identifıcation of BAY-850, a highly potent and ATAD2 (isoform A)
mono-selective inhibitor, which holds an amine substituted 3-(2-furyl)benz-
amide core. This compound shows - as revealed by size exclusion chromatogra-
phy and native mass spectrometry - a novel mode of action for a BD inhibitor
based on specifıc target dimerization. In a cellular fluorescence recovery after
photobleaching (FRAP) assay BAY-850 displaced wild-type ATAD2 from the
chromatin to the same extent as the genetic mutagenesis of ATAD2 BD. In
contrast, chemically very similar inactive control compounds showed no major
effects on ATAD2 association with the chromatin. These results qualify BAY-
850 as the fırst biologically active ATAD2 isoform A-specifıc chemical probe,
which will enable further elucidation of the cancer biology of this intriguing
protein.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Gene- and Vector-Based Therapy
#5085 SOCS-1 gene therapy combinedwith radiation therapy has a potent
antitumor effect for esophageal squamous cell carcinoma. Takahito Sugase,1
Tsuyoshi Takahashi,1 Satoshi Serada,2 Minoru Fujimoto,2 Koji Tanaka,1
Yashuhiro Miyazaki,1 Tomoki Makino,1 Yukinori Kurokawa,1 Makoto Yama-
saki,1 Kiyokazu Nakajima,1 Shuji Takiguchi,1 Masaki Mori,1 Yuichiro Doki,1
Tetsuji Naka2. 1Osaka University, Suita, Japan; 2National Institutes of Biomedi-
cal Innovation, Health and Nutrition, Ibaraki, Japan.
INTRODUCTION: Radiation therapy (RT) is one of the main strategies for
esophageal squamous cell carcinoma (ESCC) besides surgery and chemother-
apy. Although RT has shown remarkable clinical benefıts for ESCC patients,
there remains the resistance for RT. Recently, some reports show that STAT3
activation is induced by irradiation and can result in treatment-resistance for
radiotherapy in various cancer. Suppressor of cytokine signaling-1 (SOCS-1)
has been cloned as a negative regulator of various cytokine signaling. We previ-
ously reported that overexpression of SOCS-1 showed a potent anti-tumor effect
for ESCC through targeting of JAK/STAT and FAK/ERK signaling pathway.
Since these results, SOCS-1 might have a possibility to overcome the resistance
of RT. The aim of this study is to evaluate the antitumor effect of SOCS-1 gene
therapy using adenoviral vector (AdSOCS-1) combined with RT. METHODS:
At fırst, we evaluated RT resistance by the STAT3 in ESCC cell lines by using
pEB-Multi-constitutive-STAT3(c-STAT3) vector. We examined the colony
forming assay between parent (TE8, TE9, TE11, TE14) and stably expression of
c-STAT3 cells. Next, we evaluated cell growth inhibition effect of AdSOCS-1
gene therapy combined with RT in vitro and in vivo. As in vivo model, we
examined the combined effect of RT (2Gy) and AdSOCS-1 gene therapy by
usingTE14 xenograftmice (ICRnu/numice). RESULTS:At fırst, ESCC cell with
stably expression of c-STAT3 showed a signifıcant increase in colony forming
ability after RT as compared with parent andmock cell. It suggested that activa-
tion of STAT3 might be related to RT resistance in ESCC cell. Furthermore,
ESCC cells withRTwere induced the secretion of IL-6, and the activation level of
STAT3 was elevated by multiple RT. In addition, they increased the expression
of anti-apoptosis protein (mcl-1, survivin), and might have a RT resistance.
Next, we confırmed that combination therapy with RT and AdSOCS-1 had
better proliferation inhibitory effect and decreasing of colony forming ability. In
addition, we showed that AdSOCS-1 gene therapy inhibited the induction of the
expression of anti-apoptosis protein (mcl-1, survivin) by RT and induced apo-
ptosis synergistically. As in vivo model, the combination therapy group showed
a signifıcant anti-tumor effect compared to the RT alone group and AdSOCS-1
gene therapy alone group. CONCLUSIONS: The activation of STAT3 is in-
volved in resistance to radiation therapy in esophageal squamous cell carci-
noma, and SOCS-1 gene therapy combined with radiation therapy may have a
potent anti-tumor effect.
#5086 Chronic radiation induced uPA expression mediates neuroblas-
toma cells survival. Manu Gnanamony, Karen Fernández, Jaime Libes, Julian
Lin, Pushpa A. Joseph, Christopher S. Gondi.Univ. of Illinois College of Med. at
Peoria, Peoria, IL.
Neuroblastoma accounts for more than 15% of cancer-related deaths of chil-
dren in the United States. Despite aggressive treatment regimens, the long-term
survival for these children remains less than 40%. The urokinase plasminogen
activator (uPA) system plays a role in several critically important biology pro-
cesses, such as cell adhesion, migration, proliferation and survival. This system
includes uPA, a serine protease which converts a zymogen plasminogen into the
active serine protease plasmin, its surface receptor uPAR/CD57, which binds
uPA with high affınity, facilitates proteolytic activation/conversion of uPA pre-
cursor (single-chain uPA, scuPA) into the active two-chain uPA protease
(tcuPA) and mediates uPA-induced activation of several intracellular signaling
cascades, and protects against several inhibitors, e.g. PAI-1, among others. Re-
cent fındings demonstrate that dividing/proliferating cells translocate intact
scuPA to the nucleus via the nucleocytoplasmic shuttle protein nucleolin. In this
study we demonstrate that both SKNBE(2) and NB1691 neuroblastoma cells
when exposed to chronic radiation suppresses nMYC gene copy number and
induces the overexpression of cMYC and uPA expression levels without observ-
able change in uPA gene copy number. Increased uPA expression was accom-
panied with increase in the mitochondrial mass (4 fold in both NB1691 and
SKNBE (2) cells). Knockdownof uPA expression in chronic radiation cells using
siRNA resulted in reduced cell survival. RT-PCR analysis shows that uPA
knockdown resulted in reduced expression of cMYC and its target genes cyclin
A and cyclin D1. Overexpression of uPA in both SKNBE(2) and NB1691 wild-
type cells resulted in increased cMYC and cyclin D1 expression but not nMYC
expression suggesting that cMYCmay be specifıcally regulated by uPA. In con-
clusion, our study shows that uPA plays a vital role in survival of neuroblastoma
cells treated with chronic radiation by associating with cMYC to compensate for
loss of nMYC expression. Our study also implies that targeting uPA might be a
viable option as a combination therapy in the treatment of high-risk neuroblas-
toma.
#5087 Radiation enhances the intracellular delivery of anti-MGMTmor-
pholino oligonucleotides (AMONs) to enhance the cytotoxicity of chemo-
radiation in cancer cells. Prakash Ambady, Jeffrey Wu, Cymon Kersch, Dree-
Anna Morris, Michael Pagel, Leslie L. Muldoon, Edward Neuwelt. OHSU,
Portland, OR.
Background: This study evaluates the use of a sub-lethal dose of ionizing
radiation to guide and enhance the intracellular delivery of morpholino anti-
sense nucleotides designed to block O6-methylguanine DNAmethyltransferase
(MGMT) to enhance the cytotoxicity of chemo-radiation therapy (CRT).
MGMT is a DNA repair enzyme and its expression is a well-knownmechanism
for resistance to CRT in glioblastoma. Epigenetic silencing of this enzyme by
promotor methylation is associated with better response and clinically relevant
survival benefıts after CRT. We designed anti-MGMT morpholino oligonucle-
otides (AMON) using the stable vivo-morphalinos backbone. Intracellular de-
livery of morpholinos, particularly in a manner that could be clinically feasible,
continues to be a major challenge. We use sublethal ionizing radiation to en-
hance the delivery of AMON to transiently reducedMGMT protein expression.
We previously demonstrated that sublethal ionizing radiation enhances the de-
livery of AMONs to reduce MGMT expression in human cancer cells (T98G
glioma and H460 and A549 non-small cell lung cancer cell lines) in vitro as well
as the targeted knockdown of MGMT with systemically administered AMON-
sin pre-irradiated tumors. We now test whether blocking MGMT will enhance
the cytotoxicity of CRT, and investigate the mechanism by which radiation
permits cellular uptake of AMONs. Methods: MGMT expressing, human T98G
glioblastoma cells were used for all in-vitro studies. AMONs and non-specifıc
fluorescent tagged control morpholinos were synthesized and purchased from
Gene Tools, LLC (Philomath, OR, USA). High-resolution widefıeld microscopy
with image deconvolution was performed to confırm the intracellular delivery.
Cells were exposed to 1Gy radiation; 24 hrs post radiation cells were treatedwith
AMONs. Cells were then exposed to temozolomide (75 or 150g/mL) on day 3.
Lysates were obtained on days 4 and 7. Expression of cellular MGMT protein,
apoptosis markers, and key endocytosis proteins were characterized using im-
munoblotting. Results: Our results demonstrate that MGMT silencing using a
single dose of AMONs delivered with sublethal dose of radiation increased ap-
optosis by 50% and reduces cell viability by 50% at one and two days after
therapy. Further, we demonstrate an increase in caveolin 1, clathrin and dy-
namin expression after radiation exposure. Conclusions: Our results suggest
that blocking AMONs can enhance the cytotoxicity of CRT. Dynaminmediated
endocytosis appears to play a key role in this enhanced cellular update of anti-
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sense nucleotides after a sublethal dose of radiation. Since radiation is already
part of standard of care cancer therapy, the use of radiation to guide the delivery
of systemically administered anti-sense nucleotides is a novel strategy to target
key tumor associated proteins for therapeutic benefıt key.
#5088 Tumor penetratingRNAdelivery for therapeutic benefıt of pancre-
atic cancer. Liangliang Hao, Justin Lo, Sangeeta Bhatia.MIT, Cambridge, MA.
Pancreatic cancer remains a deadly disease with amedian survival of less than
one year, in part because we lack effective therapeutic strategies. Mutations of
the oncogene KRAS and the tumor suppressor genes TP53, INK4A, and DPC4
play important roles in the pathogenesis of pancreatic ductal adenocarcinoma
(PDAC); however, these driver events have proven to be challenging targets for
drug development. RNA interference through small interfering RNA (siRNA)
delivery has the potential to have an impact on silencing ’undruggable’ targets;
however, siRNA delivery in tumors has been challenging in general and wors-
ened in PDAC by the stromal barriers to drug delivery. Herein, we integrated
biomedical engineering, materials science, and pre-clinical investigation to es-
tablish a novel class of tumor-penetrating nanoparticles (TPNs) to enhance de-
livery of siRNAs in PDAC for therapeutic benefıt. Specifıcally, we adapted self-
assembled nanoparticles comprised of siRNA complexed with tandem tumor-
penetrating and membrane-translocating peptides, which enabled the specifıc
delivery of siRNA deep into the tumor parenchyma. Specifıcally, to establish
effıcacious siRNA delivery vehicles, we characterized and selected tandem pep-
tides that incorporate novel tumor-penetrating peptide domains known to tar-
get PDAC in mice. In parallel, we optimized the particle stability through
incorporation of hydrophilic molecules, focusing on achieving desirable phar-
macokinetic properties which will reduce off-target delivery and increase po-
tency of a given siRNA dose. The resulting TPNs carry siRNA into the cytosol of
monolayer cultures of tumor cells, and also exhibit penetration in pancreas
organoids derived from primary mouse and human tumors. As a proof-of-
concept, we used TPN in vivo to knockdown KRAS in a murine PDAC model,
using subcutaneously-implanted, autochthonous KRASG12D/p53-/- tumors.
Treatment of tumor-bearing mice with systemically administrated KRAS-spe-
cifıc TPNs suppressed the growth of established tumors. With the delivery plat-
form established, the ongoing goals of this project are to identify siRNA targets
that synergize with the suppression of oncogenic KRAS, and to validate syn-
thetic lethal targets by interfering with signature PDACdriver events uncovered
by functional genomic efforts. Together, these studies will provide a foundation
for translational studies involving new targets and delivery technology in pan-
creatic cancer.
#5089 Antitumor activities elicited by direct intratumoral administration
of a recombinant adenovirus expressing either IL-28A/IFN-2 or IL-29/IFN-
1.MuneoNumasaki, Hiroki Tsukamoto, Yoshihisa Tomioka. Tohoku Univer-
sity, Sendai, Japan.
Interleukin (IL)-28A/IFN-2 and IL-29/IFN-1 have been demonstrated to
elicit direct and indirect antitumor actions. In this study, we constructed an
adenovirus vector expressing either IL-28A/IFN-2 (AdIL-28A) or IL-29/
IFN-1 (AdIL-29) to evaluate the therapeutic properties of intratumoral injec-
tion of recombinant adenovirus to apply for the clinical implementation of can-
cer gene therapy. Despite the lack of antiproliferative effect on MCA205 and
B16-F10 cells, a retarded growth of established subcutaneous tumors was ob-
served following multiple injections of either AdIL-28A or AdIL-29 when com-
pared with AdNull. In vivo cell depletion experiments displayed that both NK
cells and CD8 T cells play a major role in AdIL-28A-mediated tumor growth
suppression. A signifıcant increase in the number of infıltrating CD8 T cells
into the tumors treated with either AdIL-28A or AdIL-29 was observed. More-
over, specifıc antitumor cytotoxic T lymphocyte reactivitywas detected in spleen
cells from animals treated with either AdIL-28A or AdIL-29. In IFN- defıcient
mice, the antitumor activity of AdIL-28A was completely impaired, indicating
that IFN- is critically involved in the tumor growth inhibition triggered by
AdIL-28A. IL-12 provided an additive antitumor effect when combined with
AdIL-28A. These results indicate that AdIL-28A and AdIL-29 could be success-
fully utilized as an alternative cancer gene therapy.
#5090 Effıcient KO of PD1 into primary T cells using a new non-inte-
grative lentiviral particle expressing CRISPR/Cas9 system. Pascale
Bouillé,1 Régis Gayon,2 Lucille Lamouroux,2 Alexandra Iche,2 Christine Du-
thoit,2 Jean-Christophe Pages3. 1VECTALYS and FLASHCELL, Toulouse,
France; 2VECTALYS, Toulouse, France; 3INSERMU966 Faculté de Médecine,
Tours, France.
Gene editing by the CRISPR system shows great promises for gene therapy.
Nevertheless, it must now face a number of challenges especially for the devel-
opment of safe and effıcient delivery tools for in vivo, as well as ex vivo gene
editing. Cas9 and sgRNA delivery, mediated either by viral vectors (AAV- or
Lentivirus-derived) or transfection protocols (chemical or by electroporation)
have been largely and effıciently used but they bring major drawbacks incom-
patible with clinical applications. Indeed, viral vectors can display uncontrolled
chromosomal integrations and transfection protocols are known to induce cell
toxicity and/or phenotype modifıcations of the target cells. Moreover, the
CRISPR technology entails a “hit-and-run” mechanism that only requires a
transient expression of the nuclease complex. Therefore, achieving an effıcient
delivery into hard-to-transfect cells, such as T cells, remains challenging and the
need for delivery tools that would allow effıcient transfer on most cell types
without causing any cell damages is essential for downstream therapeutic appli-
cations. Here, we present an innovative tool, named LentiFlash, allowing RNA
delivery into target cells without any genomic scar. The RNA encapsidation is
mediated via an RNA/protein interaction: the respective properties of the MS2
bacteriophage and the lentiviral vectors have been combined to build a non-
integrative packaging system in which the wild type HIV packaging sequence is
replaced by theMS2 stem-loop repeats and theMS2 coat protein is inserted into
the Nucleocapsid. This new vector breaks with all existing systems, as the result-
ing lentiparticle is able to deliver non-viral coding or non-coding RNA, at high
effıciency, into the cytoplasm of any cell type. Transduction of a large range of
cells, from immortalized cells to delicate primary cells, such as T cells and he-
matopoietic stem cells, with LentiFlash shows an effıcient, fast and transient
expression of proteins and RNA, with no cell phenotype modifıcation. In par-
ticular, LentiFlash particles were successfully used to deliver Cas9, alone or in
association with an sgRNA not only targeting a reporter gene into immortalized
cells, but outstandingly knocking-out the PD-1 gene into primary human T
lymphocytes. This new RNA delivery system is an effıcient and safe tool for the
delivery of CRISPR editing machinery in most cell types without affecting cell
viability and phenotype. The transient, RNA-based mechanism of LentiFlash
vector, preventing the risk of integration, associated with its ability to utilize
lentiviral production platforms already validated in clinical settings, make it a
promising tool for CRISPR therapeutic applications. As amatter of fact, beyond
gene editing effıciency, safety of delivery tools is a major concern that should be
addressed to move forward with CRISPR clinical development.
#5091 Activity of Bcl-2 antisense therapeutic in aggressive non-Hodgkin’s
lymphoma. Ana Tari Ashizawa,1 Yolanda Gutierrez-Puente,2 Richard Ford,3
Gabriel Lopez-Berestein3. 1Bio-Path Holdings, Bellaire, TX; 2Universidad Au-
tonoma de Nuevo Leon, Monterrey, Mexico; 3University of Texas MD Anderson,
Houston, TX.
Aggressive non-Hodgkin’s lymphoma (NHL) progresses rapidly. It makes up
about 60% of all NHL cases in the United States. The chemotherapy regimen
R-CHOP could cure up to 70%of patients with aggressiveNHL.Nonetheless, up
to 30% of patients with aggressive NHL relapse from R-CHOP within 2 years of
initial treatment. Novel therapeutics are urgently needed for patients with re-
lapsed, aggressive NHL. Bcl-2 is a potential therapeutic target for aggressive
NHL because high expression of Bcl-2 has been reported in NHL and correlated
with adverse prognosis for NHL patients. To inhibit the expression of Bcl-2
protein, BP1002 was developed. BP1002 is comprised of an uncharged P-ethoxy
antisense oligodeoxynucleotide targeted against Bcl-2mRNA. The P-ethoxy an-
tisense backbone does not have an adverse effect on bleeding and complement
activation, which are some of the toxicities that have been reported for other
antisense analogs. The Bcl-2 antisense is incorporated in neutral liposomes so
that it can be delivered systemically via intravenous infusion. The inhibitory
activity of BP1002 was determined in human lymphoma cell lines, which in-
cluded germinal center B-cell (GCB) diffuse large B cell lymphoma (DLBCL),
activated B-cell (ABC) DLBCL, mantle cell lymphoma (MCL) and Burkitt’s
lymphoma (BL). The lymphoma cell lines were incubated with BP1002 for four
days. The sulforhodamine B cytotoxicity assay showed that BP1002, at 200 mi-
crograms/mL, induced50% inhibition in 5 of 8 GCBDLBCL lines, 3 of 3 ABC
DLBCL lines, 1 of 1MCL line, and 1 of 1 BL line.We also determined the activity
of BP1002 in animal models. Severe combined immunodefıciency (SCID) mice
were implanted with CJ cells, which are transformed follicular lymphoma cells
that express high levels of Bcl-2 protein. In experiment I, 4 groups of mice were
used:Group 1 - untreatedmice;Group 2 -mice treatedwith 10mgof BP1002 per
kg ofmouse bodyweight; Group 3 -mice treated with 20mg of BP1002 per kg of
mouse bodyweight; Group 4 -mice treatedwith control empty liposomes equiv-
alent to 20 mg/kg of BP1002. One week after tumor implantation, mice were
injected with BP1002 or empty liposomes intravenously twice per week. When
micewere euthanized inweek 5, all untreatedmice andmice treatedwith control
empty liposomes reached moribund state. However, no mouse in the BP1002
treatment groups reached moribund state. In experiment II, 3 groups of mice
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were used: Group 1 - untreated mice; Group 2 - mice treated with 20 mg/kg of
liposome-incorporated control oligodeoxynucleotide; Group 3 - mice treated
with 20 mg/kg of BP1002. All untreated mice and control mice were moribund
in week 5, but only 40% of BP1002-treated mice were moribund. These in vivo
experiments indicate that BP1002 could extend the survival of mice bearing
aggressive NHL. Together, our data indicate that BP1002 is a novel therapeutic
for aggressive NHL.
#5092 ZVex® lentiviral vector strongly activates pro-inflammatory, anti-
gen processing, and anti-viral defense response pathways in monocyte-de-
rived dendritic cells. Anshika Bajaj, Lisa Y. Ngo, Peter Berglund, Jan ter Meu-
len. Immune Design, Seattle, WA.
Background: Dendritic cells (DCs) are professional antigen presenting cells
that effectively bridge the innate and adaptive immune responses and require
activation for successful priming of naïve T-cells. We have developed ZVex, an
integration defıcient, hybrid lentiviral vector engineered to target DC-SIGN
expressed on immature myeloid DCs for genetic immunization against tumor
antigens. As lentiviruses normally don’t effıciently infect DCs, little is known
about the functional effect of LV transduction of conventional DCs. Here, the
effect of DC transduction with ZVex vectors was studied by gene expression
profıling. Material and Methods: Human moDCs from multiple donors were
prepared by 5-day stimulation with IL-4 and GM-CSF and transduced with
ZVex-GFP or control vectors, such as a ZVex with nonfunctional reverse tran-
scriptase (RT-dead), ZVex particles generated to contain no vector genome
(empty ZVex), and a heat-inactivated ZVex preparation. Cellular RNA was iso-
lated at different time points from transduced DC cultures and used for gene
expression profıling with Nanostring’s human pan cancer immune panel (770
genes). Results: DCs transduced with ZVex vectors displayed statistically signif-
icant up-regulation of genes involved in pro-inflammatory, antigen processing,
and anti-viral defense pathways. Noteworthy among the up-regulated genes
were classical anti-viral response genes like OAS3, MX1, and interferon stimu-
lated genes like ISG15 and ISG20. Incubation with the RT-dead mutant vector
also led to up-regulation of these genes, albeit to amuch lower extent, suggesting
that LV-RNA itself can result in the activation of these pathways in DCs, though
reverse transcription appears to further potentiate the response. Of note, cells
transducedwith emptyZVex,which consists of an intact virion particle but lacks
encapsulated LV RNA, also mediated a lowmagnitude and breadth of DC tran-
scriptional activation, possibly via signaling through DC-SIGN. Conclusions:
ZVex incorporates several elements capable of inducing a potent innate immune
activation in DCs. DCs are relatively insensitive to lentiviral infection, but the
use of accessory proteins in ZVex makes DCs conducive to ZVex transduction
and results in the induction of a Type-1 IFN response that seems to be largely
dependent on reverse transcription. In addition, other engineered vector parti-
cle components such as non-reverse transcribed viral RNA, viral structural pro-
teins, and/or engagement of the DC-SIGN receptor, also contribute to DC acti-
vation.
#5093 In vitro, in vivo andmolecular effects of stromal selective targeting
by uPAR retargeted oncoytic measles virus on breast cancer progression.
Yuqi Jing, Valery Chavez, Nicolas Acquavella, Doraya El-Ashry, Yuguang Ban,
Xi Chen, Jaime Merchan. Univ. of Miami Sylvester Comp. Cancer Ctr., Miami,
FL.
The tumor microenvironment is a relevant target for novel biological thera-
pies. While it has been demonstrated that tumor-stromal cell interactions are
important in the sensitivity of the cancer cells to oncolytic virues, few studies
have investigated the direct effects of an oncolytic virus on the stroma, and its
implications on the virus antitumor effıcacy. MV-m-uPA and MV-h-uPA are
fully retargeted, species specifıc, oncolytic measles viruses directed against mu-
rine or human urokinase receptor (uPAR). The effects of stromal selective tar-
geting by uPAR retargeted MVs were investigated. In vitro infection, gene ex-
pression and cytotoxicity byMV-h-uPA andMV-m-uPAwere demonstrated in
human and murine cancer cells and cancer associated fıbroblasts in a species
specifıc manner. In murine fıbroblast (3T3)/human breast cancer (T47D) 3-D
co-cultures, selective fıbroblast targeting byMV-m-uPA inhibited breast cancer
cell growth. These effects were validated in vivo, in a human breast cancer
xenograft (MDA-MB-231), where intravenous administration of the murine
specifıc MV-m-uPA led to signifıcant tumor growth delay and improved sur-
vival compared to controls. Experiments comparing the effects of tumor (MV-
h-uPA) vs. stromal (MV-m-uPA) vs. combined treatment showed that tumor
and stromal targeting was associated with improved tumor control. Correlative
studies demonstrated in vivo tumor targeting, increased apoptosis, andMV-m-
uPA induced differential regulation of both stromal (murine) genes and cancer
(human) genes associatedwith inflammation, angiogenesis and survival, among
others, indicating viral inducedmodulation of tumor-stromal interactions. Our
results demonstrate for the fırst time the feasibility of stromal selective targeting
by an oncolyticMV, viral inducedmodulation of the tumormicroenvironment,
and subsequent tumor growth delay. These fındings further validate the critical
role of stromal uPAR in cancer progression and the potential of oncolytic viruses
as anti-stromal agents.
#5094 Precision therapeutic targeting of oncogenic FGFR3 fusions using
CRISPR-Cas9 genome-editing in urothelial cancer. BishoyM. Faltas, Rebecca
Meyer, Ethan Shelkey, Charles J. Murphy, Olivier Elemento, Mark A. Rubin.
Weill Cornell Medical College, New York, NY.
Introduction: Fibroblast-growth factor receptor 3 (FGFR3) fusions occur in
up to 11 % of urothelial carcinomas. These fusions drive ligand-independent
receptor dimerization and downstream oncogenic signaling and thus represent
attractive targets for gene therapy. We hypothesized that CRISPR-Cas9 gene-
editing can be used to disrupt these somatic oncogenic fusions in cancer cells.
Methods: RT112 and SW780 urothelial cancer cell lines harboring genomic
fusions of FGFR3 to TACC3, or BAIAP2L1, respectively were grown in cultures.
The fusion sequences were confırmed by Sanger sequencing and the NGG pro-
tospacer adjacent motif necessary for guide RNA (gRNA) targeting were iden-
tifıed. Unique guide RNAs spanning the fusion sequences in each cell line were
designed. An all-in-one lentiviral vector was designed to deliver both the gRNA
and the Cas9 nuclease. A scrambled non-targeting gRNA vector was used as a
control. Following transduction, genomic DNA was extracted and PCR was
performed using primer sequences flanking the fusion sequences followed by
targeted sequencing on the Illumina MiSeq platform. CrispRVariants and
CRISPResso bioinformatic tools were used to determine editing effıciency. Re-
sults: In SW780 cells transduced with the FGFR3-BAIAP2L1 fusion-targeting
gRNA vector, 64229/207425 (23.6%) reads harbored CRISPR-induced edits of
the fusion sequence compared to only 2009/313553(0.6%) reads in the scram-
bled gRNA vector-transduced cells. Similarly, in RT112 cells transduced with
the FGFR3-TACC3 fusion-targeting gRNA vector, 74292/448381 reads (14.2%)
contained random indels consistent with CRISPR-induced edits compared to
17785/428035 reads (4.0%) in RT112s cells transduced with the scrambled
gRNA vector. In the SW780 cell line, the most common indel in CRISPR-edited
fusions sequences was a deletion of a cytosine occurring in 40% of edited reads.
The second most common indel was an extra cytosine insertion and the third
most common was a 13-base deletion spanning the fusion point. In RT112 cell
line, the most common indel was an insertion of a cytosine in 13% of reads.
Sanger sequencing of the fusion sequences from SW780 single cell clones con-
fırmedMiseq results. Experiments determining the effects of these indels on the
function of the fusion protein and on the cancer phenotype are ongoing. Con-
clusions: To our knowledge, this is the fırst report of CRISPR/Cas9 use as a
therapeutic strategy for targeting oncogenic fusions. Because the fusion se-
quences are unique to cancer cells, this approach can be potentially used for
in-vivo gene therapy for urothelial carcinomas harboring FGFR3 fusions with
no off-target edits in normal cells. This approach represents a signifıcant ad-
vance towards precision gene-therapy by specifıcally targeting fusions se-
quences unique to each patient’s cancer.We envision extending this approach to
several solid and hematological malignancies driven by oncogenic fusions.
#5095 Development of a pharmacodynamic biomarker assay for
AZD4785, an antisense oligonucleotide targeting KRAS. Claire Rooney,1
Sarah Ross,1 Anna Staniszewska,1 Sabine Lennarz,1 Elaine Kilgour,1 Alexey S.
Revenko,2 A. Robert Macleod,2 Andrew Pierce,1 Paul D. Lyne,1 J. Carl Barrett,3
Elizabeth A. Harrington1. 1AstraZeneca, Cambridge, United Kingdom; 2Ionis
Pharmaceuticals, Carlsbad, CA; 3AstraZeneca, Waltham, MA.
AZD4785 is a potent and selective high affınity 2’-4’ constrained ethyl resi-
dues (cEt) containing therapeutic antisense oligonucleotide (ASO) targeting
KRAS. In a patient-derived explant model of non-small cell lung cancer
(NSCLC) carrying a KRAS G12C mutation systemic dosing of AZD4785 re-
sulted in tumor regression. To determine the level of KRASmRNA knockdown
achieved by AZD4785 at a dose which causes regression (250mg/kg/wk), tumor
samples were collected and analyzed by RT-PCR. Mean levels of KRAS mRNA
knockdown relative to the PBS control group were determined to be 61% and
78% from studies dosed for 2 and 4 weeks, respectively. However, by RT-PCR
there was signifıcant variability in KRAS mRNA levels within the PBS control
group, and level of knockdown variedwith different housekeeper normalization
genes. In early clinical studies it will be essential to measure KRAS expression in
tumor samples as a pharmacodynamicmarker forAZD4785, hencewe sought to
develop a more robust assay compatible with FFPE clinical samples with low
RNA yields. KRAS mRNA levels were quantifıed by the nanoString platform,
using the panCancer pathways 770 gene codeset. This assay generated robust
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data from RNA extracted from 2 x 5m sections of FFPE material from each
sample, despite very limited yields of RNA. AZD4785 treatment resulted in
comparable levels of KRAS knockdown to the RT-PCR assay, but assay variabil-
ity was greatly reduced, from stdev50% (RT-PCR) to 5% (nanoString) for PBS
control group samples. Using the nanoString assay, mean KRASmRNA knock-
down was 52% and 68% (p0.005). We also analyzed the effect of AZD4785
treatment on the wider 770 gene panel. Further evidence of KRAS mRNA
knockdownwas observed through signifıcant downregulation of transcriptional
targets of KRAS signalling (FOSL1, DUSP5, DUSP6) relative to the PBS control
group. Neither HRAS nor NRAS levels were affected by AZD4785 treatment.
This nanoString assaywas applied to a panel of 50 clinical FFPENSCLC samples
and KRAS mRNA was detected above baseline in all samples. Furthermore the
intrapatient variability of the KRASmRNA signal was tested in sections50m
apart within four NSCLC tissues and was found to be 21%. Taken together,
these data validate the use of the KRAS nanoString assay for use in clinical FFPE
tissues, and demonstrate the level of knockdown of KRASmRNA to be50% at
a dose of AZD4785 that causes regression in a preclinical PDX model.
#5096 Targeted ablation of essential oncogenes in rhabdomyosarcoma
with CRISPR/Cas9 gene therapy. Michael Phelps, Heechang Yang, Eleanor
Chen. University of Washington, Seattle, WA.
Targeted therapy seeks to exploit unique vulnerabilities in cancer cells not
present in normal tissue. The development of effective therapies targeting essen-
tial tumor proteins has had signifıcant challenges particularly for tumor onco-
genesmany of which have proven “undruggable”. Targeting these critical tumor
oncogenes has been one of the foremost challenges in cancer research. Current
sequencing technology facilitates rapid identifıcation of novel cancer mutations
yet there are no effective therapeutic strategies aimed at targeting essential can-
cer genes at the genome level. To overcome the challenges associated with tar-
geting “undruggable” cancer proteins, we have employed high effıciency
CRISPR/Cas9 genome editing technology to destroy cancer cells by directly
targeting the genomic DNA of essential cancer genes. We used pediatric rhab-
domyosarcoma to demonstrate the potential of CRISPR/Cas9 gene therapy in
solid tumor preclinical xenograft mouse models. Rhabdomyosarcoma is an ag-
gressive pediatric sarcoma characterized bymyogenic differentiation arrest. The
two major subtypes of rhabdomyosarcoma (RMS), embryonal (ERMS) and al-
veolar (ARMS) are defıned largely by either activation of the RAS pathway
(ERMS) or the presence of a fusion oncogene between PAX3 and FOXO1
(ARMS). CRISPR/Cas9 was fırst used to target critical exons in the activated
RAS or PAX3/FOXO1 oncogenes unique to each RMS subtype, using inducible
or viral CRISPR delivery systems. Targeting these essential genes resulted in
signifıcant regression of tumor xenografts due to a combination of cell death and
differentiation. By precisely targeting the activatingmutations in the RAS onco-
gene or the fusion site in the PAX3/FOXO1 fusion gene we further demonstrate
that tumor-specifıc CRISPR/Cas9-mediated gene therapy can also be achieved.
This strategy disrupts the essential cancer oncogenes with minimal impact to
normal cells that do not harbor the unique cancer mutations. Our results high-
light the utility of exploiting essential cancer genetic mutations for personalized
therapy. This novel approach to cancer therapy provides a potential alternative
strategy for targeting “undruggable” oncogenes while establishing a foundation
for further development of CRISPR/Cas9 gene therapy for cancer treatment.
#5097 An industrial method of manufacturing a novel RNAi anticancer
drug, DFP-10825, for the treatment of peritoneal disseminated gastric can-
cer. Tatsuhiro Ishida,1 Hidenori Ando,1 Masakazu Fukushima,2 Cheng-Long
Huang,3 Hiromi Wada3. 1Tokushima University, Tokushima, Japan; 2Delta-Fly
Pharma, Inc., Tokushima, Japan; 3Kyoto University, Kyoto, Japan.
We have developed an RNAi based anticancer drug, DFP-10825 [a cationic
liposome and short-hairpin RNAi molecule for thymidylate synthase (TS
shRNA)] and here established an industrial method of manufacturing the for-
mulation. The therapeutic effıcacy of theDFP-10825was examined in aMKN45
human gastric carcinoma xenograft mousemodel (peritoneal disseminated gas-
tric cancermodel). Themicewere received intraperitoneal injectionwith 5 doses
of DFP-10825 or control formulation (short-hairpin RNA for luciferase) (1 mg
shRNA/kg/day) once every 3 days. The treatment with DFP-10825 obviously
prolonged survival time of the mice compared to control formulation and sig-
nifıcantly suppressed the target mRNA level in the peritoneal disseminated tu-
mors. We recently reported that DFP-10825 showed a signifıcant therapeutic
effıciency in the human malignant pleural mesothelioma orthotopic xenograft
model. Accordingly, DFP-10825 may lead a clinical benefıt to patients with
pulmonary malignant mesothelioma or disseminated peritoneal tumor. In ad-
dition, we established an industrial method of manufacturing DFP-10825,
which provides a large scale preparation. Water solution of TS shRNA was
gently mixed at an optimal ratio with ethanol solution of cationic lipids, com-
posed of DC-6-14 (a cationic lipid), DOPE and DOPC. Then, the mixture was
lyophilized under optimal condition. The freeze-dried cake provided a ready for
injection formulation by a one-step hydration with saline. Physicochemical
properties of the obtained DFP-10825 such as particle size, zeta-potential, and
size distribution were almost comparable with those of conventionally prepared
DFP-10825, which prepared with conventional preparation method, mixing TS
shRNA solution and cationic liposomes. Our fındings in this study demonstrate
that intraperitoneal chemotherapy with a simple freeze-dried RNAi medicine,
DFP-10825, showing an equivalent pharmaceutical and therapeutic potency
with conventionally prepared DFP-10825, meets a criteria to use for clinical
settings and will have a clinical benefıt to treat patients with disseminated peri-
toneal and pulmonary cancers.
#5098 NG-348: a novel oncolytic virus designed to mediate anti-tumour
activity via the potent and selective polyclonal activation of tumor-infıltrat-
ing T-cells. Brian R. Champion, Matthieu Besneux, Nalini Marino, Darren
Plumb, Prithvi Kodialbail, Sam Illingworth, Rochelle Lear, Alice C. Brown.
PsiOxus Therapeutics Ltd, Abingdon, United Kingdom.
NG-348 is a transgene-modifıed variant of enadenotucirev, a chimeric
oncolytic group B adenovirus with potent and selective anti-tumor activity
against a range of epithelial cancer cells. Enadenotucirev has a blood stability
profıle that enables systemic dosing and has been administered intrave-
nously to over 90 cancer patients. These studies have demonstrated that IV
dosed enadenotucirev is delivered to tumors and subsequent virus activity is
associated with CD8 T-cell infıltration in tumor cell nests, consistent with
immune stimulation within the tumor. NG-348 encodes two immunomodu-
latory proteins in its genome: full-length human CD80, and a membrane
anchored single chain variable fragment of the mouse anti-human CD3
monoclonal antibody OKT3. Together these membrane proteins provide
both T-cell receptor (signal 1) and costimulatory (signal 2) activation signals
required to polyclonally activate tumor-infıltrating T-cells. When expressed
on the surface of NG-348 infected tumor cells the transgenes therefore en-
hance the potency of the virus by driving local T-cell immune responses
selectively in the tumor microenvironment. The expression of both trans-
genes encoded in the NG-348 virus is controlled by the endogenous virus
major late promoter. This restricts expression of the proteins to the surface
of cells permissive to virus infection (i.e. tumor cells) and prevents off-target
expression in the cells from healthy tissues. Using co-cultures of human
T-cells with human tumor cell lines, we have shown that NG-348 infected
tumor cells potently activate both CD4 and CD8 T-cells. This was demon-
strated by analysis of activation marker expression (CD25, CD69), intracel-
lular and secreted cytokines (IL-2, TNF, IFN) and induction of T-cell me-
diated tumor cell death by apoptosis (prior to oncolytic death by the virus).
Treatment of different human non-tumor cells (e.g. fıbroblasts, T-cells, PB-
MCs) with NG-348 did not lead to transgene protein expression or activation
of T-cells in co-cultures. NG-348 has also been shown to activate human
T-cells in vivo, using a human tumor xenograft model system in immuno-
defıcient mice reconstituted with human PBMCs. Collectively these data
indicate that following delivery to tumor tissues of patients, NG-348 onco-
lytic virus can selectively replicate and express it’s payload of T-cell activat-
ing ligands. NG-348 should therefore stimulate potent antigen-indepen-
dent, polyclonal activation of T-cells already present in the tumor, as well as
those recruited into the tumor in response to the virus infection, to drive
effective anti-tumor immunity. NG-348 is currently in preclinical develop-
ment with a fırst phase I study planned to initiate in Q4 2017.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Novel
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#5099 Development of novel antimetabolite, DFP-11207, with self-toxic-
ity protection and its promising preclinical and clinical profıles. Masakazu
Fukushima,1 Kenzo Iizuka,1 Kokoro Eshima,1 Chung Zhang,1 Cheng Jin,1 Ki-
yoshi Eshima,1 Jaffer Ajani2. 1Delta-Fly Pharma, Inc., Tokushima, Japan; 2Uni-
versity of Texas, Houston, TX.
Background: For over 50 years, 5-fluorouracil (5-FU) has played a critical role in
the systemic chemotherapy of various gastrointestinal cancers including gastric,
colorectal and pancreatic cancer which are the leading causes of cancer death glob-
ally. Although systemic cytotoxics such as 5-FU can modestly prolong overall sur-
vival in the adjuvant and advanced settings, but at the cost of unpleasant toxicities.
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Therefore better drug formulations are desirable. Methods: To this end, we devel-
oped a new conceptual fluoropyrimidine, DFP-11207 that is engineered to reduce
toxicity without loss of antitumor activity as well in addition to providing sustained
concentrations of the active anticancer moiety. DFP-11207 contains three compo-
nents in one formulation: 1-ethoxymethyl-5-fluorouracil (EM-FU) as a prodrug of
5-FU, 5-chloro-2,4-dihyroxypyridine (CDHP) as a potent inhibitor of 5-FU degra-
dation and cytrazinic acid (CTA) as a gastrointestinal regulator of 5-FU phosphor-
ylation. Results: In in vitrometabolism studies using cell-free extracts from plasma,
liver and tumors or intact tumor cells, DFP-11207 was rapidly hydrolyzed to 3
components and subsequently EM-FU was specifıcally converted to 5-FU by liver
microsomes, and CDHP and CTA strongly inhibited 5-FU degradation and phos-
phorylation, respectively. Following consecutive oral administration to human tu-
mor-bearing nude rats, DFP-11207 attained favorable antitumor effıcacy and long-
sustained PK profıles with lack of GI- andmyelo-toxicities. Next, in investigational
clinical study inpatientswith solid tumors, 12patientswere treated at 8 uniquedose
levels ofDFP-11207, ranging from40 to 440mg/m2/day by each 1 pt.MTDandRD
of daily and 28-day consecutive DFP-11207 was found to be 440 (n2) and 330
mg/m
2
(n6), respectively. The main AEs were nausea,, anemia, neutropenia, fe-
brile neutropenia but these events were very mild, and no thrombocytopenia was
observed as expected. Furthermore, review of the preliminary PK data, DFP-11207
at330mg/m2 resulted inadesirable lowbut effıcacious (15-30ng/ml) steady-state
plasma concentration of 5-FU. Interestingly, some of patients heavily treated with
therapeutic drugs had a stable-disease for long periods. Conclusion:Our preclinical
and early clinical data with DFP-11207 suggest that it’s a promising compound for
the treatment of gastrointestinal cancers and can overcome the shortcomings of all
other oral fluoropyrimidines.
#5100 AB61, a new potent nucleoside cytostatic: Molecular mechanisms
of action and preclinical activity. Petr Dzubak,1 Marian Hajduch,1 Pavla Per-
likova,2 Gabriela Rylová,1 Petr Naus,2 Tomas Elbert,2 Eva Tloustova,2 Aurelie
Bourderioux,2 Lenka Slavetinska,2 Kamil Motyka,3 Dalibor Dolezal,1 Pawel
Znojek,1 Alice Nova,1 Monika Harvanova,1 Michal Siler,1 Jan Hlavac,1 Michal
Hocek2. 1Palacky University in Olomouc, Faculty of Medicine and Dentistry,
Olomouc, Czech Republic; 2Institute of Organic Chemistry and Biochemistry of
the CAS, Prague, Czech Republic; 3Palacky University in Olomouc, Faculty of
Natural Sciences, Olomouc, Czech Republic.
7-(2-Thienyl)-7-deazaadenosine (AB61) showed nanomolar cytotoxic activities
against variouscancercell linesbutonlymild (micromolar) activities againstnormal
fıbroblasts. The selectivity of AB61 was found to be due to ineffıcient phosphoryla-
tion of AB61 in normal fıbroblasts. The phosphorylation of AB61 in the leukemic
CCRF-CEMcell line proceedswell and it was shown thatAB61 is incorporated into
both DNA and RNA, preferentially as a ribonucleotide. It was further confırmed
that a triphosphate of AB61 is a substrate for both RNA and DNA polymerases in
enzymatic assays.Gene expression analysis suggests thatAB61affectsDNAdamage
pathways andprotein translation/foldingmachinery. Indeed, the formation of large
53BP1 foci was observed in nuclei of AB61-treatedU2OS-GFP-53BP1 cells indicat-
ingDNAdamage.Random incorporationofAB61 intoRNAblocked its translation
inan invitroassayandreductionof reporterproteinexpressionwasalsoobserved in
mice after 4-hour treatment withAB61. AB61 also signifıcantly reduced tumor vol-
ume inmice bearing SK-OV-3, BT-549, HT-29 andMDA-MB231 xenografts. The
results indicate that AB61 is a promising compoundwith the uniquemechanismof
action and deserves further development as an anticancer agent. This work was
supported by theMinistry of Education of the Czech Republic (LO1304).
#5101 Defıning exposure-PD and effıcacy relationships with the novel
liver-targeting nucleotide prodrug MIV-818 for the treatment of liver can-
cers. Mark Albertella,1 Biljana Rizoska,1 Alastair Kyle,2 Andrew Minchinton,2
Annelie Linqvist,1 Sanja Juric,1 Susanne Sedig,1KarinTunblad,1 FredrikÖberg,1
Björn Classon,1 Anders Eneroth,1 John Öhd,1 Richard Bethell1. 1Medivir AB,
Huddinge, Sweden; 2Cabenda, Vancouver, British Columbia, Canada.
Background: Many systemic chemotherapeutics have failed to show effıcacy
in hepatocellular carcinoma (HCC), often because systemic toxicity prevents
effıcacious liver levels of the drug from being reached. MIV-818, a nucleotide
prodrug of troxacitabine-monophosphate (TRX-MP) has been designed as a
novel approach to deliver high levels of the chain-terminating nucleotide trox-
acitabine-triphosphate (TRX-TP) to the liver after oral dosingwhileminimizing
systemic exposure. We investigated MIV-818 and troxacitabine using in vivo
models in order to identify therapeutic levels of TRX-TP required in the tumors.
Methods: MIV-818 or troxacitabine were administered to nude mice with sub-
cutaneous Hep3B or Huh7 xenografts. LC-MS/MS was used to assess MIV-818
and its metabolites. Effects on tumor growth, plasma AFP, inhibition of prolif-
eration and induction of DNA damage were examined and correlated with ex-
posures to TRX-TP in the tumor. Quantitative immuno-fluorescent histology
was used to assess DNA damage (pH2AX) proliferation (BrdU), and hypoxia
(pimonidazole). Results: Compared to the parent nucleoside troxacitabine,
MIV-818 has increased potency of inhibition of HCC cell line growth, increased
conversion to its activemetabolite TRX-TP and in vitro properties optimized for
oral bioavailability and liver targeting, including permeability and intestinal
stability. MIV-818 also shows strong synergistic anti-proliferative activity with
sorafenib in a number of HCC cell lines in vitro. Pronounced tumor growth
inhibition of 70-100% and extensive tumor growth delays of up to 26 days were
observed in the Hep3B xenograft model following a fıve day period of dosing.
12-32-fold induction of DNA damage was seen throughout the tumor sections,
consistent with the expected mechanism of action, and with associated inhibi-
tion of proliferation. Clear PD responses were apparent even in hypoxic regions
of the tumor, indicating effective distribution of TRX-TP even far from blood
vessels. DNA damage persisted for up to 7 days after the fınal dose, demonstrat-
ing long-lasting effects and indicating that intermittent dosing is likely to be
effective. Similar dosing regimens given to Huh7 xenograft models resulted in
signifıcant tumor growth inhibition and induction of DNA damage. Intratu-
moral TRX-TP exposures across both models were correlated with anti-tumor
effects including DNA damage induction, proliferation inhibition and tumor
growth inhibition. Conclusions:Wehave identifıedTRX-TP exposures required
for pronounced anti-tumor effects to give a comprehensive understanding of
PK-PD-effıcacy relationships for the active metabolite of MIV-818. These data
could be used to guide dosing and dose selection in clinical studies. MIV-818 is
currently in preclinical development in preparation for the initiation of clinical
trials in patients with advanced HCC and other liver cancers.
#5102 TRXE-009-1 has pan-acting anticancer activity and potently inhib-
its colony formation of prostate cancer epithelial cell explants. Eleanor I.
Ager,1 Dominika Butler,2 Alex Stevenson,3 Eiffe Eiffe,1 Andrew Heaton,1 Brian
Gabrielli,3 Norman J. Maitland,2 David Brown1. 1Novogen, Hornsby, Australia;
2University of York, York, United Kingdom; 3University of Queensland, Wool-
loongabba, Australia.
Background: TRXE-009-1 is a novel small molecule from the super benzopy-
ran (SBP) drug family under development as an intravenous cytotoxic agent.
Cantrixil (TRXE-002-1), our lead SBP candidate targeting ovarian cancer, re-
cently achieved Investigational NewDrug (IND) status and is undergoing safety
assessment in a multi-center Phase I clinical trial. Our aim was to investigate
pathways associated with response to TRXE-009-1 and identify cancer types for
clinical translation. Methods: Eurofıns Oncopanel240 with multiplex analysis
and bioinformatic assessment was used to identify cytotoxic and pathway re-
sponse across a panel of cancer types. Western blot and live cell imaging were
used to investigate protein levels and cell cycle progression. Results: TRXE-
009-1 demonstrated broad cytotoxic activity across a large panel of cell lines and
was particularly active against kidney (RCC), liver (HCC), head andneck cancer,
lung cancer, sarcoma, prostate cancer, osteosarcoma, and neuroblastoma. Fur-
ther, TRXE-009-1 combined synergistically with two targeted agents used ex-
tensively in the clinical treatment of RCC patients. Cleaved caspase 3/7 and
G2/M arrest were strongly associated with TRXE-009-1 activity. Live imaging
confırmed G2/M arrest and implicated cytoskeleton disruption in TRXE-009-1
induced cell death. When compared to 43 reference oncology compounds,
TRXE-009-1 clustered with a known epigenetic modifıer. Additional analysis
indicated that, compared to the least sensitive lines, themost sensitive cancer cell
lines were more likely to be positive for LIN28B, a stemness marker associated
with aggressive cancers. This is in line with historical studies suggesting that
SBPs may preferentially target cancer-stem like cells. Using a panel of prostate
cancer epithelial explants in a colony forming assay, we confırmed strong activ-
ity against colony-initiating cells. Studies are current to confırm protein changes
associatedwith SBP activity and to further investigate the impact of TRXE-009-1
on the cytoskeleton. In vivo studies previously established activity of TRXE-
009-1 against melanoma, prostate, and brain cancer and additional studies are
current to optimize the delivery formulation to be used in preclinical safety
studies prior to clinical progression. Conclusion: Given that cancer stem-like
cells are typically more chemoresistant and are thought to support tumor recur-
rence, the activity of TRXE-009-1 against this subpopulation of cancer cells
makes it a particularly promising candidate for further development.
#5103 Development ofMJ-66 as anovel anticancer agent for the treatment
of malignant gliomas.Mann-Jen Hour,1 Tai-Lin Chen,1 Po-Wu Gean,2 Hong-
Zin Lee1. 1School of Pharmacy, China Medical University, Taichung, Taiwan;
2Department of Pharmacology, College of Medicine, National Cheng-Kung Uni-
versity, Tainan, Taiwan.
Malignant glioma is the most common aggressive adult primary tumor of the
central nervous system. Treatments of malignant gliomas include surgery, ra-
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diotherapy and adjuvant temozolomide (TMZ) chemotherapy.However, inher-
ent- and acquired resistance to TMZ present major obstacles to successful treat-
ment, and the prognosis of patients with malignant gliomas remains very poor.
MJ-66, a synthetic qunazoline compound, was identifıed in our study as a potent
anti-proliferative agent especially on human glioma with IC50 of approximately
60 nM. In intracranial glioma xenograftmodel,MJ-66 (0.14mg/kg in saline, i.p.,
q.d., 10 days) signifıcantly inhibited tumor growth and increased the survival of
the experimental mice, however, did not decrease the body weight of mice.
Currently, there is a profound unmet medical need for a new drug in the treat-
ment of malignant brain tumor. The MJ-66 demonstrated superior effıcacy to
TMZ that are the only fırst-line-drug in clinical use. MJ-66 is suggested to be a
promising anticancer candidate.
#5104 A novel N-mustard-quinoline conjugate is a potent agent against
colorectal cancer. Tai-Lin Chen,1 Yan-Bo Chen,2 Chia-Ning Shen,2 Tsann-
Long Su,3 Te-Chang Lee3. 1Institute of Biomedical Sciences, Academia Sinica and
Institute of Biochemistry andMolecular Biology, National Yang-MingUniversity,
Taipei, Taiwan; 2Genomics Research Center, Academia Sinica, Taipei, Taiwan;
3Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Colorectal cancer (CRC) is the third leading cancerworldwide. The prognosis
of patients diagnosed with CRC at the stage IV is poor with a 5-year survival rate
less than 10%. Combination chemotherapy with platinum-based drugs and
5-fluorouracil (5-FU) remains the fırst line treatment, while the chemotherapy
combined target therapeutic agents were decreasing the mortality of CRC pa-
tients. However, the effıcacy of platinum-based drugs has often been limited
because of the substantial risk for severe toxicities, including nephrotoxicity or
neurotoxicity. Therefore, there is an unmet need to develop a novel drug for
improving the treatment of advance colorectal cancer. We have previously de-
signed and synthesized several series of DNA-directed alkylating agents with
potent antitumor activity. Recently, one derivative ofN-mustard-quinoline con-
jugates with hydrazinecarboxamide as a linker, designated as SL-1, was selected
to explore its anti-colorectal cancer (CRC) activity because it was highly cyto-
toxic to a panel of CRCcell lines in culture. Flow cytometric analysis showed that
treatment of CRC cells with SL-1 induced G2/M arrest and triggered apoptosis.
We further demonstrated that SL-1 preferentially targeted on the selective gua-
nine sequence by sequencing gel electrophoresis. By the aid of comet assay, SL-1
in combinationwith 5-FU resulted in increasedDNA tailmoments and induced
more DNA damage. Evaluation of the potency of antitumor activity both in
culture and in xenograft models, we observed that SL-1 was more potent than
5-FU and oxaliplatin against SW620, RKO and RKO-E6 (an oxaliplatin resis-
tant-subline) cells. Notable, SL-15-FU were more effıcacious than oxalipa-
tin5-FU in suppression the growth of RKOor SW620 in xenograftmodels.We
further found that SL-1 enhanced 5-FU and induced more apoptosis by
c-caspase 3 andTUNNEL staining. Additionally, histopathological examination
showed that SL-1 by itself has no obvious kidney and liver toxicity in ICR mice
comparing to cisplatin, oxaliplatin or 5-FU. Taken together, SL-1 alone or in
combination with 5-FU may warrant our further development as a potential
antitumor agent for the treatment of CRC patients.
#5105 Structure-activity relationship study of pyrrolo[2,3-d]pyrimidines
as microtubule targeting antitumor agents. Aleem Gangjee,1 Tasdique M.
Quadery,1 Susan L. Mooberry2. 1Duquesne University, Pittsburgh, PA; 2Univer-
sity of Texas Health Science center at San Antonio, San Antonio, TX.
Microtubules are cytoskeletonprotein polymers composed of	ß-tubulin het-
erodimers which play pivotal roles in cell division, cellular transport and cell
signaling. Interfering with microtubule dynamics is a well-established strategy
for the treatment of cancer. However, clinical utility of microtubule targeting
agents (MTAs) in cancer chemotherapy is often limited by the emergence of
drug resistance. Expression of P-glycoprotein (Pgp) or the III isotype of tubu-
lin, are two clinically established drug resistance mechanisms. We previously
reported that compound AG346 binds to the colchicine site of tubulin and has
microtubule depolymerization activity in A-10 cells (EC50 365 nM). Molecu-
larmodeling anddocking studies of this compound in theX-ray crystal structure
of tubulin (PDB: 402B) suggested that the pyrrole NH can be substituted with
alkyl chains of optimal length to obtain an altered binding conformation which
can facilitate interaction with the hydrophobic pocket formed by amino acid
Val181 of side chainA, and Lys352 andThr314 of side chain B.We designed and
synthesized a variety of pyrrole NH-alkyl substituted compounds and deter-
mined that the compoundAG473 shows a 43-fold improvedmicrotubule depo-
lymerization potency (EC50  8.4 nM) in A-10 cells, compared to the lead
compound. In addition, this compound inhibited the growth of human mela-
noma cancer cell line MDA-MB-435 in culture with an IC50 of 7.2 nM, which is
a 5-fold improvement in potency over the parent compound. These analogs also
circumvented resistance mediated by Pgp and III-tubulin. These attributes
provide the impetus for further preclinical development of these compounds as
microtubule targeted antitumor agents in vivo and these studies are currently
underway.
#5106 In vitro and in vivo evaluation ofWAC-224, a novel quinolone class
of topoisomerase II inhibitor for cancer therapy. Taichi Ueshima, Tomonori
Yamaguchi, Kenji Itoh, Naoki Kashimoto, Tatsuya Hirano, Rumiko Shimabara,
Yohei Kawakubo, Masayuki Sato, Junpei Yamashita, Akira Yazaki, Koichi Ta-
mura.Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan.
Introduction: DNA topoisomerases (Topo) are classical but still attractive
targets for drug therapy in multiple types of cancers. Topo inhibitors, such as
Etoposide and Daunorubicin, have been effectively used; however, their clinical
use is often limited by drug resistance in cancer cell population. Therefore, the
development of a novel chemical class of Topo inhibitors has been desired to
overcome drug resistance. Recently, Vosaroxin (QINPREZO) is identifıed as a
fırst-in-class anti-cancer quinolone derivative targeting Topo II, which is under
development for relapsed or refractory acute myeloid leukemia (AML). In this
study, we evaluated the in vitro and in vivo activities of WAC-224, a novel
quinolone derivative for Topo II inhibition, for various cancer cell lines includ-
ing multi-drug resistant cells and in mouse xenograft models, respectively. Ma-
terials andMethods: In vitro anti-proliferative activities against over 20 cell lines
were determined usingWST cell proliferation reagent. Apoptosis wasmeasured
by Annexin-V staining. In vivo anti-tumor activity was determined in immuno-
defıcient mice bearing multi-drug resistant human uterine sarcoma MES-SA/
DX5. Results: WAC-224 accomplished extensive anti-proliferative activities for
cancer cell lines includingmulti-drug resistant oneswith the EC50 range of 0.001
to 1 microM. Especially, in MV4-11 AML cell line, WAC-224 showed a potent
and superior anti-proliferative activity compared with Doxorubicin (EC50: 1.4
nM for WAC-224 v.s. 2.5 nM for Doxorubicin). Molecular and cellular mecha-
nisms of WAC-224 were defıned as inhibition of human Topo II, induction of
G2/M phase cell cycle arrest and apoptosis. Additionally, signifıcant antitumor
effects of WAC-224 were confırmed in mouse xenograft models. Furthermore,
WAC-224 showed no toxic effect on small intestinal crypts inmice. Conclusion:
This study demonstrated that WAC-224 has strong in vitro activities against
broad cancer cell types alongwith the potent in vivo effıcacy andwell tolerability,
without gastrointestinal toxicity. These results indicate that WAC-224 is prom-
ised to provide a new therapeutic option for various cancers including multi-
drug resistant and hematological ones.
#5107 Fisetin treatment reduces tumor growth and metastasis by modu-
lating PI3K/AKT and MEK/ERK pathways in a BRAFV600E/PTENNULL
mouse model of melanoma. Harish C. Pal, Mary Katherine Montes de Oca,
Pooja Sharma, Ross L. Pearlman, Farrukh Afaq. University of Alabama at Bir-
mingham, Birmingham, AL.
Melanoma is the deadliest form of skin cancer due to its propensity to metas-
tasize. It accounts for about 80% of skin cancer-related deaths. A substitution of
valine for glutamic acid at position 600 results in the BRAFV600Emutation found
in approximately 50%ofmelanomas. TheBRAFV600Emutation drives activation
of MEK/ERK signaling and also cooperates with the PI3K/AKT pathway, thus
enhancing tumor initiation, progression,metastasis, and drug resistance. Fisetin
(3,3=,4=,7-tetrahydroxyflavone), a naturally occurring flavonoid found in fruits,
vegetables, nuts, and wine, exhibits anti-proliferative, anti-invasive, and anti-
tumorigenic properties. Earlier, we showed that fısetin treatment downregulates
the PI3K/AKT pathway and reduces phosphorylation of MEK/ERK in mela-
noma. In this study we determined the effects of fısetin on tumor growth and
metastasis in a genetically engineered transgenic mouse model of metastatic
melanoma. Melanocyte specifıc Cre activity was induced in six-week-old
BRAFV600E/PTENNull/CreTg mice by topical application of 4-hydroxytamoxifen
on shaved backs once per day for 3 consecutive days. Mice were observed daily
until a highly pigmented measurable tumor appeared. Size of the tumors was
measured twice weekly and treatment with fısetin (45mg/kg b.wt. & 90mg/kg
b.wt.; orally 5 times/week) was started when tumor size reached 100mm3. Mea-
surement and quantifıcation of tumor volume showed that fısetin administra-
tion inhibitedmelanomagrowth in thesemice as compared to the control group.
Hematoxylin and eosin staining revealed that fısetin treatment reduced pig-
mented cells in the ear and skin. In addition, fısetin treatment reduced the
metastasis of melanoma cells into the spleen and draining lymph nodes. Fur-
thermore, evaluation of tumor tissues revealed that fısetin treatment reduced the
(i) expression of PI3Kp110	 and p85, (ii) phosphorylation of AKT at Ser473 and
Thr308, (iii) phosphorylation of mTOR at Ser2481, and (iv) expression of raptor
and rictor. In addition, fısetin treatment reduced the phosphorylation of MEK
and ERK when compared to control tumor samples. Fisetin treatment also re-
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sulted in (i) cleavage of caspase-3, (ii) inhibition of Bcl2 and Bcl-xL, (iii) induc-
tion of Bax, and (iv) inhibition of PCNA and Ki67 expression. Further, fısetin
treatment reduced the expression ofmesenchymalmarker proteins (N-cadherin
and vimentin) with concomitant increase in epithelial marker proteins (E-cad-
herin and desmoglein). These data suggest the ability of fısetin to exhibit anti-
proliferative, pro-apoptotic, anti-tumorigenic, and anti-metastatic potentials in
a mouse model of melanoma. We suggest that fısetin could be used as an adju-
vant chemotherapy to prevent drug resistance and improve the therapeutic ef-
fıcacy of anti-melanoma drugs for the management of melanoma.
#5108 Potent small molecule compounds that selectively inhibit prolifer-
ation of ABC-DLBCL cell lines. Leena Khare Satyam,1 Dinesh Chikkanna,1
Vinayak Khairnar,1 Manoj Pothuganti,1 Sunil Panigrahi,1 Anirudha Lakshmi-
narasimhan,1 Narasimha Rao,1 Wesley Balasubramanian,1 Sandeep Patil,1 Sre-
evalsam Gopinath,1 Gunta Upendra,1 Jwala Nagaraj,1 Kiran Aithal,1 Vijay
Ahuja,2 SanjeevGiri,2 ChetanPandit,1Murali Ramachandra1. 1AurigeneDiscov-
ery Technologies Ltd., Bangalore, India; 2Aurigene Discovery Technologies Ltd.,
Hyderabad, India.
Diffuse large B cell lymphoma (DLBCL), which accounts for 25% of all lym-
phomas cases, has been classifıed into molecular subtypes including germinal
center B cell like (GCB) DLBCL, activated B cell-like (ABC) DLBCL, and pri-
mary mediastinal B cell lymphoma (PMBL). Among these subtypes, patients
with ABC-DLBCLs have the worst prognosis because of the high chemo-resis-
tance, and require effective therapies. Mucosa-Associated Lymphoid Tissue
Lymphoma Translocation 1 (MALT1) protease activity is linked to the patho-
genesis of ABC-DLBCL. Therefore, a focused library of covalent compounds
selected based on molecular docking on the reported crystal structure was
screened for selective sensitivity to ABC-DLBCL, but not GCB-DLBCL cell
lines. Optimization of initial hits resulted in the identifıcation of lead com-
pounds with an anti-proliferative EC50 of100 nM selectively in ABC-DLBCL
cell lines. Consistentwith the previously reported role ofMALT1 inhibitors, lead
compounds also showed anti-proliferative activity in selected melanoma and
NSCLC cell lines. The anti-proliferative activity of the lead compounds corre-
latedwell with the inhibition IL-6, a downstreammarker ofMALT1 signaling, in
ABC-DLBCL cell line such as OCI-LY3. The lead compounds exhibited excel-
lent drug-like properties including solubility, metabolic stability, lack of CYP
inhibition, permeability and desired dose-dependent oral exposure in pharma-
cokinetic studies. In a repeated dose MTD study, the lead compounds showed
good tolerability with an exposure multiple of10 over cellular EC50 for up to
8 hours. The lead compounds showed dose-dependent tumor growth inhibition
in a xenograft model upon oral dosing. In summary, we have identifıed novel
and potent MALT1 inhibitors capable of selectively inhibiting proliferation of
DLBCL cell lines with optimized drug-like properties including oral bioavail-
ability. The data presented here strongly support further development of these
compounds for DLBCL and other indications.
#5109 Beyond malaria: Second career of artesunate as cancer drug.
Thomas A. Efferth. Johannes Gutenberg Univ. Mainz, Mainz, Germany.
More than a decade ago, we initiated a research program on the molecular
pharmacology of phytochemicals derived fromChinesemedicinal herbs. Bioac-
tive plant extracts have been fractionated by chromatographic techniques. We
isolated bioactive compounds and elucidated their chemical structures by nu-
clear magnetic resonance andmass spectrometry. A promising compounds was
artemisinin from Artemisia annua L. and its semisynthetic compound artesu-
nate. Artemisinin and artesunate are anti-malarial drugs. Our data indicated
profound activity against cancer cells, but also against various viruses, Schisto-
soma, Trypanosoma, and even plant crown gall tumors. To elucidate themolec-
ular mode of actions against cancer, we applied molecular biological and phar-
macogenomic approaches in vitro and in vivo. Different signaling pathways
were identifıed not only in cancer cells but also in cells infected with viruses, e.g.
HCMV, HSV1 and others. To translate the experimental results in cell lines and
animals to the bedside, we report on the compassionate use of artesunate in
single cancer patients aswell as on our efforts to initiate several clinical phase I/II
trials in veterinary tumors as well as in human cervix or colorectal carcinoma.
These pilot studies indeed indicate that artesunate is not only useful as antima-
larial drug, but also exerts activity against cancer and viral diseases. Clinical
results will also be presented that not only artesunate as semisynthetic chemical
derivative of artemisinin, but also herbal extracts from Artemisia annua are
active in veterinary and human tumor patients. Artesunate represents an illus-
trative example for the therapeutic potential of medicinal herbs and drugs de-
rived from traditional Chinese medicine. References 1. Efferth et al.: Journal of
Molecular Medicine 2002;80:233-42. 2. Efferth: Drug Resistance Updates 2005;
8:85-97. 3. Efferth et al.: Molecular Cancer Therapeutics 2008;7:152-61. 4. Li et
al.: Cancer Research 2008;68:4347-51. 5. Shapira et al.: Clinical Infectious Dis-
eases 2008;46:1455-7. 6. Efferth et al.: Clinical Infectious Diseases 2008;47:804-
11. 7. Krishna et al.: Ebiomedicine 2014;2:82-90. 8. Saeed et al.: Pharmacological
Research 2016;110:216-226.
#5110 Anovel nucleoside analog therapeutically active against plasma cell
malignancies and other ADK-expressing cancers including colon and pan-
creatic adenocarcinomas. Jouliana Sadek,1 Utthara Nayar,2 Jonathan Reichel,3
Jennifer Totonchy,4 Shizuko Sei,5 Robert Shoemaker,5 David Warren,1 Olivier
Elemento,1 Kenneth Kaye,6 Ethel Cesarman1. 1Weill Cornell Medicine, New
York, NY; 2Dana-Farber Institute, Boston, MA; 3Memorial Sloan Kettering Can-
cer Center, NewYork, NY; 4ChapmanUniversity, CA; 5National Cancer Institute,
Frederick, MD; 6Harvard Medical School, Boston, MA.
A number of nucleoside analogues are used successfully for the treatment of
several cancers, and in particular leukemias and lymphomas, but these have
distinct effıcacies for different tumor types, and many malignancies do not re-
spond to currently available nucleoside analogues or other forms of chemother-
apy. A high throughput screen conducted in our lab to search for inhibitors of
primary effusion lymphoma (PEL) identifıed the nucleoside analog 6-ethylth-
ioinosine (6-ETI) as a potent and selective inhibitor of PEL, a largely incurable
malignancy of B cell origin with plasmacytic differentiation. 6-ETI induced ne-
crosis and ATP-depletion accompanied by S-phase arrest, DNA damage and
inhibition of DNA synthesis. To understand 6-ETI mechanism of selectivity,
RNA-seq analysis of in vitro generated drug-resistant PEL clones revealed inac-
tivating mutations and loss of expression of adenosine kinase (ADK) as the
mechanism of resistance. In vitro assays showed that 6-ETI is a pro-drug that
gets phosphorylated and activated by adenosine kinase (ADK) into its active
form. We found high ADK expression in PEL cell lines and primary specimens
of PEL, multiple myeloma (MM) and plasmablastic lymphoma (PBL) patient
samples. 6-ETI was effective at killingmultiple myeloma cell lines, primaryMM
specimens, and had a remarkable anti-tumor response in a disseminated multi-
plemyeloma andPELxenograftmousemodels. Thus,ADKexpression can serve
as a predictive biomarker to help identify patients that aremost likely to respond
to 6-ETI treatment. To further assess the spectrum of activity and sensitivity of
6-ETI, we examined ADK expression in other cancer subtypes and found that
colorectal and pancreatic adenocarcinomas also overexpress ADK and are
highly sensitive to killing by 6-ETI at the low nanomolar concentration.We also
found high ADK expression in primary colon and pancreatic adenocarcinoma
patient specimens.We compared 6-ETI to other FDA-approved purine analogs
and failed to fınd other compounds with similar potency or selectivity profıle.
Herein, we report the identifıcation of a novel purine analog, 6-ethylthioinosine,
as an effective therapeutic with exquisite sensitivity to plasma cell malignancies
and other ADK-expressing cancers. We have successfully used RNASeq-based
“resistome” analysis to identify its mechanism of specifıcity and discovered a
new biomarker that can potentially impact patient care and the treatment of
some of the most aggressive tumors.
#5111 Norcantharidin impairs tumor growth in vivo and inhibits stem-
ness of triple-negative breast cancer cells.Damian E. Berardi, Guido Cicuttin,
Maria A. Taruselli, StefanoM. Cirigliano, Elisa D. Bal de Kier Joffé, Alejandro J.
Urtreger, Laura B. Todaro. Angel H. Roffo Inst. of Oncology, Buenos Aires, Ar-
gentina.
Triple-negative breast cancer (TNBC) is characterized by an abundance of
treatment-resistant cancer stem cells (CSC). The absence of a molecular target,
coupledwith its highly aggressiveness, leads to the lack of an effective therapy for
TNBC. Norcantharidin (NCTD) is a synthetic demethylated small-molecule
analog of the naturally occurring cantharidin isolated from blister beetles (My-
labris phalerata Pall). Unlike the conventional chemotherapeutics, NCTD tox-
icity is higher to cancer cells than normal ones, making this small molecule
promising for cancer treatment. The aims of this work were: A) To study the
effect of NCTD on 4T1 cell line proliferation in vitro. B) To analyze the effect of
NCTD on 4T1 derived CSC on self-renewal and clonogenic capacity. C) To
evaluate the effect of NCTD on 4T1 tumor growth in vivo. We employed the
well-known 4T1 triple-negative breast cancer cell model, which presents a huge
proportion of CSC.We observed that NCTD treatment during 96 h signifıcantly
reduced 4T1 cell proliferation in vitro. In addition, the IC50 value of NCTDwas
27.35 2.83 M. Related to CSC, NCTD pre-treatment for 96 h impaired CSC
self-renewal (Number of secondary mammospheres: Control: 27639; NCTD:
16318; p0.05) as well as the clonogenic capacity (Number of colonies: Con-
trol: 35938; NCTD: 12211; p0.05). By q-PCR, we observed that NCTD
treatment for 48 h signifıcantly induced an increase ofGli-1 and Smooth inCSC,
keys member of Sonic Hedgehog pathway. Finally, we performed an in vivo
assay, where 4T1 cells were orthotopically inoculated on mammary gland of
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BALB/c mice, and NCTD was i.p. inoculated twice a week (5mg/kg). We ob-
served that NCTD treatment signifıcantly reduced tumor growth in vivo. Our
data suggest that NCTD treatment reduces tumor growth both in vitro and in
vivo, possibly through the direct effect on CSC self-renewal and clonogenic
capacity, by modulating Sonic Hedgehog pathway.
#5112 Evaluation of FF-10502-01, a new pyrimidine nucleoside analogue,
in pancreatic (PANC) patient-derived xenograft (PDX)models compared to
gemcitabine and in combination with nab-paclitaxel. Takeaki Suzuki,1 Linda
J. Paradiso,2 Jill Ricono,3 Jonathan Nakashima,3 Yoshihide Iwaki,4 Shinji
Mima,4 Takayuki Yamada,4 Chihaya Kakinuma,4 Hiroyuki Iwamura,4 Shinichi
Watanabe4. 1FUJIFILM Pharmaceuticals, U.S.A., Inc., Cambridge, MA; 2Strate-
gia Therapeutics, Inc., Houston, TX; 3Crown Bioscience, San Diego, CA; 4FUJIF-
ILM Corporation, Tokyo, Japan.
Introduction: FF-10502-01 is a synthetic pyrimidine nucleoside analogue
structurally similar to gemwith a substitution of sulfur for oxygen in the pentose
sugar. In previous studies, FF-10502-01 demonstrated preclinical effıcacy across
multiple solid tumors, including PANCcancer. In this study, we investigated the
anti-tumor effect of FF-10502-01 in PANC PDX models. Methods: 10 PANC
PDX tumors were sourced from primary (2) or metastatic sites (8). 7 demon-
strated high resistance (HR) to gem, 1 intermediate, and 2 low. In the dose-
fınding study, 3 PDXmodels were studied in 9 grps of NOD-SCIDmice (n10/
grp), treated with 240 or 480 mg/kg FF-10502-01, 3 or 6 mg/kg nab-pac or 240
mg/kg gem, alone and in combination for 28d, followed by 28d observation. The
defınitive study consisted of 7 PDXmodels. 6 grps (n10/grp) were treatedwith
240 or 480 mg/kg FF-10502-01, 6 mg/kg nab-pac or 240 mg/kg gem, alone
and/or in combination for 28d, followedby 28dobservation.After subcutaneous
transplantation, animals were left undisturbed for 7d. Animals were monitored
weekly and tumor volume measured with calipers. Average tumor volume
(mm3) for each group at randomization into treatment grps ranged from
184.34 – 199.51 (SD  20.94 – 30.40). Statistical signifıcance was determined
using one-way ANOVA and Tukey’s test. Results: At clinically relevant doses,
FF-10502-01, alone and in combination with nab-pac demonstrated greater tu-
mor growth suppression than vehicle-treated animals (p0.0001). In 7 models,
FF-10502-01/nab-pac demonstrated higher tumor growth suppression than
gem/nab-pac (p0.5, p0.01 or p0.001), irrespective of resistance to gem. In
3 models, there was no difference, but these models were highly responsive to
gem/nab-pac, thus minimizing the effects of FF-10502-01/nab-pac. Despite sta-
tistical insignifıcance, FF-10502-01/nab-pac still demonstrated greater tumor
growth inhibitory activity to gem/nab-pac. InHRgemmodels, FF-10502-01was
superior to gem (p0.0001, p0.001, p0.05) in 3 of 7, and FF-10502-01/nab-
pac was superior to gem/nab-pac in 6 of 7 (p nab-pac (p0.0001, p0.0001,
p0.01, p0.05). FF-10502-01/nab-pac also was more tolerable than gemcit-
abine/nab-pac, as demonstrated by lessweight loss. Conclusions: FF-10502-01 is
a new pyrimidine nucleoside analogue with demonstrated preclinical effıcacy in
solid tumors, including PANC cancer. In PANC PDX models, FF-10502-01
alone and in combination with nab-pac demonstrated higher effıcacy and better
tolerability than gem alone or gem/nab-pac. FF-10502-01 is in Phase 1 clinical
development.
#5113 Usnic acid, lichen secondarymetabolite, inhibits glioblastoma pro-
gression through the reductionof epithelial-mesenchymal transition andgli-
oma stemness factors. Kyung-Hwa Lee, Se-Jeong Oh, Shin Jung, Kyung-Keun
Kim, Jae-Hyuk Lee, Kyung-Sub Moon. Chonnam National University Hwasun
Hospital & Medical School, Hwasun-gun, Republic of Korea.
Background: Usnic acid (UA), an active compound mainly found in lichens,
has shown some anti-tumoral activities for lung and breast cancers. The thera-
peutic role of UA in glioblastoma (GM) have not yet been determined, nor has
the defınitive relationships of UAwith EMT and cancer stem cells.Methods:We
tested the anti-tumoral activities of UA against glioblastoma (GM) progression
and further investigated themechanistic linkwith epithelial-mesenchymal tran-
sition (EMT) and cancer stemness factors. The targeting and anti-tumor effect of
UAwas also checked in orthotopic mouse gliomamodel. Results: In vitro assay,
we found that UA increased apoptotic cell death and inhibited the invasion/
migration of GM cells. Sphere and colony forming abilities were also decreased
in treated GM cells. UA decreased the expression of the EMT markers (N-
cadherin, ZEB1, ZEB2, SNAIL and SLUG) and the cancer stemness markers
(CD133, ALDH1 and CD44). In orthotopicmouse gliomamodels, UA localized
in GBM and signifıcantly decreased tumor growth and progression to lead lon-
ger survival. Conclusion: Taken together, these fındings showed that UA pre-
vent GBM invasiveness and progression, through the down-regulation of EMT
and cancer stemness markers.
#5114 Design, synthesis, and biological evaluation of tricyclic thieno[2,3-d]
pyrimidines as microtubule targeting antitumor agents. Farhana Islam,1 Aleem
Gangjee,1 Xin Zhang,1 Xilin Zhou,1 Susan L.Mooberry2. 1DuquesneUniv. School of
Pharmacy, Pittsburgh, PA; 2University of Texas Health Science Center at San Anto-
nio, San Antonio, TX.
Microtubules are dynamic structures that, together with actinmicrofılaments
and intermediate fılaments, constitute the cellular cytoskeleton. Besides their
well-known roles in cell division, their functions involve maintenance of cell
shape and morphology, cellular motility, and traffıcking of organelles and vesi-
cles. Recently, we reported a compound AG 370 as a microtubule targeting
agent, that circumvented the Pgp and III-tubulin mediated drug resistance
mechanisms that limit the effıcacy of paclitaxel, docetaxel, and the vinca alka-
loids. Molecular modeling and docking studies of the parent compound (AG
370) in the colchicine binding site (PDB: 402B) suggest that the C-5 and C-6 of
parent compound are oriented towards the hydrophobic pockets with the side
chain of Ala316, Val315, Leu255 and Met259. However, this binding pocket in
tubulin is relatively large. To further explore the hydrophobic pocket, an addi-
tional cyclohexene ring was introduced at C-5 and C-6 of AG370. In the molec-
ular modeling study, the resulting tricyclic scaffold showed hydrophobic inter-
actionswith the amino acids of the colchicine binding site. The 2-Me substituent
of the tricyclic scaffold was replaced with a 2-H and a 2-NH2 group and 4-posi-
tion of the scaffold was replaced with appropriate anilines. The 2-amino- N4-
methoxyphenyl moiety (AG61) was found to be the most potent analog in the
tricyclic series in both antiproliferative assay in human melanoma cancer cell
line (MDA-MB-435 cell line, IC50 9.0 0.2 nM) and in microtubule depoly-
merization assay in A-10 cells (EC50 19 nM). Thus, we identifıed tricyclic
thieno[2,3-d]pyrimidines as a novel structural scaffold with potent antiprolif-
erative activity as well asmicrotubule depolymerizing activity. These analogs are
selected for preclinical development.
#5115 Establishing an experimental paradigm to study the interphase ef-
fects of microtubule targeting agents. April L. Risinger, Nicholas F. Dybdal-
Hargreaves, RomaKaul, AllisonD.Clark, SusanL.Mooberry.UTHealth Science
Ctr. at San Antonio, San Antonio, TX.
Microtubule targeting agents (MTAs) are highly effective anticancer drugs.
While these drugs were traditionally classifıed as antimitotics, compelling evi-
dence suggests that the ability of MTAs to interrupt microtubule-dependent
traffıcking and signaling in interphase cells contributes to their anticancer effı-
cacies. Previous studies of the interphase effects ofMTAsononcogenic signaling
pathways have led to an important reevaluation of their mechanisms of antican-
cer actions. These effects have been primarily reported in cells that have been
treated with MTAs for extended periods of time. However, MTAs rapidly alter
microtubule dynamics which results, within a few hours, in global changes to
gene expression and cellular signaling.We propose that evaluating the effects of
MTAs on oncogenic pathways at times and concentrations that are associated
with early microtubule disruption will allow analysis of the initiating events that
link the direct action ofMTAs onmicrotubule structure and dynamics to effects
on interphase signaling that contribute to anticancer effıcacy. The concentra-
tions and treatment times that were optimal for the study of clinically used
MTAs on cellular traffıcking and signaling events were fırst determined. Our
experimental paradigm of a 2 h treatment of breast cancer cells with clinically
relevant concentrations of MTAs eliminated contributions due to mitotic accu-
mulation and changes in gene expression associated with longer treatments.
While all MTAs disrupt microtubule dynamics, the differences amongMTAs in
their rapid downstream effects on cellular signaling have not been systematically
evaluated. A goal of this project was to identify differences in the effects of
diverse MTAs on interphase signaling pathways that may underlie their differ-
ential effıcacy in patient populations. This short term treatment paradigm led to
the identifıcation of profound differences among MTAs in their ability to dis-
rupt Src-dependent E-cadherin re-localization, canonical and non-canonical
TGF- signaling, and -catenin localization. These fındings demonstrate the
ability of diverse MTAs to rapidly impact interphase oncogenic signaling and
traffıcking pathways. This experimental design sets forth a method to evaluate
the initial effects of diverse MTAs to gain critical insight into their differential
abilities to inhibit key oncogenic signaling pathways. These types of studies
might, in the future, help facilitate the rational selection of specifıc MTAs for
patients depending on tumor characteristics. Funding for this work was pro-
vided by Eisai Inc.
#5116 Identifıcation of new treatment options for Merkel cell carcinoma
using high throughput chemical screening. Tara Gelb,1 Daniel Urban,2 Ken-
neth Daily,1 Ying Xiao,1 Min Shen,2 Matthew Hall,2 Isaac Brownell1. 1National
Cancer Institute, Bethesda, MD; 2National Center for Advancing Translational
Sciences Chemical Genomics Center, Rockville, MD.
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Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin
cancer with limited treatment options. Approximately 80% of MCC tumors
haveMerkel cell polyomavirus (MCPyV)DNA integrated into the host genome,
and viral oncogenes are thought to drive carcinogenesis. In contrast, MCPyV-
negative (MCPyV-) tumors have higher rates of proto-oncogene mutations.
Transcriptome differences between MCPyV and MCPyV- tumors further
suggests divergent underlying pathologies. In order to develop effıcacious treat-
ments for MCC and elucidate the pathophysiologies underlying MCPyV and
MCPyV- MCC, we screened the effects of mechanistically annotated drug li-
braries on MCC cell viability (CellTiter-Glo). We screened4,500 compounds
including theNCGCPharmaceutical Collection of approved and investigational
drugs and the oncology-focusedMIPE (Mechanism Interrogation PlatE) library
against six MCC cell lines (3 MCPyV and 3 MCPyV-). We ran follow-up
screens on the above cell lines aswell as non-MCCcontrol cells to identify agents
that specifıcally reduced viability in MCC. DNA topoisomerase inhibitors, pro-
teasome inhibitors, and PI3K inhibitors potently and effıcaciously reduced via-
bility in all MCC cell lines tested. Moreover, using hierarchical clustering we
found that viral status impacted pharmacological responses. For example, a
subset of HDAC inhibitors were more potent inMCPyV thanMCPyV-MCC
cells. In contrast, a dual RasGAP/ERK inhibitor more potently reduced viability
in MCPyV- MCC cells relative to MCPyVMCC cells. Together these results
identify existing drugs that can be repurposed for treatingMCC.Moreover, they
help elucidate the distinct pathophysiology driving MCPyV and MCPyV-
MCC.
#5117 Triplatin preferably suppress lungmetastasis of breast cancer, and
peritoneal carcinomatosis of colon and pancreatic cancer. Eriko Katsuta,1
Erica J. Peterson,2 Samantha J. Katner,2 Nicholas P. Farrell,2 Kazuaki Takabe1.
1Roswell Park Cancer Institute, Buffalo, NY; 2Virginia Commonwealth Univer-
sity, Richmond, VA.
Background: Sincemetastatic spread is often directly associatedwith the poor
outcome, an effective treatment for metastatic lesion is expected to improve
overall survival. This is particularly the case in peritoneal carcinomatosis of
pancreatic cancer where there is no effective treatment. Recent clinical trials
demonstrated that Cisplatin is effective in certainmetastatic breast cancer, how-
ever with severe side effects. Polynuclear platinum analog, Triplatin, was devel-
oped to overcome the severe toxicity. Methods: Murine cancer cell lines, 4T1-
luc2 andE0771 (breast), Panc02-luc (pancreas) andCT26-luc (colon)were used.
Cell proliferation was quantifıed by CCK8 assay. Syngeneic orthotopic implan-
tation of 4T1-luc2 cells was used for metastatic breast cancer model. For mas-
tectomy model, primary tumors were surgically removed 8 days after inocula-
tion. Syngeneic intraperitoneal injection of CT26-luc cells and Panc02-luc cells
were used for peritoneal carcinomatosis models of colon and pancreatic cancer
respectively. Triplatin (0.3mg/kg) or vehicle was administered intraperitoneally
every four days three times and tumor burden was quantifıed by biolumines-
cence imaging. Results: Triplatin suppressed cell growth of both breast cancer
and pancreatic cancer in a dose dependent manner in vitro (IC50 of 4T1-luc2,
E0771 and Panc02-luc cells were 0.08, 0.51 and 0.07M, respectively). Triplatin
did not suppress the growth of 4T1-luc2 primary breast tumor, however, ex vivo
results showed that lung metastases were signifıcantly reduced to 14% of the
control (p  0.034) in orthotopic model. This result was reproduced in post-
mastectomy “adjuvant therapy” model where Triplatin treatment was began
after primary implanted tumor was removed, which suppressed lungmetastases
down to 1.9% of control by Day21 (p  0.038), and signifıcantly prolonged
survival (p 0.007). This result led us to use Triplatin in CT26-luc colon cancer
carcinomatosis model, where Triplatin suppressed total tumor burden to 1.9%
of control by Day13 (p  0.029) and signifıcantly prolonged survival (p 
0.001). Finally, Triplatin reduced total tumor burden of Panc02-luc pancreatic
cancer peritoneal carcinomatosis model to 35% of the control by Day 9 (p 
0.337) and the survival was signifıcantly prolonged (p  0.025). Conclusion:
Triplatin demonstrated signifıcant suppression lung metastatic tumor of 4T1-
luc2 breast cancer, and peritoneal carcinomatosis of CT26-luc colon cancer and
Panc02-luc pancreatic cancer. Newer platinum compounds with less toxicity
and favorable pharmacokinetics warrant further investigation for advanced
metastatic cancer.
#5118 A novel polyamine sulfonamide with anti-leukemic activity. Vind-
hya Vijay, Amy Meacham, Leylah Drusbosky, Elizabeth Wise, Christopher
Cogle. University of Florida, Gainesville, FL.
The greatest challenge in treating Acute Myeloid Leukemia (AML) is refrac-
tory disease. Although 60-80% of AML patients achieve complete remission
after induction chemotherapy, majority of these patients relapse and die of pro-
gressive disease. New treatment options targeting the vulnerabilities of AML
biology are highly critical for disease regression, in particular the chemo-resis-
tant leukemia-initiating population, to ensure relapse-free survival in patients.
Identifying novel druggable targets that are selective to AML despite their loca-
tion in the vascular niche is thus highly warranted. We developed an in vitro
co-culture model consisting of AML cells and Bone Marrow- derived Endothe-
lial Cells (BMECs), mimicking the protective effect of the vascular niche in the
bone marrow microenvironment. Using this unique model, and taking advan-
tage of combinatorial chemistry, we performed high-throughput chemical-phe-
notypic screening of approximately 30 million novel compounds and identifıed
a novel polyamine sulfonamide 2470-51 that can selectively kill AML cells by
overcoming the protective effect of the BMECs. In addition to AML blasts,
2470-51 also exhibited highly selective activity against the leukemic stem and
progenitor cell population while sparing normal hematopoietic stem and pro-
genitor cells. In vivo studies using patient-derived xenograft models indicated
signifıcant regression inAML engraftment post 2470-51 treatment. Target iden-
tifıcation experiments involving unbiased label-free shotgun proteomic analysis
in combination with targeted Selected Ion Monitoring (SIM) revealed covalent
drug binding targets of 2470-51. By performing differential protein expression
analysis using ITRAQ analysis, we identifıed downstream mechanisms that led
tomitotic cell cycle arrest and cell death. Collectively, our fındings display the in
vitro as well as in vivo effıcacy of a novel polyamine sulfonamide in eliminating
AML, including the leukemia initiating compartment. We also uncover a novel
mechanism in AML that can be taken advantage of for selective toxicity. Fur-
thermore, we establish the role of 2470-51 as a potential therapeutic agent in
treating AML.
#5119 Evaluation of Minnelide as potential targeted therapy for triple
negative breast cancer. Mahendra K. Singh,1 Soham Shah,2 Nikita Satish
Sharma,1 BhuwanGiri,1 Sulagna Banerjee,1 Ashok Saluja1. 1University ofMiami
School of Medicine, Miami, FL; 2University of Minnesota School of Medicine,
Minneapolis, MN.
Recent advances in diagnostics and better understanding of molecular mech-
anism underlying breast cancer has let to the better therapeutic options and
disease outcome for majority of breast cancer patients. However,10 - 20% of
all breast cancers often referred to as “triple negative” as they lack expression of
the estrogen (ER), progesterone (PR), and human epidermal growth factor 2
(HER2) receptors convey a poor prognosis due in part to a lack of targeted
therapies. The aim of the current study is to evaluate whether triptolide and its
water soluble analog Minnelide is effective against triple negative breast cancer
cells. We have previously shown that triptolide/Minnelide not only reduces
tumor growth in various cancer models but it also regulates epithelial -mesen-
chymal transition (EMT), an important mechanism underlying metastasis. In
our preliminary fındings using three triple negative breast cancer (TNBC) cell
lines, MDA-MB-231, MDA-MB-468, and MDA-MB-157, we demonstrate that
triptolide not only inhibits the proliferation of TNBC cells but also regulates the
protein levels of EMT markers including -Catenin and Vimentin. In order to
elucidate the mechanism underlying triptolide mediated inhibition of cellular
proliferation and regulation of EMT markers in TNBC cells, we identifıed Src
kinase and Aurora kinase A as two new targets for triptolide action in TNBC
cells. By targeting Src andAurora kinase, triptolide disrupts the integrity of focal
adhesion structures and reduces cell spreading via regulating FAK activity. Our
preliminary fındings regarding potential use of triptolide/Minnelide in TNBC
based on in vitro experiments are promising.However, considering the complex
pathophysiology of breast cancer and other biological factors playing role in a
disease setting, in-vivo experiments to test the effıcacy of Minnelide in relevant
mouse models for mammary cancers are currently underway.
#5120 Cryptolepine a plant alkaloid, inhibits the growth of nonmelanoma
skin cancer cells through inhibition of topoisomerase and induction of DNA
damage. Harish C. Pal, Santosh K. Katiyar. University of Alabama at Birming-
ham, Birmingham, AL.
Topoisomerases are highly specialized nuclear enzymes that remove super-
helical tension on chromosomal DNA that allows replication and transcription
of DNA.Many cancer chemotherapeutic drugs used in the clinics inhibit tumor
growth by targeting topoisomerase functions resulting in DNA damage and
cancer cell death. Cryptolepine, a major alkaloid isolated from Cryptolepis san-
guinolenta plant’s roots, has shown anti-malarial, anti-bacterial, anti-fungal,
and anti-inflammatory activities. In the present study, we examined the thera-
peutic effect of cryptolepine on non-melanoma skin cancer cells (NMSCC),
SCC-13 and A431 as an in vitro model, and underlying mechanism of action
with special emphasis on topoisomerases andDNAdamage check points.West-
ern blot analysis and enzyme activity evaluation assays demonstrated that
SCC-13 and A431 cells express comparatively higher levels of topoisomerases
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and higher enzymatic activities compared with normal human epidermal kera-
tinocytes (NHEK). Topoisomerase expression and activity was greatly reduced
after 24 h treatment with 2.5, 5.0 and 7.5 M cryptolepine. Inhibition of topo-
isomerases expression and function by cryptolepine resulted in signifıcant DNA
damage and enhanced expression of DNA-PK expressions. Cryptolepine in-
duced DNA damage activated DNA damage response proteins as demonstrated
by increased phosphorylation of ATM/ATR, BRCA1, Chk1/Chk2 and H2AX.
Consequences of cryptolepine induced DNA damage were also associated with
activation of p53 signaling cascade. Cryptolepine induced post-translational
modifıcations such as phosphorylation and acetylation of p53, and inhibition of
mdm2 protein expression resulted in activation and accumulation of p53 in
SCC-13 and A431 cells. In turn, activated p53 enhanced protein expression of
cyclin-dependent kinase inhibitors p16 and p21. Activation of p16 and p21
proteins downregulated expression of cyclin-dependent kinase 2 (CDK2), cyclin
A, cyclin D1 and cyclin E and thus induced S-phase cell cycle arrest in NMSC
cells with reduced expression of cell division proteins Cdc25a and Cdc25b.
Cryptolepine treatment also enhanced release of cytochrome c frommitochon-
dria due to increased disruption of mitochondrial membrane potential. Inhibi-
tion of topoisomerase activity and activation ofDNAdamage response signaling
culminated in signifıcantly reduced cell viability and enhanced cell death of
SCC-13 and A431 cells. However, NHEK cells were least sensitive to cryp-
tolepine induced cell death. Results of our study strongly suggest for detailed
preclinical investigations in animal models to further assess its anti-skin cancer
potential and its possible use in human patients.
#5121 PEG(E)-TC11, a novel polyethylene glycol-linked phthalimide de-
rivative, inhibited high-risk MM cell growth in vivo and in vitro via cell cycle
G2/M arrest in a CRBN-independent manner. Shuji Aida,1 Daiju Ichikawa,1
Kazuki Iida,1 Masashi Hozumi,1 Misa Nakamura,1 Ryo Uozaki,1 Nahoko
Hashimoto,1 Mikio Okayama,2 Yuko Yonemura,3 Noriko Tabata,3 Taketo
Yamada,4 MaikoMatsushita,1 Takeshi Sugai,1 Hiroshi Yanagawa,3 Yutaka Hat-
tori1. 1Keio University Faculty of Pharmacy, Tokyo, Japan; 2Keio University
School of Medicine, Tokyo, Japan; 3IDAC Theranostics Inc., Tokyo, Japan;
4Saitama Medical University, Saitama, Japan.
Multiple myeloma (MM) is one of the hematological malignancy that is char-
acterized by proliferation ofmalignant plasma cells. Recent advance in the treat-
ment of MM using newly developed drugs, prognosis of the MM patients have
been signifıcantly improved. For example, immunomodulatory drugs (IMiDs)
such as thalidomide, lenalidomide and pomalidomide have been developed for
treatment of MM. However, IMiDs have only limited effects against MM pa-
tients with high risk chromosomal abnormalities such as t(4;14) and del17p
(high-risk MM). In 2010, it was reported that IMiDs directly bind to cereblon
(CRBN), a component of ubiquitin ligase 3 complex, and induced teratogenicity
as well as anti-tumor effects. We have previously reported that a novel phtha-
limide derivative, 2-(2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione
(TC11) induced apoptosis against high-risk MM cells in vivo and in vitro, and
inhibited differentiation of osteoclasts. We also reported that TC11 directly
bound to 	-tubulin and nucleophosmin-1 (NPM1), but did not bind to CRBN.
However, TC11was not well dissolved inwater with only 0.02mg/mL solubility.
Therefore, TC11 showed poor absorption into blood and limited anti-tumor
activity when it was intraperitoneally administered in tumor-bearing mice. To
resolve these problems, we synthesized PEG(E)-TC11, in which TC11 is linked
to polyethylene glycol through an ester bond, and consequently enhanced water
solubility of PEG(E)-TC11 to 88.9 mg/mL. PEG(E)-TC11 revealed as potent
growth inhibitory effect on high-risk MM cells as TC11 in vitro. In pharmaco-
kinetic study, PEG-modifıcation of TC11 improved the peak blood concentra-
tion (Cmax) from 2.6 to 24.4 M and extended elimination half-life (t1/2) from
1.4 to 2.2 hr when 186 M/kg of these compounds were intraperitoneally in-
jected. More importantly, these pharmacokinetic improvement led to more po-
tent growth inhibition of MM cells in vivo than TC11. We also explored mech-
anisms of anti-myeloma effect of PEG(E)-TC11 and found that PEG(E)-TC11
induced apoptosis via G2/M cell cycle arrest. However, unlike IMiDs family,
BIACORE assay revealed that PEG(E)-TC11 didn’t directly bind to CRBN, in-
dicating that growth inhibitory effect of PEG(E)-TC11 against MM cells was
independent of binding to CRBN. In conclusion, PEGylation of TC11 signifı-
cantly increased water solubility, resulted in potentiated anti-myeloma activity
in vivo. Furthermore, PEG(E)-TC11 inhibited cell growth via G2/M arrest in a
CRBN-independent manner. Thus, PEG(E)-TC11 is considered as a candidate
compound for overcoming high-risk MM.
#5122 Utilizing zebrafısh to study the effect strigolactone on breast cancer
cells.Kira Lin,1 ChristopherGrivas,1 Elema Boru,1 YaronDayani,2 Eric Berens,1
Anna T. Riegel,1 Eric Glasgow,2 Ronit I. Yarden1. 1Georgetown University,
Washington, DC; 2Georgetown University, Bethesda, MD.
Strigolactones (SLs) are a novel class of phytohormones that regulates shoot
branching patterns and above-ground plant architecture by inhibiting the out-
growth of axillary lateral buds ormeristems. The SL analogues (SLAs) inhibit the
growth and survival of a wide array of cancer-derived cell lines including: pros-
tate, colon, lung, melanoma, osteosarcoma and leukemic cell lines, while mini-
mally affecting normal cultured cells. Interestingly, cancer cells with high met-
astatic potential are more sensitive to the inhibitory effect of SLAs than less
aggressive cells. Treatment of cancer cells with SLAs leads to the activation of
stress-related signaling including p38MAPKs and JNK1/2, and disrupt the mi-
crotubule network. Furthermore, a reduction in acetylated-alpha-tubulin was
observed in SLA-treated MDA-MB-231 cells. Microtubules dynamics has been
proposed as one of the mechanisms that regulate cell migration by acting on
lamellipodia formation. The ECIS invasion assay data suggests that even at low
concentration of SLA and as soon as 6 hours, SLAs suppressMDA-MB-231 cells’
ability to invade the HUVECmonolayer. To further examine the effect of SLAs
on the invasive and metastatic behaviors of cancer cells in vivo, fluorescently
labeled MDA-MB-231 cells were used as xenograft models in zebrafısh. Em-
bryos injected with MDA-MB-231 cells showed 66.6% metastasis in vehicle
treated control fıshes, as compared to 22.85% in SLAs treated fıshes. This sug-
gests that SLAs are potent inhibitors of cancer dissemination and metastasis.
#5123 Targeted thieno[2,3-d]pyrimidines with fluorinated phenyl side
chains as antitumor agents. Nian Tong,1 Aleem Gangjee,1 Adrianne Wallace
Povrik,2 Carrie O’Connor,2 Aamod AamodDekhneb,2 Zhanjun Hou,3 Larry H.
Matherly2. 1Duquesne Univ., Pittsburgh, PA; 2Wayne State University, Detroit,
MI; 3Barbara Ann Karmanos Cancer Institute, Detroit, MI.
The reduced folate carrier (RFC) is ubiquitously expressed in tissues and
tumors and is the major tissue transporter for folate cofactors. Folate receptor
(FR) 	 and , as well as the proton-coupled folate transporter (PCFT), exhibit
narrower patterns of tissue expression and are likely to serve more specialized
physiologic roles. FRs are expressed in a subset of cancer cells (e.g., ovarian and
non-small cell lung cancer for FR	, acute myelogenous leukemia for FR),
whereas PCFT is expressed in a wide range of human solid tumors but not
leukemias. Earlier generations of glycinamide ribonucleotide formyltransferase
(GARFTase) anddenovopurine nucleotide biosynthesis (e.g., Lometrexol) have
shown promise as antitumor drugs. However, these compounds are excellent
substrates for RFC and thus are non-selective for tumors, leading to dose-limit-
ing toxicities. We previously reported a novel class of 6-substituted thi-
eno[2,3-d] pyrimidines with a phenyl side chain and 3- and 4-carbon bridge
lengths (AGF17 andAGF23, respectively) which selectively targeted FRs but not
RFC or PCFT. To increase antitumor effıcacy, we synthesized fluorinated ana-
logs of AGF17 and AGF23, designated as AGF309 and AGF304, respectively.
AGF309 and AGF304 potently inhibited proliferation of Chinese hamster ovary
(CHO) cell lines engineered to individually express human FR	 (IC50s of 1.08
and 2.27 nM, respectively) or FR (IC50s 0.48 and 1.14 nM, respectively).
AGF304 and AGF309 showed nominal activity toward RFC- and PCFT-ex-
pressing CHO cells. Both AGF309 and AGF304 were also potently inhibitory
toward FR	-expressing human KB human tumor cells (IC50s of 7.19 and
5.27nM, respectively). By analogy with previous iterations of 6-substituted thi-
eno [2,3-d] pyrimidine compounds, growth inhibitory activity by AGF309 and
AGF304 likely involves inhibition of de novo purine biosynthesis at GARFTase
and potentially a secondary intracellular target. Collectively, our in vitro fınd-
ings of the potent and selective antitumor activity and FR selectivity suggest that
further preclinical evaluation of AGF309 and AGF304 as potential antitumor
agents is warranted.
#5124 GNS561 a new quinoline derivative inhibits the growth of hepato-
cellular carcinoma in a cirrhotic rat andhumanPDXorthotopicmousemod-
els. Firas Bassissi,1 ZuzanaMacek Jilkova,2 Sonia Brun,1 Jerome Courcambeck,1
Jennifer Tracz,1 Keerthi Kurma,2 Gaël S. Roth,3 Cindy Khaldi,1 Corinne Chaim-
bault,1 Benoit Quentin,1 Emilie Asseraf,1 Antoine Beret,1 Eric Raymond,1
Philippe Halfon,1 Thomas Decaens3. 1Genoscience Pharma, Marseille, France;
2Université Grenoble Alpes, Institute for Advanced Biosciences, Research Center
UGA / Inserm U 1209 / CNRS 5309, Grenoble, France; 3Université Grenoble
Alpes, Institute for Advanced Biosciences, Research Center UGA / Inserm U 1209
/ CNRS 5309, Clinique Universitaire d’Hépato-gastroentérologie, Pôle Digidune,
CHU Grenoble, Grenoble, France.
Background: Hepatocellular carcinoma (HCC) remains a major health prob-
lem, often diagnosed at late stages with limited number of therapeutic options.
New drugs with original mechanisms of action are urgently aimed to improve
current armamentarium in HCC patients. Quinoline derivatives are novel class
of oral small molecules inducing multiple cellular effects such as inhibition of
autophagy, induction of apoptosis, and cell cycle modulation. The aim of these
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studies was to assess tolerance and effıcacy of a new quinolone derivative
GNS561. Material and methods: In vitro experiments were realized with viabil-
ity, apoptosis andmigration in tumor cells inHCC cell lines and primary tumor.
Drug tolerance and plasma and liver pharmacokinetic were evaluated after sin-
gle and repeated dosing in mice and rat. GNS561 and sorafenib effıcacy in vivo
were evaluated in a PDX orthotopic BALB/c-nu mouse model and in a diethyl-
nitrosamine (DEN)-induced HCC cirrhotic rat model. AFP, cell proliferation
and tumor weight and size were assessed in mice. In rat tumor progression was
followed by MRI, pathological analysis (tumor size and number), immunohis-
tochemistry and PCR analysis after 6weeks of treatment. Results: GNS 561
shows potent anti-proliferative activity when assayed against a panel of human
tumor cell lines and notably against a panel of HCC patient primry tumors even
in those with sorafenib resistance (Mean EC50 3M vs 11M for sorafenib).
GNS561 is highly selectively trapped in the liver. Plasma and liver PK in mice
and rats after single and repeated doses confırm this selectivity with good toler-
ance and oral bioavailability. In PDX mouse model, tumor growth was signifı-
cantly reduced by GNS561 with a dose-response manner, this tumor regression
was associated with AFP level decreases by 72% with GNS561 (p0.002) and
54%with sorafenib (p0.046) compared to control. In ratmodel, mean number
of tumors was signifıcantly lower in GNS561 at 15mg/kg group (n50.6), in
sorafanib at 10mg/kg (n65.1) and in combination group (n40.6), when com-
pared to control (n100.4; p0.0024, p 0.029 and p0.0002). Tumor de-
crease measured by MRI was associated with a signifıcantly reduced prolifera-
tion of tumor cells particularly in GNS561 group (70%) and combination (84%)
compared to control, whereas the effect of sorafenib alone on proliferation was
modest (30%). Conclusions:GNS561 is a liver selective drugwith good tolerance
and promising effıcacy in different HCC animal models. GNS 561 was more
effıcient than sorafenib to control tumor growth in preclinical models. Based on
its safe toxicity profıle and potent activity in rodent models, GNS 561 is now
aimed to further reach clinical development in patients with HCC in 2017.
#5125 Muscadine grape extract inhibits breast cancer brain metastatic
cells by multiple mechanisms. Wenhong Chen, Patricia Gallagher, Ann Tal-
lant, Linda J.Metheny-Barlow.Wake Forest School ofMedicine,Winston-Salem,
NC.
Tumor metastasis to the brain is a common complication of cancer, affecting
500,000 patients each year. Due to poor penetration of most chemotherapeutics
into the brain, brain metastasis may occur even while systemic disease in under
control. Despite aggressive treatments including radiation therapy, survival at
12 months following diagnosis is only 20%, underscoring the need for better
means to prevent and/or treat brain metastases. Natural products have histori-
cally been a very successful source of new drugs. We are investigating the anti-
cancer potential of a proprietary muscadine grape extract (MGE; from Pied-
mont Research & Development Corp.) on breast cancer cell lines that are
metastatic to the brain. In a colony formation assay,MGE (10g/mL) decreased
clonogenic survival of 4T1.luc2.Br5 cells by 50% (n3, p0.0001). The
Eo771.luc.Br5 cells were more sensitive to MGE, showing 33% inhibition at 5
g/mL (n3, p0.001) and 91% inhibition at 7.5g/mL (n3, p0.0001).We
also assessed response to the combined treatment of MGE and ionizing radia-
tion (IR). While MGE did not sensitize cells to IR, combined administration of
MGE and IR resulted in decreased clonogenic survival compared to either mo-
dality alone for both cell lines (n3-4 experiments, p0.01), suggesting an
additive effect. Mechanistically, acute exposure (24 h) to 10 g/mL MGE in-
duced apoptosis in 4T1.luc2.Br5 cells as evidenced by PARP cleavage and detec-
tion of activated cleaved caspase 3. Further, ERK1/2 activation was decreased
68% at this time point (n3, p0.05). In contrast, although Eo771.luc.Br5 cells
are more sensitive to clonogenic inhibition, no PARP cleavage, caspase 3 cleav-
age, or ERK1/2 inhibitionwas observed. Analysis of cyclinD1, amajor regulator
of cell cycle progression, identifıed 80% decrease following MGE treatment
(24 h, 10g/mL) in both cell lines. Together these data suggest thatMGE inhib-
its breast cancer brain metastatic cell proliferation by multiple mechanisms,
including inhibition of clonogenic growth through induction of apoptosis
and/or decreased cell cycle progression, suggesting thatMGEmay have utility in
the treatment of breast cancer brain metastasis.
#5126 Novel indolizino[8,7-b]indole hybrids with potent activity against
small cell lung cancer. Sue-Ming Chang, Ming-Hsi Wu, Hima Bindu Pidugu,
Tsann-Long Su, Te-Chang Lee. Institute of Biomedical Science, Academia Sinica,
Taipei, Taiwan.
Small cell lungcancer (SCLC) isanaggressive typeof lungcancerandaccounts for
10% to 15% of all lung cancer cases. The malignancy has a greater tendency to be
widely disseminated by the time of diagnosis aswell as to develop early resistance to
conventional treatments, a cure is diffıcult to achieve. The current standard therapy
for SCLC treatment, either withmonotherapy (platinumbased drugs) or combina-
tiontherapy(e.g., cisplatinwith irinotecanor topotecan),wasshowntocauseserious
side effects and inevitably evoke drug resistance in a short time period. We have
recently synthesized a series of novel bis(hydroxymethyl)indolizino[8,7-b]indole
hybrids by fusing -carboline and bis(hydroxymethyl)pyrrole moieties for antitu-
mor evaluation. These hybrid molecules displayed diverse mechanisms of action
involving topoisomerase II (Topo II) inhibition and induction of DNA cross-link-
ing. Our results also showed that they signifıcantly inhibited the cell growth of var-
ioushuman tumorcell lines.Of the tested tumorcell lines, theSCLCcells (H526and
H211) were the most susceptible to compounds BO-2239 and BO-2329. These hy-
brids induced cell cycle arrest at theG2/Mphase and triggered tumor cell apoptotic
death. Intriguingly, the substituent at N11 (H orMe) played a critical role inmodu-
latingTopoII inhibitionandDNAcross-linking.Compared to thecompoundswith
N11-Me group, derivatives havingN11-H group profoundly increased Topo II inhi-
bition activity but reduced DNA cross-linking activity. Among these hybrids, BO-
2239 (with N11-H) was as potent as irinotecan, but more effective than cisplatin, in
nude mice bearing SCLC H526 xenografts. Accordingly, hybrid BO-2239 may be
further developed as a potential agent for the treatment of SCLC.
#5127 In vitro and in vivo evaluation of FF-10502-01, a new pyrimidine
nucleoside analogue. Shinji Mima,1 Hiroki Nishikawa,1 Shinichi Watanabe,1
Tamami Higuchi,1 Takeaki Suzuki,2 Hiroyuki Iwamura,1 Chihaya Kakinuma,1
Takaaki Nakamura,1 Yasuhiro Shimada1. 1Fujifılm Corporation, Tokyo, Japan;
2Fujifılm Corporation, Cambridge, MA.
Introduction:FF-10502-01 is a synthetic pyrimidine nucleoside analogue struc-
turally similar to gemcitabine (gem) with a substitution of sulfur for oxygen in the
pentose ring.The anti-tumor effects of FF-10502-01were studied in solid tumor cell
lines andhuman tumor xenograftmodels.Methods:10human solid tumor cell lines
were studied and included the following: 4 pancreatic (PANC) (BxPC-3, SUIT-2,
Capan-1 andMIAPaCa-2), colon (HCT116), lung (NCI-H460), ovary (SK-OV-3),
prostate (LNCap.FGC), breast (MDA-MB231) and mantle cell lymphoma (MCL)
(Jeko-1). The effect of FF-10502-01 onDNA synthesis versus gemwas evaluated in
a PANC cell line (Capan-1). Tumor growth suppression was evaluated in human
PANC xenograft models, SUIT-2 and Capan-1. FF-10502-01 or gemwas adminis-
tered at 240 or 480 mg/kg once a week starting 7d after orthotopic transplantation
for 18 weeks, n20/grp. Animals were followed for 128d after transplantation. Ca-
pan-1 was transplanted SC into nude mice (n8/grp). FF-10502-01 or gem was
administered at 120, 240, 360 or 480 mg/kg once weekly x 4 weeks 7d after trans-
plantation. Tumor growth inhibitory effects were evaluated for 27d after starting
treatment. FF-10502-01 single-dosepharmacokinetics (PK)were investigated in the
mouse, rat and dog. Results:FF-10502-01 demonstrated in vitro activity against the
PANC, colon, lung, ovarian, prostate andMCLcell lines, with IC50s of 30 – 330nM.
The activitywas 1.5 – 15-fold lower than gem, however, FF-10502-01 demonstrated
a 23-fold higher inhibition of DNA	-polymerase-mediated synthesis over gem. In
the SUIT-2 orthotropic implant model, both gem and FF-10502-01 improved sur-
vival over vehicle controls.Med survivalwas not reached for the 480mg/kg gemgrp
or either the 240 or 480 mg/kg FF-10502-01 grps. The survival rate was 5%, 25%,
75% for the vehicle, 240 and 480 mg/kg gem grps (p0.0001 versus vehicle), and
100% for the 240 and 480 mg/kg FF-10502-01 grps (p0.0001 versus gem grps),
respectively. In the Capan-1 xenograft model, both FF-10502-01 and gem demon-
strated statistically signifıcant tumor growth suppression versus vehicle control; FF-
10502-01 demonstrated equivalent tumor growth suppression with less effect on
body weight than gem at clinically achievable doses. PK following single bolus IV
doses indicated a similar PK profıle to other pyrimidine nucleoside analogues, in-
cluding gem. Conclusions:FF-10502-01 is a new pyrimidine nucleoside analogue
with demonstrated preclinical effıcacy against solid tumors and a potentially more
tolerable safety profıle than gem.
#5128 Induction of immunogenic cell death and tumor regression inmu-
rine animal models by a novel cytolytic compound, LTX-401. Brynjar Maus-
eth,1 Liv-Marie Eike,2 Ji-Hua Shi,3 Ketil Camilio,4 Heng Zhou,5 Allan Sauvat,5
Lígia C Gomes-da-Silva,5 Sylvèr Durand,5 Sabrina Forveille,5 Kristina Iribar-
ren,5 TakahiroYamazaki,6 Sylvie Souquere,7 Lucillia Bezu,5KevinMüller,5Mar-
ion Leduc,5 Peng Liu,5 Liwei Zhao,5 Aurélien Marabelle,5 Laurence Zitvogel,6
Oliver Kepp,5 Guido Kroemer,5 Øystein Rekdal,8 Pål-Dag Line,9 Baldur Svein-
bjørnsson8. 1Institute of Clinical Medicine, University of Oslo, Oslo, Norway;
2Institute ofMedical Biology, University of Tromsø, Tromso, Norway; 3Institute of
Basal Medical Sciences, University of Oslo, Oslo, Norway; 4Institute for Cancer
Research, Oslo University Hospital, Oslo, Norway; 5Gustave Roussy Comprehen-
sive Cancer Institute, Paris, France; 6Institut de Cancérologie Gustave Roussy
Cancer Campus, Paris, France; 7Gustave Roussy Comprehensive Cancer Center,
Paris, France; 8Lytix Biopharma AS, Oslo, Norway; 9Division of Cancer, Surgery
and Transplantation, Oslo University Hospital, Oslo, Norway.
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LTX-401 is a de novo designed cytolytic compound that shares many chem-
ical features with anticancer peptides, such as amphipathicity, hydrophobicity
and overall net charge. In vitro cytotoxicity studies revealed that LTX-401 was
highly active against a panel of malignant cells including murine and human
cancer cell lines while displaying selectivity towards human red blood cells.
Furthermore, LTX-401 was found to induce immunogenic cell death as demon-
strated by the release of Damage-Associated Molecular Pattern molecules, or
‘danger signals’, such as High-Mobility Group Box-1 protein, ATP and cyto-
chrome c. Flow cytometric and confocal microscopy studies also demonstrated
reduced signal from lysosomal dye Lysotracker-DND-26, hence indicating loss
of lysosomal integrity upon induction of cell death. The latter was supported
using transmission electron microscopy, showing distinct morphological char-
acteristics of necrosis. Moreover, at low concentrations, LTX-401 selectively
enriched in the Golgi apparatus and initiated a lethal signaling event that in part
could be inhibited byBrefeldinA.Complete tumor regression has been obtained
in several rodent models, including the B16 mouse melanoma model and the
JM1 rat hepatocellular carcinoma model by intratumoral injection with LTX-
401. Additionally, previously cured animals showed protection against rechal-
lenge with live tumor cells, indicating the induction of tumor-specifıc immune
memory. The increased survival benefıt of LTX-401-treated animals provides a
rationale for further evaluation of the compound as an immunotherapeutic
agent against solid malignancies.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Novel
Drug Delivery Technology
#5129 Cell-penetrating doxorubicin released from Elastin-like polypep-
tide kills doxorubicin-resistant cancer cells. Jung Su Ryu, Drazen Raucher.
Univ. of Mississippi Medical Ctr., Jackson, MS.
A drug-releasing system facilitated by external stimuli could be used to deliver
cytotoxic chemotherapy agents to tumor sites selectively and safely. Among
many suggested strategies, elastin-like polypeptide (ELP) exploits its character-
istic of phase transitioning in response to changes in ambient temperature. This
unique property permits selective targeting of the polymer to hyperthermic tu-
mors by aggregating as it transitions. ELP therefore can be used as a thermosen-
sitive vector for the delivery of chemotherapy agents and therapeutic peptides,
resulting in a rise in drug concentration exclusively in tumors. This novel strat-
egy introduces unprecedented options for treating cancer, with fewer concerns
about indiscriminate side effects from the chemotherapy. In this study, the ELP-
drug conjugate was further modifıed with incorporation of an enzyme-specifıc
cleavable linker in order to trigger drug release within tumors. The suggested
system is composed of ELP, a matrix metalloproteinase (MMP) substrate, a cell
penetrating peptide (CPP), and 6-maleimidocaproyl amide derivative of doxo-
rubicin (Dox). Rationale for this design is that this construct may be initially
targeted to the tumor site by local application of mild heat. When the construct
reaches tumor site, it is cleaved by MMP, releasing CPP conjugated Dox, which
is able tomore effıciently infıltrate tumor tissues and penetrate cancer cell mem-
branes. This strategy shows up to 4-fold increase in cell penetration up to four
times and resultsmore cell death in breast cancer cells than the ELP-doxorubicin
complex. Even in doxorubicin-resistant cancer cells (NCI/ADR and MES/
ADR), ELP-released, cell-penetrating doxorubicin demonstrated better mem-
brane penetration (two fold), leading to at least twice killing of the resistant
cancer cells than ELP-Dox and free Dox.
#5130 Tumor-penetrating peptide-coated nanoparticles as a novel strat-
egy for the targeted therapy of neuroblastoma. Fabio Pastorino,1 Chiara Bri-
gnole,1 Laura Emionite,2 Silvia Bruno,3 Flavio Curnis,4 Daniela Di Paolo,1 Pa-
trizia Perri,1 Alessandro Gori,5 Renato Longhi,5 Michele Cilli,2 Angelo Corti,4
Mirco Ponzoni1. 1Institute G. Gaslini, Genoa, Italy; 2IRCCSAziendaOspedaliera
Universitaria San Martino–IST Istituto Nazionale per la Ricerca sul Cancro,
Genoa, Italy; 3University of Genoa, Genoa, Italy; 4San Raffaele Scientifıc Institute,
Milan, Italy; 5CNR, Milan, Italy.
Anticancer drugs loaded into tumor- and vasculature-targeted nanocarriers
(NC) can reduce side-effects and improve therapeutic effıcacy in pre-clinical
studies. However, poorly perfused and dysfunctional tumor vessels and lym-
phatics limit the transport of the payload into the parenchyma of solid tumors.
The use of NC decorated with tumor-penetrating peptides (TPPs) might en-
hance tumor penetration and antitumor effects. A previously characterized neu-
roblastoma (NB)-targeting peptide ligand was here modifıed (now referred as
TPP-NB) by adding a consensus motif as a mediator of cell, vascular and tissue
penetration via neuropilin-1 (NRP-1) receptor recognition. NPR-1 expression
was validated by FACS analysis in NB cell lines and by IHC staining in tumor
cells and tumor stroma fromNB-bearingmice. RecombinantNRP-1was used to
validate TPP-NB specifıcity. In vitro and in vivo cell association and internaliza-
tion of TPP-NB, either free or coupled to Liposomes (L) were tested by FACS
and confocalmicroscopy.Vascular permeability assay after treatmentwithTPP-
NB-targeted, doxorubicin-loaded Liposomes (TPP-NB-L[DXR]) was per-
formed evaluating the in vivo accumulation of Evans Blue dye within the tumor
mass. Therapeutic experiments with TPP-NB-L[DXR] were performed in mice
orthotopically injected with human NB cells. NRP-1 expression is validated in a
panel of NB cells and in tumors from NB-bearing mice. Differently from the
original peptide and some control ones, TPP-NB is able to recognize recombi-
nant NRP-1. The addition of the NRP-1-recognizing sequence to the original
peptide signifıcantly increases its NB cellular association in vitro. Interestingly,
the results seem to indicate that the enhanced capability by TPP-NB in binding
NB cells is related to the combination of theNRP-1-recognizing and the original
sequence. Importantly, TPP-NB coupled at the external surfaces of L[DXR]
signifıcantly increases their cellular association onNB cells in vitro. Competitive
binding assay reveals that binding of TPP-NB is specifıc and can be inhibited by
an excess of the unlabeled free peptide. The localization and the cellular distri-
bution of L evaluated by confocal microscopy in vitro and in mouse models of
NB, confırm the binding specifıcity, showing an increased selective internaliza-
tion of TPP-NB-L-FITC compared to that obtained with either untargeted L or
L decorated with the scrambled peptide. Moreover, TPP-NB-L[DXR] further
increases the vascular permeability into the NB tumor mass, but not in non-
tumor tissues. The therapeutic effıcacy of TPP-NB-L[DXR] has been investigat-
ing in terms of overall survival. On running results indicate that the novel NC
exerts an increased anti-NB effect compared to DXR-loaded L decorated with
the original peptide. Our fındings demonstrate that the achieved penetrating
features by aNB-targeting peptidemight increase liposomal drug binding, hom-
ing and antitumor effıcacy.
#5131 Effıcient delivery of siRNA targeted CCDC88A mRNA to pancre-
atic cancer tumor inhibits the invasiveness andmetastasis.Keisuke Taniuchi,
Toshio Yawata, Tetsuya Ueba, Toshiji Saibara. Kochi University, Nankoku, Ja-
pan.
Introduction: We identifıed CCDC88A messenger RNA (mRNA) that accu-
mulates in lamellipodia by binding to an RNA-binding protein IGF2BP3 with a
next generation sequencer. The objectives of this study are as follows: (1) To
identify CCDC88A specifıc small interfering RNAs (siRNAs) as RNA interfer-
ence agents that have an inhibitory effect on the invasion and metastasis of
pancreatic cancer cells in a mouse model of the invasion and metastasis of pan-
creatic cancer; and (2) To develop a nucleic-acid delivery system to effıciently
transport the siRNAs to PDAC tissue. Methods: After intravenous injection of
CCDC88A-specifıc siRNAs supplemented with folic acids that can bind to the
folic acid receptor—which are highly expressed on pancreatic cancer cells—and
polyethylene glycol-chitosan oligosaccharide nanoparticles to amousemodel of
invasion and metastasis in which a human pancreatic cell line was transplanted
to induce tumor formation in the mouse pancreas, accumulation of the siRNAs
in the pancreatic cancer tissue was determined by using an in vivo imaging
system. After CCDC88A-specifıc siRNA accumulation in the pancreatic cancer
tissue was identifıed, invasion to the retroperitoneum as well asmetastasis to the
lung or liver from the human primary pancreatic tumor was compared between
the mice in which CCDC88A-specifıc siRNA accumulation was identifıed and
those receiving a scrambled control siRNA. Results: CCDC88A-specifıc siRNAs
could be delivered to the pancreatic cancer cells of cancer-bearing nudemice by
supplementation with folic acids and chitosan oligosaccharide nanoparticles.
Supplementation with folic acids and chitosan oligosaccharide nanoparticles
caused no hemolysis and had no effect on liver, kidney, or pancreatic function.
Invasion to the retroperitoneum and metastasis to the lung or liver from the
primary pancreatic cancer were suppressed in cancer-bearing nude mice by
administration of those siRNAs,which targetCCDC88AmRNAaccumulated in
lamellipodia of pancreatic cancer cells. Conclusions: This study suggests the
potential to develop a siRNA drug to inhibit the invasion and metastasis of
pancreatic cancer.
#5132 In vitro collapsing human and murine colon cancer cells by selec-
tivity of disulfıram-loaded charge switchable nanoparticles against cancer
stem cells.MarwaAbu-Serie,1 Fatma El-Rashidy2. 1City for Scientifıc Researcher
& Technological Applications, Alexandria, Egypt; 2Faculty of Science, Alexandria
University, Alexandria, Egypt.
The different therapeutic strategies against colon cancer (CC) had led to treat-
ment failure, due to resistance to drugs which can be toxic to normal cells in
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healthy tissues and effectively eradicate bulk tumor populations, but not cancer
stem cells (CSCs). So, we targeted mitochondrial aldehyde dehydrogenase 1B1
(ALDH1B1) as marker of CSC stemness, by loading of ALDH1B1 inhibitor
(disulfıram,DS) on positively charged chitosan nanoparticles (NPs) and coating
them with negative charges of serum albumin (SA). The prepared NPs were
characterized by measuring of particle size, zeta potential, encapsulation effı-
ciency, loading capacity, release kinetics and cellular uptake as well as analyzed
by scanning electron microscope and surface-enhanced Raman scattering. The
selectivity of these NPs against in vitro chemically induced mice colon cancer
cells (CDCECs) and human colon cancer cell line (Caco-2) comparing to nor-
mal mice colon cells was determined. The investigation of their selectivity was
evaluated by MTT assay, detecting ALDH1B1 activity, flow cytometric analysis
of CD133 expression and quantifıcation of cleaved-caspase 3 level (as targets
for CC treatment). The zeta potential of coated NPs confırmed that SA-layering
confers negative charge (-10.3 mv) for the cationic DS-loaded chitosan NPs
(52.9 mv). In slightly acidic medium of tumor, the ionic bond between SA and
the loaded chitosan hydrolyzed then the positive charge was reversed (47.6 mv).
Thus coated NPs showed more controlled slow release for DS in slightly acidic
pH (tumor microenvironment) than in neutral pH (microenvironment of nor-
mal cells) and their uptake were higher in both CC cells (70%) than normal
cells (4.10.2%) in a time-dependent manner. This interpreted the highest
selectivity of coated NPs for inhibiting cellular growth by apoptosis and sup-
pressing ALDH1B1 activity, oxidizing cellular environment, eliminating
CD133CSCs and activation of caspase 3 only in CDCECs and Caco-2 cells.
Hence the coated NPs possessed the effıcient eradicating effect for colon CSCs
(40%) without a signifıcant insult ( 5%) for normal stem cells in comparison
with DS which was toxic to both normal and CSCs (90%). Because of the coated
NPs safety for healthy tissues, they may be promising therapy by their effıcient
collapsing CSCs of tumor cells. These results of this novel study that was used
charge switchable (hydrophilic) NPs to loadDS for targeting colonCSCsmay be
represent a basis for future in vivo studies.
#5133 TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibi-
tor alvocidib.Wontak Kim, Hillary Haws, Peter Peterson, Clifford J. Whatcott,
StevenWeitman, Steven L.Warner, David J. Bearss, Adam Siddiqui-Jain.Tolero
Pharmaceuticals, Inc., Lehi, UT.
Alvocidib is a potent inhibitor of cyclin-dependent kinase-9 (CDK9) and
induces apoptosis in cancer cells by reducing the expression of short-lived, anti-
apoptotic proteins such as MCL-1. Alvocidib, as a part of a sequential combina-
tion regimen with cytarabine and mitoxantrone (ACM), is currently in a Phase
II clinical trial in relapsed/refractory acute myeloid leukemia (AML). Patients
with AML that have a high dependence onMCL-1 are consideredmore likely to
benefıt from the alvocidib-containing regimen. MCL-1 has emerged as a key
protein in drug resistance of multiple solid tumor types including breast, pros-
tate and lung cancers. The use of alvocidib in clinical settings beyond the ACM
regimen is somewhat limited by the current intravenous route of administra-
tion. An orally administered form of alvocidib would allow prolonged repres-
sion ofMCL-1 through chronic dosing and scheduling. Alvocidib itself is highly
permeable in CACO-2 monolayers and is soluble at acidic pHs but solubility is
strikingly reduced at neutral or basic conditions, which could hamper the devel-
opment of an oral formulation. We hypothesized that a phosphate prodrug of
alvocidib would improve solubility under neutral or basic conditions and enable
the effıcient systemic delivery of alvocidib via oral administration. We synthe-
sized a phosphate prodrug of alvocidib, TP-1287, in three steps from the parent
compound. The solubility of TP-1287, was determined at various pH levels. It
was found to be highly soluble under acidic, neutral, and basic conditions (1.5
mg/mL at pH 2.2; 1.8 mg/mL at pH 4.5; 9.5 mg/mL at pH 6.8 and 9.3 mg/mL at
pH 8.7) compared to alvocidib (4.4 mg/mL at pH 2.2; 1.3 mg/mL at pH 4.5; 0.02
mg/mL at pH 6.8 and 0.02 mg/mL at pH 8.7). Pharmacokinetic studies were
conducted in mice in which TP-1287 was effıciently converted to the parent
alvocidib (Cmax  1922.7 ng/ml, t1/2  4.4 hr) with high oral bioavailability
(%F  182.3, compared to intravenous alvocidib). Effıcacy and pharmacody-
namic studies (measuring MCL-1 expression levels), were evaluated in tumor
xenograft models. TP-1287 demonstrated signifıcant anti-tumor effıcacy in the
MV4-11 AML mouse xenograft model and produced as much as a 61.7% inhi-
bition of the pharmacodynamic biomarkerMCL-1 in xenografted tumors, dem-
onstrating a wide, 75-fold therapeutic dosing window. In addition, TP-1287
strongly inhibited tumor growth, achieving 109.1% tumor growth inhibition
(%TGI) at the 7.5 mg/kg dose level. TP-1287 is highly soluble over a broader pH
range than alvocidib and is effıciently metabolized to the parent compound in
vivo, following oral administration. Tumor xenograft models and pharmacody-
namic studies indicate that oral delivery of TP-1287 is effıcacious inmice. Based
on these results, we anticipate moving TP-1287, as an orally delivered CDK9
inhibitor, into a forthcoming clinical trial directed towards solid tumors vulner-
able to the suppression of MCL-1.
#5134 Novel trifunctional immunoliposome delivery system to minimize
resistance and side effects for anticancer therapy. Tanaya R. Vaidya, Sihem
Ait-Oudhia. Univ. of Florida, Orlando, FL.
Background: Breast cancer (BC) is the second leading cause of cancer death in
women worldwide. About 25% of BCs have overexpression of the HER2 recep-
tor. Although HER2 targeted therapies have shown considerable improvement
in HER2-positive BC patients’ outcome, treatment resistance remains a clinical
challenge. Here, we sought to develop and evaluate a novel tri-functional im-
mune-liposome (TFIL) that overcomes HER2 treatment resistance and associ-
ated cardiotoxicity by dually targeting HER2 on BC cells and CD3 receptors on
cytotoxic T-lymphocytes (CTLs). Material and methods: Anti-HER2 (Trastu-
zumab) and anti-CD3 (OKT-3) antibodies, were conjugated to lipid nanopar-
ticles by themicelle-transfermethod, and the resulting formulationwas purifıed
by dextran gradient ultra-centrifugation. Targeted lipid nanoparticles were for-
mulated with a fluorescent lipophilic dye, DiD, for studying receptor binding
and internalization. Studies were conducted with HER2-positive BT474 cells
and CD3-positive Jurkat cells using flow cytometry analyses. Doxorubicin
(DXR) was encapsulated in the nanoparticles by the remote-loading technique
for cell-kill experiments. In vitro cell-kill studieswere conducted by co-culturing
BT474 as the target cells, and peripheral bloodmononuclear cells as the effector
cells, at varying ratios. Results: Purifıed formulations were successfully charac-
terized for conjugation by determining the protein to lipid ratio. Flow cytometry
analyses demonstrated successful cell binding and/or internalization of the TFIL
with both the HER2 and CD3-positive cell lines. Moreover, these dual-targeted
nanoparticles were able to retarget T cells to kill HER2 positive BC cells, and
showed improved effıcacy compared to non-targeted and plain HER2-targeted
formulations in vitro. Conclusion: A novel drug delivery system, TFIL, that
targets HER2 receptors on tumor cells, CD3 on CTLs, and is able to slowly
release DXR was successfully developed and evaluated in vitro on HER2 over-
expressing BC cells. Our fındings show great promise at overcoming resistance
and associated cardiotoxicity to present HER2 targeted BC therapies, and may
translate into improved anti-tumor activity clinically compared to other treat-
ment options.
#5135 Sustained and controlled in vivo therapeutic levels of drug payloads
in tumors using two separate drug combination platforms: Antibody nano-
particle-drug conjugates andmulti-drug nanoparticle-drug conjugates, with
the potential for improved drug combinability and anticancer effects. Ches-
ter A. Metcalf, Derek van der Poll, Liang Zhao, Roy I. Case, Doug Lazarus,
Donna Brown, Tiffany Halo, Lata Jayaraman, Christian Peters, Ellen Rohde,
Scott Eliasof. Cerulean Pharma, Inc., Waltham, MA.
Our nanoparticle-drug conjugates (NDCs), created at Cerulean Pharma
Inc. by conjugating drug payloads to our novel -cyclodextrin-PEG (CDP)
copolymer, are designed to signifıcantly mitigate a payload’s limitations by
providing sustained drug delivery to the tumor and superior therapeutic
index through controlled release kinetics. Cerulean has two NDCs in the
clinic, CRLX101 and CRLX301, evidencing the translatability of our tech-
nology. CRLX101 has been dosed in over 400 patients and CRLX301 is in
ongoing Phase 2a development. A key and differentiating feature of our
NDC Platform is our linker technology, which is tailored for an optimal fıt
with the conjugation functionality of the API drug payloads (e.g., alcohol,
carboxylic acid, amine, amide and urea functionality) and customizable to
achieve desired drug release profıles. As an illustration of Cerulean’s ability
to expand its NDC platform, we will present the biological and pharmaco-
kinetic (PK) data supporting our drug combination platform of antibody
nanoparticle-drug conjugates (ANDCs) and multi-drug nanoparticle-drug
conjugates (mNDCs). ANDCs combine potentially any NDC with any con-
jugatable biologic to generate an ANDC with ultra-high drug-antibody ra-
tios (DARs). Using our established NDC linker technology, we generated
Herceptin-camptothecin ANDCs with DARs as high as 500, orders of mag-
nitude higher than ADCs, and no more than 5-fold loss in binding (greater
than 90% binding up to 300 DAR) compared to native Herceptin in our
solution-based HER2 antigen binding assay. In addition, we provide evi-
dence experimentally that rhodamine-labeled ANDCs penetrate and inter-
nalize in HER2 tumor cells. The ANDCs demonstrate tunable in vitro
release kinetics and long in vivo half lives in mouse PK studies, including
sustained levels of released drug in tumors (greater than 300h) using an
ANDC (average DAR 201) delivering an 8 mg/kg camptothecin dose. The
observed mouse MTD for the ANDC was at least 3x higher than that of the
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corresponding NDC. ThemNDCs take advantage of our existing NDC linker
platform technology to conjugate diverse drug combos including DNA dam-
aging agents (DDA)DNA damage repair agents (DDR).We generated our
POC camptothecin-olaparib mNDCs spanning a range of drug combination
ratios (from 1:1 to 1:20) and all demonstrated distinguishable and tunable in
vitro release rates. PK study of a 1:1 camptothecin-olaparib mNDC
(8mg/kg each drug) demonstrated very low clearance and sustained levels
of released drug in tumor (greater than 72h). Our drug combination plat-
forms, ANDCs and mNDCs, allow delivery of therapeutic agents to their
respective biological targets at clinically-relevant doses, greatly increasing
the diversity of drug combination possibilities.
#5136 Upregulation of Salmonella motility in tumors improves disper-
sion, colonization and intracellular invasion of the bacteria. Vishnu Raman,
Nele V. Dessel, Owen O’Connor, Neil S. Forbes. University of Massachusetts-
Amherst, Amherst, MA.
Diffusion limitations in tumors prevent small molecule therapies from reach-
ing cancer cells located distally from vasculature. This is one reason why some
cancers become drug resistant and relapse. To circumvent these diffusional lim-
itations, Salmonella can be used as a drug delivery vehicle. The facultative an-
aerobe preferentially colonizes tumor tissue over normal tissue at ratios greater
than 10,000:1.Moreover, flagella allow the bacteria to penetrate deep into tumor
tissue. Finally, genetically modifıed Salmonella can invade cancer cells and de-
liver a wide range of intracellularly functioning and patient specifıc therapies
(DNA, RNA, and inhibitory peptides). But, Salmonella must distribute homo-
geneously within tumors and invade a signifıcant number of live cancer cells in
order to deliver therapies uniformly within tumors. To enable this, we hypoth-
esized that up-regulating the master motility regulator, flhDC, in Salmonella
would improve intratumoral penetration, uniform colonization and intracellu-
lar invasion of cancer cells. Salmonella utilize the transcription factor complex,
flhDC, to regulate flagella synthesis and thus, motility. This transcription factor
complex also positively influences type three secretion system (T3SS) assembly,
which, Salmonella use to intracellularly invade epithelial cells. To test this hy-
pothesis, we created a set of synthetic gene circuits that use arabinose for induc-
ible expression of flhDC, the Plac promoter for constitutive expression ofDSRed
and the PSSEJ promoter to express GFP when Salmonella invade tumor cells.
We analyzed aqueous bacterial motility with video microscopy. Finally, we ad-
ministered the motility inducible Salmonella into a tumor-on-a-chip device to
examine spatial and temporal tumor colonization characteristics of the bacteria.
In an aqueous environment, the flhDC induced Salmonella swamapproximately
33% faster than a Salmonella control (P.01). Induction of flhDC increased the
motile fraction (15-30 micrometers/second) of bacteria two-fold (P.05) while
also decreasing the non-motile fraction (0-15 micrometers/second) six-fold
(P.05)when compared to a Salmonella control. In amicrofluidic device, flhDC
induced Salmonella exhibited increased colonization and growth in tumor tis-
sue located far away from channels that were meant to resemble tumor micro-
vasculature (P.05), when compared to a control. Finally, flhDC induction in-
creased tumor cell invasion approximately two-fold in tissue located both
proximal and distal to the micro-channels within the microfluidic device
(P.05), when compared to a control. Highly motile Salmonella could reduce
the occurrence of drug resistant cancer relapse by delivering targeted therapies
uniformly to cancer cells that would otherwise remain untreated with conven-
tional therapy.
#5137 Utility of pH (low) insertion peptide (pHLIP® peptide) variants in
drug delivery. Linden C. Wyatt, Anna Moshnikova, Troy Crawford, Oleg A.
Andreev, Yana K. Reshetnyak. University of Rhode Island, Kingston, RI.
Introduction: The pH (Low) Insertion Peptides (pHLIP® peptides) show util-
ity in a wide variety of medical applications due to their ability to target cancer
cells by exploiting the acidity that is ubiquitous to tumor tissue. Targeting tumor
acidity offers many advantages over traditional biomarker targeting and has
allowed pHLIP® peptides to target primary tumor tissue aswell as sub-millimeter
metastases. Previously, pHLIP®s conjugated to PET/SPECT tracers or fluores-
cent labels have found applications in diagnostic nuclear imaging and fluores-
cence-guided surgery. The purpose of this study was to evaluate a diverse col-
lection of pHLIP® variants, including those incorporating non-standard amino
acids, consisting of two or four pHLIP®s linked together, and one of de novo
design, in order to determine the pHLIP® peptide best suited for the targeting
and intracellular delivery of therapeutic cargomolecules to primary tumors and
metastases. Methods: Biophysical experiments, namely fluorescence and circu-
lar dichroism spectroscopy, using liposomes asmodel membranes, were used to
study the localization of pHLIP® variants at the bilayer surface at high pH, the
tertiary structure and orientation within the membrane of the folded variants at
low pH, the parameters of pH-dependent peptide insertion, and the rate at
which insertion occurs. In vitro experiments, wherein the polar toxin amanitin
was conjugated to the membrane-inserting end of the pHLIP® variants via a
cleavable disulfıde bond, were used to study intracellular cargo delivery and the
resulting inhibition of cancer cell proliferation. In vivo experiments, wherein the
fluorescent dye Alexa Fluor 546 was conjugated to the non-inserting end of the
pHLIP® variants via a non-cleavable bond, were used to study biodistribution
and tumor uptake. Results: All investigated pHLIP® variants demonstrated the
behavior characteristic of wild-type pHLIP® with some differences inmembrane
affınity and membrane insertion profıles, namely pKa of insertion and cooper-
ativity. Inhibition of cancer cell proliferationwas induced by the pH–dependent
translocation of amanitin across the plasma membrane by the pHLIP® variants.
Biophysical measurements, values of EC50 obtained at pH 6.0 and pH 7.4, and
fluorescence imaging of triple-negative breast tumors in mice using pHLIP®
peptides were analyzed collectively. Conclusions: Different pHLIP® variants are
best suited for different purposes, such as the intracellular delivery of highly or
moderately toxic polar or hydrophobic payloads to primary tumor tissue as well
as metastases. pHLIP® Variant 3 (Var3), exhibited the most favorable properties
for the targeted delivery of amanitin to tumor tissue. Acknowledgement: This
research was supported by the National Institute of General Medical Sciences of
the National Institutes of Health under award number R01GM073857 to OAA
and YKR.
#5138 Development of a gold nanoparticle platform capable of selective
homing to tumor tissues for intravenous antitumor therapy. Zhen Han. Na-
tional Cancer Institute, Frederick, MD.
Intratumoral administration of high mobility group nucleosome-binding
protein 1 (HMGN1) and R848/resiquimod together with a checkpoint inhibitor
can eradicate large established tumors. However, the intratumoral route of ad-
ministration is diffıcult to use on cancers of internal organs. To improve poten-
tial clinical use ofHMGN1andR848, it is necessary to deliverHMGN1andR848
systemically to the tumor tissue. Gold nanoparticles (AuNP) have been exten-
sively studied as a vehicle for various types of drugs, including anticancer com-
pounds. In this study, we established a means of generating PEGylated Au-
HMGN1-R848 (Au-PEG-HMGN1-R848) complexes, which, upon intravenous
IV administration, preferentially target ectopic hepatoma or colon tumor tissue
and avoids uptake of the particles by liver and spleen of tumor-bearing mice.
Additionally, Au-PEG-HMGN1-R848 complexes were stable and preserved the
capacity of HMGN1 and R848 to stimulate the maturation of dendritic cells. IV
administration of Au-PEG-HMGN1-R848 complexes plus a checkpoint inhib-
itor had effective antitumor activity in curing 80% of C57BL/6 mice bearing
large (1 cm in diameter) Hepa1-6 hepatoma and Balb/c mice bearing CT26
colon tumors. Therefore, an Au nanoparticle platform capable of selectively
delivering HMGN1 and R848 systemically to tumor tissues can be used to effec-
tively to cure ectopic Hepa1-6 hepatoma and CT26 colon carcinoma.
#5140 Encapsulation of the atypical retinoid ST1926 innanoparticles pro-
longs the survival of acute myeloid leukemia xenografted mice at multiple
folds lower concentrations than the naked drug. Leeanna El-Houjeiri,1 Walid
Saad,1 Berthe Hayar,1 Patrick Aouad,1 Nadim Tawil,1 Rana Abdel-Samad,1
Claudio Pisano,2 Ali Bazarbachi,1 Hiba El Hajj,1 Nadine Darwiche1. 1American
Univ. of Beirut, Beirut, Lebanon; 2Biogem, Ariano Irpino, Italy.
Acute myeloid leukemia (AML) represents one of the most complex types of
leukemia. It is a clinically and genetically heterogeneous disorder of hematopoi-
etic progenitor cells, which have lost their ability to differentiate normally. Reti-
noids regulate vital biological processes including development, differentiation,
proliferation, and cell death of hematopoietic progenitor cells. The natural ret-
inoid all-trans retinoic acid (ATRA) became the paradigm for the treatment of
acute promyelocytic leukemia (APL), an AML subtype. However, in non-APL
AML patients, ATRA is possibly only effective in patients with Nucleophos-
min-1 mutations without FMS-like tyrosine kinase 3 internal tandem duplica-
tion (FLT-3 ITD). Therefore, synthetic retinoids, specifıcally the adamantyl
ST1926, emerged as potential alternatives. However, despite its lack of toxicity,
ST1926 development in clinic was limited due to its rapid glucuroconjugation
resulting in low plasma concentrations. Nanomedicine enables more effıcient
drug delivery and bioavailability. Here, we investigate the pre-clinical effıcacy of
ST1926 and polymer stabilized ST1926 nanoparticles in AML in vitro and in
vivo models. We show that ST1926, at low sub-M concentrations, potently
inhibited the growth of human non-APL ATRA-resistant AML cell lines and
AML patient cells while sparing resting and activated normal leukocytes at ten-
to hundred-fold higher concentrations. ST1926 induced earlyDNAdamage and
massive apoptosis in all tested AML cell lines. To optimize the drug’s bioavail-
ability burden, polymer stabilized ST1926 nanoparticles were developed using
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Flash NanoPrecipitation, and were shown to display comparable anti-growth
activities to the naked drug in vitro. In murine AML xenograft model, ST1926
and ST1926 nanoparticles signifıcantly prolonged survival. Strikingly, ST1926
encapsulated in nanoparticles extended survival in AML xenografted mice at
four-fold lower concentrations than the naked drug. These results highlight the
promise of ST1926 in AML therapy and warrant further clinical development of
this adamantly retinoid.
#5141 Optimizing peptide-drug conjugate delivery as an alternative to
antibody-drug conjugates for solid tumors. Theo L. Sottero, Emily J. Girard,
Carrie H. Myers, James M. Olson. Fred Hutchinson Cancer Research Center,
Seattle, WA.
Antibody-drug conjugates (ADCs) have been FDA approved for targeted
delivery of chemotherapy to a small subset of cancers. However, there are sig-
nifıcant limitations in their clinical utility in the majority of cancers: despite
hundreds of clinical trials, there are only two FDA approved drugs currently on
themarket. ADCs are further limited by their poor penetration into solid tumors
and an inability to cross the blood-brain-barrier (BBB). Our lab has over a
decade of experience with peptide-dye conjugates such as chlorotoxin-Cy5.5,
which demonstrates tumor-specifıc accumulation in a wide range of cancers
including solid tumors and tumors protected by the BBB. However, chloro-
toxin-Cy5.5 accumulates in mouse liver – a potential liability if a chlorotoxin-
drug conjugate exhibited similar biodistribution. Tumor Paint/BLZ-100 is a
derivative of thismolecule optimized for tumor accumulation that is currently in
clinical trials to aid in cancer surgery. We sought to expand upon the utility of
Tumor Paint and optimize a novel peptide that is capable of delivering both
imaging agents and chemotherapeutics specifıcally to tumor cells in vitro and in
vivo. We have identifıed a novel Optide (OPtimized knottin pepTIDE) able to
accumulate in a range of cancers (lymphoma, sarcoma, colon cancer, and pedi-
atric medulloblastoma). To test whether an Optide could be created with a
greater tumor specifıcity, we looked to both natural homologs as well as specifıc
charged residuemodifıcations.We have identifıed two next-generation Optides
with enhanceduptake inmousemodels of sarcoma.Wehave used these peptides
to deliver amicrotubule inhibitor to sarcoma and lymphoma in vitro and in vivo.
Using in vitro flow cytometry, we have also identifıed multiple FDA approved
drugs that upregulate or downregulate uptake of our family of peptide drug-
conjugates. In understanding the pathways regulating the uptake of these pep-
tides, we hope to both be able to identify tumors best suited for treatment with
peptide-drug conjugates (PDCs) based on our Optide scaffold.
#5142 Molecular intersection of a 3-in-1 nanomedicine targeting micro-
tubules, ERK tyrosine kinases with profound nuclear modulations, and
quantum imaging for hepatocellular carcinoma therapy. Radhika J. Poojari,
Rohit Srivastava, Dulal Panda. Indian Institute of Technology Bombay, Powai,
Mumbai, India.
Hepatocellular carcinoma is the fıfth malignant form of cancer worldwide
with poor survival rates. Despite advances in clinical diagnosis, surgery and
chemotherapy till date systemic treatment of solid tumour like hepatocellular
carcinoma has not been effective inmost cases and its clinical therapy is a major
challenge. Hence, it is important to search for innovative therapeuticmodalities.
Nanomedicines that can target bothmicrotubules and kinases may provide new
avenues to treat hepatocellular carcinoma. Small molecule inhibitors like do-
cetaxel and sorafenib represent one of them. Clinical trials have revealed unac-
ceptable toxicities such as neutropenia, severe hypersensitivity, anaphylactic re-
action, hypertension, dermatological toxicities and hand-foot skin reaction, etc
with these drugs in cancer patients. Other major drawbacks are insolubility,
poor bioavailability, short half-life and non-specifıcity. To mitigate these issues,
we developed a next generation highly compact nanocarrier system, the 3-in-1
nanomedicine platform with in-depth understanding of the intracellular ma-
chinery responsible for its uptake and the molecular mechanisms for regulating
the delivery effıcacy.Development of a 3-in-1 nanomedicine (100-200nm) com-
prised of microtubule inhibitor docetaxel, tyrosine kinase inhibitor sorafenib
and an imaging probe quantum dots encapsulated in a biocompatible polymer
PLA against human hepatocellular carcinoma cells. Monotherapy strategies in
cancer treatment fail due to several complex issues like narrow therapeutic win-
dow, non-specifıcity, administration of higher, repetitive doses, adverse clinical
toxicities and resistance mechanisms of drugs. The advantages of 3-in-1 nano-
medicine strategy are delineated. The real-time imaging of quantum dots in
hepatocellular carcinoma cells showed accelerated internalization. The 3-in-1
nanomedicine exhibited potent inhibition in hepatocellular carcinoma cell pro-
liferation, clonogenicity, induced strong G2/M phase block and apoptosis in-
duction in comparison to single drug monotherapy. The 3-in-1 nanomedicine
strongly promoted the microtubule bundling via increased polymer tubulin ex-
pression level, augmented multinucleation, aberrant mitosis, and signifıcantly
inhibited downstream protein tyrosine kinase, ERK1/2 activation in hepatocel-
lular carcinoma cells in comparison to single drugmonotherapy. These fındings
provide a signifıcant insight into the intrinsic molecular interplays of 3-in-1
nanomedicine in hepatocellular carcinoma cells. The 3-in-1 nanomedicine in-
tegrates several avenues in a single nanoscale-platform for dual-drug delivery,
and high sensitivity quantum dots imaging as well as diagnostics for hepatocel-
lular carcinoma therapy, holding high translational research potentials in the
near future.
#5143 Fusogenic targeted liposomes: novel nanotherapy for specifıc treat-
ment of prostate cancer. Jihane Mriouah,1 Rae Lynn Nesbitt,2 Susan Richter,1
Melinda Wuest,1 Desmond Pink,1 Deborah Sosnowski,1 Roy Duncan,3 Frank
Wuest,1 Andries Zijlstra,4 John Lewis1. 1University of Alberta, Edmonton, Al-
berta, Canada; 2Entos Pharmaceuticals, Edmonton, Alberta, Canada; 3University
of Dalhousie, Halifax, Nova Scotia, Canada; 4University of Vanderbilt, Nashville,
TN.
Metastatic or castrate-resistant prostate cancer is the second-leading cause of
cancer mortality in males. In the past 3 years, chemotherapies have extended
survival, but effıcacy is limited by dose-limiting toxicities due to suboptimal
biodistribution. Here, we have addressed the lack of specifıcity and accumula-
tion inCastrate Resistant ProstateCancer (CRPC) by developing a unique nano-
carrier for drug delivery:molecular targeted fusogenic liposomes. Previously, we
have developed a platform whereby lipid nanoparticles are formulated with
fusion associated small transmembrane (FAST) protein p14. The p14 protein
catalyzes mixing of the nanoparticle lipids with target plasma membrane to
deliver the cargo directly into the cytoplasm. In this study, we have engineered
the p14 protein to incorporate the prostate cancer targeting ligand bombesin,
which binds specifıcally to the Gastrin-releasing Peptide (GRPR) that is overex-
pressed in prostate cancer. We hypothesized that this novel targeted fusogenic
liposome formulation would signifıcantly improve the biodistribution and effı-
cacy of chemotherapy. A clinical liposomal doxorubicin formulation (DOXIL)
wasmodifıed to incorporate targeted fusogenic p14 protein, and the effıcacy and
biodistribution of these new formulations was evaluated using in vitro and in
vivo models of CRPC. In PC3 cells, compared to conventional liposomes, intra-
cellular levels of doxorubicin are increased by 15 and 25 times when p14 or
p14-bombesin liposomes are used. Additionally, the IC50 is reduced from
85mM to 2mM. In mice bearing PC3 tumors treated with targeted fusogenic
liposomal doxorubicin, we observed improved tumor growth inhibition by 57%
(vs control) and 1.5 fold increased accumulation in tumors within 24h after
administration. These proof of concept experiments indicate that molecular
targeted fusogenic nanomedicines can improve both the intracellular delivery
and tumor accumulation of chemotherapy, improving outcomes in this preclin-
ical model. This highlights the potential for improved outcomes in patients with
CRPC through the enhancement of approved drugs.
#5144 BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting
MT1-MMP for the treatment of solid tumors: Design of bicyclic peptide and
linker selection. Helen Harrison, Gavin Bennett, Diane Blakeley, Amy Brown,
Spencer Campbell, Liuhong Chen, Robert J. Lutz, Silvia Pavan, Katerine van
Rietschoten, Daniel Teufel, Peter U. Park, Kevin Lee. Bicycle Therapeutics Lim-
ited, Cambridge, United Kingdom.
Bicycles® are novel binding agents comprising small bicyclic peptides (1.5-3
KDa) constrained via a chemical scaffold, selected for high affınity and selectiv-
ity to targets of interest. MT1 (MMP14/MT1-MMP) is a membrane-associated
metalloprotease overexpressed in many solid tumours and is implicated in tu-
mor invasion and metastasis. MT1 expression positively correlates with poor
prognosis. Phage libraries containing 1015 unique peptide sequences were post-
translationally cyclized with thiol-reactive scaffold and used in an optimized,
high-throughput selection process to identify Bicycles® to the hemopexin do-
main of MT1. Additional iterative rounds of directed phage based screening
were used to optimize affınity and off-phage non-natural amino acids were
introduced at select positions to improve plasma stability to generate the lead
Bicycle binder. The lead anti-MT1 Bicycle was further modifıed with a sarcosyl
spacer to form N241. N241 binds specifıcally to the hemopexin domain of MT1
with a Kd of approximately 2 nM with no binding observed to the catalytic
domain of the protease nor to any of the related MMP family members tested.
Importantly and in contrast tomost antibodies, N241 binds with similar affınity
to MT1 from multiple species including rodent, dog and non-human primate.
Since the expected rapid tumor penetration and specifıc binding of these small
peptidyl-binders makes them ideal for use in targeted delivery approaches, a
series of Bicycle drug conjugates (BDCs)were prepared;N241was conjugated to
potent maytansinoid cytotoxics via linkers which varied in their cleavability.
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Though all the BDCs maintained high affınity for MT1, effıcacy toward MT1-
positive human tumormouse xenografts varied with linker stability. BDCs with
the most stable linkers were the least active suggesting that optimal tumor acti-
vation was obtained with linkers that could be cleaved more rapidly. Due to the
rapid clearance and limited systemic exposure of these small-targeting BDCs,
only the most labile linker showed toxicity in the mouse studies. Of the BDCs
tested, BT1718, composed of N241 and DM1 conjugated via the SPP linker,
demonstrated an optimal therapeutic index. Potent anti-tumor effıcacy with
BT1718 was observed across a panel of MT1-positive xenografts with complete
tumor regressions observed in most models at doses that were well tolerated. In
one example, HT-1080 fıbrosarcoma subcutaneous xenografts were intrave-
neously treated with BT1718 when the tumor size had reached approximately
180 mm3. BT1718 given at 3 mg/kg once a week resulted in tumor stasis while
BT1718 given at 10 mg/kg once a week or 3 mg/kg twice a week induced com-
plete regression. In summary, BT1718, a highly active, targeted drug conjugate
with unique pharmacological properties is a promising therapeutic candidate
for the treatment of MT1-MMP-positive solid tumors.
#5145 Demystifıcation of obstacles encountered using convection en-
hanced delivery in preclinical models of diffuse intrinsic pontine glioma.
Jamila S. Gittens,1 Sridevi Yadavilli,1 Michael Lin,2 Eshini Panditharatna,2
Suresh N. Magge,1 Roger J. Packer,1 Javad Nazarian1. 1Children’s National
Health System,Washington, DC; 2The GeorgeWashington University, Washing-
ton, DC.
Diffuse intrinsic pontine glioma (DIPG) is a pediatric brain tumor that arises
in the pons of the brainstem. The vital location of the tumor and the presence of
the impermeable blood brain barrier (BBB) make treatments ineffective and
leads to a high mortality rate of DIPG patients. Convection enhanced delivery
(CED) is a promising drug delivery method because of its ability to bypass the
BBB that is currently being investigated to deliver therapeutic agents directly to
brain tumors. Nonetheless, clinical trials investigating the use of CED to treat
patients have not shown prolonged patient survival. Previous studies have de-
termined poor distribution in clinical studies due to reflux or back flow. Addi-
tionally, by analyzing theH&E andKi67 stained brain sections of aDIPGpatient
that underwent CED, we determined that areas of radiation-induced necrosis
within the tumor were a possible reason for treatment failure. In this study, we
intend to optimize CED in orthotopic murine model of DIPG. Specifıcally, we
have tested the ideal volume and rate of injection, as well as using the combined
approach of using CED and radiation. Ideal injection rate was established by
assessing infusion profıles in agarose brain phantoms using various needles,
which resulted in the injection rate of 0.3ul/min producing the least back flow.
Next, the ideal injection rate and volumes were tested in vivo by injecting non-
tumor bearing mice with trypan blue. To assess the infusion rate, brain sections
were analyzed at necropsy to determine distributions of the injected dye. To
investigate accumulation of CED-mediated payload in necrotic sites, tumor
bearing mice were exposed to radiation and then injected with the fluorescent
dye, DiI. Formalin fıxed brain sections were stained with DAPI and fluorescent
images were taken. The results of this study indicate that a rate of 0.5ul/min
results in a signifıcantly larger distribution area compared to the 0.3ul/min in-
jection rate (50.71  4.84 compared to 30.47  1.18, p0.0462). Fluorescent
images of brain sections of mice injected with DiI indicated the accumulation of
dye in areas where there were no live cells, supporting the assumption that drug
injections may be retreating to necrotic pockets and thus preventing equal dis-
tribution of the drug in the tumor. Ongoing studies include investigating the
survival benefıts of using CED to deliver therapeutic agents in tumor-bearing
mice. Understanding the obstacles of convection enhanced delivery in murine
models can help establish better treatment regimens and devices for patients and
provide better preclinical models for drug testing.
#5146 Increasing penetration of anticancer drugs through sortilin recep-
tor-mediated cancer therapy: A new targeted and personalized Approach in
the treatment of ovarian cancer. Michel Demeule,1 Jean-Christophe Curie,1
Alain Larocque,1 Cyndia Charfı,1 Richard Béliveau,1 Claude Vezeau,2 Borhane
Annabi1. 1Université duQuébec àMontreal,Montreal, Quebec, Canada; 2Katana
Biopharma, Montreal, Quebec, Canada.
The development of personalized therapies against ovarian cancer remains
highly challenging in current modern oncology. One way to achieve greater
selectivity and better anticancer drug delivery into cancer cells is to conjugate
cytotoxic agents to specifıc peptide ligands that will selectively target receptors
abundantly and/or exclusively expressed on these cells. Increased expression of
Sortilin, a scavenging receptor, has been clinically observed in several human
cancers including breast, prostate, colon, pancreas, skin, and pituitary. In par-
ticular, Sortilin has also been reported to be overexpressed in ovarian cancers as
compared to non-malignant ovarian tissue. In light of this, we developed a
peptide conjugation platform using a new Sortilin receptor-mediated vectoriza-
tion strategy to increase cell targeting selectivity and cell delivery effıcacy of
anticancer agents. As a proof-of-concept, Doxorubicin was conjugated to pep-
tide sequences, termed Katana peptides (KA). In vitro, signifıcantly increased
Sortilinmediated intracellular delivery of the Doxorubicin-Katana peptide con-
jugate (DoxKA) was observed in SKOV3 and ES-2 ovarian cancer cell linemod-
els, with conserved effıcient Doxorubicin cytotoxic mechanism. Uptake of
DoxKA in ES-2 ovarian cancer cells was reduced when Sortilin expression was
specifıcally silenced by using siRNA or upon competition with the Sortilin li-
gands neurotensin and progranulin. In addition, DoxKA was found to bypass
the P-glycoprotein (P-gp) efflux pump since, in contrast to Doxorubicin uptake
in MDCK-MDR1 cells overexpressing the P-gp efflux pump, the uptake of
DoxKAwas unaffected by theP-gp inhibitorCyclosporinA. In vivo,DoxKAwas
better tolerated and caused a more potent inhibition of human ovarian tumor
xenografts growth than did Doxorubicin alone. These results provide strong
evidence for the potential of this drug development platform in the generation of
novel personalized therapeutics with specifıc targeting of SORT1-positive can-
cer cells.
#5147 Novel warheads for targeted therapies of cancer: The concept and
design of proPBDs. Iontcho Vlahov, Longwu Qi, Spencer Hahn, Kevin Wang,
Hari K. Santhapuram, Albert Felten, Paul Kleindl, Jeremy Vaughn, Christopher
P. Leamon. Endocyte, W. Lafayette, IN.
Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antibiotics, are a class of natural
products produced by various actinomycetes bacteria. PBDs are sequence selec-
tiveDNA-crosslinking alkylating compounds and are considerablymore potent
than systemic chemotherapeutic agents. Some PBDs have the ability to recog-
nize andbond to specifıc sequences ofDNA.After insertion in theminor groove,
a covalent aminal bond is formed through nucleophilic attack of the N-2 of a
guanine (G) base on the electrophillic C-11 imine of PBD. The end result is
obstruction of tumor cell division without any signifıcant distortion of the
DNA’s helix, thus potentially avoiding the common phenomenon of drug resis-
tance. In recent years, synthetic PBD-dimers have emerged as a promising class
of payloads for conjugates in the fıeld of targeted cancer therapies. Unfortu-
nately, many PBD conjugates preserve the strongly alkylating imine moiety
within their structural framework,which can react in a deleteriousmannerwhile
in circulation on theirway to their intended targets. As an elegant solution to this
inherent problem we designed conjugated prodrugs lacking the imine moiety.
Once the prodrug (proPBD) conjugate enters a targeted cell, cleavage of the
linker system in the construct triggers the generation of a reactive intermediate
possessing an aldehyde and aromatic amine. An intramolecular reaction subse-
quently takes place as the aromatic amine adds to the aldehyde with the loss of
water to give the imine, and as a result, the diazepine ring. In our proPBDs, we
envision to mask the aldehyde as a hydrolytically sensitive oxazolidine moiety
and to exploit its ring system as a part of an arsenal of self-immolative linker
systems for conjugation. To prove the range of applications for this new class of
latent DNA-alkylators, we designed and prepared a diverse variety of novel
warheads, consisting of proPBDdimers, hybrids of proPBDwith other powerful
alkylating agents, as well as tethers of proPBDs with sequence-selective DNA
minor groove binders. The utility of the so prepared novel warheads in the
design of small molecule drug conjugates (SMDC) for targeted cancer therapies
will be also discussed in the presented poster.
#5148 Liposomal gemcitabine, FF-10832, improves gemcitabine (GEM)
pharmacokinetics (PK) and increases anti-tumor effıcacy. Takeshi Matsu-
moto, TsukasaKitahashi, Takashi Komori,HiromuKitahara, KoheiOno,Naoki
Yamada, Hiroyuki Iwamura, Kiyohito Takada, Shinji Hagiwara, Yasuhiro Shi-
mada. FUJIFILM Corporation, Tokyo, Japan.
Introduction: FF-10832 is a liposome suspension optimized by Fujifılm nan-
otechnology containing 0.5 mg/mL GEM, cholesterol, HSPC, N-MPEG-DSPE.
FF-10832 is expected to improve GEM PK and have strong anti-tumor effects.
The PK and anti-tumor effects of FF-10832 were studied in mice and human
pancreatic cancer xenograftmodels.Methods: Single-dosemurine plasma PKof
FF-10832 1 mg/kg was compared to GEM 240mg/kg. In vivo activity of GEM
240 mg/kg and FF-10832 1-5 mg/kg IV once weekly were compared in human
pancreatic cancer murine xenograft models; 2 subcutaneous (Capan-1 [GEM-
sensitive] and BxPC-3 [GEM-resistant]), and 1 orthotopic (SUIT-2)model. The
active form of GEM (GEM triphosphate [dFdCTP]) inhibits DNA synthesis.
dFdCTP tissue concentrations following FF-10832 4mg/kg andGEM240mg/kg
were compared in these models. Results: An extended plasma t½ (10.6 vs. 2.9
hours), lower clearance, and smaller volume of distribution were observed with
FF-10832 vs. GEM, which correlated with greater dose exposure achieved with
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FF-10832 compared to GEM (AUClast 186000 vs. 73000 hr·ng/mL). FF-10832
demonstrated increased in vivo activity in SUIT-2, Capan-1, and BxPC-3 mod-
els at signifıcantly lower doses compared to GEM. In the Capan-1 and BxPC3
models, FF-10832 showed dose-dependent tumor growth suppression with FF-
10832 4 mg/kg and 5 mg/kg superior to that of GEM (p0.001), respectively.
Following 11 weekly doses in the SUIT-2 model, the survival rate was 0% and
20% for vehicle and GEM 240 mg/kg vs. 13% and 60% for 2 and 4 mg/kg FF-
10832, respectively. Median survival time was 60 (FF-10832 2 mg/kg) and 73
(GEM 240 mg/kg) vs. 26 days (vehicle) (p 0.001). Median survival was not
reached at FF-10832 4 mg/kg. In all models, FF-10832 2 mg/kg (equivalent
effıcacy to GEM 240 mg/kg) showed no body weight gain suppression. The
dFdCTP tumor/bone marrow AUC ratio was signifıcantly higher following FF-
10832 (dFdCTP AUC ratio  7) compared with non-liposomal GEM (0.8).
Conclusions: FF-10832 is a stable liposomal GEM formulation demonstrating
potent anti-tumor effıcacy in solid tumor models with a favorable pharmacoki-
netic profıle compared to non-liposomal GEM. Increased exposure achieved at
lowerGEMdosesmay potentially result in superior effıcacy and amore tolerable
safety profıle for FF-10832 compared to non-liposomal GEM.
#5150 Designing of a novel strategy for cancer gene therapy by selective
delivery of Adenovirus-based toxin.Nadir Arber, Ilana Boustanai, Shiran Sha-
pira, Dina Kazanov. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Introduction: Aberrant activation of the Ras pathway exists in many human
tumors (Lung 25%, pancreatic (PC) 95% and colorectal cancers (CRC)
50%.Development of numerous direct and in direct Ras inhibitors have failed.
This led us to think differently; we exploit the hyperactive Ras pathway rather
than trying to inhibit it. We previously had reported that recombinant adenovi-
ruses, carrying a pro-apoptotic gene (PUMA) under the regulation of Ras-re-
sponsive elements suppressed the growth of cancer cells harboring hyperactive
Ras. Moreover, replacing the PUMA gene with more potent toxins (bacterial
MazF-MazE toxin-antitoxin unique regulated system), the potency of this kill-
ing strategy was signifıcantly improved. P53 is a classical tumor suppressor mu-
tated in many tumors. Herein, the WT p53 is use to protect normal cells from
any systematic toxin leakage. Aim: To establish a tight control of the toxin
expression in malignant cells, and the anti-toxin in normal cells dual system
based on the Ras and p53 responsive elements Methods: Adenoviral vectors
carrying the toxin (PY4-MazF-mcherry) and the antitoxin (RGC-MazE-GFP)
were designed under the regulation of Ras and p53 responsive elements, respec-
tively. Those two constructs were cloned into a “fırst generation” 	E1/	E3 hu-
man type5 adenoviral vector. Virus particles were produced, their titer was cal-
culated by the End-Point Dilution Assay and their potency was tested in vitro.
Cell death was measured qualitatively by using the fluorescent microscopy and
was quantifıed by the enzymatic MTT assay. SHP77;Rasmut/p53mut, H2030;Ras-
mut/p53wt, H1650;Raswt/p53wt and H1975;Raswt/p53mut lung cancer cell lines
were used for testing the potency of the system.MIA-PACA2, Colo357, Panc-1;
Rasmut/p53mut, and BxPC3;Raswt/p53mut PC cell lines were tested as well. Dif-
ferent ratios of toxin-antitoxin (2:1, 1:1 and 1:0.5) were used. Results: Massive
cell death was induced in a dose-dependentmanner (70%with a titer of 7.5MOI
in lung cells with mutated Ras compared to 21% in cells with WT Ras). Similar
results were obtained in a colony formation assay and qualitatively confırmed by
fluorescence microscopy. Similarly, in PC, cells with mutated Ras showed 50%
cell death in a dose-dependent manner with a titer of 15MOI, compared to 18%
in cells with WT Ras. Ratio of 1:0.5, showed decrease in the mortality of the
mutated Ras cells expressingWT p53; 36%with a titer of 7.5MOI. These results
indicate that the antitoxin indeed actively protects cells withwt p53. Conclusion:
Outside the box cancer gene therapy by exploiting activate Ras and P53 path-
ways are effective in vitro. The low toxicity in WT Ras as well as WT p53 ex-
pressing holds promise for effective and safe therapy.
#5151 Nanoliposomal irinotecan (nal-IRI, MM-398) has greater anti-tu-
mor activity than topotecan and irinotecan in mouse models of small cell
lung cancer. Shannon C. Leonard, Daniel Gaddy, Helen Lee, Stephan Klinz,
Jonathan Fitzgerald, Bart Hendriks. Merrimack Pharmaceuticals, Inc., Cam-
bridge, MA.
Nal-IRI, a liposomal formulation of irinotecan, is designed for extended cir-
culation relative to non-liposomal irinotecan and to exploit leaky tumor vascu-
lature for enhanced drug delivery to tumors. Following tumor deposition, nal-
IRI is taken up by phagocytic cells followed by irinotecan release and conversion
to its active metabolite, SN-38. Sustained inhibition of topoisomerase 1 (TOP1)
by extended SN-38 exposure is hypothesized to enable superior anti-tumor ac-
tivity compared to traditional TOP1 inhibitors. Topotecan, another TOP1 in-
hibitor, is an approved second-line treatment option for small cell lung cancer
(SCLC). Here, we evaluate the anti-tumor activity of nal-IRI compared to irino-
tecan and topotecan in preclinical models of SCLC including those that have
been pre-treated with therapeutics used clinically to treat SCLC. Anti-tumor
activity of nal-IRI, irinotecan, or topotecan was evaluated based on tumor vol-
ume assessments in DMS-53, DMS-114 and NCI-H1048 subcutaneous xeno-
graftmodels inNOD-SCIDmice, aswell as in a patient-derived xenograft (PDX)
model in nu/nu mice. To approximate clinical dosing: Nal-IRI was dosed at 16
mg/kg (irinotecan HCl basis), q1w, equivalent to a proposed clinical dose of 90
mg/m2 free base, q2w; irinotecan was dosed at 33 mg/kg q1w, equivalent to a
clinical dose of 180 mg/m2 q2w; and topotecan was dosed at 0.83 mg/kg/week,
day 1-2 every 7 days, which approximates a clinical dose intensity of 1.5 mg/m2
(days 1-5 every 21 days). Additionally, the activity of these agents was evaluated
after tumors progressed following prior treatment with either topotecan, irino-
tecan or the combination of weekly carboplatin (30 mg/kg) plus etoposide (25
mg/kg), a standard fırst line regimen. Nal-IRI demonstrated anti-tumor activity
in xenograft models of SCLC at clinically relevant dose levels, and resulted in
complete or partial responses in DMS-53, DMS-114, NCI-H1048 and a PDX
model in comparison with irinotecan or topotecan, which each had limited
tumor growth control. Furthermore, Nal-IRI demonstrated anti-tumor ac-
tivity in tumors that progressed following treatment with topotecan, and
demonstrated signifıcantly greater anti-tumor activity than both topotecan
(p0.0001) and irinotecan (p0.0001) in NCI-H1048 tumors (8/8 complete
responses) that had progressed on prior carboplatin plus etoposide treat-
ment. These results support the further clinical development of nal-IRI ver-
sus IV topotecan in patients with SCLC that progressed on or after prior
platinum containing therapy.
#5152 Cancer stem cell targeted exosomes for the treatment of metastatic
breast cancer. Golam Kibria,1 Katelyn E. Lee,1 Erika K. Ramos,1 Simo Huang,1
Clifford V. Harding,1 Jan Lötvall,2 Huiping Liu1. 1Department of Pathology,
School of Medicine, Case Western Reserve University, Cleveland, OH; 2Krefting
Research Centre, Department of Internal Medicine and Clinical Nutrition, Uni-
versity of Gothenburg, Gothenburg, Sweden.
Introduction: Therapy resistance andmetastasis remain the two biggest chal-
lenges of breast cancer that result in a majority of cancer deaths. Cancer stem
cells (CSCs) are a subpopulation of cancer cells that can initiate new tumors,
remain refractory to conventional therapies, and spread throughout the body. In
order to effectively block metastasis, the present study aims to develop novel
therapeutics that specifıcally target breast CSCs and spare normal cells. While
nanomedicine represents one of the promising future directions, it is necessary
to overcome the shortcomings of synthetic nanoparticles, including bio-insta-
bility and off-target toxicity. Here, we aim to bio-engineer the naturally pro-
duced cell-secreted small vesicles, exosomes (100 nm diameter), for a novel
therapeutic delivery system.Methods: Exosomes from the humanmesenchymal
stem cells (MSCs) were isolated by differential ultracentrifugation, and charac-
terized by multiple approaches including transmission EM, Immunoblotting
and immunofluorescence assays to confırm the size, shape and presence of exo-
somal markers CD63, CD81 and LAMP2B. Exosomes were engineered to ex-
press a peptide ligand on its surface to specifıcally recognize and target CSCs,
and the presence of the ligand was confırmed by western blot, flow cytometry
(FCM) and a super resolution confocal laser scanningmicroscopy (CLSM, Leica
SP8). The CSC targeting effıciency of the exosomes was evaluated in vitro by
FCM and CLSM. Further, the exosomes were loaded with microRNAs (miR-
200, miR-30c), as one of the key factors that regulate breast CSC functions, by
following a novel transfection technology. Results: The bio-engineered exo-
somes specifıcally target and internalize into the CSCs compared to normal cells
with absent expression of the ligand-binding protein. The developed exosomes
can effectively deliver candidate miRNAs into the recipient cells and knock
down the genes important for functional CSCs. The in vivo targeting of CSCs
and therapeutic applications of the exosomes using patient-derived human-in-
mouse breast tumor xenograft models are underway. Conclusion: It is expected
that exosome-based miRNA therapeutics will have high biocompatibility, low
toxicity, high specifıcity, and promising effıciency in preclinical and clinical
applications to reduce breast cancer metastasis and improve patient survival.
#5153 Tunable Drug Conjugates: a differentiated drug conjugate (DC)
platform. Sara C. Hickey,1 Alex R. Nanna,2 Hanh N. Nguyen,1 Leslie Ofori,3
Christoph Rader,2 Michael K. Rood,1 Jutta Wanner,1 Doug S. Werner1. 1Blink-
Bio, Inc, Jupiter, FL; 2The Scripps Research Institute, Jupiter, FL; 3Genomics In-
stitute of the Novartis Research Foundation, San Diego, CA.
We have established a set of technologies called Tunable Drug Conjugates
(TDCs) that will differentiate from other DCs via a rapid payload release/rapid
systemic clearance approach intended toquickly drivehigh toxic “payload” concen-
trations within tumor cells while minimizing toxicities to patients. TDCs use pro-
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prietary Silicon-based linker chemistries (SiLinkers) in novel Payload Cassettes
(PCs) that enable the rapid and uniform release of multiple and/or mixed payloads
both in the endosome after internalization and within the necrotic microenviron-
mentof tumors.PCscan incorporatemultiple copiesof the samepayloadoroptimal
ratios of different therapeutic agents that work together synergistically to kill cancer
cells. A second technology - a Dual variable Domain-Fab (DVD-Fab) targeting ca-
pability provides a proprietary means of specifıcally targeting a broad array of cell
surface proteins. DVD-Fab containing TDCs should be cleared from the body
within hours, enabling better management of side-effects. Our Silinker system is
differentiatedby the exquisite and tunable sensitivityof the linkers to cleavageunder
the modestly acidic conditions encountered in the endosomal and lysosomal com-
partments of a cell, and in themicroenvironment of solid tumors. Good stability at
physiological pH (and in human plasma) compares to rapid cleavage at relevant
lower pHs as demonstrated usingmodel systems. SiLinkers exhibit good stability at
37°C inpH7.4 buffer (andplasma) and show rapid hydrolysis at pH5.5 to 6.5 (t1/2
15 -120min).Confocalmicroscopy studieswith imagingconstructsdemonstrate
the translation of the in vitro data to cellular systems.We assembled SiLinker based
prototype TDCs to target the folate receptor	 (FAR)with folic acid as the targeting
ligand and vinblastine analogs as the payload(s). We used single and PC drug con-
jugates to show cellular and in vivo proof-of-concept. We tested our TDCs in cell
lines overexpressing FAR and showed that cytotoxicity was blocked by excess folic
acid. Subsequent invivo studies, usinganudemousexenograftmodel, showedgood
antitumor activity for these prototype TDCs. BB-01 (a single payload construct)
showed a clear dose response and had cures in 3 out of 5 mice after 24 days on a 3
mol/kg TIW schedule. BB-03 (a triple PC construct) shows essentially complete
tumor regression compared to modest inhibition by BB-01 at doses that deliver
equivalent amounts of payload, demonstrating the synergistic potential of the PC
concept to enhance the activity. We have also synthesized DVD-Fab TDCs. DVD-
Fabs contain a reactive chemical group for seamless connection with our SiLinkers
and PCs.We will describe conjugation chemistries and present cellular and in vivo
Xenograft data for prototype DVD-Fab TDCs.
#5154 Enhancing tumor blood perfusion using orally active heparin to
increase the distribution of anticancer therapeutics inside the tumor tissue.
Jeong Uk Choi,1 Taslim A. Al-Hilal,2 SeungWoo Chung,1 Jisuk Yun,3 Hwajung
Nam,3Myungyun Lee,3 JinhaHwang,3 KyungjinKim,3 Youngro Byun,1 Young-
seok Cho,1 Seong Wook Lee1. 1Graduate School of Convergence Science and
Technology, and College of Medicine or College of Pharmacy, Seoul National
University, Seoul, Republic of Korea; 2Texas Tech University Health Science Cen-
ter, Amarillo, TX; 3Dong-A Socio Group ST Pharm Co., Ltd., Seoul, Republic of
Korea.
Here, we suggest in the fırst time that the cancer associated thrombosis-
(CAT) might be one of the major factor which limit the tumor blood perfu-
sion and drug distribution inside the tumor tissue by reducing the effective
radius of blood vessels. In order to prevent CAT and achieve enhanced drug
distribution, we developed orally active heparin to be combined with other
anti-cancer therapies. We injected dye conjugated fıbrinogen and chitosan
nanoparticles to mice which were bearing highly thrombotic tumor to visu-
alize CAT and nanoparticle distribution inside the tumor tissue. When CAT
is prevented by heparin, we found that nanoparticle distribution and accu-
mulation were signifıcantly enhanced compared to the group not treated
with heparin. This results signify that the CAT can limit the tumor perfusion
and prevention of CAT can enhance the drug accumulation and distribution.
We used highly thrombotic cancer models such as melanoma and pancreatic
cancer to evaluate the therapeutic effıcacy of the doxorubicin containing
nanoparticle and the combination of oxaliplatin and gemcitabine when they
are combined with heparin. We have found that when heparin is combined
with each therapy, their tumor inhibition effıcacy increased about 25% and
also confırmed that this synergistic effect comes from enhanced drug distri-
bution inside the tumor tissue by preventing the CAT using anticoagulant.
These results were also supported by histological analysis. We have validated
our hypothesis by showing that CAT can limit the tumor perfusion, which in
turn brings reduced drug distribution inside the tumor tissue. We also con-
fırmed that our oral heparin could enhance the tumor perfusion and the
effıcacy of anti-cancer therapeutics by preventing the CAT in the tumor
tissue.
#5155 Targeting nucleolin with doxorubicin-containing nanoparticle in-
duces a signifıcant tumorgrowth inhibition in anorthotopic animalmodel of
standard of care-resistant mesothelioma. Nuno André Fonseca,1 Vera
Moura,2 Fabiana Colelli,3 Daniela Pesce,3 Francesco Cardile,3 Claudio Pisano,3
Sérgio Simões,1 João Nuno Moreira1. 1University of Coimbra, Coimbra, Portu-
gal; 2TREAT U, SA, Coimbra, Portugal; 3Biogem - MIR, Ariano Irpino, Italy.
Mesothelioma is a malignant tumor of the mesothelium, the thin lining of
the surface of the body cavities and the organs within, and is often associated
with asbestos exposure. It has a poor prognosis, with a mean overall survival
of 8.8 months. Chemotherapy has been used for malignant pleural mesothe-
lioma as an adjuvant treatment after surgical resection (often palliative) or in
patients who have inoperable disease. A combination of cisplatin and pem-
etrexed remains as the current standard of care, with only a 9% 5-year sur-
vival rate. Herein, a novel targeted treatment for mesothelioma, based on a
doxorubicin (DXR)-containing nanoparticle functionalized with the
nucleolin-binding F3 peptide (named PEGASEMP), is proposed. It relies on
nucleolin deregulated overexpression in cancer cells and the tumormicroen-
vironment (endothelial cells from tumor blood vessels). Studies were per-
formed in an orthotopic model of human mesothelioma. Mesothelioma cells
harvested from a patient with disease progression who undergone chemo-
therapy, were stably transduced with luciferase-reporter gene, and orthoto-
pically injected intrapleurally into female immunocompromised mice. Ani-
mals were randomly allocated to different treatment groups: vehicle,
peptide-targeted DXR-containing nanoparticle (PEGASEMP) at 5.6 or 7 mg
of DXR/kg alone (q7dx5w); cisplatin at 4.0 mg/kg alone or combined with
PEGASEMP at 5.6 mg of DXR/kg (q7dx5w). A control group administered
with the standard of care, a combination of cisplatin at 4.0 mg/kg (q7dx5w)
plus pemetrexed at 100.0 mg/kg (q2dx3x5w) was also included. Biolumines-
cence was monitored weekly with live imaging using IVIS Spectrum In Vivo
Imaging system. Peptide-targeted DXR-containing nanoparticle at 7.0
mg/kg enabled a tumor growth inhibition, by the end of the treatment, that
was 183-fold higher than the standard of care. Moreover, treatment with
DXR-containing nanoparticle targeting nucleolin, either at 5.6 or 7.0 mg/kg,
enabled a 10- or 66-fold reduction of tumor burden, respectively, relative to
non-treated mice. Conversely, treatment with the standard of care did not
show any effect on tumor growth inhibition (being similar to the group
injected with vehicle) nor on tumor burden. Importantly, DXR-containing
nanoparticle targeting nucleolin, at the highest tested dose, enabled a
marked decreased of the incidence of tumor infıltration into the chest cavity,
as well as of the presence of severe lung lesions, as compared with the stan-
dard of care (57.1% versus 100% and 14.3% versus 50%, respectively). Over-
all, the novel mechanism of action associated with DXR-containing nano-
particle targeting nucleolin, enables a signifıcant benefıt in terms of effıcacy
(and safety) in the treatment of mesothelioma, as compared with the current
standard of care, thus supporting future clinical evaluation.
#5156 AsynthesizedRNAaptamer targeting and inhibitingnon-small cell
lung cancer. Hanlu Wang,1 Meng Qin,2 Zhihua Ren,1 Irvin S.Y. Chen,2 Yong-
ping Jiang1. 1Biopharmaceutical R&D Center, Peking Union Medical College of
TsinghuaUniversity, Suzhou, China; 2Department ofMicrobiology, Immunology,
and Molecular Genetics, David Geffen School of Medicine at University of Cali-
fornia, University of California Los Angeles, Los Angeles, CA.
A specifıc RNA aptamer (RA16) targeting non-small cell lung cancer (NCI-
H460 cells) was previously reported by in vivo SELEX. The aptamer RA16 was
identifıed specifıcally targeting and inhibiting human NCI-H460 cell prolifera-
tion in vitro, as well as xenograft tumor tissues in vivo. In this study, we synthe-
sized RNA aptamer (syn-RA16) and make comparison studies with transcribed
RNAaptamer (trans-RA16) in vitro in respect of the specifıc targeting and direct
inhibitory activity towards NCI-H460 cells.To characterize the targeting speci-
fıcity in vitro, biotin-labeled syn-RA16 and trans-RA16 were incubated with
NCI-H460 cells, other tumor cell lines or normal control cells. Specifıc fluores-
cent binding was observed only for NCI-H460 cells, but not forHEK293T, Hela,
and Jurkat cells or buffer control. Moreover, binding affınity of Kd values to the
NCI-H460 cells for syn-RA16 and trans-RA16 were determined at 24.752.28
nM and 12.141.46 nM(n3), respectively, by flow cytometry using streptavi-
din-PE labelling, indicating that the specifıc targeting binding affınity for syn-
RA16 was highly retained, as trans-RA16. On the other hand, syn-RA16 ap-
tamer, like trans-RA16 aptamer, was also capable of inhibiting non-small cell
lung cancer cell (H460) proliferation in a dose-dependent manner. At 300 nM,
syn-RA16 aptamer suppressed cell proliferation by 84.5%, comparing by 86.8%
with trans-RA16. The IC50 for syn-RA16 was determined at 118.41.1 nM,
while trans-RA16 was at 105.71.2 nM (n4). Intestinally, both syn-RA16 and
trans-RA16 exhibited no any inhibitory effect onHeLa and Jurkat cell lines even
at concentration of 600 nM. In conclusion, a specifıc entire RA16 RNA aptamer
was synthesized. The synthesized RA16, like transcribed RA16 aptamer, dem-
onstrated the specifıc targeting ability and inhibitory activity to human NCI-
H460 cells. The syn-RA16 could be potential to develop a diagnostic kit or
treatment for NCI-H460 cell-related non-small cell lung cancer in the clinic.
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#5157 Preparation of curcumin analog nanoparticles and determination
of their anticancer activity in prostate cancer.Maylein C. Juan-Rivera,1 Maria
M. Sánchez-Vázquez,2 Gamalier Maldonado,3 Geovanny Ruíz,3 Noralejandra
Vázquez,3 Christian Vélez,4 Beatriz Zayas,4 Carlos Cabrera,5 Magaly Martínez-
Ferrer,1 David Sanabria-Ríos6. 1University of Puerto Rico School of Pharmacy,
San Juan, PR; 2University of PuertoRicoComprehensiveCancerCenter, San Juan,
PR; 3Inter American University of Puerto Rico-Metropolitan Campus, San Juan,
PR; 4Metropolitan University, San Juan, PR; 5University of Puerto Rico-Río Pie-
dras Campus, San Juan, PR; 6Inter AmericanUniversity of Puerto Rico, San Juan,
PR.
Prostate cancer is the most frequently diagnosed cancer and the second cause
of cancer-related deaths in American men. Bioavailability of therapeutic agents
is important for the treatment effectiveness. Previous studies have shown that
the development of nanoparticles (NPs) drug delivery vehicles offers an oppor-
tunity for targeted drug delivery to tumor cells. Natural compounds such as
curcumin have shown decreased bioavailability and stability when used as anti-
cancer agents. Therefore, the purpose of this study is to synthesize the curcumin
analog m-nitrochalcone (3bNchalc) encapsulated into poly (lactic-co-glycolic
acid) (PLGA) NPs and determine the anticancer activity against prostate cancer
cell lines. In our approach, 3bNChalc were encapsulated into PLGA NPs in the
presence of PVA using the single emulsion-solvent evaporation method.
3bNChalc loading, encapsulation effıciency, and drug releasewas determined by
spectrophotometric techniques. Physico-chemical properties such as zeta po-
tential, particle size, polydispersity index (PDI), andmorphology was measured
using a combination of Dynamic Light Scattering (DLS) and Scanning Electron
Microscopy (SEM). Cell viability and proliferation of PC3 and 22RV1 prostate
cancer cell lines treated with 3bNchalc NPs and control were assessed using the
MTS assay. 3bNchalc PLGA NPs were found to have a particle size of 250 nm
and smooth spherical shape. In addition, zeta potential and mobility values
revealed that 3bNChalc PLGANPs are negatively charged and they tend to repel
each other avoiding the tendency to flocculate. Moreover, 22RV1 cells treated
with 3bNchalc PLGANPs showed decreased in viability and proliferation when
compared to control. We demonstrated that 3bNChalc was successfully encap-
sulated into PLGA NPs. In addition, our results showed that 3bNchalc PLGA
NPs decreased the viability of 22RV1 prostate cancer cells when compared to
control, suggesting that PLGA improves the delivery of 3bNChalc inside the cell.
Results of our study will impact broadly the fıeld by developing more effective
and less toxic PLGA NPs based therapies.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
Oncogenes and Tumor Suppressors as Therapeutic Targets
#5158 Anti-tumor activity of entrectinib, a highly potent pan-TRK, ROS1
and ALK inhibitor, in molecularly defıned acute myeloid leukemia. Patrick
Fagan, Maria Barrera, Colin Walsh, Danielle Murphy, Ian Silverman, Robert
Shoemaker, Ge Wei, Zachary Hornby, Gary Li, Kristen M. Smith. Ignyta, Inc.,
San Diego, CA.
Acute myeloid leukemia (AML) is the most common form of acute leukemia
in adults and comprises a heterogeneous group of diseases. A number of recur-
rent leukemogenic gene mutations or chromosomal rearrangements have been
identifıed and clinically validated in AML.However, nearly 50% of AML patient
samples lack any known AML driver mutations. Advances in molecular diag-
nostics have resulted in the identifıcation of novel and actionable gene muta-
tions or chromosomal rearrangements in these AML samples. The ETV6-
NTRK3 fusion gene is one such rearrangement identifıed in samples from
patients with AML. Fusion of ETV6 sequences to the tyrosine kinase domain of
NTRK3 results in constitutive activation of the TRKCkinase and ETV6-NTRK3
expression has emerged as one of the key oncodrivers for leukemogenesis. Con-
stitutive activation of TRK family tyrosine kinases has also been detected in a
wide range solid tumor and hematologic malignancies, including lung, colorec-
tal, salivary gland, sarcoma, thyroid, glioblastoma, melanoma, anaplastic large
cell lymphoma (ALCL) and Philadelphia-like acute lymphoblastic leukemia.
Entrectinib (RXDX-101) is an investigational, orally available, brain-penetrant,
highly potent and selective kinase inhibitor with low nanomolar potency against
TRKA/B/C, ROS1 and ALK kinase activities (encoded by NTRK1/2/3, ROS1
andALK genes, respectively). In these studies, we have demonstrated sensitivity
to entrectinib in AML cell lines with endogenous expression of the ETV6-
NTRK3 fusion gene. Entrectinib treatment blocked cell proliferation and sur-
vival in vitro with sub-nanomolar EC50 values. Phosphorylation of the ETV6-
TRKC fusion protein as well as phosphorylation of known TRKC downstream
signaling effectors was inhibited by entrectinib treatment in a dose-dependent
manner. Sensitivity to entrectinib was dependent on expression of the TRKC
fusion protein. In xenograft models, entrectinib treatment at clinically relevant
doses resulted in tumor regression, which was accompanied by elimination of
residual cancer cells from the bone marrow. The clinical relevance of activated
oncogenic tyrosine kinases resulting from chromosomal rearrangements has
been validated by the effıcacy of selective tyrosine kinase inhibitors. Our preclin-
ical data demonstrate the potential of entrectinib as an effective treatment for
patients with NTRK rearranged acute myeloid leukemias and provide rationale
for the clinical development of entrectinib in molecularly defıned hematologic
malignancies. Entrectinib is currently the subject of an ongoing global Phase 2
basket study enrolling patients across multiple tumor histologies containing
TRK, ROS1 or ALK fusions.
#5159 Characterization of a novel class of RAS inhibitory compounds
with potent anti-tumor activity. Antonio Ward,1 Xi Chen,1 Jacob Valiyaveet-
til,1 Bing Zhu,1 Veronica Ramirez-Alcantara,1 Kevin J. Lee,1 Ashley Lindsey,1
Kristy Berry,1 Tyler E. Mattox,1 Kate McConnell,1 Michael R. Boyd,2 Gary A.
Piazza,1 Adam B. Keeton1. 1Univ. of South Alabama Mitchell Cancer Inst., Mo-
bile, AL; 2ADT Pharmaceuticals, Inc., Orange Beach, AL.
Introduction: Over 30% of all human cancers harbor activating RAS muta-
tionswhich induce deregulation of the cell cycle, uncontrolled proliferation, and
decreased apoptosis. Through a phenotypic screening strategy, we have identi-
fıed a series of indene derivatives which potently and selectively inhibit growth
of tumor cells harboring activated RAS. A development candidate from this
series, DC070-547, disrupts RAS-RAF binding, inhibits RAS signaling, causes
cell cycle arrest and induces apoptosis, and exhibits strong anti-tumor activity in
a mouse KRAS mutant tumor model. Methods: Viable cell number was mea-
sured using a luminescent indicator of ATP. RAS activation was measured by
GST-RAF1-RBD pull-down and western blotting using an anti-RAS antibody.
Disruption of RAS-RAF binding was determined by pre-incubation of GST-
RAF1-RBD beads with cell lysates or recombinant RAS in the presence of test
compounds for 30 min. Cell cycle distribution was measured by DNA content
and immunofluorescent detection of cell cycle proteins. Antitumor activity was
determined in a subcutaneous mouse tumor model involving KRAS mutant
colon tumors. Results: Low nanomolar concentrations of DC070-547 selectively
inhibited growth of a diverse panel of tumor cell lines harboring activated RAS
relative to tumor cell lines lacking activated RAS. Transfection of HT-29 cells
lacking activatedRASwithmutantRAS conferred sensitivity toDC070-547. The
compounds blocked binding of RAF1-RBD to recombinant RAS, RAS from cell
lysates, as well as RAS in intact cells. Sustained and potent growth inhibitory
effects of DC070-547 were demonstrated by colony formation assays. Immuno-
blotting showed that DC070-547 inhibited EGF-induced signaling in HCT-116
colon tumor cells with activated RAS at concentrations that inhibit growth.
DC070-547 also induced apoptosis as evident by Annexin V labeling and M-
phase arrest in HCT116 cells as shown by DNA content and immunostaining of
phospho-Histone H3B and Cdc25C, an important downstream mediator of
RAS signaling. DC070-547 and three analogs from this series were evaluated for
antitumor activity in an athymic mouse model using subcutaneously implanted
KRAS mutant colon tumor cells. Treatments either completely suppressed tu-
mor growth or caused tumor regression with no discernible toxicity. Conclu-
sion: While RAS is widely considered to be non-druggable, a novel compound
series was identifıed that potently and selectivity inhibit in vitro and in vivo the
growth of tumor cells harboring activated RAS by inhibiting RAS-effector bind-
ing. Together, these fındings support further preclinical development of this
compound class for Phase I/II clinical evaluation for the treatment of RAS-
driven cancers.
#5160 Development of REDX05358, a novel highly selective and potent
pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant
tumors. Helen Mason,1 Simon Scrace,2 Richard Testar,1 Julie Rainard,1 Ryaka
Poonawala,1 Philippa Smith,1 Harriet Brooke,1 Sarah Frith,1 Jonathan Ahmet,1
Jonathan Hall,1 David Sorrell,2 Jon Moore,2 Caroline Phillips,1 Dennis France,1
Matilda Bingham,1 Richard Armer1. 1Redx Pharma, Macclesfıeld, United King-
dom; 2Horizon Discovery, Cambridge, United Kingdom.
REDX05358 has been identifıed as a novel, highly selective and potent next
generation pan RAF inhibitor with improved therapeutic potential and pre-
dicted safety profıle. Aberrant signalling via the MAPK pathway is commonly
seen in cancer. RAF inhibitors such as Dabrafenib and Vemurafenib have been
approved for the treatment of unresectable and metastatic BRAF mutant mela-
noma, but these agents lack effıcacy in BRAF mutant colorectal cancer (CRC),
partly because of EGFR-mediated feedback reactivation of the MAPK pathway
via CRAF. Furthermore, RAF inhibitor treatment of RAS-mutant, BRAF wild-
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type melanomas has been associated with other skin cancers, such as cutaneous
squamous cell carcinoma due to MAPK pathway paradoxical activation medi-
ated by CRAF. There is therefore a clinical need for novel agents targeting the
MAPK pathway that do not have these undesirable properties. Here we present,
REDX05358 that demonstrates subnanomolar binding affınity for BRAF and
CRAF with high selectivity profıle against a panel of 468 kinases that exhibits
negligible paradoxical activation due to inhibition of both RAF monomers and
dimers. As a result, REDX05358 not only inhibits MAPK signalling in BRAF
V600E mutant tumor cells, but also in those harbouring NRAS and KRAS mu-
tations. Furthermore, REDX05358 does not induce feedback reactivation of the
pathway through its ability to sustain inhibition ofMAPK signalling in CRC cell
lines. Correspondingly, profıling of REDX05358 in a panel of CRC, melanoma
and NSCLC cell lines shows it has potent anti-proliferative activity in cell lines
harbouring BRAF or RASmutations. REDX05358 is an orally bioavailable, well
tolerated small molecule that has demonstrated in vivo effıcacy in BRAF V600E
CRC xenograft model. In contrast, fırst generation inhibitors such as Vema-
rafenib andDabrafanib have been reported to be ineffective in this genetic back-
ground in CRC cell lines and patients. Thus, we have developed a pan RAF
inhibitor with unique pharmacological properties enabling it to have utility in
treating BRAF and RAS mutant cancers.
#5161 Inhibition of TBK1/IKBKE impacts tumor growth of KRAS-mu-
tant colorectal cancers. Susanna Stinson,1 Jianhua He,1 Zhiheng Jia,1 Katie S.
Walker,1 Zhi-HuaCui,1 JoshuaA. Kaplan,1 Chandrasekar Venkataramani,1 Yu-
jin Wang,1 Fatima Guevara,2 Timothy Nelson,2 Ewa Sicinska,2 Kimmie Ng,2
Charles S. Fuchs,2DavidDornan1. 1Gilead Sciences, Inc., Foster City, CA; 2Dana-
Farber Cancer Institute, Boston, MA.
Mutations in RAS occur in an estimated one third of all human cancers.
While direct targeting of RAS remains challenging, targeting downstream RAS
effectormolecules has been shown to impact the oncogenic function of RAS and
elicit anti-tumor activity. TANK Binding Kinase 1 (TBK1) and I-Kappa B Ki-
nase Epsilon (IKBKE) serine/threonine kinases are non-canonical IKK family
members. TBK1 is directly downstream of the RAS effector Ral Guanine Nucle-
otide Dissociation Stimulator (RALGDS) and may be required for RAS to elicit
its full oncogenic potential. To explore this possibility, we identifıed a potent
and selective TBK1/IKBKE inhibitor to determine whether inhibition of TBK1
impacts the growth of RAS-mutant cancer models. KRAS-mutant cancer cell
lines showed preferential sensitivity to TBK1/IKBKE inhibition over KRAS
wild-type cell lines. The TBK1/IKBKE inhibitor was then evaluated in vivo with
two KRAS-mutant colorectal cancer patient-derived xenograft (PDX) models,
one of which harbors co-occurring PIK3CA and KRAS mutations. The TBK1/
IKBKE inhibitor caused moderate tumor growth inhibition in comparison to
vehicle in both PDX models. Since RAS exerts its oncogenic effects via addi-
tional effectors, such as RAF, and that inhibition of MEK1/2 resulted in com-
pensatory activation of TBK1 in a KRAS-mutant cancer cell line, we tested if
inhibition of TBK1/IKBKE in combination with theMEK inhibitor, trametinib,
would result in superior effıcacy in PDX models. The combination of a TBK1/
IKBKE inhibitor and trametinib resulted in greater than 90% tumor growth
inhibition within both of these KRAS mutant PDX models compared to either
single agent alone. We also tested TBK1/IKBKE inhibition in a KRASwild-type
colorectal PDX model containing a BRAF mutation. In this model, TBK1/IK-
BKE did not inhibit tumor growth and, although there was signifıcant tumor
growth inhibition with trametinib alone, there was no further enhancement of
effıcacy with the addition of a TBK1/IKBKE inhibitor. Together, these data
suggest that a TBK1/IKBKE inhibitor in combinationwith aMEK inhibitormay
impact KRAS-mutant cancers.
#5162 Development of a dual inhibitor of pan-RAF and angiogenesis for
the treatment of metastatic colorectal cancer with mutant K-RAS. Sungpyo
Hong,1 YounghoonChoi,1 Ho-Seok Kwon,2 Yong Bin Park,2Min-HyoKi,2 Hee
Jong Shin,2 Michael Lee,1 Soon Kil Ahn1. 1Institute for New Drug Development,
Division of Life Sciences, Incheon National University, Incheon, Republic of Ko-
rea; 2Samjin Pharm. Co. Ltd, Seoul, Republic of Korea.
Colorectal cancer (CRC) is one of the most common cancers and a leading
cause of cancer-related death in the western world. K-RAS mutation has been
reported in 40% of colorectal cancer patients. KRAS mutations have been sig-
nifıcantly associated with lack of response to treatment with the anti-EGFR or
anti-BRAF. The FDA approved Bevacizumab as the anti-angiogenic agent for
the treatment standard of care in metastatic CRC. However, K-RAS status does
not show benefıt from the incorporation of bevacizumab to the fırst-line IFL
chemotherapy. Bevacizumab provides modest or no benefıt and almost inevita-
bly causes therapeutic resistance. Therefore, there is a need for the development
of new therapeutic approaches for the treatment of colorectal cancers with K-
RAS mutation. Because aberrant activation of the RAF- MAPK pathway is fre-
quently found in K-RASmutant cancer, the B-RAF specifıc inhibitors have been
tested. However, B-RAF specifıc inhibitor activates C-RAF in RAS mutant cells
by inducing RAF dimer formation and paradoxical activation of C-RAF. These
observations require the development of pan-RAF inhibitors without inducing
paradoxical activation. In addition, acquired resistance to anti-VEGF therapy
needs another therapeutic target, such as angiopoietin-TIE2 system. Because the
pathway is induced after exposure to anti-VEGF/VEGFR drugs. Therefore, we
tried to fınd dual inhibitors of pan-RAF and angiogenesis using structure based
molecular modeling and identifıed a selective inhibitor, SJ-C1044, which binds
to theDFG-out inactive conformation of B-RAF. SJ-C1044 potentially inhibited
B-RAF, C-RAF, B-RAF V600E, VEGFR2 and Tie2. SJ-C1044 completely inhib-
ited the phosphorylation ofMEK-ERKwithout paradoxical activation inK-RAS
mutant cells. We examined the effects of SJ-C1044 on cell proliferation of colo-
rectal cancer cells with K-RAS or B-RAF mutation. SJ-C1044 displayed potent
anti-proliferative activities not only in K-RASmutant colorectal cancer cells but
also in B-RAF mutant colorectal cancer cells. We tested SJ-C1044 in colorectal
cancer xenografts with mutant K-RAS and observed 97% reduction of tumor
volume. In this study, we discovered an orally active dual inhibitor of pan-RAF
and angiogenesis. SJ-C1044 has been shown to suppressmutant K-RAS colorec-
tal cancer cells without activating theMAPK pathway. Our fındings suggest that
SJ-C1044 could be an excellent preclinical candidate for the treatment of colo-
rectal cancer with mutant K-RAS.
#5163 Characterization of NMS-E194, a selective and potent PERK inhib-
itorwith effıcacy in theKMS-11multiplemyeloma.Claudia Perrera,Maurizio
Pulici, Davide Carenzi, Ilaria Motto, Marina Fasolini, Elena Casale, Stefania Re
Depaolini, Simona Rizzi, Daniela Asa, Fulvia Roletto, Simona Bindi, Daniele
Casero, Patrizia Banfı, ElenaArdini, NadiaAmboldi, Dario Ballinari, FabioGas-
parri, Sabrina Cribioli, LauraMancini, Marina Ciomei, Daniele Donati, Eduard
Felder, Arturo Galvani, Antonella Isacchi, Barbara Valsasina.NervianoMedical
Sciences, Nerviano, Italy.
PERK (PKR-like endoplasmic reticulum kinase) is a serine-threonine kinase
associated to endoplasmic reticulummembrane. Together withATF6 and IRE1,
PERK is a key effector of the Unfolded Protein Response (UPR), a network of
signaling pathways that ensures protein homeostasis in the endoplasmic reticu-
lum. Multiple Myeloma (MM) and other protein-secreting tumors are highly
dependent on UPR for survival, and inhibition of PERK may be an effective
strategy to inhibit growth of these tumors. Here we describe the in vitro and in
vivo properties of NMS-E194, a novel potent and selective ATP-competitive
PERK inhibitor belonging to the arylsulfonamide chemical class. NMS-E194
inhibits PERK kinase with a Ki of ca 1.5 nM in biochemical assay and possesses
high selectivity towards a panel of 54 kinases. When tested in cell proliferation
assays, NMS-E194 is preferentially active on multiple myeloma (MM) and dif-
fuse large B cell lymphoma cell lines. Inmechanismof action studies,NMS-E194
shows a bi-phasic behaviour: at low nanomolar doses it activates PERK, causing
ATF4 accumulation, while at200 nM it inhibits PERK and downstream path-
way, inducing apoptosis. NMS-E194 possesses a favourable in vitro ADME pro-
fıle and has promising PK properties in the mouse. NMS-E194 demonstrated
strong anti-tumor activity following oral administration at 25 mg/kg daily to
mice harbouring luciferized KMS-11 cells in a disseminated growth model of
MM, with no overt toxicity. Overall, the data available so far warrant further
development of NMS-E194 and support PERK inhibition as a novel therapeutic
approach in MM and other PERK-dependent tumors.
#5164 A pyrrole-Imidazole polyamide conjugate targeting KRAS onco-
genic mutations is a promising approach against KRAS mutated colorectal
andpancreatic cancers.HirokiNagase, Atsushi Takatori, TakayoshiWatanabe,
Nobuko Koshikawa, Jason Lin. Chiba Cancer Ctr. Research Inst., Chiba, Japan.
Although a tremendous amount of studies has been made to directly target
oncogenic drivers, such as RAS andMYC, no drug is clinically available because
of diffıculties to develop RAS- or Myc-targeted anti-cancer therapeutics due to
the smooth 3D surface topology. One of major limitations of targeting the RAS
pathway may be intrinsic or acquired resistance as seen in the other molecular
target therapy. A new approach that directly target driver genes may provide a
more direct route to help address unmet medical needs for refractory cancer
conquest. We therefore synthesized the Pyrrole-Imidazole polyamide conju-
gate, KR12, specifıcally alkylated KRAS codon 12 mutant DNA (G12D or
G12V). KR12 reduced expression of the mutated oncogenic-protein by RNA
transcription inhibition and induced cancer cell death at low dose (1 to 50 nM).
We also applied a novel enrichment-based sequencing and computational pipe-
line, which fırst identifıes a PIP’s genomic binding sites through next-generation
sequencing followed by gene expressionmicroarray studies. The computational
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analysis suggested non-KRAS binding overall had little contribution to changes
at the phenotypic level in colorectal cancer cell lines. We also the anti-cancer
event is not only for colorectal but also pancreatic ductal adenocarcinoma
(PDAC). Signifıcant tumor reduction was observed in a mouse model of spon-
taneous PDAC (LSL-KrasG12D/,Ptf1aCre/,Tgfbr2flox/flox). In animal
studies we also observedKR12 intakes and retentions in tumor but not any other
organs 24 hours after I.V. administration. We will summarize the sequence-
dependent alkylating approach using antibiotic mimics of alkylating PI-poly-
amide conjugates, may open a new strategy targeting the driver oncogene mu-
tatedDNA sequence. This approach should be used formedicine against variety
of unfavorable KRAS mutated cancers.
#5165 Novel RAS inhibitors DC070-547 andADT-006 potently and selec-
tively inhibit the growth of pancreatic tumor cells harboring constitutively
activated RAS by blocking RAS-effector binding and signaling. Tyler E. Mat-
tox,1 Kevin J. Lee,1 Xi Chen,1 Jacob Valiyaveettil,1 Luciana Madeira da Silva,1
Ashley S. Lindsey,1 Adam B. Keeton,1 Bing Zhu,1 Michael Boyd,2 Gary A. Pi-
azza1. 1University of South AlabamaMitchell Cancer Institute,Mobile, AL; 2ADT
Pharmaceuticals, Inc., Orange Beach, AL.
Gain-in-function mutations in RAS genes cause constitutive activation of RAS
and inductionofdownstreamsignalingpathways thatdrive tumorcell proliferation,
survival, and metastasis. Such driver mutations occur in over 90% of pancreatic
ductal adenocarcinomas (PDACs), making RAS an attractive cancer target. How-
ever, RAS is considered “undruggable”, given the lack of suitable surfaces on the
protein for small molecule binding, as well as its high affınity for GTP binding. A
phenotypic assay was developed to screen a library of indene derivatives for growth
inhibitory activity in tumor cells harboring constitutively active RAS versus tumor
cells with low levels of active RAS. A novel compound series was identifıed that
potently and selectively inhibits the growth of tumor cells with constitutively active
RAS, while havingminimal effects on tumor cells lacking constitutively active RAS
or cells derived from normal tissues. Chemical optimization resulted in a drug de-
velopment candidate, DC070-547, and several back-up analogs (e.g. ADT-006),
which showed strong antitumor activity at doses that do not cause any discernible
toxicity in preclinical mouse models. Here we report DC070-547 and ADT-006
inhibited the growth of PDAC cells with IC50 values of approximately 2 nM and 20
nM, respectively, in MIA PaCa-2 cells harboring constitutively active RAS and
greater than 350-fold selectivity over BxPC-3 cells, which lack constitutively active
RAS. Both compounds also decreased the clonogenic potential ofMIAPaCa-2 cells
at concentrations that inhibit their growth. Within the same low nanomolar con-
centration range, treatment of recombinant human K-RAS, MIA PaCa-2 cell ly-
sates, and intact MIA PaCa-2 cells blocked RAS-effector interactions as evident by
performing active RAS pull-down assays using GST-RAF1-RBD/glutathione agarose.
Treatmentof intactMIAPaCa-2cells also inhibitedRAF/MAPKandPI3K/AKTphos-
phorylation within the same concentration range. These results demonstrate that
DC070-547 andADT-006 inhibit PDACcell growth by blockingRAS-effector interac-
tions,supportingfurtherevaluationofthisnovelclassofRASinhibitorsforthetreatment
of pancreatic cancer, aswell as otherRAS-driven cancers.
#5166 Sensitivity ofmelanoma cells to a novel class of Ras inhibitors.Kate
M. Saville,1 Kevin Lee,1 Tyler E. Mattox,1 Xi Chen,1 Jacob Valiyaveettil,1 Kristy
Berry,1 Veronica Ramírez-Alcántara,1 Bing Zhu,1 Adam Keeton,1 Michael
Boyd,2 Gary Piazza,1 Ashley S. Lindsey1. 1Univ. of South AlabamaMitchell Can-
cer Inst., Mobile, AL; 2ADT Pharmaceuticals, Inc., Mobile, AL.
A high percentage of human cancers arise from mutations in the ras gene
that encodes an abnormal Ras protein locked in a constitutively active GTP-
bound state that promotes tumor cell proliferation, survival, and metastasis.
These gain-in-function mutations in the ras gene or constitutive activation
of tyrosine kinase receptors upstream of the Ras protein drive tumor cell
growth by activating Raf/MAPK and PI3K/AKT signaling pathways. Ras has
been an elusive drug target for which no inhibitors are available to treat
Ras-driven cancers. Screening a library of indene derivatives in a differential
phenotypic assay identifıed a novel compound class displaying high potency
and selectivity to inhibit the growth of tumor cells harboring mutant Ras
relative to tumor cells with wild type (WT) Ras. Lead optimization resulted
in a drug development candidate (DC070-547) and several back-up analogs
(e.g. ADT-006) with IC50 values in the low nanomolar range and selectivity
indices of 100 fold or greater to inhibit the growth of tumor cells with con-
stitutively activated Ras relative to tumor cells with low levels of activated
Ras. Sensitivity among a large panel of tumor cell lines to this compound
class strongly correlated with levels of activated Ras, but did not appear to be
limited to a specifıc ras gene mutation or Ras protein isoform. Here, we
report that DC070-547 and ADT-006 potently and selectively inhibit the
growth of the human melanoma cell line, SK-MEL-2, harboring a mutation
in the ras gene that encodes the constitutively active N-Ras protein with IC50
values of 7 and 25 nM, respectively. In addition, both compounds potently
inhibited the growth of themurinemelanoma cell line, B16-F10 withWT ras,
but harboring a mutation in a tyrosine kinase receptor upstream of Ras,
specifıcally PDGFR	, which results in high levels of active, GTP-bound Ras
as confırmed by Ras-RBD pull-down assays. To determine if treatment can
disrupt Ras signaling, B16-F10 cells were incubated with the compounds
before being subjected to Western blotting for phosphorylated signaling
molecules downstream of Ras. Treatment reduced levels of phosphorylated
c-Raf and MEK at concentrations that inhibit tumor cell growth. These fınd-
ings support further investigation of this novel class of Ras inhibitors for the
treatment of Ras-driven melanoma.
#5167 Stem-like colorectal cancer cell lines show response to the ERK1/2
inhibitor, SCH772984, alone and in combination with neratinib. Rekha Pal,1
Ning Wei,2 Nan Song,1 Shao-yu Wu,2 S. Rim Kim,1 Patrick G. Gavin,1 Peter C.
Lucas,3 Ashok Srinivasan,1 Samuel A. Jacobs,1 Soonmyung Paik,4 John C.
Schmitz,2 Kay Pogue-Geile1. 1NSABP, Pittsburgh, PA; 2University of Pittsburgh
Cancer Institute, Pittsburgh, PA; 3NSABP and University of Pittsburgh School of
Medicine, Pittsburgh, PA; 4NSABP and Yonsei University College of Medicine,
Seoul, Republic of Korea.
Background:Wehaverecently shownanassociationofcolorectal tumorsubtypes
with differential response to chemotherapy in patients (pts), and to targeted therapy
in cell lines. Pts enrolled in NSABP/NRG C-07 with stem-like tumors had a poor
prognosis regardless of stage or treatment, highlighting the importance of fınding
new treatments for stem-like tumors. Our in-vitro data showed that KRASmutant
(mt) cell lines of the intrinsic inflammatory subtype were sensitive to the combina-
tion of MEK-162 and neratinib, but stem-like subtype cell lines were resistant re-
gardless of KRAS mt status. The purpose of this study was to extend our observa-
tions to xenograft models and to identify new agents that target the stem-like
subtype.Methods:KRASmtcell lines of the inflammatory (NCI-H747)or stem-like
(SW-480) subtypewere used in xenograftmodels to test inhibition of tumor growth
by MEK-162 and neratinib, alone or in combination. Five stem-like cell lines with
KRAS wt (C2BBE1, HS675T) or KRAS mt (SW480, SW620, HCT116), and two
KRASmt inflammatory cell lines (NCI-H747, SW837) were tested for cell viability
after treatmentwith SCH772984 alone or in combinationwithneratinib. Results: In
vivo analysis showed that treatment ofNCI-H747 xenografts with a combination of
MEK-162 (3mg/kg) and neratinib (10mg/kg) led to signifıcant tumor regression
compared to treatment with either drug alone (p 0.0001 v neratinib alone; p
0.002 v MEK-162 alone). In contrast, MEK-162 alone was able to inhibit tumor
growthof stem-like cell line (SW480)xenografts (p0.0061vcontrol) butneratinib
was ineffective (p0.145 v control) as a single agent and did not add toMEK-162.
Our in-vitro and in-vivo data showed that inhibition of p-ERK directly correlated
with sensitivity to the MEK and neratinib combination in inflammatory subtype.
SCH772984 signifıcantly inhibited cell viability of both inflammatory (IC50 1-2
M) and stem-like subtype (IC50 1-2M) cell lines. The combination of neratinib
(0.125 M) and SCH772984 (1 M) was effective at decreasing cell viability by
60-70% in both inflammatory and stem-like cell lines. Inhibition of ERKphosphor-
ylation was correlated with loss of cell viability. Conclusion: The combination of
MEK-162 and neratinib work synergistically to decrease tumor growth in inflam-
matory but not stem-like colorectal cancer subtypes. We demonstrate that
SCH772984 decreases the viability of stem-like colon cancer cell lines, and works
synergistically with neratinib. The use of SCH772984 alone, but more potently in
combination with neratinib, may represent a therapeutic approach for pts with
stem-like tumors, a fınding that underscores the potential importance of employing
subtype analysis in the diagnosis of colon cancer andpotentially as to a guide to new
therapies. Support: PADoH, which disclaims certain responsibility.
#5168 KO-947, a potentERK inhibitorwith robust preclinical single agent
activity inMAPKpathwaydysregulated tumors.Francis Burrows,1 LindaKes-
sler,2 Jeffrey Chen,2 Xin Gao,2 Rasmus Hansen,2 Shuangwei Li,2 Carol Thach,2
Levan Darjania,2 Yvonne Yao,2 Yi Wang,2 Ata Zarieh,2 Ke Yu,2 Tao Wu,2
Jingchuan Zhang,2 Dana Hu-Lowe,2 Liansheng Li,2 Pingda Ren,1 Yi Liu1. 1Kura
Oncology, La Jolla, CA; 2Wellspring Biosciences, La Jolla, CA.
The RAS/RAF/MEK pathway is a major driver of malignant progression,
particularly in cancers arising frommutations inRAS, BRAFandNF1.Although
bothBRAFandMEK inhibitors have been approved for treatment ofmelanoma,
their clinical activity is commonly limited by acquired resistance due to reacti-
vation of the pathway downstream of their targets. Since the ERK1/2 kinases are
the fınal node in the MAPK signaling pathway, they are not subject to the feed-
back reactivation mechanisms that can undermine RAF or MEK blockade, of-
fering the possibility of clinical benefıt in settings where earlier drugs are inef-
fective. Here we describe the characterization of KO-947, a potent and selective
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inhibitor of ERK1/2 kinases, in biochemical, cellular and in vivo antitumor
activity assays. KO-947 was profıled in vitro in biochemical activity assays, com-
petition binding assays, and a probe-based competition binding assay in cell
lysates, and subsequently screened in a large panel of human tumor cell lines
focused onMAPK-dysregulated tumor types. In vivo studies were carried out in
well-characterized xenograft models of BRAF-, KRAS- and NRAS-mutant dis-
ease and subsequently extended to a large panel of early-passage patient-derived
xenograft (PDX) models representative of a wide range of tumor types and
molecular profıles. Biochemical assays reveal that KO-947 is a 10nM inhibitor of
ERK with at least 50-fold selectivity against a panel of 450 kinases. KO-947
blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation
of MAPK pathway signaling, including mutations in BRAF, NRAS or KRAS, at
low nanomolar concentrations. KO-947 is differentiated from other published
ERK inhibitors by an extended residence time and high potency in cell engage-
ment that translate into prolonged pathway inhibition in vitro and in vivo. In
cell-line derived xenograft studies, the drug profoundly suppresses ERK signal-
ing for up to fıve days after a single dose and induces regressions in RAS- and
RAF-mutant melanoma, NSCLC and pancreatic cancer models on administra-
tion schedules ranging from daily to weekly. Intermittent dosing enables com-
parable antitumor activity at reduced dose-intensity. PDX screening confırms and
extends these fındings to include RAS and BRAF mutant colorectal, gastric and
cervical carcinomamodels, and robust activity is also seen on bothweekly andQ2D
schedules in tumor models lacking BRAF/RAS mutations but with other dysregu-
lation of the MAPK pathway. Thus, the favorable ADME properties of KO-947
enable the achievement of optimal antitumor activity with intermittent dosing,
which may provide an opportunity to maximize the therapeutic window with flex-
ible administration routes and schedules. These results demonstrate the potential
clinical utility of KO-947 inMAPK pathway dysregulated tumors.
#5170 HDAC inhibitors and the mechanism of resistance in colorectal can-
cer: RAS and MYC - the partners in crime. Sylvia S. Ispasanie,1 Lena Boehme,1
Martin Eilers,2 Tilman Brummer,3 Kathleen Klotz-Noack,1 Natalia Kuhn,1 Bastian
Gastl,1 Christine Sers1. 1Charité Universitätsmedizin Berlin, Berlin, Germany; 2The-
odor-Boveri-Institute, Biocenter,Würzburg, Germany; 3Institute ofMolecularMedi-
cine and Cell Research, University of Freiburg, Freiburg, Germany.
Although histone deacetylase inhibitors (HDACi) are considered a promising
novel therapeutic approach in the light of their potent tumour-selective effects,
the use of these inhibitors for treatment of colorectal cancer (CRC) have thus far
demonstrated limited success as a monotherapy. What this eventually boils
down to is our incomplete understanding of the molecular mechanisms, the
impact of oncogenes, and thus the key pathways through which HDACi affect
tumour cell growth. To shed further light on this, the involvement of oncogenic
RAS - a key driver of CRC, in determining the responsiveness to HDACi has
been explored. By using cell line model systems harbouring conditional onco-
genic NRAS, KRAS and HRAS, we uncovered an oncogenic RAS-dependent
“safeguard” mechanism imposed in order to evade the cytotoxic effect of
HDACi and therefore apoptosis. Characteristically, cells harbouring oncogenic
RAS were observed to undergo a reversible senescence-like growth arrest in G2,
allowing for re-entry into cell cycle following the withdrawal of HDACi. This
mechanism is implemented as a consequence of the direct targeting of RAS by
HDAC inhibition, which resulted in a further amplifıed GTP-binding activity
and subsequent signalling through the MAPK pathway. The observed outcome
was an increase in the priming of MYC for ubiquitin-mediated proteasomal
degradation, thereby enabling the cells to exit the cell cycle and enter the pro-
tective state of G2 arrest. This process was functionally reversed with a condi-
tional non-degradable MYC (T58A/S62A), which in turn rendered the cells
more susceptible to undergo apoptosis. Conclusively, in the context of a consti-
tutively activating RAS mutation, the prospect of HDACi treatment was effec-
tively improved using current MAPK-targeted therapy by preventing the ob-
served pro-oncogenic effect of the HDACi treatment alone.
#5171 Design and development of a tankyrase inhibitor STP06-1002 as an
anticancer therapeutic agent. Kyungjin Kim,1 Uk-Il Kim,1 Hyung Tae Bang,1
Jihye Yoon,1 JinHaHwang,1 Jung-NyoungHeo,2 Kwang-RokKim,2Hwan Jung
Lim,2 Jai-HeeMoon,3 Eun Young Lee,3 Seul Lee,3 Dong-Hoon Jin3. 1ST Pharm,
Siheung-si, Republic of Korea; 2Korea Research Institute of Chemical Technology,
Daejeon Metropolitan City, Republic of Korea; 3Asan Medical Center, Seoul-si,
Republic of Korea.
Background: The Wnt/-catenin signaling pathway plays a pivotal role in nu-
merous biological processes and its dysregulation has been implicated in diverse
oncolytic initiation. Aberrant overactivation of theWnt/-catenin pathway due to
overexpression and accumulation of the-catenin has been often observed in colo-
rectal cancer (CRC). As a member of PARP family (PARP5 isoform), tankyrase
(TNKS) regulates stability of the-catenindestruction complex throughAxinpoly-
ADP ribosylationmaintaining homeostasis of level of the -catenin. Axin is a rate-
limiting component of the destruction complex and inhibition of tankyrase stabi-
lizesAxin level toprevent subsequentlyCRCdevelopmentbydownregulationof the
Wnt target genes.Weherein report anorally-active tankyrase inhibitor STP06-1002
with excellent cellular potency, good ADME properties, and in vivo anti-tumor
effıcacy with moderate safety. Results: The novel tankyrase inhibitor STP06-1002
shows good inhibition activities with IC50 29.9 nM (TNKS1) and 3.7 nM (TNKS2)
and its excellent cellular potency with IC50 6.7 nM (TCF/LEF). STP06-1002 also
shows excellent selectivity against PARP1 isoformwith IC5010M. STP06-1002
has good ADME properties, particularly low CYP450 inhibition & induction in
CYP3A and PXR, suggesting no DDI issues. It also displays good in vivo pharma-
cokinetic profıles in rats (B.A. [F]60%) and dogs (27%). No signifıcant toxicity
issues are observed from cytotoxicity studies, hERG assay and Ames test. The off-
target studies inbothPanKinasepanel (against 75cancer-focusedkinases) andLead
ProfılingScreen® (against 68 receptors and ionchannels)prove itshigh selectivity. In
thexenograft effıcacystudies for invivoproof-of-concept, thedose-dependenteffect
on Colo320DM (Wnt-dependent, KRas wild type) shows tumor growth inhibition
with 45% and DLD-1 (Wnt-dependent, KRas mutant) with 60%. In the case of
Wnt-independent cell lines HCT116 and RKO as negative controls, both did not
show any tumor growth inhibition effects. Dose range fınding study of rodent (rat)
resulted inmaximumtolerateddoseof (MTD)200mg/kg/day, and the correspond-
ing of non-rodent (dog)MTDof 30mg/kg/day. Taking these promising preclinical
results of optimal in vivo effıcacy dose, MTD and HSTD (50 mg/kg/day) into ac-
count, we suggest safety margin of the STP06-1002 as 6 to 11 folds applicable to
clinical human dosages. Discussion The preclinical studies of STP06-1002 show
successfully its potentials as an anticancer therapeutic agent. Based on the excellent
biological and preclinical profıles, STP06-1002 will be a suitable candidate as an
orally-active novel TNKS inhibitor and move toward phase I clinical trials with
strong biomarker-based strategies.
#5172 E7386, an orally active CBP/beta-catenin modulator, induces T
cells infıltration into tumor and enhances antitumor activity of anti-PD-1
mAb in Wnt1 tumor syngeneic mice model. Yusaku Hori,1 Kazuhiko
Yamada,1 Yu Kato,1 Yoichi Ozawa,1 Takenao Odagami,2 Junji Matsui,1 Tomo-
hiro Matsushima,1 Kenichi Nomoto,1 Hiroyuki Kouji,2 Takashi Owa1. 1Eisai
Co., Ltd,, Ibaraki, Japan; 2PRISM Pharma Co., Ltd., Yokohama, Japan.
Recently, immunotherapeutic approaches have come to forefront in melanoma,
non-small cell lung cancer, bladder cancer, and so on. However, suffıcient benefıts
from these treatments have been limited. T cell infıltrating into tumor tissues is
reported as one of the response biomarker candidates for the immune checkpoint
inhibitors. Recent studies have shown that the activation of the Wnt/beta-catenin
signaling pathway results in T cell exclusion and resistance to immune checkpoint
inhibitor in melanoma patients. We established the Wnt1 tumor syngeneic mice
model (Wnt1model) by implantationofmammary adenocarcinomas isolated from
MMTV-Wnt1 transgenic mice. Here we demonstrate whether E7386, a fırst-in-
classorallyactiveCBP/beta-cateninmodulator, affects therecruitmentofTcells into
tumor tissues, leading to the enhancement of anti-PD-1 mAb inWnt/beta-catenin
signaling pathway activating tumor model. The mice were treated with E7386 (50
mg/kg, orally, BID) and/or anti-mousePD-1mAb (10mg/kg, intraperitoneal, twice
aweek) for threeweeks.Tumordiameters aremeasuredwithdigital calipers, and the
tumorvolume inmm3 is calculated. Immunohistochemical (IHC)analysiswaseval-
uated for tumor-infıltrating T cells. E7386 showed signifıcant antitumor activity in
Wnt1 model, but anti-PD-1 mAb did not. In contrast, E7386 with anti-PD-1 mAb
indicated prominent antitumor activity compared to each single treatment. En-
hancement of body weight loss in combination group was not observed. In IHC
analysis, infıltration of T cells was limited in vehicle control group, in contrast T cell
infıltration into tumors was clearly observed in both E7386 treatment group and
combination group. As a result, antitumor activity of immune checkpoint inhibitor
was limited in Wnt-driven tumor model and E7386 as a novel CBP/beta-catenin
modulator enhanced the antitumor activity of anti-PD-1 mAb via induction of tu-
mor-infıltrating T cells.
#5173 Discovery of a series of benzimidazoles as potent Wnt/-catenin
signaling inhibitors in colorectal cancer cells. Yonghe Li,1 Patsy G. Oliver,2
Wenyan Lu,1 Vibha Pathak,1 Corinne E. Augelli-Szafran,1 Donald J. Buchs-
baum,2 Mark J. Suto1. 1Southern Research, Birmingham, AL; 2The University of
Alabama at Birmingham, Birmingham, AL.
Aberrant activation ofWnt/-catenin signaling is a necessary initiating event
in the genesis of most colorectal cancers. Loss-of-function mutations in the
tumor suppressor gene adenomatous polyposis coli (APC) are present in about
80% of all colorectal cancers, and gain-of-function mutations in the oncogene
CTNNB1 (-catenin encoding gene) exist in approximately 10% of colorectal
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cancers. Both APC and CTNNB1mutations lead to cytosolic accumulation and
nuclear translocation of -catenin, and therefore constitutive activation of
-catenin/TCF4-mediated gene transcription. As such, the Wnt/-catenin
pathway has emerged as one of the most promising targets for colorectal cancer
treatment. Despite tremendous efforts in the past decade, there are no small
molecule Wnt inhibitors approved by the FDA for cancer treatment. Recent
work in our laboratories has identifıed a series of benzimidazoles as potent
Wnt/-catenin inhibitors. Here, we show that several benzimidazoles displayed
strong activities against Wnt/-catenin signaling in colorectal cancer cells har-
boring mutations in CTNNB1 or APC. In particular, SRI36324, the lead com-
pound in this series, inhibited Wnt/-catenin signaling in colorectal cancer
HCT116 andDLD-1 cells with IC50 values of 4.1 and 3.7 nM, respectively.More-
over, the benzimidazole compounds exhibited potent activities against colorec-
tal cancer cell proliferation under both standard cell culture conditions (adher-
ent cells in complete medium containing 10% FBS) and conditions designed to
enrich for cancer initiating cells. In addition, the benzimidazole compounds had
no off-target effects on other pathways (e.g., STAT3 andmTORC1 signaling) in
colorectal cancer cells, and were less antiproliferative to non-cancerous cells.
Together, our fındings indicate that the benzimidazole compounds are promis-
ing candidates for development as novel therapeutic agents for colorectal cancer.
#5174 Phosphodiesterase 10A inhibition as a novel approach to suppress
-catenin signaling in ovarian cancer cells. Luciana Madeira Da Silva, Elaine
Gavin, Kevin J. Lee, Veronica Ramírez-Alcántara, Kristy L. Berry, Holly T. Tay-
lor, AllaMusiyenko, IleanaV.Aragon,AdamB.Keeton, Jennifer Scalici, Rodney
P. Rocconi, Gary A. Piazza. Univ. of South Alabama Mitchell Cancer Inst., Mo-
bile, AL.
Canonical Wnt/-catenin signaling is known to be associated with platinum
resistance in ovarian cancer in which inhibitors hold promise for the treatment
of refractory disease. Phosphodiesterase 10A (PDE10A) is a dual cyclic AMP
and cyclic GMPphosphodiesterase isozyme recently implicated in colon cancer.
PDE10A inhibition in colon cancer cells by siRNA or small molecule inhibitors
increased cGMP levels and activated PKG to inhibit-catenin signaling. Anovel
PDE10 inhibitor, ADT-061, was identifıed by screening a library of indene de-
rivatives, and showed strong antineoplastic activity in the Apc/min-FCCCmouse
(Lee K et al., unpublished data). Cyclic GMP and phosphodiesterases participate
in the ovarian follicular development, although little is known about PDE10A
expression in ovaries, especially with regard to a potential role in ovarian tumor-
igenesis. PDE10Aproteinwas found to be expressed in various established ovar-
ian cancer cell lines at higher levels than immortalized or primary ovarian sur-
face epithelial cell lines. Pf-2545920, a known PDE10A inhibitor, and ADT-061
inhibited the growth of multiple ovarian tumor cell lines with IC50s around
20M and 0.5M, respectively. Both compounds induced apoptosis after 24h
treatment, as measured by PI/Annexin-V staining and PARP cleavage. Pf-
2545920 and ADT-061 induced phosphorylation of VASP at Ser157 and Ser239
in various ovarian cancer cell lines, indicating activation of cyclic AMP and
cyclic GMP signaling, respectively. Treatment also decreased levels of-catenin
and downstream targets of TCF-dependent transcription, including c-MYC,
survivin and cyclin-D1. Homozygous knockout PDE10A clones of OV-90 ovar-
ian cancer cells obtained using CRISPR/Cas9 showed decreased clonogenic po-
tential, decreased Pf-2545920-mediated VASP phosphorylation and -catenin,
c-MYC and survivin expression. Ongoing efforts are focused on the develop-
ment of more potent ADT-061 analogs. These observations support further
study of a role of PDE10 in ovarian tumorigenesis and the development of
ADT-061 or analogs for the treatment of refractory ovarian cancer as well as the
prevention of malignant recurrence.
#5175 -Mangostin, a natural xanthone derivative targets Wnt signaling
pathway in colon cancer cells. Balaji Krishnamachary,1 Dharmalingam Subra-
maniam,2 Thomas Attard,1 Seth Septer,1 Shrikant Anant2. 1Children’s Mercy
Hospital, Kansas City, MO; 2University of Kansas Medical Center, Kansas City,
KS.
Background: Colorectal cancer is the third most common cancer in inci-
dence and cause of death in the United States. The current treatment modal-
ities include chemotherapy, radiation, and surgery. Many people are genet-
ically predisposed for colon cancer through mutations in genes such as
adenomatous polyposis coli (APC). While the absence of APC causes aber-
rant Wnt/Beta catenin signaling, the APC mutations are found in more than
80% of colorectal tumors. -Mangostin is a major bioactive compound
present in Mangosteen (Garcinia mangostana) which possess signifıcant an-
ti-cancer activity. Herein, we investigated the effects of  -Mangostin on
colon cancer growth and elucidated its mechanistic action through Wnt
signaling pathway. Methods: HCT116, SW480 and RKO cell lines were used
in the study. The effects of -Mangostin on cell proliferation were assessed
by hexosaminidase and clonogenicity assays. Effects of -Mangostin on ap-
optosis were evaluated by cell cycle and western blot analysis. Moreover the
effect of -Mangostin on colonosphere formation was also evaluated. Fur-
thermore, the effect of -Mangostin onWnt signaling proteins was evaluated
by western blot analysis. The in vivo anti-cancer effect of  -Mangostin was
investigated on the HCT116 subcutaneous tumor xenograft model im-
planted in fıve-week-old male athymic nude mice. Further, the effect of 
-Mangostin was assessed by the specifıc marker expression in tissue samples
by western blot analysis and immunohistochemistry. Results: -Mangostin
treatment resulted in a dose and time dependent inhibition of proliferation
and colony formation in all the three cell lines. Treatment also induced colon
cancer cells to undergo G0/G1 and S-phase arrest. Apoptosis was confırmed
by increased levels of Bax/Bcl2 ratio, coupled with a reduction in cyclin D1.
 -Mangostin signifıcantly reduced the number and size of colonospheres.
Moreover, -Mangostin treatment decreased the expression of Wnt signal-
ing proteins, which suggest that -Mangostin inhibits the colon cancer
growth through Wnt signaling pathway. To determine the effect of -Man-
gostin on tumor growth in vivo, nude mice harboring HCT116 tumor xeno-
grafts in their flanks were administered with 5mg/Kg -Mangostin intraperi-
toneally for 21 days. -Mangostin treatment signifıcantly reduced the tumor
growth, with notably lower tumor volume and weight. Western blot and
immunohistochemistry analyses revealed signifıcant decrease in the expres-
sion ofWnt signaling proteins. Conclusion: Together, these data suggest that
-Mangostin inhibits colon cancer growth through Wnt signaling pathway.
-Mangostin may be a potential therapeutic agent for colon cancer.
#5176 E7386, an orally active CBP/beta-cateninmodulator, effects tumor
microenvironment, resulting to the enhancement of antitumor activity of
lenvatinib. Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Yasuhiro Fu-
nahashi, Junji Matsui, Tomohiro Matsushima, Takashi Owa. Eisai co., Ltd,,
Ibaraki, Japan.
E7386, a novel orally active CBP/beta-catenin modulator, has an impact
on cancer cells with aberrant activation of Wnt/beta-catenin signaling path-
way driven by adenomatous polyposis coli (APC) mutation or beta-catenin
mutation and shows signifıcant antitumor activity in xenograft models.
CBP/beta-catenin transcriptional activation has an important role in not
only malignancy of cancer cells but also regulation of tumor microenviron-
ment such as fıbroblast, pericyte, endothelial cells and immune cells. In this
study, we investigated E7386 effect on tumor microenvironment and if it
leads to enhance antitumor activity of lenvatinib. Lenvatinib is a potent
anti-angiogenic inhibitor targeting vascular endothelial growth factor recep-
tors, fıbroblast growth factor receptors and other proangiogenic and onco-
genic kinases. Firstly, we tested the combination of E7386 with lenvatinib in
Wnt-1 tumor isogenic models, where tumors isolated from MMTV-Wnt1
transgenic mice were inoculated in mice. While E7386 and lenvatinib indi-
vidually suppressed tumor growth and caused tumor dormancy, the combi-
nation resulted in approximately 75% tumor reduction. To clarify the effect
on tumor microenvironment, we tested an isograft model of 4T1 murine
breast cancer cells which was resistant to E7386 in vitro proliferation. E7386
and lenvatinib individual treatments showed a signifıcant antitumor effect,
but the antitumor effect of the combination was signifıcantly superior to that
of each mono-treatment. Therefore, we compared effects of E7386 and len-
vatinib on tumor microenvironment in immunohistochemical analysis us-
ing CD31 Ab as an endothelial marker and alpha-SMA Ab as a pericyte and
cancerous fıbroblast marker. E7386 signifıcantly decreased alpha-SMA pos-
itive cells and microvessel density in tumors. In addition, remaining tumor
vessels were not covered with pericytes. In lenvatinib treated tumors, greater
reduction of microvessel density was observed than in E7386 treated tumors,
but tumor vessels covered with pericytes, which are known to be resistant
against VEGF inhibitors, were remained. In combination treatment, most of
the tumor vessels disappeared. The enhancement of antitumor activity in the
combination was also observed in SEKI human melanoma xenograft model
which is relatively resistant to lenvatinib. These data suggest E7386 sensitizes
tumor to lenvatinib through the modulation of the tumor microenviron-
ment that is resistant to VEGF inhibitors. Taken together, E7386 shows not
only antitumor activity via the effect on cancer cells but also through the
modulation of tumor microenvironment, and the treatment of E7386 with
lenvatinib is a novel combination therapy to overcome resistance to VEGF
inhibitors.
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#5177 E7386 : First-in-class orally active CBP/beta-catenin modulator as
an anticancer agent. Kazuhiko Yamada,1 Yusaku Hori,1 Atsumi Yamaguchi,1
Masahiro Matsuki,1 Shuntaro Tsukamoto,1 Akira Yokoi,1 Taro Semba,1 Yoichi
Ozawa,1 Satoshi Inoue,1 Yuji Yamamoto,1 Kentaro Iso,1 Kazutaka Nakamoto,1
Hitoshi Harada,1 Naoki Yoneda,1 Atsushi Takemura,1 Masayuki Matsukura,,1
Kenji Kubara,1 TakenaoOdagami,2Masao Iwata,1 Akihiko Tsuruoka,1 Toshim-
itsu Uenaka,1 Junji Matsui,1 Tomohiro Matsushima,1 Kenich Nomoto,1 Hi-
royuki Kouji,2 Takashi Owa1. 1Eisai co., Ltd., Ibaraki, Japan; 2PRISM Pharma
Co., Ltd., Japan.
Carcinogenesis is often accelerated by the aberrant activation of components
molecules of Wnt signaling pathway, especially, APC and beta-catenin are fre-
quently reported to be mutated in various cancers. Therefore, Wnt signal path-
way is thought to be one of the attractive therapeutic targets. PRI-724 generated
byPRISMPharma is a smallmolecule inhibitor of beta-catenin and its transcrip-
tional coactivator CREB binding protein (CBP) thereby specifıc modulating
Wnt/beta-catenin signaling pathway by intravenous continuous infusion. Here
we fırstly generated orally active small molecular inhibitor, E7386. E7386 dis-
rupted the interaction between beta-catenin and CBP in co-immunoprecipita-
tion assay. E7386 inhibited canonical Wnt signaling pathway /TCF reporter
gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 in a dose depen-
dent manner with IC50 values of 55 nmol/L and 73 nmol/L, respectively. E7386
modulated the expression of Wnt signaling pathway related genes including
AXIN2 and other genes, which were down-regulated by artifıcial knockdown of
beta-catenin. These results indicate that E7386 controls the expression of Wnt
target genes through modulation of beta-catenin/CBP interaction. Next we in-
vestigated anti-polyposis effect in ApcMin/mice as an in vivo proof of mecha-
nismmodel. ApcMin/mice develops polyps in the intestinal tract caused by the
aberrant activation ofWnt/beta-catenin signaling pathway. Oral administration
of E7386 signifıcantly suppressed the number of polyposis in a dose dependent
manner at the dose range from 8.5 to 50 mg/kg. In addition, E7386 signifıcantly
changed the expressions of Wnt related genes in whisker follicle of ApcMin/mice
model. Finally, we investigated anti-tumor activity of E7386 in vitro tumor
proliferation panel against 28 human tumor cell lines. E7386 showed rela-
tively potent anti-proliferative activity against cancer cell lines harboring
exclusively mutated Wnt signaling pathway molecules such as APC or beta-
catenin. E7386 also showed signifıcant antitumor activity in a dose depen-
dent manner on human tumor cell line xenograft harboring APC mutation.
Taken together, E7386 is a fırst in class orally active CBP/beta-catenin mod-
ulator and showed potent inhibitory activity against aberrant activation of
Wnt/beta-catenin signaling pathway.
#5178 CB002, a novel p53 pathway-restoring compound that induces ap-
optosis through the pro-apototic protein NOXA. Liz J. Hernandez Borrero,
ShengliangZhang,DavidT.Dicker,Wafık S. El-Deiry.FoxChaseCancer Center,
Philadelphia, PA.
P53 is a transcription factor that becomes stimulated upon genotoxic and
cellular stress signals ultimately leading to the transcriptional activation of genes
involved in processes such as DNA repair, cell cycle arrest, and apoptosis etc.
TP53 is the most commonly mutated tumor suppressor and this is associated
with cancer initiation, cancer progression and therapy resistance. P53-targeted
therapy has proven to be challenging because direct functional restoration of
p53 as a transcription factor has been diffıcult to achieve. We haven taken a
different approach by investigating small molecules that functionally restore the
p53-signaling pathway instead of direct p53 targeting. To date there is no ap-
proved drug that restores the p53 pathway in cancer cells with mutant p53.
Therefore, we performed a high-throughput screen to identify such molecules.
We identifıed a family of small molecules, CB002 and its structural analogs, as
candidates for restoration of the p53 pathway in p53-null and mutant p53-
expressing cancer cells. CB002 was specifıc in causing apoptosis in colorectal
cancer cells and not in normal human fıbroblasts cells as indicated by a Sub-G1
assay. Utilizing the xCELLigence RTCADP system andCIM-Plate we show that
CB002 treatment decreases the ability of colorectal cancer cells to migrate. The
ability of CB002 to restore the p53 pathway was validated by studying the acti-
vation of p53 target genes p21, DR5, and NOXA in various cancer cell lines and
expression of well-established apoptotic markers. Stable knockdown of NOXA
completely abrogated the expression of cleaved PARP and reduced Sub-G1 cells,
implicating the relevance of NOXA as a key mediator of cell death induction by
CB002. We are currently exploring the mechanism by which NOXA induces
apoptosis, as preliminary results suggest that degradation of Mcl-1 is not re-
quired for CB002 mediated cell death. In addition, we are evaluating the ability
of CB002 structural analogs in decreasing the stability of mutant p53 using a
larger panel of p53mutants, asCB002 appears to target R175Hp53mutants.Our
data supports the continued investigation of CB002 as a p53 pathway-restoring
compound that may be further developed as a cancer therapeutic for p53-null
tumors as well as tumors with p53 mutations.
#5179 The fırst in class FLI1 inhibitorTK-216presents both in vitro and in
vivo anti-tumor activity in lymphoma. Filippo Spriano,1 Chiara Tarantelli,1
Eugenio Gaudio,1 Elaine YL Chung,1 Alberto J. Arribas,1 Luciano Cascione,1
Sara Napoli,1 Ivo Kwee,1 Andrea Rinaldi,1 Davide Rossi,1 Emanuele Zucca,2
Anastasios Stathis,2 Katti Jessen,3 Brian Lannutti,3 Jeffrey Toretsky,4 Francesco
Bertoni1. 1Institute of Oncology Research - IOR, Bellinzona, Switzerland; 2Oncol-
ogy Institute of Southern Switzerland - IOSI, Bellinzona, Switzerland; 3Oncternal
Therapeutics, San Diego, CA; 4Georgetown University, Lombardi Institute,
Washington, DC.
Background. ETS transcription factors, such as FLI1 and SPIB, are recurrently
deregulated in human lymphomas (Bonetti et al, Blood 2013; Lenz et al, PNAS
2008). The small molecule YK-4-279 inhibits binding of EWS1-FLI1 fusion
protein to RHA resulting in growth arrest and apoptosis in Ewing sarcoma cells
(Erkizan et al, Nat Med 2009) and we previously showed that YK-4-279 has in
vitro anti-lymphoma activity (Chung et al, AACR 2015). TK-216 is a YK-4-279
clinical derivative that is in phase 1 for patientswith relapsed or refractory Ewing
sarcoma (NCT02657005). Here, we present extensive preclinical results ob-
tainedwithTK-216 in lymphomamodels.Methods. 56 cell lines [27 diffuse large
B cell lymphoma (DLBCL); 10 mantle cell lymphoma; 6 marginal zone lym-
phoma; 5 anaplastic large T-cell lymphoma; 8 others] were exposed to TK-216
increasing doses for 72h using a Tecan D300e Digital Dispenser and 384well
plates; cell proliferation was measured with MTT. In vivo studies were per-
formed in NOD-SCID mice and treatments started with approximately sc
60mm
3
tumor volumes. Results. TK-216 displayed high activity: median IC50
was 449 nM (95%CI: 367-506). Sensitivity was not affected by the lymphoma cell
of origin [B vs T; activated B cell type (ABC) vs germinal center type DLBCL] or
MYC and TP53 status. There was a non-statistically signifıcant trend for lower
sensitivity in cell lines bearing BCL2 chromosomal translocation (P0.07, DL-
BCL only; P0.06, all cell lines). Anti-tumor activity was mainly cytotoxic as
confırmed by performing cell cycle analysis andAnnexinV staining in 6DLBCL
cell lines (TMD8, U2932, HBL1, OCI-LY-18,WSU-DLCL2, DOHH2 for 24, 48,
72h), in which a time-dependent apoptosis was preceded by G2/M arrest. Anti-
tumor activity was confırmed in DLBCL TMD8 xenografts. Compared with
control group (n10),mice treatedwith TK-216 (100mg/Kg, BID; n9) clearly
presented a reduction in tumor growth, already evident at day 3 and becoming
much stronger with time (D3, D5, D8, D11: P0.01; D13, P not available since
control group had to be stopped due to tumor volume) and a 4 times reduction
in tumor volume atD11 (P0.01). TK-216was tested in combinationwith other
targeted agents in DLBCL cell lines. A benefıt was observed with the combina-
tion of TK-216 with the immunomodulator lenalidomide (synergism in 2/2
ABC DLBCL), with the BET inhibitor OTX015 (MK-8628) (synergism in 2/4
cells and additive effect in 1/4), the anti-CD20 monoclonal antibody rituximab
(synergism in 2/3 cells) and the BCL2 inhibitor venetoclax (synergism in 3/4
cells). The latter synergism could be linked to the previouslymentioned negative
trend between TK-216 IC50 values and the presence of BCL2 translocation.
Conclusions. The novel small molecule TK-216 presented strong preclinical
anti-lymphoma activity, which provides evidence for further preclinical and
clinical development as single agent and in combination.
#5180 Effects of soy isoflavones and SRC inhibitors onmetastatic activity
in prostate cancer. Lori P. Rice, DietmarW. Siemann.Univ. of Florida, Gaines-
ville, FL.
Background: In advanced prostate cancer (PCa), cells escape from the primary
tumor and enter the bloodstream, preferentially targeting the bone. This results in
weakenedbones, spinal compressions, fracturesand intensepain.Efforts to interfere
with early steps in themetastatic cascade by affecting the tumormicroenvironment
have led to the development of promising small molecule targeting agents. The
tyrosine kinase inhibitors, saracatinib and dasatinib, have been shown to inhibit
activation of Src and downstream effectors thought to be involved in cancer cell
dissemination. Soy-derived isoflavones (ISFs) have been shown to have cytostatic
effects onPCa cellswithout toxicity.Aim:The aimof these studieswas to determine
if ISFs enhance the effects of Src inhibitors on PCa cells, resulting in lower doses of
these agents needed to produce optimum results. Methods: PC-3 ML and LNCaP
cells were treated with either a Src inhibitor (dasatinib or saracatinib), a soy isofla-
vone extract (ISFs), or a combination. Modifıed Boyden transwell chambers were
used to evaluatemigration and invasion.Cell cycle andproliferationweremeasured
using FACS analyses and trypan blue staining, respectively. Results: ISFs and Src
inhibitorsdidnot causecytotoxicityor reduceproliferation.However, Src inhibitors
produced an increase in cells inG1 phase, while ISFs increased cells inG2/Mphase.
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When ISFs were combined with Src inhibitors, both phases were increased with a
concomitant decrease in S phase cells. In transwell migration studies, all agents
signifıcantly decreased the number of cells found on the bottom of the membrane:
dasatinibsaracatinibISFs. Lower doses of Src inhibitorswere needed to produce
inhibition of migration when ISFs were added to the treatment. Invasion studies
with PC-3 ML and LNCaP cells suggest that ISFs can reduce metastatic activity by
39% and 35%, respectively. Therefore, by adding ISFs, lower doses of inhibitors
might be used to achieve optimal response and decrease toxicity. Conclusions: In
vitro studies suggested that a combination of a Src inhibitors and ISFs, at non-
cytotoxic doses, results in greater inhibition of metastatic or invasion activity than
either alone. Further studies are needed to determine if this strategy could be used
clinically to treat patientswith lower doses of smallmolecule inhibitors by including
soy isoflavone concentrates in the treatment regimen.
#5181 Targeted knockdown of MYC in AML cells using G-quadruplex
interacting smallmolecules.MeganA. Turnidge,1 Apurvi Patel,1 Justin J.Mon-
toya,1DavidW. Lee,1DanielH.Wai,1 VijayGokhale,2 LaurenceHurley,2 Robert
J. Arceci,1 David O. Azorsa1. 1University of Arizona College of Medicine - Phoe-
nix, Phoenix, AZ; 2University of Arizona School of Pharmacy, Tucson, AZ.
Acute Myeloid Leukemia (AML) is a disease that occurs when genomic
changes alter expression of key genes, causing cells to resume an undifferenti-
ated state, proliferate, and maintain tumor growth throughout the body. Re-
cently, there has been an increase in efforts toward developing therapies that
specifıcally target the protein products of these aberrantly expressed genes.
However, many of the proteins are diffıcult to target because of structural chal-
lenges, protein overexpression that requires high drug doses, or mutations that
confer resistance to therapy. One potential type of targeted therapy that circum-
vents these issues is the use of small molecules that stabilize DNA secondary
structures called G-quadruplexes. G-quadruplexes are present in the promoters
of many potential oncogenes, and have regulatory roles in their transcription.
This study analyzes the therapeutic potential of compounds that target the reg-
ulatory G-quadruplex in the MYC oncogene, which is commonly misregulated
in AML. Treatment of the MYC expressing AML cell lines KG-1 and UT-7epo
with the compound GQC-05 resulted in decreased expression of MYC mRNA,
as determined by qPCR. Moreover, GQC-05 treatment induced a more signifı-
cant decrease in c-Myc protein expression than similar treatment with JQ-1(),
as shown by western blot analysis. Treatment of AML cells with GQC-05 also
decreased cell viability and increased apoptosis. Concurrent treatment of AML
cells with GQC-05 and JQ-1() showed an antagonistic effect, indicating po-
tential competition in the silencing of MYC. These results demonstrate that
targeting theMYCpromoter G-quadruplex in AML cells leads to knockdown of
MYC expression and induces apoptosis. These results further support the devel-
opment of a novel mechanism for targeting key genetic drivers in AML, and lay
the groundwork for advances in treatment of other cancers driven byG-quadru-
plex regulated oncogenes.
#5182 Targeting abnormal metabolism downstream of MYC in atypical
teratoid/rhabdoid tumors. Sabrina Wang,1 Jeffrey Rubens,1 Sariah Allen,2
Brent Orr,2 Charles Eberhart,1 Eric Raabe1. 1Johns Hopkins University, Balti-
more, MD; 2St Jude Children’s Research Hospital, Memphis, TN.
Atypical teratoid rhabdoid tumors (AT/RT) are deadly infantile brain tumors
in dire need of new, targeted therapies. Recent molecular analysis revealed con-
siderable tumor heterogeneity subdividing AT/RT into 3 distinct groups. The
MYC subgroup has a dismal 5 year survival of 18.5%. MYC is known to drive
reliance on glutamine for cellular metabolism suggesting that high-MYC ex-
pressing neoplasms may be sensitive to glutamine metabolic inhibitors. 6-Di-
azo-5-oxo-L-norleucine (DON) is a glutamine antagonist that decreases the
tumorigenicity of high MYC expressing models of medulloblastoma and neu-
roblastoma . We hypothesize that DON will reduce the tumorigenicity of the
MYC subgroup of AT/RT. High levels of c-MYC protein are expressed in about
1/3 of humanAT/RT (Immunohistochemistry for c-MYCon 22 humanAT/RT,
H-score  1 standard deviation over the median considered high c-MYC ex-
pression). Similarly twoof six ofAT/RT cell lines expressed high levels of c-MYC
protein by western blot. DON treatment slowed cell growth of high c-MYC
expressing AT/RT cell lines BT12 and CHLA06 (MTS assay p0.005 10uM
DONvsDMSOcontrol; t-test), whereas cell lines BT37 andCHLA05,which had
low c-MYC expression were not affected. Cell cycle analysis demonstrated that
DON caused cell cycle arrest in the G2/M phase for the high c-MYC expressing
lines BT12 and CHLA06 (31.2% of BT12 DMSO controls in G2/M phase vs
54.5% after 10uMDON treatment and 27.4% vs 48.9% in CHLA06). In contrast
the cell cyclewas not affected byDON treatment in the cell lineswith low c-MYC
expression (21.3% DMSO vs 20.2% after 10uM DON in BT37). DON also in-
creased apoptosis in cell lines with high c-MYC and inducedDNA strand breaks
(Western blot for c-PARP and p-H2A.X respectively). DON signifıcantly im-
proved survival in BT-12 high c-MYC expressing orthotopic mouse xenografts
(median survival increased from 21 to 36 days, p0.005; log-rank test). These
data develop the framework for future clinical trials using glutamine antagonists
to target the MYC subgroup of AT/RT.
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS:
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#5183 The radioenhancer NBTXR3 brings anticancer effıcacy to the cis-
platin-based chemoradiation in vitro and in vivo.Agnès Pottier,1 SoniaVivet,1
Sébastien Paris,1 Bo Lu2. 1Nanobiotix, Paris, France; 2Thomas Jefferson Univer-
sity, Philadelphia, PA.
NBTXR3 is a radioenhancer composed of functionalized hafnium oxide
nanoparticles, designed to enhance the radiation dose deposit within the cancer
cells when activated by ionizing radiations. NBTXR3 is intended for single in-
tratumor administration and is currently evaluated in cancer clinical trials in-
cluding soft tissue sarcoma, head and neck (H&N), prostate, liver and rectum.
Cisplatin (CDDP) is a cytotoxic agent considered to be a radiosensitizer and
inhibits the repair of sublethal damage from irradiation. Concurrent chemora-
diation using CDDP is the mainstream treatment for high risk H&N, cervix and
non-small cell lung cancer patients. We hypothesized that adding NBTXR3 to
radiation treatment (RT) may improve signifıcantly anticancer effect of the
chemoradiation combination In vitro, no specifıc clonogenic toxicity was ob-
served for the cells exposed only to NBTXR3. For the combined treatment
CDDPwas used at its IC50 concentrations. Amarked and enhanced cell destruc-
tion (DEF) was observed with the CDDP combined treatment (added 6h or 16h
prior to RT) and NBTXR3 (800M, added 16h prior to RT) at 2Gy when
compared to the single agent.
Treatment Cell line (DEF*)
CDDP NBTXR3 Irradiation FaDu NCI-H460-Luc2
6h - 2Gy 1.00.06 1.20.06
- 16h 1.40.15 1.30.25
6h 16h 1.40.14 1.60.12
16h - 1.00.12 1.90.32
- 16h 1.20.13 1.50.17
16h 16h 1.80.23 2.60.45
6h - 4Gy 1.30.08 2.20.16
- 16h 2.20.24 1.90.41
6h 16h 3.10.64 3.80.48
16h - 1.20.19 2.90.52
- 16h 2.10.31 2.80.39
16h 16h 5.30.97 7.62.76
*For a given radiation dose, theDEF valuewas obtained by taking the ratio of the
survival fraction in the control (radiotherapy alone) and the survival fraction of
the treatment. In vivo, NBTXR3 enhanced the fractionated radiation treatment
(5x2Gy) when injected intratumorally at 25% of tumor volume. NBTXR3 acti-
vated with ionizing radiation in combination with low dose of CDDP (1mg/kg
administered 5 consecutive days, 2 hours prior to RT) delayed tumor growth
when compared to single agent CDDP in combination with RT. These results
strongly support the concurrent chemoradiotherapy regimen with NBTXR3
nanoparticles as an effective radioenhancer to increase the anticancer effect. A
new phase I/II trial with H&N cancers patient receiving radiotherapy plus
CDDP has been started evaluating the optimal dose, safety and preliminary
effıcacy of NBTXR3.
#5184 Radiosensitizing effect of lapatinib inHER2-overexpressing breast
cancer cells: scientifıc rationale for RTOG1119 study. Tosol Yu, Bong Jun
Cho, Eun Jung Choi, Ji Min Park, Dan Hyo Kim, In Ah Kim. Seoul National
University, Seongnam-Si, Republic of Korea.
Trastuzumab has been widely used for the treatment of human epidermal
growth factor receptor 2 (HER2)-overexpressing breast cancer, however, it can-
not easily cross the blood-brain barrier (BBB) and is known to increase the
incidence of brain metastases. In contrast, lapatinib has a low molecular weight
and can cross the BBB and it could be useful to treat brainmetastases in patients
with HER2-positive breast cancer. To explore the impact of lapatinib on radia-
tion response, we conducted an in vitro experiment using SKBR3 and BT474
breast carcinoma cells exhibitingHER2/neu amplifıcation. Lapatinib down-reg-
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ulated phosphorylated p-HER2, p-EGFR, p-AKT, and p-ERK. Pretreatment of
lapatinib increased the radiosensitivity of SKBR3 (sensitizer enhancement ratio
[SER]: 1.21 at a surviving fraction of 0.5) and BT474 (SER: 1.26 at a surviving
fraction of 0.5) cells and hindered the repair ofDNAdamage, as suggested by the
prolongation of radiation-induced H2AX foci and the down-regulation of
phosphorylated DNAdependent protein kinase, catalytic subunit (p-DNAP-
Kcs). Increases in radiation-induced apoptosis and senescencewere suggested to
be the major modes of cell death induced by the combination of lapatinib and
radiation. Furthermore, lapatinib did not radiosensitize aHER2- negative breast
cancer cell line or normal human astrocytes. These results suggest that lapatinib
can potentiate radiation-induced cell death inHER2-overexpressing breast can-
cer cells and may increase the effıcacy of radiotherapy. Based on these fındings,
RTOG1119 study which is a phase II randomized study for lapatinib combined
with radiation therapy in patients with brain metastases from HER2-positive
breast cancer is ongoing (NCT 01622868).
#5185 Targeting inhibitors of apoptosis in combinationwith radiation for
the treatment of head and neck squamous cell carcinoma. Linlin Yang,
Bhavna Kumar, Tianyun Li, Thenodoros N. Teknos, Arnab Chakravarti, Ter-
ence M. Williams. Ohio State Univ. Comp. Cancer Ctr., Columbus, OH.
Background and purpose: Evasion of apoptosis contributes to radioresistance
of head andneck squamous cell carcinoma (HNSCC), calling for novel strategies
to overcome apoptotic resistance. Second mitochondria-derived activator of
caspase (SMAC) -mimetics are a class of targeted drugs that antagonize selected
inhibitor of apoptosis protein (IAP) to block pro-survial signalling, and eventu-
ally induce cell apoptosis. The present study was designed to investigate the
radiosensitizing effect of one SMAC mimetic, LCL161, in HNSCC and the un-
derlying mechanisms for radiosensitization. Material and methods: We ana-
lyzed the correlation between apoptotic molecules and HPV status in HNSCC
via mRNA expression using The Cancer Genome Atlas (TCGA) database, as
well as protein expression in 6 HNSCC cell lines by immunoblotting. We also
examined cIAP1 expression on a tissue microarray (TMA) of HNSCC tumors,
and assessed its correlation with HPV status and patient outcome. Clonogenic
survival andWST-1 assayswere carried out to explore the potential of LCL161 as
a radiosensitizer in HNSCC cell lines. Cell cycle analysis, Annexin-V assays and
immunoblotting were performed to investigate effects of LCL161 on radiation
induced cell apoptosis. Human tumor xenografts were generated to explore the
radiosensitization effect of LCL161 on HPV[-] tumors in vivo. Results: TCGA
database analysis and immunoblotting fromHNSCC cells revealed that expres-
sion of cIAP1, Survivin, DIABLO, p65, IK-b, TNF-	, BCL-XL, Caspase-7, and
Caspase-8 were elevated inHPV[-] compared toHPV[] HNSCC tumors. IHC
staining showed cIAP1 expression was associated with HPV[-] status
(p0.0239). In addition, cIAP1 expression was signifıcantly higher in HNSCC
comparedwith adjacent normal tissue (p0.0003). In univariate analysis, cIAP1
was signifıcantly associated with poor overall survival (p0.0359). LCL161 de-
graded cIAP1 at nanomolar concentrations but has minimal single-agent cyto-
toxicity with IC50 range of 32M–95M. Interestingly, we found that LCL161
could induce radiosensitization only in HPV[-], but not in HPV[] HNSCC
cells. Mechanistic studies showed LCL161 mediated radiosensitisation was as-
sociated with increased cell apoptosis, with enhanced activation of caspases-3,
-7, -8, -9, and PARP. Finally, in vivo data showed that LCL161 degraded cIAP1,
activated caspases, and profoundly radiosensitized two humanHPV[-] HNSCC
xenograft models. Conclusion: Taken together, our results demonstrate for the
fırst time that cIAP1 is a potential prognostic and therapeutic biomarker for
HNSCC patients. Through targeting cIAP1 and other IAP family members,
LCL161, radiosensitizes HNSCC tumors, particularly HPV [-] tumors, via
caspase activation and apoptosis induction. Taken together, LCL161 holds
promise for future clinical development as a novel radiosensitizer in the treat-
ment of HPV[-] HNSCC tumors.
#5186 Vemurafenib selectively radiosensitizes BRAF V600Emutant pap-
illary and anaplastic thyroid carcinoma cells.RyanN. Robb, Linlin Yang, Ter-
ence Williams. The Ohio State University, Columbus, OH.
BRAF activating mutations act as oncogenic drivers and are highly prevalent
in thyroid cancer, occurring in about 60% of papillary thyroid cancer (PTC) as
well as 30-40% anaplastic thyroid cancer (ATC).MAPK signaling and treatment
resistance is driven by BRAF mutations in thyroid cancer. Among the most
common of these mutations is BRAFV600E, which can be selectively inhibited by
vemurafenib. Using a panel of PTC and ATC cell lines we assessed how the
presence/absence of BRAFV600E impacts radiation sensitivity.Weused radiation
clonogenics, comet assays, nuclear foci formation, immunoblotting, andmouse
xenograftsmodels to determine the effect of vemurafenib onPTCandATCcells.
Analysis of radiation clonogenics implicated higher radioresistance in cell lines
containing the BRAFV600Emutation as compared to wild-type BRAF. Addition-
ally, forced expression of BRAFV600E in a wild-type thyroid cancer cell line in-
duced radioresistance. Vemurafenib inhibited MAPK signaling in V600E mu-
tant cell lines, but showed no effect in BRAF wild-type cell lines. Vemurafenib
pretreatment selectively radiosensitized BRAFV600Emutants in vitro, as assessed
by radiation clonogenic assays. Comet assays revealed impairment of DNA re-
pair in BRAFV600E lines when treated with vemurafenib and radiation. Addi-
tionally, -H2A.x westerns and nuclear foci staining indicated that vemurafenib
pretreatment decreases the tumor cell’s ability to repair DNA double-strand
breaks (DSB) in BRAFV600E cell lines. Vemurafenib also appeared to alter the
kinetics of formation and resolution of 53BP1 and Rad51 nuclear foci in these
cell lines. Evaluation of DSB functional repair using GFP reporter constructs,
suggests that BRAFV600E induces NHEJ repair, which can be attenuated by ve-
murafenib treatment. Finally, vemurafenib effectively increases radiosensitivity
of BRAF V600E tumors in vivo. From our results, BRAF activating mutation
appears to be associatedwith radioresistance. Vemurafenib selectively radiosen-
sitizes both PTC and ATC cells through inhibition of DNA repair mechanisms.
Combining vemurafenib and radiation may improve therapeutic control for
BRAFV600E mutant thyroid cancers.
#5187 Potent radiosensitization of adenoid cystic carcinoma in a patient
derived xenograft model using theMDM2 inhibitor AMG 232.Amal Javaid,1
AdamD. Swick,1 LaurynWerner,1 Prashanth Prabakaran,1 RongHu,1Kwangok
P. Nickel,1 Irene Ong,1 Emmanuel Sampene,1 Justine Bruce,1 Gregory Hartig,1
Aaron Wieland,1 Jude Canon,2 Paul Harari,1 Randall Kimple1. 1UW-Madison,
Madison, WI; 2AMGEN, CA.
Purpose: Adenoid cystic carcinoma (ACC) is a relatively rare cancer that
typically arises in major or minor salivary gland tissues of the head and neck.
There are currently no approved systemic agents for ACC and no established
data supporting the delivery of chemoradiation forACCpatients. The scarcity of
validated preclinical model systems has hampered research efforts. We report
the successful establishment and propagation of an ACC patient derived xeno-
graft (PDX), genomic evaluation of cancer associated mutations, and in vivo
response to MDM2 inhibition combined with radiotherapy. Because TP53 mu-
tations are seen in 5% of ACCs, we investigated the role of a small molecule
MDM2 inhibitor, AMG 232. Methods: An ACC PDX was established and as-
sessed for common cancer-associatedmutations using the IlluminaTruSeqAm-
plicon Cancer panel. Xenografts were treated with focal radiation with or with-
out AMG 232. Focal radiation was delivered at 0, 2, 5, or 8 Gy x 8 fractions
delivered twice weekly, with AMG232 (50mg/kg) delivered daily by oral gavage.
Tumor size was measured by caliper and comparisons between treatment
groups made using a repeated measures ANOVA. A TCD50 was calculated by
fıtting log-transformed data to a dose-response curve and compared using the
extra-sum-of-squares f test. Target inhibition and anti-cancer effect was con-
fırmed via immuno-blotting of tumor lysates, and IHC staining or in situ hy-
bridization of relevant targetswithin FFPE sections of tumors harvested 2 and 48
hrs post treatment. Results: The histologic characteristics of the primary human
tumor are maintained in subsequent murine passages of this ACC PDX. Muta-
tional profıling determined that the PDXwaswildtype for TP53.AMG232 alone
resulted inmodest slowing of tumor growth. Radiation alone produced a tumor
growth delay in a dose dependent manner but did not result in sustained local
tumor control. Strikingly, the combination of AMG 232 with RT (including low
dose radiation of 2 Gy) produced dramatic tumor shrinkage and potent tumor
control threemonths after the end of treatment. Target inhibition ofMDM2was
confırmed bywestern blot of tumor lysates and IHCof FFPE samples taken 2 hrs
post treatment. Antiproliferative and apoptotic effects were confırmed by west-
ern blot of tumor lysates and IHC of FFPE samples taken at 48 hrs post treat-
ment. Conclusions: This study suggests that MDM2 inhibition may provide
potent radiosensitization in TP53 WT ACC. While additional translational
models are warranted, the powerful response profıle observed suggests that
phase I clinical trial evaluation of this combination is worthy for this challenging
malignancy.
#5188 Molecular radiosensitization in soft tissue sarcomas by telomerase-
specifıc oncolytic adenovirus. Tadashi Komatsubara,1 Toshinori Omori,1 Hi-
roshi Tazawa,1 Kazuhisa Sugiu,1 Yusuke Mochizuki,1 Yasuaki Yamakawa,1
Shuhei Osaki,1 Joe Hasei,1 Tomohiro Fujiwara,1 Toshiyuki Kunisada,1 Yasuo
Urata,2 Tsoshifumi Ozaki,1 Toshiyoshi Fujiwara1. 1Okayama univ. Graduate
School of Med., Okayama, Japan; 2Oncolys BioPharma, Inc., Tokyo, Japan.
INTRODUCTION::Treatment options for soft tissue sarcoma (STS) include
surgical resection and adjuvant chemotherapy and radiotherapy. Despite the
development of combined modality treatments in recent years, a signifıcant
proportion of patients with sarcomas respond poorly to adjuvant therapy, lead-
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ing to local recurrence or distantmetastasis. Therefore, there is an urgent need to
develop novel therapeutic strategies for improvement of patient prognoses. We
previously reported the therapeutic potential of OBP-301, a telomerase-specifıc
oncolytic adenoviruses, and OBP-702, an armed OBP-301 expressing the wild-
type p53 tumor suppressor gene against bone and soft tissue sarcoma cells.
Furthermore, the synergistic anti-tumor effect of OBP-301 in combination with
radiation has been observed. While OBP-702 suppressed the viability of OBP-
301-sensitive and -resistant osteosarcoma cells more effıciently, the combina-
tion effect of OBP-702 and radiotherapy has been unknown. In this study, we
investigated the radiosensitizing effect of OBP-702 against human STS cells.
METHODS: We used four human STS cell lines, HT1080 (fıbrosarcoma),
NMS-2 (malignant peripheral nerve sheath tumor), and SYO-1 (synovial sar-
coma). Cells were irradiated 24 h after infection with OBP-301 and OBP-702,
and cell viability was assessed by XTT assay 4 days after irradiation. Combined
effect of radiation with OBP-301 and OBP-702 was analyzed with the CalcuSyn
software (BioSoft). These cells were also analyzed for apoptosis and DNA dam-
age using Western blot analysis. RESULTS: While OBP-301 and OBP-702
showed anti-tumor effect for STS cell lines respectively, HT1080 and NMS-2
were highly resistant to radiation. When combined with radiation, not only
OBP-301 but also OBP-702 enhanced the inhibitory anti-tumor effect in all STS
cell lines. The calculation of combination index demonstrated additive or syn-
ergistic anti-tumor effect in combination therapy. Further analysis revealed that
OBP-301 and OBP-702 increased radiation-induced apoptosis in STS cells. No-
tably, the radio-sensitizing effect ofOBP-702was associatedwith increase of p53
expression and interruption of anti-apoptotic myeloid cell leukemia 1 (MCL1)
expression. DISCUSSION:Our study demonstrated that OBP-702 had much
stronger anti-tumor effect compared to OBP-301, and sensitized radiotherapy
to various types of osteosarcoma cell lines. Currently, the clinical trial of OBP-
301 is performed, and preclinically OBP-702 accumulates good therapeutic re-
sults in various tumors. Thus, OBP-702 may provide a novel treatment strategy
for STSs and wide application of radiotherapy for localized as well as advanced
STSs.
#5190 Oncoprotein SET determines the radiosensitivity of hepatocellular
carcinoma cell and antagonizing SET augments the effects of radiotherapy
via reactivating PP2A-mediated Akt downregulation. Man-Hsin Hung,1
Chao-Yuan Huang,2 Chih-Ting Shih,3 Min-Hsien Tsai,2 Yung-Jen Hsiao,2
Tzu-I Chao,2 Feng-Shu Hsieh,2 Chung-Wai Shiau,3 Kuen-Feng Chen2. 1Taipei
Veterans General Hospital, Taipei, Taiwan; 2National Taiwan University Hospi-
tal, Taipei, Taiwan; 3National Yang-Ming University, Taipei, Taiwan.
Background: SET is a novel oncoprotein with growing evidence suggesting its
roles in promoting the survival of hepatocellular carcinoma (HCC) and other
types of malignant disease. Notably, pre-clinical data suggesting SET overex-
pression in cancer cell leaded to the development of resistance to various anti-
cancer medications, and antagonizing SET reversely enhanced therapeutic effı-
cacy. Radiotherapy (RT) is a commonly used anti-cancer modality, but its role
for the treatment of HCC is largely limited for the concern of endogenous ra-
dioresistance. In this report, we explored the role of SET regarding the radiosen-
sitivity of HCC cells. Furthermore, we explored whether SET serve as a valid
target to enhance RT againstHCC.Method: A panel ofHCC cell lines, including
Hep3B, PLC5, HA22T and HA59T, were used for in vitro experiments, and the
PLC5 subcutaneous xenograft mice model was used for in vivo testing. HCC
cells and tumors were treated with RT and/or SET antagonist and harvested for
subsequent experiments. The viability of cancer cells were assessed by sub-G1,
colony and sphere formation assay. Molecular events were determined by west-
ern blot and PP2A activity. Result: Throughmanipulating the expression of SET
in cancer cells, we showed the crucial role of SET in mediating the effects of RT
in HCC cells. Using colony formation and hepatosphere formation assay, we
showed that RT signifıcantly reduced the number and size of both tumor colony
and sphere formed by Hep3B and PLC5 cells. In contrast, ectopic expression of
SET in Hep3B and PLC5 cells abolished the effects of RT. More importantly,
SET-knockdown oppositely potentiated the RT-induced growth inhibition in
HCC cells. Based on our fındings, we hypothesized that targeting SETmay exert
potential to enhance RT for the treatment of HCC. In order to validate our
hypothesis, we tested the effects of RT in combine with a novel SET antagonist,
EMQA, developed and characterized in our previous works. As expected, we
found that EMQA signifıcantly potentiated the anti-HCC effects of RT in vitro
and in vivo. Moreover, we found that antagonizing SET to restore PP2A-medi-
ated p-Akt downregulation was responsible for the synergism between EMQA
and RT. Conclusion Oncoprotein SET plays a critical role in affecting the radi-
osensitivity of HCC cells. Using SET antagonist plus RT showed promising
results in pre-clinical HCC models, and yields further investigation.
#5191 A combination of Stat3 inhibitor and radiation for the treatment of
malignant pleural mesothelioma. Seiji Matsumoto, Hiroshi Doi, Akihiro Fu-
kuda, Tohoru Nakamichi, Ayumi Kuroda, Masaki Hashimoto, Teruhisa
Takuwa, Nobuyuki Kondo, Seiki Hasegawa. Hyogo College of Medicine, Nishi-
nomiya, Japan.
Background: Trimodality therapy, including surgery, is the treatment for pa-
tients with malignant pleural mesothelioma (MPM). However, the 5-year sur-
vival rate remains less than 40%. To improve the survival rate, we investigated
Stat3 as a potential therapeutic target for MPM. Methods:Cell viability was as-
sessed using Cell Counting Kit-8 (CCK-8: WST-8 Dojindo). MPM cells (NCI-
H28, NCI-H226, NCI-H2052, NCI-H2452, MSTO-211H) were seeded into 96-
well plates. After treatment with a Stat3 inhibitor (BBI-608 : napabucasin), Cell
Counting Kit-8 solution was added to each well and absorbance was measured
using a microplate reader. The level of phosphorylated Stat3 (p-Stat3) in cell
lysates was measured by ELISA. ROS level in cells was measured by FACS anal-
ysis. In the in vivo study, H226 cells were injected subcutaneously in the flank
region of nude mice randomly assigned to four treatment groups (5 mice/
group)—(1) treatment with vehicle control, (2) treatment with Stat3 inhibitor,
(3) radiation therapy (RT), and (4) Stat3 inhibitor and RT. Tumor size was
measured twice/week. Results: Napabucasin decreased the viability of MPM
cells (epithelioid, sarcoma, biphasic) in a dose-dependentmanner. p-Stat3 levels
decreased by 90% after treatment with 10Mnapabucasin in H226 cells. Napa-
bucasin treatment induced more ROS production in MPM cells than did Pem-
etrexed. Moreover, combinatorial treatment with napabucasin and radiation (2
Gy, 5 Gy) induced more ROS production than did RT alone. In the mouse
model, treatment with napabucasin alone signifıcantly suppressed tumor
growth (p  0.05), but napabucasin and RT completely suppressed tumor
growth. Conclusion:We showed that napabucasin inhibited proliferation of the
MPM cells (epithelial, biphasic, sarcomatoid) and demonstrated that combina-
tion therapy with napabucasin and radiation completely suppressed tumor
growth in a mouse model. Treatment with the napabucasin alone and the com-
bination of napabucasin and RT induced high ROS production in MPM cells.
Collectively, the combination of Stat3 inhibitor with Radiation Therapy
(START) is a promising approach for the treatment ofMPM.TheA combination
of of Stat3 inhibitor and radiation with for the treatment of malignant pleural
mesothelioma
#5192 Selection of radiosensitizers based on HRASmutation in head and
neck cancer.Michael M. Fisher, AdamD. Swick, Kwangok P. Nickel, Randall J.
Kimple. Univ. of Wisconsin-Madison, Madison, WI.
Purpose/Objective(s): The ability of activated HRAS to promote radiation
resistance and predict for sensitivity to potential radiosensitizers was tested in a
head and neck cancer model system. Materials/Methods: Mutations in HRAS,
KRAS, and NRAS were analyzed using cBioPortal in a head and neck cancer
cohort. The Illumina TruSeq Amplicon Cancer panel was used to screen a panel
of head and neck cancer cell lines for mutations in RAS-family genes. Cell
growth and radiation survival was assessed by clonogenic survival assay. Immu-
noblots were used to confırm target activation/knockdown in overexpression
and knockdown studies. A tumor control dose 50% (TCD50) assay was em-
ployed to investigate radiosensitization of a mutated-HRAS head and neck can-
cer cell line in a flank xenograft model in nude mice. Results: Activating muta-
tions in one of the three RAS genes are seen in 5-10% of head and neck cancer
patients.Mutations inHRAS represent over 50%of these. Screening our panel of
head and neck cancer cell lines identifıed a canonical activating mutation in
HRAS (i.e. G12V) in SCC22B. Consistent with known roles for activated
HRASG12V, SCC22B is relatively insensitive to both cetuximab and radiation.
Using both in vitro and in vivo studies, cetuximab exhibited no ability to radio-
sensitize SCC22B. Cetuximab treatment decreased AKT, but not ERK activa-
tion. Direct inhibition pathways downstream of HRAS by selumetinib (MEK/
ERK) or BEZ235 (PI3K/MTOR)decreased target protein activation and resulted
in signifıcant growth inhibition compared to control (p0.05). Treatment with
either selumetinib or BEZ235 radiosensitized HRASG12V expressing cells (SER
1.3-1.8) but had more modest effects on cells with wildtype HRAS. siRNA
knockdown of HRAS radiosensitized SCC22B, but not SCC1 or SCC6 cells rel-
ative to non-targeting control. Overexpression of HRASG12V conferred relative
radioresistance in wildtype cell lines. In vivo assessment of the radiosensitizing
effects of these compounds (TCD50) is pending. Conclusion: More than 5% of
head and neck cancers harbor activating mutations in one of the RAS family of
genes. These mutations lead to resistance to cetuximab, either as a single agent,
or as a radiosensitizer. Inhibition of downstream targets such as the MEK/ERK
and PI3K/MTOR pathways can radiosensitize tumors harboring activatingmu-
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tations in HRAS. Identifıcation of additional mutation/drug combinations that
result in radiosensitization may be valuable to advance the design of personal-
ized radiation therapy.
#5193 Hafnium oxide nanoparticles (NBTXR3), a novel radiation en-
hancer achieves marked antitumor effıcacy across fıve tumor types. Ping
Zhang, Sonia Vivet, Sébastien Paris, Agnès Pottier. Nanobiotix, Paris, France.
NBTXR3 are hafnium oxide nanoparticles (NPs) used for a single intratumor
administration as radioenhancer in combination with radiation therapy (RT) as
part of multi-modality of cancer treatment. The size, shape and surface of the
NPs have been designed to develop strong interactions with cancer cells - effec-
tive cell binding and uptake - and to persist within the tumor mass during the
whole RT treatment. The high electron density of the NPs is responsible for an
increased probability of interaction with incoming ionizing radiations (when
compared to tumor tissues with low electron density) and an increased energy
dose deposition within the cancer cells which results in an enhanced tumor
destruction when compared to RT alone. NBTXR3works similar to the physical
mode of action of RT, it does not rely on any biological system or target and
constantly amplifıes the radiation dose deposition (“on/off” activation).Herewe
present the transferability of the approach from one type of cancer to the other
evaluating (i) the feasibility of the intratumor injection (intratumor availability
ofNBTXR3nanoparticles byComputedTomography (CT) orCT) and (ii), the
antitumor effıcacy of NBTXR3 exposed to radiation. NBTXR3 NPs demon-
strated a good intratumor availability and persistence across all tested tumor
models (epithelial or mesenchymal origin), including human PDX tumor mod-
els. Notably, in PAC-120 tumor model the persistence of NBTXR3 NPs within
the tumor mass was observed for more than 50 days which is equivalent to the
entire duration of RT treatment. The antitumor effıcacy was systematically en-
hanced in terms of tumor growth delay for animals treated with NBTXR3 and
exposed to RT when compared to RT alone. NBTXR3 is currently in clinical
trials in seven cancer indications including: soft tissue sarcoma, head and neck
(H&N), liver, rectal and prostate. These preclinical studies support the rationale
for the development of NBTXR3 across all cancer indications where radiation
treatment is used.
NBTXR3 intratumor availability and antitumor effıcacy
Tumor model X-ray sources (antitumor effıcacy) CT or CT
Sarcoma HT1080 200kV,Ir192
LPS80T3(PDX) 200kV,Co60 x
A673 Co60
Prostate PC3 150kV x
DU145 200kV x
PAC120 (PDX) x
H&N CAL33 200kV x
FaDu 200kV x
Colorectal HCT116 Ir192 x
Lung NCI-H460-luc2 200kV x
#5194 Focal radiation enhances paclitaxel therapy in a mouse model of
triple negative breast cancer. Maryland Franklin, Thomas Dailey, Wilbur
Leopold.MI Bioresearch, Ann Arbor, MI.
Triple negative breast cancer (TNBC) accounts for 15-20% of all breast can-
cers in the US. In general, patients have poorer prognosis and therapeutic inter-
vention is more challenging due to insensitivity to hormonal and anti-HER2
therapies. Therapeutic options include chemotherapy and/or radiation (RT)
treatment. In this work we utilized HCC70, a human TNBC cell line, grown
subcutaneously in NSGmice.We investigated whether the combination of focal
RT and paclitaxel would improve anti-tumor activity over paclitaxel alone. RT
therapy has typically been delivered in lowdoses over long periods of time.More
recently higher fractions ofRT are being given in shorter time intervals.Utilizing
the Small Animal Radiation Research Platform (SARRP; Xstrahl, Suwanee, GA)
we compared a low dose (2.5Gy) fractionated regimen to a higher dose but less
frequent regimen (8Gy, QDx3) either as monotherapy or in combination with
paclitaxel (15mg/kg weekly). The total cumulative dose of radiation was 24-
25Gy in both radiation regimens. Paclitaxel alone produced moderate activ-
ity with a 10 day tumor growth delay and no tumor regressions. Treatment
with low dose RT resulted in tumor stasis for 68 days, but there were no
tumor regressions or tumor free survivors (TFS). Treatment with 8Gy, pro-
duced a 75% incidence of confırmed partial regressions (PR) and a 25%
incidence of complete regressions (CR) with no TFS. In this group we ob-
served slightly more body weight loss (BWL), more frequent clinical signs,
and more frequent need for food and water supplementation than with the
fractionated RT regimen. Mean BWL was 10% with a nadir around 8-10
days post fırst RT dose. BWL was recovered over the next 1-2 week period.
The combination of low dose focal RT with paclitaxel produced activity
similar to that with high dose radiation (50% PR, 40% CR, and 1 TFS).
Treatment with paclitaxel plus 8Gy RT was highly effıcacious, producing an
80% incidence of CRs, all of which remained tumor free at study day 108. The
remaining mouse experienced tumor stasis in excess of 63 days. Thus, a
higher dose of focal RT given in shorter intervals in combination with sys-
temic paclitaxel resulted in the most effıcacious therapeutic strategy but at
the cost of increased BWL and clinical signs.
#5195 Modulating the UPR using the impridone ONC201 to change the
impact of radiation onprostate cancer cells. FrancescaAmoroso,1 AdamPick-
ard,2 Alice McNaney,1 Rohinton Tarapore,3 Joshua E. Allen,3 Ian G. Mills1.
1Queen’s University of Belfast, Belfast, United Kingdom; 2University of Man-
chester, Manchester, United Kingdom; 3Research & Development, Oncoceutics
Inc., Philadelphia, PA.
Prostate cancer is the highest incidence non-cutaneous cancer in men, and
a signifıcant cause of cancer mortality. Localized disease is treated with sur-
gery or radiotherapy and whilst androgen deprivation therapy can extend
survival in the subset of cases that progress, metastatic disease is incurable.
We have found that oncogenic drivers of prostate cancer, as well as therapy,
lead to changes in the activation of prostate cancer cell stress signaling path-
ways and in particular the unfolded protein response (UPR). We have pre-
viously reported that the androgen receptor sustains the cytoprotective ac-
tivity of the IRE1-XBP1 arm of the UPR and represses the activation of the
PERK-ATF4 arm. We showed that treating prostate cancer cells with radia-
tion leads to the activation of all three arms of the UPR, culminating in
treatment resistance in surviving cells. In this study we assess whether the
activation of the UPR in response to radiation mirrors the immunogenic/
inflammatory response, which is known to occur in an initially acute apo-
ptotic phase before resolving to a chronic sustainable level. Further we have
evaluated the impact of combining radiation with ONC201, a novel anti-
cancer small molecule in clinical trials that is an activator of the UPR, on the
viability of prostate cancer. We fınd that ONC201 has a delayed cytotoxic
effect as a single agent, with the impact on viability occurring from 72 hours
onwards at low microMolar concentrations. However activation of multiple
arms of the UPR occurs earlier and is detectable at 24 hours for ATF4, ATF6
and IRE1-XBP1 at the protein/mRNA levels. This time difference creates a
window in which to introduce sequential administration of radiation to test
ONC201 as a primer for cytotoxic response radiation. We have undertaken
this work in a panel of cell-lines (PC3, DU145 and AR-expressing cell-lines)
in which we have also knocked down key regulators (PERK, IRE1, CHOP) of
separate arms of the UPR. This represents the fırst in vitro study to charac-
terise the impact of ONC201 on the radiation-responsiveness of prostate
cancer cells.
#5196 Recoupling nitric oxide synthetase to normalize tumor vasculature
and enhance tumor radiosensitivity and anti-tumor drug uptake. Christo-
pher S. Rabender, Sundaresan Gobalakrishnan, Li Wang, Jamal Zweit, Ross B.
Mikkelsen. Virginia Commonwealth Univ., Richmond, VA.
The aberrant nature of tumor vasculature results in uneven, heteroge-
neous blood flow and leaky, hemorrhagic blood vessels. Due to the unusual
nature of tumor vessels, areas of hypoxia develop that contribute to radiore-
sistance and ineffıciency of therapeutic drug delivery. Our current studies
examine the role of nitric oxide synthase (NOS) in tumor vasculature. NOS
has been demonstrated to be “uncoupled” in tumors and isolated tumor cells
due to reduced levels of tetrahydrobiopterin (BH4), a necessary cofactor,
resulting in superoxide and peroxynitrite formation in lieu of NO (Rabender
et al 2015 Molecular Cancer Research). NO signaling is critical for vascular
function and thus uncoupling of eNOS in tumor endothelial cells may partly
explain the poor vasculature found within solid tumors. Having previously
demonstrated that NOS can be “recoupled” and NO production restored
through treatment of tumor cells with Sepiapterin (SP), a BH4 precursor, we
examined whether SP could normalize tumor vasculature, promoting radi-
osensitivity and improving drug uptake. Multispectral optoacoustic tomog-
raphy analysis of both flank tumor xenografts and a spontaneous breast
tumor model (MMTV) demonstrate that SP given by oral gavage once a day
for 7 days signifıcantly enhances tumor BH4 levels and the percent of oxy-
hemoglobin in the tumor. Immunohistochemical analysis of tumors from
mice treated with SP showed a signifıcant reduction in CD31 staining and a
signifıcant increase in smooth muscle actin (SMA), both hallmarks of vascu-
lar normalization. A signifıcant decrease in pimonidazole staining and con-
comitant increase in Hoescht staining in MMTV mice treated with SP con-
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fırms the reduction in tumor hypoxia as well as increased tumor perfusion.
Increased tumor perfusion was also demonstrated through enhanced doxo-
rubicin uptake in tumors of mice treated with SP. Lastly, the enhanced tumor
oxygenation correlated with more than a 2-fold increase in radiation in-
duced cell killing measured by ex vivo clonogenic assay. These preliminary
data demonstrate the need for continued study of NOS uncoupling in solid
tumors, especially when we take into consideration that SP has been dem-
onstrated to be cytotoxic to both breast and colon tumors. On-going studies
are examining the consequences of enhanced drug uptake on both normal
and tumor tissue as well as the mechanism behind the vascular normaliza-
tion.
#5197 Targeting PARP-1 to deliver alpha-particles to cancer chromatin.
Laura Puentes,1 Kuiying Xu,1 Catherine Hou,1 Robert H. Mach,1 John M.
Maris,2 Daniel A. Pryma,1 Mehran Makvandi1. 1University of Pennsylvania,
Philadelphia, PA; 2Children’s Hospital of Philadelphia, Philadelphia, PA.
Introduction: Neuroblastoma (NB) is a radiosensitive pediatric cancer that
develops in the sympathetic nervous system and typically affects children under
the age of 10. High-riskNB is associated with a 40% 5-year survival rate. Nuclear
enzymepoly (ADP-ribose) polymerase 1 (PARP-1) is overexpressed in high-risk
NB, making it an attractive target for alpha-particle therapy. Alpha-particles
have a short path length and high linear energy transfer, causing dense ioniza-
tions across DNA, inducing double stranded breaks that result in cell death. The
purpose of this study was to explore a newly developed radiotherapeutic
([211At]MM4) that combines the targeting potential of a small molecule PARP
inhibitor (PARPi) with the cytotoxic effects of 211At in high-risk NB. Methods:
In vitro cytotoxicity was performed in a panel of high-risk NB cell lines to
evaluate the relative potency of [211At]MM4. Next, DNA damage was assessed
by measuring gH2AX foci formation at 1, 4, and 24 hrs after [211At]MM4 treat-
ment. In parallel, PARP-1 expression was measured in response to therapy and
cleaved PARP-1 was quantifıed to assess apoptosis. Cell cycle analysis was per-
formed after treatment to identify therapy related effects. The in-vivo biodistri-
bution of [211At]MM4 was performed alongside ex-vivo autoradiography. Tu-
mor cytology for PARP-1, gH2AX, and Ki-67 was performed in response to
therapy. Finally, in-vivo therapy experimentswere performed. Results: Cytotox-
icity data indicated a signifıcant reduction in cell viability following treatment
for all six NB cell lines, in-vitro co-incubation studies confırmed the specifıcity
of [211At]-MM4 to its drug target. Immunofluorescence analysis showed a dose-
dependent increase in both gH2AX and PARP-1 expression. The in-vivo biodis-
tribution of [211At]MM4 revealed rapid tumor targeting at 1 hr and clearance
from all tissues at 4 hrs. Ex-vivo autoradiography showed a tumor-muscle ratio
greater than 6. Tumor cytology revealedDNAdamagemeasured by gH2AX and
PARP-1 expression increased following treatment. Small colonies of proliferat-
ing tumor cells were detected after treatment using Ki-67 staining. In-vivo ther-
apy effıcacy studies revealed low fractionated doses were tolerable and resulted
in signifıcant delay in tumor regrowth. Conclusion: [211At]MM4 is a novel al-
pha-emitting radiotherapeutic that specifıcally targets nuclear PARP-1 overex-
pression in neuroblastoma and incites double-stranded breaks in cancer DNA.
The cytotoxic effects of [211At]MM4 have been experimentally validated both
in-vitro and in-vivo; the results of these experiments confırm the therapeutic
potential of [211At]MM4 as a viable treatment option for high-risk neuroblas-
toma.
#5198 Targeted alpha particle therapy for uveal melanoma. Narges K. Ta-
freshi,1NellaC.Delva,1 Christopher J. Tichacek,1Michael L.Doligalski,1DarpanN.
Pandya,2 Nikunj B. Bhatt,2 HyunJoo Kil,3 Mikalai M. Budzevich,1 Epifanio Ruiz,1
Thaddeus J.Wadas,2Mark L.McLaughlin,3 David L.Morse1. 1H.LeeMoffıtt Cancer
Center & Research Institute, Tampa, FL; 2Wake Forest University Health Sciences,
Winston-Salem, NC; 3West Virginia University, Morgantown,WV.
New effective therapies are greatly needed for uveal melanoma, the most com-
mon ocularmalignancy, which has a very poor prognosis with amedian survival of
less than one year when metastatic disease develops. The melanocortin 1 receptor
(MC1R) is expressed in 94% of uveal melanomas but is not expressed in normal
tissues of concern for toxicity. Previously, we developed an MC1R specifıc ligand
(MC1RL) with high affınity and selectivity for MC1R. We used the MC1RL as a
targeting scaffold fordevelopmentof a radiopharmaceutical byconjugationof 225Ac
chelate to form 225Ac -MC1RL-DOTA. 225Ac is a therapeutic alpha-emitting radio-
nuclide. 225Ac -MC1RL-DOTAwas synthesized with high radiochemical yield and
purity (95and99%respectively)withanexcellent invitro stability, i.e. 90%after
10 days in human serum at 37ºC. AnMTT cytotoxicity study demonstratedMC1R
specifıc antiproliferative effect in cutaneous, ocular anduvealmelanomacell lines.A
maximum tolerated dose (MTD) studywas completed, where a range of 0-148 kBq
(0-4 Ci) of 225Ac -MC1RL-DOTA was administered to groups of BALB/c mice.
The radiopharmaceutical was well tolerated at even the highest doses and animals
did not reach any clinical endpoints, such as weight loss, loss of kidney function or
abnormal pathology. Biodistribution studies on MC1R expressing tumor bearing
mice revealed tumor selectivity and a combination of renal and hepatic clearance
with minimal retention in other normal tissues. A blood PK study in rats showed
rapid clearance of the agent from the blood in60min. To determine radiodosim-
etry, gamma spectra were acquired for tumors, blood and other tissues and organs
over a 21-day timeperiod and activity curves generated for each tissue for 225Ac and
other gamma-emitting daughter products in the decay chain. An exponential line-
fıtting of these curves allowed the estimation of clearance kinetics, tissue biological
half-life and total absorbed dose (Gy) for each tissue. Doses were highest in MC1R
positive tumors and clearance organs (liver, kidney and spleen) and low in all other
tissues. In vivo effıcacy studies were performed in human A375/MC1R cutaneous
andMEL20 uveal melanoma tumors in SCIDmice, or syngeneic mouse B16mela-
noma tumors in C57BL/6mice (n10/group) injected with either 225Ac -MC1RL-
DOTA, 225Ac-scrambled-MC1RL-DOTA, La-MC1RL-DOTA (non-radioactive
control agent) or saline. In every case a tumor growth delay was observed in treated
mice relative to controls, and a percentage of mice bearing the human tumors had
complete remission. In conclusion, we evaluated the in vitro and in vivo properties
of 225Ac-MC1RL-DOTA in this study. This agent demonstrated a signifıcant
MC1R-specifıc in vivo therapeutic effıcacy in a mouse model of uveal melanoma
with low systemic toxicity.
#5199 Preclinical activity of the FGFR2-targeted thorium-227 conjugate
in preclinical models of colorectal, gastric and triple-negative breast cancer.
Urs B. Hagemann,1 Anette Sommer,2 Alexander Kristian,1 Ellen Wang,1 Ås-
mund Larsen,1 Uta Wirnitzer,3 Heidrun Ellinger-Ziegelbauer,3 Steffen Sand-
mann,3 Thorsten Poethko,3 Jenny Karlsson,1 Roger M. Bjerke,1 Lars Linden,3
Bertolt Kreft,2 Hanno Wild,3 Alan S. Cuthbertson1. 1Bayer AS, Oslo, Norway;
2Bayer AG, Berlin, Germany; 3Bayer AG, Wuppertal, Germany.
FGFR2 is a transmembrane tyrosine kinase receptor, consisting of three
extracellular N-terminal immunoglobulin-like domains which are involved
in ligand-binding as well as in receptor dimerization. Ligand-independent
activation of FGFR2 signaling either via genomic amplifıcation, gene fusion
events, mRNA overexpression, or mutations has been observed e.g. in gastric
cancer, colorectal cancer (CRC), and triple-negative breast cancer (TNBC).
As such, FGFR2 has been described to be involved in cancer progression,
promotion of oncogenesis, neoangiogenesis, as well as resistance to targeted
therapies. Overexpression of FGFR2 and relatively low levels of cell surface
expression of FGFR2 in normal human tissues renders FGFR2 an attractive
candidate to explore targeted alpha therapy (TAT). We describe the gener-
ation of a high energy, alpha-particle emitting FGFR2 targeted thorium-227
conjugate (FGFR2-TTC). The FGFR2-TTC consists of a fully human FGFR2
binding IgG1 antibody (BAY 1179470) cross-reactive with mouse FGFR2, cova-
lently linked via an amide bond to a chelatormoiety (3,2HOPO), enabling radiola-
beling with the alpha particle emitting thorium-227 (227Th). In vitro cytotoxicity
experiments with FGFR2-TTC demonstrated potency in the sub-picomolar range
compared toanon-targetingcontrol-TTCandacorrelationbetweendecrease incell
viability and increasing number of anti-FGFR2 antibodies bound per cell (ABC
counts) in a panel of FGFR2-positive cancer cell lines. Upon treatment of cells with
FGFR2-TTC, theDNAdamage responsemarker proteinH2AXwas up-regulated
indicating that the mode-of-action involves induction of DNA double strand
breaks. Furthermore, induction of the immunogenic cell death marker calreticulin
was observed Biodistribution studies of the FGFR2-TTC in mouse models, evalu-
ated by whole body autoradiography and acquisition of gamma-spectra specifıc for
thorium-227, demonstrated specifıc accumulation of thorium-227 in FGFR2-posi-
tive tumors and very limited signal in murine organs and tissues. FGFR2-TTC ex-
hibited in vivo tumor growth inhibition after a single dose inmouse xenograftmod-
els of CRC (NCI-H716) and gastric cancer (SNU-16). In addition, FGFR2-TTC
showed anti-tumor activity in the aggressive murine syngeneic orthotopic 4T1
TNBC model. In summary, FGFR2-TTC has been established as a promising tar-
geted alpha therapy (TAT) for effıcacious and selective delivery of alpha emitter-
based radiotherapy in several FGFR2-positive cancer indications. Further explora-
tion for cancer therapymay thus be of interest.
#5200 Preclinical pharmacology of the PSMA-targeted thorium-227 con-
jugate PSMA-TTC: a novel targeted alpha therapeutic for the treatment of
prostate cancer. Stefanie Hammer,1 Aasmund Larssen,2 Christine Ellingsen,2
Solene Geraudie,2 Derek Grant,2 Baard Indrevoll,2 Oliver von Ahsen,1 Alexan-
der Kristian,2 Urs B Hagemann,2 Jenny Karlsson,2 Roger M. Bjerke,2 Olav B.
Ryan,2 DominikMumberg,1 Bertolt Kreft,1 Alan Cuthbertson2. 1Bayer AG, Ber-
lin, Germany; 2Bayer AS, Oslo, Norway.
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Prostate-specifıc membrane antigen (PSMA, FOLH1) is a type II transmem-
brane glycoprotein of theM28 peptidase family that acts as a glutamate carboxy-
peptidase on various substrates. PSMA is well established as a target antigen in
prostate cancer due to its high and specifıc overexpression on the surface of
prostate cancer cells at all tumor stages, including metastatic and hormone-
refractory disease. Several PSMA targeting antibodies and ligands are currently
in clinical development or compassionate use therapeutically or as imaging
agents. Targeted alpha therapy (TAT) has an established clinical profıle with the
successful transition of Ra223, an alpha-particle emitter, from bench to bedside
in prostate cancer. Thorium-227 is the immediate precursor forRa223 via alpha-
particle emission. We herein describe the generation of a novel TAT, a high
energy, alpha-particle emitting PSMA-targeted thorium-227 conjugate (PSMA-
TTC). PSMA-TTC consists of a fully human PSMA targeting IgG1 antibody
covalently linked via an amide bond to a chelator moiety (3,2 HOPO), enabling
radiolabeling with thorium-227 (227Th). PSMA-TTC was prepared in high ra-
diochemical yield and purity and tested for binding affınity to PSMA target
(ELISA) as well as PSMA expressing cell lines (FACS). In vitro cytotoxicity
experiments were carried out on prostate CA cell lines with different PSMA
levels (from 3.000 to 150.000 mAbs bound/ cell). In vivo biodistribution and
anti-tumor effıcacy were analyzed after i.v. injection of 100-500 kBq/kg at pro-
tein doses of 0.14 mg/kg to mice bearing s.c. prostate cancer xenograft models.
Additionally, anti-tumor effıcacy was evaluated in a PSMA expressing ortho-
topic bone xenograft model (LNCaP-Luc) monitored by bioluminescence im-
aging,microCTand x-ray. PSMA-TTC retains binding affınities to PSMA target
and PSMA positive cancer cells similar to the PSMA antibody. Strong in vitro
potency and selectivity of PSMA-TTC was shown on different PSMA positive
cells. Biodistribution studies in C4-2 xenografts demonstrated specifıc tumor
uptake of PSMA-TTC with a maximum of 50 % of ID/g at t  72h post dose
administration. Selective signifıcant antitumor effıcacy was shown for PSMA-
TTC in s.c. prostate CA xenograft models with high (C4-2) and medium/low
(22Rv1) PSMA protein levels at doses of 250 and 500 kBq/kg. Furthermore,
statistically signifıcant prevention of tumor growthwas observed after treatment
with PSMA-TTC at a dose of 100 kBq/kg in an orthotopic bone xenograft model
(LNCaP-Luc). The promising preclinical antitumor activity of PSMA-TTC sup-
ports its development for the treatment of patients with metastatic prostate
cancer.
#5201 PSMA-targeted alpha radioimmunotherapy for prostate cancer
with 225Ac-J591. Jaspreet S. Batra, He Liu, Sae Kim, Vicente N. Navarro, Shan-
kar Vallabhajosula, Scott T. Tagawa, Neil H. Bander.Weill Cornell Medical Col-
lege, New York, NY.
Background: Prostate cancer (PC) is a radiosensitive disease. In addition to
external beam and brachytherapy, systemic bone-seeking radioisotopes have
been utilized clinically for many years, with radium-223 leading to overall sur-
vival benefıts. However, the available beta and alpha emitting particles in the
clinic target tumors / stroma in bone only. Biologically targeted radiopharma-
ceutical treatment has shown promising results in our earlier multiple clinical
trials using beta-emitting anti-PSMA therapy with Leutetium-177 radiolabeled
anti-PSMA monoclonal antibody (mAb) J591, with accurate targeting and tu-
mor response, but treatment is limited by myelosuppression. Both beta and
alpha-small molecule PSMA ligand directed therapy has been utilized anecdot-
ally outside of the US, but has not been systemically studied. Based upon their
biodistribution, targeting of salivary glands and potentially proximal renal tu-
bules may pose longer term toxicity issues. mAb-based targeted alpha-particle
delivery may be advantageous with less expected myelosuppression than seen
with -emitters. Experimental procedures: To optimize labeling of humanized
DOTA-J591 mAb, actinium-225 (225Ac) nitrate was obtained from Oak Ridge
National Laboratories and was dissolved in HCl solution and then mixed with
trimethyl ammonium acetate and L-ascorbic acid. This preparation was incu-
bated with DOTA-J591. The labeling effıciency (LE) was determined by ITLC-
SG. If the LE is60%, 225Ac-DOTA-J591mAbwas purifıed by gel fıltration and
sterilized by membrane fıltration. In a pilot pre-clinical study, we studied the
toxicity in non-tumor bearing BALB/c mice. Results: The radiochemical purity
is 95% and the immunoreactivity was 80%. Twenty-fıve BALB/c mice re-
ceived from 2.1 to 6.3 KBq of 225Ac-J591. Treatment was well tolerated, with all
mice alive and healthy at Day 26. Conclusions: A stable alpha emitting-antibody
complex has been produced with 225Ac-J591. Initial mouse safety experiments
have been successful. A RIT dose escalation study of PSMA-targeted alpha emit-
ter in a LNCaP xenograft model is underway.
#5202 Additive benefıts of radium-223 dichloride and bortezomib com-
bination in a syngeneic 5TGM1 multiple myeloma mouse model. Mari I.
Suominen,1 Jukka P. Rissanen,1 Anniina Luostarinen,1 Katja M. Fagerlund,1
Birgitta Sjöholm,2 Esa Alhoniemi,3 Sanna-Maria Käkönen,4 Dominik Mum-
berg,5 Jussi M. Halleen,1 Karl Ziegelbauer,5 Arne Scholz5. 1Pharmatest Services
Ltd, Turku, Finland; 2Aurexel Life Sciences Ltd, Askainen, Finland; 3Avoltus Oy,
Turku, Finland; 4University of Turku/Aurexel Life Sciences Ltd, Turku, Finland;
5Bayer, Berlin, Germany.
Radium-223 dichloride (radium-223, Xofıgo®), a targeted alpha-therapy, im-
proves overall survival in prostate cancer patients with bone metastases. It in-
hibits disease progression by reducing tumor growth and tumor-induced path-
ological bone reaction in breast and prostate cancermousemodels. Radium-223
is actively incorporated into the bone matrix by osteoblasts. Multiple myeloma
(MM) is characterized by increased osteoclast and reduced or no osteoblast
activity. Bortezomib (Velcade®), a treatment for MM, restores the impaired os-
teoblast activity in MM. Here, we report the effects of radium-223, bortezomib
and their combination on myeloma cell proliferation in vitro and on myeloma
bone disease model in mice. Proliferation assays were performed with human
plasma cell leukemia (JJN-3, L-363), human MM (LP-1, MOLP-8, RPMI-8226
and OPM-2), and mouse MM (5TGM1) cells. Corresponding in vivo effects
were studied in a syngeneic 5TGM1mouseMMmodel. Female C57BL/KaLwRij
mice (7 weeks old, n15/group) were inoculated with 5TGM1 cells via tail vein
and 26 days later, radium-223 (300 kBq/kg, single iv injection) and/or bort-
ezomib (1 mg/kg ip, twice a week; total of 3 doses) or vehicle control were
administered. The development of osteolytic lesions was detected by radiogra-
phy. Hind limbs were used for histological analyses and total activity measure-
ment was performed by a gamma-counter. TRAP-stained osteoclasts were
counted at tumor-bone interface. Bortezomib inhibited proliferation of all can-
cer cell lines tested at 25 nM (JJN3 andOPM-2 at 2.5 nM) and radium-223 at 0.8
kBq/ml (L-363 and MOLP-8 at 0.2 kBq/ml) concentrations. Additive effects
were observed with combination treatment in vitro. The 5TGM1 in vivo model
demonstrated that both bortezomib and radium-223 decreased osteolytic lesion
area as monotherapy (p0.05 and p0.01, respectively), with the combination
being more effective than either monotherapy alone (p0.001). Bortezomib
decreased the number of osteoclasts at tumor-bone interface (p0.05) and an
additive decrease was observed with combination therapy (p0.01) resulting in
almost complete eradication of osteoclasts. Incorporation of radium-223 to
bone was higher with combination therapy based on total activity measure-
ments. All treatments were well tolerated. In conclusion, radium-223 dichloride
(Xofıgo®) therapy in combination with bortezomib decreased osteolytic lesion
area and almost completely eradicated tumor-associated osteoclasts in a mouse
model of myeloma bone disease. Incorporation of radium-223 to bone matrix
was improved, possibly via induction of osteoblast activity by bortezomib. These
data suggest that combination of radium-223 and bortezomib could be a new
effective therapy in MM, which is currently being investigated in a Phase Ib/II
trial in patients with early relapsed MM (NCT02928029).
#5203 Tissue factor targeted radionuclide therapy with 177Lu-FVIIai in-
hibits tumor growth of human pancreatic cancer xenografts. Mette Munk
Jensen,1 Jesper Fonslet,2 Camilla S. Knudsen,1 Troels E. Jeppesen,3 Andreas I.
Jensen,2 Gregory W. Severin,2 Carsten H. Nielsen,1 Andreas Kjær3. 1Minerva
Imaging, Denmark; 2Hevesy Laboratory, DTU Nutech, Technical University of
Denmark, Denmark; 3Department of Clinical Physiology, Nuclear Medicine &
PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copen-
hagen, Denmark.
Introduction: Tissue factor (TF) is involved in cancer processes responsible
for aggressiveness and invasiveness and there is a correlation between tumor TF
expression, metastatic potential, and patient outcome. The aim of the study was
to develop a novel compound for localized TF targeted radionuclide therapy
based on Factor VII (FVII), the natural ligand to TF. In the current study, we
investigated the biodistribution and therapeutic potential of 177Lu labeled active
site inhibited FVIIa (177Lu-FVIIai) for radionuclide therapy targeting TF in an
experimental mouse model of pancreatic cancer. Methods: p-SCN-Bn-CHX-
A’’-DTPAwas conjugated to FVIIai followed by radiolabelingwith 177Lu (177Lu-
CHX-A’’-DTPA-FVIIai). A pancreas xenograftmousemodel (BxPC3) was used
to assess the therapeutic potential of 177Lu-FVIIai. NMRI nude mice were in-
jected subcutaneously with BxPC3 cells. When tumors reached 50 mm3, the
mice were randomized into groups receiving 177Lu-FVIIai, FVIIai, or vehicle.
177Lu-FVIIai was administered in doses of 15 MBq, 7.5 MBq or 2 x 7.5 MBq
(n8 mice/group). Tumor growth was monitored by 3 weekly measurements.
Ex vivo biodistribution of 177Lu-FVIIai was studied in several organs at 1, 4, 24,
72 and 168 hours after injection. The in vivo biodistribution was evaluated by
SPECT/CT imaging. Furthermore, competition and dose escalation experi-
EXPERIMENTAL ANDMOLECULAR THERAPEUTICS: Preclinical Radiotherapeutics
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171332
ments (1-30MBq) were performed. Toxicity effects of the treatment with 177Lu-
FVIIai were evaluated by hematology. Results: FVIIai was successfully radiola-
beled with 177Lu with a high specifıc activity of 10-25 GBq/mol after EDTA
scavenging and PD-10 purifıcation. No difference in tumor growth was ob-
served between the FVIIai and vehicle groups. Mice receiving 15 MBq 177Lu-
FVIIai had a signifıcantly reduced tumor growth from day 0 to day 19 compared
with mice from the control groups (425.544.8% versus 614.249.1%;
p0.02). No signifıcant difference in tumor growth was observed in the groups
receiving 7.5 MBq or 2 x 7.5 MBq compared with controls on day 19. There was
a signifıcant increase in the survival of mice treated with 7.5 MBq 177Lu-FVIIai
compared with the controls (p0.007). Treatment with 15 and 2 x 7.5 MBq
177Lu-FVIIai did not influence survival. Ex vivo tumor uptake of 177Lu-FVIIai
was 1.160.04, 1.970.18, 1.950.07, 1.010.06, 0.310.02 percent injected
dose per gram (%ID/g) at 1, 4, 24, 72 and 168 hours post-injection, respectively.
Competition with unlabeled FVIIai 10 minutes before 177Lu-FVIIai injection
signifıcantly reduced tumor uptake of 177Lu-FVIIai (from 2.50.16 %ID/g to
1.70.05 %ID/g; p0.05). Tumor uptake (%ID/g) of 177Lu-FVIIai was un-
changed when varying the dose from 1-30 MBq. A transient decrease in leuco-
cyte counts was observed for the mice receiving 15 and 7.5 MBq 177Lu-FVIIai.
Conclusion: FVIIai was successfully radiolabeled with 177Lu. 177Lu-FVIIai
showed therapeutic potential in a mouse model of human pancreatic cancer.
#5204 Preclinical development ofMVT-1075 as radioimmunotherapy for
pancreatic cancer and other CA19-9 positive malignancies. Jacob L.
Houghton,1 Ryan Lanning,2 Dayla Abdel-atti,3 Toni Jun,4 ChristineM. Kearns,5
Michael Schlosser,6Wolfgang Scholz,4 Jason S. Lewis,3 PaulW.Maffuid4. 1Van-
derbuilt UniversityMedical Center, Nashville, TN; 2University of Colorado School
of Medicine, Denver, CO; 3Memorial Sloan-Kettering Cancer Center, New York,
NY; 4MabVax Therapeutics Holdings, Inc., San Diego, CA; 5SciQuus Oncology,
La Jolla, CA; 6MSR Pharma Services, Chicago, IL.
Rationale: The CA19-9 antigen is frequently overexpressed in pancreatic and
other GI tumors. MVT-5873 (HuMab-5B1), a fully human monoclonal anti-
body currently in phase I study, targets the sialyl Lewis A (sLea) epitope on
CA19-9, and is a promising platform for development of a targeted radioimmu-
notherapy (RIT). MVT-5873 was conjugated with the chelator CHX-A
-DTPA
and radiolabeled with the beta-emitting isotopes Lutetium -177 (177Lu) or Yt-
trium-90 (90Y) to form the RIT agents MVT-1075 (177Lu- CHX-A
-DTPA-
HuMAb-5B1) and MVT-1916 (90Y- CHX-A
-DTPA-HuMAb-5B1), respec-
tively. The antitumor effıcacy of each of the constructs was studied in nudemice
bearing BxPC3 human pancreatic tumor xenografts, known to express CA19-9.
Methods: The initial dose-fınding studies utilized doses ofMVT-1075 of 75-450
Ci and MVT-1916 of 25-250 Ci, administered to groups of mice (n  8)
bearing subcutaneous (subQ) BxPC3 tumors ( 150 mm3). Further studies
focused onMVT-1075 and assessed antitumor effect in an orthotopic xenograft
model, the effect of dose fractionation, and biodistribution in nontumor bearing
(normal) and BxPC3 tumor-bearing mice. Results: A single dose of MVT-1075
at 75, 150, 300, or 450 Ci signifıcantly inhibited subQ BxPC3 tumor growth at
all dose levels, with sustained suppression with higher doses. MVT-1916 pro-
duced similar results. MVT-1075 was selected based on the favorable half-life of
177Lu (6.7 d) and its utility for clinical biodistribution assessments. In an ortho-
topic BxPC3 tumormodel, treatmentwith a single dose ofMVT-1075 at 300Ci
signifıcantly inhibited tumor growth, with Day 20 tumor volume approximately
50% that of the initial starting volume. A third BxPC3 xenograft study evaluated
fractionated dosing schedules, (150 Ci x 1, 75 Ci x 2, 50 Ci x3), with both
single-dose and fractionated schedules effectively inhibiting subQBxPC3 tumor
growth. Biodistribution studies in normal mice showed an expected gradually
decreasing activity in blood, heart, and lungs, with low uptake in normal pan-
creas. In subQ BxPC3 tumor-bearing mice, tumor uptake was rapid, reaching
69% ID/g by 24 h and 86% ID/g by 120 h. Otherwise, the biodistribution pattern
paralleled that of normalmice, with relative%ID/g valueswithin about 25%of
normal mice across all time points comparing blood, heart, lungs, kidneys, and
pancreas, with slightly higher uptake in liver and slightly lower uptake in spleen.
Conclusions: MVT-1075 demonstrates promising antitumor activity in a hu-
man pancreatic cancer xenograft model, with effıcacy shown in both single dose
and fractionated schedules. Biodistribution shows rapid and substantial tumor
uptake, with much lower uptake in normal organs. These fındings support the
phase I clinical trial of MVT-1075 in patients with CA19-9 positive pancreatic
cancers planned to begin in early 2017.
#5205 Poly(ADP-ribose) polymerase inhibitors induce -radiosensitiza-
tion through an altered selection of DNA double-strand break repair path-
ways. Yuji Seo, Keita Yoshizaki, Keisuke Tamari, Yutaka Takahashi, Keisuke
Otani, Masahiko Koizumi, Kazuhiko Ogawa.Osaka University Graduate School
of Medicine, Suita, Japan.
Background: Systematically reviewing published studies on a broad range of
potential radiosensitizers, we previously reported that poly(ADP-ribose) poly-
merase inhibitors (PARPi)may have a unique radiosensitizing effect to enhance
-components of the linear-quadratic model. In contrast, many other radiosen-
sitizing agents predominantly modifıed 	-components. The aim of this study is
to elucidate underlying mechanisms of “-radiosensitization”. Methods and
Results: We fırst confırmed that treatments with PARPi PJ34, olaparib, or veli-
parib two hours prior to and 48 hours after 10 Gy of ionizing radiation (IR)
potentiated radiation-induced cell death in human cancer cells HCT116, HT29,
H460 and A549 using the colony-forming assay. Tumor regrowth assay with
3-dimensional multicellular spheroids of HCT116 and H460 cells showed that
PJ34 signifıcantly delayed tumor regrowth when combined with single dose of
10 Gy but not in tumors treated with 10 Gy in 5 fractions. Similar results were
found using HCT116 tumor xenograft model in mice. We next examined what
cellular eventsmayunderlie the radiosensitizationusingPARPi PJ34 inHCT116
cells. Kinetics of DNA damage responses were fırst measured by phosphoryla-
tion of histone H2AX (H2AX). PJ34 did not change an initial increase of
H2AX following 10 Gy IR, but H2AX levels decreased faster in PJ34-treated
cells than control cells. Immunocytochemical analysis of Rad51 showed that
PJ34 reduced Rad51 foci formations up to 6 hours following 10 Gy IR. IR-
induced chromosomal aberrations were quantitated by the C-banding of meta-
phase spreads. More dicentric chromosomes were found in PJ34-treated cells
than the control. These data suggested that PARPi did not inhibit total DNA
double-strand break (dsb) repair but altered the selection in DNA dsb repair
pathways with increased end-joining type(s) of (mis)repair compensating for
reduced homologous recombination repair. Cell cycle profıles showed sustained
4C DNA cell peaks in cells treated with PJ34 up to 72 hours following 10 Gy IR.
Cell cyclemarkers (cyclin B1 and phosphorylated histoneH3) indicated that the
4C DNA peaks of the PJ34- treated cells included substantial amount of G1
tetraploid cells in addition to G2- or M-phase diploid cells. Additionally, senes-
cence-associated -galactosidase staining showed that PJ34 promoted radia-
tion-induced premature senescence, while smaller IR-induced sub-G1 popula-
tions were found in PJ34-treated cells than the control. Conclusion: PARPi
increased IR-induced chromosomal aberrations through the altered selection in
DNAdsb repair pathways. The increased quadraticmisrepair enhanced-com-
ponents of IR-induced cell death mediated by the increased formation of G1
tetraploid cells and premature senescence. DNA dsb repair pathway selection
may be a novel and effective target to elicit -radiosensitization.
#5206 IND enabling investigations of MVT-1075, a CA19-9 targeting ra-
dioimmunotherapy. Dennis Gately,1 Marvin Peterson,1 Sara Dao,1 Scott
Rudge,2 George St. George,3 Shannon Phillips,3 Paul Maffuid1. 1MabVax Ther-
apeutics Holdings, Inc., San Diego, CA; 2RMC Pharmaceutical Solutions, Long-
mont, CO; 3IsoTherapeutics Group, LLC, Angleton, TX.
Rationale: The CA19-9 antigen is overexpressed in pancreatic and other GI
tumors. MVT-5873 (HuMab-5B1), a fully human monoclonal antibody cur-
rently in phase I study, targets the sialyl Lewis A (sLea) epitope on CA19-9, and
is a promising platform for development of a targeted radioimmunotherapy
(RIT). MVT-5873 was conjugated with the chelator CHX-A
-DTPA and radio-
labeled with Lutetium-177 (177Lu) to formMVT-1075 (177Lu- CHX-A
-DTPA-
HuMAb-5B1). We have completed IND enabling process development, stabil-
ity, and characterization investigations and plan to initiate a phase I trial in
patients with pancreatic cancer and other CA19-9 positivemalignancies early in
2017. Methods: Reproducible conditions to conjugate the chelator (p-SCN-Bn-
CHX-A’’-DTPA) to MVT-5873 were developed by evaluating chelator to anti-
body ratios and incubation times. The stability of MVT-1075 was assessed in
formulation buffer at shipping/handling conditions, and in human serum via
thin layer chromatography (iTLC), size exclusion chromatography (SEC) and
ion-exchange chromatography (CEX). The immunoreactive fraction was deter-
mined at each time point using a microsphere based LINDMO method devel-
oped for this program. Results: MVT-5873 was buffer exchanged into 100mM
sodium bicarbonate buffer at pH9 and combined with p-SCN-Bn-CHX-A’’-
DTPA at 32.5°C for 90 min. Unincorporated chelator was removed by buffer
exchange into 1M ammonium acetate buffer at pH7. The resulting conjugate,
MVT-7814 (CHX-A’’-DTPA-HuMab-5B1), was characterized for degree and
location of conjugation byMS, aggregates, ELISA binding, purity by CEX and pI
determination. These analyses indicated a single CHX-A’’-DTPA on the heavy
chain as the primary conjugate. In vitro binding by ELISA was comparable to
MVT-5873. Purity by SECwas 99% showingminimal aggregation.MVT-7814 is
stored frozen at-60°C and stable to 5 freeze-thaw cycles. To qualifyMVT-1075
for clinical use, MVT-7814 was radiolabeled with 177Lu. Purity data indicate a
high degree (98%) of 177Lu incorporation by iTLC and stability in formulation
buffer up to 120 hours ( -15oC) and 24 hours ambient by immunoreactivity as
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assessed by a LINDMOmethod ( 90%) at both conditions. Serum stability at
37oC showed radiochemical purity82%by iTLC and immunoreactivity62%
after 5 days, further supporting the use of this product in clinical trials. Conclu-
sions: The conjugation of MVT-5873 with p-SCN-Bn-CHX-A’’-DTPA repro-
ducibly yields a well characterized bulk intermediate (MVT-7814) modifıed on
the heavy chain. Radiolabeling with 177Lu and stability studies in formulation
buffer and human serum indicate that MVT-1075 maintains radiochemical pu-
rity and target immunoreactivity to support clinical use. The results of these
studies were consistent with specifıcations and support the clinical utility and
submission of the MVT-1075 IND application with an expected FIH date early
in 2017.
#5207 Breast cancer-specifıc amplitude modulated radiofrequency elec-
tromagnetic fıelds (AM RF EMF) inhibits brain metastasis of breast cancer.
Sambad Sharma, Hugo Jimenez, Fei Xing, Carl Blackman, Boris Pasche, Kou-
nosuke Watabe.Wake Forest Univ. School of Medicine, Winston-Salem, NC.
Brain metastasis is evident in approximately 30% of patients with breast can-
cer and one-year survival of these patients remains less than 20%. The treatment
of brain metastasis mainly involves surgical resection in combination with
whole brain radiation therapy (WRBT), or stereotactic radiosurgery (SRS).
However, patients often suffer from the treatment’s adverse effects and experi-
ence recurrent disease. Therefore, there is an urgent need for a less invasive
therapy with minimal side effects, and improved therapeutic effıcacy. Our cur-
rent work has established a novel treatment approach for breast cancer brain
metastasis at a preclinical level by using amplitude modulated radiofrequency
electromagnetic fıelds (AM RF EMF). We have previously demonstrated that
AMRF EMF can be safely administered to patients for prolonged period of time
with virtually no toxicity and side effects. The treatment of metastatic breast
cancer patients with AM RF EMF signifıcantly impaired the growth of both
metastatic and primary tumor (1). In this study, we specifıcally observed the
effect ofAMRFEMF in brainmetastatic variants of breast cancer cells (231-BrM
and SKBr-BrM).We found that AMRF EMF signifıcantly inhibited the growth,
stemness and colony forming ability of brainmetastatic variants of breast cancer
cells. In addition, AM RF EMF inhibited the stemness of radiation resistant
variants derived from 231-BrM and SKBr-BrM cells, which indicate the poten-
tial of AM RF EMF in treatment of treatment-refractory recurrent disease. Fur-
thermore, AM RF EMF also signifıcantly suppressed the growth of orthopically
and systemically implanted 231-BrM and SKBr-BrM cells in our NOD/SCID
animal model. We then performed RNAseq expression profıle analysis and
found that expression of stemness-associated gene, HMGA2, was signifıcantly
decreased in 231-BrM and SKBr-BrM cells that were treated with AM EMF RF.
Interestingly, brain metastatic variants and radiation resistant lines of 231-BrM
and SKBr-BrM showed elevated expression of HMGA2when compared to their
parental cells. Importantly, the treatment of brain metastatic cells with AM RF
EMF also sensitized the cells to radiation in a HMGA2 dependent manner.
Furthermore, to isolate the AM RF EMF responsive biomarker, we isolated
exosomes from the SKBr-BrM cells that were treated with AM RF EMF, and
performed microRNA array. Differentially expressed miRNAs in SKBr-BrM
and 231-BrM cells derived exosomes were identifıed and verifıed by Taqman
PCR. These exosomal microRNAs can serve as excellent biomarkers for exam-
ining the effect of AM RF EMF in brain tumors. Therefore, our study has dem-
onstrated that this new approach of treating brain metastasis has a high transla-
tional potential considering signifıcant effıcacy andminimal side effect shown in
pre-clinical and clinical setting.
#5208 The role of platelet-type arachidonate 12-lipoxyganse in murine
lungs exposed to a fıbrogenic dose of irradiation. Eun Joo Chung, AylaWhite,
Deborah Citrin. NIH, Bethesda, MD.
Introduction: Ionizing radiation (RT) is employed in the treatment of approx-
imately half of patients with cancer, including those with thoracic malignancies.
Exposure of tumor adjacent normal lung may result in injury and fıbrosis. Ara-
chidonate lipoxygenase oxidizes arachidonic acid, yielding hydroperoxyl deriv-
atives including hydroperoxyeicosatetraenoic acids (HPETEs) and the reduced
form, hydroxyeicosatetraeonic acids (HETEs). Arachidonate lipoxygenases are
classifıed as 5-, 8-, 12-, or 15-LOX, according to the site of oxygen insertion
within arachidonic acid. There are two isoforms of arachidonate 12-lipoxyg-
nases in mammals, the platelet-type (12S-LOX; gene ALOX12), and the epider-
mal-type (12R-LOX; gene ALOX12B). Recently, we found an increased expres-
sion 12S-LOX in murine lungs exposed to a fıbrogenic dose of irradiation. We
hypothesized that 12S-LOX would be required for radiation-induced pulmo-
nary fıbrosis (RIPF). Methods: C57/BL6 mice (n3 per group) were exposed to
thoracic RT (0 Gy, 5 Gy, 17.5 Gy, or 6x5 Gy). Levels of 12S-LOX mRNA and
protein were assessed in isolated various cell types from lungs (In Vitro) and in
lung tissues (In Vivo) after RT with an immunohistochemical assay and quan-
titative PCR. Levels of chemokine ligands mRNA were assessed in isolated pri-
mary pneumocytes exposed to 17.5 Gy or 12S-HETE. Differential polarization
of bone marrow-derived macrophage cultures with/without 12S-HETE was ex-
amined by quantitative PCR of polarization markers. Activity of arginase-1 was
measured in lung tissue lysates at 16 weeks after RT. Results: An increase of
12S-LOX protein was observed in type2 pneumocytes at 8 weeks after exposure
with fıbrogenic doses of RT (17.5 Gy and 5x6 Gy) compared to low dose RT (5
Gy) or controls (0 Gy). 12S-LOX mRNA was signifıcantly induced in type2
pneumocytes at 3 days after receiving fıbrogenic doses compared to other cell
types in murine lung. Chemokine ligands including CCL2, which are responsi-
ble for bone marrow-derived monocytes recruitment, were induced in primary
pneumocytes treated with RT or 12S-HETE. Treatment with 12S-HETE (150
nM) augmented arginase-1 expression signifıcantly in bone marrow-derived
macrophages cultured with IL-4. Macrophages expressing active arginase-1 ac-
cumulated inmurine lungs at 16 weeks after thoracic irradiation with fıbrogenic
doses. Conclusion: These studies demonstrate that type2 pneumocytes express
12S-LOX in response to RT with fıbrogenic doses of radiation, and increased
12S-LOX contributes to the accumulation of alternatively activated macro-
phages in irradiated murine lungs. 12S-LOX may serve as a novel therapeutic
target in mitigating RIPF.
#5209 Ionizing radiation abrogates pro-tumorigenic effects from cancer-
associated fıbroblasts in xenografts. Turid Hellevik,1 Maria T. Grinde,1 Jørg
Vik,2 Ketil A. Camilio,2 Inigo Martinez-Zubiaurre2. 1University Hospital of
Northern Norway, Tromsø, Norway; 2University of Tromsø, Tromsø, Norway.
Non-malignant elements of tumors play fundamental roles in both cancer
sustainability and responses to therapies. In the context of clinical radiotherapy
(RT), all cells that reside in the tumor mass receive radiation, but the impact of
cancer-associated fıbroblasts (CAFs) to treatment outcomes remains largely un-
explored. In this study, we have investigated the effects of radiation on the
natural pro-tumorigenic actions of CAFs in animals. Ionizing radiation (IR)was
delivered to CAFs either as a single-high dose or fractionated medium doses.
Tumor development was compared in xenografts after co-implantation of A549
lung tumor cells with irradiated or non-irradiated human lung CAFs. Quanti-
tative histology and immunohistochemistry was applied to investigate potential
biological mechanisms behind tumor growth regulations. As expected, CAFs
showed resistance to radiation-induced cell death, however, the enhanced tu-
morigenic effects observed with admixed non-irradiated CAFs was nullifıed.
Quantitative determinations of parameters such as desmoplasia, angiogenesis,
inflammation, innate immunity or tumor cell proliferation revealed enhanced
blood vessel density in tumors establishedwith irradiated CAFs. Experiments to
ascertain fate of implanted CAFs showed that both irradiated and non-irradi-
ated CAFs only reside at the implantation site during early stages, suggesting
that the regulatory functions of admixed CAFs may take place during the initial
phases of tumor formation. In this study, we show that CAFs receiving ionizing
radiation lose their pro-tumorigenic potential in vivo, affecting angiogenesis
and possibly other mechanisms related to tumor engraftment. This fınding rep-
resent a previously unknown advantageous effect induced by radiotherapy,
which adds to the well-known direct cytotoxic effects on transformed epithelial
cells.
#5210 Differential cytotoxic effects of Piperlongumine analogues and
their radiotherapeutic response in breast cancer. Nurul Akmaryanti Abdul-
lah, JohnMoses, Li ChenHan, Sarah Storr, AulaAmmar, StewartG.Martin.The
University of Nottingham, Nottingham, United Kingdom.
Background: Breast cancer is the most common cancer in women in the
United Kingdom. The glutathione (GSH) system is a major redox buffering
system involved in regulating radioresponse of cancer cells. Overexpression has
been shown to cause multidrug and radiation resistance. Its modulation may
increase radiosensitivity and improve radiotherapy effıcacy. Piperlongumine
(PL) can reportedly inhibit GSH system function and reduce proliferation of a
variety cancer cells in vitro. The current study investigates novel PL analogues to
determine effıcacy in triple-negative (TNBC) and luminal breast cancer cell
lines, as both single agents and in combinationwith ionising radiation.Methods:
Two novel PL analogues (LH91 and LH92) were used along with the parental
drug, PL. Cell proliferation assays were conducted in MDA-MB-231 (TNBC)
andT47D (luminal) lines at various drug concentrations and times. At 48hr post
treatment, cells were also assessed for clonogenic survival. Clonogenic radiosen-
sitisation was assessed by treating with PL agents or L-buthionine-S, R-sulfoxi-
mine (BSO, a well characterised GSH radiosensitiser) for 48hr then irradiation
with 0-8Gy X-rays. ROS levels were evaluated using H2DCFDA flow cytometry
following IC50 drug treatment alone or with subsequent exposure to 1mMH2O2
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for 1hr. Results: PL, LH91 and LH92 inhibited proliferation and decreased
clonogenic survival in both lines. From proliferation assays,MDA-MB-231 cells
were more sensitive to PL at 48hr (P0.047) and 72hr (P0.01) with an IC50
dose of approx. 4M versus approx. 12M in T47D’s. There was a signifıcant
difference between IC50 doses of LH91 in MDA-MB-231 (5M) and T47D
(12M) cell lines at 72hr (P0.006), however this was not observed at 48hr
treatment (P0.178). In contrast, therewas no differential sensitivity of LH92 in
cell proliferation between the two cell lines at 48 and 72hr. Interestingly, in
clonogenic assays, MDA-MB-231’s were more sensitive to LH92 (P0.01) with
an IC50 of 4Mversus 11M inT47D’s. There were no signifıcant differences in
clonogenic survival between each line after treatment with PL or LH91. No
radiosensitisation was observed with PL or PL analogues in MDA-MBA-231
however BSO, as a drug comparator, enhanced radiation response with a sensi-
tizer enhancement ratio (SER) of 1.13 at 1% iso-survival. Radiation and drug
combinations in T47D cells are ongoing. There were no changes in ROS levels
with the drug alone in MDA-MB-231; however, with subsequent exposure of
H2O2, there was a 1.7-fold increase in ROS level with LH91 at 48hr (P0.002).
Conclusion: The TNBC cell line is more sensitive to the cytotoxic effect of PL
agents (PL and LH91 in cell proliferation and LH92 in clonogenic assays) in
comparison to the luminal cell line; however no altered radiosensitisation was
observed. Themechanism of such differential sensitivity is yet to be determined.
#5211 Hormophysa triquerta polyphenol, an elixir that deters CXCR4-
and COX2-dependent dissemination destiny of treatment-resistant pancre-
atic cancer cells. Sheeja Aravindan,1 Sathish Kumar Ramraj,1 Dinesh Babu So-
masundaram,1 Kathiresan Kandasamy,2 Somasundaram S. Thirugnanasam-
bandan,2 Terence Herman,1 Natarajan Aravindan1. 1Univ. of Oklahoma Health
Sciences Ctr., Oklahoma City, OK; 2Annamalai University, India.
Therapy resistant pancreatic cancer (PC) cells play a crucial role in tumor
relapse, recurrence, and metastasis. Recently, we showed the anti-PC potential
of an array of seaweed polyphenols and identifıed effıcient drug deliverables.
Herein, we investigated the benefıt of one such deliverable, Hormophysa tri-
querta polyphenol (HT-EA), in regulating the dissemination physiognomy of
therapy resistant PC cells in vitro, and residual PC in vivo. Human PC cells
exposed to clinical radiation (FIR), with/without HT-EA pretreatment were
examined for the alterations in the tumor invasion/metastasis (TIM) transcrip-
tome (93 genes, QPCR-profıling). Utilizing a mouse model of residual PC, we
investigated the benefıt of HT-EA in the translation regulation of crucial TIM
targets (TMA-IHC). Radiation activated 30, 50, 15, and 38 TIM molecules in
surviving Panc-1, Panc-3.27, BxPC3, and MiaPaCa-2 cells. Of these, 15, 44, 12,
and 26 molecules were suppressed with HT-EA pretreatment. CXCR4 and
COX2 exhibited cell line-independent increases after FIR, and was completely
suppressed with HT-EA, across all PC cells. HT-EA treatment resulted in trans-
lational repression of FIR-induced CXCR4, COX2, -catenin, MMP9, Ki-67,
BAPX, PhPT-1, MEGF10, and GRB10 in residual PC. Muting CXCR4 or COX2
regulated the migration/invasion potential of IR-surviving cells, while forced
expression of CXCR4 or COX2 signifıcantly increased migration/invasion ca-
pabilities of PC cells. Further, treatment with HT-EA signifıcantly inhibited
IR-induced and, CXCR4/COX2 forced expression-induced PC cell migration/
invasion. This study (i) documents the TIM blueprint in radiotherapy-resistant
PC cells, (ii) defınes the role of CXCR4 and COX2 in induced metastatic poten-
tial, and (iii) recognizes the potential of HT-EA in deterring the CXCR4/COX2-
dependent dissemination destiny of therapy resistant residual PC cells.
#5212 Metabolic reprogramming of radiation fıbrosis using adipose de-
rived stromal cells.XiaoZhao,1 Laleh SoltanGhoraie,1 Pamela Psarianos,1 Ken-
neth Yip,2 Laurie Ailles,1 Benjamin Haibe-Kains,1 Fei-Fei Liu2. 1University of
Toronto, Toronto, Ontario, Canada; 2PrincessMargaret Cancer Centre, Toronto,
Ontario, Canada.
Background: Soft tissue radiation fıbrosis (RF) affects up to 70% of cancer
survivors post-radiotherapy. RF is an irreversible and progressive side effect of
radiotherapy characterized by poor tissue elasticity and increased ECM deposi-
tion, clinically translating to increased morbidity due to hardening, distortion,
and pain. Recent evidence has highlighted the potential role of metabolic alter-
ations in the onset and progression of fıbrosis. Adipose derived stromal cells
(ADSCs) have been used effectively for enhancing complex wound repair in a
number of clinical trials. The therapeutic effect of ADSCs has been attributed to
its secretion of paracrine factors, which can regulate the metabolism of target
cells. Even so, themetabolic effects ofADSCs on target cells is notwell described.
Methods and Results: Transcriptomic profıling and targeted metabolomics of
human radiated tissue and a murine model of RF revealed that suppression
of fatty acid oxidation (FAO) is hallmark of RF. TGF-B, a master regulator of
fıbrosis, has a large effect in suppressing FAO in primary human fıbroblasts in
vitro through downregulating genes in the PPAR pathway, a major regulatory
pathway for FAO, and through inhibiting oxidation of the long chain fatty acid,
palmitic acid (p0.05, t-test). Treatment of TGF-B stimulated fıbroblasts with
ADSC conditioned media resulted in an improvement in FAO and a reduction
in fıbronectin, collagen-1, and PAI-1 protein levels, three of major contributors
to fıbrosis. Transplantation of ADSCs into murine RF resulted in a metabolic
shift back to FAO and a signifıcant reduction in RF both functionally (percent-
age leg contracture 36% vs 26%, 2-way ANOVA  0.05) and histologically
through image analysis of trichrome staining (p0.01, t-test). Pathway analysis
of signifıcant genes altered by ADSCs revealed an upregulation of the PPAR
pathway was the most signifıcant effect of ADSC transplantation. Untargeted
metabolomics confırmed that FAO metabolites were signifıcantly upregulated
with ADSC transplantation. To confırm the importance of metabolic regulation
by ADSCs, we utilized a pharmacogenomics strategy to uncover a compound
that mimicked the effect of ADSCs. Drug A ranked highest and replicated the
anti-fıbrotic and pro-FAO effects of ADSCs both on TGF-B stimulated primary
fıbroblasts and in murine RF. Etomoxir, a FAO inhibitor, inhibited the effect of
ADSCs and Drug A in regulating protein levels of fıbronectin and collagen,
revealing that ADSCs and Drug A require an intact FAO pathway to exert their
anti-fıbrotic effects. Conclusions: Inhibition of FAO is a novel hallmark of RF.
ADSC-mediatedmetabolic reprogramming resulted in an enhancement of FAO
and a reduction in RF through upregulating the PPAR pathway. ADSC-directed
pharmacogenomics uncoveredDrugA,whichmimicked the pro-FAOand anti-
fıbrotic effects of ADSCs. Our research has highlighted the importance of re-
versing metabolic aberrations to reduce RF.
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#5213 Aberrant tumormetabolism enables GR takeover in enzalutamide-
resistant prostate cancer. Jianneng Li. The Cleveland Clinic Lerner Research
Inst., Cleveland, OH.
It is well known that castration resistant prostate cancer (CRPC) is still driven
by the androgen axis. Therefore, the advent of new AR-targeting drugs, such as
Enzalutamide (ENZ), has been benefıcial for many patients with CRPC. ENZ is
a potent FDA-approvedARantagonist which prolongs survival for patientswith
CRPC, even after docetaxel chemotherapy. Unfortunately, although ENZ has
proven effective clinically, treatment resistance eventually arises in nearly all
patients with CRPC. Emerging data suggest that the glucocorticoid receptor
(GR) is upregulated in this context, stimulating expression of AR-target genes
that permit continued growth despite AR blockade. Hence, we hypothesize that
similar to metabolic mechanisms that elicit dihydrotestosterone (DHT) synthe-
sis, which in turn stimulate AR in CRPC, a role for GR in ENZ resistance would
be accompanied by a tumor metabolic switch that provides sustained tissue
cortisol concentrations which enable GR activation. Here, we found that long-
term ENZ treatment sustains tumor cortisol concentrations in models of pros-
tate cancer and patient tissues by using [3H]-cortisol and high performance
liquid chromatography. Further investigations with immunoblot, co-immuno-
precipitation as well as in vitro ubiquitination assays in ENZ resistant prostate
cancermodels demonstrated that autocrinemotility factor receptor (AMFR), an
ubiquitin E3-ligase, and one of its adaptors, Erlin-2,mediate loss of 11-hydrox-
ysteroid dehydrogenase-2 (11-HSD2), which sustains tumor cortisol concen-
trations, resulting in the continuous stimulation of GR and ENZ resistance.
Remarkably, reinstatement of 11-HSD2 expression, or AMFR loss, reverses
ENZ resistance in mouse xenograft tumors. Together, these fındings reveal a
surprising metabolic mechanism of ENZ resistance that may be targeted with a
strategy that circumvents a requirement for systemic GR ablation.
#5214 Activation of WNT/b-catenin signaling results in resistance to
PI3K/mTOR dual inhibitor in co-existing KRAS and PIK3CA mutant colo-
rectal cancer cells. Ye-Lim Park,1 Hwang-Phill Kim,1 Seul-Ki Cheon,1 Jun-Kyu
Kang,1 Yoojoo Lim,2 Sang-Hyun Song,1 Sae-Won Han,2 Tae-you Kim2. 1Seoul
national university, seoul, Republic of Korea; 2Seoul national university hospital,
seoul, Republic of Korea.
KRAS is a frequently mutated gene in colorectal cancer. In addition, PIK3CA
mutations commonly co-exist with KRAS mutations and lead to additive acti-
vation of the PI3K/mTOR signaling pathway. Here, we investigated preclinical
activity of gedatolisib, a PI3K/mTOR dual inhibitor, to identify mechanism of
inhibition of PI3K/mTOR in 28 colorectal cancer (CRC) cells. Cells specifıcally
with PIK3CA mutation were sensitive while those with KRAS mutation were
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resistant to gedatolisib. 9 out of 28 CRC cells harbor PIK3CA & KRAS co-
mutation and 7 out them were shown to be sensitive to gedatolisib. However,
HCT15 and LS174T cells were resistant. We identifıed that resistant cell lines
have high activity of GSK3B and TCF7 frameshift mutation (465insertC466;
H155fs*), which functions as positive regulator of WNT/b-catenin pathway.
The effects of GSK3B-knockdown showed decreased activity of mTOR down-
streammolecules in gedatolisib-treated resistant cells. Interestingly, these effects
also caused a decrease in activity ofWNT/b-catenin pathway. In addition, com-
bination treatment of gedatolisib andCHIR-99021,GSK3B inhibitor, resulted in
signifıcantly enhanced cytotoxicity against gedatolisib-resistant TCF7 frame-
shift mutant cells. Taken together, these show that aberrant regulation ofWNT/
b-catenin pathway and high activity of GSK3B by TCF7 frameshift mutation
cause resistance to PI3K/mTOR dual inhibitor. Inhibition of GSK3B activity in
colorectal cancer cells with KRAS and PIK3CA co-mutations increases sensitiv-
ity to PI3K/mTOR dual inhibitor.
#5215 Time dependent blood-brain barriermodulation by vascular endo-
thelial growth factor to improve CNS drug delivery. Matthew McCord. Na-
tional Cancer Institute, Bethesda, MD.
Introduction: Efforts to transiently increase blood brain barrier permeability
would facilitate improved CNS delivery of chemotherapy agents. Previous stud-
ies demonstrated that vascular endothelial factor (VEGF) increases permeability
in traumatic brain injury and ischemic brain disease. Exogenously administered
VEGF increases barrier permeability in the non-diseased CNS. In our study, we
investigated the role for exogenous VEGF therapy to modulate blood-brain
barrier permeabilityMethods: For in vitro studies, confluentmouse brain endo-
thelial cells (BEND.3) were treated with VEGF165. Trans-endothelial electrical
resistancemeasured cell impedance changes and immunofluorescence was used
to assess qualitative expression of tight and adherens junction proteins at key
time points. Western blotting and qPCR were done to evaluate the effect of
VEGF on expression of protein and RNA associated with tight and adherens
junctions. Results: Confluent endothelial cells treated with rVEGF165 (200ng/
mL) evaluated byTEER showa signifıcant drop in cell impedance approximately
6 hours post treatment, compared to control (more than 10-fold) reflecting
increased permeability of the monolayer. Treatment with progressively higher
doses of VEGF (200, 400, and 600ng/mL) showed a progressively greater drop in
cell impedance. Immunofluorescence of endothelial cells treated with rVEGF165
(200ng/mL) shows disassembly of both tight junctions and adherens junctions
between 4 and 8 hours post-treatment compared to controls. Western blots and
qPCR demonstrate that rVEGF165 treatment induces down-regulation of genes
associated with tight junctions, such as Claudin5, beginning as early as 4 hours
post treatment and continuing up to 24 hours post treatment. Conclusion: Our
results suggest that VEGF is capable of inducing transient breakdown of the
blood-brain barrier, whichmay facilitate improved CNS delivery of chemother-
apeutic agents. Our in vitro data warrants further investigations of the applica-
bility of VEGF therapy to induce endothelial cell permeability in animal tumor
models, potentially improving delivery of chemotherapeutic drugs.
#5216 Transient modulation of the blood-brain barrier with time depen-
dent adenosine receptor agonism.Amelie Vezina, MatthewMcCordMcCord,
Mark R. Gilbert, Sadhana Jackson. National Cancer Institute, Bethesda, MD.
Background: The blood-brain barrier (BBB), a dynamic, highly regulated and
poorly permeable blockade, is the key obstacle to effective drug delivery to the cen-
tralnervous system(CNS). Itsmain function is toprotect thebrain fromtoxicagents
such as chemotherapy. The BBB regulates drug entry by the presence of tight junc-
tions, adherens junctions andmultidrug resistance proteins. Agonism of adenosine
A2Areceptor (A2AR)byRegadenoson,aFDAapprovedA2ARagonist, innon-tumor
bearing rodents has been shown to transiently disrupt BBB permeability. Here, we
studied the time dependent impact of Regadenoson on brain endothelial cells to
transiently decrease tight and adherens junctions, while impairingABC transporter
function, thus increasingBBBpermeability.Methods:Mouse brain endothelial cells
(bEnd.3), were treated with 10M Regadenoson on a time-course of 0-24 hours.
Claudin-5, Occludin, ZO-1, VE-Cadherin, and PECAM-1 expression studies were
assessed by flow cytometry, immunofluorescence and western blotting of subcellu-
lar fractions at varied time points. Additionally, tight and adherens junctions’ gene
expressionwas assessedbyqRT-PCRusingSYBRgreen.Expressionand functionof
ABCB1, ABCG2 was reported by western blotting of whole cell lysates, qRT-PCR
and flow cytometrymeasurement of cellular uptake ofMRP substrates. Transendo-
thelial electrical resistance (TEER) was monitored by cellular impedance of endo-
thelial cell monolayers with and without Regadenoson to further describe permea-
bility changes. Results: Membrane expression of Claudin-5, Occludin, and ZO-1
was decreased approximately 30 minutes after Regadenoson treatment. Claudin-5
and Occludin expression returned to basal levels after 8 hours whereas, ZO-1 ex-
pression returned to baseline expression by 4 hours after treatment. Total protein
expression was unchanged with Regadenoson treatment, but the cytoplasmic ex-
pression of tight and adherens junctions’ proteins were increased; suggesting that
changes in protein localization is the cause of transient disruption. Eight hours after
treatment, protein concentration and tRNA expression of ABCB1 andABCG2was
decreased by 50%. TEERmeasurements demonstrated a 40% reduction in cell im-
pedance after Regadenoson. Conclusion: Our results demonstrate that A2AR ago-
nism causes transient changes in junctional and ABC transporter expression and
functionality. The short durationofRegadenoson effects onBBB functionmayhave
important implications for its clinical use to enhancedrugdeliveryof chemotherapy
and other therapies for CNS diseases.
#5217 MechanismofpolyspecifıcityofP-glycoprotein:Substitutionof fıfteen
residues in the drug-binding pocket with tyrosine reveals a negative correlation
between substrate size and transport. Shahrooz Vahedi, Eduardo Chufan, Suresh
V. Ambudkar.National Institute of Health (NIH), Bethesda, MD.
P-glycoprotein (P-gp) belongs to the superfamily of ATP-binding cassette
(ABC) transporters. This energy-dependent cell surface transporter can pump
various chemically dissimilar amphipathic or hydrophobic compounds out of
cells. In cancer cells, the expression of P-gp is often linked to the development of
multidrug resistance (MDR). Several studies have demonstrated that P-gp can
recognize and transport various chemotherapeutic drugs and limit their bio-
availability and effectiveness. The drug-substrate binding sites, translocation
mechanism, and the signal transduction between drug-binding sites and ATP-
hydrolysis at nucleotide-binding domains of this clinically important trans-
porter are not yet well defıned. Utilizing molecular modeling and mutagenesis,
we previously identifıed key amino acid residues that interact with the most
potent inhibitors of P-gp (zosuquidar, tariquidar, and elacridar). We found that
replacing key interacting amino acids (Y307, Y953, and Q725) with alanine in
the drug-binding pocket switches inhibition by these modulators of ATPase
activity to stimulation. The data demonstrated that hydrogen bond interactions
are critical for inhibition of ATP hydrolysis of P-gp by modulators. As tyrosine
and glutamine residues can function as both hydrogen bond donors and accep-
tors, we hypothesized that increasing the potential for hydrogen bond interac-
tions by introducingmore tyrosine residues into the drug-binding pocket would
increase the affınity of substrates for P-gp. To investigate this, we fırst identifıed
residues in the transmembrane domains that interact with a number of sub-
strates by employing a molecular modeling technique. Then we substituted fıf-
teen conserved residues (11 Phe, 2 Leu, 2 Ilu and 1 Met) with tyrosine, creating
amutant we named 15Y. Compared toWT, for themajority of tested substrates,
we observed normal transport of thirteen fluorescent substrates by the 15Y P-gp
mutant demonstrating that fıfteen mutations in the transmembrane domains is
well tolerated in P-gp. Additionally, these changes have no effect on the cell
surface expression or total level of the mutant protein and normal conforma-
tional changes occur during transport, further confırming flexible nature of
transmembrane domains of P-gp. Interestingly, transport of three large-size
substrates was signifıcantly decreased. Physiochemical characterization of the
substrates revealed a negative correlation between drug transport andmolecular
size for the tyrosine-enriched P-gp mutant, possibly due to increased hydrogen
bond interactions. These data also demonstrate that hydrogen bond interactions
are substrate- or modulator-specifıc.
#5218 Breast cancer resistance protein (ABCG2) and P-glycoprotein
(ABCB1) transport ibrutinib and may restrict its oral availability and brain
accumulation, whereas CYP3A4 limits ibrutinib oral availability. Stephanie
van Hoppe,1 Gert-Jan Rood,2 Els Wagenaar,1 Rolf Sparidans,2 Jos Beijnen,2 Al-
fred Schinkel1. 1NetherlandsCancer Institute, Amsterdam,Netherlands; 2Utrecht
University, Utrecht, Netherlands.
Introduction: Ibrutinib (Imbruvica, PCI-32765) is an orally administered ty-
rosine kinase inhibitor (TKI) approved by the FDA in 2014 for treatment of B-cell
malignancies. Ibrutinib is a confırmed irreversible inhibitor of Bruton tyrosine ki-
nase (BTK) with promising clinical activity and tolerability in B-cell malignancies.
Ibrutinib is converted into several metabolites, primarily by CYP3A4. Its mainme-
tabolite, PCI45227, has an inhibitory activity towards BTK approximately 10 times
lower than itsparent compound.We investigatedwhether ibrutinib is a substrate for
themultidrug efflux transportersABCG2andABCB1 andwhether these transport-
ers influence oral availability and brain and other tissue accumulation of ibrutinib.
Materials:Weused in vitro transport assays to assess human (h)ABCB1-, hABCG2-
ormurine (m)Abcg2-mediated transport of ibrutinib. To study the single and com-
bined roles of Abcg2 and Abcb1a/1b in oral ibrutinib disposition, we used appro-
priate knockout mouse strains. To assess the role of Cyp3a in the bioavailability of
ibrutinib we used knockout strains as well as humanized CYP3A4 strains andmea-
sured the ibrutinib and PCI45227 concentrations at various time points. Results:
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Ibrutinib was transported reasonably well by hABCB1 and mAbcg2, but not by
hABCG2 in vitro. Upon oral administration of ibrutinib, Cyp3a-/-, Abcg2-/-,
Abcb1a1b-/-, and Abcg2;Abcb1a1b-/- mice displayed an increase of 9.8-, 1.3-, 1.6-
and1.1 fold in ibrutinibplasmaAUC0-20min compared towild-typemice.At20min,
preliminary data indicated that the relative brain accumulation of ibrutinib was not
signifıcantly altered for the Abcg2;Abcb1a/1b-/- mice compared to wild-type mice.
Conclusion: Abcg2 and Abcb1a/1b possibly restrict oral availability of ibrutinib.
Based on our (preliminary) data ibrutinib may not substantially cross the blood-
brain barrier. Cyp3a restricts the oral availability of ibrutinib and therefore inhibi-
tion of this enzymemay be of clinical importance for patients undergoing ibrutinib
therapy.
#5219 Characterization of the breast cancer resistance protein BCRP in
clear cell renal cell carcinoma. Pascale Fisel,1 Anna Reustle,1 Olga Renner,1
Florian Büttner,1 Stefan Winter,1 Stephan Kruck,2 Steffen Rausch,2 Anne T.
Nies,1 Jörg Hennenlotter,2 Marcus Scharpf,3 Falko Fend,3 Arnulf Stenzl,2 Jens
Bedke,2 Matthias Schwab,1 Elke Schaeffeler1. 1Dr. Margarete Fischer-Bosch-In-
stitute of Clinical Pharmacology andUniversity of Tübingen, Stuttgart, Germany;
2Department of Urology, UniversityHospital Tübingen, Tübingen, Germany; 3In-
stitute of Pathology and Neuropathology, University Hospital Tübingen, Tübin-
gen, Germany.
Introduction: The breast cancer resistance protein BCRP, encoded byABCG2, is
a member of the ABC transporter family and is well-known for its contribution to
multi-drug resistance in cancer. Although BCRP expression is altered in various
cancer types, its role and function in cancer, independent fromdrug efflux, remains
largely elusive. In this study, we aimed to elucidate regulatory mechanisms of
ABCG2 expression and its biological relevance in clear cell renal cell carcinoma
(ccRCC) aswell as associationswith response to sunitinib treatment inpatientswith
metastatic ccRCC. Experimental Procedures: Data from the ccRCC cohort of The
Cancer Genome Atlas (TCGA) was used to assess ABCG2 mRNA expression
(n463), DNAmethylation (n288) and genetic variants present in tumor tissue
(n326) within the ABCG2 gene region. An independent ccRCC cohort of 64 pa-
tients was used for the analysis of ABCG2 mRNA and protein expression by Taq-
Man quantitative real time PCR or immunohistochemical staining of TMAs, re-
spectively, and for genotyping of 34 variants in the ABCG2 gene by MALDI-TOF
mass spectrometry. The influence of miRNAs on ABCG2 expression was investi-
gated in the second cohort and validated in in vitro cell culture experiments per-
formed in the renal cancer cell line A498 to confırm the interaction of selected
miRNAswith theABCG2 3=UTR.ABCG2mRNAdata and treatment information
of a third ccRCC cohort was used to elucidate potential links of ABCG2 with
sunitinib response.Results: In theTCGAcohort lowABCG2mRNAexpressionwas
signifıcantly associated with clinicopathological features (T: P4.79e-11, N:
P9.76e-04, M: P1.28e-06, G: P6.61e-15 and tumor necrosis: P9.76e-04) and
with inferior patient survival (HR0.22; 95%CI: 0.15-0.32; P[logrank]10e-14).
DNA methylation levels within the ABCG2 gene were low and hardly variable in
ccRCC patients. Somatic variants were only found in a minority of patients and
togetherwith genetic variants had only amoderate influence onABCG2 expression
and patient survival. The link between ABCG2 expression with survival could be
confırmed in the second ccRCC cohort. The investigated variants did not signifı-
cantly affect ABCG2 expression on mRNA or protein level. miR-212-3p and miR-
132-3pwere identifıed to be linked toABCG2protein expression in ccRCCpatients
of the second cohort. The interactionof thesemiRNAswith theABCG23=UTRwas
confırmed in in vitro cell culture experiments by reporter gene assays. Analysis of a
potential associationofABCG2expressionwith sunitinib response revealed a better
outcome for patients with high ABCG2 levels. Conclusion: In this study, we found
that higherABCG2expression contributes to longer survival in ccRCCpatients and
better response to sunitinib treatment. Whereas genetic variants had only a minor
impact on ABCG2 variability in ccRCC, epigenetic regulation by miRNAs, in par-
ticular miR-212-3p andmiR-132-3p, contributed to aberrant ABCG2 expression.
#5220 Chronic exposure to a novel AR-NTD inhibitor induces resistance via
a selectivemetabolismpathway. JonathonK.Obst,1 JunWang,1 DavidWilliams,2
AmyH. Tien,1 Nasrin R.Mawji,1 Yu Chi Yang,1 Raymond J. Andersen,2Marianne
D.Sadar1. 1BCCancerResearchCentre,Vancouver,BritishColumbia,Canada; 2Uni-
versity of British Columbia, Vancouver, British Columbia, Canada.
Background: The androgen receptor (AR) is recognized as playing a crucial role
in prostate cancer (PCa) maintenance and progression; therefore its inhibition has
been the cornerstone of modern therapy for men who fail primary treatment. Cur-
rent treatments are initially effective, however resistanceultimatelydevelops and the
disease progresses to a lethal form termed castration-resistant prostate cancer
(CRPC).Our labhasdiscovered anewclass ofmolecules (EPI)which inhibit theAR
by binding to the N-terminal domain (NTD). The NTD interacts with transcrip-
tionalmachinery, and its presence is vital for a transcriptionally functional receptor.
Wehavepreviously shownthatEPI-002 specifıcally inhibitsboth full-lengthARand
constitutively active AR splice variants. The effıcacy of EPI-506, the prodrug of
EPI-002, is currently being tested in a Phase I/II clinical trial for CRPC. Here we
propose novel resistance mechanisms arising from sustained AR-NTD inhibition,
with the goal of preemptively developingbackupcompounds.Methods:The andro-
gensensitivehumanPCacell lineLNCaPwasused inall experiments.Aresistantcell
line (LNCaP-EPIR) was generated by passaging parental LNCaP cells weekly in
media supplemented with EPI-002 beginning in September 2012. In vitro and in
vivo studies using LNCaP andLNCaP-EPIR cells were employed to confırmbiolog-
ical resistance. A human affymetrixmicroarray identifıed possible resistancemech-
anisms and was validated using qRT-PCR, western blot and functional studies.
LNCaP and LNCaP-EPIR cells were challenged with EPI-045, an EPI-analog pre-
dicted to remain effective in the context of EPI-002 resistance.Results: LNCaP-EPIR
cells treatedwith25MEPI-002displayedsimilargrowthrates tovehicle treatment,
both in vitro and in vivo. Conversely, parental LNCaP cells showed signifıcant
growth inhibition in response to EPI-002. LNCaP-EPIR cells retained sensitivity to
anti-androgens and AR knock-down by targeted siRNA, implying functional AR
remains essential for growth. qRT-PCR data demonstrated that EPI-002 had re-
duced ability to blockARmediated gene transcription. Interrogation ofmicroarray
data revealed candidate genes (UGT2B family) which were specifıcally upregulated
in the resistant line, and may function to metabolize EPI-002. Supporting this hy-
pothesis EPI-045which is predicted to be resistant toUGT2Bmetabolism, was able
to signifıcantly inhibit LNCaP-EPIR proliferation and AR transcriptional activity.
Conclusions: Taken together these data suggest anEPI-specifıcmechanismof resis-
tance, whereby EPI-002 is preferentially metabolized and removed from the cell.
LNCaP-EPI
R
cells remain dependent upon AR signalling, and are sensitive to anti-
androgens used clinically as well as a novel EPI-analog. This work highlights the
potential for combination or sequential therapy in the context of drug-resistant
CRPC.
CANCER CHEMISTRY: Chemical Biology and Structure Biology
Approach to Study Cancers
#5221 Target engagement approaches to validate small-molecule binders
of the pioneering transcription factor FOXA1. Helen L. Evans,1 Shelby K.
Doyle,1 Marius S. Pop,1 Becky Leifer,1 Kimia Ziadkhanpour,2 Angela N.
Koehler1. 1David H. Koch Institute for Integrative Cancer Research, Cambridge,
MA; 2Massachusetts Institute of Technology, Cambridge, MA.
The discovery of small-molecules that disrupt or promote the function of tran-
scription factors, often considered ’undruggable’ targets, is considered a signifıcant
challenge.[1] The development of general and systematic approaches to discover
small-molecule probes of transcription factors is therefore of substantial value. In
this study, ahigh-throughput small-moleculemicroarray (SMM)screenwasused to
identify initial binders of FOXA1,whichwere studiedusing a variety of biochemical
approaches to identify and characterize target engagement of these small-molecule
probes in a cellular context. Tools for validating FOXA1 as a therapeutic target do
not currently exist, although FOXA1 is a known mediator of androgen receptor
(AR) action inProstateCancer (PCa), andhas beendemonstrated to both assist and
antagonize AR activity, dependent upon the cellular context.[2,3] Using the SMM
technology, potential small-molecule binders of FOXA1 were identifıed, and an
enrichment for an interesting class of endogenousmetabolites was observed.While
an interaction between these compounds and FOXA1 has not previously been re-
ported, they were found to exhibit meaningful inhibition of FOXA1-controlled
transcription in prostate cancer cell lines. Compound-anchored beads were used to
pull-down FOXA1 in whole cell lysates, and we demonstrated via western blot that
the endogenous metabolite engages the transcription factor in this setting. Target
engagement in live cells was demonstrated using bi-functional chemical probes,
which contain a photo-reactive functional group that transforms transient protein-
ligand interactions into stable covalentbondsuponUVirradiation.Theprobeswere
also modifıed with a bioorthogonal, or click chemistry handle, which enabled for
assay read-outs using fluorescent labeling and mass spectrometry.[4] Using these
approaches, we successfully validated the bimolecular interaction between the en-
dogenous metabolites and FOXA1 in cell lysates and live cells, respectively. This
reportdetails the fırst knownsmall-molecule tobindFOXA1inacellular settingand
suggests a new perspective on the potential role of this class of endogenous com-
pound in prostate cancer. References [1]A.N.Koehler, CurrOpinChemBiol 2010,
14, 331-340. [2]W.C.Krause et al., Int JBiochemCellBiol 2014, 54, 49-59. [3]M.M.
Pomerantz et al.,NatGenet 2015, 47, 1346-1351. [4]T.Kambeet al., JAmChemSoc
2014, 136, 10777-10782 Funding Sources The Koch Institute Quinquennial Cancer
Research Fellowship. National Science Foundation Graduate Research Fellowship
Program (NSF GRFP).
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#5222 A landscapeof deubiquinating enzymes (DUB) in lung cancerusing
activity based protein profıling (ABPP). Shikha Mahajan, Bin Fang, Fumi Ki-
nose, Eric B. Haura.Moffıtt Cancer Center, Tampa, FL.
Dysregulation of ubiquitin signaling has been linked tomanydiseases, includ-
ing cancer. NumerousDUBs are implicated in key pro-cancer pathways, includ-
ing regulation of HIF1	, control of RAS signaling, signaling through both ca-
nonical and non-canonical NFB pathways, and regulation of p53 activity.
Overexpression of USP14, USP17 and USP28 is linked to promoting non-small
cell lung cancer (NSCLC). OTUB1 has shown to trigger lung cancer progress by
inhibiting RAS monoubiquitination in KRAS mutant NSCLC. Notably, BAP1
(tumor suppressor) expression decreases in lung cancer tissues although its
mRNA levels did not reflect it. Based on these fındings, we hypothesized that
profıling DUB proteins and their activity in lung cancer cells and tissues could
uncover new therapeutic targets. Since proteogenomics studies have revealed
that mRNA expression is not a reliable predictor of the protein expression, we
have used ABPP assays to profıle DUB. ABPP, which uses chemical probes
directed against the active sites of enzymes to interrogate the functional state of
enzymes in biological samples, can serve as an important tool to nominate DUB
targets. HA-tagged active site-directed ubiquitin probe, HA-Ub-VME was used
to evaluate theDUBs profıle ofKRAS andEGFRmutant cell lines. Cell lysatewas
labeled in presence or absence of DUB inhibitors (DUBi) and the modifıed
enzymes were visualized by anti-HA immunoblotting. Labeled proteome was
enriched and analyzed using mass spectrometry and data was analyzed using
APOSTL. In addition to DUB profıling, we screened lung cancer cell lines to
DUBi, including small cell lung cancer, KRASmutant, EGFRmutant, andmod-
els of EGFR TKI resistance. Immunoblotting in various KRAS and EGFR mu-
tant cell lines displayed diverse profıles of DUBs. Enrichment of DUBs in A549
cells showed 23 DUBs and competition with bAP15, a well-known DUBi for
USP14 resulted in reduced probe binding toUSP14.We optimized the approach
to capture maximum DUBs by examining parameters such as protein/probe
ratio, probe incubation time and probing different lung cancer cells that may
harvest a larger or complementary repertoire of DUBs. A preliminary screen of
DUBi across 20 SCLC and NSCLC cell lines lead to a panel of DUBi
(IC50100nM-5M), with broad or selective activity in particular cell lines.
These results are being used for competitive DUB profıling using ABPP to com-
prehend target engagement and resulting changes in cell viability induced by
DUBi. These results enable future studies to profıle the DUB landscape in lung
cancer cell lines, PDX tumor cohorts, and tumor tissues from patients. DUB
ABPP can identify important DUBs in lung cancer cells to both identify new
drug targets, as well as discern mechanism of action of drugs identifıed from
compound screening campaigns.
#5223 Differentiated receptor pharmacology of imipridoneONC201: The
fırstDRD2antagonist in clinical development for oncology.NeelMadhukar,1
Varun Vijay Prabhu,2 Lakshmi Anantharaman,3 Chidananda Sulli,4 Edgar Da-
vidson,4 Sean Deacon,3 Rohinton Tarapore,2 Joseph Rucker,4 Neil Charter,3
Banjamin Doranz,4 Wolfgang Oster,2 Olivier Elemento,1 Joshua Allen2. 1Weill
CornellMedicine, NewYork, PA; 2Oncoceutics, Inc, Philadelphia, PA; 3DiscoverX
Corporation, Fremont, CA; 4Integral Molecular, Inc, Philadelphia, PA.
ONC201 is the founding member of the imipridone class of compounds
which selectively target G protein-coupled receptors (GPCRs). ONC201, cur-
rently in clinical trials, possesses an exceptional safety profıle combined with
anti-cancer effects that are driven by activation of the integrated stress response
and inhibition of Ras signaling. In this study, we identifıed and characterized the
previously unknown binding target of ONC201. Following its phenotypic dis-
covery, a series of experiments indicated that ONC201 does not directly interact
with many known cancer drug targets. BANDIT - a machine learning based
drug target identifıcation platform - predicted that ONC201 selectively antago-
nizes the GPCR dopamine receptor D2 (DRD2). DRD2 is overexpressed in
many cancers, controls various pro-survival mechanisms including Ras signal-
ing and stress pathways, and its antagonism causes anti-proliferative and pro-
apoptotic effects in malignant cells. PathHunter® -Arrestin and cAMP assays
determined that ONC201 selectively antagonizes DRD2 and DRD3. Antipsy-
chotics antagonize multiple dopamine receptor family members that belong to
either the D1-like or D2-like subfamilies that cause opposing downstream ef-
fects. Consistent with BANDIT, in contrast to antipsychotics, ONC201 did not
antagonize other dopamine receptors or other GPCRs with known ligands.
Schild analysis and radioligand competition assays revealed a DRD2 affınity of
3uM, consistent with ONC201 anticancer activity. In accordance with supe-
rior selectivity of ONC201 among the GPCR superfamily, ONC201 exhibited a
wide therapeutic window in tumor versus normal cell viability assays compared
to antipsychotics. In support of the hypothesis that selectively targeting D2-like
receptors yields superior anti-cancer effıcacy, combined DRD2/DRD1 inhibi-
tion with tool compounds was inferior to DRD2 inhibition alone. Further char-
acterization revealed that ONC201 had a very slow association rate for DRD2
relative to antipsychotics, whereas the dissociation rate was similar to atypical
antipsychotics that are well tolerated. Shotgun mutagenesis alanine scan map-
ping across 350 amino acids of DRD2 identifıed 8 residues critical for ONC201-
mediated antagonism of dopamine-induced calcium flux. Several of these resi-
dues were not conserved among the dopamine receptor family and the residue
with the largest effect is not conserved in any other family member, suggesting
the basis of ONC201 specifıcity. Consistent with competitive inhibition, several
residues were within the orthosteric binding site, however, two allosteric resi-
dues were also identifıed. In summary, ONC201 is the fırst DRD2 antagonist
under clinical development for oncology and its differentiated receptor pharma-
cology explains its unique selectivity, anti-cancer activity, and safety that has
been observed in clinical trials.
#5224 Identifıcation of drug-target interactions through rapid selection
ofdrug resistant protein variants generatedbyCRISPR/Cas9-inducedNHEJ.
Jasper E. Neggers, Bert Kwanten, Tim Dierckx, Dirk Daelemans. KU Leuven,
Leuven, Belgium.
Identifıcation and validation of the cellular target of bioactive hits identifıed in
a phenotypic screen is crucial for their further development into a drug. The gold
standard proof for identifıcation of a small molecule’s target is the discovery of
mutations that confer resistance. However, selection of drug resistance and sub-
sequent deconvolution of the relevant mutations that confer drug resistance
remains time consuming. Therefore, amethodology that can accelerate the drug
resistance selection process and that can simplify identifıcation of relevant drug
resistancemutations would benefıt the drug discovery and development process
greatly. Here we report a simple method to rapidly identify the mechanism of
action of small molecules with anti-cancer activity. The method utilizes the
positive selection of in-frame drug resistance mutations in the target protein of
a small molecule derived from the localized genetic variation created by non-
homologous end joining (NHEJ) repair of CRISPR/Cas9-induced double strand
breaks. In brief, we introduced double strand breaks in the target proteins of
selinexor, ispinesib and triptolide and treated these cells with the respective
drug. Resistance was obtained rapidly and sequencing of resistant colonies re-
vealed known as well as many new drug resistant protein variants. Next, we
investigated whether this approach can be applied as a screening strategy on a
subset of genes to identify the direct cellular target protein of a small molecule.
We therefore, as proof of concept, designed a pooled sgRNA tiling library tar-
geting all PAM sites of multiple genes and applied this to ispinesib. Drug resis-
tant colonies formed rapidly and were enriched with sgRNAs targeting the ispi-
nesib binding site in KIF11, ispinesib’s target protein. Further sequencing of the
sgRNA target gene locus revealed drug resistancemutations inKIF11, validating
the feasibility of themethodology to uncover the target of a small molecule from
a small pool of candidate genes. To conclude, we provide a new method for
identifıcation of the cellular target protein and binding site of a small molecule
based on positive selection of drug resistant protein variants generated by tar-
geted CRISPR/Cas-induced NHEJ repair.
#5225 Novel loop interactions within a parallel-stranded G-quadruplex
formed in the human BCL-2 proximal promoter.Guanhui Wu, Clement Lin,
Danzhou Yang. Purdue University, West Lafayette, IN.
The human BCL-2 gene contains a 39-bp GC-rich region upstream of its P1
promoter which has been shown to be critical for BCL-2 transcriptional regula-
tion. Therapeutic inhibition of BCL-2 expression can reduce cell proliferation
and the apoptotic threshold of tumorigenic cells. Previously, we have reported
that themajor G-quadruplex (G4) formed in the Pu39 G-rich sequence adopts a
stable, parallel-stranded structure with two 1-nt short loops and a unique 13-nt
long central loop. Parallel G-quadruplexes have been found to be prevalent in
promoter sequences; the 13-nt loop in BCL-2 Pu39G4 is the longest in this
prototype parallel G-quadruplexes identifıed in human gene promoters. The
structure of this G4 with such a long loop is important because it can enable
specifıc small molecule recognition of this BCL-2 G-quadruplex over other G-
quadruplexes and provide a potential basis for rational drug design targeting
BCL-2 transcription. Thus, the objective of our study is to determine themolec-
ular structure of the BCL-2 Pu39 G-quadruplex and the molecular interactions
of this long loop in physiologically relevant K solution by Nuclear Magnetic
Resonance (NMR) spectroscopy.OurNMRstudy shows that the BCL-2Pu39G4
adopts a well-defıned parallel-stranded G-quadruplex structure which contains
three G-tetrads stabilized by Hoogsteen hydrogen bonding and three double-
chain reversal loops containing 1:13:1 bases. The two 1-nt double-chain reversal
loops on two edges of the tetrad provide overall stability of the BCL-2 Pu39G4.
The central 13-nt double-chain reversal long loop is more dynamic in confor-
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mation. Specifıc interactions of the long loop are observed at both the 5= and 3=
end with external tetrads as well as the flanking residues, which may also con-
tribute the stable formation of this G4. The middle region of the 13-nt central
long loop is highly dynamic and doesn’t show much interaction with the G-
quadruplex core. The specifıc molecular interactions of the unique long central
loop are specifıc to the BCL-2 Pu39G4 sequence/structure and signifıcantly dif-
fer from those in other parallel-stranded structures, e.g. c-myc and VEGF. The
specifıc interactions are supported by our mutational analyses. The results are
also supported by the DMS footprinting results which show that the guanines
involved in the tetrad formation in this major G-quadruplex are well-protected
against DMSmethylation. Therefore, the knowledge about the molecular struc-
ture of this non B-DNA conformation of the BCL-2 promoter region is essential
for using the G-quadruplex as a target for anticancer drugs, which could be a
novel approach to anti-BCL-2 drug discovery in cancer therapy.
#5226 Novel class of potent and selective inhibitors effaceMTH1asbroad-
spectrum cancer target.Manuel Ellermann,1 Anja Giese,1 Ashley Eheim,1 Ste-
fanie Bunse,1 RolandNeuhaus,1 JörgWeiske,1MariaQuanz,1AndreaGlasauer,1
Fredrik Rahm,2 Jenny Viklund,2 Martin Andersson,2 Tobias Ginman,2 Rickard
Forsblom,2 Johan Lindström,2 Lionel Trésaugues,2 Matyas Gorjanacz1. 1Bayer
Pharma AG, Berlin, Germany; 2Sprint Bioscience, Huddinge, Sweden.
Malignant transformation is accompanied by increased reactive oxygen spe-
cies (ROS) known to promote carcinogenesis and damage free nucleotides and
DNA. During replication, damaged nucleotides are incorporated into DNA re-
sulting in DNA breaks and mutations, which can ultimately lead to cell death.
Cancer cells may evade this process via overexpression ofMTH1 (also known as
NUDT1), a member of nudix phosphohydrolase protein family, which converts
the oxidized nucleotides 8-oxo-dGTP and 2-OH-dATP into the corresponding
monophosphates thus preventing their incorporation into DNA and avoiding
cell death. Initial RNAi-mediated knockdown of MTH1 and tool compounds
(TH588, (S)-crizotinib) inhibiting MTH1 supported this model. As MTH1 is
not essential for non-transformed cell survival, MTH1 was hypothesized to be a
non-oncogenic cancer addiction and a potential broad-spectrum cancer target.
Attractive target rationale combined with previous success in identifying potent
and cellularly active MTH1 inhibitors prompted us to develop new cancer ther-
apeutics inhibiting MTH1. By using fragment-based screening and structure-
based drug design, a series of 4-amino-2-carboxamide-7-azaindoles was identi-
fıed. We developed biochemically potent and selective MTH1 inhibitors with
good cell permeability and metabolic stability. These MTH1 inhibitors demon-
strated target engagement in cellular thermal shift assay (CETSA), and a strong
positive correlation between cellular and biochemical potency was observed.
One promising MTH1 inhibitor from this structural class was BAY-707. Unex-
pectedly however, these properties did not translate into accumulation of oxi-
dized nucleotides within DNA and consequent induction of H2AX and DNA
damage response. Moreover, while tool compounds (TH588, (S)-crizotinib)
were confırmed to be biochemically potent MTH1 inhibitors which stunted the
proliferation of a range of cancer cell lines, ourmore potent and cellularly active
MTH1 inhibitors, including BAY-707, demonstrated no signifıcant effect on
cancer cell survival. Furthermore, we were unable to demonstrate in vivo effı-
cacy using xenograft models of human cancers or syngeneicmouse tumormod-
els. Finally, our in vitro and in vivo combination studies with pro-oxidants,
standard-of-care drugs or radiation also failed to result in signifıcant additive or
synergistic growth inhibitory effects on cancer cells. Thus, our fındings support
the recently published observationsmadewith other potent and selectiveMTH1
chemical probes (AZ compound 15, IACS-4759, NPD7155) and CRISPR/Cas9-
mediated MTH1 knockout. Based on these observations and our additional
target validation experiments, we concluded that MTH1 is not essential for
cancer cell survival or for the sanitization of damaged nucleotides within cells
and thus not a viable target for development of novel anticancer agents.
#5227 Synthesis of a biotin probe for identifıcation of the ajoene protein
targets in cancer cells ajoene protein targets in cancer cells. Catherine H.
Kaschula,1 Daniel A. Kusza,1 Georgia Schafer,1 Arieh A. Katz,1 Shivendra V.
Singh,2 Roger Hunter1. 1University of Cape Town, Cape Town, South Africa;
2University of Pittsburgh School of Medicine, Pittsburgh, PA.
Garlic (Allium sativum) is a medicinal plant belonging to the lily family
which has been used since ancient times for its benefıcial health effects which
include protection against infections and cancer. There are a cluster of bio-
active compounds found in crushed garlic which contain sulfıde or polysul-
fıde functional groups. One of these compounds, ajoene, is able to interfere
with biological processes by undergoing thiolysis exchange reactions with
biological thiols, for example glutathione and cysteine residues on proteins.
Importantly, ajoene is cytotoxic to cancer cells in the low micromolar range.
We have previously found that ajoene targets multiple proteins in cancer
cells and the aim of this project is to identify the specifıc protein targets of
ajoene. To achieve this aim, we have synthesized a “tagged” ajoene analogue
containing a biotin functional group. As biotin may alter the biological prop-
erties of ajoene, our strategy was to initially synthesize an azide-containing
ajoene analogue (called azide-ajoene) using our 4-step synthetic route to
ajoene analogues previously published. Azide-ajoene was found to retain
cancer cell cytotoxicity similar to that of the parent ajoene. We then treated
cancer cells (MDA-MB-231 breast and WHCO1 oesophageal cancer) with
azide-ajoene to allow transfer of an azide label to the protein targets during
thiolysis exchange with ajoene. We then collected lysate from the treated
cells and performed an in vitro click reaction with a separately synthesized
biotin-alkyne partner which was synthesized via a series of substitution and
amide coupling reactions. Click chemistry covalently links biotin to the ajo-
ene-tagged protein via a triazole linkage; and the feasibility of this method
was validated by western blot. The biotinylated protein targets were purifıed
using immobilised streptavidin beads and identifıed by MALDI-TOF mass
spectrometry. It is anticipated that knowledge of the specifıc ajoene protein
targets will provide valuable insights into the cytotoxic mechanism of action
of ajoene in cancer cells.
#5228 The impact of microtubules on solution conductance and capaci-
tance; implications for the use of AC electric fıelds in cancer therapy. Jack A.
Tuszynski,1 Iara Santelices,1 Douglas E. Friesen,1 Clayton Bell,1 Jack Xiao,1 Va-
hid Rezania,1 Holly Freedman,1 Cameron Hough,1 Andrew J. Tsung,2 Kiran K.
Velpula,2 Karthik Shankar1. 1University of Alberta, Edmonton, Alberta, Canada;
2University of Illinois College of Medicine at Peoria, Peoria, IL.
Microtubules (MTs) formmitotic spindles in dividing cells but have also been
implicated in electrical signaling in biology, andmay act as biological nanowires.
Importantly, relativelyweakACelectric fıeldswith frequencies between 100-300
kHz and strengths in the range 1-2.5 V/cm, called Tumor Treating Fields
(TTFields), have been shown to arrest cancer cells’ mitosis and have led to an
FDA approved treatment of glioblastoma multiforme. TTFields’ effect on MTs
has motivated our study of their electrical properties. Here, we designed two
platinum electrodes 14 m apart and performed electrical characterization of
solutions with various concentrations of MTs, tubulin dimers and ions, at a
range of AC frequencies between 1 kHz and 1 MHz to uncover an optimal
protocol to quantify MT electrical effects in vitro. We generated a theoretical
basis for the results observed, by analyzing the response of ions as the principal
charge carriers attracted toMTs and tubulin.We observed thatMTsmeasurably
increase the solution’s conductance, and this effect is more pronounced at lower
ionic concentrations. We model the possibility that this effect is due to a larger
percentage of ions being able to use MTs as low-resistance cables. The intrinsic
conductivity of MTs has been found to be two orders of magnitude greater than
that of the buffer solution.Moreover, we found that at 100 kHz the conductance
of MTs reaches its peak. On the other hand, at low protein concentration, free
tubulin dimers decrease solution’s conductance, and wemodel this as being due
to tubulin attracting ionic charges and lowering theirmobility. Both tubulin and
MTs were found to increase capacitance of buffer solutions, due to their forma-
tion of ionic double layers. These results point toMTs being very sensitive to AC
electric fıelds and further support their electrical signaling, an emerging prop-
erty in biological organization.Modulating electrical signaling via 100kHz fıelds
may impact intra-cellular communication as well as organization of the cyto-
skeleton. These results bring insight into MTs ability to modulate the capaci-
tance and conductance of the cytoplasm and act as low resistance pathways for
ions, which has implications for understanding of the action of TTFields on
cancer cells.
#5229 High affınity interaction of K-Ras4BHVRwith calmodulin.Hyun-
bum Jang,1 Avik Banerjee,2 Vadim Gaponenko,2 Ruth Nussinov1. 1National
Cancer Institute at Frederick, Frederick, MD; 2University of Illinois at Chicago,
Chicago, IL.
Ras proteins promote cell proliferation and survival, controlling signal
transduction that involves two major pathways, such as Raf/MEK/ERK and
PI3K/Akt. K-Ras4B is the most abundant oncogenic isoform. In calcium-
and calmodulin (CaM)-rich environments, such as ductal tissues, it plays a
critical role in adenocarcinomas promoting PI3K/Akt signaling, particularly
in pancreatic, lung, and colorectal cancers. It was suggested that in adeno-
carcinomas with elevated calcium levels, Ca2/CaM recruits PI3K	 through
interaction with its n/cSH2 domains and sequesters K-Ras4B from the mem-
brane, organizing a CaM/K-Ras4B/PI3K	 ternary complex. Ca2/CaM can
replace the missing receptor tyrosine kinase (RTK) signal, acting to fully
activate PI3K	. Structural data suggests that CaM uniquely binds GTP-
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bound K-Ras4B but not N-Ras or H-Ras isoforms. Experimental evidence
points to the farnesylated hypervariable region (HVR) of K-Ras4B as a major
binding domain for CaM. Here, using molecular dynamics (MD) simula-
tions wemodeled K-Ras4BHVR interaction with Ca2/CaM. Initial contacts
of K-Ras4B HVR with CaM were determined by the nuclear magnetic reso-
nance (NMR) chemical shift perturbation(CSP) data, which guided major
interacting residue pairs between the HVR and CaM. In the simulations, two
different topologies of Ca2/CaM were modeled: CaM with stretched and
flexible linkers. CaM has N- and C-lobes connected by a linker, and each lobe
has its own hydrophobic pocket. Thus, the hydrophobic farnesyl tail of the
HVR can dock into either lobe of CaM. We observed that the HVR strongly
interacts with the linker of CaM. The K-Ras4B HVR is highly polybasic with
lysine-rich, while the linker region of CaM is negatively charged. The dock-
ing of the farnesyl group into the hydrophobic pocket additionally helps to
stabilize the HVR/CaM interaction. This added stabilization by the farnesyl
is signifıcant in the K-Ras4B/CaM interaction even though the interaction
with the Ras catalytic domain is involved. K-Ras4B has only farnesyl modi-
fıcation, while other isoforms bear farnesyl and palmitoyl groups. The addi-
tional lipid modifıcation in the HVR would obstruct CaM binding, suggest-
ing CaM’s K-Ras4B-specifıc action. Our structural model of K-Ras4B/CaM
association provides plausible clues to the PI3K	 activation involving the
ternary complex. The abundant Ca2/CaM can bind to the p85 domain of
PI3K	 while binding to the K-Ras4B farnesylated HVR, releasing catalytic
kinase domain autoinhibition and allosterically leading to full PI3K	 acti-
vation. Funded by Frederick National Laboratory for Cancer Research, Na-
tional Institutes of Health, under contract HHSN261200800001E.
#5230 Targeting two unique end-insertion G-quadruplexes formed in the
3=-end of the PDGFR- core promoter nuclease hypersensitive element with
ellipticine analog. Buket Onel,1 Prashansa Agrawal,2 Megan Carver,1 Laurence
H. Hurley,3 Danzhou Yang1. 1Purdue University, West Lafayette, IN; 2Case
Western Reserve University, Cleveland, OH; 3University of Arizona, Tucson, AZ.
Aberrant expression of PDGFR- promotes multiple hallmarks of cancer,
and its transcriptional regulation provides an attractive means to inhibit the
PDGFR- signaling pathway. The nuclease hypersensitive element (NHE)
region of the human PDGFR- core promoter has been shown to be respon-
sible in regulating approximately 60% of the PDGFR- basal promoter ac-
tivity. Multiple overlapping G-quadruplexes (G4s) have been shown to form
in this NHE region. We previously determined the most stable G4 structure
formed in the 5=-mid of PDGFR- NHE region. Signifıcantly, an ellipticine
analog, GSA1129, has been shown to selectively bind to the G4 formed in the
3=-end NHE region, thereby shifting the dynamic equilibrium toward the
3=-end G4. This selective interaction was shown to result in suppression of
PDGFR- activity in both cancer cell lines and a preclinical animal model.
Thus, characterization of 3=-end G4 provides an important basis for under-
standing the molecular recognition of this G4 and for rational drug design.
In this study, we used NMR spectroscopy to show that the PDGFR- NHE
3=-end sequence forms two novel end-insertion intramolecular G4s which
exist in a dynamic equilibrium under physiological salt condition. One is the
3=-insertion-G4 with a 3= non-adjacent flanking guanine inserted into the
3=-external tetrad. The other is a 5=-insertion-G4 with a 5= non-adjacent
flanking guanine inserted into the 5=-external tetrad. We further confırmed
that these novel end-insertion G4s can readily form in the 3=-end NHE
sequence under physiologically relevant ionic conditions using dimethyl
sulfate (DMS) footprinting experiments. To elucidate the molecular interac-
tions of ellipticine analog with the 3=-end G4s, we studied the binding of
GSA1129 to both of the end-insertion G4s. Signifıcantly, our CD melting
studies showed that GSA1129 markedly increased the stability of both end-
insertion G4s by about 25°C. Furthermore, 1H NMR titration experiments
have shown that GSA1129 selectively binds to the G4 formed in the 3=-end
NHE region. The novel end-insertion structures and the dynamic nature of
the PDGFR- NHE 3=-end G4 may make it an effective target for GSA1129
binding and regulation. Our result highlights the dynamic nature of the
PDGFR-NHE 3=-end sequence and the importance of identifying the exact
sequence for the formation of the naturally occurring G4 structure.
#5231 Undifferentiated cell maker rBC2LC-N lectin have high affınity to
pancreatic cancer cells and residual cancer cells. Osamu Shimomura,1 Tast-
suya Oda,1 Hiroaki Tateno,2 Sho Tachino,3 Junji Matsui,3 Yuusuke Ozawa,1 Jun
Hirabayashi,2 Nobuhiro Ohkohchi1. 1University of Tsukuba, Tsukuba-city, Ja-
pan; 2National Institute of Advanced Industrial Science and Technology, Tsu-
kuba-city, Japan; 3Eisai Co., Ltd., Tsukuba-city, Japan.
The glycosylation in cancer cells remains still unclear despite the whole hu-
man genome understanding. Recent technical advances give us great awareness
about the consequence of the glycosylation. The glycomes of cancer cell surfaces
are often unique with aberrant glycans, including sialylation, fucosylation, O-
glycan truncation, and N-and O-linked glycan branching. The sugar binding
proteins named ’lectins’ are helpful materials to recognize the glycan structure
and characterization. Recent study suggested lectins are more widely accepted
that involved in many biological phenomena inside mammalian or as chemical
research tools. Despite years of effort to develop cancer therapies, there were no
effective molecular targeting drugs for pancreatic adenocarcinoma (PDAC).
One possible reason for this diffıculties, PDAC cells are densely covered with
glycans which may cause the recalcitrance to approach molecular targeting
drugs. Our group developed a high-density lectin microarray using 96 kinds of
lectins, in which a panel well-defıned lectins is immobilized onto a slide, has
been successfully used for high-throughput analysis of complex carbohydrates
included in serum glycoproteins and whole cells. Using this approach, we dem-
onstrated that a recombinant lectin probe, rBC2LC-N, specifıcally bound to
undifferentiated pluripotent stem cells (ES/iPS cells), but not differentiated so-
matic cells; this has now been developed as a useful undifferentiationmarker. In
this study, we employed this lectin microarray to investigate the specifıc glycan
that covered pancreatic cancer cells with stem cell features. Firstly, we selected a
cell line which reflect clinical PDAC cells among 6 pancreatic cancer cell lines by
morphological analysis and cancer stem cell marker expressions. As previously
reported, we regarded Capan-1 cell line as a closest one which maintains both
self-renewal and differentiation capacity. As a result, we successfully identifıed
top 10 highlighted lectins which have signifıcant specifıcity to pancreatic cancer
cells. rBC2LC-N lectin was the most signifıcant one (P value  9.44E-17), fol-
lowed by ADA (P 7.05E-9), TJA2 (P 1.4E-8), ACG (P 1.11E-6).We recon-
fırmed the specifıc reactivity of these lectins to Capan-1 by FACS and lectin
histochemistry. rBC2LC-N lectin reactivity in 70 clinical cases of PDACrevealed
that all cases were confırmed to be positive. Furthermore, we investigated this
rBC2LC-N lectin have a high affınity to residual cancer cells after gemcitabine
treatment in patient derived xenograft models. These reactions well agreed with
those of undifferentiated iPS/ES cells. These coincidental match of glycan ex-
pression between on iPS/ES cells and on pancreatic cancer cells may suggest a
great benefıt to understand the ambiguous stem cell recognition in cancer com-
munity and novel therapeutic strategy.
#5232 The molecular basis for specifıc recognition of the biologically rel-
evant hybrid-2 type human telomeric G-quadruplex by epiberberine. Clem-
ent Lin,1 GuanhuiWu,1 Yong Shao,2 Danzhou Yang1. 1Purdue University, West
Lafayette, IN; 2Zhejiang Normal University, China.
G-quadruplex structures have been shown to form in human telomeres, and
the formation of G-quadruplexes can inhibit telomerase, which plays a key role
in cancers by stabilizing telomere length and integrity thereby granting limitless
replicative potential. The human telomeric G-quadruplex is thus considered to
be a potential target for cancer therapeutics. In physiologically relevant potas-
sium solution, human telomericDNA sequences form two equilibrating hybrid-
type G-quadruplex structures, with the hybrid-2 structure being the predomi-
nant form in extended sequences. We discovered that epiberberine (EPI), a
naturally occurring protoberberine alkaloid, can specifıcally bind the hybrid-2
human telomeric G-quadruplex and can induce the conversion to the hybrid-2
structure. Using nuclear magnetic resonance (NMR) spectroscopy, we deter-
mined the solution structure of the 1:1 complex of EPI and hybrid-2 human
telomeric G-quadruplex. Our NMR structure shows EPI bound at the 5= end of
the hybrid-2 telomeric quadruplex with an unexpectedly large drug-induced
conformational change in the flanking and loop regions, creating a very well-
defıned drug binding pocket with extensive capping structures. The EPI mole-
cule and 5= flanking adenine form an induced quasi-triad plane which is inter-
calated between the external 5= tetrad and capping structures. Two layers of new
capping structures are formedwith the 5= flanking segment and the second TTA
lateral loop to cover the “intercalated quasi-triad”. Notably, the well-defıned
EPI-induced multi-layer binding-site arrangement is only possible in the hy-
brid-2 folding topology of telomeric DNA. Our results provide important in-
sights into specifıc targeting of the physiologically relevant hybrid-2 human
telomeric G-quadruplex by a small molecule compound; EPI’s asymmetric cres-
cent-shape and the positioning of its dioxolane moiety, as well as the hybrid-2
folding and the loop and flanking bases in the human telomeric DNA sequence,
all contribute toward the specifıc recognition of EPI. In addition, we have con-
ducted polymerase stop assays, which confırmed that EPI can stabilize the hu-
man telomeric G-quadruplex to inhibit polymerase activity.
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#5233 Pancreatic cancer specifıc glycosylations survay by a panel of lectin
staining; Tn antigen exposure as a result of o-glycan truncation. Yusuke
Ozawa,1 Tatsuya Oda,1 Osamu Shimomura,1 Hiroaki Tateno,2 Jun Hi-
rabayashi,2 Nobuhiro Ohkohchi1. 1University of Tsukuba, Tsukuba, Japan; 2Na-
tional Institue of Advanced Industrial Science and Technology, Japan.
The outermost coating of every cell type is predominantly composed of cell-
specifıc glycans, and glycosylation changes in cancer has been used in clinical
fıeld as a tumor markers, such including AFP and CA19-9. We focused pancre-
atic cancer, the most intractable cancer with diffıculty in early diagnosis, and
insisted to glasp glycosylation patterns by using a panel of lectin histochemical
stainings. Lectins are subgroup of proteins that specifıcally recognize and bind
glycans, and thus helpful indication of glycosylation patterns. Lectin microarry
is one of the advanced technologies which inables glycosylation patters of target
materials at onece, however, obtained data with homogenized protein matelials
applied lacks histological location and information. Instead, we used a panel of
20 types of lectins histochemical staining for cancer and normal tissues. The
staining patterns were fırstlly classifıed according to the ratio between cancer
cells and stromal cells. a) Cancer high (cancer cell  and stromal cells -) b)
equal (cancer cells or and stromal cells or) c) Cancer Low (cancer
cells - or and stromal cells or). Further more, the stainig in cancer cell
were compaired with that of non cancerous pancreatic ductal epitherial cells.
Among 20 lectins, CNL, Clitocybe nebularis Lectin binds motifs containing
	/GalNAc, Tn antigen, and blood group A, showed cancer cell staining higher
than normal tissue in pancreatic cancer. Pancreatic cancer cell (31 of 58 pa-
tients,71%) were positive for CNL, but normal pancreatic duct cells (2 of 42
patients,4%) were positive in patients of pancreatic cancer. CNL is known to
recognize Tn Antigen in O-glycosylation. Previously, it reported that during
malignancy, glycosylation displays abnormal expression of shortened or trun-
cated glycans, such as a Tn antigen, T antigen and their sialylated forms, ST, STn
antigen. CNL staining pattern we showed in this report is considered to match-
ing Tn staining. Our result indicated that speccifıc affınity of CNL lectin in
pancreatic cancer and counterpart glycoprotein are STn antigen. We may insist
that STn glycoprotein antigen could be used as a diagnosticmarker of Pancreatic
cancer and also it would be a target of new tumor-targetting strategies.
#5234 Expression of cytochrome P450 in head and neck cancer cell lines.
Daniela F. Presa,1 Goreti Ribeiro Morais,1 Mark Sutherland,1 Jim McCaul,2
Jacques Robert,3 Laurence Patterson,1 Klaus Pors1. 1Institute of Cancer Thera-
peutics, University of Bradford, Bradford, United Kingdom; 2The Royal Marsden
NHS Foundation Trust, London, United Kingdom; 3Institut Bergonié, University
of Bordeaux, Bordeaux-cedex, France.
Background: The high expression of cytochrome P450 (CYP) enzymes in-
cluding isoforms CYP1A1, 1B1 and 2W1 in some tumor types compared to
normal tissue make these potential targets for targeted drug discovery. Our
efforts in this space have resulted in the discovery of duocarmycin bioprecursors
that are bioactivated by CYP1A1 and CYP2W1 expressed in malignant tis-
sues1-2. Epidemiological studies have shown that head andneck cancer (HNC) is
a complex multistage process that in part involves exposure to a combination of
carcinogens and the capacity of certain drug-metabolising enzymes including
CYPs to detoxify or activate such carcinogens.Here, we report on the expression
of CYP1A1, CYP1B1 and CYP2W1 in HNC cell lines and human primary tis-
sues. Materials and methods: A panel of HNC cell lines (FaDu, Detroit-562,
A253, OSC19) was characterized for CYP1A1, CYP1B1 and CYP2W1 gene ex-
pression using real time PCR. Furthermore, immunofluorescence (IF) was used
to detect protein expression in HNC cell lines and immunohistochemistry
(IHC) in xenografts, paraffın-embedded and snap-frozen human HNC tissue.
Anti-proliferative activity wasmeasured using theMTT assay andDNAdamage
was measured using the comet assay. Results: In the HNC cell lines signifıcant
expression (5-10 fold) was shown at the gene level for CYP1A1 and CYP1B1
whereas CYP2W1 was hardly detected. However, CYP2W1 was expressed in
FaDu andDetroit xenografts and in a small cohort of 10 humanHNC samples as
measured by IF and IHC, respectively. In agreement with CYP1 expression, the
cytotoxicity results of ICT2700 and ICT2706 revealed FaDu and Detroit-562 as
the most sensitive HNC cell lines suggesting bioactivation of these two lead
duocarmycin bioprecursors. Conclusion: Accordingly, from these data we can
conclude that CYP1A1, CYP1B1 and CYP2W1 are expressed in selected HNC
cell lines and tumor tissue. In addition, early evidence suggests that CYP2W1
expression is stimulated by the presence of an in vivo microenvironment. How-
ever a larger cohort ( 60) of clinical HNC samples will be used to confırm this
observation and will be reported at the annual AACR meeting. [1] Sheldrake et
al.Reengineering of the duocarmycin structural architecture enables bioprecur-
sors development targeting CYP1A1 and CYP2W1 for biological activity. J Med
Chem. 2013, 56, 62737. [2] Travica et al. Colon cancer-specifıc cytochrome P450
2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Can-
cer Res. 2013, 19, 295261.
#5235 Affecting activity of the linear ubiquitin chain assembly complex
(LUBAC) with stapled alpha-helical peptides. Amanda L. Whiting, Francisco
Aguilar-Alonso, Joseph J. Mitala, Federico Bernal. Center for Cancer Research,
National Institutes of Health, Frederick, MD.
The linear ubiquitin chain assembly complex (LUBAC) is the only E3 ubiq-
uitin ligase known to generate linear polyubiquitin chains in vitro. LUBAC is
composed of three proteins - HOIL-1L, HOIP and SHARPIN - of which the
interaction between HOIL-1L and HOIP has been shown to be critical for
LUBAC assembly and function. This interaction occurs between the ubiquitin-
like (UBL) domain of HOIL-1L and the ubiquitin-associated (UBA) domain of
HOIP. One known substrate of LUBAC is the regulatory subunit NEMO (NF
kappa B essential modulator), part of the IKK complex, which results in activa-
tion of NF-B. We hypothesize that disruption of the HOIL-1L-HOIP interac-
tionwould prevent LUBACubiquitylation activity and result in down-regulated
activation of NF-B. We have synthesized a family of small inhibitor peptides
designed to mimic aspects of the bent alpha-helical interacting interface of
HOIP-UBA. Here we demonstrate how single amino acid substitutions and
hydrocarbon stapling can affect overall peptide shape and helicity, and correlate
that structural information to peptide binding affınity, ability to affect LUBAC
complex formation and resulting effect on LUBAC ubiquitylation activity in
vitro. These fındings continue to validate inhibition of LUBAC via interference
with theHOIL-1L-HOIP interaction as a potential target to affect NF-B signal-
ing. Compounds which affect LUBAC activity have potential use in LUBAC-
dependentNF-B activation in the activated B cell-like (ABC) subtype of diffuse
large B-cell lymphoma (DLBCL), the DLBCL subtype that is most resistant to
current therapies.
#5236 The dynamic interplay between the cancer genome mutating en-
zymeAPOBEC3B andDNA substrates.OzlemDemir,1 Jeffrey R.Wagner,1 Ke
Shi,2 Michael A. Carpenter,2 Surajit Banerjee,3 Nadine M. Shaban,2 Kayo Kura-
hashi,2 Daniel J. Salamango,2 Jennifer L. McCann,2 Gabriel J. Starrett,2 Justin V.
Duffy,2 Daniel Harki,2 Hideki Aihara,2 Rommie E. Amaro,1 Reuben S. Harris2.
1University of California, San Diego, La Jolla, CA; 2University of Minnesota,
Minneapolis, MN; 3Cornell University, Lemont, IL.
The APOBEC3 (A3) family of enzymes catalyze deamination of cytosines to
uracils (C-to-U) in single-stranded (ss)DNA, and is an important part of innate
immune responses against viruses and transposons. Recent data also indicate
that APOBEC3B (A3B) is a major source of genomic mutations in multiple
cancers and a contributor to the evolution of drug resistance. A3B is therefore a
promising anti-cancer target. Using existing structural information and struc-
turalmodeling, we generated amodel forwild-typeA3B in complexwith ssDNA
andusedmolecular dynamics tomonitor the dynamics of the native interactions
of wild-type A3B with ssDNA. The details of A3B-ssDNA interaction and its
implications for potential inhibitor design will be presented.
#5237 Targeting DCN1-mediated neddylation in lung SCC with novel
small-molecule inhibitors. Richard Barrios,1 Jared Hammill,2 Jaeki Min,2 Kip
Guy3. 1FIU Herbert Wertheim College of Medicine, Miami, FL; 2St. Jude Chil-
dren’s Research Hospital, Memphis, TN; 3University of Kentucky College of Phar-
macy, Lexington, KY.
Due to the anti-neoplastic properties and clinical successes of the proteasome
inhibitors Bortezomib andCarfılzomib, the ubiquitin-proteasome system (UPS)
has become a new target of interest in oncology research. The clinical toxicity
induced by these inhibitors, likely caused by complete inhibition of the UPS, has
resulted in a need for the development ofmore selective UPS regulators. Amore
in depth understanding of the intrinsic molecular mechanisms that are associ-
ated with the UPS has unmasked the potential for improved therapies via more
specifıc targets such as the process of neddylation, which is thought to control
15 - 20% of the UPS (5). During neddylation, an enzyme known as DCN1 for
“defective in cullin neddylation 1” functions as a co-E3 to help steer a ubiquitin-
like protein (UBL), NEDD8, from an E2 enzyme, UBC12, to a cullin (CUL)
neddylation site (6 - 7, 9 - 11). Because DCN1 has been found to be amplifıed in
certain squamous cell carcinomas (9) (SCCs; e.g. lung, esophagus, and head and
neck), this in vitro, pre-clinical study demonstrates the potential of the DCN1-
UBC12 interaction as a therapeutic site in lung SCCs through the use of novel
small-molecule inhibitors from the St. Jude (SJ) library. After optimizing dosing
regimens, it has been determined that re-administering the SJ compounds (i.e.
SJ690, SJ447, SJ446, and SJ323) every 24-hours to address the issue of protein
turn-over, producesmore effıcacious treatment. Themost biochemically-potent
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antagonists in the compound serieswere also shown in these primary cell lines to
potentiate other therapeutic agents such as Cisplatin; however, these com-
pounds alone do not induceDNAdamage, nor do they elicit caspase 3/7 activity.
Nonetheless, combination treatment of the SJ compoundswith Staurosporine in
SCC cell lines, potentiated caspase 3/7 activity at varying degrees. Collectively,
this data enhances our understanding of themechanism bywhich the inhibition
of DCN1 affects cancer cells, informing pre-clinical development of the SJ
DCN1 antagonists.
#5238 Structural and biochemical characterization of membrane bound
KRAS. Andrew G. Stephen,1 Que Van,1 Marco Tonelli,2 William Gillette,1
Dominic Esposito,1 Ben Niu,3 Michael Gross,3 Frank Heinrich,4 Arvind Ra-
manathan,5 Christopher Stanley5. 1Frederick National Laboratory for Cancer
Research, Frederick, MD; 2National Magnet Resource Facility at Madison, Mad-
ison, WI; 3Washington University in St. Louis, St. Louis, MO; 4Carnegie Mellon
University, Pittsburg, PA; 5Oak Ridge National Laboratory, Knoxville, TN.
KRAS4b functions as a molecular switch cycling between an active GTP
bound state and inactive GDP state. Active KRAS4b binds tightly to RAF1 via its
Ras binding domain (RBD), however activation of RAF1 competent for MAPK
signal transduction requires membrane bound KRAS4b. Using recombinant
farnesylated and methylated KRAS4b (KRAS4b-FMe) we have used a variety of
biophysical methodologies including paramagnetic relaxation enhancement
NMR, neutron reflectivity, small angle neutron and x-ray scattering and protein
footprinting to gain insights into the orientation and structure of KRAS-FMe
bound to amembrane. In these experiments we have usedNanodiscs or tethered
lipid bilayers composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-choline
or -serine (70%POPC30%POPS).Our data indicate thatKRAS-FMe is oriented
perpendicular to the membrane with minimal direct contacts to the membrane.
The nucleotide bound state does not signifıcantly change the orientation relative
to the membrane. We will also present data on the effect of the RBD domain of
RAF1 binding to KRAS-FMe at the membrane.
#5239 Probing the cancer epigenome: empowering target validation by
open innovation. Ingo V. Hartung,1 Cheryl Arrowsmith,2 Volker Badock,1
Naomi Barak,1 Markus Berger,1 Peter J. Brown,2 Clara D. Christ,1 Erik Eggert,1
Ursula Egner,1 Oleg Fedorov,3 Amaury E. Fernandez-Montalvan,1 Matyas Gor-
janacz,1 Andrea Haegebarth,1 Bernard Haendler,1 Roman C. Hillig,1 Simon H.
Holton,1 KilianV.Huber,3 Seong J. Koo,1 Antonius ter Laak,1 SusanneMueller,3
Anke Mueller-Fahrnow,1 Cora Scholten,1 Stephan Siegel,1 Timo Stellfeld,1 De-
tlef Stoeckigt,1 Carlo Stresemann,1 Masoud Vedadi,2 Joerg Weiske,1 Hilmar
Weinmann1. 1Bayer AG, Berlin, Germany; 2University of Toronto, Toronto, On-
tario, Canada; 3Oxford University, Oxford, United Kingdom.
Low reproducibility of published target validation studies as well as the fre-
quent failure of genetic knock-down effects to phenocopy those of small mole-
cule inhibitors have been recognized as road blocks for cancer drug discovery.
Academic and industrial institutions have started to address these issues by
providing access to high quality small molecular probes for novel targets of
interest. Here we discuss probe discovery challenges and quality criteria based
on the generation of three novel inhibitors for epigenetic targets. ATAD2
(ATPase family AAA-domain containing protein 2) is an epigenetic regulator
that binds to chromatin through its bromodomain (BD). ATAD2 has been pro-
posed to act as a co-factor for oncogenic transcription factors such as ER	 and
Myc. A more thorough validation of ATAD2 as a therapeutic target has been
hampered by the lack of appropriate ATAD2 inhibitors. Here we disclose a
structurally unprecedented series of ATAD2 BD inhibitors identifıed from a
DNA-encoded library screen. Optimization delivered BAY-850, a highly potent
and exceptionally selective ATAD2 BD inhibitor, which fully recapitulates ef-
fects seen by genetic mutagenesis studies in a cellular assay. The three BD and
PHD-fınger (BRPF) family members are found in histone acetyltransferase
complexes. Whereas bromodomain inhibitors with dual activity against BRPF1
and 2 have been described before, we nowdisclose BAY-299, the fırst nanomolar
inhibitor of the BRPF2 BD with high selectivity against its paralogs. Isoform
selectivity was confırmed in cellular protein-protein interaction assays and ra-
tionalized based on X-Ray structures. BAY-598, a highly selective, cellularly
active and orally bioavailable inhibitor of the protein lysine methyl transferase
SMYD2, had been disclosed previously (Stresemann et al., AACR 2015). Devel-
opment of BAY-598 allowed the identifıcation of new methylation targets of
SMYD2 as well as a proposed role of SMYD2 in pancreatic cancer. These results
support further development of small molecule inhibitors as research tools to
probe the functional role of novel epigenetic targets and underscore the power of
open innovation for advancing our understanding of cancer target biology.
#5240 Induction of molecular endpoints by reactive oxygen species in
human lung cells predicted by physical- chemical properties of engineered
nanoparticles. Jeffrey A. Ross, Garret B. Nelson, Carlton Jones, Sheau-Fung
Thai. Environmental Protection Agency, Research Triangle Park, NC.
A series of six titanium dioxide and two cerium oxide engineered nanomate-
rials were assessed for their ability to induce cytotoxicity, reactive oxygen species
(ROS), and various types of DNA and protein damage in human respiratory
BEAS-2B cells exposed in vitro for 72 hours at several concentrations. Although
only limited cytotoxicity was observed at concentrations up to 300g/ml for all
of the nanomaterials, signifıcant increases in 8-oxo-deoxyguanosine, lipid per-
oxidation mediated protein adducts, and endogenous DNA adducts measured
by 32P-postlabeling were detected at concentrations as low as 30g/ml, suggest-
ing that molecular changes associated with ROS induction may provide a better
means of assessing the low-dose hazards posed by nanomaterials. To identify
molecular properties predictive of the ability of nanoparticles to induce ROS
sequelae, a least absolute shrinkage and selection operator multiple regression
approach has been used to identify relationships between assay outcomes and
nanoparticle physical/chemical properties, including particle size, surface area,
zeta potential, and elemental analysis. For several of the assay endpoints exam-
ined, concentrations of trace metals in the nanoparticles appear to be better
predictors of assay outcomes than physical properties. This is an abstract of a
proposed presentation and does not necessarily reflect EPA policy.
#5241 Using affınity probes to explore the nephrotoxicity of aristolochic
acid.Viktoriya S. Sidorenko, Kathleen G. Dickman, Thomas Rosenquist, Radha
Bonala, Sivaprasad Attaluri, Irina Zaitseva, Charles Iden, Francis Johnson, Ar-
thur P. Grollman. SUNY at Stony Brook, Stony Brook, NY.
Aristolochic acid, AA, is a natural compound found in Aristolochia plants
used in Chinese Traditional Medicine and is a component of many herbal rem-
edies used worldwide. In humans, exposure to AA is associated with kidney
toxicity and otherwise rare upper urinary tract cancer (UTUC). AA undergoes
bioactivation creating reactive species ofAA that bind covalently to proteins and
DNA. Formation of mutagenic AA-DNA adducts leads to AA-induced cancers.
We identifıed the mutational signature associated with AA exposure in patients
with UTUC in Taiwan, as well as in AA-initiated cancers in liver, bladder and
kidneys. Meanwhile, the mechanism of AA nephrotoxicity remained a mystery,
with covalent and non-covalent binding of AA or its metabolites to proteins
hypothesized to be involved in its nephrotoxic effects. As millions of people in
Asia have ingested AA and no effective therapies are known, establishing the
molecularmechanism(s) of AAnephrotoxicity is a topic ofmajor importance. A
series of AA analogs were used to design affınity probes for target identifıcation.
Structure activity relationship studies in human cells aided in identifying a po-
sition inAA suitable for introducing biotinylated, aminopropyl and alkyne link-
ers. In addition, we have developed and validatedmonoclonal antibodies against
AA-bovine serum albumin and/or AA-DNA covalent adducts. Combined with
proteomics techniques, AA-affınity probes and monoclonal antibodies provide
powerful tools for defıning AA targets in human kidneys. We attached the
aminopropyloxy derivative of AA to magnetic beads coated with N-hydroxy-
succinimido acyl linkers. These probes, in parallel with unmodifıed, “control”
beads were incubatedwith renal cortex lysates obtained fromC3Hmice selected
for their sensitivity to the effects of AA. Bound proteins were digested ‘on bead’,
then identifıed bymass spectroscopic peptide analysis, with a total of 316 bound
proteins detected. Spectral counts for 128 proteins bound to AA-beads were
higher than those for control beads. After correction for nonspecifıc binding, 18
of these proteins had spectral counts of 10 or higher. These proteins are localized
to various organelles, indicating high coverage of themajor subcellular compart-
ments. Among these proteins, Cryzl2, quinone oxidoreductase-like 2, was the
leading candidate. Based on homology, Cryzl2 belongs to the family of the qui-
none oxidoreductase-like protein and bears a mitochondrial localization se-
quence. This protein retains conserved domains for both quinone oxidoreduc-
tase activity andNAD(P) binding sites, which is of particular interest since other
oxidoreductases, such as NQO1, are known to catalyze nitroreduction, the ini-
tial step in the bioactivation of AA. In summary, our studies provide guidelines
for design of AA-affınity probes and reveal an enzyme that may be responsible
for AA activation in mitochondria, by generating active intermediates and in-
ducing mitochondrial damage in renal tissue.
#5242 Further evidence that the DNA-interactive Pyrrolobenzodiazepine
(PBD)Dimer SJG-136works through a transcription factor inhibitionmech-
anism. Julia Mantaj,1 Paul J. Jackson,2 David E. Thurston,1 Khondaker Miraz
Rahman1. 1King’s College London, London, United Kingdom; 2Femtogenix Lim-
ited, London, United Kingdom.
CANCER CHEMISTRY: Chemical Biology and Structure Biology Approach to Study Cancers
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171342
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are sequence-selective DNA
minor-groove interacting agents. The PBD dimer SJG-136 has currently been
investigated in Phase II clinical trials in ovarian cancer and leukaemia in the UK
and the USA. More recently, PBD dimer analogues are being attached to tu-
mour-targeting antibodies to create Antibody-Drug Conjugates (ADCs), some
which are now in Phase 3 clinical trials with many others in pre-clinical and
clinical development. Transcription factors (TFs) are sequence-specifıc DNA-
interacting proteins that bind to consensus DNA sequences, thereby controlling
transcription. TFs regulate processes such as cell differentiation, proliferation
and apoptosis. The interaction of a small-molecule with the consensus DNA
recognition sequences of TFs can prevent a TF from interacting with its cognate
sequence, thereby inhibiting the expression of genes critical for the survival and
proliferation of cancer cells. There is growing evidence that PBDs may exert, at
least in part, their pharmacological effect through TF inhibition in addition to
the arrest of the replication fork, DNA strand breakage, and inhibition of en-
zymes including endonucleases and RNA polymerases. For this reason, there is
now interest in using PBDs as the basis for a small-molecule strategy to target
specifıcDNAsequences for TF inhibition as a novel anticancer therapy.Wehave
developed a reversed-phase HPLC/MS method as a tool to evaluate the interac-
tion of DNA-binding PBD molecules with oligonucleotides of varying lengths
and sequences. Using this methodology, we have demonstrated that the PBD
dimer SJG-136 binds to the cognate sequences of the oncogenic transcription
factors NF-B, EGR-1, AP-1 and STAT3. Surprisingly, signifıcant differences in
the rate and extent of adduct formation between the different cognate sequences
were observed which may explain, at least in part, the differences in potency of
SJG-136 in various tumour cell lines. Furthermore, an RT PCR study has been
carried out using the human tumour cell lines MDA-MB-231 (breast) and
HT-29 (colon) to see whether these transcription factors are affected in vitro.
The results were consistent with the HPLC-MS studies in that SJG-136 was
shown to signifıcantly down-regulate a number ofAP-1- and STAT3-dependent
genes such as Bcl-2, VEGF, p53 and survivin. These fındings add signifıcantly to
knowledge of themechanism of action of SJG-136 and related PBD compounds,
and could be relevant for the correct interpretation of clinical activity of mole-
cules of this type both as standalone agents and as ADC payloads.
PREVENTION RESEARCH: Chemoprevention and Cancer
#5243 Novel non-COX inhibitory sulindac derivative with-catenin sup-
pressing activity reduces the formation of colorectal adenomas and adeno-
carcinomas in theAPC/min-FCCCmousemodel.Kevin J. Lee,1 Xi Chen,1 Jacob
Valiyaveettil,1 Ashley S. Lindsey,1 Joel Andrews,1 Veronica Ramirez-Alcantara,1
Adam B. Keeton,1 Gary A. Piazza,1 Harry Cooper,2 Margie Clapper,2 Wen-Chi
L. Chang2. 1Univ. of South Alabama Mitchell Cancer Inst., Mobile, AL; 2Fox
Chase Cancer Center, Philadelphia, PA.
Sulindac can reduce the number and size of precancerous colonic adenomas in
patients with familial adenomatous polyposis (FAP), but is not recommended for
long-term use as a cancer chemopreventive drug because of potentially fatal toxici-
ties associated with cyclooxygenase (COX) inhibition. Here we characterize the an-
tineoplastic properties of a novel sulindac derivative, ADT-061, that lacks COX-1
and COX-2 inhibitory activity. ADT-061 potently and selectively inhibited colon
tumor cell growth in vitro with IC50 values of 0.3-0.5 M by inducing apoptosis
without affecting the growth of normal colonocytes at concentrations 100x higher.
By comparison, sulindac sulfıde (SS) inhibited colon tumor cell growth with IC50
values of 40-60 M, and had only modest tumor cell selectivity. While SS non-
selectively inhibits multiple cyclic GMP phosphodiesteraes (PDE) isozymes, previ-
ous studies have suggested an important role for PDE10 in colon cancer (Li et al,
Oncogene, 2014; Lee et al, Oncotarget, 2015). At concentrations comparable to its IC50
values,ADT-061 selectively inhibitsPDE10 to inducean increase in intracellular cGMP
levels and activate protein kinase G (PKG). ADT-061 also suppressed nuclear levels of
-catenin and induced cell cycle arrest and apoptosis, within the same concentration
range that inhibits tumor cell growth.With attractive drug-like properties, the che-
mopreventive activity ADT-061was assessed using the APC/min-FCCC mouse
model of spontaneous colorectal tumorigenesis. Prior to treatment, colonoscopy
exams were performed on all APC/min-FCCC mice (males, 6-7 weeks of age) to
ensure the absence of colorectal adenomas. At 7-8weeks of age,mice were assigned
(19 per group) to receive either unsupplemented chow (control) or chow supple-
mented with ADT-061 (1500ppm) for 14 weeks. No discernible toxicity was ob-
served during the experimental period. Double-blinded pathological analysis of
fıxed colon tissues revealed that ADT-061 not only reduced the multiplicity of co-
lonic adenomas by 50% (Mean SEM, control vs. ADT-061, 3.95 0.81 vs. 1.95
0.58, P  0.05), but also decreased the incidence of colonic adenomas by 36.7%
(control vs. ADT-061, 94.7% vs. 57.9%, respectively). ADT-061 treatment reduced
the multiplicity of polypoid adenomas (36%), flat adenomas (100%, P 0.05), and
microadenomas (69%). The formation of colonic adenocarcinomas found in 15.8%
of untreatedmice was completely inhibited inmice treated with ADT-061. These data
indicatethatADT-061inhibitscolontumorigenesiswhengiventoAPC/min-FCCCmice
prior to the detection of gross colonic tumors. These observations support further eval-
uationofADT-061 and analogs for colorectal cancer chemoprevention.
#5244 Partial knockdown of RLIP76 prevents cancer susceptibility of p53
null mice. Sharad S. Singhal,1 Jyotsana Singhal,1 Joshua Tompkins,1 David
Horne,1 XiweiWu,1 Arthur Riggs,1 Sanjay Awasthi2. 1City of Hope, Duarte, CA;
2Texas Tech Health Science Center at Lubbock, Lubbock, TX.
P53 is a stress-responsive, genomeprotective, tumor suppressorwhose functions
are lost or altered in nearly all neoplasia. P53 homozygous knockout mice (p53-/-)
develop spontaneous lymphoma and othermalignancies in nearly 100%of cases by
6months of life. In stark contrast, homozygous gene knockout of the stress-respon-
sive, anti-apoptotic, mercapturic acid pathway transporter protein, RLIP76, results
in marked protection from chemical carcinogenesis. P53 expression and activation
is regulated by intermediary metabolites of this pathway, and p53 regulates the ex-
pression of key enzymes of this pathway. P53 can directly bind to RLIP76 through a
CDK-interaction domain, and inhibit its transport activity as well as endocytosis
stimulatory activity. These results indicate that RLIP76 is an effector of p53 in a
manner analogous to its known function as the fırst known effector of the Ral path-
ways that regulate membrane plasticity, motility and invasion. This translates into
reduced kinase signaling down-stream of membrane-receptor/ligand interactions.
An inverse relationshipbetweenRLIP76andp53proteinandmRNAexpressionhas
been observed in-vitro, and is confırmed by analysis of human cancer genomic
analyses in the COH database. RLIP76 depletion causes apoptosis in cancer cells
independent of p53 status, strengthening the view that RLIP76 is key down-stream
effector of p53. We reasoned that if RLIP76 is necessary for cancer to develop in
p53-defıcient animals, its suppression will reduce the incidence of malignancy in
12-week old p53-/-mice treatedwithCOHSA007phosphorothioated antisense, 200
g i.p.q.2wk till age 8 months. Results of our studies confırmed these predictions,
since 4/4 scrambled antisense treated p53-/- mice developed T-cell lymphoma
whereas 8/8 COHSA007 treated p53-/- mice survived to the end of the experiment
withoutdevelopmentof anymalignancy.These fındingsdemonstrate thatRLIP76 is
required formalignancy in the p53-/-mice. Taken in context of our previous studies
showing thatRLIP76-/-micearehighly resistant to inflammationandcarcinogenesis
inchemical carcinogenesismodelsof the skinand lung, thepresent fındings strongly
support the idea of an existential role of RLIP76 in the malignant phenotype, and
strengthen the rationale for using targeted systemic depletion of RLIP76 for treat-
ment of human neoplasia (Supported in part by the Department of Defense grant
(W81XWH-16-1-0641) and USPHS grant CA 77495).
#5245 Peretinoin prevents the accumulation of somatic gene mutations
and reverts neoplastic lesions to normal liver-like in platelet-derived growth
factor-c transgenic mice. Taro Yamashita, Hikari Okada, Masao Honda, Shui-
chi Kaneko. Kanazawa University Hospital, Kanazawa, Japan.
Hepatocellular carcinoma (HCC) develops with progressive accumulation of
multiple genetic changes. An acyclic retinoid peretinoin is reported to suppress
the development of HCC, but the molecular mechanism in detail remains to be
obscure.Herewe evaluated the effect of peretinoin onpreneoplastic nodules and
HCC developed in platelet derived growth factor-c (PDGF-C) transgenic mice
liver by gadolinium ethoxybenzyl diethylenetriamide pentaacetic acid (Gd-
EOB-DTPA)-enhanced magnetic resonance imaging (MRI) and whole exome
sequence analysis. We confırmed the progressive accumulation of somatic mu-
tations in hypervascular liver cancer tissues compared with hypovascular pre-
cancerous tissues and non-cancerous background liver tissues in PDGF-C
transgenic mice. Surprisingly, peretinoin treatment in HCC as well as preneo-
plastic nodules resulted in the accumulation of less gene mutations compared
with vehicle. Gd-EOB-DTPA uptake capacity and its transporter OATP1 was
confırmed to be re-activated in peretinoin treated nodules in mice. Gene and
protein expression analysis indicated the inactivation of cell cyclewith lowKi-67
labeling indexes in peretinoin treated nodules. The reversion of Gd-EOB-DTPA
uptake capacity was confırmed in preneoplastic nodules and a subset of classical
hypervascular HCCs. Notably, peretinoin supplementation induced the expres-
sion of OATP1B3 in mature hepatocyte-like HCC cell lines in vitro, whereas
supplementation of tretinoin (all-trans retinoic acid) had no such effects and
rather suppressed OATP1B3. Taken together, our data suggested the utility of
peretinoin to revert the malignant transformation processes of hepatocytes by
preventing accumulation of gene mutations especially in early stages of hepato-
carcinogenesis. Peretinoin but not tretinoin can induce the expression of a ma-
CANCER CHEMISTRY: Chemical Biology and Structure Biology Approach to Study Cancers
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1343
ture hepatocytemarkerOATP1B3, suggesting that peretinoinmay exert its anti-
tumor effect with hepatocytic differentiation capacity independently of the
activation of retinoic acid signaling.
#5246 Effects of bazedoxifene either alone or in combination with letro-
zole in the prevention of chemically induced mammary cancers. Barbara K.
Dunn,1 Chen Suen,1 Ronald A. Lubet,1 Vernon E. Steele,1 Clinton J. Grubbs2.
1NCI, Bethesda, MD; 2Univ. of Alabama Comp. Cancer Ctr., Birmingham, AL.
Bazedoxifene is a third-generation selective estrogen receptor modulator
(SERM) that has been clinically approved in Europe for the prevention and
treatment of postmenopausal osteoporosis. The agent has also been shown to
have therapeutic activity against estrogen receptor positive (ER) breast cancer.
Our laboratory is currently evaluating bazedoxifene for chemopreventive effı-
cacy when given alone or in combination with the aromatase inhibitor (AI)
letrozole. Initially, the agents were evaluated alone to determine effective che-
mopreventive doses in the methylnitrosourea (MNU) ERmammary cancer
model using female Sprague-Dawley rats. Bazedoxifene was mixed directly into
a standard (Teklad, 4% fat) diet, while letrozole was gavaged 7x/week (vehicle
was ethanol: PEG 400, 10:90, v/v).When evaluated alone in rats receivingMNU
at 50 days of age, bazedoxifene (started oneweek afterMNU) at doses of 100 and
30 mg/kg diet decreased mammary cancer multiplicity by 93 and 88%, respec-
tively. In a similar protocol, letrozole at a dose of 0.1 mg/kg BW/day reduced
cancer number (multiplicity) by 89%, while a dose of 0.05 mg/kg BW/day re-
duced the number by 47%. In a separate study evaluating lower doses (MNUalso
given to rats at 50 days of age), bazedoxifene at a dose of 5 mg/kg diet and
letrozole at a dose of 0.04 mg/kg BW/day both decreased mammary tumor
multiplicity by 73%. When the agents were given in combination at these lower
dose levels, cancer numberwas reduced by 91%.An additional studywas done in
which the agents were given to rats receiving MNU at an older age (100 days).
Rats receiving the agents at the original doses beginning one week after MNU
(bazedoxifene at 30 mg/kg diet; letrozole at 0.1 mg/kg BW/day) had identical
decreases in mammary tumor development (96%). It is obvious that bazedox-
ifene is as effective as letrozole in the prevention ofmammary cancers evenwhen
initiated in older rats. Furthermore, administration of the agents in combination
suggests an additive effect. The large increase in body weight gain generally
noted in letrozole treated rats was not observed in rats receiving bazedoxifene; of
interest, rats receiving the combination also had no increase in body weights.
These studies indicate that bazedoxifenemay be superior to other SERMs in that
chemopreventive effıcacy is achieved at low doses, whichmay be associatedwith
less toxicity. Supported by NCI contract HHSN261201200021I, Task Order
HHSN26100007.
#5247 -Tocopherol inhibits the development of prostate adenocarci-
noma in prostate specifıc Pten-/- mice. Xu Yang,1 Wang Hong,1 Guocan
Wang,2 Anna Liu,1 Maarten c. Bosland,3 Chung s. Yang1. 1Rutgers, Piscataway,
NJ; 2MD Anderson Cancer Center, Houston, Piscataway, NJ; 3University of Illi-
nois at Chicago, Chicago, IL.
PTEN/PI3K/AKT axis plays a critical role in regulating cell growth, metabo-
lism,migration, differentiation, and survival. Activation of this signal pathway is
frequently found in human cancers. Data from our previous studies demon-
strated that 
-tocopherol (
-T) attenuates the activation of AKT by growth
factor in prostate cancer cell lines, leading to inhibiting proliferation and induc-
ing apoptosis. Herein, we investigated whether 
-T is able to inhibit the devel-
opment of prostate adenocarcinoma in prostate-specifıc Pten-/- (Ptenp-/-) mice,
inwhich the activation ofAKT resulted from loss of Pten is the driver. By feeding
Ptenp-/-micewith theAIN93Mor 0.2% 
-T supplemented diet starting at the age
of 6 or 12weeks, we found that, at the age of 40weeks, 
-T treatment reduced the
number of invasive prostate adenocarcinoma by 53.3% (p0.005) and 42.7%
(p0.001), respectively. By immunohistochemical analysis, the activation of
AKT via phosphorylation of AKT(T308) was found reduced in the prostate of
the mice on 
-T diet. Consistently, proliferation was reduced and apoptosis was
increased in prostate of the mice on 
-T diet. We also determined oxidative
stress by immunohistochemical staining of 8-OH-dG and nitro-tyrosine, and
found that these markers were not altered during prostate tumorigenesis, nor
theywere affected by 
-T.A 0.2%	-tocopherol dietwas also used to feedPtenp-/-
mice, but did not inhibit the development of prostate adenocarcinoma, consis-
tent with previous data demonstrating that 	-tocopherol did not inhibit the
activation of AKT. Together, these results support that 
-T is effective in su-
pressing the development of prostate adenocarcinoma in Ptenp-/- mice through
inhibition of AKT activation.
#5248 Pioglitazone prevents hepatocellular carcinoma development in a
ratmodel of cirrhosis. Shen Li, SaraniGhoshal, GunishaArora, Derek J. Erstad,
Michael Lanuti, Kenneth K. Tanabe, Bryan C. Fuchs. Massachusetts General
Hospital, Boston, MA.
Introduction:Advancedhepatocellular carcinoma (HCC) is a leading cause of
mortality worldwide with limited treatment options. There is a readily identifı-
able cohort of cirrhosis patients at risk and they are ideal candidates for chemo-
prevention.Anti-hyperglycemic agents have garnered interest for their potential
anti-fıbrotic as well as chemo-preventive effects. Pioglitazone, a selective
PPAR- agonist, has been shown to reduce non-alcoholic steatohepatitis
(NASH), but its role as an anti-fıbrotic and chemopreventive agent has yet to be
elucidated. The hypothesis of this study is that Pioglitazone reduces cirrhosis
and subsequent HCC development in rats with diethylnitrosamine (DEN)-in-
duced cirrhosis. Methods: Male Wistar received DEN 50mg/kg by intraperito-
neal injection. DEN injury reliably recapitulates histological and molecular fea-
tures of humanHCC development with induction of hepatic fıbrosis at 8 weeks,
cirrhosis at 12weeks, andHCCby 18weeks. DEN-injured rats were randomized
to receive oral gavage of pioglitazone at 3mg/kg/day (n9) or vehicle control
(n9). Initiation of pioglitazone coincided with the development of liver fıbro-
sis at 8 weeks. All animals were sacrifıced at 18 weeks. Results: As expected,
repeated injections of DEN in rats resulted in progressive fıbrosis, cirrhosis,
followed by HCC formation. Treatment with pioglitazone resulted in a 56%
reduction of surface nodules relative to treatment with vehicle (7.44.9 vs.
177; p0.005). Liver sections were stained by picrosirius red to assess fıbrosis
and pioglitazone signifıcantly reduced collagen deposition in DEN-injured rats
(collagen proportional area 3.21.8% vs. 9.22%; p0.035). This histologic
observation was further confırmed by gene expression analysis with reductions
in collagen-I, 	-smooth muscle actin, and transforming growth factor beta in
rats treated with pioglitazone. Finally, weekly injection of DEN also caused a
signifıcant decrease in overall body weight in comparison to untreated rats
(398.160 vs. 59846 grams; p0.015), and pioglitazone treatment resulted in
a trend for better protection of body weight relative to vehicle (398.160 vs.
427.556.3 grams). Conclusion: Overall our data supports the hypothesis that
the anti-diabetic agent pioglitazone may be repurposed as a drug to reduce
fıbrosis and prevent HCC. This could be benefıciary in patient management
given the low cost as well as minimal side effects.
#5249 Integrative analysis of transcriptomic, proteomic, and metabolo-
mic data ofPten-knockout carcinogenicmouseprostate. Jinhui Zhang,1 Li Li,1
Sangyub Kim,2 LeeAnn Higgins,3 Yibin Deng,4 Christopher J. Kemp,5 Cheng
Jiang,2 Junxuan Lu2. 1Texas Tech University Health Sciences Center, School of
Pharmacy, Amarillo, TX; 2Pennsylvania State University College of Medicine,
Hershey, PA; 3University of Minnesota, St.Paul, MN; 4The Hormel Institute -
University ofMinnesota, Austin,MN; 5FredHutchinson Cancer Research Center,
Seattle, WA.
The prostate-specifıc Pten-knockout (KO) mouse carcinogenesis model is
highly desirable for prostate cancer chemoprevention studies due to its close
resemblance of many histopathological features of human prostate cancer in-
cluding disease progression from prostatic intraepithelial neoplasia (PIN) to
invasive adenocarcinomas. Here, we profıled the prostate proteome, transcrip-
tome and aqueousmetabolome of Pten-KOmice to identify referencemolecular
signatures that can be used for designing chemopreventive and/or therapeutic
intervention and for selection ofmolecular biomarkers of responses to interven-
tion. For proteomics, 4 pairs of whole prostates from Pten-KO mice (12-15
weeks of age, corresponding to high grade PIN) and their wild type littermate
housed in same cages were obtained from theNCIMouseModel Repository and
analyzed by 8-plex iTRAQTM. For transcriptomic/microarray andmetabolomic
analyses, 3 additional matched pairs of prostate/tumor specimens at older age
(22-20 weeks) were used. Proteomic and transcriptomic analyses using manual
annotation methods with references from PubMed revealed top signatures that
were up- and down-regulated by Pten deletion, particularly those implicated in
immune function, inflammatory response, cancer, drug metabolism, cellular
functions, prostate functions, and endoplasmic stress regulation. Similar to the
manual annotation approach, each network analysis of 203 genes and 22 pro-
teins ( 2- fold changes) by a bioinformatics software, Ingenuity PathwayAnal-
ysis (IPA) showed that inflammatory response, cellular movement, immune cell
traffıcking, immunological disease, and cancer were top 5 disease and biological
functions in Pten-KO mice. Using references from PubMed, we manually as-
signed the unmapped prostate metabolites to functional categories, which in-
cluded altered methionine-cysteine cycle fluxes and purine metabolites, in-
creased nucleotide pools, cholesterol and polyamine synthesis and suppressed
pools of sugar and choline derivatives, glycolysis intermediates, and purine
bases. IPA network analysis of 25 metabolites ( 2- fold changes) revealed the
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biological functions related tomolecular transport, amino acidmetabolism, and
small molecule biochemistry. In addition, we integrated transcriptomic, pro-
teomic, andmetabolomic data sets to identify latent biological relationships and
to gain a comprehensive understanding of Pten-defıcient prostate carcinogene-
sis. The integrative analysis predicted activation of inflammatory response and
several central signaling nodes, such as IRF7, NF-B, and IL-6. Collectively, the
integrative analyses identify both active and latent reference molecular signa-
tures and provide more insight into Pten-defıcient prostate cancer than single
omic approaches.
#5250 Cranberry proanthocyanidins reverse microbial dysbiosis and in-
hibit bile acid metabolism in association with esophageal cancer prevention.
Katherine M. Weh,1 Nita H. Salzman,1 Amy B. Howell,2 Jennifer L. Clarke,3
Bridget A. Tripp,3 Laura A. Kresty1. 1Medical College of Wisconsin, Milwaukee,
WI; 2Rutgers University - Marucci Center for Blueberry and Cranberry Research,
Chatsworth, NJ; 3University of Nebraska - Lincoln, Lincoln, NE.
Our laboratory has been investigating the cancer inhibitory potential of
cranberry proanthocyanidins (C-PAC) against esophageal adenocarcinoma
(EAC), a cancer characterized by rapidly rising incident rates and poor sur-
vival (18% 5-year survival rate for all stages combined). Utilizing a panel of
validated human esophageal cancer cell lines and OE19 xenograft bearing
mice, our laboratory reported that C-PAC activates autophagic cell machin-
ery leading to caspase-independent cancer cell death, yet linked to bile acid
sensitivity. Reflux of bile and stomach acid into the lower esophagus is con-
sidered the major risk factor for progression to EAC. Building on our initial
research, we next investigated mechanisms by which C-PAC inhibits reflux-
induced EAC with a focus on gut microbiome alterations and modulation of
bile acid metabolites. Bile acids undergo secondary metabolism in the intes-
tinal tract, but have not been evaluated in this context. We utilized the rat
surgical esophagogastroduodenal anastomosis (EGDA) model for reflux-
induced EAC. EGDA and non-surgical Sprague Dawley rats were treated
with water or C-PAC (650 g/rat/day) for 25 or 40 weeks and assessed for
cancer progression via extensive histopathological characterization. Addi-
tionally, at 40 weeks, fecal microbiome profıling was investigated and meta-
bolic profıling conducted on esophageal, liver and fecal samples. Methods
included 16s rRNA sequencing of rat fecal DNA, paired end sequencing on
Illumina MiSeq and data analysis using Qiime and the R packages phyloseq,
and edgeR to assess C-PAC-induced microbiome changes. For metabolite
profıling homogenized esophagi, liver and fecal samples were extracted in
methanol and characterized by Reverse Phase Ultra high Performance Liq-
uid Chromatography-Tandem Mass Spectrometry RP/UPLC-MS/MS, fol-
lowed by metabolite identifıcation based on Metabolon’s library of authen-
ticated standards. Study results support that C-PAC signifıcantly inhibits the
formation of EAC with concomitant restoration of the gut microbial profıle,
i.e., the bacterial profıle shifted toward increased favorable Gram Firmic-
utes and away from inflammatory-linked Gram negative Bacteroidetes. In
addition, C-PAC treatment signifıcantly reduced primary and secondary bile
acid metabolite levels in the esophagus of reflux/EGDA rats. Other metab-
olites signifıcantly reduced by C-PAC included a number of pro-inflamma-
tory Eicosanoids. In summary, these results support that (1) reflux-induced
microbial impairment correlates with the stimulation of bile acid metabo-
lism, and (2) C-PACmitigates reflux-induced inflammation and injury in the
esophagus in association with EAC inhibition. Future research with C-PAC
in patients with gastroesophageal reflux disease should include assessments
of bile acid metabolites and bacterial profıles as potential cancer-inhibitory
mechanisms.
#5251 Amentoflavone regulate Hh-Gli1 signaling pathway and inhibits
tumorsphere formation in U251 glioblastoma cells. Jing Chen, Cheng Bao.
Chung-Ang University, Anseong, Republic of Korea.
Cancer stem cells represent a rare population of cells with a self-renewal
capacity, and potentially are involved in tumor progression, tumor relapse, and
resistance to cancer chemotherapies. In this study, we investigated the effect of
an active ingredient of chamaecyaris obtuse, amentoflavone, on stemness of
U251 glioblastoma cells. We fırst found that amentoflavone from 1 to10 M
suppressed tumorsphere formation and inhibited the expression of glioblas-
toma stem cell markers CD133 and ALDH1 in a dose dependent manner. In
addition, amentoflavone signifıcantly reduced the expression ofNanog involved
in cancer stem cells maintenance in tumorsphere culture. As an upstreammod-
ulator, Hedgehog (Hh) signaling mediator Gli1 was confırmed to be highly
expressed in tumorsphere culture where the suppression of Gli1 by the treat-
ment of Hh inhibitors (vismodegib and GANT 61) or Gli1-siRNA signifıcantly
suppressed the expression of stem cell markers CD133, ALDH1, and Nanog as
well as tumorsphere formation inU251 glioblastoma cells. These results indicate
that Hh signaling plays an important role in maintaining tumorsphere and
stemness of U251 glioblastoma cells. Next, we also found that the treatment of
amentoflavone from 1 to10 M inhibited the expression of Gli1 and its down-
stream mediator Nanog in tumorsphere culture of U251 glioblastoma cells.
Taken together, amentoflavone signifıcantly suppressed Hh/Gli1 signaling
which results in inhibition of stemness of U251 glioblastoma cells.
#5252 Quercetin inhibits prostate cancer by modulating ROS and key
regulators of apoptosis and cell survival. Ashley B. Ward,1 Hina Mir,1 Neeraj
Kapur,1 Guru Sonpavde,2 Shailesh Singh1. 1Morehouse School of Medicine, At-
lanta, GA; 2UAB Comprehensive Cancer Center, Birmingham, AL.
Long latency and indolent nature of prostate cancer (PCa) provides a window
of opportunity for preventive interventions using natural and synthetic agents.
Hence, the focus of this study was to ascertain the chemopreventive role of
Quercetin, a bioflavonoid, commonly used to treat prostatitis. Human PCa cells
(LNCaP, DU145 and PC3) were treated with different concentrations of Quer-
cetin and its effect on cell survival and apoptosis was determined byMTT assay.
Human PCa cells treated with Quercetin showed signifıcant reduction in cell
viability and proliferation compared with untreated controls, which was dose
and time dependent. In addition to this our FACS analysis showed higher per-
centage of apoptotic cells afterQuercetin treatment compared to untreated cells.
Quercetin induced apoptosis in PCa cells is a cumulative effect of modulation of
key apoptotic proteins, changes inmitochondrial membrane potential and ROS
production. Our results demonstrate that Quercetin is a potent chemopreven-
tive agent, which may improve outcomes of PCa by inhibiting mechanisms
involved in tumor progression.
#5253 Arctigenin inhibits prostate tumor growth in vitro and in vivo in
obese state. PiwenWang,1 Tanya Diaz,1 Susanne Henning,2 Jaydutt Vadgama1.
1Charles Drew Univ. of Medicine and Science, Los Angeles, CA; 2University of
California Los Angeles,, Los Angeles, CA.
Arctigenin is a novel anti-inflammatory lignan derivedmainly from the seeds
ofArctium lappawhich is anherbwidely used in traditionalChinesemedicine to
treat inflammation related diseases.Wepreviously demonstrated that arctigenin
strongly inhibited prostate tumor cell growth in cell culture and mouse models
in non-obese state. The present study investigated the tumor inhibitory effect of
arctigenin in obese state. An in vitro obese setting was created by co-culture of
mouse adipocytes 3T3-L1with androgen-sensitive LAPC-4 andLNCaPprostate
cancer cells. An ELISA analysis of 3T3-L1 conditioned medium revealed that
three cytokines/growth factors were prominently secreted by 3T3-L1 cells, in-
cluding IGF-1, VEGF, andMCP-1, and the sensitivity of prostate cancer cells to
arctigenin was decreased in the obese state. However, arctigenin at a moderate
concentration (10 M) signifıcantly inhibited the proliferation of both LAPC-4
and LNCaP cell by 40-50% at 96h in the co-culture system. Male severe com-
bined immunodefıciency (SCID) mice was implanted subcutaneously with
LAPC-4 xenograft tumors to confırm the tumor-inhibitory effect of arctigenin
in vivo. Mice were fed high-fat diet containing 45% energy from fat, and treated
with arctigenin at 50mg/kg b.w. orally or vehicle control for 6 weeks (n10 per
group). The tumor growth in arctigenin group was signifıcantly inhibited by
40% compared to control, along with decreased blood concentrations of several
cytokines including IGF-1, VEGF, andMCP-1. Immunohistochemistry analysis
is ongoing to determine the molecular changes involved in tumor cell prolifer-
ation and apoptosis in response to arctigenin treatment. This study provides a
promising natural compound to enhance chemoprevention of prostate cancer
especially in obese patients. These results warrant future clinical trial studies to
confırm the anti-carcinogenic effect of arctigenin in humans.
#5254 Postoperative adjuvant chemotherapy improves survival in stage II
colon cancer? A propensity scorematching analysis. Ryoichi Tsukamoto, Kii-
chi Sugimoto, Shingo Kawano, Koichiro Niwa, Shun Ishiyama, Hirohiko Ka-
miyama, Hiromitsu Komiyama,Makoto Takahashi, Yutaka Kojima,Michitoshi
Goto, Yuichi Tomiki, Kazuhiro Sakamoto. Juntendo University Faculty of Med-
icine, Tokyo, Japan.
Objective : Stage II colon cancer with high-risk features have been tradition-
ally considered more likely to benefıt from postoperative adjuvant chemother-
apy (POAC). National Comprehensive Cancer Network (NCCN) guidelines do
not recommend routine administration of adjuvant chemotherapy for Stage II
patients, except for those with high risk features, such as poorly-differentiated
tumors, T4 disease, perforated tumors and those with inadequate lymph node
sampling. However, the use of POAC after surgery for patients with Stage II
colon cancer remains controversial. The current study was conducted to inves-
tigate the effectiveness of POAC using propensity score (PS) matching analysis,
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which can reduce or minimize the confounding that is seen frequently in obser-
vational studies of the effect of treatment on outcomes, based on prognostic
factors. Materials : Two hundred and nineteen patients with Stage II colon can-
cer who underwent surgery with curative intent between 1995 and 2005 were
enrolled. The decision regarding the use of POACwasmade for each case based
on individual patient/physician discussions. All patients were required to pro-
vide informed consent. During the present study period, patients received 5-FU
drugs orally, starting 48 weeks after surgery. The median observation period
was 73.4 months (range: 2.2 - 184.2 months). Methods : PS matching analysis
was used to adjust for differences in clinicopathological severity between the
patients with and without POAC. Recurrence-free and cancer-specifıc survival
were calculated using the Kaplan-Meier method and univariate analyses were
performed using the log-rank test. The Cox proportional-hazard model was
used to determine Hazard ratios and 95% confıdence intervals. Results : One
hundred and nineteen patients (54.3%) underwent POAC. In univariate analy-
sis, there were signifıcant differences in age, invasion depth, lymphatic invasion
and venous invasion between the patients with and without POAC. After PS
matching analysis, in univariate analysis, there were no signifıcant differences
with respect to the clinicopathological factors between the patients with and
without POAC. Before PS matching analysis signifıcant survival benefıts from
POAC were not recognized for recurrence-free survival (Hazard ratio 0.76,
95%CI 0.40-1.45, P0.41) or cancer-specifıc survival (Hazard ratio 0.52, 95%
CI 0.22-1.19, P0.12). After PS matching analysis signifıcant survival benefıts
from POAC were not recognized for recurrence-free survival (Hazard ratio
0.55, 95%CI 0.23-1.23, P0.15) or cancer-specifıc survival (Hazard ratio 0.46,
95% CI 0.16-1.18, P0.11). Conclusions : The one-to-one pair PS matching
successfully balanced the clinicopathological factors between the patients with
and without POAC. The PS matching analysis demonstrated no signifıcant dif-
ference in survival in the patients with Stage II colon cancer.
#5255 Comparison of high-fructose and standard diets in methylnitro-
sourea (MNU)-induced ERmammary cancers: Altered carcinogenesis, dif-
ferential effects of metformin, andmetabolomic differences.Mark S. Miller,1
Clinton J. Grubbs,2 Steve Stirdivant,3 Ronald A. Lubet4. 1National Cancer Insti-
tute, Rockville, MD; 2Univ. of Alabama Comp. Cancer Ctr., Birmingham, AL;
3Metabolon , Inc., Durham, NC; 4National Cancer Institute, Bethesda, MD.
TheMNU-inducedmodel of ERmammary cancers in Sprague-Dawley rats
has routinely been employed in screening for chemopreventive agents. We re-
cently reported that metformin was ineffective in preventing mammary cancers
in rats on a standard diet (Thompson, et al, Cancer Prev. Res, 8, 231-9, 2015). In
this study, we evaluated the carcinogenic response in Vehicle-treated rats and
rats receivingMetformin (150mg/Kg BW/day) on standard Teklad or isocaloric
High-Fructose diets. In the fırst study, rats were placed on Teklad or High-
Fructose diet at 43 days of age. At 100 days of age, animals were administered a
single dose of MNU. Animals were administered Metformin or tamoxifen be-
ginning 5 days later. Rats were palpated weekly for mammary tumors and sac-
rifıced at 300 days of age. Body weights between groups were not different.
Tumor multiplicity and tumor weights were: Vehicle-Teklad,1.15 and 1.44g;
Vehicle- High-Fructose, 2.10 and 2.94g; Metformin-Teklad, 1.25 and 1.91g;
Metformin -High-Fructose, 1.00 and1.99g. Tamoxifen resulted in the preven-
tion of all tumors. High-Fructose alone resulted in a 2X increase in tumor mul-
tiplicity (P0.05) and tumor weights (P0.05). In the Teklad diet, Metformin
marginally increased tumor multiplicity and weights (0.1P0.05). In the
High-Fructose diet, Metformin decreased tumor multiplicity by 50% (P0.05).
In the second study, which parallels the standard MNU model, rats were also
placed on Teklad or High-Fructose diet at 43 days of age. At 50 days of age, rats
were administered a single dose of MNU. Rats on High-Fructose diet were
administered either Vehicle or Metformin, while rats on Teklad diet were given
only Vehicle; beginning 5 days later. Rats were palpated weekly and sacrifıced at
170 days of age. Body weights between groups were not different. Tumor mul-
tiplicity and tumor weights were: Vehicle-High-Fructose, 6.00 and 7.74g; Met-
formin High-Fructose, 5.00 and 6.17g; and Vehicle-Teklad, 2.70 and 5.75g. As
indicated, Vehicle-treated rats on High-Fructose diet had twice the number of
cancers asVehicle-Teklad diet (P0.05).Metformin had aminimal effect in rats
on a High-Fructose diet; unlike our previous results in rats ( receiving MNU at
50 days of age) on Teklad or High-Fat diet where metformin increased cancer
multiplicity and cancerweights. Furthermore, we performedmetabolomic stud-
ies on both serum and cancers from animals on Teklad andHigh-Fructose diets.
It was observed (based on principal component analysis) that serum from rats
on High-Fructose and standard Teklad diet were profoundly different. Further-
more, there appeared to be a metabolic signature in rats bearing cancers. These
and other metabolomic changes will be presented. Supported by NCI contract
number HHSN261201200021I, Task Order HHSN26100005.
#5256 Intracellular lipid droplet quantity as a biomarker for obesity asso-
ciated resistance to omega-3 fatty acid colon cancer prevention.Muhammad
N. Aslam, Nithya Sridhar, Maheen Nadeem, Becky R. Simon, Jianwei Ren,
Ananda Sen, James Varani, William L. Smith, Zora Djuric, Dean E. Brenner.
University of Michigan, Ann Arbor, MI.
Rationale: Obesity induces resistance to Omega-3 (-3) FA anticarcinogen-
esis effect. Obesity associated excessive fatty acid intracellular concentration
results in excess triglycerides stored as intracellular lipid droplets, saturated
acyl-co-A transport of FA to triglycerides resulting in excess substrate for cyclo-
oxygenase metabolism with increased formation of PGE2 and other inflamma-
tory eicosanoids. Methods: Five weeks old male F344 rats were randomized
equally into two diet groups. One cohort fed a western diet of -6 fatty acids
(EPA:6 ratio of 0) and other fed an -3 fatty acid supplemented diet (EPA:6
ratio of 0.4).One half fromeachdiet groupwere further treatedwith azoxymeth-
ane/dextran sulfate sodium (AOM/DSS) and then euthanized at 21 weeks after
the carcinogen induction. Snap frozen colon tissue were assayed for Prostaglan-
dins and fatty acids. OCT fıxed colonic tissue stained with oil red O (ORO) to
detect lipid droplets which were quantifıed using Aperio image analysis. From
the second set, rat colonswere opened longitudinally and fıxed in 10%Formalin.
Tumors were identifıed and enumerated using stereomicroscope to get tumor
count, incidence and volume. These tissue were subjected to hematoxylin &
eosin staining for histological evaluation of colonic tumors. Results: The-3 FA
diet signifıcantly increased the percent of eicosapentaenoic acid (EPA) in total
fatty acids in both untreated and AOM/DSS-treated rats. EPA in the colonic
tissue was increased with-3 diet as compared to-6 from 1.40.8 to 2.61.0*
in untreated rats and from 1.31.3 to 3.31.7* in AOM/DSS-treated rats
(*p0.005). PGE2 increased with AOM/DSS treatment. The -3 diet decreased
PGE2 in colonic mucosa of untreated rats from 13264 in -6 to 7817 in -3
and 15074 in -6 to 9243 in -3 with AOM/DSS treatment. Most tumors
were found in the distal colon (DC) with -3 diet signifıcantly reducing the
number of tumors (p value0.0011). The-3 diet signifıcantly reduced colonic
adenoma volume and multiplicity. When tumors were stratifıed by size and
location, there was a signifıcant effect of diet in the DC, with -3 diet reducing
the number of tumors in the 1-3mm range (p value0.0018), 3-5mm (p
value0.0041) and 5mm (p value0.0055). -3 also reduced the number of
3-5mm size tumors in the cecum (p value0.0377). On preliminary quantifıca-
tion of lipid droplets, there was a reduction in the positive pixels divided by the
total pixels of ORO stained colonic tissue of -3 rats (0.0040.01 as compared
to 0.0130.07 in -6 rats; p value0.0121) Conclusions: Dietary -3 supple-
mentation that increases the EPA:AA ratio in colonic tissue phospholipids re-
duces excess intracellular FA concentrations reflected by a reduction in size and
number of lipid droplets. Lipid droplet number and size may be useful as a
biomarker for effective reduction of obesity associated inflammation and carci-
nogenesis risk.
#5257 Cellular pharmacology of curcumin cellular pharmacology of
curcuminpiperine.RamaMahran,1 Pan Shu,2 Duxin Sun,2 Dean E. Brenner1.
1Univ. ofMichiganMedical Ctr., Ann Arbor,MI; 2Univ. ofMichigan, AnnArbor,
MI.
Rationale: Prior reports have suggested that piperine, the major alkaloid
product derived from black and long pepper, enhances curcumin’s cancer pre-
ventive effıcacy in vitro and in vivo by an intracellular pharmacokinetic interac-
tion; yet, no previous studies have explored the pharmacokinetic interactions
between curcumin and piperine. Methods: We incubated non-transformed
breast cell line MCF10A and breast cancer SUM149 cell line with different con-
centrations of curcumin, piperine or curcumin piperine to assess cell viability
using a MTT assay. For curcumin and piperine uptake assays, we incubated
MCF10A, SUM149 and MCF7 breast cells with either 5 M curcumin or 5 M
curcumin 5Mpiperine for 0.5, 1, 4,6,8,12 and 24 h, or with 15Mcurcumin
or 15 M curcumin 10 M piperine for 0.17, 0.5, 1,2 and 4h. Media and cell
lysates were extracted for assay of intracellular curcumin and piperine by LC-
MS/MS. ALDH , ALDH-CD4424- cells were collected via FACS, incubated
with 15 M curcumin or 15 M curcumin  10 M piperine for 1 hour. Cell
lysates and media were assayed for curcumin, curcumin degradation and met-
abolic products and quantifıed using LC-MS/MS. Results: 90.70.06% and 34.8
0.002% of cells were viable after incubating MCF10A and SUM149 cells re-
spectively with 25 M curcumin compared to DMSO control. Incubation with
10 M Piperine enhanced the antiproliferative effect of 15 M curcumin by
33.60.015% (P 0.05) and 16.30.003% (P0.05) in SUM149 and MCF10A
cells respectively. We found no signifıcant increase of intracellular concentra-
tion of curcumin when coincubated with piperine in the MCF10A, MCF7 and
SUM149 cells or in the ALDH and the ALDH- CD44CD24- SUM149 cells.
Curcumin intracellular concentration was 166.722 and 151.524 ng/mg pro-
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tein in ALDH cells for curcumin alone or curcumin  piperine respectively
and 13025.4 and 13527.4 ng/mg protein in ALDH- CD44CD24- for cur-
cumin alone or curcumin  piperine respectively in SUM149 cell line. Cur-
cumin uptake was lower in MCF10A cells than SUM149 cells. The intracellular
curcumin concentration after 1 hour incubation with 5 M curcumin was
11.80.8 and 68.111.2 in MCF10A and SUM149 cells respectively. Tetrahy-
drocurcumin and curcumin sulfate conjugates were the major metabolites de-
tected in MCF7 and SUM149 cell lines. Curcumin sulfate is detectable in the
media as early as 0.5h, it increases from 1.360.06 and 1.430.05 after 0.5h to
22.60.53 and 232.2 ng/ml after 4 h for curcumin and curcumin piperine
respectively in the media of ALDH-CD44Cd24- SUM149 cells. Conclusions:
We fınd no signifıcant difference in intracellular curcumin concentration be-
tween cells treated with curcumin alone or curcumin  piperine after incuba-
tion times up to 24 hr. The additive cellular toxicity effects observed with piper-
ine curcumin is not pharmacokinetic (associatedwith efflux pump inhibition)
but rather pharmacodynamic due to piperine’s independent anti-proliferative
effects.
#5258 Benzyl isothiocyanate prevents breast cancer-induced bone erosion
in vivo. Subrata K. Pore, Shivendra V. Singh. Univ. of Pittsburgh Cancer Inst.,
Pittsburgh, PA.
Bone is one of the metastatic sites for advanced breast cancer. Nearly 70% of
breast cancer patients experience metastasis to bone due to enhanced osteoclas-
togenesis and formation of osteoclasts leading to bone resorption. We have
shown previously that benzyl isothiocyanate (BITC), a constituent of edible
cruciferous vegetables such as garden cress, is a potent inhibitor of breast cancer
cells in vitro and in vivo. The present study was designed to determine the effect
of BITC on breast cancer-induced osteoclastogenesis. Co-culture of murine
RAW 264.7 macrophages with human breast cancer cells resulted in genesis of
osteoclasts in vitro that was suppressed signifıcantly in the presence of BITC.
Runx2, a transcription factor, is abnormally expressed in breast cancer and con-
tributes to osteoclastogenesis by regulating receptor activator of NF-B ligand
(RANKL). BITC treatment downregulated expression of Runx2 in breast cancer
cells at themRNAand protein levels. Osteoclastogenesis was increased inRunx2
overexpressing MDA-MB-231 cells, whereas conditional knockdown of Runx2
in T47D cells attenuated this process. To determine the in vivo effıcacy of BITC,
MDA-MB-231-Luc cells were injected into the left ventricle of nudemice. BITC
was administrated orally at 10 mg per kg body weight. Micro-CT X-ray analysis
showed that bone metastases and erosion was decreased by about 50% upon
BITC treatment when compared with vehicle control. Cathepsin K and total
RANKL levelswere lower in the plasmaof BITC-treatedmicewhen compared to
the control group. Altogether, this study demonstrates, for the fırst time, that
BITC is a potent inhibitor of breast cancer-induced osteoclastogenesis in vivo.
This study was supported by the grant RO1 CA129347-09 awarded by the na-
tional Cancer Institute.
#5259 Urolithin A prevents pancreatic tumor growth and increases sur-
vival by inhibiting PI3K/PDK1 and STAT3 signaling. Supriya Srinivasan,1
Venkatakrishna Jala,2 Kumar Honnenahally,3 Jason Castellanos,3 Praveen Ku-
mar Vermula,4 Michael VanSaun,1 Nipun Merchant,1 Nagaraj Nagathihalli1.
1Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; 2Uni-
versity of Louisville, Louisville, KY; 3Vanderbilt University, Nashville, TN; 4Na-
tional Centre for Biological Sciences, Bangalore, India.
Pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer-
related mortality in the United States. Most patients present with an advanced
disease and the majority die within fıve years, many surviving less than six
months. Cytotoxic chemotherapy including Gemcitabine (Gem), FOLFIRI-
NOX, nab-paclitaxel offer modest improvement in survival, albeit at the cost of
increased side effects and unwanted toxicities. Therefore, developing novel che-
motherapeutic agents for PDAC treatment is critical to improve survival. Ellagic
acid/ellatitannins are abundantly present in the pomegranate and berries, are
actively metabolized by the intestinal microflora to Urolithin A (UA). Oral ad-
ministration of UA has shown to be highly bioavailable and non-toxic. UA
inhibits multiple kinases that are known to be involved in PDAC progression
and metastasis. Therefore, we hypothesized that UA would elicit potent anti-
cancer therapeutic potential in PDAC. The effect of UA on kinase activity was
assessed . Inhibition of AKT (downstream of PI3K/PDK1), p70 S6 Kinase
(PS6K) and STAT3 activation was quantifıed in PDAC cells treated with UA in
dose-dependent manner. The mechanism of action was validated for UA’s ac-
tivity on PI3K/PDK1, PS6K and STAT3 activation using immunoblot analysis.
MiaPaCa2 cellswere treatedwith specifıc inhibitors for eitherAKT (MK2206) or
STAT3 (AZD1480) and analyzed for tumorigenicity. UA treated PDAC cells
were analyzed for cell proliferation, cell invasion and colony formation. Cell
cycle analysis and cell apoptosis were measured by flow cytometry. To test the
effıcacy of UA in vivo, cells were implanted subcutaneously in athymic nude
mice. The animals received UA daily and tumor volume was measured for 5
weeks. Next, we assessed tumor growth and overall survival (OS) in PKT
(Ptf1acre/;LSL-KrasG12D;Tgfbr2fl/fl) mice, an aggressive genetically engineered
PDAC mouse model, in response to UA and/or Gem treatment. Tissues from
the xenografts and PKT mice treated with vehicle or UA were analyzed for cell
proliferation (Ki67) and apoptosis (cleaved Caspase 3) by immunohistochemis-
try. High expression levels of activated STAT3 or AKT correlate with decreased
survival in PDAC. UA treated MiaPaCa2 cells showed signifıcant dose-depen-
dent increase in apoptosis and decrease in anchorage-independent growth. UA
inhibited AKT, PS6K and STAT3 signaling. As a single agent, UA effectively
reduced in vivo PDAC tumor growth. Immunohistochemistry of UA treated
tissues from tumor xenografts and PKTmice showed inhibition of Ki67 positive
tumor cells and increased cleaved caspase 3 staining. PKTmice treated with UA
showed a decrease in tumor size and an increased OS when compared to vehicle
or Gem treated mice alone. These fındings show that UA is a novel inhibitor/
modulator/regulator for multiple signaling pathways in PDAC. These results
suggest UA has potential for pre-clinical development in pancreatic cancer.
#5260 NGS Transcriptome analysis of colon adenocarcinomas treated
with individual and combination of aspirin and omeprazole. Naveena B.
Janakiram,1AltafMohammed,1 JaganM.R. Patlolla,1 Yuting Zhang,1 Laura Bid-
dick,1 VenkateshwarMadka,1 Li Qian,1 Stan Lightfoot,1 Barbara Dunn,2 Ronald
Lubet,2 Chen S. Suen,2 Vernon E. Steele,2 Chinthalapally V. Rao1. 1Univ. of
Oklahoma Health Sciences Ctr., Oklahoma City, OK; 2National Cancer Institute,
Rockville, MD.
Colorectal cancer (CRC) is the thirdmost common type of cancer inmen and
women in US. Anti-inflammatory agents have proven to be most effective in
CRC prevention, but are associated with gastrointestinal toxicities. Hence, to
reduce the acidic environment and enhance the chemopreventive effıcacy of
anti-inflammatory agent aspirin, a combination of aspirin with acidity neutral-
izer omeprazole was used in AOM-induced F344 Rat model of CRC. Rat (36/
group) colon cancers were induced by AOM (15mg/Kg body weight) s.c., once a
week for two weeks. At adenoma stage (13 wks of age), rats were fed diets
containing aspirin (700 or 1400ppm), omeprazole (0, 250 or 500 ppm), or aspi-
rin omeprazole (700 ppm 250 ppm; 1,400 ppm 500 ppm). To identify a
molecular predictor of the benefıt of aspirin plus omeprazole we performed
next-generation sequencing of colon adenocarcinomas (AdCa) treated with as-
pirin (1400 ppm), omeprazole (500 ppm), aspirin plus omeprazole (1400 plus
500 ppm),conducted whole-transcriptome analysis and correlated the molecu-
lar portrait with chemoprevention benefıt. Aspirin plus omeprazole enhanced
colon AdCa incidence inhibitory effects by 55% (p0.0001) and multiplicity by
87% (p0.0001) respectively in F344 rats. Transcriptome profıling revealed
1525 hits with a 1.5-fold expression difference threshold in aspirin-treated colon
AdCa (722 upregulated genes, 803 downregulated genes, P  0.05), 1507 hits
with a 1.5-fold expression difference threshold in omeprazole-treated colon
AdCa (711 upregulated genes, 796 downregulated genes, P 0.05) and 1074 hits
with a 1.5-fold expression difference threshold in aspirin plus omeprazole-
treated colonAdCa (662 upregulated genes, 412 downregulated genes, P 0.05)
compared to untreated colon AdCa. Multiple comparisons using Anova with
samples from all groups revealed 691 hits with a 1.5-fold expression difference
threshold with Benjamini Hochberg correction. Pathway analyses of these al-
tered 691 genes indicated that the aspirin plus omeprazole treated colon AdCa
upregulated cellular pathways (z score 2.26), Metabolism process (6.01) and
cellular metabolic process (7.73), and downregulated signaling genes (- 8.18),
signal transduction (- 8.03), immune response (- 2.08) and inflammatory re-
sponse (- 2.95). A signifıcant upregulation of Killer cell lectin-like receptor sub-
familyK,member 1 (natural cytotoxicity receptorwhich eliminates tumor cells),
and acid phosphatase 2, lysosomal, (autophagy of tumor cells) was seen in the
combination treatment groups compared to individual and control group
AdCa. A signifıcant decrease in TGF- receptor signaling pathway gene SNX4
and ATPases was observed in combination treatments. Hence, these results
suggest aspirin plus omeprazole combination treatments were devoid of GI tox-
icity increasing chemopreventive effıcacy in colon cancer. Supported by NCI-
N01-CN-250026.
#5261 Tocopherols inhibit the estrogen-stimulated expansion of cancer
stem cells via down-regulation of OCT4 and NF	B.Min Ji Bak. Rutgers Univ.
School of Pharmacy, Piscataway, NJ.
Cancer stem cells have been suggested to play a role in tumor initiation,
maintenance, resistance, and metastasis. Breast cancer stem cells are defıned as
CD44/CD24- cell populations that have the properties of tumor-initiating abil-
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ity, self-renewal and differentiation. Although the importance of estrogen in
breast cancer is well established, the effects of estrogen on breast cancer stem
cells are not fully understood. Vitamin E, which is consisted of different forms of
tocopherols and tocotrienols, has anti-tumor effects in various cancers, includ-
ing breast cancer. In the present study, we examined the effects of 	-, -, and

-tocopherol against estrogen-stimulated expansion of cancer stem cells. To
determine the effects of tocopherols on breast cancer stem cells, the MCF-7
tumorsphere cell culture system, which enriches for mammary progenitor cells
and putative breast cancer stem cells, was utilized. Treatment of MCF-7 tumor-
sphere with estrogen for four days resulted in an increase in CD44/CD24- stem
cell populations in tumorspheres as well as the number and size of tumors-
pheres. Tocopherols at 1 and 10 M inhibited formation of estrogen-induced
stem cell enriched tumorspheres, indicating that tocopherols reversed estrogen-
induced expansion of breast cancer stem cells. Tocopherols decreased the ex-
pression of estrogen-related genes such as TFF/pS2, cathepsin D, progesterone
receptor and SerpinA1 in estrogen-stimulated tumorspheres. In addition, the
mRNA levels of stem cell markers, including OCT4, NFB, SOX-2 and CD44,
were upregulated by estrogen, which were downregulated by the treatment with
tocopherols. Our results suggest that tocopherols repress the expansion of breast
cancer stem cell population by regulating OCT4 and NFB signaling. Tocoph-
erols could be effective natural agents for the prevention and treatment of estro-
gen-induced breast cancer. (This work was supported in part by the National
Institutes of Health grant R01 AT007036.)
#5262 The inhibitory effect of combinations of curcumin, ursolic acid,
and metformin on skin tumor promotion by TPA. Lisa Tremmel, Okkyung
Rho, John DiGiovanni. The University of Texas at Austin, Austin, TX.
The purpose of this study was to examine the effects of combinations of
ursolic acid (UA), curcumin (Curc), and metformin (Met) for potential syner-
gistic chemopreventive activity to inhibit tumor promotion using the mouse
two-stage skin carcinogenesis model. UA and Curc have been shown to inhibit
tumorigenesis in several mouse models, and both have been shown to inhibit
mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA).
The anti-cancer activity of these phytochemicals is due to their anti-inflamma-
tory, anti-oxidant, and anti-proliferative effects. These effects are accomplished
by acting on a broad spectrumof signaling pathways.Met has also been shown to
have anti-cancer activity. In retrospective studies, type II diabetes patients taking
Met have been shown to have a decreased cancer incidence. Met has also been
shown to inhibit mouse skin tumor promotion by TPA. Met activates AMP-
activated protein kinase (AMPK), which in turn inhibits mammalian target of
rapamycin complex 1 (mTORC1) signaling. mTORC1 is a key kinase involved
in the phosphatidylinositol-3 kinase (PI3K)/Akt pathway, one of the most com-
monly altered pathways in human tumors. In initial short-term experiments
(mice treated twice weekly for two weeks with TPA), combinations of UA and
Curc pretreated topically inhibited TPA-induced activation of epidermal NF-
B,Cox-2, epidermal growth factor receptor (EGFR) and JNK to a greater extent
than either compound alone. Additionally, these compounds increased levels of
AMPK and programmed cell death protein 4 (Pdcd4). The alterations in these
signaling pathways by the combination of UA and Curc were associated with
decreased epidermal proliferation and skin inflammation as assessed by mea-
suring BrdU incorporation and inflammatory gene expression, respectively.
Further studies using dietary administration of a combination of UA and Curc,
as well as combinations of UA or Curc (in diet) with Met administered in the
drinking water were conducted. These combinations produced greater inhibi-
tion of TPA-induced activation of epidermal NFB, Cox-2, and EGFR than the
compounds given alone. These combinations also decreased epidermal prolif-
eration, again shown by an inhibition of BrdU incorporation. In addition to
these data, the results fromongoing skin tumor experiments (mice initiatedwith
DMBAandpromoted twiceweeklywithTPA)using both topical administration
and dietary administration of the various combinations will be presented. The
current results indicate that certain combinations of UA, Curc and Met may
inhibit mouse skin tumor promotion by TPA to a greater extent than the com-
pounds alone. The ability of the combinations toworkwhen given both topically
as well as in the diet suggests the potential for broad applications for chemopre-
ventive strategies.
#5263 Chemopreventive effects of dietary grapes on skin cancer.Chandra
K. Singh, Mary A. Ndiaye, Charlotte A. Mintie, Gagan Chhabra, Nihal Ahmad.
University of Wisconsin-Madison, Madison, WI.
Non-melanoma skin cancer (NMSC) is the most commonly diagnosed ma-
lignancy in the United States, affecting more than 3 million Americans each
year. Ultraviolet (UV) radiation from the sun, particularly its UVB component
(290-320 nm), is an established causative factor for90% of skin cancers. The
twomost common forms of skin cancer, basal- and squamous- cell carcinomas,
are treatable if detected early. However, they can be diffıcult to treat and poten-
tially fatal if left until late stages. Further, epidemiological studies have suggested
an amplifıed risk of other deadly cancers in individuals with a history of skin
cancer. Therefore, it is important to designnovel approaches, especially focusing
on prevention, for themanagement of skin cancers. Studies from our laboratory
and by others have shown that topical application of the grape antioxidant res-
veratrol possesses promise in the prevention of skin cancer. However, ideally
cancer preventive agents need to be orally administrable for ease of use and
broader human acceptability. With this in mind, in this study, we determined
the effıcacy of dietary grape powder (containing resveratrol in natural amalga-
mation with catechins, anthocyanins, polyphenols and flavonols) against UVB-
mediated skin tumorigenesis in the SKH-1 hairless mouse model, which is re-
garded to have relevance to human NMSC. We employed a UVB initiation-
promotion protocol in which themice were subjected to chronic UVB exposure
(180mJ/cm2; twice weekly, for 28 weeks). The animals received either AIN-76A
or grape powder (GP) fortifıed diet (3% and 5% GP, obtained from the Califor-
nia Table Grape Commission), all of which were sugar-matched to the highest
GP content. Our data demonstrated that the consumption of GP at both 3% and
5% resulted in a signifıcant inhibition in skin tumor incidence and delay in the
onset of tumorigenesis. The average consumption of feed per mouse was 3.5
g/day, corresponding to 105 and 174mgGP/day in the 3% and 5%GP treatment
groups. This dosing regimen seems to be easily achievable for human consump-
tion, as it corresponds to 25.5 and 42.4 g/day, which are equivalent to 1.1 and 1.8
serving of fresh grapes, respectively. Our data also demonstrated that the ob-
served skin cancer chemopreventive effects of grape powder were accompanied
by signifıcant i) decreases in cellular proliferation markers Ki67 and PCNA, ii)
decreases in the oxidative stress marker 4-HNE, and iii) increases in the levels of
cleaved caspase 7 and poly (ADP-ribose) polymerase (PARP). Interestingly,
NRF2, an activator of cellular antioxidant response, was found to be downregu-
lated in GP treated tumors, compared to UVB alone groups, suggesting a poten-
tial protective role of NRF2 in the survival of tumor cells. Overall, our study
suggests a strong chemopreventive effect of dietary grape and provides a basis
for future human studies.
#5264 Chemoprevention of rat oral carcinogenesis by black raspberry
phytochemicals. Steve Oghumu, Thomas Knobloch, Jennifer Ahn-Jarvis, Lo-
gan Weghorst, Kyle Horvath, Paul Geuy, Christopher Weghorst. Ohio State
University, Columbus, OH.
It is expected that in 2016, there will be an estimated 48,330 new cases and
9,570 deaths due to oral cancer in the US, which is about one person every hour
every day. Due to the epithelial fıeld defects associated with oral carcinogenesis,
tumor recurrence and second primary tumor incidence are common. Recently
conducted Phase I Clinical trials demonstrate the ability of black raspberries
(BRBs) to modulate inflammatory biomarkers of molecular effıcacy that sup-
ports a chemopreventive strategy against oral cancer. From these human trials
we have established a molecular signature of BRB responsive biomarkers. How-
ever, it is essential that a preclinical animal model of BRB chemoprevention
which recapitulates the fundamental features of human oral carcinogenesis be
developed, so that we can evaluate potential mechanisms of action and validate
molecular biomarkers of BRB effıcacy. We therefore established the ability of
BRB to inhibit oral lesion formation in a rat model of 4-nitroquinoline 1-oxide
(4NQO) induced oral carcinogenesis and examined molecular effıcacy using a
clinically relevant transcriptional signature. Oral cancer was induced in F344
rats using 4NQO in drinking water for 10 weeks followed by regular drinking
water for 16 weeks. Rats were administered a diet containing 5 or 10 percent
lyophilized BRBs. Tongue tissues were examined for lesion multiplicity, inci-
dence and histopathological features. Clinically derived pro-inflammatory and
pro-survival molecular biomarkers were also determined by real-time PCR and
ELISA. Dietary administration of 5 and 10 percent BRBs reduced combined
lesion incidence and multiplicity by -39.3% and -28.6% respectively. Histo-
pathological analyses of tongue sections further demonstrate the chemopreven-
tive ability of dietary BRB administration in the rat model. Pro-survival and
pro-inflammatory biomarkers were downregulated in BRB administered 4NQO
induced rats compared to untreated 4NQO induced rats. Our study shows that
dietary administration of BRB inhibits oral carcinogenesis in the rat 4NQO
model. The rat 4NQOmodel is suitable for interrogating mechanisms of action
of BRB-mediated oral cancer chemoprevention.
#5265 Breast cancer stem cell inhibition by benzyl isothiocyanate is ham-
pered by induction of Kruppel-like factor 4. Su-Hyeong Kim, Yong Wan,
Shivendra V. Singh. Univ. of Pittsburg Cancer Inst., Pittsburgh, PA.
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Breast cancer is a leading cause of cancer-related deaths among women in the
United States. Over the last decade, breast cancer stem cells (bCSC) have been
identifıed and characterized as a key player in breast cancer progression and
recurrence. Benzyl isothiocyanate (BITC) is a highly promising cancer chemo-
preventive constituent of edible cruciferous vegetables such as garden cress. We
have shown previously that BITC inhibits bCSC in cultured breast cancer cells
(MCF-7 and SUM159 cells) and in spontaneous tumors of mouse mammary
tumor virus-neu (MMTV-neu) mice in vivo. Krüppel-like factor 4 (KLF4), a
zinc fınger transcription factor, is known as both oncogene and tumor suppres-
sor in various types of human cancers and plays an important role in reprogram-
ming differentiated somatic cells into induced pluripotent stem cells. The pres-
ent study demonstrates that KLF4 impedes bCSC inhibition by BITC. Exposure
of breast cancer cells (MCF-7,MDA-MB-231, and SUM159) to pharmacological
concentrations of BITC (2.5 and 5 M) resulted in induction of KLF4 protein,
whichwas accompanied by increase of its transcription. In addition, BITC treat-
ment increased nuclear level of KLF4 in breast cancer cells. KLF4 protein ex-
pression was also higher in tumors form BITC-treated MMTV-neu mice com-
pared with the control group. Ectopic expression of KLF4 in MCF-7 cells
conferred marked protection against BITC-mediated inhibition of bCSC as ev-
idenced by aldehyde dehydrogenase 1 (ALDH1) activity. Consistent with these
observations, BITC-mediated inhibition of bCSC inMCF-7,MDA-MB-231 and
SUM159 cells was signifıcantly augmented by RNA interference of KLF4 as
evidenced by ALDH1 activity and frequency of mammospheres. KLF4 overex-
pression also increased cell migration capacity of MCF-7 cells. Furthermore
knockdown of KLF4 augmented BITC-mediated inhibition of cell migration in
SUM159 cells. These results suggest that anticancer activity of BITC may be
enhanced by KLF4 inhibition or knockdown in breast cancer cells. This study
was supported by the grant RO1 CA129347-09 awarded by the National Cancer
Institute.
#5266 The mechanisms of apoptosis induction by deubiquitylatinase in-
hibitor b-ap15 in esophageal squamous cell carcinoma cells. Pei Li, Ping
Chen, Xiao-Yu Chen, Jing-Yang Zhang, Bei-Bei Sha, Tao Hu, Yi-Lin Zhang,
Ying Du, Zi-Ming Dong. Zhengzhou University, Zhengzhou, China.
Deubiquitinases (DUBs) act on ubiquitinated substrates to catalyze the re-
moval of ubiquitin moieties which can reverse the process of protein degrada-
tion, and further affect or regulate cell metabolism, proliferation and differenti-
ation. As a novel small molecular inhibitor, b-AP15 can specifıcally inhibit the
deubiquitinating activity of 19S regulatory subunit UCHL5(ubiquitin C-termi-
nal hydrolase 5) and USP14(ubiquitin-specifıc peptidase 14) in cancer cells. In
this study, we aimed to check whether b-AP15 have anti-tumor activity in
esophageal cancer cells in vitro and try to explore the underling mechanisms.
Results: CCK-8 assay, colony formation assay and morphological observation
results indicate that b-AP15 can signifıcantly inhibit the proliferation activity of
EC1 and Kyse 450 esophageal cancer(EC) cell lines in a concentration-depen-
dent manner in vitro studies. Flow cytometry results show cells were arrested in
G2/M phase after being treated with b-AP15.Western blot results show that the
expression of G2/M phase related proteins p21, p27 and pWee1 signifıcantly
increased while the expression of the G1/S phase marker proteins including
cyclinA, cyclinD show no signifıcant change after being treated with b-AP15.
FITC annexin V Apoptosis detection kit with PI and Caspase 3 Assay kit results
show that b-AP15 treatment can signifıcantly induce apoptosis in two EC cell
lines. The results from western blot show that the expression of apoptotic pro-
tein c-PARP and c-caspase 3 signifıcantly increased and was dose-dependent.
JC-1 flow cytometry analysis show that b-AP15 treatment can signifıcantly de-
crease mitochondrial membrane potential. All these results suggest that b-AP15
can induce EC cells apoptosis andmay play certain role inmitochondrial control
of apoptosis signaling pathway. Conclusion: b-AP15 shows a signifıcantly anti-
tumor activity in vitro models of ESCC and the results confırm that b-AP15 can
inhibit proliferation of EC cell lines by inducing cell-cycle arrest and promoting
cell apoptosis. Key words: b-AP15;esophageal cancer;deubiquitylatinase(DUBs);
apoptosis;
#5267 Chemoprevention of lung carcinogenesis by dietary nicotinamide
and inhaled budesonide. Donna Seabloom,1 Beverly Wuertz,1 Art Galbraith,1
Jenny Antonides,1 Vernon Steele,2 Lee Wattenberg,1 Frank G. Ondrey1. 1Univ.
of Minnesota, Minneapolis, MN; 2NCI Chemoprevention, Bethesda, MD.
Nicotinamide, the amide form of vitamin B3, and budesonide, a synthetic
glucocorticoid used in the treatment of asthma, were evaluated for effıcacy of
chemoprevention of lung adenoma formation in a benzo(a)pyrene murine car-
cinogenesismodel. FemaleA/Jmicewere given three doses of 3mgbenzo[a]pyr-
ene three days apart and started on experimental diets either 1 week (early stage
intervention) or 8 weeks (late stage) after last carcinogen dose. Aerosol treat-
ments were delivered 5 days per week starting 1 or 8 weeks post carcinogen.
Nicotinamide, fed at a dietary concentration of 0.75% starting 1 week after last
carcinogen administration, inhibited adenoma formation by 54%, and by 39%
when begun 8weeks post fınal carcinogen. Nicotinamide fed at 0.25% of the diet
was not found to effect adenoma formation . Dietary nicotinamide under the
same conditions with budesonide administered via aerosol administration at
25g/kg, reduced lung adenoma formation by 90% at early stage intervention
and 49% at late stage intervention. Budesonide alone administered at the same
dose level gave 77% inhibition at early stage and 41% inhibition at late stage.
Decreases in adenoma formation were statistically signifıcant via ANOVA anal-
ysis at both early and late interventions. Combination therapy decreased ade-
noma formation signifıcantly over either individual therapy at the early stage
and signifıcantly compared to nicotinamide alone at the late stage. However,
administration of nicotinamide by aerosol inhalation at doses up to 15 mg/kg/
day did not result in a statistically signifıcant reduction in tumor multiplicity at
1 or 8 weeks post last carcinogen administration . There is a high level of clinical
interest in minimal toxicity lung cancer chemoprevention strategies. We feel
administration of a safe dietary agent such as nicotinamidewhen combinedwith
direct epithelial delivery of a glucocorticoid such as budesonide, commonly used
for asthma therapy, is a promising approach for aerodigestive chemoprevention.
#5268 Nexrutine and palmatine mediated effects on the STAT3/EP4/IL-6
axis in pancreatic cancer. Amanda R. Munoz, Roble G. Bedolla, Paul Rivas,
Divya Chakravarthy, Robert L. Reddick, Martha A. Hanes, Glenn A. Halff, Rita
Ghosh, Addanki P. Kumar. University of Texas Health Science Center at San
Antonio, San Antonio, TX.
With a 5 year survival of less than 8%, the poor prognosis of pancreatic cancer
(PanCA) underlines the importance of improving therapies for effective man-
agement of this disease. In previous studies, we identifıed the tumor cell growth
inhibitory activities for Nexrutine® (Nx, a bark extract from Phellodendron
amurense) and palmatine (PMT) which is a constituent of Nx. These studies
revealed an important role for downregulation of KRAS downstream effectors
including GLI, STAT3 and NF-B in mediating growth inhibitory effects. Re-
markably, both Nx and PMT exerted synergistic growth inhibitory effects in
combination with the conventional chemotherapeutic agent, Gemcitabine
(GEM). Despite such promising in vitro observations, the in vivo effıcacy of Nx
or PMT had not been established. In this investigation, we evaluated the ability
of Nx and PMT to (i) prevent the development of pancreatic tumors; and (ii)
inhibit the growth of patient derived pancreatic cancer tissue in short term ex
vivo cultures. Studies were also conducted to investigate the underlying molec-
ular mechanism using cell culture models. Our results show that both Nx and
PMTarewell tolerated in vivo as evidenced by a lack of signifıcant changes in the
body weights of athymic mice implanted with Capan-2 cells. Interestingly, both
Nx and PMT showed a signifıcant decrease in the circulating levels of inflam-
matory molecules including IL-6 and CXCL1. In this fırst proof-of-concept
study, PMT treated animals demonstrated a trend towards decreased pancreatic
tumor weight with associated histopathogical changes. Remarkably, both Nx
and PMT inhibited the growth of patient derived pancreatic cancer cells. Mech-
anistic investigations identifıed downregulation of STAT3, TrkA, Src, and RPS6
activities as potential contributors to Nx or PMT-induced synergistic growth
inhibitory effects with GEM. Further investigation of STAT3 signaling revealed
the involvement of the prostaglandin receptor, EP4, in a potential feedback loop
with STAT3 and in asserting STAT3-mediated inhibition of autophagy. Taken
together these data support potential utility for Nx and/or PMT in the manage-
ment of PanCA and suggest that these agents use multiple mechanisms to affect
growth of pancreatic tumors. Supported by NCCIH (R01 AT007448; APK) and
VA-MERIT Award (I01 BX 000766; APK).
#5269 Cryptotanshinone activate Nrf2 expression through microRNA
regulations. Rachmad A. Dongoran, Tien-Yuan Wu. Tzu Chi University,
Hualien, Taiwan.
Cryptotanshinone is a diterpene quinone derived from the roots of Salvia
miltiorrhiza Bunge. An increasing number of studies have demonstrated that
cryptotanshinone has the pharmacological activities such as anti-oxidative
stress, anti-bacteria, anti-inflammation, and anti-cancer. Cryptotanshinone has
been found to increase the ARE expression level induced by the Nrf2 and de-
crease Keap1 expression. This study investigated Nrf2 and Keap1-related
microRNA to understand the mechanisms of cryptotanshinone in antioxidant
activities. HepG2 cells were treated with cryptotanshinone 2.5 M in DMEM
medium with 1% FBS for 5 days. Total RNA was obtained for small RNA se-
quencing and real-time PCR analyses. The analyses revealed that Cryptotanshi-
none had the potential to inhibit miR-27a-5p, miR-142-5p, miR-28 and miR-
93-5p levels, which subsequently increased the Nrf2 mRNA level. On the other
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hand, the Keap1mRNA level was suppressed through up-regulation ofmiR-23a
and down-regulation of miR-7-5p. Moreover, Nrf2 and its related downstream
anti-oxidant enzymes such as NQO1 and UGT were increased and the Keap1
protein level was decreased. These fındings suggest that cryptotanshinone pos-
sesses the cancer chemoprevention activity in up-regulation of Nrf2mRNA and
protein levels through the suppression of inhibitory microRNA. Future investi-
gations that extend the current study can focus on pharmacological mechanism
of cryptotanshinone as a cancer chemoprevention agent, and the safety of long-
term uptake of cryptotanshinone for cancer prevention.
#5270 Disease subtype independent biomarkers of breast cancer preven-
tion by withaferin a. Eun-Ryeong Hahm, Suman K. Samanta, Anuradha Seh-
rawat, Su-Hyeong Kim, Subrata K. Pore, Krishna B. Singh, Susan M. Christner,
Yongli Shuai, Jan H. Beumer, Ruchi Roy, Nancy E. Davidson, Shivendra V.
Singh. Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA.
Breast cancer is a rathercomplexandheterogeneousdiseasebroadlygrouped into
four major subtypes, including luminal-type, basal-like, HER2 amplifıed, and nor-
mal-like, and each with a distinct molecular signature. A non-toxic chemopreven-
tive intervention effıcacious against different subtypes of breast cancer is still a clin-
ically unmet need. The present study not only demonstrates chemoprevention of
breast cancer in rats by the Ayurvedic medicine phytochemical withaferin A
(WA) but also identifıes its mechanistic biomarkers common to different sub-
types of this disease. Chemopreventive effıcacy of WA (4 and 8 mg per kg body
weight) was determined using a rat model of breast cancer induced by N-meth-
yl-N-nitrosourea (MNU). The mechanisms underlying breast cancer chemo-
prevention by WA were elucidated by western blotting, biochemical assays,
immunohistochemistry, and cytokine profıling using plasma and tumors from
the MNU-rat and/or mouse mammary tumor virus-neu (MMTV-neu) models.
Inhibitory effect of WA on exit from mitosis and leptin-induced oncogenic
signaling was determined using MCF-7 and MDA-MB-231 cells. Incidence,
multiplicity, and burden of MNU-induced breast cancer in rats were decreased
byWA administration. For example, the tumor weight in the 8mg per kg group
was lower by 67% compared with controls (P 0.004). Mitotic arrest and apo-
ptosis induction were common determinants of breast cancer chemoprevention
by WA in the MNU-rat and MMTV-neu models. Cytokine profıling showed
suppression of plasma leptin levels byWA in rats. WA inhibited leptin-induced
oncogenic signaling in cultured MCF-7 and MDA-MB-231 cell lines. WA is a
promising phytochemical with the ability to inhibit at least two different sub-
types of breast cancer, including neu-driven estrogen receptor negative (ER-)
breast cancer in MMTV-neu model and MNU-induced ER breast cancer in
rats. This study was supported by the grant RO1 CA142604-07 awarded by the
National Cancer Institute.
#5271 Prostate cancer chemoprevention by dietary isothiocyanates is as-
sociated with suppression of lipogenesis. Krishna B. Singh, Shivendra V.
Singh. Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA.
Isothiocyanates (ITCs), including sulforaphane (SFN) and phenethyl isothio-
cyanate (PEITC), have been studied extensively for chemoprevention of prostate
cancer using both in vitro and in vivo models, but the underlying mechanism is
not fully understood. Dependence on fatty acid metabolism is progressively
recognized as a unique trait of prostate cancer. Using in vitro and in vivo pros-
tate cancer models, we demonstrate for the fırst time, that prostate cancer che-
moprevention by ITCs is associated with suppression of fatty acid metabolism.
Exposure of human prostate cancer cells to plasma achievable concentrations of
SFN resulted in a marked decrease in levels of key fatty acid metabolism pro-
teins, including acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FASN),
and carnitine palmitoyl transferase 1A (CPT1A), that was accompanied by sup-
pression of their transcription. Consistent with the in vitro results, oral admin-
istration of prostate cancer chemopreventive concentrations of SFN (6mol per
mouse, three times per week) resulted in downregulation of ACC1, FASN, and
CPT1A proteins in prostate adenocarcinoma of TRAMP transgenic mice when
compared with control. Levels of fatty acid metabolites (free fatty acid, triglyc-
erides and phospholipids), lactate, and acetyl-CoAwere also lower in the plasma
and/or prostate adenocarcinoma of SFN-treated TRAMP mice in comparison
with controls. Because fatty acid oxidation is an important step to supply energy
to the prostate cancer cells, we explored the possibility of whether SFN could
affect the fatty acid oxidation in prostate cancer cells. Indeed, SFN exposure
signifıcantly decreased the level of proteins involved in fatty acid oxidation in
prostate cancer cells. Many of these changes were also observed with PEITC. In
conclusion, it is reasonable to propose that suppression of fatty acidmetabolism
is an important mechanism in prostate cancer chemoprevention by ITCs. This
study was supported by the grants RO1 CA115498-10 and RO1 CA101753-12
awarded by the National Cancer Institute.
#5272 Chemopreventive activities of a polyphenol rich purifıed extract
from olive oil processing on colon cancer cells. Barbara Bassani,1 Teresa
Rossi,2 Daniela De Stefano,1 Daniele Pizzichini,3 Paola Corradino,1 Antonino
Bruno,1 Douglas M. Noonan,1 Adriana Albini1. 1Irccs MultiMedica, Milano,
Italy; 2Irccs Arcispedale SantaMaria Nuova, Reggio Emilia, Italy; 3Enea Casaccia
Research Center, Rome, Italy.
Epidemiological studies showed that diet can play a relevant role in reducing the
risk of developing colon cancer (CC) and lower rate of CC insurgence has been
observed amongst populations living within the Mediterranean basin. Olive oil, a
major component of the Mediterranean diet, is an abundant source of phenolic
compounds.Oliveoilproduction is associatedwith thegenerationofwastematerial,
termed ’olivemillwastewaters’ (OMWW), thathavebeen reported tobeenriched in
polyphenols as well. Given the benefıcial activity of polyphenols on human health,
we investigated whether the use of different batches of purifıed extracts from
OMWW, termedA009,might be effective in exerting chemopreventive activities in
vitro and in vivo, on CC cell lines. Cell proliferation and survival were evaluated on
A009 treated cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay,while the inductionof apoptosiswas assessedby flowcytometry.
Further, functional studies to investigate the ability ofA009 to interferewithCCcell
lineadhesion,migration, sproutingand invasionwereperformed.Finally, theability
of A009 to interfere with CT-26 CRC tumour cell growth was assessed in vivo.
Purifıed hydroxytyrosol, the major component in the A009 extracts, was used as a
control.A009 inhibited cell proliferation,migration, invasion, adhesionand sprout-
ing of CC cells along with the release of pro-angiogenic and pro- inflammatory
cytokines (VEGF, IL-8) similar to hydroxytyrosol alone. In vivo, A009 inhibited
CT-26 tumour growth in a signifıcant manner over that of hydroxytyrosol alone.
Our results show that A009 extracts exert promising chemopreventive properties,
suggesting that different polyphenols act synergistically, improving their single
component effects in CC cell lines. Finally, our results support the idea of reposi-
tioning awaste derivedmaterial for nutraceutical employment,with environmental
and industrial cost management benefıts.
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#5273 Detection of sessile serrated adenomas/polyps in African Ameri-
cans.Nazli Fatemi, sanmet singh, Babak Shokrani, Edward Lee, Ali Afsari, Me-
hdi Nouraie, Adeyinka Laiyemo, Joseph Mathews, Carla Williams, Hassan
Brim, Hassan Ashktorab. Howard Univ., Washington, DC.
Introduction: Themajority of colorectal cancers (CRCs) develop through the
adenoma-carcinoma sequence, while 15-20% develop via the serrated pathway.
Sessile Serrated Adenoma/Polyps (SSA/P) are more diffıcult to detect during
colonoscopy and generally require a shorter time follow-up than other lesions (3
vs. 5 years). These polyps lead to cancer faster than conventional adenomas. In
order to better defıne patients at risk for these lesions, we performed a retrospec-
tive study to evaluate clinicopathological features of patients diagnosed with
SSA/P. Methods:We reviewed pathology reports of patients at Howard Univer-
sity Hospital from 2010-2015. We identifıed 5,900 patients with colorectal le-
sions, of whom 312 (5.3%) were diagnosed with SSA/P.We analyzed the specifıc
clinical, pathological and demographic features of patients with SSA/P lesions.
Results: We identifıed 312 cases with SSA/P. The incidence of SSA/P over the 5
years period was 5.3%: 198/312 (63.4%) patients had 2 or more polyps, 54.5% of
the SSA/P patients were females, 70.5% of patients were 50-64 years of age and
18% were older than 65. SSA/P lesions’ locations were as follows: rectal: 32.1%;
rectosigmoid: 18.6%; sigmoid: 16.8%; Ascending Colon: 13.2 % andDescending
Colon: 7.1%. Reasons for colonoscopy were as follows: Screening: 43.6 %; GI
bleeding: 15.1%; Abdominal Pain: 13.1%and Change in Bowel Habits: 10.2%.
Conclusion: Our results show that there is a slightly increased predominance of
SSA/Poccurrence in females.Most SSA/Poccurred in patients 50 to 64 years old.
This age range is younger in comparison to patients with conventional adeno-
mas. SSA/Ps were predominantly distal (rectal, rectosigmoid, sigmoid) whereas
previous literature reports a proximal location. Most patients in our study were
diagnosed in screening colonoscopies; however, other patients presented with
symptoms such as GI bleeding, abdominal pain, or change in bowel habits.
#5274 Risk of comorbidities among Hispanic and non-Hispanic white
breast cancer survivors compared to breast cancer free women. Avonne E.
Connor,1 Kala Visvanathan,1 Stephanie D. Boone,2 Richard N. Baumgartner,2
KathyB. Baumgartner2. 1JohnsHopkinsUniv. School of PublicHealth, Baltimore,
MD; 2University of Louisville School of Public Health & Information Sciences,
Louisville, KY.
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Hispanic women are projected to account for an increasing proportion of the
U.S. breast cancer (BC) survivor population which is reaching 3.1 million. The
number of BC survivors at risk of developing age-related comorbid conditions is
increasing. Limited studies have examined the relationship between being a BC
survivor and risk of comorbidities compared to BC free women of similar age.
Few studies have included Hispanic women, in which the prevalence of chronic
conditions, such as diabetes and hypertension are high. In this study we exam-
ined the associations between BC survivor status, ethnicity, and risk of comor-
bidities among long-term BC survivors and BC free women/controls that par-
ticipated in the NewMexicoWomen’s Health Study (NMWHS) - a population-
based case-control study from 1992-1994. The Long-Term Quality of Life
Follow-up Study (2007-2011) was conducted approximately 15 years (median)
fromBCdiagnosis for cases or selection date for controls that participated in the
NMWHS.Data for comorbid conditions, lifestyle and reproductive factors were
collected at follow-up interview. Baseline data from the NMWHS interviews
were also available. A total of 449 BC survivors (68 Hispanic, 131 NHW) and
controls (78 Hispanic, 172 NHW) were included in this analysis. Adjusted odds
ratios (ORs) and 95% confıdence intervals (CI) were calculated using logistic
regression models for the associations between survivor status, risk of disease-
specifıc conditions and comorbidities based on Charlson Comorbidity Index
(CCI) level (low-high vs none) at follow-up. The mean age at follow-up of BC
survivors (64.3 years) and controls (64.0 years) was not signifıcantly different. A
total of 128 survivors and 139 controls experienced low-high levels of CCI (chi-
sq. p0.06). The two most commonly reported CCI conditions among survi-
vors and controls were connective tissue disease (43% of survivors; 33% of con-
trols) and chronic pulmonary disease (25% of survivors; 18% of controls).
Overall, BC survivors had increased risk of CCI (OR, 1.66; 95% CI 1.10-2.51),
compared to controls. While Hispanic ethnicity was not a signifıcant predictor
of CCI, the following factors were signifıcantly associated with CCI and were
mutually adjusted for with survivor status: smoked for 6 months at baseline
(OR, 1.59; 95% CI 1.06-2.38); hypertension at follow-up (OR, 1.84; 95% CI
1.19-2.85); and history of hysterectomy (OR, 1.97; 95% CI 1.28-3.03). BC survi-
vor status signifıcantly predicted risk of connective tissue (OR, 1.76; 95% CI
1.17-2.64) and chronic pulmonary diseases (OR, 1.68; 95% CI 1.04-2.70); while
no signifıcant associations were observed for risk of diabetes, hypertension, or
heart disease. Our fındings suggest that smoking history and hysterectomy are
contextual factors when considering BC survivorship care, and comorbidities
such as connective tissue and pulmonary diseases should also be considered.
#5275 Breast cancer characteristics among Indigenous American women
from Peru. Lizeth I. Tamayo,1 Tatiana Vidaurre,2 Jeannie N. Vásquez,2 Sandro
Casavilca,2 Jessica I. Palomino,2 Monica Calderon,2 Garth H. Rauscher,1 Laura
Fejerman3. 1University of Illinois at Chicago, Chicago, IL; 2Instituto Nacional de
Enfermedades Neoplasicas, Lima, Peru; 3University of California San Francisco,
San Francisco, CA.
Background: Breast cancer prognosis depends on stage at diagnosis and varies
by intrinsic tumor subtype. In the US, the distribution of intrinsic subtypes has
been shown to differ between racial/ethnic groups, with African American and
Hispanic/Latina women more likely to be diagnosed with the more aggressive
“triple negative” breast cancer (TNBC), lacking expression of estrogen receptor
(ER), progesterone receptor (PR) and human epidermal growth factor receptor
2 (HER2), compared toNon-Hispanic/LatinaWhite women.Hispanics/Latinos
in the US are a heterogeneous group originating from different countries with
different cultures and ancestral backgrounds. Information about the distribu-
tion of tumor subtypes in Latin American regions is lacking. Methods: Data for
these analyses come from the Instituto Nacional de Enfermedades Neoplásicas
(the Peruvian National Cancer Institute), which diagnoses and treats 20% of all
breast cancers diagnosed in Peru.We have abstracted data from clinical records
for 303 patients diagnosed with breast cancer between 2010 and 2015 and who
self-reported as members of an Indigenous American community from the An-
deanMountain region (indigenous subgroups: Quechuas, Aimaras, N232) or
the Amazonian region (indigenous subgroups: Shipibo-Konibo, Awajún,
Ashaninka, Kichua, Ese Eja, Harakbut, Amahuaca, Shawi, Yanesha, Kakataibo,
Nomatsigenga, N71). We compared the distribution of age at diagnosis and
tumor characteristics by region. Comparisons between the two regions were
conducted using chi-squared tests, as well as a t-test for age at diagnosis. Breast
cancer subtype was defıned as luminal A (ER/PR/HER2-), luminal B (ER/
HER2), HER2 overexpressing (ER/PR- HER2) and triple negative (ER/PR-
HER2-) based on immunohistochemistry. Results: Overall, tumors from the 303
IndigenousAmericanwomen fromPeru included in the present studywere 37%
luminal A, 20% luminal B, 23% HER2 overexpressing and 19% triple negative.
Our analyses showed thatwomen from theAmazonian regionwere diagnosed at
a younger age (50 vs. 55 mean age at diagnosis, P value 0.001), later stage
(53.0% vs. 41.7% stage III or IV, P value0.107) and more frequently with
triple-negative tumors compared towomen from theMountain Region (30% vs.
16%, P value 0.115). Conclusion: Differences between Indigenous American
women from the Amazonian andMountain Range regions in Peru could be due
to variation in genetic predisposition to particular subtypes of the disease, vari-
ation in environmental exposures, as well as to differences in cancer awareness
and access to care between the different groups. Themore we learn by analyzing
diverse populations, subpopulations and revealing heterogeneity within Latin
Americanwomen, the better equippedwewill be to provide adequate care for all
women.
#5276 Risk factors for ductal carcinoma in situ of the breast in African
American women. Kimberly A. Bertrand,1 Traci N. Bethea,1 Lynn Rosenberg,1
Elisa V. Bandera,2 Melissa Troester,3 Thaer Khoury,4 Christine B. Ambrosone,1
Julie R. Palmer4. 1Slone Epidemiology Center at Boston University, Boston, MA;
2Rutgers Cancer Institute of New Jersey and Rutgers School of Public Health, New
Brunswick, NJ; 3University of North Carolina Lineberger Comprehensive Cancer
Center, Chapel Hill, NC; 4Roswell Park Cancer Institute, Buffalo, NY.
Introduction: The clinical signifıcance of a ductal carcinoma in situ (DCIS)
diagnosis is uncertain. While overall breast cancer mortality risk from DCIS is
very low, a recent analysis showed that African American women diagnosed
with DCIS weremore than twice as likely to die from breast cancer as U.S. white
women. Elucidation of risk factors for DCIS in African American women may
provide opportunities for risk reduction. Methods: To assess the relation of
reproductive, anthropometric, and other factors to risk of DCIS in African
American women, we pooled data from three epidemiologic studies participat-
ing in the African American Breast Cancer Epidemiology and Risk (AMBER)
Consortium - the Black Women’s Health Study, the Carolina Breast Cancer
Study, and the Women’s Circle of Health Study. These studies contributed 805
DCIS cases and 13,830 controls to the analysis. We used unconditional logistic
regression models to calculate odds ratios (ORs) and 95% confıdence intervals
(CIs) for risk of DCIS in relation to each risk factor of interest. Multivariable
models were used to mutually adjust for risk factors as well as matching factors
(age, study, geographic region, and questionnaire time period). We also com-
pared results to associations observed for invasive breast cancer (n3,765). Re-
sults: First degree family history of breast cancer was associated with an in-
creased risk of DCIS (OR 1.62, 95%CI 1.32, 1.98). Oral contraceptive use within
the past 10 years (vs. never) was also associated with increased risk (OR 1.31,
95% CI 1.01, 1.70), as was late age at fırst birth (25 years vs. 20 years) (OR
1.29, 95% CI 1.04, 1.61). Older age at menarche (15 years vs.11 years) was
associated with a reduced risk (OR 0.67, 95%CI 0.49, 0.92).Womenwith higher
body mass index (BMI) in early adulthood (25 kg/m2 at ages 18 or 21) had a
reduced risk of DCIS compared to those who had a BMI 20 kg/m2 in early
adulthood (OR 0.71, 95%CI 0.56, 0.91), but there was no association for current
BMI. In general, associations of risk factors for DCIS were similar in magnitude
and direction to those for invasive breast cancer. However, high waist-to-hip
ratio and absence of breastfeeding, two factors associated with increased risk of
invasive breast cancer, and particularly with estrogen receptor negative breast
cancer among African American women, were not associated with DCIS, either
overall or by estrogen receptor status. Conclusions: Our fındings suggest that
most risk factors for invasive breast cancer are also risk factors for DCIS among
African American women. However, two important modifıable risk factors for
invasive breast cancer in this population, higher waist-to-hip ratio and absence
of breastfeeding, do not appear to influence DCIS risk.
#5277 Proteome and transcriptome alterations in black endometrial can-
cer patients correlate with poor disease outcome.NicholasW. Bateman,1 Eliz-
abeth Dubil,2 GuisongWang,1 Brian L. Hood,1 Tracy Litzi,1 Julie Oliver,1 Kath-
leen M. Darcy,1 Chad A. Hamilton,2 Thomas P. Conrads,3 George L. Maxwell4.
1Gynecologic Cancer Center of Excellence, Annandale, VA; 2Gynecologic Oncol-
ogy Service, Bethesda, MD; 3Inova Schar Cancer Institute, Falls Church, VA;
4Department of Obstetrics & Gynecology, Falls Church, VA.
Objective: Black endometrial cancer patients are more than twice as likely to
die from their disease asWhite patients. This study sought to identify alterations
in the proteome and transcriptome of primary tumor tissues from White and
Black endometrioid endometrial cancer (EEC) patients associated with differ-
ential outcome. Methods: An integrated proteomic and transcriptomic analysis
(LC-MS/MS and RNA-seq) was performed onWhite (n13) and Black (n17)
EEC patient tissues. Signifıcant and concordantly altered protein and transcript
candidates were validated against publicly available RNA-seq data (TCGA
UCEC) fromWhite (n216) and Black (n49) EEC patients. Validated candi-
dates were further correlatedwith overall (OS, n356White andBlack patients)
and progression-free survival (PFS, n331White andBlack patients) to identify
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candidates signifıcantly associated with differential disease outcome. Altera-
tions of outcome-associated candidateswere validated in an independent cohort
of White (n115) and Black (n17) EEC patient transcript expression data.
Results: We identifıed and validated 89 proteins and transcripts signifıcantly
altered betweenWhite vs Black EEC patients. Pathway analyses revealed candi-
dates elevated in White EEC patients correlated with marked activation of mo-
lecular signaling pathways regulating viral infection, but inhibition of those
regulating cell death and necrosis. Candidates elevated in Black EEC patients
largely correlated with activation of cell viability and nucleic acid metabolism,
but inhibition of cell death, glucose metabolism disorder and inflammatory
signaling. Correlation with patient outcome measures revealed 11 candidates
signifıcantly associated with differential OS and 8 candidates with differential
PFS in EEC patients. All outcome-associated candidates elevated in White pa-
tients signifıcantly correlated with a low risk of poor OS and poor PFS (Hazard
Ratio (HR)  1, Wald p-value  0.05). Conversely, the majority of outcome-
associated candidates (88%) elevated inBlack patients correlatedwith a high risk
of poor OS and poor PFS (HR 1,Wald p-value 0.05). Several OS (27%) and
PFS (75%) candidates remained signifıcant after adjustment for disease stage
and grade as well asmyometrial invasion. Alteration trends for several OS (27%)
andPFS (25%) candidateswere validated in an independent cohort ofWhite and
Black EEC patients. Conclusions: Our analyses identifıed and confırmedmolec-
ular alterations between White and Black EEC patients, including outcome-
associated candidates largely supportive of better outcome in White patients,
but poor outcome in Black patients. These fındings defıne molecular alterations
in White and Black EEC patients consistent with the historic disparity of poor
outcome for Black patients warranting further investigation of these candidates
in Black EEC disease pathology.
#5278 Effect of centralization on health disparities in lung and bladder
cancer surgery. Wil Lieberman-Cribbin, Martin Casey, Matthew Galsky, Api-
chat Tantraworasin, Bian Liu, William Oh, Raja Flores, Emanuela Taioli. Icahn
School of Medicine at Mount Sinai, New York, NY.
Background: Centralization has been advocated for both cystectomy and
pneumonectomy, since it has been associated with reductions in mortality. Ra-
cial disparities exist for both lung and bladder cancer surgical outcomes despite
trends in hospital centralization. We hypothesized that disparities exist in the
centralization process for both lung andbladder cancer surgery, and that this has
differentially affected surgical outcomes in black and white patients. Methods:
The study population was extracted from the NewYork Statewide Planning and
Research Cooperative System (SPARCS) database spanning 1997 to 2011, and
included 26,750 lung cancer surgeries and 8,168 cystectomies. Hospitals were
classifıed according to procedure volume; patient-hospital distance (PHD) and
distance to the nearest high volume / very-high volume (HV/VHV) were calcu-
lated. Logistic models were performed to determine factors associated with the
utilization of HV/VHV or low volume / very-low volume (LV/VLV) hospitals.
Additional models were then performed to assess the association between race
and in-hospital mortality, stratifıed according to whether patients used HV/
VHV or LV/VLV hospitals. Results: For cystectomy, PHD increased over the
study period while distance to the nearest HV/VHV decreased; for lung cancer
surgery, PHD increased but distance to the nearest HV/VHV hospital was con-
stant. For both surgical procedures, black patients experienced increased odds of
LV/VLV utilization over time (for lung cancer surgery, ORadj: 1.20; 95%CI
[1.01-1.43]; for cystectomy, ORadj: 1.59; 95%CI [1.26-2.02]). When HV/VHV
hospitals were located farther from patients, the odds of HV/VHV utilization
decreasedwhile the odds of LV/VLV increased for both lung cancer and bladder
cancer patients. Lung cancer and bladder cancer in-hospital mortality was
higher in blacks (ORadj: 1.50; 95%CI [1.21-1.86]; ORadj: 1.80; 95%CI [1.12-2.90],
respectively) compared to whites. Conclusions: Racial differences persisted in
hospital utilization and in surgical outcome for both lung and bladder cancers.
While proximity and insurance are important determinants of quality care,
other personal and community variables not captured by SPARCS are influential
in lung and bladder surgical treatment and ultimately outcome. Specifıc inter-
ventions are needed to address accessing and utilizing quality care in under-
servedpopulations, including black and lowSESpatients, andpatientswith large
distances from high-volume hospitals.
#5279 Association of Vitamin D defıciency with breast cancer in African-
American and Hispanic women in south Los Angeles. Yanyuan Wu,1 Mari-
anna Sarkissyan,2 Sheilah Clayton,2 Jay Vadgama1. 1Charles R Drew Univ. of
Medicine & Science, Jonsson Comprehensive Cancer Center, David Geffen School
of Medicine, University of California at Los Angeles, Los Angeles, CA; 2Charles R
Drew Univ. of Medicine & Science, Los Angeles, CA.
Background: Experimental evidence supports a protective role of Vitamin D
level in breast carcinogenesis, but epidemiologic evidence is inconsistent. Afri-
can Americans have high prevalence of Vitamin D defıciency and the African
American women with breast cancer have the highest mortality rate. The aim of
this study is to investigate the association of Vitamin D levels with breast cancer
risk and disease progression in African American and Hispanic women. Meth-
ods: This is a cases-control study of 660 African American andHispanic women
with and without breast cancer in South Los Angeles. Blood samples were col-
lected prior cancer treatment and the serum 25-hydroxyvitamin D (25(OH) D
was measured by Quest Diagnostics. Information regarding BMI and clinical
factors were obtained by medical record abstraction. Logistic Regression with
multivariate analysis was used for determining the association of Vitamin D
defıciency (20ng/ml) with breast cancer. Kaplan-Meier survival analysis and
Cox Regression with multivariate analysis were used to assess disease-free sur-
vival and the relative risk of disease progression. Results: Our data shows that
69.2% of African American women and 37.8% of Hispanic women suffer from
Vitamin D defıciency in our cohort. African American women had signifıcant
lower level ofVitaminD3 comparedwithHispanicwomen in all age groups. The
lower Vitamin D3 level was observed among age groups of 31 to 50 in African
Americans. The defıciency in Vitamin D levels was signifıcantly associated with
breast cancer in both African Americans (OR2.5, p0.007) and Hispanics
(OR1.9, p0.009). Interestingly, we found that a signifıcant association of
VitaminD defıciency with trip negative breast cancer (TNBC) in African Amer-
icans (OR3.2, p0.04), but not in Hispanics. The lowest VitaminD3 level was
observed in African American women with TNBC. There was no signifıcant
association of Vitamin D defıciency with tumor size, lymph node involvement
and tumor stage. The defıciency of Vitamin D3 level was not associated with
disease progression in this cohort of women. Conclusion: Our data suggests that
a signifıcant association of Vitamin D defıciency with breast cancer in both
African Americans and Hispanics, especially more associated with type of
TNBC in African American women in our cohort.
#5280 Disparity-related survival among adolescent and young adult pa-
tients with sarcomas in Texas. Jaqueline Contrera Avila,1 J. Andrew Livings-
ton,2 Ana Rodriguez,1 Anne Kirchhoff,3 Yong-Fang Kuo,1 Sapna Kaul1. 1The
University of TexasMedical Branch, Galveston, TX; 2SarcomaMedical Oncology,
University of TexasMDAndersonCancer Center, Houston, TX; 3HuntsmanCan-
cer Institute, University of Utah, Salt Lake City, UT.
Purpose: Sarcomas are a rare and heterogeneous group of cancers that can
occur in both children and adults, and have a peak in incidence in adolescents
and young adults (AYAs). Sarcomas may account for10% of all invasive can-
cers among AYAs and50% of all sarcoma diagnoses occur in this age group.
Additionally, sarcoma survival among AYAs is lower than that in children or
adult patients. Furthermore, although less understood, signifıcant socioeco-
nomic disparitiesmay exist in survival amongAYAswith sarcomas. The current
project examines disparity-related survival amongAYAswith sarcoma inTexas,
one of the largest U.S. states, that has over 50% non-Hispanic white population.
Methods: N4,131 patients diagnosed with bone or soft tissue sarcomas were
identifıed in the statewide Texas Cancer Registry from 1995-2013 at ages 15-39
years (i.e., AYA age range). Socio-demographics at diagnosis (e.g., race and
ethnicity, insurance, and county of residence), clinical characteristics (e.g., early
vs. late stage, treatment (e.g., chemotherapy), and vital status as of December 31,
2013)were summarized. Associations between patient survival and demograph-
ics/clinical variables were examined using the Kaplan Meier (KM) method, and
the Cox Proportional Hazard (CPH) regressions. KM survival curves were com-
pared using log-rank tests. Results: Over half of our patients were male (57.4%).
36.6% were Hispanic, 12.7% were non-Hispanic black, and 46.6% were non-
Hispanic white. Nearly 22% of patients were uninsured. Furthermore, 20% of
patients were diagnosed with metastatic sarcoma. The average 5-year KM sur-
vival for all patients was 69.5% (95% CI67.9%-71.0%). KM survival curves
signifıcantly differed by variables such as sex, race and ethnicity, insurance and
tumor staging. KM 5-year survival was higher for females (73.7% vs. 66.1% for
males, p0.001), for non-Hispanic white patients (72.1% vs. 63.9% for non-
Hispanic blacks, p0.001), patients with private insurance (76.0% vs. 68.2% for
uninsured, p0.001), and those with early stage sarcomas (77.1% vs. 23.4%,
p0.001). After adjusting for treatment and tumor staging, the CPH model
demonstrated that males (hazard ratio (HR)1.93, 95% CI1.25-3.00,
p0.003) and those who resided in Texas counties bordering Mexico
(HR1.95, 95%CI1.04-3.67, p0.04) faced a signifıcantly higher risk of death
than their counterparts. Conclusion: Our population-based analyses show that
substantial disparity-related differences in survival exist among AYA sarcoma
patients in Texas. Further study is warranted to identify specifıc interventions to
improve survival outcomes in this high risk patient group.
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#5281 Komen Tissue Bank donors: Genetically determined ethnicity and
race. Julia R. McCarty,1 Guanlong Jiang,2 Mariah L. Johnson,1 Teresa Mahin,1
Nicholas Scherer,3 Jonathon Dunn,4 Anna Maria Storniolo,3 Natascia Marino3.
1Susan G. Komen Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN;
2Indiana University School of Medicine, Indianapolis, IN; 3Indiana University,
Indianapolis, IN; 4LGC Genomics, Beverly, MA.
Background: Several evidences indicate that different racial and ethnic back-
grounds affect the incidence and severity of diseases such as breast cancer and
diabetes, and the response to therapy. For exampleWhite andAfricanAmerican
women are more likely to develop breast cancer than Hispanic and Asian
women. Moreover, African American women are more likely to develop more
aggressive (Triple Negative Breast Cancer), more advanced-stage breast cancer
at a young age. Therefore, given the health disparity and with the advance of
personalized medicine, it is becoming critical to address population stratifıca-
tion. The Komen Tissue Bank at IU Simon Cancer Center (KTB), the only
biobank of normal breast tissue from healthy women, is employing a more
accurate approach to detect population stratifıcation through the use of Ances-
try Informative Markers (AIMs). Methodology: A total of 2,973 DNA samples
were obtained from the KTB. Genotyping was performed using the KASP tech-
nology (LGC Genomics) and a 41-SNP panel (labeled 41-AIM panel) selected
from Nievergelt et al, 2013. Genotype analysis using the 41-AIM panel along
with aBayesian clusteringmethod (STRUCTURE)was able to discern continen-
tal origins including European/ Middle East (Caucasian), East Asia, Central/
South Asia, Africa, Americas, and Oceania. A reference set was obtained from
the HeatMap. The results were compared with the self-reported data. Results/
Conclusion: Our genetic ancestry analysis indicates that out of 2,973 KTB tissue
donors, 2,132 are primarily Caucasian, 532 African, 234 of Asian, 72 Latino, 3
Oceanic origins. High mixture of racial markers was observed in several sam-
ples. Moreover, when we compare these fındings with the self-reported data we
fınd a 10.9% of discrepancies indicating the imprecision of the self-reported
information. The implementation of the genetic ancestry data into the KTB
creates the potential for a more accurate study of health disparities.
#5282 Comparison of a public versus private hospital in NewYork City in
delivering timely adjuvant chemotherapy among stage III colon cancer pa-
tients. Daniel Lin,1 Benjamin Levinson,2 Judith D. Goldberg,2 Tsivia Hoch-
man,2 Lawrence P. Leichman,1Heather T. Gold2. 1NewYorkUniversity Langone
Medical Center, New York, NY; 2New York University School of Medicine, New
York, NY.
Background: Although the optimal timing of adjuvant chemotherapy (AC)
for stage III colon cancer patients has been debated, most studies recommend
initiating AC within approximately 60 days of surgery. Signifıcant disparities in
timeliness of AC initiation in colon cancer have been reported in public versus
private hospitals, with longer time to AC at public hospitals. We evaluated
whether timeliness of AC differed between a public and a private hospital, both
affıliated with the samemajor academic institution in New York City. Methods:
We conducted a retrospective cohort study of Stage III colon cancer patients
who underwent surgery and receivedAC at the same institution from2008-2015
at NYU Langone Medical Center’s affıliated public hospital (Bellevue) or its
private hospital (Tisch). Patient data were obtained through review of hospital
tumor registry and electronicmedical records. Patient characteristics were com-
pared by hospital. We defıned timeliness as receipt of AC within 60 days post-
operatively.Univariate and stepwisemultivariable logistic regressionswere used
to identify factors associated with timely AC. Results: Forty three patients at
Bellevue Hospital and 79 patients at Tisch Hospital who underwent surgery and
received AC at the same institution were included. Median number of days to
ACwas signifıcantly greater among patients receiving care at Bellevue (53, range
31-231) compared to Tisch (43, range 25-105; p0.002). However, the percent-
age of patients who received timely AC did not differ substantially at Bellevue
and Tisch (74% vs 81%, p0.40). Individual characteristics signifıcantly associ-
atedwith timely initiation ofACwere non-Hispanic ethnicity (OR: 2.71, 95%CI:
1.06-6.95), married (OR: 2.89, 95%CI: 1.15-7.30), and laparoscopic (vs open)
surgery (OR: 4.30, 95%CI: 1.64-11.25). The odds of receiving timely AC at Bel-
levue compared toTischwas not signifıcant (OR: 0.68, 95%CI: 0.28-1.65).When
hospital and other factors were examined jointly, only age (OR: 0.95/year, 95%
CI: 0.91-0.99) and laparoscopic (vs open) surgery (OR: 5.65, 95%CI: 1.92-16.62)
remained as important factors associated with receiving timely AC (Likelihood
Ratio Chi-Square14.95, p0.0019). When hospital was omitted from multi-
variable analysis, age and surgery type still remained the only signifıcant factors
associated with timely AC (OR’s unchanged, Likelihood Ratio Chi-Square
14.81, p-value0.0006). Conclusions: The proportion of patients receiving
timely AC within 60 days of surgery was similar at both an affıliated public and
private hospital at NYU Langone Medical Center. Age and type of surgery were
signifıcant predictors of timeliness in our population. Further research should
be conducted to understand how system-level factors may promote timely re-
ceipt of care.
#5283 Association between body mass index and prostate cancer among
African American men.Margaret S. Pichardo, Cheryl J. Smith, Wei Tang, Tif-
fany Dorsey, Stefan Ambs. National Cancer Institute, Bethesda, MD.
Prostate cancer (PCa) is a leading cause of cancer death in US men. Yet, the
etiology of prostate cancer remains poorly understood, with only older age,
African ancestry, family history of the disease, and multiple germline genetic
variations being established disease risk factors. Prostate cancer occurs more
often in African-American (AA) men and Caribbean men of African descent
than inmenof other race/ethnicities.While it has been previously suggested that
obesity (measured using body mass index [BMI, kg/m2]) may worsen disease-
related outcomes among prostate cancer patients, the relationship of obesity and
prostate cancer risk, using race as a predictor, has not been fully explored. Using
multivariable logistic regression, we estimated the risk of total PCa for 976 cases
and 1,032 age-matched controls, with equal proportions of European-American
(EA) and AA men. Among men in the NCI Maryland Prostate Cancer Case-
Control Study, BMI was inversely associated with disease outcomes in AAmen,
but not amongEAmen. Consistent with previous literature, BMI in EAmenwas
shown to be positively associated with overall prostate cancer risk. Our fındings
suggest an obesity paradox, where obesity may protect against incidence of PCa
among AA men. Studies are needed to elucidate the underlying mechanisms
responsible for the differential effects of obesity inAA andEAmenwith prostate
cancer.
#5284 Gastric cancer in Alaska Native people: A cancer health disparity.
Holly Martinson,1 Steven Alberts,2 Matthew Olnes3. 1Univ. of Alaska Anchor-
age, Anchorage, AK; 2Mayo Clinic, Rochester, MN; 3Alaska Native Medical Cen-
ter, Anchorage, AK.
Gastric cancer in the Alaska Native (AN) people occurs at a 3-fold higher
incidence and 4-fold higher mortality rate compared to Non-Hispanic Whites
(NHW), representing one of the largest cancer disparities in the AN population.
We aimed to review the AN gastric cancer burden and identify clinicopatholog-
ical factors that are associated with cancer outcomes. Patient information was
collected from 132 AN gastric cancer patients diagnosed between 2006-2015 at
the Alaska Native Medical Center. The Surveillance, Epidemiology and End
Result database 18 was used to collect comparison United States NHW gastric
cancer patient data. Compared to NHW patients, AN gastric cancer patients
have a higher incidence rate, are signifıcantly younger, 60 versus 69 years, and
have a poorer 5-year overall survival rate of 10% compared to 22%. AN patients
differ from NHW patients in gastric cancer anatomic location, subtype, and
higher presence of signet ring cell carcinomas. Forty-one percent of AN patients
were positive at the time of diagnosis for Helicobacter pylori, 77% had chronic
gastritis, 30% had a family history of a fırst-degree relative with gastrointestinal
cancers, and 82% were current or former tobacco users. Using univariate anal-
ysis, diminished overall survival was observed with anatomic site, increasing
stage, no treatment, the number of lymph nodes examined during resection,
blood type, and chronic gastritis.Multivariable analysis revealed stage and treat-
ment type were independently associated with improved overall survival. AN
gastric cancer cases vary in their clinical and epidemiologic features, relative to
NHW.
#5285 Glucocorticoid-mediated upregulation of stress oncoproteins: im-
plications for prostate cancer health disparities. Leanne Woods-Burnham,1
Arthur Love,1 Christina K. Cajigas-Du Ross,1 Laura Stiel,2 Evelyn S. Sanchez,1
Kwame Amponsah,1 Susanne Montgomery,2 Colwick Wilson,2 Carlos A. Ca-
siano1. 1Loma Linda University School of Medicine, Loma Linda, CA; 2Loma
Linda University School of Behavioral Health, Loma Linda, CA.
Prostate cancer (PCa) presents the greatest US cancer health disparity in
terms of incidence and mortality, disproportionately affecting African Ameri-
can (AA)men. The biological characteristics of prostate tumors are exaggerated
inAAmen compared to EuropeanAmerican (EA)men at time of diagnosis. The
mechanisms underlying increased PCa aggressiveness in AA men are not fully
understood; therefore, there is a critical need to identify biological determinants
contributing to PCamortality disparities. Glucocorticoids—a type of stress hor-
mone—have been implicated as driving factors in PCa progression. The under-
lying mechanism involves endogenous glucocorticoid (cortisol) binding to its
glucocorticoid receptor (GR) and activating genes that promote tumor aggres-
siveness and therapy resistance. A clinical dilemma exists as glucocorticoids,
important in the palliative care of PCapatients, are now emerging as accelerators
of disease progression and shortened survival. Chronically elevated levels of
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cortisol have been documented in AA men compared to EA men. This un-
healthy cortisol production has been linked to stressful life events, which occur
more frequently in the AA population. In addition, AA men are more sensitive
to glucocorticoid exposure than EA men. These observations support the hy-
pothesis that chronic stress leading to elevated cortisol in AAmenmay contrib-
ute to PCa health disparities. This study focused on examining the effects of
glucocorticoid agonists and antagonists on the expression of stress oncopro-
teins, particularly LEDGF/p75 (Lens epithelial-derived growth factor of 75 kd)
andCLU (clusterin), which are upregulated inPCa tumors andpromote features
of tumor aggressiveness, including resistance to clinically relevant taxanes used
for advanced PCa treatment. We exposed a racially diverse panel of PCa cell
lines, MDA-PCa-2b, 22Rv1, PC3, and DU145, to glucocorticoids (cortisol and
dexamethasone), and observed by immunoblotting a time and dose-dependent
upregulation of GR, LEDGF/p75 and CLU, particularly and more robustly in
AA cells. Treatment of cells with mifepristone, a GR antagonist, attenuated this
glucocorticoid-induced upregulation. In addition, siRNA- and shRNA-knock-
down of LEDGF/p75 in PC3 cells resulted in decreased GR expression, suggest-
ing a functional interplay between these two proteins in PCa cells. Interestingly,
we also observed, using ELISA, increased circulation levels of LEDGF/p75 inAA
PCa patients compared to EA patients and non-PCa controls, suggesting that
this stress oncoprotein might play a more prominent role in AA PCa patients.
These fındings imply that activation ofGR-signaling by glucocorticoids contrib-
utes to the activation of stress survival pathways associated with PCa aggressive-
ness and chemoresistance. These results add to the emerging contribution ofGR
signaling in PCa, particularly in the context of PCa health disparities.
#5286 Type 2 diabetes and increased risk of estrogen receptor-negative
breast cancer in African American women. Julie R. Palmer, Nelsy Castro-
Webb, Kimberly A. Bertrand, Traci N. Bethea, Lynn Rosenberg. Slone Epidemi-
ology Center at Boston University, Boston, MA.
Introduction: Type 2 diabetes (T2D) is hypothesized to be a risk factor for
breast cancer. Possible mechanisms include adverse effects of impaired glucose
regulation on endogenous hormone levels and increased inflammation of adi-
pose tissue, which may be favorable to breast epithelial cell transformation,
tumor-related angiogenesis, and cancer cell invasion. Recentmeta-analyses sug-
gest that T2Dmay be associated with a 15-20% increase in risk, but whether that
increase is due to residual confounding by body mass index (BMI) is uncertain.
Further, few studies have reported results separately by estrogen receptor (ER)
status of the tumor, none have had appreciable numbers of ER- cases, and the
only previous report on the association in African American (AA) women ana-
lyzed all subtypes together. Methods: We used data from the prospective Black
Women’s Health Study to examine the relation of T2D to incidence of invasive
breast cancer, overall and by ER subtype, among 54,337 AA women free from
T2Dand breast cancer at baseline and followed for 20 years. Includedwere 1,851
incident breast cancer cases, with 468 classifıed as ER- and 914 as ER; data on
ER statuswere not available for 469 cases. Participants were asked aboutmedical
conditions on each biennial questionnaire. In a validation study, 95% of self-
reports of diabetes were confırmed by medical records. Cox proportional haz-
ards regressionwas used to compute incidence rate ratios (IRR) for breast cancer
for womenwith T2D relative to womenwithout T2D, controlling for age, family
history of breast cancer, BMI at age 18, waist-hip ratio, years of education, and
reproductive factors. Results: The multivariable IRR for T2D versus no diabetes
was 1.20 (95% confıdence interval 1.01-1.41) for all breast cancer, 1.42 (1.02-
1.98) for ER- breast cancer, and 1.06 (0.83-1.36) for ER breast cancer. Most
cases had had diabetes for at least fıve years before the breast cancer diagnosis.
IRRs for 5 years duration of diabetes were 1.46 (1.02-2.07) for ER- and 1.08
(0.83-1.41) for ER breast cancer. Recent BMI was not associated with in-
creased risk of either ER subtype and was not a confounder in the present anal-
yses. BMI at age 18, whichwas inversely associatedwith breast cancer risk in this
and other studies, was the only appreciable confounder; inmultivariablemodels
that did not control for BMI at age 18, IRRs were 1.37 (0.99-1.90) and 1.03
(0.81-1.33) for ER- and ER breast cancer, respectively. Conclusions: The fınd-
ings suggest that AAwomenwith T2D are at increased risk of ER- breast cancer.
AA women are about two times as likely to be diagnosed with ER- breast cancer
as are U.S. white women and also have a markedly higher prevalence of T2D.
Their higher prevalence of diabetes may contribute to the disparity in incidence
of ER- breast cancer. The next step will be to assess whether risk of ER- breast
cancer among diabetic women differs according to how well the diabetes is
controlled.
#5287 Recent trends in racial and regional disparities in cervical cancer
incidence and mortality. Wonsuk Yoo,1 Sangmi Kim,1 Steven Coughlin,1 Se-
jong Bae,1 Edward Partridge,2 Warner Huh,2 Sarah Dilley,2 Yunmi Chung3.
1Augusta University, Augusta, GA; 2University of Alabama at Biomingham, Bir-
mingham, AL; 3Augusta University, augusta, GA.
Background: Although black and Hispanic women experienced greater cer-
vical cancer rate reduction in recent years, they continue to have higher inci-
dence rates than whites. Great variations also exist among geographic regions of
the US, with the South having both the highest incidence and mortality rates
compared to other regions. The present study explores the question of whether
living in the South is associated with greater racial disparity in cervical cancer
incidence and mortality by examining race- and region-specifıc rates and the
trend between 2000 and 2012. Methods: The Surveillance, Epidemiology, and
End Results (SEER) 18 Program data was used. Incidence and mortality rates,
annual percent changes, and disparity ratios of cervical cancer were calculated
using SEER*Stat software and Joinpoint regression for four groups: US14-Non-
Hispanic White (NHW), US14-Non-Hispanic Black (NHB), South-NHW, and
South-NHB, where the South included 4 registries fromGeorgia and Louisiana.
Results: The incidence and mortality rates were much higher among NHB
women compared to NHW in the South and the US. The degree of racial dis-
parities between NHB and NHWwomen was greater in terms of mortality rates
than incidence rates. For all age groups, NHB women in the South consistently
had higher incidence rates than NHBwomen in the US14 region. The mortality
disparity ratios was highest among NHB women, followed by NHW women in
the South, NHW women in US14, and fınally NHB women in the South. Con-
clusions: Although racial disparity has been narrowed in recent years, there has
been little change or even a growing gap between white women in the South and
their counterparts in the US14 region. Age-specifıc analysis further indicated
that the emerging regional gap observed among white women might be attrib-
utable to the excess number of new cases and deaths among young women.
#5288 Perception of barriers and facilitators to hepatitis B virus screen-
ing, vaccination, and treatment care among Asian American physicians. Pa-
tricia Estrella,1 Ming Chin Yeh,1 Yin Tan,2 Carolyn Y. Fang,3 Sarit A. Golub,1
Grace X. Ma2. 1Hunter College, CUNY, New York City, NY; 2Temple University,
Philadelphia, PA; 3Fox Chase Cancer Center, Philadelphia, PA.
Objective: To examine practices and factors affecting Hepatitis B Virus
(HBV) screening, vaccination, and treatment among Asian-American physi-
cians in New York City. Methods: Members of the Chinese American Indepen-
dent Practice Association (CAIPA) will be recruited to participate in a compre-
hensive survey, developed based on prior research, to assess physicians’ practice
inHBV screening, vaccination and treatment. This studywill also examinebarri-
ers/facilitators towardHBV prevention and treatment in knowledge, familiarity
or awareness of guidelines, perception, attitude/behaviors, self-effıcacy, motiva-
tion, patient factors, cultural, and environmental factors. A bivariate analysis
and multivariate regressions will be conducted to evaluate factors that predict
study outcomes. Results: We hypothesize that Asian American physicians are
more likely to screen for HBV, but are experiencingmany barriers unique to the
Asian American physicians that are leading them improperly perceive certain
patients not at risk for HBV infection. Furthermore, we anticipate fınding sig-
nifıcant key barriers and facilitators amongAsianAmerican physicians forHBV
screening and vaccination and treatment towards Asian patients. Preliminary
fındings will be presented at the conference. Conclusions& Implications: Asian/
Pacifıc Islanders (APIs) are disproportionally affected by chronic hepatitis B.
Therefore, identifying chronically infected persons and linking them to care is
crucial. As a result of the reverence of the doctors, a cultural norm prevalence
within the Asian community, physicians are uniquely positioned to improve
HBV screening and vaccination rates and if necessary, recommend linkage to
care. This study will fıll in an important gap in creating a culturally-relevant,
physician-focused intervention to improve HBV care and reduce the burden of
HBV infection within the Asian community.
#5289 Assessment of environmental influences, behavioral risk factors
and genetic differences among a cohort of 819AfricanAmerican community
members. Jacquelyn Bucci,1 Ming Chin Yeh,1 Khursheed Navder,1 Joel Er-
blich,1 Elizabeth Blackman,2 Grace X. Ma,3 Camille Ragin3. 1Hunter College,
CUNY, New York, NY; 2Fox Chase Cancer Center, Temple University Health
System, Philadelphia, PA; 3Temple University, Philadelphia, PA.
Objectives: This study was designed to address genetic, environmental and
lifestyle risk factors for cancer in populations of African Ancestry. We have
established a non-cancer control registry which involves the collection of epide-
miological, lifestyle, culture and cancer prevention behaviors (such as cancer
screening and diet, etc).Methods:Datawas coded and analyzed using Stata from
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initial study surveys. Results: At analysis, the cohort consisted of 819 partici-
pants. The cohort was 65.9% female, ages 18-89 (23.5%within 50-59 age group),
35.9% college graduates, and 17.4% with income level $20,000-$25,000. Two-
thirds of the cohort had BMI greater than 25, indicating overweight or obese.
When stratifıed by country of birth, participants born in the US & Territories
were more likely to be current smokers (23.3%) and have higher rates of envi-
ronmental exposure to smoking than any other region of birth analyzed. Partic-
ipants from US & Territories had the highest access to health care (85.9%). Pap
smears were the only screening test with statistically signifıcant difference be-
tween the regions, with US & Territories having the highest rates of screening
(p  0.001). Conclusions & Implications: Overall, the cohort and its data pro-
vide researcherswith a resource to further investigate health disparities in cancer
as well as other chronic diseases and tailor culturally relevant education materi-
als to help decrease the rates of cancer in this vulnerable population.
#5290 Racial variation in terminal duct lobular unit (TDLU) involution in
Chinese and Polish breast cancer patients. Hyuna Sung,1 Changyuan Guo,2
Jennifer Guida,1 Shan Zheng,2 Erni Li,2 Jing Li,2 Nan Hu,1 Joseph Deng,1
Montserrat Garcia-Closas,1 Jonine Figueroa,3 Mark Sherman,4 Gretchen Gier-
ach,1 Ning Lu,2 Xiaohong R. Yang1. 1National Cancer Institute, Rockville, MD;
2Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Med-
ical College, Beijing, China; 3The University of Edinburgh, Edinburgh, United
Kingdom; 4Mayo Clinic, Jacksonville, FL.
Introduction: Terminal duct lobular unit (TDLU) involution, an age-related
physiological process, is characterized by the reduction of size and numbers.
Reduced involution is associated with higher mammographic density, a strong
breast cancer risk factor. Both factors predict risk of developing breast cancer
among women with benign disease. Given that prior studies have been con-
ducted mainly in White women, we compared the extent of TDLU involution
amongWestern and Asian breast cancer cases to describe potential racial heter-
ogeneity in breast cancer etiology.Method:Weobtained three TDLU involution
metrics (count/100mm2, mean span, andmean acini count/TDLU; all inversely
correlated with TDLU involution) measured in benign breast tissue sections
from 379 Chinese (254 luminal A and 125 core basal phenotype [CBP] cases)
and 476 Polish (407 luminal A and 69 CBP) breast cancer cases. Polytomous
logistic regression was performed using tertiles of TDLU measures as ordinal
dependent variable and race as an independent variable. Covariates included
age, body mass index, and parity. Analyses were performed separately by age
group (50,50) and subtype (luminal A andCBP). Results: Among luminal A
cases, Chinese had signifıcantly greater TDLU count compared with Polish in
both age groups (ORtrend 11.0; 95% CI2.80-43.2; Ptrend0.001 for age50;
ORtrend 12.1; 95%CI5.12-28.7; Ptrend1E-08 for age50). In addition, Chi-
neseweremore likely to have greatermean span and acini count among younger
cases (ORtrend2.5; 95% CI1.44-4.28; Ptrend0.001 for mean span and
ORtrend7.4; 95% CI4.13-13.4; Ptrend3E-11 for acini count) but not among
older cases. Among CBP cases, Chinese were more likely to have greater acini
count compared to Polish only among younger women (ORtrend2.6; 95%
CI1.12-6.95; Ptrend0.03 for age50). Conclusion: We found Chinese were
more likely to have reduced TDLU involution compared to Polish cases after
accounting for potential confounders, with greater differences for luminalA and
younger women. Studies of TDLU involution in diverse populations are needed
to confırm and understand whether population difference in TDLU involution
metrics are related to age at breast cancer onset and risks for specifıc tumor
subtypes.
#5291 Effect of screening CT results and features on lung cancer risk pre-
diction within the National Lung Screening Trial.Hilary A. Robbins,1 Chris-
tine D. Berg,2 Li C. Cheung,2 Anil K. Chaturvedi,2 Hormuzd A. Katki2. 1Johns
Hopkins Bloomberg School of Public Health, Baltimore, MD; 2National Cancer
Institute, MD.
BACKGROUND: In the course of screening, individual risk of disease evolves
based on screening results. We calculated how individual lung cancer risk
changes based on screening CT fındings using data from the National Lung
Screening Trial (NLST), which conducted annual screening for 3 years. METH-
ODS:We calculated lung cancer risks by combiningCT fındings with individual
predicted 1-year “pre-screening risk.” Pre-screening risk r(x) was predicted in
the absence of screening using a validated risk model (Katki et al., JAMA 2016)
with covariates (x): age, education, sex, race, smoking intensity/duration/quit-
years, body mass index, family history of lung cancer, and self-reported emphy-
sema.We used log-binomial regression to calculate the risk of an “interval” lung
cancer (within 1 year of a negative screen) or a “screen-detected” cancer detected
at the next annual screen. For each, covariates included log-transformed 1-year
pre-screening risk and CT fındings including classifıcation as negative or false-
positive and other specifıc features. RESULTS: Themedian 1-year pre-screening
risk at the fırst NLST screenwas 0.32% (interquartile range 0.19-0.53%). Among
CT-negatives, risk over the next year was substantially reduced as r(x)1.32 (me-
dian interval cancer risk 0.05%), but risk at the next screen reverted to pre-
screening risk as r(x)1. Risk at the next screen was higher for those whose CT
noted either emphysema (r(x)0.95, median risk 0.53%) or consolidation (r(x)0.76,
median risk 1.6%). Among CT-false-positives, overall risk at the next screen
increased as r(x)0.74 (median risk 1.5%). Risk was higher among those with
nodule(s) that were larger, had spiculated margins (median risk 4.1%), were
located in the upper lobes (median risk 1.4%), or grew during the most recent
screening interval (median risk 7.9%), while nodules with smooth margins in-
dicated lower risk (median risk 0.71%). Those with a smooth-margins nodule
and no risk-increasing factors essentially reverted to their pre-screening risk at
the next screen as r(x)1.01 (median risk 0.29%), as if they had screened negative.
Overall, only the immediately prior screen result, and not earlier screens, pre-
dicted lung cancer risk (all p0.2). Exponents were similar for each interval and
at each screen (all p0.07). CONCLUSIONS: CT-negatives experienced re-
duced lung cancer risk over the next year, but reverted to their pre-screening risk
at the next screen. CT-false-positives experienced substantially increased lung
cancer detection at the next annual screen, with most risks exceeding 1%. These
risk increases were explained by specifıc CT features including nodule size, lo-
cation, margins, and growth.
#5292 Multitarget fecal miRNA test combined with fecal occult blood test
and fecal miRNA test for colorectal cancer screening. Yoshikatsu Koga,1
Nobuyoshi Yamazaki,1 Yasuo Kakugawa,2 Takahisa Matsuda,2 Masaaki Ito,3
Yutaka Saito,2 Hiroshi Saito,4 Yasuhiro Matsumura1. 1National Cancer Center,
Kashiwa, Japan; 2National Cancer Center Hospital, Tokyo, Japan; 3National
Cancer Center Hospital East, Kashiwa, Japan; 4National Cancer Center, Tokyo,
Japan.
Background & Aims: The fecal immunochemical test (FIT) is used for colo-
rectal cancer (CRC) screening worldwide. However, there are several issues of
the false-positive and the false-negative. To overcome these problems, various
molecular biological tests have been combined to FIT. In this context, multitar-
get fecal DNA test was approved by FDA in August 2014. In addition, multitar-
get fecalmicrobiota has been recently reported.We have reported the usefulness
of fecalmiRNA analysis to detect CRC.Here, we investigated the applicability of
multitarget fecal miRNA test combined with FIT and fecal miRNA test using
fecal RNA extracted from FIT residua. Methods: In this study, 57 patients with
invasive CRC, 33 patients with advanced adenoma, and 60 healthy individuals
were enrolled. Each participant collected 10 mg fecal samples using the FIT
sampling container for 2 days. After FIT was performed, total RNA was ex-
tracted from the residuum and miRNA expression was analyzed by using real-
time RT-PCR. The sensitivity and specifıcity of themultitarget fecal miRNA test
combinedwith FIT and fecalmiRNA testwas analyzed by using the decision tree
analysis. Results: Approximately 1g RNAwas extracted from 10mg fecal sam-
ple. The expressions ofmiR-16, miR-92a, miR-106a, miR-142-3p, miR-223, and
miR-451 in fecal samples were signifıcantly higher in the patients with advanced
neoplasm (including invasive CRC and advanced adenoma) than in the healthy
individuals (P0.05). The sensitivity and the specifıcity of the FIT alone were
74.4% (67/90) and 93.3% (56/60), whereas those of the multitarget fecal miRNA
test were 93.3% (83/90) and 91.7% (55/60). Moreover the multitarget fecal
miRNA test could detect 81.8% of patients with advanced adenoma (27/33).
Conclusions:Multitarget fecalmiRNA test combinedwith FIT and fecalmiRNA
test may be a useful new CRC screening method.
#5293 Have you checked?Disparities in cancer screening practices among
minority populations. Tamryn F. Gray,1 Joycelyn Cudjoe,1 Hae Ra Han,1 Jen-
nifer Wenzel,1 Roland Thorpe,1 Jeanne Murphy2. 1Johns Hopkins University,
Baltimore, MD; 2National Cancer Institute, Rockville, MD.
Objective: There is a disproportionately higher burden of cancer among racial
and ethnic minorities, with the incidence only expected to increase signifıcantly
by 2050. These racial differences may be due to the quality of early detection
screening among this population. The purpose of this research is to provide case
study reports about cancer screening practices among at-risk populations aswell
as those from underrepresented racial and ethnic minority backgrounds as well
as sexual and genderminorities in order to describe disparities in cancer screen-
ing practices. These fıve case studies reveal how racial disparities vary by cancer
site. These case studies will share information about current cancer prevalence,
current recommendations for cancer prevention, national guidelines about
early detection for lung, colorectal, prostate, cervical and breast cancers, as well
as discuss ways to reduce cancer health disparities and improve screening prac-
tices. Methods: Data sources for these case studies include research reports,
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literature review, clinically-based articles, research articles, websites, as well as
clinical practice observations and experiences. Research Summary: These case
studies contribute to the growing body of knowledge related to cancer health
disparities, with a special emphasis on cancer screening behaviors among un-
derrepresented, at-risk, and racial and ethnic minority backgrounds. Since can-
cer care is multidisciplinary, these case reports also highlight the role of oncol-
ogynurses in helping to lead in educating, promoting, andbringing awareness to
cancer screening recommendations and current cancer prevention guidelines
for individuals and their families. Nurses recognize that one of the biggest bar-
riers to screening is when individual have unrelated health care priorities that
overshadow priorities related to screening, such as food, shelter, and safety.
Nurses are also positioned to provide cancer-specifıc screening guidelines and
resources to help individuals implement these recommendations into their daily
lives. Improving screening rates among minority populations requires collabo-
rations with the health care systems and the community. Conclusion: Evidence
indicates that there are signifıcant disparities that exist in cancer screening prac-
tices among minority populations as well as disproportionately higher cancer
mortality rates in these populations. Barriers to screening include lack of access
to high-quality health care, lack of health insurance, transportation issues, fear
and lack of trust in the health care team, embarrassment, stigma related to sexual
orientation or gender identity, discrimination in quality care and treatment, as
well as lack of awareness about screening recommendations. Recognition of
barriers to screening among minority populations is critical to developing tar-
geted interventions that promote adherence and decrease risks of cancer-related
mortality.
#5294 Do co-morbid conditions correlate with cancer screening aware-
ness and behaviour among older women? Findings from the fıfth Indonesian
Family Life Survey. Wahyu Wulaningsih,1 Mieke Van Hemelrijck,2 Sumadi
Anwar,3 JohnathanWatkins4. 1University College London, London,UnitedKing-
dom; 2King’s College London, London, United Kingdom; 3Universitas Gadjah
Mada, London, Indonesia; 4PILAR Research and Education, Cambridge, United
Kingdom.
Background: Cancer screening awareness may vary in low- and middle-in-
come countries lacking established national screening programmes. Addition-
ally, breast self-examination (BSE) to screen for breast cancer is common in
these countries, despite evidence suggesting its lack of benefıt. We evaluated
co-morbidities as a potential determinant of awareness to breast and cervical
cancer screening andBSE practice in older women in Indonesia.Methods: From
the fıfth Indonesian Family Life Survey (2014-2015), 6,320 women aged 40 and
older who responded to questionnaires on pap smear, mammography, and BSE
were included. To assess co-morbidities, an age-weighted score similar to the
Charlson co-morbidity index was created based on self-reported history of
chronic disease diagnoses. Weighted regression analyses were performed to as-
sess their correlations with awareness to pap smear or mammography and BSE
practice. Results: Only 22% women were aware of pap smears, and 32% among
them had undergone at least one pap smear in their lifetime. Six percent of
participants were aware of mammography, among which 4% had a mammo-
gram in the previous year. Twelve percent of women reported they performed
BSE at least once a year.With increasing co-morbidities, participants weremore
likely to be aware of pap smear (e.g. age-adjusted OR3.27, 95% CI: 1.18-9.01
for co-morbidity score of2 compared to 0). No association with awareness to
mammographywas seen.Higher frequency of BSE per yearwas seenwith higher
co-morbidity (1.96, P0.01 for co-morbidity score of 2 compared to 0).
Associations remained, albeit weaker, after exclusion of women with history of
cancer. Conclusion: Higher co-morbidities weakly correlated with being more
aware to cervical cancer screening and practicing BSE more frequently among
older women. Our fındings may imply the need for targeted health promotion
and screening for cancer in presence of limited infrastructure.
#5295 Screening performance of ultrasonography and mammography
among Chinese women at high-risk of developing breast cancer. Yubei
Huang, Fengju Song, Kexin Chen. Tianjin Medical University Cancer Institute
and Hospital, Tianjin, China.
In order to easily identify high-risk population of breast cancer and to deter-
mine the optimal screeningmodality amongChinese high-riskwomen, a total of
33234 asymptomatic Chinese women aged 45-65 years underwent breast ultra-
sound (BUS) and mammography (MAM) screening concurrently. Physicians
performed these screeningmodalities separately andblindly. Thenumber of risk
factors of breast cancer, rather than complex risk predictionmodels, was used to
identify potential high-risk women. Initially, a total of 13 factors (age at men-
arche, menopausal status, age at menopause, number of live birth, age at fırst
pregnancy, breast feeding, duration of breast feeding, abortion, oral contracep-
tive, hormone replacement therapy, obesity, history of benign breast disease,
and family history of breast cancer) were selected. After excluding correlated
factors, factors with risk frequency 20% and factors withmissing values 5%,
6 factors (age at menarche, age at menopause, age at fırst pregnancy, oral con-
traceptive, obesity, family history of breast cancer) were selected as risk-evalu-
ating factors. High-risk women was defıned as those with 1 of the abovemen-
tioned 6 factors. According to this strategy, the detection rate among high-risk
women (4.34/1000) was signifıcantly higher than their counterpart (2.23/1000,
p0.001), and the percent of high-riskwomen accounted for 34.9%of thewhole
population. . Among high-risk women, the cancer detection rate onMAM (3.2/
1000) was non-signifıcantly different from that on BUS (3.1/1000; p0.663).
Comparisons on screening accuracy showed no signifıcant difference on sensi-
tivities (73.9% vs. 68.8%, p0.663), positive prediction values (14.1% vs. 18.5%,
p0.221), and negative prediction values (99.9% vs. 99.9%, p0.574) between
MAM and BUS, but signifıcant higher specifıcity for BUS (98.6%) than MAM
(98.0%, p0.001). Comparisons on cancer characteristics showed no signifıcant
difference on breast carcinoma in situ (22.6% vs. 17.2%, p0.605), lymph-node
involvement (24.1% vs. 20.0%, p0.715), and tumor size  2 cm (25.0% vs.
35.5%, p0.350) between MAM-detected cancers and BUS-detected cancers.
Subgroup analyses stratifıed by breast densities (four groups: 025, 25 50,
51 75,75%) or age at enrolment (four groups:49, 50-54, 55-59,60 years)
also showed no signifıcant difference on sensitivities between MAM and BUS
across subgroups. In conclusion, high-risk screening strategy based on the num-
ber of exposure to risk factors is an easy-to-use method to identify potential
high-risk women of breast cancer, and the performance of BUS is very similar to
that of MAM among high-risk women.
#5296 Evaluation of p16/Ki-67 dual stain, cytology, and HPV16/18 geno-
typing for triage of HPV-positive women in a large screening population.
Nicolas A. Wentzensen,1 Barbara Fetterman,2 Renee Bremer,1 Philip Castle,3
Diane Tokugawa,4 Nancy Poitras,2 Elizabeth Hosfıeld,2 Thomas Lorey,2 Mark
Schiffman,1 Walter Kinney2. 1NCI-DCEG, Bethesda, MD; 2Kaiser Permanente
Northern California, CA; 3Albert Einstein College of Medicine, Bronx, NY; 4Kai-
ser Permanente Northern California, Richmond, CA.
Objectives: Primary HPV testing has been approved in the United States.
Screening intervals can be safely extended for HPV-negative women, but the
challenge lies in discriminating transient HPV infections from precancers
among HPV-positives. In a large study at Kaiser Permanente Northern Califor-
nia (KPNC), candidate strategies for triage of HPV-positive women are being
evaluated, including cytology, p16/Ki-67 dual stain (DS, CINtec PLUS) and
HPV16/18 genotyping (cobas). Methods: Over 13,000 HPV-positive women
participating in cervical cancer screening at KPNCwere enrolled. The dual stain
and HPV genotyping assays were implemented and conducted at KPNC. Base-
line results for 7,124 women are available and detection of CIN3 is currently
evaluated only in cytology-positivewomen. Results: Among 7,124HPV-positive
women, 4,107 (57.7%) were cytology-positive (ASC-US), 3,056 (42.9%) were
DS-positive, and 1,406 (19.7%) were positive for HPV16 or HPV18. Among all
3,017 HPV-positive, cytology-negative women, 911 (30.2%) were DS- positive,
and 508 (16.8%) were positive for HPV16 or HPV18. Of 315 CIN3 detected so
far, 280 (88.9%) were DS-positive and 176 (55.9%) were positive for HPV16 or
HPV18. Major triage strategies including cytology alone, DS alone, as well as
combinations of cytology and genotyping, and DS and genotyping will be pre-
sented at the meeting. Discussion: In one of the largest clinical implementation
studies of triage strategies, we showed that primary HPV screening followed by
DS can reduce colposcopy referral compared to HPV-cytology co-testing while
achieving high sensitivity. Additional follow-up is underway to evaluate the
programmatic performance of several major candidate strategies.
#5297 Evaluation of lung cancer risk prediction models for selecting
smokers for CT lung cancer screening. Hormuzd Katki,1 Stephanie
Kovalchik,2 Lucia Petito,3 Li C. Cheung,1 Eric Jacobs,4 Ahmedin Jemal,4 Chris-
tine Berg,1 Anil Chaturvedi1. 1National Cancer Institute, Rockville, MD; 2Victo-
riaUniversity,Melbourne, Australia; 3University of California at Berkeley, Berke-
ley, CA; 4American Cancer Society, Atlanta, GA.
Background: The US Preventive Services Task Force (USPSTF) recommends
computed-tomography (CT) lung-cancer screening for ever-smokers ages
55-80 years who smoked at least 30 pack-years with nomore than 15 years since
quitting. 8.9 million U.S. ever-smokers are eligible for screening under USPSTF
criteria. Instead, selecting ever-smokers for screening using individualized lung-
cancer risk calculations may bemore effective and effıcient than current recom-
mendations. We examined the performance of 8 risk models for estimating risk
in 2 U.S. cohorts and compared the U.S. populations selected for screening by
the models. Methods: We examined 8 models: Lung Cancer Death Risk Assess-
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ment Tool and Lung Cancer Risk Assessment Tool (Katki et. al., JAMA 2016),
PLCOM2012 (Tammemagi et al, N Engl J Med 2013), Bach (Bach et. al., JNCI
2003), LLP (Cassidy et al, Br J Cancer, 2008), LLPi (Marcus et al, Cancer PrevRes
2015),Hoggart (Hoggart et al, Cancer PrevRes 2012), and Spitz (Spitz et al, JNCI
2007). We examined the predictive ability of each model among (1) 337,388
ever-smokers in the NIH-AARP Diet and Health Study (NIH-AARP), and (2)
72,338 ever-smokers in the American Cancer Society Cancer Prevention Study
II (CPSII)Nutrition SurveyCohort. For eachmodelwe estimated the calibration
(number of model-predicted cases divided by number of observed cases (Esti-
mated/Observed)) and the discrimination (Area-Under-Curve (AUC)). Each of
the 8 riskmodels and the USPSTF criteria were used to select a population of 8.9
million individuals at highest risk of lung cancer from amongU.S. ever-smokers
ages 50-80 (as characterized by data from the 2010-12NationalHealth Interview
Surveys). Results: In both NIH-AARP and CPSII, 4 models were well-calibrated
(Expected/Observed from 0.92 to 1.12) and had higher AUCs (0.76 to 0.79). The
other 4 models had worse calibration (Expected/Observed from 1.72 to 3.69)
and worse AUCs (0.62 to 0.75). When the models were used to choose the 8.9
million U.S. ever-smokers at highest lung-cancer risk, only 1.8 million indi-
viduals were chosen by all 8 models. For a screening eligibility risk-threshold of
2.0% lung-cancer risk over 5 years, the 8models chose populations including 7.6
million to 26 million U.S. ever-smokers. Conclusions: Some risk models were
more externally-valid and had superior predictiveness than others. Differences
in calibration led to risk models choosing very different screening population
sizes under a fıxed risk-threshold. The models did not achieve consensus on
selected populations for screening.
#5298 Lung cancer risk and scarring on imaging and histology in the Na-
tional Lung Screening Trial. Alison L. Van Dyke, Christine D. Berg, Neil E.
Caporaso, Hormuzd A. Katki, Anil K. Chaturvedi, Eric A. Engels. National
Cancer Institute, Rockville, MD.
Background: The contribution of pulmonary scars to lung cancer develop-
ment and the degree towhich lung cancers cause a scarring response are unclear.
Also unknown is how lung scarring impacts lung cancer screening. Methods:
We evaluated associations between scarring and lung cancer in the National
Lung Screening Trial (NLST), a lung cancer screening trial among current or
former, heavy smokers, 55-74 years-old. Baseline scarring (presence vs. absence)
on screening low dose computed tomography (LDCT) scan was assessed at
baseline (T0). Associations of T0 scarringwith screen-detected lung cancers and
with interval-detected lung cancers missed on screening within 3 years of T0
screen were analyzed using multinomial logistic regression. Cox proportional
hazards models were used to analyze the relationship between T0 scarring and
incident lung cancers diagnosed3 years after T0. Regression models included
age, sex, race, smoking history, chronic obstructive pulmonary disease, history
of pneumonia, and family history of lung cancer. A thoracic pathologist (fırst
author) evaluated lung cancer pathology slides from the Lung Screening Study
(LSS) subset of NLST for scar grade (none, sparse, dense) and maturity (none,
immature, intermediate, mature). Associations between T0 scarring on LDCT
and histological scarring were examined by logistic regression. Results: NLST’s
LDCT arm enrolled 26,722 participants (65% from the LSS). T0 scars were pres-
ent in 132 (22%) screen-detected, 12 (29%) interval-detected, and 94 (26%)
incident lung cancer cases. T0 scarring did not increase or decrease screen-
detection of cancers [odds ratio (OR) 95% CI: 1.03 (0.84-1.26)]. However, scar-
ringmight increase the chance of an interval-detected cancer [OR (95%CI): 1.54
(0.76-3.12)]. After screening stopped, T0 scarring was associated with increased
incident lung cancer risk [hazard ratio (HR) (95% CI): 1.27 (1.00-1.62);
P0.048]. Pathology slides were available for 258 (38%) lung cancers in LSS.
Lung scarring was found in 172 (67%) of these cancers with 58 (22%) being
characterized as mature scars. On microscopic review, scars were found in 80
(66%) ADC, 46 (82%) squamous cell carcinomas, and 20 (51%) bronchioloal-
veolar carcinomas. Microscopic scarring tended to be more frequent among
cases with T0 scarring than those without T0 scarring (75% vs. 64%; P0.10)
[OR (95% CI): 1.89 (0.98-3.86)]. Conclusion: The association between T0 scar-
ring and incident lung cancer over a period of more than 3 years is consistent
with an etiologic contribution of scarring to development of lung cancer. The
relationship between T0 scarring and scarring on microscopic evaluation sug-
gests that scarring preceded the cancer, further supporting an etiologic relation-
ship. Finally, the borderline association of T0 scarring and interval cancers sug-
gests that scarring may decrease the sensitivity of screening.
#5299 Validation of the BCSCmodel within theMayo Benign Breast Dis-
ease Cohort.RyanD. Frank,1 CelineM. Vachon,1 Stacey J.Winham,1 Robert A.
Vierkant,1 Marlene H. Frost,1 Derek C. Radisky,2 Daniel W. Visscher,1 Amy C.
Degnim1. 1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Jacksonville, FL.
Background: The Breast Cancer Surveillance Consortium (BCSC)model pre-
dicts invasive breast cancer risk in women with Benign Breast Disease (BBD),
and recently incorporated BBD histology into the model. The BCSC has been
validated in the MayoMammography Health Study, but has yet to be examined
inMayoClinic’s BBDcohort. TheBenignBreastDisease to Breast Cancer (BBD-
BC) model predicts risk of both invasive and in situ breast cancer. Here we
compare the performance of the BCSC and BBD-BC in Mayo Clinic’s BBD
cohort. Methods: Eligible women underwent a breast biopsy with benign fınd-
ings at the Mayo Clinic between years 1997-2001 and had a 4-view screening
mammogram within six months of biopsy. Clinical BI-RADS density assess-
ments using the 4th edition American College of Radiology were available on all
mammograms, and were coded as almost entirely fat, scattered fıbroglandular
densities, heterogeneously dense, and extremely dense. Risk at 5 and 10 years of
invasive cancer only (BCSCmodel) or both invasive and in situ cancer (BBD-BC
model) were estimated. In situ cancers were censored at time of diagnosis for
bothmodels. Concordance statistics, i.e.model discrimination (higher is better),
for each model were calculated using a Cox proportional hazards model with
predicted risk as the sole predictor, and were compared using permutation tests.
The ratio of total predicted (sum of predicted risk) to observed number of inva-
sive breast cancers was used to assess model calibration. Calibration was not
formally compared acrossmodels due to differences in howDCIS was treated in
the development of each (BCSC censored; BBD-BC event). Results: 999 women
met inclusion criteria. BI-RADS density was categorized as fatty in 46 (4.6%),
scattered densities in 372 (37.2%), heterogeneously dense in 423 (42.3%), and
extremely dense in 158 (15.8%). 62 invasive cancers occurred over a median
13.3yrs of follow-up, with 16 (25.8%) and 48 (77.4%) of the cancers occurring
with-in 5 and 10 years. The concordance of the BCSC at 5 years was 0.550 (95%
CI 0.409—0.691), compared to 0.719 (95% CI 0.578—0.860) for the BBD-BC
(p-value0.005). At 10 years the BCSC concordance was not signifıcantly dif-
ferent from the BBD-BC, at 0.624 (95% CI 0.542—0.706) and 0.662 (95% CI
0.580—0.744), respectively (p-value0.306). The BCSC over predicted the
number invasive cancers in the BBD cohort at 5 years (predicted-to-ob-
served1.54; 95% CI 1.01—2.70), but was well calibrated at 10 years (1.06; 95%
CI 0.83, 1.47). Conclusions: The BCSC model performed reasonably well in the
BBD Cohort 10 years post-biopsy, but overestimated risk at 5 years. Additional
study is needed to improve models for prediction of breast cancer risk among
women with BBD.
#5300 Risk models for cancer screening cohorts assembled from elec-
tronic health records: Application to calculating risks that underlie current
cervical cancer screening guidelines. Li C. Cheung,1 Qing Pan,2 NoorieHyun,1
Mark Schiffman,1 Barbara Fetterman,3 Philip E. Castle,4 Thomas Lorey,3 Hor-
muzd A. Katki1. 1National Cancer Institute, Rockville, MD; 2GeorgeWashington
University, Washington, DC; 3Kaiser Permanente Northern California, Berkeley,
CA; 4Albert Einstein College of Medicine, Bronx, NY.
Introduction:We developed risk models for cancer screening cohorts assem-
bled from electronic health records. We applied them to a cohort of 1.4 million
women undergoing cervical cancer screening with human papillomavirus
(HPV) and Pap “cotesting” at Kaiser Permanente Northern California (KPNC)
to develop risk estimates to inform screening guidelines. Methods: Cohorts as-
sembled using electronic health records present 3 challenges that make it inap-
propriate to use Kaplan-Meier or Coxmodels. First, the time of disease onset for
an individual is unobserved, and falls between screens (interval-censoring). Sec-
ond, there is also prevalent disease (left-censoring). Third, prevalent disease is
not always immediately diagnosed (e.g. in thosewith negative screening results),
and thus some incident disease is actually missed prevalent disease. To address
the challenges, we propose a “logistic-Weibull”model that is a logistic regression
for prevalent disease and a Weibull survival regression for interval-censored
incident disease. We also propose a non-parametric method (no covariates) to
check the assumptions of the logistic-Weibull model. We calculate risks of cer-
vical intraepithelial neoplasia grade 3 and cancer (CIN3) for each possible
abnormal cotesting result. As an illustrative example of the biases that can occur
in real data, we present the Kaplan-Meier, logistic-Weibull, and non-parametric
cumulative risk curves for 34,261 women at KPNC who test Pap negative and
HPV positive at enrollment. Results: The non-parametric method estimates
1.99% prevalent risk of CIN3 and 5.68% 7-year cumulative risk of CIN3
among women who are Pap-negative/HPV-positive at enrollment. In contrast,
the Kaplan-Meier method estimates merely 0.18% prevalent risk of CIN3,
primarily because of prevalent disease not diagnosed at baseline. Furthermore,
the Kaplan-Meier method overestimates 7-year cumulative risk as 7.37% be-
cause it equates the time of onset with the time of diagnosis, and thus overesti-
mates the hazards of disease onset at later times. In contrast, the logistic-Weibull
estimates of 1.87% prevalent risk of CIN3 and 5.84% 7-year cumulative risk of
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CIN3 are close to the risk estimates from the non-parametricmethod. Discus-
sion: The Kaplan-Meier method provided poor risk estimates while logistic-
Weibull model-based risks were close to the risk estimates from the non-para-
metric method. Our fındings support use of the logistic-Weibull models over
Kaplan-Meier methods for developing the risk estimates that underlie current
U.S. cervical cancer screening guidelines.
#5301 Cancer causation: rethinking the role of analogy.Douglas L. Weed.
DLW Consulting Services, Salt Lake City, UT.
Introduction. Fifty years has passed since the publication of Austin Bradford
Hill’s classic paper on causal inference.Much has changed in the biomedical and
public health sciences regarding cancer causation during that half century, but
Hill’s considerations (often called “criteria”) remain durable. That said, there is
a curious phenomenon involvingHill’s seminal work that has escaped the atten-
tion of the scientifıc community. His consideration of analogy—the last on his
list just after experimentation—has all but disappeared. The purpose of this
paper is to rethink and resurrect analogy as an important consideration in causal
inference in environmental epidemiology.Methods. Given that this is a concep-
tual—non-quantitative—project, the methods used are the informal logic of
scientifıc thinking, methods of systematic reviews, and judgment. Results. In
contemporary epidemiology, analogy is either completely ignored (e.g. in many
textbooks), equated with biologic plausibility or coherence, or aligned with the
scientist’s imagination.None of these examples, however, captureHill’s descrip-
tion of analogy which emphasizes the contrast of two bodies of evidence. Cou-
pled with developments in themethods of systematic assessments of evidence—
including but not limited tometa-analysis—analogy can be restructured as a key
component of causal inference. For theoretical support see similar methods in
biomedical ethics and artifıcial intelligence. Practical examples will be discussed.
Conclusions. Analogical reasoning—an updated version of analogy—can
emerge assuming the following developments: (1) a collection—a library—of
known cases of causal inference (i.e. bodies of evidence involving established
causal relationships), including, for example, the assessments of the Interna-
tional Agency for Research on Cancer (IARC) and the National Toxicology
Program (NTP), (2) a systematic process for describing the key features of a
causal relationship creating paradigm cases, and (3) an objective comparison of
a “new” body of evidence for a putative causal relationship with a relevant par-
adigm case.
#5302 Projections of cancer incidence and burden among the HIV-posi-
tive population in the United States through 2030. Jessica Y. Islam,1 Philip S.
Rosenberg,2 H Irene Hall,3 Evin U. Jacobson,3 Eric A. Engels,2 Meredith S.
Shiels2. 1UNCChapel Hill, Chapel Hill, NC; 2National Cancer Institute, National
Institutes of Health, Bethesda, MD; 3Centers for Disease Control and Prevention,
Atlanta, GA.
Background: People livingwithHIV (PLWH) are at an elevated risk of several
cancer types. With widespread use of highly active antiretroviral therapy
(HAART) to treat HIV, survival has improved among PLWH, resulting in an
aging U.S. HIV population. Though HAART use has reduced the risk of certain
cancers, in the near future, a larger fraction of PLWH will reach age groups
where cancer risks are further elevated, potentially shifting the distribution of
cancers in the population. Here, we projected cancer incidence rates and burden
amongU.S. PLWH through 2030 for Kaposi sarcoma, non-Hodgkin lymphoma
(NHL) and cervical cancer (3 AIDS-defıning cancers [ADCs]), and anal, breast,
colon, lung, liver, prostate and oral cancers, Hodgkin lymphoma and all other
cancers combined (all non-AIDS-defıning cancers [NADCs]). Methods: We
used cancer incidence data (2000-12) collected from the HIV/AIDS Cancer
Match Study, a record linkage study of HIV and cancer registries. Using Poisson
regression, we estimated cancer incidence rates in PLWH stratifıed by age group
and, for some cancers, risk group (e.g., men who have sex withmen, people who
inject drugs) during 2013-30. The number of PLWH in the U.S. by age, risk
group and calendar year (2006-30)was estimated using a dynamic compartmen-
tal model. To estimate cancer burden, observed and projected incidence rates
andHIVpopulation counts weremultiplied. Results: The proportion of the total
U.S.HIVpopulation that is aged65 years is projected to increase from4.1% (of
1.06 million) in 2006 to 21.4% (of 1.09 million) in 2030. Based on signifıcant
declines during 2000-12, age-specifıc rates are projected to decrease across age
groups for NHL, cervical cancer, lung cancer and all other cancers, and for some
age groups for KS, Hodgkin lymphoma and colon cancer. All other age-specifıc
rates did not change signifıcantly, with the exception of prostate cancer rates,
which are projected to continue to increase. We estimated that the total cancer
burden in PLWH will decrease from 7908 cases in 2010 (2719 ADC and 5190
NADC) to 6495 cases in 2030 (701 ADC and 5794 NADC), indicating a strong
decrease in ADCs and a slight increase in NADCs. In 2030, the most common
cancers among PLWH will include: prostate (n1624), lung (n786), liver
(n498) and anal cancers (n447) and NHL (n429). Conclusions: Though
cancer rates are generally decreasing, cancer will remain an important co-mor-
bidity as the U.S. HIV population ages. If recent trends in cancer incidence
continue into the future, the burden of NADCs, particularly prostate, lung, liver
and anal cancers, will far exceed the burden of ADCs in 2030. Targeted cancer
prevention, early detection and control efforts are needed for PLWH in theU.S.,
including smoking cessation, treatment of hepatitis C and B viruses, cancer
screening and continued widespread treatment with HAART.
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#5303 FAIMS technology in urinary volatile organic compound analysis
to detect colorectal cancer. Christopher Psutka,1 Marina Yamada,2 Akihisa
Matsuda,2 Kazuya Yamahatsu,2 Satoshi Matsumoto,2 Toshihiko Kitayama,3
Nobuo Nakano,3 Jyunichi Koyano,3 Tohru Mikoshiba,1 Masao Miyashita2.
1FAIMStech Japan, Tokyo, Japan; 2Nippon Medical School Chiba Hokusoh Hos-
pital, Chiba, Japan; 3Riken Keiki, Tokyo, Japan.
Introduction: This is an investigation of the capability of FAIMS (FieldAsym-
metric Ion Mobility Spectrometry) technology as a tool for non-invasive detec-
tion of Colorectal Cancer (CRC) through urinary volatile organic compound
analysis. It expands on ‘Detection of Colorectal Cancer (CRC) by Urinary Vol-
atile Organic CompoundAnalysis‘ (Ramesh P. Arasaradnam et al, 2014) with an
increased sample population and local to Japan, also comparing in-house data of
CA19-9 and carcinoembryonic antigen (CEA) markers. Experiment: Con-
ducted at NipponMedical School Chiba Hokusoh Hospital, urine samples were
collected and frozen at -80°C from 139 patients at various stages of CRC and 78
healthy control samples. The samples were thawed in batches and placed in ice
hours prior to testing. 2 ml of each urine sample was aliquoted into 10 ml vials
for processing with the commercial FAIMS device (Lonestar, Owlstone, UK).
Each vial was heated in the device to 40°C to create headspace with suffıcient
VOCs then a carrier gas (clean dry air) delivered the headspace (0.5 L/min)
diluted with amake-up flow (2 L/min). The FAIMS device was set to scan at 0 to
100%electric dispersion fıeld in 51 steps and compensation voltage between -6V
and 6 V in 512 steps, producing data matrices for each sample’s analysis.
Principal Component Analysis (PCA) followed by Partial Least Squares Dis-
criminant Analysis (PLS-DA) of each sample was conducted using SIMCA 13
(Umetrics, Sweden). See Table Conclusions: FAIMS technology achieved a high
rate of separation between the CRC and healthy control urine samples with
64.7% sensitivity and 82.1% specifıcity overall. As the CRC stage advances the
sensitivity increased from 27.3% to 100%. Results: show excellent potential to
use FAIMS technology as an early screening tool for CRC, particularly impres-
sive compared to in-house sensitivity data of CA19-9 andCEAmarkers. Further
research into FAIMS screening of other cancer types through VOC biomarker
analysis of urine, breath, and feces is recommended.
Detection Results
CRC
STAGE
FAIMS
OTHER
MARKERS CA19-9 CEA
True
Positive
False
Negative Sensitivity
False
Positive
True
Negative Specifıcity
No. of
Samples Sensitivity Sensitivity
I 12 32 27.3% 14 64 82.1% 43 4.7% 18.6%
II 18 12 60.0% 14 64 82.1% 31 16.1% 32.3%
III 45 5 90.0% 14 64 82.1% 52 19.2% 36.5%
IV 15 0 100% 14 64 82.1% 17 35.3% 64.7%
ALL 90 49 64.7% 14 64 82.1% 143 16.1% 33.6%
#5304 A serological biopsy using fıve stomach-specifıc circulating bio-
markers for gastric cancer risk assessment: a multi-phase study. Huakang
Tu,1 Liping Sun,2 Xiao Dong,3 Yuehua Gong,2 Qian Xu,2 Jingjing Jing,2 Roberd
M. Bostick,4 XifengWu,1 Yuan Yuan2. 1University of Texas MD Anderson Can-
cer Center, Houston, TX; 2China Medical University, China; 3The University of
Texas School of Biomedical Informatics at Houston, TX; 4Emory University, At-
lanta, GA.
Objective:We aimed to assess a serological biopsy using fıve stomach-specifıc
circulating biomarkers—pepsinogen I (PGI), PGII, PGI/II ratio, anti-Helico-
bacter pylori (H. pylori) antibody, and gastrin-17 (G-17)—for identifying high-
risk individuals and predicting risk of developing gastric cancer (GC).Methods:
Among 12112 participants with prospective follow-up from an ongoing popu-
lation-based screening program using both serology and gastroscopy in China,
we conducted a multi-phase study involving a cross-sectional analysis, a fol-
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low-up analysis, and an integrative risk predictionmodeling analysis. Results: In
the cross-sectional analysis, the fıve biomarkers (especially PGII, the PGI/II
ratio, andH. pylori sero-positivity) were associated with the presence of precan-
cerous gastric lesions or GC at enrollment. In the follow-up analysis, low PGI
levels and PGI/II ratios were associated with higher risk of developing GC, and
both low (0.5 pmol/L) and high (2.0-4.7 or 4.7 pmol/L) G-17 levels were
associated with higher risk of developing GC, suggesting a J-shaped association.
In the risk predictionmodeling analysis, the fıve biomarkers combined yielded a
C statistic of 0.801 (95% CI0.787-0.815) and improved prediction beyond
traditional risk factors (C statistic from 0.580 to 0.811, P0.001) for identifying
precancerous lesions at enrollment, andhigher serological biopsy score based on
the fıve biomarkers at enrollment were associated with higher risk of developing
GC during follow-up (P for trend 0.001). Conclusions: A serological biopsy
composed of the fıve stomach-specifıc circulating biomarkers could be used to
identify high-risk individuals for further diagnostic gastroscopy, and to stratify
individuals’ risk of developing GC and thus to guide targeted screening/preci-
sion prevention.
#5305 Risk of thyroid nodules in residents of Belarus exposed to Cher-
nobyl fallout as children and adolescents. Elizabeth K. Cahoon,1 Eldar Nad-
irov,2 Olga Polanskaya,2 Vasilina Yauseyenka,2 Vasilina Yauseyenka,2 Ilya
Velalkin,2 Tamara Yeudachkova,2 Tamara Maskvicheva,2 Victor Minenko,3
Wayne Liu,1 Vladimir Drozdovitch,1 Kiyohoko Mabuchi,1 Mark Little,1 Lydia
Zablotska,1 Robert McConnell,1 Maureen Hatch,1 Kamau Peters,1 Alexander
Rozhko,2 Alina Brenner1. 1National Cancer Institute, Bethesda, MD; 2The Re-
publican Research Centre for Radiation Medicine and Human Ecology, Belarus;
3Belarusian Medical Academy of Post-Graduate Education, Belarus.
Context: The relationship between childhood radiation exposure and thyroid
nodules has not been comprehensively evaluated in young adults or for nodules
with varying histological or ultrasound features. Objective: To examine the as-
sociation between internal I-131 thyroid radiation dose and thyroid nodules in
young adults exposed during childhood. Design, setting, and participants: In
this cross-sectional study, we screened 11,970 residents of Belarus aged 18
years at the time of the Chernobyl nuclear accident (April 1986) for thyroid
disease (median age 21 years). Screening consisted of thyroid palpation, ultra-
sonography, blood and urine analysis, andmedical follow-upwhen appropriate.
Eligible participants (N11,421) had intact thyroid glands and doses estimated
using direct individual thyroid activitymeasurements.Main outcomemeasures:
Excess odds ratios per gray (EOR/Gy) for any thyroid nodule and for nodules
grouped by histological and ultrasound characteristics selected a priori. Results:
Risk of any thyroid nodule was associated with increasing I-131 in the entire
dose range (0.001-39 Gy) and radiation-related risk increased with younger age
at exposure. For participants exposed to5 Gy, we found EORs/Gy (95%CI) of
0.70 (0.33, 1.18) for any nodule, 0.32 (-0.03, 0.70) for non-neoplastic nodules,
3.82 (0.87, 15.52) for neoplastic nodules, 0.27 (-0.13, 0.70) for nodules 10
mm, 2.12 (0.96, 4.60) for nodules10 mm, 0.67 (0.30, 1.19) for single nodules,
and 0.59 (-0.29, 2.05) for multiple nodules (centered at age 5 years at expo-
sure). Conclusions: Childhood exposure to internal I-131 is associated with
thyroid nodules of various histological/ultrasound characteristics, but magni-
tude of the risk varies substantially.
#5306 p16INH4a status helps predict clinical outcome of dysplasia in the
oral cavity irrespective ofHPV status.Tarinee Lubpairee,1 Elena Prigge,2Mag-
nus von Knebel Doeberitz,2 Miriam Reuschenbach,2 Lewei Zhang,3 Miriam P.
Rosin4. 1BC Cancer Research Centre, Vancouver, British Columbia, Canada;
2University Hospital Heidelberg, Germany; 3University of British Columbia, Brit-
ish Columbia, Canada; 4Simon Fraser University, Burnaby, British Columbia,
Canada.
Objectives: p16INK4a is a key gatekeeper for multiple biological processes that
are associated with protection from cancer, including cell cycle control and
senescence. Elevated expression of this gene is strongly correlated with biologi-
cal activity of HPV infection and cancer development in uterine cervix and
tonsil. Although HPV DNA has been found in a small portion of oral cavity
cancers and dysplasia, the relevance of its presence to cancer development at this
site is unclear, as is the signifıcance of an expression change in p16INK4a as a
predictor of HPV status, tissue behavior and outcome. Methods: Formalin-
fıxed, paraffın-embedded biopsies from 164 patients with mild, moderate and
severe oral dysplasia in the “Oral Cancer Prediction Longitudinal study”
(OCPL), British Columbia, Canada, were analyzed for HPVDNA using a semi-
quantitative viral load Luminex technology. Expression of p16INK4awas assessed
and categorized into 3 staining patterns (diffuse, focal, and negative). Results:
HPVDNAwas found in 13 (8%) lesions, 7 hadHPV-16 infection and 1HPV-18.
Of the 164 samples, diffuse p16INK4a expressionwas present in 18%, focal in 56%
and no p16 staining in 23% of samples. There was no signifıcant correlation
betweenHPVDNA-positivity and p16INK4a staining. Different p16 staining pat-
terns showed signifıcantly different progression rates (P 0.0001): progression
occurred in 1/92 (1.1%) focally stained, 1/29 (3.5%) diffusely stained and 10/43
(23.3%) with no staining. Conclusion: HPV DNA-positivity occurs in a small
proportion of oral dysplasia but is poorly associated with p16INK4a expression.
Future assessment of these samples for HR-HPV oncogene transcripts will pro-
vide information on its biological activity. The low likelihood of progression of
p16INK4a focally stained lesions suggests a value of this marker in identifıcation
of low-risk cases. Acknowledgements: Supported by ElseKröner-Fresenius-Stif-
tung Foundation, Germany.
#5307 Analysis of volatile organic compounds for the diagnosis of lung
cancer. Takuya Inoue,1 Hironori Takagi,1 Yuki Owada,1 Yuzuru Watanabe,1
Mitsuro Fukuhara,1 Takumi Yamaura,1 Satoshi Muto,1 Naoyuki Okabe,1 Yuki
Matsumura,1 Takeo Hasegawa,1 Takeda Manami,2 Atsushi Sato,2 Hiroyuki Su-
zuki1. 1Fukushima Medical University, Fukushima, Japan; 2GL Sciences Inc.,
Saitama, Japan.
Background: Lung cancer is the leading cause of cancer-related deaths in the
world. The prognosis of lung cancer depends on disease detection at an early
stage. Recently, effectiveness of lung cancer screening by using low dose com-
puted tomography scanning have been showing. However, it still has problems
such as cost of screening and radiation exposure. Thus, less invasive and cost
benefıcial lung cancer screening procedure would be needed. In this context,
several study to understand the effıcacy of molecules from expiration of patients
as a lung cancer screening were showing, but it was still controversial. In this
study, we investigated to determinewhether volatile organic compounds (VOC)
from patients could be used for the detection for lung cancer by using novel
small and unique absorbent material namedMonoTrap . Method: The subjects’
gas was collected from skin and exhaled breath in a MonoTrap (GL sciences),
and the VOCs were analyzed by gas chromatography/ mass spectrometry (GC/
MS). First of all, we preliminary analyzed for both sample from skin and exhaled
breath for 12 patients and 11 healthy volunteers to clarify which samples were
more sensitive to diagnose lung cancer. Subsequently, each VOC was deter-
mined in detail for 7 healthy individuals and 4 lung cancer patients and these
values were statistically analyzed. Results: By preliminary study, characteristics
of VOCderived from skin were signifıcantly correlated with cancer condition as
comparedwith healthy volunteer by using comprehensivemultivariate analysis.
Therefore, we performed further quantitative analysis by targeting unique indi-
vidual molecules derived from skin. In VOCs from skin, Mann-Whitney U test
showed that 4-hydroxy-4-methyl-2-pentanone, hexadecane, and acetamide
were signifıcantly higher in lung cancer patients (p0.036, p0.006, p0.036,
respectively). Conclusion: In this study, we found that 3 kinds of VOCs could be
a potential diagnostic biomarkers of lung cancer. Further prospective study is
now planning to validate these data using large number samples.
#5308 Tissue-based heterogeneity in lobular carcinoma in situ. Sarah J.
Nyante, EmilyOzdowski, XianmingTan, Thomas J. Lawton.University of North
Carolina at Chapel Hill, Chapel Hill, NC.
Lobular carcinoma in situ (LCIS) is a preinvasive breast lesion associatedwith
a 6 to 11-fold increased risk of invasive breast cancer. Despite this increased risk,
little is known regardingwhat qualities of LCIS predispose individual patients to
invasive cancer. Given recent advances in understanding of the importance of
etiologic heterogeneity within breast cancer, we sought to characterizemorpho-
logicmarkers of heterogeneity in LCIS and surrounding tissue, with the hypoth-
esis that features with lesional variation may be important candidate predictors
of breast cancer risk. We identifıed 64 patients aged 18 years who were diag-
nosedwith LCIS at a single institution from2004-2014. Patientswith concurrent
invasive breast cancer in the same breast were excluded. Archival slides of each
case were reviewed by an experienced breast pathologist to confırm the presence
of LCIS and characterize the LCIS type (classic, florid, or pleomorphic). The
number of lobules involved with LCIS, presence of calcifıcations or necrosis
associated with LCIS, and presence of other benign lesions [atypical lobular
hyperplasia (ALH), atypical ductal hyperplasia (ADH), flat epithelial atypia,
fıbroadenoma, intraductal papilloma] were recorded. Age at surgery and sur-
gery type were abstracted from medical records. The two-sided Fisher’s exact
test was used to examine differences in proportions. The mean age of the cases
was 53 years, and the most common surgery type was excisional/incisional bi-
opsy or lumpectomy (55%), followed by core biopsy (25%) and mastectomy
(20%). Calcifıcations were associated with LCIS in 41% of cases. Women were
more likely to have florid LCIS when calcifıcations were present compared to
when calcifıcations were absent (P0.01). Additionally, cases with calcifıcations
were more likely to have more than 10 lobules affected by LCIS (P0.01). As-
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sociations between calcifıcations and extent of LCIS persisted when the sample
was restricted to cases where classic LCIS was the primary type. Moreover, the
presence of calcifıcations was not associated with surgery type (P0.36), sug-
gesting that the results were not due to sampling bias. Other benign lesions were
present in the majority of cases, but were not associated with LCIS characteris-
tics (all P0.05). ALH was the most common other lesion, present in 70% of
samples. Our results demonstrate that LCIS-associated calcifıcations are com-
mon and are associated with more extensive disease, even among LCIS charac-
terized as ‘classic’. In invasive breast cancer, the presence of certain types of
calcifıcations has been associated with poor prognosis. A next step in this re-
search is to understand whether the heterogeneity we observed in LCIS can be
ascribed to a specifıc calcifıcationmorphology and/or distribution.Understand-
ing this will help us elucidate the potential biological mechanism and determine
whether LCIS calcifıcations are a viable marker for the prediction of breast
cancer risk.
#5309 Dietary magnesium is inversely associated with colorectal cancer
risk in the Atherosclerosis Risk in Communities study. Guillaume C. Onyea-
ghala,1 Elizabeth Polter,1 Pamela L. Lutsey,1 Aaron R. Folsom,1 Corrine E.
Joshu,2 Elizabeth A. Platz,2 Anna E. Prizment1. 1University of Minnesota, Min-
neapolis, MN; 2JohnHopkins Bloomberg School of Public Health, Baltimore, MD.
Background: Magnesium is a key nutritional mineral required for the regula-
tion of numerous biochemical reactions throughout the body. Main food
sources of magnesium include whole grains, nuts, and green vegetables, but
more than 50% of Americans do not currently meet their daily recommended
magnesium intake. Prior research has shown that those defıcient in magnesium
have increased susceptibility to oxidative stress and chronic inflammation, lead-
ing to endothelial dysfunction and potentially stimulating cancer cell prolifera-
tion and invasiveness. Previous epidemiological studies suggested a link be-
tween a diet high in magnesium and reduced CRC, especially among women.
The American Cancer Society underscores the importance of clarifying the role
of dietary magnesium in CRC development overall and by gender. Thus, we
prospectively examined the associations between dietarymagnesium intake and
CRC risk in the ARIC study, overall, and separately in men and women. Meth-
ods: The ARIC study followed 15,792 men and women (45-64 years old at base-
line) for cancer occurrence from 1987-2006. Participants received medical ex-
aminations and completed questionnaires at 4 visits; food frequency data were
collected at Visit I (1987-89) and magnesium intake estimated. Cox propor-
tional hazards regressionwas used to calculate hazard ratios (HR) and 95%CI for
CRC associated with dietary magnesium intake in quartiles using two models:
Model 1 adjusted for baseline age, race, center, sex, energy intake, BMI, and
physical activity. Model 2 included Model 1 covariates as well as intake of alco-
hol, dietary calcium, dietary fıber, aspirin, CRP levels, and cigarette smoking.
Results: The analytic cohort (n14,160, 54.5% women, 27.3% black and 72.7%
white, 45-64 years at baseline) was followed for a median of 15.4 years; 315 CRC
cases were identifıed. Since only the highest quartile of dietary magnesium in-
take met US recommendations (300 mg/day), we examined the highest quar-
tile versus the 3 lowest quartiles combined (reference category). In Model 1, the
highest quartile of dietary magnesium was associated with lower CRC risk: HR
(95%CI) 0.68 (0.47-0.99). The inverse association between magnesium and
CRC persisted in Model 2 (HR0.70; 95% CI 0.48, 1.02). The association fol-
lowed a similar trend after stratifıcation by colon and rectal cancer cases
(HR(95% CI) 0.72 (0.48-1.08) and HR(95% CI)0.49 (0.23-1.06), respec-
tively) and by men and women (HR(95% CI)0.75 (0.42-1.21) and HR(95%
CI)0.63 (0.36-1.12) respectively). There was no interaction of dietary magne-
sium intake with dietary calcium intake, alcohol consumption use or dietary
fıber. Conclusion: Our fındings corroborate an inverse association between
higher dietary magnesium intake and CRC risk, with similar associations ob-
served in men and women. Support: NHLBI, NCI, NPCR.
#5310 A prospective study of dietary polyunsaturated fatty acid intakes
and lung cancer risk. Hung N. Luu,1 Harvey J. Murff,2 Honglan Li,3 Qiuyin
Cai,2 Yu-Tang Gao,3 Jing Gao,3 Hui Cai,2 Gong Yang,2 Qing Lan,4 Yong-Bing
Xiang,3 Wei Zheng,2 Xiao-Ou Shu2. 1University of South Florida, Tampa, FL;
2Vanderbilt University, Nashville, TN; 3Shanghai Cancer Institute, Shanghai,
China; 4National Cancer Institute, Bethesda, MD.
Background. Animal studies have shown that polyunsaturated fatty acids
(PUFAs) have antineoplastic and anti-inflammatory properties. Results from
epidemiologic studies, however, have been inconclusive.We prospectively eval-
uated the association of dietary PUFA intakes and lung cancer risk in two pop-
ulation-based cohort studies, the Shanghai Men’s Health Study (SMHS) and
Shanghai Women’s Health Study (SWHS). Methods. A total of 130,823 study
participants (i.e., 60,427 men and 70,396 women) were included in the current
analysis. Dietary fatty acid intakes were derived from data collected at the base-
line by validated food frequency questionnaires. Cox proportional hazards
model was applied to assess the association between PUFAs intake and lung
cancer risk with adjustment for age, smoking status, smoking packs-year (men
only), drinking status, BMI, physical activity status, total energy, red meat in-
take, vegetable intake, vitamin supplemental use, menopausal status and hor-
mone replacement therapy (women only). Results. We found an inverse associ-
ation between total PUFA intakes and lung cancer risk [hazard ratios (HRs) and
respective 95% confıdence intervals (CIs) for quintiles 2, 3, 4, and 5 versus quin-
tile 1were 0.73 (0.56-0.95), 0.78 (0.59-1.03), 0.64 (0.47-0.87) and 0.55 (0.37-0.82)
in SMHS and 0.69 (0.53-0.90), 0.76 (0.58-0.99), 0.60 (0.44-0.81), and 0.53 (0.36-
0.79) in SWHS)]. A similar pattern was observed for consumption of linoleic
acid, total n-6 PUFAs and the ratio n-6 PUFAs/n-3 PUFAs in adenocarcinoma
patients. This inverse association was more likely in male ever-smokers for total
PUFAs, linoleic acid and total n-6 PUFAs. On the other hand, EPA intake was
positively associated with lung cancer risk in female never-smokers [HRs and
95%CIs: 1.10 (0.85-1.42), 1.36 (1.05-1.77), 1.28 (0.97-1.88) and 1.30 (0.97-1.74),
for quintiles 2-5 versus quintile 1]. A similar positive association between DHA
intake and lung cancer risk in female never-smokers was also observed. Conclu-
sions. Total polyunsaturated fatty acid, linoleic and total n-6 PUFA intakes were
associated with decreased risk of lung cancer. EPA and DHA intakes were asso-
ciated with an increased risk of lung cancer among female never-smokers. Fi-
nancial Support: This work was supported by grants from the US National In-
stitutes of Health/National Cancer Institute (R37 CA070867 and UM1
CA182910 - toWei Zheng; R01 CA082729, UM1CA173640 and R25CA160056
- to Xiao-Ou Shu).
#5311 Weight loss over 10 years of adulthood and subsequent risk of
breast cancer: a pooled analysis of 11 cohort studies. Lauren R. Teras,1 AlpaV.
Patel,1 MolinWang,2 Bette J. Caan,3 Yu Chen,4 Avonne E. Connor,5 A. Heather
Eliassen,6 SusanM. Gapstur,1 MiaM. Gaudet,1 JeanineM. Genkinger,7 Graham
G. Giles,8 I-Min Lee,2 Roger Milne,8 Norie Sawada,9 Howard D. Sesso,6 Meir
Stampfer,6 Rulla Tamimi,6 Cynthia A. Thomson,10 Shoichiro Tsugane,9 Kala
Visvanathan,5 Anne Zeleniuch-Jacquotte,4 Walter C. Willett,11 Stephanie A.
Smith-Warner11. 1American Cancer Society, Atlanta, GA; 2Harvard Medical
School, Boston, MA; 3Kaiser Permanente Medical Care Program of Northern
California, Oakland, CA; 4NYU School of Medicine, New York, NY; 5Johns Hop-
kins Bloomberg School of Public Health, Baltimore, MD; 6Brigham andWomen’s
Hospital and Harvard Medical School, Boston, MA; 7Columbia University, New
York, NY; 8University of Melbourne, Melbourne, Australia; 9National Cancer
Centre, Tokyo, Japan; 10University of Arizona Mel & Enid Zuckerman College of
PublicHealth, Tucson, AZ; 11Harvard T.H. Chan School of PublicHealth, Boston,
MA.
Body fatness is an established risk factor for postmenopausal breast cancer,
but it is unknown if this risk associatedwith excess bodyweight is reversible.We
conducted a pooled analysis of 11 prospective studies in the Pooling Project of
Prospective Studies of Diet and Cancer. Each study had adult body weight data
at three timepoints, aswell as follow-up for subsequent risk of breast cancer after
the third weight measure. Weight change was assessed using reported or mea-
suredweight at baseline and two follow-up time points, each generally four to six
years apart (over a total of10 years). Stableweight for each intervalwas defıned
asweight within 2kg of the previousweight. The referent groupwaswomenwith
stable weight (within 2kg) at all three time points across the 10-year period.
Among 340,055 women, 10,427 breast cancers were diagnosed during follow-
up.Multivariable hazard ratios (HR) and 95% confıdence intervals (CI) control-
ling for baseline body mass index (BMI), baseline physical activity, and post-
menopausal hormone (PMH) use at the start of breast cancer follow-up, were
estimated using proportional hazards regression on an aggregated dataset from
all studies. Women who lost weight and kept the weight off, were at a lower risk
of breast cancer than women with stable weight over the 10 years:2.-4.5kg
lost between baseline and the fırst follow-up body weight measure (n482
cases): HR0.92, 95% CI: 0.83-1.03;4.5-9kg lost (n283 cases): HR0.86,
95% CI: 0.76-0.98; 9kg lost (n95 cases): HR 0.81, 95%CI: 0.65-1.00).
Women who initially lost weight (2kg), but then re-gained it had a similar
risk of breast cancer to those with stable weight over the same time period.
When results were stratifıed by baseline age and BMI, there was no associa-
tion between sustained weight loss and breast cancer among women younger
than 50 years, nor those with a normal BMI (18.5-25 kg/m2) before weight
loss. Among women who were aged 50 or more years and overweight or
obese before the weight loss period, we observed a 21% lower risk of breast
cancer for sustained weight loss of 4.5kg compared to women with stable
weight over the same time period (n245 cases, HR0.79, 95% CI: 0.68-
0.93). This observed association was driven by women who were not taking
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PMH (n156, HR0.71, 95% CI: 0.58-0.86). In this large, pooled prospec-
tive analysis of weight loss and breast cancer risk we found that losing 4.5
kg—and keeping it off—may lower breast cancer risk, particularly for
women older than 50 who are overweight or obese. The results may provide
motivation for women with elevated BMI to lose weight and potentially
reduce their risk of breast cancer.
#5312 Noassociationbetween vitaminK intake andprostate cancer risk in
the Prostate, Lung, Colorectal, andOvarian Cancer Screening Trial (PLCO).
Maggie Hoyt, Michael Reger, Jianjun Zhang. Indiana University, Indianapolis,
IN.
Prostate cancer is one of the most common cancers worldwide. The etiol-
ogy of prostate cancer largely remains unclear, with almost all established
risk factors (e.g. age, race, family history) being not modifıable. Ecological,
migrant, and temporal trend studies suggest that diet plays role in the occur-
rence of prostate cancer, but few nutrients that alter its risk have been iden-
tifıed from case-control and cohort studies. Vitamin K has two forms that
naturally occur in foods, i.e., phylloquinone (vitamin K1) and menaquinone
(vitamin K2).While phylloquinone is abundant in green leafy vegetables and
some vegetable oils, menaquinone is primarily derived from fermented food
products (e.g. cheese). Although experimental studies have shown that vita-
min K inhibits the growth of various cancer cell lines (including prostate
cancer cells), only one epidemiologic study has investigated the association
between vitamin K intake and prostate cancer risk. In that German study, a
signifıcant inverse association with advanced prostate cancer was observed
for menaquinone intake. The present study thus sought to investigate the
associations between intake of vitamin K (from both dietary and supplemen-
tal sources) and the risk of total and advanced prostate cancer among 28,356
PLCO participants. A total of 2978 cases of prostate cancer (including 490
advanced cases) have been documented during a median follow up of 11.8
years. Advanced prostate cancer were defıned as disease in stage II with a
Gleason score of 8-10, stage III, or stage IV. Usual dietary intake among
study subjects was assessed with Dietary Questionnaire (DQX) at baseline
and Dietary History questionnaire (DHQ) at year 3, both of which were
developed and validated by the National Cancer Institute. Dietary intake of
phylloquinone and menaquinones were calculated using the USDANational
Nutrient Database for Standard Reference (Release 23), supplemented with
menaquinone data from published studies. Cox proportional hazards regres-
sion was performed to estimate hazard ratios (HRs) and 95% confıdence
intervals (CIs) for dietary intake of phylloquinone and menaquinones in
relation to prostate cancer risk. After adjustment for confounders, no statis-
tically signifıcant associations were found between vitamin K intake esti-
mated from the DQX and prostate cancer risk [HR (95% CI) for the highest
quintile vs. the lowest quintile: 0.99 (0.87, 1.13) for total vitamin K, 0.99
(0.87, 1.12) for phylloquinone, and 1.02 (0.87, 1.18) for total menaquinones].
Overall null results were also observed when additional analysis was carried
out by the stage of the disease (i.e. advanced and non-advanced cases) and for
vitamin K intake data assessed with the DHQ. In summary, the present study
revealed that intake of total vitamin K and its two natural forms was not
associated with the risk of total and advanced prostate cancer.
#5313 Associations of calcium and dairy product intakes with colorectal
cancer risk among older women: the Iowa Women’s Health Study. Caroline
Um,1 Anna Prizment,2 DeAnn Lazovich,2 Roberd M. Bostick1. 1Emory Univ.,
Atlanta, GA; 2University of Minnesota, Minneapolis, MN.
tk;4Calcium has been consistently modestly associated with lower risk of
colorectal cancer, which remains the second leading cause of cancer deaths
amongmen andwomen combined in theUnited States. Dairy products, amajor
source of dietary calcium, have also been consistently inversely associated with
colorectal cancer, although inconsistencies in relation to high-fat dairy products
have been noted. Limited evidence suggests that dairy products may contain
components other than calcium and fat, such as insulin-like growth factor 1
(IGF-1), that may be independently directly associated with risk of colorectal
and other cancers. Data from the Iowa Women’s Health Study, a prospective
cohort study, were used to investigate associations of calcium, dairy products,
and the non-calcium component of dairy products with colorectal cancer inci-
dence. Dietary data were collected using a semiquantitative food frequency
questionnaire (FFQ) mailed to 55 – 69 year-old women in 1986 who had a valid
Iowa driver’s license. Among participants with no history of cancer at baseline
and who satisfactorily completed their FFQ (n35,221), through follow up in
2012, 1,731 incident cases of colorectal cancer were documented via the Iowa
SEER registry. To investigate total dairy and total, whole, and non-fat milks
independent of their calcium components, we used the residuals from linear
regressionmodels of their associations with dietary calcium. Associations of the
calcium and dairy product variables with colorectal cancer incidence were esti-
mated usingmultivariable Cox proportional hazards regression. For those in the
highest relative to those in the lowest quintiles of intakes, the adjusted hazards
ratios and 95% confıdence intervals (CI) were 0.81 (CI 0.67-0.98; P-trend 0.004)
for total calcium, 0.85 (CI 0.68-1.03; P-trend 0.07) for dietary calcium, and 0.85
(CI 0.68-1.06; P-trend 0.16) for supplemental calcium. For total dairy and total
milk, the corresponding fındings were 0.79 (CI 0.66-0.94; P-trend 0.01) and 0.82
(CI 0.69-0.96; P-trend 0.09), respectively. Low-fat dairy products, non-fat milk,
and residuals of total dairy products and total and non-fat milk were not asso-
ciated with colorectal cancer. These results are consistent with previous fındings
of lower colorectal cancer riskwith higher intakes of calciumanddairy products,
but provide little support for the hypothesis that the non-calcium, non-fat com-
ponent of dairy products may be associated with colorectal cancer.
#5314 Long-term folate intake and prostate cancer risk in the health pro-
fessionals follow-up study. Nadine M. Hamieh,1 Julie L. Batista,2 Sarah C.
Markt,1 Mary K. Downer,1 Lorelei A. Mucci,1 Meir J. Stampfer,1 Edward L.
Giovannucci,1 KathrynM.Wilson1. 1Harvard THChan School of Public Health,
Boston, MA; 2Genzyme, Boston, MA.
Background: Randomized trials of supplemental folate and observational
studies of circulating folate support a positive association with prostate cancer
risk. However, epidemiological studies of dietary and synthetic folate intake are
conflicting. Given mandatory folic acid fortifıcation of grains in the US begin-
ning in 1998, evaluation of long-term folate intake from natural and synthetic
sources in relation to prostate cancer risk is warranted. Methods: We examined
the association between folate intake andprostate cancer risk among 47,884men
in the Health Professionals Follow-up Study who were free from diagnosed
cancer at baseline in 1986. Total, natural (from food sources), and synthetic
(from supplements/fortifıcation) folate intake was assessed every 4 years using a
validated food frequency questionnaire, and categorized as the cumulative av-
erage and lagged (0-4, 4-8, 8-12, and 12-16 years in the past) intakes. Cox pro-
portional hazards regression was used to calculate multivariable hazard ratios
(HRs) and 95% confıdence intervals (CI). Results: We identifıed 6,186 incident
prostate cancer cases from 1986-2012, including 1,078 with lethal disease (dis-
tant metastasis or death). Mean total folate intake was 481 g/day in 1986 and
increased to 671 g/day by 2010. The proportion of men meeting the recom-
mended intake of 400 g/day increased from 47% in 1986 to 74% after fortifı-
cation began in 1998. Folate intake was positively correlated with physical activ-
ity, multivitamin use, and PSA testing, and inversely correlated with smoking.
Total folate intake averaged over time was not signifıcantly associated with total
prostate cancer risk: HR800 vs. 400-5991.03 (95% CI: 0.95-1.13, p-trend0.76).
Neither natural nor synthetic folate intake was associated with risk of total pros-
tate cancer. No associations were observed between total, natural, or synthetic
folate intake and risk of lethal, advanced stage, or high-grade disease. Conclu-
sions: Our fındings do not support strong associations between intakes of total,
natural, or synthetic folate and prostate cancer risk.We found no indication that
folate intake of800 g/day (twice the recommended level) increases prostate
cancer risk.
#5315 Dietary intake and risk of lung cancer in non-smoking women: a
hospital-based case-control study in Xuanwei and Fuyuan, China. Jason Y.
Wong,1 Bryan A. Bassig,1 Wei Hu,1 Jinming Zhang,1 Wei Jie Seow,1 Neil E.
Caporaso,1 Bu-tian Ji,1 Robert S. Chapman,2 George S. Downward,3 Jihua Li,4
Jun He,4 Kaiyun Yang,5 Yunchao Huang,5 Roel Vermeulen,3 Nathaniel Roth-
man,1 Qing Lan1. 1National Cancer Institute, Rockville, MD; 2Chulalongkorn
University, Bangkok, Thailand; 3Utrecht University, Netherlands; 4Qujing Center
for Diseases Control and Prevention, China; 5Yunnan Tumor Hospital, China.
Xuanwei and Fuyuan are rural counties in China that have the highest lung
cancer rates in the country among non-smoking women. This alarming public
health burden has been attributed to the combustion of smoky (bituminous)
coal for heating and cooking, which can produce carcinogenic emissions such as
polycyclic aromatic hydrocarbons (PAHs). Previous studies found that green
leafy vegetables could absorb PAHs through air and direct soil contamination.
Further, oral ingestion of PAHs was found be to associated with pulmonary
adenoma development in animal feeding studies. Therefore, we investigated the
associations between lung cancer risk and dietary intake of specifıc green leafy
vegetables and other foods in non-smoking women of this farming region. We
conducted a hospital-based case-control study of 1,074 female lung cancer pa-
tients and 977 frequency-matched controls fromXuanwei and Fuyuan, China in
2006-2013. Dietary intake was self-reported on questionnaires and categorized
as never, several times/year, several times/month, several times/week, and every
day. Unconditional logistic regression models were used to estimate the odds
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ratios (OR) and 95%confıdence intervals (CI) of lung cancer in relation to intake
of specifıc green leafy vegetables (i.e. lettuce, cabbage, fennel, spinach, hollow
vegetables), corn, buckwheat, carrots, tomatoes, dried and fresh chili, pickled
vegetables, bean curd, mushrooms, and preserved meats. Models were adjusted
for age, county, fırst-degree relative with lung cancer, passive smoke exposure,
education, lifetime smoky coal tonnage, respiratory disease history, time spent
indoors, and menopausal status. Separate models were fıtted for each dietary
factor. We found that increased consumption of several green leafy vegetables
was associatedwith increased risk of lung cancer. Eating hollow vegetables every
day was associated with 2.50 (95% CI: 1.18, 5.27) times the odds of lung cancer
compared to never. Similarly, eating lettuce (OR2.13, 95% CI: 1.41, 3.21) and
cabbage (OR1.82, 95% CI: 1.21, 2.69) every day was associated with increased
risks compared to several times a year or less. Conversely, eating bean curd
(OR0.54, 95% CI: 0.40, 0.72) several times a week was associated with de-
creased risk compared to several times a year or less; while eating buckwheat
(OR0.59, 95% CI: 0.40, 0.89) several times a week was associated with de-
creased risk compared to never. No signifıcant associations were found for fen-
nel, spinach, and other foods. Our fındings suggest that increased consumption
of a variety of green leafy vegetables may be related to elevated lung cancer risk
in non-smoking women from Xuanwei and Fuyuan, China, independent of
other risk factors. The increased risk may be due to environmental contamina-
tion of crops from coal combustion. Conversely, frequent consumption of bean
curd and buckwheat was found to be protective.
#5316 Recreational physical activity, body mass index, and waist circum-
ference in relation to lung cancer incidence in a large US prospective cohort.
Alpa V. Patel, Brian D. Carter, Victoria L. Stevens, Peter T. Campbell, SusanM.
Gapstur. American Cancer Society, Atlanta, GA.
Background: Physical activity has been associated with lower lung cancer risk
in numerous studies with estimates ranging from 20-50% lower risk in the most
versus the least active study participants. Underweight and obesity have also
been associatedwith lower lung cancer risk, with a nonlinear, invertedU-shaped
relationship. The associations between physical activity and obesity with lung
cancer are likely signifıcantly confounded by smoking since individuals who
smoke are generally less active and leaner than non-smokers. However, few
studies have been able to examine these associations stratifıed by smoking status.
Objective: To examine in detail whether an association between physical activ-
ity, BMI, and lung cancer exists in the absence of residual confounding by smok-
ing. Methods: Using data 118,225 men and women who were cancer-free at
enrollment (1992) in the American Cancer Society Cancer Prevention Study-II
Nutrition Cohort, we examined associations between recreational physical ac-
tivity (MET-hours per week; none, 0.1-8.75 (reference), 8.75-17.4, 17.5
MET-hours/week), bodymass index (BMI, weight (kg)/height (meters)2;18.5,
18.5-22.0 (reference), 22.1-24.9, 25.0-29.9, 30.0 kg/m2), and waist circumfer-
ence (measured in 1997; sex-specifıc quartiles) in relation to lung cancer risk
stratifıed by smoking status and years since quitting among former smokers
(never, current, former10 years, former, 10-19 years, former 20 years). Cox
proportional hazardsmodelingwas used to compute hazard rate ratios (RR) and
95% confıdence intervals (CI) while adjusting for potential confounders. Re-
sults: Follow-up included 2,384,545person-years during which 4,669 men and
women were diagnosed with lung cancer (453 among never smokers; 1,452
among current smokers; 1,194 among former smokers10 years since quitting;
725 among former 10-19 years; and 845 among former 20 years). Physically
activity was not associated with lung cancer risk for any of the smoking strata
except in former smokers less than 10 years since quitting (RR0.78; 95% CI
0.68-0.91 for 17.5MET-hours/week). Similarly, BMI was inversely associated
with lung cancer only in former smokers less than 10 years since quitting
(RR0.74; 95% CI 0.60-0.92 for 30 kg/m2). Waist circumference was not
associated with lung cancer risk in any smoking category. Conclusion: While
being physically active andmaintaining a healthy body weight are important for
prevention of various types of cancer, our results suggest that neither physical
activity, bodymass index, orwaist circumference are associatedwith lung cancer
risk, regardless of smoking status. Whether the associations between physical
activity, BMI and lung cancer in ex-smokers who have recently quit are due to
chance, confounding or reverse causality warrants further investigation.
#5317 Association of physical activity with risk of prostate cancer defıned
by TMPRSS2:ERG. Claire H. Pernar,1 Ericka M. Ebot,1 Andreas Pettersson,2
Rebecca E. Graff,3 Thomas U. Ahearn,1 Amparo G. Gonzalez-Feliciano,1 Sarah
C. Markt,1 Kathryn M. Wilson,1 Stephen Finn,4 Michelangelo Fiorentino,1 Ed-
ward L. Giovannucci,1 Lorelei A. Mucci1. 1Harvard T.H. Chan School of Public
Health, Boston, MA; 2Karolinska Institutet, Solna, Sweden; 3University of Cali-
fornia San Francisco, CA; 4Trinity College Dublin, Dublin, Ireland.
Background: There is growing evidence of heterogeneity in risk factor asso-
ciations for prostate cancer defıned by clinical and molecular characteristics.
Physical activity has moderate protective effects on development of prostate
cancer, in particular of advanced and fatal disease. We hypothesized that the
influence of physical activity on hormonal and anti-inflammatory pathwaysmay
differentially affect the development of TMPRSS2:ERG-positive compared to
TMPRSS2:ERG-negative tumors. Our objective was to examine the association
between physical activity and risk of prostate cancer defıned by the TMPRSS2:
ERG fusion. Materials & Methods: We followed 49,160 men in the prospective
Health Professionals Follow-up Study from 1986 to 2010. Participants were age
40 years or older, had no previous cancer diagnosis, and reported physical ac-
tivity by questionnaire.Men self-reported the average number of hours perweek
spent engaged in various forms of recreational physical activity at baseline and
every two years thereafter with greater than 90% follow-up rates. We examined
long-term physical activity type and intensity in units of metabolic equivalent of
task (MET)-hours per week. Presence of the TMPRSS2:ERG fusion in tumor
tissue was estimated by ERG protein expression using immunohistochemistry.
We used competing risks models to obtain subtype-specifıc hazard ratios (HRs)
and 95% confıdence intervals (CIs) for incidence of fusion-positive and fusion-
negative prostate cancer. Results: During 23 years of follow-up, 5,819 men were
diagnosed with prostate cancer. Of the 2,389 men who underwent radical pros-
tatectomy, 910 were assayed for ERG. Men with higher cumulative average vig-
orous activity had a lower risk of developing TMPRSS2:ERG-positive prostate
cancer (top vs. bottomquintilemultivariateHR: 0.64, 95%CI: 0.46-0.90, P-value
for trend0.01). There was no signifıcant association observed between vigor-
ous activity and risk of TMPRSS2:ERG-negative prostate cancer (HR: 0.93, 95%
CI: 0.67-1.28, P-value for trend0.46). However, the test for heterogeneity in
these associations was not signifıcant (P-value for heterogeneity0.55). No as-
sociation was observed between total activity and risk of either TMPRSS2:ERG
subtype. Conclusions: Physical activity of vigorous intensity is inversely associ-
ated with risk of TMPRSS2:ERG-positive but not TMPRSS2:ERG-negative
prostate cancer. These fındings suggest that regular vigorous activity may lower
risk of prostate cancer through mechanisms specifıc to development of this
fusion in prostate tumors. Future studies are needed to further elucidate these
mechanisms and translate these fındings into recommendations for prostate
cancer prevention.
#5318 Intake of tea and tea flavonoids, coffee and caffeine in relation to
risk of lung cancer - the Singapore Chinese Health Study. Wei Jie Seow,1
Aizhen Jin,2 Jian-Min Yuan,3 Woon-Puay Koh4. 1National University of Singa-
pore, Singapore, Singapore; 2Ministry of Health, Singapore, Singapore; 3Univer-
sity of Pittsburgh, Pittsburg, PA; 4Duke-NUS Medical School, Singapore, Singa-
pore.
Background: Coffee and tea are widely consumed beverages. Tea flavonoids
have been shown to inhibit lung tumorigenesis in in-vitro and animal models.
Conversely, coffee contains complex mixtures of biochemically active com-
pounds that may have genotoxic and mutagenic properties. However, previous
epidemiologic studies have shown inconsistent results on tea and coffee in rela-
tion to lung cancer risk. Methods: The association between intake of tea and
coffee, and their active compounds, and risk of lung cancer was investigated in
the Singapore Chinese Health Study, a population-based prospective cohort of
63,257 Singaporean Chinese men and women aged 45-74 years at enrollment
from 1993 through 1998. Information on demographic, lifestyle and habitual
dietwas collected through in-person interviews using a structured questionnaire
which included a validated food-frequency questionnaire. The intake of caffeine
and tea flavonoids was estimated for each participant based on the Singapore
Food CompositionDatabase, which was developed for this cohort and provided
96 nutritional and non-nutritional values per 100 grams of the edible portion for
each of 165 surveyed foods and beverages specifıc for the study population.
Flavonoids predominantly from black tea included theaflavin, thearubigin,
theaflavin-3-3=-digallate, theaflavin-3=-gallate and theaflavin-3-gallate while
those predominantly from green tea included catechin, epigallocatechin, epicat-
echin, epicatechin-3-gallate and epigallocatechin-3-gallate. Incident lung cancer
cases were identifıed via record linkage with the nationwide cancer registry
through 31December 2013. Cox regressionmodelswere used to estimate hazard
ratios (HRs) and 95% confıdence intervals (CIs) for the associations with adjust-
ment for potential confounders. Results: Compared to non-daily coffee drink-
ers, HR (95% CI) of lung cancer for those consuming 1 and 2 or more cups of
coffee per day was 1.16 (1.00-1.34) and 1.29 (1.02-1.64), respectively (P for
trend0.029). Among ever smokers, black tea was inversely associated with risk
of lung cancer (P for trend0.037). HR (95% CI) was 0.83 (0.69-1.00) for the
highest third of consumers (average 1.5 cups/day) compared to non-black tea
drinkers. Consistently, flavonoids predominantly from black tea were also in-
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versely associated with lung cancer risk (P for trend0.045). This risk reduction
with black tea and theirmajor flavonoids was only observed in ever smokers and
not in never smokers. There was no statistically signifıcant association for lung
cancer riskwith total caffeine, green tea or flavonoids predominantly fromgreen
tea, regardless of smoking status. Conclusions: Coffee may increase the risk of
developing lung cancer, and this effect does not seem to be mediated by its
caffeine content. Conversely, black tea and flavonoids foundmainly in black tea
may reduce the risk of lung cancer among ever smokers.
#5319 Comparison of changes in waist circumference and body mass in-
dex (BMI) through adulthood and their relationship with advanced colorec-
tal neoplasia. Wambui G. Gathirua-Mwangi, Patrick Monahan, Yiqing Song,
Terrell Zollinger, Timothy Stump, Victoria Champion, Thomas Imperiale. In-
diana University, Indianapolis, IN.
Background:Waist circumference (WC) is a stronger predictor of colon can-
cer risk than bodymass index (BMI); however, howwell change in eitherWC or
BMI over time predicts the risk of AN remains unclear. Purpose: To investigate
1) the relationship between change in adiposity measures (BMI and WC) from
early adulthood to older age and the risk of advanced colorectal neoplasia (AN)
and 2) whetherWC change or BMI change is a stronger predictor of risk of AN.
Methods: The sample included 4,500 adults, 50-80 years with no previous colo-
rectal cancer or adenomatous polyps and undergoing fırst-time screening
colonoscopy. Participants reported adipositymeasures (height, weight andWC)
at early adulthood (age 21) and at time of screening (mean age 57). Changes in
BMIwere categorized as 1) increase fromhealthy BMI to overweight or obese, 2)
increase from overweight to obese, and 3) stable BMI level at age 21 and time of
screening. WC was defıned as high-risk for females with a WC35 and males
40 inches. Changes for WC were categorized as 1) increase from a low-risk
WC to a high-risk WC, and 2) stable-risk WC at age 21 and time of screening.
Gender, age, family history, exercise, aspirin use, alcohol, smoking and intake of
red meat and vegetables were included in the logistic models. Results: Being
obese both at age 21 and at screening resulted in a signifıcant increased risk of
AN (OR1.87; 95% CI 1.08-3.23) compared to those with a stable-healthy BMI
at both time points. Stable overweight BMI at age 21 and at screening (OR1.54;
95% CI 0.97-2.45) and increased BMI from healthy to overweight or obese and
overweight to obese were not associatedwithAN, as compared to those who had
a healthy BMI at both time points. Compared to those with a low-risk WC at
both time points, those who had a high-riskWC at age 21 and at time of screen-
ing had a two-fold increased risk of AN (OR2.15; 95% CI 1.35-3.45). Increas-
ing WC from age 21 to time of screening compared to those with low-risk WC
was not associated with risk of AN (OR1.23; 95% CI 0.97-1.57). When both
WC and BMI change were included, WC change (10.15, 2 DF,
p-value0.0062) but not BMI change (5.66, 2 DF, p-value0.34) predicted
risk of AN.Conclusions:Maintaining a high-riskWCor obese BMI is associated
with increased risk for AN; however, when BMI is controlled, maintaining a
high-riskWCmay independently increase the risk for AN. Practitioners should
caution adults with high-risk WC and obese BMI values to better control their
adiposity.
#5320 Folate and other nutrients related to one-carbon metabolism and
risk ofmelanoma.AsharDhana,1Hsi Yen,2 Tricia Li,3MichelleHolmes,3 Abrar
Qureshi,4 Eunyoung Cho4. 1Groote Schuur Hospital and University of Cape
Town, South Africa; 2Harvard T.H. Chan School of Public Health, MA; 3Brigham
and Women’s Hospital, MA; 4The Warren Alpert Medical School of Brown Uni-
versity, Providence, RI.
Background: Nutrients involved in one-carbon metabolism - folate, vita-
mins B6 and B12, methionine, choline, and betaine - have been associated
with multiple cancer sites. However, no study has assessed the association
between these nutrients and risk of melanoma. Thus, the aim of this study
was to evaluate the association between intake of these nutrients and mela-
noma risk within two prospective cohorts: the Nurses’ Health Study (NHS)
and Health Professionals Follow-up Study (HPFS). Methods: The cohorts
included a total of 81,685 women in the NHS (1984 to 2010) and 49,617 men
in the HPFS (1986 to 2010). We assessed nutrient intakes using a semi-
quantitative food frequency questionnaire every 2 to 4 years. Total nutrient
intake included both dietary and supplemental intake. Dietary intake in-
cluded intake from food only. Study physicians reviewed medical and path-
ological records to confırm self-reported cases of invasive melanoma. We
used Cox proportional hazards regression to estimate hazard ratios (HRs)
and 95% confıdence intervals (CIs) and then pooled the HRs for both cohorts
using a random effects model. Results: Over 24 to 26 years of follow-up, we
documented 1,321 cases (641 men and 680 women) of invasive melanoma.
Higher intake of folate from food only, but not total folate, was associated
with increased risk of melanoma. The pooled multivariable HRs for the top
versus bottom quintiles were 1.17 (95 % CI: 0.98-1.41; P for trend 0.17) for
total folate and 1.37 (95 % CI: 1.13-1.65; P for trend 0.001) for folate from
food only. The association was statistically signifıcant in men, but not in
women. Higher intake of vitamins B6 and B12, choline, betaine, and methi-
onine was not associated with risk of melanoma. Conclusion: We found
some evidence that folate from food only, but not total folate, was associated
with a modest increased risk of melanoma - a fınding that warrants further
investigation. Conversely, our fındings suggest that other nutrients involved
in one-carbon metabolism do not play an important role in the etiology of
melanoma.
#5321 Metabolomics and bodymass index among breast cancer survivors
in The Lifestyle, Exercise, and Nutrition (LEAN) Study. Leah M. Ferrucci,1
Brenda Cartmel,1 Maura Harrigan,1 Tara Sanft,2 Mary Playdon,3 Wei Jia,4 Her-
bert Yu,4 Caroline H. Johnson,1 Lajos Pusztai,2 Anees B. Chagpar,2 Melinda L.
Irwin1. 1Yale School of Public Health, New Haven, CT; 2Yale School of Medicine,
New Haven, CT; 3National Cancer Institute, Rockville, MD; 4University of Ha-
waii Cancer Center, Honolulu, HI.
Background:While there is a growing body of literature onmetabolomics and
bodymass index (BMI), there are limited studies in relation to weight change in
overweight and obese individuals, and to our knowledge, no such studies in
breast cancer survivors. Methods: The Lifestyle, Exercise and Nutrition (LEAN)
randomized diet- and exercise-induced weight loss trial in breast cancer survi-
vors enrolled overweight or obese breast cancer survivors (Stage 0-III) identifıed
via the Yale-New Haven Hospital tumor registry or self-referral. Participants
were randomized to either usual care group (n33) or the 6-month lifestyle
intervention (11 sessions with a registered dietitian) (n67). Height and weight
were measured by study staff at baseline and 6 months, and a fasting ( 12
hours) blood drawwas also performed at these time points. Paired (baseline and
6-month) serum metabolomics data were available for 83 women. Only those
metabolites consistently detected in 80% of quality control samples with a
coeffıcient of variation30% were included in data analysis. We evaluated par-
tial Pearson correlations between the ratio of metabolites at baseline versus
6-months and change in BMI adjusted for age and intervention group. We also
assessedmean changes inmetabolites from baseline to 6-months by randomiza-
tion group using the general estimating equation in linear regression. Adjust-
ment for multiple comparisons was based on the False Discovery Rate (FDR)
with a threshold of 0.1. Results: Overall, a total of 307metabolites were analyzed;
168 were quantitated by LC-MS and 139 were semi-quantitated by GC-TOF/
MS. For BMI change from baseline to 6-months, we observed correlations with
16metabolites (isocitric acid, 3-hydroxybutyric acid, serine, L-cysteine, petrose-
linic acid, aminomalonic acid, palmitoleic acid, linoleic acid, 2-hydroxybutyric
acid, and seven unidentifıed metabolites, p0.05), however FDR correction for
multiple comparisons yielded no statistically signifıcant results. We also ob-
served differences by randomization group for L-alanine, dopamine, serotonin,
PCaaC36:1, 3-hydroxyoleoylcarnitine, and PCaeC36:1 in bivariate analyses, but
in models adjusted for age and BMI only L-alanine remained signifıcant
(p0.05). After correction for FDR, there were no signifıcant differences by
randomization group. Conclusions: There were no clear associations between
metabolites and change in BMI or randomization group among overweight and
obese breast cancer survivors enrolled in a weight loss trial. Larger sample sizes
would help to clarify if any of the potential signals observed in this population
may be associated with BMI or other lifestyle changes, such as diet quality.
#5322 BMI and esophageal adenocarcinoma survival. Elizabeth A. Loeh-
rer, David Christiani. Harvard T.H. Chan School of Public Health, Boston, MA.
Purpose: Though BMI is a known risk factor for esophageal adenocarcinoma
(EA), the effect of BMI on EA overall survival remains unclear. Procedures: The
source population is the Esophageal Cancer Study, an ongoing case-control and
survivorship study of esophageal cancer patients recruited from Massachusets
General Hospital and Dana-Farber Cancer Institute. In September of 2004, the
study introduced a new patient questionnaire that included questions on weight
throughout adulthood. For this study, we restricted our analysis to Caucasian,
male patients with histologically confırmed EA who received their initial diag-
nosis between 9/1/2004 and 12/31/2014, and who were older than age 40 at time
of diagnosis (281 patients). Our exposures of interests were BMI categories
(18.5, 18.5-24.99, 25-29.99,30) and 	BMI (the average BMI past the age of
40 minus BMI at time of diagnosis), categorized the differences into0 (people
who gained weight, 0-2 (people who lost some weight), 2 (people who lost
substantial weight). We used an extended Cox proportional hazards model to
obtain hazard ratios (HR) of BMI at diagnosis and 	BMI, stratifying baseline
hazard by cancer stage, having surgery as a time dependent covariate, and ad-
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justing for radiation and chemotherapy treatment, age, sustained inability to eat
solid foods after diagnosis, and smoking status. Results: Of the 282 patients that
met our eligibility criteria, 211 men with complete information available were
included in the analyses, and there were 131 recorded events during follow-up.
In this study population,mean age at diagnosiswas 63.7 years (SD9.8),median
survival was 2.6 years, mean average BMI after 40 years of age was 29.0 kg/
m2(SD4.5), and mean BMI at diagnosis was 27.4 kg/m2(SD4.4). Compared
to obese subjects at diagnosis, underweight, healthy weight, and overweight at
diagnosis respectively had an adjusted hazard ratios of death (HR) of 2.72(95%
CI: 0.59-12.45), 1.79 (95%, CI: 1.06-3.02) and 1.08 (95% CI: 0.65-1.74) (BMI
category p0.04), likely demonstrating reverse causation. Adjusting for con-
founders, the 	BMI model shows that patients who lost substantial weight by
diagnosis had the highest hazard of death, compared to patients who gained
weight in late life prior to diagnosis (HR0.70, 95% CI: 0.45-1.1) and patients
who lost some weight (HR0.55, 95% CI: 0.35-0.9)( 	BMI category p0.05).
The strong effect of 	BMI even after adjusting for patients’ inability or lack of
desire to eat (anorexia), implicates cachexia as a possible independent mecha-
nism of this association. In addition, age at dx, stage at diagnosis, and surgical
resection were signifıcant predictors of overall survival. Conclusion: Substantial
change in BMI prior to diagnosis indicates poor overall survival in middle-aged
and elderly Caucasian men with esophageal adenocarcinoma.
#5323 Obesity and ovarian cancer survival revisited. Elisa V. Bandera,1
Valerie Lee,2 Bo Qin,1 Lorna Rodriguez,1 Bethan Powell,3 Lawrence H. Kushi2.
1Rutgers Cancer Inst. of New Jersey, New Brunswick, NJ; 2Kaiser Permanente
NorthernCalifornia, Oakland, CA; 3Kaiser PermanenteNorthernCalifornia, San
Francisco, CA.
Research on the impact of obesity on ovarian cancer survival is inconsis-
tent but previous studies did not consider the possible impact of ascites,
bowel obstruction, or cachexia, which commonly occur in late-stage disease.
We evaluated this association in a cohort study of primary invasive epithelial
ovarian cancers diagnosed from 2000-2013 in Kaiser Permanente Northern
California (KPNC) (n1,157). Deaths were identifıed through December
2014, with median follow-up of 37 months. Proportional hazards regression
was used to estimate overall and ovarian cancer-specifıc mortality, account-
ing for prognostic variables including age at diagnosis, race, stage, grade,
histology, comorbidities, treatment, post-treatment CA125 levels, ascites,
and bowel obstruction. There was no evidence of an association between
BMI and overall or ovarian cancer-specifıc survival. However, we found
strong effect modifıcation by stage (Pinteraction.01). Compared to normal
pre-diagnosis BMI (18.5-24.9 kg/m2), for women who were obese before diagnosis
(BMI35 kg/m2) risk of ovarian cancer-specifıc mortality was increased among
thosediagnosedat stages I/II (Hazard ratio [HR]: 3.40; 95%confıdence interval [CI]:
1.16-9.99), but reduced among those diagnosed with stage IV disease (HR: 0.58;
95%CI: 0.35-0.96). Associations persisted after excluding those diagnosed with ca-
chexia (n91) and further adjusting for ascites and bowel obstruction, with no
evidence of effectmodifıcationby these factors.Associations of obesitywith ovarian
cancer survival differ by stage, with decreased survival among those with localized
disease and increased survival among those with late-stage disease. Stage-specifıc
effects of obesity on survival suggest a tailored approach to improve prognosis may
be appropriate.
#5324 ERG expression and PTEN loss by BMI and weight change in men
with prostate cancer. Janelle S. Ho,1 IbrahimKulac,1 Tamara L. Lotan,1 John R.
Barber,2 Patrick C. Walsh,1 Misop Han,1 Angelo M. De Marzo,1 Elizabeth A.
Platz,2 Corinne E. Joshu2. 1Johns Hopkins University School of Medicine, Balti-
more, MD; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Background: Obesity and weight gain are associated with poor prostate can-
cer outcome; underlying mechanisms are unknown. Obesity has been more
strongly associated with lethal disease in men positive for the TMPRSS2:ERG
gene fusion than negative for this fusion. PTEN loss is associated with increased
risk of lethal progression; its association with obesity has not been explored.We
evaluated whether prevalence of ERG expression and PTEN loss in prostate
tumors differs byBMI andweight change.Methods: Froma retrospective cohort
study of 1,337 men with clinically-localized prostate cancer who underwent
prostatectomy at Johns Hopkins (1993-2006), we sampled 291 men by combi-
nation of BMI at 1 year after surgery (normal, overweight, obese) and weight
change from 5 years before to 1 year after surgery (loss, maintenance, gain).
Within each category,menwere frequency-matchedon age,Gleason sum, organ
confınement, and surgery year. We used genetically validated immunohisto-
chemistry assays to assess ERGpositivity and heterogeneous PTEN loss. Logistic
regression was used to estimate odds ratios (ORs) and 95% confıdence intervals
(CIs) for the association of BMI andweight change (adjusted for height, starting
weight) with ERG positivity and heterogeneous PTEN loss. Results: Mean age
was 56.1 years andmeanGleason sumwas 6.2; 73% had organ-confıned disease.
Prevalence of ERG positivity did not statistically signifıcantly differ by BMI or
weight change. However, when jointly categorized by BMI and weight change,
overweight/obese men who maintained (OR2.5; 95%CI 1.1-5.7) or gained
weight (OR2.5; 95%CI 1.1-5.8), and normal weight men who gained weight
(OR4.7; 95%CI 1.4-15.2) were signifıcantly more likely to have ERG positive
tumors compared with normal weight men who maintained weight. Over-
weight/obese men were also signifıcantly more likely (OR2.4; 95%CI 1.3-4.7)
to have PTEN loss compared with normal weight men. When stratifıed by ERG
status, this association appeared to be stronger for men with ERG positive tu-
mors (OR2.9; 95%CI 1.3-6.8) than for men with ERG negative tumors
(OR1.6; 95%CI 0.6-4.9). Prevalence of PTEN loss did not differ by weight
change.When jointly categorized by BMI and weight change, overweight/obese
men who maintained (OR2.0; 95%CI 0.8-5.3) or gained weight (OR1.9;
95%CI 0.7-5.1) appeared to be more likely to have PTEN loss compared with
normal weight men who maintained weight. Conclusions: Overweight/obese
men who maintained or gained weight circa diagnosis and normal weight men
who gained weight were more likely to have ERG positive tumors. Overweight/
obesemenweremore likely to have tumors with PTEN loss; this association was
stronger among overweight/obese men who also had ERG positive tumors. The
TMPRSS2:ERG gene fusion and PTEN loss may contribute to the increased risk
of poor prostate cancer outcomes among overweight/obesemen. Funding: Pros-
tate Cancer Foundation.
#5325 Associations between adipose tissue compartments and the plasma
metabolome in colorectal cancer patients: Results from the ColoCare Study.
Jennifer Ose,1 Tengda Lin,1 Nina Habermann,2 David Achaintre,3 Pekka Keski-
Rahkonen,3 Augustin Scalbert,3 Juergen Boehm,1 Biljana Gigic,4 Dominique
Scherer,5 Johanna Nattenmueller,5 Mariam Salou,6 Lin Zielske,6 Alexis Ulrich,4
Jewel Samadder,1 Hanno Glimm,6 Stephen Hursting,7 Hans-Ulrich Kauczor,5
Cornelia M. Ulrich1. 1Univ. of Utah Huntsman Cancer Inst., Salt Lake City, UT;
2European Molecular Biology Laboratory, Heidelberg, Germany; 3International
Agency for Research on Cancer, Lyon, France; 4University Clinic of Heidelberg,
Heidelberg, Germany; 5University of Heidelberg, Heidelberg, Germany; 6National
Center of Tumor Diseases, Heidelberg, Germany; 7The University of North Caro-
lina at Chapel Hill, NC.
BACKGROUND:Obesity is associated with colorectal cancer (CRC) risk and
prognosis. We investigated associations between plasma metabolites and mul-
tiple dimensions of body fatness in early- and late-stageCRCpatients enrolled in
the ColoCare Study, a multicenter international cohort. METHODS: Pre-oper-
atively collected plasma samples of newly diagnosed CRC patients [n212;
(stage I-IV)] from theColoCare Studywere utilized to perform targetedmetabo-
lomics by mass spectrometry using the AbsoluteIDQ p180 Kit assay (Biocrates;
intra-plate CVs20%, inter-plate CVs20%) as part of the MetaboCCC con-
sortium. Abdominal adipose tissue (AT) was assessed by area-based quantifıca-
tion of visceral (VAT), and subcutaneous AT (SAT), as well as their ratio (VAT:
SAT) on levels L3/L4 and L4/L5. Bodymass index (BMI)was calculated (kg/m2).
Demographic and clinical data were abstracted from medical records. Partial
correlations and regression analyses were used, adjusting for age, sex, batch,
stage overall and in stratifıed analyses by early- (I/II; n111) and late-stage
(III/IV; n101) and corrected for multiple hypotheses testing (FDR). We used
Cox proportional hazard models to investigate overall survival (OS) after 24
months of follow-up. RESULTS: A total of 127 metabolites from 5 different
compound classes (i.e., amino acids, biogenic amines, glycerophospholipids,
sphingomyelins, acylcarnitines) were included for statistical analysis. Overall
obesity (BMI) and VAT were not associated with any metabolites in early-stage
or late-stage tumors. SAT (L3/L4 and L4/L5) was inversely associated with 3
glycerophospholipids in analyses restricted to late-stage, but not early-stage tu-
mors: PC-ae-C34_0 (pFDR0.02), PC-ae-C36_0 (pFDR0.03), PC-ae-C36_1
(pFDR0.03). A doubling of concentration in selected glycerophospholipids was
associated with a signifıcant increase in risk for death in late-stage (III and IV)
CRC. CONCLUSIONS: We observed a negative association between subcuta-
neous abdominal adiposity and glycerophospholipids in late-stage CRC. Glyc-
erophospholipids are major components of cellular membranes and are perti-
nent to cancer cells that undergo progression andmetastasis. Our results suggest
that a metabolic shift in glycerophospholipid metabolism in late-stage tumors
may take place and have potential impact on survival.
#5325A Fruit and vegetable intake and risk of breast cancer: Pooled anal-
ysis of the Nurses’ Health Study and the Nurses’ Health Study II.Maryam S.
Farvid, Walter C. Willett, A. Heather Eliassen. Harvard T.H. Chan School of
Public Health, Boston, MA.
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Fruit and vegetable intake has been hypothesized to protect against breast
cancer, but the overall evidence has not been supportive.Using pooled data from
the Nurses’ Health Study and the Nurses’ Health Study II cohorts, we evaluated
fruit and vegetable intake in relation to breast cancer risk. Diet was assessed
every 4 years using semiquantitative food frequency questionnaires. Cox pro-
portional hazards regression, adjusting for multiple breast cancer risk factors,
was used to estimate hazard ratios (HRs) and 95% confıdence intervals (CIs)for
each category, using the lowest quintile of intake as the reference category.
Among 182,204 women aged 27 to 66 years, we prospectively identifıed 10,973
invasive breast cancer cases during follow-up from 1980 through 2012 for the
Nurses’ Health Study and from 1991 through 2013 for the Nurses’ Health Study
II. Fruit and vegetable intake was signifıcantly associated with a lower risk of
breast cancer. The pooled multivariate HR (95% CIs) for highest (3.2 servings/
day) versus lowest (0.4 serving/day) quintile intake of total fruit intake was 0.93
(0.86-0.99;Ptrend0.03) and for highest (4.9 servings/day) versus lowest (1.5
servings/day) quintile intake of total vegetable was 0.92 (0.86-0.99;Ptrend0.02).
We also observed that a higher intake of yellow/orange vegetables, cruciferous veg-
etables, fruits and vegetables rich in vitamin C, fruits and vegetables rich in	-caro-
tene, fruits and vegetables rich in-carotene, and fruits and vegetables rich in lutein
was each associatedwith a lower breast cancer risk. In addition, the associationwith
vegetable intake was stronger for both estrogen and progesterone receptor negative
(HR0.91; 95%CIs0.87-0.95) than both estrogen and progesterone receptor pos-
itive cancers (HR0.98; 95%CIs0.96-1.00;Pheterogeneity0.003). Our fındings sup-
port an association of a higher fruit and vegetable intake with a lower breast cancer
risk.
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#5326 EZH2 regulation through lysine 63 linked ubiquitination in pros-
tate cancer. Wenfu Lu,1 Shenji Lu,1 Bo Li,1 Yingqiu Xie,1 Michael G. Izban,1
Billy R. Ballard,1 Sandeep A. Sathyanarayana,1 Samuel E. Adunyah,1 Robert J.
Matusik,2 Zhenbang Chen1. 1Meharry Medical College, Nashville, TN; 2Vander-
bilt University Medical Center, Nashville, TN.
Enhancer of zeste homolog 2 (EZH2) plays crucial roles on the development
of cells and tissues as well as the progression of prostate cancer (PCa) and cas-
tration resistant prostate cancer (CRPC). EZH2 can upregulate and activate
progenitor genes including androgen receptor (AR) and the target genes. How-
ever, the mechanisms by which EZH2 is regulated in PCa remain elusive. Liter-
ature reports that tumor necrosis factor (TNF) receptor associated factor 6
(TRAF6) is essential for both normal tissue development and regulation of on-
cogenic signaling pathways in cancers. In this study, we reported that EZH2 is
regulated by PTEN and SKP2 network in PCa. Specifıcally, we showed that the
aberrant upregulation of EZH2 and histone H3 lysine 27 trimethylation
(H3K27me3) in bothPtennullmouse embryonic fıbroblasts (MEFs) in vitro and
prostate tumors of Pten null mice in vivo, as compared to the controls. EZH2
levels were negatively correlated with TRAF6 in human PCa cells upon SKP2
dysregulation. Immunofluorescence (IF) staining results showed a co-localiza-
tion of EZH2 and TRAF6 in nucleus of PC3 cells, and co-immunoprecipitation
(co-IP) analysis further confırmed a physical binding of EZH2 and TRAF6 in
PC3 cells. Ectopic expression of TRAF6 promoted the K63-linked polyubiquiti-
nation of EZH2 to decrease EZH2 and H3K27me3 levels in PCa cells. Con-
versely, TRAF6 knockdown resulted in a reduction of EZH2 polyubiquitination
with an increase of EZH2 and H3K27me3 levels in PCa cells. Furthermore, the
catalytically dead mutant TRAF6 C70A abolished the TRAF6-mediated polyu-
biquitination of human EZH2 in vivo in 293T cells and in vitro in the recombi-
nant human EZH2 protein, as compared with TRAF6WT. Together, we report
for the fırst time a novel mechanism on EZH2 ubiquitination and an important
signaling network of SKP2-TRAF6-EZH2-H3K27me3 in PCa cells. Our fınd-
ings provide valuable clues on the mechanism and effıciency of targeting EZH2
in PCa and CRPC.
#5327 Glioma derived cancer stem cells are hypersensitive to proteasomal
inhibition. Dae-Hee Lee,1 Sang Cheul Oh,1 Yong Tae Kwon,2 Yong J. Lee,3
YoungDongYoo2. 1KoreaUniv.Medical Center, Seoul, Republic of Korea; 2Seoul
National University, Seoul, Republic of Korea; 3University of Pittsburgh Medical
Center, Pittsburgh, PA.
Although proteasome inhibitors (PIs) are used as anticancer drugs to treat
various cancers, their relative therapeutic effıcacy on stem cells vs. bulk cancers
remains unknown. Here, we show that stem cells derived from gliomas, GSCs,
are up to 1,000-fold more sensitive to PIs (IC50, 27-70 nM) compared with their
differentiated controls (IC50, 47-100 M). The stemness of GSCs correlates
to increased ubiquitination, whose misregulation readily triggers apoptosis. PI-
induced apoptosis of GSCs is independent of NFB but involves the phosphor-
ylation of JNK as well as the transcriptional activation of endoplasmic reticulum
(ER) stress-associated proapoptotic mediators. In contrast to the general notion
that ER stress-associated apoptosis is signaled by prolonged unfolded protein
response (UPR), GSC-selective apoptosis is instead counteracted by the UPR.
ATF3 is a key mediator in GSC-selective apoptosis. Pharmaceutical uncoupling
of the UPR from its downstream apoptosis sensitizes GSCs to PIs in vitro and
during tumorigenesis in mice. Thus, a combinational treatment of a PI with an
inhibitor of UPR-coupled apoptosis may enhance targeting of stem cells in glio-
mas. Key words: glioma; glioma stem cells; proteasome inhibitors; ubiquitin
proteasome system; apoptosis; c-Jun N-terminal kinase (JNK).
#5328 RNF12 inhibits the proliferation of hepatocellular carcinoma
through c-Myc and p21. Meng Nie, Yongsheng Huang, Lin Wang. Chinese
Academy of Medical Sciences, Beijing, China.
Purpose: RNF12/RLIM, a RING E3 ubiquitin ligase, plays an important role
in the epigenetic regulation of sex-specifıc nurturing tissues in female mice.
Recently, a few studies demonstrated a correlation between RNF12 and the
proliferation of multiple cancers. The role of RNF12 in hepatocellular carci-
noma is incompletely understood. The purpose of this study is to investigate the
effect of RNF12 on the proliferation of human hepatocellular carcinoma cells.
RNF12 is also known to interact with a number of nuclear proteins, including
CLIM, HDAC2, and Smad4. We also explored whether c-Myc and p21, an on-
cogene and tumor suppressor essential to liver tumorigenesis, were affected by
RNF12. Methods: Immunohistochemistry of RNF12 and c-Myc was performed
on surgically dissected human hepatocellular carcinoma tissues. The soft-agar
cloning, flow cytometry and Transwell invasion assays were carried out to in-
vestigate the role of RNF12 in SK-Hep1 cell proliferation, cell cycle and inva-
siveness. Real-time quantitative PCR and Western blotting were used to exam-
ine the mRNA and protein levels of RNF12 and related proteins in SK-Hep1
cells. Results: We found that the level of RNF12 was lower in hepatocellular
carcinoma, compared with the surrounding non-cancerous tissues, while the
c-Myc expression was higher. Using a SK-Hep1 cell line stably expressing
RNF12, we showed that RNF12 over-expression inhibited cell proliferation and
induced cell cycle arrest at G1 phase. Furthermore, we showed that RNF12
over-expression decreased the level of oncoprotein c-Myc, while not much af-
fecting itsmRNA level. Co-immunoprecipitationdemonstrated thatRNF12 and
c-Myc associated with each other, suggesting a direct protein-protein interac-
tion. RNF12 over-expression also markedly increased the mRNA and protein
levels of p21, a tumor suppressor and the downstream target of p53, c-Myc and
many other cancer-related regulators. Consistently, silencing of RNF12 reduced
p21 mRNA and protein levels and increased c-Myc protein. Conclusion: Our
study demonstrated reduced expression of RNF12 in hepatocellular carcinoma,
and RNF12 over-expression inhibited the proliferation and cell cycle progres-
sion of SK-Hep1 cells. Mechanistically, RNF12may directly regulate the level of
c-Myc, similarly as other transcription factors such as CLIM and Smad4. The
mechanisms underlying the increased expression of p21 is being investigated.
Taken together, RNF12 may serve as a tumor suppressor in hepatocellular car-
cinoma, partly through oncoprotein c-Myc and tumor suppressor p21.
#5329 Glycyl-tRNA Synthetase is a novel target for cancer therapeutics.
Zhongying Mo, Ze Liu, Xiang-Lei Yang. The Scripps Research Institute, La jolla,
CA.
Neddylation, an ubiquitination-like, post-translational modifıcation that
controls cell cycle and proliferation, is strongly associated with cancer. Interest-
ingly, we recently identifıed that glycyl-tRNA synthetase (GlyRS) as a critical
chaperone for neddylation1. GlyRS is also an essential enzyme for protein syn-
thesis, which is required for tumor growth. Therefore, the dual functional GlyRS
may be a novel target for anti-cancer therapy. Consistent with this idea, we
found strong positive correlation between the level of GlyRS and tumor progres-
sion in breast cancer. A proof-of-concept inhibitor of GlyRS for aminoacylation
was able to suppress neddylation in breast cancer cells, and reduce their lung
metastasis in a mouse model. Taken together, we propose that GlyRS is a novel
and promising target for cancer treatment. Reference: 1. ZY Mo, Q Zhang, J
Laurer, Z Liu, LT Sun, Y Shi, P Griffın, XL Yang. Nature Structural and Molec-
ular biology. 2016 Jun 27. doi: 10.1038/nsmb.3250.
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#5330 Targeting hepatocellular carcinoma through TGF- pathway E3
ligases. Shuyun Rao,1 Heather Levin,1 Jian Chen,2 Rehan Akbani,2 Jon White,3
Wilma Jogunoori,3 Shoujun Gu,1 Kazufumi Ohshiro,3 Sobia Zaidi,1 Bibhuti
Mishra,3 Asif Rashid,2 Shulin Li,2 Lopa Mishra1. 1George Washington Univ.,
Washington, DC; 2MDAnderson Cancer Center, Houston, TX; 3Institute of Clin-
ical Research, Washington, DC.
Hepatocellular carcinoma (HCC) is the 3rd leading cause of cancer deaths
worldwide, and rising in the United States at an alarming rate. Multiple E3
ubiquitin ligases such as the SMURFs and RINGH2 proteins have been identi-
fıed as negative regulators of the TGF- pathway. However, to our knowledge,
there remains a gap in the integration between genomics, underlying mecha-
nisms and the development of targeted therapeutics harnessing these TGF--
associated E3 ligases for HCC. The aim of this study is to elucidate the role of E3
ligases in HCC, through TCGA analyses and provide mechanistic insight into
these as therapeutic targets for HCC. We fırst analyzed the 488 hepatocellular
cancers and screened for alterations in The Cancer Genome Atlas (TCGA).
Immunohistochemistry (IHC), Q-PCR, Western blot analysis were used to val-
idate the expression levels of two of the most highly altered E3 ligases, PRAJA
and Keap1 in hepatocellular cancer tissues and cell lines in human and in TGF-
-defıcient 2SP/- mouse models. Inhibition studies of PRAJA and Keap1
were performed by lentivirus shRNA in HCC cell lines, and xenograft studies.
From the TCGA data, we observe two different signatures (activated and inac-
tivated) for 18 TGF- pathway genes. While increased levels of TGF--related
transcripts were associated with activation of hepatic fıbrosis/immunemicroen-
vironment pathways, decreased levels of TGF-members were associated with
loss of TGF- tumor suppressor function. HCCs characterized by the “inacti-
vated” TGF- signature were associated with a signifıcantly poorer survival,
compared to HCCs with the “activated” TGF- signature (p0.0027). We next
analyzed 29 TGF--related E3 ligases, and observed raised expression of the
following: PRAJA1 (12.7% of HCCs), KEAP1 (6.4%), UCHL5 (16.4%), WWP2
(11.8%), WWP1 (10%), Smurf2 (9.1%), Skp2 (9.1%), and Smurf1 (8.2%). Inter-
estingly, expression patterns corresponded with a few TGF- signaling mem-
bers regulated by some of these E3 ligases, namely Smad3 (altered in 54%) and
2SP (27%). We identifıed that PRAJA1 targets Smad3 and 2SP for ubiquiti-
nation and degradation. We further observe raised levels of PRAJA (25%) and
KEAP1 (70%) in 176 human liver cancers, by IHC, compared to normal con-
trols. Depletion of PRAJA and KEAP1 with either shRNAs or E3 ligase inhibi-
tors, substantially inhibited growth and induced apoptosis through PRAJA/
Smad3/2SP and KEAP1/Nrf signaling in HCC cell lines and xenografts. These
results suggest that E3 ligases such as PRAJA1 and KEAP1 may be valuable
therapeutic targets for liver cancer in the context of TGF- signaling, an impor-
tant approach given that few effective targeted therapeutics are available for this
cancer with poor prognosis.
#5332 ISG15 knockdown inhibits growth of pancreatic cancer. Julian
Burks, Jill Smith. Georgetown Lombardi Comp. Cancer Ctr., Washington, DC.
Background: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease
driven by mutated KRAS with an average survival of only 3-6 months from the
time of diagnosis. Interferon-Stimulated Gene 15 (ISG15) is a 15 kDa protein
induced by Type I interferons (IFN-	 and IFN-) and is a member of the ubiq-
uitin-like superfamily of proteins. The ISG15 pathway is highly elevated in var-
iousmalignancieswhere it has been shown to stabilizeKRASprotein expression.
However, very little is known about the role of the ISG15 pathway in PDAC. The
purpose of this project is to investigate the expression and proliferative effects of
the ISG15 pathway in PDAC. Methods: The ISG15 knockdown cells were cre-
ated using the CRISPR (Clustered Regularly Interspaced Short Palindromic Re-
peats) gene editing system. ISG15 was stably knocked-down in murine Panc02
pancreatic cancer cells by transfection with an ISG15 CRISPR construct from
Genscript (pSpCas9 BB-2A-Puro (PX459)) and treated with media containing
puromycin (2g/ml) for selection. Knockdownwas confırmed byRT-PCR. The
effect of ISG15 knockdown on PDAC cell growth in vitro was determined by
comparing viable cell counts on wild-type and ISG15 knockdown Panc02 cells
48 hours after plating. The effect of ISG15 knockdown on pancreatic tumori-
genesis was determined by subcutaneous inoculation of syngeneic immune
competent C57BL/6 mice with 1x106 Panc02 wild-type or ISG15 knockdown
cells. Tumor volumes were measured weekly and after 3 weeks the mice were
euthanized, tumors dissected and weighed. Results: ISG15 CRISPR treated cells
had a 50% reduction in ISG15mRNA expression as compared to wild-type cells.
ISG15 knockdown in Panc02 PDAC cells signifıcantly reduced cell growth as
compared to wild-type cells (p0.030). Tumors formed from ISG15 knock-
down Panc02 cells signifıcantly had a 74% reduction in tumor volume
(p0.031) and 78% reduction in tumor weight (p0.029) as compared to wild-
type cells. Conclusion: The ISG15 pathway contributes to PDAC by increasing
cell growth and the tumorigenic potential of pancreatic cancer cells. Ultimately,
strategies to target the ISG15 pathwaymay lead to improved survival for patients
diagnosed with PDAC. Supported by: NIH T32CA00968 grant.
#5333 Monoubiquitination inhibits the actin bundling activity of fascin.
Shengchen Lin,1 Shuang Lu,2 Mentor Mulaj,3 Bin Fang,2 Tyler Keeley,3 Lixin
Wan,2 Jihui Hao,4 Martin Muschol,2 Jianwei Sun,5 Shengyu Yang1. 1Penn State
University, Hershey, PA; 2Moffıtt Cancer Center, Tampa, FL; 3University of South
Florida, Tampa, FL; 4Tianjin Medical University, Tianjin, China; 5South China
Agricultural University, Guangzhou, China.
Fascin is the most frequently upregulated actin regulatory protein in meta-
static tumors. The elevated expression levels of fascin universally correlate with
poor clinical course and shorter survival across different cancer types. It is be-
lieved that fascin promotes cancer cell migration and invasion by crosslinking
actin fılaments into bundles. However, the molecular mehcanisms underlying
the regulation of fascin bundling activity are not completely understood. In this
study we examine the regulation of Fascin activity by monoubiquitination. IP
and LC-MS/MSwas used to identify the posttranslationalmodifıcation of Fascin
A novel chemical monoubiquitination method was employed to synthesize
monoubiquitinated Fascin. Themonoubiquitinated fascin was purifıed, and the
effect of monoubiquitination on fascin bundling activity was determined using
low speed sedimentation assay, fluorescence microscopy and transmission elec-
tronmicroscopy. Here we identifıedmonoubiquitination as a novel mechanism
that regulates fascin bundling activity and dynamics. The monoubiquitination
sites were identifıed to be K247 and K250, two residues located in a positive
charge patch at the actin binding site 2 (ABS2) of fascin. Using a chemical
ubiquitination method, we synthesized chemically monoubiquitinated fascin
(mUb-fascin) and determined the effects of monoubiquitination on fascin bun-
dling activity and dynamics. Our data demonstrated that monoubiquitination
decreased the fascin bundling EC50, delayed the initiation of bundle assembly
and accelerated the disassembly of existing bundles. By analyzing the electro-
static properties on the solvent accessible surface of fascin, we proposed that
monoubiquitination introduced steric hindrance to interfere with the interac-
tion between actin fılaments and the positively charged patch at ABS2.Mutation
of the monoubiquitination sites (K247 and K 250) to arginine inhibited fascin
monoubiquitination and enhanced pro-migration ability of fascin, supporting
the notion that monoubiquitination inhibit fascin activity. We also identifıed
Smurf1 as anE3 ligase regulating themonoubiquitination of fascin.Our fındings
revealed a previously unidentifıed regulatory mechanism for fascin, which will
have important implications for the understanding of actin bundle regulation
under physiological and pathological conditions.
#5334 Destabilization of EWS-Fli1 protein by deubiquitinase inhibition
in Ewing Sarcoma. Shan Wang, Ralf Kittler. UT Southwestern Medical Ctr.,
Dallas, TX.
Background: Ewing Sarcoma is a malignant tumor in bone or soft tissue, and
typically in teenagers and young adults. Genetically, 85% of Ewing’s Sarcoma
contains the chromosomal translocation [t(11;22)(q24;q12)], which fuses
EWSR1 gene from chromosome 11 and Fli1 gene from chromosome 22 and
generates an aberrant chimeric protein EWS-Fli1. EWS-Fli1 is essential for cell
growth and development in EWS-Fli1 positive Ewing Sarcoma cells. Therefore,
targeting EWS-Fli1 could be a promising therapeutic strategy for Ewing Sar-
coma. Methods and Results: Currently, the compounds of targeting EWS-Fli1
mainly interfere its interaction with partner or DNA. However, it could be a
more potent way to manipulate its protein stability. Firstly, the proteasome
inhibitor MG132 could retard the degradation of EWS-Fli1 protein in EWS502
cells andA673 cells, and increase its ubiquitination, which hints the degradation
of EWS-Fli1 is through the ubiquitin (Ub)-proteasome pathway (UPP). Then, to
identify the protein that interact with EWS-Fli1 and modulate its stability, we
selected the candidate deubiquitinase according to literatures and the protein
homology. And by co-immunoprecipitation assay, we identifıed a deubiquiti-
nating enzyme (DUB) binding to EWS-Fli1. RNAi-mediated knockdown or
inhibition of EWS-Fli1-DUBwith a small molecule compound caused amarked
increase in EWS-Fli1 ubiquitination, decreased levels of EWS-Fli1 in a protea-
some-dependent manner, and further inhibited the growth of Ewing Sarcoma
cells. Conclusion: The fındings indicate that EWS-Fli1 could be ablated by in-
hibiting its specifıc deubiquitinase in Ewing Sarcoma, which could be a novel
treatment approach for Ewing Sarcoma.
#5335 Dissecting the ubiquitin pathway using homogenous and sensitive
bioluminescent assay. Said A. Goueli, Kevin Hsiao, Subhanjan Mondal. Pro-
mega Corp., Madison, WI.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Cell Growth Signaling Pathways 8
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171366
Post-translationalmodifıcation of target proteins by ubiquitin (Ub) and ubiq-
uitin-like (Ubl) proteins is a fundamental mechanism for regulating protein
functions and protein stability thus affecting diverse cellular processes. Several
ubiquitin-like (Ubl) molecules have been identifıed including SUMO, NEDD8,
ATG8/15 and ISG15 which share the ubiquitin fold Ub/Ubl proteins are conju-
gated to lysine residues in substrate proteins through an ATP-dependent enzy-
matic cascade involving E1-activating enzyme, E2-conjugating enzyme and E3-
ligase. To mark proteins for degradation, multiple ubiquitins are covalently
attached to produce a Lys48 linked poly-ubiquitin chain. The poly-ubiquiti-
nated proteins are recognized by the 26S proteasome system and deubiquiti-
nated and destroyed. Substrates with ubiquitin chains linked through Lys 6, 11,
27, 29, 33 also regulate protein degradation. Substrates marked with mono-
ubiquitination or Lys63 ubiquitin chains are involved in cell signaling indepen-
dent of degradative functions. Many diseases are associated with dysfunction of
ubiquitin signaling, with the E3 ligase class of enzymes are considered to be the
most important target. However, in recent years, evidence have accumulated
demonstrating the signifıcance of E2 class of enzymes where mutations and
impairment of this class lead to severe diseases states including chromosomal
instability, cancer predisposition, neurological syndromes, and immunological
disorders. Thus, in addition to E3, E2 group of enzymes represent important
class of therapeutic targets. To address the need for developing drugs targeting
these enzymes, we have developed a novel assay that can be used to screen for
modulators of these enzymes by taking advantage of the fırst ubiquitin activating
enzyme E1 which activates free Ub forming a high-energy thioester bond be-
tween E1’s active site Cys and the C-terminus of Ub, generating AMP and py-
rophosphate (PPi) as products of the reaction. We monitor the activity of these
enzymes by determining the concentration of AMPgenerated in the reactions in
a luminescence-based assay. Our assay interrogate not only E1 but also E2 and
E3 in a very robust and sensitive manner. The assay is homogenous, biolumi-
nescent, and show a very high signal to background in a very selective manner
for each class of the ubiquitin pathway. The assay was successfully tested for
ubiquitination, SUMOlyation and Neddylation reactions and thus can be used
for screening of enzymes targeting these pathways.
#5336 Characterization of selective covalent inhibitors of USP7. Feng
Wang,1 Jian Wu,1 Liqing Wang,2 Ivan Sokirniy,1 Hui Wang,1 Charles Grove,1
Phuong Nguyen,3 Thomas Bregnard,4 Joseph Weinstock,1 Michael Mattern,1
Wayne Hancock,5 Irina Bezsonova,4 Suresh Kumar1. 1Progenra Inc, Malvern,
PA; 2Children’s Hospital of Philadelphia, Philadelphia, PA; 3Progenra, Malvern,
PA; 4UCONNHealth, Farmington, CT; 5Children’s Hospital of Philadelpha, Phil-
adelphia, PA.
The ubiquitin-specifıc protease 7 (USP7) has emerged as an attractive thera-
peutic target owing to its critical roles in several cancer signaling pathways as
well as its essential role in maintaining Foxp3 T-regulatory cell (Treg) func-
tions. Pharmacological inhibition of USP7 using Progenra’s small molecule in-
hibitors resulted in direct anti-tumor activity as well as the unleashing of anti-
tumor immunity by suppressing Treg functions. However, the precise
mechanismof action these compoundswas notwell characterized.Using a com-
bination of NMR spectroscopy, mass spectrometry, and single amino acid sub-
stitution approaches, we have now demonstrated that our USP7 inhibitors spe-
cifıcally target the catalytic cleft of USP7 and covalently modify its active site
cysteine (Cys223). Pharmacokinetic studies revealed sustained irreversible
USP7 inhibition after short term inhibitor treatment as well as subsequent
changes in the level and ubiquitylation of various pharmacodynamic markers,
including the Treg lineage specifıc transcription factor Foxp3. Detailed knowl-
edge of themechanismofUSP7 inhibition has allowed us to incorporate rational
design strategies into the lead optimization to obtain improved molecules that
will serve as the basis of a new class of anti-cancer immunotherapy agents.
#5337 USP26 regulates TGF- signaling by deubiquitinating and stabiliz-
ing SMAD7. Pieter J.A. Eichhorn, Sarah Lui, Prasanna Iyengar, Patrick Jaynes.
National University Singapore, Singapore, Singapore.
The amplitude of transforming growth factor- (TGF-) signal is tightly
regulated to ensure appropriate physiological responses. As part of negative
feedback loop SMAD7, a direct transcriptional target of downstream TGF-
signaling, acts as a scaffold to recruit the E3 ligase SMURF2 to target the TGF-
receptor complex for ubiquitinmediated degradation. Here we identify the deu-
biquitinating enzyme USP26 as a novel integral component of this negative
feedback loop. We demonstrate that TGF- rapidly enhances the expression of
USP26 and reinforces SMAD7 stability by limiting the ubiquitinmediated turn-
over of SMAD7. Conversely, knockdown of USP26 rapidly degrades SMAD7
resulting in TGF- receptor stabilization and enhanced levels of p-SMAD2.
Clinically, loss of USP26 correlates with high TGF- activity and confers poor
prognosis in glioblastoma.Our data identifyUSP26 as a novel negative regulator
of the TGF- pathway and suggests that loss of USP26 expression may be an
important factor in glioblastoma pathogenesis.
#5338 Transcriptional elongation mediates human papillomavirus type
16 late promoter activation. William Songock, Jason Bodily. Louisiana State
University Health Sciences Center, Shreveport, LA.
Human papillomaviruses (HPVs) are small DNA viruses that infect keratin-
ocytes of squamous epithelia and cause benign lesions that can progress to sev-
eralmalignancies, including cervical cancer. Upregulation of viral transcripts by
the HPV16 late promoter is dependent on host cellular differentiation. We
sought to investigate the main cellular transcription regulators that correlate
with differentiation-dependent increase in the late viral transcripts. Here,
we show evidence that the step in transcription cycle that is responsible for late
promoter activation is transcriptional elongation.We began by establishing that
the increase in viral transcripts originating from the late promoter is primarily
regulated at the transcript synthesis level rather than post-transcription level.
Based on this observation, we investigated whether there is a correlation be-
tween late promoter activation and activities that occur during the initiation,
pausing or elongation steps of transcription cycle. Using chromatin immuno-
precipitation (ChIP), we did not observed a differentiation-dependent increase
of RNA Polymerase II (RNAP II) in the late promoter region. However, there
was a signifıcant increase of RNAP II at downstream sites of late promoter
suggesting elongation is regulated by differentiation. We then sought to inves-
tigate the cyclin dependent kinases (CDKs) that are known to regulate transcrip-
tion elongation. ChIP did not show a signifıcant increase of the elongation factor
CDK9 in the late promoter; however, the enrichment of CDK9 at downstream
sites of the viral genome signifıcantly increased upon differentiation, suggesting
that differentiation induces recruitment of CDK9 to facilitate elongation. Addi-
tionally, CDK8, a component of theMediator complex that recruits CDK9 to the
RNAP II, was increased upon differentiation. Kinase inhibitors against CDK8
did not affect late viral transcripts; however, knocking down CDK8 resulted in
signifıcant reduction of viral transcripts, suggesting that CDK8 could be in-
volved in protein-protein interactions that are required for the synthesis of late
viral transcripts. These fındings suggest that HPV has evolved to utilize cellular
transcriptional elongationmachinery as a way of regulating its late gene expres-
sion. This mechanism allows the virus to persistently infect host cells and cause
HPV-associated malignancies.
#5339 Molecular phylogenetic classifıcation of human papillomaviruses
and cancer associated genes: In correlation with cervical cancer manifesta-
tion. John Idoko, Mohammed Faruk, Jigo Yaro, James Enemari, Peter Akpulu.
Abu Teaching Hospital Zaria Nigeria, Zaria, Nigeria.
Human papillomaviruses (HPVs) are a diverse group of small double
stranded Deoxyribonucleic acid viruses implicated in many malignancies in-
cluding cervical cancer. The viruses are also attributed to premalignant epithelial
lesions in this disease. Cervical cancer is a leading course of morbidity and
mortality in African women and beyond. We aimed to study the molecular
phylogenetic classifıcation of HPVs and cervical cancer associated genes in re-
lation with tumour manifestation. Phylogenetic tree was constructed based on
nucleotide sequence alignments using ClustalX 2.1 algorithms to classify 31
differentHPVDNAvirus types and 10 cervical cancer associated genes. Study of
immunohistochemistry markers associated with cervical cancer pathology was
performed. The nucleotide sequences used include HPV- 1 (V01116), HPV-14
(D90261), HPV-20 (D90262), HPV-21 (D90263), HPV-25 (D90264), HPV-5
(M22961), HPV-47 (M32305), HPV-8 (M12737), HPV-2 (X55964), HPV-57
(X55965), HPV-6: X00203), HPV-11 (M14119), HPV-13 (X62843), HPV-43
(HE962420.1 E6 gene), HPV-44 (U31788.1), HPV-42 (HE820226.1 E6 gene for
E6 protein), HPV-16 (K02718), HPV 16 (KJ869425.1 E6 and E7 variants),
HPV-35 (M74117), HPV-31 (J04353), HPV-52 (KJ869430.1), HPV-33
(M12732), HPV-58 (D90400), HPV-51 (M62877), HPV-18 (X05015), HPV-45
(M27363), HPV-39 (M38185), (ME180, M73258), HPV 16 (KJ869425.1 E6 and
E7 variants), Ki-67 (NM_002417.4), p53 (AB082923.1), EGFR (NM_005228.3),
MYC (M25803.1), KRAS (EF471957.1), TGF-B (AF254794.1) and RB
(AH002963.2) genes. The resulting phylogenetic tree provides a conventional
classifıcation of the HPVs and the cancer genes into groups encompassing the
known tissue tropism and oncogenic potential of each gene type associated with
the disease. The implications of a phylogenetic taxonomy on the diagnostic
detection of HPVs as they relate to cervical cancer associate genes are shown to
be important in disease management.
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#5340 Retrovirus insertion induces syncytin mediated exosomes delivery
in prostate cancer cells. Berna Uygur, Leonid Chernomordik. NIH, Rockville,
MD.
Activation of retroviruses in normal cells can induce tumors and a wide array
of cancers contains retrovirus-like particles. The potential role of these endoge-
nous retroviruses in the development and progression of tumors has been dis-
cussed in many studies. However the effects of retrovirus insertion into cancer
cells have not yet been fully examined. In this study, we explore genetic material
transfer either between retrovirus-transduced prostate cancer PC3 cells or be-
tween PC3 cells and their host environment through extracellular vesicles (EV)
and virus-like particles. For these purposes, we transduced PC3 cells with either
GFP-encoding retrovirus or with m-cherry-encoding lentivirus. Co-incubation
of GFP-expressing cells with m-cherry-expressing cells for 72h yielded yellow
PC3 cells. Yellow cells were also observed in the experiments where lentiviral
m-cherry expressing PC3 cells were cultured with tissue culture medium from
retrovirus GFP expressing PC3 cells. These results indicated that horizontal
genetic information transfer involves neither fusion nor contact between the
cells. Since incubation of the retrovirus GFP-expressing PC3 cells with the me-
dium from the lentivirus m-cherry expressing PC3 cells, did not yield yellow
cells the genetic material transfer requires retrovirus insertion in PC3 cells. Us-
ing Western blot and Q-PCR, we found the exosomes from the medium gener-
ated by retrovirus GFP expressing PC3 cells to carry human endogenous retro-
viral proteins syncytin 1 and 2 and contain RNAs encoding these proteins.
Exosomes from the lentivirus m-cherry expressing PC3 cells had lower protein
expression of Syncytin 1&2 than exosomes from retrovirus GFP expressing PC3
cells. Application of Syncytin 1 or 2 antibodies to the medium generated by or
co-cultured retrovirus GFP expressing PC3 and lentivirus m-cherry expressing
PC3 cells suppressed horizontal transfer of the genetic information from retro-
virus GFP expressing PC3 cells to other cells. The specifıc mechanisms by which
retroviral transduction and syncytins control the generation of a GFP-encoding
pseudotyped retrovirus or EV and the delivery of their content, as well as the role
of the virus/EV-mediated horizontal genetic material transfer between prostate
cancer cells and between prostate cancer and theirmicroenvironment remain to
be clarifıed.
#5341 HPV16 E6 oncoprotein modulates the DPPIV/CD26 in primary
keratinocytes. Aline Beckenkamp,1 Bruna Prati,2 Silvya Stuchi Maria-Engler,3
Guido Lenz,1 Diogo André Pilger,1 Enrique Mario Pierulivo,3 Andréia Buffon1.
1Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; 2Univer-
sidade de São Paulo (USP), São Paulo, Brazil; 3Universidade de São Paulo (USP,
São Paulo, Brazil.
Cervical cancer is related to the persistent infection by high-risk human papillo-
mavirus (HPV) subtypes, such as types 16 and 18. The E6 and E7 oncoproteins
signifıcantly contribute to the carcinogenic potential of high-riskHPV, through the
degradation of p53 and pRb, respectively. The exoprotease dipeptidyl peptidase IV
(DPPIV) also known as CD26, is amultifunctional protein involved in several pro-
cesses related to cancer. DPPIV/CD26 has an intrinsic peptidase activity, able to
degrade somebioactivepeptides andchemokines, thereby regulating cellmigration,
proliferation and survival. It has been reported that the reduction in DPPIV/CD26
expression is associated with tumor progression in different types of cancer. More-
over, studies in cervical cancer samples and cell lines point to a reduction in the
expressionof this protein.However, there are no studies addressing the relationship
betweenHPVinfectionandDPPIV/CD26expression.Weanalyzed the influenceof
HPVoncoproteins onDPPIV/CD26 expression in humankeratinocyte transduced
with E6, E7 and E6E7. We observed that HPV16 E6 expression is associated to a
reduction inDPPIV/CD26expressionatmRNAandprotein levels,whereasHPV16
E7 does not affect DPPIV/CD26 expression. HPV16 E6E7 co-expression leads to a
reduction in DPPIV/CD26 expression similar to that found in E6 transduced cells.
In addition, we note a more pronounced reduction in DPPIV/CD26 expression in
immortalized cells expressing E6E7. Furthermore, keratinocytes expressingHPV16
E6mutant sequence and HPV11 E6, that do not bind to E6AP and do not degrade
p53,havenoeffect onDPPIV/CD26expression.Our results suggest that theHPV16
E6 oncoprotein can downregulates DPPIV/CD26. In addition, preliminary results
suggest that modulation of DPPIV/CD6mediated by E6 can be dependent on deg-
radationofp53, sinceHPV16E6mutantand low-riskHPVE6werenotable toaffect
CD26 expression. Furthermore, the process of cell immortalization also appears to
be related to the reduction of DPPIV/CD26 expression. Therefore, these results
indicate that HPV oncoproteins promote imbalance DPPIV/CD26 expression
whichmay be relate to cervical carcinogenesis.
#5342 Epigenetic polymorphisms and human papillomavirus E6/E7 on-
coproteins transfection: Induce ATM gene deletion11q22-23 and chromo-
somal instability. EvaMcGhee,1 Liliana Zarate,1 Chiamaka Opara,1 Antoinette
Alugbue,1 Meidrah Tyler,1 Bileko Wissa,1 Billy Ballard,2 Roland Pattillo3.
1Charles R. Drew University of Medicine and Science, Los Angeles, CA; 2Meharry
Medical College, Nashville, TN; 3Morehouse School of Medicine, Atlanta, GA.
Persistent infections involving high-risk types 16 and 18 of Human Papillo-
mavirus (HPV) have been established as the etiological agent of cervical cancer.
Recent data indicate that several polymorphisms of key regulators from the
DNA damage repair pathways are associated with cancer development suscep-
tibility. The long arm of chromosome 11 has received much attention as a high
frequency of epigenetic deletions of various sites, observed in HPV-long term
infection that lead to cervical cancer, indicating the presence of putative tumor
suppressor genes and its association with disease progression. To better under-
stand the importance of chromosome 11q22-23 region in the development of
cervical cancer, we investigated genetic and epigenetic alterations of the tumor
suppressor ATM gene in human keratinocytes transfected with HPV E6/E7
oncoproteins (16-MT). In the present study we examined 16-MT cells for epi-
genetic changes and chromosome imbalances, using FISH, and arrayCGH. We
used several FISH probes, mapping to region 11q22-23 where the ATM gene is
located. Our study revealed that the ATM gene located on chromosome 11q is
deleted, relating to chromosome deletions, that are recurrent abnormalities in
cervical cancer, implicating the loss of tumor suppressor genes as a signifıcant
mechanism that drive cells to become cancerous. This study was designed to
investigate genetic instability usingHPV16 E6/E7 oncoproteins to better under-
stand the importance of chromosome 11q epigenetic changes. Deletion of
11q22-23 was observed in all metaphases scored. With restricted areas of dele-
tions, two chromosomal regions of possible importance in cervical carcinomas
could be distinguished. The fırst region is D11S1325 and the second region is
D11S2179. The second region may contain part of the ATM gene. The results
indicate that a tumor suppressor gene on chromosome 11q22-23 may be in-
volved in the carcinogenesis of the cervix and the involvement of the ATMgene,
as the driving factor remains a possibility.
#5343 The HIV shell protein Gp120 stimulates U87 glioma cell prolifera-
tion through the activation of glycolysis. Gabriel Valentin-Guillama,1 Sheila
Lopez,1 Jose Perez,1 Luis Cubano,1 Natalia Chorna,2 Jeffrey Harrison,3 Nawal
Boukli,1 Lilia Kucheryavykh1. 1Universidad Central del Caribe, Bayamon, PR;
2University of Puerto Rico, School of medicine, San Juan, PR; 3University of Flor-
ida, Gainesville, FL.
Patients infected with human immunodefıciency virus (HIV) aremore prone
to develop cancers, including glioblastomas (GBM). The median survival of
GBMpatientswithHIV is signifıcantly shorter compared toHIV-negativeGBM
patients, despite the fact that they receive the same treatments. This indicates
that HIV infection is associated with more aggressive tumor behavior and with
treatment resistance. Taking into account that HIV itself is not found in GBM
specimens, the nature of the GBM-HIV association remains poorly understood
and the underlying molecular mechanism is still unknown. Here we study the
effect of Gp120, a glycoprotein found in the HIV shell, on GBM cell growth and
chemotherapeutic resistance. U87 glioma cells were used in this study. Flow
cytometry analyses based on 7-aminoactinomycin D staining and viability as-
says were used for identifıcation of cell cycle, proliferation rates, and resistance
to temozolomide (TMZ). Combined proteomics, metabolomics, and western
blot approaches together with colorimetric pyruvate kinase activity assays were
used for evaluation ofmetabolic pathways.U87 cells treatedwithGp120 (200ng/
ml) for 10 days showed higher proliferation rates and increased cell survival in
response to treatment with TMZ (100M) compared to un-treated cells. Quan-
titative proteomics studies using isobaric tags and western blot analysis identi-
fıed expression up-regulation of several glycolytic enzymes, including enolase 2,
pyruvate kinase, hexokinase, and glyceraldehyde 3-phosphate dehydrogenase in
Gp120 treated U87 cells. Additionally, metabolite analysis revealed an increase
of pyruvate, amino acid and lipid synthesis, together with reduction of protein
degradation, in response to treatment with Gp120. In summary, we demon-
strated that Gp120 promoted proliferation and resistance to TMZ in U87 cells
through the activation of glycolysis, resulting in increased protein and lipid
synthesis This research was made possible by NIH grant numbers:
1SC2GM102040, R25GM110513, INBRE-PR NIH Grant 8P20GM103475, the
UCC RCMI Biomedical Proteomics Facility grant G12MD007583 and US De-
partment of Education Grant number P031S130068.
#5344 Understanding the structural requirements of C1 domains for
phorbol ester binding, analysis of the atypical C1 domain of STAC2. Adelle
Abramovitz, Noemi Kedei, Peter M Blumberg. NIH/NCI, Bethesda, MD.
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C1domains are the recognitionmotif for the secondmessenger diacylglycerol
and for the phorbol esters. They play a critical role in the regulation of multiple
families of signaling proteins such as protein kinase C, RasGRP, and the chima-
erins. Atypical C1 domains preserve substantial homology with the diacylglyc-
erol / phorbol ester responsive C1 domains but fail to bind these ligands. A
recent advance in the fıeld has been the recognition that the atypical C1 domains
represent a continuum of structures ranging from those with measurable but
weak phorbol ester binding affınity through those that preserve the phorbol ester
binding cleft but have residues interfering with the insertion of the C1 domain
into membranes and fınally those that lack appropriate binding cleft geometry.
STAC2 (SH3 and cysteine-rich domain 2) protein attracted our interest because,
while its C1 domain has been classifıed as atypical, it had actually not been tested
for phorbol ester binding activity and possesses marked homology to C1 do-
mains that bind phorbol esters. The strategy for analysis has been to probe the
influence of individual residues in the STAC2 C1 domain that are either not
present or are unusual in the numerous phorbol ester responsive C1 domains.
Reciprocal approaches have been to start either with the STAC2 C1 domain,
mutate the individual residues, and look for gain of phorbol ester binding activ-
ity or to start with the PKC delta C1b domain and look for residues that cause
reduction in binding affınity. The former approach is effıcient if a single residue
is responsible for the lack of binding activity; the latter approach is preferable if
multiple residues are responsible. First, we confırmed that indeed theC1domain
of STAC2 is atypical and fails to bind phorbol ester. Second, we identifıed the
residues in positions 11, 13, 24 25, 41 and 45 of the C1 domain of STAC2 as
potential candidates for interferingwith binding activity.However, replacement
of none of these residues with the corresponding residues from PKC delta C1b
suffıced to generate phorbol ester binding activity. One the other hand, intro-
ducing mutations into the C1b domain of PCK delta identifıed L24N, that
caused a signifıcant (20-fold) decrease in the binding affınity. The probable
basis for the negative effect of L24N on binding is that Leucine 24, together with
Phenylalanine 13, Leucine 20 andTryptophan 22, are all exposed at the top of the
binding cleft and insert into the lipid membrane during ligand binding. The
replacement of a hydrophobic residue at position 24 with a hydrophilic residue
should interfere with this binding. STAC2 may thus fall into the category of
proteins with atypical C1 domains that could be targeted with phorbol deriva-
tives that do not stabilize membrane insertion. Our fındings strengthen our
insight into the structural basis and understanding of the interplay between the
C1 domain, ligand and the membrane as a ternary complex.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Development of High Throughput Analytic Methods
#5345 Complementary NGS approaches on digitally sorted pure tumor
cells reveal hidden molecular characteristics in low tumor content FFPE
specimens. Claudio Forcato,1 Alberto Ferrarini,1 Genny Buson,1 Cassie Schu-
macher,2 Chiara Bolognesi,1 Paola Tononi,1 Valentina del Monaco,1 Chiara
Mangano,1 Francesca Fontana,1 Gianni Medoro,1 Timothy Harkins,2 Nicolò
Manaresi1. 1Menarini Silicon Biosystems, CastelMaggiore (BO), Italy; 2Swift Bio-
sciences Inc, Ann Arbor, MI.
Introduction: Precise characterization of tumor cell populations is an essen-
tial requirement for guiding the cancer care, allowing patients to receive person-
alized therapies. Poor biopsies with low-tumor content represent a signifıcant
barrier for sample enrollment in clinical trials. Here we describe a multi-level
approach for precisely characterizing the genetic mutation landscape of pure
tumor cell populations sorted by the DEPArray™ technology from low-cellular-
ity FFPE samples. Methods: 50m sections of FFPE from breast infıltrating
ductal adenocarcinoma with 10% tumor content were processed by DEPArray
sorting protocol. Illumina-compatible libraries were prepared from sorted stro-
mal (n497) and tumor (n419) cell pools, and from the unsorted sample. An
aliquot of these libraries was processed using SeqCap EZ MedExome enrich-
ment kit (Roche) for whole-exome sequencing (WES) with aHiSeq 2500, reach-
ing a mean coverage of 27x for tumor and 25x for stromal libraries. A second
aliquot was used for low-pass (1M fragments per sample) whole-genome se-
quencing (WGS) on aMiSeq to analyze copy-number alterations (CNA). Other
cell lysates from stromal (n104, n112) and pure tumor (n75) populations
were used in DEPArray OncoSeek amplicon-based assay for focused analysis of
clinically relevant somatic variants and copy-number alterations. Results: In
sorted pure tumor populations,WES analysis of B-allele frequencies of germline
heterozygous SNPs clearly outlined an aberrant profıle, precisely revealing sev-
eral Loss-of-Heterozygosity (LOH) and copy-altered regions. Conversely, un-
sorted gDNA showed a flat profıle non-distinguishable from sorted stromal
cells, as expected for a low-cellularity tumor sample. Similar results were ob-
tained by low-pass WGS, where the huge number of copy number aberrations
(1.2Gbp) in tumor is contrasted by lack of gains and losses in stromal cells and
unsorted gDNA. Noteworthy, WES, low-pass and targeted sequencing by On-
coSeek panel highlighted a focal amplifıcation of ERBB2 gene (13 copies),
whichwas just barely detectable as a 1-copy gain in bulk gDNA.Genetic analyses
showed a high concordance between WES and targeted panel data, with two
non-synonymous homozygous somatic mutations found in TP53 (p.L111R)
and ERBB2 (p.D769Y). In the unsorted sample, the TP53 mutation was missed
because allelic frequency was below the limit of detection due to normal-cell
dilution, while the ERBB2 mutation was still detectable only because of the
high-level amplifıcation. Conclusions: DEPArray sorting technology is an indis-
pensable tool for accurately investigating cancer genomes, enabling multi-level
applications for obtaining a fıne-grain characterization of copy-numbers, LOH,
and tumor-specifıc variants, independent of original tumor content.
#5346 Combining droplet tagged short read sequencingwith opticalDNA
mapping technology for improved assembly of cancer genomes. Yuan Jiang,
Sven Bilke, Paul S. Meltzer. National Institutes of Health / National Cancer In-
stitute, Bethesda, MD.
Kataegis, chromothripsis, chromoplexy and forms of structural hyper-muta-
tion generically described as chromoanagenesis are found inmany cancer types.
Structural rearrangements can result in deletions, translocations, inversions and
insertions, and gene amplifıcation with important functional consequenes as
cancer drivers and clonal diversity. Whole genome sequencing is increasingly
used to sensitively detect strucutural rearrangements. Yet, it remains diffıcult to
detect these events reliably without an excessive number of false positives. This
is largely a consequence of the still relatively short read-length of commonly
used sequencing platforms.As a result, in larger cohorts, PCRbasedmethods are
generally not feasible for validating all predicted structural rearrangements. Ac-
cordingly, new approaches for robust mapping of both simple and complex
rearrangements are needed. Here we used a hybrid of two technologies, 10X
genomics droplet tagged Illumina sequencing (10X Genomics ) and DNA fıber
molecular imaging (BioNano Irys) for high throughput validation. First, utiliz-
ing a sequencing-assisted synthetic genome: for each rearrangement predicted
by NGS, we build a “pseudo-chromosome” offering this structure as one alter-
native to the BioNano aligner. This combination compensates for the weak-
nesses of each platform resulting in a more robust result. In this way, even short
reads can validate structural rearrangements, as the requirement for split reads is
obviated. Provided that suffıcient coverage is achieved, statistical analysis can be
used to confıdently recognize NGS false positive predictions. This allows the
cataloging of complex repetitive regions and large-scale rearrangements. In our
studywe have evaluated this combined approach to large scale genomemapping
to identify hallmark fusions and other rearrangements from the highly complex
genomes of osteosarcoma cancer cell lines.
#5347 Molecular barcoding improves confıdence in variant calling with
low input FFPE tissue samples. Bahram Arezi,1 Bilan Hsue,1 Keith Chen,1
Brenda Rogers,1 Christian Lecocq,2 Ashutosh Ashutosh,2 Jayati Ghosh,2 Gilbert
Amparo,2 Madhuvanthi Ramaiah,2 Carlos Pabon,2 Holly Hogrefe1. 1Agilent
Technologies, La Jolla, CA; 2Agilent Technologies, Santa Clara, CA.
FFPE tissue archiving is the most widely used method for clinical sample
preservation, and provides a valuable source of diverse genetic information for
cancer biomarker discovery. NGS library preparation is often challenging, how-
ever, as FFPE-derived DNAs exhibit varying degrees of fragmentation and
chemical modifıcation depending on how tissues were handled and processed.
Moreover, the presence of low allele frequency variants because of tumor heter-
ogeneity, sample degradation, and high rate of formalin-induced mutations
make SNVcalling a challenging task. To improve variant calling and consistency
across FFPE samples of varying quality, we developed a complete workflow
solution that features DNA pre-qualifıcation, molecular barcodes for uniquely
tagging each DNA fragment, pre-capture indexing for tracking up to 192 sam-
ples, accelerated hybrid capture, and one-tube library prep, to enable the prep-
aration of complex enriched libraries in less than 8 hours from 10-200ng of
FFPE-derived DNA. We incorporate molecular barcodes at the ligation step to
enable de-duplication and generation of consensus reads using SureCall soft-
ware, which signifıcantly improves confıdence of variant calling (99% of calls
150 variant call quality threshold) at low allelic frequencies. Using ClearSeq
Comprehensive Cancer Panel which targets 151 genes frequently mutated in
solid and hematological cancers, we routinely obtain high quality libraries (with
1000X sequencing depth and after deduplication) with 99% of the targeted
region covered at 20X for high quality gDNA (FF tissue), and greater than 95%
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and 90% covered at 20X formediumand lowquality FFPE samples, respectively.
Using multiplex reference samples, we demonstrate detection of low frequency
variants (at 1-5%) including SNVs, small indels, and RET and ROS1 transloca-
tions. As we will further show, FFPE integrity scores determined by qPCR and
TapeStation (ddCq and DIN) enable researchers to choose the appropriate
quantifıcationmethod, PCR cycling, and sequencing depth for optimal sequenc-
ing coverage.
#5348 Reliable gene expression profıling from smaller and H&E stained
clinical FFPE specimens using EdgeSeq platform. Zhenhao Qi,1 Lisu Wang,1
Keyur Desai,1 John Cogswell,2 Mark Stern,3 Byron Lawson,3 Bonnie LaFleur,3
Patrik Vitazka1. 1BMS, Pennington, NJ; 2BMS, Lawrenceville, NJ; 3HTGMolecu-
lar, Tucson, AZ.
Background: The scarcity of biological specimens and suboptimal quality of
collected material, make clinical biomarker studies challenging. The EdgeSeq
system, a novel genomics analysis platform which combines quantitative nu-
clease protection assay (qNPA) technology with next-generation sequencing
(NGS), has the potential to mitigate the aforementioned challenges. The tech-
nology allows for a limited sample input and delivers high quality gene expres-
sion profıling data from challenging material such as FFPE tissues. However,
there is further unmet need toward even smaller tissue input or in taking advan-
tage of archival stained FFPE slides to fıll the data gap, specifıcally for studying
tumor microenvironment in the oncology clinical trials Methods: We per-
formed EdgeSeq analysis on six triplets of unstained, H&E stained and IHC
stained slides from non-small cell lung cancer (NSCLC) patients tumor tissue
using Oncology biomarker panel (OBP). Next, we extended the EdgeSeq OBP
analysis to 44 pairs of unstained andH&E stained slides fromNSCLC to confırm
the good correlation. To assess feasibility of limited tissue input, we fırst opti-
mized bead-to-DNAvolume ratio duringNGS library cleanup by testing 4 ratios
of bead-to-DNA from2.5 to 1.0. Next, crude lysate prepared from small cell lung
cancer (SCLC) FFPE tissue was 2-fold diluted from equivalent tissue area of
5mm2 to 0.08 mm2, and was subjected to EdgeSeq OBP profıling using the
optimal bead-to-DNA ratio. Finally, correlation of gene expression profıles be-
tween stained and unstained pairs were calculated. Results: Within the six trip-
lets of unstained, H&E stained and IHC stained slides, the gene expression
profıles from H&E slides showed good correlation with the profıles from
matched unstained FFPE. An extended NSCLC sample set of 44 pairs of un-
stained and H&E stained FFPE further confırmed overall good correlation with
84% (37 out of 44 ) pairs with Pearson correlation coeffıcients of 0.9 or higher. In
assessing the limited tissue input, crude lysate was diluted to as little as equiva-
lent tissue area of 0.08mm2. The tissue area as small as 0.31 mm2 resulted in
Pearson correlation coeffıcients of 0.9 with 5mm2 surface area input. Conclu-
sion: We demonstrated feasibility of using EdgeSeq to generate reliable gene
expression data from H&E stained FFPE tissues. In addition, we showed that
EdgeSeq platform can be used to generate reliable expression data from crude
FFPE tissue lysate equivalent to surface area as low as 0.31 mm2 (size of larger
laser microdissection tile or half of a tissuemicroarray core). The data show that
EdgeSeq can be considered as a platform of choice to analyze specimens of
suboptimal quality or of limited quantity and thusmay help to fıll the biomarker
data gap in the oncology clinical trials, including enabling research into patterns
of interactions and mechanisms of response and resistance of immune cell en-
gagement with tumor at the loco-regional level.
#5349 Accurate molecular profıling of sequence and copy number altera-
tions from sub-nanogram FFPE DNA amounts. Paola Tononi, Alberto Fer-
rarini, Genny Buson, Valentina del Monaco, Giulio Bassi, Chiara Mangano,
Claudio Forcato, Chiara Bolognesi, Francesca Fontana, Gianni Medoro, Nicolò
Manaresi.Menarini Silicon Biosystems, Castel Maggiore (BO), Italy.
Introduction: Formalin-fıxed paraffın-embedded (FFPE) specimens repre-
sent an invaluable source of material for precision oncology. However, FFPE
samples pose signifıcant challenges for molecular assays, such as targeted Next-
Generation Sequencing (NGS), because of the highly variable DNA quality and
often limited sample size. Here we present a complete workflow from sample
quality control to targeted library preparation to reliably detect sequence and
copy number alterations (CNA) through targeted NGS from extremely low in-
put FFPE samples. Materials & methods: Three FFPE specimens from patients
with breast (BrCa) or pancreatic cancer, with DNA quality varying over a broad
range and with low tumor cellularity (down to 10%) were selected for targeted
NGS profıling. The DNA quality was determined using the DEPArray™ FFPE
QCKit, a qPCR-based assay yielding aQC score defıned as the ratio between the
quantifıcation of a 132 bp amplicon, corresponding approximately to the aver-
age length (116bp) of DEPArray OncoSeek amplicons, and a shorter amplicon
of 54 bp. The QC scores of the 3 FFPE specimens ranged between 0.23 to 0.74.
We then usedQC score, multiplied by the ploidy (assessed onDEPArray during
cell sorting) and by the number of cells recovered, to estimate the effectively
amplifıable template (EAT). Thirty two pure cell populations (21 stromal and 11
tumor), with different EATs (80-300), corresponding to a wide range of number
of cells per pool (31-214), were collected with the DEPArray digital sorter. Li-
braries were prepared from each cell pool, using the single-tube, Illumina-com-
patible DEPArray OncoSeek panel comprising 63 oncology relevant genes (av-
erage 740,000 sequenced amplicons per sample). Results: Variant calling showed
sensitivity comprised between 93% and 99% and specifıcity 99% for EATs
80 equivalent to as low as 250 pg of DNA. Analysis of CNAs in stromal cells
was highly specifıc (zero false positive at 1.5 fold-change threshold). Moreover,
analysis allowed to highly reproducibly identify CNAs in CCND1 (3x), ERBB2
(8x), MYC (3x) and PIK3KA (2x) in both replicates of one BrCa sample. Simi-
larly, ERBB2 amplifıcation (7x) was found in the other BrCa sample (10% tumor
cellularity) across two replicates at different EATs (80, 120) corresponding to as
low as 59 and 75 cells. As expected by the low tumor content, in the correspond-
ing unsorted sample ERBB2 was below the 2-fold gain threshold with respect to
the stromal control, which would not qualify a sample as Her2-amplifıed. High-
lights: Starting from pure intact cells with well characterized DNA quality and
ploidy, our workflow allows reliable molecular profıling of sub-nanogramDNA
samples by determining with precision the extremely-lowminimum amount of
cells necessary to obtain highly reproducible sequence variant calling and CNAs
detection by targeted NGS.
#5350 A comprehensive and integrated approach to genomic and pro-
teomic analysis of FFPE NSCLC tumor specimens. Douglas Hinerfıeld,1 Jen-
nifer Mellen,2 Gary Geiss,1 Philippa Webster,1 Chris Merritt,1 Kristi Barker,1
GokhanDemirkan,1 Brian Filanoski,1 Roberto Polakiewicz,2KatherineCrosby2.
1NanoString Technologies, Inc., Seattle, WA; 2Cell Signaling Technology, Inc.,
Danvers, MA.
This poster describes a novel fully integrated method for the multiplexed
DNA, RNA and Protein analysis of formalin fıxed paraffın embedded tumor
specimens. Cancer progression is typically a result of aberrations in the molec-
ular pathways that regulate cell growth. Identifying and understanding these
changes is necessary for the detection of drug targets as well as the identifıcation
of novel biomarkers that can predict response to such drugs. Deep molecular
profıling of clinical tumor samples is challenged by limited material and the
compromised quality resulting from variable handling and the fıxation pro-
cesses that are commonly employed in the clinical laboratories. While multi-
plexed gene expression andmutational analysis of such samples has becomewell
established, we describe a newmethod that enablesmultiplexedDNA, RNA and
protein analysis from a single formalin fıxed paraffın embedded (FFPE) tumor
specimen on the NanoString nCounter system. We have adapted the sample
preparation methods to enable the multi-analyte analysis of FFPE samples and
have demonstrated concordance with the clinical gold standard immunohisto-
chemistry (IHC) methodology. As a proof-of-concept, fıve FFPE non-small cell
lung cancer (NSCLC) specimens were simultaneously stained with a panel of
antibodies specifıc to a variety of cancer-relevant proteins, fıve of which were
validated on serial sections by IHC using antibodies from Cell Signaling Tech-
nology. In addition to the protein analysis, from the same specimen, expression
of 770 cancer-related genes and 100 single nucleotide variants (SNVs) were
also analyzed on the nCounter platform. By integrating the analysis of DNA
SNV’s, as well as RNA and protein expression from single FFPE specimens, it is
now possible to reveal the molecular mechanisms of tumor progression, un-
cover novel drug targets and identify biomarkers from precious specimens.
#5351 A simple yet powerfulmethod to purifyNGS compatibleRNA from
formalin fıxed paraffın embedded tissues using FormaPure DNA. Jung H.
Doh. Beckman Coulter, Inc., Indianapolis, IN.
Extensive archives of formalin-fıxed, paraffın-embedded (FFPE) cancer tis-
sues and next generation sequencing (NGS) capabilities provide rich resources
for identifying and validating new cancer biomarkers. However, the ability to
conduct FFPE-NGS studies has been limited by poor nucleic acid purifıcation
methods that are generally diffıcult and cumbersome to perform, particularly
with RNA. FormaPure DNA was recently launched to provide a simplifıed
workflow to extract DNA from FFPE curls. Its nucleic acid binding chemistry
employs Beckman Coulter’s proprietary SPRI (solid phase reversible immobili-
zation) technology, which purifıes nucleic acids without centrifugation or vac-
uummanifold. The SPRI technology ensures stronger binding and higher qual-
ity purifıcation than other silica-coated beadmethods that typically lead to lower
quality results due to instances of nucleic acid shearing. Here, we present a
modifıed FormaPure DNA workflow to purify RNA from FFPE samples, offer-
ing the flexibility to examine both genomic and transcriptomic roles in cancer
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biomarkers studies. We show that our extractions yield signifıcantly more RNA
(up to 2.5g per FFPE curl) and take a fraction of the time to perform compared
to other benchmarks. Furthermore, we demonstrate that purifıed RNA can be
used to generate high quality NGS data. Lastly, our extraction method can be
automated on a variety of Beckman Coulter’s Biomek liquid handling worksta-
tions to offer an integrated solution for high-throughput FFPE-RNA-NGS ex-
periments: RNA from 96 FFPE samples can be purifıed for NGS in less than 5
hours with minimal hands-on time.
#5352 Optimization of library and enrichment procedures for RNASeq
using RNA from formalin fıxed paraffın embedded tissue. JiWen, Ying Shao,
Ruth Tatevossian, Yongjin Li, DavidW. Ellison, GangWu, Jinghui Zhang, John
B. Easton. St. Jude Children’s Research Hospital, Memphis, TN.
Large repositories of diagnostic formalin-fıxed, paraffın-embedded (FFPE)
tissue remain underutilized for transcriptome sequence analysis due to degra-
dation of the RNA from the fıxation process, which makes the samples unsuit-
able for traditional mRNA sequencing (mRNASeq). The use of random primers
to generate cDNA, and biotinylated exon baits to enrich for coding regions
allows for the generation of RNASeq data, but still yields data of variable quality,
in part due to differences in FFPE sample processing. We performed a system-
atic analysis to determine which aspects of library construction and the enrich-
ment process can be optimized to provide the best RNASeq data from FFPE
samples. The TruSeq RNA Access Library Prep Kit (Illumina) protocol was
selected to evaluate optimization procedures for RNASeq from FFPE material.
RNA was isolated from FFPE tissue using the Maxwell automated system (Pro-
mega). RNA libraries were also prepared with RNA extracted from frozen tissue
of the matching samples using the TruSeq V2mRNASeq Library Prep Kit (Illu-
mina) for a comparison of exon coverage metrics. Samples derived from differ-
ent types of pediatric cancer were selected for evaluation, including 2 low-grade
gliomas, 2 ependymomas, 9 melanomas and 1 Ewing sarcoma. All of the FF
tumor samples selected contained oncogenic gene fusions, previously identifıed
by analysis of mRNASeq data. The parameters investigated included the initial
amount of RNA input (10ng-400ng), library amplifıcation PCR cycle number (9
cycles-15 cycles), and the duration of time for exon probe hybridization (1.5
hours vs 16 hours). The quality of the data was based on the overall library
complexity and exon coverage. The complexity of the sequencing wasmeasured
using duplication rate (DupRate) defıned as a library inserts from different se-
quence reads mapping to the same location in the reference genome; while the
coverage was measured using the percentage of coding bases with coverage
20x (PCB20x). Using the RNA Access protocol, we found that the PCB20x
metrics were comparable between the FFPE samples andmatched FFmRNASeq
controls under the non-optimized conditions of 20ng of RNA input, 1.6 hour
hybridization, and 15 cycles of PCR for library amplifıcation.However, optimiz-
ing the protocol by increasing the input of RNA to 400ng, reducing the PCR to
between 9-11 cycles, and extending the hybridization time to 16 hours increased
library diversity, reduced the DupRate from greater than 80% to less than 44%,
and increased coding region coverage PCB20x by at least 10%. All expected gene
fusions identifıed in theRNASEQdata from the FF sampleswere also detected in
the FFPE samples. We have shown that increasing RNA input, reducing PCR
cycles and extending the length of hybridization can signifıcantly improve data
quality and maximize library diversity, allowing for greater utilization of archi-
val FFPE material for RNASeq.
#5353 High-throughput automation of the 10x Genomics® Chromium™
workflow for linked-read whole exome sequencing and a targeted lynch syn-
drome panel. Renata Pellegrino,1 Michael Benway,2 Paulina Kocjan,2 Andrew
Price,3 Charlly Kao,1 Brian A. Gerwe,2 Adrian Fehr,3 Fernanda Mafra,1 James
Garifallou,1 HakonHakonarson1. 1The Children’s Hospital of Philadelphia, Phil-
adelphia, PA; 2PerkinElmer, Hopkinton, MA; 310X Genomics, Inc., Pleasanton,
CA.
Traditional 2nd generation sequencing strategies have signifıcantly reduced
the cost of sequencing the human genome and provide flexibility to query spe-
cifıc gene panels, the whole exome, or the whole genome. However, these meth-
odologies are based on short reads which limit their ability to phase/haplotype
over long genomic distances, accurately map reads between highly homologous
regions (e.g., genes vs. pseudogenes), and robustly detect particular types of
structural variants (e.g., inversions and translocations). Advances in microflu-
idics technology and precision reagent delivery allow long-range information to
be rescued and preserved through the use of the 10x Genomics Chromium
platform. Each input DNA fragment (40-200kb) is partitioned into a gel-bead
in emulsion (GEM), and subsequent biochemistry generates mini-libraries of
NGS-ready molecules tagged with a barcode unique for each GEM. Thus, long-
range context is achieved by linking short reads sharing the same barcode, and
contiguity is established because they were derived from the same input frag-
ment. Importantly, the barcoded mini-libraries are compatible with short-read
sequencers and can be implemented as an add-on to existing sequencing infra-
structures. Here we describe and demonstrate how the user-friendly and
uniquely-tuned liquid handling capabilities of the PerkinElmer Sciclone® NGSx
Workstation interface with the 10x Genomics chip to successfully automate the
Chromium Genome workflow. We show the preservation of intact genomic
DNAduring automated library preparation and demonstrate that these libraries
have comparable quality to those generated by manual preparation. Following
Chromium partitioning, mini-library generation, and pooling of all the GEM
mini-libraries, samples were processed again on the Sciclone using a previously
established automated workflow for exome/panel target capture using Agilent
SureSelectTM baits. This end-to-end automated workflow was used to generate
Linked-Read whole exome data on samples with unresolved structural rear-
rangements and targeted Linked Reads in a Lynch syndrome gene, PMS2.
Linked Reads enable us to 1) fıne-map structural rearrangements detected by
karyotyping and 2) resolve variants in PMS2 versus those in its homologous
pseudogene, PMS2CL, without invoking non-NGS methods such as MLPA or
long-range PCR. The benefıts of automation are essential to the scale-up of
high-throughput projects by removing manual variability and increasing effı-
ciency. This partnership offers a unique workflow solution that enables exome
and panel-based Linked-Read sequencing at scale. For Research Use Only. Not
for use in diagnostic procedures.
#5354 Evaluationof quantity, quality andperformancewith theTruSight®
Tumor 170 solid tumor profıling assay of nucleic acids extracted from for-
malin-fıxed paraffın-embedded (FFPE) tissue sections. Jennifer S. LoCoco, Li
Teng, Danny Chou, Xiao Chen, Byron Luo, Jennifer Sayne, Ashley Adams, Nas-
eem Ajili, Cody Chivers, Beena Murthy, Laurel Ball, Allan Castaneda, Katie
Clark, Brian Crain, Anthony Daulo, Manh Do, Tingting Du, Sarah Dumm,
Yonmee Han, Michael Havern, Chia-Ling Hsieh, Tingting Jiang, Suzanne Jo-
hansen, Scott Lang, Rachel Liang, JaimeMcLean, Yousef Nassiri, Austin Purdy,
Jason Rostron, Jennifer Silhavy, June Snedecor, Natasha Talago, Li Teng, Kevin
Wu, Chen Zhao, Clare Zlatkov, Ali Kuraishy, Karen Gutekunst, Sohela De Ro-
zieres, Matthew Friedenberg, Han-Yu Chuang, Anne C. Jager. Illumina, San
Diego, CA.
Solid tumor profıling assays need to deliver accurate and consistent results in
the face of decreased quality and quantity of nucleic acids extracted from FFPE
samples. Understanding the performance of a particular solid tumor profıling
assay with FFPE tissue is critical, but with limited and non-renewable samples
available to most assay-developers, the sample number used to understand this
performance can be small. TruSight® Tumor 1701 is an Illumina-developed com-
prehensive solid tumor profıling panel targeting 170 genes usingDNA andRNA
from FFPE samples. In order to confırm the robustness of the assay with FFPE
tissue, 2310 FFPE samples were brought in-house and evaluated. Quantity of
both DNA and RNA extraction were determined by variousmethods, including
AccuClear™, Qubit™ and Quantifluor® fluourometric assays. Overall, 95% of
the samples achieved the minimum concentrations required for the TruSight®
Tumor 170 assay. As a surrogate for DNA quality, we measured the amplifıca-
tion potential of the nucleic acid by assessing a 	Cq value using quantitative
PCR after normalization to a fıxed input mass. To assess RNA quality, we used
the DV200 metric, which measures the percentage of RNA fragments200 nu-
cleotides in length. We examined	Cq and DV200 values across different tissues
and didn’t fınd a signifıcant difference between tissues. Finally, we assessed the
ability of samples to pass the sample quality control (QC) metrics in the Tru-
Sight® Tumor 170 assay. These QCmetrics ensure accurate variant calling, with
a sensitivity and specifıcity of 95%. We found that samples that had a 	Cq
value of 5 and a DV200 value of 20 achieved a QC success rate above 95%.
This data highlights the need for further investigation into the methods for
extraction, quantifıcation and quality assessment of nucleic acids for solid tumor
profıling and underscores the robustness of TruSight® Tumor 170 with FFPE
samples. 1 For Research Use Only. Not for use in diagnostic procedures.
#5355 PANCeq - Development and validation of a targeted sequencing
assay for detection of mutations and copy number changes in most recur-
rently mutated driver genes. Tobias Meissner, Anu Amallraja, Brandon Mi-
chael Young, Adam Mark, Cayce Conolly, Amanda Andrews, Casey Williams,
Brian Leyland-Jones. Avera Cancer Institute, La Jolla, CA.
Next generation sequencing is becoming increasingly prevalent as a tool for
the identifıcation of genetic variation to aid diagnosis and support therapy de-
cisions in routine clinical care. It has been shown that tumors are comprised of
subpopulations of cells with distinct genomic alterations, and hence tumor het-
erogeneity is becoming an important factor in deciding treatment. Deep se-
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quencing of tumor samples allows for the determination of number and propor-
tions of low variant allele frequency tumor subclones. Currently, high costs for
whole-exome deep sequencing ( 250X) limit its application in routine clinical
care, and there is a need for more affordable targeted approaches. Here we
present PAN Cancer Sequencing (PANCeq), a targeted deep sequencing panel
for the detection ofmutations and copy number variants (CNVs) inmost recur-
rently mutated cancer driver genes. A platform-independent computational
Docker-based pipeline for data analysis and automatic report generation was
developed. PANCeq uses customized targeted enrichment, followed by next-
generation sequencing of (FFPE) tumor and matched germline samples. We
included 12 patient samples (breast, ovarian, kidney and prostate) as well as
triplicates of 3 reference standards (HD200, HD753, HD733 - Horizon). These
were sequenced on Illumina NextSeq o an average depth of 1000X. Sequencing
data was aligned using BWA to hg19 human reference. Somatic variants and
CNVswere identifıed usingVarDict andCNVkit respectively.WeminedTCGA
data across 26 tumor types, and selected knownmutations from themost recur-
rently mutated genes, yielding 2849mutations across 467 genes. In addition, we
included 79 pharmacogenomic relevant and 218 sample tracking SNPs as well as
80 cancer relevant CNVs (whole exon), and designed a custom panel based on
their genomic locations, resulting in a panel size of 708kb. To assess perfor-
mance, we sequenced reference standards with known variants spiked-in at
varying VAF (1 - 41.5%). Somatic variant calling was performed against a wild-
type sample. For HD200, out of 21 covered mutations, 14 were correctly classi-
fıed as germline, and 7 as somatic. For HD733, out of 21 mutations, 3 were
correctly identifıed as germline, 18 as somatic. For HD753, all 6 germline and
somatic mutations were correctly identifıed. The 2 CNVs spiked-in were also
correctly identifıed. In all cases we found a good agreement between observed
and expected VAF. Somatic variant results for 12 patient samples were com-
pared with variants reported by a private vendor. While we found good agree-
ment at VAF 20%, our panel detected on average 7 additional clinically rele-
vant mutations at  20%. We demonstrate that PANCeq is an accurate and
sensitive method for timely identifıcation of clinically actionable mutations and
copy number variations across multiple cancer types.
#5356 Validation of a clinically actionable cancer core gene test for solid
tumors facilitating targetedmolecular therapy and immunotherapy. LinMa,
Michael Hua, Steven Rivera, Anna Gerasimova, Quoclinh Nguyen, Sirisha
Sunkara, Robert Lagier, Alla Smolgovsky, DavidWolfson, Jared F. Taylor, Fred-
erick Racke, Charles Strom, Andrew Grupe, Joseph Catanese, Feras Hantash.
Quest Diagnostics, San Juan Capistrano, CA.
Molecular profıling of tumor mutations has expedited molecular targeted
therapy for cancer patients. Additionally, tumor mutation load and DNA mic-
rosatellite instability (MSI) status can help predict patient’s response to immu-
notherapy. We analytically validated a gene test targeting clinically actionable
cancer mutations of all 4 major types: single nucleotide variations (SNVs); in-
sertion/deletions (INDELs); whole gene copy number variations (CNVs); and
structural rearrangements (translocations) as well as the MSI status. This test
interrogates all coding exons from 49 core cancer genes, introns for a subset of
genes selected for detection of prevalent gene rearrangements, and the TERT
(telomerase reverse transcriptase) promoter region. MSI status is determined
from a set of 5 intronic mono-nucleotide repeats collectively associated with
microsatellite instability. Targeted DNA regions are captured by in-solution
hybridization with complementary biotinylated RNA baits and sequenced on
the Illumina NextSeq®500 platform. Paired formalin-fıxed, paraffın-embedded
(FFPE) tumor samples and whole blood samples are analyzed simultaneously
for the detection of SNV, INDEL, CNV, translocation and MSI status. FFPE
samples can also be analyzed alone if the whole blood sample is not available,
eliminating the reporting of MSI status. A minimum of 50 ng FFPE DNA and
100ng ofwhole bloodDNAare required for this test. A total of 123 FFPE, 2 FFPE
FNA samples, 19 paired FFPE and whole blood paired samples covering lung
cancer, colorectal cancer, melanoma and breast cancer were included in this
validation study. Analytical validation of assay performance demonstrated that,
on average, 700-fold read depth was achieved across all targeted regions with
95% of these regions covered by a minimum of 300 unique reads. Analytical
sensitivity was 5% mutation frequency for SNV and INDEL and 20% for
translocation and CNV. Thirty-eight unique variants were confırmed between
this test and orthogonal methodologies: 22 SNVs, 6 INDELs, 5 translocations,
and 5CNV. Fifty-eight out of 59 (98% concordance) paired FFPE/blood samples
achieved the same MSI status result with this targeted sequencing approach
compared to the reference National Comprehensive Cancer Network (NCCN)
Bethesda PCR test. MSI-positive samples, on average, were determined to have
5-fold higher mutation count compared to MSI-negative samples, consistent
with the previously reported higher mutation burden. In conclusion, we have
developed and analytically validated a core cancer gene test employing NGS
technology with demonstrated high analytical sensitivity and specifıcity. Cou-
pled with clinical interpretation, this test will facilitate clinical decision-making
for molecular targeted therapy and immunotherapy.
#5357 OncoGxSelectTM - a benefıcial supplement to comprehensive can-
cer genetic test. Yang Han, Pengfei Yu, Qingxuan Song, Min Wei, Guanghui
Hu. Admera Health LLC, South Plainfıeld, NJ.
Genetic profıling of tumor has been widely accepted both in oncology research
andclinical fıeld.However, clinical doctors are sometimesoverwhelmedby tremen-
dous and complicated information provided by comprehensive genetic tests, al-
though they are welcomed by research-oriented oncologists. In order to provide
accurate key fındings to aid diagnosis and treatment in clinical practice, a careful
tailoredNGSbased test -OncoGxSelectTMwasdevelopedandvalidated.Targeting7
popular cancer types (NSCLC, Colorectal cancer, Breast cancer, Melanoma, Thy-
roid cancer, Esophageal and GIST cancer), OncoGxSelectTM detects all 4 types of
genomic alterations including single nucleotide mutation, insertion/deletion,
copy number variation and gene rearrangement in tumor tissue for 12 well-
characterized clinical actionable genes strictly followingNCCN (National Com-
prehensive CancerNetwork) guidelines. OncoGxSelectTM offers high sensitivity
and specifıcity greater than 99%, low cost and fast turnaround time using both
DNA and RNA as starting material from FFPE samples with as low as 10%
tumor cell content. This CLIA certifıed and CAP accredited genetic test panel is
a valuable supplement to clinical oncologists to further facilitate diagnosis and
treatment choosing.
#5358 Comprehensive evaluation of Illumina’s TruSight® Tumor 170
Panel to estimate tumormutational burden. Shile Zhang, Alex S. So, Shannon
Kaplan, Kristina M. Kruglyak. illumina, San Diego, CA.
Tumor mutational burden (TMB), or the density of variants in a tumor, is
typically assessed by whole exome sequencing (WES) and has been shown to
correlate with effıcacy of immunotherapy treatment. Targeted cancer gene pan-
els are broadly used to assess mutational status in cancer related genes but have
not historically been used to estimate TMB. Recently, two studies have demon-
strated that TMB can be accurately estimated using these cancer gene panelsi,ii.
Illumina’s TruSight® Tumor 170 (TST170, research use only, RUO) panel is a
comprehensive next-generation sequencing (NGS) assay that covers the coding
regions of 170 genes associated with solid tumors. TST170 targets DNA and
RNA variants from the same FFPE tumor sample in a single sequencing run.
Here we evaluate the performance of TMB estimation with TST170. TST170 is
an enrichment-based targeted panel designed to capture mutational changes,
including single nucleotide variant, indels, amplifıcations, splice variants and
fusions. The TST170 analysis pipeline is able to call variants with frequencies
down to 5%. In the current study, TMBwas calculated as the number of reported
variants permegabase after germline polymorphism fıltering. First, we evaluated
the performance of TST170 for TMB estimation using 6,000 TCGA samples that
had been analyzed by WES. TMB estimated from the TST170 targeted regions
showed a high correlation to TMB estimated from WES (R20.91). Next, we
evaluated the prognostic value of TMB estimated from TST170 by overlapping
the TST170 targeted regions with WES data for 202 subjects treated with
CTLA-4 or PD-1 from three clinical studies. Higher TMB estimated from the
TST170 targeted regions was observed in subjects who responded to checkpoint
inhibitors. Finally, we assessed the correlation of TMB estimation using
matched samples profıled with both WES and TST170 and again saw high cor-
relation between the two methods. In summary, our analysis indicates that the
panel content of TST170 can be used to accurately estimate TMB from tumor
samples. i. Garofalo A, Sholl L, Reardon B, et al. The impact of tumor profıling
approaches and genomic data strategies for cancer precisionmedicine. Genome
Med. 2016;8(1):79. doi:10.1186/s13073-016-0333-9. ii. Campesato, L., Barroso-
Sousa, R., Jimenez, L., et al. Comprehensive cancer-gene panels can be used to
estimatemutational load and predict clinical benefıt to PD-1 blockade in clinical
practice. Oncotarget, 2015;6(33), 34221-34227.
#5359 An ultrasensitive and highly reproducible hybridization capture-
based Next-Generation Sequencing clinical assay to enable precision oncol-
ogy in patients with solid tumors. Moises Hernandez, Sara King, Sharanya
Raghunath, Christopher Johnson, David Loughmiller, Lincoln Nadauld, Pravin
J. Mishra. Intermountain Precision Genomics, St. George, UT.
Sequencing whole cancer exome andwhole genome provides useful informa-
tion to study cancer evolution. However, cost and amount of data may become
overwhelming. Enrichment capture-based methods to design custom targeted
gene panel have rapidly evolved recently in cancer genomics arena. Custom
targeted gene sequencing entails several advantages (i.e., better quality, ethical,
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affordable, technically suitable, personalized and reimbursable) for cancer pa-
tients over whole exome and whole genome sequencing.With this in mind, and
to enable precision oncology in patients with solid tumors, we developed
ICG100 2.0 panel, a hybridization capture-based next-generation sequencing
assay for targeted sequencing of all exons and flanking introns of 162 commonly
mutated cancer genes in formalin-fıxed, paraffın-embedded (FFPE) tumors. To
establish ICG100 2.0 panel, we compared three commercially available capture
based technologies and evaluated reproducibility, sensitivity, specifıcity and the
detection limit for low-frequency variants using internally developed bioinfor-
matics pipeline. Cell lines, reference standards/synthetic DNA and solid tumor
sampleswith the known genetic informationwas utilized in this analysis. Results
were derived fromMiSeq and NextSeq platforms and cross-compared on other
platforms, including MassArray and ddPCR for establishing concordance and
uniformity. Intra and interrun replicates were utilized to assess the quality, pre-
cision and reproducibility of variant calling. Mean depth of coverage was ob-
served at300X with99% sensitivity and specifıcity. These fındings and ob-
servations will guide other clinical laboratories to establish new assay that
require less DNA input, enzyme based fragmentation and reduced preparation
time. While we show that the three capture based methods (after comparison)
had an overall accuracy in SNP and CNV detection similar to each other with
minor differences, we describe an approach to assess and establish the best assay
from the clinical standpoint to guide treatment decisions and match cancer
patients to the most appropriate clinical trials.
#5360 DNA repair increases sequencing accuracy without altering actual
mutation frequency in clinical samples. Pingfang Liu, Lixin Chen, Laurence
Ettwiller, EileenDimalanta, Theodore B. Davis, Thomas C. Evans.New England
Biolabs, Ipswich, MA.
Targeted cancer therapy based on genomic alterations can be remarkably
effective. Currently, cancer genome profıling using next generation sequencing
(NGS) is routinely applied in cancer care to guide personalized treatment. The
accuracy of this profıling directly impacts therapeutic choices and the outcomes
of patient care. We previously showed that false positive variants are abundant
and can account for a major fraction of identifıed somatic variations in publicly
available datasets (doi: http://dx.doi.org/10.1101/070334). These false positive
variants show signs of mutagenic DNA damage. We further demonstrated that
enzymatic DNA repair increases sequencing quality by lowering damage-in-
duced background noise. Therefore, enzymatic DNA repair has the potential to
improve sequencing accuracy, avoiding incorrect somatic variant calls and con-
sequently reducing incorrect diagnostic conclusions. In this study, we investi-
gated whether enzymatic DNA repair introduces any bias toNGS libraries using
analysis by droplet digital PCR (ddPCR) and deep sequencing. DNA Reference
Standards containing multiple common cancer mutations (Horizon Discovery,
Inc.) were spiked into formalin-fıxed paraffın-embedded (FFPE) DNA isolated
from tumor samples from different tissue types at defıned frequencies (0.5-10%
quantifıed by ddPCR).Genotyping of the FFPEDNAensured that theywere free
of any of the spiked-in mutations. After DNA repair and library preparation,
mutation frequencies were quantifıed by ddPCR, and compared to themutation
levels in inputDNAand control librarieswithout repair.Deep sequencing of 151
cancer genes including these spike-ins showed no difference in mutation fre-
quency for the spiked-in mutations between the control and repair groups.
However, the number of false positive variant calls was reduced in the repair
group. Our data demonstrates that DNA repair signifıcantly increases sequenc-
ing accuracy without altering the frequency of actual mutations in tumor sam-
ples.
#5361 Predesigned gene content for rapid deployment of custom oncol-
ogy panels. Andrew J. Barry,1 Amy Emerman,2 Sarah Bowman,2 Kruti Patel,2
Eileen Dimalanta,1 Scott Adams,1 Noa Henig,1 Fiona Stewart,1 Cynthia Hen-
drickson,2 Theodore Davis,1 Charles Elfe1. 1New England Biolabs, Ipswich, MA;
2Directed Genomics, Ipswich, MA.
Effıcient utilization of targeted gene panels for oncology research is chal-
lenged by the wide variation in gene constituents specifıc to a given study.While
focused gene panels effıciently provide the necessary depth of coverage for low
frequency variant detection, the high costs and design challenges associatedwith
de novo panel design present challenges. The NEBNext DirectTM technology
utilizes a novel approach to selectively enrich nucleic acid targets ranging from a
single gene to several hundred genes, without sacrifıcing specifıcity. The ap-
proach rapidly hybridizes both strands of genomic DNA with biotinyated
probes prior to strepdavidin bead capture, enzymatic removal of off-target se-
quence, and conversion of captured molecules into sequencer-ready libraries.
This results in a unique read coverage profıle that results in uniform coverage
across a given target. Unlike alternative hybridization methods, the approach
does not necessitate upfront library preparation, and instead converts the cap-
turedmolecules into dual-indexed illumina sequencer compatible libraries con-
taining an 8 basepair sample ID and a 12bp UniqueMolecule Index (UMI). The
UMI individually tags each molecule prior to the fınal PCR amplifıcation of the
library, enabling identifıcation of PCR duplicate molecules. The result is a 1-day
protocol that enables the preparation of sequence-ready libraries from purifıed
genomic DNA specifıc to the gene content included in the panel. We have de-
signed and developed baits specifıc to the full exonic content of 450 genes asso-
ciatedwith cancer. These are designed, balanced, and pooled on a per gene basis,
and can be combined into customized panels, allowing rapid turnaround of
specifıc custom gene subsets. Here, we present the ability to rapidly deploy
custom gene panels across a variety of panel sizes and content, while maintain-
ing high specifıcity, uniformity of coverage across target content, and sensitivity
to detect nucleic acid variants from tumor samples.
#5362 Targeting BRCA1 and BRCA2 with NEBNext Direct™. Scott M.
Adams,1 Kruti M. Patel,1 Amy B. Emerman,1 Sarah K. Bowman,1 Charles D.
Elfe,1 Noa Henig,1 Salvatore Russello,2 Andrew Barry Barry,2 Theodore Davis,2
Cynthia L. Hendrickson1. 1Directed Genomics, Ipswich, MA; 2New England Bio-
labs, Ipswich, MA.
The screening and detection of germline BRCA1 and BRCA2 mutations are
critical for the effective management of patients with breast or ovarian cancer
and for the identifıcation of individuals with a high risk of developing these
cancers. In addition, somatic detection of pathogenic variants in BRCA1/2 can
influence treatment decisions due to the susceptibility of tumors with BRCA
mutations to PARP inhibitors. Herewe introduce theNEBNextDirectTMBRCA
enrichment panel for the interrogation of BRCA1 and BRCA2 by Illumina se-
quencing. NEBNext DirectTM is a novel, hybridization-based method to selec-
tively enrich nucleic acid targets ranging from a single gene to several hundred
genes. This approach includes features such as the incorporation of uniquemol-
ecule identifıers (UMIs) and the ability to capture degraded DNA, enabling
accurate detection of low-frequency variants from formalin-compromised
DNA and other challenging sample types. We applied the NEBNext Direct
BRCA1/2 panel to frozen tissue and achieved a high specifıcity for the BRCA
targets (96% of the sequenced reads mapped to BRCA1 and BRCA2 and 80% of
the sequenced bases were within the targeted regions). In addition, the resulting
librarieswere highly uniform in coverage,with 91%of the targeted bases covered
at a value of at least 50% of the mean depth of coverage and 100% of the bases
covered at 20% of the mean or greater. Some variability in the specifıcity was
observed with formalin-fıxed, paraffın embedded (FFPE) samples, and this ef-
fect was dependent on the quality of the FFPE DNA. The UMIs were used to
identify PCR duplicates prior to variant calling, as well as for error correction,
enabling the accurate detection of low-frequency variants. The library prepara-
tion for all samples was completed in one day, and the entire process of library
preparation, sequencing on the IlluminaMiseq, anddata analysiswas completed
in a total of two days. In summary, we demonstrate that application of the
NEBNextDirectTMmethod to the enrichment of BRCA1 andBRCA2 provides a
tractable approach for the rapid and highly sensitive analysis of these cancer-
associated genes.
#5363 Measuring gene expression at the tumor microenvironment: A
comparison between nCounter PanCancer Immune Profıling Panel andOn-
comine Immune Response Research Assay. Ann Mongan, Warren Tom, Jan-
ice Au-Young, Aleksandr Pankov, Gauri Ganpule, FionaHyland.Thermo Fisher
Scientifıc, San Francisco, CA.
The tumor microenvironment, especially infıltrating T lymphocytes and in-
flammatorymolecules, is believed to be highly relevant to the tumor’s sensitivity
to cancer checkpoint blockade therapy. At the same time, the exact markers that
are predictive of response for each therapeutic agent are still the subject of active
investigations. To address the need for better understanding of the effect of
different T cell subsets, antigen presentation, and tumor killing, gene expression
profıling presents an attractive means to simultaneously evaluate the tumor
microenvironment and cancer cells. In this study we compare the results and
performance of the nCounter PanCancer Immune Profıling Panel and the On-
comine Immune Response Research Assay, both of which are designed to mea-
sure the expression of genes indicative of an immune response and potential
immune-editing activities by tumor cells. The nCounter panel detects gene ex-
pression by counting unique probes that hybridize target mRNA, while the
Oncomine panel employs NGS to sequence and count reads derived from
the targets. While both panels are designed to work with FFPE samples, The
nCounter panel expects 100 ng of unamplifıed RNA, while the Oncomine panel
requires only 10 ng total RNA with its AmpliSeq technology. The two panels
share 254 common genes, which constitute the basis for this comparison. Across
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Development of High Throughput Analytic Methods
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1373
12 cancer samples (breast, H&N, melanoma, NSCLC, and RCC), results show
that the Oncomine panel offers 20% higher dynamic range, thereby providing
more robust readouts about the differences among samples. More importantly,
with virtually no background noise, the underlyingNGS technology provides an
absolute zero readout for non-expressing geneswhich signifıcantly improves the
sensitivity for detecting low expressing genes, as their presence can be confırmed
by as few as two reads. The two technologies show moderate correlation (R 
0.7), with the Oncomine panel more strongly correlating with qPCR (R 0.9).
Finally, when clustered using all genes on the panel, only the Oncomine panel
provides clear stratifıcation of cancer types, thus allowing the panel to be used
for tissue type confırmation in addition to evaluating the immune response.
#5364 A targeted NGS solution to evaluate gene expression signature of
the tumor microenvironment from 40 NSCLC FFPE and matched fresh fro-
zen samples. Yuan-Chieh Ku,Warren Tom, Yongming Sun, Alex Pankov, Tim
Looney, Fiona Hyland, Janice Au-Young, Ann Mongan. Thermo Fisher Scien-
tifıc, South San Francisco, CA.
Cancer cells and their surrounding non-malignant cells, including immune
cells, signaling molecules, stromal and extracellular matrix, create the tumor
microenvironment (TME). The composition of this TME plays important roles
in tumor progression, evading growth suppressors and activating metastasis.
However, the regulatory mechanism and function of each constituent remains
poorly understood.With several checkpoint blockade therapy studies, the pres-
ence of PD-L1 has been reported to be a promising marker to predict positive
response. Current IHC methods to measure PD-L1 are subjective and highly
variable. A higher-throughput and standardized solution that can systematically
measure gene expression of cells present in the TME has emerged to be a more
desirable alternative. Here, we applied the OncomineTM Immune Response Re-
search Assay to measure the expression of 395 genes in non-small cell lung
cancer (NSCLC) samples from 40matched FFPE and fresh frozen sample types.
This assay leverages NGS technology to sequence and count reads derived from
the original transcript. With an input requirement of 10 ng of total RNA, librar-
ies were generated, templated on the IonChefTM and sequenced on the Ion S5TM
System. Results showed that, despite small input amount, the expression profıles
of FFPE and fresh frozen samples are highly correlated with an average correla-
tion greater than 0.9.We selected 22 genes out of the panel to validate expression
with qPCR using FFPE samples. These genes were selected to cover a range of
low, medium, and high expressors per our NGS data. Again, we observed a
strong correlation (R 0.9) between NGS and qPCR data. Approximately 80%
of the 40 samples show moderate to high expression of CD8 T cell cytokines,
IFNG and TNFa. We further found that the expression of CD8A and CD8B are
highly correlated with CD4, suggesting the co-presence of both cytotoxic and
helper T cells. High correlation among CD4, FOXP3, TGFB1, and IL2RA
(CD25) also suggests that their expression can be used as markers for the pres-
ence of Treg cells. We conducted a differential expression analysis between a
group of samples (n8) with high percentage of surrounding and infıltrating
lymphocytes and another group (n5) with low stromal content but devoid of
infıltrating lymphocytes. Interestingly, we found a large number of genes which
annotated as markers for infıltrating lymphocytes (CTSS, CXCR4, CD37,
SRGN, FCER1G, SAMHD1, and GZMA) are signifıcantly up-regulated in sam-
ples with high percentage of surrounding and infıltrating lymphocytes. In sum-
mary, this study highlights the robustness of using a targeted panel to under-
stand the composition and regulatory mechanism of the TME and tumor
immune response.
#5365 Combining enzymatic DNA fragmentation with NGS library con-
struction results in high quality, high yield libraries. Fiona Stewart, Lynne
Apone, Vaishnavi Panchapakesa, Karen Duggan, Timur Shtatland, Bradley
Langhorst, John Murdoch, Christine Sumner, Christine Rozzi, Pingfang Liu,
Keerthana Krishnan, Deyra Rodriguez, Joanna Bybee, Danielle Rivizzigno, Lau-
rie Mazzola, Eileen Dimalanta, Theodore Davis. New England Biolabs, Inc., Ip-
swich, MA.
The use of Next Generation Sequencing (NGS) data has been instrumental in
advancing our understanding of human genetics, identifying the molecular
events that contribute to human disease, and supporting drug development
targeted towards precision medicine. Continued advancement relies on over-
coming the limitations and bottlenecks associated with NGS. In this work, we
have focused on NGS library preparation, where the requirement for expensive
equipment and numerous steps can lead to sample loss, errors, and limited
throughput. Specifıcally, we have developed a library construction method that
integrates enzymatic DNA fragmentation into the workflow and combines frag-
mentation with end repair and dA-tailing in a single step. Integrating these
reactions eliminates the need for costly equipment to shear DNA and reduces
the number of sample transfers and losses. Adaptor ligation is also carried out in
the same tube, after which a single cleanup step is performed. For low input
samples, PCR amplifıcation is performed prior to sequencing. This method is
compatible with a broad range of DNA inputs and insert sizes. Libraries gener-
ated using this streamlinedmethodwith inputs ranging from 500 pg to 500 ng of
intact DNA show no signifıcant difference in coverage uniformity or sequence
quality metrics, compared to libraries generated with mechanically sheared
DNA. Similarly, libraries generated to contain insert sizes that range from150bp
to 1kb display no signifıcant difference in sequence quality from each other or
from those generated withmechanically sheared DNA. Finally, this streamlined
method generates libraries of substantially higher yields than those generated
usingmechanically fragmentedDNA, allowing the use of lowerDNA inputs and
fewer PCR cycles. The ability to generate high quality NGS libraries from intact
DNA without the need for costly equipment and numerous cleanup or liquid
transfer steps substantially reduces the time, cost and errors associated with
library construction. In addition, these advances will enable greater use and
adoption of NGS technologies in clinical and diagnostic settings.
#5366 Detectionof low-frequency somatic variants using single-molecule,
real-time sequencing. Primo Baybayan, Laura Nolden. Pacifıc Biosciences,
Menlo Park, CA.
Detection of somatic mutations, especially in heterogeneous tumor samples
where variants may be present at a low level, is challenging. Single Molecule,
Real-Time (SMRT®) Sequencing is ideal for minor variant detection because of
its ability to sequence single molecules with very high accuracy (QV40) using
the circular consensus sequencing (CCS) approach. Here, we characterize the
Sequel System for the detection of low-frequency somatic variants using con-
structs containing mutations in coding regions in EGFR, NPM1, AKT1 and
JAK2 representing deletion, insertion, substitution and homopolymer variants.
Wild type andmutant amplicons, provided by SeraCare, weremixed and serially
diluted from10%down to 0.1% allelic frequency. Independent SMRTbell librar-
ies were constructed for each dilution point, sequenced and analyzed using
SMRT Sequencing to identify the variants and determine the observed fre-
quency. The random error profıle and high-accuracy CCS readsmake it possible
to accurately detect low-frequency somatic variants. We will demonstrate sen-
sitivity of the PacBio Systems to detect mutations down to 0.1%.
#5367 Ngago: no evidence of targeted endonuclease activity. SabineTopka,
Sara Kazzaz, Kenneth Offıt, Vijai Joseph.Memorial Sloan Kettering Cancer Cen-
ter, New York, NY.
The development of a versatile and easy to use genome editing tool based on
the bacterial CRISPR/Cas9 system has led to a vast increase in applications of
genome editing in laboratories around the world. As an extremely powerful and
versatile tool it has facilitated important discoveries in both basic and transla-
tional research as well as in a potentially wide range of therapeutic applications.
Natronobacterium gregoryi Argonaute (NgAgo) protein was described as a fa-
vorable alternative to Cas9 due to its simplicity and higher endonuclease speci-
fıcity. Thus far, there are no formal reports documenting the success ofNgAgo in
other laboratory settings and cellular systems. Utilizing the identical cellular
background and protocol that was made publicly available by the authors of the
initial study, we were unable to reproduce the endonuclease function of NgAgo.
These results do not support the role of NgAgo in gene editing experiments.
#5368 Comparative analysis of multiple copy number alteration tools in
the detection of amplifıcations and deletions on both whole-exome and tar-
geted NGS panel platforms. Selene M. Virk, Sean Michael Boyle, Ravi Alla,
Jennifer Yen, Richard Chen. Personalis Inc., Menlo Park, CA.
Somatic copy number alterations, or CNAs, are frequent occurrences in the
tumor landscape and can present in the form of focal alterations or as chromo-
some level events. Reliable detection of CNAs is crucial to understanding the
impact of these events on a wide range of factors including tumor progression
and treatment outcomes. The clinical use of NGS panels, and more recently
exomes, continues to expand in cancer but the reliable detection of CNAs re-
mains a challenge. Amajor factor contributing to the challenge is the availability
of reliable tools that have been well tested and validated. We sought to charac-
terize the sensitivity and specifıcity of multiple CNA detection tools with a focus
on clinically relevant genes in NGS panel and whole-exome. Our approach uti-
lized a variety of publicly available CNA tools to identify whole gene amplifıca-
tions and deletions in a set clinically relevant genes identifıed in the Catalogue of
Somatic Mutations in Cancer (COSMIC) database. The tested CNA tools in-
cluded two that supported both whole exome and panel NGS data, allowing
cross platform in addition to cross tool comparisons. This work involved more
than 20 well characterized cell lines derived from a broad spectrum of tumor
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types, including breast, lung, melanoma, and prostate cancers. The cell lines
were analyzed in both tumor/normal and tumor only (which utilizes a proxy
normal) modes. Analyses of patient-matched and proxy-normal data were per-
formed with both assays. Using our approach, we were able to identify clinically
relevant CNAs on both platforms. The performance of the tools tested varied,
with some tools performing best on either amplifıcation or deletion events.
These results represent a comprehensive comparison of recent copy number
alteration tools and provides data that can be utilized to make the tools even
more robust and reliable.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
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#5369 Epigenetic, transciptomic andubiquitomic changes associatedwith
BAP1 loss in uveal melanoma. Stefan Kurtenbach, Jeffım N. Kuznetsov, Mat-
thewG. Field, Rohit Reddy,Margaret I. Sanchez, Christina L. Decatur, JWilliam
Harbour. University of Miami Miller School of Medicine, Miami, FL.
Uveal melanoma (UM) is the most common primary and aggressive ocular
cancer. Up to 50% of the patients develop metastasis, which are notoriously
resistant to all forms of therapy and despite medical treatment leads to death
within a mean time of 5-7 months, with a mortality rate of over 90%. We previ-
ously described that gene expression profıling can be used to classy UM tumors
into twobasic categories, class 1 (lowmetastatic risk) and class 2 (highmetastatic
risk). We further described that inactivating mutations in the ubiquitin hydro-
lase BAP1 are found in over 85%of class 2 tumors. BAP1 is involved in removing
ubiquitin from specifıc proteins to regulate their function, like histone H2A,
thereby regulating gene expression. Building on these fındings, we have gener-
ated uveal melanoma and melanocyte cell lines that allow for the inducible
knockdown of BAP1. First, we performed RNAseq on multiple cell lines before
and after BAP1 knockdown and compare the results to gene expression of class
1 and class 2 tumors. We identifıed signifıcant overlap in key genes linked to
metastasis between the primary tumors, uveal melanoma and melanocyte cell
lines. Using ChIP-seq to interrogate uveal melanoma cells depleted of BAP1, we
identifıed changes in genome wide histone marks and RNA polymerase local-
ization associated with BAP1. To gain further insight into non-histone deubi-
quitination targets of BAP1, we performed ubiquitination proteomic profıling
using the UbiScan® technology and identifıed a list of high probability BAP1
substrates. Taken together, these complementary genome-wide investigations
provide a global picture of the cellular functions of BAP1 and they provide novel
insights into the metastasis-promoting effect of BAP1 loss in UM.
#5370 Examination of DNA looping near oncogenes reveals variable pat-
terns of epigenetic landscapes in cancer.Monika Perez, Ty Johannes. Univer-
sity of Tulsa, Tulsa, OK.
INTRODUCTION: The compaction of chromatin in the nucleus into hierar-
chical three-dimensional (3D) structures plays a key role in the regulation of
gene expression. Advancements in high-throughput chromatin conformation
capture assays have enabled the determination of this hierarchical structure in a
variety of cell states, including cancer. Of note, recent studies have implicated
pathogenic alterations in 3D topology of the genome with the activation of
proto-oncogenes in a multitude of cancers. METHODS: To characterize the
topological changes associated with different cancer phenotypes, we examine
publically available epigenetic profıles from the ENCODE Project, including 3D
data from Chromatin Interaction Analysis by Paired-End Tag Sequencing
(ChIA-PET) from breast cancer and leukemia cell lines. Integrating the chro-
matin topology data with transcription factor binding, DNase accessibility, and
histonemodifıcation data, we uncover variable epigenetic landscapes associated
with differentially active oncogenes in these cancer cell lines. RESULTS: We
provide evidence of topological variability influencing differentially expressed
oncogenes and tie these observations to other epigenetic changes. In particular,
we show insulated-neighborhoods mediated by CTCF looping partition seg-
ments of the genome containing active oncogenes away from repressive mark-
ings like H3K4me3. Additionally, we show that variation in topology differen-
tially localizes H3K27ac in distal regulatory regions to promoters of oncogenes,
providing a means for gene activation in non-coding regions. CONCLUSIONS:
Variable patterns of chromatin topology provide a unique signature and mech-
anism of oncogenes for cancerous phenotypes. We use publically available data
to show mechanisms of activity associated with chromatin topology variation.
#5371 Effect of DNA methyltransferase inhibitor 5-azacitidine on 3D
chromatin structuremeasuredbyHi-C.YuchenVincentBai,1 JohnWhitaker,1
Emanuele Palescandolo,2 Vinod Krishna,1 Vipul Bhargava,1 Satya Saxena,1
Xiang Yao,1 David Pocalyko,1 Kurt Bachman1. 1J&J, Spring House, PA; 2J&J,
Beerse, Belgium.
Therapies targeting epigenetic modifıers such as the DNA methyltransferase
(DNMT) inhibitor, 5-azacytidine (Aza), are used in treating hematologicmalig-
nancies and also show promising results in subsets of solid tumors. The molec-
ular mechanisms for these results, however, are not fully understood. Nonethe-
less, a number of clinical studies using combinations of epigenetic therapies plus
chemo or immunotherapy to enhance the tumor response are ongoing. HCT-
116, a colon cancer cell line genetically defıned by microsatellite instability
(MSI), resulting in a highly mutated, yet primarily diploid genome, has been
routinely used to study epigenetic mechanisms and response to DNMT inhibi-
tion. In a previous study, we integrated a combination of data types including
DNAmethylation, DNAaccessibility, histonemodifıcations and transcriptomic
data that revealed strong correlations between epigenomic changes and gene
expression following Aza treatment. However, for some genes, we could not
predict expression changes using these unidimensional, region-specifıc analysis
methods. As others have demonstrated, genes do not work as single, isolated
units, but rather interact with distal regulatory elements. These regulatory ele-
ments, often several Mb away can control gene expression through physical
interactions such as bending and looping. We reason that in addition to direct
demethylation of the immediate regulatory elements within the gene, Aza treat-
ment can affect long-range chromosomal communications. In order to further
understand the chromatin remodeling effect of Aza treatment, we performed
high resolution genome-wide chromosome conformation capture (Hi-C) fol-
lowed by NGS. HCT-116 cells were treated with DMSO or 1MAza for 42 and
96 hours. Hi-C and RNA-Seq data was analyzed and integrated with other
datatypes. The results showed that AZA treatment alters topologically associat-
ing domains (TAD), with the formation of newTADboundaries and disappear-
ance of others. The genome was then separated into 25K base pair consecutive
bins, with each bin marked as type A (active) or type B (inactive). We observed
bin switching following AZA treatment and differential loop formations (e.g.
promoter-enhancer). Bins that switched from B to A at both time points were
found enriched in genes that are related to acute phase response, interferon
pathway, and cancer including PI3KCB, DDX58, CD274 and CDKN2A. Our
fındings using Hi-C were found to be in agreement with previous results using
alternative experimental methods, which identifıed Aza and CTCF as the top
upstream regulators of these genes.Our data also suggests that overall changes in
3D chromatin activities measured by Hi-C could be a better predictor of tran-
scriptional regulation compared to H2K27me3 and H3K4me3 alone, particu-
larly in situations where there are no signifıcant changes in those marks but
where changes in gene expression exist.
#5372 Alterations in the chromatin accessibility in nonalcoholic steato-
hepatitis-associated hepatocellular carcinoma.Mekonnen Lemma Dechassa.
NCTR/FDA, Jefferson, AR.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-re-
lated deaths worldwide. Accumulated evidence in the past decade has stablished
that NASH, in addition to other well-identifıed risk factors, is becoming amajor
cause of HCC in United States. In the present study, we investigated cancer-
associated chromatin alterations in the Stelic Animal Model (STAM) of NASH-
related HCC. Using Assay for Transposase-Accessible Chromatin with high
throughput sequencing (ATAC-seq), we identifıed 1666 differentially opened
chromatin regions in HCC tumor tissue as compared to normal livers. Annota-
tion of these regions showed that they were associated with 1773 differentially
expressed genes, which were enriched in lipid and steroid metabolism, obesity,
and cancer. Among the differentially opened chromatin regions, 10% resided
within 5 kb from the transcription start site (TSS), while the remaining 90%were
located distal to the TSS ( 5 kb). By combining ATAC-seq and transcriptomic
profıles, we demonstrated that 182 of the up-regulated genes were associated
with open chromatin regions in tumor tissue. Furthermore, 24 of these up-
regulated genes, including Apoa4, Nupr1, Anxa2, and Igfbp1, had accessible
chromatin regions located proximal to the TSS. Importantly, analysis of histone
modifıcations at the open chromatin regions of the over-expressed cancer-re-
lated Apoa4 and Anxa2 genes demonstrated enrichment by H3K4mono-meth-
ylation (H3H4me1) and H3K27 acetylation (H3K27ac), histone marks that as-
sociated with the active gene promoters (H3K27ac) and enhancers (H3Kme1
and H3K27ac). In conclusion, these data provide evidence for alterations in the
chromatin accessibility in tumor tissue and potential role of open chromatin
regions in the over-expression of critical cancer-related genes in HCC.
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#5373 3D genome architecture changes during cancer cell migration and
metastasis. Rachel Patton McCord, Rosela Golloshi. University of Tennessee,
Knoxville, TN.
Metastasis, the most deadly part of cancer, results from cancer cell migration
and invasion from a tumor into surrounding tissues. During this migration, the
cell often has to squeeze and deform its nucleus through tight spaces. This nu-
clear squeezing is a rate-limiting step in migration, and the deformations can
even rupture the nucleus. The organization of the genome inside the nucleus
into loops, domains, and territories is important for proper gene regulation,
DNA replication, and genome repair. However, little is known about the char-
acteristics of nuclear organization that might allow for the nuclear deformation
of metastatic cancer cells. We are using Chromatin Conformation Capture
(Hi-C) andmicroscopy techniques to study genome organization during cancer
cell migration. Using photoconvertible fluorophore Dendra2-H4 we draw and
monitor patterns on nuclei of cells migrating through dense collagen matrices,
Transwell fılters, or microfluidic channels. Our data show changes in these pat-
terns, indicating spatial reorganization of the genome during migration. Previ-
ous work has suggested that cancer cell migration requires global condensation
of the genome. Some cancer chemotherapeutics act on epigenetic marks to de-
condense chromatin. We are testing whether such chromatin decondensation
affects the physical deformability of the nucleus and thus effective migration.
We have used Transwell andwound healingmigration assays tomonitormigra-
tion of cells treated with histone deacetylase inhibitors and histonemethyltrans-
ferase inhibitors. Our results show that the drugs inhibit migration in a Trans-
well assay but not in the wound healing assay. This suggests that genome
decondensation prevents the passage of the nucleus through narrow 3D spaces.
But, a condensed genome organization is not necessary for 2D cell motility,
where nuclei are unconfıned. Hi-C experiments on migrating cells with de-
formed nuclei and drug-treated cells will characterize the specifıc rearrange-
ments in genome structure that occur during cancer cell migration and whether
these specifıc changes are counteracted by epigenetically active drugs.
#5374 Polyunsaturated fatty acids (PUFAs) alter the epigenetic landscape
inMDA-MB-231 triple negative breast carcinoma (TNBC).AmyM. Chattin,
Mykelti O’Brien, Ronald S. Pardini. Univ. of Nevada, Reno, NV.
Breast cancer is the second leading cause of cancer-related deaths in US
women; 10-20%ofwhich are triple-negative breast cancer (TNBC) subtypes and
have the poorest short-term prognosis. This is probably due to an epithelial to
mesenchymal transition (EMT) that tumors undergo, de-differentiating into
cancer stem cells. Epigenetic reprogramming is proposed to be required for
malignant transformation and invasion, particularly in cells undergoing EMT
transitions such as TNBC. Therefore, altering the epigenetic landscape in met-
astatic TNBC lines would provide researchers with a unique opportunity to
sensitize tumors to treatment and induce apoptosis. Epigenetic research chiefly
focuses on inhibitors of co-repressors histone deacetylase (HDACi) and DNA
methyltransferases (DNMTi). Short chain fatty acids, have proven to be effective
HDACi’s, suggesting a possible role for other fats in epigenetic regulation. Re-
search has shown that several omega-3 polyunsaturated fatty acids (PUFAs),
specifıcally docosahexaenoic acid (DHA; C22:6, n-3) and eicosapentaenoic acid
(EPA; C20:5, n-3), inhibit tumorigenesis whereas the omega-6 PUFA linoleic
acid (LA; 1C8:2, n-6) promotes neoplastic growth; supporting the association of
elevated cancer incidence with n-6 PUFA dietary intake. We initiated studies to
evaluate the impact of omega-3 fatty acids on tumor epigenetic pathways. There-
fore we monitored epigenetic alterations in MDA-MB-231 TNBC cells in re-
sponse to both omega-3 and omega-6 PUFAs in a time and dose-dependent
manner. DHA, EPA, and arachidonic acid (AA; 20:5, n-6) all elicit apoptosis in
a similarmanner, indicating that initiating apoptosis is not omega-6 or omega-3
specifıc. We now show that PUFA incorporation and the resulting attenuated
metabolism are not suffıcient to induce apoptosis in MDA-MB-231 TNBC at 3
and 12 hour timepoints. Additionally, plasma membrane integrity was not ap-
preciably altered at 3 or 12 hour time points. These data, combined with a lack
apoptosis at 12 hours, indicate that the level of intact PUFA in cell membranes
does not initiate apoptosis. Moreover, mitochondrial membrane potential was
universally diminished early and throughout the time course and, although not
limiting, decreased ATP levels were observed at 12 hours (relative to vehicle
control). Furthermore, activity of HDAC classes (I, IIa and IIb) were altered
early at 3 and 48 hours, but typically punctuated with a recovery to basal levels
noted at the 12 hour time point. Chromatin condensation was observable pri-
marily in 12 and 48 hour time points, although it was noted in DHA and EPA
treatments at 3 hours. Collectively, these data demonstrate that PUFA-mediated
epigenetic changes occur on a time scale proceeding apoptotic induction, indi-
cating that PUFAs may be useful as an epigenetically-targeted cancer therapeu-
tic agent or adjuvant therapy.
#5375 Oncogenic BRAF mutation induces widespread DNA hypermeth-
ylation in a murine model for human serrated colorectal neoplasia. Vicki
Whitehall,1 Catherine Bond,1 Cheng Liu,1 Futoshi Kawamata,1 Diane McKe-
one,1 Saara Jamieson,1 Sally Pearson,1 Susan Woods,2 Tamsin Lannagan,1
Lochlan Fennell,1Winnie Fernando,1Mark Bettington,1DanielWorthley,3 Bar-
bara Leggett1. 1QIMR Berghofer Medical Research Institute, Herston, Australia;
2University of Adelaide, Herston, Australia; 3University of Adelaide, Adelaide,
Australia.
BACKGROUND: The serrated colorectal neoplasia pathway describes the
progression of morphologically serrated polyps to cancer and accounts for ap-
proximately one third of all colorectal cancer cases. Human serrated polyps are
characterised by activating mutation of the BRAF oncogene and widespread
DNA methylation changes termed the CpG Island Methylator Phenotype. A
causative versus synergistic relationship between BRAF mutation and this
methylator phenotype has not been determined. We aimed to address this by
developing a murine model for serrated neoplasia driven by BRAF mutation.
METHODS: BrafV637E conditionally active mice were crossed with intestine-
specifıc, inducible Villin-CreERT2 mice to direct the BRAF mutation to the in-
testine at 2weeks of age. The proximal ilieumor proximal colonwere sampled at
defıned time points including 10 days, 10 weeks, 5 months, 8 months, 10
months, 12months and 14months.Macroscopic lesions larger than 10mmwere
bisected for molecular and histological assessment. The entire remaining intes-
tine was fıxed and examined histologically. DNA methylation was investigated
for 94 genes known to bymethylated in colorectal cancer using EpitectMethylII
Complete PCR Arrays (Qiagen). RESULTS: Braf mutant mice displayed histo-
logic changes analogous to the human serrated neoplasia pathway. Extensive
intestinal hyperplasia developed by 10 days post induction of the BRAF muta-
tion. By 10weeks, 50%mice had developed areas of crypt dilation reminiscent of
human sessile serrated adenomas. By 8months, themajority ofmice hadmurine
serrated adenomas with dysplasia and invasive cancer developed in 40% ofmice
by 14months, one of whichmetastasised to the liver. Compared to age-matched
control mice, Braf mutant mice showed signifıcant, gene-specifıc increases in
DNA methylation from 5 months (p0.0001). CONCLUSIONS: Using an in
vivo model we observed the temporal accumulation of DNA methylation
changes in hyperplastic epithelium in direct response to mutation of the BRAF
oncogene. This murine model morphologically and molecularly recapitulates
the human serrated neoplasia pathway and establishes a causative role for BRAF
mutation in establishing a methylator phenotype.
#5376 Requirement of TET2 inMLL-AF9mediated leukemogenesis.Dip-
moy Nath, Golam Mohi. SUNY Upstate Medical University, Syracuse, NY.
TET methylcytosine dioxygenase 2 (TET2) catalyzes the conversion of
5-methylcytosine to 5-hydroxymethylcytosine resulting inDNAdemethylation.
Loss-of-function mutations or deletions of TET2 have been found in several
myeloid malignancies including myelodysplastic syndrome (MDS), myelopro-
liferative neoplasms (MPN), chronic myelomonocytic leukemia (CMML) and
acute myeloid leukemia (AML). Moreover, deletion of TET2 leads to myeloid
malignancies in mice. Therefore, TET2 has been suggested to play a tumor
suppressor role in myeloid malignancies. In this study, unexpectedly, we have
uncovered a tumor promoter function for TET2 in MLL rearranged leukemia.
Chromosomal rearrangements of the Mixed Lineage Leukemia (MLL) gene
have been found in10% of acute leukemia and are associated with poor prog-
nosis. We observed that depletion of TET2 signifıcantly inhibited the prolifera-
tion of MLL-AF9 positive MOLM14 leukemia cells. Similarly, knockdown of
TET2 markedly reduced proliferation in murine Ba/F3 cells stably expressing
MLL-AF9. Conversely, overexpression of TET2 signifıcantly increased prolifer-
ation inMLL-AF9 expressingMOLM14 and Ba/F3 cells. In addition, deletion of
TET2 signifıcantly inhibited MLL-AF9 mediated myeloid colony formation in
the bonemarrow (BM) cells ex vivo.Next, we assessed the in vivo effects of TET2
deletion in MLL-AF9-mediated leukemogenesis using retroviral bone marrow
transduction and transplantation assays. Whereas recipients of MLL-AF9-
transduced wild type BM exhibitedmarked increase in white blood cells (WBC)
and neutrophils in their peripheral blood and signifıcant increase in the spleen
size, recipients of MLL-AF9-transduced TET2-defıcient BM showed signifı-
cantly reducedWBC and neutrophil counts and reduced spleen size. Flow cyto-
metric analysis showed signifıcantly increased myeloid precursors (Gr-1/
Mac1) and granulocyte macrophage progenitors (GMP) in the BM of
transplanted animals receiving MLL-AF9 expressing wild type BM compared
with recipients of MLL-AF9 expressing TET2-defıcient BM. Furthermore,
transplanted animals receiving MLL-AF9-transduced wild type BM showed
marked increase in hematopoietic stem/progenitor cells (LSK; Lin-Sca-1c-
kit), which was signifıcantly reduced upon TET2 deletion. Defıciency of TET2
also signifıcantly reduced MLL-AF9-mediated increase in hematopoietic pro-
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genitor colony formation in the BM. In addition, deletion of TET2 resulted in
increased overall survival in mice expressing MLL-AF9. Together, these data
indicate that TET2 is required for leukemic transformation mediated by MLL-
AF9. Our results suggest a novel tumor promoter function for TET2 in MLL
rearranged leukemia.
#5377 Intragenic DNA methylation and increased gene expression: New
directions from pan-cancer analysis. Michael H. McGuire, Shelley Herbrich,
Sherry Wu, Ying Wang, Rajesha Rupaimoole, Hui Yao, Kshipra Gharpure, Ga-
briel Lopez-Berestein, Keith Baggerly, Anil Sood.MD Anderson Cancer Center,
Houston, TX.
Purpose: While the impact of DNA methylation at the promoter region as a
repressive influence is well-known, the vast majority of DNAmethylation actu-
ally occurs outside of the promoter region. The function of intragenic DNA
methylation remains incompletely understood. Here, we investigate how intra-
genic DNA methylation impacts gene expression, and how these modifıcations
differ between normal and corresponding cancer tissues. Methods: A pan-can-
cer analysis of gene expression array data was integrated with Illumina 450k
methylation array data across ten tumor types to produce correlation values
between DNA methylation and gene expression at distinct loci on a genome-
wide basis. The probes exhibiting a signifıcant correlation between gene expres-
sion and DNA methylation were selected for further analysis. Results: We un-
covered robust positive correlations between gene expression and 3=
methylation in 3,200 genes, with 590 genes in bladder cancer, and 256 genes in
squamous cell lung carcinoma displaying a correlation coeffıcient of0.5. Fur-
thermore, we observed 44 genes with a correlation coeffıcient of0.7 in at least
two tissue types. The majority of genes with the strongest correlations are tran-
scription factors known to play roles in differentiation anddevelopment,with an
enrichment of zinc fınger and homeobox-containing genes. Further analysis of
these genes exhibit divergent 3= methylation when comparing normal and tu-
mor tissues. Importantly, the extent of 3=methylation of these genes is associated
with patient overall survival in 5 of the 10 tumor types analyzed, strongly sug-
gesting that this process plays a role in cancer pathogenesis. Conclusion: DNA
methylation of the 3= region is a functionally and clinically relevant epigenetic
modifıcation, and may serve as a novel target for inhibiting tumorigenesis and
tumor progression.
#5378 Genes involved in development and differentiation are commonly
methylated in cancers derived from multiple organs: A single-institutional
methylome analysis using 1007 tissue specimens. Kentaro Ohara,1 Eri Arai,1
Yoriko Takahashi,2 Nanako Ito,1 Ayako Shibuya,3 Koji Tsuta,4 Ryoji Kushima,4
Hitoshi Tsuda,4 Hidenori Ojima,1 Hiroyuki Fujimoto,4 Shun-ichi Watanabe,4
Hitoshi Katai,4 Takayuki Kinoshita,4 Tatsuhiro Shibata,3 Takashi Kohno,3 Yae
Kanai1. 1Keio University School of Medicine, Tokyo, Japan; 2Mitsui Knowledge
Industry Co., Ltd., Tokyo, Japan; 3National Cancer Center Research Institute,
Tokyo, Japan; 4National Cancer Center Hospital, Tokyo, Japan.
Aim: The aim of this study was to clarify the signifıcance of DNAmethylation
alterations shared by cancers derived from multiple organs. Background: Little
is known about DNA methylation alterations during carcinogenesis shared by
various organs. In this single-institutional study, consistency of sample quality,
diagnostic criteria and technical platforms may be advantageous for providing
an overall view of DNA methylation profıles of cancers arising in multiple or-
gans. Methods: We analyzed single-institutional methylome data by Infınium
HumanMethylation27 or HumanMethylation450 BeadChip (Illumina) for
1,007 samples of non-cancerous tissue (N) and corresponding cancerous tissue
(T) obtained from the lung, stomach, kidney, breast and liver. Results: Principal
component analysis revealed thatN samples of each organ showeddistinctDNA
methylation profıles, DNA methylation profıles of N samples of each organ
being inherited by the corresponding T samples and DNAmethylation profıles
of T samples being more similar to those of N samples in the same organ than
those of T samples in other organs. We identifıed 2,636, 2,209, 1,915, 2,914 and
5,665 probes that were aberrantly methylated in lung adenocarcinomas, gastric
adenocarcinomas, clear cell renal cell carcinomas, breast cancers (e.g. invasive
ductal carcinomas, ductal carcinomas in situ and invasive lobular carcinomas)
and hepatocellular carcinomas, respectively, in comparison with the corre-
sponding N samples. When we examined pairs of organs, only 6.9% (between
stomach cancers and kidney cancers) to 35.4% (between lung cancers and breast
cancers) of aberrantly methylated probes were shared between cancers of any
two organs, indicating that the majority of DNA methylation alterations were
diverse amongmultiple organs. In contrast to such organ and/or carcinogenetic
factor-specifıcity of DNA methylation profıles, when compared to the corre-
spondingN samples, 231 genes commonly showedDNAhypermethylation in T
samples in four ormore organs. Gene ontology enrichment analysis showed that
such commonly methylated genes were enriched among “transcriptional fac-
tors” participating in development and/or differentiation, which reportedly
show bivalent histone modifıcation in embryonic stem cells. Pyrosequencing
and quantitative reverse transcription-PCR revealed an inverse correlation be-
tween DNA methylation levels and mRNA expression levels of representative
commonly methylated genes, such as ALX1, ATP8A2, CR1 and EFCAB1, in
tissue samples. Conclusion: These data suggest that disruption of the differenti-
ated state of precancerous cells via alterations of expression, independent of
differences in organs and/or carcinogenetic factors,may be a common feature of
DNA methylation alterations during carcinogenesis in multiple organs.
#5379 TET2 loss and the lymphoma-associated RHOAmutation cooper-
ate to disrupt CD4 T cell function. Shengbing Zang,1 Jia Li,1 Haiyan Yang,2
Wei Han,1 Jixiang Zhang,1 Minjung Lee,1 Yubin Zhou,1 Deqiang Sun,1 Yun
Huang1. 1Texas A&M University, Houston, TX; 2Zhejiang Cancer Department,
Houston, TX.
Peripheral T cell lymphomas (PTCLs) are a group of rare but aggressive lym-
phomas derived from mature T cells or natural killer cells with a dismal prog-
nosis. Current treatments for PTCL are ineffective with high relapse rates,
largely owing to the lack of targeted therapeutics and a deepmechanistic under-
standing of the molecular etiology. Recent exome sequencing has unveiled the
frequent co-existing somatic mutations in RHOA (G17V) and TET2 in PTCLs,
but not in other types of hematological malignancies. Most notably, mutations
in both TET2 and RHOA are frequently observed (60-70%) in angioimmuno-
blastic T-cell lymphoma (AITL), which is among the most common subtypes of
PTCLs with a median overall survival of approximately 1.5 years. Patients with
AITL are often associatedwith autoimmunemanifestations, but themechanistic
underpinnings remain unresolved. To examine whether TET2 loss and
RhoAG17V alter mature T cell function, we performed adoptive T cell transfer
experiments withWT or Tet2 knockout transgenicmice. Using this strategy, we
generated four groups of recipient mice transferred with T cells as follows: WT,
RhoAG17V, Tet2-/-, or Tet2-/-RhoAG17V. Among these four groups, only recipi-
ent mice transferred with double mutant T cells displayed severe inflammatory-
like phenotypes that ultimately led to early lethality in mice. Moribund mice
transferred with Tet2-/-RhoAG17V T cells showed substantial weight loss, severe
skin ulcer on tail/paw/ear accompanied with pruritus, and lymphomegaly as
typically seen in AITL patients. Histopathological analysis on major organs de-
rived from theTet2-/-RhoAG17V group indicated severe infıltration of bothT and
B lymphocytes inmajor organs, as well as a pronounced increase in the numbers
of follicles and activated germinal centers in lymph nodes. Further analysis in-
dicates that Tet2 loss andRhoAG17Vmutation cooperated together to exclusively
promote CD4 T cell proliferation and survival, and exert no adverse effects on
CD8 T cells, which recapitulates the mutation spectrum detected in AITL
patients, i.e., RhoAG17V is primarily detected inCD4T cells but not other T cell
subsets. The functional consequence of Tet2 loss and RhoAG17V expression in
CD4 T cells is characterized by an imbalance between the effector and regula-
tory T cells, whichmay account for the overt immunoinflammatory phenotypes
seen in mouse models. The transcriptome analysis further revealed a pro-
nounced remodeling of the immune signaling network that points to the aber-
rant expression of several key transcriptional factors. In summary, our study
demonstrated a previously-unappreciated cooperativity between Tet2 loss and
RhoAG17Vmutation in disruptingmature CD4T cells function, which is made
through the synergy between epigenetic and GTPase signaling pathways. The
results obtained from this study provide an additional basis for future develop-
ment of new diagnosis, prognosis and therapy for PTCL patients.
#5380 Inactivation of endogenous genes in cancer cells using targeted
promoter DNAmethylation via CRISPR-DNMT3a fusion protein. SimonD.
Spivack. Albert Einstein College of Medicine, Bronx, NY.
Background: Developing technologies for precise manipulation of individual
DNA methylation loci is an attractive challenge in cancer and lung biology,
because aberrant expression via hyper- or hypo-methylation is so common.
Projects such as ENCODE and the RoadmapEpigenetics Project, have identifıed
thousands of epigenetic marks from human genome. However, the functional
evaluation of these marks has been largely limited to determining their associa-
tions with gene expression. Technologies for targeting manipulation of epige-
neticmarkswould allowdirect experimental testing of the impact ofDNAmeth-
ylation at specifıc residues, mechanisms of gene regulation, and potential use as
interventions, for example to silence constitutively active oncogenes. Methods:
Here, we developed a CRISPR Cas9-based tool for specifıc DNAmethylation in
which the catalytic domain of DNMT3a (DNMT3a-CD) is fused to the carboxy-
terminus of Cas9 D10A-H840A mutant (dCas9). Both construct promoter
strength and transfection strategies were optimized. Results: We demonstrated
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targeted and consistent CpG methylation in 30100bp regions downstream of
the PAM (binding) site of the gRNA guided fusion protein inHEK293 cells. The
multiple guide RNAs could target the dCas9-DNMT3A tomultiple sites consis-
tently. DNA methylation activity was specifıc for the targeted region and was
heritable across cell divisions. We also found directed promoter DNA methyl-
ation of DAL1, GATA5 and C-MYC could decrease the corresponding mRNA
expression by up to 80%; different DNA methylation positions had conse-
quently different effects on gene expression. We have now performed C-MYC
methylation-mediated knockdown in A549 lung cancer cells and are evaluating
resulting cell cycle and apoptosis phenotypes. Conclusion: We believe this new
targeted epigenetic technology can be directed to cancer cells for the purpose of
reprogramming lung cancer, and unregulated stromal and microenvironment
cells, for preventive and therapeutic uses.
#5381 Ahighly sensitivemethod for noninvasive cancer profıling through
targeted methylation sequencing of circulating cell-free DNA. Li Liu,1 Jona-
than M. Toung,1 Raakhee Vijayaraghavan,1 Ruoyu Zhang,1 Helen J. Huang,2
Toshinori Hinoue,3 Hui Shen,3 Neeraj Salathia,1 Marina Bibikova,1 Richard
Shen,1 Karen Gutekunst,1 Peter W. Laird,3 Filip Janku,2 Jian-Bing Fan1. 1Illu-
mina, San Diego, CA; 2MD Anderson Cancer Center, Houston, TX; 3Van Andel
Research Institute, Grand Rapids, MI.
Liquid biopsies, by analyzing circulating cell-free DNA (cfDNA), have
emerged as a promising tool for noninvasive cancer diagnostics andmonitoring.
Compared to the limited number of scattered DNA mutations in cancer pa-
tients, the genome-wide distribution of numerous densely clusteredDNAmeth-
ylation alterations may enable more robust cancer signal detection and higher
sensitivity in cancer diagnostics. Furthermore, the cancer type specifıc methyl-
ation signatures potentially can be used for the identifıcation of cancer tissue
origin. To enablemultivariate analysis of genome-widemethylationmarkers, we
have developed a targeted methylation sequencing assay that can measure the
methylation status of thousands of affected CpG (5=-C-phosphate-G-3=) sites
simultaneously. This assay allows low cfDNA input as little as 3ng while retain-
ing good effıciency. The targeted siteswere particularly selected for hypermethy-
latedmarkers inmore than 20major cancer types based on TheCancer Genome
Atlas (TCGA) database. Following bisulfıte sequencing of cfDNA, methylation
signals from targetedCpG siteswere aggregated into a single score thatmeasures
deviation of a sample’s methylation profıle from a reference baseline. Cancer/
normal classifıcation was performed by comparing the methylation score of a
test sample to a cutoff established by a group of plasma samples from healthy
individuals. Subsequently, methylation signals from cancer type specifıc mark-
ers were used to perform cancer type classifıcation. In a study to evaluate the
potential clinical applications of this method, we processed 25 blood samples
collected from healthy individuals and 70 blood samples collected from 63 ad-
vanced cancer patients. The assay demonstrated a specifıcity of 100% (n25),
and a sensitivity of 94.3% in colorectal cancer (n36), 72.7% in breast cancer
(n11), and 52.6% in lung cancer (n19) detection, respectively. We further
performed cancer type classifıcation on the samples that were correctly classifıed
as true positives in the cancer/normal classifıcation. Our results showed a clas-
sifıcation accuracy of 82.4% for colorectal cancer (n34), 87.5% for breast can-
cer (n8), and 70% for lung cancer (n10). In summary, we have developed a
comprehensive method that allows us to perform noninvasive cancer profıling
through targeted methylation sequencing assay and novel analysis algorithms.
This method can potentially be used in multiple validated clinical applications,
such as early cancer detection, cancer diagnostics, and monitoring of minimal
residual disease.
#5382 ADNMT3A-independent hypomethylator phenotype is a unifying
epigenetic signature of AML with good risk cytogenetics. Andrew D. Kelly,
Jozef Madzo, Priyanka Madireddi, Patricia Kropf, Charly R. Good, Jaroslav Je-
linek, Jean-Pierre J. Issa. Lewis Katz School of Medicine at Temple University,
Philadelphia, PA.
Background: Acute myeloid leukemia (AML) causes the most leukemia-re-
lated deaths in the United States, and has frequent mutations in epigenetic reg-
ulators, including DNMT3A, IDH, and TET2. Such aberrations have been pro-
posed to transform the epigenetic state in cancer, often involving DNA
hypomethylation, however, the genomic specifıcity, causes, and clinical conse-
quences of such methylation changes in AML remain unclear. Methods: We
queried genome-wide CpG methylation using The Cancer Genome Atlas
(TCGA)AML samples (n194) run on Illumina 450k arrays.We usedRNA-seq
data to study gene expression changes associated with hypomethylator pheno-
types (HP). Analysis was done using R. Results: Genome-wide analysis of CpG
sites that are highly methylated in normal blood, and variably methylated in
AML (-value standard deviation in AML  0.2; average -value in normal
blood  0.8) revealed two distinct HPs by hierarchical clustering: Good-risk
(GR) HP which included favorable cytogenetics, and DNMT-HP, which was
enriched for DNMT3A mutations. We refıned DNA methylation signatures of
each HP cluster by differential methylation analysis and re-classifıed patients
accordingly. Strikingly, all patients with t(8;21), inv(16), or t(15;17) belonged to
theGR-HP group, suggesting that a common epigenetic thread connects these
otherwise disparate genetic aberrations. From a clinical perspective GR-HP
patients were younger than GR-HP- patients, and had signifıcantly longer over-
all survival (median OS, years: GR-HP Not reached; GR-HP- 1.00; P
0.001). In contrast, DNMT-HP cases were statistically equivalent to DNMT-
HP- except for an enrichment for higherWBCcounts, includingnodifference in
survival (median OS, years: DNMT-HP  0.92; DNMT-HP-  1.34; P 
0.27). From an epigenetic perspective the two HP clusters harbored distinct
DNA methylation changes; although both favored hypomethylation within
non-CpG islands relative to CpG islands, the enrichment wasmore pronounced
for DNMT-HP (Odds ratio: hypomethylated CpG islands/hypomethylated
non-CpG islands, GR-HP 0.64;DNMT-HP 0.18). Genetic analysis revealed
that GR-HP leukemia had wild-type IDH, DNMT3A, and NPM1 genes. In
contrast, DNMT-HP AML had signifıcantly more FLT3, NPM1, and
DNMT3Amutations compared to DNMT-HP- patients. RNA-seq revealed sig-
nifıcant up-regulation of genes in both HP phenotypes (216, and 150 genes for
GR-HP and DNMT-HP, respectively at FDR  0.01 and FC  2). Pathway
analysis of these genes revealed enrichments for ion channels and the comple-
ment pathway in DNMT-HP, and for nervous system and developmental genes
in GR-HP. Conclusions: Our data suggest that two HPs exist in AML with
unique epigenetic and transcriptomic signatures. The striking association be-
tween GR-HP and different favorable cytogenetic changes suggests that a com-
mon set of epigenetic features may contribute to improved survival in these
patients.
#5383 Non-invasive diagnosis of early-stage lung cancer via targetedhigh-
throughput DNA methylation sequencing of circulating tumor DNA
(ctDNA). Xuyu Cai, Yangbin Gao, Hui Shen, Peter Laird, Jian-bing Fan,
Weihong Xu, Wenhua Liang, Jianxing He. AnchorDx Medical Co. Ltd., Guang-
zhou, China.
Current state-of-the-art lung cancer early screening involves using low-dose
CT scan to identify lung nodules smaller than 3cm indiameter.However, it’s still
a clinical dilemma to differentiate between malignant and benign nodules. We
took the approach of methylation profıling by high-throughput bisulfıte DNA
sequencing in tissue samples to identify specifıc methylation signatures. We
learned methylation patterns that differentiate malignant vs. benign lesions
from tissue samples by in-depth datamining, and then used patternmatching to
classify plasma samples. Given the usual low amount of ctDNA in plasma, we
also developed an ultra-sensitive library preparation method to perform tar-
geted bisulfıte DNA sequencing from as low as 1ng of cfDNA or 1mL of plasma.
From a training set of 88 tissue samples, which includes 60malignant specimens
with different subtypes (invasive adenomas, IA; minimally invasive adenomas,
MIA; atypical adenomatous hyperplasia, AAH; adenocarcinoma in situ, AIS;
carcinoid; lymphoepithelioma-like carcinoma of the lung, LELC; squamous car-
cinoma, SC; as well as 28 benign specimens in different categories including
hematomas, granuloma, tuberculosis, inflammatory pseudotumor (IPT), scle-
rosing hemangiomas (SHL) and infections, we were able to achieve a sensitivity
of 95% for identifıcation of malignant lesions, with a specifıcity of 78.6%. From
an independent validation set of 45 plasma samples, we achieved a sensitivity of
94.7% and a specifıcity of 85.7% for differentiating patients with malignant tu-
mor from patients with benign lesions. Specifıcally, our assay is demonstrated to
be highly sensitive towards early-stage lung cancer detection,with a sensitivity of
93.3% in a total of 15 patients with stage IA/B lung cancer. In summary, we have
developed a highly sensitive blood-based non-invasive diagnostic assay for iden-
tifıcation of early stage lung cancer, which can aid clinical decisions for patients
with a CT scan positive for lung nodules. This approach can also be extended to
non-invasive early screening for various cancer types.
#5384 Aberrant methylation of ANK1, the host gene for miR-486, distin-
guishes lung tumors by histology and smoking status. Mathewos Tessema,1
Christin M. Yingling,1 Maria A. Picchi,1 Guodong Wu,1 Tyron Ryba,2 Young
Lin,1 StevenA. Belinsky1. 1Lovelace Respiratory Research Institute, Albuquerque,
NM; 2New College of Florida, Sarasota, FL.
MicroRNAs (miRs) regulate many fundamental biological processes primar-
ily through inhibiting the transcription and/or translation of their target genes.
MiR-486 is an intragenic miR located within ANK1, a gene that encodes for the
adapter protein ankyrin-1. Although the tumor suppressor role of miR-486-5p
and its down-regulation in non-small cell lung cancer (NSCLC) is well estab-
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lished, the mechanism(s) leading to its repression is unclear. In this study, we
investigated epigenetic regulation of ANK1 and its impact on miR-486-5p ex-
pression in lung cancer. DNA methylation and expression levels of ANK1 and
miR-486-5p in lung tumor-normal pairs, NSCLC cell lines, as well as various
normal blood and lung epithelial cell controls were evaluated using qualitative
and quantitative assays. The genome-wide impact of epigenetic repression of
ANK1was evaluated using siRNA.The results show thatmiR-486-5p expression
in lung tumors and NSCLC cell lines was signifıcantly reduced compared to
distant normal lung tissue pairs (p 0.0006) and strongly correlatedwithANK1
expression. InNSCLC cell lineswith strongly reduced expression ofmiR-486-5p
and ANK1, treatment with the DNA methylation inhibitor 5-aza-2-deoxycyt-
idine signifıcantly increased the expression of both the miR and its host gene.
Human ANK1 is a large (230kb) gene with three promoter regions regulating
tissue specifıc expression of three (ANK1B, ANK1E, and ANK1A) transcript
variants. ANK1B (the longest of the three variants) is the primary transcript
expressed in lung tissue, while ANK1E and ANK1A are weakly and rarely ex-
pressed in lung epithelial cells. ANK1B promoter contains a large CpG island
that is methylated in 45% (118/262) of lung tumors but not in normal lung or
blood samples. The prevalence for ANK1Bmethylation was signifıcantly higher
(p  0.001) in lung adenocarcinoma (101/200, 51%) compared to lung squa-
mous cell carcinomas (17/62, 27%) after adjustment for smoking. Comparison
of methylation by patients’ smoking history also revealed that ANK1B methyl-
ation in lung adenocarcinoma was signifıcantly more prevalent in smokers
(57%, 73/128) than in never smokers (39%, 28/72), p 0.014; HR 2.086 (CI:
1.157 - 3.759). These fındingswere confırmedby quantitativemethylation assays
and independently validated using publicly available methylation data for large
(n 809)NSCLC cases from theCancerGenomeAtlas database. Finally, siRNA
mediated knockdown of ANK1 in lung cancer cell lines followed by transcrip-
tome-wide expression and pathway analysis revealed that ANK1 repression pri-
marily alters cancer development and progression pathways. Taken together,
our data indicates that aberrantmethylation of ANK1B promoter is highly prev-
alent in lung cancer, discriminates lung tumors by histology and smoking his-
tory, and represses the expression of ANK1 along with the tumor-suppressor
miR-486-5p it hosts within its last intron.
#5385 Colorectal cancermethylome and laterality. ShoHirabayashi,Masa-
michi Hayashi, Goro Nakayama, Keisuke Kurimoto, Hiroshi Tanabe, Mitsuro
Kanda, Hideki Takami, Yukiko Niwa, Naoki Iwata, Daisuke Kobayashi, Chie
Tanaka, Suguru Yamada, Hiroyuki Sugimoto, Masahiko Koike, Tsutomu Fujii,
Michitaka Fujiwara, Yasuhiro Kodera. Nagoya University Graduate School of
Medicine, Nagoya, Japan.
Background: Colorectal cancers are anatomically derived from Midgut area
(from cecum tomid transverse colon) andHindgut area (frommid transverse to
anal canal). The laterality of colorectal cancers was reported as one of the prog-
nosis markers of these cancers. Midgut originated cancers had statistically
poorer overall survivals than Hind gut (Yahagi et al, J Gastrointest Surg, 2016).
In addition to clinical reasons, for example its symptomless nature of the bowel
obstruction on the right side, the difference of genetic and/or epigenetic profıles
between both side colorectal cancersmay exists.Methods: Surgically resected 30
colorectal cancers (Midgut n9,Hidgut n21)were included. Any clinicopath-
ological factors except for tumor site was not statistically different between 2
groups. We decided to focus on colon cancer methylome and laterality in this
study. Two novelmethylationmarkers of colon cancers (PAX5 andVGF)which
were extracted from microarray analysis were used, and quantitative methyla-
tion-specifıc PCR (QMSP) assay was performed for each marker. Results: Both
PAX5 and VGFmethylations were extremely tumor-specifıc markers (P0.001
and P0.011). Interestingly, Both markers tended to have high methylation
frequency inMidgut derived cancers. High frequency of PAX5 promoter meth-
ylation was found in 9/9 cases (100%) of Midgut and 15/21 cases (71%) of
Hindgut (P0.141), while that of VGF was found in 6/9 cases (67%) of Midgut
and 4/21 cases (19%) of Hindgut (P0.030). In addition, three multiple colon
cancers were found in the cohort. All of them were derived from Midgut area
(T1/T1, T3/Tis and T3/Tis), and had high frequency of both PAX5 (2/3, 67%)
and VGF (3/3, 100%) methylation. Conclusion: Cancer methylome between
Midgut and Hindgut seemed to be different, and it may affect tumor malig-
nancy, plurality and chemotherapy sensitivity. Now we are in progress of in-
creased colorectal cancer cases (over 100) and methylation markers.
#5386 Does chemotherapeutics contribute to DNMT1 expression level in
colorectal cancer cells. Nuray Varol, Suna Arikan Teri, Zafer Soylemez, Han-
dan Yildiz,MujganOzdemir,Mustafa Solak.Afyon Kocatepe University, Faculty
of Medicine, Afyonkarahiasr, Turkey.
Epigeneticmodifıcations, particularlyDNAmethylation in selected gene pro-
moters is a pivotal role in the development of colorectal cancer. DNA methyl-
ation is considered as one of themost important epigeneticmechanisms and it is
catalyzed by DNAmethyltransferases (DNMTs). DNMT1 abundance has been
frequently seen in colorectal cancers but the reasons are notwell understood.We
investigated to the effect of chemotherapeutics used in treatment of colorectal
cancer on expression ofDNMT1 and this effect is achieved overwhich signalling
pathway. In this study, GSK3; IWP2 for -catenin) and chemotherapeutics
(oxaliplatin, fluorouracil, irinotecan) were detected by WST1. DNMT1 expres-
sion level was determinated by real-time PCR; and protein levels of GSK3,
pGSK3(Ser9), Akt1, pAkt1(Ser473), -catenin, p-catenin(Ser675) and
DNMT1 by western blot. Our results indicated taht Akt1 increased the protein
level of DNMT1 expression with coordinate transcriptional change via
-catenin pathway. Fluorouracil and irinotecan decreased DNMT1 expression
at both transcriptional and translational levels but not oxaliplatin. Oxaliplatin
increased DNMT1 expression at mRNA and protein levels. This effect is
achieved by specifıc phosphorylation of -catenin protein. The results revealed
that use of some chemotherapeutic, particularly oxaliplatin, with spesifıc inhib-
itors (such as -catenin inhibitor) in combination led to a reduced DNMT1
expression. Our fındings may offer a new approach for determining the molec-
ular effects of -catenin signal pathway on DNMT1. This may allow us to iden-
tify new molecular targets for the treatment of colorectal cancers. However, the
results revealed that some chemotherapeutics may contribute the aberration of
DNA methylation.
#5387 Droplet digital PCR for sensitive quantifıcation of DNA methyl-
ation in non-invasive material: Development of a robust control. Heidi D.
Pharo, Kim Andresen, Marine Jeanmougin, Guro E. Lind. Institute for Cancer
Research, Oslo, Norway.
Background: Droplet digital PCR (ddPCR) is a highly sensitive method for
quantifıcation of nucleic acids, with great potential for detection of biomarkers
present in low quantities. As for DNAmethylation analyses using ddPCR, there
is no consensus on whether or not a control should be included. The aim of the
present study was to; 1) demonstrate that use of a control is essential in such
analyses, and 2) develop a robust control with better performance than the
existing alternatives. Results and methods: A 4-gene control panel was devel-
oped in our lab, and its performance compared to the existing alternativesACTB
and C-LESS-C1. This was done through analyzing the methylation level of four
target genes inDNA from34 colon cancer cell lines. All ddPCRswere performed
using the QX200™ PCR platform (BioRad). Details will be presented. Conclu-
sions: In summary, use of a control is essential for robust and consistent ddPCR
based DNAmethylation, and can prevent erroneous interpretation of technical
artifacts.
#5388 Molecular profıling of protein methyltransferases in prostate can-
cer and their clinical signifıcance. Yuanyuan Jiang, Lanxin Liu, David Wein-
feld, Wenqi Shan, Huimei Yu, Xuhui Guo, Zhe Yang, Zeng-Quan Yang.Wayne
State Univ. School of Medicine, Detroit, MI.
Prostate cancer is one of the most commonly diagnosed cancers among
men worldwide. Most deaths of prostate cancer patients occur after the
disease has progressed to castration-resistant prostate cancer, accompanied
by metastatic dissemination and resistance to androgen-deprivation ther-
apy. Therefore, an urgent need exists to identify druggable targets that will
improve the treatment of this deadly and devastating disease. Epigenetic
alteration has been identifıed as one the major causes of prostate cancer.
Protein methyltransferases (PMTs), a large class of epigenetic enzymes that
add one or more methyl groups to lysine (K) and arginine (R) residues on
histones and non-histone proteins, play critical roles in chromatin function,
transcriptional regulation, genomic stability, DNA repair and RNA metab-
olism. Although dysregulation of several PMTs has been reported in prostate
cancers, there has been no systematic analysis of genomic anomalies and
expression of PMTs in prostate cancer. In addition, the clinical relevance of
alterations of each PMT in prostate cancer has yet to be fully explored. Here,
we performed an integrated genomic and transcriptomic analysis of 68 PMT
genes in prostate cancer (TCGA dataset) and identifıed associations among
recurrent copy number alterations, gene expressions, clinicopathological
features, and survival of patients. In addition to well-known EZH2 and
WHSC1, we identifıed several additional PTMs, including SETDB1, SETD5
and PRDM12, which were signifıcantly overexpressed in high-grade and
high-stage prostate cancer. We also found that SETDB1 overexpression was
signifıcantly associated with biochemical recurrence of prostate cancer pa-
tients. To assess the contribution of endogenous SETDB1 overexpression to
prostate cancer growth and progression, we examined the effects of knock-
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ing down SETDB1 in two prostate cancer cell lines CWR22Rv1 and DU-145.
SETDB1 knockdown dramatically reduced CWR22Rv1 and DU-145 cell
growth compared with the non-silencing control. We also identifıed all
SETDB1 binding sites across the human genome in DU-145 prostate cancer
cells by using an unbiased ChIP-seq approach. In summary, our integrated
genomic and transcriptomic analysis identifıed a broad spectrum of genetic
alterations in PMT genes involved in prostate cancer progression. Our fınd-
ings suggest a promising avenue for future research—to focus on a subset of
PMTs to better understand the molecular mechanisms and to identify ther-
apeutic targets in prostate cancer.
#5389 A personalizedmedicine approach to identifying dysregulated epi-
genetic enzymeactivity in thedevelopment of castrate-resistant prostate can-
cer. Jin-Hee Lee,1 Melissa Boersma,2 Bing Yang,1 Nathan Damaschke,1 Eva Co-
rey,3 JohnDenu,1David F. Jarrard1. 1Univ. ofWisconsin-Madison,Madison,WI;
2Wisconsin Institutes for Discovery, Madison, WI; 3Univ. of Washington, Seattle,
WA.
Purpose: Recent advances in proteomic and chromatin immunoprecipi-
tation tools have been vital in studying cancer epigenetics, but the ability to
measure directly the enzyme activities of dysregulated histone-modifıers
understudied. We utilize a novel approach to identify altered histone-mod-
ifying enzymes in the progression from hormone sensitive (HS) to castrate-
resistant prostate cancer (CRPC) progression. Methods: We developed, val-
idated and utilized a high-throughput peptide microarray assay to identify
altered histone lysine (de)acetylation activity in tumor lysates. Functional
assays, novel HS and CRPC human tumor arrays and xenografts were uti-
lized to confırm these fındings. Results: This microarray-based activity assay
revealed up-regulated histone acetyltransferase (HAT) activity against spe-
cifıc histone H3 sites in a castrate-resistant (CR) PCa cell line compared to its
hormone-sensitive (HS) isogenic counterpart. NAD-dependent deacetyla-
tion assays revealed down-regulated Sirtuin activity in validated CR lines.
Levels of acetyltransferases GCN5, PCAF, CBP and p300 were unchanged
between matched HS and CR cell lines. However, auto-acetylation of p300 at
K1499, a modifıcation known to enhance HAT activity and a target of
deacetylation by SIRT2, was highly elevated in CR cells, while SIRT2 protein
level was reduced in CR cells. Interrogation of HS andmatched CR xenograft
lines reveals that H3K18 hyperacetylation, increased p300 activity, and de-
creased SIRT2 expression are associated with progression to CR in 8/12
(66%). Tissue microarray analysis revealed that hyperacetylation of H3K18
is a feature of CRPC. Inhibition of p300 results in lower H3K18ac levels and
increased expression of androgen receptor. Conclusions: This novel mi-
croarray approach provides a method to identify commonly dysregulated
chromatin enzymes during progression providing a personalized therapeu-
tic strategy to direct available drugs to target enzymes. Reduced SIRT2 ex-
pression and increased p300 activity lead to a concerted mechanism of hy-
peracetylation at specifıc histone lysine sites (H3K9, H3K14, and
H3K18).Support: DOD PCRP (Jarrard).
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#5390 BroadGenomics andCancer Programdevelopment of comprehen-
sive blood biopsy sequencing capabilities to support direct-to-patient cancer
research initiatives.Carrie Cibulskis, AndrewHollinger.Broad Institute ofMIT
and Harvard, Cambridge, MA.
Genomic profıling of cell free tumor DNA (Blood Biopsy) offers the potential
to revolutionize cancer precision medicine. As a proxy for tumor tissue profıl-
ing, successful blood biopsy analysis can help select appropriate patients for
clinical trials, provide useful data for treatment monitoring, and discover
genomicmechanisms of disease resistance. Recognizing these potential benefıts,
we aim to enable large-scale genomic data generation and analysis of cfDNA
samples to support the patient driven Metastatic Breast Cancer Project (mb-
cproject.org) and many other such efforts. The widespread adoption of cfDNA
sequencing technology in clinical research will require low cost, effıcient, and in
some cases clinically-validated processes. Commercial offerings in this fıeld are
focused on analysis of small targeted hotspot panels due to the challenges of
more complete sequencing approaches for cfDNA (e.g. variability in the fraction
of tumor present and high false positive rates). Working in collaboration with
the Broad Institute Cancer Program, we have developed a process to overcome
these challenges and provide high quality comprehensive exome analysis of
cfDNA. Our process includes screening samples using ultra low pass, UMI-
enabledwhole genome sequencing to quantify the%of tumorDNAavailable for
sequencing. Qualifıed samples are then moved into automated processes for
exome sequencing and somatic mutation detection. In our initial validation
study of 23 breast and prostate cancer patients with matched cfDNA and tumor
tissue sequencing, we are able to identify 90% of clonal and 45% of subclonal
mutations found in thematched tumor biopsy. In our effort to scale this process,
and fully characterize the benefıts and limitations of this technology we will
present additional validation analysis. We will evaluate the relative importance
of using paired sample analysis (tumors and matched normals) with analysis of
tumor sequencing alone and assess sensitivity and specifıcity of somatic altera-
tions as a function of tumor fraction and sequencing depth.
#5391 Low frequency variant detection and tissue-of-origin exploration
using liquid biopsies. Justin S. Lenhart, Ashley Wood, Sukhinder Sandhu,
Cassie Schumacher, Laurie Kurihara, Vladimir Makarov, Tim Harkins. Swift
Biosciences, Ann Arbor, MI.
The promise of liquid biopsy assays lies in the non-invasive monitoring of
diseases, such as cancer, through circulating, cell-free DNA (cfDNA) or circu-
lating tumor cell DNA. This may assist in advancing early-stage diagnosis while
simultaneously monitoring treatment response over time. Since these materials
are often limited, most liquid biopsy assays incorporate targeted sequencing to
enable cost-effective deep coverage of target loci for detection of low frequency
pathogenic variants. Yet a critical aspect in attaining the necessary sensitivity is
an assay that produces uniform, comprehensive coverage from low DNA input
quantities.We have developed a liquid biopsy workflow to enable low frequency
variant detection from a 10 mL blood draw using the Promega Maxwell RSC
combined with Swift Biosciences Accel-NGS 2S® library preparation methodol-
ogies. In addition, we explore whether methylation patterns of the extracted
cfDNA possess information of the tissue-of-origin. Whole blood samples were
collected in Streck cell-free DNA BCT vials from patients with late stage cancer
and cfDNA was extracted with the Promega Maxwell RSC. This instrument
yielded DNA outputs ranging from 8-32 ng, with a size profıle defıned by a
predominant peak of 170bp and a mean Alu repeat qPCR integrity score of
0.22, characteristic of high quality cfDNA lacking cellular DNA content. A total
of 20 ng cfDNA was used to make an Accel-NGS 2S Hyb library followed by
hybridization capture using Agilent SureSelect Human All Exon probes. The
Accel-NGS 2S Hyb Kit exhibits a 90% library conversion rate with cfDNA and
provides high complexity libraries with uniform target coverage. In addition,
molecular barcodes were incorporated to label each library molecule uniquely
prior to PCR amplifıcation. Thesemolecular barcodes were utilized for accurate
removal of PCR duplicates while simultaneously preserving naturally occurring
fragmentation and strand duplicates tomaximize data recovery. Secondly, these
barcoded molecules were grouped to generate consensus sequences after re-
moval of false positives originating from PCR and sequencing errors. Variant
calling was performed using Vardict and Lofreq enabling highly sensitive and
precise detection of variants down to a 0.5% allele frequency. In parallel, we have
developed aworkflow to determine if the epigenetic status of cfDNAcan identify
tissue-of-origin. This workflow utilizes the Accel-NGS Methyl-Seq DNA Li-
brary Kit to enable unbiased characterization from low (5 ng) cfDNA inputs.
Through whole genome bisulfıte sequencing, using a priori knowledge of differ-
entially methylated regions characteristic of different human tissues, we can
identify the predominant tissue source of cfDNA in blood.
#5392 Targeted next-generation sequencing of cell-free tumor DNA to
longitudinally monitor cancer burden and progression. Jonathan C. Irish,1
Cassie A. Schumacher,1 Navya Nair,2 Olga Camacho-Vanegas,2 Jordan Rose-
Figura,1 Ashley Wood,1 Sukhinder Sandhu,1 Sushma Chaluvadi,1 Sergey Chu-
preta,1 Laurie Kurihara,1 Timothy Harkins,1 John A. Martignetti,2 Vladimir
Makarov1. 1Swift Biosciences Inc., Ann Arbor, MI; 2The Mount Sinai Hospital,
New York, NY.
Targeted sequencing of cell-free (cfDNA) and circulating tumor DNA
(ctcDNA) from blood enables detection of cancer-relatedmutations usingmin-
imally-invasive sample collection methods, and may make early detection of
cancer possible, as well as improvemonitoring of disease burden in translational
research studies. We have developed a series of targeted panels for detection of
multiple cancer-relatedmutations. The panels are designed to effıciently amplify
damaged or short fragments of DNA derived from FFPE and cfDNA/ctcDNA,
where hundreds of primer pairs can be amplifıed in a single tube from overlap-
ping targets using only 10 ng input material, making these panels ideal for lim-
iting liquid biopsy samples. A panel which covers known “hotspot”mutations in
56 oncology-related genes has been used in a pilot research study to monitor
gynecological cancer in 11 women in a longitudinal study, which found a cor-
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relation between the presence of cancermutations andmorbidity andmortality.
In 2 of 11women, the initial absence ofmutations above 1% allele-frequencywas
followed by the appearance of mutations in 1-3 genes at allele frequencies of
5-78% in the later time point. These 2 patients experienced increased morbidity
ormortality. In 9 of the 11women, nomutations were observed, and 6 remain in
remission, while 3 are living with cancer. In an effort to further improve both
workflow and performance, we are developing two technologies to incorporate
into the panel design for future studies. The fırst will normalize library yield
during PCR amplifıcation for simple library pooling, which eliminates the re-
quirement for library quantifıcation and minimizes the time from sample to
sequence. The second technology is a molecular ID (MID) system to tag each
amplicon uniquely to allow data tracking to individual DNA fragments from the
sample, and to increase confıdence in variant calling by fıltering PCR and se-
quencing errors. By incorporating technologies that reduce steps in the work-
flow, the likelihood of error is minimized, and combined with methods that
increase confıdence in low frequency variant calling, an ideal workflow for liquid
biopsy samples is created.
#5393 BRAF mutant allele fraction in circulating tumor DNA as marker
of treatment response in BRAF mutated non malignant melanoma cancers
identifıed in the Copenhagen Prospective Personalized Oncology study. Lise
Barlebo Ahlborn, Ida Viller Tuxen, Olga Oestrup, Ane Yde Schmidt, Cecilia
Brunhoff Håkansson, Finn Celius Nielsen, Ulrik Lassen, Christina Westmose
Yde, Morten Mau-Sorensen. Rigshospitalet, Copenhagen, Denmark.
Background: BRAF inhibitors have been approved in BRAF mutated malig-
nant melanoma. However, in other BRAF mutated cancers, the effect of BRAF
inhibition has been studied less extensively. BRAFmutated non-melanoma can-
cer patients (pts) were identifıed in a prospective genomic profıling study. The
effect of targeted treatment was assessed by BRAFmutant allele fraction (AF) in
circulating tumor DNA (ctDNA) and radiological response. Methods: Pts had
tumor biopsies performed at enrolment and, if feasible, on or after treatment.
Biopsies were subjected to whole exome sequencing, RNA sequencing and SNP
array. Blood samples for ctDNA analysis were collected at baseline and longitu-
dinally during treatment. Mutant BRAF fragments were quantifıed using drop-
let digital PCR (ddPCR) or by targeted next generation sequencing (NGS). Ra-
diological response was evaluated according to RECIST 1.1. Results: Twenty-
two BRAFmutated non-melanoma cancer pts (lung n2, colorectal n14, bile
duct n4, prostate n1, pancreas n1)were identifıed out of a total of 405 (5%)
pts enrolled in the Copenhagen Prospective Personalized Oncology (CoPPO)
study. In all tumors we identifıed the BRAF V600E mutation except in one
prostate cancer pt (BRAF K601E). Fifteen pts were treated with dabrafenib/
trametinib (lung, bile duct), vemurafenib/panitumumab /- irinotecan (colo-
rectal) or vemurafenib (pancreas, prostate). Two pts were non-evaluable be-
cause one patient requested early termination and one has pending tumor
evaluation. All pts had tumor reduction, except one patient with colon cancer.
Six out of 13 (46%) pts achieved partial response (lung n2, bile duct n1,
colorectal n 3) and 7/13 (44%) had stable disease (prostate n1, bile duct n1,
colorectal n 5) as best response according to RECIST 1.1.Median progression-
free survival was 20 weeks. Eighteen pts analysed by ddPCR or NGS at baseline
had detectablemutant BRAF in the plasma obtained before initiation of therapy.
Eight of the 18 pts had ctDNA assessed during treatment and all presented with
a reduction inmutant BRAFAF corresponding to a reduction in tumor volume.
Moreover, in 5/8 pts, time of best radiological response coincided with the low-
est detectable BRAFmutant AF. Analysis of on- and post treatment biopsies and
matched ctDNA samples are pending to identify putative mechanisms of resis-
tance and will be reported at the meeting. Conclusion: Targeted therapy seems
active in BRAF mutated non-melanoma cancer pts and treatment response is
evaluable by monitoring mutant BRAF in ctDNA during therapy.
#5394 The clinical impact of multiplex ctDNA gene analysis in lung can-
cer. Smadar Geva,1 Anna Belilovski Rozenblum,1 Tal Twito,2 Addie Dvir,2 Lior
Soussan-Gutman,2 Maya Ilouze,3 Laila C. Roisman,3 Elizabeth Dudnik,3 Alona
Zer,3 Richard B. Lanman,4 Nir Peled3. 1Sackler Faculty of Medicine, Tel Aviv
University, Tel Aviv, Israel; 2Teva Pharmaceutical Industries Ltd., Israel; 3Insti-
tute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva,
Israel; 4Guardant Health, Inc., Redwood City, CA.
Background: Next-generation sequencing (NGS) of cell-free circulating tu-
mor DNA (ctDNA) enables a non-invasive option for comprehensive genomic
analysis of lung cancer patients. Currently there is insuffıcient data in regard to
the impact of ctDNA analysis on clinical decision making. In this study, we
evaluated the clinical utility of ctDNA sequencing on treatment strategy and
progression-free survival. Methods: In this retrospective study, data was col-
lected from fıles of 92 NSCLC patients monitored between the years 2014-2016
at the Thoracic Center Unit at Davidoff Cancer Center, Rabin Medical Center,
Israel. Plasma samples from stage IIIb/IV non-small cell lung cancer (NSCLC)
patients were analyzed by a commercial test (Guardant 360), using hybrid cap-
ture, single molecule barcoding and massively parallel paired-end synthesis to
sequence a targeted gene panel. This test allows the detection of somatic altera-
tions such as point mutations, indels, fusions and copy number amplifıcations.
Results: 92 consecutive NSCLC patients were included in this study.Median age
at diagnosis was 63 years, male:female ratio was 1:1.6. 40% (37/92) were never-
smokers, 84% (77/92) had adenocarcinoma. 38% (35/92) performed ctDNA
analysis before 1st line therapy and 62% (57/92) on progression. ctDNA analysis
yielded lung cancer related actionable mutations in total 39% (36/92) of the
patients; 31% (11/35) among upfront testing and 44% (25/57) among patients at
progression onmatched therapy. Treatment decisionwas taken toward targeted
therapy subsequent to NGS analysis in 23% (8/35) and 26% (15/57) respectively
(total 25%; 23/92). 53 individual actionable genomic alterationswere found. The
most common genes were sensitizing EGFR mutations (47.2%; 25/53), MET
amplifıcations and/or exon 14 skipping mutations (17%; 9/53) and resistance
EGFR mutations (13.2%; 7/53). Response assessment (RECIST) for 18 patients
with evaluable response to targeted therapy showed complete response in 6%
(1/18), partial response in 39% (7/18), stable disease in 22% (4/18) and progres-
sive disease in 33% (6/18). Total objective response rate (ORR) was 45% and
disease control rate was 67%. Conclusions: Comprehensive ctDNA testing re-
vealed possible treatment options for two-thirds of patients analyzed. ctDNA
analysis impacted clinical decisionmaking in a quarter of the patients. Although
this topic needs to be further assessed in large randomized controlled trials, these
positive results emphasize the utility of liquid biopsy analysis to guide clinicians
to select the right therapy for the right patient.
#5395 Genomic variations in plasma cell free DNA from small cell lung
cancer.Meijun Du, Hannah Fisher, Peng Zhang, Huijuan Zhang, Liang Wang.
Medical College of Wisconsin, Brookfıeld, WI.
Background: Small cell lung cancer (SCLC) is a highly aggressive malignancy
with rapid development of chemo resistance and a high rate of recurrence. Al-
though tumor tissues-based studies have shown characteristic genomic changes
in SCLC, it is little known about tumor-derived genomic variations in cell free
DNA (cfDNA), a promising source of genetic materials for monitoring disease
progression, evaluating treatment effıcacy and predicting clinical outcomes.
Methods: We collected plasma from 26 SCLC patients and extracted cfDNAs
from 250l of plasma. We prepared DNA libraries and analyzed sequencing
data using a various bioinformatic tools. We binned read counts from the
mapped sequence fıles into 60kb windows and performed log2 ratio-based copy
number analysis using segmentation-based approach.We compared copy num-
ber changes detected in cfDNA to previously reported genomic regions from
tumor tissues-based studies. Results: The whole genome sequencing generated
approximately 9.4 million mappable sequence reads per subject and 175 read
counts per 60kb genomic region. Copy number analysis using log2 ratios be-
tween cfDNA andmatched gDNA showed signifıcant genomic abnormalities in
17 of 26 plasma samples. Overall, we observed the most frequent deletion of 3p,
13q,17p,10p and amplifıcation of 3q, 5p, 8q,1p, which were consistent with pre-
vious reports from tumor tissues-based studies. To further defıne the copy num-
ber changes, we performed a detailed analysis at chromosomal regions showing
frequent aberrations in SCLC. Among these, deletion of gene RASSF1 at 3p21.3
was most frequently observed (12 deletions in 26 samples). Another common
deletion was RB1 at 13q14 (5/26), TP53 at 17p13 (4/26). The most common
amplifıcation was involved inMYC gene at 8q24(18/26). Other common ampli-
fıcations included SOX2 at 3q26 (17/26), MYCL at 1p34.2 (9/26) and FGF10 at
5p13 (9/26). We also observed low frequent genomic alterations at other
genomic regions such as PTEN loss at 10q23(1/26) and FHIT loss at 3p14 (1/26).
Interestingly, we observed contradictory genomic changes at MAD1L1 locus.
Among the 26 cfDNA samples, we detected ten patients withMAD1L1 loss and
three patients with MAD1L1 gain. Past studies have shown that the MAD1L1
locus at 7p22 is frequently ampliated in SCLC patients. We are currently ana-
lyzing if these genomic variations are associated with disease progression and
overall survival. Conclusions: This study provides a comprehensive analysis of
genomic alterations in plasma cfDNAs from SCLC.We identifıed multiple can-
didate genes whose genomic aberrations may be used as biomarkers for access-
ing treatment effıcacy and predicting prognosis. Our result supports blood
plasma as an alternative sample source for tumor-associated genomic analysis in
SCLC patients. Further targeted sequencing and clinical association analyses is
needed to fully validate the potential clinical utilities of cfDNA-based liquid
biopsy for clinical management of this deadly disease.
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#5396 An NGS workflow to detect down to 0.1% allelic frequency in
cfDNA for breast and colon cancers.DaliaDhingra,1 RichardChien,1 JianGu,2
Dumitru Brinza,1 Ruchi Chaudhary,1 Kunal Banjara,1 Yanchun Li,2 Efren Ball-
esteros-Villagrana,2 Kelli Bramlett2. 1Thermo Fisher Scientifıc, South San Fran-
cisco, CA; 2Thermo Fisher Scientifıc, Austin, TX.
Noninvasive detection of rare mutations in blood could allow tumor moni-
toring for research purposes. Research studies have suggested that cfDNA con-
tainsDNA from tumor cells with somaticmutations that could informon tumor
progression and therapeutic resistance. Here, we demonstrate a complete work-
flow froma single tube of blood through data analysis for research samples down
to a 0.1% allelic frequency. The low abundance tumor mutations found in
cfDNA requires sensitive and accurate mutation detection. We have developed
two panels that utilize an amplifıcation-based assay that generates tagged DNA
copies, which allows detection of low abundance tumor mutations found in
cfDNA. The two panels allow multiplex interrogation of primary driver and
resistance mutations specifıc to ctDNA from breast and colon cancer. The On-
comine Colon cfDNA panel targets 236 hotspots within 14 genes while the
Oncomine Breast cfDNA panel covers 157 hotspot mutations in 10 genes. This
workflow was validated frommatched single blood tubes, Streck and K2EDTA.
Additionally, the utility for cancer researchwas demonstratedwith concordance
studies using matched FFPE and plasma from oncology samples. To further
characterize these panels we have developed an oncology control for cfDNA
with nucleosome fragment sizing and minimal sonication damage. This engi-
neered control contains SNPs and indels at 0.1% allelic frequencies, orthogo-
nally confırmed with TaqMan based Rare Mutation assays. With this control,
the Oncomine Breast cfDNA panel had over 81% sensitivity and 99.9% specifıc-
ity. The Oncomine Colon cfDNA panel had over 85% sensitivity and 100%
specifıcity. The Oncomine Breast cfDNA panel and Oncomine Colon cfDNA
panel integrated into a complete workflow starting from a single tube of blood
can advance oncology research with the ability to detect blood based cancer
biomarkers present at 0.1%.
#5397 Characterizing the genomic landscape of bladder cancer with cir-
culating tumor DNA. Gillian R. Vandekerkhove,1 Tilman Todenhöfer,2 Matti
Annala,3 Werner J. Struss,1 Kevin Beja,1 Amanda Wong,1 Scott North,4 Bernie
Eigl,5 Peter Black,1 Alexander W.Wyatt1. 1Vancouver Prostate Centre, Vancou-
ver, British Columbia, Canada; 2University Hospital Tübingen, Tübingen, Ger-
many; 3Institute of Biosciences and Medical Technology, Tampere, Finland;
4Cross Cancer Institute, Edmonton, Alberta, Canada; 5British Columbia Cancer
Agency, Vancouver, British Columbia, Canada.
Background: Targeted agents are emerging as promising treatment options
for patients with metastatic bladder cancer (BCa). However, since the genomic
landscape of BCa is highly heterogeneous, future clinical trial success will likely
depend upon tumor molecular stratifıcation and therefore require a practical
method for somatic genome analysis. Circulating cell-free tumorDNA (ctDNA)
collected from peripheral blood has been established in several major solid ma-
lignancies as aminimally-invasive tool to profıle the tumor genomebut is under-
explored in BCa. Goal: Our aim was to identify the spectrum of clinically-infor-
mative genomic alterations detectable in plasma cell-free DNA (cfDNA)
collected from patients with BCa. Patient cohort and methodology: We re-
cruited 45 patients with BCa, 14 with localized disease and 31 with metastatic
disease, and collected whole blood samples for isolation of cfDNA. Isolation of
plasma cfDNAwas performed using theQIAAmpCirculatingNucleic Acid Kit,
while germline control DNA was extracted from buffy coat using the DNEasy
Kit (Qiagen).A custom targeted next-generation sequencing (NGS) strategywas
employed to detect BCa- specifıc somatic alterations in ctDNA; samples under-
went deep (500X) targetedDNA sequencing using theNimbleGen SeqCap EZ
Choice system and Illumina technology. Our custom panel included key tumor
suppressors (e.g. TP53, RB1, CDKN2A), cell cycle drivers (e.g. CCND1,
CCNE1), DNA repair genes (e.g. ATM, BAP1, ERCC2), PI3K pathway genes
(e.g. PIK3CA, PTEN, AKT1), and other oncogenes (e.g. RAS/RAF, EGFR,
ERBB2, PPARG, FGFR3). Results: The majority of patients with metastatic BCa
(18/31 patients, 24/43 samples) had robust evidence of somatic alterations and
therefore ctDNA. Our fındings were consistent with the known landscape of
BCa, including mutations in TP53 and ARID1A (and other chromatin modifı-
ers), hotspot activating mutations in PIK3CA, as well as typical copy number
changes such as focal amplifıcations of ERBB2, KRAS, and CCNE1. In addition,
we identifıed complex gene rearrangements including in one case an activating
FGFR3 gene fusion. Some samples had evidence of very high mutation rates,
indicative of somatic ’hypermutation’. Interestingly, in contrast to themetastatic
setting, 85% of patients with localized BCa had no evidence of ctDNA, despite
elevated cfDNA yields in some patients. Conclusion: The majority of metastatic
BCa patients have high levels of ctDNA suitable for standard targeted sequenc-
ing approaches, while patientswith localizedmuscle-invasive tumors appear not
to harbor ctDNA at fractions greater than 1-2%. The robust detection of so-
called ‘actionable’ copy number alterations, mutations and rearrangements in
ctDNA provides an unparalleled opportunity for practical molecular stratifıca-
tion of patients in clinical trials of novel targeted agents.
#5398 High-throughput clonal analysis of AML tumors with droplet mi-
crofluidics.Dennis Eastburn,1Maurizio Pellegrino,1 Sebastian Treusch,1 Adam
Sciambi,1 Bill Hyun,2 Jamie Yates1. 1Mission Bio, Inc., San Francisco, CA; 2Uni-
versity of California, San Francisco, San Francisco, CA.
Single cell analysis tools are crucial to better understand the role that rare or
heterogeneous cancer cells play in the evolution of tumor progression. Al-
though, it is now feasible to perform single-cell RNA-Seq on thousands of, sev-
eral challenges remain for high-throughput single-cell DNA sequencing. To
address these challenges and enable the characterization of genetic diversity in
cancer cell populations, we developed a novel approach that barcodes amplifıed
genomic DNA of individual cells confıned to microfluidic droplets. The bar-
codes are used to reassemble the genetic profıles of individual cells from next
generation sequencing data. A key feature of our approach is the “two-step”
microfluidic workflow that releases genomic DNA from cellular proteins prior
to amplifıcation. Themicrofluidic workflow fırst encapsulates individual cells in
droplets, lyses the cells and prepares the lysate for genomic DNA amplifıcation
using proteases. Following this lysate preparation step, the proteases are inacti-
vated and droplets containing the genomes of individual cells are then paired
with molecular barcodes and PCR reagents. We demonstrate that the two-step
microfluidic approach is vastly superior to workflows without the two-step pro-
cess for effıcient DNA amplifıcation on tens of thousands of individual cells per
run with high coverage uniformity and low allelic dropout of targeted genomic
regions. To apply our single-cell sequencing technology to the study of acute
myeloid leukemia (AML), we developed a targeted panel to sequence genes
frequently mutated in AML including TP53, DNMT3A, FLT3, NPM1, NRAS,
KRAS, JAK2, IDH1 and IDH2. Using this panel, we were able to identify clonal
populations fromAML research samples;moreover, the single-cell nature of our
approach enabled the correlation of multiple mutations within subclones and
determination of whether the mutations existed as as a homozygote or hetero-
zygote. Collectively, our results show a greater degree of heterogeneity in AML
tumor samples than is commonly appreciated with bulk sequencing methods.
#5399 Investigating phenotypic plasticity in breast cancer with high-
throughput nanogrid single-nucleus RNA sequencing. Ruli Gao,1 Charissa
Kim,1 Emi Sei,1 Jie Yang,1 Leo Chan,2 Maithreyan Srinivasan,2 Hong Zhang,1
FundaMeric-Bernstam,1Nicholas E. Navin1. 1University of TexasMDAnderson
Cancer Center, Houston, TX; 2WaferGen Inc., CA.
Single-cell RNA sequencing (RNA-seq) is a powerful tool for investigating
rare tumor subpopulations and resolving intra-tumor heterogeneity, but is low
throughput, expensive, and requires fresh tissue samples. To address these lim-
itations, we developed a 5= high-throughput single-nucleus RNA sequencing
(SNRS) approach that uses nanogrid technology to perform single-cell imaging
and sequencing of 500-2500 nuclei in parallel. The automated image scanning
procedure allowed us to exclude doublets and select live cells with DAPI/PI
staining. This approach allows the transcriptomic profıling of frozen tissue sam-
ples, in which the cytoplasmic membrane is ruptured in cells, but leaves the
nuclear membrane intact. We validated SNRS in a breast cancer cell line (SK-
BR-3) and compared the transcriptomes of 500 nuclei to 500 whole cells, which
revealed a high concordance in the number of genes expressed as well as their
expression levels. We also performed bulk RNA-seq of isolated nuclear and
cellular fractions from 5 breast cancer cell lines, which showed a high concor-
dance in genes and expression levels. Differentially expressed genes in the nu-
cleus mainly included lincRNAs, pseudogenes and mitochondria genes, but did
not affect most cancer genes and pathway analysis. We further applied SNRS to
sequence 500 nuclei from a triple-negative breast cancer patient and identifıed
diverse phenotypes in tumor cells, including variation in cell proliferation, mi-
gration, invasion, and epithelial-to-mesenchymal transition. These studies dem-
onstrated the technical feasibility of using a nanogrid platform to perform high-
throughput single-cell RNA sequencing and showed that nuclei from cell lines
and tumors can be used to study signaling pathways and gene networks that play
an important role in tumor progression.
#5400 Accurate identifıcation of single nucleotide variants in whole ge-
nome amplifıed single cells. Xiao Dong, Lei Zhang, Brandon Milholland,
Moonsook Lee, Alexander Y. Maslov, Tao Wang, Jan Vijg. Albert Einstein Col-
lege of Medicine, Bronx, NY.
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Single cell sequencing for analyzing DNA mutations across the genome in
somatic tissues is critically important for studying development, cancer and
aging. However, current procedures are prone to artifacts and to date a reliable
protocol for single-cell somaticmutation analysis remains to be developed.Here
we address the two largest sources of artifacts, i.e., DNA denaturation-related
cytosine deamination and allelic bias-driven whole genome amplifıcation er-
rors. We fırst reconfıgured multiple displacement amplifıcation (MDA) into an
effıcient protocol for whole genome amplifıcation of single cells without cyto-
sine deamination artifacts, i.e., Single Cell MDA (SCMDA).We then developed
a new single-cell SNV caller (SCcaller) that distinguishes real somaticmutations
and amplifıcation errors by utilizing a SNP-based localized estimate of allelic
amplifıcation bias. The procedure was validated by comparing SCMDA-ampli-
fıed single cells with unamplifıed clones derived from single cells from the same
population. Together with SCcaller, SCMDA provides a fırm foundation for
analyzing cellular heterogeneity in somatic mutational landscapes in tumor and
surrounding, normal tissues.
#5401 Assessment ofwhole genome amplifıcation forwhole exome sequenc-
ing in detecting genetic mutation.Crystal Xue, Laura Gardner, Guanglong Jiang,
Fei Shen, Bryan Schneider. Indiana Univ. Cancer Ctr., Indianapolis, IN.
Whole exome sequencing (WES) has been widely used for studying genetic
mutations in DNA coding regions to elucidate cancer etiology and for identify-
ing biomarkers to optimize chemotherapy. However, these studies can be lim-
ited when only small amount of DNA is available. Whole genome amplifıcation
(WGA) technology can be combinedwithWES tomake these studies technically
possible. Here, we evaluated WGA using a phi 29 polymerase prior to library
preparation for WES in samples with various DNA concentrations. WES was
performed by targeted exon amplifıcation followed by massively parallel se-
quencing. We compared the base calls of single nucleotide variants for individ-
ual same samples with or without WGA prior to library construction to deter-
mine the concordance rate of variant calls. We also assessed genetic variant call
rate in the same samples with or without WGA. The number of variants ob-
tained ranged from 159,851,999 to 390,784 in the non-amplifıed samples and
from 353,215 to 384,118 in the same amplifıed samples. The average concor-
dance rate of identical variants in the samples with or withoutWGAwas 96.5%.
Our results indicate thatWGA in prior toWES can increase detection effıciency
of single nucleotide variants in samples with relatively small amount of DNA
and/or low DNA concentration.
#5402 Single cell sequencing of high grade serous ovarian cancer.Timothy
K. Starr,1 BorisWinterhoff,1MakaylaMaile,2 Kenneth Beckman,2 Jerry Daniel,2
Melissa Geller,2 Martina Bazzaro,2 Molly Klein,2 Raffaele Hellweg,2 Juan Abra-
hante,2 Amit K. Mitra,2 Atilla Sebe,3 Sally A. Mullany1. 1Univ. of Minnesota
Medical School, Minneapolis, MN; 2Univ. of Minnesota, Minneapolis, MN; 3Paul
Ehrlich Institute, Langen, Germany.
We performed RNA sequencing of single cells derived from a high grade serous
ovarian cancer (HGSOC) specimen to determine the extent of heterogeneity and to
determine if itwas feasible to identify cancer stemcells or geneexpression signatures
of chemo resistance. ToperformRNAsequencingwe enzymatically digested a fresh
specimen from anHGSOCderived from the ovary. Immune cells were depleted by
flow cytometry and single cell sequencing was performed using the Fluidigm C1
chip in tandemwith IlluminaHiSeq2500 sequencing.Multiple bioinformatics tools
were used to identify subgroups and activated pathways. Immunohistochemistry
was performed on an adjacent tumor section to analyze markers of epithelium,
stroma and stem cells. We found that gene expression patterns in single cells could
beused to separate cells into stroma-like and epithelial-like groups.Gene set enrich-
ment analysis identifıedproliferative genesets (oxidativephosphorylationandMYC
targets) associated with the epithelial-like cells while epithelial-to-mesenchymal-
transition (EMT) genes associated with the stroma-like cells. Neither group was
signifıcantly associated with genesets derived from chemo-resistant cells. Using
knownmarker analysis, we could identify a small percentage of cells that expressed
ovariancancer stemcellmarkersandwecouldgroupcells into functional categories.
Using fourmolecular subtypes established from large-scale bulk sequencing studies
we show that single cells froma singlepatient areheterogeneous andeachmolecular
subtype is represented. In conclusion, we show the feasibility of performing single
cell sequencing on an epithelial ovarian cancer and reveal a heterogeneous popula-
tion of cells. Expanding these fındings to a larger cohort of patients could allow for
identifıcation of targetable sub-populations of cells that were previously undetect-
able in studies that use bulk samples to interrogate the transcriptomeandgenomeof
ovarian cancer patients.
#5403 Reproducible elevation of RNA versusDNAmutation signal in low
purity breast tumors. Jerez Te,1 Coralie Viollet,1 Xijun Zhang,1 Jatinder Singh,1
Jeffrey A. Hooke,2 Harvey B. Pollard,1 Hai Hu,3 Craig D. Shriver,2 Clifton L.
Dalgard,1 Matthew D. Wilkerson1. 1Uniformed Services University; The Ameri-
can Genome Center, Bethesda,MD; 2John P.Murtha Cancer Center;Walter Reed
NationalMilitaryMedical Center, Bethesda,MD; 3Chan Soon-Shiong Institute of
Molecular Medicine at Windber, Windber, PA.
Background:Accurate detection of somaticmutations is critical for informing
targeted therapy options. Prevalent non-cancer cell admixture complicates this
detection in breast cancer. Conventional mutation detection relies on DNA
sequencing; however in prior work, we demonstrated that combining RNA and
DNA sequencing increases mutation signal strength, or mutant allele fraction
(MAF). The ratio of RNAMAF versus DNAMAF (RNA:DNAMAF) was great-
est in low purity breast tumors. We hypothesized that this elevation is biologi-
cally driven and would be conserved in a second, distinct tissue specimen of the
same tumors. Here, we compare mutation characteristics between two tissue
blocks in a cohort of breast tumors (n 8) to evaluate possible preservation of
RNA versus DNAmutation signal throughout the tumor.Methods:We selected
four high purity and four low purity breast tumors (“Block1”) from The Cancer
Genome Atlas (TCGA) cohort and associated ABSOLUTE purity analysis. For
these tumors, we acquired a second tissue block (“Block2”) not analyzed by
TCGA, cut sections, analyzed sections by H&E stains, and extracted nucleic
acids. Whole genome DNA sequencing and mRNA sequencing was performed
for Block2 specimens using Illumina X and NextSeq 500 sequencers, respec-
tively. Somaticmutations inBlock2were detected usingUNCeqRand compared
to published UNCeqR somatic mutations from TCGA. We then evaluate MAF
characteristics in the entire TCGA breast tumor cohort (n  695). Results:
Tumor purity estimates, determined by histology and by sequencing, were re-
duced in Block2 of the low purity tumor set versus the high purity tumor set,
consistent with Block1 analysis. Molecular properties of genome-wide gene ex-
pression and somatic DNA copy number were highly similar between block-
mated specimens (p 0.01).We then identifıed expressedmutations present in
Block1 and Block2 of the same tumor and compared the MAFs on these com-
mon mutations. DNA MAF and RNA MAF were each signifıcantly correlated
between Block1 and Block2 (p 1e-12 in both cases). The average RNA:DNA
MAFwas 2.5 for the cohort, indicating that RNAmutation signal is greater than
DNA in general. In Block2 specimens, the RNA:DNA MAFs were signifıcantly
greater in the low purity tumor set than the high purity tumor set (mean 2.7
versus 2.1, p  6e-5), reflecting the same trend observed in Block1 specimens.
Analyzing the entire TCGA cohort, RNA:DNA MAF was positively correlated
with proliferation pathway gene expression (p 3e-16 ) and was greatest in the
Basal subtype versus other subtypes (p 2e-9). Conclusion: Mutant allele frac-
tion both of DNA and of RNA was conserved across breast tumor subsections.
Low purity and basal subtype breast tumors had elevated RNA:DNAMAF sup-
porting a relationship to underlying biology and identifying classes of tumors
with pronounced benefıt for DNA and RNA integrated mutation analysis.
#5404 Functional analysis of lncRNAs in pancreatic ductal adenocarci-
noma. Luis Arnes, Jiguang Wang, Zhaoqi Liu, Carlo Maurer, Lori Sussel, Ken-
neth P. Olive, Raul Rabadan. Columbia University, New York, NY.
Pancreatic ductal adenocarcinoma (PDA) is anticipated to be the second leading
cause of cancer relateddeath inwestern countries by 2030with a 5-year survival rate
of 6%. Recently, genome wide sequencing and transcriptome analysis have been
applied to identify cancer-drivingmutations andmRNAexpressionprofıles of pan-
creatic tumors. Despite a better understanding of the molecular drivers and the
signaling pathways dysregulated in PDA, this knowledge has not been able to iden-
tify novel therapeutic targets. A common limitation for the aforementioned studies
is that they have been performed in bulk samples, and they have been focused on
mutations and gene expression analysis of protein-coding genes, which represents
less than 2%of the genome. Long non-coding RNAs are emerging as essential play-
ers in the biology and progression of a variety of tumors. However, this concept has
not been extensively explored to the study of PDA. We have developed computa-
tional methods and performed experimental validation to identify functional ln-
cRNAs drivers of tumor progression in pancreatic cancer. Specifıcally, we have de-
veloped computational tools to identify lncRNAs associated with genomic traits of
PDA using genome wide high throughput data. The analysis uncovered the exis-
tence of 1741 lncRNAs thatwe termedncPDAs (non-coding PDA).Using a unique
RNA-seq dataset from 200 laser capture microdissected pancreatic tumors, we
selected those ncPDAs that are expressed specifıcally in the neoplastic epitheliumof
human pancreatic tumors. Within the top 100 ncPDAs enriched in neoplastic epi-
thelial cells, we identifıed known lncRNAs drivers in other tumor types such as
CRNDE (ncPDA4), Pvt1 (ncPDA 9), HOTAIR (ncPDA 39), Malat1 (ncPDA 68)
and Neat1 (ncPDA 71). We are currently exploring the role of several ncPDAs in
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pancreatic cancer cell lines. Loss of function studies suggest that several ncPDAs are
required for tumor progression. Our investigation will continue to unravel the role
of ncPDAs in the initiation and progression of pancreatic cancer.
#5405 Comprehensive analysis of long non-coding RNAs in human stom-
ach adenocarcinomamolecular subtypes. JianChen, Jiun-ShengChen,Keping
Xie, John R Stroehlein, Marta Davila, Xiaoping Su. UT MD Anderson Cancer
Ctr., Houston, TX.
Objective: Long non-coding RNA (lncRNA) plays key role in cell biology
including epigenetic remodeling and post-transcriptional regulation. The po-
tential roles of lncRNAs as biomarkers and therapeutic targets have been proven
in solid tumors. Molecular profıling in stomach adenocarcinoma (STAD) has
been characterized using The Cancer Genome Atlas (TCGA) database. How-
ever, there are no current lncRNA comprehensive analyses and the relationships
between patterns of molecular subtypes and the signature of lncRNA in in hu-
man stomach adenocarcinoma are unclear. Methods: (1) The Cancer Genome
Atlas (TCGA) 312 primary STAD RNA-Seq data (bam fıles) and their related
clinical data were obtained from the Cancer Genomics Hub and TCGA Data
Portal. (2) We fıltered the dataset to remove lncRNAs with low expression,
defıned as having an RPKM value1 in at least 90% of the tumor samples. (3)
We generated a correlationmatrix between lncRNAs andmRNAs by computing
the Pearson correlation coeffıcient between all pairs of signifıcant lncRNAs and
mRNAs. A matrix was constructed with entries in the ternary scale (-1, 0, 1),
where the top 1% with negative correlation was assigned -1; the top 1% with
positive correlation was assigned 1; and the others were assigned 0. The matrix
was clustered and visualized using a Euclidian distance metric and complete
linkage clustering. Results: (1) Using stringent criteria, we identifıed 1830 ex-
pressed lncRNAs in human genome in STAD. (2) Unsupervised clustering of
lncRNA expression in STAD revealed fıve robust categories: clusters C1-C5. (3)
We further performed concordance calculation between lncRNA-based cluster-
ing and other clusters identifıed in TCGA molecular, mRNA, miRNA and
SCNA subtypes, respectively. We also investigated the association of lncRNA
subclasses with distinct clinicopathological and genomic features of STAD. We
found that C2 is signifıcantly associated with MSI molecular subtype, MHL
silencing, and mRNA C2, miRNA C2, methylation C2 subtypes. Cluster C3 is
signifıcantly associated with EBV-positive molecular subtype, CDKN2A silenc-
ing and mRNA C2, miRNA C2, methylation C1 subtypes; C4 is most signifı-
cantly associated with CIN molecular subtype, p53 mutation and high SCNA,
methylation C4 subtypes; C5 is signifıcantly associated with GS molecular sub-
type, diffuse Lauren subtype, and mRNA C1, miRNA C4, methylation C1 sub-
types. Interestingly, C5 defınes themost aggressive tumorswith theworst overall
survival. Conclusions: Our study represents the fırst comprehensive analysis of
lncRNAs in STADcancers, with integrative analysis revealing that the signatures
of lncRNAs we characterize here appear to have prognostic signifıcance. The
additional association with the STADmolecular subtypes and genomic features
supports new approaches to developing biomarkers and setting the stage for a
new framework for future research in the role of lncRNAs in STAD.
#5406 Low-input transcript profıling with enhanced sensitivity using a
highly effıcient, low-bias and strand-specifıc RNA-Seq library preparation
method. Keerthana Krishnan, Erbay Yigit, Mehmet Karaca, Deyra Rodriguez,
Bradley Langhorst, Timur Shtatland, Daniela Munafo, Pingfang Liu, Lynne
Apone, Vaishnavi Panchapakesa, Karen Duggan, Christine Sumner, Christine
Rozzi, Fiona Stewart, LaurieMazzola, Joanna Bybee, Danielle Rivizzigno, Eileen
T. Dimalanta, Theodore B. Davis. New England Biolabs, Ipswich, MA.
RNA-seq has become the most popular method for transcriptome analysis
and is widely used to study gene expression, detectmutations, fusion transcripts,
alternative splicing, and post-transcriptional modifıcations. It is becoming the
method of choice to detect alterations in diseases, especially cancer, to provide
insights on the various molecular pathways perturbed by changes in the tran-
scriptome and study their implications. As RNA-seq is being adopted in molec-
ular diagnostics and biomarker identifıcations, the need for good quality, repro-
ducible library preparation methods using very low amounts of RNA input, or
precious clinical samples, is increasing. To address these challenges, we have
developed a strand-specifıc RNA-seq library preparation method that retains
information about which strand of DNA is transcribed, from as low as 5 ng total
RNA input. Strand specifıcity is important for correct annotation of genes, iden-
tifıcation of antisense transcripts with potential regulatory roles, and accurate
determination of gene expression levels in the presence of antisense transcripts.
Enhanced sensitivity to detect transcripts with even coverage across their length
offers a non-biased approach for accurate quantifıcation of transcript levels.
Methods: Enriched poly-A mRNA or ribo-depleted RNA (Universal Human
Reference RNA) was used to make libraries with our strand specifıc library
preparation method. Library quality and quantity were analyzed on an Agilent
Bioanalyzer, pooled at equimolar ratio and sequenced on Illumina’s Nextseq
500. Paired end reads were mapped to a human reference genome (hg19) using
Hisat2 and sequencing metrics were calculated using Picard’s RNA-seqMetrics
and RSeqC tools. Transcript abundance was measured using Salmon and the
Ensembl GRCh38 CDS sequences. Results: Libraries prepared with our stream-
lined method using inputs that range from 5ng to 1ug show greater than 98%
directionality at all input levels. GC content analysis, gene body coverage and
gene expression correlation are similar for all inputs tested (5ng to 1ug), even
though input amounts vary by over three orders of magnitude. These consistent
results are recapitulated with the spiked-in ERCC controls at all inputs. Conclu-
sions: Our library preparationmethod is streamlined and can be used for a wide
range of input RNAwithout any major modifıcations to the protocol, making it
an easy to follow, convenient method for RNA-seq library preparation. In addi-
tion, our method has increased sensitivity and specifıcity, especially for low-
abundance transcripts, reduced PCR duplicates and sequence bias, delivering
high quality strand-specifıc data even for low input RNA. Finally, our method is
compatible with both poly A-tail enriched and ribosomal RNA depleted sam-
ples, and is amenable to large-scale library construction and automation.
#5407 Integrated analysis of genome-wide microRNA and mRNA profıl-
ing reveals unregulated miR-125b associated with poor prognosis by reduc-
ing cell apoptosis in gastric cancer. Ben Liu,1 Da Yang,2 Fengju Song,1 Xining
Zhang,1 Yan Guo,1 Yanrui Zhao,1 Hong Zheng,1 Wei Zhang,3 Kexin Chen1.
1TianjinMedical University Cancer Institute andHospital, Tianjin, China; 2Uni-
versity of Texas MD Anderson Cancer Center Informatics Center, TX; 3Compre-
hensive Cancer Center of Wake Forest Baptist Medical Center, Winston Salem,
NC.
Background & Aims: In our prior study, an integrated analysis of microRNA
and mRNA profıling of gastric cancer (GC) revealed a mRNA-regulatory net-
work. It defıned a GCmicroRNA subtype that was associated with poor survival
in 90 GC cases. In this study, we further demonstrate that miR-125b, a key node
in this microRNA regulatory network, is upregulated in GC and associated with
poor overall survival by interfering in the apoptosis pathway. Methods: To fur-
ther investigate the role of miR-125b in GC, we conducted both an in vitro
experiment and clinical study (cohort of 373GC samples).miR-125b and targets
in the network were validated through RT-PCR and tissuemicroarray GC cases.
The miR-125b targeted gene and related pathway were identifıed by a gene
expression profıle analysis in miR-125b transfected GC cell lines. The Annexin
V-FITC and TUNEL assay were used to assess apoptosis. MTT and flow cytom-
etry were performed to detect the effect of miR-125b on proliferation and cell
cycle. Thewoundhealing test and transwell assaywere used to analyzemigration
and invasion. Results: The markly upregulated expression of miR-125b was
validated in 373 GC samples.. Univariate andmultivariate analyses fınd that the
miR-125b was associated with poor prognosis (p0. 011). Pathway analysis
shows that the predicted targets of miR-125b are highly involved in apoptosis/
program death pathway. The robust apoptosis genes, BIK and CASP6 are vali-
dated as the directed targets of miR-125b. miR-125b can suppress apoptosis and
increas cell growth, migration and invasion in GC cell lines. Furthermore, low
expression of BIK (p0. 034) andCASP6 (p0.048) inGCwere associated with
poor disease-free survival. Conclusions: The apoptosis pathway was found to be
dominant in the pathway construction based on target genes of miR-125b. Our
fındings suggest thatmiR-125b-regulated apoptosis pathway is important toGC
progression and that the miR-125 may be an important clinical biomarker for
GC survival and possible therapeutic target for GC treatment.
#5408 RNA fusion detection in thyroid nodules with a targeted RNA se-
quencing panel. Song Tian,1 Michelle Baird,1 Frank Reinecke,2 Jixin Deng,1
Mohammad Nezami Ranjbar,1 Raed Samara,1 Eric Lader1. 1QIAGEN Sciences
Inc., Frederick, MD; 2QIAGEN GmbH, Hilden, Germany.
Thyroid nodules are quite common and detected in as high as 67% of the
population. Only a small portion of thyroid nodules are malignant thyroid can-
cers. Advances in understanding the molecular pathology of thyroid cancer are
leading to the development of better biomarkers and novel targeted therapies.
The tumorigenic role of RNA fusions has been reported in many forms of can-
cer. Fusions can result from structural rearrangements like translocations and
deletions, transcription read-through of neighboring genes, or the trans- and
cis-splicing of pre-mRNAs. Many fusions act as key drivers for cancer develop-
ment. Detection of fusion RNA is a challenge with traditional technologies like
FISH and qPCR, as they are laborious, low throughput, and do not provide
detailed information about the fusion. Here we explored the possible use of a
tumor fusion-targeted RNA-based panel (QIAseq targeted RNAscan panel,
which is targeting 223 fusion gene pairs, 576 unique fusions) as a tool to study
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: Genomic Analyses of Circulating Tumor Material and RNA
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171384
fusions in thyroid nodules. The presence of these fusions were surveyed in RNA
samples from 10 thyroid cancer (PTC and FVPTC) samples and 19 non-cancer
control samples (NH and FA) using this oncology targeted panel and sequenced
on the Illumina NextSeq. PAX8-PPARG, a fusion gene with a well-established
link to thyroid cancer, was found in the cancer group. In addition, we observed
a universal expression of a recurrent read-through transcript,HALC1-COQL, in
all thyroid nodules. Our results suggest that a targeted RNA-based panel pro-
vided a useful tool for fusion gene study in thyroid cancer. The role of the
expected rearrangement and the unexpected read-through fusion in thyroid
nodules needs to be further evaluated, as it could provide useful information for
thyroid nodule differentiation.
#5409 Assessment of the MammaPrint 70-gene profıle using RNA se-
quencing technology. LorenzaMittempergher,1 Jacob B. Spangler,2 Mireille H.
Snel,1 Leonie J. Delahaye,1 Iris de Rink,3 Sun Tian,1 Annuska M. Glas,1 Rene
Bernards1. 1Agendia NV, Amsterdam, Netherlands; 2Agendia NV, Irvine, CA;
3Netherlands Cancer Institute, Amsterdam, Netherlands.
Introduction: Improvements in RNA processing have enabled microarray
diagnostics for formalin-fıxed, paraffın-embedded (FFPE) tissue. Recently,
MammaPrint, a prognostic 70-gene profıle for early-stage breast cancer, was
successfully translated to FFPE tissue showing to be substantially equivalent to
fresh tissue. In recent years, RNA-sequencing (RNA-Seq) became the standard
method for transcriptome analysis, because of its low background signal and its
ability of quantifying a large dynamic range of expression levels. Here we report
a preliminary analysis of the FFPEMammaPrint 70-gene profıle using RNA-Seq
technology and the comparison with the MammaPrint® microarray diagnostic
test in a series of FFPE samples. Methods: RNA-Seq was carried out using a
strand-specifıc RNA library preparation followed by target enrichment of the
coding region of the human transcriptome without relying on the presence of
poly-A tail. RNA sequencing libraries were prepared starting from a minimal
amount of 20 ng of total RNAbased on theDV200metric assessment. The library
pools were single-end sequenced on the Illumina HiSeq 2500 instrument at the
length of 65bp. The resulting sequences were mapped to the human reference
genome (build 38) using TopHat v2.1. Tophat was guided by using a transcrip-
tome index from Ensembl (version 77). The HTSeq-count tool was used to
generate the total number of uniquelymapped reads for each gene. Gene expres-
sions were normalized with Count Per Million (CPM) normalization and log2
transformed afterwards. Microarray data of the sample were available for anal-
ysis comparison. Results: On average, we obtained 22 million reads assigned to
gene per sample (min15M, max28M). The number of reads assigned to
genes vary from 61% to 70% of the total number of reads. Between 80% and 90%
of the reads assigned to genes mapped to protein coding genes which is compa-
rable to fresh frozenmaterial. The 70-gene signature was successfullymapped to
the RNA-Seq genes. A median raw read-count of 384 was observed for the
70-gene profıle among the samples. Importantly, we observed a high concor-
dance (R2 Pearson correlation0.97) between the MammaPrint index calcu-
lated using the RNA-Seq data and the correspondent Microarray MammaPrint
index. Additionally, the BluePrint profıle, a microarray diagnostic test for breast
cancer molecular subtyping, was successfully translated to the RNA-Seq plat-
form. As with the MammaPrint profıle, BluePrint showed high concordance
between the two technologies with high correlation values for each of the sub-
types (Luminal R2 Pearson correlation0.98, Basal R2 Pearson correla-
tion0.97, HER2 R2 Pearson correlation0.77). Conclusions: Next Generation
RNA-sequencing is a feasible technology to assess diagnostic signatures, such as
the 70 gene MammaPrint and BluePrint profıles.
#5410 Optimization and evaluation of SMART-Seq v4 kit for low input
RNA sequencing. Dan Su, Thomas Halsey, Martin Buchkovich, Jason G. Pow-
ers, Steven Abbott, Jenny Shu, John Pufky, Michell Chang, Victor Weigman,
Patrick Hurban. Q2 Solutions- EA Genomics, Morrisville, NC.
Recent advances in library preparation methodology from limiting amounts
of total RNA have facilitated the characterization of rare cell-types in various
biological systems. The SMART-Seq v4 Ultra Low Input RNA Kit incorporates
a number of workflow improvements, including fewer purifıcations to increase
yield, a locked nucleic acid (LNA) template-switching oligo to enhance stability,
and an improved polymerase designed to reduce amplifıcation bias of GC-rich
regions. Certain workflow challenges remain however, including variability in
library insert size, which can lead to less predictable sequencing results.We have
modifıed the SMART-Seq v4 method to incorporate library size selection be-
tween 250-650 bp, and have characterized analytical performance of the modi-
fıed procedure. A total of 63 libraries were generated using 10 pg - 10 ng of
Universal Human Reference RNA (UHRR), Human Brain Reference RNA
(HBRR), and total RNA isolated from multiple human tissues, including lung,
colon, spleen, adrenal tumor, heart, and lung tumor. To facilitate the compari-
son between libraries, we normalized library read counts by down-sampling to
24 million reads prior to further processing with an internally-developed se-
quence analysis pipeline (RNAv9_rsem). The values for ERCC Limit of Detec-
tion ranged between 3-50 copies with a mean of 22 copies, which confırmed the
high absolute sensitivity of SMART-seq v4 workflow. The total number of genes
detected (RPKM, or reads per kilobase per million mapped 3) varied as a
function of the amount of input RNA, with as many as 19,500 genes detected.
Gene detection was highly consistent across replicates utilizing 100 pg-10 ng
input RNA, with a precipitous decline in genes detected using 10 pg of RNA
input. This is due to less reliable detection of low abundance genes, which in turn
leads to increased discordance in detected genes between replicates, possibly due
to increased sampling error. Nonetheless, when genes are commonly detected,
their normalized read counts are highly correlated at any given RNA input, with
correlation coeffıcients (r) ranging from 0.977 to 0.993. Compared to previous
versions of the SMARTer method, the modifıed SMART-Seq v4 procedure im-
plemented at Q2 Solutions - EA Genomics signifıcantly improved the percent-
age of reads aligned to the transcriptome, as well as the total number of genes
detected, all with reduced technical variability. Our study demonstrates an im-
proved strategy for expression profıling via RNA sequencing from limiting
amounts of RNA.
#5411 Demonstrated improvements in tumor profıling with enzymatic
ribosomal RNA depletion and streamlined RNA-sequencing library prepa-
ration.Nancy H. Nabilsi,1 Drew Cheney,1 Leendert Cloete,2 Ida van Jaarsveld,2
Rachel Kasinskas,1 Jennifer Pavlica1. 1Roche Diagnostics, Wilmington, MA;
2Roche Sequencing Solutions, Salt River, Cape Town, South Africa.
High resolution RNA analysis using next-generation sequencing (RNA-seq)
is a rapidly growing application in cancer research. Formalin-fıxed paraffın-
embedded (FFPE) tissue is a ubiquitous resource for clinical studies. However,
the ability to generate high quality libraries is confounded by the low quality and
yield of RNA extracted fromFFPE specimen. To enable optimal interrogation of
such a clinically-relevant tissue resource, it is critical to identify RNA-seq library
construction workflows that improve performance using challenging and de-
graded sample types. In this study, the effects of RNA type, quality, and quantity
on RNA-seq library construction are assessed, and expectations regarding se-
quencing data quality are addressed. Included are recommendations for quality
control measures and input-specifıc modifıcations that may improve perfor-
mance Three workflows employing either bead-based or enzymatic strategies
for the removal of ribosomal RNA content were used to prepare RNA-seq li-
braries from degraded paired breast normal and tumor samples. Enzymatic
depletion followed by library preparation using the KAPA RNA HyperPrep1
workflow identifıed the highest number of transcripts for each sample, translat-
ing to a 4.9-fold increase in number of differentially expressed transcripts de-
tected between normal and tumor samples. Of the transcripts identifıed as dif-
ferentially expressed exclusively byKapa, 174 are protein-codingRNAs,many of
which are frequently dysregulated in breast cancer. In contrast, only two pro-
tein-coding RNAs were identifıed exclusively by the alternative workflows. Re-
alTime Ready Custom panels were used for independent quantitative rt-PCR
assessment. Of a subset of 71 transcripts identifıed exclusively by Kapa, up to 69
(97%) were validated as differentially expressed. Additional performance im-
provements of the KAPA RNA HyperPrep workflow include coverage balance
across transcripts, lower duplication rate, technical replicate reproducibility,
agreement across input quantities, and gene expression concordance between
paired fresh frozen and FFPE samples. 1For Research Use Only. Not for use in
diagnostic procedures.
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#5412 Expression and inhibition of monocarboxylate transporters in ca-
nine osteosarcoma.Heather L. Gardner,1 JoelleM. Fenger,1 Vincent P. Sandan-
ayaka,2 Cheryl A. London3. 1The Ohio State University, Columbus, OH; 2Niro-
gyone Therapeutics, Worcester, MA; 3Tufts Medical Center, Boston, MA.
Background: A distinguishing feature of cancer cells is their ability to undergo
aerobic glycolysis, even in the presence of oxygen. This process generates lactic
acid, whichmust be removed from the cell in order tomaintain proliferation and
survival. Monocarboxylate transporters (MCTs) move lactic acid across the
plasma membrane, providing a mechanism for tumor cells to meet their bioen-
ergetic needs during glycolysis in a variety of limiting microenvironments. The
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objective of this work is to determine the biologic effects of modulating cellular
metabolism through inhibition of MCT1 and MCT4 in canine osteosarcoma
(OS), a well-established spontaneous large animal model of the human disease.
Methods: MCT1 and MCT4 expression was assessed in canine OS cell lines
using qRT-PCR and western blotting. Immunohistochemistry and qRT-PCR
were performed to determine relative MCT1 and MCT4 expression in primary
canine OS tissues. The effects of small molecule inhibitors (NGY066 and
NGY008) and shRNA approaches targeting MCT1 and MCT4 on proliferation
and survival of canine OS were examined using the CyQUANT Cell Prolifera-
tion and Caspase-3/7 assays, respectively. The impact of MCT1/4 inhibition on
cellular oxygen consumption was evaluated using the Seahorse Cell Mito Stress
Test. Lastly, potential synergistic effects of combining metformin and doxoru-
bicin withMCT1/4 inhibition in canine OS cell lines were investigated using the
CyQUANT Assay. Results: We found that while both MCT1 and MCT4 are
expressed in canine OS lines and tissues, MCT1 is expressed at higher levels
relative to MCT4 in the cell lines. Small molecule inhibitors directed against
MCT1 and MCT4 did not signifıcantly inhibit cell proliferation or induce apo-
ptosis even in the presence of limiting cell culture conditions. Maximal respira-
tory capacity was not increased in canine OS cell lines following inhibition of
MCT1 andMCT4 function. However, synergistic anti-proliferative activity was
observed when OS cells were treated with doxorubicin or metformin in the
presence of MCT1 and MCT4 inhibitors. Conclusions: MCT1 and MCT4 are
expressed in canine OS, and therefore represent a good model to evaluate the
therapeutic potential of manipulating lactic acid transport. Importantly, drug
combinations with synergistic activity may be necessary to realize the full po-
tential of MCT1/4 inhibition.
#5413 Multiplexed phosphoprotein cell signaling analysis inmultiplemy-
eloma reveals a pro-survival pathway elicited by amino-acid starvation.Ales-
sandraRomano,1 FlorianaCremasco,1 Antonella Chiechi,2 Francesca Paradiso,1
Enrico Milan,1 Francesca Fontana,1 Jose M. Manteiga,1 Francesco Di Rai-
mondo,3 Alexander I. Spira,4 Amy Van Meter,2 Emanuel Chip Petricoin,2 Vir-
ginia Espina,2 Lance A. Liotta,2 Simone Cenci1. 1San Raffaele Scientifıc Institute,
Milano, Italy; 2George Mason University, Manassas, VA; 3University of Catania,
Catania, Italy; 4Fairfax Northern Virginia Hematology &Oncology, Fairfax, VA.
Background: Substantial advances in our understanding of the biology of the
incurable plasma cell (PC) malignancy multiple myeloma (MM) came from the
study of the bone marrow (BM) microenvironment (BMME). Our previous
work disclosed an essential role for autophagy in sustaining MM cell prolifera-
tion and survival. However, the control exerted on PC autophagy by the BMME
and its pathophysiological signifıcance are virtually unknown. Experimental
design: We integrated ex vivo multiplexed phosphoprotein cell signaling analy-
ses of primary MM and BMME cells, metabolomic profıling of patient-derived
BM and peripheral plasma, and in vitro studies on human MM cell lines. Pri-
mary CD138MM and BMME CD138- cells were isolated from BM aspirates
obtained from 35 clinically characterized MM patients and 60 proteins - repre-
sentative of autophagy, cell survival, proliferation, protein degradation and
translation pathways - were analyzed by Reverse Phase Protein Arrays (RPPA).
Comprehensive metabolomics profıling was achieved by ultra-high perfor-
mance liquid and gas chromatography followed by mass spectrometry (UH-
PLC/GC-MS) on ad hoc-collected B and peripheral plasma samples from pa-
tients at different disease stages (30 MGUS, 17 smoldering MM, 16 MM) and
age-matched healthy donors (29). For in vitro studies, human MM lines were
exposed to amino acid (AA) depletion and selected responses evaluated by
quantitative RT-PCR and immunoblotting analyses. Results: First, RPPA re-
vealed that patients with the most aggressive clinical presentation (refractori-
ness, short time to progression and active bone disease) displayed higher activity
of the PI3K/AKT/mTOR pathway associated to higher expression of the au-
tophagic proteinsATG5, LC3B andp62. In search for extrinsic stimuli capable of
raising both mTOR and autophagic activity, we recapitulated such expression
pattern in MM cells through selective starvation of tryptophan (Trp) and argi-
nine (Arg), twoAA endowedwith distinctive immune regulatory activity.When
exposed toTrp-free orArg-freemedium, humanMMcell lines activatedGCN2-
mediated responses, increasing mTOR, p-S6RP, CHOP, p62 and Blimp-1 and
immunoglobulin secretion; conversely, stable lentiviral p62 silencing reduced
Blimp-1 and caused the in vitro extinction of MM cell lines within 10 days of
culture. UHPLC/GC-MS metabolomics analysis of plasma samples revealed a
progressively and signifıcantly lower concentration of Trp and Arg associated
with disease evolution and shorter progression-free survival. Conclusion: Taken
together, our fındings disclose a novel extrinsic circuit whereby reduced concen-
tration of the essential immunoregulatory AA Trp and Arg sustains PC cell
fıtness and survival. Attesting to pathophysiologic relevance, this mechanism
appears coopted by MM as a component of its vicious BMME.
#5414 Kaiso influences the exosome profıle required to induce cell prolif-
eration, migration and metabolism in breast cancer. Md Shakir U. Ahmed,1
Shweta Triphati,1 William E. Grizzle,2 Honghe Wang,1 Clayton C. Yates1.
1Tuskegee University, Tuskegee, AL; 2University of Alabama at Birmingham, Bir-
mingham, AL.
Purpose: Breast cancer is the most frequent tumor in women, afflicting Afri-
canAmerican (AA) females to a greater degree thanCaucasians (CAs). Recently,
we and others have found that Kaiso expression is elevated in AA patients rela-
tive to CA patients, and its expression correlates with tumor recurrence and
metastasis. Exosomes are considered important modulators of cellular behavior
through their cellular communication by transferringmRNA,microRNAs, pro-
teins among cells. Here, we study the role of Kaiso on the biological function of
breast cancer exosomes. Experimental procedures: Exosomes were isolated by
ultracentrifugationmethod and characterized by antibody array.We performed
exosome internalization assay, cell proliferation assay andmigration assay. Cel-
lularmetabolic activity wasmeasured by Seahorse Analyzer. Exosome proteom-
ics was performed by LC-MS/MS and analyzed quantitatively by Panther and
DAVID bioinformatics resources. Results: Isolated exosomes were effectively
internalized by MCF7 cells. MCF7 cells treated with exosomes of Kaiso-knock-
downed MDA-MB-231 cells (sh-Kaiso) showed a decreased proliferation as
compared to exosomes of Kaiso-scrambled MDA-MB-231 cells (sh-Scr). We
further observed that treatment of MCF7 cells with sh-Kaiso exosomes de-
creased cell migration when compared to sh-Scr. To determine the proteins
responsible for this observation, we performed exosome proteomics profıling.
Exosomes released from sh-Kaiso compared to sh-Scr cells showed differential
enrichment of protein expression. In sh-Kaiso exosomes, 36 proteins were
down-regulated and most of these proteins are involved in cell invasion and
metastasis; whereas 172 proteinswere up-regulated in sh-Kaiso ofwhichmost of
them are involved in protein folding, protein complex assembly, biogenesis and
repair. In proteomics data, lactate dehydrogenases (LDH) A&B which are met-
abolically important proteins and are involved in the critical step of inter-con-
version of lactate to pyruvate, expressed differentially between sh-SCR and sh-
kaiso. Furthermore, using Seahorse Analyzer we determined enhanced oxygen
consumption rate, an indicator of oxidative phosphorylation and elevated ex-
tracellular acidifıcation rate, an indicator of enhanced metabolism; in sh-SCR
exosome treated MCF7 cells as compared to sh-Kaiso exosome treated MCF7
cells. Conclusions: Our fındings demonstrate that Kaiso plays an important role
in the content of exosome cargo, which in turn has an effect promoting cell
growth, migration and metabolism of breast cancer cells. We suggest that Kaiso
has defıned role in limiting important cellular information in breast cancer
exosome cargo.
#5415 Targeted depletion of polo-like kinase 1 altersmetabolic regulation
in melanoma. Rosie E. Gutteridge, Chandra K. Singh, Mary A. Ndiaye, Nihal
Ahmad. University of Wisconsin-Madison, Madison, WI.
Polo-like kinase 1 (PLK1), a critical regulator of mitosis, is shown to be over-
expressed in a variety of cancers. PLK1 overexpression has also been linked to
poor disease prognosis and a lessened survival in cancer patients. Previously, we
have shown that PLK1 is overexpressed in human melanoma and its inhibition
causes signifıcant anti-proliferative response in vitro (in multiple melanoma
cells) as well as in vivo (in human melanoma xenografts). Further, in another
study we demonstrated, based on a large-scale label-free comparative proteom-
ics analysis, that PLK1 inhibition via the small-molecule inhibitor BI 6727 (Vo-
lasertib) in human melanoma cells resulted in an alteration of certain metabo-
lism-associated proteins with an associated decrease in cellular metabolism. In
this study, to further explore the association between PLK1 and cellular metab-
olism, we utilized a doxycycline-inducible PLK1 knockdown approach in A375
melanoma cells coupled with a Human Glucose Metabolism PCR array that
covers 84 key genes involved in the regulation and enzymatic pathways of glu-
cose and glycogen metabolism. We found that PLK1 knockdown resulted in a
signifıcant downregulation of 29 genes and upregulation of 3 genes (more than
2 fold change) associatedwith cellularmetabolism. IDH1, PDP2 and PCK1were
3-fold downregulatedwhile FBP1was7-fold upregulated. Through Ingenu-
ity Pathway Analysis (IPA), we identifıed glycolysis and the pentose phosphate
pathway as major canonical pathways altered by PLK1 inhibition. Further, IPA
identifıed that PLK1 inhibition-modulated genes were largely associated with
the proliferation of cells, where FBP1 appeared as a key regulatory player. PCK1
was found to be highly downregulated in our array, and IPA identifıed it as part
of a monosaccharide regulation network. We further validated our data in vivo
and found that BI 6727 treatment resulted in a decrease in PCK1 and increase in
FBP1 in A375 melanoma cell implanted xenografts. In addition, we observed a
strong inverse correlation between PLK1 and FBP1 in multiple melanoma cell
lines, with FBP1 expression signifıcantly downregulated in a panel of melanoma
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cells compared to normalmelanocytes.Moreover, BI 6727 treatment resulted in
an upregulation in FBP1 in A375, Hs 294T and G361 melanoma cells. Interest-
ingly, in recent studies, FBP1 (fructose-bisphosphatase) that is a rate-limiting
enzyme in gluconeogenesis, has been shown to function as a tumor suppressor
in certain cancers. Overall, our study support the hypothesis that PLK1 is a
regulator of metabolism maintenance that affects the melanoma cell growth.
#5416 Downregulation of PRMT6 promotes the Warburg effect in hepa-
tocellular carcinoma via PKM2. Tin LokWong, Lok Hei Chan, Stephanie Ma.
The University of Hong Kong, Hong Kong, Hong Kong.
Hepatocellular carcinoma (HCC) is one of the top ranked causes of cancer
death in the world, accounting formore than 740,000 deaths in 2012. Treatment
of HCC is hindered by recurrence and resistance to chemotherapy. Altered
metabolism in cancer has been linked to increased tumorigenicity and resistance
to chemotherapeutics. One of the main features of altered metabolism is the
Warburg effect, which is widely observed in solid tumor including HCC. Re-
cently, our group have identifıed protein argininemethyltransferase 6 (PRMT6)
as a tumor suppressor protein in HCC. Protein arginine methylation is a post-
translational modifıcation implicated in a variety of cellular functions including
signaling and regulation of gene expression.Downregulation of PRMT6 expres-
sion was observed inHCCpatients and knockdown of PRMT6 inHCC cell lines
increased the tumorigenicity and sensitivity to both chemo- and molecular-
targeted therapies. Other members of the Type 1 PRMT protein has previously
been reported to be involved in glucose metabolism. Microarray profıling of
HCC cells stably knockdown and overexpressed of PRMT6 showed enrichment
of genes in glycolysis. We therefore hypothesize that reduced expression of
PRMT6 in HCC drives the Warburg effect to support cancer progression.
Metabolome profıling of HCC cells stably knockdown and overexpressed of
PRMT6 showed enrichment of metabolites in glycolysis. Using Seahorse Extra-
cellular Flux Analyzer, we show that stable knockdown of PRMT6 in HCC cell
line drives glycolysis. This enhanced glycolysis rate is coupled with increased
uptake of glucose, lactate production and pyruvate kinase activity. mRNA ex-
pression level of several glycolysis-related geneswas screened by real-time quan-
titative PCR and we identifıed PKM2, a well-known regulator of the Warburg
effect, as a potential link between PRMT6 and enhanced glycolysis. Knockdown
of PRMT6 leads to an increase in mRNA and protein expression level of PKM2,
but not PKM1 and PKLR, suggesting that PKM2 is the sole contributor for
enhanced pyruvate kinase activity. In addition, by immunofluorescence stain-
ing, PKM2 is shown to accumulate in the nucleus following PRMT6 knock-
down,where it has been shown to drive the expression of other glycolysis-related
genes. In conclusion, PRMT6 regulates the expression level PKM2 and glycoly-
sis of HCC cell. Ongoing studies are in progress to delineate the underlying
mechanisms by which PRMT6 regulates PKM2 to drive Warburg effect.
#5417 The tumor suppressor klotho: Amaster regulator ofmetabolism in
breast cancer. Tami Rubinek, Ido Wolf. Tel Aviv Medical Center, Tel Aviv,
Israel.
One of the hallmarks of cancer is reprogramming of energy metabolism,
characterized by a shift to aerobic glycolysis (Warburg effect). Amajor regulator
of this phenomenon is the IGF-1/Pi3K/AKT pathway. Klotho is a transmem-
brane protein, which can be cleaved, shed and act as a circulating hormone.
Klotho-defıcient mice manifest a syndrome resembling accelerated aging, while
klotho overexpression extends life span. Klotho is a potent tumor suppressor in
BC. As klotho is a potent inhibitor of the IGF-1/Pi3K/AKT pathway in BC, we
hypothesized that it may revert the metabolic switch in BC cells. We fırst ana-
lyzed the effect of klotho on the energy sensor enzyme AMP-activated kinase
(AMPK) and its down-stream effector acetyl CoA carboxylase (ACC). Overex-
pression of klotho, or treatment with the soluble protein, elevated AMPK and
ACC phosphorylation in three BC cell lines. AMPK is activated by the tumor
suppressor liver kinase B1 (LKB1) and elevatedAMP/ATP ratio. Expression of a
dominant negative LKB1 prevented activation of AMPK by klotho and de-
creased the ability of klotho to inhibit cell growth and migration, implying that
klotho tumor suppressor activities are LKB1 dependent. We next analyzed the
effects of klotho on critical components of glucose metabolism. Treatment with
soluble klotho reduced expression of the glucose transporterGLUT1 and the key
glycolytic enzymes hexokinase2 (HK2), phosphofructokinase1 (PFK1), pyru-
vate kinaseM2 (PKM2) and pyruvate dehydrogenase kinase 1(PDK1).Using the
Seahorse analyzer we noted reduced oxidative mitochondrial metabolism and
glycolysis following klotho treatment. Energy is obtained essentially in the mi-
tochondria with the transfer of protons across the inner membrane that pro-
duces ATP. We, therefore, analyzed klotho effect on the mitochondria mem-
brane potential and noted reduction in the mitochondria potential following
treatment with klotho. Finally, we examined the effects of klotho on specifıc
metabolites and also conducted an NMR-based metabolic profıling. In accor-
dancewith the alterations in signaling pathways and levels of glycolytic enzymes,
klotho reduced glucose uptake and inhibited lactate, pyruvate and 3-hydroxy-
butyrate production. Furthermore, klotho also inhibited ATP production.
Taken together, our data indicate klotho as a regulator of metabolic activity in
BC and suggest that reversal of the metabolic switch is a key mechanism of
klotho-mediated tumor suppressor activities.
#5418 Deciphering the dynamics of alternative pre-mRNA processing of
glutaminase in metastatic ovarian cancer. Chioniso P. Masamha, Patrick La-
Fontaine, Bettine E. Gibbs. Butler University, Indianapolis, IN.
The chronically proliferative cancer phenotype requires metabolic repro-
gramming to meet the increased energy and biosynthetic demands of rapid cell
division. This results in increased glucose uptake and usage (the Warburg ef-
fect). Cancer cells that undergo the Warburg effect may also become reliant on
glutamine, a term called ’glutamine addiction’. Recent studies in ovarian cancer
suggest that highly invasive ovarian cancer cells show a remarkable dependence
on glutamine, hence implicating glutamine metabolism in metastasis. Glutam-
inase is the fırst enzyme that is involved in glutaminolysis and it catalyzes the
rate-limiting conversion of glutamine to glutamate and ammonia. There are two
genes that code for glutaminase in the human genome, glutaminase 1 (GLS1),
and glutaminase 2 (GLS2). GLS2 is associated with cell differentiation whereas
GLS1 expression is up-regulated in cancer. Hence, GLS1 had been proposed to
be better adapted to meet the altered metabolic needs of the tumor phenotype.
GLS1 can be alternatively spliced into two isoforms, KGA and GAC. Although
bothKGAandGAChave been implicated in cancer cellmetabolism, there is still
controversy over the actual isoform that is most important for tumorigenesis.
Whereas the KGA isoform is repressed by miR-23, there is no documented
miRNA repression of GAC suggesting that GAC is more tumorigenic. Using
next-generation sequencing, we recently identifıed an unannotated novel KGA
transcript with a truncated 3= untranslated region (3=UTR) which is more stable
than the traditionally known KGA transcript. Our goal is to determine the ex-
pression profıle of different glutaminase isoforms in the highly lethal gyneco-
logical malignancy, ovarian cancer, and their role in tumorigenesis and metas-
tasis.We have developed amplicons tomeasure total GLS1 andGLS2 transcripts
using quantitative real time PCR (qRT-PCR). Although we unexpectedly de-
tected both GLS2 and GLS1 transcripts, the mRNA levels of GLS2 were signifı-
cantly lower than those of GLS1. To determine the specifıc GLS1 isoforms ex-
pressed we used isoform specifıc amplicons and detected both GAC and KGA
using qRT-PCR. Western blot analysis was able to detect both GAC and KGA
protein in one cell line only suggesting that the KGA mRNA we detected was
subject to miR-23 repression. Inhibition of total GLS1 activity with a glutami-
nase inhibitor resulted in decreased colony formation as shown by soft agar
assays. In conclusion, the expression profıle of different GLS1 isoforms in highly
invasive ovarian cancer supports the role of glutaminemetabolism inmaintain-
ing the metastatic phenotype. This makes glutamine metabolism a viable thera-
peutic target for metastatic ovarian cancer.
#5419 The relationship between glutamatergic signaling and altered glu-
tamine metabolism in melanoma. Raj Shah, Andrew Boreland, Suzie Chen.
Rutgers University, Piscataway, NJ.
Aberrant glutamatergic signaling has been implicated in many cancer types,
and is associated with dysregulated growth leading to cellular transformation
and tumorigenesis. Our laboratory has previously illustrated the oncogenic
properties of a neuronal receptor,metabotropic glutamate receptor 1 (GRM1) in
melanocytes. Glutamate is the natural ligand of GRM1 and the major excitatory
neurotransmitter in the central nervous system. Our group has demonstrated
that glutamate production/release is upregulated in GRM1 expressing mela-
noma cells, resulting in constitutive activation of GRM1 and GRM1-associated
downstream signaling pathways. We hypothesize that this activation of GRM1
in melanoma cells is associated with higher expression of c-Myc and increased
enzymatic activity of glutaminase (GLS) converting glutamine to glutamate.We
showed that reducing the extracellular glutamate levels by an inhibitor of gluta-
mate release, Riluzole, led to signifıcantly reduce melanoma cell proliferation in
vitro and tumor progression in vivo. We also demonstrated that inclusion of
CB-839, a potent, selective, and orally bioavailable GLS inhibitor, resulted in a
signifıcant inhibition of GRM1-expressing melanoma cell proliferation com-
pared to GRM1 negative melanoma cell lines. Interestingly, we found that si-
multaneous targeting of glutamate production (CB-839) and release (Riluzole)
in GRM1 expressing melanoma cells led to enhanced suppression of cell prolif-
eration in vitro. Additionally, we found that wild type BRAFmelanoma cells are
more sensitive to CB-839 than mutated BRAF cells while responses to Riluzole
were independent of BRAF genotypes. Furthermore, our data indicate that CB-
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839 acts by reducing the function, not the expression, of GLS. Currently, we are
investigating the relationship between GRM1, c-Myc and GLS by genetic and
pharmacological approaches, and if this cascade of events is linked with altered
glutamine metabolisms described for many human cancers including mela-
noma.
#5420 PGAM1-REDD1 pathway promotes paclitaxel resistance through
enhancing aerobic glycolysis in ovarian cancer cells. Yan Feng, Weiguo Lv,
Xing Xie. Women’s hospital School of Medicine Zhejiang Univ., Hangzhou,
China.
Aerobic glycolysis is a dominant pathway for energy production in cancer
cells, but the association of this phenomenonwith chemoresistance remains still
uncertain. Here, we found that the expression of phosphoglycerate mutase 1
(PGAM1), a key catalytic enzyme in aerobic glycolysis, was signifıcantly higher
in paclitaxel-resistant ovarian cancer cell line SKOV3. Up-regulated PGAM1
expression by gene transfection and down-regulated PGAM1 expression by
siRNAknockdown altered the process of aerobic glycolysis, paclitaxel sensitivity
and DNA damage response 1 (REDD1) expression in ovarian cancer cells
(SKOV3 andA2780). Further, the change of the concentration of pyruvic acid or
lactic acid in culture medium and REDD1 expression by gene transfection or
siRNA knockdown also altered the sensitivity to paclitaxel. REDD1 knockdown
of by siRNA reversed partially paclitaxel resistance induced by PGAM1 over-
expression in cancer cells, vice versa. Structural interaction between PGAM1
and REDD1 was predicted by molecular docking. Our results suggested that
PGAM1-REDD1 pathway promotes paclitaxel resistance through enhancing
aerobic glycolysis in ovarian cancer cells.
#5421 Differential expression of lysosomal acid lipase (LAL) between be-
nign and malignant tissues among human organs. Mohamed EI Gassim,1
Jinghe Mao,2 Tangen Ma,1 Xinchun Zhou1. 1Univ. of Mississippi Medical Ctr.,
Madison, MS; 2Tougaloo College, Tougaloo, MS.
Background: Lysosomal acid lipase (LAL), a lysosomal enzyme is able to de-
grade cholesteryl esters to free fatty acids and cholesterol. The information on
the association of LAL with malignancies is limited. This study is to determine
the difference in expression level of LAL between benign and malignant tissues
among human organs. Method: Immunohistochemistry (IHC) for human LAL
was performed on A tissue microarray (TMA) containing 360 benign and ma-
lignant tissues from 36 human organs. The expression level of LAL was repre-
sented by an IHC score calculated by multiplying area score (0-3) with intensity
score (0-3), ranged from 0 to 9. Student’s t-test was used to compare the mean
IHC score between benign and malignant tissues in same organs. Results: Eigh-
teen out of 36 human organs have IHC stains on both benign and malignant
tissues. As shown in Table 1, LAL expression level was higher in malignancy
than in benign tissues in 9 organs. The difference in LAL expression level was
signifıcantly (or nearly lower in malignant tissues of adrenal gland, stomach,
liver, testis and kidney. Conclusion: The expression level of LAL varies among
human organs. As compared with elevation of LAL expression level, decreased
expression level of LAL in malignancies could be of more signifıcance.
Table 1 Difference in expression level of LAL
Organ malignant Benign p M/B
n Mean SE n Mean SE value Ratio
Adrenal Gland 3 1.67 0.73 5 6 0.95 0.02 1.36
Stomach 13 1.17 0.45 8 3.13 0.82 0.035 2.7
Liver 13 1.35 0.34 8 3.56 0.49 0.001 2.6
Larynx 8 0.25 0.09 4 0.63 0.38 0.22 2.5
Testis 4 1.63 0.47 4 3.75 0.75 0.054 2.3
Uterus 13 1.62 0.42 7 2.57 0.97 0.302 1.6
Kidney 12 2.92 0.31 3 4.5 0.87 0.051 1.5
Prostate 15 2.97 0.51 4 4 1.22 .389 1.3
Urinary Bladder 11 0.68 0.17 5 0.7 0.3 0.956 1
Cervix 4 1.63 0.47 5 1.25 0.56 0.636 1.3
Colon 16 2.34 0.39 9 1.5 0.28 0.145 1.6
Esophagus 4 1.63 0.99 2 1 0 0.695 1.6
Ovary 4 3.63 1.07 4 1.94 0.93 0.278 1.9
Skin 8 3.59 1.32 5 1.85 0.72 0.349 1.9
Breast 14 2.86 0.58 6 1.38 0.55 0.139 2.1
Pancreas 10 1.8 0.55 9 0.83 0.14 0.126 2.2
Brain 3 2.17 0.44 5 0.8 0.56 0.144‘ 2.7
Lung 8 1.97 0.74 5 0.60 0.29 0.19 3.3
#5422 Synergistic effects ofmetabolic inhibitors on radiochemosensitized
spheroid prostate cancer cells. Saheed O. Oseni,1 Rolando Branly,2 Mirjana
Pavlovic,3 James Kumi-Diaka1. 1Florida Atlantic University, Davie, FL; 2Bro-
ward College, Davie, FL; 3Florida Atlantic University, Boca Raton, FL.
One of the ways by which prostate cancer cells survive or become resistant to
conventional therapies is through the ability to reprogram their metabolic path-
ways. Thus, justifying the need for studies to elucidate the effıcacy of metabolic
inhibitors in prostate cancer intervention. The purpose of this study was to
investigate the synergistic effects of two metabolic pathway inhibitors - 3-bro-
mopyruvate (3-BrPA) and genistein - on androgen sensitive (LNCaP) and an-
drogen insensitive (DU145) spheroid prostate cancer cells separately primed or
irradiated with very low doses of x-ray radiation (VLDR) and low frequency
weak magnetic fıeld radiation (MFR). Methods: Both PCa cells were cultured
until they form spheroids and then irradiated with either VLDR (20mGy/hr) or
MFR (10mT; 50Hz/hr) in separate groups. Cells were seeded and treated with
varying doses of 3-BrPA and genistein in single or combination regimen. Cell
viability, metabolic activity and cytotoxicity or LDH release levels were mea-
sured using MTT, Alamar blue and LDH assays respectively. NBT assay was
used to determine treatment-induced ROS levels. mitochondrial membrane po-
tential was determined by Rh123 and ethidium bromide fluorescent staining.
Modes of Cell death were determined by fluorescent staining with acridine or-
ange and ethidium bromide dyes, and by morphological identifıcation of apo-
ptotic and autophagic PCa cells. CompuSyn programwas used to determine the
time- and dose-dependent synergism between combination regimens. Results:
Our results show thatVLDRandweakMFRmoderately inhibit cell proliferation
in both PCa cell lines.However, LNCaPPCa cells were found to bemore respon-
sive to both VLDR or weak MFR compared to DU-145 PCa cells. Both VLDR
and MFR suppresses ATP generation and increases ROS generation time-de-
pendently in both cell lines. The most common cell death event found in MFR-
exposed cells was a mixture of mitotic catastrophe and autophagy, while au-
tophagic and slight apoptotic responses were observed in VLDR-exposed cells.
3-BrPA triggers more autophagic response in irradiated DU145 cells compared
more apoptotic response in LNCaP cells. In contrast, genistein induced cell
growth inhibition in both cell lines, butmore effect was observed in LNCaP cells
with dose-dependent apoptotic response. Combination of 3-BrPA and genistein
forced PCa cells to undergo reprogrammed cell death, decreased the mitochon-
drial membrane potential and LDH levels signifıcantly in a dose and time-de-
pendently. Conclusion: The combination treatments show synergistic and sig-
nifıcant inhibition of the glycolytic and mitochondrial metabolic pathways
resulting in induction of apoptosis in radiochemosensitized PCa cells. Priming
of cells with VLDR or MFR also enhanced the therapeutic effects of both meta-
bolic inhibitors. Hence, reinforcing the potential benefıt of metabolic inhibitors
in prostate cancer treatment.
#5423 ZAP70 alters metabolism in chronic lymphocytic leukemic cells.
Subhadip Das,1 RF Dielschneider,2 Elizabeth S. Henson,3 Spencer B. Gibson3.
1Cancer Care Manitoba & University of Manitoba, Winnipeg, Manitoba, Can-
ada; 2University ofManitoba,Winnipeg,Manitoba, Canada; 3Cancer CareMan-
itoba, Winnipeg, Manitoba, Canada.
Chronic lymphocytic leukemia (CLL) has the highest incidence among adults
in western countries. Prognosis of CLL is highly variable but one of the bio-
marker zeta-chain-associated protein 70 (ZAP70) over expression is associated
with aggressive disease with time to treatment being 2.6 years for ZAP70 ex-
pressing (ZAP70) patients and 8 years for ZAP70 defıcient (ZAP70-) patients.
Thus ZAP70may play a role in CLL progression. Metabolic reprograming plays
a central role in cancer progression and is altered in CLL cells. However, the role
of ZAP70 in metabolism in CLL cells is remains unclear. We found that ZAP70
binds to pyruvate kinase M2 (PKM2). PKM2 is key isoform of pyruvate kinase
which is rate limiting enzyme of the glycolytic pathway and provides ametabolic
advantage to tumour cells allowing for increased growth. Our results also indi-
cated the PKM2 is expressed inCLL cells and binding toZAP70 is not affected by
glucose starvation or treatment with kinase inhibitors. Furthermore immuno-
fluorescence microscopy revealed that ZAP-70 and PKM2 colocalize in CLL
cells in the cytoplasm. In addition,we foundZAP70 cells have increased rate of
oxygen consumption from basal level determined by addition of inhibitor (Oli-
gomycin A) and mitochondrial uncoupler (FCCP). Simultaneously ZAP70
cells also have higher extracellular acidifıcation rates. This indicates ZAP70
CLL cells have increasedmitochondrial respiratory capacity with high glycolytic
rate. In addition, fluorometric analysis indicates ZAP70 CLL cells have high
glucose consumption rate towards production of lactate compared to ZAP70-
CLL cells. Collectively, our data reveals a new function for ZAP70, which is to
regulate the Warburg effect and may play a role in CLL progression and may
identify new therapeutic targets.
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#5424 Metformin increases PDH and suppresses HIF1A under hypoxic
conditions and induces cell death in oral squamous cell carcinoma. Talita
Guimarães,1 Lucyana Farias,1 Carlos Fraga,1 Alfredo De Paula,1 Sergio Santos,2
Ricardo Gomez,2 Andre Guimaraes1. 1Unimontes, Montes Claros, Brazil; 2Uni-
versidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Background: Metformin is a biguanide, belonging to the oral hypoglycemic
agents and is a widely used in the treatment of type 2 diabetes. Evidence indicate
that Metformin inhibits cell proliferation in several human cancers and inhibits
the Warburg phenomenon in tumor cells. Objective: The present study aims to
explore the effects of Metformin in hypoxic conditions. Specifıcally, we focused
onpyruvate dehydrogenase (PDH), (hypoxia-inducible factor 1	)HIF-1	 levels
and the oral squamous cell carcinoma (OSCC) cell phenotype. Additionally, we
also investigated a theoretical consequence of Metformin treatment. Methods:
PDH levels in patients withOSCC and oral dysplasia were evaluated.Metformin
was administered in vitro to test the effect of Metformin under hypoxic condi-
tions. The results were complemented by Bioinformatics analyses. Results: Low
PDH levels were observed in OSCC, and Metformin promotes an increase in
PDH levels in hypoxic conditions. Metformin also reduced HIF-1	mRNA and
protein levels. Metformin demonstrated antiproliferative effects, inhibited mi-
gration, increased the number of apoptotic cells and increased the transcription
of caspase 3. Conclusions: In conclusion, our current fındings show that Met-
formin reduces HIF-1	 gene expression and increases PDH expression. Met-
formin inhibits cell proliferation and migration in the OSCC cell line model.
Additionally, Metformin enhances the number of apoptotic cells and caspase 3
levels. Interestingly enough, Metformin did not increase the mutant p53 levels
under hypoxic conditions.
#5425 The role of six transmembrane epithelial antigen of the prostate 2 in
hepatocellular carcinoma. Carla R. Zeballos, Hakim Bouamar, Xiang Gu, Yi-
dong Chen, Francisco G. Cigarroa, LuZhe Sun. University of Texas Health Sci-
ence Center at San Antonio, San Antonio, TX.
Introduction: The incidence of hepatocellular carcinoma (HCC) inHispanics
is three times higher than non-Hispanic whites, and even higher in South Texas
(STX) Hispanics. This is attributed to a higher prevalence of hepatitis C, diabe-
tes, obesity and perhaps genetic and epigenetic alterations. Knowledge regard-
ing genetic alterations in Hispanics is sparse as demonstrated by the lack of
Hispanics with HCC in The Cancer Genome Atlas (TCGA). Therefore, our
group sequenced paired adjacent liver and HCC tumor samples from STX His-
panics, which highlighted a gene over-expressed in tumors of Hispanics, called
the Six Transmembrane Epithelial Antigen of the Prostate 2 (STEAP2). STEAP2
is a metalloreductase of iron and copper and is implicated in increased iron and
reactive oxygen species in the liver which can lead to the progression of inflam-
mation and cirrhosis. STEAP2 may play an important oncogenic role in HCC,
especially in the setting of obesity. We propose to test the hypothesis that over-
expression of STEAP2 will lead to malignant property in HCC cells resulting in
enhanced proliferation, survival, invasiveness, and eventually development of
HCC, especially in obese hosts. Methods: Hispanic paired tissue continues to be
collected from our institution for RNA sequencing and establishment of His-
panic HCC cell lines. STEAP2 RNA and protein expression levels in Hispanic
paired samples versus Caucasian paired samples were evaluated by RT-PCR,
Western blot, and immunohistochemistry. Knockdown and overexpression of
STEAP2 were established in HCC cell lines and in primary Hispanic HCC cell
lines to examine the effects on iron levels, oxidative stress, proliferation, inva-
siveness, apoptosis and cell cycle in vitro. Results: Hispanic HCCRNA sequenc-
ing data compared to TCGA HCC RNA sequencing data (no Hispanics) dem-
onstrated the overexpression of STEAP2 in HCC tumors in Hispanic patients,
whichwere validated byRT-PCRdata andWestern blot data. Lipid peroxidation
product, 4-hydroxynonenal, and copper levels were higher in HCC tumor ver-
sus adjacent tissue. Iron levels were higher in adjacent tissue versus tumor tissue
in Hispanics. Knockdown of STEAP2 in SNU398 cells decreased proliferation
andmigration, while inHUH7 cells STEAP2 knockdown only decreasedmigra-
tion. Conclusions: STEAP2 is specifıcally overexpressed in HCC tumors in His-
panics in comparison to HCC tumors in non-Hispanic whites and appears to
play a malignant-promoting role in HCC cells. Further studies to establish the
role of STEAP2 as a tumor promoter in HCC and the mechanisms by which it
promotes carcinogenesis are underway. The proposed studies will likely yield
mechanistic insights into the molecular mechanisms that drive HCC develop-
ment and progression in South Texas Hispanics and potential therapeutic tar-
gets involving STEAP2-mediated metal ion metabolism and oxidative stress.
#5426 LPA stimulates glycolytic shift in ovarian cancer. Ji Hee Ha, Ran-
gasudhagar Radhakrishnan, Jeremy D.Ward, Muralidharan Jayaraman, Danny
N. Dhanasekaran. University of Oklahoma Health Sciences Center, Oklahoma
City, OK.
Cancer cells resort to aerobic glycolysis to meet the increased energy con-
sumption and growth requirement during active proliferation.While it has been
observed that the cancer cells preferentially shift to aerobic glycolysis, the extra-
neous growth factors involved in this process is largely unknown. Since our
previous studies have shown that lysophosphatidic acid (LPA) plays a critical
role in the pathophysiology of ovarian cancers, we investigated the role of LPA in
the metabolic reprogramming of ovarian cancer cells. Our results using XFe96
analyzer indicate that LPA stimulates aerobic glycolysis inmultiple ovarian can-
cer cell lines as well as in patient-derived ovarian cancer cells. Physiological role
for LPA in this process is demonstrated by the observation that the inhibitors of
LPA-receptors attenuate the glycolytic shift stimulated by the ascitic fluid de-
rived cancer patients. We further demonstrate that the silencing G	i2, a down-
stream signaling mediator for LPA, inhibits LPA-stimulated glycolytic shift in
ovarian cancer cells. Further analyses indicated that LPA-stimulated metabolic
reprogramming involves the generation of reactive oxygen species (ROS). Treat-
ment of cells with N-Acetyl Cysteine (NAC), a ROS-scavenger, inhibited the
glycolytic shift stimulated by LPA. In addition, our studies point to a role for
LPA-stimulated HIF1	 activation in this process. These results indicate that
LPA-stimulatedmetabolic reprogramming in ovarian cancer cells involve ROS-
generation via LPA-G	i2-HIF1	-dependent signaling pathway. Together with
the fındings that the glycolytic shift is crucially involved in tumor cell survival
our studies point to LPA-G	i2-HIF1	 signaling axis as a potential target for
therapy in ovarian cancer.
#5427 Distinctions between the metabolic changes in glioblastoma cells
and glioma stem-like cells following irradiation. Elizabeth I. Spehalski, Cord
Peters, Philip Tofılon, Kevin Camphausen. NIH, Bethesda, MD.
Glioblastoma multiforme (GBM) is the most common primary malignant
brain tumor in adults and, even with aggressive treatment that includes surgical
resection, radiation, and temozolomide administration, prognosis is poor due to
tumor recurrence. There is evidence thatwithinGBMs a small number of glioma
stem- like cells (GSCs) exist, which are thought to be radiation resistant andmay
be capable of repopulating a tumor after treatment. Like most cancers, GBMs
largely employ aerobic glycolysis to create ATP, a phenomenon known as the
Warburg effect. Experiments have shown that the cellular metabolism of GSCs
differs from that of differentiated cells, making them an attractive target for
novel therapeutic approaches. Much work has been done to analyze the meta-
bolic profıles of GSCs with the goal of identifying potential therapeutic targets,
but little data exists linking metabolic changes to radiation resistance. The pur-
pose of this study is to characterize the metabolic differences between glioma
stem- like cells and traditional GBM tumor cells with and without radiation
treatment (IR). To this end, we compared the metabolism of a human derived
GSC line with two commonly used GBM cell lines before and after IR. At base-
line, we fınd that glioma stem-like cells are more quiescent than GBM cells,
which have higher levels of both glycolysis and oxidative phosphorylation. GBM
lines show higher levels of both basal and maximal respiration, as well as basal
glycolysis and glycolytic capacity than GSCs. They also express higher levels of
energy, glycolysis, and TCA cycle metabolites than GSCs. Inversely, GSCs dem-
onstrate metabolic signs of quiescence such as decreased NEAA synthesis. After
IR, the radiation- sensitive GBM tumor cell line (U251) exhibits increases in all
metabolic pathways, whereas the levels of glycolytic and oxidativemetabolites in
the GSCs remain unchanged. All cell lines show an increase of ATP and NAD
production following IR. These fındings indicate that the metabolism of GSCs
undergoes different alterations than that of GBM tumor cells after IR, making
them an attractive target for novel therapeutic approaches in conjunction with
radiation therapy. Additionally, differences in metabolic signatures between
GSC lines could be useful for non-invasive diagnosticmodalities such as 13CMR
spectroscopy.
#5428 Lactate production as a potential marker of HER2-addiction and
Trastuzumab susceptibility. Lorenzo Castagnoli,1 Egidio Iorio,2 Ada Ko-
schorke,1 Cristina Ghirelli,1 Gianmauro Palombelli,2 Debora Giani,1 Matteo
Dugo,1 DanieleMorelli,1 Rossella Canese,2 Elda Tagliabue,1 SerenellaM. Pupa1.
1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2Istituto Supe-
riore di Sanità, Rome, Italy.
Background: Although the introduction of the HER2-specifıc humanized
monoclonal antibody Trastuzumab (T) in clinical practice revolutionized the
treatment of HER2-positive breast cancer (BC), about half of the T-treated pa-
tients do not benefıt or become refractory after its administration. Despite dif-
ferent molecular tumor profıles signifıcantly associated with T benefıt were re-
ported, the identifıcation of a non invasive clinical approach to select patients
responsive or not to T is still a clinical unmet task. We recently reported that
mammary cancer cell lines derived from spontaneous nodules arisen in mice
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transgenic for the human d16HER2 splice variant (HER2-addicted) were signif-
icantly enriched in genes involved in glycolysis pathway versus those developed
in mice transgenic for the human full-length HER2-positive (WTHER2)
(HER2-non addicted) (1,2). Accordingly, the aim of our study was to defıne
whether tumor lactate levels could reflect HER2 addiction and, in turn, T sus-
ceptibility. Methods: The metabolite content in murine and human HER2-pos-
itive cell lines and specimens was determined by quantitative Nuclear Magnetic
Resonance (NMR) spectroscopy. The optical metabolic imaging that quantifıes
the levels of the anaerobic glycolysis-related metabolite nicotinamide adenine
dinucleotide (NADH) and the aerobic metabolite flavin adenine dinucleotide
(FAD) was represented by Optical redox ratio (NADH/FAD). The extracellular
levels of lactate were calculated by blood gas analyzer. Results: The metabolic
profıle of HER2-addicted (MI6, MI7) versus -non-addicted (WTHER2_1,
WTHER2_2) murine tumor cells revealed higher intracellular levels of metab-
olites associated to glycolysis in MI6 and MI7 cells versus WTHER2-positive
cells. In keeping, also the evaluation of the metabolic profıle of human HER2-
positive BC cell lines classifıed as addicted (SKBR3 and BT474) or not
(MDAMB453 and MDAMB361) to HER2-signaling (3) confırmed signifıcant
higher intracellular and extracellular levels of lactate in HER2-addicted versus
-non-addicted cells. The extracellular levels of NADH and NADH/FAD ratio
further sustained a signifıcantly higher activity of an anaerobic metabolism in
HER2-addicted cells. Noteworthy, themetabolic profıle of 27HER2-positive BC
cases treated with T, classifıed as HER2-addicted or not on the basis of the
activation status of d16HER2 (1), provided further evidence of signifıcantly
higher levels of lactate in tumorsHER2-addicted. Conclusions: Overall, even if a
dysregulated glucose metabolism is a tumor hallmark, our results provide rele-
vant in vitro and in vivo evidences of the potential future non-invasive lactate
detection as a possible biomarker of HER2-addiction and T-responsiveness.
Supported by the ItalianMinistry ofHealth andAIRC. References: 1) Castagnoli
L et Al, Cancer Res 2014. 2) Castagnoli L et al., Oncogene 2016. 3) Shiu KK et Al,
Oncogene 2014.
#5429 The Warburg Effect: protons suck. Shonagh Russell, Liping Xu,
Rober J. Gillies.Moffıtt Cancer Center, Tampa, FL.
Aerobic glycolysis (the Warburg Effect) is a hallmark of cancer and is associ-
ated with local invasion and metastasis. This metabolic phenotype results in
acidifıcation of the microenvironment in solid tumors, which is responsible for
many of the known sequelae. For example, systemic buffer therapy directly and
specifıcally increases extracellular tumor pH and reduces spontaneous and ex-
perimental metastasis in vivo. Further, extracellular acidosis can be a potent
inhibitor of anti-tumor immunity. Removal of glycolytically-derived acids re-
quires the activity of proton transportingmechanisms, such as NHE, V-ATPase
and CA-IX. While it is commonly believed that these transporters are respond-
ing to the demands imposed by increased glycolytic flux, an alternative hypoth-
esis states that glycolytic flux is increased to satisfy the demand driven by these
transporters. Hence, expression of transporters that drive extracellular acidosis
would induce a more glycolytic phenotype. To test this, we have transfected
lowly glycolytic and non-metastatic MCF-7 breast adenocarcinoma cells with
two different proton transporters. In the fırst model, we used the yeast plasma
membrane protonATPase 1 (PMA1); a Type 1 P-typeATPase. PMA1was stably
over-expressed inMCF7 cell line and over-expression of PMA1 transformed the
cells into a more aggressive phenotype with increased glucose consumption,
lactate production, and proton production. Phenotypically, the transfected
clones had elevated rates of migration and invasion in vitro and increased me-
tastasis in vivo. This experimental evidence supports the hypothesis that proton
export alone could drive theWarburg phenotype. Hence, in this system, glucose
is metabolized to replenish either the ATP expended or the exported hydrogen-
ions. In the second model we used CA-IX; an exofacial carbonic anhydrase that
is highly expressed in invasive cancers and materially participates in acidifying
themicroenvironment. CA-IX is upregulated inmultiple cancer typeswithmin-
imal expression in normal tissue, and is therefore an attractive and biologically
relevant therapeutic target. In vitro, we have observed thatmany cells expressing
a glycolytic phenotype have elevated CA-IX expression, leading us to postulate
that these phenotypes are coupled. To test this, we stably overexpressed CA-IX
in MCF7 cells and again this resulted in a stable, glycolytic phenotype with
increased glucose consumption, lactate production, and proton production ob-
served using assay kits and live cell metabolic phenotyping with the Seahorse
Extracellular Flux Analyzer. Through this study we have shown that acidosis
leads to amore aggressive behavior and that CA-IX expression alone can induce
a glycolytic phenotype. Hence, we hypothesise this is due to the enzymatic ac-
tivity of CA-IX “sucking in” glucose to replenish intracellular H that are ex-
ported by this mechanism.
#5430 GAPDH loss in a tumorigenic human glioblastoma cell line. Zach-
ary Gaertner, Yi Lu, Jinsuh Kim, Gayatry Mohapatra, Ankit Mehta, Sanjani
Lakka, Herbert Engelhard. Univ. of Illinois at Chicago, Chicago, IL.
Background: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a
ubiquitous, multifunctional 37 kDa enzyme best known for catalyzing the sixth
step in glycolysis. GAPDH expression is so consistent that it has been granted
“housekeeping” status, and is used as a standard (along with -actin) for nor-
malizingWestern blots.While increasedGAPDHexpressionhas beendescribed
in hypoxia, diabetes, and some cancers, decreased expression is rare. Here we
describe a new human glioblastoma cell line that exhibits GAPDH loss, while
maintaining a high degree of malignancy. Methods: Primary cultures of human
glioblastoma cells were initiated and maintained in DMEMwith 10% FBS. This
particular cell line (designated E297) grew readily, and was passaged more than
40 times. E297 cells were confırmed to be negative for HIV, HTLV, hepatitis B
andC, CMV, andmycoplasma contamination. Cells in exponential growthwere
stained for routine markers, and studied by DNA flow cytometry. GAPDH ex-
pression was studied by Western blot analysis using polyclonal rabbit anti-hu-
man GAPDH IgG (Abcam, Rosemont, IL), with HeLa, U138, U87 and U251
cells (as well as -actin staining) as positive controls. For intracranial implanta-
tion intoWistar-Furth rats (male, 10-11 weeks), cells were suspended at 20 x 106
cells/ml. Using aseptic technique, rats were anesthetized, and placed into a ste-
reotactic frame. A burr hole was drilled 3 mm right of the bregma and 25 l of
suspension injected (5 mm depth) over 10 min. by Hamilton syringe. Rats were
studied by MRI and euthanized when symptomatic. Results: E297 cells have
glial/epithelioid morphology, with a doubling time of 24 2 hours in logarith-
mic growth phase, with a single DNA subpopulation with 28% S phase. They
stain positively for GFAP, vimentin, bFGF, c-myc and p53, but fail to express
GAPDH. 10/10 animals implanted intracerebrally developed tumors, becoming
symptomatic and requiring sacrifıce at 25 days (mean). Loss of GAPDH expres-
sion was confırmed by Western blot analysis. Conclusions: The E297 human
glioblastoma cell line is highly aggressive and proliferates rapidly. It is tumori-
genic in nonimmunosuppressed rats but lacks GAPDH protein. We conclude
thatGAPDHexpression is not essential for glioblastoma cell proliferation under
routine culture conditions, and care needs to be taken when using GAPDH as a
normalization standard for Western blots of cancer cells.
#5431 Androgen receptor regulates themitochondrial pyruvate carrier to
fuel oncometabolism in prostate cancer. David A. Bader, Nagireddy Putluri,
Sean M. Hartig, Sean E. McGuire. Baylor College of Medicine, Houston, TX.
The metabolic underpinnings of androgen receptor (AR)-driven growth in
prostate cancer (PCa) are underexplored, hindering the development of strate-
gies to leverage themetabolic properties differentiating PCa fromnormal tissue.
To this end, we discovered a subunit of the mitochondrial pyruvate carrier
(MPC),MPC2, is a direct AR target gene that is increased in PCa specimens and
associated with clinical outcomes. Our observation suggests a targetable link
between AR signaling and carbon traffıcking in PCa. Indeed, MPC inhibition
delays proliferation and alters metabolic properties in hormone sensitive and
castrate resistant AR-driven PCa models. Next, using 13C metabolic flux anal-
ysis coupled with a reverse phase protein array, we determined MPC inhibition
results in activation of the eIF2	/ATF4 integrated stress response pathway to
partially compensate for MPC inhibition by coordinating increased glutamine
incorporation into the citric acid cycle. Therefore, to amplify the effect of MPC
inhibition, we restricted glutamine availability during MPC inhibition and
found this combination resulted in proliferative arrest. Last, we extended our
efforts in-vivo and demonstrated combinatorial MPC/glutaminase inhibition
resulted in a signifıcant reduction in castrate-resistant prostate tumor xenograft
growth in mice with no overt host toxicity. We anticipate our fındings will
accelerate the development of clinical strategies to therapeutically manipulate
carbon flux to starve clinically lethal castrate-resistant PCa.
#5432 Characterization of metabolic fuel dependency in multidrug resis-
tant breast cancer cells. Yoonseok Kam, Natalia Romero, Pamela Swain, Brian
P. Dranka. Agilent Technologies, Lexington, MA.
Multidrug resistance (MDR) is a common resistant mechanism of cancer
cells to cytotoxic drugs in systemic therapy. MDR is characterized by in-
creased expression of ATP-dependent drug exporting pumps which remove
cytotoxic compounds from the cytosol. However, the mechanism whereby
cancer cells rapidly respond to this increased ATP demand is not fully un-
derstood although the glycolytic nature of MDR phenotype has been evi-
denced repeatedly by previous reports. We thus hypothesized that flexibility
and dependency on mitochondrial fuels would be altered in concert with the
switch to glycolysis. In order tomore accurate analyze glycolytic pathway, we
newly developed an assay to improve glycolytic rate measurements by ac-
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counting for TCA-dependent CO2 contribution to extracellular acidifıcation
and to correlate Seahorse extracellular flux data with lactate production. In a
comparison of glycolytic rates between MCF7 breast cancer cell line and its
MDR variant MCF7/Dox using this new assay, we confırmed that in MCF7/
Dox cells glycolysis rate under basal conditions is signifıcantly increased
compared to wild type cells. Furthermore, MCF7Dox presents a signifıcant
increase in compensatory glycolysis when mitochondrial ATP production is
blocked. This metabolic profıle switch is accompanied by a decreased depen-
dency on glutamine to fuel mitochondrial respiration an increased tolerance
of the MCF7/Dox cells to glutamine deprivation as compared to the MCF7
wild type. In contrast, dependency on glucose and fatty acids mitochondrial-
oxidation was largely unchanged in MDR cells. Additionally, an increase in
long chain fatty acid oxidation is observed when glucose and glutamine
oxidation is blocked indicating that MDR cells has higher mitochondrial
flexibility to compensate for inhibition of alternative fuels utilization al-
though it preferentially uses glucose. Together these data demonstrate that
acquisition of multidrug resistance in MCF7 cells fundamentally changes
their metabolism from a glutamine-driven, oxidative phosphorylation de-
pendent phenotype to a highly glycolytic and glucose-dependent phenotype.
These fındings have potential therapeutic relevance in the context of inhibi-
tion of specifıc mitochondrial fuel pathways to prevent therapy resistance.
#5433 -Tubulin inhibitors reduce GLUT1 membrane traffıcking to at-
tenuate tumorigenesis in glioblastoma subtypes. Collin M. Labak,1 Maheed-
hara R. Guda,1 Swapna Asuthkar,1 Neha Jain,1 Yining Lu,1 Ian Purvis,1 Jack
Tuszynski,2 Ichiro Nakano,3 Andrew J. Tsung,1 Kiran K. Velpula1. 1Univ. of
Illinois College of Med. at Peoria, Peoria, IL; 2University of Alberta, Edmonton,
Alberta, Canada; 3University of Alabama, Tuscaloosa, AL.
Glioblastoma is an aggressive, high-grade tumor with poor prognosis due
to lack of sound therapeutic options. Mesenchymal subtype GBMs are par-
ticularly diffıcult to treat because they tend to proliferate in the sub ventric-
ular zone, an area that breeds stem-like neural cells and proves nearly im-
possible to access for surgical resection. They also contribute to creating a
hypoxic microenvironment and switch to glycolytic metabolism in what is
known as the Warburg Effect. Here, we hypothesize that strategically inhib-
iting the glucose transporter, GLUT1, through cytoskeletal components that
traffıc it to the cell membrane may reverse the Warburg Effect, attenuating
further tumorigenesis and decreasing the stemness of such cells. Datamining
studies and immunoblot analysis conducted on human glioblastoma patient
specimens (hGBM) demonstrated that GLUT1 is highly upregulated. Limit-
ing dilution assay conducted using GLUT1 inhibitors- fasentin and 2-De-
oxy-D-glucose reduced the proliferation in mesenchymal cancer stem cell
(CSC) subtype in in vitro culture. Simultaneously, mass spectrometric anal-
ysis revealed signifıcant association between GLUT1 and -tubulin 4
(TUBB4) in mesenchymal subtyped cells. This association was further con-
fırmed by large-sample datamining and in immunoprecipitation studies
from hGBM specimens, suggesting that TUBB4 may be a viable target in
deterring the traffıcking of upregulated GLUT1 to the membrane. Collec-
tively, these studies confırm that GLUT1 is associated with TUBB4, and that
targeting TUBB4 via siRNA or colchicine derivatives could prove effective in
reversing the Warburg Effect in GBM cells and ultimately improve patient
outcomes.
#5434 Tumor necrosis factor receptor-associated protein 1 (TRAP1) as a
potential target for glutamine addicted cancer cells. Vu T. Vo,1 Ai N. Phan,1
Tuyen N. Hua,1 Yangsik Jeong,1 Byoung Heon Kang,2 Hyun-Won Kim,1 Jong-
Whan Choi1. 1Yonsei University Wonju college of Medicine, Wonju, Republic of
Korea; 2UNIST, Ulsan, Republic of Korea.
Glutamine, a non-essential amino acid, is an important nutrient which is
involved in many biochemical pathways such as energy production, macromo-
lecular synthesis, and oxidative stress scavenging. Glutaminemetabolism is dys-
regulated in many cancers which mostly display glutamine addiction for cell
proliferation. Thus, glutamine metabolism has become a potential target for
treating cancer. Here we report that glutamine-dependent cancer cells are more
susceptible for inhibiting cell proliferation with inhibitor treatment of Tumor
Necrosis Factor Receptor-Associated Protein 1 (TRAP1), a downstream factor
of oncogenic c-Myc involved in glutamine metabolism. Using cell proliferation
and cell viability assays, we examined growth inhibitory effects of TRAP1 inhib-
itor, gamitrinib-triphenylphosphonium (G-TPP), on two groups of cell lines,
glutamine-deprivation sensitive versus resistant cell lines. Included are cell lines
for each group:HCC827 acquired gefıtinib resistance andA549 for the sensitive;
HuH7 for the resistant group. Glutamine-deprivation sensitive cell lines showed
signifıcant growth inhibition with TRAP1 inhibitor treatment while the corre-
sponding resistant group of cell lines showed no growth inhibitory effects in the
same treatment condition. This suggests a potential mechanistic connection of
TRAP1 to c-Myc regulation in glutaminemetabolism. Taken together, this fınd-
ing provides a better understanding of oncogene-driven glutamine metabolism
as well as evidence that TRAP1 is a promising therapeutic target for glutamine
addicted cancer cells.
#5435 Beta-3 adrenergic antagonism can alleviate energy wasting associ-
ated with cancer-induced cachexia. Fredrick Anderson, Stefan K. Nilsson, Jo-
nas A. Nilsson. Umeå University, Umeå, Sweden.
Introduction: Cancer-associated cachexia (CAC) is a wasting syndrome char-
acterized by atrophy of adipose tissue and skeletal muscle as a consequence of
cancer. CAC has been shown to be responsible for approximately 20% of cancer
deaths alone and reduces tolerance to treatment. The pathological mechanisms
underlying this syndrome remains elusive and the treatment options are scarce.
One proposed mechanism is the tumor-induced activation of brown adipose
tissue (BAT); a thermogenic organ that wastes energy by producing heat via
activation of uncoupling protein 1 (UCP1). 3 adrenergic signaling is a strong
activator of BAT and the browning of white adipose tissue (WAT). We hypoth-
esized that treatment with a specifıc3 antagonist could alleviate CAC.Method:
To study cachexia, the LuCAP32 xenograftmodel of humanprostate cancerwas
utilized in immunodefıcient balb/ca nude mice. After two weeks of tumor
growth, treatment with the specifıc 3 antagonist SR59230A (SR) was started
using subcutaneous micro osmotic pumps. Vehicle substance and nontumor
bearing (NTB) mice were used as controls. The mice were sacrifıced after a
treatment period of four weeks and tissues were harvested for subsequent anal-
ysis. The PCR analysis was normalized to NTB mice. Results: The mice with
tumor started losing weight 20 days after tumor implantation while the nontu-
mor bearing controls gained weight throughout the experiment. The group
treated with SR also lost weight but to a signifıcantly lesser degree than vehicle
treated animals (-1.7 vs -3.2 g, p0.032). This was also seen when looking at
individual fat depots.Whole body composition,measured by echoMRI, showed
that all groups equally lost fat mass over time. However, leanmass in the vehicle
group decreased whereas the SR group gained lean mass (-0.41 vs 1.18 g,
p0.036). With respect to total body weight this gain in lean mass was counter-
acted by the loss of fat mass. PCR analysis of subcutaneous WAT showed a
signifıcant decrease in expression of ATGL (2.84 vs 1.98 FC, p0,006), PPAR
(2.33 vs 1.45 FC, p0.026) andCD36 (2.11 vs 1.3 FC, p0.008) for the SR group
compared to vehicle, indicating a decreased lipolysis and influx of fatty acids to
WAT. The SR treated mice also had a signifıcantly lower expression of UCP1 in
WAT compared to controls (2.23 vs 0.58 FC, p0.023), supporting the notion
that the browning of WAT is a driving force for CAC. Conclusion: Our data
show that treatment with a specifıc 3 adrenergic antagonist alleviates CAC
through decreased lipolysis ofWAT and decreases the expression ofmarkers for
WAT browning. This indicates a correlation between decreased browning and
severity of CAC. We also provide evidence that 3 antagonism helps preserve
musclemass, which is ofmajor importance for treatment ofCACand something
that few other treatment options have been able to show.
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#5436 Identifıcation of early lung cancer miRNA biomarkers using qRT-
PCR and novel label-free nanoarray technology. Julia M. Santos,1 Aby Joia-
kim,1 David A. Putt,1 Pilar Herrera-Fierro,2 Vishva Ray,2 Alan Dombokowski,3
Guoan Chen,2 David G. Beer,2 Hyesook Kim1. 1Detroit R&D, Inc., Detroit, MI;
2University of Michigan, Ann Arbor, MI; 3Wayne State University, Detroit, MI.
Whereas over 75% of lung cancer patients are diagnosed at an advanced or
metastatic stage and their 5-year survival rate is5%, patients diagnosed at an
early stage, Stage I, have70% 5-year survival rate. In the present study, Stage I
lung cancermiRNAbiomarkerswere identifıed using qRT-PCRandnovel label-
free facile nanoarray technology for early lung cancer detection. Total RNA
from human A549 lung and ACHN kidney cancer cell lysates and media were
isolated and qRT-PCR/Taqman® analyses (two-step RT-PCR) were carried out
for 8 miRNA lung cancer biomarker candidates. The 8 miRNA levels were nor-
malized by the miR16 level (no change reported in lung cancer). Ratios of
miR486/miR16 andmiR29c/miR16 increased10-fold inA549 lung cancer cell
lysates and media compared with those in ACHN kidney cells. Total RNA frac-
tions were isolated from 11 healthy subjects, 21 Stage I and 19 Stage II/III ade-
nocarcinoma and 5 squamous lung cancer patients and levels of the 8 miRNAs
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were measured by qRT-PCR/Taqman® analysis (in total, 1,026 analyses) and
normalized by the miR16 level. miR486 levels were up-regulated (p0.02) and
miR203 (p0.0005) and miR205 (p0.041) levels were down-regulated in
Stages I and II/III adenocarcinoma. Whereas miR122 and miR29c were not
detected in serum samples from the majority of healthy subjects, the miRNAs
were expressed in 82% and 71%, respectively, of Stage I and 90% and 100%,
respectively, of Stages II/III lung cancer patients. A novel label-free facile 90 nm
(diameter) miRNA nanowell technology was developed. Electrochemical anal-
yses of the early lung cancer biomarker candidates, miR486 andmiR29c, and, an
internal control, miR16, were carried out using various concentrations of
miRNA standards (0 to 100 fM) with biotinylated cDNA captured by streptavi-
din coated on the nanogold surface. TheNyquist plots showed a dose-dependent
increase in impedance (-Z” kohm) and sensitivity of the miRNA nanowell elec-
trochemical technology was1 fM. The impedance level obtained withmiR29c
inA549 lung cancer cellmediawas2.8-fold higher (mean value SD, 163.9
32.8 kohm) comparedwithACHNkidney cancer cell media (60.8 33.1 kohm)
by 90 nm nanowell analysis (p0.000019). Electrochemical analyses of a serum
sample obtained from a lung cancer patient revealed that miR486 and miR29c
levels were 2-fold (p0.0031) and 9-fold (p0.0006) higher, respectively,
compared to the pooled human control sera. This result agreed with the result
obtained by qRT-PCR/Taqman® analysis of human serum samples. Our results
suggest thatmiR486 andmiR203 levels up- and down-regulated, respectively, in
lung cancer serum samples are biomarkers for early (Stage I) lung cancer diag-
nosis. Supported by NCI SBIR Phase I contract, N261201500040C (Topic 337).
#5437 miR-302b as adjuvant therapeutic tool to improve chemotherapy
effıcacy in human triple-negative breast cancer. Alessandra Cataldo,1 Ilaria
Plantamura,1 Elvira D’Ippolito,1 Sandra Romero-Cordoba,2 Sara Baroni,1 Val-
eria Cancilia,3 Claudio Tripodo,3 Dario Palmieri,4 Marilena V. Iorio1. 1Istituto
Nazionale dei Tumori,Milan, Italy; 2INMGEN,Mexico City,Mexico; 3University
of Palermo, Palermo, Italy; 4Ohio State University, Columbus, OH.
Introduction: Triple-negative breast cancer (TNBC) accounts for 15-20% of
all breast cancer cases, with the worst outcome of all subtypes. For TNBC, still
lacking targeted therapies, the only therapeutic option is currently chemother-
apy, and despite a good initial response, patients often develop drug resistance.
MiRNAs canmodulate chemoresistance by affectingDNA repair, cell cycle pro-
gression, apoptosis and also tumormicroenvironment. Macrophages constitute
amajor component of the immunemicroenvironment of cancer and pro-tumor
M2 macrophages have been associated with resistance to chemotherapeutic
treatments. Our previous data showed thatmiR-302b over-expression enhances
sensitivity to cisplatin in breast cancer cell lines by targeting directly E2F1 and
indirectlyATM.Here,we investigated the potential ofmiR-302b as a therapeutic
tool to enhance cisplatin response in a TNBCmousemodel andwhich pathways
are involved in this mechanism both in tumor cells and microenvironment.
Moreover, miR-302b prognostic value was assessed in a cohort of TNBC pa-
tients with available clinical outcome . Finally, we evaluated if miR-302b en-
hances the sensitivity to doxorubicin, another chemotherapeutic agent used as
fırst-line therapy inTNBCpatients.Material andmethod:MDA-MB-231TNBC
cells were injected into the mammary fat pad of female SCID mice and then
treated with lipid nanoparticles containing miR-302b or cel-miR-67 control,
alone or in combination with cisplatin. Gene expression profıle on collected
tumors was performed by microarray and tumor sections were stained with
anti-arginase 1 (M2marker) to evaluate thenumberofM2macrophages.MiR-302b
expressionwas assessed in 39TNBC treatedwith chemotherapy in adjuvant setting,
and associated with prognosis. Finally, MDA-MB-231 cells were transfected with
miR-302b precursor or control treated with doxorubicin for 24h and then assessed
forcell viability.Results:Our results showthatmiR-302bcombinationwithcisplatin
signifıcantly impaired tumor growth in comparison with cel-67 control and cispla-
tin (p 0.03), and reduced the number ofM2macrophages in the tumormicroen-
vironment (p0.005). Moreover, gene expression profıle of collected tumors con-
fırm immune system modulation. Notably, miR-302b expression was associated
with disease-free survival and overall survival in TNBC patients treated with adju-
vantchemotherapy.Furthermore,we foundthatmiR-302balsoenhances sensitivity
to doxorubicin in vitro, affecting cell viability and cell cycle transition throughE2F1
regulation. Conclusion: Our data demonstrate that miR-302b can be exploited as a
new therapeutic tool to improve the response to chemotherapy, modulating tumor
microenvironment. Moreover, this miRNA has prognostic signifıcance in TNBC
patients, and might also represent an useful predictive biomarker for response to
chemotherapy.
#5438 Knowledge ofwhichmiRNA isoforms are expressed in a sample can
successfully discriminate amongst the 32 TCGA cancer types. Aristeidis G.
Telonis, Rogan Magee, Phillipe Loher, Inna Chervoneva, Eric Londin, Isidore
Rigoutsos. Thomas Jefferson University, Philadelphia, PA.
Background: Next-generation sequencing (NGS) technologies made possible
the generation of large amounts of data quickly and inexpensively process. As a
result, the challenge nowadays is how best to manipulate and analyze Big Data.
Among non-coding RNAs, microRNAs (miRNAs) are the best studied to date.
MiRNAs have attracted a lot of attention because they are centrally involved in
homeostasis and can regulate thousands of coding and non-coding transcripts.
The complexity of miRNA-mediated regulation increased further with the re-
cent discovery that miRNA isoforms (isomiRs) are produced constitutively and
that isomiR expression depends on a person’s sex, population origin, race and
also on tissue type, tissue state, and disease subtype. Methods: We computed
and analyzed isomiR profıles across 10,271 short RNA-seq datasets from The
Cancer Genome Atlas (TCGA) repository, which represent 32 cancer types.
Focusing on the isomiRs of each dataset, we built a classifıer that relied solely on
“binarized” isomiR profıles: in a dataset, an isomiR was labeled ‘present,’ if its
expression exceeded a threshold that depended on the depth of sequencing, and
‘absent’ otherwise. This differs radically from previous methods in that it at-
tempts to classify by relying on the presence or absence of isomiRs, intentionally
discarding all information about the isomiRs’ expression level. We also built a
classifıer that relied solely on “binarized” miRNA arm profıles: a miRNA arm
was labeled ‘present’ if at least one of the isomiRs it produces is ’present’ in the
same dataset. Results: The classifıer we built using binarized isomiR profıles
discriminated among all 32 TCGA cancer types and classifıed datasets with
sensitivity 90% and a false discovery rate (FDR)  3.0%. The ability of this
classifıer to correctly distinguish among the 32 cancers persisted even after a 15x
reduction in the number of isomiRs used. The classifıer we built using binarized
miRNA arm profıles could also discriminate among all 32 TCGA cancers albeit
with a lower sensitivity (83%) and a slightly higher FDR (6%).We also examined
how well the various miRNA loci have been studied over time by measuring the
corresponding number of published articles. Surprisingly, the miRNAs whose
isoforms have the highest ability to classify tumors are not those with the most
articles in PubMed. Conclusions: The presence or absence of a specifıc isomiR
provides adequate discriminatory power to accurately classify a sample as be-
longing to one of the 32 TCGAcancers. The fındings suggest that isomiRs can be
used as potent, novel, cancer-specifıc biomarkers. By ignoring the expression
levels of isomiRs, we effectively show that the same miRNA produces different
clouds of isoforms in each cancer type.And, since distinct isomiRs target distinct
mRNAs, it follows that a miRNA locus will target different mRNAs in different
cancers simply by expressing different clouds of isoforms each time.
#5439 The chronological analysis of previously-reported serum mi-
croRNAexpression in colorectal cancer.YukihiroYoshikawa,1Mitsuko Fuku-
naga,2 Takaaki Masuda,1 Miwa Noda,1 Hiroaki Wakiyama,1 Yuta Koyama,1
Shinya Kidogami,1 Kuniaki Sato,1 Qingjiang Hu,1 Sho Nambara,1 Tomoko
Saito,1 Shotaro Sakimura,1 Naoki Hayashi,1 Yohsuke Kuroda,1 Shuhei Ito,1
Yuichiro Doki,3 Masaki Mori,3 Koshi Mimori1. 1Kyushu University Beppu Hos-
pital, Beppu, Oita, Japan; 2Coloproctology Center Takano Hospital, Kumamoto,
Japan; 3Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Background: Colorectal cancer (CRC) is a major cause of cancer-associated
death in the world. Despite surgical resection and pre- and postoperative che-
motherapy, recurrence is common in patients with CRC. Many studies have
examined potential biomarker of recurrence in CRC in attempt to improve
patients’ prognosis. MicroRNAs (miRNAs), the small noncoding RNAs that are
associated with the development of cancer, in serum have been shown to be
potential biomarkers in various type of cancers and several miRNAs have been
reported in colorectal cancer. However, no miRNAs has been applied in a clin-
ical setting because of small amount of each samples. In the present study, we
evaluated the clinical effectiveness of previously-reported serum miRNAs ex-
pression in CRC using periodically gathered serum.Materials andMethods:We
obtained 328 serum samples, which gathered periodically (preoperative, post-
operative one month, three months, six months, one year, and two years), from
71 patients with stageII/III CRC (stageII: 31 patients, stageIII: 40 patients). Thir-
teen patients had a recurrence. The miRNAs were extracted from serums, and
miRNA microarray analysis was performed. Previously-reported sixteen miR-
NAs (let-7a, miR-15b, miR-18a, miR-19a, miR-21, miR-23a, miR-29a, miR-31,
miR-92a, miR-150, miR-181b, miR-203, miR-223, miR-335, miR-1229 and
miR-1246) were quantifıed by microRNA microarray analysis. Results: In no
recurrence cases, preoperative miR-1246 expression is higher than postopera-
tive miR-1246 expression; preoperative; 5.6  1.8, postoperative one month:
4.1 1.6 (p 0.05), postoperative three months: 3.4 1.9 (p 0.05) , postop-
erative six months: 4.8 1.5 (p 0.05) , postoperative one year: 4.0 1.6 (p
0.05), postoperative two years: 4.8  1.5 (p  0.05). We observed trend of
miR-1246 re-elevation before recurrence. The sensitivity and specifıcity of miR-
1246 for detection of CRC are 52.8% and 84.9% (AUC0.746). This result is
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almost as same as that of serum CEA which is major tumor marker of CRC
(sensitivity: 22-48%, specifıcity: 63-100%). In our data, the sensitivity of CEA is
38% and the specifıcity is 94% (cutoff: 5 ng/ml). The sensitivity and specifıcity
ofmiR-1246 is higher than ofCEA.Conclusion: SerummiR-1246 are best prom-
ising biomarker for CRC because of high sensitivity and specifıcity. On the other
hand, previous reported miRNAs excluding miR-1246 are inadequate as bio-
marker of CRC in our data. Next we are going to identify novel microRNAs
which has higher sensitivity and specifıcity using our microarray analysis.
#5440 miRNAs as novel therapeutic adjuvants for improving the effıcacy
of vincristine and radiation therapy in treating medulloblastoma. Nourhan
Abdelfattah, Subapriya Rajamanickam, Panneerdoss Subbarayalu, Santosh
Timilsina, Benjamin Onyeagucha, Yidong Chen, Manjeet Rao. UT Health Sci-
ence Ctr. at San Antonio, San Antonio, TX.
Medulloblastoma (MB) is the most common malignant pediatric brain tumor.
Despite recent improvements in the overall survival, only a modest percentage of
patients surviveMyc-driven high-riskMB. The quality of life for surviving patients
is substantially reduced due to the devastating and often irreversible side effects of
radiation and chemotherapy. Recently, in a large unbiased genomic screen, we un-
covered a group ofmicroRNAs (miRNAs) capable ofmeditating drug sensitivity in
c-myc amplifıed high-riskMB.Our functional screen of1900miRNAs identifıed
miR-584-5p as apotent candidate that uniquely sensitizes high-riskMB to radiation
as well as vincristine (VCR) (20 to 25-fold dose reduction), an anti-mitotic agent
routinely administered alongside radiation and in combination with other chemo-
therapeutic drugs to treatmedulloblastomapatients.Our studies revealed thatmiR-
584might act as a potent tumor suppressor as it inhibitedMBgrowth in vivo aswell
as migration and invasion of c-myc amplifıedMB.We show that miR-584 overex-
pression results in defectivemitosis leading tomitotic catastrophe, apoptosis, DNA
damage and G2-M cell-cycle arrest in high-risk MB cells without affecting normal
neural stem cell growth. Notably, we discovered thatmiR-584 directly regulates the
expression and activity of genes including histone deacetylase 1 (HDAC1), and
eukaryotic translation initiation factor 4e familymember3 (EIF4E3) that areknown
to play important roles in microtubule dynamics, metaphase-anaphase transition
and radio-resistance.Moreover, silencing either of these two target genes resulted in
signifıcant inhibition of MB growth and enhanced sensitivity to VCR and ionizing
radiation. Overexpressing miR-584 or silencing either HDAC1 or EIF4E3 also in-
hibited theMB stem cell proliferation and self-renewal. We report that while miR-
584-5p ispredominantly expressed innormalbrainandcerebellum, its expression is
signifıcantly reduced inMB patient derived xenografts (PDXs). In contrast tomiR-
584, EIF4E3 and HDAC1 were found to be overexpressed in medulloblastoma pa-
tients. These fındings are highly signifıcant, unexpected and innovative as this
miRNAand its target genes are the fırst to be shown to affect the therapeutic effıcacy
of VCR and radiation in c-myc amplifıed high-risk medulloblastoma.
#5441 Circulating exosomal microRNA-203 and microRNA-373 as non-
invasive biomarkers for predicting prognosis and metastasis in human hep-
atocellular carcinoma. Gyeonghwa Kim,1 Eunhye Lee,1 Se Young Jang,2 Won
Young Tak,2 Young Oh Kweon,2 Soo Young Park,2 Keun Hur1. 1Department of
Biochemistry and Cell Biology & BK21 Plus KNU Biomedical Convergence Pro-
gram, Kyungpook National University School of Medicine, Daegu, Republic of
Korea; 2Kyungpook National University Hospital, Daegu, Republic of Korea.
Background andAimHepatocellular carcinoma (HCC) is the fıfthmost com-
mon cancer and the most leading cause of cancer-related death worldwide. Al-
though considerable progress has been made in treatment of HCC, early detec-
tion is still highly considered the key to improved survival. Thus, for the earlier
diagnosis and accurate prediction of HCC, identifıcation of non-invasive mo-
lecular biomarkers for HCC patients is an imperative need. Recently, cancer
cell-derived extracellular vesicles (EVs) have been known to contain various
intracellular biomolecules including microRNAs (miRNAs). The aim of this
study was to evaluate whether exosomal miRNAs can serve as a serum-based
biomarker in HCC. Materials and Methods We isolated exosome from serum
samples from HCC patients as well as normal healthy controls using ultracen-
trifugation, and it was confırmed by expression of exosome markers (CD9,
CD63, ALIX, and TSG101) based on immunoblotting. Next, the expression of 6
miRNAs (miRNA-24, -130a, -182, -203, -373, and -423) was analyzed in the
exosome samples. We also investigated expression status of the 6 miRNAs in
matched HCC tissues and corresponding normal liver tissues. MiRNAs expres-
sion was determined by quantitative real-time PCR (qRT-PCR), and miRNAs
expression was normalized relative to cel-miR-39 and RNU6B expression for
serum and tissue samples, respectively. Results We successfully purifıed exo-
some from serum clinical samples and detected miRNAs in the exosome. We
observed that a subset of miRNAs from serum exosome, including miRNA-24,
-130a, -182, -203, and -373 were enhanced inHCCpatients than normal healthy
controls. In further comparison between early stage and advanced stage of HCC
patients, serum exosomal miRNA-203 (P0.05) and miRNA-373 (P0.05)
were signifıcantly up-regulated in advanced HCC patients. While no signifıcant
changes in the expression of other serum exosomalmiRNAs (miRNA-24, -130a,
-182, and -423) according to HCC progression. More interestingly, high serum
exosomal miRNA-203 and miRNA-373 was associated with HCC progression
(P0.01) as well as prognosis (P0.05) of HCC patients. Conclusions We pro-
vided the novel evidence for usefulness of serum circulating exosomal miR-203
andmiR-373 expressions as strong potential biomarkers for predicting progno-
sis and metastasis of HCC patients.
#5442 Down-regulation ofmiRNA-214 expression by bioactivemolecules
mitigates invasive potential of melanoma cells through ALCAM/TFAP2 sig-
naling. Ram Prasad, Santosh K. Katiyar.Univ. of Alabama at Birmingham, Bir-
mingham, AL.
Melanoma is responsible for 80% of skin cancer related deaths in the United
States and represents fıfth most common neoplasia in humans. Over the past
decades, the incidence of melanoma has increased by 3% to 8% per year in
western countries. Therefore, it is essential to understand the molecular regula-
tory pathways that contribute to melanoma aggressiveness and metastatic dis-
semination. MicroRNAs (miRNAs) are small noncoding regulatory RNAs that
contribute to tumor formation and progression, for their ability to regulate gene
expression post-transcriptionally by either inhibiting protein translation or de-
grading targetmRNAs.miR-214 is overexpressed in various types of cancers and
is associated with the regulation of numerous carcinogenic processes including
cell differentiation, senescence, angiogenesis and cellmigration/invasion, etc. In
the present study, we demonstrated thatmiR-214 shows distinct over expression
in melanoma cell lines (A375, Hs294t, SK-Mel119, and SK-Mel28) as compared
to its expression in normal human epidermal melanocytes (NHEM), and this
overexpression of miR-214 in melanoma cells was associated with the invasive
potential than NHEM. Treatment of melanoma cells with an inhibitor of miR-
214 (50 nM) resulted in inhibition of cell invasion ability. We also determined
the effects of bioactive phytochemical grape seed proanthocyanidins (GSPs) on
the expression levels of miRNA-214 in melanoma cell lines (A375 and Hs294t)
and its underlying molecular targets. Treatment of A375 and Hs294t cells with
GSPs resulted in suppression of the levels of miRNA-214, which leads to de-
crease in migration potential of melanoma cell lines. By using 3D melanoma
progressionmodel, we also verifıed this suppressive effect of GPSs onmelanoma
invasion. The transition from the non-invasive to the invasive and metastatic
stage is accompanied by the loss of AP-2 transcription factors (TFAP-2) and
expression of activated leukocyte cell adhesion molecule (ALCAM) and those
are associated with miRNA-214 overexpression. Here, we observed that the
treatment of GSPs decreases ALCAM expression and restore TFAP-2 levels in
melanoma cell lines. Further, dietary administration of GSPs signifıcantly re-
duce the metastasis potential of A375 cells in different vital organs such as lung,
liver, kidney, and spleen, and this suppressive effect of GSPs on invasive poten-
tial of A375 cells was associated with the reduction in the levels of miRNA-214
and ALCAM. Our results indicate that modulation of miR-214 influences in
vitro cell movement and extravasation from blood vessels in vivo. Together,
these studies suggest that an identifıcation of metastasis related miRNAs may
provide potential diagnostic biomarkers and better understanding of the com-
plex functions of miRNAs, as well as therapeutic targets for clinical application.
#5443 Developing a novel miR-15a mimic as a potential therapeutic mol-
ecule to eliminate resistant colorectal cancer stemcells.AndrewT. Fesler,Hua
Liu, Ning Wu, Jingfang Ju. Stony Brook University, Stony Brook, NY.
In the last 15 years, it has become well established that microRNA play im-
portant roles in cancer biology. Due to their ability to regulate the expression of
important target genes, aberrant expression of miRNAs has been linked to can-
cer development and progression. Based on these important functions, there is
great interest in developing miRNA based therapeutics. In colorectal cancer,
treatment using 5-flurouracil (5-FU) based chemotherapy has improved patient
outcomes. However, there remain challenges associated with chemoresistance
and recurrence for patientswith advanced stage colorectal cancer.miRNAbased
therapeutics may represent an potential novel therapeutic option for colorectal
cancer therapy either alone or in combination with 5-FU based chemotherapy.
miR-15a was of the fırst miRNAs identifıed to be associated with cancer, and has
been shown to have important roles in several tumor types. miR-15a is down-
regulated in colon cancer and associated with poor patient prognosis. We have
identifıed several important cancer related targets of miR-15a in colon cancer,
including YAP1, DCLK1, BMI1 and BCL2. Through the regulation of these
targets, miR-15a expression can be used as a potent inhibitor to reduce colon
cancer cell proliferation, invasion and improve sensitivity to 5-FU, as well as
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decreasing tumor growth in vivomouse colon tumormodels using colon cancer
stem cells. In the interest of developing miR-15a based colon cancer therapeu-
tics, we have made a modifıed miR-15a mimic that shows enhanced abilities to
disrupt resistant colon cancer cell proliferation and induction of cell cycle arrest
when compared to unmodifıed miR-15a. Following transfection with miR-15a
mimic, cell number was reduced by 84% compared to control and 66% com-
pared to miR-15a precursor. Cell cycle analysis showed that G1/S ratio was
increased from 1.07 for control to 2.87 for precursor miR-15a and 7.07 for
miR-15a mimic. This miR-15a mimic also maintains its ability to regulate these
important target genes in colon cancer stem cells. In mouse models using colon
cancer stem cells, miR-15a mimic has demonstrated therapeutic potential by
reducing tumor growth. Based on these fındings, there is potential thatmodifıed
miR-15a could be adapted for treatment of patients to improve survival of ad-
vanced stage colorectal cancer patients.
#5444 Therapeutic potential of miR-195 in non-small cell lung cancer.
Xiaojie Yu,1 Xiuye Ma,1 Yiqiang Zhang,1 Zhenze Zhao,2 Liqin Du,2 Alexander
Pertsemlidis1. 1University of Texas Health Science Center at San Antonio, San
Antonio, TX; 2Texas State University, San Marcos, TX.
Introduction: MicroRNAs (miRNAs) play important roles in nearly all cellu-
lar physiological and pathological pathways. Dysregulated miRNAs have been
shown to contribute to the tumorigenesis of most cancers, including lung can-
cer.We aim tomodulatemiRNAactivity as a potential therapeutic avenue either
alone or in combination with other drugs. Methods: A high throughput screen
with a library of 1,239miRNAmimics was performed inNSCLC cells to identify
miRNAs that both inhibit cancer cell growth and sensitize cells to microtubule-
targeting agents (MTAs). The functions of candidate miRNA(s) were validated
both in vitro and in vivo. Results: miR-195 causes G1 phase arrest by targeting
CCND3. miR-195 induces apoptosis and senescence and represses migration
and invasion ofNSCLC cells by targeting BIRC5.Conversely, over-expression of
CCND3 compromises the inhibition of cell growth bymiR-195; over-expression
of BIRC5 abrogates the inhibition of cell growth, migration and invasion by
miR-195. miR-195 also synergizes with MTAs paclitaxel and eribulin to inhibit
the growth of NSCLC cells by regulating CHEK1. Lung tumors with miR-195
over-expression grow signifıcantly slower and respond better to eribulin treat-
ment than tumors in control animals. Induction of miR-195 expression after
tumor initiation slows tumor growth and that combination of doxycycline with
eribulin shows stronger inhibition on tumor growth than eribulin. In addition,
miR-195 inhibits lung tumor metastasis. Analysis of miRNA and gene expres-
sion profıles fromTCGA shows thatmiR-195 expression is negatively correlated
with that of BIRC5 and CHEK1. Clinical data fromTCGA show that miR-195 is
signifıcantly down-regulated in lung tumors compared to adjacent normal tis-
sues and that its down-regulation in lung cancer patients is associated with
worse survival. TCGA data also show that BIRC5 and CHEK1 are signifıcantly
up-regulated in lung tumors compared to adjacent normal tissues and that their
up-regulation is associated with worse survival. Conclusions: We report the
identifıcation of miR-195 as a tumor suppressor and chemotherapy sensitizer in
NSCLCmediated by its repression ofCCND3, BIRC5 andCHEK1.Mouse xeno-
grafts with miR-195 over-expression or induced miR-195 expression indicate
that tumors with high miR-195 expression are more sensitive to drug treatment
and that induction of miR-195 in tumors represses tumor growth and sensitizes
tumors to eribulin treatment. These results highlight the potential use of miR-
195 expression level as a biomarker to predict patient response to MTAs and of
miR-195mimics as a therapeutic agent or adjuvant to chemotherapy. This proj-
ect was supported by NIH R01 CA129632 and CPRIT Training Grant
RP140105.
#5445 Inhibition of tumor suppressor function of RUNX3 by miR-301a
facilitates the progression of castration resistant prostate cancer. Venkatesh
Kolluru, Balaji Chandrasekhar, Collin McKenzie, Houda Alatassi, Murali
Ankem, Chendil Damodaran. University of Louisville, Louisville, KY.
Treatment of prostate cancer is still clinically challenging due to lack of reli-
ablemarkers for diagnosis and prognosis. Serumprostate specifıc antigen (PSA)
is of limited clinical utility due to poor sensitivity and specifıcity. A large number
of false positives (50%) with traditional PSA testing lead many patients to un-
dergoing unnecessary prostate biopsy and exposure to unnecessary risk of com-
plications. So the goal of this study is to identify a reliable, non-invasive bio-
marker that can distinguish patients with benign, indolent and aggressive
prostate cancer in various clinical settings. MicroRNAs (miRNAs) are small
noncoding (18 to 28 nucleotides) RNA molecules that are present in all human
cells, and their expression patterns are correlated with many cancer types, in-
cluding CaP. In our results, we found a signifıcant differential expression
(p0.013) of miR-301a in both tumor tissues (Gleason-6 and -7) and serum
samples in comparison to benign prostatic hyperplasia (BPH) or adjacent be-
nign samples. We observed a negative correlation between miR-301a and
RUNX3 expression in human CaP samples suggesting tumor suppressive
role RUNX3might be compromised in CaP. To determineMiR-301a regulation
on RUNX3, we evaluated miR-301a and RUNX3 protein in panel of prostate
cancer cell lines, normal prostate epithelial cells and Benign Prostate Hyperpla-
sia (BPH). Similar results such as inverse correlation between miR-301a and
RUNX were found in cell culture models. Also, over expression of miR-301a
down regulates RUNX3 activation in prostate cancer cell lines and silencing
miR-301a expression reverts RUNX3 activation in BPH cells. While evaluating
the reporter activity of RUNX3 either by co-transfectingwithmimic or inhibitor
of miR-301a in BPH and prostate cancer cells: over expression of miR-301a
down regulated RUNX3 reporter activity which corresponded with RUNX3
protein expression. Similarly, silencing miR-301a reverted RUNX3 promoter
activity and protein expression suggesting RUNX3 is a direct target ofmiR-301a
inCaP cells. SilencingmiR-301a reverted the pro-apoptotic function of RUNX3,
results in reduced colony formation, adhesion, invasion and migration of CaP
cells. Investigating the mechanistic link miR-301a and RUNX3 may explore
whether it could facilitate clinical decision making such as the decision to pro-
ceed with early surgery rather than active surveillance for intermediate risk
prostate cancer patients deemed to be at high risk of progression.
#5446 Tumor-derived miR-200c and 141 contribute to high levels of
plasma microRNA-200c and 141 through exosomes. Lizhong Wang, Runhua
Liu, Song Gao, Yicun Wang, Meng Wang, Zhi Li. University of Alabama at
Birmingham, Birmingham, AL.
CirculatingmicroRNAs (miRs) have potential as cancer biomarkers, but their
regulatory mechanisms remain elusive. Here we used a breast cancer model
(Foxp3 heterozygous Scurfymutant femalemice, Foxp3sf/) for identifıcation of
circulating miR biomarkers, and the formation and regulation of these miRs
were investigated. Aging Foxp3sf/ female mice developed spontaneous breast
cancers and lung metastases. Levels of miR-200c and 141 were lower in the
Foxp3
sf/
breast cancer cells than in normal breast epithelial cells, but plasma
levels of miR-200c and 141 in the Foxp3sf/mice increased during tumor pro-
gression, especially during metastasis to the lung. Likewise, 259 participants,
including patients with breast cancer or benign breast tumors, members of
breast cancer families, and matched normal healthy controls, were assessed for
circulating levels of candidate miRs. The results showed that: 1) the levels of
miR-200c and 141 were lower in the FOXP3low breast cancer cells relative to
those with FOXP3high, especially for late-stage andmetastatic cancer cells; 2) the
levels of miR-200c and 141 were higher in plasma of patients with metastatic
breast cancer than in plasma of those with localized breast cancer, with benign
breast tumors, with a family history of breast cancer, or normal healthy controls.
Furthermore, in Foxp3sf/mice, plasma miR-200c and 141 were released from
tumor cells through exosomes. Thus, plasma levels of miR-200c and 141 are
potential biomarkers for early detection ofmetastases.MiR-200c and 141 appear
to be released from breast cancer cells, through exosomes, into the circulation.
#5447 AmicroRNA signature for the classifıcation of renal cell carcinoma
subtypes. Ashley Di Meo,1 Mereet Hanna,2 Rola Saleeb,1 Samantha Wala,1
Adriana Krizova,2 Manal Gabril,3 Haiyan Zhai,4 Maria Pasic,1 Andrew Evans,5
Fadi Brimo,6 George Yousef1. 1University of Toronto, Toronto, Ontario, Canada;
2The Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario,
Canada; 3London Health Sciences Center and Western University, London, On-
tario, Canada; 4BioGenex Laboratories, Fremont, CA; 5University Health Net-
work, Toronto, Ontario, Canada; 6McGill University Health Centre, Montreal,
Quebec, Canada.
Introduction: Renal cell carcinoma (RCC) accounts for 90% of all kidney
cancers. It comprises a heterogeneous group of renal tumors with distinct ge-
netic and molecular characteristics including clear cell RCC (ccRCC), papillary
RCC (pRCC) and chromophobe RCC (chRCC). The differential diagnosis of
RCC subtypes relies on distinct morphology which is not always accurate. Ac-
curate classifıcation of RCC subtypes is critical since each exhibits different
clinical behaviour, prognosis and response to therapy. The purpose of this study
is to determine whether a limited number ofmiRNAs can classify RCC subtypes
with high accuracy. Experimental Design:We extracted RNA from 90 formalin-
fıxed paraffın-embedded (FFPE) tissues including 27 clear cell RCC, 29 papillary
RCC, 19 chromophobe RCC, 4 unclassifıed RCC tumors and 11 oncocytomas.
We measured the absolute expression of six miRNAs by qRT-PCR. Receiver
operator characteristic curves were constructed and the area under the curve
(AUC) was calculated to assess diagnostic performance. We also tested miRNA
expression by in situ hybridization (ISH) in an independent set of ninety-eight
FFPE renal tumors. Results: We developed a two-step miRNA classifıer. In the
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fırst step, expressions of selected miRNAs were found to discriminate clear cell
RCC and papillary RCC from chromophobe RCC and renal oncocytoma. Two
miRNAs were able to discriminate clear cell RCC and papillary RCC from chro-
mophobe RCC and oncocytoma. miR-221 was signifıcantly overexpressed in
chromophobe RCC and oncocytoma compared to clear cell RCC and papillary
RCC (4.49-fold change, p 6.398e-010) and was able to discriminate between
the two groups (AUC: 0.9637, 95%CI: 0.9132 to 1.014, p0.0001). In the second
step, the absolute expression of two miRNAs could distinguish clear cell RCC
from papillary RCC (10.4-fold change, p  1.243e-013). Moreover, an addi-
tional two miRNAs could differentiate chromophobe RCC from renal oncocy-
toma (3.30- fold change, p  1.751e-006). In situ hybridization revealed that
miRNAs display a nuclear staining pattern that was able to distinguish clear cell
RCC from papillary RCC (p0.001) and chromophobe RCC from renal onco-
cytoma (p 0.009). Conclusion: miRNA expressions were able to distinguish
between RCC subtypes and renal oncocytoma. miRNA assessment by in situ
hybridization is a clinically useful diagnostic tool that can complement current
methods for RCC classifıcation.
#5448 An exosomal biomarker for prostate cancer.Divya Bhagirath, Thao
Yang, Kirandeep Sekhon, Nathan Bucay, Shahana Majid, Yutaka Hashimoto,
Priyanka Kulkarni, Pritha Dasgupta, Marisa Shiina, Varahram Shahryari, Mit-
suho Imai-Sumida, Soichiro Yamamura, Z Laura Tabatabai, Yuichiro Tanaka,
Rajvir Dahiya, Guoren Deng, Sharanjot Saini. Veterans Affairs Medical Center
and University of California, San Francisco, CA.
Prostate tumors are highly heterogeneous and molecular characterization
based on biopsy sampling is often challenging. Hence, it is desirable to have an
easily accessible, minimally invasive way to determine themolecular imprints of
a patient’s tumor. Exosomes in blood are an important source of non-invasive,
circulating biomarkers and provide an enriched source of microRNAs.With an
objective of identifying microRNA based markers, we developed a comprehen-
sive procedure for exosomal microRNA profıling analyses from sera of prostate
cancer patients employingNanostring nCounter technology. In a pilot study, we
profıled exosomal miRNAs from a training cohort of normal individuals, pa-
tients with benign prostate hyperplasia (BPH), indolent formof PCa and aggres-
sive metastatic prostate cancer. Exosomes were extracted from serum and the
integrity of exosomal preparationswas confırmed bynanoparticle tracking anal-
ysis and Western blot analyses for exosomal markers CD63, CD9 and TSG101.
Levels of two miRNAs were signifıcantly upregulated and several candidate
miRNAs were markedly downregulated in metastatic PCa serum samples com-
paredwith controls. The candidatemicroRNAswere further validated in a larger
cohort by real time PCR based microRNA assays. Of signifıcance, we validated
miR-1246 as an exosomal marker for prostate cancer. miR-1246 levels were
specifıcally altered in prostate cancer patients and not signifıcantly altered in
BPH. Our analyses suggest that miR-1246 is a promising diagnostic biomarker
for prostate cancer.
#5449 Nanoparticle delivery of miRNAs to inhibit GBM stem cells. Her-
nando Lopez-Bertoni. Johns Hopkins School of Medicine, Baltimore, MD.
Cancer cells arise from multiple complementary genomic and epigenomic
abnormalities that deregulate pathways that control cell proliferation and tissue
homeostasis. Epigenetic modifıcations, involving deregulation of non-coding
RNAs, are emerging as critical determinants of gene expression and essential
drivers of neoplastic phenotypes. Our knowledge of how these complex epige-
netic mechanisms operate in the context of cancer cell phenotype regulation
remains limited. Non-coding RNAs, in particular miRNAs, are emerging as
critical epigenetic regulators of cell fate and oncogenesis. MiRNAs act by selec-
tively inhibiting gene expression primarily by targeting mRNA for degradation
usually via complementary 3=-UTR seed sequences. Numerous miRNAs have
been found to regulate tumorigenesis and cancer cell stemness by virtue of their
capacity to target tumor-suppressing or tumor promoting transcripts. We re-
cently showed that the coordinated actions of Oct4 and Sox2 induce a tumor-
propagating stem-like state inGBMcells through amechanism that involves the
induction of DNMTs and down-regulation of a network of miRNAs through
promoter DNAmethylation. Two of themiRNAs repressed byOct4/Sox2,miR-
148a and miR-296-5p, effıciently inhibit the tumor propagating capacity of
GBM stem-like, making them excellent candidates for therapeutic intervention.
Options for treating high-grade brain tumors remain limited. Recent develop-
ments in nanomedicine provide new and exciting opportunities to treat and
manage brain tumors. Cationic polymers are a class of biomaterials with great
promise for targeted molecular therapeutics. We combined this cutting-edge
technology with our newly discovered stem cell inhibiting miRNAs to develop
nano/miR conjugates to treat gliomas. We show these nano/miR conjugates
distribute throughout an established tumor in vivo, and more importantly, de-
livering these tumor-suppressing miRNAs using PBAE polymers inhibits the
growth of established GBM tumor in mouse models. Our fındings demonstrate
that identifying and validating stem cell-inhibitory in combination with current
advances in nanomedicine will undoubtedly impact the development of novel
therapies for targeting the CSC population and treating GBM.
#5450 Urinary microRNA as diagnostic and prognostic biomarkers for
prostate cancer. Jacob Fredsøe,1 Anni K. Rasmussen,2 Anni R. Thomsen,2 Peter
Mouritzen,2 Søren Høyer,3 Michael Borre,4 Torben F. Ørntoft,1 Karina D. Sø-
rensen1. 1Department of Molecular Medicine, Aarhus N, Denmark; 2Exiqon A/S,
Vedbaek, Denmark; 3Institute of Pathology, Aarhus C, Denmark; 4Department of
Urology, Aarhus N, Denmark.
Widespread use of Prostate Specifıc Antigen (PSA) testing for prostate cancer
(PC) detection has led to extensive overdiagnosis and overtreatment. Thus, we
aimed to train and validate urine-based microRNA (miRNA) biomarkers that
may assist in the diagnosis and prognosis of PC. To this end, we profıled the
expression levels of 92 miRNAs by RT-qPCR in exosome-enriched cell-free
urine samples from20 patients with benign prostatic hyperplasia (BPH) and 188
patients with clinically localized PC (cohort 1). The diagnostic potential of in-
dividual miRNAs and multi-miRNA ratio models were assessed by receiver
operating characteristic (ROC) curve analysis. Prognostic potential was evalu-
ated by Kaplan-Meier, uni- and multivariate Cox regression analyses using bio-
chemical recurrence (BCR) after radical prostatectomy (RP) as endpoint. Our
fındings were validated in an independent cohort of 20 BPH patients and 197
patients with clinically localized PC (cohort 2). We identifıed and validated
several deregulated miRNAs in urine samples from PC patients. In addition, we
trained a novel diagnostic 3-miRNA model that distinguished BPH and PC
patients with an area under the curve (AUC) of 0.95 in cohort 1, and which was
successfully validated in cohort 2 (AUC0.89). Furthermore, we trained a novel
prognostic 3-miRNAmodel that predicted time to BCR after RP independently
of routine clinicopathological parameters in cohort 1, and was successfully val-
idated in cohort 2.
#5451 Panel of urinary cell-free microRNAs in detection of urinary blad-
der cancer. Jaroslav Juracek,1 Tana Machackova,1 Marek Vecera,1 Kamila
Souckova,1 Jiri Sana,1 Parwez Ahmad,1 Natalia Anna Gablo,1 Ondrej Slaby,1
Michal Stanik,2 Jan Dolezel2. 1CEITEC - Central European Institute of Technol-
ogy, Brno, Czech Republic; 2MMCI - Masaryk Memorial Cancer Institute, Brno,
Czech Republic.
Bladder cancer is the most common cancer of the urinary tract. More than
90% of bladder cancers are urothelial carcinoma, which are divided into non-
muscle-invasive and muscle-invasive forms. Non-muscle-invasive tumors fre-
quently recur (50-70%) and can also progress to invasion form (10-15%). These
patients are monitored by cystoscopy and may have multiple resections over
many years. Improved monitoring method is needed, ideally via urine analysis,
which could reduce the morbidity and costs associated with long follow up.
Currently there are no molecular biomarkers which could diagnose or accu-
rately predict disease progression. We aimed to develop a clinically applicable,
specifıc and sensitive panel of urine microRNAs enabling detect bladder cancer
and predict risk of progression to muscle-invasive form.Within the exploratory
phase of study we have analyzed expression profıles of 1733 miRNAs in urine
supernatant of 16 bladder cancer patients (6muscle invasive, 5 high-grademus-
cle non-invasive, 5 low-grade muscle non-invasive), 17 controls, 10 RCC pa-
tients and 4 urinary tract infections (UTI) using Affymetrix miRNA microar-
rays. Diagnostic and prognostic potential of selected microRNAs was further
validated on independent samples in training phase (50 bladder cancer patients,
15 controls) and validation phase (100 bladder cancer patients, 55 controls, 45
renal cancer patients) using specifıc TaqMan assays and qRT-PCR method.
Global expression profıling identifıed set of 76miRNAs able distinguish bladder
cancer patients from healthy controls (P 0,01), thereof 64 highly up-regulated
and 12 down-regulated. Moreover 23 miRNAs were able distinguish invasive
and non-invasive forms of UCUB (P  0,01) and 18 miRNAs high-grade and
low-grad non-invasive (p  0,01). Set of 12 miRNAs with highest expression
level and statistical signifıcance was validated in training phase of study. Based
on the results the panel of three miRNAs (miR-31, miR-93, miR-191) was pro-
fıled. In validation phase we confırmed diagnostic potential and ability of this
urine miRNA-based panel to diagnose patients with bladder cancer with high
sensitivity and specifıcity (AUC  0,8794, sensitivity  82%, specifıcity 
80%).Our data have shown that urinarymicroRNAs could serve as sensitive and
specifıc biomarkers of urinary bladder cancer and could be useful tool to in-
crease sensitivity of standard cytological examination and reduce costs associ-
ated with long-term follow-up of bladder cancer patients. This work was sup-
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: MicroRNA Diagnostics and Therapeutics in Cancer
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1395
ported by Ministry of Health of the Czech Republic, grant nr. 15-33158A, 15-
34553A, 15-31627A, 15-34678A, 16-31314A, 16-31765A and by grant of Czech
Grant Agency nr. 16-18257S.. All rights reserved.
#5452 Antitumor activity of miR-34a in peritoneal mesothelioma relies
on c-MET andAXL inhibition: Persistent activation of ERK andAKT signal-
ing as a possible cytoprotective mechanism. Rihan El Bezawy, Michelandrea
De Cesare,Marzia Pennati, Marcello Deraco, Paolo Gandellini, Valentina Zuco,
Nadia Zaffaroni. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
The value ofmicroRNAs (miRNAs) as novel targets for cancer therapy is now
widely recognized. However, no information is currently available on the ex-
pression/functional role of miRNAs in diffuse malignant peritoneal mesotheli-
oma (DMPM), a rapidly lethal disease, poorly responsive to conventional treat-
ments, for which the development of new therapeutic strategies is urgently
needed.Here,we evaluated the expression andbiological effects ofmiR-34a -one
of the most widely deregulated miRNAs in cancer and for which a lipid-formu-
lated mimic is already clinically available- in a large cohort of DMPM clinical
samples and a unique collection of in house-developedDMPMpreclinicalmod-
els, with the aim to assess the potential of a miR-34a-based approach for disease
treatment. miR-34a was found to be signifıcantly down-regulated in forty-fıve
DMPM clinical specimens and fıve established cell lines compared to normal
peritoneum. miR-34a reconstitution inhibited cell proliferation in a time-de-
pendentmanner, though to a different extent andwith a different kinetics across
individual cell lines. Such a variable antiproliferative effect was paralleled by a
different kinetics of apoptosis induction. In addition, miR-34a ectopic expres-
sion signifıcantly declined DMPM cell invasion ability and impaired the secre-
tion of angiogenesis-related factors. Phenocopy experiments showed that miR-
34a oncosuppressive activities mainly rely on c-MET andAXL down-regulation
and the consequent interference with the activation of downstream signaling.
Interestingly, a persistent activation of ERK1/2 andAKT in twomiR-34a-recon-
stituted cell lines was found to counteract the antiproliferative and proapoptotic
effects of miRNA, yet not affecting its anti-invasive activity. Most importantly,
when three subcutaneous/orthotopic DMPM xenograft models were used to
examine the impact of miR-34a on tumorigenicity, a signifıcant reduction in
tumor take and growthwas consistently observed. Our preclinical data, showing
impressive inhibitory effects induced by miR-34a on DMPM cell proliferation,
invasion and growth in immunodefıcient mice, strongly suggest the potential
clinical utility of a miR-34a-replacement therapy for the treatment of such a still
incurable disease. On the other hand, we provide the fırst evidence of a potential
cytoprotective/resistance mechanism that may arise towards miRNA-based
therapies through the persistent activation of receptor tyrosine kinase down-
stream signaling.
#5453 Dysregulation of miRNAs in esophageal cancer: function and clin-
ical implication. Rinu Sharma. Guru Gobind Singh Indraprastha Univ., New
Delhi, India.
Background: Growing evidence suggests importance of aberrant microRNA
(miRNA) expression in development and progression of cancer. Recent studies
have demonstrated the potential of miRNA panels as promising diagnostic,
prognostic and predictive biomarkers. Objective: The purpose of the present
study was to evaluate the clinical and functional signifıcance of miRNAs in
esophageal cancer (EC).Methods: Herein, we evaluated the diagnostic potential
of a fıve miRNA panel (consisting of miR-21, miR-144, miR-107, miR-93 and
miR-342) in EC detection using quantitative real time PCR (qRTPCR). To eval-
uate the discriminatory power of miRNA panel, receiver operating characteris-
tic curve (ROC) curves were generated for each of the miRNAs followed by risk
score analysis. Briefly, linear regression models were fıtted using the cancer
status and each of the risk score as input. ROC curves were then used to evaluate
the diagnostic potential of the panel and to fınd out the appropriate cut-off point.
Sensitivity and specifıcity of the panel were then determined. Further, pathway
enrichment analysis was carried out to fınd the most signifıcant pathways tar-
geted by these miRNAs. Next, we elucidated the role of miR-144, by silencing it
in KYSE-410 cells followed by MTT assay, cell cycle analysis, colony formation
assay and scratch assay. Potential targets of miR-144 were predicted by in silico
approach followed by in vitro validation by luciferase reporter assay. Results:
The ROC curve analysis indicated that the panel of fıve miRNAs (AUC0.851,
p0.001) constitutes a more sensitive and specifıc diagnostic marker as com-
pared to any of the single miRNAs. Most importantly, panel of circulating
miRNAs showed enhanced sensitivity (87.5%) and specifıcity (90.4%) with an
AUC of 0.96 (p0.001) in discriminating EC patients from normal subjects.
Inhibition ofmiR-144 signifıcantly suppressed the proliferation of ESCC cells by
42.0851.73% at 72 h post transfection. Moreover, knockdown of miR-144
decreased (p0.046) the migration potential of KYSE-410 cells as compared to
the cells treatedwith negative control. In silico analysis and further validation by
dual-luciferase reporter assay revealedPURA to be a direct downstream target of
miR-144. Conclusion: Herein, we have demonstrated the potential diagnostic
implication of fıvemiRNApanel. Further, we have shown thatmir-144 acts as an
oncogenic miRNA by targeting PURA and promotes EC cell proliferation.
#5454 Serum circulatingmicroRNAs as potential biomarkers for prostate
cancer. Khanmi Kasomva,1 Ignacimuthu Savarimuthu,1 Gabriel Michael Paul-
raj,1 Arnab Sen,2 Stephen Sailo,3 Ngachan SV2. 1Entomology Research Institute,
Loyola College, Chennai, Chennai, India; 2ICAR Research complex for NEH re-
gion, Umiam, India; 3North Eastern Indira Gandhi Regional Institute of Health
and Medical Sciences, Shillong, India.
MicroRNAs (miRNAs) are small non-coding RNA, whose differential ex-
pression has been involved in the development and progression of cancers,
including prostate cancer (PCa). In recent studies circulating miRNAs have
been demonstrated to have the potential as non-invasive biomarkers in various
types of cancer. The aim of this study was to investigate the serum circulating
miRNA-103 could be used in diagnosis of prostate cancer in North-Eastern
India patient population. To evaluate this study blood samples were collected
from prostate cancer patients and healthy controls following ethical approval
and informed consent. The samples were reverse transcribed using stem loop
primers and expression levels of miRNA-103 were determined using real time
PCR.Differential expressions ofmiRNA-103 for each casewere used to compare
PCa serum with healthy serum samples. Serum circulating miR-103 levels was
signifıcantly down-regulated in the PCa patients comparison with healthy con-
trol. The serum circulating miRNA-103 could be potential for the diagnosis of
PCa in North-Eastern India Population.
#5455 NovelmiRNA-based therapeutic approach to selectively targetmu-
tant p53 in cancer. Amriti R. Lulla, Margret B. Einarson, Yan Zhou, David T.
Dicker, Wafık S. El-Deiry. Fox Chase Cancer Ctr., Philadelphia, PA.
Tumor suppressor p53, guardian of the genome, is frequently mutated or
functionally dysregulated in more than 50% of human tumors. p53 mutation is
a later event in tumorigenesis and a number of p53 mutants have “Gain of
Function” (GOF) properties that have been shown to promote invasive and
more aggressive phenotypes in cancer cells. Mutant p53 has been an attractive
andpromising therapeutic target for advanced stages of tumors. Yet,mutant p53
has proved to be one of the most undruggable targets. Thus, there is continued
interest in understanding the GOF properties of mutant p53 and in designing
novel strategies to target mutant p53 and/or key GOF pathways. Mature
MicroRNAs (miRNAs) are 22 nt endogenous, non-coding RNA sequences
that bind to 3=UTR of their target genes and inhibit their translation. miRNA
mimics are emerging therapeutics and attractive tools for mapping pathway
networks. We developed a novel functional high throughput screening (HTS)
assay to identifymiRNAs that selectively targetmutant p53-expressing cell lines.
The HTS was performed in isogenic TP53/ (wild-type), TP53-/- (null) and
TP53 R175H (mutant) HCT-116 colorectal cancer cell lines. Cell viability was
used as the HTS read-out of our functional screen. Of 2754 miRNA mimics
screened, we identifıed 56miRNAs that selectively target TP53 R175H (mutant)
cells. Our ongoingwork is directed to further validating and identifyingwhich of
these miRNA mimics selectively induce apoptosis in mutant p53-expressing
cells. We are also using reporter-based assays to identify a fraction of the 56
miRNAs that can bind to the p53 3=UTR. Our long-term goal is to selectively
target mutant p53-expressing cells using miRNA mimics as single agents or in
combination with FDA-approved or experimental therapeutics. Our strategy is
may provide a unique opportunity for development of targeted therapy for TP53
mutant tumors.
#5456 Avoiding chemotherapy resistance in squamous cell carcinomas:
anticancer activities of terpenoids and their impact on the regulation of
microRNAs. Camila Hernandes,1 Bruna da Silva,1 Maria de Fatima Guarrido
Klingbeil,2 Monica Beatriz Mathor,3 Ana Maria Soares Pereira,4 Patricia Sev-
erino1. 1Albert Einstein Research & Education Inst., São Paulo - SP, Brazil; 2Nu-
clear and Energetic Research Institute IPEN/CNEN, São Paulo - SP, Brazil; 3Nu-
clear and Energetic Research Institute IPEN/CNEN, Sao Paulo - SP, Brazil;
4Universidade de Ribeirao Preto, Ribeirao Preto - SP, Brazil.
MicroRNAs are small noncoding RNAs that play important roles in cellular
biology. They have been implicated in pharmacogenomics by down-regulating
genes that are essential for drug function. In this work we verifıed the potential
anticancer activity of the quinone methide triterpenes maytenin and 22--hy-
droxymaytenin, as well as of a quinonemethide triterpene-rich extract obtained
from cultivated Maytenus ilicifolia root cells, and evaluated the associated
microRNA expression following half maximal inhibitory concentration (IC50)
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treatment. Standard selectivity index (SI) for the isolated compounds and the
root cell extract was determined by the logarithmic shift in effective concentra-
tion (IC50) between cancer cell lines and oral keratinocytes. Both isolated mol-
ecules as well as the root cell extract presented pronounced antiproliferative and
pro-apoptotic activities in four cell lines derived from head and neck squamous
cell carcinomas, including a metastasis-derived cell line. A positive SI, with an
average 2-fold increase in potency, was detected for single agents and for the
extract. MicroRNA expression profıles were assessed at 24h, 48h and 72h fol-
lowing treatment and an average of 100 molecules presented consistent marked
variation in expression levels. Considering associations of microRNAs, genes
they regulate, and the drugs effects dependent on these genes, the down-regula-
tion of miR-193a-3p and miR-21 in treated cells is of particular interest. Both
microRNAs have been involved in 5-fluorouracil and cisplatin resistance, cur-
rent agents of standard chemoradiotherapy for locally advanced head and neck
cancer. Squamous cell carcinoma of the head and neck is one of the most com-
mon cancer types worldwide whereas treatment options based on conventional
therapies or targeted therapies under development have limited effıcacy. Plant-
derived products are valuable sources for the development of new therapeutic
options for cancer treatment or as synergistic agents in existing regular care.
MOLECULAR AND CELLULAR BIOLOGY / GENETICS:
Oxidative Stress, Autophagy, and Senescence
#5457 OGTrestrains theNRF2 antioxidant pathway viaO-GlcNAcylation
ofKEAP1.Po-HanChen, Timothy J. Smith, JianliWu,Michael Boyce, Jen-Tsan
Ashley Chi. Duke University, Durham, NC.
O-GlcNAcylation is a reversible post-translational modifıcation that adds an
O-linked -N-acetylglucosamine (O-GlcNAc) moiety onto serine/threonine
residues of target proteins. This modifıcation is regulated by only two enzymes:
O-GlcNAc transferase (OGT, the writer) and O-GlcNAcase (OGA, the eraser)
in mammals. Recent studies have revealed that OGT expression and O-GlcNAc
modifıcations are elevated in several cancers, but specifıc O-GlcNAc targets are
not well defıned. We conducted a global transcriptome profıling in MDA-MB-
231 breast cancer cells to search for signaling events that respond to O-GlcNAc
fluctuation. We found signifıcant up-regulation of genes involved in the NRF2-
dependent stress response when OGT activity is inhibited in different tumor
types. We also discovered a strong positive correlation of gene signatures be-
tween low OGT activity and NRF2 activation in multiple human tumor gene
expression datasets. NRF2, the primary regulator of redox balance, is usually
activated by oxidative stress and repressed under basal conditions by the
KEAP1-CUL3 ubiquitin ligase complex. However, we found that OGT inhibi-
tion increases NRF2 protein level through reducing poly-ubiquitination of
NRF2 in the absence of oxidative stress. By chemical sugar labeling and mass
spectrometry assays, we identifıed that KEAP1 is directly O-GlcNAcylated by
OGT especially within the BTB and Kelch motifs. Of all 11 putative O-GlcNAc
sites on KEAP1, we found serine 104 is responsible for regulating NRF2 activity
through affecting KEAP1-CUL3 interaction. Interestingly, we found the
amount of intracellular glucose co-vary with KEAP1 O-GlcNAcylation and
NRF2 protein, suggesting that glucosemetabolitesmay utilize the nutrient sens-
ing O-GlcNAcylation to fıne-tune the antioxidant response. We propose that
cancer cells could utilize O-GlcNAcylation, specifıcally on KEAP1, to regulate
NRF2-mediated stress responses in response to the dynamics of intracellular
glucose level. Since the NRF2 pathway is inappropriately activated in certain
tumor types due to dysregulated function of KEAP1, such as non-small cell lung
cancer, where it provides stress resistance and a growth advantage. Our study
could provide new insight into redox cancer biology and provide novel strategy
to modulate NRF2 activity during tumor development.
#5458 OncostatinM induces epithelial-mesenchymal transition and stem
cell properties in senescent human mammary epithelial cells. Benjamin L.
Bryson, Damian J. Junk, Mark W. Jackson. Case Western Reserve University,
Cleveland, OH.
The Interleukin-6 (IL-6) cytokine family member Oncostatin M (OSM) in-
duces epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC)
properties in transformed cancer cells. Paradoxically, OSM induces a growth-
inhibiting senescence response in normal human mammary epithelial cells
(HMEC). Senescence is induced in normal cells by various stresses, such as
aberrant oncogene signaling, and serves as a major tumor-suppressive barrier
that must be bypassed for cellular transformation in vitro and tumorigenesis in
vivo. Previous reports show that aberrant reactivation of EMT-inducing tran-
scription factors (EMT-TFs) promotes senescence bypass. Thus, aberrant EMT
may drive tumor initiation in addition to providing cancer cells withmesenchy-
mal cell and stem cell properties that drive tumor progression, metastasis, and
tumor recurrence. Conversely, our studies here indicate that much like aberrant
oncogene signaling, aberrant EMT and CSC-properties induced by OSM may
actually engage senescence in normal cells. Infecting Primary HMEC isolated
from reduction mammoplasty tissue with lentivirus encoding shRNA to p16
created indefınite lifespan “Normal” HMEC. Subsequent infections with viruses
encoding shRNA to p53, then constitutive expression of MYC and RAS created
“Transformed” HMEC. After treating HMECwith recombinant OSM, prolifer-
ation and senescence were assessed by growth assays and qRT-PCR analysis of
senescence-associated-galactosidase (GLB1) expression. EMTandCSC-prop-
erties were assessed by western and qRT-PCR analysis of an epithelial marker
E-cadherin (CDH1), a mesenchymal marker Vimentin (VIM), the EMT-TF
Snail (SNAI1), and the CSCmarkers CD44 andHAS2. Flow cytometry examin-
ing BrdU-incorporation and CD24/CD44 surface expression also assessed pro-
liferation and a CSC phenotype. OSM reduced growth by 80% and induced
GLB1 expression in Normal HMEC, but not in Transformed HMEC. OSM-
induced senescence was accompanied by Snail induction, changes in EMT-as-
sociated markers (reduced E-cadherin/increased Vimentin), and CSC marker
(CD44 and HAS2) induction. Notably, OSM induced immediate SNAI1 and
HAS2 expression; and a majority of the OSM-induced CD44 population con-
sisted of non-proliferating (BrdU-) cells. Unexpectedly, Snail and CD44 were
also induced during oncogenic RAS-induced senescence; and Snail expression
alone reduced growth and induced CD44 in normal HMEC. These results sug-
gest that much like aberrant oncogene signaling, aberrantly induced EMT and
CSC-properties may engage senescence in normal cells rather than promoting
senescence bypass.Defıning themechanism linking senescence, EMT, andCSC-
properties will identify targets for novel “pro-senescence” therapies that may
inhibit metastasis and tumor recurrence, and expand our repertoire of therapies
that enhance cancer patient outcomes.
#5459 Autophagy and senescence as possible mechanisms leading to pro-
liferative recovery and escape from treatment-induced tumor dormancy.
Liliya Tyutyunyk, Theresa Thekkudan, Tareq Saleh, David A. Gewirtz. Virginia
Commonwealth University, Richmond, VA.
Despite the ability of chemotherapy to eliminate the majority of tumor cells,
some are able to escape cell death and proliferate. In this study we evaluated
mechanisms of autophagy and senescence, that in theory allow cells to escape
apoptosis and might be responsible for cancer recurrence. Autophagy and se-
nescence, either alone or in concert, may result in temporary growth arrest
followed by proliferative recovery. With regard to autophagy, its function may
be either cytoprotective, where autophagy inhibition results in sensitization to
therapy or nonprotective, where autophagy inhibition does not alter sensitivity
to chemotherapy and/or ionizing radiation. To determine the mode of au-
tophagy inmurinemetastatic carcinoma 4T1 cell lines, autophagy was inhibited
pharmacologically using chloroquine, and by genetic silencing of the Atg5 au-
tophagy associated protein. Cells were treated with 1 M Adriamycin, stained
with Acridine Orange to assess autophagy by fluorescent microscopy (autopha-
gosomes appear orange-red) and autophagy quantifıed by Flow Cytometry. In-
duction and blockade of autophagy by chloroquine was confırmed by Western
blotting for the appearance of LC3B and degradation of p62. Senescence was
monitored by -galactosidase staining and quantifıed by Flow Cytometry based
on C12FDG staining; senescence was confırmed based on the induction of p21
and p16. Adriamycin (doxorubicin) exposure resulted in breast tumor cell death
as well as prolonged growth arrest; some of the arrested cells eventually recov-
ered and formed colonies. After exposure to doxorubicin, 4T-1 cells were sorted
based on intensity of-galactosidase staining and increased size (senescent cells
experience changes in size andmorphology). -galactosidase positive cells were
plated and monitored over time during which some of the cells recovered the
capacity to proliferate. In separate studies with mouse mammary carcinoma
cells, radiation also promoted cell death and prolonged growth arrest from
which some cells were able to recover proliferative capacity. Our data suggests
that although chemotherapy and radiation induce prolonged growth arrest and
senescence, these features are not permanent and cells are able to escape and
re-emerge from the senescent state to generate proliferating daughter cells. As
pharmacologic inhibition of autophagy did not result in increased sensitivity to
doxorubicin in 4T1 cells (or to radiation in themousemammary tumor cells) or
interfere with proliferative recovery, we postulate that inhibition of senescence
associated pathways may block proliferative recovery and/or promote tumor
cell killing in response to chemotherapy and/or radiation. Studies in progress are
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focused onmodulation of c-myc andmiR34 levels and the IL1/6/8 signaling axis
as potential strategies for interference with senescence and suppression of resid-
ual (dormant) tumor growth and cancer recurrence.
#5460 Targeting tumors by inhibiting mitochondrial electron transport.
Arvinder Kapur, Amruta P. Nayak, Thomas Beres, Kavya Rathi,Mildred Felder,
Amani Gillette, Spencer Ericksen, Melissa Skala, Lisa Barroilhet, Manish S. Pa-
tankar. Univ. of Wisconsin-Madison, Madison, WI.
Recently, we demonstrated that themonoterpene, citral, is potent inhibitor of
cell proliferation.Here, we are demonstrating that the	,-unsaturated carbonyl
functionality of citral is responsible for its biological activity causing substantial
increase in intracellular oxygen radicals. The resulting oxidative stress activates
p53. Neutralization of oxygen radicals by N-acetylcysteine attenuates the cyto-
toxic effect of citral and inhibits activation of p53. Inhibition of p53 by pifıthrin-
	 inhibits citral-induced apoptosis. Oxidative stress caused by citral initiates
downstream events causing apoptosis of cancer cells. With the identifıcation of
	,-unsaturated carbonyl group as the obligatory functionality for the anti-
cancer effects of citral, we surveyed other small molecule drugs that shared this
chemical entity. Cinnamaldehyde, nonenal, perillaldehyde, curcumin, and
plumbagin have the	,-unsaturated carbonyl functional groups and have dem-
onstrated anti-cancer effects. Using curcumin and plumbagin as prototypes, we
were able to demonstrate similarities in the cytotoxicmechanismwith citral. The
oxidative stress caused by curcumin and plumbagin is the initiating step re-
quired for cancer cell apoptosis. Fluorescent Lifetime Imaging Microscopy
(FLIM) showed that exposure to plumbagin results in an increase in free NADH
levels and a decrease in the NADH/FAD ratio. Additionally, in silico modeling
showed that plumbagin and curcumin docked to the active site of complex I and
III of the mitochondrial electron transport chain. Using the Seahorse analyzer,
our experiments showed that plumbagin and curcumin inhibited the oxygen
consumption rate in treated cells. These results indicate that the 	,-unsatu-
rated carbonyl containing compounds produce their cytotoxic effects by inter-
fering with the electron transport chain. The cancer cells respond to the surge in
oxygen radicals by increasing the expression of Nrf-2, the transcription factor
that regulates major anti-oxidant responses. This compensatorymechanism is a
form of chemoresistance that allows cancer cells to evade the cytotoxic effects of
agents such as citral. We will present data from strategies to inhibit the Nrf-2-
mediated compensation and thereby enhance the cytotoxic activity of citral,
curcumin and plumbagin. The data obtained through these experiments is pro-
viding important information that will allow designing of novel agents that can
interferewith the electron transport chain and inhibit tumor growth by inducing
oxidative stress.
#5461 Nuclear localization of the caspase 3 cleaved formof p73 in anoikis.
Samar Alsafadi, Sophie Tourpin, Sophie Salome-Desnoulez, Nadia Bessoltane,
Fabrice Andre, Jean Charles Ahomadegbe. Gustave Roussy, Villejuif, France.
The transcription factor p73 is a homologue of p53 that can be expressed as
pro- or anti-apoptotic isoforms. Unlike p53, p73 is rarely mutated or lost in
cancers and it is found to replace defective p53 inducing apoptosis. Here, we
investigated the p73 involvement in anoikis, a type of apoptosis caused by inad-
equate cell-matrix interactions. Breast cancer cell lines with different p53 status
were treated with doxorubicin or docetaxel and cells detached from the extra-
cellular matrix were analyzed. We demonstrate for the fırst time that doxorubi-
cin-induced cell detachment is associated with p73 cleavage and caspase activa-
tion, independently of the p53 status.However, we did not detect p73 cleavage or
caspase activation in detached cells under docetaxel treatment. Overexpressing
the apoptotic isoform of p73 led to cell detachment associated with p73 cleavage
and caspase activation. Interestingly, p73 cleaved forms localize to the nucleus
during the late phase of cell death indicating an increase in the transcriptional
activity. Our study suggests that the cleavage of p73 on specifıc sites may release
its pro-apoptotic function and contribute to cell death.
#5462 GTP cyclohydrolase in brain tumor stem cells is implicated in gli-
oblastoma growth.AnhN. Tran,1 KieraWalker,1 DavidHarisson,2Wei Chen,2
James Mobley,1 Lauren Hocevar,1 James R. Hackney,1 Randee S. Sedaka,1 Jen-
nifer S. Pollock,1 Sara J. Cooper,3 George Y. Gillespie,1 Anita B. Hjelmeland1.
1University of Alabama at Birmingham, Birmingham, AL; 2Vanderbilt Univer-
sity, Nashville, TN; 3HudsonAlpha Institute for Biotechnology, Huntsville, AL.
Glioblastomas (GBMs) are themost common primary brain tumors in adults
and one of the most aggressive cancers with high rates of recurrence and thera-
peutic resistance. In GBMs, subpopulations of highly tumorigenic cells called
brain tumor initiating cells (BTICs) have been characterized by their unique
capacity to promote tumor maintenance, therapeutic resistance, and angiogen-
esis. BTIC maintenance is known to be regulated by reactive oxygen and nitro-
gen species. GTP cyclohydrolase, or GCH1, is a critical molecule regulating
reactive species levels. We found that expression of GCH1 RNA and protein
were upregulated in BTICs in comparison to non-BTICs. Overexpression of
GCH1 in glioma cells increased cell growth in vitro and increased tumor forma-
tion and decreased survival in an intracranial GBM mouse model. In contrast,
GCH1 depletion with short hairpin RNA in GBM cells led to growth inhibition
in vitro as well as increased survival in animal orthotopic models. Furthermore,
genetic modulation of GCH1 led to altered ROS levels in GBM xenolines. In
silico analyses demonstrate that higher GCH1 levels in glioma patients correlate
with higher glioma grade, recurrence and worse survival. Together, our data
suggest that upregulation of GCH1 in BTICs promotes tumormaintenance and
is a key regulator of reactive oxygen species in glioblastoma.
#5463 Disulfıram suppresses metastasis via induction of anoikis and cal-
pain activation in triple-negative breast cancer. Eunhye Oh, Daeil Sung,
Youngkwan Cho, Ji Young Kim, Nahyun Lee, Yoon-Jae Kim, Tae-Min Cho, Jae
Hong Seo. Korea University, Seoul, Republic of Korea.
Triple-negative breast cancers (TNBC) exhibit aggressive phenotypes and are
associated with poor clinical outcomes due to a lack of effective therapeutic
strategies. Disulfıram (DSF) is a clinical therapeutic drug for the treatment of
alcoholism, and has also been shown to exhibit antitumor activity in TNBC cells
in a copper (Cu)-dependent manner, although how this occurs has not been
clearly elucidated. We sought to investigate the mechanisms responsible for
DSF/Cu-dependent induction of apoptosis and suppression of lung coloniza-
tion by TNBC cells. DSF/Cu treatment signifıcantly induced apoptosis, accom-
panied by an increase in the sub-G1 population, as well as caspase-3 activation.
DSF/Cu strongly suppressed cell migration and invasion, while inducing sup-
pression of focal adhesion kinase (FAK) phosphorylation and focal adhesions,
concomitant with an observed reorganization of cytoskeletal F-actin and col-
lapse of the plasma membrane. These effects were associated with calpain acti-
vation, coinciding with the breakdown of vimentin, FAK and talin, presumably
allowing for cell detachment. In a xenograft tumor model, DSF suppressed tu-
mor growth and lung colonization, which was also associated with calpain acti-
vation. Taken together, these fındings warrant further investigation of disul-
fıram as a potential treatment for metastatic TNBC.
#5464 Catalase mediates the survival of anchorage-independent ovarian
cancer cells.Cassandra L. Libbing, Calli A. Versagli. SaintMary’s College, Notre
Dame, IN.
Among United States women, ovarian cancer is the fıfth leading cause of
cancer-related death and the deadliest of the female reproductive system can-
cers. This is due to a lack of early detection, in effect, leading to primary diag-
nosis in later, metastasized stages for which there are few effective treatment
options. In order to metastasize, ovarian cancer cells must be able to survive
detachment from the extracellular matrix (ECM). When a non-tumorigenic
mammary epithelial cell detaches from the ECM, research has shown that levels
of Reactive Oxygen Species (ROS) rise in the cell and inhibit cell metabolism
resulting in decreased cell survival. Previous research has also shown that ECM-
detached breast cancer cells are able to utilize antioxidant enzymes to neutralize
ROS thereby rescuing ATP levels and promoting cell survival. This antioxidant
activity has also been shown to bolster cancer cells’ survival in anchorage inde-
pendence. Although studied in breast cancer cells, no work has been done in
ovarian cancer, which exhibits a very unique mode of metastasis through the
peritoneal fluid. To begin to understand the role of antioxidant enzymes in
metastatic ovarian cancer cells, we have worked to characterize the role of cata-
lase, a prominent antioxidant enzyme, in the survival of ECM-detached SKOV3
ovarian cancer cells. In order to do so, we utilized short hairpinRNA (shRNA) to
engineer SKOV3 cells defıcient in catalase. The catalase-defıcient cells were then
tested for colony formation in detachment and cell viability and proliferation in
both attachment and detachment. The results show that elimination of catalase
expression does not have a signifıcant effect on proliferation in attachment or
detachment, but signifıcantly decreases both cell viability and colony formation
of SKOV3 cells grown in ECM-detachment. This suggests that elimination of
catalase expressionmayhold promise for targeted treatment in late stage ovarian
cancer, calling for further investigation of the mechanisms behind these results
and the role that other antioxidant enzymes play in ovarian cancer. Future stud-
ies include looking at this phenomenon in other ovarian cancer cell lines, and
usingmouse xenograft studies to examine the effects of antioxidant compounds
on survival of metastatic ovarian cancer cells.
#5465 Persistent oxidative stress inmouse intestinal and colonic epithelial
cells after exposure to 12C-ion radiation. Shubhankar Suman, Santosh Kumar,
Albert J. Fornace, Kamal Datta. Georgetown Univ., Washington, DC.
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Purpose: 12C-ion radiotherapy is demonstrating favorable results compared
to photon radiotherapy for select cancers.While normal tissue exposure is lower
with 12C-ions relative to -rays, it cannot be completely eliminated and there-
fore, late tissue toxicity, inflammation and secondary carcinogenesis cannot be
ruled out. The goal of this study was to assess the extent of persistent oxidative
stress (POS) after 12C radiation exposure and compare the results to that after 
radiation exposure.Methods andMaterials:Mice (C57BL/6J; 6 to 8weeks;male)
were irradiated with 0.5 or 1.3 Gy of  or 12C-ion, and intestinal (IEC), colonic
(CEC) epithelial cells and tissues were collected 2 months after radiation expo-
sure. In epithelial cells, intracellular ROS,mitochondrial superoxide, mitochon-
drial membrane potential (MMP), and cardiolipin oxidation were studied by
flow-cytometry. Superoxide dismutase (SOD), catalase, and NADPH oxidase
activity along with lipid oxidation were also assessed in epithelial cells using
biochemical assays. Results: Our results clearly showed radiation quality and
dose-dependent induction of POS. Both intestine and colon showed a higher
elevation of intracellular ROS, mitochondrial superoxide, NADPH oxidase ac-
tivity, and mitochondrial cardiolipin oxidation after 12C relative to  radiation.
Moreover, antioxidant enzyme activity in intestine and colon was also signifı-
cantly reduced in 12C-irradiated mice. Compared to  radiation, membrane
lipid damage was remarkably higher in both intestine and colon of 12C-ion
irradiated mice. At 0.5 Gy, persistent oxidative damage indicated by 4-hy-
droxynonenal was 3-fold in colon and 1.6 fold in intestine after 12C relative 
radiation. Conclusions:Mitochondrial deregulation, increasedNADPHoxidase
activity and loss of SOD and catalase activities were the major contributory
events in 12C-ion-induced POS in mouse GI-tissues. Compared to intestine,
colon was more susceptible to POS induction that might be due to progressive
cell turnover in intestine resulting in faster elimination of initial damage signal
in a given time than colon. Taken together, our data suggest that normal tissue
exposure to 12C radiation carries higher long-term risk relative to -rays at
comparable doses and further detail evaluation is warranted.
#5466 Mitochondrial superoxide inhibits autophagy and induces apopto-
sis through SQSTM1-mediated mechanism.Heather G. Hambright, Addanki
P. Kumar, Rita Ghosh. UT Health Science Center at San Antonio, San Antonio,
TX.
Metastatic melanoma has a dismal survival rate for patients, despite recent
advances in targeted and immune-therapies. Recent studies show that elevated
autophagy and redox imbalance in melanoma cells contributes to chemothera-
peutic resistance, making these biological processes ideal therapeutic targets.
However, gaps still exist regarding the mechanism by which pro-oxidant thera-
peutics affect autophagic signaling and the ultimate impact on melanoma cell
fate. We previously demonstrated that pro-oxidant compound Nexrutine (NX)
selectively inhibits melanoma cell survival and autophagy through autophagy
scaffolding protein SQSTM1/p62. However, the mechanism by which NX-in-
duced oxidative stress inhibits autophagy through p62 remained unknown.
Thus, the primary objective of this studywas to determine howp62 regulates cell
fate during oxidative damage. We used a panel of primary melanocyte and mel-
anoma cells to evaluate i) proteasomal degradation of p62 during oxidative
stress-induced autophagy blockade, ii) the requirement for p62 during NX-
induced apoptosis, iii) effect of NX-induced superoxide on autophagy and cell
survival, iv) association of p62 with caspase-8 during oxidative damage, and v)
subcellular localization of NX. Proteasomal degradation was evaluated using
MG132 andwestern blotting for p62 followingNX.We used genetic approaches
(RNAi and overexpression using HA-p62) to determine the role of p62 in cell
fate as determined by survival, apoptosis, and autophagy measurements. Fluo-
rescence microscopy was used to determine the subcellular localization of NX.
Generation of superoxide was determined using mitoSOX and mitoTEMPO
pre-treatment was used to determine specifıcity. We found that i) NX-induced
ROS inhibits p62 protein by stimulating proteasomal degradation, ii) p62 me-
diates apoptosis in response to high levels of oxidative damage through
caspase-8 iii) NX generates superoxidewhich inhibits autophagy andmelanoma
cell survival, and iv) NX accumulates selectively in mitochondria. Overall, we
show that oxidative stress induced byNXoccurs upstreamof its inhibitory effect
on p62, autophagy and cell survival. Further, we demonstrate that NX induces
superoxide, which leads to autophagy inhibition through increased p62 degra-
dation, that ultimately inhibits melanoma cell survival, while not affecting pri-
marymelanocytes.We also show that p62mediates apoptosis through increased
association with caspase-8 in melanoma cells during superoxide generated by
NX.We also demonstrate for the fırst time that NX localizes to mitochondria of
melanoma cells and results in membrane potential loss due to its generation of
high amounts of superoxide. This study demonstrates that pro-oxidants likeNX
can successfully target two pro-survival melanoma features simultaneously and
may be useful melanoma therapeutic agents. Supported by R21 CA125719 &
ACRCF (RG); NIDCR T32 DE14318/COSTAR (HGH).
#5467 Phosphoproteomic analysis of pyruvate dehydrogenase in response
to environmental stress.Wendi O’Neill,1 Tereza Golias,2 Martin Benej,1 Nich-
olas Denko1. 1The Ohio State University, Columbus, OH; 2Slovak Academy of
Sciences, Bratislava, Slovakia.
Pyruvate dehydrogenase is a mitochondrial enzyme that regulates the flux of
carbohydrates into oxidative phosphorylation. The activity of PDH is largely
regulated by reversible phosphorylation. The pyruvate dehydrogenase kinases
add inhibitory phosphorylations to PDH on the E1	 subunit at positions 232,
293, and 300. Interestingly, there is a family of 4 related PDHK genes with
overlapping affınity for the 3 phosphorylation sites. PDHK1 and PDHK3 have
been identifıed as hypoxia-inducible at the transcriptional level, and PDHK1has
been shown to be important for the growth ofmodel tumors. Thiswork attempts
to more carefully defıne the functions of PDHK1 and 3 using CRISPR technol-
ogy in colorectal cancer lines in vitro and genetically engineered mice in vivo.
Using antibodies specifıc for the phosphorylated sites on E1	, we fınd that
PDHK1 is essential for the phosphorylation of the 232 site in response to hyp-
oxia and partially responsible for the hyperphosphorylation of 293 and 300. The
level of phosphorylation in response to hypoxia is also sensitive to nutrients in
the environment, with high levels of glucose enhancing E1	 phosphorylation in
hypoxia. Analysis of the number of phosporylations on individual E1	 mole-
cules using isoelectric focusing shows a range of events, with some molecules
having 2 or 3 phosphorylations, while a large fraction of the E1	 remains un-
phosphorylated in hypoxia. This type of pattern suggests a non-random phos-
phorylation of the multiple sites. Analysis of PDH activity supports the in vitro
fındings that any single phosphorylation event is suffıcient to inhibit PDH com-
plex activity. Preliminary mitochondrial oxygen consumption experiments
show that colorectal cancer cells are less dependent on PDHK1 for regulating
mitochondrial function compared to published data in pancreatic and head and
neck cancer. Finally, analysis of PDH phosphorylation in mice supports a role
for PDHK1 in the regulation of PDH activity in response to fasting and blood
glucose levels. In conclusion, regulation of PDH in normal and cancerous
colonocytes appears to be sensitive to environmental oxygen and nutrients.
PDHK1 is the PDHK familymember with the greatest influence on the addition
of non-random inhibitory phosphorylation events. These in vitro fındings will
be analyzed with respect to the fındings obtained using the new PDHK1 fl/fl
villin Cre mouse.
#5468 Expression of aquaporin 11 as a potential predictor of cisplatin
sensitivity. Jason V. Evans,1 Anwari Akhter,2 David P. Carbone,2 Mikhail M.
Dikov,2 Elena E. Tchekneva2. 1West Virginia University, Morgantown, WV;
2Ohio State University, Columbus, OH.
Platinum-based combination is a standard of care treatment for lung cancer
patients. Accumulating evidence indicates that aquaporins are emerging targets
in cancer. Aquaporin 11 (AQP11), a non-ubiquitous member of aquaporins
family, is an endoplasmic reticulum (ER)-specifıc water channel mostly present
in epithelial cells and is implicated in themaintenance of ER homeostasis. In our
recent publications, we demonstrated that under the stress the reduction of
AQP11 expression is a pro-apoptotic factor in normal epithelial cells. We re-
vealed that under normal conditions AQP11 is heavily S-nitrosylated forming
functionally important multimeric structures ( 1000 kDa), whereas cisplatin
treatment interferes with AQP11 causing its structural and post-translational
modifıcation.We hypothesized that if tumor cells express AQP11 then cells with
lower levels of AQP11 are not protected from cisplatin-associated ER stress and
develop higher sensitivity to drug treatment. In normal lungAQP11 is expressed
at low levels. We evaluated the expression of AQP11 in lung cancer cells to
determine whether the AQP11 expression correlates with cisplatin sensitivity
and whether lower AQP11 expression in lung tumor associates with positive
overall survival in patientswith lung adenocarcinoma.A strong link between the
level of AQP11 protein expression and cell sensitivity to CP was detected using
MTT assay. Screening lung cancer cell lines we found that all tested cancer cell
lines expressed AQP11 protein at various levels. Western blot of stress markers
showed that cisplatin-treated cells with higher AQP11 expression had lowered
cellular and ER stress. Reduction of AQP11 expression using shRNA AQP11
silencing in cispaltin-resistant A549 and HCC827 cell lines, resulted in the sig-
nifıcantly increased up to 3-fold sensitivity to cisplatin compared with control
shRNA transfected or parental non-transfected cells (p0.001). In sensitive
H460 cells, knocking downAQP11did not change sensitivity to cisplatin. TCGA
database analysis of previously untreated lung adenocarcinoma, detected 13%
tumors with elevated AQP11 mRNA expression. Lower AQP11 expression was
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signifıcantly associated with higher OS and higher median survival rate (52.5 vs.
34.47 mo) than in patients with high AQP11 expression (p0.05). AQP11 gene
is locatedwithin oncogenic 11q13-q14 amplicon, which is a common aberration
in solid tumors associated with poor prognosis. The AQP11 is a pro-survival
factor protecting tumor cells from cisplatin-induced stress. LowAQP11 expres-
sion associates with higherOS in lung adenocarcinoma patients andwith higher
cispaltin sensitivity in lung cancer cell. The ER stress aggravation via interfer-
ence with AQP11 could become a prospective therapeutic approach in anti-
tumor treatment.
#5469 Low dose ionizing radiation induces persistent activation of NA-
DPH oxidase pathway in mouse colon. Santosh Kumar, Shubhankar Suman,
Bo-Hyun Moon, Albert J. Fornace, Kamal Datta. Lombardi Cancer Center,
Georgetown University, Washington, DC.
Exposure to ionizing radiation has been linked to persistent oxidative stress.
The purpose of the current studywas to characterize the role ofNADPHoxidase
pathway in radiation-induced increased oxidant production in colon epithelial
cells. Mice (C57BL/6J; 6-8 weeks, male) were exposed to either sham or 0.5 Gy 
radiation, and NADPH oxidase pathway and oxidative stress markers were as-
sessed in colon samples 60 d after exposure. Radiation exposure led to higher
elevation of 4-HNE and 8-oxo-dG staining relative to unirradiated control. We
also observed increased staining for the proliferative marker phospho-histone
H3 in colon sections of irradiated mice. PCR analysis showed increased expres-
sion of two NADPH oxidase isoforms, Nox1 and Nox3, in irradiated samples.
Additionally, expression of NoxA1 and Noxo1 along with Hif1	 were also in-
creased after radiation. Immunoblot analysis confırmed the PCR results, and
ChIP assay revealed greater binding of stress response factor GATA6 andHif1	
to Nox1 and Nox3, and Nox3 promoters respectively after radiation exposure
relative to control. Co-immunoprecipitation experiments show enhanced bind-
ing of Rac1, an activator ofNADPHoxidase, toNox1 andNox3. In summary, we
demonstrated that exposure to a low dose of  radiation caused long-term up-
regulation of NADPH oxidase isoforms as well as its regulators and activators
such as NoxA1, Noxo1, Hif1	, TLR4, GATA6, Doux1, and Doux2. When con-
sidered along with our results on oxidative stress and proliferative markers, our
observations on NADPH oxidase pathway provides new insight into molecular
events contributing to radiation-induced persistent oxidative stress and cell pro-
liferation in colon, and have implications for colorectal carcinogenesis.
#5470 Reversibility of therapy-induced senescence in non-small cell lung
cancer as a model of cancer recurrence. Tareq Saleh, Emmanuel K. Cudjoe, S
Lauren Kyte, Scott C. Henderson, LynneW. Elmore, David A. Gewirtz.Virginia
Commonwealth University, Richmond, VA.
Disease recurrence at either primary or metastatic tumor sites arising from
dormant tumors is largely responsible for the morbidity and mortality of many
cancers. Although cellular quiescence has been proposed as a mechanism of
dormancy, the nature of the growth arrest that allows tumor cells to re-emerge
months or years after treatment has never been directly determined. The current
work was designed to examine the hypothesis that the senescence induced by
cancer chemotherapeutic drugs could be reversible, with implications for tumor
dormancy and disease recurrence. Studies were performed using etoposide in
models of non-small cell lung cancer (NSCLC). Exposure to etoposide at sub-
lethal concentrations resulted in growth arrest accompanied by the induction of
senescence and autophagy. Growth arrest was transient in that proliferative
recovery was evident by day 7 post-etoposide exposure. Analysis of senescence
based on -galactosidase activity demonstrated that the restoration of prolifer-
ative capacity coincidedwith a decline in the extent of senescence. Real-time live
microscopy demonstrated heterogeneous fates of senescent cells, where the bulk
of the cell population remaining in a state of stasis, a subset of cells undergoing
apoptosis, and a fraction of the large, flattened, and polyploid cells spontane-
ously entering into mitosis. Neither genetic nor pharmacological inhibition of
autophagy influenced the senescence response to etoposide, the eventual prolif-
erative recovery, or sensitivity to etoposide. These fındings indicate that the
induction and resolution of senescence is independent of the accompanying
autophagy, and that the autophagy induced by etoposide is non-cytoprotective
in function. These observations suggest that therapy-induced senescence may
ultimately be a transient process in that at least a subpopulation of tumor cells
can andwill regain proliferative capacity. Consequently, therapy-induced senes-
cence could potentially be studied as a model of tumor dormancy, and the
reversibility of senescence as a model of disease recurrence.
#5471 LSD1 stimulates cell survival and epigenetic homeostasis via snail
in hepatocellular carcinoma.YongHwa Jo,MinhNamNguyen, TaeGyuChoi,
Sung Soo Kim. Kyung Hee Univ. - Seoul Campus, Seoul, Republic of Korea.
HCC is the fıfthmost commonmalignancy in theworld.HCCgenerally arises
in the context of chronic liver diseases, or other metabolic, dietary or toxic
factors. Hypoxia is a critical microenvironment in hepatcarcinogenesis. It oc-
curs in series of distinct steps that include tumor cell invasion and proliferation.
The process of EMT required for liver cancer cell invasion is regulated by a
family of E-box-binding transcription repressors, which include Snail and Slug.
Protein N, the fırst discovered histone methylase, is an epigenetic enzyme play-
ing important role in regulation of gene expression and function by removing
mono- or dimethyl moieties from H3K4 and H3K9. However, the molecular
mechanisms underlying these biological behaviors have not been completely
elucidated. Here, we present the fırst evidence that expression of Protein N was
transcriptionally induced by Hif1 under hypoxia condition. We also showed
that the up-regulated Protein N enhanced HCC cell survival and sustained epi-
genetic homeostasis via activating Snail under hypoxic conditions in vitro/in
vivo. Furthermore, we revealed that Protein N/Snail stimulated Hif1 expression
by a positive feedback loop. Conclusively, we elicited that Protein N is an essen-
tial mediator in epigenetic aberrances of HCC (This work was supported by the
National Research Foundation of Korea (NRF) grant funded by the Korea gov-
ernment (MEST) (NRF-2016R1D1A1B03933763)).
#5472 YeastBax Inhibitor (BXI1) is involved in redox and calciumhomeo-
stasis of the ER in S. cerevisiae.David Eagan, JosephAlisch, LiamMcDonough,
Savannah Benko, Walter Jacob, Lukas Ritzer, James Mullin, John O’Reilly, Ni-
canor Austriaco. Providence College, Providence, RI.
In mammals, the Bax inhibitor (TMBIM) family of proteins has cytoprotec-
tive properties that are most evident in paradigms of endoplasmic reticulum
(ER) stress. The canonical gene of the family called BI-1 has been linked to
several human cancers. The crystal structure of a prokaryotic member of the
family, BsYetJ, has revealed that the Bax inhibitor proteins are pH sensitive
calcium leaks. Our published studies have shown that the yeast Bax Inhibitor,
Bxi1p, is localized to the endoplasmic reticulum and is involved in the unfolded
protein response (UPR) that is triggered by endoplasmic reticulum (ER) stress.
We now show that cells lacking BXI1 have an altered redox microenvironment
in the ER: The ER of	bxi1 cells exposed to dithiothreitol (DTT) and tunicamy-
cin, two drugs known to induce the unfolded protein response (UPR), become
more reduced than their wildtype counterparts. Moreover, we also report that
cells lacking BXI1 accumulate more calcium in the ER than wildtype cells. To-
gether, our data suggests that Bxi1p is involved in regulating the ER microenvi-
ronment. Other members of the TMBIM family may have the same role in
normal and cancer cells. [Our laboratory is supported by grant NIGMS R15
GM110578, awarded to N. Austriaco.]
#5473 Towards a better understanding ofMTH1 as a therapeutic target in
RAS-driven cancer. Govindi J. Samaranayake,1 Clara I. Troccoli,1 Mai Q.
Huynh,1 Andrew Win,1 Debin Ji,2 Eric T. Kool,2 Priyamvada Rai1. 1Univ. of
MiamiMiller School ofMedicine,Miami, FL; 2StanfordUniversity, PaloAlto, CA.
Oncogenic RAS signaling-generated reactive oxygen species (ROS) drive tu-
mor progression by the hyperactivation of proliferative, anti-apoptotic, and
metastatic pathways. ElevatedROS levels however can also cause oxidativeDNA
damage, leading to oncogene-induced senescence (OIS) and cell death. To avoid
such tumor-suppressive outcomes, RAS-driven tumors often upregulate redox-
protective proteins. The collective research from our group over the last few
years has shown that oncogenic RAS elevates expression of the mammalian
8-oxo-dGTPase MutT Homolog 1 (MTH1), which in turn enables evasion of
OIS, promotes transformation effıciency, and facilitates tumorigenicity. Our
prior work has therefore demonstrated that MTH1 is benefıcial to the spectrum
of RAS-driven transformation, and that its shRNA-mediated targeting in onco-
genic RAS-harboring lung cancer cells produces robust tumor-suppressive out-
comes. However the fırst wave of chemical MTH1 inhibitors has led to contro-
versial and conflicting results regarding MTH1 as a chemotherapeutic target.
Here we evaluate the benefıt of MTH1 inhibitors in wildtype. vs. oncogenic
KRAS expressing cells, and directly assess the effects of oncogenic KRAS as well
as three recently developed inhibitors on MTH1 8-oxo-dGTPase activity. Our
results support that introduction of oncogenic KRAS elevates both MTH1 ex-
pression and activity, presumably through its elevation of ROS levels, and thus
sensitizes cells to MTH1 inhibitors. The degree of this sensitization has a com-
plex dependence on residual 8-oxodGTPase activity in the different cells follow-
ing treatment with the MTH1 inhibitors, alternate antioxidant responses, and
induction of different tumor suppressor pathways. Our data therefore highlight
the importance of evaluating the molecular contexts and outcomes of MTH1
inhibition when determining its utility as a chemotherapeutic target.
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#5474 Sphingosine kinase 2/sphingosine 1-phosphate signaling regulates
p16mediated accelerated aging innormal somatic tissues and tcf21mediated
tumor suppression in lung cancer. Shanmugam Panneer Selvam,1 Marion
Cooley,1 Kristi Helke,1 Elizabeth Garrett-Mayer,1 Charles D. Smith,2 Besim
Ogretmen1. 1Medical University of South Carolina, Charleston, SC; 2Apogee Bio-
technology Corporation, Hummelstown, PA.
Sphingosine 1-phosphate (S1P), a pro-proliferative sphingolipid generated by
Sphingosine Kinases is upregulated in many cancers. Telomerase (hTERT), is a
ribonucleoprotein that extends the ends of chromosomes (telomeres), to pro-
mote lung cancer growth. We discovered that SK2 generated S1P binds and
stabilizes telomerase in the nuclear periphery by allosterically mimicking pro-
tein phosphorylation. Mechanistically, S1P binding protected telomerase from
MKRN1 mediated degradation thereby preventing telomere dysfunction and
senescence. The objective of this study is to delineate the molecular mechanism
of SK2-S1P mediated telomere dysfunction in aging and lung cancer. SK2
knockout mice tissues showed increased telomeric DNA damage and senes-
cence associated-beta galactosidase activity. Moreover, SK2 knockout mice dis-
played aging phenotypes by reduced subcutaneous fat, atrophy in spleens and
hypoplasia in mice testes. Also, SK2 knockout fıbroblasts showed increased se-
nescence and robust p16 expression and interestingly, p16 ablation rescued SK2
knockout fıbroblasts from senescence. Importantly, we found SK2 and telomer-
ase protein levels to be upregulated in lung cancer tumor tissues (n48). Mech-
anistically, pharmacological inhibition of SK2 by ABC294640 (in Phase II clin-
ical trials) leads to telomere dysfunction inA549 cells and interestingly wild type
and a phosphomimicking S921D-hTERT mutant of human telomerase overex-
pression prevented telomere dysfunctionwhereas S1P defectivemutantD684A-
hTERTdid not. In vivo, inhibition of SK2 byABC294640 or shRNAknockdown
displayed reduced tumor volume, decreased telomerase protein levels and in-
creased TUNEL positive cells. Interestingly, qPCR based gene array revealed
robust increase in TCF21 tumor suppressor in stable shSK2 tumors. Further-
more, shRNA against TCF21 following SCID mice xenograft studies showed
protection against ABC294640 induced tumor suppression. Interestingly, SK2
inhibition showed ATM/ATR kinase mediated p-CHK1 increase and subse-
quent activation of caspase-3 in both in vivo and in vitro experiments and stable
TCF21 knockdown prevents apoptotic cell death. Importantly, p16 overexpres-
sion in p16 defıcient A549 lung cancer cells prevented caspase-3 activation and
leading to senescence induction following inhibition of SK2-S1P byABC294640
or shRNA against SK2. Overall, our data suggest that SK2-S1P regulates telo-
mere dysfunction through p16 mediated aging in normal somatic tissues and
TCF21 mediated tumor suppression in lung cancer and interestingly SK2-S1P
and p16 acts as a molecular switch between senescence and apoptosis in normal
and cancer cells respectively.
#5475 Functional profıling of germline EPAS1 variants associated with
pheochromocytoma and paraganglioma. Edward Kim, Diana E. Benn, Roder-
ick J. Clifton-Bligh, Trisha Dwight. Kolling Institute of Medical Research, St.
Leonards, Australia.
Background: Endothelial PAS domain-containing protein 1 (EPAS1), encod-
ing hypoxia-inducible transcription factor 2-alpha (HIF2	), is involved in reg-
ulation of cellular hypoxia responses and has been shown to play a role in several
cancers including renal cell cancer and pheochromocytoma/paraganglioma
(PPGL). HIF2 levels are tightly regulated, being low in normoxia but increased
in hypoxia. Studying heritable PPGL syndromes has uncovered diverse genetic
events that lead to oxygen-independent HIF stabilization. Using massively par-
allel sequencing, we noted several germline EPAS1 variants that occurred in
subjects also carrying pathogenic mutations in either VHL or SDHB. In addi-
tion, two distinct EPAS1 variants were identifıed in separate individuals who did
not harbor germlinemutation in other known susceptibility genes.We therefore
investigated whether these variants affected EPAS1 function. Method: Six dif-
ferent EPAS1 variants were identifıed in the germline of patients with PPGL;
p.His194Arg, p.Arg247Ser, p.Phe374Tyr, p.Thr766Pro, p.Pro785Thr and
p.Ile789Val. GFP-taggedHIF2	 expressing constructs - expressing either empty
vector, wildtype or mutant HIF2	- were generated (including positive control
p.Pro531Thr) and transfected into HEK293 cells. HEK293 cells transfected with
wildtype HIF2	 were also subjected to hypoxic conditions for use as a positive
control. Co-immunoprecipitation followed by Western blotting analyses were
performed to determinewhether: a)HIF2	mutants are still able to interact with
VHL and ARNT; and b) HIF2	mutants are stabilized under normoxia. Candi-
date target gene expression (CCND1 and SLC2A) was measured by RT-qPCR.
Results: Western blot analyses showed that p.Arg247Ser, p.Phe374Tyr,
p.Pro531Thr and p.Pro785Thr amino acid changes in HIF2	 were all more
stable than wild-type HIF2	 under normoxia. Co-IP of HIF2	 with VHL
showed signifıcantly reduced interaction with p.Arg247Ser and p.Pro531Thr
(p0.05). Co-IP of HIF2	 with ARNT failed to show any effect on interaction
occurring as a result of the HIF2	 variants. Interestingly only p.Pro531Thr was
able to induce CCND1 and SLC2A gene expression (p0.05). Conclusion:
Germline EPAS1 variants p.Arg247Ser and p.Phe374Tyr share some functional
features in common with the known oncogenic somatic variant p.Pro531Thr.
These variantsmay therefore be functionally relevant to developing cancers that
are dependent upon pseudo-hypoxia.Whether any of these EPAS1 variants will
affect response to HIF2	 antagonist therapies is yet unknown and may be of
importance.
#5476 CIP2A can be a therapeutic target of rapamycin in radioresistant
head and neck cancer with P53 mutation. Song Hee Kim,1 Won hyeok Lee,1
Myung Jin Lee,1 Hyo Won Chang,1 Ji Won Kim,1 Mi Ra Kim,2 Jung Je Park,3
MyungWoul Han,1 Sang Yoon Kim1. 1Univ. of Ulsan, Seoul, Republic of Korea;
2Inje University College of Medicine, Busan, Republic of Korea; 3Gyeongsang Na-
tional University, Jinju, Republic of Korea.
The presence of p53 mutation was associated with poor survival in various
tumors. The involvement of p53 in apoptosis and cell-cycle control makes it a
plausible biomarker of prognosis . Classifying TP53 mutations in HNSCC de-
scribed disruptive TP53mutation in either the L2 or L3 loop of theDNAbinding
domain, resulting in polarity change within the protein, or stop cordon. Disrup-
tive TP53 mutation in HNSCC tumors predicts for locoregional recurrence,
due to increased radioresistance via the inhibition of senescence. Senescence
induction contributes to cancer therapy responses and is crucial for p53-medi-
ated tumor suppression. However, whether p53 inactivation actively suppresses
senescence induction has been unclear. Here, we found that overexpression
CIP2A (cancerous inhibitor of protein phosphatase 2A) positively correlated
with presence of p53 mutation in head and neck cancer and mediates radiore-
sistance through suppression of radiation induced senescence. And we demon-
strated that rapamycin could induce senescence via CIP2A downregulation and
increase radiosensitivity in p53 disruptive mutation cell line. This is the fırst
investigation to analyze the role ofCI2A in resistance to the radiotherapy of head
and neck cancer. As a consequence, a greater understanding of radioresistance
mechanisms through our results in head and neck cancer with p53mutationwill
enable the rational design of combination regimens and sequential treatment
algorithms to improve clinical outcomes and points to the usefulness of CIP2A
as a biomarker to predict clinical response to rapamycin in head and neck can-
cer.
#5477 Hydrogels to study ECM-oxygen gradient interactions for sarcoma
cell migration.Daniel M. Lewis,1 Sharon Gerecht,1 T. S. Karin Eisinger-Matha-
son2. 1Johns Hopkins Univ., Baltimore, MD; 2University of Pennsylvania Perel-
man School of Medicine, Philadelphia, PA.
Hypoxia is a critical factor in the progression andmetastasis of many cancers,
including soft tissue sarcomas. Frequently, oxygen (O2) gradients develop in
tumors as they grow beyond their vascular supply, leading to heterogeneous
areas of O2 depletion. Here, we report the impact of hypoxic O2 gradients and
collagen fıbers on sarcoma cell invasion and migration. We begun with O2 gra-
dient measurements and found that large sarcoma mouse tumors (300 mm3)
contain a severely hypoxic core [0.1% partial pressure of O2 (pO2)] whereas
smaller tumors possessed hypoxic gradients throughout the tumor mass (0.1–
6% pO2). To analyze tumor invasion, we used O2-controllable hydrogels to
recreate the physiopathological O2 levels in vitro. Small tumor grafts encapsu-
lated in the hydrogels revealed increased invasion that was both faster and ex-
tended over a longer distance in the hypoxic hydrogels compared with nonhy-
poxic hydrogels. Tomodel the effect of the O2 gradient accurately, we examined
individual sarcoma cells embedded in the O2-controllable hydrogel. We ob-
served that hypoxic gradients guide sarcoma cellmotility andmatrix remodeling
through hypoxia-inducible factor-1	 (HIF-1	) activation. We further found
that in the hypoxic gradient, individual cellsmigratemore quickly, across longer
distances, and in the direction of increasingO2 tension. Treatment withminoxi-
dil, an inhibitor of hypoxia-induced sarcoma metastasis, abrogated cell migra-
tion and matrix remodeling in the hypoxic gradient. Next, we have developed
hypoxic hydrogels where we can control collagen fıber density and cross-linking
density independently from oxygen gradients. Using this new platformwe show
that an increase in fıber density in conjunctionwith the hypoxic oxygen gradient
leads to an increase in sarcoma cell migration. This increase in migration speed
was also correlated with quicker stress relaxation times of the collagen gel and
larger pore size. Using these platforms we are able to create a novel 3D experi-
mental system with control over mechanical properties (crosslinking density,
binding sight density, fıber density, stress relaxation time, and stiffness) inde-
pendently from oxygen concentration. Overall, we show that O2 acts as a 3D
physicotactic agent during sarcoma tumor invasion and that this migration is
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modulated by collagen fıber density and pore size, in the surrounding matrix.
We propose the O2-controllable hydrogels as a predictive system to study early
stages of the metastatic process and therapeutic targets.
#5478 The TRPA1Ca2-permeable channel mediates a non-canonical re-
dox adaptation in cancer cells. Nobuaki Takahashi,1 Hsing-Yu Chen,1 Isaac
Harris,1 Daniel Stover,1 Roderick Bronson,1 Thomas Deraedt,1 Karen
Cichowski,1 Alana Welm,2 Gordon Mills,3 Joan Brugge1. 1Harvard Medical
School, Boston, MA; 2University of Utah, Salt Lake City, UT; 3The University of
Texas MD Anderson Cancer Center, Houston, TX.
Generation of reactive oxygen species (ROS), a natural byproduct of oxygen
metabolism, occurs in all aerobic organisms at a controlled rate. Cancer cells are
subjected to numerous cellular insults, including dysregulated oncogenes and
dissociation from their natural extracellularmatrix (ECM) niches, leading to the
generation of high levels of ROS.Although cancer cells possess enhanced canon-
ical antioxidant programs that neutralize ROS, they nevertheless exhibit prom-
inent ROS levels in response to these insults, suggesting the existence of addi-
tional programs that allow cancer cells to tolerate elevated ROS. In this study, we
provide evidence for an unconventional mechanism for redox adaptation in-
volving the ROS-activated, Ca2-permeable TRPA1 channel, which normally
functions as an irritant receptor in sensory neurons but is highly upregulated in
breast, lung, malignant neural sheath, and other tumors. We found that TRPA1
overexpression enhances survival and proliferation of MCF-10A cells under
conditions of matrix-detachment and this effect was dependent on TRPA1 ac-
tivation by ROS generated as loss of matrix anchorage. In MCF-10A acini,
TRPA1 expression induced Ca2 entry in ECM-deprived cells in the luminal
space and promoted their survival and proliferation. Conversely, TRPA1 knock-
down inhibited Ca2 responses to ROS generated through ECM detachment
and induced clearance of cells from the luminal space in breast cancer spheroids.
TRPA1 was also activated by ROS-inducing chemotherapies and drove
chemoresistance in breast, lung and malignant peripheral nerve sheath tumor
cells, and its downregulation suppressed breast xenograft tumor growth and
enhanced chemosensitivity. TRPA1mediated these effects independent of anti-
oxidant responses, but through activation of cellular survival and anti-apoptotic
programs involving the RAS-ERK/AKT/mTOR pathways. Together, our fınd-
ings describe an unexpected mechanismwhereby cancer cells co-opt the neuro-
nal TRPA1 channel in order to adapt to oxidative environments. This TRPA1-
induced response is distinct from canonical redox adaptation mechanisms that
rely on antioxidant program. As TRPA1 inhibitors are currently in clinical trials
for pain and respiratory therapies, these studies raise the possibility of using
these inhibitors as therapeutic chemosensitizers in TRPA1-enriched tumors.
#5479 Redox stress as a therapeutic Achilles heel in castration-resistant
prostate cancer. Clara I. Troccoli, Govindi J. Samaranayake, Mai Q. Huynh,
Karen Kage, Deukwoo Kwon, Yuguang Ban, Xi S. Chen, Enrique R. Zarco,
Merce Jorda, Kerry L. Burnstein, Priyamvada Rai. Univ. of Miami Miller School
of Medicine, Miami, FL.
Androgen deprivation therapy (ADT) initially suppresses prostate cancer
(PC) progression. However, castration resistant PC (CRPC) cells inevitably
emerge, resulting in incurable disease. We recently demonstrated that AD pro-
duces a form of cellular senescence leading to outgrowth of CRPC subpopula-
tions from the AD-sensitive parental cells. Gene expression profıling studies
comparing the parental LNCaP line to the senescence-resistant, early CRPC
variant, LNCaP SB5, revealed an enrichment of thiol-based redox-protective
proteins in the latter under AD conditions. This fınding suggests that redox
stress due to hyperactivated mitogenic/survival signaling or metabolic stresses
may be an important and understudied Achilles heel in the progression to
CRPC. Here we present the effects of inhibiting thioredoxin-1 (TRX1), a redox-
protective protein that was identifıed as being elevated in our early CRPC LN-
CaP SB5 model. Suppression of TRX1 expression via shRNA led to profound
growth suppression of CRPC cells, relative to their AD-sensitive counterparts,
and signifıcantly reduced CRPC xenograft tumor growth. Furthermore, under
AD, TRX1 suppression promoted p53-induced cell death, which was accompa-
nied by increased reactive oxygen species (ROS). These in vitro and in vivo
results were recapitulated using a Phase II clinical trial-tested chemical TRX1
inhibitor. Thus our results point to TRX1 as a critical requirement for CRPC
progression and provide a rationale for using TRX1 inhibitors in conjunction
with ADT to limit CRPC.
#5480 Peroxiredoxin 2 mediates the survival of ECM-detached ovarian
cancer cells. Calli A. Davison-Versagli. Saint Mary’s College, Notre Dame, IN.
Non-tumorigenic epithelial cells require anchorage to the extracellularmatrix
(ECM) in order to survive; however, it has been recognized that metastatic
cancer cells must have the ability to survive in anchorage independence. Ap-
proximately 70% of epithelial ovarian cancer (EOC) cases are diagnosed after
EOC cells have already metastasized, making EOC more diffıcult to treat. EOC
cells shed from the primary tumor and accumulate in ascites in the peritoneal
cavity before attaching and forming secondary tumors throughout the perito-
neal cavity. A better understanding of themolecularmechanisms involved in the
survival of this non-adhesive subset of cells that survive in anchorage indepen-
dence in the ascites could lead to the development of improved chemotherapeu-
tics and thus resulting in better survival rates of EOC patients. Striking increases
of reactive oxygen species (ROS)mediated byECM-detachment has been shown
to inhibit survival in non-tumorigenic mammary epithelial cells. Furthermore,
previous publications from our laboratory suggest that the antioxidant enzymes
catalase, superoxide dismutase 1 (SOD1), and superoxide dismutase 2 (SOD2)
are critical for metabolic maintenance and survival of ECM-detached breast
cancer cells; however, many other antioxidant enzymes and their role in the
survival of ECM-detached ovarian cancer cells have yet to be unveiled. Here,
we have found that the antioxidant enzyme, Peroxiredoxin 2, is important in
the survival of ECM-detached ovarian cancer cells, and elimination of this en-
zyme in SKOV3 cells results in decreased ability to survive in anchorage inde-
pendence. Thus, our data reveal that Peroxiredoxin 2may be an attractive target
for the design of chemotherapeutics aimed at eliminating metastatic ovarian
cancer cells. Given these data, we are working to understand the role of other
members of the Peroxiredoxin family, namely Peroxiredoxin 1, in the survival of
ovarian cancer cells in anchorage independence.
#5481 Role and regulation of Peroxiredoxin antioxidant proteins in K562
leukemia cells.Elizabeth Szabo, ShelleyA. Phelan. FairfıeldUniversity, Fairfıeld,
CT.
Peroxiredoxins are a family of antioxidant proteins that have found to play a
key role in many diseases, including cancer. A wide number of studies have
found that Peroxiredoxin levels are elevated in several cancers, and reducing
these levels can aid in inhibiting cell growth of cancer cells, suggesting that
Peroxiredoxins confer resistance to reactive oxygen species (ROS)-induced cel-
lular toxicity in cancer cells. Specifıc research has demonstrated that Peroxire-
doxin levels are elevated in leukemia cells, and that targeting and inhibiting
Peroxiredoxins in these cells can induce differentiation. Studies have also shown
the use of doxorubicin as an effective chemotherapy treatment to signifıcantly
decrease cell proliferation and viability in leukemia. The purpose of this study is
to examine Peroxiredoxin levels in K562 cells, a human chronic myelogenous
leukemia cell line, and determine if high levels of Peroxiredoxins have the ability
to protect cells from chemotherapy-induced death and possibly aid in chemore-
sistance. We fırst demonstrated that serum-deprived K562 cells exhibited sig-
nifıcant growth inhibition over a 72 hour time period, but had no signifıcant
effect on viability. We also showed that treating K562 cells with 50 nM doxoru-
bicin signifıcantly decreased proliferation and viability. Corresponding changes
in Peroxiredoxin protein levels are currently being analyzed to determine the
effect of both growth-inhibition and chemotherapy-induced cytotoxicity on the
Peroxiredoxin family inK562 cells, and siRNAexperiments are being conducted
to examine the protective role of Peroxiredoxins in these cells. Based onprevious
studies on MCF-7 cells conducted in our lab, we predict that Peroxiredoxin
levels will be modifıed under both conditions, and that suppression of Prdxs by
siRNA will increase chemotherapy susceptibility.
#5482 Constitutive overexpression of nrf2 in esophageal adenocarcinoma
protects cancer cells from bile salts-induced DNA damage and favors cancer
cell survival.Dunfa Peng, TianlingHu, ShouminZhu,Wael El-Rifai.Vanderbilt
University Medical Center, Nashville, TN.
Background: Esophageal adenocarcinoma (EAC) is the major type of malig-
nant cancer of esophagus in the USA. The incidence rate has increased 4-10%
per year amongmen since 1976 in theUSA,more rapidly than for any other type
of cancer. EAC is known to originate from premalignant Barrett’s esophagus
(BE) through BE-dysplasia-EAC process. Normal cells have intact anti-oxida-
tive mechanisms, among which NFE2related factor 2 (Nrf2) plays a pivotal role
in regulating cellular response to various stimuli. Cancer cells have high levels of
reactive oxygen species and oxidative stress due to activation of oncogenes,
inflammatory microenvironment, and dysfunction of anti-oxidative mecha-
nisms. However, the role of NRF2 in Barrett’s related esophageal carcinogenesis
is barely known.Methods and Results:We have found that Nrf2 protein expres-
sion is signifıcantly upregulated in EAC cell lines as compared to BE cell lines
(CPA, BAR10T) and normal esophageal squamous cell lines. We detected a
similar overexpression ofNRF2 in primary EAC tissue samples. Using luciferase
reporter assay, we demonstrated signifıcant induction of NRF2 transcription
activity in EAC cells in response to exposure to acidic bile acids, as compared to
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controls (P.01). We detected signifıcant increase in the expression of Heme
Oxygenase 1 (HO-1) and Glutathione Reductase (GR) in these cells (P.01).
Knockdown of NRF2 by siRNA or crisp/cas9, signifıcantly increased cellular
ROS level, oxidative DNA damage (8-oxoguanine), and double strand DNA
breaks (p-H2AX). Knockdown of NRF2 sensitized cells to apoptosis following
exposure to bile acids and CDDP. Concordant with these results, the use of
NRF2 inhibitor, Brusatol, sensitized EAC cells to CDDP treatment with a sig-
nifıcant increase in cell death, as compared to single agent treatment (P.01).
Conclusion: These results indicate that constitutive overexpression of NRF2 in
EAC cells protects cancer cells from high level of ROS and promotes cancer cell
survival. Inhibition of NRF2 through its specifıc inhibitor may have therapeutic
value in EAC.
#5483 Investigating the role of the retinoblastoma protein in induction
andmaintenance of oncogene-induced cellular senescence in tumor suppres-
sion.MohamadHarajly, Hasan Zalzali, Farah Ghamloush, RayaH. Saab.Amer-
ican Univ. of Beirut, Beirut, Lebanon.
Oncogene-induced cellular senescence is a tumor suppressor response result-
ing in irreversible cell cycle exit, and is dependent on the p53 and RB pathways.
Loss of p53 has recently been shown to allow re-entry of senescent cells into the
cell cycle. The role of theRB1protein inmaintenance of the senescent state is less
well studied.We investigated whether RB1 is necessary for the induction as well
as the maintenance of oncogene-induced senescence, and we also evaluated
whether RB1 activation is suffıcient to induce and/or maintain senesce in the
absence of a functional p53 pathway. Inactivation of RB1 prior to onset of se-
nescence led to failure of senescence induction, with impaired cell cycle exit and
failure to induce senescence markers. On the other hand, loss of RB1 after cells
had already entered oncogene-induced senescence was able to reverse some
features of the senescence phenotype, but did not result in successful cell divi-
sion and accumulation. Interestingly, in the absence of p53, constitutively active
RB1was suffıcient for cells to undergo oncogene-induced senescence, and effec-
tively prevented colony formation. Finally, while p53 inactivation was suffıcient
for senescent cells to re-enter the cell cycle, constitutive activation of RB1 pre-
vented cell cycle re-entry, even in the absence of p53.Our fındings show that RB1
is necessary for both the induction and maintenance of oncogene-induced se-
nescence, and that active RB is suffıcient for senescence induction as well as its
maintenance, both in the presence and absence of p53. These results have direct
implications on targeting RB activation as a senescence-inducing approach in
both p53 wild type and p53-defective premalignant and malignant tumors.
#5484 Structural domains of III-Tubulin regulate multiple stress re-
sponses and influence cell growth and survival in glucose-deprivednon-small
cell lung cancer. Amelia L. Parker, Wee S. Teo, Joshua A. McCarroll, Maria
Kavallaris. Children’s Cancer Institute, Randwick, Australia.
BACKGROUND: Non-small Cell Lung Cancer (NSCLC) survival rates are
dismal and elevated III-tubulin expression is associated with chemotherapy
resistance and tumor aggressiveness1. III-tubulin modulates glucose metabo-
lism and stress response signaling to support cancer cell survival and prolifera-
tion in glucose starvation conditions in the tumor microenvironment2. III-
Tubulin shares sequence similarity with other -tubulin isotypes, differing in
the C-terminal tail region of the protein, however the function of III-tubulin
structural domains remain uncharacterized. This study investigated the impor-
tance of theIII-tubulin body and tail structural domains in conferring survival
advantage to glucose-starvedNSCLC cells.METHODS:H460NSCLC cells were
gene-edited at the endogenousIII-tubulin gene using zinc fınger nuclease tech-
nology to replace the endogenous III-tubulin protein with either the full-
length or truncated III-tubulin protein, or replacement of the III-tubulin
body or tail with the I-tubulin sequence, each fused to a GFP tag. Clones
expressing themodifıedIII-tubulin proteinswere cultured in glucose-free con-
ditions for 48h to 10 days and cell growth and viability weremeasured byTrypan
Blue Dye Exclusion and Annexin-V apoptosis assay. The effect of the III-
tubulin modifıcations on the endoplasmic reticulum (ER) stress response, au-
tophagy andAkt signaling were examined bywestern blotting. RESULTS: Char-
acterization of the gene-edited clones revealed that loss of the III-tubulin
C-terminal tail or substitution of theIII-tubulin body or tail sequencewith that
of the I-tubulin sequence did not alter the microtubule architecture, cellular
proliferation rate or viability in normal growth conditions. However, loss of the
III-tubulin C-terminal tail signifıcantly reduced the viability of H460 cells by
37  0.05% in acute glucose starvation. Substitution of the III-tubulin body
with the I-tubulin body signifıcantly reduced cell number by 53 0.01% dur-
ing prolonged glucose starvation. Loss of the III-tubulin C-terminal tail in-
creased Akt activation and LC3B-II expression in glucose-rich conditions and
potentiated the increase in ER stress responsemarkersGRP78,ATF4 andCHOP
in response to glucose starvation. These results indicate that the III-tubulin
body and tail differentially confer a survival advantage to glucose-starved H460
cells and modulate multiple stress response signaling pathways in an isotype-
dependent and independent manner. CONCLUSION: This study provides in-
sight into the importance of III-tubulin structural domains in conferring III-
tubulin function in NSCLC, thereby advancing our understanding of the role of
tubulin isotypes in cell biology and themechanisms contributing to poor patient
outcome in this disease. 1Kavallaris, Nat Rev Cancer 2010 2Parker et al., Carci-
nogenesis 2016
#5485 The combined effects of polyamine and GSH inhibition on the vi-
ability of human cancer cell lines. John Grady, Davey Holzer, Kaci Keleher,
Emma Meetz, Russ Feirer. St. Norbert College, De Pere, WI.
Polyamines play essential roles in DNA stability and cell proliferation, mak-
ing polyaminemetabolism a potential target for cancer therapeutics. The sperm-
ine analog N1,N11- Diethylnorspermine (DenSpm) reduces levels of ODC, the
enzyme responsible for polyamine biosynthesis, and also induces the enzyme
SSAT, responsible for the catabolism of polyamines. Polyamines have been
shown to inactivate reactive oxygen species (ROS), including peroxides, protect-
ing mammalian cells from oxidative damage to nucleic acids. The catabolism of
polyamines by SSAT, in contrast, leads to the production of ROS, which results
in cellular death and limits the progression of cancer. Buthionine sulfoximine
(BSO) selectively depletes stores of intracellular glutathione GSH, an antioxi-
dant that neutralizes ROS. We hypothesized that treating cancer cell lines with
bothDenSpm andBSOwill have a synergistic cytotoxic effect on the cells, due to
the depletion of ROS-scavenging polyamines, the generation of ROS caused by
DenSpm and the absence of GSH. Treatment of the four cell lines, MCF-7,
MDA-MD-231, Caco-2 and PANC-1, with DenSpm resulted in moderate re-
ductions in cell viability as measured using the Cell Titer Blue assay (Promega,
Inc.). As has been widely reported in other mammalian systems, DenSpm (10
M) reduced intracellular polyamine concentrations (HPLC of benzoylated
polyamine derivatives) and induced SSAT (Western Blots). Treatment of cells
with BSO (500 M) caused a signifıcant decrease in intracellular GSH levels.
Similar fındings have been reported in previous studies with human neuroblas-
toma lines (Anderson, et al. 1999). The combination of BSO and DenSpm had
effects markedly greater than either compound alone. Pretreatment of cells with
BSO (500 M) for 24 hours with subsequent removal of BSO before DenSpm
(10, 100, 1000 M) addition resulted in signifıcantly reduced viability in all cell
lines. DenSpm was found to be most effective in the continued presence of BSO
as compared to a 24-hour BSO pretreatment. The compounds used in combi-
nation also enhanced ROS production, further demonstrating their synergistic
effects.
#5486 Oxidative stress and selective protein carbonylation in human
breast cancer tissue.Baikuntha P. Aryal, Ashutosh Rao. Food andDrug Admin-
istration, Silver Spring, MD.
Protein carbonylation is an irreversible modifıcation to the side chain of
amino acid residues induced by severe oxidative stress. Reactive oxygen species
(ROS) are constantly produced under normal as well as stress-induced condi-
tions, and play a role in both cancer progression and cancer suppression. Tumor
tissue are known to have higher ROS levels compared to surrounding healthy
tissue but ROS-induced specifıc protein carbonylation and its unique role in
cancer progression/suppression are poorly understood. In this study we com-
pared the relative total and specifıc protein carbonylation in flash frozen human
breast cancer andmatched adjacent normal tissue using ELISA, two-color west-
ern blot, mass spectrometry, and immunoprecipitation approaches. To under-
stand antioxidant capacity in tumor tissue, we analyzed superoxide dismutase
(SOD) for its antioxidant activity and protein level. Our results indicate that
tumor tissue has greater total protein carbonylation, lower SOD activity, lower
SOD protein levels, and elevated levels of autophagy compared to matched ad-
jacent healthy tissue. We also identifıed three specifıc proteins that showed
higher level of carbonylation selectively in tumor tissue compared to adjacent
normal tissue. Our fındings were further confırmed using the immortalized
MDA-MB-231 breast cancer cell line and MCF-12A noncancerous normal hu-
man epithelial breast cell. Identifıcation of selectively carbonylated proteins in
cancer tissue, and understanding their specifıc role in cancer progression may
promote the development of targeted therapeutic approaches to mitigate or
enhance oxidative damage of such proteins selectively in tumor tissue.
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#5487 Identifıcation of super-enhancer-associated cancer genes provides
novel therapeutic targets in adult T-cell leukemia/lymphoma. Takaomi
Sanda,1 Regina WJ Wong,1 Phuong TN Cao,1 Wei Zhong Leong,1 Alice WY
Yam,1 Tinghu Zhang,2 Shinsuke Iida,3 Takashi Okamoto,3 Ryuzo Ueda,4 Na-
thanael S. Gray,2 Takashi Ishida3. 1National Univ. of Singapore, Singapore, Sin-
gapore; 2Dana-Farber Cancer Institute, Boston, MA; 3Nagoya City University
Graduate School of Medical Sciences, Nagoya, Japan; 4Aichi Medical University
School of Medicine, Nagoya, Japan.
Super-enhancers are often enriched at cancer genes in various malignancies.
Identifıcation of such enhancers would pinpoint critical factors that directly
contribute to pathogenesis. Adult T-cell leukemia/lymphoma (ATL) is a highly
aggressive lymphoproliferative disorder that arises from CD4mature T-lym-
phocytes. A recent genome-wide sequencing study revealed a large number of
genetic and chromosomal abnormalities. However, there is still a lack of func-
tional evidence for these genetic abnormalities in ATL pathogenesis due to the
large mutational burden and the considerable genetic heterogeneity. Here, we
performed super-enhancer profıling combined with gene expression analysis in
primary ATL samples and cell lines. Super-enhancers are frequently enriched at
genes involved in T-cell activation andT-cell receptor signaling pathway in both
ATL and normal CD4 T-cells, reflecting the origin of leukemia cells. Super-
enhancers at the CCR4 gene, a known therapeutic target in ATL, were observed
in all ATL cases. Additionally, we identifıed previously-uncharacterized genes
that were highly activated in ATL cells and required for cell growth. A small-
molecule inhibitor of CDK7 effıciently downregulated the expression of these
genes and inhibited cell growth. Our study provides a novel strategy to identify
critical cancer genes in cancer.
#5488 APOBECsignaturemutationgenerates anoncogenic enhancer that
drives LMO1 expression in T-ALL. Zhaodong Li,1 Brian Abraham,2 Alla Ber-
ezovskaya,1 Nadine Farah,3 Yu Liu,4 Theresa Leon,3 Adele Fielding,3 Shi Hao
Tan,5 Takaomi Sanda,5 Abraham Weintraub,2 Benshang Li,6 Shuhong Shen,6
Jinghui Zhang,4 Marc Mansour,3 Richard Young,2 Thomas Look1. 1Dana-Far-
ber Cancer Institute, Boston, MA; 2Whitehead Institute for Biomedical Research,
MA; 3UCL Cancer Institute, United Kingdom; 4St. Jude Children’s Research Hos-
pital, MA; 5Cancer Science Institute of Singapore, Singapore; 6Shanghai Chil-
dren’s Medical Center, China.
Oncogenic driver mutations are those that provide a proliferative or survival
advantage to neoplastic cells resulting in clonal selection. Althoughmost cancer
causing mutations have been detected in the protein-coding regions of the can-
cer genome, driver mutations have recently also been discovered within non-
coding genomic sequences. Thus, a current challenge is to gain precise under-
standing of how these unique genomic elements function in cancer
pathogenesis, while clarifying mechanisms of gene regulation and identifying
new targets for therapeutic intervention. Here we report a C-to-T single nucle-
otide transition that occurs as a somatic mutation in noncoding sequences 4 kb
upstream of the transcriptional start site of the LMO1 oncogene in primary
samples from patients with T-cell acute lymphoblastic leukaemia. This single
nucleotide alteration conforms to an APOBEC-like cytidine deaminase muta-
tional signature, and generates a new binding site for the MYB transcription
factor, leading to the formation of an aberrant transcriptional enhancer complex
that drives high levels of expression of the LMO1 oncogene. Since APOBEC-
signature mutations are common in a broad spectrum of human cancers, we
suggest that noncoding nucleotide transitions such as the one described here
may activate potent oncogenic enhancers not only in T-lymphoid cells but in
other cell lineages as well.
#5489 Using genetic and chemical approaches to probe the mechanism of
DOT1L recruitment inMLL fusion leukemia. SierrahM.Grigsby, JamesRopa,
Justin Serio, Chenxi Shen, Jennifer Chase, Ivan Maillard, Andrew Muntean,
Zaneta Nikolovska-Coleska. University of Michigan, Ann Arbor, MI.
Mixed lineage leukemia (MLL) is an aggressive form of leukemia where the
MLL gene is translocated and fused to more than 80 different nuclear, cytoplas-
mic and membrane proteins. MLL-AF9 is one of the most common MLL-fu-
sions. This fusion partner is known to recruit several multiprotein complexes
including the AEP, SEC and DOT1L complexes leading to transcriptional acti-
vation. In particular, the recruitment of Disruptor of telomeric silencing 1-like
(DOT1L), a H3K79 histone methyltransferase, is essential for leukemogenesis
bymultipleMLL fusion proteins.Wemapped the binding site to a 10 amino acid
segment (865 - 874) on DOT1L where AF9 binds. Peptides derived from this
region that show dose-dependent disruption of this interaction. We also dem-
onstrated that DOT1L mutants lacking these 10 residues did not support trans-
formation byMLL-AF9. Encouraged by these results, we generated both genetic
and chemical tools to elucidate the role ofDOT1L recruitment to theMLL fusion
partners and the mechanism of leukemogenic inhibition by disrupting the pro-
tein-protein interaction (PPI) between MLL-AF9 and DOT1L. Fl/Fl DOT1L
MLL-AF9 Cre cell lines were generated with different constructs of DOT1L.
These constructs consisted of DOT1L mutants lacking the 10 amino acid bind-
ing site, a I867A point mutant known to block DOT1L binding, and an enzy-
maticmutant known to yield a catalytically inactive protein. As control cell lines,
MLL-AF6, a MLL-fusion containing a cytoplasmic protein, and E2A-HLF, a
non-DOT1L dependent fusion, were generated to demonstrate the specifıc ef-
fects of generated DOT1L mutant constructs. Both DOT1L PPI mutants im-
paired the transformation by MLL-AF9 and induced cell death by inducing
apoptosis and cell cycle arrest similarly to enzymatic inhibition. These results
established a foundation for discovering small-molecule inhibitors that disrupt-
ing theAF9-DOT1L as potential disease-specifıc therapies that target chromatin
modifıcations in this highly aggressive leukemia. A high throughput screening
was conducted identifying several different chemical classes of small molecules
that bind to the AF9 C-terminal hydrophobic binding site and disrupt the PPI
between DOT1L andMLL-AF9 fusion protein. Identifıed small molecule inhib-
itors were validated with series of biochemical, functional and cell-based assays.
Validated compounds selectively inhibit the growth of the DOT1L dependent
murine cells and induce cell death in a similar manner to the genetic approach.
The small molecules also showed specifıcity in killing human MLL-fusion cell
lines in comparison to non-MLL fusion leukemia. These results show that block-
ing the recruitment of DOT1L by AF9 using both genetic and chemical tools
eliminate MLL-AF9 mediated immortalization emphasizing an essential func-
tion for this interaction in leukemogenesis and warrant further development of
the identifıed small-molecule inhibitors.
#5490 Non-overlapping promoter and super-enhancer-associated depen-
dencies in multiple myeloma.Mariateresa Fulciniti,1 Charles Y. Lin,2 Mehmet
K. Samur,1 Richard Young,3 Herve Avet-loiseau,4 Kenneth Anderson,1 James
Bradner,5 Nikhil Munshi1. 1Dana-Farber Cancer Institute, Boston, MA; 2Baylor
College of Medicine, Houston, TX; 3Whitehead Institute for Biomedical Research,
Cambridge,MA; 4CentreHospitalierUniversitaire (CHU) deToulouse, Toulouse,
France; 5Novartis, Cambridge, MA.
The relationship between promoter proximal transcription factor-associated
gene expression and super-enhancer-driven transcriptional programs are not
well-defıned. We explored the transcriptional and functional interrelationship
between E2F transcription factors and BET transcriptional co-activators to
identify their individual contribution to eventual functional effect in multiple
myeloma (MM). To better understand how E2F1 and DP1 drive proliferation,
we mapped the global occupancy of E2F1/DP1 in MM. Integration of E2F1 and
DP1 genomic localization to MM reference epigenome revealed specifıc co-
occupancy of the factors at promoters of active genesmarked byH3K4me3, with
a strong positive correlation between E2F and RNA Polymerase II (RNA Pol II)
binding at transcription start sites. In contrast, active enhancers, as defıned by
promoter distal Mediator (MED1) peaks and marked by H3K27ac and BRD4,
showed virtually no E2F binding. Unbiased hierarchical clustering revealed dis-
tinct regulatory axes for E2F and BETs, with E2F predominantly localized to
active gene promoters of growth/proliferation genes and BETs disproportion-
ately at enhancer- regulated tissue specifıc genes confırming that these factors
establish distinct target gene programs. At the extremes, we found less than 10%
of geneswere among the top 500 inBRD4 enhancer signal (i.e. SE-regulated) and
top 500 E2F promoter signal. We hypothesized that the presence of BETs and
E2F in distinct regulatory axes divides active genes inMM into those that can be
selectively influenced by BET inhibition or E2F perturbation, but not both. In
line with this we have observed that dual E2F and BET inhibition is synergistic
for MM cell growth, both in vitro and in vivo. In conclusions, our results high-
lights the existence of distinct regulatory axes controlled by promoter and en-
hancer driven processes, suggesting a sequestered cellular functional control
that may be perturbed in cancer with potential for development of a promising
therapeutic strategy.
#5491 Identifıcation of transcriptional controls responsible for differen-
tial gene expression of the proton-coupled folate transporter in human solid
tumors.ZhanjunHou, CarrieO’Connor, SteveOrr, LarryH.Matherly.Barbara
Ann Karmanos Cancer Inst., Detroit, MI.
The majority of folate uptake into tissues and tumors involves facilitated
carriers, the reduced folate carrier (RFC) and proton-coupled folate transporter
(PCFT). PCFT is highly expressed in a wide range of human tumor cell lines and
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primary tumor specimens from a variety of lineages, with modest expression in
most normal tissues. PCFT transports optimally at pHs characterizing the tumor
microenvironment. We discovered novel 6-substituted pyrrolo[2,3-d]pyrimi-
dine folate analogs with substantial selectivity for PCFT over RFC, resulting in
potent antitumor effıcacy in vitro and in vivo. However, in some cases PCFT
levels varied substantially. Studies were performed to characterize the basis for
these dramatic differences in PCFT gene expression between HepG2 (elevated)
and HT1080 (negligible) tumor cells. Low levels of PCFT gene expression in
HT1080 cells were not likely due to methylation of CpG islands in the PCFT
promoter since 5-aza-2=-deoxycytidine treatment did not restore PCFT gene
expression. A PCFT promoter reporter construct -2005/96 in pGL3 (tran-
scription starts at1) was generated and showed high levels of activity in HeLa
cells by luciferase reporter assays. For HepG2 andHT1080 cells, wide variations
in PCFT transcript levels by real-time RT-PCR were paralleled by reporter gene
activitieswith the -2005/96 construct, suggesting that thesewere primarily due
to PCFT transcriptional regulation. Progressive deletion analysis of the -2005/
96 construct and reporter assays in HepG2 and HT1080 cells localized the
minimal promoter region to between -50 and 96. Additional deletion con-
structs (-35/96, -20/96, -15/96 and -10/96) were generated and studied.
Whereas the -35/96, -20/96, -15/96 promoter constructs retained 50%
activity for HepG2 cells and 10-15% activity for HT1080 cells relative to the
-50/96 construct, in both cases the -10/96 construct was essentially inactive.
Two critical cis elements were identifıed in the PCFT minimal promoter by
deletion analysis located between positions -50 and -35, and -15 and -10. Bioin-
formatics analysis localized putative cis elements for KLF-15 (-50 to -35) and
NRF1 (-15 to -10) binding. The functional importance of these elements was
confırmed by mutations of core consensus sequences in the -50/96 construct
and reporter gene assays. Binding of NRF1 and KLF15 to the endogenous PCFT
promoter in HepG2 and HT1080 cells was confırmed by ChIP assays which
paralleled patterns of differential PCFTgene expression. Collectively, our results
suggest that NRF1 and KLF15 contribute to dramatic variations in PCFT gene
expression between tumor cells. Better understanding the key determinants of
PCFT transcriptional control may lead to strategies for modulating PCFT levels
in combination with PCFT-targeted 6-pyrrolo[2,3-d]pyrimidine folate analogs
for treating solid tumors.
#5492 Comprehensive analysis of the dynamics of aberrant WNT signal-
ing on global gene expression and nuclear structure. Markus A. Brown. Na-
tional Institutes of Health, Bethesda, MD.
The organization of the genome in the nucleus is complex and dynamic.
Features of the nuclear architecture, including the spatial arrangement of
genomic sequences, the structure of chromatin, and the accessibility of regula-
toryDNAelementsmodulate nuclear processes such as gene transcriptionDNA
replication, DNA repair, RNA processing, and mRNA transport. However, the
interplay between nuclear architecture and gene expression is poorly under-
stood.We propose to elucidate the impact of silencing the prominent transcrip-
tion factor, TCF7L2, the major effector of the WNT signaling pathway, on the
transcriptional equilibrium and nuclear architecture of the nucleus in human
colorectal cancer cells. Our multidisciplinary approach combines targeted si-
lencing of TCF7L2, 3D-FISH, RNA-seq, and Hi-C chromosome conformation
capture, in parallel with mathematical modeling to delineate structure/function
relationships in the interphase nucleus. This approach will elucidate the intrica-
cies of a dynamic cellular signaling pathway in three-dimensional space.
#5493 The cistrome of estrogen receptor beta in colorectal cancer cells.
Rajitha Indukuri, Jun Wang, Fahmi Mesmar, Cecilia Williams. SciLifeLab,
Solna, Sweden.
Colorectal cancer (CRC) is the second leading cause of death in the United
States and a truly preventive approach still remains to be developed. Men have
the highest incidence rate for CRC and pre-menopausal women have a lower
incidence of CRC, suggesting hormonal factors mediate protective roles. ER is
the predominantly expressed estrogen receptor in the colonic epithelium and is
lost during CRC progression. In colon cancer cell lines re-expression of ER has
anti proliferative and anti-inflammatory properties, there is however little un-
derstanding of the mechanism whereby ER mediates these effects in colon
cells. In order to elucidate the mechanism of ER in CRC, we re-expressed this
receptor using lentivirus in four different CRC cell lines. We optimize chroma-
tin-immunoprecipitation (ChIP) with an antibody thoroughly validated for this
purpose and used IgG and input as well as cell lines without ER expression as
controls. ChIP-seq was performed using Illumina library preparation and next
generation sequencing. Alignment of sequence reads against the reference ge-
nome of version hg19 was done using Bowtie, and statistically signifıcant peaks
(FDR)were identifıed usingMACS. Results were compared toRNA-seq analysis
of the same cell lines. Key binding-sites and corresponding gene regulations
were confırmed using qPCR. We present for the fırst time, the cistrome of ER
in different CRC cell lines. We identify key binding motifs, including ERE and
AP-1 sites. Together, our results uncover ER as an important determinant for
attenuating cancer progression.
#5494 Hypoxia viaHIF1alpha can regulateWnt signaling in human colon
cancer cells. Yung Lyou,1 Amber Habowski,2 Stephanie Sprowl-Tanio,2 Kira
Pate,2 George Chen,2 Marian L. Waterman2. 1UCI Medical Center, Orange, CA;
2University of California Irvine, Irvine, CA.
Standard-of-care treatment for metastatic colorectal cancer combines che-
motherapy with bevacizumab, an angiogenesis inhibitor that depletes nutrients
and triggers hypoxia. Unfortunately, this strategy extends patient survival only a
fewmonths because tumors acquire adaptive resistance, enabling resumption of
angiogenesis. Adaptive resistance arises from reprogrammed metabolism, but
the regulatory networks that govern reprogramming are not defıned. Our stud-
ies have shown that overactiveWnt signaling, which is the most common cause
of colon cancer, programs cancer metabolism by promoting glycolysis and an-
giogenesis. Interestingly, metabolic genes targeted byWnt are also regulated by
the hypoxia transcription factor HIF1alpha suggesting there may be crosstalk
between the two pathways. Several studies suggest that HIF1alpha can influence
Wnt signaling, but the reported effects are variable ranging from positive to
negative. We fınd that HIF1alpha and LEF/TCF/beta-catenin complexes co-
regulate metabolic targets including LEF1 and TCF1 (TCF7) expression. Using
luciferase reporters driven by LEF/TCF promoters, we observe signifıcantly in-
creased LEF1/TCF1 but not TCF3(TCF7L1)/TCF4(TCF7L2) promoter activity
in hypoxic colon cancer cells. We identifıed putative hypoxia responsive ele-
ments (HREs) in the humanLEF1 promoter and deletion of theseHREs reduced
responsiveness to hypoxia. Furthermore, when colon cancer cells were treated
with inhibitors that either inactivate or reduce HIF1alpha protein, there was a
signifıcant decrease in Wnt reporter activity. These results suggest that hypoxia
and theWnt pathway crosstalk wherein hypoxia co-regulates metabolism genes
and increases Wnt signaling capacity via LEF/TCF expression. Current studies
are underway to investigate the mechanisms of crosstalk and joint regulation of
metabolic gene programs during adaptive resistance.
#5495 GANT61-induced cell death involves inhibition of transcription
and DNA licensing at GLI sites in the promoters of GLI-dependent target
genes in human colon carcinoma cells. Ruowen Zhang,1 Jiahui Wu,2 Sylvain
Ferrandon,2 Katie J. Glowacki,1 Janet A. Houghton1. 1Southern Research Insti-
tute, Birmingham, AL; 2Cleveland Clinic, Cleveland, OH.
The GLI genes, GLI1 and GLI2, are transcriptional regulators of the Hedge-
hog signaling response, binding at promoters to GACCACCCA-like consensus
sequences. From genetic and biochemical studies, GLI2 is the primarymediator
of HH signaling, which activates GLI1 to transcriptionally regulate target genes.
In cancers both GLI1 and GLI2 are oncogenes, aberrantly and constitutively
activated by oncogene-driven signaling pathways, in particular KRAS/BRAF in
colon cancer. GANT61, a specifıc GLI inhibitor, induced extensive cytotoxicity
in humanmodels of colon cancer, indicating GLI to be a critical target in cancer
cell survival.We have determined FOXM1 to be a transcriptional target of GLI1
at a GCCCACCCA consensus sequence. In HT29 cells, inhibition of GLI bind-
ing to the FOXM1 promoter by GANT61 led to inhibition of binding of the
pause-release factors DSIF, NELF, and p-TEFb in the region of the TSS, with
inhibition of binding of Pol II at both GLI and TSS sites. In R-loop regions,
RNA:DNA hybrid formation was reduced at both the GLI and TSS sites in the
FOXM1 promoter by GANT61, sensitive to RNaseH. Bisulfıte conversion/PCR
also determined 50% reduction in ssDNA (C-T conversions) in the GLI
binding region in GANT61-treated cells. Data support GANT61-induced inhi-
bition of GLI-dependent transcription at the PIC before R-loops are formed.
Pretreatment of HT29 cells with 	-amanitin (Pol II inhibitor) reduced
GANT61-induced H2AX foci, indicating the importance of transcription in
GANT61-induced DNA damage. Co-localization of GLI1 and BrdU foci, inhib-
ited by GANT61, indicated GLI1 and DNA replication were linked. By co-im-
munoprecipitation, GLI1 bound the DNA replication licensing factors ORC4,
CDT1, andMCM2, decreased in the presence of GANT61. By confocal micros-
copy, signifıcant co-localization of GLI1 and ORC4 foci was inhibited by
GANT61, and enrichment of ORC4 occurred at the GLI binding site in the
FOXM1 promoter. In addition to non-transcriptional mechanisms of interac-
tion between GLI1 and DNA licensing factors, CDT1 was found to be a tran-
scription target of GLI1 at a putative GACCACCCG consensus sequence in the
promoter. ChIP analysis determined signifıcant enrichment of H2AX at this
site in GANT61-treated HT29 cells. Overexpression of CDT1 in HT29 cells
reduced GANT61-induced cell death and cleavage of caspase-3, indicating a
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signifıcant role of DNA replication licensing in the mechanism of induction of
GANT61-induced cell death. In summary, we have demonstrated inhibition of
GLI-dependent transcription by GANT61 at the PIC during the initiation
of RNA synthesis, and the importance of inhibitingDNA replication licensing at
sites in promoter regions that bind the transcription factor GLI1 by both non-
transcriptional and transcriptional mechanisms. Supported by NCI Award 1
RO1 CA183921-01A1 and by Southern Research Institute.
#5496 Intratumor estradiol increment mediated by CtBP1/CYP19A1 de-
creases the proliferation of androgen insensitive prostate tumor cells. Cintia
Massillo,1 Guillermo N. Dalton,1 Juliana Porretti,1 Georgina Scalise,1 Paula L.
Farré,1 Colin Clyne,2 Paola De Luca,1 AdrianaDe Siervi1. 1Instituto de Biologia y
Medicina Experimental (IByME-CONICET), Autonomous City of Buenos Aires,
Argentina; 2Hudson Institute of Medical Research, Melbourne, Australia.
The normal growth and development of the prostate requires the action of
estrogens and estrogens receptors (ER) a and ß. Estrogen-related pathways are
clearly important in the development and progression of hormone-dependent
cancers such as prostate cancer (PCa), but the role of ERß remains controversial.
The production of estrogens from androgens is mediated by the aromatase en-
zyme. Aberrant expression of aromatase plays a critical role in PCa development
and progression. Metabolic syndrome (MeS) causes sex hormone imbalance
and has been identifıed as a risk factor for PCa. Recently, we found that C-ter-
minal binding protein (CtBP1), a transcriptional co-repressor of tumor suppres-
sor genes, is a novel molecular link betweenMeS and PCa.We developed aMeS
mice model that were inoculated with PC3 stable CtBP1 depleted or control
cells. MeS mice showed hormone imbalance and high levels of intratumor es-
tradiol. Interestingly, CtBP1 strongly repressed aromatase expression in these
xenografts. The aim of this study was to understand the transcriptional regula-
tionmechanismof aromatasemediated byCtBP1 in aMeS/PCamodel. To fulfıll
our aim, PC3 cells were co-transfected with a CtBP1 expression plasmid and a
panel of ten reporter vectors containing different lengths (27-1,004 bp) of
CYP19A1 promoter, cloning upstream to the luciferase gene. CtBP1 signifı-
cantly repressed the activity of all the studied promoters. By chromatin inmu-
noprecipitation (ChIP) and RT-qPCR we determined that CtBP1 associated to
CYP19A1 promoter and repressed its transcription. To identify possible CtBP1
partners in CYP19A1 expression regulation we investigated several transcrip-
tion cofactors. ByChIP, we found that p300 (histone acetyl transferase) and ERß
associated to aromatase promoter in PC3 cells. Using gene reporter assays, we
established that CtBP1 and p300 synergistically repressed, while ER ß activated,
aromatase promoter activity. Interestingly, estradiol exposure of PC3 cells, re-
leased CtBP1 from the aromatase promoter triggering its expression. Further-
more, we found that estradiol dramatically increased the viability and the S
phase percentage of the androgen sensitive LNCaP and, its derivative, C4-2 cells;
dramatically reducing apoptosis. Accordingly, estradiol decreased androgen in-
sensitive PC3 cell viability and G1 phase arrest. In summary, CtBP1 represses
aromatase expression in PCa. Nevertheless, MeS increases intratumor estradiol,
which releases CtBP1 from aromatase promoter activating aromatase expres-
sion, which in turn, modulates prostate tumor cell proliferation.
#5497 LSD1modulates androgen receptor cistrome in prostate cancer via
regulation of FOXA1 chromatin binding. Shuai Gao,1 Sujun Chen,2 Dong
Han,1WantingHan,1 Steven P. Balk,3HoushengHansenHe,2 ChangmengCai1.
1University of Massachusetts-Boston, Boston, MA; 2Ontario Cancer Institute,,
Toronto, Ontario, Canada; 3Beth Israel Deaconess Medical Center and Harvard
Medical School, Boston, MA.
Patients with castration-resistant prostate cancer (PCa) benefıt from
CYP17A1 inhibitors and more potent AR antagonists, but still relapse with
tumors expressing high levels of AR and AR regulated genes, indicating resto-
ration of AR activity. Therefore, there remains a pressing need for further de-
velopment of novel AR targeted therapies. One major mechanism that contrib-
utes to the PCa development is reprogramming of AR cistrome by
transcriptional factors and chromatin modifıers. In this process, AR is recruited
to a subset of newly established enhancers that can drive the expression of pro-
liferation genes. FOXA1 is one such transcriptional factor that determines cell-
lineage and is characterized as a “pioneer” factor to facilitate the access of addi-
tional transcription factors (such as AR or ER) to the regions with compact
chromatin. A recent study by comparing the AR cistrome in normal prostate
and PCa tissues suggests that FOXA1 is responsible for driving AR reprogram-
ing. Whole genome analyses in PCa cells have revealed that FOXA1 can recog-
nize enhancer regions with active histone marks (H3K4me1,2) and then further
open up the sites to allow subsequent AR binding. However, the molecular
mechanism on how FOXA1 is guided to the target region in PCa is still elusive
and studying this mechanism exhibits signifıcant translational potential on
modulating AR activity in PCa. Lysine Specifıc Demethylase 1 (LSD1/KDM1A)
is an important epigeneticmodifıer that can function as a repressor by demethy-
latingH3K4me1,2. However, LSD1 also often associates with enhancers and can
function as an activator in some contexts. Our previous studies showed that
LSD1 binding signifıcantly overlaps with FOXA1 and the overlapping sites that
are marked by high levels of H3K4me2 enrich for AR activated genes. LSD1 also
interacts with FOXA1 and this interaction enhances binding of both proteins at
AR-mediated enhancers. These fındings suggest that LSD1 may regulate the
availability of enhancers to AR via interaction with FOXA1 and hence may
reprogram AR cistrome in PCa cells. In this study, we performed ChIP-seq
analyses of FOXA1 andAR in PCa cells treatedwith LSD1 inhibitors. The results
showed that the global FOXA1 binding was drastically diminished by inhibiting
LSD1, indicating that its demethylase activity is required for FOXA1 binding.
Importantly, inhibiting LSD1 also results in distinct AR binding patterns with
the expression of many classic AR-activated genes being impaired and new
AR-activated genes emerged.We are currently carrying out xenograft studies to
examine the impact on tumor progression and AR cistrome by LSD1 inhibitor.
Overall, our results suggest that the LSD1-FOXA1 interaction functions as an
important modulator of AR cistrome and targeting LSD1 in conjunction with
AR antagonists may be a promising therapeutic approach to treat PCa.
#5498 Autoregulation of protein kinase D1 (PRKD1) expression in pros-
tate cancer. Bita Nickkholgh, Sittadjody Sivanandane.Wake Forest Univ., Win-
ston Salem, NC.
Protein kinase D1 (PRKD1) is down regulated in gastric, breast and prostate
cancer. Several regulatory mechanisms modulate PRKD1 activity in cancers. In
colon cancer, it has been shown that PRKD1 is down regulated by nuclear beta-
catenin. We explored whether beta-catenin is involved in regulation of PRKD1
expression in prostate cancer as well. A CHIP assay performed using prostate
cancer LNCaP cell lysate and pull down with beta -catenin antibody, which
demonstrated recruitment of beta -catenin to promoter of PRKD1 gene as well
as at downstream regions in the gene suggesting that beta -catenin could be
involved in PRKD1 regulation. To identify the exact binding site of beta-catenin
to PRKD1 gene, we carried out CHIP sequencing. The beta -catenin protein
complex was bound to a 166 bp sequence near exon 2 (chr14:29899631-
29899796). Because beta -catenin is a coactivator and not a known transcription
factor, we performed a transcription factor promoter array, which showed that
the MYC/MAX transcription factor complex may be the mediator of the regu-
latory effect of beta -catenin on PRKD1 expression. We validated the results by
performingCHIP assay usingMYC andMAXantibodies which showed recruit-
ment of both MYC and MAX to the same beta -catenin binding site to PRKD1.
In order to assess the functional impact of beta -catenin regulation of PRKD1 in
prostate cancer, beta-catenin mutated at threonine 120 residue (we have previ-
ously shown that PRKD1 is the only known kinase to phosphorylate the site)
demonstrated increased nuclear translocation of beta-catenin and increase
down regulation of PRKD1 and increased androgen receptor (AR) activity (in-
creasedARactivity iswell established to be associatedwith PCprogression).Our
data has identifıed a novel auto-regulatory mechanism of PRKD1 expression
through beta-catenin phosphorylation.
#5499 The reprogramming of the steroid receptor binding landscape at
active enhancers is associated with a fast DNA residence time through a
mechanism termed dynamic assisted loading in breast cancer cells. Erin
Swinstead, TinaMiranda,Ville Paakinaho, SongjoonBeak,GordonHager.NCI/
NIH, Bethesda, MD.
The transcription factor (TF), FoxA1 has been described as a pioneer factor,
implicated in steroid receptor (SR) binding patterns. Classically it has been pro-
posed that the pioneer factor model is a slow and static binding event. However,
it has recently been described that the estrogen and glucocorticoid receptors (ER
and GR), can regulate the binding patterns of each other in a mouse mammary
cell line defıned as dynamic assisted loading. Further, this phenomenonhas been
extending demonstrating that both ER and GR can recruit FoxA1 to specifıc
binding sites associated with an increase in chromatin accessibility and fast
DNA residence times. This was also associated with the absence of a DNaseI
footprint for the initiating and secondary factor supporting the assisted loading
model. To further investigate the molecular mechanism behind the dynamic
assisted loading model we have characterized the binding and transcriptional
landscape of ER and GR in a number of breast cancer cell line models. Genome
wide analysis of ChIP and DNaseI hypersensitivity assays upon single and dual
activation show that both SRs can recruit each other to a specifıc subset of
binding sites associated with an increase in chromatin accessibility. Therefore,
depending on the chromatin landscape, one factor functions as the initiating
factor and the other the secondary factor. Further, RNA polymerase II (RNAP
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II), p300, and H3K27ac binding patterns are associated with the newly pro-
gramed ER or GR binding sites. Together this suggests chromatin reorganiza-
tion upon dual activation of either ER or GR (the initiating factors) and recruit-
ment of the secondary factor (ER or GR) through an assisted loading
mechanism. Further, we have demonstrated an association of the transcriptional
machinery at these newly acquired binding sites at active enhancers. These re-
sults propose that many TFs in a given cell have the potential to affect the
binding landscape of other TFs, depending on the chromatin context. In addi-
tion, this study has shifted our classical understanding of pioneer factors in
breast cancer, demonstrating that not only can SRs alter the response of FoxA1
but also each other though highly dynamic and fast DNA interactions associated
with active enhancers and transcription.
#5500 KMT2C directs estrogen receptor activity in normal and trans-
formedmammary cells.Kinisha Gala,1 Amit Sinha,2 Francisco Sanchez-Vega,1
Young Rock Chung,1 James Hseih,1 Michael Berger,1 Nikolaus Schultz,1 Ales-
sandro Pastore,1 Omar Abdel-Wahab,1 Sarat Chandarlapaty1. 1Memorial Sloan
Kettering, New York, NY; 2Basepair, Inc., New York, NY.
Estrogen receptor alpha (ER	) is a ligand-activated nuclear receptor that
regulates proliferation and differentiation in mammary epithelial cells. ER	 ac-
tivity is likely dependent on the actions of pioneer factors and H3K4 methyl-
transferases which can establish a genomic landscape permissive for ER	 bind-
ing. Here, we identify the H3K4 methyltransferase KMT2C as essential for ER	
activity in mammary gland development and ER breast cancer growth.
KMT2C suppression decreases estrogen-dependent gene expression and causes
H3K4me1 loss at ER	 target gene enhancers. Consequently, KMT2C loss selec-
tively suppresses estrogen-driven breast cancer proliferation. Moreover, mam-
mary-specifıc Kmt2c knockout mice have defects in pubertal ductal formation
similar to Esr1 defıcient mice. Although KMT2C loss disrupts estrogen-driven
proliferation, it conversely promotes tumor outgrowth under hormone-de-
pleted conditions. Consistent with this, gene expression signatures of KMT2C
loss are associated with poor outcomes. We conclude that KMT2C is a key
regulator of ER	 activity whose loss uncouples mammary phenotypes from
hormone availability.
#5502 Functional evaluation of superenhancers as mediators of epithelial
ovarian cancer risk. Kevin C. Vavra,1 Simon Coetzee,1 Janet M. Lee,1 Paul
Pharoah,2 Dennis J. Hazelett,1 Kate Lawrenson,1 Simon A. Gayther1. 1Cedars-
Sinai Medical Center, Los Angeles, CA; 2University of Cambridge, Cambridge,
United Kingdom.
Superenhancers are master regulators of genes involved in cellular differen-
tiation and tumorigenesis.While it is nowwell established that typical enhancers
are key mediators of alleles associated with a mild risk of polygenic diseases,
including cancer, the role of superenhancers is less understood. We evaluated
the role of superenhancers in mediating risk of epithelial ovarian cancer (EOC).
Using FunciVar software and superenhancers defıned using H3K27ac chroma-
tin immunoprecipitation followed by next generation sequencing, performed in
cell lines and tissues, we characterized the superenhancer-risk SNP intersect and
identifıed a series of risk-associated loci where multiple candidate causal alleles
overlap with ovarian superenhancers. In particular, locus 3q25, the locus most
associated with epithelial ovarian cancer (EOC) risk from GWAS studies, has
70 candidate causal risk SNPs, all of which coincide with superenhancers
detected in ovarian cancer precursor cells (ovarian and fallopian tube epithelia)
but not in ovarian cancers. We are proposing that the presence of one or more
SNPs occurring at this locus leads to a higher expression of one ormore genes by
modulating activation of the superenhancer region. We tested the effect of de-
creasing the binding affınity of BRD4, a protein that binds superenhancer re-
gions, using a small molecule inhibitor on the expression of genes in this locus.
We identifıed three candidate genes—LEKR1, SSR3, and TiPARP—that dem-
onstrated a decrease expression level as a result of BRD4 binding inhibition.
Preliminary results show that partial knockdown of either SSR3 or TiPARP
decreases normal ovarian and fallopian cell proliferation, and knocking down
both SSR3 and TiPARP simultaneously shows an enhanced proliferation de-
crease compared with knockdown of a single gene. We then created stable
knockout (KO) models using the CRISPR-Cas9 system to fully KO one, two or
all three of our candidate causal genes: LEKR1, SSR3, and TiPARP. Functional
evaluation of these KOmodels is currently underway to test the hypothesis that
risk SNPs may regulate more than one gene at this locus. In all we identify a
potential role for superenhancers at a subset of EOC risk loci, and present a
functional pipeline for identifıcation of the target gene/genes and evaluation of
their role in neoplastic transformation.
#5503 Interplay between the transcription factors PRRX1 and FOXM1 in
pancreatic cancer. Benoit Marchand,1 Maximilian Reichert,2 Meredith A. Col-
lins,1 Anil K. Rustgi1. 1University of Pennsylvania, Philadelphia, PA; 2Technical
University of Munich, Munich, Germany.
Introduction: We have identifıed previously the Paired Related Homeobox 1
gene (Prrx1) as a key regulator of embryonic ductal development, acinar-to-
ductal metaplasia (ADM) and pre-cancerous lesion (PanIN)/pancreatic ductal
adenocarcinoma (PDAC) progression (ReichertM. et al Genes&Dev 2013).We
discovered an isoform switch between PRRX1A and PRRX1B occurring in
EMT-MET plasticity in pancreatic tumorigenesis (EMT) andmetastatic coloni-
zation of the liver (MET) (Takano S. et al Genes & Dev 2016). The transcription
factor FOXM1 is also implicated inEMTof pancreatic cancer cells. Interestingly,
both transcription factors, FOXM1 and PRRX1, are overexpressed in PDAC.
The aim of this studywas to investigate if PRRX1, specifıcally its isoforms,might
interact with FOXM1, to regulate gene transcription in pancreatic cancer.Meth-
ods: Experiments were performed in human pancreatic cancer cells (PANC1,
MIA PaCa2 and BxPC3), and HEK293T cells. Epitope-tagged PRRX1 and
FOXM1 proteins (wild type or deletion mutants) were either transiently or sta-
bly expressed in these cells. Immunoprecipitation and western blot were per-
formed to evaluate potential interaction between PRRX1 and FOXM1. As a
functional readout, the TnC and 6xFOXM1 luciferase reporters were used to
measure Tenascin C and FOXM1 transcriptional activities. Results: Immuno-
precipitation of tagged-PRRX1 or endogenous FOXM1 showed co-binding of
both PRRX1 isoforms (A and B) with FOXM1 in pancreatic cancer cells. We
further characterized this interaction using deletion mutants of PRRX1 C-ter-
minal region, FOXM1 binds to the 200-222 amino acid region of PRRX1. Sim-
ilarly, using deletion mutants of the FOXM1 N-terminal region we mapped
PRRX1 binding to the winged helix DNA binding domain of FOXM1. Interest-
ingly, we also observed co-binding of HA-tagged PRRX1A with either Flag-
tagged PRRX1A or PRRX1B suggesting homo and heterodimerization of the
PRRX1 isoforms. Next, we found that co-expression of PRRX1 and FOXM1
cooperatively induced transcriptional activity of a known PRRX1 target gene,
Tenascin C. Furthermore, co-expression of PRRX1A and FOXM1 cooperatively
induced FOXM1 transcriptionnal activity. FOXM1 has been reported to regu-
lateWnt signaling in glioblastomas (ZhangN. et al. Cancer Cell 2011). Given the
importance of Wnt signaling in early pancreatic carcinogenesis, we observed
co-binding of PRRX1 and FOXM1 with beta-catenin. Conclusion: Our results
provides new insights in the interaction of PRRX1 and FOXM1 with functional
activation of FOXM1mediated transcriptional activity, and potential regulation
of the Wnt pathway.
#5504 Regulation of the receptor for advanced glycation end products by
estrogen receptor ligands in endometrial cancer. Julia Davies, Deyarina Gon-
zalez, R.Steven Conlan. Swansea University, Swansea, United Kingdom.
Endometrial cancer has numerous established risk factors including excessive
unopposed estrogen exposure, tamoxifen, obesity and polycystic ovary syn-
drome (PCOS). These risk factors may promote inflammation, an important
hallmark of cancer. Since the endometrium is a site of regular and repeated
inflammation during the menstrual cycle, the regulation of inflammation may
be involved in endometrial cancer. The receptor for advanced glycation end
products (RAGE) stimulates numerous inflammatory signalling pathways and
its expression is elevated in a number of inflammatory pathologies including
diabetes and more recently cancer. This work aims to investigate the regulation
of RAGEby estrogen receptor ligands in endometrial cancer. RAGE and estogen
receptor isoform protein expression were examined in a patient cohort by im-
munohistochemistry. RAGE and ER isoform expression was assessed following
estrogen receptor ligand exposure in both type I and type II endometrial cancer
cell line models. ER	, ER, p65 and ER co-regulator recruitment to the RAGE
promoter following ER ligand treatment was determined in vitro by chromatin
immunoprecipitation. Data revealed (i) RAGE and ER isoform endometrial
expression is altered in endometrial cancer patients and patients receiving ta-
moxifen compared to postmenopausal women, (ii) RAGE is expressed in type I
and II endometrial cancer cell lines and its expression can be modulated by
estrogen and tamoxifen exposure, and (iii) by chromatin immunoprecipitation,
estrogen receptor ligands were shown to alter ER	, ER and ER co-regulator
binding at the RAGE promoter. To conclude, results from this work suggest
RAGE is associated with endometrial cancer development. Once clinically vali-
dated, RAGE and associated targets investigated in this study could be poten-
tially used as a panel of endometrial cancer biomarkers and may also be used to
indicate if patients are at risk of the adverse agonist action of tamoxifen in the
endometrium.
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#5505 TERT promoter mutations in primary papillary thyroid carcino-
mas and matched local / distant metastases. Noa Feás Rodríguez,1 Miram
Corraliza Gómez,1 Tomás Alvarez Gago,2 Juan JoséMateos Otero,2 RaquelMu-
ñoz Martínez,1 Ginesa Maria Garcia-Rostan1. 1Institute of Molecular Biology
and Genetics (IBGM), Valladolid, Spain; 2School of Medicine - Valladolid Uni-
versity, Valladolid, Spain.
TERT promoter (TERTp)mutations represent a common oncogenic event in
sporadic thyroid follicular cell carcinogenesis. Though TERTp mutations have
been statistically associated with aggressiveness and metastatic spreading, their
involvement in lymph node metastases (LNMs) and / or distant metastases
(DMs) development among papillary thyroid carcinoma (PTC) patients re-
mains to be defıned. To evaluate the role of TERTp mutations on metastatic
tumor expansion, primary tumors (Pt) and matched LNMs and/or DMs were
genotyped by means of PCR-direct sequencing in a cohort of 33 patients diag-
nosed of PTC, which had been previously analyzed for BRAF and RAS muta-
tions. Focal changes in the growth pattern ormicroscopic grade within the Pt or
the metastases were separately genotyped to determine the clonal/subclonal na-
ture of TERTp mutations, their association with particular histological variants
of PTC or their presence in intra-tumoral PDC-like foci. Results were correlated
with clinico-pathological parameters of pour outcome and survival. The analysis
of 99 tumor samples obtained from 33 PTC cases revealed that TERTp muta-
tions were quite common (42.4%).The mutation C228T was much more com-
mon than the C250T (78,6% vs 21,4%). TERTpmutations did not correlate with
specifıc PTC subtypes [CL-PTC, FV-PTC orMixed-PTC] andwere subclonal in
half of the cases. The mutations segregated to LNMs in 73% of cases [100%
CL-PTC and FV-PTC; 57% Mixed PTC]. In 2 Mixed-PTC cases the mutation
seemingly originated the novo in the LNM.TERTpmutationswere present in all
samples ofDM.While 71%of the casesmutated at TERTp bore the BRAFV600E
mutation, the coexistence of TERTp and RAS mutations was exceptional.
TERTp mutations were found to be signifıcantly correlated with age 45 years
old, high grade poorly differentiated PTC foci or nesting-PDC-like foci, stage at
diagnosis or at last follow-up and patient status. A trend of correlationwithmale
sex, vascular invasion, tumor recurrence and development of LNM during the
follow-up was also seen. Tumor multifocality was inversely correlated with
TERTpmutations. The coexistence of TERTp andBRAFV600Emutants did not
increase the prognostic power of TERTp mutations alone. All of the patients
who died of disease displayed TERTp mutations. Kaplan-Meier analysis re-
vealed that patients with PTC bearing TERTp mutations had a poor prognosis
showing a higher tumor recurrence probability [p 0.0085] and a reduced dis-
ease specifıc survival [p0.0001]. The coexistence of other mutations did not
signifıcantly increase the risk of recurrence or dying of disease. The study indi-
cates that TERTpmutations: 1) are common inmetastatic PTC; 2) are subclonal
in half of the cases; 3) spread inmost cases withmetastatic cells to LNMandDM
but do not drive the development of LNM; 4) identify PTCs patients with in-
creased risk of recurrence and mortality; 5) represent “per se” a biomarker for
poor outcome among PTCs.
#5506 SOX11 acts as part of the MYCN-WEE1 regulatory protein com-
plex implicated in neuroblastoma. Bieke Decaesteker,1 Sara De Brouwer,1
Fanny De Vloed,1 Geertrui Denecker,1 Suzanne Vanhauwaert,1 Jolien De
Wyn,1 Geneviève Laureys,1 BjornMenten,1 Pauline Depuydt,1 Patrick Reyn-
olds,2 Jo Vandorpe,3 Kris Gevaert,4 Jan Koster,5 Sara Ek,6 Frank Speleman,1
Katleen De Preter1. 1Centre for Medical Genetics Ghent, Ghent, Belgium;
2Texas Tech University Health Sciences Center, Lubbock, TX; 3University
Hospital Ghent, Ghent, Belgium; 4VIB Proteomics Expertise Center (PEC),
Ghent, Belgium; 5Academic Medical Center (AMC), Amsterdam, Nether-
lands; 6Lund University, Lund, Sweden.
Neuroblastoma (NB) is an aggressive lethal pediatric cancer of the developing
sympatho-adrenergic nervous system and characterised by a lowmutation bur-
den while exhibiting recurrent DNA copy number alterations including chro-
mosome 2p gain andMYCN amplifıcation. Rare amplifıcations have previously
allowed to identify additional oncogenes implicated in NB such as ALK and
LIN28B. Here we report on three NB tumours and two NB cell lines with high
level focal gain containing the SRY-related HMG-box transcription factor 11
(SOX11) as only protein-coding gene in the smallest region of overlap. The high
expression levels of SOX11 in NB and the developing sympathetic nervous sys-
tem, and high correlation of SOX11 mRNA and protein levels with survival
outcome, suggested a role for SOX11 as oncogene and prompted us to further
investigate its role in MYCN driven NB formation. SOX11 knock down in NB
cell lines showed reduced colony formation capacity and G1-S cell cycle arrest.
We observed increased SOX11 levels uponMYCN induction in NB cell lines, in
MYCN overexpressing mouse neuroblastomas compared to normal ganglia as
well as a high correlation of SOX11 andMYCNmRNA and protein levels in cell
lines and tumors. As these data could indicate direct MYCN regulation of
SOX11, we performed MYCN ChIPseq and indeed confırmed binding of
MYCN to the SOX11 promotor. Next, we demonstrated MYCN and SOX11
cooperative binding to common targets using SOX11 and H3K27ac ChIP-se-
quencing. First, we showed localisation of more than half (62%) of the SOX11
binding sites at enhancers.Moreover, 19% of SOX11 targets contained an E-Box
motif, typically known to be targeted byMYCN, and we showed overlap of 30%
of SOX11 and MYCN binding targets. In a further step to unravel SOX11 func-
tion in NB cells, we analysed SOX11 binding partners using IP-MS and identi-
fıed 9 robust interaction partners in multiple NB cell lines. These included
MYCN which was confırmed by reciprocal co-IP, as well as WEE1, a tyrosine
kinase critically implicated in G2-M checkpoint control for which multiple po-
tent and specifıc small molecule inhibitors are available. Remarkably, upon test-
ing of the AZD-1775WEE1 inhibitor in 10 NB cell lines, we observed the stron-
gest effects in cells with the highest SOX11 protein levels indicating that SOX11
expression levels can serve as predictive biomarker for AZD-1775 treatment
response. In conclusion we identifıed high-level focal gain of SOX11 in NB
tumors and cell lines and demonstrated the oncogenic role of SOX11 in MYCN
driven neuroblastoma with therapeutic opportunities through interaction with
WEE1.
#5507 Investigation of the effects of alterations in the glutamate receptor,
GRIK2onosteosarcoma tumorigenesis. JustinG.Mayers,1NalanGokgoz,2 Jay
S. Wunder,3 Irene L. Andrulis1. 1University of Toronto, Toronto, Ontario, Can-
ada; 2Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada; 3Si-
nai Health System, Toronto, Ontario, Canada.
Osteosarcoma is a primary, malignant bone tumour mainly affecting young
adults with a fıve-year survival rate of 60-70% depending on presentation of
metastasis at diagnosis. Tumours are marked by genetic instability and hetero-
geneity and for this reason, molecular subtypes have yet to be characterized.
Survival rates have remained consistent over the past few decades and novel
molecular targets for treatment are needed. Current genomic strategies have
identifıed recurrent copy number alterations. In a study of 44 flash frozen osteo-
sarcoma tumours which were obtained at the time of biopsy and 25 blood-
matched samples we identifıed recurrent copy number losses including a region
at 6q16.3 in 14% of tumours. Focal deletions were observed in the 5= intergenic
space and fırst intron of the GRIK2 gene and do not overlap with any coding
sequence. The relationship between alterations in this region and osteosarcoma
tumourigenesis has yet to be explored in depth. GRIK2 encodes an ionotropic
glutamate receptor that has been implicated as a tumour suppressor in gastric
cancer. An interesting feature of the tumours was the overlap of focal deletions
with a SETDB1 histone methyltransferase binding site indicating a potential
connection with epigenetic regulation of GRIK2. The goal of this study is to
examine the effects of non-coding, focal deletions on GRIK2 gene expression,
function and regulation in osteosarcoma cells. GRIK2 transcript levels were
measured in osteosarcoma tumours and cell lines using qRT-PCR. Functional
assays were performed to characterize the role of GRIK2 in osteosarcoma cell
proliferation, migration and apoptosis in vitro. Gene editing with CRISPR/cas9
was performed to examine the link between non-coding deletions and GRIK2
expression. GRIK2 transcript levels varied in tumours; several tumours with
focal deletions had increased transcript levels relative to cell lines which dem-
onstrated low expression levels. Due to the observation of low transcript levels, a
gain of function approach was employed to examine GRIK2 function in vitro.
Overexpression of GRIK2 decreased proliferation, migration and increased ap-
optosis in osteosarcoma cells. Gene editing of the SETDB1 binding site resulted
in increased GRIK2 transcript levels relative to untreated cells. This study sug-
gests that non-coding focal deletions are linked to high expression levels of
GRIK2 whichmay confer a less aggressive phenotype and are involved in epige-
netic regulation of the gene.
#5508 Histone modifıcations affect differential regulation of TGF-beta-
induced Nox4 by p53.Howard E. Boudreau, Wei Feng MA, Agnieszka Korze-
niowska, Jonathan J. Park, Thomas L. Leto. NIH-NIAID, Washington, DC.
Recent studies suggest p53 plays an important role in TGF--mediated cell
signaling and migration. Previously, we showed wild-type (WT) and mutant
(mt) forms of p53 differentially regulate reactive oxygen species (ROS) genera-
tion by NADPH oxidase-4 (NOX4). We found that WT-p53 suppresses TGF-
-induced NOX4, ROS production, and cell migration, whereas tumor-associ-
ated p53-mt proteins enhance NOX4 expression and cell migration by TGF-/
SMAD3-dependentmechanisms. In this study, we utilized The Cancer Genome
Atlas (TCGA) to perform statistical analysis on gene expression data from pri-
mary tumor samples and found a correlation between tumors with p53 “hot-
spot” mutations and increased NOX4 mRNA expression. Furthermore, we ex-
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amined the basis of human NOX4 promoter regulation by p53 and SMAD3. By
deletion analysis of the NOX4 promoter, we found two critical SMAD3 binding
elements (SBE) are also required for p53-dependent promoter activity. Con-
versely, promoter activity was abolished by dose-dependent heterologous ex-
pression of p53-WT. Moreover, expression of active SMAD3 resulted in robust
NOX4 promoter activity, which was abolished when co-expressed with p53-
WT. Chromatin immunoprecipitation (ChIP) analysis revealed SMAD3 and
p53-WT or p53-mt were associated with specifıc SBEs and p53 response ele-
ments (p53-RE) in a TGF--dependent manner. Interestingly, the repressive
effect by p53-WT on NOX4 was relieved upon treatment with histone deacety-
lase (HDAC) inhibitors ormutation of the transactivation domain. Overexpres-
sion of p300, a known p53-mt-binding transcriptional co-regulator and histone
acetyltranserfase (HAT), enhanced p53-mt-mediated NOX4 promoter activity,
whereas the HAT-inactive p300-mt reduced promoter activity. Furthermore,
overexpression of p53-mt augmented TGF--mediated acetylation of histones
associated with the NOX4 promoter. Finally, scratch wound assays demon-
strated NOX4 and p300 promote TGF-/mutant p53-mediated cell migration.
Collectively, these data and provide new insight on TGF-/SMAD3 andmutant
p53-mediated NOX4 induction involving epigenetic control of NOX4 in tumor
cell migration.
#5510 Pro inflammatory cytokines induce synergistic gene expression by
assisted loading of STAT3 at a subset of primed enhancers. Ido Goldstein,1
Songjoon Baek,1 Myong-Hee Sung,2 Gordon L. Hager1. 1National Cancer Insti-
tute, Bethesda, MD; 2National Institute on Aging, Baltimore, MD.
During inflammation, the liver responds to pro-inflammatory signals by pro-
ducing and secreting acute phase reactants (APR) involved in the inflammatory
process. The notable increase in the level of these proteins is due to transcrip-
tional induction that is jointly mediated by the pro-inflammatory cytokines
IL-1, TNF	 and IL-6. Although critical to restoring homeostasis during infec-
tion or trauma, the hepatic response to these cytokines can be deleterious in
pathologies involving chronic inflammation such as cancer. We set out to deci-
pher how pro-inflammatory cytokines cooperate to elicit a transcriptional re-
sponse in hepatocytes.We examined the transcriptome of primarymouse hepa-
tocytes treated with different combinations of cytokines and found several gene
expression patterns showing a complex cross-talk between cytokine signaling
pathways. Specifıcally, we found that a dual treatment of IL-1 and IL-6 results
in a synergistic expression of 164 genes, many of which are APR genes. TNF	
had an effect similar to IL-1, albeit weaker. A sequential rather than a com-
bined treatment attenuated the synergistic effect, suggesting direct cooperation
between the two cytokines in inducing transcription (as opposed to a cascade of
transcription). Assaying enhancer activity by H3K27ac ChIP-seq revealed the
dynamic nature of cytokine-responsive enhancers, with hundreds of enhancers
changing their activity level following either treatment. Importantly, enhancers
becoming more active upon dual IL-1/IL-6 treatment were enriched with bind-
ing sequences for STAT3, CEBP, AP1 and NFkB. Because IL-6 is the major
pro-inflammatory cytokine and its transcriptional effects are mediated by the
STAT3 transcription factor (TF), we assayed STAT3 binding patterns by ChIP-
seq. As expected, STAT3 binding was elevated following IL-6 treatment ge-
nome-wide. Surprisingly, in 351 enhancers, STAT3 binding was markedly in-
creased in the dual treatment compared to IL-6 treatment alone, suggesting a
supporting role for IL-1 in assisting STAT3 loading at a subset of enhancers.
This sub-population of enhancers had lower motif scores compared to unas-
sisted STAT3 binding sites, indicating optimal STAT3 binding at these enhanc-
ers might require some facilitation by other factors. Accordingly, these enhanc-
ers were less active at the untreated state, but increased in activity following
IL-1 treatment, an effect we termed ’IL-1 priming’. Our results are consistent
with a scenariowhereby IL-1-activatedTFs (C/EBP, AP1 and/orNFB) assist
STAT3 loading by binding a subset of enhancers, activating them thereby aug-
menting STAT3 binding. This unexplored mechanism of transcriptional regu-
lation by cytokines may be targeted to alleviate the deleterious effects of pro-
tumorigenic inflammatory programs.
#5511 Lineage-specifıc and shared cytokine-sensing genes respond dis-
tinctly to the master regulator STAT5. xianke zeng, Michaela Willi, Ha Youn
Shin, Chaochen Wang, Lothar Hennighausen. NIH, Bethesda, MD.
JAK/STAT signaling pathways are critical for cell response to cytokines
across multiple tissues, genetic variation in this pathway could associate with
neoplastic diseases. STAT5, the most common used STAT family member,
differently activates two distinct classes of genes. It activates cell-specifıc
genes up to two orders of magnitude higher than shared genes expressed
across different cell types. Socs2 (Suppressors of cytokine signaling 2), a
widely expressed STAT5 target gene and a negative regulator of cytokine
feedback loops, contains STAT5 response element within its promoter re-
gion. In our study, we demonstrated that STAT5 preferentially binds to
promoter sequence of shared STAT5 targeted genes and to distal putative
enhancers of lineage-specifıc genes. DNase-seq demonstrated that chroma-
tin accessibility of STAT5-based enhancers was greatly dependent on cyto-
kine exposure, while common STAT5 promoter targets were constitutively
accessible. CRIPSR /Cas9 gene editing was used to delete the generic STAT5
binding sites in Socs2 locus in mice. Prolactin induction of Socs2 was abro-
gated both in liver and mammary gland, and resulted in elevated STAT5
activation and precocious mammary development in mutant mice. Taken
together, we demonstrated that promoter-bound STAT5modulates cytokine
responses of universal STAT5 target genes, while enhancer-bound STAT5 is
necessary for linage-specifıc target gene activation. This study provides new
insight into the mechanism of used by a generic cytokine response element
controlling lineage-specifıc transcription.
#5513 Notch directly represses transcription by recruitment of PRC2 to
the ternary complex. Xiaoqing Han, Prathibha Ranganathan, Anthony Capo-
bianco. University of Miami, Miami, FL.
It is well established that Notch functions as a transcriptional activator
through the formation of a ternary complex that comprises Notch, Maml and
CSL. This ternary complex then serves to recruit additional transcriptional co-
factors that link to higher order transcriptional complexes. The mechanistic
details of these events remain unclear. In this study, we report that the Notch
ternary complex can also serve to direct the formation of a repressor complex to
terminate genes expression of select target genes. Herein we demonstrate that
p19Arf and Klf4 are transcriptionally repressed directly by Notch. Data indicate
thatNotch recruits PRC2 andLsd1 to these promoters, which leads to changes in
the state of the epigenetic landscape and repression of transcription. The de-
methylase activity of Lsd1 is a pre-requisite for Notch-mediate transcriptional
repression. Furthermore, we identifıed a stable Notch transcriptional repressor
complex containing Lsd1, PRC2 and the Notch ternary complex. This study
demonstrates proof of concept for a novel function of Notch and provides fur-
ther insight into themechanisms ofNotchmediated tumorigenesis. This fınding
provides rationale for the targeting of epigenetic enzymes to inhibit Notch ac-
tivity or use in combinatorial therapy to provide a more profound therapeutic
response.
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#5514 Loss of expression of the recycling receptor, FcRn, promotes tumor
cell growth by increasing albumin consumption. Rafal Swiercz, Min Mo, Pri-
yanka Khare, Zita Schneider, Raimund Ober, Sally Ward. Texas A&M Health
Science Center, College Station, TX.
Tumor cells rely on high concentrations of amino acids to support their
growth and proliferation. Although increased macropinocytic uptake and lyso-
somal degradation of the most abundant serum protein, albumin, in Ras-trans-
formed cells can meet these demands, it is not understood how the majority of
tumor cells that express wild type Ras achieve this. In the current studywe reveal
that the neonatal Fc receptor, FcRn, regulates tumor cell proliferation through
the ability to recycle its ligand, albumin. By contrast with normal epithelial cells,
we show that human FcRn is present at very low or undetectable levels in the
majority of tumor cell lines analyzed. Remarkably, shRNA-mediated ablation of
FcRn expression in an FcRn-positive tumor cell line results in a substantial
growth increase of tumor xenografts, whereas enforced expression of this recep-
tor by lentiviral transduction has the reverse effect. Moreover, intracellular al-
bumin and glutamate levels are increased by the loss of FcRn-mediated recycling
of albumin, combined with hypoalbuminemia in tumor-bearing mice. These
studies identify a novel role for FcRn as a suppressor of tumor growth and have
implications for the use of this receptor as a prognostic indicator and therapeutic
target.
#5515 Dicer suppresses cytoskeleton remodeling and tumorigenesis of
colorectal epitheliumbymiR-324-5pmediated suppressionofHMGXB3and
WASF-2. Lina Sun, Jianming Li. Soochow University, Su Zhou, China.
Emerging evidence indicates that microRNAs, a class of small and well-con-
served noncoding RNAs, participate in many physiological and pathological
processes. RNase III endonuclease DICER is one of the key enzymes for mi-
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croRNA (miRNA) biogenesis. However, the role of Dicer and its downstream
miRNAs in colorectal cancer (CRC) remain largely unclear. Here, we found that
Dicer was downregulated in tumour samples of CRC patients at both mRNA
and protein levels. Importantly, more tumours were developed in mice with
intestinal epithelial cells specifıc deletion of Dicer (Dicerloxp/&VillinCre
mice) after azoxymethane (AOM) and dextran sulfate sodium (DSS) adminis-
tration. Interestingly, deletion of Dicer in intestinal epithelial cells led to severe
chronic inflammation and cytoskeleton remodeling of intestinal epithelium
layer in mice with or without DSS administration. Microarray analysis of 3
paired Dicer deletion CRC cell lines (RKO-WT/RKO-DICER-/-, HCT116-WT/
HCT116-DICER-/- and DLD-WT/DLD-DICER-/-) showed that miR-324-5p
was one of the most signifıcant decreased miRNAs. In the intestinal epithelium
of Dicerloxp/loxp&VillinCre mice, miR-324-5p was also found to be markedly
downregulated. Mechanistically, miR-324-5p directly bound to the 3=untrans-
lated regions (3=UTRs) ofHMGXB3 andWASF-2, two key proteins participated
in cytoskeleton remodeling, to suppress their expression. Intraperitoneal injec-
tion of miR-324-5p AgomiR curtailed chronic inflammation and cytoskeleton
remodeling of colorectal epithelium and restored intestinal barrier function in
Dicerloxp/&VillinCre mice induced by DSS. Therefore, our study reveals a
key role of a DICER/miR-324-5p/HMGXB3/WASF-2 axis in cytoskeleton re-
modeling and maintaining integrity of intestinal barriers and as such alludes to
the possibility of screening for small-molecule compounds that boost Dicer
activity as a potential strategy in the treatment of colorectal cancer.
#5516 Regulation of TFPI-2 in the progression of ovarian cancer. Jacque-
line Fry,1 Sumie Kato,2 LorenaAbarzua,2 PamelaGonzalez,2 Carolina Ramirez,2
Elisa Cumsille,2 Erasmo Bravo,3 Raimundo Correa,4 Juan E. Leiva,4 Cesar Pare-
des,4 Juan C. Roa,2 Carolina Ibañez,1 Mauricio Cuello,2 Gareth I. Owen,5 Maria
L. Bravo5. 1Pontifıcia Universidad Catolica de Chile, Millenium Institute Immu-
nology and Immunotherapy, Santiago, Chile; 2Pontifıcia Universidad Catolica de
Chile, Santiago, Chile; 3Hospital Gustavo Fricke, Santiago, Chile; 4Hospital Re-
gional de Talca, Santiago, Chile; 5Pontifıcia Universidad Catolica de Chile, Mil-
lenium Institute Immunology and Immunotherapy, Biomedical ResearchConsor-
tium Chile, Santiago, Chile.
Ovarian cancer metastasis occurs when malignant cells migrate from the pri-
mary tumor into the ascitic fluid and form a secondary tumor in the peritoneal
cavity. The cells responsible for this process, Metastases Initiating Cells (MICs),
suffer a series of changes in protein expression, with increased Epithelial Mes-
enquimal Transition and stem cell markers having been reported. Tissue Factor
Pathway Inibitor-2 (TFPI-2) is a serine proteinase inhibitor and potential tumor
suppressor gene, whose reduction is correlated with more metastases and poor
prognosis. As the exact stage of TFPI-2 loss is still unknown, the purpose of our
study was to determine TFPI-2 during ovarian cancer progression. Protein and
RNA levels were assessed in primary tumor andmetastatic tissue from papillary
serous carcinoma by immunohistochemistry and qPCR, respectively. TFPI-2
RNA and protein levels were analyzed in cancer cell lines and primary cultured
cancer cells isolated from ascitic fluid of advanced ovarian cancer patients and in
cancer spheres derived from these cultures. Epigenetic changes of 3 CpG were
analized by bisulfıte and pirosequencing technique in ovarian cancer cell lines
and in cancer spheres derived from these cultures. We report that signifıcantly
decreased TFPI-2 protein levels in metastatic tissue compared to the primary
tumor, a result confırmed in matched primary and metastatic lesions from the
same ovarian cancer patients. Furthermore, cancer spheres (representing poten-
tialMICs) displayed signifıcantly lower levels of TFPI-2 than corresponding cell
line and some primary cultured cancer cells. The cancer spheres showed amod-
est increase in methylation percentage in three specifıc CpG sites within the
TFPI-2 promoter. Our results suggest that TFPI-2 loss plays a role in the cancer
cell escape from the primary tumor. Future studies will determine the mecha-
nismand the biological consequences of the progressive loss of TFPI-2 in cancer.
Funding: FONDECYT 11140657, 1160800, 1140970, 3140335, 3150028,
CORFO L2 13IDL2-18608, IMII-P09/016-F, CONICYT-FONDAP 15130011,
BMRC 13CTI21526-P6.
#5517 Antitumor effect of LRIG1, negative regulator of ErbB, in lung
cancer harboring mutant-EGFR. Hidejiro Torigoe, Shinichi Toyooka, Masa-
kiyo Sakaguchi, Kazuhiko Shien, Hiromasa Yamamoto, Junichi Soh, Hiroaki
Asano, Shuta Tomida, Kazunori Tsukuda, Shinichiro Miyoshi. Okayama Univ.
Hospital, Okayama, Japan.
Introduction: EGFR is a member of the ErbB family of tyrosine kinase
receptors (RTKs) and plays important roles in the pathogenesis of certain
human cancers. In non-small cell lung cancer (NSCLC), mutations in EGFR
gene are commonly known as oncogenic driver mutation and targeted for
treatment. Leucine rich repeat and immunoglobulin-like domain protein-1
(LRIG1) is a cell surface protein and known as a negative regulator of ErbB
family. In brain tumor, LRIG1 was reported to downregulate not only wild-
type EGFR, but also EGFRvIII, mutant-type EGFR. But there has been no
report about the relationship between LRIG1 and EGFR mutation in the
kinase domain frequently found in lung cancer. In this study, we investigate
the role of LRIG in EGFRmutant lung cancer from the view point of its effect
on signal transduction and cell proliferation and invasion. Method: We ex-
amined the LRIG1 expression levels in lung cancer cell lines and the surgi-
cally resected primary lung cancer tissues by quantitative PCR assay. We
made stable clone of EGFR-mutant cell line (HCC827; exon19del E746-
A750) overexpressing GFP tagged LRIG1, and compared with stable clone
overexpressing GFP alone. Results: The LRIG1 expression levels in lung
cancer cell lines and the surgically resected primary lung cancer tissues were
much lower than that in normal bronchial epithelial cells and their normal
tissues, respectively. The introduction of LRIG1 decreased EGFR expression
and their phosphorylation in EGFR-mutant cell line. LRIG1 strongly sup-
pressed cell proliferation, invasion and migration of EGFR-mutant cell line.
In addition, a phospho-RTK array revealed that LRIG1 also downregulated
the other RTKs, such as HER2, HER3, MET, and IGF-1R. Conclusion: Our
fındings demonstrates that LRIG1 decreases the expression and phosphory-
lation of mutant-EGFR protein and has strong anti-tumor effect in lung
cancer harboring EGFR mutation. These fındings suggest the importance of
LRIG1 related studies to develop a novel strategy for EGFR mutant cancers.
#5518 Rgs8 and Rgs16 are tumor suppressor genes in mouse pancreatic
ductal adenocarcinoma. Shreoshi Pal Choudhuri, Yalda Zolghadri, Luke Mas-
carenhas, Ozhan Ocal, Thomas Wilkie. UT Southwestern Medical Center, Dal-
las, TX.
We have identifıed regulators of G protein signaling (Rgs8 and Rgs16) as a
new class of tumor suppressor genes in a mouse model of pancreatic ductal
adenocarcinoma (PDA). PDA is the 3rd leading cause of cancer related
deaths in the United States. Kras mutations (e.g. KrasG12D) are associated
with over 90% of human PDA and are an early event in the multistep process
leading to PDA. Kras can be activated by protein kinase and GProtein Cou-
pled Receptor (GPCR) signaling. Rgs proteins regulate GPCR signaling by
accelerating the GTPase activity of Gq- and Gi class alpha subunits. Activat-
ing alleles of Gq that are resistant to Rgs inhibition are associated with PDA
in humans. We found Rgs8 and Rgs16 are in vivo reporters of Kras activity in
pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous
neoplasm (IPMN), and PDA progression (DMM 8, 2015). Rgs8 and Rgs16
are expressed in PanIN and IPMN, precursors of PDA, in KC mice (LSL-
KrasG12D; p48::Cre). To test if Rgs8-16 function as tumor suppressor genes,
we crossed the Rgs8-16 double knockout into KC (termed KCR8-16) mice.
Compared to KC, PDA initiates earlier, is more aggressive, and KCR8-16
mice die earlier. Our study suggests that Rgs8 and Rgs16 control Kras-de-
pendent PDA initiation and progression.
#5519 psiTPTE22-HERV functions as a tumor suppressor in gastric can-
cer and is associated with disease outcome. Jessie Qiaoyi Liang,1 Fei Xu,2 Shu
Zheng,2 Jun Yu1. 1The Chinese University of Hong Kong, Shatin, Hong Kong;
2Zhejiang University, Hangzhou, China.
Background and aim: The novel gene psiTPTE22-HERV identifıed by us pre-
viously is a human endogenous retrovirus (HERV)-related gene located adja-
cent to the gene psiTPTE22. With a high GC content around the promoter
region, expression of psiTPTE22-HERV can be regulated epigentically by DNA
methylation. We aimed to elucidate the clinical signifıcance of epigenetic alter-
ation and biological function of psiTPTE22-HERV in gastric cancer. Methods
and results: psiTPTE22-HERV was ubiquitously expressed in normal adult tis-
sues including stomach, but was frequently silenced/down-reguated in gastric
tumors and cancer cell lines as evidenced by RT-PCR. Bisulfıte genomic se-
quencing results indicated that psiTPTE22-HERV was silenced by promoter
DNAmethylation, and its expression could be restored by demethylation treat-
ments in gastric cancer cell lines. Ectopic expression of psiTPTE22-HERV sig-
nifıcantly suppressed cell viability, clonogenicity and cell cycle progression, in-
duced apoptosis, and inhibitedmigration and invasion of SGC7901 andMKN45
gastric cancer cells. In contrast, knock-down of psiTPTE22-HERV in the gastric
cancer MKN1 cells signifıcantly increased cell growth and migration ability,
promoted cell cycle progress and inhibited cell apoptosis. psiTPTE22-HERV
signifıcantly suppressed subcutaneous tumorigenicity of SGC7901 cells in nude
mice andmetastasis (liver implantation) in tail vein injectionmodels. Promoter
methylation level of psiTPTE22-HERV was signifıcantly higher in gastric tu-
mors than in adjacent non-tumor tissues as revealed by bisulfıte genomic se-
quencing (P0.05); methylation levels in both tumors and adjacent non-tumor
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tissues of gastric cancer patients were signifıcantly higher than in normal stom-
ach tissues (both P0.001). Multivariate Cox regression analysis demonstrated
that promoter methylation of psiTPTE22-HERV in primary gastric tumors was
an independent risk factor for poor survival. Kaplan-Meier survival curves
showed that high-methylation of psiTPTE22-HERV promoter was signifıcantly
associated with shortened survival in gastric cancer patients from two indepen-
dent cohorts (both P0.05). Conclusion: psiTPTE22-HERV functions as a tu-
mor suppressor that is commonly down-regulated by promoter methylation in
gastric cancer, which may serve as a prognostic biomarker for gastirc cancer
patients.
#5520 CCN5/WISP-2 is a negative regulator of epithelial tomesenchymal
transition and stemness in breast cancer. Gargi Maity, Amlan Das, Sandipto
Sarkar, Snigdha Banerjee, Sushanta K. Banerjee. VA Medical Center, Kansas
City, MO.
Background and Objective: Breast cancer is the most common cancer in
women and a leading cause of cancermortality inwestern countries. CCN5 (also
known asWnt-1-induced signaling protein-2 orWISP-2) is a 29-31-kDamatri-
cellular protein that plays as a negative regulator of breast carcinoma. Our pre-
vious studies had shown the importance of CCN5/WISP-2 in the suppression of
breast and pancreatic cancer progression through the regulation of the invasive
phenotypes. Considering the previous report, our aim is to investigate whether
human recombinant CCN5 inhibit pathobiological events like epithelial tomes-
enchymal transition (EMT), migration and stemness in triple negative breast
cancer cells. Methods: To investigate the negative impact of CCN5 on EMT and
stemness of TNBC, we performed several techniques like western blot, clonoo-
genic assay, soft agar assay, sphere formation assay etc. Results andConclusions:
The exposure of triple negative human breast cancer cells (TNBC), MDA-MB-
231 and HCC-70, to recombinant CCN5 (hrCCN5), resulted in a dose-depen-
dent inhibition of cell-proliferation through the induction of apoptotic cell
death. The treatment of hrCCN5 regulates various pathobiological events in
breast cancer cells, such as reprogramming the mesenchymal to epithelial tran-
sition (MET) followed by reduction of stemness features as confırmed by sphere
formation assay and delaying in vitro migration. Finally, treatment with
hrCCN5 in TNBC cells signifıcantly inhibited anchorage-dependent and inde-
pendent growth of TNBC. Collectively, CCN5=s control of cancer cell physiol-
ogy indicates that hrCCN5 has the potential of being used as amajor therapeutic
agent against triple negative breast cancer.
#5521 Loss of Lcn2 promotes development of smoking-associated Kras
mutant lung cancer. Joshua Kapere Ochieng,1 Wenhua Lang,1 Sayuri Nuno-
mura-Nakamura,1 Christina McDowell,1 Ralph Arlinghaus,1 Yuki Imaoka,2
Takashi Hori,3 Junya Fukuoka,2 Paul Scheet,1 Junya Fujimoto,1 Humam Ka-
dara4. 1UTMDAnderson Cancer Ctr., Houston, TX; 2Nagasaki University Grad-
uate School of Biomedical Sciences, Nagasaki, Japan; 3Toyama University Hospi-
tal, Toyama, Japan; 4American University of Beirut, Beirut, Lebanon.
Lung adenocarcinoma (LUAD) represents the most commonly diagnosed
lung cancer subtype. LUADs in smokers frequently exhibit mutations in the
Kras oncogene. Relative to other LUADs, Kras mutant LUAD displays dismal
prognosis, warranting the need for new strategies for early treatment of LUAD.
Despite this urgency, we have a poor understanding of events that drive devel-
opment of Kras mutant LUAD and would thus constitute targets for early pre-
vention and treatment.We recently found thatmicewith knockout of the airway
lineage gene G-protein coupled receptor 5A (Gprc5a-/-), in contrast to wild type
(WT) littermates, not only developed LUADs after tobacco carcinogen (nico-
tine-specifıc nitrosamine ketone/NNK) exposure but that these lesions harbored
somatic Kras mutations, the same variants thought to act as drivers of LUAD in
human smokers. We then also found by RNA-sequencing (RNA-Seq) and im-
munohistochemical analyses markedly elevated expression of the lipocalin 2
(Lcn2) gene in airways of Gprc5a-/- mice and preceding tumor development.
While Lcn2 has been suggested to function as a putative oncogene (e.g., in
mammary tissue), little is known about the role of Lcn2 in LUAD. To fıll this
void, we developed mice with knockout of both Gprc5a and Lcn2 (Gprc5a
-/-
/
Lcn2-/-) and examined lung tumorigenesis following NNK exposure in these
mice relative to similarly treated Gprc5a-/- littermates. We found that Gprc5a
-/-
/
Lcn2-/- mice, relative to Gprc5a-/- littermates, exhibited markedly and signifı-
cantly increased lung tumor burden and growth at three and seven months
following NNK exposure. Moreover, when we injected Kras mutant Gprc5a-/-
cells (MDA-F471) into the tail veins of mice, we noted a trend for increased
tumor development in lungs of Gprc5a-/-/Lcn2-/- relative to Gprc5a-/- litter-
mates. To gain global insights into the impact of Lcn2 on gene expression and
signaling in Kras mutant LUAD cells, we employed RNA-Seq coupled with
pathways analysis to survey differentially expressed transcripts between MDA-
F471 cells stably transfected with Lcn2-specifıc shRNA and cells with control
shRNA. Pathways and gene network analysis of the differentially expressed tran-
scripts revealed that Lcn2 knockout leads to a heightened malignant phenotype
in the Kras mutant LUAD cells via the activation of various signaling nodules
including Tnf, Erk1/2 and Akt.We confırmed the RNA-Seq and pathways anal-
ysis by western blotting demonstrating increased phosphorylated levels of
Erk1/2 and Akt in cells with knockdown of Lcn2. All in all, our preliminary data
suggest that Lcn2 expression plays a tumor suppressor role downstream of
Gprc5a and tobacco carcinogen exposure in the pathogenesis of Kras mutant
LUAD in part by inhibiting Erk1/2 and Akt oncogenic signaling.
#5522 Novel myogenic differentiation transcription factor CASZ1 sup-
presses rhabdomyosarcoma tumor growth.Zhihui Liu,1 Norris Lam,1 Arnulfo
Mendoza,1 Jun S. Wei,2 John F. Shern,1 Marielle Yohe,2 Javed Khan,2 Carol J.
Thiele1. 1NCI-CCR, Pediatric Oncology Branch, Bethesda, MD; 2NCI-CCR, Ge-
netics Branch, Bethesda, MD.
Disruption of muscle regulatory factors (MRFs) in muscle progenitor cells
results in a failure to withdraw from cell cycle and terminal differentiation and is
proposed to contribute to rhabdomyosarcoma (RMS) tumorigenesis. Zinc fın-
ger transcription factor CASZ1 is a tumor suppressor gene and regulates normal
nervous system and heart development. CASZ1 is known to regulate a subset of
genes that are involved in skeletal muscle development although the function of
CASZ1 in normal myogenesis and RMS tumorigenesis is unknown. CASZ1
levels increase over 20-fold when C2C12myoblasts differentiate into myotubes.
To probe its role in normal myogenesis we performed genetic knockdown or
overexpression experiments in C2C12 myoblasts. When CASZ1 expression is
silenced using RNAi, there is a signifıcant reduction in myotubes upon induc-
tion of differentiation. RealtimePCR shows that knockdownofCASZ1 increases
Myf5, a MRF that determines early commitment of muscle precursor cells, but
decreases Myogenin (2-fold, p0.01), a MRF required for terminal differentia-
tion and myotube formation. Knockdown of CASZ1 also decreases late skeletal
differentiation genes Acta1, Ckm, Tnnt1 and Tnni2 ( 2-fold, p0.01). Over-
expression of CASZ1 induces expression of Myogenin, Acta1, Ckm and Tnnt1,
represses Myf5 and accelerates myotube formation. This indicates that CASZ1
regulates genes important in the transition from early to late myogenic differ-
entiation. To investigate the role of CASZ1 in RMS, we fırst evaluated the ex-
pression of CASZ1 in primary RMS tumors using public available microarray
database. CASZ1 mRNA levels are1.5-fold lower in embryonal RMS (ERMS)
samples compared to normal muscle (p0.001), while levels of CASZ1 in alve-
olar (ARMS) are similar to levels in normal muscle. CASZ1 levels increase over
3-fold when RD cells (ERMS) were cultured in differentiationmedium (100 nM
12-O-tetradecanoylphorbol-13-acetate, TPA). Knockdown of CASZ1 in the RD
cells suppressed TPA induced expression of myogenic markers TNNT1 and
TNNI2 while CASZ1 overexpression stimulated expression of TNNT1 and
TNNI2 (all p0.05). An in vivo spontaneous xenograftmodel showed that over-
expression of CASZ1 signifıcantly suppressed RD tumor growth (p0.005). In
RMS patients, NexGen sequencing of 85 tumors identifıed 4 samples with non-
synonymous single nucleotide variants (SNVs) inCASZ1 that were absent in the
1000Genomes databases.We engineered these SNVs into CASZ1 construct and
transfected them into C2C12 cells. We found that the R25C SNV had impaired
nuclear localization and failed to activate skeletal muscle gene transcription
(p0.03). Taken together, our results suggest that the regulation of muscle dif-
ferentiation program by CASZ1 in C2C12 is integral to proper myogenic differ-
entiation, and genetic variants of CASZ1 disrupt early myogenesis and may
contribute to ERMS tumorigenesis and progression.
#5523 Loss of RAB25 cooperates with oncogenes in the transformation of
human mammary epithelial cells. Pooja Sridhar Joshi. Southern Illinois Univ.
School of Medicine, Springfıeld, IL.
The RAB guanosine triphosphates (RAS-related in brain) belong to the Ras
superfamily of GTPases, and loss of RAB 25 expression has been reported in a
number of breast cancer cases containing H-Ras point mutations, particularly
triple negative breast cancers (TNBC), one of the most aggressive subtypes of
breast cancer and associated with a poor prognosis. Themechanism involved in
the progression of these tumors is poorly understood. In this study, we are trying
to understand if loss of RAB25 expression in Human Mammary Epithelial Cell
(HMEC) lines co-operates withH-Rasmutations and contributes to tumorigen-
esis. HMEC were immortalized by transduction with LXSN CDK4 R24C, a
mutant formof cyclin-dependent kinase, followed by transductionwith hTERT,
catalytic subunit of the telomerase enzyme that permits the cells to exceed the
Hayflick Limit and become immortal. We have found that with loss of RAB25
and over expression of mutant H-Ras61L, immortal HMEC undergo transfor-
mation. We have looked into the co-operativity between loss of Rab25 and
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H-Ras61L mutant by in-vitro studies to show their anchorage independent
growth and increased ability to migrate. Furthermore, cells express low CD24,
high CD44, and very low levels of Claudin indicating that cells acquire stem-like
properties upon transformation. Loss of RAB25 and over-expression of
H-ras61L resulted in increased expression of transcription markers Snail and
Slug that drive these cells to lose E-cadherin and undergo Epithelial Mesenchy-
mal Transition (EMT).We also intend to carry out nudemice studies to look for
the potential of these cells to form tumors andmetastasize. This study shows that
loss of RAB25 and over-expression of mutant H-Ras can transform HMEC and
give rise to mesenchymal stem-like tumors. Our fındings reveal that RAB25
functions as a tumor suppressor gene, and loss of RAB25 could serve as a novel
biomarker in the prognosis of Claudin-low type of TNBC.
#5524 Gene 33/Mig6 regulates apoptosis and the DNA damage response
through independent mechanisms. Cen Li, Soyoung Park, Xiaowen Zhang,
Leonard Eisenberg, Hong Zhao, Zbigniew Darzynkiewicz, Dazhong Xu. New
York Medical College, Valhalla, NY.
Gene 33 (Mig6, ERRFI1) is an inducible adaptor/scaffold protein whose ex-
pression can be induced by both stress and mitogenic signals. It contains mul-
tiple domains for protein-protein interaction and is involved in a broad spec-
trum of cellular functions including cell proliferation, cell migration, cell
apoptosis, and cell senescence. Many functions of Gene 33 are attributable to its
ability to bind to the kinase domain of the EGFR family receptor tyrosine kinases
thereby inhibiting their activities. Gene 33 also binds and activates tyrosine
kinase c-Abl and is involved in other signing pathways such asNF-B,HGF, and
JNK. Growing evidence at the genetic, cellular, and animal levels indicates that
Gene 33 functions as a tumor suppressor in the lung. Gene 33 has been shown to
promote apoptosis. A recent study has linked this protein to the DNA damage
response induced by hexavalent chromium [Cr(VI)]. In the current study we
fınd that ectopic expression of Gene 33 strongly induces apoptosis by both acti-
vating the c-Abl/p73 pathway and inhibiting the EGFR/AKT pathways in
BEAS-2B lung epithelial cells and A549 lung carcinoma cells. Surprisingly, ec-
topic expression of Gene 33 also triggers theDNAdamage response in anATM-
dependent fashion and through pathways with and without association with
apoptosis. We observed striking presence of Gene 33 in the nucleus and chro-
matin, which is in contrast with the belief that Gene 33 is an exclusively cyto-
plasmic protein. Our data show that chromatin localization of Gene 33 is par-
tially dependent on the EBDmotif of Gene 33, a domain required for interaction
with EGFR and c-Abl. Our data also indicate that Gene 33 may regulate chro-
matin targeting of c-Abl and EGFR. Furthermore we fınd that both endogenous
and ectopically expressed Gene 33 strongly interact with histone H2AX. Our
data have revealed potential nuclear/chromatin-associated mechanisms that
underline the function of Gene 33 in apoptosis and the DNA damage response.
#5525 Induced expression of PPM1A in ER-negative breast cancer cells
inhibits growth by suppressing CDK phosphorylation. Abhijit Mazumdar,
Jamal Hill, Yun Zhang, Lakshmi Reddy Bollu, Anna Tsimelzon, Jenny Chang,
Gordon Mills, Powel Brown. UTMD Anderson Cancer Ctr., Houston, TX.
Background: Estrogen receptor (ER) -negative breast cancer is a clinical sub-
type that is overrepresented among younger women and is associated with a
poor prognosis. Current treatments for ER-negative tumors include cytotoxic
chemotherapy, or for those overexpress HER2, the anti-HER2 antibody. Tar-
geted therapy for triple-negative breast cancers is urgently needed. In this proj-
ect, we investigated phosphatases that are differentially expressed in ER-nega-
tive as compared to ER-positive breast cancers. We hypothesized that: (1)
specifıc phosphatases govern the growth of ER-negative cancers, (2) Induced
expression of specifıc phosphatases that are under expressed in ER-negative
cancers will suppress the growth of ER-negative breast cancers. Methods: Using
102 human breast tumors (57 ER-positive & 45 ER-negative) from the neo-
adjuvant studies from the Baylor Breast Center tumor bank, we isolated RNA
and performedAffymetrixmicroarray studies. Statistical analysis was donewith
dChip software, and phosphatases over (1.5 fold; FDR 0.05) or under
(0.66-fold; FDR0.05) expressed in ER-negative breast cancers as compared
to ER-positive cancers were selected for further study. One of the phosphatases
under expressed in ER-negative breast cancer was PPM1A. Regulated expres-
sion of PPM1A was achieved using a Tet-regulated vector. Cell growth in soft
agar and cell cycle analyses were performed using previously published proto-
cols. Mouse xenograft experiments were performed by injecting inducible
PPM1A-clones and vector- clones in mammary fat pad of athymic mice and
tumor growth was measured over time in randomized groups. To induce
PPM1Aexpression one groupwas treatedwith doxycyclinewhen tumor volume
reached 50mm3. Survival analyses were done usingOncomine datasets. Results:
We identifıed 20 over-expressed and 29 under-expressed phosphatases in ER-
negative breast cancers. We selected the under expressed phosphatase PPM1A,
for further study. Multivariate cox regression analysis shows PPM1A is an inde-
pendent predictor for breast cancer survival. Induced expression of PPM1A in
ER-negative cells inhibited anchorage-dependent and independent growth but
had no effect on ER-positive cell. PPM1A expression also inhibited MDA-MB
231 cells growth in vivo. Induced expression of PPM1A blocked cell cycle pro-
gression atG1phase. PPM1A interactswithCDK6 and inhibits phosphorylation
of CDK and MDM2. Conclusions: We identifıed a set of over- and under- ex-
pressed phosphatases in ER-negative breast cancers as compared to ER-positive
cancers. Overexpression of PPM1A in ER-negative breast cancer cells inhibits
growth. By identifying the molecules that regulate breast cancer cells growth we
are identifying potential new targets for the treatment of these aggressive ER-
negative breast cancers. Supported by Komen Promise grant KG081694 &
Komen SAB grant.
#5526 Tumor suppressive role ofBMI-1 through inhibition of JAK-STAT
signaling in leukemia.YukMan Lam, Stephen Sze Yuen Lam, Anskar YuHung
Leung, Ray Kit Ng. The University of Hong Kong, Hong Kong, Hong Kong.
BMI-1, which is one of the core components of polycomb repressive com-
plex 1, is frequently found deregulated in patients with hematological disor-
ders. In last decades, researchers concordantly agree that BMI-1 mediates
tumorigenesis of leukemia stem cells through p16INK4A leukemogenic path-
way. However, accumulating evidences contradict the idea that BMI-1 solely
plays an oncogenic role in tumorigenesis. It has been shown BMI-1 depletion
favors the development of myelofıbrosis in mice; whereas high BMI-1 ex-
pression suppressed colony forming ability of MLL-ENL-transformed bone
marrow and correlated with higher survival in some cancers. In this study,
we hypothesized that BMI-1 plays a tumor suppressive role, which is inde-
pendent of the regulation of INK4A-ARF locus, in human leukemia. BMI-1
was over-expressed in a panel of myeloid and lymphoid lineage leukemia
cells, including HL-60, MV4-11, MonoMac-6, SEM, Nalm-20 and RS4;11.
We observed no deregulation of p16INK4A and p14ARF genes by BMI-1, sug-
gesting the regulation of INK4A-ARF locus is independent of BMI-1 mod-
ulation in leukemia cells. Nevertheless, over-expression of BMI-1 resulted in
signifıcant reduction of leukemia cell proliferation. It is noted that constitu-
tively active JAK-STAT signaling pathway is crucial to leukemia cell survival.
By modulation of BMI-1 level, we demonstrated suppression of the activated
JAK-STAT signaling pathway in most of the leukemia cell lines with the
exception of MonoMac-6 and RS4;11. This is in agreement with the high
sensitivity to ruxolitinib, a JAK-STAT inhibitor, in all the tested leukemia
cell lines except RS4;11. Importantly, we showed that BMI-1 over-expression
could sensitize RS4;11 cells to reduce cell proliferation under ruxolitinib
treatment. These results suggest that higher effıcacy of ruxolitinib treatment
could be achieved under a condition of high cellular level of BMI-1. We
further demonstrated that ruxolitinib treatment was more effective in a co-
hort of AML patient samples (n  25) with a context of higher BMI-1 ex-
pression (p  0.05). Altogether, our results suggest that BMI-1 functions as
a tumor suppressor gene via inhibition of the JAK-STAT signaling pathway.
The endogenous level of BMI-1 could be served as an indicator for the
effective treatment of JAK-STAT-dependent leukemia cells using rux-
olitinib.
#5527 Effects of PTEN localization and phosphatase activity on gene ex-
pression profıling of glioblastoma cells.YubingWang, AndrewM. Chan.Chi-
nese University of Hong Kong, Shatin, Hong Kong.
PTEN possesses both protein and lipid phosphatase activities, with its
tumor-suppressor function mainly depends on its lipid phosphatase activity
through inhibiting the PI3K/AKT signaling pathway at the cell membrane.
However, increasing evidence have demonstrated that PTEN also localizes to
other intracellular organelles such as the endoplasmic reticulum, the mito-
chondria, or the nucleus where it plays important roles in multiple cellular
processes. To further understand how PTEN localization affects the gene
expression profıling in cancer cells, a PTEN null glioblastoma cell line,
U87MG, was stably expressing wild-type, nuclear localization signal (NLS)-
tagged, nuclear export signal (NES)-tagged and myristoylation (MYR)-
tagged PTEN. Ion Torrent based whole transcriptome sequencing was used
for gene expression analysis. Gene ontology enrichment analysis showed
that the most common cellular component regulated by PTEN over-expres-
sion was extracellular factors, which function as growth factor-binding or
fıbronectin-binding molecules related to cell adhesion or organ system de-
velopment. In contrast, nuclear PTEN promoted the enrichment of genes in
collagen-binding and integrin-binding, which may be related to blood vessel
development or cell motility. KEGG pathway enrichment also confırmed
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that PTEN over-expression upregulated focal adhesion pathway, an impor-
tant pathway that frequently disrupted in PTEN Hamartoma Tumor Syn-
drome (PHTS). Moreover, nuclear PTEN differentially regulated genes
showed higher enrichment in immune response signaling pathways. This
unique gene expression profıling driven by NLS-PTEN indicated that be-
sides the phosphatase activities, nuclear PTEN may have additional func-
tions than merely inhibiting the PI3K signaling pathway. The transcriptome
data showed potential downstream targets of PTEN in different subcellular
localizations, which may lead to unique biological functions. More func-
tional studies will be carried out to further validate how intracellular PTEN
regulates the expression of these genes, and what are the signaling pathways
involved in the regulatory processes. Funding sources - This work was sup-
ported by the Hong Kong PhD Fellowship (PF12-13876) to WY. AC was
supported by a General Research Fund grant (#460713), a Collaborative
Research Fund grant (C014-14G) from the Hong Kong University Grants
Committee, a Lo Kwee-Seong Biomedical Research Seed Fund, and the Brain
& Mind Institute.
#5528 The protein phosphatase 2A regulatory subunit PR70 is a gono-
somal melanoma tumor suppressor gene. Léon C.L. Van Kempen,1 Margaret
Redpath,1 Mounib Elchebly,2 Kathleen Oros Klein,2 Andreas Papadakis,2 James
Willmott,3 Richard Scolyer,3 Per-Henrik Edqvist,4 Fredrik Ponten,4 Dirk Scha-
dendorf,5 Anke van Rjk,2 Stefan Michiels,6 Anne Dumay,6 Anne Helbling-
Leclerc,6 Philippe Dessen,7 Jasper Wouters,8 Marguerite Stass,8 Celia Green-
wood,1 G. Elias Ghanem,9 Joost van den Oord,8 Jean Feunteun,6 Alan Spatz1.
1McGill University,Montréal, Quebec, Canada; 2LadyDavis Institute forMedical
Research, Montréal, Quebec, Canada; 3Royal Prince Alfred Hospital and Univer-
sity of Sydney, New South Wales, Australia; 4Uppsala University, Uppsala, Swe-
den; 5University Hospital Essen, Essen, Germany; 6Institut Gustave Roussy, Ville-
juif, France; 7Université Paris-Sud, Paris, France; 8HospitalsUniversity of Leuven,
Leuven, Belgium; 9Insitut Jules Bordet, Brussels, Belgium.
Male gender is independently and signifıcantly associated with poor progno-
sis in melanoma of all clinical stages. The biological underpinnings of this sex
difference remain largely unknown, but we hypothesize that gene expression
from gonosomes may play an important role. The current study demonstrates
that loss of the inactivated X chromosome in melanomas arising in females is
strongly associated with poor distant metastasis-free survival, suggesting a dos-
age benefıt of two X-chromosomes. The gonosomal PPP2R3B gene is located on
the pseudo-autosomal region (PAR) of the X-chromosome in females and
on the Y-chromosome in males. We observed that despite its location on the
PAR that predicts equal dosage across genders, PPP2R3B expression is lower in
males than in females, and is independently correlated with poor clinical out-
come. PPP2R3B codes for the PR70 protein, a regulatory substrate recognizing
subunit of PP2A, that decreasesmelanoma growth by negatively interferingwith
DNA replication and cell cycle progression through its role in stabilizing CDC6/
CDT1 interaction that delays the fıring of origins of DNA replication. As such,
PR70 behaves functionally as an X-linked tumor suppressor gene.
#5529 CD177 suppresses breast cancer progression by regulating the ca-
nonical WNT -Catenin pathway. Paige N. Kluz,1 Ryan Kolb,1 Qing Xie,2
Nicholas Borcherding,1 Linna Wang,3 James P. De Andrade,1 Phillip M. Span-
heimer,1 Wei Li,1 Katherine N. Gibson-Corley,1 Andy W. Tao,3 Sonia Sugg,1
Ronald J. Weigel,1 Weizhou Zhang1. 1University of Iowa, Iowa City, IA; 2Xinx-
iang Meidal University, China; 3Purdue Univesity, West Lafayette, IN.
To better treat breast cancer patients, it is imperative to be able to predict
breast cancer relapse and metastasis. Here, we identifıed the cluster of differen-
tiation 177 (CD177) expression is positively correlated with relapse-free and
metastasis-free survival of breast cancer patients. CD177 protein is highly ex-
pressed in normal breast epithelial cells and is signifıcantly reduced in invasive
cancers. Using mouse models, we found that CD177 suppresses breast cancer,
primarily by forming a complex with E-Cadherin and b-Catenin at adherens
junctions. The physical interaction prevents the activation of b-Catenin-medi-
ated transcription by the canonical WNT signaling as demonstrated by a TOP-
flash dual luciferase assay. In conclusion, we have identifıed CD177 as a novel
breast cancer suppressor and uncovered a new regulatory mechanism for the
canonical WNT/b-Catenin-mediated oncogenic signaling transduction.
#5530 Evidence linking aquaporin-3 loss to increased invasiveness in
bladder cancer. Arpita Roy, Dinuka M. DeSilva, Donald P. Bottaro. NCI-NIH,
Bethesda, MD.
Bladder cancer (BCa) is the most common type of urothelial cancer (UC).
According to American Cancer Society, in 2016, diagnoses of 76,960 new cases
of bladder cancer (BCa) and 16,390 BCa associated deaths have been estimated.
More than 90% of bladder cancer starts in the innermost transitional epithelium
(urothelium) of the bladder. Aquaporin 3 (AQP3), one of 13 members of a
transmembrane channel forming protein family (AQP0-12), has an N-terminal
basolateral sorting signal and localizes to the basolateral membrane in epithelial
tissues. Recent studies have shown that AQP3 expression is decreased in UC
thus supporting a newhypothesis that alteration of the expression ofAQP3plays
a role in the pathogenesis of UC. However, it remains to be determined whether
AQP3 is involved in the invasion andmetastasis ofUCcells. In the present study,
human bladder cancer cell lines of different grades, SW780 (G1) and TCCSUP
(G4) were studied. Transcript and protein levels of AQP3 expression were sig-
nifıcantly higher in low grade, SW780 cells when compared to the higher-grade
TCCSUP cells. Inhibition of AQP3 by CuSO4 or siRNA specifıc knockdown of
AQP3 resulted in increasedmigration in thewound-healing scratch assay.Over-
expression of AQP3 plasmid resulted in reduced migration. It is known that
epithelial cell polarity contributes to tumor suppression and that loss of E-cad-
herin is a crucial step in epithelial-to-mesenchymal transition (EMT). Our re-
sults indicate that AQP3 overexpression induced expression of E-cadherin, con-
sistent with a role for AQP3 as a tumor suppressor bymaintaining epithelial cell
polarity and inhibiting EMT inBCa. Conversely, reducedAQP3 levels leading to
reduced E-cadherin levels in high-grade BCa cells may result in loss of cell
polarity, increased invasiveness and increased EMT.
#5531 Signifıcance and functions of estrogen receptor beta (ESR2) iso-
forms in glioblastoma. Jinyou Liu, Gangadhara Reddy Sareddy, Mei Zhou,
Suryavathi Viswanadhapalli, Andrew Brenner, Rajeshwar R. Tekmal, Ratna K.
Vadlamudi. UT Health Science Center at San Antonio, San Antonio, TX.
Background: Glioblastoma (GBM) are the deadliest form of primary brain
neoplasms. Several lines of evidence suggest tumor suppressive role of female
sex hormones on brain tumors. However, mechanisms by which estrogens me-
diate protection against the GBM remains unknown. GBM preferentially ex-
press estrogen receptor beta (ESR2). Emerging evidence suggests that ESR2 is
expressed as multiple isoforms, (ESR2-1 to 5, with variation at the C-terminal
domain); however, much of the published information is focused primarily on
ESR2-1. Little is known about the expression and functions of other ESR2 iso-
forms in GBM. The objective of this study is to examine the expression and
determine the functions of ESR2 isoforms inGBMcells.Methods: Expression of
ESR2 isoforms was profıled using 10 different patients derived and 5 established
GBM cells. To study the functions of individual ESR2 isoforms in GBM cells, we
have generated ESR2 knockout (ESR2-KO) cells usingCRISPR/Cas9 system and
then established GBMmodel cells expressing individual ESR2-1, 2, and 5 using
lentiviral transduction in the ESR2-KO background GBM cells. IPMS analysis
was used to identify binding proteins of each ESR2 isoforms. Effect of each
isoform on the growth, apoptosis, cell cycle progression,migration and invasion
was analyzed using established methods. Mechanistic studies were conducted
using reporter gene assays, RT-qPCR and signaling analysis. Results: RT-qPCR
results demonstrated that ESR2-5 is highly expressed inmajority of primary and
established GBM cells compared to ESR2-1 and ESR2-2, with ESR2-4 is the least
expressed. Expression of ESR2-1 but not ESR2-5 signifıcantly reduced prolifer-
ation of GBM cells. Further, ESR2-KO cells exhibited high migratory and inva-
sive potential compared to parental GBM cells and re-expression of ESR2-1, but
not ESR2-5 resulted in reduction in migratory and invasive potential of GBM
cells. ESR2-KO GBM cells exhibited decreased levels of cell cycle arrest and
apoptosis proteins p27, p21 and PUMA compared to parental GBM cells and
re-expression of ESR2-1 or ESR2-5 in ESR2-KO cells rescued the phenotype.
IPMS studies identifıed several common and unique proteins that bind to each
of the isoforms. Both ESR2-1 and ESR2-5 interacted with mTOR, while ESR2-5
uniquely interactedwith several proteins related toDNA repair, immunomodu-
latory and apoptosis pathways. Overexpression of ESR2-1 reduced the activa-
tion of mTOR signalingmolecules including p-mTOR, p-S6K and p-S6 in GBM
cells compared to ESR2-KO cells, while ESR2-5 enhanced mTOR downstream
signaling. Conclusion: Using ESR2KO cells, we have provided genetic evidence
for the role of ESR2-1 in GBM tumor suppression. Our results also discovered
that ESR2-5 is highly expressed in GBMs. Unlike ESR2-1, ESR2-5 has lesser
tumor suppression ability and its interactions with mTOR, DNA repair, and
apoptotic pathways may have important implications in GBM progression.
#5532 Functional role of Friend Leukemia Integration-1 (FLI1) in gastric
carcinogenesis.ArmandoDel Portillo, Elena V. Komissarova, Anne Koehne de
Gonzalez, Aqiba Bokhari, Helen Remotti, Jorge Sepulveda, Antonia Sepulveda.
Columbia University, New York, NY.
Gastric adenocarcinoma (GC) is the 5thmost common cancer worldwide but
is the 3rd leading cause of cancer death. FLI1 (Friend leukemia integration-1) is
an ETS family transcription factor that regulates genes involved in proliferation
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and differentiation. FLI1 is implicated in tumorigenesis, such as in Ewing’s sar-
coma where a translocation creates an EWS-FLI1 oncogenic fusion protein.
However, few studies have examined the role of FLI1 in carcinomas. In human
breast cancer, overexpression of FLI1 led to inhibition of apoptosis, thereby
promoting survival and malignant potential. In functional studies in a murine
breast cancer model, however, downregulation of FLI1 increasedmalignant po-
tential. In human GCs, we recently reported that FLI1 expression is inversely
correlated with its promoter CpG methylation of the FLI1. To determine if
decreased expression occurs in GC epithelial cells or background non-epithelial
cells, we analyzed 91 human GC tumors by immunohistochemistry (IHC) for
FLI1 and compared them to normal gastric mucosa and intestinal metaplasia
(IM) using an IHC composite scoring system accounting for intensity and per-
centage of epithelial cells expressing FLI1. We found that FLI1 is strongly ex-
pressed in normal gastric glandular epithelium and in IM, and that decreased
expression was seen inmost humanGCs (P 1x10-17 vs normal, P 1x10-26 vs
IM). These fındings suggest that FLI1 acts as a tumor suppressor gene in GC. To
test this hypothesis, we used an invasion assay and the human GC cell lines
NUGC3 and SNU638, which have little to no FLI1 expression, respectively.
CulturedGC cells were transduced to overexpress FLI1 or control, alongwith an
eGFP reporter from an IRES (Lv203, Genecopoeia). After selection by puromy-
cin, these GC cells were plated in serum-free media in the upper chamber on a
Matrigel coated 8m pore opaque membrane. Complete media with 10% fetal
calf serum was plated in the lower chamber. Images were obtained of the lower
membrane with an inverted fluorescent microscope and cellSens imaging soft-
ware. Overexpression of FLI1 signifıcantly decreased invasion by NUGC3 cells
at 24 hours (P 0.013) but not at 48 hours (P 0.268) as compared to control.
Overexpression of FLI1 signifıcantly decreased invasion by SNU638 cells at both
24 and 48 hours (P  0.027 and 0.012, respectively) as compared to control.
Since NUGC3 cells have low FLI1 expression, we knocked down FLI1 by using a
FLI1 shRNA lentiviral system with mCherry from an IRES as a reporter
(LvRU6MP, Genecopoeia). Using the same invasion assay, knockdown of FLI1
trended towards a signifıcant increase in invasion as compared to control at 48
hrs (P 0.14), but not at 24 hrs (P 0.73). In summary, the combined obser-
vations in human GC tissue samples and the functional analyses in GC cells
support a tumor suppressor role for FLI1 in human GC and also suggest that
FLI1 and/or its target genes may be involved in regulatory mechanisms driving
invasive properties of GC.
#5533 Signaling pathways that regulate LMO2 oncogene expression in
pediatric high riskT cell acute lymphoblastic leukemia.Chandrika S.Gowda,1
YaliDing,1Chunhua Song,1MalikaKapadia,1Kimberly J. Payne,2 SinisaDovat1.
1Penn State University, Hershey, PA; 2Loma Linda University, Loma Linda, CA.
T-cell Acute Lymphoblastic Leukemia (T-ALL) accounts for about 15% of
pediatric ALL and is characterized as a high-risk disease with frequent relapse,
chemotherapy resistance, and a poorer prognosis. LIM domain only protein 2
(LMO2) is a regulator of hematopoiesis and an oncogene that is overexpressed
in about 10% of T-ALL. The IKZF1 gene encodes a zinc fınger protein called
Ikaros which is a master regulator of lymphoid development and a tumor
suppressor. In pediatric ALL, Ikaros alteration is considered independent prog-
nostic marker for poor outcome. Pro oncogenic Casein Kinase II (CK2) is over-
expressed in various malignancies including leukemia. CK2 directly phosphor-
ylates Ikaros in vivo and inhibits its function as transcriptional regulator.
Inhibition of CK2 restores Ikaros tumor suppressor function and results in
anti-leukemic effect. Objective of this study is to understand the mechanisms of
transcriptional regulation of LMO2 in T-cell ALL. Global chromatin immuno-
precipitation (ChIP) coupled with the next-generation sequencing (ChIP-seq)
studies in primary human ALL cells and in cell lines, demonstrated Ikaros oc-
cupancy of the promoter of LMO2 gene. We hypothesize that Ikaros negatively
regulates expression of LMO2 at transcriptional level and CK2 impairs Ikaros
mediated repression of LMO2 in T-cell ALL. Results: qChIP in primary leuke-
mia cells confırmed that Ikaros binds to the promoter region of LMO2. Using
gain-of-function and loss-of-function experiments we dissected the role of
Ikaros in regulation of LMO2 transcription in T-ALL. Ikaros silencing using
shRNA transfection revealed increase in LMO2 expression as measured by qRT
PCR. Conversely, overexpression of Ikaroswas associatedwith strongly reduced
transcription of LMO2. T-ALL cells that are derived from Ikaros-knockout
mousemodels express high level of LMO2. Retroviral transduction of these cells
with Ikaros, resulted in signifıcant reduction of LMO2 expression. Next we
investigated how CK2 affects the regulatory functions of Ikaros towards LMO2.
Molecular and pharmacological inhibition of CK2 resulted in reduced expres-
sion of LMO2 in primary human T-ALL. Ikaros binding at promoter of LMO2
was noted to be signifıcantly increased following CK2 inhibition. This effect was
not seen when cell were subjected to CK2 inhibition after Ikaros silencing. Fur-
ther, we analyzed changes in the histone markers at the heterochromatin at the
LMO2 promoter following Increased Ikaros binding such as reduced histone
H3K9ac andH3K4me3markers. This suggests that Ikaros regulates LMO2 tran-
scription via chromatin remodeling. Conclusion: This data reveals new regula-
torymechanism for oncogene LMO2 in pediatric T-ALL.New evidence suggests
that repression of LMO2 expression in T cell ALL via Ikaros can be potentiated
using CK2 inhibitors. Findings provide the rationale for the use of CK2 inhibi-
tors in T-ALL with LMO2 overexpression.
#5534 Runx1possesses anti-tumor activity and inhibits stemness in breast
cancer cells. Deli Hong, Andrew J, Fritz, Kristiaan Finstad, Mark P. Fitzgerald,
Janet L. Stein, Jane Lian, Gary S. Stein. University of Vermont, Burlington, VT.
Background:Despite advances in detection and therapies, breast cancer is still
the most common malignant disease in women worldwide. Cancer stem cells
(CSC) play an important role in formation, growth, drug-resistance and recur-
rence of tumors. Transcription factor Runx1 has received recent attention for its
potential tumor suppressor activity in solid tumors. We previously showed that
Runx1 represses the epithelial to mesenchymal transition in breast cancer cells.
The objective of the present study is to investigate Runx1 functional effects on
cellular activities, and its contribution to inhibitingCSC-like properties in breast
cancer cells. Methods: We generated Runx1 overexpression and Runx1 knock-
down stable cell lines in both malignant MCF10AT1 and metastatic
MCF10CA1a cells. Cells were analyzed for tumorsphere formation, protein
(Western) and RNA (RT-qPCR) expression analysis. Cellular activity assays
(cell proliferation, migration, and invasion) were performed to measure the
tumorigenic potential of the cells. Xenograft studies were used to determine
whether Runx1 overexpression in breast cancer cells represses tumor growth in
vivo. Results: Upon overexpressing Runx1, both MCF10AT1 and MCF10CA1a
cells reduce their proliferation, migration and invasion, which support the con-
cept that Runx1 acts as a tumor suppressor in breast cancer cells. Notably, over-
expressing Runx1 inhibited the formation of tumorspheres and effectively re-
duced the stem-like population in these two breast cancer cells. These
observations are consistent with the results of Runx1 knock-down in early stage
ER positive MCF7 breast cancer cells which showed increased tumorsphere
formation effıciency. Furthermore, Runx1 tumor suppressor activity was con-
fırmed in mouse xenograft by showing that Runx1 overexpression inhibits tu-
mor growth. Conclusion: Our studies show that Runx1 inhibits proliferation,
migration, and invasion, reflecting its tumor suppressor activity. Runx1 medi-
ated reduction of tumorsphere formation suggests that Runx1 also contributes
signifıcantly to inhibit the population of the breast cancer stem cells. Therefore
these studies offer Runx1 as a novel bio-therapeutic molecule for breast cancer
intervention.
#5535 Effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibitor
in non-small-cell lung cancer. Takehito Shukuya,1 Tadaaki Yamada,2 Michael
J. Koenig,1 Mohammad A. Rahman,1 Joseph M. Amann,1 David P. Carbone1.
1The Ohio State University, Columbus, OH; 2Kanazawa University, Kanazawa,
Japan.
The serine-threonine liver kinase B1 (LKB1, also called STK11) is a tumor
suppressor that functions as master regulator of cell growth, metabolism, sur-
vival and polarity. Germline mutation of LKB1 causes Peutz-Jeghers syndrome,
which is an autosomal dominant disease characterized by mucocutaneous pig-
mentation and hamartomatous polyps. In non-small-cell lung cancer (NSCLC),
LKB1 is frequently rendered non-functional, either through mutation or down
regulation. As a tumor suppressor and a protein whose function is lost, identi-
fying pathways that are activated with LKB1 loss may be the only way to target
such tumors. Some previous studies have suggested that inhibition of mTOR, a
growth promoting pathway negatively regulated by LKB1, as a potential target in
LKB1 mutant NSCLC. In this study, we investigated the effect of LKB1 activity
on the sensitivity to a PI3K/mTOR inhibitor using four LKB1 mutant NSCLC
cell lines to which LKB1 gene was transduced and one LKB1 wild type NSCLC
cell line in which LKB1 gene was knocked out by CRISPR technology. Trans-
duction of LKB1 resulted in signifıcant resistance to a PI3K/mTOR inhibitor in
two of the four LKB1 add-back cell lines, while knocking out LKB1 in the LKB1
wild type cell line induced PI3K/mTOR inhibitor sensitivity. The mechanism
behind these observed results appears to be through regulation of phosphoryla-
tion of AKT. The presence of LKB1 led to a persistent AKT phosphorylation
even in the presence of the PI3K/mTOR inhibitor, both in add back cell andwild
type cells. Our data suggest that the identifıcation of LKB1 activity may be a
promising biomarker for the sensitivity to PI3K/mTOR inhibition. Further in-
vestigation into the mechanism of LKB1 loss and increased sensitivity to inhi-
bition of the PI3K and mTOR pathways is warranted.
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#5536 Themetastasis suppressor NME1 regulates stemness inmelanoma.
Ying Wang, David M. Kaetzel. University of Maryland Baltimore, Baltimore,
MD.
Melanoma is a lethal skin cancer that is highly resistant to therapy and prone
to metastasize to distant organs. The quiescence melanoma stem cells are be-
lieved to account for the resistance to therapies. Traditional chemotherapies
designed to target fast-proliferative tumor cells tend tomiss quiescent stem cells.
The escaped quiescent stem cells may accumulate oncogenic mutation from
common mutagenic sources and fınally lead to tumor relapse. NME1 is a me-
tastasis suppressor gene that inhibits the metastatic potential in melanoma and
other cancers. In this study, we focus on the role of NME1 in the regulation of
stemness and quiescence of melanoma stem cells. We fınd that the genesis and
growth of stem cell spheroids derived from melanoma cell lines are abrogated
after knockdown of NME1. We also fınd that the mRNA level of several mela-
noma stem cell markers are elevated when we knockdown NME1. These results
suggest that NME1 regulates the survival and stemness of melanoma stem cells.
In addition, we demonstrate that melanoma stem cells are heterogeneous in
NME1 expression. Specifıcally, the NME1 expression is markedly elevated in a
highly proliferative subpopulation in the spheroids that express the stem cell
markers OCT4, SOX2 and SOX10. Conversely, we observe another subpopula-
tion of these spheroids that exhibits low NME1 expression and is non-prolifer-
ative. We hypothesize that this subpopulation consists quiescent melanoma
stem cells that are more resistance to therapies, and that their quiescent status is
controlled by the level of NME1.We are now employing CRISPR technology to
separately study potentials in tumorigenesis, metastasis, and therapy-resistance
of the stem cell subpopulations.
#5537 Loss of ITM2A, a novel tumor suppressor of ovarian cancer
through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovar-
ian cancer. So Young Kim, Eun-Ju Lee, Min Ji Cho, Hyemin Rhee. Chung-Ang
University School of Medicine, Seoul, Republic of Korea.
Integralmembrane protein 2A (ITM2A) is a type 2 transmembrane protein of
unknown function. The aim of this study was to investigate its expression pat-
tern, clinical signifıcance, and biological function in epithelial ovarian cancer.
ITM2A expression in 35 normal, 20 adenoma, 11 borderline and 90 cancerous
ovarian tissues was measured by immunohistochemistry. Clinicopathological
parameters were obtained from medical records. Survival data was analyzed
using Kaplan-Meier estimates and multivariate analysis using the Cox-regres-
sionmethod.Anti-tumor activities of ITM2Awere explored by cell proliferation
and colony formation assays, flow cytometry, Western blots and animal studies
using ovarian cancer cell lines. Chemoresponsiveness was evaluated bymeasur-
ing IC50 and confırmed by animal studies using an intraperitoneal orthotropic
model. ITM2A was signifıcantly downregulated in invasive carcinomas com-
pared to normal, adenoma and borderline tumor tissues. ITM2A loss occurred
in 45.6% (41 of 90) of invasive carcinomas and was signifıcantly associated with
FIGO stage, type II tumors, suboptimal debulking operation, recurrence and
chemoresistance. ITM2A loss and higher FIGO stage were independent factors
for poor prognosis. Expression of ITM2A inhibited growth and induced G2/M
cell cycle arrest by attenuating cdc2, cyclin B1, cdc25c and p-cdc2 (Thr 161). In
vitro and in vivo experiments showed that ITM2A expression signifıcantly re-
duced the paclitaxel and carboplatin IC50 and tumormass after paclitaxel treat-
ment. ITM2A is a new biomarker of poor prognosis in ovarian cancer. It is a
novel tumor suppressor that induces cell cycle arrest, acts as a chemosensitizer,
and has therapeutic potential for ovarian cancer.
#5538 Functional analysis of BAP1, de-ubiquitination enzyme, in intra-
hepatic cholangiocarcinoma. Kentaro Ishii,1 Masaharu Ishida,1 Shinobu
Ohnuma,1 Katsuyoshi Kudoh,1 Fuyuhiko Motoi,1 Takeshi Naitoh,1 Florin Se-
laru,2MichiakiUnno1. 1TohokuUniversity Graduate School ofMedicine, Sendai,
Miyagi, Japan; 2Johns Hopkins University School of Medicine, Baltimore, MD.
BACKGROUND: BRCA associated protein 1 (BAP1) was discovered as a
protein associated with the breast cancer susceptibility gene (BRCA), and
genetic mutations of BAP1 gene have recently been found in somemalignant
tumors, such as melanoma, mesothelioma, and renal cell carcinoma. Since
the mutations of BAP1 gene resulted in loss of function of this protein and
were associated with poor prognoses of the malignancies, BAP1 is now con-
sidered as a tumor-suppressor gene. Recent studies have shown that BAP1
mutations were also observed in patients with intrahepatic cholangiocarci-
noma (IHCC), which is one of the most aggressive carcinoma with poor
prognoses. However, only a few studies have investigated the role of BAP1
mutation on biological function of tumor cells and on clinicopathological
features of IHCC. PURPOSE: The purpose of this study was to elucidate the
association of BAP1 and IHCC. METHOD: The expression of BAP1 was
immunohistochemically analyzed in surgically resected IHCC specimens,
and the cases were classifıed into three groups based on the result of immu-
nostaining concentration; positive or weakly positive or negative. The clin-
icopathological factors, such as the disease stage of IHCC, curability and
overall survival (OS), were compared among the groups. In cell culture anal-
yses, the expression of BAP1 in IHCC cell lines (HuCC-T1 and TFK-1) was
down-regulated by Zinc-fınger nuclease (ZFN) and siRNA in vitro. Then,
cell-proliferation assay, migration assay, invasion assay, and drug-suscepti-
bility test were performed on BAP1 down-regulated cells. RESULTS: The
immunohistochemistry of BAP1 on IHCC specimens showed that OS was
not signifıcantly changed among three groups. However, the cases with
lower expression of BAP1 including weakly positive and negative tended to
be advanced in disease stage compared with cases with BAP1 positive. Inter-
estingly, in the patients received postoperative gemcitabine, a standard
chemo-drug for cholangiocarcinoma, cases with lower expression of BAP1
showed prolonged survival compared with cases with BAP1 positive. In cell
experiments, the knock-down of BAP1 did not affect cell-proliferation of
IHCC cells, however, it promoted migration and invasion of IHCC cells.
Furthermore, the suppression of BAP1 enhanced chemosensitivity to gem-
citabine. CONCLUSIONS: Our study suggested that lower expression of
BAP1 was associates with the progression of IHCC and with enhanced che-
mosensitivity to gemcitabine. BAP1 might be one of the target genes in the
treatment of IHCC.
#5539 The phenotypic characterization of Lrig null mouse embryonic fı-
broblasts. Carl Herdenberg, Håkan Hedman. Radiation Sciences, Umeå, Swe-
den.
The LRIG gene family consists of LRIG1, LRIG2 and LRIG3. The most stud-
ied of these is LRIG1, which is a tumor suppressor gene. The LRIG1 protein is
downregulated in various types of cancer and it negatively regulates receptor
tyrosine kinases including the EGF- and PDGF-receptors. Lrig1 also regulates
stem cell homeostasis in mouse skin and intestine. The functions of LRIG2 and
LRIG3 are less known, but some fındings imply that they might antagonize
LRIG1. Intriguingly, the sole LRIG homolog in C. elegans, Sma-10, positively
regulates BMP signaling. Thus, it is not known towhat degree the LRIG proteins
have the same, overlapping, or opposing functions, and the molecular mecha-
nisms involved are poorly characterized. To elucidate the functions of the three
LRIG proteins we generated a series of wildtype and LRIG-null (Lrig1-/-;Lrig2-/-;
Lrig3-/-) mouse embryonic fıbroblast (MEF) lines. These cell lines were created
from homozygous Lrig1flox/flox;Lrig2flox/flox;Lrig3flox/flox mouse embryos. The
FLOXed Lrig genes were then deleted with CRE-recombinase, thereby creating
Lrig-null MEFs. ddPCR analysis showed that the Lrig-null MEF lines were con-
taminated with less than 1% of cells carrying wildtype Lrig3 alleles. Lrig-null
MEFs showed a higher proliferation rate andmigratedmore in trans-well cham-
bers than the wildtype cells. These cell lines will also be useful to investigate the
importance of Lrig proteins for other cellular functions such as, signal transduc-
tion, lipidomics, transcriptomics, secretomics, metabolomics, and oxidative
stress sensitivity. We also transduced the Lrig-null cells with individual induc-
ible Lrig-genes thus creating a powerful system for the examination of the biol-
ogy of the specifıc Lrig proteins.
#5540 Transcriptional control of signaling pathways in T-cell lympho-
blastic leukemia by Ikaros tumor suppressor. Tommy Hu, Mario Soliman,
Malika Kapadia, Elanora Dovat, Jonathan Payne, Chunhua Song, Sinisa Dovat.
Penn State College of Medicine, Hershey, PA.
Cellular proliferation in T-cell acute lymphoblastic leukemia is regulated by
multiple signaling pathways. The Phosphoinositide 3-kinase (PI3K)/AKT path-
way is frequently dysregulated inT-ALL. Targeting the PI3Kpathway has shown
promise as a novel therapeutic approach for T-ALL. However, regulation of the
PI3K pathway is still not well understood. Here, we report that PI3K activity in
T-ALL can be controlled by transcriptional regulation of key members of this
pathway, PIK3CD and PIKFYVE. DNA binding analysis of primary T-ALL
using qChIP revealed that the tumor suppressor protein, Ikaros, binds the pro-
moter regions of PIK3CD and PIKFYVE. Since Ikaros acts as a regulator of
transcription, we tested whether Ikaros binding to PIK3CD and PIKFYVE af-
fects their expression. Overexpression of Ikaros results in reduced transcription
of PIK3CD and PIKFYVE in T-ALL. Targeting Ikaros with a specifıc shRNA,
resulted in increased transcription of PIK3CD and PIKFYVE in T-ALL. To-
gether, these results demonstrate that Ikaros functions as a transcriptional re-
pressor of both PIK3CD and PIKFYVE, and suggest that Ikaros can regulate the
PI3K pathway in T-ALL. It has been previously shown that Ikaros function in
B-cell acute lymphoblastic leukemia is regulated by oncogenic Casein Kinase II
(CK2).We tested whether Ikaros ability to repress transcription of PIK3CD and
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PIKFYVE is regulated by CK2. Inhibition of CK2 by a specifıc pharmacological
inhibitor, CX-4945, resulted in increased Ikaros binding to the promoters of
PIK3CD and PIKFYVE, as well as in transcriptional repression of both of these
genes. These results suggest that Ikaros function as a repressor of PIK3CD and
PIKFYVE transcription is impaired by CK2 in T-ALL. CK2 inhibition restores
Ikaros-mediated transcriptional repression of PIK3CD and PIKFYVE, which
results in downregulation of the PI3K pathway. In conclusion, the presented
data demonstrate that the PI3K signaling pathway is regulated by transcriptional
repression of PIK3CD and PIKFYVE by Ikaros in T-ALL. Results reveal inter-
play between two signaling pathways in T-ALL, CK2 and PI3K, where CK2
positively regulates the PI3K pathway by inhibiting Ikaros function. These data
reveal novel mechanisms that regulate cellular proliferation in T-ALL.
#5541 Identifıcation of sod and sod2 as potential prognostic biomarkers
for patients with non-small cell lung cancer. Chen Yin, RenWang, Xiao-xing
Li, Yang Yang, Mei-yin Zhang, Hui-Yun Wang, Steven X. Zheng. Sun Yat-sen
Univesity Cancer Center, Guangzhou, China.
Background: Reactive oxygen species (ROS) is accumulated in cancer cells
related to increased metabolism, which is characteristic of cancer progression.
With the rapid advance of cancer research, redox regulation has drawn more
and more attentions. The superoxide dismutases SOD1 and SOD2 are essential
enzymes for eliminating ROS. To date, SOD1 or SOD2 have not been well char-
acterized in non-small cell lung cancer(NSCLC). Here we compared the expres-
sion of SOD proteins between normal and cancer tissues and investigated its
prognostic signifıcance in NSCLC patients. Method: we detected the expression
of SOD1 and SOD2 in 178NSCLC samples by immunohistochemistry and their
clinical signifıcances were analyzed. Western blotting is used to confırm the
protein level of SOD1 and SOD2 in the normal and cancer tissues of NSCLC
patients. Results: The expression of SOD1 and SOD2 is signifıcantly higher in
both adenocarcinoma or squamous cell carcinoma (p0.0001), compared to
matched adjacent normal tissues. Correlation analysis indicates that SOD1 ex-
pression is reversely associated with TNM stage, and SOD2 is negatively corre-
lated with tumor size, tumor number and TNM stage remarkably (all p0.05).
Moreover, higher expression of SOD1 and SOD2 is correlated with better prog-
nosis of NSCLC patients. Finally, Univariate and multivariate Cox regression
modes further indicate that SOD1 and SOD2 can be used as independent prog-
nostic factors in NSCLC patients. Conclusion: Higher expressions of SOD1 and
SOD2 in NSCLC tissues are observed compared to adjacent tissues and indicate
better prognosis, suggesting that SODproteins are potentially useful biomarkers
for prognostic evaluation of patients with NSCLC.
#5542 Regulation of cell cycle control in T-cell acute lymphoblastic leuke-
mia by Ikaros and Casein Kinase II.Mario A. Soliman,1 Tommy Hu,1 Malika
Kapadia,1 Elanora Dovat,1 Yali Ding,1 Chunhua Song,1 Jonathon L. Payne,2
Sinisa Dovat1. 1Penn State University College of Medicine, Hershey, PA; 2Loma
Linda University School of Medicine, Loma Linda, CA.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological
malignancy that represents a therapeutic challenge. Next-generation sequenc-
ing revealed that a subset of T-ALL harbors inactivatingmutations or deletion of
one allele of the IKZF1 tumor suppressor. These data suggest that IKZF1 acts as
a tumor suppressor in T-ALL. The IKZF1 gene encodes the Ikaros protein that
functions as a regulator of transcription and a tumor suppressor in B cell acute
lymphoblastic leukemia. However, the molecular mechanism of Ikaros tumor
suppressor function in T-ALL is unclear. Using quantitative chromatin immu-
noprecipitation (qChIP), we determined that Ikaros binds to the promoter re-
gions of the CDC2 and CDC7 cell cycle genes in primary T-ALL cells in vivo.
Gain-of function experiments showed that Ikaros overexpression in T-ALL re-
sults in reduced expression of CDC2 and CDC7, as evidenced by quantitative
RT-PCR (qRT-PCR) andWestern blot. The knock-down of Ikaros with shRNA
in T-ALL cells resulted in increased transcription of CDC2 and CDC7 as indi-
cated by qRT-PCR. These data suggest that Ikaros can regulate cell cycle pro-
gression in T-ALL by repressing transcription of the CDC2 and CDC7 genes.
Next, we studied the mechanisms that regulate Ikaros’ ability to repress CDC2
and CDC7 in T-ALL. Ikaros function as a transcriptional repressor is regulated
by Casein Kinase II (CK2). CK2 is overexpressed in hematopoieticmalignancies
and increased expression of CK2 results in T-ALL in murine models. We tested
the effect of CK2 inhibition on Ikaros’ ability to regulate transcription of CDC2
and CDC7 in human T-ALL. Molecular inhibition of CK2 with shRNA against
the CK2 catalytic subunit resulted in reduced transcription of CDC2 andCDC7,
as evidenced by qRT-PCR. This was associated with increased DNA-binding of
Ikaros to promoters of CDC2 andCDC7, as shownby qChIP. These data suggest
that CK2 impairs Ikaros’ ability to transcriptionally repress CDC2 and CDC7
and to regulate cell cycle progression in T-ALL. Inhibition of CK2 enhances
transcriptional repression of CDC2 and CDC7 by Ikaros, resulting in improved
control of cell cycle progression in T-ALL. In conclusion, our results show that
control of cell cycle progression in T-ALL occurs trough Ikaros-mediated tran-
scriptional regulation of CDC2 and CDC7. Overexpession of CK2 impairs
Ikaros ability to repress CDC2 and CDC7 expression, which contributes to de-
regulation of cell cycle control in T-ALL. Results suggest a potential mechanism
of therapeutic action of CK2 inhibitors for the treatment of T-ALL.
BIOINFORMATICS AND SYSTEMS BIOLOGY: Systems Biology
Approaches to Cancer Diagnostics and Disease Management
#5543 Network guided modeling allows tumor type independent predic-
tion of sensitivity to retinoic acid. Enrico Garattini, Marco Bolis, Maddalena
Fratelli, Mineko Terao. Istituto di Ricerche Farmacologiche Mario Negri, Milan,
Italy.
Background: All-trans retinoic acid (ATRA) is a differentiating agent used in
the treatment of acute-promyelocytic-leukemia and it is under-exploited in
othermalignancies despite its low systemic toxicity. A rational/personalized use
of ATRA requires development of predictive tools allowing identifıcation of
sensitive cancer types and responsive individuals.Materials andMethods: RNA-
Sequencing data for 10080 patients and 33 different tumor-types were derived
from the TCGAand Leucegene datasets and completely re-processed. The study
was performed using machine learning methods and network analysis. Results:
We profıled a large panel of breast-cancer cell-lines for in vitro sensitivity to
ATRA and exploited the associated basal gene-expression data to initially gen-
erate a model predicting ATRA-sensitivity in this disease. Starting from these
results and using a network-guided approach, we developed a generalizedmodel
(ATRA-21) whose validity extends to tumor-types other than breast cancer.
ATRA-21 predictions correlate with experimentally determined sensitivity in a
large panel of cell-lines representative of numerous tumor-types. In patients,
ATRA-21 correctly identifıes APL as the most sensitive acute-myelogenous-
leukemia subtype and indicates that uveal-melanoma and low-grade glioma are
top-ranking diseases as for average predicted responsiveness to ATRA. There is
a consistent number of tumor-types for which higher ATRA-21 predictions are
associated with better outcomes. Conclusions: In summary, we generated a tu-
mor-type independentATRA-sensitivity predictorwhich consists of a restricted
number of genes and has the potential to be applied in the clinics. Identifıcation
of the tumor-types which are likely to be generally sensitive to the action of
ATRA paves the way to the design of clinical studies in the context of these
diseases. In addition, ATRA-21 may represent an important diagnostic tool for
the selection of individual patients who may benefıt from ATRA-based thera-
peutic strategies also in tumors characterized by lower average sensitivity.
#5544 New technologies to probe the systems glycobiology of cancer. Pau-
line M. Rudd, Mark Hilliard, Mohankumar Muniyappa, Roisin O’Flaherty,
Radka Saldova.National Institute for Bioprocessing Research and Training, Dub-
lin, Ireland.
A robotic 384 well based platform was developed to release and label the
human serum N-glycome. Improved separation of the glycan pool, based on
hydrophilic interaction UPLC chromatography combined withmass spectrom-
etry (Waters Corporation) and computer assisted data interpretation (NIBRT
Glycobase) enabled us to build a database after assigning the detailed structures
ofmore than 170N-glycans. The aim of the project was to use these technologies
and databases to link glycosylation changes in individual patients’ serum with
features of cancer and with changes in a range of other –omics data acquired
from the same patients. Alterations in glycosylation in various breast cancers
were mapped to changes in the serum glycomes and aligned with genetic, tran-
scriptomic and proteomic data. Pathway analysis showed strong associations
between these glycan changes and the –omics data. This revealed that many of
the glycan changes are directly associated with pathways involved in cancer
metastasis. Our next aimwas to demonstrate the feasibility of collecting person-
alised data from individual patients from each of the –omics analyses to build up
a dataset of the changing glycosylation over time. This opens up the possibility of
linking these data to explore pathways of disease and, in particular, nodal points
where the patient can no longer compensate for the effects of an altered pathway
that is leading to disease. To this end, single glycoproteins from8 controls and 26
ovarian cancer patients were sequentially purifıed from 5ul of serum on affınity
plates and the released glycans were analysed. Rather than the conventional way
of looking at markers which compare a patients’ data with averages, the control
can nowbe the blood of the patient themselves taken at an earlier time point. The
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automation, sensitivity, quantitation and resolution of the new technology plat-
forms coupled with dedicated software open up new possibilities for precision
medicine and early intervention based on the biochemical profıle of the patient.
References: Association of N-glycosylation with breast carcinoma and systemic
features using high-resolution quantitative UPLC. Saldova R, Asadi Shehni A,
Haakensen VD, Steinfeld I, HilliardM, Kifer I, Helland A, Yakhini Z, Børresen-
Dale AL, Rudd PM. J ProteomeRes. 2014May 2;13(5):2314-27. SerumN-glycan
analysis in breast cancer patients–Relation to tumour biology and clinical out-
come.HaakensenVD, Steinfeld I, SaldovaR, ShehniAA,Kifer I,NaumeB,Rudd
PM, Børresen-Dale AL,Yakhini Z. Mol Oncol. 2016 Jan;10(1):59-72.
#5545 Integrated system-level analyses of androgen receptor variant net-
works to identify novel prostate cancer-relevant genes. Fiorella Magani, Eric
R. Bray, Ning Zhao, Stephanie Peacock, Kerry L. Burnstein.University of Miami
Miller School of Medicine, Miami, FL.
Unbiased high-throughput approaches provide a global view of the massive
genetic and transcriptomic changes that occur in and potentially drive cancer.
Such approaches permit the discovery of novel markers and therapeutic targets.
Current treatments for advanced prostate cancer (PC) focus on inhibiting the
androgen receptor (AR). However, PC inevitably progresses to a stage termed
castration-resistant prostate cancer (CRPC), which is incurable. In CRPC, C-
terminal truncated, constitutively activeAR splice variants (such asAR-V7) play
key transcription-regulatory roles resulting in treatment resistance and disease
progression. However, designing high-affınity drugs to target the amino termi-
nus of AR and AR variants is a major challenge due to the intrinsic disorganized
structure of this region. Thus there is an imperative need to identify novel
AR-V7 hub genes in PC that may serve as therapeutic targets. We performed an
extensive and highly robust gene expression meta-analysis on PC patient sam-
ples.We defıned genemodules correlated with disease progression using a pow-
erful systems biology approach termedWeightedGene-Co-expressionNetwork
Analysis (WGCNA). Further, we mapped the AR-V7 interactome for the fırst
time using a novel high-throughput synthetic genetic array screening in yeast,
known as Yeast Augmented Network Analysis (YANA). YANA was performed
by crossing yeast expressing AR-V7 with a large collection of yeast strains lack-
ing non-essential genes, and identifying those genes that caused a change in
yeast growth (fıtness). Human orthologs of the identifıed yeast genes were used
to build an AR-V7 functional gene network. Finally, we combined the results
from our independent system-level analyses with experimental data to identify
hub genes that are upregulated in PC patients, regulated by AR-V7, and also
functionally interact with AR-V7. The identifıed genes not only include select
genes previously linked to PC, such asmembers of the cyclin and topoisomerase
families, but also genes that have not been previously linked toAR-V7 activity or
PC progression. Moreover, our gene expression signature predicts a higher risk
of PC recurrence after primary treatment in patients. In sum, we show here an
unbiased and novel gene discovery strategy using bioinformatics in concert with
experimental approaches to identify new candidate genes inCRPC thatmay lead
to prognostic markers and future targeted therapies.
#5546 Modeling of gastric cancer with lymphovascular invasion and H.
pylori: a systems approach. Samuel Perez. Penn State Univ., Phoenix, AZ.
Background: Modeling behaviors of gastric cancer system with an H.Pylori
co-morbidity allows clinician- educators to describe cancer metastasis through
the lens of a system approach. Lymphovascular invasion in gastric cancer has
shown to have low survival rate within a fıve year period. The unresolved pres-
ence of H. Pylori in the gastric chamber allows for pervasive inflammation of the
mucosal lining. Lymphovascular invasion supported with extracellular mem-
brane (ECM) detachment and anoikis suppression exhibit elements of a systems
approach such as inputs, processes, output and a feedback loop. Methods: In-
sightmaker.com is a simulation and modeling program used to create the stock
and flow models. This system based approach allows a user to create primitives
such as stock and variables and add connections using link and flow elements. A
simulation run provides a visualization of the defıned stock against a timeline on
a dynamic graph. Results: A generalized metastasis model was fırst generated in
insightmaker.com. An organ specifıc model was used to model how cancer cells
interact with the gastric mucosal lining and its spread to the lymphovascular
system.This organ specifıcmodelwill help a clinician- educator represent chem-
ical pathways and relationships to explain the secondary growth of tumors from
its original site. Conclusion: The initial instructional activity was designed with
an easy to follow demoof an actual working systemsmodel in systems biology or
population ecology. This allows for the content to be familiar to the student. A
team of 4 students constructed a systemsmodel of a portion of the gastric tumor
metastasis cycle such as ECMdetachment or suppression of the anoikis process.
An evaluation rubric was used to guide the development of the group created
student model with evaluation categories such as narrative of the systemmodel,
attributes of the system, data flow and values used and a personal reflection of
their experience. The successful implementation of a system approach is pack-
aging the instructional activity and its supporting content in bite size pieces, an
incremental approach and explicit description of the activity’s deliverables. The
drag and drop interface and intuitive icon driven menu of insightmaker.com is
ideal for lowering the learning curve for a systems thinking instructional activity
and can fıt in the time constraints of an oncology course block as part of a case
based instruction session in an undergraduate medical curriculum.
#5547 A computational approach to predict tissue level cell cycle regula-
tory network for normal proliferating and cancer cells. Tao Sheng, Sha Cao,
Chi Zhang, Ying Xu. Univ. of Georgia, Athens, GA.
Cell cycle control and regulation has been widely studied in terms of cyclin-
dependent kinases (CDKs) activities, while only limited information are avail-
able on tissue contexts and signaling. In this study, we adopted a systems biology
approach aiming to comprehensively capture how tissue level signaling events
orchestrate cell cycle phases in a CDKs activities independentmanner in both of
normal and tumor tissues.Wehave applied our in house gene co-expression and
bi-clustering analysis on a collection of 8 single cell transcriptomic sequencing
datasets of normal proliferating human embryonic cells, 17 RNA-seq transcrip-
tomic datasets of inflammatory tissues and 30 microarray data sets of chronic
inflammatory diseases as normal proliferating reference and TCGA RNA-seq
data for 20 cancer types aiming to identify cell cycle associated gene co-expres-
sion modules. Our results suggest that the tissue level signaling events are gen-
erally show distinct regulatory structures between tumor and normal tissues: 1)
the Rho GTPase signaling pathways that control cell polarity, activate in G2/M
transition phase in normal tissue, while mainly in G1 and S phases in tumor. 2)
Focal adhesion kinases (FAK) drives G1/S transition in normal tissues, while
activated in multiple phases in tumor. 3) Hippo signaling for cell size control
activates at G2/M transition phase in normal tissue while in multiple phases in
tumor. In addition, we have also generated tissue level regulatory networks for
cell cycle controls by predicting possible collective effects of extra- and intra-
cellular signaling for both normal proliferating and cancer cells.
#5548 Genomic signatures for tumor-to-treatment stratifıcation in pan-
creatic cancer. Olga H. Nikolova, Laura Heiser, Adam A. Margolin. Oregon
Health and Science University, Portland, OR.
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is the fourth lead-
ing cause of cancer deaths. PDAC is a broadly heterogeneous disease making it
diffıcult to treat; each patient’s tumor is unique, but it can be classifıed into
different subtypes, and identifying the right therapeutic strategy for each sub-
type is key to improving patient outcomes. Three sets of transcriptional signa-
tures for PDAC subtype classifıcation have been proposed in the literature; how-
ever, preliminary data from in vitro cell line models indicates that they are
associated with sensitivity for only a handful of compounds. Computational
methods can identify effective individual therapies by robustly analyzing ge-
nome-scale data frommultiple experimental platforms to derivemolecular clas-
sifıers predictive of drug response (drug signatures). Methods: We developed a
novel Bayesian framework approach called Gene-wise prior Bayesian Group
Factor Analysis (GBGFA) for predicting drug sensitivity in a given sample from
genomic data. Our approach integrates data from different omic platforms by
modeling the statistical dependencies of measurements made for the same gene
via a model parameter called “gene prior”. We identify gene signatures for the
clinically relevant to PDAC compounds olaparib and palbociclib, leveraging
data from 44 pancreatic cell lines. Using hybrid capture mutation, gene expres-
sion, and copy number data, we applied ourmodel to score genes for their ability
to predict drug response in pancreatic cell lines and compiled the top predictors
into drug signatures. Results: Our results across a pan-cancer cell line collection
and100 compounds show improved ability to recapitulate known biomarkers
and drug targets compared to other state of the art methods. For the MEK1/2
inhibitor selumetinib, we successfully recapitulated BRAF mutation as the top-
scored biomarker of sensitivity. In addition, we identifıed four genes that carry
additional information that can be used to stratify samples into sensitive or
resistant groups: all werewild type in the sensitive cell lines andmutated in some
of the resistant lines.We hypothesize that these genes could be used in conjunc-
tion with BRAF mutation status to refıne the stratifıcation to selumetinib ther-
apy. We also identifıed several highly expressed genes in the resistant cell lines,
and we hypothesize that these genes may mediate drug resistance. Similar anal-
ysis are currently ongoing for olaparib and palbociclib, comparing our fındings
to the subtypes currently proposed in the literature. Conclusions:Our integrated
approach identifıes drug-specifıc gene signatures in PDACcell lines.We derived
genomic signatures for two clinically relevant to PDAC compounds in the con-
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text of the established in the literature PDAC subtypes, and hypothesize that
these signatures could be used to identify patientsmost likely to respond to these
therapies.
#5549 Novel network predictor for drug sensitivity in cell line response
data. Ana Brandusa Pavel,1 Bin Li,2 Andrew Krueger2. 1Graduate Program in
Bioinformatics, Boston University, Boston, MA; 2Takeda Oncology, Cambridge,
MA.
Sequencing patient tumors has enabled the design of treatment regimens that
exploit sensitizing genomic alterations. Associating drugs with mutations that
enhance their effect is a key component of the American Society of Clinical
Oncology vision for the next two decades of cancer treatment. Methods that
distinguish drug sensitizing molecular events from the millions of extraneous
alterations common within a tumor will help researchers implement precision
medicine strategies. Here we use molecular data from the cancer cell line ency-
clopedia; including mutations, copy number alterations and gene expression
changes along with drug response data, to identify subnetworks of interacting
proteins that contain drug sensitizing alterations. Building upon the ability of
fuzzy logic models to capture gene activity from different molecular data types,
we create ’Network-FLM’, a method to identify drug sensitizing molecular
markers using a subnetwork model that distinguishes a drug sensitive sample
from a drug insensitive one. Because the subnetwork model incorporates the
sign and direction of network edges and themagnitude of gene activity changes,
biologically meaningful features are captured. We integrate protein interaction
information fromMetacore database with somatic mutation, copy number and
gene expression measurements, profıled by CCLE. Using cross validation, we
evaluate the mean AUC of the predictor for 24 anti-cancer compounds (Bar-
retina et al., 2012). We build subnetwork classifıers for each compound using
mutation, copy number and expression data separately and in all possible com-
binations. We fınd that the Network-FLM approach performs well for targeted
agents such as Sorafenib, and also for drugs with pleitropic mechanisms of
action. Gene expression data alone creates effective predictive subnetworks for 8
compounds (Nilotinib, Sorafenib, Irinotecan, PLX4720, Paclitaxel, Topotecan,
TAE684, and Erlotinib). Adding copy number changes to gene expression data
created better predictive networks for 8 compounds (PF2341066, AZD6244,
L685458, RAF265, PD0325901, ZD6474, PHA665752, and 17-AAG). Likewise,
three compounds benefıt from adding mutation data to expression data (Pano-
binostat, PD0332991, and Lapatinib). Combining all datatypes created the best
predictors for AEW541 and AZD0530. For three compounds, mutation data
alone and together with copy number alterations is the best input for building
predictive models. We identifıed hyper-active subnetworks in cancer cell lines
and used them to predict drug sensitivity. We plan to further explore the poten-
tial of these networks to improve patient response to anti-cancer drugs.
#5550 Collaborative analyses for delineating mutation variations among
different ethnic patients of prostate cancer based on genomic data integra-
tion. Qingyu Xiao,1 Yidi Sun,1 Hong Li,1 Yixue Li,1 Guo-Ping Zhao,1 Wendy
Wang,2 Sudhir Srivastava2. 1CAS-MPG Partner Institute for Computational Bi-
ology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
Shanghai, China; 2National Cancer Institute, National Institutes of Health,
Bethesda, USA, Bethesda, MD.
Emerging data support the hypothesis that both inherited and somatic alter-
ations of genomes of African American (AA) prostate cancer (CaP) patients are
signifıcantly different from that of Caucasian American (CA)men. Recent stud-
ies from our and other groups have established that frequencies of the most
common genomic alteration, TMPRSS2-ERG fusion, which apparently causes
the high expression of ERG oncoprotein, is markedly lower in AA than in CA
patients. Some works indicated that the frequency of CaP ERG fusion is the
lowest in Asian patients, but this frequency changed from 11% to 78% in differ-
ent Asian cohorts. Further analysis in Asian men is necessary. In order to sys-
tematically and comprehensively address this and related problems, Uniformed
Services University of the Health Sciences-Center for Prostate Disease Research
(CPDR), the US National Cancer Institute (NCI) and CAS-MPG Partner Insti-
tute for Computational Biology (PICB), Shanghai Institutes for Biological Sci-
ences (SIBS), Chinese Academy of Sciences (CAS), China, launched an interna-
tional collaboration project. The overall goal of the project is to evaluate
difference of driver gene mutations of prostate cancer in various ethnic groups
by integrating genomic and transcriptomic data from CPDR, TCGA and the
Chinese Prostate Cancer Consortium (CPCC), specially focusing on somatic
alterations (ERG and others), microbiome, mitochondrial sequences and mi-
croRNAs.We integrated gene fusion, copy number, and gene expression data to
detect potential driver genes and, as anticipated ERG alteration was one of the
most commonly detected. The frequency of ERG fusion is the highest for CA,
intermediate for AA and the lowest for Asianmen, while its expression is signif-
icantly higher inERG-fusion tumors than other tumors cross over all of the three
ethnic groups.We did fınd some genes alteredmore frequently inAsian patients
than inAmerican patients, subject to further validations.We explored themeth-
odology for microbiota profıling using prostate cancer WGS sequencing data.
To this date, we have developed an analysis pipeline for the detection of micro-
biome from prostate tumor tissues and the corresponding blood samples with
high confıdence but inadequate sensitivity likely due to the low availability of
both microbial sequences and bacterial reference genomes. Our preliminary
analyses highlight the potential of international collaboration. CPDR-PICB-
NCI will work on a seamless approach for data integration, particularly of the
raw data to truly enhance CaP diagnosis and treatment by providing more in-
formative biomarker and therapy targets relevant to ethnically diverse patient
populations.
#5551 Systematic analysis of novel noncoding genes associated with poor
prognostic pathways in lung adenocarcinoma. Jou-Ho Shih, Yuh-Shan Jou.
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Non-coding genes are shown to play important roles in cancer progression
with potential for serving as theranostic biomarkers.However, there is still a lack
of studies to predict the biological roles of novel non-coding genes in tumori-
genic pathways and associations with patient survival. Lung adenocarcinoma
(LUAD) is the predominant histological subtype of lung cancer, which is the
leading cause of cancer death. Nowadays, target therapies have improved LUAD
patients’ survival about 6-12 months, but limited improvement of long-term
survival, suggesting that discovering new therapeutic targets are important.
Therefore, here we applied weighted correlation network analysis (WGCNA) to
cluster highly correlated genes of transcriptomic data to accurately investigate
the functions of non-coding genes with poor prognosis in lung adenocarcinoma
(LUAD). We discovered a total of 627 differential expressed coding and non-
coding genes (DEGs) from 6 transcriptomic datasets derived from LUAD pa-
tients with survival information. By using WGCNA, we discovered 6 non-cod-
ing candidates (PTTG3P, MIR497HG, HSP078, TBX5-AS1, LOC100506990,
and C14orf64) and their core networks of DEGs, which were highly associated
with patient survival and clustered in modules functioning in cell cycle and
migration. We noticed that a previously known processed pseudogene,
PTTG3P (Pituitary Tumor-transformingGene 3), is highly correlatedwith poor
survival and associated with mitosis of the cell cycle. Up-regulated PTTG3P
expression in LUAD was in silico validated of RNA-seq data from TCGA com-
pared to normal lung tissues (fold-change 2, p-value 0.0001) and associated
with poor 5-year survival rates (HR 1.83, p-value 0.012). We further con-
fırmed PTTG3P is highly expressed and associated with poor survival outcome
of LUADpatients in Taiwan (HR 1.75, p-value 0.037) with RNA-ISH exper-
iments. To examine the coding potential of pseudogene PTTG3P, we found that
PTTG3Pmight encode a consensus 21 kDanovel polypeptide froma single exon
by using various prediction programs of coding potential. Ectopic expression of
PTTG3P in lung cancer cells indicated that PTTG3P protein can be detected
resulted in shortening the process of metaphase to anaphase in cell cycle pro-
gression and promotion of cell proliferation. Knockdown experiments of
PTTG3P further reversed aforementioned experiments. Together, we estab-
lished a powerful and systematic strategy for functional classifıcation of non-
coding genes in association with poor prognosis of LUADpatients.We revealed
that commonly annotated and processed pseudogenes defıned as non-coding
genes for lacking of introns and promoter regions could still be translated into
functional polypeptides. We found processed pseudogene PTTG3P can be
translated to a protein, whichmight play an important role in predicted function
of mitosis and impact on poor survival in LUAD patients.
#5552 Differential proteomic responses of luminal-A and basal-like
breast cancer cell lines during growth inhibition induced by co-culture with
agarose encapsulated murine renal adenocarcinoma (RENCA) cells.Melissa
A. Laramore,1 Peter James,2 Prithy C. Martis,1 Atira Dudley,1 Lawrence S.
Gazda,1 Carl A. Borrebaeck,2 Barry H. Smith3. 1The Rogosin Institute - Xenia
Division, Xenia, OH; 2Lund University, Lund, Sweden; 3The Rogosin Institute,
New York, NY.
The existence of a tumor growth regulatory network that is conserved across
tumor types and species has been hypothesized. Our evidence for this regulatory
network is derived from studies demonstrating tumor growth inhibition by
agarose encapsulated cancer cells (cancer macrobeads). The ability of encapsu-
lated, thus growth restricted cells, to inhibit freely growing cancer cells has been
shown when the encapsulated cells are murine (RENCA) or human (e.g., J82).
Clinical trials are underway (NCT01053013, NCT02046174). We have shown
that RENCAmacrobeads release10 known tumor inhibitory proteins target-
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ing several signaling pathways including Akt/PI3. To better understand the
mechanism(s) of growth inhibition, we used a systems biology approach to
identify protein profıles and interactions frommacrobead-treated human breast
carcinoma cell lines that are either mildly aggressive (MCF7) or highly aggres-
sive (MDA-MB231 [MDA]). Target cells were co-cultured with RENCA mac-
robeads or left untreated for 5 days. Lysates of target cells were prepared in
Laemmli buffer, frozen, and sent for MS/MS. Samples were run in duplicate,
protein intensities normalized, and the treated/untreated ratio log10 trans-
formed to get a normal distribution. Protein profıles were analyzed using Key
Pathway Analysis (KPA) andMetacore software. Growth inhibition by RENCA
macrobeads was confırmed (MCF7 25%; MDA 57%). KPA of MCF7 proteins
showed upregulation of ubiquitin pathways involved in degradation of mis-
folded proteins. Stress induced apoptosis and DNA damage (which correlates
with the growth inhibition) were the top 2 pathways upregulated using Pathway
and Process Enrichment analysis. This is in line with a strong epigenetic gene
deregulation (Metacore). Transcription Factor and Network analyses show up-
regulation of CREB, A2MR and ATF3 networks. Also, Regulated Network anal-
ysis suggests a role for A2MR or RAGE in the inhibition of proliferation and
increased apoptosis. Macrobead-treated MDA cells showed no signifıcant
changes using KPA. Pathway, Network and Process enrichment (Metacore)
showed 5 of the top 10 upregulated processes were associated with cytoskeleton
remodeling. Cell cycle and protein folding processes were also upregulated.
Transcription factors associatedwith this responsewere similar to that ofMCF7.
RAGE again appears in many of the pathways as indicated by Network and
Regulated Network analysis. The protein response to RENCA macrobeads dif-
fers for these 2 cell lines. Proteins related to apoptosis are upregulated in the
MCF7 cells whereasMDAhave a preference for cytoskeleton remodeling. These
data support the hypothesis that distinctive tumors may respond differently to
RENCA macrobead exposure at both an epigenetic and protein level, nonethe-
less resulting in growth inhibition.
#5553 A computational model for integrating genomic data with public
datasets for molecular tumor board recommendations. R Joseph Bender,1
Edik Blais,1 Apoorva Kulkarni,1 Michael J. Pishvaian,2 David Halverson,1 Jona-
than R. Brody,3 Emanuel Petricoin,1 SubhaMadhavan2. 1Perthera, Inc, McLean,
VA; 2GeorgetownUniversity Lombardi Comprehensive Cancer Center,Washing-
ton, DC; 3Thomas JeffersonUniversity Pancreas, Biliary and Related Cancer Cen-
ter, Philadelphia, PA.
Recent genomic profıling studies in pancreatic adenocarcinoma (PDA) have
revealed actionablemutations affectingmultiple signaling pathways, but in spite
of these mutations, targeted inhibitors of these pathways have low success rates.
A possible reason for these failures is that single-gene biomarkers (e.g. a KRAS
mutation as an indicator of MEK inhibitor sensitivity) fail to account for cross-
talk within and between dysregulated pathways. We have previously curated a
knowledgebase of published studies as evidence to support molecular tumor
board recommendations to cancer patients after multi-omic profıling. Here we
present a computational framework for integrating this knowledgebase with
drug response data from cancer cell lines to propose “actionable” biomarkers
based on a panel of pathways instead of targeting a single gene mutation. We
constructed a computational model encompassing a broad range of cancer-
related pathways, including RAS/RAF/MEK/ERK, PI3K/AKT, cell cycle regula-
tion, and DNA repair. The model consisted of a set of ordinary differential
equations (ODE) with protein interactions following Hill-type kinetics and the
rate of cell division and apoptosis modeled dependent on key signaling nodes,
including the level of phosphorylated ERK andAKT.We integrated two sources
of publicly available data: 1) published studies correlating phosphoproteinmea-
surements and resistance pathways to targeted inhibitors in clinical develop-
ment; and 2) mutation data correlated with drug-specifıc response metrics (e.g.
IC50 values), such as CCLE and NCI-60.We systematically screened frequently
observed overlapping disrupted signaling pathways (i.e., combinations of mu-
tations) by simulating predicted IC50 values for targeted inhibitors. Based on
these simulations, we then simulated the effect of pairs of drugs to explore which
drug combinationsmay be best suited for inhibiting tumor growthwhen tumors
harbor multiple mutations. We present two applications of this computational
approach: a comparison of CDK4/6 inhibition in CDKN2A-mutated PDA vs.
hormone receptor-positive breast cancer and a comparison of PARP inhibition
in BRCA1/2-mutated PDA and ovarian cancer. The predictions generated by
our simulations were consistent with clinical observations in that fewer combi-
nations ofmutations in PDAwere sensitive to these inhibitors than in breast and
ovarian cancer, suggesting ways to refıne biomarkers for sensitivity to these
drugs in PDA. The computational approach presented here takes into account
multiple datasets from a knowledgebase to provide a prioritized list of treat-
ments thatmatch a patient’s molecular profıle while also providing the rationale
for the recommendation. This represents a step toward incorporation of systems
biology in precision oncology.
#5554 Metabolic reprogramming in non-small cell lung cancer: a preci-
sion oncology approach. Iman Tavassoly, Ravi Iyengar. Icahn School of Medi-
cine at Mount Sinai, New York, NY.
Lung cancers are among the most common invasive cancers worldwide and
annually lead to high mortality and morbidity. Genomic alterations have been
known to control the evolution of hallmarks of cancer in a dynamic way. These
molecular alterations combined with epigenomic and post-genomic modifıca-
tions contribute to formation of these neoplasms. Multiplicity of these changes
has made development of personalized therapeutic regimens for these cancers a
complex problem.Metabolic reprogramming is one of the main mechanisms in
progression of cancers. There have been efforts to model the metabolic repro-
gramming in cancer usingmetabolic networks of cancer cells, but there has been
no computational framework tomodel these metabolic transitions in cancer for
precision and personalizedmedicine.We have combined computational, math-
ematical and experimental methodologies to develop a platform for precision
oncology in non-small cell lung cancer (NSCLC) by in silicomodels ofmetabolic
switches. Our integrative analysis of genomic data from NSCLC has led to dis-
covery of genomic signatures controlling metabolic reprogramming in NSCLC
with KRAS mutations. This discovery was proved in vivo and in vitro using
drugs blocking different metabolic pathways. We have shown that NSCLC cells
and tumorswhich carry KRASmutations and have these genomic signatures are
addicted to the pentose phosphate pathway (PPP).We have verifıed and proved
the predictive value of these genomic signatures using Patient Derived Xeno-
graft (PDX) tumor models of NSCLC. We are developing a mathematical and
computational framework to model these metabolic switches. Our platform is
capable of using genomic data from a cell line or tumor to determine the meta-
bolic dependency of them quantitatively and predict the optimized personalized
treatments for modulating metabolic pathways aiming to control cancer pro-
gression.
#5555 Integrative network variomics reveals complex genotype to pheno-
type relationships in cancer. Nidhi Sahni, Song Yi. UT MD Anderson Cancer
Ctr., Houston, TX.
Proteins interact with othermacromolecules in complex cellular networks for
signal transduction and biological functions. Recently a deluge of genomic in-
formation becomes available from patients stricken by a variety of cancer types.
In cancer, genetic aberrations have been traditionally thought to abolish the
entire gene function. It has been increasing appreciated that each genomic mu-
tation of a gene could have a subtle but unique effect on protein function or
network rewiring, contributing to diverse phenotypic consequences across can-
cer patient populations. In this study, we designed an integrative multi-omics
platform using systems biology approaches to functionally assess the effects of
cancer genetic variants. We compared a broad spectrum of mutation classes for
a wide range of mechanistic effects on gene function in the context of signaling
networks. Our results reveal a functional landscape of context-specifıc signaling
network perturbations underlying cancer genetic heterogeneity at the base-pair
resolution. Such information is critical for understanding the complex pleiotro-
pic effect of cancer genes, and provides a possible link between genotype and
phenotype in cancer. Furthermore, this study suggests new perspectives in tar-
geted therapy and precision medicine.
#5556 Widespread protein interactome network rewiring in human can-
cer. Song Yi, Nidhi Sahni. UTMD Anderson Cancer Ctr., Houston, TX.
In the past decade, genome and exome sequencing projects have identifıed
thousands of genetic variants in patients across a large number of cancer types.
However, the explosion of genomic information has left many fundamental
questions regarding genotype-phenotype relationships unresolved. One critical
challenge is to distinguish causal disease mutations from non-pathogenic poly-
morphisms. Even when causal mutations are identifıed, the functional conse-
quence of suchmutations is often elusive. Classical “one gene, one function, one
disease” models can not reconcile with the complexity that different mutations
of the same gene often lead to different phenotypes. The extent towhich network
perturbations are involved in disease malfunction and how distinct interaction
perturbation patterns can distinguish cancer mutations are largely unknown.
Here we report a systematic approach to investigate genetic variant-specifıc
effects on molecular interactions at large scale across diverse human cancers.
Remarkably, in comparison to non-disease polymorphisms, disease mutations
are more likely to associate with interaction perturbations. A large fraction of
missense disease mutations are found to cause protein interaction alterations.
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While some result in loss of all their interactions, many exhibit selective elimi-
nation of specifıc interactions (“edgetic”). Different mutations of the same gene
give rise to different interaction profıles, accounting for distinct disease out-
comes. Edgetic mutations perturb interactions through disrupting specifıc in-
teraction interfaces, and the perturbed partners are more likely expressed in
relevant disease tissue. Together, our approach is insightful in prioritizing dis-
ease-causing variants, and uncovering patient mutation-specifıc disease mech-
anisms at a base-pair resolution, a critical step towards personalized precision
medicine. Furthermore, our results suggest distinct interaction perturbations as
a widespread mechanism underlying genetic heterogeneity, providing a funda-
mental link between genotype and phenotype in cancer.
#5558 Deconstruction of a human tumor microenvironment. Frances R.
Balkwill,1 Oliver M. Pearce,1 Robin Delaine-Smith,1 Eleni Maniati,1 Sam Nich-
ols,1 JunWang,1 Conrad Bessant,2 Martin Knight2. 1Barts Cancer Inst., London,
United Kingdom; 2QueenMary University of London, London, United Kingdom.
The purpose of this study was to understand the relationships between the
molecularmechanisms of disease progression and higher-order features such as
tissue stiffness, extent of disease and cellularity in the tumormicroenvironment,
TME. Using samples of human high-grade serous ovarian cancer metastases,
ranging from normal to heavily diseased, we identifıed molecular components
of the TME using transcriptomic and proteomic analysis. We integrated these
data against higher-order features of the tissue, namely the biomechanics, cel-
lularity, and disease score. We then used bioinformatics andmultivariate statis-
tics to identifying components of the TME that best model the higher-order
features. For the fırst time, we revealed the complexity of extracellular matrix
remodeling during metastases development, defıning patterns of extracellular-
matrix associated genes and proteins that predicted both extent of disease and
tissue modulus. This allowed us to identify a core group of twenty-two matrix-
associated molecules that modeled the dynamic process of tissue remodeling
during tumor progression. We used these data to generate a ’matrix index’, a
quantitative measure of the gene expression of the twenty-two molecules. In
cancer transcriptomic databases, this matrix index had prognostic signifıcance
in thirteen solid cancers including high-grade serous ovarian cancer, even after
multivariate analysis. We conclude that there may be a common host matrix
response to human solid cancers.
#5559 Using cancer dependency data to discover tumor suppressive and
oncogenic functional modules. Joshua Pan,1 Robin M. Meyers,2 Brittany C.
Michel,1 Ann E. Sizemore,2 Francisca Vazquez,2 Barbara A. Weir,2 William C.
Hahn,1 Aviad Tsherniak,2 Cigall Kadoch1. 1Dana-Farber Cancer Institute, Bos-
ton, MA; 2Broad Institute, Boston, MA.
Efforts to defıne protein complexes and their functional networks are critical
for systems-level understanding of the pathways involved in human cancer.
Current methods to catalog human protein complexes via physical interaction
are often unable to resolve functional differences between complex members or
infer relationships governed by sub-stoichiometric interactions. While func-
tional wiring maps in yeast have been generated by measuring epistatic interac-
tions between pairs of genes, efforts to scale this concept in individual human
cell lines have been met with challenges and have only been able to characterize
limited numbers of genes at a time.We have developed a scalable approach that
can measure functional similarity without the constraints of pairwise genetic
interaction experiments. Using data from genome-wide RNAi and CRISPR
dropout screens performed in hundreds of cancer cell lines, we leveraged the
heterogeneity of gene dependencies across cancer types to measure functional
similarity between thousands of genes at once, which in turn allowed us to
recreate known inter- and intra-complex functional relationships and to un-
cover tumor suppressive and oncogenic functional modules in cancer-relevant
pathways such as proteolysis, metabolism and transcription. Applying these
approaches to the mammalian SWI/SNF (BAF) chromatin remodeling com-
plex, which is mutated in over 20% of human cancer, revealed three functional
modules that arose separately during metazoan evolution, one of which is en-
tirely novel and uncharacterized. We then performed biochemical experiments
that fully support three specialized complex confıgurations, each with distinct
size, subunit composition, and function. These data reorganize the BAF com-
plex into previously unrecognized modules that better explain mutational bur-
den in human cancer. Notably, we observe that that all known BAF-driven,
highly penetrant rare cancers and neurodevelopmental disorders involve dis-
ruption within a single functional module we defıned, underscoring the value of
evaluating disease genomics through the lens of functional modularity.
#5560 Systemic map of protein phosphatase 2A (PP2A)-regulated phos-
photargets and drug responses in cancer cells. Otto Kauko,1 Susumu Imani-
shi,2 Evgeny Kulesskiy,3 Teemu D. Laajala,1 Laxmana Yetukuri,1 Artur Padzik,1
Mikael Jumppanen,1 Pekka Haapaniemi,1 Bhagwan Yadaw,3 Veronika Suni,1
Taru Varila,1 Garry Corthals,1 Wennerberg Krister,3 Tero Aittokallio,1 Jukka
Westermarck1. 1University of Turku, Turku, Finland; 2MeijoUniversity, Nagoya,
Japan; 3University of Helsinki, Helsinki, Finland.
Despite the pivotal role of phosphatases in cancer cell signalling, systemic
understanding of phosphatase targets is still at infancy. Protein phosphatase 2A
(PP2A) is a human tumor suppressor complex. PP2A inhibition is a require-
ment for human cell transformation and PP2A regulates many cancer critical
signalling pathways. Importantly, emerging data indicates that reactivation of
PP2A tumor suppressor activity could provide entirely novel approach for can-
cer therapy. Here, we present fırst systemic analysis of phosphoprotein targets
(dephosphorylome) regulated by PP2A in cancer cells. Based on data, PP2A
regulates cancer critical signalling pathways, including entire EGFR-RAS-RAF-
MEK-ERK cascade, and functions as a master regulator of MYC function. At
network level, PP2A targets critical cellular processes such as chromosome or-
ganization, RNA splicing, and nuclear envelope assembly. Surprisingly, soft
clustering of PP2A dephosphorylome revealed that most phospho-target resi-
dues are subject to only unidirectional regulation in cancer cells. Moreover,
targets show intracellular gradient where phosphatase inhibition dominates nu-
clear phosphorylation balance. Since phosphoregulation is critical for cancer
drug responses, dephosphorylome was correlated with cancer cell responses to
over 300 drugs. Importantly, cancer therapies could be broadly classifıed based
on their dephosphorylome, both at quantitative and qualitativemanner. Finally,
we demonstrate the utility of this large dataset by validating the role of PP2A in
MEK inhibitor resistance in KRAS mutant cancer cells via regulation of RAF,
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mTor and MYC. The study presents fırst systemic resource to understand po-
tential of PP2A manipulation in cancer cell signalling and drug responses. The
study also uncovers generally important insights to phosphoregulation.
#5561 Single-cell analysis reveals an adaptive, transiently heritable, slow-
ly-dividing, drug-resistant state inhibitable by drug combinations.Moham-
mad Fallahi-Sichani,1 Verena Becker,1 Benjamin Izar,2 Gregory J. Baker,1 Jia-
Ren Lin,1 Sarah A. Boswell,1 Levi A. Garraway,2 Peter K. Sorger1. 1Harvard
Medical School, Boston, MA; 2Dana Farber Cancer Institute, Boston, MA.
Adaptation and fractional response of tumor cells to targeted inhibitors of
oncogenic pathways creates a population of viable tumor cells from which fully
resistant clones can ultimately arise. Thus, understanding transient drug adap-
tation is key for both improving the effectiveness of treatment and delaying/
controlling acquired resistance. Despite the wealth of information available
about feedback mechanisms associated with adaptive resistance, most of our
knowledge in this area comes from studying drug response in bulk tumor cell
populations. Furthermore, the phenotypic consequences of drug adaptation
have been often studied at a few fıxed time-points, when drug-adapted cells
exhibit a high population-average activity in multiple pro-growth signaling cas-
cades. It therefore remains unclear how the initial responses to drug relate to
subsequent phenotypes such as cell death or adaptation. This is likely a key point
for designing novel approaches to overcome fractional drug response in tumor
cells and to achieve durable therapy. We use real-time live-cell imaging, single-
cell analysis and molecular profıling to show that exposure of BRAFV600E mela-
noma cells to RAF/MEK inhibitors elicits a time-variable and heterogeneous
response in which some cells die, some arrest and the remainder adapt to drug.
Drug-adapted cells up-regulate markers of the neural crest (e.g. NGFR), a me-
lanocyte precursor, and grow slowly. The drug-induced slowly-cycling NF-
GRHigh state is only transiently stable, reverting to the drug-naïve state within
two weeks of drug withdrawal as measured by the restoration of RAF/MEK
inhibitor sensitivity, accelerated rate of cell division and reduced expression of
NGFR. Transcriptional and biochemical profıling of cell lines and human tu-
mors implicates a role for the c-Jun/ECM/FAK/Src cascade in driving the de-
differentiated resistance program.We identifymultiple drugs targeting this cas-
cade as well as BET bromodomain inhibitors that block this resistance program
in cell lines and in a BRAFV600E melanoma xenograft model and increase sensi-
tivity and maximal effect (Emax) of RAF/MEK inhibitors. Our study reveals
directly how drug adaptation happens in individual tumor cells leading to emer-
gence of heterogeneous cell sub-populations with reduced drug-sensitivity that
may be targeted by drug combinations.
#5562 Integrating evolutionary dynamics into treatment of metastatic
castrate-resistant prostate cancer: a pilot multidisciplinary study. Jingsong
Zhang,1 Jessica J. Cunningham,1 Joel S. Brown,2 Robert A. Gatenby1. 1H Lee
Moffıtt Cancer Center, Tampa, FL; 2University of Illinois at Chicago, Chicago, IL.
Background: Prior studies have investigated “intermittent therapy” to delay
hormone resistance in prostate cancer but did not explicitly include quantitative
analysis of the evolutionary dynamics.We hypothesize that evolution-informed
strategiesmay prolong time to progression but require amultidisciplinary effort
to simulate intratumoral Darwinian dynamics and design a clinically feasible
treatment protocol.Methods:We investigate intratumoral evolutionary dynam-
ics during treatment of metastatic castrate resistant prostate cancer (mCRPC)
with abiraterone, which blocks CYP17A1 autosynthesis of testosterone from
endocrine precursors. We build a mathematical model assuming three compet-
ing phenotypes: (i) TP cells express CYP17A1 and produce testosterone; (ii) T
cells require exogenous androgen; and (iii) T- cells are androgen-independent
and resistant to abiraterone. Model predictions were tested in a pilot clinical
trial. Results: Mathematical Model: Computer simulations demonstrate contin-
uous maximum dose abiraterone treatment produces competitive release of re-
sistant T- cells. However, limited treatment designed to maintain residual TP
and T populations and suppress proliferation of T- cells was predicted to
prolong responsewhile lowering the required drug dose. Clinical Trial: In a pilot
clinical trial, 11 men with asymptomatic mCRPC were treated with abirateone
according to an evolution-informed, patient-specifıc algorithm based on the
modeling results. Pre-treatment biopsies (available for 3 patients) demonstrated
the predicted tumor subpopulations. Cycles of response and regrowth similar to
model simulationswere observedwith cycle lengths varying from3months to
1 year. Over amedian followup period of 18months, 10 subjects remain respon-
sive to Abiraterone without PSA or radiographic progression. Median time to
PSA progression signifıcantly (P0.001) exceeds the 11.1 months historical
control. As predicted by the simulations, tumor control required signifıcantly
less abiraterone with average cumulative dose less than 40% of standard of care
(P0.001). Conclusion: Integration of mathematical models and Darwinian
fırst principles into trial design, may allow patient-specifıc modifıcations to pro-
long response while lowering drug doses in mCRPC.
#5563 3D Biology™ view of cancer: Simultaneous detection of somatic
DNA mutations and expression profıling of genes and signaling proteins
from melanoma tumor FFPE samples. Jinho Lee,1 Christopher P. Vellano,1
Gavin Meredith,2 Jill Mckay-Fleisch,2 P. Martin Ross,2 Michael Tetzlaff,1 Alex-
andre Reuben,1 Courtney Hudgens,1 Jennifer Wargo,1 Jessica Garber,2 Andrew
White,2 Joseph Pan,2 Mike Krouse,2 Mekala Pansalawatta,2 Lucas Dennis,2 An-
isha Kharkia,2 Erin Piazza,2 Afshin Mashadi-Hossein,2 Rich Boykin,2 Nathan
Elliott,2 Brian Filanoski,2 Gokhan Demirkan,2 SarahWarren,2 Gary Geiss,2 Dae
Kim,2 Joseph Beechem,2 Gordon B. Mills1. 1UT MD Anderson Cancer Center,
Houston, TX; 2Nanostring technologies, Inc, Seattle, WA.
Prognosis is favorable in patients with primary localized melanoma but poor
in patients with metastatic disease. With more than 76,000 cases expected to be
diagnosed in 2016, more precise prognostic technologies and new therapies are
needed. Although targeted treatment regimens have been approved in recent
years, resistance has emerged in large part due to adaptive responsemechanisms
and intratumoral heterogeneity. Analysis of tumor samples across multiple mo-
lecular platforms will help elucidate the complexities within and across tumors
whichmay underlie response to therapy as well as assist in identifying predictive
biomarkers; however, these approaches require signifıcant amounts of sample,
time, and resources. In order to integrate the strengths of analyzing different
molecular analytes, we have modularized Nanostring Technologies’ molecular
barcoding technology to permit simultaneous digital measurement of cancer-
associated DNA mutation variants, mRNA expression, and protein expression
in one assay from the same sample (3D Biology). Novel nucleotide variant
probes enable sensitive and specifıc identifıcation of DNA mutant allele se-
quences down to a level of detection of  5% from 5 ng of FFPE-extracted
genomic DNA. Gene expression is measured via unique digital barcoding tech-
nology to measure mRNA transcripts, and protein expression and activity (via
phosphorylation) is measured by DNA-labeled antibodies. The multi-omic
workflow requires only two 5-10 micron sections of FFPE tissue, whereby DNA
and RNA are extracted from one section and multiplex digital protein profıling
is conducted on the second. As proof of concept demonstrating the utility of this
3D Biology platform, we have simultaneously analyzed DNA variants, RNA
expression, and protein expression using NanoString’s nCounter Vantage 3D™
Solid Tumor Panel on 12 FFPEmelanoma tumor samples and one normal tissue
from six patients. This sample set included two metastatic tumors from each
patient, and in one instance multiple regions from each metastatic site (7 and 2
regions) in order to assess intratumoral heterogeneity. Importantly, this sample
set has associated mRNA expression measured using the nCounter® PanCancer
Pathways for Human panel as well as whole exome sequencing (WES) data.
Somatic variants seen in this latter dataset were compared with the results from
the DNA SNV Solid Tumor Panel. Samples with variants that were detected in
the nCounter assay but not WES were subjected to deep sequencing for valida-
tion. Overall, we show that this multiplex and multi-omic platform has the
potential for rapid and sensitive assessment of patient samples that will impact
clinical care.
#5564 The interplay between etiology-dependent genomic and epigenetic
signatures: The paradigm of liver cancer. Izhak Haviv,1 Shira Perez,1 Anat
Lavi-Itzkovitz,1 Antony Kaspi,2 Ana Tover,3 Assam El-Osta,2 Gur Yaari,1 Salo-
mon Stemmer,3 Meital Gal-Tanamy1. 1Bar Ilan Univ., Zfat, Israel; 2Baker IDI
Heart & Diabetes Institute, Melbourne, Australia; 3Clalit, Petach Tiqwa, Israel.
The evolutionary theory assumes that occurrence of mutations in cancer is
random. However, recent studies suggest that passenger mutations are not ran-
domly scattered in cancer genomes and that chromatin organization dictate
mutations profıles. Hepatocellular carcinoma (HCC) serves as a model of di-
verse spectrum of cancers, since it is induced by a number of well-known etio-
logical agents, mainly Hepatitis C virus (HCV) and Hepatitis B virus (HBV).
This provides a unique opportunity to test whether different etiological agents
dictate distinct mutational landscapes across the genome through a unique epi-
genetic signature. The HCC-specifıc genomic mutations were studied in 80
HCC biopsies from three etiology groups - HBV, HCV, or other. To explore the
mutational signature we performed target high-resolution sequencing that en-
ables the detection of low-frequency passengermutations. By using this strategy
we identifıed novel distinct etiology-dependent regional mutations signature in
specifıc genes and pathways in HCC that was not detected previously by exome
sequencing of liver tumors. These observations suggest that viral infectionmod-
ulate somatic mutations causing HCC. To explore the link between genomic
signature and genome wide chromatin organization we studied the epigenetic
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changes occur following HCV infection. Epigenetic analysis unraveled known
and novel pathways that are controlled by the virus such as Hepatic lipidmetab-
olism, cell motility, cell cycle and immunity. Invers correlation between high
mutation rate and enrichment of chromatin modifıcations associated with ac-
tive transcription provides a link between etiology and cancer genome. Our
novel approach offers a perspective into the mechanisms that shape mutational
signature development in cancer.
#5565 Multi-omic profıling of prostate cancer evolution in 39 patients.
Qing Zhong,1 Tiannan Guo,2 Nora Toussaint,2 Ulrich Wagner,1 Konstantina
Charmpi,3 Laurence Calzone,4 Andreas Beyer,3 Ruedi Aebersold,2 Peter J.
Wild1. 1University Hospital Zurich, Zurich, Switzerland; 2ETH Zurich, Zurich,
Switzerland; 3University of Cologne, Cologne, Germany; 4Institut Curie, Paris,
France.
The pathological molecular events occurring during prostate cancer (PCa)
progression have not been comprehensively investigated. It remains elusive how
genomic aberration is transcribed into transcriptomic abnormalities that even-
tually influence proteins in the progression of PCa. We aimed to study the
biological information flow along the central dogma and to identify critical
molecularmechanisms in PCa evolution.We performed comprehensive, multi-
omics analyses of 105 prostate samples, consisting of both benign prostatic hy-
perplasia regions and malignant tumors from 39 PCa patients. Patients were
from different risk groups, including 12 low-grade (Gleason score  7), 17
intermediate (Gleason score7), and 10 high-grade (Gleason score 7) PCas.
The omics data comprised exome sequencing, copy number variation (CNV)
analysis, RNAseq, quantitative proteomics, and tissue morphology. Further-
more, peripheral blood samples from each patient were genomically profıled as
reference.We detected 806 somatic genemutations from the 105 tissue samples,
out of which 18 genes were mutated in three samples and 129 genes were mu-
tated in two samples. More mutations were detected in patients with higher
Gleason scores.We also found the copy numbers of 914 genes to be substantially
up- or down-regulated in at least one sample. For RNAseq, we determined genes
with either strictlymonotonically increasing or decreasing expression fromnor-
mal to intermediate andhigh-gradePCaper patient andper patient group, based
on the regularized log-transformed read counts. Moreover, we collected tissue
punches and analyzed each punch in technical duplicates by PCT-SWATH and
usedOpenSWATH software for data interpretation.We obtained precise quan-
tifıcation for several thousand proteins. The differential analysis revealed in-
creasing and decreasing patterns of proteins of interest. Furthermore, we used
network smoothing to determine overlapping molecular aberrations by com-
paring shortlisted DNA-mRNA-protein pathways. By integrating proteog-
enomics with additional omic information, we demonstrated that molecular
changes in PCa at genomic level are buffered at transcriptional level, and further
condensed to a few modular changes in protein networks. We also found high
correlation between pathway activities with tumor progression and heterogene-
ity. Ourmulti-omic profıling further revealed PCa evolution by usingmolecular
alterations at different layers with associated mutant allele frequencies and un-
covered several protein modules as key events in the progression of prostate
cancer.
#5566 African American esophageal squamous cell carcinoma expression
profıle reveals dysregulation of stress response and detox networks.Hayriye
Verda Erkizan,1 Jack Lichy,2 Vincente Notario,3 Robert Wadleigh2. 1Institution
for Clinical Research, Veterans AffairMedical Center DC,Washington, DC; 2Vet-
erans Affair Medical Center DC, Washington, DC; 3Lombardi Comprehensive
Cancer Center, Georgetown University, Washington, DC.
Background: Esophageal carcinoma is the third most common gastrointesti-
nal malignancy worldwide and is largely unresponsive to therapy. African-
Americans have an increased risk for esophageal squamous cell carcinoma
(ESCC), this subtype that shows a marked variation in geographic incidence. So
far, the molecular architecture of African-American ESCC is still poorly under-
stood. It is unclear why African-American ESCC is more aggressive and the
survival rate of these patients worse than those of other ethnic groups. Our aim
is to investigate the central question of whether there is a genetic basis for the
aggressive nature of ESCC among African-Americans through analysis of ge-
netic overlaps and differences between African-American ESCC and reported
Asian data. Methods: We conducted microarray expression profıling in pairs of
esophageal squamous cell tumors and matched controls to defıne genetic alter-
ations that occur in African American ESCC. We then utilized Ingenuity Path-
way Analysis (IPA) to analyze the differentially expressed genes in African-
American ESCC. We conducted a meta-analysis of differentially expressed
genes of African American ESCC and those of Asian ESCC through IPA. Re-
sults: Transcriptome profıling of African- American ESCC tumors versus adja-
cent normal esophageal tissues revealed signifıcant differential expression of 756
genes. Among the most strongly up-regulated genes were keratin 17, immuno-
globulin genes and ornithine decarboxylase 1. Genes that showed a great loss of
expression included cysteine-rich secretory protein 3 and sciellin. We per-
formed pathway and network analysis on signifıcantly dysregulated genes using
IPA to determine the overall biological impact of the widespread transcriptional
aberration in African-American ESCC. We found signifıcant dysregulation of
genes encoding drug-metabolizing enzymes and stress response components of
the NRF2- mediated oxidative damage pathway, potentially representing key
genes in carcinogenesis in ESCC in African Americans. Loss of activity of drug
metabolizing enzymes would confer increased sensitivity of esophageal cells to
xenobiotics, such as alcohol and tobacco smoke, and may account for the high
incidence and aggressiveness of ESCC in this ethnic group. A meta-analysis of
ESCC expression profıles in our African American sample and those of several
Asian samples determined genes in the NRF2 pathway are uniquely and signif-
icantly altered in African-American ESCC. Down-regulation of TP53 pathway
components represented themost common feature in ESCCof all ethnic groups.
Importantly, this analysis revealed a potential distinctive molecular property of
African-American ESCC a widespread and prominent involvement of NRF2
pathway. Conclusion: Taken together, these fındings highlight the remarkable
interplay of genetic and environmental factors in the pathogenesis of African-
American ESCC.
#5567 A scalable and integrated computational and experimental work-
flow to identify new driver genes in cancer genome data. Heiko Horn,1 Mi-
chael S. Lawrence,2 Candace R. Chouinard,2 Yashaswi Shrestha,2 Jessica Xin
Hu,3 ElizabethWorstell,2 Emily Shea,2 Nina Ilic,4 Eejung Kim,4 Atanas Kambu-
rov,2 Alireza Kashani,5 William C. Hahn,4 Joshua D. Campbell,2 Jesse S.
Boehm,2 Gad Getz,5 Kasper Lage5. 1National Cancer Institute, Bethesda, MD;
2Broad Institute of Harvard and MIT, Cambridge, MA; 3University of Copenha-
gen, Copenhagen, Denmark; 4Dana-Farber Cancer Institute, Boston, MA; 5Mas-
sachusetts General Hospital, Boston, MA.
High throughput sequencing has revolutionized the study of the cancer ge-
nome, enabling numerous discoveries in basic and clinical research. However,
considerable sample sizes are required to fınd cancer driver genes with interme-
diate and low mutation frequencies, and for a large proportion of patients the
molecular cause (e.g. driver gene(s)) of disease is unknown.Here, we describe an
integrated computational and experimental workflow that combines cancer ge-
nome data, molecular network information, multiplexed in vivo tumorigenesis
assays, and reanalysis of driver-gene-negative cancer patients to predict and
validate new driver genes.We develop a statistic, networkmutation burden, that
combinesmolecular network informationwith data from 4,742 cancer genomes
to accurately classify known driver genes across 21 tumor types and predict 62
driver gene candidates.Of these, 35 gene candidates were tested in multiplexed
in vivo tumorigenesis cell assays using sensitized immortalized human embry-
onic kidney (HA1E-M) and immortalized human lung epithelial (SALE-Y) cell
lines.Tumor formation in vivo was observed for 11 genes (2 in HA1E-M, 3 in
SALE-Y, 6 in both). By reanalyzing 242 lung adenocarcinoma patients with an
unknown molecular cause of disease we show that two of these candidates,
TFDP2 and AKT2, are signifıcantly amplifıed in multiple samples.Overall, we
describe a scalable combined computational and experimental framework to
predict and validate driver genes across many tumor types. Our proof-of-con-
cept approach should become increasingly useful as the number of cancer ge-
nomes continues to grow.
#5568 Towards decoding the interplay between glycolysis and oxidative
phosphorylation in cancer. Dongya Jia,1 Linglin Yu,1 Mingyang Lu,1 Eshel
Ben-Jacob,1 Jianpeng Ma,1 Herbert Levine,1 Benny A. Kaipparettu,2 Jose
Onuchic1. 1Rice University, Houston, TX; 2Baylor College of Medicine, Houston,
TX.
Abnormalmetabolism is a hallmark of cancer, yet its regulatorymechanism is
poorly understood. Cancer cells were considered to mostly utilize glycolysis,
referred to as theWarburg effect. However recent evidence suggests that oxida-
tive phosphorylation also plays a crucial role during cancer progression.Herewe
utilized a systems biology approach to decipher the regulatory principle of gly-
colysis and oxidative phosphorylation. Integrating information from literature,
we constructed a regulatory network of genes and metabolites, from which we
extracted a core circuit containing HIF-1, AMPK and ROS. Our circuit analysis
showed that while normal cells have an oxidative state and a glycolytic state,
cancer cells can access an additional hybrid state with both metabolic modes
coexisting, due to higher ROS production and/or oncogenic activation, such as
RAS, MYC and c-SRC. The anti-correlation between AMPK and HIF-1 and the
association of metabolic states with oncogenes were further confırmed using
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TCGA patient transcriptomics data of multiple cancer types and single-cell
RNA-seq data of lung adenocarcinoma. We propose that the hybrid phenotype
contributes to metabolic plasticity, allowing cancer cells to adapt to various
microenvironments. Using model simulations, we predicted the effıcacies of
several metabolic cancer therapies based on their effectiveness in reducing met-
abolic plasticity. Our theoretical framework of metabolism can serve as a plat-
form to decode cancermetabolic plasticity and design cancer therapies targeting
metabolism.
#5568A A network based analysis for the treatment of triple negative
breast cancer. Brett A. Fleisher, Sihem Ait-Oudhia. Univ. of Florida, Orlando,
FL.
Background: Triple-negative breast cancer (TNBC) is a complex hetero-
geneous disease characterized by the absence of three hallmark receptors:
human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER),
and progesterone receptor (PR). Compared to other breast cancer subtypes,
TNBC is more aggressive, has a higher prevalence in African Americans, and
more frequently affects younger patients. Currently, TNBC lacks clinically-
accepted targets for tailored therapy, warranting the need for candidate bio-
markers. Methods: BiomarkerBase, a biomarker knowledgebase developed
by Amplion uses a comprehensive list of synonyms to identify biomarkers
registered in the records of clinical trials via the government website clini-
caltrials.gov. Under each of the registered breast cancer biomarkers (with the
exceptions of HER2, ER, and PR), sub-searches were conducted for clinical
trials that explicitly used TNBC (or the full name, triple negative breast
cancer) in the title of the biomarkers’ studies. Of note, most trials in this
review were completed phase II or III. The selected candidate biomarkers
were classifıed into four FDA biomarker categories (surrogate, prognostic,
predictive, or pharmacodynamic (PD)) as well as by location (blood/plasma,
cell surface, cytoplasm, or nucleus). Current literature about the biomarkers
was further examined using PubMed. There, we sought to fınd papers that
studied how the biomarkers may interact. These markers were further orga-
nized into a “cellular protein network” that demonstrates potential connec-
tivity. Results: Blood biomarkers include VEGF/VEGFR and IL-8; cell sur-
face biomarkers include EGFR, IGFBP, c-Kit, c-Met, and PD-L1; cytoplasm
biomarkers include PIK3CA/AKT/mTOR-related metabolites (GPC, PCh,
Lactate/ glucose), pPKM2, F1,6BP, SPHK1, STAT1/IRF2BP2, S6, p4E-BP1,
SUV39H1, PTEN, and ALDH1; and nucleus biomarkers include BRCA1, the
glucocorticoid receptor (GR), TP53, and Ki67. Conclusion: To date, there
are no clinically-validated biomarkers for TNBC, which has hindered the
development of tailored therapy for both chemosensitive and refractory
TNBC. Before validation and use of these biomarkers occurs, stringent-
clinical criteria must be met fırst. The list and cellular protein network pro-
vided is an inventory and reference point for promising biomarkers for
breakthrough, targeted therapies in TNBC.
IMMUNOLOGY: Enzymes and Hormones and Metabolism in
Tumor Immunity
#5569 The impact of ADI-PEG20 on PDL1 expression in ASS1 defıcient
uveal melanoma. Ramsay S. Khadeir,1 Melissa M. Phillips,1 Mandeep Sagoo,2
Victoria Cohen,2 Caroline Thuang,2 Peter W. Szlosarek1. 1Barts Cancer Insti-
tute, London, United Kingdom; 2Moorfıelds Eye Hospital, London, United King-
dom.
Uveal melanoma (UM), involving the iris, choroid and ciliary body, is the
commonest intraocular tumor in adults.Half of patients developmetastasis with
a high mortality despite currently available systemic therapies including im-
mune checkpoint blockade. Studies show that while CTLA4 antagonism has a
modest effect in UM, PD1/PDL1 blockade is largely ineffective whereas trials of
combination checkpoint blockade are yet to report. We confırmed previously
that defıciency of argininosuccinate synthetase 1 (ASS1), a key enzyme involved
in arginine synthesis, sensitizesUMcells to arginine deprivation using pegylated
arginine deiminase or ADI-PEG20. Early trials of ADI-PEG20 in UM have
shown safety and effıcacy in the clinic and thus we tested the potential for a
combined immunometabolic strategy. ASS1-defıcient UM cell lines (OMM1,
OMM2.5, MEL270) were analyzed for the immune checkpoint protein PDL1
along with their sensitivity to arginine depletion. We also tested metastatic UM
for ASS1 and PDL1 expression, and the impact of ADI-PEG20 treatment using
samples from a current clinical trial (NCT02029690).We showed that ASS1 and
PDL1 protein expression were absent in the 3 UM cell lines and in a majority of
primary tumors (75/102 for ASS1 and 83/102 for PDL1; 5% threshold of expres-
sion) and all metastatic tumor biopises (n16/16 for both). Transfection of
ASS1 in OMM1, OMM2.5, MEL270 led to an increase in PDL1 expression by
qPCR, western blotting and FACS, which was reversible following knockdown
of ASS1. Induction of PDL1 expression by ASS1 was accompanied by interferon
(IFN)-alpha and beta (but not IFN-gamma) release into the cell supernatant,
and was abrogated using the pan-STAT inhibitor ruxolitinib. Next, PDL1 ex-
pression was signifıcantly increased in the 3 ASS1-negative UM cell lines with
ADI-PEG20 treatment by 24hrs and was associated with Type I IFN signaling
which waned along with PDL1 expression by 48hrs. The ADI-PEG 20 induction
of PDL1 was abolished using ruxolitinib, indicating that the upregulation of
Type I IFNs is critical for regulation of the PDL1 checkpoint protein. While
analysis ofUMbiopsies of patients progressing onADI-PEG20 revealed upregu-
lation of ASS1 (n2/2; and thus resistance to ADI-PEG20) a concomitant in-
crease in PDL1was not observed (n0/2). Collectively, our data show that ASS1
is absent in a majority of patient biopsies of primary andmetastatic UM tumors
and is tightly correlated with PDL1 expression. UM cells lines displayed sensi-
tivity to ADI-PEG20, which upregulated levels of PDL1 expression via Type 1
interferon signaling that may enhance the currently limited effıcacy of check-
point blockade in UM. Further studies are ongoing of the IFN-mediated signal-
ing between ASS1 and PDL1 in UM in response to arginine deprivation with
ADI-PEG20.
#5570 Anovel approach to targeting the IDO/TDOpathway through deg-
radationof the immunosuppressivemetabolite kynurenine.Michelle Zhang,1
Everett Stone,2 Todd A. Triplett,2 Kendra Triplett,2 Candice Lamb,2 Christos S.
Karamitros,2 John Blazek,2 George Georgiou,2 Mark G. Manfredi1. 1Kyn Ther-
apeutics, Cambridge, MA; 2University of Texas Austin, Austin, TX.
Checkpoint inhibitors have become the cornerstone for new innovation in
immune-based oncology therapy. Several orthogonal immune pathways are
currently being investigated to relieve suppression or boost activity of the innate
and adaptive immune system. The IDO immune-metabolism pathway was re-
cently clinically validated in melanoma in combination with checkpoint inhibi-
tion. This opens up a new approach to relieving suppressivemediators and lends
credence to the tumor microenvironment containing small molecule metabo-
lites that induce immune tolerance. Both indoleamine-pyrrole 2,3-dioxygenase
1 (IDO1) and Tryptophan 2,3-dioxygenase (TDO) enzymes metabolize trypto-
phan, formingKynureninewhich binds the aryl hydrocarbon receptor (AHR) in
multiple innate and adaptive immune cell types causing a net immunosuppres-
sive effect. Both enzymes are upregulated across many tumor types, however,
only the IDO1 enzyme has thus far been addressed in the clinic with small
molecule inhibitors. We have postulated that enzyme-mediated depletion of
Kynurenine into safe and immunologically inertmetabolites can alleviate tumor
immunosuppression. We have cloned and characterized several bacterial
Kynureninases (KYNase) which preferentially degrade Kynurenine with a
1,000 higher kcat/KM as opposed to mammalian enzymes that cleave 3-OH
Kynurenine. We show that PEGylated bacterial KYNases can deplete Kynure-
nine produced by IDO1, TDO and IDO1/TDO dual positive human can-
cer cells whereas, the IDO1 inhibitor epacadostat or TDO inhibitor 680C91 only
selectively inhibited Kyn production in IDO1 or TDO cells respectively.
In vivo, a single subcutaneous dose of KYNase in B16F10 tumor-bearing
mice was able to deplete Kynurenine in both the plasma and tumors and
increase effector T-cells in the tumor. KYNase demonstrated signifıcant tu-
mor growth inhibition and survival benefıt either as a single agent or in
combination with checkpoint inhibitors (anti-PD1 or anti-CTLA4) in
B16F10, CT26 and 4T1 models. Interestingly, KYNase combined with anti-
PD1, showed greater effıcacy than epacadostat / anti-PD1 combination in
CT26 tumor bearing mice. A pharmacologically optimized human KYNase
is currently moving toward clinical development for the treatment of cancers
where both IDO/TDO pathways play a signifıcant immunosuppressive role
through kynurenine production.
#5571 Immune-checkpoint inhibition via enzyme-mediated degradation
of kynurenine. Todd A. Triplett,1 Kendra Triplett,1 Everett Stone,1 Michelle
Zhang,2 Mark Manfredi,2 Candice Lamb,1 Yuri Tanno,1 Lauren Ehrlich,1
George Georgiou1. 1University of Texas at Austin, Austin, TX; 2Kyn Therapeu-
tics, Austin, TX.
Tryptophan oxidation and the ensuing production of Kynurenine (Kyn) and
downstream products have been established to play an important role in immu-
nosuppression within the tumor microenvironment (TME). The rate limiting
step in Tryptophan oxidation is catalyzed by the IFN- inducible IDO-1 enzyme
which is upregulated in numerous cancers and also, in some instances via the
ectopic expression of TDO, which is normally expressed primarily in the liver.
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Currently, IDO-1 small molecule inhibitors in combination with checkpoint
inhibitor antibodies are being evaluated in12 clinical trials. However, whether
the immune-suppressive effects of Tryptophan catabolism results from its de-
pletion in the TME, or from the accumulation of Kynurenine, is not known. To
distinguish between the effects of Trp depletion and Kyn accumulation in the
TME we used an engineered Kynureninase (KYNase) enzyme that selectively
degrades Kyn into immunologically inert and non-toxic metabolites. Peritu-
moral injection of PEGylated KYNase completely depletes serum and tumor
Kyn levels for up to 72 hrs, while leaving Trp concentrations in both compart-
ments unaffected. In the IDO-1 expressing CT26 colon carcinoma model KY-
Nase treatment as monotherapy resulted in 16% complete and durable re-
sponses, accompanied by long-term immunity to tumor re-challenge. KYNase
had no effect on tumor growth in IDO-/- mice, nor in RAG-/- or in CD8 T cell
depletedmice. Analysis of the TMEdemonstratedKYNase treatment resulted in
increased accumulation of CD8 cells, with a greater proportion expressing
Granzyme B, undergoing proliferation and permeating the tumor interior. This
effect was specifıc to the TME, as no detectable changes to the immune compart-
ment occurred in other organs examined, nor overt signs of autoimmunity and
toxicity. The increase in CD8 cells was consistent with in vitro data showing
that elevated concentration ofKyndirectly induces apoptosis of activatedCD8
T cells partially through IL-2 suppression. No changes to the Treg percentages
and phenotypes in the TME were observed, indicating that the Treg compart-
ment is not impacted by treatment with KYNase. Cytokine analysis of tumor
digests revealed increased IL-2 concentrations, as well as IFN and IL-9, in
tumors after KYNase treatment. Furthermore, ex vivo stimulation of TIL after
KYNase treatment demonstrated that the increase in cytokines in theTME is not
solely due to an increase in TIL, but also an increased effector cytokine capacity
on a per cell basis. Administration of KYNase together with either 	CTLA4 or
	PD1 synergistically elicited complete and durable regression ofmultiple estab-
lished tumor models. In summary, our data support the hypothesis that Kyn
accumulation in the TME rather than Trp depletion is the dominant IDO-me-
diated immune suppressive mechanism, and that enzyme-mediated Kyn deple-
tion is a promising cancer immunotherapeutic approach.
#5572 AX09: an immunotherapy candidate targeting the breast cancer
stem cell protein xCT. John O’Rourke,1 Elisabett Bolli,2 Valeria Rolih,2 Laura
Conti,2 Stefania Lanzardo,2 Jayne Christen,1 Federica Pericle,1 Federica Cav-
allo2. 1Agilvax, Inc, Albuquerque, NM; 2University of Torino, Torino, Italy.
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer
that lacks the estrogen, progesterone and HER2 receptors, and accounts for
15-20% of all breast cancers in the US. The particularly aggressive features of
TNBCmay be due to the enrichment of breast cancer stem cells (BCSC). Due to
their resistance to traditional radio- and chemo-therapies, BCSC represent a
reservoir for the relapse, metastatic evolution and progression of the disease
after treatment. Therefore, successful eradication of BCSC represents a major
barrier towards effective cancer treatments. The ability of BCSC to resist com-
mon cytotoxic therapies relies on different mechanisms, including improved
detoxifıcation ability. The cystine-glutamate antiporter protein xCT (SLC7A11)
regulates cystine intake, conversion to cysteine and subsequent glutathione syn-
thesis, protecting cells against oxidative and chemical insults via the p38MAPK
pathway. xCT expression is highly restricted to a few normal cell types but is
upregulated in a variety of breast cancer subtypes where its expression correlates
with poor prognosis. xCT is highly expressed in a variety of solid tumor CSC
including BCSC where it interacts with CD44 and plays a functional role in
BCSCbiology.Agilvax has developed anovel immunotherapy candidate (AX09)
based on our virus-like-particle technology for the treatment and prevention of
metastatic breast cancer that targets the BCSC protein xCT. Immunization with
AX09 elicited a strong antibody response against xCT including high levels of
IgG2a antibody. Immune sera from AX09 mice bound to tumorsphere derived
BCSC and impacted BCSC function and biology in vitro. To assess if AX09
immunization would decrease metastases, we employed a syngeneic transplan-
tation model, in which purifıed BCSC derived from TUBO cells were injected
into the tail vein of vaccinated female BALB/c mice. Multiple independent ex-
periments showed that immunization with AX09 conferred a signifıcant reduc-
tion in the number of pulmonary metastases compared to vaccination with
control VLP alone. In a pilot study, BCSC were transplanted into the mammary
fat pad and mice were treated with AX09 after primary tumors were 1.5 mm in
diameter. Results indicate that AX09 immunization conferred a reduction in
lung metastases compared to controls. These data show that an active immuni-
zation approach targeting xCT can signifıcantly reduce metastatic progression
in preclinical models. Ongoing experiments are further characterizing thera-
peutic mechanisms and evaluating effıcacy of AX09 in combination with front
line chemotherapy and checkpoint inhibitors.
#5573 A high-affınity Optide (optimized peptide) inhibitor of the Hippo
pathway’s YAP-TEAD interaction. Zachary R. Crook,1 Philip Bradley,1 Greg-
ory Sevilla,1 Della Friend,1 Chris King,2 AndrewMhyre,1 Roland Strong,1 David
Baker,2 James M. Olson1. 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA.
The HIPPO pathway plays a critical role in contact inhibition, a pathway that
is commonly dysregulated inmany human cancers (including liver, colon, ovar-
ian, and lung). The signaling pathway culminates in the intranuclear interaction
of the transcriptional co-activator YAP and the transcription factor TEAD. This
is representative of a number of cancer driving pathways that have proven nearly
impossible to drug, as they are mediated by intracellular protein-protein inter-
actions. High throughput screening campaigns with small molecule libraries
have failed to provide specifıc, high affınity binders capable of disrupting larger
protein-protein interfaces (such as YAP-TEAD), while at the same time, anti-
bodies cannot penetrate the cell membrane to access cytosolic and nuclear tar-
gets. Optides are small disulfıde-knotted peptides (knottins) that are large
enough to interfere with protein-protein interactions, but small enough to ac-
cess compartments beyond the reach of antibodies. Examples include the cal-
cines, activators of sarcoplasmic reticulum ryanodine receptors, and BLZ-100, a
knottin-fluorophore conjugate that is capable of accumulating in awide range of
tumor types. Using the computational design software Rosetta, we created a
library of Optides designed to interact with TEAD in locations that overlap YAP
binding. Mammalian surface display screening against soluble TEAD yielded a
candidate (Hit1) that binds TEAD with nanomolar affınity and inhibits YAP
binding. Affınity maturation, using site saturation mutagenesis, produced an
improved sub-nanomolar variant (IV1) with potent YAP inhibition. This vari-
ant was also found to be highly resistant to reduction and proteolysis, crucial for
a disulfıde-knotted peptide with a cytosolic target in the proteinase-rich tumor
milieu. With this highly potent YAP inhibitor, efforts are now focused on cell
penetration and biodistribution with the long-term goal of advancing a clinical
development candidate.
#5574 Retinoic acid as a therapeutic adjuvant in low-grade gliomas.
Aparna Rao,1 Xiaoran Zhang,2 Jason Kim,1 Alexander Pomerantz,3 Youngmi
Kim,4 Eric Holland,4 Nduka Amankulor1. 1University of Pittsburgh, Pittsburgh,
PA; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 3Carnegie Mellon
University, Pittsburgh, PA; 4Fred Hutchinson Cancer Center, WA.
Introduction: Malignant gliomas are incurable brain tumors and the most
commonprimary brain tumors in adults.Mutations in isocitrate dehydrogenase
(IDH) are enriched in a subset of malignant low-grade gliomas (MLGGs) that
arise as lower grade neoplasms and steadily progress to more aggressive and
universally fatal glioblastomas (GBMs) usually within 5-10 years after initial
diagnosis. Gliomas with IDH1/2 mutations are characterized by hypermethyl-
ation ofmultiple genes, including immune genes, thereby rendering themhighly
immune evasive. Retinol binding protein 1 (RBP1) gene, that encodes a protein
involved in retinoic acid (RA) generation, is signifıcantly hyper-methylated in
IDHmutant cells. Since RA is instrumental in the induction ofmultiple immune
genes including immune-activating ligands such as NKG2D ligands (NKG2D-
L), we hypothesized that treatment of IDHmutant cells withRAwill increase the
expression ofNKG2D-Lon the tumor cells, leading to increased recognition and
lysis by immune cells. In addition, we hypothesized that RBP1 methylation was
crucial to development of the IDH mutant immune-evasive phenotype. Meth-
ods: Primary glioma cells (IDHWT andmutant) were treated with 1MRA for
48 hours. The cells were assessed for changes in expression of NKG2D-L and
other type-1 immune response genes. Effect of RA treatment on NK killing and
immune cell chemotaxis were evaluated. We also assessed the impact of RBP1
knock-down in IDH WT cells. Finally, we evaluated the effıcacy of RA as a
therapeutic modality for low-grade gliomas in a murine model. Results: RA-
treated IDHmutant gliomas had a higher expression of NKG2D-L and a higher
sensitivity to killing by NK cells, when compared with untreated IDH mutant
cells. RA treatment of IDH mutant cells also induced increased chemotaxis of
NKs and CD8 T cells in a CCL2-dependant manner. In addition, RA demon-
strated superior anti-tumor effıcacy in vivo, compared with controls. Finally, we
demonstrated that RBP1 knock-down in IDH WT cells was suffıcient to repli-
cate the immune evasive phenotype observed in IDHmutant cells. Conclusions:
RA treatment reverses the immune evasion in IDH mutant cells primarily by
inducing the upregulation of NKG2D-L and by mediating increased NK and
CD8 T cell chemotaxis via CCL2 induction. Additionally, we established that
RBP1 gene silencing is crucial for the development of the immune evasive IDH
mutant phenotype.
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#5575 Androgen receptor stimulation with 5
-dihydrotestosterone
(DHT) decreases PD-L1 expression in androgen-responsive thyroid cancer
cells. Timmy J. O’Connell,1 Melanie Jones,2 Anvita Gupta,1 Tali Lando,1 Deya
Jourdy,1 Edward Shin,3 Augustine Moscatello,1 Raj Tiwari,1 Jan Geliebter1.
1New York Medical College, Valhalla, NY; 2United State Military Academy Pre-
paratory School, West Point, NY; 3New York Eye and Ear Infırmary of Mount
Sinai, New York, NY.
Thyroid cancer is the most rapidly increasing cancer in the US with 64,300
new cases expected in 2016. However, there is a disparity in the incidence of
thyroid cancer between females andmales, with women (49,350 expected cases)
developing thyroid cancer three times more often than men (14,950 expected
cases). Immune elimination of nascent tumor cells may explain the difference in
disease incidence between men and women. To address this hypothesis, the
effect of androgen on the expression of immune checkpoint molecules in an
androgen responsive-thyroid cancer cell line was examined. The undifferenti-
ated thyroid cancer cell line, 8505C, does not express a functional androgen
receptor (AR). 84E7 is a clone of 8505C that was transfected with an AR con-
taining plasmid resulting in constitutively expressed AR. Transcriptome analy-
sis via RNASeq was performed on 8505C and 84E7, with and without 5	-dihy-
drotestosterone (DHT) treatment. Raw sequencing reads were aligned to the
UCSC hg19 human reference genome with Tophat, and Cufflinks was used to
measure transcript abundances in Reads Per Kilobase of exonmodel perMillion
mapped reads (RPKM) as well as to fınd genes with statistically signifıcant
changes in expression. DHT treatment of 84E7 resulted in 2 fold expression
changes in 1,552 genes.We examined the immune checkpoint ligands expressed
on 84E7 such as CD80, CD86, PD-L1, PD-L2, ICOSL, B7-H3, B7-H4, HVEM,
4-1BBL, OX40L, CD70, CD40, and GAL9. PD-L1 was the sole immune check-
point molecule that exhibited a signifıcant expression change in DHT-treated
84E7 cells with a 1.8 log2 fold decrease (p0, q0), or 72% reduction inmRNA
content. Additional studies confırmed the RNASeq results and provide evidence
of both qualitative (immunofluorescence) and quantitative (flow cytometry and
western blotting) decreases in PD-L1 expression with DHT treatment. These
results are signifıcant in that PD-L1 is produced by tumor cells as a strategy for
subverting and evading the immune response, specifıcally T cells, allowing for
continued tumor growth and metastases. In the thyroid, the presence of acti-
vated androgen receptors could lead to an environment that is more favorable
for immune system activation and may help eliminate nascent thyroid cancer
cells. Thus, men may experience a decreased incidence of thyroid cancer due to
an enhanced and less inhibited anti-tumor environment.
#5576 BPM 31510, a clinical stage candidate demonstrates potent anti-
tumor effect in an immune-competent syngeneic pancreatic cancer model.
Shiva Kazerounian, Aishwarya Sarma, Nidhi Gaur, Maria D. Nastke, Tulin
Dadali, Anne R. Diers, Stephane Gesta, Vivek K. Vishnudas, Rangaprasad Sa-
rangarajan, Niven R. Narain. BERG, LLC, Framingham, MA.
BPM 31510, a clinical stage nanodispersion of ubidecarenone, demonstrates
anti-tumor effects by eliciting an anti-Warburgmetabolic switch in cancer. Pre-
vious studies in an immune compromised PaCa2 xenograft model has unequiv-
ocally demonstrated signifıcant effıcacy of BPM 31510 on tumor volume and
survival. The fundamental property of BPM 31510 to influence mitochondrial
bioenergetics and the recognized interplay between T cell metabolism andmat-
uration prompted investigation into the effects of BPM 31510 on T lymphocyte
functions in eliciting anti-cancer effects. In this study BPM 31510 selectively
influenced activation and maturation of T cells in murine peripheral blood
mononuclear cells (PBMCs). Moreover, in addition to determining changes in
the CD3 population, changes in surface expression of PD-1 and CTLA4 along
with the IFN- secretion were examined. Murine cancer cell lines exposed to
BPM 31510 were associated with variable sensitivity with highly metabolic tu-
mor types being most sensitive. Next, the anti-cancer activity of BPM 31510 in
an in vivo immunocompetent syngeneic Pan02 rodent model was investigated.
Murine Pan02 pancreatic cancer cells were implanted subcutaneously into
C57BL/6 mice. Tumors with mean volume of 80 mm3 were treated twice a day
with vehicle control or BPM 31510 at 25, 50, 100mg/kg, administered intraperi-
toneal. Tumor volumes were measured every 4 days. At day 21 post treatment,
tumors were harvested and analyzed for the level of infıltrating immune cells by
immunofluorescent staining with CD8 for T cells and F4/80 for tumor mac-
rophages. These results demonstrate a dose-dependent reduction in tumor vol-
ume following 21 days of BPM31510 treatment. In summary, BPM31510 exerts
potent anti-tumor effects through its dual function of modulating tumor cell
metabolism and potentially influencing immune check-point to improve overall
survival outcomes.
#5577 A novel CD73-blocking antibody reduces production of immuno-
suppressive adenosine and restores T cell function. Emily C. Piccione, Glen
Mikesell, Barbara Daine-Matsuoka, Kimberly Walter, Richard Miller, Ian Mc-
Caffery. Corvus Pharmaceuticals, Burlingame, CA.
Adenosine is present at high concentrations in the tumor microenvironment
and is immunosuppressive acting on multiple cell types, including suppression
of effector T cells. CD73, an ectonucleotidase that converts AMP to adenosine, is
expressed on a subset of B and T cells and is a major source of extracellular
adenosine. ElevatedCD73 expression has been observed inmultiple tumor types
and is prognostic in triple negative breast cancer supporting a role for CD73 in
tumor progression1. Inhibiting catalytic activity of CD73 is an attractive thera-
peutic strategy to reduce adenosine-mediated suppression of tumor immunity.
Wedeveloped two types of humanizedmonoclonal anti-CD73 antibodies. CPX-
006 inhibits CD73 catalytic activity by competing directly with AMP for the
active site with an affınity of 0.64 nM. CPX-016 is similar to anti-CD73 antibod-
ies described by others2, and inhibits CD73 activity allosterically by binding to a
distal site. This was demonstrated using CD73 expressing cells incubated with
APCP, a non-hydrolyzable analog of AMP. APCP competes with CPX-006 for
binding to CD73 in contrast to CPX-016. The CPX-016 mechanism requires
higher order complexes and results in loss of inhibition at high CPX-016/CD73
ratios. In contrast, CPX-006 reduces catalytic activity completely in cell based
assays to levels seen when CD73 gene is deleted using CRISPR technology and
inhibition was unaffected at high CPX-006/CD73 ratios. In a functional assay,
CPX-006 inhibited immune suppression of T cell function induced by exposure
of human PBMCs to AMP through direct inhibition of catalytic activity with a
mean EC50 of 137 nM (interferon gamma production) and 189 nM (T cell
proliferation) (n12 donors). We analyzed the prevalence of CD73 expression
across tumor histologies by immunohistochemistry including renal cell carci-
noma (RCC, n62), non small cell lung cancer (NSCLC, n68),melanoma (n
68) and breast cancer (n94). CD73was found to be heterogeneously expressed
on tumor cells, immune cells and other stromal elements within each of the
histologies examined. Expression on tumor cell only was found in 15% of mel-
anoma and 14% of squamous NSCLC cases. In contrast, tumor cell staining was
found in a signifıcant fraction of the adenocarcinoma sub-type ofNSCLC (55%).
Stromal cell staining to varying degrees was seen in all tumor tissues. In sum-
mary, we have a generated a therapeutic antibody, CPX-006, that utilizes a novel
mechanism of binding to the CD73 active site to completely inhibit CD73 enzy-
matic activity and restore T cell function. The fınding of CD73 expression on
tumor cells and stromal cells in a variety of tumors suggest this as a potential new
target for immunotherapy of thesemalignancies. 1. Loi et al., Proc Natl Acad Sci
USA 2013; 110: 11091-11096. 2. Geoghegan et al., mAbs 2016; 8: 454-467.
#5578 Small molecule modulators to understand the role of IDO1 and
TDO2 in cancer. Shivani Rao Garapaty,1 Dhanalakshmi Sivanandhan,1 Guru
PavanKumar Seerapu,1 SurendraNaidu,1 ShaliniChakelam,1 PradeepNagaraj,1
Reshma Das,1 Saravanan Vadivelu,1 Pravin Iyer,2 Chandrika Mulakala,1 Kan-
nan Murugan,1 Somnath Mondal,1 Anjali Gautam,1 Saravanan Kandan,1 Man-
ish Kumar Thakur,1 Sridharan Rajagopal,1 Sriram Rajagopal1. 1Jubilant Biosys
Ltd., Bangalore, India; 2NA, Bangalore, India.
Introduction: Tumor immune escape mechanisms have been established as
suitable targets for cancer therapy. Among these, tryptophan catabolism plays a
central role in creating an immunosuppressive environment, leading to toler-
ance to potentially immunogenic tumor antigens. Tryptophan catabolism is
initiated by either indoleamine 2,3-dioxygenase (IDO1/2) or tryptophan 2,3-
dioxygenase 2 (TDO2), resulting in biostatic tryptophan starvation and
l-kynurenine production. Recent literature has shown that IDO1 and TDO2 are
expressed in multiple tumors, including solid tumors and play key roles in tu-
mor progression other than immune escape. It has also been shown that IDO1
and TDO2 play distinct roles in driving the downstream effectors suggesting
that their roles are perhaps non-redundant. Therefore, we developed series of
novel small molecule modulators against IDO1 and TDO2 to understand their
role in disease biology formultiple indications including cancer, depression and
autoimmune disorders. Methods: Rational design approaches were used to de-
sign novel IDO1 and TDO2 specifıcmodulators; Potency of these inhibitors was
assessed in the in vitro assays using purifıed IDO1 and TDO2 enzymes and in
IDO1 andTDO2over-expressingHEK293T cells bymeasuring the formation of
kynurenine. Results: In the in vitro biochemical assay using purifıed human
TDO2, one of theNCEs from inhibitor series showed an IC50 of 0.09Magainst
TDO2.Against purifıed human IDO1, this compoundwas inactive up to 30M,
thereby showing300-fold selectivity against IDO1. This TDO2 inhibitory ac-
tivity translated well in TDO2-overexpressing HEK293 cells and, these NCEs
inhibited kynurenine formation with an EC50 of2.5 M. A second chemical
series showed comparable dual inhibition of IDO1 and TDO2 activity. One of
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the molecules from this series showed IC50 of 0.2 and 0.08 M in the biochem-
ical assay and 1.7 and 0.8 M in the cell based assay against IDO1 and TDO2,
respectively. In addition, another series of NCEs showed strong activation of
IDO1 and TDO2 activity. As compared to untreated control, formation of
kynurenine was increased in a dose-dependent manner as observed by increase
in fluorescence up to of 3-10 folds. One of the compounds from this series
showed an EC50 of 20- 30 M in the biochemical assay as well as in 293T-
based assay. Furthermechanistic studies to understand the immunemodulatory
activity of these selective TDO2modulators is underway. These tool compounds
are being further optimized for potency and ADME properties to be developed
as potential drug candidates. Conclusion: To our knowledge such IDO1 and
TDO2 specifıc small molecule activators have not been reported earlier. There-
fore, these activators and inhibitors would serve as useful tool compounds in
understanding the specifıc role(s) of IDO1 and TDO2 in disease biology and
would also provide us the opportunity to target this pathway for various diseases,
including cancer.
#5579 Strategic inhibition of adenosineA2A receptor (A2AR) byCPI-444
improves CD8:Treg ratios and enhances T-cell killing of a HER-2/neu ex-
pressing murine tumor. Blake A. Scott,1 Todd Armstrong,1 Stephen Willing-
ham,2 Ian McCaffery,2 Elizabeth M. Jaffee1. 1Johns Hopkins University School of
Medicine, Baltimore, MD; 2Corvus Pharmaceuticals, Burlingame, CA.
It has been demonstrated that a higher CD8 to CD4FoxP3 T regulatory
cells (Tregs) ratio coincides with improved therapeutic outcomes for patients
receiving immunotherapies in the clinic. The last several years of research have
drawn attention tomany such therapeutics and strategies. Adenosine is an abun-
dant extracellular signalingmolecule in the tumormicroenvironment (TME) of
many cancers. Signal transduction through the GPCR A2AR enhances the im-
munosuppressive activity of Tregswhile simultaneously attenuating tumor-spe-
cifıc CD4/CD8T cells.We have evaluated the appropriate coordination and
dosing for a small-molecule inhibitor of A2AR in a Her-2/neu expressing mu-
rine model of breast cancer. We have demonstrated its capacity to augment
existing therapeutic strategies in this tolerant model. To test our hypotheses on
the ability of the smallmolecule towork in concert with existing therapeutics, we
tested the role of CPI-444 when given with a T cell-inducing vaccine. Neu-
expressingmammary tumor bearingHER-2/neu transgenic (Neu-N)mice were
administered combinations of low-dose cyclophosphamide (Cy) to deplete
Tregs, followed one day later with a granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) and neu-expressing whole cell vaccine (GVAX). The day
following administration of GVAX, mice received adoptively transferred high-
avidity naïve neu-specifıc CD8 T cells intravenously one day after vaccination.
Administration of specifıc components in this strategy (i.e. Cy, GVAX, adoptive
transfer) were altered to gain insight into the mechanistic effects of CPI-444 in
vivo through analysis of tumor progression, tumor clearance, and flow cytomet-
ric analysis of the TIL. Mice treated with the A2AR inhibitor or the vehicle
control were administered each by oral gavage daily for 14 days (survival) or
until 4 days post-adoptive transfer (TIL) at the peak infıltrate time. Of the strat-
egies tested, Cy, followed by concomitant administration of GVAX with
100mg/kg of CPI-444 for 14 days, and a single adoptive therapy treatment pro-
vided a 55% overall survival (OS) compared with 0%-20%OS in vehicle controls
(P0.005). Further, we have observed both broad and specifıc changes in the T
cell compartment of the tumor-infıltrating leukocyte (TIL) population. Broadly
we have observed a refınement in the T cell portion of the TIL with decreased
numbers of T cells overall, but an increase in specifıc prognostic ratios, namely a
relative increase in favorability of the CD8:Treg ratio when compared to con-
trols (P0.05). We hypothesize that strategic combination therapy of CPI-444
with existing therapeutics can refıne the local immune profıle to enhance favor-
able outcomes in vivo. CPI-444 is currently involved in numerous clinical trials;
this workmay provide rationale for the expansion of these trials into new cancer
types.
#5580 Preclinical pharmacodynamics and antitumor activity of
AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine
mediated T cell suppression.Alexandra Borodovsky,1 YanjunWang,1 Minwei
Ye,1 Joseph C. Shaw,1 Kris F. Sachsenmeier,1 Nanhua Deng,1 Kelly J. Del-
Signore,1 Adrian J. Fretland,1 James D. Clarke,1 Richard J. Goodwin,1 Nicole
Strittmatter,1 Carl Hay,2 Vasu R. Sah,1 Deborah Lawson,1 Corinne Reimer,1
Miles Congreve,3 Jonathan S. Mason,3 Fiona H. Marshall,3 Paul Lyne,1 Richard
Woessner1. 1AstraZeneca, Waltham, MA; 2MedImmune, Gaithersburg, MD;
3Heptares Therapeutics, London, United Kingdom.
Accumulation of extracellular adenosine within the microenvironment is a
strategy exploited by tumors to escape immunosurveillance. Adenosine signal-
ing through the high affınity adenosine 2A receptor (A2AR) on immune cells
elicits a range of immunosuppressive effects which can promote tumor growth
and limit the effıcacy of immune checkpoint inhibitors such as anti-PD-1 or
anti-PD-L1 Abs. AZD4635 (HTL-1071), an oral A2AR antagonist, binds to hu-
man A2AR with a Ki of 1.7 nM and with 30-fold selectivity over other aden-
osine receptors. Accumulation of intratumoral adenosine, measured by desorp-
tion electrospray ionisation - mass spectroscopy (DESI-MS), demonstrated that
adenosine levels are spatially heterogeneous in mouse syngeneic tumors, with
levels varying up to 50 fold among regions of a single tumor. To assess whether
AZD4635 can reverse the inhibitory effects of different concentrations of aden-
osine, CHO cells stably expressing human A2AR were incubated with concen-
trations of adenosine ranging from 0.1 to 10M. In the presence of 0.1, 1 and 10
M adenosine, the IC50 of AZD4635 for inhibition of cAMP production was
0.79, 10.0 and 142.9 nM, respectively. In an ex vivoCD8T cell assay, AZD4635
reversed suppression and restored IFN secretion in cells incubated with 5=-N-
ethylcarboxamidoadenosine (NECA), a stable analog of adenosine. The thera-
peutic benefıt of A2aR blockade was evaluated in syngeneic mouse tumor mod-
els. Inhibition of A2aR signaling led to a reduction in tumor growth alone and in
combination with checkpoint inhibitors. Tumors harvested from the treated
mice exhibited changes in infıltrating lymphocyte populations and increases in
the functional activity of T cells. These results demonstrate that AZD4635 is a
potent and selectiveA2aR inhibitor, and that blockade ofA2aR signalingwith an
inhibitor such as AZD4635 can reduce tumor burden and enhance antitumor
immunity. AZD4635 is currently in a Phase 1 clinical trial as a single agent and
in combination with durvalumab (anti-PD-L1 Ab) in patients with solid malig-
nancies.
#5581 Development of 2nd generation indoleamine 2,3-dioxygenase 1
(IDO1) selective inhibitors. Thomas Pesnot, Sachin Mahale, Philip MacFaul,
John Maclean, Caroline Phillips, Matilda Bingham, Catherine Eagle, James
Kelly, Abhijith Thippeswamy, Simon Armitage, Aleksandr Grisin, Sheenagh
Aiken, Lucy Cartwright, Richard Armer. REDX Pharma, Macclesfıeld, United
Kingdom.
Harnessing the immune system via immune checkpoint blockade (e.g. anti
PD-1, anti PD-L1, anti CTLA4) has led to fast and long lived responses in
cancer patients. Response rates however are low and new treatments that
enhance these rates are needed. Recent studies have shown that the admin-
istration of immune checkpoint blockers is associated with the overexpres-
sion of indoleamine 2,3-dioxygenase 1 (IDO1). The resulting immunoregu-
latory phenotype counteracts immune checkpoint blockade and allows for
cancer progression. The discovery of IDO1 inhibitors, and the potential to
combine them with immune checkpoint blockers, therefore represents an
attractive strategy to fıght cancer. We carried out a ligand-based virtual
screen with  1,000,000 commercially available small molecules. In vitro
screening of the resulting 610 virtual hits provided us with 2 IDO1-selective,
2 TDO2-selective and 2 IDO1/TDO2-dual confırmed hits. (TDO2 is a pro-
tein with similar biochemical activity to IDO1 that is essential to tryptophan
homeostasis.) A subsequent Hit to Lead campaign led to the identifıcation of
novel chemotypes that display potency similar or superior to IDO1 inhibi-
tors currently under clinical investigation in IFN- stimulated (i.e. IDO1)
HeLa cells, with no sign of cytotoxicity. We have demonstrated that these
compounds are  1000-fold selective for IDO1 over TDO2 using cellular
assays. IDO1 upregulation by cancer cells is known to be one of the mecha-
nisms by which cancer cells evade the immune system. In an in vitro co-
culture assay of cancer cells and T cells we have demonstrated our com-
pounds can rescue T cell proliferation with EC50 values between 10 and 50
nM.We have also demonstrated that our compounds inhibit IDO1 in mono-
cyte derived human dendritic cells. Interestingly, despite this potent cellular
activity demonstrated in multiple disease relevant cellular assays, this che-
motype failed to inhibit recombinant IDO1 in an isolated biochemical assay
performed under reducing conditions, whereas the reference compound ep-
acadostat provided activity comparable to literature values. In order to con-
fırm our cellular effects were due to direct inhibition of IDO1 we set up
thermal shift assays. Thermal shift assays using purifıed IDO1 protein have
demonstrated that our compounds directly bind IDO1, and cellular thermal
shift assays have confırmed direct target engagement in intact cells (stimu-
lated for IDO1 expression). These compounds have physicochemical prop-
erties that would support oral dosing and display low in vitro CYP450 and
hERG inhibition, thus reducing the risk of toxicity in the clinic. Our IDO1
inhibitors show a novel differentiatedmode of action at the cellular level, and
the consequences of this profıle in terms of in vivo characterisation is ongo-
ing.
IMMUNOLOGY: Enzymes and Hormones and Metabolism in Tumor Immunity
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171426
#5583 Pegylated adenosine deaminase 2 (PEG-ADA2) abrogates the cyto-
protective effects of adenosine against chronic lymphocytic leukemia cells.
Sara Serra,1 Cinzia Bologna,1 Luz Londono,2 Lin Wang,2 Michael Shepard,2
Sanna Rosengren,2 Christopher Thanos,2 Silvia Deaglio1. 1Human Genetics
Foundation and University of Turin, Turin, Italy; 2Halozyme Therapeutics, San
Diego, CA.
Extracellular adenosine can be generated from ATP and/or ADP through
the concerted action of the ectoenzymes CD39 and CD73. Adenosine can
bind different type-1 purinergic receptors eliciting potent cytoprotective
and immunosuppressive effects. We previously focused on chronic lympho-
cytic leukemia (CLL), a disease characterized by the progressive expansion of
a mature population of B lymphocytes, showing that a subset of patients with
a CD73 clone possess a poor prognosis. This patient subset can actively
generate adenosine, which favors leukemic cell survival, synthesis of immu-
nosuppressive cytokines, while inhibiting T lymphocyte proliferation.
ADA2 is a human enzyme that catalyzes the conversion of adenosine into
inosine. We hypothesized that depletion of high adenosine levels from the
tumor microenvironment through the administration of exogenous ADA2
could be therapeutically relevant to limit tumor protection and immunosup-
pression. Several engineered PEG-ADA2 variants possessed improved en-
zyme activity and pharmacokinetics compared to wild-type ADA2. Inhibi-
tion of adenosine receptor activation was evaluated by measuring
intracellular cAMP concentrations in T lymphocytes purifıed from healthy
donors. Adenosine depletion was observed with increasing concentrations
of PEG-ADA2-R222Q/S265N and signifıcantly reduced cAMP levels. PEG-
ADA2 variants were then tested on CD73 CLL lymphocytes to determine
their effects on extracellular adenosine and inosine. Treatment of leukemic B
cells with PEG-ADA2-R222Q/S265N and PEG-ADA2-R222Q/S265N/
K374D resulted in complete removal of high levels of adenosine, as measured
by HPLC. Conversely, PEG-ADA2-E182T, which possesses signifıcantly at-
tenuated catalytic activity, was less effective in reducing adenosine. The
functional effects of adenosine depletion on CLL cell survival were analyzed
following treatment with the chemotherapeutic, DNA-damaging agent eto-
poside that robustly induces apoptosis within 16 hours. Addition of exoge-
nous adenosine to cultures of purifıed CD73 CLL cells signifıcantly rescued
cells from etoposide-induced apoptosis. However, when these primary leu-
kemic cells were pretreated with PEG-ADA2-R222Q/S265N or PEG-ADA2-
R222Q/S265N/K374D, the cell viability rate was signifıcantly decreased, ab-
rogating the cytoprotective effects of adenosine. On the contrary, PEG-
ADA2-E182T had a minimal effect, suggesting enzymatic depletion of
adenosine is critical to observe these effects. Similar effects were observed by
the PEG-ADA2 variants on a CLL cell line expressing CD73. These prelim-
inary results suggest that enzymatic depletion of extracellular adenosine
following treatment with PEG-ADA2 is a relevant approach to counteract
the cytoprotective effects of adenosine, warranting further development of
PEG-ADA2 as a possible approach to treat CLL.
#5584 PHY906(YIV-906), an adjuvant based on a 1800-year-old Chinese
medicine, enhanced the anti-tumor activity of Immune checkpoint blockade
therapy: anti-PDL1, anti-PD1, anti-PD1/CTLA4 against melanoma. Wing
Lam,1 Zaoli jiang,1 Xue han,2 Shwu-Huey Liu,3 Lieping Chen,2 YungChi
Cheng1. 1Yale Univ. School ofMedicine. Dept. of Pharmacology, NewHaven, CT;
2YaleUniv. School ofMedicine.Dept. of Immunobiology,NewHaven, CT; 3Yiviva
Inc, New York, NY.
Immune checkpoint blockade therapy has recently been recognized as a
breakthrough in cancer treatment. Currently the FDAhas approved Ipilimumab
(anti-CTLA4), Pembrolizumab (anti-PD1) and Nivolumab (anti-PD1), and At-
ezolizumab (anti-PDL1) for the treatment of several types of cancers, including
melanoma. However, colitis and diarrhea are commonly found in these immu-
notherapies, particularly in anti-PD1/CTLA4 therapy. PHY906(YIV-906) is in-
spired by the Huang Qin Tang, which was fırst described in Chinese texts 1800
years ago for the treatment of numerous gastrointestinal symptoms. Consistent
preparations of PHY906 could be manufactured apart 10 years. In animal stud-
ies, PHY906 can increase the anti-tumor activity of a broad spectrum of chemo-
therapies while promoting damaged intestinal tissue recovery via mutliple tar-
gets. Several clinical results suggest that PHY906 had potential to increase the
therapeutic index of cancer treatments (chemotherapy, radiation) by prolong-
ing life and improving patient quality of life. We hypothesize that PHY906 can
reduce diarrhea caused by anti-PD-L1, anti-PD1, and/or in combination with
CTL4 without compromising their anti-tumor activity. We studied the effect of
PHY906 in combination with anti-PDL1, anti-PD1, anti-CTLA4 and anti-PD1/
CTLA4, using subcutaneously implanted B16F10 melanoma in Black B16 mice.
Results indicated that PHY906 enhanced the anti-tumor activity of anti-PD1,
anti-PDL1, or anti-PD1/CTLA4; but not anti-CTLA4 alone, in vivo. In addition,
PHY906 did not compromise the action of anti-PD-L1 in brain implanted B16
tumor. PHY906 in combinationwith all of the antibodies had no impact of body
weight change or different type of blood cells counts. PHY906 reduced mRNA
expression of several inflammation markers, including TNFa, MCP1, ICAM,
IL2, in ileum or colon tissues following anti-PD1 or anti-CTLA4 treatment. In
cell culture, PHY906 was found to have modulation effect on Indoleamine 2,3-
dioxygenase (IDO)which is a key resistance factor to immune checkpoint block-
ade therapies. Overall, PHY906 can increase the therapeutic index for anti-
PDL1, antiPD1, or anti-PD1/CTLA4 in against melanoma. We are planning to
initiate a clincal trial to determine if PHY906 could enhance the therapeutic
index of anti-PD1/CTLA4 for the treatment fo melanoma in patient. This work
was supported by grant (1PO1CA154295-01A1) fromNational Cancer Institute
(NCI), NIH, USA. Dr. Yung-Chi Cheng is a fellow of National Foundation for
Cancer Research (NFCR), USA.
#5585 TGF-ß insensitive PSMA-specifıc CD8 T cells derived from met-
astatic castration resistant prostate cancer (MCRPC) patients enhance the
tumorkilling ability.QiangZhang,1 TimothyKuzel,2 BrianHelfand,3Ximing J.
Yang,1 Weijun Qin,4 Chung Lee,1 Benedito Carneiro,1 Francis J. Giles1. 1North-
western University, Chicago, IL; 2Rush University, Chicago, IL; 3NorthShore Uni-
versity Healthsystem, Evanston, IL; 4The Fourth Military Medical University,
Chicago, China.
Introduction: Manufacturing tumor specifıc CD8 T cells has been an obsta-
cle for developing prostate cancer (PCa) immunotherapies for men with
MCRPC. We report a highly effıcient method to expand human TGF-ß insen-
sitivity PSMA-specifıc CD8 T cells from MCRPC patients using a FDA ap-
proved Cell ProcessingWork Station (CPWS, Panasonic). Methods: Peripheral
blood CD8 T cells were collected from men with MCRPC by leukapheresis,
and cultured in CPWS in TexMACSTMmedium with CD-3 Biotin/CD28/Anti-
Biotin Beads, 5% human serum, and IL-2.We developed a TRIIDN-TK-IRES-
PZ1 chimeric T cell receptor retroviral construct using an anti-PSMA IgTCR()
gene (PZ1) and a dominant negative TGF-ß type II receptor (TßRIIDN), that
could induce CD8 T cells to be PSMA reactive and insensitive to TGF-ß. PC-3
cells (PSMA negative) or PSMA positive PC-3-PSMA cells (PSMA positive)
were exposed to TGF-ß and used as target cells. Cytotoxicity assays were per-
formed by LDH/NADH analysis (target cells: CD8 T cells at 1:20, 1:50 and
1:100 respectively). Live interactions between CD8 T cells and PCa cells was
recorded by Nikon BiostationIMQ. Apoptosis of PCa was evaluated by immuno-
fluorescence staining for Annexin V and 7-Amino-actinomycin D (7-AAD)
respectively. Results: On Day 0, 2x106 CD8 T cells were placed in culture, in-
fected with TßRIIDN-TK-IRES-PZ-1 on Day 8, and expanded 96 fold
(1.92x108) by Day 36. The cellular expansion plateaued by Day 40 (1.95x108),
when the ratios of CD8 (95.2%), CD45 (96.6%) and CD3 (97.2%) were
maintained. The cells strongly expressed PZ1 and TK gene (71.1%), and p-
SMAD2 was inhibited 95%. Under TGF-ß treatment for 7 days, the growth of
infected CD8 T cells was not signifıcantly changed, while the naïve CD8 T
control cells were suppressed by 44.8%. PC3-PSMA cells released 25.64 and 4.19
nmol/50ul/105 NADH when co-cultured with infected CD8 T cells or with
naïve CD8 T cells respectively (p0.05). There was no signifıcant difference
when PC3 cells were co-cultured with infected CD8 T cells (7.35) or naïve
CD8 T cells (7.59). Infected CD8 T cells induced 32.0% and 13.7% expres-
sion of Annexin V in PC3-PSMA and PC3 cells respectively, while naïve CD8
T cells induced only 6.9% in both groups (p0.05). Furthermore, Infected
CD8 T cells induced signifıcant higher expression of 7-AAD in PC3-PSMA
(0.688%) compared to naïve CD8 T cells treatment (0.03%). There were close
interactions between infected CD8 T cells and PC3-PSMA, which was not
observed in other groups. Conclusion: Our study supports expansion and ret-
roviral infection generating TGF-ß insensitive PSMA-specifıc CD8 T cells
ex-vivo within 4 weeks in CPWS without any exogenous specifıc stimulation
signal. These cells can enhance the PSMA expressed PCa killing ability and
escape the inhibition by tumor secreted TGF-ß, which have a potential to over-
come many of the current barriers of immunotherapies for men with MCRPC.
#5586 PPMX-T003, a fully human anti-TfR1 antibody with potent effı-
cacy against hematologic malignancies. Lilin Zhang,1 Fumiko Nomura,1 Yoi-
chiAikawa,1 YoshikazuKurosawa,2KazuhiroMorishita,3 Yukio Sudo1. 1Perseus
Proteomics, Inc., Tokyo, Japan; 2Fujita Health University, Nagoya, Japan; 3Uni-
versity of Miyazaki, Tokyo, Japan.
Transferrin receptor1 (TfR1) is a type II transmembrane glycoprotein that
involves intracellular uptake of iron. TfR1 is ubiquitously expressed at low levels
in normal cells except erythroblasts and placental trophoblasts, which express
high levels of TfR1 due to the need of up taking a large amount of iron. Accu-
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mulating studies have shown elevated levels of TfR1 in both solid tumor cells, as
well as hematologic malignant cells when compared to their normal counter-
parts. Since TfR1 is implicated in growth and survival in various cancer cells,
targeting TfR1 could be attractive strategy for cancer therapeutics. To this end,
we have developed a fully human antibody against TfR1, PPMX-T003, which
displayed potent anti-tumor activity in vitro and in vivo. PPMX-T003 induced
apoptosis or cell cycle arrest with EC50s of 3200ng/ml in various tumor cell
lines. Mechanistically, PPMX-T003 triggers apoptosis or cell growth arrest by
inhibiting binding of TfR1 to its ligand transferrin and blocking iron uptake. In
addition, PPMX-T003 elicits antibody dependent cellular cytotoxicity (ADCC)
activity in cancer cells. Importantly, PPMX-T003 showed potent effıcacy against
several blood cancer xenograft models. PPMX-T003 completely eradicated es-
tablished subcutaneous tumors in two acute myeloid leukemia (AML) models
generated by Kasumi-1 and HL-60, at a dose of 10 mg/kg when administrated
(I.V.) once a week for 4 weeks. Moreover, PPMX-T003 completely eradicated
established tumors in a lymphoma xenograft model (SU-DHL-2) at a dose of 3
mg/kg. Furthermore, PPMX-T003 greatly prolonged mice survival in a dissem-
inated leukemia model (CCRF-CEM: acute lymphoblastic leukemia cell line).
The control mice engrafted with CCRF-CEM cells (n10) developed leukemia
and died within 42 days, whereas 8 of the 10 mice treated with PPMX-T003
survived 179 days until the experiment was terminated. A preliminary toxicol-
ogy study in Cynomolgus monkeys with multiple doses was also carried out.
Although moderate anemia was observed at the dose of 30 mg/kg, no other
abnormalities were observed, indicating a tolerable safety profıle. Taken to-
gether, these results indicate that PPMX-T003 could be a potent therapeutic
antibody for the treatment of hematologic malignancies.
#5587 Novel monoclonal antibodies block N-glycosylation Sites of the
MUC16 ectodomain in ovarian carcinoma. Dharmarao Thapi,1 Alberto Fer-
nandez-Tejada,2 Abraham J. Axelrod,1 Nestor Rosales,1 Xiujun Yan,1 Marina
Stasenko,1 Sahityasri Thapi,1 Amy Wang,1 Samuel J. Danishefsky,1 David R.
Spriggs1. 1Mem. Sloan Kettering Cancer Ctr., New York, NY; 2University of Ox-
ford, Oxford, United Kingdom.
TheMUC16 gene encodes the CA125 antigen that imparts a negative survival
impact on patients with high-grade serous ovarian cancer. Short elements from
the C-terminal region of MUC16 transform 3T3 cells. Introduction of the 114
amino acid C-terminal portion of MUC16 promotes invasive growth in xeno-
graft models. This effect is dependent on N-glycosylation sites of MUC16 and
interactions present on the cell surface. Mechanisms by which the ectodomain
promotesMUC16 oncogenic behaviors, the function of N-glycosylation and the
implicated cell surface receptors are not fully delineated. To unravel the complex
MUC16 cancer biology, in this study we investigated the glycosylation-based
mechanisms and potential partners involved in MUC16 oncogenic effects, and
show that site-specifıc glycosylation ofMUC16 plays a key role inmucin-related
transformation bymediating complex cell surface interactions. These effects are
mediated throughMGAT5-dependent N-glycosylation of two proximal N- gly-
cosylation sites within the 58 amino acid retainedMUC16 ectodomain acting in
combination with Galectin-3 and growth factor receptors. Neither N- nor O-
glycosylation sites in the more distally located MUC16 regions can functionally
substitute for those two sites. The tumor-enhancing properties of MUC16 de-
pend on co-localization ofMUC16, Galectin-3, and growth factors receptors on
lipid rafts. Loss of either Galectin-3 expression or the glycosylation enzyme
MGAT5 completely abrogates MUC16 tumor promotion. Using synthetic gly-
copeptides, we have developed novel monoclonal antibodies (mAbs) directed at
the crucial ectodomainN-glycosylation sites to inhibit the glycosylation- depen-
dent effects of MUC16 onmetastasis and invasion. These novel antibodies were
characterized in vitro and in vivo studies using various ovarian cancer cell lines.
All of the antibodies against the N- glycosylation sites closest to the cell mem-
brane of MUC16 block Galectin-3-mediated polymerization to cell surface sig-
naling molecules and inhibit the tumor-promoting effects of MUC16. The im-
plications are broad: both for the biological understanding of cancer mucin
biology and for potential therapeutic strategies.
#5588 Brentuximab vedotin-driven immunogenic cell death enhances an-
titumor immune responses, and is potentiated by PD1 inhibition in vivo.
Anthony T. Cao, Che-Leung Law, Shyra J. Gardai, Ryan A. Heiser. Seattle Ge-
netics, Bothell, WA.
Brentuximab vedotin (BV) is an antibody-drug conjugate directed against
CD30 consisting of a monoclonal antibody conjugated to monomethyl aurista-
tin E (MMAE), a microtubule-disrupting agent. BV antitumor activity is
thought to be primarily the result of intracellular payload release leading to
mitotic arrest and apoptotic cell death. We have demonstrated that BV drives
apoptosis in a manner consistent with immunogenic cell death (ICD) including
activation of the unfolded protein/ER stress response with a concomitant in-
crease in surface expression of calreticulin and HSP70. In this study, we provide
evidence that in vivo administration of BV leads to directed proinflammatory
immune responses against the tumor and this activity is further potentiated by
anti-PD-1 therapy. To examine the immunomodulatory effects of BV-induced
ICD in vivo, we employed 3 murine model systems. In the fırst model, BV
treatment induced ICD in subcutaneously-engrafted CD30 L540cy cells, gen-
erated strong chemotactic responses detectable within the tumor and in circu-
lation, and increased infıltration of dendritic cells into the tumormicroenviron-
ment. To assess whether BV-driven ICD could confer specifıc antitumor
immunity, we used a model in which ICD was induced in BV-treated human
CD30-expressing A20 lymphoma cells in vitro. These cells were used to immu-
nize wild-type BALB/cmice followed by live A20 challenge. Immunization with
BV-treated cells, undergoing ICD, delayed tumor growth and improved survival
compared tomice immunized with flash-frozen cells. Furthermore, administer-
ing anti-PD-1 tomice immunized with BV-treated cells displayedmarked com-
binatorial effects, leading to improved tumor clearance compared to either treat-
ment alone.Additionally, T cells isolated frommice immunizedwithBV-treated
cells and transferred into tumor-bearing immunodefıcient mice resulted in tu-
mor regression and survival, demonstrating robust T cell memory. Lastly, we
employed a humanized tumormodel pairing CD30 PDL1 PDL2 lympho-
blastoid cell line (LCL) xenografts with adoptively transferred autologous
PBMC. In this setting, mice treated with suboptimal doses of BV showed greatly
enhanced cytotoxic T cell and NK cell accumulation in LCL tumors resulting in
accelerated immune-mediated tumor clearance. Tumor regression was further
accelerated by treatingmice with a combination of BV and a human PD1 inhib-
itor, demonstrating complementary modes of action for these agents. Together,
these data indicate that targeted treatment with the MMAE antibody drug con-
jugate brentuximab vedotin drives an immunogenic form of tumor cell death
that enhances innate and adaptive antitumor immunity. Combination of BV
with PD1 inhibitors resulted in greater antitumor activity than either agent
alone. Multiple clinical trials are ongoing to evaluate the effıcacy of this treat-
ment pairing.
#5590 Combination of an oncokinase inhibitor merestinib with anti-
PD-L1 results in enhanced immune mediated antitumor activity in CT26
murine tumor model. Sau-Chi Betty Yan,1 Victoria L. Peek,1 Jennifer R. Ste-
phens,1 Um L. Um,1 Amaladas Nelusha,2 Colleen A. Burns,2 Kelly M. Credille,1
Thompson N. Doman,1 Scott W. Eastman,2 Beverly L. Falcon,1 Gerald E. Hall,2
Philip W. Iversen,1 Bruce W. Konicek,1 Jason R. Manro,1 Any T. Pappas,1 Julie
A. Stewart,1Michael B. Topper,2 Swee-SeongWong,1Michael Kalos,2 RuslanD.
Novosiadly,2 Richard A. Walgren,1 David Schaer2. 1Eli Lilly and Company, In-
dianapolis, IN; 2Eli Lilly and Company, New York, NY.
The combination of tumor targeted therapeutics with PD-L1 checkpoint
blockade is being explored as a method to increase the clinical benefıts of im-
munotherapy, and expand response to additional cancer types. Merestinib
(Mer) is a kinase inhibitor targeting several oncokinases1 (including MET,
MST1R, AXL, MERTK, andMKNK1/2) that can potentially modulate immune
function, angiogenesis, as well as target the tumor 1-5. To determine the combi-
natorial potential with immunotherapy, the effects of Mer were evaluated in
vitro on human T cells, PBMCs and murine tumor lines CT26 colon carcinoma
(harbors KRASmt G12D expresses low Met/no p-Met/high Axl/p-Axl) and
B16F10 melanoma (expressing high Met/pMet/peIF4E). Additionally, the anti-
tumor effect of Mer was tested in vivo on established CT26 and B16F10 tumors
compared to MET specifıc TKIs (savolitinib, PF4217903) alone or in combina-
tion with PD-L1 antibody (Ab) blockade. In vitro, Mer showed no signifıcant
effects on either T cells or PBMCs, but was able to inhibit downstream signaling
in both CT26 and B16F10 showing activity on murine tumor cell lines. In vivo,
dailyMermonotherapy (6, 12 or 24mg/kg) showed signifıcant anti-tumor effect
at all doses in bothCT26 and B16F10, that was not seenwith either savolitinib or
PF4217903. Concurrent combination of Mer (12 mg/kg) and anti-PD-L1 Ab
(0.5 mg qw) in CT26 was found to have anti-tumor activity that was synergistic
as compared to each single agent alone. While the effect of Mer monotherapy
was lost when treatment ended, tumors continued to regress in the combination
group even upon cessation of therapy. The combination was well tolerated and
resulted in 90% complete responders compared to 30% with anti-PD-L1 Ab
alone, 35 days after completing dosing. To test the ability to generate immuno-
logic memory, complete responders were re-challenged with CT26 cells on the
contralateral side. All mice in the combination group resisted re-challenge,
showing that Mer/PD-L1 Ab combination was triggering immunologic mem-
ory. Although there was no signifıcant change in intra-tumor immune cell pop-
ulations between groups, combination therapy showed an enhanced and unique
intra-tumor immune activation/inflammation gene expression signature com-
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pared to PD-L1Abmonotherapy. The enhanced immune activation of the com-
bination therapy, leading to synergistic anti-tumor effıcacy, demonstrates that
merestinib has the potential to augment immunotherapy while targeting the
tumor directly. This preclinical data provides the rationale for the clinical inves-
tigation of merestinib in combination with checkpoint therapies targeting the
PD-L1/PD1 axis (NCT02791334). 1 - Yan et al. Invest New Drugs 2013;31:
833-44 2 - Balan et al. J Biol Chem2015;290:8110-20 3 - Eyob et al. CancerDiscov
2013;3:751-60 4 - LemkeG.CSHPerspBiol 2013;5:a009076 5 - Piccirillo et al.Nat
Immunol 2014;15:503-11
#5591 Mek/erk inhibition enhances anti-pd-l1 effects on the susceptibility
toNK cytotoxicity of cisplatin-resistant non-small cell lung cancer.MingJing
Shen, LiJun Xu, Ying Tsai, Peter C. Keng, Soo Ok Lee, Yuhchyau Chen.Univ. of
Rochester Medical Ctr., Rochester, NY.
Background: Immunotherapy is often used after chemotherapy failure or in
combination with chemotherapy. Initial chemotherapy may yield clinical ben-
efıt, however; after continuous chemotherapy treatments, chemoresistance in-
variably develops. Immunotherapy has shown effects in a fraction of patients,
but not all patientswith chemoresistant non-small cell lung cancer (NSCLC)will
respond. We investigated a new mechanism to enhance natural killer (NK) cell
cytotoxicity against cisplatin-resistant NSCLC and propose to inhibit MEK/Erk
pathway to enhance anti-PD-L1 effects on the susceptibility to NK cytotoxicity
of cisplatin-resistant NSCLC. Methods: NK cell mediated cytotoxicity was con-
ducted using two NK cell sources: NK92 cell line and primary NK cells. LDH
release-based NK cytotoxicity test and the colony formation assay were applied
tomonitor NK cytotoxicity. NK cell cytotoxicities to parental vs. cisplatin-resis-
tant A549 and H157 sublines (A549CisR and H157CisR) were compared. We
investigated signaling molecules/pathways that are responsible for the constitu-
tively up-regulated expression of PD-L1 and down-regulatedNKG2D ligands in
cisplatin-resistant cells using qPCR and Western blot analyses and inhibition
studies using inhibitors of each signaling pathway were conducted in parallel.
Results: We found cisplatin-resistant NSCLC cells were resistant to NK cell
cytotoxicity, due to the up-regulation of PD-L1 and down-regulation ofNKG2D
ligands inA549CisR andH157CisR cells compared to parental cells. In addition,
we found that the expression of PD-1 in NK cells was induced after co-culture
with cisplatin-resistant cells, but not with parental cells. Susceptibility of cispla-
tin-resistant cells to NK cell cytotoxicity increased when the PD-L1/PD-1 inter-
action was inhibited by Abs of PD-1 or PD-L1. In inhibitor studies, we found
that the inhibition of MEK/Erk signaling effectively reduced the PD-L1 level
while recovered the NKG2D ligands levels in cisplatin-resistant cells. Subse-
quently, adding the MEK/Erk inhibitor enhanced the PD-L1 Ab effect in in-
creasing the susceptibility of A549CisR and H157CisR cells to NK cell cytotoxic
action. Conclusion and Impacts: Our data suggest that the inhibition of MEK/
Erk pathway may enhance the anti PD-L1/PD-1 therapy effıcacy in increasing
the susceptibility of cisplatin-resistant cells to NK cell cytotoxicity via reducing
the constitutively expressed PD-L1 levels, while simultaneously recovering
NKG2D ligand levels in these cells. This strategy of dual effects has the thera-
peutic potential for molecular targeted drug development. The immune escape
of cisplatin-resistant cells is an emerging task to overcome in lung cancer ther-
apeutics, thus positive outcome of our studies may result in clinical signifıcance.
#5592 Metformin improves immune function of exhausted peripheral
CD8 T cells derived from cancer patients. Mototsugu Watanabe, Shingo
Eikawa, Kazuhiko Shien, Hiromasa Yamamoto, Tadahiko Shien, Junichi Soh,
Hiroyoshi Doihara, Shinichi Toyooka, Shinichiro Miyoshi, Heiichiro Udono.
Okayama University, Okayama, Japan.
Background: Immunotherapy has been developed and shown a drastic effect
on several malignancies. However, in the tumor microenvironment, CD8 tu-
mor infıltrating lymphocytes (CD8 TILs) are repeatedly exposed to tumor
antigens and lose their anti-tumor activities. We have recently shown that met-
formin can show anti-tumor effect thorough improving immune function in
mouse models. Increased numbers of such multifunctional CD8 TILs have
well correlated with tumor retardation, suggesting an underlying mechanism of
metformin in tumor immunity. The objectives of this study are to evaluate the
effıcacy of metformin on human immune function. Methods: We obtained pe-
ripheral blood mononuclear cells (PBMC) from healthy volunteers (HV) and
cancer patients (CP) before and after takingmetformin orally for about 2 weeks.
We cultured the PBMC in a presence of stimulation with phorbol 12-myristate
13-acetate (PMA) / ionomycin in vitro for 6 hours. Expressions of markers for
immune-check points (PD-1 and Tim-3) were examined together with accumu-
lated intracellular cytokines, IFN-, IL-2 and TNF-	 by flow cytometry analysis.
Results: We obtained consents for take part in our clinical research from 20 HV
and 15 CP (10 breast cancer, 4 metastatic lung cancer and 1 primary lung can-
cer). CD8 T cells which expressed both of PD-1 and Tim-3 derived from CP
were higher than those of HV (p  0.041). Increased production of multiple
cytokines, IFN-, IL-2 and TNF-	 was observed in CD8 T cells of almost all
cancer patients by metformin treatment and its increasement was signifıcant
(p 0.01), whereasmarginal difference before and aftermetformin administra-
tion was detected in the samples from healthy volunteers so far (p  0.051).
Conclusion: Metformin treatment might be useful in reversion of exhausted
CD8T cells in cancer bearing patients.
#5593 Inhibition of A2AR induces anti-tumor immunity alone and in
combination with anti-PD-L1 in preclinical and clinical studies. Stephen
Willingham,1 Andrew Hotson,1 Po Ho,1 Carmen Choy,1 Kim Walter,1 Erik
Yusko,2 Sharon Benzeno,2 Ginna Laport,1 Richard Miller,1 Ian McCaffery1.
1Corvus Pharmaceuticals, Burlingame, CA; 2Adaptive Biotechnologies, Seattle,
WA.
Adenosine signaling via A2A receptor (A2AR) on immune cells suppresses
anti-tumor immunity and limits the effıcacy of immunotherapy, chemotherapy,
CAR-T, and vaccines. CPI-444 is a potent and selective oral A2AR antagonist.
Daily treatment ofmicewithCPI-444 led to dose-dependent inhibition of tumor
growth in multiple syngeneic tumor models. Combining CPI-444 with anti-
PD-L1 treatment synergistically eliminated tumors in up to 90% of treatedmice,
including restoration of immune responses inmodels that are poorly responsive
to anti-PD-1 or anti-PD-L1 monotherapy. We have initiated a Phase 1/1b clin-
ical trial to examine safety, tolerability, biomarkers, and preliminary effıcacy of
CPI-444 as a single agent and in combination with the anti-PD-L1 antibody,
atezolizumab, in patients with non-small cell lung, melanoma, renal, triple neg-
ative breast, and other (bladder, prostate, head and neck, colorectal) tumors.
Step 1 of the trial focused on determining the optimal dose and schedule for
CPI-444; Step 2 is currently evaluating the effıcacy of optimal CPI-444 dosing
alone and with atezolizumab. In 48 patients treated in Step 1, CPI-444 was well
tolerated with 1 Grade 3 or 4 treatment related adverse events. Preliminary
evidence of clinical activity was observed in patients treated with single agent
CPI-444, including patients who previously failed anti-PD-1 therapy. A pCREB-
based pharmacodyamic assay showed that 100mg, BIDdose ofCPI-444 resulted
in a complete, sustained inhibition of A2AR on circulating immune cells. CPI-
444 treatment alone or in combination with atezolizumab resulted in increased
frequency of circulating CD8PD-1 cells and memory/effector subsets of
CD4 and CD8T cells. Substantial changes in TCR repertoire (Morisita Index
0.9) were observed in both anti-PD-1 native and refractory patients and cor-
related to patient responses. CD73 expression, CD8 infıltration, TREG distri-
bution, and gene expression signatures are currently being evaluated in serial
tumor biopsy specimens and will be presented. In total, this shows that CPI-444
is well tolerated in cancer patients, exhibits functional inhibition of adenosine
signaling, and treatment is associated with activation of anti-tumor immunity
and clinical activity.
#5594 High throughput combinatorial profıling of checkpoint inhibitor
antibodies on the iQue® Screener PLUS.TomHasaka. IntelliCyt, Albuquerque,
NM.
Checkpoint inhibitors have become valuable immuno-modulatory targets in
the advancement of cancer treatment. Looking for the synergy between new
checkpoint inhibitor antibodies and known inhibitors is an important aspect of
this research. The iQue Screener PLUS platform is a powerful tool to simulta-
neously assess these interactions in a single well of a microtiter plate. ForeCyt®
software provides plate-level analytics andhigh content visualization to generate
deep insight rapidly. Using a mixed lymphocyte reaction (MLR) model, we
profıled potential synergies of several known checkpoint inhibitors antibodies.
Responses of PD-1, PD-L1, and CD73 inhibitors both individually, and in com-
bination with CTLA-4 inhibitors, were assessed for proliferation, viability and
cytokine secretion simultaneously in the same well. MultiCyt® cell-based and
bead-based reagents were used for this analysis. Synergies ranging from 2-10
fold increase over CTLA-4 alone were observed in the secretion of TNF	 and
IL-1. Results were obtained and analysis completed in a 384-well plate in 30
minutes. In conclusion, this study highlights the power of the iQue Screener
PLUS platform to rapidly characterize multiple endpoints and the ForeCyt soft-
ware to provide high content visualization that reveals actionable insights.
#5595 HDAC inhibitor Entinostat disrupts function of PMN-MDSC.
Ayumi Hashimoto,1 Vinit Kumar,1 Peter Ordentlich,2 Dmitry I. Gabrilov-
ich1. 1The Wistar Institute, Philadelphia, PA; 2Syndax Pharmaceuticals, Inc.,
Waltham, MA.
Myeloid-derived suppressor cells (MDSCs), consisting of subpopulations of
polymorphonuclear (PMN; CD11bLy6GLy6Clo) and monocytic (M;
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CD11bLy6G-Ly6Chi)MDSCs play amajor role as immune suppressors in can-
cer. MDSC-targeted therapy has not been developed yet. Histone deacetylases
(HDAC) are critically involved in epigenetic regulation of multiple genes and
may regulate MDSC number and function. The purpose of this study was to
evaluate the effect of the class I HDAC inhibitor, entinostat on differentiation
and function of MDSCs in mouse tumor models of lung cancer (Lewis Lung
Carcinoma, LLC) and colon cancer (CT26). LLC and CT26 tumor-bearingmice
were treated with entinostat (10 mg/kg, p.o. daily for two weeks). Entinostat
caused signifıcant increase in the presence of CD45 CD11bmyeloid cells in
bonemarrow, spleen and tumors. This increase was largely due to accumulation
of Ly6ClowLy6GPMN.Unexpectedly, this was associatedwith a small decrease
in the presence of common myeloid progenitor (CMP) and granulocyte-mac-
rophage progenitor (GMP) cells in bone marrow. This suggests that entinostat
affects differentiation of PMN downstream of GMP. Experiments in vitro dem-
onstrated that entinostat increased differentiation of enriched hematopoietic
progenitor cells (HPC) to PMN in the presence of tumor explant supernatant
(TES),which supported the in vivo result. To assess the effect of entinostat on the
function of PMN-MDSCs, Ly6G cells were purifıed from spleen and tumor of
LLC tumor-bearing mice treated with entinostat or vehicle alone and tested for
their ability to suppress antigen-specifıc T cell. As expected Ly6GPMN-MDSC
from tumor-bearing mice treated with vehicle alone had strong suppressive
activity. In contrast, Ly6G cells from spleen and tumor of entinostat-treated
LLC tumor-bearing mice show signifıcantly reduced suppressive activity. This
result was confırmed in experiments with Ly6G cells differentiated from HPC
culture with/without entinostat treatment. To determine whether entinostat
inhibition of PMN-MDSC immunosuppressive function could enhance im-
mune checkpoint activity, entinostat combined with an anti-PD-1 antibody was
evaluated using the LLC tumor-bearing mice. These mice were treated with
entinostat (10 mg/kg, p.o., daily) and anti-mouse PD-1 rat antibody (10 mg/kg,
i.p., twice a week). Entinostat or PD-1 antibody alone did not signifıcantly in-
hibit the tumor growth. In striking contrast, the combination treatment blocked
tumor progression. Our data demonstrate that entinostat increases a population
of PMN-MDSCs that are no longer immunosuppressive leading to enhanced
anti-tumor activity when combined with an immune checkpoint inhibitor. This
novel phenomenon provides further rationale for combination therapy of enti-
nostat with anti-PD-1 antibody or other checkpoint inhibitors in clinical set-
tings.
#5596 Intratumoral administration of a TLR9-adjuvanted nanoparticle
cancer vaccine stimulates more effective immunity in both injected and un-
injected tumor sites compared to subcutaneous administration. Edwina
Naik,1 Chi Ying,1 Robert Milley,1 Carlo Calacsan,1 Stewart Chipman,1 Thomas
Tüting,2 Robert Coffman,1 Cristiana Guiducci1. 1Dynavax Technologies, Berke-
ley, CA; 2Universitätsklinikum Magdeburg A.ö.R., Magdeburg, Germany.
Therapeutic success of a cancer vaccine requires substantial expansion of
vaccine-primed CTL and effıcient differentiation to polyfunctional T cells capa-
ble of migrating from the site of vaccination to metastatic sites. We have evalu-
ated the tumor itself as a potential site of vaccination, compared to vaccination at
subcutaneous sites distant from the tumor. For vaccination, we have developed
a highly effıcient nanoparticle platform comprised of multiple copies of a CpG-
rich oligonucleotide (a TLR9 agonist) and long peptide tumor antigens, both
covalently linked to the sucrose polymer Ficoll. Multiple peptide antigens where
studied, including ovalbumin and a long peptide comprising epitopes from
three melanocyte differentiation antigens. In all of these models, intratumoral
vaccination was superior to subcutaneous vaccination for elimination of both
injected tumors and, more importantly, distant site skin and lung metastases.
Intratumoral vaccination substantially increased the magnitude of the systemic
CTL response measured in the blood and in the spleen and enhanced capacity
cell homing to distant site tumors. A greater fraction of tumor-antigen specifıc
CD8 T cells generated in the tumor were polyfunctional, expressing both
IFN- and TNF-	. They were also less exhausted as measured by decreased
overall PD-1 levels, increased T bet and the increased number of PD-1 cells
that retained cytotoxicity and proliferative capacity. Intratumoral vaccination
also induced spread of the CD8T cell response to tumor antigens not included
in the vaccine. These results demonstrate that direct intratumoral immunization
with peptide antigens combined with a strong TLR9-activating adjuvant signif-
icantly increases the magnitude and quality of vaccine-primed CTL and en-
hances control of metastatic disease.
#5597 Genomic profıling of syngeneic mouse cell lines and in vitro screen
of the models against checkpoint inhibitors and target agents for preclinical
application. Frank Xing,1 Wubin Qian,1 Chunlan Dong,1 Xiaoxi Xu,2 Sheng
Guo,1 Qian Shi1. 1Crown Biosciences, Taicang, China; 2Crown Biosciences, Bei-
jing, China.
Cancer immunotherapy has provided substantial clinical benefıt in a signifı-
cant number of patients with advanced diseases. In pre-clinical studies, Crown-
Bio has developed a large collection of syngeneic models to facilitate in vivo
effıcacy testing of immune-oncology agents inmice (MuScreenTM). To combine
the ostensibly separate therapeutic strategies of activating immune cells against
and targeting the unique genetic characteristics of a tumor model, we sought to
thoroughly characterize themutation profıles of these syngeneicmouse cell lines
and examine drug response profıles of these cell line models. The goal of this
work was to provide an in vitro system in evaluating combination effectiveness
when targeting both immune checkpoint markers and oncogenic targets in pre-
clinical studies. To this end, we investigated mutation and gene expression pro-
fıles of 18mouse cancer cell lines out of the panel of 23 syngeneic mousemodels
included in the MuScreenTM for 50 well defıned cancer-related mutations
among 30,690 variants in exonic regions called by RNAseq (Illumina HiSeq
X10). The somatic mutations revealed through the bioinformatics analysis in-
cludeALK (3 - frequency, same for the rest), BRAF (4), BRCA1 (7), BRCA2 (12),
EGFR (3), ERBB2 (6), EGFR3 (2), FBXW7 (10), FLT3 (12), HRAS (1), KRAS (8),
NRAS (1), PDGFRA (11), PTCH1 (9), PIK3CA (2), PTEN (6), RET (3), SETD2
(5), SMAD4 (3), SMO (13), TRP53 (13), TSC1 (3), and TSC2 (10). All of these
oncogenic alterations are clinically actionable (Cancer Discovery 2, 82-93,
2012). The same set of genes was also subject to mRNA expression change
analysis. We screened the 18 mouse cell lines with a few selected target therapy
agents, and performed combination assays of these agents together with check
point inhibitors such as aPD1, aPDL1, in a co-culture systemwithmouse T cells.
An IncuCyte real-time imaging platform was used to distinguish activities on T
cells and tumor cells. The results and the implications will be discussed.
#5598 Adenosine signaling through A2AR limits the effıcacy of anti-
CTLA4 and chemotherapy in preclinical models. Po Ho, Meng-Yin Hsieh,
Andrew Hotson, Richard Miller, Ian McCaffery, Stephen Willingham. Corvus
Pharmaceuticals, Burlingame, CA.
Elevated levels of extracellular adenosine within the tumor microenviron-
ment create an immunosuppressive niche that promotes tumor growth and
metastasis. Adenosine signaling via the A2A receptor (A2AR) on immune cells
suppresses anti-tumor immunity and has been shown to limit the effıcacy of
immunotherapies such as anti-PD-L1 or anti-PD-1 monoclonal antibodies
(mAbs). CPI-444 is a potent and selective oral A2AR antagonist that is currently
being investigated in Phase 1/1b clinical trials alone and in combination with an
anti-PD-L1 antibody (Atezolizumab) in selected solid tumors. New preclinical
data suggests that combining CPI-444 with anti-CTLA-4 mAbs as well as che-
motherapy treatment are also promising therapeutic strategies in solid tumors,
suggesting a broad role for adenosine as an immune suppressive mechanism.
The effıcacy of CPI-444 anti-CTLA-4mAb treatment was evaluated inMC38
and CT26 syngeneic mouse tumor models. In CT26, combination treatment
eliminated established tumors in up to 90% ofmice approximately 2 weeks after
treatment was initiated. InMC38, combination CPI-444 and anti-CTLA-4mAb
treatment prolonged survival of 80% ofmice compared to only 40% ofmice that
received CPI-444 or anti-CTLA-4 mAbs alone. The effect of CPI-444  anti-
CTLA-4 treatment on T-cell proliferation, T cell activation, and TREG function
will be discussed. Chemotherapy releases adenosine and ATP into the tumor
microenvironment (TME). Multiple chemotherapies have also been shown to
up-regulate the ecto-enzymes CD39 and CD73 that produce adenosine and
further suppress immune function. In the MC38 model, CPI-444 treatment
synergized with doxorubicin and eliminated established tumors 80% of treated
mice. CPI-444 treatment was also synergistic with cyclophosphamide, inhibit-
ing the growth of RENCA tumors, a model that is considered resistant to che-
motherapy. Ongoing studies are evaluating the effect of CPI-444 chemother-
apy on tumor infıltrating lymphocyte localization, activation, and expression of
CD73 and CD39. These results suggest that blockade of the adenosine signaling
pathway may be vital for enhancing anti-tumor responses in solid tumors that
show an incomplete response to anti-CTLA4 therapy or chemotherapy.
IMMUNOLOGY: Immune Checkpoints and Immunosurveillance
#5599 Soluble PD-L1 as a surrogate biomarker of metastatic progression
and resistance to antiangiogenic therapy. Michalis Mastri,1 Amanda Tracz,1
Yuhao Shi,2 Georg Bjarnason,3 Tran Nguyen,2 Brian Rini,4 John M.L. Ebos1.
1Roswell Park Cancer Institute, Buffalo, NY; 2State University of New York, Uni-
versity at Buffalo, Buffalo, NY; 3University of Toronto, Toronto,Ontario, Canada;
4Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
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Immune-checkpoint inhibitors are now approved for the treatment of early- and
late-stage cancers. These include agents that block theT-cell regulatory protein pro-
grammed cell death 1 (PD-1) from being activated by the PD-1 ligand 1 (PD-L1)
expressed on cancer cells. There is an urgent need to identify biomarkers of PD-1
pathway inhibition that would predict patient populations responsive to treatment
and/or serve as surrogates for drug activity and resistance. PD-L1 expression on
tumors is currently a biomarker candidate, but reliable detection and quantifıcation
methodologies have proven challenging to standardize. Recently, a soluble PD-L1
(sPD-L1) fragment was identifıed that can derive from cell-bound PD-L1. Retro-
spective clinical examinations of sPD-L1 levels in cancer patients suggest a potential
use as a surrogate for disease progression and response to treatment; but few pre-
clinical studies have been performed to test this predictive value. We undertook
experiments to evaluate plasma sPD-L1 in mouse tumor models during localized
primary tumor growth (after orthotopic cell implantation) and spontaneous meta-
static disease progression (after surgical removal of the primary). Mouse syngeneic
andhumanxenograft implantationmodels includedbreast, kidney, colon, andmel-
anoma cell systems. Our results show that circulating plasma sPD-L1 can correlate
withprimaryandmetastaticprogression inastageandmodel specifıcmanner.Next,
we evaluated sPD-L1 following treatment with neutralizing antibodies to PD-1 and
PD-L1 in tumor-freemice and found signifıcant dose-dependent sPD-L1 increases,
suggesting systemic changesmay have utility as ameasurement of target saturation
and dosing independent of tumor growth. Finally, with current approvals of PD-1
inhibitors in renal cell carcinoma (RCC) patients previously treatedwith antiangio-
genic agents that block vascular endothelial growth factor (VEGF), we evaluated
plasma in mouse models of sunitinib resistance - a VEGF receptor tyrosine kinase
inhibitor (RTKI). Our results demonstrate that VEGF pathway resistance yields
changes in sPD-L1 andmay be useful in predicting response to PD-1 pathway inhi-
bition in therefractorysetting.Together, these investigationssuggest thatcirculating
sPD-L1changesduringdiseaseprogression(both local anddisseminated)mayserve
as a potential predictive biomarker for immune-checkpoint and antiangiogenic
therapy.
#5600 Simultaneous measurement and clinical signifıcance of PD-1,
LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC). Ila J. Datar,1 Jun
Wang,1 Nikita Mani,1 Franz Villarroel-Espindola,1 Patrick Ryan,1 Miguel F.
Sanmamed,1 Kristen McEachern,2 David Jenkins,2 David L. Rimm,1 Leiping
Chen,1 Roy Herbst,1 Kurt Schalper1. 1Yale School of Medicine, New Haven, CT;
2TESARO, Inc, Waltham, MA.
Introduction: The ineffective anti-tumor immune response is characterized
by increased immune suppressive signals in the tumor microenvironment. In
particular, T-cells recognizing tumor antigens can express diverse immune in-
hibitory receptors mediating lymphocyte inactivation and limiting tumor rejec-
tion. Blockade of these receptors such as PD-1 induces prominent clinical ben-
efıt in patients with NSCLC. However, the expression and signifıcance of
additional potentially actionable immune inhibitory receptors in lung cancer is
poorly understood. Methods: After careful validation of assays and using mul-
tiplexed quantitative immunofluorescence (QIF) wemeasured the levels of CD3
(rabbit polyclonal, Dako), PD-1 (clone EH33, CST), LAG-3 (Clone 17B4, Ab-
cam) and TIM-3 (clone D5D5R, CST) in 698 stages I-IV formalin-fıxed paraffın
embedded (FFPE) lung carcinomas represented in three tissue microarrays (co-
hort #1 [Yale n186], cohort #2 [Yale n192, and cohort #3 [Greece n320]).
We also included a collection of lung adenocarcinomas with molecular annota-
tion (cohort #4 [Yale n106]). The targets were measured in all cells of the
preparation using fluorescence co-localization with DAPI and specifıcally in
CD3-positive T-lymphocytes. Associations between themarkers andwithmajor
clinico-pathological variables, driver mutations and survival were studied. Re-
sults: All the targets were detected predominantly in CD3 T-cells with mem-
branous staining. Expression of PD-1, LAG-3 and TIM-3 in T-cells across all
NSCLC cohorts was 68.7%, 39.7% and 55.8%, respectively. Elevated levels of
PD-1, LAG-3 or TIM-3 were signifıcantly associated with increased tumor in-
fıltrating lymphocytes and with the co-expression of one or more of the other
inhibitory receptors (P0.001). Simultaneous co-expression of all 3 markers
was identifıed in 32.6% of cases. No consistent association was seen between the
targets and patient age, gender, smoking status, clinical stage, tumor histology
and overall survival. PD-1, TIM-3 andCD3 expressionwas signifıcantly lower in
EGFR and KRAS mutant lung adenocarcinomas than in tumors lacking muta-
tions in these oncogenic drivers (P0.05). Conclusion: PD-1, LAG-3 andTIM-3
are differentially expressed in NSCLC, show frequent co-expression and associ-
ation with elevated CD3 T-cells. Our results support the biological role of
PD-1, LAG-3 and TIM-3 in NSCLC and suggest co-activation of these immune
inhibitory pathways in a proportion of cases. Modulation of these receptors
could enhance the anti-tumor immune response in lung cancer.
#5602 Regulation of immune checkpoint genes revealed by a melanoma
tumor cancer genome atlas (TCGA) analysis - potential implications for im-
proving immunotherapy. Raya Leibowitz-Amit,1 Jason Roszik,2 Dror Avni,1
Elizabeth Grimm2. 1Sheba medical center, Tel Hashomer, Israel; 2The University
of Texas MD Anderson Cancer Center, TX.
Introduction: The interface between T lymphocytes and cancer or antigen
presenting cells (C/APCs) is multi-faceted and complex. This interface, now
designated ‘the immunological synapse’, comprises of both co-inhibitory and
co-stimulatory transmembrane protein pairs (‘checkpoint proteins’) that all
serve to modulate the signal transmitted to the T lymphocyte, leading to either
activation, anergy or exhaustion. Immune checkpoint inhibitors have anti-neo-
plastic activity in a wide range of malignancies, but not all cancers and not all
patients with a given cancer respond to the currently available checkpoint in-
hibitors. Micro-RNAs (miRNAs) are short intracellular RNAmolecules known
to bemaster regulators of gene expression.Our aimwas to study the associations
between amiRNA that was previously implicated in cancer and immune check-
point genes. Methods: Bioinformatic analyses of the expression of mRNAs and
miRNAs from451 sampleswas performedusing themelanomaTCGAdatabase.
Correlation coeffıcients between the expression ofmRNAs ormRNAs/miRNAs
were calculated using the Spearman rho method. Survival analysis was per-
formed using the Kaplan-Meier method. Potential 3=UTR binding sites of
miRNAs were found using the web-based tool www.targetscan.org. Results: Of
22 mRNAs of checkpoint genes assessed, the expression of 19 was highly posi-
tively correlated to each other. These mRNAs code for both co-inhibitory and
co-stimulatory proteins at the T cell and the C/APC sides of the immunological
synapse, suggesting that there is joint transcriptional regulation on the expres-
sion of these checkpoint genes. The expression of one specifıc miRNA was also
signifıcantly positively correlated with the expression of eight of these check-
pointmRNAs (PD1L, PD1L, B7.1, ICOS, BTLA, LAG3,CTLA4, TNFRSF9). The
signifıcant positive correlation between this miRNA and B7.1 and PD1L was
verifıed in 18 cell lines in vitro, with rho correlation coeffıcients of 0.72 and 0.61,
respectively (p0.001 and 0.01, respectively). This possibly indicates a joint
transcriptional regulation on this miRNA and the mRNAs. Bioinformatic anal-
yses suggest that this miRNA may potentially target the 3=UTR of 6 of these
mRNAs (PD1, PD1L, B7.1, ICOS, BTLA, TNFRSF9). Data from 163 stage III
melanoma patients with documented survival data show that a high expression
level of this miRNA and a low expression level of either B7.1, B7.2, CD28, ICOS,
ICOSL, OX40, OX40L, TNFRSF18 or PD1L was each signifıcantly associated
with poor prognosis relative to all other expression groups. Eight of these nine
mRNAs are co-stimulatory. Conclusions: It is tempting to speculate that aber-
rant co-regulation of the miRNA-mRNAs, leading to high levels of the miRNA
and low levels of co-stimulatory checkpoint genes is associated with worse out-
come, potentially as a result of ‘immune evasion’ due to decreased co-stimula-
tion at the synapse.
#5603 Melanoma PD1 expression is upregulated by MAPK inhibitors
leading to an immune-independent synergism with anti-PD1 antibodies.
Martina Sanlorenzo,1 Igor Vujic,2 Arianna Floris,1 Mauro Novelli,3 Chiara Do-
nini,1 Loretta Gammaitoni,4 Lidia Giraudo,4 Marco Macagno,1 Pietro Qua-
glino,3 Maria Teresa Fierro,3 Silvia Giordano,1 Fabrizio Carnevale-Schianca,4
Massimo Aglietta,1 Dario Sangiolo1. 1University of Torino, Candiolo Cancer In-
stitute IRCCS, Candiolo, Italy; 2Sigmund Freud University, Vienna, Austria;
3University of Torino, Section of Dermatology, Torino, Italy; 4Candiolo Cancer
Institute FPO-IRCCS, Candiolo, Italy.
Background Antibodies blocking the inhibitory checkpoint PD1, expressed
by T lymphocytes, and kinase inhibitors of BRAF andMEK (MAPKi) are main-
stays of current treatment for patientswithmetastaticmelanoma.Mousemodels
point towards a synergistic antitumor activity of anti-PD1-antibodies and
MAPKi, explaining the fındings by an enhanced lymphocytic activity opposing
tumor adaptive resistance. Recently PD1 was found expressed by a subpopula-
tion of melanoma cells where it could mediate tumorigenic effects, but no data
exist showing howMAPKi couldmodulate its expression.We hypothesized that
MAPKi may upregulate PD1 expression and enhance the direct, immune-cell
independent antitumor action of anti-PD1 antibodies.We fırst explore the exact
prevalence andmagnitude of PD1 expression in patients and cell lines. Then we
test the effect of MAPKi on its expression and explore possible immune-inde-
pendent synergisms with anti-PD1-antibodies. Methodology and results. Prev-
alence of PD1 expression by melanoma cells was explored in the Cancer Cell
Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) datasets.
CCLE included 61 melanoma cell lines, which all expressed PD1 (Affymetrix
mRNA 4.20 [3.81- 4.65]) with values comparable to PDL1 (4.63, range 3.73
-7.84) and PDL2 (3.73, range 3.97-8.50). The TCGA analysis included 114 mel-
anomas, excluding those with evidence of immune infıltrate (n256) or stromal
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cells (n100) potentially interfering with PD1 assessment. PD1 mRNA was
expressed by all samples (median FPKMvalues: 64.7, range 0.4-1461.3). Next we
assessed by flow-cytometry themembrane expression of PD1 in 4melanoma cell
lines and 3 patient-derived melanoma cultures, harboring BRAF and NRAS
mutationsWe confırmed that low rates of PD1 were expressed by all melanoma
(median 1.2%, range 0.7- 4.3). The median rate of viable PD1melanoma cells
signifıcantly increased (12.9% range 5.9-20, p0.0180, n 7) following treat-
ment (96h) with MAPKi (dabrafenib and trametinib) but not with chemother-
apy (fotemustine). Longer treatments (8 days) further increased the rate of
PD1

melanoma cells (31.8% range 15.0-50.3, n3) and the effect was reversed
by drug withdrawal. The MAPKi modulatory effect on PD1 expression was
therapeutically exploited in vitro. The addition of PD1 blocking antibody en-
hanced the inhibitory activity of MAPKi on melanoma proliferation (mean in-
hibition rate: 66%vs 40%, n2) in the absence of any immune cells. Conclusions
We report a new expression pattern of PD1 receptor on melanoma and its
potential therapeutic perspective. PD1 is directly expressed by a small but con-
sistent rate of melanoma cells. Treatment with MAPKi signifıcantly enhanced
the rate of PD1 melanoma cells and direct synergism with PD1 blockade was
reported without the involvement of immune response. Our fındings may be
clinical relevant in settings of patients treated with MAPKi.
#5604 Novel biomarkers Ly6E/K play important role in drug resistance
and tumor immune escape. Midar A. Hossiny,1 William R. Frazier,1 Noriko
Steiner,1 Bhaskar Kallakury,1 Rakesh Kumar,2 Geeta Upadhyay1. 1Georgetown
Univ., Washington, DC; 2Georgetown Washington., Washington, DC.
Stem cell antigen Sca-1 is implicated in murine cancer stem cell biology and
breast cancer models, but the role of its human homologs Ly6K and Ly6E in
breast cancer are not established.Herewe report increased expression of Ly6K/E
in human breast cancer specimens correlates with poor overall survival, with an
additional specifıc role for Ly6E in poor therapeutic outcomes. Increased ex-
pression of Ly6K/E also correlated with increased expression of the immune
checkpoint molecules PDL1 and CTLA4, increased tumor-infıltrating T regula-
tory cells, and decreased natural killer (NK) cell activation. Mechanistically,
Ly6K/Ewas required for TGF signaling and proliferation in breast cancer cells,
where they contributed to phosphorylation of Smad1/5 and Smad2/3. Further-
more, Ly6K/E promoted cytokine-induced PDL1 expression and activation and
binding ofNKcells to cancer cells. Finally, we found that Ly6K/E promoted drug
resistance and facilitated immune escape in this setting. Overall, our results
establish a pivotal role for a Ly6K/E signaling axis involving TGF in breast
cancer pathophysiology and drug response, and highlight this signaling axis as a
compelling realm for therapeutic invention.
#5605 Frequencies of HLA-Class I and II alleles betweenGerman patients
with renal cell carcinoma and healthy controls can be different. Steffen Gö-
bel,1 Astrid Kehlen,1 Karen Bluemke,1 Wolfgang Altermann,1 Gerald Schlaf,1
Kersten Fischer,1 Paolo Fornara,1 Bernd Wullich,2 Sven Wach,2 Helge W.
Taubert2. 1Univ. of Halle, Halle, Germany; 2Univ. of Erlangen, Erlangen, Ger-
many.
The human leukocyte antigen (HLA) system is a major part of the human
immune system and has an impact on tumor initiation, tumor progression and
immunosurveillance. Renal cell carcinoma tumors are considered to be immu-
nogenic. Therefore, we studied the allele frequencies of four gene loci (HLA-A,
-B, -C and HLA-DR) in a cohort of 106 German renal cell carcinoma (RCC)
patients and in 201 healthy controls. HLA-A-C were determined using serolog-
ical methods, whereas HLA-C12, C14, C16, C18 and HLA-DR were character-
ized through the use of standard molecular biological methods. The presence of
HLA-A andHLA-B alleles did not differ signifıcantly between RCCpatients and
healthy controls. However, the occurrence of the HLA-C*12 allele was signifı-
cantly increased in German RCC patients compared with healthy controls (P
0.005; RR2.3; Fisher’s exact test), whereas the occurrence of the HLA-
DRB1*04 allele was signifıcantly reduced in RCC patients compared with
healthy controls (P 0.05; RR0.7; Fisher’s exact test). But the presence of allele
HLA-C*12 was not signifıcantly associated with 10 years overall survival. We
suggest that the frequency of HLA alleles can affect development of RCC and
could add knowledge as predictive marker for future immunotherapies.
#5606 Fibrinogen-like protein 2 drives malignant tumor progression in
glioma. Khatri Latha,1 Jun Yan,1 Yuhui Yang,1 Loyola V. Gressot,2 Lingyuan
Kong,1 Ganiraju Manyam,1 Ravesanker Ezhilarasan,1 Qianghu Wang,1 Erik P.
Sulman,1 Jingda Xu,1 Richard E. Davis,1 Suyun Huang,1 Gregory N. Fuller,1
Arvind Rao,1 Amy B. Heimberger,1 Shulin Li,1 Ganesh Rao1. 1MD Anderson
Cancer Center, Houston, TX; 2Baylor College of Medicine, Houston, TX.
Gliomas are the most common type of brain tumor in both children and
adults. Several low-grade gliomas (LGG) have the ability to progress into more
aggressive tumors -high-grade gliomas (HGG) including glioblastoma (GB).
Although patients harboring a LGGmay survive for years, after the tumor trans-
forms to HGG, life expectancy rapidly declines to 12 to 15 months in adults and
40 months in children. Thus, inhibiting this process of malignant transforma-
tion (MT) is an attractive therapeutic strategy because of the more indolent
course associated with LGGs. Immune response plays a critical role in surveil-
lance against malignant transformation. Our previous study shows that fıbrin-
ogen-like protein 2 (FGL2) is a key hub of tumor-mediated immune suppres-
sion. Hence, we investigated the role of FGL2 in promoting tumor progression
from LGG to HGG in glioma. Analysis of TCGA expression data showed that
increased FGL2 expression is associated with poorer survival in LGG and GB
patients. And there is a positive correlation of expression level between FGL2
and mesenchymal glioma marker CD44, and a negative correlation between
FGL2 and proneural gliomamarkerOLIG2. Engineered expression of FGL2 in a
PDGFB-dependentmousemodel of oligodendroglioma, a common glioma sub-
type, yielded a signifıcantly higher rate of HGGs (72% vs 29%, p0.034) and
poorer-symptom free survival (63 vs 90 days, p0.003) than PDGFB expression
alone. And HGGs from FGL2 PDGFB expressing mice exhibited a distinct
mesenchymal phenotype validating TCGA data. Further, FGL2 induced high
numbers of CD4FoxP3 cells from an early time point of tumor formation
underscoring its role in tumor progression. And FGL2 overexpression educated
M2 skew in the tumors characterized by high expression of Iba1 and Arginase1
in macrophages. Finally, treatment with anti-FGL2 antibody signifıcantly im-
proves survival in mice, shifts the phenotype from mesenchymal HGG to pro-
neural LGG, and rescues M2 macrophage skewing. Our results show that FGL2
is critical for malignant progression of glioma by inducing immunosuppression
in tumor microenvironment, and raise the potential of FGL2 to be a promising
target to suppress/reverse glioma progression and provide survival benefıt in
clinical.
#5607 Copy-number profıling of single, digitally-sorted PD-L1 positive
cells in NSCLC FFPE tissues.Giulio Bassi, Chiara Bolognesi, ChiaraMangano,
Claudio Forcato, Alberto Ferrarini, Valentina Del Monaco, Paola Tononi,
Genny Buson, Gianni Medoro, Manaresi Nicolò, Francesca Fontana.Menarini
Silicon Biosystems, Castel Maggiore, Italy.
Introduction: Immune system strongly affects cancer cell fate; indeed, im-
mune-checkpoint blockade is emerging as an effective therapeutic strategy in a
broad range of tumor types. The effectiveness of these therapies depends on
different aspects of tumor biology such as the expression of immune checkpoint
proteins, the presence of infıltrating active immune cells and many others. To
date, a robust biomarker to predict therapeutic response to these drugs has not
been found yet. Among all the strategies used to identify effective biomarkers, a
single-cell level molecular profıling of tumor, stromal and infıltrating cells, has
not been explored due to technical challenges. Here we present amethod for the
digital isolation of single PD-L1 cells from FFPE tissues, along with their
genetic characterization for the identifıcation of novel biomarkers. Methods:
FFPE tissue sections from two NSCLC patients, were independently tested for
PD-L1 expression using IHC VENTANA PD-L1 (SP142) Assay and scored in
terms of tumor content (30%, 85%), percentage of PD-L1 positive tumor cells
(70%, 95%), PD-L1 intensity, and H-score (130, 175). From the same tissue
blocks, additional FFPE sections were dissociated down to cell suspension, and
immunofluorescently labelled using Keratin-AlexaFluor®488, Vimentin-Alex-
aFluor®647 and PD-L1 (clone SP263)-AlexaFluor®546. Four cell populations
(KeratinPD-L1-, KeratinPD-L1, VimentinPD-L1- and VimentinPD-
L1) were identifıed at theDEPArray™ platform and, for each, we isolated pools
of precise number (range 43-121) of cells, alongwith pure single cells. Recovered
cells were whole genome amplifıed (Ampli1™ WGA), and genome-wide copy-
number aberrations (CNA) profıles were obtained by Ampli1™ LowPass kit and
IonTorrent sequencing. Results: The expression of PD-L1 on cellmembranewas
attributed -bymeans of co-expression of either keratin or vimentin- to tumor or
stromal cells, respectively. For both patients, in the tumor populations numer-
ous gains and losseswere clearly identifıed along the genome;KeratinPD-L1
and KeratinPD-L1- pooled cells displayed comparable profıles. Notably, in
both patients copy gains were identifıed on chromosome 9 region including the
PD-L1 gene. A variable range of alleles (3 to 6) on the same PD-L1 locus was
detected on single tumor cells, alongwith a high inter-cell heterogeneity in terms
of gain extent and genomic regions involved, suggestive of the presence of dif-
ferent tumor clones, hidden in pooled cells data. All the stromal
(VimentinPD-L1/-) cells showed flat profıles. Conclusions: This study dem-
onstrates an innovative approach for isolation and genetic profıling of single
pure PD-L1 cells from FFPE tissue. DEPArray™ sorting combined with low-
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pass whole genome sequencing enables high quality genome-wide profıling of
pure single cells and pools isolated from phenotypically distinct populations in
FFPE tumor tissue.
#5608 Correlation of phosphatase activity with lymphocyte infıltrates in
metastatic renal cell carcinoma tissues. Rob Ruijtenbeek,1 Liesbeth Houkes-
van Kerkhoff,1 Jeannette Oosterwijk,2 Liesbeth Hovestad-Bijl1,1 Riet Hilhorst,1
Alejandro H. Gomez,3 Juan F. Rodriguez,3 Jesus Garcia-Donas,3 Bart Kieme-
ney,2 Egbert Oosterwijk2. 1PamGene International B.V., BJ’s-Hertogenbosch,
Netherlands; 2RadboudUniversityMedical Center,Nijmegen,Netherlands; 3Cen-
tro integral oncológico Clara Campal, Madrid, Spain.
Introduction: Protein tyrosine phosphatases (PTPs) are important regulators
of signal transduction in immune cells. While most analytical methods focus on
the detection of these crucial enzymes at the RNA or protein level, a methodwas
lacking to monitor multiple enzymatic activities in patient-derived materials
like blood and (tumor) tissues. Such a substrate-specifıc assay is a new tool for
biomarker discovery in immuno-oncology (I-O), because the I-O targets -
checkpoint and immune receptors like PD1, CTLA4, LAG3, 4-1BB, CD40,
CD20, OX40, TIGIT andGITR - are controlled by phosphatases. The aim of this
study was to develop a multiplex PTP assay and investigate the phosphatase
activity in metastatic renal cell carcinoma (mRCC) tissues with high and low
levels of TILs (tumor-infıltrating lymphocytes). Methods: On the basis of hema-
toxylin and eosin staining ofmRCC tissues, 9 tissues with high TILS-scores were
selected, as well as 10 tissueswithout TILS,matched on basis of the percentage of
viable tumor cells. The technology used is a second generation peptide microar-
ray, which is fully automated with short turnaround times and a high through-
put of clinical samples in a 96-well setup. Arrays comprise 46 unique nitrophos-
photyrosine containing peptides derived from known phosphosites. When a
clinical sample is applied to this peptide microarray, this will lead to a pattern of
peptide dephosphorylations, which is monitored in real time (kinetic readout).
Results: The PTP assay was fırst developed for PBMC profıling. 0.10 ug protein/
array was used, corresponding to 10000 cells. The signals were concentration
dependent and could be inhibited by PTP inhibitors. For tissue profıling 2.0 g
protein input (0.02mm3 tissue) was used. A 2-group comparison analysis of the
phosphatase activity in tissues with high scores of TILs (massive infıltration,
N9) vs. without (N10), revealed that 29 of 46 peptide substrates showed
signifıcantly higher dephosphorylation (PTP) activities in the tissues with high
levels of lymphocyte infıltrates. A PCA revealed a clear separation between the
groups of high and low TILS scores. Discriminating phosphosites (p0.0002)
were derived from the following 10 signaling proteins RET, ERBB2, PAXI, PG-
FRB, CBL, FRK, PDPK1, INSR, PECA1 and the T-cell kinase LCK. Conclusions:
Proof of concept was shown in mRCC samples that high PTP activity correlates
with high levels of TILS. As a TILS-score itself is already regarded to be a candi-
date biomarker for I-O therapy response, the observed correlation is a basis
for the development of more mechanistic biomarkers predicting therapy re-
sponse. Thismethod can be a starting point for the development of an enzymatic
and thus sensitive and quantitative TILS test. This study has received funding
from the European Union’s Seventh Framework Programme (FP7/2007-2013)
under grant agreement no 259939.
#5609 Macrophages in secondary lymphoid organs regulate t cell toler-
ance and immunosurveillance in pancreatic cancer. Fee Bengsch, Anni Liu,
Kathleen Graham, Gregory L. Beatty. UPenn, Philadelphia, PA.
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that shows
striking resistance to standard therapies. Immunotherapy is an exciting new
treatment strategy for PDAC, but has yet to reproducibly demonstrate clinical
effıcacy. This fınding may reflect poor effector T cell infıltration into PDAC or
mechanisms of peripheral T cell tolerance. We hypothesize that successful im-
munotherapy in PDAC will require strategies that reverse elements of innate
immunity that regulate T cell tolerance. This hypothesis is based on our prior
studies in the KrasG12D/;Trp53R172H/;Pdx-1-Cre (KPC) mouse model of
PDAC where macrophages residing outside of the tumor microenvironment
were found to regulate the effıcacy of a vaccine strategy involving the combina-
tion of chemotherapy and a CD40 agonist (FGK45). Specifıcally, we found that
depletion of peripheral phagocytes using clodronate-encapsulated liposomes
(CEL) was necessary for gemcitabine chemotherapy and a CD40 agonist to in-
duce productive anti-tumor T cell immunity against spontaneously arising
PDAC tumors in the KPCmodel. We now investigate the mechanism by which
CEL-depleted phagocytes regulate T cell tolerance in PDAC using the KPC
mouse model and an orthotopic implantation model. We found that CEL de-
pletesmacrophages in the spleen and abdominal lymphnodes, thereby reversing
the pathologic accumulation of macrophages in these secondary lymphoid or-
gans that is induced by PDAC tumors. CEL targeted twomacrophage subsets in
the lymph node, CD11bCD169F4/80neg subcapsular sinus macrophages
(SSM) and CD11bCD169F4/80 medullary sinus macrophages (MSM).
These macrophage populations may be exposed to tumor-derived antigens and
apoptotic cell vesicles entering the lymph node, and have been previously iden-
tifıed as central orchestrators of tolerance in autoimmune models. We found
that both fluorescently-labeled liposomes and OVA-FITC peptide injected into
the peritoneal cavity were specifıcally targeted to SSM and MSM with little
uptake by dendritic cells (DC). In contrast, depletion of these fırst-line phago-
cytes by CEL shifted the cellular uptake of these model antigens increasing up-
take by CD11bCD11c DC which are more effıcient in antigen presentation
and show increased expression of co-stimulatory molecules after FGK45 treat-
ment. Using an orthotopic model of PDAC, we then determined that CEL can
enhance the T cell stimulatory capacity of gemcitabine chemotherapy in com-
binationwith FGK45 as seen by a signifıcant increase in CD38, CD44, CD69 and
PD-1 expression on CD4 and CD8 T cells in secondary lymphoid organs. To-
gether, our fındings suggest that tumor-derived antigens may be sequestered by
tolerogenicmacrophages in peritumoral lymph nodes that act to impair optimal
induction of T cell responses. Thus, strategies aimed at disrupting the tolero-
genic functions of thesemacrophagesmay offer a novel approach for improving
immunotherapy in PDAC.
#5610 Quantitative cell-based bioassays to advance individual or combi-
nation immune checkpoint immunotherapy. Jamison Grailer, Pete Stecha,
Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong, Zhi-jie Jey Cheng. Promega
Corp., Madison, WI.
Immune checkpoint receptors play a critical role in maintaining immune
homeostasis and are genetically and functionally associated with autoimmune
disease, cancer and persistent viral infections. Blockade of immune checkpoints
(e.g., PD-1 and CTLA-4) has emerged as a promising new approach to enhance
anti-tumor immune responses. While immunotherapies directed against PD-1
and CTLA-4 are showing unprecedented effıcacy in the treatment of cancer,
many patients and tumor types remain refractory to these therapies. This has
resulted in a broadening of immunotherapy research and development to in-
clude additional immune checkpoint receptors (e.g., LAG-3, TIGIT, CD112R)
targeted individually or in combinationwith other immunotherapy strategies. A
major challenge in the development of biologics that target immune checkpoints
is access to quantitative and reproducible functional bioassays. Existing meth-
ods rely on primary cells and measurement of complex functional endpoints.
These assays are cumbersome, highly variable, and fail to yield the quality of data
that is required for drug development in a quality-controlled environment. To
address this need, we have developed a suite of immune cell line-based biolumi-
nescent reporter bioassays for individual and combination immune checkpoint
immunotherapy targets including PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3,
TIGIT, PD-1TIGIT and more. These assays consist of stable cell lines that
express luciferase reporters driven by specifıc response elements under the pre-
cise control of intracellular signals mediated by the T cell receptor and immune
checkpoint target(s). These mechanism of action-based bioassays are available
in “thaw-and-use” format and demonstrate high specifıcity, sensitivity and re-
producibility. The bioassays are pre-qualifıed according to ICH guidelines and
demonstrate the performance required for use in antibody screening, potency
testing and stability studies.
#5611 Use of ecto-domain vimentin to target brain cancers. Ivan Babic,1
RajeshMukthavaram,1 Pengfei Jiang,1 Eric Glassy,2 NatsukoNomura,1 Sandeep
Pingle,1 Mark C. Glassy,3 Santosh Kesari1. 1JohnWayne Cancer Institute, Santa
Monica, CA; 2Pathology, Inc., Torrance, CA; 3Nascent Biotech, Inc., San Diego,
CA.
Pritumumab is a natural human IgG1 kappa antibody derived from a regional
draining lymph node of a patient with cervical carcinoma. The recognized an-
tigen is an altered form of vimentin, called ecto-domain vimentin (EDV), that is
expressed on the cell surface of epithelial tumor cells. For brain cancers, immu-
nohistological analysis showed the binding of pritumumab to EDV to be re-
stricted to tumor cells and not normal cells and tissues suggesting EDV may be
a useful biomarker. A recombinant version of the mAb was made using the
GPEx® system in CHO cells that showed comparable binding activity by flow
cytometry, immunohistochemical analysis, Western blot analysis, and Anti-
body-Dependent Cell-Mediated Cytotoxicity (ADCC; EC50 of 39.6ng/ml) ac-
tivity. Further studies include establishing xenograftmodelswith both SCIDand
athymic nude mice in which pritumumab was effective in preventing tumor
growth of both brain cancer stem cells as well as pancreatic cancer in nude mice
but not in SCID mice suggesting an active immune response is necessary for
optimal treatment. Analysis of a blood brain barrier model suggests pritu-
mumab shows minimal distribution in normal brain tissues and signifıcant
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binding in tumor areas of brain tissues indicating the mAb crosses the tumor
brain barrier. Overall, these data together suggest that EDV is a suitable target
and biomarker for brain cancers.
#5612 Cancer-immune interactions in luminal breast cancers: PI3KCA
mutations, PI3K/AKT/mTOR activation and tumor-infıltrating lympho-
cytes. Marcelo Sobral-Leite,1 Izhar Salomon,1 Mark Opdam,1 Karin Beelen,1
Ronald L. van Vlierberghe,2 Erik J. Blok,2 Hugo M. Horlings,1 Joyce Sanders,1
Koen Van de Vijver,1 Peter J. Kuppen,2 Sabine Linn,1 Marjanka K. Schmidt,1
MarleenKok1. 1TheNetherlands Cancer Institute, Amsterdam,Netherlands; 2Le-
iden University Medical Center, Leiden, Netherlands.
Introduction: Therapy resistance to adjuvant tamoxifen in estrogen receptor
positive (ER) breast cancer (BC) is related to activation of downstream pro-
teins in the PI3K/AKT/mTOR pathway. However, clinical effıcacy of mTOR
inhibitors has so far been modest. Growing evidence shows that genomic
make-up of cancer cells plays a crucial role in an anti-cancer immune response
and this is reflected in the presence of tumor infıltrating immune cells. This begs
the need for understanding the relationship between tumor-related immune
activity, PIK3CA hot-spot mutations (PIK3CAm) and PI3K/AKT/mTOR path-
way activation in ERBC. Material and methods: The IKA trial recruited stage
I to III postmenopausal BC patients (1982 till 1994), who were randomized to
tamoxifen or no adjuvant therapy. Sequenom mass spectrometry-based geno-
typing was used for PIK3CAm assessment. Immune markers and phosphoryla-
tion status of proteins in the PI3K/AKT/mTOR pathway [p-AKT (Thr308 and
473), p-mTOR, p-ERK1/2, p-p-70S6K and p-4EBP1] were assessed by immuno-
histochemistry and scored by two pathologists. Expression of CD4, CD8 and
FOXP3 was evaluated using automatic scoring by image-analysis software
(SlidePath® or AxioVision®) and compared with manual scoring by two pathol-
ogists. Associations were assessed using multivariable logistic regression mod-
els, including as co-variables: age, tumor grade, lymph node status, tumor size,
and progesterone receptor and HER2 status. Results: We included 563 ERBC
cases. PIK3CAm were found in 159 (32%) of the 486 tumors genotyped. On
average, PI3K/AKT/mTOR downstream proteins and immune markers were
scored in 409 tumors (range: 366 to 438). Stromal CD8 expression, but not CD4
or FOXP3, was signifıcantly higher in PIK3CA mutated tumors (OR1.11;
95%CI: 1.02-1.22). Stromal FOXP3 expression, but not CD4 or CD8, was signif-
icantly increased in tumors with activated proteins from the PI3K/AKT/mTOR
pathway (except p-mTOR). The largest association was with p-4EBP1
(OR1.34; 95%CI: 1.21-1.48) and smallest with p-70S6K (OR1.15; 95%CI:
1.08-1.22). Conclusion: In our dataset of ERBC, PIK3CAmare associatedwith
higher level of CD8 T cells. Tumors with activation of the PI3K/Akt/mTOR
pathway tend to have more FOXP3 T cells. Together, our results suggest that
PIK3CA mutation/activation harbor an immune-related tumor microenviron-
ment.
#5613 PD-1 and TIGIT are major immune checkpoint receptors ex-
pressed in breast cancer-infıltrating T cells. Jee YeKim,1MinsukKwon,2 Sung
Mook Lim,1 Joo Heung Kim,1 Hyung Seok Park,1 Seho Park,1 Seung Il Kim,1
YoungUpCho,1 Soonmyung Paik,1 Eui-Cheol Shin2. 1Yonsei University College
of Medicine, Seoul, Republic of Korea; 2KAIST, Daejeon, Republic of Korea.
Immune checkpoint blockers, which target co-inhibitory receptors of T cells,
have provided promising responses against various tumors. However, the ex-
pression of immune checkpoint receptors (ICRs) in breast cancer remains
poorly understood. We aimed to investigate the expression pattern of multiple
ICRs in tumor-infıltrating and peripheral blood (PB) lymphocytes in human
breast cancer. We isolated lymphocytes from fresh breast tumor and paired PB
from 21 patients who underwent surgery between July 2016 and November
2016. Multi-color flow cytometry was performed primarily focusing on expres-
sion of multiple ICRs in CD8 T cells and regulatory T cells (Tregs). In CD8 T
cell subsets, PD-1 or TIGIT cells were more frequently observed in tumor-
infıltrating CD8 T cells than in PB CD8 T cells (p0.0001 and p0.02, re-
spectively). Around half of the tumor infıltrating CD8 T cells expressed PD-1
(median 58.20%) and TIGIT (45.95 %). In contrast, LAG3 and TIM3 were
hardly detected in both tumor-infıltrating and PB CD8 T cells. Intriguingly,
about 40% of tumor-infıltrating CD8 T cells were PD-1TIGIT, and70%
of PD-1 tumor-infıltrating CD8 T cells co-expressed TIGIT, indicating that
functional exhaustion of breast tumor-infıltrating CD8 T cells might be medi-
ated not by PD-1 alone but bymultiple receptors includingTIGIT.However, the
expression of PD-1 and TIGIT showed different patterns in detail. PD-1 was
frequently expressed by CCR7-CD45RA- effector memory T cells (TEM)
(p0.001) whereas TIGIT was frequently expressed by CCR7-CD45RA effec-
tor memory RA T cells (TEMRA) (p0.03), suggesting that TIGIT is expressed
during terminal differentiation of CD8 T cells. Next, we examined breast tu-
mor-infıltrating Tregs. The frequency of CD25FoxP3 Tregs among CD4 T
cells were higher in tumor than in PB (16.60%vs. 7.86%; p0.002). In particular,
CD45RA-FoxP3hi activated suppressive Tregs account for 77.6% of tumor-infıl-
trating Tregs (vs. PB 32.2%; p0.005). Tumor-infıltrating Tregs showed higher
expression of CD39 (p0.005), amarker of the suppressive activity of Tregs.We
also examined the expression of ICRs onTregs as upregulation of these receptors
is associated with enhanced suppressive activity of Tregs. CD4CD25FoxP3
Tregs in tumors showed higher expression levels of PD-1, TIGIT and CTLA-4
compared to PB Tregs (p0.05). There were no noteworthy correlations be-
tween ICR expression and clinical features, such as age, stage and subtype. We
show that PD-1 and TIGIT are major ICRs expressed in breast tumor-infıltrat-
ing CD8 T cells. Moreover, we found that CD4CD25FoxP3 Tregs are
abundant in breast tumors and overexpress PD-1, TIGIT andCTLA-4. Our data
provide an understanding of comprehensive phenotypes of immune checkpoint
expression on T cells in breast cancer. Functional changes of CD8 T cells and
Tregs by blocking of single or multiple ICRs are being investigated.
#5614 NovelmRNApurifıcationmethodwith RNaseIII improves effıcacy
of RNA chimeric antigen receptor T cells. Jessica Foster, Namrata Choudhari,
Adam Resnick, David Barrett. The Children’s Hospital of Philadelphia, Philadel-
phia, PA.
Chimeric Antigen Receptor (CAR) T-cells madewithmRNAoffer a transient
and safe alternative to viral CARs, mitigating the concern for persistent un-
wanted side effects from constitutively active T-cells. Previous studies have
shown that mRNACARs are transiently effective, but lack CAR persistence and
have struggled to show success across tumor types.We hypothesized the effıcacy
of mRNA CARs could be improved by utilizing recent advancements in RNA
technology including the use ofmodifıed uracil and a novel purifıcationmethod
with RNaseIII to prevent double stranding that induces toxicity. Using the es-
tablished CD19 CAR model in B-cell acute lymphoblastic leukemia, we created
mRNA CARs using previously described methods and compared them to
mRNACARs created usingmodifıcation of uracil and/or purifıcation to remove
any aberrant double stranded mRNA. Comparing the modifıed and purifıed
mRNA CAR T cells to those created using prior methods of making mRNA,
both modifıed and purifıed mRNA CAR T cells showed a two-fold increase in
expression of the CAR on their surface initially, as well as a two-fold improve-
ment in cytotoxic killing of leukemia cells in vitro that persisted for up to fıve
days. Both the modifıed and purifıed mRNA CAR T cells also showed reduced
expression of negative checkpoint regulators compared to original RNACAR T
cells. However, in vivo studies using a patient-derived xenograft model with a
single dose of CAR T cells revealed purifıed RNA CAR T cells offered the most
robust 2-log enhanced suppression of leukemic burden. RNaseIII is a novel
purifıcation technique that has not yet been reported in the literature for RNA
manufacturing.Our results provide a time effıcient purifıcationmethod that can
be easily incorporated into RNA production for use in clinical trials, and poise
RNA CARs for increased effıcacy as new CAR targets emerge and are being
tested. Additional studies are ongoing investigating if the observed improved
effıcacy will translate to improved cytotoxicity in solid tumor models.
#5615 Genomic differential expression analysis of fusion proteins incor-
porating the pro-apoptotic molecule Granzyme B reveals new potential tar-
gets for treatment of breast cancer. Khalid A. Mohamedali, Lawrence H.
Cheung, Ana Alvarez-Cienfuegos, Michael G. Rosenblum. UT MD Anderson
Cancer Center, Houston, TX.
Granzyme B (GrB) is a member of the serine protease family of enzymes that
play a critical role in the body’s defense against viral infection and tumor devel-
opment. Cytotoxic T lymphocyctes (CTL) and natural killer (NK) cells directly
deliver granzymes to target cells, which induces apoptosis through both caspase-
dependent and caspase-independent multiple-cascade mechanisms. Anti-tu-
mor effıcacy studies have suggested that the targeted delivery of human Gran-
zyme B to tumor cells has a signifıcant potential for cancer treatment. We had
previously developed a novel fusion construct composed of theVEGF121 growth
factor and human GrB. The GrB/VEGF121 construct was found to be highly
cytotoxic to vascular endothelial cells expressing the R2 (KDR) receptor for
VEGF. In this study, we examined the mechanism of GrB/VEGF121-induced
cytotoxicity against cells in culture at the genomic level. The TNBC cell line
MDA-MB-231 was treated with an IC50 dose of GrB/VEGF121 for 24 hours; the
cells were then harvested and the effect of GrB/VEGF121 on intracellular events
was examined by extraction of mRNA followed by microarray analysis. Gene-
level differential expression analysis revealed that a total of twenty genes were
upregulated by over 3-fold, while 25 were downregulated 3-fold or more. These
included genes involved in signal transduction, stress response, cell cycle con-
trol, hypoxia and metastasis. Particularly impacted were the Nuclear Receptors
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Meta pathway, NRF2 pathway, nuclear receptors in lipid metabolism and tox-
icity, matrix metalloproteinases, and the notch signaling pathway. Validated
data will be reported following complete analysis of gene level differential ex-
pression and alternative splicing. Our data suggests that GrB/VEGF121 induces
expression of genes known to be induced by VEGF alone, as well as molecules
previously not associated with either Granzyme B or VEGF.This data suggests a
previously unsuspected impact of the serine protease GrB on various molecular
pathways within the cell and may lead to a new understanding of how these
agents operate at the molecular level. Research conducted, in part, by the Clay-
ton Foundation for Research.
#5616 Activation of CD137/CD137L results in reduced tumor cell prolif-
eration in human colon cancer. Tanja Grimmig, Simone Callies, Hannes Nae-
gele, Martin Wagner, Romana Moench, Buelent Polat, Christoph-Thomas
Germer, Martin Gasser, Ana Maria Waaga-Gasser. University of Wuerzburg,
Wuerzburg, Germany.
Background: CD137L is expressed on antigen presenting cells and CD137/
CD137L interaction co-stimulates activation and proliferation of CD137 ex-
pressing T cells. CD137L expression has also been detected on various cancer
cells. While signaling in immune cells showed both inhibiting and activating
effects the impact of CD137L induction on tumor cells is poorly understood. In
this study, the expression of CD137 and CD137L and the effects of CD137L
activation were analyzed in human colorectal cancer (CRC). Methods: Expres-
sion of CD137 and CD137L was examined in human colon cancer cell lines
HT29, SW480 and SW620 treated with or without hypoxia using RT-qPCR,
Western blot and FACS analysis. Its differentiated expression was further ana-
lyzed in human CRCs by immunofluorescent double-staining. To dissect the
effects of CD137L activation on cancer cells, MTS proliferation assays were
additionally performed. Results: All three human colon cancer cell lines dem-
onstrated high cellular (FACS) and protein (Western Blot) CD137L expression.
CD137 was found only in SW480 cells at weak expression. Additionally, both
CD137 andCD137Lwere signifıcantly upregulated in cells treatedwith hypoxia.
In human CRCs both CD137 and CD137L expressing tumor cells were detected
by immunofluorescent double-staining. Interestingly, activation of CD137L by
immobilized CD137-Fc resulted in reduced cancer cell proliferation compared
to IgG1-Fc controls. Conclusion: Our results demonstrate tumor cell mediated
expression of the costimulatory molecule CD137 and its ligand CD137L in both
colon cancer cell lines and human colorectal cancer. Moreover, CD137L reverse
signaling was found to reduce cancer cell proliferation in vitro. Based on these
data, the CD137/CD137L signaling pathway seems to present a promising target
for cancer therapy in CRC.
#5617 Combined intratumoral electroporation and allogeneic vaccina-
tion of Gp96-Ig/Fc-OX40L stimulates CD8 T cell cross-priming to tumor
specifıc neoantigens and enhanced anti-tumor response. Suresh de Silva,1
George Fromm,1 Anandaroop Mukhopadhyay,2 Jean Campbell,2 Robert
Pierce,2 Taylor Schreiber1. 1Heat Biologics, Durham, NC; 2Oncosec Medical Inc.,
San Diego, CA.
Growing clinical evidence has unequivocally proven that combination ap-
proaches are leading the way in increasing the overall response rates in cancer
immunotherapy (IT), compared to single agent therapies. Most cancer ITs have
a higher likelihood of succeeding if the targeted tumor has a preexisting state of
inflammation elicited by the combined presentation of shared- and neo-anti-
gens from tumor cells. Certain cancers have been deemed to be non-immuno-
genic due to tumor intrinsic strategies that evade immune recognition. Thus,
novel combination treatment modalities are needed to convert non-immuno-
genic, ‘cold’ tumors into inflamed ’hot’ tumors that are amenable to IT. Gp96-
Ig/Fc-OX40L is a re-engineered molecular chaperone, designed to export and
deliver MHC I-associated antigens to APCs in context of the immune costimu-
lator, OX40L. Allogeneic cancer vaccine cell lines designed to co-secrete
Gp96-Ig and Fc-OX40L, generate antigen-specifıc CD4/CD8 anti-tumor
responses in both highly immunogenic (CT26) and less immunogenic (B16)
mouse tumors (Frommet al., Cancer ImmunolRes, 2016). Such a strategy allows
for Gp96-Ig-mediated chaperoning of antigens from the allogeneic vaccine cell
line (shared antigens), which could benefıt further from increased presentation
of tumor-derived peptides (neo-antigens) that are only accessible if Gp96-Ig/Fc-
OX40L is expressed from within the tumor. To achieve this, we have employed
an in vivo electroporation-based strategy (EP) to deliver Gp96-Ig/Fc-OX40L
expressing DNA to tumor cells in situ. Herein we set out to test whether a
combination approach of intratumoral EP ofGp96-Ig/Fc-OX40LDNAand vac-
cination with allogeneic cells co-secreting the same effector molecules would
lead to enhancedCD4/CD8T cell cross-priming to tumor neo-antigens and
superior anti-tumor activity over the individualmonotherapies in a non-immu-
nogenic B16 tumor model. To assess antigen-specifıc CD8 T cell expansion,
mice were adoptively transferred withOT-I cells after B16-ovalbumin cells were
injected to generate primary and contralateral melanotic tumors. Contralateral
tumors were monitored to assess whether a systemic CD8 T cell response
could be elicited following vaccination and primary tumor EP. The combination
approach lead to a signifıcant synergistic expansion of OT-I cells in tumors and
in the peripheral blood compared to the individualmonotherapies. A synergistic
increase in SIINFEKL-positive CD8 TIL cells was also observed in treated
tumors, which was associated with superior anti-tumor response in both the
EP-treated primary and untreated contralateral tumors. These fındings suggest
that a combination approach of allogeneic vaccination and in situ tumor EP of
Gp96-Ig/Fc-OX40L may have signifıcant benefıt in eliciting a potent immune
response in less-immunogenic tumors.
#5618 Correlation between MET gene amplifıcation and TP53 mutation
in upregulating PD-L1 expression in EGFR wild-type lung cancer. Maher
Albitar, MD, Sucha Sudarsanam, MS, Wanlong Ma, BS, Shiping Jiang, MD,
Wayne Chen, MD, Vincent Funari, PhD, Steven Brodie, PhD, Sally Agersborg,
MD, PhD. NeoGenomics Laboratories, Aliso Viejo, CA.
Introduction: MET gene activation has been reported to be associated with
resistance to EGFR inhibitors in lung cancer. Resistance to EGFR inhibitors is
also reported to be associated with upregulation of PD-L1. We studied PD-L1
expression levelswithMETgene amplifıcation andmutation in EGFR,KRAS, or
TP53 in a large number of primary untreated lung cancers. Methods: Tissue
samples collected from 397 core biopsies or resections from lung cancers were
studied for MET gene amplifıcation by fluorescent in-situ hybridization (FISH)
usingMET (7q31) probe and centromere 7 as a control. Signals were quantifıed.
PD-L1 expression on the same samples was evaluated using clone SP142 and
standard immunohistochemistry (IHC) procedure. Samples were also se-
quenced using next generation sequencing (NGS) formutations in TP53, KRAS,
and EGFR. Results: PD-L1 expression was detected in 166 patients (42%).
Twenty seven (7%) had expression between 1% and 5%, 61 (15%) between 1%
and 20%, 92 (23%) between 1% and 50%, and 105 (26%) had PD-L1  50% in
tumor cells. Ratio of MET: centromere signals was 1.5 in 16 (4%) of patients.
Patients with MET ratio 1.5% had signifıcantly higher (P0.004) percentage
of PD-L1 as a continuous variable as well as when cut-off points of 5% (P0.01),
20% (P0.0006), and 50% (P0.01) were used. Patients with EGFR mutation
had signifıcantly lower levels of PD-L1 expression (P0.003). When a cut-off
point of 50% is used for PD-L1 expression, the EGFR-mutant cases had signifı-
cantly less number of positive cases (P0.0003). There was no correlation be-
tween the presence of High MET: Ratio and EGFR mutation. There was no
correlation between KRAS mutation and overall PD-L1 expression (P0.4).
There was no correlation betweenMET ratio andKRASmutation. Patients with
TP53 mutation had signifıcantly higher MET ratio when a cut-off at 1.5 is used
(P0.01). Also there was signifıcant correlation between TP53 mutation and
overall PD-L1 expression (P0.0001). This remained signifıcant when cut-off
point of 50% or 5% are used (P0.0004 and P0.007, respectively). TP53 mu-
tation was signifıcantly more common in EGFR wild-type cases (P0.0002).
Conclusions: Extra copies of MET gene as detected by FISH testing in therapy-
naïve lung cancer patients is associated with higher expression of PD-L1, while
EGFR-mutant lung cancers had signifıcantly lower expression of PD-L1 when
clone SP142 is used and NGS is used for detecting EGFR mutations. Patients
with TP53 mutation had strikingly high expression of PD-L1 using SP142 clone
and higher copy number of MET gene. This data suggests that in lung cancer,
both MET and TP53 genes play a direct role in regulating PD-L1 expression
opposing the EGFR gene, which appears to suppress PD-L1 expression. KRAS
gene may not be involved in PD-L1 expression in lung cancer.
#5619 Development of a TK1 specifıc chimeric antigen receptor T-cell for
the treatment of non-small-cell lung cancer. Edwin J. Velazquez, Kiara Vaden,
Michelle H. Townsend, Evita G.Weagel, ScottWeber, Richard A. Robison, Kim
L. O’Neill. Brigham Young University, Provo, UT.
Our current research explores the development and tumoricidal activity of
chimeric antigen receptor T-cells targeting a new immunotherapeutic target,
thymidine kinase 1 (TK1), against non-small lung cancer (NSCLC), both in vitro
and in vivo. There has been recent success utilizing CAR T-cell therapy in clin-
ical trials, but it has been mainly focused on the treatment of haematological
malignancies targeting CD19. Lung cancer is the most common cause of cancer
mortality globally and is responsible for more than one million of deaths every
year.Moreover, NSCLC comprises approximately 85% of all lung cancers. Clin-
ical trials against NSCLC using engineered T-cells targeting NY-ESO-1,
VEGFR2,MAGE-A3, andmesothelin are currently ongoing. In spite of efforts to
fınd new molecular targets, CAR T-cell therapy still faces several challenges in
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the treatment of solid malignancies due to the lack of specifıc molecular targets.
We have previously reported the up-regulation of TK1 in multiple malignant
tissues including lung cancer tissues and the presence of TK1 on the cell surface
of different NSCLC cell lines, such asH460 andA549. Flow cytometry, scanning
electron microscopy and confocal microscopy showed evidence of TK1 on the
surface of these cancer cells lines. We have built third generation TK1-CARs
with lentiviral and retroviral vectors. The constructions include a single chain
variable fragment for TK1, a CD28 and 4-1BB moieties connected with a CD3
signaling domain. Confırmation of the CAR expression on transduced humanT
cells was performed by flow cytometry and confocal microscopy, and approxi-
mately 50 % of the transduced T-cells expressed TK1-CARs. Upon co-culturing
TK1-CAR T-cells there was a signifıcant increase in T-cell activity and cancer
cell lysis elevated as high as 48% in comparison to negative controls. Cytokine
profıles revealed a signifıcant increase of the levels of IL-2 and IFN- after 24 hrs
of co-culturing, indicating T-cell activation. TK1-CAR T-cells, untransduced
T-cells, and transduced T-cells with empty vectors were co-cultured with H460
cells and time-lapse videos were recorded, every 5 minutes between 12 and 24
hrs post transduction. Clustering of TK1-CAR T-cells around lung cancer cells
and induction of cell death after T-cell synapsis with target cells was observed.
Preliminary in vitro data has shown that TK1-CAR T-cells induce specifıc cell
lysis in NSCLC cells. In vivo experiments using xenografts models in SNGmice
will be performed. Statistical differences between survival curves of mice treated
with TK1 CART-cells, untransduced T-cells and transduced T-cells with empty
vectors are expected.
#5620 Acquisition of P- and E- selectin binding capacity by effector T cells
is required for the abscopal response following experimental high dose radi-
ation therapy. JosephW. Scarpelli, Ryan S. Lane, JoshuaM.Walker, Charles R.
Thomas, Jeffrey C.Nolz, AmandaW. Lund.OregonHealth& ScienceUniversity,
Portland, OR.
High dose radiation therapy generates systemic adaptive immunity that limits
distal tumor progression and synergizes with immune checkpoint blockade.
Preclinical data demonstrate that ionizing radiation may sensitize otherwise
refractory tumors to immunotherapy through mechanisms of lymphocyte acti-
vation and intratumoral recruitment, however, the molecular mechanisms that
govern this response remain poorly understood. Selectins are critical regulators
of leukocyte traffıcking and migration, and facilitate the compartmentalization
of naïve, effector andmemoryT cells to their respective organ sites. Importantly,
inflamed vascular endothelium expresses P- and E-selectin, which facilitate pe-
ripheral tissue infıltration of effector andmemory lymphocytes. Therefore, both
the acquisition of functional selectin ligands expressed by T cells, as well as
endothelial activation coordinates peripheral tissue infıltration following infec-
tion or tissue injury. In this work we test the hypothesis that the immunogenic
potential of high dose radiation therapy is suffıcient to stimulate synthesis of
selectin ligands onT cells, which is required for their subsequent infıltration into
distal tumors and the abscopal response.We have established a mouse model of
the abscopal effect, where radiotherapy-induced immune mediated-tumor re-
gression is observed at sites distal to the primary, irradiated tumor. B16 F10
murine melanomas expressing model and endogenous antigens are implanted
intradermal on opposing flanks. One day prior to radiation, naïve TCR-trans-
genic CD8 T cells are transferred into tumor bearing mice and 20Gy is deliv-
ered to a single tumor by half beamblock.Using thismodel, we demonstrate that
local high dose radiation therapy is suffıcient to activate and expand naïve tu-
mor-specifıc CD8T cells in the tumor draining lymph node. Following a single
high dose of radiation, tumor-specifıc CD8 T cells become activated and sub-
sequently traffıc to and accumulate in distal, contralateral tumors where they
limit tumor growth, thus recapitulating the clinical observation of the immune-
mediated abscopal effect. Importantly, we demonstrate that high dose radiation
is suffıcient to upregulate selectin family of oligosaccharide binding adhesion
molecules on newly activated antigen-specifıc CD8 T cells. The acquisition of
P- and E-selectin binding capacity by effector CD8 T cells is required for the
abscopal response as administration of selectin blocking antibodies reduced
intratumoral CD8 T cell infıltration and failed to mediate regression of distal
tumors post radiation. Our data demonstrate that the acquisition of P- and
E-selectin ligands requires prior antigenic stimulation and as such, these T cells
represent a completely novel population of tumor-specifıc, homing competent
CD8 T cells that may predict response to therapy in patients.
#5621 Prevalence of GITR expression and pharmacodynamic (PD) bio-
markers in syngeneic tumor models treated by a GITR agonist (GITRL-Fc).
Min Wang, Fiore Cattaruzza, Pete Yeung, Alayne Brunner, Erwan LeScolan,
YuwangLiu, JenniferCain,GilbertOYoung, Earth Light Lowe, BelindaCancilla,
RoseHarris, TimHoey, Austin Gurney, John Lewicki, GretchenArgast, AnnM.
Kapoun. Oncomed Pharmaceuticals, Inc., Redwood City, CA.
GITRL (Glucocorticoid-Induced Tumor Necrosis Factor Receptor Ligand,
TNFSF18) is a member of the tumor necrosis factor (TNF) ligand superfamily.
GITRL binds and activates the co-stimulatory surface receptor GITR, which
promotes proliferation and activation of effector T cells (Teff) and inhibits sup-
pressive activity of regulatory T cells (Treg). It is thus hypothesized that co-
stimulation of GITR by agonist agents will promote anti-tumor immunity. We
generated a novel single-gene GITRL trimer fused to an immunoglobulin Fc
domain (GITRL-Fc) that shows robust single agent antitumor effıcacy and im-
mune effects in multiple syngeneic mouse models, suggesting its potential ben-
efıt in cancer immunotherapy To investigate the prevalence of GITR expression
in human tumors, RNA-Seq data analyses of 33 tumor types in TCGA showed
GITR is highly expressed in a subset of solid tumors, including head & neck,
lung, breast, esophageal, and bladder cancers. In most solid tumors, GITR ex-
pression correlated poorly with T cell markers, implying that GITR may not be
exclusive to immune cells and may be expressed in tumor cells as well. Similar
fındings emerged from RNA-Seq data analysis of patient-derived xenograft
(PDX) samples from24 tumor types. The gene expression datawas corroborated
by immunohistochemistry (IHC) analysis of GITR expression in 17 tumor types
which showed that in addition to immune cells, GITR was expressed on tumor
cell membranes. Amulti-platform approach was taken to investigate GITRL-Fc
pharmacodynamic (PD) biomarkers in tumors and in matched whole blood
samples from mice bearing CT26 colon, 4T1 breast, and B16F10 melanoma
carcinomamodels. Global gene expression levels were profıled bymicroarray on
treated and control tissues. We also monitored the changes of immune cell
populations and cytokine secretions by flow cytometry, Luminex and IHC. Im-
mune gene changesweremore robust in tumors than in blood samples. In tumor
samples, GITRL-Fc increased the gene expression associatedwith T cells, CD8T
cells, cytotoxicity, Th1 cells, interferon gamma (IFN-), natural killer cells, Teff
cells, and T cell activationmarkers. These gene changes were validated by quan-
titative real-time PCR. Similarly, flow cytometry analysis showed thatGITRL-Fc
promoted activation of CD4 effector cells, decreased Treg frequency, and in-
creased the ratio of CD8 T cell/Treg in the tumor. GITRL-Fc also modulated
secretion of cytokines in splenocytes, including an increase in IFN-. Taken
together, the PD biomarker changes in immune-related gene expression, im-
mune cell populations, and cytokine secretions observed in these preclinical
tumor models are consistent with GITRL-Fc mechanism of action and demon-
strated target engagement of GITRL-Fc. Additional approaches, including in-
silico sorting, tomonitor rare immune cell populations in tumor samples will be
discussed.
#5622 Acquired resistance to EGFR-TKI upregulates the expression of
PD-L1 and promotes immune escape in lung cancer. Shunli Peng, Qi Li, Wei
Wang. Nanfang hospital, Southern medical university, Guangzhou, China,
Guangzhou, China.
Background and purpose: Acquired resistance is a severe problem of EGFR
inhibitors (EGFR-TKIs) therapy in lung cancer patients. Immune checkpoint
therapy is a new revolution in cancer treatment with dramatic outcomes in a
subset of patients. In this study, we explored the possibility of immune check-
point therapy in lung cancers with three well-known resistant mechanisms to
EGFR-TKIs, T790M, MET amplifıcation and hepatocyte growth factor (HGF),
and investigated internal regulation mechanisms. Experimental Design: PD-L1
expression and immune escape ability were evaluated in EGFR-TKIs resistant
lung cancer cells by MET amplifıcation, HGF, and T790M, as well as T790M
transfected-human renal derived cells (293FT).MAPK and PI3K pathways were
investigated simultaneously. PD-L1 gene deleted resistant cells were used in
NOD-SCID xenograft models to evaluate immune escape in vivo. Results: All of
three resistant mechanisms increased PD-L1 expression. BothMAPK and PI3K
pathways are involved in MET amplifıcation or HGF induced PD-L1 overex-
pression, whereas only MAPK pathway mediated it in T790M-transfected cells.
The decreased cytotoxicity of lymphocytes can be restored by anti-PD-L1 anti-
bodies. Moreover, xenograft tumors by EGFR-TKIs sensitive cells but not resis-
tant cells responded to treatment of human lymphocytes. However, deletion of
PD-L1 successfully restored cytotoxicity of lymphocytes in EGFR-TKIs resistant
tumors. Conclusion: Acquired Resistance to EGFR-TKIs augments the expres-
sion of PD-L1 and promotes immune escape in EGFR mutant lung cancer.
Immune checkpoint therapymight be a promising alternative therapeutic strat-
egy for NSCLC that acquired resistant to EGFR-TKIs.
#5623 A comparative study of four PD-L1 immunohistochemical assay in
non-small cell lung cancer and evaluation of scoring system. Hyojin Kim,
Hyun Jung Kwon, Soo Young Park, Eunhyang Park, Jin-Haeng Chung. Seoul
National University Bundang Hospital, Gyeonggi-do, Republic of Korea.
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Background: Clinical trials of immune checkpoints modulators, including
both programmed cell death-1 (PD-1) and programmed cell death-ligand 1
(PD-L1) inhibitors, have recently shown promising activity and tolerable toxic-
ity in pre-treated and fırst line NSCLC patients. At least fıve PD-L1 IHC assays
with custom reagents and scoring-criteria are evaluated in clinical trials. How-
ever, current assays for the prognostic and/or predictive role of tumor PD-L1
expression are not standardized and the role of PD-L1 expression as a biomarker
is still controversial.Materials andMethods: Retrospectively collected formalin-
fıxed paraffın-embedded whole-tissue sections (WTS) from 97 NSCLC cases
from Seoul National University BundangHospital were obtained.We tested the
samples divided “training set” and “validation set”: A set of 50 NSCLCWTS (32
adenocarcinoma and 18 squamous cell carcinoma) resected from 2010 to 2011
was designated “training set” and the other set of 47 NSCLC WTS (32 adeno-
carcinoma, 14 squamous cell carcinoma, and 1 pleomorphic carcinoma) re-
sected from 2015 to 2016 was designated “validation set”. We examined PD-L1
protein expression using four different antibodies (Clone E1L3N, SP142, SP263
and 22C3) using Ventana XT platform with optiview detection kit for E1L3N,
SP142 and SP263, and DAKO link 46 platform with pharmDx kit for 22C3 by
immunohistochemical analysis. Staining of tumor cells (Tumor proportion
score, TPS) and immune cells were evaluated. Results: PD-L1 protein expression
was observed in 18 %, 16%, 11% and 12% of total tumors with E1L3N with
Ventana optiview kit (5% cutoff), SP142 with Ventana optiview kit with ampli-
fıcation (1% cutoff), SP263 with Ventana optiview kit (25% cutoff) and 22C3
with DAKO PharmDx kit (50% cufoff), respectively. There was no different
positive rate between “training” and “validation” set, which means there was no
effect of the age of paraffın block on PD-L1 expression. Regarding staining
proportion of tumor cells, 22C3 yields more stained tumor cells (highest TPS)
and SP142 consistently labels fewer tumor cells (lowest TPS). Among 38 cases
which were positive in one or more assays, 28.9% showed discrepant results for
PD-L1 expression between the assays according to each criterion. When the
same criterion applied for all assays, discrepant rate is higher (63.1 % with 1%
cutoff, 71.0% with 5% cutoff). Conclusion: Although comparative determina-
tion of PD-L1 protein levels in NSCLC reveals inter-assay variability of tumor
cell staining, positive rate is similar under each criterion. Therefore, there is a
potential for different diagnostic results according to the key clinical cut-offs if
assays and algorithms are mismatched and we should be careful when interpret
the PD-L1 expression with different assays.
#5624 Characterization of proliferation in multiple T-cell subsets in the
CT26 murine colon carcinoma model by multi-color flow cytometry. Matt
Thayer, AldenWong, David Draper, Dan Saims, Scott C. Wise.MI Bioresearch,
Ann Arbor, MI.
The effıcacy of immune-modulating anti-cancer therapeutic antibodies that
have been FDA-approved in recent years, such as anti-CTLA-4, anti-PD-1 and
anti-PD-L1, has altered the paradigm of cancer treatment. Subsequently, the
growing interest in the development of new single agent and combination ther-
apies with immune-modulatory effects has generated a need for more powerful
immunophenotyping techniques capable of in-depth cell characterization and
proliferation assessment. To this end, using the CT26 syngeneic murine colo-
rectal cancermodel we have developed an 8 color flow cytometry antibody panel
that focuses on the identifıcation of lymphocyte subsets and analysis of prolif-
eration within them utilizing the high-throughput-capable 4-laser, 14-color At-
tune NxT FlowCytometer (Thermo Fisher Scientifıc). Splenocytes from tumor-
naïve and CT26 tumor-bearing C57BL/6 mice were stained with CFSE
(carboxyfluorescein succinimidyl ester), an amine-reactive fluorescent dye
which enables generational tracking for up to seven rounds of cell division,
allowing for proliferation to be quantifıed. Splenocytes from these mice were
then stimulated with anti-CD3, anti-CD28, and IL-2. After stimulation for four
days, cells were stained with antibodies against CD45, CD3, CD19, CD49b,
CD335, CD4, CD8, and FoxP3.Wewere able to identify differential proliferative
capacity between naïve and tumor-bearing mice in CD4 T-cell, CD8 T-cell,
regulatory T-cell, and B-cell populations. Finally, we show that the accuracy of
analysis is enhanced by the use of fluorescence minus-one (FMO) controls to
identify thosemarkers that generate dim signals, as well as a viability dye used to
exclude dead cells from analysis. Identifıcation of potentially responsive im-
mune compartments, as well as characterizing proliferation, will facilitate iden-
tifıcation and development of potential combination therapies by expanding the
depth of our ability to provide mechanistic descriptions of drug function and
effıcacy. Following this proof-of-concept work, we will also present data from
tumor-bearing mice treated with immune checkpoint inhibitors in order to
identify potential differences in proliferation after treatment with immune-
modulating agents.
#5625 Identifıcation and validation of a PD-L1 specifıc peptide for deter-
mination of PD-L1 expression in tumors. Charles Caldwell, Cory Johnson,
Richard Hammer, Raghuraman Kannan. University of Missouri-Columbia, Co-
lumbia, MO.
In recent years, immunotherapy has seen a resurgence as a promisingmethod
of treating cancers. The interaction between Programmed Death Ligand 1 (PD-
L1) and its receptor, Programmed Death 1 receptor (PD-1) has been of partic-
ular interest. Many different types of tumors have been shown to overexpress
PD-L1, which causes host immune cells that express the PD-1 receptor and bind
PD-L1 to cease killing the tumor. Patients who have tumors exhibiting high
levels of PD-L1 show poor prognosis compared to those who do not. Inhibition
of the PD-L1 PD-1 binding axis has been shown to restore host immunity to the
tumor, and recently many new drugs such as atezolizumab and pembrolizumab
have been developed to target this interaction. Current methods of PD-L1 diag-
nosis have shown to vary based on the antibody, detection kit brand, antigen
retrieval method, and clinically strict defıned methods for use by the FDA for
assessment. To refıne detection of PD-L1, we have identifıed a PD-L1 specifıc
peptide which can be used to detect PD-L1 expressing tumors using either con-
ventional immunohistochemistry or flow cytometry. Immunohistochemistry
using this peptide was tested against the FDA-approved PD-L1 (SP263) Rabbit
monoclonal primary antibody on biopsied patient tissues. Flow cytometry was
performed on both cultured cell lines and patient tissues. We have shown that
our PD-L1 peptide shows specifıc staining in the tumor regions of FFPE tissues
where the SP263 kit does not stain, and we can also detect PD-L1 expression in
both cell samples and patient tissues using flow cytometry.
#5626 Investigation of T cell activation by anti-human PD-1 antibodies
Nivolumab, Pembrolizumab and BGB-A317 using tumor-infıltrating lym-
phocytes (TILs) from colorectal cancer and colorectal liver metastasis pa-
tients. Lusong Luo,1 Xiaoran Wu,1 Tong Zhang,1 Chunyan Fu,1 Yanjuan
Zhang,1 Amy Guo,1 Dongping Zhou,1 Lianhai Zhang,2 Kun Wang,2 Baocai
Xing,2 Jiafu Ji,2 LaiWang,1 Kang Li1. 1BeiGene(Beijing) Co., Ltd., Beijing, China;
2Peking University Cancer Hospital and Institute, Beijing, China.
Blockade of the PD-1 pathway with anti-PD-1 antibody, such as nivolumab
(nivo) andpembrolizumab (pembro), has led to remarkable clinical responses in
patients with many different cancer types. In this study, we investigated the
activation of tumor-infıltrating lymphocytes (TILs) from patients with colorec-
tal cancer (CRC) and colorectal liver metastasis (CLM) by nivo, pembro and
BGB-A317, a novel humanized IgG4 anti-PD-1 antibody under clinical devel-
opment. BGB-A317 has a unique binding signature to PD-1 with high affınity.
Additionally, it is engineered to remove Fc gamma receptor (FcR) binding,
including FcRI, FcRIIA, FcRIIB and FcRIIIA. In our studies, all three anti-
PD-1 antibodies showed signifıcant increases in IFN- and TILs proliferation in
a 3D tumor spheroid model. In both CRC and CLM patients, BGB-A317 treat-
ment at concentration levels of 0.1, 1 and 10g/mL led to higher IFN- produc-
tion than that in nivo and pembro treated groups. The enhanced TILs function
was associated with a high density of CD8T cells, but inversely correlated with
the percentage of CD11bmyeloid cells in CRC tumors. Of interest, BGB-A317
showed better activation of TILs in the liver metastasis tumor microenviron-
ment (TME) wheremacrophages weremore abundant. This observation is con-
sistent with the hypothesis that removal of FcR binding might offer advantage
to PD-1 mAbs in tumor microenvironment enriched with macrophages.
#5627 Uncovering novel signaling pathways that mediate tumor cell kill-
ing by T effector cells. Thomas Kuilman, David Vredevoogd, Daniel S. Peeper.
Netherlands Cancer Institute, Amsterdam, Netherlands.
Recent advances in the understanding of tumor immunology have led to the
development of various immunotherapeutic strategies, some of which show
unprecedented clinical effıcacies. Two of the most effective treatments, ipili-
mumab and pembrolizumab / nivolumab target the immune checkpoints fac-
tors CTLA-4 and PD-1, respectively. While not all patients respond to immu-
notherapy, those that do frequently show long-lasting clinical responses. These
accomplishments have led to a surge in research focusing on the question how
the immune system can be stimulated for more common durable therapy re-
sponses. A current focus of tumor immunological research is the identifıcation
of mechanisms allowing cancer cells to evade recognition and/or killing by the
immune systemwhile facing immunotherapy. For example, abrogation of inter-
feron-γ signaling pathway has been shown to result in escape of immune sur-
veillance after pembrolizumab treatment. However, it is likely that other tumor
cell-intrinsic mechanisms play a role, too. To uncover novel pathways that are
involved in resistance to immune checkpoint inhibitors, we aim to identify tran-
scriptional changes in tumor cells that result from effector T-cell exposure. To
this end, we established a co-culture platform of a panel of Mart1-expressing
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melanoma cell lines with primaryCD8T cells expressing amatching TCR. The
cell lines display varying degrees of sensitivity to T cells, allowing us to bioinfor-
matically uncover differential expression depending on this range of sensitivi-
ties. Rather than concentrating on single genes, we have focused on pathways,
gene sets and ontologies. These analyses have been integrated with various pub-
lically available transcriptomic data sets to identify a set ofmechanisms thatmay
contribute to T-cellmediated killing.Wewill systematically abrogate key factors
using CRISPR technology in our co-culture platform and assess whether this
affects T-cell mediated killing. Our ultimate goal is to test whether these factors,
or their signaling pathways, are involved in resistance to immunotherapy in
patients, and to develop new strategies to prevent immunotherapy resistance.
#5628 Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the effıcacy of
combination chemotherapy and immune checkpoint inhibitor treatment in
preclinical models. Jessica A. Sorrentino, Anne Y. Lai, Jay C. Strum, Patrick J.
Roberts. G1 Therapeutics, Inc, Research Triangle Park, NC.
While immune checkpoint inhibitors are effıcacious and lead to durable re-
sponses in patients with various cancers, only aminority of patients respond. An
approach to increase the response rate of immune checkpoint inhibitors is to
combine them with chemotherapy in order to enhance immunogenic cell death
and “prime” the immune system. However, chemotherapy itself can cause dam-
age to various cell types of the immune system, potentially diminishing the
activity of the chemotherapy/checkpoint inhibitor combination. Therefore, a
targeted approach to preserve immune system function during chemotherapy
would allow optimal activity of the checkpoint inhibitor therapy. Trilaciclib
(G1T28), a potent and selective IV CDK4/6 inhibitor, preserves hematopoietic
stem cells and enhances immune system function during chemotherapy. We
and others have previously shown T lymphocytes are extremely sensitive to
CDK4/6 inhibition causing a transient arrest of proliferation and protection
from damage by chemotherapy. Post treatment with trilaciclib and chemother-
apy, T lymphocytes are released from the transient arrest in the presence of
chemotherapy-induced immunogenic cell death allowing better priming of an
anti-tumor immune response. To evaluate the effect of trilaciclib combination
treatments, MC38 tumor bearing mice were treated with trilaciclib, oxaliplatin,
or anti-PD-L1 alone or in combination, and tumor size was measured during
and post treatment for 100 days. Our results demonstrate that the addition of
trilaciclib to an oxaliplatin/anti-PD-L1 combination (TOP) treatment signifı-
cantly improves anti-tumor activity. Specifıcally, twice as many mice treated
with TOP for 15 days had a complete response (CRs) when compared to oxalip-
latin/anti-PD-L1 (OP); 6/10 CRs vs 3/10 CRs, respectively. In addition, the CRs
were durable and without any evidence of recurrence at 100 days. Furthermore,
TOP treatment caused a 60% increase in overall survival (OS) compared tomice
treated with OP; median OS for TOP was 98 days compared to 61 days (HR,
0.53) for theOP treatment group. Assessment of ex-vivo stimulation of cytokine
release from harvested splenocytes to measure T-cell activation, and evaluation
of immune infıltrates and T-cell receptor repertoire within the tumors are on-
going. Taken together, we demonstrate that the short-acting IV CDK4/6 inhib-
itor, trilaciclib, which has been shown to preserve immune function during
chemotherapy, enhances the anti-tumor activity of chemotherapy/anti-PD-L1
combination therapy.
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#5629 Modeling cyclophosphamide induced ovarian toxicity in a novel
translational canine model. Puja Basu,1 Rebecca Egbert,1 Evan Pasternak,1
Brian Petroff,1 Nucharin Songsasen2. 1Michigan State Univ., East Lansing, MI;
2Smithsonian Conservation Biology Institute, Front Royal, VA.
Reproductive failure following chemotherapy and/or ionizing radiation is a
major adverse event, for which there are no established preventive measures. In
previous studies, our laboratory has documented that the selective estrogen
receptormodulator, tamoxifen (TAM) is effective in both prevention and rever-
sal of ovarian toxicity from cyclophosphamide (CTX) in rodent models. To
validate the effectiveness of this approach in a more relevant model system, we
have developed a canine ovarian explant tissuemodel system.Dogs present with
many cancers spontaneously and their pathology and treatment approaches
mirror those of the human cancers. Thus, canine cancers and their treatments
are excellent translational models for human diseases. Furthermore, dogs share
the same environment as humans and have longer life spans than rodents. Our
laboratory has recently established a dog ovarian explant tissue model system
using fresh ovaries collected at the time of ovariohysterectomy. In the current
study, we hypothesized that ovarian toxicity induced by CTXwill be reduced by
co-administration of TAM. Using this system, freshly prepared ovarian cortical
tissue sections are cultured in the presence of TAM and CTX. Ovarian tissue
viability is assessed by primordial and primary follicle morphometry, where the
number of primordial, primary and apoptotic follicles were counted in 9 sec-
tions of 1 mm3 of ovarian cortical tissue from each dog, using CTX (at 0, 1 and
10M) concentrations combined with TAM (0 and10M). The number and
percentage of each follicle was assessed. In addition, granulosa cells proliferation
is assessed using bromodeoxyuridine (BrdU) incorporation. Further, we show
that, as in women, anti-mullerian hormone (AMH) can be used as an indicator
of follicle reserves in the dog, thereby establishing their use as an in-vivo moni-
toring system to test ovarian viability in future clinical studies. This study is
intended to underpin a subsequent canine clinical trial testing TAM as a coun-
termeasure against infertility from cancer treatment in dogs.
#5631 SRC1-driven network of transcription factors mediates hormone
treatment resistance. Damir Vareslija, Alacoque Browne, Ailis Fagan, Nicola
Cosgrove, Elspeth Ward, Leonie Young. Royal College of Surgeons in Ireland,
Dublin, Ireland.
Despite the clinical benefıt in treating ER positive breast cancer, hormone
therapy resistance occurs in 40% patients leading to disease progression. Steroid
receptor co-activator 1 (SRC1) enhances target gene transcription and has a
critical role in breast cancer cell tumorigenicity. There is now key evidence that
SRC1 is vital to the capacity of hormone-dependent tumors to adapt and over-
come targeted therapy. Utilizing a genome wide multi omics sequencing of
breast cancer patients and models, this study aimed to defıne the programs of
SRC1 controlled transcriptional networks, identifying both interacting partners
and downstream transcription factor (TF) targets that mediate the treatment
resistant phenotype. RIME uncovered novel SRC1 interacting partners (includ-
ing STAT1, PRMT1, and HDAC2) and associated TF partner networks in the
hormone treatment resistant LY2 cells. In parallel, RNA-seq of LY2s with SRC1
stable knockdown revealed SRC1 regulated transcriptome networks identifying
1731 up regulated genes, including 153 TFs. SRC1 cistrome, characterized by
ChIP-seq analyses was combinedwithmotif binding analysis, to further validate
40 TFs directly regulated by SRC-1 and its interaction network. Dependence on
SRC1 was confırmed through SRC-1 siRNA and CRISPR validation. Upon this
discovery, validation and functional interrogation studies we identifıed a cadre
of 4 TFs including E2F7, DEK, TRPS1 and SMARCA1 that execute SRC1 role in
hormone treatment resistance. Functional analysis of this 4 gene TF network
found it to be co-operating as a driver of hormone resistant cell by coupling
activation ofmotility with stemness. TFs can reprogram resistant cells by revers-
ing differentiation as demonstrated in the mammosphere, 3D acinar assays and
CD24/44 flow cytometry analysis. This TF gene set is a signifıcant predictor of
poor recurrence free survival in hormone treated patients, supporting its role in
increased metastatic risk in breast cancer and the clinical relevance of our fınd-
ings. Furthermore, in an ERve PDX, established from resistant and treatment
naïve patient, protein expression of the TF networkmembers co-expressed with
SRC1 and were only found in the hormone treatment resistant PDX models.
This study highlights SRC1 regulated disease progression program in hormone
treatment-resistant disease. Identifıed SRC1 interactome and its regulated tran-
scriptome are active independent of its ER co-activator role. The SRC1mediated
TF network is involved in reprogramming of resistant cells, whose concerted
activity is responsible for driving dedifferentiation of cells and enhancing their
stem like and highly migratory tumor initiation population. This work provides
key evidence on the mechanism of resistance in ERve hormone resistant can-
cer and has substantial implications both for the treatment of hormone depen-
dent breast cancer and for identifying the mediators of metastatic potential.
#5632 Thyroid carcinoma in The Sudan.Mohamed ElMakki Ahmed.Univ.
of Khartoum Faculty of Medicine, Khartoum, Sudan.
Introduction: Goiter is endemic in Sudan and thyroidectomy is a daily prac-
tice in most surgical lists across the country. The most common indications are
cosmoses and pressure with respiratory choking. In 10% of cases a surprise
histopathology on cancer is reported . This study aims to report on thyroid
carcinoma on patients presenting to the surgical department in Khartoum
Teaching Hospital. Methods: This study is an overview on pattern, clinical pre-
sentation a management of thyroid carcinoma in Khartoum during the period
2007 - 2014. Thyroidectomy was the standard procedure when feasible and
postoperative radio iodine given. External radiotherapy was given in aggressive
anaplastic carcinoma. Results: 166 patients with thyroid cancer were studied.
Themean age was 51/-SD 17yrs and the age range between 15 - 85 years.Male
to female ratio was 1.0:2.4. Clinical presentation was a goiter that was showing a
IMMUNOLOGY: Immune Checkpoints and Immunosurveillance
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171438
recent rapidly growth with either respiratory choking, pain and dysphagia. Fol-
licular carcinoma was 43%,papillary 27%, anaplastic 10% 2%medullary. Sar-
coma and lymphoma 5% and missing data in 13%. Six per cent of patients
presented with lung and bone metastasis. 20 patients had long standing goiter
before development of cancer. Different types of total thyroidectomy done in
81%, no surgery in 7% and missing data in 12%. 18 patients needed postopera-
tive tracheostomy, 7 developed permanent hypocalcaemia, 15 recurrent nerve
palsy and a 30 days mortality was 10% and all were anaplastic carcinoma where
recurrence occurred within weeks following thyroidectomy or dublking inmost
cases. Conclusion: Patients with thyroid cancer presents late. The dominance of
follicular type indicates the signifıcance of underlying endemic goiter in its eti-
ology. Anaplastic is very aggressive and lethal outcome.
#5633 Unique modulation of estrogen-induced apoptosis with structural
analogues of endoxifen in long-term estrogen-deprived (LTED) breast can-
cer cells.Balkees Abderrahman,1 SeanW. Fanning,2 DanielaQuintana Rincon,1
Geoffrey Greene,2 Philipp Y. Maximov,1 V. Craig Jordan1. 1UT MD Anderson
Cancer Center, Houston, TX; 2University of Chicago, Chicago, IL.
Endoxifen, a non-steroidal anti-estrogen is the active hydroxylated metabo-
lite of N-desmethyltamoxifen. The structure is based on a synthetic triphenyl-
ethylene-type angular estrogen. Endoxifen is in clinical trials as a therapeutic
agent to treat aromatase resistant breast cancer. Paradoxically, LTED breast
cancer is known to respond to synthetic andnatural estrogens through estrogen-
induced apoptosis. A series of synthetic endoxifen analogs, were used to modu-
late estrogen-induced apoptosis in LTED breast cancer cells (MCF7:5C). X-ray
crystallography was performed on endoxifen, bisphenol, and diethylstillbestrol
(DES), bound to the ligand-binding domain (LBD) of the human estrogen re-
ceptor (ER). Cellular studies established that (MCF-7:5C) of estrogen-induced
apoptosis was dependent on the LBD of the ER. Similarly, endoxifen blocked
estrogen-induced apoptosis in a concentration and time-dependent manner.
Apoptosis triggered by DES was blocked by endoxifen and was ER-dependent.
X-ray crystallography of both endoxifen and DES illustrate the two extremes of
estrogen-induced apoptosis, which is dependent upon the closure of helix 12
over the LBD to generate estrogenic activity. Despite the fact that bisphenol, an
analog of endoxifen without the anti-estrogenic monomethylamino ethyl side
chain, is an estrogen that causes breast cancer cell replication; bisphenol initially
inhibits estrogen-induced apoptosis, but triggers estrogen-induced apoptosis
itself after 7 days of treatment of LTEDbreast cancer cells. X-ray crystallography
demonstrates that bisphenol can produce a unique complex with the ER:LBD,
which is similar to the DES:LBD estrogenic complex. In both cases, the ligands
are sealed into the LBD by helix 12. This delay in apoptosis caused by an analog
of endoxifen, that is an angular estrogen, possess unique biological features. We
hypothesize that in LTED cells the complex passes through an anti-estrogenic
conformation to evolve into an estrogenic complex with helix 12 sealing the
LBD. We describe a unique property of a ligand:receptor complex. For the fırst
time we demonstrate that a ligand:receptor complex is slowly activated from an
antagonist to an agonist complex over a period of days.
#5634 Characterization ofmolecularmechanisms of cytoplasmic traffıck-
ing and nuclear translocation of AR splice variants ARv7. Eiman Mukhtar,
Seaho Kim, Paraskevi Giannakakou. Weill Cornell Medical College - Cornell
University, New York, NY.
Androgen receptor (AR) signaling is critical to not only hormone-sensitive
but also advanced castration-resistant prostate cancer. AR inhibitors (abi-
raterone and enzalutamide), the next generation of androgen deprivation ther-
apy (ADT) have been used for metastatic castration-resistant PC (mCRPC)
treatment, however, themajority of patients progress due to the development of
drug resistance. AR variants has emerged as one of themechanisms of resistance
to these drugs. ARv7 and Arv567 splice variants that found lacking the ligand
-binding domain are constitutively active in the nucleus and thus restore AR
function despite AR inhibitors treatment. We have reported that microtubules
and dynein motor protein is required as transportation system for AR for its
nuclear translocation and activity and that taxanes inhibit AR signaling down-
stream of microtubule inhibitors. In addition, we identifıed that the AR hinge
regionmediates binding tomicrotubules is present in ARv567 butmissing from
ARv7. ARv7 is expressed in about 60% of CRPC patients and has been shown to
confer clinical resistance to next generation AR signaling inhibitors. Currently,
there is no therapeutic modality targeting specifıcally ARv7 expression or func-
tion. Using fluorescent recovery after photobleaching experiments (FRAP) we
have shown that ARv7 translocation to the nucleus occurs much faster than
AR-FL (t1/2 11s and 23 s respectively) and that its nuclear import is independent
of the importin a/b pathway utilized byAR-FL and proteins with canonical NLS.
Furthermore, transient expression of the Q69L RanGTPmutant protein, which
acts as dominant negative by occluding the nucleoporins, hadminimal effect on
ARv7 nuclear import, while it completely blocked AR-FL and AR-v567. Collec-
tively, these data suggest that the nuclear import pathway for ARv7 is distinct
from that utilized by AR-FL. We believe that ARv7 undoubtedly uses facilitated
transport because of its size (75 kDa), thereforewe are tackling three possibilities
of nuclear translocation of ARv7. First, ARv7 could interact directly with FG
repeat nucleoporins (without receptor) as reported for beta catenin. We are
investigating this by the use of importin -(71-876) mutant cell line for in vitro
studies which blocks all members of the importin family. In addition, we are
investigating the role of karyopherin transport receptors by individual knock-
down experiments coupled with live cell imaging and kinetic quantitation of
ARv7 nucleocytoplasmic traffıcking. Further, ARv7could translocate to nucleus
by utilizes a piggyback on another protein with a classical nuclear localization
signals. Overexpression of glutathione S-transferase- importin  binding do-
main fragment which will block all importin  pathways will exclude this mech-
anism. Elucidation of this mechanism will be vital to facilitate design an alter-
native therapeutic modality to halt AR signaling for CRPC treatment.
#5635 Vitamin D supplementation decreases serum 27-hydroxycholes-
terol and expression of CYP27A1 in tumors of breast cancer patients. Cath-
erine Going,1 Ludmila Alexandrova,2 Ken Lau,1 Christine Yeh,1 Melinda Telli,1
Kristin Jensen,1 David Feldman,1 Sharon Pitteri1. 1Stanford University School of
Medicine, Palo Alto, CA; 2Vincent Coates Foundation Mass Spectrometry Labo-
ratory, Stanford University, Palo Alto, CA.
The goal of this study was to investigate whether vitamin D regulates the
conversion of cholesterol to 27-hydroxycholesterol (27HC), an endogenous se-
lective estrogen receptor modulator (SERM) that can act as a driver of estrogen
receptor positive (ER) breast cancer, particularly in post-menopausal women
with low circulating estrogen levels. The hypothesis of this study was that the
active metabolite of vitamin D, calcitriol, can inhibit expression of CYP27A1,
the synthesizing enzyme for 27HC, thereby decreasing the concentration of
27HC in the blood. Both 27HC and 25-hydroxyvitaminD (25OHD)were quan-
tifıed by LC-MS/MS in the serum of 29 breast cancer patients, 26 of which had
ER cancer, pre- and post-treatment with either a low dose (control) of 400 IU
vitaminD or a high dose of 10,000 IU vitaminD per day during the neoadjuvant
period, which ranged between 7 and 37 days. In addition to these blood samples,
tissue biopsies pre-treatment and the excised tumor collected post-treatment
were tested for gene expression by microarray analysis. A signifıcant increase
(p 4.3E-5) was observed in serum 25OHD for patients who received the high
dose vitamin D compared to those who received the low dose, whose 25OHD
values remained stable. A greater decrease (p 1.7E-1) was observed in serum
27HC for the high dose group compared to the low dose group, with greater
decreases in 27HC on average for those with larger increases in 25OHD concen-
tration. Gene expressionmeasurements showed a decrease in CYP27A1 expres-
sion (p 4.5E-1) in breast cancer tissue for the high dose group compared to the
low dose group, with greater decreases in expression observed for patients on
high dose vitamin D treatment for longer times. These preliminary data show
good evidence that high dose vitamin D supplementation can decrease 27HC
levels in the body by inhibiting expression of CYP27A1 and that the longer this
treatment, the greater the effect.While larger scale studies are needed, the data in
this study point to vitamin D supplementation as a possible simple method for
inhibiting ER breast cancer growth and suggests this reduction in CYP27A1
expression as an additional pathway by which vitamin D can mitigate risk and
improve outcomes for ER breast cancer patients.
#5636 Targeting of NOXA overexpression in anaplastic thyroid cancer
(ATC).Niklas K. Finnberg, Junaid Abdulghani, Hormoz Ehya, Wafık El-Deiry.
Fox Chase Cancer Center, Philadelphia, PA.
Anaplastic thyroid cancer (ATC) is a rare, aggressive and fatal cancer with a
median survival of 3-5 months after diagnosis. Our long-term goal is to develop
better therapies based on the biology of ATC that contributes to improved tu-
mor response and a reduced risk of potential side-effects. We recently showed
that the anti-apoptotic BCL2 family memberMCL1 is overexpressed in a subset
of ATC and that targeting of MCL1 with quinacrine leads to increased sensiti-
zation to the BRAF inhibitor sorafenib. To further investigate the importance of
BCL2 family proteins in ATC, we analyzed gene expression data from several
published independent gene expression studies. We discovered that both papil-
lary thyroid cancer (PTC) and ATC surprisingly overexpress the mRNA of the
pro-apoptotic BCL2 family member NOXA. However, despite the observed
overexpression of NOXA mRNA in several ATC cell lines, we fınd that NOXA
protein expression, by contrast, is low. NOXA protein has previously been
shown to be subject to ubiquitination and proteasomal degradation. Indeed,
through bioinformatics, we fınd overexpression of several ubiquitin enzymes in
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ATC suggesting that the half-life of NOXAproteinmay be selectively reduced in
this tumor type. We are further assessing differences in the turnover of NOXA
protein in ATC cells and are investigating if restoringNOXAprotein expression
may synergize with the pharmacologic targeting of MCL1 and other anti-apo-
ptotic BCL2 family members. Interestingly, through TCGA analysis, we discov-
ered that BCL2 overexpression is associated with a poor prognosis in thyroid
cancer (THCA) patients. Indeed, treatment with the BCL2/BCLXL inhibitor
navitoclax showed encouraging effıcacy and synergized with the neddylation
inhibitor MLN4924 in the ATC cell line 8505C. This was based on the expecta-
tion that MLN4924 would rescue NOXA protein expression. We are pursuing
mechanistic studies in a larger panel of thyroid cancer cell lines and in vivo
effıcacy and toxicity studies. We conclude that restoring NOXA protein expres-
sion can together with the rational targeting of anti-apoptotic BCL2 family
members may allow for the expansion of the limited ATC-selective treatment
strategies currently available.
#5637 AnoralAndrogenReceptorPROTACdegrader for prostate cancer.
Taavi K.Neklesa,1 Lawrence B. Snyder,1MarkBookbinder,1 XinChen,1Andrew
P. Crew,1 Craig M. Crews,2 Hanqing Dong,1 Deborah Gordon,1 Jennifer Ma-
caluso,1 Kanak Raina,1 AnnMarie Rossi,1 Ian Taylor,1 Nicholas Vitale,1 Jing
Wang,1 Ryan R.Willard,1 Kurt Zimmermann1. 1Arvinas, NewHaven, CT; 2Yale
University, New Haven, CT.
The Androgen Receptor (AR) remains the principal driver of castration-re-
sistant prostate cancer during the transition from a localized to metastatic dis-
ease. Most patients initially respond to inhibitors of the AR pathway, but the
response is often short-lived. The majority of patients progressing on enzalut-
amide or abiraterone exhibit genetic alterations in the AR locus, either in the
form of amplifıcations or point mutations in the AR gene. Given these mecha-
nisms of resistance, our goal is to eliminate theARprotein using the PROteolysis
TArgeting Chimera (PROTAC) technology. Further, we sought to make an
orally bioavailable AR PROTAC. Medicinal chemistry efforts yielded a small
molecule AR PROTAC that simultaneously binds E3-ubiquitin ligase and AR,
thus leading to ubiquitination and degradation of AR. This molecule has been
characterized in in vitro and in vivo preclinical studies. Our lead oral AR
PROTAC degrades approximately 98% of total AR in all cell lines tested, with
50%degradation concentration (DC50) 1 nM.ARdegradation suppresses the
expression of AR-target gene PSA, inhibits cell proliferation, and induces potent
apoptosis in VCaP cells. No activity is observed in AR-null cell lines, such as
PC-3. While enzalutamide loses its activity in the presence of elevated andro-
gens, AR PROTAC maintains its antiproliferative activity. Further, AR
PROTAC is able to degrade all clinically relevant mutant AR proteins. A robust
oral bioavailability is observed across multiple species and overall ADME prop-
erties are encouraging. Approximately 95% AR degradation is observed in AR-
amplifıed VCaP xenografts at doses as low as 10 mg/kg. Congruent with AR
degradation, a dose responsive tumor growth inhibition is observed in AR-
dependent xenograft studies. In summary, we report the fırst orally bioavailable
AR PROTAC that robustly degrades AR in vitro and in vivo.
#5638 Combination use of EF2K and VPS34 inhibitors with anti-andro-
gen against drug-resistant castration resistant prostate cancer. Joy C. Yang,
Vito Cucchiara, Allen C. Gao, Christopher P. Evans. UC Davis Medical Ctr.,
Sacramento, CA.
INTRODUCTION AND OBJECTIVES: Modulating the activity of eukary-
otic elongation factor 2 kinase (eEF2K) has been suggested to regulate protein
elongation to block autophagy in the tumor microenvironment. Among inhib-
itors of eEF2K, one would also inhibit VPS34, a class III phosphatidylinositol-3
kinase, and abrogate autophage flux to impair the survival escape mechanism.
We tested the eEF2K and VPS 34 inhibitors from Janssen alone or in combina-
tion with anti-androgens for their effects on proliferation of prostate cancer cell
lines, especially some castration resistant PC (CRPC) lines. MATERIALS AND
METHODS: Cell proliferation was assessed with various concentrations of the
EF2K or VPS34 inhibitor on CRPC lines using WST-1 viability assay. Effect of
combinations of EF2K or VPS34 inhibitor with anti-androgens abiraterone
(Abi) or enzalutamide (Enza) on drug-resistant CRPC cells was further ex-
plored. Western blot analysis was performed to examine the response of key
autophagic molecules, androgen receptor (AR) and variant. Real time RT-PCR
(RT-qPCR) was used to elucidate the effect of EF2K or VPS34 inhibitor alone or
together with anti-androgens on AR, AR variant and their downstream mole-
cules. RESULTS: EF2K and VPS34 inhibitors suppressed CRPC cell growth in a
dose-response manner with IC50 ranging from 1 to 5 M. These inhibitors
displayed synergy with Abi and Enza against drug-resistant CRPC cells; espe-
cially on the pair of enza EF2K inhibitor with p 0.02 for signifıcant differ-
ence when compared to enza or EF2K inhibitor alone. To our surprise, no sig-
nifıcant autophagy was induced by these two inhibitors according to the
autophagy markers detected byWestern blots. VPS34 inhibitor alone and when
combined with Abi and Enza showed AR/variant degrading ability. This down-
regulation was at the expression level with signifıcant change of AR and V7,
together with their transactivation markers PSA, TMPRS2, NKx3.1 and FKBP5
detected by RT-qPCR. CONCLUSION: EF2K andVPS34 inhibitors when com-
bined with anti-androgens may solicit profound inhibitory effect on drug-resis-
tant CRPC cells. Molecular delineation demonstrated the direct target might be
AR and its variants. These combinations offered a new therapeutic option for
advanced PC treatments.
#5639 Diagnosing indeterminate thyroid nodules: combining next gener-
ation sequencing and gene expression analysis. Vivian L. Weiss,1 Robert
Daber,2 Michael Moreau,2 Alisa Gaskell,2 Kim Ely,1 Alice Coogan,1 Thomas
Stricker1. 1Vanderbilt University Medical Center, Nashville, TN; 2Bio-Refence
Laboratories Inc., NJ.
Thyroid nodules are common in the United States and are currently diag-
nosed using fıne needle aspiration (FNA) biopsy. FNA evaluation provides a
defınitive diagnosis in the majority of cases, but about 20-30% of nodules are
deemed indeterminate. Targeted next generation sequencing (NGS) and gene
expression analysis have been used as ancillary tests to provide additional infor-
mation about the malignancy risk for indeterminate thyroid lesions. Here we
develop a 31 geneNGS panel, as well as a 14 gene expression panel, and test their
performance on thyroid lesions with known diagnosis. Formalin-fıxed paraffın
embedded tissue from 23 resected thyroid lesions (1 non-neoplastic, 3 follicular
adenomas (FA), 1 medullary carcinoma (MC), 7 follicular carcinomas (FC), 7
papillary carcinomas (PC), 4 follicular variant of papillary carcinomas (FVPC))
was evaluated. Total nucleic acid extraction, NGS (31 genes including: NRAS,
HRAS, KRAS, CTNNB1, PIK3CA, BRAF, RET, PTEN, AKT1, TP53, GNAS,
ALK, DDR2, EGFR, ERBB2, FGFR1/2/3, GNA11, GNAQ, IDH1/2, KIT,
MAP2K1, MET, MTOR, NOTCH1, PDGFRA, EPHA2, ESR1, RAC1, and
ROS1) through Bio Reference Laboratories, and gene expression analysis (14
genes: KRT7, TTF-1, TG, PGK-1, CK-20, PTH, CALCA, RAP2A, PLAB,
HMGA2, FN-1, GAL-3, CK19, and NIS) were performed. This assay detected
mutations in 14/19 malignant lesions including 4/7 FCs (NRAS, TP53), 4/4
FVPC (BRAF, NRAS, HRAS, PTEN), 5/7 PCs (BRAF, NRAS), and 1/1 MC
(RET). No mutations were detected in the non-neoplastic thyroid and 1/3 FAs
contained a KRAS mutation. All three mutation-negative FCs were oncocytic
variants and showed upregulation of 2 cancer-associated genes including
FN-1, GAL-3, HMGA2, PLAB, and RAP2a. The two mutation-negative PCs
showed upregulation of 4 cancer-associated genes including FN-1, CK-19,
GAL-3, HMGA2, and PLAB. This upregulation was not seen in non-neoplastic
thyroid and was seen in only 1 of the FAs (FN-1, GAL-3, and PLAB). This small
study demonstrates that a combination of NGS and gene expression increases
the assay sensitivity (100% versus 74% sensitivity) and negative predictive value
(100% versus45% for NGS or gene expression alone). The positive predictive
value of the combined assay was 90% versus 93% for either assay alone. The
addition of gene fusions will likely further improve the assay’s diagnostic capac-
ity. In conclusion, the addition of a gene expression assay to this thyroid NGS
assay allowed for identifıcation of mutation-negative thyroid malignancies. The
improved detection ofmalignant thyroid lesions will allow for better risk assess-
ment for indeterminate nodules as well as improved treatment algorithms.
#5640 The prognostic role of estrogen receptor beta in a female cohort of
colorectal cancer. Geriolda Topi,1 Roy Ehrnström,2 Ingrid Palmquist,3 Marie-
Louise Lydrup,3 Anita Sjölander1. 1Department of Translational Medicine, Divi-
sion of Cell Pathology, Lund University, Malmö, Sweden; 2Department of Trans-
lational Medicine, Division of Pathology, Lund University, Malmö, Sweden;
3Department of Clinical Sciences, Division of Surgery, Lund University, Malmö,
Sweden.
Background: The estrogen receptor beta (ER) is the predominant estrogen
receptor in the colon mucosa, and has been reported to have anti-proliferative
and pro-apoptotic effects. However, the role of estrogen signaling in colorectal
cancer (CRC) progression remains unclear. Aim: To investigate the prognostic
role of ER in a female cohort of CRC. Methods: A tumor tissue microarray of
primary CRCs from 333 female patients was stained with a mouse monoclonal
anti-ER antibody. The intensity of staining was evaluated using immunohis-
tochemistry technique. The expression of ERwas scored using the semi-quan-
titative method [IRS (immune-reactive score)  SI (staining intensity) x PP
(percentage of positive nuclei)]. Overall survival (OS) and disease-free survival
(DFS) were the primary outcomes. Preliminary results are presented. Results:
From 321 patients eligible for survival analysis only 315 had successfulmeasure-
ment of ER (141 with low expression and 174 with high expression). The
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univariate analysis showed no effect of ER onOS, but high ERwas associated
with lower risk of cancer recurrence as indicated by DFS (HR, 0.61; CI, 0.38-
1.02). Cox multivariate analysis indicated that, compared to low expression,
high expression of ER was signifıcantly associated with a decreased risk of
cancer recurrence (HR, 0.39; CI, 0.20-0.77), after adjustment for age, tumor
stage, tumor intravascular invasion and hormonal contraception use. Likewise,
high ER expression was associated with better OS in patients with cancer stage
I-III (HR, 0.52; CI, 0.29-0.94) that did not receive adjuvant treatment after op-
eration. Premenopausal women had a higher mean of IRS for ER compared to
postmenopausal women (p  0.03). Conclusion: High levels of ER signifı-
cantly correlate with a decreased risk of cancer recurrence in CRC patients. We
also noted longer overall survival in the subgroup of patients with cancer stage
I-III that had not received adjuvant treatment after operation. The same results
of OS were observed for colon cancer patients, but not for rectal cancer patients.
A possible explanation could be that most of the rectal cancer patients have
undergone radiotherapy before surgery, which might affect the status of ER.
#5641 Effects of G1T48, a novel orally bioavailable selective estrogen re-
ceptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor
growth in animal models of endocrine resistant breast cancer. Suzanne E.
Wardell,1 Alexander P. Yllanes,1 Jennifer G. Baker,1 Robert M. Baldi,1 Taylor K.
Krebs,1 Jessica Sorrentino,2 John Bisi,2 Jay Strum,2 John D. Norris1. 1Duke Uni-
versity, Durham, NC; 2G1 Therapeutics, Research Triangle Park, NC.
Background: The combination of targeting the CDK4/6 and ER signaling
pathwayswith palbociclib and fulvestrant is a proven therapeutic strategy for the
treatment of ER positive breast cancer. However, the poor physicochemical
properties of fulvestrant require monthly intramuscular injections to patients,
which limit the pharmacokinetic and pharmacodynamic activity of the com-
pound. Therefore, an orally available compound that more rapidly reaches
steady state may lead to a better clinical response in patients. Here we report the
preclinical characterization of G1T48, a novel, orally bioavailable, non-steroidal
small molecule inhibitor of ER	, which is a potent, selective antagonist that
down regulates ER	 in vitro and in vivo in ER-positive models of breast cancer.
Methods: Breast cancer cells expressing clinically relevant ESR1mutations (ER-
Y537S, ER-D538G) were threated with G1T38, G1T48, andmechanistically dis-
tinct SERMs/SERDs and cellular proliferation was assessed by measuring DNA
content (Hoechst dye).Ovariectomizednu/numice bearing xenograft tumors of
clinically relevant tamoxifen (TamR) and aromatase (long term estrogen de-
prived) resistant ER breast cancer were treated with G1T38 and G1T48, alone
or in combination, with clinically relevant comparators. Time to progression
and tumor volume were assessed over a 4 week dosing period. Results: G1T38
and G1T48 signifıcantly inhibited cellular proliferation of MCF7 breast cancer
cells bearing endocrine resistant ER mutations, ER-Y537S and ER-D538G.
G1T48 treatment led to dramatic reductions in ER protein levels. Importantly,
tumor growth inhibition was observed in mouse models of sensitive and resis-
tant human breast cancer when G1T48 was dosed as a single agent or in combi-
nationwithG1T38, a potent, selective CDK4/6 inhibitor. Conclusions: G1T38, a
novel CDK4/6 inhibitor, and G1T48, a novel SERD, either alone or in combina-
tion, demonstrated highly potent inhibition of tumor growth in animal models
of tamoxifen and aromatase resistance. G1T48 also demonstrated activity in
models of endocrine resistance mediated by ER mutation. G1T48 is currently
completing IND enabling studies.
#5642 Quantitative comparison of hydrocortisone and prednisone in the
postoperative hormone therapy of hypercortisolism. Kunlong Tang,1 Yuting
Huang,2 ShangwenDong,1 PengGao3. 1TianjinMedicalUniversityGeneralHos-
pital, Tianjin, China; 2TianjinMedical University Cancer Institute and Hospital,
Tianjin, China; 3University of the District of Columbia, Washington, DC.
Tumors and several types of malignancies including lung cancer, pancreatic
cancer, pituitary tumor, and most often adrenal adenoma, may cause hypercor-
tisolism, which requires glucorticoid (GC) replacement following adrenalec-
tomy and/or surgical resection of the tumor. Based on our previous report of a
simplifıed GC therapy scheme and the perioperative observation, we further
investigated its effıcacy and safety up to 6months post-surgery in this retrospec-
tive cohort study. All patients received no GC before surgery. The i.v. doses of
hydrocortisone (HC) were 100 mg during surgery, 100 mg bid on day 0 and day
1, followed by 100 mg qd on the morning of day 2 post-surgery. Patients were
grouped by oral reception of eitherHC or prednisone since day 2. The doses and
the withdrawal schedule are shown in Table. We found in adrenal adenoma
patients, the adrenocorticotropic hormone (ACTH) levels were normal, and
suffıcient to stimulate the recovery of the dystrophic adrenal cortex, thus exog-
enous supplemental ACTH might not be necessary. By 6 months post-surgery,
prednisone andHCexhibited similar effıcacy in correcting hypertension, hyper-
glycemia, and hypokalemia (p0.05). Most patients lost weight. Both groups
reported signifıcant improvement in a subjective evaluation questionnaire. HC
showed advantages over prednisone in improving liver function (p0.035), but
also caused signifıcant leg edema (p0.034). Both groups developed adrenal
insuffıciency (AI) during GC withdrawal, with no signifıcant difference regard-
ing the incidence rate or severity. Most AI symptoms were relieved by resuming
the prior oral doses, while the severe cases were treated in hospital. No particular
variable was identifıed as risk factor for AI. The withdrawal process may last
longer time for HC than prednisone. HC may be prioritized for patients with
hyperglycemia or abnormal liver function, while prednisone may reduce the
incidence of leg edema.
hydrocortisone prednisone
pathology 22 20
adrenal adenoma 14/22 16/20
Cushing’s Disease 8/22 4/20
oral glucorticoid scheme
dose on day 2 40 mg, tid 10 mg, tid
withdrawal 20 mg/week 5 mg/week
average length (month) 6.6 4.9
correction of symptoms
hypertension 10/15 12/19
hyperglycemia 6/11 7/10
hypokalemia 12/12 11/11
abnormal liver panel 7/8 2/7 *
weight loss 20/22 17/20
adrenal insuffıciency 10/22 7/20
severe case 1/10 1/7
leg edema 6/22 0/20 *
#5643 Physical and functional interactions of exon-skipping variants of
androgen receptor with the full-length counterpart. Takuma Uo,1 Cynthia C.
Sprenger,1 Shihua Sun,1 Robert K. Bradley,2 Peter S. Nelson,2 Stephen R. Plym-
ate1. 1Univ. of Washington Medical Ctr., Seattle, WA; 2Fred Hutchinson Cancer
Research Center, Seattle, WA.
The androgen receptor (AR) is arguably the critical driver of not only early but
also advanced prostate cancer. The recent comprehensive splicing landscapes
revealed that metastatic castration resistant prostate cancer harbors multiple
forms ofARvariants (AR-Vs),many ofwhich have diverse patterns of inclusion/
exclusion of exons (E4-8) corresponding to the ligand-binding domain.We had
used AR-negativeM12 prostate cancer cell line and recently reported character-
istics of AR-Vs with respect to their subcellular localization and transcriptional
activation on luciferase reporter driven by probasin-based promoter (AR2PB-
luc)(1). While ARv5es is predominantly nuclear and constitutively active like
well-documented ARv567es, many others are castration -induced variants are
inactive. AsmanyAR-Vs and the full-lengthAR (AR-FL) are co-expressed in the
same cell, it is important to determine how these inactive AR-Vs interact with
active AR including AR-FL. To this end, we examined two inactive AR-Vs
namely v7es and v56es in relation to AR-FL. ARv7es, which skips exon 7, is
predominantly localized in cytoplasm. ARv7es physically interacted with AR-
FL.Moreover, nuclear accumulation ofARv7eswas promoted by the addition of
dihydrotestosterone (DHT) only in the presence of AR-FL, suggesting that
ARv7es and AR-FL heterodimerize in the nuclear compartment. However,
DHT-dependent transactivation of AR-FL was not affected by the presence of
ARv7es.More specifıcally, inM12 cells, AR2PB-lucwas transactivated byAR-FL
to the similar extents either in the presence or absence of ARv7es. In addition, in
doxycycline (Dox)-inducible ARv7es stable LNCaP cell line (LNCaP/ARv7es),
the presence of ARv7es did not affect DHT-induced expression of endogenous
PSA and NKX3.1 transcripts as well as transactivation of AR2PB-luc. In the
similar setting, when we examined ARv56es which also physically interacted
with AR-FL, Dox-induced expression of ARv56es in LNCaP/ARv56es was suf-
fıcient to induce expression of endogenous PSA and NKX3.1 transcripts. Fur-
ther, DHT-induced expression of these transcripts was enhanced by ARv56es in
LNCaP/ARv56es. Accordingly, we propose that AR-Vs display differential
modes of action on AR-FL as exemplifıed by ARv7es as the bystander and v56es
as the effector. 1. Oncogene (PMID: 27694897).
#5644 The emergence of resistance to tamoxifen in relation to meno-
pausal status, HER-2 status, status of steroid receptor and lymph nodes me-
tastases status. Sinisa Maksimovic. Public Health Institution Hospital ‘Sveti
Vracˇevi’ in Bijeljin, Bijeljina, Bosnia and Herzegovina.
Background: The study used data from medical and counselling of patients
whowere diagnosed with hormonedependent breast cancer. Aim: The objective
of the paper is to identify within a group of patients diagnosed with hormone
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sensitive breast cancer and those who have received adjuvant tamoxifen, and
then to isolate the patients with whom the therapeutic effect of tamoxifen
stopped. Methods: The study analyzed 153 patients in the period from 2005 to
2011, at the Public Health Institution Hospital, Sveti Vracˇevi‘ in Bijeljina. Resis-
tance to tamoxifenwas developed by 60 patients (39.2%) and 93 patients (60.8%)
did not develop resistance to it. Results: More common emergence of resistance
is in the premenopausal group of patients (p0.001). Statistically signifıcant
difference in frequency of resistance to tamoxifen was observed in the group of
patients with ER-/PrR status of steroid receptors (p0.001). In relation to
HER-2 status of diagnosed cancer, a statistically signifıcant difference in fre-
quency of resistance emergence during tamoxifen therapy in patients with
HER2-positive status (p0.001) was observed. We found that there is a statisti-
cally signifıcant difference between patients with metastatic in lymph nodes
compared to patients who had no metastases in lymph nodes (X239.494;
p0.001). Conclusions: The analysis of menopausal status of patients, status of
ER/PgR receptors status, HER-2 status of diagnosed cancer and status of lymph
nodes trying to sort out the parameters on the basis of which a group of patients
who can be expected to develop resistance to tamoxifen could be differentiated.
#5645 Associations between biomarkers and outcome in a patient cohort
with invasive lobular carcinoma.RachelC. Jankowitz,1Kevin Levine,1Maryam
Zamanian,1 Matthew Sikora,2 Nilgun Tasdemir,1 Priscilla McAuliffe,1 David
Dabbs,1 Nancy Davidson,1 Brenda Diergaarde,1 Steffı Oesterreich1. 1University
of Pitttsburgh, Pittsburgh, PA; 2University of Colorado, Denver, CO.
Invasive lobular carcinoma (ILC) represents only 5-15% of all breast cancer.
However, if it were an independent cancer type, it would rank as the sixth most
common cancer in women, as common as non-Hodgkin lymphoma or mela-
noma. ILC is chronically understudied as a breast cancer subtype, but compared
to invasive ductal carcinoma (IDC) ILC is more often HR-positive, HER2-neg-
ative, and lower histologic grade. Despite these favorable tumor characteristics,
recent studies suggest outcome in ILC is not consistent with these favorable
characteristics. We herein describe our single institution experience with ILC.
Using cancer registry data, we identifıed 709 women over the age of 18 (includ-
ing 85 with recurrences) diagnosed at our institution between 1990 and 2011
with HR-positive, early-stage (I-III), primary ILC and potentially available
banked tissue samples. We implemented a case-cohort design to investigate
molecular tumor characteristics associated with ILC prognosis. Patients were
excluded for a history of synchronous bilateral breast cancer at the time of
diagnosis, a prior history of invasive breast cancer, or a diagnosis of non-breast
malignancywithin 5 years prior to their diagnosis of ILC. Originally, a sample of
200 subjects was selected for further study and molecular characterization.
However, tissue acquisition, subject eligibility and verifıcation of recurrences
yielded a sample of in total 131 subjects (including 33 with recurrences), and the
case-cohort design was recreated for this fınal sample. All available information
regarding patient and tumor characteristics, treatment history, and outcome
was collected from medical records. ER, PR, and Ki67 protein (IHC) and RNA
(Nanostring analysis) levels were analyzed with respect to outcome of patients.
PRH-score, but not ERH-score, was signifıcantly associatedwith survival in our
overall ILC cohort. In the case-cohort analysis there was a weak correlation
between ER, PR and Ki67 RNA levels (measured by nanostring) and ER, PR and
Ki67 protein levels (measured by IHC) in the ILC tumor samples. After the
Nanostring data was normalized, box plots were constructed for ESR1, PR and
MKI67 so that a simple t-test could look at gene expression in recurrences and
non-recurrences. There was no signifıcant difference in ER expression between
non-recurrences and recurrences. The recurrence cases had signifıcantly lower
PR expression levels. We will present quantitative ER and PR data, as well as
detailed clinical characteristics for this cohort in relation to outcome.
#5646 Germline activating mutations in the proto-oncogene GCM2 in
primary hyperparathyroidism. Bin Guan,1 James M. Welch,1 Julie C. Sapp,1
Hua Ling,2 Meghana Vemulapalli,1 Yulong Li,1 Jennifer J. Johnston,1 Electron
Kebebew,1 Leslie G. Biesecker,1 William F. Simonds,1 Stephen J. Marx,1 Sunita
K. Agarwal1. 1NIH, Bethesda, MD; 2Johns Hopkins University, Baltimore, MD.
Primary hyperparathyroidism (PHPT) is a common endocrine disease caused
by parathyroid tumors (adenoma or hyperplasia). The hypersecreting parathy-
roid tumor elevates serum parathyroid hormone level, which causes hypercal-
cemia and the classical symptoms of PHPT, including kidney stones, osteopo-
rosis, and neuromuscular symptoms associated with hypercalcemia, such as
muscle weakness, drowsiness, and depression. Familial PHPT occurs in an iso-
lated nonsyndromal form, termed familial isolated hyperparathyroidism
(FIHP), or as part of a syndrome, such as multiple endocrine neoplasia type 1 or
hyperparathyroidism-jaw tumor syndrome. We performed exome sequencing
on germlineDNAof eight index cases from eight unrelated kindreds with FIHP.
Rare variants were identifıed (minor allele frequency 1%), and selected vari-
ants were assessed for co-segregation in affected family members by Sanger
sequencing. Candidate genes were then screened in an additional 32 kindreds
with FIHP. The functional consequence of variants in one FIHP candidate gene
(GCM2, a parathyroid tissue-specifıc transcription factor) was analyzed in a cell
culture model. In eight kindreds with FIHP, we identifıed three rare GCM2
missense variants. Functional characterization of GCM2 variants and deletion-
analyses revealed a small C-terminal Conserved Inhibitory Domain (CCID).
Twoof the three rare variantswere recurrent, located in theCCID that enhanced
the transcriptional activity of GCM2, and found in seven of 40 (18%) kindreds
with FIHP. Functional assays for transcriptional activity demonstrated that
these two rare variants acted as gain-of-function mutations, suggesting that
GCM2 is a parathyroid proto-oncogene.We further investigated the ethnicity of
individuals with GCM2 CCID activating variants in PHPT patient samples and
in genome survey datasets. Our results demonstrate that germline activating
mutations in theGCM2CCIDcan cause FIHP, and specifıc activatingmutations
expose a large population at risk for PHPT. Our fındings of the fırst gene with
mutations specifıc for FIHP are expected to have an important impact on clinical
practice, including treatment decisions and genetic testing of individuals with
PHPT and family members.
CLINICAL RESEARCH: Innate Immunity to Generate Adaptive
Immunity
#5647 Intron retention as a novel source of tumor neoantigens associated
with response to checkpoint inhibitor therapy.Alicia C. Smart,1 Claire Marg-
olis,1 DianaMiao,1 David Liu,1 Jihye Park,1 Meng Xiao He,1 Brendan Reardon,1
Stephanie Mullane,1 Bastian Schilling,2 Levi A. Garraway,1 Dirk Schadendorf,2
Eliezer M. Van Allen1. 1Dana Farber Cancer Institute, Boston, MA; 2University
Hospital, University Duisburg—Essen, Essen, Germany.
Background: Development of immune checkpoint inhibitors has substan-
tially improved outcomes in patients diagnosed with metastatic melanoma.
However, only a minority of patients treated experience long-term clinical
benefıt, and clinicians have limited ability to predict which patients will
respond. Recent studies have demonstrated that the burden of tumor neo-
antigens generated by expressed somatic mutations is predictive of response
to immunotherapy. Intron retention, which is widespread in cancer tran-
scriptomes, represents a putative source of tumor neoantigens by generating
peptides that are available for presentation through the MHC I pathway.
Methods:We developed a neoantigen prediction pipeline to identify patient-
specifıc neoantigens from transcriptome sequencing data, which enables
identifıcation of retained intron neoantigens from clinical cohorts receiving
checkpoint inhibitor therapy. This pipeline incorporates published methods
for detecting intron retention events from transcriptome data, detects open
reading frames that extend from normal transcripts into intronic sequences,
and identifıes neoepitopes predicted as strong binders based on the patient’s
HLA molecules. We applied this pipeline to a cohort of 41 melanoma pa-
tients receiving checkpoint inhibitor therapy and classifıed patient outcomes
as receiving clinical benefıt (CB) (n14), no clinical benefıt (NCB) (n22),
or long-term survival without clinical benefıt (LS) (n5). Results: Our initial
analysis identifıed a mean retained intron neoantigen burden of 7709 per
sample, without signifıcant difference between response groups. In one pa-
tient who derived clinical benefıt from checkpoint inhibition, neoantigen
load from nonsynonymousmutations was low (407, 0.34 standard deviations
(SD) below a mean of 1,015 among CB patients), while retained intron neo-
antigen load was high (14579, 1.7 SDs above a mean of 7517 among CB
patients), suggesting that retained intron neoantigen load may explain re-
sponse in some patients with lowmutational burden. Preliminary analysis of
specifıc neoantigens suggests that a retained intron in ZNF880 identifıed in
patients expressing HLA-A01:01 is present in 6 of 6 patients experiencing
clinical benefıt, but only 2 of 7 patients not experiencing clinical benefıt. The
same analysis was performed on two additional cohorts of melanoma tumor
samples to assess whether a larger sample size could aid in the identifıcation
of recurrent neoepitopes generated by retained introns. Conclusions: Appli-
cation of this approach to data from patients receiving checkpoint blockade
with selective response identifıes response-associated neoantigens that may
warrant further investigation. Identifıcation of a novel source of neoantigens
associated with immunotherapy response will provide valuable prognostic
information to patients and inform the development of next generation im-
munotherapeutics.
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#5648 Combined immune checkpoint targeting with anti-PD-1 plus anti-
CD40 antibodies as the most effective approach to eradicate head and neck
squamous cell carcinomas (HNSCCs) in mouse models. Jose Augusto Mon-
teiro deOliveira Novaes, Alissa R. Poteete,Marlese A. Pisegna, UmaGiri, Fahao
Zhang, Patrick Hwu, John V. Heymach, William N. William. The University of
Texas MD Anderson Cancer Center, HOUSTON, TX.
Introduction: Immunotherapy with single agent anti-PD-1 antibody confers
modest overall survival benefıts in patients with recurrent/metastatic HNSCCs.
Combined immune checkpoint targeting has shown promising results for mel-
anomas and other solid tumors. Thus, evaluation of combination immunother-
apy in animal models specifıc to HNSCCs could inform prioritization and de-
sign of human clinical trials for this disease. We conducted this pre-clinical
study to test the hypothesis that combining anti-PD-1 with either anti-CTLA-4
or co-stimulatory immune checkpoint agonist antibodies would be more effec-
tive than anti-PD-1 monotherapy in a mouse model of oral carcinoma. We also
aimed at identifying the combination regimen with highest anti-tumor activity.
Methods: C57BL/6 mice were subcutaneously grafted with 2x106 mouse oral
cancer 1 (MOC1) cells derived from a carcinogen-induced tumor molecularly
similar to human HNSCC. After 25 days, mice were randomized into one of 12
treatment groups (IgG, or antibodies targeting PD-1, CTLA-4, CD40, OX-40,
GITR, 4-1BB, PD-1CTLA-4, PD1CD40, PD-1OX-40, PD-1GITR, or
PD-14-1BB), N8-9 mice/group. Antibodies were administered every 4 days
for 3 doses. Tumors were measured twice per week. The primary endpoint was
overall survival.Micewere sacrifıcedwhen tumor diameter was2 cmor tumor
ulceration was5mm. Survival curves were computed using the Kaplan-Meier
method and compared using the log-rank (Mantel-Cox) test. Results: In analogy
to human clinical trials, anti-PD-1 therapy led to a modest improvement in
survival compared to IgG [HR0.41; 95%CI 0.06-0.53; P0.015], indicating
that this model recapitulates, in part, the effects of immunotherapy in HNSCC
patients; none of the animals survived long term. Monotherapy with anti-
CTLA-4, anti-CD40, anti-OX-40, or anti-4-1BB also improved survival com-
pared to IgG (P0.0001, 0.003, 0.02, and 0.003, respectively), but were notmore
effective than anti-PD-1 alone (P0.09, 0.12, 0.72, and 0.77, respectively). Com-
bination therapy did not prolong survival compared to anti-PD-1 alone,with the
exception of anti-PD-1 anti-CTLA4 [HR0.36; 95% CI 0.07-0.6; P0.016],
and anti-PD-1 anti-CD40 [HR0.125, 95%CI 0.02-0.24; P0.0003].Notably,
50% of mice receiving anti-PD-1 anti-CD40 antibodies had complete tumor
eradication and are alive and disease-free 120 days after tumor grafting. Con-
clusions: Single agent immunotherapy targeting PD-1, CTLA-4, CD40, OX-40
and 4-1BB modestly improved survival in a mouse model of oral cancer. Com-
bination with anti-PD-1 anti-CTLA4 and anti-PD-1 anti-CD40 antibodies
outperformed anti-PD-1 monotherapy. Complete responses were exclusively
seen with PD-1CD40 dual targeting. This regimen should be prioritized for
evaluation in HNSCC clinical trials.
#5649 Cell-intrinsic PD-L1 directs tumor initiating cell fate and rapamy-
cin and interferon- response.Harshita B.Gupta,1 CurtisA.Clark,1 BinYuan,1
Gangadhara Sareddy,1 Srilakshmi Pandeswara,1 Alvaro S. Padron,1 Vincent
Hurez,1 Jose-Conejo Garcia,2 Ratna Vadlamudi,1 Rong Li,1 Tyler J. Curiel1.
1UTHSCSA, San Antonio, TX; 2The Wistar Institue, Philadelphia, PA.
Tumor initiating cells (TIC) foster treatment resistance and tumor relapse.
We show here that in mouse B16 (melanoma) and ID8agg (ovarian carcinoma),
andhumanovarian cancer ES2, PD-L1 knockdown (shRNA) reducedTICnum-
bers and functions. Data shown are from 2 PD-L1lo clones/cell type. Sorted,
control CD44CD133CD24 (B16), CD44CD24 (ID8agg) and ALDHhi
(ES2) TIC formed 50-75% more and bigger spheres vs. PD-L1lo TIC in vitro,
consistent with reduced TIC self-renewal in PD-L1lo. In vivo, PD-L1lo B16 and
ID8agg TIC exhibited reduced tumorigenicity in wild typemice, consistent with
poor TIC function, but immune effects could not be excluded. B16 and ES2
PD-L1lo TIC had signifıcantly reduced tumorigenicity versus control TIC in
immune defıcient NSG mice consistent with cell-autonomous, immune-inde-
pendent TIC promotion by PD-L1. In further confırmation, we found reduced
serial transplantability of PD-L1lo B16 TIC in NSG mice. The canonical stem-
ness genes nanog and pou5f1 (oct4) were signifıcantly higher in control vs.
PD-L1lo TIC for B16 and ID8agg. The canonical stemness gene SOX2 was sig-
nifıcantly higher in control vs. PD-L1lo ES2 TIC. Altogether, these data validate
effects in human cells, and are consistent with PD-L1 driving TIC through stem-
ness gene control, although specifıc genes differed in distinct tumors (likely due
to differing mutational landscapes). mTORC1 signaling linked to stemness (as-
sessed by raptor) was lower but mTORC2 was unaffected (rictor) in PD-L1lo vs
control TIC from all 3 tumors, suggestingmTORC1 control of PD-L1-mediated
TIC generation. In support, the mTORC1 inhibitor rapamycin reduced control
TIC signifıcantly (50% vs. untreated). Strikingly, rapamycin signifıcantly in-
creased PD-L1lo TIC in all 3 tumors, suggestingmTORC1 effects differ by tumor
PD-L1 status. Interferon (IFN)- similarly reduced control TIC and augmented
PD-L1lo TIC numbers, suggesting the novel concept that PD-L1 alters IFN-
signals. PD-L1 sensitization of TIC to IFN- and rapamycin is the fırst example
of amolecule enhancing TIC treatment response to our knowledge.We recently
reported that	PD-L1 directly reduces B16 and ID8agg proliferation in vitro and
in vivo (accession no. 27671674). Preliminary data now show that 	PD-L1 (and
	PD-1) directly reduce TIC proliferation, and these effects differ fromnon-TIC.
We challenge the paradigm that tumor PD-L1 is primarily an immune escape
molecule and that 	PD-L1 works primarily to block T cell PD-1 interactions.
#5650 Enhancement of CAR-T cell activity via PD-1 knockdown by self-
deliverable RNAi. Alexey Wolfson,1 Alexey Eliseev,1 Taisia Shmushkovich,2
Monica Betancur-Boissel,2 Monica Betancur-Boissel,2 Nathalie Scholler3. 1Mir-
Immune, Boston, MA; 2Advirna, Cambridge, MA; 3SRI International, Menlo
Park, CA.
Background: A growing body of evidence indicates that the blockade of PD-1
and other immunosuppressive receptors can increase the effıcacy of adoptively
transferred cells in immunotherapy for cancer. The expression of PD-1 can be
suppressed by ex vivo treatment of transferred lymphocytes by self-deliverable
RNAi (sd-rxRNA®) compounds. sd-rxRNAs are based on proprietary chemical
modifıcations of siRNA compounds making them stable to nuclease degrada-
tion and capable of penetration into target cells without the use of transfection
reagents or physicalmethods.Aim:Todeterminewhether the reduction of PD-1
by ex vivo treatment of mesothelin-targeting CAR-T cells with sd-rxRNA will
improve the effıcacy of meso-CAR-T cells in a mouse model of ovarian cancer.
Methods: Second-generation human CAR-T cells expressing P4 antibody frag-
ments targeting mesothelin (meso-CAR-T) were treated ex vivo with PD-78, a
self-deliverable siRNA silencing the PD-1 gene. The meso-CAR-T cells were
then injected into tumors in a xenograft mouse model of human ovarian cancer
(A1847 cell line expressing mesothelin and PD-L1) in NSG mice. The tumor
volumes were monitored over the course of one month. After the animals were
sacrifıced, human CD45-containing cells extracted from the tumor were ana-
lyzed for PD-1 expression by flow cytometry. Results:We observed a statistically
signifıcant reduction in tumor growth in the group of mice injected with meso-
CAR-T cells pretreated ex vivo with PD-78. The post-mortem tumor analysis by
flow cytometry showed that the expression of PD-1 in meso-CAR-T cells was
signifıcantly suppressed for the full duration of the experiment (one month).
Conclusion: Our results suggest that the silencing of immunosuppressive genes
by ex vivo treatment with sd-rxRNAmay improve effıcacy of CAR-T cells in the
treatment of solid tumors. A similar approach may be applied to other types of
adoptive cell transfer.
#5651 A LAG-3/PD-L1 bispecifıc antibody inhibits tumor growth in two
syngeneic colon carcinoma models. Matthew Kraman, Katarzyna Kmiecik,
Carlo Zimarino, Katy Everett, Mustapha Faroudi, Mateusz Wydro, Jacqueline
Doody. F-star Biotechnology Ltd, Cambridge, United Kingdom.
Combining immunotherapeutic antibodies in cancer treatment has shown
benefıts over single agents. An alternative to combining two antibodies is the
development of bispecifıc antibodies that not only bring two biologies together
but may result in novel mechanisms of action that are impossible to attain with
combinations. Lymphocyte Activation Gene-3 (LAG-3) is a member of the Ig
superfamily expressed on activated T cells, NK cells, pDCs, B cells,
T cells and
participates in immune suppression. Programmed Cell Death receptor (PD-1)
binds to its ligand PD-L1, expressed not only on activated immune cells to
inhibit cellular immune responses but also on tumor cells. Expression of both
these surface molecules therefore leads to T cell exhaustion allowing the tumor
to escape immune surveillance. AmAb² TM (bispecifıc antibody)was engineered
which binds murine LAG-3 and PD-L1 simultaneously and with nanomolar
affınities. The anti-LAG-3/PD-L1 mAb² inhibits LAG-3 binding to MHCII and
PD-L1 binding to PD-1 and CD80, resulting in T cell activation in vitro. This
translates into in vivo effıcacy, where the mAb² decreased tumor burden in the
MC38 colon carcinoma tumor model. At the end of the study tumor-free ani-
mals were more numerous in the LAG-3/PD-L1 bispecifıc group than in the
group given a combination of individual anti-LAG-3 andPD-L1 antibodies. The
results were recapitulated in the CT26 murine colon cancer model, where
the mAb² showed an increase of antitumor activity as compared to the antibod-
ies given in combination. Thus, the preclinical data supports developing an
anti-human LAG-3/PD-L1 mAb² for the treatment of cancer patients.
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#5652 Translational evidence of reactivated innate and adaptive immu-
nity with intratumoral IMO-2125 in combination with systemic checkpoint
inhibitors from a Phase I/II study in patients with anti-PD-1 refractorymet-
astatic melanoma. Cara Haymaker,1 Marc Uemura,1 Ravi Murthy,1 Marihella
James,1 Daqing Wang,2 Julie Brevard,2 Suzanne Swann,2 James Geib,2 Mark
Cornfeld,2 Srinivas Chunduru,2 Sudhir Agrawal,2 Cassian Yee,1 Jennifer
Wargo,1 Rodabe Amaria,1 Sapna Patel,1 Hussein Tawbi,1 Isabella Glitza,1 Scott
Woodman,1 Wen-Jen Hwu,1 Michael A. Davies,1 Patrick Hwu,1 Willem Over-
wjik,1 Chantale Bernatchez,1 Adi Diab1. 1UT MD Anderson Cancer Center,
Houston, TX; 2Idera Pharmaceuticals, Inc., Cambridge, MA.
Background: While checkpoint inhibitor (CPI) therapy has transformed
metastatic melanoma (MM) treatment, many patients remain refractory.We
reasoned that combining CPI with an agent that activates antigen presenting
cells and improves T-cell priming may result in improved response. Our
approach is to modulate the tumor microenvironment through image-
guided intratumoral (i.t.) injection of the TLR9 agonist, IMO-2125, in com-
bination with either ipilimumab (ipi) or pembrolizumab (pembro). We hy-
pothesize that this will result in dendritic cell (DC) activation and induction
of tumor-specifıc CD8T-cells which will synergize with ipilimumab or
pembrolizumab to overcome immune-escape. Based on this rationale we
initiated a phase I/II clinical trial. Study Design/Methods: Adults with re-
fractory MM that have had prior PD-1 blockade therapy (with or without a
BRAF inhibitor) are eligible. IMO-2125, in doses escalating from 4mg to
32mg, is given i.t. weeks 1, 2, 3, 5, 8, and 11 along with standard doses of
ipilimumab or pembrolizumab. Primary endpoints are safety, tumor re-
sponse, and PK. Multiple biopsies are obtained in both the injected and
distant tumor pre- and on-treatment. Immune analyses include DC subsets
and their activation status as well as T cell activation, function and prolifer-
ation. T-cell repertoire diversity is evaluated by high-throughput CDR3 se-
quencing and changes in gene expression signatures are assessed by nanoS-
tring. Changes in circulating cytokines are also being assessed during
therapy. Results: Enrollment is proceeding on both the IMO-ipilimumab
and IMO-pembrolizumab dose-escalation arms of the trial. Safety is accept-
able with no DLT recorded to date. Durable clinical responses (including 1
CR) have been observed with IMO-ipilimumab in patients who were refrac-
tory to PD-1 inhibitor. Fresh tumor biopsies showmaturation (upregulation
of HLA-DR) of the myeloid DC1 subset (CD1cCD303-), upregulation of
PD-L1 by malignant cells, as well as an IFN	 response gene signature in the
IMO-2125 injected tumor lesion 24 hrs post-treatment compared to pre-
treatment biopsy. On-treatment biopsy results show a higher expression of
CD56 and Ki67 effector CD8 T-cells in responding patients. Initial
CDR3 sequencing demonstrates increased diversity in the injected lesions of
all patients assessed and expansion of top clones present in the distant lesion
in a responding patient. Plasma analysis showed an increase in IFN levels in
the plasma of responding patients. Conclusions: These results demonstrate
that IMO-2125 with a checkpoint inhibitor is a viable strategy to revive the
immune response in tumors that are refractory to PD-1 inhibitors. Further
clinical evaluation of both the IMO-ipilimumab and IMO-pembrolizumab
combination is planned in a Phase 2 expansion of the current trial.
#5654 Lymphodepletion induces T cell homeostatic proliferation and
augments antitumor effects of PD-1/PD-L1 blockade therapy.Masashi Arita,
Satoshi Watanabe, Takahashi Miho, Miyuki Sato, Aya Ohtsubo, Kosuke
Ichikawa, Rie Kondo, Tetsuya Abe, Junta Tanaka, Toshiyuki Koya, Toshiaki
Kikuchi. Niigata University, Niigata City, Japan.
Programmed death receptor-1 (PD-1)/programmed death receptor ligand-1
(PD-L1) blockade therapy has demonstrated to enhance antitumor immunity.
Recent evidence has shown that anti-PD-1/PD-L1 therapy restores the function
of exhausted effector T cells and augments antitumor immune responses. The
expression of PD-L1 has been best studied as a biomarker for the anti-PD-1/
PD-L1 therapy. Because PD-L1 expression on tumor cells is induced by IFN-
which is mainly produced by effector T cells, induction of antitumor effector T
cells in cancer patients could be an important for the anti-PD-1/PD-L1 therapy.
Indeed, previous studies have suggested that the increase of tumor-infıltrating
lymphocytes is the predictive biomarker for PD-1/PD-L1 blockade therapy.We
and others have demonstrated that lymphodepletive therapies, such as chemo-
therapy and radiotherapy, induce tumor-specifıc effector T cells from naïve T
cells. Naïve T cells rapidly proliferate and elicit memory-like functions after
lymphodepletion (homeostatic proliferation). These fındings indicate that lym-
phodepletive regimens could augment the antitumor effıcacies of the anti-PD-
1/PD-L1 therapy. In the current study, we transferred naïve T cells into mice
after whole-body irradiation or chemotherapy. These mice were inoculated s.c.
with PD-L1 B16F10 melanoma cells or PD-L1- MCA205 fıbrosarcoma and
then were treated with anti-PD-1 mAbs. Lymphodepletion by whole body irra-
diation, but not cytotoxic agents following the transfer of naïve T cells signifı-
cantly enhanced antitumor immunity of anti-PD-1 mAbs. This augmentation
required both of CD4 andCD8T cells, but not NK cells. Further experiments
revealed that immune cells infıltrating MCA205 expressed PD-L1. Transfer of
naïve T cells from IFN- knockout mice abrogated the enhancement of antitu-
mor effects of anti-PD-1 mAb therapy by lymphodepletion. These results sug-
gest that lymphodepletion induces homeostatic proliferation of T cells and aug-
ments antitumor effects of PD-1/PD-L1 blockade therapy.
#5655 Inhibition of CCR2 potentiates checkpoint inhibitor immunother-
apy in murine model of pancreatic cancer. Christine Janson, Heiyoun Jung,
Linda Ertl, Shirley Liu, TonDang, Yibin Zeng, Antoni Krasinski, JeffMcMahon,
Penglie Zhang, Israel Charo, Rajinder Singh, Thomas J. Schall. ChemoCentryx,
Mountain View, CA.
Pancreatic cancer is an aggressivemalignancywith a 5 year survival rate of less
than fıve percent. The predominant immune cells infıltrating the tumor mi-
croenvironment are monocytes/macrophages, which are reported to support
tumor growth by suppressing host immune responses to the tumor. Recruit-
ment of monocytes to various tissues, including tumors, is dependent upon
activation of the chemokine receptor CCR2 by one or more of the chemokines
CCL2, CCL8 and CCL13. In preclinical and clinical studies, inhibition of CCR2
in pancreatic cancer has shown to decrease tumor progression by blocking re-
cruitment and accumulation ofmonocytes/macrophages in the tumormicroen-
vironment. Analysis of human pancreatic tumors revealed elevation of both
CCL2 and CSF1, which recruit monocytes, as well as the monocyte marker
CD14, in advanced pancreatic cancers. Current immunotherapy using check-
point inhibitors are effective in some tumors, but lack effıcacy in immune insen-
sitive cancers, including pancreatic cancer. Here, we report that the inhibition of
CCR2 using a small molecule antagonist potentiates anti-PD-1 immunotherapy
in a syngeneic, orthotropic mouse model of pancreatic cancer. Our data reveal
that blocking CCR2 decreases tumor burden by blocking monocyte infıltration
and creating a microenvironment more favorable for CD8 T cells activity, and
provide a mechanistic rationale for investigating the combination of a CCR2
antagonist and an immune checkpoint inhibitor in pancreatic cancer.
#5656 Quantitative measurement of PDL1 expression across tumor types
using laser capture microdissection and reverse phase protein microarray.
Elisa Baldelli,1 Valerie Calvert,1 K. Alex Hodge,1 Maria Isabella Sereni,1 Guido
Gambara,1 Eric B. Haura,2 Lucio Crino’,3 Bryant Dunetz,4 Sergio Pecorelli,5
David J. Perry,6 Stephen P. Anthony,7 Nicholas Robert,8 DonaldW. Northfelt,9
Mohammad Jahanzeb,10 Emanuel F. Petricoin,1 Mariaelena Pierobon1. 1George
Mason University, Manassas, VA; 2H. Lee Moffıtt Cancer Center and Research
Institute, Tampa, FL; 3S.Maria della Misericordia Hospital, Perugia, Italy; 4The
SideOut Foundation, Fairfax, VA; 5University of Brescia, Brescia, Italy; 6MedStar
Washington Hospital Center, Washington DC, DC; 7Evergeen Hematology &
Oncology, Spokane,WA; 8Virginia Cancer Specialists, Fairfax, VA; 9Mayo Clinic,
Scottsdale, AZ; 10University of Miami, Miami, FL.
Background: The effıcacy of immunotherapy, including therapeutic strat-
egies capable of modulating innate/adaptive immune resistance, varies
greatly across tumor types. As the number of available immunotherapies
accelerates, the study of predictive markers by IHC (e.g. PDL1 expression) is
under intense investigation. However, staining protocol inconsistency, vari-
ation across scoring systems, and subjective interpretation of the immuno-
staining have produced conflicting results thus far. This work explored the
role of Laser Capture Microdissection (LCM) coupled with Reverse Phase
Protein Microarray (RPPA) as an alternative high throughput, quantitative,
operator independent platform for measuring PDL1 expression across tu-
mor types. Material andMethods: Pure epithelial cells were isolated via LCM
from 178 samples including: 72 ovarian cancers (OC), 57 lung adenocarci-
nomas (LC), 30 metastatic breast cancers (MBC), and 19 pancreatic cancers
(PC). PDL1 expression was measured on a continuous scale using quantita-
tive RPPA based analysis. Each tumor type was processed and arrayed inde-
pendently. Experimental samples and reference standards used for inter-
assay normalization were printed in triplicates. Results: PDL1 expression
varied greatly across tumor types. LC were characterized by the greatest
intra-tumor fold dynamic range ( 35-fold), followed by OC ( 13-fold),
MBC ( 4-fold), and PC ( 2-fold). PDL1 expression of 46/57 (80.7%) LC,
17/30 (56.7%) MBC, 6/19 (31.5%) PC, and 20/72 (27.8%) OC was greater
than the population median of all tumors combined. Within the LC samples
with PDL1 expression equal to the top quartile of the population, 10 (71.4%)
were KRAS mutant lesions and 4 (28.6%) were WT tumors. Finally, amongst
LC and PC harboring a KRAS mutation, PC showed an overall lower expres-
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sion of PDL1 with only 2/19 (10.5%) cases been above the populationmedian
and none within the top quartile of the population. Conclusions: The LCM-
RPPA workflow has the unique ability to capture immune checkpoint ex-
pression on a continuous quantitative scale as well as capture its broad dy-
namic range. Because RPPA is unconstrained by antigen retrieval issues as
well as subjectivity of IHC interpretation, this approach may generate more
accurate cut-point of therapeutic response prediction. Overall the dynamic
range of PDL1 was broader in LC compared to other solid tumors, and LC
had a much higher proportion of patients with tumors expressing high levels
of PDL1. These quantitative differences may explain therapeutic effıcacy of
PDL1 inhibition across tumor types. Such speculative hypothesis should be
further validated in prospective clinical trials. Finally, these preliminary data
suggest that organ specifıc microenvironments more than specifıc driving
mutations (e.g. KRAS)may strongly influence PDL1 expression inmalignant
lesions.
#5657 Objective measurement and signifıcance of VISTA (PD-1H) ex-
pression in non-small cell lung cancer (NSCLC). Franz Villarroel-Espindola,1
Ila J. Datar,1 Vamsidhar Velcheti,2 David L. Rimm,1 Roy S. Herbst,3 Kurt A.
Schalper1. 1Yale School of Medicine, New Haven, CT; 2Cleveland Clinic, Cleve-
land, OH; 3Medical Oncology Yale Cancer Center, New Haven, CT.
Introduction: VISTA (PD-1H) is a member of the B7 family of immune co-
regulatory molecules and has been proposed as a novel anti-cancer immuno-
therapy target. The intra- and extracellular domains of VISTA show homology
to PD-1 and PD-L1, respectively, suggesting a role in anti-tumor immune eva-
sion. The expression of VISTA, its association with PD-1 axis components and
biological role in humanNSCLCare unknown.Methods:Usingmultiplex quan-
titative immunofluorescence (QIF), we simultaneously measured the levels of
VISTA (clone D1L2G, CST), PD-L1 (clone 405.9A11, CST) and PD-1 (clone
EH33, CST) protein in 732 stage I-IV NSCLCs from 3 retrospective collections
represented in tissue microarray format (cohort #1 [n297, Yale], cohort #2
[n329, Greece]; and cohort #3 [n106, Yale]). To evaluate the tumor tissue
distribution, VISTA was also selectively measured in cytokeratin tumor cells,
CD3 T-cells, CD4 T-helper cells, CD8 cytotoxic T-cells and CD20 B-
lymphocytes. Associations between the marker levels, clinico-pathological-mo-
lecular variables and survival were studied. Results: VISTA protein was detected
in all NSCLCs, showed a membranous staining pattern and was localized pre-
dominantly in the tumor cells in 27.4%of cases; and in the stromal compartment
in 98.5%. Although VISTAwas detected in all major tumor infıltrating lympho-
cyte (TIL) subsets, the signalwas higher inCD20B-cells than inCD3T-lym-
phocytes (P0.05); and in CD4 helper than in CD8 cytotoxic T-cells
(P0.001). Using the median score as cut point, elevated VISTA in tumor
and/or stromal cells was signifıcantly associated with high PD-L1, PD-1 protein
expression and increased CD8TILs in the cohorts (P0.001 - P0.05). No
consistent association between VISTA levels and age, gender, smoking status,
specifıc NSCLC histology, stage, EGFR/KRAS mutations and overall survival
was found. Conclusion: VISTA is expressed in the majority of NSCLCs and
shows differential distribution in tumor/stromal cells and TIL subsets, suggest-
ing a complex function as a ligand and receptor. Elevated expression ofVISTA in
NSCLC is associated with increased PD-1 axis targets and cytotoxic T-cell den-
sity, indicating its possiblemodulation by pro-inflammatory signals. Our results
support VISTA as a candidate target for anti-cancer immunotherapy in NSCLC
alone or in combination with PD-1 axis blockers.
#5659 Local treatment with novel TLR9 agonist IMO-2125 demonstrates
antitumor activity in preclinical models of pancreatic cancer. Daqing Wang,
Evren Kocabas Argon, Fugang Zhu, Sudhir Agarwal. Idera Pharmaceuticals,
Inc., Cambridge, MA.
Pancreatic cancer remains a serious unmet medical need. The majority of
pancreatic tumors are composed of stromal cells that make tumors resistant to
conventional therapies. We are developing an approach in which a TLR9 ago-
nist, IMO-2125, is administered intratumorally, which induces local Th1 re-
sponses andmodulates the tumormicroenvironment. This approach has shown
promising antitumor activity in preclinical models of multiple tumor types in
combination with checkpoint inhibitors. We are employing a similar approach
to the treatment of pancreatic cancer.We evaluated the local therapeutic effect of
IMO-2125 in a murine syngeneic pancreatic ductal adenocarcinoma (Panc02)
cancer models. In the fırst study, C57BL/6 mice were intraperitoneally (i.p.)
implanted with Panc02 cells to generate peritoneal metastatic cancer. Tumor-
bearing mice (n10 per group) were then treated with 2.5 mg/kg IMO-2125
either by i.p. or subcutaneous (s.c.) injections for six times in two weeks. In the
second study, to establish dual solid tumors in C57BL/6 mice, Panc02 cells were
subcutaneously implanted in both the right and left flanks of the animals.When
tumors reached to 50-150mm3, we started the intratumoral (i.t.) administration
of IMO-2125 in right tumors at doses of either 0.25mg/kg, 1mg/kg or 2.5mg/kg,
or PBS (n10 per group), 3x/week for three weeks. In the peritoneal metastatic
pancreatic tumor model, 80% of IMO-2125 intraperitoneally treated mice sur-
vived formore than 88 days, while 90% of the control group died within 29 days.
Compared to i.p. treatment, the s.c. treated group survived for only 36 days.
Tumor-free mice from the IMO-2125 i.p treatment group (n7) rejected the
same tumor rechallenge, suggesting establishment of durable tumor-specifıc
immune response. In the dual solid pancreatic tumormodel, intratumoral IMO-
2125 treatment led to a dose dependent antitumor activity in both injected and
distant tumors. Tumors treated with 0.25, 1 and 2.5 mg/kg doses of IMO-2125
showed reductions in tumor volume by 66% (p 0.004), 74% (p 0.002) and
95% (p 0.003), respectively. Moreover, the distant tumors exhibited a reduc-
tion of 0% (p  0.65), 64% (p  0.006) and 69% (p  0.001), respectively.
Antitumor activity was associated with increased T-cell infıltration and upregu-
lation of the gene expression of various checkpoints in both treated and distant
tumors. In an independent study, treatment with a control IMO showed mini-
mal antitumor activity. All treatments were well tolerated. In summary, local
treatment with IMO-2125 exerts antitumor activity in preclinical pancreatic
cancer models, associated with an increase in T-cell infıltration in the tumor
microenvironment, providing a novel approach to the treatment of pancreatic
cancer. The clinical trial of intratumoral IMO-2125 is in progress in patients
with melanoma.
#5660 Tumor cell death caused by INT230-6 induces protective T cell
immunity. Anja C. Bloom,1 Lewis H. Bender,2 Ian B. Walters,2 Katharine T.
Clark,1 Masaki Terabe,1 Jay A. Berzofsky1. 1National Cancer Institute, Bethesda,
MD; 2Intensity Therapeutics Ltd, Westport, CT.
Standard care for many types of cancer involves systemic administration of
cytotoxic agents. Thismay result in lowdrug concentration at tumor sites, which
limits cell killing. More recently it has been shown that cytotoxic formulations
designed for intratumoral delivery improve drug effıcacy presumably by in-
creasing drug concentration at the tumor site. Furthermore, it has been discov-
ered that the mechanisms of anticancer agents extend beyond direct tumor cell
lysis. One major aspect is that cell death often induces an immune response.
Different types of cell death such as necrosis, apoptosis and autophagic cell death
induced by cytotoxic agents trigger immune responses with varying degrees of
inflammation and involving different types of immune cells. The ideal immune
responses that may give maximum benefıt to patients would be strong and long
lasting anti-tumorT cell responses. In this study, a novel, tissue and cell diffusive
cytotoxic formulation, INT230-6, was administered intratumorally over 5 se-
quential days into subcutaneous 300mm3 murine Colon26 tumors. Treatment
resulted in regression from baseline of 100% of the tumors and up to 80% com-
plete response (CR). We then analyzed the T cell responses in the protection
induced by INT230-6. No animals achieved a CR after CD8 or CD8/CD4 double
depletion at treatment onset, indicating a critical T-cell role in tumor regression.
Mice with CRs were protected from re-challenge by either subcutaneous or
intravenous re-inoculation of the Colon26. The protection was abrogated by
CD4/CD8 double depletion prior to the re-challenge, indicating that immuno-
logical T cell memory was induced and was necessary for protection. Hence,
INT230-6 given locally to treat tumors induces tumor-specifıc protective T cell
immunity. Colon26 tumors express the endogenous retroviral protein gp70
containing the AH-1 CTL epitope. AH-1-specifıc CD8 T cells were detected in
tumors of mice without treatment. However, these highly expressed PD-1. This
was consistent with the observation that the PD-1 blockade enhanced the effı-
cacy of INT230-6. Conversely, INT230-6 enhances the effıcacy of checkpoint
inhibitors.
#5661 TargetingCD47 expression onmacrophages regulates immunome-
tabolismenhancing tumoricidal activity against cancer cells.AshleyA. Smith,
Adam S. Wilson, David R. Soto-Pantoja.Wake Forest School of Medicine, Win-
ston Salem, NC.
Macrophage mediated elimination of cancer cells is critical for control of
tumor growth. Cancer cells evade immune recognition by expressing receptors
that send inhibitory signals to prevent macrophage mediated cytotoxicity. Clin-
ical studies show that overexpression of the cell surface receptor CD47 is a poor
prognostic factor in cancer, allowing tumors to bypass immunosurveillance and
activation pro-growth pathways. Prior studies have described that CD47 cell
surface expression on cancer cells inhibits phagocytic activity through engage-
ment of its counter receptor SIRP	 onmacrophages. However, the role of CD47
expression on macrophage function is not known. Here, we show that CD47 is
expressed on primary mouse macrophages, RAW 264.7 and the U937 cell lines.
Moreover, knockdown of CD47 on macrophages enhanced the tumoricidal ca-
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pacity against melanoma and breast cancer cells as measured by cell impedance
and LDH release. Blockade of CD47 enhanced the macrophage-mediated cyto-
toxicity against B16 melanoma and 4T1 cells when compared to untreated ef-
fector/target pairs. Blockade of CD47 on differentiated U937 humanmonocytes
also enhanced tumoricidal activity against the triple-negative breast cancer cell
line MDA-MB-231 by over 50% when compared to untreated co-cultures. This
indicates that expression of CD47 on macrophages may play a role in polariza-
tion and macrophage tumoricidal capacity against cancer cells beyond the
known interactions with SIRP	. Our previous studies show that blockade of
CD47 preserves T cell viability under stress by increasing glycolytic flux. Acti-
vation of M1 cytotoxic macrophages requires a shift in metabolism from oxida-
tive phosphorylation to glycolysis. Our data shows that blockade of CD47 on
RAW 264.7 macrophages increases glycolytic flux when compared to untreated
controls as measured by extracellular acidifıcation rate (ECAR) using a Sea-
horse© XF analyzer. The increase in glycolysis was associated with a signifıcant
elevation of glucose uptake by macrophages treated with anti-sense CD47 mor-
pholino, indicating that targeting this receptor regulates glucose metabolism to
improve macrophage tumoricidal activity. Interestingly, blockade of CD47 in
the 4T1 breast cancer cell line reduced ECAR and reduced glucose uptake indi-
cating that targeting CD47 reverses Warburg metabolism in cancer cells. Over-
all, these results show a new role of CD47 expression that extends beyond sup-
pressing macrophage mediated killing through engagement of SIRP	.
Therefore, anti-CD47 immunotherapymay regulate immunometabolism to im-
prove clinical outcomes of cancer patients.
#5662 MEK inhibitors potentiate tumor immune surveillance by enhanc-
ing cancer cell response of IFN.Mengyu Xie, Hong Zheng, Amer Beg.Moffıtt
Cancer Center, Tampa, FL.
FDA approved mitogen-activated protein kinase (MAPK) kinase (MEK) tar-
geting inhibitors such as trametinib have recently been reported to enhance
anti-tumor immunity in multiple preclinical models. It is hypothesized that the
combination of such MEK inhibitors with immune checkpoint blockade will
have synergistic effects and cause further tumor regression. Immune checkpoint
inhibitors such as anti-PD-1 overcome immunosuppressive signaling in the
activated T cells, yielding higher levels of Interferon-gamma (IFN) release.
IFN plays a key role in a wide range of immune responses by direct activation
of JAK-STAT1 pathway through the binding of IFN receptor. JAK-STAT1
regulates transcription of downstream effector genes that are involved in tumor
immune surveillance. Many studies have shown that in cancer cells, transcrip-
tion of T cell chemokines CXCL9,10,11, as well as PD-L1 and MHC-I are in-
duced upon stimulation with IFN. While there are some recent studies indi-
cating MEK inhibitors enhance T cell activity and function, here we report for
the fırst time that targeted inhibition of MEK increases tumor cells response to
IFN and results in signifıcant upregulation of target genes including T cell
chemokines, MHC-I, as well as PD-L1. We treated a panel of 20 human lung
cancer cell lines with MEK inhibitor U0126 followed by IFN stimulation, and
showed that the expression of CXCL10 is signifıcantly increased as compared to
IFN stimulation alone. Furthermore, we found that instead ofMEK inhibition,
knock down of KRAS in the KRAS mutant cell lines such as A549 and H2122
results in more dramatic CXCL10 upregulation upon IFN stimulation. This
indicates the potential of increasing tumor T cell infıltration uponMEK targeted
therapy. Next, to elucidate the underlying molecular mechanism, we analyzed
JAK-STAT1 pathway inmouse lung cancer cell lines LKR, 344, and colon cancer
cell line CT26, in which trametinib mediated synergistic expression of
CXCL9,10, 11 and MHC-I, PD-L1 were observed. The phosphorylation as well
as total protein of JAK2, STAT1 are increased in cells that are pre-treated with
trametinib, as compared to IFN stimulation alone. Treatment of JAK inhibitor
Ruxolitinib as well as knockout of IFNR1 in LKR cells completely abolishes
CXCL10 expression. Importantly, trametinib enhanced response to PD-1 block-
ade in the lung tumor models. In conclusion, our study demonstrates that tar-
geting MEK signaling in cancer cells increases the response of IFN through
JAK-STAT1 pathway, whichmay potentially enhance immune surveillance and
response to immune checkpoint blockade.
#5663 A potential role for NKG2A to influence post-transplant outcomes
in multiple myeloma. Jennifer Cooperrider,1 Paul D. Ciarlariello,2 Tiffany
Hughes,2 Nita Williams,2 Craig Hofmeister,2 Robert Baiocchi,2 Don M. Ben-
son2. 1Ohio State University College of Medicine, Columbus, OH; 2Ohio State
University, Columbus, OH.
While there is currently no clear consensus regarding optimal maintenance
therapy after autologous stem cell transplant (autoSCT), the early post-trans-
plant setting is a potential site of augmentation to improve post-transplant out-
comes. We previously characterized stem cell graft lymphocytes in association
with progression free survival (PFS) after autoSCT in multiple myeloma (MM),
and showed that there was an inverse correlation between NKG2A expression
onCD56dimNKcells andPFS. Therefore, we aimed to investigate a potential role
for NKG2A modulation, especially in the post-transplant setting with mainte-
nance chemotherapy. We performed immunophenotypic analyses of NK cells
frompatients in the immediate post-transplant setting as well as frompatients at
various time points after transplant on lenalidomide maintenance therapy. In
the immediate post-transplant setting (mean time since transplant13 days)
NKG2Awas upregulated onNK cells when comparedwithKIR2DL1 (p0.001)
and KIR2DL2 (p0.002). Additionally, in immunophenotypic analyses of
PBMC from MM patients on various treatments, patients receiving lenalido-
mide maintenance therapy that recently underwent stem cell transplant (mean
time since transplant0.53 years) had elevatedNKG2A expression compared to
patients receiving no treatment (p0.029). Conversely, patients receiving lena-
lidomide maintenance therapy over years (mean time since transplant4.21
years) after transplant showed reduced NKG2A expression compared to pa-
tients receiving no treatment (p0.0161). In bone marrow aspirates from pa-
tients with MM, primary CD138-positive myeloma cells in the bone marrow
express HLA-E, the cognate antigen for NKG2A, which makes the overexpres-
sion of NKG2A biologically relevant. These data suggest that the NKG2A/
HLA-E checkpoint axismay bemore biologically relevant thanKIR inmyeloma,
particularly in the post-transplant setting. This has important potential impli-
cations for treatment, as it demonstrates that NKG2A could serve as a potential
target for modulation in the immediate post-transplant setting to improve sur-
vival, especially in the setting of maintenance chemotherapy. Further investiga-
tion should be aimed delineating the potential effect of NKG2Amodulation on
immune recovery and tumor surveillance to increase survival in the post-trans-
plant setting.
#5664 PLAG prevents the loss of circulating neutrophils in the chemo-
therapy induced neutropeniamodel.Yong-Jae Kim,1 Jinseon Jung,2 Ha-Reum
Lee,3 Ki-Young Sohn,3 Heung-Jae Kim,3 Sun Young Yoon,3 Jae Wha Kim1.
1Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of
Korea; 2University of Science and Technology, Daejeon, Republic of Korea; 3En-
zychem Lifesciences, Daejeon, Republic of Korea.
Chemotherapy-induced neutropenia (CIN) is a common dose-limiting tox-
icity in cancer patients undergoing cytotoxic chemotherapy. It is generally un-
derstood thatmyelosuppression is themajormechanism resulting inCIN.How-
ever, an excessive extravasation (diapedesis) of neutrophils in response to tissue
damage-caused by anti-cancer agents is also a possiblemechanism. In this study,
we have investigated the effects of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol
(PLAG) for the maintenance of circulating neutrophil in the gemcitabine in-
duced neutropenia. In CIN mouse model using anticancer drugs, PLAG effec-
tively protected the loss of circulating neutrophils as similar to CXCR2 antago-
nist, reparixin. And succeeded in vitro neutrophil migration assay also revealed
that chemo-attractive activity of neutrophil induced by treatment of anticancer
drugswas completely interrupted byPLAGaddition. Chemokine (C-X-Cmotif)
ligand 2 (CXCL2) and CXCL8 were effectively induced by treatment of gemcit-
abine with dose dependent manner in monocyte cell lines and mainly mediated
via the signal transducer and activator of transcription 3 (STAT3) signaling
pathway. PLAG effectively attenuated gemcitabine induced CXCL2 and CXCL8
expression via interrupting STAT3 activity and also regulated gemcitabine in-
duced macrophage 1 antigen (MAC-1) and L-selectin expression, which means
that PLAG interrupted the acceleration of neutrophil extravasation under CIN.
Alsowe have verifıed that PLAG analogues andmetabolites were not affected on
neutrophilmigration unlike PLAG, suggesting that acetylated diacylglycerol has
a key role to regulate on neutrophil migration. Collectively, modulating effect of
PLAG on excessive neutrophil extravasation by chemotherapy via attenuating
STAT3/CXCL2(8) pathway could be used as very powerful regimen for prevent-
ing of neutropenia during diverse chemotherapy.
#5665 Physical crosstalk between CD8T and natural killer cells elicits
antitumor effector response. Roman V. Uzhachenko,1 Ashutosh Singhal,1
Shawn J. Goodwin,1 William H. Hofmeister,2 Anil Shanker1. 1Meharry Medical
College, Nashville, TN; 2University of Tennessee Space Institute, Tullahoma, TN.
The interaction between the innate and adaptive immune components is fun-
damental for an effective antitumor immunity. Our studies in murine solid
tumor models showed that productive antitumor effector response relies on
functional crosstalk between innate immune effectors—natural killers (NK),
and adaptive immune effectors—cytolytic CD8T lymphocytes.We found that
this lymphocyte cooperativity between CD8T and NK cells can prevent the
development of antigen-escape tumor variants. In this study, we fırst investi-
gated the role of physical contacts in during the functional crosstalk between
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CD8T and NK cells. Since, studying dynamic lymphocyte interactions present
extreme challenges, in this study, we engineered a 3D nanofıber matrix to pro-
vide lymphocytes a 3D culture environment for a controlled interaction. Con-
focal imaging showed that CD3/CD28-activated CD8T cells (CD69CD25)
formed multiple intercellular contacts with several naïve NK cells upon cocul-
ture, while naïve CD8T cells made single or no contact with NK cells. In lym-
phocyte coculture (physical contact possible) we found that activated CD8T
and NK cells cross-regulate each other phenotype wherein NK cells polarize
activated CD8T cells towards “T central memory phenotype” and activated
CD8T lymphocytes induce acquisition of “effector/regulatory phenotype” by
naïve NK cells. This cross-regulation of lymphocytes disappeared in trans-well
system (no physical contact) indicating the necessity of cell-to-cell physical in-
teraction during CD8T—NK crosstalk. Notably, intercellular physical interac-
tion led to cross regulation of mitoCa2 oscillations in both activated CD8T
and NK cells. Inhibition of mitochondrial Ca2 uptake or Na/Ca2 exchanger
with Ru360 andCGP37157, respectively, mimicked observed alterations in both
lymphocytes. Further, NK cells displayed increased oxidative signaling, Tyk2,
Jak 1 and 3, Stat2 and Stat6 phosphorylation while inhibiting TCR- and various
cytokine receptors-mediated signaling. In turn, NK cells selectively restrain IL-2
signaling in CD8T cells by dampening activation-induced up-regulation of
CD25, Stat5 phosphorylation, IL-2 synthesis and elevation in IL-2 uptake. These
data underscore a novel mitochondrial Ca2 transport-regulated acquisition of
activation/regulatory phenotype byNKandCD8T cells upon their interaction.
Understanding the critical factors involved in this NK—CD8T cells immuno-
logical synapse allowing their functional remodeling with the intact tissues in
tumor settingswill lead to novel strategies for effective cancer immunotherapies,
with a potential of relapse-free survival in cancer patients.
#5666 Safety of the fırst-in-class anti-NKG2A monoclonal antibody
monalizumab in combination with cetuximab: a phase Ib/II study in recur-
rent or metastatic squamous cell carcinoma of the head and neck (R/M
SCCHN). Roger B. Cohen,1 Sébastien Salas,2 Caroline Even,3 Nuria Kotecki,4
Antonio Jimeno,5 Anne-Marie Soulié,6 Anne Tirouvanziam-Martin,6 Robert
Zerbib,6 Pascale André,6 Agnès Boyer-Chammard,6 Jérôme Fayette7. 1Abram-
son Cancer Center, Philadelphia, PA; 2Assistance Publique-Hôpitaux de Mar-
seille, Marseille, France; 3Gustave Roussy, Villejuif, France; 4Centre Oscar Lam-
bret, Lille, France; 5University of Colorado Cancer Center, Aurora, Denver, CO;
6Innate Pharma, Marseille, France; 7Centre Léon Bérard, Lyon, France.
Background: Monalizumab (IPH2201) is a fırst-in-class immune checkpoint
inhibitor targeting CD94-NKG2A receptors expressed on tumor infıltrating cy-
totoxic CD8 T lymphocytes and NK cells. HLA-E, the ligand of this inhibitory
checkpoint receptor is up-regulated in SCCHN, protecting cancer from killing
by CD94-NKG2A cells. Monalizumab blocks binding of CD94-NKG2A to
HLA-E, reducing inhibitory signaling and thereby enhancing NK and T cell
anti-tumor responses. Cetuximab is an anti-EGFRmonoclonal antibody block-
ing oncogenic signaling and inducing Fc receptor-mediated antibody depen-
dent cellular cytotoxicity (ADCC). In vitro cetuximab-mediatedADCC is inhib-
ited byHLA-E expression on target cells and this inhibition can be circumvented
with CD94-NKG2A blockade. Combination of monalizumab and cetuximab
might provide greater antitumor activity than either drug alone. Methods: A
multicenter, non-randomizeddose-escalation and expansion study is evaluating
monalizumab plus cetuximab in patients with R/M SCCHN (NCT02643550).
Patients  18 years who progressed after platinum-based chemotherapy (re-
gardless of the number of previous lines of treatment) were enrolled, without
regard to HLA-E or human papilloma virus status. Using a 33 design, 5 dose
levels ofmonalizumab (0.4, 1, 2, 4 or 10mg/kg every 2weeks)were exploredwith
fıxed doses of cetuximab (400 mg/m² load followed by 250 mg/m² weekly).
Patients were treated until disease progression or unacceptable toxicity. The
primary objective was to evaluate safety and Dose Limiting Toxicity (DLT). The
secondary objectiveswere to estimate theMaximumToleratedDose (MTD) and
the Recommended Phase IIDose (RP2D), and to determine the pharmacokinet-
ics, pharmacodynamics and immunogenicity of the combination. Results: En-
rolment began inDecember, 2015. As of October 11, 2016, 13 patients with R/M
SCCHN were enrolled at dose levels 0.4, 1, 2 and 4 mg/kg. Median age was 60
years (range: 40-74); 92%weremale; PSwas 0 or 1; all patients had received prior
systemic therapy (1 prior line in 1 patient and 2 lines in 12 patients) for R/M
SCCHN including platinum based chemotherapy (100% of the patients) and
cetuximab (85%). There were no DLTs, infusion related reactions, immune re-
lated disorders or deaths related to treatment.Nodiscontinuation attributable to
treatment-related adverse events and no treatment-related grade 3 and 4 adverse
events were reported, except fatigue (grade 3) in one patient. Updated data
including pharmacodynamics and pharmacokinetics on the full dose escalation
part will be presented. Conclusion: Monalizumab cetuximab were well toler-
atedwith no additional safety concerns compared tomonalizumabor cetuximab
alone. The dose-expansion phase of the study will be initiated in the near future.
#5667 Exposure of tumor-associated macrophages to apoptotic pancre-
atic cancer cells promotes cancer stem cell chemoresistance. Gabriele
D’Errico, Mireia Vallespinos, Sonia Alcala, Sandra Valle, Laura Martin-Hijano,
Bruno Sainz. Autónoma University of Madrid, Madrid, Spain.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of
cancer related deaths worldwide. This is largely due to the existence of a subpop-
ulation of stem-like cells present within the tumor, known as cancer stem cells
(CSCs) that drive metastasis and chemoresistance. In addition, we have now
come to realize that the tumor-associated microenvironment not only provides
structural support for tumor development, but more importantly the microen-
vironment provides cues to CSCs that regulate their biological properties. Che-
motherapy often leads to apoptosis of cancer cells, and in previous studies we
have shown that tumor-associatedmacrophages (TAMs) exponentially increase
following chemotherapy. We hypothesized that TAMs, in response to chemo-
therapy-induced apoptosis, secrete factors that potentiate PDAC chemoresis-
tance. In linewith this hypothesis, we show thatmonocyte-derivedmacrophages
cultured in the presence of apoptotic PDAC cells polarize towards an M2 pro-
tumor phenotype and secrete factors that render naïve PDAC cells, specifıcally
CSCs, resistant to Gemcitabine- or Abraxane-induced apoptosis, irrespective of
mutations in p53. Importantly, chemoresistant cells showed increased sphere
formation capacity and increased tumorigenesis as measured in an extreme
limiting dilution assay in nudemice, confırming an enrichment in CSCs. More-
over, using a syngeneic orthotropic in vivo model of PDAC, we were able to
signifıcantly augment the anti-tumor potential ofGemcitabine by pharmacolog-
ically eliminating TAMs using clodronate liposomes. To determine the mecha-
nism by which TAMs promote PDAC chemoresistance, we performed pro-
teomic analyses on macrophage conditioned media and identifıed several
proteins specifıcally induced and secreted when macrophages were co-cultured
with apoptotic PDAC cells, including 14-3-3 protein zeta/delta (14-3-3), a ma-
jor regulator of apoptotic cellular pathways.We present additional data to show
that TAM-seceretd 14-3-3 promotes CSC chemoresistance. Taken together,
the sum of these data highlight a unique regulatory mechanism by which che-
motherapy-induced apoptosis acts as a switch to initiate a pro-tumor/anti-apo-
ptotic mechanism in PDAC, challenging the idea that apoptosis of tumor cell is
therapeutically benefıcial, at least when immune sensor cells, such asmacropah-
ges, are present.
#5668 CCL2/CCR2-driven monocyte recruitment to the tumor following
radiotherapy influences the outcome of the treatment of head and neck can-
cer.MicheleMondini,1 Pierre L. Loyher,2 Kevin Berthelot,1 Céline Clémenson,1
Alexandre Boissonnas,2 Eric Deutsch1. 1Gustave Roussy, Villejuif, France; 2IN-
SERM U1135, Paris, France.
Local radiotherapy is the major treatment to control locally advanced head
and neck cancer. Evidence supporting the importance of immune response in
the response to radiation therapy is growing and the possibility to potentiate the
effects of radiotherapy by modulating the function of the immune system offers
new exciting therapeutic perspectives. Preclinical fındings suggest that immu-
nomodulatory agents may synergize with radiotherapy, increasing local re-
sponse rates and inducing sustained systemic responses. The role of monocytes/
macrophages in the response to radiotherapy is under extensive investigation.
Among themany cytokines secreted by tumor cells, CCL2 is involved in inflam-
matory monocyte recruitment from bone marrow to the inflammatory site. We
have recently developed a model of human papillomavirus (HPV)-related head
and neck cancer using immunocompetent mice and validated its usefulness to
evaluate the tumor response to radiotherapy. Using the same model, based on
the injection of TC1/luciferase cells in the inner lip of C57Bl/6 mice, we show
that local radiotherapy induces an increase of CCL2 levels in the bloodstream
and intratumorally accompanied by a neo-infıltration of monocytes in the tu-
mor that subsequently differentiate into tumor-associatedmacrophages (TAM).
When TC1/Luc cells were engrafted in CCL2-/- or CCR2-/- mice, the tumor
response to radiotherapy and survival were improved. This was accompanied by
an impaired infıltration of inflammatory monocytes, and a subsequent decrease
of TAM levels at later time points. In vitro, exposure to ionizing radiation in-
creased the secretion of CCL2 by TC1/Luc cells, and such increase was signifı-
cantly enhanced when tumor cells were co-cultured with irradiated RAW 264.7
macrophage-derived cells. This data suggests interplay between tumor and
TAM that can amplify the effects of radiotherapy on the immune system. We
propose that reducing radiation-induced monocyte recruitment may yield im-
proved results in the treatment of HPV-related head and neck squamous cell
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carcinomas by radiotherapy. Immunologically-augmented radiotherapy could
allow reduction of the delivered radiation dose, thus minimizing the risk of
treatment sequelae while maintaining optimal tumor control.
#5669 Targeting post-surgical breast cancer metastasis through combin-
ing natural killer T cell immunotherapy and low dose chemotherapy. Simon
Gebremeskel, Kaitlyn Tanner, Lynnea Lobert, Brent Johnston. Dalhousie uni-
versity, Halifax, Nova Scotia, Canada.
Breast cancer is themost common cancer inCanadianwomen and the second
leading cause of cancer deaths. Given that most mammary tumors are surgically
resectable and over 90%of breast cancer-associated deaths are due tometastasis,
new therapeutic strategies targeting metastasis are required. Natural killer T
(NKT) cells are a rare population of immune cells that have been shown to limit
primary tumor growth and target distant metastatic disease in various animal
models.Wehave shown thatNKT cell activation improves survival in amodel of
post-surgical metastatic breast cancer. We are now expanding this work to de-
termine whether NKT cell activation can be combined with chemotherapies to
improve outcomes. In our model, 4T1 mammary carcinoma cells were injected
into the mammary fatpad of syngeneic BALB/c mice. Tumors were resected at
day 12, and mice were treated with cyclophosphamide or gemcitabine. On day
17, NKT cells were activated by transfer of dendritic cells loaded with the glyco-
lipid antigen 	-GalCer. We also examined whether gemcitabine or mafosph-
amide (active component of cyclophosphamide) would induce immunogenic
cell death of 4T1 cells in culture. Chemotherapeutics did not affect NKT cell
activation as measured by serum IFN levels. Treatment with cyclophosph-
amide, gemcitabine, or 	-GalCer-loaded dendritic cells alone reduced metasta-
sis and prolonged survival. Combined treatments signifıcantly enhanced sur-
vival. NKT cell activation decreased the frequency and immunosuppressive
function of myeloid derived suppressor cells (MDSCs). Treatments resulted in
enhanced tumor specifıc immunity as surviving mice exhibited slower tumor
growth following secondary tumor challenge. Gemcitabine and mafosphamide
also increase the immunogenicity of cancer cells in vitro by increasing the expo-
sure/release ofMHCI,MHCII, CD1d, Calreticulin, HMGB1 andATP. NKT cell
activation therapy can successfully be combined with low doses of gemcitabine
or cyclophosphamide to enhance protection against tumor metastasis and re-
currence. This work provides a clear rationale for combining chemotherapy
withNKT cell immunotherapy to targetmetastatic disease in the clinical setting.
#5671 AFM26 - A novel CD16A-directed bispecifıc TandAb targeting
BCMA for multiple myeloma. Thorsten Gantke, Uwe Reusch, Kristina Ell-
wanger, Ivica Fucek, Michael Weichel, Martin Treder. Affımed GmbH, Heidel-
berg, Germany.
Multiple myeloma (MM) is the second most common haematological cancer
and is characterized by the accumulation of neoplastic plasma cells in the bone
marrow and production of high levels of monoclonal immunoglobulin (M-
protein).While historically considered incurable, recent approvals and ongoing
clinical trials with monoclonal antibodies (mAbs) targeting surface antigens
promise greatly improved outcomes and have heralded a new era of MM treat-
ment in which immunotherapies are expected to take center stage. However, an
unmet need remains as patients eventually relapse and/or become refractory to
currently available treatments. Consequently, novel immunotherapeutic ap-
proaches are needed to provide improved treatment options to MM patients.
Among the currently explored targets, B-cell maturation antigen (BCMA,
CD269) is considered to be particularly attractive due to its limited expression
on healthy tissues and almost universal expression on myeloma cells in the
majority of patients. Natural killer (NK) cells are cytotoxic effectors of the innate
immune system capable of rapidly eradicating infected and transformed cells.
The cytolytic activity of NK-cells can be used therapeutically to induce tumor
cell lysis by direct engagement of the activating receptor CD16A (FcRIIIa)
using mAbs (ADCC). Despite similar mechanisms of target cell lysis, activation
of NK-cells is not associated with the systemic symptoms of high level cytokine
release as seen with direct T-cell engagement. Hence, it is considered a potent
immunotherapeutic approach with reduced toxicity and a well-manageable
safety profıle. NK-cells readily infıltrate bone marrow and are thought to con-
tribute to the effıcacy of current myeloma treatments. Therefore, redirecting
NK-cell cytotoxicity tomalignant plasma cells appears to be a suitable therapeu-
tic approach for MM. Here we describe the characterization of AFM26, a novel
tetravalent bispecifıc tandem diabody (TandAb) that specifıcally targets BCMA
and CD16A with high affınity and induces potent and effıcacious myeloma cell
lysis. AFM26 incorporates an affınity-improved anti-CD16A domain and inter-
acts bivalently withNK-cells, resulting in high avidity and prolonged cell surface
retention that is largely unaffected by the presence of polyclonal IgG. Notably,
AFM26 potently induces NK-cell-mediated in vitro lysis of target cells express-
ing low levels of BCMA at low effector:target ratios, even in presence of poly-
clonal IgG. This may suggest that AFM26, in contrast to classical mAbs, retains
ADCC activity at low antibody concentrations in presence of serum IgG and
despite high levels of IgG M-protein occurring in about half of MM patients.
AFM26 exhibits high protein stability, full cross-reactivity with cynomolgus
antigens (BCMA and CD16A) and does not bind APRIL and TACI, two func-
tionally related receptors. These data suggest that TandAb AFM26 is a promis-
ing and highly potent drug candidate for MM treatment.
#5672 Quantitative cell-based assays for characterization of antibodies
targeting co-stimulatory immune checkpoint receptors. Julia K. Gilden, Jun
Wang,Michael Beck, JamisonGrailer, JimHartnett, Frank Fan,Mei Cong, Zhe-
jie Jey Cheng. Promega Corporation, Madison, WI.
The human immune system is regulated by a broad network of co-inhibitory
and co-stimulatory receptors that control the type, scale, and duration of im-
mune responses. These receptors are now recognized as promising immuno-
therapy targets for the treatment of many cancers and autoimmune diseases.
Immunotherapies that block co-inhibitory receptors such as PD-1 and CTLA-4
are showing unprecedented effıcacy in the treatment of some tumors, and have
generated interest in the characterization of additional immunotherapy targets
that may broaden the number of patients who can be helped by these drugs.
Immunotherapy research programs are now exploring a wide range of both
co-inhibitory (e.g. LAG-3, TIGIT, Tim-3) and co-stimulatory (e.g.GITR, 4-1BB,
OX40) receptors, individually and in combination. Quantitative and reproduc-
ible functional bioassays are essential tools in the development of biologics for
cancer immunotherapy. Most existing assays rely on primary cells and suffer
from lengthy protocols and high day-to-day and donor-to-donor variability.
These approaches are cumbersome, error-prone, and do not produce data of the
quality required for drug development in a quality control environment. To
address this, we have developed a suite of cell line-based reporter bioassays for
co-stimulatory immune checkpoint targets including GITR, 4-1BB, OX40, and
CD40. In these assays, stable cell lines express luciferase reporters driven by
response elements under the precise control of intracellular signals mediated by
each co-stimulatory receptor. These bioassays reflect mechanisms of action for
drug candidates designed for each co-stimulatory receptor and demonstrate
high specifıcity, sensitivity and reproducibility. Reporter-based bioassays can
serve as powerful tools in immunotherapy drug development for antibody
screening, potency testing and stability studies.
#5673 Large establishedB16 tumors inmice are eradicated byZVex® (den-
dritic cell-targeting lentiviral vector) and G100 (TLR4 agonist) combination
immunotherapy through increasing tumor-infıltrating effector T cells and
inducing antigen spreading. Tina C. Albershardt, Andrea J. Parsons, Jardin
Leleux, Peter Berglund, Jan ter Meulen. Immune Design, Seattle, WA.
INTRODUCTION: Effective immunotherapy requires the presence of effec-
tor T cells penetrating the tumor. ZVex is a hybrid lentiviral vector platform that
targets dendritic cells in vivo to express genes of tumor-associated antigen
(TAA)-of-interest and activate TAA-specifıc CD8 T cells. G100 is the intratu-
moral (IT) injection of formulated glucopyranosyl lipid A (a synthetic TLR4
agonist) and has been shown to induce T cell homing chemokines, CXCL9 and
CXCL10. We report here that G100 promoted an inflamed tumor microenvi-
ronment (TME) and improved infıltration of ZVex-induced TAA-specifıc CD8
T cells to the TME, thereby eradicating large established B16 tumors. This was
previously achieved only with a complex vaccine/anti-tumor antibody/check-
point inhibitor/IL-2 regimen (Moynihan, Nature, 2016). RESULTS: B16-OVA
tumor-bearingmice were randomized into 4 treatment cohorts: 1) untreated; 2)
ZVex expressing ovalbumin (ZVex/OVA), subcutaneously (SC); 3) G100 (IT);
4) ZVex/OVA (SC) and G100 (IT) combination.While mice in Cohorts 2 and 3
exhibited delayed tumor growth, nearly all mice (16/18) from Cohort 4 had
completely regressed tumors and survived tumor-free until end of study (109
days). CD8 T cell depletion abrogated this anti-tumor response. Cohort 4 mice
with regressed tumors were then randomized and re-challenged with either a)
B16-OVA or b) parental B16 (lacking expression of the ZVex-targeted antigen,
OVA): a) B16-OVA re-challenge was rejected by 100% of recipient mice - con-
sistent with induction of T cell memory; and b) B16 re-challenge was rejected by
30%-50% of recipient mice - demonstrating functional antigen spreading. T cell
receptor deep sequencing showed that ZVex/OVA alone increased tumor-infıl-
trating T cell clones specifıc for OVA, validated by pMHC-multimer staining.
ZVex/OVA and G100 combination expanded additional T cell clones, further
evident of antigen spreading. Lastly, the TMEof Cohort 4mice showed themost
profound pro-inflammatory changes, as assessed by RNA transcriptional pro-
fıling. CONCLUSIONS: These data collectively demonstrate that anti-tumor
effıcacy observed inCohort 4micewasmediated largely by ZVex/OVA-induced
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effector T cells and that TMEmodulation with G100 drastically shifted the TME
to a more inflamed milieu, promoting T cell proliferation, antigen spreading,
and generation of immunological memory. To our knowledge, this is the fırst
time that large established B16 tumors have been completely eradicated using a
combination of systemic and in situ immunizations, a potentially effective strat-
egy to convert non-inflamed tumors to inflamed tumors. Both ZVex and G100
are in multiple clinical trials, and their combination is currently being investi-
gated in a phase I trial in soft tissue sarcoma patients with injectable tumors.
#5674 Cancer immunogenomics for the development of personalized
ovarian cancer vaccine.Muzamil Y. Want, Takemasa Tsuji, Richard Koya, Se-
bastiano Battaglia. Roswell Park Cancer Institute, Buffalo, NY.
Ovarian cancer (OC) is the fıfth leading cause of cancer death in the United
States with approximately 20,000 women being diagnosed every year. Since OC
development is mainly asymptomatic, patients are often diagnosed at late stage
and present local and distal metastases. This offers a clinical challenge, as
roughly 70% of the patients develop chemoresistant disease. With the advent of
cancer immunogenomics it is now possible to identify tumor specifıcmutations,
or neoantigens/neoepitopes, that can be exploited for the development of per-
sonalized T cell therapies via DC vaccines or adoptive cell therapy (ACT). We
therefore hypothesize that tumor cells isolated frommalignant ascites reflect the
genomic landscape of the primary tumor, offering a unique opportunity to iden-
tify clinically actionable tumor neoantigens. We utilized primary tumor, tumor
cells isolated from malignant ascites and metastatic samples to create patient-
derived xenografts (PDX) mice and to interrogate the tumor mutational land-
scape. Somatic mutations were identifıed by whole exome sequencing (WES)
and RNASeq analysis in tumor samples, using PBMCs as germline control. In
parallel 20 PDX of ovarian cancer were established in NSG mice by injecting
2106 cells/mouse subcutaneously (SQ, n10) and intraperitoneally (IP,
n10). Tumor growth was monitored weekly via caliper measurement for mice
injected SQ and via abdominal circumference for mice injected IP. Mutational
analysis and prediction of high affınity peptides was done using bioinformatics
approach. We have utilized different algorithms that are based on Artifıcial
Neural Networks or published motifs for predicting binding of 8-11 mer pep-
tides to number of HumanMHC alleles (HLA) and out of 168mutated peptides
identifıed, 30 were found to have high affınity for different HLAs compared to
wild type peptide. Mutated and wild type peptides were pulsed into dendritic
cells and co-cultured with CD8 T cells for 20 days. Validation of stimulated
CD8

T cells by these mutated peptides using ELISPOT is underway. TCR spe-
cifıc for neoantigen from CD8T cells will be identifıed and cloned using retro-
viral vectors. Transfected CD8 T cells with neoantigen specifıc TCR will be
confırmed by co-culturing them with dendritic cells pulsed with wild type and
mutated peptides. Further engineeredCD8T cells specifıc for neoantigenswill
be tested for adoptive cell therapy in the established PDX models of ovarian
cancer.
#5675 A novel PI3K inhibitor suppresses tumor progression by immune
modulation. Zusheng Xu,1 Yangtong Lou,1 Yingying Qu,2 Wei Wang,2 Xia-
odong Wu,2 Xiaomei Ge,2 Ying Gu,2 Yingjia Zhang,2 He Zhou2. 1Shanghai
Yingli Pharmaceuticals Co. Ltd., Shanghai, China; 2Shanghai ChemPartner Co.,
Ltd., Shanghai, China.
Phosphoinositide 3-kinase delta (PI3K
) inhibitors have shown anti-tumor
effıcacy in leukemia in the clinic and one such compound, idelalisib, was ap-
proved by the FDA for the treatment of relapsed chronic lymphocytic leukemia
(CLL) in 2014. A novel PI3K
 inhibitor, YY-20394, was developed with specifıc
selectivity against PI3K
 and inhibited PI3K
 expressing human tumor cells
growth both in vitro and in vivo. In addition, our previous data have shown
YY-20394 signifıcantly inhibited primary tumor growth in immune-competent
mice with 4T1 and CT26 tumors, as well as 4T1 lung metastasis with dose
dependency. The anti-tumor effıcacy of YY-20394 was largely mediated by T
cells. More importantly, YY-20394 synergistically enhanced the anti-tumor ef-
fıcacy of anti-PD-L1 antibody in CT26 model and achieved long-term immune
memorywhich is specifıc for CT26 tumors, but not for unrelatedA20 tumors. In
vitro mechanistic studies showed YY-20394 signifıcantly inhibited T cell differ-
entiation into Treg both in mouse splenocyte and in human primary CD4 T
cells, andwas especially potent inhibiting their IL-10 secretion in vitro. Analyses
of tumors treated with YY-20394 reviewed that YY-20394 decreased the per-
centage of Treg in the tumor infıltrating leukocytes, as well as IL-10 secretion. It
also showed some effects on the myeloid populations in the tumors. These data
suggest the YY-20394, a novel PI3K
 inhibitor, represents a promising and safe
immunemodulator and shows great potential as a cancer immuno-therapeutics.
#5676 Functional pairing of immunomodulatory targets in anaplastic
thyroid cancer. Sanjukta Chakraborty, Rachana R. Maniyar, Neha Y. Tuli,
Ghada BenRahoma, CameronBudenz, Sarnath Singh, JanGeliebter, Raj Tiwari.
New York Medical College, Valhalla, NY.
Thyroid cancer is themost common type of endocrinemalignancy that has an
escalating global frequency. Although most well differentiated thyroid cancers
(WDTC) are manageable and respond to current therapeutic modalities, undif-
ferentiated anaplastic thyroid cancers (ATC) exhibit a dramatically different
clinical behavior and poor prognosis.With the recent development of immuno-
therapies, targeted, well-defıned treatment plans can demonstrate promising
treatment outcomes in ATC patients. Precise immunological targets in ATCs
with potential clinical relevance are unknown.Major progress has beenmade in
last 5 years toward development of immune checkpoint inhibitors using anti-
CTLA-4 and anti-PD-1/PD-L1 antibodies for cancer treatment which has made
immunotherapies one of the mainstream treatment choices. Few additional
members of the immunoglobulin superfamily of receptors, like LAG3, TIM3
and VISTA have recently been identifıed as potential checkpoint targets. Inter-
estingly some of these molecules including TIM3 and PD-L1 promote tumor
progression and immune escape. Identifıcation of specifıc immunotherapeutic
targets requirs a better understanding of the immune microenvironment in
ATC. To this end we evaluated the expression of prominent co-stimulatory and
co-inhibitory cell surface molecules by RT-PCR in three thyroid cancer cell
lines - TPC-1 (papillary), CGTH-W-1 (follicular) and 8505C (anaplastic). We
observed thatmany co-inhibitorymolecules were upregulated in all three tumor
cell lines. CTLA4, interestingly, had the highest expression in 8505C. Addition-
ally we observed differential expression of BTLA, LAIR1, TIM3 and VISTA
between TPC-1 and 8505C. LAG3, PD-1 and PD-L1 were also upregulated in
8505C compared to TPC-1. Similar pattern was observed with the expression of
co-stimulatory molecules, CD40L and GITR . GITR has been shown to have a
tumor suppressor function in multiple myeloma. Another co-stimulatory mol-
ecule OX40, which has shown promise in tumor recession when targeted, was
upregulated in all three cell lines and 8505C showed the highest expression. Our
fındings suggest that the aggressive and less immunogenic phenotype of ATC
might be attributed to the differential expression of these molecules. Targeting
these immunomodulatorymolecules inATCwarrants a better understanding of
the crosstalk between them and it might provide an effıcient means for the
disease management.
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#5677 Performance of a robust and sensitive liquid biopsy workflow for
mutation detection in plasma. JonathanChoi, CindyChoi, JorgeDinis, Jingch-
uan Li, Sean Chien, Bosun Min, AbrahamMunoz, Janet Jin, Amrita Pati, Liang
Feng, JohnnyWu, Ashla Singh, Fergal Casey.Roche Sequencing Solutions, Pleas-
anton, CA.
The discovery of circulating tumor DNA (ctDNA) and the development of
highly sensitive technologies have made the utility of liquid biopsies in clinical
practice more feasible. Potential applications for liquid biopsies include early
cancer detection, tumor genotyping in the absence of tissue biopsies, disease
monitoring, and identifıcation of drug resistance markers. However, there is a
multitude of technical challenges to accurately detect ctDNAwith high sensitiv-
ity and reproducibility. Variousmethods have been established by research cen-
ters and companies, each with its advantages and limitations. We have devel-
oped a sensitive NGS-based liquid biopsy assay, called the AVENIO ctDNA
Analysis Kits (research use only), which includes three panels targeting bio-
markers for solid tumors. The AVENIO ctDNA Analysis Kits include cfDNA
extraction from up to 5ml plasma input, optimized reagents and workflow for
NGS library preparation and target enrichment. It is accompanied with an in-
tuitive software and data analysis package to easily obtain results. The assay
sensitively detects 4 cancer relevant mutation classes - single nucleotide varia-
tions (SNVs), insertions/deletions, copy number variations and structural rear-
rangements. We conducted a study with 200 samples of plasma-derived
cfDNA, cell line blends containing relevant cancer mutations, and clinical sam-
ples, with which we demonstrate the analytical sensitivity of the three distinct
AVENIO gene panels (covering 17, 77 and 197 genes). We demonstrate95%
sensitivity for SNVs at 0.5% mutant allele frequency; 95% sensitivity for 1%
indels;95% sensitivity for 1% structural variants. We also demonstrate assay
robustness through multiple replicates, day-to-day, and operator-to-operator
reproducibility. In conclusion, the AVENIO ctDNA Analysis Kits for solid tu-
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mors encompasses a comprehensive assay and analysis workflow aimed to pro-
vide researchers with robust, reliable, highly sensitive and ease to use liquid
biopsy assays to conduct the necessary studies to demonstrate the utility of
circulating biomarkers in routine clinical testing.
#5678 Novel serum microRNAs that enable liquid biopsy for colorectal
cancer: validation study of large cohort. Hiroyuki Takamaru,1 Yutaka Saito,1
Taku Sakamoto,1 Seiichiro Abe,1 Masayoshi Yamada,1 Takeshi Nakajima,1 Ka-
zuki Sudo,1 Ken Kato,1 Junpei Kawauchi,2 Satoko Takizawa,2 Hiromi Saka-
moto,3 Motohiro Kojima,4 Atsushi Ochiai,4 Shumpei Niida,5 Hideshi Ishii,6
Tomoko Takamaru,7 Juntaro Matsuzaki,3 Takahisa Matsuda,1 Takahiro
Ochiya3. 1National Cancer Center Hospital, Tokyo, Japan; 2Toray Industries,
Inc., Tokyo, Japan; 3National Cancer Center Research Institute, Tokyo, Japan;
4National Cancer Center Hospital East, Tokyo, Japan; 5National Center for Geri-
atrics and Gerontology, Tokyo, Japan; 6Osaka University Graduate School of
Medicine, Osaka, Japan; 7Showa University, Tokyo, Japan.
Introduction: Recent studies have reported that serum microRNAs (miRNAs)
are potentially useful biomarkers for cancer. However, the detection system
using serummiRNAs is not established in colorectal cancer (CRC). The aims
of this study are 1) to identify specifıc serum miRNAs and establish the
discriminant model for CRC detection and 2) to validate the miRNAs and
the discriminant model using a large cohort. Methods: First, we identifıed
serum miRNAs related with the presence of CRC and constructed the dis-
criminant model for CRC detection using the publicly-released serum
miRNA database including 50 patients with CRC and 90 healthy individuals
(GSE59856 and GSE73002). Comparing serum miRNA levels between pa-
tients with CRC and healthy individuals, we picked up miRNAs (p0.05 by
t-test and fold change  2). Using these miRNAs, Fisher’s linear discrimi-
nant analysis was performed and the diagnostic models were constructed
using less than 7 miRNAs. Subsequently, 1117 patients of National Cancer
Center Hospital with CRC were enrolled as a validation cohort. Patients with
the following criteria were excluded; (i) patients simultaneously or previ-
ously diagnosed as the other cancers, (ii) patients who were treated for CRC
previously and (iii) patients with familial adenomatous polyposis or Lynch
syndrome. Control blood samples were obtained from patients without any
history of cancer who were admitted or referred to National Center for
Geriatrics and Gerontology or Yokohama Minoru Clinic between 2010 and
2015. A total of 1013 CRC patients and 4384 non-cancerous patients were
analyzed. Total RNA was extracted from 300 micro L of serum and compre-
hensive miRNA expression analysis was performed using a 3D-Gene mi-
croarray. ROC analysis was performed to evaluate the previous discriminant
models. The sensitivity in each pathological stage and location of CRC was
also investigated.This research is partially supported by the “Development of
Diagnostic Technology for Detection of miRNA in Body Fluids” grant from
the Japan Agency for Medical Research and Development (AMED). Results:
First we picked up 30 miRNAs for CRC diagnosis. Fisher’s analysis revealed
107611 candidates of numerical formulas, that showed  80% of sensitivity
and specifıcity. We could narrow these candidates to 43 formulas with vali-
dation analysis. By ROC analysis, the AUC, sensitivity and specifıcity of the
discriminant formula with best performance was 0.904, 79.6% and 86.5%,
respectively. The sensitivities of each pathological stage were as follows;
pStage 0: 79.0%, pStage I: 90.7%, pStage II: 85.1%, pStage III: 73.7%, pStage
IV: 62.2%. The sensitivity of CRC in the right side of the colon was 79.4%,
whereas that in the left side was 79.7%. Conclusions:We identifıed novel
serum miRNAs for CRC detection. Our discriminant using these miRNAs
can diagnose CRC including early stage. Furthermore, the sensitivity was
high irrespective of the tumor location.
#5679 Using droplet digital PCR to analyze MYCN copy number in
plasma from patients with high-risk neuroblastoma.Marco Lodrini,1 Annika
Sprüssel,1 Kathy Astrahantseff,1 Daniela Tiburtius,1 Robert Konschak,1 Holger
Lode,2Matthias Fischer,3 Johannes H. Schulte,1 Angelika Eggert,1 Hedwig Deu-
bzer1. 1Charite, Berlin, Germany; 2Greifswald University Hospital, Greifswald,
Germany; 3University Hospital Cologne, Cologne, Germany.
The invasive nature of surgical biopsies most often prevents their sequen-
tial application to monitor disease in patients with high-risk neuroblastoma.
Even when available, single biopsies often fail to reflect neuroblastoma dy-
namics, intratumor heterogeneity and drug sensitivities likely to change dur-
ing neuroblastoma evolution and treatment. Implementing molecular char-
acterization of cell-free neuroblastoma-derived DNA (cfDNA) isolated from
blood plasma would improve outcome prediction, patient monitoring and
treatment selection for high-risk neuroblastoma patients, by providing a
method to follow clonal evolution in tumor subpopulations and treatment
response as well as capture the molecular landscape of all tumor clones. As a
fırst step, we established a digital droplet PCR (ddPCR) protocol to analyze
the MYCN copy number status. Analyzing the dilution series of a synthetic
MYCN template consisting of 70 nucleotides demonstrated a strong corre-
lation between theoretically calculated MYCN copy number and the MYCN
copy number measured using our ddPCR protocol. We compared MYCN
copy number status in a large panel of neuroblastoma cell lines with MYCN
copy number determined from cfDNAs isolated from cell culture media
from the corresponding cell lines. Our ddPCR protocol reliably detected
MYCN status in the cell line using cfDNA analysis. Next, we turned to a
subcutaneous MYCN-driven neuroblastoma xenograft model to compare
MYCN copy number in the xenografted tumor to MYCN copy number de-
termined from cfDNA isolated from the mouse blood plasma. MYCN copy
numbers also positively correlated using this model. We then analyzed
MYCN copy number status in primary neuroblastoma samples from 10 pa-
tients and compared these values to the MYCN copy number determined
from cfDNA isolated from 200 l of blood plasma collected from the corre-
sponding patients. These fınal validation steps demonstrated that our
ddPCR protocol for cfDNA from patient blood plasma reliably detects
MYCN copy number status in the tumor. Our data justify the further devel-
opment of molecular neuroblastoma characterization from cfDNA in pa-
tient blood plasma. An expanded molecular diagnostic monitoring palette
will improve monitoring of disease progression including relapse and met-
astatic events as well as therapy success or failure in high-risk neuroblastoma
patients.
#5680 Clinical signifıcance of low frequency EGFR and KRAS mutations
of cell free DNA using Ion AmpliSeq Cancer Hotspot Panel in lung cancer
patients. Jae Sook Sung,1 JongWon Lee,1 Boyeon Kim,1 Saet Byeol Lee,1 Chang
WonPark,2 HaeMiKim,2Nak-JungKwon,2Won Jin Jang,3 Yoon Ji Choi,3 Jung
Yoon Choi,3 Eun Joo Kang,4 Kyung Hwa Park,3 Sung Yong Lee,4 Yeul Hong
Kim3. 1Cancer Research Institute, Korea University, Seoul, Republic of Korea;
2Marcrogen, Seoul, Republic of Korea; 3Division of Oncology/Hematology, De-
partment of Internal Medicine, Korea University Anam Hospital, Korea Univer-
sity College of Medicine, Seoul, Republic of Korea; 4Department of Internal Med-
icine, Korea University Guro Hospital, Seoul, Republic of Korea.
Cell free DNA (cfDNA) present in the blood stream shows great potential as
a useful cancer marker for molecular diagnosis and cancer progression moni-
toring. Especially, analyzing the cfDNA with Next Generation Sequencing
(NGS) technology allows high through put examination of various genes con-
currently at a low cost. However, there are still debates regarding clinically
meaningful variant frequency to identify mutations in cfDNA, especially with
ultra-deep sequencing. In this study, we examined the clinical utility of Ion
AmpliSeq Cancer Hotspot Panel v2 (ICP; Ion Torrent) with Proton platforms.
ICP, covering 2800 COSMIC mutations from 50 cancer genes was used to ana-
lyze cfDNA of 125 serum samples from lung cancer patients. The percentage of
on target was 92% with mean depth of 22,868x. We identifıed aberrations of
TP53 (72%), EGFR (43%), PTEN (26%), PIK3CA (26%), BRAF (16%), KRAS
(14%), KIT (10%) and RET (10%) with the cut-off criteria of variant frequency
0.1% and p0.01. To validate the results, we analyzed EGFR gene status by
direct sequencing in available 100 FFPE tumor tissues (tDNA). Out of 17 pa-
tients with EGFR mutations in tDNA, 9 patients showed very low frequency
(0.05%) of same EGFR mutation in cfDNA. To validate the results of ICP,
droplet digital PCR (ddPCR) was carried out with same cfDNA. From those 9
patients, EGFR mutations in cfDNA were detected in fıve patients (minimum
frequency 0.01%) by ddPCR. From the patients with wild type EGFR in tDNA,
EGFR exon 19 deletion or exon 21 point mutation were detected by ICP in 19
patients using cfDNA. Again, ddPCR was carried out with same cfDNA to con-
fırm the result. EGFR mutations were confırmed in nine patients (47.4%) by
cfDNA ddPCR and among the 6 patients treated with EGFR TKI, 4 patients
showed response or stabilization of disease. Also, we identifıed 18 patients with
KRASmutations in ICP results of 125 cfDNA. The result of ddPCRwasmatched
in 80% of patients. Interestingly, 2 patients had multiple KRAS mutations in
cfDNAwith ICP as well as ddPCR. In our study, we demonstrated that ICPwith
Proton system is a useful assay to identify somatic mutations using cfDNA in
lung cancer patients. Also, we suggest that even EGFR mutation of very low
frequency (0.05%) might have clinical signifıcance in NGS analysis using
cfDNA. Serial blood sample obtained during treatment in these patients will be
analyzed by ICP and ddPCR. [This research was supported by the Korea Health
Technology R&D Project through the Korea Health Industry Development In-
stitute (KHIDI), funded by theMinistry of Health &Welfare, Republic of Korea
(HI14C0066)].
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#5681 Utility of a targeted NSCLC genomic test for cfDNA variants in the
community setting. Westen Hahn,1 Scott Thurston,1 Leisa Jackson,1 Amanda
Weaver,1 Cherie Tschida,1 Brent Sage,1 Kristin Alexander,1 Tunee Pelletier,1
Nia Charrington,2 Samantha Cooper,2 DiannaMarr,2 Paul M. Bowling,3 Hestia
Mellert,1 Gary Pestano1. 1Biodesix, Inc., Boulder, CO; 2Bio-Rad, Inc., Pleasanton,
CA; 3East Carolina University, Greenville, NC.
Time to treatment can have signifıcant impact on progression of cancer, and
treatment decisions rely heavily upon genomic and proteomic testing. However,
multiple factors candelay the availability ofmoleculardiagnostic test results, includ-
ing the use of tissue-based testing. Almost one third of patients with non-small cell
lung cancer (NSCLC) are either not candidates for biopsies, or have insuffıcient
tissue samples from their initial biopsy. Additionally, most physicians in the com-
munity setting want to initiate treatment quickly but do not have access to on-site
molecular testing at their practice.As a result, physiciansmaydelay their decision to
commence treatment with specifıc targeted therapies or treat before the mutation
status is known. The goal of this study was to assess the utility of a blood-based
cell-free (cf) nucleic acid Laboratory Developed Test (LDT) in the community set-
ting. The tests utilizeDropletDigital™ PCR (ddPCR) technology to detect the EGFR
sensitizing mutations L858R and exon 19 deletion (E746 - A750), the EGFR resis-
tance mutation (T790M), the KRAS mutations G12C, G12V and G12D, and the
BRAF V600E mutation. Patient samples for testing were collected and shipped at
ambient room temperature using a Biodesix® whole blood sample collection kit and
processedat theBiodesix laboratory.Metricswere reviewed fromthe real-timemea-
surement of establishedmolecular diagnosticmarkers in theplasmaof patientswith
NSCLC. For this study we analyzed results from greater than 4,000 patient cases
(24,000 individual variants). Greater than 70% of test orders were received from
physician practices that self-identifıed as community based. Test mutation status
results were reported within 72 hours of sample receipt from the physician’s offıce
(95%). The percentage of tests requested thatwere positive for each variant category
were 9% for EGFR sensitizing, 9% for EGFR resistance, 11% for KRAS, and 1% for
BRAF.Notably,wegenerated test results successfully for 98%of tests submitted.We
have developed fast, highly robust and sensitive blood-based assays to expedite time
to treatment and expand the laboratory testing options for patients with NSCLC.
#5682 Circulating tumour DNA following decompression using selfex-
pandable metallic stent. Goro Takahashi, Takeshi Yamada, Takuma Iwai, Ko-
hki Takeda, Michihiro Koizumi, Seiichi Shinji, Yasuyuki Yokoyama, Keisuke
Hara, Hiroyasu Furuki, Atsushi Watanabe, Keiichro Ohta, Eiji Uchida. Nippon
Medical School, Tokyo, Japan.
Background: Decompression using selfexpandable metallic stent (SEMS) has
been reported to improve short-term outcomes in patients withmalignant large
bowel obstruction (MLBO). However, some reports suggest that SEMS worsen
long-term survival. Conversely, trans-anal drainage tubes (TDT), which are
similar to the ileus tubes widely used in Japan for MLBO, have had no reports
suggesting reduced survival. SEMS worsen long-term survival by compressing
tumor continuously and induce tumor cell death which can lead production of
various types of mediator which could negatively affect prognosis. In this study,
we investigated tumor cell death induced by decompression procedure by using
circulating tumour DNA (ctDNA). Methods: Plasma samples were obtained
before and 1, 3 and 7 days after decompression. First, we purifıed circulating cell
freeDNA (ccfDNA) from1mLof plasma andmeasured the concentration using
fluorometer. Second, we measured mutated fragment of ccfDNA (circulating
tumour DNA) which is derived from tumor cell. Mutational analysis from the
main tumourwas performed using Ion PGM™Sequencer following library prep-
aration with Ampliseq CHPver.2 (Thermo Fisher Scientifıc). Each mutant frag-
ment in ccfDNAwas quantifıed using digital PCR (QuantStudio 3D® digital PCR
system). Results:We enrolled 30 patients (22 SEMS and 8 TDT). CcfDNA levels
on day7 was signifıcantly increased in the SEMS group (before; 623ng/ml, day7;
1455ng/ml, p0.006) but TDT group. Sequencing result revealed that the aver-
age number ofmutation per tumorwas 3.7 (e.g. APC,TP53, andKRAS) out of 50
genes. Mutant fragments (ctDNA) were detected in the ccfDNA in all cases.
Mutant fragment also increased after decompression in SEMS group(before;
6.2copies/l, day3; 22.6copies/l, p0.03)but in TDT group. Conclusion:
SEMS insertions increased plasma levels of not only ccfDNA but also ctDNA in
patientswithMLBO.This indicated that SEMSwould inducemassive cancer cell
death. This tumor cell death can drain various mediators, including DAMPs,
into blood flow and may worsen prognosis of patients with MLBO. Conversely,
TDT may not induce massive tumor cell death.
#5683 Evaluation of the utilization of blood collection tubes for cell-free
DNA research. Fumitaka Endo, Takeshi Iwaya, Takehiro Chiba,Mizunori Yae-
gashi, Kei Sato, KoheiKume,AtsuhiroArisue, YutakaNishinari, RyokoKawagi-
shi, Takenori Segawa, Satoshi Nishizuka, Akira Sasaki. Department of Surgery,
Iwate Medical University School of Medicine, Morioka, Iwate prefecture, Japan.
Many studies have been conducted investigating cell-free DNA (cfDNA) for
disease diagnosis. To prevent cellular DNA release into the plasma, plasma sep-
aration within 2 hours of blood collection is required, when utilizing the most
commonly used type of tube (BD Vacutainer® CPTTM; CPT). These temporal
restrictions render operations requiring plasma separation a laborious task. It
has been demonstrated that Cell-Free DNA BCT® tubes (Streck Inc; BCTs) pre-
vented nucleated cell disruption. The use of BCTs may enable us to separate
plasma without temporal restrictions. The aim of this study was to evaluate
changes in DNA levels in plasma after preservation using two types of collection
tubes. Samples were drawn from 7 healthy donors into CPTs and BCTs, and
stored at room temperature. Plasma was separated immediately (d0), and on
days 3, 6, 9, 12, and 14 after blood collection. The concentrations of DNA in the
extracted plasma samples were measured. Blood stored in CPTs showed in-
creases in plasma DNA concentrations over time. The mean DNA concentra-
tions at each time-point were 0.39 (d0), 2.96 (d3), 40.4 (d6), 84.9 (d9), 91.4 (d12),
and 94.9 ng/l (d14). However, plasma DNA levels remained stable in BCTs
from 6 days. There were signifıcant differences between the DNA concentra-
tions in BCTs on d0 (0.74 [0.43-1.44] ng/l) and d14 (1.78 [0.63-4.20] ng/l)
(p  0.0378). Although signifıcant differences were only observed between d0
and d14 in BCTs, the amount of plasma DNA gradually increased after d6.
Furthermore, obvious color changes in the plasma were observed, and the
boundary between plasma and PBMCs became unclear over time. These results
indicate that BCTs may yield stable cfDNA samples for up to 6 days after blood
collection. BCTs may be a novel collection tube for cfDNA research, including
liquid biopsies in cancer patients.
#5684 NSABP FC-7 correlative study: HER2 amplifıcation (amp) in cir-
culating cell-free DNA (cfDNA) in metastatic colorectal cancer (mCRC) re-
sistant to anti-EGFR therapy (tx). S. Rim Kim,1 Ashok Srinivasan,1 Carmen J.
Allegra,2 Samuel Jacobs,1 Rebecca J. Nagy,3 Richard B. Lanman,3 AmirAli Tala-
saz,3 Patrick Gavin,1 Rekha Pal,1 Peter C. Lucas,4 Kay Pogue-Geile1. 1NSABP,
Pittsburgh, PA; 2NSABP, and UF Health, Gainesville, FL; 3Guardant Health,
Redwood City, CA; 4University of Pittsburgh School of Medicine, Pittsburgh, PA.
Background: FC-7 is a phase Ib study hypothesizing that dual ERBB blockade
(neratinib and cetuximab) could overcome an acquired resistance mechanism to
anti-EGFR tx in KRAS/NRAS/BRAF/PI3KCAwild type (wt)mCRC patients (pts).
Previously we demonstrated a 36% rate of HER2 amp in post- anti-EGFR biopsies
(bxs). Assay of plasma cfDNA is minimally invasive andmay provide comprehen-
sive genomic profıling. We tested the accuracy of a cfDNA assay for HER2 amp,
comparing results frommatched bxs to evaluate molecular changes in HER2 copy
number. Methods: 23 pts with mCRC resistant to anti-EGFR tx were enrolled and
treated with cetuximab and neratinib. 17 paired bxs (6 post-tx bxs had insuffıcient
tumor) were assessed for HER2 amp using chromogenic in situ hybridization
(CISH) (Dako PharmDxTM). HER2 was considered amplifıed when HER2/CEP17
ratiowas2. cfDNAwas extracted fromplasmaof 11pts after 1st line anti-EGFR tx
but before addition of cetuximab and neratinib. 5-30 ng of DNA was sequenced
across 512 exons in 54 genes with HiSeq (Illumina). Copy number variants (CNV)
were quantifıed using a customized pipeline (Guardant 360). One plasma sample
failed to yield suffıcient cfDNA. 10 pts had comparison of cfDNAwith pre- or post-
anti-EGFR bx. Results: 4 of 9 plasma samples (1 non evaluable) had HER2 amp, all
concordant with pre- or post- anti-EGFR tx tissue. 3 pts converted to HER2 amp
after anti-EGFR tx (pts 3, 5, 7), and for 2 of these conversions (pts 5, 7), the amplifı-
cation was evident in cfDNA.
Pt
Pre- anti-EGFR
CISH
Ratio
Post- anti-EGFR
CISH
Ratio
Post- anti-EGFR
cfDNA
CNV
Concordance of
cfDNAwith pre-
or post-anti-EGFR
TissueSamples
1 Neg (1.0) Neg (1.3) Non evaluable NA
2 Pos (2.5) Neg (1.5) Pos (2.66) Pre-Tx
3 Neg (1.0) Pos (3.7) Neg Pre-Tx
4 Neg (1.0) Neg (1.8) Neg Both
5 Neg (1.2) Pos (2.7) Pos (2.48) Post-Tx
6 Pos (10) QNS Pos (21.86) Pre-Tx
7 Neg (1.1) Pos (2.0) Pos (2.20) Post-Tx
8 Neg (1.3) Neg (1.1) Neg Both
9 Neg (1.0) Neg (1.3) Neg Both
10 Neg (1.0) Neg (1.5) Neg Both
Conclusion: In this sample set,HER2 ampdetected in plasma-derived cfDNA from
mCRC pts resistant to anti-EGFR tx is comparable to amp assessed in primary or
metastatic tissue. Given advantages of liquid bx relative to repeated tissue bxs,mea-
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surement ofHER2 amp in cfDNAmay be of utility inmonitoring pts for resistance
to anti-EGFR tx. Thiswill need to be confırmed in a trial incorporating both plasma
and tissue samples. Support: Puma Biotechnology, Inc.
#5685 An evaluation of DNA and RNA based blood biomarkers in pros-
tate cancer. Jenny Antonello,1 Jakub Chudziak,1 Alan Redfern,1 Victoria Foy,1
Shambhavi Srivastava,1 Adnan Syed,1 Deborah Burt,1 Mahmood Ayub,1
Bedirhan Kilerci,1 Marina Parry,1 Richard Marais,1 Esther Baena,1 Crispin
Miller,1 Dominic Rothwell,1 Noel Clarke,2 Caroline Dive,1 Ged Brady1. 1CRUK
Manchester, Manchester, United Kingdom; 2Christie NHS Foundation Trust
Manchester, Manchester, United Kingdom.
Background: Prostate cancer (CaP) is the second-leading cause of male
cancer-related mortality in Western societies. Localised prostate cancer
(Loc-CaP) can be classifıed into low-, intermediate-, or high-risk groups.
Active surveillance is recommended for low-risk patients, whereas radio-
therapy or surgery is often indicated in intermediate- and high-risk patients,
with possible intensifıcation using hormone therapy treatment. Despite ad-
vances in radiation delivery and surgery,20% of patients will not be cured
with local treatment and require androgen deprivation therapy (ADT). The
majority will develop resistance to ADT resulting in castration resistant
prostate cancer (CRPC) with poor prognosis and increased risk of metastatic
disease (mCRPC). Biomarkers are being developed based on tumour biop-
sies which may help stratify patients and allow more effective treatment.
However tumour biopsies are invasive, demanding for patients and surgeons
as well as challenging for longitudinal sampling. Here we evaluate a range of
blood biomarkers suitable for longitudinal sampling including circulating
tumour cells (CTCs), circulating tumour DNA (ctDNA) and Tumour edu-
cated platelet mRNA (TEP-RNA). Methods: A blood sampling, processing
and banking pipeline has been established for CaP patients providing
ctDNA, enriched and single CTCs as well as TEP-RNA. Following ctDNA
isolation, next generation sequencing (NGS) libraries are prepared to gen-
erate copy number alteration (CNA) data and mutation profıles. CTCs are
enriched using both the epitope independent Parsortix (P-CTC) (Chudziak
J. et al, 2016) and the epitope dependent (EPCAM and KRT19) CellSearch
(CS-CTC) platforms. Genomic analysis of CTCs is carried out by NGS of
whole genome amplifıed (WGA) single and pooled CTCs. CTC and TEP-
RNAmRNA profıles are established using both the Fluidigm RT qPCR (Flui-
digm Biomark™ HD system) and RNA-Seq. Results: Over 160 Loc-CaP and
100 mCRPC blood samples have been collected, processed and banked. In keeping
withpublisheddata53%of the100mCRPCpatientshave&gt5CS-CTCs (apoorprog-
nostic indicator)comparedto100%ofLoc-CaPhaving2CTCs.Controlcell“spikein”
RNAdata showed1000 fold enrichment of epithelial mRNAs post Parsortix CTC
enrichment indicate an equivalent enrichment of the “spiked in” cells. Similar epithelial
mRNAenrichmentwas seen in3/5mCRPCclinical samples tested.Tumourassociated
CNAchangeswere clearly detected in at least 15 of the 1st 22mCRPC ctDNA samples.
Sample processing and statistical analysis is ongoing to evaluate if these bloodbiomark-
ers, either alone or in combination, canbe linked to clinical status or outcome.
#5686 Long RNA sequencing of human plasma exosomes reveals full cov-
erage of diverse protein coding and long non coding RNA. Sudipto K.
Chakrabortty,1 Lisa Bedford,2 Hidefumi Uchiyama,2 Vasisht Tadigotla,1 Mi-
chael D. Valentino,1 Dominik Grimm,1 Dalin Chan,1 Sunita Badola,2 Graham
Brock,1 Johan Skog1. 1ExosomeDiagnostics, Inc., Cambridge,MA; 2TakedaPhar-
maceuticals International Co. Translational and Biomarker Research, Cam-
bridge, MA.
Growing research in oncology implicates exosomes in cell-to-cell commu-
nication and various cancer patho-physiologies. Vesicle-mediated signaling
is thought to occur via both protein and RNA transport. However, there is a
fundamental lack of understanding regarding the long RNA cargo within
exosomes. Previous RNASeq studies on exosomes have largely focused on
the small RNA fraction, although the clinical biomarker space remains dom-
inated by mRNA. These studies have reported a relatively small proportion
and poor transcript coverage of long RNA which has led many to conclude
that exosomes only carry short fragments of mRNA and ncRNA. To address
this, we have developed a novel platform specifıcally designed to perform
RNASeq on long RNA from exosomes to effıciently interrogate these as RNA
biomarkers. Paired-end sequencing revealed the presence of a wider diver-
sity of annotated mRNA and ncRNAs than previously recognized in exo-
somes. Employing our whole transcriptome unique molecular indexing
strategy, we were able to accurately quantify the number of unique RNA
molecules. We detected a total of over 1.4 million unique RNA molecules in
our libraries, with 271,308mapped to protein-coding regions from as little as
2 ml of plasma. We observed that even at a shallow sequencing depth (15
million read pairs), we could detect more than 10,000 genes, composed of
40,000 mRNA and 37,000 ncRNA annotated transcripts. ERCC spike-in
analysis indicates that our RNASeq platform is highly sensitive, detecting as
few as 8 copies of RNA. Long non-coding RNAs dominated the ncRNA
classes and accounted for over 95% of all uniquely detected ncRNAs.We also
observed a bimodal distribution of transcript coverage, similar to cellular
and tissue derived RNA. In excess of 15,000 transcripts were detected with
80% coverage and of these high-coverage transcripts, more than 25% were
over 1kb in length, the longest being 17.6kb. Taken together, these fındings
suggest exosomes harbor more than just small RNA transcripts and short
fragments of mRNAs as was previously thought and is a treasure trove of
RNA biomarkers. Current research in the liquid biopsy space has been lim-
ited to variant detection in cell-free DNA and circulating tumor cells but
transcriptional dysregulation is also an important feature of cancer. Our
results shed new light on the biology of exosomes and indicate that, in addi-
tion to well-recognized small RNA cargo, plasma exosomes carry an abun-
dance of long RNAs that can be interrogated by our optimized workflow. As
exosomes provide a rich and protected source of RNA in biofluids, sequenc-
ing both long and small RNA from exosomes has the potential to identify
biomarkers without the need for invasive tissue biopsies and allow us to have
amore complete picture of how the RNA transcriptome in plasma changes in
health and disease.
#5687 Detection and monitoring of IDH mutations in unamplifıed
plasma cell-free DNA in patients with advanced cancers treated with IDH
inhibitors. Filip Janku,1 Helen J. Huang,1 Rachna T. Shroff,1 Milind Javle,1
Anthony P. Conley,1 Anjali Raina,1 Veronica R. Holley,1 Aung Naing,1 Daniel
D. Karp,1 David Fogelman,1 Ahmed O. Kaseb,1 Rajyalakshmi Luthra,1 George
A. Karlin-Neumann,2 Funda Meric-Bernstam1. 1The University of Texas MD
Anderson Cancer Center, Houston, TX; 2Bio-Rad, Pleasanton, CA.
Background: Cell-free (cf) DNA from plasma of patients with advanced can-
cers offers an easily obtainable material for detection of IDH mutations, which
can be used for diagnostics and monitoring purposes. Methods: Plasma was
serially collected from patients with advanced cancers with IDH1 R132 or IDH2
R172 mutations, who were enrolled to clinical trials with IDH1, IDH2 or pan-
IDH inhibitors. cfDNAwas purifıed and up to 16 ng of each DNAwas tested for
mutations in the R132 hotspot of IDH1 and R172 hotspot of IDH2 using the
QX200 Droplet Digital PCR™ platform (Bio-Rad). Results (mutation allele fre-
quency [MAF] in the wild-type background or the number of IDH-mutant
copies/mL of plasma) were compared both to treatment outcomes and to the
results ofmutation analysis of either archival primary ormetastatic tumor tissue
obtained at different points of clinical care from a CLIA-certifıed laboratory.
Results:Of the 28 patients (cholangiocarcinoma, 24; other cancers, 4)with IDH1
R132 mutations (N25) or IDH2 R172 mutations (N3) in the tumor tissue,
IDH mutations were detected in 26 (93%) of plasma cfDNA samples even
though median time from tissue to plasma sampling was 16.5 months (3.5-71.1
months). Quantity ( median vs.  median MAF or copies/mL) of IDH-mu-
tant cfDNA was not associated with survival (median not reached vs. 11.1
months, P0.26). The best radiological response to treatment with IDH inhib-
itors was stable disease for 4months (5/28, 18%) and themedian progression-
free survival was 1.8 months (95% CI 1.4-2.2). The median quantity of IDH-
mutant cfDNA (MAF and copies/mL) at baseline, on therapy and at disease
progression did not differ (P0.16). Changes in quantity (MAF and copies/mL)
of IDH-mutant cfDNA within fırst 3 weeks of therapy were not associated with
response on radiographic imaging (P0.65) or progression-free survival
(P0.12). Conclusions: Detection of IDH mutations in a small amount of un-
amplifıed plasma cfDNA using ddPCR has excellent sensitivity compared to
conventional clinical IDHmutation testing of archival specimens. Quantity and
change in IDH-mutant cfDNA did not correspond with treatment outcomes.
#5688 Routine testing for KRAS mutations in cfDNA from blood of ad-
vanced cancer patients. Mónica Garzón Ibañez,1 Clara Mayo de las casas,1
Nùria Jordana Ariza,1 Ariadna Balada Bel,1 Beatriz Garcia,1 Sergio Villatoro,1
Jordi Bertrán-Alamillo,1 AlejandroMartinez-Bueno,2 Santiago Viteri Ramirez,2
Ana Pérez Rosado,1 Daniela Morales Espinosa,2 Maria José Catalán,1 Niki Ka-
rachaliou,3 Miguel Ángel Molina-Vila,1 Rafael Rosell2. 1Pangaea Oncology, Bar-
celona, Spain; 2Oncology Institut Dr Rosell, Dexeus University Hospital-Quirón-
salud Group, Barcelona, Spain; 3Sagrat Cor Hospital-Quirónsalud Group,
Barcelona, Spain.
Background:Mutations in theKRASproto-oncogene,GTPase (KRAS)aredriver
alterations in several tumors, such as non-small-cell lung (NSCLC) and colorectal
cancer (CRC). However, their role as a prognostic marker in liquid biopsies is un-
clear.We studied the status ofKRASmutations in the peripheral blood of advanced
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NSCLC and colorectal cancer patients visited in our hospital and evaluated its po-
tential value as amonitoringmarker in the clinical practice.Methods:Wedeveloped
a sensitive TaqMan assay, in the presence of a PNA clamp, for the determination of
KRAS mutations (codons 12, 13 and 61) in circulating-free DNA (cfDNA). The
assay detected 2.5 pg mutated DNA/L and a ratio of KRAS mutated versus wild
typealleleof1:20000andwasvalidated in80cancerpatientspreviouslygenotyped in
tumor tissue showing a clinical sensitivity of 72.5% and specifıcity of 100%. cfDNA
was isolated from serum and plasma specimens, using an automatic extractor and
mutational analyses were performed in quadruplicates samples. Serum and plasma
samples were drawn at diagnosis, during follow-up and progression. Results: 239
NSCLC and 11 colorectal cancer patients were screened for KRAS mutations in
cfDNA at presentation in the period of 2013 to 2016. In addition, 160 cfDNA sam-
ples collected during disease monitoring of 61 patients were analyzed. Paired biop-
sieswereavailable from110/250patdiagnosis (60positive forKRAS inFFPEand50
WT). TheKRASmutationwas detected in the cfDNAof 76.6% (46/60) p positive in
tumor tissue vs. only in 1/50WTpatientswhere aG12Cwas detected in cfDNA in a
consistent manner, probably associated with a heterogeneity of the tumor. In pa-
tients with no biopsy available, we detected KRAS mutations in cfDNA in 14.3%
(20/140) cases at diagnosis. Themost prevalentmutations observed in cfDNAwere
G12C (44.7 %), G12V (22.4%) and G12D (10.4%) for NSCLC patients and G13D
(5.9%) forcolorectalpatients.TheQ61Hmutationwasdetected in thecfDNAofone
NSCLCandoneCRCp.Of the67patient’spositive incfDNAatpresentation,KRAS
mutations were detected in serum and plasma in 38 patients, only in plasma in 24
and only in serum in 5. Regarding the 61 patients with serial blood samples, we
observedacorrelationbetween theKRASmutation load incfDNAand thecourseof
the disease,with a decrease in patients responding to chemotherapy and an increase
during disease progression. Conclusions: Our results demonstrate the feasibility of
KRASmutation analysis in the cfDNAof advancedNSCLC and colorectal patients.
Analysis of KRAS mutations in the blood of mutated patients can have a value in
patients with no biopsy available and tomonitor the course of the disease.
#5689 Identify tissue-of-origin in cancer cfDNA by whole genome se-
quencing. Yaping Liu,1 Sarah Reed,2 Atish D. Choudhury,3 Heather A. Par-
sons,3 Daniel G. Stover,3 GavinHa,2GregoryGydush,2 Justin Rhoades,2 Denisse
Rotem,2 Samuel Freeman,2 Viktor Adalsteinsson,2 Manolis Kellis1. 1MIT, Cam-
bridge, MA; 2The Broad institute of MIT and Harvard, Cambridge, MA; 3Dana-
Farber Cancer Institute, Boston, MA.
Cell free DNA (cfDNA) has been shown to be an emerging non-invasive bio-
marker tomonitor tumor progression in cancer patients. Elevated cfDNAhas been
foundnotonly fromtumors,butalso fromnormal tissues.Thus, the identifıcationof
cfDNA’s tissue-of-origin is critical to understand the mechanism of cfDNA release
and tumor progression. Recent efforts to identify cfDNA’s tissue-of-origin begin to
utilize cfDNA’s epigenomic status, suchasDNAmethylationandnucleosome spac-
ing.However, bothof thesemethodshave limitations: (1) Fornucleosomeposition-
ing, lack of reference nucleosome maps in different tumor and normal tissues has
limited its application to tissue-of-origin deconvolution; (2) ForDNAmethylation,
largeDNAdegradation duringwhole genome bisulfıte sequencing (WGBS) library
preparation, evenwith current low-input DNA technology, is still themajor hurdle
for its clinical application, althoughextensiveDNAmethylationstudiesbyWGBSin
tumor and normal tissues during the last decade have provided many reference
maps. Very recently, a pioneer study showed signifıcant differences between DNA
fragment lengths ofmethylated andunmethylated cfDNA.Taking advantageof this
experimental observation, we developed a machine learning approach to infer the
base pair resolution DNA methylation level from fragment size information in
whole genome sequencing (WGS). The predictedDNAmethylation, fromnot only
high coverage but also dozens of ultra-low-pass WGS (ULP-WGS), showed high
concordancewith theground truthDNAmethylation level fromWGBS in the same
cancer patients. Furthermore, by using hundreds ofWGBS datasets from different
tumor and normal tissues/cells as the reference map, we deconvoluted cfDNA’s
tissue-of-origin status by inferredDNAmethylation level at ULP-WGS from thou-
sands of breast/prostate cancer samples and healthy individuals. The cfDNA’s tis-
sue-of-origin status in cancer patients showed high concordance with confırmed
metastasis tissues from physicians. Interestingly, some clinical information, such as
cancer grades/stages, seemed to be correlated with cfDNA’s tissue-of-origin status.
Overall, ourmethods here pave the road for cfDNA’s application in clinical diagno-
sis andmonitoring.
#5690 Optimized molecular barcoding enables accurate targeted muta-
tion detection in circulating cell-free DNA (cfDNA).Carlo G. Artieri, Kyle A.
Beauchamp, Valentina S. Vysotskaia, Noah C. Welker, Eric A. Evans, Clement
Chu, Haluk Tezcan, Imran S. Haque. Counsyl Inc., South San Francisco, CA.
The evaluation of cfDNA allows novel approaches to noninvasive detection of
actionable alterations, resistance mechanisms, and tumor monitoring in patients
with cancer. Importantly, tumor-specifıc DNA fragments represent a small minor-
ity of the cfDNA and can be obscured by false positive (FP) variants introduced by
chemical damage and sequencer error. To address this, we improved key processes
in the design of NGS libraries, including a newmolecular barcoding approach, that
maximizemolecular recoverywhile eliminating spurious variants.We engineered a
set of Illumina sequencing chemistry compatible adaptors incorporating unique
molecular identifıers (barcodes) enabling reconstruction of the sequence of both
strands of the original DNAmolecule. These barcodes incorporate a number of key
design improvements as compared to published methodologies, which enhance
sequencer cluster density, thereby increasing library diversity andmolecular recov-
ery.Our newdesign identifıed both chemical and sequencer errors, reducing incor-
rect base calls to rates below 5e-7.We validated ourmethodology for use in cfDNA
using both dilution experiments and patient blood samples with known oncogenic
alterations via a custom capture panel targeting actionable genomic alterations in a
55kb region. By identifying the molecular origin of each read, we found that the
sensitivity of detection obtained from barcoded libraries followed ideal binomial
sampling expectations.Weobtained an averagemolecular depth of 1,000molecules
per site from the plasma extracted from a single blood collection tube, which corre-
sponded to an 80% sensitivity of detection of known oncogenic single-nucleotide
and indelmutations at 0.15%mutant allele frequency (MAF) in cfDNAwith no FP
calls. Furthermore, we successfully detected known gene-fusions at 0.5%, and am-
plifıcations (10 copies) down to 1%MAF. We designed and validated a custom-
engineered error-correcting sequencing adapters, ideal for broad range of applica-
tions requiring high accuracy detection of ultra-low frequency alterations.
#5691 ESR1 methylation in plasma cfDNA of patients with high-grade
serous ovarian cancer. Lydia Giannopoulou,1 Sophia Mastoraki,1 Areti Strati,1
Isaam Chebouti,2 Sabine Kasimir-Bauer,2 Evi S. Lianidou1. 1Analysis of Circu-
lating Tumor Cells lab, Lab of Analytical Chemistry, Department of Chemistry,
University of Athens, University Campus, Athens, Greece; 2Department of Gyne-
cology andObstetrics, University Hospital of Essen, University of Duisburg-Essen,
Essen, Germany.
Introduction: ESR1 methylation is frequently observed in many types of solid
malignancies, but few studies attempted to investigate ESR1 methylation status in
ovarian cancer so far. We examined for the fırst time ESR1 methylation in plasma
samples of high-grade serous (HGSC) ovarian cancer patients, using a novel real-
timeMSP assay. Materials andmethods: We fırst developed and validated a highly
specifıc and sensitive real-time MSP assay for ESR1 methylation. A commercially
available 100%methylated standardwas used as positive control in all experiments.
We then evaluated ESR1 methylation in plasma (2mL) of 59 pre-surgery, mainly
advanced stageHGSCpatients. A control group of 51 plasma samples fromhealthy
women was recruited for the evaluation of specifıcity of our assay. All cfDNA sam-
ples isolated from plasma were subjected to sodium bisulfıte (SB) treatment and
were then analyzed by real-timeMSP for ESR1methylation. For the normalization
of the results,weusedACTBas a reference gene.The real-timePCRassay forACTB
was designed to amplify specifıcally SB treated DNA. Results: The real-time MSP
assay is highly sensitive, as it detects down to 0.1% of ESR1 methylation in the
presence of 99.9% non-methylated sequences. ESR1 methylation was detected in
18/59 (30.5%) high-grade serous ovarian patients, but only in 1/51 (2.0%) of healthy
women. All results were obtained after normalization with ACTB as a reference
gene.Conclusion:Wereport for the fırst time thatESR1methylationcanbedetected
in cfDNA of high-grade serous ovarian cancer patients, but not in healthy women.
Further investigation is required to determine the clinical signifıcance of ESR1
methylationstatus incfDNAofHGSCpatients.Wealsoaimtoevaluateour fındings
in a larger group of patients.
#5692 Cross-platform detection and quantifıcation of actionable muta-
tions in cell-free DNA shows high concordance and correlation between
next-generation sequencing and droplet digital PCR. Bryan C. Ulrich,1 Re-
becca J. Nagy,2 Justin I. Odegaard,2 Richard B. Lanman,2 Geoffrey R. Oxnard,1
Cloud P. Paweletz1. 1Dana-Farber Cancer Institute, Boston, MA; 2Guardant
Health, Redwood City, CA.
Background: Non-invasive genotyping of cell-free DNA (cfDNA) provides phy-
sicians with the ability to identify genomic alterations, evaluate response to treat-
ment, and uncover potential mechanisms of resistance. Here, we analyze the con-
cordanceof next-generation sequencing (NGS) anddroplet digital PCR (ddPCR) in
detectingandquantifyingactionablemutations fromcfDNAof lung, colorectal, and
breast cancer patients. Methods: We studied a cohort of 221 advanced cancer
cfDNA samples with completed Guardant360 digital sequencing results. Variant
allele frequencies (%AFs) ranged from less than 0.2% to greater than 90% for com-
mondriver and resistancemutations. Blinded toplasmaNGS results,weperformed
ddPCR using our validated assays for EGFR L858R, exon19 del, T790M (113 pre-
sumed lung cases); BRAF V600E, KRAS G12X (77 colorectal cases); ESR1 D538G,
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Y537C and PIK3CA H1047R (31 breast cases). Following unblinding, qualitative
and quantitative accuracy were compared. Results: Qualitative results (Table 1)
show a high concordance between NGS and ddPCR, with 98.3% (576/586) of all
assays run being concordant. 9/22 of samples that had an AF below 0.4% were
discordant,while only one sample above 0.4%AFwasdiscordant.AFs calculated by
NGSandddPCRwere strongly correlatedby linear regression (Rbetween0.951 and
0.999).Notably, the slope of the ddPCRAFversusNGSAFgraph for EGFRex19del
was 0.725,which improved to 0.95with the adoptionof an alternate callingmethod.
Conclusions: This interlaboratory comparison of actionable mutations in cfDNA
from lung, colorectal, and breast cancers by orthogonal genotyping platforms dem-
onstrates a substantial concordance in detection and quantifıcation between NGS
and ddPCR. Our cross-platform study establishes the feasibility of standardization
of qualitative and quantitative measurements of cfDNA-detected alterations.
Table 1
Lung EGFR L858R EGFREx19 del EGFRT790M
(n113) G360 G360- G360 G360- G360 G360-
ddPCR 58 0 51 0 53 0
ddPCR- 0 55 4 58 4 56
Breast ESR1 Y537C ESR1 D538G PIK3CA H1047R
(n31) G360 G360- G360 G360- G360 G360-
ddPCR 1 0 22 0 2 0
ddPCR- 0 30 0 9 0 29
Colorectal BRAF V600E KRAS G12X
(n78) G360 G360- G360 G360-
ddPCR 22 0 57 1
ddPCR- 0 55 1 18
#5693 Low coverage genome-wide sequencing of cell-free DNA enables
detection, therapeutic monitoring, and characterization of copy number al-
terations in patients with solid tumors. Christopher K. Ellison,1 Aaron M.
Goodman,2 Sabine Riethdorf,3 Amin R. Mazloom,1 Lisa Tran,2 Prachi Na-
kashe,1 Erin McCarthy,1 Tobias Gorges,3 Alexander Stein,4 Julia Quidde,4 Dan-
iel S. Grosu,1 Mathias Ehrich,1 Taylor J. Jensen,1 Klaus Pantel,3 Razelle Kurz-
rock2. 1Sequenom, Inc., San Diego, CA; 2Moores Cancer Center, San Diego, CA;
3University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; 4Univer-
sity Medical Centre Hamburg, Hamburg, Germany.
Circulating tumorDNA (ctDNA) has been detected in the blood of patients with
many cancer types and is thought to reflect the combined genetic profıle of the
primary tumor and metastases. The majority of studies into “liquid biopsies” have
focused on detecting focal events including single nucleotide variants, fusions, and
specifıc copy number alterations (CNAs); however, these assays are limited to mu-
tations occurring in targeted regions and require deep sequencing. The objective of
this study was to use low coverage, genome-wide sequencing of cell-free DNA
(cfDNA) to evaluate the frequency, distribution, and persistence of genome-wide
CNAs in the plasma of patients with solid tumors. cfDNAwas isolated from a total
of 203plasmaaliquots from72patientsdiagnosedwith avarietyof solid tumors. For
almosthalf of thepatients,multiple collectionswere available (range: 2-13) to enable
longitudinal monitoring of treatment response. Greater than 25% of baseline
cfDNA samples showed evidence of one or more CNAs and greater than 40% of
patients had a CNA detected in at least one sample. Among patients with longitu-
dinal monitoring, greater than 35% of individuals showed evidence of CNAs at
baseline and approximately 25% of samples showed similar evidence in subsequent
sampling. Collectively, CNAs were detected on all autosomes, suggesting that ge-
nome-wideprofıling is necessary to fully assessCNAdistributions.Additionally,we
devised a metric which quantifıed the level of genomic instability. This metric,
termed the genomic instability number (GIN), was associated with disease classifı-
cation. In patients capable of longitudinal monitoring, GIN values were observed
concomitantwith therapeutic response (including, interestingly, response to immu-
notherapy) or disease progression and may provide information earlier than stan-
dard imaging-based methods. In addition, total cfDNA amount was evaluated as a
predictor.When analysis was performed across all patients, there was a poor corre-
lation between total cfDNA amount and the GIN; however, total cfDNA amount
was strongly correlated with the cumulative abundance of CNA events within indi-
vidual patients, suggesting that theCNAs detected in the cfDNAwere derived from
the additional genetic material contributed by the tumor. These data demonstrate
the feasibility of detecting ctDNAina signifıcantportionof cancerpatients solely on
thebasisof lowcoverageCNAprofıling.Further, thenatureofCNAeventsobserved
varied both between patients and across longitudinal samples from individual pa-
tients, suggesting potential formonitoring therapy response or disease progression.
This study suggests that genome-wide CNA profıling may be useful alone or as a
complement to standard variant detection strategies in the development of liquid
biopsy technologies.
#5694 Multi institutional evaluation of a new NGS assay for mutation
detection from cfDNA in lung cancer. Jose L. Costa,1 Robbert Weren,2 Anna
Maria Rachiglio,3 Andrea Maffıcini,4 Henriette Kurth,5 Anne Reiman,6 Audrey
Didelot,7 Alexander Boag,8 Claudia Vollbrecht,9 Kazuto Nishino,10 Harriet E. Fei-
lotter,8 Pierre Laurent-Puig,7Orla Sheils,11Aldo Scarpa,4Marjolijn Ligtenberg,2 Ian
A. Cree,6Michael Hummel,9 Jose CarlosMachado,1 Nicola Normanno12. 1i3S/Ipa-
timup, Porto, Portugal; 2Radboud university medical center, Nijmegen, Netherlands;
3Centro di RicercheOncologiche diMercogliano (CROM)-IstitutoNazionale Tumori
“Fondazione G. Pascale”-IRCCS, Naples, Italy; 4ARC-NET: Centre for Applied Re-
search on Cancer, Verona, Italy; 5Viollier AG, Basel, Switzerland; 6University Hospi-
tals Coventry andWarwickshire, Coventry, United Kingdom; 7University Paris Des-
cartes, Paris France Assistance Publique-Hôpitaux de Paris, European Georges
Pompidou Hospital, Paris, France; 8Queen’s University, Kingston, Ontario, Canada;
9Charité - University Hospital Berlin, Charité Campus Mitte, Institute of Pathology
German Cancer Research Center (DKFZ), Berlin, Germany; 10Kinki University Fac-
ulty of Medicine, Osaka, Japan; 11Trinity Translational Medicine Institute, Dublin,
Ireland; 12Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori “Fondazione
G. Pascale”, Naples, Italy.
Introduction: The detection of actionable mutations in lung cancer is still a
major challenge due to the lack of tissue specimens formolecular profıling of the
tumor in approximately 25% of patients. The circulating cell-free tumor DNA
(ctDNA) isolated from plasma of cancer patients is an alternative, minimally
invasive source of tumor DNA that also allows rapid determination of the mu-
tational status of the tumor. However, the intrinsic low abundance of mutations
in cfDNAmakes their detection and quantifıcation in plasma a challenging task.
Here we report a multi-institutional validation of the Oncomine cfDNA Lung
Cancer assay for the analyses of cfDNA in molecular pathology laboratories.
Methods: The Oncomine cfDNA Lung assays is a multiplexed sequencing assay
for liquid biopsy that generates reads containing targeted ctDNA regions along
with amolecular tag. In order to allow an initial uniform evaluation of the assay,
the Multiplex I cfDNA Reference Standard (Horizon Dx) derived from human
cell lines, and fragmented to an average size of 160bp10% (144bp–176bp) to
closely resemble cfDNA extracted from human plasma, was used. The reference
sample covers 8mutations in the EGFR, KRAS, NRAS and PIK3CA genes at 5%,
1%, 0.1% allelic frequencies and wildtype allele. The same lot of control sample
was distributed to the participating laboratories within the OncoNetwork Con-
sortium. Samples were sequenced twice in each laboratory either using the Ion
PGM system or the Ion S5 system. Libraries were templated using the Ion Chef
and multiplexed as four libraries on a 318/520 chip or eight libraries on a 530
chip. A bioinformatics pipeline within the Torrent Server software allowed for
automated variant calling. Results: The laboratories involved in the study were
able to detect the 8 hotspot base changes and indels present in the control sam-
ples at allelic frequencies from 0.1% to 5% with an average 94.05% sensitivity
(range 87.50% - 97.92%) and an average 99.87% specifıcity (range 99.53% -
100%).When only considering variants at the 0.1% allelic frequency, the average
sensitivity was 83.04% (range 68.75% - 99.95%) and the average specifıcity was
99.95% (range 99.68% - 99.95%). Notably, at the 0.1% allelic frequency, all the
participating laboratories were able to detect the challenging EGFR p.T790M
variant that is a marker of sensitivity to EGFR tyrosine kinase inhibitors. Con-
clusions: These preliminary data confırm the potential of the Oncomine cfDNA
lung assay for plasma genotyping to allow for the noninvasive, multiplexed
detection of complex, targetable genomic alterations in lung cancer.
#5695 Increased sensitivity for detection of oncogenic mutations present
in circulating cell-free tumor DNA.Aaron R. Thorner, Michael K. Slevin, An-
drea Clapp, Haley A. Coleman, Suzanne R. McShane, Samantha D. Drinan,
Edwin Thai, Bruce M. Wollison, Robert T. Burns, Alex Frieden, Matthew D.
Ducar, AnweshaNag, Laura E.MacConaill,MatthewL.Meyerson.Dana-Farber
Cancer Institute, Boston, MA.
Molecular pathways involved in tumor survival and progression are often
activated by genetic alterations, and anticancer agents specifıcally targeting
many oncogenic pathways have entered clinical trials. Precision cancer medi-
cine takes advantage of genomic technologies (e.g., massively parallel sequenc-
ing, MPS) to perform robust tumor genomic profıling in the clinic, enabling
identifıcation of “druggable” mutations. To date, the vast majority of genomic
profıling has been performed on DNA extracted from solid tumor biopsies.
However, liquid biopsies offer advantages over solid tumor biopsies; chief
among them are their non-invasive nature and quick turn-around time when
assessed using MPS. Furthermore, liquid biopsies allow for sequential analysis
throughout a course of therapy permitting real-time monitoring of treatment
effects on tumor expression and subsequent surveillance for development of
new oncogenic alterations. Circulating cell-free tumor DNA (cfDNA) derived
from plasma represents a convenient assay material that has been effectively
CLINICAL RESEARCH: Liquid Biopsies 5: cfDNA, MicroRNA, and Protein
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171454
analyzed for oncogenic mutations in specifıc forms of cancer such as non-small
cell lung cancer.However, introduction cfDNA for clinical genotyping is limited
by sensitivity requirements. cfDNA is typically present at 20-100 ng/mL of
plasma, ofwhich the cancer fraction can be below1%. Error rates associatedwith
PCR amplifıcation and base calling (Illumina HiSeq platform) are approxi-
mately 2%, preventing confıdence in rare variants with allele fractions (AF) at or
below that percentage. We conducted an evaluation of commercially available
kits to determine 1) kit sensitivity and if necessary 2) modify the protocol to
achieve sensitivity of 1%AF. To evaluate kit sensitivity gDNA from a trans-
location positive cell line wasmixed at 5% and 20%with normal cell line gDNA.
Libraries were prepared for each percent mix using 10 ng of input. Raw mean
target coverage (MTC) was similar for evaluated kits (MTC, 250-300X); Percent
Duplication, 34%. Comparison of 20% and 100% translocation samples
showed similar levels of unique single nucleotide variant (SNV) detection.How-
ever, 5% mixtures showed a10 fold reduction in SNV detection compared to
both 20% and 100% translocation samples. Furthermore, translocation rear-
rangement was only detectable in one third of the 5% translocation samples.
Increased sensitivity requires unique molecular barcodes coupled with refıne-
ments in bioinformatics analysis for clinical implementation of these assays.
#5696 Emerging KRAS mutation can play a considerable role to get ac-
quired resistance to EGFR blockade. Takeshi Yamada, Goro Takahashi, Ta-
kuma Iwai, Kouki Takeda, Michihiro Koizumi, Akihisa Matsuda, Seiichi Shinji,
Yasuyuki Yokoyama, Masahiro Hotta, Keisuke Hara, Satoshi Matsumoto,
Keiichiro Ohta, Eiji Uchida. Nippon Medical School, Tokyo, Japan.
Background: Epidermal growth factor receptor (EGFR) blockade can achieve
considerable tumor shrinkage in patients with metastatic colorectal cancer
(CRC). However, most patients who benefıt from EGFR blockade acquire resis-
tance within a year. It was previously reported that nine of 24 (38%) patients
whose tumors initially exhibited wild type KRAS developed detectable muta-
tions in KRAS in their sera after acquiring resistance to EGFR blockade. How-
ever, the mechanisms of this acquired resistance remain unclear. In this study,
we aimed to identify the mechanisms underlying acquired resistance to EGFR
blockade byusing circulating cell-free (ccf)DNA to track emergingKRAS, BRAF
and S492R mutations during chemotherapy. Methods: We enrolled 29 patients
with metastatic CRC and no RAS mutations in their primary tumors. Patients
were treated with fırst-line systemic chemotherapy that included EGFR block-
ade. We purifıed ccfDNA from 1 mL of serum from each patient before they
started chemotherapy, and every 2-3months during chemotherapy until disease
progression. We detected KRAS (codons 12, 13, 61, and 146), BRAF (V600E)
and S492R mutations using digital polymerase chain reaction. Results: KRAS
mutations were detected in the ccfDNA of three of the 29 patients (10%) before
chemotherapy. The response rate was 86% (25/29); the four non-responders
were the three patients with KRAS mutations, and another who exhibited
ccfDNA BRAF mutations before starting chemotherapy. All patients with no
KRAS or BRAF mutations in their ccfDNA before chemotherapy responded to
the chemotherapy (25/25). Of these 25 initially responsive patients, 13 (52%)
acquired resistance. We detected emerging KRAS mutations in the ccfDNA of
11 of these 13 patients (84%); eight of these patients hadmultiplemutations.We
also detected BRAF mutations in six patients (46%); none of the patients had
solo BRAF mutations. Five patients (38%) had S492R mutations; one had mu-
tations in S492R only. Only one patient had no KRAS, BRAF or S492R muta-
tions. Discussion: EGFR blockade has no benefıcial effect in patients with KRAS
or BRAFmutations in their ccfDNAprior to starting chemotherapy. Emergence
of KRAS, BRAF or S492R mutations that were undetectable before the start of
chemotherapy may be a mechanism underlying acquisition of resistance to
EGFR blockade. Notably, emerging KRAS mutations were detected in most of
the patients (84%) who acquired resistance. This indicates that the emergence of
KRASmutations may play a considerable role in the acquisition of resistance to
EGFR blockade.
#5697 Proteomic analysis of prostate cancer-related exosomes isolated by
anti-PSMA antibody beads. Kosuke Mizutani,1 Kyojiro Kawakami,2 Yasunori
Fujita,2 Kengo Horie,1 Koji Kameyama,1 Masafumi Ito,2 Takashi Deguchi1.
1Gifu University Graduate School of Medicine, Gifu, Japan; 2TokyoMetropolitan
Institute of Gerontology, Tokyo, Japan.
Purposes of the study: Exosome has been demonstrated to be a useful non-
invasive biomarker for several cancers including prostate cancer. For better
understanding cancer-derived exosome, their proteomic analysis is necessary.
The aim of this study is to establish the method for isolation and analysis of
prostate cancer-related exosomes. Experimental procedures: Total exosomes
were isolated from the conditionedmedia of LNCaP cells by ultracentrifugation.
Then, exosomes positive for CD9 or prostate specifıc membrane antigen
(PSMA) were isolated by magnetic beads conjugated with anti-CD9 or -PSMA
antibody, respectively. Isolated exosomes were subjected to proteomic analysis.
The PSMApositive fractionwas also collected by anti-PSMAbeads fromdiluted
serum of 3 prostate cancer patients and analyzed by proteomics. Results: A total
of 126, 139 and 13 proteins were detected in the LNCaP exosome fractions that
were isolated by ultracentrifugation, anti-CD9 beads and anti-PSMA beads, re-
spectively. Out of 126 proteins identifıed in ultracentrifuge isolated exosome, 56
and 6 protein were found in exosomes that were isolated by anti-CD9 beads and
anti-PSMA beads, respectively. Seven proteins were commonly detected in exo-
somes that were isolated by both beads. Fifty, 54 and 48 proteins were identifıed
in the PSMA positive fraction from serum of 3 prostate cancer patients (P1:
localized prostate cancer, P2: advanced prostate cancer and P3: castration resis-
tant prostate cancer). Thirty-three proteins were detected in one patient, 22 in
two patients and 25 in three patients. Most proteins detected in all patients were
serum- or immunoglobulin-related proteins. The numbers of proteins that were
detected only in P2 and P3 were 16 and 8, respectively. Six proteins were found
in both P2 and P3 patients. Conclusion: In the present study, we analyzed pros-
tate cancer-related exosomes that were isolated by immunoaffınity-based
method. Although most proteins were serum- or immunoglobulin-related pro-
teins, proteins that had been reported as a cancer marker were also detected,
which could be candidates for exosomal marker of prostate cancer.
#5698 Next generation sequencing of circulating-free DNA from ad-
vancednon small cell lung cancer patients usingGeneReader®.ClaraMayo de
las Casas,1 Mónica Garzón,1 Nuria Jordana Ariza,1 Ariadna Balada,1 Jordi Ber-
tran-Alamillo,1 Beatriz García,1 SergioVillatoro,1 ErikaAldeguer,1 Sonia Rodri-
guez,1 Raquel Campos,1 Santiago Viteri Ramirez,2 Maria Gonzalez-Cao,2 Niki
Karachaliou,3 Rafael Rosell Costa,2 Miguel Angel Molina-Vila1. 1Pangaea On-
cology, Barcelona, Spain; 2Dr. Rosell Oncology Institute, Dexeus University Hos-
pital-Quirónsalud Group, Barcelona, Spain; 3Sagrat Cor Hospital-Quirónsalud
Group, Barcelona, Spain.
Background: Stand alone tests such as PCR-derived techniques, FISH or IHC
are usually employed to determine clinically relevant alterations in non-small
cell lung cancer (NSCLC).However, they target single genes and proteins.Muti-
plex techniques can reduce the turnaround time and quantity of sample in this
setting, but require a careful validation. Methods: A total of 41 cfDNA samples
from serum and plasma from advanced NSCLC p were analyzed with the Ac-
tionable Insights Tumor Panel, which covers mutations in 15 clinically relevant
genes, using the Gene Reader platform (Qiagen). The samples had been previ-
ously genotyped for EGFR, KRAS and BRAF mutations by stand alone, PNA-
Taqman assays. Paired biopsies were available in 37 cases. The remaining 4
corresponded to p.T790M-positive blood samples of p progressing to EGFR
TKIs. Results: Of the 41 samples taken into theGeneReader workflow, some had
aDNA input concentration below specifıcations, in spite of this limitation, good
results were obtained. 14 mutations were fully concordant between tissue, Taq-
man and GeneReader and the four p.T790M mutations were concordant be-
tween Taqman and GeneReader. Five mutations present in tissue were detected
by GeneReader and not by Taqman and 11mutations detected by Taqman were
below the 1% detection threshold of GeneReader. Finally, 12 mutations present
in tissue were not detected in cfDNAby any of the assays. Concordance between
the stand alone tests and the Gene Reader in cfDNA was 64%, raising to 84% if
mutations1% allelic fractionwere excluded. Conclusions: Application ofNGS
to liquid biopsies is challenging and requires a careful validation. However, once
fully validated,NGSwill probably become themethodology of choice for cfDNA
analysis in NSCLC patients at presentation and at progression.
#5699 Detection of genetic and epigenetic DNA markers in urine for the
early detection of liver cancer. Surbhi Jain,1 Jamin D. Steffen,1 Yih-Ping Su,2
Jeremy Wang,1 Ting-Tsung Chang,3 Chi-Tan Hu,4 Wei Song,1 Ying-Hsiu Su2.
1JBS Science, Inc, Doylestown, PA; 2The Baruch SBlumberg Institute, Doylestown,
PA; 3National Cheng Kung University Medical College, Tainan, Taiwan; 4Bud-
dhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan.
The purpose of this studywas to explore the potential of urineDNAbiomark-
ers for the early detection of primary hepatocellular carcinoma (HCC). HCC is
an aggressive disease with a 5-year survival rate of 26% in early-stage cancers,
and amere 2% in later stages. Themost commonly used screening biomarker for
HCC is serum alpha-fetoprotein (AFP), which detects only 40-60% of cases.We
have previously shown that urine contains fragmented, circulation-derived, cell-
free DNA that can be used for detection of cancer-related DNA markers, if a
tumor is present. Given the molecular heterogeneity of HCC, we assembled a
panel of frequently reported early detection DNA biomarkers for HCC that
included genetic mutations (TERT -124 G to A, TP53 249 G to T and CTNNB1
hotspot at codon 32-45) and methylation markers (GSTP1, RASSF1A,
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CDKN2A, SFRP1, TFPI and MGMT). In this present study, we developed spe-
cialized short amplicon PCR assays optimized to detect these biomarkers from
the urine of patients with cancer and tested the panel of biomarkers in urine of
hepatitis, cirrhosis and HCC patients to demonstrate the feasibility of a break-
through urine DNA test for HCC screening and early detection. Our evaluation
indicated that the TP53 mutation, methylation of RASSF1A and GSTP1 urine
DNA biomarkers were signifıcantly higher in HCC than in non-HCC popula-
tion. A correlation analysis indicated that these three markers do not correlate
with each other and are suitable to be combined in a panel of biomarkers for the
early detection ofHCC.The 3-markerHCCurineDNApanel had anAUROCof
0.880 for distinguishing HCC from cirrhosis and hepatitis. By logistic regres-
sion, the sensitivity of the 3-DNA marker urine panel alone or in combination
with AFP is 84.5% or 89.5% respectively, with a specifıcity of 90% for detecting
HCC with AUROC of 0.951. Furthermore, these 3-DNA markers scored 43 of
the 49 (87.8%) AFP-negative (less than 20 ng/mL) HCC urine samples ‘positive‘
in this study population. A novel statistic model was built by using Random
Forest machine learning method as compared to full logistic regression in both
open labeled urine samples and 242 blinded urine validation samples. A sensi-
tivity of 92.3%at a specifıcity of 87%was obtained by applying the random forest
algorithm generated from the open labeled data (at 90% specifıcity cutoff) to the
validation study, where as a sensitivity of 76.9% at a specifıcity of 84.7% was
obtained from the full logistic regression derived from the open labeled data set.
In conclusion, HCC DNA markers can be detected in urine of patients with
HCC by short-amplicon, PCR-based assays and this urine test has the potential
to become the fırst line of screening for HCC in high risk populations.
#5700 CircSarc: Disease monitoring by liquid biopsies in sarcomas.Heidi
M. Namløs,1 Seyed Hossein Moosavi,1 Bodil Bjerkehagen,1 Olga Zaikova,1 Syn-
nøve Granlien,1 Stine Næss,1 Nina Louise Jebsen,2 Skyler Mishkin,3 Eva W.
Stratford,1 Else Munthe,1 Kirsten S. Hall,1 Lars B. Aasheim,1 Eivind Hovig,1
Brian Kudlow,3 OlaMyklebost,4 Kjetil Boye,1 LeonardoA.Meza-Zepeda1. 1Oslo
UniversityHospital, Oslo,Norway; 2HaukelandUniversityHospital, Bergen,Nor-
way; 3Archer, Boulder, CO; 4University of Bergen, Bergen, Norway.
The CircSarc study aims to provide new insights into the clinical utility of
liquid biopsies in soft tissue sarcomas. At present, mutational profıles of solid
tumours are obtained from tissue biopsies or surgical specimens. Recent ad-
vances in technology now allows to use blood plasma as a “liquid biopsy”, ex-
amining circulating tumour DNA (ctDNA) shed by the tumour cells into pe-
ripheral blood. ctDNA in plasma carries tumour-specifıc alterations that can be
used to monitor minimal residual disease, response to therapy, tumour burden
and evolution throughout the course of the disease. In CircSarc, we have en-
rolled 30 high-grade soft tissue sarcoma patients, with localised disease, that are
being followed throughout the course of their disease. Plasma from each patient
is collected longitudinally; before and after surgery, at each routine control and
before and after each treatment cycle. Patient’s tumour and germline DNAwere
exome sequenced to identify tumour-specifıc mutations, and ctDNA is being
sequenced using a comprehensive 900 cancer gene panel. The level of ctDNA in
plasma, represented by the tumour-specifıc biomarkers, are then monitored
throughout the course of the treatment, and acts as an indicator of tumour
burden. In addition, we are analysing plasma samples from 70 Gastro Intestinal
Stroma Tumour samples using targeted resequencing with AnchoredMultiplex
PCR. The levels of KIT and PDGFRAmutations in ctDNA are being correlated
with clinical and pathological features. The established targeted resequencing
protocols for ctDNAprovide different levels of complexity and sensitivity. In the
fırst screening, we have successfully detected somatic mutations in plasma at
time of surgery in 70%of the samples analysed.Mutations present in the tumour
at an allele frequency large than 20% can be robustly identifıed in plasma. In
addition, analysis of plasma samples identifıed novel mutations not detected in
the primary tumour, possibly reflecting intra-tumour heterogeneity. These mu-
tations are being followed throughout the course of the disease to monitor tu-
mour evolution and resistance. In a proof-of-concept study, we have shown that
that levels of tumour-specifıc mutations in liquid biopsies correlated to clinical
manifestation ofmetastatic disease in aggressive sarcoma, and have the potential
to detect disease progression at an early stage. Our work provides new insights
into the clinical signifıcance of ctDNA in sarcomas. By repeated sampling of
liquid biopsies, somatic mutations identifıed in ctDNA can be used as unique
non-invasive tumour-specifıc biomarkers for monitoring tumour burden and
disease evolution throughout the course of the disease.
#5701 Innovative approach for isolationof circulating cell-freeDNAfrom
liquid biopsies. Andrei Malykh,1 Vladimir Evtushenko2. 1Capital Biosciences,
Inc., Gaithersburg, MD; 2Russian State Center of Radiology and Surgery Technol-
ogies, Saint Petersburg, Russian Federation.
We developed a new approach for isolation of circulating cell-free DNA
(cfDNA) from liquid biopsies (plasma or serum). Our technology is based on
using the proprietary bi-functional substance X (SubX®) that binds DNA under
physiological conditions (e.g. directly in biological liquids), followed by adsorp-
tion of [DNA- SubX®] complex on a solid phase matrix. Since SubX®) captures
DNA via phosphate groups it allows for elimination of bias related to both
AT/CG content and DNA fragments length, thus improving extraction effıcacy
and accuracy of downstream applications. All currently available commercial
kits are [silica-chaotropic salt]-based and exhibit bias for either short or long
DNA fragments, as well as for the GC content. In addition, such systems require
at least 4- fold dilution of starting volume of bio liquid with concentrated (5.0
M) guanidine thiocyanate (GTC) to keep resulted GTC concentration at about
least 3.0M. Thus, already low concentrations of cfDNAare signifıcantly reduced
and may negatively influence extraction effıcacy of low abundance DNA frag-
ments. Since our method does not require chaotropic salt for DNA capture, no
dilution of startingmaterial (and thus cfDNA) takes place. DNA-bindingmatrix
SubX® allows either scaling the procedure to either large volumes of starting
material or extra low volumes and adaptation of the protocol for 96/384 well
format. Separation of cfDNA from the bulk of proteins occurs in a single vortex-
spin step without employing chaotropic agents thus speeding-up isolation pro-
cedure and reducing the costs. Thewhole procedure can be completedwithin an
hour and cfDNA is eluted in small volume of TE buffer. Average DNA yield
from0.2ml of double centrifuged bloodplasma fromnormal donors, cancer and
multiple sclerosis patients was 7.54.2 ng (n96).
#5702 A targeted re-sequencing assay for molecular profıling of somatic
mutations from plasma cell-free dna (cfdna) for bladder cancers. Liqin
Dong,1 Pramit Khetrapal,2 Simon Rodney,2 Wei Shen Tan,2 Sheida Rezaee,1
Patricia de Winter,2 John Kelly,2 Andrew Feber1. 1University College London,
Cancer Institute, London,UnitedKingdom; 2Division of Surgery& Interventional
Science, UCL Medical School, UCL, London, United Kingdom.
Bladder cancer (BC) is the 5thmost common cancer inWestern societies with
a rising global incidence. The major challenge to improving patient outcomes is
to better identify patients at risk for recurrence, progression, andmetastasis, and
to monitor treatment response. A non-invasive monitoring assay is needed in
order to interrogate the molecular features and clinical tumor heterogeneity of
bladder cancers, which will potentially lead to better stratifıed patient manage-
ment. We developed a targeted amplicon-based re-sequencing workflow for
detecting and tracking genomic mutations in cfDNA using dual molecular in-
dexed primers for specifıc amplifıcation of a panel of 20 of known (TERT,
FGFR3, PIK3CA, HRAS) and novel BC mutations. Only 3hr time is needed for
the total workflow for the library generation and followed by next generation
sequencing (NGS) performed on Illumina MiSeq sequencing platform. Data
analysis and variants callingwas performed. After a thorough test, optimization,
and validation of the targeted panel and the workflow on selected samples of
matched bladder tumor-blood pairs and controls, 45 samples were included for
testing the workflow, which includes samples of 16 matched bladder tumor-
blood pairs, technical duplicates of cfDNADNAReference Standards (Horizon
Discovery) with mutations at known allelic frequencies. Technical duplicates of
cfDNA extracted from blood from patients with metastatic BC (pre and post
chemotherapy) were also included in this study. Somatic variants frommatched
tumor-blood pairs were detected. We showed that detection sensitivity at 1.0%
allelic frequency was achieved. Our preliminary results demonstrated that we
were able to detect mutation burden from cfDNA samples and track mutation
burden change in response to chemotherapy for patients with metastatic BC.
Here we developed a sensitive, non-invasive targeted NGS workflow to detect
somatic mutations for bladder cancers from both tumor DNA and cfDNA sam-
ples. Our early results demonstrated that we can detect and track mutational
changes from patients with metastatic BC.
#5703 An ultra-sensitive multiplex allele-specifıc real-time PCR (Udx-
PCR) assay for detection ofESR1mutations inmetastatic breast cancer. Jiasu
Liu,1 Yaohuai Wang,2 Shengrong Sun,2 Dehua Derek Yu1. 1USK Bioscience,
Shenzhen, China; 2Wuhan University Renmin Hospital, Wuhan, China.
Activatingmutations of estrogen receptor	 (ESR1) are attributed to acquired
resistance to estrogen-deprivation therapy in patients with metastatic breast
cancer (MBC). Thus, detection of these mutations is clinically critical for mon-
itoring early progression and effective therapeutic options in treatment of BC
patients under hormonal therapy. However, current investigations for detection
ESR1 mutations mainly focus on digital PCR technology due to low abundance
of the cfDNA in plasma samples, which is not a currently feasible method for
clinical diagnosis. Herein, we developed a multiplex allele-specifıc real-time
(ARMS) PCR assay for detection of ESR1 four mutations (Y537S, Y537C,
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Y537N, and D538G) in a single tube reaction. In this real-time PCR system, the
wild-type ESR1 DNA is completely blocked by a modifıed probe with a higher
annealing temperature, and themutant gene is selectively amplifıed by themod-
ifıed ARMS primers. The assay was found to be highly specifıc and sensitive.
With this assay, as low as 0.1% mutant DNA template in the background of a
total of 10ng wild-type genomic DNA could be detected. By using this assay, we
analyzed theESR1mutations in 50ChineseMBCFFPE andplasma samples. The
ESR1 mutations were detected in 3 FFPE and 6 plasma samples, which were
confırmed by pyrophosphate sequencing. Themultiplex allele-specifıc real-time
PCR assay provides a rapid and reliable diagnostic tool for accurate detection of
ESR1 mutations with potential for clinical application.
#5704 Ultrasensitive mutational analysis in cell-freeDNA by targeted
next-generation sequencing with molecular tags. Nga Wan Rachel Tam,
Irmina Diala, Xiaoji Chen, Walter Darbonne. Genentech, South San Francisco,
CA.
Circulating cell-free DNA (cfDNA) in plasma offers a non-invasive ap-
proach to monitor tumor molecular profıling in real-time at multiple time-
points, detection of emerging genomic alterations associated with drug re-
sistance and clarifying cancer prognosis and diagnosis of cancer recurrence
or progression. Therefore, it is crucial to improve our current NGS technol-
ogy to detect low frequency alleles in cfDNA. There are many technical
challenges in NGS technology, including base errors generated from library
preparation and sequencing, making it hard to distinguish real mutations
from false positives produced from amplifıcation sequencing and base-call-
ing processes. We have adopted a more sensitive approach to overcome this
challenge. We used short, random DNA sequences called unique molecular
tags (UMTs) during library preparation to label input DNA. This technique
can remove background errors, false positives during data analysis, provid-
ing high confıdent mutation calls with better sensitivity down to 0.1% (de-
pends on DNA input amount). We will present data showing validation of
this NGS platform using commercially available DNA control, archival FFPE
tissue and cfDNA matched samples and demonstrate robust sensitivity and
specifıcity by using the off-the-shelf Archer Reveal ctDNA panel for Illumina
covers 28 oncogenes. This molecular-tagged NGS panel can detect muta-
tions down to 0.1% allelic frequency. This robust NGS platform is being used
in our lab to analyze cfDNA samples, enabling the development of a non-
invasive method to overcome existing challenges to provide molecular un-
derstanding of patient’s tumor evolution in real time, and aid in the devel-
opment of personalized therapies for cancer patients.
#5705 Analytical validation of Guardant360 v2.10. James Vowles,1 Justin
Odegaard,2 Stefanie Mortimer,2 Stephen Fairclough,2 Marcin Sikora,2 Diana
Abdueva,2 Reza Mokhtari,2 Arthur Baca,2 AmirAli Talasaz2. 1Guardant Health,
Redwood City, CA; 2Guardant Health, San Jose, CA.
Guardant360 is a cell-free circulating tumor DNA (ctDNA) test that geno-
types all guideline-recommended solid tumor somatic genomic treatment tar-
gets from a single non-invasive blood draw. The new version, v2.10, was rede-
signed to enhance sensitivity and specifıcity across 73 cancer-related genes. It
detects all four major variant classes (single nucleotide variants, SNVs, in all 73
genes; indels in 23 genes; gene amplifıcations, CNAs, in 18 genes; and fusions in
6 genes). Analytical performance was assessed throughout the reportable range
via multiple serial dilution studies of orthogonally-characterized contrived and
patient samples. Analytical specifıcity was assessed by calculating the false pos-
itive rate in pre-characterized healthy donor sample mixtures serially diluted.
Positive predictive value (PPV) was estimated as a function of allelic fraction/
copy number from pre-characterized samples and prevalence-adjusted using a
cohort of 2,585 consecutive clinical samples. Confırmationwas performed using
ddPCR. Analytical specifıcity was 100% for SNVs, fusions, and CNAs and 96%
for indels across 25 defıned samples. Relative to Guardant360v2.9, v2.10 dem-
onstrated 20-50% increase in fusion molecule recovery. Retrospective in silico
analysis of 2,585 consecutive clinical samples demonstrated a 15% increase in
actionable fusion detection, a 6%-15% increase in actionable indel detection
(excluding newly reportable indels), and a 3%-6% increase in actionable SNV
detection.
Alterations
Reportable
Range
95%
Limit
of Detection
Allelic
Fraction/
Copy
Number
Analytical
Sensitivity
Allelic
Fraction/
Copy
number PPV
SNVs 0.04% 0.25% 0.25% 99.9% 0.25% 98.7%
0.05–0.25% 63.8% 0.25% 92.3%
Alterations
Reportable
Range
95%
Limit
of Detection
Allelic
Fraction/
Copy
Number
Analytical
Sensitivity
Allelic
Fraction/
Copy
number PPV
Indels 0.02% 0.2% 0.25% 99.9% 0.25% 98.4%
0.05–0.25% 67.8% 0.25% 88.5%
Fusions 0.04% 0.4% 0.3% 100% any 100%
0.3% 83.0%
CNAs 2.12
copies
2.24-2.93
copies
2.3 copies 95.0% any 100%
Guardant360 analytical performance characteristics based on standard cfDNA
input (30ng). Analytical sensitivity/limit of detection estimates are provided for
clinically actionable variants and may vary by sequence context and cfDNA
input. PPV is estimated across entire reportable panel space (PPV was 100% for
clinically actionable variants). Conclusion:Guardant360 v2.10 comprehensively
detects all adult solid tumor guideline-recommended somatic genomic variants
with unparalleled sensitivity, accuracy, and specifıcity.
#5706 Gene expression profıle of peripheral blood mononuclear cells in
breast cancer patientsmay be contribute to the identifıcation and the immu-
nological classifıcation of breast cancer patients by blood test. Eiji Suzuki,1
Kosuke Kawaguchi,2Masahiro Sugimoto,3 Fengling Pu,1 Ryuji Uozumi,4 Ayane
Yamaguchi,1 Mariko Nishie,1 Moe Tsuda,1 Takeshi Kotake,1 Satoshi Morita,4
Masakazu Toi1. 1Kyoto Univ. Hospital, Kyoto, Japan; 2Massachusetts General
Hospital, Harvard Medical School, Boston, MA; 3Keio University, Yamagata,
Japan; 4Kyoto University, Kyoto, Japan.
It is reported that gene expression profıle of peripheral blood mononuclear
cells (PBMCs) exhibits unique gene expression signature in cancer patients in-
cluding renal cell carcinoma, pancreatic cancer and lung cancer. Since pancre-
atic cancer diagnosis is diffıcult in not only early detection of the disease but also
in the diagnosis itself, development of novel diagnostic tools in addition to
conventional diagnostic strategy has been awaited. On the other hand, in breast
cancer, because early diagnosis by mammography and ultra sound examination
on breast is established successfully, exploration of gene expression profıle of
PBMCs may be important in terms of insight to host antitumor immune re-
sponse aspects. In the current study, we performed RNA sequencing (RNA-seq)
analysis on RNA of PBMCs from 3 healthy volunteers, 6 early and 7 metastatic
breast cancer patients including all phenotypes defıned by ER, PgR and HER2.
Genes that showed FDR0.05 and fold change of0.5 and 2.0 in comparison
of healthy volunteers and breast cancer patients were applied to clustering anal-
ysis by Ward method. We found signifıcant unique gene expression signature
between healthy volunteers and breast cancer patients. Furthermore, it was
shown that HER2 overexpressing breast cancer patients, which breast cancer
patients were divided into 3 clusters including HER2 type and other 2 different
groups, seemed to be classifıed into healthy group different from other pheno-
types of breast cancer patients. These fındings suggested that evaluation of gene
expression patterns of PBMCs of breast cancer patientsmight distinguish breast
cancer patients from healthy subjects and the gene expression signature of PB-
MCs which divided breast cancer patients into 3 groups might reveal immuno-
logically important biologic properties such as response prediction of cancer
immunotherapy including immune checkpoint inhibition treatment.
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#5707 STAT3 and STAT5a are potential therapeutic targets in castration-
resistant prostate cancer. Sambit K.Mohanty,1 Kader Yagiz,1 Luthringer Luth-
ringer,1 Mahul B. Amin,1 Serhan Alkan,1 Bekir Cinar2. 1Cedars Sinai Medical
Center, Los Angeles, CA; 2Clark Atlanta University, Atlanta, GA.
Background: Currently, there is no effective pharmacotherapy for metastatic
castration-resistant prostate cancer (mCRPC). The mechanisms underlying
mCRPC are not clearly understood, thus hindering rational-based drug design.
Evidence suggests that signal transducer and activator of transcription 3
(STAT3) and 5a/b (STAT5a/b), key components of the JAK/STAT pathway,
play a signifıcant role in aggressive PC. However, expression of STAT3/5 in
prostate tumor samples have not been studied. Here, we evaluated the possible
role of STAT3/5a in aggressive PC. Materials and Methods: Expression of
STAT3 and STAT5a in high grade PC (HGPC, n15) and in benign prostatic
hyperplasia (BPH, n15) tissue sections were evaluated by immunohistochem-
istry (IHC) according to the protocol approved by Institutional Review Board.
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Age ranged from 59 to 95 years (median 81) in the former and 57 years to 86
years (median 68 years) in the latter category. In addition, the effects of STAT
inhibitor, Pimozide, on androgen-sensitive LNCaP and its castration-resistant
subline C4-2 PC cell growth were assessed in vitro. Results: A strong nuclear
immunoreactivity for STAT3 and STAT5a in 93% (n14) and 80% (n12) of
HGPC cases, respectively, were observed. Only one BPH case showed strong
STAT3 expression. Focal and weak positivity for STAT3 and STAT5a were
noted in 47% (n7) and 67% (n10) of BPH cases. None of the BPH cases
showed strong STAT5a expression. HGPC cases showed signifıcantly higher
STAT3 positivity comparedwith BPH (p0.01). No signifıcant differences were
observed for STAT5a expression between HGPC and BPH group (p0.4).
However, multifocal or diffuse and strong STAT3 (p0.0001) and STAT5a
(p0.0001) expression was signifıcantly higher in HGRPC than BPH. Pimozide
exposure signifıcantly inhibited LNCaP cell proliferation at 10MandC4-2 cell
proliferation at 20Mconcentration. Conclusion: Our results demonstrate that
increased expression of STAT3 and STAT5amay serve as a predictive biomarker
for effıcacy of the JAK/STAT targeted therapy. Since JAK/STAT and androgen
receptor signaling are functionally synergistic in contributing PC progression,
the inhibition of JAK/STAT-alone or in combination with AR may lead to a
novel treatment modality for mCRPC.
#5708 HOXA4 and HOXB3 gene expression signature as a biomarker of
tumor recurrence in patients with high-grade serous ovarian cancer (HG-
SOC) following primary cytoreductive surgery and fırst-line adjuvant che-
motherapy. Jai N. Patel,1 KatherineMiller,1 James Symanowski,1 Jalid Sehouli,2
Chad Michener,3 Ioana Braicu,2 Darla Destephanis,1 Ashley P. Sutker,1 Eric J.
Norris,1 David Tait,1 Wendell Jones,4 Qing Zhang,1 Chad Livasy,5 Charles
Biscotti,3 RamN.Ganapathi,1MahrukhK.Ganapathi1. 1Levine Cancer Institute,
Charlotte, NC; 2Charite Medical University of Berlin, Berlin, Germany; 3Cleve-
land Clinic, Cleveland, OH; 4EA Genomics, Morrisville, NC; 5Carolinas Health-
Care System, Charlotte, NC.
Background: Aberrant HOX gene expression has been observed in various
malignancies; however, their role as a biomarker for recurrence in patients with
HGSOC is unknown. We tested the hypothesis that a HOX gene signature is a
biomarker for disease-free survival (DFS) inHGSOCpatients following primary
cytoreductive surgery and adjuvant platinum-based chemotherapy.Methods: A
panel of HOX genes associated with DFS in a discovery cohort of 19 HGSOC
patients with available RNA-Seq data, and/or previously reported as associated
with survival endpoints in the literature, were selected for testing by qPCR using
the Fluidigm platform in an independent training cohort of primary tumors
from 73HGSOC patients. Cox proportional hazards model was used to identify
HOX genes signifıcantly associated with DFS. A prognostic gene signature was
developed based on the combined linear predictor from the fınal multivariable
Cox model. Patients were stratifıed into risk groups using the optimal cutoff of
the linear predictor risk score, whereby the optimal cutoff was defıned as the
value that maximized the log-rank test statistic. Risk group stratifıcation was
further tested for associationwithDFS in a largerHGSOCdataset (N414)with
similar clinical characteristics from The Cancer Genome Atlas (TCGA). The
role of the identifıedHOXgenes in influencing drug sensitivity was examined by
overexpressing these genes in a HGSOC cell line, PEO1. Results: Of 23 HOX
genes selected for testing in the training cohort, overexpression of HOXA4
(HR1.21, 95% CI1.08-1.35, P0.001) and HOXB3 (HR1.09, 95%
CI1.02-1.17, P0.016) were signifıcantly associated with decreased DFS in
multivariate analysis. The median DFS in patients with a HOXA4/HOXB3 risk
score  the optimal cutoff was  80 months (not yet reached), whereas the
median DFS in patients with a HOXA4/HOXB3 risk score the optimal cutoff
was 16.9 months (HR7.85, 95% CI4.19-14.69, P0.001). The HOXA4/
HOXB3 risk score remained signifıcantly associated with DFS in the HGSOC
dataset from the TCGA (P0.02). In vitro studies demonstrated that PEO1 cells
overexpressing either HOXA4 or HOXB3 were signifıcantly (P0.05) more
resistant to cisplatin and carboplatin, but not to paclitaxel, as compared to empty
vector transfected cells. Conclusion: TheHOXA4/HOXB3 risk score was signif-
icantly associated with DFS in a training cohort of HGSOC patients, and re-
mained signifıcantly associated in a larger independent HGSOC dataset from
the TCGA. Further, in vitro studies suggest that HOXA4 and HOXB3 overex-
pression is associated with platinum resistance. Thus, overexpression of
HOXA4 andHOXB3 in primaryHGSOCmay serve as a potential biomarker for
recurrence and the risk score model developed warrants prospective validation
in HGSOC patients.
#5709 Variation in Merlin expression and its prognostic signifıcance in
malignant pleural mesothelioma. Ajay Dhakal, Saraswati Pokharel, Katy
Wang, Todd Demmy, Chukwumere E. Nwogu, Sai S. Yendamuri, Grace Dy.
Roswell Park Cancer Institute, Buffalo, NY.
Introduction: Malignant Pleural Mesothelioma (MPM) is an aggressive can-
cer with overall survival (OS) of about 8 months. Prognostic biomarkers allow-
ing for biology-driven individualized therapies are lacking inMPM. Alterations
in a tumor suppressor gene NF-2 are seen in 20-40% ofMPM. NF-2 encodes for
Merlin, which suppresses tumorigenesis by regulating pathways likemTOR and
Hippo.Merlin status had been proposed as a predictive biomarker for treatment
with the focal adhesion kinase (FAK) inhibitor. The purpose of our study is to
examine differences in Merlin expression among histologic subtypes of MPM
and its prognostic impact on clinical outcome.Materials andMethod: 48 cases of
MPM from 1993-2013 with available archival tissues were identifıed. H/E
stained sections were reviewed by a pathologist and categorized into 3 histologic
subtypes, namely epithelioid (E), sarcomatoid (S) and biphasic (B). Immunohi-
sochemistry-based Merlin expression score from 0 to 3 were given to the sam-
ples, accounting for both intensity and frequency of staining. Chart review was
performed to obtain clinical data. Kruskal-Wallis Test was used to compare
mean Merlin scores, and Logrank test was used to compare OS between low
Merlin (LM,3) and highMerlin (HM, 3) groups. Results:Mean age of patients
was 66.75 years (HM 64.58, LM 68.92). Other demographic profıle (HM%,
LM%) includedmale sex 89.5% (51, 49), current or past smokers 66.6% (47, 53),
current or past Asbestos exposure 71% (35, 65), resectable disease 89% (51, 49),
stages 3 or 4 disease 64% (56, 44), and 85% (56, 44) received surgery. Mean
Merlin scores among 3 histologic types were different (Mean, Std. Dev: B 2.25,
0.48; E 2.74, 0.54; S 2.56, 0.53; p 0.0037). Mean Merlin score of E component
was signifıcantly higher than that of S component within BMPM (E 2.75, 0.45; S
1.75, 0.68; p0.0001). Interestingly, mean Merlin score of S was signifıcantly
higher than that of S component of BMPM (S 2.56, 0.53; B 1.75, 0.68; p0.005)
making S component of BMPM leastMerlin expresser. There was no signifıcant
difference in response rate to platinum and in progression-free survival between
LM and HM. Median OS (months) for LM was 8.8 compared to 12.9 for HM
(p0.0262). Among different variables analyzed (age, sex, smoking history, his-
tology, and upfront treatment modalities), age was associated with OS. After
controlling for age, therewas no statistically signifıcant difference inOS between
LM and HM (p0.11). Conclusion: Merlin expression level is different among
E, S and BMPMs. Moreover, it is signifıcantly lower in S component of BMPM
than S. Its prognostic ability appears to be confounded by the association with
age in our cohort. A larger study is needed to further explore the prognostic
impact of this biomarker.
#5710 PGRMC1 is a biomarker for breast cancer cell proliferation and
early relapse. Elizabeth S. McDonald, Dhruv K. Pant, Tien-chi Pan, David A.
Mankoff, Robert H. Mach, Lewis A. Chodosh. University of Pennsylvania, Phil-
adelphia, PA.
Background: Breast cancers may recur following a long latency period, im-
plying a dormant or quiescent phase, however little is known about the biology
of cellular quiescence and few markers exist for this clinically important state.
The purpose of this study was to investigate whether progesterone receptor
membrane component family 1 (PGRMC1), which is expressed in both prolif-
erating and quiescent tumor cells, is a prognostic biomarker in human breast
cancer and to defıne its expression in breast cancer subtypes. Methods: Seven-
teen publicly available data sets were combined to analyze PGRMC1 expression
in 4,463 invasive breast cancers as a function of established molecular and phe-
notypicmarkers, estimates of cellular proliferation, and recurrence-free survival
data. A gene expression signature-based assay was utilized to estimate cellular
proliferation.Association between gene expression and relapse-free survivalwas
assessed using Cox proportional hazards regression while controlling for the
effect of proliferation. Results: PGRMC1 expression was analyzed stratifıed by
immunohistochemical and molecular subtype, tumor grade and size and com-
pared with a known triple negative breast cancer biomarker, BCL11a. PGRMC1
and BCL11a each exhibited a robust positive correlation of comparable magni-
tude with proliferation across all breast cancer subtypes (r0.27, p6.5x10-17
and r0.29, 1.7x10-41, respectively), and PGRMC1was strongly associated with
proliferation within the basal subtype (r0.42, p2.4x10-37 PGRMC1 versus
0.31, p1.1x10-8 BCL11a). PGRMC1 expression was associated with a higher
risk of early breast cancer recurrence (HR1.25, 95% CI [1.12,1.39],
p6.4x10-5) and this association was dependent upon its association with pro-
liferation. Conclusions: PGRMC1 is a breast cancer proliferation biomarker.
Further study of the function of this protein is warranted.
#5711 Gene expression profıles in BRAF V600Emutant colorectal cancer
and association with SFRP2 methylation status. Kazuya Yasui,1 Takeshi Na-
gasaka,1 Toshiaki Toshima,1 Takashi Kawai,1 Kunitoshi Shigeyasu,1 Yoshiko
Mori,1 Junko Haraga,1 Keiichiro Nakamura,1 Yuzo Umeda,1 Hiroshi Tazawa,1
Ajay Goel,2 Toshiyoshi Fujiwara1. 1Okayama Univ. Graduate School of Med.,
Okayama, Japan; 2Baylor University Medical Center, Dallas, TX.
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Background: Classifıcation of colorectal cancer (CRC) according to gene ex-
pression profıling remains controversial with regards to their ability to stratify
patients for precision therapy. Several studies have suggested that ‘stem cell like’
or ‘epithelial-mesenchymal transition (EMT)’ signature associates with poor
prognosis. Meanwhile CRCs with BRAFV600Emutation have shown poor out-
comes in several clinical trials, but the biological roles of BRAF mutation have
not been fully elucidated.Materials andMethods: To evaluate biological roles of
BRAF mutations in CRC, we performed mRNA microarray analysis in the fol-
lowing three subsets; eight BRAF-mutant CRC tissues without MSI, six BRAF-
mutant CRCs with MSI and fıve BRAF-wild type CRCs with MSI. Pathway
analyses were performed by Gene Set Enrichment Analysis (GSEA). Following
identifıcation of candidate biomarkers that influence poor outcomes and asso-
ciate with BRAFV600Emutation, we examined these candidate biomarkers in a
cohort of 1068 CRC patients who underwent surgical resection of their primary
tumor and/or metastatic lesions from 1994 to 2015 at the Okayama University
Hospital. Results: By the GSEA, prominent signatures enriched in CRCs with
BRAF V600E mutation vs. wild-type were EMT-related processes (EMT and
myogenesis). Additionally, CRC with BRAF V600E mutation strongly associ-
ated with inactivation of Wnt signaling and intestinal differentiation-related
genes. Among the differentially expressed genes between CRCs with BRAF
V600E mutation versus wild-type, Wnt-antagonist, Secreted frizzled-related
proteins (SFRPs) were signifıcantly upregulated in CRCs with BRAF V600E
mutation. As SFRPs are well known to be inactivated in CRCs by promoter
hypermethylation, and up to 80% of CRCs are methylated in the promoter
region of the SFRP2 gene, we focused and analyzed SFRP2 promoter methyl-
ation status in 782 stage II-IV CRCs of our cohort by amodifıed highly sensitive
assay for bisulfıte DNA followed by fluorescence-based PCR, as we previously
reported (JNCI 2009). SFRP2 methylation was observed in 498 (64.2%) stage
II-IV CRCs. Interestingly, SFRP2 unmethylated CRCs with genetic mutation in
the KRAS/BRAF genes demonstrated signifıcantly poorer outcome in RFS com-
pared with SFRP2methylated CRCs with genetic mutations in the KRAS/BRAF
genes (5-years RFS rate were 46.8% vs 72.1%; P 0.015, Hazard ratio 2.06 [95%
CI, 1.12 to 3.69]; P 0.021). Conclusion: Our results suggest that SFRP2 meth-
ylation status could be a potential prognostic biomarker for stage II-IV CRCs,
especially with genetic mutations in the KRAS/BRAF genes.
#5712 Potential clinical signifıcance of downregulation of MAPK path-
way components mRNA expression in head and neck squamous cell carci-
noma (HNSCC). Hoi Lam Ngan,1 Vivian W.Y. Lui2. 1The University of Hong
Kong, Hong Kong, Hong Kong; 2The Chinese University of Hong Kong, Hong
Kong, Hong Kong.
We previously showed theMAPKpathway can bemutationally activated, and
may implicate drug sensitivity in HNSCC [1]. Here, we report that RNA expres-
sion of several MAPK pathway components may be associated with HNSCC
patients’ outcome based on the US-TCGA Provisional data. We found that loss
of DUSP4, a negative regulator of MAPK pathway, was correlated with poor
overall survival (OS; P0.0286) and disease free survival (DFS) in HNSCC
(0.00150; median progression time  38.11 vs. 71.22 months in DUSP4-unal-
tered patients) which can potentially be explained by activation of oncogenic
MAPK pathway upon DUSP4 underexpression. Interestingly, we identifıed a
group of HNSCC patients with homozygous loss andmRNAdownregulation of
MAPK pathway scaffold protein components (GRB2, SHC2 and SHC3) with
signifıcantly poorer DFS (P0.000871). RPPA analysis showed a trend of de-
creased protein expression level of phospho-RAFs, downstream of scaffold pro-
teins, decreased MEKs and MAPKs, supportive of an overall decreased MAPK
pathway signaling in this subset of patients. Unexpectedly, downregulation (ho-
mozygous deletion/ RNA expression less than 2 SD) ofmultipleMAPKpathway
components which normally support activation of the pathway: RAF1 (9%),
MAPK1 (3%) andRPS6KA1 (1.9%)was found to be signifıcantly associatedwith
poorer DFS (P6.643x10^-5) withmedian time to progression of 18.17months
vs. 71.22 months in the unaltered group. Subsequent proteomic analysis of the
respective patient tumors from the TCGA cohort (N357 with RPPA data)
showed that these patient tumors had elevated levels of E2F1 protein expression
(P0.0146), alongwith increase FOXM1 expression (P8.499x10^-4), which is
known to drive cell cycle progression [2]. As E2F1 is involved in cell survival
upon DNA damage [3], it is likely that upregulation of E2F1 protein expression
may enable cancer cells to survive after DNA insults by radiotherapy or chemo-
therapy, and contributes to disease relapse. Acknowledgements: VWYL is
funded by the Research Grant Council, Hong Kong (#17114814, General Re-
search Fund), Theme-based Research Scheme (T12-401/13-R), and the Start-up
Fund from the School of Biomedical Sciences, Faculty of Medicine, the Chinese
University of Hong Kong. Reference: 1. Van Allen, E.M., et al., Genomic Corre-
late of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carci-
noma. JAMA Oncol, 2015. 1(2): p. 238-44. 2. Barger, C.J., et al., Genetic deter-
minants of FOXM1 overexpression in epithelial ovarian cancer and functional
contribution to cell cycle progression. Oncotarget, 2015. 6(29): p. 27613-27. 3.
Berton, T.R., et al., Regulation of epidermal apoptosis and DNA repair by E2F1
in response to ultraviolet B radiation. Oncogene, 2005. 24(15): p. 2449-60.
#5713 PIGN gene expression aberration weakens chromosomal stability
via altering its interactionwith the spindle assembly checkpoint protein com-
plex during leukemogenesis. Jeffrey J. Pu,1 Emmanuel K. Teye,1 Abigail Sido,1
Yuka I. Kawasawa,1 Ping Xin,1 Niklas K. Finnberg,2 Wafık S. El-Deiry,2 Sara
Shimko1. 1Penn State Hershey Cancer Institute, Hershey, PA; 2Fox Chase Cancer
Center, Philadelphia, PA.
Previous studies have linked increased frequency of glycosylphosphatidyli-
nositol-anchor protein (GPI-AP) defıciency with genomic instability and the
risk of carcinogenesis. Recently, Phosphatidylinositol Glycan Anchor Biosyn-
thesis; Class N (PIGN), a gene participating in GPI-AP synthesis, was suggested
as a cancer chromosomal instability suppressor in a colon cancer model. We
investigated the association of PIGN with genomic instability and leukemogen-
esis. A Random Forest analysis of the gene expression array data from 55 MDS
patients (GSE4619) demonstrated a signifıcant (p 0.0007) correlation (Pear-
son r-0.4068) betweenGPI-anchor biosynthesis gene expression and genomic
instability, in which PIGNwas ranked as the thirdmost important in predicting
risk of MDS progression. We observed that PIGN gene expression aberrations
(increased transcriptional activity but diminished to no protein production)
were associated with increased frequency of GPI-AP defıciency in leukemic cells
during leukemic transformation/progression. The PIGN gene expression aber-
rations were attributed to partial intron retentions between exons 14 and 15
resulting in frameshifts and premature termination which were confırmed by
examining the RNA-seq data from a group of AML patients (phs001027.v1.p1).
PIGN gene expression aberration correlated with the elevation of genomic in-
stability marker expression that was independent of the TP53 regulatory path-
way. PIGN protein expression suppression/elimination caused a similar pattern
of genomic instability that was rescued by PIGN restoration. Furthermore,
PIGN bound to the spindle assembly checkpoint proteins and regulated their
expression during the cell cycle. In conclusion, PIGN gene is crucial in the
regulation of mitotic integrity to maintain chromosomal stability and prevents
leukemic transformation/progression.
#5714 AXL and GAS6 Co-expression in lung adenocarcinoma as a prog-
nostic classifıer. Masahiro Seike, Ritaro Noro, Cheol-Hong Kim, Fenfei Zou,
Kaoru Kubota, Akihiko Gemma. Nippon Medical School, Tokyo, Japan.
AXL, a receptor tyrosine kinase implicated in cell survival, proliferation, and
migration, is also associatedwith acquired resistance to epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor therapy. However, its prognostic sig-
nifıcance in lung adenocarcinoma (AD) remains unclear. We therefore evalu-
ated the prognostic signifıcance of the expression of AXL and/or its ligand,
growth arrest-specifıc 6 (GAS6), in completely resected lung AD. We evaluated
the relationship between AXL, GAS6, and vimentin expression, as determined
by immunohistochemistry (IHC) analysis, with overall survival and disease-free
survival in 113 patients with stages I-III lung AD. Protein expression was also
assayed using western blot analysis in 10 lung AD cell lines. AXL-positive
(AXL), GAS6-positive (GAS6), or AXL/GAS6 staining was signifıcantly
associated with vimentin-positive (vimentin) expression. AXL/GAS6 and
vimentin showed a negative tendency toward an association with EGFR mu-
tation. AXL, GAS6, or AXL/GAS6 statuses signifıcantly correlated with
poor overall survival. In stage I cases, an AXL/GAS6 status signifıcantly
correlatedwith poor overall survival and disease-free survival, especially in cases
with wild-type EGFR. In multivariate analysis, AXL/GAS6 classifıcations in
stage I as well as in stages I-III lungADwere found to be independent factors for
poor patient outcomes. Unlike lung AD cell lines withmutant EGFR, those with
wild-type EGFR closely correlated with AXL and vimentin expression by west-
ern blotting. AXL and GAS6 expression is relevant to a poor prognosis in
resected lungADpatients at stage I. AXL/GAS6might serve as crucial predictive
and prognostic biomarkers and targets to identify individuals at high risk of
post-operative death.
#5715 Gene body methylation and expression of SHOX2 gene are potent
prognosticmarkers for survival in intermediate grade gliomas and renal can-
cers. Yu-An Zhang,1 Yunyun Zhou,2 Xin Luo,1 Guanghua Xiao,1 Adi F. Gaz-
dar1. 1UT SouthwesternMedical Ctr., Dallas, TX; 2University ofMississippiMed-
ical Ctr, Jackson, TX.
Background: Previous data indicated that low level of promoter methylation
of the SHOX2 gene was a prognostic marker for worse progression-free survival
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for non-small cell lung cancer. Purpose: (a) to determine the relationship be-
tween SHOX2 gene methylation and expression; b) to determine whether
SHOX2 gene methylation and expression were prognostic markers for other
cancers. Methods: We examined multiple methylation and expression datasets
available from The Cancer Genome Atlas (TCGA) and other previously pub-
lished studies. Data from a total of more than 1000 intermediate grade gliomas
and 1100 renal cancer cases were examined, along with smaller number of cor-
responding non-malignant tissues. We performed Kaplan-Meier survival anal-
yses and univariate and multivariate Cox regression model analyses. Results:
SHOX2 gene contains three CpG islands encompassing the promoter region
and body.Methylation of various regions of SHOX2 gene body was signifıcantly
positively correlated with its expression in gliomas and renal cancer. Aberrantly
high methylation and expression of SHOX2 gene, which were signifıcantly
higher than the corresponding nonmalignant tissues, were identifıed in subsets
of gliomas and renal cancers. Survival analysis of patients indicated that the
methylation and expression of SHOX2 gene in gliomas and renal cancer (both
clear cell and papillary cell carcinomas) were highly potent markers for poor
survival. We further investigated the combination of SHOX2 with other known
clinically relevant glioma markers (IDH genotype status, TERT expression, 1p/
19q chromosome co-deletion, MGMT methylation, ATRX mutation and NES
expression). When combined with SHOX2 expression, we identifıed subsets of
glioma patients with signifıcantly favorable survival outcomes, especially in the
subgroup (i.e., IDH wild-type) associated with worse prognosis for each indi-
vidual marker. Multivariate analysis demonstrated that SHOX2 was a potent
independent survival marker for gliomas. Conclusion: Gene body methylation
and expression of SHOX2 gene are tightly positively correlated and are potent
new markers for overall survival prognosis for intermediate grade gliomas and
renal cancer. The combination of IDH or other relevant prognostic markers
with SHOX2 identifıed intermediate grade glioma subsets with improved sur-
vival outcomes.
#5716 Tristetraprolin is a prognostic biomarker for biochemical recur-
rence in lowGleason score patients.Anders E. Berglund, Travis Gerke, Shivan-
shu Awasthi, G. Daniel Grass, Hyun Y. Park, John L. Cleveland, Jong Y. Park,
Kosj Yamoah, Robert J. Rounbehler. H. Lee Moffıtt Cancer Center & Research
Institute, Tampa, FL.
PURPOSE:Most prostate cancer patients currently classifıed as having a low-
risk of disease-specifıc death are overtreated in the United States, resulting in
hundreds of thousands ofmen to have debilitating side effects fromunnecessary
treatment. However,30% of low-risk patients on active surveillance are later
reclassifıed and require therapeutic intervention. Thus, there is a dire need for
biomarkers that can discriminate which prostate tumors currently classifıed as
low-risk will progress into aggressive disease. EXPERIMENTAL DESIGN: Ret-
rospective analyses of two independent prostate cancer expression datasets were
performed to determine the relationship between the expression levels of the tu-
mor suppressor Tristetraprolin (TTP, ZFP36) and biochemical recurrence
(BCR). Further, TTP expression levels were measured by quantitative real-time
PCR (qRT-PCR) in a cohort of prostate tumors from Moffıtt Cancer Center
patients having long-term follow-up (n382), and will be correlated to associ-
ated clinical data, including BCR. Finally, the Cancer of the Prostate Risk As-
sessment Postsurgical (CAPRA-S) scores, a clinical tool used to predict prostate
cancer outcomes following radical prostatectomy, were calculated along with
BCR for the patients in one of the prostate cancer datasets. RESULTS: Analysis
of The Cancer Genome Atlas (TCGA) prostate adenocarcinoma dataset re-
vealed that tumors with low TTP expression have an increased rate of BCR
compared to those with high TTP levels (p0.0096). Further, assessment of the
GEO dataset GSE21034 (Taylor et al., Cancer Cell, 2010) established that pros-
tate cancer patients with low Gleason scores (6 and 34) have an increased
chance of BCR if their tumors express low levels of TTP compared to men with
high TTP expressing tumors (p0.0001). To validate these fındings, patients
with lowGleason score tumors anddecreased levels of TTP in theMoffıtt Cancer
Center cohort are being analyzed to determine their rate of BCR. In contrast,
CAPRA-S scores for lowGleason score tumors in theGSE20134 dataset failed to
distinguish if a patient would have BCR (p0.0511). CONCLUSIONS: Prostate
cancer patients with Gleason score 6 or 34, which are currently classifıed as
having a low-risk of dying from prostate cancer, have an increased risk of BCR if
their tumor expresses low levels of the tumor suppressor TTP.Our data suggests
that TTPmay be a biomarker that clearly discriminates which lowGleason score
tumors will progress into aggressive disease.
#5717 PKR promotes EphA2 and other proteins degradation and is pre-
dictor of survival in lung cancer. Apar Pataer, Ruping Shao, Bulent Ozpolat,
Bingliang Fang, Stephen G. Swisher. UT MD Anderson Cancer Ctr., Houston,
TX.
Relative expression of PKR and EphA2 was a signifıcant predictor of survival
in non-small cell lung cancer. To study the PKR-regulated protein, we evaluated
expression of 149 proteins in lung cancer cells by reverse-phase protein assay
(RPPA) after induction of PKR. Expression of several proteins (EphA2, IRS1,
Chk1 and c-Raf and paxillin) was inhibited by PKR. In validating the downregu-
lated proteins by western blot analysis, we observed that PKR reduced EphA2,
IRS1, Chk1 and paxillin protein expression. We next investigated the involve-
ment of the proteasomes and lysosomes in PKR-induced protein degradation.
Human lung cancer H1299 and A549 cells were transfected with Ad-PKR for
48 h in the presence or absence of the proteasome inhibitorMG132 or lysosome
inhibitor (3MA: 3-methyladenine). We observed that MG132 prevented PKR-
induced IRS1 and Chk1 degradation, but not PKR-induced EphA2 and paxillin
degradation in these cells. However, we found that 3MA prevented PKR-in-
duced EphA2 and paxillin degradation in these cells. These data suggest that
PKR is involved in proteasome as well as lysosome function. To study the in-
volvement of autophagy pathway in PKR mediated protein degradation, we
evaluated proteins which known involved in autophagy by Western blotting
after induction of PKR on these cancer cells. We observed slightly decrease of
LC-3, ATG5 and Beclin1 in these cancer cells after induction of PKR. Our data
suggest that PKR may directly involve in in lysosome function.
#5718 Outcome prediction in colorectal cancer using digitized tumor
samples and machine learning. Dmitrii Bychkov, Riku Turkki, Caj Haglund,
Nina Linder, Johan Lundin. University of Helsinki, Helsinki, Finland.
Additional prognostic stratifıcation of colorectal cancer patients is needed
to improve management of patients. Visual microscopic assessment of tu-
mor samples remains the standard method for disease subtyping. However,
visual analysis of samples is subjective and weakly reproducible due to inter-
and intra-observer variations. Recent progress within machine learning, es-
pecially its novel branch called deep learning, enables accurate evaluation of
complex patterns observed in microscopic tissue images. Here, we combined
deep learning techniques to evaluate a set of digitized formalin fıxed paraffın
embedded hematoxylin-eosin stained tumor tissue microarray (TMA) sam-
ples from 420 randomly selected patients with colorectal cancer. For each
patient a set of clinicopathological characteristics including histological
grade, Dukes stage and age at diagnosis are available as well as outcome data.
Using convolutional neural networks and Long Short-Term Memory net-
works we validated the predictive power of the colorectal TMAs with regards
to patient outcome. Univariate Cox proportional hazard regression analysis
demonstrated that the prognostic accuracy of the deep learning algorithm on
TMAs (hazard ratio 2.3; CI 95% 1.79-3.03) outperforms visual histological
grading performed by a certifıed pathologist on a whole slide level (hazard
ratio 1.65; CI 95% 1.30-2.15). In multivariate Cox proportional hazard re-
gression, the deep learning based model was a prognostic factor, indepen-
dent of histological grade, Dukes stage and age at diagnosis (Wald p-value
0.001). Thus, we demonstrate that novel deep learning models can serve as
digital prognostic biomarkers in colorectal cancer.
#5719 Long intergenic non-coding RNAs: a new independent risk predic-
tors inmultiple myeloma.Mehmet K. Samur,1 Annamaria Gulla,1 Mariateresa
Fulciniti,1 Anil Aktas Samur,1 Raphael Szalat,1 Masood Shamas,1 Florence
Magrangeas,2 StephaneMinvielle,3 Kenneth Anderson,1 Giovanni Parmigiani,1
Hervé Avet-Loiseau,4 Nikhil Munshi1. 1Dana Farber Cancer Institute, Boston,
MA; 2Centre Hospitalier Universitaire de Nantes, France; 3Université de Nantes
Institut de Recherche Thérapeutique, France; 4Unité de Génomique duMyélome,
University Hospital; CRCT, INSERM U 1037; Université Paul Sabatier, France.
RNA has diverse sets of regulatory functions and a recent analysis of RNA
repertoire has identifıed a large numbers of non-coding transcripts. One of
which, long intergenic non-coding RNA (lincRNA) with transcripts longer
than 200 nucleotides, are located between the protein coding genes and do
not overlap exons of either protein-coding or other non-lincRNA genes.
lincRNAs have been considered to provide regulatory functions, however,
their precise role in cellular biology remains unclear. Here, we have studied
lincRNAs using uniformly treated patients to show their impact on survival
outcome in MM. We performed RNA-seq on CD138 MM cells from 360
newly-diagnosed patients and 18 normal plasma cells (NPM) and analyzed
for lincRNA and protein coding genes. MM patient data for clinical charac-
teristics, cytogenetic and FISH as well as clinical survival outcomes were also
analyzed and correlated with lincRNA data. Our data showed expression of
951 lincRNAs (median TPM 1) with 351 lincRNAs differentially expressed
between MM and normal plasma cells. Using only the expressed lincRNAs,
we applied log rank tests for quartile 1 (Q1) versus Q2 through Q4 and Q4
versus Q1 through Q3 in order to identify under- and overexpressed prog-
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nostic genes, respectively. Four under and seven overexpressed genes were
selected for fınal model. We used Más-o-menos for fınal predictive model,
which simply calculates the risk score, by using expression values. The Ka-
plan-Meier estimates of EFS at 4 years were 53.3% (95% CI, 45.1% to 63.1%)
and 32.6% (95% CI, 25.1% to 42.2%), and OS at 4 years were 93.2% (95% CI,
88.9% to 97.6%) and 71.1% (95% CI, 62.9% to 80.3%) in our patients having
a low or high risk score. When applied to patient cohort separated by other
risk categorization including minimal residual disease status (MRD), cyto-
genetic risk status (del17p, t(4;14) and t(14;16)) and International Staging
System (ISS), lincRNA signature was able to further identify patients with
signifıcant differential survival outcomes. In summary, we report that lin-
cRNAs have an independent effect on survival outcome in MM and provides
rational for its use in risk stratifıcation as well as to understand biological
impact.
#5720 Serum interleukin-18 and metalloproteinase-1 predict long-term
prognosis of breast cancer. Ji-Yeon Kim,1 Kyunghee Park,2 Eunjin Lee,2 Hae
Hyun Jung,3 Seok JinNam,1 JeongEonLee,1 SeokWonKim,1 JongHanYoo,1 Se
Kyung Lee,1 Soo YounBae,1 Jin SeokAhn,1 Young-Hyuck Im,1 YeonHee Park1.
1SamsungMedical Center, Seoul, Republic of Korea; 2Samsung Genome Institute,
Seoul, Republic of Korea; 3Samsung Advanced Institute for Health Sciences and
Technology, Seoul, Republic of Korea.
Introduction: Intrinsic subtyping and twenty-one gene expression assay using
tumor tissue indicates gene expression profıle had advantage to predict breast
cancer(BC) patients’ prognosis. However, these tumor biomarker assays had
many limitations as like as high cost, demand for large amount of tumor sample
and limited use for specifıc subtype of BC. Therefore, we conducted this study to
fınd serum biomarker predicting BC prognosis. Materials and Methods: This
study was conducted by retrospective analysis of patients with stage I to IIIC
invasive breast cancerwho received curative surgery at SamsungMedical Center
between 2003 and 2004. We performed multiplex immunoassay using 45 cyto-
kine and 8 MMP multiplex immunoassay panels (Bio-Rad Laboratories Inc,
Irvine, CA, USA). Among clinical factors, operational stage was re-categorized
into stage I & II vs. stage III andHormone receptor(HR) status was grouped into
HR positive vs. negative. For each protein, proteins signifıcantly associated with
overall survival(OS) in univariate analyses were candidates for the multivariate
analysis. Results: In total, 246 patients who received curative surgery for breast
cancer were enrolled. Of 246 patients, serum cytokine analyses were performed
in 229 patients. Of clinical characteristics, ten year OS of BC with stage III was
76.2% compared to 92.7% of stage I and 88.6% of stage II (hazard ratio (Stage III
vs. stage I/II) : 2.62 (95% CI: 1.26-5.48), p-value0.016) and HR expressed BC
had 91.1% of 10year OS, compared to 81.9%of HR negative BC (hazard ratio
(HR positive): 0.47 (95% CI: 0.23-0.95), p-value 0.035). In terms of serum
biomarker, high expression of IL-18was associatedwith good prognosis (hazard
ratio: 0.45 (95% CI: 0.21-0.96), p-value0.033) in contrast with poor prognosis
of MMP-1 expression (hazard ratio: 1.96 (95% CI: 0.94-4.08), p-value0.067).
Multivariate analysis showed that BC stage, HR positivity, serum IL-18 and
MMP-1 affected patients’ OS. Stage I/II HR positive BC with low MMP-1 and
high IL-18 increased OS about 5 times compared to stage III HR negative BC
with high MMP-1 and low IL-18 (hazard ratio:0.21 (95% CI:0.1-0.48), c-index:
0.731, p-value0.001). Internal validation using 10,000 times of bootstrapping
showed that this prediction model was suitable for BC prognosis prediction
(c-index: 0.705, p-value 0.041). Conclusion: Our research suggested that the
level of serum IL-18 and MMP-1 would help to predict BC patients’ prognosis.
Further external validation of these biomarkers would be warranted.
#5721 Genome-wide discovery and identifıcation of a novel microrna sig-
nature for recurrence prediction in colorectal cancer.Raju Kandimalla,1 Feng
Gao,2 Naoki Takahashi,3 Yasuhide Yamada,3 TakatoshiMatsuyama,1 Toshiyaki
Ishikawa,4 Xin Wang,2 Ajay Goel1. 1Baylor University Medical Center, Dallas,
TX; 2City University of Hong Kong, Hong Kong; 3National Cancer Center Hospi-
tal, Tokyo, Japan; 4Tokyo Medical and Dental University Graduate School of
Medicine, Tokyo, Japan.
Purpose: Colorectal cancer (CRC) is one of the leading causes of cancer-
related deaths worldwide. In 2016, there were estimated 95,270 newly diagnosed
CRC cases, and 49,190 deaths from this disease in the United States. Survival of
patients is closely associated with the tumor stage at the time of diagnosis as
5-year relative survival rates range from 65% for all stages, 90% for localized
primary tumor, 71% for regional metastasis and 13% for distant metastasis.
Post-surgery, adjuvant therapy is only recommended to those with high risk
stage II, as well as stage III and IV tumors. However, approximately 40-50% of
the patients undergo curative surgery only and 20-30% that are treated with
adjuvant chemotherapy, eventually relapse and experience a metastatic disease
and eventual death. The current gold standard TNM (Tumor, Node,Metastasis)
staging for determining the prognosis of CRC patients remains inadequate at
identifıcation of high-risk stage II and III patients that have a high potential of
developing tumor recurrence. MicroRNAs (miRNAs) play an important role in
CRC development and are emerging as important disease biomarkers. There-
fore, in this study we sought to determine the prognostic potential of the
miRNAs using a systematic, genome-wide biomarker discovery approach, fol-
lowed by validation of biomarkers in multiple patient cohorts Experimental
design: Three independent publicly available genome-wide miRNA expression
datasets were used for miRNA biomarker discovery (n158) and validation
(n109 andn40) of thismiRNAsignature for recurrence prediction in stage II
and III CRC using multivariate Cox regression analysis. The eight gene miRNA
signature discovered from the genome-wide analysis was analytically validated
in two independent patient cohorts (n127 and n96) using Taqman-based
RT-PCR assays. Results: The genome-wide comprehensive analysis led to the
identifıcation of an eight gene miRNA classifıer that signifıcantly predicted re-
currence free survival (RFS) in training (log-rank p0.003) and two indepen-
dent validation cohorts (log-rank p0.0001 and p0.002). The RT-PCR based
training and validation of the eight gene classifıer in two independent clinical
cohorts signifıcantly associated with poor prognosis in stage II and III CRC
patients (log-rank p0.004 and p0.0001). Multivariate analyses performed in
these two patient cohorts revealed that the eight genemiRNA classifıer served as
an independent predictor of poor prognosis in stage II and III CRC patients.
Conclusions: In conclusion, we have identifıed a novel miRNA-based classifıer,
which is robustly predictive of poor prognosis in patents with stage II/III CRC,
andmight facilitate identifıcation and stratifıcation of high-risk patients that are
candidates for adjuvant chemotherapy and clinical surveillance.
#5722 Serum Sonic hedgehog (Shh) and interleukin-(IL-6) as dual prog-
nostic biomarkers in progressive metastatic breast cancer. Sonam Akther,1
Abu Shadat M. Noman,1 Junayed Nayeem,1 Zaheer Raihan,1 Irfanur Rashid,1
Lutfur Rahman,1 David Barua,1 Afrin Sultana,1 Afsana Shirin,1 Jannatul Fer-
dous,1 Rashed Parag,1Mizanur Rahman,1 ReazMahmud,1 Chandsultana Jerin,1
Nusrat Jahan,1 Ayesha Siddiqua,1 Emran Sabur,1 Sabrina Alam,1 Sunanda
Baidya,1 Saiful M. Islam,2 Syed S. Islam3. 1University of Chittagong, Chittagong,
Bangladesh; 2Royal Hospital,Muscat, Oman; 3King Faisal Specialist Hospital and
Research Centre, Riyadh, Saudi Arabia.
Objectives: Breast cancer (BC) still remains the leading cause of mortality in
women worldwide despite substantial developments in diagnosis and therapeu-
tic interventions. Several factors, i.e. different molecular subtypes, biological
behaviors, and risk profıles still pose a challenge for prognostication and clinical
management. Traditional prognostic and treatment options for BC patients are
largely based on careful histological analysis of tumor size, tumor grade, lymph
node metastasis and tumor subtypes. Molecular mechanisms play critical roles
in developing tumors as well as early and late stage tumor progression of meta-
static disease. It is not surprising thatmany genes are shared amongst the various
gene signatures and may have a similar performance in survival risk assessment
of the BC patients. Given the production of Shh and IL-6 in the breast tumor
microenvironment, we hypothesized that Shh and IL-6 might be detectable in
the general circulation. If positive, then it would be clinically useful to identify
whether robust expression of serum Shh and IL-6 is correlated with BC progno-
sis, distant metastasis, lymph node positivity, multidrug resistance as well as
self-renewal and maintenance of BC stem cells. We evaluated relative clinical
outcome of Shh and IL-6 in the serum from a cohort of patients with untreated
early operable and progressive metastatic BC. Patients and Methods: One hun-
dred and ten breast cancer patients and 30 healthy female volunteers, enrolled in
this study and, were evaluated for serum levels of Shh and IL-6 using human
ShhN and IL-6 specifıc enzyme-linked immunoassays. All patients were regu-
larly monitored for event free survival (EFS) and overall survival (OS). Results:
Overall outcome analysis was based on serum Shh and IL-6 levels from 45 early
operable and 65 progressive metastatic BC patients. In patients with progressive
metastatic BC, serum Shh was elevated in 44% (29 of 65) and IL-6 in 63% (41 of
65). Serum Shh (p0.0001) and IL-6 (p0.0001) levels were signifıcantly ele-
vated in BC patients compared to low levels in healthy volunteers, and tended to
increase with metastatic progression and lymph node positivity. High serum
Shh and IL-6 levels were associated with inferior EFS and OS opposite to nega-
tive or lower levels of serum Shh and IL-6. Elevated levels of both serum Shh and
IL-6 were mainly observed in hormone refractory BC patients, who had a sig-
nifıcantly higher risk of early recurrence, bone metastasis and death. Conclu-
sion: Elevated levels of serum Shh and IL-6 are associated with increased risk of
recurrence and a worse survival for patients with progressive metastatic BC.
Further studies are warranted for validating these biomarkers as prognostic and
predictive therapeutic tools in a larger patients cohort.
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#5723 MAPK pathway mutations in head and neck cancer and its clinical
signifıcance. Vivain W.Y. Lui,1 Hoi Lam Ngan2. 1The Chinese University of
Hong Kong, Hong Kong, Hong Kong; 2The University of Hong Kong, Hong Kong,
Hong Kong.
The PI3K pathway is themost frequentlymutatedmitogenic pathway in head
and neck squamous cell carcinoma (HNSCC) [1]. Clinical testings of PI3K in-
hibitors are ongoing based on the mutational status of the patients’ tumors.
Second to the PI3K pathway, the MAPK pathway mutations are commonly
found in 16% (83/510 cases) of HNSCC primary tumors (TCGA, Provisional),
with the pathway components defıned as: GRB2 SHC1 SHC2 SHC3 HRAS
KRAS NRAS ARAF BRAF RAF1 DUSP1 DUSP4 MAP2K1 MAP2K2 MAPK1
MAPK3 RPS6KA1 RPS6KA4 RPS6KA5. Similar to the PI3K pathway, muta-
tions of the entire MAPK pathway gene components are not associated with
patient overall survival (OS) and disease-free survival (DFS) (pn.s.). With
HRAS, MAPK1, BRAF and RPS6KA1 gene mutations being most commonly
mutated in 6%, 1.7%, 1.7% and 1.7% in the US-TCGA cohort, we conducted
survival analyses of each of themutated gene component alone to examine their
individual clinical correlation based on the available clinical data. Our results
show that HRAS mutation, BRAF mutation and RPS6KA1 mutation do not
associatewith patientOSnorDFS (OS: P0.285, P0.300 andP0.197, respec-
tively;DFS: P0.714, P0.995 andP0.0786 respectively). This is similar to the
fındings that PIK3CAmutation alone is also not associatedwithHNSCCpatient
OS (P0.976), nor DFS (P0.469). MAPK1 mutation alone shows a trend for
better OS (P0.162) in this TCGA cohort. Notably, MAP2K2(or MEK-2)-mu-
tated patients show a trend for poor OS (P0.0768), and a subset of HNSCC
patients with MAP2K2-mutation/or overexpression (RNA seq, Expression 5
SD)has very poorOS (P0.00459,withmedian survival of 18.53months vs. 56.9
months in the MAP2K2-unaltered group), as well as signifıcantly poorer DFS
(P0.0188; median time to progression 17.05 vs. 67.74months). Our fındings
fırst implicate that MAP2K2 activation by genomic events may contribute to
HNC tumorigenesis and progression. However, MAP2K1 (also called MEK1)
mutated patients only show a weak trend for better OS (P 0.216). Lastly, we
note that except for MAP2K2, patients with somatic mutations of multiple pos-
itive regulators of the MAPK pathway (RAF1 MAP2K1 MAPK1 HRAS BRAF)
are associated with signifıcant better OS (p0.0293). Proteomic analysis sug-
gests that mutations of these MAPK positive regulators are associated with
downregulation of snai1 (P2.8x10-7; via cbioportal) and, likely a pan-down-
regulation of multiple components of the PI3K/AKT signaling in patients’ tu-
mors. Acknowledgements: VWYL is funded by the Research Grant Council,
Hong Kong (#17114814, General Research Fund), Theme-based Research
Scheme (T12-401/13-R), and the Start-up Fund from the School of Biomedical
Sciences, Faculty ofMedicine, the Chinese University of Hong Kong. Reference:
1. Lui, V.W., et al., Frequent mutation of the PI3K pathway in head and neck
cancer defınes predictive biomarkers. Cancer Discov, 2013. 3(7): p. 761-9.
#5724 Circulatory microRNA expression profıling between HCV-in-
fectedAfrican&CaucasianAmericans: implications for racial health dispar-
ities. Pradip Devhare,1 Robert Steele,1 Adrian M. Di Bisceglie,1 David E. Ka-
plan,2 Ratna B. Ray1. 1St Louis University, St Louis, MO; 2University of
Pennsylvania, Philadelphia, PA.
The purpose of the study: Hepatocellular carcinoma (HCC) is global problem
and incidence ofHCC is increasing in last several years. Hepatitis C virus (HCV)
infection is one of themajor cause towards development ofHCC.HCV infection
is highly prevalent in African American population compared to other ethnic
groups and these people are less likely to naturally clear HCV. Higher incidence
of HCC and mortality was noted in HCV infected African Americans as com-
pared to Caucasians. However, the explanation for this disparity and themolec-
ularmechanisms behind this are currently unknown. CirculatingmicroRNAs in
the blood are emerging as biomarkers for pathological conditions. Differential
expression ofmiRNAs among ethnic groups would be important for optimizing
personalized treatment strategies. Experimental procedures: In this study, we
assessed the differential expression of circulatory miRNAs from HCV infected
African Americans and Caucasians by cancer specifıc miRNA array profıling.
Expression of signifıcantly altered miRNAs was validated by qRT-PCR. Results:
We identifıed increased expression ofmiR-146a, miR-150 andmiR-155 inHCV
infected African Americans patient sera as compared to sera of Caucasians.
Further analysis demonstrated that these miRNAs were signifıcantly elevated in
African Americans diagnosed with HCV-mediated HCC. Higher expression of
miR-150 was also noted in cirrhosis andHCC inAfrican Americans, whichmay
serve as predictor of liver disease progression in this population. Conclusion:
The differential expression of miRNAs suggests that these miRNAs and their
target genes could be useful to gain furthermechanistic insight of racial disparity
associated with HCV pathogenesis.
#5725 Search for a combination of risk stratifıcation markers for recur-
rence after curative resection of gastric cancer. Takashi Oshima,1 Yohei
Miyagi,2 Yayoi Kimura,1 Kentaro Sakamaki,1 Shoji Yamanaka,1 Naohide Oue,3
Toru Aoyama,1 Tsutomu Sato,1 Haruhiko Cho,2 Manabu Shiozawa,2 Takaki
Yoshikawa,2 Yasushi Rino,1 Wataru Yasui,3 Toshio Imada,4 Munetaka
Masuda1. 1Yokohama City University, Yokohama, Japan; 2Kanagawa Cancer
Center, Yokohama, Japan; 3Hiroshima University, Hiroshima, Japan; 4Saiseikai
Yokohamashi Nanbu Hospital, Yokohama, Japan.
Objective: Adjuvant chemotherapy after curative resection is standard treat-
ment for stage II/III gastric cancer. Personalized therapy based on biomarker
analysis is expected to further improve outcomes. We analyzed frozen speci-
mens of gastric cancer to investigate markers for stratifıcation of recurrence risk
and report our fındings. Methods: We studied 778 patients with stage II/III
gastric cancer in whom5 years had elapsed since curative resection. We fırst
measured the expression levels of 127 genes in gastric cancer tissue by quantita-
tive polymerase-chain-reaction (PCR) assay in 255 patients (training set, 145;
validation set, 110) to identify poor prognostic factors. Next, we studied patients
who received 1 year of adjuvant chemotherapy after curative resection of T4a,
Nx, M0, stage III gastric cancer and performed an exploratory proteomic anal-
ysis to compare the expressions of 1756 proteins between 12 patientswhodied of
recurrencewithin 3 years and 12 patients who survivedwith no recurrence for at
least 5 years. Proteins with a max fold change of2 and signifıcant differences
(P0.001) were identifıed. Immunostaining of tissue microarray sections from
another cohort of 499 patients was performed to confırm our results and to
identify combinations of markers for risk stratifıcation. Results: On quantitative
PCR assay, SPARC, HER2, CXCR4, INHBA, VSNL1, MMP11, CCR7, MRP1,
CEACAM7, p53, EZH2, PDGFRB, and VCAM1 were identifıed as candidate
markers. On exploratory proteomic analysis, SPARC, CLC, PRG2, and PRG3
were identifıed. A tissue microarray was constructed for the 16 candidate mark-
ers to evaluate combinations of markers. The combination of SPARC, EZH2,
HER2, and p53 could be used for risk stratifıcation (5-year survival rate, 68% vs.
33%; P0.0111). Conclusions: The combination of SPARC, EZH2, HER2, and
p53 can be used as a marker to stratify the risk of recurrence after curative
resection of stage II/III gastric cancer.
#5726 Anovel tumor-promoting role formiR-4516 in glioblastoma.Tian-
tian Cui,1 Ashley Gray,1 Ziyan Liu,1 Marjolein Geurts,2 Pierre Robe,2 Joseph
McElroy,1 Erica Hlavin Bell,1 Arnab Chakravarti1. 1The Ohio State University,
columbus, OH; 2University Medical Center of Utrecht, Utrecht, Netherlands.
Background: Glioblastomas are the most aggressive high-grade brain tu-
mors, which are often life-threatening due to their location and rapid
growth. Although survival rates differ depending on a variety of genetic and
environmental factors, the average survival rate for a glioblastoma (GBM)
patient is less than 15 months. Although the mechanisms of tumorigenesis
are still being elucidated, miRNAs are promising candidates to explore as
novel and prognostic biomarkers in GBM. Here we demonstrate a novel role
for miR-4516 in promoting growth and migration of GBM and establish the
molecular mechanismsmediating these functions. Methods: Formalin-fıxed,
paraffın-embedded tissue blocks (n268) were collected for all patients and
total RNA was isolated. miRNAs were analyzed simultaneously using the
nCounter human miRNA v2 assay (NanoString Technologies; Seattle,WA).
Functional characterization studies were conducted in vitro and in vivo. The
effect of miR-4516 on GBM cell growth and motility were evaluated by cell
proliferation assay, migration and invasion assay, and Annexin-V assay.
Realtime PCR, immunoblotting, and 3= untranslated region luciferase assays
were used to analyze miR-4516 targets and signaling pathways. Intracranial
injection will be performed to investigate the role of miR-4516 in tumor
growth in vivo. Results: Univariate analysis showed that miR-4516 expres-
sion in GBM patients was inversely correlated with overall survival
(FDR0.002, p1.02E-05). Knockdown ofmiR-4516 blocked tumor growth
and induced cell apoptosis. Tumor cell growth, migration and invasion were
induced in both transient miR-4516 overexpressed GBM cells (LN229,
LN18, and U87) and stable miR-4516 overexpressed GBM cells (U87-EGFR-
vIII). These miR-4516 tumor-promoting effects were mediated in part via
direct targeting PTPN14 and CDKN1A. Investigation of the other miR-4516
targets and in vivo functional study are in process. Conclusion: Taken to-
gether, these results suggest that miR-4516 acts as a prognostic biomarker for
GBM patients. Funding Information: 1R01CA169368 (PI: Houghton; Co-I:
Chakravarti); 1R01CA11522358Multiple-PI R01: Chakravarti (PI); Xia (PI);
1R01CA1145128 Baroukhim (PI); Chakravarti (Co-PI) 7/2015-6/2020;
R01CA108633 (PI:Chakravarti); 1RC2CA148190 (Scientifıc PI: Chakra-
varti).
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#5727 A functional polymorphism in DTX1 gene of Notch pathway pre-
dicts the prognosis of surgically resected non-small cell lung cancer. ShinYup
Lee,1 Janghyuck Lee,1 Kyung Min Shin,1 Ji Woong Son,2 Jae Yong Park1.
1Kyungpook National Univ. School of Med., Daegu, Republic of Korea; 2Konyang
Univ. School of Med., Daejeon, Republic of Korea.
Notch signaling pathway has been implicated in the prognosis of non-
small cell lung cancer (NSCLC). This study was conducted to determine the
association between single nucleotide polymorphisms (SNPs) in the Notch
pathway genes and survival outcomes of surgically resected NSCLC. Among
the 64 SNPs analyzed in the discovery set, 8 SNPs were signifıcantly associ-
ated with overall survival (OS) or disease-free survival (DFS). Among the 8
SNPs, the association was consistently observed only for DTX1
rs1732786AG in the validation sets. In combined analysis, the
rs1732786AG was signifıcantly associated with better OS and DFS (ad-
justed HR aHR for OS, 0.81; 95% CI, 0.68-0.95; P 0.01; aHR for DFS, 0.82;
95% CI, 0.72-0.94; P 0.003; under codominant model). To verify the func-
tional relevance of the rs1732786AG in DTX1 promoter region, we con-
ducted dual-luciferase reporter assays. The G allele showed signifıcantly
higher luciferase activity than the A allele (P  0.005) in lung cancer cell
lines. The relative expression level of DTX1mRNAwas signifıcantly lower in
tumor tissues than in nonmalignant lung tissue (P  0.003). Moreover, the
level of DTX1 mRNA expression in tumor tissue increased as the number of
G allele increased (P trend 0.02). Higher levels of DTX1mRNA expression
were signifıcantly correlated with a better OS and DFS (P  0.03 and P 
0.002). Our results suggest that the DTX1 rs1732786 AG polymorphism
may affect DTX1 expression and may be a useful marker for predicting the
prognosis of patients with early stage NSCLC.
#5728 Metabolomic pathway alterations in endometrial cancer. Tatiana
Altadill. Vall d’Hebron Research Institute, Barcelona, Spain.
Introduction: Endometrial cancer is the most frequent gynecological can-
cer diagnosed in United States, accounting for 76,000 deaths every year. Up
to now, it has been broadly described the proteomic and the transcriptomic
profıles of endometrial cancer (EC). However, the metabolomic content of
EC tissues is largely unknown. In this work, we aim to characterize the
pathways dysregulated in EC tumorigenesis and the changes that the metab-
olites experience along the progression of the disease. Methods: We per-
formed an untargeted discovery using liquid chromatography coupled with
electro-spray quadrupole time of flight mass spectrometry (UPLC-ESI-
QTOF-MS). We analyzed the metabolomic and lipidomic profıle of a set of
56 tumor tissues, corresponding to 39 different stages of endometrioid EC
tumors (10 FIGO stages IA, 9 stages IB, 10 stages II and 10 stages III), and 17
benign endometrium tissues. Verifıcation of initiation and progression
markers was performed by MS/MS. Furthermore the dysregulated pathways
were validated by Real Time quantitative PCR (RTqPCR) and Immunohis-
tochemistry (IHQ) in an independent cohort of 60 and 109 patients, respec-
tively. Results: A total of 8,146 features were detected in the positive and
7,558 in the negative electrospray ionization mode. Among those, a list of 40
signifıcant differentially expressed metabolites (FC2) was verifıed. The
lipid metabolism appeared highly upregulated; with an important number of
PCs, PSs, PEs, PIs and PGs. Linoleic acid, 3-Deoxyvitamin D3, and UDP-N-
acetyl-D-galactosamine were also upregulated in EC. Differently, the peptide
Glu Phe Arg Trp, some amides (palmitamide, stearamide and oleamide), PA
(18:0/18:1), PE (20:1/22:6), PE (22:6/P-18:1), PG (19:0/22:4), inosine and
picolinic acid were downregulated in the tumor tissue. Regarding tumoral
progression, we showed a signifıcant and non-gradual dysregulation of PC
(16:0/20:5), the PC (16:0/22:6), PE (16:0/22:6), PE (22:6/P-18:1) and PE (18:
1/22:6) at different stages of cancer progression. A signifıcant decrease of the
levels of UDP-N-acetyl-D-galactosamine and Arachidonic acid at advanced
stages of the tumor was detected. We confırmed by RTqPCR and by IHQ the
downregulation of the 3 adenosine-to-inosine editing enzymes (ADAR1,
ADAR2 and ADARB3) in EC patients compared to the control group. We
also observed a higher expression of the enzymes in the most aggressive
(serous EC tumors) compared to the less aggressive tumors (endometrioid
EC tumors). We are currently performing studies to understand the role of
the RNA editing pathway in EC. Conclusions: In this study we described the
metabolome and lipidome of EC initiation and progression. We verifıed and
validated several metabolites that are signifıcantly differentially found in
control subjects compared to EC patients and along tumoral progression.
These results also depictured the metabolism of EC and deciphered, for the
fırst time, an alteration in the adenosine-to-inosine editing pathway in EC.
#5729 Loss of USP10 and p14ARF protein expression is associated with
poor prognosis patients with small intestinal adenocarcinoma. Joon Seon
Song,1 Hanbyoul Cho,2 Joon-Yong Chung,3 Ilseon Hwang,4 Hee Jin Lee,1
Seung-MoHong,1 StephenM.Hewitt5. 1University of Ulsan College ofMedicine,
Asan Medical Center, Seoul, Republic of Korea; 2Gangnam Severance Hospital,
Yonsei University College of Medicine, Seoul, Republic of Korea; 3Experimental
Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, Na-
tional Cancer Institute, National Institutes of Health, Bethesda, MD; 4Keimyung
University Dongsan Medical Center, Daegu, Republic of Korea; 5Experimental
Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, Na-
tional Cancer Institute, National Institutes of Health, Bethesda, Bethesda, MD.
Ubiquitin Specifıc Peptidase 10 (USP10) is amember of the ubiquitin-specifıc
protease family and its related pathways are apoptosis, autophagy and DNA
damage. P14ARF is encoded by an alternative reading frame within the INK4a/
ARF locus at chromosome 9p21, which is related with cell cycle arrest and
apoptosis. Recently, ablation of USP10 prevented c-myc induced cellular senes-
cence by destabilization of p14ARF andp53, and accelerated hyper-proliferation
and transformation of normal cells, suggesting USP10 have a crucial role in
oncogenes induced senescence by keeping the stability of p14ARF and p53, key
regulator of cellular senescence. However, knowledge on the clinical and prog-
nostic signifıcance of USP10 and p14ARF expression in patients with small
intestine adenocarcinoma is limited. In the present study, we investigated the
prognostic signifıcance of USP10 and p14ARF by immunohistochemistry. 195
of resected small intestine adenocarcinomas were retrieved from 22 South Ko-
rean institutions by Korean Small Intestinal Cancer Study Group. Tissue mi-
croarrays were constructed using formalin-fıxed paraffın-embedded specimen.
70 (35.9 %) out of 195 patients showed immunoreactivity for USP10 and 124
(63.6 %) showed loss of immunoreactivity for USP10. 120 (61.5 %) of 195 pa-
tients were immunopositive for p14ARF and 75 (38.5 %) patients showed loss of
immunoreactivity for p14ARF. Loss of USP 10 was correlated with male pre-
dominancy (p0.014), higher pT stage (p0.044), presence of lymphatic inva-
sion (p0.033), absences of sporadic adenoma (p0.024) and absences of peri-
tumoral dyplasia (p0.019). On multivariate survival analysis, loss of USP10
expression was independent poor prognostic factor ( HR3.04, 95% CI 1.79-
5.18, p  0.001) and also both loss of USP10 and p14ARF expressions showed
similar result ( HR3.76, 95% CI 1.93-7.23, p 0.001) while loss of p14ARF
was not an independent prognostic factor ( p 0.587).Our fındings indicate that
loss of USP10, associated with loss of p14ARF protein expression, could be poor
prognostic factors in small intestine adenocarcinoma.
#5730 Increased FGFRL1 expression is associated with prostate cancer
progression. Lan Yu,1 Mervi Toriseva,1 Andrew Erickson,2 Heikki Seikkula,3
Martti Nurmi,3 Pekka Taimen,3 Peter Boström,3 TuomasMirtti,4 Kalle Alanen,3
Markku Kallajoki,3 Johanna Tuomela,1 Mattias Nees,1 Pirkko Härkönen1. 1In-
stitute of Biomedicine, Cell Biology and Anatomy, University of Turku, Turku,
Finland; 2Institute for Molecular Medicine Finland, Helsinki, Finland; 3Univer-
sity of Turku, Turku, Finland; 4Institute for Molecular Medicine Finland and
Helsinki University Hospital (HUSLAB), Helsinki, Finland.
Prostate cancer (PCa) is the most diagnosed cancer in men in developed
countries. Fibroblast growth factor receptors (FGFRs) have been demonstrated
to play an important role in PCa initiation and progression. Fibroblast growth
factor receptor like 1 (FGFRL1) is the most recently identifıed member of the
FGFR family. Its extracellular domain shares high similarity to FGFR1-4 but it
lacks the cytoplasmic domainwith tyrosine kinase activity. Thus, FGFRL1 is able
to bind FGF ligands but the subsequent intracellular signaling cascade is defec-
tive. We observed up-regulation of FGFRL1 mRNA expression in PCa in a
public genome-wide cancer transcriptome data base (cBioPortal). To validate
the expression data and to investigate the putative role of upregulated FGFRL1
protein in normal prostate and PCa, tissue microarrays containing different
types of benign and malignant prostate tissue were used. Altered FGFRL1 pro-
tein expression was correlated with clinical parameters; and both in vitro and in
vivo experiments were applied to study the biological functions FGFRL1 in PCa
cell lines. Our results confırmed that FGFRL1 expression is upregulated in PCa
compared to normal prostate. More specifıcally, increased cytoplasmic and nu-
clear FGFRL1 expression was associated with high Gleason score and Ki67 ex-
pression, whilemembrane-associated FGFRL1 showed the opposite correlation.
To investigate the effects of androgens on FGFRL1 in vitro, PCa cells were
treated with dihydrotestosterone and/or MDV3100, an androgen receptor in-
hibitor. Dihydrotestosterone increased FGFRL1 expression and MDV3100 in-
hibited endogenous FGFRL1 expression, but not when stimulated by dihy-
drotestosterone, suggesting indirect androgen-mediated regulation. The in vitro
studies also showed that FGFRL1 is able to attenuate the phosphorylation of
FRS2	 and ERK1/2 by FGF ligands, providing evidence for the assumed decoy
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function of membranous FGFRL1. However, knock-down of FGFRL1 in PC3M
cells resulted in reduced cell growth in tumor xenografts. Additionally, mRNA
sequencing on PC3M cells with FGFRL1 knock-down revealed differential ex-
pression of about 250 molecules, including several metalloproteinases and
FGFR1, compared to control cells (FDR0.1 and -1logFC1). In conclusion,
we suggest that upregulation and altered subcellular localization of FGFRL1, in
PCa, directly or indirectly, promotes tumor growth and progression. The results
suggest that FGFRL1 is a potent regulator of gene expression and may be in-
volved in diverse functions depending on its cellular localization.
#5731 The prognostic signifıcance of EGFR, HER-2, HER-4, EGFRvIII,
c-MET, Ki67 and CD44 in patients with FIGO stages III and IV ovarian
cancer. SoozanaPuvanenthiran,1 SharadahEssapen,2 BenHaagsma,2 Izhar Bag-
wan,2 Alan Seddon,1 Helmout Modjtahedi1. 1Kingston University, Kingston-up-
on-Thames, United Kingdom; 2Royal Surrey County Hospital, Guildford, United
Kingdom.
Overexpression and activation of HER (human epidermal growth factor re-
ceptor) family members have been reported in a wide range of epithelial tu-
mours. Although several monoclonal antibodies (mAbs) and small molecule
tyrosine kinase inhibitors (TKIs) specifıc for the HER members have been ap-
proved for the treatment of patients with a wide range of tumours, none has yet
been approved for the treatment of patients with ovarian cancer. In some stud-
ies, the co-expression of other growth factor receptors (e.g. c-MET), the pres-
ence of cancer stem cells (CSCs) have been associated with resistance to therapy
with the HER inhibitors. The aim of the present study was to determine the
expression level and prognostic signifıcance of the EGFR, HER-2, HER-4 and
EGFRvIII, as well as c-MET, CD44 and cell proliferation marker Ki67 in 60
patients with FIGO stage III and IV ovarian cancer. The expression levels of
these markers were determined, at different cut off values, using immunohisto-
chemistry (IHC), and their associations with the overall survival and disease free
survival were evaluated using Chi-squared and Kaplan-Meier survival curves
and log-rank test as well as the univariate Cox-regression analysis. At cut off
values of 5% of tumour cells with positive immunostaining, 62%, 93%, 45%,
3%, 21%, 48%, and 95%, of the cases were positive for EGFR, HER-2, HER-4,
EGFRvIII, c-MET, CD44, Ki67 respectively and 28% were positive for the co-
expression of EGFR/HER-2/HER-4. The cellular location of immunostaining
was membranous for EGFR, HER-2, c-MET and CD44 and was present in 33%,
10%, 3% and 50% of the cases examined respectively. In univariate analysis, the
expression of EGFR at cut-off values of50% (HR, 3.57; 95% CI, 1.07 to 11.85;
P0.0001) andCD44with 3 intensity at cut-off values5% (HR, 8.20; 95%
CI, 2.02 to 33.2; P 0.0001) were associated with poorer overall survival. In
contrast, the positive immunostaining of Ki67 at cut-off value5% of tumour
cells, was associated with better overall survival (HR, 0.13; 95% CI, 0.02 to 0.73;
P 0.021 respectively). In addition, at cut-off value of5% of tumour cells with
positive immunostaining, EGFR expression (HR, 2.83; 95% CI 1.18 to 6.77; P
0.019) and 10% (HR, 2.40; 95% CI 1.07 to 5.37; P 0.032 ), as well as the
co-expression of EGFR/HER-2 (HR, 2.83; 95% CI 1.18 to 6.77; P 0.019),
EGFR/c-MET (HR, 3.05; 95% CI 1.2 to 7.75; P 0.019) and EGFR/Ki67 (HR,
2.83; 95% CI 1.18 to 6.77; P 0.019) were all associated with poorer disease free
survival in these patients. Our results suggest that co-expression of EGFRER-
2ER4 is common in patients with Stages III and IV ovarian cancers and sup-
port the need for investigations on the therapeutic potential of various forms of
pan-HER inhibitors in such patients.
#5732 PI3K/Akt activity regulates androgen receptor expression and pre-
dicts poor clinical outcome in non-metastatic hormone-naïve prostate can-
cer. Sami Blom,1 Petra Mäki-Teeri,1 Andrew Erickson,1 Lassi Paavolainen,1
Tuomas Mirtti,2 Antti Rannikko,2 Swapnil Potdar,1 Päivi Östling,1 Wytske van
Weerden,3 Olli Kallioniemi,1 Teijo Pellinen1. 1Institute for Molecular Medicine
Finland FIMM, Helsinki, Finland; 2University of Helsinki, Helsinki, Finland;
3Erasmus MC, Helsinki, Netherlands.
Activation of PI3K/Akt pathway is associated with adverse outcome and ag-
gressive disease in many cancers. In prostate cancer (PCa), the activity of this
pathway has been shown to promote disease progression and metastasis. How-
ever, it is still controversial how PI3K/Akt regulates androgen receptor (AR), a
central signaling molecule in prostate pathophysiology, and whether it has an
active role in hormone naïve non-metastatic PCa. Here, we show using immu-
nohistochemistry (IHC) and advanced quantitative multiplexed IHC that the
expression of phosphorylated-Akt(S473) andARare highly correlated in clinical
PCa, even at the cellular level. Furthermore, we found that high expression of
p-Akt(S473) predicts poor clinical outcome in two independent hormone-naïve
non-metastatic PCa cohorts. To study whether PI3K/Akt regulates AR expres-
sion, we performed an in vitro drug screen with 32 PI3K/Akt/mTOR inhibitors
in PC346C, an AR expressing cell line derived from a hormone-naïve primary
tumor of prostate. We observed a strong correlation between p-Akt(S473) and
AR also in vitro in individual cells independent of the inhibitor used. Although
both PI3K and Akt specifıc inhibition reduced cell viability, the response in
nuclear expression of AR was highly dependent on the target of inhibition: Akt
specifıc inhibition reducedAR nuclear expression and resulted in large, spindle-
shaped cells, whereas PI3K specifıc inhibition increased AR nuclear expression
and resulted in smaller, round-shaped cells. These data suggest that PI3K and
Akt have different roles in sustaining AR activity in PCa as perturbations of the
two components leads to differential responses in terms of AR nuclear expres-
sion and cell morphology. In conclusion, activated Akt associates with AR ex-
pression and predicts poor clinical outcome in hormone-naïve non-metastatic
PCa. Furthermore, the differing roles of PI3K andAkt inAR regulationwarrants
for further studies as it may have implications in the design of PCa therapy
targeting PI3K/Akt, especially when the inhibitors are administered in combi-
nation with anti-androgens.
#5733 Expression levels of UL16 binding protein 1 and natural killer
group 2 member D in patients with gastric cancer. Kiyoshi Yoshimura,1
Moeko Inoue,1 Tetsuhiko Asao,1 Masanori Fuse,1 Satoshi Wada,2 Atsuo Kura-
masu3. 1National Cancer Center, Chuo-ku, Tokyo, Japan; 2Kanagawa Cancer
Center, Yokohama, Kanagawa, Japan; 3Yamaguchi University Graduate School
of Medicine, Ube, Yamaguchi, Japan.
UL16 binding protein 1 (ULBP1) expressed on the tumor cell surface binds to
the natural killer group 2 member D (NKG2D) receptor presenting on natural
killer (NK), CD8T, and gammadelta T cells. However, the roles ofULBP1 and
NKG2D expression and associated immune responses in gastric cancer are un-
clear. Here, we investigated the relationships between ULBP1 and NKG2D ex-
pression and clinical outcomes in patients with gastric cancer. The expression
levels of ULBP1 and NKG2D were examined in human gastric cancer cell lines
and gastric cancer tissues from 98 patients who underwent surgery from 2004 to
2008. MKN-72 cells expressed ULBP1 with ULBP2, -5, or -6. NKG2D was ex-
pressed at a higher level after activation on T cells and NK cells. Among tissue
sections positive for NKG2D expression, six cases were positive for CD8 and
CD56. In all tissues, NKG2D-expressing cells were typically aCD8 T cells.
Patients with NKG2D expression in tumors had signifıcantly longer overall sur-
vival (OS) than patients without NKG2D expression in tumors (p  0.0217).
The longest OS was observed in patients positive for both ULBP1 and NKG2D,
whereas the shortest OS was observed in patients negative for both ULBP1 and
NKG2D. The interaction between ULBP1 and NKG2D may improve OS in
patients with gastric cancer and may have applications in immunotherapy for
induction of adaptive immunity in patients with cancer. Moreover, ULBP1 and
NKG2D may be useful as prognostic biomarker in gastric cancer.
#5734 The influence of body mass index on overall survival following
surgical resectionof non-small cell lung cancer.Xi Liu,1 Boris Sepesi,1 Kathryn
A. Gold,2 Arlene M. Correa,1 John V. Heymach,1 Ara A. Vaporciyan,1 Jason
Roszik,1 Ethan Dmitrovsky1. 1UTMDAnderson Cancer Ctr., Houston, TX; 2UC
San Diego Health, San Diego, CA.
Prior work implicated an association between increased bodymass index (BMI)
and lower risk of mortality from lung cancer. The aim of our study was to compre-
hensively evaluate the influence of BMI on long-term overall survival in surgical
patients with non-small cell lung cancer. This study investigated 1935 patients who
underwent surgical resection for lung cancer atMDAndersonCancerCenter (from
2000 - 2014). Study variables includedboth patient and treatment related character-
istics. Univariate andmultivariate Cox regression analyses were performed to iden-
tify variables associatedwith overall survival. By univariate analysis, signifıcant pre-
dictors of better survival were higher BMI, pathologic tumor stage (stage I versus
stages II, III, or IV), type of surgery (lobectomy/pneumonectomy versus wedge
resection/segmentectomy), younger age, female gender, and adenocarcinoma his-
tology (versus squamous) (all p  0.05). Patients considered morbidly obese
(BMI 35) had a trend towards better outcomes than those classifıed as obese
(BMI 30 and35) (p 0.05), overweight (BMI25 and30) (p 0.13), or
healthy weight (BMI  25) (p  0.37) (HR 0.727, 0.848, 0.926, and 1, respec-
tively). By multivariate analysis, BMI remained an independent predictor of
survival (p  0.02). Propensity matching analysis showed signifıcantly better
overall survival (p 0.008) in patientswith BMI 30 as compared to BMI 25.
For exploratory analysis of expressed mRNAs associated with obesity in lung
cancer, the association between obesity-related species (LEP, LEPR, PCSK1,
POMC, MC4R, BMIQ1, BMIQ2, BMIQ3, UCP2, BMIQ5, BMIQ6, INSIG2,
FTO, TMEM18, GNPDA2, NEGR1, BDNF, KCTD15, SH2B1, MTCH2 and
NPC1) and survival was explored using The Cancer Genome Atlas (TCGA).
Kaplan Meier analyses demonstrated signifıcantly improved overall survival in
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lung cancer patients with higher Uncoupling Protein 2 (UCP2) expression, as
will be presented. In summary, this large, single center series, after controlling
for disease stage and other variables found higher BMI was associated with
improved overall survival following surgical resection of non-small cell lung
cancer. Studies are underway to elucidate the underlying mechanisms respon-
sible for this association between BMI and lung cancer survival.
#5735 Comprehensive analysis of serum levels of VEGF and its receptors
in patients with uterine cervical cancer. Daiken Osaku,1 Tetsuro Oishi,1
Mayumi Sawada,1 Hiroaki Komatsu,1 Jun Chikumi,1 Akiko Kudoh,1 Michiko
Nonaka,1 Shinya Sato,1 Muneaki Shimada,1 Hiroaki Itamochi,2 Tasuku
Harada1. 1Tottori Univ. School of Medicine, Yonago, Japan; 2Iwate Medical Uni-
versity, Morioka, Japan.
Objective: Angiogenesis is one of the processes that is critical for the growth,
invasion andmetastasis of solid tumors, including uterine cervical cancer (CC).
The vascular endothelial growth factor (VEGF) family is one of the major path-
ways involved in tumor angiogenesis. The aim of this study was to determine
whether serum levels of these angiogenic factors could be used as biomarkers in
patients with CC.Methods: A total of 107 patients with International Federation
of Gynecology and Obstetrics (FIGO) stage IB to IIB CC who were treated at
Tottori University Hospital between 2006 and 2015 were enrolled in this study.
The study was approved by the Institutional Review Board of the School of
Medicine of Tottori University. All patients gave written informed consent be-
fore the collection of specimens according to institutional guidelines. Serum
samples were collected before initial surgery and levels of VEGF-A, -C,
VEGFR-1, and VEGFR-2 were analyzed by enzyme-linked immunosorbent as-
say (ELISA).We evaluated the association between the levels of these angiogenic
factors and clinicopathologic variables. With a median follow-up duration of
1743 days, survival analysis of 93 patients treated between 2006 and 2013 was
performed.We also determined the mRNA expression of VEGF-A by real-time
RT-PCR in fresh frozen tumors and the protein expression by immunohisto-
chemical staining in paraffın-embedded tumors from CC patients. The mRNA
levels of VEGF-A relative toGAPDHwere used for the analysis. Results:Median
levels of serum VEGF-A, -C, VEGFR-1, and VEGFR-2 were 313, 8122, 68, and
6210 pg/ml, respectively. We found a signifıcant positive correlation between
VEGF-A levels and the maximum tumor diameter (P0.010). Patients with
pelvic lymph node involvement (PLNI) showed signifıcantly higher levels of
VEGF-A and VEGFR-2 than those without PLNI. Patients with bulky tumor or
parametrial infıltration (PI) also showed signifıcantly higher levels of VEGF-A.
In contrast, patients with a bulky tumor or PLNI showed signifıcantly lower
levels of VEGFR-1. Both histological types and FIGO stage were not related to
levels of these angiogenic factors. We set the cutoff values of these factors at the
median levels of the angiogenic factors. The 5-year overall survival rate (OS) for
patients with high VEGF-A levels was signifıcantly lower than those with low
levels (92.9% vs. 72.8%, P  0.014). The 5-year OS for patients with high
VEGFR-2 levels was signifıcantly lower than those with low levels (94.7% vs.
73.8%, P  0.012). PLNI and PI were prognostic factors for overall survival.
Multivariate analysis revealed that PLNI, VEGF-A, and VEGFR-2 levels were
independent prognostic factors. The mRNA and protein expressions of
VEGF-A were strongly observed in the cancer cells. There was no correlation
between mRNA levels and serum levels of VEGF-A. Conclusion: These results
suggest that serum VEGF-A may be a promising prognostic biomarker for CC.
#5736 Clinical impact of high serum hepatocyte growth factor in ad-
vancednon-small cell lung cancer.TakahiroTsuji,HiroakiOzasa, Yuichi Saka-
mori, Takashi Nomizo, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Hi-
roki Nagai, Young Hak Kim. Kyoto Univ. Graduate School of Medicine, Kyoto,
Japan.
Activation of c-MET through hepatocyte growth factor (HGF) increases tu-
morigenesis, induces resistance, and is associatedwith poor prognosis in various
solid tumors. We previously reported that lung cancer cell lines had increased
expression of c-MET due to gene amplifıcation-induced cytotoxic drug resis-
tance, and that resistant cells paracrine HGF and promote its resistance. How-
ever, the clinical signifıcance of sHGF in patients with advanced or recurrent
NSCLC, especially in patients treated with cytotoxic chemotherapy, is yet to be
identifıed. Here, we present sHGFmay be useful to predict tumor response and
PFS in patients with advanced NSCLC. A total of 81 patients with 101 treatment
regimens were investigated; 53 patients received fırst-line therapy and 48 pa-
tients received second-line therapy during the observation period. sHGF levels
were evaluated using ELISA at 4 time-points: at pre-treatment, at response-
evaluation (1-2 months after treatment initiation), at the best tumor response,
and at the disease progression.As a control biomarker, serumcarcinoembryonic
antigen (CEA) was also evaluated. sHGF at response-evaluation in patients with
progressive disease was higher compared with that of disease controls in both
fırst-line and second-line treatment (median value (MV): under the limited of
detection (LOD) vs. 0.40; P0.0086 andMV: under the LODvs. 0.41; P0.0035,
respectively). Positive-sHGF at response-evaluation predicts poor progression-
free survival (PFS) compared with negative-sHGF in both fırst-line (median,
153.5 vs. 288.0; P0.047) and second-line treatment (87.0 vs. 219.5; P0.014).
Lung adenocarcinoma subgroup analysis showed that in patients receiving sec-
ond cytotoxic chemotherapy, there were no signifıcant differences in PFS or HR
between patients with low-CEA compared with those with high-CEA, but pos-
itive-sHGF at pre-treatment or at response-evaluation predicts poor PFS (35 vs.
132; P0.0045, 50 vs. 215; P0.0047, respectively). Simple and repeatablemark-
ers for activation of theHGF/c-METpathwaywould provide rationale for future
research investigating the merit of sHGF as a potential clinical biomarker to
indicate administration of MET inhibitors.
TUMOR BIOLOGY: Carcinogenesis and Human Tumors
#5737 YAP1 and COX2 converge to regulate SOX2 and urothelial cancer
stem cells. Akira Oki, Noah Hahn, Mohammad Hoque. Johns Hopkins Univ.
School of Medicine, Baltimore, MD.
Since cancer stem cell (CSC) are resistant to conventional chemotherapies that
effıciently eliminate bulk tumor cells, the elimination is indispensable in treating
malignant diseases. However, the underlying mechanisms responsible for the
urothelial CSC traits remain elusive. The tumor microenvironment reinforces a
chronic inflammatory state to support tumor progression by triggering CSCs. In
addition, chemotherapy-induced apoptotic cells release COX2-derived PGE2,
which in turn promotesCSCexpansion. Environmental risk factors, such as arsenic
(As), cause chronic inflammation and have been linked to urothelial carcinoma
incidence.Wepreviously developed an in vitro stepwisemodel for urothelialmalig-
nant transformation by As exposure in normal urothelial cells line (HUC1), which
mayreveal the intimateconnectionsbetweencarcinogenesis, chronic inflammation,
andCSCsandprovideclues todevelopnovel therapeutic strategies.As-exposedcells
displayedmore aggressive phenotype than As-unexposed cells in a time dependent
manner. In gene set enrichment analysis of expression array of chronic As-exposed
andunexposed cells; EGFR,COX2andYAP1were top-rankedoncogenic signature
inAs-exposedcells.Moreover,Asexposure inducedmalignant stemnessproperties.
In stem cell-specifıc RT-PCR array, SOX2 has been gradually overexpressed in line
with acquired spheroid formation and self-renewal capacities. SOX2 is frequently
overexpressed in numerous Urothelial carcinoma (UC) cell lines as well as in As-
exposed cells, especially in the spheroid cells. Stable knockdownof SOX2 reduces in
vitro CSCs properties and also in vivo tumorigenicity. COX2/PGE2 and YAP1 sig-
naling pathways are required to accelerate SOX2 activity. Mechanistically, COX2/
PGE2 signaling induces promotermethylation of let-7 host gene via inducingDNA
methyltransferases, resulting in downregulated let-7 expression and subsequent
SOX2 expression. On the other hand, YAP1 induces COX2/PGE2 signaling-inde-
pendent SOX2 expression, and these signaling mutually compensate via negative
feedback mechanism of SOX2, indicating that dual blockade of these signaling is
indispensable to eradicate urothelial CSCs. The pharmacological inhibition of
COX2 and YAP1 elicited long-lasting therapeutic response by subverting CSCs ex-
pansion following chemotherapy in both UC cells-derived and patient-derived
xenograftmodels. Inbasal typeUC,EGFR-targeted therapywaseffective in linewith
previous reports, but the acquired resistance is inevitable.We reveal that COX2 and
YAP1signalingdetermineacquired resistance to treatmentwith theEGFR inhibitor
via SOX2. Thus, our fındings indicate that the combined inhibition of YAP1 and
COX2/PGE2signaling couldbeaneffective therapeutic strategy to slowCSCexpan-
sion andUC progression.
#5738 Tracking the genetic relationship between fırst and late-onset sec-
ond urothelial cancers by mutational signature analysis. Xavier Castells,1
Maude Ardin,1 Sandrine Rorive,2 Nilufer Broeders,3 Yan Song,4 Stephanie Vil-
lar,1 Christine Carreira,1 Pierre-Paul Bringuier,5 Adriana Heguy,6 Thierry
Quackels,7 Thierry Roumeguere,7 Joelle Nortier,3 Jiri Zavadil1. 1International
Agency for Research on Cancer, Lyon, France; 2Pathology, Université Libre de
Bruxelles, ErasmeUniversityHospital, Brussels, Belgium; 3Nephrology,Université
Libre de Bruxelles, Erasme University Hospital, Brussels, Belgium; 4Cancer Insti-
tute andHospital, Chinese Academy ofMedical Sciences, Beijing, China; 5Hôpital
Edouard Herriot, Lyon, France; 6New York University Langone Medical Center,
New York, NY; 7Urology, Université Libre de Bruxelles, Erasme University Hos-
pital, Brussels, Belgium.
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Exposure to aristolochic acid (AA, IARC Group 1 carcinogen) present in
some traditional herbal medicines leads to aristolochic acid nephropathy
(AAN), often complicated by development of multiple urothelial carcinomas of
sequential onset. We used genome-scale mutational signature analysis of mul-
tiple urinary tract tumors of AAN cases from a unique patient group to deter-
mine the relationships of the patients’ late-onset second cancers to the AA ex-
posure as well as to the fırst cancers. Aristolactam-DNA adduct-positive AAN
patients (n4) who developed cancer within 8 years following the initial expo-
sure to AA were chosen for analysis of their fırst cancers (upper tract urothelial
carcinomas, UTUC) and second cancers of delayed onset (1-9 years after fırst-
cancer diagnosis, involving the bladder or ureteral meatus). All patients had
received a kidney transplant before developing the second cancers and had a
functional renal graft prior to prophylactic nephroureterectomy. Genomic
DNAs were isolated from FFPE sections of the renal cortex and from the upper
and lower tract tumors of each patient using laser capture micro-dissection or
macro-dissection of the tumor areas. Low-coverage (15x) exome 100-bp
paired-end sequencing was performed using Illumina HiSeq2500. Customized
variant calling identifıed somatic variants absent in non-tumor tissues. Non-
negativematrix factorization was applied to extract mutational signatures in the
tumor tissues. In all cases, we established the mutational signature of AA (the
COSMIC signature 22) in the fırst UTUC as well as second cancers involving
the bladder or lower ureter (meatus). Additionally, the fırst and second cancers
harbored considerable overlaps in exposure-specifıc (AT) somatic mutations.
This fınding provides evidence that the delayed onset of bladder urothelial car-
cinomas inAANpatients is likely due to distal seeding of cancer cells originating
from the primaryUTUC tumors.Our fırst-of-its-kind study addresses the risk as
well as mechanistic factors leading to the second, late-onset bladder urothelial
carcinomas following kidney transplantation and primary UTUCdevelopment.
Our results underline the importance of long-term bladder follow-up in high-
risk populations with established or suspected AA exposure. Funding: IARC;
NYU Genome Technology Center is partially supported by the NIH/NCI
(P30CA016087) grant.
#5739 Nicotine promotes stemness-related properties and cell migration/
metastasis through IGF-1R regulation in triple negative breast cancer.Yung-
Che Kuo,1 Jan-Show Chu,2 Kha-Liang Lee,1 Victor James Drew,1 Wei-Zhan
Zhuang,1 Chi-Long Chen,2 Yuan-Soon Ho,3 Yen-Hua Huang1. 1Department of
Biochemistry and Molecular Cell Biology, School of Medicine, Taipei Medical
University, Taipei, Taiwan; 2Department of Pathology, School ofMedicine, Taipei
Medical University, Taipei, Taiwan; 3Graduate Institute ofMedical Sciences, Col-
lege of Medicine, Taipei Medical University, Taipei, Taiwan.
Purpose: To determine the role of insulin-like growth factor (IGF)-I receptor
(IGF-IR) in alpha 9 nicotinic acetylcholine receptor (	9-nAChR)-induced
stemness-related properties and to assess the therapeutic potential for prevent-
ing early tumor relapse andmetastasis of TNBCs. Experimental Design: Expres-
sion levels of stemness-related genes, 	9-nAChR and IGF-IR in tissues (n 67)
were analyzed by real-time Q-PCR and the correlation of different gene levels
were calculated by the Pearson correlation analysis. The effects of either 	9-
nAChR activation or IGF-1R transactivation on stemness expression in TNBC
were examined using ALDEFLUOR assay with flow cytometry, RNA interfer-
ence, wound closure/migration/invasion assay, and animal models. The 	9-
nAChR, OCT4 and IGF-1R protein, p-IGF-1R in tissues were detected by im-
munohistochemical staining. Results: A high positive correlation between the
gene expression levels of OCT4/NANOG/CD24/CD44 and 	9-nAChR/IGF-IR
in human breast cancer tissues was observed. Nicotine induced 	9-nAChR ac-
tivation trans-activates an IGF-IR expression and a phosphorylation of STAT3,
which stimulated stemness-related properties in both the cell lines and the xe-
nografted mouse tumors. The inhibition of either 	9-nAChR or IGF-IR activa-
tion by RNA interference signifıcantly suppressed the nicotine-induced stem-
ness-related properties and cell metastasis both in vitro and in vivo.
Conclusions: IGF-1R signal regulates the nicotine/	9-nAChR-induced stem-
ness properties and cell metastasis therefore convene poor prognosis in TNBCs.
#5740 Aberration of (pro)renin receptor induces genomic instablity in
human pancreatic ductal epithelial cells. Yuki Shibayama,1 Jun Yasuda,2
Daisuke Yamazaki,1 Asadur Rahman,1 Shinichi Yachida,3 Akira Nishiyama1.
1Kagawa University, Kagawa, Japan; 2Tohoku University, Sendai, Japan; 3Na-
tional Cancer Center Research Institute, Tokyo, Japan.
Background: We have recently shown the potential contribution of (pro)
renin receptor ((P)RR) to tumorigenesis of pancreatic ductal adenocarcinoma
(PDAC) through an activation of Wnt/-catenin signaling pathway (Sci. Rep.,
2015). We also found that signifıcant (P)RR expression was synchronized with
an appearance of atypical nuclei in PanIN-2 of PDAC tissues. Furthermore,
(P)RR knockdown reduced a total of DNA amount in human PDAC cell lines.
Based on our fındings, we have hypothesized that an aberration of (P)RR leads to
a failure of genome homeostasis. Accordingly, we explored whether an aberrant
expression of (P)RR induces genomic instability in human pancreatic ductal
epithelial (HPDE) cells which are capable of developing to the PDAC.Methods:
HPDE cells transfected by episomal vector inserted with ATP6ap2 encoding
(P)RR were established. HPDE cells transfected by vector without the insertion
ofATP6ap2was noted asMock.We also performed a comet assay to evaluate the
defects ofDNArepair capacity, flow-FISH tomeasure the length of telomere and
western blotting to confırm the activation of DNA damage pathway by measur-
ing protein levels of - H2AX and p53. Then, comparative analyses of human
whole genome in Mock- expressing and (P)RR-expressing HPDE cells were
examined. Furthermore, we implanted 14-passage HPDE cells expressed by ei-
ther Mock or (P)RR into the renal subcapsules of immunodefıcient mice to
investigate whether (P)RR-expressingHPDE cells show a precancerous status in
vivo. Results: (P)RR overexpression led to inactivation of -H2AX and p53 as
the components of DNA damage pathway, which were associated with a disap-
pearance of comet tail and shorten telomere length. Substantial structural vari-
ations, e.g., inter- and intra- chromosomal translocations throughout all the
chromosomes were observed in HPDE cells expressed by (P)RR under the anal-
ysis by BreakDancer. Analyses with Bcftool showed that the number of all the
somaticmutations was approximately 2-fold greater inHPDE cells expressed by
(P)RR than those expressed byMock (Mock: 124,579 vs. (P)RR: 239,080). (P)RR
overexpression also signifıcantly increased the number of somatic mutations in
several genes which were commonly detected in PDAC tissues. The area occu-
pied by (P)RR-expressing HPDE cell population remarkably expanded after the
implantation to renal subcapsules of all the immunodefıcient mice. However,
there were no KRAS 12 codonmutations which are prevalent in PDAC patients.
Conclusion: We have demonstrated that (P)RR overexpression induces
genomic instability on global genome level in HPDE cells. These data are con-
sistent with our hypothesis that (P)RR is essentially involved in the early carci-
nogenesis of PDAC.
#5741 Evaluating the role of recurrent ESR1-CCDC170 fusion in breast
cancer endocrine resistance. Yiheng Hu,1 Jamunarani Veeraraghavan,2 Xian
Wang,1 Ying Tan,2 Jin-Ah Kim,2 Rachel Schiff,2 Xiao-Song Wang1. 1University
of Pittsburgh, Pittsburgh, PA; 2Baylor College of Medicine, Houston, TX.
Background: Recurrent gene fusions resulting from chromosome rearrange-
ments are central to the formation of cancer. Previously, our lab identifıed re-
current rearrangements between the estrogen receptor 	 (ER	) gene ESR1 and
its neighbor gene CCDC170, in6-8% of luminal B tumors, a more aggressive
form of ER breast cancer that has worse clinical outcome after endocrine
therapy. ESR1-CCDC170 rearrangements enable the expression of different-
sized N-terminally truncated CCDC170 (	CCDC170) under ESR1 promoter,
such as the E2-E7 or E2-E10 variants in which exon 2 of ESR1 fused with exon 7
or exon 10 of CCDC170. Consistent with the behavior of luminal B tumors,
ectopic	CCDC170 expression in ER breast cancer cells transformed cells to a
more aggressive form and led to reduced endocrine sensitivity in vitro, as well as
enhanced xenograft growth in vivo. In the present study,we examined the role of
ESR1-CCDC170 in breast cancer endocrine resistance in vivo and further elu-
cidated the potential engaged mechanisms of its actions. Results: Our in vivo
endocrine sensitivity study showed that, while tamoxifen (Tam) treatment ren-
dered tumor regression in the vector-expressing T47D xenograft tumors, it
made the E2-E7 overexpressing T47D xenografts static and less likely to regress,
whereas the E2-E10 overexpressing xenografts, though grew initially upon Tam
treatment, became cytostatic and showed signifıcant reduction in tumor regres-
sion. Kaplan-Meier analysis revealed a signifıcantly worse progression-free sur-
vival for E2-E7 (p0.01) and E2-E10 (p0.001) overexpressing tumors treated
with Tam compared to the control tumors. These data suggest that ESR1-
CCDC170 variants differ in level of reduced responsivity to Tam, and may ren-
der theT47Dxenografts less sensitive or resistant toTam in vivo. Further studies
suggest that 	CCDC170 protein preferentially localizes to cytoplasm (different
fromwild-typeCCDC170protein enriched in nucleus), physically interactswith
ER	 andHER2, and formshomodimers. RPPAanalysis showed that silencing of
ESR1-CCDC170 repressed ER	 and BCL2 protein levels, as well as total/phos-
pho-HER2 levels, consistent with the fındings of 	CCDC170 interactions with
ER	 andHER2. Importantly, analysis of	CCDC170 protein sequence revealed
a potential high-affınity ATP-binding pocket at its C-terminus, suggesting that
	CCDC170may be directly druggable. Conclusion: These data suggest a poten-
tial role of ESR1-CCDC170 in mediating breast cancer endocrine responsivity,
which may possibly through cytoplasmic mislocalization of 	CCDC170 and
interactions with ER	 and HER2. Further studies will affırm and elucidate the
role of overexpressed or endogenous ESR1-CCDC170 in breast cancer endo-
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crine resistance, and pinpoint the precisemechanisms of its oncogenic function,
in order to develop a novel target therapy against it for the fusion-carrying
patient community around the world.
#5742 Identifying likely breast carcinogens using complementarymecha-
nistic approaches. Ruthann A. Rudel,1 Janet M. Ackerman,1 Megan R. Schwar-
zman,2 Julia G. Brody1. 1Silent Spring Institute, Newton, MA; 2University of Cal-
ifornia-Berkeley, Berkeley, CA.
Many commercial chemicals and environmental pollutants show chemical or
mechanistic similarity with known breast carcinogens such as ionizing radia-
tion, hormones, alcohol, and tobacco. Regulatory agencies like the US Environ-
mental Protection Agency (EPA) are charged with evaluating these chemicals
for safety, which requires predicting theoretical effects on cancer risk that are
often small for any individual, but signifıcant across the population because
exposures are widespread. Current approaches to chemical screening and as-
sessment are being re-envisioned, driven by innovations in chemical safety test-
ing, new regulations, anddemand for information onhealth effects.We reversed
the usual direction of inquiry by beginningwith an outcome - breast cancer - and
using three complementary approaches to identify biological processes that
could be the focus of chemical toxicity screening. First, an expert panel identifıed
key processes whose perturbationmay alter breast cancer risk, including cellular
and molecular events, tissue changes, and factors that alter susceptibility. Com-
parison of these endpoints with those included in US EPA’s ToxCast and Endo-
crine Disruptor Screening Program identifıed important endpoints not cur-
rently evaluated by US testing programs, including altered mammary gland
development, Her2 activation, progesterone receptor activity, prolactin effects,
and aspects of estrogen receptor  activity. Second, investigation of the mecha-
nistic basis for many known breast cancer risk factors indicates biological pro-
cesses relevant to breast cancer. For example, the body of evidence indicates
HRT as a tumor promoter in the breast, while studies ofDES show that hormone
exposure in utero alters breast development and subsequent breast cancer risk.
Chemicals with similar properties and biological activitymay also pose prevent-
able risks. Third, we compiled chemicals shown to increasemammary tumors or
alter mammary gland development in rodents and identifıed key modes of ac-
tion. We used data from ToxCast – a project that screened over 1000 chemicals
in almost 800 in vitro assays – for 75 rodent mammary carcinogens and 18
disruptors of mammary development to identify mechanisms of mammary car-
cinogenesis and highlight gaps. Our analysis confırms that many mammary
carcinogens are genotoxic, estrogenic, or both.We also observed thatmammary
toxicants increased activation of glucocorticoid and androgen receptors, as well
as of PXR and CYP19A1, xenobiotic metabolizing systems involved in steroid
hormone synthesis and metabolism, compared to other chemicals in ToxCast.
Taken together, these approaches identifymechanisms by which chemicals may
alter breast cancer risk and can shape chemical testing programs to increase their
relevance to breast cancer. This approach can be extended to identify biological
processes and screening methods relevant for other common cancers.
#5743 Characterization ofmitochondrialDNAmutations and tumor evo-
lution in ulcerative colitis-associated colorectal cancer.KathrynTerese Baker,
DanielaNachmanson, Scott R. Kennedy, TeresaA. Brentnall, RosaAnaRisques.
University of Washington, Seattle, WA.
The role of mitochondrial DNA (mtDNA)mutations in cancer is highly con-
troversial. While specifıc mtDNA mutations have been associated with certain
cancers, it has been recently reported that mtDNA mutations are negatively
selected in most tumors. We aimed to clarify the role of mtDNA mutations in
cancer progression by: 1) capitalizing on the multi-step sequence of tumorigen-
esis in ulcerative colitis (UC), a premalignant disease ideal for the study of tumor
progression, and 2) employing a highly accurate, ultra-deep sequencingmethod
to fully characterize the mtDNA mutational profıle at different stages of tumor
evolution. UC is an inflammatory bowel disease characterized by chronic co-
lonic inflammation that increases the risk of colorectal cancer (CRC). UC CRC
evolves through a stepwise process that involves the accumulation of molecular
alterations in otherwise histologically normal epithelium, low-grade dysplasia
(LGD), high-grade dysplasia (HGD), and cancer. Our lab has previously identi-
fıedmitochondrial alterations as a facet of dysplastic progression inUC.Herewe
have worked to fully characterize the spectrum and frequency of mtDNA mu-
tations in UC tumorigenesis by applying a novel, highly sensitive NGS technol-
ogy, Duplex Sequencing (DS), that can accurately detect mutant allele frequen-
cies (MAF) as low as 0.01%. For two patients that developed cancer, we analyzed
15-20 colon biopsies obtained at colectomy, representing all stages of tumori-
genesis. The median duplex sequencing depth was 4,000x, which allowed un-
precedented resolution to detect subclonal mutations (MAF 1-99%) and rare
mutations (MAF1%). Several subclonalmutationswere present in all biopsies,
but with variable MAF, thus enabling construction of phylogenetic trees via
PHYLIP analysis. Rare mutations were abundant in all biopsies; on average one
in every 10,000 nucleotides sequencedwasmutated.Most raremutationswereG
to A transitions, indicative of replicative errors, but G to T and C to A transver-
sions, the oxidative damage mutational signature, were prevalent in some biop-
sies. We conclude, therefore, that most mtDNAmutations are caused by prolif-
eration with a contribution by inflammatory processes, and that this may have
greater implications for their role in other cancer types.
#5744 The role of atypical protein kinaseC in colorectal cancer cell growth
and proliferation. S M Anisul Islam, Mildred Acevedo Duncan. Univ. of South
Florida, Tampa, FL.
Colorectal cancer (CRC) is the secondmost common cancer in the world and
death from colorectal cancer accounts for 8% of all cancer deaths both in men
and women in the United States. CRC is life threatening disease due to therapy
resistant cancerous cells. The exact mechanisms of cell growth, survival, metas-
tasis and inter & intracellular signaling pathways involved in colon cancer are
still a major challenge for scientists. Hence, investigating the signaling pathways
that lead to colon carcinogenesis may give insight into the therapeutic target. In
this study, the role of atypical Protein kinase C (aPKC) on colon cancer was
identifıed by using four inhibitors of that particular protein class: 1) ACPD
(2-acetyl-1,3-cyclopentanedione and 2) DNDA (3,4-diamino-2,7 naphthalene-
disulfonic acid) are non-specifıc inhibitors of aPKCs; 3) -Stat (8-hydroxy-1, 3,
6-naphthalenetrisulfonic acid) is a specifıc inhibitor of PKC-; and 4) ICA-I (4,
5-amino-4-carbamoylimidazol-1-yl-2, 3-dihydroxycyclopentyl) methyl dihy-
drogen phosphate) is a specifıc inhibitor of PKC-. The cell lines tested were
HT-29 colon cancer and CCD18CO normal colon epithelial. Although PKC- is
an oncogene in many cancers, we found that the PKC- was responsible for the
abnormal growth and proliferation in HT-29 colon cancer cells. Additionally,
the inhibition of aPKCs did not bring any signifıcant toxicity on CCD18CO
normal colon cell line. These results suggest the potentiality of utilizing aPKC-
inhibitors to block colon cancer cell growth and proliferation.
#5745 Study on telomere shelterin component TPP1 in esophageal squa-
mous cell carcinoma. Lihua Yao,1 Jiang Zou,1 Ru Sun,1 Jiajing Cai,1
Guangcheng Huang,1 Qiang Ma,2 Lei Xu,1 Mayong Fu,2 Xiaolan Guo2. 1North
SichuanMedical College, Nanchong, China; 2AffıliatedHospital of North Sichuan
Medical College, Nanchong, China.
Esophageal cancer (EC) is one of the most aggressive cancer and ranks the
sixth leading cause of cancer-relatedmortalityworldwide, approximately 70%of
global esophageal carcinoma cases occur inChina and esophageal squamous cell
carcinoma (ESCC) is the most frequent histological subtype of EC. Lacking of
reliable early diagnostic markers and effıcient medical and surgical treatment
approaches, the fıve-year survival rate of ESCC is only about 4.4%.Therefore
exploration of the genetic basis and the affıliated molecular mechanisms in
ESCC could be benefıcial to improve the diagnosis, therapy, and prevention of
this disease. As an important telomere binding protein, TPP1 protects the ends
of telomeres and maintains the genomic stability and integrity of chromosomes
in eukaryotes. Previous investigation discovered that TPP1 might play an im-
portant role in the carcinogenesis and progression of some cancers. However,
whether and/or how TPP1 participates in ESCC remains unclear. Here TPP1
was studied in 65 ESCCpatients’ specimens including tumor tissue, the adjacent
tissue, and the peripheral blood leukocytes, also the ESCC cell lines were em-
ployed to further explore the molecular mechanisms of TPP1 involved in the
tumorigenesis of ESCC. In this study, TPP1 mRNA and protein were measured
in the ESCC tissue specimens, peripheral blood leukocytes and also in ESCC cell
lines using real time RT-PCR and Western Blot. The results showed that TPP1
mRNA level was signifıcantly higher in ESCC tumor tissues compared with the
adjacent tissues (P0.05); the same trend was observed in ESCC cells (Eca109,
Kyse150) vs human esophageal epithelial cells (HET-1A), respectively. How-
ever, in peripheral blood leukocytes, the expression of TPP1 did not show any
difference between the cancer patients and the healthy controls. Among the 65
ESCC patients, TPP1 protein expression in 46 patients was obvious higher in
tumor tissues than that in the matched adjacent tissues, although there were 19
patients in exception. Moreover, the TPP1 expression was correlated with the
lymph nodes metastasis and CYF2, which is one of the potential tumor markers
for diagnosis of esophageal carcinoma. To further explore the potential biolog-
ical function of TPP1 in ESCC, stably- transfecting shRNA-TPP1 (sh-TPP1) and
shRNA-NegativeControl (sh-NC) expression constructs in ESCC cell lineswere
performed to study TPP1’s roles in ESCC. The colongenic assay showed that
depletion of TPP1 decreased ESCC cells proliferation and cell growth, and the
wound healing experiment and cell invasion transwell chamber test demon-
strated that down-regulation of TPP1 suppressed the cell migration and inva-
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sion capabilities in vitro. Taken together, our fındings revealed that TPP1might
play crucial roles in the pathogenesis of ESCC and targeting TPP1 could be a
valuable potential for ESCC early diagnosis, intervention and therapeutics.
#5746 TRAF1 is required for solar UV-induced skin carcinogenesis. Hi-
royuki Yamamoto,1 Joohyun Ryu,1 Eli Min,1 Naomi Oi,1 Ruihua Bai,1 Tatyana
A. Zykova,1 DongHoon Yu,1MargaritaMalakhova,1 KenjiMoriyama,2 AnnM.
Bode,1 ZigangDong1. 1University ofMinnesota, Austin,MN; 2MukogawaWom-
en’s University, Nishinomiya, Japan.
Tumor necrosis factor receptor-associated factor 1 (TRAF1) is a member of
the TRAF protein family, which regulates the canonical and non-canonical
NF-B signaling cascades. Although aberrant TRAF1 expression in tumors is
reported, the role of TRAF1 remains elusive. Here, we report that TRAF1 is
required for skin carcinogenesis induced by chronic solar UV radiation. In vivo
studies with solarUV exposure indicate that the deletion of TRAF1 results in the
inhibition of AP-1 activity by down-regulating the induction of c-Fos and c-Jun
by regulating ERK5 activity. Furthermore, we show that TRAF1 is required for
solar UV-induced ERK5 activation. Mechanistic studies revealed that TRAF1
expression enhances the ubiquitination of ERK5 onK184, which is necessary for
AP-1 activation. Altogether, our results suggest that TRAF1 mediates ERK5
activity by regulating the upstream effectors of ERK5 and also bymodulating its
ubiquitination status. Targeting TRAF1 function might lead to strategies for
preventing and treating skin cancer.
#5747 Influence of air carcinogenic pollution on oncological morbidity.
Olga Ostash,1 Igor Chernichenko,1 Olga Litvichenko,1 Sergei Tsymbaliuk,2
Nina Balenko,1 Larissa Sovertkova,1 Oksana Shvager3. 1O.M.Marzeyev Institute
for Public Health of the National Academy of Medical Sciences of Ukraine,yiv,
Ukraine; 2Kyiv City Clinical Endocrinology Centre, yiv, Ukraine; 3Bogomolets
National Medical University,yiv, Ukraine.
Cancermorbidity inUkraine (according to theNational cancer Registry data)
of one and half times has increased over the last 20 years. At the same time the
changes occurred in the structure of diseases. These changes can be caused by
negative impact of environmental factors especially air-pollution carcinogens
which altered qualitatively and quantitatively for this period. The aim was to
evaluate the role of air-pollution carcinogens in cancer incidence forming and to
establish quantitative parameters of their influence. Association between popu-
lation cancer incidence and air pollution carcinogens was investigated. We an-
alyzed the dynamics of city air-pollution and population cancer incidence of
separate organs during the last 20 years also. Investigations were conducted in
Ukraine several cities with different character industrial development and air-
pollution levels. We studied 8 priority carcinogenic compounds. Benzo(a)pyr-
ene, N-nitrozodymetylamin, N-nitrozodietylamin have been studied according
to the result of own monitoring. Formaldehyde and heavy metals (cadmium,
nickel, plumbum and chromiumVI) were investigated by analyzing database of
the Central Geophysical observatory of Ukraine Ministry of Emergency situa-
tion. We calculated indexes of individual, total and population cancer risks for
these carcinogens influence on the population with using Risk Assessment
Methodology (IARC, 1997). It was established territorial peculiarities of cancer
risk forming. We defıned the atmospheric air-pollution contribution in the de-
velopment of population oncologic morbidity. We determined period of maxi-
mum manifestation of carcinogenic effect for separate chemicals, i.e. latent pe-
riod of appearing oncologic diseases. For example there are 10 years for thyroid
cancer, 7 years for respiratory organs cancer, 8 years for stomach and urinary
bladder. Calculated regression coeffıcients allowed predicting incidence of some
nozologic forms of cancer at the levels change of total carcinogens pollution or
separate carcinogenic chemicals. The obtained results allowed substantiating
preventive measures to reduce compounds hazard influence on population.
#5748 Roles of miR29c-ID2 axis in tumor initiating cells of breast ductal
carcinoma in situ.YinLiu,1 PuspaR. Pandey,2 Sambad Sharma,1KeruiWu,1 Fei
Xing,1 Kounosuke Watabe1. 1Wake Forest School of Medicine, Winston Salem,
NC; 2National Institute of Health, Bethsda, DC.
Ductal carcinoma in situ (DCIS) is an early-stage form of breast cancer that
accounts for over 20% of all breast cancers in the US. Therefore, prevention of
DCIS is a major goal for reducing breast cancer incidence. However, the under-
lying molecular and pathological mechanisms of DCIS remain poorly under-
stood. It is believed that tumor-initiating cells are formed at a very early stage of
tumorigenesis, which then leads to the progression of DCIS. Our recent work
that focused on tumor-initiating cells of DCIS revealed that the expression of
miR29c in tumor-initiating cells was signifıcantly down-regulated in DCIS cells
compared to that in normal cells. Furthermore, we found that the ID2 gene is
one of the targets ofmiR29c in tumor-initiating cells and thatmiR29c suppresses
the ID2 gene by directly binding to the 3=-UTR sequence. ID2 is a well-known
dedifferentiation factor in embryonic development, and the ID family is in-
volved in progression of cancer by affecting cell differentiation and prolifera-
tion. We also found that ectopic expression of ID2 in premalignant cells accel-
erated tumor growth and promoted self-renewal of tumor-initiating cells in
DCIS, suggesting that ID2 also controls cancer cell dedifferentiation and pro-
motes tumor-initiating cells formation. These results indicate that the miR29c-
ID2 axis plays a critical role in self-renewal of DICS in vivo and that ID2 is a
potential biomarker for tumor-initiating cells inDCIS. ID2 is thought to seques-
ter E-protein transcription factors and thus regulates a wide range of gene ex-
pression. Our data suggest that ID2 upregulates expression of several cancers
stem cell genes including SOX2, which is a well- known self-renewal regulator of
stem cells. ID2 also upregulates the fatty acid synthase gene (FASN), which
promotes cancer cell proliferation and survival. We also found that FASN ex-
pression was signifıcantly suppressed by pterostilbene, indicating potential util-
ity of this natural compound for preventing DCIS formation. Taken together,
these results suggest that miR29c-ID2 functions as master regulators in forming
DCIS. ID2 promotes self-renewal of tumor-initiating cells by regulating expres-
sion of the SOX2 and FASN genes.
#5749 VCAN promotes clear cell renal cell carcinoma tumor progression
and metastasis, and predicts poor prognosis. Yozo Mitsui,1 Taku Kato,2
Shigekatsu Maekawa,2 Yutaka Hashimoto,2 Marisa Shiina,2 Mitsuho Imai Su-
mida,2 Ryan Kenji Wong,2 Soichiro Yamamura,2 Varahram Shahryari,2 Sha-
hana Majid,2 Sharanjot Saini,2 Guoren Deng,2 Rajvir Dahiya,2 Koichi Naka-
jima,1 Yuichiro Tanaka2. 1Toho University Faculty of Medicine, Tokyo, Japan;
2San Francisco Veterans Affairs Medical Center and University of California San
Francisco, San Francisco, CA.
Introduction and Objectives: Although versican (VCAN) is known to pro-
mote tumor progression and enhance metastasis of several types of cancers, its
role in clear cell renal cell carcinoma (ccRCC) remains unknown. Interestingly,
a recent report showed that VCAN is an important target of chromosomal 5q
gain, one of the most prevalent genetic abnormalities in ccRCC cases. In the
present study, we investigated whether VCAN expression is associated with the
pathogenesis of ccRCC.Methods: VCAN expressionwas analyzed in 3 RCC and
normal kidney cell lines, as well as 84 matched ccRCC and normal renal tissues.
We also performed various functional analyses of growth and progression prop-
erties using VCAN-depleted ccRCC cells. Microarray analysis was then em-
ployed to investigate the target genes of the pathway involved in ccRCC tumor-
igenesis and development. Results: There are 4 isoforms of VCAN containing
the N-terminal globular (G1 domain) and C-terminal globular (G3 domain)
domains, each of whichwas found to be over-expressed in the ccRCC samples as
compared to the controls. Higher VCAN expressionwas signifıcantly correlated
with metastasis (p0.001) and worse 5-year overall survival after a radical ne-
phrectomy (p0.014). In vitro, VCAN knockdown by siRNA in Caki-2 and
786-O cells signifıcantly decreased cell proliferation and increased apoptosis,
and was also found to be associated with alteration of several TNF signaling-
related genes, such as TNF-	, BID, and BAK. Furthermore, VCAN depletion
markedly decreased cell migration and invasion associated with reducedMMP7
and CXCR4 levels. Conclusion: Our results demonstrate that VCAN promotes
ccRCC tumorigenesis and metastasis, showing it to be an attractive novel target
for diagnostic, prognostic, and therapeutic strategies for affected patients.
#5750 USP15 inhibits HPV16 E6 degradation and catalytically inactive
USP15 has reduced inhibitive activity. Aoi Tokuda, Masafumi Yoshimoto,
Yuji Yaginuma. Kumamoto Univ. Graduate School of Health Sci., Kumamoto,
Japan.
HPVs can be classifıed as either high-risk or low-risk depending on the trans-
forming potential of the virus.Most cervical cancers and a signifıcant proportion
of other anogenital cancers have been associated with infection by a small num-
ber of high-risk genital HPV types. Tumorigenesis induced by high-risk genital
HPVs has been linked to the expression of two viral oncoproteins, E6 and E7,
which cooperate in cellular immortalization and transformation processes.
HPV16 E6 is an oncoprotein that causes the development of high-risk type
human papilloma virus (HPV) and induces cancers, including oropharyngeal,
anal, and cervical cancers. The stability of E6 is essential for its complete func-
tion as an oncoprotein. Using the yeast two-hybrid system, we identifıed ubiq-
uitin-specifıc protease 15 (USP15) as an HPV16 E6-interacting protein. USP15
encodes a protein that consist of 952 amino acids and functions as a deubiquiti-
nating enzyme. Deubiquitination is an essential process that releases ubiquitin
chains from ubiquitin-protein conjugates. Aberrations in the ubiquitin-protea-
some systemhave been recently connected to the pathogenesis of several human
protein degradation disorders, including cancer and neurodegenerative diseases; as
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such, the proteasome is now considered to be important in the mechanism of
carcinogenesis. USP15 cleaves polyubiquitin chains of HPV16 E6 and/or ubiq-
uitin precursors. Immunohistochemical analysis showed that USP15 was highly
expressed in normal cervical squamous cells, and cervical cancer cells. Our re-
sults indicated that USP15 can increase the level of HPV16 E6 by inhibiting E6
degradation. USP15 dose-dependently inhibited the degradation of HPV16 E6.
In contrast, catalytically inactive mutants of USP15 had a reduced inhibitory
effect on E6 degradation. In particular, USP15 mutants of all three cysteine
boxes and the NHL mutant of the KRF box had a drastically reduced inhibitive
effect on HPV16 E6 degradation. In addition, HPV16 E6 mRNA was not in-
duced by USP15; therefore, HPV16 E6 appears to be post-translationally regu-
lated. These results suggest that USP15 has the ability to stabilize E6 as a deu-
biquitinating enzyme, and HPV16 E6 can affect biological functions as an
oncoprotein in infected human cells.
#5751 Induction of cancer stem cell like characteristics by overexpression
of CDX1. SANG IL CHOI, Kyoung-Ok Hong, Mi Ree Park, Yun Hee Na, Soo-
Jeong Cho. National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Republic of
Korea.
Intestinal metaplasia (IM) has been regarded as the most signifıcant risk fac-
tor for gastric cancer (GC). However, the molecular mechanisms of the patho-
genesis of IM and the progression of GC remain unclear. The aim of this study
was to evaluate the role of CDX1 in IM and GC using stable CDX1 overexpres-
sion inHFE 145 gastric epithelial cells, and its expression in patient samples. For
CDX1 overexpression, we generated lentiviral CDX1 and infected is to HFE 145
cells. We found that CDX1 overexpression induced an increase of IM related
markers such as villin and SI and a decrease of gastric epithelial marker such as
MUC 5AC. Overexpression of CDX1 in HFE 145 cells caused an increase in cell
proliferation (P0.05) and showed 2.7-fold higher clonogenic ability than that
of control cells. The expression of CDX1 induced in vitro invasiveness 1.9-fold
higher compared to HFE 145 control cells with statistical signifıcance
(p0.004), augmented the expression of MMP-9 and phosphorylation of FAK
and paxillin. Overexpression of CDX1 also induced anchorage-independent
colony formation and spheroid formation, and enhanced the expression of stem
cell markers including SOX2, Oct4, NANOG and c-Myc in HFE 145 cells, sug-
gesting CDX1-induced stem cell like phenotype of gastric epithelial cells. HFE
145 cells infectedwithCagA-positiveHelicobacter pylori (G27wild type) caused
an increase in expression of CDX1 compared to HFE145 cells infected with
CagA-negative H. pylori (G27 	CagE). Using luciferase promoter assay, we
confırmed that the expression ofCDX1was regulated by theCagA secreted from
H. pylori. In clinical practice, the Operative Link on Gastric Intestinal Metapla-
sia Assessment (OLGIM) staging system is often used to evaluate the degree of
IM in biopsy samples or surgical specimen. We measured expression of CDX1,
SI, and villin adjusted by glyceraldehyde 3-phosphate dehydrogenase expression
using densitometry in 9 patients with various OLGIM stage (2 in stage 0, 1 in
stage 1, 2 in stage 2, 1 in stage 3, 3 in stage 4). We were able to fınd out that the
patients with higher OLGIM stage (stage 3-4) tended to have higher expression
of CDX1 (3.935 vs. 0.416, p0.160), SI (9.739 vs. 0.311, p0.088), and villin
(7.785 vs. 0.868, p0.119) compared to patients with lower OLGIM stage (stage
0-2). Taken together, these results suggest that CDX1 overexpression could be
one of the causes ofGC tumorigenesis and progression. Further investigation on
CDX1 molecule would encourage development of specifıc target for cancer
treatment.
#5752 Susceptibility of cells fromcervical transformation zone toHPV-16
induced immortalization and dysplastic differentiation.HanDeng, Eric Hill-
pot, Philomina Yeboah, Sumona Mondal, Craig D. Woodworth. Clarkson Uni-
versity, Potsdam, NY.
Persistent infection of high-risk human papillomavirus (HPV) is a major risk
factor for cervical cancer. Greater than 90% of these cancers originate in the
cervical transformation zone (CTZ), a narrow band of squamous metaplastic
epithelium between ectocervix and endocervix. It is unclear why the CTZ has
high susceptibility tomalignant transformation and few studies have specifıcally
examined cells from this region. We hypothesized cells cultured from human
CTZ are uniquely susceptible to cellular immortalization and dysplastic differ-
entiation, two alterations that contribute to malignant development. Primary
epithelial cells were cultured from each region of human cervix (ectocervix,
endocervix and CTZ) and characterized for expression of differentiation
markers to assess their origin. We examined susceptibility of cells from each
region to immortalization after transfection with the complete HPV-16 genome
or infection of HPV-16 E6/E7 retroviruses. In addition, we evaluated the extent
of dysplastic epithelial differentiation in organotypic cultures of HPV16-im-
mortalized cell lines derived from each region of cervix. Our results showed that
cells from the CTZ express specifıc keratin markers (keratin 14 and 18) that
confırm their origin. Primary cell cultures from CTZ and ectocervix are more
susceptible to immortalization by the HPV16 complete genome or E6/E7 retro-
viruses. In contrast, preliminary results indicate that HPV-immortalized CTZ
and endocervical cells are more susceptible to dysplastic differentiation when
maintained in organotypic culture. Our results may help to identify important
signal pathways or biomarkers that are unique to cells fromCTZ and that can be
targeted for improved screening, prevention or therapy.
#5753 Inhibition of CCAR1, a coactivator of -catenin, suppresses the
proliferation andmigration of gastric cancer cells. Te-Sheng Chang,1 Chung-
Kuang Lu,1 Kuo-Liang Wei,1 Yi-Hsing Chen,1 Ying-Tung Cheng,2 Shui-Yi
Tung,1 Cheng-Shyong Wu,1 Ming-Ko Chiang2. 1Chang Gung Memorial Hospi-
tal, Chiayi, Taiwan; 2National Chung Cheng University, Chiayi, Taiwan.
Given a current hypothesis that cancer arises from cancer stem cells
(CSCs), targeting key signaling pathways that support CSC self-renewal ap-
pears to be a useful approach to cancer therapy. Derranged expression of
Wnt signaling is among the major pathways implicated in regulating the
stenmess properties of a variety of human cancers, including gastric cancer.
Cell cycle and apoptosis regulator 1 (CCAR1) is a transcriptional coactivator
which has been shown to be a component of Wnt/-catenin signaling, and
plays an important role in transcriptional regulation by -catenin. However,
the function and clinical signifıcance of CCAR1 in gastric cancer have not
been elucidated. Here we show the elevated CCAR1 nuclear expression cor-
relates with the occurrence of gastric cancer. In addition, RNAi-mediated
CCAR1 reduction not only suppressed the cell growth and increased apo-
ptosis in gastric cell lines AGS and MKN28, but also reduced the migration
and invasion ability of these cells. Furthermore, In vivo xenograft assay
revealed that the expression level of CCAR1 was critical for tumorigenesis.
Our data demonstrates that CCAR1 contributes to carcinogenesis in gastric
cancer and is required for the survival of gastric cancer cells. Moreover,
CCAR1 may serve as a diagnostic marker and a potential therapeutic target.
#5754 The genetic aberrations in carcinogenic sequence of colitis-associ-
ated cancer. Nobuyuki Kakiuchi,1 Kenichi Yoshida,1 Yusuke Shiozawa,1 Akira
Yokoyama,1 Keisuke Kataoka,1 Yoshikage Inoue,1 Yasuhide Takeuchi,1 Ya-
sunori Kogure,1 Ayana Kon,1 Masahiro Nakagawa,1 Kenichi Chiba,2 Hiroko
Tanaka,2 Yuichi Shiraishi,2 Satoru Miyano,2 Kenji Kawada,1 Hideaki Okajima,1
Yoshiharu Sakai,1 Takaki Sakurai,1 Hironori Haga,1 Hiroshi Nakase,3 Motoi
Uchino,4 Hiroki Ikeuchi,4 Takako Kihara,4 Seiichi Hirota,4 Takahiro Hori-
matsu,1 Minoru Matsuura,1 Hiroyuki Marusawa,1 Hiroshi Seno,1 Seishi
Ogawa1. 1Kyoto University, Kyoto, Japan; 2The University of Tokyo, Tokyo, Ja-
pan; 3Sapporo Medical University, Sapporo, Japan; 4Hyogo College of Medicine,
Nishinomiya, Japan.
Colitis-associated cancer (CAC) is a common complication among pa-
tients with a long history of ulcerative colitis (UC). Previous studies revealed
that dysplasia precedes CAC development, and more than 20% of CACs are
multicentric, suggesting the presence of a fıeld effect on colorectal carcino-
genesis in UC patients. However, the genetic basis of the fıeld effect in UC
patients is poorly understood.To address this issue, we isolated single crypts
from non-tumorous colon mucosa from 6 UC patients, as well as those from
apparently normal mucosa from non-UC patients, and “single crypt-derived
DNA” was analyzed for somatic mutations using whole-exome sequencing
(WES). In total, 19 crypts from histologically non-dysplastic, but inflamed
mucosa, and 2 from apparently normal mucosa were isolated from 6 UC
patients, including 4 with pancolitis, 1 with left-sided colitis and 1 with
proctitis, while 32 crypts were obtained from normal mucosa from 20
non-UC patients, including 10 with colorectal cancer, 6 with adenoma and 4
healthy volunteers. Regardless of the disease status, mutations were detected
in all crypts analyzed with the median of 43/crypt (3  121), showing high
variant allele frequencies (VAFs) (0.5), suggesting that these mutations
were shared by all cells within single crypts and therefore by crypt-maintain-
ing stem cells. The number of mutations increased with age, in crypts from
both UC and non-UC patients (P  10-9), showing clear age-related C to T
transition in both normal and UC-inflamed crypts. Strikingly, however, the
age-adjusted number of mutations was signifıcantly higher in UC-derived
crypts than in those from non-UC individuals (P  10-3). KRAS and TP53
mutations were reported to be the most prevalent alterations in UC-associ-
ated CAC, but only rarely seen in UC-derived normal crypts. Next, to eval-
uate clonal expansion of mutated clones, we performed WES for the bulk
specimens composed of 20 - 30mutually adjacent crypts. However, this time,
mutations and copy number alterations (CNAs) with high VAFs were de-
tected only in UC-inflamed mucosa, suggesting that clonal crypt expansion
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occurred only in UC-derived mucosa. WES was also performed for 14 CACs.
The number of non-synonymous mutations (101/sample) in CAC were sig-
nifıcantly higher than that in UC-derived normal crypts (38/sample) and
recurrently involved known driver genes, such as TP53 (71%) and KRAS
(36%). CNAs were also more frequent in CAC than UC-derived, normal
crypts. In conclusion, our study revealed that somatic mutations accumu-
lated in normal mucosa of both UC and non-UC cases, but the mutational
burden increased in UC-inflamed mucosa. Chronic inflammation caused
clonal expansion of crypts even in histologically non-dysplastic mucosa in
UC case, accompanied by acquisition of driver mutations and CNAs, which
could trigger the development of CAC. Our fındings provide novel insights
into the carcinogenic sequence in UC-derived CAC.
#5755 In vitro reconstitution of high-grade serous ovarian carcinoma from
primary fallopian tube secretory epithelial cells.Kohei Nakamura,1 Kentaro Na-
kayama,1 TohruKiyono,2Noriyoshi Ishikawa,1 ToshikoMinamoto,1 Tomoka Ishi-
bashi,1 Kaori Sanuki,1 Hitomi Yamashita,1 Ruriko Ono,1 Kouji Iida,1 Hiroki
Sasamori,1 Razia Sultana,1MohammadMahmudHossain,1Masako Ishikawa,1 Sa-
toruKyo1. 1ShimaneUniversityFacultyofMedicine, Izumo, Japan; 2NationalCancer
Center Research Institute, Tsukiji, Chuo-ku, Japan.
Purpose: Recent studies suggest that fallopian tube secretory epithelial cells
(FTSECs) are potential cells-of-origin for high-grade serous ovarian carcinoma
(HGSOC). Several genetic alterations are involved in HGSOC carcinogenesis, but
the minimal requirement for tumor initiation remains unclear. Therefore, we
sought to identifyoncogenicmutations indispensable forHGSOCcarcinogenesis in
a stepwise model using immortalized FTSECs. Experimental Design: We estab-
lished an in vitro stepwise carcinogenesis model using immortalized FTSECs over-
expressing cyclin D1, CDK4R24C, and hTERT, and mimicked select genetic abnor-
malities identifıed as gene alterations essential for carcinogenesis, including p53,
c-Myc,orRAS/PI3Kpathwaymutations.Results:Ouranalyses revealed twodistinct
patterns of gene alterations essential for HGSOC carcinogenesis: p53/KRAS/AKT
andp53/KRAS/c-Myc.Dominant-negative p53 expression aloneor in combination
with oncogenic KRAS (KRASV12), constitutively active AKT (CA-AKT), or c-Myc
in immortalized cells failed to induce a tumorigenic phenotype; however, overex-
pression of either CA-AKT or c-Myc in combination with dominant-negative p53
andKRASV12 was suffıcient to confer tumorigenic potential. Importantly, all trans-
formed FTSECs formed tumors in xenograft mice, which were grossly, histologi-
cally, and immunohistochemically similar to human HGSOC. Interestingly, mice
harboring tumors with c-Myc amplifıcations displayed extensive metastases, con-
sistent with the increased dissemination observed in their human counterparts. C-
Myc is associated with cell proliferation in vitro; therefore, this genetic abnormality
maypromoteHGSOCprogression.Conclusions:Collectively, ourdata showed that
aberrant p53/KRASV12/c-Myc or p53/KRASV12/PI3K-AKT signaling is the mini-
mal requirement for FTSEC carcinogenesis. Moreover, the model generated with
this evidence will likely facilitate analysis of early events in HGSOC carcinogenesis.
#5756 Effects of Epstein-Barr virus latentmembrane protein 1 (LMP1) on
cell invasiveness and expression of endogenousmicroRNAs in human cells in
vitro. Bárbara Grasiele Müller-Coan,1 Ethel Cesarman,2 Deilson Elgui De Ol-
iveira1. 1Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil; 2Weill
Medical School at Cornell University, New York, NY.
Infection by the Epstein-Barr virus (EBV) is associated with a variety of hu-
man cancers, notably Burkitt lymphoma andnasopharyngeal carcinoma (NPC).
Most malignant cells within EBV-associated cancers are latently infected, and
some viral products expressed during the latent phase of the viral cycle have
well-described carcinogenicity, including the EBV latent membrane protein 1
(LMP1). Distinct viral genotypes described so far include the B95.8, the most
studied viral strain originally found in an elderly patient with transfusion-in-
duced infectious mononucleosis, and the M81 strain, isolated from a NPC case
from a Chinese patient. Compared to B95.8, the EBVM81 strain infects epithe-
lial cells more readily, and it is more likely to induce spontaneous viral lytic
reactivation. However, whether these EBV strains have distinct biological fea-
tures relevant for the progression of EBV-associated cancers remains to be elu-
cidated. Thus, this study aimed to evaluate whether the expression of B95.1 and
M81 variants of EBV LMP1 have different impact on cell migration and inva-
siveness of human cells lines in vitro, as well as on the expression of selected
endogenous microRNAs (miRs) that were previously reported to have a role on
cancer progression. Expression of EBV LMP1 was achieved in 293 and NP69
cells transfected with vectors encoding its B95.8 orM81 variants. In vitromigra-
tion and invasion rates were assessed by the scratchwound healing assay and the
Boyden chamber assay, respectively. The expression of 91 selected miRs were
evaluated by a customized qPCR-array approach. Cells expressing EBV LMP1
showed increased migration and invasion rates compared with mock-trans-
fected cells. However, the differences observed between B95.8 andM81 variants
did not achieve statistical signifıcance. Conversely, 293 cells expressing theM81
variant of LMP1 showed hyperexpression of human miRs 497-5p, 17-3p, and
34a-5p, compared toB95.8. The in silico target prediction for thesemiRs showed
enrichment of gene targets involved in the MAPK, NF-B, and PI3K/AKT in-
tracellular signaling pathways. This would reflect in negative regulation of cell
proliferation and cell motility/adhesion, as well as higher levels of apoptosis.
Based on these data, it is plausible to suggest that EBV LMP1 from M81 viral
strain is somewhat less effective in terms of carcinogenicity, and this might be a
reflect of the improved ability of EBV M81 to induce lytic viral infection com-
pared to the B95.8 strain, as previously reported. In conclusion, the results indi-
cate that cells expressing LMP1 from EBV isolates B95.8 and M81 showed dif-
ferences in terms of miR expression signatures, which ultimately might impact
the pathogenesis and progression of EBV-associated cancers.
#5757 Study of human mammary tumor virus (HMTV) in human breast
cancer by NanoString nCounter and FISH analysis. Stella M.Melana,1 Joseph
Tripodi,2 Digna Nosike,1 Jaffer Shabnam,2 Polly Etkind,1 Beatriz GT Pogo,1
James F.Holland1. 1TheTishCancer Institute. Icahn School ofMedicine atMount
Sinai, New York, NY; 2Department of Pathology. Icahn School of Medicine at
Mount Sinai, New York, NY.
HumanMammary Tumor Virus (HMTV), a retrovirus 90-98% homologous
to Mouse Mammary tumor Virus (MMTV), the etiological agent of murine
mammary cancer, has been detected by PCR in 40% of American women’s
breast cancers, but not in healthy tissues of the same breast (Cancer Research
1995, 55:5173-79; Clin. Cancer Research 2001, 7-283-4). A complete 9.9 kb
HMTV proviral sequence has been detected in breast cancer genomic DNA
(Cancer Res 2001,61:1754-9). HMTV viral particles with betaretrovirus charac-
teristics have been isolated from metastatic breast cancer cells in effusions
(MSSM cells). Expression of HMTV proteins has been detected in MSSM cells
by western blot, fluorescence-activated cell sorting analysis, and immunofluo-
rescence assays but not in normal mammary epithelial cells (J Virol Methods
2010, 163(1): 157-61). PCR is a sensitive technique susceptible of contamination,
which due to amplifıcation, could result in false positive detection. Although
murine DNA was not found by PCR, the possibility still exists that HMTV in
humanDNAcould be a result of laboratory contamination.Despite the substan-
tial evidence supporting the presence ofHMTV in breast cancer the controversy
continues because the chance of contamination has led to doubt that murine-
like viruses are human pathogens. We now report additional analyses of breast
cancer specimens employing other methods for HMTV detection that reinforce
previous fındings. NanoString nCounter, a new technology using specifıc 100
mer oligonucleotides as probes bound to reporter molecules that can detect
HMTV gag, env and LTR sequences as well as two murine specifıc probes in a
single reaction without amplifıcation. Flourescence in situ hybridization (FISH)
assays with a HMTV probe is a technology that permits visualization of HMTV
proviral DNA in the nuclei of surgical samples of breast cancer as well as in
MSSM cells. Results from Nanostring nCounter, and FISH analysis show the
presence of HMTV DNA in surgical cancer specimens and in MSSM cells. The
data exclude contamination and confırm the authenticity of HMTV in human
breast cancer. Next-generation sequencing and other studies are in progress to
determine the role of HMTV in the pathogenesis of breast carcinoma.
#5758 Elevated level of estrogen enhances chemotherapeutic effıcacy po-
tentially through epigenetic mechanism in human breast cancer cells. Yu-
Wei Chang, Kamaleshwar Singh. The Institute of Environmental and Human
Health, Lubbock, TX.
Effectiveness of chemotherapy depends on the age of breast cancer pa-
tients. Breast tissues are estrogen sensitive and the levels of ovarian estrogen
are age-dependent variable among the breast cancer patients. Whether this
variation in estrogen levels influences the chemotherapeutic effıcacy in
breast cancer patients is unclear. Therefore, the objective of this study was to
determine the effects of natural estrogen 17 beta-estradiol on the effıcacy of
chemotherapy in breast cancer cells. Estrogen responsive MCF-7 breast can-
cer cells were long-term exposed to 100 pg/ml estrogen for three months.
Using these estrogen exposed MCF-7 cells, the effıcacy of chemotherapeutic
drugs doxorubicin and cisplatin were determined. The result of cell viability
and cell cycle analysis revealed increased effıcacy of doxorubicin and cispla-
tin in estrogen-exposed MCF-7 cells as compared to control MCF-7 cells.
Gene expression analysis of marker genes for cell cycle, anti-apoptosis, DNA
repair, and drug transporter genes further confırmed the increased effıcacy
of chemotherapeutic drugs in estrogen-exposed cells at molecular level. To
further understand the role of epigenetic mechanism in enhanced chemo-
therapeutic effıcacy by estrogen, cells were pre-treated with epigenetic drugs,
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5-Aza-2-deoxycytidine and Trichostatin A before doxorubicin and cisplatin
treatments. The enhanced effıcacy of doxorubicin and cisplatin in estrogen-
treated cells was signifıcantly decreased by 5-aza-2 deoxycytidine pre-treat-
ment, suggesting the role of estrogen-induced hypermethylation in en-
hanced sensitivity of these drugs in estrogen-exposed cells. In conclusion,
results of this study demonstrate that sensitivity to chemotherapy depends
on the levels of estrogen in breast cancer cells. Findings of this study will have
clinical implications in selecting the type and dose of chemotherapy in breast
cancer patients depending on the serum estrogen levels that varies in be-
tween pre- and post-menopausal age of the patients.
#5759 Histopathologic patterns of nasopharyngeal malignancy in Lagos,
Nigeria and its association with Epstein-Barr virus (EBV): a 10-year retro-
spective study. Oladipo Omoseebi,1 Olakanmi Akinde,1 Omobolade Obad-
ofın,1 Nzechukwu Ikeri,1 Gabriel Ogun,2 Adekumbiola Banjo1. 1Lagos Univer-
sity Teaching Hospital, Lagos, Nigeria; 2University College Hospital, Ibadan,
Nigeria.
Background: Nasopharyngeal cancer (NPC) is a rare cancer worldwide. It is
now found to be increasing in incidence in Nigeria, though the incidence is
lower when compared to countries in the Mediterranean basin, North Africa
and Southeast Asia. NPC is frequently associatedwith Epstein-Barr virus (EBV),
but no previous study has been done in Lagos to document the association.
Objective: To determine the prevalence, histologic types and age distribution of
nasopharyngeal malignancy in Lagos University Teaching Hospital (LUTH)
and its association with EBV over a period of 10 years, between January 2003 to
December 2012. Materials and Methods: Slides and formalin-fıxed paraffın-
embedded (FFPE) tissue blocks, hospital request forms, referral cards, patients’
case notes and duplicate copies of histopathology reports of cases of histologi-
cally diagnosed nasopharyngeal malignancy in the Anatomic and Molecular
Pathology department of LUTH within the study period were retrieved. The
cases were reclassifıed into epithelial and non-epithelial malignancies. The epi-
thelial malignancies were reclassifıed according to WHO classifıcation. Immu-
nohistochemistry (IHC) for EBV latent membrane protein-1 (LMP-1) was car-
ried out on cases with viable FFPE to evaluate the prevalence of the virus in
Nasopharngeal malignancy. Results: A total of 75 histologically confırmed cases
of nasopharyngeal malignancy were seen during the study period, which con-
stituted 1.1% of the total cancer recorded in this center. There were 47 males
(63%) and 28 females (37%) with a male to female ratio of 1.7:1. The age ranged
from 3 to 75 years, mean age was 44.1 years, the peak age group was 40 -49 years
for males and 50 - 59 years for females. On histological classifıcation, undiffer-
entiated carcinoma (WHO type III) was the commonest (49.3%), differentiated
non-keratinizing squamous cell carcinoma, SCC (WHO type II) and keratiniz-
ing SCC (WHO type I) accounted for 24% and 9.3% respectively. Thus, NPC
accounted for 82.6%of the total cases of nasopharyngealmalignancy seen.Other
histological types seen were non-Hodgkin lymphoma (NHL) 13.3%, well differ-
entiated adenocarcinoma 2.7% and low grade mucoepidermoid carcinoma
1.3%. EBV LMP-1 IHC was positive in 30 (86%) out of the 35 cases studied.
These consisted of 14 undifferentiated carcinoma, 5 NHL, 2 adenocarcinoma,
7differentiated non-keratinizing SCC (WHO type II) and the 2 cases of keratin-
izing SCC (WHO type 1). Conclusion: Nasopharyngeal malignancy is not un-
common in this environment. It occurredmore frequently inmales than females
with the peak age of incidence at 5th decade of life, undifferentiated carcinoma
(WHO type III) is the commonest histologic type and it is highly associated with
EBV.
#5760 Identifying cell of origin for Group 3 medulloblastoma. Ran Tao,
Najiba Murad, Zhenhua Xu, Yanxin Pei. Children’s National Medical Center,
Washington, DC.
Medulloblastoma (MB) is the most common malignant pediatric brain tu-
mor. Although surgery, radiation and high-dose chemotherapy have led to in-
creased survival rates, many patients still die from their disease and those who
survive often suffer severe long-term side effects. Group 3 MB is the most ag-
gressive subtype ofMB,which is often resistant to therapy, and patients with this
tumor have an extremely poor prognosis. Thus, developing novel and more
effective therapeutic approaches is desperately needed for treating this disease.
Improved approaches are likely to come from a deeper understanding of the
molecular and cellular basis of the disease. Group 3MB is characterized by large
cell/anaplastic histology with a high proliferative index and is associated with
MYC amplifıcation or overexpression. Our previous studies suggest that MYC-
driven MB can be generated by infecting granule neuron progenitors (GNPs,
Math1) or neonatal cerebellar stem cells/progenitors (CD133) with viruses
encoding MYC and dominant negative p53 (DNp53) and transplanting these
cells into the cerebella of immunocompromised mice (NSG). Although this
model resembles Group 3MB in terms of histology and gene expression, it most
likely does not faithfully recapitulate humanMB becausemutation and deletion
of p53 are rarely detected in human Group 3 MB at diagnosis. This observation
prompted us to ask whether there might be a cell type in which the MYC onco-
gene alone is suffıcient to induce MB. Sox2 expression has been found in neural
stem cell/progenitor cells in cerebellum. Moreover, it has been reported that
70% human Group 3 MB express Sox2, and that its expression is correlated
with poor prognosis. Thus we hypothesize that Sox2-positive cells with MYC
overexpression can develop tumors. We FACS-sorted Sox2GFP-positive or
Sox2GFP-negative cells from Sox2-GFP mice at P5, infected these cells with MYC
virus and transplanted them into the cerebella of NSG mice. Animals (n10)
receiving Sox2-positive cells developed highly aggressive tumors and had to be
sacrifıced within 3-6 weeks. In contrast, only one of the animals (n10) that
received Sox2-negative cells developed a tumor at 8 weeks. These results suggest
that the MYC oncogene alone is suffıcient to induce tumorigenesis in Sox2-
positive cells, without requiring loss of p53. Further studies demonstrate that the
tumors that were generated from Sox2-positive cells resemble Group 3 MB at a
histological, immunohistochemical andmolecular level, indicating thatGroup 3
MB may originate from Sox2-positive cells during cerebellar development. We
will use this model to investigate the mechanisms that make these cells sensitive
to transformation. These studies will pave the way for the development of novel
approaches to treating this devastating tumor.
#5761 C-Fos drives non-tumorigenic head and neck squamous cell carci-
noma cells to tumorigenic by promoting cancer stem cells like properties.
Naoshad Muhammad, Sourav Bhattacharya, Robert Steele, Nancy Phillips,
Ratna B. Ray. Saint Louis University, Saint Louis, MO.
Purposes of the study: Head and neck squamous cell carcinoma (HNSCC) is
the sixth most widespread cancer and leading cause of cancer related death
world widely. Regardless of the advancement in treatment processes the overall
survival rate of patients having this cancer has not substantially improved in the
past few decades. Development of tumor and its progression exclusively resides
in a small population of cancer cells, termed as cancer stem cells (CSCs). This
population of cells can self-renew and re-form the ordered organization of tu-
mors. CSCs contribute toHNSCCandmay offer prominent therapeutic strategy
for the management of HNSCC. We previously observed that c-Fos was highly
up-regulated in the HNSCC sphere forming cells. In the present study, we ex-
plored the role of c-Fos in the tumor initiation in relation with cancer stemness
and EMT. Experimental procedures: We examined whether overexpression of
c-Fos has an effect on tumorigenicity and stemness. For this, c-Fos was overex-
pressed in non-tumorigenic HNSCC cell lines and tumor growth was investi-
gated. We also examined the expression of different CSC marker genes expres-
sion by Western blot analysis. Summary: Our results demonstrated that
exogenous expression of c-Fos in non-tumorigenicMDA1386Tu cellsmakes the
cells tumorigenic in nude mice. Mechanistic investigations showed that c-Fos
overexpression in MDA1386Tu cells enhanced epithelial-mesenchymal transi-
tion (EMT)/CSC properties and increased numbers of oralspheres when grown
in ultra-low binding plate. Conclusions: Collectively, our data strongly demon-
strate that c-Fos plays a critical role in the modulation of EMT and cancer stem
cell reprogramming in HNSCC cells and enhance tumor growth.
#5762 PR55-alpha associated PP2A promotes pancreatic tumorigenesis.
Ying Yan, Ashley L. Hein, Parthasarathy Seshacharyulu, Satyanarayana Racha-
gani, YuriM. Sheinin,MichelM.Ouellette,Moorthy P. Ponnusamy, SurinderK.
Batra. University of Nebraska Medical Center, Omaha, NE.
PP2A holoenzyme consists of a catalytic subunit, a scaffold subunit, and a
regulatory subunit. Loss of function analysis using PP2A catalytic inhibitors or
inhibition via tumor viral proteins suggest PP2A as a putative tumor suppressor.
However, PP2A has also been shown to facilitate the activation of oncogenic
signaling pathways when associated with specifıc regulatory subunits. In this
study, we investigated the possible oncogenic role of PP2A in pancreatic cancer.
We found a striking increase in the expression of PR55	, a PP2A regulatory
subunit, in pancreatic cancer cells compared to normal pancreatic epithelial
cells. Consistently, PR55	 expression was markedly elevated in pancreatic duc-
tal adenocarcinoma tissues compared to adjacent normal pancreatic tissues
(P0.0001) and correlated with poor survival of pancreatic cancer patients
(P0.0003). RNAi-mediated depletion of PR55	 in pancreatic cancer cells re-
sulted in diminished phosphorylation of both AKT and ERK1/2 and decreased
protein levels of -catenin. Accordingly, pancreatic cancer cells with reduced
PR55	 expression exhibited signifıcantly impaired properties of transforma-
tion, including attenuated cell growth, clonogenicity, mobility, and anchorage-
independent growth. Moreover, orthotopic implantation of PR55	-depleted
pancreatic cancer cells into nude mice showed a marked reduction in tumori-
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genicity (P0.001) and distant metastases. These results suggest that PR55	
promotes pancreatic cancer development by sustaining hyperactivity of multi-
ple oncogenic signaling pathways, including AKT, ERK and Wnt.
#5763 Investigating the carcinogenic potential of various types ofmineral
fıbers in the development ofmesothelioma.David Larson,Mika Tanji, Andrea
Napolitano, Sandra Pastorino,Michele Carbone,HainingYang.Univ. ofHawaii
Cancer Ctr., Honolulu, HI.
Malignant mesothelioma is a very aggressive tumor and has been linked to
occupational and environmental exposure to carcinogenic mineral fıbers
such as asbestos. It was discovered recently that individuals carrying germ-
line BAP1 mutations are predisposed to mesothelioma in presence of even
minimal exposure to carcinogenic mineral fıbers. Mesothelioma causes
about 3,200 deaths per year in the U.S. and over 40,000 deaths per year
worldwide. Most malignant mesothelioma studies have focused on carcino-
genesis due to occupational exposure to the six regulated industrial mineral
fıbers collectively called ‘asbestos’. Besides this family of six regulated asbes-
tos minerals, there are other non-regulated fıbers that possess physical and
chemical structures that are similar to industrial asbestos, and may also be
carcinogenic. However, many of those mineral fıbers are unknown for their
carcinogenesis. We conducted serious studies on this topic and established
in vitro and in vivo assays to help determine the carcinogenesis of various
types of mineral fıbers. We found that high mobility box 1 protein (HMGB1)
is a key initiator of asbestos-induced inflammation, which plays critical roles
in the development and growth of mesothelioma, and that HMGB1 may be a
good indicator for fıber carcinogenesis and a biomarker for fıbers exposure.
Moreover, we found that specifıc immune system changes that occur after
exposure to carcinogenic fıbers, which may be a useful tool to help interro-
gate the carcinogenic potential of mineral fıbers. In particular, the ability to
induce an M2 macrophage response appears related to the potent tumor-
inducing capacity of carcinogenic mineral fıbers.
#5764 Oncogenic role of GAEC1 and its potential modulation with p53 in
pathogenesis of colon cancer. Riajul Wahab, Farhadul Islam, Vinod Gopalan,
Alfred King-Yin Lam. Griffıth University, Southport, Gold Coast, Australia.
Introduction: GAEC1 (Gene amplifıed in esophageal cancer 1), is fre-
quently amplifıed and overexpressed in colon cancer tissues. In the present
study, we aimed to unveil the oncogenic potential of GAEC1 in carcinogen-
esis of colon cancer by studying the underlying cellular functions and mo-
lecular interactions by in vitro and in vivo experiments. Method: Transient
overexpression of GAEC1 with pcDNA3.1-GAEC1 and silencing with
GAEC1-siRNA was performed and several downstream assays were done
such as migration, clonogenic and apoptotic assay. Analysis of cell kinetics
was done using flow cytometry and cell counting kit-8 was used for cell
proliferation assay. Immunofluorescence and Western blot assay were used
to determine the expression of different target proteins. Co-immunoprecipi-
tation was used to confırm the protein-protein interaction. For xenotrans-
plantation the severely combined immunodefıcient (SCID) mice (4 groups, 6
in each group) were injected subcutaneously with GAEC1 shRNA and con-
trol shRNA transfected (stable) SW480 and SW48 colon cancer cells. Result:
The overexpression of GAEC1 increased cell proliferation, migration, re-
duced apoptosis in colon cancer cells. Also, these cells showed cell cycle
arrest at the synthetic phase, activation of Bcl-2, K-ras, pAKT proteins as well
as inhibition of p53, PUMA, p21 and BAX proteins. Conversely, knockdown
of GAEC1 reduced cell proliferation, migration, decreased the phosphory-
lation of AKT, and induced apoptosis, G2/M phase arrest and cleavage of
poly (ADP-ribose) polymerase (PARP). Co-immunoprecipitation revealed
GAEC1’s interaction with p53. In addition ectopic over expression and si-
lencing of GAEC1 lead to reciprocal effects of p53 protein expression. More-
over, knockdown of GAEC1 reduced the nuclear translocation of murine
double minute 2 protein (mdm2) indicating that GAEC1 is responsible for
the degradation of p53 through the direct interaction between mdm2-p53 in
nucleus. Furthermore, our in vivo data demonstrate that the loss of GAEC1
inhibits the tumor formation in xenograft model. Conclusion: Collectively
our study demonstrates that GAEC1 exhibits the oncogenic role in colon
cancer by reducing expression of p53 through protein-protein interaction
which leads to the inhibition of PUMA, p21, BAX, and activation of Bcl-2,
K-ras and pAKT protein expression.
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#5765 Noninvasive characterization of 3D morphology and pathophysi-
ology ofmulticellular tumor spheroids using optical coherence tomography.
YongyangHuang,1 ShunqiangWang,1 SarahKessel,2 IanRubinoff,1 Leo Li-Ying
Chan,2 Peter Li,2 Yaling Liu,1 Jean Qiu,2 Chao Zhou1. 1Lehigh University, Beth-
lehem, PA; 2Nexcelom Bioscience LLC, Lawrence, MA.
Screening of anti-cancer drug candidates follows a step-by-step testing pro-
cedure on different models, involving in vitro cell cultures, in vivo animal mod-
els and humans. Traditionally, in vitro 2D cell cultures are frequently used
to evaluate cytotoxic effects of drug candidates on tumors. Although simple and
effıcient, 2D tumor cultures do not accurately reflect drug responses in a 3D
environment, which hampers the use of these models for in vivo studies. Multi-
cellular tumor spheroids (MCTS), a 3Dmodel, have attractedmuch attention in
cancer research due to their physiological similarities with in vivo tumors, such
as their structures, oxygen and nutrient gradients, and drug resistances. There-
fore, they can serve as a more predictive model for the cancer drug discovery.
High-throughput screening (HTS) systems employing various imaging ap-
proaches, e.g. bright-fıeld microscopy, fluorescence microscopy or confocal mi-
croscopy, have been employed to perform routine imaging and analyses of struc-
tures and functions ofMCTSs. One drawback of the current HTS systems is that
they do not readily provide a 3D view of the entire MCTS, especially for large
spheroids (500m), due to limited imaging penetration, which hampers ac-
curate characterization of the spheroid volumetric changes. In this work, we
developed a new screening system to visualize the entire 3D structure of MCTS
in 96-well ultra-low attachment (ULA) round bottommicroplates using optical
coherence tomography (OCT), a high resolution and 3D imaging modality. We
showed that this imaging systemwas able to perform longitudinal tracking of 3D
structural changes, e.g. sizes, shapes and volumes, for individual MCTS. In par-
ticular, we demonstrated that spheroid volume measured based on 3D OCT
imaging data provided amore accurate and robust result as compared to volume
calculated based barely on the spheroid size (diameter). Furthermore, we dem-
onstrated that this system could perform non-invasive, label-free monitoring of
pathophysiological status of MCTS over time. The 3D distribution of a spher-
oid’s necrotic core could be assessed based on intrinsic optical contrast. This
OCT-based screening systemwould open up new opportunities for accurate 3D
characterization of morphological and pathophysiological features of MCTS,
and benefıt the development of the state-of-the-art 3D HTS system for cancer
drug discovery.
#5766 High-content microscopy-based screening of colorectal organoids.
Niklas T. Rindtorff,1 Johannes Betge,1 Jan Sauer,1 Thilo Miersch,1 Tianzuo
Zhan,1 Florian Heigwer,1 Claudia Scholl,1 Matthias Ebert,2 Bernd Fischer,1 Mi-
chael Boutros1. 1DKFZ Heidelberg, Heidelberg, Germany; 2University Hospital
Mannheim, Mannheim, Germany.
High-content screening of cells has become a widespread approach for cellu-
lar assays due to its capacity to capture complex biological processes. However,
conventional cell culture is limited with respect to cell and tissue architecture.
Organoids are a unique model system for the intact and diseased intestinal
epithelium. The 3Dmodel can be used for the functional study of cancer devel-
opment and, potentially, prospective therapeutic testing of drugs in patient de-
rived tumor organoids. Here, we present a high-content microscopy based
screening workflow to study organoid self-organization and growth with up to
single cell resolution. After seeding of organoid fragments in a basal membrane
extract, screening plates are incubated to allow for organoid formation. Subse-
quent treatment and incubation is followed by staining and imaging on a high-
throughput microscopy platform followed by automated image analysis using
open-source software. Profıling of both complete organoids and their individual
architecture enables the quantitative description of population and tissue heter-
ogeneity in the context of various perturbations. We generated four distinct
colon organoid lines frommice carrying mutations of APC and KRAS in differ-
ent combinations. These are profıled for differential phenotypic responses to a
library of1000 drug-like compounds. Also, thismethodology is used to screen
for clinically relevant differential treatment responses in patient derived tumor
and normal colon organoids. Hence, based on this work we are able to analyze
gene-drug interactions in early colon cancer development and drug response of
patient derived colorectal cancer organoids.
#5767 Ex vivo three-dimensional tumor growth assay: 3DX-TGA.Praveen
Nair,1 Dileep Nair,1 Kaede Hinata,1 Cyrus Mirsaidi,2 Junjie Wu,2 Yong Hu,2
Brett M. Hall1. 1Molecular Response, San Diego, CA; 2Bioduro, San Diego, CA.
With a 7% likelihood of regulatory approval, oncology drug registration fail-
ure rates lead all therapeutic areas. Further complicating the drug development
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process, preclinical oncology models poorly reflect tumor tissue biology and
produce a high level of false positive data. Yet, monocellular two-dimensional
(2D) tissue culture remains the preferred platform for most laboratory preclin-
ical studies. The popularity of 2D tissue culture was driven predominantly by
fast and dependable proliferation of human tumor cells rather than alignment to
the pathophysiology of human cancer. As a consequence of this artifıcial selec-
tion bias, many registered oncology drugs today are highly toxic with a propen-
sity to attack any dividing cell (i.e., non-targeted). Fortunately, recent advances
in genomics, metabolomics and immunology have aided in development of new
targeted agents,many ofwhich have achieved regulatory approval.Nevertheless,
rational drug combinations and identifıcation of clinically meaningful drug tar-
gets persist as major challenges in oncology, and each can be meaningfully ad-
dressed using more diverse and biologically relevant preclinical models. Ex vivo
tumor tissue transplant models, such as patient-derived xenografts (PDX) offer
greater model diversity andmore faithfully reflect patient tumor genetics. How-
ever, cost and scalability barriers tend to limit widespread and practical model
utility. In addition, there remains a strong selection bias for autocrine human
tumors that can quickly adapt to a cross-species mouse host. As a practical
alternative to PDX models, we established, serially propagated and molecularly
characterized 300 ex vivo 3D (3DX) models spanning 15 tumor indications.
Given patient tumor seeding success rates of over 95%, the 3DX-TGA model
enabled diverse pharmacologic evaluation for the vastmajority of cancer patient
models attempted. After achieving suffıcient tumor biomass, typically within 7
to 8 weeks, thirty-one drugs were screened for proliferation and viability end-
points over a three-log dose range. Resistance and sensitivity profıles mirrored
population-based response rates for indication-aligned FDA-registered drugs.
Taken together, the 3DX-TGA model represents a powerful preclinical ex vivo
model that: (1.) more faithfully recapitulates human tumor biology, (2.) can be
scaled at a fraction of time and cost compared to PDXmodels, and (3.) provide
a superior screening platform for novel drugs and drug-drug combinations.
#5768 Intrahepatic cholangiocarcinoma cells can be converted into func-
tional hepatocytes by inhibition of Wnt signaling pathway. Toshiaki Na-
kaoka,1 Yoshimasa Saito,1 Toshihide Muramatsu,1 Hidenori Ojima,2 Yae Ka-
nai,2 Yuko Sugiyama,2 Masaki Kimura,1 Takanori Kanai,2 Toshiro Sato,2
Hidetsugu Saito2. 1Keio University Faculty of Pharmacy, Tokyo, Japan; 2Keio
University School of Medicine, Tokyo, Japan.
Background and Aim: Intrahepatic cholangiocarcinoma (IHCC) is the sec-
ond most prevalent malignancy in the liver, and is one of the most aggressive
malignancies characterized by a poor prognosis. It is believed that IHCC is an
epithelial cell malignancy arising from cholangiocytes composing the intrahe-
patic bile ducts. However, patients with viral hepatitis develop IHCC, suggesting
that IHCC is derived from transformed hepatocytes. Indeed, recent studies have
revealed that IHCCcan arise fromNotch-mediated conversion of hepatocytes in
mice. The new 3D culture system called organoid culture has been developed,
which allows long-term expansion of Lgr5-positive stem cells. To clarify
whether IHCC cells harbor the potency of conversion into functional hepato-
cytes, we established organoids derived fromhuman IHCCand cultured them in
different culture conditions. Methods: We established organoids derived from
human IHCC and cultured these organoids with expansion medium (EM) con-
taining R-spondin 1. Conversion of IHCC cells into hepatocytes was conducted
by organoid culture with differentiation medium (DM) containing BMP7,
DAPT, FGF19 and dexamethasone. Results: Gene set enrichment analysis
(GSEA) showed that genes associated with hepatocyte differentiation signature
were signifıcantly enriched in IHCC organoids cultured with DM compared
with those cultured with EM. IHCC organoids cultured with DM induced up-
regulation of hepatocyte markers albumin, HNF4a and CYP3A4, and acquired
mature hepatocyte functions including albumin secretion, bile acid production
and increased CYP3A4 activity. Removal of R-spondin 1, a ligand of Wnt sig-
naling pathway, fromEMenhanced hepatocyte differentiation. IHCCorganoids
cultured with DM signifıcantly reduced the malignant potential in vitro and in
vivo compared with those cultured with EM. Further studies using thioacet-
amide (TAA)-induced IHCCmodelmice showed that TAA-induced inflamma-
tion in the liver promoted recruited macrophages to secrete Wnt3a. Conclu-
sions: These fındings indicated that IHCC cells can be converted into functional
hepatocytes by inhibition of Wnt signaling pathway. Activation of Wnt signal-
ing pathway by recruited macrophages may play a critical role in the malignant
transformation of hepatocytes into IHCC, which could be an important thera-
peutic target for IHCC.
#5769 Modeling the tumor invasion front using 3D fluidic tumoroid cul-
ture of cancer cells. KohMeng Aw Yong, Christopher Oliver, Megan Altemus,
Zhi Fen Wu, Sofıa Merajver. Univ. of Michigan, Ann Arbor, MI.
To realize the promise of precision medicine, it is important to integrate
phenotypic assessment of cell populations to genomic data. The analysis of in-
vading leader cells at the tumor invasion front is of interest as theymay be guided
by a targetable molecular phenotype. However, there is a lack of suitable plat-
forms on which to analyze the tumor invasion front. In this study, we have
designed and constructed a fluidic device for long-term (several days to weeks)
3-dimensional tumoroid culture of diverse cancer cells.Using this device,we can
recapitulate the tumor invasion front and at the same time quantify the invasive
potential of different breast cancer cell line models. Analyses of the tumor inva-
sion front indicated a region of higher proliferation and suggest that the leader
cells possess a different molecular phenotype from the tumoroid mass. Interest-
ingly, signifıcant heterogeneity among invading cells was still observed, suggest-
ing that there could be: 1) the presence of multiple subpopulations of invasive
cells, each with a different clonal genetic signature; and/or 2) reversible pheno-
typic switching occurring among invading cells due to phenotypic plasticity.
These results obtained using this innovative device highlight and present a
promising solution to the challenges developing adequate therapeutics account-
ing for tumor phenotypic heterogeneity. There is potential for the device for use
in personalized medicine at diagnosis, allowing for both the quantifıcation of
disease progression risk as well as the molecular characterization of the invasive
subpopulations from patient samples and their response to tailored therapies.
#5770 in vitro PDXmodels: 3D cultured patient-derived tumors for com-
pound evaluation. Sander Basten,1 Bram Herpers,1 Julia Schueler,2 Torsten
Giesemann,2 Leo S. Price1. 1OcellO B.V., Leiden, Netherlands; 2Charles River
Laboratories, Freiburg, Germany.
Background. Patient-derived xenograft (PDX) models in immune-compro-
mised mice allow propagation of and compound testing in human-derived tu-
mors in vivo. To expand the potential of these human-relevant PDXmodels, we
sought to develop 3D in vitro culture methods for PDX-derived tumor cells that
show in vivo-like growth characteristics, invasion and responses to therapeutics.
In combination with advanced 3D image analysis methods, we created a unique
high throughput in vitro PDX screening platform that not only allows effıcient
identifıcation of active and selective molecules but also enables selection of the
optimal PDX tumor models for subsequent validation of candidates in vivo.
Results. Each PDX model has its own unique growth characteristics. Hydrogel
and growth media composition were optimized to support growth of tumor
tissues in vitro from cells derived frombladder, stomach, breast, pancreas, colon
and lung cancer PDX tumors. Tumor tissues were cultured in a 384-well format
and used to test chemotherapeutics (e.g. 5-FU, doxorubicin, paclitaxel, cispla-
tin), small molecules (e.g. erlotinib, lapatinib, trametinib, everolimus), antibod-
ies (e.g. cetuximab, trastuzumab) and antibody-drug-conjugate (ADC, T-DM1)
dose ranges. Using OcellO’s 3D image analysis platform, Ominer, tumoroid
growth, cell proliferation, apoptosis, invasion, cell polarity, differentiation and
other aspects of cell and tissue architecture were analyzed and the effects of
compound exposure on tumoroids was determined. By performing feature
training based on reference compounds, we selected 10 morphological fea-
tures (out of more than 500) to generate a phenotypic signature that described
the unique phenotypic change induced by each compound. Different com-
pounds that target the same molecule were found to induce a similar morpho-
logical change whereas compounds with off-target effects could be discrimi-
nated. This approach enabled a high resolution evaluation and comparison of
compound activity in an automated manner. Conclusions. We established sev-
eral PDXmodel-derived 3D tumor cultures inwhich standard-of-care andnovel
therapeutic agents (small molecules, antibodies and ADCs) can effıciently be
screened, based on therapeutically relevant parameters and their changingmor-
phological profıle. This method enables both the in vitro selection of promising
compounds in a pre-clinically relevant setting and the selection of optimum
PDX tumor models for follow-up in vivo studies. This highly translational in
vitro-in vivo PDX pipeline is expected to reduce attrition and increase effıciency
in early drug-discovery.
#5772 Developing a patient derived 3D co-culture model of prostate or-
ganoids to examine biological mechanisms involved in prostate cancer dis-
parities. Joseph Marsili,1 Zachary Richards,2 Jason Garcia,2 Cindy Voisine,1
Larisa Nonn2. 1Northeastern Illinois University, Chicago, IL; 2University of Illi-
nois at Chicago, Chicago, IL.
The prostate is composed of a fıbro-muscular stromal and glandular epithelial
cells. Cross-talk between these cell populations is essential for normal prostate
development and is involved in carcinogenesis. In the past year, an estimated
220,800 new cases of prostate cancer (PCa) were diagnosed and 27,540 died of
PCa. PCa in African Americanmen occurs more frequently, develops at a much
earlier age, and is more aggressive and lethal compared to men of European
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descent. Both biological and socioeconomic factors likely contribute to this dis-
parity. There is currently a paucity of relevant preclinical models in which to
examine biological mechanisms in African American PCa. Patient-derived or-
ganoids are a recently developed in vitro preclinical model which facilitate ex-
amination of underlying mechanisms of disease etiology. However, current
models of epithelial organoid growth lack the prostate stroma. To address this
unmet need, we began development of a 3D organoid model that incorporated
both primary human prostatic epithelial (PrE) and stromal (PrS) cells to better
mimic the microenvironment of the organ. Prostate organoids were derived
from cells collected from radical prostatectomy tissues from patients (UIC IRBs:
2006-0679 (PI Behm), (2013-0341(PI Nonn). Mixtures of single PrE-derived
and single PrS-derived cells were seeded in 3D in matrigel. Bright-fıeld micros-
copy of live organoids and histological examination of fıxed organoids showed
that the addition of PrS cells to the culture altered the shape of the organoids
compared to the spherical phenotype observed in PrE only cultures. Immuno-
fluorescent analysis of the basal cell marker p63 showed increased epithelial
differentiation in the co-culture organoids. In summary, these data suggest that
inclusion of prostate stroma in co-culture organoid models influences prostatic
epithelial organoid development in vitro. Ongoing studies are focused on mo-
lecular analysis or organoid phenotypes and comparison of AA and EA-derived
organoids.
#5773 Automation and miniaturization of 3D tumor models for com-
pound screens. Michael Kowalski,1 Kayla Hill,2 Vipat Raksakulthai,2 Kristin
Prasauckas,2 Tara Jones-Roe1. 1Beckman Coulter, Indianapolis, IN; 2Molecular
Devices, Sunnyvale, CA.
Three-dimensional (3D) systems of cell culture can provide a more represen-
tative model of solid tumors and more physiologically relevant outputs from
drug screens than two-dimensional cell cultures. A diverse array of 3D models
have been used to investigate tumor physiology and susceptibility to chemother-
apeutics but all of thesemodels present challenges to establish andmanipulate at
the high throughputs required for screens. Cancer spheroids are large clusters of
cells formed in suspension to replicate the gradients of gases, nutrients, and
drugs seen by solid tumors. In contrast, Matrigel® or other hydrogel cultures are
often used to replicate native cellmorphology and polarity or to enable studies of
3D structure formation or cell migration. To overcome manual challenges and
improve reliability, we automated the plating, drug treatment, and analysis of
these 3D models. We were able to form consistent cancer spheroids in both
hanging drop and low attachment plates and used imaging and flow cytometry
to gain a more complete understanding of the cytotoxic drug response in this
model. Cells were also plated on top of and embedded within Matrigel and cell
growth and apoptosis induction was measured with standard and confocal im-
aging approaches. Both 3D models were miniaturized to 384-well format,
thereby enabling the throughput required for large-scale screens to identify
novel cancer treatments.
#5774 Effect of extrinsic and intrinsic solid stress on tumor spheroid
growth. Ludivine Guillaume, Annaick Desmaison, Bernard Ducommun, Valé-
rie Lobjois. Univ. of Toulouse, Toulouse, France.
Growth-induced intrinsic solid stress and adaptive response to extrinsic me-
chanical cues have been recognized as major hurdles to overcome in cancer
treatment and any approach that could signifıcantly modulate these parameters
would have an impact in improving therapies. An attracting in vitro model to
explore this issue is the Multicellular Tumor Spheroid, a 3D culture model re-
producing the non-vascularized microtumor environment, proliferation gradi-
ent and cellular interactions. To explore and assess spheroid growth-induced
solid stress, we couple biological approach to the application of mechanics and
modeling. We adapted a method, which consist in partial sectioning of the mi-
crotumor and measuring tissue relaxation parameters. Using this strategy, we
showed that cell proliferation induced the accumulation of intrinsic mechanical
constraint. To investigate the consequence of the accumulation of solid stress at
the cell scale, we analyzed 3D cellular organization within spheroids. Using 3D
light sheet microscopy (LSM) visualization on optically cleared spheroids com-
bined with 3D reconstruction and automatic algorithms, we were able to deter-
mine cell density, nuclear orientation and nuclear shape in whole 3D spheroids.
We found that stress accumulation is associated with an increase in cell density
and a regionalization of nuclei organization. We also explored the impact of
extrinsic stress in 3D culture condition under constraint. We found that me-
chanical constraint and cytoskeleton control nuclei orientation and using live
3D LSMmicroscopy we show that mechanical constraint induces an actin cyto-
skeleton-dependent prometaphase delay. We anticipate that this work will pro-
vide key information and parameters to improve our knowledge of the crosstalk
between mechanical parameters and tumor growth.
#5775 A unique 3D tissue-engineered human melanoma model combin-
ing lymphatic and blood microvasculature to study cancer cell dissemina-
tion. Jennifer Bourland, Julie Fradette, FrançoisA.Auger.Centre de recherche en
Organogénèse Expérimentale de l’Université Laval/LOEX, CRCHU de Québec-
Université Laval, Quebec, Quebec, Canada.
INTRODUCTION: Melanoma is amongst malignancies with constantly in-
creasing incidence in developed countries.One of the underlying causes of death
for patients diagnosed with melanoma is metastasis, which can spread through
lymphatic or blood vessels.Mechanisms controlling the dissemination paths are
poorly understood and relevantmodels for studyingmetastasis physiopathology
are often inadequate. To address this, we hypothesized that the human tumor
microenvironment can be mimicked in vitro by combining tissue-engineered
microvascularized skin and melanoma microtissues. METHODS: Tissue-engi-
neered skin was produced using primary dermal, epidermal and microvascular
endothelial cells by the self-assembly technique without any exogenous bioma-
terial. Tumor microtissues were produced using the hanging drop method. Six
melanoma cell lines were used originating from primary tumor sites (A375,
SK-MEL 28 and WM983a) and from metastatic sites (RPMI 7951, Malme 3M
and WM983b). Tumor development and growth were assessed by histology,
immunofluorescence and confocal microscopy, while cytokine secretion pro-
fıles were determined byELISA.WM983a andWM983bmodelswere treated for
11 days with vemurafenib. Response to treatment was assessed by counting the
ratio of tumor cells positive for Ki67, representative of the tumor proliferation.
RESULTS:We obtained a tissue-engineered skin displaying two distinct micro-
vascular networks: a VE-cadherin CD31 blood network, and a PDPN
LYVE-1 CD31 lymphatic network. Blood capillaries were thin and highly
connected whereas lymphatic capillaries were larger and presented a distinct
morphology.Histological analyses revealed tumormicrotissue integration at the
dermoepidermal junction within the reconstructed skin. The pro-lymphangio-
genic factor and tumor-secreted VEGF-C was detected in conditioned media
from themelanomamicrotissues (662 pg/ml). Furthermore, CCL21, a chemoat-
tractant known to be secreted by lymphatic endothelial cells, displayed secretion
levels that were 10-fold higher in microvascularized tissues compared to the
non-microvascularized skin (P 0.001). Both of these cytokines are involved in
the cross-talk between tumor cells and capillaries, and thus in tumor dissemina-
tion. The 3D melanoma model responded to vemurafenib with up to a 5-fold
decrease of tumor cell proliferation and a partial pigmentation of the tumor.
CONCLUSION: This unique 3D in vitro melanoma model mimics tumor mi-
croenvironment by combining blood and lymphatic capillaries with melanoma
microtissues in a reconstructed skin. Being responsive to treatment such as
vemurafenib, it represents a valuable tool for studyingmechanisms ofmetastasis
and drug response in a fully human cell andmatrixmicroenvironment, and thus
testing anti-metastatic compounds could better predict their safety and effıcacy.
#5776 Glioblastoma tumormodel to analyze themechanismsof resistance
to tyrosine kinase inhibitors. Sara Pedron,1 Gabrielle L.Wolter,1 Emily Chen,1
Jann N. Sarkaria,2 Brendan A. Harley1. 1University of Illinois at Urbana-Cham-
paign, Urbana, IL; 2Mayo Clinic, Rochester, MN.
The extracellularmatrix (ECM) is increasingly recognized as having a key role
in cancer development. We have developed a biomaterial tumor mimic that
recapitulates systematically the main characteristics and heterogeneities of gli-
oblastoma ECM. With the use of these 3D in vitro platforms we seek to under-
stand the key features thatmake this cancer so challenging to treat.We are using
this device in three different ways: (1) to further understand how particularities
of brain tumor ECM affect cancer cells and assist in the diagnostic of different
glioblastoma (GBM) tumor types, (2) provide newmodels for drug screening to
afford more personalized therapies and (3) study the mechanisms of resistance
to current therapies in order to identifymore effective combinatorial treatments
and new therapeutic targets. Hyaluronic acid (HA), is the main component of
the brain ECM and GBM is associated with aberrant HA secretion and overex-
pression of receptors associated withHA, such as CD44 and EGFR.We cultured
GBM patient-derived xenograft (PDX) cells within gelatin based hydrogels that
contained variable concentrations ofHA. Cell proliferation and gene expression
analyses demonstrate that biomimetic hydrogels support xenograft culture and
cells upregulate matrix remodeling genes and others related to tumor growth in
response to matrix biophysical properties. We also used these platforms to eval-
uate the mechanisms of cell resistance to tyrosine kinase inhibitors. For this
purpose, we fırst focused on the epidermal growth factor receptor (EGFR),
whichhas been identifıed as amolecular target and associatedwithworse clinical
outcomes. We characterized the 3D in vitro behavior of 3 PDX that represent
these EGFR variants: GBM10 (EGFR, wild type), GBM12 (EGFR) and GBM6
(EGFRvIII). We studied the relationship between the HA contained in the sur-
roundingmatrix and response of GBM cells to a tyrosine kinase inhibitor (TKI),
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erlotinib. Results indicate that while EGFR cells are sensitive to TKI in HA
hydrogels, HA seems to collaborate with EGFRvIII signaling to stir cell activity.
Immunoblots demonstrate that this enhanced cell activity is related to a signif-
icant increase in PDGFR concentration. Blockade of the CD44 receptor, in com-
bination with erlotinib treatment, does not affect phosphorylation rates of PI3K
or ERK, however, it leads to a signifıcant decrease of STAT3 phosphorylation.
This is translated into a lower tumor cell metabolic activity in HA matrices.
Finally, we show that, patient-derived xenograft cells resistant to erlotinib in
vivo (GBM10), become sensitive when CD44 is blocked in HA-containing ma-
trices, as demonstrated by a decrease of phosphorylated PI3K. In summary, we
highlight the importance of extracellular HA in EGFR inhibition effıciency. We
demonstrate that this biomaterial tumor model can be used as a valuable tool in
themechanistic studies of tumor development and prediction of tyrosine kinase
inhibitors effıcacy.
#5777 Translation of HPVmediated immortalization to cancer precision
medicine. Aleksandra Dakic, Nancy Palechor-Ceron, Ewa Krawczyk, Hang
Yuan, Frank Suprynowicz, Seema Agarwal, Richard Schlegel, Vera Simic,
Praathibha Sripadhan, Chen Chen, Jie Lu, Tung-Wei Hou, Sujata Choudhury,
Xuefeng Liu. Georgetown Univ. School of Medicine, Washington, DC.
The E6/E7 oncogenes of the high-risk HPVs are both necessary and suffıcient
to immortalize HFKs and their presence and expression is required for the con-
tinued proliferation of HPV-positive cervical cancer cells. We and others have
shown previously that hTERT induced by E6 and cytoskeleton alteration by E7
are critical. Both E6 and feeder cells activate telomerase, while both E7 and Rock
inhibitor (Y-27632) disrupt the actin cytoskeleton and inactivate Rho. Feeders
and Y-27632 to induce unlimited cell proliferation of human keratinocytes.
Unexpectedly, we observed that feeders and Y-27632 could be used to establish
both normal and tumor cell cultures fromnon-keratinocyte tissues. This culture
has been termed as “conditional reprogramming”, since CR cultures stop pro-
liferating or terminally differentiate after its removal, depending on culture con-
ditions. The Combination of CR and Organoids ( (Matrigel, air-liquid interface
(ALI)) cultures represents next generation human cancermodels and functional
diagnostics for cancer precision medicine as described in August 2015 in the
NCI precision medicine initiative and three nature review articles (Nat Rev
Cancer. 2015Dec; Nat RevGenet. 2015 Jul; Nat RevClinOncol. 2014Nov.). The
technique is relatively simple and has been reproduced in more than 50 labora-
tories (including an original and independent article in Science fromMassachu-
setts General Hospital) (Science. 2014, 346(6216):1480-6.). Importantly, the CR
technology can generate 2x106cells in a week from small biopsies, and can
generate cultures from cryopreserved tissue and small biopsies. We therefore
initiated studies to examine whether CR cultures reflected the biology and ge-
notype of the original tumor and whether cultures might be used to predict
clinical responses. Moreover, the epithelial cells can be propagated indefınitely
in vitro, yet retain the capacity to become fully differentiated when placed into
conditions that mimic their natural environment. Thus, the CR method signif-
icantly advances applications for regenerative medicine.
#5778 A three-dimensional RAFTTM co-culture as advanced model for
breast cancer drug discovery. Ying Nie, Krista L. Garner, Theresa D’Souza.
Lonza Walkersville Inc., Walkersville, MD.
High-throughput screening (HTS) using two-dimensional (2D) cell culture
models (2D HTS) is essential for rapid identifıcation of drug candidates from
chemical libraries. However, it often results in a large number of poorly qualifıed
leads that exert extra burden on the downstream, preclinical animal studies and
that cannot be translated into clinical success, because 2D culture cannot repre-
sent the complexity of the tumormicroenvironment in vivo. The progression of
tumors and their response to drugs in vivo are regulated by their interactions
with neighboring cells, and the natural gradients of nutrients, cytokines, wastes,
oxygen, which can be bettermimicked with three-dimensional (3D) cell-culture
models. We constructed a breast cancer model using the RAFTTM 3D Cell Cul-
ture System. The essential component of this system is a collagen matrix con-
densed to the physiologically-relevant collagen density by removing the major-
ity of the liquid from the collagen hydrogel with specialized absorbers. Our 3D
model is a co-culture of humanmammary fıbroblasts (HMFs), embedded in the
RAFTTM Collagen matrix, and the MCF7 human breast cancer epithelial cells,
overlaying on top of the matrix, to model the interaction of breast cancer cells
and stromal cells in vivo. As non-tumorous control, humanmammary epithelial
cells (nHMECs), isolated from normal breast tissue, were used to replaceMCF7
cells in such a co-culture. Amedium formulation combining fıbroblast medium
FGM2TM and mammary epithelial cell medium MEGMTM was optimized to
grow both cell types in the co-culture. The RAFTTM co-cultures were stained
with standard immunocytochemistry protocol to reveal the morphology of the
cells. After three days in culture, the HMFs, evenly interspersed in the matrix,
fully stretched out in the collagenmatrix, and the nHMECs grew to reach above
90% confluence on the collagen matrix. The cell proliferation in the co-culture
was quantifıed with the ViaLightTM Plus Cell Proliferation and Cytotoxicity
BioAssay, which measures cell viability with bioluminescent detection of cellu-
lar ATP. Based on this assay, the viabilities of the RAFTTM cultures of single cell
types, as well as those of the co-cultures, increased fromDay 1 to Day 3. Normal
HMECs proliferated much faster than MCF7 cells on the matrix. We demon-
strate here the feasibility of co-culturingHMFs andmammary epithelial cells, in
the RAFT
TM
System, as a 3D breast cancer model. The effıcacy of anti-cancer
drugs can be assessed bymeasuring the cell viability with the ViaLightTM Assay.
This 3D model can be used to bridge the gap between 2D HTS and preclinical
animal studies. It may provide physiologically-relevant data and better predic-
tion of the in vivo effıcacy and dosage of the drug candidates identifıed in HTS,
and reduce the burden of animal studies in breast cancer drug discovery.
#5779 Building a novel 3D hyaluronan-based tri-culture model of the
bone metastatic microenvironment for cancer studies. Lindsey K. Sablatura,1
Daniel A. Harrington,2Mary C. Farach-Carson2. 1Rice University, Houston, TX;
2University of Texas Health Science Center at Houston School of Dentistry, Hous-
ton, TX.
The high attrition rate of potential anti-cancer drugs entering clinical trials
predicates a need for more predictive pre-clinical model systems. Three-dimen-
sional (3D) culture systems provide cells a more physiological microenviron-
ment than traditional cell culture methods—including relevant extracellular
matrix (ECM) cues and cell-cell interactions—while allowing greater experi-
mental control and higher-throughput studies than animal models. Prevalent
cancers, including breast and prostate cancer,metastasize preferentially to bone,
where they become incurable. The bone marrow microenvironment is a com-
plex network of interacting bone homeostatic and hematopoietic niches that
contribute to osteotropic cancer homing, proliferation, and treatment resis-
tance. We created a 3D in vitro tri-culture model of the bone metastatic mi-
croenvironment to serve as a new platform to study the “trialogue” between
bone metastatic cancer, bone marrow stroma, and bone marrow endothelial
cells. This tool can be used to inform drug discovery and to combat treatment
resistance. Within the present study, the utility of peptide-functionalized hya-
luronan hydrogels for supporting the self-organization of 3D bone marrow mi-
crovascular networks was explored. Gel crosslinking density was varied to ex-
amine the effect ofmatrix porosity on cellmigration and organization over time.
Tubule length and diameter were quantifıed and the endothelial structures were
assessed for indicators of mature vasculature, including lumen formation, base-
ment membrane production, and the recruitment of supporting stromal cells.
Breast/prostate cancer cell growth, survival, and physical association with bone
marrow stromal and bone marrowmicrovascular endothelial cell networks was
examined in tri-culturemodels. Ongoing studies seek to identify and disrupt key
cell signaling pathways thatmediate cell-cell interaction andpromote cancer cell
proliferation and survival, providing new tools to combat bone metastatic dis-
ease.
#5780 3D ex-vivo assay platformusing primary lung cancer cells inmalig-
nant pleural effusions as predictor for clinical outcome of personalized che-
motherapy. Cheng-guang Wu,1 Francesca Chiovaro,2 Tamara Tanos,2 Alex
Soltermann,1 Sumeer Dhar2. 1University of Zurich, Zurich, Switzerland; 2In-
Sphero AG, Zurich, Switzerland.
Background: Despite advances in therapeutic programs to treat various can-
cer types, dismal overall response rates for several entities has posed dilemma for
oncologists and researchers alike. Therefore, there is an immense need in accel-
erating therapeutic programs towards clinical success in cancer patients. It is
well established that patients suffering from same cancer typemay respond very
differently to a given chemotherapeutic regimen. We propose the development
of a unique patient-derived 3D ex-vivo drug testing platform as a valid decision
making tool for 2nd or 3rd line treatment regimens. Materials and Methods: In
this ex-vivo platform freshly collectedmalignant pleural effusions from patients
were processed for cytological diagnosis on cell blocks, using respective im-
mune-histochemicalmarkers. Effusions were prepared for a 96 well based 3D ex
vivo assay format using the hanging drop method and a parallel 2D cell culture
format. Subsequently, we compared the original cell composition of the malig-
nant effusion with respective microtumors generated in the 3D format. Micro-
tumors were then fıxed, embedded in paraffın and processed like original cell
blocks. IHC including respective markers for tumour cells such as TTF1, CDX2
and oestrogen receptor and for non-tumour cellular fractions like calretinin,
CD45, andMPOwere processed. Results: The microtumors generated (ranging
from 300 to 500m) retained the native tumor morphology and cellular com-
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position, thereby presenting tumour microenvironment like conditions in this
ex vivo system. These cultures contain all cellular components of a malignant
effusion at the beginning. Next to cancer cells, mesothelial cells, lymphocytes
and granulocytes were main constituents. Cellular ratios were measured by
computerized image analysis. Both cell sediments and supernatants are amena-
ble to profıling strategies by next generation sequencing andmass spectrometry.
Conclusion: Our model presents an optimal condition to conduct chemosensi-
tivity/-resistance profıling in individual cancer patients using standard drug
combinations. Furthermore, we are currently developing an immune competent
3D model to access cancer cell interaction with surrounding immune cells. We
expect that original immune cells will be quenched out during culture, thus these
micro tumors can be supplemented with activated effectors in particular, T and
NK cells (autologous system) to investigate novel drug combination approaches
including immune-stimulating agents such as anti-PD-L1 antibodies.
#5781 Establishment of a 3D ex-vivo assay as a preclinical drug testing
platform for personalized cancer therapy. Sumeer Dhar,1 Francesca Chio-
varo,1 Tamara Tanos,1 Tomas Hejhal,1 Seife Heilemariam,1 Jens Kelm,1 Anja
Irmisch,2 Mitchell Levesque2. 1InSphero AG, Zurich, Switzerland; 2University of
Zurich, Zurich, Switzerland.
In vitro cell based drug testing tools have been widely used in drug discovery
and early development to evaluate novel drug entities for further evaluation in
preclinical in vivomodels. However, a poor correspondencewith in vivomodels
has compelled oncologists to pursue complementary in vitro strategies with
better outcomes. Within this realm, a 3D ex vivo platform is being extensively
used to evaluate the activity of cytotoxic drugs, targetedmolecules, and antibod-
ies. To increase the translational value of this model, maintenance of the tumor
microenvironment (immune and other stromal cells) is highly pertinent. We
have established a 3D ex vivo assay as a patient drug testing platform for per-
sonalized medicine therapies in collaboration with our clinical partners. In this
study we setup the protocols for obtaining single cell suspensions from biopsy
and/or tumor resection samples from patients presenting with Urothelial can-
cers, Renal cell carcinoma, Pancreatic, NSCLC, Ovarian, and Melanomas to
generate 3Dmicrotumors in 96 well format cultured over a period of 7-15 days.
Themicrotumors weremonitored for growth characteristics, biomarker pheno-
type and drug activity profıle. As expected the growth characteristics for each
tumor varied, corresponding very well with clinical disease progression. Subse-
quently, these microtumors were assessed using a standard clinical immunohis-
tochemistry diagnostics approach to evaluate disease specifıc biomarkers and
were compared to the clinical diagnostics profıle of the patients. The biomarker
profıle from 3D derived tumor samples showed concordance with the patient
diagnostics profıle. In the instances were clinical information and treatment
regimens were available, the microtumors were tested and followed with single
and pairwise drug treatments. The ex vivo 3D treatment outcome clearly re-
flected the clinical outcome. Currently, this platform is being used to develop 3D
ex vivo immune-competent models to study immunomodulatory therapies.
Based on the overall data we conclude that the 3D ex vivo assay system offers a
highly pertinent platform to perform chemosensitivity testing providing predic-
tive information on the clinical outcome, which enables oncologists to redefıne
individualized chemo/targeted treatments.
#5782 A novel method for high-throughput drug screening in 3D tumor
organoids. Nhan Phan, Jessica Huang, David Eisenberg, Sanaz Memarzadeh,
Alice Soragni. UCLA, Los Angeles, CA.
3D tumor organoids are pivotal tools to study tumor development, propaga-
tion and invasive properties (Tanner and Gottesman, 2015). They closely reca-
pitulate many characteristics of the tumor of origin in terms of structure, heter-
ogeneity, complexity and response to drug treatment. As such, they are
considered an accurate pre-clinical model for drug discovery and development
(Nyga et al, 2011; Tanner and Gottesman, 2015; Shroyer, 2016). Nevertheless,
reliable methods to perform high-throughput drug screenings using tumor or-
ganoids are limited and require extensive manipulation such as sample transfer
from plate to plate. In addition, thick 3D matrix supports may hinder drug
penetration. Here we introduce a robust method to generate, treat and assay 3D
tumor organoids in standard, uncoated 96- or 384-well plates. By plating cells
around the rim of the wells we generate an ultrathin layer ofMatrigel that allows
penetration of smallmolecules and bulkier peptide drugs.Media change is easily
performed from the center of the well without perturbing the organoids. After a
2-day treatment course, organoids are released by dispase treatment and assayed
in the same well by performing a CellTiter-Glo assay (Promega). The method
exhibits low plate-to-plate, experiment-to-experiment and operator-to-opera-
tor variability. In addition, it can be extended to patient-derived tumor or-
ganoids (PDTO) generated from primary tumors. We show how PDTO from
high-grade serous ovarian carcinoma (HGSOC) specimens are generated with a
success rate 95%. Given the low number of cells required and high assay
sensitivity, we can seed 200 wells from 1Mio cells derived from a tumor biopsy,
and test over 60 different drugs/concentrations in triplicates. Moreover, we
show how drug combination studies are feasible and allow assessing treatment
synergies. As an example, we combined a peptidic inhibitor of p53 aggregation,
ReACp53 (Soragni et al, 2016), with carboplatin in PDTO HGSOC established
from a panel of patients harboring different p53 mutations. Drug interaction
studies are performed across a range of ReACp53 and carboplatin concentra-
tions and cell viability assessed at day 2 is used to compute drug-response curves,
EC50 values and combination indexes. In conclusion, we are introducing an
inexpensive, robust, easily automatedmethod to performhigh-throughput drug
screenings in 3D organoids and PDTO and demonstrate its utility in determin-
ing drug sensitivities and optimizing multi-drug combinations in vitro.
#5783 In vitromodeling of patient derived bladder cancer cell lines in 3D
culture systems. May Elbanna,1 Sreenivasulu Chintala,1 Eric Ciamporcero,2
Remi Adelayie,1 Ashley Orillion,1 Sreevani Arisa,1 Nur Damayanti,1 Michelle
Grimard,1 TJ Puls,3 Sherry Harbin,3 Melissa Fishel,1 Roberto Pili1. 1Indiana
University School of Medicine, Indianapolis, IN; 2The Janssen Pharmaceutical
Companies of Johnson & Johnson, Antwerp, Belgium; 3Purdue University, West
Lafayette, IN.
Background: Drug screening is a key component for drug development and
optimizing anti-tumor therapies. Traditionally, in vitro drug testing has been
conducted inmonolayer systems that are not capable of recapitulating the tumor
complexity. Recently, the fıeld has witnessed the rise of interest in 3D culture
systems which are capable of reproducing tumor complexity while circumvent-
ing the cost associated with in vivo drug testing. Our access to fresh patient
samples has enabled us to establish a novel 3D culture system consisting of
bladder cancer patient derived cell lines. Using a wide range of matrices and
co-culture conditions with tumor associated stromal cells we were able to estab-
lish a unique high throughput drug testing tool. Methods:Matrigel and collagen
based matrices were used to establish 3D culture systems of bladder cancer
patient derived cells. Tumor cells were cultured in 3D conditions either alone or
in coculturewith tumor associated stromal cells. Response toCisplatin andPI3K
pathway targeted agents (i.e. LYLY3023414)was tested in both conditions.High
throughput imaging via ThermoArrayScanXTIwas used to assess the biological
behavior of spheroids as well as their response to therapies overtime. Confocal
microscopy was used to validate the biological mimicry of tumor derived spher-
oids to the original patient tumors. Integration of RNA-seq data from the pa-
tient-derived tumor cells with the biological behavior and therapeutic response
in 3D culture is ongoing for the purpose of characterizing the 3Dmodel Results:
In 3D culture conditions; bladder cancer derived cells were able to re-express
E-cadherin that was suppressed upon propagation inmonolayer. The re-expres-
sion of the epithelial marker (E-cadherin) observed in 3D accuratelymirrors the
original tumors; which are of epithelial origin. Phenotypic differences were ob-
served across different matrix conditions and also among different tumor de-
rived cells. Bladder 3D organoids of luminal origin were more sensitive to both
cisplatin and PI3K pathway inhibitors as compared to those of basal origin. This
drug response profıle was reminiscent of what we observed in vivo using patient
derived xenograft (PDX)models derived from the same tumors. The phenotypic
as well as the drug response variations observed in our 3D culture correlated
with variable gene expression profıles (luminal vs basal) that were detected in
our RNA-seq data. Conclusion: As compared to monolayer, 3D culture is more
capable of recapitulating tumor complexity and accurately reflects the drug re-
sistance / sensitivity profıles that are observed in PDXmodels in vivo. Therefore,
a 3D culture systemprovides an invaluable tool for high throughput screening of
drugs in bladder cancer and providing a better understanding of tumor biology
in the search of more effective treatments for bladder cancer patients.
#5785 Characterization of a novel microfluidic in vitro model of the
blood-tumor and blood-brain barrier. Jessica Griffıth, Tori Terrell-Hall,
Amanda Ammer, Paul Lockman.West Virginia University, Morgantown, WV.
Background: There is a need for a cost-effective and reliable in vitro model of
the blood-tumor barrier (BBB) and blood-brain barrier (BTB) for primary and
metastatic lesions in brain. Current models do not accurately recapitulate phys-
iological conditions and are unreliable with up to a 100-fold variance in predict-
ing drug permeability into brain tumors. Methods: Human umbilical vein en-
dothelial cells (HUVECs) were cultured with either CTX-TRD2 rat astrocytes
(BBB) or Met-1 murine breast cancer cells (BTB) in a microfluidic chip, which
contained chambers separated by a porous wall. Shear stress was induced on
HUVECs by perfusion of media through the apical chamber, and permeability
was characterized by the diffusion of fluorescent tracers, one of which is subject
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to P-gp efflux. Data was compared to in-vivo work. Results: Permeability of free
Texas Red was signifıcantly higher (p0.05) in BTB chips (kin 13.1  1.3 X
10-3) than in the BBB chips (Kin2.5  0.3 X 10-3). There was a similar trend
observed in largermarkers, but these were not signifıcantly different. Themove-
ment of Rhodamine 123 was also restricted, indicating functional P-gp efflux in
vitro, similar to data from published in vivo studies. In the BBBmodel, diffusion
ofRho123 increased 14-fold in the presence of verapamil (kin14.7 7.5X10-3)
and eight fold with the addition of Cyclosporine A (kin8.8 1.8 X 10-3). In the
BTB model, this increase was also observed, but to a lesser extent, as only 3 and
2-fold increases in permeability were observed, respectively. The magntidue of
permeability changes were not signifıcantly different from in-vivo models in
both passive diffusion and active efflux experiments. Conclusion: The novel
microfluidic chip is a cost-effective in vitro model which recapitulates the BTB
and BBB physiology and can predict permeability more reliably than current
in-vitro models.
#5786 Histopathology of patient derived organoids for the quantitative
analysis of response to microenvironmental perturbations. Sarah J. Choung,
Erin Spiller, Roy Lau, Shannon Mumenthaler. Lawrence J. Ellison Institute for
Transformative Medicine of USC, Los Angeles, CA.
Patient derived organoids are becoming a popular 3D in vitro model that
more accurately recapitulate in vivo conditions compared to standard 2D cul-
ture systems. Organoids consist of epithelial cells and lack stroma and mesen-
chyme, allowing cells of interest to be studied as an isolated system.However, the
tunability of the organoid model also permits the re-addition of microenviron-
mental factors, i.e. cancer associated fıbroblasts (CAFs), resulting in awide range
of experimental capabilities. Organoids are easily scalable, making them more
effıcient and cost-effective than traditional animal models. Despite the popular-
ity of animal models for pre-clinical drug testing, there still remain issues with
translating results fromanimal testing to patient outcomes; evenpatient-derived
xenograph models experience non-physiological mouse-human interactions.
Therefore, studying the impact of microenvironmental perturbations, such as
the presence of CAFs, or nutrient and drug gradients, on organoids may reduce
translational error. Using our biorepository of patient derived colon cancer (pri-
mary and liver metastases) organoids, we can observe changes in tumor archi-
tecture and cell growth or death, allowing us to more accurately assess the effı-
cacy of drug therapies and observe how interpatient heterogeneity impacts their
effıcacy. Here we focus on the histopathology of different patient derived or-
ganoids to quantitatively study cell growth or death under drug treatments (/-
CAFs) which could ultimately become a standard procedure for drug screening.
Here we investigate the effects of CAF co-culture in patient derived organoids in
response to standard chemotherapies such as Irinotecan and Oxaliplatin. Fol-
lowing treatment, the organoids are paraffın fıxed to retain their structural in-
tegrity, then sectioned. The samples are stained with H&E to show the tumor
architecture, and immunofluorescent antibodies (IF) to identify cells that are
proliferating (Ki67) or apoptotic (TUNEL). As a result, we are able to investigate
how tumor microenvironmental factors affect the tumor architecture of an in-
dividual patient tumor. We also examine the cytotoxic or cytostatic effects of
standard chemotherapies by quantitating the number of proliferative and apo-
ptotic cells, as well as their locationwithin the tumor, in response to the presence
of bothCAFs and therapy.Ultimately, we envision themethodoutlined herewill
further personalize medicine by allowing physicians to more rapidly assess an
individual patient’s response to therapy and adjust treatment accordingly. Ad-
ditionally, thismethod could prove to be amore inexpensive and fastermeans of
screening new drug compounds. By creating a system that more closely recapit-
ulates patient outcomes, we hope to move therapies towards faster approval
while still retaining results representative of in vivo outcomes.
#5787 Validation of spheroids with long-term incubation for high-
throughput screening. Jesse J. Parry, StevenM.Garner, Lee R. Cavedine, Alyssa
M. Cracchiolo, Brogan A. Epkins, Samantha C. Burkart, Timothy J. Sindelar,
Charles R. Wageman, Usha Warrior, Alastair J. King. Eurofıns Panlabs, Inc., St.
Charles, MO.
The OncoPanelTM service has established 100 genomically-characterized hu-
man tumor cell lines as targets for the screening of compounds in 3D spheroid
models. We sought to (1) expand the cell line capability of the service and (2)
validate the cell lines in a long-term (10-day) assay. For the cell line expansion,
cells were plated at two densities in 384-well, spheroid-promoting plates, and
were incubated for 3 days to allow formation of spheroids. The growth media
were then removed and replaced with media containing the hypoxia probe,
Lox-1. Twenty-four hours later, the ability to form spheroids was determined by
bright-fıeld, high-content imaging, and fluorescent detection of the Lox-1 probe
in the hypoxic core of the spheroids. Cells were then seeded in assay plates at
pre-determined densities, along with a time zero (T0) plate, and were incubated
for 4 days to allow spheroid formation. Spheroid formation was verifıed by
bright-fıeld, high-content imaging, as previously mentioned. The growthmedia
were removed and replaced with fresh media, followed by the addition of stau-
rosporine over a range of 10 concentrations, using acoustic liquid transfer. At
this time, the T0 plate was processed for subsequent doubling calculations. The
assay plates were incubated for 10 days, re-imaged, and the spheroids were lysed
using CellTiter-Glo® 3D viability reagent. Data were analyzed as the relative cell
count, where the measured bioluminescence intensity was transformed to per-
cent of control, as compared with a vehicle-treated control. Cellular response
parameters were calculated using nonlinear regression to a sigmoidal single-site
dose response model. A vehicle CV of30% was required, as one criterion, for
each cell line to pass quality control. Based on our tests of spheroid formation in
the expansion cell lines, we have added 36 cell lines to the spheroid- or loose
aggregate-forming cell line panel, with 20 cell lines validated in the long-term
assay. Through the use of high-throughput screening andhigh-content imaging,
we can verify and validate spheroid formation and growth in a 384-well format,
with which we can test agents for drug discovery projects and provide value for
potentially greater therapeutic outcomes.
#5788 Development of cellular morphology-based separation system for
three-dimensional culture. Hirofumi Matsui,1 Shinji Sugiura,2 Masato Ta-
mura,2 Toshiyuki Kanamori,2 Toshiyuki Takagi,2 Taku Satou,2 Ryuji Kato,3 Kei
Kanie,3 Mayu Shibuta3. 1University of Tsukuba, Tsukuba, Japan; 2National In-
stitute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan;
3Nagoya University, Nagoya, Japan.
The present study includes proof concept of morphology-based cell sepa-
ration and development of automatic cell separation system. 3D culture
environment with a specifıc extracellular matrix regulates cellular function
and phenotype. In addition, cancer cell morphology changes depending on
its malignancy in 3D culture environment. The cell separation system in 3D
culture environment should need to obtain the cells according to its mor-
phology, which includes cell phenotypes. Recently, we developed gelatin-
based photodegradable hydrogels, and applied this hydrogels to optical cell
separation. The target cells in the photodegradable hydrogels were success-
fully separated by the optical cell separation, the separated cells was growth
on another dish. On the other hand, we recently developed the predication
model of stem cell differentiation by image analysis. The image analysis
technique and the photodegradable gelatin hydrogels are included in the
automated morphology-based cell separation system in the 3D culture envi-
ronment. For forming cell encapsulated-photodegradable hydrogels, sus-
pension of cells including heterogeneous population is mixed with pregel
solutions and cells are encapsulated in the gelatin-based photodegradable
hydrogels. After the culture in 3D environment, microscopic images of the
cells are captured. The captured images are analyzed to distinguish the target
cells from the other cells by using the image analysis algorithm, which we
previously developed for analyzing stem cells. The hydrogels around the
target area is irradiated with light (365nm). The cells in the irradiated area
are collected by automated pipetting system. We developed automated sys-
tem for this optical cell separation procedure, including cultivation, image
acquisition, image analysis, light irradiation, and pipetting for cell collec-
tion. We demonstrated automated optical cell separation using the model
culture system. Normal gastric mucosal cells were cultured in the photode-
gradable hydrogels. After cultivation for 1 week, the cells were irradiated the
light for 5 to 20 min. The cells in the irradiated area were collected by
automated pipetting and transferred into a collection dish. The collected
cells were viable and attached in the collection dish after collection. We are
currently developing an automated image analysis algorithm to distinguish
cancer cells from normal cells under 3D environment. The automated opti-
cal cell separation systemwith image analysis algorithmwill be applied to the
establishment of novel cancer-cell lines from clinical samples such as biopsy
tissue.
#5789 Characterization of mixed-cell spheroid as an in vitro model of
hepatocellular carcinoma for epithelial-to-mesenchymal transition and
chemoresistance. Hyo-Jeong Kuh, Iftikhar Ali Khawar. The Catholic Univ. of
Korea, Seoul, Republic of Korea.
Interaction between cancer cells and stromal components in the tumor mi-
croenvironment is well known for their signifıcant roles in tumor progression
and subsequent treatment failure. Hepatic stellate cells (HSCs), as a predomi-
nant cell type in the microenvironment of hepatocellular carcinoma (HCC), are
involved in creating desmoplastic and chemoresistance-inducing microenvi-
ronment. HSCs secrete various paracrine factors that modify the HCC tumor
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microenvironment leading to tumor growth, drug resistance and metastasis via
promoting epithelial-to-mesenchymal transition (EMT). Although several
studies using 2D co-culture system have shown bidirectional cross-talk between
cancer cells and HSCs, data obtained remain limited in their clinical relevance
due to lack of in vivo tumor-like characteristics. We developed a mixed-cell
spheroidmodel which recapitulates direct 3D tumor-HSCs interactions in para-
crine and contact-mediated manners. Huh-7, human HCC cells, were mixed
co-cultured with LX-2 cells, immortalized human HSC at 1:3 ratio using liquid
overlay technique in 96-well plates. Electron microscopy was used to examine
subcellular structural changes. Cellular distribution within spheroids was ob-
served by labeling LX-2 cells with fluorescent tracer. The expression of pro-
fıbrotic and EMTmarkers was detected by immunohistochemistry or immuno-
fluorescence staining on paraffın embedded sections. Invasion ability was
determined usingmigration assay into 3Dmatrigelmatrix.Dose-response curve
was obtained by using APH assay and Ki-67 detection. Mixed co-culture of
Huh-7 and LX-2 cells showed a spontaneous self-organization forming highly
compact mixed-cell spheroids with well-defıned contour. Heterotypic cell-to-
cell contact increased as shown by gap junction and desmosomes in the mixed-
cell spheroids. LX-2 cells were uniformly distributed within the spheroids. Ex-
pression of fıbroblast-associated factors such as 	-SMA, collagen I, TGF- and
CTGF showed similar patterns of distribution to that of LX-2 cells, but at an
elevated level in the mixed-cell spheroids compared to that of cancer cell-alone
spheroids. An increased expression of EMT-related factors was observed along
with enhanced invasion into 3Dmatrix. Differential drug sensitivity was shown;
mixed-cell spheroids were sensitive to sorafenib but not to other agents includ-
ing oxaliplatin, gemcitabine, and 5-FU. Based on these results, the mixed cell-
spheroids of HCC cells-HSCsmay be proposed as a useful 3Dmodel for in vitro
therapeutic screening of targets and agents as well as for the study of malignant
progression in HCC.
#5790 Assessing the effects of TIMP2 knockout on lung cancer cell lines
cultured in 3D. David Peeney. NCI, Bethesda, MD.
Tissue inhibitor of matrix metalloproteinases (TIMPs) are a small family
of endogenous proteins that classically function to inhibit metalloproteinase
activity. Since the original description of this protein family in the 80s and
90s, various MMP-independent biological functions of TIMPs have been
described. This built the impression that MMP/TIMP ratios may play an
important role in tissue homeostasis, an idea which is supported by the
observation that altered MMP/TIMP expression ratios are often associated
with a number of human conditions such as cancer, cardiovascular and CNS
disease. TIMP2 is the most abundantly expressed protein in this family and
has previously been shown to interact with several membrane proteins in-
cluding MT1-MMP, insulin-like growth factor-1 receptor (IGF-I-R) and
alpha3 beta1 integrin (	31) to mediate downstream intracellular signaling.
In addition, TIMP2 has been shown to inhibit growth factor stimulated
proliferation, angiogenesis and tumor cell invasion and metastasis, high-
lighting the potential for TIMP2-based cancer bio-therapies that can be used
in conjunction with conventional treatments. Recent studies in our lab high-
light that syngeneic lung tumors (LL2 cells; Lewis lung carcinoma) devel-
oped in C57BL mice harboring a loss-of-function mutation in TIMP2 are
signifıcantly larger than tumors grown in their WT counterparts. To gain a
deeper understanding of the role of TIMP2 in tumor initiation and progres-
sion we have used CRISPR-Cas9 to develop stable TIMP2 knockout (T2KO)
human lung cancer cell lines. Although indistinguishable in 2D culture,
T2KO tumor cells display a morphologically distinct phenotype when grown
in spheroids. Preliminary data show that, when grown in spheroids, T2KO
cells exhibit enhanced EGFR activation in comparison to WT cells. By as-
sessing the functional characteristics and gene expression of T2KO cells
grown in 3D culture conditions we hope to gain further insight into the
biological functions of TIMP2 and to provide a mechanistic link between the
loss of TIMP2 activity and enhanced tumor formation that is observed in our
mouse model.
#5791 3D tissue engineering bladder model for cancer invasion study.
Cassandra Ringuette Goulet, Geneviève Bernard, Stéphane Chabaud, Frédéric
Pouliot, Stéphane Bolduc. Université Laval, Quebec, Quebec, Canada.
INTRODUCTION: Our understanding of the biological processes in-
volved in bladder cancer (BCa) is greatly limited by the models currently
available. In fact, the combination of in vitro and in vivo models of BCa has
failed to elucidate all the fundamental aspects of the disease. The eighth most
commonly diagnosed cancer in Western societies, BCa has become a grow-
ing public health concern, and more realistic models are needed to reveal the
mechanisms involved in tumor initiation and progression. METHODS:
Bladder substitutes have been constructed by tissue engineering with healthy
human fıbroblasts and urothelial cells, using the self-assembly method.
Meanwhile, spheroids have been produced from non-invasive (RT4) and
invasive (T24) BCa cell lines expressing DsRed fluorescent protein. The in-
vasive potential of these spheroids was characterized in a type-I collagen gel
(2.5mg/mL). Then, the spheroids were implanted on the surface of bladder
substitutes, after which their development was followed by fluorescence mi-
croscopy. RESULTS: Both of the cancer cell lines used were able to form
compact spheroids and grow on bladder equivalents. The invasive behaviour
of spheroids varied depending on the nature of the cells used. The non-
invasive RT4 cell line was unable to cross the basal lamina whereas the
invasive T24 cell line was able to do so. CONCLUSION: The establishment of
such a model for studying cancer biology in a physiological environment will
help bridge the gap between overly simple cell culture models and more
complex transgenic mice models. This new model offers a unique opportu-
nity to study separately the players involved in the development of BCa and
thus represents a powerful tool for the mechanistic analysis of this complex
pathology.
#5792 Development of cell line derived organoids to evaluate stroma tar-
geted therapies in pancreatic cancer. Bradley Hall,1 Bindu Santhamma,2 An-
drew Cannon,1 Rakesh Bhatia,1 Sushil Kumar,1 Chandrakanth Are,1 Hareesh
Nair,2 KlausNickisch,2 Surinder Batra1. 1University of NebraskaMedical Center,
Omaha, NE; 2Evestra, Inc, San Antonio, TX.
Background:Most solid tumors have extensive stroma that not only facilitates
the tumor progression but also impedes the delivery of the chemotherapeutic
agents. Due to lack of any in-vitro system, presently it is diffıcult to evaluate any
stroma-targeted therapies. Therefore, we developed an organoid system using
labeled pancreatic cancer and stellate cell lines. Methods: Murine (FC 1295 and
imPSCc-2) cell lines cultured in different combinations were grown as an or-
ganoid systemusingmatrigel. The organoids, starting day fourwere treatedwith
either gemcitabine or EC359, a novel mifepristone derived steroidal cytotoxic
agent that targets tumor stroma, or both in combination. qRT-PCR analysis of
activated stroma signature genes was performed on the mRNA isolated from
different treatment groups. H&E, immunohistochemistry, and western blot
analysis were performed to further validate our fındings. Results: Histologically,
these cell line derived organoids develop ductal structures surrounded by fıbro-
blast as seen in the pancreatic tumors. Immunohistochemistry demonstrated
alpha-SMA staining of imPSCc-2 while FC 1295 cells were stained positive for
CK19 and Na/K-ATPase. Gemcitabine treatment of the organoids resulted in
98% relative reduction in GFP fluorescence while EC359 decreased the fluores-
cence by 46% as compared to control. qRT-PCR demonstrated signifıcant re-
duction (p0.01) in the expression of activated stroma associated genes such as
COL1A1, POSTN, SPARC, COL3A1, COL5A2 and THBS2. However, there was
a signifıcant increase in the expression of COL10A1, suggesting the differential
regulation of stroma associated genes to stroma-targeted therapies. Further,
western blot analysis demonstrated that EC359 reduced the expression ofmark-
ers of activated stroma including alpha-SMA, and vimentin. Conclusions: Our
novel cell line derived organoid model can be utilized for fast, and inexpensive
evaluation of stroma-targeted therapies. Also, our study demonstrates that gem-
citabine and a novelmifepristone-derivative can be used as combination therapy
to simultaneously target cancer cells and associated stroma for the treatment of
pancreatic cancer.
#5793 Comparison of EMT biomarker expression in 2D monolayer and
3D spheroid cultures in a prostate cancer cell model. Jen Carlstrom, Jeanine
M. Hinterneder, Lindsay Nelson, Stephen Hurt. PerkinElmer, Hopkinton, MA.
The purpose of this study was to examine the induction of epithelial to mes-
enchymal transition (EMT) in a prostate cancer cell line by measuring classical
biomarker expression in three-dimensional (3D) spheroid cultures compared to
traditional 2D monolayers in an effort to develop a more biologically relevant
assay. Using Ultra-Low Attachment (ULA) microplates, we grew spheroids
from a human prostate cancer cell line (DU 145). Numerous studies have im-
plicated a role for EMT in carcinoma invasion and metastasis. EMT is charac-
terized by rearrangement of the extracellular matrix (ECM) and differential
regulation of ECMproteins.We induced EMTusing TGF-beta and phorbol-12-
myristate-13-acetate (PMA) and compared expression levels of specifıc bio-
markers, such as E-cadherin, fıbronectin, and IL-6, using AlphaLISA and
LANCE (TR-FRET) assay technologies.We confırmed that treatment ofDU145
cells with TGF-beta is suffıcient for inducing changes in both EMT biomarker
expression and characteristic cellular morphology in monolayer cultures. How-
ever, in 3D spheroid cultures, we observed only a partial EMT response to the
same TGF-beta treatment as demonstrated by changes in the expected bio-
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marker expression pattern. Using the small molecule, PMA, we see signifıcant
differences in the levels of IL-6 secretion after EMT induction between cells
grown in monolayer and those grown in spheroids. Cellular proliferation,
growth and vitality were assessed using ATPlite luminescence assays and con-
focal microscopy of live-stained cells with a high content imaging system.
Though we observe increased proliferation in monolayer cultures compared to
3D spheroids, the changes observed in protein expression patterns cannot be
suffıciently explained by differences in cell number or viability. These data illus-
trate the differences in protein expression levels and in cellular tolerance for
compound treatment between a humanprostate cancer cell line grown inmono-
layers and those same cells grown in 3D spheroids.
TUMOR BIOLOGY: Effects of Tumor-Microenvironment Cross-
talk on Metastasis
#5794 TrkB-mediated signaling contributes to malignant phenotypes of
gallbladder cancer. Makoto Kawamoto, Hideya Onishi, Keigo Ozono, Akio
Yamasaki, Akira Imaizumi, Masafumi Nakamura.Kyushu University, Fukuoka,
Japan.
Background: Brain derived neurotrophic factor (BDNF)/ Tropomyosin-re-
lated kinase B (TrkB) signaling has been shown to be associated with aggressive
phenotype in some cancers.However, the contribution of BDNF/TrkB signaling
to gallbladder cancer (GBC), one of refractory malignancies, still remains un-
clear. This study aims to analyze the biological signifıcance of BDNF/TrkB sig-
naling in GBC. Methods: 1) Clinical experiment: 69 patients with primary GBC
who underwent curative surgical resection were enrolled in this study. We in-
vestigated TrkB expression by immunohistochemistry and analyzed the corre-
lation between TrkB expression and clinicopathological fındings. 2) In vitro
experiment: BDNF/TrkB signalingwas inhibited using k252a or siRNA, andwas
activated by recombinant humanBDNF (rhBDNF). Then, whether BDNF/TrkB
signaling contributes to the biological function was estimated by proliferation
assay and Matrigel invasion assay, using TrkB-expressing 5 GBC cell lines
(NOZ, TGBC2TKB, GBd15, TYGBK-1, TYGBK-8). Furthermore, we deter-
mined the mechanisms of invasion in terms of epithelial mesenchymal transi-
tion (EMT) and matrix metalloproteinases (MMPs). We also examined the re-
lationship between TrkB expression and the level of vascular endothelial growth
factors (VEGFs) and hypoxia-inducible factor-1	 (HIF-1	) in GBC. 3) In vivo
experiment: Tumorigenesis and tumor growth of TrkB siRNA-transfected GBC
cells were analyzed, using xenograft mice model. Results: 1) Clinical results;
TrkB expressionwas detected in 63 (91.3%)GBC specimens. TrkB expression in
the invasive front correlated with T factor (p0.0391) and clinical staging
(p0.0391). Overall survival was lower in patients with high TrkB expression in
the invasive front than in thosewith lowTrkB expression (p0.0363). 2) In vitro
results; Proliferation was unaffected by rhBDNF treatment; however, K252a
treatment and TrkB siRNA transfection decreased proliferation. rhBDNF treat-
ment increased invasiveness by inducing EMT and activating MMP-2/MMP-9,
whereas K252a treatment abrogated these effects. TrkB or BDNF siRNA trans-
fection suppressed invasiveness. TrkB siRNA transfection decreased HIF-1	,
VEGF-A, and VEGF-C/-D expressions. 3) In vivo results; TrkB siRNA transfec-
tion decreased tumorigenicity and tumor growth in NOZ and TYGBK-1. Con-
clusion: These fındings demonstrate that TrkB-mediated signaling contributes
to the induction of malignant phenotypes (proliferation, invasiveness, angio-
genesis, lymphangiogenesis, and tumorigenesis) in GBC.
#5795 Loss of CDCP1 in patient prostate cancer metastasis leads to un-
coupling of beta-1 integrin from its cytoplasmic signaling through FAK. Sara
G. Pollan,1 Fangjin Huang,1 Joshua M. Lang,2 Jamie M. Sperger,2 Kavita Shah,3
Beatrice S. Knudsen1. 1Cedars-Sinai Medical Center, Los Angeles, CA; 2Univer-
sity of Wisconsin, Madison, WI; 3Purdue University College of Science, West
Lafayette, IN.
The Cub-Domain Containing Protein - 1, CDCP1, is a transmembrane gly-
coprotein, which is able to sequester Src and PKC
 into unique microdomains
within the plasma membrane. CDCP1 can either promote or suppress tumor
metastasis, dependent on the cancer type and experimental system.How the loss
of CDCP1 leads to tumor metastasis is not well understood. We demonstrated
for the fırst time in patients with prostate cancer (PCA), a signifıcant reduction
of CDCP1 expression in circulating cancer cells (CTC) and tumor metastasis
relative to primary tumors and concordant analytical results. To investigate how
the loss of CDCP1 facilitates PCA metastasis, we determined the consequences
of CDCP1 loss in non-adherent cancer cells, which provide an experimental
model system of CTCs. In this system, CDCP1 silenced cells exhibit 3-fold
higher proliferation, 4-fold greater anchorage independent growth with colo-
nies exceeding 5 microns in diameter, and a 2-fold reduction in migration abil-
ity. In 10% human plasma, these cells up-regulate p-FAK, p-SRC, p-AKT and
p-MAPK expression, and at the same time loose expression of activated 1-
integrin. The loss of inside-out activation of1-integrin occurs through preven-
tion of TALIN phosphorylation. Upon loss of CDCP1, Talin is no longer phos-
phorylated by CDK5 and this causes the disassembly of the 1 integrin - Talin
complex. In addition, 1-integrin dissociates from CDK5 and from the CDK5-
regulatory subunit, p35, but remains bound to p-FAK.We determined the path-
way by which the loss of CDCP1 arrests CDK5 kinase activity. Upon loss of
CDCP1, SRC phosphorylates p35. This generates a binding site for the C2 do-
main of PKC
 and phosphorylation of CDK5-T77 by PKC
. The subsequent
dissociation of the regulatory subunit abolishes the activity of CDK5. We show
that both SRC inhibition and silencing of PKC
 reestablish the inside-out acti-
vation of 1-integrin. Altogether we discovered a newmechanism of regulation
of CDK5 in prostate cancer cells, which leads to the uncoupling of 1-integrin
and FAK. The potential biological and clinical consequences of this mechanism
are (1) a switch from cell-matrix to cell-cell adhesion, (2) increased sensitivity of
CTCs to FAK inhibitors and (3) improved adaptation and survival of cancer cells
in the circulation and at the metastatic sites.
#5796 Heparan sulfate proteoglycans mediate tumor cell invasion and
metastasis. Henry Qazi,1 Zhong-Dong Shi,2 Jonathan W. Song,3 Limary M.
Cancel,1 Lance L. Munn,4 John M. Tarbell1. 1The City College of The City Uni-
versity of New York, New York, NY; 2Sloan-Kettering Institute, New York, NY;
3The Ohio State University, Columbus, OH; 4Edwin L. Steele Laboratory for Tu-
mor Biology, Massachusetts General Hospital, Charlestown, MA.
The surface proteoglycan/glycoprotein layer (glycocalyx) on tumor cells has
been associated with cellular functions that can potentially enable invasion and
metastasis. In addition, aggressive tumor cells with high metastatic potential
have enhanced invasion rates in response to interstitial flow stimuli in vitro. Our
previous studies suggest that heparan sulfate (HS) in the glycocalyx plays an
important role in this flowmediatedmechanostransduction and upregulation of
invasive and metastatic potential. In this study, highly metastatic renal cell car-
cinoma cells were genetically modifıed to suppress HS production by knocking
down its synthetic enzyme NDST1. Using modifıed Boyden chamber and mi-
crofluidic assays, we show that flow-enhanced invasion is suppressed in HS
defıcient cells. To assess the ability of these cells to metastasize in vivo, parental
or knockdown cells expressing fluorescence reporters were injected into kidney
capsules in SCID mice. Histological analysis confırmed that there was a large
reduction (95%) in metastasis to distant organs by tumors formed from the
NDST1 knockdown cells compared to control cells with intact HS. The ability of
these cells to invade surrounding tissue was also impaired. The substantial inhi-
bition of metastasis and invasion upon reduction of HS suggests an active role
for the tumor cell glycocalyx in tumor progression.
#5797 Semaphorin 5Apreserves epithelial phenotype in pancreatic cancer
cells by regulating cross-talk between Wnt and TGF- signaling. Sugandha
Saxena,1 Abhilasha Purohit,2 Surinder K. Batra,1 Rakesh K. Singh1. 1Univ. of
Nebraska Medical Ctr., Omaha, NE; 2The Wistar Institute, Philadelphia, PA.
Pancreatic cancer (PC) is one of the deadliest forms of cancers. In spite of
recent advances, minimal progress has been made in our understanding of PC
progression, metastasis, and treatment of PC patients with advanced disease.
Striking similarity between the process of cancer metastasis and guidance of
neuronal cells to their target sites has generated interest in pharmacologically
targeting guidance cue molecules for treatment of metastasis. Among the guid-
ance cue family members, Semaphorin5A (SEMA5A), was found to be involved
in organ-specifıc homing during PCmetastasis.With an interest to delineate the
function of SEMA5A in PC, we generated SEMA5A knockdown in metastatic
PC cell lines. Knock down of SEMA5A expression resulted in loss of cellular
differentiation and epithelial phenotype with higher motility as compared to
vector control cells. This observation is in accordance with our previous fınding
that SEMA5A expression was higher in well-differentiated tumors in compari-
son with undifferentiated pancreatic tumors. Loss of SEMA5A increased
TGF-2 production, decreased expression of E-cadherin, and nuclear translo-
cation of -catenin. Furthermore, we observed higher Wnt activity and in-
creased expression of the transcription factor SNAIL in SEMA5A knockdown
cells in comparison with vector control cells. Higher Wnt signaling along with
increased TGF-2 production explains the loss of differentiation and epithelial
markers. Moreover, we observed that non canonical TGF-2/AKT mediated
inhibition of GSK3- is responsible for increased stability of -catenin and
SNAIL, thereby activating Wnt signaling in SEMA5A knockdown cells. Our
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observations demonstrate that SEMA5A has a potential role in maintaining the
epithelial phenotype in PC cells by keeping cross-talk betweenWnt and TGF-
signaling under check.
#5798 Exosomal oncogenic proteins promote tumor progression, metas-
tasis and chemoresistance in ovarian cancer. Kalpana Deepa Priya Dorayap-
pan, Ross A. Wanner, Roman A. Zingarelli, Uksha Saini, Selvendiran Karup-
paiyah, David E. Cohn. The Ohio State University, Columbus, OH.
Introduction: Ovarian cancer is the most lethal gynecological malignancy.
Despite its clinical signifıcance, the factors that regulate the development and
tumor progression and metastasis are among the least understood of all major
human malignancies. In this study we show that the oncogenic proteins which
are specifıcally packed in the cargo of the exosomes released from the ovarian
cancer cells play a role in tumor progression, metastasis and chemo-resistance.
Methods: The exosomes were isolated using Exo-quick solution from different
primary ovarian cancer cells (POCC),HGSOC cell lines, normal ovarian epithe-
lial cells (OSE) and patient ascites. Further quantifıed by NTA and morpholog-
ically characterized by TEM, their purity was validated by the presence of exo-
some specifıc markers and absence of golgi matrix protein. Protein profıling in
exosomes was done using Capillary LCMS/MS analysis. Proteomic data sets
were analyzed by (http://www.qiagen.com/ingenuity) Ingenuity Pathway Anal-
ysis (IPA) to gain biological insight in disease mechanisms, associated to the
observed expression changes. Cell proliferation assay and cell migration assay
were carried out in normal and ovarian cancer cell lines with and without exo-
some co-culture. STAT3 and Hepatocyte growth factor (HGF) expression in
exosomes and Matrix metalloproteinases (MMPs) in different cell lines were
analyzed using Western Blotting. Also in-vivo studies were carried out using
orthotopic tumor model in mice. In addition cisplatin accumulation studies
were done using ICP-MS. Results: The exosome concentration from POCC and
HGSOC cells was much higher (2-10 fold times) than from the OSE cells. Ex-
pression of CD9, CD63, TSG101 and EpCAM confırmed the exosomes. HGF,
Complement factor H (CFH) and Lysyl oxidase- 2 (LOXL2) were selected from
the top 25 proteins identifıed by IPA based on their expression ratio and disease
relevance. IPA scored STAT3 as the top regulator effect network and further-
more HGFwas activated in our data set. The expression of activated STAT3 and
HGF were confırmed in the exosomes from HGSOC cells and patient ascites.
Cell proliferation and migration was signifıcantly increased with concurrent
increased expression of MMP-2 and -9 in- vitro favoring the role of exosomal
oncogenic proteins in tumor progression andmetastasis as evidenced in in-vivo
orthotopic tumor mice. The decrease in cisplatin accumulation in OVCAR8
cells observed,when co-culturedwith exosomes fromCisplatin resistant cell line
suggests its role in chemo-resistance as well. In addition, blocking exosome
function inhibits cell proliferation and increases the cytotoxicity to cisplatin.
Conclusion: The results conclude that tumor exosomes carry a unique set of
highly elevated oncogenic proteins that play a very important role in mediating
tumor progression and metastasis while inducing chemo-resistance as well and
are evident from our in-vitro and in-vitro studies.
#5799 Targeting CX3CR1 impairs the reseeding of cancer cells recirculat-
ing frommetastatic tumors.ChenQian,1 AsurayyaWorrede-Mahdi,1 Raman-
preet Kaur,1 Fei Shen,2 Joseph Salvino,1 Olimpia Meucci,1 Alessandro Fatatis1.
1Drexel University, Philadelphia, PA; 2University of pennylvania, Philadelphia,
PA.
Cancer cells re-enter systemic blood from established metastatic tumors.
Recent evidence indicates that these recirculating cancer cells further seed
and colonize skeleton and soft tissues to expand metastatic dissemination,
thus precipitating the clinical progression to terminal disease. We have pre-
viously shown that the chemokine receptor CX3CR1 is implicated in the
metastatic seeding of breast cancer cells and that novel small-molecule an-
tagonists for this receptor effectively contains the number and size of sec-
ondary tumors in animal models. Using the samemodels, we now report that
targeting CX3CR1 also restrains the re-seeding of skeleton and soft-tissue by
circulating cancer cells (CTCs) departing from existing metastatic lesions.
Notably, we also found that CTCs unable to re-seed are forced to remain in
the blood circulation longer, eventually succumbing to apoptotic death. It
has been proposed that when either spontaneously or forcibly (re)circulating
in the blood, cancer cells from solid tumors are more vulnerable to the effects
of both cytotoxic and targeted therapeutics. Given the role of CX3CR1 an-
tagonists in prolonging the time spent by CTCs in the blood, we sought to
assess whether these compounds could synergize with docetaxel by extend-
ing bioavailability and its cytotoxic effects. Thus, we tested this paradigm on
CTCs departing from skeletal and soft-tissue lesions generated by breast and
prostate cancer cells in mice. Based on the results obtained from these ex-
periments, it can be concluded that implementing the development of
CX3CR1 antagonists and promoting their clinical use will provide novel and
effective tools to contain the progression of metastatic disease in cancer
patients.
#5800 Epidermal growth factor-induced ANGPTL4 enhances anoikis re-
sistance and tumor metastasis in head and neck squamous cell carcinoma.
Yu-Han Liaong. National Cheng Kung University, Tainan, Taiwan.
Epidermal growth factor (EGF) is important for cancer cell proliferation,
angiogenesis and metastasis in many types of cancer. However, the mecha-
nisms involved in EGF-induced head and neck squamous cell carcinoma
(HNSCC) metastasis remain largely unknown. In this study, we reveal that
angiopoietin-like 4 (ANGPTL4) plays an important role in the regulation of
EGF-induced cancer metastasis. We showed that EGF-induced ANGPTL4
expression promoted anoikis resistance and cancer cell migration and inva-
sion in head and neck squamous cell carcinoma (HNSCC). In addition,
depletion of ANGPTL4 inhibited EGF-induced cancer cell invasion. Auto-
crine production of EGF-induced ANGPTL4 regulated the expression of
MMPs. The induction of MMP-1 gene expression by ANGPTL4-activated
integrin 1 signaling occurred through the AP-1 binding site in the MMP-1
gene promoter. Furthermore, down-regulation of MMP-1 impeded EGF-
and recombinant ANGPTL4-enhanced HNSCC cell migration and invasion.
Depletion of ANGPTL4 signifıcantly blocked EGF-primed anoikis resistance
and extravasation. Moreover, depletion of ANGPTL4 signifıcantly blocked
EGF-primed metastatic seeding of tumor cells and MMP-1 expression in
lungs. However, no effect of ANGPTL4 on tumor growth was observed.
These results suggest that EGF-induced expression and autocrine produc-
tion of ANGPTL4 enhances HNSCC metastasis via the up-regulation of
MMP-1 expression. Inhibition of ANGPTL4 expression may be a potential
strategy for the treatment of EGFR-mediated HNSCC metastasis.
#5801 Loss of core 11,3-galactosyltransferase (C1GALT1) in pancreatic
cancer leads to altered mucin glycosylation and increased tumor aggressive-
ness. Seema Chugh,1 Satyanarayana Rachagani,1 Xinheng Yu,2 Sriram
Neelamegham,2 Lijun Xia,3 Michel M. Ouellette,4 Moorthy P. Ponnusamy,1 Su-
rinder K. Batra1. 1University of Nebraska Medical Center, Nebraska, NE; 2State
University of New York, NY; 3University of Oklahoma Health Sciences Center,
OK; 4Internal Medicine Division of Gastroenterology-Hepatology, NE.
Background: Aberrant expression of mucins underlie pancreatic cancer (PC)
progression and metastasis. Mucin-type O-glycosylation is the principal post-
translational modifıcation on mucins and is regulated by myriad of glycosyl-
transferases. Not much has been investigated about the specifıc glycosyltrans-
ferases involved in increased PC aggressiveness. We found that core 1 1,3-
galactosyltransferase (C1GALT1), which is essential for O-glycosylation, is not
expressed in some of the PC patients. C1GALT1 adds galactose in O-glycosyla-
tion pathway that forms core 1 structure, which is usually elongated to several
carbohydrate structures. Loss of C1GALT1 is accompanied by incomplete O-
glycosylation that results in increased expression of truncated carbohydrate an-
tigens (Tn and sTn). Increased expression of these truncated carbohydrate an-
tigens on mucins has been associated with augmented aggressiveness in several
malignancies. Based on these results, we hypothesized that loss of C1GALT1 in
PC patients is associated with altered mucin O-glycosylation and increased ag-
gressiveness. Methods: Expression of C1GALT1 was examined in HPNE (hu-
man pancreatic nestin expressing cells) and oncogenic transformedHPNE cells.
To understand the role of C1GALT1 in PC, CRISPR/Cas9mediated knockout of
CIGALT1 was performed in PC cells. Impact of C1GALT1 knockout on glyco-
sylation profıle and mucin glycosylation was evaluated using lectin blotting and
lectin-pull down assay. Wound-healing assay was performed to examine the
effect of C1GALT1 knockout onmigration. To gainmechanistic insight, protein
expression of signalingmolecules involved in growth andmotility was evaluated
using western blotting. Orthotopic implantation of C1GALT1 knockout cells
was carried in pancreas of nude mice to study its role in tumor growth and
metastasis. KPC mouse model (KrasG12D; Trp53R172H/; Pdx-1- Cre) of PC
progression was crossed with C1galt1 floxed mice (resulted in KPCC mice) to
study the involvement of C1galt1 in disease progression and metastasis in vivo.
Results: Oncogenic transformed HPNE cells showed decreased expression of
C1GALT1 as compared to untransformed HPNE cells. Knockout of C1GALT1
in PC cells resulted in increased expression of truncated carbohydrate antigens
(Tn and sTn). Further, knockout cells displayed increased cellular protrusions,
which was associated with signifıcantly increased migration. Western blotting
demonstrated increased expression of proteins involved in growth andmotility.
Lectin-pull down assay revealed altered MUC16 glycosylation in C1GALT1
knockout cells. In vivo studies using orthotopic implantation and KPCCmouse
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model demonstrated increased tumor weight and metastasis with knockout of
C1GALT1.Conclusion:Overall, our results indicate that loss of C1GALT1 in PC
is associated with altered MUC16 glycosylation and increased PC aggressive-
ness.
#5802 Role of mesenchymal stem cells in acquisition of metaplasia in
AKU-BC42 breast metaplastic carcinoma cell line.Nazia Riaz,1 Sadia Habib,2
Azhar Hussain,2 El-Nasir Lalani2. 1Centre for Regenerative Medicine and De-
partment of Surgery, Aga Khan University, Karachi, Pakistan; 2Centre for Regen-
erative Medicine, Aga Khan University, Karachi, Pakistan.
Introduction: Metaplastic carcinoma (MCa) is a rare and aggressive sub-
type of invasive breast carcinoma exhibiting epithelial to mesenchymal tran-
sition (EMT) where tumor of epithelial origin manifests differentiation into
non-glandular, mesenchymal phenotypes such as spindloid, chondroid or
osseous components. Acquisition of EMT is associated with low expression
of e-cadherin, claudins and high expression of vimentin. Biological mecha-
nisms for acquisition of metaplastic components within MCa are not well
understood. The present study was undertaken to establish and characterize
a cell line from a patient diagnosed with MCa and to evaluate the role of
mesenchymal stem cells (MSC) in attainment of metaplastic phenotype.
Methodology: AKU-BC-42 was established from a 65 years old Pakistani
female patient diagnosed with T4N1M0 MCa. Specimen was procured and
processed under sterile conditions and cultured in DMEM supplemented
with 10% FBS. Epitheloid colonies were visualized after 3 weeks of culture,
which were passaged and propagated. AKU-BC-42 was phenotypically and
genotypically characterized using karyotyping, gene expression analysis, im-
munocytochemistry and florescent insitu hybridization. MSC marker ex-
pression was assessed by flow-cytometry. AKU-BC-42 was cultured under
appropriate conditions for assessment of differentiation along osteogenic,
adipogenic and chondrogenic pathways. Lineage differentiation was evalu-
ated by special immunohistochemical stains and induction of lineage differ-
entiation genes was assessed by Q-PCR. Results: AKU-BC-42 was found to
have a human karyotype with multiploidy and population doubling time of
60 hours. Gene expression profıling revealed negative expression for estro-
gen and progesterone receptors and positive expression of androgen recep-
tor (AR) and HER-2/neu. FISH analysis was negative for HER-2/neu ampli-
fıcation. Basal (5, 14 & 19) and luminal cytokeratins (8 & 18) were expressed
at mRNA level along with myoepithelial markers (CD10, S100A7, p-cad-
herin, desmin, S100A4, S100A2 & á-SMA). AKU-BC-42 demonstrated MSC
pool with expression of CD73 (79.2%), CD90 (10.3%) and CD105 (30.2%) as
revealed by flow-cytometry. Osteogenic differentiation was assessed by von
kossa stain for mineralization with up-regulation of ALPL and OPN genes.
Similarly, differentiation of AKU-BC-42 into mature adipocytes was evalu-
ated with Oil red O staining of lipid droplets and expression of FABP4 gene.
Chondrogenic induction was achieved by performing pellet cultures. Colla-
gen synthesis in extracellular matrix of chondrogenic beads was assessed by
mason trichrome staining with up-regulation of ACAN, COL10A1 and
COMP. Conclusions: We report a novel MCa cell line containing a MSC
pool. MSC pool withinMCamay be responsible for acquisition of metaplasia
in this rare subtype of breast cancer. Further studies on this cell line may
reveal the biological mechanisms of MCa of the breast.
#5803 Role of Neuropilin 2 in osteoclasts promoting prostate cancer bone
metastasis.Navatha shree Polavaram, Arup Bag, Sohini Roy, Samikshan Dutta,
Kaustubh Datta. University of Nebraska at Medical Center, Omaha, NE.
Background: Bone metastasis is one of the major clinical concerns that
causes skeletal related malignancies and increased mortality. Bone is one of
the preferred sites for metastatic prostate cancer. The tumor cells interact
with bone cells (osteoblasts and osteoclasts) resulting in an imbalance in the
bone homeostasis causing metastatic bone disease. Unlike other cancers, the
bone maturation promoted by metastatic prostate cancer (PCa) leads to
increased osteoblastic activity resulting in osteoblastic bone lesions. How-
ever, bone resorption promoted by PCa cells precedes bone production lead-
ing to release of growth factors that aid PCa cells to develop into an overt
metastasis. Our preliminary data indicated a non-tyrosine kinase receptor
Neuropilin 2 (NRP2) is expressed in osteoclasts (OC) induced by PCa cells.
The objective of our current study is to study the role of NRP2 in PCa-
induced OCs. We hypothesize that PCa-induced NRP2 expression in OC is
necessary for low osteolytic activity and that it negatively regulates the OCs
leading to PCa bone metastasis. Methods: Mouse OC precursors were iso-
lated from bone marrow of C57BL/6 mice and differentiated into OCs under
conditions of RANKL and M-CSF and in conditioned medium (CM) col-
lected from PCa cell line LNCaP C4-2B (promotes high osteoblastic and low
osteoclastic activity) and PC3 (predominantly osteoclastic activity) to mimic
the conditions in normal bone and PCa bone metastasis. NRP2 expression at
protein and mRNA was evaluated. TRAP staining and activity were con-
ducted to confırm the differentiation of OCs. Results & Discussion: We
observed that NRP2 was expressed in OCs induced under standard condi-
tions and in PC3 and C4-2B CM. TRAP staining and activity confırmed the
differentiation of OCs under these conditions. Interestingly, depletion of
NRP2 and treatment either in standard conditions or C4-2B CM exhibited a
drastic increase in osteoclastogenesis. However, NRP2-depleted OC precur-
sors when treated with PC3 CM showed no change in osteoclastogenesis.
These fındings advocate a role of NRP2 in inhibiting osteoclastic activity in
PCa bone metastasis and osteolytic PCa evades NRP2 inhibition. Protein
analysis of the time course of NRP2 in OC in PC3 CM and C4-2B CM showed
a differential NRP2 expression. This difference in the NRP2 levels can be
impacted at either transcription or post-translational level. No change was
observed in the NRP2 expression at transcriptional level in both the condi-
tions suggesting that this difference can be due to either translation or rapid
degradation of NRP2. Using in-vitro and transgenic mice, we will examine
how PC3 CM-induced OCs escapes the inhibition of NRP2. We will also
determine whether NRP2 expression regulates the transcription of genes
involved in OC differentiation and activation. Together, this approach will
elucidate the role of NRP2 axis on OCs in promoting PCa-induced bone
metastasis and will aid in determining whether NRP2 axis can be a therapeu-
tic target.
#5804 Heterogeneity in androgen receptor and IL-1beta expression by
prostate cancer cells in skeletal metastases. Asurayya A. Worrede-Mahdi,1
Melisa Diaz,2 Alessandro Fatatis1. 1Drexel University College of Medicine, Phil-
adelphia, PA; 2Drexel University, Philadelphia, PA.
Bone metastases are a prevalent complication of advanced prostate cancer
(PCa). The current standard of care for advanced PCa patients is androgen
deprivation therapy (ADT), which fails within approximately two years and
patients progress to castration resistant prostate cancer (CRPC). CRPC presents
with additional metastasis in soft tissues and is incurable.We have found that in
PCa patients, bone metastases have heterogeneous Androgen Receptor (AR)
expression, and that cells lacking AR are the only PCa cell type that secretes the
cytokine Interleukin-1 beta (IL-1). Furthermore, pre-clinical work in our lab
has revealed the role for IL-1 in promoting bone colonization by AR PCa
cells and generation of heterogeneous skeletal metastases. A signifıcant barrier
to studying tumorheterogeneity in PCametastasis has been the lack of an animal
model to study the interaction between multiple PCa phenotypes in the bone
microenvironment. By engrafting a suspension containing both AR andAR
cells directly into the left cardiac ventricle of mice, our lab has developed an in
vivo model that allows us to study the progression of both AR and AR cells
in skeletal and soft tissue metastases. AR and AR cells were genetically en-
gineered to express two different Luciferase constructs (630 nmRed-shifted Luc
and 540 nm Luc2 respectively) thereby allowing the progression of AR and
AR cells to be independently tracked and quantifıed. We used this model in
combination with histological and radiographic analyses to assimilate the path-
ological features of our in vivo mixed AR/AR metastases to the human
clinical scenario. Finally, we used castrated mice to determine whether IL-1
secreting PCa cells could support the growth and survival of IL-1–/AR cells
in androgen deprived conditions. Co-injection of AR (PC3-ML) and AR
cells (LNCaP, VCaP, and 22Rv1) leads to increased establishment of soft tissue
metastases as compared to injecting AR cells alone. Unlike the metastases
generated by PC3-ML cells alone, which show exclusively osteolytic activity,
AR/AR mixed metastases are both osteosclerotic and osteolytic, thereby
recapitulating clinical pathology. Finally, preliminary results suggest that co-
injection with IL-1-secreting AR cells enables the growth of androgen-de-
pendent AR cells in castrated mice. This animal model of metastasis hetero-
geneity recapitulates human pathology and enables further interrogation of the
mechanismbywhich IL-1 supports survival of AR cells and the potential role
for AR in evading AR-targeted therapy during castration resistant prostate
cancer (CRPC).
#5805 Myosin 1e colocalization with 1-intergin and association with
tumor progression in colorectal cancer. Jeffrey Pfannenstein,1 Filippo Bori,2
Alessandro Bombonati,2 David Zuzga1. 1La Salle University, Philadelphia, PA;
2Einstein Medical Center, Philadelphia, PA.
For colorectal cancer (CRC), the risk of relapse among stage II and stage III
a/b patients is 20-30% and the benefıt of treating these patients with chemother-
apy is uncertain. As a result, many patients are undertreated, putting them at
increased risk for disease relapse, or overtreated, exposing them to unnecessary
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and harmful chemotherapy with little potential benefıt. Therefore, defıning
prognostic biomarkers to more accurately determine each person’s risk of re-
lapse and need for chemotherapy is a priority in CRC research. Promising tar-
gets for biomarker discovery are actin-binding proteins. As a broad class, these
proteins regulate the actin cytoskeleton and serve as direct, proximal regulators
of invasive and metastatic phenotypes. Further, the prognostic utility of several
of these proteins has recently been reported in the literature.Myosin 1e (Myo1e)
a long-tailed, class I myosin, is one such protein with proposed clinical utility as
a prognostic biomarker. In kidney podocyte cells, Myo1e regulates endocytosis,
adhesion, migration, and invadosome dynamics. Despite its expression in nu-
merous cancers, the functional role of Myo1e specifıcally in cancer cells and its
association with tumor progression remains elusive. To defıne a role in cancer
cells, the localization ofMyo1ewas examined in vitro by immunofluorescence in
T84 human CRC cells. Myo1e co-localized with actin, cortactin and 1 integrin
at membrane ruffles, which regulate integrin endocytosis and traffıcking. Inter-
estingly, both Myo1e and 1 integrin also co-localized with caveolin-1, a regu-
lator of integrin endocytosis, suggesting Myo1e expression may regulate cave-
olae-dependent integrin endocytosis and traffıcking. To evaluate potential
prognostic utility, Myo1e expression in colorectal tumors and matched normal
adjacent tissue (NAT) was examined by immunohistochemistry in a tissue mi-
croarray constructed from duplicate tissue cores from 119 CRC patients. The
patient cohort was well balanced across TNM stage: stage 0 (10.1%), stage 1
(20.2%), stage 2 (26.9%), stage 3 (31.1%), and stage 4 (12.6%), and the majority
(68.9%) of CRC tissues examined were of moderate tumor grade. The ratio of
Myo1e expression in tumors compared toNATwas signifıcantly correlatedwith
clinicopathologic indicators of disease progression, including clinical stage,
depth of invasion at the primary tumor (T-score), and lymph node metastasis.
Together, these data suggest Myo1e expression correlates with tumor progres-
sion and may regulate invasive phenotypes through integrin traffıcking path-
ways. Examining the prognostic utility and biologic function of Myo1e may a
defıne a novel biomarker with translational utility for improved clinical man-
agement of colorectal cancer patients.
#5806 Exploring the role of copper-dependent lysyl oxidase (LOX) inmet-
astatic growth. Kimberly Jasmer-McDonald, Michael Petris, Vinit Shanbhag,
Nikita Gudekar. University of Missouri, Columbia, MO.
Copper is an enzymatic cofactor required for cellular respiration, iron ho-
meostasis, melanogenesis, neurotransmitter biosynthesis, and connective tissue
formation. Copper defıciency in humans is evidenced by Menkes disease, a
lethal pediatric disorder caused by mutations in the ATP7A copper transporter.
ATP7A, a ubiquitously expressed copper transporting P-type ATPase, trans-
ports copper from the cytoplasm into the Golgi complex to supply copper to
secreted copper-dependent enzymes. Additionally, ATP7A functions to export
copper from cells to avoid copper toxicity. Aberrant copper metabolism is char-
acteristic of many cancers. Copper-chelating drugs such as tetrathiomolybdate
or penicillamine have been shown to have anti-angiogenic and anti-neoplastic
activity. Copper also appears to be rate limiting for mitogenic signaling path-
ways necessary for tumor growth such as RAS/RAF/MAPK signaling. The re-
quirement for lysyl oxidase (LOX) proteins in tumor metastasis is further illus-
trative of copper’s role in cancer biology. Copper-dependent LOX proteins
catalyze the oxidation of lysine residues within collagen and/or elastin, stabiliz-
ing crosslinks between these fıbrous proteins during the formation or remodel-
ing of the extracellular matrix. While research implicates a direct role for LOX
proteins in many types of cancer, the use of copper chelators or other strategies
to starve LOX enzymes of copper as a therapeutic strategy has been largely
overlooked. LOX family members acquire copper in the secretory pathway via
theATP7Aprotein. Consistentwith this requirement, LOXactivity is reduced in
cultured fıbroblasts derived from patients with Menkes disease that lack func-
tional ATP7A protein. As the cancer promoting properties of LOX enzymes
have been shown to require catalytic activity, we hypothesize that blocking the
ATP7A protein could be a powerful approach to inhibit LOX-dependent pro-
tumorigenic and pro-metastatic pathways. In this study, we have found that
genetic ablation of ATP7A using CRISPR/Cas9 inhibits the tumorigenic and
metastatic potential of a multiple cancer cell lines in vivo. These fındings could
be attributed to a variety of copper functions or those of copper-dependent
enzymes, such as LOX. In this study,we investigate the role of copper-dependent
enzymes, such as LOX, using in vitro and in vivo methods. While others have
implicated lysyl oxidase secreted by cancer cells in tumorigenesis andmetastasis,
the contributions of lysyl oxidase at the metastatic site have not been evaluated.
Here, I describe a novel conditional mouse model that we use to explore this
question.
#5807 Disseminated tumor cell clearance by the immune system. Raziye
Piranlioglu, Eun Mi Lee, Maria Ouzunova, Ali S. Arbab, Paulo C. Rodriguez,
Asm L. Iskander, Hasan Korkaya. Augusta University, Augusta, GA.
The classical model of metastasis suggests that the tumor cell dissemination
occurs late in tumor development, however accumulating evidence coming
from mouse studies and clinical data provide striking evidence that tumor cells
start to disseminate during the initial steps of tumor development. However, the
dissemination from the primary area does not always result inmetastasis. Due to
the non-permissive nature of microenvironment in distant sites, these early
disseminated tumor cells might be cleared ormaintained in a non-proliferative/
dormant state. The mechanism by which some early disseminated tumor cells
colonize and generatemetastatic growth while some remain dormant is not well
known. In order to understand the underlying factors thatmay contribute to the
metastatic growth, we performed time course experiments by utilizing murine
mammary tumors (4T1 as metastatic and EMT6 as less metastatic) in a synge-
neic mouse model. Luciferase expressing 4T1 or EMT6 tumor cells were ortho-
topically implanted into the fat pads and tumor cell dissemination was analyzed
over 3-week time points. We determined that both 4T1 and EMT tumors dis-
seminated as early as one to two-week post implantation, however only 4T1
tumor developmetastasis in distant organs. Moreover, we also resected primary
tumors 1, 2 and 3-week post implantation of EMT6-Luci or 4T1-Luci tumors
and observed distant metastasis via optical imaging of luciferase expression in
live animals. Although themajority of 4T1 tumor-bearingmice (80%) develop
pulmonary metastasis when 4T1 tumors resected 2 and 3 weeks post-implanta-
tion only 10% of mice develop metastasis when primary tumor resected one-
week post implantation. In contrast, EMT6 tumors following resection only
relapsed in the primary tumor site but failed to developmetastasis. Furthermore,
EMT6 tumor-bearing mice effıciently cleared tail vein injected EMT6-luci cells
in the lungs. We investigated the possible mechanism by which EMT6 tumor-
bearing mice clears disseminated tumor cells in the lung. We provide evidence
that pulmonary infıltrated mMDSCs mediate tumor cell killing via secretion of
high levels of cytotoxic granules, granzyme A, granzyme B, perforin. This was
confırmed by mouse transcriptome and qPCR analyses as well as biochemistry
using in vivo samples and in vitro co-culture samples. Our studies provide a new
paradigm in the understanding of the fate of disseminated tumor cells in sec-
ondary organs and the role of the immune system in this process.
#5808 The role of breast cancer-derived exosomes in brain metastasis.
Golnaz Morad, Jiang Yang, Marsha A. Moses. Boston Children’s Hospital, Har-
vard Medical School, Boston, MA.
The development of brainmetastasis is associatedwith a signifıcant reduction
in the survival rate of breast cancer patients. Improving the prognosis of women
with brain metastasis from breast cancer relies on the elucidation of the mech-
anisms underlying this process. Our group and others have shown that the
formation of brainmetastases occurs along the abluminal side of brain vessels, a
process called “vessel co-option”. These observations prompted our hypothesis
that the cellular and extracellularmatrix (ECM) components of the blood-brain-
barrier (BBB) can serve as a pre-metastatic niche for breast cancer brain metas-
tases. The role of tumor-derived exosomes (TEx) in the preparation of a pre-
metastatic niche in distant organs has been shown in a number of cancers. To
investigate the mechanisms driving the vessel co-option of breast cancer brain
metastases, we studied the role of breast cancer-derived exosomes in prepara-
tion of the BBB for metastasis formation. Exosomes were isolated from the
MDA-MB-231 breast cancer cell line, a brain-seeking variant of these cells, and
a bone-seeking variant as a non-brainmetastatic control. Brain endothelial cells,
astrocytes, and brain vascular pericytes, the three components of the BBB, were
treated with exosomes for 3 days to recapitulate the continuous exposure of cells
to the circulating TEx in vivo. The treated cells were analyzed for cellular activ-
ities relevant to pre-metastatic niche preparation in the brain such as the integ-
rity of the BBB, expression of cytokines, and modulation of the ECM. An initial
screen was performed using cytokine antibody arrays and PCR arrays for ECM
and adhesionmolecules and results were validated in three separate experiments
usingwestern blots, ELISA, andMultiplex assays. Exosomes derived frombrain-
seeking cells signifıcantly increased astrocyte migration and decreased the ex-
pression of Integrin 1 in brain endothelial cells, both of which can lead to the
disruption of the BBB integrity. Moreover, the expression of Interleukin 8 was
increased by TEx in astrocytes. TEx also increased the expression ofMMP-3 and
-9 (Matrix Metalloproteinases) from an undetectable baseline level and de-
creased the expression of TIMP-1 and -2 (Tissue Inhibitors of MMPs) in astro-
cytes.While the importance of these twoMMPs for brainmetastasis from breast
cancer has been previously reported, our study is the fırst to demonstrate that
secretion of these MMPs is triggered by TEx. Surprisingly, we did not observe
any signifıcant TEx-derived modulations in the expression of cytokines, ECM,
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and adhesion molecules in brain pericytes. These fındings indicate that within
the BBB, astrocytes and endothelial cells, but not pericytes, can be affected by
breast cancer-derived exosomes in such a way that can potentially lead to prep-
aration of a suitable niche for future metastasis formation along the brain vas-
culature. (This work is supported by the Breast Cancer Research Foundation.)
#5809 Fluorescence-guided spatiotemporal dynamics of epithelial-mes-
enchymal transition under inflammatory microenvironment during colo-
rectal cancer progression. Takeshi Ieda,1 Hiroshi Tazawa,1 Satoru Kikuchi,1
Shinji Kuroda,1 Toshiaki Ohara,1 Kazuhiro Noma,1 Hiroyuki Kishimoto,1
Takeshi Nagasaka,1 Masahiko Nishizaki,1 Shunsuke Kagawa,1 Takeshi Ima-
mura,2 Toshiyoshi Fujiwara1. 1Okayama University, Okayama, Japan; 2Ehime
University, Ehime, Japan.
Background: Epithelial-mesenchymal transition (EMT) is a biological
process, by which epithelial cancer cells acquire mesenchymal phenotype
with malignant properties for invasion and metastasis, leading to poor prog-
nosis. Inflammatory microenvironment has been shown to be responsible
for the development and progression of colorectal cancer. However, the role
of inflammatory microenvironment in the EMT-related tumor progression
remains unclear. To explore the relationship between inflammatory mi-
croenvironment and EMT, a live imaging system for EMT is a promising
strategy on the in vitro and in vivo experiments. In this study, we developed
a fluorescence-guided live cell imaging system for the assessment of spatio-
temporal dynamics of EMT, and investigated the potential of inflammatory
microenvironment for the induction of EMT phenotype in human colorectal
cancer. Methods: Two human colorectal cancer cell lines, HCT116 and RKO,
were stably transfected with vimentin promoter-driven red fluorescence
protein TurboFP635 expression vector. Both cell lines were treated with
inflammatory cytokines, IL-1 (1 ng/ml) and TNF-	 (20 ng/ml), or co-
cultured with mouse macrophage cell line RAW264.7 in the presence of
lipopolysaccharide (LPS) (200 ng/ml). The time-lapse live imaging was ob-
served by confocal laser scanning microscope. Migration and invasion prop-
erties were examined by transwell chamber assays. The fluorescence inten-
sity was measured by microplate reader and flow cytometric analysis. The
expression of EMT-related markers was assessed by Western blot analysis
and q-PCR. EMT-induced HCT116 and RKO cells were treated with anti-
inflammatory agents, aspirin (1mM) and salicylic acid (1 mM), for the sup-
pression of EMT. Results: Inflammatory cytokines (IL-1 and TNF-	)
induced red fluorescence intensity and morphological change like mesen-
chymal phenotype in HCT116 and RKO cells. Removal of inflammatory
cytokines attenuated red fluorescence intensity andmorphological change in
both cells. Inflammatory cytokines also induced the migration and invasion
properties in association with EMT-related markers. Moreover, co-culture
with LPS-stimulated inflammatory macrophages also induced red fluores-
cence intensity andmorphological change as well as inflammatory cytokines.
Anti-inflammatory agents signifıcantly suppressed the fluorescence-related
EMT phenotype under inflammatory microenvironment. Conclusions:
These results suggest that inflammatory microenvironment has a great po-
tential for the induction of EMT process during colorectal cancer progres-
sion. This unique fluorescence-guided EMT imaging system is useful
method for the exploration of inflammation-mediated tumor progression.
#5810 microRNAs targeting EMT transcription factorsmay be associated
to lymph node metastasis in breast cancer tumors. Elisa Pérez-Moreno,1 Ga-
briela Valarezo,1 Valentina Zavala,1 Wanda Fernández,2 Pilar Carvallo1. 1Pon-
tifıcia Universidad Católica de Chile, Santiago, Chile; 2Hospital San Borja Arri-
arán, Santiago, Chile.
Breast cancer is the leading cause of cancer-associated deaths in women.
Lymph node near to the primary breast tumor have a high chance of devel-
oping a secondary tumor, representing one of the fırst signs of metastasis in
breast cancer. Metastasis is promoted by epithelial-mesenchymal transition
(EMT), process leaded by the transcription factors SNAIL, SLUG, ZEB and
TWIST. MicroRNAs are small non-coding RNAs, whose expression has
been demonstrated to be altered in different cancer types. Because of their
ability to regulate large sets of genes involved in cancer growth and metas-
tasis, microRNAs have emerged as candidate molecular biomarkers and
novel therapeutic targets. The aim of this study is to identify microRNAs
differentially expressed in breast tumors in relation to EMT-transcription
factor expression and lymph node metastasis, and that are involved in epi-
thelial-mesenchymal transition. For this purpose, we used microRNA mi-
croarray data from 50 fresh frozen breast tumors with different tumor grades
(1 to 3), 28 from patients with lymph node metastasis. Microarray data
analysis using RankProd (R package) revealed approximately 40microRNAS
down-regulated in breast tumors with expression of EMT-transcription fac-
tors (p0.05). Several of the identifıed microRNAs have been previously
described to regulate early steps of metastasis in different cancer types, like
members of the miR-200 family (miR-200c and miR-141), miR-205 and
miR-30a. In addition we found other microRNAs not previously associated
to metastasis. Our results suggest that down regulation of specifıc microR-
NAs, and up regulation of their targets, may induce a metastatic behavior of
tumor cells of the primary breast tumors, promoting invasion and coloniza-
tion of the lymph nodes. In this sense, the changes in the expression of
microRNAs may serve as biomarkers of breast cancer prognosis in patients.
#5811 HMP19, a pancreatic cancer metastasis suppressor, is secreted in
extracellular vesicles and inhibits EGFRactivity. SharonManley, Gada al-Ani,
Danny Welch. University of Kansas Medical Center, Kansas City, KS.
Pancreatic cancer is usually diagnosed when the cancer is already at an
advanced stage. The presence of metastases contributes to the poor progno-
sis as do the limited treatment options, resulting in an urgent need for early
detection methods and novel treatments. HMP19 was identifıed as a metas-
tasis suppressor in pancreatic duct adenocarcinoma (PDAC) using unbiased
genome wide shRNA screen assay (Kurahara et al. 2016). HMP19 is localized
to the membrane of Golgi apparatus and has been implicated in the vesicular
traffıcking in neurons (Saberan-Djoneidi et al. 1994). HMP19 is a predicted
type II, single-pass transmembrane protein with protein binding domains at
the N- and C- terminals, although, the physiological function of HMP19
remains undefıned. Our lab showed that HMP19 attenuates nuclear ERK1/2
activity in PDAC cells. Furthermore, we found that ectopic HMP19 is se-
creted in the extracellular vesicles (EVs) in non-metastatic PDAC cell line,
Suit2 subclone 028 (S2-028), but not in metastatic PDAC cell line, S2-007.
Furthermore, silver staining and mass spectrometry showed that the EVs
protein profıles between S2-028 and S2-007 EVs are distinct. We hypothesize
that secreted HMP19 regulates cell migration and proliferation, and also
negatively regulates signaling pathway(s) upstream of ERK. To examine ef-
fects of HMP19-containing EVs on parental cells, HMP19-containg EVs
were incubated with parental cells and proliferation andmigration then were
quantifıed. HMP19-containing EVs treatment inhibited migration but not
proliferation of metastatic S2-007 cells, but not non-metastatic S2-028 cells.
We identifıed several proteins as HMP19 binding partners in the co-immu-
noprecipitation followed by mass spectrometry study and were subsequently
validated by co-immunoprecipitation followed by immunoblot. HMP19 was
found to interact with multiple proteins, including ERK regulators such as
MET and epithelial growth factor receptor (EGFR). We then investigate the
role of HMP19 on the MET and EGFR signaling pathway. Intriguingly,
HMP19 down regulates EGFR phosphorylation and protein expression in
metastatic S2-007, but not non-metastatic S2-028 PDAC cells. Moreover,
HMP19 expression had no effect on phosphorylated and total MET and
Janus kinase (JAK) total protein levels. Altogether, the data suggest that
HMP19 may inhibit metastasis through down regulation of EGFR signaling
pathway. In conclusion, we showed that HMP19 is secreted in EVs and these
EVs attenuate PDAC cell migration, and mechanistically, HMP19 down reg-
ulates EGFR in metastatic PDAC cells. Future studies will further bridge the
effects of HMP19 on the EGFR signaling cascade and the extracellular
HMP19-mediated inhibition of migration.
#5812 MIEN1 promotes breast cancer cell migration and invasion by reg-
ulating cytoskeletal dynamics via focal adhesion kinase andN-WASP. Pankaj
Chaudhary, Marilyne Kpetemey, Timothy Van Treuren, Jamboor K. Vishwa-
natha. University of North Texas Health Science Center, Fort Worth, TX.
Short Description: Migration and invasion enhancer 1 (MIEN1) is an impor-
tant regulator of cell migration and invasion. MIEN1 overexpression represents
an oncogenic event that promotes tumor cell dissemination andmetastasis. The
underlying mechanism by which MIEN1 regulates migration and invasion has
yet to be deciphered. Methods: Immunofluorescence, actin polymerization, Im-
munoprecipitation, migration, invasion, and adhesion assays were performed
using breast cancer cell lines,MDA-MB-231 andMCF10CA1a to investigate the
mechanisms by which MIEN1 potentiates cell motility. Results: Our results
show that MIEN1 acts as a cytoskeletal-signaling adapter protein to drive breast
cancer cell migration. Knockdown of MIEN1 led to the loss of actin-protrusive
structures whereas the overexpression of MIEN1 resulted in rich and thick
membrane extensions. Knockdown of MIEN1 also decreased the cell-substra-
tum adhesion, suggesting a role for MIEN1 in actin cytoskeletal dynamics. Our
results show that MIEN1 supports the transition of G-actin to F-actin polymer-
ization and stabilizes F-actin polymers. Additionally, MIEN1 promotes cellular
adhesion and actin dynamics by inducing phosphorylation of FAK at Tyr-925
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and reducing phosphorylation of cofılin at Ser-3, which results in breast cancer
cell migration. Furthermore, we found that MIEN1 associates with cytoskeletal
proteins involved in motility processes. Conclusion: Our results show that
MIEN1plays an essential role inmaintaining the plasticity of the dynamicmem-
brane-associated actin cytoskeleton, which leads to an increase in cell motility.
Hence, targeting MIEN1 might represent a promising means to prevent breast
tumor metastasis.
#5813 RabGTPase 3C promotes colon cancermetastasis via regulation of
IL-6 secretion and STAT3 signaling pathway.Chi-Long Chen. Taipei Medical
Univ., Taipei, Taiwan.
RAB GTPases is involved in membrane traffıcking vesicle formation and cell
motility. Recently, exocytotic RABs received growing attention in cancer re-
search. However, the molecular mechanism of exocytotic RABs in colorectal
tumorigenicity remains unclear. In this study, we found RAB GTPase 3C
(RAB3C) has the most signifıcant association with higher pathological stage,
tumor recurrence, frequent distant metastasis, and poor prognosis in 215 colo-
rectal adenocarcinoma cohort using tissue microarray (TMA) analysis. In mul-
tivariate analyses, highRAB3C expression retained its independently prognostic
signifıcance for both overall survival (p0.001) and disease-free survival (p 
0.001). Further experimental results showed increased migration and invasion
ability in RAB3C overexpressing colon cancer cells compared with control
group in vitro and in vivo. The cell culture medium collected from RAB3C
overexpressing model could promote parental colon cancer cells further indi-
cated that themetastasis-promoting role of RAB3C is exocytosis dependent.We
then integrated the results from previously microarray and proteomics datasets
and discovered that increased production of multiple cytokines in RAB3C over-
expressing cell lines. Of these cytokines, IL-6 pathway is the top pathway corre-
sponding to gene expression changes after RAB3C overexpression. Blocking of
IL-6 function with IL-6 antibody or IL-6 knockdown signifıcantly reduced the
migration ability in RAB3C overexpressing colon cancer cells. Furthermore,
secretion of IL-6 after RAB3C overexpression promoted the JAK2-STAT3 sig-
naling with increased STAT3 phosphorylation levels to promote migration. In
addition, Ruxolitinib, a JAK2 inhibitor, was found to signifıcantly inhibited
RAB3C induced colon cancer cell migration through blocking STAT3 phos-
phorylation. In conclusion, our study showed that RAB3C overexpression pro-
moted tumor metastasis and is associated with poor prognosis of colon cancer
patients throughmodulating the IL6 exocytosis of cancer cells to activate JAK2-
STAT3 pathway. These fındings suggest a new therapeutic strategy through the
inhibition of STAT3 signaling pathway in RAB3C-IL-6 axis by Ruxolitinib to
prevent metastasis of colon cancer.
#5814 Engineered microfluidic 3D human microvasculature identifıes
Talin-1-dependent adhesion and FAK activation as the key promoter of can-
cer cell trans-endothelialmigration.MaraGilardi,1 Simone Bersini,1 RosaMa-
riaMoresco,2MarcoVanoni,3 RogerD. Kamm,4MatteoMoretti1. 1IRCCSGale-
azzi Institute Milano, Milan, Italy; 2San Raffaele Hospital, Milan, Italy;
3University of Bicocca - Milano, Milan, Italy; 4Massachusetts Institute of Tech-
nology, Cambridge, MA.
In extravasation cancer cells and vascular niche are involved in a tight cross-
talk which has been defıned as the rate-regulating event formetastases establish-
ment [1]. Recent, animal studies support the hypothesis that metastatic defı-
ciency lies in focal adhesion complex alterations, however, it still needs to be
elucidated which are the specifıc regulators of each event composing extravasa-
tion. Focal adhesion proteins Talin-1 (TLN-1) and Focal Adhesion Kinase
(FAK) are up-regulated in breast cancer. Both targets due to their structural and
functional role, dramatically influence cancer mechanotransduction leading to
endothelial junction disruption, critical in extravasation process [2]. Here, we
generated ad hoc engineered models for each extravasation step allowing single
cell behavior analyses through high resolution real time imaging in a reliable and
quantitative way in a physiological environment. Through this novel approach
we analyzed the effect of TLN-1 and FAK and their genetic and chemical inhi-
bition in breast cancer extravasation. The 3D-microfluidic vasculature displayed
maturation markers and physiological permeability (1.50.76*10-6cm/s) and
allowed cancer cell injection through the hollow vessels.Western blot confırmed
TLN-1 and FAK knock down (KD) in MDA-MB231. Both targets signifıcantly
affected morphology and proliferation (p0.001). We demonstrated the in-
volvement of both targets in adhesion to the endothelium (p0.001). Trans
endothelial migration (TEM)was decreased in TLN-1 KD (p0.05) and in FAK
KD (P0.01). Both TLN-1 and FAK KD cells were trapped into the vessels and
were not able to extend pseudopodia. Cancer migration tracking in 3D matrix
was statistically lower in both KD (p0.001). The calculated ratios of adhesion/
TEM and invasion/TEM were lower in TLN-1 compared to FAK KD, demon-
strating that TLN-1 plays a major role in adhesion to endothelium and early
invasion while FAK was identifıed as the main driver in TEM. Additive (TLN-1
and FAK) KD did not show signifıcant difference respect to the target that
mostly affected adhesion and invasion demonstrating TLN-1 role in these
events. Additive KD was statistically lower compared to TLN-1 KD (P0.05),
supporting FAK crucial role in TEM. Inhibition of TLN-1 and FAK phosphor-
ylation revealed that actin polymerization andpseudopodia formation (required
for extravasation) were dependent by their structural role andwere independent
by their phosphorylation. However, the inhibition of FAK activity showed FAK
phosphorylation as the key driver of TEM mechanism (p0.01). Concluding,
our results supported by in vivo data (p0.05) showed that TLN-1 and FAK
inhibition may represent novel strategies challenging mechanisms leading to
metastatic establishment. 1. Cell,2011.147(2):p.275-92; 2. Proc Natl Acad Sci
USA,2015.112(1):p.214-9.
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#5815 The HBP1 tumor suppressor is a negative epigenetic regulator of
MYCN driven neuroblastoma through interaction with the PRC2 complex.
Geertrui Denecker,1 Shana Claeys,1 Irina Lambertz,1 Els Janssens,1 Suzanne
Vanhauwaert,1 Bieke Decaesteker,1 TomVanMaerken,1 BramDeWilde,1 Gen-
evieve Laureys,2 Kristina Althoff,3 Johannes Schulte,3 Jean-Baptiste Demoulin,4
Stephen S. Roberts,5 Laurel Bate-Eya,6 Jan J. Molenaar,6 Frank Westermann,7
Katleen De Preter,1 Frank Speleman1. 1Center for Medical Genetics Ghent, Gh-
ent, Belgium; 2Ghent University Hospital, Ghent, Belgium; 3University Children’s
Hospital Essen, Essen, Germany; 4Université catholique de Louvain, Woluwe-
Saint-Lambert, Belgium; 5Memorial Sloan Kettering Cancer Center, New York,
NY; 6Academic Medical Center, University of Amsterdam, Amsterdam, Nether-
lands; 7German Cancer Research Center, Heidelberg, Germany.
MYCN is a key driver in initiation and progression of neuroblastoma (NB)
and represents a major target for novel drug strategies. We previously reported
that the MYC repressor gene HBP1 was down regulated by mutant ALK via the
PI3K-AKT-FOXO3 signaling axis1. Here, we further demonstrate that HBP1
upregulation suppresses proliferation of neuroblastoma cells by decreasing the
MYCN signaling pathway. HBP1 levels were also shown to be repressed in neu-
roblastoma cells through MYC/MYCN driven upregulation of the miR-1792
cluster, indicating that MYCN and mutant ALK both act to inhibit HBP1 ex-
pression inNB.Next, we tested the green tea polyphenol epigallocatechin gallate
(EGCG), known to upregulate HBP1, and the BET inhibitor JQ1, which re-
presses MYCN activity in neuroblastoma cells, and showed in vitro and in vivo
synergistic effects on cell viability and tumor growth. Treatment with the PI3K/
mTOR dual inhibitor BEZ-235 together with JQ1 also showed very strong syn-
ergistic effects. Further dissection of theHBP1 regulome using Gene Set Enrich-
ment Analysis (GSEA) and iRegulon analysis (http://iregulon.aertslab.org)
allowed identifıcation of the PRC2 component SUZ12 as a central node inHBP1
regulated signaling, mainly through controlling the repression of MYCN regu-
lated genes. In keeping with this fınding, GSEA analysis of our HBP1 overex-
pression data set revealed also strong enrichment for genes that are differentially
expressed upon EZH2 inhibition in neuroblastoma cells. Because HBP1 has
previously been shown to interact with HDAC, we tested the effects of the
HDAC inhibitors vorinostat and panobinostat as single agents and in combina-
tion with BEZ-235. Both combinations showed a strong synergistic effect on cell
viability. The molecular mechanism of this synergism will be explored through
RNAseq expression analysis. We conclude that HBP1 is a crucial component in
MYCN controlled repression of gene activity through PRC2 interaction and
demonstrate novel opportunities for precision drugging ofMYCN overexpress-
ing NB cells. 1Lambertz et al. Clin Cancer Res. (2015).
#5816 Ablation of oncogenic MYCN expression by hTERT-driven onco-
lytic adenovirus induces cell death in MYCN-amplifıed neuroblastoma.
Terutaka Tanimoto,1 Hiroshi Tazawa,1 Hiroshi Noso,1 Takanori Oyama,1 Ya-
suoUrata,2 Shunsuke Kagawa,1 TakuoNoda,1 Toshiyoshi Fujiwara1. 1Okayama
University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Okayama, Japan; 2Oncolys Biopharma, Inc., Okayama, Japan.
Background: Neuroblastoma (NB) is a primary malignant tumor of the pe-
ripheral sympathetic nervous system. Amplifıcation and overexpression of the
MYCN proto-oncogene occur in approximately 20% of NB. Since MYCN acti-
vation is highly associated with poor prognosis,MYCN is an attractive target for
the treatment ofMYCN-amplifıed NB.MYCN is a transcriptional activator that
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induces the expression of many down-stream target genes including human
telomerase reverse transcriptase (hTERT). We developed two types of hTERT-
driven oncolytic adenoviruses, OBP-301 and OBP-702, in which the hTERT
promoter drives the expression of the viral E1A and E1B genes for tumor-spe-
cifıc virus replication, and OBP-702 further expresses tumor suppressor p53
protein. Although hTERT-driven oncolytic viruses are expected to be effective
against MYCN-amplifıed NB with hTERT activation, the therapeutic potential
of these viruses in MYCN-amplifıed NB remains unclear. In this study, we in-
vestigated whether OBP-301 and OBP-702 induce cell death and modulate
MYCN expression in MYCN-amplifıed NB cells. Methods: We used 3 human
NB cell lines with MYCN amplifıcation, including IMR-32, CHP-134 and
LA-N-5. The antitumor effect of OBP-301 and OBP-702 was evaluated using
XTT assay. Virus-mediated cell death and modulation of MYCN and E2F1 ex-
pression were analyzed by Western blot analysis. The mRNA expression of
hTERT andMYCNwas analyzed by real-time RT-PCR analysis. To explore the
role of E2F1 in the virus-mediated MYCNmodulation, Ad-E2F1, a replication-
defective adenovirus expressing E2F1 gene, was further used. Results: AllNB cell
lines showed high hTERT mRNA expression. OBP-301 and OBP-702 showed
profound antitumor effect through autophagy-related cell death in all NB cell
lines. Both viruses induced E1A and its targetmediator E2F1 expression in these
cell lines. Expression ofMYCNmRNA and protein was downregulated by these
viruses. Replication-defıcientAd-E2F1 infection also downregulated the expres-
sion ofMYCN.Conclusions: These results suggest that hTERT-driven oncolytic
adenoviruses are promising antitumor agent for the treatment of MYCN-am-
plifıed NB. These viruses induce profound autophagy through hTERT-depen-
dent viral replication. E2F1 upregulation by viral infection is supposed to be one
of the causes for MYCN downregulation and autophagy-related cell death. In
vivo experiments are under way to investigate the antitumor effect of these
viruses against xenograft NB tumors.
#5817 Protein phosphatase 1 regulatory subunit 1Apromotes tumorigen-
esis andmetastasis in Ewing sarcoma.WenLuo,1 ChangxinXu,2 Janet Ayello,1
Filemon De La Cruz,3 Jeremy Rosenblum,1 Stephen L. Lessnick,4 Mitchell S.
Cairo1. 1New York Medical College, Valhalla, NY; 2James J. Peters Veterans Af-
fairs Medical Center, Bronx, NY; 3Memorial Sloan Kettering Cancer Center, New
York, NY; 4Nationwide Children’s Hospital, Columbus, OH.
Background: Ewing sarcoma (ES) is a highly invasive andmetastatic pediatric
soft tissue and bone tumor. Children with metastatic ES have a cure rate of less
than 30% (De loris MA et al, 2013). Novel and specifıc therapeutic targets are
urgently needed. ES is characterized by the oncogenic fusions, mostly EWS/FLI,
which functions as an aberrant transcription factor to deregulate downstream
targets andmediate ES pathogenesis. By comparing genes dysregulated by EWS/
FLI across multiple model systems (Niedan S et al, 2014; Sankar S et al, 2013;
Tirode F et al, 2007), we identifıed protein phosphatase 1 regulatory subunit 1A
(PPP1R1A), a potent protein phosphatase 1 (PP1) inhibitor upon PKA phos-
phorylation, as one of the core EWS/FLI targets (Luo W et al, 2016). Objective:
In the current study, we seek to defıne the role of PPP1R1A in ES pathogenesis.
Methods: Quantitative reverse transcription polymerase chain reaction and lu-
ciferase reporter assays were performed to investigate transcriptional regulation
of PPP1R1A by EWS/FLI. In vitro functional assays and orthotopic injections in
immune-defıcient mice were conducted to investigate the effect of PPP1R1A on
ES oncogenic transformation and cell migration, and tumorigenesis andmetas-
tasis, respectively.High-throughput sequencing and functional annotationwere
utilized to identify PPP1R1A regulated genes and cellular functions. Drug treat-
ment was performed to test the effect of PKA inhibitors on ES cell proliferation
and tumor development. Results: We found that PPP1R1A is directly up-regu-
lated by EWS/FLI via a GGAA microsatellite enhancer element. Depletion of
PPP1R1A caused a signifıcant decrease in oncogenic transformation (p0.05)
and cell migration (p0.009) in vitro and limited xenograft tumor growth
(p0.0009) and metastasis (p0.009) in vivo. We also discovered that
PPP1R1A regulates genes involved in various cellular processes including acting
binding, cell adhesion, and differentiation. Interestingly, PPP1R1A regulated
gene set signifıcantly overlap with that of ZEB2 (p2.67246E-33) and EWS
(p1.2559E-45), which regulates metastasis and neuronal differentiation in ES,
respectively. Further, we demonstrated that PKA phosphorylation and activa-
tion of PPP1R1A, and subsequent PP1 binding and inhibition by activated
PPP1R1A, is required for PPP1R1Amediated ES pathogenesis, likely by increas-
ing the phosphorylation level of various PP1 substrates, such as RB and CREB,
which are critical for fundamental cellular functions including proliferation and
differentiation. Consistently, we found that PKA inhibitors impaired ES cell
proliferation and xenograft tumor growth and metastasis. Conclusion: Collec-
tively, we identifıed an essential kinase and phosphatase pathway, PKA/
PPP1R1A/PP1, that plays a critical role in ES tumorigenesis andmetastasis, and
thus is a potential therapeutic target in the treatment of primary and metastatic
ES.
#5818 Disrupting the Aurora kinase A interactome in pediatric cancer.
Sucheta Mukherjee, Carolyn Tu, Clay Gustafson. UCSF, San Francisco, CA.
Neuroblastoma is the most common extra-cranial solid tumor of childhood.
Amplifıcation of the MYCN proto-oncogene occurs in 50% of the high-risk
neuroblastoma and indicates an aggressive and lethal form of the disease. As a
transcription factor with no apparent small-molecule surfaces, direct inhibition
ofMYCN has proven challenging. Proteolytic cleavage ofMYCN is regulated in
part by an activity-independent scaffold function ofAuroraKinaseA (AURKA).
The dynamic expression and activation of AURKA allows for precise cell cycle
regulation of several substrates identifıed by protein-protein interaction studies
that are also viable anti-cancer targets, such as the aforementioned MYCN on-
coprotein. Utilizing co-immunopreciptation, flow cytometry, and other perti-
nent cell biology techniques, we aim to delineate a novelmechanism of targeting
the AURKA interactome by conformation disruption of AURKA. We have re-
cently described a neoteric class of confırmation disrupting “amphosteric” in-
hibitors of AURKA (CD-AURKAi) that orthosterically inhibit theATP-binding
pocket to dramatically disrupt the active conformation of AURKA to dissociate
and degrade MYCN, a critical oncogenic driver of the pediatric cancer neuro-
blastoma. In addition to MYCN, our preliminary results show CD532 will also
dissociate other oncogenic proteins that interact with AURKA.We hypothesize
that conformationdisruption ofAURKAand subsequent blockade of an array of
protein-protein interactions will delineate the roles of AURKA, MYC, and
MYCN in the cell cycle and expand the clinical applications for CD-AURKAi in
cancer to include non-MYCN driven diseases.
#5820 Targeting the PIM protein kinases for the treatment of a T-cell
acute lymphoblastic leukemia subset. Sathish Kumar Reddy Padi,1 Libia Lu-
evano,1 Neha Singh,1 Jiin Song,2 Ritu Pandey,2 Jon C. Aster,3 Xue-Zhong Yu,4
Shikhar Mehrotra,4 Andrew Kraft1. 1University of Arizona Cancer Center, Tuc-
son, AZ; 2University of Arizona, Tucson, AZ; 3Harvard Medical School, Boston,
MA; 4Medical University of South Carolina, Charleston, SC.
While intensive chemotherapy regimens result in remission in approximately
80% of pediatric and 45% of adult ALL patients, new approaches are needed for
the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL)who
fail to achieve remission with chemotherapy. Early T-cell precursor (ETP) ALL,
a subset of T-ALL associated with a higher rate of relapse and induction failure,
with a 10-year overall survival of 19% as compared with 84% for all other T-
ALLs. PIM protein kinases are overexpressed in a number of hematopoietic
malignancies, includingALL,with its overexpression being associatedwith poor
prognosis. Pan-PIM inhibitors (PIMi) are being tested in clinical trials in pa-
tients with relapsed/refractory multiple myeloma and acute myeloid leukemia.
Analysis of the effects of PIMi (AZD1208/LGB321) on human T-ALL cell lines
demonstrated that the sensitive cell lines expressed higher PIM1 levels, whereas
T-ALL cell lines with NOTCH mutations tended to have lower levels of PIM1
kinase and were insensitive to these inhibitors. NOTCH-mutant cells selected
for resistance to gamma secretase inhibitors developed elevated PIM1 kinase
levels and increased sensitivity to PIM inhibitors. Immunophenotype of all the
PIMi insensitive cells lines was consistent with a more mature T-ALL pheno-
type. In contrast, sensitive cells, had an immature or ETP-ALL phenotype.
Bioinformatics analysis of three independent T-ALL patient datasets
(GSE28703, E-MEXP-313, and GSE62156) demonstrated overexpression of
PIM1 in the majority of ETP-ALLs and in a small subset of non-ETP-ALL. We
also identifıed 58 genes changing signifıcantly between PIMi sensitive versus
insensitive cell lines that were common to the differential genes between ETP
versus non-ETP ALL cases from GSE28703, suggesting that high PIM1 expres-
sion along with 58 gene signature could be a driver of the ETP phenotype.
Importantly, we have made the novel observation that, combination of
Ponatinib, a tyrosine kinase inhibitor (TKI) with the PIMi is synergistically
lethal to T-ALL cells with ETP phenotype. These agents appear to work together
by inducing PARP andCaspase cleavage, suffıcient to drive apoptosis. Following
engraftment of NSG mice with H-SB2-Luc cells, three weeks of dual therapy
with AZD1208 (30mg/kg/day) and Ponatinib (3mg/kg/day) signifıcantly abro-
gated leukemia as evidenced by optical scanning for luciferase cells, and reduced
number of hCD45 leukemic cells in the peripheral blood and bone marrow.
Also, the dual therapy signifıcantly prolonged the survival of the treatedmice. In
summary, ourwork demonstrates a strong preclinical rationale for a novel treat-
ment strategy of combining PIMi and TKI to treat T-ALL patients with high
PIM expression.
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#5821 Loss ofPin1 suppressesHedgehog-drivenmedulloblastoma tumor-
igenesis. Jean-Francois M. Rual. Univ. of Michigan, Ann Arbor, MI.
Medulloblastoma is the most common malignant brain tumor in children.
Therapeutic approaches to medulloblastoma (combination of surgery, radio-
therapy and chemotherapy) have led to signifıcant improvements, but are
achieved at a high cost to quality of life. Alternative therapeutic approaches are
needed. Genetic mutations leading to the activation of the Hedgehog pathway
drive tumorigenesis in 30% of medulloblastoma. In a yeast two-hybrid pro-
teomic screen, we discovered a novel interaction between GLI1, a key transcrip-
tion factor for the mediation of Hedgehog signals, and PIN1, a peptidylprolyl
cis/trans isomerase that regulates the post-phosphorylation fate of its targets.
The GLI1/PIN1 interaction was validated by reciprocal pulldowns using
epitope-tagged proteins inHEK293T cells aswell as by co-immunoprecipiations
of the endogenous proteins in amedulloblastoma cell line. Our results support a
molecular model in which PIN1 promotes GLI1 protein abundance, thus con-
tributing to the positive regulation of Hedgehog signals. Most importantly, in
vivo functional analyses of Pin1 in the GFAP-tTA;TRE-SmoA1mousemodel of
Hedgehog-driven medulloblastoma demonstrate that the loss of Pin1 impairs
tumor development and dramatically increases survival. In summary, the dis-
covery of theGLI1/PIN1 interaction uncovers PIN1 as a novel therapeutic target
in Hedgehog-driven medulloblastoma tumorigenesis.
#5822 Increase in protein expression and copy number drives the activa-
tionofNPY/Y5Rpro-survival loop in chemotherapy-treatedneuroblastoma.
Selene Elifıo-Esposito,1 Akanksha Mahajan,2 Aline S. Fonseca,2 Susana Galli,2
Lucia Noronha,1 Lisiane C. Poncio,3 Bonald C. Figueiredo,3 Joanna B. Kitlin-
ska,2 Luciane R. Cavalli2. 1Pontifıcia Universidade Católica do Paraná, Curitiba,
Brazil; 2Georgetown University, Washington, DC; 3Instituto de Pesquisa Pelé
Pequeno Principe, Curitiba, Brazil.
Neuroblastoma (NB) is a tumor derived from neural crest cells, primitive
progenitors of sympathetic ganglia. It accounts for 6-10%of all pediatric cancers
with approximately 700 new cases per year throughout the US. Although there
are highly effective therapies for patients with low-risk and intermediate-risk
disease who have local relapses, recurrent disease in patients with high-risk NB
is mostly refractory to therapy. Neuropeptide Y (NPY) is a sympathetic neu-
rotransmitter highly expressed in NB. Its elevated release from tumor tissue is
associated with unfavorable clinical outcome. NPY, acting via its Y5 receptor
(Y5R), stimulates NB cell survival and chemoresistance, however the mecha-
nisms underlyingNPY/Y5R axis activation in these tumors remain unclear. The
aim of this work was to investigate the correlation between the expression of
NPY and NPY5R proteins and the copy number status of the NPY and NPY5R
genes in pre- and post-chemotherapy NB. Eighty-fıve tissue samples, including
specimens from the primary tumors, distant metastases and local relapses, pre-
and post-chemotherapy, were collected from the Hospital Pequeno Principe,
Parana, Brazil. Protein expression was investigated by immunohistochemistry.
Copy number alterations (CNAs) for NPY and NPY5R genes were determined
using TaqMan copy number assay. Additionally, FISH analysis was performed
to assess MYCN amplifıcation status, a genetic marker of high risk NB. Our
results show that elevated extracellular NPY staining, which reflects peptide
release, correlates with patients’ age above 18 months, relapse and poor clinical
outcome. Moreover, the intensity of NPY staining was increased in chemother-
apy-treated NBs, as compared to tumors at diagnosis. However, the differences
in NPY CNAs between these samples were not statistically signifıcant. Thus,
chemotherapy-induced increase inNPY levels observed in post-treatmentNB is
driven by its elevated expression rather than genomic changes. For NPY5R,
signifıcantly higher level of CNAs was observed in the post-chemotherapy sam-
ples (P0.05), independently of the MYCN status. These fındings are in line
with previous studies reporting elevated NPY5R expression in chemotherapy-
treated NB tumors and cell lines. Therefore, for this receptor genomic changes
may play an important role in conferring chemotherapy-driven Y5R up-regula-
tion. Altogether, our results confırm activation ofNPY/Y5Rpro-survival loop in
chemotherapy-treated NB tumors. However, these coordinated increases in the
NPY and NPY5R expression levels are driven by different molecular mecha-
nisms.
#5823 Modulation of the Hippo pathway protein YAP as a mechanism of
resistance toMEK inhibition inMAPKhyperactivatedneuroblastoma.Grace
E. Coggins, Lori S. Hart, Jimmy Elias, John M. Maris. Children’s Hospital of
Philadelphia, Philadelphia, PA.
Background: Current therapies for high-risk neuroblastoma are highly toxic
and ineffective, as a majority of patients will face therapy-resistant relapses. Our
recent whole genome sequencing analysis revealed that a majority of relapsed
tumors had mutations causing RAS-MAPK pathway activation. Recent studies
have implicated the Hippo pathway transcriptional coactivator protein YAP in
relapsed neuroblastoma as well as resistance to MEK inhibition in other cancer
models. Based on these fındings, we hypothesized that YAP activity may lead to
acquired resistance to MEK inhibition, and that dual inhibition of these two
pathways may have synergistic therapeutic effıcacy. Methods: We selected the
cell line NLF from a panel of NB cell lines due to its high YAP expression and
NF1 loss. NLF cells were treated with MEK inhibitor trametinib (20 nM) over a
72-hour period and whole cell lysates and nuclear lysates were collected for
immunoblot. Effects of YAP knockdown via siRNA transfection with and with-
out trametinib co-treatment on survival were assessed by CellTiter-Glo and
RT-CES. Cell signaling analyses of tumor lysates from mouse SKNAS (NRAS
Q61K) xenografts treated with vehicle, 0.3 mg/kg, 1 mg/kg, or 3mg/kg for YAP,
ERK, and apoptosis pathways were performed via immunoblot. Results: Immu-
noblots of 72-hour time course treatments of trametinib in NLF showed de-
creased pYAP, the cytosolic inactive form of the YAP protein, indicating in-
creased YAP capable of translocating to the nucleus, which was confırmed by
analyses of nuclear extracts. siRNA-mediated knockdown of YAP alone in NLF
cells had amodest effect on survival, while combinatorial inhibition ofMEK and
YAP signaling caused a signifıcant reduction in cellular proliferation and sur-
vival. Immunoblotting of trametinib-treated SKNAS xenografts indicated de-
creased pYAP and pERK in response to increasing trametinib dose, while total
YAP levels remained constant. Conclusion: Our results demonstrate that pro-
longed trametinib exposure causes a marked nuclear enrichment of unphos-
phorylated YAP and co-inhibition of MEK and YAP in neuroblastoma models
effectively reduces proliferation and survival. We are currently investigating the
effects of MEK inhibition on the expression of YAP target genes and on cellular
proliferation upon modulation of YAP protein expression.
#5824 MHCclass I immunogenicity and novel tumor antigen discovery in
neuroblastoma. Mark Yarmarkovich,1 Moreno Di Marco,2 Olivia Padovan,3
Jenna Lobby,3 Laurence Eisenlohr,3 DimitriosMonos,3 Stefan Stevanovic,2 John
M. Maris3. 1University of Pennsylvania, Philadelphia, PA; 2University of Tübin-
gen, Tübingen, Germany; 3Children’s Hospital of Pennsylvania, Philadelphia, PA.
Background: Neuroblastoma is a childhood tumor characterized by relatively
few somatic mutations and low MHC expression, which has thus far largely
precluded it from investigation using adoptive immunotherapy. Methods: We
characterized MHC-presented antigens in 8 patient derived xenograft (PDX)
tumors using LC/MS/MS immunopeptidomics. We developed a method to
identify antigens derived from differentially expressed proteins by combining
RNA-seq data from 153 neuroblastoma and 1641 healthy tissues, and ligando-
mic data from 190 healthy tissues. We also performed functional characteriza-
tion on the ability HLA-A2 neuroblastoma lines to elicit a T-cell response using
CEF1 antigen-specifıc T-cell hyrbidoma when challenged with flu virus, and
performed bioinformatic analysis of the TME. Results: From 8 PDX tumors, we
identifıed a total of 14119 MHC-presented antigens. Interestingly, we observed
antigens from all tumors which stained negative for MHC by IHC, suggesting
that antigens can be identifıed from tumors below the detection limits of the
standard staining protocols. We fırst searched the ligandome dataset for all
possible neoantigens of 8-14aa arising from known mutations. Not having
found any mutated neoantigens, we developed a method to search for tumor
antigens derived neuroblastoma-specifıc proteins. We discovered 83 MHC li-
gands that derive from neuroblastoma-specifıc proteins, which we expect to be
promising targets for adoptive T-cell therapy.We also found a number of recur-
rent antigens across tumor samples, suggesting that the proteins from which
these antigens derive could be used in HLA-agnostic tumors vaccines. To test
whether the MHC expression in neuroblastoma is suffıcient to induce a T-cell
response, we characterized the ability of neuroblastoma cells to elicit a CD8
response to CEF1 antigen.We demonstrate that despite lowMHC expression in
all lines tested, 4/7 lines are able to induce a robust T-cell response to flu antigen
greater than HLA-A2 melanoma cells (20pg/mL IL-2 release in all responsive
lines).We also characterized immune activity in patient tumors usingGranzyme
A (GZMA) and Perforin (PRF1) as surrogates for T-cell activity. We observed a
strong correlation between known T-cell-recruiting cytokines (particularly
CXCL5/9/10) and GZMA/PRF1 (p2.51x10-35), providing further evidence
that T-cells are active in the tumormicroenvironment despite lowMHC expres-
sion on tumor cells. Conclusions: We identify neuroblastoma-specifıc MHC
class I antigens in each of the 8 PDX tumorswe tested, yielding a total of 83 novel
antigens. We conclude that neuroblastoma tumors harbor promising tumor-
specifıc targets for immunotherapy despite low rates of somatic mutation and
lowMHCexpression, and that at least a subset of these tumors are able to induce
a robust response using antigen-specifıc T-cell hybridomas. We also describe
methods of identifying tumor-specifıc MHC antigens in other tumors with low
mutational burden.
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#5825 Mechanisms of intrinsic and acquired resistance to antibodies tar-
geting IGF-1R in pediatric sarcoma cell lines. Terry J. Shackleford,1 Seethal-
akshmi Hariharan,1 Doris Phelps,1 Hemant Bid,2 Hiahong Zhong,3 Peter
Houghton1. 1Greehey Children’s Cancer Research Institute, UT Health San An-
tonio, San Antonio, TX; 2Resonant Therapeutics, Inc., University of Michigan,
Ann Arbor, MI; 3MedImmune, Inc., Gathersberg, MD.
Background: Pediatric bone and soft tissue sarcomas are heavily dependent
on the Type 1 insulin-like growth factor receptor (IGF-1R) signaling axis, which
promotes tumorigenic properties such as proliferation, survival, angiogenesis
andmetastasis.While a substantial proportion of patients demonstrate intrinsic
resistance to monoclonal antibodies targeting IGF-1R, a strong and sustained
response is seen in a limited number of patients, and disease stabilization in
about 30%of patients.Understanding these resistancemechanismsmay identify
combinations of targeted therapies that optimize therapeutic effıciency of IGF-
1R-targeted antibodies. Methods: For intrinsic resistance, we used a panel of
Ewing sarcoma (ES; n10) and rhabdomyosarcoma (RMS; n10) cell lines
that, with the exception of Rh41, are all intrinsically resistant to TZ-1, a mono-
clonal antibody that targets IGF-1R. For acquired resistance, we developed a
TZ-1 resistant RMS cell line, Rh41/TZ-1. We utilized Receptor Tyrosine Kinase
(RTK) Arrays to analyze the phosphorylation status of 49 RTKs. The cell lines
were treated with TZ-1 and changes in RTK expression were assessed by quan-
titative PCR. Results: RMS cells intrinsically resistant to TZ-1 treatment ex-
pressed multiple activated RTKs including EGFR family of receptors, IGF-1R,
IR, PDGFR, FGFR4, HGFR4, RYK, ALK, DDR1, AXL, DTK. Interestingly, ES
cells (n5) had either a complex pattern of activated RTK expression similar to
RMS cells or a relatively less complex set (n5) of activated RTKs (IGF-1R, IR,
HGFR, ERBB4, AXL, DTK). TZ-1 treatment of these cell lines with intrinsic
resistance demonstrated decreased phosphorylation of IGF-1R, but had little
effect on other RTKs. In contrast TZ-1 treatment of Rh41 cells rapidly induced
activation of several RTKs including: AXL, PDGFRB, FGFR4 and ALK. In-
creased expression of these receptors was confırmed by qPCR. In contrast,
Rh41/TZ-1 cells selected for acquired resistance to TZ-1 constitutively ex-
pressed activated RTKs (PDGFRB, FGFR4, AXL, DTK, VEGFR1). In Rh41 cells
treated with TZ-1, the BRD4 inhibitor, JQ1 (500 nM, 24Hr), blocked the induc-
tion of IGF-1R, IRB, AXL, PDGFR-A/-B, VEGFR1 and ALK. However, it had
less effect on the induction of FGFR 2/3/4 receptors. Further, combined treat-
ment of TZ-1 and JQ1 reduced cellular proliferation of Rh41 cells more than
TZ-1 treatment alone. Conclusions: We demonstrate that intrinsic resistance to
the IGF-1R targeted antibody TZ-1 is characterized by constitutive activation of
multiple RTKs. In response to TZ-1 treatment in a sensitive cell line there is
rapid induction ofmultiple RTKs indicating a dynamic response to inhibition of
IGF-1R. Our data suggests that BRD4 is involved in induction of these signaling
molecules and that combined inhibition of BRD4 along with the IGF-1R tar-
geted therapy can overcome this resistance and warrants further investigation.
Support: US Public Health Service Grant CA165995.
#5826 Essential role for cyclic-AMP responsive element binding protein 1
(CREB1) phosphorylation in the survival of medulloblastoma patients.Wal-
derik W. Zomerman,1 Sabine L. Plasschaert,2 Frank J. Scherpen,1 Harm Jan J.
Lourens,1 Geesina C. Huizinga,1 Eelco W. Hoving,1 Wilfred F. den Dunnen,1
Sophia Bruggeman,1 Eveline S.J.M. de Bont1. 1University Medical Center Gro-
ningen, Groningen, Netherlands; 2PrinsesMaximaCenter for Pediatric Oncology,
Utrecht, Netherlands.
Prognosis for recurrent medulloblastoma patients is extremely poor, with a
median survival of 26.8 months. Treatment options for recurrent medulloblas-
toma patients are limited and ineffective due to resistance to chemotherapeutic
agents and radiotherapy. Therefore, more research is required to address the
high mortality of medulloblastoma patients that have therapy-resistant medul-
loblastoma. In a previous, study, we showed that cyclic-AMP responsive ele-
ment binding protein (CREB1) was highly phosphorylated in primarymedullo-
blastoma specimens. CREB is an important transcription factor involved in
cerebellar cell proliferation and survival. In various cancers types, the expression
of CREB is associated with prognosis. Untill now, CREB expression and its
relation with overall survival has not been studied in medulloblastoma patients.
In this study, we determined CREB phosphorylation levels and mRNA levels of
CREB and its transcriptional co-activators CREBBP and EP300 using peptide
phosphorylation and gene expression arrays in a cohort of 50 pediatric medul-
loblastoma patients. Furthermore, we performed shRNA-mediated knockdown
of CREB, CREBBP and EP300 mRNA levels in medulloblastoma cell line
DAOY.Knockdownwas confırmed bymeans of qRT-PCRandwestern blotting.
Next, cell viability assays were used to investigate the effect of chemotherapeutic
reagents (etoposide and/or cisplatin) on cell viability in CREB, CREBBP or
EP300 knockdown cells or in combination with a small molecule CREB inhibi-
tor (KG-501).Low CREB phosphorylation levels in combination with low
CREBBP and EP300mRNA levels was signifıcantly associated with poor overall
survival (p0.0001) with a median survival of 11.7 months in medulloblastoma
patients. High CREB phosphorylation in combination with high CREBBP and
EP300 mRNA levels was associated with a favourable prognosis (5 year-overall
survival: 91%). Supervised clustering of gene expression data based upon low
versus high CREB phosphorylation and CREBBP/EP300mRNA levels and sub-
sequent gene ontology analysis showed signifıcant enrichment of genes associ-
ated with cerebellar and neuronal differentiation and development. Further-
more, knockdown with shCREB.3, shCBP.1-2 or shEP300A completely rescued
DAOY cells from the etoposide-induced decrease in cell viability that was ob-
served in the scrambled control. Similarly, addition of the CREB inhibitor KG-
501 (2M) completely rescued DAOY cells from the etoposide-induced de-
crease in cell viability and partially rescued DAOY cells from the cisplatin-
induced decrease in cell viability.Together, these fındings support an important
role for CREB in neuronal differentiation, chemosensitivity and in the overall
survival of pediatric medulloblastoma patients.
#5827 Role of Ewing sarcoma EWS/FLI1 protein in midzone formation
during mitosis.Mizuki Azuma. University of Kansas, Lawrence, KS.
Ewing sarcoma remains the secondmost common form of bone and cartilage
cancer in children. Although EWS/FLI1 fusion protein (derived by chromo-
somal translocation) is known to induce aberrant transcription in the patient
cells, why and how this molecule leads to tumorigenesis specifıcally in skeletal
cell lineage is not understood.We previously reported a novel role of EWS/FLI1,
which interacts with EWS and leads to mitotic defects through an inhibition of
EWS function.We further demonstrated that EWS interacts with Aurora B and
relocates from inner centromere to the midzone (a midline structure that is
consisted spindles called the central spindle) during anaphase of mitosis. Dis-
ruption of EWS-directedAuroraB-relocation leads to defects in cytokinesis, and
to induction of chromosome instability (CIN). EWS is an abundant molecule
that is localized throughout the entire cytoplasm of anaphase, but how EWS
specifıcally regulates midzone formation is not understood. A potential candi-
date mechanism is post-translational modifıcation of EWS to modulate its ac-
tivity in a spatial-temporal manner. Because previous studies showed that EWS/
FLI1-T79 is a potential modifıcation site of O-GlcNAcylation and
phosphorylation, we hypothesized that theO-GlcNAcylation of EWS/FLI1 con-
tributes to the impairment of Aurora B-relocation. Our study shows that high
cellular O-GlcNAc increases the level of O-GlcNAcylation of EWS/FLI1 accom-
panied by the impairment of the Aurora B relocation and of central spindle
formation. Contrary, EWS/FLI1-T79A and EWS/FLI1-T79D (phospho-mimic
mutant) does not impair themislocation of Aurora B at themidzone, suggesting
that theO-GlcNAcylation of EWS/FLI1 is responsible formislocation of Aurora
B at themidzone. TheO-GlcNAc-dependent impairment ofmidzone formation
by EWS/FLI1 may lead to the identifıcation of therapeutic targets for Ewing
sarcoma patients.
#5828 Targeting the polyamine-hypusine nexus for the treatment of neu-
roblastoma.Andre S. Bachmann,1 Raid El-Khawaja,2 Chad Schultz1. 1Michigan
State Univ., Grand Rapids, MI; 2Grand Valley State University, Allendale, MI.
The highly conserved and unique post-translational hypusinemodifıcation is
essential for the activation of a single cellular protein called eukaryotic initiation
factor 5A (eIF5A). Hypusination of eIF5A represents an essential mechanism in
the control of cell proliferation and has been linked to cancer. The hypusine
modifıcation of eIF5A requires the enzymes deoxyhypusine synthase (DHPS)
and deoxyhypusine hydroxylase (DOHH) and, importantly, uniquely depends
on the polyamine spermidine as a selective substrate. Polyamines including
spermidine are frequently dysregulated in neoplastic disease and are critical for
cell proliferation. Ornithine decarboxylase (ODC) is the sentinel enzyme in
polyamine biosynthesis. We pioneered the repurposing of the irreversible ODC
inhibitor alpha-difluoromethylornithine (DFMO) for neuroblastoma (NB), a
devastating pediatric cancer of the sympathetic nervous system. Our preclinical
work was confırmed by other groups and spurred two consortia (NMTRC and
NANT) to testDFMO in independent phase I/IINB clinical trials. The oncogene
MYCN is commonly amplifıed in high-risk NB patients and predicts poor prog-
nosis.MYCNdirectly activatesODC (and eIF5A) and drivesNB tumor progres-
sion, presumably through the activation of polyamines, but the precise molecu-
lar mechanisms are not fully understood. Since spermidine is the only molecule
that can activate eI5FA through hypusine modifıcation, we hypothesized that
the polyamine-hypusine nexus provides a rational target site to identify new
drug combinations that trigger synergistic anti-tumor effects. In this study we
found that DFMO combined with DHPS inhibitor GC7 induced synergistic
drug reactions in NB at concentrations that are not lethal on their own. While
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each drug alone at higher concentrations induced p27/Rb-mediated G1/S cell
cycle arrest, the combination of both drugs resulted in the induction of pro-
grammed cell death (apoptosis). The intracellular free polyamine levels (pu-
trescine, spermidine, and spermine) were quantifıed by C-18 RP-HPLC and
responded directly to drug treatments, suggesting specifıc drug targeting effects.
This dual-pronged drug combination approach that specifıcally targets the
blockade of the unique polyamine/spermidine-dependent hypusine-eIF5A sig-
naling circuit known to be involved in cell proliferation might lead to more
effective DFMO treatment options by reducing high DFMO doses currently
needed while achieving better therapeutic outcomes in NB.
#5829 Targeting TSLP-induce upregulation of Mcl-1 for the treatment of
Ph-like ALL with CRLF2 alterations. Cornelia Stoian,1 Nathaniel George
Mambo,2 Pierce McCarthy,2 Veriah Vidales,1 Jacqueline S. Coats,1 Ineavely
Baez,1 Sinisa Dovat,3 Shadi Farzin Gohar,1 Dhimant Desai,4 Muhammad Ka-
mal,1 Kimberly J. Payne1. 1Loma LindaUniv., Loma Linda, CA; 2California State
University San Bernardino, CA; 3Pennsylvania State University, PA; 4Pennylva-
nia State University–Hershey, Hershey, PA.
B cell precursor acute lymphoblastic leukemia (B-ALL) is the most common
childhood cancer. The subset of pediatric B-ALL patients at greatest risk for
relapse and death have a gene expression profıle similar to Philadelphia chro-
mosomepositiveALL.Approximately half of these Ph-like B-ALL are defıned by
genetic alterations that result in overexpression of the cytokine receptor, CRLF2.
Stimulation of the CRLF2 receptor by the cytokine, TSLP, causes downstream
activation of the JAK/STAT5 and PI3/AKT/MTOR pathways. Activation of
these pathways has been associated with oncogenesis and chemoresistance. A
gene target of activated STAT5 in B cell precursors is Mcl-1, a Bcl2 family pro-
survival molecule. Further, Mcl-1 protein levels are increased through post-
transcriptional mechanisms induced by activation of the mTOR pathway. We
hypothesized that circulating TSLP cytokine contributes to chemoresistance by
increasing CRLF2 activation leading to increased Mcl-1 expression and that
targeting Mcl-1 could be an effective strategy for treating Ph-like B-ALL with
overexpression of CRLF2 (CRLF2 B-ALL). To test this hypothesis we cultured
human CRLF2 B-ALL cell lines (MUTZ5 and CALL4) with and without TSLP
for 3 days and evaluated expression of Mcl-1 by flow cytometry. We found that
TSLP induced signifıcant increases in Mcl-1 proteins in both cell lines. To de-
termine if these results are reflective ofwhat happens in patients, primaryCRLF2
B-ALL cells from pediatric patients were cultured with physiological levels of
TSLP (20 pg/ml) and similarly evaluated. Physiological TSLP signifıcantly
increased Mcl-1 protein in primary CRLF2 B-ALL cells, including those with
activating JAK mutations. Our next question was whether TSLP-induced in-
creases in Mcl-1 could be effectively targeted with Mcl-1 inhibitors (MIM-1 or
Maritcolax). CRLF2 B-ALL cells were incubated with and without TSLP and
treated with increasing doses of Mcl-1 inhibitor. Dose responses were evaluated
by flow cytometry after 2 or 3 days. Mcl-1 inhibitors induced dose-dependent
decreases in cell count and increases in caspase-3 activation and apoptosis (An-
nexin V/7-AAD). These corresponded with dose-dependent decreases inMcl-1
protein, suggesting that both inhibitors target Mcl-1 for degradation. MIM-1
and Maritoclax showed effıcacy against both CRLF2 B-ALL cell lines and pri-
mary patient samples, including those with activating JAKmutations, although
cells cultured with TSLP typically required twice the dose of Mcl-1 inhibitor to
achieve the same effect observed without TSLP. These data provide evidence
that TSLP can contribute to leukemia cell survival and identify Mcl-1 inhibitor
as a candidate therapy for CRLF2 B-ALL. Ongoing studies are evaluating the
effıcacy of the Mcl-1 inhibitor, Maritoclax, in novel patient-derived xenograft
models of CRLF2 B-ALL that provide physiological levels of human TSLP.
#5830 A novel Notch-YAP circuit drives stemness and tumorigenesis in
embryonal rhabdomyosarcoma. Katherine K. Slemmons, Lisa E.S. Crose, Ste-
fan Riedel, Manuela Sushnitha, Brian Belyea, Corinne M. Linardic. Duke Uni-
versity, Durham, NC.
Introduction: Rhabdomyosarcoma (RMS), a tumor characterized by skeletal
muscle features, is the most common soft tissue sarcoma in children and ado-
lescents. The standard of care treatment has not changed in over 40 years, re-
sulting in a stagnant survival rate of less than 30% for high risk groups. Previous
studies have identifıed the developmental pathways Notch and YAP as potent
oncogenic signals in the embryonal subtype of RMS (eRMS). Understanding the
signaling between Notch and YAP in cancers driven by these pathways, such as
eRMS, will be crucial to designing rational combination therapies. Experimental
Procedures: For in vitro assays, we utilized 3D sphere cell culture methods that
permit the study of stem cell behavior. To analyze signaling, we performed
genetic gain and loss-of-function (dox-inducible shRNAs and constitutively ac-
tive constructs), and pharmacologic inhibition. Target validation was assessed
by qPCR and immunoblot, and mechanism was determined by ChIP and limit-
ing dilution assays. For in vivo experiments, we performed subcutaneous xeno-
grafts in immunocompromised mice. Immunohistochemistry was used to ana-
lyze protein expression in human and murine tumors. Statistical analysis was
performed to assess signifıcant differences. Results: We have discovered a novel
Notch-YAP circuit that drives cancer cell stemness and tumorigenesis. In eRMS
3D spheres, Notch transcriptionally upregulates YAP and increases its activity,
while YAP transcriptionally upregulates the Notch ligands JAG1 and DLL1 and
the core Notch transcription factor RBPJ to provide positive feedback. In vivo,
YAP suppression decreases Notch signaling, stemness, and proliferation. This
circuit boosts expression of the stem cell gene SOX2, which is functionally re-
quired for eRMS cell stemness. Inhibiting one node of the circuit, for example
through Notch pharmacologic blockade, is not suffıcient to shut down the cir-
cuit, as stemness and cell growth can be rescued by ectopic YAP. Rather, dual
inhibition of Notch and YAP is necessary to silence the circuit’s signaling and
sphere growth. Importantly, nuclear Notch and YAP protein expression corre-
late in eRMS patient tumor samples, suggesting this circuit is intact in human
eRMS tumors. Conclusions: While unidirectional signaling between these two
pathways has been reported in metazoan development and rarely in human
malignancy, this is the fırst fınding of an intact bidirectional circuit between
Notch and YAP that supports cancer cell stemness and tumorigenesis. This
study provides mechanistic insight into the long-standing question of how
eRMS cancer stem cells maintain plasticity. Additionally, while this signaling is
identifıed here in RMS, it could be applicable to many cancer types that are
Notch and YAP-dependent. Lastly, this work provides evidence and rationale
for research into combination therapies targeting this Notch-YAP signaling cir-
cuit.
#5831 Activated Wnt signaling for the treatment of recurrent medullo-
blastoma. Branavan Manoranjan,1 Chitra Venugopal,1 Zvezdan Pavlovic,2 Da-
vid Bakhshinyan,1 Michelle Kameda-Smith,1 Minomi Subapanditha,1 Sujeivan
Mahendram,1 JasonMoffat,2 BradleyW.Doble,1 Sheila Singh1. 1McMaster Stem
Cell and Cancer Research Institute, Hamilton, Ontario, Canada; 2University of
Toronto, Ontario, Canada.
Brain tumors represent the leading cause of childhood cancer mortality, of
which medulloblastoma (MB) is the most frequent malignant pediatric brain
tumor. Currentmolecular subgroups ofMB recognize distinct disease entities of
which activated Wnt signaling (monosomy 6, exon 3 mutations in CTNNB1,
and Wnt gene signature) is associated with a distinct subgroup and the best
overall outcome. In contrast, only non-WntMBs are characterized bymetastatic
disease, increased rate of recurrence, and poor overall survivorship. Given the
excellent clinical outcome in patients withWnt-drivenMB, we aimed to convert
treatment-resistant MB subgroups into an ostensibly benign tumor through
selective targeting by small molecules and transgenic patient-derived lines con-
taining a stabilized beta-cateninmutant. ActivatedWnt signaling byway ofWnt
agonists in treatment-refractory MBs resulted in decreased in vitro self-renewal
and promoted differentiation. Comparative gene expression profıling of control
and transgenic lines containing a stabilized beta-cateninmutant demonstrated a
reduction in stem cell self-renewal genes following beta-catenin overexpression,
including Sox2 and Bmi1. In order to validate the therapy-sensitive nature of
Wnt-activated cells, we developed stable patient-derived lines containing a
7XTOPFlash reporter for endogenous Wnt signaling. Rare subclonal Wnt-ac-
tive cells demonstrated a reduced self-renewal and tumor-initiating capacity
through in vivo limiting dilution assays when compared to bulk Wnt-inactive
cells. The therapeutic relevance of these fındings were demonstrated with an in
vivo survival advantage in mice with orthotopic injections of cells containing a
stabilized beta-catenin mutant representative of constitutively active Wnt sig-
naling or endogenous Wnt-active cells. Xenografts generated from Wnt-acti-
vated tumors were smaller in size, maintained a lower rate of proliferation, and
reduction in MB self-renewal genes. To further illustrate the clinical utility of
activated Wnt signaling, we modifıed the Children’s Oncology Group therapy
protocol for childhoodMB so that xenografts may receive chemo/radiotherapy.
Tumors generated fromWnt-active xenografts were much more radiosensitive
and displayed a signifıcant reduction in spinal metastasis when compared to
mice receiving standard therapy withoutWnt activation. To develop a rationale
clinical therapeutic, we developed unique agonist antibodies that target theWnt
co-receptor LRP5. Treatment with LRP5 antibodies showed a signifıcant reduc-
tion in tumor burden and increase in survival of patient-derived tumors that
were otherwise treatment-resistant. Our work establishes for the fırst time acti-
vated Wnt signaling as a novel treatment paradigm in childhood MB, identifıes
a rationale therapeutic approach for recurrent MB, and provides evidence for
the context-specifıc tumor suppressive function of the canonical Wnt pathway.
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#5832 Rho-associated kinase is a therapeutic target in neuroblastoma.
Cecilia H. Dyberg,1 Susanne Fransson,2 Teodora Andonova,1 Baldur Sveinb-
jörnsson,3 Jessika Lännerholm-Palm,1 David Forsberg,1 Eric Herlenius,1
Tommy Martinsson,2 Per Kogner,1 John Inge Johnsen,1 Malin Wickström1.
1Karolinska Institutet, Stockholm, Sweden; 2Department of Medical and Clinical
Genetics, Sahlgrenska Academy at the University of Gothenburg, Gothenburg,
Sweden; 3University of Tromsö, Norway, Norway.
Background: Neuroblastoma is a peripheral neural system tumor that origi-
nates from the neural crest and is the most common and deadly tumor of in-
fancy. The non-canonical Wnt/planar cell polarity (PCP) signaling pathway
regulates cytoskeletal organization, migration and maturation of neural crest
cells during neuritogenesis. Here we show that neuroblastoma harbors frequent
mutations of genes controlling the PCP signaling pathway and Rac/Rho signal-
ing cascade important for proper migration and differentiation of neural crest
cells during neuritogenesis. The majority of these mutations were detected in
GTPase activating proteins and guanine nucleotide exchange factors genes,
which may result in inhibition of Rac and activation of Rho and was associated
with aggressive high-stage neuroblastomas. Methods: We performed whole-
exome sequencing of neuroblastoma samples of all clinical subgroups to search
for mutations and genetic aberrations. Cytotoxic activity of Rho-associated ki-
nases (ROCK) inhibitors was studied in cell viability assays. Morphology and
invasion were studied with microscopy. The molecular mechanisms were char-
acterized using cell- and molecular biology techniques. In vivo studies (xeno-
grafts and the transgenic mouse model TH-MYCN) in mice were carried out to
validate the therapeutic effects and toxicity. Results: Exome sequencing detected
frequentmutations and gene aberrations in genes controlling the activity of PCP
signaling. Analysis of gene signatures and immunohistochemistry showed that
high expression of ROCK1 and ROCK2 correlated with poor patient survival.
Several mediators of Rac/Rho were differentially expressed in cell lines and
patient samples. Pharmacological or genetic inhibition of ROCK, a keymolecule
in Rac/Rho signaling resulted in differentiation, inhibition of neuroblastoma
cell growth and migration and degradation of MYCN protein. Finally, ROCK
inhibition reduced the growth of established neuroblastoma xenografts in nude
mice and repressed tumor progression in a MYCN-driven mouse model of
neuroblastoma (T-MYCN) Conclusions: These results provide evidence that
inhibition of the non-canonical/PCP signaling cascade using ROCK inhibitors
suppress the growth of neuroblastoma in preclinical models and suggest possi-
bilities for improved treatment of high-risk neuroblastomas.
#5833 Targeting the transcription co-activator TAZ inhibitsMYC-driven
medulloblastoma. Yingchao Xue, Mingyao Ying. Kennedy Krieger Research
Inst., Baltimore, MD.
Medulloblastoma (MB), the most commonmalignant pediatric brain tumor,
results in signifıcant neurological, intellectual and physical disability or death.
Four MB subtypes (WNT, SHH, Group 3 and 4) have recently been identifıed.
Group 3 MB, the most aggressive subtype, is more frequently associated with
gene amplifıcation and/or protein overexpression of the MYC (c-Myc) onco-
gene, hereby referred to as MYC-driven MBs. It is still unclear how MB cells
activate and maintain high MYC expression, as only a small portion of MYC-
high MBs is caused by MYC genomic amplifıcation. MYC-targeted MB thera-
pies are also lacking. TargetingMYCupstream activators is a promising strategy
for inhibitingMYC-drivenMBs, when compared to direct MYC inhibition that
is still challenging.Here, we focus on the transcription co-activator TAZ, a novel
MYC upstream activator and a potential therapeutic target for inhibitingMYC-
driven MBs. TAZ (transcriptional co-activator with PDZ-binding motif) is an
oncogenic driver in multiple human cancers. TAZ and its paralog YAP form
complexes with other transcription factors, such as TEAD, to activate down-
stream gene targets. TAZ and YAP are transcriptional effectors of various sig-
naling pathways, such as the Hippo pathway. We found for the fırst time that
TAZ is an essential MYC activator in MB cells. TAZ but not its paralog YAP is
highly expressed in MYC-amplifıed MB cells and their xenografts. TAZ silenc-
ing downregulates MYC and inhibits MB cell proliferation. Enforced TAZ ex-
pression inducesMYCexpression inMBcells and promotesMB cell growth.We
further showed that TAZ forms complex with transcription activator TEAD to
bind to and transactivate MYC enhancers. For pharmacological TAZ targeting,
we found that the FDA-approved drug Verteporfın (VP) inhibits TAZ-TEAD
interaction, suppresses MYC expression and inhibits MB cell tumor propaga-
tion in vivo.We have also developed a nanoparticle formulation by usingDSPE-
mPEG2000micelles to achieveVP delivery cross the blood-brain barrier inmice
bearing brain tumor xenografts. In summary, our results provide novel insights
into MYC upstream activators in MB, and also identify TAZ as a potential
therapeutic target for inhibitingMYC-drivenMBs. This knowledge may also be
widely applicable to other TAZ/MYC-expressing human cancers, such as glio-
blastoma. Moreover, our studies support the effectiveness of VP treatment in
pre-clinical MB models. These results and also the nanocarrier system for sys-
temic VP delivery provide a solid foundation for VP clinical trials in patients
with MB and likely other MYC-driven cancers.
#5834 Serum induces differentiation in aggressiveMYCN-amplifıed neu-
roblastoma patient-derived xenograft cells. Camilla U. Persson,1 Kristoffer
von Stedingk,1 Daniel Bexell,1 MyMerselius,1 David Gisselsson,2 Siv Beckman,1
Sofıe Mohlin,1 Sven Påhlman,1 Caroline Wigerup1. 1Translational Cancer Re-
search, Lund University, Lund, Sweden; 2Department of Clinical Genetics, Lund
University, Lund, Sweden.
Background: Cancer cell lines have traditionally been established in serum-
containing medium though it has been questioned whether serum-grown cell
lines faithfully represent the tumors they are derived from. Potential serum-
induced differentiation of in vitro cultured cells could partly explain why xeno-
grafted cell lines often lack invasive growth and robust metastasis. Direct im-
plantation of patient tumor material into mice, i.e. patient derived xenografts
(PDXs), has shown tomore closelymimic the original tumor growth pattern. By
isolating cells from neuroblastoma PDXs and culturing the PDX cells under
serum-free conditions, we expect to preserve a less differentiated phenotype,
enabling us to use PDX cells as a source for identifying potential neuroblastoma
stem-like cells. Moreover, to facilitate future drug screening, we investigated
conditions that would allow us to grow neuroblastoma PDX cells adherently,
without compromising their tumorigenic or metastatic capacity. Materials &
Methods: PDX cells were cultured in stem cell medium or serum-containing
medium for up to 7 days. IHC, RT-qPCR and WB were used to investigate the
expression of sympathetic neuronal differentiationmarkers. Formonolayer cul-
ture, cellswere grownon laminin. Results: PDXcells can routinely be established
as neurospheres in serum-free medium with retained tumorigenic and meta-
static capacity. Addition of serum induces loss of sphere formation, adherent
growth and a robust increase in sympathetic differentiation markers, both at
mRNA and protein level. Serum-cultured cells also show a decreased cell prolif-
eration (without increased apoptotic rate, as determined by sub-G0/G1 analy-
ses). The serum-induced differentiation was not irreversible since transferring
serum-grown cells back to serum-free medium resulted in a phenotypic switch,
with recovered proliferation and decreased expression of differentiation mark-
ers. Growing cells on laminin achieved adherent culture of PDX cells. This
resulted only in slight morphological differentiation but did not affect growth
rate or the cells tumorigenic and metastatic capacity. Conclusion: Culturing
neuroblastoma PDX cells in serum-containingmedium results in amore differ-
entiated phenotype. Thus, avoiding serum appears to be a key strategy in order
to preserve the phenotypic origin of these cells. The phenotypic effects of serum
on tumor cells have largely been overlooked and might be a general effect on
tumor cells explaining why serum-established cell lines do not metastasize and
grow invasively.
#5835 Oncogenic activation of the serine synthesis pathway by the scaf-
folding protein menin. Laurie Kathleen Svoboda, Selina Shiqing Teh, Sudha
Sud, Armand Bankhead, Brian Magnuson, Mats Ljungman, Costas Lyssiotis,
Tomasz Cierpicki, Jolanta Grembecka, Elizabeth R. Lawlor. Univ. of Michigan,
Ann Arbor, MI.
Developmental transcription programs are epigenetically regulated bymulti-
protein complexes including the MLL-containing trithorax (TrxG) complexes,
which methylate H3K4 to promote gene transcription. We recently reported
that the TrxG proteinMLL1 and its binding partnermenin are overexpressed by
and function as oncogenes in Ewing sarcoma. Moreover, small molecule inhi-
bition of themenin-MLL1protein-protein interaction leads to loss ofmenin and
MLL1 protein expression and to inhibition of growth and tumorigenicity. For
the current study we investigated the mechanistic basis of menin-MLL1 medi-
ated oncogenic activity in Ewing sarcoma. Bru-seq analysis was performed to
identify changes in nascent gene transcription in Ewing sarcoma cells following
exposure to the menin-MLL interaction inhibitor MI-503. Identifıed targets
were validated by qRT-PCR, western blot, immunocytochemistry and by inter-
rogation of published databases. Loss of function was achieved by lentiviral
shRNAs and by inhibitor treatment. Exposure of three independent Ewing sar-
coma cell lines toMI-503 resulted in signifıcant and reproduciblemodulation of
nearly 100 genes. Bioinformatics analysis of MI-503-regulated genes revealed
that the serine synthesis pathway (SSP) was the most signifıcantly impacted
pathway downstream of MI-503 treatment. The SSP has recently emerged as a
major mediator of tumorigenicity in multiple human cancers. qRT-PCR con-
fırmed reduced expression of SSP enzyme-encoding genes PHGDH, PSAT1 and
PSPH in MI-503 treated cells. To determine if the SSP contributes to Ewing
sarcoma pathogenesis we evaluated expression of SSP genes and proteins in
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tumors and cell lines. Our fındings showed that Ewing sarcomas express high
levels of PHGDH, PSAT1, and PSPH and interrogation of the Cancer Cell Line
Encyclopedia revealed that PHGDHexpression is higher in Ewing sarcoma than
in any other cancer in the database. Studies of Ewing sarcoma cells in serine and
glycine free media showed that cells retain viability but that exposure to the
PHGDH inhibitor, CBR-5884, inhibits survival in both standard and serine/
glycine-free conditions, confırming the importance of the pathway to tumor
pathogenesis. To determine how menin-MLL1 promote SSP activation we per-
formed loss of function studies and discovered that knockdown of menin, but
not ofMLL1, leads to a signifıcant reduction in SSP gene expression, implicating
menin as the primary mediator of SSP gene activation. Transcriptional up reg-
ulation the SSP pathway has been linked to ATF4 in non-small cell lung cancer.
Signifıcantly, ATF4 protein expression is high in Ewing sarcoma cells and ATF4
transcript and protein expression are down regulated following MI-503 treat-
ment and menin knockdown. Together these data demonstrate that the SSP is
highly active in Ewing sarcoma and that its activation is induced, at least in part,
by a novel menin-ATF4 transcriptional axis.
#5836 Activation of Wnt/beta-catenin alters the Ewing sarcoma secre-
tome - Implications for tumor:tumor microenvironment crosstalk. Allegra
Hawkins, Colin Sperring, Venkatesha Basrur, Alexey Nesvizhskii, Elizabeth
Lawlor. University of Michigan, Ann Arbor, MI.
Ewing sarcoma is the second most common bone cancer in children and
adolescents. Patients with metastatic disease have less than a 25% chance of
survival making it imperative to understand the mechanisms that drive metas-
tasis.Wepreviously showed that activation ofWnt/-catenin signaling inEwing
sarcoma cells alters the tumor cell transcriptome, promoting transition to a
moremetastatic cellular phenotype. In addition, primary tumorswith high-level
Wnt activation were associated with worse clinical outcomes, supporting a role
for canonical Wnt signaling in metastatic progression. Signifıcantly, extracellu-
lar matrix (ECM) protein genes were among the most affected by Wnt/-
catenin, suggesting that activation of the pathwaymight lead to alterations in the
local tumor microenvironment (TME). Crosstalk between the TME and tumor
cells regulates fundamental aspects of themetastatic cascade including invasion,
migration, and angiogenesis. It is our goal to defıne the impact ofWnt/-catenin
signaling on the TME and elucidate how these changes contribute tometastasis.
Our specifıc hypothesis is that activation of Wnt/-catenin in Ewing sarcoma
cells leads to changes in the tumor secretome that result in altered TME compo-
sition and tumor:TME crosstalk. To address this hypothesis, conditionedmedia
from Ewing sarcoma cell lines cultured in the presence and absence of Wnt3a
was collected for proteomic analysis.We used label-freemass spectrometry with
spectral counting to quantify proteins that passed a1% FDR threshold. Signif-
icance was defıned as greater than 4.5 or less than 0.2 fold difference in counts
betweenWnt3a and control conditions.Western blot of conditionedmedia was
used to validate identifıed proteins. Preliminary analysis of the TC32 cell line
identifıed 49 proteins up regulated in Wnt3a treated media in comparison to
control. Signifıcantly, Tenascin C (TNC), was among the most signifıcantly up
regulated proteins, validating our prior data that TNC is a transcriptional target
of Wnt/-catenin and a promoter of the metastatic phenotype in vivo. Gene
ontology analysis of the signifıcantly differentially expressed proteins revealed
enrichment of proteins involved in ECM-receptor signaling, ECMorganization,
cell adhesion, and collagen catabolism. These biologic processes all play critical
roles in tumor:TME interactions and together contribute to the early steps of
adhesion, migration and invasion that are responsible for initiation of metasta-
sis. These preliminary studies confırm that Wnt/-catenin-dependent changes
in the Ewing sarcoma transcriptome are associated with changes in tumor cell
secretome. We are now validating these fındings in additional cell lines and
updated results will be presented. These studies will elucidate how changes in
tumor cells can lead to changes in the local TME and in tumor:TME crosstalk
that promote metastatic progression of Ewing sarcoma.
#5837 Phosphoproteomic landscape of sarcoma: novel subgroups and ac-
tionable targets. Emmy D. Fleuren,1 Myrella Vlenterie,2 Winette van der
Graaf,1 Melissa Hillebrandt-Roeffen,2 Sabri Cebeci,2 Amy van de Ven,2 Uta
Flucke,2 JianminWu,3 Yvonne Versleijen-Jonkers,2 Roger Daly4. 1The Institute
of Cancer Research, London, United Kingdom; 2Radboud UMC, Nijmegen, Neth-
erlands; 3PekingUniversity CancerHospital & Institute, China; 4MonashUniver-
sity, Melbourne, Australia.
Sarcomas comprise a heterogeneous group of malignant tumors of the con-
nective tissue, and disproportionally affect the young. Despite intensive, multi-
modal treatments, survival is still limited and accompanied by many early and
late side effects. In contrast to advances in carcinomas, specifıc targetable driver
mutations have not or rarely been found in sarcoma and targeted therapies have
met with disappointing clinical results, stressing the need for an unbiased and
comprehensive analysis of oncogenic signaling networks to reveal therapeutic
targets and personalized treatment strategies. We utilized a mass-spectrometry
(MS)-based phosphoproteomics screening approach to profıle the largest and
most heterogeneous set of sarcoma cell lines (n20) to date, including both
adult (gastrointestinal stromal tumor (GIST) and angiosarcoma (AS)) andmul-
tiple pediatric/adolescent and young adult (AYA; synovial sarcoma (SS), Ewing
sarcoma (ES) and rhabdomyosarcoma (RMS)) sarcomas, as well as soft-tissue
sarcomas (STS) and bone sarcomas. We specifıcally included cell lines and SS
and AS subtypes that were never phosphoprofıled before, to reveal completely
novel molecular insights into sarcoma pathology. Validations were performed
in vitro, in vivo, and on patient tumor material. Our unique tyrosine phosphor-
ylation data revealed a novel subclassifıcation of sarcoma, and showed that
particularly the pediatric/AYA sarcoma models did not cluster within their his-
tological subgroup. Particular tyrosine kinases exhibited enhanced phosphory-
lation in particular subtypes, and we identifıed driver kinases with outlier levels
of activation. ALKwas identifıed as a completely novel and unexpected driver in
the Aska-SS SS cell line, which was explained by an underlying ALK transloca-
tion. Functional ALK dependency was confırmed with in vitro proliferation
assays, showing high sensitivity for the ALK inhibitor TAE684 (IC50 263 nM)
and the ALK/MET inhibitor crizotinib (IC50 465 nM). Patient specimens con-
fırmed a clinical role forALK in SS,withALK immunopositivity in 14% (6/43) of
patients and one 16y old patient harboring an ALK translocation, present in
both her primary tumor as in 4 metastases. Other SS cell lines and sarcoma
subtypes exhibited multiple activated tyrosine kinases, providing a rationale for
combined targeting approaches. Indeed, highMET and PDGFR	 phosphoryla-
tion in Yamato-SS SS cells predicted sensitivity to crizotinib and pazopanib
(PDGFR) in vitro and in vivo. The clinical signifıcance was again confırmed in a
cohort of SS patients, inwhichMETor PDGFR	 expressionwas detected in 58%
and 84% of SS patients, respectively, with co-expression in 56%. Altogether, this
is the fırst study to provide a deep insight into activated networks andmolecular
clustering patterns in sarcoma. Our integrated approach systematically identi-
fıed and validated ALK and MET as novel and actionable drivers in SS.
TUMOR BIOLOGY: Radioprotectors, Radiosensitizers, and
Radiation Resistance
#5838 Adhesion- and stress-related adaptation mechanisms eliciting gli-
oblastoma radiochemoresistance can be effectively circumvented by beta1
integrin/JNK co-targeting. Anne Vehlow,1 Erik Klapproth,1 Katja Storch,1 El-
len Dickreuter,1 Michael Seifert,2 Antje Dietrich,1 Rebecca Bütof,1 Achim
Temme,3 Nils Cordes1. 1OncoRay - National Center for Radiation Research in
Oncology, Dresden, Germany; 2Institute for Medical Informatics and Biometry,
Dresden, Germany; 3Department of Neurosurgery, Dresden, Germany.
Glioblastoma multiforme (GBM) is the most common brain tumor in adults
and characterized by poor clinical outcome due to genetic and epigenetic alter-
ations in resistance-mediating genes and destructive infıltration into the normal
brain. Upon therapy, malignant tumors show adaptation to maintain their ho-
meostasis. Two critical determinants of this adaptation process are cell adhesion
by beta1 integrins and stress signaling via c-JunN-terminal kinases (JNK).Here,
we evaluated the potential of simultaneous beta1 integrin/JNK targeting to over-
come GBM adaptation controlling radiochemoresistance and invasion. Com-
parativeOncomine data base analysiswas performedon the expression of JNK1/
2/3 isoforms, beta1 integrin and its ligands inGBMwith normal brain. Different
human GBM cell populations (patient-derived, stem-like, established) were an-
alyzed for sphere formation, clonogenicity, 3D collagen type-1 invasion, cell
cycling, chromatin organization, DNA double strand break (DSB) repair
(H2AX foci assay), broad-spectrumphosphoproteome analysis, FACS analysis
and protein expression/phosphorylation upon irradiation (0-6 Gy X-rays) and
chemotherapy (Temozolomide) with and without single and simultaneous in-
hibition of beta1 integrin (AIIB2) and JNK (SP600125, JNKi). The radiochemo-
sensitizing potential of AIIB2/JNKi was also investigated in an orthotopic GBM
mouse model using stem-like cells. In contrast to JNK isoforms, beta1 integrin
and col1 showed signifıcant overexpression in GBM compared with normal
brain. While single inhibition of beta1 integrin and JNK mediated cytotoxicity,
only combined targeting resulted in radiochemosensitization. Intriguingly,
double AIIB2/JNKi treatment abrogated GBM cell invasion. Importantly, dual
beta1 integrin/JNK inhibition elicited a signifıcant reduction in tumor growth
and longer survival of mice concomitantly treated with radiotherapy/Temozo-
lomide. Mechanistically, JNK blocking induced beta1 integrin expression for
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stimulating diverse signaling pathways controlling cell cycling, invasion and
radiochemosensitivity. Radiosensitization byAIIB2/JNKi is caused by enhanced
ATM phosphorylation and prolonged G2/M cell cycle arrest as well as impaired
DNAdouble strand break repair in the context of elevated levels of euchromatin.
In summary, our data reveal that dual beta1 integrin/JNK targeting effıciently
impairs adhesion and stress-related adaptation mechanisms involved in ra-
diochemoresistance and invasion. More in-depth evaluation is warranted to
clarify the potential of this kind of beta1 integrin/JNK multi-targeting strategy
administrated concomitantly to standard radiochemotherapy in patients suffer-
ing from GBM.
#5839 Androgen receptor (AR): A novel target for radiosensitization in
triple-negative breast cancers (TNBC). Benjamin C. Chandler,1 Corey W.
Speers,1 Shuang G. Zhao,1 Meilan Liu,1 Kari Wilder-Romans,1 Eric Olsen,1
ShyamNyati,1 Daniel Spratt,1 DanielWahl,1 Daniel Hayes,1 Felix Y. Feng,2 Lori
J. Pierce1. 1University ofMichigan, Ann Arbor, MI; 2University of California, San
Francisco, San Francisco, CA.
Purpose: Increased rates of local recurrence (LR) have been observed in
TNBC despite chemotherapy and radiation (RT). Thus, approaches that result
in radiosensitization in TNBC are critically needed. We characterized the RT
response of 21 breast cancer cell (BCC) lines using clonogenic survival assays
and paired this with high-throughput drug screen data, identifying AR as a top
target for radiosensitization. We demonstrate that AR inhibition confers radio-
sensitization in vitro and in vivo, identifıed a biomarker of response, and char-
acterize themechanism of AR-mediated radiosensitization in TNBC.Materials/
Methods: Clonogenic survival assays determined the intrinsic RT sensitivity of
21 BCC lines. IC50 values were determined for 130 clinical compounds and
correlation coeffıcients were calculated using IC50 values and SF-2Gy. Gene and
protein expressionwasmeasured using RNASeq andRPPA arrays, respectively,
in tumor samples (n2,061) and BCC lines (n51). AR function was assessed
using gene knockdown (KD) or functional inhibitionwith anti-androgen drugs.
We measured in vivo tumor growth with varying control and treatment groups
(16-20 tumors/group). Kaplan-Meier analysis was performed to estimate local
control. A Cox proportional hazards model and MVA were used to determine
variables associated with LRF survival. Results: Our unbiased drug radiosensi-
tizer screen nominated bicalutamide as an effective drug in treating RT-resistant
BCC lines (R2 0.46, p-value0.01). We interrogated the expression of AR in
2000 human breast tumor samples and 51 BCC lines and found heterogeneity
in AR expression with strongly correlated expression of protein and RNA levels
in TNBC (R20.89, p-value0.001). Inhibition of AR, using both KD and drug
(MDV3100) inducedRT sensitivitywith an enhancement ratio (ER) of 1.35-1.42
in AR TNBC lines with no effect on controls. Radiosensitization was at least
partially dependent on impaired dsDNA break repair mediated by DNAPKcs.
AR inhibition withMDV3100 signifıcantly radiosensitized TNBC xenografts in
mouse models and markedly delayed tumor tripling time (TTT) and tumor
growth (median TTT 17.4 days for RT alone vs. not reached after 50 days for
MDV3100RT, p-value 0.001). Activated DNAPK was identifıed as a bio-
marker of response. Clinically, TNBC patients whose tumors had higher than
median expression ofARhad higher rates of LR after RT (HR for LR3, p-value
0.01, 2 independent datasets). In MVA, high AR expression was the variable
most signifıcantly associatedwithworse LRF survival after RT inTNBCpatients,
outperforming all other variables (HR of 3.58; p-value 0.01). Conclusion: Our
results implicate AR as a mediator of radioresistance in breast cancer and sup-
port the rationale for developing clinical strategies, including clinical trials, to
inhibit AR as a novel radiosensitizing target in TNBC.
#5840 Radiosensitization with the c-MET inhibitor crizotinib in KRAS
mutant colorectal cancer. Kyle C. Cuneo, Himabindu Kurapati, Ranjit Mehta,
Theodore S. Lawrence, Mukesh K. Nyati. University of Michigan, Ann Arbor,
MI.
Background: KRAS mutant colorectal cancers (CRC) are resistant to many
targeted therapies including cetuximab. Novel molecular targets for KRAS mu-
tant tumors may enhance the effıcacy of chemoradiation. C-MET plays impor-
tant roles in treatment resistance, tumor invasion, and metastasis. In this study,
we used a small molecule inhibitor of c-MET, crizotinib in cetuximab resistant
mutant KRAS driven CRC cell lines and assessed radiosensitization. Methods:
To test the effect of c-MET inhibition on CRC cells we used the KRAS mutant
cell lines HCT116, DLD1, and LoVo. Colony formation assays were performed
to assess the effects of crizotinib and cetuximab. Immunoblot analysis was used
to determine the effect of crizotinib on c-MET and downstream pathways in-
cluding ERK and AKT phosphorylation. We then selected doses of crizotinib
below the IC50 and assessed clonogenic survival with radiation. To study poten-
tial mechanisms of radiosensitization cell cycle analysis was performed using
flow cytometry. The effect of c-MET inhibition on cellular functionwas assessed
using cell migration assays. Results: We fırst performed a series of clonogenic
survival assays with crizotinib and cetuximab to determine the IC50 for each cell
line. As expected, the KRAS mutant cell lines LoVo, HCT116, and DLD1 were
resistant to cetuximab (surviving fraction greater than 95% at 100g/ml). These
cell lineswere sensitive to the c-MET inhibitor crizotinibwith IC50 values of 14.4
nM for LoVo, 316 nM forHCT166, and 217 nM forDLD1. Immunoblot analysis
showed that crizotinib at concentrations near the IC50 for each cell line attenu-
ated c-MET phosphorylation and downstream signaling pathways including
ERK and AKT. Crizotinib further blocked radiation induced c-MET phosphor-
ylation and attenuated activation of downstream signaling pathways. We then
performed a series of clonogenic survival assays to study the radiosensitizing
potential of crizotinib. Pretreatment with crizotinib for 24 hours radiosensitized
LoVo and DLD1 cell lines with enhancement ratios of 1.66 and 1.25, respec-
tively. Interestingly, treatment with crizotinib for 1 hour prior to radiation had
only modest dose enhancement, suggesting that prolonged exposure to crizo-
tinib is required for optimal radiosensitization. Cell cycle analysis revealedmin-
imal G1 arrest with crizotinib. Additionally, crizotinib completely blockedHGF
and EGF induced cell migration. Conclusions: Inhibition of c-MET with crizo-
tinib effectively sensitizes cetuximab resistant KRAS mutant CRC cell lines to
radiation. Given the important role c-MET plays in treatment resistance, crizo-
tinib has the potential to improve the outcome of patients with locally advanced
rectal cancer undergoing radiation therapy.
#5841 Hypoxic tumors canbe sensitized to radiation therapy by repurpos-
ing papaverine as an inhibitor of mitochondrial respiration. Martin Benej,1
Ioanna Papandreou,1 XiangqianHong,2 BingYu,2NicholasDenko1. 1Ohio State
University Wexner Medical Center, Columbus, OH; 2The University of Akron,
Akron, OH.
Tumor hypoxia is a characteristic feature of solid tumors. Lowoxygen tension
represents a barrier to effective radiation therapy because oxygen is required to
fıx the DNA damage induced by ionizing radiation. Many strategies have been
proposed as a means to increase the radiosensitivity of hypoxic tumors but the
clinical benefıts have been disappointing. Finding an effective way to radiosen-
sitize hypoxic tumors thus represents a major challenge for improving the cur-
rent protocols for clinical radiation therapy. Decreasing the demand for oxygen
within the tumor has been proposed as a way to reduce hypoxia, as reduced
demand could lead to increased tumor oxygenation prior to delivery of radia-
tion. Although several compounds have been proposed based on this approach,
the toxicity and/or required dose have proven to be a limitation of their potential
clinical benefıt. Papaverine is an opiate alkaloid that has been used in clinical
practice for over 70 years as a smooth muscle relaxant. The drug has a long
established safety profıle, short biological half-life and most importantly, high
potency in its off-target effect limiting mitochondrial oxygen consumption. We
therefore hypothesized that papaverine could effectively radiosensitize hypoxic
tumors by decreasing tumor hypoxia. At clinically achievable concentrations in
the low micromolar range, papaverine effıciently reduced the rate of oxygen
consumption (OCR) in all tested cell lines in vitro. Within the fırst 30 minutes,
10 uMof the drug reduced theOCR by 30-40%.We identifıed themechanism of
OCR reduction as direct binding and inhibition of mitochondrial complex I,
independent of the drug’s activity as a phosphodiesterase inhibitor. More im-
portantly, a single dose of 2 mg/kg papaverine injected I.V. signifıcantly in-
creased tumor oxygenation in vivo by 1.2-1.3 fold in nude mice harboring
EO771 and A549 xenografts. Because normal tissue is fully oxygenated, we
found muscle oxygenation remained unchanged after drug delivery. Finally, 2
mg/kg papaverine injected 35 minutes prior to a single dose of irradiation re-
sulted in a 2.0 fold relative growth delay in E0771 tumors compared to irradia-
tion alone. In addition, in the more hypoxic A549 xenografts, the benefıt pro-
vided by papaverine was a 3.0 fold relative growth delay. In conclusion,
according to our data a single, clinically relevant dose of papaverine adminis-
tered shortly before irradiation reduces tumor hypoxia and thus provides sig-
nifıcant benefıt over irradiation alone, strongly highlighting its potential to im-
prove current strategies to enhance response to radiation therapy.
#5842 Therapeutic enhancement of aminolevulinic acid-mediate tumor
fluorescence and photodynamic therapy with kinase inhibitors. Bin Chen,
Pratheeba Palasuberniam. Univ. of the Sciences in Philadelphia, Philadelphia,
PA.
Photodynamic therapy (PDT) involves the combination of a photosensitizer
and light of a specifıc wavelength. Upon light activation in the presence of oxy-
gen, photosensitizer molecules generate reactive oxygen species that cause cyto-
toxicity by inducing oxidative stress. Aminolevulinic acid (ALA) is a pro-drug
used for the diagnosis and PDT treatment of various solid tumors based on
TUMOR BIOLOGY: Radioprotectors, Radiosensitizers, and Radiation Resistance
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1491
endogenous production of heme precursor protoporphyrin IX (PpIX). Al-
though all human cells express heme biosynthesis enzymes and produce PpIX,
tumor cells are often found to have higher PpIX production and accumulation
than normal cells, allowing for the detection and treatment of solid tumors. In
exploring ALA-based tumor detection and therapy in breast cancer, we have
reported that high ABCG2 transporter activity in triple negative breast cancer
cells (TNBC) contributes to reduced PpIX levels in tumor cells, causing cell
resistance to ALA-PDT. The administration of an ABCG2 inhibitor Ko143 was
able to reverse cell resistance to ALA-PDT by increasing PpIX levels. In this
study, we showed that some kinase inhibitors were able to increase ALA-medi-
ated PpIX by inhibiting ABCG2 activity. Particularly, our results demonstrate
that lapatinib, a dual inhibitor of EGFR andHer2, increased the ALA-PpIX level
and cell sensitivity to ALA-PDT in the MDA-MB-231 TNBC cells. Lapatinib
treatment had little effect on MCF10A breast epithelial cells. These results indi-
cate that small molecule kinase inhibitors such as lapatinib can be used for
enhancing ALA-based tumor detection and PDT in tumors with high ABCG2
activity.
#5843 Role of CDK9 inhibition as a sensitizer to radiation in esophageal
adenocarcinoma: In vitro and in vivo effıcacy study. Omkara Lakshmi M.
Veeranki, Rashmi Dokey, Alicia Mejia, Zhimin Tong, Jianhu Zhang, Yawei
Qiao, Pankaj Kumar Singh, Riham Katkhuda, Barbara Minoo, Jaime Rodriguez
Canales, Steven Lin, Sunil Krishnan, Dipen Maru. UT MD Anderson Cancer
Ctr., Houston, TX.
Preoperative chemoradiation in neoadjuvant setting is the standard of care
for loco-regional esophageal adenocarcinoma (EAC).However, less than 30%of
patients develop complete pathological response indicating need for newer ther-
apeutic strategies. Cyclin dependent kinase 9 (CDK9) is found to be over ex-
pressed in EAC compared to Barrett’s esophagus. Our previous studies demon-
strated strong antitumor effects on inhibition of CDK9 in EAC both in vitro and
in vivo. Here we report augmented tumor regression in irradiated xenografts on
combinationwith Flavopiridol, a well-established clinically usedCDK inhibitor,
compared to single modality treatments. In vitro studies indicate that Flavopiri-
dol could radiosensitize FLO-1 and SKGT4 EAC cells with sustained 53BP1 foci
especially in SKGT4 cells. Flavopiridol and BAY1143572, a more selective in-
hibitor of CDK9, could radiosensitize additional EAC radiation sensitive and
resistant cell lines (SKGT4-R, OE-33 and OE-33-R) as analyzed by MTT assay,
apoptosis, formation of 53BP1 foci and clonogenic assay. Flavopiridol and
BAY1143572 showed a radio-synergistic action by downregulating MCL-1 and
Axl. In conclusion, the radio-sensitizing capacities of CDK9 inhibitors pre-
sented here suggest that their adjuvant administrationmight improve EAC ther-
apy.
#5844 Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor,
improved radiosensitivity of human hepatocellular carcinoma. Fang-Hsin
Chen,1 Ching-Fang Yu,2 Ji-Hong Hong2. 1Chang Gung University, Taoyuan
City, Taiwan; 2Chang Gung Memorial Hospital, Taoyuan City, Taiwan.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related
death worldwide. Radiotherapy (RT) is one of modalities for HCC therapy in
clinics, but the therapeutic effect is unsatisfıed due to high radiosensitivity of
normal liver tissues that limits the optimal dose. This study is to develop a
new theraprutic approach to enhance the effıciency of RT on HCC tumors.
Suberoylanilide hydroxamic acid (SAHA), a FDA approved chemotherapeu-
tic drug, is an inhibitor of histone deacetylase (HDACs) and has been re-
ported to enhance radiosensitivity in many cell lines. This study hypothe-
sized that combination of SAHA and RT could improve tumor control on
HCC tumors. HCC-834 cell, a primary culture of human HCC, had a dose-
dependent response to RT when analyzed by clonogenic assay. SAHA had
mild cytotocixity to HCC-834 cell (IC501M). Combination of SAHA and
RT reached a synergestic effect to prevent colony formation. In detailed,
SAHA treatment did not induce DNA damage on HCC-834 cells when as-
sayed by the expression of H2AX. RT of 2Gy induced highest H2AX
expression within 10min and quickly returned to baseline after 24hrs. The
expression of H2AX was sustained at 24hrs when treated by SAHA and RT,
and gradually recovered after 48hrs. This data indicated that SAHA inhibited
the DNA repair process in HCC-834 cell lines after RT. An orthotopic tumor
model was developed for further exploring the role of SAHA on HCC tumor
radiotherapy. Mice were orally fed with SAHA (100mg/kg) 3hrs and 24hrs
before RT of 25Gy. Mice were sacrifıced at day10 after RT and maximum
tumor area was examined by H&E staining. Either RT (38.81 15.6mm2) or
SAHA alone (45.09 4.493mm2) inhibited tumor growth signifıcantly com-
pared with control tumors (99.1  0.732mm2). Combined SAHA with RT
had an additive effect on tumor control (28.0312.25mm2). These results
supported our hypothsis and demonstrated that SAHA combined with local
RT was effective on inhibiting DNA repair and anti-tumor growth. This
study provided a new strategy onHCC tumor therapy that SAHA could act as
a radiosensitizer to improve the therapeutic effıciency of RT onHCC tumors.
#5845 Identifıcation of proteosome pathway and a novel serine threonine
kinase DCLK3: Potential therapeutic targets for innately radiation resistant
glioblastoma cells. Jacinth Rajendra,1 Keshava Datta,2 , Sheikh Burhan Ud Din
Farooqee,1 Raja Reddy,1 Nilesh Gardi,1 Ekjot Kaur,1 Ketaki Patkar,1 Aliasgar
Moiyadi,1 PrasannaVenkataraman,1Kakoli Bose,1 AmitDutt,1HarshaGowda,2
Shilpee Dutt1. 1Advanced Centre for Treatment Research and Education In Can-
cer, Khargar, Navi Mumbai, India; 2Institute Of Bioinformatics, Bangalore, In-
dia.
INTRODUCTION: Glioblastoma resistance and recurrence is attributed
to the presence of innately Radiation Resistant (RR) cells present in the
heterogeneous parent tumour. However, targeting these cells has been im-
possible due to inaccessibility of these cells. METHODOLOGYWe therefore
recapitulated clinical scenario of resistance in a cellular model developed
from fresh primary GBM patient samples and cell lines. The model allowed
us to capture 1) Parent cells 2) innately Radiation Resistant cells - less than
10% of the parent population and 3) Relapse (R) cells. To identify the tar-
getable proteins governing the survival of RR cells, we performed iTRAQ
based quantitative proteomic analysis on all the three populations from
GBM cell line (SF 268). RESULTS The proteomic data analysis identifıed 34
proteins as differentially present in RR population of which 22 were upregu-
lated and 12 were downregulated. A GENE STRING analysis of all the dif-
ferential proteins in RR population revealed putative interaction of a novel
serine threonine kinase DCLK3 with 14-3-3 zeta. The increased expression
of DCLK3 and 14-3-3 zeta was confırmed by western blot in RR cells of two
GBM cell lines and 8 patient samples. Meta-analysis of 242 tumor samples
from COSMIC database showed DCLK3 overexpression in 232 tumors. Fur-
thermore, it harbours 8 missense deleterious mutations, 6 of which were in
the kinase domain, indicating towards an important kinase function of this
protein. We hypothesized that DCLK3 mediated interaction and phosphor-
ylation of 14-3-3 zeta modulated 14-3-3 zeta functions facilitating RR cell
survival. For this, fırst we wanted to see if DCLK3 and 14-3-3 zeta can inter-
act together. In silico docking of DCLK3 with 14-3-3 zeta did show interac-
tion of 14-3-3 zeta and the kinase domain of DCLK3 kinase. This interaction
was confırmed by in vitro immunoprecipitation studies. Further studies are
ongoing to understand the importance of these proteins and their interac-
tion in GBM recurrence. Additionally, pathway analysis of differentially
upregulated proteins in RR cells revealed deregulation of the proteins in-
volved in Ubiquitin-Proteasome System. Indeed, proteasome activity assay
showed increased proteosome activity in the RR population of GBM cell
lines and Patient samples. Accordingly, Bortezomib, a proteosome inhibitor
induced signifıcant apoptosis in the RR population at a concentration sig-
nifıcantly lower than that required for inducing apoptosis in the parent cells.
SIGNIFICANCE In conclusion this is the fırst study to identify a proteome
signature of innately radiation resistant cells of GBM and identify proteo-
some pathway and a novel serine-threonine kinase DCLK3 in RR cells as a
potential therapeutic target to inhibit GBM radioresistance and recurrence.
#5846 The use of sodium sulfıde, a hydrogen sulfıde donor, to sensitize
glioblastoma multiforme to photon and proton radiotherapy. Adam Xiao,1
Rajesh Pidikiti,2 Matthew Maynard,2 Nader Sheibani,3 Lynn Harrison1. 1Loui-
siana StateUniversityHealth Sciences Center Shreveport, Shreveport, LA; 2Willis-
KnightonCancer Center, Shreveport, LA; 3University ofWisconsin School ofMed-
icine and Public Health, Madison, WI.
Glioblastomamultiforme (GBM) is themost commonglial tumoraccounting for
12-15% of all brain tumors worldwide. It is a rapidly progressing, life-threatening
diseasewithamediansurvivalof3-6monthswhen leftuntreated.Minimal advance-
ments in the treatment of GBM have limited its management. Conventional treat-
mentwith surgical resectionof the primary tumor followedbyphoton radiation (60
Gy in 2 Gy fractions) in combination with adjuvant chemotherapy can limit recur-
rence and prolongmedian survival to 15months. Proton radiotherapy has received
increased attention in recent years due to its more precise energy deposition and
10% higher relative biological effectiveness (RBE) when compared to photon ther-
apy. Several clinical trials have shown thathighdosephoton/proton therapy reduces
central recurrence rate and extends median survival of GBM patients to 21.6
months. Unfortunately, the high rate of radionecrosis has limited its widespread
adoption. Radiosensitization agentsmayovercome this problemby allowing for the
use of lower radiation doses to achieve comparable cytotoxic effects; however, no
radiosensitizers are currently approved for the treatmentofGBM.Thecurrent study
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examines the use of sodium sulfıde (Na2S), a hydrogen sulfıde donor, as a radiosen-
sitizing agent for both photon and proton therapy in two human glioblastoma cell
lines, T98G and U87-MG. Survival curves were generated for T98G cells using a
colony forming assay. Protonshad an increasedRBEof 1.18,which is in close agree-
ment to the accepted RBE of 1.1. Na2S (0M, 10M, 100M, 500M, 1000M)
was given as a pre-treatment in two 2-hour incubations: 2 hours prior to radiation
and again immediately before radiation. Na2S alone exhibited a concentration de-
pendent cytotoxic effect with maximal killing of approximately 50% at 500 M.
Further increases in sodium sulfıde up to 1000M had no effect on cell survival.
Similar killing was not observed in a non-cancer mouse retinal endothelial cell line
evenat extremelyhighdosesof1000Msuggesting thatNa2Scytotoxicity is specifıc
and limited to cancer cells. Na2S increased killing in both photons and protons at 6
Gy by decreasing the surviving fraction from 27.7% to 20% and 16% to 3% respec-
tively. Initial studies into themechanism of radiosensitization using bleomycin as a
radiomimetic agent have suggested Na2S increases the number of DNA double
strand breaks (DSB), a highly cytotoxic form of DNA damage, as seen by H2AX
staining in both T98G andU87-MG cells. The benefıts of high dose radiation ther-
apy, particularly with proton boost, in the treatment of high-grade central nervous
systemtumors suchasGBMareapparent, but the increasedriskof radionecrosishas
limited its use. While further studies need to be conducted to elucidate the exact
mechanism, preliminary results strongly suggest that sodium sulfıde can act as a
radiosensitizing agent by increasing DNADSB formation.
#5847 SIRT1 protects against radiation-induced lung injury via de-acety-
lating the Ku70 and P65. Jianxin Xue,1 Lin Zhou,1 Feifei Na,1 Lei Deng,1 Jie
Lan,1 Bo Lu,2 AdamDicker,2 You Lu1. 1West China hospital, Sichuan university,
Chengdu, China; 2Thomas Jefferson University, Philadelphia, PA.
Radiation-induced lung injury (RILI) is a common and serious complication
in the radiation therapy of thoracic cancer, which signifıcantly restricts the ra-
diation doses of tumor. The prevention and treatment of RILI have long been
clinical challenges. SIRT1 is an NAD dependent protein deacetylase and the
exact role of SIRT1 in RILI remains unclear. The aim of this study is to investi-
gate the prevention and repairing effıcacy of RILI by adenovirus-mediated
SIRT1 gene overexpression in a mice model. Our studies confırmed that the
protein expression and activity of SIRT1 in lung tissues were decreased in RILI
mice models in a time-dependent manner, but the mRNA expression level was
not obviously changed. The activity of SIRT1 was elevated by orally given res-
veratrol, an agonist of SIRT1. The extent of RILI could be evidently alleviated by
orally given resveratrol, as assayed by histopathology, malondialdehyde (MDA)
and plasma cytokines (IL-1, TNF-	 and active TGF-1). Overexpressing
SIRT1 could obviously mitigate the extent of RILI (H&E staining and CT scan),
the concentration ofMDAandROS in lung, IL-1 and activeTGF-1 in plasma;
as well as improve the mice survival. Moreover, SIRT1 could inhibit the radia-
tion-inducedDNA damage in vivo and in vitro, and decreased the expression of
acetylated- Ku70 in the lung. In vitro Co-IP experiment showed that the expres-
sion of SIRT1 in irradiated cells was reduced and the acetylated- Ku70 was
increased; over-expressing SIRT1 promoted the de-acetylation of Ku70; inter-
ference of Ku70 could reverse the effect of SIRT1 in DNA repair. Furthermore,
overexpressing SIRT1 could inhibit the acetylation level ofNF-B subunit RELA
(P65) in the lung; in vitro report gene experiment showed that SIRT1 suppressed
the NF-B transcriptional activity. In conclusion, our results suggest that SIRT1
could evidently mitigate the RILI, repair the irradiation-induced DNA damage
and inflammation via de-acetylating the Ku70 and P65. Our study may provide
new avenue for the prevention and treatment of RILI in clinic.
#5848 Fucoidan adminstration attenuates radiation pneumonitis and fı-
brosis through reducing inflammatory cytokine expression in lung tissue.
Szu-Yuan Wu. Taipei Medical University - Wan Fang Medical Center, Taipei,
Taiwan.
Purpose: There is no well-known compound to prevent radiation pneumoni-
tis (RP) or prophylactically use to attenuate the toxicity of RP. RP is one ofmajor
complications in chest part irradiation and limitations of radiation dose. Fu-
coidan is a sulfated polysaccharide found mainly in various species of brown
algae and brown seaweed. Recent studies have demonstrated its anti-inflamma-
tion effect. Since RP is an radiation induced inflammatory and fıbrosis related
complication, we investigated the effect of fucoidan adminstration on radiation
pneumonitis and fıbrosis. Materials and Methods: In this study, we compared
the pneumonitis and fıbrosis in lung tissue specimen between the lungs irradi-
ated (10Gy/one shot) C57BL/6 mice with or without Fucoidan adminstration
(200mg/kg /day, oral gavage for 14 days). Results: The results demonstrated that
fucoidan adminstration attenuates pneumonitis and fıbrosis in lung tissue. We
found the accumulation of neutrophils in irradiated lung tissue was decreased,
and the radiation induced Masson trichrome staining fıbrosis was decreased.
We also investigate the inflammatory -cytokine profıles in the irradiated lung
tissue by protein array. The results revealed that fucoidan adminstration
changes the inflammatory -cytokine expression pattern in in the irradiated lung
tissue. Conclusions: This study demonstrated that inflammatory -cytokine ex-
pression after whole lung irradiation is correlatedwith neutrophil accumulation
and radiation induced fıbrosis. Interestingly, Fucoidan adminstration changes
the inflammatory -cytokine expression pattern which may lead to attenuates
radiation pneumonitis and fıbrosis. It is potential to be a therapeutic molecular
to attenuate or prevent radiation pneumonitis.
#5849 Exosomes promote survival and migration in squamous head and
neck cancer cells after ionizing radiation: Evidence for a bystander effect.Lisa
Mutschelknaus,1 Omid Azimzadeh,1 Theresa Heider,1 Klaudia Winkler,1 Mar-
cus Vetter,2 Soile Tapio,1 Juliane Merl-Pham,1 Rosemarie Kell,1 Stephan Hu-
ber,3 Lena Edalat,3 Vanja Radulovic,1 Natasa Anastasov,1 Carsten Peters,4 Mi-
chael John Atkinson,1 Simone Moertl1. 1Helmholtz Zentrum München,
Neuherberg, Germany; 2Independent Scientist, Germany; 3University of Tübin-
gen, Tübingen, Germany; 4Technical University of Munich, Munich, Germany.
Exosomes are important intercellular communicators in the acute radiation
stress-response. Here we show that exosomes from head and neck tumor cells
confer protective signals to their neighboring cells. This promotes the tumori-
genic and radioresistant phenotype of head and neck cancer cells. Isolation of
exosomes was performed by serial ultracentrifugation of conditioned medium
collected from irradiated or non-irradiated head and neck cancer cell lines BHY
and FaDu. Quantifıcation by NanoSight technology indicated an increased exo-
some release from irradiated compared to non-irradiated cells 24 hours after
treatment. To test whether the released exosomes influence the radiation re-
sponse, exosomes isolated from non-irradiated and irradiated donor cells were
transferred on non-irradiated and irradiated recipient cells. We found an en-
hanced uptake of exosomes, when transferred to irradiated recipient cells com-
pared to the transfer to non-irradiated cells. Functional analyses indicate in-
creased survival of irradiated recipient cells after exosome transfer. These
fındings mesh with increased DNA double strand break repair that we found
after the transfer of exosomes isolated from irradiated cells. Moreover we ob-
served an increased migration and enhanced chemotaxis induced motility after
the transfer of exosomes isolated from irradiated cells. To investigate whether
differential protein loading into exosomes is responsible for the functional dif-
ferences we performed proteome analysis of the exosomes. We have identifıed
679 proteins, of which 39 were up- and 36 were downregulated by irradiation of
the donor cells. In a good agreement with our functional assays, the proteome
profıling showed that exosomal proteins were mainly involved in wound heal-
ing. Exosomes are functional components of the response of tumor cells to
therapeutic radiation exposure. In a clinical context these results suggests that
radiotherapy modifıed exosomes may influence the cancer progression, metas-
tasis and therapeutic success.
#5850 Salicylate sensitizes prostate cancer (PrCa) to radiotherapy; activa-
tion of AMPK and suppression of lipogenesis. Theodoros Tsakiridis,1 Ka-
tarina Marcinko,2 Linsday Broadfıeld,2 Linda Villani,2 Carrie Gerdes,1 Danitra
Maharaj,1 Tom Farell,1 James Wright,1 Gregory Steinberg2. 1Juravinski Cancer
Center, Hamilton, Ontario, Canada; 2McMaster Univ., Hamilton, Ontario, Can-
ada.
Radiotherapy (RT) is a key therapeutic modality for PrCa that achieves reason-
able disease control rates in localized disease. However, this requires dose-escalated
RT, which is associated with increased toxicity to surrounding tissues and leads to
deterioration of patient quality of life. Improving the therapeutic ratio in PrCaRT is
of high clinical importance.Aspirinhas an established role in cancerpreventionand
studies suggested association with improved PrCa outcomes. It was shown that its
metabolite salicylate (SAL) binds directly and activates the metabolic stress sensor
AMP-activatedkinase (AMPK).This is likely achieved throughdirectbinding to the
AMPK 1 subunit, leading to enhanced AMPK activity through suppression of
AMPK	-subunitT172de-phosphorylation. In this studyweexamined theabilityof
SAL to sensitize PrCa to RT. Hormone insensitive (PC3) and sensitive (LnCap)
human PrCa cells, as well as PC3 xenografts grown in immunocompromised nude
mice were subjected to SAL and RT treatments. SAL mediated a dose-dependent
inhibition of proliferation and clonogenic survival in both PrCa cell lines and sup-
pressed de novo lipogenesis (DNL). This was detected atMconcentrations of the
drug, which can be safely achieved in human circulation. SAL (100-500M) radio-
sensitized PC3 and LnCap cells, and enhanced the ability of SAL to inhibit DNL. In
animals treatedwithconformalRT(10Gy) to the tumorxenografts, Salsalate feeding
(chowdiet containing2.5gr/kg) enhanced thecytotoxicityofRTdetectedas reduced
tumor growth kinetics and weight and volume at sacrifıce. Salicylate treatment of
cells or salsalate feeding ofmice led to increasedAMPKactivity in cells and tumors,
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inhibitory phosphorylation of Acetyl-CoA Carboxylase and reduction of Akt-
Thr308 phosphorylation. These results indicate that SAL could improve radiation
response in PrCa through a mechanism involving the suppression of DNL. This is
achieved at clinically attainable doses of SAL.Thiswork supports prospective inves-
tigation of SAL as a radio-sensitizer in early phase clinical trials of localized PrCa.
#5851 Detection of proliferating tumor cells in orthotopic xenografts ini-
tiated fromglioblastoma stem-like cells and the influence of radiation.Cindy
R. Timme, Marzia Shah, Kevin Camphausen, Philip J. Tofılon.National Cancer
Institute, Bethesda, MD.
Brain tumor xenografts initiated from human glioblastoma (GBM) stem-like
cells (GSCs) simulate many of the characteristics of GBMs in situ including
extensive invasiveness, phenotypic heterogeneity and radioresistance. As an ap-
proach to investigating the relationship between these aspects of GBM biology
and tumor cell proliferation, we used the halogenated thymidine analog CldU
(5-chloro-2=-deoxyuridine), which is incorporated intoDNAduring S-phase, to
identify proliferating cells in orthotopic brain tumor xenografts. Specifıcally,
CD133 NSC11 GSCs were implanted into the right striatum of nude mice; at
various times after tumor cell implantation CldU was delivered in a series of
daily intraperitoneal (IP) injections. Subsequent immunohistochemical analy-
ses of CldU incorporation along with the GSC marker SOX2 was then used to
determine the percentage of proliferating tumor cells in themouse brain.NSC11
tumors are fırst detectable using bioluminescent imaging (BLI) at day 21 post-
implantation. After 4 daily injections of CldU beginning on Day 21, approxi-
mately 60% and 30% of tumor cells were CldU positive in the white matter
(corpus callosum) and grey matter (striatum), respectively. However, when
CldU injectionswere initiated onDay 28 post-implantation, approximately 80%
of cells were positive in both tissue locations after 4 doses, which corresponds to
a rapid tumor growth phase according to bioluminescent imaging. Tumor cells
were also detected in the left hemisphere and had lower percentages of CldU
positive cells as compared to the right hemisphere (site of implantation), which
illustrates the extensive invasive capacity of this GSC line and is consistent with
the “grow or go” concept whereby GBM cells switch between proliferative and
migratory states. NSC11 cells also displayed the hallmark GBM cell migration
along white matter tracts. To determine the pattern of proliferating tumor cell
after irradiation, NSC11 brain tumor xenografts received three daily doses of
12Gy, which results in an approximate 10-day survival advantage, followed by a
series of 4 daily IP injections of CldU. After the 4 doses of CldU, approximately
2% of tumors cells were CldU positive in the whitematter of the 3x12Gy-treated
tumors and no proliferating cells were detected in the grey matter. These values
can be compared to 50% and 40% CldU positive cells in the white and grey
matter, respectively, of the sham irradiated tumors. When the CldU injections
were initiated 4 days post-3x12Gy, discrete pockets of CldU positive tumor cells
began appearing in both white and grey matter from 7-8 days after the comple-
tion of radiation treatment. These pockets of proliferating cells may reflect ra-
dioresistant subpopulations and provide a framework to further characterize
radioresistance based on phenotype and/or microenvironmental niche.
#5852 DUOX2, a key player for chemopotentiation by low-dose fraction-
ated radiation therapy in gastric cancer cells. Palak R. Parekh, Elizabeth
Chang, Navesh K. Sharma, France Carrier.Univ. of Maryland, Baltimore, Balti-
more, MD.
One of the most conventional therapy for solid tumors is radiotherapy. Still,
this modality presents a challenge when it comes to managing highly dissemi-
nated gastrointestinal cancers due to increased toxicity to surrounding tissues.
Recent laboratory and clinical data indicate that Low Dose Fractionated Radia-
tion Therapy (LDFRT) can potentiate systemic chemotherapy and presents the
possibility to revisit the concept of Whole Abdominal Radiotherapy (WART)
for disseminated intra-abdominal gastric cancers. Earlier work considered LD-
FRT ineffective for tumor removal but we now know that LDFRT induces hy-
per-radiosensitivity (HRS) in a number of proliferating cells. We have recently
shown that dual oxidase (DUOX2) is a major contributor to induce HRS at
radiation doses as low as 0.15 Gy and sensitize human gastric cancer cells to
chemotherapy. The aim of our study is to determine the utility of DUOX2 as a
potential biomarker for the clinical application of chemopotentiation by LD-
FRT. First, we performed immunohistochemistry (IHC) on 48 human gastric
samples with progressive grades. Our data indicate that only about 50% of hu-
man gastric cancers are positive for DUOX2. The reason for DUOX2 variability
of expression is not clear butmay be linked to inflammation since six of the seven
(86%) gastritis samples we examined expressed strong levels of DUOX2 in the
surface of epithelial cells. Our data also indicate that expression of DUOX2
signifıcantly increases the levels of macrophages infıltration in tissue expressing
DUOX2 as well as in the stroma surrounded by cells expressing DUOX2. This
suggests that expression of DUOX2 could impact on the dynamic of the tumor
microenvironment. Expression of DUOX2 in response to LDFRT is conserved
since we also observed this in mice primary gastric cancer cells as well as cancer
stem cells. Furthermore, as a fırst step to develop DUOX2 as an accessible bio-
marker, we studiedDUOX2 activity bymeasuring the accumulation of oxidative
serum proteins in gastric cancer cells media. Our data indicate that down regu-
lation of DUOX2 signifıcantly reduces the levels of serum protein oxidation.
Taken together these data suggest that DUOX2 could potentially be used as a
biomarker to stratify patients and follow the effıciency of clinical application of
chemopotentiation by LDFRT.
#5853 Peroxiredoxin I-targeted AMRI-59 has a role of radiosensitizer by
promoting induction of ROS/H2AX/caspase pathway and suppression of
ERK.Wan Gi Hong,1 Jeong Hyun Cho,1 Ju Yeon Kim,1 EunAh Lee,2 Sang-Gu
Hwang,1 Tong-Shin Chang,3 Hong-Duck Um,1 Jong Kuk Park1. 1KIRAMS,
Seoul, Republic of Korea; 2Kyung Hee University Hospital, Seoul, Republic of
Korea; 3Ewha Womans University, Seoul, Republic of Korea.
We have identifıed AMRI-59, one of small molecule, is specifıc pharmaceutical
inhibitor of peroxiredoxin (PRX) I enzyme activity in our previous study. In this
study, we tried to prove whether AMRI-59 has role of radiosensitizer against non-
small cell lung cancer cells - NCI-H460 andNCI-H1299. The radiosensitizer effects
of AMRI-59 were tested with clonogenic assays. The intracellular mechanism un-
derlying this effect was determined by performing immunoblotting andmeasuring
ROSgeneration,mitochondrial potential and cell death. The radiosensitizer activity
of AMRI-59 in vivo was tested in nudemice by treating with AMRI-59 and IR, and
measuring tumor volume and assessing apoptosis. Dose-enhancement ratios of 30
MAMRI-59 inNCI-H460 andNCI-H1299 are 1.57 or 3.38, respectively. Combi-
nation with AMRI-59 and IR also increased the production of ROS and disruption
ofmitochondrial potential via enhancement of PrxI oxidation, which subsequently
induced one of DNA damage markers - phospho-H2AX, and suppressed phos-
phorylation of ERK, and, fınally, activated caspase-3. Notably, inhibition of ROS
production prevented ERK suppression, and inhibition of ERK in addition of com-
bination with AMRI-59 and IR increased caspase activation and apoptosis. In a
xenograft assay, combination with AMRI-59 and IR delayed tumor growth by 11.4
days compared with controls, yielding an enhancement factor of 1.48. Collectively,
these results indicate that AMRI-59 functions as a Prx I - targeted radiosensitizer by
induction of apoptosis through activation of a ROS/H2AX/caspase pathway and
suppression of ERK.
#5854 TIE2-mediated epigenetic marks regulate therapeutic resistance of
glioblastoma.Mohammad Belayat Hossain,1 Rehnuma Shifat,1 Jingyi Li,1 Yisel
Rivera-Mokina,1 Francisco Puerta Martinez,1 David G. Johnson,2 Mark T. Bed-
ford,2 Mien-Chie Hung,1 Erik P. Sulman,1 Frederick Lang,1 Raymond Sawaya,1
Juan Fueyo,1 Candelaria Gomez-Manzano1. 1UT MD Anderson Cancer Center,
Houston, TX; 2UT MD Anderson Cancer Center, Smithville, TX.
Glioblastomas (GBs), the most common subtype of primary brain tumors in
adults, are resistant to current strategies of surgery, irradiation and chemotherapy
with a median survival that ranges from 9 to 15 months. GBs invariably recur after
therapy due to the presence of cells exhibiting a multidrug-resistance phenotype in
the core of the tumor. There is an urgent need of developing the new therapeutic
strategies for brain tumor treatment including the identifıcation of novelmolecular
pathways regulating this resistant phenotype. One of the key phenomena of GB is
that tyrosine kinase receptors (TKRs) are abnormally regulated and related to poor
treatment outcomes.Wehave previously reported the expressionofTIE2 inhuman
surgical glioma specimens in relation to malignancy, and the role of TIE2 in endo-
thelial-glioma adhesion, tumor invasion and multi-drug resistance of gliomas. Re-
cently, we have identifıed that the unexpected membrane-to-nuclear traffıcking of
TIE2 is related to radioresistance of brain tumor stem cells. Interestingly, TIE2
binds, upon IR stress, to DNA/protein complexes and directly phosphorylates core
histones. SpecifıcallywediscoveredanewhistoneH4mark (H4pY51) that is readby
ABL1. TIE2/H4pY54/ABL1 complex binds to DNA repair proteins, such as ATM,
DNA-PK, and pChk2, activating a NHEJ DNA repair mechanism. In an effort to
fınd the molecular mechanisms underlying TIE2 nuclear translocation, we identi-
fıed that TIE2 binds and directly phosphorylates caveolin-1 (CAV1) at Tyr14 resi-
due in vitro and in vivo. Importantly, CAV1-pTyr14 is necessary for the transloca-
tionof bothTIE2 andCAV1 to thenucleus.WealsouncoverednewTIE2-mediated
epigenetic marks. Thus, TIE2 binds and phosphorylates histone H2B at Tyr37 and
this modifıcation enhances the recruitment of DNA repair proteins to the DNA
damage site.Our results summarize that upon IR stressTIE2 localizes to thenucleus
where it is involved in key cellular functions by directly phosphorylating core his-
tones, and recruiting SH2 domain proteins to theDNAdamage sites, that are com-
plexing to the DNA repair machinery. Our discovery related to tyrosine modifıca-
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tion of core histones might be of high signifıcance to understand the resistance of
cancer to DNA-damage inducers, which eventually might result in the design of
TIE2-targeting combinational therapies for patients with GBs.
#5855 Radiosensitization of cervical cancer cells byHDAC inhibitors. Ima
Paydar,1 Alfredo Velena,2 Scott Grindrod,3 Mira Jung2. 1MedStar Georgetown
University Hospital,Washington, DC; 2GeorgetownUniversity,Washington, DC;
3Shuttle Pharmaceuticals, Inc, Rockville, MD.
Introduction: While histone deacetylase (HDAC) inhibitors have demon-
strated in vitro and in vivo radiosensitization in several human cancer cell lines,
the effıcacy and mechanism of action of HDAC inhibitors in HPV-positive
cancers are poorly understood. We hypothesize that HDAC inhibitors can be
used to treat HPV-positive squamous cell carcinomas by enhancing radiation
sensitivity. Methods: The cellular cytotoxicity of ten HDAC inhibitors was ex-
amined inHPV-positive (CaSki, SiHa,HeLa) andHPV-negative (C33a) cervical
cancer cell lines by the WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophe-
nyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] assay, and the
drug with the highest cytotoxicity (pan-HDAC inhibitor SP-1-161) was selected
for further analysis. SAHA was used as a control. Evaluation of the cell cycle
phase distribution was performed by flow cytometry using FACS analysis fol-
lowing treatment with drugs at 24, 48, and 72 hours as well as in combination
with radiation in CaSki cells (HPV-16 positive). The extent of radiation sensiti-
zation was confırmed by cellular clonogenic assays in CaSki cells. Results: Of all
drugs tested, cytotoxicity was demonstrated in a dose-dependent manner. The
values of IC50s were at 1.071, 1.567, 1.71, and 0.929 M (SAHA) and 0.054,
0.3554, 0.0994, and 0.095 M (SP-1-161) for CaSki, SiHa, HeLa, and C33a cell
lines, respectively. SP-1-161 conferred signifıcant cytotoxicity (0.054 M) in
CaSki cells. Cellular radiation sensitivity is tightly associated with cell cycle
phases and varies as a function of the position in the cell cycle. To assess the
effects of HDAC inhibitors on the cell cycle, CaSki cells were treated with IC50
dosage (SP-1-161 at 0.054 M, SAHA at 1 M) for 24 hours, 48 hours, and 72
hours and then treatedwith radiation. The drugs alone arrested cells primarily in
the G1 phase of cell cycle (77.3% for SP-1-161, 84% for SAHA), a relatively
radiation sensitive phase. Pre-treatment of SP-1-161 for 24 hours prior to radi-
ation (5 Gy) increased cell cycle arrest in the G1 phase as well. To determine the
radiosensitization property of SP-1-161, the radiation clonogenic survival assay
was performed following pre-treatment of SP-1-161 for 24 hours. Cells were
exposed to graded doses of -radiation, and the data were fıtted using the single-
hit multitarget and the linear-quadraticmodels. Comparisons of survival curves
revealed smaller D0 (D0 ratio 1.43) for cells irradiated in the presence of SP-1-
161 (D0 1.4) than for controls (D0 2.0). Interestingly, treatment with SAHA
did not impact radiosensitization (D0  1.9, D0 ratio 1.05). Conclusion: SP-1-
161 conferred signifıcant toxicity inCaSki cells andprimarily arrested cells in the
G1 phase of cell cycle. Furthermore, treatment with SP-1-161 enhanced radio-
sensitization,while SAHAshowed little change despite cell cycle arrest primarily
in the G1 phase. Together, our results support SP-1-161 as a new therapeutic
agent with potential for cervical cancer.
#5856 Molecular mechanism underlying breast cancer cell radioresis-
tance: role of radiation-induced NF-B self-sustenance. Hui Yu,1 Natarajan
Aravindan,2 Ji Xu,3 Mohan Natarajan1. 1UT Health Science Ctr. at San Antonio,
San Antonio, TX; 2University of Oklahoma Health Sciences Center, Oklahoma
City, OK; 3Basic Medical College, Zhengzhou University, Henan, China.
Understanding themechanismof breast cancer cell radioresistance and the asso-
ciated selection pressure, tumor recurrence, would help us to develop molecular
interventions and achieve disease/progression-free survival in patients with cancer.
In the present study,we investigated themolecularmechanismsprompted in breast
cancer cells in response toclinical radiationand theassociatedcoordinationof intra-
and inter-cellular signaling that orchestrate radioresistance and tumor relapse/re-
currence.Our fındings showed that clinical doses of radiation increaseNF-B tran-
scriptionandDNA-bindingactivity.Further, radiationexposure resulted indenovo
TNF-	 synthesis and secretion. An NF-B gene manipulation approach revealed
thatNF-BtriggeredNF-B-mediatedTNF-	 transcriptionalactivity.NF-BDNA
binding kinetic analysis demonstrated both sustained and dual phase NF-B acti-
vationwithradiation.RadiationpromptedNF-B-dependent synthesis/secretionof
TNF-	, a requisite for the second phase of NF-B activation and maintenance.
Radiation-associated NF-B-dependent secretion of TNF-	 from irradiated cells
also activatedNF-B in the non-irradiated, non-targeted bystander cells. Together,
these fındings demonstrated that radiation-triggered NF-B-dependent TNF	 se-
cretion is critical for self-sustenance ofNF-B (through autocrine positive feedback
signaling) and for coordinating bystander response (through intercellular signaling:
denovoactivationofNF-Binbystandercells) after radiationexposure.Further, the
data suggest that this NF-B¡TNF-	¡NF-B feedback-dependent self-suste-
nance of NF-B could drive the selection pressure (proliferation, clonal expansion)
of surviving breast cancer cells and subsequent tumor relapse/recurrence.
#5857 HER2-targeted thorium-227 conjugate (HER2-TTC): Effıcacy in a
HER2 positive orthotopic bone model. Jenny Karlsson,1 Urs B. Hagemann,1
Christoph Schatz,2 Derek Grant,1 Christine Ellingsen,1 Alexander Kristian,1
Dessislava Mihaylova,1 Steinar R. Uran,1 Mari Suominen,3 Roger M. Bjerke,1
Olav B. Ryan,1 Carl F. Nising,2 DominikMumberg,2 Alan Cuthbertson1. 1Bayer
AS, Oslo, Norway; 2Bayer AG, Berlin, Germany; 3Pharmatest Services Ltd, Turku,
Finland.
In 2015, the estimated incidence of new breast cancer (Ca) cases in theUSwas
234.190 and number of deaths 40.730. Human epidermal growth factor receptor
2 (HER2) is encoded by the proto-oncogene c-erbB-2 and initiates downstream
signaling pathways leading to cell proliferation and tumorigenesis. HER2 is
overexpressed in several cancer types and has emerged as one of the most
strongly validated targets for the treatment of breast and gastric cancer serving as
both a prognostic and predictive biomarker. Given that 20% of breast Ca pa-
tients areHER2 positive and 70%of patients withmetastatic disease will develop
bonemetastases and associatedmorbidities, there is still an unmetmedical need
for improved therapies targeting HER2. Radium-223 (Ra-223) is a novel tar-
geted alpha therapeutic for treatment of patients with castration-resistant pros-
tate cancer and bone metastases. Localized high energy alpha particle emission
induces double-strandedDNAbreaks and cellular apoptosis. Thorium-227 (Th-
227) is the immediate precursor for Ra-223 which, in contrast to Ra-223, can be
complexed by chelating agents at high affınity, allowing targeted delivery to
tumor cells via antibodies. We describe herein the generation of a novel HER2-
targeted Th-227 conjugate (HER2-TTC). HER2-TTC consists of the humanized
HER2 targeting IgG1 antibody trastuzumab covalently linked via an amide bond
to a 3,2-hydroxypyridino-based chelatormoiety, enabling effıcient radiolabeling
with the alpha particle emitting radionuclide Th-227. Anonymized samples of
consenting breast cancer patients were analyzed by Immunohistochemistry
(IHC). The IHC data demonstrated HER2 positive expression in breast tumor
and matched bone metastases, supporting the preclinical evaluation of the anti-
tumor effıcacy of HER2-TTC in the BT-474 orthotopic bone mouse model.
HER2-TTC was prepared at high radiochemical yield and purity. When tested
for binding to recombinant HER2, HER2-TTCwas shown to retain comparable
binding affınity to trastuzumab. In vitro cytotoxicity experiment of HER2-TTC
demonstrated target mediated in vitro cytotoxicity in the pM-range on breast
cancer cell line BT-474 (430 000 mAbs bound/ cell as determined by FACS).
Anti-tumor effıcacy of HER2-TTC was evaluated at 250 and 500 kBq/kg at a
protein dose of 0.14mg/kg. X-ray imaging, serumbone formationmarker PINP,
micro CT 3D reconstruction imaging and histological analysis demonstrated
signifıcantly reduced bone lesions and tumor induced bone remodeling. The
promising preclinical anti-tumor activity supports the development of the
HER2-TTC as a novel targeted alpha therapeutic for the treatment of patients
with HER2 positive bone metastatic disease.
#5858 MicroRNA-338-5p regulates radioresistance by directly targeting
survivin in esophageal squamous cell carcinoma. Misun Park, Hyeon-joon
Yoon,MoonChulKang, JunAhLee, JunhyeKwon,HaewonLee.Korea Institute
of Radiological and Medical Sciences, Seoul, Republic of Korea.
Radioresistance is a challenge in the treatment of esophageal squamous cell
carcinoma (ESCC).MicroRNAs (miRNAs) are known to play an important role
in the functional modifıcation of cancer cells and resent studies have reported
themiRNA-mediated radiotherapy resistance.However, further researchwould
be necessary to reveal the regulation mechanisms and the treatment strategies
using miRNA have yet to be established in ESCC. We compared the miRNA
expression profıle in ESCC parental (TE-4) and acquired radioresistance (TE-
4R) cell line using miRNA microarray and qRT-PCR. Our data showed that
miR-338-5p, one of the target miRNA biomarkers, was signifıcantly downregu-
lated in TE-4R. Ectopic overexpression of the miR-338-5p induced apoptosis
and sensitivity to radiation treatment by interfering the survivin, which is
known to play an inhibitor of apoptosis. Over expression of survivin using plas-
mid vector reversed miR-338-5p induced apoptosis. From tumor xenograft ex-
periments, we found that therapeutic delivery of the miR-338-5p mimics via
direct injection to tumor mass increased sensitivity to radiation therapy. In
conclusion, these fındings suggested that miR-338-5p is a potential radiosensi-
tizer and may be one of the therapeutic biomarkers for radioresistant in ESCC.
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#5859 HER2-targeted thorium-227 conjugate (HER2-TTC): Effıcacy in
preclinical models of trastuzumab and T-DM1 resistance. Jenny Karlsson,1
Urs B. Hagemann,1 Christoph Schatz,2 Derek Grant,1 Alexander Kristian,1
Christine Ellingsen,1 DessislavaMihaylova,1 Solene Geraudie,1 Bård Indrevoll,1
Uta Wirnitzer,3 Roger M. Bjerke,1 Olav B. Ryan,1 Carl F. Nising,2 Dominik
Mumberg,2 Alan Cuthbertson1. 1Bayer AS, Oslo, Norway; 2Bayer AG, Berlin,
Germany; 3Bayer AG, Wuppertal, Germany.
The human epidermal growth factor receptor 2 (HER2) is encoded by the proto-
oncogene c-erbB-2 and initiates downstreamsignalingpathways leading to cell pro-
liferation and tumorigenesis. HER2 is overexpressed in several cancer (Ca) types
and is one of the most strongly validated targets for the treatment of breast and
gastric cancer serving as both aprognostic andpredictive biomarker. SeveralHER2-
targeting antibodies as well as antibody-drug conjugates are either approved or are
in clinical development. Prolonged treatment with monoclonal antibodies and an-
tibodydrugconjugateshaveresulted indevelopmentof resistanceandso there is still
an unmetmedical need for drugs of newmechanismof action targeting this impor-
tant receptor system. We describe herein the generation of a high energy, alpha-
particle emitting HER2 targeted thorium-227 antibody-chelator conjugate. HER2-
TTC consists of the humanized HER2 targeting IgG1 antibody (trastuzumab)
covalently linked via an amide bond to a 3,2-hydroxypyridino-based chelator moi-
ety, enabling effıcient radiolabeling with the alpha particle emitting radionuclide
thorium-227 (Th-227). HER2-TTC was prepared at high radiochemical yield and
purity. When tested for binding to recombinant HER2, HER2-TTC was shown to
retain comparablebindingaffınity to trastuzumab. Invitro cytotoxicity experiments
were performed on 8 cell lines with different HER2 expression levels (from 7 000 -
500 000 mAbs bound/ cell as determined by FACS) of breast, ovarian, gastric and
lung cancer origin. HER2-TTC demonstrated target mediated in vitro cytotoxicity
in the pM-range. In vivo biodistribution and anti-tumor effıcacy ofHER2-TTCwas
evaluated in the dose range 100-500 kBq/kg at a protein dose of 0.14mg/kg and i.v.
injection in the s.c. KPL-4 breast and Calu-3 lungmodel previously described to be
resistant to trastuzumab. The biodistribution study demonstrated specifıc tumor
accumulation of HER2-TTC in both models with a maximum of 77 and 50 %ID/g
227Th at t 168 h post dose (decay corrected to T0), respectively. Signifıcant antitu-
moreffıcacywas shownforHER2-TTCin the JIMT-1s.c. breastCaxenograftmodel
resistant to trastuzumab andT-DM1.The promising preclinical anti-tumor activity
supports the development of the targeted alpha therapeutic HER2-TTC for the
treatment of trastuzumab and T-DM1 resistant patients.
#5860 Genomic architecture of prostate cancer at recurrence following
radiotherapy. Melvin L.K. Chua,1 Erle Holgersen,2 Veronica Sabelnykova,1
Adriana Salcedo,1 Alice Meng,1 Michael Fraser,1 Theodorus van der Kwast,3
Paul C. Boutros,2 Robert G. Bristow1. 1Princess Margaret Cancer Centre, To-
ronto, Ontario, Canada; 2Ontario Institute of Cancer Research, Toronto, Ontario,
Canada; 3University Health Network, Toronto, Ontario, Canada.
Aim: Spatial intra-tumoural heterogeneity of prostate cancer is secondary to
differential genomics andmulti-clonality, even for tumours with the sameGlea-
son grade. These unique features promote resistance to treatment. Here, we
investigated if clonal selection or adaptation of new clones dominates in prostate
cancer at the time of recurrence following high dose precision radiotherapy.
Methods: We identifıed 11 patients with biopsy-proven multi-focal recurrent
prostate cancer following defınitive image-guided radiotherapy/brachytherapy.
Copy number aberration (CNA) profıling was performed on 33 anatomically
distinct tumour foci with 11 matched-normals in the radio-resistant cohort. To
assess clonality, 4 cases had matched pre-radiotherapy tumours for copy num-
ber profıling. We evaluated for recurrent driver amplifıcations and deletions,
and genomic instability as measured by percent genome aberration (PGA). We
also compared these genomic indices against 373 comprehensively profıled spo-
radic prostate cancers from the Canadian Prostate Cancer Gene Network
[Fraser, et al., Nature, 2016]. Results: Independent of Gleason grade, we ob-
served large intra-patient (COV of 0.66-1.13) and inter-patient heterogeneity (p
0.001, one-way ANOVA) in the levels of genomic instability, as judged by
PGA scores, among the radioresistant tumours. Interestingly, although total
CNA counts did not differ between the radioresistant and sporadic (CPC-
GENE) cohorts (median CNAs of 40, radioresistant vs 33, sporadic, p 0.20],
we observed a trend for increased genomic instability in the radioresistant co-
hort (median PGA of 8.8 vs 4.9, p  0.059). This concurs with the fındings on
intra-tumoural spatial CNA analyses, which revealed the acquisition of CNAs
that were both common and non-recurrent in the multi-focal radioresistant
tumours, thus suggesting a common origin with subsequent divergent evolu-
tion. Importantly, we observed a mixture of CNAs, including known drivers of
aggressive prostate cancer, namely NKX3-1, PTEN, TP53, CDKN1B, and
CDH1, that was shared between pre-radiotherapy and radioresistant tumours,
supporting a clonal selection process.We also discovered a novel deleted region
on Chr3p, consisting of RAD18 and FANCD2, which was unique only in the
radioresistant tumours. Conclusions: Our novel observations in a small cohort
of radioresistant prostate cancers favour the model of selection of radioresistant
clones, as opposed to new-onset tumours. These results support the current
approach of discovering biomarkers a priori, and molecular therapeutic targets
for these radioresistant clones, so as to improve the therapeutic ratio of precision
radiotherapy.
#5861 Enhanced radiosenistivity of EGFR-TKI sensitive and resistant
NSCLCcells by abemaciclib ismediatedby alteredDNArepair andmetabolic
pathways. Sarwat Naz, William DeGraff, Anastasia Sowers, Rajani Choudhuri,
Maria Wissler, Janet Gamson, John Cook, James B. Mitchell. National Cancer
Inst., Bethesda, MD.
Dysregulation of the p16(INK4a)-CyclinD-CDK4/6-Rb pathways in patients
with NSCLC (Non-Small Cell Lung Cancer) is a rational therapeutic target. The
current study investigated the radiosensitizing potential of a novel CDK4/6 in-
hibitor, LY2835219 (LY, Abemaciclib) in NSCLC cell lines with varied genomic
context to identify genomic and metabolic biomarkers that are predictive of a
response over conventional EGFR-tyrosine kinase inhibitor (EGFR-TKI) ther-
apy. NSCLC cell lines were exposed to LY (0-10uM) for 24 hr immediately after
0-10 Gy radiation. Cell survival was assessed by clonogenic assay and cell cycle
distribution was quantifıed by flow cytometry. Dose modifying factors (DMF)
were calculated at 10% survival from radiation survival curves. Altered DNA
repair pathways and metabolic profıling of cells post LY treatment was assessed
by immunoblot and LC/MSmass spectrometry analysis. LY treatment enhanced
radiosensitivity of EGFR-TKI sensitive (HCC827, PC9) andEGFR-TKI resistant
(H820 and H1975) cell lines with DMF of 1.3 (0.06), 1.4 (0.30), 1.5 (0.51)
and 1.3 (0.02), respectively. Values in the parenthesis indicates standard devi-
ation.Wild type EGFR expressing cells (A549 andH460) also showed enhanced
radiosensitivity by LY with DMF of 1.6 (0.09) and 1.75(0.15), respectively.
Interestingly, no radiation enhancement by LY was observed for cells defıcient
in functional PTEN (H1650), Rb (H82) and p53 (H460 DNp53 and H1299)
protein. Radiosensitization was also observed for cells made resistant to third
generation EGFR-TKI, AZD9291. Flow cytometry analysis of majority of cell
types exposed to LY exhibited 55% to 94% G1 arrest (depending on cell type).
Mechanistically, the combinatorial treatment in radiosensitive cells showed el-
evated phosphorylated-H2Ax. Combination treatment also reduced expres-
sion of ATR, ATM, DNA-PK, Rad51 and Chk-2 suggestive of reduced DNA
repair compared to radiation alone. LY treatment brought major changes in the
glycolysis/TCA/ total amino acids. LY increased signifıcantly Acetyl-CoA, fu-
marate and malate, indicating enhanced oxidative phosphorylation. LY signifı-
cantly elevated Uric acid levels suggestive of oxidative stress and elevated nucle-
otide degradation. Finally, administration of 100mg/kg LY2835219 for fıve days
in combination with fractionated dose of radiation (3 Gy) signifıcantly delayed
tumor regrowth in H460 xenograft (p 0.014). Collectively, our pre-clinical
data indicates altered Rb, p53 and PTEN status are distinct predictive biomark-
ers of response for LY mediated radiosensitivity and provides an alternative
therapeutic option in overcoming EGFR-TKI resistance in NSCLC.
#5862 YAP1 mediated CDK6 activation confers radiation resistance in
esophageal cancer: rationale for the combination of YAP1 and CDK4/6 in-
hibitors in EC. Fan Li, Xiaoquan Dong, Haitao Zhu, AilingW. Scott, Lang Ma,
Jiankang Jin, Jeannelyn Santiano Estrella, Heath Skinner, Randy L. Johnson,
Shumei Song, Jaffer A. Ajani. UTM.D. Anderson Cancer Ctr., Houston, TX.
Background: Esophageal carcinoma (EC) is a lethal disease with high inci-
dence globally and often exist therapy resistance. Alterations (either overexpres-
sion or amplifıcation) of YAP1 and CDK4/6 were found frequently in esopha-
geal cancer. Deregulation of these pathways may represent key elements for
resistance in esophageal cancer. Methods: Expression of YAP1 and CDK4/6
were examined in esophageal tumor tissues as well as cell lines using immuno-
histochemistry and immunoblotting. Inducible YAP1 overexpression in EC
cells by lentivirus systemwas performed to test YAP1mediated CDK4/6 expres-
sion and activation and association with radiation resistance. YAP inhibitor
CA3 andCDK4/6 inhibitor Lee001were used to test their antitumor activities in
vitro and in vivo. Cell proliferation assay (MTS), Flow cytometry and immuno-
fluorecence and tumor sphere formation assay were performed to test cell cycle
distribution, cancer stem cell (CSC) population maintenance and over growth
and therapy resistance. Results: We demonstrate that overexpressed YAP1 is
positively associated with CDK4/6 expression in resistant tumor tissues and EC
cell lines. Overexpression YAP1 by inducible lentivirus system in EC cells up-
regulates expression of CDK4/6 at level of its transcription, while knock down
YAP1 in JHESO EC cells dramatically decreased CDK6 expression as well as its
transcription. CA3, a novel YAP1 inhibitor, was able to decrease activation of
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CDK4/6 and phosphorylation RB and cell cycle progression induced by YAP1.
Interestingly, we found that inducible YAP1 high EC cells are resistant to radi-
ation resistance andCDK6 knockout by Lenti-Crisp sensitize radiation resistant
in EC cells induced by YAP1. Further, we demonstrated radiation resistant cells
are enriched CSC population and demonstrated increased level of both YAP1
and CDK4/6, while blocking the YAP and CDK4/6 pathway by using their in-
hibitor CA3 or Lee001 reduced EC cell growth andCSCs properties especially in
EC resistant cells. Most importantly, we found combination of Lee001 and CA3
exert a synergistic anticancer effect in radiation resistant EC cells with high
YAP1 and CDK4/6 in Vitro and in Vivo. Conclusions: Our data provide evi-
dence that YAP1 mediated CDK4/6 up-regulation plays an important role in
conferring radiation resistance in esophageal cancer cells. Targeting both YAP1
and CDK4/6 may provide novel therapeutic strategies in EC. Corresponding
Authors: Shumei Song, Tel:713-834-6144; Email: ssong@mdanderson.org; or
Jaffer A. Ajani, Tel: 713-792-3685; Email: jajani@mdanderson.org
#5863 Identifying the radiosensitizing effects of PARP inhibitor in ovar-
ian cancer. Yue Bi,1 Ioannis Verginadis,1 Souvik Dey,1 linlang Guo,2 Lilie Lin,1
Yanfang Zheng,2 Constantinos Koumenis1. 1University of Pennsylvania, Perel-
man School of Medicine, Philadelphia, PA; 2ZhuJiang Hospital of Southern Med-
ical University, Guangzhou, China.
Ovarian cancer is the seventh-most common cancerwith a highmortality rate
among women. Radiation therapy (RT) is used in ovarian cancer for local re-
lapse, but doses are limited due to concern for small bowel obstruction in pa-
tients who have had multiple surgeries and chemotherapeutic regimens. There-
fore, it’s an ideal setting to improve the therapeutic window by combining RT
and a radiosensitizer. Poly (ADP-ribose) polymerase-1 (PARP-1) is involved in
the recognition of DNA damage and the facilitation of DNA repair by recogniz-
ing DNA single-strand breaks (SSB). Inhibition of PARP1, especially in tumors
driven by BRCA1 or 2 mutations, has been shown to potentiate the DNA-dam-
aging effects of radiation in vitro and in vivo and to increase tumor vasculature
perfusion and oxygenation. Approximately half of ovarian cancers have germ-
line or somatic BRCA gene mutation, epigenetic silencing or other mutations
that affect homologous recombination (HR) competency resulting in DNA re-
pair defects, making this tumor particularly susceptible to the radiation-sensi-
tizing effects of PARP inhibitors. Here, we investigated the therapeutic effects of
the PARP inhibitor olaparib in preclinical models of ovarian cancer. Basic
BRCA1 and PARP1 protein and mRNA levels were characterized in a panel of
ovarian cancer cell lines. The radiosensitizing effects of olaparib were tested on
both HR-profıcient and HR-defıcient ovarian cancer cells by evaluating the col-
ony formation, DNAdamage, apoptosis, and PARP1 activity. Survival benefıt of
olaparib was also examined in xenograft models of ovarian cancer. Our results
demonstrate that combination of olaparib with IR decreased colony formation,
inhibitedDNAdamage (H2AX) repair, and inducedmore apoptosis compared
to olaparib or IR alone. In addition, HR-defıcient cells were more sensitive to IR
than HR-profıcient cells in the presence of olaparib. Furthermore, olaparib in-
hibited PARP1 activity in vivo, signifıcantly decreased tumor growth and in-
creased overall survival when combined with IR in mice bearing subcutaneous
xenografts of HR-defıcient OVCAR8 cells while producing a relative modest
effect on overall survival of mice bearing xenografts of HR-profıcient SKOV3
cells. These results provide a preclinical rationale for improved treatment mo-
dalities using olaparib as an effective radiosensitizer in ovarian cancer, particu-
larly in tumors with HR-defıciencies.
#5864 Targeting brain cancer stem cells by potentiating radiation-in-
duced ER stress. Regina M. Graham, Sumedh S. Shah, Alexis J. Musick, Win-
ston Walters, Ricardo J. Komotar, Jeffery S. Prince, Steven Vanni. Univ. of Mi-
ami Miller School of Medicine, Miami, FL.
Background. Glioblastoma (GBM) is one of themostmalignant brain tumors
occurring in both children and adults. Despite an aggressive treatment regimen
consisting of surgical resection, radiation therapy and chemotherapy the fıve-
year survival rate is less than 5%. This poor outcome has been attributed to the
existence of therapy-resistant GBM stem-like cells (GSCs), which are believed to
be responsible for tumor recurrence and patient relapse. Understanding the
resistance mechanisms employed by brain tumor stem cells and developing
novel methods to target these cells is necessary for prolonged patient survival.
Recent evidence suggests that the endoplasmic reticulum stress response path-
way may mediate therapeutic resistance in cancer. Here we sought to examine
the ER stress response pathway of GSCs in response to ionizing radiation and to
increase the extent of ER stress in an effort to promote cell death using the
glycolytic inhibitor, 2-deoxy glucose (2-DG). Methods. GSC lines were derived
from resected tumor sections. GSCs were irradiated using the Rad Source 2000
Series Biological Irradiator. Transmission ElectronMicroscopy (TEM)was used
to investigate the ultra-structural alterations of GSCs following exposure to 8Gy
radiation. Viability was determined using trypan blue exclusion, MTS and LDH
assays. Cell signaling pathways were investigated by western blot analysis. Re-
sults. Consistent with previous fındings, minimal cell death was observed in
GSCs exposed to 2-20Gy radiation. TEManalysis revealed that exposure to 8Gy
signifıcantly increased ER lumen dilation, suggestive of ER stress. Western blot
analysis indicated an increase in ER stress markers GRP78, GRP94 and CHOP,
confırming that radiation induces ER stress in GSCs. Treatment with 2-DG
induced an increase in ER lumen diameter and ER stress markers. Combined
2-DG (0.5mM and 2mM) and radiotherapy (8 Gy) signifıcantly increased ER
luminal diameter andER stressmarker expression over radiation or 2-DGalone.
In addition, combined radiation and 2-DG (0.1-2mM) signifıcantly reduced
GSC viability compared to radiation or 2-DG alone. Conclusion. The ER stress
response pathway is an adaptivemechanism and thought tomediate therapeutic
resistance. Here we demonstrate that radiation induces ER stress response path-
way including ER lumen dilation and an increase in molecular chaperone ex-
pression in GSCs. Potentiating ER stress can switch the pathway from one of
adaptation to cell death. 2-DG increased radiation-induced ER stress and pro-
moted cell death. Our data suggests that targeting this adaptive response could
increase the effıcacy of radiotherapy and prolong patient survival.
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#5866 t-Darpp chemoresistence protein: insights into its structure, oli-
gomerization status, calcium-binding properties and phosphorylation sites.
Patrycja Magdziarz,1 You Feng,1 Dianlu Jiang,1 Elizabeth Parga,1 Arianna Ce-
lis,1 Erin Denny,2 Xiaoying Wang,1 Martin Phillips,3 Feimeng Zhou,1 Susan E.
Kane,2 Jamil Momand1. 1California State Univ.-Los Angeles, Los Angeles, CA;
2Beckman Research Institute of City of Hope, Duarte, CA; 3University of Califor-
nia Los Angeles, Los Angeles, CA.
t-Darpp, one of two protein isoforms encoded by the PPP1R1B gene, is over-
expressed in gastric, esophageal, colon, prostate, and breast cancers; and confers
resistance to trastuzumab in Her2 breast cancer cells. To gain insight into the
trastuzumab-resistance mechanism of t-Darpp, we studied its structure, oli-
gomerization status, metal-binding properties, and sites of phosphorylation.
Circular dichroism spectroscopy analysis showed that recombinant t-Darpp ex-
hibits 12% alpha helix, 29% beta strand, 24% beta turn and 35% random coil
character at 25°C. Upon mild heat treatment (50°C for fıve min) the secondary
structure does not appreciably change. Metal ion-binding analyses through in-
ductively coupled plasma-mass spectrometry and graphite furnace-atomic ab-
sorption indicated that t-Darpp co-purifıes with calcium, but not other metals
commonly found in biological systems. The T75 site, critical for t-Darpp activa-
tion of the Akt signaling pathway, is a substrate for phosphorylation by cyclin-
dependent kinase 1 (CDK1) and cyclin-dependent kinase 5 (CDK5). Gel fıltra-
tion chromatography, sedimentation equilibrium analysis, native blue gel
electrophoresis, and glutaraldehyde-mediated crosslinking experiments showed
that the majority of t-Darpp (calculated mass  19 kDa) exists as a monomer,
but forms low levels ( 3%) of hetero-oligomers with its longer isoformDarpp-
32. t-Darpp has a relatively large Stokes radius of 4.4 nm, suggesting an elon-
gated structure. In summary, this study indicates that t-Darpp is an elongated,
mild-heat-stable, and monomeric calcium-binding protein that is capable of
being phosphorylated at T75 by CDK1 and CDK5. Blockage of t-Darpp calcium
binding capacity or T75 phosphorylation may therefore help sustain Her2
breast cancer sensitivity to trastuzumab therapy.
#5867 Reversal of drug resistance in prostate cancer using PBMnanopar-
ticle. Santosh K. Singh, James W. Lillard, Rajesh Singh. Morehouse School of
Medicine, Atlanta, GA.
Multidrug-resistance (MDR) is the major reason behind the failure of pros-
tate cancer (PCa) therapy. ATP-binding cassette (ABC) transporters contribute
to drug resistance via ATP-dependent drug efflux. P-glycoprotein (Pgp), which
is encoded by MDR1 gene, confers resistance to certain anticancer agents. The
development of agents able to modulate MDRmediated by Pgp and other ABC
transporters remained a major goal for PCa therapy. The proposed study eval-
uated a novel method for targeted delivery of resveratrol alone or in combina-
tion with docetaxel at desired rates for reversal of drug resistance.We described
a proprietary planetary ball milling approach (PBM) that uses a natural polysac-
charide (starch; FDA approved) to create a drug-polysaccharide nanoparticle as
a core that is subsequently coated with novel folate-conjugated poly (-capro-
lactone) / poly (ethylene glycol) co-polymer, which allows binding to high-
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affınity folate receptors presents on PCa cells. The resulting PBM nanoparticles
were shown to be rapidly internalized and induce signifıcant cancer cell apopto-
sis at lower doses compared to unformulated resveratrol and/or docetaxel. Our
data showed that resveratrol potently synergizes with docetaxel to inhibit pro-
liferation and induce cell death in resistance PCa cells. The up-regulation of
pro-apoptotic (BAX, BID, BAK), p53 and down regulation of anti-apoptotic
(BCL-2, MCL-1), Pgp and NF-B protein confırmed that a synergistic combi-
nation of resveratrol-docetaxel with targeted delivery to tumor cells could pro-
vide a more potent therapeutic effect at lower drug concentrations and improve
the therapeutic index. These results suggested that the co-delivery of resveratrol,
and a cytotoxic agent in a PBM nanoparticle might potentially improve the
treatment of drug-resistant tumors. [This work is supported from Grant #
5SC1CA193758-03]
#5868 Role of STAT3 vs AKT in cellular survival.Maximilian Niit, Joshua
Rosen, Rozanne Arulanandam, Victoria Hoskin, Bruce Elliott, Leda Raptis.
Queen’s University, Kingston, Ontario, Canada.
Cell to cell adhesion is mediated by the cadherin family of proteins. We pre-
viously demonstrated that cadherin engagement (which is favored under con-
ditions of confluence) triggers a dramatic increase inRac protein levels, followed
by an increase in IL6 secretion and Stat3 (Signal Transducer and Activator of
Transcription-3) activation. This is critical for survival of both normal and neo-
plastic cells. On the other hand, cell adhesion to the substratum, ie the extracel-
lularmatrix at the focal adhesion sites, ismediated by the integrin receptors. The
focal adhesion kinase (FAK) binds 1-integrins and this forces FAK in an open
confıguration and autophosphorylation at tyr397 which constitutes a binding
site for Src-SH2. This results in phosphorylation of FAK at tyr 576, 577, 861 and
925. The FAK/Src complex then activates downstream effectors such as Ras/Erk
and phosphatidylinositol-3 kinase (PI3k)/Akt. Our results demonstrate that
mouse fıbroblasts or epithelial cells placed in suspension (ie in the absence of
anchorage to a substratum or cell to cell adhesion) have very low levels of acti-
vatedAkt-pser473, but levels are increased dramatically upon subsequent aggre-
gation, ie cadherin engagement. Interestingly, cells growing attached in mono-
layers had highAkt-pser473 levels at low densities, which increased only slightly
with confluence. This pointed to the possibility that a kinase may be phosphor-
ylating Akt upon attachment to the substratum. The results showed that FAK
knockout cells have very lowAkt-pser473 at low cell densities, while reintroduc-
tion of wt-FAK reinstated the high Akt-pser473 levels. Furthermore, expression
of a mutant form of FAK where the 5 sites that are phosphorylated by Src are
converted to phenylalanine, did not result in an increase in Akt-pser473 levels,
demonstrating a Src requirement for Akt, pser473 phosphorylation. Conclu-
sions: Cell survival signals are a prerequisite for tissue function, as well as drug
resistance. In cultured, non-neoplastic cells grown to low densities the integrin/
FAK/cSrc signal activates PI3k/Akt and promotes survival, in the absence of
cadherin engagement. Interestingly, the integrin/FAK signal does not activate
Stat3, despite the fact that mutationally activated Src is a potent Stat3 activator.
Additional mechanisms, perhaps involving Jak and/or activated receptors may
also be required for Stat3 activation in cells grown attached but at low densities.
On the other hand, upon cadherin engagement at high cell densities, activation
of both the cadherin/Stat3 and integrin/FAK/Akt pathways can promote sur-
vival. Therefore, co-ordinate activation of these complementary pathways could
greatly enhance survival and growth of disseminated tumor cells at distant me-
tastastic sites, andmight promote resistance to chemotherapeutic agents. In this
scenario, pharmacological inhibition of both FAK/Src and Stat3 would enhance
patient survival.
#5869 Resistance mechanism against trastuzumab in HER2-positive can-
cer cells and its negation by Src inhibition.Meihua Jin, Ah Rong Nam, Ji Eun
Park, JuHeeBang, Yung JueBang,DoYounOh.Cancer Research Institute, Seoul
National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea.
Background: Trastuzumab in combination with chemotherapy is a standard
of care for patients with HER2-positive breast and gastric cancer. Resistance
mechanism to trastuzumab, anti-HER2 therapy, includes multiple pathways.
Among them, Src is not well known especially in HER2-positive gastric and
biliary tract cancers. We investigated the role of Src involved in trastuzumab
resistance and explored the potential of Src inhibition as a trastuzumab resis-
tance overcoming strategy. Methods: Four trastuzumab-resistant (HR) cells
(SNU216HR, N87HR, SNU2670HR, SNU2773HR) were established from 2
HER2-amplifıed gastric cancer cells (SNU216,NCI-N87) and 2HER2-amplifıed
biliary tract cancer cells (SNU2670, SNU2773). For Src inhibition, bosutinibwas
used. MTT assay, colony formation assay, cell cycle analysis by FACS Calibur
flow cytometer, and cell migration assay were done. Animal experiments were
conducted to test anti-tumor effect of bosutinib using SNU2670 and
SNU2670HR xenograft models. Results: SNU2670HR/NCI-N87HR cells
showed pSrc activation, in contrast, SNU216HR/SNU2773HR cells exhibited
decreased pSrc expression. In these pSrc decreasedHR cells, pFAKwas elevated.
Bosutinib downregulated Src-FAK signalingmore obviously in Src activatedHR
cells than parental cells. In pSrc decreased HR cells, bosutinib reduced Src-
dependent FAK phosphorylation to affect cell fate. Bosutinib inhibited the
growth of both parental cells and HR cells, and induced apoptosis and G1 arrest
in HR cells. Bosutinib suppressed HR cell migration more effectively compared
with parental cells. Bosutinib exhibited potent tumor growth inhibition in both
SNU2670 and SNU2670HR xenograft models and more signifıcantly sup-
pressed tumor growth inHRmodels. Conclusion: Src activationmay contribute
to trastuzumab resistance in part in HER2-positive gastric and biliary tract can-
cer cells. Targeting Src might be a candidate strategy to overcome trastuzumab
resistance in HER2-positive cancers.
#5870 Epigenetic drug treatment overcomes osteoblast-induced chemo-
protection by suppressing cell adhesion and related signaling.Anthony Qua-
gliano, Sonali Barwe, Anilkumar Gopalakrishnapillai. Nemours/A.I. duPont
Hospital for Children, Wilmington, DE.
Acute lymphoblastic leukemia (ALL) is themost commonly diagnosed cancer
in pediatric patients. Recent advances have allowed for improved effıcacy of
treatment allowing 95% of patients to achieve remission following chemother-
apy. However, nearly 20% will have a second recurrence that is often more
aggressive and diffıcult to treat. One reason for this high rate of relapse may be
due to the role of the bone marrow microenvironment (BM) consisting of os-
teoblasts, endothelial cells, adipocytes, and stromal cells as well as extracellular
matrix proteins. Interaction between leukemic cells and BM elements activates
intracellular signaling pathways that protect ALL cells from chemotherapy.
Many of these pathways can be aberrantly activated due to changes in methyl-
ation patterns during leukemogenesis. Therefore, utilizing epigenetic modifıers
offers a unique approach to overcoming the chemoprotective effects of the BM.
The aim of our study is to identify if the combination of the epigenetic drugs
azacitidine (DNA methyltransferase inhibitor) and panobinostat (histone
deacetylase inhibitor) is successful in overcoming these effects. We demon-
strated that azacitidine and panobinostat are more effective in killing ALL cells
in coculture with osteoblasts than chemotherapy alone. This required direct
interaction between ALL cells and osteoblasts and could not be replicated when
ALL cells were suspended in Transwells above the osteoblast monolayer. Addi-
tionally, ALL cells pretreated with non-killing concentrations of azacitidine and
panobinostat were sensitized to chemotherapy even in the presence of osteo-
blasts. These effects were replicated ex vivo in primaryALL patient samples with
a variety of cytogenetic characteristics. These patient samples have been xeno-
grafted inmice to observe the effıcacy of this combinationwith chemotherapy in
comparison to chemotherapy alone.We also observed that treatmentwith azaci-
tidine and panobinostat decreases the ability of ALL cells to effectively adhere to
osteoblasts, suggesting a role that down-regulation of cell adhesion molecules
(CAMs) may play in mediating this response. Due to the need for direct contact
of ALL cells with osteoblasts for the chemoprotective effects, we investigated
how treatment with azacitidine and panobinostat could affect the expression
levels of certain CAMs. We found that N-cadherin was induced in ALL cells in
coculture with osteoblasts and that increase was partially reversed by azacitidine
and panobinostat. -catenin, which is known to interact with N-cadherin, was
also up-regulated in ALL cells cocultured with osteoblasts and was reversed by
azacitidine and panobinostat. These data suggests that azacitidine and panobi-
nostatmay overcomemicroenvironment-induced chemoprotection by decreas-
ing the expression of certain CAMs like N-cadherin and interfering with their
downstream signaling pathways.
#5871 Characterizing hormone therapy-resistance phenotypes in meta-
static breast cancer conferredby estrogen receptor (ER)mutations. Shanhang
Jia,1 RyanHessenius,2MarilynNgo,2 PeiluWang,1 Amir Bahreini,3 NingChen,2
ZhijieDing,2 Tong ying Shun,2 LansingTaylor,2 ShannonPuhalla,2 Adrian Lee,2
Steffı Oesterreich,3 Andrew M. Stern,2 Mark T. Miedel2. 1Tsinghua University,
China; 2UPDDI, Pittsburgh, PA; 3UPMC, Pittsburgh, PA.
232,000 new cases of invasive breast cancer will be diagnosed in 2016. 40,300
patients will die primarily from metastatic disease. Mortality results from the
ability of cancer to evolve and evade therapy. Estrogen receptor (ER) breast
cancer accounts for 70% of invasive breast cancer. The mainstay treatment of
ER breast cancer involves estrogen deprivation therapy using aromatase in-
hibitors as well as estrogen receptor antagonists and degraders. We and others
have shown that patients treated with aromatase inhibitors often (14-54%) ac-
quire ESR1 mutations in their metastases in contrast to only a 0.5% ESR1 mu-
tation frequency detectable in their primary tumors. We hypothesize that ESR1
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mutations are selected during estrogen deprivation therapy as a result of Dar-
winian forces of evolution and represent targetable dependencies for ERmet-
astatic disease. We reasoned that characterization of the phenotype engendered
by ESR1 mutations under physiologically relevant conditions will help us un-
derstand the mechanism of ER()metastatic cancer. To achieve this objective
we have stably expressed the twomost commonESR1mutations observed in the
clinic (i.e., D538GandY537S) in a parental humanbreast cancer cell line (T47D)
using both lentiviral transfection and CRISPR/Cas9 gene editing. We used an
estrogen response element (ERE) transactivation luciferase-based reporter assay
to determine the estrogen response of each ESR1mutant expressing cell line and
their respective sensitivity to approved and investigational ER antagonist drugs.
Expression of each mutant confers estrogen-independent (constitutive) ERE
transactivation in contrast to the parental and wild type control cells. Further-
more, partial and potentially clinically relevant resistance of these ESR1mutant-
expressing cells to ER antagonists such as fulvestrant and 4-hydroxytamoxifen
was evident. In addition, using this reporter assay, mutant ESR1-expressing cell
lines show similar resistance in the absence of estrogen. We are using a human
microphysiological model of liver metastasis as a complementary approach to
patient-derived xenograft models to investigate metastatic associated pheno-
types conferred by these mutations. Since our previous studies indicated the
existence of polyclonal mutations within individual patients (P.Wang, A. Bah-
reini et al., CCR 2016), we are testing the hypothesis that the persistence of this
heterogeneity results from cooperation among these mutant-expressing clones.
These studies form the basis for our continuing efforts to understand ER
metastatic disease and use this knowledge to identify more effective therapies.
#5872 Stat3 feedback activation-induced PTGIS expression is associated
with acquired resistance to EGFR-TKI in lung cancer. Hsuan-Heng Yeh,
Shang-YinWu, Chun-Hua Hung, Wu-Chou Su. National Cheng-Kung Univer-
sity, Tainan, Taiwan.
Targeted cancer therapies can effectively promote tumor regression in clinical
responses. Eventually, most tumors develop resistance to these drugs. Stat3 ac-
tivation has been suggested as one of the mechanisms that cause acquired resis-
tance to EGFR-tyrosin kinase inhibitor (TKI) in non-small cell lung cancer
(NSCLC). However, the underlyingmolecularmechanisms are not well studied.
In this study, we found that treatment of gefıtinib (EGFR-TKI) in NSCLC cell
lines harboring EGFR-TKI sensitive mutation induced feedback activation of
Stat3 in a time- and dose-dependent manner. High levels of IL-6 were detected
in the conditioned medium of gefıtinib-treated cells by cytokine array and were
confırmed by ELISA. We demonstrated that IL-6 treatment could induce Stat3
activation and conditioned medium treatment-induced Stat3 activation was
suppressed by IL-6 neutralizing antibody. We also demonstrated that gefıtinib
treatment-induced IL-6 secretion could be inhibited by knockdown of Stat3
expression. Moreover, pharmacological inhibition and genetic inhibition of
Stat3 activation increased cell cytotoxicity of gefıtinib in both PC9 and HCC827
cells that harboring EGFR-TKI sensitive mutation. Our data suggested that ge-
fıtinib treatment could induce activation of IL-6/Stat3 signaling loop and mod-
ulate cell cytotoxicity of gefıtinib. Microarray and Ingenuity Pathway Analysis
(IPA) analysis revealed prostaglandin I2 synthase (PTGIS) as a downstream
target gene of IL-6/Stat3 signaling and PTGIS was up-regulated by gefıtinib
treatment. The induction of PTGIS by gefıtinib via Stat3 feedback activationwas
confırmed in vitro genetically and pharmacologically. Moreover, we showed
that cotreatment with PTGIS inhibitor improves the effıcacy of EGFR inhibition
in PC9 and HCC827 cells. Importantly, high expression of PTGIS was found in
gefıtinib-resistant PC9 cells (PC9/gef) compared with gefıtinib-sensitive PC9
cells. Targeting PTGIS was also effective in decreasing viability of cells with
acquired resistance to gefıtinib in PC9/gef cells. Taken together, our study indi-
cated that Stat3 feedback activation-induced PTGIS expression participates in
modulating gefıtinib effıcacy and Stat3/PTGIS inhibition could potentially over-
come acquired resistance to gefıtinib in NSCLC.
#5873 Chaetocin sensitizes GBM cells to TRAIL and BH3 mimetics in-
duced apoptosis. Ezgi Özyerli,1 ZeynepKahya Yeşil,1 UdoOppermann,2 Tuğba
Bağcı Önder1. 1Koç Univ., Istanbul, Turkey; 2University of Oxford, Oxford,
United Kingdom.
Glioblastoma Multiforme (GBM) is the most common and aggressive brain
tumor, which lacks effıcient therapy. TRAIL is an antitumor agent that triggers
apoptosis selectively on tumor cells, thus can be utilized as therapeutic approach
for GBM. However, most GBM cells confer TRAIL resistance and how this
resistance is regulated at a molecular level is not completely clear. Epigenetic
deregulation has been increasingly recognized as a hallmark of cancer. In this
study, we conducted a drug screen against selected chromatin modifıers in
U87MG GBM cells and identifıed Belinostat, Trichostatin A and Chaetocin as
potential apoptosis regulators. While Belinostat and Trichostatin A are well-
characterized histone deacetylase inhibitors in the context of malignancies,
Chaetocin’s role in cancers is less well-known and its relation to TRAIL is novel.
Chaetocin is a fungal mycotoxin that inhibits Suv39H1, a histone methyltrans-
ferase (HMT) that catalyzes H3K9 methylation. In this study, we investigated
howChaetocin affects the response of GBM cells to apoptotic stimuli by TRAIL.
To this end, GBM cell lines U87MG and U373 are treated with varying dose of
Chaetocin and cells’ viability and apoptosis responses to varying doses of TRAIL
are analyzed. Chaetocin decreased viability down to 11% of control in U87MG
cells upon TRAIL treatment, without inducing cellular toxicity and apoptosis by
itself. Chaetocin was shown to upregulate the expression of proapoptotic genes
while downregulating antiapoptotic gene expression. In addition, elevated
Caspase3/7, Caspase8 and Caspase9 activities were detected in U87MG upon
Chaetocin treatment together with PARP cleavage as indicator of apoptosis.
Chaetocin also sensitized GBM cells to BH3 mimetic ABT263 which indicates
that sensitization ofGBMcells byChaetocin is not limited toTRAIL but is rather
a general phenomenon for apoptosis. We infer from these fındings that Chaeto-
cin plays critical and specifıc role in apoptotic pathway. Our future work is
directed towards examining the changes in gene expression profıling of GBM
cells upon Chaetocin treatment and understanding the functional role of H3K9
Methylation in GBM cell apoptosis. To this end, RNAseq analysis is currently
being performed and expected to enlighten Chaetocin’s mechanism of action.
These fındings support our motivation that identifying epigenetic modifıer
drugs as apoptosis sensitizermay be a promising therapeutic approach for GBM
treatment.
#5874 Cdk4/6 kinase inhibitor resistance in prostate cancer. Renee de
Leeuw,1Matthew J. Schiewer,1 ChristopherMcNair,1 Michael A. Augello,1 Aki-
hiro Yoshida,2 Edward S. Hazard,2 Sean Courtney,2 Gerard T. Hardiman,2 Jus-
tin Drake,3 Felix Y. Feng,4 Scott Tomlins,5 Maha H. Hussain,6 J. Alan Diehl,2
William K. Kelly,1 Karen E. Knudsen1. 1Thomas Jefferson University, Philadel-
phia, PA; 2Medical University of South Carolina, Charleston, SC; 3Rutgers Uni-
versity, New Brunswick, NJ; 4University of California San Francisco, San Fran-
cisco, CA; 5University of Michigan, Ann Arbor, MI; 6Northwestern University,
Chicago, IL.
Non-organ confıned prostate cancer (PCa) is often effectively, but only tran-
siently treated by targeting the androgen receptor (AR) signaling axis through
androgen depletion strategies, often coupled with AR antagonists. Unfortu-
nately, disease recurs within a median of 3-4 years, presenting as castration
resistant PCa (CRPC), for which there are limited therapeutic options. This
emphasizes the need for more effıcacious drugs and a patient-tailored approach
towards cancer therapy to improve disease outcome. One class of drugs cur-
rently tested clinically, Cdk4/6 kinase inhibitors, blocks phosphorylation of the
retinoblastoma (RB) tumor suppressor, thereby boosting its function, and likely
preventing castration resistance. As Cdk4/6 inhibitor resistance has already
been reported in other cancers, some PCa patients are anticipated to develop
drug resistance. Here, we created palbociclib-resistant PCa cell models by con-
tinuously culturing them in presence of the drug to unravel mechanisms of
acquired resistance, and assessed them for cross-resistance to ribociclib and
response to other therapeutics. While the parental PCa cell models, Cdk4/6
inhibitors effıciently induce a G1 cell cycle arrest, the resistant cell lines bypass
this cell cycle checkpoint. Although loss of RB is a known mechanism for
Cdk4/6i resistance, none of the models lost RB expression. Strikingly, these
originally hormone-sensitive cell lines, upon developing Cdk4/6 inhibitor resis-
tance display altered response to selected therapeutic regimens. Mechanisms of
resistance, as informed by Whole Exome Sequencing and RNASeq, will be dis-
cussed.
#5875 Schlafen 11 (SLFN11) induces lethal S-phase arrest in response to
DNA damage: A novel mechanism of how cancer cells are killed by DNA
damaging agents. Junko Murai, Yves Pommier. National Cancer Institute, Na-
tional Institutes of Health, Bethesda, MD.
The putative DNA/RNA helicase, Schlafen 11 (SLFN11), is a recently discov-
ered determinant of sensitivity to DNA damaging agents such as platinums,
topoisomerase I and II inhibitors (camptothecins, etoposide, doxorubicin), cis-
platin, gemcitabine (1-3) and PARP inhibitors (olaparib, talazoparib) (4). Be-
cause SLFN11 expression is suppressed in 45% cancer cell lines, SLFN11 in-
activation is potentially one of the most prevalent mechanisms of resistance to
DNA damaging agents. However, the molecular mechanisms of SLFN11 action
in the DNA damage response have not been solved. Using isogenic cell lines of
SLFN11-knockout and SLFN11-overexpression, we will show that SLFN11
binds to chromatin in response to camptothecin within 2 hours. ChIP-seq anal-
ysis reveals that SLFN11 preferentially binds to replication origins under camp-
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tothecin treatment. We identify two helicases DHX9 and MCM3, which are
involved in replication and origin fıring, as binding partners of SLFN11 by
IP-MS analysis. Cell cycle analyses revealed that SLFN11 inhibits replication in
response to camptothecin, which irreversibly lasts until apoptosis is exerted.
Notably, the S-phase arrest by SLFN11 is independent ofATR-mediated S-phase
checkpoint. Unscheduled origin fıring by ATR inhibition under camptothecin
treatment is suppressed in the presence of SLFN11. Hence, SLFN11 enforces
irreversible S-phase arrest in damaged cells possibly by inhibiting dormant ori-
gin fıring and inactivating the MCM helicase in conjunction with DXH9. We
conclude that the irreversible S-phase arrest by SLFN11 leads to cell death in
response to DNA damaging agents, which is a novel mechanism of how cancer
cells are killed by DNA damaging agents. 1. Sousa FG, Matuo R, Tang SW,
Rajapakse VN, Luna A, Sander C, et al. Alterations of DNA repair genes in the
NCI-60 cell lines and their predictive value for anticancer drug activity. DNA
Repair (Amst) 2015;28:107-15. 2. Zoppoli G, Regairaz M, Leo E, Reinhold WC,
Varma S, BallestreroA, et al. PutativeDNA/RNAhelicase Schlafen-11 (SLFN11)
sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A
2012;109(37):15030-5. 3. Barretina J, Caponigro G, Stransky N, Venkatesan K,
MargolinAA,KimS, et al. TheCancerCell Line Encyclopedia enables predictive
modelling of anticancer drug sensitivity. Nature 2012;483(7391):603-307. 4.
Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, et al. Resistance to PARP
inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Onco-
target 2016.
#5876 Osimertinib (AZD9291), a mutant-selective EGFR inhibitor, re-
verses ABCB1-mediated drug resistance in cancer cells. Xiao-Yu Zhang,1 Zi-
Ning Lei,1 Yun-Kai Zhang,1 Yi-Jun Wang,1 Pranav Gupta,1 Leli Zeng,1 Megan
Xu,2 Xiu-QiWang,3 Dong-Hua Yang,1 Zhe-Sheng Chen1. 1St. John’s University,
Queens, NY; 2John L. Miller Great Neck North High School, Great Neck, NY;
3South China Agricultural University, Guangzhou, China.
In recent years, tyrosine kinase inhibitors (TKIs) have been shown capable of
inhibiting the ATP-binding cassette (ABC) transporter-mediated multidrug re-
sistance (MDR). In this study, we determine whether osimertinib, a novel selec-
tive, irreversible EGFR (epidermal growth factor receptor) TKI inhibitor, could
reverse ABC transporter-mediated MDR. The results showed that at non-toxic
concentrations, osimertinib signifıcantly sensitized both ABCB1-transfected
and drug-selected cell lines to substrate anticancer drugs colchicine, paclitaxel,
and vincristine. Osimertinib signifıcantly increased the accumulation of [3H]-
paclitaxel in ABCB1 overexpressing cells by blocking the efflux function of
ABCB1 transporter. In contrast, no signifıcant alteration in the expression levels
and localization pattern of ABCB1 was observed when ABCB1 overexpressing
cells were exposed to 0.3M osimertinib for 72 h. In addition, ATPase assay
showed osimertinib stimulated ABCB1ATPase activity. Molecular docking and
molecular dynamic simulations showed osimertinib has strong and stable inter-
actions at transmembrane domain of human homology ABCB1. Taken to-
gether, our fındings suggest that osimertinib, a clinically approved third-gener-
ation EGFR TKI, can reverse ABCB1-mediated MDR, which supports the
combination therapywith osimertinib andABCB1 substratesmay potentially be
a novel therapeutic treatment in ABCB1-positive drug resistant cancers.
#5877 The functional role(s) of serum amyloid A1 (SAA1) polymor-
phisms in integrin-mediated cell adhesion in nasopharyngeal carcinoma
(NPC) cells.OnYingMan, Hong Lok Lung. Baptist University of Hong Kong,
Hong Kong, China.
Serum amyloid A1 (SAA1) was previously identifıed as a tumor suppressor
gene with anti-angiogenic activities in nasopharyngeal carcinoma (NPC). Three
SAA1 isoforms (SAA1.1, 1.3, and 1.5) were observed with disproportionate fre-
quencies among the NPC patients and healthy people. SAA1.1 and 1.3 are the
functional isoforms to inhibit angiogenesis whereas SAA1.5 was the defective
gene. Our immunohistochemical results showed that the loss of SAA1 staining
in the metastatic NPC tissues was signifıcantly associated with tumor progres-
sion. We aim to investigate the functional roles of the three SAA1 isoforms in
NPC metastasis in the present study. We want to investigate whether the func-
tional SAA1.1 and 1.3 isoforms can suppress tumor metastasis by antagonizing
the integrin-FAK signaling pathway in the NPC tumor cells. The focal adhesion
assay was performed by seeding the tumor cells with or without the integrin
alphaVbeta3/beta5 ligand vitronectin. Both the vector-alone control and the
SAA1.5-expressing NPC cells began to spread out and adhered to the bottom of
the culture dish in the presence of vitronectin from 7 to 9 hours, whereas the
SAA1.1 and SAA1.3-cells remained in the round-up morphology with minimal
attachment. Interestingly, after 48 hours the SAA1.1 and SAA1.3-expressing
cells formed adherents junction among the cells. In order to study the viability of
the effects of the three SAA1 isoforms on NPC cells, MTT viability assay was
performed. The results showed that the viability of the SAA1.1 and SAA1.3-
expressing cells were around 50 % lower than both the vector-alone and the
SAA1.5-expressing cells. It is likely that the loss of focal adhesion after seeding of
the SAA1.1 and SAA1.3-expressing cells will affect the survival of NPC cells.
Furthermore, we found that the presence of the recombinant SAA1.1 and SAA
1.3 proteins could reduce the number of viable NPC cells compared with the
solvent control and the SAA1.5 protein. We previously reported that the SAA1
proteins can physically interact with the integrin alphaVbeta3. Taken together,
we suggested that the secreted SAA1 proteins from the NPC cells could directly
affect the NPC focal adhesion as well as the cell viability by blocking the integrin
on the NPC cell surface. We acknowledge the fınancial support of the General
Research Fund (grant number HKBU17115114 to HLL) of the Research Grants
Council of the Hong Kong Special Administrative Region.
#5878 Trichostatin A overcomes chemotherapeutic resistance of urothelial
carcinomacells through the inactivationof c-Raf/ERKpathway.Kuan-LinKuo,1
Chung-Sheng Shi,2 Ju-Tong Hsieh,1 Shiang-Peng Chen,1 Wei-Chou Lin,3 Shih-
Ming Liao,1 Shing-Hwa Liu,1 Kuo-HowHuang1. 1National TaiwanUniversity Col-
lege of Medicine, Taipei, Taiwan; 2Chang Gung University College of Medicine,
Taoyuan, Taiwan; 3National Taiwan University Hospital, Taipei, Taiwan.
Trichostatin A (TSA), a potent histone deacetylase (HDAC) inhibitor, has
been reported to elicit anti-proliferative response in various tumors. Here, we
investigated antitumor effect of TSA alone or in combination with conventional
chemotherapeutic agents on urothelial carcinoma (UC) cells. We use one high-
grade UC cell line (T24) and another UC cells (NTUUC) obtained by primary
culture from the surgical specimen of a women with high-grade and metastatic
bladder UC. The cytotoxicity and apoptosis induced by TSA alone , chemother-
apeutic agents (cisplatin, gemcitabine and doxorubicin) and combined treat-
ment were assessed by MTT assay and fluorescence-activated cell sorting and
flow cytometry. The expression of phosphor c-Raf, phosphor-MEK1/2, and
phosphor-ERK1/2 were measured by Western blot. urther elucidation on the
role of Raf/MEK/ERK pathoway on the TSA-enhanced cytoxicity were ex-
mained by using ERK1 siRNA knockdown and the specifıc MEK inhibitor
(PD98059). Our results showed TSA markedly enhances the cytotoxicity and
apoptosis of three chemotherapeutic agents in UC cells with concurrent sup-
pression of Raf/MEK/ERK signaling pathway. Consistently, inhibition of
Down-regulation of ERK by MEK inhibitor or by ERK 1 siRNA knockdown
potentiated the chemotherapeutic agnet-induced cytotoxicity of TSA in UC
cells. We concluded that TSA potentiates the therapeutic effıcacy of cisplatin,
gemcitabine and doxorubicin in human UC cells through Raf/MEK/ERK sig-
naling pathway. These fındings provide a new treatment strategy against UC.
#5879 Establishing doxorubicin resistant HCC1806 triple negative breast
cancer cell lines result in the differential expression of let7a and miR34a.
Checo J. Rorie, Malcolm M. Moses, Mohammed K. Musa, Sherette S. Godfrey.
North Carolina A&T State Univ., Greensboro, NC.
Resistance to chemotherapy is one of themajor diffıculties in the treatment of
triple negative breast cancer. Besides the typical known causes of drug resistance,
tumor microenvironment can also promote resistance by preventing the drug
from accumulating in tumor cells in order to elicit a cytotoxic response. TNBC is
characterized by the loss or low expression of estrogen receptor, progesterone
receptor, and HER2 proteins that have been targeted and established as some-
what effective therapy regiments in other breast cancer subtypes including lim-
inal breast cancer. Since TNBC tumors are missing these well-known drug tar-
gets, there is little to no advancement in the establishment of drug therapies to
accurately target this breast cancer subtype. TNBC is termed as aggressive due to
the fact of its invasiveness and metastatic properties. One potential mediator of
TNBC aggressive behavior may be due to the fact that this breast cancer subtype
mayhave as high as an 80%p53 tumor suppressor genemutation ratewhichmay
also play a role in the ability of TNBC to recur as a result of the inability to kill all
remaining TNBC cells leading to chemotherapy resistance. In these studies, we
hope to mimic TNBC recurrence by establishing doxorubicin resistant
HCC1806 TNBC cell lines. Here we show that wewere able to sustain TNBC cell
growth after pulse treatments with increasing concentrations of doxorubicin,
and we revealed that p53-relatedmiRNAs, let7a andmiR34a, were differentially
expressed after pulse treating the HCC1806 cells. Understanding the molecular
and mechanistic factors related to recurrence and doxorubicin-resistance in
HCC1806 cells may help to develop a list of possible targets for molecular ther-
apy to overwhelm tumor drug resistance in triple negative breast cancer andmay
develop or establish a list of potential targets for disabling, or combating resis-
tance to doxorubicin treatment in TNBC patients.
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#5880 Acquiredchemotherapeuticdrugresistance incolorectal cancer is reg-
ulated by epithelial-to-mesenchymal transition and altered cellular pathways.
LahiruGangoda,1NidhiMathew,1MichaelLiem,1 ShivaKeertikumar,1Ching-Seng
Ang,2 John Mariadason,3 Suresh Mathivanan1. 1La Trobe Institute for Molecular
Science, LaTrobeUniversity,Bundoora,Australia; 2TheBio21Molecular Scienceand
Biotechnology Institute, University of Melbourne, Parkville, Australia; 3Olivia New-
ton John Cancer Research Institute, Heidelberg, Australia.
Colorectal cancer (CRC) is the third most common cancer and the second
leading cause of cancer-related death in the western world. Chemotherapy is the
mainstay in the treatment of metastasized CRC. However, cancer cells acquire
resistance to treatment by various mechanisms resulting in treatment failure.
Even though the molecular mechanisms regulating acquired drug resistance is
critical to overcome chemoresistance, it is poorly understood. We developed a
panel of sevenCRC cells resistant to 5-FU. The parental and 5-FU resistant CRC
cells were assayed for proteins known for their involvement in chemotherapeu-
tic resistance. In addition, an unbiased quantitative proteomics andDNAmeth-
ylation analysis was performed on the panel of seven parental and 5-FU resistant
CRC cells. The integrated analysis revealed multiple mechanisms contributing
to chemotherapeutic drug resistance including epithelial-to-mesenchymal tran-
sition (EMT), deregulation of apoptosis, increased survival autophagy and epi-
genetic modifıcations resulting in altered drugmetabolite potency. Inhibitors of
EMT and autophagy sensitized the 5-FU resistant CRC cells. Furthermore,
CRIPSRbased gene knockouts of these candidate genes (both up anddownregu-
lated) either sensitized the CRC cells or rendered them resistant to 5-FU. As a
follow up, PDX mouse models were established and made resistant to 5-FU.
Follow up quantitative proteomics and biochemical validations of 5-FU resis-
tant PDX tissue lysates confırmed the role of EMT in acquired chemoresistance.
Overall, this project unravelled multiple mechanisms by which CRC cells may
become resistant to 5-FU. Importantly, some of these mechanisms are also con-
served in many cancer types and hence targeting these mechanisms can over-
come chemoresistance and increase patient survival rates.
#5881 Identifıcation of resistance mechanisms to IGF-IR targeting in tri-
ple negative breast cancer. Jennifer Tsui, George Vaniotis, Maria Celia Fernan-
dez, Pnina Brodt.McGill University, Montreal, Quebec, Canada.
The triple negative subtypes of breast cancer (TNBC) are associatedwith poor
prognosis. Unlike HER2 and hormone receptor-positive BC, TNBC do not
respond to targeted therapy and chemotherapy remains the primary treatment
option. There is therefore an unmet need to develop effective therapy for TNBC.
The insulin-like growth factor 1 (IGF-I) axis plays a critical role in BC progres-
sion by conveying survival and growth signals. Our laboratory reported on the
production of a soluble fusion protein comprised of the extracellular domain of
human IGF-IR fused to the Fc portion of human IgG (the IGF-Trap). The IGF-
Trap reduces the bioavailability of circulating and locally produced IGF-I,
thereby limiting tumor growth. When human TNBC MDA-MB-231 cells were
xenotransplanted into nude mice and treated with the IGF-Trap, we observed
variability in the response as it ranged from complete tumor regression to dis-
ease stabilization and tumor progression in some mice. This suggested that
MDA-MB-231 cells are heterogeneous in respect to their sensitivity to IGF-IR
signaling blockade. The aimof the present studywas to identify resistancemech-
anisms that allow the cells to progress in the face of IGF-IR signaling blockade by
the IGF-Trap.We fırst analyzed the tyrosine kinase receptor profıle of these cells
and confırmed by PCR that in addition to IGF-IR, they express epidermal
growth factor receptor (EGFR), c-Met, and fıbroblast growth factor receptor 1
(FGFR1). They also produce IGF-I, EGF and relatively high level of FGF1 that
could provide potential autocrine signaling to compensate for IGF signaling
blockade. Using limiting dilution cloning, we isolated MDA-MB-231 cells with
a range of IGF-IR expression levels, as confırmedby qPCRandWestern blotting.
We found that clones with higher basal IGF-IR activation levels, independently
of expression levels had increased sensitivity to IGF-Trap treatment in the pres-
ence of serum, identifying them as IGF-addicted clonal subpopulations. Fur-
thermore, an IGF-Trap resistant population selected from MDA-MB-231 cells
by prolonged exposure to the IGF-Traphad an increased proliferation rate in the
presence of the IGF-Trap as compared to unselected cells, as assessed by MTT
and showed higher p-EGFR and p-ERK levels, suggesting that prolonged IGF-
Trap treatment enriched an IGF-I-independent population with increased ag-
gressiveness. Collectively these results showed that MDA-MB-231 cells are het-
erogeneous in respect to IGF-IR expression levels and that IGF-Trap sensitivity
correlated with constitutive IGF-IR activation levels. Moreover, IGF-Trap resis-
tance in these cells was associated with increased EGFR signaling and prolifer-
ation. Further interrogation of the gene expression profıle of these cells will
defıne a “resistance signature” with potential relevance to personalized treat-
ment with IGF-targeting drugs. Supported by the CIHR and Mitacs.
#5882 FAK is required for the survival of tumor cells in MMTV-Wnt1
driven basal-like mammary tumors. Ritama Paul,1 Syn K. Yeo,1 Ming Luo,2
Susan Waltz,1 Jun-Lin Guan1. 1University of Cincinnati, Cincinnati, OH; 2Uni-
versity of Michigan, Ann Arbor, MI.
Breast cancer is a heterogeneous disease. Stratifıcation of patients based on the
subtype of breast cancer is a key to successful treatment of breast cancer. Focal
Adhesion Kinase (FAK), a cytoplasmic tyrosine kinase is over expressed and
activated in several cancers including breast cancer. Our earlier studies have
shown inhibition of FAK in MMTV-PyMT mouse mammary tumors that are
classifıed as Luminal B subtype, delays tumor onset and reduces tumor growth.
To address whether inhibition of FAK would be benefıcial in basal-like mam-
mary tumors, we generated a conditional deletion of FAK and a knock in mu-
tation of FAK lacking its kinase activity, inMMTV-WNT1mousemodel, which
classifıes as basal-like. Similar to PyMTmammary tumors we found that loss of
FAK or its kinase function delays tumor onset and tumor growth of basal like
WNT1 mammary tumors. However unlike the PyMT tumors, the reduced tu-
mor growth inWNT1model is not due to decreased proliferation. Interestingly
loss of FAK activity inWNT1 tumors results in accumulation of cleaved caspase
3, suggesting that loss of FAK activity results in compromised tumor cell sur-
vival. When we investigated the pathways through which FAK could affect sur-
vival, we found that loss of FAK activity reduces activation of AKT. Reduced
AKT activation induces the expression of pro-apoptotic genes. In summary our
studies show that in a basal-like tumormodel, FAK is required for survival of the
tumor cells. Hence inhibition of FAK could be benefıcial for elimination of
basal-like tumor cells.
#5883 CHD1 as regulator of cell adhesion in Ets fusion negative prostate
cancer. Aparna Kareddula,1 Whitney Petrosky,1 Irina Tereshchenko,1 Daniel
Medina,1 Hana Aviv,2 Eric Singer,1 Robert S. DiPaola,3 Kim M. Hirshfıeld1.
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; 2Rutgers Robert
Wood JohnsonMedical School, New Brunswick, NJ; 3School of Medicine, Univer-
sity of Kentucky, Lexington, KY.
Prostate cancer (PCa) develops into lethal disease in about 10% of men diag-
nosed with this malignancy. Common genomic changes are seen in PCa such as
alterations in CDKN1B, RB1, TP53, PTEN,NKX3-1,MYC and androgen recep-
tor. Oncogenic fusions involving the Ets family are seen in 50-70%PCa patients,
the most common of which is TMPRSS2-ERG. TMPRSS2-ERG influences cell
migration, particularly when PTEN is co-deleted or PIK3CA activating muta-
tions are present. However, in the absence of ERG fusions, molecular drivers of
the PCa phenotype are less clear but include alterations in SPOP (6-15%of PCa),
SPINK1 (10%), MAP3K7 (18-38%) and CHD1 (15-27%). CHD1 (Chromo-do-
main Helicase DNA Binding Protein-1) is a chromatin remodeling factor with
many roles including homologous recombinationmediatedDNA repair of dou-
ble strand breaks and maintenance of genomic stability and therefore it is hy-
pothesized to cause the predominant intrachromosomal rearrangements ob-
served in Ets fusion negative tumors. This study was undertaken to evaluate the
cellular effects that follow CHD1 deletion that could aid PCa initiation and
progression. CHD1 was knocked out in the non tumorigenic, HPV16 immor-
talised prostate epithelial cell line, RWPE-1, using CRISPR/Cas9. Compared to
parental RWPE-1 and non target cells (NT2), the CHD1 KO cells had a smaller
and rounder morphology and were less adherent to tissue culture plates. To
study expression of extracellular matrix and adhesion molecules, RT profıler
assay was performed using RWPE-1 parental and CHD1 KO cells. CHD1 KO
cells showed a decrease in the expression of SPARC, MMP2, ITGA2, ITGA5,
ITGA6, FN1, LAMB3, collagen, tenascin and vitronectin as compared to paren-
tals and NT2. Reduction in extracellular matrix and adhesion molecules and
altered morphology of CHD1 KO cells as compared to parentals and NT2 cells
suggest that loss of CHD1 reduces cell-cell and cell-matrix adhesion. These
results suggest that in the absence of PTEN loss in Ets negative tumors, deletion
of CHD1 gene could change cell adhesion dynamics ascribing a new role for
CHD1 in the development and progression of PCa.
#5884 UGDH is required for KLF4-mCpG dependent increase in GBM
cell migration.Olutobi Oyinlade,1 Jun Wan,2 Shuang Wei,1 Jiang Qian,3 Heng
Zhu,4 Shuli Xia1. 1Kennedy Krieger Institute, Baltimore, MD; 2Wilmer Eye Insti-
tute, Johns Hopkins University School of Medicine, Baltimore, MD; 3Johns Hop-
kins School of Medicine, Baltimore, MD; 4Johns Hopkins University School of
Medicine, Baltimore, MD.
CpG methylation in cis-regulatory elements is generally believed to repress
gene expression by disrupting transcription factor (TF)-DNA interactions di-
rectly or indirectly via the recruitment of proteins containing methyl-CpG-
binding domain (MBD), which are largely sequence independent. However, this
dogma is challenged by several recent studies including a recent publication by
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us. In this study, many TFs, including krüppel-like factor 4 (KLF4), were found
to preferentially bind to mCpG-containing motifs and transactivate gene ex-
pression. Using a site-specifıc KLF4 mutant (R458A) that abolishes its binding
activity to mCpG, but has no impact on binding to its canonical unmethylated
motif, we investigated biological function of mCpG-dependent gene regulation
by KLF4 in glioblastoma cells. Our studies showed that KLF4 promotes cell
adhesion, migration, and morphological changes, all of which are abolished by
R458A mutation. We identifıed over a 100 genes were directly activated via
mCpG-dependent KLF4 binding activity. These targets were associated with
multiple pathways including pathways involved in cytoskeletal organization,
cell adhesion, cytoskeleton, and extracellular matrix. Genes such as NGEF,
UGDH, PHLDB2, LIMS2, LM07 and Rabex-5/RABGEF1involved in migration
and cytoskeletal organizationwere highly induced.We validated these targets by
Bisulfıte Sequencing, ChIP-PCR, RT-PCR and western blot to confırm that they
are indeedKLF4-mCpGdirect targets. To understand the biological implication
of KLF4-mCpG activity and broaden the current understanding of the role of
DNA methylation in transcriptional regulation, we utilized one of the direct
KLF4-mCpG targets UGDH to investigate this novel epigenetic regulation.
UGDH (UDP-	-D-glucose 6-dehydrogenase) is involved in the biosynthesis of
the glycosaminoglycan precursor UDP-	-D-glucuronic. Glycosaminoglycans
(GAGs) are one of the major components of the cellular environment. Certain
GAGs such as Hyaluronic acid (HA) participate in numerous cellular phenom-
ena, including adhesion, motility, angiogenesis and wound healing. UGDH,
although upregulated in GBMs has not been implicated in GBM tumor biology.
We show that UGDH is required for KLF4-mCpGdependent increase inmigra-
tion and UGDH knockdown decreases GBM cell proliferation, migration and
the abundance of GAGs. Elevated glycosaminoglycan formation is implicated in
a variety of human diseases, including the progression of tumors. The inhibition
of synthesis of UDP-	-D-glucuronic acid using UGDH antagonists might
therefore be a useful strategy for therapy.
#5885 Sialyl Lewis X-P-selectin connection between ovarian tumor-meso-
thelium in early stage metastasis. Shan-Shan Li, Carman K. M. Ip, Ayon A.
Hassan, Matthew Y. H. Tang, Susan Yung, Tak-Mao Chan, Ho Cheung Shum,
Alice S. T. Wong. The University of Hong Kong, Hong Kong, China.
Metastasis is one of the major challenges for the treatment of ovarian cancer.
Unlike other solid tumors, ovarian cancer primarily disseminateswithin the perito-
neal cavity. A crucial step inmetastasis formation is the adhesion of ovarian cancer
cells onto the peritoneal mesothelium under ascitic shear flow. However, the adhe-
sion mechanisms engaged in this tumor-mesothelium interaction remain elusive
due to a lack of physiologically relevant model to manipulate and investigate this
dynamic process. In this study, using a 3Dmicrofluidic platform, we found that the
metastatic population of cancer stem cells (M-CSCs) exhibited slower rolling veloc-
ity and higher binding ability to the peritoneal mesothelium than non-metastatic
(NM)-CSCs under flow condition. This adhesion cascadewasmediated by P-selec-
tinwhich expressed on the peritonealmesothelium.The key carbohydrate determi-
nant on M-CSCs was a glycoprotein, but not a glycolipid, with its recognition as
sialyl-Lewis X (sLeX) in a sialic acid- and fucose-dependent manner. Moreover,
several glycosyltransferase genes including B4GALT4, ST3GAL3, ST3GAL4 and
FUT-5 involved the synthesis of sLeXwereupregulated inM-CSCs.Knockingdown
FUT-5 signifıcantly inhibited ovarian tumor cell adhesion on the mesothelium in
vitro and reduced the metastatic potential in vivo. Taken together, our fındings
revealed that a distinct sLeX-P-selectin axis of ovarian tumor-mesothelium interac-
tion inearlymetastasis andmayoffer thepossibilityofnewtherapeutic targets. (This
work is supported by RGC grant 17122014.)
#5886 High-throughput mutagenesis reveals novel mechanisms of drug
resistance in the proto-oncogene Src kinase. Ethan Ahler, Sujata Chakraborty,
Linglan Fan, Dustin J. Maly, Douglas M. Fowler. University of Washington,
Seattle, WA.
Kinase inhibitors are integral for the treatment of certain cancers, but the
emergence of drug resistance limits their long-term effectiveness. Resistance can
arise through multiple routes, including via mutations in the kinase that render
it insensitive to drug. Although some resistance mutations for a few inhibitors
are well characterized, most remain uncharacterized or even unidentifıed, par-
ticularly in new or emerging kinase targets. Ideally, we could characterize every
possible resistance mutation that could arise during treatment with each inhib-
itor. The resulting comprehensive data could improve clinical decision-making
for patients with drug-resistant tumors. However, current experimental meth-
ods for discovering resistance mutations cannot achieve the required scale, pre-
venting us from realizing this goal. We developed a method for parallel assess-
ment of the degree of inhibitor resistance of nearly all possible single mutants of
the promising drug target Src kinase. We generated a comprehensive single
mutant library of Src and subjected it to selection for Src activity either alone or
in the presence of the inhibitor dasatinib. Then, we measured the change in
frequency of each mutant during selection by deep sequencing. Using this data,
we classifıed the impact of each Src mutant, both in terms of activity and resis-
tance to dasatinib. Our method identifıed dozens of previously uncharacterized
dasatinib-resistance mutations in Src. As expected, some of these novel resis-
tance mutations cluster near the ATP-binding cleft of the catalytic domain.
However, a surprisingly large number occur at residues distal to dasatinib’s
binding site. Biochemical validations of a subset of these newly identifıed resis-
tancemutants are ongoing. Although dasatinib is not currently approved for Src
inhibition, these results could be useful to direct treatment for those patients
currently enrolled in dasatinib clinical trials. Our results demonstrate the power
of ourmethod for the characterization of resistancemutations in drug targets. In
contrast with previous low-throughput and retrospective methods, our ap-
proach enables the comprehensive and prospective identifıcation of resistance
mutations. The approach can reveal resistance mechanisms, even before a drug
is clinically approved. Importantly, our method allows for the rapid profıling of
other Src inhibitors and potentially the discovery of inhibitor-specifıc resistance
mutations. Finally, we are using our data to explore hypotheses regarding the
structure, function, or regulation of Src kinase.
#5887 The role of FAK in tumor microenvironment. Hsin-Jung Wu, Syn
Kok Yeo, Megan Wilson. University of Cincinnati, Cincinnati, OH.
Focal Adhesion Kinase (FAK) is a cytoplasmic non-receptor tyrosine kinase
important in mediating signal transduction in cell migration, survival and pro-
liferation. Up-regulation of FAK in the tumor cells has been shown to enhance
tumor malignancy and correlate with poor prognosis. FAK signaling has also
been implicated in impacting tumor microenvironment, including endothelial
cells and fıbroblasts. However, much less is known about how FAK in the tumor
stroma affects tumor progression, or how stromal FAK cross-talks with cancer
cells. Here we use an inducible Col1	2-creERT, FAK f/f genetic engineered
mouse model (GEMM) to specifıcally delete FAK in the fıbroblasts. Using the
GEMM, we found that FAK in stromal fıbroblasts facilitates breast tumor
growth andmetastasis in vivo.We further showed that conditionedmedia (CM)
from human breast cancer cells induced FAK Y397 autophoslphorylation and
expression of smoothmuscle actin (SMA, a marker for cancer-associated-fıbro-
blasts [CAFs]) of normal human lung fıbroblasts. Interestingly, only the breast
cancer CM educated fıbroblasts, but not the naive un-treated fıbroblasts, were
able to promote breast cancer cell migration and invasion. Lastly, knockdown of
FAK in these “educated” fıbroblasts abolished their ability to promote breast
cancer cell migration and invasion. Taken together, these data suggest a poten-
tial role of stromal FAK in creating a pro-tumorigenic microenvironment for
breast cancer development and progression, and provide further rationale in
therapeutic benefıts of FAK inhibition against various solid tumors.
#5888 Tmem 205-mediated cisplatin resistance in ovarian clear cell carci-
noma (OCCC) is overcome by herpes simplex virus (oHSV)/cisplatin combi-
nation therapy.Uksha Saini,1Maria Riley,1 KalpanaDeepaDorayappan,1 Chel-
sea Bolyard,1 Balveen Kaur,1 Roman Zingarelli,1 Ikuo Konishi,2 Periannan
Kuppusamy,3 George Larry Maxwell,4 David E. Cohn,1 Karuppaiyah Selvendi-
ran1. 1Ohio State Univ. Medical Ctr., Columbus, OH; 2Kyoto University, Sakyo-
Ku, Kyoto, Japan; 3Dartmouth-Hitchcock Medical Center, Lebanon, NH; 4Inova
Fairfax Hospital, Falls Church, VA.
Objectives:Ovarian clear cell carcinoma (OCCC) is anaggressive formofovarian
cancer and unfavorable treatment outcomes have been attributed to its relative
chemoresistance and recurrence, limiting the available treatment options. There-
fore, identifying novel unique protein(s) involved in OCCC chemoresistance and
designing a therapeutic modality selectively targeting those proteins would make a
signifıcant impact on therapy. TMEM 205 is one such protein which has been re-
cently linked tocisplatin resistance inhumanepidermoidcarcinoma,but theprecise
molecular mechanism of this resistance still needs to be elucidated. This proposed
study was planned to a) decipher the role of TMEM205 expression in OCCC (rela-
tive to HGSOC) b) mechanism by which TMEM205 imparts chemoresistance c)
evaluate the in vitro and in vivo effıcacy of oHSVas a single agent or in combination
with standard chemotherapyMethods: Human patient tissue samples fromOCCC
patients as well as OCCC cell lines like JHOC, OVTOKO, OVISE and ES2 were
analyzed for the expression of TMEM205 using Western blot, IHC/ICC and real
timeqPCR. InsitupO2wasmeasured in thecells aswell asmiceusingEPRoximetry.
Exosomes were isolated and characterized using NTA. TMEM205 overexpression
andknockdownexperimentswere performed in vitro inOVTOKOcells to confırm
the role of TMEM205 inOCCC. Cispaltin accumulation in cells and exosomes was
quantifıed using ICP-MS. oHSV virus therapywas further tested in vitro or in vivo-
alone or combined with cisplatin treatment. Results demonstrate that the OCCC
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tissues aswell as cell lines have high expression of TMEM205.OCCCcells andmice
injected with these cells are severely hypoxic and cisplatin accumulation is more in
the exosomes derived from them, which goes down with the knockdown of
TMEM205. oHSV treatment suppresses TMEM205 expression in OVTOKO and
JHOCcells. Further, ICC showed that TMEM205 andoHSVco-localize in the cells,
indicating that oHSVmay interact with TMEM205 and suppress its expression and
activity. oHSV pretreatment followed by treatment with cisplatin (CP) increases
apoptosis and decreases cell survival, in vitro within 48 hours as well as in vivo.
Conclusions: TMEM205 mediates drug resistance through exosomes and knock-
down of TMEM205 in OCCC contributes to enhanced chemotherapy sensitivity.
This will pave the way for exploring the clinical implications of TMEM205 in
OCCC, and evaluating whether TMEM205 expression is key to higher risk of resis-
tance and recurrence seen in OCCC.
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#5889 Cancer associated fıbroblasts regulate cancer stem cell functions in
pancreatic ductal adenocarcinoma. Asma Begum,1 Ross McMillan,1 Yu-tai
Chang,1 Vesselin Penchev,1 NV Rajeshkumar,1 Anirban Maitra,2 Michael G.
Goggins,1 James R. Eshelman,1 Christopher Wolfgang,1 Zeshaan A. Rasheed,1
William H. Matsui1. 1Johns Hopkins University, Baltimore, MD; 2University of
Texas M.D. Anderson Cancer Center, Houston, TX.
Introduction:Despite recent advancements in treatment, the outcomeof pan-
creatic ductal adenocarcinoma (PDAC) remains dismal due to high relapse rate
andmetastatic dissemination. PDAC cancer stem cells (CSCs) have been shown
to play a role in these processes and are associated with worsemedian survival in
patients. Several cell-intrinsic mechanisms of CSC regulation have been identi-
fıed in PDAC, however the role of the altered tumormicroenvironment remains
largely unknown. We focusd on the impact of cancer associated fıbroblasts
(CAFs) on CSCs properties in PDAC. Methods: Stromal fıbroblast lines were
established from surgically resected PDAC tissues and were marked by specifıc
fluorophore. Following co-culture with CAFs, tumor cells from PDAC cell lines
or low passage xenografts derived from primary surgical specimens cells were
isolated and evaluated for colony formation and migration. The effect of Focal
Adhesion Kinase (FAK) on CAF-mediated clonogenic growth was evaluated
using the small molecule FAK inhibitor PF573228 or overexpression of full-
length of FAK in PDAC cells. Results: Following co-culture with CAFs, the
clonogenic growth of PDACcell lines increased by 1.3-2.5 fold compared to cells
incubated alone (p 0.05). Furthermore, CAFs enhanced colony formation of
cells from patient derived xenografts by at least 4 fold (p 0.001). To examine
the effect of CAFs on PDAC self-renewal, tumor colonies were harvested and
replated in methylcellulose. Although cells were not further exposed to CAFs,
secondary colony formation of cells originally co-cultured with CAFs increased
by  1.3 fold. We also found that the frequency of ALDH PDAC CSCs in-
creased by 12-19 fold compared to control cells. CSCs are also highly migratory
and express factors suggestive of the epithelial to mesenchymal transition
(EMT) suggesting that they play an important role inmetastatic disease. Follow-
ing co-culture, the migration of PDAC cells increased by 1.2-2.1 fold (p 0.05)
with increased expression of the EMT associated genes SNAIL1, SNAIL2, ZEB1,
ZEB2, N-cadherin, and Vimentin. PDAC cells induced CAF activation as evi-
denced by enhanced 	SMA expression. Since activated CAFs are known to
secret extracellular matrix proteins, we examined the activation of FAK down-
stream of integrin signaling and found increased phosphorylation of FAK at
Y397. To determine the importance of FAK activation on the interaction be-
tweenCAFs andPDACcells, cells were treatedwith the FAK inhibitor PF573228
that signifıcantly inhibited tumor colony formation. In contrast, the overexpres-
sion of FAK-FL further increased CAF-mediated PDAC clonogenic growth.
Conclusion: CAFs enhance PDAC CSCs including clonogenic growth, migra-
tion, and self-renewal. These effects are partially mediated by FAK, and FAK
inhibitors may represent a novel strategy to modulate the interaction of PDAC
cells and the tumor microenviroment.
#5890 Osteoblasts are educated into a tumor-associated stromal cell by
disseminated breast cancer cells and mediate breast cancer cell proliferation
in the bone microenvironment. Frank Marini,1 Julia Chifman,2 Janet Tooze,1
Candelaria Gomez-Manzano,3 Karen M. Bussard4. 1Wake Forest Comprehen-
siveCancerCenter,Winston-Salem,NC; 2AmericanUniversity,Washington,DC;
3The University of Texas MD Anderson Cancer Center, Houston, TX; 4Thomas
Jefferon Univ. Kimmel Cancer Ctr., Philadelphia, PA.
Breast cancer has a predilection for bone metastasis, where the fıve-year sur-
vival rate is bleak. Disseminated breast cancer cells invade bone and can remain
undetectable and untreatable for decades during a period of reduced prolifera-
tion. Our work reveals that osteoblasts are educated into a tumor-associated
stromal cell by disseminated breast cancer cells and alter their production of
exosomal microRNAs that regulate cancer cell cycle. Osteoblasts were grown to
various stages of maturity and incubated with the conditioned medium (CM)
from human breast cancer cells to produce tumor-associated osteoblasts
(TAOs). TAOs and their CM were characterized, then TAO cells admixed with
human breast cancer cells in-vitro or in-vivo to elucidate the impact of TAOs on
the tumor microenvironment. Osteoblasts undergo an inflammatory stress re-
sponse and gain tumor-associated stromal cell-like properties when either co-
cultured or treated with the CM of human breast cancer cells. These changes
were mediated by crosstalk via gap junction intercellular communication (con-
nexin 43) and exosome exchange that occurred between TAO cells and human
breast cancer cells. TAO-derived exosomes were found to contain increased
amounts of microRNAs 320a and 193b compared to normal osteoblasts or
breast cancer cells. microRNA 320a is associated with decreased cellular prolif-
eration and induction of G0 phase of the cell cycle. miR 193b has been shown to
regulate cyclin D1 expression and repress cellular proliferation. Knock-down of
miRs 320a and 193b in breast cancer cells resulted in a reduced number of cancer
cells in G0 and increased numbers of cancer cells in G1/S/G2/M phases of the cell
cycle. Furthermore, TAO cell CM led to decreased activation of TRAP oste-
oclasts. When TAO cells were admixed with human breast cancer cells and
inoculated in-vivo in mice, tumors grew more slowly and were at least 50%
smaller than tumors composed of normal osteoblasts plus breast cancer cells, or
breast cancer cells inoculated alone.Mice inoculatedwith an admix of TAO cells
plus human metastatic breast cancer cells lived 20 days longer than mice in-
oculated with an admix of normal osteoblasts plusmetastatic breast cancer cells,
or breast cancer cells alone. These data also suggest that TAO cells regulate the
proliferation of metastatic breast cancer cells in the tumor microenvironment.
Overall, these date suggest that osteoblasts are an important source of factors,
specifıcally exosomal microRNAs, in breast cancer bone metastasis. The nature
of these factors suggest their importance for facilitating disseminated breast
cancer cell proliferation, as well as osteoclast activation in the bone microenvi-
ronment. Supported by NIH 1RC1 CA146381, 1R01NS06994, P50 CA083639
for FCM; (NRSA) T32 CA079448, NIH 3 R00 CA178177 for KMB.
#5891 DCIS to invasive progression in breast cancer is delayed by restor-
ing CCN5. Sandipto Sarkar, Arnab Ghosh, Gargi Maity, Snigdha Banerjee, Su-
shanta Banerjee.University of Kansas Medical Center/ VAMedical Center, Kan-
sas City, KS.
Malignant progression of breast cancer from pre-invasive to invasive lesions
remains a mechanistically unknown event and a major challenge in medical
research. By revealing the mechanism of action, our new and substantially dif-
ferent approach aims to demonstrate that CCN5/WISP2 might play a role in
negative regulation of progression of pre-invasive lesion ductal carcinoma in-
situ (DCIS) to invasive carcinoma (IC). DCIS to IC transition results primarily
from the loss of themyoepithelial cell (MEC) layer surrounding the breast ducts
& lobules and basement membrane (BM) degradation followed by invasion of
cancer cells into the surrounding stromal tissue and vasculature. It has been
recently discovered that CCN5, a matricellular protein, is highly expressed in
DCIS patient specimens and facilitates regression of aggressive phenotypes. Our
in-vitro studies with myoepithelial cell lines (MECs) indicate that CCN5 may
prevent the DCIS to IC transition through the protection of the MEC layer.
CCN5 performs it’s protective role by regulating sonic hedgehog (SHh) expres-
sion inMECs. It has been previously shown in separate studies that Neuropilin1
(Nrp1) positively regulates expression of SHh and Nrp1 is exclusively expressed
in MEC layer in breast tissues. An extension of our studies indicate that CCN5
might regulate the integrity of the mammary ductal architecture by protecting
the MEC layer through a novel Nrp1-SHh signaling axis. Collectively, our stud-
ies indicate that regulating CCN5 expression level in breast cancer tissues might
help us controlling the rate of progression of the disease from DCIS to an inva-
sive stage.
#5892 Induction of stromal fıbrosis accelerates tumorigenesis in NeuT
mice. Robert I. Glazer, Hongyan Yuan, Lu Jin. Georgetown University Medical
Center, Washington, DC.
Background: One of the central challenges in cancer prevention is the identi-
fıcation of factors in the tumor microenvironment (TME) that increase breast
cancer susceptibility. The stromal composition of the breast is largely adipose
and fıbroblast tissue, and thus it is important to understand how alterations in
these constituents affect in the onset of stromal fıbrosis (SF) and cancer progres-
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sion. To address these questions, MMTV-NeuT mice were crossed into the
FAT-ATTAC (fat apoptosis through targeted activation of caspase 8) back-
ground (NeuT/ATTAC), wherein conditional dimerization of the FKBP-
caspase 8 fusion transgene in female mice results in mammary fat ablation and
its replacement with fıbrotic tissue. Results: Induction of mammary fat ablation
in NeuT/ATTAC mice over 4 weeks resulted in increased ductal proliferation
and SF as denoted by increased collagen deposition and expression of Fibroblast
Activation Protein and	-smoothmuscle actin.Maintaining SF over 3-5months
resulted in a 40% reduction in tumor onset and a 2.5-fold increase in tumor
multiplicity, which was associated with increased infıltration by myeloid-de-
rived suppressor cells. Gene expression profıling of tumors frommice with and
without SF identifıed increased expression of the immune-related genes Cxcl1,
Ly6d and CD14, as well as acute phase proteins Saa1 and S100a6 in NeuT/
ATTAC mice with SF. Conclusion: Induction of SF in an erbB2-dependent
breast cancer model resulted in a tumor microenvironment more conducive to
tumor progression and immune tolerance. These results suggest alternative
therapeutic approaches that could be taken, eg. chemokine receptor antagonists,
to increase the effectiveness of immunotherapy and chemotherapy. Supported
by a grant from the Avon Foundation for Women and Award 1P30CA051008
from theNational Cancer Institute, NIH, to the Lombardi Comprehensive Can-
cer Center.
#5893 Bioenergetic signature from cocultures of pancreatic tumor cell
lines and fıbroblasts. Mª Teresa Agulló-Ortuño,1 Elena Prieto-García,1 C.
Vanesa Díaz-García,1 Irene Otero Blas,2 Inmaculada García-Ruíz,1 José A.
López-Martín2. 1Instituto de Investigación SanitariaHospital 12 deOctubre,Ma-
drid, Spain; 2Hospital Universitario 12 de Octubre, Madrid, Spain.
Pancreatic ductal adenocarcinoma (PDAC) is one of the tumors with greater
invasiveness andmetastasis. PDAC is associated with a large desmoplastic reac-
tion, characterized by fıbroblastic proliferation and extracellular matrix secre-
tion. Besides, cellular bioenergetics has become a central issue of investigation in
cancer biology, because the altered energy metabolism of cancer cells has been
proposed as a potential target for cancer treatment. We have established co-
cultures between PDAC cell lines (Capan-1 or PL-45) and fıbroblasts (LC5). A
reverse phase protein microarray (RPMA) approach has been applied to quan-
tify proteins of energy metabolism in theses co-cultures, with the aim of identi-
fying potential biomarkers in PDACs. The fıfteen proteins of energymetabolism
studied included members of the mitochondrial oxidation of pyruvate, the tri-
carboxylic acid cycle,-oxidation of fatty acids, electron transport and oxidative
phosphorylation, glycogen metabolism, glycolysis and oxidative stress using
highly specifıc antibodies. Co-cultures modifıed proteins expression of energy
metabolism, respect to monocultures. Capan-1 in co-culture increased several
proteins belonging to OXPHOS (NDUFS3, SDHB, CORE2 and COXII), the
antioxidant SOD2, the mitochondrial HSP60, and G6PDH. The expression of
the glycolitic PKM2 decreased. Their fıbroblasts partners increased the expres-
sion of SDHB and also decreased PKM2. PL-45 in co-culture, experimented an
increase in HADHA. Their fıbroblasts partners showed a decrease in PKM2,
LDHA, IF1, PDHe and HSP60.Capann-1 and PL-45 in co-culture with fıbro-
blast, differ en their energy metabolism phenotype. Overall, the results indicate
that the quantifıcation of bioenergetic signature offers potential biomarkers that
could be implemented to refıne the understanding of the biological principles of
PDAC and, eventually, the management of patients with these tumors.
#5894 Stromal fıbroblasts from metastatic breast cancer promote prolif-
eration and migration of breast cancer cell and regulate its stemness. Yirui
Gui, Adriana Aguilar-Mahecha, Marguerite Buchanan, Mark Basik. Ladi Davis
Institute for Medical Research, Jewish General Hospital, McGill University, Mon-
treal, Quebec, Canada.
Breast cancer is one of the most common causes of cancer-related death in
women in the world. Although most research is focused on the tumor cells, it
is important to elucidate themolecular nature of the tumor-stromal relation-
ship to truly understand the biology of breast tumor growth. Cancer-associ-
ated fıbroblasts (CAFs) are the major cellular constituents in the tumor
microenvironment. CAFs are in direct contact with the adjacent cancer cells
and crosstalk with them through soluble cytokines, growth factors and exo-
somes during carcinogenesis in human breast cancer. To determine for the
fırst time the function of CAFs in metastatic sites of breast cancer, we col-
lected CAFs from human patients of metastatic sites (m-CAFs) and com-
pared themwith CAFs from primary tumor (p-CAFs) and normal fıbroblasts
(NFs). We found that m-CAFs expressed higher levels of 	-smooth muscle
actin (SMA) compared with p-CAFs and NFs. The proliferation of MDA-
MB-436 breast cancer cells was signifıcantly increased by treatment with
conditioned medium (CM) from m-CAFs compared with p-CAFs in vitro.
Also, CM by m-CAFs induced paclitaxel resistance in MDA-MB-436 cells,
suggesting that soluble factors produced by m-CAFs promote chemo-resis-
tance, to a greater extent than CM from p-CAFs. The migration and invasion
ability ofMDA-MB-436 cells co-cultured withm-CAFs CMwas signifıcantly
greater than that of the p-CAFs CM. m-CAFs outperformed the p-CAFs and
NFs in terms of their ability to promote sphere-forming activity in a 3D in
vitro culture model. Furthermore, m-CAFs protected MDA-MB-436 cells
from the cytotoxic effects of doxorubicin more than p-CAFs in this spheroid
3-D culture.WhenMDA-MB-436 cells were sorted from these spheroids and
grew in the respective CMs, they showed higher expression of the stemness
markers of CD44CD24- compared with cells obtained from p-CAFs/MDA-
MB-436 spheroids. Also these cells from the co-culture with m-CAFs expe-
rienced with the cadherin switch. Nanog has been demonstrated to promote
chemoresistant and epithelial-mesenchymal transition (EMT). The results
displayed that MDA-MB-436 cells incubated with the CM from the m-CAFs
had a higher expression of Nanog compared with that of p-CAFs. RNA-seq
results showed that IGF2 is one of the most different genes between m-CAFs
and p-CAFs, its expression was more signifıcant in m-CAFs co-cultured with
MDA-MB-436 cells than p-CAFs. The signaling pathway in MDA-MB-436
cells were comparable between co-cultured with m-CAFs CM and the IGF2
stimulation at 2 hours. All these data illustrates that fıbroblasts isolated from
metastatic site differed in terms of their ability to promote breast cancer cells
progression compared to p-CAFs. Our data suggests that m-CAFs are more
potent than p-CAFs in inducing the proliferation, migration, drug resistance
and cancer stemness of breast cancer cells in an in vitro model.
#5895 Circulating CAF and cCAF circulating tumor cell co clusters are
associated with metastatic breast cancer. Utsav Sharma, Philip Miller, Kelsie
Medina-Saenz, Pedro Ferrer, Svetlana Speransky, Toni Yeasky, Dorraya El-
Ashry. University of Miami, Miami, FL.
Background: Breast cancer metastasis is the cause of breast cancer-related
mortality. The tumor microenvironment (TME) plays a critical role in gov-
erning tumor initiation, progression and metastasis. In breast cancer, cancer
associated fıbroblasts (CAFs) are master regulators of the TME. Cancer me-
tastasis occurs in part by transport of circulating tumor cells (CTCs) in the
circulation. CTCs in clusters, rather than individual CTCs, have a greater
capacity to establish metastases. We recently demonstrated that CAFs also
circulate (cCAFs), both in clusters with CTCs and individually, in the blood
of the majority of breast cancer patients with metastases, some patients
without overt metastases, and in no patients with no evidence of disease. Our
lab has also established primary breast cancer and primary CAF cell lines
from dissociated breast tumors of different molecular subtypes; these are
ideal models to dissect tumor-stromal interactions, both in vitro and in vivo.
We hypothesize that cCAFs originate from the primary tumor, and further,
that cCAFs cluster with CTCs to facilitate metastatic seeding. Methods: We
used separately labeled CAFs and primary breast cancer cells (DT28) co-
injected into NSG mice and followed by a novel 2-color IVIS. We also mod-
eled the ability of CAFs and breast cancer cells to form clusters in culture and
used our microfluidic fılter technology to evaluate the composition of clus-
ters resulting from admixed CAFs and BC cells of differing metastatic capac-
ity – metastatic DT28 and non-metastatic MCF-7. Results: Through sequen-
tial dual-color IVIS we demonstrate that we can monitor the presence of
CAFs and breast cancer cells at orthotopic tumor injection sites and to sites
of distant metastasis, indicating that cCAFs originate from the primary tu-
mor. Evaluation of cCAFs and CTCs in tumor bearing mice indicates that
breast cancer cells with high metastatic potential mobilize greater numbers
of cCAFs. CAFs formed robust clusters with metastatic DT28 cells, while
non-metastatic MCF-7 cells clustered with each other but not with CAFs
suggesting that the ability of breast cancer cells to form clusters with CAFs,
both in vitro and in vivo, is reflective of the metastatic capability of the breast
cancer cell line. Conclusions: The intrinsic metastatic capabilities of breast
cancer cells are augmented by contact and clustering with cCAFs. In turn,
the ability of CAFs to mobilize into circulation is in part conferred by prop-
erties of aggressive breast cancer cells. These data corroborate observations
from our pilot clinical study that indicated the presence of cCAFs is over-
whelmingly associated with the presence of metastatic breast cancer.
#5896 IL-8 signaling enhances TNBC growth andmetastasis via crosstalk
with stromal components. Kideok Jin, Niranjan B. Pandey, Aleksander S. Po-
pel. Johns Hopkins Univ. School of Medicine, Baltimore, MD.
Triple negative breast cancer (TNBC) as a metastatic disease is currently in-
curable. Reliable and reproducible methods for testing drugs against metastasis
are not available. We have previously developed a robust metastatic model in
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which mice are pretreated with tumor cell-conditioned media (TCM) from hu-
man TNBC cells (MDA-MB-231 and SUM149) for 2 weeks prior to tumor cell
inoculation. In this model we found reproducible spontaneous metastases in
lymph nodes (LN) and lungs within 4-5 weeks after orthotropic tumor inocula-
tion. We have discovered that the TNBC tumor cells secrete large amounts of
interleukin-6 (IL-6) that “educates” lymphatic endothelial cells (LEC) in the LN
and lungs. Stat3, a transcription factor, gets activated and induces the synthesis
of CCL5 andVEGF among other factors. CCL5 recruits the tumor cells to the LN
and lungs; VEGF helps build blood vessels in the LN to facilitate tumor cell
survival; VEGF produced in the lung helps the tumor cells extravasate into the
lung.We have confırmed the importance of these factors by showing that inhib-
itors of these factors signifıcantly inhibit metastasis. In this report, using a hu-
man antibody array, we identifıed factors secreted by fıbroblasts and macro-
phages upon induction byMDA-MB-231 TCM.We ranked the expression level
of each factor by real time qRT-PCR and determined that interleukin 8 (IL-8)
was the top candidate. We confırmed by ELISA that IL-8 secreted from either
fıbroblasts or macrophages treated with MDA-MB-231 TCM was upregulated
compared to treatment with serum free media (SFM). Our data showed that the
proliferation of MDA-MB-231 cells co-cultured with fıbroblasts or macro-
phages was enhanced compared to monoculture. Furthermore, MDA-MB-231
cell migration, a key step in tumormetastasis, was promoted by CM fromTCM-
induced fıbroblasts or macrophages. Knockdown of CXCR2, IL-8 receptor, ex-
pression by CRISPR-Cas9 system reduces MB231 cell proliferation and migra-
tion compared to wild type. In a mouse xenograft tumor model, the tumor
growth of MB231-CXCR2-/- cell was signifıcantly decreased. In addition, the
incidence of thoracic metastasis of MB231-CXCR2-/- tumor was reduced com-
pared toWT.We found that the auto- and paracrine loop of IL-8 exists between
TNBC cells and stroma, which results in enhanced IL-8 secretion from the stro-
mal components. Signifıcantly, inhibition of the IL-8 signaling pathway by Re-
parixin, an inhibitor of the IL-8 receptor CXCR1/2, abrogated MDA-MB-231
tumor growth and metastasis. These fındings implicate IL-8 signaling as a crit-
ical event in TNBC tumor growth and metastasis via crosstalk with stromal
components. Further, these studies suggest that IL-8 acts as a key regulator
orchestrating TNBC metastatic breast cancer. Therefore, we have provided ev-
idence that supports the hypothesis that functional antagonism of the IL-8 sig-
naling pathway has the potential to circumvent TNBC breast cancer growth and
metastasis.
#5897 Single cell-derived analysis of desmoid tumors for studying tumor-
stroma interactions. Mushriq Al-Jazrawe,1 Steven Xu,2 Qingxia Wei,2 Ray-
mond Poon,2 Benjamin Alman3. 1University of Toronto, Toronto, Ontario, Can-
ada; 2Hospital for Sick Children, Toronto, Ontario, Canada; 3Duke University,
Durham, NC.
Cancer associated fıbroblasts play an important role in the maintenance and
remodeling of the tumor microenvironment, providing the appropriate condi-
tions for neoplastic cell growth and invasion. Desmoid tumors (DT), also called
aggressive fıbromatosis, are rare, locally invasive soft tissue tumors that consist
of fıbroblastic cells embedded in extracellular matrix. Identifıcation of the stro-
mal cells to study tumor-stroma interactions is diffıcult due to both populations
displaying a fıbroblastic phenotype, and no cell marker exists that reliably dif-
ferentiates between the two populations. Majority of DT arise sporadically due
to somatic activating mutations in beta-catenin (CTNNB1), a major effector
molecule of canonicalWnt signaling.We established single cell derived colonies
frommultipleDT samples and characterized the beta-cateninmutation status of
each clone by Sanger sequencing. Indeed, we were able to establish both mutant
and non-mutant colonies from DT samples. Quantitative PCR for beta-catenin
targets AXIN2 and LEF1 confırmed differential activity between themutant and
non-mutant colonies. The specifıc CTNNB1 codon mutation had no difference
on beta-catenin transcriptional activity. We next performed a high throughput
surface antigen screen to identify cell markers that can distinguish between the
two subpopulations. Our screen found CD142 to be uniquely expressed by the
mutant colonies, while the non-mutant colonies uniquely expressed Podopla-
nin. Quantitative PCR confırmed the differential expression of these markers.
Furthermore, theCD142-positive population in heterogeneousDT samples cor-
related with their mutation frequency. Importantly, CD142-based cell sorting
allowed the isolation of themutant subpopulation even in samples that appeared
as wild-type by Sanger sequencing. We also studied the expression of secreted
factors in ourmutant and non-mutant populations.We observed that CTHRC1,
a ligand related to the Wnt/PCP pathway, is highly elevated exclusively in the
mutant subpopulations. Recombinant CTHRC1 increased the proliferation rate
of DT primary cultures, as measured by BrdU incorporation, while neutralizing
antibodies against CTHRC1 decreased cell proliferation. The importance of
tumor-stroma interactions cannot be studied without fırst identifying and char-
acterizing the two populations. This has been especially diffıcult in soft tissue
sarcomas where both the neoplastic and stromal cells exhibit a mesenchymal
phenotype. Our study offers a novel method for identifying the mutant and
non-mutant subpopulations within desmoid tumors to study how they may
interact. Rapidly quantifying tumor composition will also support efforts to
understand the natural progression of disease and how it responds to therapy.
#5898 The consomic xenograft model identifıes genetic changes in the
tumor microenvironment that alter the growth and metastasis of head and
neck cancers. Michael W. Straza,1 Amy Rymaszewski,1 Kwangok P. Nickel,2
Anne Frei,1 Anirban Chatterjee,2 Rachel Schlaak,1 Amit Joshi,1 Michael Flister,1
Randy J. Kimple,2 Carmen Bergom1. 1Medical College of Wisconsin, Milwaukee,
WI; 2University of Wisconsin, Madison, WI.
Background: The tumor microenvironment (TME) is known to impact tu-
mor growth, metastatic potential, and treatment response. Nearly all studies of
head and neck cancer (HNC) have focused on somatic mutations in the malig-
nant cells. We hypothesized that genetic determinants limited to the microen-
vironment would influence HNC growth and metastatic potential. Approach:
To demonstrate the impact of genetic differences in theTMEonHNCcell line in
vivo growth we utilized a novel tool, the consomic xenograft model (CXM). A
consomic rat has an entire chromosome substituted into the isogenic back-
ground of another inbred strain by selective breeding. Use of immunodefıcient
(IL2R-/-) consomic rats allows one to study the influence of stromal genetics on
tumor biology without the confounding effect of differences in the immune
system through the orthotopic implantation of cancer cells into different con-
somic rat strains. In this system, any differences in tumor growth or metastases
are due to differences in the TME rather than cancer cells or immune response.
We utilized SS and SS.BN3 consomic rat strains, previously shown to affect the
growth of breast tumors, to study the effects of the TME onHNC tumor growth
using two well-characterized HPV negative HNC cell lines, SCC-6 (base of
tongue derived) and SCC-22b (derived from a hypopharyngeal cancer that had
metastasized to lymph nodes). Both cell lines were modifıed to stably express
luciferase. HNC cells were inoculated into the tongue of SS and SS.BN3 animals
and tumor growth was monitored by biophotonic imaging after luciferin injec-
tion. Results: A signifıcant difference in the tumor growth was seen between rat
strains for both cell lines, with the SS.BN3 rats exhibiting less tumor growth and
metastasis. Median luciferase activity from baseline increased by 4.1-fold vs. 1.1
fold in SCC-6 tumors in SS vs SS.BN3 rats, respectively (p0.03). SCC-22B
tumors demonstrated a signifıcant difference in tumor size as well, with median
luciferase activity from baseline 12.7 vs 4.4 fold on day 26, for SS vs SS.BN3,
respectively (p0.05). A signifıcant differences in lungmetastases was also seen
between strains. Lung metastases were seen in 88% of SS and 0% of SS.BN3 rats
(n6 per group) inoculated with SCC-6 (p0.02) and in 75% of SS and 30% of
SS.BN3 rats (n10 per group) inoculated with SCC-22b (p0.08). Despite a
non-statistically signifıcant difference in the number of SCC-22b inoculated
animals with lungmetastases, there was a signifıcantly highermetastatic burden
as measured by luciferase signal, with the median signal 6.8 fold higher in SS as
compared to SS.BN3 (p0.03). Conclusions: The use of the CXM model dem-
onstrates an important role for the TME in the growth and metastatic spread of
HNC cell lines. This model allows for future congenic mapping to identify the
causative genetic variants in the TME mediating the HNC changes in tumor
growth and metastasis.
#5899 Compartment-resolved proteomics reveal NNMT as a master met-
abolic regulator of cancer associated fıbroblasts. Mark A. Eckert,1 Fabian
Coscia,2 Shawn Pan,1 Samantha M. Tienda,1 Agnieszka A. Chryplewicz,1
Chun-YiChiang,1AnthonyMontag,1 S.DianeYamada,1MatthiasMann,2 Ernst
R. Lengyel1. 1University of Chicago, Chicago, IL; 2Max Planck Institute for Bio-
chemistry, Martinsried, Germany.
The poor outcome of ovarian cancer patients is due to late detection and the
ability of ovarian cancer cells to metastasize quickly throughout the abdominal
cavity. Recent research, including histopathological studies and experiments
with mouse models, suggest that ovarian cancer may actually arise in the fallo-
pian tube as serous tubal intraepithelial carcinomas (STIC). Lesions of the ovary
would, therefore, represent metastases from the fallopian tube. To better under-
stand the molecular events that occur in both the tumor and stromal compart-
ment during ovarian cancer progression, we performed shotgun proteomics on
laser-microdissected tumor and stromal compartments from anatomic sites
representing the hypothetical progression series for ovarian cancer (STIC ¡
fallopian tube ¡ ovary ¡ omentum). With an optimized sample preparation
technique, we successfully quantifıed 4-5000 proteins per anatomic site with
high reproducibility and with as few as several thousand microdissected cells
derived from formalin-fıxed and paraffın-embedded (FFPE) biobank speci-
TUMOR BIOLOGY: Tumor Microenvironment 8
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1505
mens. Proteomics of the tumor compartments revealed high inter-patient het-
erogeneity, with no conserved protein signatures associated with invasion or
metastasis. In strong contrast, a highly conservedmolecular signature of stromal
proteins associatedwithmetastasis to the omentumwas identifıed. In particular,
nicotinamide N-methyl transferase (NNMT) was highly upregulated in the
stroma of omental and peritoneal metastases. Functionally, NNMT was neces-
sary and suffıcient for multiple aspects of the cancer associated fıbroblast (CAF)
phenotype, including expression of CAFmarkers and secretion of cytokines and
oncogenic extracellular matrix. NNMT expression was necessary for the ability
of CAFs to support ovarian cancer cellmigration, proliferation, adhesion, and in
vivo growth. Mechanistically, high expression of NNMT in CAFs led to a deple-
tion of S-adenosyl methionine (SAM) and a reduction in histone methylation
associated with gene expression changes in the tumor stroma. This work sup-
ports the use of ultra-low input proteomics for compartment-resolved identifı-
cation of candidate drivers of disease phenotypes and identifıes NNMT as a
central, metabolic regulator of CAF differentiation.
#5900 Transforming growth factor-beta (TGF-) inhibitor modulates
cancer stroma in a pancreatic cancer orthotopic mouse model. Takashi Mu-
rakami,1 Yukihiko Hiroshima,2 Kentaro Miyake,1 Tasuku Kiyuna,1 Ho Kyoung
Hwang,1 Kei Kawaguchi,1 Jonathan C. DeLong,1 Thinzer M. Lwin,1 Kentaro
Igarashi,1 Ryusei Matsuyama,2 Ryutaro Mori,2 Takafumi Kumamoto,2 Takashi
Chishima,2 Kuniya Tanaka,2 Michael Bouvet,1 Itaru Endo,2 Robert M. Hoff-
man1. 1University of California, San Diego, San Diego, CA; 2Yokohama City
University Graduate School of Medicine, Japan.
Background: The tumor microenvironment (TME) contributes to the recal-
citrance of this disease. Cancer-associated fıbroblasts (CAFs) are thought to be
important for the pancreatic cancer TME. Transforming growth factor-beta
(TGF-) has an important role for CAF induction. The present report describes
the effıcacy of a TGF--inhibitor to modulate pancreatic cancer stroma in an
orthotopic mouse model. Materials and methods: BxPC-3 human pancreatic
adenocarcinoma cells expressing green fluorescent protein (GFP) were im-
planted subcutaneously in athymic nude mice expressing red fluorescent pro-
tein (RFP). Established dual-color tumors, with GFP cancer cells and RFP
stroma, were cut into small fragments and then implanted orthotopically onto
the tail of the pancreas of RFP-expressing nude mice. Fourteen mice were ran-
domized into control group (n 7, vehicle, i.p., weekly, for 3 weeks) and treated
group (n  7, SB431542 (TGF- inhibitor) 0.3 mg, i.p., weekly, for 3 weeks)
when tumor diameters reached to 7 mm. Pancreatic cancer stroma was evalu-
ated weekly for 3 weeks by real time intravital imaging with the FV-1000 confo-
cal microscope. Stroma ratio, the percentage of the RFP fluorescence area from
the stromal cells relative to the total fluorescence area, was calculated with Im-
ageJ. Tumors were resected on the 21st day from the initial treatment for histo-
logical evaluation. Microvessel density using anti-CD31 antibody and expres-
sion of TGF- were examined by immunohistochemical staining. Results: The
GFP cancer cells and RFP stromal cells were distinctly imaged. The stroma ratio
signifıcantly decreased in theTGF--inhibitor treatedmice compared to control
untreated mice from day 7 to 21. TGF- expression and microvessel density
were reduced in the treatedmice. Conclusions: The present study demonstrated
selective anti-stromal and anti-angiogenetic activity of TGF- inhibitor in a
dual-color pancreatic orthotopic mouse model. These results indicate potential
benefıt of TGF- inhibitor to facilitate drug delivery and improve chemotherapy
of pancreatic cancer.
#5901 Involvement of VEGF-A signaling in the acquisition and mainte-
nance of human prostate carcinoma-associated fıbroblast phenotype. Javier
Cerda Infante, Marianela Sanchez, Paola Conejeros, Alejandra Alarcón, Ale-
jandro Godoy, Enrique Brandan, Viviana P. Montecinos. P. Catholic University
of Chile, Santiago, Chile.
Introduction: Progression of prostate cancer (CaP) is modulated by the car-
cinoma-associated fıbroblasts (CAFs) within the tumor microenvironment.
However, little is known about the specifıc mechanisms involved in the activa-
tion of the benign prostate fıbroblasts (BAFs) to CAFs in CaP and the specifıc
signaling altered in CAFs that are needed to maintain its activated phenotype.
Vascular endothelial growth factor-A (VEGF-A) is overexpressed in CaP and,
additionally to the angiogenic effect, a non-angiogenic effects of VEGF-A on
cancer cells have been recently reported. This study seeks to evaluate the poten-
tial role of VEGF-A signaling in the activation of BAFs and/or in the mainte-
nance of the activated phenotype presented in CAFs. Material and Methods:
Primary cultures of BAFs and CAFs were characterized by gene expression pro-
fıle, qPCR, WB and ELISA for the expression and/or secretion of VEGF-A and
its receptors. Dose-response and time course analysis for the effect of exogenous
VEGF-A, TGF-1 and conditioned medium from CAFs (CM-CAFs) were ana-
lyzed by RT-qPCR, immunocytochemistry andWB for the stroma cell markers:
Vimentin, Pro-collagen, 	-SMA, Tenascin, Fibronectin and FSP-1. The contri-
bution of VEGF-A signaling to the pgenotype of CAFs was determined by
siRNA assays for the VEGFRs and the functional effect of CAFs on cancer
progression was studied using CM-CAFs or CM from VEGFR siRNA-CAFs
over PC3 cancer cells growth in vitro and in vivo. Results: Exposure of primary
cultures of BAFs to exogenous VEGF-A, TGF-1 and CM-CAFs upregulate
stroma cell markers associated with the appearance of CAFs phenotype and it is
reversed with the pre-treatment of the VEGF-A antibody Bevacizumab. Fur-
thermore, CAFs, but not BAFs, produced massive levels of VEGF-A and over-
express its cognate receptors. siRNA studies demonstrated that knock down
VEGFRs in CAFs reverse the activated phenotype andCM fromVEGFRsiRNA-
CAFs failed to increase themigration and invasion potential of PC3 cells in vitro
and tumor growth in vivo. Discussion: Our data indicate that VEGF-A signaling
plays a key role in the activation of human prostate fıbroblasts. Furthermore,
VEGF-A and TGF-1 interactions may cooperatively regulate activation of fı-
broblasts within the tumor microenvironment in CaP. These fındings also sug-
gest that blockade of this signaling cascade in the activated fıbroblasts could be a
potential therapeutic target designed to prevent disease progression.
#5902 Roles of tumor microenvironment in pancreatic cancer progres-
sion. Kei Takahashi, Shogo Ehata, Daizo Koinuma, Kohei Miyazono. The Uni-
versity of Tokyo, Tokyo, Japan.
Although it has been recognized that tumormicroenvironment plays a pivotal
role in cancer progression, little is known about how differences of microenvi-
ronment affect malignant characteristics of cancer cells. In the present study, we
tried to investigate the roles of pancreatic tumor microenvironment by use of
several mouse inoculation models. First, human pancreatic cancer SUIT-2 cells
(parental cells) were inoculated into pancreas orthotopically or into subcutane-
ous tissue ectopically. In order to expose cancer cells to eachmicroenvironment
for long period, processes of inoculation and extraction of cancer cells from
primary tumor were repeated. After 3 circles of inoculation, cancer cells were
collected from primary tumors in each model and established as distinct cancer
cell lines, that is, 3P cells from pancreas in the orthotopic model and 3sc cells
from subcutaneous tissue in the ectopic model, respectively. Orthotopic inocu-
lation of these established cells revealed that the 3sc cells, andmore prominently
the 3P cells, showed higher tumorigenicity in vivo than parental cells. In addi-
tion, the 3P cells specifıcally exhibited low E-cadherin expression and high in-
vasiveness, suggesting that the 3P cells possessed the highest malignant charac-
teristics. Next, gene expression profıles in these cells were examined. RNA-
sequence analysis demonstrated that distinct signaling pathways were activated
in the 3P or 3sc cells. Pathways associated with extracellular matrix disassembly
or collagen catabolic process were commonly activated in the 3P and 3sc cells.
On the other hand, pathways including stem cell development or axon guidance
were activated only in the 3P cells. These fındings suggested that interactions
between cancer cells and pancreatic microenvironment are necessary to obtain
highly malignant traits. We are currently focusing upon somemolecules, which
are expressed specifıcally in the 3P cells, and fıguring out their roles in pancreatic
cancer progression. Finally, we also tried to uncover the underlyingmechanisms
of developing highly malignant 3P cells. Two processes are expected to be in-
volved; small fractions of highly malignant cancer cells were adapted to pancre-
aticmicroenvironment (“selection”) or parental cellswere affected by pancreatic
microenvironment (“education”). To address this hypothesis, several clones
within the parental SUIT-2 cells were isolated and inoculated as described pre-
viously. Individual clones varied in their tumor-forming ability, indicating that
heterogeneity is present amongst the parental cells. However, we found that the
gene expression profıle in each clone was altered after in vivo orthotopic inocu-
lation, suggesting that pancreatic microenvironment may have influence on
phenotype of cancer cells. Based on these observations, we postulated that not
only “selection” process but “education” process is involved in establishment of
highly malignant cancer cells.
#5903 Interaction with extracellular matrix enhance the chemoresistance
via CXCL12/CXCR4 and integrin signal activation by cancer-associated fı-
broblasts in gastric cancers. Keisuke Miyake, Takatsugu Ishimoto, Daisuke
Izumi, Kota Arima, Tsugio Eto, Daisuke Kuroda, Masaaki Iwatsuki, Yoshifumi
Baba, Yasuo Sakamoto, Naoya Yoshida, Hideo Baba. Kumamoto University,
Kumamoto, Japan.
Purpose: Gastric cancers (GCs) is an aggressive cancer metastasizing with a
high propensity for peritoneal dissemination and liver metastasis. Some studies
have been shown that not only cancer cells but also cancer environment, espe-
cially cancer-associated fıbroblasts (CAFs) play an important role in tumor de-
velopment. Previously, we reported that CXCL12-CXCR4 and integrin beta 1
TUMOR BIOLOGY: Tumor Microenvironment 8
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171506
signal activation by CAFs co-operates for promoting FAK phosphorylation and
enhances the invasiveness of GC cells in extracellular matrix (ECM). On the
other hand, a previous study presented that CXCR4 and integrin signaling co-
operates in mediating adhesion and chemoresistance in small cell lung cancer
cells. Therefore, we hypothesized that CXCL12-CXCR4 and integrin signal ac-
tivation by CAFs enhances the chemoresistance in GCs as well. The aim of
current study is to elucidate the signifıcance of cancer microenvironment with
CAFs mediating signal activation for chemoresistance in GCs. Experimental
Design: We fırst performed reactive oxygen spices (ROS)-sensitive assay and
chemo-sensitive assays usingGC cells culturedwith freshmediumorwithCAF-
conditioned-medium (CM), and these experiments were conducted on non-
coated andMatrigel-coated plates. Next, we examined the CXCL12-CXCR4 and
integrin related signaling by western blotting analysis. Furthermore, we investi-
gated the critical molecule for chemoresistance using silencing CXCR4 or integ-
rin beta 1 in GC cells. Results: ROS-sensitive assay and chemo-sensitive assays
revealed thatGCcells culturedwithCAF-CMshowedmore resistant toROS and
cisplatin than those cultured with fresh medium. Moreover, GC cells with
CAF-CM on Matrigel-coated plates exhibited remarkable resistance in these
assays. On the other hand, western blotting analysis showed that Akt activity in
GC cells cultured with CAF-CM was up-regulated in concurrence with FAK
phosphorylation. Finally, the chemoresitance induced byCAFswas signifıcantly
suppressed by CXCR4 or integrin beta 1 silencing. Conclusions: These results
suggest that interaction with ECM is important for enhance chemoresitance
mediatedCXCL12/CXCR4 and integrin beta 1 signal activation byCAFs inGCs.
Thismechanismunderlying the chemoresistancemay provide a novel therapeu-
tic target in advanced GCs.
#5904 Stiffness of extracellularmatrix regulates breast cancer progression
by stimulating mesenchymal stem cells. Seiichiro Ishihara, David R. Inman,
Wan-Ju Li, Suzanne M. Ponik, Patricia J. Keely. University of Wisconsin-Madi-
son, Madison, WI.
The tumormicroenvironment contains cancer cells, non-cancerous cells, and
extracellular components such as extracellular matrix (ECM). Previous studies
have demonstrated that interactions between the cells and the microenviron-
ment contribute to cancer progression via chemical stimuli, such as growth
factors, and mechanical stimuli, such as stiffness of the ECM. Recently, it has
been reported that mesenchymal stem cells (MSCs) differentiate into cancer
associated fıbroblasts (CAFs) in response to chemical stimuli from cancer cells
and thereby promote cancer progression. However, the contribution of me-
chanical stimuli to MSCs in cancer is poorly understood. In this study, we re-
vealed that MSCs showed CAF phenotypes and promote mammary cancer pro-
gression in response to mechanical stimuli. On a stiff substrate, MSCs treated
with conditioned media from cancer cell culture expressed increased levels of
alpha smooth muscle actin (alpha-SMA), a marker of CAFs, compared to the
MSCs cultured on a soft substrate. MSCs grown on a stiff substrate displayed
higher expression and activity of YAP and increased phosphorylation ofmyosin
light chain (MLC) compared to MSCs grown on a soft substrate. In addition,
knockdown of YAP by shRNA decreased the expression of alpha-SMA and
phosphorylation of MLC in MSCs on a stiff substrate. Pharmacological inhibi-
tion of MLC phosphorylation by H1152 treatment also reduced expression of
alpha-SMA and activity of YAP in MSCs. Cell-cell communication between
MSCs and carcinoma cells was bi-directional, as conditioned medium from
MSCs cultured on a stiff substrate, but not a soft substrate, increased growth of
mammary carcinoma cells. The soluble factor prosaposin was highly secreted by
the MSCs on a stiff substrate, and the addition of recombinant prosaposin in-
creased proliferation and survival of mammary carcinoma cells. Furthermore,
secretion of prosaposin was promoted in YAP-overexpressed MSCs on a soft
substrate. Mammary carcinoma cells treated with prosaposin showed increased
level of phosphorylation in Akt at T308. In addition, inhibition of phosphoryla-
tion ofAkt at T308 prevented proliferation and survival inmammary carcinoma
cells. These results suggest that increased stiffness of the ECM in the tumor
microenvironment induces differentiation of MSCs to CAFs via YAP and acto-
myosin contractility, secretion of prosaposion fromMSCs, and as a result, trig-
ger progression of mammary cancer via phosphorylation of Akt at T308.
#5905 Cancer associated fıbroblasts promote tumormetastasis coexisting
with cancer cells in blood circulation. Hajime Kashima, Kazuhiro Noma, Hi-
roaki Sato, Yuki Katsura, Takuya Kato, Toshiaki Ohara, Hiroshi Tazawa, Ya-
suhiro Shirakawa, Toshiyoshi Fujiwara. Okayama University, Okayama, Japan.
Background: Cancer associated fıbroblasts (CAFs) are activated fıbroblasts
and an important player in the tumor microenvironment. Their activity pro-
motes cancer cell proliferation, migration, and invasion, and metastasis. The
most prognostic factor in tumor progression is metastasis. Cancer metastasis is
a multi-step process that tumor cells detach from primary site, survive in the
bloodstream, and seed in target organ. Although previous studies have focused
on the interaction betweenCAFs and cancer cells in primary tumor site, the roles
of CAFs in blood circulation remain largely unknown.We investigated the effect
of CAFs coexisting with cancer cells in bloodstream on tumormetastasis in vivo
mouse model, and also examined the effect of CAFs in subcutaneous tumor.
Methods: We used female BALB/c-nu/nu mice and BALB/c mice in the exper-
iments. Cancer cells weremousemammary carcinoma cell lines 4T1 transfected
with luciferase, colon cancer cell lines Colon 26 transfected with luciferase. Fi-
broblast cell lines were mouse embryonic fıbroblast MEF and NIH-3T3. In ve-
nous injection mouse model, we injected 1 106 cancer cells alone or the same
number of cancer and fıbroblast co-cultured together. When we injected cancer
cells transfected with luciferase, the mice were subjected to in vivo imaging
system (IVIS) andmeasured luminescence intensity ofmetastatic sites.We have
also harvested lung and compared its weight and metastatic nodule under mi-
croscopy. Furthermore, in subcutaneous tumormetastaticmousemodel, cancer
cells alone ormixed with cancer cells and CAFs were subcutaneously inoculated
into the mice. Results: In the group of mice injected with cancer cells and fıbro-
blasts, luminescent intensity of each lungs were higher than cancer cell alone.
Harvested lungweight and the number ofmetastatic nodules were also higher in
the group with cancer cells and fıbroblasts.In subcutaneous model, mice inocu-
latedwith cancer cells and fıbroblast hadmuchmoremetastatic sites than cancer
cells alone. Conclusions: Our data indicate that CAFs promote tumormetastasis
by stimulating cancer cells in blood circulation, as well as in primary tumor
site.These fındings suggest that CAFs in both bloodstream and primary site
could be a promising therapeutic target. CAF-targeted therapy could reduce
tumor metastasis and improve the prognosis of cancer patients.
#5906 TIMP-1 expression is inversely correlatedwithmiRNA125a-5p and
let-7e in non-small-cell lung carcinoma. Ammar Kutiyanawalla, Sampa Gho-
shal-Gupta, Byung R. Lee, Ashis Mondal, Ravindra Kolhe, Amyn M. Rojiani,
Mumtaz V. Rojiani. Medical College of Georgia- Augusta University, Augusta,
GA.
Epigenetic alterations are emerging as signifıcant elements in our under-
standing the biology of lung cancer which remains the leading cause of cancer
deaths worldwide. In earlier studies we have shown that tissue inhibitor of met-
alloproteinase 1 (TIMP-1) overexpression in NSCLC cells results in aggressive
tumors in mice.We have also demonstrated TIMP-1’s anti-apoptotic activity in
these cells. It is well documented that miRNAs are involved in many physiolog-
ical and neoplastic processes, including apoptosis. We have previously shown
that knocking down TIMP-1 in A549 NSCLC cells alters the miRNA profıle in
these cells with upregulation of miR-125a-5p. Subsequently, we have identifıed
that miR let-7e is also upregulated in TIMP-1 KD clones. The present study is
focused on confırming the involvement of miR-125a-5p with TIMP-1 by using
mimics and antagomirs of 125a-5p. Furthermore, we have sought to validate this
relationship in vivo by examining these patterns in clinical samples. We added
mimics of miR-125a-5p into the parental A549 cells, which resulted in down
regulation of TIMP-1 levels. We were then able to rescue TIMP-1 downregula-
tion by adding antagomirs ofmiR-125a-5p to the same cells.MiR-125a-5p bind-
ing sites were identifıed in TIMP-1 3= UTR and using luciferase assay, we have
confırmed that TIMP-1 is indeed a bona fıde target of miR-125a-5p. Transla-
tional studies were carried out using archived NSCLC adenocarcinoma tissues
from the Surgical Pathology archives at AUMedical Center. We fırst measured
expression level of TIMP-1 byRT-PCR in 20 tumors and paired normal adjacent
tissues and divided the samples into 2 groups, those with low and high TIMP-1
expression levels. Tissues were then interrogated for TIMP-1 and miR-125a-5p
and let- 7e miRNA expression using chromogenic in situ hybridization. We
identifıed negative correlation pattern between tumor and paired normal adja-
cent tissue samples. Generally, TIMP-1 was highly expressed in the tumor re-
gion, while miRNA expression was relatively decreased when compared with
adjacent normal tissues. miRNA 125a-5p and let- 7e are known tumor suppres-
sors in NSCLC. Analyzing secondary data (adenocarcinoma) by KM plotter we
found that highTIMP1 correlatedwith lower patient survival with a hazard ratio
of 3.17 (2.3-4.37) and a log rank p value of 8.1e-14. These studies provide addi-
tional clarity and further extend our understanding of the relationship between
these miRNA families and TIMP-1 expression.
#5907 Radiotherapy-induceddamage to cancer-associated fıbroblasts and
its reciprocal influence on cancer progression: Impact of soluble factors.Ol-
ivier De Wever,1 Joke Tommelein,1 Marc Bracke,1 Tom Boterberg,1 Pieter
Demetter,2 Laurin Verset2. 1Ghent Univ. Hospital, Ghent, Belgium; 2Université
Libre de Bruxelles, Brussels, Belgium.
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Preoperative radiotherapy is a mainstay in current management of colorectal
cancer. Several tumor types, including colorectal cancer, show an abundant
desmoplastic stroma, characterized by cancer-associated fıbroblasts (CAFs).
Nevertheless the effects of radiation to the CAFs in the stroma and its reciprocal
impact on the response of CRC cells to irradiation have not been studied. We
investigated the functional (cell number, morphotype) and biochemical (tran-
scriptomics,metabolomics and kinomics) phenotype ofCRCcells in response to
paracrine signals from irradiated CAFs. Using neutralizing antibodies and small
molecule inhibitors, we analysed the role of tyrosine-kinase receptor activation
in CRC cells in response to supernatants from irradiated CAFs. Furthermore,
the impact of tyrosine-kinase receptor neutralization in combination with RT
was evaluated in an orthotopic CRC model. The level of mTOR activation, a
downstream tyrosine-kinase receptor intermediate, was analysed in response to
neoadjuvant treatment in human CRC specimens. Further work will reveal
which soluble factor(s) are implicated in the communication between irradiated
CAFs and colorectal cancer cells.
#5908 Cancer-associated fıbroblast driven drug resistance in colorectal
cancer. Colleen M. Garvey, Oscar Chen, Shannon M. Mumenthaler. University
of Southern California, Los Angeles, CA.
Drug resistance remains a major problem in the treatment of most cancers.
For example, KRAS wild-type colorectal cancers (CRCs) are typically treated
with the anti-epidermal growth factor receptor (EGFR) therapy cetuximab in
combination with standard chemotherapy; however, of the 40% of patients that
do respond, virtually all relapse within 3-12 months. Additionally, around 25%
of nonresponders have no identifıable resistancemechanisms. This suggests that
it is not just cell-intrinsic mechanisms that result in resistance, but that extrinsic
factors play a role. The purpose of this studywas to investigate how the dynamics
of the tumor microenvironment, specifıcally cancer-associated fıbroblasts
(CAFs) and hypoxia, modify the response of CRC cells to cetuximab.We used a
novel high-content imaging platform to generate quantitative phenotypic data
(i.e. morphology, birth/death rates) of cellular co-cultures perturbed by multi-
ple, co-occurring microenvironmental conditions. Preliminary data demon-
strated reduced sensitivity of tumor cells to cetuximab in the presence of CAFs,
whichwas dependent on patient specifıcs and time scale of co-culture. Addition-
ally, we found that low oxygen conditions altered the effect of CAFs on tumor
cell phenotypes, which highlights the importance of studying co-occurring mi-
croenvironmental factors. This work underlies the importance of considering
not just the genetic makeup of patient tumors, but also the heterogeneity of the
surrounding microenvironment when designing personalized treatment strate-
gies.
#5909 Microfluidic vertical adhesion-suspension co-culture platform for
studying cancer stem cell-fıbroblast interactions. Yu-Chih Chen, Zhixiong
Zhang, Yu-Heng Cheng, Euisik Yoon, Max S. Wicha. University of Michigan,
Ann Arbor, MI.
Considerable evidence suggests that cancer-stem-cells (CSCs) play critical
roles in tumorigenesis and metastasis .Although surface marker expression or
enzymatic activity of CSC has proven useful, variability of expression highlights
the need for the development of high throughput functional CSC assays. One
such approach utilizes the capability of CSC’s to form single-cell-derived
spheres in suspension environments (functional CSCs). Microfluidic tools are
suitable for handling andmonitoring a large number of single cells in suspension
as well as for examining the interaction of these cells with those in the tumor
micro-environment including cancer associated fıbroblasts (CAF’s).In order to
accomplish this, we have developed a high-throughput (10,000-well), simple-to-
use, vertical platform for CSC/CAF co-culture. The platform consists of a non-
adherent substrate having 10,000 micro wells for single-cell-derived sphere for-
mation and a porous trans well for CAF adherent co-culture. As predicted by
Poisson’s distribution, approximately 30% of micro wells capture single cells
when T47D breast cancer cells are loaded at a concentration of 200k/ml. After
cell seeding, trans wells containing CAFs are placed onto the substrate. 0.4m
pores on the trans well allow for secretion-based cellular interaction while pre-
venting direct CSC/CAF cell contact. This cell separation facilitates sample cell
retrieval without cell cross contamination. Utilizing this device, we determined
that co-culture of tumor cells with CAF’s doubled the frequency of sphere for-
mation. Spheres derived from individual CSCs were then retrieved and dissoci-
ated for single-cell transcriptome analysis utilizing RNA barcoding followed by
RNAseq. Molecular analysis revealed signifıcant cellular heterogeneity among
sphere derived cells. In addition, principal component analysis of single cell
RNAseq, reveled signifıcant differences in gene expression between mono-cul-
tured and CAF co-cultured cells isolated from tumor spheres. These genes rep-
resent potential therapeutic targets for interfering with CSC stromal cell inter-
actions in the tumor microenvironment. The vertical adhesion suspension co-
culture platform provides a system to identify and evaluate novel CSC targeted
therapeutics.
#5910 Influence of 3D- cultured prostate cancer and stromal cells on drug
response.Dominique N. Gales, SonniMiller, Temesgen Samuel, Clatyon Yates.
Tuskegee University, Tuskegee, AL.
Background: Response to chemotherapeutic drugs presents a signifıcant
challenge to effective treatment of advanced prostate cancer. Exploration of
therapeutic response has focused largely on the tumor cell. However, evi-
dence suggests mechanisms that involve the tumor microenvironment me-
diate response to therapeutics. Therefore, it is imperative to mimic the in
vivo tumor microenvironment, to bridge the gap between in vitro studies
and the development of therapeutics. The concept of three-dimensional
(3D) cell culture and co-culture of multiple cell types is critical to predict
therapeutic effıcacy and outcome. Thus, these studies sought to determine
the distinct responses to anti-cancer drugs in 3D cell spheroids. Methods: In
this study, we utilized metastatic prostate cancer cells (PC3) and fluores-
cently labeled prostate bone stromal cell line (HS27a) to generate tumor
spheroids. Tumor spheroid viability was measured at 72 and 120 h using the
CellTiter-Glo 3D assay after treatment with three common anti-cancer
drugs, Docetaxel (4M), Enzalutamide (30M), and Bicalutamide
(30M).Treatments were compared with spheroids originated from HS27a
and PC3 cells alone and in co-culture. The cell viability percentage was
normalized using the untreated cells as 100% cell survival. Results: Spheroid
formation increased resistance to Docetaxel, Enzalutamide, and Bicaluta-
mide. However, PC3 spheroid cells was signifıcantly higher compared to
HS27a and co-culture spheroids. For all three spheroids, as the size of the
spheroids increase, cellular resistance to anti-cancer and hormone drugs
increased. Conclusion: The fındings in this study demonstrated that the use
for 3D-cell cultures influence many aspects of PCa behavior including, pro-
liferation rates, and response to chemotherapeutics.
#5911 Omentin drivesmetabolic shift in ovarian cancer cells in the omen-
tal tumor microenvironment. Chi Lam Au Yeung,1 Abhinav Achreja,2 Hon-
gyun Zhao,2 Tsz-Lun Yeung,1 Rosemarie Schmandt,1 Daniel K. Yip,3 Karen H.
Lu,1 Deepak Nagrath,2 Samuel C. Mok1. 1UT MD Anderson Cancer Center,
Houston, TX; 2Rice University, Houston, TX; 3University of South Florida,
Tampa, FL.
Advanced stage high grade serous ovarian cancer (HGSC) metastasizes pref-
erentially to the omentum, which is a well-vascularized fold of peritoneal tissue
and is a major site of adipose tissue accumulation. The mechanisms by which
omental adipose tissue interact with ovarian cancer cells and promotes tumor
growth and disease progression are not entirely clear. We previously showed
that a novel adipokine called omentin (Intestinal Lactoferrin Receptor ITLN1)
produced by the omental adipose tissue was signifıcantly down-regulated in
patients with HGSC compared with those in BMI matched healthy individuals,
and omentin suppressed ovarian cancer cell growth only in the presence of
adipocytes in vitro. Since we and others demonstrated that omentin induced
insulin-dependent glucose uptake exclusively in adipocytes, we therefore hy-
pothesized that omentin may suppress ovarian cancer growth via driving met-
abolic shift in ovarian cancer cells in the omental microenvironment. Using a
cancer cell/adipocyte-co-culturemodel, we demonstrated that omentin reduced
both glucose uptake and lactate secretion in ovarian cancer cells when they were
co-culturedwith adipocytes but notwith other stromal cell types, suggesting that
omentin-induced glucose uptake in adipocytes may deplete the surrounding
glucose that fuels the glucose-addicted ovarian cancer cells in the omental mi-
croenvironment and thus drivemetabolic shift in ovarian cancer cells. To delin-
eate the underlying mechanism by which omentin induced glucose uptake in
adipocytes, expression levels of the adipocyte-specifıc glucose transporter
GLUT4 induced by omentin in adipocytes and the effect of GLUT4 silencing in
adipocytes using GLUT4 specifıc siRNAs on ovarian cancer growth were exam-
ined. The results showed that omentin up-regulated GLUT4 in adipocytes and
GLUT4 silencing in adipocytes abrogated the effects of omentin on glucose
uptake in adipocytes and ovarian cancer cell growth in the co-culture model.
Taken together, this study shows that omentin plays an important role in driving
metabolic shift in ovarian cancer cells in the omental microenvironment. Ther-
apeutic strategies based on up-regulating omentin in ovarian cancer patients
may inhibit ovarian cancer progression and improve patient survival rates.
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#5912 Tumor micoenvironment modulates RTK signaling. Dhruv
Thakar,1 Shalini T. Low-Nam,2 Jay T. Groves,2 Valerie M.Weaver1. 1University
of California San Francisco, San Francisco, CA; 2University of California Berke-
ley, Berkeley, CA.
Receptor tyrosine kinases (RTKs) and their associated signalingmolecules are
mutated or dysregulated in many aggressive cancers such as non-small cell lung
carcinoma (NSCLC), breast cancer, and colorectal cancer. Despite therapeutic
interventions such as tyrosine kinase inhibitors (TKI) that target RTKs,majority
of patients develop resistance even after initial tumor regression. Although clin-
ical studies suggest sequential treatments with TKI, chemotherapy, and radia-
tion can eliminate most cancer cells, resistance inevitably emerges (Sequist, et
al., Sci Trans Med, 2011). We demonstrated that alterations in the extracellular
matrix (ECM) correlate with cancer progression and that RTK signaling is sub-
ject to spatiotemporal regulation (Paszek, et al., Cancer Cell, 2005.; Salaita, et al.,
Science, 2010). Thus, geometric and mechanical properties of the ECM may
directlymodulate RTK signaling.Here, we use silicone gel substrates that exhibit
tunable stiffness in the physiological range (100s Pa - 100s kPa) to measure
RTK-adaptor protein interactions in mammary epithelial cells (MECs;
MCF10A) (Ou, et al. Integ. Biol., 2016). These gels are compatible with total
internal reflection fluorescence (TIRF) imaging and enable single molecule de-
tection of activated RTK phosphotyrosine residues via recruitment of Grb2
tagged with the fluorescent protein mEos3.2. We demonstrate a spectrum of
Grb2 behaviors that are determined by the stiffness of the substrate. This indi-
cates that the same receptor is capable of different signaling activities that are
dictated bymaterial properties. These new insights create opportunities to target
the tumor microenvironment to address RTK inhibitor resistance and metasta-
sis in cancer patients and to develop effective therapeutic strategies for better
prognosis and prolonged patient survival.
#5913 The impact of daily exercise on tumor perfusion. Jennifer M. Wig-
gins,1 Sharon Lepler,1 Christine Pampo,1 Lori Rice,1 Jennifer A. Lee,2 Dietmar
Siemann1. 1University of Florida, Gainesville, FL; 2National Cancer Institute,
Bethesda, MD.
Aberrant blood vessel networks in solid tumors lead to impaired tissue per-
fusion and areas of hypoxia (pO2  10 mmHg). Tumor hypoxia is associated
with aggressive progression, dissemination, and therapeutic resistance. It is
found in 40%of breast cancers, and can constitute amajor obstacle to anticancer
therapy. Exercise is associated with improvements in cardiovascular and respi-
ratory function, aerobic capacity and overall health. In cancer patients undergo-
ing therapy, exercise has been shown to decrease treatment related side effects
and general fatigue. The goal of the present investigation was to determine
whether aerobic exercise could be applied to improve tumor perfusion and ox-
ygenation in a breast cancer model. Such modulation of the tumor physiology
and host environment would be expected to lead to enhanced antitumor effıcacy
when combined with radiotherapy or chemotherapy. The effects of a single and
daily bouts ofmoderate intensity treadmill runningwere studied inmice bearing
the syngeneic murine mammary carcinoma 4T1. The exercise intensity was
determined by measuring the anaerobic threshold, which was assessed by mea-
suring the steady rise in blood lactate during exercise. Initial studies examined
the effect of a singlemoderate bout of exercise (18m/min) inmice bearing500
mm3 orthotopic tumors. In subsequent experiments mice were exercised at 18
m/min, 5 days a week, for 8 weeks prior to orthotopic injection of tumor cells
and continued exercise (5 days a week) for 2 weeks during tumor growth. Con-
trols for each treatment consisted of sedentary mice exposed to a stationary
treadmill for the equivalent amount of time. At the end of each of the exercise
regimen, tumors were harvested, sectioned, stained, and tile mapped to assess
physiological changes by immunofluorescence. The detection of open blood
vessels (Hoechst-33342) was used as an indirect indicator of perfusion. Tumor
hypoxia was determined using the 2-nitroimidazole (EF5). Blood vessels were
stained using the endothelial cell marker CD-31. All markers were quantifıed
using Photoshop and ImageJ NIH software. Our results indicate that in the 4T1
breast cancermodelmoderate intensity exercise did not signifıcantly alter tumor
growth, oxygenation or blood vessel number. However, daily bouts of exercise
did signifıcantly increase the number of open tumor vessels indicating improved
tumor perfusion. These results suggest that a daily exercise regimen may have
the potential to improve drug delivery to mammary tumors
#5914 A soft microenvironment protects from failure of midbody abscis-
sion and multinucleation downstream of EMT initiators. Allison K. Simi,1
Alisya A. Anlas,1 Sherry X. Zhang,1 Tiffaney Hsia,1 Derek C. Radisky,2 Celeste
M. Nelson1. 1Princeton University, Princeton, NJ; 2Mayo Clinic Cancer Center,
Jacksonville, FL.
This study investigates how increased stiffness of the tumor microenviron-
ment can induce cellular multinucleation, an easily observable marker of polyp-
loidy. Up to 37% percent of tumors exhibit whole-genome doubling, which
typically precedes other somatic copy number alterations. Additionally, induc-
tion of tetraploidy in human cells promotes increased tolerance for mutation,
resistance to chemotherapeutic drugs, and transformation in culture. Tumors
are inherently stiffer than normal tissue, and this property has been shown to
affect cell growth and proliferation. Similarly, cell cycle errors have long been
linked to chromosomal abnormalities. Here, we used engineered two-dimen-
sional substrata that mimic the stiffness of tumor and normal microenviron-
ments to investigate how matrix stiffness regulates multinucleation in mam-
mary epithelial cells.Multinucleationwas quantifıed by stainingwithHoescht to
visualize the nuclei. Timelapse microscopy enabled visualization of the process
by which cells become multinucleated. Changes in gene expression were deter-
mined by quantitative RT-PCR. Cells cultured on “stiff” substrata, representing
tumor tissue, showed a nearly 14-fold increase in multinucleation compared to
cells cultured on “soft” substrata, representing normal tissue. We found that
multinucleation was regulated in part by signaling downstream of matrix met-
alloproteinase-3 (MMP3), which is commonly upregulated in cancer and
known to induce epithelial-mesenchymal transition (EMT). This signaling de-
pended on expression of the Rac1 splice variant, Rac1b, production of ROS, and
expression of Snail. Under all conditions, cells cultured on soft substrata main-
tained a low frequency of multinucleation. Multinucleation on stiff substrata
primarily resulted from midbody abscission failure. A soft microenvironment
protected the stability of the genome in epithelial cells by preventing midbody
stability, which depended on septin 4, a novel target of Snail. Importantly, we
found that transforming growth factor- (TGF), another EMT-inducer, also
causedmultinucleation downstreamof Snail, whichwas prevented by culture on
soft substrata. Our data thus suggest that tissue stiffening during tumorigenesis
synergizes with oncogenic signaling to promote genomic abnormalities that
drive cancer progression. Further, our results suggest that EMT-related signal-
ing pathways are associated with disease progression not necessarily because
they induce metastasis, but because they induce genomic instability.
#5915 Three-dimensional, 3-D, multiplex imaging of biomarkers in tu-
mor tissue. Sharla L. White, Sarah McCurdy, Laurie J. Goodman. Clearlight
Diagnostics, Sunnyvale, CA.
Background: Obtaining high-resolution information from solid tumors,
while maintaining the spatial perspective needed to understand the heteroge-
neous tumor microenvironment, represents a key challenge for preclinical and
clinical cancer applications. Methods: We utilized a novel method CLARITY
that has been shown to transform intact rodent tissues into an optically trans-
parent and permeable hybridized-hydrogel form that can undergo immuno-
staining followed by 3-D imaging of nucleic acids and proteinsmarkers, without
the need to separately analyze hundreds of conventional FFPE thin sections. In
this study, human breast and lung cancer excision biopsy samples were obtained
commercially. Murine orthotopic MCF-7 xenograft and patient-derived-xeno-
graft (PDX) breast tumors were explanted and prepared as fresh samples. The
intact tissues were incubated in a mixture of 4% paraformaldehyde/4% acryl-
amide/0.05% bis-acrylamide for 48 hours, and polymerized in the presence of a
thermal initiator, VA-044, for 3 hours at 37°C to form an intact hydrogel/tissue
matrix. The tissues were then lipid-cleared in a solution of 0.2M borate buffer
containing 8% SDS, pH 8.5 at 45-55°C from 5-35 days, depending on sample
size. The cleared tissues were then stained with two multiplex antibody panels
that were selected to highlight the microenvironment of the tissue including,
immune cells (CD-3 or CD-8), vasculature (Lectin-Texas Red or CD-31), and
tumor (cytokeratin [818] or PD-L1, directly conjugated to Alexa Fluor® 647).
For non-directly conjugated antibodies, the tissues were then subjected to a
secondary goat anti-mouse or goat anti-rabbit antibody conjugated to either
Alexa Fluor® 568 or 700 followed by a nuclear counterstain, Sytox Blue. Samples
were then placed in an appropriate refractive index solution for imaging on a
laser scanning confocal microscope. Results: The tissues remained intact
throughout the procedure and the cellular morphology of the tissue was well
preserved. The individual components of the microenvironment could be iden-
tifıed, demonstrating that the tissues could be successfully interrogated with a
multiplex of indirect and directly conjugated commercially available antibodies.
These preliminary studies, provide evidence for the use of this novel technology
for detecting the heterogeneity of biomarker expression within the tumor mi-
croenvironment.Most notably, the analysis of a lymph node from a patient with
metastatic breast cancer revealed variation across the tissue which may have
implications for the detection of micro-metastasis in patients with early stage
disease when using conventional thin section histological methods. Conclusion:
These results implicate CLARITY as a powerful next generation tissue process-
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ing technology for profıling the intact tumor microenvironment, eliminating
the need to recapitulate this spatial and quantitative information with standard
thin section techniques.
#5916 Proton-sensor GPR4 potentiates intestinal inflammation in the
DSS-induced colitis mouse model. Edward J. Sanderlin,1 Nancy R. Leffler,1
Kvin Lertpiriyapong,1Qi Cai,1HengHong,1 VasudevanBakthavatchalu,2 James
G. Fox,2 Joani Z. Oswald,1 Calvin R. Justus,1 Elizabeth A. Krewson,1 Dorcas
O’Rourke,1 Li V. Yang1. 1East CarolinaUniv. School ofMedicine, Greenville, NC;
2Massachusetts Institute of Technology, Cambridge, MA.
Inflammation and tissue acidosis are two factors that co-exist in inflammatory
bowel disease (IBD) and can contribute to increased risk of colorectal cancer
(CRC) development. GPR4 is a proton-sensing G protein-coupled receptor that
can be activated by extracellular acidosis through several histidine residues and
subsequently signal through downstream G-protein pathways. Recently, GPR4
has been shown to be activated by acidosis and can increase the expression of
numerous inflammatory and stress response genes in vascular endothelial cells
(ECs) and has functionally increased EC-leukocyte adhesion. Subsequently, ge-
netic and small molecule approaches for the inhibition of GPR4 activity have
reduced endothelial cell inflammation. In this study, we examined the role of
GPR4 in intestinal inflammation using a dextran sulfate sodium (DSS)-induced
colitis mouse model. We observed that GPR4 mRNA expression was increased
in mouse and human IBD tissues when compared to control intestinal tissues.
To determine the function of GPR4 in intestinal inflammation, wild-type and
GPR4-defıcient mice were treated with 3% DSS for acute and chronic time
points for the induction of colitis. Our results showed that the severity of colitis
was decreased in GPR4-defıcient DSS-treated mice in comparison to wild-type
DSS-treatedmice. Clinical parameters, macroscopic disease indicators, and his-
topathological features were less severe in the DSS-treated GPR4-defıcient mice
than theDSS-treatedwild-typemice. Inflammatory gene expression, endothelial
adhesionmolecule expression, leukocyte infıltration, and isolated lymphoid fol-
licle (ILF) formation were reduced in intestinal tissues of DSS-treated GPR4-
null mice. In summary, our results suggest GPR4 potentiates intestinal inflam-
mation as the absence of GPR4 ameliorates intestinal inflammation in the DSS-
induced colitis mouse model. Use of GPR4 inhibitors could prove a valuable
therapeutic in the reduction of intestinal inflammation and subsequent CRC
development.
#5918 Collagen enhances tumorigenicity of papillary thyroid cancer.
Anna Sharabura, Laura MacDonald. Hendrix College, Conway, AR.
While themutationsassociatedwith thyroidcancerarewelldefıned, less isknown
about how the tumormicroenvironment contributes to thyroid cancer progression.
Papillary thyroid cancer is most common and is associated with activating
BRAFV600E mutations. Jolly et al. recently found that murine papillary thyroid can-
cers with consitutively active BRAF and a PTEN deletion recruit cancer-associated
fıbroblasts that enrich the tumor with collagen, a component of the extracellular
matrix. Our study addresses how collagen impacts tumorigenicity of papillary thy-
roid cancer cells. Cell lines derived frommouse models of papillary thyroid cancer
with BRAFV600E mutations and PTEN deletions were grown in the presence or
absence of collagen and assessed for cellular proliferation, altered cellularmorphol-
ogy, secretion of microvesicles, and altered cellular signaling. Our results show that
papillary thyroid cancer cells increase microvesicle secretion and have increased
growth rates. Collectively, our study suggests that collagen enhances tumorigenic
characteristics of papillary thyroid cancer cells.
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#5919 Identifıcation of a novel molecular interaction, targeted by Met-
formin, between breast cancer and white adipose tissue progenitors. Franc-
esca Reggiani, Valentina Labanca, Patrizia Mancuso, Andrea Manconi, Fran-
cesco Bertolini. European Inst. of Oncology, Milan, Italy.
The white adipose tissue (WAT) contains a resident population of progenitors
with mesenchymal- or endothelial-like phenotype, able to promote breast cancer
(BC) progression (Orecchioni et al., 2013). We recently characterized a novel mo-
lecular axis underneath the interaction betweenBC andWATprogenitors, possibly
explaining the acquisition of a cancer-associated phenotype by WAT progenitor
cells and the establishment of a permissive tumor microenvironment. GM-CSF
balance was identifıed to be the principal regulator of the transcriptional alteration
occurring in WAT progenitors exposed to BC: GM-CSF, produced by BC cells,
dramatically changed the secretion profıle of progenitors, enhancing its own pro-
duction through a positive regulatory loop and inducing the expression of several
factors involved in inflammation (IL-1), ECM remodeling and angiogenesis
(MMP9). IL-1 was strongly down-regulated by GM-CSF neutralization in WAT
progenitors in vitro and in preclinical models. Induction of IL-1 by GM-CSF was
able, in turn, to up-regulate MMP9 in the same cells. The markedly increased ex-
pression ofMMP9was already observed in BC-associatedWATprogenitors, being
addressed to increased local and metastatic tumor growth in obese mice. GM-CSF
production was signifıcalntly enhanced in the presence of concomitant obesity in
preclinicalmodels of BC, both in orthotopicmodels (MMTV-neu/ErbB2; 4T1) and
in spontaneous tumor-bearing mice (MMTV-PyMT). GM-CSF neutralization in
several obese syngeneic models of BC signifıcantly reduced immunosuppressive
cells in tumors and in the surrounding WAT, including T-regs (CD4
CD25brightCD127low), Granulocytic myeloid-derived suppressor cells (G-MDSCs,
CD11bLy6C-Ly6G), tumor-associated macrophages (TAMs, F4/80CD206
MCHIIlow) and tumor infıltrating lymphocytes (TILs, CD8PD1). Different BC
types produce distinct amounts of GM-CSF: triple negative BC (TNBC) expressed
higher levels compared to hormone receptors positive cells, correlating GM-CSF
expression to higher tumor grade. In the context of targetingWAT-BC interaction,
Metformin was able to impair tumor growth, metastasis and angiogenesis in pre-
clinical models (Orecchioni et al., 2015) and affecting immune cells, including T-
regs, TAMs andMDSCs. From our data, GM-CSFwas identifıed to be a new target
of Metformin in both BC and WAT progenitors, suggesting a novel inhibitory
mechanismmediated by the drug.Metformin displayed the same effıcacy in reduc-
ing BC growth, metastatic spread and immune system regulation, when compared
toGM-CSF specifıc neutralization inobese syngeneicmodels. Taken together, these
results indicate GM-CSF as a new molecular target of Metformin and support the
role of this novel mechanism in BC progression. Ongoing studies also suggest that
thispathwaymightbe induced inWATprogenitorsbyother solid tumors, including
non-Hodgkin’s B-lymphoma.
#5920 Paraendocrine interactions between bone marrow mesenchymal
stem cells and prostate cancer cells: impact on tumor cell invasive and prolif-
erative capacity. Karen O’Leary,1 Sarah Ridge,1 William Watson,2 Antoinette
Perry,2 Stephen Finn,3 Raymond McDermott,3 Sharon Anneve Glynn1. 1Na-
tional University of Ireland Galway, Galway, Ireland; 2National University of
Ireland Dublin, Dublin, Ireland; 3Trinity College Dublin, Dublin, Ireland.
Introduction: The primary site of prostate cancer metastasis is to the bone.
Bone marrow derived mesenchymal stem cells (BM-MSCs) are multipotent
stem cells resident in the bonewith the potential to differentiate into osteoblasts,
chondrocytes and adipocytes. They have been shown to home to sites of inflam-
mation, including prostate cancer, contributing to tumor growth and progres-
sion. This study aims to explore the impact of metastatic prostate cancer patient
derived BM-MSCs on prostate cancer cell proliferation and invasive capacity.
Methodologies: BM-MSCs were isolated from bone marrow aspirates from pa-
tients diagnosed with metastatic prostate cancer (both androgen deprivation
treatment naïve and commenced). Co-culture models were used to examine the
impact onpatient BM-MSCs versus healthy donorBM-MSCs onprostate cancer
cell proliferation, PSA and cytokine secretion, and induction of cell migration
and invasion. The impact of metastatic prostate cancer cells on healthy donor
BM-MSCs was also examined. Results: Here we show that metastatic prostate
cancer cells (PC-3 and DU145), reprogram normal donor BM-MSCs to a pro-
inflammatory secretory phenotype that in turn induces prostate cancer cell in-
vasion using a 3D spheroidmodel of invasion into amatrigel-collagen gel, while
restricting BM-MSCs with the 3D spheroid. Additionally we isolated a series of
BM-MSCs frommetastatic prostate cancer patients (n10). Results show that a
proportion of prostate cancer patient derived BM-MSCs patients have a reduced
differentiation capacity to osteocytes while maintaining normal adipocyte ca-
pacity. Additionally patient derived BM-MSCs increase prostate cancer cell
(MDA-PCa-2b) secretion of PSA and display increased expression of inflamma-
tion associated enzymes including the immunosuppressive enzyme indoleam-
ine- 2,3-dioxygenase and its metabolite kynurenine. Conclusions: Ultimately,
we seek to decipher the role of BM-MSCs in metastatic prostate cancer, in the
context of impact on androgen receptor signaling, chemotherapeutic drug re-
sponse, and themaintenance and promotion ofmetastatic lesions. Future direc-
tions will use 3D co-culture models to identify the key regulatory networks
co-activated in prostate cancer and BM-MSCs that facilitate chemotherapeutic
drug resistance and metastatic progression.
#5921 Microenvironmental changes in the progression from adenocarci-
noma in situ to early-invasive adenocarcinoma of the lung.Masahito Naito,1
Yukitoshi Satoh,1 Genichiro Ishii2. 1Kitasato University, Sagamihara-shi, Japan;
2Exploratory Oncology Research & Clinical Trial, Japan.
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Introduction: Lepidic predominant adenocarcinoma of the lung was classi-
fıed into adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma
(MIA) and invasive lepidic predominant adenocarcinoma (LPA) in current
WHO classifıcation, 4th edition. Furthermore, LPA is thought to progress in a
stepwise fashion from AIS and MIA. However, those classifıcations were diag-
nosed by observation of pathologists based onmorphology only. The aim of this
study was to investigate the microenvironmental changes in the process of de-
velopment from AIS, MIA to LPA, and subjective marker of stepwise progres-
sion. We have published a part of data in this study in Lung Cancer (100:53-62,
2016), and we believe that this study makes a contribution to elucidate the
mechanism of development of LPA of the lung. Materials and Methods: Clini-
copathological characteristics of AIS (n51), MIA (n59), LPA smaller than 3
cm (S-LPA, n113), and LPA larger than 3 cm (L-LPA, n47) were analyzed.
We then immunohistochemically evaluated the expression levels of epithelial-
mesenchymal transition (EMT)-related molecules (E-cadherin, S100A4), inva-
sion-related molecules (laminin-5, ezrin), and growth factor receptors (EGFR)
in cancer cells of each group (n20). The number of tumor-promoting stromal
cells, including podoplanin-positive cancer-associated fıbroblasts (PDPN
CAFs), CD204-positive tumor-associated macrophages (CD204 TAMs), and
CD34 microvessel cells, were also analyzed. Results: LPA-S showed signifı-
cantly frequent vascular and pleural invasion than MIA (p0.05); however, no
signifıcant difference in those factors was found between S-LPA and L-LPA.
Laminin-5 expression in the non-invasive component of MIA was signifıcantly
higher than that of AIS (p0.001). During the progression fromMIA to S-LPA,
the expression level of laminin-5 in the invasive component was signifıcantly
elevated (p0.01). Moreover, tumor-promoting stromal cells were more fre-
quently recruited in the invasive area of LPA-S (PDPN CAFs; p0.05,
CD204 TAMs; p0.001, CD34 microvessel; p0.05). Ezrin expression in
the invasive component of L-LPA was signifıcantly increased (p0.05) com-
pared to S-LPA; however, the number of tumor-promoting stromal cells were
not different between these two groups. Conclusion: Our current study indi-
cated thatmicroenvironmentalmolecular changes occur during the progression
from MIA to S-LPA. Thus, it was suggested that this process may play an im-
portant role in disease progression from AIS to LPA of the lung.
#5922 Cellular interaction between pancreatic cancer cells and MSC as
tumor microenvironment. Eisaku Kondo, Ken Saito. Niigata Univ. Grad.
School of Medical Dental Sci., Niigata, Japan.
Tumor microenvironment such as neoangiogenesis, stroma and tumor im-
munity has recently gainedmuch attention because it is signifıcantly involved in
tumor progression. Pancreatic adenocarcinoma (PAC; pancreatic invasive duc-
tal carcinoma) is recognized as one of the most intractable malignancies and
required to disclose a key biological characteristics to provide a clue for its
diagnosis and therapeutics. Here we focus on the biological role of bone mar-
row-derived human mesenchymal stem cells (MSCs) in PAC, which were re-
ported to be accumulated in various cancer tissues such as colon, breast cancers.
We detected small numbers of MSCs in the stroma of PAC in human patholog-
ical tissues using double immunofluorescence in combination with severalMSC
markers includingCD73, 105, 34, 45, SMA and so on. Then, in in vitro coculture
system, we found that MSCs signifıcantly facilitated invasion of BxPC3 cells, a
human PAC cell line, in comparison with the culture of BxPC3 cell alone by
transwell chamber assay. Proteome profıling of the cocultured supernatant re-
vealed augmented production of solublemolecules includingCXCL7, CCL7 as a
cytokine, integrin beta1, transferrin R, ALCAM, andAmphiregulin (AREG) as a
soluble receptor and ligand, metalloprotease (MMP), ADAMTS-1 as a soluble
protease-related molecule, all which were signifıcantly increased comparing to
the culture sup. of BxPC3 alone or MSC alone. Based on the result of proteome
profıling,we further examinedmRNAupreguttion on the cells of each culture by
real-time PCR (qPCR) to identify which molecule would be more specifıcally
upregulated by the coculture sample of PAC cells and MSCs. Consequently,
upregutaion of AREG and MMP-3, in addition to downregulation of MMP-9
was observed by qPCR, and knockdown of AREG using the specifıc siRNA on
the cocultured cells corroboratedmarked decrease of PAC invasion in transwell
chamber assay. Interestingly, AREG expression on the tumor cells of tissue spec-
imens of the patient with PAC was observed especially on the cells at invasive
front, which suggests stromal MSCs may interact with PAC cells and facilitate
invasion of cancer cells by regulating expression of the specifıc genes such as
AREG and MMPs.
#5923 Developing a novel system for studying tumor microenvironment
heterogeneity in pancreatic adenocarcinoma. Jinyang Li. Univ. of Pennsylva-
nia, Philadelphia, PA.
Pancreatic cancer (PDA) has a dismal prognosis and responds poorly to all
existing therapies. This is largely attributed to the existence of dense stroma and
lack of T cell infıltration. PDA exhibits heterogeneous tumor microenviron-
ments that are composed of various stromal cells. Human PDA has been shown
to have various levels of T cell infıltration. The mechanisms underlying the
inter-tumor heterogeneity of immunemicroenvironment in PDA and its effects
on distinct responses of PDA to therapies, especially immune-modulating ther-
apies, remain largely unknown. Our lab has demonstrated that there is no dif-
ference in somatic mutation burden or neo-epitope load between human PDA
tumorswith high or low amount of cytolytic T cells.We hypothesize that tumor-
cell-intrinsic determinants, transcriptional and/or epigenetic factors, shape the
heterogenous tumor immunemicroenvironment, and thereby result in different
responses to therapies. For the reason that tumor cellularity of PDA is very low,
the profıling of bulk tumor samples cannot provide enough information for
understanding tumor-cell-intrinsic molecular events associated with differen-
tial immune microenvironment. Therefore, we developed a panel of 60 cell
lines (diversity-cell-panel) from PDA tumors derived from inbred C57BL/6
KPCmouse model, which recapitulates the major histopathological and molec-
ular features of human PDA. Our preliminary results have demonstrated that
the diversity-cell-panel recapitulates the immunemicroenvironments heteroge-
neity in PDA. Tumor cells mainly fell into two subgroups: T-cell-high and T-
cell-low. Tumors resulted from T-cell-high tumor cells also possess less amount
of immune-suppressivemyeloid cells. To studywhether this difference is caused
by various amount of mutations, we performed exome-sequencing for 8 cell
lines within this cell-panel, and showed that T cell-high and T-cell-low tumor
cells have similar amount of mutations and neo-epitopes. To further study the
distinct molecular features of T-cell-high and T-cell-low tumor cells, we will
perform RNA-seq and ATAC-seq on tumor cells sorted from resulting tumors.
To understand whether T cell infıltration affects the response of PDA tumors to
immune-modulating therapies, I have been testing the response of T-cell-high
and T-cell-low tumors to a group of therapies, including chemotherapy, CD40
therapy and immune checkpoint blockade therapy. Utilizing this novel system,
the cell-panel, this study will delineate in unprecedented detail the novel molec-
ular determinants of immune heterogeneity in PDA and the implication of the
heterogeneity to therapies. This diversity-cell-panel will also be useful for un-
derstanding other aspects of tumor heterogeneity, including angiogenesis, drug
resistance and metastatic disease.
#5924 Necrotic cells promote microglia infıltration in glioblastoma
through regulating MCP-1 and MIP-3
 expression. Yieun Jung,1 So-Hee
Ahn,1 Hyunju Park,1 Jiwoo Lim,1 Jihee Lee Kang,1 Youn-Hee Choi,1 Eun Ju
Kim2. 1Department of Physiology, Tissue Injury Defense Research Center, Ewha
Woman’s Unversity School ofMedicine, Seoul, Republic of Korea; 2Department of
MolecularMedicine, Tissue Injury Defense Research Center, EwhaWoman’s Un-
versity School of Medicine, Seoul, Republic of Korea.
Glioblastoma multiform (GBM), a grade IV astrocytoma, is most lethal and
common adult primary intracranial tumor. GBM is characterized by diffuse
infıltration into normal brain parenchyma, rapid growth and the presence of
necrosis and microglia/macrophage infıltration. Among these properties of
GBM, necrosis has been implicated to be a strong predictor of poor prognosis;
however, the effect of necrosis on GBM progression is poorly understood at
present. In this study, we examined the effect of necrosis on glioblastoma cells by
exploring molecular mechanisms underlying gene expression and chemokine
expression. Data obtaining from chemokine array and ELISA showed that
CRT-MG human gliomablastoma cells secreted several chemokines including
MCP-1 and MIP-3	 in response to necrotic cells. Expression levels of mRNA
and protein of MCP-1 and MIP-3	 were also increased by treatment with ne-
crotic cells in CRT-MG in a dose-dependent manner. Necrotic cells induced
NF-B/AP-1 activation and their binding to theMCP-1 andMIP-3	 promoter,
leading to enhanced MCP-1 and MIP-3	 production in GBM cells. Finally,
transwell migration assay showed that incubation with necrotic cells signifı-
cantly enhanced the migration of microglia. Our data demonstrate that when
GBM cells are exposed to and stimulated by necrotic cells, the expression and
secretion of MCP-1 and MIP-3	 are enhanced in GBM cells and microglia
infıltration/migration to the tumor site are facilitated.
#5925 Mapping themolecular communicationwithin the tumormicroen-
vironment of pancreatic cancer as well as between tumor and peritumoral
tissue. Mohamed S. Alhamdani, Andrea S. Bauer, Jörg D. Hoheisel. German
Cancer Research Center (DKFZ), Heidelberg, Germany.
We are analyzing in detail the molecular communication between the differ-
ent cell types in the microenvironment of pancreatic ductal adenocarcinomas
(PDAC). Also, its regulation is being investigated, looking at aspects such as the
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kind and mixture of molecules needed for triggering a particular regulative
function, and unraveling the inter- and intracellular processes utilized to trans-
mit a molecular message. Although a rare tumor entity, adding up to only about
3% of all cancer cases in the Western world, PDAC is the fourth most frequent
cause of cancer-related death; mortality is nearly identical to incidence. There is
no real remedy apart from surgery, which can be applied to only 10 to 20% of
patients. Even then, basically all patients will experience tumor recurrence. Our
study is based on a large basic set of data at the levels of DNA, RNA and protein
thatwas generated from some1000pancreatic tumor samples [1], supplemented
with information from studies that aim at an elucidation of functionalmolecules
and comparative analyses in other tumors. This has already led to the creation of
basic functional knowledge about metastasis [e.g., 2], the establishment of
means for diagnosis [3, 4], an accurate disease prognosis [1], the characteriza-
tion of communication processes [5] and the identifıcation of new therapeutic
avenues [6]. At the conference, we will report about the status of mapping par-
ticularly the protein-mediated communication between the different cell types
in the tumor microenvironment. Also, we will show results about the effect that
PDAC tissue has on the wider peritumoral environment and vice versa. The
peritumoral tissue is exhibiting a fıeld defect that does not seem to be dependent
on DNA-methylation. A comparison of PDAC and cystic pancreatic tumors
revealed that differences in communicating with the peritumoral tissue could
actually be more important to the known pathological difference between the
two cancer entities than themolecular variations in the tumor cells. 1. Bauer et al.
(2017), work submitted for publication 2. Botla et al. (2016) Cancer Res. 76,
4149-4159 3. Keller et al. (2014) BMC Med. 12, 224 4. Moskalev et al. (2015)
Oncotarget 6, 4418-4427 5. Dror et al. (2016) Nature Cell Biol. 18, 1006-1017 6.
Jandaghi et al. (2016) Gastroenterology, in press (doi: 10.1053/j.gas-
tro.2016.08.040) www.dkfz.de/funct_genome/.
#5927 Eribulinmodulates tumormicroenvironment through vascular re-
modeling for antitumor effect inmultiplemouse xenograftmodels.Ken Ito,1
Shusei Hamamichi,2 Takanori Abe,1 Tsuyoshi Akagi,1 Hiroshi Shirota,1 Satoshi
Kawano,1 Makoto Asano,1 Osamu Asano,1 Akira Yokoi,1 Junji Matsui,1 Izumi
O. Umeda,2 Hirofumi Fujii2. 1Eisai Co., Ltd., Tsukuba, Japan; 2National Cancer
Center, Kashiwa, Japan.
Eribulin mesilate (Eribulin), a fırst-in-class halichondrin B-based microtu-
bule dynamics inhibitor, has been reported to remodel tumor vasculature (i.e.,
improvement of tumor vessels and perfusion) in human breast cancer xenograft
models; however, the role of this vascular remodeling in anti-tumor effects is not
fully understood. Here, we investigated the effects of eribulin-induced vascular
remodeling on anti-tumor activities in multiple human cancer xenograft mod-
els. Microvessel densities (MVDs) were evaluated by immunohistochemistry
(CD31 staining), and anti-tumor effects were examined in 10 human cancer
xenograft models treated with eribulin. Eribulin treatment signifıcantly in-
creased MVDs compared to the corresponding control groups in 7 out of 10
models with a correlation between enhancedMVD levels and anti-tumor effects
(R20.55). Because of observed increases in MVDs, we next utilized 111In-la-
beled PEGylated liposomes to examine if eribulin treatment would result in
increased tumoral accumulation levels of such liposomes, and indeed, we found
that eribulin, unlike vinorelbine another tubulin inhibitor, enhanced them.
Since eribulin treatment increased accumulation of 111In-labeled PEGylated li-
posomes, we postulated that this treatment might enhance anti-tumor effect of
Doxil (a liposomal anti-cancer agent). As expected, eribulin enhanced anti-tu-
mor activity of Doxil in the PE-H1650 xenograft model. Then, we evaluated
whether eribulin facilitated the recruitment of immune cells into the tumor.
Infıltrating CD11b-positive immune cells were signifıcantly increased in the
multiple eribulin-treated xenografted tumors, and natural killer (NK) cell deple-
tion reduced anti-tumor effects of eribulin. Collectively, these fındings sug-
gested a contribution of the immune cells for anti-tumor activities of eribulin.
Taken together, our results obtained from multiple human cancer xenograft
models suggested that vascular remodeling induced by eribulin therapy would
act as a microenvironment modulator, and contributed to show anti-tumor
effects of eribulin.
#5928 Discoidindomain receptor-1 (DDR1) is an independent prognostic
marker of poor prognosis in esophageal squamous cell carcinoma. Kiichi
Sugimoto,1 Tomoaki Ito,2 Hajime Orita,3 Koichi Sato,3 Kazuhiro Sakamoto,1
Mutsumi Sakurada,3 Tomoyuki Kushida,3 Hiroshi Maekawa,3 Ellen Tully,2
JuhyungWoo,2 Edward Gabrielson2. 1Juntendo University, Faculty of Medicine,
Tokyo, Japan; 2JohnsHopkinsUniversity, Sydney Kimmel Comprehensive Cancer
Center, Baltimore, MD; 3Juntendo University, Faculty of Medicine, Shizuoka,
Japan.
Introduction: Esophageal squamous cell carcinoma (ESCC), which is the
most common type of esophageal cancer, is one of the most common cancers in
eastern Asia and one of the leading causes of cancer-related death worldwide.
This unsatisfactory outcome in ESCC is thought to mainly result from late di-
agnosis, the aggressiveness of this disease, and the lack of the understanding in
effective treatment strategies. Therefore, new targetable drugs are required to be
investigated and developed in order to improve treatment strategies. The discoi-
din domain receptors (DDRs) are a set of receptor tyrosine kinases (RTKs) that
are activated by collagen and crucial role in key regulators in cancer progression
by controlling the interactions of tumor cells with their surrounding collagens.
DDR1 is expected to be involved in ESCC,which demonstrates aggressive tumor
proliferation and devastating prognosis. However, there have been only a few
reports about DDR1 in ESCC. We retrospectively investigated DDR1 in ESCC.
Methods: A total of 60 formalin-fıxed paraffın-embedded (FFPE) primary tu-
mor samples were collected from patients with ESCC who underwent surgery
with curative intent. DDR1 immunohistochemistry (IHC) was conducted on
ESCC FFPE tissue specimens. Clinicopathological factors, DDR1 immunohis-
tochemistry (IHC) and survival data were analyzed in this study. Results: When
compared the clinicopathological factors between theweak and the strong group
in the intensity of DDR1 IHC, in univariate analysis there were signifıcant dif-
ferences between the two groups in age (P0.007), histological grade (P0.04),
invasion depth (P0.0001), stage (P 0.0001). There were no signifıcant differ-
ences between the two groups with respect to the other clinicopathological fac-
tors. In univariate analysis, signifıcant differences in recurrence-free survival
were recognized with respect to invasion depth (T3, 4) (P0.007), lymph node
metastasis (LNM) (N2, 3) (P0.0005) and DDR1 IHC expression (strong)
(P0.0009). When these clinicopathological factors were used as co-variables
for the multivariate analysis, LNM and DDR1 IHC expression were found to be
signifıcantly independent prognostic factors (LNM; P0.04, HR4.20, DDR1;
P0.03, HR4.27). Conclusion: DDR1 IHC expression was found to be useful
as a biomarker to predict long-term outcome.
#5929 A novel image cytometric analysis method for T-cell-mediated cy-
totoxicity of 3D tumor spheroids. Leo Li-Ying Chan,1 Laure Humbert,2 Scott
Cribbes1. 1NexcelomBioscience LLC, Lawrence,MA; 2Immunocore Limited, Lon-
don, United Kingdom.
Cell-mediated cytotoxicity assays have been frequently performed to charac-
terize cancer cytotoxic potential of immune cells, antibodies, and drug com-
pounds. Traditionally, these assays are performed using release assays such as
Cr51 (radioactivity), Calcein (fluorescence), or LDH (enzymatic). However, re-
lease assays have limitations such as the handling of hazardous material, the
indirect measurement of cell death leading to an under estimation of cytotoxic-
ity, the requirement for a large volume of cell sample, and the inability to visually
confırm, image ad track the assay kinetically. In the recent years, Celigo image
cytometry has been used to performhigh-throughput cell-mediated cytotoxicity
assays using a direct cell countingmethodwhere cancer cells (Target) are stained
with Calcein AM. Upon the addition of effector immune cells with the fluores-
cently stained Target cells in the presence or absence of antibody or drug com-
pounds, the Celigo image cytometer is used to capture bright-fıeld and fluores-
cent images and analyze the change in Target cell count over time to determine
the cytotoxicity percentage. In general, these assays are performed in a 2D cul-
tures. The 2D assays for cancer drug discovery have had some diffıculty in iden-
tifyingmore qualifıed drug candidates for clinical testing, thus there has been an
increase in interest of performing cytotoxicity assays in 3D tumor models. Tra-
ditional 3D spheroid analysis methods require the use of standard microscopy,
which is time-consuming and subjective. Celigo imaging cytometer has also
been used to rapidly analyze drug effects on 3D tumor spheroids. In this work,
we demonstrate a novelmethod of analyzing T cell-mediated cytotoxicity on 3D
tumor spheroids in the presence of absence of ImmTAC molecules, which can
promote higherT cell killing. In this experiment,MDA-MB-453GFP expressing
breast cancer cells are used to form tumor spheroids in an ultra-low attachment
plate. The spheroids are then treated with primary T cells at 1:10 and 1:50 E:T
ratios, as well as 10, 1, 0.1, 0.01, and 0.001 nM ImmTAC. The results showed a
dose response effect of T cell killing with the addition of ImmTACmolecules by
measuring spheroid size in GFP fluorescence and viability using propidium
iodide. The image cytometry method was able to monitor changes in spheroid
size and fluorescence over time and rapidly quantify T cell killing, which was as
high as 75%. The captured bright-fıeld and fluorescent images also clearly
showed the cytotoxicity effect from the combination of T cells and ImmTAC.
The ability to screen cytotoxic effects of immune cells, antibody, and drug com-
pounds on 3D tumor spheroids can provide an alternative tumor model for
identifying more qualifıed cancer drug candidates for drug discovery cam-
paigns.
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#5930 Osteoblasts protect AML cells from cytarabine-induced death. Ro-
salieM. Sterner, Kimberly N. Kremer, Amel Dudakovic, Jennifer J.Westendorf,
Andre J. van Wijnen, Karen E. Hedin.Mayo Clinic, Rochester, MN.
The hematological malignancy acute myeloid leukemia (AML) interacts
closely with osteoblasts within the protective bone marrow microenvironment.
The bone marrow microenvironment protects tumor cells from chemothera-
pies, which can prevent suffıcient eradication of tumor cells. To study the role of
osteoblasts in the bonemarrowmicroenvironment, our lab utilized a co-culture
model of osteoblasts (MC3T3 osteoblast cell line) and acute myelogenous leu-
kemia cells (KG1a AML cell line or AML patient samples from bone marrow
aspirates).Osteoblastswere culturedwithAMLcells, orAMLcells were cultured
alone; AML cells were challenged with the standard chemotherapeutic agent
cytarabine (Ara-C) at doses of 0M, 0.1M, 0.5M, 1M, 5M, or 10Min the
presence or absence of osteoblasts; and AML cells were assayed by flow cytom-
etry to assess cell death via annexin-V staining.Our lab has previously found that
differentiating osteoblasts protect AML cells from an apoptosis inducing agent
naturally present in the bone marrow. We now show that osteoblasts are also
capable of protecting AML cells from the standard chemotherapeutic cytara-
bine. In addition, we have found that treatment of osteoblasts with the histone
deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA) pre-
vents these treated osteoblasts from protecting AML cells from cytarabine treat-
ment, which is consistentwith our lab’s previous fındings thatHDACi treatment
inhibits protection of AML cells from an apoptosis inducing agent naturally
present in the bone marrow. We have preliminary data that indicates that
TAZS89A over-expression, a constitutively active form of TAZ, which is a tran-
scriptional modulator that regulates osteoblast differentiation, may be suffıcient
to inhibit osteoblast mediated protection of AML cells from cytarabine. This
fındingwould be consistentwith theHDACimanipulatedNherf1-protein phos-
phatase 1	-TAZ signaling pathway that we have previously found to be suffı-
cient to inhibit protection of AML cells from an apoptosis inducing agent nat-
urally present in the bonemarrow. Overall, these studies have delivered insights
into the role of osteoblasts in protecting AML cells from chemotherapy in the
bone marrow microenvironment and begun the characterization of mecha-
nisms and targets responsible for the protective effects of osteoblasts. Manipu-
lating differentiating osteoblasts within the bone marrow microenvironment
therapeutically could aid inmore complete destruction of the tumor cell burden
and improve patient survival.
#5931 Effect of necrosis on the migration, invasion and miRNA-mRNA
association in glioblastoma cells. So-Hee Ahn,1 Hyunju Park,1 Jeong Seon
Kim,2 Young-Ho Ahn,2 Sewha Kim,3 Min-Sun Cho,3 Jihee Lee Kang,1 Youn-
Hee Choi1. 1Department Physiology, Tissue Injury Defense Research Center,
EwhaWomans University School of Medicine, Seoul, Republic of Korea; 2Depart-
mentMolecularMedicine, Tissue InjuryDefense ResearchCenter, EwhaWomans
University School of Medicine, Seoul, Republic of Korea; 3Deparment of Pathol-
ogy, Ewha Womans University School of Medicine, Seoul, Republic of Korea.
Grade IV astrocytoma, also called glioblastoma multiforme (GBM), is con-
sidered the most malignant glial tumor. The purpose of our study is to under-
stand the molecular mechanisms underlying the signaling network between
necrotic tissues and GBM cells by exploring the effect of necrosis on GBM
migration, invasion and miRNA-mRNA association. The migration and inva-
sion of the CRT-MG human astroglioma cells were signifıcantly enhanced by
treatment with necrotic cells, as shown by assays for scratch wound healing and
spheroid invasion. Incubation with necrotic cells induced IL-8 secretion in
CRT-MG in dose-dependent manner. Immunohistochemical and immunoflu-
rorescence analysis for IL-8 in human GBM tissues showed that positively
stained cells were mainly distributed in perinecrotic region. Necrotic cells in-
duced NF-B and AP-1 activation and their DNA binding to IL-8 promoter,
leading to enhanced IL-8 production and secretion in GBM cells. To determine
the effect of necrosis on the miRNA profıles and regulatory relationship, the
expression profıles of miRNA and mRNA and association between mRNA and
their corresponding miRNAs were analyzed by next-generation sequencing
(NGS). Our results demonstrate that necrotic cells enhance the migration and
invasion of GBM cells throughNF-B/AP-1/IL-8 signaling pathway and induce
dysregulation of miRNA and mRNA expression profıles in GBM cells.
#5932 Targeting tumor acidity with the LDHA inhibitor (FX11) and
CAIX inhibitor (DH348) overcomes resistance toPD-1blockade and inhibits
metastasis in apancreatic cancermodel.ArigA. IbrahimHashim,1Dominique
Abrahams,1 Liping Xu,1 Barbra Centeno,1 Enakshi Sunassee,1 Rasha Abddel-
gader,1 Ludwig Dubois,2 Philippe Lambin,2 Robert A. Gatenby,1 Robert J. Gil-
lies1. 1Moffıtt Cancer Center, Tampa, FL; 2Maastricht UniversityMedical Center,
Maastricht, Netherlands.
Prior work by us and others has demonstrated that the extracellular pH
(pHe) of solid tumors is acidic, due to a combination of increased fermen-
tative metabolism, resulting in lactic acid production and poor perfusion.
This acidity promotes tumor progression and metastasis formation. Re-
cently we have shown in melanoma and pancreatic cancer models that acid-
ity inhibits antitumor immunity by preventing T-cell activation. Reversal of
acidity with buffer therapy (200mM NaHCO3) synergized with checkpoint
blockade (anti-CTLA4 and anti-PD1) and adoptive T-cell therapy has re-
sulted in cures. While this is promising, concerns are high regarding the
ingestion of such large amounts of sodium bicarbonate, whichmakes clinical
translation a challenge. Hence, we hypothesize that alternative pharmaco-
logical interventions can neutralize the pHe of tumors and remove this im-
munosuppressive effect. To study this we fırst investigated a series of agents
for their ability to inhibit metastasis in the PC3 prostate cancer model, which
is exquisitely sensitive to inhibition with buffer therapy. In this study, male
SCID mice were grouped in to 6 groups (n5) and treated with tap water,
200 mM bicarbonate ad lib, 30 mg/kg daily (q.d.) intraperitoneal (i.p.) Ac-
etazolamide (CA inhibitor), 1.2 mg/kg q.d.i.p. Furosemide (diuretic), 10
mg/kg q.d.i.p. DH348 (selective CAIX inhibitor) or 2.1 mg/kg q.d.i.p. FX-11
(LDHA inhibitor). Mice were intravenously injected with 5*10^6 PC3M-luc
cells and ventral bioluminescence images were acquired at time 0 and weekly
thereafter. Our results showed that FX-11, acetazolamide, DH348 and bicar-
bonate were able to effectively (p0.004) suppress metastasis formation in
this system, whereas furosemide was not. Based on these results, a subse-
quent study investigated the combination of bicarbonate, FX-11 or DH348
with immune checkpoint blockade in a Panc02 mouse model of pancreatic
cancer. Animals were inoculated orthotopically with Panc02 cells and ran-
domized into 8 groups (n10). Once tumors reached 0.3 cc in size, mice
were treated with either 15 mg/kg anti-PD-1 antibody or normal rat IgG
controls twice weekly alone or in combination with bicarbonate; FX-11 or
DH348 and tumor response was evaluated using US 3D-Mode imaging and
volume analysis (FUJIFILM VisualSonics) and histopathology. Anti-PD-1
antibody was ineffective as a monotherapy in this system. Both bicarbonate
and DH348 neutralized tumor acidity and reduced tumor growth as mono-
therapies. Notably, despite the fact that FX-11 was shown to inhibit LDH-A
in pancreatic cancer models, it did not affect pH and had no effect on tumor
growth as monotherapy. However, FX-11 signifıcantly reduced tumor
growth (p 0.01) and metastasis formation in combination with anti-PD-1
antibody, suggesting that inhibition of LDH-A might be effective in combi-
nation with checkpoint blockade.
#5933 Cancer-associated fıbroblasts (CAFs) release exosomalmicroRNAs
that dictate an aggressive phenotype in breast cancer. Gerolama Condorelli,1
Elvira Donnarumma,1 Danilo Fiore,1 Martina Nappa,1 Giuseppina Roscigno,1
Assunta Adamo,1 Margherita Iaboni,1 Valentina Russo,1 Alessandra Affınito,1
Cristina Quintavalle,2 Anna Rienzo,3 Salvatore Piscuoglio,2 Renato Thomas4.
1Univ. of Naples Federico II, Naples, Italy; 2University Hospital Basel, Basel, Swit-
zerland; 3IEOS, CNR, Naples, Italy; 4Clinica Mediterranea, Naples, Italy.
Cancer-associated fıbroblasts (CAFs), the major components of the tumor
microenvironment may drive tumor progression. Exosomes mediate hori-
zontal transfer of miRs, mRNAs and proteins, thus affecting breast cancer
progression. Differential expression profıle analysis identifıed three miRs
increased in exosomes from CAFs as compared from normal fıbroblasts.
Immunofluorescence indicated that exosomes may be transferred from
CAFs to breast cancer cells, releasing their cargo miRs. Breast cancer cells
exposed to CAF exosomes or transfected with those miRs exhibited a signif-
icant increased capacity to form mammospheres, increased stem cell and
epithelial-mesenchymal transition (EMT) markers, and anchorage-inde-
pendent cell growth. These effects were reverted by transfection with anti-
miRs. Similarly to CAF exosomes, normal fıbroblast exosomes transfected
with CAFs-miRs promoted the stemness and EMT phenotype of breast can-
cer cells. Thus, we provided evidence of the role of CAF exosomes and their
miRs in the induction of the stemness and EMT phenotype in different breast
cancer cell lines.
#5934 Cancer-associated fıbroblasts contribute to tumor immunosup-
pression by regulating tumor-infıltrating lymphocytes. Takuya Kato, Ka-
zuhiro Noma, Hajime Kashima, Yuki Katsura, Hiroaki Sato, Takayuki Ni-
nomiya, Toshiaki Ohara, Yasuhiro Shirakawa, Toshiyoshi Fujiwara. Okayama
University, Okayama, Japan.
Background: As like rising of PD-1 antibody, targeting therapy to tumor
immunosuppression have been shown dramatic cure responses in mela-
noma and other malignancies. However there are still problems that the
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responders of those checkpoint inhibitors are limited. Recently, it is consid-
ered that tumor immunosuppression may be caused by not only cancer cells
but also tumor microenvironments (TME). Cancer-associated fıbroblasts
(CAFs) are one of the major components and have a central role for tumor
progression in TME. It has been hypothesized that they can also play an
essential role in tumor immunosuppression. In this study, we evaluated the
correlation between CAFs and tumor immunity system, especially tumor-
infıltrating lymphocytes (TILs) in clinical samples and further in vivo study.
Materials and methods: Total 140 cases of esophageal cancer were evaluated
for the presence of CAFs and TILs by immunohistochemistry (IHC). CAFs
were defıned as fıbroblasts expressing alpha smooth muscle actin. CD8
cytotoxic T lymphocytes and FoxP3 regulatory T cells were investigated as
TILs in each specimen’s intratumoral and peritumoral tissues. The outcome
was set as the correlation between CAFs and TILs, and Overall survival. In
vivo experiments, we used a mouse-derived cancer cell (colon26-Luc) and
mouse embryonic fıbroblasts (NIH/3T3). BALB/c or BALB/c-nu/nu mice
were inoculated with only cancer cells (control) or cancer cells with CAFs
(co-CAFs) into right flank to examine the immunosuppression affected by
CAFs. The proliferation was examined by in vivo imaging system. Result: In
clinical analysis, CD8 TILs and CAFs demonstrated strong relations,
which were signifıcantly “negative” correlation and showed moderate corre-
lation coeffıcient in intratumoral tissues (P0.001, r-0.416). In FoxP3
TILs, “positive” correlation was detected signifıcantly (P0.001, r0.484).
In terms of prognosis, high group of CD8 TILs had a good prognosis
signifıcantly (P0.001), whereas high group of FoxP3 TILs had a poor
prognosis signifıcantly (P0.001) in intratumoral tissues. However, there
was no difference of the correlation and the prognosis in peritumoral tissues.
In vivo experiments demonstrated that promoted ratio of tumor progression
by co-CAFs was more strongly demonstrated in BALB/c mice rather than
BALB/c-nu/nu mice, suggesting that the group co-CAFs showed inducing
immunosuppression in TME. IHC analysis of those tumors showed that
accumulation of CD8 TILs was decreased in tumors of co-CAFs as com-
pared with tumors of control. On the other hand, accumulation of FoxP3
TIL was increased, showing the same trends as clinical analysis. Conclusion:
Our results suggest that Both CD8 and FoxP3 TILs in intratumoral tis-
sues are independent prognostic factors, and CAFs have a signifıcant corre-
lation to those TILs. We consider that CAFs may affect tumor immunosup-
pression by regulating the migration of TILs.
#5935 Higher tumor mutation burden (TMB) is associated with the pres-
ence of DNA repair gene mutations, T-cell infıltration, and favorable sur-
vival outcome in ovarian carcinoma. Young Kwang Chae,1 William H. Bae,2
Sabina Murshudova,1 Jonathan F. Anker,1 Young Suk Kim,3 Mario J. Pineda,1
Wilberto Nieves-Neira,1 Daniela Matei,1 John R. Lurain,1 Shohreh Shahabi,1
Francis J. Giles1. 1Northwestern University, Chicago, IL; 2Yonsei University Col-
lege of Medicine, Seoul, Republic of Korea; 3Carnegie Mellon University, Pitts-
burgh, PA.
Immunotherapy is being explored as a promising therapeutic option in
ovarian cancer. However, little progress has beenmade in our understanding
of the immune cell landscape in the tumor microenvironment and its asso-
ciation with genomic features in ovarian cancer. The RNA-seq values of
immune “metagene” markers that are specifıc to each of 28 cell types (An-
gelova et al. 2015) from the TCGA database were analyzed to determine the
tumor infıltration by immune cells in 307 patient samples (185 sequenced)
with ovarian carcinoma. Tumor tissues were most frequently infıltrated by
all T cells (46.91%), activated CD4 T(19.87%) and activated CD8 T(16.94%)
cells. Activated CD8 T cells were signifıcantly co-infıltrated by NK56 bright,
effector memory CD4 T, activated CD4 T, myeloid dendritic cell (DC) and
plasmacytoid DC. The tumors with mutated homologous recombination
(HR) genes, including ATR, ATM, CHEK1, CHEK2, BRCA1, BRCA2, BAP1,
BARD1, FANCD2, FANCE, FANCC, FANCA, RAD50, RAD51, and PALB2,
demonstrated a signifıcant 1.36-fold increase in average mutation counts
compared to the wild-types (p 0.01). Mutations in mismatch repair genes
had no statistically signifıcant association with the average mutation counts.
Tumors with high mutation counts showed a signifıcantly increased infıltra-
tion by activated CD8 T cells and immature DCs (Table1, p  0.05). The
highest quartile in tumor mutation burden (TMB) was associated with a
signifıcant 16.7 months longer overall survival (OS) compared to the lowest
quartile (p  0.01). Our study demonstrated that higher TMB is associated
with the presence of DNA repair gene mutations, activated CD8 T cell infıl-
tration, and favorable survival outcome in ovarian carcinoma.
Fold change in the percent of patients with infıltration by each immune cell
High TMB Low TMB
Fold
change† p-value††
Immune
cell
subtypes*
Percent of
patients
with
infıltration
(%)
Percent of
patients
without
infıltration
(%)
Percent of
patients
with
infıltration
(%)
Percent of
patients
without
infıltration
(%)
iDC 3.24 47.57 0.00 49.19 NA 0.01
Th17 2.16 48.65 0.54 48.65 4.00 0.19
Immature B cells 3.24 47.57 1.08 48.11 3.03 0.16
Mast cells 2.70 48.11 1.08 48.11 2.50 0.27
Macrophages 3.78 47.03 1.62 47.57 2.36 0.21
Activated CD8 11.89 38.92 5.41 43.78 2.48 0.03
Effector Memory
CD4
5.41 45.41 2.70 46.49 2.05 0.20
mDC 3.78 47.03 2.16 47.03 1.75 0.38
Activated B cells 4.32 46.49 3.24 45.95 1.32 0.62
All B cells 5.41 45.41 4.32 44.86 1.24 0.67
All immune cells 31.35 19.46 27.57 21.62 1.26 0.43
All T cells 23.78 27.03 23.78 25.41 0.94 0.83
NK56 dim 2.16 48.65 2.16 47.03 0.97 0.96
Activated CD4 8.11 42.70 9.19 40.00 0.83 0.62
Th1 3.78 47.03 4.32 44.86 0.83 0.74
Treg 1.08 49.73 1.62 47.57 0.64 0.62
NKT 1.62 49.19 2.70 46.49 0.57 0.44
Central Memory
CD8
1.08 49.73 2.70 46.49 0.37 0.23
*Excluded cell types with 5 tumor infıltrations. iDC, immature dentric cells; mDC,
myeloid dendritic cells; NKT, NK T cells; Treg, regulatory T cells. †Fold change Propor-
tion of tumors infıltrated by immune cells among high TMB tumors / Proportion of tumors
infıltrated by immune cells among low TMB tumors. ††Chi-squared test
#5936 Comparisonof carbonic anhydrase and activity between triple-neg-
ative & luminal breast cancer cells. Zhijuan Chen, Mam Y. Mboge, Ching-
kuang Tu, LingbaoAi, CoyHeldermon, SusanC. Frost.Univ. of Florida, Gaines-
ville, FL.
Tumormicroenvironment substantially influences the process of tumorigen-
esis. Extracellular acidifıcation within the tumor microenvironment is an indi-
cator of an aggressive cancer and a marker for poor patient outcome. In solid
tumors, hypoxia leads to extracellular acidosis. Carbonic anhydrases (CA) are
thought to regulate intracellular and extracellular pH (pHi and pHe, respec-
tively). To explore the effect of CAs in breast cancer, we compared the expres-
sion and activity of twomembrane boundCAs, CAIX andCAXII, between triple
negative breast cancer cells (TNBCs) and luminal breast cancer cells (LBCs).We
chose fıve different TNBC and LBC lines. Our data show that, among the TNBC
lines, CAIX expression increased in three of the fıve lines: HBL100, SUM159,
and the new UFH-001 cells under hypoxic condition. UFH-001 cells also
showed strong constitutive expression. None of these TNBC lines expressed
CAXII or estrogen receptor (ER). In LBC lines, four of the fıve lines constitu-
tively expressed CAXII: T47D, MCF7, SKBR and SUM52 cells. CAXII expres-
sion was not hypoxia-dependent. Each of the fıve luminal lines expressed ER.
We also examinedCA expression in a tumor graftmodel. In tumors grown from
cells derived from TNBC patients, we observed CAIX expression in four of six
sample sets. In tumors derived from ER-positive LBC patients, all fıve expressed
CAXII.We also used the 18O exchangemethod to assess CA activity. TwoTNBC
lines: UFH-001 and HBL100 cells showed that CAIX activity increased in hy-
poxic conditions which was blocked by an impermeant sulfonamide CA inhib-
itor (N3500). In the luminal lines, we detected CAXII activity in T47D and
MCF7 cells that was also inhibited by N3500. Like CAXII protein expression in
these cells, CAXII activity was not affected by hypoxia. We also evaluated the
effect of pH on CA activity in TNBC and LBC lines. Both CAIX and CAXII
showed increased activity in response to reduced pH, which is expected in a
bicarbonate-based system. However, UFH-001 cells also exhibited a hypoxic-
dependent increase in CAIX activity which is associated with increased protein
expression. In conclusion, these observations demonstrate that CAIX expres-
sion is associated with the TNBC phenotype. Based on our activity data, we
would predict that CA activity in TNBC tumors will be sensitive to both hypoxia
(based on enhanced expression) and reduced pH. This change in activity may
serve to regulate pH in the tumor microenvironment favoring an aggressive
phenotype. On the other hand, LBC tumors, which are ER-positive, are only
associated with CAXII expression. In luminal cells, we expect that only pH and
not hypoxia will affect CAXII activity. This may, in part, explain the more pos-
itive prognosis in patients with CAXII expression.
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#5937 Obesity-induced destabilization of p16INK4A promotes the pro-
carcinogenic effects of breast stromal adipocytes through miR-141/miR-
146b-5p-dependent inhibition of leptin. Huda H. Alkhalaf,1 Abdelilah
Aboussekhra2. 1KACST, Riyadh, Saudi Arabia; 2KFSHRC, Riyadh, Saudi
Arabia.
Obesity, a disease linked to increased number of adipocytes in various tissues,
is increasingly recognized as a risk factor for the development of breast cancer.
However, the molecular basis of adipocyte-related breast carcinogenesis re-
mains elusive. In this study, we established and characterized normal stromal
adipocytes from post-plastic surgery of breast tissues from obese and lean
women.We have shown that adipocytes from obese women express low level of
the tumor suppressor p16 protein, have higher secretion of various adipokines
and higher invasion and migration capabilities as compared to adipocytes from
lean women. In addition, down-regulation of p16INK4A by shRNA in adipocytes
from lean women increased the expression/secretion levels of various adipo-
kines including leptin, activated breast adipocytes and enhanced their migra-
tion/invasion abilities. Consequently, media conditioned with p16-defıcient
adipocytes or adipocytes from obese women promote epithelial-to-mesenchy-
mal-transition in normal breast luminal cells in a leptin-dependent manner and
induced tumor growth in vivo. Indeed, p16INK4A suppresses Leptin at themRNA
level through miR-141 and miR-146b-5p, which inhibits Leptin expression
through a specifıc sequence at the Leptin 3=UTR. These results show the exis-
tence of active adipocytes in the mammary gland of obese women in absence of
breast cancer cells and provide the fırst indication that p16INK4A through target-
ing miR-141 and miR-146b-5p suppresses Leptin and its procarcinogenic ef-
fects. This indicates that p16 pathway has non-cell-autonomous tumor suppres-
sor function in breast stromal adipocytes.
#5938 In vivo targeting of laminin-411-1 integrin-Notch signaling path-
way using nanobioconjugate alters glioma microenvironment for effective
treatment. Julia Y. Ljubimova. Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Brain gliomas have been extensively characterized by genomic
and molecular marker analysis. These studies have underscored glioblastoma
multiforme (GBM)heterogeneity, whichmay underlie failure of even the newest
drugs to improve patient survival. For this reason, we turned to genetic modu-
lation of glioma microenvironment using a novel nanobioconjugate. Methods/
Results: Clinicalmaterial from107GBMpatientswas analyzed, and tumorswith
overexpression of “malignant” tumor vascular basement membrane laminin-
411 were found to have higher recurrence rate and shorter patient survival. In
92% of human GBM samples, overexpression of laminin-411 was associated
with high expression of cancer stem cell (CSC) markers. To examine the inter-
action mechanisms between GBM cells and their extracellular matrix microen-
vironment, blood-brain barrier (BBB) passing nanobioconjugates based on
poly(-L-malic acid) (PMLA) were synthesized that specifıcally inhibit 	4 and
1 chains of trimeric laminin-411. In vitro. Normal brain endothelial cells and
astrocytes had higher expression of 1 integrin, Notch-1, and Notch ligands
when seeded on “malignant” laminin-411 as compared with “normal” laminin-
421. All these markers were downregulated in two GBM cell lines treated with
antisense oligonucleotides against laminin 	4 and 1 chains, suggesting regu-
lation of Notch pathway by laminin-411 through integrin 1. In vivo. In GBM
xenograft mouse models increased expression of laminin-411 correlated with
overexpression of integrin 1 and Notch signaling pathway members. In two
mouse models with intracranial human LN229 and U87MG GBMs, treatment
with PMLA-based nanobioconjugate against tumor microenvironment protein
laminin-411 led to signifıcantly increased animal survival, associated with
marked suppression of laminin-411- 1 integrin-Dll4-Notch axis and CSC
markersCD133,Nestin, and c-Myc.Conclusion: BBB crossing andbrain tumor-
targeted nanodrug therapy using laminin-411 suppression provided a unique
tool to study mechanistic interactions between tumor microenvironment and
signaling pathways, and showed promise for effıcient GBM treatment affecting
both the bulk of tumor cells and CSC. Support: NIH grants U01 CA151815, R01
CA136841, R01 CA188743, R01 CA209921
#5939 Dissemination of breast cancer. Samata Kakkad, Mikayla Hanna,
Desmond Jacob, Balaji Krishnamachary, Zaver M. Bhujwalla. Johns Hopkins
University School of Medicine, Baltimore, MD.
Breast cancer is the second leading cause of death in US women. Despite
advances in early detection, diagnosis and treatment of breast cancer, metastasis
and tumor recurrence persist leading to continued morbidity and mortality.
Several breast cancer studies have highlighted the role of cyclooxygenase-2
(COX-2) and its interaction with the tumormicroenvironment (TME) in breast
cancer progression. The TME consists of stromal cells that include fıbroblasts,
macrophages, the extracellular matrix (ECM), and several secreted factors that
contribute to aggressiveness of the cancer and resistance to therapy. Increased
density of collagen 1 (Col1) fıbers, a major structural component of the ECM in
solid tumors, and their alignment in tumors frequently result in increased inva-
sion andmetastasis of cancer cells. To understand the role of COX-2 at the lung
metastatic site, and its relationship with Col1 fıbers, COX-2 overexpressing tri-
ple negative SUM-149 human breast cancer cells (SUM-149-COX-2) or empty
vector SUM-149 cells (EV) were injected through tail vein in SCID mice to
compare Col1 fıber patterns in metastatic lesions. We isolated the lungs, pro-
cessed the tissue, and imaged for Col1 fıber by second harmonic generation
microscopy on H&E stained sections. The number of cancer associated fıbro-
blasts (CAFs)were detected in adjacent sections by immunostaining for	-SMA.
COX-2 overexpression did not increase the size of the cancer cell emboli in
blood vessels or the size of pulmonarymetastasis formed in the lungs. However,
COX-2 overexpression did signifıcantly increase the number of pulmonary me-
tastases. Signifıcantly higher Col1 fıber volume was observed in emboli com-
pared to pulmonary metastases independent of COX-2 overexpression. Inter-
estingly, the Col1 fıbers were signifıcantly more aligned in the COX-2
overexpressing pulmonary metastases compared to COX-2 overexpressing and
EV emboli. TheCOX-2 overexpressing emboli had signifıcantly higher amounts
of CAFs detected by 	-SMA expression compared to the EV emboli and the EV
and COX-2 overexpressing pulmonary metastases. Pulmonary metastases from
COX-2 overexpressing cells were detected further away from the nearest blood
vessel compared to the metastases from EV cells suggesting that COX-2 may
facilitate the formation of distant metastases. These data provide new insights
into the role of COX-2, Col1 fıbers, and CAFs in enabling emboli to extravasate
to form pulmonary metastatic foci. These insights are important as COX-2 up-
regulation during treatment may potentiate metastasis. This work was sup-
ported by NIH R01 CA82337.
#5940 TheHU177 collagen neo-epitope regulates nuclear YAP accumula-
tion and melanoma tumor growth and metastasis in vivo. Xianghua Han,
Jennifer M. Caron, Peter C. Brooks.Maine Medical Center, Scarborough, ME.
The extracellular matrix (ECM) plays a central role in controlling cellular
behavior and integrin receptors play key roles in this process. Signifıcant molec-
ular insight is available on how structurally intact forms of collagen regulate
integrin-signaling, however unique collagen neo-epitopes can be generated dur-
ing tumor development and these neo-epitopesmay differentially bind to integ-
rin receptors. These fındings raise an interesting question as to whether signal-
ing initiated by collagen neo-epitopes as compared to intact collagen,
differentiallymodify the fınal signaling out-put. Integrin A10B1 is a receptor for
the HU177 collagen neo-epitope, however, little is known about the down
stream signaling events stimulated by this receptor-ligand interaction. We pro-
vide evidence that melanoma cell interaction with denatured collagen results in
enhanced adhesion and migration. Talin is a molecule that facilitates integrin-
associated linkages to the cytoskeleton and helps govern adhesive cellular pro-
cesses. Melanoma cell interactions with denatured as compared to intact colla-
gen, resulted in enhanced Talin phosphorylation and surprisingly increased the
levels of Cyclin Dependent Kinase 5 (CDK5), a molecule implicated in Talin
phosphorylation and motility. Melanoma cell interactions with denatured col-
lagen also led to elevated nuclear accumulation of the Yes-associated protein
YAP. Given these results, we examined the effects of anti-HU177 antibody on
adhesion and migration. Targeting the HU177 neo-epitope inhibited cell adhe-
sion andmigration on denatured collagen and also inhibited YAP nuclear accu-
mulation. Knocking down YAP in melanoma cells resulted in the generation of
cells that were resistant to the inhibitory effects of anti-HU177 antibody, sug-
gesting that part of the inhibitory activity of anti-HU177 antibody may be asso-
ciated with its ability to alter YAP activity. We next examined the role of the
HU177 neo-epitope and its receptor, A10B1, on melanoma tumor growth and
metastasis. Targeting theHU177 neo-epitope inhibited tumor-angiogenesis, ac-
cumulation of ASMA positive stromal cells in melanomas and tumor growth in
vivo. Importantly, knock down of A10B1, or direct targeting of the HU177
neo-epitope inhibited experimental metastasis of melanoma cells. Taken to-
gether, these studies provide new insight into the role of the HU177 collagen
neo-epitope in melanoma tumor growth and metastasis and provide a novel
strategy to inhibitmelanoma progression through selective targeting of a A10B1
ligand, rather than the integrin itself.
#5941 Integrin signaling modulation demonstrates potential therapeutic
strategy in bladder cancer using three-dimensional organoid culture.
LaMont Barlow, Rebecca Meyer, Ethan Shelkey, Bishoy Faltas, Mark Rubin.
Weill Cornell Medical Center, New York, NY.
Introduction: Integrin signaling plays an important role in cellular prolifera-
tion and migration via interactions with extracellular matrix proteins. Prior
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studies indicate that integrin signaling facilitates tumor invasion andmetastasis,
and there are several ongoing clinical trials using agents that modulate this
pathway.We recently identifıed clonal enrichment inmissensemutations in the
integrin cell surface interactions pathways in advanced chemotherapy-resistant
urothelial carcinoma. An ideal strategy for investigating integrin signaling is via
3D organoid culture, maintaining intercellular interactions that replicate the
epithelial microenvironment. We hypothesize that pharmacologic integrin sig-
naling modulation will impair organoid growth in human bladder cancer cells
and demonstrate a potential therapeutic utility for this approach.Methods: RT4
human bladder cancer cell line was used as well as a second cell line established
from a patient-derived bladder cancer sample (PM748). Cells were grown in 3D
organoid culture as previously described. For in vitro integrin modulation, de-
factinib (VS-6063), an orally-bioavailable selective inhibitor of focal adhesion
kinase (FAK, a convergent and conserved enzyme activated by integrin ligand
binding), was used. SDS-PAGE and immunoblottingwere performed to show in
vitro FAK inhibition. Single-cell suspensions and formed organoids were plated
in the presence of various concentrations of defactinib to determine the impact
on organoid formation and regression. Results: Both RT4 and PM748 bladder
cancer cell lines demonstrated consistent organoid growth in three-dimensional
culturing conditions. Addition of defactinib to cultured cells showed a dose-
dependent decrease in autophosphorylation of FAK for both cell lines, demon-
strating effective FAK inhibition. 3D culture of single cells in the presence of
defactinib produced a dose-dependent decrease in organoid size after 96 hours
(mean size for DMSO only, 100nM, 1uM, and 10uMwere 128um, 75um, 48um,
and 26um, respectively; p0.0001 versus DMSO for all dilutions). Established
bladder cancer organoids showed a dose-dependent regression in size after 72
hours of defactinib exposure (mean size for DMSO, 100nM, 1uM, and 10uM
were 225um, 96um, 70um, and 34um, respectively; p0.0001 versus DMSO).
Experiments utilizing Crispr-Cas9-mediated FAK knock-out as well as in vivo
studies with FAK inhibitors inmouse xenograft models are currently underway.
Conclusions: Integrin modulation via FAK inhibition with defactinib causes
both inhibition of organoid formation aswell as regression of formed organoids,
and the effects are seen at concentrations well below the cytotoxic range for the
drug. This study suggests a utility for these agents in bladder cancer treatment.
#5942 Collagen proly-hydroxylase regulates breast cancer progression
and chemoresistance.Gaofeng Xiong, Ren Xu.Univ. of Kentucky Markey Can-
cer Ctr., Lexington, KY.
Collagen prolyl hydroxylation (P4H), an enzyme hydroxylating proline resi-
dues in -X-Pro-Gly- sequences, is a potential therapeutic target for the disorders
associated with increased collagen deposition. Upregulation of collagen prolyl-
4-hydroxylase in cancer cells is required for breast cancer promotion. P4HA1
mRNA levels were signifıcantly upregulated in triple-negative breast cancer
(TNBC) compared to other cancer subtypes. Increased mRNA levels of P4HA1
correlated with poor clinical outcome in breast cancer patients. Silencing
P4HA1 expression or treatment with the P4HA inhibitor signifıcantly inhibited
cell proliferation and suppressed aggressive phenotypes of breast cancer cells in
3D culture, accompanied by reduced deposition of collagen. We found that
activation of the P4HA1 in TNBC cells enhanced cancer cell stemness. We also
found that knockdown of P4HA1 inhibited mammary tumor growth and me-
tastasis to lungs in xenograft models. Inhibition of P4HA1 activity with the P4H
inhibitor sensitized TNBC to the docetaxel treatment in the patient-derived
organoid (PDO) and xenograft models. Therefore, these results suggest the cru-
cial role of P4HA1 in breast cancer progression and that targeting collagen P4H
is a promising strategy to inhibit tumor progression and to sensitize TNBC to
chemotherapy.
#5943 Role of tissue stiffness and oxygen tension in promoting breast
cancer stem cells. Mei-Fong Pang,1 Derek C. Radisky,2 Celeste M. Nelson1.
1Princeton Univ., Princeton, NJ; 2Mayo Clinic Cancer Center, Jacksonville, FL.
Breast tumors are stiff and hypoxic. Nevertheless, it remains unclear how stiff
and hypoxic conditions within the tumor microenvironment promote breast
cancer progression. Using an innovative engineered culture model to recapitu-
late these features, we found that, under stiff and hypoxic conditions, breast
cancer cells have enhanced integrin-linked kinase (ILK) expression and acquire
cancer stem cell (CSC)-like traits, suggesting tissue stiffness and oxygen tension
can modulate ILK expression to induce breast CSC formation. Knocking down
ILK impairs themechanosensing of invasive breast cancer cells on stiffmicroen-
vironments, inhibits CSC markers and properties. In contrast, ectopic expres-
sion of ILK promotes breast CSC formation. In addition to promoting CSC-like
phenotype, microarray analysis reveals that stiff and hypoxic microenviron-
ments also regulate genes involved in mRNA processing, splicing and the spli-
ceosome. These data suggest that the non-cellular compartment of the tumor
microenvironment, namely tissue mechanics and oxygen tension, can promote
breast cancer progression by controlling mechanotransduction and post-tran-
scriptional regulation of breast cancer cells.
#5944 Matrilysin/MMP-7 compromises a novel border interaction be-
tween perlecan/HSPG2 and semaphorin 3A to support prostate cancer inva-
sion. Brian J. Grindel,1 Daniel A. Harrington,2 Leland Chung,3Mary C. Farach-
Carson2. 1Rice University, Houston, TX; 2University of Texas Health Science
Center at Houston School of Dentistry, Houston, TX; 3Cedars-Sinai, Los Angeles,
CA.
Prostate cancer (PCa) cells interact with the stroma and extracellular matrix
(ECM) during tumor expansion and invasion during metastasis. Dissecting the
complex matrix-cancer interplay is essential to halting tumor progression. A
vital component of the ECM is perlecan/heparan sulfate proteoglycan 2
(HSPG2). As a large extracellular proteoglycan, perlecan helps orchestrate tu-
mor angiogenesis, proliferation, differentiation and invasion. Actively metasta-
sizing cancer cells must proteolytically degrade several tissue borders which
perlecan patrols, including the basement membrane, vasculature, reactive stro-
mal matrix and bonemarrow. Investigating the effects of perlecan onmetastatic
PCa cells showed full length perlecan and specifıcally conserved domain IV of
perlecan triggers clustering of PCa cells. Perlecan cleavage by the pro-tumor
protease matrilysin/matrix metalloproteinase (MMP-7) reverses this, favoring
cell dispersion and tumor dyscohesion. Network analysis of a reverse phase
protein array and subsequent western blots revealed clustered cells on intact
perlecan/Dm IV induced a strong focal adhesion kinase (FAK) dephosphoryla-
tion/deactivation. Alternatively, FAK was highly phosphorylated/activated on
MMP-7 cleaved perlecan/Dm IV consistent with an adhesive and dispersive/
metastatic phenotype. Several lines of evidence indicate Dm IV interacts with
the classically known axon guidance protein semaphorin 3A (Sema3A), to shut
off pro-metastatic FAK activation. Notably, a C-terminus directed Sema3A an-
tibody mimics the clustering activity of Dm IV. We showed Dm IV binds to
Sema3A in ELISA and quartz crystal microbalance experiments and the inter-
action is abrogated by the Sema3A antibody. Interestingly, Sema3A also is sen-
sitive toMMP-7 proteolytic activity. Finally, transient knockdown of Sema3A in
PCa cells inhibits the clustering effect by a Dm IV substrate. This work shows
that perlecan is an effective bordermolecule because it coordinateswith Sema3A
to repulse and cluster cells by switching off FAK activity. However, PCa cells
expressing active MMPs, such as MMP-7, can destroy this Sema3A/perlecan
complex to develop an invasive, metastatic phenotype associated with lethal
disease.
#5945 CRISPR-Cas9 dissection of heparan sulfate. Ryan J. Weiss, Philipp
N. Spahn, Nathan E. Lewis, Jeffrey D. Esko. University of California, San Diego,
La Jolla, CA.
Heparan sulfate proteoglycans (HSPGs) are expressed on virtually all an-
imal cells and play important roles in tumor growth and metastasis. Each
HSPG consists of a core protein with one or more covalently attached linear
heparan sulfate (HS) chains composed of alternating glucosamine and
uronic acids that are heterogeneously N- and O-sulfated. These complex cell
surface carbohydrates regulate important biological processes including cell
proliferation and development through their interaction with a large num-
ber of matrix proteins and growth factors. The arrangement and orientation
of the sulfated sugar residues of HS specify the location of distinct ligand
binding sites on the cell surface, and these modifıcations can vary temporally
during development and spatially across tissues. Previous studies have
shown that HSPGs can modulate tumor growth kinetics and are abundantly
expressed on the cell surface of many types of cancer. Additionally, geneti-
cally reducing the sulfation of HS has been shown to selectively inhibit tumor
angiogenesis and lymph node metastasis. While most of the enzymes in-
volved in HS biosynthesis have been studied extensively, much less informa-
tion exists regarding the specifıc mechanisms that give rise to the variable
composition and binding properties of HS. The overall goal of this project is
to uncover and characterize novel genes whose expression influences HS-
mediated regulatory networks in tumor growth and metastasis. A genome-
wide CRISPR/Cas9-mediated screen was developed to uncover and charac-
terize novel genes other than those encoding known HS biosynthetic
enzymes. A lentiviral single guide RNA (sgRNA) library was utilized to
knock down gene expression across the entire genome in a humanmalignant
melanoma cell line. Subsequently, a high-throughput screening assay was
adapted to identify lentiviral-encoded sgRNAs that induce resistance to cy-
totoxins whose action depends on HSPGs. Parallel screens using alternative
HS-dependent toxins or plant lectins that cause cytotoxicity dependent on
other types of glycosylation were performed in order to sort genes that se-
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lectively affect HS biosynthesis. From the toxin screens, we identifıed previ-
ously studied genes essential for HS formation and factors involved in the
intoxication of cells by diphtheria toxin, an HS-dependent exotoxin. Fur-
thermore, we uncovered potential candidate genes whose function is un-
known relative to HS biosynthesis. Top hits from the screens were charac-
terized and categorized based on their predicted gene functions and are
currently being individually validated and examined for their potential in-
volvement in the regulation of HS biosynthesis. Overall, these studies will
provide a better understanding of the genetic regulatory factors involved in
HS biogenesis. Additionally, the factors we identify could reveal novel tar-
gets for anti-cancer therapies, as well as lead us to methods to manipulate HS
and its activities in other cellular processes that go awry in human diseases.
REGULATORY SCIENCE AND POLICY: Recent Trends in
Regulatory Science
#5946 Universal consent for biospecimens: a novel electronic/video con-
sent. Arash Naeim,1 Neil Wenger,1 Antonia Petruse,1 Liliana Sanchez,1 Azita
Sharif,2 Sarah Dry1. 1David Geffen UCLA School of Medicine, CA; 2Daedalus
Software, Inc., MA.
Background: Developing innovative, effıcient and institutionally scalable
bio-specimen consent for remnant tissue that meets the NIH consent guide-
lines for genomic and molecular analysis is essential for precision medicine
efforts in cancer. Solutions in this arena need to satisfy the needs of patients,
researchers, ethicists, IRB and compliance leadership, while fıtting as seam-
lessly as possible into existing clinical workflows. Methods: UCLA developed
a video-application kiosk-based approach for providing universal consent to
repurpose clinical remnant bio-specimen for research. The process was de-
signed to be self-service, comprehensive yet fast (mean shorter than 5minute
for completion). The consent additionally asked the patient if they were
willing to be contacted directly for future research projects. This approach
was piloted with 474 patients who were coming in for routine services in
laboratory medicine, radiology, oncology, and hospital admissions. Of the
pilot population, 175 individuals had targeted surveys to evaluate drivers for
opting-in or opting-out of the consent for allowing the collection and use of
their remnant tissue for research. The cognitive survey was online and pre-
sented immediately after the consent process was completed. Results: The
opt-in rate for the pilot was 90.7%, and 56% agreed to direct contact for
future research. Only 7% needed help navigating the online consent process.
Of the subgroup of pilot population who completed the targeted survey,
there was no difference between individuals who opted in and out regarding
ease of use, of the consent application with about 75% stating it provided
mostly or very useful information, 90% stating it was mostly or very easy to
understand, and 85% stating they trusted the information. However, there
were signifıcant differences between those that opted-in and opted-out in
their beliefs concerning usefulness of tissue, trusting researchers, impor-
tance of contributing to science and privacy risk with those opting in
strongly supporting these beliefs (90%) compared to those that opted out
(40%), p0.001. Conclusions: Video-application approach for allowing
individuals to consent for remnant specimens to be collected and used for
research, including cancer research, can be effıcient, patient-centric and
meet the NIH requirements. This method could increase the availability of
blood and tissue for cancer research and should be tested for scalability as an
enterprise solution.
#5947 TheNCI Best Practices for Biospecimen Resources: 2016 revised rec-
ommendations. Abhi Rao, Jim Vaught, Ping Guan, Carol Weil, Helen M.
Moore. NIH, Bethesda, MD.
Improved biospecimenhandling practices are increasingly important for can-
cer research as advanced molecular analysis becomes routine in clinical trials
and more frequently available in standard of care medicine. Biospecimens and
associated clinical data collected in a consistent, established fashion can greatly
facilitate cancer biomarker validation and development and validation of clini-
cal diagnostic assays. In order to establish a set of guidelines to improve the
quality of biospecimen-related research, theNCI’s Biorepositories andBiospeci-
men Research Branch developed the NCI Best Practices for Biospecimen Re-
sourceswhich includes technical recommendations on biospecimen handling as
well as ethical and regulatory best practices. The 3rd, 2016 revised version of
these Best Practices focused onupdating technical and operational best practices
with recommendations based on more recent research, guidance and standards
for collecting, processing and storing biospecimens; revised informatics best
practices; and updated ethical, legal and policy sections describing new devel-
opments on return of research results, informed consent for genomics research,
data sharing, and community engagement. These Best Practices aim to help
patients by improving the reproducibility of cancer research data. The NCI Best
Practices are also foundational to the NIH PrecisionMedicine Initiative, part of
which aims to establish the world’s largest research biobank that will support
studies that utilize biospecimens from a cohort of one million individuals in the
United States.
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Mechanisms Regulating Immune Checkpoint Therapies
#NG01 Evolution of neoantigen landscape during immune checkpoint blockade in
non-small cell lung cancer. Valsamo Anagnostou, Kellie N. Smith, Patrick M. Forde,
Noushin Niknafs, Rohit Bhattacharya, James White, Vilmos Adleff, Jillian Phallen, Neha
Wali, Carolyn Hruban, Violeta B. Guthrie, Kristen Rodgers, Jarushka Naidoo, Hyunseok
Kang, William Sharfman, Christos Georgiades, Franco Verde, Peter Illei, Qing Ka Li,
Edward Gabrielson, Malcolm Brock, Cynthia Zahnow, Stephen B. Baylin, Rob Scharpf,
Julie R. Brahmer, Rachel Karchin, Drew M. Pardoll, Victor E. Velculescu. Sidney Kimmel
Comprehensive Cancer Center, Baltimore, MD.
Tumor cells contain nonsynonymous somatic mutations that alter the amino acid
sequences of the proteins encoded by the affected genes. Those alterations are foreign
to the immune system and may therefore represent tumor-specific neoantigens capable
of inducing antitumor immune responses. Somatic mutational and neoantigen density
has recently been shown to correlate with long-term benefit from immune checkpoint
blockade in non-small cell lung cancer (NSCLC) and melanoma, suggesting that a
high density of neoepitopes stemming from somatic mutations may enhance clinical
benefit from blockade of immune checkpoints that unleash endogenous responses to
these mutation-associated neoantigens (MANAs). Expression of the programmed cell
death ligand 1 (PD-L1) in tumors or tumor-infiltrating immune cells has been
associated with responses to PD-1 blockade; however, PD-L1 expression or other
immune biomarkers have not been sufficient to fully explain therapeutic outcomes.
Among the patients that initially respond to PD-1 blockade, some become resistant to
the therapy. Up-regulation of alternate immune checkpoints, loss of HLA haplotypes,
or somatic mutations in HLA or JAK1/JAK2 genes have been proposed as mecha-
nisms of evasion to immune recognition in some patients, but the mechanisms
underlying response and acquired resistance to immune checkpoint blockade have
remained elusive. To examine mechanisms of resistance to immunotherapy, we
performed genome-wide sequence analysis of protein coding genes and T-cell recep-
tor (TCR) clonotype analysis, followed by functional assays of autologous T-cell
activation of patients who demonstrated initial response to immune checkpoint
blockade but ultimately developed progressive disease.Of a cohort of 42 NSCLC
patients treated with single-agent PD-1 or combined PD-1 and CTLA4 blockade, we
identified all consecutive cases that at the time of the analysis developed acquired
resistance (two subjects treated with nivolumab and two with ipilimumab and niv-
olumab) and where paired tumor specimens were available both before and after
therapy. To examine the landscape of genomic alterations and associated neoantigens,
we performed whole exome sequencing of tumors from these patients. Pretreatment
and postprogression specimens were obtained from the same anatomic location or
from sites in close anatomic proximity. We examined multiple immune-related
parameters of peptides stemming from somatic alterations using a computational
multidimensional neoantigen prediction platform. This approach allowed for identi-
fication of peptides within mutated genes that were predicted to be processed and
presented by MHC class I proteins and therefore had the potential to elicit an immune
response. The algorithm evaluated the binding of mutant peptides (8-11mers) to
patient-specific HLA class I alleles and ranked the neoantigens according to MHC
binding affinity, antigen processing, and self-similarity.
Analyses of matched pretreatment and resistant tumors identified genomic changes
resulting in loss of 7 to 18 putative mutation-associated neoantigens in resistant
clones. While algorithm-based predictions of antigenicity are valuable in narrowing
down the large number of peptides capable of being generated by a mutation to a set
potential antigenic peptides presented by self-MHC alleles, functional T cell recog-
nition is critical to evaluate immune responsiveness. To this end, we developed a
sensitive approach for assessing T-cell response to candidate MANAs (cMANAs) that
utilized next-generation sequencing of TCR-Vb CDR3 regions as a measure of T-cell
clonality. To evaluate T-cell recognition of eliminated neoantigens, purified periph-
eral blood T cells from the patients described above were stimulated with autologous
peripheral blood mononuclear cells (PBMCs) loaded with cMANA peptides in a
ten-day culture system. We subsequently used TCR next-generation sequencing to
assess the differential abundance of neoantigen-specific T cell clonotypes in these
expanded T cell populations. In order to further investigate the importance of
eliminated MANAs, we generated peptides from retained and gained MANAs and
assessed their potential to elicit a MANA-specific T-cell expansion. Peptides gener-
ated from the eliminated neoantigens elicited clonal T-cell expansion in autologous
T-cell cultures, suggesting that they generated functional immune responses. These
findings indicate that patient-derived T cells recognized the eliminated neoantigens
and suggest that these neoantigens were relevant targets for the achievement of initial
therapeutic response to checkpoint blockade. Conceptually, neoantigen loss occurs
through elimination of tumor subclones or through deletion of chromosomal regions
containing truncal alterations. To evaluate the contribution of these mechanisms to the
loss of neoantigens, we analyzed the tumors both before and after therapy using the
SCHISM pipeline and incorporating mutation frequency, tumor purity, and copy
number variation to infer the fraction of cells containing a specific mutation (mutation
cellularity). Consistent with our hypothesis, we observed both mechanisms of neo-
antigen elimination: loss of truncal changes through genetic events involving chro-
mosomal deletions and loss of heterozygosity (LOH) and loss of subclonal neoanti-
gens either by LOH or through elimination of tumor subclones. Both truncal and
subclonal changes were among the eliminated neoantigens that were functionally
validated.
To evaluate the impact of changes in neoantigen landscape on cytotoxic T-cell receptor
repertoire, we analyzed serially collected PBMCs, prior to immunotherapy initiation, at
clinical response, and at resistance. We hypothesized that loss of neoantigens would lead
to a decrease in clonality of cytotoxic TCR clonotypes, thus reflecting tumor immune
evasion at the time of emergence of resistance. We observed peripheral T-cell expansion
of a subset of the top 100 most frequent intratumoral clones, with the most frequent clones
reaching up to a 44-fold increase in abundance in the blood at the time of response,
followed by a decrease to pretreatment levels at the time of resistance. As a comparison,
such decreases in TCR frequencies were not observed in a NSCLC patient with durable
response to PD-1 blockade and no change in intratumoral TCR frequencies was seen in a
NSCLC patient with primary resistance to PD-1 blockade. Taken together, these obser-
vations suggest that TCR expansion may be both a useful measure of response to
checkpoint blockade and an indicator of acquired therapeutic resistance through neoan-
tigen loss.
As immune checkpoint therapy has become standard of care for many cancer types, the
development of acquired resistance is being recognized more commonly. Through our
comprehensive genomic analyses, we have identified changes in the genomic landscape of
tumors during immune checkpoint blockade. These analyses show that emergence of
acquired resistance is associated with loss of mutations encoding for putative tumor-
specific neoantigens, through both elimination of tumor subclones and chromosomal loss
of truncal alterations. Using a new approach to assess neoantigen reactivity by T cells, we
found that some of these eliminated mutations indeed encoded peptides recognized by T
cells in the peripheral circulation of the respective patients. Given that the antitumor
efficacy of checkpoint blockade likely involves release of endogenous T-cell responses to
tumor antigens generated by coding mutations, our findings are consistent with a mech-
anism of acquired resistance to immune checkpoint blockade that involves therapy-
induced immune editing of MANAs.
Acquisition of somatic resistance mutations is a common mechanism of therapeutic
resistance to targeted therapies. However, elimination of genomic alterations and
more specifically loss of somatic mutations through subsequent genetic events is
uncommon in the context of natural tumor evolution or therapeutic resistance. Elim-
ination of mutation associated antigens by a T-cell-dependent immunoselection pro-
cess has been proposed as a mechanism of cancer immunoediting in melanoma after
adoptive T cell transfer; however, the evolution of neoantigen loss as an escape
mechanism under the selective pressure of immune checkpoint blockade in lung
cancer has not been previously studied. In addition, we examined a variety of other
mechanisms that have been proposed in the development of resistance to immuno-
therapies. We did not observe any differences in PD-L1 expression in tumor cells
between responsive and resistant tumor samples. Likewise, we evaluated known
potential genomic mechanisms of immunotherapy resistance; however, there were no
new genomic alterations in the CD274 gene encoding for PD-L1, PDCD1 encoding for
PD-1, CTLA4, JAK1 or JAK2 genes, in HLA genes, beta 2 microglobulin, or other
antigen presentation-associated genes.
This work demonstrates for the first time that acquired resistance to anti-PD-1 or
anti-PD1/anti-CTLA4 therapy in lung cancer can arise in association with the evolving
landscape of mutations, some of which encode tumor neoantigens recognizable by T cells.
These observations imply that widening the breadth of tumor neoantigen reactivity may
mitigate the development of acquired resistance.
The Effects of Tumor Microenvironment on Metastasis and
Therapy Resistance
#NG02 Lymphatic vessels: Balancing immune priming and immune evasion in
melanoma. Ryan S. Lane, Julia Femel, Jamie Booth, Christopher Loo, Nicholas Nelson,
Takahiro Tsujikawa, Guillaume Thibault, Amanda W. Lund. Oregon Health & Science
University, Portland, OR.
Lymphatic vessel remodeling and lymphangiogenesis is correlated with melanoma
progression and lymph node metastasis. While lymphatic vessels provide an important
route for disseminating tumor cells, they are also a crucial interface between a developing
malignancy and the host immune response. Rather than acting as passive conduits,
lymphatic vessels directly regulate their transport function and facilitate leukocyte traf-
ficking for efficient induction of adaptive immunity in downstream draining lymph nodes.
We recently published that in the absence of dermal lymphatic vessels, the tumor
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microenvironment of murine melanoma remains completely uninflamed and fails to
induce a robust T-cell response (1). Consistently, TCGA analysis of human cutaneous
metastatic melanoma identified positive correlations between LEC gene expression and
immune genes, including a T cell-inflamed signature, indicating a relationship between
lymphatic vessel remodeling and local immunity. Furthermore, others have recently
demonstrated that lymphatic vessel density (LVD) in combination with intratumoral T cell
function stratified best overall survival in nonmetastatic and metastatic colorectal cancer
(2). In contrast to this, however, many reports independently correlate peritumoral LVD
with lymph node metastasis and some poor prognosis (3). Furthermore, our previous work
demonstrated that vascular endothelial growth factor C (VEGFC)-driven lymphangiogen-
esis in the context of murine melanoma drove increased leukocyte infiltration but asso-
ciated with poor CD8 T cell priming in draining lymph nodes (4). We therefore
hypothesize that lymphatic vessels are (A) required for induction of adaptive immunity
but (B) acquire immunosuppressive activity as a function of the accumulation of local
cytotoxic immunity. Furthermore, we predict that LVD may be a relevant biomarker of in
situ immune responsiveness and response to therapy (5).
To test the first part of this hypothesis (A), we have continued our published work
and used a cutaneous model of viral infection to demonstrate the requirement for
lymphatic vessel drainage in cutaneous immunity. Following cutaneous vaccinia
infection we demonstrate that in the absence of lymphatic vessel transport, both
cellular and humoral adaptive immune responses fail to initiate, leading to enhanced
cutaneous immunopathology and persistent viral load. The complete absence of
primed CD8 and CD4 T cells in cutaneous tissue following challenge mirrors our
observations in melanoma and is consistent with correlations of intratumoral lympho-
cytes and LVD both by our group in cutaneous metastatic melanoma as well as by
others. This unequivocal requirement for a functional lymphatic vasculature in the
priming of cutaneous immunity further supports the prediction that LVD may be a
novel biomarker of immune reactivity within tumor parenchyma. To test this, we
simultaneously evaluated immune and vascular components in human primary mel-
anoma samples using a multiplex-immunohistochemistry-based approach. Tissue re-
gions that include tumor/stroma borders and show high CD8 T-cell infiltrates are
selected for analysis, followed by tissue segmentation, and automated detection of cell
populations within intratumoral regions and bordering stroma. Interestingly, those
tumors with enhanced hematopoietic infiltrate (CD68 and CD8) also appear to
demonstrate increased vasculature, both blood (CD31 and CD34) and lymphatic
(D2-40 and Prox1). Preliminary data demonstrate that lymphatic vessels, blood
vessels, and CD8 T cells are significantly enriched at the tumor-stroma border in
primary melanoma and positively correlate with one another, indicating that lymphatic
vessels may be a dynamic component of the “T cell-inflamed” microenvironment.
While we demonstrate that lymphatic vessels are necessary for immune induction,
we further hypothesized (B) that in the context of an ongoing immune response
lymphatic vessels adapt their function to promote immune resolution. The adaptive
resistance hypothesis proposes that upon accumulation of local cytotoxic immunity,
both tumors as well as stromal components adapt and acquire therapeutically relevant
immunosuppressive function. We demonstrate that peripheral, tumor-associated lym-
phatic endothelial cells (LEC; CD45-CD31gp38) acquire expression of immuno-
regulatory proteins, most notably programmed death receptor ligand-1 (PD-L1) and
major histocompatibility complex II (MHCII), coincident with CD8 T-cell infiltra-
tion in an interferon gamma (IFNg)-dependent manner. Adoptive transfer of activated
CD8 T cells induced higher expression of PD-L1 by LECs in B16 F10 tumors, while
neutralization of IFNg reduced levels to that of naïve skin. Furthermore, conditional
knockout of the IFNgR (Lyve1-Cre) prevented upregulation of PD-L1 on tumor-
associated LECs. Notably, lymph node LECs constitutively express PD-L1 and this
expression contributes to the attenuation of self-reactive CD8 T-cell responses (6).
Importantly, in the absence of IFNgR on peripheral LECs we observed significantly
enhanced accumulation of antigen-specific CD8 T cells in cutaneous tissue. Thus,
cutaneous lymphatic vessels, while necessary for immune induction, acquire immu-
nodulatory properties in a context-dependent manner and may participate in immune
evasion within tumor microenvironments.
In conclusion, our work across multiple model systems provides strong experimental
evidence to indicate that the lymphatic vasculature is an important, active component of the
antitumor immune response and may represent a biomarker to stratify patient response and
survival for effective clinical immunotherapy. These data indicate a need to revisit the passive
paradigm of lymphatic vessel involvement in tumor progression and metastasis to a more
active model whereby lymphatic vessels are both required for antitumor immunity but
functionally evolve in response to accumulating cytotoxicity to drive immune evasion.
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Recent Advances in Prevention Research
Diet and Precision Medicine in Cancer Prevention: The Role of
Genetic Background, the Microbiome, and Epigenetic Mechanisms
#NG03 Marine Omega-3 polyunsaturated fatty acid and colorectal cancer preven-
tion and treatment. Mingyang Song,1 Kana Wu,2 Shuji Ogino,3 Jeffrey A. Meyerhardt,4
Charles S. Fuchs, Wendy Garrett, Edward L. Giovannucci, Andrew T. Chan. 1Massachu-
setts General Hospital, Harvard Medical School, Boston, MA; 2Harvard T.H. Chan
School of Public Health, Boston, MA; 3Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA; 4Dana-Farber Cancer Institute, Harvard Medical School, Boston,
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Background: Lifestyle factors are important determinants for the development and
progression of colorectal cancer (CRC) (1). An estimated 50-60% of new CRC cases and
deaths in the U.S. could be potentially prevented through modification of lifestyle,
including diet (2). Fish oil, a rich source of marine omega-3 polyunsaturated fatty acid
(MO3PUFA), is one of the most popular natural dietary supplements used by U.S. adults
(3). MO3PUFA has potent anti-inflammatory activity, and substantial experimental data
support its beneficial effect for CRC prevention and treatment (4). However, the relevance
of these findings to human cancer has been largely unknown. I have led a series of studies
linking MO3PUFA to CRC, leveraging data from two large prospective cohort studies, the
Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) that
have provided detailed information on lifestyle and diet in relation to CRC.
Study setting: The NHS cohort enrolled 121,701 female nurses aged 30-55 years in
1976, and the HPFS cohort enrolled 51,529 men aged 40-75 years in 1986. In both studies,
we have followed up participants through a biennial questionnaire to collect their updated
lifestyle and medical information. We have also collected dietary data every 4 years
through the food frequency questionnaire, which has been validated for MO3PUFA
assessment. CRC diagnoses are first self-reported by participants on the questionnaires
and then confirmed through review of medical records. We also retrieve formalin-fixed
paraffin embedded (FFPE) tissue blocks from hospitals where participants undergo
surgical resection. We identify deaths through family members or the postal system in
response to the follow-up questionnaires as well as by search of the National Death Index.
Study physicians confirm the cause of death from death certificates or review of medical
records. Taken together, the two cohorts provide an ideal setting for studying the
relationship of long-term MO3PUFA intake with CRC, due to the large sample size,
prospective design with more than 20 years of follow-up, repeated dietary assessments
using validated instruments, and detailed data on additional cancer risk factors. Moreover,
by integrating the rich epidemiologic data with the tumor molecular features characterized
in the FFPE tissue, I am able to study how MO3PUFA is associated with specific subtypes
of CRC arising from distinct mechanisms.
Main findings: In our first study (5), we showed that the relationship between
MO3PUFA and CRC risk differed according to anatomic subsite of the tumor. While
MO3PUFA intake was not associated with incidence of distal colon cancer, a nonsignif-
icant protective association was found for proximal colon cancer and rectal cancer.
Moreover, we found that high MO3PUFA intake assessed 12-16 years before diagnosis
tended to be associated with lower CRC risk, suggesting that MO3PUFA may start
exerting its protective effect at an early stage of CRC development. These findings
provided thus far the most comprehensive data about the MO3PUFA-CRC relationship.
Given the large variation of genetic and epigenetic alterations in cancers along anatomic
subsite, we further examined whether the differential association of MO3PUFA observed
in proximal versus distal colon tumors was attributable to differences in tumor molecular
features. Through molecular pathologic assessment of tumor specimens, we classified
cases into distinct subtypes according to common CRC molecular characteristics. By
linking MO3PUFA intake to these CRC subtypes (6), we found that high MO3PUFA
intake was primarily associated with lower risk of microsatellite instable (MSI) tumors, a
CRC subtype arising from defective DNA mismatch repair mechanisms with predomi-
nance in the proximal colon, whereas no association was found for microsatellite-stable
(MSS) tumors. These findings are consistent with experimental data supporting the
involvement of inflammation in MSI development (7,8), and generate novel hypotheses
for the potential anticancer activity of MO3PUFA.
Considering the long-recognized role of MO3PUFA in the immune system and the
close link between immune dysregulation and MSI, we further assessed whether the
variation in tumor immune infiltrates might contribute to the preferential benefit of
MO3PUFA for MSI tumors (9). We first quantified the density of CD3, CD8,
CD45RO, and FOXP3 T cells in the tumor microarrays by immunohistochemistry and
Ariol image analysis system. We then classified CRC cases into subtypes with low-level
versus high-level infiltrate of each of the T-cell markers, and tested whether the associ-
ation of MO3PUFA intake with CRC risk differed according to T-cell densities in tumor
tissues. We found that the beneficial associations of high MO3PUFA intake with CRC
appeared confined to tumors with high infiltrate of FOXP3 T cells. Although FOXP3
T cells were more enriched in MSI tumors, the inverse association of MO3PUFA with
FOXP3 T-cell-high tumors was independent of the MSI status, suggesting that MSI may
be a surrogate marker for tumors with high FOXP3 T-cell infiltration. FOXP3 is a
prerequisite transcription factor for T regulatory (Treg) cells, which have potent immu-
nosuppressive activity and may facilitate tumor evasion by suppressing T effector cell-
mediated antitumor immune surveillance (10). Therefore, it is possible that MO3PUFA
may protect against development of CRC, especially those with MSI, by ameliorating
Treg-mediated immune suppression and unleashing antitumor immunity. Indeed, this
hypothesis is supported by our functional experiment, in which MO3PUFA decreased the
T-cell suppressive activity of intestinal FOXP3 Treg cells (9).
Invited Abstracts
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 2017 1519
Given the increasing data linking the tumor immune response to cancer prognosis, I led
further studies assessing the relationship of MO3PUFA intake with CRC survival. We
found that patients with high MO3PUFA intake after CRC diagnosis had a significantly
longer survival than those with low intake 11), suggesting that MO3PUFA may exert a
beneficial effect across the continuum of colorectal carcinogenesis. We have recently
validated these findings in the cohort of CALGB 89803 (Van Blarigan EL et al.,
manuscript in preparation).
Future plan: Based on this work, I now propose to better understand the intricate
relationship between MO3PUFA, immune response, and CRC through the develop-
ment of an independent research program. First, given the increasing data supporting
a pivotal role of gut microbes in integrating dietary cues with host immunity and
potentially mediating the anticancer effect of MO3PUFAs, I have proposed to study
how MO3PUFAs modulate the gut microbial composition and function, thereby
shaping the gut immune response and suppressing CRC. The findings from this study
will provide translational insights into novel dietary and microbial strategies for CRC
prevention. Second, to better understand the immunomodulatory effect of MO3PUFA
in the tumor microenvironment, I plan to characterize the MO3PUFA-asssociated
tumor immune signature and study whether MO3PUFA improves CRC survival by
ameliorating the immunosuppressive microenvironment. Because the immunosup-
pressive mechanisms have been implicated in the development of resistance to
powerful cancer immunotherapeutic agents, our findings may open new avenues for
incorporating natural products into existing cancer immunotherapy paradigms for
optimized clinical benefit. In both these areas, I will take an integrated approach that
combines the power of population science and clinical research to establish causality
and facilitate clinical translation. This approach will also provide a foundation for my
research program as I transition into independence.
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Major Symposia
Mechanisms of Primary and Acquired Resistance to
Immunotherapy
#NG04 Mechanisms of resistance to anti-PD-1 immunotherapy through interferon
pathway mutations. Jesse Zaretsky, Angel Garcia-Diaz, Daniel S. Shin, Helena Escuin-
Ordinas, Willy Hugo, Siwen Hu-Lieskovan, Zeynep Eroglu, Davis Y. Torrejon, Paul C.
Tumeh, Roger S. Lo, Antoni Ribas. University of California at Los Angeles, Los Angeles,
CA.
Checkpoint blockade immunotherapy can produce dramatic, durable tumor regression, is
now being deployed or tested in a growing list of cancer types, and has received FDA approval
for the treatment of metastatic melanoma, Hodgkin’s lymphoma, and lung, renal, and head and
neck carcinomas. Depending on cancer type, higher CD8 infiltration, PD-L1 expression, and
mutational load have all been reported as positive prognostic factors for response. We studied
response to antiprogrammed cell death 1 (PD-1) or PD-1 ligand (PD-L1) therapy in a cohort
of 55 patients from centers in the US and Australia with advanced desmoplastic melanoma (a
rare subtype, less than 4% of patients). Our analyses further highlight the relationship between
clinical benefit from immune checkpoint blockade therapy and higher mutational load and
PD-L1 expression. Objective tumor responses were noted in 39 patients (71%), with most
being long lasting. Our analyses reveal that baseline tumor biopsies have significantly higher
tumor parenchymal PD-L1 expression than nondesmoplastic skin melanomas that is highly
correlated with CD8 T-cell infiltration in the invasive margins, reflective of adaptive
immune resistance as a result of active antitumor immune process. Desmoplastic melanoma
has a known relationship to ultraviolet light radiation damage, resulting in one of the highest
mutational burdens among all cancer types. Whole-exome sequencing in this cohort confirms
this finding, with a median of 1315 somatic nonsynonymous mutations per tumor, as
compared with a median of 485 mutations per tumor in nondesmoplastic melanomas (P 
0.01).
However, accumulating data from cutaneous melanoma suggest that primary and
secondary resistance to therapy remains a major challenge. Recent pooled data from 655
patients on a clinical trial of the antiprogrammed death 1 (PD-1) therapy antibody
pembrolizumab reported that 60% of patients with metastatic melanoma had no re-
sponse to therapy (primary resistance), while 25% of those with initial objective tumor
regression had progressed as much as two years later despite continuous therapy (sec-
ondary or acquired resistance). Potential mechanisms of resistance conceptually stratify
into either T-cell dysfunction (lack of recognition, trafficking, intrinsic exhaustion, or
extrinsic suppression) or tumor-based escape (loss of antigen presentation, resistance to
killing, or upregulation of suppressive factors).
We have recently reported two genetic mechanisms of acquired resistance to
anti-PD-1 therapy (1). In this study, we analyzed melanoma cases with late acquired
resistance after strong initial response to anti-PD1 therapy, with the hypothesis that
changes from baseline would be mechanistically meaningful in this setting, particu-
larly with respect to immune function or mutations acquired by surviving clones. To
investigate this, we performed whole exome sequencing and immunohistochemistry
on four cases with paired pre/postrelapse tumor samples, followed by in vitro
modeling with primary tumor cell lines.
First, we studied the local immune environment at relapse to rule out a lack of
tumor-specific T-cell effectors. Immunohistochemistry revealed that CD8 T cells were
present in baseline tumors, and remained present at relapse in large numbers around the
tumor margins. This is a pattern that our lab and others have shown would otherwise be
predictive of response to PD1 therapy. Futher studies using targeted sequencing of the
T-cell receptor population in biopsies from the four reported cases showed that the top
T-cell clones at baseline or during active response were detected at similar frequencies in
the relapsing tumors, indicating that the local T-cell repertoire had not changed. Addi-
tionally, clones that significantly increased in frequency in the peripheral blood during
active response were highly enriched among the top clones in the relapsing tumor.
Together, these data indicate the T cells present at relapse are likely the same tumor-
specific clones that mediated the original response. Multiplexed immunofluorescence
showed that stromal cells in the tumor microenvironment at progression were strongly
positive for PD-L1 expression in areas of high T-cell density. PD-L1 is often upregulated
in response to the interferon gamma produced by activated T cells, raising the possibility
that these T cells were currently or had recently been active.
With evidence that T cells were still present and possibly active in the resistant lesions,
we investigated relapse-specific changes within the tumors themselves by whole exome
sequencing. We identified new homozygous loss-of-function mutations in the interferon
receptor pathway-associated kinases in the relapse biopsies of two separate cases (JAK1
Q503* and JAK2 F547_splice-site). In addition to the clinical radiographic evidence of
relapse in situ, we found strong genetic evidence that the progressing lesions were directly
derived from the baseline lesions by clonal selection and outgrowth. Despite up to two
years between biopsies, the resistant tumor shared 92% of nonsynonymous mutations
originally identified at baseline. The relapsing tumors also contained the same initial
chromosomal loss-of-heterozygosity (LOH) pattern as baseline, and the JAK mutations
become homozygous as part of additional LOH events. Neither JAK mutation was
detected pretherapy, either in the exome sequencing reads or by targeted amplicon
resequencing, suggesting these represent a de novo mutation or extremely rare preexisting
clone.
While the JAK kinases are known to associate with growth factor, cytokine, and interferon
receptors, in the context of immune resistance we focused on their role in interferon sensitivity.
Interferons cause phosphorylation of the STAT transcription factors, and upregulate expres-
sion of chemokines, antigen presentation machinery, and PD-L1. In vitro western blot, RNA
(Nanostring), and flow cytometry studies using primary cell lines derived from pre- and
postprogression biopsies from the JAK2 mutated case showed that the JAK2 mutated cells
were entirely insensitive to interferon gamma. Other melanoma cell lines with JAK1 or JAK2
deleted by CRISPR-Cas9 approach produced similar results. We also found the JAK mutant
cell lines to be resistant to interferon-gamma induced growth inhibition, while the baseline and
JAK wild-type cell lines remained sensitive. Notably, the JAK2 mutant cell lines were still
sensitive to growth inhibition by interferon-alpha/beta or a STING agonist (all of which are
JAK2-independent), showing the lack of growth arrest was specific to interferon gamma
resistance and not a generalized phenomenon.
In a third case, we also identified a new truncating mutation in the antigen presentation
gene beta-2 microglobulin (B2M), which led to loss of surface expression of major
histocompatibility complex (MHC) class I. This mechanism has been previously impli-
cated in immune escape. Since the publication of this work we have gathered seven
additional biopsies of late secondary progression from patients with advanced melanoma
(four of them with a paired baseline) in order to assess the frequency of acquired genetic
mutations in the interferon gamma and antigen presentation pathways, as well as define
other potential mechanisms.
Our studies of primary resistance to anti-PD-1 therapy provide further support that loss
of function mutations in JAK1 or JAK2 are of high relevance for resistance to antipro-
grammed death protein 1 (PD-1) therapy. Immune selection may lead to similar mutations
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in previously untreated patients, which would result in lack of adaptive PD-L1 response
by cancer cells to a T-cell infiltrate, and result in primary resistance to anti-PD-1 therapy.
Whole-exome sequencing of metastatic melanoma biopsies from 23 patients treated with
the anti-PD1 revealed a JAK1 missense mutation with chromosomal amplification in the
tumor from a nonresponding patient who otherwise had the highest mutational load in the
cohort. Similarly, among 16 patients with mismatch repair deficient colon cancer treated
with PD-1 blockade, we again found a homozygous JAK1 loss-of-function mutation in the
tumor of a nonresponding patient. Analysis of genomic and proteomic data from the
TCGA suggests that JAK1/2 loss-of-function alterations confer adverse outcomes in
patients, which may result from an immune-editing process. Therefore, we propose that
JAK1/2 loss-of-function mutations are positively selected for by immune-editing pro-
cesses, leading to primary as well as secondary resistance to PD-1 blockade therapy.
The relevance of genetic alterations in the interferon gamma receptor pathway is
highlighted by the results published by another group (2). In their study, knockdown of the
interferon gamma receptor in a mouse model of melanoma showed impaired tumor
rejection in response to anti-CTLA4 therapy, and they identified increased frequency of
mutations in interferon-related genes in patients who failed to respond to the anti-CTLA-4
antibody ipilimumab. While the final frequency of interferon signaling or B2M defects
and their contribution to primary versus secondary resistance remains to be seen, cata-
loguing these and other mechanisms will be important for determining who will benefit
from immunotherapy and designing rational next-generation drug combinations to im-
prove outcomes with these therapies.
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Dysregulation of MicroRNAs Leads to Target Therapy
#NG05 TP53-mediated human cancer susceptibility is defined by epigenetic dys-
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Mutations in the TP53 tumor suppressor gene are the most common genetic aberrations
across all human cancers. Germline TP53 mutations are also the hallmark genetic event
in Li-Fraumeni syndrome (LFS), a highly penetrant human cancer susceptibility syn-
drome, conferring a predisposition to developing early-onset breast cancer, leukemias,
bone and soft tissue sarcomas, brain tumors of various histologies, adrenocortical carci-
nomas, and a wide range of other malignancies. Although the link between mutant TP53
and human cancer is unequivocal, the mechanism by which this genetic aberration
predisposes an individual to cancer remains to be elucidated.
To address this gap, we surveyed the epigenome and describe herein the largest
systematic analysis of DNA methylation in patients harboring germline TP53 mutations
and TP53 wild-type individuals. Specifically, we performed genome-wide methylation
analyses of peripheral blood leukocyte DNA in germline TP53 mutation carriers (n72)
and TP53 wild-type individuals who developed histologically comparable cancers
(n111). Targeted bisulfite pyrosequencing was performed on peripheral blood DNA in
a validation cohort (n76), and candidate sites were further evaluated in primary tumors
from LFS patients.
The differential methylation analysis demonstrates that in 183 patients, distinct DNA
methylation signatures are associated with deleterious TP53 mutations. TP53 mutation-
associated DNA methylation marks occur in genomic regions harboring known p53
binding sites and within genes encoding p53 pathway proteins. Moreover, loss-of-function
TP53 mutations are significantly associated with differential methylation at the locus
encoding miR-34A–a key component of the p53 regulatory network (adjusted
p-value3.1X10-15)–and validated in an independent patient cohort (n76, 1.9X10-8).
Targeted sequencing demonstrates that miR-34A is inactivated by hypermethylation
across many different histologic types of primary tumors from LFS patients, such as brain
tumors, osteosarcomas, rhabdomyosarcomas, and adrenocortical carcinomas. miR-34A
promoter hypermethylation in tumors is also associated with decreased overall survival in
a cohort of 29 patients with choroid plexus carcinomas, a characteristic LFS tumor
(p0.05). The relationship between miR-34A hypermethylation and TP53 mutation was
further validated in sporadic cancers, using the publicly available TCGA dataset. This
demonstrates the robustness of this correlation and the applicability of these findings to
other cancer contexts.
This study refines the role of epigenetics in a cancer predisposition syndrome and is the
first to implicate a microRNA, miR-34A, in human cancer susceptibility and provides a
repository of genomic regions of deregulated methylation in the context of dysfunctional
TP53. These findings suggest that deregulated DNA methylation at defined genomic loci
may be an important hallmark of TP53-mediated cancer susceptibility. The most striking
finding from this study is the relative miR-34A promoter hypomethylation at two adjacent
CpG sites in peripheral blood from TP53 mutation carriers, confirmed in two independent
cohorts and shown to cosegregate with TP53 mutations in LFS families. This result is
remarkable since miR-34A is a central microRNA in the p53 network and the first
microRNA identified as a direct proapoptotic target of the p53 pathway.
The detection of miR-34A promoter hypomethylation in TP53 mutant cells that have
not undergone malignant transformation supports a putative model whereby wild-type p53
may influence methylation patterns at this locus. In particular, in nontransformed cells that
do not harbor mutations in TP53, wild-type p53 may be recruited to the miR-34A locus
and sustain hypermethylation. We have performed a series of in vitro studies on primary
patient-derived lymphoblastoid cell lines to corroborate this model. Conversely, in the
setting of loss-of-function or deleterious mutations in TP53, mutant p53 may not able to
maintain hypermethylation of the miR-34A promoter, leading to upregulation of miR-
34A. Owing to the known redundant cellular roles of p53 and miR-34A, upregulation of
miR-34A may be beneficial to cells harboring mutant p53 by supplementing the necessary
basal tumor suppressive function that is lost when p53 is mutated. This mechanism may
serve to guard against mutant p53, even when the wild-type allele remains. Accordingly,
this may explain why miR-34A promoter hypermethylation is characteristic of TP53-
mutant tumors that lack wild-type p53 because this microRNA serves a critical role in cell
maintenance, and its loss may cooperate with other genetic and/or epigenetic events to
drive malignancy.
It is therefore not surprising that, akin to p53, somatic miR-34A deregulation is
pervasive in human cancer and miR-34A inactivation by focal deletion or promoter
hypermethylation has been reported in the literature to occur in a multitude of human
malignancies. The precise mechanisms of how the miR-34A promoter undergoes somatic
epimutation in tissues remains to be elucidated, and likely various pathways may converge
to yield this outcome in different tissues.
Given the high frequency of TP53 mutations in human malignancies, the relationship
between mutant p53 and miR-34A has strong implications for the targeting of miR-34A
in cancer. Encouragingly, studies have demonstrated in vivo the utility of miR-34A-based
therapies in cancer, including intratumor or systemic delivery of lipid-formulated syn-
thetic miR-34A.
To further probe these intriguing findings, we conducted mechanistic studies aimed at
functionally interrogating the the miR-34A-p53 axis. We utilized in vitro-based assays to
modulate miR-34A levels in primary patient-derived fibroblast cell lines, and subse-
quently performed by RNA-sequencing of the transcriptional responses. Our results
uncover a number of novel cellular roles for miR-34A in cell maintenance. Significantly,
the transcriptional response to miR-34A inhibition revealed that this microRNA may be
a crucial switch that can lead to numerous changes to noncoding RNA networks as well
as known p53 pathways. Markedly increased expression of key components of the U12
(minor) spliceosome occurs when miR-34A expression is diminished, thereby identifying
a novel putative role of miR-34A in modulating transcription of the U12 spliceosomal
machinery. The majority of TP53 mutation-associated transcripts are involved in chro-
matin remodeling and nucleosome assembly, and are enriched for histone cluster 1 genes.
These linker histones are crucial for maintaining higher-order chromatin structure and for
regulating gene expression, demonstrating the interplay between genetic and epigenetic
states. Lastly, miR-34A is associated with transcriptional regulation of a host of lin-
cRNAs, including LINC-PINT, a p53-induced lincRNA. These results are the first to
identify miR-34A as an important node in the transcriptional regulation of numerous
noncoding RNAs and point to further study of these pathways.
Taken together, these findings provide strong support for the impact of TP53 mutations
on epigenetic dysregulation in human cancer susceptibility and demonstrate that miR-34A
may be important in the pathogenesis of TP53-mediated cancer susceptibility. Moreover,
miR-34A may be a putative novel therapeutic target and a marker for clinical prognos-
tication. These studies also demonstrate that miR-34A is a central node in numerous
p53-dependent and independent networks and provide further insight into the role of this
critical tumor-suppressive microRNA. Further work aimed at refining our understanding
of miR-34A-mediated pathways may yield additional molecular insight into the role of
this microRNA in malignant transformation.
Recent Advances in Organ Site Research
Bladder Cancer
#NG06 Genomic dissection of the clonal evolution dynamics of chemotherapy-
resistant urothelial carcinoma. Bishoy M. Faltas,1 Davide Prandi,2 Scott T. Tagawa,1
Ana M. Molina,1 David M. Nanus,1 Cora Sternberg,3 Jonathan Rosenberg,4 Juan Miguel
Mosquera,1 Brian Robinson,1 Olivier Elemento,1 Andrea Sboner,1 Himisha Beltran,1
Francesca Demichelis,2 Mark A. Rubin1. 1Weill Cornell Medicine, New York, NY;
2University of Trento, Trento, Italy; 3San Camillo and Forlanini Hospitals, Rome, Italy;
4Memorial Sloan-Kettering Cancer Center, New York, NY.
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Introduction: Chemotherapy-resistant urothelial carcinoma (UC) has no uniformly
curative therapy. Understanding how selective pressure from chemotherapy directs UC’s
evolution and shapes its clonal architecture is a central biologic question with important
clinical implications.
Methods: To address this question, we performed whole-exome sequencing and clon-
ality analysis of 72 UCs including 16 matched sets of primary and advanced tumors
prospectively collected before and after chemotherapy.
Results: Our analysis provided several important insights. Our findings show that
chemotherapy-treated UC is characterized by significant intrapatient mutational het-
erogeneity. The majority of mutations were not shared. On average, only 28.4% (range
0.2%-76.4%) of mutations were shared between pre- and postchemotherapy samples.
This effect was consistent across primary-primary tumor pairs and primary-metastatic
tumor pairs (p0.17, Wilcoxon test). Surprisingly, even mutations in previously
reported driver genes, including PIK3CA, KMT2D (MLL2), ATM, and TP53, were
not consistently shared between matched prechemotherapy and postchemotherapy
tumors. We confirmed these findings with targeted sequencing of 250 common driver
genes achieving an average coverage of 400x and an excellent concordance with
variant allele frequencies obtained from whole exome sequencing (Pearson correla-
tion  0.93, P10-171). Phylogenetic analysis revealed that both branching evolution
and metastatic spread were very early events in the natural history of UC. At the copy
number level, our analysis revealed limited intrapatient heterogeneity with respect to
interpatient heterogeneity, suggesting that each patient’s cancer is relatively stable
during evolution at the copy number level. We discovered two distinct copy-number-
based clusters. Cluster A was defined by 9p21 (CDKN2A, CDKN2B, and MTAP)
deletions in the setting of euploid copy number background. Cluster B was charac-
terized by several enriched amplifications, including 1q21.1 (SETDB1 and MLLT11)
amplifications (P0.0002, Fisher’s exact test) and 6p22.3 (E2F3) amplifications
(P0.001, Fisher’s exact test). This cluster was also enriched with TP53 mutations
(P0.0001, Fisher’s exact test). We validated the presence of these clusters in the
TCGA dataset of untreated UC and confirmed that these copy-number alterations
predate chemotherapy and are clonally static during the lifetime of UC tumors. On the
other hand, the mutational landscape of UC tumors evolved significantly after che-
motherapy. We observed a significant increase in the number of clonal mutations in
the postchemotherapy samples across the study cohort (P0.0134, Fisher’s exact
test). Chemotherapy-treated UC was enriched with clonal mutations involving L1-cell
adhesion molecule (L1CAM) and integrin-signaling pathways. To understand the
mutational mechanisms driving the evolution of UC, we compared the patterns of
single base transitions between chemotherapy-naïve and chemotherapy-treated tu-
mors. We observed a significant increase in CA nucleotide substitutions in tumors
treated with cisplatin-based chemotherapy consistent with previously described spe-
cific mutagenesis signature induced in C. elegans genome after cisplatin treatment.
Further analysis of context motifs of various base substitutions showed enrichment in
C T or G changes at the TCW motifs (where W  A or T), which is highly
suggestive of APOBEC-induced mutagenesis. APOBEC induced-mutations were
clonally enriched in chemotherapy-treated UC and continued to shape UC’s evolution
throughout its lifetime.
Conclusions: Our findings have several potential clinical implications: First, genomic
divergence between untreated and treated clones suggests that clinically actionable mo-
lecular targets in metastatic chemotherapy-treated tumors will be potentially missed when
relying only on biopsies of untreated primary tumors at the time of diagnosis, and that
repeat metastatic biopsies during the course of clinical care would be needed to detect the
most recent version of the rapidly changing molecular landscape of a given patient’s UC.
Second, further study of the functional role of L1CAM and integrin signaling in mediating
chemotherapy resistance in UC could lead to a potential strategy for reversing or
preventing chemotherapy resistance by targeting these pathways. Third, despite its initial
effectiveness in eliminating cancer cells, platinum-based chemotherapy is associated with
unintended significant mutagenic editing of the genomic landscape of postchemotherapy
tumors. Our insight into the nature of these edits is crucial towards a complete under-
standing of the basis of chemotherapy resistance in advanced UC, which lays the
foundation for the development of rational therapeutic strategies for preventing the
emergence or reversing the chemotherapy-resistant state of UC. In summary, our results
demonstrate that advanced chemotherapy-treated UC undergoes extensive and dynamic
clonal evolution throughout the lifetime of the tumor with significant genetic editing that
continues during and after chemotherapy. Our findings lay the foundation for an evolu-
tionary understanding of advanced chemotherapy-treated UC and present opportunities for
advancing cancer precision medicine.
Drug Deveopment Sessions
New Drugs on the Horizon 1
#DDT01-01 The discovery and preclinical characterization of AMG 176: A first in
class Mcl-1 inhibitor in clinical development for multiple myeloma. Paul E. Hughes.
Amgen, Inc., Thousand Oaks, CA.
Mcl-1 is a prosurvival member of the Bcl-2 family of proteins, which regulate
programmed cell death via protein-protein interactions between prosurvival and
proapoptotic members of the family. A variety of studies have demonstrated that
Mcl-1 is a key prosurvival factor for many human cancers, making it a highly
desirable target for therapeutic intervention. However, targeting Mcl-1 to induce
tumor cell death has been an exceptional challenge for the development of drug-like
small molecule inhibitors due to the high-affinity interaction of Mcl-1 with proapo-
ptotic binding partners and the lack of an obvious small molecule binding pocket. In
this presentation we will describe the application of structural analysis and molecular
modeling to the optimization of an HTS screening hit that culminated in the identi-
fication of a clinical candidate, AMG 176. In addition, we will present data demon-
strating that AMG 176 is a potent, highly selective, and reversible Mcl-1 inhibitor.
Mechanism-of-action studies revealed that AMG 176 induces a rapid and irreversible
commitment to apoptosis in tumor cells via the disruption of protein-protein interac-
tions with proapoptotic members of the Bcl-2 family. Furthermore, the extensive
profiling of a large and diverse tumor cell line panel revealed that lines derived from
hematologic malignancies, such as multiple myeloma, acute myeloid leukemia, and
non-Hodgkin lymphoma, are particularly sensitive to Mcl-1 inhibition with the
expression of Bcl-xL inversely correlating with response. In addition, cell line
profiling data revealed an activity profile distinct from a selective Bcl-2 inhibitor,
further underscoring the unique therapeutic opportunity for an Mcl-1 inhibitor.
Synergistic combinations were identified with therapies selectively targeting Bcl-2,
the MAPK pathway, and proteasome inhibitors. In vivo, AMG 176 demonstrated
robust inhibition of tumor xenograft growth with a clear PK/PD relationship, exhib-
iting on-mechanism activity as measured by Bak and caspase activation on a discon-
tinuous dosing schedule of once or twice weekly. An ongoing phase 1 clinical trial is
currently evaluating AMG 176 in multiple myeloma.
#DDT01-02 AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for
treatment of hematologic cancers. Alexander W. Hird,1 J. Paul Secrist,1 Ammar Adam,1
Matthew A. Belmonte,1 Eric Gangl,1 Frank Gibbons,1 David Hargreaves,2 Jeffrey W.
Johannes,1 Stephen L. Kazmirski,1 Jason G. Kettle,2 Stephen E. Kurtz,3 Michelle L.
Lamb,1 Martin J. Packer,2 Bo Peng,1 Craig R. Stewart,4 Jeffrey W. Tyner,3 Wenzhan
Yang,1 Qing Ye,1 XiaoLan Zheng,1 Edwin A. Clark1. 1AstraZeneca, Waltham, MA;
2AstraZeneca, Cambridge, United Kingdom; 3Knight Cancer Institute, Portland, OR;
4AstraZeneca, Macclesfield, United Kingdom.
Mcl-1, a member of the Bcl/Mcl family, is a key protein involved in evasion of
apoptosis in a wide variety of tumors. Its amplification and overexpression have also been
implicated in innate and acquired resistance to anticancer drugs. Mcl-1 is capable of
preventing induction of apoptosis, both by binding and inactivating the pro-apoptotic
executioner Bcl-2 protein, Bak, as well as by sequestering other pro-apoptotic BH3-only
proteins such as Bim and Noxa. AZD5991 is a rationally designed macrocycle with
sub-nanomolar affinity for Mcl-1. It demonstrates all the hallmarks of a true Mcl-1
inhibitor: 1. potent, selective, and rapid apoptosis in Mcl-1-dependent cell lines (e.g., GI50
as low as 10 nM in multiple myeloma cell lines); 2. loss of activity upon overexpression
of Bcl-xL or siRNA-mediated knockout of Bak; 3. Mcl-1:Bak complex disruption as
demonstrated by co-immunoprecipitation. AZD5991 is active in vivo, with complete
(100%) tumor regression demonstrated in several mouse xenograft models after a single
tolerated dose. We have also demonstrated synergistic in vivo efficacy in combination
with standard-of-care agents. Analysis of ex vivo activity in primary samples from
leukemia patients indicates that a high percentage of leukemia patients should respond to
drug treatment, which supports our plan for a phase I trial of AZD5991 in patients with
hematologic cancers.
#DDT01-03 ABBV-621: A best-in-class TRAIL-receptor agonist fusion protein that
enhances optimal clustering for the treatment of solid and hematologic tumors. Susan
E. Morgan-Lappe. AbbVie, North Chicago, IL.
Tumor necrosis factor (TNF)–related apoptosis-inducing ligand (TRAIL) is a member
of the TNF superfamily of proteins that play diverse roles in the activation of several
intracellular signaling pathways that control cell proliferation, survival, and apoptosis.
Activation of the TRAIL pathway has been viewed as an attractive therapeutic approach
for the treatment of cancer because of its distinct role in the induction of tumor cell
apoptosis. TRAIL can bind as a trimer to membrane-bound or soluble receptors, and only
the two closely related cell surface death receptors TRAIL-R1 (DR4) and TRAIL-R2
(DR5) can preferentially trigger the extrinsic pathway of tumor cells, leading to apoptotic
cell death. The BCL-2 family member-driven mitochondrial apoptotic pathway can also
serve to amplify the extrinsic pathway through further downstream activation of caspases.
Given the crosstalk between the extrinsic and intrinsic cell death pathways, several
resistance mechanisms have emerged to escape TRAIL-induced apoptosis. These include
altered receptor regulation, overexpression of cellular FLICE-like inhibitory protein
(cFLIP) that inhibits the proapoptotic activity of the DISC, overexpression of the prosur-
vival BCL-2 family member proteins, and the inhibitor of apoptosis proteins (IAPs) that
directly inhibit caspases. In addition, TRAIL can induce non–cell death signaling path-
ways (e.g., NF-B, MAPK, PI3K) to promote tumor cell growth as a potential resistance
mechanism. Results of several clinical trials that targeted DR4 and DR5 with first-
generation agonistic anti-TRAIL antibodies or human recombinant TRAIL indicated that
these agents failed to demonstrate significant improvement in patient progression-free
survival compared to standard-of-care therapy. The major contributing factor in this lack
of clinical activity is believed to be the suboptimal TRAIL receptor clustering by these
agonists.
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ABBV-621 is a novel, second-generation TRAIL receptor agonist comprising a
human IgG1-Fc linked to native single-chain TRAIL-receptor binding domain (sc-
TRAIL-RBD) monomers that are covalently connected by glycosylated linkers, re-
sulting in two sets of trimeric RBDs. ABBV-621 is designed to maximize receptor
clustering but does not require Fc-R-mediated crosslinking for optimal in vivo
efficacy, which has been deemed an activity-limiting step for the competitor anti-DR4
and anti-DR5 antibodies in the clinic. In-house studies have demonstrated the require-
ment for enhanced caspase-8 aggregation into the death-inducing signaling complex
(DISC) to induce potent tumor cell death, providing mechanistic insights as to why
death receptor agonists originally failed and further distinguishing ABBV-621 from
the first-generation agents.
ABBV-621 induces dose-dependent apoptotic cell death at sub- to single-digit
nanomolar potencies across a large panel (100) of human hematologic and solid
tumor cell lines in vitro. ABBV-621 activity is on-target and mechanism-based as
demonstrated by a rapid activation of downstream apoptotic signaling events (cleav-
age of caspase-8, caspase-3, and PARP). In human tumor xenograft models, ABBV-
621 exhibits potent antitumor activity in vivo as a monotherapy and in combination
with targeted agents or chemotherapy using xenograft tumors derived from colorectal,
lung, leukemia, and lymphoma cell lines. This activity is on-target, mechanism-based,
and dose-dependent as indicated by rapid activation of tumor caspase-8 and caspase-3
after a single ascending dose of ABBV-621 in a colorectal carcinoma xenograft
model. ABBV-621 exhibits a dose-proportional pharmacokinetic (PK) profile in mice
and cynomolgus monkeys, and the projected human half-life is estimated to be 2
days. PK/pharmacodynamic (PD) assessments estimate that achieving exposure above
an efficacious concentration for 4-7 days is sufficient to maintain tumor regressions
up to 4-7 weeks.
Screens against 95 patient-derived xenograft (PDX) models consisting of 12 different
solid tumor types uncovered single-agent activity (regressions) in 50% of all PDXs
tested. PDX models can be more reflective of human disease by providing estimation of
effects of tumor heterogeneity on ABBV-621 activity. Models that were partially sensitive
or completely resistant to treatment were also identified, and collectively these responses
are being utilized with associated pre- and post-treatment genomic/proteomic information
to further inform potential patient stratification markers. To demonstrate on-target bio-
logic activity in the clinic, proximal and distal target engagement markers will be pursued.
In a GLP monkey toxicity study, ABBV-621 was well tolerated with no adverse test
item–related findings.
The first-in-human (FIH) phase 1/1b study with ABBV-621 will enroll subjects with
previously treated advanced solid tumors and hematologic malignancies. The phase 1
objectives will be to establish the safety and tolerability of ABBV-621, as well as to
understand the PK properties. Secondary objectives will be to explore target engagement
and efficacy biomarkers and to evaluate clinical activity.
#DDT01-04 Discovery and development of H3B-6545: A novel, oral, selective
estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer.
Peter G. Smith,1 Xiaoling Puyang,1 Craig Furman,1 Guo Zhu Zheng,1 Deepti Banka,1
Michael Thomas,1 Vanitha Subramanian,1 Sean Irwin,1 Nicholas Larsen,1 Benjamin
Caleb,1 Craig Karr,1 Jeremy Wu,1 Morgan O’Shea,1 Joyce Yang,1 Allison Davis,1 Amy
Kim,1 Nathalie Rioux,1 Victoria Rimkunas,1 Huilan Yao,1 Crystal MacKenzie,1 Pavan
Kumar,1 Sherri Smith,1 Sean Eckley,2 Andrew Hart,2 George Lai,2 Christopher Rowbot-
tom,2 Peter Fekkes,1 Silvia Buonamici,1 Dominic Reynolds,1 Lihua Yu,1 Tarek Sah-
moud,1 Markus Warmuth,1 Lorna Mitchell,1 Ping Zhu,1 Manav Korpal1. 1H3 Biomedicine
Inc., Cambridge MA; 2Eisai Inc., Andover, MA.
Mutations in the estrogen receptor (ER) are detected in up to 30% of patients that
initially respond but subsequently relaps to anti-endocrine therapies. ER mutations,
likely through constitutively activating ER, can functionally confer resistance to
existing classes of endocrine therapies. Current endocrine therapies are only partially
effective in the ER mutant setting and a significant proportion of endocrine-therapy
resistant breast cancer metastases continue to remain dependent on ER signaling for
growth/survival indicating a critical need to develop the next generation of ER
antagonists that can overcome ER wild-type and mutant activity. Here we describe
a novel series of compounds with a unique mode of inhibition that potently target both
wild-type and mutant ER. These compounds are Selective Estrogen Receptor Co-
valent Antagonists (SERCAs) that inactivate the estrogen receptor by targeting a
cysteine that is not present in other nuclear hormone receptors, leading to a unique
biological and activity profile differentiated from Selective Estrogen Receptor Mod-
ulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs). Using struc-
ture-based drug design approaches we have identified a first-in-class clinical candi-
date, H3B-6545. H3B-6545 is a highly selective small molecule that potently
antagonizes wild-type and mutant ER in biochemical and cell based assays. In vitro
comparisons with standard of care and other experimental agents confirm increased
cell potency of H3B-6545 under continuous as well as washout treatment conditions.
In vivo, once daily oral dosing of H3B-6545 shows potent activity and superior
efficacy to fulvestrant in the MCF-7 xenograft model with maximal antitumor activity
at doses 10x below the maximum tolerated dose in mice. In addition, H3B-6545
shows superior antitumor activity to tamoxifen and fulvestrant in patient derived
xenograft models of estrogen receptor positive breast cancer including models carry-
ing ER mutations In non-clinical safety studies in rat and monkeys, H3B-6545 is
well tolerated across a broad dose range and at exposures that significantly exceed
those required for efficacy in mouse xenograft models.
In summary, H3B-6545 is a first-in-class, orally available and potent selective estrogen
receptor covalent antagonist with a compelling pre-clinical efficacy and safety profile that
is being developed for the treatment of breast cancer.
New Drugs on the Horizon 2
#DDT02-01 Discovery of GDC-0077, a highly isoform selective inhibitor of PI3K
that promotes selective loss of mutant-p110. Steven T. Staben. Genentech, Inc,
Emerald Hills, CA.
PIK3CA, the gene that encodes for the p110 catalytic subunit of phosphatidylinositol-
3-kinase (PI3K), is frequently mutated in cancer, with activating and transforming
mutations of PIK3CA occurring in approximately 17% of cancers diagnosed annually.
The narrow therapeutic index of PI3K inhibitors evaluated in the clinic thus far may be
due to insufficient selectivity for PI3K isoform or mutant oncogenic driver. We report the
results of our efforts directed at improving efficacy and safety of a class of benzoxazepin
inhibitors of PI3K. A structure- , property- , and phenotype-guided strategy directed at
high PI3K-isoform and PIKK-family selectivity, as well as a distinct cellular mechanism
of action, culminated in the discovery of GDC-0077. Differences in primary and tertiary
structure among PI3K isoforms were leveraged to achieve 300-fold selective inhibition
of the PI3K isoform over the , , and  isoforms in biochemical assays. Very high
selectivity over PIKK-family proteins such as mTOR, DNA-PK and VPS34 was also
achieved through this process. In vitro and in vivo data indicate that GDC-0077 operates
by a mechanism that promotes the selective degradation of “hotspot” p110 mutants
(H1047R, E545K). Treatment of nude mice bearing PIK3CA-mutant breast tumor xeno-
grafts with oral GDC-0077 resulted in tumor regressions at well-tolerated doses. Together,
the high degree of isoform selectivity, selective degradation of mutant-p110, and in vivo
PK/efficacy support the clinical evaluation of GDC-0077 as a treatment for patients with
locally advanced or metastatic, PIK3CA-mutant cancer.
#DDT02-02 SGN-2FF: A novel small molecule inhibitor of fucosylation with pre-
clinical antitumor activity through multiple immune mechanisms. Stephen C. Alley,
Megan O’Meara, Shyra J. Gardai, Nicole M. Okeley. Seattle Genetics, Inc., Bothell, WA.
Increased fucosylation is associated with tumor progression and metastasis, and target-
ing fucosylation is a novel strategy in cancer therapy. 2-Fluorofucose (SGN-2FF) has been
shown to inhibit cellular fucosylation by depletion of the fucosylation substrate GDP-
fucose, as well as by direct inhibition of fucosyltransferases, leading to the production of
afucosylated glycoproteins including antibodies. SGN-2FF has antitumor activity in
multiple mouse tumor models, showing substantial tumor growth delay. SGN-2FF also
enhanced the protective effect of a lymphoma vaccine in a syngeneic mouse model (1).
This protection was determined to be immune dependent since depletion of CD4 and CD8
T cells reduced the SGN-2FF/vaccine activity. In vitro, SGN-2FF has been shown to
activate human T cells in an antigen-dependent manner. Therefore, by inhibiting fucosy-
lation SGN-2FF can potentially work through multiple mechanisms, including but not
limited to effects on immune cells, tumor cells, and the tumor microenvironment. A
first-in-human, phase 1, multicenter dose-escalation study of SGN-2FF is ongoing to
investigate the safety, pharmacokinetics, and antitumor activity of SGN-2FF given orally
to patients with advanced solid tumors (NCT# 02952989). Pharmacodynamic effects,
including markers of fucosylation status, will also be evaluated to help determine the
optimal biologic dose. This presentation reviews the preclinical activity data of SGN-2FF
and describes the design of the phase 1 study, showing how demonstrated preclinical
pharmacodynamic effects on fucosylation status informed how activity and pharmacody-
namics will be monitored and evaluated in the phase 1 study.
Reference
1. Okeley NM, Alley SC, Anderson ME, Boursalian TE, Burke PJ, Emmerton KM, et
al. Development of orally active inhibitors of protein and cellular fucosylation. Proc
Natl Acad Sci U S A 2013;110:5404-9.
#DDT02-04 A novel PRMT5 inhibitor with potent in vitro and in vivo activity in
preclinical lung cancer models. Dirk Brehmer,1 Tongfei Wu,1 Geert Mannens,1 Lijs
Beke,1 Petra Vinken,1 Dana Gaffney,2 Weimei Sun,2 Vineet Pande,1 Jan-Willem Thur-
ing,1 Hillary Millar,1 Italo Poggesi,1 Ivan Somers,1 An Boeckx,1 Marc Parade,1 Erika van
Heerde,1 Thomas Nys,1 Carol Yanovich,2 Barbara Herkert,1 Tinne Verhulst,1 Marc Du
Jardin,1 Lieven Meerpoel,1 Christopher Moy,2 Gaston Diels,1 Marcel Viellevoye,1 Wim
Schepens,1 Alain Poncelet,3 Joannes T. Linders,1 Edward C. Lawson,2 James P. Ed-
wards,4 Dushen Chetty,2 Sylvie Laquerre,2 Matthew V. Lorenzi2. 1Janssen R&D, Beerse,
Belgium; 2Janssen R&D, Springhouse, PA; 3Janssen R&D, Val de Reuil, France; 4Jans-
sen R&D, San Diego, CA.
PRMT5 is a type II methyltransferase that specifically adds methyl groups to arginine
as a long-lasting post-translational modification. The PRMT5/MEP50 complex regulates
a plethora of cellular processes, such as epigenetics and splicing, which are notable events
involved in tumorigenesis. Although not frequently mutated or amplified in tumors,
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elevated PRMT5 protein levels in lung and hematologic cancers are correlated with poorer
survival. The PRMT5 inhibitor JNJ-64619178 has been selected as a clinical candidate
based on its high selectivity and potency (subnanomolar range) under different in vitro and
cellular conditions, paired with favorable pharmacokinetics and safety properties. JNJ-
64619178 binds into the SAM binding pocket and reaches the substrate binding pocket to
inhibit PRMT5/MEP50 function in a time-dependent manner. Broad cell line panel
profiling of JNJ-64619178 revealed a wide range of sensitivity, which is indicative of a
genomic dependency instead of a general cytotoxic on-target consequence of PRMT5
inhibition. Further investigations indicate a synthetic lethal correlation between PRMT5
inhibition and key cancer driver pathways. JNJ-64619178, dosed orally (10 mg/kg, every
day), showed selective and efficient blockage of the methylation of SMD1/3 proteins,
which are crucial components of the spliceosome and substrates of PRMT5/MEP50.
JNJ-64619178 also demonstrated tumor regression in a biomarker-driven human small
cell lung cancer xenograft model (NCI-H1048) and prolonged tumor growth inhibition
after dosing cessation. In rodent and nonrodent toxicology studies, a tolerated dose of
JNJ-64619178 has been identified, with the observed toxicity consistent with on-target
activity. In summary, JNJ-64619178 has a favorable preclinical package that supports
clinical testing in patients diagnosed with lung cancer and hematologic malignancies.
Cancer Development and Outcomes Related to Tobacco Use
#SY01-03 Reducing harm by targeting the addictiveness of combusted tobacco
products through regulated reductions in nicotine content. Eric Donny. University of
Pittsburgh, Pittsburgh, PA.
Nicotine is the primary addictive constituent in cigarettes, driving chronic dependent
use in millions of Americans. Approximately half of those individuals will die as a result
of smoking unless they quit. One strategy for greatly reducing the harm caused by
smoking is to limit the nicotine content of cigarettes and other combusted tobacco
products to levels that are less addictive. This approach differs from so-called “light” and
“ultralight” cigarettes, which have nicotine content similar to full-flavored cigarettes; light
cigarettes reduce machine-measured nicotine yield as a consequence of ventilation, a
design feature that smokers can easily overcome (e.g., by inhaling larger volumes) to
maintain high levels of nicotine exposure. True regulated reductions in nicotine content
became possible in 2009 when the Family Smoking Prevention and Tobacco Control Act
gave the U.S. Food and Drug Administration (FDA) the authority to reduce (but not
eliminate) the nicotine in tobacco products. Consequently, the FDA and NIH are sup-
porting a large portfolio of research aimed at evaluating the potential public health impact
of product standards that would reduce the nicotine content of cigarettes. This presentation
focuses primarily on recent randomized clinical trials in which participants are provided
investigational cigarettes with varying levels of nicotine and followed over weeks to
months to assess the potential benefits and risks of regulated reductions in nicotine. These
studies indicate that reducing the nicotine content of cigarettes by approximately 85% or
more leads to fewer cigarettes smoked per day, reduced nicotine exposure, and/or reduced
nicotine dependence with little evidence of compensatory smoking or other unintended
consequences. In addition, preclinical data from rat models of nicotine self-administration
indicate that nicotine reduction would likely also decrease the initiation of use among
nicotine-naïve adolescent users. These data, if supported by other ongoing trials, raise
critically important questions about whether and how a product standard that limits the
nicotine content of all combusted tobacco products might be promulgated to reduce the
harms associated with smoking. Further discussion of this approach and how it might
interact with the rapidly changing landscape of tobacco products (e.g., e-cigarettes) should
be a high priority for all those interested in the prevention of tobacco-related disease.
Funding: Research reported in this presentation was supported by the National Institute on
Drug Abuse and FDA Center for Tobacco Products (CTP) (U54 DA031659). The content
is solely the responsibility of the authors and does not necessarily represent the official
views of the NIH or the Food and Drug Administration.
Major Symposia
Cancer Metabolism: Moving towards the Clinic
#SY02-01 Understanding metabolic phenotypes in human tumors. Ralph J. Debe-
rardinis. UT Southwestern Medical Ctr., Dallas, TX.
Metabolic reprogramming—the regulated alteration of flux through metabolic path-
ways in cancer cells—is an essential component of malignancy (1). In particular, path-
ways involved in bioenergetics, anabolism, and redox homeostasis are commonly altered
by cancer-promoting mutations in oncogenes and tumor suppressor genes, and these
metabolic activities support the enhanced survival and growth of cultured cancer cells in
vitro (2). The relevance of these reprogrammed pathways to bona fide human cancer is
less well established, however, and the knowledge gap between cultured cell models and
tumors has created a bottleneck in translating metabolic reprogramming into new ap-
proaches for clinical imaging and cancer therapy. Thus, a major current challenge is to
develop approaches that can characterize metabolic activity in intact tumors, particularly
from human subjects.
The metabolic phenotypes of malignant cells within human tumors result from the
integrated effects of a large number of intrinsic (e.g., genetic) and extrinsic (e.g.,
environmental) factors. The complexity of these influences results in a great deal of
metabolic heterogeneity among tumors and even within different regions of the same
tumor (3, 4). A complete understanding of cancer metabolism will demand approaches
that can report the effects of both intrinsic and extrinsic influences on metabolic pathway
preferences within tumors. Medical imaging techniques such as multiparametric magnetic
resonance imaging (mpMRI) and positron emission tomography (PET) provide informa-
tion about various aspects of tumor biology predicted to influence metabolism. Intraop-
erative infusions of isotope-labeled nutrients such as 13C-glucose provide a means to
assess metabolic fluxes within living tumors in patients and mouse models and to compare
these activities to adjacent benign tissue (5-8). I discuss approaches to understand
metabolic phenotypes in human non–small cell lung cancer (NSCLC). We use a multi-
disciplinary clinical protocol designed to integrate presurgical imaging, including mpMRI
and PET, with intraoperative infusions of isotope-labeled nutrients so that we can register
specific metabolic fluxes to specific regions of these biologically heterogeneous tumors
(4). This approach has allowed us to characterize fuel utilization within human lung
tumors and to identify some of the factors that influence fuel preferences. I also discuss
the unexpected contribution of alternative fuels other than glucose to energy metabolism
in human NSCLC tissue.
Supported by grants to R.J.D. from the National Cancer Institute (2 R01 CA157996-
06), the V Foundation (Translational Research Award), and the Howard Hughes Medical
Institute (Faculty Scholars Program).
References
1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg
did not anticipate. Cancer Cell 2012;21(3):297-308. doi: 10.1016/j.ccr.2012.02.014.
PubMed PMID: 22439925; PMCID: PMC3311998.
2. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv 2016;
2(5):e1600200. doi: 10.1126/sciadv.1600200. PubMed PMID: 27386546; PMCID:
PMC4928883.
3. Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The
metabolic profile of tumors depends on both the responsible genetic lesion and tissue
type. Cell Metab 2012;15(2):157-70. doi: 10.1016/j.cmet.2011.12.015. PubMed
PMID: 22326218; PMCID: PMC3282107.
4. Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, et al. Metabolic
heterogeneity in human lung tumors. Cell 2016;164(4):681-94. doi: 10.1016/
j.cell.2015.12.034. PubMed PMID: 26853473; PMCID: PMC4752889.
5. Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered
regulation of metabolic pathways in human lung cancer discerned by (13)C stable
isotope-resolved metabolomics (SIRM). Mol Cancer 2009;8:41. doi: 10.1186/1476-
4598-8-41. PubMed PMID: 19558692; PMCID: PMC2717907.
6. Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, Hatanpaa KJ, et
al. Metabolism of [U-13 C]glucose in human brain tumors in vivo. NMR Biomed
2012;25(11):1234-44. doi: 10.1002/nbm.2794. PubMed PMID: 22419606; PMCID:
PMC3406255.
7. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, et al. Analysis
of tumor metabolism reveals mitochondrial glucose oxidation in genetically
diverse human glioblastomas in the mouse brain in vivo. Cell Metab 2012;15(6):
827-37. doi: 10.1016/j.cmet.2012.05.001. PubMed PMID: 22682223; PMCID:
PMC3372870.
8. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S,
et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases.
Cell 2014;159(7):1603-14. PubMed PMID: Medline:25525878.
#SY02-02 Exploring the lung cancer metabolome, in vivo and ex vivo, for individ-
ualized medicine. Teresa W. Fan,1 Ramon Sun,1 Marc Warmoes,1 Qiushi Sun,1 Huan
Song,1 Angela Mahan,1 Jeremiah Martin,1 RICHARD M. Higashi,2 Andrew N. Lane3.
1Univ. of Kentucky, Lexington, KY; 2Richard M. Higashi, Lexington, KY; 3Andrew N
Lane, Lexington, KY.
Lung cancer is a leading cause of cancer death worldwide. This disease is of serious
concern in Kentucky, which leads the nation in both lung cancer incidence and
mortality. The past decade of research in cancer metabolism reveals the untapped
value of exploring human metabolome for the discovery of novel therapeutic and
diagnostic biomarkers for human cancers and other diseases. To better understand
metabolic reprogramming in individual tumors of lung cancer patients, we have
developed stable isotope tracers (e.g., [13C6]-glucose) coupled with NMR and MS-
based stable isotope-resolved metabolomics (SIRM) analysis directly in patient and in
patient-derived ex vivo and in vivo models. In the in vivo patient study, we mapped
differential metabolic network between paired cancerous (CA) and noncancerous
(NC) tissues procured from non–small cell lung cancer (NSCLC) patients infused with
[13C6]-glucose and snap-frozen immediately after resection (1). In particular, we
uncovered elevated anaplerotic pyruvate carboxylase (PC) activity in CA versus
paired NC tissues. Proliferating cancer cells require active Krebs cycle for generating
anabolic precursors, in addition to energy production. Diversion of the Krebs cycle
intermediates to meet anabolic demands cannot be sustained without anaplerosis.
Pyruvate carboxylation represents one of the two major anaplerotic pathways that
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replenish the Krebs cycle intermediates; the other involves glutaminolysis initiated by
glutaminase (GLS). We also found that PC but not GLS protein was overexpressed
(median 8-10 fold; n86) in CA tissues relative to paired NC tissues and that PC
expression was functionally important to NSCLC cell growth both in vitro and in vivo
(1). We also utilize the “Warburg slice” concept to systematically define metabolic
distinctions between thinly sliced paired CA versus NC lung tissues freshly resected
from individual NSCLC patients and cultured in stable isotope tracers. This ex vivo
tissue slice culture system is excellently suited for delineating reprogrammed meta-
bolic pathways in CA tissues without systemic interferences (2-4). These lung tissue
slices were metabolically viable for up to 72 hr, while maintaining their 3D archi-
tecture and microenvironment (4). We found that the reprogrammed metabolic net-
work in the cultured human tissue slices recapitulated that in vivo (1). These
advantages make the ex vivo human tissue slice systems a unique preclinical model
for exploring human target tissue metabolism and how it underlies the response to
anticancer agents such as chemopreventive Se compounds, enzyme inhibitors (5), and
the immune modular -glucan (4). We found that selenite blocked PC anaplerosis and
elicited massive necrosis in CA but not in NC lung tissues. CA lung tissue slices also
responded to -glucan with perturbed metabolic activity and histopathologic changes,
which were consistent with polarization towards M1-type macrophages. We were
intrigued to find that the metabolism and histopathology of these CA lung tissue slices
from different patients responded distinctly to these anticancer agents, which could be
translated into individual patients’ response to drugs. Furthermore, to delineate
systemic and microenvironmental influences on cancer metabolism, we compared and
found that the ex vivo tissue slice cultures incorporated to a higher extent 13C from
[13C6]-glucose into glycolytic, PPP, and purine nucleotide products than the corre-
sponding mouse PDX in vivo, illustrating the high metabolic viability of the ex vivo
tissue slice cultures. These new developments in preclinical models and mechanistic metabolic
interrogations promise to provide rigorous prediction for individual patients’ response to
therapeutics while revealing new and exciting targets for the next generation of personalized
therapeutics. Supported by 1R01CA118434-01A2, 1P01CA163223-01A1, 1R01ES022191-
01, 3R01ES022191-04S1, 3R01CA118434-02S1, 1U24DK097215-01A1, P30CA177558;
KLCRP, and the KY Challenge for Excellence.
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#SY02-03 Imaging cancer metabolism in patients: FDG PET and beyond. David A.
Mankoff. University of Pennsylvania, Philadelphia, PA.
The identification of altered energy metabolism as a hallmark of cancer (1) leads to
opportunities to exploit cancer metabolism as a target for diagnosis. This has been
most widely exploited using the elevated rate of glycolysis observed in most tumors
as a target for imaging (2)–in particular, positron emission tomography (PET) imaging
of the glucose analog 18F-fluorodeoxyglucose (FDG). FDG PET, now combined with
anatomic imaging in the form of PET/CT, has become an important tool for cancer
detection, staging, and response assessment, widely used in oncologic clinical prac-
tices around the world (3,4). Clinical use of FDG PET has increased our appreciation
of aberrant glycolysis as a feature of more aggressive, less differentiated tumors (5,6).
At the same time, the variability of tumor FDG uptake seen in clinical imaging has
highlighted some of the limitations of imaging tumor glycolysis and has spurred the
development of new imaging probes and novel imaging modalities designed to image
other facets of cancer energy metabolism. In addition, the use of therapeutics that are
targeted to and/or influenced by cancer metabolic phenotype (7) drives applications of
cancer metabolic imaging to clinical challenges beyond detection to predicting and
and monitoring response to targeted therapy (8). This talk highlights current uses of
FDG PET/CT for cancer staging and response evaluation, as well as alternative PET
probes targeted to other metabolic substrates such as amino acids, lipids, and TCA
intermediates (9). It also highlights other methods for imaging cancer metabolism in
patients, including magnetic resonance spectroscopy, optical imaging, chemical ex-
change saturation transfer (CEST), MR metabolomics, and MR imaging of hyperpo-
larized 13C-labeled metabolic substrates such as pyruvate (10-14). Unique features
and advantages of each modality are highlighted, as are approaches to image analysis
common across modalities, including quantitative imaging and kinetic analysis. Fi-
nally, the talk emphasizes the benefit of multimodality imaging as an approach to fully
characterize cancer metabolism, using glutaminolysis imaging as an example of active
investigation. Supported in part by Komen SAC130060, DOE DE-SE0012476, NIH
P30-CA016520, and NIH R01-CA211337.
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Emerging Targets in Immunotherapy
#SY03-02 Preclinical assessment of JTX-2011, an agonist antibody targeting ICOS,
supports evaluation in ICONIC clinical trial. Jennifer S. Michaelson,1 Christopher
Harvey,1 Kutlu Elpek,1 Ellen Duong,1 Lindsey Shallberg,1 Matthew Wallace,1 Robert
Mabry,1 Jenny Shu,1 Amit Deshpande,1 Tong Zi,1 Stephen Sazinsky,1 Joshua Apgar,2
Barbara Mounho-Zamora,3 Michael Briskin,1 Elizabeth Trehu,1 Jason Reeves,1 Heather
Hirsch,1 Sriram Sathyanarayanan,1 Deborah Law1. 1Jounce Therapeutics, Cambridge,
MA; 2Applied Biomath, MA; 3ToxStrategies, CA.
ICOS (the inducible T-cell co-stimulator) is a co-stimulatory molecule expressed on
the surface of T cells and a member of the CD28 family, which includes clinically
validated targets of cancer immunotherapies, such as PD-1 and CTLA-4. Clinical data
identified ICOS as a potentially key molecule in providing optimal antitumor benefit
following anti-CTLA-4 therapy. We have developed a species cross-reactive human-
ized IgG1 agonist antibody, JTX-2011, that binds ICOS and is designed to induce an
antitumor immune response. Our preclinical data suggest that JTX-2011 functions
through a dual mechanism of action, by stimulating T effector cells (Teff) and
depleting intratumoral T regulatory cells (Tregs). The ICOS antibody is efficacious as
a single agent in mouse syngeneic tumor models and demonstrates enhanced activity
when administered in combination with anti-PD-1. Single-agent activity in the pre-
clinical models appears to correlate with ICOS expression, with greater efficacy
observed in tumor models that exhibit a higher percentage of ICOS-expressing
immune cell infiltrate. An integrated expression analysis of human tumors identified
non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma
(HNSCC) as indications with higher percentages of ICOS-expressing cell infiltrate.
Preclinical studies performed in rodent and monkeys evaluated safety, pharmacoki-
netics, and pharmacodynamics of JTX-2011 to inform the first in-human study. The
ICONIC phase I/II clinical trial is currently ongoing for evaluation of JTX-2011 alone
or in combination with the anti-PD-1 antibody Nivolumab in patients with advanced
solid tumors and incorporates a patient enrichment strategy design based on the
preclinical and translational findings.
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Genetic Predisposition to Cancer: Implications for Risk
Management and Clinical Care
#SY04-03 Three components of inherited cancer risk and their implications in
personalized cancer screening. Jianfeng Xu. Northshore University Health Systems,
Evanston, IL.
Inherited risk for cancer has been well established from twin studies and family studies.
For example, a large, population-based study in Scandinavian countries of more than
200,000 same-sex twin pairs found that heritability was 33% for overall cancer and 57%
for prostate cancer (1). At present, family history is the most commonly used method for
evaluating an individual’s inherited risk for cancer. For those individuals with a strong
family history, typically defined as multiple affected relatives or relatives who died of
cancer at an early age, genetic testing of specific genes may also be recommended.
However, recent data suggest that this standard of care is insufficient and inadequate for
identifying individuals with higher inherited risk.
Several recent studies suggest that inherited mutations in a number of high-penetrance
genes (HPGs) are more common in cancer patients than previously estimated. In one study
based on The Cancer Genome Atlas (TCGA) data, 4-19% of cancer patients harbored an
HPG mutation, with 8% of prostate cancer patients found to be HPG mutation carriers (2).
Furthermore, many mutation carriers do not have a positive family history. In our recent
study of patients with prostate cancer, 60% of pathogenic mutation carriers of BRCA1/2
and ATM had a negative family history of prostate cancer (3). Therefore, it is necessary
and relevant to include HPGs in cancer risk assessment among all subjects, regardless of
family history.
Another major component of inherited risk is cancer risk–associated SNPs. Many
cancer risk–associated SNPs have been identified through genome-wide association
studies. The validity of these SNPs has been well established, as they are statistically
significant (P5E-08) and have been replicated among independent study popula-
tions. Although each SNP has a small individual effect on cancer risk, they have a
strong cumulative effect. The cumulative effect of these SNPs can be measured using
several methods, including genetic risk score (GRS) (4). Because GRS is based on
individuals’ genotypes and is a continuous variable, it is objective and informative in
stratifying inherited risk of developing specific cancers. More importantly, GRS can
identify considerably more high-risk subjects in the general population than family
history. For example, in the Prostate Cancer Prevention Trial (PCPT), 24% of men in
the study population had a GRS 1.4 and the prostate cancer detection rate during the
7 years of the study in these men was 33% (5). In contrast, 17% of men in the cohort
had a positive family history and the prostate cancer detection rate in these men was
29%.
Taken together, the latest data suggest that a comprehensive assessment of inherited cancer
risk should include family history, HPGs, and GRS. These measures are complementary and,
used together, can better identify subjects in the general population at elevated inherited risk
for cancer. Using prostate cancer as an example, approximately 7-17% of men in the U.S.
population have a positive family history of the disease and are therefore considered to have
elevated inherited risk for prostate cancer (6,7). In addition, approximately 2% of men in the
general population have a considerably higher inherited risk for prostate cancer due to
harboring at least one pathogenic mutation in an HPG for prostate cancer (8). Many of these
men do not have a positive family history. Finally, approximately 24% of men in the general
population have higher GRSs (1.4) and have an estimated prostate cancer risk equivalent to
or even higher than a positive family history (5). Considering all three risk factors, approxi-
mately 36% of men in the general population are estimated to be at higher inherited risk for
prostate cancer using this comprehensive risk assessment strategy, more than twice that of the
current standard of care risk assessment.
The more comprehensive assessment of inherited cancer risk has important clinical
implications, both for asymptomatic subjects in the general population as well as for
cancer patients. The most notable clinical utility is for developing individualized
cancer screening strategies. A personalized cancer screening approach can maximize
benefits and minimize harms associated with cancer screening. For example, offering
PSA screening among men with higher inherited risk based on family history, HPGs,
and GRS is a rational approach to address the current debate on prostate cancer
screening. It is important to note that individualizing cancer screening is the most
impactful component of precision medicine, as it can effectively reduce cancer-related
mortality and improve quality of life.
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Myelomonocytic Cells and Stroma as Therapeutic Targets
#SY06-01 Tumor-associated myelomonocytic cells as therapeutic targets. Maria
R. Galdiero,1 Martina Molgora,2 Cecila Garlanda,3 Gianni Marone,1 Alberto Man-
tovani3. 1University of Naples Federico II, Naples, Italy; 2IRCCS Humanitas Clinical
and Research Center, Rozzano, Milano, Italy; 3Humanitas University, Rozzano,
Milano, Italy.
Since Rudolf Virchow’s discovery in 1863 of the link between inflammation and
cancer, our knowledge about the physiopathologic processes underlying cancer-related
inflammation has steadily increased (1). In their seminal paper in 2000, Hanahan and
Weinberg proposed that most—if not all—human cancers have acquired six functional
capabilities during their development: self-sufficiency in growth signals, insensitivity to
antigrowth signals, tissue invasion and metastasis, limitless replicative potential, sustained
angiogenesis, and evading apoptosis (2). This engagingly simple scheme has dictated the
cancer research scenario over the past decade. Consequent to the intense experimental
work devoted to the cellular and molecular mechanisms underlying carcinogenesis and
tumor progression in the twenty-first century, Hanahan and Weinberg added four other
capabilities to the scheme: altered metabolism, genetic instability, escape from immuno-
surveillance, and chronic inflammation (3) This new point of view emphasized the striking
concept that tumors should no longer be viewed as cell-intrinsic genetic diseases. Indeed,
it is recognized that cancers arise, progress, and respond to therapy from within a complex
microenvironment with which they continuously interact.
The tumor microenvironment (TME) is a complex network, which includes soluble
factors and components of the extracellular matrix as well as stromal, endothelial, and
immune cells. Immune cells and, among them, myeloid cells play important roles in
cancer development and can promote or inhibit cancer initiation and progression (4).
Among tumor-infiltrating immune cells, macrophages are well-known determinants of
cancer-related inflammation and are typically characterized by their remarkable
plasticity. This consists of the ability to acquire a wide spectrum of activation states
in response to various signals derived from the microenvironment. Classical M1 and
alternative M2 macrophages represent the paradigm of this property. Tumor-associ-
ated macrophages (TAMs) usually display a so-called “M2-like” phenotype that
can foster tumor progression in different ways, namely by promoting genetic insta-
bility, angiogenesis, and metastasis and by restraining antitumor adaptive immunity.
Notably, TAMs can also play a dual role in the response to conventional antitumor
therapies: they can enhance the antineoplastic effect or, in contrast, they can sustain
a tumor-promoting response and so foil the anticancer power of these drugs (5).
Given their roles in tumor development, a number of macrophage-targeted antican-
cer approaches are currently being evaluated. They include inhibition of macrophage
recruitment and/or survival at tumor sites, functional reprogramming of TAMs to the
antitumor M1-like phenotype, and enhancement of killing and/or phagocytosis of
cancer cells. Moreover, TAMs express checkpoint proteins that modulate T-cell
activation in such a way that they can be targeted by checkpoint-blockade immuno-
therapies. Also, neutrophils can affect the TME. However, unlike macrophages, they
do so by releasing stored and newly synthesized inflammatory mediators. In the
“classic,” albeit now obsolete, point of view, neutrophils were viewed as terminally
differentiated effector cells that play major roles in the acute inflammatory response
and antimicrobial defense. This limited standpoint was challenged by the finding that
neutrophils can infiltrate tumors, interact with a number of cell populations, and
produce a wide array of cytokines and effector molecules that exert a plethora of
effects on tumor behavior (6, 7). Therefore, macrophages and neutrophils are both
involved in the regulation of the innate and adaptive immune responses in various
inflammatory situations, including cancer.
Besides immune cells, innate immunity comprises a humoral arm that includes a
variety of molecules, namely complement components, collectins, ficolins, and pen-
traxins. The role of the humoral arm of the innate immune system in cancer-related
inflammation is still being evaluated. PTX3 deficiency was recently found to increase
susceptibility to mesenchymal and epithelial carcinogenesis in mice (8). In detail,
tumor-infiltrating leukocytes and endothelial cells were found to be a major source of
PTX3 and to contribute to PTX3-mediated protection against carcinogenesis. PTX3
deficiency was associated with enhanced macrophage infiltration, proinflammatory
cytokine production, angiogenesis, complement C3 deposition, and C5a levels, which
suggests exacerbated cancer-related inflammation. Moreover, genetic inactivation of
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C3 reverted the increased susceptibility to 3-MCA-induced carcinogenesis and mac-
rophage recruitment. PTX3 regulated C3 deposition on sarcoma cells by recruiting the
negative complement regulator factor H. In addition, CCL2 inhibition was sufficient
to revert the increased susceptibility of PTX3-deficient mice to carcinogenesis and the
M2-like phenotype of TAMs. Thus, in 3-MCA sarcomas, unleashed complement
activation and increased C5a production associated with PTX3 deficiency is likely to
increase the production of CCL2, which in turn recruits tumor-promoting macro-
phages and favors M2-like polarization. PTX3 deficiency was also associated with
increased DNA damage, which is in accordance with the theory that cancer-related
inflammation contributes to the genetic instability of tumors. Moreover, the PTX3
gene was found to be highly methylated in some human mesenchymal and epithelial
tumors, and these epigenetic modifications were responsible for silencing of PTX3
protein. Thus, an essential component of the humoral arm of innate immunity and
regulator of complement activation works as an extrinsic oncosuppressor gene in mice
and humans by modulating complement-mediated, macrophage-enhanced, tumor-
promoting inflammation (8).
In an increasingly more personalized treatment approach, the more accurate under-
standing of cancer-related inflammation has led to new therapeutic options that target
the TME. These strategies include inhibition of inflammatory mediators or of their
downstream signaling molecules, blockage of recruitment/activation of myeloid cells,
modulation of their immunosuppressive properties, and re-education of TME. These
novel therapeutic strategies could synergize with conventional anticancer treatment
and so significantly improve the patient’s clinical outcome and follow-up.
#SY06-02 Macrophage targeted cancer immunotherapy. Carola Ries. Roche Inno-
vation Center Munich, Penzberg, Germany.
Combining immunotherapies that harness cytotoxic T cells to fight cancer has
become a major effort in treating metastatic cancer patients. We present data on an
example of cancer immunotherapy combination targeting innate immune cells, in
particular tumor-associated macrophages (TAMs), that is currently being tested in the
clinic. Combination of a TAM-depleting anti-CSF-1R antibody with an activating
anti-CD40 agonist demonstrated synergistic antitumoral efficacy resulting in complete
tumor remission in preclinical mouse cancer models. Ex vivo RNA sequencing of
sorted TAM revealed that only the combination treatment induced a transient, pro-
found repolarization of TAMs towards an immunostimulatory M1 phenotype. How-
ever, these TAM populations are ultimately eliminated. The central role of macro-
phages was further substantiated by complete loss of therapeutic benefit when TAMs
were depleted prior to combinational treatment. Furthermore, rechallenge and deple-
tion experiments demonstrated that tumor rejection is finally mediated by an antitu-
moral T-cell response. In colorectal cancer patients coexpression of human CSF1R
and CD40 on TAMs was detected, providing the basis to explore this combination in
the clinic.
#SY06-03 Reprograming the tumor microenvironment to improve responses to
therapy. David G. Denardo. Washington Univ. School of Medicine, Saint Louis, MO.
Immunotherapeutics represent highly promising agents with the potential to im-
prove patient outcomes in a variety of cancer types. Unfortunately, single-agent
immunotherapy has achieved limited clinical benefit to date in patients suffering from
pancreatic ductal adenocarcinoma (PDAC). This may be due to the presence of a
uniquely immunosuppressive tumor microenvironment (TME) present in PDACs,
which creates a barrier to effective immune surveillance. Critical obstacles to immu-
notherapy in PDAC tumors include the dense desmoplastic stroma that acts as a
barrier to T-cell infiltration and the high numbers of tumor-associated immunosup-
pressive cells. We have identified hyperactivated focal adhesion kinase (FAK) activity
in neoplastic PDAC cells as a significant regulator of the fibrotic and immunosup-
pressive TME. We found that FAK activity was elevated in human PDAC tissues and
correlates with high levels of fibrosis and poor CD8 cytotoxic T-cell infiltration.
Single-agent FAK inhibition (VS-4718) significantly limited tumor progression, re-
sulting in a doubling of survival in the p48-Cre/LSL-KrasG12D/p53Flox/ (KPC)
mouse model of human PDAC. This alteration in tumor progression was associated
with dramatically reduced tumor fibrosis, decreased numbers of tumor-infiltrating
immature myeloid cells, and immunosuppressive macrophages. We postulated that
these desirable effects of FAK inhibition on the TME might render PDAC tumors
more sensitive to immunotherapy. Accordingly, we found that FAK inhibition ren-
dered the previously unresponsive KPC mouse model responsive to anti-PD1 and
anti-CTLA4 antagonists, leading to a near tripling of survival times. These data
suggest that FAK inhibition increases immune surveillance by overcoming the fibrotic
and immunosuppressive PDAC TME and thus renders tumors responsive to immu-
notherapy. To test this hypothesis in human PDAC patients, we have opened a phase
I clinical trial testing the safety and impact on the tumor microenvironment of the
FAK inhibitor defactinib, in combination with pembrolizumab and gemcitabine
(NCT02546531). These studies are ongoing in patients with advanced cancer, includ-
ing metastatic PDAC. Early biomarker studies on PDAC tissue collected pre- and
post-therapy suggest that this combination impacts the immunosuppressive TME.
Obesity, Inflammation, and the Adipose Microenvironment in
Cancer
#SY07-02 Adipose stromal cells: A player in cancer progression and a therapeutic
target. Mikhail Kolonin. The University of Texas Health Science Center at Houston,
Houston, TX.
Prostate cancer (PCa) is promoted by white adipose tissue (WAT) overgrown in
obesity. As an underlying mechanism, we have discovered the recruitment of adipose
stromal cells (ASC) by tumors. We reported that CXCL1 expressed by cancer cells
chemoattracts ASC expressing its receptor CXCR1. As a candidate upstream mech-
anism, we identified interleukin 22 secreted by WAT-infiltrating leukocytes and
signaling through IL-22R in cancer cells. Our experiments in Hi-Myc mice indicate
that obesity promotes epithelial-mesenchymal transition (EMT). We show that ASC
directly induce EMT in adenocarcinoma cells. To test whether cancer progression can
be blocked by ASC targeting, we have used a hunter-killer peptide D-WAT composed
of an ASC-homing and a pro-apoptotic domain. D-WAT administration depleted
prostate stromal cells expressing a chemokine SDF1 and suppressed the EMT. Our
results indicate that ASC promote the EMT, at least in part, via SDF1a paracrine
signaling and validate ASC as a therapeutic target.
Mechanisms Regulating Immune Checkpoint Therapies
#SY09-01 Next-generation anti-CTLA-4 antibodies. Alan J. Korman,1 John Engel-
hardt,1 John Loffredo,2 Jose Valle,1 Rahima Akter,1 Raja Vuyyuru,2 Natalie Bezman,1
Paula So,1 Robert Graziano,2 Kimberly Tipton,3 James West,3 Bryan Irving,3 Mark
Selby1. 1Bristol-Myers Squibb Co., Redwood City, CA; 2Bristol-Myers Squibb Co.,
Lawrenceville, NJ; 3CytomX Therapeutics, South San Francisco, CA.
The activity of ipilimumab as a single agent and in combination with nivolumab
(anti-PD-1) in melanoma, as well as the use of ipilimumab/nivolumab combinations
in other malignancies, has confirmed the importance of CTLA-4 blockade in immu-
notherapy. The antitumor effect of this treatment also results in significant immune-
related adverse events that limit dosing and result in patient discontinuation. We have
taken two approaches to alter the activity of ipilimumab so as to improve its potency
and its safety profile. One approach is to enhance the antibody-dependent cellular
cytotoxicity (ADCC) activity of ipilimumab in order to increase the potential for Treg
depletion at the tumor site; this would be expected to increase the activity of the
antibody. The second approach is to produce a prodrug form of ipilimumab (an
anti-CTLA-4 Probody therapeutic) that will have reduced activity systemically, but
will become proteolytically cleaved at the tumor site to produce the fully functional
antibody; the goal of this approach is to reduce the adverse event profile while
retaining the antitumor activity of ipilimumab. It has previously been shown that
antitumor activity of anti-CTLA-4 antibodies in mouse models of cancer is dependent
on the ability of the antibody to bind activating FcRs and mediate ADCC against
Tregs at the tumor site (1, 2). Although human IgG1 Abs have been shown to be
effective mediators of ADCC in patients with hematologic malignancies, it is still
unclear whether ipilimumab mediates Treg depletion in solid tumors. Using in vitro
ADCC assays, we have found that a nonfucosylated (NF) version of ipilimumab
(ipilimumab-NF) has increased activity compared to ipilimumab. Ipilimumab-NF also
demonstrates increased IL-2 secretion in peripheral mononuclear cells treated with the
superantigen SEB as compared to ipilimumab. Transgenic mice that express human
FcRs in the place of mouse FcRs were used to investigate the activity of anti-mouse
surrogate CTLA-4 antibody engineered with either a human IgG1 or human IgG1-NF
Fc region in a mouse tumor model. In these mice, the IgG1-NF version of anti-mouse
CTLA-4 was found to significantly increase antitumor activity and Treg depletion at
the tumor site compared to the IgG1. These data suggest that the clinical activity of
ipilimumab could be enhanced by use of the nonfucosylated version of the Ab. In
addition, ipilimumab-NF was tested for its ability to enhance a vaccine response in
Mauritian cynomolgus macaques. Ipilimumab-NF was shown to result in increased
vaccine-induced T-cell responses compared to ipilimumab using two replication-
incompetent adenovirus serotype 5 viral vectors encoding SIV antigens as assessed by
MHC-I tetramers and IFN-gamma ELISPOT in Mauritian cynomolgus macaques
expressing the common allele, Mafa-A1*063. In a second approach, using Probody
platform technology developed by CytomX, we have developed an anti-CTLA-4
Probody therapeutic (Probody Tx) based on ipilimumab. Probody Txs utilize a
masking peptide that binds to the antigen-binding site of the Ab to reduce target
binding. The mask extends from the light chain of the Ab via a linker sequence that
contains cleavage sites for proteases preferentially active at the tumor site relative to
healthy tissue. The ipilimumab Probody Tx binds to CTLA-4 with significantly lower
affinity than the parental antibody and has reduced activity in in vitro assays. When
tested in a mouse tumor model using human CTLA-4 KI mice, the ipilimumab-
Probody Tx has comparable antitumor activity and Treg depletion at the tumor
compared to ipilimumab. In contrast, ipilimumab-Probody Tx-treated mice show
reduced levels of activated peripheral Tregs compared to ipilimumab-treated mice,
even at doses 8-fold higher than are required for antitumor efficacy, consistent with
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reduced activity of the Probody Tx outside the tumor microenvironment. The devel-
opment of next-generation anti-CTLA-4 antibodies holds promise for improving the
utility of ipilimumab for single-agent or combination therapy. The two improvements
to ipilimumab outlined above could each lead to a superior therapeutic outcome and
merit further investigation.
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#SY09-02 A novel genetic mechanism of evading antitumor immunity in multiple
human cancers. Seishi Ogawa. Kyoto Univ. Graduate School of Medicine, Kyoto-shi
Sakyo-ku, Japan.
Immune checkpoint blockade therapy using antibodies against programmed cell
death 1 (PD-1) and PD-1 ligand 1 (PD-L1) is revolutionizing cancer treatment.
Surprising therapeutic responses to these agents are obtained in many advanced cancer
patients with different tumor types, such as melanoma, non-small-cell lung cancer,
kidney cancer, and Hodgkin lymphoma, suggesting that cancer cells depend critically
on evading immune surveillance for their malignant growth. Accumulating evidence
suggests that these antibodies convey their therapeutic effects through targeting the
PD-1/PD-L1 immune checkpoint to unleash antitumor immune responses. However,
the genetic basis for the PD-1/PD-L1-mediated immune escape has not been fully
elucidated, with the exception of enhanced PD-L1 expression by gene amplification
and utilization of an ectopic promoter by translocation, which were reported in
Hodgkin and other B-cell lymphomas as well as stomach adenocarcinoma. Only a few
genetic markers are currently available to reliably predict response to anti-PD-1/
PD-L1 therapy as well. I will show a unique genetic mechanism of immune escape
caused by structural variations (SVs) commonly disrupting the 3= region of the PD-L1
gene. Widely affecting multiple common human cancer types, including adult T-cell
leukemia/lymphoma (27%), diffuse large B-cell lymphoma (8%), and stomach ade-
nocarcinoma (2%), these SVs invariably lead to a marked elevation of aberrant PD-L1
transcripts that are stabilized by truncation of the 3=-untranslated region (UTR).
Disruption of Pd-l1 3=-UTR in mice enables immune evasion of EG7-OVA tumor
cells with elevated PD-L1 expression in vivo, which is effectively inhibited by
PD-1/PD-L1 blockade, supporting the role of relevant SVs in clonal selection through
immune evasion. Our findings not only unmask a novel regulatory mechanism of
PD-L1 expression, but also suggest that PD-L1 3=-UTR disruption could serve as a
genetic marker to identify cancers that actively evade antitumor immunity through
PD-L1 overexpression.
Pan-cancer Genomic Analysis
#SY10-02 Pan-cancer study of recurrent and heterogeneous RNA aberrations and
association with whole-genome variants. Samirkumar Amin,1 Philip Awadalla,2 An-
drew Biankin,3 Paul Boutros,4 Alvis Brazma,5 Angela Norie Brooks,6 Claudia Calabrese,5
David Chang,3 Aurélien Chateigner,7 Ken Chen,8 Zechen Chong,8 Brian Craft,6 Chad
Creighton,9 Deniz Demirciog˘lu,10 Nuno Fonseca,5 Milana Frenkel-Morgenstern,11 Gad
Getz,12 Jonathan Göke,10 Mary Goldman,6 Liliana Greger,5 Syed Haider,7 Yao He,13
Katherine Hoadley,14 Yuan Ji,15 Andre Kahles,16 Ekta Khurana,17 Jan Korbel,18 Kjong
Lehmann,19 Han Liang,8 Fenglin Liu,13 Maximillian Marin,6 Matthew Meyerson,20
Akinyemi Ojesina,21 Francis Ouellette,7 Chandra Pedamallu,20 Marc Perry,7 Gunnar
Rätsch,22 Roland Schwarz,23 Yuichi Shiraishi,24 Cameron Soulette,6 Oliver Stegle,25
Patrick Tan,10 Alfonso Valencia,26 Linda Xiang,7 Christina Yung,7 Junjun Zhang,7 Fan
Zhang,13 Zemin Zhang,13 Jingchun Zhu6. 1The UT MD Anderson Cancer Center, TX;
2University of Toronto, Ontario, Canada; 3Glasgow Royal Infirmary; 4University of
Toronto; 5European Molecular Biology Laboratory; 6UC Santa Cruz, Santa Cruz, CA;
7OICR; 8MD Anderson; 9Baylor College of Medicine; 10National University of Singa-
pore; 11Bar-Ilan University; 12Massachusetts General Hospital; 13Peking University;
14UNC; 15The University of Chicago; 16Eidgenoessische Technische Hochschule Zuerich;
17Weill Cornell Medical College; 18European Molecular Biology Laboratory (EMBL);
19ETHZ; 20Broad Institute; 21HudsonAlpha Institute for Biotechnology; 22Swiss Federal
Institute of Technology; 23Max Delbrück Center for Molecular Medicine; 24University of
Tokyo; 25European Bioinformatics Institute; 26Spanish National Bioinformatics Institute.
Whole-exome sequencing studies have transformed our understanding of recurrent
somatic mutations that contribute to cancer pathogenesis; however, these studies limit our
ability to identify cancer-associated mutations to those that cause protein-coding changes.
To more comprehensively catalogue cancer-associated gene alterations, we have exten-
sively characterized tumor transcriptomes from 1,220 donors with matched whole-genome
sequence data to identify recurrent RNA-level aberrations. Specifically, we created a
unified RNA-Seq analysis pipeline including sequence alignment and quality control and
subsequently identified gene alterations through outlier detection from estimated gene
expression levels, alternative splicing, alternative transcription starts, and allele-specific
expression and through identified RNA-edited sites and gene fusions. Our data represent
an extensive catalog of RNA aberrations for each gene across 27 cancer types. We have
also tested for genetic associations with these RNA phenotypes. Using an integrative
analysis approach, we have mapped genome-wide cis and trans effects on individual RNA
phenotypes, considering both common germline variants as well as somatic SNVs in gene
promoters, enhancers, and intronic and other regions. Many of the regulatory associations
we identify are not accessible by exome sequencing, underlining the importance of
whole-genome sequence data. Utilizing this RNA-centric view, we have identified genes
that are recurrently altered, yet have not been previously characterized as cancer genes or
identified through DNA-level driver gene analysis. To identify further supporting evi-
dence that these recurrent alterations are potential drivers, we identified genes with
mutually exclusive RNA-level alterations. Our findings reveal new insights into selective
advantages of somatic changes and molecular mechanisms of cancer. This work is by the
Transcriptome Working Group of the Pan-Cancer Analysis of Whole Genomes (PCAWG)
consortium and authors are listed in alphabetical order.
The Unfolded Protein Response in Tumor Biology
#SY13-03 GRP78/BiP: Cancer’s comrade in crime. Amy S. Lee, Jieli Shen, Daisy
Rangel, Chun-Chih Tseng, Yuan Li Tsai, Dat P. Ha, He Zhao, Louis Dubeau. USC Norris
Comprehensive Cancer Center, Los Angeles, CA.
The 78 kDa glucose-regulated protein (GRP78), also referred to as BiP/HSPA5, is a
major endoplasmic reticulum (ER) chaperone with antiapoptotic properties and also
serves as a regulator of ER stress signaling (1). Tumor cells are subjected to ER stress due
to intrinsic factors such as genetic mutations, altered metabolism and hyperproliferation,
as well as extrinsic factors in the tumor microenvironment including oxygen and nutrient
deprivation (2). As an adaptive measure, cancer cells turn on the unfolded protein
response (UPR), and ER stress induction of GRP78 in cancer cells represents a major
prosurvival response, suppressing apoptosis while promoting proliferation and invasive-
ness. Thus, GRP78 is an emerging target for therapy to blunt cancer development,
progression, and drug resistance. GRP78 conditional knockout mouse models further
established the requirement of GRP78 in solid and blood tumorigenesis driven by
mutation of the tumor suppressor gene PTEN and that GRP78 is an upstream regulator of
the PI3K/AKT/S6 pathway (3,4).
KRAS is commonly mutated in various cancers, including pancreatic adenocarcinoma
(PDAC) and lung cancer, and thus far is deemed “undruggable”. We discovered that
haploinsufficiency of a single moiety, GRP78, while having no effect on the normal
pancreas, is sufficient to impede acinar-to-ductal metaplasia, block oncogenic signaling,
curb PDAC progression, and prolong survival. Similarly, Grp78 haploinsufficiency is able
to suppress mutant KRAS-driven lung cancer development. Further, we recently estab-
lished that ER stress can actively promote cell surface localization of GRP78, where it
assumes novel co-receptor functions with cell surface protein partners in regulating signal
transduction pathways (5). Our studies uncover that csGRP78 interacts with specific cell
surface signaling partner proteins and through those interactions impacts cancer cell
adhesion, polarity, migration, and survival.
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Presidential Select Symposium: Cancer Health Disparities
#SY14-01 Colon cancer screening and genetics. John M. Carethers. Univ. of Michigan,
Ann Arbor, MI.
Colorectal cancer (CRC) is the third most prevalent and second deadliest cancer in the
U.S. with 134,490 cases and 49,190 deaths in 2016. Its pathogenesis stems from genetic
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susceptibility coupled with environmental interactions in the colon that synergize ideal
conditions for neoplastic growth, initially from benign adenomatous polyps that might
progress to carcinoma over several years. Adenoma initiation and progression to carci-
noma may take one of a few identified genetic pathways that determine the tempo of
progression as well as morbidity and mortality of the patient. Each patient’s CRC is
genetically unique with variable numbers of passenger mutations and propelled by 2-8
driver mutations. CRCs can be classified as hypermutated, possessing hundreds to
thousands of somatic mutations and including CRCs driven by defects in DNA mismatch
repair and POLE mutations; and non-hypermutated, with tens of somatic mutations
containing multiple copy number alterations and aneuploidy with oncogenic activation of
KRAS and PIK3CA coupled with mutations and loss of heterozygosity of tumor suppres-
sors APC and TP53. Epigenetic events as well as inflammatory-driven cellular alterations
in DNA mismatch repair further contribute to CRC pathogenesis and metastasis. Because
CRC is deadly, prevention through screening (and/or surveillance in high-risk patients) is
an ideal and effective approach. Screening provides the opportunity to identify and
remove the adenoma precursors before they can become CRC; it also can utilize the
somatic genetic knowledge to effectively screen patients noninvasively. There are seven
CRC screening tests suggested by the USPSTF and a Multi-society Task Force for
effective screening, with varying abilities to detect significant colonic neoplasia and
various specificities; even the most noninvasive and least sensitive test has shown a
durable reduction in CRC mortality and is cost effective. Thus, any of the seven CRC
screening tests is better than no test. Noninvasive strategies include guaiac-based fecal
occult blood testing, fecal immunochemical testing, fecal DNA testing, and CT colonog-
raphy. Luminal-invasive tests include flexible sigmoidoscopy and colonoscopy and their
combinations with a noninvasive test. If any of the noninvasive tests shows a positive
result, a colonoscopy should be performed to identify the cause of the positive test. For
high-risk patients or the surveillance of patients, colonoscopy is the modality that should
be used. Knowledge of the patient’s age and family history and personal adenoma or CRC
history can influence when to commence screening; additionally, multiple lines of
evidence suggest that race should be included in the algorithm influencing the timing and
tempo of screening and/or surveillance.
#SY14-04 Cancer health disparities in American Indian and Alaskan Native pop-
ulations. Cheryl L. Willman. University of New Mexico School of Medicine and Univer-
sity of New Mexico NCI Comprehensive Cancer Center, Albuquerque, NM.
American Indian and Alaska Native communities constitute 562 federally recognized
independent sovereign nations within the United States, including 229 located in Alaska
and the remainder in 33 other states. These tribal nations and communities are highly
diverse in ethnicity, language, customs, modes of tribal governance, and cultural perspec-
tives and beliefs, particularly regarding cancer etiology and the conduct of research and
healthcare or community interventions. These nations have very significant cancer health
disparities, disproportionately low rates of cancer screening, and more limited access to
state of the art cancer diagnosis and treatment and cancer clinical trials when compared to
other Americans. Cancer incidence and mortality rates vary, often dramatically, among
different tribal nations in different geographic regions of the U.S. (see American Indian
and Alaska Native Cancer Profiles at surveillance.cancer.gov and http://statecancerpro-
files.cancer.gov). These variations may result from differing cancer etiologies, environ-
mental exposures, social behaviors (including diet and tobacco use), spectra of cancer-
associated somatic mutations and genetic susceptibilities to cancer and pre-cancerous
conditions (such as diabetes), limited rates of community-based cancer screening, and
limited access to health care. American Indian and Alaska Natives are often diagnosed at
later stages of disease and have a poorer prognosis for several types of cancer when
compared to other racial/ethnic groups. Regional variations in cancer staging and survival
within specific cancers are also observed. Highlighting specific examples of cancer health
disparities, lung cancer incidence rates for American Indians and Alaska Natives in the
Northern Plains and Alaska are currently among the highest in the world. In contrast, lung
cancer rates in American Indians in the Southwestern U.S. are among the lowest in the
country. Kidney and hepatobiliary cancers are increasing in incidence in many tribal
communities and occur at a significantly higher frequency than observed in other racial
and ethnic groups. American Indians and Hispanics, particularly in the Southwest, have
the nation’s highest rates of hepatocellular carcinoma, gall bladder cancer, and cholan-
giocarcinoma. Colorectal cancers are also seen at higher rates in American Indian and
Alaska Native communities, which may be a result of exceedingly low rates of colorectal
cancer screening. Tribal women and girls are also disproportionately impacted by higher
rates of cervical cancer, despite implementation of more robust cervical cancer screening
programs. Hispanic and American Indian children and adolescents affected by acute
lymphoblastic leukemia (ALL) also have significantly poorer outcomes than other racial
and ethnic groups in the U.S. Strikingly, Hispanic children now have the highest ALL
incidence in the United States, increasing from 8% of all pediatric ALL cases reported in
1990 to nearly 25% in 2005. Our genomic studies, supported by the NCI TARGET /
TCGA (ocg.cancer.gov) programs, discovered that American Indian children affected by
ALL, and Hispanics with a significant degree of American Indian genetic ancestry, have
a high frequency of unique leukemia-causing mutations compared to other racial/ethnic
groups (such as those in CRLF2/JAK signaling pathways or novel fusions involving genes
encoding tyrosine kinases or genes regulating tyrosine kinase signaling pathways) and a
higher frequency of unique ALL risk alleles (including those in GATA3). These mutations
can be targeted with tyrosine kinase inhibitors (TKIs) or novel therapeutic strategies that
are now being tested in national clinical trials, focused on improving overall outcomes in
these diseases.
In recognition and respect of the sovereign nation status of American Indian and Alaska
Native communities, of tribal laws, of requirements for tribal membership, and of unique
cultural perspectives and beliefs, meeting and overcoming cancer care delivery challenges
and significant cancer health disparities through research and engagement requires unique,
sustained, collaborative, community-engaging, partnership models. Such partnerships
must address the concerns of American Indian and Alaska native communities regarding
research and health care intervention, including joint oversight of collaborative projects;
regular communication of data and results; genetic privacy; appropriate and potentially
more limited informed consent for specific studies; appropriate oversight of biospecimen
acquisition and utilization of samples collected and stored for specific research projects;
intellectual property; and access to data and modes of data sharing and utilization. The
National Cancer Institute, The Centers for Disease Control, and the Indian Health Service
have supported several projects within tribal communities, largely focused on cancer
control. Such activities include the provision of educational materials (such as Native
Circle) to communities, the development of high quality cancer registries for American
Indians and Alaska Natives including 12 Tribal Epidemiology Centers (tribalepicenter-
s.org), and training and education programs targeted to American Indian and Alaska
Native students. The NCI SEER/New Mexico Tumor Registry at the University of New
Mexico Comprehensive Cancer Center, which holds cancer registry data from American
Indian communities in New Mexico and Arizona and supports the Cherokee Native
Cancer Registry and the Alaska Native Tumor Registry, is working with the NCI to
develop an integrated Native American Cancer Registry to facilitate the rigor of data
collection to allow American Indian and Alaska Native communities to track their cancer
data and monitor the incidence and outcome of cancers in their communities. New
collaborative partnership models (such as The Southcentral Foundation of Alaska, the
TGEN/Pima Indian Nation Partnership in Arizona, and evolving partnerships in New
Mexico, Utah, and other regions of the U.S.) with full engagement of tribal nations and
collaborating universities, research entities, and health systems are providing new oppor-
tunities for American Indian and Alaska Native communities to engage in and benefit
from cancer research focused on gene-environment interactions and cancer causation,
cancer precision medicine and discovery of the spectrum of cancer-associated mutations
in cancers disproportionately affecting these communities, cancer education and screening
interventions, and cancer clinical trials.
Diet, Microbiome, and Cancer
#SY17-03 Can a change in diet change your cancer risk? Stephen J. O’Keefe.
University of Pittsburgh, Pittsburgh, PA.
There is a remarkable variation in gastrointestinal cancer risks around the world, best
illustrated by colon cancer, where the incidence varies 20-fold between Westernized and
less-developed countries. Overwhelming experimental and human study evidence shows
that the variation can be accounted for by environmental factors rather than genetic
constitution. For example, studies have shown that migration from a low-incidence
country to a high-incidence country results in a change in risk to that of the host country
within one generation. This is insufficient time for genetic mutation to account for the
change. Less than 10% of cancers are due to inherited genetic aberrations, and GWAS
studies have struggled to identify mutations that strongly influence risk for developing
sporadic colon cancer. On the other hand, there is convincing evidence, based on
observational and intervention studies, that risk of colon cancer is increased by consump-
tion of meat and processed meats but suppressed by the consumption of fiber-rich foods,
suggesting that the primary environmental factor that drives risk is what we eat. Recent
studies of ours in African Americans, who suffer the highest rates of colon cancer
incidence and death in the U.S., showed that a change to a traditional ‘African’ high-fiber
(55 gm/day), low-meat diet suppressed mucosal biomarkers of colon cancer risk in their
colons within 2 weeks (1). Furthermore, these biomarkers were increased when rural
Africans were given a ‘Western‘ diet for only 2 weeks. We obtained evidence that these
benefits were mediated by the colonic microbiota, which break down undigested food into
metabolites that either support mucosal health and are antineoplastic, for example short-
chain fatty acids such as butyrate, or are inflammatory and carcinogenic, such as
conjugated bile acids (which increase in a high-fat diet) and nitroso-compounds (which
increase with a high-meat diet). Butyrate has a remarkable array of colonic health-
promoting and antineoplastic properties: It is the preferred energy source for colonocytes,
it maintains mucosal integrity, and it suppresses inflammation and carcinogenesis through
effects on immunity, gene expression, and epigenetic modulation (2). There is experi-
mental and epidemiologic evidence that the current recommended fiber intakes proposed
by the U.S. Department of Agriculture of 22 gm/day for women and 38 gm/day for men,
which were formulated to support cardiovascular health, are insufficient to prevent colon
cancer. Our results suggest that the quantity should be closer to 50 gm/day, which is what
is contained in the rural African diet; rural Africans rarely get colon cancer. This talk will
discuss the mechanisms behind these diet-microbial-metabolite effects, which could be
modified by diet change, to achieve the objective of preventing colorectal cancer in
Western societies.
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Inflammation and Cancer
#SY19-01 Tumor-elicited inflammation in colorectal cancer. Michael Karin. UCSD,
La Jolla, CA.
The majority of sporadic human colorectal cancer is initiated by genetic loss or
inactivation of tumor suppressor APC (Absent in Polyposis Coli). In addition to activation
of beta-catenin signaling, we found that loss of APC results in upregulation of IL-6 signal
transducer (IL6/gp130), thereby leading to activation of STAT3 and YAP, two transcrip-
tion factors that make important contributions to colorectal tumorigenesis. In addition,
APC loss results in deterioration of the intestinal epithelial barrier and immune homeo-
stasis, barrier loss due to downregulation of genes encoding tight junction proteins, and
suppression of mucin production. Together, such changes promote the invasion of in-
flammation-inducing colitogenic bacteria and their products. Loss of immune homeostasis
is due to defective luminal transport of IgA dimers caused by loss of polyimmunoglobin
receptor (PIgR) and CCL28, a chemokine responsible for recruitment of IgA-producing
plasma cells. Defective luminal transport of IgA results in dysbiosis and over-represen-
tation of inflammation-causing bacteria that can accelerate colorectal tumor genesis
through upregulation of IL-17 production.
#SY19-03 Inflammation-driven cancer: Host and microbial pathways. Fiona Powrie,
Sarah McCuaig, Nathan West, Grigory Ryzhakov. University of Oxford, Oxford, United
Kingdom.
The gastrointestinal (GI) tract is home to a large number and vast array of bacteria that
play an important role in nutrition, immune system development, and host defense. In
inflammatory bowel disease (IBD) there is a breakdown in this mutualistic relationship,
resulting in aberrant inflammatory responses that can progress to colon cancer. Our studies
in model systems have implicated innate lymphoid cells and production of IL-22 as key
drivers of neoplasia and cancer in the intestine. In this presentation I will discuss new
checkpoints that control bacteria-driven innate inflammation in the intestine as well as the
functional effects of IL-22 on intestinal epithelial cells and interactions between IL-22
signaling and oncogenic mutations. Further understanding of the interactions between host
genetics, gut microbiota, and deranged inflammatory pathways will yield new approaches
to patient stratification and personalized therapy.
Targeting Residual Disease
#SY21-03 Cancer evolution as a therapeutic target. Alberto Bardelli. Univ. of Turin
School of Medicine, Candiolo, Italy.
When metastatic cancers are challenged with targeted agents, almost invariably a subset
of cells insensitive to the drug emerges. As a result, in most instances targeted therapies
are only transiently effective in patients. Strategies to prevent or overcome resistance are
therefore essential to design the next generation of clinical trials. How can we overcome
the near-certainty of disease recurrence following treatment with targeted agents? Ad-
dressing this question means considering as a target not “only” individual oncogenes but
also the evolving nature of human tumors. We used colorectal cancer (CRC) as a model
system to test the hypothesis that by understanding tumor’s evolution, the emergence of
drug resistance can be controlled. We find that clonal dynamics can be monitored in real
time in the blood of patients, and liquid biopsies can be used to intercept the emergence
of resistant clones before relapses are clinically manifest. We discovered that a multistep
clonal evolution process driven by progressive increases in drug fitness underlies the
development of resistance in cells and patient avatars. To have long-term efficacy, the use
of targeted therapies must take into account the continuous evolution of cancer cells; that
is to say, therapies must adapt to tumor evolution. One possibility is to anticipate the
changes the tumors will make. For example, by knowing in advance how CRC cells
overcome resistance to EGFR blockade, we devised further rounds of therapy. Another
approach is to unleash the ability of the immune system to recognize drug-resistant cells.
We tested this possibility in syngeneic mouse models of CRC sensitive to targeted
therapies. Our findings indicate that manipulation of the mutational loads can trigger
prolonged therapeutic responses that are not observed when cancer cells are challenged
with targeted drugs alone. We postulate that rationally combined targeted therapies and
immunotherapies can restrain tumor evolution and can limit the emergence of drug
resistance, thus leading to long-term responses.
AACR-JCA Joint Symposium: Cancer Metabolomics
#SY22-02 Tumor suppression by p62 through the metabolic reprogramming of the
stroma. Jorge Moscat. Sanford Burnham Prebys Medical Discovery Institute Inst., La
Jolla, CA.
Large-scale genomic and transcriptomic interrogation of cancer has underscored the
complexity of its genetic landscape, revealing a massive number of genetic alterations
that results in the impossibility of distinguishing “driver” from “passenger” mutations.
This makes oncogene-targeting therapies extremely challenging. This variability is
well exemplified in hepatocellular carcinoma (HCC), in which more than 28,000
different somatic mutations have been identified. HCC development is a relatively
long and complex process including chronic hepatitis, fibrosis, cirrhosis, and stromal
activation, which are key mediators of a microenvironment conducive to tumorigen-
esis. Infection with hepatitis B and C viruses (HBV and HCV) has been considered the
major HCC risk factor. Not surprisingly, obesity-induced nonalcoholic fatty liver
disease (NAFLD), and its more severe consequence nonalcoholic steatohepatitis
(NASH), have progressively become critical promoters of HCC. Chronic liver injury
sets in motion a vicious circle of hepatocyte cell death, inflammation, and fibrosis that
results in cirrhosis and cancer. A critical player in that process is hepatic stellate cells
(HSCs). Recent reports highlight the potential central role of HSCs in the generation
of proinflammatory signals important for HCC development. More recently, the study
of pancreatic cancer suggests that pancreatic stellate cell reprogramming by targeting
the vitamin D receptor (VDR) might improve therapeutic responses. Nononcogenic
addiction can reveal new tumor vulnerabilities that can be exploited therapeutically
for cancer treatment. In this regard, metabolic reprogramming and autophagy are
progressively being considered as a new, rich source of possible therapeutic targets in
cancer irrespective of the genetic landscape of the tumor. p62 is a signaling and
autophagy adaptor that accumulates in premalignant liver diseases and most hepato-
cellular carcinomas (HCCs). p62 was the first identified autophagy adaptor; however,
at least other four other proteins have similar functions, including NBR1, TAX1BP1,
NDP52, and OPTN. Importantly, p62 is a signaling regulator residing in the late
endosome lysosome, and unlike other autophagy adaptors except for NBR1, p62 is
also a central regulator of signaling pathways controlling cell survival and growth.
This is because it interacts with key signaling proteins through well-defined structural
elements. Although p62 was proposed to participate in the formation of benign
adenomas in autophagy-deficient livers, its role in HCC initiation was not explored.
Importantly, we show that the upregulation of p62 in hepatocytes during HCC
initiation is necessary and sufficient for tumor induction in mice and is highly
expressed in human HCC patients. The mechanism for this relies on the ability of p62
to activate hepatocyte NRF2 and mTORC1 pathways and differs from its protumori-
genic role in lung adenocarcinomas that mostly relies on the activation of NF-B.
However, although p62 is a protumorigenic molecule in epithelial cancer cells, more
recent results reveal that it plays a tumor-suppressor role in the stroma. Interestingly,
most studies addressing the role of p62 in cancer have focused on its function in
transformed epithelial cells, but only very recently has the concept of p62 as a tumor
suppressor in the cancer stroma emerged from our studies of prostate cancer. We
discuss recent observations demonstrating a novel role of p62 as a promoter of stromal
reprogramming in both prostate cancer and HCC due to its ability to repress the
stromal activation of prostate fibroblasts and HSCs in the liver, through different
mechanisms. This suggests that in parallel to epithelial cancer heterogeneity, there is
a completely unexplored diversity of stromal cells that utilize distinct mechanisms to
impact tumor initiation and progression. We propose that therapies aimed at repress-
ing the downregulation of stromal p62, and likely that of other autophagy adaptors,
will positively impact therapies targeting the tumor epithelium.
#SY22-03 Multi-omics analysis of paired normal and tumor tissues reveals when
and what causes altered metabolism in colorectal cancer. Tomoyoshi Soga. Keio
University, Tsuruoka, Japan.
Metabolic reprogramming is a common hallmark of cancer. Most cancer cells
produce ATP and the precursors of biomass (e.g., nucleotides, amino acids, and lipids)
by shifting from oxidative phosphorylation to aerobic glycolysis, commonly known as
the “Warburg effect.” Recently these cancer-specific metabolic pathways have been
considered as attractive targets for cancer therapy. However, the mechanisms under-
lying the control of cancer cell metabolism are poorly understood. To address
underlying mechanisms that induce metabolic reprogramming of cancer metabolism,
we applied capillary electrophoresis mass spectrometry (CE-MS) metabolic profiling
to paired normal tissues and tumor tissues obtained from 275 patients with colon
cancer. Significant changes in the levels of many metabolites were observed between
normal and tumor tissues. Unexpectedly, metabolite levels altered quite early and
remained unchanged among cancer stages. S-Adenosylmethionine (SAM) was the
most increased metabolite. Glucose was the second most decreased metabolite in
tumor tissues, whereas lactate, the final product of glycolysis, was increased, which
indicates activation of glycolysis (the Warburg effect). We then applied transcriptome
analysis to paired normal-cancer colon tissues and revealed that alterations in mRNA
levels also occurred at the adenoma stage. Regarding energy metabolism, mRNAs
encoding glycolysis purine/pyrimidine synthesis, one-carbon metabolism, and fatty
acid synthesis were highly expressed, whereas those in fatty acid oxidation were
down-regulated in tumor tissue. Colon cancer is associated with mutations in onco-
genes and tumor suppressor genes such as adenomatous polyposis coli (APC),
Kirsten-ras (KRAS), and TP53. We applied next-generation sequencing technologies
for the detection of somatic mutations to the tumor tissues and found mutation
frequencies of 78% in APC, 68% in TP53, and 48% in KRAS. Similar to metabolome
and transcriptome data, these mutations were umbiased among cancer stages. We
investigated whether gene mutations including APC, KRAS, and TP53 mutations
affected metabolism. Regardless of the presence or absence of the mutations, the
Invited Abstracts
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171530
levels of most metabolites were unaltered in tumor tissues. This raises the question of
which molecules contribute to the regulation of metabolic reprogramming of colo-
rectal cancer metabolism.
Host Immunity to Oncogenic Viruses
#SY23-01 KSHV: Immune evasion and oncogenesis. Blossom A. Damania. Univ. of
North Carolina at Chapel Hill, Chapel Hill, NC.
Infection of cells with oncogenic DNA viruses, including herpesviruses, triggers innate
immune responses mediated by DNA sensors. Cyclic GMP-AMP synthase (cGAS) is a
key DNA sensor that upon activation produces the cyclic dinucleotide cGAMP, which
binds and activates Stimulator of Interferon Genes (STING), leading to interferon pro-
duction and an antiviral response. Kaposi’s sarcoma-associated herpesvirus (KSHV) is an
oncogenic herpesvirus that is linked to several human malignancies including Kaposi’s
sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman’s disease
(MCD). We have found that KSHV infection activates the cGAS-STING pathway and that
cGAS and STING also play an important role in regulating KSHV reactivation from
latency. Furthermore, we have identified several KSHV viral proteins that inhibit the
cGAS-STING pathway. It appears that modulation of this pathway is important for viral
transmission and the lifelong persistence of oncogenic herpesviruses in the human
population.
#SY23-02 Host immune responses to HPV and HPV vaccines. Ligia Pinto. Leidos
Biomedical Research, Inc., Frederick National Laboratory, Frederick, MD.
Human papillomavirus (HPV) infection is the cause of multiple cancers in both
women and men. There are three different licensed HPV prophylactic vaccines.
Currently licensed L1 virus-like particles (VLP)– based HPV vaccines target two to
nine different HPV types and have demonstrated excellent efficacy against the
targeted HPV types and associated disease. Host immune responses to HPV vaccines
and infection will be presented and discussed. Briefly, HPV vaccines induce nearly
100% seroconversion to all HPV types included in the vaccine. High titers of
high-affinity anti-L1 IgG antibodies, to the HPV types included in the vaccine, are
generated after vaccination, and these persist for several years after vaccination at
levels considerably higher than those observed in natural infection. Although corre-
lates of vaccine protection have not been identified, neutralizing antibodies are
believed to be the main effectors of protection against HPV infection. Vaccine-
induced antibodies are detectable not only in serum but also at mucosal sites of
infection, such as the cervix and oral cavity. Local HPV-specific antibody levels,
although lower, correlate well with circulating levels. Immunogenicity data have
shown noninferiority of antibody responses after two doses of HPV vaccine, and the
recommended number of vaccine doses was recently reduced from three to two. There
is some evidence suggesting that even one dose of the bivalent HPV vaccine may
provide similar protection to the recommended dose regimens. Antibody levels
following one dose of the bivalent vaccine, although lower, have been shown to be
stable over 4 years of follow-up and vaccine recipients remained HPV16/18 seropos-
itive, suggesting that a single dose of the bivalent vaccine may provide durable
protection against infection. The robust immunogenicity of the HPV vaccines con-
trasts with the immune responses observed after natural infection, in which serocon-
version has been shown in only a percentage of individuals with incident HPV
infection. Furthermore, levels of antibodies induced by vaccination are much higher
than the levels observed after infection and appear to be preserved over time. A better
understanding of long-term protection of the vaccine as well as a more comprehensive
evaluation of correlates of immune protection against HPV infection are still needed.
#SY23-03 How does HTLV-1 cause leukemia? Charles Bangham. Imperial College
London, London, United Kingdom.
The retrovirus human T-lymphotropic virus type 1 (HTLV-1) causes an aggressive,
rapidly fatal malignancy of CD4 T cells, called adult T-cell leukemia/lymphoma (ATL),
in 5% of infected individuals. Recent evidence on the clonal diversity and molecular
virology of HTLV-1 and on the host genetic and immune response is changing the
understanding of oncogenesis in HTLV-1 infection. It was previously believed that
HTLV-1 was latent in vivo and persisted by continuous oligoclonal proliferation of about
100 clones of HTLV-1-infected CD4 T cells, and that this oligoclonal proliferation
predisposed to the malignancy ATL. However, we have shown that a typical individual
carries between 104 and 105 clones and that the proviral load–the chief correlate of
disease–is determined by the number of clones, not by oligoclonal proliferation. The
central challenge remains to explain the regulation of HTLV-1 latency in vivo and the role
of the host immune response in determining the set-point proviral load and the risk of
ATL. I propose here three hypotheses. First, that ATL results from the accumulation of
replicative mutations in HTLV-1-infected T-cell clones that persist for decades, typically
over 40 years. Second, that the quality of the host immune response, chiefly the CTL
response, determines the size and clonal diversity of the HTLV-1 reservoir, the net
proliferation rate of HTLV-1-infected T cells, and therefore the risk of ATL. Third, that
abnormal chromatin looping in the host genome caused by HTLV-1 can deregulate host
gene expression and so contribute to the risk of ATL.
Liquid Biopsies: Emerging Technologies to Monitor Cancer
Progression and Guide
#SY24-01 High throughput CTC detection for noninvasive cancer monitoring.
Shyamala Maheswaran, Mark Kalinich, Irun Bhan, David Miyamoto, Yu Zheng, Xin
Hong, Tanya Todorova Kwan, Ravi Kapur, Lecia Sequist, Ryan Sullivan, Aditya Bardia,
Richard Lee, David Ting, Mehmet Toner, Daniel A. Haber. Massachusetts General
Hospital, Charlestown, MA.
Circulating tumor cells (CTCs) provide a noninvasive source of patient-derived mate-
rial to repeatedly sample cancer cells during the course of therapy, assessing changes in
tumor burden, genetic composition, and transcriptional and RNA-based abnormalities.
While some CTCs are viable and tumorigenic ex vivo, the majority of these cells die in
the circulation, and some localized cancers with vascular invasion appear to shed CTCs
long before the initiation of metastatic lesions. CTC detection therefore also offers an
opportunity for early cancer detection. Two major technologic hurdles have limited the
broad clinical application of CTC analyses: 1) the capture of these rare cells, estimated at
approximately one tumor cell per billion normal blood cells in the circulation; and 2) the
complex imaging criteria required for scoring rare and heterogeneous tumor cells using
antibody-dependent staining. To address the primary challenge of capturing rare CTCs
admixed with large numbers of normal blood cells, we have previously described a
microfluidic device, the CTC-iChip, capable of high throughput depletion of normal
hematopoietic cells, producing an output that is highly enriched for CTCs. This negative-
depletion strategy enables isolation of CTCs across most types of cancer, independent of
cell surface markers, and it ensures the highest quality of cellular RNA for downstream
molecular analyses. To address the secondary challenge of imaging CTCs using accurate
and high throughput platforms, we took advantage of the intact cancer cell–derived
transcriptome within microfluidically enriched cancer cells to establish digital PCR
platforms, capable of highly sensitive, reliable, and robust detection of CTCs from
different cancer types. As proof of principle, we tested the application of such a digital
CTC detection in patients with hepatocellular cancer, prostate cancer, and melanoma,
demonstrating accurate measurement of tumor burden and associated RNA-based altera-
tions and genotypes, as well as cancer cell–derived predictive markers of drug response.
Taken together, the digital scoring of CTCs from microfluidically enriched blood cell
populations provides a high throughput and highly quantitative platform for serial non-
invasive monitoring of cancer. For future early cancer detection applications, the use of
intact cancer cells in the circulation as a source of molecular markers may help distinguish
invasive from indolent cancers.
Mechanisms of Primary and Acquired Resistance to
Immunotherapy
#SY25-02 Antigenic strength vs. tumor microenvironment in determining cancer
immunosurveillance. Robert H. Vonderheide. Abramson Cancer Ctr. of Univ. of Penn.,
Philadelphia, PA.
We evaluated immune surveillance in pancreatic ductal adenocarcinoma (PDA), which
exhibits far fewer missense mutations and potential neoepitopes than classically described
carcinogen-induced, highly mutated tumors. In contrast to these immunogenic tumor
models from which the theory of elimination-equilibrium-escape was determined, we
found no evidence for immunoediting in a mutant Kras-driven murine model of PDA.
These tumors progress the same with or without a functional adaptive immune system,
similar to other mouse tumors that have also been shown to grow independently of T cells.
Tumors arising in T cell–depleted mice grew unchecked in immune-competent hosts. We
further show that KPC pancreatic tumors have few if any predicted neoepitopes derived
from somatic tumor missense mutations and that an immunoediting phenotype can be
rescued by ectopic expression of a neoantigen (OVA) in the same tumor model. Thus, the
manifestations of cancer immune surveillance in the KPC model depend on tumor
antigenic strength; the lack of neoepitopes is not a consequence of immunoediting in this
model. These findings suggest an alternative biologic mechanism in which tumor out-
growth reflects immune quiescence, which is linked to, and regulated by, poor tumor
antigenicity—a conclusion with potential relevance to human cancers with a low burden
of mutations and minimal neoepitopes.
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#SY25-03 From the clinic to the lab: Investigating response and resistance mech-
anisms to immune checkpoint therapy. Padmanee Sharma. UT MD Anderson Cancer
Ctr., Houston, TX.
Immune checkpoint therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1, have
led to significant clinical responses in cancer patients. To investigate immunologic
changes and mechanistic pathways that are elicited by these therapies, we conducted
presurgical and tissue-based clinical trials, which permit access to tumor tissues for
laboratory studies. To compare and contrast data, we chose one tumor type that responds
well to immune checkpoint therapy and one that does not. The first presurgical trial was
conducted with anti-CTLA-4 (ipilimumab) in a cohort of patients with localized bladder
cancer. The second presurgical trial was conducted with anti-CTLA-4 (ipilimumab) in
patients with localized prostate cancer. In addition, we evaluated data from patients with
melanoma who received immune checkpoint therapy. These data enabled us to identify the
ICOS/ICOSL pathway as relevant for antitumor immune responses in the setting of
anti-CTLA-4 therapy. We also identified resistance mechanisms, including expression of
other immune inhibitory pathways such as VISTA and loss of the IFN signaling pathway
in tumor cells. These data will be discussed in greater detail.
#SY25-04 Tumor and host factors regulating immunotherapy responsiveness.
Thomas Frank Gajewski. Univ. of Chicago, Chicago, IL.
Checkpoint blockade immunotherapy is favored in patients having a T cell-inflamed
tumor microenvironment at baseline. Therefore, absence of a T cell-inflamed phenotype
represents a first approximation of immunotherapy resistance. Investigation of molecular
features of tumor genomics, host genetics, and commensal microbiota that correlate with
the degree of spontaneous T-cell infiltration has revealed multiple layers of pathways that
impact on relative response versus resistance to immunotherapeutic interventions. The
first tumor-intrinsic oncogene pathway demonstrated mechanistically to mediate T-cell
exclusion from the tumor microenvironment and lack of checkpoint blockade efficacy is
the Wnt/-catenin pathway. Additional molecular aberrations correlated with deficient
immune infiltration in various cancers include loss of function mutation or absence of
PTEN, LKB1, or p53 and activation of FGFR3 or PPAR-. Mouse modeling has revealed
that tumor cell-intrinsic -catenin pathway activation also mediates downstream resis-
tance to adoptive T-cell therapy, due to defective expression of key chemokines. In one
patient case analyzed, transition from a -catenin-negative to a -catenin-positive phe-
notype has been associated with secondary resistance to immunotherapy. TCGA and other
large genomic datasets have been an invaluable tool for identifying such molecular
correlates, through availability of tumor RNAseq and exome sequencing data as well as
germline SNP analysis. Host germline polymorphisms also have been identified that
correlate with the degree of T-cell infiltration in the tumor, and mouse models are being
utilized to investigate mechanisms. Specific commensal bacteria associated with the
degree of T-cell infiltration also have been identified in animal models, and similar
analyses are ongoing with human stool samples in patients undergoing checkpoint
blockade therapy. A common feature of non-T cell-inflamed tumors is a relative lack of
Batf3-dendritic cells and absence of a type I IFN gene signature. Thus, regulation at the
level of innate immunity seems to be a key determining factor. Strategies aimed at
boosting innate immune activation in the tumor microenvironment represent a major
category of therapeutic intervention to convert non-T cell-inflamed tumors to T cell-
inflamed, and STING agonists and probiotics are beginning to be investigated clinically.
Systemic Metabolic Dysfunction and Cancer
#SY28-01 Stromal contributions of adipocytes to cancer. Philipp E. Scherer. UT
Southwestern Medical Ctr., Dallas, TX.
The past few years have provided substantial evidence for the vital role of the local
tumor microenvironment in various aspects of tumorigenesis. With obesity and its
pathophysiologic sequelae still on the rise, the adipocyte is increasingly moving to center
stage in the context of tumor stroma-related studies. To date, we have limited insights into
how systemic changes associated with obesity and altered adipokine secretion influence
the incidence and progression of obesity-associated cancers. Adipocytes are the major
constituents of adipose tissue and play a key role in whole body metabolism. They not
only fulfill an important role as a buffer for excess triglycerides, but they also secrete
many lipid and protein factors and are therefore considered major endocrine cells that
influence metabolism of other tissues, including liver, muscle, brain, and pancreatic
-cells. With chronic excess of energy intake, adipocytes develop hypertrophy and face
various physiologic insults, such as hypoxia, oxidative stress, and disruptions in the
protein secretory pathway due to ER stress. As a result, adipocytes become dysfunctional
and less efficient at fulfilling their primary function of storing and neutralizing potentially
toxic free fatty acids. Adipocyte dysfunction has been widely appreciated as a major cause
underlying obesity-related metabolic disorders, including insulin resistance, type 2 dia-
betes, cardiovascular disease, chronic inflammation, and cancers due to inappropriate
release of mitogenic and inflammatory factors. As a result, these dysfunctional adipocytes
also support the growth of infiltrating transformed ductal epithelial cells in the mammary
gland, at the level of secretion of critical growth factors, proinflammatory cytokines,
increased ECM production, and support of tumor lesion growth through release of critical
metabolites. Therefore, the adipocyte with its paracrine influence on the microenviron-
ment as well as its endocrine functions is an important area of research for both primary
and metastatic tumor growth.
#SY28-02 The adipose-cancer link: From microenvironment to metabolomics. Cor-
nelia M. Ulrich. Univ. of Utah Huntsman Cancer Inst., Salt Lake City, UT.
This presentation will showcase the interface of systemic and localized disturbances in
metabolism with tumor development, specifically focusing on colorectal cancer. Colorec-
tal cancer is the second leading cause of cancer-related death worldwide among both men
and women. Risk and preventive factors are well established and include, among others,
lack of physical activity and obesity (risk) as well as aspirin use and screening (preven-
tion). Adipose tissue is emerging as a key player in carcinogenesis through the secretion
of proinflammatory cytokines and adipokines. The colon is surrounded by adipose tissue,
which supports the direct (paracrine) adipose-colon crosstalk and influence as a tumor
microenvironment, as well as systemic influences on colon carcinogenesis factors secreted
into the bloodstream. As part of the ColoCare cohort, an international, multicenter cohort
of colorectal cancer patients, we have investigated adipose tissue distribution, composi-
tion, characteristics, and possible influence on colorectal tumors. In an integrated analysis
of the transcriptome and metabolome of visceral and subcutaneous adipose tissue (VAT
and SAT, respectively), we showed that there are distinct differences that may play a
central role in driving carcinogenesis (1). These analyses are ongoing and have been
extended to blood-based measures of the inflammasome and metabolome, as well as
tumor characteristics. Adipose tissue biology can also be directly affected by weight-loss
interventions through diet and exercise. As part of the Nutrition and Exercise in Women
(NEW) study, we showed that weight loss results in changes in adipose tissue gene
expression as well as corresponding reductions in biomarkers, including inflammatory
biomarkers (2, 3).
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Targeting DNADamage/Repair in the Genome
#SY29-01 Targeting DNA repair factor dysfunction in advanced prostate cancer.
Karen E. Knudsen. Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA.
Prostatic adenocarcinoma (PCa) is the third leading cause of cancer death in U.S. men.
Organ-confined PCa can be effectively managed, but there is no durable treatment for
advanced disease. Advanced PCa is treated through androgen deprivation therapy, often
coupled with direct androgen receptor (AR) antagonists, as PCa is exquisitely dependent
on AR activity for cell survival and proliferation. Unfortunately, relapse is common;
recurrent disease arises largely due to resurgent AR activity with 2-3 years, and there is
no cure for this castration-resistant phase (castration-resistant PCa; CRPC). Thus, there is
a significant need to develop new means for targeting recurrent AR activity or to develop
adjuvant therapies in advanced PCa. Emerging data from our laboratory and others
strongly support the concept that alterations in DNA damage repair (DDR) pathways are
more common than previously thought in sporadic PCa, and that alterations in these
pathways may afford new, more effective means of therapeutic intervention. New studies
to be discussed will address underlying mechanisms of action with regard to the pathway
and identify clinically actionable ramifications of DNA repair dysfunction. Major con-
cepts to be considered include 1) new findings implicating differential functions of p53
somatic mutations on PCa behavior and response to therapeutic intervention and 2)
differential roles of DNA-dependent protein kinase (DNAPK) in controlling PCa progres-
sion. Findings to be discussed strongly support a model wherein selected DDR pathways
can be developed as therapeutic targets to tailor treatment for prostate cancer and improve
outcome for advanced disease.
#SY29-02 Novel mechanisms of PARP inhibitor resistance. Alan D. D’Andrea.
Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical
School, Boston, MA.
Large-scale genomic studies have demonstrated that approximately 50% of high-grade
serous ovarian cancers (HGSOCs) harbor genetic and epigenetic alterations in homolo-
gous recombination repair (HRR) pathway genes. The most commonly altered HRR genes
Invited Abstracts
Proceedings of the American Association for Cancer Research Y Volume 58 Y April 20171532
are BRCA1 and BRCA2, followed by other Fanconi anemia genes including FANCN/
PALB2, FANCO/RAD51, FANCJ/BRIP, and FANCA. Loss of HRR causes genomic
instability, hyperdependence on alternative DNA repair mechanisms, and enhanced sen-
sitivity to platinum analogues, topoisomerase inhibitors, and PARP-inhibitors (PARPi).
The synthetic lethal interaction with PARPi is being exploited therapeutically in diverse
clinical contexts and most notably in ovarian cancer, where the PARPi olaparib is FDA
approved for use in patients with germline BRCA1/2 mutations. PARP inhibitor resistance
has already emerged as a vexing clinical problem for the treatment of BRCA1/2-deficient
tumors. The most prevalent mechanism of PARPi resistance is secondary events that
cancel the original HRR alteration and restore HRR proficiency. However, PARPi
resistance may still develop without restoration of HRR proficiency via disruption of
multiple proteins, such as PTIP or CHD4, that leads to replication fork (RF) stabilization.
Importantly, this latter mechanism—namely, the restoration of RF stability—appears to be
a highly prevalent mechanism of PARP inhibitor resistance in vitro and in vivo, partic-
ularly in tumor cells with an underlying BRCA2 deficiency. Due to their underlying
deficiency in BRCA2 and inability to generate RAD51 nucleofilaments, these tumor cells
are unable to restore HRR mechanisms. Instead, these cells acquire PARP inhibitor
resistance by limiting the nucleolytic degradation of their stalled replication forks. We
have recently made the surprising observation that BRCA2-deficient tumors can become
resistant to PARPi by downregulating the expression of the polycomb repressive complex
PRC2, a methyltransferase complex containing EZH2, SUZ12, EED, and RbAp48.
Importantly, downregulation of PRC2 results in the reduced recruitment of the nuclease
MUS81 to the RF, thereby providing a novel mechanism of RF protection and PARPi
resistance. A molecular understanding of PARP inhibitor resistance mechanisms may
allow the generation of a new class of drugs or a repurposing of existing drugs, which may
reverse this resistance and extend the use of PARP inhibitors to more tumor types.
Biology of Metastasis: Mechanisms, Models, and Medicine
#SY31-02 Macrophages–evildoers in cancer. Jeffrey W. Pollard. MRC Centre for
Reproductive Health, University of Edinburgh, Edinburgh, United Kingdom.
Tumor evolution to malignancy requires manipulation of its tissue microenvironment to
be promoting. This is particularly true for the immune infiltrate that is biased away from
responding to the tumor to effect control and instead actively promotes progression. The
tumor immune response thus downregulates cytotoxic T-cell responses and promotes
tissue repair and morphogenic activities of the infiltrating immune cells (1). Thus the
environment tends to be dominated by innate immune cells, particularly macrophages and
neutrophils, while cytotoxic T cells are often excluded. Our interest has been in macro-
phages as these, in many different mouse models of cancer, promote tumor progression
and enhance metastasis. In fact, macrophages appear to be involved in every step of tumor
progression. They stimulate tumor initiation, enhance angiogenesis, promote tumor cell
migration and intravasation, increase stem cell viability, suppress immune responses, and,
at the metastatic site, promote extravasation and persistent growth. Consequently, mac-
rophage ablation results in inhibition of tumor progression and metastasis (2). These
macrophage biologic activities are induced through a dynamic interplay with tumor cells
that often involves reciprocal signaling. We have been particularly interested in the
involvement of macrophages in enhancing metastasis since it is metastatic disease that is
responsible for most cancer deaths. We have demonstrated a chemokine-signaling cascade
that results in the recruitment of the progenitor monocytes and their retention in the tissue
(3, 4). This results in differentiation of what we have termed metastasis-associated
macrophages (MAMs) that confer survival signals and growth advantage to metastatic
cells. These MAMs in term respond to local signals to upregulate an inflammatory gene
signature through the tyrosine kinase transmembrane receptors, vascular endothelial
growth factor receptor 1 (VEGFR1 or FLT1) and colony stimulating factor 1 receptor
(CSF1R) (5). Furthermore, monocytes appear to be preadapted by the primary tumor to
promote metastasis by the generation of preferred sites know as premetastatic niches (6).
Thus, understanding monocyte biology, the mechanisms of their recruitment, and differ-
entiation is of central importance to the fundamental appreciation of the role of macro-
phages in the tumor. My talk will focus on these questions.
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Dysregulation of MicroRNAs Leads to Target Therapy
#SY32-01 The new genetics and treatment of CLL. Carlo M. Croce. Ohio State
University Comprehensive Cancer Center, Columbus, OH
Loss of miR-15/16 on chromosome 13q14 is the most common genetic alteration in
CLL. Recently, we discovered that miR-15/16 target BCL2, an antiaptoptic gene we
discovered and named in 1984. Thus, loss of miR-15/16 leads to overexpression of BCL2
(the driver) and causes sensitivity of CLL cells to the antiBcl2 drug venetoclax that is
capable of inducing complete remission of CLL in patients and was approved by the FDA
in April 2016. The discovery of the involvement of miR-15/16 in CLL also indicated that
alterations in genes not encoding proteins can cause cancer. Before our publication of
2002, the dogma was that alterations in protein coding genes, oncogenes, and suppressor
genes, cause cancer. We speculate that by looking at other targets of miR-15/16 we might
discover other biomarkers that are overexpressed because of miR-15/16 loss, providing
novel opportunities to discover targetable targets. Since it seems likely that among the
billions of leukemic cells in patients, there are a few that do not respond to the drug—for
example, because of mutations in the Bcl2 pocket binding the drug—it is important to
develop other drugs capable of killing CLL cells because they have lost miR-15/16. We
propose to define whether loss of miR-15/16 may lead to overexpression of specific
surface markers that can be targeted by specific monoclonal antibodies. The availability
of these antibodies will allow the killing of the same leukemic cells by using a combi-
nation of the antibodies and venetoclax minimizing the possibility of drug resistance.
Finally, we will assess the role of a new family of short noncoding RNAs we have
discovered, ts-RNAs, in the pathogenesis of CLL.
#SY32-04 About Chomsky, patterns, and noncoding RNAs cancer therapeutics.
George A. Calin. UT MD Anderson Cancer Ctr., Houston, TX.
Resistance to therapy is an important issue in the treatment of cancer, responsible for
many cancer-related deaths. Despites decades of research into overcoming this resistance,
only modest advances have been made and the resistance mechanisms remain poorly
understood. Although to date the most studied noncoding RNAs (ncRNAs) are miRNAs,
the importance of long noncoding RNAs (lncRNAs) in cancer is increasingly being
recognized. Here we summarize the roles of miRNAs and lncRNAs in cancer, with a focus
on the recently identified novel mechanisms of action, and discuss the current strategies
in designing ncRNA-targeting therapeutics, as well as the associated challenges. We are
further presenting a novel strategy to identify new therapeutic ncRNA targets by using
Chomsky-type grammars based on combinatorial use of coding and noncodingRNAs.
Immunometabolism in Immunotherapy
#SY33-01 Targeting metabolism to enhance immunotherapy. Jonathan D. Powell,
Robert Leone, Judd Englert, Rana Rais, Barbara Slusher. Johns Hopkins Kimmel Comp.
Cancer Ctr., Baltimore, MD.
The extraordinary proliferative capacity of cancer necessitates specialized metabolic
programming on the part of cancer cells. Indeed, this specialized metabolism not only
facilitates growth but also creates a hypoxic, acidic, nutrient-deprived tumor microenvi-
ronment able to thwart immune destruction. We hypothesized that by targeting tumor
metabolism we could not only slow down tumor growth but also “condition” tumors to be
more susceptible to immunotherapy. Inherent to the specialized metabolism of tumors is
a markedly increased requirement for glutamine. To this end we have devised a novel
glutamine antagonist that is delivered as an inert prodrug that is converted to the active
drug by enzymatic activity, which is enriched in tumors. In syngeneic mouse models of
cancer our prodrug (JHU-083) markedly inhibited tumor growth, leading to cure of mice
after only 14 days of monotherapy. Importantly, targeting glutamine metabolism led to a
decreased extracellular acidification rate (ECAR), decreased hypoxia, and increased
nutrient availability. Furthermore, we observed decreases in MDSC and fibrocytes with a
concomitant increase in inflammatory (TNF-producing) tumor-associated macrophages
(TAMs). Likewise, there was an increase in the CD8:Treg ratio and in some tumors a
decrease in PDL1 expression on both tumors and infiltrating immune cells. Most impor-
tantly, JHU-083 markedly enhanced the efficacy of immunotherapy in the form of
checkpoint blockade, adoptive cellular therapy (ACT), and A2aR blockade. Overall our
studies define a novel compound for targeting metabolism as a means of enhancing
immunotherapy for cancer.
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#SY33-02 Fueling T cells and antitumor immunity. Jeffrey C. Rathmell. Vanderbilt
University School of Medicine, Nashville, TN.
Lymphocyte activation leads to rapid proliferation and differentiation, and we have
shown that T-cell subsets require distinct metabolic programs. The effector CD4 T-cell
fates (Th1, Th2, Th17) activate a highly glycolytic program. Regulatory CD4 T cells
(Treg), in contrast, utilize a more oxidative metabolism and utilize lipids as a major fuel.
These metabolic distinctions may allow new understanding of T-cell function in tumors
and approaches to manipulate immunity. We have now examined the metabolism of Treg
in detail and found that FoxP3 itself can promote oxidative metabolism characteristic of
Treg and that this is critical to maximize Treg suppressive capacity. Treg can be glycolytic
and proliferative in vivo. We found, however, that glucose uptake and glycolysis impaired
Treg stability. Thus, Treg regulate glycolytic and oxidative metabolism to balance
proliferation and suppressive function. Conversely, the requirement of effector T cells for
glucose uptake and glycolysis poses a barrier to inflammatory function in tumors.
Understanding mechanisms that regulate T-cell metabolism may provide new tools to
modulate immunity through the balance of T-cell effector and regulatory populations.
Surgery in the 21st Century: Convergence of Genes, Imaging, and
Robots
#SY36-01 Optimizing neoadjuvant therapy prior to surgery: Biomarker and target
discovery. Dan Theodorescu. University of Colorado Cancer Center, Aurora, CO.
Surgery is the oldest type of cancer therapy and remains at the forefront of modern
oncology because of its effectiveness in the treatment of many types of cancer. In most
patients presenting with localized cancer, surgical advances over the past 30 years offer
effective local control of the lesion, and in many this translates to cancer cure. However,
in a number of patients tumor recurrence, commonly at distant sites rather than at the local
site, occurs and is commonly associated with a fatal outcome. Future surgery includes
using progressively less invasive approaches to accomplish local tumor control and
combining this efficacious intervention with other approaches in order to reduce meta-
static recurrence and thus improve overall cure rates. With surgery as the “curative” or
“primary” modality, therapies that enhance the outcome of surgery are termed neoadju-
vant or adjuvant when delivered before or after surgery, respectively. Here we discuss
neoadjuvant chemotherapy (NAC) prior to bladder cancer surgery as a model applicable
to other cancer types of how this is being used to develop biomarkers of therapy prediction
while identifying novel therapeutic targets.
Bladder cancer is the second most common cancer of the genitourinary tract, and
primary treatment consists of transurethral resection of the tumor. At diagnosis, 30% of
patients present with muscle-invasive disease (MIBC), in which case standard of care
consists of removal of the bladder (radical cystectomy; RC) and pelvic lymph node
dissection. Despite this extensive surgery, 5-year survival rates do not exceed 60%, due
to the presence of occult nodal or visceral micrometastases at the time of surgery. The use
of platinum-based NAC has improved outcome in MIBC patients, with the most com-
monly used regimen being gemcitabine/cisplatinum. The benefit of NAC is a reduction of
14% in the risk of death. Importantly, pathologic complete response (i.e., stage pT0) at RC
is associated with an excellent 5-year survival rate of 85%, but only 25% of patients
experience this. The remaining 75% of patients are exposed to complications such as
neutropenia (70-80%), neutropenic sepsis (2-14%), mucositis (1-22%), and death (1-3%),
without an improved outcome. These patients are also subjected to a delay in RC, which
might negatively affect their prognosis.
Given this situation, the search for tools that can predict which patients benefit from
NAC has been a focus of investigation. The NAC approach has two major advantages for
biomarker discovery: 1) robust surrogate outcomes of survival (i.e., stage pT0 at RC) and
2) ability to examine pre- and post samples collected during standard of care, which
greatly facilitates biomarker discovery both practically and scientifically. Gene expression
analysis has been used in an attempt to predict response to NAC. An early study has
shown that gene expression can be used to build predictive models of the response to a
single drug as well as to combination regimens. In this study, baseline gene expression
profiles from a panel of 40 bladder cancer cell lines were used to develop chemotherapy
response prediction models, which showed highly significant concordance with empirical
patient responses. In another study by Takata and colleagues, gene expression was
measured in tumor samples from 27 patients with MIBC prior to neoadjuvant treatment
with methotrexate vinblastine, Adriamycin, and cisplatin (MVAC) chemotherapy. The
authors identified a set of 50 genes that significantly differed between 14 responders and
13 nonresponders. The same investigators have subsequently validated their predictive
signature on 22 additional patients, showing that their gene expression signature could
predict MVAC response in 19 out of 22 cases. Als and colleagues analyzed gene
expression in 30 patients with locally advanced or metastatic bladder cancer, identifying
55 genes that proved to be expressed at lower levels in patients with longer survival. Two
genes that discriminated patients by their survival—EMMPRIN and survivin—were
further investigated by immunostaining, which showed they were significantly associated
with overall survival, with double-positive tumors exhibiting a response rate of 27% and
double-negative tumors exhibiting a response rate of 82%.
The use of molecular profiles to predict treatment outcomes requires a training dataset
to identify the profile and a second independent clinical trial to validate it. This strategy
is useful when patient material is available but usually cannot be used to develop response
biomarkers to regimens before clinical studies are carried out. A new strategy was
proposed by our group that extrapolates in vitro drug response data to make in vivo
predictions based on the gene expression profiles that are common to both. This approach,
called COXEN (COeXpression ExtrapolatioN), uses expression microarray data as a
“Rosetta stone” for translating between drug activities in a cancer cell line panel and drug
activities in a set of clinical tumors. Using a variety of cancer cell lines and their gene
expression profiles and drug sensitivity, Lee et al. used COXEN to predict sensitivity to
cisplatin and paclitaxel chemotherapies in bladder cancer cell lines and sensitivity to
docetaxel and tamoxifen in breast cancer patients, and also demonstrate the utility of
COXEN in drug screening. This approach was used to identify a promising new agent in
bladder cancer, called C1311, while predicting the response of bladder cancer patients to
chemotherapy both in the neoadjuvant and treatment settings.
In 2011, next-generation sequencing (NGS) began identifying mutations in urothelial
bladder cancer. This first breakthrough study was followed by several others, including
work by The Cancer Genome Atlas (TCGA), which have enabled comprehensive cata-
loguing of genomic alterations. Given that such alterations number in the hundreds,
evaluating their functional impact individually is challenging. Still, evaluating their
function is absolutely necessary if we are to translate sequencing data into novel avenues
for therapeutic intervention. Given this need, we developed and implemented a high
throughput strategy that tests the hypothesis that some of these alterations are indeed loss
of function in tumor growth suppressors. We tabulated gene alterations discovered by
next-generation sequencing in bladder cancer and employed RNA interference (RNAi)–
based gene depletion to study the impact of gene expression on tumor phenotypes in vitro
and in vivo. This led to the functional identification of a number of novel tumor
suppressors and promoters. Similar experiments with overexpression gene libraries were
carried out to define genes whose overexpression drives tumor progression and could then
be considered for development as drug targets.
This approach provides a novel framework for the efficient functional evaluation of
hundreds of genomic alterations found in cancer and allows us to define those that are
drivers rather than passengers in tumor growth. In addition, it can also be applied to define
which RNA and DNA gene alterations found to be associated with drug resistance in
patients are functional drivers of this phenotype. These could then constitute targets of
second-line drug therapy. Two recent studies have used NGS to explore the genomic
landscape of chemotherapy-resistant urothelial carcinoma. The first study performed
whole-exome sequencing on pretreatment tumor and germline DNA from patients with
muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemo-
therapy followed by RC to identify somatic mutations that occurred preferentially in
chemotherapy responders. The authors found ERCC2, a nucleotide excision repair gene,
to be the only significantly mutated gene enriched in the cisplatin responders compared
with nonresponders. The second study performed whole-exome sequencing and clonality
analysis of bladder cancers collected before and after chemotherapy. Analysis of these
data indicated that chemotherapy-treated bladder cancer is characterized by intrapatient
mutational heterogeneity and that such chemotherapy-treated urothelial carcinoma is
enriched with clonal mutations involving L1 cell adhesion molecule and integrin signaling
pathways. Both studies provide new perspectives on the mechanisms and genes driving
chemotherapy resistance and possible avenues of overcoming this.
In conclusion, surgery, the oldest type of cancer therapy, when used in combination
with systemic therapy guided by discoveries made with molecular tools, promises to not
only advance our understanding of cancer but also lead to a quantum improvement in
patient outcome. There is every expectation that, given their effects on metastatic disease,
the use of neoadjuvant and adjuvant immunotherapy with surgery will also have a
significant impact and can be studied using the same tools described here.
Transformative Small Molecule Therapies
#SY37-02 Ligand-directed degradation of GSPT1 by a novel cereblon modulator
drives potent anti-tumor effects. Mary Matyskiela,1 Gang Lu,1 Takumi Ito,2 Barbra
Pagarigan,1 Chin-Chu Lu,1 Karen Miller,1 Wei Fang,1 Nai-Yu Wang,1 Derek Nguyen,1
Jack Houston,1 Gilles Carmel,1 Tam Tran,1 Mariko Riley,1 Lyn’Al Nosaka,3 Gabriel
Lander,3 Svetlana Gaidarova,1 Shuichan Xu,1 Alexander Ruchelman,1 Hiroshi Handa,2
James Carmichale,1 Thomas O. Daniel,1 Brian E. Cathers,1 Antonia Lopez-Girona,1
Philip Chamberlain1. 1Celgene, San Diego, CA; 2Tokyo Medical University, Tokyo,
Japan; 3The Scripps Research Institute, San Diego, CA.
The protein cereblon is part of the CRL4-CRBN E3 ubiquitin ligase complex, and has
been shown to be the molecular target for the drugs lenalidomide and pomalidomide.
These drugs bind to the surface of cereblon, triggering the recruitment of substrate
proteins to the ligase complex where they can be ubiquitinated and subsequently degraded
by the proteosome. By this mechanism, lenalidomide and pomalidomide cause the
degradation of the zinc finger transcription factors Ikaros and Aiolos, which mediate the
antimyeloma activity of these compounds. Here we describe the discovery of CC-885, a
novel cereblon modulator with potent and broad-spectrum antiproliferative activity
against a panel of tumor cell lines. Acute myeloid leukemia (AML) cell lines and
patient-derived AML cells show particular sensitivity to CC-885 treatment. CC-885
achieves this activity by causing the degradation of G1 to S phase transition 1 (GSPT1),
a translation termination factor required for the release of nascent peptides from the
ribosome. A crystal structure of cereblon in complex with the ligase adapter protein
DDB1, as well as CC-885 and GSPT1, reveals that GSPT1 interacts with both CC-885 and
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the surface of cereblon. The principal molecular feature on GSPT1 that binds to cereblon
is a beta-hairpin incorporating a glycine residue that docks against CC-885. Surprisingly,
we found evidence that a similar molecular feature mediates Ikaros recruitment, even
though there is no common structural fold or sequence homology other than the key
glycine residue. We thereby define the common molecular feature, or degron, shared by
the known cereblon neomorphic substrates. We further describe a novel therapeutic target,
GSPT1, with promise in cancer such as AML. These results further show that cereblon-
mediated protein degradation can be directed against new proteins and that this mecha-
nism enables the targeting of multiple protein classes that may be considered undruggable
with conventional approaches.
Bridging Big Data and Clinical Practice
#SY40-02 Identification of novel modulators of response to immune checkpoint
blockade in lung cancer patients through the marrying of clinical and genomic data.
Phil Stephens. Foundation Medicine, Inc., Cambridge, MA.
The increasing use of comprehensive genomic profiling (CGP) in clinical practice for
the genomic characterization of tumors is having an increasingly important impact on
patients with cancer, empowering the rational use of both targeted therapies and immu-
notherapies and driving smarter, faster drug development. While some of the insights from
clinical tumor sequencing have been realized, there remains a large gap between our
understanding of the mutational landscape in cancer and its implication for patient
treatment and outcomes. Furthermore, given the increasing subcategorization of cancer
types by genetic lesion, efforts to understand the relationship between cancer genetics and
clinical outcomes will require the use of large data sets. To date, the majority of these
efforts have been largely confined to academic centers and limited by either number of
patients or number of genes sequenced.Through a groundbreaking partnership between
Foundation Medicine and Flatiron Health, a real-world dataset has been enabled, linking
rich genomic and clinical outcomes data for over 20,000 oncology patients, the majority
of whom have been treated in the community setting, in an HIPAA-compliant fashion.
Within this cohort, longitudinal records from over 1,500 patients with NSCLC have been
de-identified and consolidated in a research-grade clinico-genomic registry. These data
include full somatic genomic records across the cohort, treatment histories, response to
oncologic therapeutics, and multiple outcomes including PFS and OS, in addition to
baseline clinical characteristics. The capabilities of these data and these novel methods of
real-world observation are only beginning to be understood. Initial analytical validation
has confirmed expected distributions of genomic findings and clinical characteristics, and
early work still in progress had corroborated a number of known clinical and genomic
correlates with survival, which will be presented. In a separate study marrying genomic,
protein, and outcome data in a cohort of 1,000 non–small lung cancer patients,
modulators of response to immune checkpoint blockade were identified. These biomarkers
include both immunosuppressors that explain why some patients with high tumor muta-
tion burden (TMB) do not respond and immunogenic markers that explain why some
patients with low TMB respond. Given the high cost and broadening use of immunother-
apies, if validated in larger cohorts, these biomarkers will be important to more effectively
stratify NSCLC patients by likelihood of response to immunotherapy.
Plenary Sessions
Opening Plenary: The Road to Cancer Cures—Discover, Predict,
Prevent, and Treat
#PL01-03 Earlier detection as a key to lower cancer death rates. Bert Vogelstein.
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD.
Two disciplines within cancer research—secondary prevention and cancer therapeu-
tics—have historically been viewed as distinct. I will argue that these two disciplines are
intertwined and that their joint pursuit is the optimal way to reduce cancer deaths. At
present, the preferred way to treat cancers, in fact the only way that generally cures
patients, is surgery. It is therefore widely recognized that the detection of cancers prior to
the onset of metastasis is vital to reducing cancer deaths. What is less widely recognized
is that the detection of metastatic cancers can also be life-saving—as long as this detection
occur priors to the formation of bulky metastatic disease. Therapies that only modestly
extend life when administered to patients with measurable metastases can be curative
when administered to patients with metastatic disease that is present but undetectable by
imaging. Such therapies include conventional cytotoxic drugs as well as genome-targeted
agents and immunotherapeutics. A new paradigm for designing clinical trials to test such
agents in adjuvant settings will be described. Genome-based diagnostic approaches for
detecting cancers earlier will be discussed, as these are integral to the design of the next
generation of adjuvant trials. In aggregate, these issues support the importance of mod-
ulating the focus of cancer research and treatment from patients with advanced disease
towards patients with less-advanced disease. They also highlight the importance of
developing novel diagnostic approaches that will allow the detection of smaller tumors.
Convergence, Computation, and Cancer
#PL04-01 G-quadruplexes and DNA dynamics. Shankar Balasubramanian. University
of Cambridge, Cambridge, United Kingdom.
DNA is structurally dynamic in ways that have a consequence for biologic processes.
A class of four-stranded DNA structure, called the G-quadruplexes, can be formed from
G-rich single-stranded DNA. There is now a good level of understanding of the structural
biophysics of G-quadruplexes along with a large body of work on the design and synthesis
of small organic molecules that can target such structures. Some such molecules have been
found to have antiproliferative effects on human cancer cells along with specific effects
on the activity of certain genes, raising intriguing hypotheses about their existence and
function in cells. Recent results from my laboratory provide new insights into when and
where such non-Watson-Crick structures may exist in cellular DNA, together with a
perspective on whether this structural motif in DNA presents new opportunities to think
about intervention and future therapeutics.
#PL04-04 Novel vapproaches for personalizing treatments: From nutrition to can-
cer. Eran Segal. Weizman Institute of Science, Rehovot Israel, Israel.
Elevated blood glucose levels are rapidly increasing in the general population, resulting
in a sharp incline in the prevalence of prediabetes and impaired glucose tolerance and
eventual development of type 2 diabetes mellitus. Dietary intake is considered a central
determinant of glucose levels, with high postmeal glucose levels affecting weight gain,
obesity, hunger, and energy dips and being associated with increased risk of cardiovas-
cular disease, cancer, and overall mortality. However, despite their importance, existing
dietary methods for controlling postmeal glucose levels have limited efficacy. By con-
tinuously monitoring week-long glucose levels in over 1,000 people, we found high
variability in the response of different people to identical meals, suggesting that generic
population-wide dietary recommendations have limited utility and are ineffective in
achieving proper glycemic control. We devised a machine-learning algorithm that inte-
grates blood parameters, dietary habits, anthropometrics, physical activity, and gut mi-
crobiota measured in this cohort and showed that it accurately predicts personalized
postprandial glucose responses to real-life meals. Moreover, a blinded randomized con-
trolled dietary intervention based on this algorithm resulted in significantly lower post-
prandial responses in a cohort of prediabetics and consistent alterations to gut microbiota
configuration. These results suggest that personalized diets may successfully modify
elevated postprandial blood glucose and its metabolic consequences. As another example
of personalized medicine approaches that we are developing, I present our work on
functional profiling of a library of over 10,000 variants that we generated for the tumor
suppressor p53, the most frequently mutated gene in human cancers. Remarkably, the
mutational effects observed in large-scale in-vitro assays with this library correspond to
p53 mutation recurrence in patients and provide many novel insights on adverse and
benign variants, protein structure, and evolutionary conservation. Apart from gaining
comprehensive insights into the effects of the p53 “mutome,” our results may lead to
better understanding of patients’ response to treatment based on their p53 sequence,
potentially contributing to the development of novel patient-specific therapeutics. Finally, I
also present our studies of the mechanisms driving recurrent postdieting obesity in which we
identified an intestinal microbiome signature that persists after successful dieting of obese
mice. This microbiome signature contributes to faster weight regain and metabolic aberrations
upon re-exposure to obesity-promoting conditions and transmits the accelerated weight regain
phenotype upon interanimal transfer. Notably, a microbiome-based machine-learning algo-
rithm enabled personalized prediction of the extent of postdieting weight regain. We further
find that the microbiome contributes to diminished postdieting flavonoid levels and reduced
energy expenditure and demonstrate that flavonoid-based ‘postbiotic‘ intervention ameliorates
excessive secondary weight gain. These results thus highlight a possible microbiome contri-
bution to accelerated postdieting weight regain and suggest that microbiome-targeting ap-
proaches may help to diagnose and treat this common disorder.
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